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6Liver Fatty Acid Binding Protein (L-FABP) Initiates Budding of the Pre-
Chylomicron Transport Vesicle (PCTV) from Intestinal ER. Siddiqi S.a., Storch
J, Mansbach, C.M. University of Tennessee, Memphis, Tn and Rutgers
University, New Brunswick, Nj
Shadab A. Siddiqi, Judith Storch, Charles M. Mansbach
The rate-limiting step in the transit of triacylglycerols (TAG) from absorption to its secretion
from the enterocyte is its exit from the endoplasmic reticulum (ER) in its carrier vesicle,
PCTV. We have shown that PCTV are of appropriate size to contain chylomicrons, contain
apolipoproteins B48 and AIV, are sealed, and can bud from ER in the absence of COPII
proteins. PCTV contain vesicle associated membrane protein 7 (VAMP7) which is unique
for an ER to Golgi transport vesicle and which forms part of the fusion complex with the
cis Golgi. We now wished to identify the protein(s) that initiates budding of PCTV from
intestinal ER. We first fractionated intestinal cytosol on a sizing column, Sephacryl S-100,
and tested the eluted fractions for budding activity by incubating 3H-TAG loaded rat intestinal
ER (500 µg) with the test fraction (100 µg) or cytosol (1 mg), ATP, and Mg2+ at 35o for
30 min, collecting PCTV by floatation on a continuous sucrose gradient and measuring TAG
dpm. We found budding activity to be in the small Mr fractions, just larger than cytochrome
C (12 kDa). Further chromatography on heparin-sepharose, and DEAE eluted at pH 6.9
and 8.0 resulted in one major and one minor band on SDS-PAGE that contained all the
budding activity. Tandem mass spectroscopy of the bands revealed 6 proteins. Recombinant
proteins (40 µg) were obtained for each and tested for budding. Only L-FABP and I-FABP
(20% the activity of L-) could generate PCTV. To establish if the rL-FABP generated vesicle
was bona fide PCTV, we found that the vesicle contained apoB48 and apoAIV and the cargo
apoB48 was resistant to proteinase K treatment indicating a sealed vesicle. The size (as
judged by size exclusion chromatography [Sepharose CL-2B]) and morphology (EM) was
similar to PCTV. The vesicles contained VAMP7 and excluded the ER proteins calnexin and
calreticulin as do PCTV. Cytosol from L-FABP knock out mouse intestine was found to
have a 40% reduction in activity compared to wild type mouse intestine which was restored
on addition of rL-FABP. We tested if the rL-FABP vesicles could fuse with and deliver pre-
chylomicrons to cis Golgi membranes. Unlike PCTV generated in cytosol, we found they
could not. As expected in the absence of cytosol, we found no Sar1, the initiator of COPII
protein addition to vesicles, on rL-FABP vesicles in contrast to PCTV which contains Sar1.
We conclude that rL-FABP, a 14 kDa protein, can on its own bud and select cargo for pre-
chylomicron containing vesicles from intestinal ER membranes. The inability of these vesicles
to fuse with Golgi indicates a lack of proteins other than VAMP7 required for fusion, perhaps
COPII proteins.
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Dexamethasone Up-Regulates Niemann-Pick C1-Like 1 Expression in Human
Intestinal Epithelial Cells
Pradeep Kumar, Fadi Annaba, Seema Saksena, Dhirendra Kumar, Pradeep K. Dudeja,
Ravinder K. Gill, Waddah A.alrefai
High levels of plasma corticosteroids in adrenal hyperfunction are associated with increased
risk of cholesterol-related disorders such as atherosclerosis. Treatment with glucocorticoids
also results in hypercholesterolemia that is directly related to dosage and duration of the
therapy. The mechanisms by which glucocorticoids cause disturbances in cholesterol
homeostasis are poorly understood. In this regard, the intestinal Niemann-Pick C1-like 1
(NPC1L1) cholesterol transporter plays an essential role in the maintenance of cholesterol
homeostasis. However, it is not known whether glucocorticoids modulate NPC1L1 expres-
sion. Therefore, the current studies were designed to investigate the effect of dexamethasone
on human NPC1L1 expression and its promoter activity in Caco2 monolayers. NPC1L1
gene fragment (-1741/+59) was amplified from human genomic DNA and cloned into pGL2
vector upstream of luciferase reporter gene. Caco2 cells were transiently transfected with
NPC1L1 promoter constructs and human glucocorticoid receptor (GR). Luciferase assays
were used to measure NPC1L1 promoter activity. The relative abundance of NPC1L1 mRNA
and protein were evaluated by real time PCR and Western blotting, respectively. GR activation
by dexamethasone (0.1-1.0 μM, 24h) stimulated NPC1L1 promoter activity in a dose
dependent manner with a maximal induction (~ 4 fold) at 0.5 μM concentration. This effect
on NPC1L1 promoter activity was abrogated in the presence of 0.5 μM of GR antagonist,
RU-486. Deletion of NPC1L1 promoter construct to -291 nucleotide did not affect dexame-
thasone-induced stimulation. These data indicated that GR cis-element is located in the
region between -291 and +56 of NPC1L1 gene. Consistent with the promoter activity,
dexamethasone significantly increased the relative abundance of NPC1L1 mRNA in Caco2
cells (~ 60.4 ± 0.5 %). Similarly, dexamethasone resulted in up-regulation of NPC1L1 protein
level (~ 2 fold) and this effect was blocked by RU-486. Conclusion: Our studies, for the
first time, demonstrate the modulation of intestinal NPC1L1 expression and its promoter
activity by dexamethasone. We speculate that glucocorticoid-induced increase in NPC1L1
expression may contribute to the pathophysiology of associated hypercholesterolemia. Our
studies provide new insights into the mechanisms underlying glucocorticoid-induced hyper-
cholesterolemia and may aid in the development of improved therapeutic modalities in
future. (Supported by Dept of Veteran Affairs and NIDDK).
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Taurodeoxycholic Acid Induces Calcium Oscillations in Isolated Human
Colonic Crypts
Mark Williams, Theodore Spahos, Amy Reynolds, Alyson Parris, Richard Tighe, Chris
Speakman, Ian Beales, Mike Lewis
Previous studies have led to the proposal that elevated levels of secondary bile acids contribute
to the pathogenesis of conditions such as secretory diarrhoea, inflammatory bowel disease
and colon cancer. Increasing evidence suggests that these conditions arise in part from bile
acid modulation of cellular signalling pathways. Studies on intestinal cell lines suggest that
dihydroxy bile acids, and taurodeoxycholate (TDC) in particular, may act directly on the
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intestinal epithelium by modulating calcium signalling, possibly via activation of acetylcholine
receptors. AIMS: To investigate taurodeoxycholate modulation of calcium signalling in intact
human colonic crypts. METHODS: Colonic crypts were isolated from tissue biopsies obtained
at sigmoidoscopy from healthy-subjects (Ethical approval). Isolated crypts were attached to
collagen-coated coverslips and cultured for 24 hours - 3 days in serum-free DMEM (5%CO2/
37oC). For calcium imaging experiments colonic crypts were loaded with the calcium-
sensitive dye Fura2-AM. RESULTS: Application of TDC (100μM - 1 mM) elicited oscillations
of intracellular calcium levels along the entire crypt-axis (n>20). The frequency of calcium
oscillation was typically 14.0 ± 2.4 per hour (n=40, 1 mean ± SD,mM). TDC induced
calcium oscillations were still evident in the absence of calcium in the bathing medium.
Depletion of calcium from intracellular stores by thapsigargin (1 μM) abolished the onset
of TDC induced calcium oscillations as did pre-incubation with TMB-8 (100 μM), an inhibitor
of intracellular calcium mobilisation. The pacemaker region for TDC induced oscillations
did not reside at the crypt base. In contrast, acetylcholine (10 μM) induced non-oscillatory
biphasic calcium signals at the crypt base that propagated in a unidirectional manner along
the crypt axis. Atropine (1μM) inhibited the ACh response, but did not affect TDC-induced
calcium oscillations. TDC did not compromise the viability of colonic crypt cells. CONCLU-
SION: (Patho)physiological levels of taurodeoxycholate are sufficient to set in to motion a
train of intracellular calcium oscillations along the crypt axis. The consequences to human
colonic crypt fluid secretion and tissue renewal are expected to be significant and will impact
on conditions such as secretory diarrhoea and colon cancer. The molecular target for TDC
remains to be determined, but is unlikely to be a member of the muscarinic receptor family.
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Bile Acid Malabsorption (BAM) and Ileal Histology in Diarrhoea-Predominant
Irritable Bowel Syndrome (D-IBS)
M. Srinivas, P. Basumani, Barbara Dawson, M. Smith, John Lee, Karna D. Bardhan
Introduction and Aim: BAM is characterized by watery diarrhoea and confirmed by sub-
normal (<10%) 7-day retention of 75-seleno-homo-taurocholic acid (SeHCAT). It occurs
almost invariably after ileal resection and frequently in severe ileal disease, e.g. Crohn's. We
observed BAM in one-third of D-IBS patients (Smith MJ et al, J R Coll Physicians London
2000; 34:448-51), an unexpected finding without obvious explanation. Terminal ileal (TI)
villous atrophy in association with BAM has occasionally been reported. We therefore studied
the association prospectively in patients with D-IBS. Methods: All patients with D-IBS (ROME
II criteria) with or without BAM, seen over the last 24 months, were followed up. Data on
SeHCAT retention, TI histology (light microscopy H & E stain) and daily stool frequency
were collected. Results (Table) ●73 patients with D-IBS were studied; 32 had BAM ●TI
histological changes occurred in one-fifth of patients with BAM but only rarely in those
without ●Mild non-specific inflammation was the most common histological abnormality;
ileal villous atrophy was rare (n=2) and noted only with BAM ●Stool frequency >2 per day
was slightly commoner in those with BAM Conclusion Bile acid malabsorption in D-IBS is,
in our experience, rarely associated with major ileal histological abnormalities. We therefore
suggest that other mechanisms must be involved in causing BAM.
*Two-tailed Fisher exact test
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Elevated Bile Acid Levels Precede Ileal Damage and Inflammation During the
Development of Necrotizing Enterocolitis
Melissa Halpern, Ludmila Khailova, Dania Molla hosseini, Charity A. Reynolds, Kelly
Arganbright, Bohuslav Dvorak
Background: Necrotizing enterocolitis (NEC), characterized by an extensive hemorrhagic
inflammatory necrosis of the distal small intestine, is a devastating gastrointestinal disease
of premature infants. We have recently shown that ileal bile acid (BA) levels are elevated
and positively correlated with ileal damage during experimental NEC. However, a clear
cause and effect relationship between elevated BAs and disease development has not been
established. In addition, inflammation has been shown to affect BAs, but the temporal
relationship between BAs and inflammation has not been elucidated in experimental NEC.
Objective: To identify if BA dysregulation causes or is a consequence of ileal injury and
inflammation. Methods: Prematurely born Sprague-Dawley rats were hand-fed with cow's
milk-based formula and exposed to asphyxia and cold stress twice daily. Animals were
sacrificed post-birth at 24 (n = 6), 48 (n = 6), 72 (n = 6) or 96 hours (n = 5). A 3 cm
section of distal ileum from each animal was flushed with 400 ul sterile, cold PBS to evaluate
total luminal BA levels. After flushing with an additional 500 ul PBS, this section of ileum
was homogenized in 400 ul fresh PBS to determine intra-enterocyte BA levels. Total BA
levels were determined using the Diazyme Total BA Kit. An adjacent section of distal ileum
was evaluated for histological damage by a blinded observer using our previously published
scoring system where 0 is normal ileum and 4 indicates full necrosis. Macrophages were
visualized using the rat macrophage marker ED1 via immunohistology and counted from
15 intact villi from each animal by a blinded observer. Results: By 48 hours, both ileal
luminal and intra-enterocyte BA levels were elevated in animals in the NEC group, but
histological damage did not significantly increase until the 72 hour observation point. In
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addition, intra-enterocyte BA levels increase prior to macrophage infiltration during the
development of experimental NEC. Conclusion: Because luminal and intra-enterocyte BA
levels increase prior to ileal damage, these data strongly suggest that elevated BA levels
contribute to ileal damage rather than result from ileal damage. Further, because BA levels
increase prior to ileal macrophage infiltration, it is unlikely that inflammation causes elevation
in BA levels. Thus, BAs induce ileal damage and inflammation during the development of
experimental NEC. Supported by NIH grant HD039657.
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Altered Bile Acid Metabolism in Childhood Constipation: Inactivation of
Secretory Bile Acids By Sulfation
Alan F. Hofmann, Vera Loening-baucke, Joseph H. Steinbach, Lee R. Hagey, Christine A.
Packard, Terrance L. Griffin, Dale A. Chatfield
It is well established that an elevated concentration of dihydroxy bile acids in the colon
causes diarrhea, and that administration of bile acid sequestrants causes constipation. Recent
structure-activity studies of bile acid-induced secretion with T84 cells indicate that of the
broad spectrum of colonic bile acids, only deoxycholic acid (DCA) and chenodeoxycholic
acid (CDCA) are potent secretagogues (Keely et al, Am J Physiol, in press). These data
suggested to us that these two dihydroxy bile acids are endogenous cathartics, and led us
to hypothesize that inactivation of these bile acids by tissue sulfation or bacterial epimerization
of their hydroxy groups could play a role in childhood constipation. To test this hypothesis,
fecal bile acid composition was determined in 72 constipated children and 99 non-constipated
children (control subjects) using capillary gas chromatography-mass spectrometry (GC-MS)
and electrospray ionizationMS (ESI)-MS;in addition, liquid chromatography (LC-MS) was
performed on selected samples (N=28). Results: By ESI-MS, a greater proportion of dihydroxy
bile acids was sulfated in constipated children (14.0±19.9, M±SD) than in control subjects
(8.8±8.3) (p<0.03). Sulfation exceeded 30% in 14 of 72 constipated patients, but in only
4 of 99 control subjects. By LC-MS, the dominant dihydroxy bile acid sulfate was the 3-
sulfate of non-amidated CDCA. The origin of the 3-sulfo-CDCA is unknown, but we propose
that it is formed by a novel pathway consisting of bacterial deconjugation of CDCA conjugates
in the small intestine, uptake of the CDCA by enterocytes, sulfation of CDCA by enterocytes,
and transporter-mediated extrusion of the 3-sulfo-CDCA back into the intestinal lumen.
Because 3-sulfates are hydrolyzed by bacterial sulfatases and because such hydrolysis should
be greater during the prolonged colonic transit in constipated children, sulfation is likely
to have been still greater in bile acids entering the colon. In contrast to the difference in
bile acid sulfation, the fecal bile acid spectrum (sulfated and unsulfated), as determined by
GC-MS, did not differ in the two groups, being composed mainly of DCA, lithocholic acid,
and their corresponding 3 beta-hydroxy epimers. We conclude that a subset of constipated
children have altered bile acid metabolism evidenced by an increased proportion of sulfated
CDCA. The result of this novel conjugation pathway is a decrease in the load of secretory
dihydroxy bile acids to the colon. Our results suggest that abnormal small intestinal bacterial
colonization and subsequent enterocyte sulfation play a role in constipation in some children.
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Liver Fatty Acid Binding Protein 1 (FABP1) Regulates the Alternative Bile
Acid Synthetic Pathway and Promotes Cholehepatic Shunting of Bile Acids
Mulugeta Seneshaw, Elizabeth P. Newberry, Elke Preiss, Guido Adler, Nicholas O.
Davidson, Michael Fuchs
Fabp1 is an abundant intracellular protein involved in binding cholesterol, fatty acids and
bile acids in hepatocytes and enterocytes. Our previous studies in Fabp1 -/- mice suggested
a role in intracellular lipid trafficking and others have demonstrated alterations in biliary
bile acid secretion. We therefore investigated whether Fabp1 participates in the regulation
of bile acid synthesis. Male wild type (wt) and Fabp1 -/- mice were either fed a cholic acid
(CA; 0.5% w/w), chenodeoxycholic acid (CDCA; 0.5% w/w) or ursodeoxycholic acid (UDCA;
0.5% w/w) supplemented diet or a chow diet for two weeks, respectively. Thereafter, hepatic
bile was collected for lipid analysis and bile acid composition employing gas chromatography
mass spectrometry. mRNA and protein expression of key enzymes of bile acid (Cyp7a1,
Cyp27a1, Cyp8b1, Cyp7b1) were studied with real-time PCR and Western Blot analysis.
Food intake (2.4 - 3.8 g per day) did not differ significantly among groups and body weight
loss was not observed under any of the diets given. Hepatic bile composition of chow-fed
mice was predominantly CA (49-53%) and muricholic acids (44-46%). Bile of both wt and
Fabp1 -/- mice became enriched with CA (96-98%) and UDCA (95-97%) upon feeding
chow diet supplemented with these bile acids. By contrast, in response to CDCA, Fabp1
-/- mice displayed substantially lower amounts of UDCA (6 vs.19%) and higher amounts
of muricholic acids (26 vs.14%) compared with wt mice. This indicates altered metabolism
of CDCA in Fabp1 -/- mice, yet the hydrophobic-hydrophilic balance of the circulating bile
acid pool was unchanged. Bile flow and biliary lipid secretion were comparable in chow-
fed wt and Fabp1 -/- mice, and both parameters increased in response to bile acid feeding
- most pronounced with CA. However, the choleretic effect of UDCA was much less pro-
nounced in Fabp1 (-/-) despite circulating bile acid pools of similar hydrophilicity. All three
bile acids markedly suppressed Cyp7a1 and Cyp8b1 mRNA expression by more than 70%
in wt and Fabp1 -/- mice, respectively. Interestingly these changes only translated into
significant changes in protein expression for Cyp8b1 but not Cyp7a1. Compared to chow
fed mice, inhibition of Cyp27a1 and Cyp7b1 mRNA and protein expression was suppressed
most dramatically with CDCA and UDCA feeding and was greater in Fabp1 -/- mice. These
results demonstrate for the first time that Fabp1 regulates the alternative pathway of bile
acid synthesis and promotes cholehepatic shunting.
A-2AGA Abstracts
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The Methionine Choline Deficient (MCD) Diet Leads to Intrahepatic Lipid
Accumulation By Increasing Hepatic Fatty Acid Uptake and Decreasing VLDL
Secretion in Db/M Mice
Mary Rinella, Marc Elias, Tao Fu, Jayme B. Borensztajn, Richard M. Green
Mice fed an MCD diet develop steatohepatitis similar to human NASH. The aims of this
study were to define the mechanisms of hepatic steatosis induced by the MCD diet using
insulin resistant db/db mice and db/m (control) mice. 8-10 week old female db/db and db/
m mice were fed the MCD or control diet for 4 weeks. Real time PCR was used to quantify
hepatic expression of fatty acid transport protein (FATP) genes. As a functional assay of
hepatic fatty acid uptake, we examined the effects of the MCD diet on hepatic uptake of
14C-oleate gavage in db/db and db/m mice. Serum triglycerides (TG) were measured at
various time-points and the livers harvested 240 min after gavage. VLDL secretion was
determined in fasted mice by assaying serum TG levels and Apo B protein levels following
Triton WR-1339 injection, which inhibits lipoprotein lipase. Relative changes in visceral
(VF) and subcutaneous fat (SF) were also compared between groups. In db/db mice, FATP-
1, 3 and 4 were up-regulated 2, 1.5 and 2-fold, respectively by the MCD diet (p<0.05),
whereas FATP 2 and 5 did not change. The MCD diet increased hepatic uptake of oleate
significantly in both strains. In db/m mice the MCD diet increased hepatic fatty acid uptake
by 211% (p=0.0003). In db/db mice, the MCD diet increased fatty acid uptake by 66% (p=
0.003). The MCD diet did not alter the intestinal absorption of dietary lipids indicating that
decreased hepatic 14C-oleate in control diet fed mice was not due to impaired absorption.
We subsequently examined the effects of the MCD diet on VLDL secretion. VLDL secretion
was decreased by the MCD diet in db/m mice. Serum TG levels (representing VLDL secretion)
0, 3 and 6 hours after Triton injection were 38+/-1.8, 416+/-42, and 816+/-40 mg/dl in
mice fed the control diet and 45+/-8, 209+/-60 and 508+/-176 mg/dl in MCD fed mice (p=
0.03 at 3 hours). This decrease in VLDL secretion was also evident by decreased serum
ApoB100 and ApoB48 levels in db/m mice fed the MCD diet. Paradoxically, the MCD diet
had the opposite effect on VLDL secretion in db/db mice. Three hours after Triton injection
db/db mice had higher serum TG, ApoB 100 and ApoB48 levels than control diet fed mice
(p=0.0004). In db/m mice, the MCD diet reduced VF by 50% and SF by 100% whereas in
db/db mice reductions were less pronounced; 20% VF and 30% SF. The MCD diet results
in increased hepatic fatty acid uptake in both db/db and db/m mice. In db/m mice VLDL
secretion is impaired by the MCD diet, further promoting lipid accumulation. These data
provide putative mechanisms for the intrahepatic lipid accumulation caused by the MCD diet.
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Overexpression of Estrogen Receptor α (ERα) Induces Gallbladder
Hypomotility During Cholesterol Gallstone Formation in Mice
Helen H. Wang, Piero Portincasa, David quan-hai Wang
The association of increased estrogen levels and impaired gallbladder motility in women
supports the critical role of gallbladder stasis in the pathogenesis of cholesterol gallstones.
Aim: We explored whether ERα activated by estrogen impairs signal transduction by inhibit-
ing CCK-1 receptor (CCK-1R)-G protein coupling on gallbladder smooth muscle. This
sequence should decrease CCK-induced gallbladder contraction and promote cholesterol
gallstone formation. Methods: At weaning, female ERα (-/-) and (+/+) mice were ovariectom-
ized. At 8 wk of age, the mice were implanted subcutaneously with pellets releasing 17β-
estradiol (E2) at 6 μg/day and treated IP with the CCK-1R antagonist devazepide at 0 or 1
mg/day. Gallbladder contraction in response to exogenous CCK-8 was determined. Gene
expression and protein levels of CCK-1R, ERα, Gαi3 and Gαs were measured by real-time
PCR and Western methods. During 56 days on a lithogenic diet (1% cholesterol and 0.5%
cholic acid), cholesterol crystallization and gallstones in gallbladder biles were quantified
by microscopy. Results: Fasting gallbladder volumes (61±15 μl) were larger (P<0.01) in (+/
+) mice than in (-/-) mice (30±10 μl) in exposure to high doses of E2. Expression levels of
ERα were up-regulated and expression levels of CCK-1R and CCK binding capacity of
gallbladder CCK-1R's were reduced in the gallbladders of (+/+) mice treated with E2. Thus,
CCK-8-mediated gallbladder emptying was diminished and resulted in enlarged fasting and
residual gallbladder volumes, mostly contributable to impaired gallbladder contractility. In
contrast, these gallbladder phenotypes were not detected in (-/-) mice exposed to E2,
in which fasting and residual gallbladder volumes remained normal. Whereas, protein
concentrations of Gαi3 were significantly reduced and Gαs content was increased in the
gallbladders of (+/+) mice at 56 days compared with those on day 0, this was not the case
in (-/-) mice. When the gallbladder CCK-1R was blocked by its antagonist devazepide, (+/
+) mice showed the E2 modulation of G protein function with an increase in protein
concentrations of Gαs but not in Gαi3. In contrast, these changes were not observed in (-/-
) mice. Thus, cholesterol crystallization and gallstone formation were greatly accelerated in
(+/+) mice compared with (-/-) mice (80% vs 20%). Conclusions: The E2-ERα pathway
regulates gallbladder motility through both CCK-1R and G proteins in the gallbladder.
Overexpression of ERα stimulated by E2 induces signal-transduction decoupling in the
gallbladder smooth muscle and decreases gallbladder contractile in response to CCK, which
results in gallbladder stasis and enhanced cholelithogenesis.
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Deficiency of the Potent Calcification Inhibitor Fetuin-a Promotes Cholesterol
Crystallization in Murine Gallbladder Bile In Vivo
Sonja Hillebrandt, Cora Schäfer, Willi Jahnen-dechent, Frank Lammert
Most gallstones have a pigment-rich, calcium salt nidus, consistent with calcium precipitation
favoring heterogeneous nucleation of cholesterol crystals in bile. Recently we have shown
that serum protein alpha2-Heremans-Schmid glycoprotein (AHSG, A.k.a. fetuin-A) is a
systemically acting potent inhibitor of ectopic calcification (Schäfer et al. J Clin Invest
2003;112:357-66). Since fetuin-A is also present in bile, our aim now was to assess its
effect(s) on cholesterol crystallization in gallbladder bile In Vivo. Methods: Sixty male and
female fetuin-A knockout [Ahsg (-/-)] mice and Ahsg (+/+) wild-type littermates (genetic
background C57BL/6) were challenged with the lithogenic Paigen diet (containing 15%
dairy fat, 1% cholesterol and 0.5% cholic acid) for up to 4 weeks. AHSG concentrations
were measured using ELISA. To characterize crystallization phenomena in fresh bile, we
employed polarizing and phase contrast microscopy. Lipid compositions of pooled biles
were determined by standard methodology, and gallbladder volumes were determined gravi-
metrically. Results: All Ahsg (-/-) mice appear phenotypically normal on chow. Upon chal-
lenge with the lithogenic diet, Ahsg (-/-) mice display small and aggregated liquid crystals
in gallbladder bile, and 90% precipitate cholesterol monohydrate crystals after 4 weeks. In
contrast, wild-type controls also develop liquid crystals, but only 8 - 35% form cholesterol
crystals after 2 to 4 weeks of feeding the lithogenic diet. Of note, semiquantitative crystal
scores [0 - 3] are significantly (P < 0.01) higher in Ahsg (-/-) mice (0.90 ± 0.17), compared to
controls (0.30 ± 0.12). Interestingly, “anhydrous” cholesterol crystals, which might represent
transient intermediate polymorphs (Weihs et al. J Lipid Res 2005;46:942-8) are exclusively
observed in fetuin-A knockout mice after 2 and 4 weeks. Cholesterol saturation indexes
and gallbladder volumes do not differ significantly between knockout and wild-type mice.
Conclusions: Taken together, our data demonstrate a potential role of fetuin-A as inhibitor
of crystallization in gallbladder bile In Vivo. Since calcium affects solid crystal number in
proportion to its concentration but does not influence cholesterol crystallization pathways
In Vitro (Wang & Carey J Lipid Res 1996;37:606-30), fetuin-A deficiency might modulate
distinct gallbladder phenotypes.
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Changes of Morpho-Functional and Redox Status of Colonic Mucosa Parallel
Liver Injury in the Early Phase of Bile Duct Ligation
Piero Portincasa, Ignazio Grattagliano, David q.-h. Wang, Helen Wang, Michele Vacca,
Maria lucia Caruso, Antonio Moschetta, Giuseppe Calamita, Giuseppe Palasciano
Background: Whereas long-term cholestasis results in changes of intestinal function including
increased permeability to hepatotoxins, the overall effects of short-term bile duct ligation
(BDL) remain poorly understood. Aims: to asses intestinal morphology, function, and redox
status in colonic mucosa of rats undergoing short-term BDL. Methods: BDL and sham-
operated rats were studied for histology, changes in protein redox status in the colon and
liver at days 1, 3, 7, and 10. Electrophysiological changes in colonic mucosa were studied
in the Ussing chambers. Results: No major change at colonic and liver level was observed
in the sham group and BDL 1-3 days. In the colon, BDL was associated with reduced
epithelium thickness plus vanishing phenomena in 40% (day 7) and 70% (day 10) rats. At
day 10, there was a significant decrease (P<0.05 vs. sham) of total protein content (from
167±12 mg to 130±16 mg protein/g tissue) as well as total glutathione (from 0.9±0.1 to
1.2±0.1 umol/g tissue), protein sulfhydryls (from 20.8±3.1 to 29.6±3.6 nmol/mg protein)
as well as glutathione-peroxidase and reductase activities. By contrast, increased were oxidized
proteins (from 0.6±0.2 to 1.3±0.3 nmol/mg protein) as well as oxidized glutathione. Colon
transmural potential difference, short-circuit current and transepithelial resistance showed
a mean decrease of 50% at day 10 BDL. In the liver, ongoing cholestasis was associated
with oxidative changes especially in mitochondria, where GSSG/GSH ratio increased from
3.3±1.1% to 9.7±1.7% at day 10 (P<0.05), protein sulphydrils decreased and correlated
negatively with glutathione-protein mixed disulfides (r=-0.807, P<0.001). Glutathione-per-
oxidase and reductase activities were significantly increased. Conclusions: Early cholestasis
results in distinctive functional and oxidative changes of colonic mucosa and parallel hepatic
oxidative damages.
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Activated Muscularis Macrophages Contribute to Muscle Cell Dysfunction in
Cholesterol Gallstone Patients
Michele pier luca Guarino, Simone Carotti, Sergio Morini, Giuseppe Perrone, Annamaria
Altomare, Rossana Alloni, Renato Caviglia, Sara Emerenziani, Michele Cicala
Activated muscle layer macrophages seem to be related to impaired muscle contractility at
different level of the gastrointestinal tract since they produce excessive amount of inflammat-
ory mediators such as prostaglandins. In patients with cholesterol gallstones a reduced
gallbladder (GB) muscle cell contractility together with chronic inflammatory changes in
the mucosa have been reported, but the presence and the role of macrophages in the muscle
layer has never been evaluated. The hydrophilic ursodeoxycholic acid (UDCA) has been
reported to restore GB contractility and to antagonise macrophage activation in the liver.
AIM: to determine 1) the presence of macrophage infiltrate and cyclooxygenase-2 (COX-2)
expression in the GB muscle layer and the relation with muscle cell contractility in cholesterol
gallstone patients, 2) the effect of short-time UDCA administration. METHODS: GB tissue
was obtained from 8 patients with cholesterol gallstone untreated or 8 treated with UDCA
(10 mg/kg/day) for 8 weeks prior to surgery; 6 patients with GB polypoid lesion represented
the control group. The presence of monocyte-macrophages (CD68 positive) and COX-2
expression was determined immunohistochemically. Contraction was studied in enzym-
atically dissociated muscle cells. RESULTS: At the muscle layer, positivity of COX2 was
expressed exclusively by monocyte-macrophages infiltrating. The presence of CD68 positive
cells in the muscle layer was significant increased in gallstone patients compared to control
group (p<0.05). In UDCA treated patients, CD68 positive cells were significantly decreased
when compared to untreated patients (p<0.05). Treatment with UDCA significantly improved
dose-dependent muscle cell contraction. The maximal contraction induced by CCK-8 (10-
8 M) after UDCA was 25.1±3 (mean±SD) higher than that in untreated patients (12±4;
p<0.001). CONCLUSIONS: In cholesterol gallstone patients a relevant inflammatory mono-
cyte-macrophage infiltrate is present in the GB muscularis. UDCA significantly improves
GB muscle cell contraction as well as decreases the amount of macrophages in the muscle
layer. It is conceivable that in cholesterol gallstone patients activated macrophages contribute
to muscle cell dysfunction by means of prostaglandin release.
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Detection of Colorectal Adenoma and Cancer By Blood-Based Analysis of DNA
Methylation
Cathy Lofton-day, Fabian Model, Theo Devos, Reimo Tetzner, Matthias Schuster, Ralf
Lesche, Andrew Sledziewski, Robert Day, Matthias Ebert
Background: Colorectal cancer is one of the most common cancers world-wide and patients
have been shown to benefit from early detection of the disease through regular screening.
New population-based screening tests should attain both high sensitivity and high specificity
to be effective. Tests should also be easily available and acceptable to the patient. Our aim
is to provide an easily administered, blood-based test for detection of colorectal adenoma
in order to prevent colorectal cancer. Methods: Plasma samples were collected from patients
with colorectal cancers and polyps to test sensitivity of the methylation-based marker assay
and from colonoscopy-verified healthy individuals to test specificity. In addition, to identify
conditions that could result in false positives, we analyzed a number of critical controls
including various cancers other than colorectal cancer and acute and systemic conditions.
For the analysis of samples, free-DNA was first extracted from plasma samples using an
automated MagNaPure device, then bisulfite treated to preserve methylation information
and lastly analyzed for methylation of the Septin 9 and ALX4 gene by real-time PCR. Results:
Real-time PCR analysis of Septin 9 methylation in free-DNA from colorectal cancers plasmas
resulted in detection of 176/336 (52.4%) cancers. In the colonoscopy verified healthy samples
15/316 were positive (4.7%). 4/45 polyps < 1 cm were detected (8.8%) and 15/65 polyps
> 1cm were detected (23.1%). However, all polyp patients (11/11) with tubular or villous
adenomas and a size of >1cm were identified when Septin9 and ALX4 methylation were
both assessed. Of 93 other cancer plasma tested, 9 were found to be positive (9.7%) and
of 196 acute local and systemic diseases, 23 were detected (11.7%). Conclusions: Methylation
analysis of free-DNA from plasma using a real-time assay for the Septin 9 gene results in
sensitive and specific detection of colorectal cancer. Detection of large adenomas with
advanced histology was possible when ALX4 and Septin 9 were both assessed. Thus, our
study indicates that early and non-invasive colorectal cancer diagnosis may be feasible and
could be extended even to preneoplastic lesions which would have a positive effect on
cancer incidence and prognosis.
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Stool DNA Screening for Colorectal Neoplasia: Prospective Multicenter
Comparison with Occult Blood Testing
David A. Ahlquist, Daniel J. Sargent, Theodore R. Levin, Douglas K. Rex, Dennis J.
Ahnen, Kandace Knigge, M. P. Lance, Charles L. Loprinzi, Lawrence J. Burgart, James E.
Allison, Michael J. Lawson, John M. Millholland, Jonathan J. Harrington, Shauna L.
Hillman, Mary E. Devens
Stool DNA testing has emerged as an approach to colorectal cancer (CRC) screening. A stool
DNA test (SDT) that incorporates an improved marker panel and DNA capture method was
studied. Aim: To compare the accuracy of SDT with that of Hemoccult (HO) and Hemoccult
Sensa (HOS) for the detection of screen-relevant neoplasia (SRN (CRC, high grade dysplasia
(HGD), and adenomas≥ 1cm)). Methods: This blinded multicenter NCI study (CA 89389)
comprised 4010 asymptomatic average risk adults. Subjects collected 3 whole stools without
preservative buffer and smeared HO/HOS cards with same-day shipment to a central pro-
cessing facility. SDT was performed on one stool/subject at EXACT Sciences, and HO/HOS
from 3 stools/subject were developed at Mayo Clinic. SDT was positive if any marker (APC
scan, Kras, methylated vimentin, long DNA) was abnormal. HO and HOS were positive if
any window on the 3 cards reacted. After stool collection, a verified complete colonoscopy
served as the gold standard. All SRN histology was confirmed. Test comparisons are based
on random subjects from SRN subsets and from the colonoscopically-normal group. Addition-
ally, stools from 20 symptomatic CRCs (10 with preservative buffer, 10 without) and from
18 healthy controls (8 with buffer, 10 without) were sent blindly for SDT analysis. Results:
For the 218 asymptomatic subjects selected for comparisons (median age 67, 51% men),
stool test results are displayed (Table). CRC detection rates by individual SDT markers were
42% by APC, 37% by vimentin, 16% by Kras, and 5% by long DNA. Among the supplemental
symptomatic CRCs, long DNA was positive in 50% of buffered stools but in none of the
unbuffered stools (p= 0.01), and it remained negative with buffered and unbuffered stools
from controls. With buffered stools, the full panel SDT was positive in 90% of symptomatic
CRCs and none of the controls. Conclusions: 1. In the screening setting, SDT detects
significantly more SRNs than does HO (3X more) and HOS (2X more), but at significantly
lower specificity. 2. The substantially higher adenoma detection rate by SDT could translate
into more effective CRC prevention. 3. Use of a buffer with stool collection preserves long
DNA yield and may have improved SDT performance had it been applied in this study.
*Unbuffered stools
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Prevalence of Aberrant Crypt Foci: An Ancillary Study to Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial
Matthew Mutch, Robert E. Schoen, James W. Fleshman, Christopher J. Rall, David
Seligson, Susan Dry, Aline Charabaty, David Chia, Asad Umar, Paul Pinsky
Introduction: Aberrant crypt foci (ACF) are putative precursors of colorectal adenomas and
postulated as a potential biomarker for colorectal cancers. However, there is limited data
regarding the prevalence and risk factors for these lesions. Methods: In a multicenter study,
a sample of subjects who completed the baseline flexible sigmoidoscopy examination in
the PLCO trial was recruited ACF examination. A standardized protocol using magnified
endoscopy and mucosal staining with methylene blue was implemented to detect and biopsy
ACF in the rectum. Results: A total of 511 (66% male) patients from four institutions were
examined. Two hundred seventeen (42%) of the patients had no prior history of adenoma,
168 (33%) patients had a non-advanced adenomas, and 126 (25%) had an advanced
adenoma. Of all subjects, 32% had no ACF identified, 43% had 1-3 ACF, 19% had 4-6
ACF, and 5% had ≥7 ACF identified (Table). The mean number of ACF did not differ
across the three categories of patients (Table). Of the 206 endoscopic ACF examined histolog-
ically, 60% were confirmed as ACF. A logistic model was used to identify risk factors for
the presence of any endoscopically identified ACF, and for patients with≥3 ACF. We found
that current smoking (OR 2.6.; 95% CI 1.2-5.5) and former smoking (OR 1.6; 95% CI 1.1-
2.4), were associated with any ACF and that BMI > 30 (OR=0.55; 95% CI 0.35-0.85) was
associated with a lower prevalence of ACF. For patients with ≥ 3 ACF, current smoking
(OR 4.1, 95% CI 2.1-8.0) was the only risk factor, and BMI > 30 (OR=0.6; 95% CI 0.4-
0.9) was again protective. Sixty percent of all patients in this study reported regular ASA
or NSAID usage, and there was no difference in the prevalence of ACF between users and
non-users. Also, age and family history of CRC were not associated with ACF. Conclusions:
ACF were observed commonly, but in contrast to the literature, prior history of adenoma
or advanced adenoma was not associated with increased number or prevalence of ACF.
Smoking was associated with ACF and BMI >30 was protective, but ASA and NSAID use
did not impact the prevalence of ACF. These results raise concern about the use of ACF as
a biomarker of CRC.
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Increased Biomarkers of Colorectal Carcinogenesis Associated with Obesity
and Roux-en-Y Gastric Bypass (RYGB)
Anita Sainsbury, Gerard Robins, Robert Goodlad, Stephen Pollard, Mark Hull
Introduction: The mechanistic basis of the link between obesity and increased colorectal
cancer (CRC) risk is unclear. One hypothesis is that chronic inflammation associated with
obesity drives colorectal carcinogenesis. Therefore, we compared mucosal epithelial biomark-
ers from severely obese patients and individuals with a normal body mass index (BMI). The
same parameters, as well as levels of mucosal and circulating pro-inflammatory mediators,
were measured in the same patients before and after Roux-en-Y gastric bypass (RYGB).
Methods: Rectal mucosa and serum were obtained before and 6 months post-RYGB from
26 severely obese patients and 21 normal BMI individuals. In each case, crypt mitosis, area
and fission were determined in 40 micro-dissected crypts, in a blinded manner. Changes
in mucosal pro-inflammatory gene mRNA levels were quantified by real-time RT-PCR using
the ΔΔCt method, with GAPDH as the control transcript. Serum levels of C-reactive protein
(CRP), IL-6 and TNFα were quantified by immunoassay. Results: Patients with severe obesity
(mean BMI [SEM] 54.4 [2.0] kg/m2) had a significantly higher mean crypt mitosis count
(median 4.2), mean crypt area (median 0.035 mm2) and number of biopsies with crypts in
fission (54%) than individuals with a normal BMI (mean 22.5 [0.5] kg/m2) who had values
2.7 (p<0.001), 0.028 mm2 (p<0.001) and 20% (p<0.001) respectively. Following RYGB,
mean BMI was 41.8 [1.7] (23.4% decrease). This was associated with a mean 2.1 fold
increase in crypt mitosis count [95%CI 1.6-2.6] (with upward expansion of the crypt
proliferative zone) and increased crypt fission (68%; p<0.001). At the same time, mucosal
COX-1 (mean fold increase [2ΔΔCt] 7.5), COX-2 (4.1) and IL-6 (3.4) mRNA levels increased
significantly. There was no significant difference in IL-1, TNFα and MIF transcripts. The
mean [SEM] serum CRP level fell from 8.6 [1.6] to 3.8 [0.9] mg/l (p<0.001) and serum IL-
6 fell from 5.2 [0.5] to 3.2 [0.3] pg/ml (p<0.01). By contrast, serum TNFα levels increased
(1.2 [0.07] vs 1.7 [0.08] pg/ml; p<0.001). Conclusion: This is the first demonstration of
an association between increased mucosal epithelial biomarkers of carcinogenesis risk and
obesity. Surprisingly, there was a further increase in mucosal biomarkers following RYGB-
induced weight loss, which was associated with increased mucosal pro-inflammatory tran-
script levels (although circulating CRP and IL-6 concentrations decreased). These data have
important implications for future CRC risk in obese individuals, especially after RYGB. We
hypothesize that changes in mucosal pro-inflammatory gene expression may be due to
altered colonic luminal factors following RYGB.
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Tumor Budding, Intratumoral and Peritumoral Lymphocytic Infiltration in
Colorectal Cancer: Pathogenetic Aspects At the Invasive Margin and Clinical
Correlations
Alessandro Lugli, Inti Zlobec, Kristi Baker, Sabrina Roth, Parham Minoo, Shinichi
Hayashi, Luigi Terracciano, Jeremy Jass
Background and aim: Morphological findings at the invasive tumor margin provide independ-
ent prognostic information in colorectal cancer (CRC). A diffusely infiltrative margin is
associated with tumor budding in which there is a transition from glandular structures to
single cells or clusters of up to four cells at the invasive margin. Reliable assessment of this
feature can only be achieved in surgical specimens. The aim of this study was to identify
immunohistochemical markers of budding within the main tumor body that can be applied
to pre-operative biopsies. Additionally, we hypothesised that this approach to predicting
budding would have limitations on both sensitivity and specificity as a result of the active
destruction of buds by immune cells. We therefore correlated the findings with the presence of
peritumoral lymphocytes (PTLs) and tumor infiltrating (intra-epithelial) CD8+ lymphocytes
(TILs). Methods: Twenty potential markers of tumor budding (APAF-1, APC, b-catenin, bcl-
2, CD44s, E-cadherin, EphB2, Her2/neu, MST1, MUC1, MUC2, p21, p27, p53, pAKT,
pERK, pSMAD2, RHAMM, RKIP, TGF-b) were evaluated in tissue microarrays (TMAs)
obtained from 1,164 DNA mismatch repair-proficient CRCs randomized into two study
groups (Group 1 n=582, Group 2 n=582). Optimum scoring cut-offs were determined by
receiver operating characteristic (ROC) curves. The findings were correlated with budding,
TILs, PTLs and survival. Results: In Group 1, significant associations between tumor budding
and MST1, E-cadherin, EphB2, bcl-2, p21, CD44, APAF-1 and TGF-b were obtained. The
final multivariate model included E-cadherin (p = 0.028), APAF-1 (p = 0.006), and TGF-
b (p = 0.018). Tumor budding was associated with MST1, E-cadherin, EphB2, bcl-2,
pSMAD2, CD44, b-catenin, APAF-1 and RKIP in study Group 2. The optimal multivariate
model included E-cadherin (p = 0.003) and APAF-1 (p = 0.005) (sensitivity 70.3% and
specificity 48.2% for loss of one and/or other). PTLs were observed more frequently in CRCs
with loss of either E-cadherin or APAF-1 that were budding-negative. PTLs and TILs were
strongly correlated. The absence of TILs increased the adverse prognostic impact of E-
cadherin and APAF-1 loss. Co-occurrence of E-cadherin loss, APAF-1 loss and low TIL
count was an independent prognostic factor. The findings were verified in whole tissue
sections from 88 CRCs with known KRAS mutation status (which was not associated with
budding). Conclusions: Loss of expression of E-cadherin and APAF-1 within the main body
of CRCs are independent predictors of tumor budding. The prognostic benefit of lymphocytic
infiltration may be explained by the immune destruction of budding cells.
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Mdr1 P-Glycoprotein Expression in Human Gastric Tissue: From Ontogenesis
to Carcinogenesis
Alba Rocco, Debora Compare, Patrizia De colibus, Giovanni Autiero, Germana De nucci,
Brunella Marotti, Loredana Pica, Gerardo Nardone
Tumorigenesis can be imagined to mirror organogenesis. Indeed, tumorigenesis seems to
inversely recapitulate the step-wise process of development. In both processes apoptosis
plays a key role. Recently, it has been reported that P glycoprotein (P-gp), one of the main
factor implicated in cancer multidrug resistance, can act as a primary antiapoptotic agent.
P-gp is implicated in apoptotic process by reducing the pool of plasma membrane phospholip-
ids or by inhibiting caspase-mediated apoptosis. P-gp, undetectable in normal gastric mucosa,
is overexpressed in up to 50% of gastric cancers. Aim: To study P-gp expression in normal
gastric mucosa, in preneoplastic and neoplastic gastric lesions and during stomach develop-
ment. Methods: The study was comprised of 40 H. pylori-negative normal gastric mucosa
samples, 134 H. pylori-positive chronic gastritis with (36) and without (98) intestinal meta-
plasia, 69 gastric cancers (45 intestinal type and 24 diffuse type) and 10 abortive human
fetuses between 17th and 36th week of gestational age. The specimens were obtained during
upper endoscopy in patients with gastritis, gastrectomy in patients with cancer and autopsy
in fetuses. P-gp expression was investigated by immunohistochemisty (anti MDR1-glycopro-
tein p, dilution 1:150) and Western Blot. Results: P-gp was undetectable in all normal gastric
mucosa sample while it was detected in 41/77 H. pylori-positive chronic gastritis without
metaplasia and in all (36/36) H. pylori-positive chronic gastritis with metaplasia. In gastric
cancer, an intense P-gp immunostaining was found in 40/45 of intestinal type and in 4/24
of diffuse type. In human fetal stomach P-gp was expressed in the glandular cells progressively
stronger from earlier stage (17th and 19th week) to later stage (from 24th -to 36th week).
Further, P-gp was found expressed in blood vessel wall but not in the stromal cells. Conclu-
sion: Our data suggest the P-gp plays a key role during organogenesis and in the early phase
of gastric tumorigenesis.
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Mesenchymal Stem Cells Forced to Replicate Acquire P53 Mutations and
Clonally Expand in the GI Tract of Mice
Hanchen Li, Xueli Fan, Ramesh C. Kovi, Steven R. Grossman, Evelyn Kurt-jones, Jean
marie Houghton
Background and Significance: Many cancers of the GI tract, including inflammation related
colon, gastric and esophageal cancer arise in a field of defective tissue (field defect). Field
defects are widespread, include seemingly normal appearing or dysplastic cells and commonly
carry p53 mutations. Recent evidence suggests that bone marrow derived mesenchymal
stem cells (MSC) play a role in gastrointestinal mucosal repair, and cancer formation. We
hypothesize that MSC tracking to areas of inflammation undergo mutations and form the
basis of this abnormal field of tissue. Here we investigate the accumulation of p53 mutations
in MSC forced to replicate, and tract the fate of these cells In Vivo. Methods: MSC were
isolated from 4-6 week old C57BL/6 male mice and confirmed to be CD31(-),CD34(-
),CD45(-), desmin(-), alpha smooth muscle actin(-) S100(-),vimentin (-), and CD44(+) by
a combination of IHC and FACS. Cells were continually passaged and 13 subpopulations
isolated and stably transfected with monomeric-DS red (DS-redMSC). Doubling time was
evaluated by cell counts and CSFE, p53 status determined by western blot, IHC and direct
p53 sequencing. In Vivo activity of cells was determined by tail vein injection of 5 million
cells into a non-irradiated female C57BL/6 mice. Mice receiving 5 million freshly isolated
male GFP-MSC with or without prior irradiation served as controls. Mice were euthanized
at 1, 3, 6 and 9 months and the luminal GI tract examined. Results: After destabilization
in culture, MSC have a doubling time of 29 hours compared to 55 hours for age matched
non-destabilized cells. p53 sequence analysis revealed wt p53 sequence in the control MSC
and several missense mutations clustered in the DNA binding domain in the DS-redMSC,
correlating with common mutations found in human colorectal cancer. After IV injection
into mice, control GFP labeled MSC were recovered as single cells, at low frequency from
the GI tract of mice at all time points evaluated. DS-redMSC engrafted infrequently at early
time points, however the number of recovered cells increased with the age of the mouse.
At 6 and 9 months, clusters of cells were recovered suggesting retention of and clonal
expansion of individual cells creating a field of abnormal issue. Conclusion: Using mesenchy-
mal stem cells destabilized in culture, we show MSC acquire clinically relevant point muta-
tions in p53, display a growth advantage and comprise a field of abnormal tissue similar to
field defects seen associated with human cancer. Challenge with organ specific carcinogens
is ongoing to determine if tumors will arise in these areas.
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Overepression of IL-1β Induced Gastric Inflammation and Carcinoma Through
Dysfunction of Immunity and Change of Gastric Microenvironment in
Transgenic Mice
Shuiping Tu, Guanglin Cui, Shigeo Takaishi, Govind Bhagat, Evelyn A. Kurt-jones, Iva
Smirnova, Kelly Betz, Melitta Penz-oesterreicher, Timothy C. Wang
Background: Interleukin-1β(IL-1)β is a multifunctional, proinflammatory cytokine that has
profound effects on immunity and gastric physiology. IL-1β polymorphisms have been
associated with an increased risk of gastric cancer although direct evidence for a pathogenic
role in cancer has been lacking. We have previously reported that human IL-1β (hIL-1β)
transgenic mice with targeted expression of a mature secreted form of hIL-1β cDNA in the
stomach using the murine H/K-ATPase promoter have spontaneously developed gastric
inflammation and dysplasia. Here, we investigate mechanism of IL-1β-induced-inflammation
and carcinogenesis. Methods: Iradiated lethally IL-1β and wild type mice were transplanted
with whole bone marrow from β-actin-EGFP transgenic mice. The mice were infected with
Helicobacter felis (H. felis) one month after transplantation and then received IL-1 receptor
antagonist (IL-1RA) or saline for 12 weeks. Inflammation and pathological changes in the
gastric mucosa were examined histologically. The levels of various cytokines in the gastric
mucosa and sera were determined by ELISA. Gene expression was determined by semi-
quantitative RT-PCR and protein expression by immunohistochemistry and Western blot.
Gastric leukocyte subsets and levels of circulating progenitors were analyzed by FACS.
Result: hIL-1β transgenic mice expressed high levels of human IL-1β in the gastric mucosa
resulting in hypochlorhydria, hypergastrinemia, and chronic active gastritis with a significant
increase in the number of activated T cells, Neutrophils, and macrophages in the gastric
mucosa. Older mice showed spontaneous progression to metaplasia and dysplasia, and 30%
male IL-1β transgenic mice progressed to gastric cancer. Progression to gastric cancer
correlated with increased circulating levels of TNF-α and IL-6 and changes in the gastric
microenvironment, leading to overexpression of COX-2, MMP-9, α-SMA, and VEGF. H.felis-
infection accelerated the development of gastric inflammation and resulted in increased
mobilization of bone marrow-derived cells (BMDC) and accelerated gastric engraftment.
Treatment of infected hIL-1β transgenic mice with (IL-1RA)inhibited cytokine production,
mobilization of circulating BMDC, and histologic progression. Our results demonstrate for
the first time that IL-1β overexpression was sufficient to induce gastric neoplasia, possibly
by deregulating the immune response and altering tumor microenvironment.
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Identification of a Specific Bone Marrow-Derived Cell Subset That Contributes
to the Gastric Epithelium
Tomoyuki Okumura, Shigeo Takaishi, Sheng-wen Wang, Vivian Ng, Anil K. Rustgi,
Timothy C. Wang
Background: Recent studies from our laboratory showed that chronic Helicobacter felis
infection of C57BL/6 mice induces repopulation of the gastric epithelium with bone marrow-
derived stem cells (BMDC), and subsequently, these cells progress to intraepithelial cancer.
Although the mesenchymal stem cell (MSC) population was suggested as a probable source
of the BMDCs, direct evidence of MSC contribution to the gastric epithelium has not yet
been reported. Methods: MSCs were established from wild type C57BL/6 mice by culturing
whole bone marrow in plastic tissue culture plates. The mouse K19 promoter and EGFP
gene were cloned and the K19-EGFP expression construct was generated. MSCs were
transfected with the K19-EGFP construct or a K19-mock vector and individual stable clones
were established. MSC clones were treated with gastric extract for 5 days and expression
of gastric phenotypic markers (such as K19, TFF2, MUC5AC, MUC6, H/K-ATPase, Intrinsic
Factor, and Chromogranin A) was detected by real time RT-PCR. MSC clones were injected
into the stomachs of C57BL/6 mice and sections were prepared two weeks after injection
and the expression of cytokeratins and H/K-ATPase was determined by immunostaining
using Texas Red conjugated antibodies. Results: GFP was expressed in 3 of 11 stable MSC
clones (designated No3, No4, No5) established by transfection of the K19-EGFP vector.
The percentages of GFP positive cells assessed by flow cytometry were 10.0%, 96.2%, and
78.6% for K19GFP clones No3, No4, and No5, respectively. Real time PCR analysis showed
65-, 40-, and 35- fold increases in K19 mRNA expression level in k19GFP clones No3,
No4, and No5, respectively, compared to parent cells and mock transfectants. All 3 clones
demonstrated osteocyte and adipocyte differentiation under appropriate culture conditions.
After incubation with gastric extract, the mRNA expression of gastric phenotypic markers
were increased 60-, 300-, and 170- fold in K19GFP clones No3, No4, and No5, respectively,
while less than 10-fold increases were observed in parent cells and mock transfectants. After
injection of MSC clones into the gastric wall of C57BL/6 mice, small GFP-positive epithelial
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nodules were noted in stomachs injected with K19GFP No4, while fewer numbers of GFP
positive cells scattered epithelial cells were seen in animals injected with K19GFP clones
No3, No5, and MSCs from a control chicken beta-actin EGFP mice. Cytokeratin and H/K-
ATPase expression were detected in GFP positive glandular cells in stomachs injected with
k19GFP clone No4. Conclusion: Our study suggests that bone marrow-derived MSCs which
strongly express K19 can contribute to the gastric epithelium.
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A Molecular Signature of Transdifferentiation of Chief Cells Into Spasmolytic
Polypeptide Expressing Metaplasia (SPEM)
Koji Nozaki, Masako Ogawa, Sachiyo Nomura, Bonnie Lafleur, James R. Goldenring
Oxyntic atrophy is a critical precursor for the development of gastric metaplasia and cancer.
Mice or rats treated with high doses of oral DMP777 (>200 mg/kg/d) demonstrate a rapid
loss of parietal cells with three days of administration. After 7 to 10 days of oxyntic atrophy,
Spasmolytic Polypeptide Expressing Metaplasia (SPEM) develops in the fundus. However,
in gastrin KO mice, we have observed the rapid induction of metaplasia after only one day
of DMP-777 treatment. The emergence of SPEM cells expressing both intrinsic factor and
TFF2 after only one day of DMP-777 treatment has led to the hypothesis that SPEM arises
from transdifferentiation of chief cells. Methods: To examine this hypothesis more directly,
we have microdissected chief cells from the very bases of untreated gastrin knockout mice
as well as SPEM cells at the base of fundic glands after 1 and 3 days of treatment with
DMP-777. Total RNA was prepared from 10,000 cells isolated from 4 different mice in each
group and used to probe Affymetrix Mouse 2.0 gene microarrays. Genes up-regulated greater
than 4-fold were identified and selcted markers were validated by immunohistochemistry.
Results: We did not detect any pro-apoptotic genes in the cohort of gene transcripts up-
regulated on both 1 and 3 days of treatment. Rather, we did identify 20 up-regulated genes
involved in the G1/S transition including 5 MCM proteins, Brca1, Ris2, RAD51, TACC3
and ligase1. We have confirmed by immunocytochemistry the upregulation of MCM3 as
well as TACC3 in SPEM cells located at the base of fundic glands in mice treated for 1 or
3 days with DMP-777. All of these changes are consistent with alterations moving towards
a proliferative phenotype. However, while we have previously noted that treatment of gastrin
KO mice with DMP-777 causes the emergence of BrdU labelled cells at the bases of fundic
glands, the increase in labeling does not account for the emergence of the SPEM phenotype.
Interestingly, MCM3 expressing cells were far more widely distributed within SPEM cells
compared with BrdU labeled cells. Conclusions: The up-regulation of proteins involved in
the G1/S interface suggests an increase in proliferative cells at the bases of fundic glands,
but is also consistent with transdifferentiation of chief cells into SPEM, since such changes
would require a global change in the transcriptome requiring unwinding of DNA (the major
function of the MCM complex). Still the presence of BrdU labeled cells at the bases of glands
indicates that some SPEM cells may eventually become self-renewing or be influenced by
inflammatory regulators towards metaplastic expansion or dysplastic transformation.
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5asa Attenuates Stem Cell Activation in Colitis-Induced Cancer
Gery Grimm, Jeffrey Brown, Jennet Manjali, Navdha Mittal, Elizabeth Managlia, Goo Lee,
Ramanarao Dirisina, Terrence A. Barrett
Background and Aims: In colitis-induced cancer, oxidative stress correlates with crypt cell
proliferation and elevated p53. We found that epithelial proliferation increased in a genetic
model of elevated PI3 kinase signaling (Mx1Cre x PTENfl/fl) where increased intestinal stem
cell (ISC) activation was detected by nuclear (activated) beta-catenin staining in crypt epithe-
lial cells (He et al Nat Genetics 2004, 2006). In colitis (IL-10-/- mice), we detected increased
oxidative stress, PI3K signaling and numbers of activated ISC associated with dysplasia and
progression to invasive cancer. As 5ASA is a potent oxygen radical scavenger shown to
reduce dysplasia in ulcerative colitis, we examined effects of 5ASA on inflammation, colitis-
induced dysplasia, ISC activation, p53 levels and PI3K signaling (phospho-Akt, P-Akt) in
IL-10-/- mice. Methods and Results: 100% of IL-10-/- mice fed piroxicam for 2 weeks
(240ppm/320ppm) developed colitis and 75% had evidence of dysplasia by day 28. Sub-
sequent progression to cancer was seen at day 70. Low dose (LD) and high dose (HD) 5ASA
regimens were given by feeding 100mg 5ASA/250g chow or 300mg/250g respectively. To
assess the suppressive effect of 5ASA on colitis-induced intestinal stem cell activation, 5ASA
treatment was initiated on d28 and continued through day 70. LD treatment was relatively
ineffective with only a 3% reduction in histologic inflammation and no effect on dyplasia;
however, HD therapy reduced inflammation by 92% while abrogating the appearance of
dysplasia. HD treatment reduced ISC activity demonstrated by a 76% decrease in nuclear beta-
catenin staining and 19% reduction in protein levels shown by western blot. Additionally, HD
treatment reduced apoptosis (80% decrease in TUNEL positive cells and 42% decrease in
nuclear p53 protein levels). Decreased protein levels of P-AKT (19%) indicate the HD 5ASA
also has an effect on the PI3K pathway. Conclusion: IL-10-/- mice develop dysplasia and
cancer related to intestinal stem cell activation through PI3K signaling. 5ASA therapy reduced
nuclear beta-catenin, p53 levels and the progression of dysplasia and cancer. Taken together,
these data suggest that 5ASA therapy alters intestinal stem cell activation in a model of
colitis-induced cancer. As aberrant stem cell activation has been linked to the onset of
colorectal cancer, it is possible that the effects of 5ASA on stem cell activation in the
current model may help explain the chemo preventative effect of 5ASA in patients with
ulcerative colitis.
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Identification of a Putative Intestinal Stem Cell and Tumor Initiation Marker;
Dcamkl-1
Randal May, Terrence Riehl, Clayton Hunt, Brian K. Dieckgraefe, Shrikant Anant,
Courtney W. Houchen
Introduction: Colorectal cancers arise from stem cells, located near the base of intestinal
and colonic crypts. Only a few cells however, within the tumors are stem cells. Identifying
gut stem cells is difficult, because no definitive intestinal stem cell markers are known. The
canonical Wnt cascade is a critical regulator of stem cells. Wnt signaling, which is activated
in many cancers induces β-catenin translocation to the nucleus. APC mutation leads to
dysregulated stabilization of β-catenin. DCAMKL-1, expressed in post-mitotic neurons, was
recently identified in small intestinal and gastric epithelial progenitor populations, suggesting
that it may be a potential stem cell marker. Aims: 1) To study the effects of APC mutation
on DCAMKL-1 expression 2) To determine the effects of radiation injury on DCAMKL-1
expression in intestinal stem cells. Methods: Adult APC/min mice were analyzed for intestinal
DCAMKL-1 expression using a rabbit polyclonal antibody. Immunohistochemistry was per-
formed for PCNA (as a marker for proliferation) and β-catenin to determine its localization
in the APC/min mice adenomas. For radiation experiments, adult C57BL/6 (WT) mice were
sacrificed at 0-144 hrs following 6- or 12-Gy whole body γ-irradiation (IR). Small intestine
was evaluated for the presence of apoptosis, mitoses and DCAMKL-1. Results: In WT mice,
cytoplasmic DCAMKL-1 staining was observed in single cells in the putative stem cell zone
in intestinal crypts. Expression was also observed in epithelial cells of APC/min mice.
Interestingly, only a few cells within the adenomas expressed DCAMKL-1. Furthermore,
these cells were negative for PCNA and therefore quiescent. However, β-catenin was primarily
observed in the nucleus in these cells. DCAMKL-1 protein was observed in single crypt
epithelial cells in the stem cell zone at 6 h after IR. Morphologically appearing apoptotic
cells were noted at the crypt base but not in DCAMKL-1 positive cells. However, by 24 h
post IR, DCAMKL-1 positive cells also appeared apoptotic. Surprisingly, many of these
apoptotic cells were also in the process of mitosis. In addition, adjacent epithelial cells often
expressed DCAMKL-1 and exhibited mitotic features. Conclusions: These data suggest that
DCAMKL-1 is an adult intestinal stem cell marker, whose expression is restricted to the
stem cell zone under basal conditions. Furthermore, DCAMKL-1 may be a tumor stem
cell marker in APC/min mice. Moreover, these data demonstrate that intestinal stem cell
characteristics can be transferred to adjacent cells following radiation injury. Taken together,
these results suggest that DCAMKL-1 may be a novel chemotherapeutic target.
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Eosinophil Derived Adenosine Stimulates Remodeling Genes in Squamous
Epithelial Cells
Andreas Robinson, Lisa Shaffer, Nancy Louis, Glenn T. Furuta
Background- Eosinophils have the capacity to synthesize and release adenosine tri-phosphate
(ATP). ATP is converted to adenosine by epithelial cell surface ectonucleotidase molecules
CD39 and CD73. Adenosine possess' A broad spectrum of potential anti- and pro-inflammat-
ory actions including induction of cytokine production, promotion of angiogenesis and
stimulation of fibroblast differentiation. Hypothesis- Eosinophil derived adenosine stimulates
tissue remodeling in the squamous epithelium. Methods- Human peripheral eosinophils and
AML 14 3D10 eosinophil cells were stimulated with PMA (100 ng/ml) for 10 minutes and
supernatants were harvested. ATP was measured from cell supernatants (Chromolume assay).
Squamous epithelial cells (Ect1/E6E7-kind gift from R. Fichorova) were stimulated with
supernatants harvested from PMA stimulated AML 14 3D10 eosinophils , supernatant from
resting AML 14 3 D10 eosinophils and PMA (100 ng/ ml-control). Some cells were pre-
treated with alpha beta methylene-ADP (10 uM) (APCP=inhibitor of CD73) for 2 hrs. At
various times, supernatants were harvested, RNA extracted and real time PCR was performed
on epithelial cell RNA for tissue remodeling genes (TIMP-1, MMP-1,-2, -9, TGF-beta,
fibronectin-1, IL-6, Collagen 8A1.) Results- PMA stimulated peripheral eosinophils and
AML14 3D10 eosinophil to release significantly more ATP compared to unstimulated eosino-
phils (13.1 fold p<0.01 and 1.86 fold p<0.05 increase over control respectively). Squamous
cells exposed to supernatants from PMA stimulated 3D10 eosinophils demonstrated increase
in remodeling genes compared to control squamous cells (see table lines 1 and 3) while
others were relatively unaffected. When epithelia were pre-treated with CD73 inhibitor, all
upregulated genes were inhibited (see table- lines 2 and 4) Conclusion- AML 14 3D10
eosinophil derived adenosine stimulates tissue-remodeling genes thru CD79 ectonucleotid-
ase. Speculation- Eosinophils participate in tissue remodeling in squamous epithelial cells.
mRNA fold change relative to control (PMA alone)
A-6AGA Abstracts
31
Serum Eosinophil Cationic Protein and Eosinophil Derived Neurotoxin Are
Potential Non-Invasive Biomarkers for Eosinophilic Esophagitis
Mirna Chehade, Oksana Yershov, Hugh A. Sampson
Background: Eosinophilic esophagitis (EE) is characterized by eosinophilic infiltration of
the esophageal mucosa. Its diagnosis requires invasive endoscopic biopsies for histological
analysis. Peripheral eosinophilia is present in only 50% of children with EE. Our goal was
to identify other potential non-invasive markers for this disease in children. Eosinophil
cationic protein (ECP) and eosinophil derived neurotoxin (EDN) are cationic proteins present
in eosinophil granules. Their levels have been found to be elevated in the serum of patients
with atopic dermatitis. Methods: 20 children with biopsy-confirmed EE (>20 esophageal
intraepithelial eosinophils in the maximally involved 400x high power field) and 22 controls
(normal esophageal histology upon biopsy) were included. Sera obtained from the subjects
close to the time of endoscopy were assayed for ECP by fluoro-enzyme immunoassay and
for EDN by enzyme-linked immunosorbent assay. Patients' medical records were reviewed,
and peripheral eosinophil counts performed close to the time of endoscopy were recorded.
Results: Children with EE had significantly higher serum levels of ECP and EDN than
controls. The median level of ECP [interquartile range] was 32.8 ng/ml [16.0-61.6] in EE
versus 14.0 [7.9-22.6] in controls, p<0.01. For EDN, median levels were 100.9 ng/ml [56.0-
127.5] in EE versus 44.0 [29.9-56.6] in controls, p<0.001. Levels of these biomarkers
correlated significantly with the number of peripheral blood eosinophils (r=0.48 for ECP,
p<0.01; r=0.62 for EDN, p<0.001). Peripheral eosinophilia (>500 eosinophils/microliter)
was present in 57% of the children with EE. When levels of ECP and EDN above the 75th
percentile of control levels were considered elevated, 71% of EE patients now had elevated
ECP, EDN or peripheral eosinophilia. Furthermore, 50% of children with EE had elevated
ECP and EDN levels despite normal peripheral eosinophil counts. These findings highlight
the potential utility of serum ECP and EDN as novel biomarkers for EE, in combination
with measurement of peripheral blood eosinophil counts. Conclusions: Serum levels of ECP
and EDN could serve as potential non-invasive biomarkers for diagnosing and monitoring
eosinophilic esophagitis in children.
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Esophageal Dysmotility in Eosinophilic Esophagitis: Analysis Using High
Resolution Esophageal Manometry
Joan Chen, Sudip K. Ghosh, John Pandolfino, Peter J. Kahrilas, Ikuo Hirano
BACKGROUND: Eosinophilic esophagitis (EE) is an increasingly recognized cause of dys-
phagia and food impaction. In many cases, strictures are not apparent on endoscopy, raising
questions as to the mechanism of impaired deglutition. Prior reports have documented
eosinophilic infiltration of the muscularis propria and myenteric plexus that could induce
esophageal dysmotility. AIM: Characterize esophageal motor function in EE utilizing high
resolution esophageal manometry (HRM) and newly described manometric parameters.
METHODS: 24 patients (pts) with EE were studied with a 36-channel solid state HRM
assembly and analyzed using ManoView software (Sierra Scientific). Analysis was based on
ten 5ml water swallows per pt. Esophageal peristalsis was quantified by distal esophageal
body peristaltic point velocity and Pressurization Front Velocity (PFV) which was the propaga-
tion rate of an intact 30 mmHg pressure wave. In the absence of a continuous propagation
wave, a swallow was classified as a null PFV. A pt was classified as null, normal or elevated
PFV based on the dominant pattern (≥6) of 10 swallows. Esophagogastric junction (EGJ)
relaxation was quantified using the lowest mean residual pressure over a 3 second interval
(E-sleeve relaxation) and Integrated Relaxation Resistance (IRR). A higher IRR signifies
impaired EGJ relaxation and consequently higher resistance to esophageal emptying. All
abnormal HRM values were referenced to the 95% upper limit of normal values derived
from 75 controls. RESULTS: The median pt age was 42 (14-80). The most common
presenting symptoms were dysphagia (83%) and heartburn (12.5%). Endoscopic findings
included rings (50%), furrows (58%), and exudates (33%). On HRM, 14 pts (58%) had
increased distal segment contraction velocity (median 8.4 cm/s) while 3 (12%) had an
elevated PFV (median 4.2 cm/s). Two pts had elevated intrabolus pressures as evidenced
by an elevated PFV but normally propagated peristaltic contraction. 9 pts were classified as
having a null PFV and only one had significantly elevated esophageal contractile pressures
(295 mmHg). 7 pts had an elevated IRR (median 3.3mmHg/sec) and of this group, 5 pts
also had increased E-sleeve relaxation pressures (median 18 mmHg). CONCLUSIONS: (1)
Manometric manifestations of EE are heterogeneous. (2) An elevation in esophageal peristaltic
velocity was the most common abnormality. (3) Subsets of EE pts demonstrated failed
esophageal peristalsis (null PFV) and impaired EGJ relaxation (elevated IRR). (4) Functional
abnormalities on the basis of neuromuscular involvement could contribute to dysphagia in EE.
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A Prospective Clinical Trial of Allergy Testing and Food Elimination Diet in
Adults with Eosinophilic Esophagitis (EE)
Nirmala Gonsalves, Sally Ritz, Guang-yu Yang, Anne Ditto, Ikuo Hirano
Background: EE is a common cause of dysphagia and food impaction in adults. In children
with EE, both six food elimination diet (SFED) and elemental diet have been effective
therapies. Dietary elimination has not been formally tested in adults with EE. Aim: To assess
the efficacy of food elimination diet on histologic improvement in adults with EE. Secondary
aims include symptomatic improvement based on dysphagia and SF36 scores. Methods:
Adults newly diagnosed with EE, based on ≥20 eosinophils/high power field (eos/hpf), or
with a prior diagnosis having a relapse were offered the trial. Patients (pts) underwent Bravo
or 24h pH testing and if positive, were treated with twice daily proton pump inhibitor prior
to initial endoscopy (EGD). After skin prick testing (SPT) for food and aeroallergens, pts
completed a 6 wk trial of a SFED (milk, soy, egg, wheat, nuts, seafood). Other foods positive
on SPT were also eliminated. Aeroallergens were not concomitantly treated. After 6 wks,
pts had repeat EGD with biopsies from the proximal and distal esophagus. Resolution of
EE was defined as peak count ≤5 eos/hpf. Biopsies were evaluated for peak eos/hpf and
stained for ki-67 and p63, markers of epithelial hyperplasia, before and after treatment. Pts
completed SF36 and dysphagia symptom scores before and after the trial. Results: 9 pts
(4M/5F) to date are undergoing the trial with mean age of 36 yrs (range 25-54). Most
common symptom was dysphagia with mean duration of 7.7 yrs. Food and aeroallergens
were found in 100% of pts. Common food allergens were nuts, soy, wheat, egg and seafood
and common aeroallergens were tree, grass, ragweed, and dustmite. 3 pts to date have
completed the trial and repeat EGD. Average eos/hpf pre and post treatment were 52 ± 26
and 20 ± 16 in proximal and 52 ± 28 and 31 ± 29 in distal biopsies, respectively. One pt
had complete resolution of EE, one had significant reduction of eos without resolution, and
one had no change. Staining for ki-67 and p63 showed marked reduction in epithelial
hyperplasia in pts who responded. Symptom scores decreased 30% post treatment. SF36
scores showed no significant change but were lower than the general population. Conclusions:
(1) Allergy testing and elimination diet is feasible and successful in reducing histologic
eosinophilia, epithelial hyperplasia, and symptoms in some adults with EE, confirming a
role for food allergens in this cohort. (2) Since aeroallergens were not treated, this may be
the trigger in pts who didn't respond. (3) Further studies will need to address predictors
of treatment failure in this group (4) EE does affect quality of life in adults.
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Eosinophilic Esophagitis: Prevalence, Symptoms, and Treatment Response in
Patients with Symptoms of Gastroesophageal Reflux Disease
Wilfred M. Weinstein, John T. Monyak, Debra G. Silberg
Background: Eosinophilic esophagitis (EOSE) may go unrecognized in patients presenting
with typical symptoms of gastroesophageal reflux disease (GERD). Treatment for EOSE
generally includes GERD therapy with additional therapy reserved for those who have
residual symptoms. Aim: To evaluate the prevalence of EOSE in patients with typical GERD
symptoms, the presenting symptoms, and the symptom resolution rates after esomeprazole
therapy Methods: A post-hoc analysis was conducted on histology data from a multicenter,
open-label study in adults with frequent heartburn with or without erosive esophagitis (EE).
At baseline, 3 biopsy specimens each were taken from 1 and 3 cm above the Z-line.
EOSE was defined as ≥1 biopsy specimen with ≥15 eosinophils in 2 high-power fields.
Esomeprazole 40 mg once daily was taken for 4 weeks. Biopsy specimens were processed
in a central laboratory and evaluated by a single observer [WMW]. All patients had endoscopy
with biopsy; however, admission to treatment was stratified by EE status (present/absent)
in a 1:1 ratio. Patients completed a GERD symptoms questionnaire at baseline and at 4
weeks. Resolution was defined as no GERD symptoms (none), on a scale of none, mild,
moderate, or severe. Results: Of 376 patients, 25 had EOSE: prevalence 6.6% (95% CI,
4.1-9.2%). Of the 25 EOSE patients, 14 (56%) had endoscopically diagnosed EE. Compared
with non-EOSE patients, EOSE patients were more likely to be men (64% vs 41%; P =
0.025) and younger (mean age, 36 vs 45 years; P = 0.003). Symptom resolution data were
available in 343 patients, including 23 with EOSE; all had heartburn at baseline. EOSE
patients had predominantly moderate heartburn severity scores (76%); 92% had acid regur-
gitation; 76%, epigastric pain; and 56%, dysphagia. Post-treatment symptom resolution rates
for EOSE patients (Table) were similar to those for EE patients without EOSE but were not
statistically different from either group. Conclusions: After treatment with esomeprazole
40 mg once daily, GERD symptom resolution rates in EOSE patients were comparable with
those in non-EOSE patients. These data support the approach to initially treat EOSE with
GERD therapy. The subset that does not respond may require additional or alternative
therapy. Supported by AstraZeneca LP (study no. D9612L00083)
Table. Patients [n (%)] with GERD symptom resolution at week 4
* Without EOSE.
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Eosinophilic Gastrointestinal Disease As a Presenting Sign of Severe Immune
Dysregulation in Children
Karen A. Francolla, Annette D. Segura, William J. Grossman, Richard J. Noel
Eosinophilic gastrointestinal diseases (EGIDs) are characterized by the presence of eosino-
philic mucosal inflammation of the gastrointestinal tract in the absence of infection, malig-
nancy, or drug effect. We present a series of pediatric patients in which EGID was not the
primary disease, but a manifestation of an identifiable immune dysregulation syndrome.
METHODS: A retrospective review of known patients with EGIDs and immune dysregulation
was performed. Data including demographics, laboratory and endoscopic data, histology,
and clinical course were gathered. RESULTS: Eleven patients were identified (54% female;
age at diagnosis 37 ± 42 months (mean ± st dev)). All patients had eosinophilic inflammation
with architectural distortion affecting the upper and/or lower gastrointestinal tract; two
patients also had duodenal enteropathy with lymphocytic inflammation. Presenting signs
included diarrhea (82%), abdominal pain (64%), vomiting (46%), failure to thrive (27%),
and intestinal failure requiring parenteral nutrition (18%). Endoscopy/colonoscopy with
biopsy diagnosed eosinophilic gastroenteritis (EGE) in nine patients and eosinophilic eso-
phagitis (EE) combined with celiac disease in two others. Immune abnormalities and pheno-
types are tabulated below. Immune studies identified need for IVIG (9 patients) and Pneumo-
cystis and/or fungal prophylaxis (6 patients). One patient required bone marrow transplanta-
tion and two others are on maintenance calcineurin inhibitors. CONCLUSIONS: EGIDs
may be a manifestation of underlying immune dysregulation and not a primary disease.
Patients diagnosed with EGIDs, particularly EGE or coincident EE and celiac disease, merit
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a thorough investigation of immune function with quantification of immunoglobulin produc-
tion, assessment of vaccine response, and flow-cytometric analysis of lymphocytes. Findings
may significantly alter clinical management.
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Interrupting PI3K Signaling Worsens Colitis During Citrobacter rodentium
Infection
Jeffrey Brown, Gery Grimm, Goo Lee, Navdha Mittal, B. mark Evers, Terrence A. Barrett
Background and Aims: PI3K activity has clearly been shown to regulate cellular proliferation,
growth, and apoptosis and play a critical role in multiple cancers, including colon cancer.
Its role in host-defense is less clearly defined. The current study examined the role of the
PI3K signaling which induces phosphorylation of AKT (pAKT), nuclear beta-catenin, and
cytoplasmic translocation of FOXO-1 (which reduces FOXO-1's mitochondrial pro-apoptotic
effect) in mice infected with Citrobacter rodentium, an attaching-effacing enteric bacterial
pathogen. Methods and Results: C57BL/6 mice were infected via oral gavage withC. rodentium
and tissues were examined 13 days after infection. Mice developed expected distal colitis
with marked hyperplasia of crypts and mucin depletion. Examination of isolated epithelial
cell protein analyzed by western blot demonstrated a 37-fold increase in pAKT, a 4-fold
increase in cytosolic FOXO-1, and a 2-fold increase in nuclear beta-catenin consistent with
activation of the PI3K pathway. BrdU staining increased 6-fold and TUNEL staining increased
6-fold. To examine the role of PI3K signaling, mice were treated with either DMSO (vehicle
control) or LY294002 (LY), an inhibitor of PI3K, at day 6 and 10 after inoculation. On day
13, LY-treatment reduced cytoplasmic protein levels of FOXO-1 by 36% and decreased
nuclear beta-catenin protein by 59%. BrdU staining was not significantly effected; TUNEL
was reduced by 28%. In spite of blocking this pro-proliferative pathway, colitis was noted
to be increased in LY-treated mice as measured by crypt length. Infection resulted in a 2.3-
fold increase in crypt length. LY-treatment further increased crypt length another 33%. Next,
the experiment was repeated using p85-specific siRNA as an inhibitor of the PI3K pathway.
Again, protein levels were reduced in the treatment group (pAKT by 15%, FOXO-1 by 75%,
and nuclear beta-catenin by 19%) with a similar histologic effect on crypt lengths. Conclusion:
C. rodentium infection induces proliferation, nuclear beta-catenin, and PI3K signaling. PI3K
blockade reduced beta-catenin signaling and cytoplasmic translocation of FOXO-1. The
novel detection of worse colitis with PI3K signaling blockade suggests this pathway may
play an important role in host-defense.
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Transcription Factor Xbp1 Regulates Paneth Cell Function and the
Inflammatory Tone of the Intestinal Epithelium
Arthur Kaser, Ann-hwee Lee, Celiné Lefebvre, Jonathan Glickman, Herbert Tilg, Edward
e.s. Nieuwenhuis, Darren E. Higgins, John D. Rioux, Laurie H. Glimcher, Richard S.
Blumberg
Background. A single layer of intestinal epithelial cells (IEC) is the structure in immediate
contact with the commensal microbiota and provides an immunologically functional barrier
between luminal microbes and the hematopoietic system. Paneth cells (PC), at the crypt
base, contain anti-bacterial peptides, α-defensins (cryptdins). A subset of CD is linked to
mutations in NOD2/CARD15, in association with reduced expression of α-defensins. The
unfolded protein response (UPR) is activated upon stress in the endoplasmic reticulum (ER),
and is required for efficient protein production in highly secretory cells. Methods. We
hypothesized that ER stress regulates PC and IEC function. To address this, we generated
two IEC specific (using Villin-Cre) knock-out mouse models of X box binding protein-1
(XBP1), a key transcription factor of the ER stress response. Results. Constitutive genetic
deletion of XBP1 in IEC led to development of spontaneous enteritis with features character-
istic of IBD, including crypt abscesses. IEC from these mice showed increased grp78 expres-
sion, a marker of ER stress. XBP1 deletion resulted in the absence of PC, associated with a
virtual absence of cryptdin and lysozyme mRNA and protein expression, and decreased
antimicrobial activity as demonstrated by 2-log higher Listeria monocytogenes c.f.u. in the
faeces of XBP1-/- mice upon oral infection. Using a second conditional IEC knock-out mouse
of XBP1 with Cre activation by tamoxifen, we demonstrated apoptotic death of PC as the
underlying mechanism for the absence of PC. ER stress results in increased JNK phosphoryl-
ation, due to the interaction of IRE1, the endoribonuclease activating XBP1, and TRAF2.
We therefore assessed JNK activation in IEC and found JNK phosphorylation in XBP1-/-,
but not XBP1+/+ epithelium, demonstrating an inflammatory tone of IEC. Consistent with
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this, XBP1-silenced MODE-K cells secreted increased CXCL1 after flagellin or TNF treatment,
which was dependent on increased JNK phosphorylation. XBP1-/- mice were more sensitive
to dextran sodium sulphate colitis. We then investigated the activation state of the ER stress
response in the ileum of patients, and detected increased grp78 expression and XBP1 splicing,
indicators of ER stress, in human IBD. Conclusion. We demonstrate the ER stress response
as being of central importance for IEC and PC function. XBP1 function integrates the two
aspects considered central for IBD; regulation of the intestinal microbiota (through effects
on PC), and an inflammatory tone of the mucosal immune system. This leads to spontaneous
enteritis upon selective deletion solely in the intestinal epithelium.
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Endoplasmic Reticulum Stress in Goblet Cells Leads Directly to Intestinal
Inflammation with Similarities to Ulcerative Colitis
Rajaraman D. Eri, Timothy H. Florin, Gareth Price, Chad K. Heazlewood, Matthew C.
Cook, Christopher C. Goodnow, Michael A. Mcguckin
Ulcerative colitis (UC) is a disease of as yet unclear multifactorial etiology. Using ENU
mutagenesis we developed two strains of mice, Win and Eey, selected for diarrhea, rectal
bleeding and rectal prolapse. Both strains have missense mutations in the Muc2 mucin
causing aberrant Muc2 assembly and endoplasmic reticulum (ER) stress in goblet cells,
resulting in a UC-like goblet cell/mucus phenotype. We have investigated histological and
molecular evidence of spontaneous inflammation in these mice as well as their susceptibility
to a luminal toxin. Methods: Win, Eey and C57BL/6 (WT) mice were treated with 0.5-3%
DSS in drinking water and body weight loss, faecal occult blood, colon length and histological
colitis assessed. The intestinal transcriptome was analysed at 8 weeks in WT, Win and Eey
mice (n=3/strain) using Affymetrix 430_2 genechips, focusing on genes with altered expres-
sion (mean >2 fold) in both mutant strains. Results: Spontaneous mild inflammation including
neutrophilic infiltration, crypt abscesses and focal erosions, occurred in Win and Eey,
particularly in the distal colon and rectum. DSS treatment at all doses caused significantly
increased body weight loss, rectal bleeding, colon shortening and histological colitis in Win
and Eey mice. Continuous 0.5% DSS caused progressive weight loss and 100% mortality
in Win mice by 30 days, while WT mice gained weight and survived for at least 9 weeks.
A strong correlation in gene expression was observed between Win and Eey mice. Functional
classification of genes with altered expression in both strains revealed genes involved in: ER
stress and Ca2+ metabolism (Grp78, Grp94, Sec61, PDI, phospholamban), wound repair
and cell cycle regulation (amphiregulin, epiregulin, hbEGF, stratifin, cyclin B1, p21, PTK6),
inflammation/anti-microbial (SLPI, lipocalin-2, IL-1b, IL-1b RA, SOCS3, CD14, S-100 A14
and A16, CXCL9), apoptosis (Bcl-2, intectin, RIP3 kinase). Comparison of published human
IBD gene expression/proteome studies and public domain IBD microarray datasets with
Win/Eey identified gene expression changes similar to UC rather than Crohn's disease.
Conclusions: Win/Eey mice closely mimic UC in clinical symptoms, goblet cell morphology
and reduction in the mucus barrier. We demonstrate that goblet cell stress leads to spontan-
eous histological and molecular inflammation and wound repair, with an intestinal tran-
scriptome similar to UC. Furthermore, goblet cell stress leads to an extreme sensitivity to
luminal toxin induced colitis. ER stress in goblet cells, which may be due to MUC2 poly-
morphisms and/or host or environmental ER stressors, is a novel candidate pathway to UC.
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Crosslinking Two Glycolipids Is Sufficient for Trafficking Cholera Toxin
Retrograde Into the ER of Intestinal Cells
Anne A. Wolf, Michael G. Jobling, David Saslowsky, Eli Kern, Kimberly Drake, Anne
Kenworthy, Randall K. Holmes, Wayne I. Lencer
Cholera toxin (CT) causes disease by hijacking an endogenous lipid-dependent trafficking
pathway to enter the ER of host intestinal epithelial cells. CT consists of an enzymatic A-
subunit, and a homopentameric B-subunit. The B-subunit binds specifically to five GM1
gangliosides in the host cell plasma membrane (PM). GM1 carries the A-subunit all the way
from PM to ER where a portion of the A-subunit unfolds and retro-translocates to the cytosol
to cause disease. Other gangliosides do not transport CT retrograde into the ER in intestinal
cells, and how GM1 induces such specificity in lipid trafficking remains unexplained. Here
we AIM to test whether toxin function depends upon clustering GM1 by multivalent binding
via the pentameric B-subunit. METHODS: We prepared chimeric CT B-subunits (CTB-
W88K/G33D) with only one or two functional GM1 binding sites by co-expression of two
mutant monomers CTB-G33D and CTB-W88K that cannot bind GM1. The binding pocket
depends on G33 and W88 contributed from adjacent B-subunits. We also prepared CT B-
subunit variants lacking functional binding sites (CTB-G33D). Holotoxin variants (W88K,
G33D and W88K/G33D) were made similarly by co-expressing the gene encoding CTA.
Toxin binding to GM1 and lipid microdomains was assessed biochemically and by Fluores-
cence Recovery After Photobleaching (FRAP); and toxin function by measuring cAMP-
dependent Cl- secretion (Isc). RESULTS: G33D, with mutation in all five binding pockets,
did not bind T84 cells or GM1. The chimera W88K/G33D with 1 or 2 GM1 binding sites
bound T84 cells similarly to wt CT but with the expected decreased affinity. Only wt CT
and W88K/G33D co-immunoprecipitated GM1 from solubilized T84 monolayers prebound
with toxin at 4°C. The relative stoichiometry for binding GM1 of the chimera, however,
was 1:1 (compared to 5:1 for wt CT) suggesting that CTB-W88K/G33D contained only 1
or 2 binding sites for GM1. wt CT fractionated fully with detergent resistant-membranes
(DRMs), and half the mass of W88K/G33D associated with DRMs. FRAP of CT and W88K/
G33D bound to COS-7 cells showed that both toxins had limited membrane diffusion,
consistent with their binding GM1 in membrane microdomains. When tested for function
W88K/G33D induced only a strongly attenuated Isc as compared to wt CT. W88K and
G33D were inactive. CONCLUSION: Clustering GM1 in the plane of the PM enhances CT
function. Because the chimera W88K/G33D does induce Isc, we also conclude that binding
only one or two GM1 gangliosides provides a sufficient sorting motif to associate with lipid
rafts, and presumably to traffic retrograde into the ER of host cells.
A-8AGA Abstracts
40
Myosin Light Chain Kinase (MLCK) Mediates the IL-1β-Induced Increase in
Intestinal Epithelial Tight Junction Permeability
Rana Al-sadi, Thomas Y. Ma
Background: Previous studies have shown that IL-1β at physiologically relevant concentra-
tions (1-25 ng/ml) caused an increase in intestinal epithelial tight junction (TJ) permeability.
The IL-1β-induced increase in intestinal TJ permeability has been proposed to be an important
mechanism contributing to intestinal inflammation. However, the intracellular mechanisms
that mediate the IL-1β-induced increase in TJ permeability remain unclear. The purpose of
this study was to examine the possible involvement of myosin light chain kinase (MLCK)
in regulating the IL-1β-induced increase in TJ permeability. Methods: Filter-grown Caco-2
monolayers were used as an In Vitro intestinal epithelial model system and a range of
molecular and biochemical methods were used. Results: 1) IL-1β (10 ng/ml) caused a
significant decrease in Caco-2 trans-epithelial resistance (TER) (~30% drop) and increase
in permeability to paracellular marker inulin (20-fold increase), indicating an increase in
TJ permeability. 2) IL-1β-induced increase in Caco-2 TJ permeability was accompanied by
a time-dependent increase in MLCK protein expression. 3) The IL-1β-induced increase in
Caco-2 MLCK protein expression directly correlated with an increase in MLCK activity. 4)
Specific MLCK inhibitors, ML-7 (10μM) and ML-9 (20μM), prevented the IL-1β-induced
increase in MLCK activity and drop in Caco-2 TER, suggesting that MLCK activity was
required for the IL-1β induced drop in Caco-2 TER. 5) IL-1β-induced increase in MLCK
protein expression was preceded by an increase in MLCK mRNA expression, suggesting
that the increase in MLCK protein expression was related to an increase in MLCK transcript.
The inhibition of IL-1β-induced increase in MLCK mRNA transcription by a known transcrip-
tion inhibitor actinomycin-D prevented the IL-1β increase in MLCK mRNA and protein
expression. 6) To further validate the central requirement of MLCK protein in mediating
the IL-1β-induced increase in Caco-2 TJ permeability, MLCK expression was silenced by
transfection of Caco-2 monolayers with MLCK siRNA. MLCK depletion by siRNA transfection
completely prevented the IL-1β-induced drop in Caco-2 TER, confirming that MLCK protein
expression was required for the IL-1β-induced increase in Caco-2 TJ permeability. Conclu-
sion: In these studies, we show for the first time that IL-1β induces an upregulation of
MLCK transcription and translation. Our findings indicate that IL-1β-induced increase in
MLCK protein expression (and accompanying increase in activity) is a central mechanism
mediating the IL-1β-induced increase in intestinal TJ permeability.
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The Human ATP-Binding Cassette (ABC) Transporters Superfamily and
Xenobiotic-Transcriptional Regulators: Analysis of Intestinal Epithelial Gene
Expression in Inflammatory Bowel Disease
Gwo-tzer Ho, Colin L. Noble, Jennine Cornelius, Ian D. Penman, Ian D. Arnott, Lauri
Diehl, Jack Satsangi
Introduction: The ATP-binding cassette (ABC) transporters regulate many important physio-
logical processes, such as gut barrier defence, bile acid/lipid homeostasis, and innate immun-
ity. Inherited variations of ABC transporters (ABCB1/MDR1 and ABCC3) and the transcrip-
tional regulator, PXR have been implicated in IBD susceptibility. Aims/Methods: The aim
of this study was to characterize comprehensively the gene expression patterns of the entire
ABC superfamily (48 genes) and the key transcriptional mediators (PXR, FXR, LXR and
CAR) in human IBD based on the Agilent whole human genome microarray chip. Mucosal
specimens (colon & t. ileum) from 53 Crohn's disease (CD) and 67 Ulcerative Colitis (UC)
patients were studied. We performed comparative analyses with subanalyses for regional
expression, inflammation status with healthy and non-IBD inflammatory controls (30 indi-
viduals). Results: Overall, 15 (31%) ABC genes were differentially expressed in IBD. In non-
inflammatory states, 7 ABC transporters (3 members of sub-family B, MDR1,ABCB4&5)
were significantly downregulated in UC and CD compared with healthy controls (p values
0.05-0.0001; MDR1 in UC, p=0.003). In inflamed states, a further 6 and 2 genes were
significantly down- and upregulated in UC/CD respectively (p values 0.04-0.0001; CFTR
in UC and CD, p=0.008) compared with inflammatory controls. 3 ABC transporters were
significantly expressed differentially irrespective of inflammation status (ABCE1, ABCF1/2).
There were no differences in the expression of PXR between IBD and controls (with sub-
analyses for disease location/activity). In contrast, the transcriptional regulator LXR, was
significantly expressed differentially in inflamed states (upregulated in CD, p=0.008) and
FXR downregulated in non-inflamed states (p=0.02) in IBD. Multiple logistic regression
analyses revealed significant contribution of inflammatory status to the expressions of MDR1,
ABCB2, ABCE1 and transcription factors, PXR, FXR, CAR and LXR irrespective of disease
phenotype and control status (p=0.02-0.005). In addition, MDR1, ABCC3, ABCC6 and
ABCE1 genes display differential expression gradients independent of disease phenotype
and control status (0.01>p>0.001). Of interest, MDR1 and ABCC3 demonstrated a similar
expression pattern from proximal to distal colon (decreasing gradient). Conclusions: The
current data show significant alterations in key ABC genes and transcriptional factors in
IBD. Previously implicated genes such as MDR1 along with novel transporters emphasized
the importance of this class of proteins/transporters in the maintenance of epithelial defence
and provide further insights for the pathogenesis of IBD.
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Acid Related Esophageal Sensitivity, Not Dysmotility, Differentiates Subgroups
of Patients with Non-Erosive Reflux Disease
Nora M. Thoua, Deanna Khoo, Chrysostomos Kalantzis, Charles D. Murray, Anton V.
Emmanuel
Introduction: Patients with non-erosive reflux disease (NERD) account for 50-70% of patients
with gastro-oesophageal reflux disease. They experience reflux symptoms in the absence of
any endoscopic mucosal breaks and often experience symptoms with a similar frequency
and severity as those with erosive reflux (ERD). Patients with NERD can be stratified by
whether there is a relationship between symptoms and acid exposure (NERD:acid+), or not
(NERD:acid-). Differences in the intra-oesophageal distribution and the perception of acid
reflux have been demonstrated between NERD and ERD patients, which may relate to
differences in oesophageal motility and sensitivity between the two groups. The aim of this
study was to investigate the effect of oesophageal infusion of hydrochloric acid (HCl) on
oesophageal motility and sensitivity in patients with NERD. Methods: 39 consecutive patients
with reflux disease (11 NERD:acid+ [oesophageal acid exposure >4%], 14 NERD:acid- and
14 ERD - demographically matched groups) attending for oesophageal function studies were
studied, along with 12 healthy controls. HCl pH1 or saline were infused at 400ml/hr in
random order into distal (5cm above lower oesophageal sphincter [LOS]), then proximal
(20cm above LOS) sites in the oesophagus. The following observations were made at baseline
and after 30 minutes of each infusion: oesophageal contraction amplitude, duration and
waveform, LOS pressure, pain intensity by VAS. Results: NERD patients had significantly
higher pain sensitivity to acid compared to ERD and controls (proximal VAS 6.6 vs 3.9 vs
2.8 resp, p<0.03 both; distal 4.8 vs 3.2 vs 2 resp, p<0.04 both). ERD patients differed from
controls (p<0.05 for both proximal and distal acid). Proximal acid infusion caused greater
pain than distal only in NERD patients (p<0.05), not ERD or controls. When comparing
NERD:acid- with NERD:acid+ patients the acid and saline sensitivity were more pronounced
in the former (proximal acid 7.2 vs 5.8 resp, p<0.03; distal acid 5.5 vs 3.9 resp, p<0.01;
proximal saline 4 vs 3.1 resp, p<0.05). There were no significant differences in oesophageal
contraction or LOS pressure between the groups in any of the motility parameters. Conclu-
sions: NERD patients, and to a lesser extent ERD patients, are sensitive to acid in the
oesophagus, being more sensitive proximally than distally. Hypersensitivity is most marked
with NERD patients who have a normal pH profile. The relationship of these changes to
symptom index and psychological state remains to be determined. This sensitivity is inde-
pendent of significant motility change.
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Increased Intrabolus Pressure: A Novel Pathophysiologic Factor in Non-
Obstructive Dysphagia?
Mentore Ribolsi, Edoardo V. Savarino, Daniel Pohl, Michael Fried, Radu Tutuian
Introduction: There are only limited data on the pathophysiologic mechanisms esophageal
dysphagia in the absence of structural lesions or major motility abnormalities (i.e. non-
obstructive dysphagia). Dysphagia cannot be attributed to bolus retention since many patients
with non-obstructive dysphagia have normal bolus transit. Aim: To compare intrabolus
pressure in patients with dysphagia, gastro-esophageal reflux (GERD) symptoms and non-
cardiac chest pain. Methods: Patients referred to our laboratory underwent combined imped-
ance-manometry testing using 10 saline (5ml each) and 10 bread swallows in recumbent
position. With the distal pressure sensor located in the LES, manometric and impedance
data were recorded at 5, 10, 15 and 20cm above the LES. In each channel intrabolus pressure
(IBP) was calculated as average pressure measured during the time interval elapsed between
bolus entry and exit. Average intrabolus pressures were calculated for liquid and bread
swallows. General linear model (GLM) was used to evaluate effects of bolus consistency and
presenting symptom on IBP. Results: In 58 patients (34 females, mean age 47, range 23-
81; 18 dysphagia, 17 chest pain and 12 GERD ). Intrabolus pressure was higher during
bread compared to saline swallows (p<0.001). Dysphagia patients had higher IBP during
saline (p<0.05) and bread (p<0.05) swallows compared to chest pain and GERD patients.
Patients with dysphagia had shorter (p<0.01) LES relaxations (8.0 ± 0.3 sec) compared to
chest pain patients (9.1 ± 0.3 sec) during bread swallows. Conclusion: Increased intrabolus
pressure might be a key factor in the pathophysiology of non-obstructive dysphagia. Providing
pressure and bolus presence data combined impedance manometry (MII-EM) is an ideal
tool for monitoring IBP.
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Absence of Augmentation of the Cortical Swallowing Network By Subliminal
Esophageal Acid Exposure in GERD Patients
Krisna Chai, Mark K. Kern, Venelin Kounev, Stephen J. Antonik, Rachel Mepani, Candy
Hofmann, Reza Shaker
Introduction: Swallowing is a major mechanism for esophageal acid clearance. Earlier studies
have shown a greater increase in functional MRI regional cortical activity after subliminal
esophageal acid stimulation in GERD patients compared to controls, suggestive of increased
afferent sensitivity, but the response of the swallowing network to acid exposure in GERD
patients is unknown. Aim: To determine the effect of subliminal esophageal acid stimulation
on the defined swallowing cortical network in GERD patients and compare these findings
with healthy controls. Methods: 13 right-handed subjects (7 healthy, 6 asymptomatic GERD
on PPI (2 Barrett's)) were studied by high-resolution fMRI scanning of the left cortical
hemisphere during swallowing (event-related design, voxel size: 2.5x2.5x4.5mm) before
and after alternating saline and 0.1 N HCl mid-esophageal infusion at 1mL/min, for a total
of 16mL of acid over 42 minutes. We studied the anterior, middle, and posterior cingulate
gyrus (AC,MC,PC), the insula (Ins), and the motor cortex (Mot). Results: Contrary to controls,
GERD patients did not show a significant increase in the number of activated fMRI voxels
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in the studied brain regions (Table). No subjects experienced heartburn. Conclusions: 1)
Subliminal acid-induced esophageal sensory input sensitizes the cortical swallowing network
in healthy individuals but not GERD patients. 2) This difference may reflect desensitization,
or alternatively, a ceiling effect of the afferent pathways in GERD patients.
* = P value <0.05; Error values expressed as standard error of the mean.
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Distension-Induced Pain in the Esophagus Correlates with Wall Stress and
Strain But Not with Mucosal Perfusion in Healthy Volunteers
Dag arne L. Hoff, Hans Gregersen, Svein Odegaard, Odd helge Gilja, Jan gunnar
Hatlebakk
BACKGROUND AND AIMS: Functional chest pain of presumed esophageal origin is common
in the population but its pathophysiology is essentially unknown. Bag distension in the
esophagus can often reproduce the pain in patient and healthy volunteers. The purpose of
this study was to investigate the relation between pain and wall-stress,-strain and -perfusion
in healthy subjects. METHODS: Twenty-nine healthy volunteers were studied. Four to five
bag distensions were performed in each volunteer using a novel catheter design incorporating
high frequency intraluminal ultrasound (20 Mhz, 360°), laser Doppler flowmetry and mano-
metry. We used an isovolumetric ramp distension protocol at 10 ml min-1, preconditioned
the tissue and trained the volunteer in assessing sensations on an electronic visual analogue
scale (VAS). Distensions were reversed at VAS = 7 (moderate pain). During the last 1-2
distensions, butylscopolamine (BS) was given to obtain a state of approximate passive stretch
condition. At each VAS 1-7 without and with BS, ultrasound images were traced and
simultaneous bag pressures and perfusion data were sampled. Biomechanical strain and
stress were calculated. The zero stretch state-condition was defined as VAS = 1 (first sensation)
after BS was administrated. Correlation was tested using multiple linear regression analysis
with VAS as the dependent variable, wall stress, strain and perfusion as the independent
variables. RESULTS: Data from 22 volunteers (14 F and 8 M, mean age 43, 6, range 24-
67) were analyzed and data from both genders could be pooled. Seven volunteers were
excluded mainly due to VAS = 7 not being reached or difficulties in image tracing. Cross
sectional area (CSAi) of the lumen calculated as mean ± SEM at VAS = 1, VAS = 5 (pain
threshold) and VAS = 7 did not significantly differ without and with BS. Using two-way
repeated measures ANOVA, no significant differences were seen for CSAi, CSAwall, or bag
pressure without or with BS. An average decline in perfusion units from VAS 1-5 and 1-7
of 17% and 26% without BS and 7 % and 15% with BS was found. Stress and strain
correlated significantly with the VAS response (P < 0.05). No significant correlation was
found for mucosal perfusion. CONCLUSION: We found a significant correlation between
wall stress, wall strain and sensation, indicating that the pain response caused by bag
distension in the esophagus is mechanical, rather than ischemic in healthy volunteers. Future
studies are needed to evaluate pain mechanisms in patients with functional chest pain who
show an accentuated pain response to distension.
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High-Resolution Manometry (HRM) in the Detection of Achalasia:
Computerized Algorithms of Analysis Tested On 400 Consecutive Patients
John Rice, John Pandolfino, Sudip K. Ghosh, John O. Clarke, Qing Zhang, Peter J.
Kahrilas
Aim: Given that achalasia is a disorder of LES relaxation, the detection of abnormal EGJ
relaxation is a primary objective of manometry. We hypothesized that the technical advance-
ments inherent in HRM coupled with computerized algorithmic analysis should objectify
the assessment of EGJ relaxation. Methods: 400 consecutive manometry patients and 75
controls were studied with a 36-channel HRM assembly (1 cm spacing) during water
swallows. Automated computer programs were written to calculate the integrated relaxation
resistance (IRR) and the pressurization front velocity (PFV). The IRR examines the entire
spatial domain of the EGJ both in terms of the completeness and persistence of relaxation
while the PFV quantified the velocity with which a 30mmHg pressure front traversed the
distal esophagus, be that attributable to a conducted contraction or intrabolus pressure.
Results: Using the 95th percentile values from controls (IRR, 3.0 mmHg/sec; PFV 4.5 cm/
sec) as a cutoff, 85 patients had a high IRR and 86% of them had a dominant symptom of
dysphagia. After correlation with other clinical data, 61/85 (72%) of patients with an IRR>3
had achalasia compared to 8/311 (2.6%) with normal IRR. These patients were then secondar-
ily characterized by PFV that led to 4 combinations of findings (Table). Of the 24 non-
achalasia patients, 6 were post-fundoplication or had a mechanical obstruction and 2 had
a brief LES relaxation in the setting of DES. The remaining 16 clearly exhibited a functional
disturbance but did not fit a conventional diagnosis and ultimately remained undefined.
Conclusion: HRM analysis paradigms utilized herein (IRR and PFV) offer a method to assess
abnormalities of EGJ function in greater detail than conventional manometry. The most
common HRM manifestation of achalasia was of abnormal outflow resistance coupled with
a rapidly propagated intrabolus pressure, often mimicking spasm.
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post-fundoplication (post-FP), diffuse esophageal spasm (DES)
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Investigation of Esophageal Sensation and Biomechanical Properties in
Functional Chest Pain
Issam Nasr, Mary Lamoureux-hartzler, Jose M. Remes-troche, Robert W. Summers, Satish
S. Rao
OBJECTIVES: There is limited data, and that too in small number of patients suggesting
that esophageal hypersensitivity and altered biomechanics may play a role in the pathogenesis
of functional chest pain. Our aims were to prospectively assess symptoms and the biomechan-
ical and sensory properties of the esophagus in consecutive patients with unexplained chest
pain and compare this to healthy controls. METHODS: Esophageal balloon distention test
(EBDT) was performed using impedance planimetry and increments of pressure in 174 (m/
f = 53/123; mean age 47 yrs) consecutive patients with noncardiac (normal stress thalium),
non-reflux (normal EGD, pH test or failed PPI therapy) chest pain, and 23 (m/f = 10/13;
mean age 43 yrs) healthy controls. The biomechanical and sensory properties of patients
with a positive EBDT (first perception ≤ 30 cm H2O distention and pain ≤ 55 cm H2O
distention pressure) were compared to those of healthy controls and patients with a negative
EBDT. Subjects also scored the frequency, intensity and duration of chest pain on a Likert
scale of (1-3). RESULTS (see table): 131 (75 %) patients had hypersensitive esophagus
whereas 43 (25%) had a normosensitive esophagus. Patients with positive EBDT demon-
strated larger cross sectional area (p<0.02), lower strain (p<0.02) and lower thresholds for
first perception (p<0.01), discomfort (p<0.01) and pain (p<0.01) when compared to the
other 2 groups. The reactivity of the esophageal wall was similar. Typical chest pain was
reproduced in 97/131 (74%) patients. Mean (sd) chest pain frequency was scored as 2.5
+/- 0.3, intensity as 2.2 +/- 0.2 and duration as 2.2 +/- 0.2 suggesting moderately intense
chest pain lasting 10 to 30 minutes. CONCLUSION: In this large series, 75% of patients
with well characterized functional chest pain demonstrated a hypersensitive esophagus with
a larger CSA and decreased wall strain or deformability. These findings confirm that visceral
hyperalgesia and sensori-motor dysfunction of the esophagus play a major role in the
pathogenesis of chest pain. EBDT can provide useful diagnostic and mechanistic insights
regarding functional chest pain.
bold = p< 0.02
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Estrogen Stimulates Duodenal Mucosal Bicarbonate Secretion Via CFTR
Channels
Hui Dong, Anders Smith, Cheyanne Contreras, Andrew Huynh, Marjan Hovaida,
Dongbao Chen
Background & Aims: Estrogen exerts protective effects against the development of many
disorders in women, but limited information is available regarding the protection of sex
hormones in the intestinal tract. A few epidemiological studies indicate that men possess at
least 2-fold incidence in duodenal ulcers than age-matched women. However, the underlying
mechanism of the gender difference in duodenal ulcers is currently unknown. Because the
most striking difference between men and women is sex steroid hormones particularly
estrogen, we propose that estrogen may be the major cause attributing to the gender
differences in duodenal ulcers. Since cystic fibrosis transmembrane conductance regulator
(CFTR)-mediated duodenal mucosal bicarbonate secretion (DMBS) is one of the main protect-
ive mechanisms against gastric acid-induced injury, in this study we tested whether estrogen
stimulates DMBS via CFTR channels. Methods: Duodenal mucosae from C-57 black mice
were stripped of seromuscular layers and mounted in Ussing chambers. Both short-circuit
current (Isc) and HCO3- secretion were measured In Vitro. DMBS from C-57 black mice and
CFTR knock out mice was also measured in In Vivo studies. Western blot analysis and cell
digital Ca2+ imaging were performed in duodenal epithelial cells to detect expression of
estrogen receptors (ER) and their signaling pathway. Results: Acid (10 mM)-stimulated
DMBS is 2-fold greater in C-57 black female than male mice (net peak DMBS: 20.3 ± 0.54
vs. 8.4 ± 1.5 μmol/cm.h, P<0.001, n=5) and DMBS response to acid was abolished by an
estrogen receptor (ER) antagonist, tamoxifen. Perfusion of duodenal lumen with 17β-estradiol
(E2) at 100 nM rapidly stimulated DMBS in female mice in In Vivo experiments (2.6 ± 0.4
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μmol/cm.h, P<0.01, n=5), which again was attenuated by tamoxifen. E2 (10-100 nM)
stimulated DMBS In Vitro in a dose-dependent manner, but did not alter basal duodenal
Isc. Moreover, E2 was unable to stimulate DMBS in CFTR-null mice (3.8 ± 0.4 μmol/cm.h
for wild-type vs. 0.7 ± 0.2 μmol/cm.h for knock-out, P<0.001, n=5). Western blot analysis
demonstrated expression of ERα and ERβ proteins in duodenal epithelial cells. E2 rapidly
increased free cytoplasmic Ca2+ levels ([Ca2+]cyt) in these cells, which was mimicked by E2-
BSA, a membrane-impermeable E2 analog. Conclusion: Our data suggest that upon ER
stimulation, DMBS is rapidly increased in association with a rise in [Ca2+]cyt in duodenal
epithelial cells. Furthermore, the estrogen-induced DMBS may be mediated via a CFTR-
dependent pathway.
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Role of Phosphatidylinositol 3-Kinase in Murine Duodenal Ion Transport and
Bicarbonate Secretion
Biguang Tuo, Guorong Wen, Yalin Zhang, Hui Dong
Background&Aims: Phosphatidylinositol 3-kinase (PI3K) is an important signaling pathway
involved in cell growth regulation, migration, metabolism and intestinal Cl- secretion. How-
ever, very little is known about the role of PI3K in the duodenal ion transport, particularly
duodenal mucosal bicarbonate secretion (DMBS). Since DMBS is a major protective mechan-
ism against gastric acid-induced injury, the aim of the present study was to test whether
PI3K plays import roles in duodenal ion transport and DMBS; and if any, what the underlying
mechanisms are. Methods: Murine duodenal mucosae were stripped of seromuscular layers
and mounted in Ussing chambers. Both short-circuit current (Isc) and HCO3- secretion
were measured In Vitro. Cell digital Ca2+ imaging and phosphorylation of cystic fibrosis
transmembrane conductance regulator (CFTR) were also performed in duodenal epithelial
cells. Results: Carbachol (CCh, 100 μM), forskolin (10 μM), or 8-Br-cGMP (200 μM)
markedly stimulated duodenal Isc and DMBS (n≥8 in each series, P<0.0001) via a Ca2+,
cAMP, or cGMP signaling pathway in CFTR wild type mice, but not in CFTR knockout
mice. Wortmannin (0.1 μM), a PI3K inhibitor, reduced CCh-, forskolin- or 8-Br-cGMP-
induced DMBS in CFTR wild type mice by 45.07%, 46.67% or 54.76%, and Isc by 46.15%,
50.93% or 48.76% (n≥8 in each series), respectively. LY294002 (15μM), another structurally
and mechanically distinct PI3K inhibitor, exerted similar inhibitory effects on CCh-, forskolin-
or 8-Br-cGMP-induced DMBS and Isc. Moreover, CCh, forskolin or 8-Br-cGMP induced
phosphorylation of CFTR in duodenal epithelial cells (n=3 for each activator), which was
markedly inhibited by wortmannin. CCh raised free cytoplasmic Ca2+ in intestinal epithelial
cells via induction of intracellular Ca2+ release and extracellular Ca2+ entry (n=50 cells,
p<0.05). Again, either wortmannin or LY294002 markedly reduced CCh-induced intracellu-
lar Ca2+ release and extracellular Ca2+ entry (n=50 cells for each inhibitor, p<0.05). Conclu-
sion: PI3K is an essential signaling pathway for Ca2+-, cAMP- or cGMP-mediated duodenal
ion transport and bicarbonate secretion. PI3K may cross talk with cytoplasmic Ca2+-, cAMP-
or cGMP, and regulate CFTR channels.
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CFTR Inhibition Activates Nhe-3 During Luminal High CO2 Exposure in Rat
Duodenal Mucosa
Misa Mizumori, Yuri Choi, Paul H. Guth, Eli Engel, Jonathan D. Kaunitz, Yasutada Akiba
The duodenum absorbs most of the gastric acid output by luminal neutralization with
secreted HCO3- and absorption of generated CO2. We hypothesized that in addition to bulk
luminal neutralization, cell surface neutralization occurred by either HCO3- or H+ secretion
via apical membrane transporters. We thus examined the effect of inhibition of Na+/H+
exchanger-3 (NHE-3), CFTR or apical anion exchangers on CO2 diffusion and HCO3-
secretion in rat duodenum. Duodena were perfused with pH 6.4 high CO2 solution (PCO2 =
260 Torr) or pH 2.2 solution (PCO2 ≈ 0) +/- co-perfusion of the NHE-3 inhibitor, S3226
(10 µM) or the anion transport inhibitor DIDS (0.1 mM), or pretreatment with the potent
CFTR inhibitor, CFTRinh-172 (1 mg/kg, ip, 1 hr prior). Flow-through pH and CO2 electrodes
simultaneously and continuously measured perfusate and effluent pH and [CO2]. Portal
venous (PV) pH and PCO2 were analyzed at the end of the luminal challenge. Luminal
perfusion with the high CO2 solution increased CO2 loss from the perfusate and increased
net HCO3- secretion into the lumen, compared with pH 6.4 saline, accompanied by PV
acidification and PCO2 increase. CFTRinh-172 alone had no effect on basal CO2 or HCO3-
movement or on PV pH and PCO2, but increased net HCO3- absorption, while inhibiting
PV acidification during CO2 challenge. S3226 itself had no effect on CO2 absorption from
the lumen into the PV, but nevertheless reversed CFTRinh-associated increased CO2 and
HCO3- absorption in the presence of high luminal CO2. DIDS inhibited HCO3- secretion
during CO2 challenge, with no further effect of S3226. Furthermore, luminal pH 2.2 challenge
increased H+ and generated CO2 absorption and acidified the PV, inhibited by CFTRinh-
172 and DIDS, but not by S3226. CFTR inhibition reversed HCO3- secretion to HCO3-
absorption, and inhibited PV acidification during CO2 challenge, suggesting that HCO3-
secretion helps facilitate CO2/H+ absorption. Reversal of increased HCO3- loss by NHE-3
inhibition is consistent with NHE-3 activation during CFTR inhibition, increasing cell surface
H+ available to neutralize luminal HCO3- with consequent CO2 absorption. The lack of
S3226 effect after DIDS suggests that inhibition of HCO3- secretion alone was insufficient
to activate NHE-3. These results suggest, as has been demonstrated previously, that CFTR
and NHE-3 are reciprocally activated; with CFTR inhibition activating NHE-3, best observed
during luminal CO2 rather than H+ stress. Epithelial HCO3- secretion is essential for CO2/
H+ absorption by neutralization and conversion in rat duodenal mucosa. These results further
explain defective cellular acidification associated with CFTR dysfunction.
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The Role of Slc26a6 and CFTR in Acid-Induced and Prostaglandin E2-
Stimulated Duodenal Bicarbonate Secretion In Vivo
Anurag Singh, Markus Sjöblom, Anja Krabbenhöft, Brigitte Riederer, Manoocher
Soleimani, William Colledge, Ursula Seidler
Duodenal mucosal HCO3- secretion is a key factor in epithelial protection against injury by
the acid discharged from the stomach. The aim of this investigation was to elucidate the
role of the chloride/base exchanger SLC26A6, which is highly expressed in duodenal brush
border membrane, and the cystic fibrosis transmembrane regulator (CFTR) in basal and
stimulated murine duodenal HCO3- secretion In Vivo. Methods: Basal, forskolin- and PGE2-
stimulated HCO3- secretion was examined in Slc26a6- and CFTR-deficient mice and in their
wild type (WT) counterparts. The isolated proximal duodenum was perfused in situ with
isotonic saline, and HCO3- secretion was determined by back-titration in the basal state
and during the luminal stimulation with PG E2, forskolin and after exposure to acid (luminal
pH 2.5). Results: The basal secretory rates of bicarbonate were similar in Slc26a6-deficient
and WT mice, but significantly reduced in mice deficient in CFTR. Luminal acidification
induced the same increase in HCO3- secretion in Slc26a6-deficient and WT mice (net peak,
1.71 ± 0.31 vs. 1.49 ± 0.36 µmol x cm-1 x h-1 respectively, p = 0.61). Slc26a6-deficient
mice displayed a significant reduction in HCO3- secretion in response to 10-5 M luminal
PGE2 compared to WT mice (net peak, 2.37 ± 0.29 vs. 4.61 ± µmol x cm-1 x h-1, p =
0.01), while forskolin-stimulated HCO3- secretion was not different. CFTR-deficient mice
displayed a substantial reduction in both PGE2-stimulated and acid-induced HCO3- secre-
tion. Conclusion: SLC26A6 plays an important role in PGE2-stimulated murine duodenal
HCO3- secretion In Vivo. The HCO3- secretory response to acid, however, is not influenced
by the lack of SLC26A6, whereas it is markedly depressed in the absence of CFTR.
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Role of the Nherf Adapter Proteins NHERF1, NHERF2/E3karp and NHERF3/
Pdzk1 in the Regulation of Murine Duodenal Bicarbonate Secretion In Vivo
Anurag Singh, Anja Krabbenhöft, Brigitte Riederer, Boris Hogema, Hugo De jonge, Mark
Donowitz, Edward Weinman, Oliver Kocher, Ursula Seidler
Heterologous expression studies have demonstrated that a family of adapter proteins called
the NHERF family bind to the cystic fibrosis membrane regulator (CFTR) and modulate its
membrane expression, conductivity and interaction with other transport proteins. Their role
in the regulation of CFTR-dependent intestinal anion secretion In Vivo has not been studied.
The aim of this investigation was to elucidate the role of these adaptor proteins in regulation
of murine duodenal bicarbonate secretion In Vivo. Methods: Basal and stimulated duodenal
HCO3- secretion was examined in the NHERF1, E3KARP (NHERF2), PDZK1 (NHERF3),
double (NHERF1 and PDZK1) and triple (NHERF1/E3KARP/PDZK1) +/+ and -/- mice. The
triple ko mice displayed a delayed growth rate but no gross pathology. After anaesthesia,
the proximal duodenum was cannulated and perfused with isotonic saline, and HCO3-
secretory rates in the basal state and after stimulation with luminal forskolin was determined
by back-titration. Results: The basal secretory rates of bicarbonate were similar in E3KARP-
deficient and wt mice, but significantly reduced in mice deficient for NHERF1 (40% of the
respective wt littermate), for PDZK1 (45%), for NHERF1/PDZK1 (38%) and for NHERF1/
E3KARP/PDZK1 (53%). The secretory response to luminal perfusion with 100 µM forskolin
was significantly reduced only in the NHERF1-deficient (47% of the respective wt mice), the
NHERF1/PDZK1-deficient (36%) and the NHERF1/E3KARP/PDZK1-deficient mice (53%).
Conclusions: 1) By studying basal and cAMP stimulated duodenal HCO3- secretion we
demonstrated that different NHERF proteins are necessary for basal vs stimulated secretion.
2) The absence of the adapter proteins NHERF1 as well as NHERF3/PDZK1 resulted in
significantly reduced basal HCO3- secretion in a non-additive manner. This indicates both
NHERF1 and NHERF3/PDZK1 are necessary for some aspects of the basal pathway. 3) In
contrast, the duodenal HCO3- secretory response to elevated cAMP only dependent on
NHERF1. This suggests not only that cAMP turns on additional regulatory steps involved
in HCO3- secretion but that it turns off the NHERF3/PDZK1 steps involved in basal HCO3-
secretion. 4) The major NHERF adaptor protein involved in regulation of duodenal bicarbon-
ate secretion is NHERF1.
53
Hydrogen Sulfide Stimulates HCO3- Secretion in Rat Stomachs: Involvement of
Prostaglandins, Nitric Oxide and Sensory Neurons
Fumitaka Ise, Eitaro Aihara, Koji Takeuchi
Background/Aims: Hydrogen sulfide (H2S), generated endogenously from L-cysteine by
cystationine-β-synthase (CBS) and cystathionine-γ-lyase (CSE) in mammalian cells, has
recently been recognized as an important gaseous mediator that affects various functions
under physiological and pathological conditions. However, the functional role H2S plays in
the gastrointestinal tract remains unknown. In the present study, we examined the effect
of NaHS, a H2S donor, on HCO3- secretion in rat stomachs and investigated the mechanism
involved in this response induced by H2S. Methods: Male SD rats were used after 18 h
fasting. Under urethane anesthesia, the stomach was mounted on an ex vivo chamber and
perfused with saline. Acid secretion had been inhibited by omeprazole (30 mg/kg) given
IP. Under these conditions, the secretion of HCO3- was measured at pH 7.0 using a pH
stat-method and by adding 10 mM HCl. NaHS (0.5~20 μmol/ml) or HCl (mucosal acid-
ification; 200 mM) was applied topically to the stomach for 5 min or 10 min, respectively,
whereas prostaglandin (PG) E2 (0.3 mg/kg) was given IV as a single injection. Indomethacin
(5 mg/kg, SC), glibenclamide (KATP channel blocker; 10 mg/kg, IP), pinacidil (KATP channel
opener; 10 mg/kg, IP) or propargylglycine (CSE antagonist; 50 mg/kg, IP) was given 30
min before NaHS treatment, while L-NAME (nitric oxide (NO) synthase inhibitor; 20 mg/
kg, SC) was given 3 h before. Results: Intraluminal application of NaHS significantly and
dose-dependently increased the secretion of HCO3- in the stomach. This action of NaHS
was significantly attenuated by indomethacin, L-NAME and glibenclamide as well as chemical
ablation of capsaicin-sensitive afferent neuron, but not by pinacidil. On the other hand,
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PGE2 stimulated gastric HCO3- secretion, and this action was totally inhibited by ONO-
8711, the EP1 antagonist, and partially mitigated by glibenclamide but not indometahcin,
L-NAME, pinacidil or sensory deafferentation. In addition, it was found that the acid-
induced HCO3- secretion was also partially but significcantly mitigated by glibenclamide
or propargylglycine. Conclusions: These results suggest that H2S increases HCO3- secretion
in rat stomachs, and this action is partly mediated by PG, NO and sensory neurons and
associated with the activation of ATP-sensitive K+ channel and EP1 receptors. Furthermore,
since the acid-induced HCO3- secretion was negatively affected by the inhibitor of H2S
production, it is assumed that this gaseous mediator is involved in the regulatory mechanism
of gastric HCO3- secretion.
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Adiponectin a Novel Marker of Disease Severity in Crohn's Disease
Razvan I. Arsenescu, Houssam E. Mardini, Harry Elvanides, Trevor A. Winter, Deborah R.
Flomenhoft, Lisbeth A. Selby, Munira Nasser, Michelle Glenn, Brett Spear, Willem J. De
villiers
Background & Aims: Crohn's disease (CD) is a chronic inflammatory bowel disease character-
ized by transmural inflammation and mesenteric fat hypertrophy from the onset of disease.
The association of fat hypertrophy with Crohn's disease raises the possibility that adipokines
regulate the immune response in this disease entity. We investigated whether Adiponectin,
an abundant anti-inflammatory adipokine, is associated with a favorable outcome in Crohn's
disease. Methods: We prospectively followed 52 CD patients over a nine months interval.
Disease phenotype, need for surgery, body mass index (BMI), waist to hip ratio (WHR),
disease activity, serum levels of adipokines, Adiponectin fractions, Th1 and Th2 cytokines
were recorded at 3 time points. Adiponectin gene polymorphisms in the promoter region
(A>G11426, G>A11377), were determined. Patient's characteristics were compared between
those with and without a specific mutation. Matched controls were selected form healthy
individuals presenting for screening colonoscopy. Results: After correcting for BMI and
WHR, CD patients were found to have higher levels of total Adiponectin. In controls, high
molecular order Adiponectin (HMWA), the main anti-inflammatory fraction, represented >
90% of circulating Adiponectin compared with a 30-50% decrease of HMWA in CD patients.
Among patients with CD, lower Adiponectin levels correlated significantly with stricturing
disease or need for surgery. There was no association with disease activity or location. There
was a statistically significant, positive association between Adiponectin and the Th2 cytokine
IL-4 (p=0.0001). Adiponectin gene polymorphisms in the promoter region (A>G11426,
C>G11377) were associated with more aggressive/complicated phenotypes, p = 0.0001 and
0.039 respectively. Compared to patients with inflammatory phenotype those with stricturing
disease were more likely to be A>G11426 heterozygote or homozygote, odds ratio (OR) for
heterozygote and homozygote combined 5.4, (CI: 3.7-14.5). In addition, patients with
fistulizing disease were more likely to be heterozygote OR 6.8, (CI 4.8-18.6). C>G11377
heterozygosity was associated with stricturing disease only OR 2.1; CI 1.4-4.4). Conclusions:
Adiponectin is associated with a favorable outcome in CD. Failure to upregulate the HMW
fraction of this adipokine as well as single nucleotide polymorphisms in the proximal
promoter region of the Adiponectin gene are associated with an aggressive phenotype in
Crohn's disease. Adiponectin promotes a beneficial Th2 response (IL-4). Pharmacologic
manipulation of Adiponectin levels might represent a novel approach in the treatment of CD.
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Role of Intestinal Lipid and Apolipoprotein (APO) A-IV in the Systemic
Inflammatory Response to Experimental Sepsis in Mice
Jorg Glatzle, Donia Bohan, A. Konigsrainer, Helen Raybould
Lipid in the intestine activates a cholecystokinin type 1 receptor (CCK1R), vagal afferent
anti-inflammatory pathway in rats (Luyer et al, J Exp Med 202: 1023, 2005). Apo A-IV is
released from enterocytes during active lipid absorption; apo A-IV has anti-inflammatory
actions (Vowinkel et al, J Clin Invest 114: 160, 2004) and mediates activation of the CCK
1R, vagal afferent pathway and functional responses to intestinal lipid (Whited et al, J Physiol.
569: 949, 2005). Hypothesis: Apo A-IV mediates the CCK 1R-dependent anti-inflammatory
pathway induced by intestinal lipid. Methods: Experiments performed in C57/B6 (apo A-
IV+/+, WT) or apo A-IV-/- (KO) mice. Mesenteric lymph was obtained from lymph fistula
donor mice for 6h before (control lymph, CL) and for 6 h after induction of sepsis (lipopoly-
saccharide, LPS, 5mg/kg IP; sepsis lymph, SL). During lymph colleciton, mice were intestinally
infused with either glucose or a 1% olive oil solution (ClinOleic, Baxter; 0.5ml/h). Cytokines
(Il-6, IL-10, TNFα, IFNγ) were detected in lymph using Bio-Plex multiple bead ELISA
system. Lymph (CL and SL) collected from WT and KO mice given either glucose or lipid
intraduodenally was infused into separate recipient C57/B6 mice for 2 h (0.5ml/h, IV). Lung
tissue was harvested and analyzed for myelo-peroxidase (MPO) positive cells (measure of
inflammatory response) and TUNEL positive cells (measure of apoptosis) using the Leica
Quantimed system (n=3 mice per group, n=30 optical sections per mouse). Results: The
number of MPO or TUNEL positive cells in lungs of recipient mice was significantly increased
after infusion of SL compared to CL (# MPO positive cells; 1 ± 1 vs 22 ± 1, CL with glucose
vs SL with glucose; p<0.01); duodenal perfusion with lipid produced a protective effect
which was significantly reduced in A-IV-/- compared to WT mice (# MPO positive cells; 23
± 2 vs 14 ± 1 vs 23 ± 2; SL with glucose vs SL with lipid vs SL with lipid in apo A-IV-/-;
p<0.05, n=3). Sepsis induced an increase in mesenteric lymph concentrations of TNFα (86
± 12 vs 780 ± 311 pg/ml), IL-10 (1764 ± 1426 vs 13458 ± 707 pg/ml) and IL-6 (3327 ±
1284 vs 28849 ± 17414 pg/ml) (CL with glucose vs SL with glucose, n=5). Sepsis-induced
increases in TNFα and IL-10 were reduced by 60% and 70%, respectively, by intraduodenal
lipid perfusion. Conclusion: Septic shock releases inflammatory mediators, including cyto-
kines, into mesenteric lymph which induce lung inflammation in recipient mice. The protect-
ive effect of lipid on sepsis-lymph induced inflammation requires apo A-IV. Activation of
the lipid-induced anti-inflammatory pathway mediated by CCK1R and vagal afferents may
involve apo A-IV.
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Enteric Neural Pathways Mediate the Anti-Inflammatory Actions of Glucagon-
Like Peptide 2
David L. Sigalet, Laurie Wallace, Jens J. Holst, Gary Martin, Tatsuru Kaji, Hiroaki Tanaka,
Keith A. Sharkey
Aims/Background : Glucagon-like peptide-2 (GLP-2) is an important regulator of nutritional
absorptive capacity with anti-inflammatory actions. GLP-2 receptors are found on vasoactive
intestinal polypeptide (VIP) immunoreactive enteric neurons. We hypothesized that GLP-2
reduces intestinal mucosal inflammation by activation of VIP neurons of the submucosal
plexus. Methods: Ileitis or colitis was induced in rats by injection of trinitrobenzene sulfonic
acid (TNBS), or colitis by administration of dextran sodium sulphate (DSS) in drinking
water. Subsets of animals received (1-33) GLP-2 (50 μg/kg s.c. bid) either immediately, or
2 days following the establishment of inflammation and were followed for 3-5 days. The
involvement of VIP neurons was assessed by concomitant administration of GLP-2 and the
VIP antagonist VIP 7-28-Neurotensin-6-11 and by immunohistochemical imaging of GLP-
2 activated submucosal neurons. Results: In all models, GLP-2 treatment, whether given
immediately, or delayed until inflammation was established, resulted in significant improve-
ments in animal weights, mucosal inflammation indices (myeloperoxidase [MPO] levels,
histological mucosal scores) and reduced levels of inflammatory cytokines (IFNγ, TNFα,
IL-1β) and iNOS, with increased levels of IL-10 in TNBS-ileitis and DSS-colitis. Reduced
rates of crypt cell proliferation and in apoptosis within crypts in inflamed tissues were also
noted with GLP-2 treatment. These effects were abolished with co-administration of GLP-
2 and the VIP antagonist (body weight [% of initial], TNBS, -11.7 ± 1.5; TNBS+GLP-2, -7.8
± 1.5; TNBS+GLP-2+VIP antagonist, -15.1 ± 1.7; p<0.05; MPO [U/mg], TNBS, 18.3 ± 6.1;
TNBS+GLP-2, 4.8 ± 1.4; TNBS+GLP-2+VIP antagonist, 37.3 ± 12; p<0.05; IL-1β [pg/g],
TNBS, 5,287 ± 398; TNBS+GLP-2, -3,199 ± 211; TNBS+GLP-2+VIP antagonist, 6,017 ±
1,669; p<0.05). GLP-2 was shown to activate VIP neurons in the submucosal plexus of the
ileum, as determined by immunohistochemical co-localization of cFos and VIP (Control,
4.0 ± 0.7 Fos cells/ganglion; GLP-2, 8.2 ± 1.6 Fos cells/ganglion). Conclusions: These
findings suggest that GLP-2 acts as an anti-inflammatory agent through activation of enteric
VIP neurons, independent of proliferative or apoptotic effects. They support further studies
to examine the role of neural signalling in the regulation of intestinal inflammation. Supported
by the Crohn's and Colitis Foundation of Canada and NPS Pharmaceuticals.
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Regulation of Sonic Hedgehog By Pro-Inflammatory Cytokines
Meghna Waghray, Yana Zavros, Andrea Todisco, Robert H. Gilman, Juanita L. Merchant
Objective: The molecular mechanisms, underlying changes in the gastric mucosa from
chronic inflammation to atrophy and eventually to cancer, are not well understood. Recent
studies from different groups showed changes in the morphogen sonic hedgehog (Shh),
during gastric transformation. During the progression from inflammation to atrophy the
parietal cells are replaced by Shh expressing mucous cells, the cell type that presumably
progresses to cancer. H. pylori infection is marked by a Th1 cytokine profile, which includes
IFN-γ, IL-1β and TNFα. Thus we tested whether these three proinflammatory cytokines
regulated Shh expression. Methods: Sections from H. pylori infected patients were stained
with anti-H+,K+-ATPase and anti-Shh antibodies. Primary canine parietal and NCI-N87 cells
were treated with IFN-γ, IL-1β, and TNF-α. The amount of Shh in cell extracts and the
media for each treatment was analyzed by immunoblot. Shh in the media was fractionated
on a size exclusion column Superose 12, concentrated and analyzed. Each fraction was
resolved on a 4-20% SDS-PAGE. Results: Atrophic changes were detected in patients infected
with H. pylori. There was reduction in Shh staining of the parietal cells, whereas levels of
Shh were significantly elevated in the mucous cells. When parietal cell cultures were treated
with IFN-γ, IL-1β, TNF-α, we found that there are differential effects of these three cytokines
on parietal cell expression of Shh. IFN-γ−stimulated, but IL-1β, and TNF-α inhibited Shh
expression. Interestingly when NCI-N87 cells were treated with IFN-γ, IL-1β, and TNF-α,
we found that all three cytokines enhanced Shh cell expression . Conclusion: There are
differences in the levels of Shh expression as a function of cell type. Specifically only IFN-
γ stimulates Shh in parietal cells; whereas IFN-γ, IL-1β, and TNF-α stimulate Shh in a
mucous cell line.
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Nitrosylation of Tyrosine Residues of Smooth Muscle Calcium Channels
During Colonic Inflammation
Minho Kang, Gracious R. Ross, Mary Drozd, Hamid I. Akbarali
Colonic inflammation results in attenuated Ca2+ currents and impairs muscle contraction.
The high basal levels of the non-receptor tyrosine kinase, c-src kinase, in smooth muscle
are known to regulate Ca2+ channels via interaction with its carboxy terminus. We have
previously shown that colonic inflammation markedly reduces src kinase mediated modula-
tion of the Ca2+ channels and may account for the decreased currents (Kang et al., 2004).
The objective of the present study was to determine the mechanisms by which src-kinase
regulation is altered during inflammation. GST-fusion proteins were constructed by PCR of
(i) the C-terminus (aa: 1865-2172) of human jejunum α1c (GST-CT), (ii) with deletion of
the proline rich domain (aa 1191-1999: RGWPPQP) GST- ΔPRD, and (iii) SH3 and SH2
binding domains of c-src kinase (GST-SH3, GST-SH2). Pull down assays revealed association
of src-kinase with GST-CT but not GST-ΔPRD. Overlay binding assays of purified CT and
ΔPRD with GST-SH3 showed that SH3 binding was prevented in ΔPRD while binding to
GST-SH2 only occurred following phosphorylation by src kinase. Single mutations of each
of the 3 tyrosine residues (Y1837F; Y1861F; Y2134F) within CT, did not prevent SH2
interaction or tyrosine phosphorylation as detected by immunoblot. SH2 binding was how-
ever inhibited in the double mutant (Y1837F/Y2134F). Pretreatment of the CT fragment
with peroxynitrite/SIN-1 prevented src-mediated phosphorylation and GST-SH2 binding of
the double mutant. Immunoblot with anti-nitrotyrosine antibody (Ab-NY) revealed nitrotyro-
sylation of CT and single mutants but not the double mutant. Nitrotyrosylation of the
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smooth muscle Ca2+ channel was examined by immunoprecipitation with anti-α1c followed
immunoblot with Ab-NY from control and TNBS inflamed mice colon. Inflamed lysates
showed nitrotyrosylation of the 240kDa Ca2+ channel but not in controls. Contractile
responses of control and inflamed colonic tissues were measured by isometric tension
recordings. In K+ depolarizing solutions, contractile responses to 1 mM Ca2+ were markedly
reduced (60%) by PP2 (10 μM), a src kinase inhibitor, in control but not in inflamed tissues.
Following pretreatment with peroxynitrite/SIN-1, maximal contraction to Ca2+ was reduced
by 46±7% in controls but unaffected in inflamed and the effects of PP2 were inhibited.
These studies suggest that posttranslational modification of the Ca2+ channels during inflam-
mation due to nitrosylation of the residues Y1837 and Y2134, prevents c-src kinase regulation
of Ca2+ channels resulting in decreased Ca2+ influx.
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Adiponectin and the Plant Agonist Osmotin Promote IL-10 Production in a
Murine Model of Colitis
Razvan I. Arsenescu, Jian Zhong, Meena Narsimhan, Joanne Wroblewski, Violeta
Arsenescu, Eric Eckhardt, Willem De villiers
Background and aims: Adiponectin, an adipokine secreted exclusively by adipocytes has
potent anti-inflammatory properties. Mesenteric fat hypertrophy is associated with Crohn's
disease. The role of Adiponectin in Crohn's disease is unresolved. In the present study we
investigated whether Adiponectin and the plant-derived agonist Osmotin are beneficial in
a murine model of colitis. Methods: Male C57BL/6 mice with dextran sodium sulfate (DSS)-
induced colitis, received either Adiponectin (via adenovirus vector) or reporter LacZ gene,
48 hrs prior to DSS exposure. In a second experiment mice with DSS colitis received Osmotin
or saline, subcutaneously, via osmotic pumps. Disease progression was evaluated for 10
days by measuring body weight, stool consistency and rectal bleeding. Postmortem colon
lengths and histology were used to compare the groups. Levels of the acute phase protein
serum amyloid A (SAA), Adiponectin, pro-inflammatory cytokines IL-1β, IL-12 and adipok-
ines Leptin and Rezistin, the anti-inflammatory cytokine IL-10, were measured in the serum.
Supernatants from homogenized colon samples were analyzed for IL-10, IL12, Adiponectin,
Adiponectin receptors, COX-2 and FAS. Results: Following DSS exposure, Adiponectin
treated mice exhibited significantly decreased disease activity compared to control mice, as
evidenced by reduced rectal bleeding, weight loss, and histological intestinal injury (P<0.001).
The colonic epithelium in the treated group displayed reduced apoptosis and increased
proliferation as judged by levels of COX-2, Fas and PCNA (proliferating cell nuclear antigen).
Furthermore, serum level of SAA was nearly abolished in the treatment group while proin-
flammatory adipokines- Leptin, Rezistin and cytokine IL-12 decreased significantly. IL-10
increased significantly in the treatment group both in the serum and colon (P<0.001).
Macrophage infiltration into colonic tissue was markedly attenuated in the Adiponectin
treatment group. The Osmotin treated mice showed a statistically significant improvement
in anemia and body weight. Serum levels of IL-1β, IL12 and Leptin decreased significantly
while IL-10 increased. Conclusions: Adiponectin and the plant agonist Osmotin attenuate
murine colitis. Their anti-inflammatory action involves systemic and local production of IL-
10. Adiponectin and the naturally occurring plant agonist represent novel therapeutic agents
for inflammatory bowel diseases.
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Statin Use and the Risk of hepatocellular carcinoma
Hashem El-serag, Michael Johnson, Mark Kuebeler, Robert Morgan
Background Experimental studies indicate a potential cancer prevention effect for statins.
The current epidemiological evidence is scant. Given the increasing prevalence of statin use,
and the rising incidence of hepatocellular carcinoma (HCC), the potential association between
statins and HCC is an important issue. Methods We conducted a case-control study nested
within a cohort of patients with diabetes. The cohort was constructed from newly identified
diabetes during CY 1997 through CY 2002 from inpatient and outpatient files of national
VA databases and linked to VA pharmacy use and Medicare files for 1999-2002. Cases
comprised HCC occurring at least 6 months following entry in the cohort. Cases were
matched on incidence density sampling to controls who remain at risk at the date of the
HCC diagnosis for the case, as well as on age and gender. Cases and controls had to have
continuous enrollment in non HMO Medicare and to have at least one VA pharmacy use.
We identified statin prescriptions as well as potential confounders. Odds ratios (OR) as
estimates of the relative risk for HCC associated with statin use and 95% CIs were obtained
using conditional logistic regression. To examine confounding by indication, we analyzed
non-statin cholesterol as well as triglyceride lowering medications. Results We examined
1303 cases matched to 5212 controls, who fulfilled our inclusion and exclusion criteria.
The mean age was 72.3 (+/- 8.2), 98.7% were men, and the ethnic distribution was 82.3%
white, 13.7% black, and 4.0% other. The average follow up was 2.4 years (max. 4) preceding
cancer date. A significantly smaller proportion of cases (53.1%) had at least one statin
prescription compared with controls (34.3%) of control. The unadjusted OR for the associ-
ation of HCC and any statin prescription was 0.46 (0.40-0.52); p<0.0001. To reduce the
potential confounding effect of existing liver disease, we analyzed a subgroup of 788 cases
and 4733 controls with no recorded cirrhosis, alcoholic liver disease, hepatitis B or C, or
alcoholism. The ORs were slightly attenuated but remained highly significant both for any
statin prescription (0.61 (0.52-0.72); p<0.0001), and for statin prescriptions longer than 3
years (0.66 (0.52-0.86); 0.002). No significant association was observed between HCC and
either non-statin cholesterol or triglyceride lowering medications. Conclusions In patients
with diabetes, statin use may be associated with a significant 40% to 50% reduction in the
risk of hepatocellular carcinoma. These findings are also observed in a subgroup of patients
with no known viral or alcoholic liver disease.
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Oral Contraception and the Risk of hepatocellular carcinoma: A Meta-Analysis
Shail Maheshwari, Amrou Sarraj, Jennifer R. Kramer, Hashem B. El-serag
Background: We performed a meta-analysis of observational epidemiological studies to
examine the association between oral contraceptives (OC) and hepatocellular carcinoma
(HCC). Methods: Two independent researchers conducted PubMed searches followed by
systematic abstraction of studies that compared OC use between patients with HCC and a
group of controls. For each study, odds ratios (OR's) both unadjusted as well as adjusted
were obtained or calculated, if possible. Pooling of OR's was conducted using a random
effects model. Heterogeneity and publication bias among studies were examined. Results:
Twelve case-control studies that included 740 cases and 5,223 controls met the inclusion
and exclusion criteria. The most recent study was conducted in 1997. Eight studies reported
adjusted OR's; The pooled estimate was 1.22 (95% CI=0.76-1.96, p=0.40) with a moderate
heterogeneity of I2=24.4. The pooled unadjusted estimate of OR's from all twelve studies
was 1.43 (95% CI=0.90-2.26, p=0.13) with a heterogeneity of I2=38.4. Six studies examined
the effect of duration and showed a significant 2 to 20-fold increase in HCC risk with longer
durations of OC use (typically more than 5 years). Conclusions: Short-term OC use is not
associated with an increased risk of HCC. However, there is an indication of a weak association
between long-term OC use and increased HCC risk. Future studies should focus on newer
OCP preparations, the duration, intermittency, and recency of OC use.
Forest plot showing unadjusted OR's and 95% CI for the association between OC and HCC
in twelve studies. All but one study showed a non-significant association between OC use
and HCC as indicated by unadjusted OR. The calculated pooled estimate of unadjusted
OR's for any OC use (bottom diamond) was 1.43 (95% CI=0.90-2.26, p=0.13).
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Risk of Hepato-Pancreatico-Biliary Tumors Following Hepatitis C Virus
Infection: A Population-Based Study On U.S. Veterans
Hashem El-serag, Eric A. Engels, Louise Henderson,, Ola Landgren, Thomas P. Giordano
Background: Hepatitis C (HCV) may increase the risk of hepato-pancreatico-biliary tumors,
other than hepatocellular carcinoma. Previous case-control studies in elderly Medicare recipi-
ents indicated a possible association between HCV and intra hepatic cholangiocarcinoma
(ICC). Little is known about the association between HCV and extra hepatic cholangiocarcin-
oma (ECC) or pancreatic cancer. Methods: We conducted a cohort study including 146,394
HCV-infected and 572,293 HCV-uninfected users of U.S. Veterans Affairs healthcare facilities.
We used the inpatient, outpatient, and death files of the national computerized VA adminis-
trative databases. Patients with two visits with a diagnostic code for HCV infection from
1996-2004 were included, as were up to four HCV-uninfected subjects for each HCV-
infected subject, matched on age, gender, and baseline visit date. Risks of ICC, ECC,
pancreatic cancer, and hepatocellular carcinoma were assessed using proportional hazards
regression, adjusting for selection factors, race, use of medical services, and potential con-
founders. Chart review of 62 ECC and ICC cases indicated a high positive predictive value
for the algorithm used to identify cholangiocarcinoma (85.7% for ICC, and 73.5% for
ECC). Findings: There were 75 cases of ECC, 37 ICC, 617 pancreatic cancer, and 1679
hepatocellular carcinoma during follow up that started 6 months following index date. Risk
for ICC was elevated with HCV infection with (Hazard ratio (HR): 2.50 (95% CI: 1.29-
4.86)). The adjusted hazard ratios (aHR) ranged between 2.07 and 2.76 adjusting for
cirrhosis, diabetes, IBD, hepatitis B, alcoholism or alcoholic liver disease (up to 3 covariates
at a time). We found no increased risk for ECC (HR 1.05; 0.60-1.85). The risk of pancreatic
cancer was slightly elevated (HR: 1.23, 1.02-1.49), but was attenuated when adjusting for
acute or chronic pancreatitis or alcoholism (aHR 1.18; 0.97-1.42). As expected, the risk of
hepatocellular carcinoma associated with HCV was very high (HR 14.8; 13.2-15.6). Conclu-
sions: HCV infection confers more than two-fold elevated risk of ICC. There does not appear
to be an association between HCV and ECC, while the association with pancreatic cancer
needs further study.
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Failure to Screen for hepatocellular carcinoma (HCC) in Cirrhotic Patients Is
Primarily Due to Patient Non-Compliance: Experience At a High Volume
Urban Hepatology Practice
Ricardo Restrepo, Victor Araya, Andres Riera, Kenneth D. Rothstein, Mauricio Orrego,
Hisham Elgenaidi, Santiago J. Munoz
Background: HCC incidence is increasing worldwide. Currently, it is the fifth most common
cancer and the third most common cause of cancer-related death in males. Surveillance
strategies have been proposed for early detection in cirrhotics that include either an imaging
study (i.e., an ultrasound (US), a triple phase computer tomography (TPCT)scan or magnetic
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resonance imaging with contrast (MRI)) in combination with an alpha-feto-protein level
(AFP) at 6 months intervals. Aim: To determine physician and patient compliance rate of
HCC surveillance with an imaging study and an AFP every 6 months in cirrhotic patients
and to use published national compliance rates with colon cancer screening as a benchmark
comparison. Methods: Retrospective review of establish cirrhotic patients' adherence to HCC
surveillance documented in progress notes or correspondence for patients seen in our practice
between 2004 and 2006. The recommendation of an imaging study and AFP every six
months was clearly communicated to the patient and their referring physician. The patients
were distributed into the following groups: Group 1: patients who did the screening as
recommended; Group 2: patients that did not screen in spite of recommendation; Group
3: screening needed but not recommended. Patients' demographics in each group was
collected in order to target non-compliant groups. Results: 145 patients were randomly
selected from our database of cirrhotic patients. The overall physician HCC screening
compliance rate was 95%, i.e. 139 patients had an AFP and an imaging test ordered every
6 months. 33% of the patients were in Group 1, 62% in Group 2, and 5% in Group 3.
There were no differences between the groups in terms of race, gender, employment status,
necessity of an insurance referral, referring physician type or distance to our Liver Center.
In contrast, published colon cancer screening compliance rates are up to 19% for colonoscopy
and up to 31% for annual fecal occult blood test (FOTB). Conclusions: Patient compliance
with HCC surveillance recommendation was low but higher than reported for colon cancer
screening with colonoscopy yet similar to FOTB. Strategies need to be developed to increase
patient adherence to this important recommendations. Verbal and written recommendations
are insufficient to ensure patient compliance
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Is There a Benefit from Pretransplant Treatment of hepatocellular carcinoma
Patients Who Fulfill Milan Criteria
Mohamed O. Amer, Yuko Kono, Lisa M. Richards, Jessica Hall, Lita Petcharaporn, Claude
B. Sirlin, Elliot Alpert, Ajai Khanna, Steven Rose, Tarek Hassanein
Hepatocellular Carcinoma (HCC) patients who are candidates for liver transplantation (OLT)
are those who fulfill Milan Criteria. Most patients receive ablation therapy modalities while
awaiting OLT to prevent tumor growth. Aim: To evaluate the impact of pretransplant ablative
therapies in patients with HCC, who fulfill the Milan Criteria, in terms of recurrence and
survival post OLT. Methods: A retrospective analysis of the data of HCC patients who were
transplanted between 2001 and 2006. 66 consecutive patients were identified. 44 patients
had ablative therapy before OLT (group A), of which 39 had chemoembolization and 5 had
radiofrequency ablation. 22 patients did not receive any intervention before OLT (group
B). Results: There was no significant difference in the age, sex, etiology of liver disease
between both groups. The median follow-up was 23 (3-108) and 23 (1-45) months for
groups A and B respectively (p=0.11). There were no significant differences in CTP, MELD
score, and CLIP score between both groups. The median duration between diagnosis of
cancer and liver transplantation was 4 (1-30) months in group A and 2 (1-21) months in
group B. The median post transplantation follow-up was 17 (1-56) and 19 (1-45) months
for both groups respectively. Explants showed a median tumor size of 2.2 (1-6) and 2 (1-
8) and multifocality was detected in 54% and 50% of patients in both groups respectively
(table). 2 patients in each group had recurrence. Of which, vascular invasion occurred in
one patient in each group. Post OLT death occurred in 5 (11.3%) patients in group A and
4 (18.1%) patients in group B. 1 patient in group A (2.3%) and 1 patient in group B (4.5%)
died due to recurrence of HCC. Conclusion: There was no significant difference in the rate
of recurrence of HCC and survival after liver transplantation between patients who received
ablative therapy before liver transplantation and those who did not treated as long as the
patient fulfilled the Milan Criteria.
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Clinical Usefulness of 18F-Fdg PET/CT in Differentiating Malignant from
Benign Extrahepatic Biliary Strictures: Comparison with Mdct, MRCP, and
ERCP
Jong ho Moon, Jung mi Park, Hee kyung Kim, Kye won Kwon, Sung jin Park, Young
koog Cheon, Young deok Cho, Joon seong Lee, Moon sung Lee, Hae kyung Lee, Chan
sup Shim, Boo sung Kim
BACKGROUND/AIM: The differential diagnosis of extrahepatic biliary strictures is a continu-
ing challenge. FDG-PET has been a useful procedure for the differentiation of benign from
malignant lesions. CT adds the anatomic details that PET lacks. This study conducted to
evaluate the usefulness of FDG-PET/CT as a new noninvasive procedure in differentiating
malignancy in patients with biliary stricture by comparing with the established diagnostic
methods including MDCT, MRCP, and ERCP. METHODS: From 2005 through 2006, Fifty
three patients (25 men, mean age 65.6 years) with clinical presentation of biliary stricture
were enrolled. MDCT, MRCP, and ERCP were performed prospectively; images of these
tests were reviewed blindly under standardized conditions. Reference standards for compar-
ison were surgery, a biopsy confirming malignancy, or the clinical course during follow-up
in cases without histopathologic proof of malignancy. The sensitivity and specificity of FDG-
PET/CT in diagnosing malignancies were evaluated and compared with those of other studies.
RESULTS: Malignant diseases were diagnosed in 42 patients with cholangiocarcinoma in
25 patients. In diagnosing malignancy in patients with biliary stricture, overall sensitivity
and specificity were 83.3%, and 54.6% for MDCT, 78.6%, and 54.6% for MRCP, 95.2%,
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and 81.8 %, for ERCP and 90.5%, 81.8% for PET/CT. Malignant biliary stricture presented
with increased uptake with an SUV of 4.7±3.2 (range; 2.2-19.7), compared with 1.8±1.0
(range; 0.1-4.3) in patients with benign causes of strictures (P<0.05). Thirty two (76.2%)
patients with malignant biliary stricture typically showed an intense focal uptake. PET/CT
identified distant metastases that were not detected by CT in four patients. CONCLUSION:
PET/CT can be helpful for noninvasive detection of malignant diseases in patients with
biliary strictures. Adding of PET/CT in conjunction with conventional modalities may be
useful to establish a precise differential diagnosis in biliary strictures.
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C-Terminal Src Kinase (CSK) Induction Modulates the Pro-Apoptotic Effects
of Nonsteroidal Anti-Inflammatory Drugs, (NSAIDs) in the Chemoprevention
of Colorectal Cancer (CRC)
Dhananjay Kunte, Ramesh K. Wali, Jennifer Koetsier, Mary Nyhuis, Hemant K. Roy
Background:Induction of apoptosis by NSAIDS is critical for CRC chemoprevention; however
the molecular mechanisms remain unclear, with numerous molecular targets proposed. Src
is a potent anti-apoptotic proto-oncogene. While it is established that Src is implicated in
most human CRCs, we were the first to demonstrate Src activation, through downregulation
of its inhibitor CSK, in the predysplastic mucosa using the azoxymethane (AOM)-rat
model.(FEBS Lett 2005). Thus, in the present study, we focused on the CSK-Src axis as a
logical albeit previously unexplored NSAID target in chemoprevention. Methods: AOM-
treated male Fisher 344 rats were fed with AIN-76 diet alone or supplemented with sulindac
(320 ppm) for 10 weeks prior to sacrifice. The levels of CSK and p-Src-527 were assessed
by western blotting and immunohistochemistry. The CRC cell line HT-29 was grown in
standard conditions. Src activity was gauged through immunopercipitation-kinase assay and
also through immunoblotting Src phosphorylated at tyrosine 527 (the site for the inhibitory
effect of CSK). Apoptosis was quantified using flow cytometry. In order to demonstrate the
importance of CSK in NSAID induced apoptosis, we constructed a stable HT-29 cell line
with knock-down of CSK gene expression using a short chain hair-loop RNA (shRNA)
vector. Results: In the AOM-treated rats, sulindac treatment dramatically increased CSK
(174% of control, p<0.01) with concomitant rise in p-Src 527 (suggesting inhibition).
Treatment of HT-29 cells with sulindac sulfide (100 µM for 72 h) resulted in a significant
CSK induction (144% of vehicle, p=0.014) with corresponding increase in Src 527 (141%
of vehicle, p=0.021) and a marked decrease in Src activity (70 % of vehicle p<0.05). However,
in the CSK shRNA stable construct, sulindac sulfide did not induce CSK. The importance
of CSK was underscored by the demonstration that while sulindac sulfide treatment caused
a dramatic increase (389% of vehicle p=0.03) in apoptotic cells in the wild type HT-29 cells
as assessed by subdiploid fraction (via propidium iodide staining), this effect was minimal
in the (138 % of the vehicle, p=N.S.) in the CSK shRNA construct. These results were
duplicated using the M30 cytoDeath apoptosis assay. Conclusion: We demonstrate, for the
first time, that the CSK-Src axis is modulated by NSAIDS during chemoprevention both In
Vivo in the AOM-rats and also in HT-29 cells. The studies with CSK shRNA construct
underscore the importance of the Src-CSK axis in NSAID-apoptosis. This work has implica-
tions for designing more specific chemopreventive strategies with small molecule inhibitors
of Src or inducers of CSK.
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Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Overexpression May
Be Associated with Apoptosis Resistance and Predictive of Clinical Outcomes
in Colon Cancer
Wooin Lee, A. C. Lockhart, Abbes Belkhiri, Nipun Merchant, Timothy J. Yeatman, Robert
J. Coffey, Mary kay Washington, Wael M. El-rifai
Background: OATP1B3, an organic anion transporting polypeptide (OATP), is overexpressed
in many gastrointestinal tumors and tumor cell lines. OATP1B3 is known to transport a
number of endogenous substances and xenobiotics in the normal liver. However, the func-
tional consequences or clinical significance of tumoral OATP1B3 expression has not been
examined. Methods: To examine the functional impact of OATP1B3 overexpression on
tumor cell survival and apoptosis, we developed colon cancer cell line models (HCT-8
and RKO) that stably and transiently overexpress OATP1B3. To probe the anti-apoptotic
mechanisms of OATP1B3 expression, we performed experiments to assess the involvement
of p53-dependent pathways using a p53-responsive reporter plasmid (pG13-Luciferase) in
H1299 cells. In clinical samples, we assessed the expression of OATP1B3 in colorectal
adenocarcinomas, premalignant polyps and normal colonic mucosa using quantitative RT-
PCR and immunohistochemistry (IHC) on a tumor tissue microarray (TMA) containing 110
tumors of various clinical stages. Results: Stable transfection of OATP1B3 in HCT-8 cells
conferred a survival advantage when exposed to the anti-cancer agents, camptothecin and
paclitaxel (ATP assay or MTT assay). RKO cells transiently transfected with OATP1B3 were
resistant to apoptosis (TUNEL assay) after treatment with camptothecin. The results from
the p53-responsive reporter assay in H1299 cells indicated that OATP1B3 expression causes
a substantial decrease (by ~80%) in p53 transcriptional activity, suggesting the involvement
of a p53-dependent mechanism. In the clinical samples, OATP1B3 mRNA was markedly
overexpressed in colon adenocarcinomas (123-fold increase, n=17) and premalignant polyps
(104-fold increase, n=11) in comparison to normal colonic tissues (n=17). The IHC on TMA
demonstrated moderate to strong OATP1B3 staining in a majority (67 out of 89 total
specimens evaluated, 75%) of colon tumors whereas normal colon tissues (n=12) had no
detectable immunostaining. Although not statistically significant, survival curves generated
for high and low OATP1B3 expression in a punctate pattern demonstrated curve separation
with an association between high OATP1B3 expression and improved survival. Conclusion:
Our results suggest that OATP1B3 overexpression is an early event in colon tumorigenesis
and its overexpression is observed in colonic tumors of all stages. OATP1B3 overexpression in
colon cancer may confer a survival advantage through anti-apoptotic/pro-survival pathways.
Further studies are on-going to comprehensively assess the functional and prognostic signific-
ance of OATP1B3 overexpression in colon cancers.
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Matrix METALLOPROTEINASE-7 (MMP-7) Mediates Bile Acid-Induced
Transactivation of EGF Receptors (EGFR) and Proliferative Signaling in
Human Colon Cancer Cells
Kunrong Cheng, Guofeng Xie, Jean-pierre Raufman
Fecal secondary bile acids are colon cancer promoters. Previously, we showed that conjugated
secondary bile acids promote H508 colon cancer cell proliferation by transactivation of
EGFR (Biochem Pharmacol 2005;70:1035). To explore the mechanism underlying this action,
we tested the hypothesis that bile acids activate a matrix metalloproteinase (MMP) that
catalyzes release of an EGFR ligand. GM6001, a broad-spectrum MMP inhibitor blocked
the actions of deoxycholyltaurine (DCT, 50 μM), thereby implicating MMP-catalyzed release
of an EGFR ligand. DCT-induced cell proliferation was reduced by increasing concentrations
of EGFR kinase inhibitors, by antibody to the ligand-binding domain of EGFR, by neutralizing
antibody to heparin binding-EGF-like growth factor (HB-EGF) and by CRM197 a diphtheria
toxin analogue that inhibits HB-EGF release. These findings and observations with more
selective MMP inhibitors suggested that MMP-7, an enzyme known to release HB-EGF from
pro-HB-EGF in other tissues, plays a key role in mediating bile acid-induced H508 colon
cancer cell proliferation. Recombinant HB-EGF and MMP-7 both mimicked the signaling
and proliferative actions of bile acids. Strikingly, reducing MMP-7 expression in H508 cells
with either neutralizing antibody or increasing concentrations of siRNA (Fig. 1) attenuated
DCT-induced cell proliferation. RT-PCR confirmed MMP-7 expression in H508 cells and
confocal immunofluorescence microscopy revealed co-localization of pro-MMP-7 and pro-
HB-EGF at the cell surface. Collectively, these findings provide strong evidence that in H508
human colon cancer cells, bile acid-induced transactivation of EGFR is mediated by MMP-
7-catalyzed release of the EGFR ligand HB-EGF. MMP-7 may provide a novel therapeutic
target to prevent the proliferative effects of bile acids on colon cancer.
Fig. 1. Transfection of H508 cells with MMP-7 siRNA inhibits proliferative actions of DCT
(*p<0.05 vs cells incubated with DCT alone; n=3).
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Krüppel-Like Factor 5 (KLF5) Is An Important Mediator of Mouse Colonic
Crypt Cell Hyperplasia Caused By Citrobacter rodentium
Beth B. Mcconnell, Jan-michael A. Klapproth, Maiko Sasaki, Mandayam O. Nandan,
Vincent W. Yang
BACKGROUND: Krüppel-like factor 5 (KLF5) is a transcription factor that is highly expre-
ssed in dividing crypt cells of the intestinal epithelium. Previous studies have shown that
KLF5 has a pro-proliferative effect in intestinal epithelial cells. Citrobacter rodentium is a
bacterial pathogen that colonizes the mouse colon, inducing transmissible murine colonic
hyperplasia. We recently reported that Klf5 expression is increased in mouse colonic tissues
infected with C. rodentium [McConnell, et al. (2006) Gastroenterology 130, A141]. Here,
we use a Klf5-heterozygous (Klf5+/-) knockout mouse model to address whether hyperprolifer-
ative responses to infection with C. rodentium are dependent on Klf5 expression. METHODS:
Klf5+/- mice were generated from mouse embryonic stem cells carrying an insertional disrup-
tion of the Klf5 gene. Klf5+/- mice and wild-type littermates were infected with 5 X 108
colony forming units of C. rodentium by oral gavage (N=5). Controls received phosphate-
buffered saline. At 14 days post-infection (p.i.), mice were sacrificed and distal colons
harvested. Colonic crypt heights were determined from sections stained with hematoxylin
and eosin. Frozen tissues were stained for immunofluorescence using polyclonal antibodies
against Klf5 and the proliferation marker, Ki67. Immunofluorescence intensities of Klf5
expression per cell were measured using Metamorph software. Numbers of proliferating
cells were determined by counting Ki67-positive cells per crypt. RESULTS: Infection of
wild-type mice with C. rodentium resulted in a 2-fold increase in colonic crypt heights at
14 days p.i. This increase was accompanied by a 1.5-fold increase in Klf5 expression, as
measured by Klf5 immunofluorescence signal in crypt epithelial cells. Infection of Klf5+/-
mice showed an attenuated induction of Klf5 expression, increasing 1.3-fold versus 1.5-
fold in wild-type mice (p<0.05). This effect correlated with reduced colonic epithelial cell
hyperplasia at day 14 p.i. compared to hyperplasia seen in wild-type littermates, with crypt
heights being increased by 75±8% compared to 102±12% in wild-type mice. Correspond-
ingly, the average number of Ki67-positive epithelial cells per crypt following infection
with C. rodentium was 12.6±1.1 in Klf5+/- mice compared to 17.1±1.4 in wild-type mice.
CONCLUSION: Our study demonstrates that Klf5 expression is induced in hyperproliferat-
ing mouse colonocytes in response to infection withC. rodentium, and that reduced expression
of Klf5 results in attenuation of hyperproliferative responses. We conclude that Klf5 is
an important mediator of crypt cell proliferation in the colon in response to pathogenic
bacterial infection.
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Radioprotective Effect of Uroguanylin in Intestinal Epithelial Cells
Monica p. Garin-laflam, Kris A. Steinbrecher, Jeffrey A. Rudolph, Juxian Mao, Jennifer
Hawkins, Mitchell B. Cohen
Introduction: Increased cyclic GMP (cGMP) protects against apoptosis in a number of non-
intestinal systems. Within the intestine, uroguanylin (UGN) is a peptide hormone that binds
to and activates the intestinal epithelial cell (IEC) transmembrane receptor guanylate cyclase
C (GC-C), which in turn increases intracellular cGMP. Gene targeting of murine UGN or
GC-C results in significantly lower levels of cGMP in IECs. We therefore hypothesized that
loss of UGN would increase intestinal epithelial apoptosis following radiation-induced injury.
Methods: Apoptosis was induced by 5Gy of γ-irradiation. Tissue from the proximal jejunum
of Balb/c WT and UGN knockout (KO) mice (n=12-15/group) was harvested three hours
post irradiation. cGMP levels were quantified by ELISA from jejunal mucosal scrapings.
Identical experiments were performed after intraperitoneal (IP) injection of 1mM 8BrcGMP
(n=12/group) to increase levels of cGMP in KO animals. Lastly, we performed identical
irradiation experiments in GC-C receptor KO mice (n=11/group). For all experiments, we
assessed apoptosis in a blinded fashion by quantitating 1) morphological indications of cell
death (hematoxylin and eosin) and/or 2) cleaved caspase 3 immunohistochemistry (IHC).
Results: Following γ-irradiation, UGN KO mice had 43% more apoptotic bodies/crypt that
WT littermate controls (2.86 ± 0.19 vs 2.00 ± 0.20, respectively p<0.01). By cleaved caspase
3 analysis, 20% more positive cells/crypt were observed in UGN KO vs WT animals (1.56
± 0.08 vs 1.30 ± 0.09, respectively, p<0.05). As expected, cGMP levels were 70% lower at
baseline in UGN KO mice and did not increase with radiation in KO or WT animals.
8BrcGMP injected UGN KO mice had 43% less apoptotic bodies/crypt than vehicle injected
KO mice (0.97± 0.06 vs 1.69± 0.19, respectively, p<0.01). By cleaved caspase 3 IHC, a
trend toward decreased positive cells/crypt was observed (0.60 vs 0.81, respectively p=0.18).
Similar to UGN KO animals, GC-C receptor KO mice had 58% more apoptotic bodies/
crypt after irradiation than WT controls (3.38± 0.34 vs 2.17± 0.16, respectively, p<0.01).
Conclusions: These In Vivo studies suggest an cytoprotective function for the GC-C signaling
pathway and are consistent with cGMP as a primary downstream mediator of this effect.
Our data, combined with work demonstrating a role for GC-C activation in IEC proliferation
and anti-apoptotic effects of cGMP accumulation, suggest that GC-C activity modulates
epithelial monolayer homeostasis and, therefore, susceptibility to injury.
71
Tumor Suppressor Foxo3a Is Involved in Regulation of Proliferation of
Colonic Epithelia Infected with Citrobacter rodentium
Suzana Savkovic, Stanford Peng
Introduction: Colonic hyperproliferation is a critical early event in colon carcinogenesis
although the molecular mechanisms are incompletely understood. Our laboratory has been
investigating the role of the tumor suppressor gene, Foxo3a. While Foxo3a regulates genes
critical in suppressing cell proliferation, little is known about its role in the pathogenesis
of colon cancer. We, therefore, investigated Foxo3a regulation with a well-validated murine
model of colon carcinogenesis, infection with the luminal bacteria, Citrobacter rodentium
(CR) (J Infect Dis. 2001, 184:227) Methods: Mouse intestinal epithelial cells (IEC), CMT-
93 and C57BL/6J mice were infected with CR and examined for proliferation (In Vitro by
3[H]tymidine incorporation and In Vivo for crypt highs in H&E stained colonic samples).
The status of Foxo3a in colonic epithelia was determined by immunoblotting, immunofluo-
rescent and immunohistostaining. The role of Foxo3a in proliferation In Vitro was determined
in IEC transfected with retroviral vector pMX-Foxo3a-IRS-GFP, which allows over-expression
of Foxo3a, (empty vector was used as a negative control). In Foxo3a deficient mice (KO)
colonic epithelia was examined in H&E stained samples. Results: In CR infected mice crypt
heights increased twice in a 14 days (control 172±15 µm; CR 367±53 µm, n=10 p<0.005)
with a concomitant increase in cell proliferation. Next we assessed the effect of CR infection
on Foxo3a In Vitro and In Vivo. During CR infection of IEC, Foxo3a is phosphorylated,
translocated from the nucleus into the cytosol and thus Foxo3a was unable to act as a
transcriptional regulator. This was confirmed In Vivo where the prominent nuclear Foxo3a
staining was lost in the CR infected mice. In order to assess a cause-and-effect relationship,
we assessed the Foxo3a over-expressing IEC transfectants and noted. The IEC over-expressing
Foxo3a for 48 h proliferate 32% slower, then control cells (empty vector 119±12, Foxo3a
81±7µg prot/well, n=24 p<0.001), which suggest that active Foxo3a attenuates proliferation
of IEC. Our preliminary data supports the role of Foxo3a In Vivo by demonstrating that
Foxo3a KO mice, when compared to wild types, had evidence of increase colonic epithelial
proliferation. Conclusions: Our data indicates that Foxo3a is a downregulated by pro-
proliferate carcinogens in the colon. Furthermore, Foxo3a manipulation appears to be
sufficient to alter colonocyte proliferation. Studies are being conducted to further elucidate
the role of Foxo3a on initiation of colon carcinogenesis
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Discovery of a Novel Pancreatic Cancer Related Gene LBFL313 As a Potential
Target for the Molecular Therapy
Sun a Kim, Esther dawoon Jung, Yang soon Lee, Kyung hwa Park, Jeong youp Park,
Seungmin Bang, Seung woo Park, Jae bock Chung, Sang seok Koh, Si young Song
Pancreatic cancer is the fourth most common cause of cancer-related death. Identification
of tumor specific protein or antigen may lead to potential diagnostic and therapeutic applica-
tions in cancer treatment. We used cDNA microarray to accrue broad spectrum of differently
expressed pancreatic cancer related genes, and selected a novel overexpressed EST gene (>
9 fold). A novel EST (LBFL313), full-length of 718 bp with an open reading frame of 196
A.a was retrieved. It was localized on Homo sapiens 16p13.3 chromosomal locus and had
a calculated molecular mass of 20.5 kDa with potential glycosylation, phosphorylation and
myristoylation. Reverse transcription-PCR and western blot confirmed that LBFL313 was
highly expressed in most of pancreatic cancer cell lines. Immunostaining in TMA of human
pancreatic cancer tissue revealed that LBFL313 was observed at the cytoplasm, and the
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immunoreactivity was stronger in pancreatic cancer tissues than non-tumor tissues. To
examine its involvement in pancreatic carcinogenesis, we induced LBFL313 cDNA into
Chinese hamster ovary cell (CHO) and established stable cell line expressing LBFL313 (CHO/
LBFL313). LBFL313 protein was secreted into culture medium and had a molecular mass
of 25/27 kDa modified post-translationally. The induction of LBFL313 cDNA into CHO cell
(CHO/LBFL313) lead to altered behavior. Compare to the mock, proliferation rate increased
1.2-fold, migration activity increased 1.5-fold, and invasion activity increased 2.6-fold.
Xenografting with CHO/LBFL313 cell resulted in larger tumor size (5.7-fold) and more
neovascularization (4.2-fold) than control. These tumorigenic effects were inhibited by
shRNA and polyclonal antibody generated with recombinant LBFL313 In Vitro and In Vivo.
Collectively, our results suggest that LBFL313 is a novel secretory protein and involved in
pancreatic carcinogenesis. It might provide a potential target for the diagnosis and treatment
of pancreatic cancer.
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Human Ent1 Is Predictive of Response to Gemcitabine Treatment in Patients
with Pancreatic Cancer: Results from the Rtog 9704 Prospective Randomized
Trial
James J. Farrell, Miguel Garcia, Raymond Lai, W. Regine, R. Abrams, A. Bowen benson, J.
Macdonald, C. Cass, Hany Elsaleh, John Mackey
Background: Human equilibrative nucleoside transporter (hENT1) is responsible for gemcita-
bine transport into cells. Small retrospective studies in pancreatic cancer suggest that hENT1
tumor levels may have prognostic and predictive value. We studied hENT1 protein expression
in a cohort of pancreatic adenocarcinoma patients from the RTOG 9704: a large prospective
randomized adjuvant treatment trial. Methods: RTOG 9704 randomized 538 patients after
surgical resection to treatment containing either 5-FU or Gemcitabine. A tissue microarray
was constructed using 3 separate cores from each of 225 resected pancreatic tumors from
RTOG 9704. HENT1 immunohistochemistry was performed and scored as having no staining,
low staining or high staining (>50% cells positive). Associations between hENT1 protein
expression, either dichotomized (no staining vs. low and high staining) or ungrouped (no
staining vs. low vs high staining) with treatment outcome (overall survival and disease free
survival), were analyzed by logistic regression analysis using the Chi-square test and the
Cox proportional hazards model. Both treatment arms of the study were analyzed. Results:
198 patients from both arms of the study had analyzable hENT1. hENT1 expression was
not associated with overall or disease-free survival in a univariate or multivariate model in
patients in the 5-FU treatment arm (n=107) for either the dichotomized or ungrouped
hENT1 level variables. Univariate and multivariate analyses for hENT1 in the Gemcitabine
treatment arm (n=91) is shown in Table 1 (expressed as hazard ratio (HR) (95% confidence
intervals)). Conclusion: In this prospective randomized trial, hENT1 protein expression is
associated with a statistically significant improvement in overall survival and disease free
survival in pancreatic cancer patients receiving gemcitabine, but not in those not receiving
gemcitabine.This prospective data suggests that hENT1, a gemcitabine transporter, is a useful
mechanistic predictive marker of response to gemcitabine in patients with pancreatic cancer.
Table 1: hENT1 and Survival(HR) in Pancreatic Adenocarcinoma treated with Gemcitabine
HR: Hazard Ratio (95% confidence intervals)(p values). HR<1: survival benefit.
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Small Interfering RNA Targeting Protein Kinase N3 (PKN3) Inhibits Tumor
Growth and Metastatic Spread in Orthotopic Pancreatic Cancer Models
Petra Schulz, Annett Rexin, Sandra Rudloff, Svenja Rieke, Jörg Kaufmann, Bertram H.
Wiedenmann, Klaus Giese, Arne Scholz
Introduction: Until now, therapeutic results in advanced pancreatic cancer have been disap-
pointing. Clearly, an unmet need exists especially in this tumor entity with regard to new
agents. We have tested the therapeutic efficacy of a new antiangiogenic strategy which is
based on an innovative liposomally formulated siRNA (siRNA-lipoplex) directed against
protein kinase N3 (Atu027) in 2 orthotopic mouse models of pancreatic carcinoma. Methods:
Immunodeficient mice (nu/nu and NOD/SCID, respectively) bearing orthotopic pancreatic
tumors derived from either non-metastatic human DAN-G cells or metastatic human MiaPaca
A2 cells were treated intravenously 3 times per week with formulated Atu027 or vehicle
control. Furthermore, additional groups of MiaPaca A2 tumor-bearing mice received a
combination of gemcitabine/Atu027 or gemcitabine/vehicle. Based on the known different
growth behaviour of the two tumor cell types, 7 injections over 16 days in DAN-G and 10
injections over 21 days in MiaPaca A2-bearing mice were performed. Treatment efficacy
was evaluated based on body weight, tumor weight, invasive growth into adjacent organs,
metastatic spread. Effects on angiogenesis were examined by (immuno-)histochemical ana-
lysis of endothelial (CD31) and lymphendothelial (Lyve-1) markers. Results: In both models,
intravenous administration of Atu027 did not influence the body weight indicating good
systemic tolerability. Side effects were restricted to local inflammatory reactions at the
injection site. In nonmetastatic DAN-G tumors, Atu027 treatment significantly reduced
primary tumor weight (500mg vs. 296mg, p=0.0155), microvessel density (p=0.0148) and
lymphatic vessel density (p<0.0001) indicating anti-(lymph-)angiogenic mechanisms of
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action. Atu027 treatment in mice bearing established MiaPaca A2 tumors for over 3 weeks
similarly resulted in a significant inhibition of the tumor weight (p=0.0267). In addition,
fewer MiaPaca A2 tumors showed invasion into adjacent organs (p=0.0043) and also reduced
metastatic spread (p=0.0092) in the Atu027 treatment group. Metastasis formation was not
only reduced in comparison to vehicle-treated controls, but also in comparison to gemcitabine
treated animals (13% vs. 78% of animals, p=0.0152). Conclusions: This novel antiangiogenic
siRNA-based treatment is well -tolerated and effective In Vivo, resulting in a reduction of
primary tumor growth and metastasis formation. Based on the observed reduction of micro-
vessel and lymph vessel density, the anti-tumor action of Atu027 likely resulted from a
reduction of tumor-induced angiogenesis and lymphangiogenesis.
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Neutrophil Gelatinase-Associated Lipocalin: A Novel Suppressor of Invasion in
Pancreatic Cancer
Zhimin Tong, Huamin Wang, Sushovan Guha
Background: Gene expression analyses of pancreatic cancer (PaCa) had identified neutrophil
gelatinase-associated lipocalin (NGAL) as a potential early biomarker. Recently, proteomic
analysis of pancreatic exocrine secretions showed significantly high secreted NGAL levels
in PaCa patients. NGAL, a 25-kD lipocalin, is a secreted acute phase protein, which is also
upregulated in multiple cancers including breast, lung, and pancreas. NGAL is a prosurvival
factor in breast and lung cancer cells when challenged with xenotoxic agents. However, its
role in pancreatic cancer is completely unknown. Aim: To determine the functional role of
NGAL in PaCa and correlate that with survival, proliferation, invasion, and/or metastasis of
PaCa cells. Methods and Results: Well to moderately differentiated PaCa cells, including
AsPC-1, BxPC-3, and Capan-2 had very high expression of NGAL, while the poorly differenti-
ated PaCa cells including Panc-1 and MIA PaCa-2 had no detectable levels of NGAL as
detected by RT-PCR and western blots. Immortalized HPDE (human pancreatic ductal
epithelium) cells had no NGAL expression but HPDE cells transformed with K-RasG12V
(HPDE-Kras) showed significant NGAL expression. IHC of untreated human PaCa tissue
micro-arrays (160 PaCa) showed 40% positive luminal and cytosolic NGAL expression.
NGAL was detected in the adjacent chronic pancreatitis area and also in all PanIN lesions.
However, the normal pancreatic tissue, and the poorly differentiated or invasive PaCa showed
no NGAL expression by IHC. We created 4 stable PaCa clones: 2 over-expressing NGAL
(Panc-1-NGAL and MIA PaCa-2-NGAL) and 2 down-regulating NGAL (BxPC-3 shRNA and
AsPC-1 shRNA). There was no effect of NGAL over-expression or down-regulation on
proliferation (MTS assay) or viability (AnnexinV-FITC assay) of PaCa cells. However, NGAL
down-regulation significantly increased adhesion to fibronectin (static adhesion assay). Inter-
estingly, NGAL over-expression significantly suppressed (55%) and conversely, NGAL down-
regulation significantly increased (45%) invasion of PaCa cells through matrigel In Vitro.
Finally, NGAL over-expression potently decreased tyrosine-397 phosphorylation of focal
adhesion kinase (FAK) in PaCa. Conclusion: We demonstrated for the first time that NGAL
is selectively expressed in well to moderately differentiated PaCa including PanIN lesions.
NGAL inhibits adhesion/invasion of PaCa cells by suppressing FAK activation. Thus, loss
of NGAL expression in the exocrine pancreatic secretions will be an early indicator for
locally advanced or metastatic PaCa.
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A Novel Molecular Diagnostic Approach in Pancreatic Cancer: Quantitative
Analysis of Nptx2 Hypermethylation in the Plasma of Pancreatic Cancer
Patients
Joo kyung Park, Sang hyub Lee, Ji won Yoo, Sang myung Woo, Ji kon Ryu, Yong-tae
Kim, Yong bum Yoon
Background & Aims: The majority of pancreatic cancers are found out to be unresectable
and there is only chance to cure in early detection and complete resection. The serum of
cancer patients often harbors increased free DNA levels, which can potentially be used for
cancer detection. Recently, several genes (including NPTX2) have been discovered to be
aberrantly methylated in primary pancreatic cancer tissue. The aim of study was to develop
a novel molecular diagnostic approach based on epigenetic characteristics of pancreatic
cancer, and to investigate possibility of differential diagnostic method in high risk group of
pancreatic cancer such as chronic pancreatitis. Methods: We prospectively enrolled 148
pathologically proven pancreatic cancer patients and 47 chronic pancreatitis patients with
informed consent. We collected blood samples before surgery or any kinds of treatment
modalities. From each blood sample, the plasma was selectively separated and DNA was
extracted. The bisulfite-modification was performed, and NPTX2 CpG island was examined
by real-time PCR amplification using oligonucleotide primers and a TaqMan probe specific
for a fully methylated bisulfite converted portion of the NPTX2 gene.Results: There were
148 pancreatic cancer patients and their AJCC stages were as followed; 2 in stage IA, 11in
IIA, 11in IIB, 60 in III, 63 in IV. Of the 148 plasma samples from pancreatic cancer and
42 plasma samples from chronic pancreatitis, 11 and 5 of them didn't amplify beta-actin
and NPTX2 curve respectively, which means that there is no free DNA. We could see NPTX2
amplification in 96 out of 137 plasma samples in pancreatic cancer patients and 18 out of
42 plasma samples in chronic pancreatitis patients. Also, the plasma samples from pancreatic
cancer patients had statistically significant higher levels of NPTX2 hypermethylation com-
pared to chronic pancreatitis. The sensitivity and the specificity of NPTX2 hypermethylation
in plasma of pancreatic cancer were 70% and 71% respectively. In pancreatic cancer patients,
there were statistically significant NPTX2 amplification rate and the higher percentage of
NPTX2 hypermethylation among the different AJCC stages.Conclusions: The quantitative
analysis of NPTX2 hypermethylation revealed that aberrantly hypermethylated NPTX2 gene
could be detected from the plasma of pancreatic cancer patients and it was significantly
higher levels compared to chronic pancreatitis. Our findings suggested the possibility that
NPTX2 hypermethylation might be used as a molecular diagnostic marker in detection of
pancreatic cancer, especially from the high risk patients such as chronic pancreatitis.
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Protein Kinase D Enhances Growth in Human Pancreatic Cancer Cells
Krisztina Kisfalvi, Enrique Rozengurt
Background: Ductal adenocarcinoma of the pancreas is a devastating disease with overall
5-year survival rate of 3-5%. The major challenge is to identify novel targets and develop
strategies for its treatment. New approaches will most likely arise from a detailed understand-
ing of molecular signaling pathways that stimulate the unrestrained proliferation of these
cells. Protein kinase D (PKD) is implicated in the transduction of specific PKC signals, which
are shown to increase growth in multiple cell types. Our hypothesis was that PKD pathway
plays a role in promoting proliferation of pancreatic cancer cells. Methods: To determine
the effect of PKD on growth we derived PANC-1 cells that stably and inducibly express
high levels of PKD. We utilized a model system in which wild type or mutant (constitutively
active or kinase dead mutants) PKD was expressed under the control of a modified ecdysone
receptor enhancer/promoter. To determine whether overexpression of PKD stimulates growth
in PANC-1 cells, we measured DNA synthesis ([3H]-thymidine incorporation) and anchorage-
independent growth (in cultures growing on PolyHEMA-coated dishes) of cells treated in
the absence or presence of ecdystone. Results: PANC-1 cells treated with ecdysone promoter
agonist ponasterone A at 1 mM (a concentration that induces maximal expression of wild type
PKD) showed two-fold increase in [3H]-thymidine incorporation (p<0.005). On PolyHEMA-
coated dishes overexpression of PKD, in response to ponasterone A, induced marked increase
in the number of PANC-1 cells (p<0.005). In contrast, overexpression of kinase-deficient
PKD had no effect on [3H]-thymidine incorporation or on anchorage-independent growth.
Most pancreatic cancer cells examined in our studies express functional receptors for neurot-
ensin and other GPCR agonists.Expression of mRNA for the neurotensin receptor is markedly
increased in pancreatic cancer samples as compared with normal controls. We have demon-
strated that neurotensin induces PKD activation and acts as a potent growth factor for
pancreatic cancer cells. Here, we determined whether PKD overexpression enhances neurot-
ensin-induced ERK activation and proliferation.We found that PKD overexpression strikingly
potentiated DNA synthesis induced by neurotensin and markedly prolonged the duration
of neurotensin-stimulated ERK activation in PANC-1 cells. Conclusion: Our results indicate
that PKD promotes proliferation of pancreatic cancer cells and suggest that PKD is a key
element in the mitogenic signal transduction pathway stimulated by GPCR agonists. Con-
sequently, we propose that PKD is a potential target for antiproliferative interventions in
pancreatic cancer.
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Clinical and Endoscopic Outcome After the First Corticosteroid Course in
Newly Diagnosed Ulcerative Colitis: A 5-Years Follow-Up Inception Cohort
Study
Sandro Ardizzone, Andrea Cassinotti, Chiara maria Penati, Piergiorgio Duca, Alessandro
Massari, Gianpiero Manes, Venerina Imbesi, Salvatore Greco, Elisa Radice, Emilia Bareggi,
Giovanni Maconi, Gabriele Bianchi porro
Background: Corticosteroids are the mainstay of treatment of moderate-severe ulcerative
colitis (UC). However, very few studies have analysed the short term clinical outcome
(maximum 1 year) and even fewer have evaluated the endoscopic response. Aims: To
prospectively investigate the clinical and endoscopic outcome after the first corticosteroid
course in newly diagnosed UC. Patients and methods: A cohort of 108 patients (M/F 70/
38, mean age 32 years) with active moderate-severe UC needing their first systemic steroid
therapy within 12 months of diagnosis were prospectively evaluated according to clinical
[Powel-Tuck (P-T)] and endoscopic [Baron (Ba)] indices at 3 and 6 months and then every
6 months for 5 years. Early outcome (clinical and/or endoscopic remission) at the third
month (T3) was used to identify patients with complete response (group A, PT and Ba =
0), partial (group B, PT = 0 and Ba = 1-3) and no response (group C, persistence of intestinal
symptoms and endoscopic lesions), and its influence on subsequent outcome. Results: At
T3 evaluation, 46.6% of patients achieved complete response, 25.2% partial response and
28,2% no response. While no differences were observed in colectomy rates among the three
groups, groups B and C both experienced a more frequent use of immunosuppressors (p=
0.029), higher hospitalisation rate (p=0.006), and shorter time to relapse (p= 0.001) in
comparison to group A. During the 5-year follow-up period, 45% of patients maintained
complete response at every follow-up visit. Seventy-three percent of patients relapsed within
1 year after the first steroid course. Overall colectomy rate at 5-years was 14,5%. Conclusions:
Not achieving endoscopic remission at the end of the first steroid course in newly diagnosed
UC patients is not uncommon and could predict a more aggressive course of disease. Thus
we suggest that the achievement of not only clinical but also endoscopic remission should
be a more useful therapeutic target.
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Risk Factors for Initial Surgery in Pediatric Patients with Crohn's Disease: A
Population-Based Cohort Study
Gwénola Vernier-massouille, Mamadou Baldé, Corinne Gower-rousseau, Franck Brazier,
Audrey Girard, Véronique Merle, Raymond Marti, Eric Lerebours, Olivier Mouterde, Jean-
louis Dupas, Florence Richard, Antoine Cortot, Dominique Turck, Jean-louis Salomez,
Jean-frédéric Colombel
Introduction: The cumulative incidence of intestinal resection in children and adolescents
with Crohn's disease (CD) ranges from 17 to 47% at five years from the time of diagnosis.
Few studies have investigated risk factors for surgery. Patients and method: In a population-
based incidence cohort diagnosed from 1988 to 2002 (EPIMAD registry), we identified all
patients with CD before the age of 17. During this period, 472 cases were recorded with a
follow-up of more than 2 years in 404 (218M and 186F with a median age at diagnosis of
14 Q1=11-Q3=15]). The cumulative risk of first resection surgery was estimated through
Kaplan-Meier method. Factors associated with surgery were analyzed using Cox proportional
hazard models. Variables tested were evolution of disease, location and behaviour, disease
activity, medication and surgery. Results: Median follow-up time was 84 mos [52-124]. One
hundred and seventy seven patients (44%) underwent surgery. The cumulative risk of surgery
was respectively 10% (95% CI=7%-13%), 22% (17%-25%) and 36% (29%-40%) at 1, 3
and 5 years from the time of diagnosis. In univariate analysis, stricturing (3.00; 2.19-4.13)
and penetrating behaviour (7.52; 3.47-16.31) at diagnosis, use of artificial nutrition (1.89;
1.40-2.57) and a high percentage of follow-up time with moderate or high disease activity
(1.69; 1.15-2.48) were associated with an increased risk of surgery. Use of 5-aminosalicylates
(0.37; 0.23-0.57), azathioprine (0.59; 0.43-0.80) and infliximab (0.46; 0.27-0.77) were
associated with a decreased risk of surgery. The risk of surgery in patients with upper gastro
intestinal location at diagnosis and use of corticosteroids were 0.71 [0.50-1.03] and 1.45
[0.93-2.28] respectively and were included in a multivariate model. Multivariate Cox models
showed that stricturing (3.09; 2.22-4.28) and penetrating behaviour (6.88; 3.07-15.45) at
diagnosis, use of corticosteroids (1.86; 1.14-3.06), artificial nutrition (1.80; 1.31-2.49) and
a high percentage of follow-up time with moderate or high disease activity (2.23; 1.49-
3.33) were associated with an increased risk of surgery. Use of 5-aminosalicylates (0.32;
0.20-0.51), azathioprine (0.38; 0.27-0.55) and infliximab (0.43; 0.25-0.75) were associated
with a decreased risk of surgery. Conclusion: In this population-based cohort, more than
one third of children required surgery 5 years after diagnosis. Complicated behaviour at
diagnosis, time spent in activity, use of steroids and artificial nutrition were associated with
an increased risk of surgery. Treatment with 5-aminosalicylates, azathioprine and infliximab
were associated with a decreased risk for intestinal resection.
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Validation of Predictors of 5-Year Disabling CD in a Population Based Cohort
from Olmsted County, Minnesota, 1983-1996
Philippe Seksik, Edward V. Loftus, Laurent Beaugerie, William S. Harmsen, Alan R.
Zinsmeister, Jacques Cosnes, William J. Sandborn
Background & Aims: The standard therapeutic approach currently used in Crohn's disease
(CD) is the step-up strategy. Top-down strategy to avoid consequences of the disease has
been proposed, but theoretically should be reserved for selected patients who will experience
disabling CD. In a previous work (Beaugerie et al, Gastroenterology 2006), we identified at
diagnosis 3 factors (steroids required for the first flare, age below 40 years, and presence
of perianal disease at diagnosis) independently associated with an increased risk of a disabling
CD clinical course within the next 5 years. The aims of the present study were to estimate
the prevalence of patients with disabling CD in a population-based cohort from Olmsted
County, Minnesota, and to validate the ‘predictors' of subsequent 5-year disabling CD in
this population. Methods: The study comprised 90 Olmsted County patients first diagnosed
with CD between 1983 and 1996 and with a minimum of 5 years of follow-up. Patients
operated on within the first 3 months of the disease (18, 20%) were excluded. The 72
remaining patients were classified as having a disabling CD when at least 1 of the criteria
of clinical severity within the 5-year study period was present. In the present study, the
original criteria were slightly modified to more conservative criteria and were: (I) more
than 2 steroid courses required; (II) further hospitalization after diagnosis for flare-up or
complication of the disease; (III) disabling symptoms (3 or more outpatient visits for perianal
disease or extra-intestinal symptoms); (IV) need for immunosuppressive therapy; and (V)
intestinal resection or surgical operation for perianal disease. Results: In this cohort of CD
patients, 37 (51.4%) were males and the median age at diagnosis was 30.0 years (range,
8.3-82.0 years). CD initially involved small bowel only, small bowel and colon, or colon
alone in 21.8%, 21.8%, and 56.2% of the patients, respectively. Perianal lesions were present
at diagnosis in 7 (9.7%) patients. Steroids were required for treating the first flare-up in 22
(30.5%). The cumulative prevalence of having a disabling CD over the first 5 years was
54.2%. The positive predictive value of disabling disease in patients with 2 and 3 predictors
was 0.62 and 0.75, respectively. Conclusions: In CD patients from Olmsted County, the
rate of 5-year disabling CD was 54.2%. An additional 20% of patients required operation
within 3 months of diagnosis. Thus, in this population-based cohort, 74.2% of patients
might benefit from a top-down strategy. Predictive factors for a 5-year disabling course of
CD are valid in this community patient population.
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Predictors of Severe Crohn's Disease
Catherine Loly, Jacques Belaiche, Edouard Louis
Crohn's disease (CD) is a progressive inflammatory disease that may be associated with the
development of stricturing and fistulizing complications, often requiring surgery. It is hoped
that an early immunosuppressive and/or anti-TNF treatment could avoid the development
of these complications. Ideally, such an early treatment should target patients at risk for the
development of early complicated disease. Predictive factors for early severe disease were
recently determined in a large cohort of patients from France, but severe disease represented
about 3/4 of their whole cohort. Our aim was (1) to try and confirm the predictive factors
established in the French cohort, (2) to try and refine these parameters by differentiating
very severe from moderately severe disease. Patients and methods: we performed a retrospect-
ive study based on our CD database. Overall, we studied 361 patients with a follow up
longer than 5 years. Patients were first classified as severe or non severe disease within 5
years after diagnosis, according to French criteria, and factors previously studied were tested
in our cohort. Subsequently patients with severe disease according to French criteria were
subdivided into very severe (>70 cm intestinal resection, >2 intestinal resections, colectomy,
stoma, complex perianal disease) and moderately severe CD. Demographic and clinical
parameters were tested as predictors of severe CD in the whole cohort as well as biological
markers in a subgroup of 73 patients. Results: 209/361 (57.8%) of our patients had developed
severe disease within 5 years after diagnosis according to French criteria. We could confirm
the predictive value of an age <40 at onset (P<0.0001)and the presence of perianal lesions
at diagnosis (P=0.0006). According to our proposed modified criteria, 18.0% had developed
very severe disease, 39.9% moderately severe disease, and 42.1% non severe disease within
5 years. The development of very severe disease was associated with age<40 at diagnosis
(P=0.04), stricturing (P=0.001) or intra-abdominal fistulising (P=0.013) CD at diagnosis,
fever at diagnosis (P=0.012), loss of weight > 5Kg at diagnosis (P=0.001), and increased
platelet count at diagnosis (P=0.02). Conclusion: after confirming the predictive value of
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French criteria for the development of severe disease (representing 2/3 of our patients), we
could determine a new set of clinical and biological markers associated with the development
of very severe CD, representing 1/5 of our patients. Putting in balance benefits and risks,
this smaller subset of patients may be a more appropriate group for early immunosuppressive
and/or anti-TNF treatment.
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Increased Immune Reactivity Predicts Aggressive Complicating Crohn's
Disease in Children
Marla C. Dubinsky, Subra Kugathasan, Ling Mei, Yoana Picornell, Justin Nebel, Iwona T.
Wrobel, J. antonio Quiros, Gary Silber, Ghassan Wahbeh, Eric Vasiliauskas, Ron J. Bahar,
Anthony Otley, David R. Mack, Jonathan S. Evans, Joel R. Rosh, Maria Oliva hemker,
Neal S. Leleiko, Wallace V. Crandall, Christine Langton, Kent D. Taylor, Stephan R.
Targan, Jerome I. Rotter, James F. Markowitz, Jeffrey S. Hyams
Background Crohn's disease (CD) is a heterogeneous disorder characterized by diverse
clinical phenotypes (inflammatory, fibrostenosing [FS], internal penetrating [IP]) that appear
to be influenced by genetic and immune factors. Children frequently manifest an aggressive
disease course, and the ability to identify those at risk for complicated disease at diagnosis
would be invaluable in guiding initial therapy. Aim: To examine the association of serological
immune responses and CARD15 with CD phenotype in a large well-characterized pediatric
collaborative cohort. Methods: Sera were collected from 797 prospectively followed pediatric
CD cases and tested for immune responses to microbial antigens: anti-Cbir1 (flagellin), anti-
outer membrane protein C (anti-OmpC) and anti-Saccharomyces-cerevisiae (ASCA) using
ELISA. Genotyping (TaqmanMGB) was performed for 3 CD-associated variants of CARD15
(SNPs 8, 12, 13). Disease phenotypes were determined blinded to genotype and immune
responses. Associations between immune responses, CARD15 and clinical phenotype were
evaluated. Results: CARD15 variants and immune responses were present in 34% and 78%,
respectively. Small bowel (SB) location, IP and/or FS disease behavior were present in 68%
(n=542) and 20% (n=152) of children after a median follow-up of 31 months. The odds
of developing IP and/or FS disease were highest in patients positive for all 3 immune
responses (Table 1). The highest level for each individual antibody was associated with IP
and/or FS with the odds being highest when using the sum of all immune response levels
(Table 2). Multivariate analysis confirmed the Anti-OmpC (p<0.0002) and anti-Cbir1 (p=
0.005) association with IP as well as ASCA (p=0.02) and anti-Cbir1 (p=0.04) with FS.
CARD15 was associated with small bowel disease (OR=1.7; p < 0.0001) only, not with
disease behavior.Conclusions: The rate of complicated CD increases in children as the
number and magnitude of immune reactivity increases. Baseline immune response assessment
may identify children at risk for complicating IP/FS phenotypes, for whom early, aggressive
immunomodulatory therapy could be of benefit.
Qualitative Analysis
Quantitative Analysis
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Genetic Markers and the Risk of Complicated Disease Behaviour in Crohn's
Disease Patients
Liesbet Henckaerts, Isabel Verstreken, Kristel Van steen, Robert Vlietinck, Paul Rutgeerts,
Severine Vermeire
Introduction & aims: The majority of Crohn's disease (CD) patients develop complications
(fistulae or strictures) in the course of the disease and often require surgery. It is important
to identify patients who are at high risk to develop complications early, as this may have
therapeutic implications. We investigated if CD-associated genes may influence time to onset
of complications and need for abdominal surgery, and if a risk model for disease progression
could be identified. Methods: A cohort of 505 patients with CD (41.2% male; median age
at diagnosis 24.4y (IQR 19.2-31.3) was genotyped for variants in NOD2/CARD15, TUCAN/
CARD8, NOD1/CARD4, TLR1, TLR2, TLR4, TLR6, OCTN1, OCTN2 and DLG5, and were
reviewed for age and smoking at diagnosis, disease location, time to onset of fistulising or
stricturing behaviour, need for surgery and presence of extra-intestinal manifestations.
Results: With a median follow-up (FU) of 15.6y (IQR 8.5-23.1), 48.7% and 56.0% of
patients developed fistulae and strictures respectively and 60% needed resective surgery.
Using Kaplan-Meier method, a significant difference in stricture and surgery free survival
rate was seen, with a gene dosage effect for 0, 1 and 2 CARD15 variants respectively (figure,
logrank p<0.0001). This effect was independent of disease location as it was observed for
both ileal and colonic disease. Patients with younger age at diagnosis developed more fistulae
during their disease course (58% <16y, 51.1% 17-40y, 33.3% >40y), independent of FU
time (multivariate p=0.009 for age at diagnosis and p=0.0002 for FU time). Conclusion:
CD patients carrying CARD15 variants have a shorter time to onset of stricturing disease
and subsequent abdominal surgery. Genotyping for CARD15 at the time of diagnosis may
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therefore be useful to identify those patients who might benefit from early introduction of
aggressive treatment.
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Functional and Phenotypic Characterisation of Beta-3 Adrenoceptor in Human
Enteric Neurons
Nadia Hafsi, Jutta Wollmann, Claus W. Hann von weyern, Florian Zeller, Gareth J.
Sanger, Wendy J. Winchester, Kevin Lee, Selim Cellek, Michael Schemann
We have previously demonstrated expression of beta-3 adrenoceptor (beta-3 AR) in the
human enteric nervous system. In addition we have shown that activation of this receptor
with a selective agonist inhibited diarrhoea and visceral pain in rat models. In this study
we investigated the effect of beta-3 AR activation on the excitability of human enteric neurons
and characterised the neurochemical phenotype of the beta-3 AR immunoreactive (IR)
neurons. Neuro-imaging with the voltage sensitive dye Di-8-ANEEPS was used to record
membrane potential changes, in particular spike discharge, in neurons of the human colon
submucosal plexus (12 ganglia from 11 patients). Microejection of 100µM nicotine evoked
spike discharge at a frequency of 13Hz on average. Perfusion of the selective beta-3 AR
agonist GW427353 at 0.1, 0.3 or 0.5µM significantly suppressed nicotine-evoked spike
discharge in 71% of the neurons to 8Hz, 7Hz or 4Hz, respectively (12 patients, 20 ganglia).
This inhibitory effect was reversible after 30-60min wash-out. Perfusion of the beta-3 AR
antagonist SR59230A (1µM) caused a potentiation of the nicotine-evoked spike discharges
from 7Hz to 16Hz. In the presence of SR59230A the inhibitory action of GW427353 was
fully blocked (5 patients, 5 ganglia). In the same neurons inhibitory action of 0.5µM
GW427353 were restored after 1hr wash-out of SR59230A. Beta-3 AR was expressed in
2.6±0.6% and 72.3±3.1% of human colon myenteric (n=5595) and submucosal (n=1048)
neurons, respectively. In both plexuses numerous nerve fibres were beta-3 AR-IR. In the
myenteric and submucosal plexus 98.5±1.5% and 85.3±7.4% of beta-3 AR-IR neurons were
choline acetyltransferase-IR, respectively. In the myenteric plexus no beta-3 AR-IR neurons
were somatostatin-IR, in the submucosal plexus only 1.8±0.6% of beta-3 AR-IR neurons
were somatostatin-IR. These results suggest that beta-3 AR activation causes suppression of
neuronal activity in the human enteric nervous system. Beta-3 AR is almost exclusively
expressed on cholinergic neurons in both myenteric and submucosal plexuses. The potentiat-
ing effect of the beta-3 AR antagonist on basal neuronal activity suggests the presence of a
beta-3 AR-mediated sympathetic tone which may contribute to low excitability of enteric
neurons under physiological conditions. The sensitivity of enteric neurons to various stimuli
might be decreased by activation of beta-3 AR; therefore this receptor may be a promising
target to reduce neuronal hyperexcitability in the diseased gut.
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Synaptic Activation of Trpc Channels By Metabotropic Purinergic P2Y1
Receptors in the Submucosal Plexus of the Guinea-Pig Small Intestine
Mei-hua Qu, Hong-zhen Hu, Na Gao, Guo-du Wang, Xiyu Wang, Guijun Fei, Fie Zou,
Yougin Du, Yun Xia, Jackie D. Wood, Sumei Liu
Canonical transient receptor potential channels (TRPC) are store-operated and receptor-
operated non-selective cationic channels. TRPC channels are activated by Gq-coupled recep-
tors and/or depletion of intracellular Ca2+ stores. TRPC-like channels are known to mediate
excitatory neurotransmission at glutamatergic synapses in multiple regions of the brain. The
aim of the present study was to test the hypothesis that opening of TRPC channels underlies
the slow excitatory synaptic potentials (slow EPSPs), which are evoked by activation of the
purinergic P2Y1 receptor subtype expressed by secretomotor neurons in the submucosal
plexus. Intracellular “sharp” microelectrodes filled with the intraneuronal marker, biocytin,
were used to record stimulus-evoked slow EPSPs. Single or double-label immunofluorescence
and Western blot analysis were used to study the expression of TRPC channels. Slow EPSPs
with decreased input resistance were evoked in 13 of 15 submucosal neurons that had
S-type electrophysiological behavior, uniaxonal morphology, immuno-reactivity (IR) for
vasoactive intestinal peptide (VIP) and stimulus evoked noradrenergic inhibitory postsynaptic
potentials. Application of the selective P2Y1 receptor antagonist, MRS2179, either suppressed
or abolished the slow EPSPs in 8 of 13 S-type neurons. The TRPC channel blockers SKF96365
(30µM), flufenamic acid (100uM), ruthenium Red (100µM), and 2-APB (100µM) suppressed
the amplitude of the slow EPSPs by 67.3±6.3% (n=4), 67.8±7.6% (n=5), 70.3 ±1.2% (n=
3), and 78.0±2.3% (n=3), respectively. Application of 3-µM ATP evoked slowly activating
membrane depolarization associated with decreased input resistance in 5 of 6 neurons. The
ATP-evoked slow EPSP-like responses were suppressed by MRS 2179 (10µM) and by the
TRPC channel blockers flufenamic acid (100µM) and 2-APB (100µM). Slow EPSPs recorded
in AH-type submucosal neurons were unaffected by MRS 2179, SKF96365 or flufenamic
acid. Immunofluorescence and Western blotting revealed expression of TRPC1, TRPC4, and
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TRPC6 proteins in the submucosal plexus. TRPC1-IR was expressed in 55.6% of the neurons
and was co-localized with ChAT-/calretinin-IR neurons, ChAT-/neuropeptide Y-IR neurons,
and VIP-IR neurons. TRPC4-IR was expressed in 34.0% and TRPC6-IR in 39.5% of the
submucosal neurons. TRPC4-IR and TRPC6-IR were expressed exclusively in VIP-IR
secretomotor neurons. Our results support the hypothesis that slow EPSPs in secretomotor
neurons are mediated by release of ATP, activation of P2Y1 receptors and opening of TRPC4
and TRPC6 channels. (Supported by NIH RO1 DK-37238 and RO1 DK-068258)
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Synaptophluorin Mice: A Novel Model to Study Synaptic Transmission in the
Enteric Nervous System
Pieter Vanden berghe, Valentine Van den abbeel, Priya Gomes, Werend Boesmans, Jozef
Janssens, Jan Tack
Coordination of gut function depends on efficient synaptic transmission, a key event in the
transfer and integration of information in the enteric nervous system (ENS). Currently
available electrophysiology and imaging techniques, assess the consequences of synaptic
transmission, but do not provide information on the exact site of neurotransmission. Here
we present a novel transgenic mouse model, generated by Li et al. (2005), which expresses
synaptopHluorin (sypH), a fusion protein of a pH-sensitive eGFP (Miesenböck et al., 1998)
and synaptobrevin, a protein present in neurotransmitter containing vesicles. The eGFP-
moiety of the fusion protein is located in the vesicle lumen where it is fully quenched by
the acidic pH. Upon vesicle fusion and neurotransmitter release, this moiety is briefly exposed
to the extracellular medium (pH 7.4) in the synaptic cleft. It was shown in central neurons
expressing sypH that, upon vesicle release, the sypH is unquenched, leading to a transient
increase in fluorescence intensity. During endocytosis, acidification and refilling of the
vesicles, sypH becomes quenched again. Our aim was to investigate the use of these mice
to assess neurotransmission in the ENS. We found expression of sypH in the stomach, small
intestine and colon. The punctate expression was consistent with the location of synaptic
contacts, displaying either long strings of intense puncta in fiber strands or basket-like
structures surrounding individual neurons. SypH expression was present in the submucous
and myenteric plexus, as well as the circular, but not the longitudinal muscle layer. Tissue
culture (48hr) did not alter the expression, indicating that expression of the protein does
not exclusively originate from extrinsic fibers. All sypH expressing puncta co-localized with
synaptophysin as seen from immunohistochemical labeling and a subset of nitric oxide
synthase (NOS) expressing neurons received clear input from sypH neurons. In live imaging
experiments we observed transient activation of sypH puncta upon high K+ depolarization
and electrical fiber tract stimulation. Superfusion of NH4Cl (50 mM), which alkalinizes
vesicular content artificially, was used to identify all available and correctly sorted sypH
molecules, allowing us to quantify the fraction of activated synapses upon stimulation. These
feasibility studies strongly suggest that the synaptopHluorin transgenic mouse model offers
a novel method to study sites of synaptic transmission in the ENS, which will be useful to
identify intrinsic pathways.
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Functional Interaction Between P2X and Nicotinic Acetylcholine Receptors in
Enteric Neurons and in Transfected HEK-293 Cells
Dima Alkawwas, James J. Galligan
P2X2 and nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that
mediate fast synaptic excitation in the enteric nervous system (ENS). Although these channels
are distinct they are closely coupled in the membrane and they exhibit a mutually inhibitory
interaction. It is unclear if the interaction is mediated by direct coupling between the ion
channels or if other proteins are involved. These studies determined if P2X2 receptors and
α3β4 subunit-containing nAChRs expressed in HEK-293 cells exhibited the same functional
interaction as is present in enteric neurons. Whole-cell patch clamp techniques were used
to measure currents caused by activation of P2X receptors and nAChRs in cultured myenteric
neurons, and in HEK-293 cells expressing these receptors. Maximum concentrations of
acetylcholine (ACh, 3 mM) and ATP (1 mM) were used to activate nAChRs and P2X receptors.
In myenteric neurons, ACh and ATP currents were 0.5 ± 0.2 and 0.8 ± 0.2 nA, respectively.
In the same neurons, agonist co-application evoked an inward current of 0.8 ± 0.2 nA which
was only 57 ± 6% of the predicted current (1.4 ± 0.4 nA, P < 0.05, n=8) that would have
occurred if the two channels were activated independently. ACh did not cause an inward
current in HEK-293 cells expressing only P2X2 receptors and ACh did not alter currents
caused by ATP in these cells (ATP alone = 3.0 ± 0.7 nA, ATP plus ACh = 3.0 ± 0.6 nA; P
> 0.05). In HEK-293 cells expressing α3β4 nAChRs, ACh caused an inward current of 1.6
± 0.5 nA while ATP did not produce a response in these cells. Combined application of
ATP and ACh caused an inward current of 1.5 ± 0.6 nA that did not differ from ACh
application alone (P > 0.05, n= 7). HEK-293 cells stably expressing P2X2 receptors were
transiently transfected with α3and β4 nAChR subunits. Mean inward currents caused by
ATP and ACh were 2.9 ± 0.4 and 2.0 ± 0.5 nA, respectively. Co-application of ATP and
ACh in the same cells caused an inward current of 3.0 ± 0.5 nA; this was only 61 ± 3% of
the predicted current (4.9 ± 0.8 nA P < 0.05, n = 9) that would have occurred if the channels
functioned independently. These data indicate that the functional properties of P2X2 and
nAChRs can be reproduced in HEK-293 cells and that the mutually inhibitory mechanism
does not require myenteric neuronal specific proteins. This strongly suggests a direct protein-
protein interaction occurs between P2X2 and α3β4 nAChRs. Heterologous expression of
P2X2 and α3β4 nAChRs in HEK-293 cells allows a study of the molecular details of receptor
interaction. This information will provide a more complete understanding of synaptic mech-
anisms in the ENS.
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Expression of PKG1α in Intrinsic Primary Afferent Neurons of the ENS:
Potential Role in Development of Long-Term Hyperexcitability and IBS
Zhishan Li, Ying-ju Sung, Richard T. Ambron, Michael D. Gershon
The molecular basis of the visceral hypersensitivity associated with the irritable bowel
syndrome (IBS) is currently unknown. Long-term hyperexcitability (LTH) in primary nocicep-
tive neurons that is associated with chronic pain can be caused by nerve injury and/or
inflammation. The induction of LTH in primary nociceptive neurons involves alterations in
gene expression, which are mediated by activation of the Type Iα isoform of protein kinase
G (PKG). PKGIα is present in the visceral nociceptive neurons of dorsal root ganglia;
therefore, it is possible that PKGIα might also be expressed in the peripheral processes of
these cells in the bowel and, if adequately perturbed by inflammation or injury, mediates
the induction of LTH and the visceral hypersensitivity of IBS. We thus examined PKG
expression and distribution in the gut. Isolated myenteric ganglia were found by immunoblot-
ting to contain PKG1α but not the muscle-associated PKG1β. In tissue sections, PKGIα
immunoreactivity was detected in subsets of fibers and cell bodies in both the submucosal
and myenteric plexuses and in nerves of the deep muscle plexus and mucosa. In whole
mounts, PKGIα immunoreactivity was found, not only in axons, but also in intrinsic neurons,
identified by immunostaining the markers β3-tubulin and Hu, and in interstitial cells of
Cajal (ICCs), identified by their Kit immunoreactivity. The PKG-immunoreactive neurons
constituted 13 ± 3% (PKG/Hu) of myenteric and 22 ± 3% (PKG/Hu) of submucosal neurons.
In contrast to PKG1α, enteric neurons were not immunostained with antibodies to PKG1β.
We tested the hypothesis that the PKG1α-immunoreactive neurons were intrinsic primary
afferent neurons (IPANs) by co-immunostaining with antibodies to the IPAN markers calbin-
din and NeuN. Coincident localization was found between PKG1α and both calbindin and
NeuN. In the myenteric plexus, co-localization of PKG1α immunoreactivity was 100% with
that of calbindin and 98 ± 1% with that of NeuN. In the submucosal plexus all calbindin-
immunoreactive neurons contained PKG1α, but a subset of PKG1α neurons did not contain
calbindin; The co-localization of NeuN with PKG1αwas 97 ± 1%. Because PKG1α expression
characterizes nociceptive neurons in DRG, its expression in IPANs of the ENS suggests that
common processes occur in each type of cell. This shared property is consistent with the
possibility that provocations that evoke PKG1α-mediated LTH in DRG nociceptive neurons
(injury, inflammation) may also do so in IPANs and contribute to the pathogenesis of IBS.
Supported by NIH grants NS12969 and NS12250.
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Brain-Derived Neurotrophic Factor (BDNF) Enhances Enteric Nervous System
Signaling Both at the Pre- and Postsynaptic Level
Werend Boesmans, Priya Gomes, Jozef Janssens, Jan Tack, Pieter Vanden berghe
BDNF promotes motility in several species and has been implicated in the control of peristalsis
(Grider, 2006). Besides its important role in neuronal growth and differentiation, BDNF is
also a potent modulator of neuronal activity and synaptic transmission. The aim of our study
was to elucidate the mechanisms governing BDNF's effect on motility. Immunohistochemistry
revealed the presence of BDNF and its receptor TrkB in mucosa, submucosal plexus and
myenteric ganglia of the guinea pig ileum. Primary cultures of myenteric neurons also
expressed BDNF and TrkB and were consequently used as a model to study the physiological
effects of BDNF. By analogy with the acute depolarizing effect BDNF has on hippocampal
neurons, we first tested, using Fluo-4 AM, the ability of BDNF to induce acute intracellular
Ca2+ concentration ([Ca2+]i) changes in myenteric neurons. None of the neurons studied
(n=90) displayed a [Ca2+]i. change when challenged with BDNF (50ng/ml, 10s). However,
2, 24 and 48 hours of BDNF incubation, enhanced the number of neurons responding to
5-HT (10µM) with 17% (χ2;p<0.05) and the [Ca2+]i peak amplitudes upon 5-HT rose
gradually (up to 26%; ANOVA; p<0.05; n=256) with duration of BDNF incubation. Similarly,
24 and 48 hours of exposure to BDNF caused increased Ca2+ rises (up to 12%; ANOVA;
p<0.05; n=215) to SP (1µM) compared to control. Next, we examined the influence of
BDNF on the density of synaptic contacts in primary cultures by quantifying synaptophysin
immunoreactive puncta per neuronal fiber length. BDNF incubation (48hrs) resulted in a
28% (Student's t; p<0.05; n=1956 puncta) increase in the number of synaptic vesicle clusters.
By monitoring [Ca2+]i changes, we observed that the increased synaptic density was reflected
in more spontaneous network activity. Both number of neurons taking part in network
activity and frequency of Ca2+ rises were higher (42% increase; χ2; p<0.05 and 37% increase;
Student's t; p<0.05 respectively; n=204) in BDNF-treated cultures. To evaluate modulation of
neurotransmitter release kinetics in enteric synapses, we analyzed the fluorescence destaining
profiles from enteric terminals loaded with the vesicle recycling dye FM1-43 and found that
BDNF treatment facilitates FM dye destaining during field stimulation (Student's t; p<0.05;
n=234). Our findings demonstrate that BDNF enhances ENS signaling both at the pre- and
postsynaptic level. The promotion of motility in the presence of exogenous BDNF can
therefore be attributed to its enhancing effects on agonist signaling and synaptic transmission.
Whether or not endogenous BDNF has a similar role in normal gut physiology remains to
be determined.
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Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort
Study
Dominique Turck, Corinne Gower-rousseau, Gwénola Vernier-massouille, Emma Tilloy,
Mamadou Baldé, Franck Brazier, Véronique Merle, Jean-louis Dupas, Olivier Mouterde,
Raymond Marti, Eric Lerebours, Antoine Cortot, Jean-louis Salomez, Jean-frédéric
Colombel
Introduction: The natural history of ulcerative colitis (UC) is poorly described in children
and a limited number of population-based studies is available. The aim of this study was
to describe the natural history of pediatric UC in a population-based cohort. Patients and
methods: In a geographically derived incidence cohort diagnosed from 1988 to 2002 (Registre
EPIMAD), we identified all patients with onset of UC before the age of 17 years. During
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this period, 151 cases of pediatric UC were recorded (4.5% of all the UC cases in Northern
France) with a mean standardized incidence of 0.8/105. The cumulative risk of colectomy
was estimated through Kaplan-Meier method. Results: 113 of 151 children (44 M and 69
F) with a median age at diagnosis of 14 years [Q1=10-Q3=16] were followed for a median
of 76 months [46-127]. UC location at diagnosis and last follow-up was proctitis (28% and
14%), left colitis (below splenic flexure) (33% and 26%) and pancolitis (39% and 60%)
respectively. Extra-intestinal manifestations occurred in 7% at diagnosis and in 22% at last
follow-up including joints in 14%, skin in 7% and primary sclerosing cholangitis in 3%.
At last follow-up 35% (39/113) had a history of serious complication including acute colitis
in 20% (23/113). During disease course, 77% received oral 5-aminosalicylates (5-ASA) and
21% topical 5-ASA. Within the first year after diagnosis, 68% required treatment with
corticosteroids. Corticosteroid resistance occurred in 14% and corticosteroid dependence
in 29%. Immunomodulators (aziathoprine and/or methotrexate) were initiated in 26% (29)
21 months after the diagnosis [8.5-42.5] with a response in 55%, intolerance in 7% and
failure in 38%. Ciclosporine was used in 13% (14) with a response in only one patient and
a colectomy rate of 93% within 1 month [0-2]. Twenty-seven patients (24%) underwent
surgery. The cumulative colectomy risk was 9% (95% CI=4%-14%), 15% (9%-22%) and
20% (12%-28%) at 1, 3 and 5 years from the time of diagnosis and was not different
according to the initial extent of disease. One patient died of primary sclerosing cholangitis
evolving for 12 years, resulting in a global mortality rate of 0.9% within the whole cohort.
One patient with a 14-year pancolitis had a rectal adenocarcinoma. Conclusions : In this
population: pediatric UC was characterized by a widespread location at diagnosis and follow-
up and frequent extra-intestinal manifestations. A high percentage of patients required early
corticosteroid therapy with occurrence of corticosteroid dependence in more than one fourth.
Despite frequent and early use of immunomodulators, 20% of patients were colectomized
5 years after diagnosis.
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Increased Degree of Histological Inflammation Predicts Colectomy and
Hospitalization in Patients with Ulcerative Colitis
David T. Rubin, Dezheng Huo, Jeremy T. Hetzel, Alana P. Bunnag, Mina Sedrak, John A.
Hart, Jerrold R. Turner
We previously used the University of Chicago IBD Endoscopy Database to identify patients
with ulcerative colitis (UC) and created a novel 6-point scale for grading of histologic
inflammation. A case-control analysis with prospective grading of inflammation by two GI
pathologists blinded to clinical outcomes demonstrated that increased histological activity
is an independent risk factor for colonic neoplasia (DDW, 2006). Our aim in this study
was to determine if other clinically-relevant outcomes were associated with increased inflam-
mation as assessed by our 6-point scale grading of histological activity. METHODS: This
is a subset analysis of the previous neoplastic risk study. The medical record review of
106 non-neoplastic control patients was extended to determine the number of UC-related
hospitalizations, colectomies, endoscopies, clinic encounters, radiological exams, and steroid
exposures. Survival analysis with Cox models and time-varying covariates was performed
to assess the relationship between these outcomes and histologic grade of inflammation.
RESULTS: Of the 106 patients studied, there were 20 hospitalizations and 13 colectomies.
The median age at UC diagnosis was 27 years (IQR 21-32 years) and the median duration
of disease was 13.5 years (IQR 8-20). In Cox modeling with time-varying covariates, a 1
point increase in inflammation grade resulted in a statistically significant increase in risk of
colectomy (Hazard Ratio =1.90, 95% CI 1.02-3.51; P=0.042) and a 52% increased risk of
hospitalization was marginally significant (HR=1.52, 95% CI 0.90-2.6; P=0.123). The grade
of histologic inflammation was not correlated with number of endoscopies, clinic encounters,
radiological exams, or steroid exposure. CONCLUSIONS: Increased histological activity
grade is associated with increased risk of colectomy and hospitalization, but not with
other clinical variables examined. Together with our previous study showing that increased
histological activity grade is associated with neoplasia, this information suggests that inflam-
matory activity grade, as assessed by our criteria, may be useful for prognosis. Moreover,
the data suggests that the goal of treatment in UC should not only be symptom control,
but should include successful sustained histological mucosal healing.
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Increasing Incidence and Prevalence of Inflammatory Bowel Disease in
Olmsted County, Minnesota, During 2001-2004
Steven B. Ingle, Edward V. Loftus, William J. Tremaine, William S. Harmsen, Alan R.
Zinsmeister, L. joseph Melton, William J. Sandborn
Background: We have reported that the prevalence of Crohn's disease and ulcerative colitis
in Olmsted County, Minnesota had risen significantly between 1940 and 1993 and then
remained relatively stable through 2000 (Loftus CG et al, DDW abstract 2003 and Inflamm
Bowel Dis 2007 in press). Some recent data suggests the incidence of inflammatory bowel
disease may be increasing in North America. We sought to update the incidence and
prevalence of these conditions in our region through 2004. Methods: The Rochester Epidemi-
ology Project allows for population-based studies of disease in residents of Olmsted County
(estimated 2005 population, 135,189). Crohn's disease and ulcerative colitis were defined
by previously used criteria. County residents newly diagnosed between 2001 and 2004 were
identified as incidence cases, and persons with these conditions alive and residing in the
county on January 1, 2005 were identified as prevalence cases. All rates were adjusted to
2000 U.S. Census figures for whites. Results: From 2001-2004, 63 new cases of ulcerative
colitis (59% males) and 65 new cases of Crohn's disease (51% males) were diagnosed in
Olmsted County residents. The age- and sex-adjusted incidence rate for ulcerative colitis in
2001-04 was 12.5 cases per 100,000 person-years (95% confidence interval [CI], 9.4-15.6),
compared to an incidence of 10.7 per 100,000 (8.7 - 12.6) in 1991-2000. The age- and
sex-adjusted incidence rate for Crohn's disease in 2001-04 was 12.9 per 100,000 (9.7-16.1),
compared to an incidence of 9.0 per 100,000 (7.2 - 10.8) in 1991-2000. On January 1,
2005, there were 378 residents with ulcerative colitis, for an age and sex-adjusted prevalence
of 273 per 100,000 (245-300), and 306 residents with Crohn's disease, for an adjusted
prevalence of 222 per 100,000 (197-247), compared to 214 per 100,000 and 174 per
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100,000, respectively, on January 1, 2001. Conclusion: Although incidence rates of Crohn's
disease and ulcerative colitis had remained relatively stable in Olmsted County between
1970 and 2000, the incidence of both conditions appears to have increased somewhat over
the past 5 years. The prevalence of inflammatory bowel disease has similarly increased.
Since 2001, the prevalence of ulcerative colitis increased by 21%, and the prevalence of
Crohn's disease increased about 22%. Extrapolating these figures to an estimated U.S.
population of 300 million persons, there were approximately 1.5 million people with inflam-
matory bowel disease in the U.S. in 2005.
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A Population-Based Study of Arterial Thromboembolic Events in IBD
Charles N. Bernstein, Andre Wajda, James F. Blanchard
In 2001 we reported that both Crohn's disease (CD) and ulcerative colitis (UC) were
associated with an increased risk for venous thrombosis of 3-4fold. We aimed to determine
if there was an increased risk for arterial thromboembolic diseases (ATED). We used the
University of Manitoba IBD Epidemiology Database (1984-2003), a validated population
based database of all Manitobans with IBD (n=8060) and a control group matched for age,
sex and geography (n=80489) drawn from the Manitoba Health administrative database.
Each individual has a unique personal health identification number and each health system
encounter is identified by a diagnostic code (ICD-9). We compared the incidence of ATED
after the diagnosis of IBD compared to the general population for (ICD-9 codes follow each
diagnosis); acute myocardial infarction (410), other acute and subacute forms of ischemic
heart disease (411), old myocardial infarction (412), angina pectoris (413), other forms
of chronic ischemic heart disease (414), subarachnoid hemorrhage (430), intracerebral
hemorrhage (431), occlusion & stenosis of precerebral arteries (432), occlusion of cerebral
arteries (434), transient cerebral ischemia (435), acute, but ill-defined, cerebrovascular
disease (436), arterial embolism & thrombosis (444), and atheroembolism (445). Groupings
for analysis were ICD-9 codes 410-414, 430-436, and 444-445. Data were assessed for all
IBD, CD, UC, females, males, ages 0-39, 40-59 and 60+. For disease group 410-414 see
Table. For disease groups 430-436 only CD was associated with an increased ATED risk
(IRR=1.32, 95%CI 1.05-1.66). For 444-445 females with IBD (IRR=1.96, 95%CI 1.24-3.10)
and those aged 0-39y (IRR=19.95, 95% CI 1.81-219.92) and 40-59y (IRR=3.17, 95% CI
1.27-7.91) had significantly increased risks. Conclusions: IBD patients are more likely to
have cardiac ATED, regardless of diagnosis. Females are at increased risk for cardiac and
cerebral ATED. Older IBD patients are at increased risk for cardiac ATED, while younger
IBD patients are at increased risk for otherwise unspecified ATED. Smoking, the prothrom-
botic aspect of systemic inflammation or a genetic predisposition may contribute to the risk.
The IRR for IBD vs controls for ICD-9 codes 410-414 occurring AFTER IBD Dx
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Excess Hospitalization Burden Due to Clostridium difficile in Patients with
Inflammatory Bowel Disease
Ashwin N. Ananthakrishnan, Emily L. Mcginley, David G. Binion
Introduction: Clostridium difficile (C difficile) is an important cause of diarrhea in hospitalized
patients with an estimated hospitalization burden in excess of $1 billion. There is growing
evidence about a rise in the number of cases of C difficile colitis in patients with inflammatory
bowel disease (IBD; Crohn's disease (CD), Ulcerative colitis (UC)), but these have been
limited to single institution academic tertiary medical centers. Methods: We analyzed data
from the National Inpatient Sample, the largest all-payer inpatient database in the US, for
the year 2003. Our primary case population (C difficile-IBD group) included adult patients
with a primary diagnosis of C difficile colitis and a secondary diagnosis of either CD or UC.
Our control groups were comprised of patients hospitalized with a primary diagnosis of CD
or UC without a diagnosis of C difficile colitis (IBD group) and patients with a primary
diagnosis of C difficile colitis but no listed diagnosis of IBD (C difficile group). Our primary
outcomes were in-hospital mortality, length of hospital stay and total hospital charges.
Results: There were 2,804 patients in the C difficile-IBD group, 44,400 patients in the C
difficile group, and 77,366 patients in the IBD group. Patients in the C difficile group tended
to be older (mean age 68.2 years) than patients with IBD (44.6 years) or with both conditions
(53.7 years) (p<0.05). Nearly three-fourths of the patients admitted for C difficile (72.1%)
had some co-morbidity compared to 42.9% in the C difficile-IBD group and 28.6% in the
IBD group (p<0.05). On multivariate analysis, patients in the C difficile-IBD group had a
four-fold greater mortality than patients hospitalized for IBD alone (OR 4.57, 95% CI 2.75-
7.69). They also had a higher odds of death compared to patients hospitalized for C difficile
alone (OR 1.90, 95% CI 1.19-3.03). Patients in the C difficile-IBD group stayed in the
hospital for 3 days longer compared to patients with IBD alone (3.04 days, 95% CI 2.30-
3.77 days) or C difficile alone (2.97 days, 95% CI 2.19-3.74 days). We found significantly
higher mortality, endoscopy and surgery rates in patients with UC compared to CD, but
no significant difference in length of stay or mean hospital charge. Conclusion: C difficile
colitis contributes a significant healthcare burden in patients with IBD and carries a higher
mortality than in patients without IBD. There is an urgent need for research into the
mechanisms of increased susceptibility as well as optimal treatment regimens for C difficile
infection in IBD patients.
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Osteonecrosis in Inflammatory Bowel Disease: Case-Control Analysis of
Potential Contributing Factors
Kevin A. Karls, William J. Sandborn, William J. Tremaine, L. joseph Melton, Miguel E.
Cabanela, William S. Harmsen, Alan R. Zinsmeister, Prabin Thapa, Edward Loftus
Purpose: Osteonecrosis, or avascular necrosis (AVN), is a rare complication of inflammatory
bowel disease (IBD) often attributed to systemic corticosteroid therapy. We sought to better
define the etiologic role of corticosteroids in this subset of patients (pts), and identify other
potential factors that may independently lead to AVN in IBD. Methods: A centralized
diagnostic index identified all pts with IBD and AVN evaluated at our institution between
1976 and 2003. Medical records were abstracted for pt demographics, subtype and duration
of IBD, treatment received including corticosteroids, selected co-morbid conditions, AVN
stage and joints involved, and AVN treatment and outcomes. A control group (IBD pts
without AVN) was matched based on age at initial IBD diagnosis, date of Mayo IBD confirma-
tion, gender, IBD subtype, geographic region of residence, and length of follow-up. Odds
ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic
regression adjusting for age at initial diagnosis and Mayo IBD confirmation date. Results:
We identified a total of 94 pts with both IBD and AVN (cases), of which 52 had ulcerative
colitis (UC) and 42 had Crohn's disease (CD). Surprisingly, 6 cases had never been exposed
to systemic corticosteroids. Thus far, 91 matched controls have been identified for 53 cases—
this represents a preliminary analysis, and results in full will be presented. In estimating
the odds for being a case relative to control, the OR for being a case was numerically higher
but the CI's are as yet fairly wide. UC-AVN cases tended to more often have severe UC (OR
6.7; CI 1.1-43) or fulminant UC (OR 5.8; CI 0.5-64) relative to mild or moderate, systemic
steroid exposure (OR 17.7; CI 0.7-450), hematological malignancy (OR 7.5; CI 0.1-459),
non-malignant hematological condition (OR 8.5; CI 0.1-852), prior thrombotic event (OR
2.8; CI 0.3-23.8), osteoporosis (OR 3.1; CI 0.6-16.1), parenteral nutrition usage (OR 8.3;
CI 0.7-99), and smoking history (OR 6.1; CI 0.8-47). CD-AVN cases tended to more often
have severe/fulminant CD relative to mild or moderate (OR 2.8; CI 0.2-15.8), systemic
corticosteroid exposure (OR 1.9; CI 0.1-41), estrogen therapy (OR 4.6; CI 0.2-119), prior
arthropathy (OR 2.1; CI 0.3-16), and smoking history (OR 1.6; CI 0.3-7.1). Conclusions:
AVN is a rare but serious complication seen in IBD. Systemic corticosteroid therapy does
appear to play a prominent role in the development of AVN, although IBD severity itself
may indeed represent an independent risk factor for this rare condition. Additionally, our
results suggest that smoking may be an important risk factor, particularly in UC pts.
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Anorectal-Cortical Function Is Impaired in Patients with Dyssynergic
Defecation
Jose M. Remes-troche, Jessica Paulson, Thoru Yamada, Shaheen Hamdy, Satish S. Rao
Background/Aim: Impaired recto-anal coordination, anal sphincter dysfunction and rectal
hyposensitivity have been described in subjects with constipation and dyssynergic defecation
(DD) using standard physiologic testing. However, the underlying mechanism(s) remains
unknown. In particular, it is unclear whether the brain-gut axis is disrupted in dyssynergia.
Our aim was to examine the visceral afferent gut-brain axis, by examining cortical evoked
responses following anal and rectal electrical stimulations in patients with DD. Methods:
In 16 DD (Rome III) subjects (15 F, mean age 38 yrs), mean duration of symptoms ≥ 1
year; cortical evoked potentials (CEP) were assessed by electrical stimulation of the ano-
rectum with a novel probe (Koningsberg, Pasadena,CA) containing 2 pairs of bipolar steel
ring electrodes, each 2 cm apart. Data were compared with 25 aged matched healthy
volunteers (18 F, mean age 39 yrs). CEP activity was recorded from Cz to Fz at a stimulation
frequency of 0.2 Hz and a sampling rate of 2 KHz, with an epoch duration of 300 ms. Four
runs of 50 stimuli were averaged. The thresholds to first perception and pain (mA), latencies
(milliseconds) and amplitudes (microvolts) for the anorectal CEP were recorded. CEP wave
morphology was analyzed according to conventional definitions. Results: Anal sensory
thresholds for pain were significantly higher in DD subjects when compared to controls (68
± 25 vs. 43 ± 4 mA, p<0.0001). Likewise, rectal sensory thresholds for pain were higher
in DD (55 ± 28 vs.32 ± 10 mA, p<0.002). By contrast, DD patients had a longer P1, N1,
and P2, mean latencies compared to controls (Table), and P1/N1 amplitudes were lower
(p<0.05, Table). Conclusions: Our findings demonstrate that DD patients have prolonged
latencies and attenuated amplitudes of anorectal CEP responses. These data suggest that the
afferent neuronal transmission is impaired in DD and provides new evidence that the gut-
brain axis is abnormal in patients with constipation and dyssynergia.
*p<0.05 vs.controls
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A Novel Implantable On-Demand Microstimulator Can Increase Resting Anal
Sphincter Pressure: A Pilot Study in a Porcine Model
John O. Clarke, Eun J. Shin, Priscilla Magno, Samuel A. Giday, Jonathan M. Buscaglia,
Gevorg Sedrakyan, Anthony N. Kalloo, Sergey V. Kantsevoy
Background: Fecal incontinence is a significant problem that affects 47% of nursing home
residents and up to 15% of community-dwelling adults. Due to lack of efficacy of traditional
therapeutic options, neurostimulation with surgically or laparoscopically implantable stimula-
tors has been examined as a possible treatment modality. However widespread use of
neurostimulation has been limited due to large device size and the need for surgical implanta-
tion.. Aim: To evaluate in a porcine model a novel technique of anal sphincter on-demand
stimulation with an implantable microstimulator (IMS) inserted under endoscopic guidance.
Methods: Under general anesthesia anorectal manometry (ARM) was performed using a
standard pull-through technique to obtain baseline pressures. Under endoscopic guidance
a specially-designed trochar was inserted into the submucosa along the posterior wall of
the rectum approximately 3cm from the anus. A 3mm x 28mm microstimulator (Bion®)
was inserted via the trochar into the rectal wall. This device is powered by an internal
battery, activated with a remote control, and recharged remotely through an external device.
ARM was repeated and post-implantation pressures were recorded with the IMS in the “on”
and “off” settings. The stimulation amplitude was varied from 3mA to 9mA with a fixed
frequency of 20pps and pulse-width of 400μsec. The rectoanal inhibitory reflex was assessed
both prior to IMS implantation and with the IMS “on” at a setting of 9mA. Results: The
mean anal sphincter resting pressure was 7.9 ± 3.99 mmHg. There was no change following
IMS implantation (6.8 ± 3.4 mmHg). After IMS activation at settings of 3mA, 5mA, 7mA
and 9mA, the resultant anal sphincter resting pressures were 12.8 ± 8.5 mmHg, 25.5 ±
12.0 mmHg, 27.6 ± 13.4 mmHg and 25.3 ± 13.7 mmHg, respectively - greater than 3-fold
higher than the post-implantation baseline (p<0.01). The rectoanal inhibitory reflex was not
affected by IMS implantation and activation at any settings. The time interval between IMS
activation and anal sphincter pressure increase was 3 seconds; The time interval between
IMS deactivation and anal sphincter relaxation was less than 1 second. At necropsy the IMS
was located in the muscularis layer of the rectum with no evidence of perforation or
hemorrhage. Conclusions: Rectal implantion of microstimulator can consistently and select-
ively increase resting anal sphincter pressure on-demand without affecting the rectoanal
inhibitory reflex. This novel technique is technically simple, minimally-invasive and may
improve the treatment of fecal incontinence and other gastrointestinal motility disorders.
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Determining the Site of Origin of the Defaecatory Urge Using Combined
Impedance and Manometry in the Human Ano-Rectum
Philip G. Dinning, Taher Omari, Ian J. Cook
Rectal hyper or hyposensitivity, as determined through rectal balloon inflation, is implicated
in various forms of constipation, yet none consistently so. A body of evidence suggests that
under normal physiological conditions the rectum plays little or no role in the urge sensation.
Aims; 1: Determine proof of principle for use of impedance as a means of measuring stool/
gas movement in the distal colon. 2. To identify the location of the receptors responsible
for the defaecatory urge in the healthy colon. Methods: After an overnight fast 6 healthy
subjects (4 female, 2 male) were given a distal colonic washout. With the aid of a flexi-
sigmoidoscope, a combined high-resolution manometry (18 sideholes @ 3cm - spanning
distal sigmoid colon, rectum and anal canal) and impedance (3 channels in the sigmoid
colon @ 3 cm and 3 channels in the mid rectum to anal verge @ 3cm) catheter was positioned
with the tip fixed in the sigmoid colon by endoclips. Subjects were given 4 durolax tablets
to induce rectal filling. When subject perceived an urge to defaecate an event marker was
pressed to record the time on the combined manometry/impedance trace. Onset of the urge
was correlated with motor patters and changes in impedance at the various colonic regions
Results: The urge to defaecate was recorded in our 6 volunteers on 132 occasions. These
urges were associated with a common cavity recorded throughout sigmoid, rectum and ano-
rectum regions. On 96% of occasions the urge sensation was associated with an impedance
rise at the ano-rectal verge. 120 common cavities were also recorded in the absence of the
urge sensation. These common cavities were of significantly reduced amplitude compared
to those associated with an urge (15.8 ± 3.9 mmHg vs 24.7 ± 8.7 mmHg; p = 0.008) and
they occurred in the absence of an impedance rise at the ano-rectal verge. Summary/
Conclusions: These data indicate; 1. Recording of impedance in the human distal colon is
feasible; 2. The urge sensation may require stimulation of tension receptors at the anorectal
verge secondary to the distal colonic common cavity.
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Which Factors Predispose to Incontinent Bowel Movements in Women with
Fecal Incontinence?
Adil E. Bharucha, Barbara M. Seide, Alan R. Zinsmeister, L. joseph Melton
Background - Clinical observations and epidemiological studies suggest that most women
with fecal incontinence (FI) in the community have intermittent symptoms; 79 % have
symptoms ≤ 1/week (Gastroenterology 2005). Though an association between FI and
disordered bowel habits is recognized, the factors which influence when incontinence occurs
have not been rigorously evaluated. Our hypothesis was that variations in bowel habits or
activities of daily living (e.g., traveling) partly explain FI. To evaluate this hypothesis, we
compared the characteristics of bowel habits for continent and incontinent stools in women
with FI. Methods - Using a validated mailed questionnaire, we previously identified 507
women with FI among an age-stratified random sample of 5200 Olmsted County, MN
women. From this group of 507 women, 200 randomly selected women were invited to
participate and 152 women participated in a case-control study during which they recorded
every bowel movement and FI episode in detailed diaries for 2 weeks. Among women who
had any FI during the 2 week period, several features were compared between continent
and incontinent bowel movements. Results - 105 women [(age 60 ± 1 years (Mean ± SEM)]
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had ≥ 1 episode of FI; 16% of all bowel movements were associated with FI (i.e., staining
- 8%, soiling of underclothes - 4%, and change of outerwear - 2%). Compared to continent
bms, incontinent bms were more likely to be associated with looser stools and rectal urgency
and were less likely to occur at rest (Table). However, stool frequency was comparable for
days with (1.2 bms/day) and without FI (1.5 bms/day). Conclusions - Among women with
FI, bowel patterns, rectal urgency, and activities of daily living influence the occurrence of
FI. However, on average, women were incontinent for soft but formed stools and stool
frequency was comparable between continent and incontinent bms, suggesting that anorectal
sensorimotor dysfunctions also contribute to FI. Underscoring this concept, 71% of all FI
episodes occurred while women were at rest or engaged in household chores, suggesting
they had little time to get to a toilet.
Comparison of Continent and Incontinent BMs
Mean ± SEM *p < 0.0001 # p = 0.06 vs continent bms ‡ 17% of continent and 21% of
incontinent bms occurred during other activities
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Predictive Factors for Successful Sacral Nerve Stimulation in the Treatment of
Faecal Incontinence: A 10 Year Cohort Analysis
Thomas C. Dudding, David Parés, Carolynne J. Vaizey, Michael A. Kamm
Background: Sacral nerve stimulation is an established treatment for faecal incontinence,
with proven short and medium term efficacy. However it is unknown which patients benefit
most from therapy. We aimed to identify specific factors that could predict the outcome of
temporary and permanent stimulation. Methods: A retrospective analysis was undertaken
of all 81 patients who underwent temporary sacral nerve stimulation at a single institution
over a ten-year period (June 1996 to June 2006). Data were obtained from prospectively
collected patient symptom diaries and quality of life questionnaires (SF-36 and ASCRS FIQL
questionnaires), operation reports, anorectal physiology studies, endoanal ultrasound images
and radiology of lead placement. A univariate and multivariate analysis was performed to
identify potential predictive factors in which temporary and permanent stimulation failure
was the dependent outcome variable. Results: The clinical outcome of temporary screening
was not affected by patient gender, age, body mass index, severity or length of symptoms.
A repeat temporary procedure was associated with subsequent failure during screening (p=
0.008). A low stimulation amplitude threshold to obtain a reflex motor response during
screening temporary peripheral nerve evaluation was associated with an improved outcome
(p=0.048); this also showed a significant correlation with the sensory threshold (r=0.523,
p=0.015) during the temporary screening phase. In 18 patients (29.5%) a successful outcome
occurred despite the absence of toe or forefoot flexion during peripheral nerve evaluation.
Endoanal ultrasonographic evidence of anal sphincter trauma was associated with a greater
risk of having less than 50% improvement in symptoms from chronic stimulation (p=0.040).
However, 76% of such patients still had > 50% improvement in symptoms and there was
no difference in medium term outcome between patients with external anal sphincter defects
and patients with intact anal sphincters. Conclusions: Variables have been identified that
aid selection for, and predict the outcome of, treatment with sacral nerve stimulation. Failed
temporary screening is not worth repeating. A low motor response obtained during peripheral
nerve evaluation predicts success. Patients with an external anal sphincter defect should not
be denied treatment.
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Functional Constipation (FC): Relation of the Clinical and Functional
Features to Rectal Sensory Threshold (RST)
Belen Herreros, Miguel Minguez, Cristina Monton, Amaya Basagoiti, Pedro Almela,
Vicente Sanchiz, Francisco Mora, Adolfo Benages
Antecedents: Rectal hyposensitivity (RH) is related to an abnormal perception of rectal
distension. The clinical significance of this abnormality is unclear. Aim: To evaluate the RST
and its relation with clinical and functional features in patients with FC. Patients and
Methods: Patients with FC (Roma II criteria) were evaluated prospectively. A thirty-day
diary, including characteristics of stools and symptoms, was filled out by patients. All patients
underwent CTT (radio-opaque marker technique), anorectal manometry, balloon expulsion
test and assessment of rectal sensory threshold (minimum intrarectal volume necessary to
reach desire to defecate). A defecography was performed in patients with a manometric
obstructive pattern of defecation and/or in those with symptoms of difficult evacuation.
According to Rome II criteria, pelvic floor dyssynergia (PFD) was diagnosed retrospectively
(manometric plus defecographycal findings). Normal values of RST were obtained from 46
healthy volunteers (27M/19F, 51±16 yr.), and were considered as the mean + 2 SD. Depending
on results from RST, two groups of study were established (normal RST and hyposensitivity).
Data from diary, CCT, expulsion test and presence of PFD were statistically compared between
groups. Results: 155 patients with FC were included (147F and 8M, age: 40.65±16.13 yr.,
range: 18-75). 25/155 patients (16.1%) showed criteria of PFD. Mean of RST in control
group was 23±9 ml. According to RST, 67 patients (43.2%) showed a normal RST and 88
patients (56.8%) showed a rectal hyposensitivity (RST >41 ml). The relation between results
of RST and clinical features, presence of PFD, results from expulsion test and CTT is shown
in Table. Conclusion: Rectal hyposensitivity is associated with a delayed colonic transit and
the presence of PDF in patients with FC.
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P: level of significance * Chi-square test (Yate's correction and Fischer's exact test) ** t-
Student test (unpaired data)
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Involvement of the Anterior Cingulate Cortex in Visceral Pain: Mediation By
NMDA Receptors and Ca2+/Calmodulin-Dependent Protein Kinase II
Dependent Pathways
Zhijun Cao, Xiaoyin Wu, Shengliang Chen, Jiyao Li, Chung Owyang, Ying Li
Early studies indicate that the anterior cingulate cortex (ACC) mediates affective processing
of sensory information. Electrophysiological studies have shown sensitization of ACC neurons
in the visceral hypersensitive (VH) rats. However, the actual role of the ACC in visceral
pain has not been established. We hypothesize that ACC sensitization enhances visceral
pain. To induce VH rats, we employed chicken egg albumin. These rats demonstrated
enhanced visceromotor response (VMR) to colorectal distension (CRD) suggesting colonic
hyperalgesia. Electrical stimulation of the ACC (100 Hz, 0.2 ms, 100 µA) increased VMR
to CRD at 20, 40 and 60 mmHg from (control) 3, 24 and 39 to (stimulated) 38, 49 and
53 contractions/5 seconds suggesting stimulation of ACC facilitates reflexive visceral pain
responses. Lesioning of the rostral ACC by bilateral administration of ibotenic acid did not
affect VMR in the normal rats, but it induced a 63%, 34%, and 26% reduction in VMR to
CRD (20, 40 and 60 mmHg) suggesting tonic activation of ACC neurons intensifies visceral
pain in the VH rats. To identify the receptors involved we microinjected glutamate into
ACC, and thereby dose-dependently increased VMR to CRD. In contrast, NMDA receptor
antagonist AP5 (20 mM) induced a 54% and 71% reduction in VMR to CRD (40 and 60
mmHg) in the VH rats. The AMPA receptor antagonist CNQX had no effect. Western blot
analysis showed an increase in the level of NR2B receptor expression in the ACC of VH
rats suggesting upregulation of this receptor may contribute to hyperalgesia. Given the key
role of CaMKII in synaptic plasticity, behavioral learning and memory, we hypothesize
that CaMKII mediates signal transduction in ACC neurons in response to NMDA receptor
activation, and contributes to enhanced visceral pain. To down regulate the gene expression
of CaMKII, we administrated an α-CaMKII-specific siRNA and a plasmid pEGFP-N1 carrying
the gene for green fluorescent protein (GFP) into the rostral or caudal ACC neurons by
electroporation in the VH rats. The rats with electroporation of only plasmid pEGFP-N1
were served as the control group. Immunocytochemistry of GFP showed gene transfer was
limited to the rostral ACC regions. The success in knocking down the target genes was
validated by RT-PCR and western blot analysis. CaMKII siRNA treated rats showed a mean
67% reduction in the VMR in the VH rats compared to control. Conclusion: ACC sensitization
plays a central role in pain responses in the VH rats. This process involves activation of
NMDA receptors which utilize Ca2+/CaM-dependent signaling pathways. Electrotransfer of
the CaMKII siRNA into the rostral ACC suppresses pain in the VH rats.
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Brain Processing of Somatic Pain and of Endogenous Somatic Pain Modulation
in Irritable Bowel Syndrome
Guang hui Song, Steven Graham, Khek yu Ho, Khay guan Yeoh, Philina Ng, Clive
Wilder-smith
Increased pain sensitivity to visceral and somatic tonic stimuli is evident in many IBS patients.
Abnormal central processing of visceral pain and recently also abnormal endogenous visceral
pain modulation have been demonstrated in IBS (Wilder-Smith CH. Gut 2004). This study
investigated central processing of somatic pain and activation of endogenous modulation of
somatic pain using heterotopic stimulation (effect of simultaneously applied second pain
on primary pain). Endogenous pain modulation is central to sensory sensitisation. Electrical
pain thresholds on the hand and cold pain on the foot (4°C water) were determined in 14
IBS patients and 14 matched healthy controls. Following randomized stimuli were applied
during brain fMRI (3T, TR=3000msec, TE:30msec, 64x64 pixel matrix, 2.7mm thickness):
foot cold pain, hand pain (pain threshold +20%) alone or with foot cold pain (heterotopic
stimulation), sham hand pain. Analysis: group-level activation maps using random effects
general linear model for stimuli versus baseline; selection of voxels activated above threshold
(p<0.001 uncorrected); activation peaks for each ROI. Mean titrated hand electical and sham
pain scores (VAS:0-100) were 57±16 and 0 in IBS and 58±25 and 0 in controls. Change
in hand pain with heterotopic stimulation was 0±8 in IBS and -9±12 in controls (p<0.05).
Main brain activation differences between stimulation paradigms: Hand pain minus sham
pain: in IBS: right postcentral gyrus, right middle temporal gyrus, right precuneus, posterior
cingulate cortex, left middle temporal gyrus. In controls: left postcentral gyrus, right supram-
arginal gyrus, bilateral midcingulate gyrus (BA 24). Heterotopic stimulation minus hand
pain: in IBS: right precuneus, right insula, bilateral cerebellum, left posterior cingulate, left
paracentral lobule, left middle & superior temporal gyrus. In controls: right precuneus,
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right temporal lobe, bilateral cerebellum, right frontal lobe (sensorimotor cortex), bilateral
thalamus, left anterior cingulate gyrus (BA 32), right midcingulate gyrus (BA 24), left
brainstem/pons, periaqueductal grey, left dorsolateral prefrontal cortex, left supramarginal
gyrus. Suprathreshold hand pain stimulation corrected for anticipatory effects was processed
differently in IBS mainly in areas of multimodal sensory integration, emotional responses,
self-conciousness, mentalizing and memory. During heterotopic stimulation changes in
similar regions were seen in IBS rather than in the fronto-limbic-pontine areas associated with
endogenous pain modulation in healthy controls. Endogenous pain modulatory networks for
somatic pain are abnormal in IBS.
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Attenuation of Colitis By a Tricyclic Anti-Depressant Is Mediated Via the
Vagus Nerve
Jean-eric Ghia, Patricia Blennerhassett, Stephen M. Collins
BACKGROUND: While there is growing awareness of a relationship between depression
and a susceptibility to inflammatory conditions, the role of depression in the natural history
of inflammatory bowel disease is not known. In recent studies, we have shown that mice
subjected to maternal deprivation develop a more severe experimental colitis compared to
controls. In addition, we have shown that the vagus nerve exerts a tonic counter-inflammatory
influence in experimental colitis. The aims of this study were: 1. to determine whether the
induction of depression in adult mice alters the severity of colitis; 2. whether antidepressant
therapy attenuates this susceptibility; and 3. whether the vagus is involved in the action of
the antidepressant. METHODS: Reseprine (1 μg/day) was administered for 14 days to C57BL/
6 mice via an implanted intra-cerebral-ventricular (icv) cannula. Control mice received icv
vehicle. Bilateral truncal sub-diaphragmatic vagotomy plus pyloroplasty (VXP) was performed
on the same day and sham operated mice served as controls. Behavior was assessed before
and at 8 days post-surgery by the tail-test. Colitis was then induced by the ingestion of 5%
DSS for 5 days. Separate sets of VXP and sham-operated mice were given either saline or
the antidepressant desipramine (DMI) 15 mg/kg once daily starting two days after the
surgery. Disease activity index was evaluated daily after induction of colitis. At sacrifice,
disease severity and inflammation were evaluated clinically and by myeloperoxidase activity
(MPO) in colonic tissue. C-reactive protein (CRP) and pro-inflammatory cytokines were
determined by ELISA. RESULTS: Reserpinized mice (RM) mice showed depressive-like
behavior and a more severe colitis compared to non-depressed control mice. Antidepressant
therapy significantly improved the parameters of depressive-like behavior by 63% and
reduced the vulnerability to DSS colitis in RM mice. Macroscopic scores, MPO and CRP
levels were 36%, 38% and 73,5% lower in RM-DMI-treated mice compared to RM. TNF-
a, IL-6 and IL-1b tissue level were 29%, 58,8%, 18,5% lower in RM-DMI-treated mice
compared to RM mice. DMI had no effect on colitis in mice without depression. The
attenuation of colitis by desipramine was not evident in depressed mice that had been
vagotomized. CONCLUSIONS: Pre-existing depression increases vulnerability to intestinal
inflammation and this vulnerability is reversed by a tricyclic antidepressant, acting via the
vagus nerve. These findings suggest that depression could influence the natural history of
IBD and that anti-depressants may play a role in attenuating both the depression and the
severity of inflammation.
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Chronological Assessment of Ultrastructural Gut Inflammation in a Rat Model
of Persistent Natural Stress
María Vicario, Javier Santos, Ping-chang Yang, Carmen Alonso, Mar Guilarte, Laura
Ramos, Cristina Martinez, Esteban Saperas, Juan-r. Malagelada
Stress-induced intestinal mucosal inflammation can help to explain the development and
severity of Irritable Bowel Syndrome.Although epithelial abnormalities and mucosal inflam-
mation have been described in response to stress, the dynamics of ultrastructural epithelial
changes during chronic stress have not been delineated. METHODS:WKY rats were submitted
to crowding stress (CS; 8 rats/cage) or sham stress (SS; 2 rats/cage) for 15 days.Throughout
the stress period, plasma corticosterone was assessed at baseline and 30 min after saline or
corticotropin-releasing hormone (CRH, 5 mg i.p.) administration. Jejunum (J), ileum (I)
and colon (C) segments were obtained on days 1, 3, 7 and 15 and processed for myeloperoxid-
ase (MPO) determination and scan (SEM) and transmission electron microscopy (TEM).
RESULTS:CS increased basal corticosterone from d1 (CS:223±44 vs SS:49±7.4 ng/mL;
P<0.05) to d15 (CS:139±23 vs SS:42±4.5 ng/mL; P <0.05). Corticosterone responses to
CRH were conserved throughout the study with similar increases in both groups. CS induced
mucosal inflammation as indicated by enhanced MPO activity (UI/g) that peaked at d3 in the
J (CS:0.28±0.09 vs SS:0.13±0.09; P<0.05) and at d7 in the I (CS:0.44±0.17 vs SS:0.17±0.10;
P<0.05), proximal C (CS:0.58±0.16 vs SS:0.30±0.12; P<0.05) and distal C (CS:0.89±0.45
vs SS:0.47±0.10; P<0.05 ). SEM showed that CS was also associated with progressively
higher density of inflammatory cells appearing on the epithelial surface (Fig1).The percentage
of mucosal mast cells showing piecemeal-degranulation on TEM was not modified by SS
throughout the experimental protocol (J:6±2%; I:7±2%; proximal C:4±1%; distal C:5±2%).
However, CS markedly increased mast cell activation already at d1 increasing over time to
d15 in the J (d1:19±3% vs d15:32±3%;P<0.05), the I (d1:16±3% vs d15:27±3%; P<0.05),
the proximal C (d1:25±5% vs d15:38±4%;P<0.05) and the distal C (d1:25±4 vs
d15:41±6;P<0.05) with signs of epithelial damage indicated by ballonization of enterocyte
and colonocyte mitochondria also peaking at d3. CONCLUSIONS: chronic heterotypic social
stress induces maintained and extensive structural epithelial abnormalities and progressive
mast cell activation.
118
The Role of NMDA Receptors in Chronic Visceral Hyperalgesia Following a
Neonatal Somatic Stimulus
Adrian Miranda, Daniel Thibaudeau, Banani Banerjee, Jyoti N. Sengupta
Background: Somatic pain experienced in early life influences the response and behavior of
colorectal distension sensitive (CRD) spinal neurons through viscero-somatic convergence
and results in visceral hyperalgesia. The n-methyl-D-aspartate (NMDA) receptors may play
an important role in the long-term alterations in visceral sensitivity that result from the
neonatal stimulus. Methods: Neonatal male Sprague-Dawley rats received saline injections
of pH 4.0 (0.1ml) into the gastrocnemius muscle every other day starting at postnatal day
8 (PN8-18). Visceral sensitivity was assessed in adult rats (PN 60) using EMG from the
external oblique muscle. Following a baseline visceromotor response (VMR) to CRD (10-
80mmHg, 30s, 180s inter-stimulus intervals), the NMDA receptor antagonist CGS-19755
was given (20nmol, i.t.) and a second VMR was recorded. Extracellular single-unit recordings
from lumbo-sacral spinal neurons (L6-S1) were performed in adult that developed hyperalge-
sia and in naïve controls. The spontaneous firing and response to CRD was recorded before
and after CGS-19755 (20µmol/kg, i.v.). In a separate group of naïve and pH 4.0 injected
rats, the DRG were removed from the L2-L4 and L6-S1 spinal segments bilaterally at 1
month of age (PN30). Immmunohistochemistry was performed in both groups to measure
the expression of NR1 subunit of NMDA receptors. Results: At distensions > 20mmHg, an
increase in the VMR to CRD was observed in the pH 4.0 injected group compared to the
naïve group (n=5) (P<0.05). The observed visceral hyperalgesia was significantly attenuated
by CGS-19755 at CRD pressures >30mmHg (p<0.05). The spontaneous firing of spinal
neurons (mean: 20.6 ± 2.2 imp/s, n=3) in the pH 4.0 treated rats (n=3) was significantly
higher than control (mean: 2.6 ± 0.8 imps/s, n=3). The response of the spinal neurons to
CRD in the pH 4.0 group was higher at distension pressures > 20mmHg and was significantly
decreased following CGS-19755 application (p<0.05). The proportion of NR1 immunoreac-
tive neurons in the DRG of pH 4.0 injected rats was markedly increased in both L2-L4
(69.1± 2.3%, n=3) and L6-S1 (58.4 3.9%, n=3) compared to naïve controls (L2-L4 55.5 ±
5.0% and L6-S1 41.9 ± 4.0%, n=2). Conclusion: Nociceptive somatic stimulation in neonatal
rats results in chronic visceral hyperalgesia with increased spontaneous firing of spinal
neurons and response to CRD. These alterations can be attenuated by the competitive NMDA
receptor antagonist CGS-19755. Increased expression of NMDA receptors peripherally may
contribute to the observed changes in adult rats.
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Decreased Cortical Activation During Rectal Distention in Patients with
Functional Constipation with Normal Rectal Compliance
Annie on on Chan, Wai mo Hui, Nina yh Wong, Gigi Leung, Shiu kum Lam, Benjamin
cy Wong
Background: Patients with chronic constipation have loss of or diminished urge sensation.
The underlying cortical processing for the alteration of urge sensation is unknown. We
postulated there might be abnormal or diminished cortical processing in patients with
constipation. Aim: to investigate cortical processing in patients with functional constipation.
Methods: Patients with functional constipation (n=19) and normal healthy subjects (n=13)
were recruited. The rectal compliance in both group was determined using barostat. The
mean urge sensation of the normal subjects were calculated and then the subliminal, liminal
and supraliminal pressures were determined. Patients were required to press a button
indicating urge or strong sensation. Functional MRI based on the Oxygenation Level Depend-
ent (BOLD) effect carried out in a 3T MRI System was performed for both groups with the
barostat connected. The distention paradigm consisted of subliminal, liminal and supraliminal
pressures interleaved with rest period. The software SPM99 was used for data analysis.
Results: There was no difference in sex (p=0.6), age (p=0.15) or rectal compliace (6.6 ± 3.7
vs 6.0 ± 1.6 ml/mmHg, p=0.064) in the constipated and control groups. The mean urge
sensation of the healthy subjects was 30mmHg, therefore the subliminal, liminal, and
supraliminal pressures were 15mmHg, 30mmHg, and 45mmHg, respectively. The cortical
areas represented at subliminal and supraliminal pressures were similar in both groups.
However, the volume of cortical activity at parietal lobe and precuneus was lower in constip-
ated subjects at liminal pressure (P<0.003). There was frontal and limbic lobe activation in
the normal subjects at urge sensation but not in constipated subjects (p<0.0034). Conclusion:
Patient with functional constipation have impaired afferent pathway leading to abnormal
urge sensation.
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Aspirin Use and the Risk of Colorectal Cancer According to Cyclooxygenase-2
Expression
Andrew T. Chan, Shuji Ogino, Charles S. Fuchs
Background: In observational and randomized intervention studies, regular aspirin use
reduces the risk of colorectal neoplasia. Nonetheless, the mechanism by which aspirin affects
colorectal carcinogenesis is not well understood. Aspirin inhibits cyclooxygenase-2 (COX-
2), which promotes inflammation and cell proliferation and is overexpressed in the majority
of human colorectal cancers. However, aspirin decreases proliferation and increases apoptosis
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in colorectal cancer cell lines that have no detectable COX activity and aspirin has well-
documented non-COX effects. If aspirin principally works via COX-2 inhibition, we hypo-
thesized that aspirin use should reduce preferentially the risk of tumors that overexpress
COX-2. Methods: We immunohistochemically assayed cyclooxygenase-2 (COX-2) expression
in paraffin-embedded colorectal cancer specimens from two large cohorts who provided
prospective data on aspirin use and other colorectal cancer risk factors biennially since 1980.
We used competing risks duplication method Cox regression to prospectively compare the
effect of aspirin on colorectal cancers according to tumoral COX-2 overexpression. Results:
During the 2,446,431 person-years of follow-up among 82,911 women and 47,363 men,
636 incident colorectal cancers accessible for COX-2 expression were documented. The
effect of aspirin differed significantly according to COX-2 expression (P for heterogeneity=
0.02). Regular aspirin use conferred a significant reduction in the risk of colorectal cancers
that overexpressed COX-2 (multivariate RR, 0.64; 95% CI, 0.52-0.78), whereas regular
aspirin use had no influence on tumors with weak or absent expression (multivariate RR,
0.96; 95% CI, 0.73-1.26). The protective effect of aspirin on COX-2 overexpressing cancers
was significantly stronger with both increasing aspirin dose (P for trend<0.001) and increasing
duration of use (P for trend<0.001). No significant dose (P for trend=0.52) or duration (P
for trend=0.25) effect was observed for cancers with weak or absent COX-2 expression.
Conclusions: Regular aspirin use appears to reduce risk of colorectal cancers with COX-2
overexpression but not cancers with weak or absent COX-2 expression. By providing a
mechanistic basis for the effect of aspirin on colorectal neoplasia, our results offer compelling
evidence of causality and highlight the importance of the COX-2 pathway in carcinogenesis.
Our findings also support the need for further investigation into COX-2 and related pathways
and the potential use of molecular alterations in tumors for targeted prevention and treatment.
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Daily Intake of Sulphoraphane-Rich Broccoli Sprouts Prevents Colon Tumor
Formation in Mice Treated with Dextran Sodium Sulfate and Azoxymethane
Via Stimulating Nrf2-Dependent Antioxidant Enzymes
Akinori Yanaka, Ichinosuke Hyodo, Masayuki Yamamoto
Sulforaphane protects cells from oxidative injury by activating NF-E2 p45-related factor2
(nrf2) mediated antioxidant enzymes (PNAS, 94:10367, 1997) and prevents tumor formation
in froestomach in benzopyrene-treated mice (PNAS 99:7610, 2002). Broccoli sprouts are
rich source of sulforaphane glucosinolate (glucoraphanin) which is enzymatically converted
to sulforaphane upon ingestion of fresh sprouts. We have previously shown that sulforaphane
mitigates high salt diet-induced gastritis in H. pylori-infected mice via activation of nrf2
dependent anti-oxidant enzyme activities (Gastroenterology 124:A5, 2003). However, the
effects of sulforaphane on colonic mucosa have not previously been reported. The aim of
this study is to determine if daily intake of sulforaphane-rich broccoli sprouts mitigates
dextran sodium sulfate (DSS)-induced colitis and inhibits tumor formation in DSS + azoxyme-
thane(AOM)-treated mice. Methods: Wild type (nrf2+/+) and nrf2-gene knockout type
(nrf2-/-) C57BL/6 female mice were treated for 7 days with oral adminstration of 3% DSS
with free drinking water, followed by single i.p. injection of 1% AOM. Subsequently,
mice were fed with or without broccoli sprouts, which contain 2.5 mmol sulforaphane
glucosinolates. Mice were sacrificed at 4 and 8 wks after the AOM treatment. Degree of
colitis, incidence of aberrant cript foci (ACF) and polypoid tumors in colonic mucosa were
quantitatively evaluated. Antioxidant activity was evaluated by measuring GST-1, and HO-
1 mRNA expression by real time RT-PCR. DNA damage was estimated by measuring mucosal
level of 8-OHdG. Expressions of TNF-α and IL-1β were analyzed by ELISA. Results: 1. In
nrf2+/+ mice, treatment with broccoli sprouts upregulated expression of GST, and HO-1,
accompanied by downregulation of TNF-α, IL-1β, and decrease in 8-OHdG production
induced by DSS treatment. In nrf2-/- mice these effects of sulforaphane were completely
abolished. 2. In nrf2+/+ mice, treatment with broccoli sprouts attenuated DSS-induced
colitis, and inhibited subsequent formation of ACF and colon tumors, which were induced
after the AOM injection. In nrf2-/-mice, the protective effects of broccoli sprouts against
colitis and colon tumor formation were completely abolished. Conclusions: The present
results show that daily intake of sulforaphane-rich broccoli sprouts improves DSS-induced
colitis and inhibits colon tumor formation induced by DSS+AOM. Our data further suggest
that a diet rich in sulforaphane glucosinolate may be useful in chemoprevention against
colon cancer.
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Statins Induce Colorectal Cancer Cell Apoptosis Through the Induction of
Bone Morphogenetic Proteins
Liudmila L. Kodach, Sylvia A. Bleuming, Maikel P. Peppelenbosch, Gijs R. Van den brink,
James C. Hardwick
Despite reports of up to 50% reductions in the incidence of colorectal cancer (CRC) in long
term statin users, the epidemiological evidence for a beneficial effect of statins on the
incidence of CRC is conflicting. Statins induce apoptosis in CRC cell lines but the detailed
biological mechanism of action of statins in CRC remains obscure. Statins induce Bone
Morphogenic Protein (BMP) in bone and we have shown that BMPs act as tumour suppressors
in CRC. We investigated the effects of statins on CRC lines and xenografts in mice in order
to test the hypothesis that statins act on CRC through their actions on the BMP pathway.
Smad4-wt cell lines HCT116 and DLD1 were more sensitive to statin treatment than SW480
and HT29 that express no Smad4. At lower doses there was even a slight growth stimulatory
effect of statins in HT29 cells. In statin-sensitive HCT116 cells treated with Lovastatin, levels
of BMP2 protein increased with increased levels of phosphorylated Smad1,5,8 and ID-2.
Similarly ID1-Bre-Luc and BMP2-Luc reporter constructs were both activated when transi-
ently transfected HCT116 cells were treated with Lovastatin. The addition of a specific
inhibitor of BMPs, Noggin was able to prevent Lovostatin-induced apoptosis as effectively
as adding back mevalonate. In the Smad4-null cell lines lovastatin did not increase
pSMAD1,5,8 or ID2. Furthermore Noggin treatment was not able to reverse the low levels
of apoptosis induced in these cell lines. To further investigate the importance of Smad4 for
the sensitivity of cell lines to statins we studied HCT116 Smad4 -/- cells generated by
targeted deletion of the Smad 4 gene. These cells are far less sensitive to Lovastatin treatment
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than their Smad4 wt counterparts. They also show no upregulation of BMP2, pSmad1,5,8
or ID-2 and no increased ID1-Bre-Luc or BMP2 reporter construct activity. Treatment nude
mice with HCT116 or HT29 xenografts with oral Simvastatin resulted in significant inhibition
of HCT116 tumour growth but increased HT29 tumour growth compared to controls. In
conclusion, statins induce apoptosis in CRC cells by the induction of proapoptotic BMPs.
CRC cells lacking Smad4 are insensitive to statins and show a tendency towards increased
growth. This may help explain why reports on the effects of statins on the incidence of
CRC are conflicting. Caution in commencing large scale trials and more investigation into
whether statin therapy in CRC needs to be molecularly targeted to Smad4 expressing cancers
is required. The development of statins with enhanced effects on the BMP pathway may
offer increased benefit in the treatment of CRC while maintaining the excellent safety profile
of the statins.
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Are Statins Associated with a Decreased Risk of Colorectal Cancer?: A Nested
Case-Control Study Investigating the Potential Role of Statins for
Chemoprevention
Monika Sarkar, James D. Lewis, Sean Hennessy, Kathleen Propert, Wei-ting Hwang, Yu-
xiao Yang
Background: Experimental evidence suggests that statins may reduce the risk of colorectal
cancer (CRC) through the induction of apoptosis and inhibition of proliferation. However,
epidemiologic studies on this association have yielded conflicting results. We sought to
clarify whether long-term statin therapy has a chemopreventive effect on the risk of CRC
in a large, population-representative cohort. Methods: We conducted a nested case-control
study in the General Practice Research Database (GPRD) (1987- 2003). The GPRD is a
computerized medical record system from the United Kingdom containing complete, pro-
spectively-collected prescription data and validated diagnostic information on CRC. The
study cohort included all patients aged ≥ 50 years and with > 5 years of CRC-free initial
follow-up in the GPRD. Cases included all patients with an incident CRC diagnosis. Up to
10 controls were selected for each case using incidence density sampling, matching on
practice site, calendar period, and duration of follow-up prior to the index date. The primary
exposure of interest was ≥ 5 years of cumulative statin use. Dose effect was assessed
based on cumulative defined daily dose. Adjusted odds ratios (AORs) were estimated using
conditional logistic regression adjusting for sex, age, chronic NSAID/aspirin use, prior lower
GI endoscopy, alcohol use, smoking and body mass index. Interaction between NSAID/
aspirin use and statin use was examined. Results: We identified 4,432 incident CRC cases
and 44,292 controls. The use of statins for >5 years was not associated with a decreased
risk of CRC (AOR 1.0; 95% CI, 0.7-1.5). Chronic recent NSAID/aspirin use was independently
association with a reduced CRC risk (AOR 0.7, 95% CI: 0.7-0.8) but did not modify the
primary association between statins and CRC (test for interaction, p=0.5). Furthermore, no
association with CRC was found for the highest quartile of cumulative defined daily dose
of statins vs. non-users (AOR 1.2; 95% CI, 0.9-1.7). Conclusion: Long-term statin therapy
was not associated with a significantly reduced risk of CRC.
125
A Prospective Study of Aspirin Dose and Duration of Use and Risk of
Colorectal Cancer Among Men
Andrew T. Chan, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs
Background: Randomized trials of short-term aspirin use in prevention of recurrent colorectal
adenoma have provided compelling evidence of a causal relationship between aspirin and
colorectal neoplasia. Nonetheless, prospective data on long-term risk of colorectal cancer
according to dose or duration of therapy remain limited. Although a recent intervention
trial of aspirin did not find a benefit in colorectal cancer risk, the dose used may have been
inadequate. We hypothesized that a reduction in colorectal cancer risk requires consistent,
long-term use of aspirin at moderate to high doses. Methods: We conducted a prospective
study of 47,363 male health professionals, without a prior history of cancer, inflammatory
bowel disease, or familial polyposis. Biennially, we collected data on aspirin use and other
colorectal cancer risk factors from participants, who were ages 40-75 years old at enrollment
in 1986. We confirmed all reports of colorectal cancer through 2002 by review of medical
records and death certifications. We used Cox proportional hazards modeling to examine
the influence of aspirin on risk of colorectal cancer while controlling for other risk factors.
Results: During 16 years of follow-up, we documented 853 cases of colorectal cancer over
704,499 person-years. After adjustment for age, family history of colorectal cancer, smoking,
prior polyp, screening endoscopy, and other dietary and lifestyle risk factors, men who
regularly used aspirin (2+ times per week) experienced a multivariate relative risk (RR) for
colorectal cancer of 0.79 (95% confidence interval, [CI], 0.68-0.90), compared with non-
regular users. The benefit appeared to be related to increasing cumulative average dose:
compared to men who denied any aspirin use, the multivariate RRs for cancer were 0.90
(95% CI, 0.71-1.14) for men who used 0.5 to 1.5 standard aspirin per week, 0.78 (95%
CI, 0.62-0.99) for 2 to 5 aspirin per week, 0.80 (95% CI, 0.63-1.03) for 6 to 14 aspirin
per week, and 0.40 (95% CI, 0.16-0.97) for greater than 14 aspirin per week (P trend=
0.005). Notably, a significant risk reduction was not evident until at least 6-10 years of use
(P trend=0.001). Conclusions: Regular, long-term aspirin use modestly reduces the risk of
colorectal cancer among men. However, the benefit of aspirin necessitates at least 6-10 years
of continuous intake with maximal risk reduction at doses greater than 14 tablets per week.
These data provide additional evidence that optimal chemoprevention for colorectal cancer
requires long-term, continuous use of aspirin doses substantially higher than those recom-
mended for prevention of cardiovascular disease.
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EGFR Pathtway As a Critical Target in Folic Acid Mediated Inhibition of
Recurrence of Colorectal Adenoma
Nataliya Razumilava, Edi Levi, Yingjie Yu, Nadeem Ullah, Martin Tobi, Richard Jaszewski,
Arun Rishi, Adhip N. Majumdar
Introduction: Accumulating murine as well as epidemiologic and case-controlled human
studies suggest that the water-soluble vitamin folic acid may be chemopreventive for colorectal
neoplasia. Data from our recently completed double-blind, placebo-controlled clinical trial
revealed that in polypectomized patients, supplementation of folic acid (5 mg/day) for 3
years significantly decreased the recurrence of colorectal adenomas compared with the
placebo treated subjects. The mean number of recurrent polyps at year 3 was 0.36±0.69
for folic acid treated patients compared with 0.82±1.17 for placebo treated patients [t=
-2.26; p<0.02, 95% CI 0.06 to 0.84], resulting in an odds ratio of 2.7 for polyp recurrence
in placebo group. Although the regulatory mechanisms for folic acid mediated decreased
recurrence of polyps are not fully understood, we hypothesize that this could partially be
the result of inhibition of proliferation and/or stimulation of apoptosis through modulation of
EGFR signaling pathway via induction of CARP-1 (Cell-cycle Apoptosis Regulatory Protein).
CARP-1, a novel parinuclear protein, which we recently isolated, is shown to be critically
involved in regulating EGFR dependent growth-related processes. Methods: Of 153 polypec-
tomized patients enrolled in the study, 94 subjects completed the 3-year study: 46 in the
folic acid group and 48 in the placebo group. Mucosal biopsies, taken from macroscopically
normal rectal mucosa (≤10 cm anal verge) at baseline and at 3-year follow-up colonoscopy,
were analyzed immunohistochemically for changes in (a) proliferative activity, (b) apoptosis,
(c) EGFR and (d) CARP-1 expression, and also (e) EGFR promoter methylation. Statistical
analysis was performed using “MedCalc” software. Results: At baseline, no significant differ-
ence in any of the above mentioned parameters was observed between the two groups.
However, supplemention of folic acid for 3 years resulted in a statistically significant [20-
30%; P<0.0009] reduction in proliferative activity without an apparent change in apoptosis
in the colonic mucosa. This was associated with a marked reduction in the relative abundance
of EGFR [50-60%; P<0.01] and stimulation of CARP-1 expression [>30%, P=0.06]. Hyperme-
thylation of the EGFR gene could partly be responsible for decreased EGFR expression in
folic acid treated group. Conclusion: Our data suggest that folic acid inhibits the recurrence
of colorectal adenomas via reduction in proliferation and EGFR appears to play a critical
role in regulating this process.
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Enhanced Expression of Genes Associated with Visceral Hypersensitivity in
the Small Intestine of Irritable Bowel Syndrome Patients
Angele Kerckhoffs, Jose Ter linde, Louis M. Akkermans, Melvin Samsom
Background: Visceral hypersensitivity of the colorectal region as well as the small intestine
has been demonstrated in irritable bowel syndrome (IBS) patients. An increased serine
protease activity was found in the colonic mucosa of IBS patients. Moreover, IBS mucosal
supernatant-induced hyperalgesia to colorectal distension was diminished after preincubation
with a serine protease inhibitor. The serine protease trypsin IV, an agonist of protease
activated receptor (PAR)-2, may be involved. Increased PAR-2 expression and/or activation
promotes hyperalgesia. Furthermore, alterations in components of the serotonergic system
that increase serotonin (5-HT) availability may underlie visceral hypersensitivity. Abnormal
mucosal 5-HT content and altered expression of tryptophan hydroxylase (TPH)-1, rate-
limiting enzyme in 5-HT biosynthetic pathway, and the specific 5-HT transporter (SERT)
in rectal biopsies of IBS patients have been reported. Data on small intestinal serine protease
and serotonergic signalling have not been reported. Aim: Gain insight into the role of
abnormal mucosal serine protease and serotonergic signalling in small intestinal visceral
hypersensitivity of IBS patients. Materials and methods: Mucosal biopsies from the duodenum
of 34 IBS patients (10 constipation predominant (IBS-C), 11 diarrhea predominant (IBS-
D), and 13 alternating IBS patients) and 20 healthy subjects (HS) were collected. Transcript
levels of trypsinogen IV, the inactive form of trypsin IV, PAR-2, TPH-1, SERT and several
5-HT3 receptor subunits were quantified by real-time PCR. For normalization PBGD and
GAPDH were measured. Furthermore 5-HT content was determined by ELISA. Results: IBS
patients showed 1.5-fold higher trypsinogen IV mRNA level, normalized against PBGD,
compared to HS (P=0.003). For the subgroups of IBS-D and IBS-C the relative increase was
1.8-fold compared to HS (P=0.010 and P=0.016 respectively). SERT expression, normalized
against PBGD, was 1.9-fold higher in IBS patients compared to HS (P=0.010). Increased
expression of trypsinogen IV and SERT in IBS patients was confirmed using GAPDH for
normalization. Mucosal 5-HT content was 1.7-fold higher in IBS patients compared to HS
(P=0.015). The relative increase was 2.1-fold in IBS-C patients compared to HS (P=0.018).
Transcript levels of PAR-2, TPH-1 and 5-HT3 receptor subunits did not differ between IBS
patients and HS. Conclusions: Enhanced trypsinogen IV expression in IBS may cause
increased PAR-2 activation. Increased SERT expression and mucosal 5-HT content in IBS
patients suggest higher 5-HT availability. Both are likely to contribute to small intestinal
visceral hypersensitivity in IBS patients.
127
Different Clinical Characteristics of Patients with Non-Erosive Disease and
Reflux Esophagitis
Xiaohong Sun, Chunxiao Chen, Meiyun Ke, Yanli Zhang, Zhifeng Wang
Background and aim: It has been assumed that non-erosive disease (NERD) and reflux
esophagitis (RE) are two distinct entities of GERD instead of a continuous spectrum. The
aim of this study was to evaluate the demographics, symptom spectrum, quality of life, and
psychological disorders in patients with NERD and RE.Methods: We prospectively recruited
consecutive patients with acid reflux, regurgitation, heartburn or chest pain for at least 6
months. Exclusion criteria included those patients with peptic ulcer, systematic disease and
second esophagitis or history of gastrointestinal surgery. All patients were asked to complete
a symptom questionnaire, including reflux symptoms, extra-esophageal symptoms or overlap-
ping symptoms and a GERD-health related quality of life questionnaire (0-50 points, the
higher mark, the more poor Quality of life, QOL), a SF-36 questionnaire covering eight
health concepts: physical functioning(PF), role-physical(RP),bodily pain(BP),general heal-
th(GH),vitality (VT),social functioning(SF),role-emotional(RE),mental health(MH)(each
domain is scored from 0 to 100,with the more higher, the better),and questionnaire of
psychological status (Zung depression and anxiety score, over 50 point means abnormal).The
patients divided into NERD and RE according to presenting of gastroendoscopy.Results:158
patients (NERD:94, RE:64, mean age 52.96±15.73, male 42.4%) were study. There was no
difference between NERD and RE in marriage states, education, occupation, eating habit
and body mass index. There was no difference between NERD and RE on reflux symptoms
score, however, percentage of extra-esophageal symptoms in patients with NERD and RE
was 77.7% and 56.3%, respectively (P<0,05). Overlapping symptoms in NERD also was
higher than in RE (77.7% Vs 59.4%, P<0.05). Prevalence of psychological disorder in NERD
patients was significantly higher than RE patients (68.1% Vs 45.3%, P<0.05). Marks of
GERD-HRQL in NERD patients was significantly higher than in RE patients (18.17 ± 6.65
vs13.53 ± 6.68), and 5 of 8 domains of the SF-36 were significantly abnormal when compared
with RE patients.Conclusion: NERD and RE patients have different clinical characteristics.
NERD patients have higher prevalence of extra-esophageal symptoms, over lapping symptoms
and psychological disorders, poorer quality of life, suggesting that NERD and RE may be
exist different mechanisms, may be, NERD is partially related with brain-gut interaction.
128
Evidence for Familial Aggregation of IBS in a Large Family Case-Control
Study
Yuri A. Saito, Nicholas J. Talley, G. richard Locke, Janice M. Zimmerman, Joseph J.
Larson, Brooke L. Fridley, Mariza De andrade, Gloria M. Petersen
Background: Twin studies support a genetic and environmental basis for IBS, but surprisingly,
pedigree studies are lacking. We conducted a large family-based case-control study of nearly
1000 cases and controls and collected gastrointestinal symptom data from their first-degree
relatives (FDRs) in order to construct pedigrees and to further evaluate the potential genetic
and environmental contributors to IBS. Aims: 1) To determine whether IBS aggregates in
families by comparing prevalence of IBS in case-relatives with control-relatives, 2) To deter-
mine whether relationship to the proband affects the probability of having IBS, 3) To
determine whether relatives of probands with IBS have a higher risk of IBS than the general
population . Methods: Outpatients with IBS and group-matched controls seen at a major
medical institution were recruited and completed a questionnaire and family contact form.
FDRs were then mailed a recruitment letter, consent form, and questionnaire. Pedigrees
were constructed. Percent of cases and controls with a family history were compared and
odds ratios computed using chi-square test; recurrence risks to relatives were computed
using logistic regression and GEE for specific relationship pairs; and recurrence risk of the
case-relatives compared to the general population was computed. Results: Data was collected
from 573 cases, 401 controls, 1122 case-relatives, and 755 control-relatives. Cases and
controls had a median age of 50.1 and were 74.6% female. FDRs had a median age of 50.9
and were 59.6% female. The distribution of predominant IBS symptom among cases was:
10.0% C-IBS, 41.5% D-IBS, 42.9% A-IBS, and 5.6% other. Based on relative-self report
data, 39% of case- and 19% of control-families had a positive family history of IBS yielding
an odds ratio of 2.7 (95% CI: 2.0-3.6). By relationship, odds ratios comparing number of
affected case-relatives and control-relatives were 1.7 (mother), 1.9(father), 3.2(brothers),
4.3(sisters), 4.9(sons), 3.0(daughters), 1.1(spouse), with all odds ratios significant at the
0.05 level except mothers, fathers, and spouses. The relative risk of IBS was 1.8-3.4 fold
higher for case-relatives relative to the general population. Conclusions: IBS aggregates
strongly in families, and IBS risk is greater for FDRs in families with at least one affected
individual than in the general population. The strength of the association does vary somewhat
by relationship to proband, but the lack of association in spouses supports either a possible
genetic etiology or a childhood environmental exposure. Further studies are warranted to
delineate the genetic and environmental contributors to IBS. DK066271.
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Prevalence of Idiopathic Fecal Incontinence in a Community Sample
Alexandra Ilnyckyj, Lance Roberts
Background: The epidemiology of fecal incontinence (FI) is incompletely understood. Preval-
ence rates vary widely from 0.7-10%. Aim: The aim of this study was to define a community
sample and administer a validated question to determine the prevalence of idiopathic FI.
Methods: Using random digit dialing, professional interviewers conducted telephone surveys
(1). The household was the primary sampling unit. An eligible respondent was 18 or
older, lived at the address, matched a randomly pre-assigned gender and provided consent.
Respondents were asked if a diagnosis of colon cancer, ulcerative colitis, Crohn's disease or
irritable bowel syndrome (IBS) had ever been given to them by a physician. Then they were
asked “In the past 12 months have you experienced accidental leakage of liquid or solid
stool?” disregarding short term diarrheal illness (2). Respondents also ranked 8 attributes
of bowel habit on a 10 point scale. Those ranking 5 or greater were defined as having the
attribute. Results: In the mid-western Canadian city of Winnipeg, population 650,000, 1153
households were contacted. Of these, 727 (63%) agreed to participate. 50% of the sample
was male with mean age 47. Sample demographics were comparable to Canadian Census
data. FI was reported by 3.7% of the sample. There were no differences in gender/age
between those reporting FI and the sample. With physician diagnosed GI conditions removed
from the analysis, 2.0% of the sample reported FI. Of the GI conditions, only the incidence
of IBS demonstrated a significant relationship with FI: chi-square 11.567, df 1, p=.0001).
Four attributes were related to the presence/absence of FI, p=.0001 (independent groups t-
test). Those reporting FI had higher levels of 1) any type of bowel accident 2) inability to
delay toileting 3) inability to control passage of stool 4) need to wear a pad due to soiling.
These attributes were reported by 1.5%, 22%, 2.4% and 1.5% respectively of the sample.
Conclusion: The prevalence of idiopathic FI in a well defined community sample using a
validated question was 2.0%. The mean age of those with FI was 53 and 50% of those
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afflicted were men. It is imperative to control for subjects with known IBS as their inclusion
will increase the prevalence of FI in a population. Inability to delay toileting correlated
strongly with FI. 22% of the sample cited this attribute suggesting many community adults
may have challenges with continence. 1. Roberts L, Lewis TK. The 2006 Winnipeg Area
Study. Research Report No. 69. Deparment of Sociology. University of Manitoba; 2006.
2.Bharucha AE et al. Am J Gastro 2006 Jun;101 (6):1305-12.
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Irritable Bowel Syndrome (IBS) Is Strongly Associated with Generalized
Anxiety Disorder (GAD): A Population-Based Study
Justin Wu, Adley Tsang, Jenny Ng, Joseph J. Sung, Sing Lee
Aim: IBS is associated with psychological morbidity in referral centers but data from general
population is lacking. We evaluated the prevalence and association of IBS and GAD in a
population-based study. Methods: A random telephone survey of the general population
aged 15-65 years was conducted. In the telephone interview, the participants were invited
to complete a validated, 40-item structured diagnostic questionnaire for various subtypes
of IBS based on Rome III criteria (diarrhea, constipation, mixed and unclassified) and GAD
based on DSM-IV criteria, respectively. Impairment of various daily activities was evaluated
by Sheehan score (0-40). Results: 2005 participants (M: 948, F: 1057; cooperation rate:
66.6%) completed the interview. The prevalence of IBS was 5.4% (N=109), whereas the
12-month prevalence of GAD was 4% (N=80). IBS-diarrhea was the commonest form of
IBS in the general population (diarrhea: 2.1%, constipation: 1.1%, mixed: 0.4%, unclassified:
1.9%). There was no gender difference in prevalence of IBS (Male Vs female: 4.6% Vs 6.2%,
p=0.13) but GAD was more prevalent in female (Male Vs female: 2.7% Vs 5.2%, p=0.005).
The prevalence of GAD was significantly higher in IBS+ (N=18, 16.5%) Vs IBS- (3.3%,
p<0.001) participants. Using logistic regression analysis, GAD was strongly associated with
IBS (odds ratio: 6.0, 95% CI: 3.3-11.1, p<0.001). Participants with both IBS and GAD had
more severe impairment of daily activity than those with IBS alone (Sheehan score: 21.7±7.9
Vs 13.8±7.9, p<0.001) but there was no significant difference in proportion of healthcare
consulters (IBS+GAD Vs IBS alone: 61% Vs 43%, p=0.16). Conclusion: IBS was strongly
associated with GAD in general population. The strong association between psychological
morbidity and IBS observed in referral centers reflects a genuine phenomenon in general
population instead of difference in health seeking behavior.
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The 102 T/C Polymorphism of the 5-HT2A Receptor Gene Is More Frequent
in IBS in Mexico, and More Likely to Be Associated with IBS Females and
IBS-C
Max Schmulson, Norma Morales-rochlin, Rosalinda Martinez-garcia, Blanca Farfan-
labone, Carmen Escobar-villanueva, Concepción Gutierrez-ruiz, Dana Lau, Gabriela
Gutierrez-reyes
BACKGROUND & AIMS: A high prevalence of the homozygote C allele of the 102 T/C and
homozygote A allele of the -1438 G/A promoter region of the 5-HT2A receptor, have been
described in Irritable Bowel Syndrome (IBS). Also, the T/T genotype was associated with
more severe pain. (J.Clin.Gastroenterol. 2004;38:561) On the other hand, irritable bowel
syndrome IBS females (Am.J.Physiol. 2006;291:R277) and those with IBS constipation related
symptoms (Am.J.Gastroenterol. 2000;95:2129) are the ones with lower thresholds to rectal
distension. Therefore our aims were to determine the association of these polymorphisms
with IBS in Mexico, gender and bowel habit predominance. METHODS: Thirty eight Rome
II subjects with IBS (F: 76%, mean±EE: 34±4 years) were compared with 89 healthy controls
(70%, 34±4 years). IBS was sub-classified as diarrhea (IBS-D): 34%, constipation (IBS-C):
32% and alternating (IBS-A): 34% bowel habit predominance. Venous blood samples were
drawn from each volunteer to extract DNA. The T to C transition at position 102 and G
to A in the promoter region -1438 polymorphisms, were evaluated by the PCR-based
restriction fragment length polymorphism assay (PCR-RFLPs). The 102 T allele was repres-
ented by the uncut 342-bp product, while the C consisted of 2 fragments at 215 and 126-
bp. The -1438 A allele was represented by the uncut 468-bp product and the G by 2
fragments at 244 and 224-bp. The chi-square and the OR with 95% CI were used for the
statistical analysis. RESULTS: Significant disease and gender differences were found. The
frequency of 102 T was higher in IBS vs. controls: 53 vs. 29% (p=0.012). Also, IBS females
had a higher frequency compared to IBS males: 58 vs. 31% (p=0.004) and vs. control
females: 28% (p=0.005). The frequency of T/T genotype was higher in IBS vs. controls: 34
vs. 11%, while the C/C was higher among controls: 29 vs. 53% (p=0.004, OR: 5.55 95%CI:
1.72-18.40). Finally, the T/C was higher in IBS-C compared to the non constipated IBS: 67
vs. 23% (p=0.027, OR:0.33 95%CI: 0.01-4.89). There were no differences in the -1438 G/
A genotype. CONCLUSIONS: In Mexico, the T allele of the 102 polymorphism of the 5-
HT2A receptor is more prevalent in IBS compared to controls, and within IBS it is more
likely to be associated with females and those with constipation. The above findings support
a role of this polymorphism in pain perception and visceral sensitivity in these groups. More
studies are needed to study this relationship.
132
The Accuracy of Fiber Optic Based Manometric Sensors for Recording of
Esophageal Pressures
John W. Arkwright, Simon Doe, Michael Smith, Neil Blenman, Nathalie Rommel, Michal
M. Szczesniak, Phil Dinning, Ian J. Cook, Taher Omari
INTRODUCTION: Fiber optic technologies offer the potential for low cost, high fidelity,
multi-channel, intraluminal, manometric recordings. Using multiple fiber Bragg gratings
(FBGs), large pressure sensor arrays can be built onto a single optical fiber allowing for the
performance of high-resolution esophageal manometry. We report the results of a trial
assessing the accuracy of FBGs for recording the characteristics of esophageal pressure waves.
METHODS: 10 single sensor optical catheters were fabricated, each with an FBG pressure
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sensing element located 5 cm from the catheter tip. Each FBG was encased in a pressure
sensitive diaphragm such that distortion of the membrane resulted in a proportionate change
in the pitch of the FBG and therefore a change in reflected optical wavelength. Tracking
the optical wavelength thus allowed the ambient pressure around the sensor to be monitored.
Ten healthy adult volunteers (6M, age 21-48 years) were intubated with both a FBG catheter
and a solid state catheter (GaelTech Ltd). For each subject, esophageal pressure waves
initiated during swallowing were recorded during 10 x 10 ml liquid bolus swallows with
the catheters positioned 35-45 cm (distal), 25-35 cm (mid) and 15-25 cm (proximal) from
the nares (30 swallows per subject). The recordings made with both devices were analysed
for intrabolus pressure (IBP), pressure wave slope and pressure wave peak amplitude and
compared. RESULTS: The characteristics of esophageal pressure waves recorded by the FBG
and solid state catheters were similar (refer to table of data presented as mean (95%
Confidence Interval.) and r (p-value) for Pearson Product Moment Correlation). CONCLU-
SIONS: Fiber optic manometric assemblies incorporating FBG sensor elements are capable
of accurate manometric recordings of esophageal pressure. Initial studies demonstrate that
the fiber optic results agree well with an industry standard device. This technology offers
the potential of large pressure sensor arrays to be fabricated using a single optical and
therefore without the need to increase the external dimension of the catheter or the complexity
of the recording system as the sensor count increases.
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Physiologic Effects of Bolus Consistency, Body Position and Psychosocial
Stress On Esophageal Peristalsis: Study in Normal Volunteers
Radu Tutuian, Daniel Pohl, Kerstin Suarez, Bernadette Stutz, Ulrike Ehlert, Michael Fried
Background: Esophageal motility is conventionally assessed during liquid swallows in recum-
bent position in order to eliminate the effects of gravity on esophageal bolus transit. While
physiologic deglutition occurs in upright position, it has been advocated to include esophageal
motility testing for solids in upright position. Aim: To evaluate the effect of body position,
bolus consistency and acute psychosocial stress on esophageal peristalsis in healthy volun-
teers. Methods: Healthy volunteers (HV) underwent high resolution manometry testing using
a 32-channel water-perfused system on 2 distinct days. Randomly, on one day subjects
underwent a standardized stress (Trier Social Stress Test) prior to manometry. Each subjects
received 10 water swallows (10cc each) and 10 bread swallows in upright and left lateral
decubitus position. Swallows were considered normal if the isocontur peristaltic band
>30mmHg spanned >5cm in the distal esophagus, ineffective if the pressure band was <5cm
and simultaneous if the onset velocity of the pressure band >30mmHg was >8 cm/sec. We
determined % manometric normal, ineffective and simultaneous swallows in each patient
stratified by body position and consistency. A general linear model (GLM) was used to
evaluate the effects of body position, bolus consistency, stress, 1st vs. 2nd day and individual
subjects' response. Results: 1. In 12 male HV % normal peristaltic contractions decreased
with increasing bolus consistency (p<0.001) and body position (p<0.001). 2. Stress (p=
0.46) and testing day (p=0.51) had no significant influence on % normal peristaltic responses.
3. In HV, % simultaneous contractions was low and not influenced by body position, bolus
consistency or acute stress. Conclusions: The influence of bolus consistency and body
position on esophageal peristalsis should be taken into account in order to avoid overdiagnos-
ing ineffective esophageal motility. Conversely, distal esophageal spasms should not be
attributed to changes in body position, bolus consistency or acute psychosocial stress.
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Esophageal Bolus Retention in Patients with Chestpain, Dysphagia and GERD:
Studies Using Combined Impedance-Manometry Testing
Edoardo Savarino, Daniel Pohl, Mentore Ribolsi, Michael Fried, Radu Tutuian
Introduction: Esophageal motility abnormalities and abnormal bolus transit are frequently
encountered in patients with esophageal symptoms. There are limited data on the site of bolus
retention and possible correlation between symptoms and bolus retention site. Combined
impedance-manometry (MII-EM) measures esophageal peristalsis and bolus transit without
the use of radiation allowing evaluation of a large number of swallows. Aim: To evaluate
differences in bolus retention patterns in patients with chest pain, dysphagia and GERD
symptoms. Methods: Combined MII-EM testing was used to measure bolus presence at 2,
5, 10, 15 and 20 cm above the lower esophageal sphincter (LES) during 10 liquid and 10
bread swallows in recumbent position. The highest Eraflux item score was used to classify
patients as presenting primarily for chestpain, dysphagia or GERD symptoms. Bolus retention
at one site was declared if bolus entered but did not exit that site. Complete bolus transit
was declared if the bolus entered the most proximal site (20 cm above the LES) and exited
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all four distal impedance-measuring sites. Incomplete bolus transit was considered if the
bolus did not exit any one of the four distal impedance-measuring sites. Results: Of 59
patients (35 f, mean age 49, range 23-81) 17 presented primarily with chestpain, 23 with
GERD symptoms and 19 with dysphagia. Liquid boluses were more commonly retained at
15cm above the LES. For bread there was no predominant site of bolus retention. Dysphagia
patients had a higher proportion of saline swallows with incomplete bolus transit (22%)
compared to patients with chest pain (17%) and GERD symptoms (11%; p<0.01). Liquid
bolus retention in the proximal esophagus was more common in patients with dysphagia
and chestpain than in GERD patients. The highest percentage of bolus retention was noticed
in patients with dysphagia (table 1). Conclusion: The site of bolus retention has a major
impact on the character of esophageal discomfort. Thus bolus retention in the proximal
esophagus might be perceived more often as chestpain while bolus retention in the distal
esophagus might be perceived as dysphagia.
Table 1: Percentage of swallows retained at a given site during saline and bread swallows
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How Useful Is Esophageal Sensory (Balloon Distention) Testing in Evaluation
of Functional Chest Pain
Issam Nasr, Satish S. Rao
Objectives: Balloon distention test has been advocated for the evaluation of functional
esophageal (Non Cardiac) chest pain (NCCP), but its clinical utility is not known. Our aims
were to prospectively assess the diagnostic yield of esophageal balloon distention test (EBDT)
in clinical practice in patients with NCCP and compare its yield with that of standard tests
of esophageal structure and function. Methods: Over a period of 6 years, patients referred
with chest pain and negative cardiac work up, underwent sequential testing with an EGD
followed by esophageal manometry and 24 hour pH study and lastly EBDT using impedance
planimetry, to elucidate an esophageal source. Patients with a definite abnormality, for
example erosive esophagitis on EGD, were considered to have a positive test that explained
their chest pain and were excluded from further work up. Results (see figure): Off 342 (m/
f =103/239; mean age 46 yrs) NCCP patients, 16 (5%) were excluded (13 = new cardiac
cause, 3 = musculoskeletal) and 326 (95%) were felt to have an esophageal source. Among
these, 48 (14%) had macro/microscopic esophagitis on EGD/biopsy, 7 (2%) had achalasia,
and 96 (28%) had abnormal pH study (fraction time pH ≥ 4.5%). The remaining 176
(52%) patients had EBDT, out of which 128 (37%) patients had an abnormal test. Esophageal
hypersensitivity was diagnosed if patients reported first perception ≤ 30 cm H2O distention
and pain ≤ 55 cm H2O distention pressure. Chest pain was reproduced in 97 patients.
There were 33 patients with nutcracker, 7 with DES and 21 with non-specific dysmotility;
of whom 9, 1, and 11 had abnormal pH and 11, 5 and 4 had abnormal EBDT. 48 (14%)
patients had negative work up suggesting a non-esophageal source. Conclusions: Our pro-
spective study demonstrates that sequential evaluation of esophageal structure and function
can reveal an esophageal source for functional chest pain in 86% of patients. EBDT can
identify visceral hyperalgesia in over 1/3rd of these subjects. We therefore recommend that
EBDT should be routinely performed in patients with unexplained non-cardiac, non reflux
chest pain.
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Use of the Amyl Nitrite Test to Assess Impaired LES Relaxation During
Manometry
Lilani P. Perera, Candy Hofmann, Walter J. Hogan, Benson T. Massey
BACKGROUND: Incomplete fall of pressure at the gastroesophageal junction (GEJ) with
deglutition can be the result of impaired relaxation of the smooth muscle LES, other non-
smooth-muscle processes (crural contraction, tight fundoplication wrap, stricture), or a
combination of the two. Because of its rapid inhibition of smooth muscle tone, amyl nitrite
inhalation (AN) has been felt to be useful to distinguish between these processes. AIMS: To
assess the response to AN in patients with apparent impaired deglutitive LES relaxation.
METHODS: Retrospective review of records over a 3 year period of all patients referred to
our manometry laboratory for symptomatic evaluation. Patients with deglutitive residual
GEJ pressures (GEJPs) > 10mmHg above gastric pressure were given AN, and response of
GEJP noted. 3 different criteria for a positive AN test response were assessed: > 50% fall in
GEJP, absolute GEJ pressure < 10 mmHg, and post-AN GEJP< 10 mmHg below deglutitive
residual GEJP. RESULTS: 95 patient records were analyzed. Findings in 4 different patient
groups are shown in the Table. For discriminating achalasia from other groups, the 3 criteria
respectively had sensitivity/specificity of 96%/52%, 31%/93%, and 82%/86%. The patient
with concurrent achalasia and a tight fundoplication was only detected by the last criteria.
About 70% of achalasia patients had > 10mmHg pressure at GEJ that did not result from
smooth muscle tone. CONCLUSION: The additional fall in GEJP with AN below that seen
with deglutition best distinguishes achalasia from other groups. LES tone does not account
for all of GEJ pressure in most achalasia patients. An important minority of non-achalasia
patients have evidence for impaired deglutitive LES relaxation. Supported in part by NIH
grant T32 DK61923.
Results of AN Criteria in DIfferent Patient Groups
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Predictors of Symptomatic Recurrence Following Pneumatic Dilation in the
Patients with Idiopathic Achalasia
Hwan sic Yun, Poong-lyul Rhee, Yong sung Choi, Jun haeng Lee, Hee jung Son, Dong
kyung Chang, Young-ho Kim, Jae J. Kim, Jong chul Rhee
Background and aims Although pneumatic dilation (PD) is known to be an effective therapy
for idiopathic achalasia, symptomatic recurrence is frequent in long-term follow-up irrespect-
ive of improvement of clinical parameters after PD. The aim of this study is to evaluate the
correlation between recurrence and clinical parameters, and to determine the factors capable
of predicting the symptomatic recurrence following PD. Method From March 2000 to
August 2006, among 48 consecutive patients with achalasia who underwent PD and fulfilled
scheduled follow-up evaluation, 43 patients who had no previous management for achalasia
were enrolled. Baseline characteristics including age, gender, BMI, symptomatic character-
istics and recurrence were evaluated. In addition, manometric, high-frequency intraluminal
ultrasonograpic (HFIUS) and esophagographic findings before and after PD were compared
between symptomatic recurrence group (n=10) and success group (n=33). Result Recurrence-
free survival after PD was 82.9%, 75.0% and 60.0% at one, three and five years, respectively.
LES pressure, LES relaxation and cross-sectional area on HFIUS were improved after PD
significantly, however the differences were not significant between recurrence group and
success group. Lower BMI (<20 kg/m2 ) and shorter duration of symptom (< 5 yrs) were
found to be risk factors in univariate analyses. Less than 5 years of symptom duration before
PD was an independent risk factor for symptomatic recurrence in multivariate analyses
(hazard ratio = 8.74, 95% CI=1.07-71.73). Conclusion Although manometry, HFIUS and
esophagography demonstrated the significant improvement after PD, no parameter could
predict the symptomatic recurrence after PD. In the patients with rapid progression of
symptom, who needed PD, symptomatic recurrence was more frequent following PD.
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Protection of B Cells from Apoptosis in Acute Helicobacter pylori Infection
Daniel P. Barry, Rupesh Chaturvedi, Kshipra Singh, Mohammad Asim, Kristen L. Hoek,
Wasif N. Khan, Keith T. Wilson
Background: We have recently reported that chronic gastric infection with H. pylori (Hp)
protects splenocytes from spontaneous apoptosis, and that this occurs primarily in B cells,
indicating communication between gastric antigen presenting cells and splenic lymphocytes.
Mucosa-associated lymphoid tissue (MALT) lymphoma derives from a monoclonal population
of B lymphocytes infiltrating the stomach. It has been suggested that this process requires
chronic antigenic stimulation and T cell help. However, because we have also found that
isolated B cells from naïve mice exhibit protection from apoptosis when stimulated with
Hp ex vivo, we hypothesized that there are early systemic responses to Hp infection. Methods:
C57BL/6 mice were infected with Hp strain SS1 by gavage and spleens were dissected 48
h later. Using multicolor flow cytometry, immunophenotyping of splenocytes was performed
using antibody to CD19 (for B cells), followed by B cell subtype analysis with antibodies
to IgM, IgD, and CD9 to distinguish immature transitional type 2 (T2) cells (IgMhighIgDhigh),
mature follicular cells (IgMlowIgDhigh), marginal zone cells (IgMhighIgDlowCD9high) and imma-
ture transitional type 1 (T1) cells (IgMhighIgDlowCD9low). Apoptosis was quantified by annexin
V/7-AAD staining. Since the transcription factor c-Myc and its downstream target ornithine
decarboxylase (ODC) are linked to lymphomagenesis, mRNA levels of these genes were
assessed by RT-PCR/real-time PCR in B cells purified by negative selection using magnetic
beads. Results: Splenocytes from acutely infected mice showed decreased apoptosis. Similar
to our previous findings in chronic Hp infection, this protection was only observed in CD19+
B cells and not in the CD19- population, with apoptosis decreasing from 30.1 ± 1.0% in
cells from naïve mice to 24.7 ± 1.1% in cells from infected mice (p < 0.01). Immunophenotyp-
ing analysis of B lymphocytes revealed that apoptosis was only significantly reduced in the
mature follicular B cells with a decrease in apoptosis from 27.9 ± 1.7% in cells from naïve
mice to 21.6 ± 1.9% in cells from infected mice (p < 0.05). Cells of T1, T2, and marginal
zone subsets from infected mice were not protected from spontaneous apoptosis. Expression
of both c-Myc and ODC mRNA was significantly increased in B cells from infected mice
when compared to those from naïve mice. Conclusions: There is protection from B cell
apoptosis as early as 48 h post Hp infection. This immediate systemic response to Hp and
induction of c-Myc and ODC likely promotes survival of activated B cells and may have an
important role in establishing the chronic inflammatory response and risk for MALT
lymphoma.
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Host Genetics and Environmental Factors Associated with Risk of H. pylori
(HP) Infection
Dulciene M. Queiroz, Luciana I. Gomes, Gifone A. Rocha, Andreia maria C. Rocha,
Fabrício F. Melo, Juliana B. Guerra
Although there are evidences that genetic factors may contribute substantially to determine
who will be infected with HP, there are few studies on this subject. We investigated associ-
ations between functional polymorphisms in genes linked to the innate and adaptative
immune response and susceptibility to HP infection in logistic models, adjusting for demo-
graphic and environmental factors. We included 541 blood donors in whom HP status was
determined by ELISA. IL1B-511C/T, TNFA-307G/A, TLR4+896A/G and TLR2+2251G/A were
genotyped by PCR-RFLP, IL1RN by PCR, IL1B-31T/C and IL2-330T/G by PCR-CTPP and
TLR5+1174C/T by allele specific PCR. All results were confirmed by sequencing. IL1B-511
and IL1B-31 were in almost complete linkage disequilibrium, whereas the other loci segreg-
ated independently. The models were well fitted and in the univariate analysis, age(p=0.001),
gender(p=0.02), crowding index(p=0.20), socio-economic level(p=0.00), TNFA(p=0.11) and
IL2 polymorphism(p=0.02) were selected. In the multivariate analysis, age(p=0.02, OR=
1.03, 95%CI=1.01-1.05), socio-economic level(p=0.00, OR=0.58, 95%CI=0.42-0.78) and
polymorphic allele of IL2-330(p=0.04, OR=0.67, 95%CI=0.45-0.95) remained independently
associated with the infection. The IL2-330TG was over represented in the HP-negative group.
When symptomatic HP-positive adults with gastritis(n=307), duodenal ulcer(n=240) and
gastric cancer(n=164) where compared with the HP-negative blood donors, the difference
(p=0.04) was maintained. Since the infection is mainly acquired in childhood and the main
function of IL-2 is to induce proliferation of Treg (TGF-β producing cells), we determined
prospectively the level of IL-2 and TGF-β in the gastric mucosa of HP-positive(n=59) and
-negative(n=60) children submitted to endoscopy due to dyspeptic symptoms. IL-2 and
TGF-β levels were assessed by ELISA (Biosource, Camarillo/CA) and expressed in pg/mg
protein. Gene polymorphism did not associate with gastric cytokine mean levels in HP-
negative children. Conversely, TG polymorphic allele was significantly associated with higher
levels of TGF-β (9,684.6 vs 6,135.4 pg/mg; p=0.001) in HP-positive children. In this group,
although not significant, the mean level of IL-2 was higher in TG than in TT carriers
(681.4 vs 555.5 pg/mg). Furthermore, both IL-2(p=0.04) and TGF-β(p=0.000) levels were
significantly higher in HP-positive (602.6 and 7,447.1 pg/mg) than in -negative (339.8 and
2,098.6 pg/mg) children, respectively. In conclusion IL2 polymorphism may prevent HP
colonization by suppressing gastric inflammation and inflammation may be important to
HP establishment and persistence in the gastric mucosa. Grants: CNPq/FAPEMIG
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Essential Role of Peyer's Patches in the Development of Helicobacter-Induced
Gastritis
Norihiko Watanabe, Keiichi Kiriya, Akiyoshi Nishio, Masahiro Kido, Kazuyuki Saga,
Junya Tanaka, Takuji Akamatsu, Shinya Ohashi, Masanori Asada, Toshiro Fukui, Kazuichi
Okazaki, Tsutomu Chiba
Background: Helicobacter bacteria colonize in the stomach and induce strong, specific local
and systemic humoral and cell-mediated immunity. Helicobacter binds to the host epithelial
cells, directly triggering the recruitment of neutrophils. Local inflammatory processes in the
gastric mucosa are followed by extensive immune-cell infiltration, resulting in chronic active
gastritis characterized by a marked infiltration of Th1 cytokine-producing CD4+ T cells.
The mechanisms underlying the development of Th1 cell-mediated chronic gastritis, however,
are not clear. Peyer's patches (PPs), the major inductive sites for mucosal immunity in the
gut system, might orchestrate Helicobacter-specific local and systemic humoral and cell-
mediated immunity. Aim: The aim of this study is to examine the roles of PPs in the
development of Helicobacter-induced gastritis. Methods: Because IL-7 receptor mediated
signaling plays an essential for the early step in the embryonic formation of the PPs,
administration of anti-IL-7 receptor blocking antibody into C57BL/6 pregnant mice can
transplacentally manipulate PP formation of offsprings. Using this method, we generated
PP-null mice that normally develop well-organized lymphoid organs except for PPs and
intragastrically infected the resulting PP-null mice with Helicobacter felis. After the infection,
the assessment of Helicobacter colonization, histologic examination, measurement of serum
levels of anti-Helicobacter Ab and flow cytometry analysis of Helicobacter-specific CD4+ T
cells were performed. Results: PP deficiency severely impaired both the development of Th1
cell-mediated gastritis induced by Helicobacter and the production of anti-Helicobacter
antibodies despite marked bacterial colonization of the gastric mucosa. Although PP defi-
ciency did not impair the differentiation of Helicobacter-specific CD4+ T cells into IFN-γ-
producing Th1 cells, Helicobacter-specific IFN-γ-producing CD4+ T cells in PP-null mice
lacked the ability to migrate into Helicobacter-colonized gastric mucosa. Conclusion: These
findings suggest that PPs have an important role in Helicobacter-specific local and systemic
humoral and cell-mediated immunity, including the development of Helicobacter-induced
gastritis.
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Macrophage Arginase Restricts Host Defense to Helicobacter pylori By
Inhibiting Inducible NO Synthase
Nuruddeen D. Lewis, Rupesh Chaturvedi, Kshipra Singh, Mohammad Asim, Daniel P.
Barry, Jean-luc Boucher, Keith T. Wilson
Background: L-arginine (L-Arg) is the common substrate for both inducible nitric oxide
(NO) synthase (iNOS), which produces NO, and arginase, which produces ornithine. H.
pylori (Hp) upregulates both iNOS and arginase II in macrophages (MΦs). For MΦs to exert
an NO-dependent bactericidal effect on Hp In Vitro, concentrations of L-Arg are required
that exceed circulating levels in mammals. We determined if substrate competition by
arginase acts to limit NO synthesis by MΦs. Methods: RAW 264.7 MΦs were incubated
in L-Arg-free and serum-free medium to which L-Arg was then added. MΦs were stimulated
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with lysates of Hp SS1 in the presence and absence of the arginase inhibitor S-boronoethyl-
L-cysteine (BEC; 60 μM). MΦs were also transfected with siRNA for arginase II or scrambled
siRNA. Additionally, C57BL/6 mice were treated with 0.1% BEC or vehicle in the drinking
water and infected with Hp SS1. MΦs were isolated from stomach 48 h later by enzymatic
digestion and positive selection with the MΦmarker F4/80 using magnetic beads. We assessed
iNOS mRNA by real-time PCR, iNOS protein by Western blotting, and NO production by
NO2- levels using the Griess reaction. Results: When RAW 264.7 cells were stimulated with
Hp in the absence of L-Arg, iNOS mRNA was induced, but there was no iNOS protein and
no increase in NO2- levels, and BEC had no effect. However, at concentrations of L-Arg
from 0.1 to 1.6 mM, BEC significantly increased Hp-stimulated NO2- levels (Table) and
iNOS protein levels in parallel. In contrast, the level of iNOS mRNA induction was not
upregulated by BEC. Arginase II knockdown also significantly potentiated Hp-stimulated
NO2- and iNOS protein levels, but not iNOS mRNA levels. Infection of mice with Hp
resulted in a 6-fold increase in iNOS mRNA levels in gastric MΦs that was not affected by
BEC treatment. NO2- levels in gastric MΦs only increased from 3.8 ± 0.6 to 6.4 ± 2.3 μM
with Hp infection, but were increased to 11.6 ± 0.6 μM with In Vivo BEC treatment (p <
0.05 vs. Hp alone). Conclusions: When arginase was inhibited, MΦs were able to produce
more NO in response to Hp, whether activated In Vitro or In Vivo. Arginase limits the
availability of substrate for iNOS and this competition results in decreased iNOS protein
synthesis. Arginase activity in MΦs may contribute to the failure of the host innate immune
response to Hp, and its inhibition could result in a more successful defense against Hp.
[NO2-] in Hp-stimulated MΦs
*p < 0.05, **p < 0.001 vs. (-) BEC.
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Helicobacter pylori-Pulsed Dendritic Cells Induced Regulatory T Cells
Min Zhang, Bradford E. Berndt, Kathryn A. Eaton, Anna Pierzchala, Kevin Lai, John
Zhang, John Y. Kao
Background: Helicobacter pylori (HP) is a highly adaptive organism capable of escaping host
immune attack. We previously showed HP secreted factors selectively inhibited dendritic
cell (DC) IL-12 release. We hypothesize that the resultant IL-10 producing DCs are capable
of priming regulatory T cell (Treg) response seen in patients infected with HP (Rad et al.
Gastroenterology 2006; 131(2):525-37). Aim: To show H. pylori-pulsed DCs can induce
Tregs In Vitro and In Vivo. Methods: Day-6 bone marrow (BM)-derived DCs were generated
using GM-CSF/IL-4. BM-DCs were coculutred with PBS or 10^8 CFU/mL live HP-SS1,
Escherichia coli, or Acinetobacter lwoffi for 18h and then washed prior to adding the DCs
to naïve syngeneic splenocytes for 72h. Relative CD4+CD25+Foxp3+ Treg numbers per
gated CD4+ populations were determined by FACS. C57BL/6 mice (n=15 per group) were
adoptively i.p. transferred with 10^6 DCs (PBS- or HP pulsed DCs) on day 0 and day 14.
Mice were challenged with 3 oral gavages of 10^8 CFU/mL live HP SS1 on day 21. Animals
were then sacrificed and stomach removed for mRNA extraction using TRIZOL reagent. HP
colonization was assessed by qRT-PCR (16S rRNA specie specific for Helicobacter). The gastric
mRNA expressions of Foxp3, IL-10, and TGF-β (normalized to GAPDH) were measured by
RT-PCR (band intensity). Mouse spleens were also removed and CD4+ T cells isolated using
MACS microbeads and cocultured with BM-DCs and HP SS1 sonicate (10μg/mL) for 7d.
IL-10 production was determined by ELISA. Results: The relat ive numbers of
CD4+CD25+Foxp3+ Tregs induced by BM-DCs pulsed with H. pylori was higher than DCs
pulsed with E. coli or A. lwoffi (413.8±36.8 vs. 244.0±4.0 or 239.3±14.6, respectively, n=
3, P<0.05). In Vivo, H. pylori-pulsed DCs induced higher production of IL-10 by splenic
CD4+ cells than PBS-pulsed DCs (109.7±27.1 vs. 27.8±2.3, respectively, n=3, P<0.05). H.
pylori-pulsed DC transferred mice expressed higher levels of Treg markers than PBS-pulsed
DC transferred mice (Foxp3, 179.4±11.9 vs. 81.3±11.5; IL-10, 149.0±17.9 vs. 64.9±13.2;
and TGF-β, 191.9±9.9 vs. 93.8±8.7, respectively, P<0.05). Furthermore, we found that
adoptive transfer of H. pylori-pulsed DCs failed to significantly reduce H. pylori colonization
compared to PBS-pulsed DC mice (5.2x109±1.4x108 vs. 6.5x109±3.5x109, respectively,
P=0.10). Conclusions: H. pylori-pulsed DCs exhibit a toleragenic phenotype In Vitro and In
Vivo and may be responsible for the increased CD25+Foxp3+ Tregs seen in patients infected
with H. pylori. Understanding the mechanisms of H. pylori induction of toleragenic DCs will
lead to development of more effective anti-H. pylori vaccines.
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Changing Epidemiology of Peptic Ulcer Bleeding - A Prospective 10 Year
Whole Community Study
John M. Thomson, Umesh Basavaraju, David L. Armour, N ashley G. Mowat, Andrew
Fraser
Peptic Ulcer (PU) is still the most common cause of upper GI bleeding. Our gastrointestinal
bleeding unit (GIBU) has accepted all admissions from a stable population of 485,600 since
1991. Patients are managed according to an agreed protocol defining transfusion requirements
and surgical referral which has been reviewed and undergone modification over the years,
and has seen the established relevance of H. pylori infection and usage of proton pump
inhibitors. Aims and Methods This dedicated unit provides an ideal opportunity to assess
the natural history and epidemiology of peptic ulcer bleeding. Analyses were performed on
the prospectively collected data from all admissions to GIBU with bleeding from a peptic
ulcer from October 1991 to 2001. Results Of 1978 admissions, 737 had a bleeding gastric
ulcer (GU) and 1241 bled from a duodenal ulcer (DU). The total number of bleeding ulcers
has fallen (p<0.001), principally among the male patients with DU, but there has been a
slight increase in bleeding GU. The median age for all peptic ulcer bleeders has increased
from 67 in year 1 to 70 in year 10 (p=0.02) and has been accompanied by a rise in the
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comorbid disease. Aspirin ingestion has almost doubled from 24% in year 1 to 44% in year
10 (p<0.001), as have those taking warfarin therapy from 3.8% to 7.2% (p=0.002). The
percentage taking NSAID (24%) and acid suppression (22%) has remained unchanged.
Despite a population decrease in smoking, the percentage of peptic ulcer bleeding patients
who smoke has increased from 31% in year 1 to 36% in year 8 before falling to 27% in
year 10. The number of significant bleeds has remained unchanged at 64%, although the
number requiring a blood transfusion has decreased (p=0.002). In the first 2 years, as part
of the management protocol, only a few (8%) had endoscopic therapy, by year 10 this number
had increased to 28%. During the same period the surgical referral rate has progressively fallen
from 46% in year 1, to 19% in year 3 and 8% in year 10 (p<0.001). On the other hand,
the rebleeding rate has been stable at 16% and the 30 day all cause mortality rate for PU
bleeding has remained stable at around 7%. Conclusions The natural history of peptic ulcer
bleeding is changing. The decreasing incidence of DU is likely to be as a result of decreased
rates of H. pylori infection. Despite an ageing population with more comorbid disease, aspirin
and anti-coagulation use, alongside utilisation of endoscopic therapy, a decrease in blood
usage and need for surgical intervention, the mortality rate has remained stable.
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Non-Variceal Upper GI Bleeding (NVUGIB) in Patients Already Hospitalized
for Another Condition: A Distinct Clinical Entity
Tanja Müller, Alan N. Barkun, Myriam Martel, Investigators Rubge
Background: Contemporary outcomes and their predictors are well characterized for patients
presenting to hospital with NVUGIB. This is not so for those developing NVUGIB while
already hospitalized for another condition. Aim: To compare characteristics between patients
having started to bleed as outpatients (OP) or while already in the hospital (inpatients =
IP), and to assess predictors of outcomes in IP. Methods: Using the Canadian Registry on
NVUGIB and Endoscopy (RUGBE), we identified 1395 OP and 469 IP with a NVUGIB.
Data were extracted from records at 18 community and tertiary care centers. Information
was collected on 217 clinical, endoscopic, and laboratory variables. Extensive data validation
procedures were carried out. Descriptive and inferential analyses were carried out, and
multivariate logistic regression models created.Results: Patient characteristics differed signific-
antly between IP and OP, respectively, with regards to disease acuity scores (1-2: 26% vs
45%, 3: 50% vs 44%, 4-5: 25% vs 11%), numbers of co-morbidities (3.1±1.7 vs 2.3±1.5),
and past history of UGIB/ulcers (10% vs 22%, and 17% vs 29%). IP were admitted significantly
longer (7.2±7.4d vs 5±5.4d), and more often in ICU (40.5% vs 16%). Endoscopic findings
were comparable (gastroduodenal ulcers or erosions in 83% vs 85%), as were endotherapy
rates (38% vs 36%). H. pylori was found significantly less often in IP (35.4% vs 47%). More
IP received a PPI (88% vs 83%), with similar mean daily doses (57±58mg versus 57± 2mg).
Mortality was significantly higher for IP (11% vs 3.5%), but not rebleeding or surgery (15.7%
vs 13.4%, and 6.9% vs 6.4%). Amongst IP, high-risk stigmata (OR= 3.80, 95% CI: 2.06-
7.02) significantly increased re-bleeding, while PPI use prevented it (OR= 0.21, 95% CI:
0.10-0.42). The presence of many co-morbidities tended to increase rebleeding (OR= 1.16,
95% CI: 1.01-1.32), while endoscopic hemostasis tended to decrease this outcome (OR=
0.65, 95% CI: 0.35-1.2). Significant predictors of mortality included disease acuity (scores
of 1 and 2, OR= 0.19; 95% CI: 0.04-0.83), the presence of endoscopic high-risk stigmata
(OR= 2.59, 95% CI 1.03-6.51), and the occurrence of rebleeding (OR= 4.30, 95% CI: 2.16-
8.53). Conclusion: IP developing NVUGIB are much sicker, on average, than OP. The H.
pylori carriage rate is lower, suggesting a differing etiology for what are most often gastroduod-
enal ulcers or erosions treated similarly, with equivalent resulting rebleeding rates. The 3-
fold greater mortality amongst IP is dependent on disease acuity, and the presence of high-
risk stigmata, but appears less altered by pharmacologic and endoscopic therapies of bleeding.
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Differential Characteristics of the Non-Variceal Upper Gastrointestinal
Bleeding in Anti-Coagulated Or Anti-Aggregated Patients
Juan Ortuño, Vicente Ortiz, Marisa Iborra, Belén Beltrán, Julio Ponce
The prevalence of anti-coagulated (AC) and anti-aggregated (AG) patients keeps increasing
in recent decades. In those patients, it is not well known whether the episodes of non-
variceal upper gastrointestinal bleeding (UGB) present differential characteristics from the
bleeding of patients not AC or AG (NOACAG). Aim: To evaluate the influence of AC
and AG on the initial haemodynamic severity, the prognostic index, the aetiology of the
haemorrhage and the severity of the lesions evidenced by endoscopy, of a non-variceal UGB.
Methods: A prospective observational study of a series of cases of consecutive patients
admitted into a tertiary hospital due to a non-variceal UGB (hematemesis or melena) between
January and October 2006. The parameters evaluated were: a) Initial haemodynamic severity
(heart rate and blood preassure) b) Rockall prognostic index, c) Endoscopic diagnoses
(performed during the first 12 h of arrival) and d) Forrest classification (when a gastroduod-
enal ulcer was detected). Other parameters collected were: drugs (NSAIDs, AC or AG),
number of days spent in hospital, transfusions, re-bleeding and mortality. Results: 185
patients were included, mean age of 63.2 years + 18.2, 65 % men. Eighty patients (43.3%)
were taking AC treatment (acenocumarol: 22 cases, 11.9%) or AG treatment (AAS and/or
clopidogrel: 58 cases, 31,4%). AC patients had a similar haemodynamic severity and the
same severity of the ulcers (Forrest) that the AG patients and that the NOACAG patients.
The 86.4% (19/22) of the AC and the 72.4% (42/58) of the AG had a prognostic index
(Rockall) moderate or high, compared to a 58.1% (61/105) of the NOACAG (p=0.020).
The most frequent cause of UGB was the gastroduodenal ulcer which was present in the
59% of the AG, a higher percentage that the 33.3% of the AC and the 42.3% of the NOACAG
(p=0.05). There were no significant differences among the groups when analysing the rest
of the causes of UGB. The mean stay in hospital of AC patients was of 8.45 days, which
was higher that the rest of the patients (p=0.025). The 53% of the patients required blood
components transfusions, with a superior need in AC patients (77.3%) and in AG patients
(63.8%) than in the NOACAG (41.9%) (p=0.001). Global re-bleeding rate was of 8.1% and
mortality of 7.6%, without differences among the groups.Conclusions: 1) The AC and the
AG are associated to a worse prognostic index; 2) The gastroduodenal ulcer is cause of non-
variceal UGB in the majority of AG patients; 3) Neither AG nor AC affect the initial
haemodynamic state or the severity of the endoscopic lesions; 4) AC patients have higher
transfusion requirements and number of days spent in hospital.
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The Role of Acid Suppression in Preventing Upper GI Bleeding After
Cardiovascular Surgery: A Case-Control Study
Martin Larocque, Alan N. Barkun, Marcos Amorim, Karl Herba, Benoit Devarennes,
Myriam Martel, Elham Rahme
Background: It is unclear if acid suppression prevents UGIB following CS. Aim: To assess
whether acid suppression (with H2 receptor antagonists [H2RA] or proton pump inhibitors
[PPI]) prior to CS decreases the subsequent risk of UGIB. Methods: A case-control study
was carried out in which all cases developed UGIB after CS. For each case, 2-3 controls
were matched for age (±5 years), sex, and date of admission to hospital (±6 months). Clinical
information was abstracted from charts, laboratory, and pharmacological databases. Using
conditional logistic regression, associations between H2RA and PPI uses with the development
of post-CS UGIB were quantified while adjusting for possible confounders of outcome,
including the Parsonnet score. Results: 518 patients (131 cases) were included with mean
ages of 68.8±10.8y (cases) vs 68.8±10.2y (controls); mean pre-operative Parsonnet scores
were 24.6±14.2 vs 20.8±14.2, coagulation parameters were INR: 1.71±1.60 vs 1.27±0.58,
and PTT=53.3±35.6 vs 52.9±39.3, and platelets were 244±133 109/L vs 239±108 109/L,
respectively. Peri-operative exposures to drugs that may cause GI bleeding are shown below.
H2RA and PPI uses amongst cases and controls were 26.6% vs 27.7%, and 11.3% vs 10.8%.
Post-CS complications were, respectively, C difficile infection 13% vs 3.6%, mediastinitis
7.5% vs 1.2%, dialysis 16.8% vs 5.9%, bowel events 8.4% vs 1.8%, and CHF 47.9% vs
33.7%. Significant predictors of post-CS bleeding were prolonged mechanical ventilation
(HR=2.57, [1.26;5.25]), an elevated INR (Hazard Ratio=2.02, [1.38; 2.96], and the occurrence
of C difficile infection (HR=2.77, [1.06; 7.25]). The Parsonnet score, H2RA and PPI did
not predict or influence bleeding. Conclusion: The use of PPI or H2RA prior to CS does
not appear to significantly alter the rates of subsequent bleeding. The prediction of bleeding
appears to be less dependent on the patient's pre-operative status (pre-CS Parsonnet's score),
and more dependent on the post-CS clinical course (prolonged ventilation, presence of
acoagulopathy, and development of C difficile infection).
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Adherence to “Best Practices” in Nonvariceal Upper GI Hemorrhage (Nvugih):
A National Vignette Survey of Experts Versus Community Providers
Brennan M. Spiegel, Ian M. Gralnek, Loren Laine, Dennis M. Jensen, Gareth S. Dulai,
Eric Esrailian
Background: Although management of NVUIGH is as much art as science, accumulating
evidence now supports a set of diagnostic and therapeutic “best practices.” These practices
have been disseminated in several guidelines, but it remains unclear whether providers
adhere to these guidelines. We conducted a national survey to compare adherence to NVUGIH
best practices in a group of experts vs. “non-expert” community providers. Methods: We
developed an online survey with 3 clinical vignettes in NVUGIH. The vignettes were
developed with a panel of content experts to ensure face validity and comprehensiveness.
In each vignette, respondents first viewed a standardized patient presentation, and then
received management questions guided by branching conditional logic. Upon EGD, respond-
ents viewed an image of an actively spurting vessel in the 1st vignette, a clean-based ulcer
in the 2nd vignette, and an adherent ulcer clot in the 3rd vignette. The survey elicited
knowledge and beliefs about NVUGIH care, including a core set of items regarding 17 best
practices (Table 1 lists examples). We surveyed a random sample of 360 GIs from the AGA
and 40 internationally recognized NVUGIH experts, and compared guideline compliance
between groups. Results 47% responded (N=188; 25 experts). Experts endorsed more “best
practices,” on average, than non-experts (93% vs. 85%; p=0.002). Table 1 shows data for
example individual practices. In regression adjusting for provider demographics, practice
setting, and experience, expert status (p=0.02), lower age (p=0.05), and higher clinical
experience (p=0.02) independently predicted higher compliance. Conclusions: Experts are
more likely than non-experts to comply with best practices in NVUGIH, although compliance
is high in both groups. Non-experts diverge from experts in the dosing of IV PPIs (more
likely to use bolus dosing vs. experts) and choice of endoscope in high-risk bleeding (more
likely to use small channel scope vs. experts). These data suggest that best practices have been
generally well disseminated, but that persistent disconnects exist that should be addressed.
Table 1. Agreement with “Best Practices” by Group (sub-set of full 17 indicator set)
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Molecular Characterization of the Anti-Angiogenic Properties of the
Pentacyclic Triterpene Ursolic Acid
Sandra Ulrich, Stefan Büttner, Jürgen Stein
Background: Angiogenesis is the formation of new blood vessels from the pre-existing
vasculature, which is required at almost every stage of cancer progression. Anti-angiogenic
therapy therefore is regarded as a promising approach to control cancer. Previous studies
could demonstrate that ursolic acid (UA), a pentacyclic triterpene found in berries and
plants, posses potent cancer chemopreventive and therapeutic efficacy. The objective of this
work was to elucidate underlying molecular mechanisms of anti-angiogenic effects of ursolic
acid. Materials and Methods: Caco-2 and Human umbilical vein endothelial cells (HUVEC)
were cultured under standard conditions and were treated with increasing concentrations
of ursolic acid [5-30µM] for different time intervals. Hypoxia was induced by stimulating
Caco-2 cells with CoCl2 [100µM]. HUVEC cells were activated with VEGF [50ng/ml]. Cell
growth was determined by BrdU incorporation and crystal violet staining. The protein levels
of the proangiogenic vascular endothelial growth factor (VEGF), hypoxia-inducible factor
1α (HIF1α) and COX-2 were determined by western blot analysis. The VEGF content of
the culture supernatants was measured using ELISA. Migration of HUVECs was determined
by an In Vitro cell invasion assay. Results: VEGF expression and release induced by CoCl2
could be significantly counteracted by the treatment with ursolic acid in a time and dose-
dependent manner (Means ± SE, **p<0.01). Another reduction could be observed in the
protein levels of HIF1α (~40% at 15µM) and COX-2 (~40% at 15µM) after 24h of treatment
which play an essential role in the regulation of VEGF. Furthermore UA significantly reduces
cell growth of HUVECs in a time- and dose-dependent manner (Means ± SE, *p<0.05),
coincident with a reduction of VEGF-induced cell migration (~30% at 15µM). Conclusion:
These data demonstrate that ursolic acid mediates its anti-angiogenic effects in colorectal
cancer cells via two different strategies. On the one hand via inhibition of production and
release of proangiogenic factors from tumor cells, and on the other hand via inhibition of
endothelial cell activation, proliferation and migration.
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Gastric Cancer and the Synergy of Selenium, Host Cytokine Risk Genotypes,
and H. pylori Infection in Central America
Douglas R. Morgan, Ricardo Dominguez, Temitope O. Keku, Paris . Heidt, Joseph
Galanko, Robert S. Sandler
BACKROUND Gastric cancer(GC) is the second-leading cause of cancer mortality worldwide,
with significant geographic variability. The adenocarcinoma model proposes the combination
of a proinflammatory host cytokine risk genotype profile (IL-1β,IL-10,TNFα) and H. pylori
infection leads to mucosal inflammation, gastric atrophy, intestinal metaplasia and adenocar-
cinoma. Dietary factors are operative in early and late pathway events. Selenium is a trace
element with a postulated antioxidant role as a cofactor for reduction of antioxidant enzymes.
Selenium deficiency contributes to gastrointestinal cancers(esophagus, colon, rectum). The
role in GC is unclear, and studies in Latin America are lacking. Importantly, plasma selenium
has been shown to be equivalent to toenail assessment, and therefore reflective of long-term
selenium intake and useful in diet and cancer studies [Satia J, Ann Epid 2006]. Our aim
was to investigate the role of nutrition, specifically selenium, in conjunction with risk
genotypes and H. pylori, in a high incidence region. This is the first study to simultaneously
evaulate these factors. METHODS We conducted a population-based case-control study in
western Honduras, identifying 170 incident gastric cancer cases and 162 healthy village
controls for genotyping (IL-1β-511 C>T, IL-10-1082 G>A) and H. pylori determination.
Interim data was obtained for plasma selenium among 50 cases and 50 controls. The annual
cancer incidence is 30 per 100K (M,39; F,21 per 10OK, 2001). RESULTS In population-
based controls, an extremely high prevalence of pro-inflammatory cytokine risk alleles was
observed: IL1β-511T*, 81%, and IL-10-1082A*, 93%. Endemic H. pylori infection was
noted, 85%. In spite of the high prevalence of risk alleles in controls, the high risk haplotype
was associated with gastric cancer (IL-1β-511TT/IL-10-1082AA): OR 2.6, 95%CI 1.0-6.8.
A significant difference is noted in mean plasma selenium in cancer cases versus controls:
86 mcg/L vs 117 mcg/L (p<0.001). The range (25%tiles) in cases was 45-140 mcg/
L(63,83,100). In controls: 95-170 mcg/L(110,110,120). Logistic regression confirms that
lower plasma selenium is a significant risk factor for GC: ORa 0.90 (95%CI, 0.85-0.96),
when adjusted for age, gender, H. pylori infection, and host IL-1β/IL-10 risk allele status.
CONCLUSIONS This is the first population-based study to examine the interaction between
host genetic factors, H. pylori infection, and selenium in gastric cancer. Decreased plasma
selenium is a risk factor for gastric cancer, in the setting of endemic risk genotypes and H.
pylori infection - suggesting the potential for dietary intervention.
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L-2395: A Small Novel Molecule Curcumin Derivative Inhibits Growth of
Colon Cancer Tumor Xenografts Through the EGFR Pathway
Dharmalingam Subramaniam, Randal May, Brian Dieckgraefe, Courtney W. Houchen,
Rama P. Ramanujam, Shrikant Anant
Curcumin is an anticancer chemotherapeutic and chemopreventative agent. Here, we have
determined the effects of a novel water-soluble derivative of curcumin, diphenyldifluroketone
(L-2395) on colon cancer growth. Methods: Increasing doses of L-2395 on HCT-116, HT-
29 and SW480 colon adenocarcinoma cells proliferation was determined by hexosaminidase
assay. Apoptosis was determined by caspase 3/7 activation. Tumor xenografts were established
by injecting a single-cell suspension of >95% viable HCT-116 cells implanted subcutaneously
into the backs of Balb/c athymic nude mice. L-2395 was injected intraperitoneally from day
7 until day 30 to determine effects on tumor growth. Tumor sections were stained for CD31
to determine microvessel density. Real Time RT-PCR was performed to determine the
cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) and interleukin-8
(IL-8) expression in the tumors. Western blot analyses were performed to determine the
level of phosphorylated EGFR-receptor (Tyr1086), and its downstream targets AKT (Thr308)
and ERK (Thr185/Tyr187). Western blot and immunohistochemistry analyses were also
performed to determine COX-2 and VEGF protein levels in the tumor xenografts. IL-8
levels were determined by an ELISA assay. Results: L-2395 demonstrated a dose-dependent
inhibition of proliferation and induction of caspase-3 mediated apoptosis of a variety of
adenocarcinoma cells. Treatment of tumor xenografts with L-2395 resulted in significant
decrease in the growth of the tumors, with notably lower tumor volume and weight.
Tumor angiogenesis, based on microvessel density was also significantly lower in the tumors
following L-2395 treatment than in control tumors. Western blot analyses demonstrated
decreased expression activation of EGFR and that of AKT and ERK suggesting inhibition of
EGFR-mediated signaling. Real Time PCR analyses demonstrated significant inhibition of
COX-2, IL-8 and VEGF mRNAs. Furthermore, western blot analyses demonstrated inhibition
of COX-2 and VEGF protein expression, and ELISA assay demonstrated decreased IL-8
levels in the xenograft tissues. Conclusion: L-2395 is a potent inhibitor of tumor growth
and angiogenesis through modulation of epidermal growth factor activity. Our findings
suggest potential use of L-2395, a curcumin derivative as a therapeutic or chemopreventative
agent for colorectal cancers.
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Resveratrol Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Cell
Growth Inhibition
Sandra Ulrich, Waranya Kampan, Jürgen Stein
Background: Resveratrol is a natural occuring polyphenol found in grapes, peanuts and red
wine. Previous results indicate, that resveratrol inhibits cell growth of colon carcinoma cells
via PPARγmediated activation of spermine/spermidine acetyltransferase (SSAT) [Cancer Res,
2006]. Conventional cancer therapies as single modalities have a limited but important role
in the overall treatment of most solid tumors. Thus, the strategies of cancer treatment using
combined therapies are considered more promising for higher efficacy. The objective of this
study was to investigate whether resveratrol can potentiate the antitumor activities of the
common chemotherapeutic oxaliplatin in a cell culture model of colorectal cancer. Materials
and Methods: Caco-2 cells expressing PPARγ were treated with increasing concentrations
of resveratrol [10-200µM] and oxaliplatin [100nM-10µM]. For co-incubation the cells were
pre-treated with resveratrol [10-50µM] for 24h. Cell growth was determined by BrdU
incorporation and crystal-violet staining. Activity of spermine/spermidine acetyltransferase
was assayed with a radiometric technique measuring the amount of synthesized [acetyl-
14C]-spermidine. Apoptosis induction was detected by measuring DNA fragmentation.
Caspase-3 induction was determined via an activity assay. Drug interactions were assessed
using the combination-index (CI) method as defined by median-effect analysis. CI<1 indicates
synergism. Results: Resveratrol [IC50=75µM] and oxaliplatin [IC50=7,5µM] significantly
inhibit cell growth of Caco-2-cells in a dose dependent manner after 24h (***p<0.001).
These IC50 values were reduced to [25µM] and [1µM] when the drugs were used in
combination (CI=0.466, ***p<0.001). Furthermore, oxaliplatin synergistically increased
SSAT activity in pre-treated Caco-2 cells up to 300% in a dose dependent manner after 24h
(***p<0.001). This effect was strictly related to the ability to induce apoptosis, as Caspase-3-
activity (~40% vs. resveratrol, *p<0.05) as well as DNA-fragmentation (~40% vs. resveratrol,
**p<0.01) were significantly increased in pre-treated Caco-2 cells after incubation with
oxaliplatin [1µM] for 24h. Conclusions: These data suggest that the polyphenol resveratrol
sensitizes colon cancer cells to oxaliplatin-induced cell growth inhibition, which may be
due to the conspicuous induction of apoptosis. These effects are mediated, at least partly,
by an activation of SSAT, the catabolic key enzyme of polyamine metabolism, which is
associated with intracellular apoptotic responses.
154
Regulation of the Intrinsic Apoptotic Pathway By Docosahexaenoic and
Eicosahexaenoic N-3 Fatty Acids in Colorectal Cancer Cells
Anna Giros, Elisenda Pons, Xavier Llor, Jessica Fernandez-morales, Rosa m Xicola, Miquel
a Gassull
Introduction: We have shown that the main fatty acids present in FO, Docosahexaenoic
(DHA) and Eicosahexaenoic (EPA) acids inhibit cell growth and induce apoptosis in colorectal
cancer cells. We have seen that both, the extrinsic and the intrinsic pathways, are implicated
in the induction of this apoptosis. The determinant event of the intrinsic pathway is the
depolarization of the mitochondrial membrane which prompts the release of cytochrome c
and the subsequent activation of effector caspases. The interaction of several pro and anti
apoptotic proteins of the Bcl-2 family is crucial in the regulation of the mitochondrial
depolarization. Aims: To determine which are the main elements implicated in the regulation
of the intrinsic pathway activated by DHA and EPA in colorectal cancer cells. Methods:
Caco-2 and HT-29 human colorectal cancer cells were fed sera-free media supplemented
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with DHA, EPA or vehicle at 200uM. Mitochondrial membrane depolarization was assessed
by JC1 staining, which allows the detection of changes in mitochondrial membrane potential
according to the emitted color. Proteins from cytosolic and mitochondrial fractions were
isolated and western blots were performed with Bcl-2 family proteins, Cytochrome-c, and
Smac/DIABLO antibodies. To determine the interaction of Bax with other Bcl-2 family
proteins, Bax was immuno-precipitated from whole cell lysates and bloated with different
Bcl-2 family protein antibodies. Results: DHA and EPA induced an important down-regulation
of the anti-apoptotic Bcl-xL protein in both cell lines 4 hours after supplementation. Pro-
apoptotic Bax protein expression did not change but it did co-immunoprecipitate with Bcl-
xL, Bid, Bak and with itself. JC1 stain showed a marked depolarization of the mitochondrial
membrane. This process was followed by cytochrome c and Smac/DIABLO (an inhibitor of
the Inhibitor Apoptosis Proteins family) release. Conclusions: The regulation of the intrinsic
apoptotic pathway by DHA and EPA on colorectal cancer cells is mediated by the dimerization
of Bax which forms mitochondrial membrane pores. These pores allow the release of cyto-
chrome c and Smac/DIABLO as well as the depolarization of the membrane that end up in
the irreversible apoptotic cascade.
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Life Long Vegetarian Diet Reduces the Risk of Colorectal Cancer
Yogesh Shastri, Mohandas K. Mallath, Mrunal Shirodkar
INTRODUCTION: The role of vegetarian diet in preventing colorectal cancer (CRC) remains
unresolved in the new millennium. All the interventional studies had used middle-aged
subjects. This raises a possibility of carcinogensis starting before the intervention. We hypo-
thesize that vegetarian diet may help in CRC prevention if started very early in life. METHODS:
We used a prospectively created database of 8877 patients managed in our clinical nutrition
service from January 1st 2000 to December 31st 2005, to examine the association of life-
long vegetarianism with CRC. During the evaluation for nutrition support, a history of life
long vegetarianism (due to religious reason) was obtained from all patients to plan the
appropriate diet. The association between vegetarianism and other risk factors were estimated
by case-control analysis. Patients with CRC (n=796) comprised the Case-patients. Three
groups of controls were generated from the same cohort for separate comparison with cases.
This included all patients with non-CRC cancers (Control group-1, n=7273), patients with
non-CRC and tobacco related cancers (Control group-2, n=1844) and patients with benign
disorders (Control group-3, n=74). Multivariate analysis was performed by adjusting for
age, gender, body mass index and economic status in 7641 patients. RESULTS: 2092
(27.4%)patients from the cohort were lifelong vegetarians, and 178 (22.4%) cases with CRC
were vegetarians. Vegetarianism was significantly (p<0.05) associated with age >64 years,
male gender, BMI <20 Kg/M2, and economic deprivation. In univariate analysis CRC was
positively associated with old age and male gender, and inversely associated with vegetarian
diet, low BMI and economic deprivation. In multivariate analysis by logistic regression, there
was an inverse association of CRC with life long vegetarianism; OR = 0.71, 95%CI 0.59-
0.85, p=0.000 (Control group-1); OR = 0.61, 95%CI 0.49-0.77, p=0.000 (Control group-
2); OR = 0.60, 95%CI 0.31-1.13, p=0.113 (Control group-3). CONCLUSION: Life long
vegetarianism is associated with reduced risk of sporadic CRC. Use of diseased controls is
a limitation of this study.
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Bone Marrow-Derived Pancreatic Stellate Cells in Rats
Gisela Sparmann, Nicole Hofmeister-mielke, Marie-luise Kruse, Katrin Sievert, Robert
Jaster, Stefan Liebe, Daniel Wolff, Joerg Emmrich
Background and aims: The crucial role of pancreatic stellate cells (PSC) in the pathogenesis
of pancreatic fibrosis is generally accepted. However, the cell turnover remains obscure. The
present study addressed the issue of a potential bone marrow origin of PSC during pancreatic
regeneration. Methods: Female F1 hybrid BN/LEW rats received 4x10E7 bone marrow cells
of enhanced green fluorescence protein (eGFP)-transgenic female LEW rats one day after
total body irradiation with 7.5Gy. After achieving a stable hematopoietic chimerism (2
months) detected by FACS analysis of eGFP+ cells in the peripheral blood, 12 animals were
treated with a single intravenous injection of 4 mg dibutyltin dichchloride (DBTC)/kg body
weight inducing a mild acute pancreatitis recovering after one week. Eight days after DBTC
treatment, rats were killed and the pancreas was subjected to two procedures: i) tissue was
fixed in 2.5% paraformaldehyd and stored at -80°C. EGFP+-PSC were identified in cryosec-
tions by means of immuno-fluorescence methods. Binding of antibodies (AB) directed against
cell specific markers (vimentin, desmin, α-SMA, collagen type I or III) was visualized by
fluorescence dyes (Cy3, AlexaFluor555 and 633) using a LSM. ii) PSC were isolated and
cultivated according to standard protocols. In addition to the analysis of immuno-fluores-
cence, genomic DNA as well as proteins of PSC cultivated for at least 14 days were extracted.
PSC containing the eGFP gene or expressing the eGFP protein were detected by PCR and
immunoblotting, respectively. Results: Leukocytes as well as eGFP+ stellate cells in terms
of positive immunostaining for collagen type I and III, α-SMA and desmin could be detected
in the pancreatic tissue. EGFP fluorescence, analysis of the genomic DNA through PCR as
well as of the protein by immunoblotting provided evidence that about 25% of PSC after
two weeks in culture contained the eGFP gene. Evaluation of bone marrow-chimeric rats
that did not receive DBTC showed also eGFP+ stellate cells migrated into the pancreatic
tissue but to a lower degree (~ 10%). Conclusion: Our results suggest for the first time that
bone marrow-derived cells contribute to the stellate cell population in the pancreas. Further
experiments are necessary to investigate the migration process in detail and to identify the
progenitor cell(s).
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Overexpression of Interleukin-1beta in the Murine Pancreas Results in
Chronic Pancreatitis
Frederic Marrache, Shui ping Tu, Swaroop Pendyala, Govind Bhagat, Christoph
Oesterreicher, Melitta Penz-oesterreicher, Kelly Betz, Doris Stoffers, Walden Ai, Shigeo
Takaishi, Jacqueline Baumgartner, Timothy C. Wang
Background: Chronic pancreatitis is a well established risk factor for pancreatic adenocarcin-
oma. However, the role of chronic inflammation in the pathogenesis of pancreatic cancer
development has been minimally explored in experimental model systems, primarily due
to the lack of a convenient animal model. Since previous work from our laboratory showed
that transgenic expression of interleukin 1beta in the mouse stomach could induce chronic
atrophic gastritis, metaplasia and dysplasia, we sought to generate a transgenic mouse model
of chronic pancreatitis based on the targeted expression to the pancreas of a secreted form
of human interleukin 1beta. Methods: A DNA transgenic construct containing a fusion gene
composed of human interleukin 1beta and a signal sequence from IL-1RA under the control
of the elastase promoter was created and microinjected in the pronucleus of fertilized 129
x C57BL/6J oocytes. Positive founders were mated with C57BL/6J mice, and F1 or F2
generations were sacrificed for analysis. Histology was studied using H&E staining. Sirius
red staining and morphometric analysis were used to quantify collagen content. Proliferation
was assessed using BRDU labeling, and apoptosis by the TUNEL assay. RNA expression was
assessed using reverse transcription PCR, and alpha-smooth muscle actin level by western
blot. Results: Three transgenic lines were generated. Analysis of a group (n=4) of 7 week-
old mice from two lines (L123-124) was initially performed. Macroscopically, the pancreas
was atrophic and in one case, the pancreatic main duct and the biliary duct were dilated
upstream a fibrotic stenosis. Pancreatic histology showed typical features of chronic pancreat-
itis, i.e. loss of acinar cells, marked fibrosis, tubular complexes and mixed cellular infiltrate.
Compared to age-matched wild type controls collagen content was significantly increased
(Sirius red positive area 19.47% +/- 5.97 (CI95%) vs 1.8% +/- 0.88). In addition, there was
increased acinar proliferation (8.27% +/- 0.27 vs 0.96% +/- 0.24) and an increased acinar
apoptotic index (2.59% +/- 1.36 vs 0). Reverse transcription PCR demonstrated human
interleukin 1beta transgene gene expression, and increased mRNA levels of interleukins 6
and 10, CXCL1, TNF-alpha, SDF1, CXCR4, TGF-beta1, and MMP9. Western blot analysis
showed an increased level of alpha-smooth muscle actin. Long term follow-up of aged
cohorts is ongoing. Conclusion: Elastase-interleukin 1beta transgenic mice display an early
and marked chronic pancreatitis phenotype, and may represent a potentially useful model
to study the role of inflammation in pancreatic carcinogenesis.
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Acute Pancreatitis(AP)in Df508 Mutated CF Mice(Most Common Human CF
Gene Mutation) Is Characterized By a Unique Inhibition of Apoptosis Signal
Transduction: Treatment Target Implication
Sae-hong Lee, Shi-yi Zhou, Chung Owyang, Matthew J. Dimagno
Background & Aims: We previously reported (Gastro 130(4):A-382, 2006) that within exon
10 of the CFTR gene, both the UNC cftr “null” mutant mice and DF508 mutation CF mice
(arising from amino acid substitutions) have the same anti-apoptotic pancreatic phenotype
and more severe AP than wild type mice, but distinctly different apoptosis execution steps.
Thus, different amino acid substitutions in the exon 10 region may modulate different
apoptotic pathways. Impairment of acinar apoptosis is important because it may enhance
necrosis and worsen acute pancreatitis. We tested if apoptotic pathways of the 2 types of
CF mice differed in caspase-3 catalysis and in the expression of the major inhibitor of caspase
signaling, XIAP, by performing experimental AP studies in UNC cftr “null” mutant mice
and in the more clinically relevant but less well characterized CF mouse model having the
DF508 mutation in exon 10 of the CFTR gene. Methods: DF508 cftr (+/-) mice were bred
& weaned offspring were fed Peptamen. In Vivo AP was induced by 12 hourly IP caerulein
injections (50 ug/kg). Histological severity of AP was characterized by assessing three sequen-
tial execution steps of apoptosis (caspase-3 catalysis, PARP cleavage and DNA fragmentation)
and a major inhibitor of caspase-3 signaling, XIAP. Results: During AP cftr (-/-) and DF508
cftr mice had reduced apoptosis, based on undetectable DNA fragmentation (laddering) in
mutant mice (& strong laddering in WT group) & 50% less cleavage of PARP, a caspase-
3 downstream target. Whereas caspase-3 catalysis (graded 0-4 by immunofluorescence) was
not increased in cftr (-/-) acinar cells after induction of AP, DF508 cftr vs WT groups had
a mild baseline increase (1.1 vs 0; p<0.05; n=5) and a dramatic increase after induction of
AP (3.6 vs 0.9; p<0.05; n=5). Downstream, expression of the caspase inhibitor XIAP was
increased (2.5-fold) only in the DF508 cftr pancreas. Conclusions: This study supports the
clinical observation that CFTR gene mutations within exon 10 of the CFTR gene may
predispose to pancreatitis. Further, the “null” gene mutation and the DF508 mutation (arising
from amino acid substitutions) contribute to an anti-apoptotic pancreatic phenotype and
more severe AP, but by effecting different apoptosis execution steps, including expression
of the caspase inhibitor XIAP. Thus different amino acid substitutions in the exon 10 region
may modulate different apoptotic pathways. Moreover, in the DF508 CF mouse the specific
alterations in apoptosis signal transduction from execution caspase-3 to downstream PARP
is likely attributable to XIAP overexpression, which might be a novel target for potential ther-
apies.
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Persistent and Increased Fibrosis in Mice with Pancreatic Deletion of Rela/p65
Following Repetitive Caerulein Challenge
Matthias Treiber, Hana Alguel, Elisabeth Anetsberger, Hassan Nakhai, Marina Lesina,
Stephan Paxian, Roland M. Schmid
Introduction: Chronic pancreatitis (CP) is a continuing or relapsing inflammatory disease
leading to irreversible morphological changes. The aim of this study was to investigate the
role of the proinflammatory transcriptionfactor NF-κB/Rel in the development of CP.
Methods: loxP-sites flanking exon 7 and 10 of the rela gene were introduced into the mouse
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genome. To obtain deletion of this part of rela encoding the Rel homology domain (RHD)
and the nuclear localization site (NLS), mice were crossed with ptf1a-Cre mice expressing
the Cre-recombinase in the pancreas (rela Δ/Δ). Some mice underwent additional deletion
of rela in myeloid cells (rela Δ/Δmye). rela Δ/Δmice, rela Δ/Δmye mice and wildtype controls
(rela F/F) were injected thrice weekly over a period of six weeks with 50 μg/KG caerulein.
One and six weeks after the last injection, mice were sacrificed and organs were harvested.
The pancreas was analyzed morphologically. Fibrosis was quantified by analyzing expression
levels of collagen α1(I)/α3(I) and fibronectin mRNA. Results: Chronic exposure of rela Δ/
Δ mice to caerulein provoked markedly increased fibrosis within the pancreatic parenchyma
after 1 week, which was still present 6 weeks after the end of stimulation. Floxed wild-type
littermates displayed only mild fibrosis, which was hardly detectable at late stages. High
expression levels of the extracellular matrix proteins collagen α1(I), collagen α3(I) and
fibronectin as well as the pancreatic stellate cell activator TGF-β were found in the pancreas
of rela Δ/Δ mice. Moreover we found numerous tubular complexes and higher proliferation
rates in the pancreas of mice with selective ablation of RelA/p65. Additional deletion of
RelA/p65 in macrophages/neutrophils yielded in a partial rescue of this phenotype. In these
mice, we observed similar amounts of acinar cell loss but attenuated fibrogenesis. Conclusion:
Functional inactivation of RelA/p65 in the pancreas does not prevent fibrogenesis following
repetitive challenge with caerulein. In contrast, it enhances fibrosis and proliferation in the
pancreas as evaluated morphologically and biochemically. However, additional deletion of
RelA/p65 in myeloid cells attenuates fibrosis despite comparable levels of acinar destruction.
Our model resembles major features of human CP and raises caution that should be exerted
in developing inhibitors of NF-κB/Rel for the treatment of CP.
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IL-13 Promotes the Proliferation of Activated Rat Pancreatic Stellate Cells
Through Multiple Signaling Pathways Including Autocrine TGF-β1/Nf-κB-, Akt-
, and S6 Kinase-Dependent Pathways
Satoshi Shinozaki, Hirohide Ohnishi, Kouji Hama, Kentaro Sugano
Background and aims : Interleukin (IL)-13 is one of the pro-fibrotic cytokines. In chronic
pancreatitis, pancreatic stellate cells (PSCs) play a central role in pancreatic fibrogenesis.
In the pancreas of chronic pancreatitis patients, PSCs are activated and transformed to
myofibroblast-like cells, proliferating and expressing α-smooth muscle actin (α-SMA) and
collagen-1. PSC proliferation is tonically inhibited by autocrine TGF-β1. We hypothesized
that IL-13 may take part in pancreatic fibrogenesis and studied IL-13 effect on culture-
activated rat PSCs. Methods: IL-13 expression in rat pancreas was assessed using immuno-
histochemistry. Rat PSCs were isolated with Nycodentz gradient method. Expression of IL-
13 receptor components was evaluated by immunocytochemistry and RT-PCR. Proliferation
of PSCs was examined using [3H]-thymidine incorporation assay. TGF-β1 peptide secretion,
mRNA expression and promoter activity of PSCs were analyzed by ELISA, real-time quantitat-
ive RT-PCR and luciferase assay, respectively. Expression of α-SMA and collagen-1, and Akt
activation were examined by western blotting. NF-κB activity in PSCs was measured by
ELISA using nuclear extracted protein. Results: IL-13 was expressed in rat chronic pancreat-
itis tissue, especially in fibrotic regions, but not in normal pancreas. PSCs expressed a
receptor system for IL-13 ligand, involving IL-4Rα and IL-13Rα1. IL-13 did not affect the
expression of α-SMA or collagen-1 in PSCs. However, IL-13 promoted PSC proliferation,
and concomitantly decreased TGF-β1 secretion, mRNA expression and promoter activity of
PSCs, indicating that IL-13 promotes PSC proliferation by decreasing autocrine TGF-β1. We
next elucidated that IL-13 inhibits autocrine TGF-β1 by attenuating NF-κB activity. Namely,
IL-13 suppressed NF-κB activity, which is constitutively enhanced in activated PSCs. In
addition, adenovirus-mediated mutant I-κB expression attenuated NF-κB activity in PSCs
and consequently inhibited TGF-β1 mRNA expression and peptide secretion of PSCs. Further,
we found out other intracellular pathways through which IL-13 promotes PSC proliferation.
IL-13 activated Akt in PSCs, and adenovirus-mediated dominant-negative Akt expression
attenuated PSC proliferation enhanced by IL-13. Additionally, pre-treatment with S6 kinase
inhibitor (rapamycin) also attenuated PSC proliferation promoted by IL-13. Conclusion:
IL-13 is expressed in chronic pancreatitis tissue, and PSCs express the receptor system for IL-
13 ligand. IL-13 promotes PSC proliferation by decreasing autocrine TGF-β1 via attenuation of
NF-κB activity. Further, IL-13 also enhances PSC proliferation via both Akt- and S6 kinase-
dependent pathways.
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Chymotrypsin C Regulates Degradation of Human Cationic Trypsin
Richard Szmola, Béla ózsvári, Miklós Sahin-tóth
Background and Aims: Cationic trypsin (PRSS1) is the major trypsin isoenzyme in the human
pancreatic juice, and it is the most abundant digestive enzyme in humans. Additionally,
mutations of cationic trypsin are associated with hereditary pancreatitis, a chronic inflammat-
ory genetic disorder of the pancreas. Degradation of cationic trypsin has been suggested to
occur through an autocatalytic mechanism, termed autolysis. Physiologically, autolysis is
thought to be responsible for intestinal trypsin degradation, whereas intrapancreatic trypsin
degradation through autolysis was postulated to be a failsafe mechanism against unwanted
trypsin activity. However, In Vitro studies indicate that cationic trypsin is highly resistant
against autolysis, suggesting that other proteases might be important for its degradation.
The aim of the present study was to investigate the role of pancreatic chymotrypsins in
trypsin degradation. Methods: Human chymotrypsinogens B1, B2 and C were expressed in
HEK 293T cells via transient transfection, whereas human cationic trypsinogen was expressed
in E. coli. Proteases were purified with ion-exchange and inhibitor affinity chromatography.
Degradation of cationic trypsin was followed by enzymatic assays, SDS-PAGE, and N-terminal
sequencing. Results: Chymotrypsin C selectively cleaved the Leu81-Glu82 peptide bond
within the calcium binding loop of cationic trypsin. In contrast, chymotrypsin B1 and
B2 were ineffective. Consistent with the location of the cleavage site, calcium inhibited
chymotrypsin C cleavage. Although autolysis of intact cationic trypsin was very slow, the
chymotrypsin C cleaved form underwent rapid autolytic degradation. Importantly, pancreat-
itis associated cationic trypsin mutations N29T, E79K and R122H afforded significant protec-
tion against chymotrypsin C mediated degradation. Conclusions: The results suggest that
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under physiological conditions intestinal degradation of cationic trypsin is regulated by
chymotrypsin C in a calcium dependent manner. The finding that cleavage by chymotrypsin
C is required for efficient autolysis of cationic trypsin stands in contrast with the widely
held notion that physiological trypsin degradation is purely autolytic in nature. Furthermore,
the profound effects of pancreatitis associated mutations suggest that chymotrypsin C medi-
ated trypsin degradation plays a protective role against premature trypsin activation in the
human pancreas.
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IL-27 Contributes to Protective Colonic Immune Response in Acute DSS-
Induced Colitis
Stefan J. Wirtz, Ingrid Tubbe, Christoph Becker, Benno Weigmann, Mark Birkenbach,
Peter R. Galle, Richard S. Blumberg, Markus Neurath
IL-27 is a novel IL-12 related cytokine, which is expressed primarily by activated antigen
presenting cells including macrophages and dendritic cells (DC). Initial studies have described
the IL-27/IL-27R pathway as a promoter of Th1 differentiation. However, it has also been
shown that IL-27 has important immunoregulatory functions In Vivo by modulation of the
generation of proinflammatory IL-17 producing T helper (Th-17) cells. We have shown
recently that IL-27 modulates early immune responses during acute sepsis/septic shock
induced by the intestinal microflora suggesting that IL-27 can be an important regulator of
the biological functions of innate immune cells. Since transcripts of IL-27 subunits EBI3
and p28 have been shown to be upregulated in human inflammatory bowel disease, we
evaluated in the present study the contribution of IL-27 expression to murine dextran
sodium sulphate (DSS) induced colitis, a model mainly dominated by the innate immune
system. We analyzed in initial studies the expression of IL-27 subunits in healthy controls
and mice with DSS colitis using quantitative PCR and ELISA. As a result we observed that
IL-27 p28 transcripts were barely detectable in the non-inflamed colonic tissue, whereas
IL-27 EBI3 was expressed particularly in epithelial cells. In contrast, there was a strong
upregulation of both subunits in the gut of mice with DSS colitis. Immunohistochemistry
and FACS/ELISA analysis of isolated lamina propria mononuclear cells (LPMC) showed that
there was a strong accumulation of CD11c positive DC in DSS colitis that produce IL-27.
In order to investigate if the increased presence of IL-27 in the inflamed gut is somehow
associated with colitis development/colitis severity, we analyzed IL-27 EBI3 deficient mice
in the DSS colitis model. 10 days after DSS treatment in the drinking water both EBI3-/-
mice and Ebi3+/+ mice lost weight, however somewhat surprisingly, wasting disease was
significantly more prominent in the EBI3-/- group. Macroscopically the colon of EBI3-/- was
shortened and displayed more signs of inflammation associated changes. Miniature endoscopy
and histology demonstrated that the EBI3-/- mice have indeed more severe colitis than the
wildtype controls. Immunostaining of colon cross-sections for MPO showed that colitis in
EBI3-/- mice is reflected by a markedly increased presence of neutrophil granulocytes in
the mucosa of EBI3-/- mice. These results suggest that IL-27 contributes to protective colonic
immune response and cytokine regulation in acute DSS-induced colitis, and that a loss of
IL-27 immune regulatory function results in more severe inflammation in the gut.
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The Murine Small Intestine Contains Discreet Clusters of Dendritic Cells with
a Phenotype Distinct from Dendritic Cells in the Diffuse Lamina Propria
Keely Mcdonald, Caihong Wang, Brian K. Dieckgraefe, Rodney D. Newberry
Background: Dendritic cells (DC) are the most potent antigen presenting cells with respect
to initiating primary immune responses and are key players in the process of protection
from invading pathogens at the mucosal surface. Recent studies have highlighted the increas-
ing levels of complexity of intestinal DC populations, particularly those located within the
diffuse lamina propria. Methods: Standard and modified immunohistochemical techniques
and flow cytometry were used to examine DC cell localization and phenotypes in wildtype,
lymphotoxin α (LTα) knockout, and lymphotoxin beta receptor (LTβR) knockout mice and
wildtype mice given GM-CSF, blocking antibodies to GM-CSF, or control immunoglobulin.
Results: We identified two non-Peyer's patch DC populations, those diffusely distributed
throughout the villi and those located within clusters at the base of villi. The DC clusters
were less numerous than cryptopatches (CP) and more numerous than isolated lymphoid
follicles (ILFs). Some DC clusters co-localized with ILFs, while all of the DC clusters co-
localized with CP. Like CP and ILFs, formation of the DC clusters was dependent upon
LTα and LTβR. Treatment of mice with GM-CSF, an agent demonstrated to increase all DC
populations, increased DC numbers, but had no effect on the numbers of DC clusters, while
treating mice with antibodies blocking GM-CSF resulted in decreased numbers of DC clusters.
Using flow cytometry, we observed that the ILFs, which co-localized with the DC clusters,
lacked CD11b+ CD11c+ DC, which are abundant in the diffuse lamina propria, but contained
CD8α+ CD11c+, CD8α- CD11c+, and B220lo CD11c+ cell populations. Conclusions: Two
groups of non-PP intestinal DC populations can be identified base upon their anatomic
location and CD11b expression; those distributed diffusely throughout the villi, which
contain a substantial CD11b+ population, and those clustered at the base of villi, which are
CD11b-. The numbers of structures, the co-localization with a subset of CP and all ILFs,
and the requirements for the development of DC clusters, suggest that the clustering of DC
at the base of villi is an event that precedes the influx of lymphocytes into ILFs, and marks
the transition of CP into ILFs. The reliance of DC cluster formation on GM-CSF, but the
inability to augment the numbers of clusters with exogenous GM-CSF indicates that limiting
event in the clustering of DC is not DC number, but similar to ILF development may be
responses to exogenous stimuli.
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The Ubiquitin-Editing Enzyme A20 Is Required for Limiting NOD2 Dependent
NFkB Signaling
Osamu Hitotsumatsu, Regina-celeste Ahmad, Catherine Werts, Emre Turer, Nataliya
Shifrin, Bettina Lee, Dana J. Philpott, Averil Ma
Crohn's disease(CD) has been linked to a mutation in the NOD2 gene, a cytoplasmic protein
expressed in innate immune cells that is required for recognition of muramyldipeptide(MDP).
MDP is derived from bacterial peptidoglycan, and it is thought that MDP stimulates the
oligomerization of Nod2, leading to recruitment of receptor-interacting protein 2 (RIP2)
and activation of IKKg and NFkB signaling. Here we show that the ubiquitin-editing enzyme
A20 inhibits MDP and Nod2 induced NFkB activity by reporter assay, as well as RIP2
induced NFkB activity, indicating that A20 can block this important signaling pathway. In
addition, bone marrow derived dendritic cells(BMDCs) from A20 deficient (A20-/-) mice
produce much more inflammatory cytokines than BMDCs from A20+/+ mice after MDP
stimulation, indicating that A20 is physiologically required for restricting MDP induced
inflammatory responses. Moreover, we show that bone marrow derived macro-
phages(BMDMs) from A20-/- mice exhibit exacerbated NFkB activity upon MDP stimulation
when compared to those from A20+/+ mice. We have also investigated the biochemical
mechanisms by which A20 regulates MDP induced NFkB activation. First, we show that
RIP2 is ubiquitylated in cells. Secondly, we demonstrate that A20 reduces ubiquitylation in
cells and removes ubiquitin chain from RIP2 in cell-free conditions. Finally we have estab-
lished that endogenous RIP2 is ubiquitylated after MDP stimulation in BMDMs and that
RIP2 ubiquitylation is exacerbated in A20-/- BMDMs compared with A20+/+ BMDMs. Taken
together, these findings indicate that A20 plays a crucial and novel role in regulating RIP2
ubiquitylation and thereby restricting MDP induced Nod2 signals.
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Dysregulated NF-kB Signaling Leads to Enhanced IL-23p19 Production in
Murine Bone Marrow Derived Dendritic Cells Derived from IL-10-/- Mice
Marcus Muehlbauer, Christian Jobin
Introduction: IL-23 (p19) is responsible for T cell mediated chronic intestinal inflammation
in IL-10-/- mice through induction of T lymphocytes producing IL-17 (ThIL-17) and IL-6.
In addition genetic variants of IL-23R have been shown to either associate positively or
negatively with the development of inflammatory bowel disease. However, the molecular
mechanism controlling IL-23p19 gene expression is largely unknown. Aim: Characterize
the mechanism involved in the regulation of IL23p19 gene expression in bone marrow
dendritic cells (BMDC) generated from wt mice and IL-10-/- mice. Methods: BMDC were
generated from IL-10-/- and wt mice and stimulated with various amounts of LPS. Bioinform-
atics was used to identify potential NF-kB binding sites in the murine p19 gene promoter.
Chromatin immunoprecipitation (ChIP) was used to study RelA and RNA polymerase II
recruitment to the IL-23p19 gene promoter. IL-23p19 expression was analyzed by RT-PCR
and ELISA. RelA and IkB-phosphorylation was determined by western blot analysis and RelA
translocation was assayed by immunofluorescence staining. Molecular and pharmacological
inhibition of NF-kB signaling was performed using Ad5dnIKKb and Bay 11-7082 respectively.
Results: LPS-induced IL-23p19 mRNA accumulation and protein secretion was higher in
IL-10-/- (2400pg/ml) compared to wt (300pg/ml) BMDC. Interestingly, LPS-induced IkB
phosphorylation/degradation, RelA phosphorylation and NF-kB nuclear translocation were
similar between wt and IL-10-/- BMDC. Bioinformatic analysis revealed two potential NF-
kB binding sites within the murine IL-23 promoter (-39 and -576). Using ChIP analysis,
we found an enhanced recruitment of RelA in both sites whereas RNApolII is only recruited
to the proximal site following LPS stimulation. Molecular and pharmacological blockade of
NF-kB signaling with Ad5dnIKKb or Bay 11-7082 prevented LPS-induced IL-23p19 gene
expression. Interestingly, LPS-induced recruitment of RelA and RNApolII to the p19 gene
promoter is transient (max 4h) in wt mice whereas a prolonged (8h) loading is observed
in BMDC from IL-10-/- mice. Conclusion: LPS-induced p19 gene expression requires activa-
tion of NF-kB in BMDC. Enhanced LPS-induced IL-23 expression in IL-10-/- BMDC is due
to a persistent recruitment of NF-kB to the gene promoter. Modulation of signaling events
leading to IL-23 gene expression may represent a therapeutic alternative for the treatment
of IBD.
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The Crohn's Disease Associated T Cell Co-Stimulator Tl1a Is Induced By FCγ
Receptor Signaling But Not By TLR Ligands Or Pro-Inflammatory Cytokines in
Human Monocytes and Dendritic Cells
Kathrin S. Michelsen, John Prehn, Lisa Thomas, Carol J. Landers, Qi Yu, Stephan R.
Targan
Background and significance: The novel TL1A/DR3 ligand/receptor pair mediates strong co-
stimulation of Th1 cells. Activation of T and NK cells induces DR3 expression, permitting
soluble recombinant TL1A to increase IFN-γ production and proliferation of these cells. In
Crohn's disease (CD) gut T cells and macrophages express increased levels of TL1A, and
there is a strong association between CD and TL1A single nucleotide polymorphisms (SNPs).
Murine studies demonstrated up-regulation of TL1A and its receptor DR3 in inflamed mucosa
in chronic models of ileitis implicating TL1A in chronic intestinal inflammation. Aim: To
determine the signaling pathways that lead to TL1A induction in antigen-presenting cells
(APC). Methods: To determine whether professional antigen presenting cells can express
TL1A, fresh blood monocytes and monocyte-derived DC were stimulated with various
activating ligands, including TLR ligands, IFN-γ, TNF-α, IL-1β, and immune complexes.
TL1A mRNA expression was measured by real-time PCR and protein expression was measured
by flow cytometry and ELISA. To determine functional relevance of TL1A induction stimu-
lated monocytes were co-cultured with CD4+ T cells. IFN-γ production by T cells was
measured by ELISA. Results: FcγR stimulation strongly induced TL1A mRNA (690-fold and
216-fold increase in monocytes and DC, respectively; n=5 and 7) in both cell types, which
correlated with the detection of TL1A on the cell surface (average of 48.5 % and 12.6 %
TL1A+ cells for monocytes and DC, respectively; n=4) and in cell culture media (1.3 and
2.7 ng/1 x 106 cells for monocytes and DC, respectively; n=5 and 3). TLR agonists capable
of inducing IL-6 and TNF-α in monocytes and DC did not induce surface nor soluble TL1A.
TNF-α and IL-1β, both known inducer of TL1A in human endothelial cells, failed to induce
TL1A mRNA or protein expression in DC or monocytes. Furthermore, using a monocyte-T
cell co-culture system we demonstrate here that FcγR-induced TL1A production in monocytes
leads to enhancement of autologous T cell responses as measured by IFN-γ production and
this IFN-γ production could be blocked by TL1A antibodies. Conclusion: The stimulation
of the FcγR signaling pathway leads to induction of TL1A on APC that can bind to its
receptor on CD4+ T cells and triggers co-stimulatory signals in T cells that significantly
amplify the production of IFN-γ. The interaction of APC and T cells via TL1A with its
subsequent functional outcome as well as CD-associated TL1A SNPs suggest an important
role for APC-induced TL1A in Th1 responses in CD.
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APC Regulate Th1/Th17- Mediated Colitis in IL-10 Deficient Mice
Bo Liu, Lisa Holt, R balfour Sartor
IL-10 plays a critical role in maintaining mucosal homeostasis. However, the relative func-
tional role of IL-10 produced by antigen presenting cells (APC) vs. T lymphocytes in
immunoregulation is unclear. Recently we demonstrated that transfer of CD4+ T cells from
inflamed IL-10-/- or disease free wild-type (WT) donors induced more colitis and higher
amounts of IFNγ, IL-17 and IL-12p40 by cecal bacteria lysate (CBL)- stimulated MLN cells
in IL-10-/-Rag2-/- recipients than in IL-10+/+Rag2-/-recipients. This demonstrated that IL-
10 secreting CD4+ T cells are not sufficient to regulate mucosal homeostasis in the absence
of IL-10 derived from APC. The current study further tests the hypothesis that APC rather
than T cells regulate susceptibility to TH1-mediated colitis in IL-10-/- mice. Methods: APC
from IL-10-/-Rag2-/- or IL-10+/+Rag2-/- mice were pulsed overnight with CBL with or
without addition of anti-IL-10R mAb or recombinant mIL-10, washed, and then co-cultured
with CD4+ T cells from inflamed IL-10-/- or disease free- WT mice. Cytokines in 3-day
culture supernatants were measured by ELISA. Result: CBL-pulsed APC of IL-10-/- Rag2-/-
mice induced high levels of IFNγ and IL-17 production by co-cultured CD4+ T cells from
either IL-10-/- (IFNγ 7,717 ± 195 pg/ml; IL-17 37,123 ± 1095 pg/ml) or WT mice (IFNγ
6,696 ± 216 pg/ml; IL-17 38,022 ± 951pg/ml). High IL-12p40 production was also detected
in the IL-10-/- APC-CD4+ T cell co-cultures (3,351 ± 173pg/ml with IL-10-/- CD4+ T cells;
3,052 ± 158 pg/ml with WT CD4+ cells). Significantly lower cytokine secretion was present
when CBL-pulsed IL-10+/+ Rag2-/- APC were cultured with CD4+ T cells from IL-10-/-
mice (IFNγ 458 ± 16 pg/ml; IL-17 1,739 ± 73 pg/ml; IL-12p40 630 ± 72 pg/ml) or WT
mice (IFNγ 156 ± 15 pg/ml; IL-17 6,950 ± 830 pg/ml; IL-12p40 576 ± 69 pg/ml (p<0.001
vs. IL-10-/- APC). In these studies the source of CD4+ T cells (IL-10-/- vs. WT mice) did
not affect results, only the source of APC. Blocking endogenous IL-10 signaling by anti-IL-
10R antibody significantly increased production of IFNγ and IL-12p40 in IL-10+/+Rag2-/-
APC co-cultured with CD4+ T cells from either from KO (IFNγ 1,896 ± 85 pg/ml; IL-12p40
1204 ± 51pg/ml) or WT mice (IFNγ 2,897 ± 194 pg/ml; IL-12p40 1021 ± 11pg/ml).
Recombinant mIL-10 significantly reduced IFNγ and IL-12p40 production by co-cultured
IL-10-/-Rag2-/- APC and CD4+ T cells from either KO or WT mice. Conclusion: IL-10
produced by APC is the primary regulator of IFNγ and IL-17 production by bacterial antigen-
responsive CD4+ T cells In Vitro. APC appear to be the dominant determinant of susceptibility
to TH1 and TH17-mediated- intestinal inflammation.
173a
Inhibitors of Phosphodiesterase 5 - a Novel Therapy of Portal Hypertension
Peter Deibert, Martin Rössle, Hinrich Bremer, Michael Dreher, Anna-katharina Kurz-
schmieg, Wolfgang Kreisel
Introduction: Portal hypertension is caused by mechanical factors (e. g. disturbed liver
architecture, regeneratory nodules, fibrosis) and by a functional component consisting of
increased splanchnic inflow and a sinusoidal constriction due to intrahepatic NO deficiency.
The latter may be compensated by an inhibition of phosphodiesterase 5 (PDE 5). Therefore,
we investigated the effect of inhibitors of PDE 5 on liver hemodynamics. Patients and
methods: In 10 healthy male individuals liver hemodynamics were measured by Doppler
ultrasonography before and after 100 mg Sildenafil. Corresponding measurements were
performed in 4 healthy persons and 5 patients with liver cirrhosis after 10 mg Tadalafil.
The data were compared with the results obtained in 18 healthy individuals and 18 patients
with liver cirrhosis Child A after 10 mg Vardenafil (Deibert P et al. 2006). In 6 patients
with liver cirrhosis hepatovenous pressure gradient (HVPG) was measured invasively after
Vardenafil. In one patient with portopulmonal hypertension we measured HVPG after
Vardenafil and after Tadalafil. In three cirrhotics blood flow through the reopened umbilical
vein was quantified before and after Vardenafil and Tadalafil, respectively. Results: With all
three inhibitors of PDE 5 comparable results were obtained. 1. Sildenafil increased portal
venous blood flow (PVBF) in controls by 25%. Vardenafil increased PVBF in healthy subjects
by 17% and in patients with liver cirrhosis by 24%. Tadalafil increased PVBF by 30%. 2.
With all three compounds celiac and hepatic artery resistivity indices rose significantly,
whereas resistivity indices of the superior mesenteric artery remained constant. 3. Systemic
hemodynamic parameters showed only minor changes. 4. Continuous measurements showed
an effect on PVBF already 15 minutes after oral administration of Sildenafil, Vardenafil, and
Tadalafil. 5. The mean decrease of HVPG after Vardenafil amounted to 22% (16%, 16%,
50%, 13%, 0%, and 30%). 6. Inhibitors of PDE 5 led to a > 30% decrease of umbilical vein
blood flow. 7. In a patient with portopulmonal hypertension Vardenafil lowered mean
pulmonal arterial pressure by 30% and HVPG by 30%, Tadalafil by 24% and 30%, respect-
ively. Conclusion: Inhibitors of phosphodiesterase 5 increase portal venous blood flow and
lower hepatovenous pressure gradient in liver cirrhosis by a reduction of intrahepatic sinus-
oidal resistance. The autoregulation of hepatic arterial blood flow (hepatic buffer response)
remains intact. These data strongly suggest a specific effect of inhibitors of PDE 5 on liver
hemodynamics promising a new treatment option in portal hypertension or liver injury.
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Abrogation of Portal Hypertension Via Prostacyclin Receptor Antagonism
Nicholas J. Skill, Nicholas G. Theodorakis, James V. Sitzmann
Aim: Whereas the role of cyclooxygenase isoforms in the development of experimental portal
hypertension (PHT) has been well documented, the direct action of secondary prostanoid
metabolites (e.g. prostacyclin) is limited. Moreover, the recent question regarding the use
of cyclooxygenase inhibitors argues against their use in the abrogation of PHT. Therefore,
we aim to identify targets downstream of cyclooxygenase isoforms in order to prevent PHT
with minimal disruption of the prostanoid cascade. Methods: Pre-hepatic PHT was induced
in wild type (C57B/6J) mice by partial ligation of the portal vein using a 27G needle (n=3
per group). Mice were given 2mg/kg CAY10441, a prostacyclin receptor antagonist, or
vehicle IP 1 day prior to and for 7 days following PVL or sham surgery. The development
of PHT was determined by measuring: 1) splenic pulp pressure, 2) abdominal aortic flow
(Qao), 3) splenomegaly and 4) portal-systemic shunting. Results: In vehicle controls all
hemodynamic measurements were increased in PVL mice when compared to sham mice.
Prostacyclin receptor antagonism using CAY10441 had no effect in sham operated mice but
significantly reduced Qao, splenomegaly and portal-systemic shunting in PVL mice when
compared to vehicle treated PVL controls (see table below). However, the splenic pulp
pressure in CAY10441 treated PVL mice was increased when compared to vehicle treated PVL
controls (20.6±0.85 vs. 32.6±0.7mmHg vehicle vs. CAY10441). Conclusion: Prostacyclin
receptor antagonism clearly has an effect on the portal hemodynamics of pre-hepatic PHT
mice and despite an increase in splenic pulp pressure prostacyclin receptor antagonism
presents as a potential target to abrogate PHT. We believe that the increased splenic pulp
pressure in CAY10441 treated mice is unique to the PVL model and is related to the reduction
of portal-systemic shunting which normally decompresses the portal system in the PVL
model. Additional studies are planned using intra-hepatic PHT models (CCl4 and bile
duct ligation) to further elucidate the potential of prostacyclin receptor antagonism to
abrogate PHT.
Portal hemodynamics measurments post PVL and prostacyclin antagonism
* p<0.05 (2 tailed ttest sham vs. PVL). # p<0.05 (2 tailed ttest vehicle vs. CAY10441).
CAY10441 = 4,5-dihydro-N-[4-[1-(methylethoxy)phenyl]methyl]phenyl]-1H-imadazol-2-
amine (Cayman Chemicals, MI)
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Decreasing in-Hospital Mortality Associated with Esophageal Variceal
Hemorrhage in the United States
M. mazen Jamal, Jason B. Samarasena, Mehrtash Hashemzadeh
Background/Aims: To date, no study has analyzed nationwide trends of in-hospital mortality
related to esophageal variceal hemorrhage in the United States. The aim of this study was
to analyze trends of in-hospital mortality related to esophageal variceal bleeding over the
past two decades using a large national database. In addition, our aim was to study patient
demographics and to identify risk factors for in-hospital mortality based on administrative
data routinely collected in this population. Methods: The Nationwide Inpatient Sample data
was used from 1988 to 2002. Patients with an ICD-9-CM discharge diagnosis of esophageal
variceal bleeding were included. Patient demographic, hospital and admission characteristics
were collected. T-test and Poisson regression analysis were used to evaluate trends. Logistic
regression analysis was performed to determine the relationship between mortality and
patient/hospital characteristics. Results: From 1988 to 2002, the in-patient mortality rate
related to bleeding esophageal varices decreased from 18.0% to 11.6%. Poisson regression
analysis confirmed a decrease in the mortality rate ratio from 1988 to 2002 after controlling
for simultaneous variations in age, ethnicity, and gender. For the year 2001, the highest
mortality rate was observed among males, African Americans and mortality rate increased
with patient age. Highest mortality rates were observed in hospitals with large number of
beds, teaching hospitals, and location in the Northeast region. Conclusions: The in-hospital
mortality of patients with esophageal variceal bleeding has decreased over the past two
decades and is likely due to the advances made in the acute management of variceal bleeding
as well as improved resuscitative methods. Higher in-hospital mortality is seen in males and
African Americans. In-hospital mortality increases with patient age. Higher mortality rates
are seen in large sized hospitals, teaching hospitals, and location in the Northeast region.
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Minimal He After TIPS Insertion Is Associated with a Reduced Quality of Life
Hanan Mardini, Steven Masson, John Rose, Christopher O. Record
Background One of the main drawbacks of TIPS is the development of hepatic encephalopathy
(HE). The diagnosis of HE is typically clinical yet this is insensitive; the development
of psychometric testing has allowed the detection of subtler degrees of neuropsychiatric
impairment - subclinical or ‘minimal' HE. However, the morbidity associated with minimal
HE and the extent to which this affects quality of life (QOL) is unclear. We aimed to
determine the incidence of minimal HE after TIPS insertion and the impact this had on
perceived health status and QOL. Methods From our database of patients in whom TIPS
has been inserted in the last decade (n=197), those still attending (n=59) were invited to
attend for psychometric testing. A test battery for the detection of minimal HE, the psychomet-
ric hepatic encephalopathy score (PHES), was derived from six paper and pencil tests.
Computerized psychometry (CDR) was also undertaken within one week of the paper and
pencil tests by the same operator (HM). Blood was collected at the time of testing for Child/
Pugh and MELD score and whole blood ammonia. These patients were asked to complete
2 health profile questionnaires - the Short Form 36 (SF-36) and the chronic liver disease
questionnaire (CLDQ). Results PHES were available in 35/59 (59%) patients. Testing was
undertaken at a mean length of 81 months (range 3-123) after TIPS insertion. PHES was
abnormal (score -5 to -18) in 17 patients (49%); some (n=6) had no clinically evident HE
during FU. PHES was normal (-4 to 2) in 18 patients. The CDR score was significantly
lower in those with abnormal PHE scores (p<0.01) and was in the normal range (-3 to +5)
in only 14 of the 36 tests performed (39%). QOL questionnaires were completed by 19/
35 (54%) of those who underwent psychometric testing. In both the SF-36 and CLDQ
questionnaires, the total scores for patients with abnormal psychometric test results were
significantly lower than that for patients with normal psychometric test results (p<0.05).
This difference was significant in the domains covering physical health in the SF-36 question-
naire and in the domains of fatigue, systemic symptoms and activity in the CLDQ. Conclusion
Abnormal PHE scores are seen in around half of all patients after TIPS insertion. This
subclinical abnormality represents psychomotor slowing along with impairment of visual
perception and attention i.e. minimal HE. Additionally, this results in a globally diminished
functional level, with impairments in dimensions of physical and mental health. Minimal
HE is associated with a reduced perceived and actual QOL.
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Aggressive Endoscopic Band Ligation Dramatically Reduces Rates of Recurrent
Variceal Bleeding in Patients with Portal Hypertension: a Retrospective Cohort
Study
Westyn Branch-elliman, Sarah M. Sled, Steven L. Flamm
Background: Variceal bleeding secondary to portal hypertension has high mortality and high
rates of recurrence. Endoscopic band ligation (EBL) is typically performed to reduce re-
bleeding in cirrhotic patients with hx of bleeding esophageal varices; however, a recent
meta-analysis reported a re-bleeding rat of 19% for patients treated with EBL. At surveillance
EGD, many groups perform prophylactic EBL only when veins are >5 mm. Surveillance
EGD is often performed only on an annual basis. We employ an aggressive EBL protocol
and have anecdotally noted much less re-bleeding than has been reported. Aim: We sought
to assess the variceal re-bleeding rate with aggressive serial EBL in patients with a prior hx
of variceal bleeding. Methods: The medical records of 420 consecutive patients treated at a
tertiary care ctr between 12/31/97 and 12/31/05 who underwent EBL were reviewed. 245
pts were excluded because they underwent EBL for primary prophylaxis, received only 1
EGD, and/or had follow-up <3 mos. The final study grp consisted of 175 pts followed for
3 mos to 6.9 yrs (median 16 mos and mean 24 mos). At the initial bleed, all esophageal
varices were ligated regardless of size. All pts were subsequently treated with aggressive
EBL. EBL was performed every 2 wks until varices were minimal or obliterated. The EBL
interval was gradually increased from 2 wks to 1-2 mos, to 4-6 mos, and finally to 9-12
mos and continued indefinitely. EBL was performed on any visible varix no matter what
the size. Data collected included demographic, biochemical, histological and extensive clinical
information. Event-free survival was calculated and defined as lack of variceal bleeding until
liver transplantation, death, TIPS placement or until last office visit. STATA program was
used to analyze the data. Results: 175 pts were included for analysis. The mean age was
62.7 and 65.1% were men. 118/175 (67.4%) were maintained on beta blocker prophylaxis.
14 pts were followed for >5 yrs. Only 8% overall suffered from re-bleed over the entire
time period. The 6 mos variceal re-bleeding rate was 2.3%, 12 mos rate was 3.4% and 2
yr rate was 4.6%. No patients on concomitant beta blocker therapy suffered a re-bleed.
Conclusions: 1) Aggressive EBL (frequent EGD with band ligation of all visible varices)
significantly reduces recurrent variceal bleeding in pts with hx of variceal bleeding in
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comparison to historical controls long-term follow up. 2)Aggressive EBL in conjunction with
beta blocker prophylaxis eliminated variceal bleeding in this cohort. 3) Aggressive EBL in
comparison to a standard approach warrants additional evaluation within the context of a
randomized clinical trial.
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Length of Stay in Patients with Decompensated Liver Disease: Impact of a
Specialized Housestaff Hepatology Service
Jennifer C. Lai, Alex Montero, Benjamin Lebwohl, Robert S. Brown
BACKGROUND: Retrospective studies have measured the impact of hepatology attending
care on outcomes in hepatology, but no study has assessed quality outcomes in hepatology
patients cared for in a dedicated housestaff clustering model. In June 2004, our institution
implemented a specialized housestaff hepatology service dedicated to patients with decom-
pensated liver disease, consisting of geographically localized patients supervised directly by
the liver transplant team. Prior to this, these patients were managed by the same attendings
but on multiple wards with several general medicine housestaff teams in a private patient
model. AIM: To study the impact of a specialized housestaff hepatology service on patients
hospitalized with decompensated liver disease. METHODS: This study included a retrospect-
ive cohort of 423 consecutive patients admitted to a transplant hepatologist during the study
period. Data was obtained from an electronic medical record database. The primary outcome
was length of stay (LOS). Our independent variable was liver team status (pre/post). Covariates
included age, MELD score, and case-mix index (CMI, a measure of patient acuity). Univariate
analysis was carried out; any variable associated with LOS (p<.20) was included in our
multivariate analysis. To examine secular trends in the primary outcome, we investigated
LOS for a non-specialized, medicine housestaff ward on the same floor during the same
period. RESULTS: Baseline characteristics were similar between the two groups (n=171vs
n=252), including %male (54% vs 59%), age (54.1±13.3 vs 54.9±13.3), admission MELD
(20.1±10.0 vs 19.6±9.5), and CMI (Table). There was a reduction in mean (Table) and
median (8.0 vs 7.3) LOS. In univariate analysis, the Liver Team, MELD and CMI were
associated with a statistically significant reduction in LOS (p≤.04). In multivariate analysis,
Liver Team status (p=.003) and CMI (p<.001) remained associated with LOS. In contrast,
there was a statistically significant increase in length of stay (p<.0001) on a comparable
non-specialized medicine housestaff ward (Table), before and after adjustment for CMI.
CONCLUSION: The implementation of a specialized housestaff hepatology service is associ-
ated with a decreased LOS after adjustment for age, MELD score, and case-mix index. The
secular trend of increased LOS during the period suggests that the close interaction between
housestaff and attending had a beneficial impact on LOS.
TABLE: MULTIVARIATE ANALYSIS OF LOS, ADJUSTED FOR CMI
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The TNF-β Polymorphism Ncoi Is Associated with An Increased Risk of
Developing Barrett's Esophagus and Esophageal Adenocarcinoma in Gastro-
Esophageal Reflux Disease
V. Menke, J. G. Kusters, L. M. Moons, R. G. Pot, P. D. Siersema, E. J. Kuipers
Background: TNF is a key cytokine of the cell mediated immune response. Genetically
determined differences (polymorphisms) in the promoter region of the TNF-β gene are
associated with high TNF expression levels, and an increased risk of cancer development.
Barrett's esophagus (BE) is a pre-malignant condition of the esophagus with an increased
risk of developing esophageal adenocarcinoma (EAC) in patients with reflux esophagitis
(RE). Aim: To determine the association of the polymorphism TNF-β (NcoI) with the RE-
BE-EAC cascade compared to a healthy control group. Methods: DNA was obtained from
197 healthy controls (100% Caucasian; mean age 57y ± 14; 59% male), 305 patients with
endoscopically confirmed RE (100% Caucasian; mean age 55y ± 13; 55% male), 257 patients
with BE (100% Caucasian; mean age 61y ± 12; 69% male), with a segment of ≧2 cm
specialized intestinal metaplasia and 128 patients with EAC (100% Caucasian; mean age
63 ± 10y; 82% male). The gene polymorphism of the TNF-β (NcoI) was determined by a
modified TAQMAN assay. Logistic regression was used to calculate odds ratio (OR) and
95% confidence intervals (CI) for variant genotypes. Results: The allele frequency of the
major allele (A) was 60.9% in the control group, 66.2% in RE, 69.5% in BE, and 71.1%
in EAC, and the frequency of haplotype A/A increased equally in this cascade. TNF-b (NcoI)
A/A homozygosity in RE (OR=0.70; 95% CI:0.39-1.26), BE (OR=0.76; CI:0.41-1.43), and
EAC (OR=0.63; CI:0.28-1.44) was not different compared to controls. However, TNF-β
(NcoI) A/G heterozygosity was observed more frequently in BE (OR=1.60; 95% CI:1.07-
2.38) and EAC (OR=1.66; 95% CI:1.04-2.67), but not in RE (OR=1.23; 95% CI:0.83-1.80)
compared to controls, meaning that this polymorphism is associated with a 1.6-fold increased
risk of developing BE and EAC. Conclusions: The TNF-β (NcoI) A/G polymorphism is
associated with an increased risk of BE and EAC development. This is in concordance with
recent data showing that the same polymorphism had a modulating effect on TNF expression
and disease induction in gastritis and gastric adenocarcinoma. Our findings indicate that in
addition to risk factors like gender, Caucasian race, age and obesity, there is also a genetic
immune-based component in the development of BE and EAC. Hence anti-inflammatory
treatment of RE patients might reduce their risk of EAC development.
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Ribonucleotide Reductase Single Nucleotide Polymorphisms: Markers of
Response to Gemcitabine in a Prospective Pancreatic Cancer Treatment
Trial(Rtog 9704)
James J. Farrell, Miguel Garcia, Ali Ammar, W. Regine, R. Abrams, A. Bowen benson, J.
Macdonald, P. Schaefer, C. Willett, Hany Elsaleh
Background: Ribonucleotide reductase (RR) is a rate-limiting enzyme in DNA synthesis and
repair. It is composed of 2 subunits (proteins M1 and M2), and is important in gemcitabine's
mechanism of action. RRM2 overexpression is associated with gemcitabine chemoresistance
in pancreatic cancer cells. Suppression of RRM2 expression using RNA interference enhances
the drug-induced cytotoxicity. We aim to study the prognostic and predictive value of RRM1
and RRM2 polymorphisms in patients enrolled in a prospective randomized adjuvant trial
in pancreatic cancer. Methods: RTOG 9704 prospectively randomized 538 patients after
pancreatic resection to receive either RT+5-FU or RT+Gemcitabine. Known SNP genotypes
in RRM1 and RRM2 were analyzed in patients from both treatment groups, and were
correlated with treatment outcome (overall survival and disease free survival) in patients
from both treatment groups by unconditional logistic regression analysis using the Chi-
square test and the Cox proportional hazards model. Results: Of the 538 patients entered into
RTOG 9704, 268 patients were randomized to RT+Gemcitabine and 270 were randomized to
RT+5-FU.89 and 100 were eligible for SNP analysis in both groups respectively. The RRM1
SNP was not found to be polymorphic in this study. One of the RRM2 SNPs (rs 6741290;
(TT vs CC/CT)) was found to be statistically associated with overall survival in the
RT+Gemcitabine group but not in the RT+5-FU group. Table 1 shows univariate analyses
for selected SNPs (expressed as hazard ratio ((HR) (95% confidence intervals)) for the
patients treated with RT + gemcitabine. Conclusion: In this prospective randomized adjuvant
study of patients with pancreatic cancer receiving either RT + gemcitabine or RT+ 5-FU, a
minor allele intron SNP in RRM2 (rs 6741290, TT) is associated with a statistically significant
improvement in overall survival in patients receiving gemcitabine compared with those who
did not. This suggests that this RRM2 SNP may be a predictive marker of response in
patients with pancreatic cancer receiving gemcitabine.
Table1:Ribonucleotide Reductase (RR) SNP correlation with overall survival in Pancreatic
Cancer patients treated with Gemcitabine.
ID: NCBI DB Accession number; SNP: Gene location and nucleotide change; HR: Hazard
Ratio (>1 indicates increased risk of death)
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Increased Risk of Colorectal Neoplasia Associated with the E1317q Variant of
APC and the Potential for Risk Modification By Other Genetic Loci
Oleg Dolkart, Michael J. Hall, Eliezer Liberman, Eyal Sagiv, Aharon Hallak, Menachem
Moshkowitz, Alfred I. Neugut, Nadir Arber
Background: Mutations in the APC gene are found in the majority of sporadic colorectal
cancer (CRC). The I1307K variant of the APC gene confers a modestly increased susceptibility
for CRC and is more prevalent among Ashkenazi Jews than other racial or ethnic groups
studied to date. The clinical significance of another APC variant, E1317Q, has recently been
under debate. Rozek et al found no association between the E1317Q variant and a history
of CRC in their analysis of 1834 cases (CEBP, 2006). CD24 is a novel oncogene in CRC
recently discovered by our lab (Gastroenterology, 2006). A polymorphism of the CD24 gene
(c.170C>T) results in an alanine to valine substitution (Ala57Val) at a strategic position in
the protein. Objective: To prospectively investigate the association of the E1317Q variant
with CR neoplasia in a large population. Methods: 2,076 consecutive subjects (between
12.00-11.06) were consented. All subjects underwent colonoscopic examination and their
neoplasia status (healthy, adenoma, or carcinoma) was recorded. Personal history of CR
neoplasia was also recorded. The APC gene was amplified from DNA from peripheral blood
lymphocytes by real time PCR using primers that were specifically designed to detect the
I1307K and E1317Q variants. The CD24 locus was examined for 923 subjects using regional
PCR amplification followed by a BstX1 restriction reaction. Reliability of genetic testing was
confirmed by repeat testing in a random sample of the study population (approximately
25% of the total). Results: Overall, the E1317Q variant was detected in 26/2076 (1.25%)
individuals undergoing testing. Colorectal neoplasia was significantly associated with carrying
the E1317Q variant [OR 3.73, 95% CI 1.44-11.4](p=0.0025). The mean age of CRC diagnosis
in E1317Q carriers was 56.4 yrs, compared to 61.8 yrs in controls (p=NS). No individuals
were found to carry both the E1317Q and the I1307K variants. Among E1317Q+ individuals,
6 were found to be homozygous A/A at the CD24 locus, 6 heterozygous A/V, and 2
homozygous V/V. A history of colorectal neoplasia was found in 3/6 E1317Q carriers
homozygous (A/A) for CD24, and 7/8 E1317Q carriers heterozygous (A/V) or homozygous
(V/V) for CD24 (OR=7). Conclusions: E1317Q is a rare gene variant of APC that conveys
a significantly increased risk for CR neoplasia. It is suggested that carriers of the E1317Q
variant may benefit from intensive colonoscopy screening program. The simultaneous pres-
ence of E1317Q and the A/V or V/V genotype of CD24 may augment the risk for developing
colorectal neoplasia. Sequence variations in CD24 should be studied more thoroughly.
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Identification of Mutyh Gene Variants in a Cohort of German Patients with
Familial Colorectal Cancer (FCRC)
Frank Grünhage, Matthias Jungck, Christoph Lamberti, Micaela Mathiak, Tilman
Sauerbruch, Frank Lammert
Introduction: Although up to 20% of colorectal cancer (CRC) patients show some kind of
familiarity, genetic factors underlying polygenic fCRC have yet to be identified. Recently
mutations of the base excision repair gene MUTYH have been reported as underlying genetic
defect in autosomal-recessive colorectal adenomatous polyposis, with Y165C and G382D
representing the most common mutations. Our aim now was to test a group of patients
with strong evidence for CRC familiarity (but exclusion of the monogenic CRC syndromes
FAP and HNPCC) for association with these two MUTYH mutations Y165C and G382D in
comparison to (i) patients with sporadic CRCs and (ii) healthy controls. Methods: We
recruited 93 patients with fCRC, as defined by two of the following criteria: (1) three affected
relatives, one of them a first-degree relative of the others; (2) one member diagnosed with
CRC before age 50; or (3) two affected generations. All tumours showed regular expression
of MLH1 and MSH2, and microsatellite instability was excluded. For comparison, we studied
93 CRC patients without inherited CRC syndromes and a negative family history as well as
93 'hyper-normal' controls who displayed no adenomatous polyps on colonoscopy. Allelic
discrimination was performed using a fluorescent dye marked reporter assay with predesigned
probes (Taqman assays). Results: The Y165C risk allele was observed in 3% of the fCRC
patients, but was absent in patients with sporadic CRCs and controls. For the risk allele of
the G382D variant, allele frequencies were 2% (fCRC), 1% (CRC), and 1% (controls).
Overall, 4.0% of fCRC, 2.2% of CRC patients and 1.0% of controls harboured a mutation in
the MUTYH gene. Of note, we detected one Y165C/Y165C and one 'compound heterozygous'
patient in the fCRC group. Applying Armitage's trend test revealed a significantly increased
odds ratio for the risk allele of the Y165C mutation in fCRC patients compared to sporadic
CRCs and controls (OR 2.38; p = 0.03). Conclusions: In our cohort the prevalence of
pathogenic MUTYH mutations was consistently increased among fCRC patients compared
to sporadic CRCs and controls. As we found a significant association of the Y165C variant
with fCRC, the presence of MUTYH variants might be a susceptibility factor for fCRC.
178
Non-Synonymous IL-10R1 Variants and the Risk of Colorectal Cancer
Christoph Gasche, Paul Grundtner, Sabine Gruber, Manuela Nemeth, Neeraja Kambham,
Teri a Longacre, Peter Fuszek, Peter Lakatos, Maria gloria Luciani
Approximately 20% of human cancers are estimated to develop from chronic inflammation,
one important example being UC-related colorectal cancer (CRC). Recently, the JAK/STAT
pathway was shown to play a role in promoting CRC in SOCS1-/-Tg mice (Hanada T, JEM
2006), a phenotype that has also been observed in IL-10-/- mice. Our group has previously
shown that the IL-10R1 S138G variant protects from UC. In this study, we aimed to investigate
the role of IL-10R1 non-synonymous variants (S138G and G330R) for susceptibility to
CRC. METHODS: DNA from 224 patients with sporadic CRC and 315 controls were
genotyped for both IL-10R1 variants. The cDNA of IL-10R1 haplotypes was cloned and
expressed in HeLa cells. Differential IL-10 signaling was analyzed by phospho-specific STAT1
and STAT3 western blotting. In order to confirm these data TaqMan-real time PCR was
performed from total cDNA using SOCS3 expression as read out. Relative mRNA expression
of SOCS3 was determined by normalizing to the expression of the housekeeping gene
GAPDH. RESULTS: Both IL-10R1 alleles were significantly less frequent in CRC compared
to controls (S138G 12.3% vs. 17.2%, p=0.035; G330R 21.8% vs. 33.3%, p<0.0001). The
genotype distribution of S138G was 0.0% (GG), 24.7% (AG), and 75.3% (AA) in CRC and
2.2%, 29.9%, and 67.8% in controls (p=0.026). The genotype distribution of G330R was
4.5% (AA), 34.7% (AG), and 60.8% (GG) in CRC and 10.5%, 45.7%, and 43.8% in controls
(p=0.0002). HeLa cells stably expressing each IL-10R1 haplotype were sorted for comparable
IL-10R1 expression by flow cytometry, stimulated with IL-10 (0-10ng/ml for 30 min),
and the phosphorylation of STAT1 and STAT3 was analyzed. In S138G clones, STAT3
phosphorylation was reduced and STAT1 phosphorylation was almost absent even at the
highest IL-10 concentration used (fig). Relative quantification of SOCS3 expression revealed
a loss of IL-10 dependent signaling in all clones expressing the IL-10R1 variants (normalized
delta-CT values: WT 1.00, S138G 0.45, G330R 0.29, and S138G+G330R 0.4). CONCLU-
SIONS: Non-synonymous variants in IL-10R1 protect from sporadic CRC, a mechanism
that may involve diminished STAT1 and STAT3 activation and reduced expression of STAT-
dependent genes (such as SOCS3). These data link the JAK/STAT pathway to human
colorectal carcinogenesis.
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Glutathione S-Transferase Polymorphisms (Gsts) and Risk of hepatocellular
carcinoma (HCC): A Meta-Analysis
Donna L. White, Donghui Li, Zhannat Z. Nurgalieva, Hashem El-serag
Background: GSTs are a highly polymorphic gene family encoding phase II isoenzymes
important in cellular detoxification of carcinogens. GSTM1 and GSTT1 have common deletion
polymorphisms leading to absent or reduced enzymatic activity. To date, few studies have
evaluated GST polymorphisms as potential risk factors for HCC. Interpretation of these
studies' findings has been limited, possibly due to restricted sample sizes. Our goal was to
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
identify available studies and perform meta-analyses to clarify the role of both GSTM1 and
GSTT1 null genotypes in relative risk of HCC. Methods: We performed keyword searches
in multiple databases including PubMed and Dissertation Abstracts. Eligible studies had a
case-group with HCC and an adequate control group (i.e., non-related, without HCC).
Searches and abstraction were performed by two reviewers and there were no restrictions
placed on language or sample size. A criterion of Higgins I2>49% was used to decide if
substantive between-study heterogeneity existed, necessitating use of a random-effects model.
We used meta-regression to identify possible sources of heterogeneity and Egger's test to
assess potential publication bias. Results:We identified 14 eligible studies (n= 2,254 cases,
n=4,176 controls). All 14 evaluated GSTM1 and 12 also evaluated GSTT1. All had case-
control designs. Most (10 studies)were performed in Asian populations. Substantive between-
study heterogeneity was apparent for both polymorphisms necessitating use of random-
effects models. Pooled estimators suggested possible small excess risk of HCC with GSTM1
or GSTT1 null genotypes; however, findings were significant only for GSTT1 (ORGSTM1=
1.23, 95% CI 0.93-1.62, ORGSTT1=1.22, 95% CI 1.004-1.492). Exploratory meta-regression
suggested differing sources of heterogeneity. For GSTM1, it was source of the controls, with
greater risk among hospital-based controls (ORhospital-based=1.52, 95 % CI 1.08-2.15 vs.
ORnon-hospital based=0.92, 95% CI 0.68-1.26). For GSTT1, it was ancestry, with greater risk
among Asians (ORAsians=1.31, 95% CI 1.003-1.72 vs. ORAfricans=1.02, 95% CI 0.75-1.39
vs. OREuropeans=1.09, 95% CI 0.71-1.68). Egger's test was non-significant for both polymorph-
isms suggesting absence of strong publication bias. Conclusions: In this meta-analysis, the
pooled estimators for GSTM1 and GSTT1 suggest possible small excess risk of hepatocellular
carcinoma with the null genotype. Additional research in larger samples and in other
populations is needed to further clarify the role of both polymorphisms in the etiology of
HCC and to investigate gene-environment interaction.
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Peripheral CRF Peptides and Stress-Induced Colonic Motor Alterations
Involve Cholinergic and Opioidergic Pathways in Rats
Mulugeta Million, Pu-qing Yuan, Juan C. Marvizon, Yvette Tache
Background: Corticotropin releasing factor receptor 1 (CRF1) and CRF2 are present in the
colonic tissue of rats and humans (J Neurochem. 90(2):309-16, 2004). Whereas CRF1
mediates stress and CRF-induced defecation and diarrhea in conscious rats (Gastroenetrology,
119:1569-79, 2000), the role of CRF2 receptors in the colon is unknown. The mechanism(s)
through which CRF receptors mediate colonic responses to CRF or stress is not clear. Aims:
1) Study the mechanisms involved in intraperitoneal (ip) injection of urocortin 1 (Ucn1)
and stress-induced colonic motor alterations in rats; 2) determine the role of peripheral
CRF2 in the response. Methods: Adult male SD rats (280-320 g) were injected IP, in 10
min interval, with either saline + saline; saline + non selective CRF1/CRF2 agonist Ucn1 (3
or 10 µg/kg); saline + selective CRF2 agonist, Ucn2 (10 µg/kg); A selective CRF2 antagonist,
astressin2-B (100 µg/kg) + Ucn1 (3 or 10 µg/kg); naloxone (1 mg/kg, sc) + Ucn1 (3 µg/
kg); or atropine (1 mg/kg, sc) + Ucn1 (3 µg/kg). In a separate study, rats were pretreated
with saline, Ucn2, naloxone or atropine and were submitted to 60 min water avoidance
stress (WAS). In all cases fecal pellet output (FPO) and diarrhea were monitored for 60
min. Colonic longitudinal muscle myenteric plexus (LMMP) whole mount preparations were
immunostained for CRF2 receptors, opioids, and NOS colocalization. Results: Compared
to saline (0.3±0.3 pellets/h and 0% diarrhea), Ucn1 at 3 and 10 µg/kg, increased FOP to
4.8±0.6 and 7.0±1.0 pellets/h and induced diarrhea in 0 % and 44% rats respectively.
Astressin2-B and naloxone enhanced the Ucn1 (3 µg/kg)-induced FPO to 7.1±1.2 and
7.0±1.3/h and the diarrhea response to 40%. By contrast, Ucn2 and atropine inhibited the
Ucn1 (3 µg/kg)-induced FPO to 1.2±0.5/h and 1.0±0.6/h respectively. Naloxone enhanced
the WAS-induced FPO (3.6±0.8 vs 6.8±1.1/h) while Ucn2 (0.5±0.5/h) and atropine (0.2±0.2/
h) inhibit the response. In colonic LMMP, CRF2 receptors are colocalized with CRF1 and
NOS and are in close proximity to opioid-positive fibers. Conclusions: Ucn1 or stress-
induced stimulation of colonic motor function is potentiated by blockade of CRF2 and
opioid receptors and abolished by cholinergic receptor blockade or activation of CRF2
receptors. The data suggest that the response involves interplay between a CRF1 mediated
excitatory cholinergic pathway that is opposed by simultaneous activation of a CRF2 mediated
inhibitory opioidergic pathway. CRF2 inhibitory signaling may play a stress-coping role
against the overwhelming CRF1-mediated colonic motility and secretion during stress. Sup-
ported by DK68155(MM), DK57238(YT)
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Stimulation of Neurokinin 3 Receptor (NK3R) Activates Protein Kinases (PK)
Cε and D in Intrinsic Primary Afferent Neurons (Ipans) of the Myenteric
Plexus
Daniel P. Poole, Silvia Amadesi, Enrique Rozengurt, Nigel W. Bunnett, John B. Furness
Activation of PKC enhances the excitability of IPANs of the small intestine through suppres-
sion of potassium currents. PKD, a family of 3 Ser/Thr kinases can be activated through a
PKC-dependent mechanism. However, the expression and function of PKD in the enteric
nervous system is unknown. By immunostaining, we localized PKD1/2 in 85±6% of NeuN-
positive IPANs in the myenteric plexus of the guinea-pig ileum, where PKD1/2 colocalized
with PKCε. We investigated activation of PKCε and PKD by studying trafficking in whole
mounts of longitudinal muscle-myenteric plexus. In untreated preparations, PKCε and PKD
were localized in the cytosol and there was no detectable signal for activated phospho-PKD-
S916. Senktide, an NK3R agonist, evoked a transient translocation of PKCε and PKD1/2
from the cytosol to the plasma membrane, and induced phospho-PKD-S916 at the plasma
membrane, indicative of activation. PKCε translocation to the membrane was maximal at
10 sec and returned to the cytosol within 2 min. PKCε translocation was observed in IB4,
NOS, calretinin and NPY-positive neurons, congruent with the NK3R expression pattern.
Phospho-PKD-S916 was also detected at the plasma membrane within 15 sec, and then
translocated to the cytosol by 2 min, where it remained active up to 30 min after NK3R
stimulation. PKD activation was detected in a subset of IPANs (69±10%), was reduced by
57% (p<0.05) using a PKCε translocation inhibitor peptide (1 µM), and prevented by the
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NK3R antagonist, SB235375 (1 µM). Tetrodotoxin (1 µM) had no effect on senktide-stimu-
lated activation of PKCε and PKD. To confirm that senktide activates PKCε and PKD, we
studied HEK293 cells transiently expressing NK3R and GFP-tagged kinases. In unstimulated
cells, PKCε and PKD1-3 were cytosolic. Senktide (1 µM) induced membrane translocation
of all kinases within 30 sec. After 15 min, kinases had almost entirely returned to the cytosol.
To confirm PKD activation, we used an antibody to phospho-PKD-S744/748. In unstimulated
cells, there was minimal detectable PKD phosphorylation. Senktide increased phospho-PKD-
S744/748 at the plasma membrane within 30 sec, and phospho-PKD-S744/748 was detected
in the cytosol after 15 min. Using phospho-PKD-S744/748, PKD activation was confirmed
by Western blotting. Thus, stimulation of NK3R results in activation of PKCε and PKD at
the plasma membrane, and PKCε mediates PKD activation. Since NK3R partially mediates
the slow synaptic transmission between IPANs, these kinases may regulate the excitability
of IPANs and thereby contribute to functional bowel disorders. Supported by NIH DK39957,
DK57840, NH&MRC Australia.
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Intestinal Afferent Nerve Sensitivity to Bradykinin Is Reduced Following
Pretreatment with a New Herbal Preparation in Rat In Vitro
Mario H. Müller, Qian Gong, Andrej Sibaev, Olaf Kelber, Martin Storr, Li Yongyu, Martin
Kreis
Background: Visceral afferent sensitivity seems to be involved in the pathophysiology of
functional bowel disorders. The herbal preparation STW 5 containing 9 different extracts
reduces intestinal afferent nerve sensitivity to different mechanical and chemical stimuli
(Neurogastroent Motil 16: 759-64 (2004). We aimed to determine whether a new simplified
herbal preparation also reduces sensitivity to intestinal afferents in rat. Methods: The prepara-
tion STW 5-N II (containing 6 herbal extracts) or vehicle were administered orally in male
Wistar rats (250-350g) at a dose of 2.5, 5 or 10 mlkg-1 (n=6-7 per group, gavage volume
always 10 mlkg-1). Two hours later, animals were anesthetized (pentobarbitone 60 mgkg-
1, i.p.) and extracellular multi-unit mesenteric afferent nerve recordings were obtained in
the proximal jejunum. Afferent discharge to luminal distension (0-60 cmH2O), bradykinin
(15, 30 and 60 µg kg-1 i.v.) and 5-HT (5, 10, 20 and 40 µg kg-1, i.v.) were recorded. Peak
discharge frequency was analyzed by two-way ANOVA. Results: At baseline, spontaneous
afferent nerve discharge was not different following pretreatment with the various doses of
STW 5-N II compared to vehicle. Afferent nerve sensitivity to bradykinin but not to 5-HT
was significantly different depending on the dose of pretreatment with STW 5-N II. After
the highest oral dose (10 ml), afferent discharge to bradykinin was 106±19, 153±22, and
156±25 impsec-1 (bradykinin at 15, 30, 60 µgkg-1, mean±SEM) compared to 160±15,
228±14 and 221±16 impsec-1 following vehicle pretreatment (p<0.05 for both, dose of
bradykinin and STW 5-N II dose). A pressure-dependent increase in afferent nerve discharge
was observed during intraluminal distension that was not different following pretreatment
with any dose of STW 5-N II. Conclusions: The herbal preparation STW 5-N II desensitized
intestinal afferents selectively to systemic bradykinin, which is a key mediator for pain
perception. The reduced number of ingredients in this new preparation may account for
its selective action in contrast to the previously investigated STW 5. STW 5-N II may have
a beneficial effect in patients suffering from disorders associated with visceral hypersensitivity.
183
The Glucagon-Like Peptide -1 (GLP-1) Agonist Exendin-4 Excites Nodose
Ganglion Neurons and Inhibits Voltage Gated Potassium Currents
Gregory Gaisano, Michael Beyak
GLP-1 is well known as an incretin hormone, enhancing glucose stimulated insulin secretion.
Recent human and animal studies have indicated that GLP-1 and the GLP-1 agonist, exendin-
4, inhibit food intake and result in weight loss, indicating that GLP-1 receptors may be
target for anti-obesity therapies. The satiety actions of GLP-1 are believed to occur through
effects on vagal afferents. However the mechanism of action on vagal afferents is unknown.
Aims: To characterize the effects of GLP-1 agonists on nodose ganglion neurons, and test
the hypothesis that activation of the GLP-1 receptor inhibits voltage gated potassium channels.
Methods: Nodose ganglia were harvested from male mice, and neurons were dissociated
and plated onto glass coverslips. Perforated whole cell patch clamp recordings were performed
24-48 hours later. Responses of the membrane potential to GLP-1 agonists were tested in
physiological solutions. Potassium currents resulting from a series of voltage commands
were recorded in Na free external solution. Drugs were applied using a fast flow perfusion
system. Exendin-4 was used as a GLP-1 agonist. Results: Exendin-4 (100nM) depolarized
40% (6/15) of nodose ganglion cells. The mean depolarization was 6.5±.45 mV, and in 2
cells this resulted in spiking. In spontaneously active cells (n=4), Exendin -4 resulted in a
marked increase in the firing rate (2.5±.4 spike/s vs 5.5±0.7 spikes/s, p=0.02). In voltage
clamp recordings, stepwise voltage commands resulted in outward currents with the charac-
teristics of transient Ia and sustained Ik (delayed rectifier) currents in all cells tested. Exendin-
4 (100nM) resulted in a significant suppression of potassium currents in 38% of nodose
cells, the effect becoming apparent within 2 minutes, and becoming maximal at 6 minutes.
The peak outward current was suppressed by 43±6.5% (p<0.05). Conclusions: GLP-1
receptor activation results in depolarization of a subpopulation of mouse nodose ganglion
neurons. Mouse nodose ganglion neurons express Ia and Ik like voltage gated potassium
currents. Voltage gated potassium currents were suppressed by the GLP-1 agonist, exendin-
4. As potassium currents are a major mechanism limiting neuronal excitability, suppression
of voltage gated potassium currents is a likely mechanism by which GLP-1 receptor activation
increases vagal afferent activity, and therefore a likely mechanism by which they limit
food intake.
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Agonists of Bitter Taste Receptors Activate the Vagal Afferent Pathway Via
Cholecystokinin Type 1 Receptors (CCK1Rs) and PYY Type 2 Receptors
(Y2Rs) in the Gastrointestinal Tract in Mice
Shuzhen Hao, Catia Sternini, Helen Raybould
Recent evidence suggests that the G-protein coupled receptors signaling bitter taste (T2Rs)
in the gustatory system are expressed in the GI tract. The α subunit of the taste-specific G-
protein gustducin (Gαgust) co-localizes with PYY and activation of T2Rs increases CCK
release from the enteroendocrine cell line, STC-1. The aims of the present study were to
determine whether activation of T2Rs in the GI tract stimulates the vagal afferent pathway
via CCK1Rs or Y2Rs and determine the effect on food intake. Methods: Activation of the
vagal afferent pathway was determined by immunohistochemical localization of Fos protein
in neurons in mid-region of nucleus of solitary tract (NTS; bregma -7.32 to -7.76 mm)
following intragastric gavage of a mixture of bitter taste agonists (denatonium, DB 10mM;
phenylthiocarbamide, PTC 10mM; 6-propyl-2-thiouracil 5mM; quinine 5mM; D-[-]salicin
5mM) or vehicle (0.1 ml water), or after intragastric administration of agonists DB and PTC
(10 mM) specific for two different T2R transcripts, mT2R108 and mT2R138, respectively.
Experiments were performed in mice pretreated with the CCK1R antagonist devazepide (1
mg/kg IP) or peripherally-acting Y2R antagonist BIIE0246 (2mg/kg IP), or in CCK1R-/- mice
and wildtype controls. Food intake of chow was determined during the dark cycle in mice
fed ad libitum after gavage of DB or PTC (10 mM) or vehicle control. Results: Intragastric
administration of the mixture of T2R agonists significantly increased the number of fos-
positive neurons in the NTS (# fos-positive neurons; 154 ± 30 vs 456 ± 96, vehicle vs T2R
agonists, p<0.05, n=4-5 in each group); subdiaphragmatic vagotomy abolished the NTS
response to the mixture (p<0.05, n=4). Agonists for specific T2R transcripts, DB and PTC,
both activated neurons in the NTS (p<0.01; n=4,5). Lack of CCK1R (CCK1Rs-/- mice) or
CCK1R blockade abolished the activation of NTS neurons in response to DB, but had no
effect on the response to PTC. Similarly, administration of the Y2R antagonist blocked
activation of NTS in response to DB (p<0.05, n=4) but not PTC. Intragastric administration
of PTC, but not DB, before onset of feeding significantly inhibited food intake (food intake
in 2 hr in mgs/gm BW; 90 ± 8 vs 67 ± 5 mgs, water vs PTC, P<0.05; n=5. Conclusions:
Activation of T2Rs in the GI tract stimulates neurons in the NTS via the vagal pathway via
a pathway involving CCK1Rs and Y2Rs. These data suggest that T2Rs play a role in regulating
GI function via release of regulatory peptides and activation of the vagal afferent pathway.
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Acute Stress-Induced Hypersensitivity to Rectal Distension Depends Upon
Increase of Luminal Serine-Protease Activity in Rats: Involvement of CRF
Helene Eutamene, Vassilia Theodorou, Chantal Chabo, Mathilde Leveque, Aurelie Waget,
Jean Fioramonti, Laurent Ferrier, Lionel Bueno
Background and aims: Increase of colonic paracellular permeability induced by partial
restraint stress (PRS) triggers rectal hypersensitivity to distension in rats. Intracolonic infusion
of proteinase-activated receptor-2 agonist or serine proteases such as trypsin also increases
colonic permeability and sensitivity. The aims of this study were to determine whether 1)
PRS is able to increase colonic or fecal serine-protease activity in rats; 2) this increase
participates to stress-induced rectal hypersensitivity; 3) the increase of colonic protease
activity involves corticotrophin-releasing factor (CRF). Methods: Groups of female Wistar
rats were used. Serine protease activity (SPA) and Rat Mast Cell Protease II (RMCPII) levels
were determined in both colonic contents and fecal pellets in rats submitted to 1) IP
administration of CRF (50 μg/kg), 2) a 2 hour PRS session, 3) a PRS plus α-helical CRF 9-
41 (250 μg/kg IP) or SSR-125543 (a CRF-1 receptor antagonist, 10 mg/kg IP) or vehicle
pre-treatment. The abdominal cramps reflecting visceral pain were assessed in rats previously
fitted with an intracolonic catheter and equipped with electrodes implanted in the abdominal
striated muscle. Four hours before and 20 min after PRS, a RD was performed using a
Fogarty probe inflated from 0 to 1.2 ml in rats intracolonically infused with nafamostat (a
serine-protease inhibitor, 0.5 mg/rat) or vehicle (NaCl 0.9%) 1 h before and during the PRS
session. Results: Compared to control, CRF as well as PRS significantly increased SPA in
both fecal (0.92 ± 0.25; 1.10 ± 0.18 vs 0.40 ± 0.12 UA trypsin/mg protein) and colonic
content (0.80 ± 0.13; 0.89 ± 0.20 vs 0.43 ± 0.09 UA trypsin/mg protein) in rats. A previous
treatment by α-helical CRF 9-41 or SSR-125543 suppressed the PRS-induced colonic/fecal
contents SPA increase. In contrast, no changes in RMCPII levels determined in fecal pellets
or colonic contents in the different groups of animals were observed. PRS significantly
increased (p<0.05) the number of abdominal cramps for all RD volumes applied, reflecting
colonic hypersensitivity. Intracolonic infusion of nafamostat supressed (p<0.05) the increase
in number of abdominal cramps induced by PRS, for all RD volumes. Conclusion: The
increase of colonic serine protease-activity induced by stress is mediated by CRF release
and participates, through altered permeability, to stress-induced rectal hypersensivity in rats.
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Prevalence and Geographical Distribution of Crohn's Disease and Ulcerative
Colitis in the United States
Michael Kappelman, Sheryl Rifas-shiman, Athos Bousvaros, Richard J. Grand, Daniel
Ollendorf, Ken Kleinman, Jonathan Finkelstein
Background and Aims: Previous U.S. epidemiologic studies of IBD have sampled small,
geographically restricted populations and may not reflect the nation as whole. We sought
to 1) Determine the prevalence of Crohn's disease (CD) and ulcerative colitis (UC) in a
large, national sample and 2) Compare their prevalence across geographic regions and
sociodemographic characteristics. Methods: We analyzed a proprietary database of adminis-
trative data pooled from 87 health plans in 30 states, and identified cases of CD and UC,
among all persons with 2 years of continuous enrollment, using a threshold of at least 3
IBD-associated visits or at least 1 visit and 1 IBD-specific prescription filled. Prevalence (the
number of cases divided by persons in the source population) was stratified by geographic
region (NE, S, MW, and W), age, gender, and insurance type (Medicaid vs. Commercial).
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Odds ratios (OR) with 95% confidence intervals (CI) from logistic regression were used for
comparisons among geographic regions and sociodemographic variables. To estimate the
number of cases of IBD in the U.S., the prevalence for each age group was weighted by
corresponding U.S. Census 2000 data. Results: Among the source population of 9 million
Americans, the overall prevalences of CD and UC among children and adolescents (age <
20) were 43 (95% CI 40-45) and 28 (95% CI 26-30) per 100,000. In adults, the overall
prevalences of CD and UC were 201 (95% CI 197-204) and 238 (95% CI 234-241),
respectively. The prevalence of each condition increased with age, though leveled off for
CD after age 30. The prevalence of CD was highest in the Northeast and least in the South
(OR 1.2, 95% CI. 1.1-1.2); this was similar in UC (OR 1.2 95% CI 1.2-1.3). For children,
the prevalence of CD was lower in females (OR 0.82, 95% CI 0.73- 0.92); UC was similarly
less common in females (OR 0.91, 95% CI 0.78, 1.05). In adults, CD was more common
in females (OR 1.2, 95% CI 1.1- 1.2], but no gender difference was seen in UC (OR 1.0,
95% CI 0.97 - 1.0). Commercially insured individuals appeared more likely to have CD
(OR 1.4, 95% CI 1.2- 1.7) and UC [OR 2.1, 95% CI 1.7- 2.5) than those insured by
Medicaid. Conclusions: Based on these data from a large, geographically and sociodemo-
graphically diverse population, and extrapolation using US Census data, approximately
450,000 Americans have CD, and 520,000 have UC. Nearly 28,000 CD and 19,000 UC
patients are children, thus emerging IBD therapies qualify for orphan drug designation. The
prevalence of IBD is dependent on age, gender, socioeconomic status, and geographic region;
however, geographic variation may be less than previously reported.
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Co-Existence of IBS-Related Symptoms in Patients with Crohn's Disease - A
Real Association Or a Reflection of Occult Inflammation?
John Keohane, Caitlin O'mahony, Liam O'mahony, Seamus O'mahony, Eamonn M.
Quigley, Fergus Shanahan
Background: It has been suggested that some of the symptoms of Crohn's disease (CD)
patients may be related to co-existing irritable bowel syndrome (IBS). However, if both
inflammatory bowel disease (IBD) and IBS are, by definition, mutually exclusive, this becomes
a circular argument and difficult to resolve without repeated invasive tests. The availability
of a non-invasive surrogate marker of acute inflammation, such as fecal calprotectin, may
help resolve whether symptoms in patients thought to be have quiescent disease are due to
co-existing IBS, or in fact, are secondary to occult inflammation. Aims: (1) To determine
the prevalence of IBS symptoms in patients thought to be in remission with Crohn's disease;
(2) To determine whether IBS symptoms in these patients correlate with fecal calprotectin.
Methods: Consecutive patients were prospectively recruited from a specialty IBD clinic.
Clinical remission with was defined in advance, on the basis of both the patient's and
physician's assessments, and by CDAI < 150, CRP < 10, while off corticosteroids or acute
immunomodulatory drugs. Quality of life (by IBDQ) and the hospital anxiety and depression
scale (HAD) were also both assessed. Faecal calprotectin was measured using a quantitative
enzyme linked immunosorbent assay specific for calprotectin (Phical test, CALPRO AS).
Results are available for the first 44 patients (F:M=18:26) of this ongoing study; 45 % (
n=20) fulfilled Rome ΙΙ criteria for IBS, despite being considered to be in remission for CD
by the predefined criteria (above). However, fecal calprotectin levels were significantly
elevated (574+/- 126 mg/kg mean +/- SEM) over normal (<60) indicating the presence of
occult inflammation. Furthermore, calprotectin levels in the group of CD patients with IBS
criteria were significantly higher than in those without IBS-type symptoms (402.0 ± 112 vs
180.2 ± 74.3, SEM; p=0.034). There was no significant difference between the groups in
terms of gender, smoking status, surgical history or previous immunomodulatory drug use.
HAD scores (mean=11.4) were elevated but with no significant difference between the
groups. Conclusions: (1) Symptoms compatible with IBS are common in patients with
Crohn's disease attending a specialist referral clinic who are thought to be in clinical remission;
(2) Since IBS-related symptoms were linked with elevated calprotectin levels, it is likely that
the mechanism is due, in most cases, to occult inflammation rather than truly co-existing IBS.
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Outcome of Sporadic Adenomas and Adenoma-Like Dalms in Patients with
Ulcerative Colitis
John B. Kisiel, Edward Loftus, William S. Harmsen, Alan R. Zinsmeister, William J.
Sandborn
Background: Patients (pts) with ulcerative colitis (UC) are at increased risk of colorectal
cancer (CRC), with extent and duration of disease and primary sclerosing cholangitis (PSC)
being important risk factors. Recent studies suggest that sessile or pedunculated dysplastic
lesions resembling sporadic adenomas may be safely removed with endoscopic polypectomy,
despite occurring in involved mucosa. Methods: A centralized diagnostic index was used to
identify CUC pts at our institution between 1994 and 2004 who were found to have polypoid
dysplasia and were followed from the time point of polypectomy until the most recent
colonoscopy. They were stratified into two groups by polyp occurrence within (adenoma-
like DALM, ALD) or outside (sporadic adenoma, SA) the most proximal endoscopic or
histologic extent of colitis. End-points were progression to cancer or the occurrence of flat
dysplasia and all-cause mortality. Those with prior flat lesions and CRC were excluded.
Survivals were estimated using Kaplan Meier method and factors associated with survival
were assessed using Cox proportional hazards regression. Results: A total of 102 CUC pts
were found to have polypoid dysplasia-of these, 85 underwent polypectomy. Forty-two pts
(49%) had ALDs and 43 (51%) had SAs. Median age at UC diagnosis was 42 years (range,
14-83). Median duration of CUC prior to first polyp occurrence was 10.7 years (0-46). The
median duration of follow-up in the 80 pts without flat dysplasia or cancer at latest follow-
up was 1.8 years (1 day -20 years). Five-year survival was 88% (95% CI=80%-97%) in the
polypectomy group overall, and 87% and 90% among SA and ALD pts, respectively (p=
0.54). Four pts in the ALD group (9.5%) had prior PSC as did 5 patients in the SA group
(12%). In a model including ALD status, PSC was associated with an increased risk of all
cause mortality (HR 4.7, 95% CI = 1.0-21). None of the pts with PSC in either group
developed flat dysplasia or cancer. One pt in each of the groups developed a cancer. Three
in the ALD group developed subsequent flat dysplasia or cancer, compared to 2 in the SA
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group (HR 0.99, 95% CI=0.2-6.0). The cumulative incidence of cancer or flat dysplasia at
1, 3, and 5 years was 0%, 7%, and 19%, respectively, among those with SAs, versus 3%,
8%, and 18% among those with ALD. Discussion: Previous studies have concluded that
polypectomy may be safe for the management of adenomas occurring in CUC pts. In our
large cohort, which included pts with PSC, this may also be a safe strategy. However, the
occurrence of the combined end-point of cancer or flat dysplasia was higher than previously
reported (6% verus 0-3%).
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The HLA-G 14bp Ins-Del Polymorphism Influences Response to Methotrexate
in Inflammatory Bowel Disease
Bijay Baburajan, Natalie Prescott, Melissa Smith, Azhar Ansari, Monica Arenas, Klaus
Herrlinger, Fraser Cummings, Mark Tremelling, Miles Parkes, Chris Mathew, Derek P.
Jewell, Anthony M. Marinaki, Jeremy D. Sanderson
Introduction: HLA-G antigens have a recognised role in chronic inflammation and auto-
immune diseases. Membrane bound and soluble HLA-G has been shown to correlate with
increased IL-10 levels. A 14-bp deletion polymorphism in exon 8 at the 3' UTR of the HLA
-G gene has been associated with the development of auto immune disease. It has also been
associated with efficacy of Methotrexate (MTX) therapy in rheumatoid arthritis possibly via
increased IL-10 levels. MTX is well established as a standard second line immunosuppressant
in the treatment of inflammatory bowel disease (IBD). Aims: The aim of this study was to
determine the influence of the HLA-G 14bp ins-del polymorphism on clinical response to
MTX in patients with IBD and compare this to any effect amongst those receiving azathioprine
(AZA). Methods: 171 patients with IBD treated with Methotrexate and 96 treated with
Azathioprine were included. Clinical response was defined as complete steroid withdrawal
for at least 3 months with a duration of immuno modulatory therapy of at least 3 months.
Genotyping was performed by fluorescent PCR and size-based allelic discrimination by
capillary based liquid polyacrylamide gel electrophoresis. The two sided Fisher's exact test
was used to calculate significance. Odds ratios are reported. Conclusions: The hypothesis
that the 14 bp ins/del mutation influences clinical response to MTX therapy is confirmed
and suggests that upregulation of IL-10 expression plays an important role in the mechanism
of action of MTX in IBD. The lack of a correlation with response to AZA, which has a
differing mode of action, is in keeping with this. The SNP will require further validation in
a large series to confirm it's role as a clinically useful pharmacogenetic marker of MTX efficacy.
MTX Group
The two-sided P value = 0.0063, Relative risk = 1.723, 95% CI: 0.136 to 2.613
AZA Group
The two-sided P value is 0.5238, Relative risk = 0.8373,95% CI: 0.5696 to 1.23
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Hospital Acquired Infections Increase Mortality and Length of Stay in IBD
Raffi Karagozian, Richard S. Johannes, Stephen Kurtz, Robert Burakoff
INTRODUCTION: The recent activity surrounding public reporting of hospital acquired
infections (HAI) has stimulated attention and new questions. There has been little information
about disease specific risks and disease specific outcomes outside of the ICU setting. Patient
data was generated from the Cardinal Health Research Database, a large population dataset
that has supported publicly reported hospital performance in Pennsylvania (PA) for 20 years.
This was supplemented by recent PA data, the first state to issue a public report on HAI,
to examine risk adjusted affects of HAI on mortality and length of stay (LOS) outcomes for
patients hospitalized for inflammatory bowel disease (IBD). METHODS: The population for
this study was all discharges from acute care hospitals in PA with ICD-9CM codes of 555.x,
556.x, 564.7 or 569.82. An existing logistic risk adjustment model for mortality that has
been previously applied to a variety of intestinal diseases was recalibrated for the IBD
population. This model contains 9 covariates including age, vital signs (pulse, respiratory
rate), laboratory data (albumin, BUN, Na, K, Ca, history and physical exam findings (megaco-
lon, vascular insufficiency) and has a c-statistic of 0.921. These data were linked to the
Cardinal Database and a 5 to 1 multivariate matching was done to create a comparison
population with equivalent admission risk. Mortality and LOS were the outcomes examined.
RESULTS: In 2004, there were 2986 IBD cases across 173 hospitals. There were 32 deaths
and 27 reported cases of HAI, (Table 1). The mortality rate for HAI in IBD was 11.1%
compared with 0.7% in risk matched controls (p<0.015, Fisher's Exact) and the odds ratio
for mortality was 16.8 (1.7, 167.8 95CI). The mean LOS for HAI in IBD was 26.2 days
versus 7.7 days in the controls (p < 0.001, Student's t-test). Of the 27 cases with HAI and
IBD, 16 were attributed to urinary tract infection, 7 to blood stream infection and 4 to multiple
sources. CONCLUSIONS: Large population based dataset suggests a large incremental effect
in adverse mortality & LOS outcomes in IBD who develop HAI. The majority of these cases
appear to be from urinary sources. These findings are currently being corroborated with a
retrospective chart review with patients admitted with IBD at Brigham and Women's Hospital.
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However, it appears that vigilance against HAI in IBD cases could substantially improve out-
comes.
Outcome of IBD cases across 173 hospitals in Pennsylvania, 2004.
Table 1
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Do Currently Available Disease Activity Indices Measure the Symptoms That
Ulcerative Colitis Patients Experience During a Flare?
Akbar K. Waljee, Joel C. Joyce, Tahira M. Khan, Ellen M. Zimmermann, Patricia Wren,
Peter D. Higgins
Background: The current disease activity indices for ulcerative colitis (UC) were developed
without formal patient input. It is not known whether these indices reflect the symptoms
that are important to patients in evaluating the severity of a flare of UC. Aim: To evaluate
whether the symptoms that patients report as important to them during an ulcerative colitis
flare are represented in current disease activity indices for UC. Methods: Qualitative study
conducted in 2006 involving five focus groups (25 total patients). Patients over the age of
18 who had biopsy-proven UC and who had not undergone total colectomy for UC particip-
ated in an in-depth semi-structured group interview. This convenience sample of participants
was identified by ICD-9 code 556 in University of Michigan records, and recruited by direct
mailing. Focus group meetings were audiotaped and transcribed. NVivo 2.0, a qualitative
research software program, was used to code relevant symptom domains. The transcripts
were independently coded by two reviewers and codes were compared for agreement. The
symptom items included in commonly used UC disease activity indices (Mayo Index, UCDAI,
UCCS, St. Mark's Index, Lichtiger Index, SCCAI, Seo Index) were pooled to generate a
comprehensive list of 27 items for comparison. Results: Without specific prompting, patients
in this sample confirmed 16 items but did not discuss or mention 11 other items found in
the commonly used UC activity indices. Items endorsed by patients and the UC activity
indices included stool frequency, urgency, blood, and consistency. Symptom items that were
not mentioned as important by patients included tachycardia, physician assessment, anemia,
need for antidiarrheals, arthritis, eye symptoms, and skin manifestations of IBD. In focus
groups, patients identified an additional 14 items not included in commonly used UC activity
indices which they believed to be important in personally evaluating the onset or severity
of a UC flare. These included: flatulence, stool mucus, fatigue, chills, lightheadedness, aching,
bloating/distension, insomnia, anxiety, and borborygmi. Additionally, patients reported other
factors related to food, emotions, and their sense of self control that were important aspects
of their experience of flares that were distinct from their disease symptoms. Conclusions:
Current indices capture only a portion of the clinical symptoms that are important to patients
in a UC flare. A number of symptoms included in current indices were not identified as
important by patients. Current indices may neither accurately measure nor fully reflect
patients' experience of UC.
192
Chemokine Receptor Cxcr4 in IBD Patients May Contribute to Progression to
Cancer By Stimulating EGFR Signaling and Metalloprotease Expression
Christopher B. Forsyth, Ali Banan, Ashkan Farhadi, Dana Hayden, Ali Keshavarzian
Inflammation is a risk factor for many cancers. For example, inflammatory bowel disease
(IBD), which includes Ulcerative Colitis (UC) and Crohn's Disease (CD), is associated with
increased risk for colorectal cancer (CRC). But the mechanisms underlying inflammation-
induced CRC initiation and progression are not known. Chemokines are secreted peptides
used to communicate between cells and are typically upregulated in inflammation and
cancer. One chemokine receptor/ligand pair recently shown to play a key role in breast cancer
progression and metastases is CXCR4/CXCL12. The goal of this study was to investigate a
possible role for CXCR4/CXCL12 in progression of IBD to CRC. Hypoxia (low oxygen) is
common at sites of inflammation including IBD and cancer and both CXCR4 and CXCL12
have hypoxia-inducible elements in their promoters. Because normal intestinal epithelial
cells (IEC) express low CXCR4/CXCL12, we hypothesized their upregulation in IBD due to
chronic hypoxia could play a role in progression to CRC in some patients. We therefore
examined the expression of CXCR4 and CXCL12 in biopsy samples from IBD patients and
normal controls. RT-PCR data show low basal expression of CXCR4 and CXCL12 in normal
controls with dramatically increased expression 3-5 fold in biopsy samples from IBD patients.
We next sought to determine mechanisms by which CXCR4 signaling could promote carcino-
genesis. Two key factors overexpressed in CRC are the epidermal growth factor receptor
(EGFR) and matrix metalloproteases (MMPs). Using an In Vitro IEC cell line (human Caco-
2) we show that CXCL12 stimulates transactivation of the EGFR. This transactivation can
be blocked with inhibitors of CXCR4 and PKC as well as the EGFR and metalloproteases,
indicating cleavage of EGFR ligands is required for transactivation. We next sought to
determine the effect of CXCR4 stimulated EGFR signaling on MMP production by IEC.
Under normoxic conditions only low levels of MMPs were produced. However, under
hypoxic conditions CXCL12 simulated 10-20 fold increased production of MMP-2,-7, and
-9, all MMPs associated with CRC progression and poor prognosis. In addition our RT-PCR
data confirms the upregulation of these MMPs in biopsies from IBD patients correlates
closely with increased CXCR4 expression. In conclusion our ex vivo and In Vitro data support
a model in which hypoxia present in IBD may drive expression of CXCR4/CXCL12. Increased
CXCR4 signaling could drive progression to CRC via increased EGFR signaling as well as
increased expression of CRC promoting MMPs. These data support CXCR4 as a possible
prognostic and therapeutic target in future studies of IBD-induced CRC.
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Chemopreventive Effects of mesalazine Through Inhibition of DNA
Methyltransferases and Reactivation of Methylation-Silenced Genes in Human
Colon Cancer Cells
Ajay Goel, Takeshi Nagasaka, Christoph Gasche, C. richard Boland
Current literature indicates that mesalazine has anti-inflammatory effects in inflammatory
bowel disease (IBD), and prevents IBD-associated colorectal cancer (CRC). However, the
molecular mechanisms by which mesalazine inhibits carcinogenesis are uncertain. It has
been proposed that mesalazine may participate in the control of cell cycle progression,
apoptosis, NF-kB activation, and improvement of DNA replication fidelity which stabilizes
microsatellite sequences. Although never previously studied in the context of mesalazine,
methylation-induced silencing of tumor suppressor genes is another key mechanism that
has been demonstrated in IBD-associated CRC. Aim: In this study we tested the hypothesis
that mesalazine may prevent inflammation-driven carcinogenesis through promoter
demethylation, which would permit re-expression of methylation-silenced tumor suppressor
genes. Methods: Four human CRC cell lines (SW48, RKO, HT-29 and SW837) were treated
with growth inhibitory concentrations (0-2.5 mM) of mesalazine for 7-14 days. Following
treatment, the cell lines were harvested and the cell pellets processed for DNA, RNA and
protein extractions. TaqMan reverse transcriptase polymerase chain reactions (RT-PCR) were
performed to determine mRNA expression levels of the DNA methyltransferases (DNMT)
DNMT1 and DNMT3b. DNA was bisulfite-modified and subjected to combined bisulfite
restriction analysis (COBRA) methylation analysis of MGMT, HPP1, SFRP2, CDKN2A and
3OST2 genes. COBRA analyses were subsequently confirmed by direct bisulfite sequencing,
as well as pyrosequencing. Results: Mesalazine treatment resulted in a significant inhibition
in mRNA expression of DNMT1 (p<0.001) and DNMT3b (p<0.01) in HT-29, SW837 and
RKO cells after 7 and 14 days of treatment. Mesalazine treatment resulted in a marked
demethylation of the promoter regions of MGMT and SFRP2 in SW48 and SW837 cells.
All methylation changes observed by quantitative COBRA and pyrosequencing analyses were
confirmed by automated direct bisulfite sequencing of the methylated gene promoters.
Conclusions: These results demonstrate a novel molecular mechanism for the action of
mesalazine, in which inhibition of key DNA methyltransferases is associated with demethyl-
ation of transcriptionally-silenced genes implicated in CRC. Since aberrant methylation of
tumor suppressor genes is an epigenetic modification that is important in the development
of IBD-associated CRC and happens early in the multistep progression of these neoplasms,
screening patients for epigenetic signatures of gene methylation and timely institution of
mesalazine therapy may improve the control of IBD-associated CRCs.
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Toll-Like Receptor-4 (TLR4) Is Required for Colitis-Associated Neoplasia in a
Murine Model of Inflammatory Bowel Disease (IBD)
Masayuki Fukata, Anli Chen, Keith Breglio, Daisy Conduah, Tyralee Goo, Ruliang Xu,
Andrew Dannenberg, Kotha Subbaramaiah, Harry S. Cooper, Maria T. Abreu
Background: The link between inflammation and cancer in patients with IBD remains unclear.
We have recently demonstrated that TLR4 regulates intestinal cyclooxygenase-2 (Cox-2)
expression and prostaglandin E2 (PGE2) production in acute colitis. We have also described
TLR4-induced EGFR activation. In this study, we tested the hypothesis that TLR4 is involved
in tumorigenesis in the setting of chronic inflammation. Methods: Azoxymethane (AOM)
injection followed by dextran sodium sulfate (DSS) treatment was used to induce colonic
tumors in TLR4-deficient (TLR4-/-) or wild-type (WT) mice. Inflammation, polyps, and
microscopic dysplasia were scored. Intestinal epithelial cell (IEC) proliferation was assessed
using BrdU staining. Cox-2 and PGE2 production were analyzed by real-time PCR, immuno-
histochemistry, or enzyme immunoassay. TLR4 expression and EGFR phosphorylation were
examined by Western blot analysis and immunohistochemistry. Results: All WT mice (n=
18) had at least one dysplastic lesion and up to 17 lesions per mouse. In contrast, only 5
of 18 TLR4-/- mice (27.8%) had one or two dysplastic lesions (tumors/animal: WT 5.4±1.2
vs. TLR4-/- 0.4±0.2, P<0.001). The absence of TLR4 signaling also decreased the size of
colorectal dysplasia (average size: 3.6±0.4mm in WT mice vs. 1.3±0.3mm in TLR4-/- mice,
P<0.05). Increased proliferation was observed in IEC within dysplastic lesions and in the
surrounding epithelium in WT mice compared with TLR4-/- mice. TLR4 expression was
increased in dysplastic lesions of WT mice. Both Cox-derived PGE2 and EGFR can contribute
to deregulated cell proliferation. Consistent with this notion, Cox-2 expression,and mucosal
PGE2 production were significantly decreased in TLR4-/- mouse colons. Phosphorylation of
EGFR was increased in the dysplastic lesions of WT mice but not of TLR4-/- mice. Conclusion:
TLR4 signaling is critical for both initiation and growth of tumors in the setting of chronic
colitis. Sustained activation of TLR4 may promote development and growth of dysplasia via
Cox-2-induced PGE2 production and EGFR activation. TLR4 may be a target for prevention
of colitis-associated neoplasia.
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Activated Neutrophils (Pmns) Increase Mutations At Repetitive (Ca)
Sequences in Colon Epithelial Cells
Christoph Campregher, Maria gloria Luciani, Christoph Gasche
Exposure of colon epithelial cells to ROS has been implicated in inflammation-driven carcino-
genesis. Previously we introduced a coculture model with PMNs that activates an hMLH1-
independent G2-M checkpoint in colon epithelial cells (Campregher, DDW2006). Herein,
we tested the effect of PMNs in increasing mutations at poly-(CA) tracts, which is considered
an early feature of inflammation-driven cancer. METHODS: HCT116 (hMLH1-/- clones A1.3
and A2.1) and HCT116+ch3 (hMLH1-/+ clones A3.1 and A3.7) which had been stably
transfected with pIREShyg2-EGFP/CA13 (Gasche, PNAS 2003) were cocultured with freshly
isolated human PMNs. Before co-culture, PMNs were activated with PMA (50ng/mL for
30min), washed twice, and O2− release was measured by lucigenin-amplified chemilumines-
cence. Cells were cultured at ratios from 1:10 to 1:200 (target:effector cells) for 24 hours
before PMNs were removed. Target cells were grown for additional 7 days. The total cell
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number (c) and the EGFP-positive fraction [mutant fraction (MF)] were analyzed by flow
cytometry. The mutation rate [m/(CA)13/generation (gen)] was estimated by m = MF/(gen+1)
and gen =log2(c/1000 x cloning efficiency). The amount of apoptosis was measured by
annexin/PI staining. Data are mean (SD). RESULTS: At a ratio of 1:10, apoptosis increased
in HCT116+ch3 from 5.9% (0.8) to 13.4% (0.7) and in HCT116 from 6.0% (1.2) to 7.2%
(0.1). The total cell number (c) decreased upon co-culture according to cell ratios and
hMLH1-status of target cells but less to O2− release (table). The MF and m increased in
clones A3.1 (harboring 1 plasmid copy) and A3.7 (harboring 2 plasmid copies) but not in
hMLH1-/- cells. These effects plateaued at ratios above 1:100. No changes in c, MF and m
were observed with non-activated PMNs. CONCLUSIONS: Our data suggest that coculture
of activated PMNs causes an increase of mutation rate at poly-(CA) tracts in target cells. As
frameshift mutations occur as a time-dependent function of polymerase errors followed by
failure of post-replicational repair, and as such an increase was not present in hMLH1-/-
cells, we believe that factors released by PMNs interfere with post-replicational repair rather
than polymerase fidelity or DNA integrity.
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Nf-κB As a Target for Histone Deacetylase Inhibitors in Models of
Inflammation-Related Tumorigenesis
Rainer Glauben, Arvind Batra, Thorsten Stroh, Catherine Krauser, Hans-anton Lehr, Paolo
Mascagni, Martin Zeitz, Britta Siegmund
Histone deacetylase inhibitors (HDACi) have been described initially for their anti-proliferat-
ive effect in cancer cell lines as well as for their reduction of experimental tumor growth
In Vivo. Furthermore, several HDAC inhibitors are currently in clinical studies for a variety
of solid and hematological cancers. In addition, recent studies from our own group provide
evidence for an anti-inflammatory potency of HDACi In Vitro and In Vivo by using various
models of experimental colitis. To characterize the combined effect of the anti-inflammatory
and anti-proliferative potency of HDACi In Vivo, the AOM/DSS-model as well as the IL-
10KO-model of inflammation-mediated colon carcinogenesis were applied. In IL-10KO mice,
tumor development was accelerated by administration of the Cox2-inhibitor Celecoxib. The
HDACi SAHA and ITF2357 were administered throughout the entire experimental period
via oral gavage and the progression of tumorigenesis was monitored by lower endoscopy.
In both models, HDACi treatment resulted in a delay of tumor development as evaluated
by endoscopy and histology. In addition, the absolute number of adenomas was significantly
reduced in the HDACi-treated groups when compared to vehicle-treated animals as deter-
mined by histology. Remarkably, the strongest suppression of tumorigenesis was observed
in animals treated with ITF2357. Recently it was descibed that the transcription factor
NF-κB acts as a key molecule within the process of inflammation-linked carcinogenesis.
Furthermore, several studies indicate that inhibition of HDAC affects the NF-κB pathway.
Hence, to further explore the mechanistic effects of HDACi treatment in the employed
models of tumorigenesis, nucleus extraction experiments from colon sections of the ITF2357
treated as well as untreated IL10-KO mice were performed. These experiments indicate,
that the HDACi treatment inhibits the translocation of p65, a subunit of NF-κB, into the
nucleus. Consequently, the inhibition of tumor development by HDACi is paralleled by a
reduced activation of NF-κB at the site of inflammation. Since inflammatory bowel desease
(IBD) in humans is associated with an increased risk of colorectal cancer, a pharmacological
strategy exerting anti-inflammatory as well as anti-proliferative properties would be highly
intriguing for the long-term therapy in IBD.
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Biomarker-Based Prediction of Inflammatory Bowel Disease-Related Neoplastic
Progression
M. M. Gerrits, M. Chen, C. J. Van der woude, H. Van dekken, E. J. Kuipers, P. D.
Siersema, J. G. Kusters
Background: Patients with prolonged inflammatory bowel disease (IBD) are at increased
risk of developing colorectal cancer (CRC). Therefore, a regular bi-annual colonoscopic
surveillance of this high-risk patient group is recommended. The sensitivity of conventional
colonoscopy for the detection of dysplastic lesions in IBD is however insufficient. Accuracy
of screening may increase using a biomarker-based surveillance strategy. Aim: To evaluate
the value of biomarker-based surveillance for predicting neoplastic progression in long-term
IBD patients. Methods: Dutch IBD patients with CRC (n=14), comprised of patients with
Crohn's disease (CD: n=5) and ulcerative colitis (UC: n=9), and 17 controls without neoplastic
progression (CD: n=8, UC: n=9) were included in this study. Biopsies from follow-up were
available in all patients. DNA ploidy and p53 status were detected by flow cytometry
and immunohistochemistry, respectively. Histological staging was determined by an expert
gastrointestinal pathologist. The cut-off values for DNA ploidy and p53 expression are >
1.35 (aneuploidy) and >15%, respectively. Results: 83 biopsies (CD: n=25, UC: n=58) were
obtained from the later cancer cases compared to 144 biopsies (CD: n=55, UC: n=89) from
the controls. The mean follow-up time of the CD and UC cancer cases prior to CRC diagnosis
was 4 (range 1-7) and 6.5 yrs (range 1-14), respectively. In 66% of the CD and UC cancer
cases, DNA ploidy and/or p53 were positive in surveillance biopsies at a mean time of 5
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yrs (CD: 4.25 (range 1-7), UC: 5.5 yrs (range 1-12) prior to cancer development. In biopsies
without histological evidence for neoplastic progression, DNA aneuploidy and increased
p53 expression was seen in respectively 53% vs 2% (p<0.001) and 32% vs 8% (p=0.03)
for the CD cancer cases compared to the controls. For UC, these values were 58% vs 8%
(p<0.001), and 40% vs 13% (p=0.01), respectively. Furthermore, the cancer cases had
evidence of diffuse mucosal spread of DNA aneuploidy and p53 expression (mean distance
from the lesion, 58 cm (range 51-65) and 53 cm (range 51-55), respectively). This diffuse
expression contrasted with the more focal presence of dysplasia, usually confined to regions
in the immediate vicinity of the tumor. Conclusion: DNA aneuploidy and p53 expression
predicted neoplastic progression in patients with a long history of IBD. Both markers are
earlier and more diffusely expressed than dysplasia in IBD-related neoplastic progression.
Biomarker-based surveillance may well increase the early stage detection of IBD-related
neoplastic progression in these patients.
198
Sacral Nerve Stimulation for Constipation: An International Multi-Centre
Study
Michael A. Kamm, Thomas C. Dudding, Jarno Melenhorst, Michael Jarrett, Steen
Buntzen, Brigitte Holzer, Claes Johansson, Soren Laurberg, Harald Rosen, Carolynne J.
Vaizey, Klaus Matzel, Cor Baeten
Background: In patients with idiopathic constipation in whom conservative treatment has
failed, surgical procedures, such as colectomy, are associated with a high failure rate and
substantial morbidity. We wished to explore an alternative approach - modulating the
extrinsic nerve supply to the bowel. We evaluated the symptomatic response and physiological
effect of sacral nerve stimulation (SNS) in patients with slow transit constipation and normal
transit constipation with impaired evacuation. Methods: A prospective multi-centre trial was
performed at 5 European sites. 65 patients (58 female), median age 40 (range 17-79) years,
who had failed treatment with laxatives and biofeedback, underwent test stimulation. Each
patient served as their own control. The effect of temporary SNS was assessed by a 21 day
bowel habit diary. Patients with >50% improvement in symptoms were eligible for permanent
SNS. Long-term results were assessed by bowel habit diary, symptom questionnaire, Cleve-
land Clinic constipation score (CCCS), visual analogue score (VAS), short form-36 (SF-36)
quality of life questionnaire, anorectal physiology and colonic transit studies. Primary end-
points were an increase in the frequency of defaecation, reduction in straining and reduction
in the sensation of incomplete evacuation. Results: 43 (66%) patients proceeded to chronic
stimulation. Mean baseline and latest follow-up data (median 12 (range 1-24) months) are
reported. Frequency of defaecation increased from 3.4 to 6.1 evacuations per week (p<0.001).
Evacuation days per week increased from 2.4 to 4.4 (p<0.001). Time spent on toileting
decreased from 17.6 to 9.3 minutes (p<0.001), straining decreased from 4.4 to 2.9 episodes
per week (p=0.114), abdominal pain decreased from 4.4 to 2.0 days per week (p<0.001)
and perception of incomplete evacuation decreased (p=0.022). The CCCS (0 = no constipa-
tion, 30 = severe constipation) decreased from 18.0 to 10.2 (p<0.001). Mean VAS (0 =
severe symptoms, 100 = no symptoms) increased from 18 to 66 (p<0.001). Subjects with
both slow transit and impaired evacuation benefited from therapy. SF-36 subsets of physical
functioning, general health, vitality, social functioning and mental health significantly
improved. Rectal sensation was altered with reduction in urge volume (p=0.056) and maximal
tolerated volume (p<0.001). Colonic transit normalized in one half of the patients who
demonstrated slow transit at baseline (p=0.039). Conclusion: SNS is effective in the treatment
of idiopathic constipation resistant to conservative treatment. Improvement occurs in bowel
frequency, associated symptoms, quality of life, and objectively measured colonic transit.
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Evidence of Enteric Neuronal Loss,Altered Chemical Coding and Increased
Oxidative Stress in Colons from Diabetic Patients
Richard Blatt, Bindu P. Chandrasekharan, Shahed Brown, Marney Goldstein, Simon
Mwangi, Shanthi Sitaraman, Shanthi Srinivasan
Introduction-Gastrointestinal dysfunction is very common in patients with diabetes. Almost
seventy five percent of patients with diabetes experience some form of gastrointestinal
dysfunction likely a result of altered gut motility. Common GI complaints include dysphagia,
reflux, early satiety, nausea, abdominal pain, diarrhea or constipation. We assessed the
changes in the enteric nervous system using colectomy specimens (Control-6, diabetic-3)
and intestinal biopsies (Control-10, diabetic-14). Methods-There was no significant difference
in the age of control and diabetic subjects. Hemi-colectomies were performed for bleeding
or malignancy, and the samples were collected from the non-diseased portion of the colon.
For immunohistochemistry, the samples were embedded in paraffin, and 5 micron slices
were mounted on slides. Hematoxylin and eosin staining was done to assess ganglion size.
Immunostaining was carried out using fluorescent antibodies to the following neuronal
markers: peripherin, neuronal Nitric Oxide Synthase (nNOS), Choline Acetyl Transferase
(ChAT), Vasoactive Intestinal Peptide (VIP) and Neuropeptide Y (NPY). Using fluorescent
microscopy, the ganglia were analyzed for percentage of specific stained area using the meta-
morph software. Oxidative stress was assessed by estimation of total reduced glutathione
(GSH) by HPLC. The longitudinal muscle strip with myenteric plexi was subjected to
isometric muscle recording with electrical field stimulation for motility assessment. Results-
The ganglion size was significantly smaller in diabetic colons compared to controls (p<0.001).
Chemical coding showed a selective loss of populations of nNOS, NPY and ChAT neurons
(p<0.01). No difference in VIP staining was noted. The extent of loss of nNOS and NPY
was more than ChAT indicating that inhibitory subset of neurons was more susceptible to
damage in diabetes (p<0.01). Total reduced glutathione concentration in colon samples
from diabetic patients was significantly less (62.46 ± 10.37 nmol) than the control patients
(84.51 ± 15.35, p<0.0001) indicating increased oxidative stress. Isometric muscle recording
of myenteric plexi strips from a diabetic subject showed impaired contraction responses
when compared to the healthy controls (n=2). Conclusions Changes in the human enteric
nervous system due to diabetes have not been described. Here, we demonstrate loss of
enteric neurons in patients with diabetes and the presence of increased oxidative stress in
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diabetic colons. Increased oxidative stress in the colon can contribute to the neuronal damage
seen in diabetes and result in subsequent motility disturbances in human diabetes.
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Abnormalities of Prostaglandins and COX Enzymes in Female Patients with
Slow Transit Constipation
Jose Behar, Ping Cong, Ling Cheng, Victor Pricolo, Piero Biancani
Chronic constipation due to slow transit (STC) is more common in female than in male
patients from the ages of 12 to 60 years. We have previously shown that these gender
differences in the incidence of STC may be due to an over expression of progesterone (PG)
receptors that alter the patterns of G proteins. These abnormalities consist of down regulation
of Gq/11 and up regulation Gs proteins. Gq/11 proteins mediate the actions of agonists that
induce muscle contraction whereas Gs proteins mediate the actions of agonists that cause
relaxation. These abnormal G protein patterns lead to an impaired contraction induced by
agonists that act on plasma membrane receptors or agonists that directly activate G proteins.
The present studies were aimed at elucidating the mechanisms responsible for the reduction
in basal colonic motility in female patients with STC. Circular muscle tissues from eight
females with STC and eight controls with adeno-carcinoma of the colon were studied.
Prostaglandins were determined by immunoassay, COX enzymes by Western blot and COX
enzymes and progesterone receptors mRNA's by RT-PCR. The results of these studies showed
that muscle strips placed in the muscle bath from STC patients have a lower colonic motility
index than muscle strips from control females (p<0.001). The muscle tissues from STC
patients also had lower TxA2 and PGF2α (p<0.01) and higher PGE2 levels (p<0.01) than
controls. TxA2 and PGF2α contract and PGE2 relax circular muscle cells of the colon. STC
had lower COX-1 protein expression and mRNA levels and higher COX-2 protein expression
and mRNA levels than controls (p<0.01). These abnormalities were reproduced in normal
colonic muscle cells after treatment with PG (10-5 M) for 6 h. PG treatment decreased TxA2
and PGF2α and increased PGE2 levels (p<0.01). These changes in the levels of prostaglandins
were associated with a concomitant decrease in COX-1 protein expression and mRNA levels
and increase in COX-2 proteins and mRNA levels. Treatment of normal colonic muscle cells
with specific COX-1 inhibitor resulted in lower TxA2 and PGF2α levels and a specific COX-
2 inhibitor caused a reduction of PGE2 levels. STC patients had higher expression of PG
receptors by Western blot and mRNA levels by RT-PCR than controls (p<0.01) suggesting
an over expression of these receptors. These findings suggest that the impaired basal motility
index of STC is due to abnormal levels of prostaglandins and COX enzymes, probably
caused by an over expression of PG receptors that make the circular muscle cells of the
colon more sensitive to normal circulating levels of PG.
201
Association of Faah Gene Variation in Metabolism of Endocannabinoid and
Phenotype of Functional Gastrointestinal Disorders and Gastrointestinal
Transit
Paula Carlson, Sanna Mckinzie, Irene Busciglio, Duane Burton, Kari Baxter, Michael Ryks,
Alan R. Zinsmeister, Michael Camilleri
Background: Cannabinoid receptors (CBR) are on cholinergic neurons, are involved in
nociception, and a CBR agonist inhibits gastric and colonic motility in humans (Neurogastro
Motil 18:668-9, 2006). Endocannabinoids include anandamide, which is inactivated by a
fatty acid amide hydrolase (FAAH). A single nucleotide polymorphism (SNP) in the human
FAAH gene (C385A, rs324420) is the only common SNP (Human Genet 120:581-8, 2006).
This SNP converts a conserved proline residue in FAAH to threonine (P129T), reducing
FAAH protein and enzymatic activity. It is unclear whether this SNP influences symptom
phenotype or gastrointestinal motor function in functional gastrointestinal disorders (FGIDs).
Methods: This study assessed 337 FGID patients (Rome II positive) and 132 healthy
volunteers recruited to studies of symptom phenotype and genotype from 2000-2006. All
underwent bowel disease (including somatic symptom) questionnaires, and 62 underwent
gastrointestinal and colonic transit over 48 h by scintigraphy and gastric volume by 99mTc-
SPECT. FAAH genotype was determined by an investigator blinded to all clinical information
using TaqMan assays (Applied Biosystems, CA) and confirmed by direct sequencing of
representative samples. The primary study goals were to evaluate the associations between
wildtype (CC) versus polymorphic (CA/AA) FAAH and either FGID symptom phenotype or
gastric emptying (GE 4 h) and colonic transit (colon GC 24 and 48 h). Results: The genotype
distribution of FGID patients and healthy volunteers did not deviate significantly from
Hardy-Weinberg equilibrium at the polymorphic locus (respectively CC/CA/AA: 55/40/5 %
in FGID and 67/29/4 % in healthy volunteers), similar to that reported in Caucasian controls
[67/31/2 (Human Genet 120:581-8, 2006)]. There was a borderline significant association
of genotype with FGID phenotype (Chi square, p=0.06). FAAH CA/AA increases the odds
(relative to healthy volunteers) for constipation [OR=1.96 (1.17,3.30)] and chronic abdominal
pain [OR=3.00 (1.00,8.96)]. FAAH CA/AA genotype was also associated with slower gastric
emptying of solids (p=0.077) and with lower postprandial change in gastric volume (p=
0.037), but not with colonic transit. Conclusions: Genetic variation in the metabolism of
endocannabinoids appears to be associated with symptom phenotype and gastric function
in FGIDs. The effects of this genetic variation on gut function and responses to cannabinoid
modulation deserve further study.
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Role of Platelet Activating Factor (PAF)-Induced H2O2 Production Via
Activation of NADPH Oxidases in Sigmoid Motor Dysfunction in Ulcerative
Colitis (UC)
Sharad Kunnath, Victor E. Pricolo, Neal S. Leleiko, Weibiao Cao
We have previously shown that sigmoid circular muscle cells from UC patients exhibit
reduced contraction and Ca2+ signaling in response to the endogenous neurotransmitter
neurokinin A (NKA) and that hydrogen peroxide (H2O2) is elevated in the UC circular
muscle layer. The H2O2 scavenger catalase restored the decreased Ca2+ signal and cell
shortening to normal levels, suggesting that H2O2 contributes to the motor dysfunction of
UC. It is known that PAF levels are elevated in colonic mucosa from patients with ulcerative
colitis. In the present study we examined the role of PAF in motor dysfunction and H2O2
production in UC. PAF levels were 19.1±4.4 ng/mg protein in sigmoid circular muscle
from patients with ulcerative colitis, which was significantly higher than normal controls
(6.4±1.1ng/mg protein). Treatment of normal sigmoid circular smooth muscle cells with
PAF significantly decreased NKA-induced contraction, a decrease which was significantly
restored by H2O2 scavenger catalase, suggesting that H2O2 mediates PAF-induced reduction
in muscle contractility. Western blot analysis showed that the levels of p47phox, a regulatory
subunit of NADPH oxidase, were significantly increased in UC sigmoid circular muscle. In
addition, PAF significantly increased H2O2 production in sigmoid smooth muscle cells in
primary culture, and H2O2 production was abolished by the NADPH oxidase inhibitor
apocynin and by knockdown of p47phox with p47phox small interfering RNA, suggesting
that NADPH oxidases may mediate PAF-induced production of H2O2. We conclude that
PAF may contribute to motor dysfunction of sigmoid colon in UC and that PAF-induced
H2O2 production depends on activation of NADPH oxidases. Supported by NIDDK R21
DK62775-01.
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Colonic Hypomotility Associated with Butyrate-Induced Non-Inflammatory
Hypersensitivity of the Colon Can Be Restored By Estrogen Substitution in
Ovariectomized Rats
Bruno M. Balsiger, Thomas Hubacher, Christine Baumgartner, Luis Tovar, Mareike
Oulevey, Christian Knuesel, Manfred Essig, Ulrich Scheurer, Juergen M. Gschossmann
BACKGROUND: Symptoms of functional bowel disorders (FBD) in females tend to be
periodical, suggesting a link to the menstrual cycle. We have shown a visceral hyperalgesic
effect of estrogen in both naïve and trinitrobenzene sulfonic acid-treated rats (Gschossmann
et al, 2002). A new model for FBD with butyrate enemas to induce persistent hypersensitive
non-inflammatory conditions has been recently published (Bourdu et al, 2005). Studies
analyzing colonic motility in FBD and the role of estrogen for alterations in motility are
limited. AIM: To study colonic motility: (1) in rats with colonic hypersensitivity and (2)
under the influence of estrogen. METHODS: Spontaneous contractile activity of full thickness
colonic muscle strips was assessed in organ chambers (OC). All rats were ovariectomized.
Four groups were studied (n>4 rats; 8 strips per rat): two groups with implanted estradiol
pellets and 2 groups with sham pellets. One estradiol and one sham group were treated
three weeks later with butyrate enemas (200mM; 1ml) for three consecutive days. The other
estradiol and sham group received saline (1ml) rectal enemas. Six to 9 days thereafter, OC
experiments were performed. Contractile activity was measured as area under the contractile
curve and shown as mean ± sem g*5Min. RESULTS: Contractile activity in rats following
treatment with butyrate enemas was smaller compared with saline-treated animals (188±8
vs. 213±10; p=0.005). Both groups with estradiol pellets showed increased spontaneous
activity compared to groups with sham pellets (219±6 vs. 180±5, p<0.05). The lowest
activity was found in butyrate-treated rats with sham pellets (166±4). In butyrate-treated
rats with estradiol pellets, contractile activity was restored to 209±10 (p=0.0002). This
activity was similar to the activity of the control group with sham pellets and saline enema
(196±9; p>0.05). The highest activity was seen in the saline-treated rats with estradiol
(227±8; p=0.01 to saline-treated animals with sham pellets). SUMMARY: In butyrate-treated
rats with sham pellets, colonic contractile activity of isolated muscle strips was decreased,
whereas butyrate-treated rats with estradiol pellets had restored colonic contractile activity
similar to the control group with saline treatment and sham pellets. CONCLUSION: Butyrate-
induced colonic hypersensitive non-inflammatory condition in rats is associated with reduced
colonic contractile activity. Our results suggest that this hypersensitivity-associated hypomot-
ility is restored to a normal colonic contractile activity level by estrogen substitution. Thus,
these findings could result in a new approach for future treatment modalities of FBD.
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Adenosine 2b Receptor Blockade Ameliorates Murine Colitis
Vasantha L. Kolachala, Brittani K. Ruble, Shanthi Srinivasan, Matam Vijay-kumar, Lixin
Wang, Andrew Gewirtz, Joel Linden, Didier Merlin, Shanthi V. Sitaraman
Background and Aims: Adenosine 2b (A2b) receptor is the predominant adenosine receptor
expressed in the colon. Acting through A2b receptor, adenosine mediates chloride secretion,
fibronectin, IL-6 synthesis and secretion in intestinal epithelial cells. A2b receptor mRNA
and protein expression are increased during human and murine colitis. However, the effect
of A2b receptor in the intestinal inflammatory response is not known. In this study, we
addressed the effect of A2b receptor antagonist on murine colitis. Methods: Dextran sodium
sulfate (DSS)-induced colitis and piroxicam-treated IL-10-/- mice were used as animal models
of colitis. A2b receptor specific antagonist, ATL-801, (1mg/Kg or 10mg/Kg) was given in
the diet. Results: Mice treated with A2b receptor antagonist, ATL-801, showed significantly
reduced extent and severity of colitis in a dose dependent fashion in DSS-treated mice as
evidenced by reduced clinical score 6.8 ± 0.8 (1.0mg/kg ATL-801+DSS) p<0.03; 4.4 ±
1.5 (10.0mg/kg ATL-801+DSS) p<0.003 compared to 9.4 ± 1.1 (DSS alone) and reduced
histological score 6.2 ± 2.4 (1.0mg/kg ATL-801+DSS), 4.1 ± 1.8 (10.0mg/kg ATL-801+DSS)
compared to 9.1 ± 2.1 (DSS alone). MPO activity of mice fed with ATL-801+DSS was
significantly lower 2.3 ± 0.4 compared to mice given DSS alone 11.6 ± 2.0, p<0.03. The
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administration of ATL-801 prevented weight loss and suppressed inflammatory infiltrate
into colonic mucosa in piroxicam treated IL-10-/- mice with histological score of 1.3 ± 0.3
compared to 2.8 ± 1.0 in piroxicam treated IL-10-/- mice. Pro-inflammatory cytokine IL-6
concentrations in the supernatants of colonic cultures were significantly reduced by ATL-
801 (0.46 ± 0.1 ng/ml) compared to piroxicam group (1.9 ± 0.3, p<0.006). In addition,
IL-8 (KC) levels were significantly lower in ATL-801 group (3.7 ± 0.8 ng/ml) compared to
mice treated with piroxicam alone (5.6 ± 0.6, p<0.003). Conclusions: Taken together, these
data demonstrate that intestinal epithelial A2b receptor is an important mediator of pro-
inflammatory responses in the intestine, and A2b receptor blockade may be an effective
therapeutic strategy to treat inflammatory bowel disease.
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Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells
Ameliorated 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS)-Induced Colitis in
Rats
Yujiro Hayashi, Shingo Tsuji, Masahiko Tsujii, Tsutomu Nishida, Shuji Ishii, Masato
Komori, Takanobu Irie, Hideki Iijima, Hiroshi Eguchi, Norio Hayashi, Sunao Kawano
Background and Aim: Mesenchymal stem cells (MSCs), a subpopulation of adult bone
marrow-derived stem cells, are attractive sources in regenerative medicine owing to their
multipotentiality. However, there is little report of therapeutic effects concerning gastrointesti-
nal diseases. We examined whether MSCs transplantation ameliorated TNBS-induced colitis
and explored the mechanism of ameliorated colitis by transplanted MSCs. Methods: MSCs
were isolated from bone marrow aspirates of male SD rats and expanded in culture. MSCs
(passage 5) were labeled fluorescent dyes with PKH67 green fluorescent kit (Sigma). Experi-
mental colitis were induced by the method reported by Uchida et al. (J Pharmacol Sci.
2005;97(2):285-8.) with minor modifications. TNBS (0.15M in 35% ethanol) was injected
into the luminal side of the clamped portion in male SD rats. Immediately after inducing
colitis, fluorescent labeled-MSCs (1×107 cells) or vehicle were injected into the colonic
subserosa. Results: MSCs (passage 5) expressed mRNAs of transforming growth factor-beta1
(TGF-beta1) and vascular endothelial growth factor (VEGF). MSCs were transplantable to
colonic mucosa surrounding colitis. Most of engrafted MSCs were positive for vimentin (an
interstitial cell marker). And some of them were positive for alpha-smooth muscle actin (a
myofibroblast marker) and desmin (a smooth muscle cell marker). Compared with vehicle
injection, MSCs transplantation reduced the severity of TNBS-induced colitis and siginific-
antly mitigated changes in the body weight loss and mortality. Engrafted MSCs expressed
the TGF-beta1 and VEGF. Conclusions: MSCs transplantation ameliorated TNBS-induced
colitis. The beneficial effects of MSCs might be mediated not only by their differentiation
into colonic interstitial cells but also by their ability to supply anti-inflammatory and angiog-
enic factors.
206
Translational Inhibition of Colonic Epithelial Heat Shock Proteins By
Interferon-Gamma and TNF-Alpha in IBD
Shien Hu, Mae J. Ciancio, Mikihiro Fujiya, Lev Lichtenstein, Shrikant Anant, Mark W.
Musch, Eugene B. Chang
Background & Aims: The inducible heat shock proteins (iHsp), Hsp72 and Hsp25/27, have
an important role in maintaining intestinal homeostasis. Paradoxically, their expression is
reduced in mucosal inflammation which would render the mucosa more susceptible to
injury. We therefore examined potential mechanisms underlying impaired iHsp expression
in colitis and In Vitro. Methods: The expression of inducible Hsps was assessed in human
colonic biopsies and IL-10-/- gene deficient mice by immunohistochemistry, Western blot
and real-time PCR. Young Adult Mouse Colonic (YAMC) epithelial cells were used to help
elucidate the mechanisms of IFN-g and TNF-a induced down-regulation of iHsp expression.
Phosphorylation of double-stranded RNA-dependent protein kinase (PKR) and eukaryotic
initiation factor-a (eIF-2a) were determined by Western blot. Results: Hsp25/27 and Hsp72
levels were selectively reduced in areas of active mucosal inflammation associated with
human IBD and IL-10-/- gene deficient mice with colitis. Wild-type mice treated In Vivo
with a combination of pro-inflammatory cytokines, IFN-g and TNF-a, demonstrated reduced
mucosal Hsp25 and Hsp72. The combination of IFN-g and TNF-a also inhibited Hsp25
and Hsp72 induction on YAMC cells. This cytokine affect was not associated with changes
in respective Hsp mRNA or Hsp half-lives, but the result of suppressed de novo Hsp synthesis,
consistent with translational inhibition. Activation and phosphorylation of PKR, resulting
in phosphorylation of eIF-2a, contributes to inhibition of iHsp translation. Conclusions:
Translational down-regulation of Hsps by pro-inflammatory cytokines is in part mediated
by activation and phosphorylation of PKR and eIF-2a. In the context of IBD, we propose
that this mechanism contributes to the severity, extent, and persistence of inflammation-
induced mucosal injury.
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Pkcη Regulates the Assembly and Maintenance of Epithelial Tight Junctions
(TJ): Direct Interaction of Pkcη with Occludin and Phosphorylation of
Occludin On Thr Residues
Takuya Suzuki, Bertha Elias, Radhakrishna (rk) Rao
Evidence indicates that TJ dynamics are regulated by a variety of signaling molecules,
including protein kinase C (PKC). Epithelial tissues express high levels of PKCη, and therefore
we hypothesized that PKCη plays a role in the regulation of TJ. Methods: Caco-2 and
MDCK cell monolayers were incubated with PKCη-PS (pseudo substrate, a specific PKCη
inhibitor). Endogenous PKCη was depleted by transient transfection of shRNA in pRNAt-
in(GFP) vector. Cells were transfected with wild type (WT), constitutively active (CA), and
dominant negative (DN) PKCη in pAcGFP vector and expressed as GFP fusion proteins.
Basal integrity of TJ and their reassembly by calcium were evaluated by measuring TER,
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FITC-inulin flux, and distribution of TJ-proteins by confocal microscopy and detergent-
insoluble fraction of TJ-proteins. Interaction between PKCη and occludin was determined
by co-immunoprecipitation and pair-wise binding assays, using recombinant PKCη and
GST-Occludin-C (C-terminal 150 A.a.). Thr-phosphorylation of occludin in cells and GST-
occludin-C was determined by immunoprecipitation or kinase assay and immunoblot ana-
lysis. Phosphorylation sites in GST-Occludin-C were determined by site-directed mutation
of Thr. Results: PKCη-PS dose-dependently (10-50 μM) increased inulin flux in Caco-2
and MDCK cell monolayers; this was associated with redistribution and decrease in detergent-
insoluble fractions of occludin and ZO-1, and dephosphorylation of occludin on Thr. PKCη-
PS (1-3 μM) also prevented calcium-induced assembly of TJ. Depletion of PKCη by shRNA
reduced TER and increased inulin flux compared to those in vector-transfected cells. In
shRNA-transfected cells (GFP positive), the junctional organization of occludin and ZO-1
was disrupted as compared to the adjacent, non-transfected (GFP negative) cells in the same
monolayer or vector-transfected (GFP positive) cells. DN-PKCη increased inulin flux, while
WT and CA-PKCη reduced it. DN-PKCη reduced the detergent-insoluble fraction and
junctional distribution of occludin and ZO-1, and attenuated Thr-phosphorylation of occlu-
din; Thr-phosphorylation was higher in WT and CA-PKCη-transfected cells. Occludin was
co-localized and co-immunoprecipitated with PKCη. Pair-wise binding and kinase assay
showed that PKCη directly interacts with occludin and phosphorylates it on Thr. Mutation
of highly conserved Thr (T400, T403, T404) to Ala in GST-Occludin abolished more than
90% of PKCη-induced Thr-phosphorylation, suggesting that these Thr residues are targets
of PKCη. Conclusion: Results show that PKCη plays a crucial role in regulation of occludin-
phosphorylation and TJ integrity. Support: DK55532 and AA12307.
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Mechanism of Inhibition of Na-Glucose Co-Transport By Prostaglandin E2 in
Intestinal Epithelial Cells
Jamil Talukder, Ramesh Kekuda, Prosenjit Saha, Uma Sundaram
Background: Na-dependent glucose co-transport (SGLT1) is present on the brush border
membrane (BBM) of the absorptive villus cells in the rabbit small intestine. This co-transport
process is inhibited in the chronically inflamed small intestine secondary to a reduction in
the number of the co-transporters. Prostaglandin E (PGE2) is markedly increased in
enterocytes during chronic enteritis. Whether the inhibition of SGLT1 during chronic enteritis
may be mediated by PGE2 is unknown. Aim: Determine the effect of PGE2 on SGLT1 in
enterocytes. Methods: Rat small intestinal epithelial cells (IEC-18) were grown on transwell
plates and confluent monolayers were used for transport experiments at the 10th day post
confluence. 3H-OMG was utilized to determine Na-dependent glucose uptake in IEC-18
cells. Na+/K+-ATPase activity was determined by measuring the inorganic phosphate forma-
tion. Total RNA was isolated from IEC-18 cells using TRIzol reagent. SGLT1 mRNA from
both groups was quantified by real-time PCR. Western blotting for SGLT1 was performed
using rabbit polyclonal antibody and plasma membranes from control and PGE2 treated
IEC-18 cells. Results: Na-dependent 3H-OMG uptake in IEC-18 cells was significantly
inhibited by PGE2 (342±30 nmol/mg protein/2 min in control cells and 58±5 in PGE2
treated cells, p<0.01, n=4). Since Na+/K+-ATPase provides the favorable Na+-gradient for
this co-transporter, it was measured and found not to be altered (28±4 nmol/mg protein/
min in control and 27±4 in treated cells, n=6). Kinetic studies revealed that the mechanism
of inhibition of SGLT1 by PGE2 in IEC-18 cells was secondary to a decrease in the maximal
rate of uptake (Vmax) without a significant alteration in the affinity for glucose. Real-time
PCR demonstrated that SGLT1 mRNA was reduced 2-fold by PGE2 treatment (n=3, p<0.01).
Western blot studies demonstrated that the immune reactive level of SGLT1 decreased 2-
fold in IEC-18 cells treated with PGE2 (n=3, p<0.01) Conclusions: These studies demonstrate
that PGE2 inhibits Na-dependent glucose co-transport in intestinal epithelial cells. This
inhibition is not secondary to an alteration in the Na extruding capacity of the cells. The
mechanism of inhibition of Na-dependent glucose co-transport in IEC-18 cells by PGE2 is
secondary to a decrease in co-transporter numbers without a significant change in affinity
of the co-transporter. This mechanism of inhibition of Na-glucose co-transport In Vitro is
identical to that seen in the rabbit model of inflammatory bowel disease where mucosal
levels of PGE2 are known to be elevated.
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TNF-α Inhibits Human Intestinal Napi-Iib Gene Expression in Caco2 Cells
Huacong Chen, Hua Xu, Jiali Dong, Fayez Ghishan
Introduction: Phosphate (Pi) homeostasis is critical for many physiological functions includ-
ing bone formation and energy metabolism. Dietary Pi is absorbed in the small intestine
and filtered and reabsorbed in the kidney. In the intestine, Pi is absorbed across the
brushborder membrane (BBM) of enterocytes via type IIb sodium-phosphate cotransporters
(NaPi IIb) and the basolateral membrane via Pit family transporters. Several physiological
factors such as dietary Pi intake, vitamin D, estrogen, EGF and glucocorticoids regulate
intestinal Pi transport. However, not much known regarding Pi regulation in pathological
conditions, such as inflammatory bowel disease and celiac disease. We hypothesized that
inflammatory mediators, especially TNF-α, may alter Pi transport. Thus, this study was
conducted to determine the involvement of NaPi-IIb in inflammatory disorders. Methods:
Caco2 cells were treated with different amount of TNF-α, and the treated cells were harvested
at various time points. RNA was then purified from these cells and Real-Time PCR was
performed to determine the expression levels of NaPi-IIb gene expression in TNF-α treated
or non-treated Caco2 cells. The human NaPi-IIb gene promoter was subcloned into pGL3
basic vector and used to study the effect of TNFα on NaPi-IIb gene promoter activity in
Caco-2 cells. Results: Real-Time PCR with human NaPi-IIb primers and TBP (TATA binding
protein) primers showed that the human NaPi-IIb mRNA expression was reduced by ~ 44%
in TNF-α (20-100 ng/ml, 40 hrs) treated Caco2 cells. Promoter assays indicated that the
human NaPi-IIb (hNaPi-IIb) gene promoter construct responds to TNF-α treatment in Caco2
cells. TNF-α treatment inhibits the hNaPi-IIb gene promoter activity by ~ 40%. The TNF-
α response region is located in the proximal promoter region of the human NaPi-IIb gene.
Conclusion: The human intestinal phosphate transporter is altered in setting of TNF-α
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mediated intestinal inflammation. The human NaPi-IIb expression was decreased by proin-
flammatory cytokine TNF-α in Caco2 cells. The mechanism of this inhibition may involve
a reduction in hNaPi-IIb gene promoter activity by TNF-α. This investigation was supported
by AGA student research award (Chen, H) and NIH grant R37-DK33209 (Ghishan, FK).
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The Association Between Gastrointestinal Ulcer Disease and Diabetes
Donald A. Garrow, Hugh E. Thompson, Mark H. Delegge
BACKGROUND: Peptic and duodenal ulcers are seen more frequently in patients with
chronic medical conditions such as chronic obstructive pulmonary disease (COPD), coronary
artery disease (CAD) and chronic renal insufficiency. We sought to determine if individuals
with diabetes have a greater frequency of gastrointestinal ulcers than non-diabetics. A review
of the literature reveals no significant data regarding this issue. METHODS: Data source is
the National Health Interview Survey (NHIS), combined years 1997-2003. The NHIS is a
comprehensive nationally-representative survey conducted by the National Center for Health
Statistics. It is weighted to represent the U.S. adult population. There were 226,953 individual
subjects represented in the combined seven years of the NHIS. Multivariable logistic regres-
sion was used to determine whether diabetes was independently associated with gastrointesti-
nal ulcers, after controlling for known confounders. Analyses were performed with SAS
version 9.1.3, which accounted for the complex survey design of the NHIS and generated
population estimates. RESULTS: Individuals with diabetes were almost twice as likely to
have a history of gastrointestinal ulcers than individuals without diabetes (prevalence =
14.4% vs. 7.7%, p < 0.001). After controlling for relevant confounders, the approximated
risk of having a history of gastrointestinal ulcers among diabetics was 23% higher than for
individuals without diabetes (Adjusted Odds Ratio = 1.23; 95% Confidence Intervals = 1.09
- 1.40). Other covariates which significantly impacted the model and were controlled for
included older age, males, body mass index > 30, smoking, current alcohol use, COPD,
CAD and chronic renal insufficiency. CONCLUSIONS: The prevalence of gastrointestinal
ulcers is nearly twice as high for individuals with diabetes. After controlling for relevant
confounders, the risk of having gastrointestinal ulcers was almost 25% higher among people
with diabetes. Individuals over age 50, males, obesity, smoking, current alcohol use, COPD,
CAD and chronic renal insufficiency were also found to be significant predictors of gastrointes-
tinal ulcer disease. This appears to be the first large population-based study to find that
diabetics may be at greater risk for gastrointestinal ulcers. If this association remains positive
in prospective trials, people with diabetes may require more careful consideration for gastroin-
testinal ulcer disease when complaining of abdominal pain or other ulcer-like symptoms.
Future research should be directed at understanding the pathophysiologic reasons why
diabetes is associated with gastrointestinal ulcer disease.
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Gene Polymorphisms, Cytokine Concentrations and Duodenal Ulcer in Adults
and Children
Dulciene M. Queiroz, Luciana I. Gomes, Gifone A. Rocha, Andreia maria C. Rocha,
Fabrício F. Melo, Juliana B. Guerra, Rodrigo Corrêa-oliveira
Helicobacter pylori(HP) is indubitably associated with duodenal ulcer (DU), but host genetics
have been also postulated as important factor in the development of the disease. Recently
we have demonstrated that polymorphic alleles of ILRN were independently associated with
DU in children, but not in adults. Furthermore, polymorphisms in genes that code for other
inflammatory cytokines were not associated with DU in our population. We evaluated the
gastric cytokine levels in adults and children HP-negative (n=36 and n=60, respectively)
and HP-positive with (n=50 and n=12, respectively) and without (n=100 and n=60, respect-
ively) DU, correlating the results with the polymorphic pattern of genes linked to the innate
and adaptative immune response. Cytokine polymorphisms were genotyped by molecular
methods. HP status was evaluated by culture, PCR, urease test and UBT and cagA status
by PCR. Gastric cytokine levels were assessed by ELISA (Biosource/Camarillo, CA) and
expressed in pg/mg protein. The levels of IL1α (300.8 vs 113.0, p=0.000), TNFα (402.8
vs 216.6, p=0.000) and TGFβ (15,476.7 vs 7,626.1, p=0.000) were twice higher in DU
than in gastritis adults, but IL1β level was lower in DU group (244.0 vs, 293.3 p=0.07).
These differences were not seen in children with and without DU (p>0.4); but IL8 was
increased in DU (3,373.2 vs 1,131.5, p<0.000). The levels of all cytokines were 2 to 3x
higher in HP-positive than -negative patients (p<0.000), except IL1β levels in gastritis adults
(p=0.7). cagA status associated only with IL8 levels in both adults, and children irrespective
of DU presence (p<0.000). In regard to the gene polymorphism, higher levels of IL1β was
observed in carriers of IL1RN polymorphic alleles in the group of HP-positive (291.7 vs
222.4, p=0.008), but not HP-negative (p>0.5) patients. When they were stratified by diseases,
associations remained only in gastritis group (308.4 vs 225.1, p=0.01). No associations were
observed between IL1B and TNFA polymorphism and IL1β and TNFα gastric levels in both
adults and children (p>0.4). These results are in agreement with our previous studies
demonstrating that IL1B and TNFA polymorphisms are not associated with gastric carcinoma
(GC) in our population. Otherwise, ILRN polymorphism is associated to GC in adults and
DU in children and this polymorphism was the only one associated to increased IL1β
expression in the gastric mucosa. Conclusions: a) High levels of cytokines in the gastric
mucosa of adults with DU do not rely on gene polymorphism; b) The gastric immune
response to HP differs between children and adults with DU pointing to different pathophysi-
ological disease mechanisms. CNPq and FAPEMIG
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Differing Clinical Manifestations in Complicated and Uncomplicated Peptic
Ulcer Disease: Abnormal Visceral Sensory Function May Be a Key
Montri Gururatsakul, Birgit Adam, Tobias Liebregts, Richard H. Holloway, Nicholas J.
Talley, Gerald Holtmann
Background: Manifestations of peptic ulcer disease (PUD) include dyspepsia and life
threatening bleeding. It is a common clinical observation that patients with peptic ulcer
bleeding are often asymptomatic until the bleeding occurs. Data on the proportion of patients
without symptoms before ulcer bleeding are lacking. A lack of dyspeptic symptoms could
be explained by impaired visceral sensory function but this has not been studied so far.
Aims: To assess symptom profiles and compare visceral sensory thresholds in patients with
bleeding peptic ulcer (BPU), uncomplicated PUD and healthy controls (HC). Method: 22
patients with BPU (15 M, 28-79 yr mean 61.8), 5 uncomplicated PUD (4 M, 26-77 yr mean
48.2) and 18 HC (10 M, 42-78 yr mean 60.8) without dyspeptic symptoms were recruited.
After an 8 hr fast, all subjects received 200 ml of a standardized oral feeding solution
(Ensure®) every 5 min up to a cumulative volume of 800 ml. After each 200 ml drink, 6
key symptoms (fullness, nausea, abdominal pain, retrosternal burning, regurgitation, other)
were assessed with the Adelaide-Dyspepsia-Tool and the peak and cumulative symptom
response determined. In ulcer patients, this was done at least 6 weeks after starting treatment.
Healing of ulcers was verified by the time of the study. Data analysis: Proportions and 95 %
confidence intervals for patients with and without symptoms were calculated. The cumulative
symptom response during the nutrient challenge test was used as the primary outcome
parameter. Analysis of variance adjusting for age, gender and BMI was used to compare the
cumulative symptom response. Results: 17/22 (77%, 95 % CI 55-93) patients with BPU
had no symptoms prior to bleeding compared to 0/5 uncomplicated ulcer patients. Patients
with BPU and HC had significantly lower symptom responses (BPU 148±38, HC 81±43)
to the nutrient challenge test than uncomplicated PUD (498±80, p<0.001). Patients with
dyspeptic symptoms (10/27) had significantly higher symptom responses (371±327) to the
nutrient challenge test than the 17/27 patients without symptoms (120±147, p<0.001).
Conclusions: The majority of patients with peptic ulcer bleeding present without dyspeptic
symptoms. Even after healing of the ulcer, patients with a history of uncomplicated ulcers
and ulcer symptoms have a significantly augmented symptom response to a standardized
nutrient challenge compared to patients with complicated ulcers. The data suggest that
differences in the processing of upper GI visceral afferents may play a major role in the
clinical presentation of patients with complicated PUD.
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Oral Buffered Esomeprazole Is Superior to IV Pantoprazole for Rapid Rise of
Intragastric pH: A Wireless pH Metry Analysis
Rupa Banerjee, Rajesh Gupta, Manu Tandan, G venkat Rao, D. N. Reddy
Introduction: A pH >6 is required for clot stability and adequate haemostasis. Intravenous
proton pump inhibitors (PPIs) have a rapid onset of action compared to oral and hence
have been preferred for the management of nonvariceal upper GI bleeding. IV Pantoprazole
has been used extensively. Buffered esomeprazole (BE) is a novel oral preparation consisting
of an inner core of non enteric coated esomeprazole with a shell of sodium bicarbonate.
The buffer protects against acid degradation of the PPI in addition to its immediate antacid
action. Objective: To assess the efficacy of BE for raising and maintaining intragastric pH
above 6 in comparison to IV Pantoprazole in equivalent dosing. Methods: A randomized
two way crossover study was conducted. Ten H. pylori negative healthy volunteers were
randomized to twice daily BE 40mg or Pantoprazole 40mg IV bolus. Intragastric pH was
measured with a previously described technique of using a wireless pH radiotelemetry
capsule (Bravo, Medtronic) (1).A two week wash out period was given between doses.
Results: BE achieved a steady pH >6 in a median time of 2 min (range 1-5min) after the
first dose (Table 1). This was significantly superior to IV Pantoprazole with a median time
of 90 min (range 80- 180 min). The % time pH>6 was also significantly higher with BE
(86.9% vs. 63.6%). Conclusion: Our study shows for the first time that BE achieves and
maintains a pH>6 within minutes of administration. This was significantly superior to IV
Pantoprazole in equivalent dosing. This finding could have implications in the management
of nonvariceal bleed where a rapid and sustained pH >6 is desirable. 1. Banerjee R, Lakhtakia
S, Tandon M, Rao GV, Reddy DN. Endoscopy-assisted wireless intragastric pH measurement.
Endoscopy. 2005 Sep; 37(9):922.
Intragastric pH with buffered esomeprazole
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Preventing NSAID-Induced GI Complications: An Economic Evaluation of
Alternative Gastrointestinal Prophylaxis Strategies in At-Risk Patients
Chris G. Cameron, Sander Veldhuyzen van zanten, Chris Skedgel, Ingrid Sketris, Gordon
Flowerdew
Objectives: Determine how the presence of risk factors and decision makers' willingness
to pay affects the cost-effectiveness of alternative gastrointestinal prophylaxis strategies.
Methods: A cost-utility analysis, using a decision analytical model (TreeAge Pro 2005) was
developed to evaluate NSAID-induced GI complications and associated costs in hypothetical
cohorts of patient's beginning a 6-month course of NSAIDs. A baseline study population
was examined (ages 17-85) along with patients with the following risk factors: age 65-75,
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age≥ 75, history of a complicated GI event, and baseline corticosteroid use. Patients entering
the model were treated with either: (1.) No Prophylaxis, (2.) standard dose Proton Pump
Inhibitors (generic PPI od) (3.) misoprostol (200ug bid), (4.) misoprostol (200ug qid), (5.)
ranitidine (150mg bid), (6.) ranitidine (300mg bid). Event rates were obtained from system-
atic reviews and meta- analysis, cost-effectiveness analyses, and large prospective RCTs.
Costs were from the perspective of a 3rd party payer of a Canadian provincial seniors drug
plan. Cost-Utility was measured in terms of cost per quality adjusted life year (QALY) gained
relative to no prophylaxis. Probabilistic sensitivity analysis using Monte Carlo Simulation
was used to generate measures of uncertainty of the results, along with cost-effectiveness
acceptability curves. Results: In the baseline study population cohort, Misoprostol (200μg
bid) has the highest likelihood of being the optimal cost-effective strategy at a willingness
to pay (WTP) of $50,000 per QALY. Standard dose PPI's have the highest likelihood of
being the optimal cost-effective strategy at a WTP of $50,000 per QALY in patients' age ≥
75 and in patients with a history of a complicated GI event. No samples from the no
prophylaxis and ranitidine (300mg bid) treatment arms in the cost-effectiveness simulation
were economically optimal in the age 65-75, age ≥ 75, and prior complicated GI event
cohorts. Conclusions: The economically preferred strategy is dependent upon the presence
of risk factors and decision maker's willingness to pay. As the presence of risk factors and
willingness to pay increase, the likelihood that standard dose PPI is the most cost-effective
strategy increases. Results are dependent upon base-case estimates obtained from RCTs and
may differ in the “real world” where low levels of prescribing and non-adherence to therapies
have been reported. Large RCT's examining clinically important outcomes in PPIs and H2RAs
are needed.
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Isolation of a KitLowCd44+Cd34+ Cell Line with Stem Cell-Like Characteristics
from the Gastric Tunica Muscularis of C57bl/6 Mice
Andrea Lorincz, Michael R. Bardsley, Doug Redelman, Hui Chen, David L. Young, Viktor
J. Horvath, Tamas Ordog
Recently we have identified rare KitlowCD44+CD34+ cells in the murine gastric tunica muscu-
laris that serve as potential progenitors of interstitial cells of Cajal (ICC) (Gastroenterology
2006;130(4; Suppl 2):A-538). We have also reported that a conditionally immortalized cell
line derived from these cells (2xSCS70) displayed stem cell-like features, e.g., clonality,
extensive self-renewal and ability to differentiate into various lineages (ICC, smooth muscle,
neurons, glia, epithelium and antigen-presenting cells) both In Vitro and after transplantation
into chick embryos (Neurogastroenterol Motil 18:757, 2006). The aim of this study was to
create comparable nonimmortalized cell lines from gastric muscles of D7 C57Bl/6 mice.
Stem cells presumed to be present in mixed primary cell cultures from these tissues were
isolated by serial single-cell sorting following expansion by culturing for 150 days with
media shown to support the growth of the 2xSCS70 cells after inactivation of the immortaliz-
ing protein. Expression profiling was performed by immunohistochemistry (IHC), hybridiza-
tion to Affymetrix GeneChips and RT-PCR. Of the 960 single cells sorted from the mixed
primary cultures, 24 were found capable of significant clonal expansion. The fastest-growing
clone expressed markers for ICC, smooth muscle, neurons, glia, epithelium, antigen-pre-
senting and mast cells by RT-PCR. Of the 480 single cells derived from this primary clone,
17 were able to expand significantly while maintaining the same multipotent expression
pattern. One of these subclones (2xSCS2F10) has now been grown beyond 166 population
doublings and found to have the capacity to generate Kit+ ICC, smooth muscle myosin- or
desmin-expressing smooth muscle cells, p75NTR and PGP 9.5+ neurons, GFAP+ glial cells
and cytokeratin 1-18+ epithelial cells by IHC. Similarly to the immortalized 2xSCS70 line,
2xSCS2F10 cells expressed CD34, CD44 and CD56; low levels of Kit, CD13 and Flk-1, but
not CD27, CD45, CD90.2, CD115, CD133, or SSEA-1 by flow cytometry. These observations
indicate that both cell lines are distinct from murine hematopoietic, neuronal and mesenchy-
mal stem cells and multipotent adult progenitors. Expression profiling with Affymetrix
GeneChips showed that both lines significantly overexpressed several members of the poly-
comb family of transcriptional repressors (Suz12, Asxl1, Cbx2, Cbx4, Cbx8, Pcgf5, and
Trim27) and Myc, which have been shown to contribute to the maintenance of embryonic
stem cells in an undifferentiated state (“stemness genes”). We conclude that ICC progenitors
may represent a novel class of multipotent stem cells. Supported by NIH Grants DK58185
and RR16464.
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Functional Analysis of Murine Esophageal Stem Cells
Takaomi Okawa, Kenji Oyama, Munenori Takaoka, Hiroshi Nakagawa, Carmen
Michaylira, Claudia D. Andl, Doug Stairs, Meenhard Herlyn, Anil K. Rustgi
Background: Stem cells are thought to reside in the basal layer of the stratified squamous
epithelium of the esophagus with the ability to self-renew, resist apoptosis and give rise to
transit amplifying cells. The identification of such stem cells would have great applications
in understanding mechanisms underlying epithelial cell renewal, response to injury, transdif-
ferentiation to intestinal metaplasia, and malignant transformation. In this study, we have
detected and characterized a population of stem cells in murine esophageal esophageal
epithelia. Methods: Label retaining cells (BrdU positive cells) and Side population (SP) cells
(by Hoechst 33342 staining) are considered as a robust stem cell population. Previously,
we showed these cells are consistent with esophageal stem cells. In this study, mRNA from
SP cells and non-SP cells were amplified and gene microarrrays were performed in order
to detect potential stem cell markers. In addition, to characterize stem cell function, colony
formation assay and spheroid cultures were performed. Results:Label retaining cells were
found only in the basal layer, and represented less than 1% in the esophageal epithelial cell
population. The total percentage of SP cells was 0.1-3%. From the gene array results, 629
genes (including CD34 and ABCG2) are more than 5 fold increased and 492 genes (including
integrin alpha6 and CD71) are more than 5 fold decreased in SP cells compared to non-SP
cells. We focused on the CD34 gene to detect further stem cells. CD34 positive population
is 7~15 % in non-SP cells but 85~95% in SP cells. CD34 positive cells were also pancytokeratin
positive. These results suggest that CD34 positive cells are derived from epithelial cells and
a candidate gene of stem cells. In colony formation assay, CD34 positive cells and SP cells
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showed an increased number of small colonies when compared to CD34 negative cells or
non-SP cells. Spheroid cultures revealed that SP and CD34 positive cells resulted in larger
colonies. Conclusion: Here we have identified for the first time label retaining cells and a
side population of cells within the esophageal epithelia that are consistent with stem cells.
Functional assays revealed that CD34 positive cells and SP cells might possess the ability
to self-renew, which would be important in epithelial renewal and tissue regeneration.
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Gene Expression Profiling of SP-Sorted Putative Intestinal Epithelial Stem
Cells
Ajay Gulati, Chad Shaw, Susan Henning
Background: The high rate of turnover of the intestinal epithelium is maintained by a group
of stem cells which reside at the base of the crypts of Lieberkuhn. While the existence of
these intestinal epithelial stem cells (IESCs) has been well established, their study has been
limited due to the inability to isolate them. Work by Dekaney et al. (Gastroenterology, 2005)
has utilized side population (SP) sorting to isolate a viable fraction of cells enriched for
putative IESCs. In the present study, we have begun to characterize the molecular features
of this putative stem cell population using functional genomics to mine our data for genes
implicated in the biology of these cells. Methods: Mouse jejuni were subjected to SP sorting
as described by Dekaney et al. RNA was extracted from the CD45-negative SP cell fraction,
as well as from intact jejunum. 4 biological replicates underwent gene expression profiling
using Affymetrix 430 2.0 gene chips. Using a fold change of >2 and an adjusted p-value of
<0.05, a list of transcripts enriched in the CD45-negative SP cells was generated. Further
analysis using Gene Ontology (GO) and pathway mapping tools allowed for identification
of genes of biological interest. These were further evaluated by in situ hybridization (ISH)
to determine their localization along the crypt-villus axis. Results: To validate our gene list,
we looked first for enrichment of putative stem cell and crypt base transcripts such as Msi1,
EphB3, and Sox9 within our data set. These mRNAs were found to be enriched in the CD45-
negative SP cells relative to intact jejunum. GO analysis revealed biological processes such as
exocytosis, development and secretion to be highly enriched in our putative IESCs. Additionally,
pathway mapping identified numerous genes of the MODY pathway to be highly represented.
Genes of interest identified using this functional genomics approach include Ngn3, Pax4,
Pax6, Nkx2-2, and NeuroD1. ISH reveals that many of these transcripts are localized primarily
to the base of the crypt. Conclusions: Our findings support the use of SP-sorting of mouse
small intestine mucosa to isolate a population of crypt base cells which are enriched in
putative stem cell markers such as Msi1. Interestingly, a significant number of enriched
transcripts appear to be involved in the development of the enteroendocrine system. This
points to either a substantial number of enteroendocrine precursors within the CD45-
negative SP cell population, or to the novel concept that IESCs express enteroendocrine
regulatory pathways. Support: This work has been supported by NIH grants R01 DK 069585,
T32 DK 07664, and P30 DK 56338.
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Intestinal Stem Cell Organoid Transplantation Generates Neomucosa in Dogs
Vatche G. Agopian, David C. Chen, Jeffrey R. Avansino, Matthias Stelzner
Background: Intestinal malabsorption syndromes lead to significant morbidity. Intestinal
stem cell organoid transplantation is a possible treatment option. It generates functional
intestinal neomucosa in rodents, and we have used it to treat bile acid malabsorption in
rats. However, successful generation of intestinal neomucosa using organoid transplantation
has never been reported in large animals. Hypothesis: Intestinal stem cell organoid trans-
plantation can be used to generate neomucosa in dogs. Study Design: Beagle dogs (N=8)
were used in two experimental groups. In Group 1, two-month old dogs (n=4) underwent
autotransplantation of intestinal organoids prepared from a resected segment of their own
distal ileum using a modified rodent protocol. Intestinal organoids were transplanted into
65 recipient sites. They were seeded at a concentration of 20,000 organoids per cm2 into
either polyglycolic acid (PGA) biopolymer tubes that were wrapped in omentum, into
intestine whose mucosa had been chemically stripped, or into intestine whose mucosa had
been surgically stripped. Before seeding, organoids were labeled with vital stains (DiI,
CFDA, eGFP-lentivirus). In Group 2, ten-month old pregnant females (n=4) were used in
allotransplantation experiments. The fetuses from each pregnant female (gestational day 40-
50) were harvested and used as organoid donors. Organoids were seeded at a concentration
of 20,000 per cm2 into 12 PGA tubes which were wrapped in omentum. Recipient dogs
were immunosuppressed with cyclosporine and prednisone to prevent rejection of the
organoids. Tissues from Group 1 and Group 2 were harvested after 4 weeks and analyzed
by H&E histology and fluorescent microscopy. Results: In juvenile dogs of Group 1, a
modified rodent harvest protocol produced large numbers of organoids. However, after 4
weeks, neither labeled mucosal cells nor neomucosal growth were identified at any of the
engraftment sites. In Group 2, large numbers of organoids were harvested. After 4 weeks,
neomucosal growth with large areas of crypts and villi was identified on the PGA scaffolds
in 3 of 4 dogs (75%). A total of 303 mm2 of neomucosa was generated. The neomucosa
resembled normal canine mucosa in structure and composition. Conclusions: Autotransplant-
ation of juvenile intestinal organoids into different graft beds failed to generate neomucosa.
Allotransplantation of fetal intestinal organoids into PGA scaffolds generated intestinal neo-
mucosa with a 75% success rate in our dog model. This is the first report of successful
generation of intestinal neomucosa using intestinal stem cell organoid transplantation in a
large animal model.
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Involvement of Inducible Hsp72 in Defining Colonic Stem Cell Niche
Lev Lichtenstein, Mae J. Ciancio, Kazuhiko Uchiyama, Robert H. Whitehead, Eugene B.
Chang
Background: Epithelial cell proliferation in the distal colon is confined to a compact compart-
ment at the very bottom of colonic crypts. Mechanism(s) that restricts the proliferative zone
is unknown. It has been suggested that, in addition to the factors that stimulate proliferation
at the bottom of the crypts, there is a “stop-signaling system” that restrict proliferation to
the lower third of crypts. Heat shock proteins (HSPs) are a family of evolutionarily conserved
chaperone proteins. In addition to their protective functions during stress, inducible HSPs,
in particular Hsp72, have been reported to participate in cell signaling. While the effect of
Hsp72 on apoptosis and survival of colonic cancer cells is well recognized, little is known
regarding its role in the regulation of proliferation of non-tumorous colonocytes or in
controlling intestinal stem cell proliferation and compartmentalization within the colon.
Aim: The purpose of this study, therefore, was to determine the potential role of Hsp72 in
regulating colonic stem cell proliferation. To achieve this goal, we used 70.1/70.3 double
knock-out (Hsp72 KO) mice and the corresponding C57BL/6 wild-type controls. Results:
Using immunohistochemical staining of colonic specimen for proliferation markers (BrdU,
Ki-67), intestinal stem cell markers (BrdU retention, Musashi-1), and TUNEL, with quantifica-
tion of the signal with Chromovision® counter, we found that deletion of Hsp72 affects
the localization of stem cells within the crypt, but does not alter neither the intestinal stem
cell content nor the total number of proliferating cells in the crypts. In the distal colon of
Hsp72 KO mice, up to 30% of the proliferating cells and a comparable proportion of
intestinal stem cells were found relocated from their expected “niche”, resulting in unusually
large numbers of dividing cells within middle and even upper areas of the crypts. This
change in the proliferative compartment did not result from changes in epithelial cell turnover
or cell death. In addition, we found an abnormal distribution of pericryptal myofibroblasts
to the upper areas of the colonic crypts; we believe this change is intimately related to the
changes in the epithelial cells' proliferative compartment. Conclusions: Our data suggest
that Hsp72 is involved in defining the colonic stem cell niche in distal colon; either by
influencing intracellular proliferation signaling or by providing “stop-signaling” that restricts
the area designed for the stem cells. Specific deletion of Hsp72 results in disorganization
of the stem cell compartment and in the appearance of functioning stem cells in the upper
regions of distal colon crypts.
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Identification and Characterization of Small Intestinal Stem Cells
Robert K. Montgomery, Diana L. Carlone, Daniel E. Henderson, John J. Fialkovich, Selma
O. Algra, David T. Breault
We report the identification, isolation, and characterization of putative intestinal stem cells
(ISC) using telomerase (mTert)-GFP transgenic mice. Immunohistochemical analysis demon-
strated that rare GFP+ cells, which display co-staining with long term BrdU label retaining
cells, are present as single cells in the intestinal crypts of mTert-GFP mice. Some GFP+
crypt cells co-stain with DCAMKL1, a recently suggested ISC marker. These data indicate
that GFP expression provides a marker for the ISC. GFP+, CD45- cells isolated by FACS
from small intestinal epithelium of male donors were functionally tested by injection into
3.5 day old mouse blastocysts. PCR analysis of genomic DNA prepared from multiple organs
of female 16.5 dpc chimeric mice demonstrated sry (Y chromosome marker) specifically in
the small or large intestine or both in 7 of 9 mice. In contrast, no sry was detected in liver,
stomach, pancreas, lung, brain, placenta or skin. At 3 weeks of age, low level chimerism in
the small intestine was demonstrated by PCR in 1 of 3 mice. Long term survival of the cells
was demonstrated by harvest of small intestinal epithelial cells from 3 chimeric mice at 6
weeks of age. GFP+ cells were isolated by FACS from all 3 mice and verified to be GFP
positive by PCR. These findings were confirmed and extended by lineage tracing in similar
experiments carried out by injection of LacZ+, GFP+ cells. Postive cytoplasmic LacZ staining
was identified in the intestinal epithelium, but in no other tissue, from five of seven 16.5
dpc chimeric mice. Chimerism was confirmed by PCR. Whole mounts of the stomach, small
intestine, and large intestine were stained for β-galactosidase at post natal days 10-19; in 2
of 6 mice, the small intestinal epithelium, but no other tissue, was positive. Positive staining
was confirmed by PCR analysis. Staining was detected both in absorptive enterocytes, and
in goblet and enteroendocrine cells, representing the two epithelial cell lineages. In mice of
11 and 25 weeks of age, PCR analysis of DNA from fecal material containing shed epithelial
cells indicates long term persistence of chimerism. CONCLUSIONS: These data demonstrate
that 1) Using mTert-GFP transgenic mice, GFP+ epithelial cells can be identified and isolated,
2) These GFP+ cells engraft the ISC niche during fetal development, 3) GFP+ cells give rise
to the two intestinal epithelial lineages (absorptive and secretory), and 4) Engrafted cells
persist long-term in adult chimeric animals. These data are consistent with the identification
of the GFP+ crypt cells as intestinal epithelial stem cells.
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The Physical and Mental Quality of Life (QoL) in Chronic (CP) and Relapsing
Acute (RAP) Pancreatitis Is Worse Than Other Chronic Conditions
Stephen T. Amann, Micheal Barmada, Dhiraj Yadav, David C. Whitcomb
Background: CP and RAP are inflammatory disorders of the pancreas that often require
chronic medical therapy and narcotics or surgery to control the symptoms. However, the
impact of CP and RAP on QOL has not been adequately studied in the United States. Nor
has the impact CP and RAP have on QOL been compared to other common disorders.
Methods: The North American Pancreatitis Study 2 (NAPS2) is a 20 site prospective study
of CP and RAP in the USA and recently completed enrollment. Over 1000 subjects and
600 matched study controls were ascertained. CP was defined on clinical and radiographic
criteria. RAP was recurrent episodes of acute pancreatitis without firm evidence of CP.
Controls are spouse, family member, or unrelated. We reviewed the clinical history and
QOL by SF12 in the NAPS2 data set. The SF-12 is a short, validated, multipurpose generic
measure of QOL and depicts a mental and physical component summary (PCS, MCS). The
scores were norm based for easy comparison, 50 is the general population norm. A value
< 50 is below the general population norm. Also compared are historical diseased and age-
matched healthy summary scores. A preliminary evaluation was conducted on 795 subjects
(430 CP, 365 RAP) and 559 study controls. Data is median and interquartile ranges as
appropriate. Results: See tables below. Conclusions: The impact of CP and RAP on both
the physical and mental quality of life appears substantial. It is worse than many chronic
conditions. The PCS is affected most, and worse than in chronic heart disease, diabetes or
rheumatoid arthritis which have obvious physical impairment. This large pancreatitis cohort
using the SF-12 supports its usefulness in evaluating QOL in pancreatitis and for comparison
across disease states. Considering QOL as an endpoint will help to quantify individual
patient's perceptions of treatment paradigms
Table 1 :Demographics
Table 2: QOL SF-12 summary scores
group* to control comparisons were statistically significant. Also noted are historical disease
data and age matched Healthy
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Rate of Progression to Imaging Positive Chronic Pancreatitis in Patients with a
Positive Secretin Stimulation Test and Negative Abdominal Imaging. Results of
a Ten- Year Follow-Up
Alphonso Brown, Benjamin Young, Steven D. Freedman, Sunil Sheth
Goal: The diagnosis of early chronic pancreatitis can be difficult to make. Early fibrotic
changes in the pancreas may be below the limits of detection of current imaging modalities.
We present a follow-up study of all subjects seen in our institution over the last decade
who had unexplained chronic abdominal pain and normal abdominal imaging and a positive
secretin stimulation test (SST). The goal of this study was to determine the percentage of
subjects who developed imaging evidence of chronic pancreatitis during the 10-year follow-
up period. Methods: We evaluated all subjects who had a positive SST at our medical center
during the period from Jan 1995-December 2005. A positive study was defined as measured
peak bicarbonate of 70 meq/L. Individuals with a positive SST were considered to have
early chronic pancreatitis (early CP). All subjects who undergo SST at our institution have
no evidence of CP on imaging studies. Medical record review and telephone follow-up was
performed on all subjects. Subjects were evaluated for imaging evidence of CP and any
interventions such as surgery, stent placement or ERCP. Results: Twenty four subjects
satisfied criteria for inclusion in the study. The follow-up time ranged from 2- 10 years.
Three subjects could not be contacted. Eight of the remaining subjects 8/21 had progressed
to imaging evidence of chronic pancreatitis. Two of the remaining subjects had not undergone
a repeat imaging study. The remaining subjects (19) had no imaging evidence of chronic
pancreatitis. Three of the subjects in the positive group and five in the negative group had
undergone an endoscopic or surgical intervention. Conclusions: During a 10 year follow-
up subjects suspected of having CP with chronic abdominal pain and normal abdominal
imaging approximately 38% had developed imaging evidence of chronic pancreatitis. Surgical
and endoscopic intervention did not appear to influence progression to chronic pancreatitis.
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Long Term Follow-Up of Patients with Chronic Abdominal Pain and Suspicion
of Chronic Pancreatitis to Determine Diagnostic Accuracy of CCK Pancreatic
Function Test and ERCP for Diagnosis of Early Chronic Pancreatitis
Mansour A. Parsi, Darwin Conwell, Gregory Zuccaro, Rocio Lopez, John A. Dumot, John
J. Vargo
Background: In patients with chronic abdominal pain, diagnosis of early chronic pancreatitis
before the development of visible structural abnormalities is challenging. Abnormalities in
pancreatic acinar cell function may precede structural abnormalities in patients with early
chronic pancreatitis but long term follow-up studies are non-existent. Aim: To assess the
“true” diagnostic accuracy of CCK pancreatic function test and ERCP for diagnosis of chronic
pancreatitis. Methods: Consecutive patients with chronic abdominal pain and suspicion of
chronic pancreatitis being evaluated at Cleveland Clinic during a one year period from 1999
to 2000 who fulfilled the inclusion criteria were prospectively evaluated. All patients had
ERCP and CCK endoscopic pancreatic function test (ePFT) as part of their initial evaluation.
Pancreatograms obtained during the ERCP were scored according to Cambridge classification
(0-IV). The ePFT was performed after continuous intravenous infusion of synthetic CCK
(Kinevac, Bracco Diagnostics; Princeton, NJ). Duodenal fluid was collected with an upper
endoscope (Olympus, Melville, NY) at 30, 40, 50, and 60 minutes during the CCK infusion
and the peak lipase concentration was determined in all patients. The gold standard for
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the diagnosis of chronic pancreatitis (“the truth”) was long term follow up to clearly establish
or rule out chronic pancreatitis. Results: Thirty five patients were studied. The median
duration of follow up was 7 years (Interquartile range (IQR): 3, 7). Twenty four patients
were diagnosed with chronic pancreatitis. Among these patients, the ePFT was positive in
23 patients and ERCP was positive in 17 patients. Chronic pancreatitis was ruled out in 11
patients. Among these patients, the ePFT was positive in 7 while ERCP was positive in 1
patient. Statistical diagnostic inferences of ePFT and ERCP for diagnosis of chronic pancreatitis
are shown in the Table. Conclusion: Using long term follow-up as the gold standard, CCK
pancreatic function test has excellent sensitivity but poor specificity for diagnosis of chronic
pancreatitis in patients with chronic abdominal pain and suspicion of chronic pancreatitis.
Clinical Implication: In clinical practice, CCK pancreatic function test can be used to rule
out chronic pancreatitis in patients with chronic abdominal pain and suspicion of chronic
pancreatitis with a very high degree of certainty.
PPV=positive predictive value; NPV=Negative predictive value; PLH=positive likelihood ratio;
NLR=Negative likelihood ratio
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Is There a Role for Extensive CFTR Genotyping to Determine a CF Diagnosis
in Patients with Idiopathic Pancreatitis?
Tanja Gonska, Lynda Ellis, Sheelagh Martin, Julian Zielenski, Annie Dupuis, Elizabeth
Tullis, Michele D. Bishop, Steven D. Freedman, Peter R. Durie
Background: About 20% of Cystic Fibrosis (CF) patients with a pancreatic sufficient status
develop acute, recurrent or chronic pancreatitis (Durno et al, Gastroenterol 2002). In addition,
about 40% of patients presenting with idiopathic pancreatitis carry at least one Cystic Fibrosis
Transmembrane Regulator (CFTR) gene mutation (Bishop et al, Hum Genet 2005). Since
most CFTR mutations are rare, identification requires extensive analysis. Extensive genotyping
for CFTR mutations of patients with idiopathic pancreatitis is offered for clinical purposes
(Keiles et al, Pancreas 2006). However, the clinical role of mutation analysis, especially to
establish or exclude a diagnosis of CF disease, has received limited attention. This is a critical
issue, because approximately 2-3% of the reported 1400 mutations (www.genet.sickkid-
s.on.ca/cftr) are proven to be CF-disease causing mutations on the basis of the consensus
statement on CF diagnosis (Rosenstein et al, J Pediatr 1998). Aim: We are assessing the role
of extensive CFTR genotyping in relation to ion channel measurements (sweat test and nasal
potential difference [NPD]) for establishing or excluding a diagnosis of CF disease. Method:
We are prospectively assessing children and adults with CF-like phenotypes including
idiopathic pancreatitis. Between 1998 and 2006 we ascertained 40 patients with idiopathic
acute recurrent or chronic pancreatitis (14 patients were reported by Bishop et al, 2005).
The mean age was 24 years (range 5-59 years), including 25 female and 15 male patients.
Results: At least one CFTR mutation was identified in 19/40 (47%) patients. This included
(a) 12 proven CF-disease causing mutations (deltaF508,R553X,W1282X,3849+10kbC>T)
and (b ) 15 CFTR muta t i ons tha t a r e no t p roven to be CF-di seas e caus ing
(1716G>A,R117H,D1152H, R75Q,S1235R,3659delC,M348K and 5T). In 8/19 (42%)
patients had CFTR mutations on both alleles. Genotyping led to a CF diagnosis in only one
of these patients. In contrast, genotyping was inconclusive in 4 other patients for whom a
CF diagnosis was established based on elevated sweat Cl- concentration and/or NPD. In the
3 remaining patients with 2 CFTR mutations a CF diagnosis could not be established
according to current criteria. Discussion: In conclusion, identification of CFTR mutations
partially explains susceptibility for the development of pancreatitis. However, extensive
CFTR genotyping shows limited value for establishing or excluding a diagnosis of CF disease.
Thus, we question the value of routine CFTR testing for clinical purposes. Instead, we
suggest referring patients with idiopathic pancreatitis to an established CF Centre for fur-
ther assessment.
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Igg4-Hepatopathy: Association of Igg4-Bearing Plasma Cells in Liver with
Autoimmune Pancreatitis
Takeji Umemura, Yoh Zen, Hideaki Hamano, Shigeyuki Kawa, Yasuni Nakanuma, Kendo
Kiyosawa
Background & Aims: Autoimmune pancreatitis (AIP) is characterized by irregular narrowing
of the main pancreatic duct, swelling of the pancreas, high serum IgG4 concentrations,
lymphoplasmacytic infiltration including abundant IgG4-bearing plasma cells, and a favorable
response to corticosteroid treatment. Although IgG4-related sclerosing cholangitis has been
reported in connection with AIP, it remains unclear whether other lesions are present in
the liver as well, since liver dysfunction is frequently observed in patients with AIP. We
sought to determine whether histological features of the liver, including the presence of
IgG4-bearing plasma cells, reflected the clinical features of AIP, including serum level of
IgG4. Methods: We examined the clinical features, histology, and IgG4-bearing plasma cell
infiltration of liver biopsies from 17 patients with AIP and 63 patients with autoimmune
hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or chronic viral hepatitis.
We also examined the histological changes in the AIP liver before and after glucocorticoid
therapy. Results: The liver histology of AIP was classifiable into 6 patterns: evident portal
inflammation with or without interface hepatitis (6 cases), large bile-duct obstructive features
(8 cases), portal sclerosis (8 cases), lobular hepatitis (5 cases), canalicular cholestasis (4
cases), and fatty liver (2 cases), with some histological features coexisting in the same liver.
The number of IgG4-bearing plasma cells was significantly higher in AIP patients (5.0/high
power fields [HPF]) compared with other groups (0.0/HPF; P < 0.01), and was significantly
correlated with serum IgG4 concentration (P = 0.0014). The median number of IgG4-bearing
plasma cells in patients with severe, mild and absent thickness of bile duct wall were 29.0/
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HPF, 5.5/HPF and 2.5/HPF, respectively, which were found to be positively correlated P =
0.046. Glucocorticoid therapy ameliorated IgG4-bearing plasma cell infiltration in the liver
(before 8.0 vs. after 0.0/HPF; P = 0.031) and all histological findings, with the exception
of fatty change. Conclusions: Serum IgG4 concentration is closely associated to numbers of
IgG4-bearing plasma cells in inflammatory infiltration in patients with AIP. Histological
findings in the AIP liver are variable, yet can be classified into specific groups and clearly
relate to disease severity. Treatment with glucocorticoid therapy ameliorates serum IgG4
concentration, IgG4-bearing plasma cell infiltration, and histological findings in AIP, whose
diagnosis may be confirmed though liver biopsy findings to distinguish it from other autoim-
mune diseases that affect the liver.
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Long-Term Outcome of Autoimmune Pancreatitis
Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta, Atsutake Okamoto
Background and Aims: Autoimmune pancreatitis (AIP) is morphologically characterized by
enlargement of the pancreas and irregularly narrowing of the main pancreatic duct. Steroid
therapy is currently common treatment for AIP, but the clinical course after steroid therapy
is unknown. We examined the long-term outcome of AIP patients including morphological
changes of the pancreas and extrapancreatic lesions, and pancreatic endocrine and exocrine
function after steroid therapy. Methods: Clinical course of 33 AIP patients were examined.
Nineteen patients underwent steroid therapy. Initial dose of oral prednisolone was 30 mg/
day and it was subsequently tapered. Follow-up period ranged from 8 months to 24 years,
with an average of 7 years. Results: Spontaneous regression of pancreatic swelling was
observed in 2 patients. In all 19 patients treated with steroid, pancreatic enlargement and
narrowing of the pancreatic duct improved. However, the pancreas became atrophic in 11
patients and irregularity or mild dilatation of the main pancreatic duct remained in 8 patients.
Biliary stenosis improved to various degrees and biliary drainage tube can be withdrawn.
Other extrapancreatic lesions including swelling of salivary or lacrimal glands, lymphaden-
opathy, and retroperitoneal fibrosis also improved with steroid therapy. Although diabetes
mellitus didn't improve in patients who were not treated with steroid, diabetes mellitus
improved in 8 of 13 patients after steroid therapy. Pancreatic exocrine dysfunction improved
in 9 of 10 patients with steroid therapy. Deterioration of pancreatic exocrine function was
not detected except 2 patients who underwent pancreatoduodenectomy on suspicion of
pancreatic cancer. AIP recurred in 1 patient during maintenance therapy (prednisolone 5
mg/day) 20 months after the onset of AIP and retreated with high-dose steroid. Pancreatic
stones appeared in the pancreatic head in this patient. Six patients died at the age of 75-
86 years. Cause of death was associated malignancy in 3 patients, but no patients died of
AIP related diseases. Conclusions: AIP treated with steroid has a favorable long-term outcome
based on the morphological findings and assessments of pancreatic function. Since AIP
occurs predominantly in the elderly, clinicians should pay attention to the complicated
diseases in follow-up of AIP patients. To avoid futile surgery, in elderly male patients with
pancreatic mass, preoperative clinical suspicion of AIP is mandatory.
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Functional and Intracellular Signalling Differences Associated with the
Helicobacter pylori Alpab Adhesin from Western and East Asian Strains
Hong Lu, Jeng yih Wu, Ellen J. Beswick, Tomoyuki Ohno, Stefan Odenbreit, Rainer Haas,
Victor E. Reyes, Masakazu Kita, David Y. Graham, Yoshio Yamaoka
Background: Following adhesion of Helicobacter pylori to gastric epithelial cells intracellular
signaling leads to cytokine production which causes H. pylori-related gastric injury. Two
adjacent homologous genes (alpA and alpB) which encode H. pylori outer membrane adher-
ence-associated proteins are thought to be associated with adhesion and cytokine induction.
Methods: To test this hypothesis, we co-cultured gastric epithelial cells with wild-type H.
pylori strains and their corresponding alpA/alpB deleted mutants. Results were confirmed
by complementation. Interleukin (IL)-6 and 8 levels were measured by ELISA, binding
ability to gastric epithelial cells by flow cytometry, and cellular signaling pathways, including
activation of transcription factors, by immunoblot, real-time RT-PCR, luciferase reporter
gene assay and electrophoretic mobility shift assay. Six-week old male C57BL/6 mice were
also inoculated orally with wild-type H. pylori or alpA/alpB deleted mutants and examined
at 8 weeks. Gastric mucosal KC and IL-6 levels were also measured by ELISA. Results:
Flow cytometry confirmed that AlpAB was involved in cellular adhesion. Deletion of alpAB
reduced IL-6 induction in gastric epithelial cells. Deletion of alpAB from East Asia but not
from Western strains led to reduced IL-8 induction. All AlpAB positive strains tested, activated
the ERK→c-Fos/CREB→CRE/AP-1 pathway. However, activation of the JNK→c-Jun→AP-
1 and JNK→NF-κB pathways was exclusive for AlpAB from East Asian strains. In addition,
East Asian wild type strains led to significantly more activation of JNK, c-Jun and NF-κB
than did Western WT strains. alpA/alpB deleted mutants mutants poorly colonized the
stomachs of C57BL/6 mice and this was associated with a reduced mucosal response of KC
and IL-6. Conclusions: Our results suggest that AlpAB is involved in gastric injury by
mediating adherence to gastric epithelial cells and by modulating proinflammatory intracellu-
lar signaling cascades. Known geographical differences in H. pylori-related clinical outcomes
may depend, in part, on the differential abilities of East Asian and Western types of AlpAB
to stimulate NF-κB-related proinflammatory signaling pathways.
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Helicobacter pylori-Induced Gastric Cancer Is Dependent On Caga
Aime Franco, Elizabeth Johnston, Judith Romero-gallo, Richard M. Peek
Persistent gastritis induced by Helicobacter pylori is the strongest known risk factor for distal
gastric adenocarcinoma. H. pylori strains that possess the type IV cag secretion system, which
translocates the bacterial substrate CagA into host epithelial cells, further augment cancer
risk. We previously reported that an In Vivo-adapted H. pylori strain, 7.13, induces gastric
adenocarcinoma in two independent rodent models of gastritis. In model gastric epithelia,
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oncogenic strain 7.13 stimulates nuclear translocation of β-catenin and activates a β-catenin-
responsive reporter, events that are dependent upon CagA. The goals of these experiments
were to define the role of CagA in H. pylori-mediated inflammation, dysplasia, and cancer
In Vivo. Methods: Male Mongolian gerbils were infected with wild-type strain 7.13, isogenic
cagA- or vacA- mutants, or medium alone for 6 to 52 weeks. Gastric inflammation, dysplasia,
and cancer were evaluated and scored by a pathologist blinded to treatment groups. Results:
Colonization efficiency was similar between gerbils challenged with the WT or mutant H.
pylori strains. Severe chronic active gastritis developed in gerbils infected with WT H. pylori
strain 7.13, which was characterized by ulceration, transmural inflammation with peritoneal
abscess formation, and extension into the pancreas. Inactivation of vacA had no effect on
the development of pathologic lesions compared to the WT strain at any time point. Gerbils
infected with the cagA- mutant strain for < 24 weeks only developed mild chronic antral
gastritis. As infection persisted for > 24 weeks, differences in inflammatory scores between
gerbils challenged with WT strain 7.13 or its cagA- mutant resolved, and gerbils infected
long term with either strain developed marked chronic active gastritis with lymphoid follicle
formation, ulceration and transmural acute inflammation. Gastric dysplasia and carcinoma
developed in 55% of gerbils infected with WT strain 7.13 for greater than 16 weeks. In
contrast, none of the gerbils infected with the cagA- mutant strain ever developed gastric
dysplasia or carcinoma. Conclusions: Loss of CagA slows, but does not prevent, the develop-
ment of gastric inflammation within gerbil gastric mucosa. In contrast, inactivation of cagA,
but not vacA, completely abrogates the development of gastric neoplasia in this model,
underscoring the oncogenic potential of this bacterial effector.
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Regulation of the H. pylori Cellular Receptor Decay-Accelerating Factor (DAF)
Daniel O'brien, Judith Romero-gallo, Elizabeth Johnston, Uma Krishna, Dawn Israel, Seth
Ogden, Richard M. Peek
Chronic gastritis induced by Helicobacter pylori is the strongest known risk factor for peptic
ulceration and distal gastric cancer. Adherence of H. pylori to gastric epithelial cells is critical
for induction of inflammation and injury. We previously identified Decay-accelerating factor
(DAF) as a novel cellular receptor for H. pylori and a mediator of the gastric inflammatory
response. H. pylori induces DAF expression in human gastric epithelial cells In Vitro and In
Vivo. Therefore, we sought to define the mechanism by which H. pylori up-regulates DAF
In Vitro and to investigate whether DAF is induced in a mouse model of H. pylori-induced
gastric adenocarcinoma. Methods: MKN28 gastric epithelial cells were co-cultured with the
H. pylori cag+ strain J166 or isogenic mutants for 24h in the presence or absence of the
transcription or translation inhibitors actinomycin D (ActD) or cyclohexamide, respectively.
DAF expression was determined by Western immunoblotting and real-time RT-PCR. INS-
GAS mice were infected with the rodent-adapted carcinogenic H. pylori cag+ strain 7.13 or
broth alone and sacrificed 12 and 24 weeks post-challenge. Colonization density was deter-
mined by quantitative culture. DAF was detected using immunohistochemistry and scored
from 0-4 by a pathologist blinded to treatment groups. Results: Co-culture of wild-type H.
pylori strain J166 with MKN28 cells induced the expression of DAF, which was attenuated
by disruption of cagE (encoding a structural component of the cag pathogenicity island),
but not by disruption of the gene encoding the translocated effector protein CagA. H. pylori-
induced DAF expression, as determined by real-time RT-PCR, was significantly inhibited
by ActD and cyclohexamide. H. pylori-infected INS-GAS mice demonstrated significantly
(p=0.0043) increased DAF expression in the gastric epithelium vs. uninfected controls at
both 12 and 24 weeks (uninfected, n=5; infected, n=6 per time point). DAF immunoreactivity
was prominent in epithelial foveolar cells of infected mice, and staining paralleled the
distribution of H. pylori. Conclusions: Co-culture of H. pylori with gastric epithelial cells
In Vitro induces the transcriptional up-regulation of DAF in a cag PAI-dependent manner,
indicating that cag+ strains have the capacity to up-regulate a cognate H. pylori receptor.
An H. pylori cag+ strain similarly induces epithelial DAF expression in a mouse model of
gastric cancer, which reflects the pattern of H. pylori-mediated DAF induction in human
gastric tissue.
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Activation of Akt By Helicobacter pylori Is Dependent On the Cag
Pathogenicity Island
Toni Nagy, Mark Frey, Aime Franco, Seth Ogden, Daniel O'brien, Lydia Wroblewski, Uma
Krishna, Judith Romero-gallo, Stuart Hobbs, Dawn Israel, D. brent Polk, Richard M. Peek
Background and Aims: Helicobacter pylori-induced gastric inflammation is a strong risk
factor for gastric adenocarcinoma. AKT is a target of phosphatidylinositol 3-phosphate kinase
(PI3K), which can be regulated by Src kinases and by transactivation of epidermal growth
factor receptor (EGFR). A downstream effector of activated AKT is the mitogen-activated
protein kinase extracellular signal-regulated kinase (ERK), and H. pylori can activate ERK
and transactivate EGFR in gastric epithelial cells. PI3K/AKT signaling is activated in gastric
cancer, but the relationship between this cascade and H. pylori infection remains unclear.
Since PI3K-induced activation of AKT can lead to tumorigenesis, we determined whether
H. pylori alters AKT activation and investigated the molecular pathways mediating these
events. Methods: AGS gastric epithelial cells were co-cultured with the wild-type cag+ strains
7.13 or J166, or isogenic cagA- or cagE- mutants, in the absence or presence of inhibitors
of PI3K, EGFR, or Src. Levels of total and phosphorylated AKT, ERK, and p38 were detected
in H. pylori/AGS cell co-culture lysates by Western blot analysis. Results: H. pylori strains
7.13 and J166 significantly increased AKT and ERK activation in AGS cells in a time-
dependent manner, and this was abolished by PI3K or Src inhibition. As expected, treatment
of AGS cells with epidermal growth factor (EGF) led to ERK activation, but not p38 activation,
in an AKT-dependent manner, confirming a functional EGFR axis in this model. H. pylori-
induced AKT activation was dependent on transactivation of EGFR, as treatment with the
EGFR inhibitor AG1478 completely blocked AKT activation in response to this pathogen.
Inactivation of cagE, but not cagA, attenuated AKT activation compared to levels induced
by wild-type H. pylori. Conclusions: H. pylori enhances AKT activation in gastric epithelial
cells in a PI3K- and Src-dependent manner, and this activation is dependent upon specific
components within the cag pathogenicity island. Transactivation of EGFR is also required
for H. pylori-induced activation of AKT. Identification of mechanisms that regulate AKT
activation may provide deeper insight into the ability of H. pylori to lower the threshold
for carcinogenesis.
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Pleotropic Action of Helicobacter pylori Vacuolating Cytotoxin, Vaca On
Gastric and Esophageal Cell Types
Hajime Isomoto
Background and aims: Helicobacter pylori vacuolating cytotoxin, VacA, which causes vacuola-
tion of some cell types, is known to exert pleotropic biological actions. We have recently
demonstrated that VacA induces cytochrome c release and cell death independent of vacuola-
tion in gastric cancer cells. Myeloid cell leukemia 1 (Mcl-1), a key proapoptotic Bcl-2 protein
is regulated by signal transducers and activators of transcription 3 (STAT3), a transcription
factor. Map kinase (MAPK) p44/42 is a representative mitotic signal pathway upregulating
cyclooxygenase 2 (COX-2). Methods: The studies were performed in the human gastric
adenocarcinoma cell lines, AZ-521 and AGS and esophageal squamous cell carcinoma cell
line, OE21. Immunoblot analysis was employed to assess cellular expression of Mcl-1, COX-
2 and MAPK p44/42. STAT3 protein and mRNA expression were examined by immunoblot-
ting and real-time PCR, respectively. Secreted levels of prostaglandin E2 (PGE2) into culture
media were assessed by ELISA. Results: Incubation of AZ-521 and AGS cells with VacA
resulted in a substantially decreased STAT3 protein, but not mRNA, accompanied by
enhanced cellular apoptosis. There was a dose-dependent reduction of STAT3 expression
in response to VacA. Consistent with the STAT3 degradation, cellular levels of Mcl-1 was
decreased. The STAT3-Mcl-1 response to VacA seen in the gastric cancer cells was absent
in OE21 cells in line with rather proliferating reaction of the cell line. Incubation of OE21
cells with VacA caused sustained phosphorylation of MAPK p44/42, leading to enhanced
expression of COX-2 and elevated levels of PGE2. A selective MEK inhibitor, PD98059
inhibited their overexpression. Conclusions: VacA induced apoptotic cell death in the aden-
ocarcinoma cells in part through the inhibition of proapoptotic STAT3-Mcl-1 lineage, while
the mitotic MAPK pathway in the squamous cells was activated by the cytotoxin. These
results indicate that VacA can independently act on the diverse cellular targets in each cell
type and be responsible for dysregulation of the pivotal cell signaling pathways.
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The Acidity of the Gastric Surface: Analysis By the Gastric Transcriptome of
Helicobacter pylori
David Scott, Elizabeth A. Marcus, Yi Wen, Jane Oh, George Sachs
Background: There is controversy concerning the pH at the surface of the gastric mucosa.
Open tip pH micro-electrode data suggests a barrier to acidification due to mucus or
bicarbonate secretion such that even at an intra-luminal pH of 1, the surface is pH 6. Using
pH sensitive fluorescent dyes and confocal microscopy the epithelial surface was found to
be pH 4 at a luminal pH of 3 but the barrier disappeared when pHout was 2. No direct In
Vivo measurements have been made. Aim: To determine the acidity of the environment of
H. pylori infecting the surface of the gerbil stomach by analyzing expression of acid acclimation
genes. Methods: Gerbils were infected by the GFP expressing H. pylori strain, 69A. Bacterial
mRNA was separated from gastric mRNA and the expression profile analyzed on a H. pylori
genomic microarray. Results: H. pylori was seen adherent to the gastric surface. It is able to
colonize the mammalian stomach in part due to expression of a group of acid acclimation
genes that encode proteins able to buffer its periplasm and cytoplasm. In Vitro transcriptomal
analysis showed that when exposed to stable acidity, there is increased expression of several
genes regulated by the acid sensing two component ArsRS system consisting of a histidine
kinase ArsS (HP0165) and the essential response regulator ArsR (HP0166). Comparison of
the In Vivo transcriptome to the In Vitro pH 7.4 transcriptome showed increased up-regulation
of these genes (see table). Increased gene expression was confirmed by qPCR. Conclusion:
The increase in expression of the acid acclimation genes shows that H. pylori inhabits an
acidic niche on the surface of the stomach. In particular, the up-regulation of ureI encoding
a proton-gated urea channel essential for infection and survival, shows that 4 is the upper
limit of the pH at the gerbil gastric surface whose intragastric pH is similar to man.
Bolded genes are members of the ArsRS regulon. 1Pflock et al 2006 J Bact 188:3449-62.
2Wen et al 2002 J Bact 188:1750-61.
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Epac and NHERF1 Are Differentially Involved in cAMP Inhibition of NHE3
Activity in Mouse Ileum and Proximal Tubule: Initial Demonstration That
Epac Effect Is NHERF1 Dependent
Rakhilya Murtazina, Olga Kovbasnjuk, Nicholas Zachos, Yueping Chen, Xuhang Li,
Debbie Steplock, Boris Hogema, Kazie Hogue, Ming Tse, Ursula Seidler, Hugo Dejonge,
Edward Weinman, Mark Donowitz
Recently we showed that the PDZ-domain containing scaffold NHERF1 has different roles
in cAMP inhibition of NHE3 in mouse ileum and proximal tubule. NHERF1 knock mice
exhibited cAMP inhibition of NHE3 in ileum that was similar to that in wild type mice;
however, cAMP had no effect on NHE3 in proximal tubule BB vesicles or primary cultures
while there was inhibition in wild type kidney. Also it was shown that EPAC is an intermediate
in cAMP inhibition of NHE3 in proximal tubule. However, no studies have defined the role
of EPAC in ileal regulation of NHE3 or the role of NHERF1 in NHE3 regulation by cAMP
in intact kidney proximal tubule Therefore, we tested the hypothesis that cAMP inhibition
of NHE3 occurred by very different mechanisms in ileum and kidney and that commonly
expressed intermediates, EPAC and NHERF1, had different roles in cAMP regulation of
NHE3 in these tissues. Initial rates of NHE3 activity in the intact kidney cortex and ileum
of wild type and NHERF1 null mice were determined using two-photon microscopy with
the intracellular pH-sensitive dye, SNARF-4F. In ileum isolated from NHERF1 null and WT
mice, PKA antagonist H-89 completely abolished inhibitory effect of cAMP on NHE3 activity,
while in kidney proximal tubule from WT mice, H-89 eliminated only 50% of the effect of
cAMP. 8-pCPT-2'-O-Me-cAMP, an EPAC agonist, inhibited proximal tubule NHE3 activity
in WT mouse and the magnitude of the effect was ~ 50% of the effect of 8-Br-cAMP. This
EPAC agonist inhibited NHE3 activity only in WT kidney and had no effect in NHERF1
-/- mice. Both ileum and proximal tubule epithelium expressed EPAC1, with higher expres-
sion level in kidney. No physical association of NHERF1 and EPAC could be demonstrated
In Vivo or In Vitro. Conclusions: 1) cAMP regulation of NHE3 activity in ileum and kidney
proximal tubule is carried out by two different mechanisms, classical PKA-dependent inhibi-
tion in ileum and by both PKA-dependent and PKA independent (EPAC) mechanisms in
kidney; 2) cAMP inhibition of NHE3 activity in kidney but not ileum is NHERF1 dependent;
3) EPAC inhibition of NHE3 is NHERF1 dependent. 4) Despite NHERF1 being present in
both ileum and proximal tubule, it serves different signal-specific functions in these tissues.
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Role of Irf-1 in the Regulation of the Human Anion Exchanger Slc26a6 Gene
Expression By IFNγ
Seema Saksena, Alka Dwivedi, Ravinder K. Gill, Sangeeta Tyagi, Waddah Alrefai,
Krishnamurthy Ramaswamy, Pradeep K. Dudeja
SLC26A6 (Putative Anion Transporter 1) plays an important role in mediating the luminal
Cl-/HCO3- (OH-) exchange process in the mammalian intestine. Very little is known about
the molecular mechanisms involved in the transcriptional regulation of SLC26A6 gene
expression in the intestine. Previous studies from our laboratory have demonstrated the
inhibitory effects of IFNγ (30 ng/ml, 24h) on SLC26A6 expression and promoter activity.
Current studies were, therefore, undertaken to further delineate the molecular mechanisms
involved in IFNγ induced inhibition of SLC26A6 promoter activity. To identify the region
of the SLC26A6 promoter responsive to IFNγ, we examined the effects of IFNγ on various
5′-deletion constructs of SLC26A6 promoter in Caco2 cells. Deletions from p-964/+156 to
p-414/+156 did not alter the inhibitory effects of IFNγ on promoter activity. However,
further deletion to p-214/+156 completely abolished the inhibitory effects of IFNγ indicating
that the IFNγ response element is located in the -414/-214 region. Earlier studies have
shown that the effects of IFNγ could be mediated through IRF-1. Therefore, sequence analysis
of the -414/-214 region was carried out to determine the presence of binding site for IRF-
1 and our results revealed the presence of potential Interferon Stimulated Responsive Element
(ISRE), a binding site (-318/-308) for Interferon Regulatory Factor-1 transcription factor
(IRF-1). Interestingly, mutations in the potential ISRE of the SLC26A6 promoter completely
abrogated the inhibitory effects of IFNγ. The binding of ISRE to IRF-1 was examined
by electrophoretic gel shift assays. EMSA demonstrated increased protein binding to the
oligonucleotide spanning the potential ISRE site (-318/-308) in IFNγ-treated nuclear extracts.
The binding was abolished in the presence of excess of cold potential ISRE oligo, consensus
IRF-1 oligo and IRF-1antibody, but not in the presence of mutant IRF-1 oligo. Conclusion:
Our studies provide novel evidence for the involvement of IRF-1 in the regulation of SLC26A6
gene expression by IFNγ in the human intestine. We speculate that IRF-1 may contribute
to the pathophysiology of diarrhea associated with inflammation. (Supported by Dept. of
Veteran Affairs and NIDDK).
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Identification of Down-Regulated in Adenoma (DRA, Slc26a3) As the Primary
Cl-/HCO3- Exchanger Involved in Coupled Nacl Absorption Across Murine
Jejunal Epithelium
Nancy M. Walker, Janet E. Simpson, Pei-fen Yen, Clifford W. Schweinfest, Lane L. Clarke
Electroneutral NaCl absorption involving coupled Na+/H+ and Cl-/HCO3- exchangers in
intestinal epithelia contributes to the maintenance of extracellular fluid volume. Studies
using mice with gene-targeted deletion of epithelial Na+/H+ exchanger isoforms have shown
that most intestinal Na+ absorption occurs via NHE3. However, the functional identity of
the Cl-/HCO3- exchanger necessary for Cl- absorption across native intestinal epithelium has
not been elucidated. Two members of the multifunctional anion exchanger family Slc26a3
(DRA) and Slc26a6 (putative anion transporter-1, PAT-1), demonstrate Cl-/HCO3- exchange
activity and have been immunolocalized to the apical membrane of intestinal epithelium.
Using mice with gene-targeted deletions of NHE3, DRA or PAT-1, we investigated the
identity of the coupled Cl-/HCO3- exchanger using BCECF microspectrofluorometry to
measure intracellular pH (pHi) and isotopic fluxes to measure rates of transepithelial NaCl
transport. BCECF studies revealed that basal pHi in the upper villous epithelium of the
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NHE3(-) intestine was acidic relative to wild-type (WT), consistent with continued activity
of Cl-/HCO3- exchange. DRA(-) epithelium was alkaline relative to WT, consistent with
continued activity of Na+/H+ exchange. In contrast, PAT-1(-) epithelium was slightly acidic
relative to WT (n = 5 - 7). Isotopic NaCl flux measurements of DRA(-)intestine under basal
conditions revealed similar rates of net Na+ absorption as compared to WT, whereas net
Cl- absorption was dramatically reduced by > 85% [WT = 12.9 ± 2.8 vs. DRA(-) = 1.6 ±
1.2 µeq/cm2-h, n = 6, p < 0.05] as a result of decreased mucosal-to-serosal Cl- flux [WT =
36.0 ±3.6 vs. DRA(-) = 23.1 ± 2.2, p < 0.05]. Following stimulation with 0.01 mM forskolin,
net NaCl absorption was abolished and net Cl- secretion was established at rates similar to
WT intestine. In PAT-1(-) intestine, net Na+ absorption under basal conditions was slightly
reduced relative to WT whereas net Cl- absorption was not significantly changed. Interest-
ingly, following forskolin stimulation, PAT-1(-) intestine demonstrated reduced rates of net
Cl- secretion [WT = -14.3 ± 0.8 vs. PAT-1(-) = -11.1 ± 1.1, p < 0.05] and serosal-to-mucosal
Cl- flux relative to WT [WT = 30.0 ± 1.5 vs. PAT-1(-) = 23.9 ± 1.6, p < 0.05], but no
change in the magnitude of the short-circuit current. From these studies of small intestinal
epithelium we conclude that 1) Slc26a3 (DRA) is the major Cl-/HCO3- exchanger coupled
to NHE3 in the process of electroneutral NaCl absorption, and 2) Slc26a6 (PAT-1) contributes
little to net NaCl absorption but facilitates the process of Cl- secretion during cAMP stimula-
tion.
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Changes of the Expression of the Na+/H+ Exchanger NHE3 and the Pdz-
Adapter Proteins Pdzk1 and NHERF1 During Inflammation in the Colon of
the Interleukin-10-Deficient Mouse
Henrike Lenzen, Andre Bleich, Michael P. Manns, Ursula Seidler
Impaired absorption of salt and water is a crucial factor in the pathogenesis of diarrhoea in
inflammatory bowel disease. The Na+/H+ exchanger isoform NHE3 is the major transport
protein for Na+ and water absorption in the ileum and proximal colon. Recently, PDZ-
domain adapter proteins have been shown to be central players in the targeting, membrane
retention, and signal complex formation of membrane proteins, including NHE3. We investig-
ated the gene and protein expression of NHE3 and different PDZ-adapter proteins in the
chronic phase of intestinal inflammation. Interleukin-10-deficient (Il10tm1Cgn, Il10-/-) and
wild type (WT) mice on a C57BL/6J background were raised under conventional or strict
barrier SPF conditions. Total RNA was extracted from colon mucosa of 6-9 months old
mice. Gene expression of different cytokines, adapter and transport proteins was measured
by quantitative RT-PCR. Protein expression was studied by Western Blot analyses. Tissue
sections were examined morphologically by light microscopy using hematoxylin/eosin stain-
ing as well as immunohistochemically using specific antibodies against the proteins of
interest. Il10-/- mice maintained under conventional conditions developed chronic colitis
while WT or Il10-/- mice kept under strict SPF conditions remained unaffected. In the
inflamed mucosa of the colon, the proinflammatory cytokines IL-1-beta, IL-12, and TNF-
alpha were highly expressed on the gene and protein level while IFN-gamma was only
slightly increased. iNOS expression was also increased. Morphological analyses revealed
crypt hyperplasia and submucosal leukocyte infiltration in Il10-/- mice. Expression of NHE3
was not downregulated in the inflamed colon, though we know from earlier studies in this
mouse model that its functional activity is severely impaired. Immunofluorescence staining
of NHE3 confirmed this observation. PDZK1 expression was downregulated in the colon,
while NHERF1 expression was not affected. The data suggest that in the chronic phase of
immune-mediated intestinal inflammation, gene expression of NHE3 is not downregulated,
though the absorptive function of the colon is impaired, manifesting with diarrhoea and
weight loss in the Il10-/- mice. This functional impairment of the colon may be related to
the strong downregulation of PDZK1, which retains NHE3 in the plasma membrane and
regulate its transport function. This is supported by the fact that the same functional defect
has been observed in the colon from PDZK1-deficient mice. The selective downregulation
of the PDZ-adapter protein in the course of the inflammatory process may be of significant
pathophysiological relevance for the disease process.
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Compensatory Regulation By Constitutive Nitric Oxide of Na:H and Na
Glucose Co-Transport in Intestinal Epithelial Cells
Steven Coon, Ramesh Kekuda, Uma Sundaram
BACKGROUND:While, constitutive nitric oxide (cNO) has been shown to affect intestinal
electrolyte transport, whether it can compensatorily regulate two distinct intestinal brush
border membrane (BBM) Na absorptive processes is unknown. AIM: Determine whether
cNO can compensatorily regulate Na:Proton exchange (NHE3) and Na-glucose co-transport
(SGLT1) and the mechanisms of regulation in intestinal epithelial cells. METHODS:Rat small
intestinal epithelial cells (IEC-18) monolayers on transwell plates 10 days post confluence
were utilized. Nw-Nitro-L-arginine methyl ester hydrochloride (L-NAME, 1 mM) was used
to inhibit cNO in IEC-18 cells. Na-dependent 3-OMG uptake and amiloride-sensitive 22
Na uptake were measured to determine SGLT1 and NHE3 activity. SGLT1 and NHE3 RNA
were quantitated by real time PCR. RESULTS:Inhibition of cNO inhibited SGLT1 in IEC-
18 cells (Na-dependent 3-OMG uptake was 307±47 nmol/mg prot./2 min in control and
64±14 in L-NAME treated cells, p<0.01, n=6). In contrast it stimulated Na:H exchange
(22Na uptake was 583±78 nmol/mg prot./2 min in control cells and 2474±290 in L-NAME
treated cells, p< 0.01, n=6). An inactive analog of L-NAME, D-NAME, had no effect on
SGLT1 or NHE3. Kinetic studies demonstrated that the mechanism of inhibition of SGLT1
by L-NAME was secondary to a decrease in the affinity of the co-transporter for glucose..
In contrast, L-NAME mediated stimulation of NHE3 was secondary to an increase in the
maximal rate of uptake (Vmax). Real time PCR demonstrated no change in SGLT1 mRNA
while NHE3 mRNA was significantly increased in L-NAME treated cells. Since cNO may
mediate its effect by cGMP, guanylate cyclase was inhibited with 1H-[1,2,4]Oxadiazolo[4,3-
a] quinoxalin-1-one (ODQ, 500 uM). ODQ treatment also inhibited SGLT1 (189±21 nmol/
mg/prot./2 min in control cells and 39±1.8 in ODQ treated cells, n= 5, p<0.05) while NHE3
was stimulated (749±93 nmol/mg prot./2 min in control and 2210±197 in ODQ treated
cells, p< 0.05, n=5). Further, since cGMP is known to mediate its effect via cGMP kinase
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it was inhibited with RP-8-bromo-cGMPS (50 uM). Inhibition of cGMP kinase also inhibited
SGLT1 while it stimulated NHE3 similar to that seen when guanylate cyclase was inhibited
(data not shown). CONCLUSIONS:Inhibition of cNO in intestinal epithelial cells inhibited
SGLT1 by reducing the affinity of the co-transporter while it stimulated NHE3 by increasing
exchanger numbers. cGMP and its dependent kinase mediate these unique alterations. These
studies demonstrate the unique and compensatory regulation of two important Na absorptive
processes on the BBM of intestinal epithelial cells by constitutive nitric oxide.
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Anti Inflammatory Peptide (Kpv) Delivery Via Pept1 Reduces Intestinal
Inflammation
Guillaume Dalmasso, Pallavi Garg, Laetitia Charrier, Shanthi V. Sitaraman, Didier Merlin
Since we previously demonstrated that hPepT1 is expressed in inflamed colonic epithelial
cells, we hypothesized that colonic-expressed hPepT1 could be used for uptake of small
anti-inflammatory peptides. Here, we demonstrate that the anti-inflammatory peptide,
[3H]KPV (Lys-Pro-Val), is transported by hPepT1 in Caco2-BBE cells since this uptake was
reduced by ~80% in the presence of 20 mM Gly-Leu. Interestingly, Caco2-BBE cells incubated
with KPV prior to Il-1β treatment show reduced activation of NF-κB and MAP kinases
(ERK1/2, JNK, p38) and decreased secretion of IL-8. The KPV effect was hPepT1 depedent
since that in a cell line that does not express hPepT1 (HT29-Cl.19A), KPV did not affect
inflammatory pathways stimulated by IL-1β. Finally, we found that giving KPV in drinking
water reduces DSS-induced intestinal inflammation in mice. We observed a decrease in
colonic damages and a significant down-regulation of pro-inflammatory cytokines IL-6 and
IL-12. These data collectively suggest that colonic-expressed PepT1 may transport tri-peptides
(e.g. KPV), leading to decreased activation of intracellular inflammatory signaling pathways.
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The Role of Akt in the Regulation of Goblet Cell-Specific Gene Expression
Mei-lun Wang, Tanesha Cash-mason, Sue A. Keilbaugh, Gary D. Wu
Background: PI3-kinase and AKT signaling pathways play critical roles in nutrient and
hormone-dependent signaling, leading to alterations in cell proliferation, growth and survival.
Herein, using the expression of the RELMβ gene as a model, we show that these same pathways
are critical for goblet cell-specific gene activation in the intestine. We have previously shown
that Th2-dependent immune responses, typically induced by parasitic nematode infections,
can signal through PI3-kinase and AKT to activate RELMβ mRNA expression in the LS174T
cell line. In this study we examine the role of AKT to activate RELMβ gene expression in
goblet cells In Vivo and identify its effect on promoter activation In Vitro. Methods and
Results: Wild-type BALB/c, IL4Rα-/-, and Stat6-/- mice were infected with the intestinal
nematode, Heligmosomoides polygyrus, a parasite that is encysted in the muscularis propria
and submucosa 6 days post infection (6 dpi) and is located in the intestinal lumen at 21
dpi. Duodenal tissue was isolated for RELMβ mRNA quantification and immunohistochem-
istry. While RELMβ was induced in goblet cells in all three mouse genotypes at 6 dpi,
goblet cell-specific expression of this gene was induced only in wild-type mice at 21 dpi,
demonstrating that RELMβ gene activation was dependent upon the location of the nematode
in the intestinal tract. Remarkably, this result indicates that Th2-type immune signaling
through the IL-4 receptor is not required for the activation of RELMβ expression when the
nematode is encysted within the intestinal wall. Immunostaining of these same tissues for
FOXO1, a surrogate marker for the activation of AKT signaling, demonstrated that AKT is
activated in the intestinal epithelium by H. polygyrus infection in both the encysted and
luminal phase of the infection. Finally, using a pharmacologic inhibitor of both AKT1 and
2 in luciferase reporter assays, we show that this signaling pathway is responsible for the
activation of the RELMβ core promoter. Conclusions: Previous studies have shown that Th2
immune responses, which signal through the IL-4 receptor, lead to alterations in goblet cell
number and size. Our results demonstrate that AKT plays a critical role in the activation of
goblet cell-specific gene expression and promoter activation in both IL-4 receptor-dependent
and independent pathways.
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The Enteropathogenic E. coli Effector Protein Espf Decreases Sodium
Hydrogen Exchanger 3 Activity
Kim Hodges, Neal M. Alto, Kris Ramaswamy, Pradeep K. Dudeja, Gail A. Hecht
Enteropathogenic E. coli (EPEC) has been previously shown to decrease sodium hydrogen
exchanger 3 (NHE3) activity in human intestinal epithelial cells. However, further character-
ization of this response in cultured human intestinal epithelial cells was confounded by
variable expression levels of NHE3, the need for isoform-specific NHE inhibitors, and the
presence of a second apical NHE isoform, NHE2. Therefore, the aim of this study was to
characterize EPEC effects on NHE3 in absence of other NHE isoforms. PS120 fibroblasts
were transfected with NHE3 alone or were co-transfected with the scaffolding/regulatory
proteins NHERF1 (EBP50) or NHERF2 (E3KARP). Net 22Na+ uptake was calculated as the
EIPA-inhibitable (50μM) 22Na+ uptake over 5 min and expressed as nmol/mg protein/5
min. Infection with EPEC strain E2348/69 for 2 hours caused a 36+/-4% decrease in NHE3
activity (P<0.05, n=9) in PS120 fibroblasts as compared to uninfected cells. NHE3 activity
was further decreased to 56+/-4% and 65+/-2% by co-transfection with NHERF1 (EBP50)
or NHERF2 (E3KARP) (P<0.05, n=9). Infection with non-pathogenic E. coli HB101 had no
effect on NHE3 activity (5.8+/-0.3 vs. 6.1+/-1 nmol/mg protein/5 min for HB101 vs. controls,
P>0.05, n=4). A functional type III secretion system (TTSS) was required as the TTSS
defective mutant ΔescN failed to decrease NHE3 activity (6.7 nmol/mg protein/5 min for
both uninfected and ΔescN, P>0.05, n=8). Mutation of the gene encoding the translocated
intimin receptor (Tir) did not impact NHE3 activity (1.8+/-0.5 vs. 1.7+/-0.4 for wt vs. Δtir,
respectively), indicating that intimate attachment was not necessary for this phenotype
(P>0.05, n=3). Despite its ability to bind to NHERF proteins, the EPEC effector Map was
not involved in regulation of NHE activity as both Δmap and ΔmapTRL, specifically defective
in NHERF binding, reduced NHE3 activity by levels equivalent to wt EPEC. Instead, EspF
appears to be solely responsible for decreasing NHE3 activity. Infection of PS120 cells co-
transfected with NHE3 and NHERF2 was reduced from 7.5+/-0.8 to 3.4+/-0.2 by infection
with wt EPEC, while infection with ΔespF failed to inhibit NHE3 activity (7.9+/-0.7, P>0.05,
n=4). We conclude that the EPEC-induced decrease in NHE3 activity is mediated by the
effector EspF and may contribute to diarrhea associated with infection by this pathogen.
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Diarrheal Mechanisms of Human Norovirus Infection
Hanno Troeger, Thomas Schneider, Christoph Loddenkemper, Hans-joerg Epple, Eckart
Schreier, Martin Zeitz, Michael Fromm, Joerg D. Schulzke
Background & Aims: Norovirus infection is the most frequent cause of infectious diarrhea
in the western world. The infection leads to outbreaks of nausea, vomiting and watery
diarrhea. So far, the virus could not be replicated in cell culture, therefore the pathomechan-
isms of disease are unclear. This study aimed to characterize the pathomechanisms of the
diarrhea due to norovirus infection in human biopsies. Methods: Duodenal biopsies from
6 patients with acute norovirus infection and 7 controls were obtained endoscopically.
Norovirus infection was diagnosed by PCR analysis from stool samples. Short circuit current
and mannitol fluxes were measured in miniaturized Ussing chambers. Impedance spectro-
scopy discriminates epithelial from subepithelial resistance. Transport mechanisms were
characterized by adding bumetanid and NPPB. Histological analysis was performed and tight
junction proteins were characterized in membrane fractions by immunoblotting. Results:
In norovirus infection, epithelial resistance was decreased to 10 ± 1 Ω cm2 versus 24 ± 2
Ω cm2 in controls. Mannitol flux was 113 ± 24 nmolh-1 cm-2 in controls and increased to
242 ± 29 nmolh-1 cm-2 in norovirus-infected specimens. Histological sections of duodenal
biopsies showed no gross morphological alterations such as erosions or villous height
reduction. In contrast, expression of tight junction proteins occludin and claudin-4 was
decreased to 62 ± 11% resp. 63 ± 10% of controls. Furthermore, basal short circuit current
increased from 81 ± 10 in controls to 150 ± 18 µAh-1 cm-2 in norovirus infection, which
could be reduced by inhibitors of chloride secretion. Conclusions: For the first time this
study elucidated mechanisms of diarrhea in human norovirus infection. Norovirus infection
leads to severe epithelial barrier dysfunction in combination with stimulated anion secretion,
paralleled by a reduction of the tight junctional proteins occludin and claudin-4. Thus, the
diarrhea in norovirus infection is driven by both, a leak flux and a secretory component.
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TLR5 Protects the Intestine from Salmonella But Promotes the Systemic
Disease Caused By This Pathogen
Matam Vijay-kumar, Catherine Sanders, Shizuo Akira, Shanthi V. Sitaraman, Andrew S.
Neish, Andrew Gewirtz
BACKGROUND: Recognition of bacterial products by toll-like receptors (TLR) provides
broad innate protection against a variety of microbes but may also underlie much of the
infectious inflammatory pathology. Consequently, TLRs may also aid a pathogen's dissemina-
tion throughout its host. Bacterial flagellin is recognized by TLR5 and is thought to be a
dominant innate immune activator of intestinal epithelial cells. GOAL: Investigate the role
of TLR5 in the pathophysiology of Salmonella infection using murine models of typhoid
fever and Salmonella-induced gastroenteritis. METHODS: Gene-targeting in ES cells was
used to make chimeric TLR5KO mice on an SL/J background, which were then backcrossed
to C57BL/6 mice for 6 generations to generate both TLR5KO mice and wild type (WT)
littermates (all experiments then compared the TLR5KO mice directly to their WT littermates).
Salmonella-induced typhoid fever was modeled by orally infecting mice with 106-108 S.
typhimurium SL3201 or isogenic aflagellate mutant and measuring body weight and mortality
daily. Salmonella gastroenteritis was modeled by orally pre-treating mice with streptomycin
and 24 h later orally infecting with 1x108 CFU S. typhimurium, for 48 h at which time
we measured levels of serum amyloid (SAA) and assayed cecal inflammation/pathology based
on weight, gross morphology, H&E staining, and levels of myeloperoxidase (MPO). RESULTS:
While both WT and TLR5KO exhibited rapid weight loss upon Salmonella infection, a
relatively low dose of 1x106 CFU per mouse was sufficient to kill all of the WT mice whereas
TLR5KO mice uniformly survived this challenge. TLR5KO mice also uniformly survived
challenge with 1x108 CFU and were relatively resistant to 5x108 CFU. In accordance, TLR5-
deficient mice had less CFU in the liver and spleen and, concomitantly, exhibited less
enlargement of these organs (assessed at 7-days post infection). Such resistance of TLR5KO
mice was specific for flagellated Salmonella via the oral route of infection as TLR5KO
and WT mice succumbed at similar rates to both oral challenge with flagellin-deficient S.
typhimurium and low-dose intraperitoneal challenge with WT S. typhimuirium. In contrast,
in the model of Salmonella gastroenteritis, TLR5KO mice exhibited more severe gut pathology,
as assessed by all parameters assayed. Mice lacking the global TLR signaling molecule MyD88
exhibited no gut pathology suggesting that the inflammation in this model is driven by
other TLRs CONCLUSIONS: TLR5 protects the intestine from Salmonella typhimurium.
However, TLR5 activation may be used by Salmonella to promote its dissemination and
thus may increases susceptibility to typhoid fever.
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Lactobacillus acidophilus Secreted Effector Molecule(s) Increase Cl-/OH-
Exchange Activity in Caco-2 Cells Via PI-3 Kinase Mediated Pathway
Alip Borthakur, Ravinder K. Gill, Athanasia Koutsouris, Fadi Annaba, Gail A. Hecht,
Krishnamurthy Ramaswamy, Pradeep K. Dudeja
Probiotics are viable non-pathogenic microorganisms that may confer health benefits to host
by ameliorating disease. Some of the commensal flora represented by Lactobacilli are protective
against pathogenic infections and have been currently used as alternative treatments for
diarrhea. However, very limited studies have been carried out to investigate the direct effects
of probiotics on intestinal electrolyte absorption. Diarrhea occurs due to increased secretion,
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decreased absorption or both. Therefore, the current studies were designed to examine the
effects of Lactobacillus, a probiotic bacterium, on luminal Cl- /OH- exchange activity in
human intestinal epithelial cells. Post-confluent Caco-2 cell monolayers were treated with
Lactobacillus strains, viz., L. acidophilus, L. casei, L. plantarum or L. rhamnosus for 3 hrs at a
multiplicity of infection (MOI) of 1:50. Cl-/OH- exchange activity was measured as DIDS-
sensitive 36Cl uptake in base-loaded cells. Treatment of Caco-2 cells with L. acidophilus
caused a significant increase in Cl-/OH- exchange activity (~50%, P<0.05), whereas, other
Lactobacillus strains were ineffective. Similar to the live bacteria, the conditioned medium
(supernatant) of L. acidophilus also increased 36Cl uptake. This increase was not associated
with a change in pH of the incubation media, as there was no change in pH after 3 hrs of
treatment with either the probiotic or the conditioned medium. Heat killed L. acidophilus
did not increase Cl-/OH- exchange activity. The ability of L. acidophilus or its conditioned
culture medium to enhance Cl- uptake was blocked by PI-3 kinase inhibition (LY294002,
10 μM), but was unaffected by MAP kinase inhibition (U0126: MEK1 and 2 inhibitor or
SB203580: p38 inhibitor). Conclusion: Our results suggest that L. acidophilus secretes soluble
effector molecule(s) into the culture media that exert stimulatory effects on apical Cl-/OH-
exchange activity in Caco-2 cells via a PI-3 kinase mediated mechanism. We speculate that
this mechanism is related to PI-3 kinase dependent increase in trafficking of the chloride
transporter(s) to the membrane surface resulting in increased Cl-/OH- exchange activity.
Our findings are of significant relevance in increased understanding of probiotic regulation
of intestinal electrolyte absorption in normal and pathophysiological conditions. (Supported
by Dept of Veteran Affairs and NIDDK).
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Transcutaneous Immunization with Shiga Toxin B Subunit Protects Against
Intestinal and Renal Effects of Shiga Toxin-Producing Escherichia coli (STEC)
Infection
Chengru Zhu, Jianmei Yu, Baoan Wang, Gregory Glenn, Edgar Boedeker
Transcutaneous Immunization (TCI) using semi-occlusive patches, with or without co-
administered E.coli heat labile toxin (LT) as adjuvant, induces systemic IgG responses to
administered antigens. We postulate that induction of systemic antibody responses to the
B subunit of Shiga toxin should protect against hemorrhagic colitis and hemolytic uremic
symdrome caused by STEC infection. Preventing the interaction of the toxin with microvascu-
lar receptors should ameliorate vascular injury in both intestine and kidneys. To test this
hypothesis, we evaluated the safety, immunogenicity and protective efficacy of the B subunit
of Stx1 (Stx1B) administered by TCI to Dutch Belted Rabbits which are susceptible to
development both hemorrhagic colitis and renal vascular lesions. Three groups of Dutch
Belted Rabbits received patches containing Stx1B, Stx1B with E. coli LT, or LT alone.
An additional group of naïve rabbits served as immunization controls. Following three
immunizations at 2 week intervals, serum antibodies specific to Stx1B and LT in serum and
bile were serially assessed. Protective efficacy of the immunization protocols was evaluated
by challenge with the virulent STEC strain RDEC-H19A, an Stx-1-producing derivative of
REPEC RDEC-1 capable of inducing hemorrhagic colitis and renal lesions in Dutch Belted
Rabbits. The clinical course of disease was observed for seven days. Animals were then
sacrificed for histological examination of cecum and kidney. Rabbits receiving Stx1B or
Stx1B/LT showed increased serum IgG ELISA titers specific to Stx1B antigen and Stx1
neutralization titers. Rabbits vaccinated with Stx1B also demonstrated improved weight gain
and reduced Stx-induced-histopathology in the intestine. In the kidney, all animals developed
lesions associated with HUS including glomerular heterophile infiltrates, glomerular conges-
tion, fibrin like deposits in medium vessels, cortical congestion, and perivascular edema. In
Stx1 immunized animals, glomerular heterophiles, cortical congestion, and perivascular
edema were significantly reduced. This study demonstrates that Stx1B subunit protein
delivered by TCI induces systemic immune responses which effectively protect against colitis
induced by Stx1 and may ameliorate renal lesions of HUS.
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Modulation of Hepatocellular Cancer Stem Cells By TGF-Beta and IL-6
Signaling Pathways
Yi Tang, Krit Kitisin, Varalakshmi Katuri, Eugene A. Volpe, Jon Mendelson, Wilma
Jogunoori, Cuiling Li, Chu-xia Deng, Anton Sidawy, Stephen Evans, Kirti Shetty, Blair M.
Marshall, Michael Zasloff, Bibhutibhushan Mishra, Prem kumar Reddy, Lynt B. Johnson,
Lopa Mishra
Hepatocellular cancer (HCC) is considered to arise from a single progenitor/stem cell. Yet
the identification of this cell type, and pathways activated in such a cell have remained
elusive but can be identified from tissue with long-term label retaining cells. Aims: We
hypothesized that post regeneration human liver tissue is a source of expanded numbers of
stem cells that would be transformed in HCC. Furthermore the phenotypic characteristics
of this stem cell could direct mouse genetic studies and provide an ideal functional model
to determine pathways in transformed stem cells. Methods and Results: 1. Using post
regeneration human liver tissues from 4 living donor recipients, we identify an expanded
small population of cells that simultaneously express stem cell markers Stat3, Oct4, Nanog
as well as pro-differentiation TGF-beta signaling pathway proteins TBRII and ELF. 2. In
human hepatocellular cancers, such clumps of cells continue to express Stat3 and Oct4 but
undergo a marked loss of TBRII and ELF, suggesting that HCC formation from a transformed
stem/progenitor cell driven by stem cell factors such as stat3 in the setting of inactivated
TGF-beta signaling 3. Mouse models confirm HCC formation with disruption of TGF-beta
signaling as we observe in elf+/- mice. These mice also display markedly activated IL-6/Stat3.
4. We generated a knockout of an IL-6/stat3 regulated protein, ITIH4 in which IL-6/stat3
signaling is disrupted. 5. To further determine the functional role of IL-6/Stat3 and TGF-
beta signaling in HCC, elf+/- mice were crossbred with itih4-/- mice. The elf+/- and elf+/-/itih4-/-
offspring were autopsied to determine the development of any abnormalities. HCC incidence
is dramatically decreased in elf+/-/itih4-/- mice. Only 1/25 elf+/-/itih4-/- mice developed a small
HCC at 15 mos (4%) compared to 40 percent of elf+/- mice with spontaneous HCC at this
age (10/25). 6. Microarray and immunoblot profiles of elf+/- indicated a marked activation
of the IL-6/Stat pathways that is abrogated in itih4-/- and elf+/-/itih4-/- liver tissues. Conclusions:
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1. We identified a stem/progenitor cells in human liver tissues expressing both stem cell
markers as well as differentiating factors. 2. Maintenance of a stem cell phenotype with IL-
6/Stat3 signaling in the absence of TGF-beta signaling potentially leads to formation of HCC
stem cells and HCC. 3. Loss of IL-6/Stat3/ITIH4 plays critical role in suppression of HCC
induced by inactivation of TGF-β/ELF pathway. 4. This study reveals an unexpected link
between a major stem cell signaling pathway and the TGF-beta signaling pathway in the
modulation of mammalian HCC, a lethal cancer of the foregut.
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A Critical Role for T-Cells and Th1 Induced Inflammation in Murine
Cholestrerol Cholelithogenesis
Kirk J. Maurer, Varada P. Rao, Martin C. Carey, James G. Fox
Introduction: Utilizing T and B lymphocyte deficient (Rag) and immunocompetent wild-
type (wt) BALB/c mice we demonstrated previously that adaptive immunity is critical for
cholesterol gallstone formation (Maurer et al. Gastroenterology 130 (4) 2006 abstract 592).
We now wished to determine if this was mediated by T or B-lymphocytes and in so doing
to characterize the inflammatory response of the gallbladder during cholesterol cholelithogen-
esis. Methods: We studied Rag mice on a BALB/c background and divided these mice into
three groups. Group one was untreated (n=36), group two and three received either 2
million splenic T or B-cells (n=15 each) from naïve wt donors at 6-8 weeks of age. All mice
were fed a lithogenic diet for eight weeks beginning at 8-9 weeks of age. Results: Transfer
of T-cells to Rag mice increased cholesterol monohydrate crystal formation (53% vs. 17%,
P<0.05) and cholesterol gallstone formation markedly (40% vs. 3%, P<0.05) whereas transfer
of B-cells failed to increase either (13% for each). We then transcriptionally analyzed 84
inflammatory genes from the gallbladders of Rag mice and mice that received T-cells and
further analyzed mice on the basis of whether their bile progressed to cholesterol monohydrate
crystal formation (either free crystals or in stones) or not (4 groups, n=5-6 per group). Mice
receiving T-cells and developing cholesterol monohydrate crystals displayed a marked Th1
immune response, as evidenced by the upregulation of three Th1 cytokines (Tnf-α, Il1β,
and Ifn-γ, P<0.05 upregulation compared to all other groups, mean 30 fold increase compared
to Rag mice with cholesterol monohydrate crystals). In contrast, genes involved in a Th2
response (e.g. Il4, Il10, and Il13) were not expressed to any appreciable degree in any of
the groups. Conclusions: These data imply that T-cells are critical in murine cholesterol
cholelithogenesis and that the formation of cholesterol monohydrate crystals induces a local,
T-cell mediated, Th1 inflammatory response which likely contributes to cholesterol gallstone
formation via gallbladder mediated injury. These data strongly argue that an immune response
and inflammation are key contributors to cholesterol cholelithogenesis rather than being
the result of the process.
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The Vagus Nerve Is Involved in Constitutive Downregulation of Acute and
Chronic Intestinal Inflammation Through the Alpha7 Nicotinic Receptor
Pathway
Hanneke P. Van der kleij, Paul Forsythe, John Bienenstock
There is constant communication between the immune and nervous system. The vagus
nerve is an important bidirectional pathway signaling between the G.I. tract and brain.
Subdiaphragmatic vagotomy was performed to examine the role of the vagus nerve during
intestinal inflammation. To induce acute colitis, male BALB/c mice were given 4% dextran
sulphate sodium (DSS) solution freely for 5 consecutive days followed by distilled water for
another 2 days. Furthermore, vagotomized mice were treated with nicotine (s.c. 50 μg twice
daily for 10 days) and exposed to DSS to explore a role for the anti-inflammatory pathway
in this model. In a separate set of experiments, mice were injected (i.p.) with the nicotinic
antagonist mecamylamine (1 mg/kg) or the more selective α7 receptor antagonist methyllyca-
conitine (5 mg/kg), starting 1 day before DSS. In addition, the effect of vagotomy was
evaluated after chronic DSS, induced by 4 cycles of 4% DSS for 5 days followed by 10 days
of water. In the acute model, large scale epithelial loss and mucosal degeneration was observed
together with an accumulation of inflammatory cells in colonic mucosa and increased tissue
levels of MCP-1, IL-6 and TNF. MPO levels and TNF levels were significantly elevated in
vagotomized mice compared to sham-operated mice and were decreased by nicotine treat-
ment. In addition, In Vitro levels of CD3/CD28 stimulated mesenteric lymphocytes of vagoto-
mized mice exposed to DSS showed higher levels of IFN-γ, MCP-1, IL-10, TNF and IL-6.
The nicotinic antagonist mecamylamine significantly increased the level of MPO together
with levels of MCP-1, TNF and IL-6 compared to DSS alone and the α7 receptor inhibitor
methyllycaconitine even further increased these biomarkers. In the chronic situation the
increase in inflammation was also more pronounced in vagotomized mice, reflected in clinical
score and increased MPO and cytokine levels in colonic tissue and stimulated mesenteric
lymphocytes. In addition, vagotomy alone induced higher levels of TNF in colonic tissue
and higher levels of MCP-1 and IL-6 in CD3/CD28 stimulated mesenteric lymphocytes
suggesting a constitutive beneficial role of the vagus. Taken together, we provide evidence
for a protective involvement of the vagus nerve in intestinal inflammation in mice. Further-
more, we show that nicotinic receptors and more specific α7nicotinic receptors are part of
an important constitutive anti-inflammatory mechanism. The cholinergic anti-inflammatory
reflex appears to be operational in acute and chronic G.I. inflammation and may have an
important therapeutic potential in IBD. This work is supported by a grant from the Broad
Medical Research Program.
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Trypsin IV and P23 Cleave Protease-Activated Receptors 1 and 2 On Afferent
Nerves to Cause Neurogenic Inflammation and Pain
Wolfgang Knecht, Graeme S. Cottrell, Silvia Amadesi, Johanna Mohlin, Anita Skåregärde,
Karin Gedda, Anders Peterson, Morley D. Hollenberg, Nathalie Vergnolle, Nigel W.
Bunnett
Although principally produced by the pancreas to degrade dietary proteins in the intestine,
trypsins are also expressed by extrapancreatic epithelial cells and in the nervous system,
where they have diverse actions that could be mediated by protease-activated receptors
(PARs). Our aim was to characterize the enzymatic properties and biological actions of
human trypsin IV (mesotrypsin) and rat p23, inhibitor-resistant trypsins that are present in
pancreatic and extrapancreatic tissues, where they are upregulated and activated during
inflammation. We expressed trypsinogen IV and prop23 with hexa-histidine tags in E. coli and
purified them to apparent homogeneity using immobilized metal ion affinity chromatography.
Enteropeptidase cleaved both zymogens, liberating trypsin IV and p23, which degraded the
synthetic substrate tosyl-GPR-pNA. The polypeptide inhibitors soybean trypsin inhibitor
and aprotinin, which potently inhibit pancreatic trypsin I and II, did not strongly inhibit
trypsin IV or p23. Trypsin IV cleaved N-terminal fragments of PAR1, PAR2 and PAR4 at
sites that would expose the tethered ligand domains with rates of PAR1=PAR4>PAR2, consist-
ent with receptor activation. p23 also cleaved fragments of PAR1 and PAR2 at a similarly
rapid rate to expose tethered ligands. Trypsin IV increased [Ca2+]i in transfected KNRK cells
expressing human PAR1 and PAR2 with similar potencies (PAR1, 0.45 µM; PAR2, 0.59 µM).
p23 also increased [Ca2+]i in these cells, with greater potency than trypsin IV. Trypsin IV
and p23 increased [Ca2+]i in rat dorsal root ganglion neurons in culture that responded to
capsaicin and which thus mediate neurogenic inflammation and nociception. Pretreatment
with proteases desensitized responses of neurons to PAR1 and PAR2-selective activating
peptides, suggesting that trypsin IV and p23 signal to neurons by cleaving these receptors.
Intraplantar injection of trypsin IV in mice induced marked edema and granulocyte infiltra-
tion, which were not observed in PAR1-/- and PAR2-/- mice. Trypsin IV caused hyperalgesia
to a thermal stimulus and allodynia and hyperalgesia to mechanical stimuli. These effects
were absent in PAR2-/- mice but maintained in PAR1-/- mice. Thus, trypsin IV and p23 are
inhibitor-resistant forms of trypsin that can cleave and activate PAR1 and PAR2 in transfected
cells and afferent neurons. Neuronal activation induces inflammation that depends on PAR1
and PAR2, and PAR2-dependent hyperalgesia. These mechanisms may contribute to pain
and inflammation in conditions of pancreatic and intestinal inflammation, where trypsin
IV and p23 are upregulated and activated. Supported by NIH DK43207, DK57480 and
Astra-Zeneca
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Significant Long Term Reduction in Colorectal Cancer Mortality with
Colonoscopic Polypectomy: Findings of the National Polyp Study
Ann G. Zauber, Sidney J. Winawer, Michael J. O'brien, Weiji Shi, Sharon Bayuga
The National Polyp Study (NPS) demonstrated that colonoscopic polypectomy markedly
reduced expected colorectal cancer (CRC) incidence. A more definitive indicator of the
success of colonoscopic intervention would be a reduction of both incidence and mortality.
Long term mortality follow-up (FU) of the NPS was obtained through a match of the NPS
cohort with that of the death certificate records of the National Death Index (NDI). Methods:
All patients (pts) prospectively referred for initial colonoscopy at the 7 participating centers
of the NPS who had one or more polyps removed were matched to the NDI for years 1980
through 2003. This cohort included pts with adenomas (ADN) (n=2600) and with non-
adenomatous polyps only (hyperplastic and other) (NAD) (n=773). The ADN pts included
1416 in the NPS randomized control trial (RCT) with structured surveillance intervals 1980-
1991 (ADN-NPS) and 1184 ADN pts eligible but declined randomization into the NPS RCT
(ADN-NR). All pts had initial protocol colonoscopy to the cecum and all polyps removed.
NPS records were matched with the NDI based on social security number, month and year
of birth, and sex with further consideration of marital status and state of birth. Underlying
cause of death was also obtained from the NDI. A subsample of known deaths of patients
in the RCT who died within the period of active NPS FU 1980-1991 were used as an
assessment of the completeness of the NPS match to the NDI. Age and sex standardized
mortality ratios (SMR=Observed/Expected deaths) were derived based on the US CRC mortal-
ity rates for 1980-2003 over all years followed, as well as short term (the first 10 years),
and long term (10 or more years) after initial colonoscopy. The percent reduction was
100*(1-SMR). Results: Of those with ADN there were 12 CRC deaths (5 for ADN-NPS, 7
for ADN-NR), and of those with NAD 1 CRC death. None of the 5 previously detected CRC
incident cases from the structured surveillance period in the ADN-NPS died of CRC. FU
was up to 23 years with a mean of 14 years and 48,743 person years at risk. Of the subsample
of 161 known deaths in the ADN-NPS, 157 (98%) matched to the NDI. CRC mortality was
markedly reduced in all ADN pts (69%; 95% CI=46%-84%) with 76% for ADN-NPS and
61% for ADN-NR. The reduction was for both short term (81%; 95% CI=52%-95%) and
long term FU (54%; 95% CI 9%-80%) for all ADN. For the NAD pts, there was an 80%
reduction for short term and 90% reduction overall (95% CI=44%-99.7%). Conclusion:
Substantial long term reduction in colorectal cancer mortality based on 48,743 person years
at risk was demonstrated in the NPS adenoma cohort following polypectomy.
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A Community Based Study of Utilization of Surveillance Colonoscopy
Robert E. Schoen, Paul Pinsky, Joel Weissfeld, Lance Yokochi, Douglas J. Reding, Richard
B. Hayes, Paul Doria-rose, Susan Yurgalevich, Christine for the plco cancer screening trial
Berg
Surveys suggest that physicians recommend surveillance colonoscopy in excess of guidelines,
but no studies have measured actual use in relation to histologic findings. Methods: A cohort
of subjects from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
with abnormal screening flexible sigmoidoscopy and diagnostic colonoscopy within 1 year,
with ≥5 years of observation was queried about subsequent colonoscopy use. Medical
records to confirm reported colonoscopy were abstracted in a standardized fashion. Logistic
regression was used to estimate risk factors for not receiving follow up (f/u) colonoscopy
and for receiving≥2 surveillance colonoscopies. Results: 3,674 subjects (95% response rate,
60% male, mean age 64, median 9 yrs f/u) from 9 U.S. PLCO centers were classified by
baseline exam as: Advanced adenoma (AA) (n=1350), Non-advanced adenoma (AD) (n=
1046), hyperplastic polyp (HP) (n=724), and no polyp (NP) (no adenoma nor hyperplastic)
(n=554). Based on medical record review, the cumulative probability of subsequent colonos-
copy at 5 years was AA=61%, AD=47%, HP=38%, and NP=39% and at 7 years was AA=
76%, AD=68%, HP=58%, and NP=56% (all pairwise comparisons p<.0001 except HP vs.
NP (ns)). With 7 yrs of f/u, ≥2 surveillance colonoscopies occurred in AA=33%, AD=20%,
HP=14%, and NP=13% (p<.0001 for AA vs. others and for AD vs. HP, p<.003 for AD vs.
NP, and HP vs NP (ns)). Regarding risk factors for or against use of surveillance, at 7 yrs,
subjects with AA were more likely not to receive f/u if they were age 70-74 at time of the
baseline exam (35% did not get surveillance) (OR=1.7 (p=.01)), and less likely not to have
f/u colonoscopy with a family history of CRC (OR=0.5 (p=.004)). For ≥2 surveillance
colonoscopies for subjects with HP + NP, only family history of CRC was associated with
increased use (OR=1.7 (p<.01)). Conclusions: 1) Surveillance colonoscopy utilization is
more frequent among subjects with AA; 2) However, nearly 40% of subjects without an
adenoma (hyperplastic polyp, a non-adenomatous biopsy finding, or no polyp) undergo
repeat colonoscopy within 5 years, and nearly 60% undergo repeat colonoscopy by 7 years,
while 25% of subjects with AA do not undergo surveillance within 7 years; 3) About 14%
of subjects without an adenoma at baseline undergo 2 or more surveillance colonoscopies
within 7 yrs. Therefore, interventions to implement more appropriate use of surveillance
colonoscopy are needed.
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Antioxidant Supplementation for Pain Relief in Chronic Pancreatitis: A
Randomized Placebo Controlled Double Blind Trial
Payal Bhardwaj, Pramod K. Garg, Anoop Saraya, Subrat Acharya
Background: Oxidative stress is implicated in pathophysiology of chronic pancreatitis (CP).
Observational studies showed antioxidant supplementation to be effective for pain relief in
CP. Objective: To study the effect of antioxidant supplementation on pain relief, oxidative
stress and antioxidant status in CP. Methods: Consecutive patients with CP and abdominal
pain were randomized to receive either placebo (n=56) or antioxidants (n=71) (600μg
selenium, 0.54g vitamin C, 9000IU β-carotene, 270IU vitamin E, 2g methionine) daily for
6 months. Outcome measures were pain relief (primary) and markers of oxidative stress
[thiobarbituric acid reactive substances (TBARS), serum superoxide dismutase (s-SOD)] and
antioxidant status [ferric reducing ability of plasma (FRAP), vitamins A, C and E, erythrocyte
SOD (e-SOD), erythrocyte total glutathione (E-TGSH)] measured by spectrophotometric
methods. CONSORT guidelines were followed, ethical clearance obtained and trial was
registered at clinicaltrials.gov. Results: From October 2003-January 2006, 127 patients (age
30.5±10.5 yrs; 86 males; 35 alcoholic, 92 idiopathic CP) were included. Regression analysis
showed that antioxidant supplementation was the only independent predictor of response.
Conclusion: Antioxidant supplementation was effective in relieving pain in CP with a decrease
in oxidative stress and increase in antioxidants status.
Post supplementation
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A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody
to IL-12/23p40 (Cnto 1275) in Patients with Moderately to Severely Active
Crohn's Disease
William J. Sandborn, Brian G. Feagan, Richard Fedorak, Ellen Scherl, Mark Fleisher,
Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts
Background: The type 1 cytokines IL-12 and IL-23 are implicated in the pathophysiology
of Crohn's disease (CD). In this 54-week study, the safety and efficacy of either a single
intravenous (IV) infusion or 4 subcutaneous (SC) injections of CNTO 1275 were evaluated
in patients with moderate to severe CD, including infliximab non-responders. Methods: 104
patients (Population 1) with moderate to severe CD (Crohn's Disease Activity Index [CDAI
≧ 220 to ≦ 450]) despite treatment with 5-ASA, antibiotics, corticosteroids, infliximab,
and/or immunomodulators were randomized to 1 of 4 groups (~25 patients/group). Group
I: SC placebo at wks 0, 1, 2, 3, and SC CNTO 1275 (90mg) at wks 8, 9, 10, 11. Group
II: SC CNTO 1275 (90mg) at wks 0, 1, 2, 3, and placebo at wks 8, 9, 10, 11. Group III:
IV placebo at wk 0 and IV CNTO 1275 (4.5mg/kg) at wk 8. Group IV: IV CNTO 1275
(4.5mg/kg) at wk 0 and IV placebo at wk 8. Additionally, patients (Population 2) who
previously failed to respond or lost response to infliximab were randomized to open-label
therapy in either Group V (n=14): SC CNTO 1275 (90mg) at wks 0, 1, 2, 3, or Group VI
(n=13): IV CNTO 1275 (4.5mg/kg) at wk 0. Clinical response was defined as a reduction
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from baseline in the CDAI of ≧ 25% and ≧ 70 points. The primary endpoint was clinical
response at wk 8 for Population 1 (IV and SC combined). Data through week 16 are
presented. Results: At wk 8, 49.0% of patients in Population 1 receiving CNTO 1275 were
in clinical response vs. 39.6% who received placebo (p=0.34). At wk 4 and at wk 6, 52.9%
of patients receiving CNTO 1275 were in clinical response vs. 30.2% receiving placebo (p=
0.02). 49.0% of patients receiving CNTO 1275 were in response at wk 8 using ≧100 point
CDAI reduction vs. 30.2% receiving placebo (p=0.05). For patients with prior infliximab
experience in Population 1 (n=49), 59.1% receiving CNTO 1275 were in clinical response
at wk 8 vs. 25.9% receiving placebo (p=0.02). In Population 2, clinical response rates at
wk 8 for CNTO 1275 were 42.9% (SC) and 53.8% (IV), respectively. Similar proportions
of adverse events were reported for CNTO 1275 and placebo patients. No serious infections
occurred in Population 1; two occurred in Population 2: disseminated histoplasmosis [in a
patient receiving prednisone (80mg/d), AZA and ~3-yrs prior infliximab use] and food
poisoning. Three patients experienced injection site reactions in both of the CNTO 1275
and placebo groups. Conclusion: Short-term treatment with CNTO 1275 was generally well-
tolerated and demonstrated a beneficial effect in moderate to severe CD patients. This effect
was most prominent in infliximab-experienced patients.
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Can We Screen for the Risk of PML; A Case Control Cohort Study in Crohn's
Disease Patients Treated with Immunosuppressives
Gert Van assche, Jannick Verbeeck, Séverine Vermeire, Maja Noman, Elke Wollants, Marc
Van ranst, Paul Rutgeerts
Background. Anti α4 integrin therapy with natalizumab has shown consistent efficacy in
refractory Crohn's disease (CD) but carries a 1/1000 risk (95%CI: 0.2-2.8/1000) of progressive
multifocal leukencephalopathy (PML). Since there is clearly a medical need for this therapy
it is necessary to develop a screening strategy for the risk of PML. Aim. To explore the use
of JC viral load in different blood compartments and urine as a screening test for the PML
risk in immunosuppressed Crohn's disease (CD) patients. Methods. Urine, serum, plasma
samples and buffy coats were prospectively obtained from CD patients on at least one
immunomodulator therapy (n=125, AZA/MTX: 73, infliximab 111) and from a control group
of GI patients without IBD or immunomodulation (n=100) and healthy volunteers (HV, n=
106). Two additional sets of samples were collected from CD patients after 4-8 wks. and
after 12-16 wks. JC viral loads were quantified using a specific real-time PCR and a 215-
bp fragment of the VP1 major capsid protein was amplified to discriminate between the 7
JC virus genotypes and multiple subtypes. Blood counts and differentials were performed
at each time point. Results. At baseline, JC virus DNA was detected in the urine from 28.8%
(n=36) of CD patients, 25.5% (n=27) of HV and 44% (n=44) of GI controls. CD patients
had higher median levels than HV (p=0.0012), and than GI controls (p=0.0110) (Fig1). JC
virus was also detected in the plasma of one patient, and in the plasma, serum and buffy
coat of a second patient. 2 patients cleared JC viral DNA from the urine after 4-8 weeks.
At this time point the 2 positive blood derived samples remained positive, but turned
negative at the 12-16 weeks point. At this time JC virus appeared in the urine of one more
patient. The most common genotype 4 was found in 41.2% of patients. Infliximab (OR:
0.70, 95%CI: 0.22-2.25), AZA/MTX (OR: 0.62, 95%CI: 0.28-1.35) and lymphopenia (OR:
1.44, 95%CI: 0.62-3.338) were not predictive of JC virus shedding. Conclusion. JC virus
was detected in the urine of 30-40% of subjects but titers are higher in Crohn's disease
patients treated with immunosuppressives and in these patients the virus is rarely found in
the blood compartment. Whilst the natural history of JCV in CD patients is unknown,
screening in the blood before and potentially during treatment with anti-α4 integrin therapies
should be considered in patients with viral shedding in the urine. Patients with JC virus in
the blood at baseline should be excluded from therapy with these agents. This work was
supported by a grant from GSK
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Azathioprine (AZA)/6-Mercaptopurine (6MP) Therapy Has NO Significant
Effect On Cellular Or Humoral Immune Responses in Patients with
Inflammatory Bowel Disease
Iris Dotan, Sharon Vigodman, Lisa Malter, Seamus J. Murphy, Noya Horowitz, Jorge
Pfeffer, Lael Werner, Thomas A. Ullman, Maria T. Abreu, Zamir Halpern, Lloyd Mayer
Background: AZA/6MP are immunomodulatory agents effectively used in the treatment of
Inflammatory Bowel Disease (IBD) patients. Down regulation of lymphocyte function has
been suggested as a major therapeutic mechanism. The majority of studies evaluating the
immunosuppressive effects of AZA/6MP have been conducted in patients taking higher doses
than those used to treat IBD. Aim: to evaluate the effects of AZA/6MP on cellular and
humoral immune responses in IBD patients, In Vivo and In Vitro. Methods: IBD patients
referred for AZA/6MP treatment for either flare, post-op prophylaxis or initiation of infliximab
therapy were prospectively studied. Blood was obtained before (time 0) and during (12 and
24 weeks) therapy. Lymphocyte counts and phenotype, response to mitogen (Con A, PHA)
and antigen (Ag) (Candida, Tetanus) stimulation, total and subclass immunoglobulin (Ig)
levels and response to vaccines In Vivo (Pneumovax, tetanus, influenza and HIB) were
determined. Results: 36 IBD (26 Crohn's disease, 10 ulcerative colitis) patients and 49
healthy controls were included. Mean ages were 35.1+13.4, and 37+10 years, respectively.
Only 6 patients were on steroids. Pre-treatment responses to mitogens were lower than
controls (PHA>Con A) but Ag and vaccine responses were comparable. After 24 weeks the
average AZA/6MP dose was 2.5±0.5/1.4 ±0.5 mg/kg respectively. Nine patients stopped
AZA/6MP due to side effects. Compared to baseline values, a significant decrease in WBC
was observed (time 0=8.8±3.3, 24 weeks=5.8±1.8, p=0.006). This correlated with a significant
decrease in all lymphocyte populations. Following treatment the response to mitogens and
Ags as well as Ig levels were basically unchanged although PHA (but not Con A) responses
were further reduced. Importantly, vaccine responses after 24 weeks of therapy were compar-
able to controls suggesting that patients were immunologically intact on AZA/6MP and
capable of generating normal immune responses In Vivo. Conclusion: In IBD patients there
is no evidence for an intrinsic systemic immunodeficiency. AZA/6MP therapy, at the doses
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used for the treatment of IBD, has no significant suppressive effect on systemic immune
responses and supports our ability to vaccinate patients while on these medications.
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Genetic Damage to Sperm Following Treatment with Azathioprine/6-
Mercaptopurine (AZA/6MP) in Men with Inflammatory Bowel Disease (IBD)
Uma Mahadevan, Fernando Velayos, Douglas A. Corley, Yelena Idomsky, Donald Evenson,
Paul Turek
Introduction: Safety of 6MP/AZA exposure during conception in men with IBD is not well
studied. Human studies are conflicting and animal studies suggest a decrease in fertility,
which has never been studied in humans. The aim of this study was to compare rates of
genetic damage in sperm among men with IBD exposed and unexposed to 6MP/AZA using
sperm chromatin structure analysis (SCSA), an established technique to study male infertility.
Flow cytometry is used to define abnormal chromatin structure as an increased susceptibility
of sperm DNA to acid-induced denaturation, which reflects DNA breaks and alterations in
the quantity of protamines and in composition and level of disulfide groups. Methods: This
prospective pilot study enrolled men with IBD in remission. Corticosteroids, sulfasalazine,
other immunomodulators and biologics were not allowed. Demographic data and fertility
history were gathered. Disease activity and 6MP metabolite levels were measured. Two
semen analyses with strict morphology and SCSA were performed on each patient. Results:
20 patients were enrolled - 8 not exposed (controls), 12 exposed (cases) to AZA/6MP. Table
1 lists patient demographics. Controls reported 5 prior pregnancies, all live births. Cases
had 2 prior pregnancies: 1 miscarriage, 1 therapeutic abortion. One case had a history of
infertility, due to problems in partner. Table 2 documents results of semen studies. DNA
Fragmentation Index is the % of cells containing damaged DNA, < 15% is excellent. High
DNA stainability is the % of cells with immature chromatin, <15% is normal. All controls
had excellent sperm DNA integrity. Among cases there were 8 excellent, 3 good and 1 fair
to poor DNA integrity. Conclusions: Men with IBD on AZA/6MP were numerically more
likely to have sperm DNA integrity in the abnormal range, although the numbers enrolled
were too small to determine statistical significance. Larger numbers of patients are needed
to determine the significance of these findings and the relationship to dose of medication used.
Patient Demographics
Results of Sperm Analysis
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Combination Therapy with Metronidazole and Azathioprine Reduces Severe
Postoperative Recurrence of Crohn's Disease: A Double-Blind Controlled
Randomized Trial
Geert R. D'haens, Maja Noman, Gert A. Van assche, Gust Van olmen, Isolde Aerden,
Severine Vermeire, Paul J. Rutgeerts
Introduction: More than 80% of Crohn's disease (CD) patients (pts) undergoing resection
of terminal ileum +/-right colon suffer recurrence in the following years. Controlled trials
suggest that aminosalicylates and azathioprine (AZA) reduce severity of recurrence. Overall,
success rates have been disappointing. Nitroimidazole antibiotics reduce recurrence rates
but often with important toxicity. The severity of endoscopic lesions in the first year after
surgery predicts the further clinical course of CD. Goal: to examine if a combination of AZA
with a 3 month course of metronidazole (MET) further reduces recurrence in postoperative
CD. Methods: CD pts who had undergone ileocecal resection having ≥ 1 risk factor for
severe recurrence (age <40, perforating disease, steroids at surgery, ≥ 2nd resection) were
started immediately after surgery on open label MET 250 mg TID for 3 months + AZA (100
mg/day if BW< 60 kg, 150 mg/day if BW>60 kg) or placebo (PLA) for 12 months. Pts
underwent ileocolonoscopy at 3 and 12 months. The primary endpoint was the proportion
of pts with severe endoscopic recurrence (Rutgeerts' score≥i2). Results: Eighty-one pts (46%
female) were randomized; 73 pts reached month 3 and 61 month 12. Patient characteristics in
both groups were comparable. At 3 months, 32/73 pts (60%) had severe recurrence (20/
38 (52.6%) on PLA and 12/35 (34%) on AZA, p=0.11). At 12 months, 34/61 pts (55.7%)
had severe endoscopic recurrence (20/29 (69%) on PLA, 14/32 (44%) on AZA, p<0.05).
Very severe recurrence (i3+i4) was rare in both groups (3/73 (4.1%) at month 3 and 14/
61 (22.9%) at month 12) and was not more frequent in either group. Absence of lesions
(i0) at month 12 was more frequent in the AZA than in the PLA group (7/32 vs 1/29, p=
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0.04). Reasons for discontinuation before week 12 included withdrawal of consent, liver
toxicity and abscess in 8 pts. Between week 12 and 52, 12 additional pts discontinued: 3
for severe CD relapse, 1 for pregnancy, 2 for arthralgia, 2 for liver toxicity and 4 because
of non-compliance, evenly distributed in both groups. Other adverse events were mild and
transient, with more liver toxicity in the AZA group. Conclusions: In this cohort of pts with
an elevated risk of postoperative CD recurrence, the incidence of severe endoscopic recurrence
was significantly reduced 12 months after surgery with combination therapy of MET for 3
months and AZA for 12 months. Very severe recurrence was rare in both groups, reinforcing
the efficacy of a 3 month MET course immediately post surgery. Combination with AZA
should be considered in the prevention of postoperative recurrence in CD patients at high risk.
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Azathioprine/6-Mercaptopurine (AZA/6-MP) Reduces the Risk of Intestinal Re-
Operation in Crohn's Disease(CD)
Pavol Papay, Elien Ho, Walter Reinisch, Wolfgang Miehsler, Harald Vogelsang, Gottfried
Novacek
Background/Aim:Despite increased use of immunosuppressive drugs a reduction of intestinal
surgery has not been demonstrated recently. As immunosuppressants might be applied too
late before first resection we aimed to investigate the influence of AZA/6-MP on the risk
of intestinal re-operation in CD. Methods:The charts of 579 CD patients were reviewed
retrospectively with regard to intestinal re-operation and therapy with AZA/6-MP after first
intestinal resection. Intestinal surgery was performed in 377 patients (65.1%). In 333 cases
data for further analysis were available. Those patients were stratified into no or≤ 2 months
(mo) AZA/6-MP therapy (n=214), 3-11 mo (n=23), 12-35 mo (n=43), ≥ 36 mo (n=53).
Chi-square test, stepwise logistic regression and Kaplan-Meier analysis were performed.
Results:Intestinal re-operation was performed in 132 patients (40%). The rate of re-operation
was 49% in patients with no or <2 mo AZA/6-MP and 24% in patients under AZA/6-MP
(p<0.001). This benefit was observed in patients with stricture as well as in patients with
internal fistula as main indications for first surgery (p<0,001 and p=0,044 respectively).The
probability to remain free of intestinal re-operation after 5 years of follow up was significantly
reduced in patients who were treated with AZA/6-MP ≥ 12 mo (log-rank test; 12-35 mo
p=0.026, ≥ 36 mo p=0.003) and after 10 years in those patients who were treated with
AZA/6-MP >36 mo (log-rank test; ≥ 36 mo p<0.001). Multivariate analysis revealed that
no or <2 mo of AZA/6-MP therapy after first intestinal surgery (OR 3,0; 95% CI 1,8-
4,9) as the only independent risk factor for re-operation. Conclusion:Immunosuppressive
treatment with AZA/6-MP after the first intestinal surgery reduces the risk for re-operation
in CD.
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Prevalence of Nodular Regenerative Hyperplasia (NRH) in IBD Patients
Treated with Azathioprine (AZA)
Jacques Cosnes, Laurent Beaugerie, Gwenola Vernier, Marc Lemann, Jean-frederic
Colombel, Jean-yves Mary, Jean-pierre Gendre, Philippe Seksik
Cases of NRH in IBD patients have been reported in relation to the use of 6-thioguanine,
leading its withdrawal in IBD treatment. In parallel, an increasing number of cases of NRH
in patients receiving AZA have been published. The aim of this study was to evaluate the
prevalence of NRH and its predictive factors in IBD patients treated with AZA. Methods:
From a series of 5530 IBD patients seen consecutively (1974-2006) in the same tertiary
referral center, 2269 were treated with AZA. Patients in whom AZA was stopped within the
first 2 months because of intolerance (n=273) or surgery (n=83), patients with follow-up
less than 2 months (n=130), and patients who developed unexplained hepatic biological
abnormalities during treatment (n=29) were excluded from analysis. In the 1730 patients
included, median duration of AZA treatment (target dose 2.5 mg/kg/d) was 30 mo and
median follow-up after starting AZA was 50 mo. Diagnosis of NRH was based on acquired
thrombopenia or portal hypertension and was proven by liver biopsy in all cases except
one. The cumulative risk of NRH was estimated through Kaplan Meier method. Factors
associated with NRH were analysed by using log rank method and multivariate Cox model.
Data were collected when starting AZA. Variables tested were gender, age, IBD type (Crohn's
disease or UC), disease duration, disease location, disease behaviour (intestinal stricture,
intestinal perforation, fistulizing perianal disease), prior intestinal surgery, extent of small
bowel resection (50 cm), appendectomy, family IBD history, obesity, smoking habit, use of
oral contraceptives, and prior arterial or venous thrombosis. Results: 13 patients developed
NRH after a median treatment duration of 44 mo (15-214 mo). The cumulative risk of NRH
was 0.7 +/- 0.2% five years after starting AZA, and 1.3 +/- 0.5% at 10 years. In univariate
analysis, factors associated with NRH (p<0.05) were male gender, disease duration, small
bowel involvement, colonic sparing, prior intestinal perforation, and prior small bowel
resection > 50 cm. According to Cox model, hazard ratios (95% CI) were 8.3 (1.8-38.8)
for male gender and 3.3 (1.1-9.7) for prior small bowel resection > 50 cm, respectively.
Male patients with prior small bowel resection > 50 cm (n=79) had a 10-year risk of NRH
of 11.4 +/- 5.1%. Conclusion: The risk of developing NRH during AZA treatment is low
(0.7% at five years). However this figure should be regarded as minimal as in our cohort
only cases with clinical and/or biological consequences were collected. This study suggests
that male patients with prior small bowel resection > 50 cm are at higher risk of developing
NRH than other patients.
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Risk of Mortality and Cancer Incidence in Barrett's Esophagus
Michael B. Cook, Chris P. Wild, Simon Everett, Laura J. Hardie, David Forman
INTRODUCTION: There are very few prospective follow-up studies of Barrett's esophagus
(BE) cohorts assessing the risk of extra-esophageal cancer incidence or mortality. Such
studies are necessary in order to understand the overall risks of cancer and death experienced
by BE patients. AIMS & METHODS: This analysis set-out to assess these risks in a cohort
of 597 BE patients recruited at Leeds General Infirmary, England. Patients were excluded
from the analysis if they had a cancer diagnosis (excluding non-melanoma skin cancer) prior
to or within 6 months of their BE diagnosis or if they were aged less than 18 years at BE
diagnosis. Mortality and cancer incidence information were provided by the Office of National
Statistics. Using the general population for calculation of expected numbers of events,
standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) were calculated
using indirect standardization and STATA 8.2. RESULTS: After exclusions, 502 BE patients
remained for analysis, of which 431 had a BE diagnosis of specialized intestinal metaplasia
(SIM) and 71 had a diagnosis of columnar-lined esophagus. Each analysis was conducted
for all BE patients and the SIM group alone, results of which did not differ. Therefore the
results of the full BE cohort are discussed. All-cause mortality was found to be elevated in
BE patients (SMR=1.21; 95% CI: 1.06, 1.37; p<0.01) and remained so after esophageal
cancers were excluded (SMR=1.16; 95% CI: 1.01, 1.32; p<0.05). Increased risks were also
found for malignant neoplasms of the esophagus (SMR=7.26; 95% CI: 3.87, 12.42; p<0.001)
and diseases of the digestive system (SMR=2.03; 95% CI: 1.11, 3.40; p<0.05). No statistically
significant modified risks were seen for any of the other disease categories (including
colorectal cancers, cerebrovascular diseases and circulatory diseases) although, for the SIM
group, mortality from circulatory disease was borderline statistically significant (SMR=1.24;
95% CI: 1.00, 1.52). In the cancer incidence analyses esophageal malignancies (SIR=8.66;
95% CI: 4.73, 14.53; p<0.001) and esophageal adenocarcinomas (SIR=14.29; 95% CI: 7.13,
22.56; p<0.001) were found to be increased in BE. There was a statistically significant
increased SIR found for malignant neoplasm of digestive organs, but this disappeared once
esophageal malignancies were excluded. No altered risk was seen for other analyses including
that of colorectal cancer. CONCLUSION: Whilst these results show anticipated increased
risk estimates for esophageal cancer incidence and mortality in BE, there is no evidence for
increased risks of other forms of cancer or causes of death as have been proposed.
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Radiofrequency Ablation Is More Cost-Effective Than Endoscopic Surveillance
Or Esophagectomy Among Patients with Barrett's Esophagus and Low-Grade
Dysplasia
John M. Inadomi, Ryan D. Madanick, Ma Somsouk, Nicholas J. Shaheen
Background/Aim: Management of patients with Barrett's esophagus (BE) with low-grade
dysplasia (LGD) is controversial. Strategies include endoscopic surveillance, esophagectomy,
or radiofrequency ablation (RFA). The aim of this study was to compare the incremental
cost-effectiveness between these competing strategies. Methods: A mathematical model was
created to simulate the natural history of a cohort of patients with BE and LGD from age
50 to 80 years or death using a third-party payer perspective. Interventions included annual
endoscopic surveillance with esophagectomy for cancer (SURV), immediate esophagectomy
(ESOPH), or ablation using RFA with surveillance depending on whether there was residual
LGD (1-year intervals) or no dysplasia (3-year intervals). Outcomes included the incremental
cost-effectiveness ratio (ICER) comparing total direct costs and quality adjusted life years
(QALYs) between competing strategies, and a sensitivity analysis identifying the thresholds
at which the preference for strategies changed. Diagnostic error was incorporated. Utilities
were based on existing literature, as was the efficacy of ablation therapy (residual LGD=
30%; BE without dysplasia=10%, no BE=60%). RFA was modeled using a combination of
the BÂRRX Halo 360 device, a circumferential ablation balloon catheter, with follow-up
treatment using the Halo 90 device, a treatment device for focal disease, as necessary.
Complications of endoscopy and surgery were included, as were increased rates of stricture
and perforation in the ablation arm. Results: Compared to the natural history of LGD (total
direct costs $615, 14.34 QALYs), the ICER of SURV ($8081, 15.25 QALYs) was $8200 per
QALY gained. However, the ICER for RFA ($10457, 16.14 QALYs) was lower: $2670 per
QALY gained over SURV, thus RFA was preferred to SURV based on extended dominance.
ESOPH ($39720, 14.84 QALYs) was more expensive and less effective (dominated) than
SURV and RFA. Using more conservative estimates, assuming that no complete ablation of
metaplasia was achieved, RFA remained the preferred strategy if the proportion of patients
with residual LGD after ablation was 0% (willingness to pay [WTP] $50000 per QALY) or
<40% (WTP $100000 per QALY); otherwise SURV was optimal. These results were robust
to variation in other variables. Conclusions: Our base case suggests that RFA therapy may
be the most cost-effective option in patients with BE and LGD. If the effectiveness of RFA
is substantially lower than current estimates, however, surveillance may be preferred.
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Prior Malpractice Defendants Recommend Aggressive Use of Screening and
Surveillance for Esophageal Adenocarcinoma
Joel H. Rubenstein, Sameer Saini, Latoya Kuhn, Laurence F. Mcmahon, Pratima Sharma,
Philip Schoenfeld
Background: The efficacy of screening for esophageal adenocarcinoma (EAC) is controversial,
and the practice of screening is variable. We hypothesized that financial incentives and
history of being identified in a malpractice suit influence gastroenterologists' usual practices
regarding screening and surveillance. Methods: We surveyed gastroenterologists attending
board review courses (n=224) regarding their usual practice of screening or surveillance for
EAC, belief in the efficacy of screening for EAC, demographic factors, knowledge of published
guidelines, practice characteristics (academic/private/mixed and solo/single-specialty/multi-
specialty), compensation structure (productivity-based, salaried with incentives, or salaried
without incentives), volume of endoscopies, and malpractice history. Results: 20.1% of
respondents reported being identified as a defendant in at least one malpractice suit regarding
any medical issue. Prior malpractice defendants had practiced gastroenterology longer (12.7
vs. 7.4 years, p = 0.002) and performed a higher volume of endoscopies (93.9% vs. 60.3%
> 10 EGDs per week, p = 0.0007), but had similar knowledge regarding published EAC
screening guidelines as those who had not been defendants (p = 0.33). Prior malpractice
defendants were more likely overall to be aggressive rather than conservative in screening
and surveillance for EAC (odds ratio 2.96, 95%CI 1.05 - 8.37), and remained so after
controlling for other factors. In particular, they were more likely to recommend screening
for young women with short duration of reflux symptoms (odds ratio 4.16, 95%CI 1.70 -
10.18), and surveillance every 3 months for findings of low-grade dysplasia (odds ratio
2.43, 95%CI 1.08 - 5.48). Prior malpractice defendants also tended be more likely to
recommend surveillance sooner than 3 years for patients with Barrett's esophagus and no
dysplasia (odds ratio 2.35, 95%CI 0.67 - 8.30) and repeat screening at a later date for
patients with no Barrett's esophagus found on initial screening (odds ratio 1.85, 95%CI
0.65 - 5.25). Other factors were not associated with usual practice, including compensation
structure, volume of endoscopies, or stated belief in the proportion of EAC deaths preventable
by screening and surveillance. Conclusions: Malpractice suits are associated with greater
volume and duration of patient care. History of at least one prior malpractice suit is associated
with more aggressive use of endoscopic screening and surveillance for EAC, irrespective of
physician belief regarding the efficacy of that strategy in reducing mortality. Hypervigilance
and fear of future malpractice suits may drive this increased use.
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Population-Based Temporal Trends in Esophageal Strictures
Hashem El-serag, Melvin Lau
Background The use of proton pump inhibitors (PPI) for GERD could result in a decline
in new as well as recurrent GERD-related esophageal strictures. The temporal trends of
esophageal strictures have not been examined in large population-based studies. Methods
We examined the age-adjusted incidence rates of new esophageal strictures with or without
esophageal dilation in a sample of Medicare beneficiaries between 1992 and 2000. We also
examined recurrent dilations recorded at least three months after the index date of a new
stricture or the date of the preceding recurrent stricture. The risk of recurrent strictures was
examined using Cox proportional hazards (PH) model for multiple failures. Results The
number of patients with new esophageal stricture declined from 2764 to 1871 between
1992 and 2000. Similarly, the number of patients with new esophageal stricture accompanied
with dilation declined from 348 to 291. The age-adjusted rates for strictures accompanied
with dilation declined by 11% from 215.9 per million to 192.5 per million (Figure). Recurrent
dilation within one year following the first dilation declined dramatically from 16.4% in
1992 to 7.5% in 2000. In PH model, there was a 30% risk reduction of recurrent esophageal
strictures diagnosed within one year following the index stricture in the period between
1992 and 2000. Conclusions This study indicates that the incidence of new as well as
recurrent esophageal strictures has been declining since the early 1990s. In the face of rising
incidence of other GERD-related complications, it is important to understand the explanation
of the present observation.
Temporal Trends in Total Counts (bars, left Y-axis) and Age-Adjusted Incidence Rates (lines,
right Y-axis) of new esophageal strictures.
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Tricyclic Antidepressants and the Risk of Reflux Esophagitis
E. M. Van soest, J. P. Dieleman, P. D. Siersema, L. Schoof, M. C. Sturkenboom, E. J.
Kuipers
Objectives: Incompetence of the lower esophageal sphincter (LES) is a key factor in the
pathogenesis of gastro-esophageal reflux disease (GERD). Anticholinergic drugs have been
suggested to promote gastro-esophageal reflux by decreasing LES basal pressure. Tricyclic
antidepressants (TCAs) are known for their anticholinergic adverse effects, but their effect
on LES pressure and the occurrence of GERD remains controversial. Aim: To investigate
whether the use of TCAs is associated with an increased risk of reflux esophagitis (RE).
Methods: A population-based case-control study was conducted within the Integrated Primary
Care Information database over the period 1996-2005. Cases with endoscopy confirmed
RE were identified and each matched on gender, age, general practitioner practice and
calendar time with up to 10 controls. Exposure to TCAs was assessed in the year prior to
the index date (start of symptoms cases) and categorized as current (last prescription covered
or ended within 1 month prior to the index date), past or no use. The relative risk of RE
was estimated by adjusted odds ratios (OR) with 95%-confidence intervals (95%CI) using
multivariate conditional logistic regression analysis. Results: During the study period, 1,462
cases with endoscopy-confirmed RE were identified and 13,462 controls were matched. The
risk of RE was increased in current TCA users (OR: 1.61, 95%CI: 1.04-2.50). Drug-specific
analyses revealed that only clomipramine was associated with an increased risk of RE (OR:
4.6, 95%CI: 2.0-10.6). The risk associated with current clomipramine use increased with
a longer period of prescription (OR: 7.1, 95%CI: 2.7-19.2) for >180 days) and with dose
(OR: 9.2, 95%CI: 1.6-51.5 for >1 DDD equivalent/day). Clomipramine was more frequently
prescribed for a general anxiety disorder (52%) than the other prescribed TCAs (10%). The
risk of RE associated with the use of clomipramine was higher than that with other TCAs
across all indications, but in drug-specific analyses the risk of RE was highest when the
drug was prescribed for a general anxiety disorder. Conclusions: The use of clomipramine
was associated with an increased risk of RE in a dose- and duration-dependant manner.
This association was not shown for other TCAs, contradicting the overall hypothesis that
the anticholinergic properties of TCAs decrease LES basal pressure and increase the risk of
RE. Future research should establish if the effect seen in users of clomipramine is truly
drug-related or rather due to the indication for which it was prescribed.
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Long-Term Course of Gastro-Esophageal Reflux Symptoms (GERS) in the
Community, a Prospective Follow-Up Analysis of Symptoms, Quality of Life,
and Health Care Use
Jane M. Hansen, Mette Wildner-christensen, Ove B. Schaffalitzky de muckadell
The prevalence of GERS in the population is high; however, data on long term follow-up
and incidence of GERS in the community are sparse. This study describes the long-term
natural history of GERS and the related health care use and quality of life in a population
followed for 5 years. Methods: 10,000 randomly selected inhabitants 40-65 years old received,
as a part of a controlled trial of Helicobacter pylori screening and treatment (control group), a
mailed questionnaire regarding demographic data, symptoms (the Gastrointestinal Symptom
Rating Scale (GSRS)), and quality of life (SF-36) at inclusion and after 5 years. GERS was
defined as a score ≥2 in the reflux dimension in GSRS. Information on use of health care
resources was drawn from the questionnaires and registers. Results: 6781 answered the first
questionnaire and 5-year symptom data were complete for 5592 (82%). Mean age at inclusion
was 52.3 year, 48% were men. At inclusion, 22% reported GERS. At 5-year follow-up
symptoms were resolved in 43%, of which 10% received acid inhibitory treatment. The
incidence of GERS was 2.2% per year. Health care use during follow-up was significantly
higher in individuals with GERS at baseline compared to individuals without GERS (table).
Quality of life at 5-year follow-up was lower in individuals with GERS at inclusion compared
to individuals without GERS at inclusion. Conclusion: GERS is a prevalent condition in the
community with long lasting symptoms resulting in impaired quality of life despite a high
health care use.
GP: general practitioner, PPI: proton pump inhibitor, sd: standard deviation, DDD: defined
daily dose
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EGF Induces COX-2 Expression Through Increased Polysome Association:
Potential Role of Protooncogene Rbm3
Sripathi M. Sureban, Aubrey Morrison, Brian Dieckgraefe, Courtney W. Houchen,
Shrikant Anant
RBM3 is a RNA binding protein, which is ubiquitously expressed and a translation inducer.
We have determined that RBM3 interacts with RNA stabilizing protein HuR on AU-rich
sequences (ARE) located in the 3'untranslated region (3'UTR) of cyclooxygenase-2 (COX-
2) mRNA. Furthermore, ectopic overexpression of RBM3 and HuR increased the translation
of both endogenous COX-2 mRNA and a luciferase reporter mRNA encoding the full-length
COX-2 3'UTR. Moreover, RBM3 levels were significantly upregulated in human colorectal
cancers. The aim of the current study is to determine the mechanism by which RBM3
expression is induced in tumorigenesis. Epidermal growth factor (EGF) plays an important
role in colorectal tumorigenesis in part by upregulating COX-2 expression. To determine if
EGF regulates RBM3 expression, HCT116 colon adenocarcinoma cells were treated with
EGF from 0-24 h. Real Time PCR and western blot analyses showed that EGF induced the
luciferase activity from a luciferase transcript encoding the full length 2.3 kb COX-2 3'UTR.
On the other hand, when RBM3 was decreased using targeted siRNA, EGF did not induce
COX-2 expression. To determine whether EGF enhances RBM3 binding to the COX-2
mRNA, a coupled immunoprecipitation followed by RT-PCR was performed. Treatment of
HCT116 cells with EGF significantly increased the amount of RBM3-bound COX-2 mRNA
compared to untreated cells. Further, we fractionated the cytoplasmic extracts on sucrose
gradient for polysome preparations and subjected to westernblot analyses. RBM3 was
observed in the lighter monosome fraction in control, untreated cell. To confirm this finally,
we performed a polysome profile analyses by fractionating the cytoplasmic extracts on
sucrose gradient. Western blot analyses demonstrated that RBM3 is present in the lighter
monosome fraction in control, untreated cells. However, following EGF treatment, signific-
antly higher amounts of RBM3 was associated in the fractions with the 40s and 60s ribosomal
subunits. Furthermore, RT-PCR analysis of RNA also demonstrated a shift in COX-2 mRNA
to the ribosomal fractions following EGF treatment. These data, taken together, imply that
increased COX-2 mRNA translation following EGF treatment is mediated by increased
ribosomal loading of the transcript by RBM3. We conclude that EGF mediated increased
COX-2 expression occurs in part by the novel mechanism of increased polysome loading
through the actions of the protooncogene RBM3.
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Suppressed Prostaglandin E2 Levels Delays K-RasG12V-Dependent Tumor
Formation in Nu/Nu Mice
H. Pham, Benny Chong, Romina Vincenti, Daniel hsin-hsiung Tai, Guido Eibl, Lee W.
Slice
Background: K-Ras mutations are common early events in colorectal cancers that correlate
with elevated levels of prostaglandin E2 (PGE2). PGE2 synthesis is largely controlled by
induced expression of cyclooxygenase-2 (COX-2) and membrane-associated prostaglandin
E synthase-1 (mPGES-1) whereas degradation of PGE2 is by 15-hydroxyprostaglandin dehy-
drogenase (PGDH). Decreased PGDH expression has been observed in colorectal cancers
suggesting a decrease in PGE2 degradation may account for the transformation of intestinal
epithelial cells. Aim: This study focused on whether over-expression of PGDH attenuated
PGE2 levels can decrease the tumorigenecity of Ras-transformed intestinal epithelial cells.
Methods: Transduced rat ileum epithelial cell line (IEC-18) with lentivirus containing GFP
(18.GFP), K-RasG12V (18.Kras) or PGDH/K-RasG12V (18.Kras.PGDH) were injected subcu-
taneously in the right flank of nude male mice (Nu/Nu) and monitored continuously over
several weeks. Tumors were excised and analyzed by immunohistochemistry. Prostanoid
levels and proliferation were measured by EIA, mRNA expression by RT-PCR, protein
expression by Western blotting, and PGDH activity by [15-3H]-PGE2 catabolism. Results:
18.GFP cells had low basal levels of PGE2 and COX-2 expression and did not produce
tumors in the mice. Mice injected with 18.Kras cells developed tumors within 2 weeks and
maintained elevated levels of PGE2, and increased expression of COX-2 and mPGES-1.
PGDH expression and activity were decreased in 18.GFP and 18.Kras cells whereas PGDH
activity was increased in 18.Kras.PGDH cells. Increased growth rate and proliferation was
observed in 18.Kras compared to 18.GFP and 18.Kras.PGDH. 18.Kras.PGDH cells injected
into mice developed tumors by 8 weeks and showed decreased PGE2 levels as compared
to 18.Kras tumors. Antibody staining for the proliferative marker, Ki-67, showed peripheral
localization in 18.Kras tumors whereas Ki-67 expression was dispersed in 18.Kras.PGDH
tumors. Apoptotic index analysis by in situ DNA strand break detection (TUNEL) showed
a decrease in 18.Kras tumors in comparison to 18.Kras.PGDH tumors. COX-2 and mPGES-
1 expression in 18.Kras tumors were elevated while PGDH expression was not detected.
Conversely, 18.Kras.PGDH tumors showed elevated PGDH expression as well as the presence
of COX-2 and mPGES-1 expression. Conclusion: Over-expression of PGDH in K-RasG12V
expressing intestinal epithelial cells decreased PGE2 levels that correlated with delayed tumor
formation, suggesting that PGE2 is critical in regulating tumor growth.
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Krüppel-Like Factor 4 Represses Wnt Signaling By Regulating the β-Catenin/
Tcf Complex
Wen Zhang, Xi Chen, Paul M. Evans, Jun Yang, Chunming Liu
Background: Wnt/β-catenin signaling plays an essential role in intestinal homeostasis and
colon carcinogenesis. We found that Krüppel-like factor 4 (KLF4) interacts with β-catenin
and represses Wnt signaling in colon cancer cells. KLF4 is a zinc-finger protein, and its
expression is down-regulated in many colorectal cancers. We found that KLF4 inhibits
xenograft tumor growth in athymic nude mice, further suggesting that KLF4 is a tumor
suppressor in GI cancers. Here, we delineated the interactions between KLF4 and β-catenin
and found that KLF4 represses Wnt signaling by regulating β-catenin/TCF complex. Methods:
We have established stable colon cancer cell lines that inducibly express KLF4 or DnTCF
(dominant negative TCF). β-catenin target genes were analyzed by RT-PCR. Protein-protein
interactions were analyzed by immunoprecipitation and GST pull-down. LEF-β-catenin and
β-catenin-VP16 fusion constructs were cloned into CS2+vector. β-catenin/TCF activity was
analyzed using TopFlash reporter assay. Chromatin immunoprecipitation (ChIP) assay was
performed with antibodies against β-catenin, TCF4, KLF4 and acetylated-Histone H3. Results:
We compared the effects of DnTCF and KLF4 on the expression of β-catenin target genes
in the colon cancer cell line LS174T. DnTCF is a dominant negative inhibitor for Wnt
signaling, and thus repressed β-catenin target genes, such as c-Myc and Axin2. KLF4 has
a similar effect. We found that the N-terminus of KLF4 interacts with the C-terminal
transactivating domain of β-catenin. KLF4 inhibits both LEF-β-catenin- and β-catenin-VP16-
induced TopFlash reporter activity, suggesting that KLF4 inhibits the activity of β-catenin
C-terminus as well as the function of the β-catenin/TCF complex. To further determine the
mechanisms of how KLF4 represses β-catenin-mediated transcription, chromatin remodeling
at the promoter region of β-catenin-target genes and the interaction between these promoters
and β-catenin/TCF complex were analyzed by ChIP assay in colon cancer cells with or
without expression of KLF4. Conclusion: KLF4 interacts with and inhibits β-catenin/TCF
complex on the promoters of β-catenin target genes. The interaction between KLF4 and
Wnt signaling will have important implications within several fields, including GI biology,
cancer biology and stem cell biology.
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Phosphotidylinositol-3 Kinase (PI3K) Mediates TGFβ-Induced Supression of
Pten in Colon Cancer Cells
Jimmy Y. Chow, Jennifer Cabral, Khai Quack, John M. Carethers
Background: The mechanism for transforming growth factor-beta (TGFβ) to convert from
a tumor suppressor to a tumor promoter is not known. TGFβ utilizes SMAD signaling to
mediate growth suppression; however, other TGFβ-induced pathways that typically fine-
tune the TGFβ response may become more apparent when SMAD signaling is abrogated as
often seen in colon and other gastrointestinal cancers. Here, we examined TGFβ's regulation
of the tumor suppressor PTEN to determine pathways that upregulate or downregulate its
expression. Methods: SMAD4-null SW480 colon cancer cells were lysed, and cellular proteins
were analyzed by immunoprecipitation and Westerns using the p85 subunit of PI3K and
phosphotyrosine antibodies. PTEN mRNA levels were assessed by reverse transcriptase-PCR.
SMAD2 and SMAD3 transcriptional activities were assessed by p3TP-luciferase and pCAGA-
luciferase constructs. Dominant negative (DN) SMAD2 and DN-p85 constructs were used
to block the downstream action of SMAD2 and PI3K, respectively. Results: PTEN mRNA
is downregulated by TGFβ in SMAD4-null SW480 cells. In assessing SMAD signaling, TGFβ
induced both SMAD2 and SMAD3 nuclear translocation, but only triggered SMAD2 specific
transcriptional activity in the absence of SMAD4. Inhibiting RAS/ERK, which slows SMAD
translocation, reversed TGFβ-induced PTEN suppression, while inhibiting SMAD2 enhanced
TGFβ-induced cell proliferation. TGFβ increased PI3K tyrosine phosphorylation, and inhibi-
tion of PI3K either pharmacologically or by DN-p85 reversed TGFβ-induced PTEN suppres-
sion and reversed TGFβ-induced cell proliferation. Conclusion: TGFβ modulates the PTEN/
PI3K ratio in SW480 cells, which has cell growth consequences. TGFβ-SMAD2 signaling
maintains or enhances PTEN expression, which is antagonized by RAS/ERK, to control
growth. TGFβ also activates PI3K to downregulate PTEN and enhance cell proliferation.
Modulation of PTEN/PI3K by TGFβ may be one mechanism to reverse the normal growth
suppression by TGFβ.
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Defective Gp130 Signaling in Murine Macrophages and the Implications for
Gastric Tumourigenesis
Louise M. Judd, Anastasia Kalantzis, Andrew S. Giraud
Background and Aims: Stroma contributes to neoplastic progression. The non-malignant
stromal compartment includes fibroblasts, leukocytes, endothelial cells and extracellular
elements and is termed the tumor microenvironment (TM). One part of the TM, tumor
associated macrophages (TAMs) play a major role in determining tumor outcome. Despite
the strong causative links between inflammation and gastric cancer progression, very little
is known of the role of TAMs in this disease. We have utilized a model of gastric tumourigen-
esis (Judd et al., Gastro 126 , 2004) to address this. The gp130757FF mouse has a mutated
IL-6 family cytokine receptor gp130 which prevents SHP2/ras/ERK signaling and leads to
constitutive STAT3 transcriptional activation. Antral tumor development occurs due to loss
of tumor suppressor TFF1 and oncogenic expression of STAT3. Tumorigenesis in this model
is inflammation-dependent since IL-11 is absolutely required, and development is inhibited
by NSAIDs and microbial eradication (Judd et al., Gastro 131, 2006), but an adaptive
immune response is dispensable for tumor growth (Howlett et al., Gastro 129, 1005, 2005).
The project aim was therefore to assess the effect of the gp130757FF mutation on macrophage
function to address the role of macrophages in tumor formation. Methods: Peritoneal macro-
phages were isolated from wildtype, gp130757FF, IL-6 null and gp130757FF x IL-6 null
mice. Cells were cultured with or without IL-11. Protein and mRNA was extracted from
cells and the activation status of macrophages was assessed. Results: The gp130757FF
mutation results in unbalanced gp130 signal transduction in the gastric antrum with
decreased ERK1/2 activation and constitutive phosphorylation of STAT3. This abnormal
signaling is replicated in isolated macrophages. In the antrum increased activation of STAT3
is unaffected by depletion of the ligand IL-6. However in macrophages an absence of IL-6
results in higher basal STAT3 activation thus demonstrating the suppressive role of IL-6 on
macrophages. The gp130757FF mutation results in macrophages with decreased IL-6 and
increased iNOS mRNA expression reflecting higher basal activation. Finally manipulations
of the gp130757FF mouse that reduce tumor size (eg. antibiotic treatment, STAT3 hemizygos-
ity and NSAID treatment) also coincidently result in reduced macrophage infiltration of the
antral mucosa. Conclusions: Macrophages of gp130757FF mice, like gastric epithelium,
display unbalanced gp130 signaling, resulting in exaggerated responses to stimuli. The key
difference between the antral epithelium and macrophages is how unbalanced gp130 signaling
affects transcriptional changes in target genes.
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Activin Is Growth Suppressive Through P21 Protein Stabilization, Is
Modulated By ERK and Pi3 Kinase, and Enhances Migration in Colon Cancer
Cells
Barbara H. Jung, Stayce E. Beck, Jennifer Cabral, Jessica Gomez, John M. Carethers
BACKGROUND: Activin is a growth suppressive ligand of the transforming growth factor
β (TGFβ) superfamily and its signaling pathway is targeted for disruption in colon cancers.
Its primary receptor, activin receptor 2 (ACVR2) is mutated in more than 80% of microsatellite
unstable (MSI-H) and a subset of microsatellite stable colon cancers, causing loss of ACVR2
protein. Activin binds to ACVR2, triggering phosphorylation of intracellular SMAD proteins
that translocate to the nucleus to affect transcription of target genes to slow cellular growth.
Mitogenic signaling via MAPK/ERK and phosphatidylinositol 3 kinase (PI3K) is commonly
activated in colon cancers. Here, we dissected the effect of mitogenic pathways on activin
signaling, p21 expression, and activin-mediated growth and migration utilizing a native
ACVR2-wild type colon cancer cell line and a MSI-H colon cancer cell model with mutated
and restored ACVR2. METHODS: HCT116 cells, which are hMLH1 and ACVR2 mutated,
were stably transferred with chromosome 2 (HCT116+chr2) restoring a single wild type
ACVR2. Pharmacologic inhibitors of MAPK/ERK and PI3K were used to assess for modulation
of activin signaling. Expression of pSMAD2, SMAD- and p21-specific transactivation, tran-
scription, and protein stability, as well as cell growth, cell death and migration were assessed.
ACVR2-specific siRNA was used to assess for reversal of activin-induced effects. RESULTS:
While neither p21-specific transactivation nor p21 mRNA were increased following activin
treatment, activin increased p21 protein levels through stabilization from 4 to 24 hours post
treatment. Activin-induced p21 protein stability is enhanced further to 48 hours with
simultaneous inhibition of PI3K or MAPK/ERK. Activin-induced signaling, transactivation,
growth suppression and cell cycle arrest were enhanced with concomitant inhibition of
MAPK/ERK or PI3K in ACVR2-restored HCT116+chr2 and ACVR2-native FET, but not
ACVR2-mutated HCT116 colon cancer cells. Activin enhanced cell migration in ACVR2-
restored colon cancers cells, which was reversed with ACVR2-specific knockdown. CONCLU-
SIONS: Growth suppression induced by activin signaling is modulated by mitogenic signaling
and is at least in part mediated by an increase in p21 stability. Disruption of activin signaling
by component inactivation or mitogenic signaling, often seen in colorectal cancers, reverses
these effects. Conversely, intact activin signaling enhances migration of colon cancer cells
in a ACVR2-dependent manner, the effect of which would be lost in ACVR2-mutant forms
of colon cancers, such as those displaying microsatellite instability.
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Pasteurization of Beta-Lactoglobulin Promotes Allergic Sensitization in Mice
By Enhancing Uptake Through Peyer's Patches
Franziska Roth-walter, M. cecilia Berin, Paul M. Arnaboldi, Stephanie Dahan, Lloyd
Mayer
Background: Although food allergy is steadily increasing in the industrialized world, the
underlying mechanisms that are critical to sensitization to dietary antigens remain elusive.
Aim:To study the effect of pasteurization of three different milk allergens, a-lactalbumin
(ALA), b-lactoglobulin (BLG) and casein (CAS) using a murine model of food allergen-induced
anaphylaxis. Methods & Results: Pasteurization (past) changed the physical properties of
the whey protein BLG, and to a lesser extent ALA, causing aggregation. CAS in its natural
state is in aggregates, in micelles, and as a consequence past had no impact. Pasteurization
also had a profound impact on ALA and BLG uptake, in that they were no longer readily
taken up by intestinal epithelial cells In Vitro using polarized Caco2 monolayers (In Vitro
transcytosis rate: 3.4 ± 0.5 vs. 1.6 ± 0.3 mg/ml non-past vs. past ALA, 7.4 ± 1.1 vs, 1.4 ±
0.2 mg/ non-past vs. past BLG and 1.2 ± 0.3 vs, 2.0 ± 0.7 mg/ml non-past vs. past CAS).
Pasteurization resulted in altered Ag uptake In Vivo as well, away from enterocytes and
redirected to Peyer's patches. Redirecting allergens to Peyer's patches resulted in significantly
higher Th2-associated antibody and cytokine production (e.g. IgE-levels for ALA: 39.7 ±
4mg/ml and ALA past 60 ± 5 mg/ml, p< 0.05; BLG: 24.6 ± 4 mg/ml and BLG past:61 ±
5mg/ml, p<0.001; CAS: 51 ± 6 mg/ml and CAS past: 54 ± 8 mg/ml, p= n.s.; interleukin 5-
levels for ALA 7.8 ± 3.3 pg/ml and ALA past 19.5 ± 6.9 pg/ml, p= n.s.; BLG 4.3 ± 2.6 pg/
ml and BLG past 33.9 ± 11.1 pg/ml, p<0.05, CAS 58.1 ± 21.8 pg/ml and CAS past 64.16
± 15 pg/ml, p= n.s.). However, despite higher antigen-specific IgE-levels, mice sensitized
to pasteurized ALA or BLG did not develop anaphylaxis to oral allergen challenge, and
reacted only upon administration of the allergen systemically suggesting that the allergic
response was dependent on the transfer of protein across the enterocyte. Conclusion: These
results indicate that the ability to trigger an allergic response is dependent on the combination
of 1) the degree of sensitization and 2) efficient transfer of the protein across the enterocyte.
Furthermore, our data point out that sensitization can be greatly enhanced when uptake of
dietary antigen occurs through Peyer's patches. Since the majority of common food allergens
tend to form aggregates, this might be of clinical importance.
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Induction of Indoleamine 2,3 Dioxygenase Contributes to Protective Effects of
Immunostimulatory DNA On TNBS Colitis
Matthew A. Ciorba, Filipe Muhale, Rodney D. Newberry, William Stenson
BACKGROUND: Immunostimulatory DNA sequences (CpG) have previously been shown
to protect against various models of experimental murine colitis. CpG, a toll-like receptor
9 (TLR9) agonist, has also been implicated as mediating the anti-inflammatory effects of
probiotics on trinitrobenzene sulfonic acid (TNBS) hapten induced colitis. These studies
indicate that CpG effects are mediated in part by modulation of cytokine response from the
innate immune system, including the induction of Type I IFN's. IFNα is a known potent
stimulus for induction of Indoleamine 2,3 dioxygenase (IDO). OBJECTIVES: We have
previously demonstrated that IDO is induced in TNBS colitis and that IDO inhibition with
1-methyl tryptophan (1-MT) results in worsened colitis. We now sought to determine if
IDO is induced in the colon by CpG, and if so, whether the upregulation of IDO contributes
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to its protective effects in TNBS colitis. METHODS: 6-10 week-old SJL/J mice (n=9-11/
group) were treated as follows: 1- intrarectal TNBS (0.5mg); 2- intraperitoneal CpG (20 μg
one-day before TNBS); 3- intraperitoneal CpG (20 μg one-day before TNBS) along with
time-release pellet of 1-MT (a specific inhibitor of IDO). Colons were recovered and colitis
severity was determined by clinical and histological criteria. IDO expression was detected
by immunohistochemistry. We also determined In Vitro the ability of CpG (15μg/ml @ 20
hrs) to induce IDO mRNA expression by real-time PCR in sorted fractions of colonic lamina
propria mononuclear cells (LPMNC). FACS sorting was used to isolate CD11chigh cells (as
a marker for dendritic cells). RESULTS: Survival, weight loss and morphological scores are
summarized in the table: the clinical benefits of CpG treatment were lost when 1-MT was
co-administered. Immunohistochemistry showed rare and faint IDO positive cells in the
lamina propria of the untreated control mice. Immunostaining for IDO was increased by
CpG treatment. Incubation of the isolated CD11chigh population with CpG led to a 5.7
fold increase in IDO mRNA expression over the control group. CONCLUSIONS: CpG
administration upregulates IDO in CD11chigh LPMNC's. The beneficial effects of CpG on
colitis are blocked by 1-MT coadministration. Together this suggests that IDO upregulation
contributes to the ameliorative effects of CpG on TNBS colitis.
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TNF Receptor Type-I Dependent Activation of Intestinal Innate Responses to
Prevent Lethal Inflammation-Induced Damage
Emiko Mizoguchi, Mayumi Kawada, Yuriko Hachiya, Atsuhiro Ogawa, Ken Sugimoto,
Atsushi Mizoguchi, Daniel K. Podolsky
Background: Ligation of tumor necrosis factor receptors (TNFRs) with TNFα plays a critical
role in the pathogenesis of IBD. It has been well demonstrated that TNFα/TNFRs interactions
are critical for the major pathogenic effects in T cells. However, the role of TNFRs in innate
immune responses involved in the pathogenesis of colitis has not fully been defined. Methods:
To address the role of TNFRs in innate immune responses, we generated recombination
activating gene (RAG)-1 based TNFR1 and/or TNFR2 double KO (DKO) or triple KO (TKO)
mice. To further examine the functional importance of TNFRs on non-lymphoid cells, bone
marrow (BM) cells from RAG-1 KO mice were peritoneally injected into TNFR1 x RAG-1
DKO mice. Histology, TUNEL assay, activation of MAP and NF-kB pathways and bacterial
invasion rate were analyzed. Results: Mice lacking both RAG-1 and TNFR1 exhibited high
mortality (>80 %) rate with a impaired colonic epithelial cell (CEC) regeneration as compared
to RAG-1 KO or RAG-1 x TNFR2 DKO mice with DSS colitis. RAG-1 x TNFR1 x TNFR2
TKO mice, which do not express TNFR1 nor TNFR2, were unable to survive after the
cessation of DSS without entering the recovery phase. Large numbers of bacteria were
detected from the culture of spleen, liver, mesenteric lymph nodes, colon and peripheral
blood of RAG x TNFR1 DKO and RAG x TNFR1 x TNFR2 TKO mice but not RAG-1 KO
mice during the course of DSS colitis. In contrast, transplantation of the RAG-1 KO derived
BM cells, which can express TNFR1, restored the CEC regeneration and rescued the recipient
RAG x TNFR1 DKO mice from the DSS-induced mortal damage. These observations suggest
that the TNFR1expressed on non-lymphoid, myeloid lineage cells in LP is a critical regulator
for recovering from DSS induced acute colitis. In addition, after the BM transplantation,
RAG x TNFR1 DKO mice significantly increase the expression of apoptosis related molecules
(caspase-1, caspase-8, Bcl-3), mitogen activated protein kinase kinase kinase 3 (MKK3),
interferon regulatory factor 1 (IRF1) and Thymoma viral proto-oncogene 1 (AKT-1). From
the result, we found that after RAG-1 KO BM transplant, apoptotic and MAPK pathways
rather than NF-kB pathway were activated in the colon of BM transplanted RAG x TNFR1
DKO mice compared to RAG x TNFR1 DKO mice on DSS day 8. In addition, the BM
transplantation enhanced the proliferation of CECs with activation of MAPKp42/44 pathways
and increased TUNEL positive cells in LP. Conclusions: TNFR1-signaling cascade in colonic
lamina proprial myeloid lineage cells contributes to suppress acute colitis-induced mortal
damage by enhancing innate responses presumably by mediated by CECs.
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Selective Induction of Crohn's Disease (CD) and Ulcerative Colitis (UC)
Lamina Propria Mononuclear Cells (Lpmc) Apoptosis By Probiotics:
Involvement of Bacterial Sphingomyelinase (SMase)
Sandra Angulo, Silvio Danese, Nicole Pultz, Maria grazia Cifone, Albert Morales, Claudio
De simone, Jose carlos Fernandez-checa, Julian Panes, Curtis J. Donskey, Claudio Fiocchi,
Miquel Sans
Background: Probiotics appear to be beneficial in inflammatory bowel disease (IBD), but
their mechanism of action is poorly understood. Lactobacillus brevis (LB) and Streptococcus
thermophilus (ST), two probiotic bacteria included in VSL#3, have high levels of neutral
SMAse, an enzyme leading to ceramide-mediated apoptosis. Aim: We investigated the ability
of probiotics to induce apoptosis of immune cells as well as the influence of the degree of
cell activation and the role of SMAse on this form of apoptosis. Methods: LPMC were
obtained from CD (n=10) and UC (n=7) patients, and normal colon (n=21), and peripheral
blood mononuclear cells (PBMC) from healthy volunteers. Fresh LPMC and PBMC were
used as resting or activated cells after stimulation with anti-CD3+CD28. Bacterial sonicates
were obtained from LB, ST, and a non-pathogenic E. coli (EC) and S. faecalis (SF), as non-
probiotic bacteria. LPMC and PBMC cells were exposed to bacterial sonicates (1 mg protein/
mL), ceramide (30 mg/mL), dihidroceramide (30 mg/mL), or medium alone for 24 hours.
In some experiments, sonicates were preincubated with GW4869, a specific inhibitor of
neutral SMAse. Apoptosis was assessed by flow cytometry of propidium iodide-stained cells
and expressed as percentage of apoptotic cells. SMAse activity was measured by TLC assay,
using NBD-sphingomyelin as a substrate. Results: LB and ST sonicates induced significantly
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(p<0.01) more apoptosis in CD (55.1±4.7 and 32.7±3.3%) and UC (44.1±6.4 and 24.6±4.1)
than in control LPMC (28.2±1.6 and 15.9±2.1%). EC and SF sonicates completely failed
to induce apoptosis of all cell types. Stimulation with anti-CD3+CD28 induced a significant
(p<0.01) and time-dependent increase in LB-induced apoptosis of both LPMC and PBMC.
Ceramide induced significantly (p<0.05) more apoptosis in CD (30.8±3.1) and UC (24.1±3.1)
than in control LPMC (16.3±1.1), whereas dihidroceramide had no effect. Inhibition of
SMAse by GW4869 caused a dose-dependent reduction of LB-induced apoptosis, which
was significantly higher (p<0.005) in CD (64%) and UC (60%) than in control LPMC (26%).
SMAse activity of LB and ST was 10-fold that of EC and SF sonicates. SMAse activity of LB
sonicate was completely abrogated by GW4869. Conclusions: Enhanced apoptosis of CD
and UC LPMC appears to be a selective effect of the probiotics LB and ST, since other
enteric bacteria like EC and SF fail to enhance apoptosis. Probiotic-induced apoptosis is
modified by the degree of cell activation and bacterial SMAse plays a key role on this process.
These results suggest that induction of immune cell apoptosis is one of the mechanisms
mediating the therapeutic effects of probiotics in IBD.
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Differential Induction of Apoptosis and Mapk Activation By the Anti-TNF
Agents Infliximab, Adalimumab, Etanercept, and Certolizumab Pegol Via
Reverse TNF Signaling in Primary Monocytes
Philip Rosenstiel, Stefanie Derer, Andreas Till, Valentina Medici, Dirk Seegert, Stefan
Schreiber
Background: It has been hypothesized that the efficacy of anti-TNFα therapies in steroid-
refractory Crohn's disease (CD) may critically depend on the induction of apoptosis via
binding of the transmembrane precursor of TNFα (mTNFα). However, we have recently
reported that both responders and nonresponders to infliximab are characterized by a strong
initial induction of apoptotic signaling in lamina propria mononuclear cells, but differ in
downstream events of the p38 and ERK MAPK cascades also induced by mTNFα reverse
signaling. Aim: To elucidate the differential reverse signaling mechanisms induced by TNF
binding agents infliximab (chimeric anti-TNFα antibody), adalimumab (humanized anti-
TNFα antibody), etanercept (TNFR2:Fc fusion protein), and certolizumab pegol (pegylated
anti-TNF Fab' fragment) in primary mononuclear cells. Methods: Signaling pathways induced
by ligation of mTNFα were investigated using phospho-specific Western blots and reporter
gene assays. Apoptosis was assessed using MTT assays, caspase activity measurements, and
Annexin V fluorescent activated cell sorter. Induction of specific transcriptional patterns
upon anti-TNF stimulation was assessed using oligonucleotide microarrays and Taqman
real-time PCR. Results: Infliximab, adalimumab, and etanercept exert immunoregulatory
functions by induction of death receptor-independent apoptosis in primary human monocytes
and in the monocytic cell line THP-1 through reverse signaling via mTNFα. Molecular
mechanisms of mTNFα-induced apoptosis involve release of cytochrome c and activation
of caspases 9 and 3. Interestingly, certolizumab pegol did not induce apoptosis, whereas a
strong activation of the MAPK p38α and ERK1/2 was still observable. Changes in transcrip-
tional signatures induced by treatment of primary monocytes and THP-1 cells with the anti-
TNF agents In Vitro encompassed a complex cellular program characterized by shared
and compound-specific changes in transcripts encoding cytokines (IL-1β, IL-8), cell death
regulators, and cell cycle-associated proteins (cdc42, cdk4). Conclusions: This mechanism
supports the notion that the therapeutic efficacy of TNFα blocking agents in CD therapy
may also depend on mechanisms other than mere neutralization of soluble TNFα or induction
of apoptosis. Molecular dissection of the nonapoptotic signaling induced by mTNFα ligation
may have important implications for the design of future therapeutic strategies in inflammat-
ory bowel disease.
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Increased Expression of the Iap Family Member Survivin in Crohn's Disease:
An Explanation for the Increased Proliferation and Decreased Apoptosis of
Mucosal T Cells
Heitor Souza, Manijeh Phillips, Gail West, Melanie Rhee, Claudio Fiocchi
Survivin is a member of the inhibitor of apoptosis (IAP) gene family and plays a fundamental
dual role in cell survival and mitosis. Because Crohn's disease (CD) is characterized by both
decreased apoptosis and uncontrolled T cell proliferation, we investigated survivin expression
and function in CD, ulcerative colitis (UC) and control mucosal T cells. Survivin expression
was assessed in whole mucosal tissue, isolated lamina propria mononuclear cells (LPMC)
and T cells (LPT), as well as cytosolic and nuclear fractions by immunohistochemistry,
mRNA, Western blotting, and immunoprecipitation. LPMC and LPT were cultured alone
or activated with IL-2 or anti-CD2±CD28, and treated with cycloheximide, proteasome
inhibitors (MG132 and lactacystin), or leptomycin B (an inhibitor of nuclear protein export).
Immunohistochemistry showed a markedly increased number of survivin-positive T cells
in CD, but not in control or UC mucosa. Survivin mRNA levels were similar in freshly
isolated IBD and control LPMC, but protein levels were significantly (p=0.015) higher in
CD compared to control and UC LPMC. In the presence of IL-2 the number of LPMC
increased progressively, significantly (p=0.006) more in CD than control and UC cultures
and in parallel with an increase of survivin mRNA and protein. In the absence of IL-2, cell
numbers and survivin decreased in control and UC cultures, while CD cells died significantly
(p=0.001) less and unexpectedly increased their survivin level (r=0.975; p=0.005). Activation
with anti-CD2±28 enhanced survivin content, peaking 24-48 hrs earlier in CD than control
or UC LPMC. Investigation of post-translational modifications revealed greater phosphoryl-
ation of survivin in CD LPT compared to control cells by both western blot and immunopreci-
pitation, while cycloheximide induced a drop in cytosolic but not nuclear survivin in CD,
UC and control LPMC. Proteasome inhibitors increased survivin levels by preventing its
degradation, and reciprocal immunoprecipitation with ubiquitin antibodies revealed that
survivin ubiquitination was greater in CD than UC or control LPT. The above results show
that survivin is a master controller of gut mucosal T cell function, as shown by its effect in
promoting cell proliferation and antagonizing apoptosis. In mucosal T cells survivin is
controlled by the ubiquitin/proteasome pathway, and the greater accumulation of total and
ubiquinated survivin in CD is apparently due to defective proteasomal degradation, thus
explaining why T cells proliferate more and die less in this condition.
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Inhibition of the Apical Sodium-Dependent Bile Acid Transporter in
Experimental Necrotizing Enterocolitis
Ludmila Khailova, Dania Molla hosseini, Kelly Arganbright, Charity A. Reynolds,
Bohuslav Dvorak, Melissa Halpern
Background: Necrotizing Enterocolitis (NEC) is the most common gastrointestinal disease
of prematurely born infants. We have previously shown that ileal bile acid (BA) accumulation
contributes to ileal damage in a neonatal rat model of NEC. Ileal luminal BAs are transported
across the apical membrane of enterocytes via the apical sodium-dependent bile acid trans-
porter (Asbt); we have also shown that Asbt is significantly elevated in experimental NEC.
However, the contribution of luminal versus intra-enterocyte BA accumulation has not been
delineated during disease development. SC435, a specific inhibitor of Asbt, inhibits only
intestinal Asbt when given orally. Thus, SC435 can be utilized to inhibit ileal uptake of
BAs. Objective: To determine if accumulation of intra-enterocyte BAs causes the ileal damage
observed in NEC by inhibiting Asbt. Methods: Prematurely born Sprague-Dawley rats were
hand-fed with formula and exposed to asphyxia and cold stress twice daily to develop NEC.
Pups were divided into 2 experimental groups: NEC + SC435 (n = 16), pups orally gavaged
with 5ug/g/day SC435 or NEC (n = 16), pups given vehicle alone. Animals from both groups
were sacrificed at 96 hours post-birth. A 3 cm section of distal ileum from each animal was
flushed with 400 ul sterile, cold PBS to evaluate total luminal BA levels. After flushing with
an additional 500 ul PBS, this section of ileum was homogenized in 400 ul fresh PBS to
determine intra-enterocyte BA levels. Total BA levels were determined using the Diazyme
Total BA Kit. An adjacent section of distal ileum was evaluated for histological damage by
a blinded observer using an scale of 0 (normal ) - 4 (necrosis). For NEC incidence, animals
with an ileal damage score of 2 or greater were considered to have developed NEC. Results:
Luminal BA levels were similar between groups. However, intra-enterocyte BA levels were
significantly lower in animals given SC435. In addition, both the incidence and severity of
NEC were significantly reduced when BA uptake was inhibited. Conclusion: Intra-enterocyte
BA accumulation contributes to ileal damage in experimental NEC. Further, the data suggest
that the up-regulation of Asbt observed during NEC plays a role in disease development.
Supported by NIH grant HD047237.
BA levels are expressed as mean(SEM); *p < 0.05; #p < 0.01.
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Necrotizing Enterocolitis Is Reduced in IL-18 Knockout Mice
Melissa Halpern, Ludmilla Khailova, Dania Molla hosseini, Charity A. Reynolds, Kelly
Arganbright, Bohuslav Dvorak
Background: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease pre-
dominantly of prematurely born infants, characterized in its severest from by extensive
hemorrhagic inflammatory necrosis of the distal ileum and proximal colon. Pro-inflammatory
cytokines have been implicated in the development of NEC and we have previously shown
that the IL-18 is significantly elevated in neonatal rats with NEC. Objective: The goal of
this study is to determine if IL-18 contributes to intestinal pathology in NEC. Methods:
Newborn, never suckled B6.129P2-Il18tm1Aki/J (IL-18 -/-) and wild-type (control) mice
were hand fed every 3 hours with cow's milk-based formula and exposed to asphyxia and
cold stress twice daily. After 72 hours, animals were sacrificed and distal ileum and liver
were removed. Histological changes in the ileum were scored by a blinded evaluator and
graded using our previously published NEC scoring system where 0 is normal and 4 indicates
full necrosis. Incidence of NEC was determined based on a histological damage score of 2
or greater indicating the development of NEC. Ethanol-fixed, paraffin-embedded liver and
ileum were serial-sectioned, deparaffinized, and subjected to immunohistological staining
with anti TNF-α, anti macrophage, anti IL-12 and anti IL-1β. Stained slides were evaluated
by a blinded observer and enumeration of positively stained cells was accomplished by
counting ten 40X microscopic fields. Results: The incidence and severity of NEC was
significantly reduced in IL-18 -/- mice compared to controls. Further, mean ileal macrophages
and hepatic IL-1β were significantly reduced in IL-18 -/- mice subjected to the NEC protocol.
There were no statistically significant changes in Kupffer cells, hepatic TNF-α, ileal IL-1β
or IL-12. Conclusion: IL-18 plays a crucial role in experimental NEC pathogenesis. These
data suggest that neutralization of IL-18 may be a valid therapeutic approach to NEC.
Supported by NIH grant DK067954.
Mean data are expressed as mean(SD). *p < 0.05; **p < 0.01; #p < 0.001.
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Interferon-Gamma Knockout Mice Are Protected from the Development of
Necrotizing Enterocolitis: Evidence for a Role for Gap Junctions Within
Enterocytes
Cynthia Leaphart, Selma Cetin, Jun Li, Theresa Dubrowski, David Hackam
Background and Aims: Necrotizing enterocolitis (NEC) is characterized by inadequate
mucosal healing due to impaired enterocyte migration and the release of interferon gamma
release. Because adjacent enterocytes migrate together, inter-enterocyte communication may
be required for mucosal healing. Many cells communicate via connexin43-containing gap
junctions. We hypothesize that enterocyte migration requires inter-enterocyte communica-
tion, that interferon gamma (IFN) impairs enterocyte migration by impairing connexin-43
targeting and function, and that IFN knockout mice may be protected from NEC through
effects on gap junctions. Methods: NEC was induced in 10day-old C57/Bl-6 or IFN-/- mice
by hypoxia/gavage. Restitution was determined by assessing labeled enterocytes along the
crypt-villus axis +/- gap junction inhibitor oleamide, or time-lapse microscopy of wounded
IEC-6 enterocytes. Gap junction function was assessed by live cell confocal microscopy
using fluorescence recovery after photobleaching. Primary cells were obtained from murine
ilea and plated on matrigel. Results: IEC-6 enterocytes and primary enterocytes expressed
connexin43, and communicated via gap junctions. Gap junction inhibition significantly
reduced enterocyte migration In Vitro and In Vivo. The induction of NEC in C57BL-6 mice
was associated with interferon release and the loss of enterocyte connexin43 expression.
IFN release inhibited enterocyte migration by reducing gap junction communication through
the de-phosphorylation and internalization of connexin43, whereas phosphatase inhibition
with calyculin-A restored enterocyte migration after interferon exposure (Figure). In C57Bl-
6 mice, injection with the gap junction inhibitor oleamide significantly increased NEC
severity, whereas IFN-/- mice were protected from the development of NEC, and demon-
strated a restoration of connexin43 phosphorylation and expression. Conclusion: Interferon
gamma inhibits enterocyte migration by preventing inter-enterocyte gap junction commun-
ication, providing insights into the mechanisms by which IFN-/- may be protected from the
development of NEC.
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Clc-2 Knockout Mice Have Impaired Post-Ischemic Intestinal Barrier Recovery
Prashant K. Nighot, Adam J. Moeser, Kathleen A. Ryan, James Melvin, Anthony T.
Blikslager
In our previous In Vitro experiments we have shown that pharmacologic inhibition of ClC-
2 chloride secretion inhibits recovery of barrier function in ischemia-injured porcine Ileum.
To seek a definitive role of ClC-2 chloride channel in intestinal barrier recovery In Vivo, we
studied barrier function recovery in ischemia-injured small intestine of ClC-2 knockout
mice. Intestinal segments from around 6-month-old wild type (WT) and knockout (ClC2-/-
) mice siblings were subjected to In Vivo complete mesenteric ischemia for 45 minutes. The
ischemic intestinal segments were then allowed to recover for either 1.5 or 3 hours after
which In Vivo blood-to-lumen clearance of 3H-mannitol was studied as a measure of intestinal
permeability. Control and ischemia-injured intestinal tissues were processed for histological
and electron microscopic examination. In WT mice, after 1.5 and 3 hours of recovery, 3H-
mannitol flux did not differ significantly between control and ischemia injured intestinal
segments (3H-mannitol clearance = 0.16 + 0.02 and 0.23 + 0.08 ml/hr x 100g for control
and ischemic intestinal loops, respectively, at 1.5 hours recovery, and 0.28 + 0.20 and 0.38
+ 0.22 ml/hr x 100g for control and ischemic intestinal loops, respectively, at 3 hours
recovery). Alternatively, in ClC-2-/- mice, 3H-mannitol flux in ischemia-injured intestines
was significantly higher at 1.5 and 3 hours recovery than that of control intestine by 226%
and 122%, respectively (3H-mannitol clearance = 0.07 + 0.03 and 0.24 + 0.09 ml/hr x 100g
for control and ischemic intestine at 1.5 hours, p<0.01, and 0.09 + 0.02 and 0.22 + 0.06
ml/hr x 100g for control and ischemic intestine at 3 hours, P<0.01). Histological examination
of intestinal tissues revealed near complete epithelial restitution by the end of 1.5 hour
recovery period and histological parameters including villus height and width, crypt depth,
and percent denudation of villi did not differ from respective control and ischemic loops,
regardless of genotype. However, electron microscopic examination revealed dilated tight
junctions in ischemic intestinal tissues from ClC-2-/- mice as compared with WT ischemic
loops after 1.5 as well as 3 hours of recovery. Overall, the In Vivo blood-to-lumen mannitol
clearance data demonstrates delayed recovery of intestinal barrier function in ClC-2-/- mice
after ischemic injury. Impaired barrier recovery in ClC-2-/-mice was associated with dilated
tight junctions and independent of epithelial restitution.
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Potassium Channel Blockade Prevents Increased Colonic Permeability During
Ischaemia - A Novel Therapeutic Strategy to Prevent Sepsis
Arun Loganathan, John E. Linley, Sashi Kopanati, Peter Lodge, Malcolm Hunter, Geoffrey
I. Sandle
Background: Gut ischaemia during major surgery is associated with increased intestinal
permeability, bacterial translocation, and systemic sepsis. K+ channel activation occurs in
response to metabolic inhibition in cardiovascular tissue, and in liver, biliary and colonic
cell lines. In cultured monolayers of T84 colonic adenocarcinoma cells, mastoparan (a G
protein agonist) increased paracellular permeability 4-fold, which was dependent on an
increased basolateral membrane K+ conductance. Thus, modulation of basolateral K+ channels
represents a potential target for reducing the risk of systemic sepsis due to hypoxic intestinal
injury. Aims: To determine (1) whether acute metabolic stress activates basolateral K+
channels in human colonic crypts, and (2) whether specific K+ channel blockers prevent
hypoxia-related changes in colonic permeability. Methods: Crypts were isolated by Ca2+
chelation from human colonic biopsies obtained with informed consent, and exposed to
100μM dinitrophenol (DNP) + 5mM deoxyglucose (DG) to produce cell hypoxia. Whole-
cell currents were measured using the perforated patch-clamp technique (amphotericin in
pipette). Paracellular conductance (permeability) of isolated sheets of resected human sigmoid
colonic mucosa mounted in Ussing chambers was estimated using the nystatin-permeabilized
apical membrane technique. Results: 100μM DNP + 5mM DG activated whole-cell currents
within 5 minutes, increasing whole-cell conductance from 0.91 ± 0.21nS to 2.65 ± 0.51nS
(P<0.025; n = 7), and hyperpolarizing the cell membrane from -55 ± 6mV to -74 ± 3mV
(P<0.02). Specific blockers (10μM clotrimazole, CLT and 100nM TRAM-34) of the interme-
diate conductance K+ channel (IK or KCNN4) completely inhibited the hypoxia-stimulated
increase in whole-cell conductance (P<0.05). 100μM DNP increased colonic paracellular
conductance from 5.67 ± 1.1 mS.cm-2 to 12.8 ± 1.7 mS.cm-2 (P<0.01, n = 6), a response
which was prevented by the prior addition of 20-50μM CLT (n = 9). Conclusion: Metabolic
stress activates basolateral IK channels in human colonic crypts. Specific IK channel blocking
drugs prevent the associated increase in colonic permeability during cell hypoxia, and their
use may provide a novel approach to the prevention of gut-derived sepsis.
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Activation of Myd88 Signaling Pathway Inhibits Ischemia-Reperfusion Injury
in Small Intestine
Atsushi Kobata, Toshio Watanabe, Tetsuya Tanigawa, Masatsugu Shiba, Kazunari
Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi, Koji Takeuchi,
Tetsuo Arakawa
Background/Aim: Toll-like receptors (TLRs) recognize microbial components and trigger
the signaling cascade that activates innate and adaptive immunity. All TLRs identified to
date except TLR3 use a common adaptor protein, MyD88, to transduce activation signals.
We investigated role of MyD88 in ischemia-reperfusion (I-R) injury of the small intestine
in mice. Methods: Female C57BL/6 (wild-type), MyD88, and cyclooxygenase-2 (COX-2)
knockout mice were used. Under urethane anesthesia, the superior mesenteric artery was
clamped (ischemia), and reperfusion was established 45 min later by removal of the clamp.
After a 60 min-reperfusion period, the intestine was excised. Intestinal injury after reperfusion
was evaluated by measuring luminal contents of hemoglobin (a marker of intestinal bleeding)
and by histological examination. Small intestinal tissue was subjected to measurement of
myeloperoxidase (MPO) activity, a marker of neutrophil infiltration, and prostaglandin E2
(PGE2) concentration, and assay of levels of mRNAs for cytokines, COX-1, and COX-2 by
real-time RT-PCR. Results: I-R induced small intestinal injury characterized by infiltration
by inflammatory cells, disruption of the mucosal epithelium, and destruction of villi as well
as increased luminal concentrations of hemoglobin in wild-type mice. MyD88 deficiency
worsened the severity of mucosal injury by I-R, and increased luminal hemoglobin concentra-
tion. I-R increased MPO activity and levels of mRNA expression of tumor necrosis factor-
α (TNF-α) and KC (interleukin-8 homolog) by 9.4-fold, 2.9-fold, and 14.2-fold, respectively.
MyD88 deficiency markedly inhibited the increase in mRNA expression of TNF-α and KC,
but did not affect MPO activity. I-R significantly enhanced expression of mRNA of COX-2,
but not that of COX-1, and increased PGE2 concentration of the small intestine. The increases
in COX-2 expression and PGE2 concentration were inhibited in MyD88 knockout mice. In
COX-2 knockout mice, I-R-induced injuries were exacerbated, as assessed by histology and
luminal hemoglobin concentration. Conclusion: These findings suggest that the MyD88
signaling pathway may inhibit I-R injury in small intestine via induction of COX-2 expression.
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High Resolution Manometry Reveals the Maturation of Pharyngo-Oesophageal
Motility in Healthy Preterm Infants
Nathalie Rommel, Michiel P. Van wijk, Geoff Davidson, Louise Goodchild, Ros Lontis,
Lisa Mccall, Ross Haslam, Geoff Hebbard, Taher I. Omari
Background: Oral feeding capacity in infants depends upon adequate suck-swallow-breath
coordination. The swallow consists of coordination of pharyngeal peristalsis with UOS
relaxation and is poorly characterised. Standard manometric assessment of pharyngo-oeso-
phageal (PE) motility has shown little developmental changes in infants over 32w post-
menstrual age (PMA). High resolution manometry (HRM) enables a more detailed analysis
of the spatio-temporal coordination of motor events along the PE segment. Aim: To assess
the development of the pharyngeal phase of swallowing in healthy preterm infants. Patients/
Methods: We studied 10 preterm infants, born at 26-33w gestational age weighing 850-
1930g at birth. All infants were healthy and received full enteral feeding by NG-tube at
time of oral feeding introduction (31-33wPMA). HRM was performed using a perfused
catheter with 8 sideholes spaced 5mm apart. Manometric recordings were made at first oral
feeding attempt and at weekly intervals thereafter for 4 weeks. Data acquisition/analysis was
performed using Trace!®. PE pressures (mean±SD) and timing of events were determined.
Results: 320 nutritive swallows were analysed. In infants of 31-32wPMA, peak pharyngeal
A-58AGA Abstracts
pressure during swallowing was lower at 1-1.5cm above the UOS (18±6-20±6 mmHg)
compared to peak pharyngeal pressures recorded at 0.5, 2, 2.5, 3cm proximal of the UOS
(29±14, 24±5, 23±6, 23±11mmHg)(p<0.05). This drop of pharyngeal contraction was age-
related and disappeared in infants >35w. Peak pharyngeal contraction occurred at the time
of nadir UOS relaxation in infants of 31-32w(0.0±.17sec). However, UOS relaxation nadir
occurred before peak pharyngeal contraction in older infants (0.05±0.18/0.13±0.15sec at
33-34w/35-36w, p<0.001). Patterns of pressure wave sequences changed in the proximal
pharynx from being mostly synchronous/retrograde at 31-32w to predominantly antegrade
at 35-36w (Table). Conclusion: Analysis of pharyngeal segments and timing of motor events
using HRM allows detection of developmental changes in infant pharyngeal physiology. Our
data indicate that motor mechanisms regulating the pharyngeal component of nutritive
swallowing are not fully matured at 31-32w and continue to develop between 31-35w.
Immature pharyngo-oesophageal motility may contribute to the incapacity of preterm infants
to feed orally.
Patterns of peristalsis in proximal pharynx according to age
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Multi-Channel Intraluminal Impedance (pH-MII) Does Not Predict Clinical
Outcome in Patients with GERD Undergoing Fundoplication
Rachel L. Rosen, Julia Fritz, Kathleen Donovan, Samuel Nurko
Background: pH-MII is a tool to measure gastroesophageal reflux but no studies have been
done to determine if the results of pH-MII predict clinical outcome. Methods: 200 consecutive
pH-MII studies in patients with intractable reflux symptoms were reviewed. Patients who
underwent fundoplication based on clinical evaluations (FP) were identified and age matched
with patients who underwent medical management with acid suppression therapy (MM).
pH-MII characteristics and outcomes between symptomatic responders and non-responders
were compared. Results: 46 patients were included; 23 patients underwent fundoplication.
The mean ages of FP and MM patients were 76±67 months and 79±67 months, respectively.
There were no significant differences in the reflux profiles of FP patients who did and
did not experience symptomatic improvement postoperatively (Table 1). Baseline reflux
characteristics between FP and MM patients were then compared; no significant differences
were found between the two groups (p=NS). Within the MM group, there were no significant
differences in reflux profiles between patients who did and did not experience symptomatic
improvement after acid suppression therapy (Table 2). Conclusions: FP patients who experi-
ence symptomatic improvement did not have more reflux detected by pH-MII or a higher
symptom index than those patients with no symptomatic improvement. pH-MII may not
accurately predict which patients with intractable symptoms will have a favorable postoperat-
ive outcome.
Table 1. pH-MII profiles in fundoplication patients with and without symptomatic improve-
ment postoperatively
Table 2. pH-MII profiles in medical management patients who did and did not experience
symptomatic improvement
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Activated Phosphatidylinositol 3'-Kinase (PI3K) Signaling in Pten-Mutated
Hamartomatous Polyps
Irene Wong, Stayce E. Beck, John M. Carethers, Sherry C. Huang
Background: PI3Ks are a family of lipid kinases that play a crucial role in a wide range of
important normal cellular processes, but are associated with malignant behavior in neoplastic
cells, including cell growth, migration, and survival. Increased PI3K activity has been reported
in sporadic colorectal cancers through activating mutations or dysregulation. The tumor
suppressor PTEN antagonizes PI3K function. Germline mutations in PTEN are associated
with Hamartomatous Polyposis Syndromes, which carry increased malignant risk in various
organs. To determine if germline and somatic loss of PTEN in polyps from kindreds with
Hamartomatous Polyposis Syndrome have altered PI3K signaling, we characterized Hamarto-
matous Polyposis kindreds for germline mutations in PTEN, and examined their non-
dysplastic polyps for expression of PI3K downstream component activation and signaling.
Methods: Blood-derived DNA analysis for PTEN was performed on 7 polyposis kindreds.
Resected colonic polyps were collected from affected kindreds for immunohistochemical
analysis. Downstream proteins activated by PI3K were evaluated by immunohistochemical
analysis with antibodies for AKT, mTOR, and phosphorylated and total p70 (S6K1). Results:
Of the 7 hamartomatous polyposis kindreds, 3 had PTEN germline mutations. Loss of PTEN
expression was notable in the polyp cystic epithelium in the PTEN mutated polyps, indicating
bi-allelic loss of PTEN expression. The polyps demonstrated prominent increased expression
of AKT, mTOR, and phosphorlyated p70 within the epithelium of the PTEN mutated polyps.
Polyps from kindreds who were PTEN wildtype demonstrated low expression of AKT,
mTOR, and phosphorlyated p70, when compared to mutated PTEN polyps. Conclusion:
Hamartomatous polyps from germline PTEN-mutated patients completely lose PTEN expres-
sion through germline mutations followed by somatic events. The PTEN-null epithelium from
these polyps display prominent PI3K activation, triggering known mitogenic proliferative
pathways typically activated in malignant cells. These findings suggest that the loss of PTEN
from the epithelium of hamartomatous polyps may prime the non-dysplastic epithelium
for dysplastic transformation through enhanced or uncontrolled PI3K and downstream
component activation.
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A Detailed Haplotype-Tagging Investigation Into the Role of Rick/Ripk2
Germline Variation in Childhood Onset Inflammatory Bowel Disease
Johan Van limbergen, Richard K. Russell, Elaine R. Nimmo, Hazel E. Drummond, Linda
Smith, Niall H. Anderson, Gail Davies, Peter M. Gillett, Paraic Mcgrogan, Kamal Hassan,
Lawrence T. Weaver, Michael W. Bisset, Gamal Mahdi, David C. Wilson, Jack Satsangi
Background & Aims: The discovery of the NOD2/CARD15 gene in Crohn's Disease (CD)
has shifted the research focus to the innate immune system. Both NOD2/CARD15 and
NOD1/CARD4 depend on a CARD-CARD interaction with RICK/RIPK2 (Receptor-interacting
serine/threonine-protein kinase 2) to activate the transcription factor NF-κB. The aim of
this study was to assess the influence of RICK/RIPK2 on susceptibility and phenotype in a
Scottish childhood onset inflammatory bowel disease (IBD) cohort using a gene wide associ-
ation approach. Subjects & Methods: 1308 subjects comprising of 352 IBD patients (232
CD, 88 Ulcerative Colitis (UC), 28 IBD type unclassified), aged ≤ 16 years at diagnosis
(median age at diagnosis 11.2y (Q1-Q3: 8.7y-13.1y)), 586 parents and 370 controls were
genotyped for 6 single nucleotide polymorphisms (SNPs) tagging the RICK/RIPK2 gene.
SNPs were selected based on HapMap data (Release 20/Phase II, solid spine of LD, haplotype
& minor allelic frequency >10%). The 3 common NOD2/CARD15 variants were previously
genotyped. Allelic, genotype and haplotype frequency comparisons between cases and con-
trols using χ2, multimarker transmission disequilibrium testing (TDT) and a log-likelihood
analysis were used to assess association with IBD. Genotype-phenotype analyses (Montreal
classification, need for surgery - including stratification for NOD2/CARD15 variant carriage)
were also performed. Results: After correction for multiple testing, no significant associations
were observed between any of the RICK/RIPK2 SNPs studied and IBD or CD (p≥ 0.05).
Haplotype case-control analysis was negative in IBD and CD (p≥0.05). NOD2 variant
carriage did not influence the effect of RICK/RIPK2 haplotype on CD susceptibility. In UC,
one rare haplotype (211121) conferred increased susceptibility (11% vs 5%, p=0.003 OR
2.39 CI 1.33-4.32). The first SNP of this rare risk haplotype, rs218906, was also associated
with UC (allelic frequency 15.5% vs 8.5%, p-uncorrected = 0.006 / p-corrected =0.04,
OR 1.97 CI 1.20-3.22). Using log-likelihood analysis, no significant effect of RICK/RIPK2
haplotypes on susceptibility to IBD, CD and UC was observed (1000 permutations - p≥0.20
for all models). Genotype-phenotype analysis in CD and UC did not show any significant
influence of RICK/RIPK2. Conclusion: This is the first study to assess the contribution of
RICK/RIPK2 to IBD using a gene-wide haplotype-tagging strategy. In our childhood onset
cohort, germline variants of RICK/RIPK2 do not play a significant role in determining IBD
and CD susceptibility and phenotype. However, a weak effect on UC susceptibility cannot
be excluded.
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Self Administered Guided Imagery Used At Home Is An Effective Treatment
for Functional Abdominal Pain in Children
Miranda A. Van tilburg, Olafur S. Palsson, Marsha Turner, Denesh K. Chitkara, Martin
Ulshen, William E. Whitehead
Guided Imagery (GIM) is a psychological treatment similar to self-hypnosis. Hypnosis and
GIM have been shown to be effective in treating adult irritable bowel syndrome [Gastroenterol
2002; 123:2132-47] and children with functional abdominal pain (FAP) [BMC Pediatrics
2006; 6: 29]. However, GIM for abdominal symptoms is not available to most patients
because there are few therapists to offer such treatment for GI disorders, insurance coverage
is limited, and GIM requires multiple clinical visits, resulting in days missed from school
(child) and work (parents). GIM can be self administered. We developed a 2 month self-
directed GIM therapy for FAP in children delivered through the use of video/audio materials
that is used at home, eliminating the need for a trained therapist and multiple clinic visits.
The aim of the present pilot study was to compare home based GIM to standard medical
care (SMC). Methods: Children age 7-15 with FAP (N=23) were referred by a pediatric
gastroenterologist. Children were randomly assigned to either 2 months of GIM or 2 months
of SMC; The SMC group was crossed over to GIM after 2 months. Children and parents
completed the Abdominal Pain Index (API) pre and post treatment. Parents rated the global
change in symptoms (7 point scale) after GIM. Results: The treatment program was easy
to use and well liked. Adherence was 100%. No children needed help from their parents.
ANCOVA with baseline API sum scores as covariate, and post treatment sum scores as the
dependent variable yielded significantly lower pain scores in GIM compared to SMC for
both parent (F2, 20 = 3.74.; p < .05) and child reports (F2, 20 = 4.43; p < .05). Paired t-tests
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showed no changes in pain before and after SMC. GIM resulted in improvements in pain
frequency (M=2.2 vs 3.9; p <.001) duration (M=3.0 vs 5.7; p < .01) and intensity (M=2.9
vs 5.5; p < .01) by parent report and pain frequency (M= 2.4 vs 3.1; p < .05) by child
report. The majority of parents (75%) reported that their children were somewhat to markedly
better after GIM; only 1 child did not report any change at all, and none became worse.
Conclusion: A self-taught guided imagery program that children can use at home with litlle
guidance from parents and clinicians is effective in reducing abdominal pain complaints in
children with FAP. Delivering GIM in the convenience of one's home without dependence
on a therapist can make this type of treatment available to more children. It will enable
GIM to be prescribed by pediatricians who do not have access to this type of treatment in
their community. [Supported by grant R24 DK067674 and RR00046]
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Profound Lean Body Mass Deficits in Children with Crohn Disease: A 2-Year
Longitudinal Study from Diagnosis
Francisco Sylvester, Jeffrey Hyams, Trudy Lerer, Miriam Lincoln, Anne M. Griffiths
Background: Cross-sectional studies have suggested persistent lean body mass (LBM) deficits
in children with Crohn disease (sarcopenia). We hypothesized that LBM accrual is delayed
in children with Crohn disease. Aim: To measure body composition longitudinally for 2
years from diagnosis in children with Crohn disease. Methods: Children with Crohn disease
and healthy children up to 17 years of age were evaluated at two North American centers.
The following variables were examined: weight, height, and body mass index (BMI, kg/m2),
and fat mass (FM). LBM and bone mineral content (BMC) were determined by dual X-ray
absorptiometry (Lunar DPX-L, GE Lunar Corporation, Madison, WI, with pediatric software
version 1.5h). Parameters were normalized to Z-scores adjusted for height-age. The Pediatric
Crohn Disease Activity Index (PCDAI) was used as an indicator of disease severity. Total
serum insulin-like growth factor I (IGF-I) was measured (Diagnostic Systems Laboratories,
Inc., Webster, TX). Mean values were compared by Student's t test. Results: At diagnosis
82 children with Crohn disease (age 12.6 ± 2.6 y, 28 F) and 81 unaffected children (age
12.6 ± 2.4 y, 34 F) were assessed; 49 children with Crohn disease completed the 2-year
study. Mean PCDAI was 33, 10 and 8 at 0-, 1- and 2-years, respectively. Serum IGF-I at
diagnosis (ng/mL) was 177 ± 201 (Crohn disease) and 519 ± 345 (control, p<0.001). For
anthropometric variables, mean Z-scores at diagnosis were (Crohn vs. control): LBM (-1.35
vs. -0.19; p<0.001), FM (-0.70 vs. -0.25; p<0.05), BMI (-0.93 vs. 0.11; p<0.001), BMC
(0.19 vs. 1.24; p<0.001), and height (-0.18 vs. 0.41; p<0.001). The increment of each Z-
score over the course of the study defined a regression line with the following slope: LBM
0.50 ± 0.14, FM 0.49 ± 0.11, BMI 0.38 ± 0.12, BMC 0.76 ± 0.19, and height -0.02 ± 0.11.
Consequently, LBM and FM Z-scores increased at a similar rate over the 2 year duration of
the study, but the starting Z-score was lower for LBM. Conclusions: LBM deficits are
profound at diagnosis in children with Crohn disease. LBM Z-score continued to steadily
increase for the first 2 years after diagnosis, while the increase in FM Z-score slowed down
after the first year. BMC Z-score appeared to accelerate 1 year after diagnosis. Height Z-
scores remained stable over the course of the study.
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Pharmacogenomics of Clonidine in Irritable Bowel Syndrome
Irene Busciglio, Paula Carlson, Sanna Mckinzie, Duane Burton, Kari Baxter, Michael Ryks,
Alan R. Zinsmeister, Michael Camilleri
Background: Adrenergic (ADR) and serotonergic (5-HT) mechanisms alter gut motor func-
tions; genetic variation in these mechanisms and G-protein translation are reported to be
associated with different IBS phenotypes. Single nucleotide polymorphisms (SNPs) in genes
for α2C receptor and SERT-P (SLC6A4) are associated with IBS-C and high somatic scores
(SSC), suggesting effects on nociception. Hypothesis: The effects of the α2 receptor agonist,
clonidine, on motor and sensory functions in IBS are modulated by these genetic variations.
Methods: 88 IBS patients (Rome II positive, 2 male) and 35 healthy controls underwent
the following validated studies before and during 6 days of double-blind treatment with
clonidine, 0.1mg or 0.15mg bid: gastric volume by 99mTc-SPECT; satiation using a nutrient
drink test; and rectal compliance and sensation by barostat. The primary endpoints were:
fasting and postprandial gastric volume (GV), maximum tolerated nutrient drink volume
(MTV) and symptoms; colonic compliance [pressure at half maximum volume (Pr1/2)],
sensory thresholds and ratings for pain and urgency in response to distensions. SNPs tested
were:α2A adrenergic (C-1291G),α2C (Del 332-325), SERT-P (SLC6A4), and GNβ3 (C825T).
Results: The table summarizes observations at baseline (pre-drug) and post-clonidine. The
doses of clonidine used had no significant effect on the sensory thresholds or compliance
or motor endpoints. Clonidine had an overall treatment effect on pain sensory ratings in
IBS (p=0.035) when adjusting for SLC6A4 genotype. Association of SLC6A4 genotype and
sensory ratings to distension with clonidine was significant (p=0.04). There were significant
interactions in pain ratings, disease group and combination of SLC6A4 and α2A or GNβ3.
Conclusions: These data suggest that the effect of clonidine on sensory response to distension
in IBS is influenced by genetic variation in SLC6A4, consistent with the hypothesis that
ADR and 5-HT mechanisms interact in the control of pain perception in patients with IBS.
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TD-5108, a Selective 5-HT<4> Agonist with High Intrinsic Activity, Shows
Immediate and Sustained Prokinetic Activity in Healthy Subjects
M. R. Goldberg, S. L. Wong, J. Ganju, Y. P. Li, C. H. Ballow, M. M. Kitt
TD-5108, a selective 5-HT<4> agonist with high intrinsic activity, is being evaluated for the
treatment of disorders of reduced GI motility. We evaluated the effects of single- and
multiple-doses (SD and MD) of TD-5108 in 48 healthy subjects. In the SD study, subjects
were dosed weekly with rising doses of TD-5108 (0.1 to 70 mg; and 1 subject at 90 mg)
or placebo (PBO) in 2 alternating panels of 10 subjects and a 3rd panel of 10 subjects. In
the MD study, 18 subjects received TD-5108 (50 mg, N=9) or PBO (N=9) once daily, after
an overnight fast, for 2 weeks (wk). Subjects were monitored for safety and evidence of
prokinetic effects using a stool diary card. Time and consistency (Bristol score) of each
bowel movement (BM) were recorded. In the SD study, median time to first stool (TFS)
was 7.9 hours (hr) on PBO, 1.6 hr at 10 mg (p=0.012, log rank test), and 1.1 hr at 30 and
50 mg (p<0.01) and 0.9 hr at 70 mg (p<0.01). The mean (StD) number of BM in the 24
hr post dosing period was 1.3 (1.4) on PBO, 2.0 (1.5) at 20 mg, 3.6 (2.4) at 30 mg, 5.9
(3.9) at 50 mg and 6.0 (3.0) at 70 mg (p< 0.01 for 50 and 70 mg, ANOVA). On PBO,
average Bristol score was 3.2 (0.7) with a dose dependent increase to a plateau of 5.4-6.0
at 20-70 mg, e.g. at 50 mg, 5.6 (0.9), indicating softer BM. On the next day, effects were
not apparent. In the MD cohort, median TFS was 7.1 hr on PBO and 1.5 hr at 50 mg
(p<0.01). Mean BM/day over the 2 wk period were 0.9 (0.2) on PBO and 1.5 (0.7) at 50
mg TD-5108 (p=0.043). Bristol score on PBO averaged 2.6 (0.4) and 2.7 (0.6) in wk 1 and
2, respectively, and, on 50 mg TD-5108, averaged 4.3 (1.2) and 3.2 (1.2) in wk 1 and 2,
respectively. TD-5108 was generally well tolerated following SD and MD, without changes
in lab tests, ECGs, or vital signs. Notable adverse experiences included headache, nausea
(occasionally with vomiting), flatulence and diarrhea which lasted for 1-2 days in the MD
study. In conclusion, in healthy subjects, TD-5108 once daily shows immediate and sustained
prokinetic activity which persists for a 2 wk period. TD-5108 was well tolerated with notable,
but not persistent GI adverse effects. These results suggest that TD-5108 has the potential
for prokinetic activity in patients with chronic constipation, IBS-C, and other GI motility
disorders. A Phase 2 trial with TD-5108 in patients with chronic constipation is ongoing.
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VIP: A Novel Class of Promotility/Prokinetic Agents
Xuan-zheng Shi, Sushil K. Sarna
Background: Vasoactive intestinal polypeptide (VIP) has been proposed as an inhibitory
neurotransmitter in the gut based on pharmacological and immunohistochemical evidence.
However, recent findings suggests that the physiological release of endogenous VIP may be
in insufficient quantities to affect smooth muscle contractions. We reported recently that,
In Vitro, VIP induces gene transcription of the pore-forming α1C subunit of Cav1.2 (L-
type) calcium channels, resulting in an increase in calcium influx and hence contractility
of colonic circular smooth muscle cells. In this study, we tested the hypothesis that In Vivo
administration of VIP acts as a promotility agent and that of VPAC1/2 receptor antagonist,
(p-chloro-D-Phe6, Leu17)-VIP (VPAC Ant.), acts as an anti-motility agent. Methods: The
VIP and VPAC Ant. were administered i.m. in intact rats @ 20 nmol/day for 7 days by a
surgically implanted osmotic pump. Results: The 7-day infusion of VIP significantly enhanced
expression of the α1C subunit in rat colonic circular smooth muscle cells to 170 ± 15% of
control and their contractile response to KCl in an organ bath to 157 ± 12% of control
(both p<0.05). On the contrary, the 7-day infusion of VPAC Ant. significantly suppressed
the expression of α1C and the contractile response to KCl to 70 ± 10% and 61 ± 5% of
control respectively (both p<0.05). These effects were greatest in the middle colon that also
had the highest expression of VPAC1/2 receptors determined by western immunoblotting.
VIP infusion accelerated colonic transit (center of gravity (COG) 4.3 ± 0.5 units) and VIP
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Ant. infusion retarded it (COG 2.9 ± 0.1 units) on day 7 when compared with the vehicle
control (COG 3.3 ± 3 units; both p<0.05). The infusion of VIP increased the number of
pellets/24 hr from 50.3 ± 4.5 to 64.7 ± 7.6 (p< 0.05) and that of VPAC Ant. reduced them
to 36 ± 7 on day 7 (both p<0.05). VIP infusion had no significant effect on the moisture
content of the pellets, whereas the infusion of VIP Ant. reduced it on day 7(both p<0.05).
There was no difference in weight gain between the vehicle-treated control rats and those
infused with VIP or VPAC Ant. for 7 days. Conclusions: 1) VIP is released spontaneously
from the enteric inhibitory motor neurons and it maintains the expression of Cav1.2 (L-
type) calcium channels in colonic circular smooth muscle cells.2) The administration of
exogenous VIP acts as a promotility/prokinetic agent and that of its receptor antagonist as
an anti-motility/anti-kinetic agent.3) These agents may have potential therapeutic applications
in functional bowel disorders, such as in patients with constipation and diarrhea predominant
IBS .
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Lack of Effect of the NK3 Receptor Antagonist, Talnetant SB223242 On
Symptoms of IBS: Results of 2 Randomized, Double-Blind, Placebo-Controlled
Dose Ranging Trials
George E. Dukes, Odile E. Dewit, Gareth J. Sanger, Vanessa Z. Ameen, Allison R.
Northcutt, Teresa L. Perschy, Ginny D. Schmith, Abbas G. Hamedani, David H. Alpers
Background: NK3 receptor antagonists reduce rat viscero-motor responses to noxious col-
orectal distension, possibly by inhibiting the actions of tachykinins released from enteric
IPANs following a supra-maximal or noxious stimulus (Sanger, 2004, Br J Pharmacol, 141,
1303). We have evaluated the significance of these findings in IBS patients using talnetant,
an orally active, competitive, non-peptide, selective NK3 receptor antagonist. Methods: 2
double-blind, placebo-controlled, parallel group, multi-center studies were conducted in
patients with at least a 6 month history IBS meeting Rome II criteria and having an average
of mild to moderate abdominal pain during a 2 week baseline period. The initial study
(067) evaluated therapy with 5 mg QD, 25 mg QD, or 100 mg QD. Primary endpoint was
average adequate relief of IBS pain and discomfort (yes/no; assessed weekly) over the final
4 weeks of the 8 week treatment period. Post-hoc responder analysis (adequate relief in
each of last 4 weeks of therapy) indicated potential effect at the top dose. Therefore, a
second study (068) was conducted with dosing regimens designed to provide greater systemic
exposure (100 mg BD, 200 mg BD, 400 mg BD) using the responder definition as the
primary endpoint. Results: Study 067 enrolled 618 subjects (80% female). Study 068
enrolled 732 subjects (74% female). The primary analysis population for 067 was all IBS
subtypes and for the 068 study was non-diarrhea and non-constipation predominant IBS.
Talnetant failed to provide a statistically significant difference in adequate relief of IBS pain
and discomfort, pain severity, bowel symptoms, or IBSQOL at any dose or resulting systemic
exposure (AUC). Conclusion: Talnetant, a potent and specific NK3 receptor antagonist, had
no dose or exposure related effect in producing adequate relief of IBS pain and discomfort.
Although there are limited data that suggest NK3 antagonism is effective in preclinical models
of visceral pain, inhibition of this single tackykinin in man does not alter symptoms of IBS.
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Long-Term Mast Cell Stabilization Downregulates Mucosal Microinflammation
in the Jejunum of Diarrhea-Prone Irritable Bowel Syndrome (IBS)
Laura Ramos, Cristina Martinez, Carmen Alonso, Mar Guilarte, María Vicario, Ines De
torres, Francesc Casellas, Esteve Saperas, Javier Santos, Juan-r. Malagelada
Background: Intestinal mucosal micro-inflammation associated with increased numbers of
mast cells and their products has been observed in patients with chronic diarrhea and
recurrent abdominal pain and related to symptom onset and clinical severity. We investigated
the effect of mast-cell stabilization on mucosal inflammation and the clinical response.
Methods: Seventeen patients, newly diagnosed, previously untreated, non-allergic and non-
celiac, manifesting chronic diarrhea for the last 6 months (IBS, Rome II) were included.
Jejunal biopsies were obtained by Watson's capsule at baseline (n=5, Group A) or 6 months
after no treatment (n=5, Group B) or oral sodium cromoglycate 200 mg/8h (n=7, Group
C). Mucosal inflammation was evaluated by numbering lamina propria mast cells using
immunohistochemistry with CD117 (c-kit). Biological inflammation was evaluated in pooled
biopsies by quantitative real time PCR to analyze the expression of 32 preselected genes
implicated in innate inmunity (Toll-like receptors (TLR) and defensins (DEF)), mast cell
activation and growth and neuronal regulation. Abdominal pain (0-10) and stool consistency
(0-4) were evaluated by analogical scales at the time of biopsy. Results: Six months after
cromoglycate treatment up to 13 genes (40.6%) were differentially expressed when compared
to patients at baseline (C vs A, Table). Remarkably, genes involved in innate immune
response were down-regulated after treatment as were genes involved in mast cell activation
and growth and neuronal regulation including tryptase and the stress-related receptors CRH-
R1 and ADRA-2. Moreover, natural evolution of the disease was associated with up-regulation
or maintenance of most of these genes (B vs A, Table). Immunohistochemical staining
revealed a non significantly decrease of mast cells numbers after cromoglycate (A=25.9±6.9;
B=27.2±7.5; C=20±12.3). Sodium cromoglycate significantly improved stool consistency
(A=3±0.2; B=3.0±0.1; C=1.5±0.8; p<0.05 C vs A) and abdominal pain scores (A=5.2±0.8;
B=4.5±1.6; C=1.8±1.7; p<0.05 C vs A). Conclusion: Pharmacological stabilization of mucosal
mast cells effectively reduces pro-inflammatory gene expression profiles in the jejunal mucosa
of D-IBS patients and concomitantly improves clinical manifestations. Treatment strategies
directed to prevent mast cell activation might benefit patients with diarrhea predominant IBS.
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The Effect of Ghrelin On Gut Transit in Man
Ylva Haglund, Gareth J. Sanger, Odile E. Dewit, George E. Dukes, Per M. Hellstrom, Erik
Naslund
Background: Earlier studies have demonstrated that ghrelin increases fasting small bowel
motility in rats and that gastric emptying is accelerated in humans. The aims of this study
were (a) to see how a six hour infusion of ghrelin affects gut transit in healthy human
volunteers and (b) attempt to isolate a site of action by investigating the effects of ghrelin
on human stomach, small intestine and colon In Vitro. Methods: A 6-hour infusion of ghrelin
(15 pmol/kg/min; known to stimulate gastric emptying) or saline was started in the morning
(9 am) after an overnight fast and an energy fixed breakfast in 12 healthy male volunteers.
Prior to the infusion on day -1 (6 pm) and day 0 (7 am) a Sitzmarks capsule containing
different shaped radio opaque markers was swallowed. Just before the infusion 1.5 g acetamin-
ophen and 15 ml of lactulose (670 mg/ml) was taken. Plasma samples were obtained for
analysis of acetaminophen (marker of gastric emptying), glucose, ghrelin and other gut
peptides. The concentration of hydrogen in exhaled air was obtained throughout the study
(small bowel transit). VAS for hunger, fullness and nausea were obtained. A plain film of
the abdomen was obtained on day 1 and day 2 to study the distribution of markers. A
questionnaire regarding bowel habits was completed. Isolated GI tissues were obtained after
informed consent and suspended in tissue baths for isometric recording of muscle tension.
Results: There was no significant difference between the total number and distribution of
remaining radio opaque markers at either day during saline or ghrelin infusion. There was
no significant difference in the small bowel transit during saline infusion (46 ±9.7 min) and
ghrelin infusion (40 ±7.8 min) or in the reported bowel movements. As expected, hunger
was significantly increased during the ghrelin infusion compared to the saline infusion and
subsequently fullness was higher (p<0.05). There was no significant difference in nausea
rating. Plasma concentrations of ghrelin rose 4-fold during ghrelin infusion (1016 ±205 pg/
mL p<0.05). In isolated GI tissues, ghrelin 0.01-10 μM had no effects on contractility (n =
3-5 each); metoclopramide 30 μM caused contraction in all tissues studied. Discussion:
Ghrelin when administered intravenously to humans has a prokinetic effect on the stomach,
increasing the rate of emptying. This is not true for small bowel or colonic transit. These
data suggest differences between the effects of ghrelin in humans and in rodents, where
activity of ghrelin has also been reported In Vitro. Our data do not rule out the possibility
that ghrelin can increase intestinal motility by acting within the brain or spinal cord.
327
The Effect of Colostrum Fractions On the Structure and Function of the
Developing Intestine in Neonatal Piglets
Coryn Commare, Sharon M. Donovan, H. R. Gaskins, Jens J. Holst, Kalathur S.
Ramanujam, Kelly A. Tappenden
Colostrum provides trophic factors which enhance intestinal development and essential
immunoglobulins for immunity. Preterm infants have an underdeveloped gastrointestinal
tract and are unable to tolerate colostrum or enteral feedings in amounts necessary to meet
their energy and nutrient requirements, therefore preterm infants receive parenteral nutrition
for these demands. As a strategy to stimulate intestinal growth, partial enteral nutrition
(PEN) is often provided. We tested the hypothesis that a high growth factor/high IgG bovine
colostrum supplemented formula, administered as PEN, would augment neonatal piglet
intestinal development more than conventional premium preterm formula. Thirty-six 48-
hour old piglets were randomized into one of the following treatments: 100% standard
parenteral nutrition (TPN); 100% total enteral nutrition (TEN) from premium premature
infant formula, or 80% PN plus 20% EN of either; formula A (PEN A), a premium premature
infant formula; formula B (PEN B), the premium formula supplemented with low growth
factor/low IgG; formula C (PEN C), the premium formula supplemented with high growth
factor/high IgG; or formula D (PEN D), the premium formula supplemented with low growth
factor/low supplemented to high IgG. Duodenal and jejunal villus length of PEN B and
ileum PEN D achieved the same length as TEN controls. Similarly, both PEN B and PEN
D crypt depth was equivalent to the TEN positive control. The number of PCNA positive
crypt cells of PEN B exceeded (P=0.0007) that of all other PEN groups as did enterocyte
migration rate (P=0.0002). Duodenal resistance, a measure of barrier function, of PEN B
exceeded (P=0.0003) all other PEN treatment groups, whereas active ion transport was lower
(P=0.04), mimicking TEN. Nutrient transport of the PEN D group was greater than all
other treatments for glucose (P=0.0007), glutamine (P<0.0001), and dipeptide (P<0.0001)
transport. The plasma concentration of the intestinal trophic peptide, GLP-2, was increased
(P<0.0001) in the plasma of PEN B and PEN D above all other PEN treatment groups and
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TPN. These results indicate that colostrum containing low growth factor concentrations
(PEN B and PEN D) enhanced intestinal structure and function when contained in a formula
administered as PEN. Efforts to improve the composition of conventional premature infant
formulas with the addition of colostrum fractions may be important to facilitate intestinal
structure and function in preterm infants. (Funded by Wyeth Nutrition)
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Clinical Outcomes and Risk Factors for Pediatric short Bowel Syndrome
Following Operation for Necrotizing Enterocolitis: A Multicenter, Prospective
Cohort Study
Debora Duro, Christopher Duggan, Tom Jaksic, Maggie Mccarthy, Patrick Johnston, Leslie
A. Kalish, James Dunn, Mary L. Brandt, Kerilyn Nobuhara, Karl Sylvester, R. lawrence
Moss
Background: The incidence of and risk factors for short bowel syndrome (SBS) have previ-
ously been determined in small, retrospective, single-center case series. Aims: To prospect-
ively determine outcomes and risk factors for SBS in a cohort study of infants who underwent
surgery for necrotizing enterocolitis (NEC) at six academic medical centers. Methods: We
prospectively enrolled infants who met criteria for NEC from January 2004 to March 2006.
We defined SBS as the requirement for parenteral nutrition for ≥ 60 days after surgery.
Surgical NEC without SBS was defined by achieving full enteral nutrition or discharge home
< 60 days after surgery. Logistic regression was used to identify predictors of the combined
outcome of SBS or death. Results: Among 326 patients enrolled in the cohort, 114 required
surgery, and 102 of these had sufficient follow up and resection information for analysis.
Of the 102 infants, 33 (33%) developed SBS, and 18 (18%) died before 60 days due to
complications of NEC. The incidence of SBS or death was 51% and ranged from 28% to
68% among the six sites (p=0.078). Univariate analysis of risk factors associated with poor
outcome are given in the table below. Maternal use of steroids, infant use of vasopressors,
and use of breastmilk were not significantly different between the two groups. In multivariate
analysis, we identified four independent risk factors for SBS or death: gestational age ≤27
weeks (OR=3.4, p=0.018); any small bowel resection (OR=4.0, p=0.007); antibiotic use at
day of NEC diagnosis (OR=6.7, p=0.028); and creation of jejunostomy (p=0.010). Conclu-
sion: The incidence of prolonged dependence on parenteral nutrition or death due to NEC
is quite high in a cohort of infants undergoing surgery for NEC. Lower gestational age, small
bowel resection or jejunostomy, and use of antibiotics at NEC diagnosis were identified as
independent risk factors for poor outcome. Select maternal and infant clinical characteristics
were unable to predict poor outcomes including death or prolonged dependence on parenteral
nutrition. Additional biomarkers are needed to identify patients with NEC at risk of poor out-
comes.
Univariate risk factors for SBS or death
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Acute Effects of Continous Glucagon-Like Peptide (GLP)-2 and GLP-1
Infusion On Oral Intake and Intestinal Absorption in with short Bowel
Syndrome (SBS) Patients. A Placebo-Controlled Study
Palle B. Jeppesen, Ida B. Gottschalck, Jens J. Holst, Per B. Mortensen
Background: The “ileal brake hormones” glucagon-like petides 1 and 2 are co-secreted from
intestinal L-cells in relation to meals. Both peptides reduce gastric emptying and secretion.
In addition, GLP-2 is intestinotrophic. GLP-2 has successfully been shown to improve
intestinal absorption and nutritional status in short bowel patients in open-label, non-
randomized, uncontrolled studies. This is the first placebo-controlled study comparing acute
effects of GLP-1 and -2 on oral intake and intestinal losses in SBS patients. Methods: Nine
short bowel IBD patients (5F, 4M; mean age 47±11 years; remnant small bowel 126±63
cm; 2 with >50% colon; 7 received home parenteral nutrition or fluids) were continuously
infused GLP-1 (1 pmol/kg/min~0.28±0.05 mg/d), placebo and GLP-2 (1 pmol/kg/
min~0.32±0.06 mg/d) intravenously for 72 hours during 3 admissions at least 4 weeks
apart. Patient assessment of appetite, nausea and abdominal pain was evaluated on 10 cm
Visual Analog Scales (VAS). Patients received individualized, fixed diets and leftovers were
collected. A duplicate of the diet consumed and 72-h fecal and urinary collections were
analyzed. Parenteral support was kept constant. Energy (by bombcalorimetry) and wet weight
absorption (by total weight) was the difference between diet intake and fecal excretion.
Results: In Table. Conclusions: GLP-2 had no significant acute effects on appetite, sense of
nausea or abdominal pain evaluated by VAS-scores. Oral wet weight intake was maintained,
and since fecal wet weight decreased by 387±333 g/d, the overall wet weight absorption
increased by 399±323 g/d compared to placebo. GLP-1 scored less favorably regarding the
VAS-scores on appetite and sense of nausea. GLP-1 also decreased fecal wet weight excretion,
but since this was accompanied by a reduced oral wet weight intake, no effects were seen
on overall wet weight absorption. Fecal energy losses decreased in relation both GLP-1 and
-2 infusions, but due to a trend toward lower oral energy intake, neither of the infusions
had effect on overall energy absorption compared to placebo.
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a, b ~Student-Newman-Kreuls Method p<0.05
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Use of Longitudinal Distraction Forces for Developing a Novel Intestinal
Lengthening Procedure for short Bowel Syndrome
Hiroyuki Koga, Xiaoyi Sun, Hua Yang, Keisuke Nose, Mohamed El-sawaf, Khalil Bitar,
Sita Somara, Daniel H. Teitelbaum
Background: We have previously shown that we can double the length of an isolated
intestinal segment with the use of linearly directed distractive forces over one week; resulting
in increased surface area and epithelial cell proliferation. The aim of this study was to
evaluate the function of these lengthened segments after re-implantation into normal jejunum.
Methods: Our intestinal lengthening device was inserted into isolated jejunal segments in
pigs, and fully expanded over 8 days. A control intestinal segment contained the device but
was not lengthened. Lengthened segments (N=5) were then re-implanted into normal intest-
inal continuity. Pigs were sacrificed after another 28 days. Function was assessed by motility,
barrier function and ion transport of the bowel. Data (mean±SD) were analyzed using
ANOVA or t-test;*P<0.05. Results: Lengthened segments were significantly longer than
controls, and had a nearly 2-fold greater surface area. Bowel lengthening slightly increased
after re-implantation, going from 9.4±1.7cm at re-implantation to 11.3±1.9cm after 28 days.
Motility was assessed by upper GI transient time and passage of activated charcoal. Motility
was similar to non-operated pigs. (upper GI,5.4±0.8hours vs 6.3±0.6; re-implanted vs non-
operative; passage of activated charcoal, 17.6±1.7hours vs 17.1±1.3). Smooth muscle cells
(2.5x104) were harvested and assessed for contractility 30 seconds after application of
acetylcholine. A transient decline in function was seen after 8 days of lengthening (28.8±4.5
vs. 50.3±0.7; % contraction from baseline in lengthened vs. non-operated bowel); however
contractility began to approach normal levels (39.1±1.9 vs. 50.2±1.0) after re-implantation.
The table shows mucosal disaccharidase activity results. Ussing chamber experiments were
done to further assess the absorptive (glucose-driven sodium) and secretory (carbachol-
driven chloride) capacity. Conclusion: Bowel lengthening results in a transient decline in
mucosal absorptive function and smooth muscle contractility, while maintaining barrier
function. However, function approaches that of normal bowel after re-implantation into
enteric flow. Further, the gain in length is preserved after re-implantation. This technique
may be a potential new option for the treatment of patients with short bowel syndrome.
Ion-transport represents change in injected short circuit current by glucose (sodium transport)
or carbachol (chloride transport).
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Vitamin B6 Deficiency After Intestinal and Multivisceral Transplantation
Laura E. Matarese, Lillian M. Martin, Darlene Koritsky, June Stamos, Patricia Folk,
Guilherme Costa, Geoffrey Bond, Kareem M. Abu-elmagd
Purpose: Intestinal and multivisceral transplantation has been very successful in restoring
the gastrointestinal nutritional autonomy in patients with gut failure. However, we have
recently observed individual cases with severe vitamin B6 deficiency while conducting a
battery of biochemical and metabolic tests to identify the underlying etiology of unexplained
new onset peripheral neuropathy and/or myopathy. This study is the first to report such an
observation and describe the clinical manifestations associated with the deficiency. Methods:
Serum levels of vitamin B6 were measured in a cohort of 41 adult intestinal and multivisceral
recipients with fully functioning grafts and off all non-volitional feedings at the time of
measurement. Results: Out of the 41 studied patients, 28 (70%) exhibited depleted serum
vitamin B6 levels. The average time interval between transplantation and date of B6 measure-
ment was 15.4 ± 16.9 (range: 1.7-81.3) months. Of the 28 recipients with B6 deficiency,
19 (68%) had undetectable levels and the remaining 11 had a depleted serum level of 3.0
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± 0.3 ng/ml. Significant clinical neurologic and musculoskeletal symptoms with unexplained
neuropathic and myopathic pathology were reported in 19 (68%) of the vitamin B6 depleted
recipients. Vitamin B6 repletion initiated with a single intravenous dose followed by daily
oral dose (25-50 mg) ameliorated and commonly cured the clinical symptoms with full
restoration of the vitamin B6 serum levels. Conclusion: Vitamin B6 deficiency is not uncom-
mon in patients after intestinal and multivisceral transplantation despite clinical achievement
of full nutritional autonomy. Accordingly, vitamin B6 levels should be monitored and
deficiency should be suspected and promptly corrected in patients with unexplained muscu-
loskeletal and neurological symptoms.
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The Impact of Disease Severity On Protein Metabolism in Acute Pancreatitis
Stephen J. O'keefe, Neeraj Kaushik, Barbara Stoll, Cyrus Kangemi, James Delaney
Most patients (i.e. 80%) with acute pancreatitis get better within 5 days and do not need
nutritional support. However, the remainder develop severe disease, multiple organ failure
(MOF), need ventilation, and cannot eat for several weeks. In these patients, the degree of
negative nitrogen balance is directly related to mortality, which approaches 40%. The aim
of the study was to investigate which patients develop protein catabolism - which would
indicate the urgent need for nutritional support - and which organs are affected. The method
used was the 6h primed, continuous enteral and IV infusion of 13C- and deuterium-labeled
leucine (AJPhys 2005) to measure systemic and splanchnic amino acid metabolism during
feeding with an elemental formula diet providing 1.5g/kg amino acids and 30Kcal/kg energy
per day. Patients included 6 with mild (>3 Ranson's criteria) disease, 5 with moderate (>3
RCs) and 12 with severe necrotizing disease complicated by MOF (n=12). Results were
evaluated by comparison to 18 healthy volunteers. There were no significant differences
detected in protein metabolism during feeding between patients with mild and moderate
disease and healthy volunteers (Table). However, patients with necrotizing disease with
MOF had significant increases in both splanchnic and systemic amino acid turnover indicating
that the catabolic loss of protein responsible for the excessive negative nitrogen balance
associated with high mortality was derived both from both body stores (e.g. skeletal muscle)
and the splanchnic injury due to pancreatic necrosis and pro-inflammatory cytokine-induced
protein catabolism. In conclusion, our results suggest that patients with mild and moderate
acute pancreatitis are not hypercatabolic and therefore do not need urgent nutritional
support. In contrast, patients with severe necrotizing disease have accelerated rates of protein
catabolism chiefly in the splanchnic bed, indicating the urgent need for enteral nutritional
support to prevent protein depletion and stimulate organ repair
Table 1 Amino Acid Turnover Rates (umol/kg/min)
Statistics: Mann-Whitney NP test: * p=0.05, ** p=0.01 vs. healthy volunteers
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Exogenous IL-25 Exerts Region-Specific Effects On Gut Epithelial Cell
Function and Promotes a Th2 Environment
Kathleen B. Madden, Aiping Zhao, Rex Sun, Jennifer Stiltz, Thomas Sutton, Diana Riera,
Ildy M. Katona, Joseph Urban, Terez Shea-donohue
Nematode infection-induced upregulation of Th2 cytokines is necessary for the alterations
in epithelial cell function that facilitate worm expulsion. IL-25 (a newly-identified member
of the IL-17 family) is proposed to facilitate worm expulsion, but its effects on mucosal
function are unknown. Aim: To investigate the effects of exogenous IL-25 on intestinal and
colonic epithelial cell function. Methods: BALB/c mice were infected with Nippostrongylus
brasiliensis (Nb) to determine if IL-25 is upregulated during a Th2 response. Separate groups
of mice were injected with IL-25 (0.7 μg/mouse in PBS i.v.) or vehicle daily and were studied
7 days later. Muscle-free segments of jejunum or colon were placed in Ussing chambers to
assess changes in the short circuit current (Isc) in response to the addition of 5-HT or ACH
(100 μM) to the serosal side. Transepithelial resistance (TER), an index of tissue permeability,
was measured in muscle-free segments of jejunum or colon mounted in microsnapwells.
mRNA expression was determined by real-time PCR. Results: Nb infection induced a 19-
fold upregulation of IL-25 in the small intestine. Exogenous IL-25 decreased TER and
secretory responses to both 5-HT and ACH in the small intestine (table). These effects were
associated with significant (p<0.05) upregulation in the expression of IL-25 receptor (5.1±0.2
fold), as well as mediators of the Th2 response, IL-13 (5.4±1.2 fold), and GATA-3 (1.9±0.4
fold). There was a downregulation in the expression of Th1 cytokine, IL-12/IL-23p40 (0.2±0.1
fold). The expression of the Th2 cytokine, IL-4, or of the pro-inflammatory mediators, IFN-
γ, IL-17A, and T-bet, was unchanged in response to exogenous IL-25 (data not shown). In
contrast, in the colon, IL-25 administration had no effect on TER or secretory responses to
5-HT and ACH. Conclusions: These data indicate that the immunoregulatory cytokine IL-
25 exerts differential effects on epithelial cell resistance and secretory responses in the gut,
serving as a site-specific modulator of physiologic function. These changes are associated
with a promotion of Th2, and inhibition of Th1, cytokine profiles and are similar to those
observed previously after exogenous IL-13 treatment. Such region-restricted responses may
provide the host with multiple mechanisms that maintain gut homeostasis while facilitating
worm expulsion.
*p≤0.05 vs vehicle; TER=Ω*cm2; changes in Isc=μA/cm2
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Salmonella Effector Avra Acts As a Deubiquitinase to Inhibit Inflammation in
Intestinal Epithelial Cells In Vivo
Zhongde Ye, Elaine Petrof, David L. Boone, Erika C. Claud, Jun Sun
Every year, approximately 40,000 cases of salmonellosis are reported in the United States.
Most persons infected with Salmonella develop diarrhea, fever, and abdominal cramps 12
to 72 hours after infection. AvrA is a Salmonella effector translocated into host cells by a
Type three secretion system (TTSS). Recently studies showed that the AvrA gene is present
in 80% of Salmonella enterica serovar. Although its exact function is not entirely clear, AvrA
belongs to the family of cysteine proteases regulating diverse bacterial-host interactions. In
this study, we hypothesize that AvrA, as a deubiquitinase, has anti-inflammatory functions
by blocking nuclear factor kappa B (NF-κB) activity and activating the β-catenin pathway
in intestinal epithelial cells. β-catenin is a multi-functional protein that plays an important
role in embryonic development and neoplasia such as in colon cancer. We report here that
the AvrA protein from Salmonella typhimurium blocks degradation of the inhibitor of κB
(IκBα) and of β-catenin in epithelial cells In Vivo. Target genes of the NF-κB pathway, such
as IL-6, were down-regulated during bacterial infection with Salmonella expressing AvrA,
while target genes of the β-catenin pathway, such as c-myc and cyclinD1, were up-regulated
with AvrA expression. Additionally, we purified AvrA and AvrA mutant proteins and charac-
terized their deubiquitinase activity in a cell-free system. AvrA, as a deubiquitinase, removes
the ubiquitin from IκBα and stabilizes IκBα, which leads to the inhibition of NF-κB activation.
AvrA also deubiquitinates β-catenin, thus stabilizing β-catenin, which further negatively
regulates the NF-κB pathway. While examining NF-kappaB and beta-catenin nuclear translo-
cation, transcriptional activity and target gene expression, we also investigated inflammatory
cytokine expression, as well as effects on epithelial cell proliferation and apoptosis induced
by AvrA-deficient and -sufficient bacterial strains. We demonstrate that Salmonella with
AvrA overexpression stabilizes both IκBα and β-catenin in cultured human epithelial cells
and in mouse models. The role of bacteria in the pathogenesis of inflammation is widely
acknowledged. Our findings strongly suggest that AvrA regulates both the NF-κB and β-
catenin signaling pathways in intestinal inflammation In Vivo and may be one aspect of
the complex interaction between bacterial and intestinal epithelial cells involved in the
development and chronicity of mucosal inflammation.
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Abnormally Differentiated Intestinal Macrophages in Human Crohn's Disease
Produce Excess IL-23 in Response to the Enteric Bacteria
Nobuhiko Kamada, Tadakazu Hisamatsu, Hiroshi Chinen, Taku Kobayashi, Susumu
Okamoto, Toshifumi Hibi
Background & aims: We have previously reported that murine intestinal macrophages (MΦs)
show anti-inflammatory phenotypes, which produced IL-10 but not IL-12/23 and regulated
the excess immune response to commensal bacteria. In contrast, intestinal MΦs from IL-
10 deficient mice revealed abnormal differentiation and produced abundant levels of IL-12/
23 in response to bacteria (J Immunol. 2005; 175: 6900-8). In the present study, we
examined the pathogenic role of intestinal MΦs in human Crohn's disease (CD). Material
& methods: (1) Human intestinal MΦs were purified from intestine of normal (NL), ulcerative
colitis (UC) and CD patients. Surface markers expression and cytokine production of purified
human intestinal MΦs were assessed. (2) Lamina propria mononuclear cells from NL, UC
and CD intestinal mucosa were isolated and cultured for 60 hours. Culture supernatants
were collected as conditioned media (CM). Peripheral blood CD14+ monocytes were obtained
from NL and differentiated with M-CSF. To elucidate the effect of inflammatory environment
for the differentiation of MΦs, these CMs were added into differentiation process (10% of
final volume). Results: (1) CD14+CD33+CD68+ intestinal MΦs were identified from NL
and IBD intestine. These cells showed typical MΦs morphology, but they also expressed
some DC markers, such as CD209. These MΦs did not show any difference among NL,
UC and CD in surface phenotype, however, intestinal MΦs from CD patients produced
larger amount of IL-12/23p40 and IL-23 in response to enteric bacteria compared to NL
and UC (p40: NL; 196.7±77.7, UC; 173.4±41.7, CD; 409.0±74.2) (IL-23: NL; 28.7±28.7,
UC; 34.7±15.3, CD; 99.1±36.1). (2) M-CSF derived MΦs from NL controls showed anti-
inflammatory phenotype which produced large amount of IL-10 but not IL-23. NL-, UC-,
and CD-CM altered MΦ surface phenotype into intestinal-like, and there were no significant
differences among them. On the other hand, UC- and CD-CM induced MΦs produced
larger amount of IL-6, while NL-CM did not affect cytokine production profiles. Interestingly,
CD-CM induced MΦs produced higher amount of IL-12/23p40 and IL-23 compared to NL
and UC-CM (p40: NL; 107.5±18.1, UC; 175.6±47.0, CD; 471.1±245.1) (IL-23: NL;
78.9±21.4, UC; 158.6±49.2, CD; 611.9±325.9). Conclusions: Intestinal MΦ from CD patients
produced larger amount of IL-23 in response to enteric bacteria. Moreover, intestinal inflam-
matory environment of CD patients lead to the abnormal MΦ differentiation into IL-23
producible phenotype. Thus, abnormally differentiated intestinal MΦs produced abundant
levels of IL-23 in response to commensal bacteria, and contributed the pathophysiologies
of human CD.
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TLR-Induced Nf-κB Signaling Derived from Mucosal Immune Cells Is Critical
for Commensal Bacteria-Induced Experimental Colitis in IL-10-/-;Nf-κBegfp
Mice
Thomas Karrasch, Joo-sung Kim, Marcus Muhlbauer, Scott T. Magness, Christian Jobin
Background: Although the commensal bacterial flora has been associated with the develop-
ment of intestinal inflammation in a susceptible host, the mechanism responsible for this
pathology has not been elucidated. Aim: To determine In Vivo the role of Toll-like receptor
(TLR)/NF-κB activation in the initiation and perpetuation of experimental colitis. Methods:
A NF-κB reporter gene mouse (NF-κBEGFP) was crossed to the colitogenic susceptible strain
IL-10-/- and derived into germ-free conditions using embryo-transfer technology. To assess
the importance of commensal bacteria in driving experimental colitis, germ-free IL-10wt/
wt;NF-κBEGFP and IL-10-/-;NF-κBEGFP mice were dual-associated with the non-pathogenic
commensal bacteria strains Enterococcus faecalis and Escherichia coli (E. faecalis/E. coli). At
different time points after association, macroscopic and confocal microscopic EGFP imaging
and immunohistochemistry for NF-κB-activation, PCR analysis for proinflammatory cytokine
mRNA accumulation, ELISA assay for proinflammatory cytokine protein expression, flow
cytometry (FACS) and histological analysis were utilized to characterize the bacteria-induced
host responses and the developing intestinal inflammation. Bone marrow derived dendritic
cells (BMDC) isolated from IL-10wt/wt, IL-10-/- and IL-10-/-;MyD88-/- mice were used to
assess E.faecalis/E.coli induced TLR-dependent signaling and IL-23 gene expression. Results:
Dual-associated IL-10-/-;NF-κBEGFP mice developed severe inflammation by 7 weeks. Mac-
roscopic analysis showed elevated EGFP expression throughout the colon of bacteria-associ-
ated IL-10-/-;NF-κBEGFP mice. Confocal microscopy analysis revealed EGFP positive
enterocytes during the early phase of bacterial colonization (1 week) in both IL-10wt/wt
and IL-10-/- mice, while the signal shifted towards lamina propria T-cells, dendritic cells,
neutrophils and macrophages in IL-10-/- mice during colitis (7 weeks). The NF-κB inhibitor
BAY 11-7085 attenuated E. faecalis/E. coli-induced EGFP expression and development of
colitis. Additionally, E. faecalis/E. coli-induced NF-κB signaling, IL-23 gene expression and
IL23p19 protein secretion were blocked in BMDC derived from IL-10-/-;MyD88-/- mice.
Conclusions: Intestinal epithelial cells are early responders/sensors of bacteria and initiate
a rapid and transient TLR/NF-κB dependent host response. In a susceptible host (IL-10-/-
), IEC-derived NF-κB activation then leads to persistent activation of intestinal immune cells
and the development of colitis. Consequently, blocking TLR-induced NF-κB activity may
represent an attractive strategy to treat immune-mediated intestinal inflammation.
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Enhanced Cbir1 Specific Induction of Monocyte (IL-6) and T Cell
(Proliferation and IFN-γ) Responses in Crohn's Disease Patients
Chong Shen, Carol Landers, Carrie Derkowski, Charles O. Elson, Stephan R. Targan
Background: Crohn's disease (CD) is a result of an aberrant immunologic response to
commensal bacteria. The bacterial flagellin CBir1 has been identified as a dominant antigen
with a role in both the innate and adaptive immune responses in mouse models of colitis.
Anti-CBir1 responses are associated with CD and more severe disease. Aim: To determine
whether CBir1 can also stimulate innate and antigen-specific T-cell responses in CD patients.
Methods: 1) Peripheral blood (PB) monocytes from healthy donors or CD patients were
isolated and incubated for 4 hours with recombinant CBir1. IL-1 and IL-6 were measured
by RT-PCR and calculated as the percentage of the housekeeping gene β-actin expression.
2) CBir1-specific peripheral T-cell responses were analyzed by Thymidine H3 incorporation.
The mean cpm of triplicate wells is shown. 3) Induction of IFN-γ of lamina propria mononu-
clear cells (LPMCs) by CBir1 from CD, ulcerative colitis (UC) and control patients was
evaluated by Elispot. The mean number of IFN-γ+ spots /4×105 LPMCs of triplicate wells
were calculated. Results: 1) CBir1 induced a significantly higher amount of IL-6 in monocytes
from CD patients (n=32) than healthy donors (n=12) (11.3±1.6 vs. 3.9±0.8, p<0.001), but
not IL-1 (233.5±48.7 vs. 212.9±29.4, p=0.461). 2) A significant increase from baseline in
CBir1 mediated peripheral T cell proliferation was observed. This was more evident in cells
from CD patients (from 212.4±49.9 to 3428±1121, p<0.001, n=9) compared to those from
healthy donors (from 150.9±111.1 to 1987±1151, p=0.195, n=8). 3) In the presence of
CBir1, Elispot revealed elevated amount of IFN-γ+ spots in LPMCs from CD (32.9±6.1, p=
0.032, vs. controls, n=5), compared to 11.6±3.7 from UC (n=4) and 8.0±3.9 from controls
(n=5). Conclusion: These results demonstrate that CBir1 induces enhanced peripheral innate
responses, as well as peripheral and mucosal antigen specific T-cell responses in CD. Consist-
ent with results of mouse models of colitis, CBir1 immune activation could play a role in
the mucosal inflammation seen in CD.
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A Guanine Nucleotide Exchange Factor Is Required for Cell Invasion By
Shigella flexneri and the Initiation of Mucosal Defense Signals
Atsuko Fukazawa, Beth A. Mccormick, Karl Matter, Hans-christian Reinecker
Background and Aim: The enteroinvasive pathogen S. flexneri targets components of tight
junctions to gain basolateral access and invade intestinal epithelial cells. We aimed to
elucidate the signaling events initiated by GEF-H1, a tight junction-associated guanine
nucleotide exchange factor for RhoA, during invasion of the polarized epithelium by S
flexneri. Materials and Methods: S. flexneri serotype 2a (2457T) or GFP-expressing mutants
were used to infect Caco-2 and MDCK epithelial cell model monolayers cultured on permeable
filter support. GFP- and RFP-tagged GEF-H1, RhoA, Rac1, Cdc42 and their dominant
negative or constitutive active mutants and specific siRNAs were utilized to investigate the
role of GEF-H1 dependent signaling during cell invasion. Subcellular distribution and
association of GEF-H1 with tight junctional protein complexes and bacterial entry sites was
assessed by confocal microscopy and protein subfractionation. GEF-H1 mediated transcrip-
tional activation was assessed by dual-luciferase assays using reporter constructs containing
NF-κB consensus binding motifs or the human IL-8 promoter. The activation of small
GTPases was determined by GST-pull down assays. Gentamicin protection assays were
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employed for the assessment of bacterial invasion. Results: GEF-H1 was redistributed from
the apical junctional complex into the cell cytoplasm during the disruption of the tight
junctional seal by S. flexneri. The release of GEF-H1 let to the RhoA dependent activation
of NF-κB and the induction of the IL-8 promoter activity in epithelial cells. Surprisingly,
GEF-H1 was subsequently recruited to the bacterial attachment and invasion foci, which
were created by S. flexneri after gaining access to the basolateral membrane compartment
of epithelial cells. This recruitment of functional GEF-H1 to the bacterial attachment sites
was necessary to facilitate invasion. Expression of GEF-H1 mutants, unable to activate RhoA,
inhibited invasion of the epithelium resulting in a 60 % decrease of intracellular detectable
S. flexneri 90 minutes after infection. Conclusions: We demonstrate that GEF-H1 can serve
as a sensor for the disruption of the tight junctional complexes by enteroinvasive pathogens
initiating mucosal defense and repair responses. Furthermore, GEF-H1 mediated activation
of RhoA is required to facilitate S. flexneri cell entry into host cells. GEF-H1 may be a central
target for the molecular pathways evolved by S. flexneri to regulate its invasion through host
cell Rho GTPases.
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Biomarkers in the Therapy of Barrett's Esophagus with High-Grade Dysplasia
Ganapathy A. Prasad, Kenneth K. Wang, Kevin C. Halling, Shannon Brankley, Navtej
Buttar, Louis-michel Wong kee song, Lori S. Lutzke, Lynn S. Borkenhagen
Rationale: Photodynamic therapy (PDT) has been recently shown to be effective in the
treatment of high-grade dysplasia (HGD) in Barrett's esophagus (BE), however a substantial
proportion of patients do not respond. Aims: To determine if biomarkers known to be
important in Barrett's neoplasia can predict response to PDT in patients with BE and HGD/
mucosal cancer. Methods: Patients with BE and HGD/mucosal cancer seen at the Mayo
Clinic were prospectively studied from 2002 to 2005. All patients underwent a protocol
assessment with EGD, 4 quadrant biopsies every centimeter, endoscopic mucosal resection
(EMR) of visible nodules and EUS. Biomarkers were assessed using FISH. Biomarkers assessed
included: 9p21 (site of p16 gene) and 17p13.1 p53 gene) loci; gains of the 8q24(c-myc),
17q (HER2-neu) and 20q13 loci. Cells were also assessed for loss or gain of chromosomes
(aneusomy and polysomy). Patients were treated with PDT 48 hours using diffusing fibers
(wavelength of 630 nm and energy of 200 J/cm fiber)following administration of sodium
porfimer.Demographic and clinical variables were prospectively collected. Univariate and
multivariate logistic regression was performed to determine predictors of response to PDT
(defined as the absence of dysplasia at surveillance biopsies 3 months following PDT).
Results: 125 patients (70 who underwent PDT and 55 patients who did not undergo PDT,
as controls) were included in this study. Median age was 68.4 years (IQR 60.5-75). 113
(90%) were males. 104 (83%) had HGD and the remainder had mucosal cancer. The mean
BE segment length was 5.2 cm (SD 3.4). 59 (83%) patients had EMR done before PDT. 38
(53.5%) patients were responders at 3 months following PDT. On univariate analysis, BE
segment length (OR 0.7[0.53, 0.85]), PDT (OR 9.4 [3.1, 28.4]), p16 loss (OR 0.14 [0.04,
0.49]), 8q24 gain (OR 6.4 [1.09, 37.2] and polysomy or any gain (OR 0.09 [0.12, 0.71]
were significant predictors of response to PDT. Age, gender, EMR, and other biomarkers
were not significant predictors on univariate analysis. Factors significant on multivariate
analysis are displayed in the table. Conclusion: This is the first large prospective study which
identifies biomarkers using FISH as predicting response to PDT in HGD/cancer. This may
help in the selection of appropriate therapy for patients and improve treatment outcomes.
Multivariate Analysis
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Balloon-Based Circumferential Ablation Followed By Focal Ablation of Barrett
Esophagus Containing High-Grade Dysplasia Effectively Removes All Genetic
Alterations
Joep J. Gondrie, Agnieszka M. Rygiel, Carine Sondermeijer, Paul Fockens, Fiebo J. Ten
kate, Kausilia K. Krishnadath, Jacques J. Bergman
BACKGROUND: Radiofrequency energy Ablation (RFA) is a promising new ablative modality
for treating Barrett's esophagus (BE) with dysplasia. RFA has been shown to eliminate BE
and restore a normal appearing neo-squamous epithelium. AIM: The aim of this study was
to evaluate whether genetic abnormalities, as found in dysplastic BE, are effectively eradicated
by this ablative modality and absent in the resulting neo-squamous epithelium. METHODS:
10 consecutive BE patients with high-grade dysplasia (HGD) underwent circumferential RFA
using a balloon-based electrode (HALO360 System, BÂRRX Medical, Sunnyvale, CA, USA)
as primary therapy, followed by focal RFA using an endoscope-mounted electrode (HALO90
System) as secondary therapy. At baseline and 2 mos after the final ablation, patients
underwent EGD with 4Q/q 1cm large cup biopsies from the BE (pre-RFA) or neosquamous
mucosa (post-RFA). Additionally, brush cytology specimens were obtained from the BE
(pre-RFA), neosquamous mucosa (post-RFA) and proximal squamous mucosa (pre- and
post-RFA) using 5-cm and 1-cm cytology brushes (Wilson-Cook, Limerick, Ireland). Biopsy
specimens were investigated by an expert pathologist for dysplasia and intestinal metaplasia
(IM). Proliferative activity (Ki67) and p53 accumulation were evaluated using immunohisto-
chemical (IHC) staining. Multi-color fluorescent in-situ hybridization (FISH) was performed
on all brush cytology specimens using DNA probes for the centromeric regions of chromo-
some 1 and 9, and locus-specific probes for 9p(p16) and 17p(p53). Results were analyzed
with manual scoring and an automated fluorescence microscope with Spot counting software
(Applied Imaging, Newcastle, UK). Normal proximal squamous epithelium was used as
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control. RESULTS: All patients had complete endoscopic and histological eradication of all
dysplasia and IM. Pre-RFA BE biopsies showed abnormal Ki67 and p53 staining in all
patients. All post-RFA biopsies showed normal squamous mucosa with normal Ki67 and
p53 staining. No areas of “buried” IM were found in any of the 149 post-RFA neosquamous
biopsies. All pre-RFA BE cytology brushes showed FISH abnormalities, either numerical
chromosomal changes (n=6; 60%), loss of p16/p53 (n=9; 90%) or both (n=5; 50%). In
contrary to these pre-RFA findings, all post-RFA neo-squamous brush cytology specimens
showed a normal diploid signal count for all FISH probes. CONCLUSIONS: RFA of Barrett's
esophagus with HGD is an effective treatment for removal of dysplasia and intestinal meta-
plasia. RFA eradicates pre-existing genetic abnormalities and results in restoration of a
neosquamous epithelium without these genetic abnormalities.
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Methylation Biomarkers in Prediction of Response to Photodynamic Therapy
of Barrett's Esophagus
Kenneth K. Wang, Stephen J. Meltzer, Michel Wongkeesong, Navtej Buttar, Lori S.
Lutzke, Lynn S. Borkenhagen
Photodynamic therapy (PDT) has been approved for use in Barrett's esophagus with high-
grade dysplasia but is associated with cutaneous photosensitivity and strictures. 23% of
patients also do not respond to treatment. We have previously found that loss of heterozygos-
ity of p16 was an important determinant of lack of response to ablation. To confirm this
finding, we wished to assess if another mechanism of gene inactivation, promoter methylation
was also correlated. Aim: To determine if gene promoter hypermethylation can be correlated
to response to photodynamic therapy. Methods: This was a retrospective cohort study in
which 30 patients with Barrett's esophagus and high-grade dysplasia were identified that
underwent PDT. 15 had been found to respond to PDT (complete elimination of all dysplasia
on follow-up biopsy) and 15 had failed to respond (continued high-grade dysplasia after
treatment). Slides from tissue blocks that were obtained pre-therapy were de-identified and
send blinded to Dr. Meltzer's Laboratory at John's Hopkins University for assessment of
hypermethylation of promoter regions of RUNX, HPP1, and p16 (previously published as
important predictors of cancer development in Barrett's esophagus) using extracted genomic
DNA. DNA was treated with bisulfite to convert unmethylated cytosines to uracils prior to
methylation specific PCR (MSP). DNA methylation status was determined by real-time
quantitative MSP using the ABI 7700 Sequence Detection (Taqman) System. A normalized
methylation value (NMV) was created that reflects the percentage of DNA methylated for
the gene of interest. Results: We used a univariate log transformed logistic analysis (adjusts
for non-Gaussian distribution) to correlate the normalized mean values of the methylated
genes to the response to photodynamic therapy of these patients of these 30 patients. We
found that the level of promoter methylation significantly correlated with methylation of
the p16 promoter on univariate analysis with a p=0.045 though this did not quite reach
significance on multivariate analysis with a p value=0.08. Conclusions: This preliminary
data provides independent corroboration that intact p16 is needed for PDT of Barrett's
esophagus. Methylation of the promoter of p16 with subsequent inactivation appears to be
detrimental to the treatment response as we previously shown with p16 LOH.
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NO Occult Cancer At Esophagectomy in Patients with Barrett's Esophagus
with High-Grade Dysplasia Who Have Undergone Surveillance with the
Seattle Biopsy Protocol
Jean S. Wang, Hilary Cosby, Lisa Hicks, Elizabeth A. Montgomery, Malcolm Brock, Marcia
I. Canto
Introduction: Historical studies in the surgical literature have reported the prevalence of
occult cancer in patients undergoing prophylactic esophagectomy for Barrett's esophagus
with high grade dysplasia to be as high as 30-43%. However, it is unclear what type of
endoscopic surveillance biopsy protocol was performed in these patients prior to surgery.
Aim: To determine whether use of the Seattle endoscopic biopsy protocol in patients with
high grade dysplasia significantly reduces the prevalence of occult cancer at the time of
esophagectomy. Methods: We reviewed medical records of patients who underwent prophy-
lactic esophagectomy for Barrett's esophagus with high-grade dysplasia at Johns Hopkins
Hospital from 1994-2006. Clinical records were examined to determine whether the Seattle
endoscopic biopsy protocol was followed during endoscopy performed prior to surgery.
Pathology reports were examined to determine whether occult adenocarcinoma was detected
during surgery. Results: A total of 39 patients underwent prophylactic esophagectomy for
Barrett's esophagus with high grade dysplasia during the study period. Among patients who
had undergone endoscopic surveillance with the Seattle biopsy protocol, there were no (0/
15) invasive adenocarcinomas detected within their resected surgical specimens. In contrast,
among patients who had not undergone endoscopic surveillance with the Seattle biopsy
protocol, 33% (8/24) had invasive adenocarcinoma detected in their resected surgical speci-
mens. Conclusions: The prevalence of occult adenocarcinoma in patients with Barrett's
esophagus and high-grade dysplasia is very low if the Seattle biopsy protocol is followed
during endoscopic surveillance. Therefore, the standard care of esophagectomy for Barrett's
esophagus with high-grade dysplasia should be reconsidered.
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Endoscopic Mucosal Resection in Barrett;S Esophagus: Predictors of Success
and Complications
Kenneth K. Wang, Navtej Buttar, Ganapathy A. Prasad, Michel Wongkeesong, Lori S.
Lutzke, Kelly Dungan, Lynn S. Borkenhagen
Endoscopic mucosal resection has been recently adopted for the diagnosis and treatment
of Barrett's esophagus. Aim: To determine factors predicting pathological results and com-
plications of endoscopic mucosal resection in Barrett's esophagus. Methods: This is a cohort
study of patients who underwent endoscopic mucosal resection in our Barrett's Esophagus
unit in a prospectively maintained database from 1996 to 2006. Mucosal resection was
performed by three techniques; A standard variceal band ligator that captured tissue that
is then resected with a snare. The second was cap EMR that used a crescent snare around
the lip of the cap. The third used a modified band ligation cap that allows a snare to be
placed to allow immediate resection after banding. These EMR procedures were assessed
for histology, margins of resection, and any complications that Results: A total of 466
patients, 386 males with a median age of 70 (IQR 60-76 years), underwent a total of 832
endoscopic mucosal resection sessions. The mean Barrett's length was 4 centimeters. The
majority had high grade dysplasia (64%) or cancer (23%). 178 (21%) patients had nodules
a mean of 1.2 centimeters in diameter, 8 (1%) had ulcerations, 301 (36%) had nodularity,
137 (16%) had only slight mucosal irregularity, 21 (3%) had an erythematous patch, and
178 (21%) had normal appearing mucosa but positive prior biopsies. The technique used
was the EMR cap in 683 (82%) resections, the Duette system in 81 (10%), and banding
with a variceal ligator device and snare resection in 68 (8%). The majority 573 (69%) were
single EMR while 172 (21%) were doubles. Mean diameter was 1.0 centimeter in diameter.
The majority of mucosal resections contained high grade dysplasia 342 (41%) or cancer
168 (20%). Complications occurred in 62 (7%) with strictures the most common 51 (6%),
11 (1%) bleeding, and no perforations. We performed multivariate regression analysis of
lesion size, lesion type, length of Barrett's esophagus, technique of EMR, number of EMR,
EMR size, age to examine their correlation with complications and pathology of EMR.
Complications could only significantly be correlated with use of PDT (stricture formation)
(p<0.03). Significant histology (cancer or HGD) could be correlated with number of EMR's
performed and type of lesion (p<0.01). Conclusions: EMR is a very safe technique with few
serious complications other than strictures that were related to PDT used in conjunction
with EMR. Nodules and nodular lesions in Barrett's esophagus were more likely to correlate
with significant histological lesions.
379
Patients with Inflammatory Bowel Disease Have Evidence of Systemic
Endothelial Dysfunction
Idan Roifman, Jason Fedwick, T. Anderson, A. Sun, Remo Panaccione, Paul L. Beck
Vascular dysfunction has been postulated to play a role in the initiation and progression of
inflammatory bowel disease (IBD) this disease. Impaired blood flow secondary to endothelial
dysfunction may trigger the disease and may impair wound healing. Endothelial dysfunction
is known to be a prominent feature of coronary artery disease (CAD). Endothelial dysfunction
is common in chronic diseases such as rheumatoid arthritis, chronic renal failure and lupus
and is thought to be involved in the pathogenesis and/or reflect the increased CAD in these
patients. Cardiac risk and endothelial dysfunction have yet to be assessed in IBD, however;
The changes in disease activity related to smoking is thought to be due, in part, to alterations
in intestinal blood flow. Hypothesis: patients with IBD have a significantly greater degree
of endothelial dysfunction than the general population. Aim: To assess endothelial function
in patients with (IBD). Methods: 100 patients were enrolled in this study; 50 with IBD and
50 controls. The control was of similar age, family history of cardiac disease, sex ratio,
smoking status and body mass index. Endothelial function was assessed in these patients
by brachial artery ultrasound and finger plethysomnography (PAT) (a noninvasive way to
accurately assess endothelial function (lower scores are indicative of dysfunction)).Screening
blood work including CBC, ESR, CRP, fasting glucose, fasting lipid profiles was performed
on all patients. Results: Patients with IBD had significantly (p=0.007) lower PAT scores
(1.80 ± 0.07) than the control group (2.09 ± 0.08) and significantly higher systolic and
diastolic blood pressures (p= 0.02- 0.001). Both Crohn's (CD) (33) and ulcerative colitis
(UC) (17) patients had lower PAT scores than control groups (p=0.03) but there was no
difference UC vs CD. Further analysis is pending in regards to correlation with disease
activity and inflammatory markers. Conclusions: These results indicate that patients with
IBD have a significantly higher rate of endothelial dysfunction than the general population.
To our knowledge this is the first study to show such a phenomenon. These results may
enhance our understanding of the pathogenesis of IBD and may have implications in its
management. Furthermore, these results suggest that IBD patients may be at higher risk to
develop atherosclerosis and CAD. More research is required to determine if this greater risk
translates into higher cardiovascular events.
380
Incidence Rates and Risk Factors for Microscopic Colitis: A Large Population-
Based North American Study
Jennifer Williams, Gilaad G. Kaplan, Stefan J. Urbanski, Marc Dupre, Sapna Makhija,
Remo Panaccione, Paul L. Beck
Microscopic colitis (lymphocytic (LC) and collagenous colitis (CC)) is thought to be an
important cause of diarrhea. Despite its importance, the epidemiology of microscopic colitis
(MC), in a non-selected population, has been poorly defined and few large studies have
assessed MC in a North American Population. Aims: The objective of this study was to
identify the incidence of and explore risk factors for MC in a well defined North American
population. Methods: A population-based cohort study was conducted in the Calgary Health
Region (CHR) (population 1.2 million) between April 1, 2002 and March 31, 2004. All
adult (>18years) CHR residents were identified through the Calgary Laboratory Services'
regionalized pathological database. Charts were reviewed to confirm the diagnosis and record
risk factors for acquisition. Category- specific risks for developing MC were reported as
relative risks (RR) with exact 95% confidence intervals. Results: We identified 164 residents
of the CHR with a new diagnosis of MC for an annual incidence of 9.95 per 100,000 person-
years. The annual incidence rates for LC and CC were 5.40 and 4.55, respectively. The
incidence rate of MC increased with advancing age. The median age was 59.6 years (IQR)
and patients over the age of 65 were over five times more likely to develop MC (RR 5.6;
95% CI, 4.0-7.7; p<0.0001). Females were at a higher risk of acquiring MC as compared
to males (RR 4.3; 95% CI, 2.8-6.5; p<0.0001) and this was demonstrated across all age
groups. In addition to age and gender, a number of co-morbid illnesses were associated
with a higher risk for developing MC including celiac disease (RR 7.9; 95% CI, 4.0-14.2;
p<0.0001), patients with a past or current history of malignancy (RR 7.2; 95% CI, 4.2-11.7;
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p<0.0001), hypothyroidism (RR 6.1; 95% CI, 3.5-10.0; p<0.001), and diabetes (RR 2.26;
95% CI: 1.1 - 4.1). Conclusions: To our knowledge this is the largest study to date on MC
and one of the few in a North American population. It reports higher rates of MC than
previously studies and it confirms previous observations that MC increased with age, was
more common in females and it is associated with both thyroid and celiac disease. This is
the first study to report an increased relative risk for developing MC with a past or current
history of malignancy.
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Patients with Coronary Artery Disease Had High Prevalence of Colorectal
Cancer and Adenoma: END-Results of Metabolic Syndrome and Smoking
Annie on on Chan, Man hong Jim, Kwok fai Lam, David cw Siu, Teresa Tong, Fook hong
Ng, Siu yin Wong, Wai mo Hui, Chi kuen Chan, Kam chuen Lai, Ting kin Cheung,
Pierre Chan, Grace Wong, Man fung Yuen, Yuk kong Lau, Stephen Lee, Ming leung
Szeto, Shiu kum Lam, Benjamin c.y. Wong
Background: Our previous study showed an association between colorectal neoplasm (CN)
and coronary artery disease (CAD), probably due to sharing of common risk factors. Aim:
To investigate the prevalence of CN in patients with and without CAD in those aged ≥50
years prospectively and to identify the underlying risk factors. Methods: Patients were
recruited for screening colonoscopy after undergoing coronary angiography. They were
defined as CAD+ (n=206) if ≥50% diameter stenosis was observed in any one of the major
coronary arteries, and CAD- (n=208) if not. A second age and sex matched control group
was recruited from the general population (n=207). The prevalence of colonic lesions and
underlying risk factors was compared by Pearson chi-square test. A bivariate logistic regression
analysis was performed to adjust for age and sex and to identify independent risk factors.
Results: The prevalence of the lesions in the CAD+, CAD- and general population group
were 40.3%, 28.8%, and 32.9% (p=0.045) for endoscopic polyp, 34.0%, 18.8%, and 20.8%
(p<0.0001) for CN, 18.4%, 8.7%, and 5.8% (p<0.00001) for advanced lesion, and 4.4%,
0.5%, and 1.4% (p=0.014) for cancer, respectively. All except one cancers were detected
at early stage. After adjusting for age and sex, smoking history (OR: 4.74, CI: 1.38 to 19)
and metabolic syndrome (OR: 5.99; CI: 1.43 to 28.0) were independent factors for the co-
existence of CAD and advanced lesion. Conclusion: Life style modification is important to
prevent the development of both CAD and advanced colonic lesions simultaneously. CAD+ is
a surrogate marker for high prevalence of CN, necessitating immediate colonoscopy screening.
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Abnormal Gastric and Colonic Permeability in Children with Recurrent
Abdominal Pain (RAP)
Robert J. Shulman, Danita Czyzewski, Monica E. Jarrett, Lonnie Zeltzer
Background: Recent histologic studies have suggested evidence of low grade inflammation in
many patients with irritable bowel syndrome (IBS). Additionally, small intestinal permeability
recently has been reported to be abnormal in some adults with IBS. Whether the same is
true for children with RAP, a condition that affects 10-15% of school age children and bears
many similarities to IBS in adults has received little attention. Design/Methods: Children
(age 7-10 yr.) were identified by chart review in pediatrician's or pediatric gastroenterologist's
offices. Children with RAP (n=70) met Rome II criteria for functional abdominal pain or
IBS. Non-RAP healthy Control subjects (n=31) were recruited through the same pediatrician's
offices. Phone screening confirmed current symptoms. After instruction in the home by
research assistants the children underwent measurement of gastrointestinal permeability
using sucrose (S), lactulose (L), mannitol (M), and sucralose (Sucra) to measure gastric (S/
L ratio), small intestinal (L/M ratio), and colonic permeability (Sucra/L ratio). Children also
kept a 2-wk diary to record pain frequency and severity and number and character of stools.
Results: There were no differences between groups in age (RAP: 8.5 ± 0.1 vs. C: 8.7 ± 0.1;
mean ± SEM). Gastric and colonic permeability were significantly greater in children with
RAP than in Controls (Table). No differences were detected in small intestinal permeability.
Mean pain score, maximum reported pain, and number of pain episodes also were greater
in RAP than in Controls (Table). Number of stools and stool consistency (watery, mushy,
formed, hard balls) were similar between the groups. There was no relationship between
gastric, small intestinal, or colonic permeability and pain or stool reports for the groups
combined or separately. Conclusions: 1) Children with RAP have evidence of gastric and
colonic injury; 2) Pain and stooling pattern do not appear to be related directly to intestinal
permeability; 3) Abnormal intestinal permeability does not appear to play a significant role
in pain and bowel symptoms in children with RAP. (Supported by R01 NR05337).
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Subsurface In Vivo Microscopic Analysis with Confocal Laser Endomicroscopy
in Patients with Chronic Diarrhoea
Ralf Kiesslich, Ana-paula Barreiros, Martin Goetz, Arthur Hoffman, Constantin Schneider,
Katharina Lammersdorf, Michael Vieth, S. Biesterfeld, Peter R. Galle, Markus Neurath
Introduction: Confocal laser endomicroscopy (CLE) is a newly available diagnostic tool
enabling In Vivo microscopy of the mucosal layer at subcellular resolution. Aim of the current
study was to define the clinical value of CLE in patients with chronic diarrhoea. Methods:
Consecutive patients with newly developed diarrhoea (>4 weeks) without known history of
inflammatory bowel diseases and colon neoplasia were scheduled for Fluorescein aided (5ml;
10%; intravenously) CLE (EC-3870CIFK; Pentax, Tokyo, Japan). First, endoscopic, initial
diagnosis was made based on the macroscopic appearance. Subsequently, endomicroscopy
was performed in a targeted fashion on visible lesions or untargeted at four defined locations
(terminal ileum, right sided colon, sigmoid, rectum). Confocal images were immediately
judged for the presence of vascular, cellular or connective tissue based abnormalities. Optical
biopsies were subsequently followed by targeted biopsies and endomicroscopically online
diagnosis was compared with final histology, bench top confocal microscopy, immuno
histochemistry, microbiological or virological work up. Results: 64 patients [42 male; age
72.3] were included in the study. Final histology revealed new diagnosed UC and Crohn's
disease in 23. In 18 cases mucosal based fluorescence bacteria in the pericryptals space
could be readily identified and confirmed using bench top confocal microscopy due to the
presence of bacterial DNA. In three patients after orthotopic liver transplantation (OLT) and
diarrhoea characteristic owl eye cells could be identified. CMV infection could be virologically
confirmed in all cases. Further 4 patients after OLT presented fluorescence bands in the
lamina propria of the rectum. Targeted biopsies proved the presence of amyloidosis. 12
patients with macroscopically normal colonic mucosa presented thickened collagenous bands
within the lamina propria. Histopathology after targeted biopsies diagnosed microscopic
colitis in all cases. 2 patients with colorectal cancer and 20 patients with unknown cause
for chronic diarrhoea were further evaluated. Initial endoscopically normal appearing mucosa
(47 patients) changed. Specific diagnosis in spite of initial endoscopically normal appearing
mucosa was made in 44.7% (21/47) based on microscopic evaluation. Conclusions: Confocal
laser endomicroscopy is a very useful diagnostic tool in patients with unclear chronic
diarrhoea. CLE led to significant changes in endoscopic diagnosis in over 40% of cases due
to specific microscopic subsurface imaging of mucosal alterations.
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Prognosis of Post-Infectious Irritable Bowel Syndrome (PI-IBS) Six Years After
the Walkerton Outbreak of Waterborne Gastroenteritis (GE)
John K. Marshall, Marroon Thabane, Amit X. Garg, William F. Clark, Stephen M. Collins
Background and Aim: In May 2000, municipal water contamination by E. coli 0157:H7 and
Campylobacter species caused a large outbreak of acute GE in Walkerton, Ontario. The
natural history of PI-IBS was assessed in a well-defined study cohort. Methods: Walkerton
Health Study participants were invited for follow up in 2006. Standardized interviews
included a modified Bowel Disease Questionnaire to diagnose IBS by Rome I criteria. Subjects
age > 16 and permanent residents of Walkerton in May 2000 with no prior diagnosis of
IBS or inflammatory bowel disease were included in the study cohort (Gastroenterology
2006;131:445-50). The prevalence, incidence and prognosis of IBS among participants with
and without GE in 2000 were assessed. Risk factors for IBS in 2006 were identified by
multiple logistic regression. Results: 2739 of 4537 participants enrolled in the Walkerton
Health Study returned in 2006, including 1288 subjects eligible for the study cohort (57.5%
female; mean age 48.6±15.9). Of these, 173 (13.4%) fulfilled Rome I criteria (42.2% IBS-
D, 15.0% IBS-C). Independent risk factors for IBS after GE included younger age, female
gender, weight loss, stool frequency and duration of acute diarrhea. Over 6 years, the
prevalence of IBS among subjects who had been exposed to GE declined (239/838 [28.5%]
at 2-3 years, 185/838 [22.1%] at 4 years, and 140 [16.7%] at 6 years) but remained higher
than the prevalence of IBS among subjects who had remained well during the outbreak (33/
450 [7.3%], p<0.0001). The rate of new IBS diagnosis at 6 years was not increased among
subjects with vs. without exposure to GE (23/838 [2.7%] vs. 11/450 [2.4%], p=N.S.). Among
239 subjects with IBS 2-3 years after acute GE, only 120 (50.2%) at 4 years and 93 (38.9%)
at 6 years still had IBS. Over the same interval, “sporadic” IBS (among subjects with no
exposure to acute GE during the outbreak) persisted at a similar rate (16/47 [34.0%], p=
N.S.). Conclusion: The prevalence of IBS remains elevated 6 years after a waterborne outbreak
of acute GE and a diarrhea-predominant phenotype remains common. However, the rate
of new IBS diagnosis is no longer elevated and the prognosis of PI-IBS appears favorable.
Symptoms remit spontaneously in most patients.
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Screening and Surveillance for Colorectal Carcinoma in Patients with
Ulcerative Colitis and Crohn's Disease: Are Current Surveillance Guidelines
Adequate? Interim Analysis of a Retrospective Multi-Center Descriptive Study
Maurice W. Lutgens, Frank P. Vleggaar, Bas Oldenburg, Marguerite Schipper, Pieter C.
Stokkers, Janneke Van der woude, Gerard Dijkstra, Dirk j De jong, Melvin Samsom
Background & Aim: Patients suffering from inflammatory bowel disease (IBD) have a higher
risk of developing colorectal cancer (CRC) than the general population. In an attempt to detect
precancerous dysplasia or asymptomatic cancer many of these patients enter a surveillance
programme following American Gastroenterology Association (AGA) or British Society of
Gastroenterology (BSG) guidelines. Based on disease duration and extent of disease these
guidelines recommend initiating surveillance after 8-10 years of disease for Crohn's disease
and extensive colitis, and after 15-20 years for left-sided colitis. Strong scientific evidence
is not yet available for these starting points. Furthermore, we encountered a number of IBD
patients who developed CRC earlier than aforementioned starting points. Our aim was to
assess the time-intervals between onset of IBD symptoms or diagnosis of IBD and diagnosis
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of CRC, and subsequently evaluate how many patients developed CRC before their surveil-
lance is recommended to commence. Methods: We used a nationwide automated pathology
database (PALGA) to identify patients with IBD-associated CRC in all university medical
centers in the Netherlands. Only patients who had IBD and CRC diagnosed synchronously
or metachronously in a pathology report from January 1990 until June 2006 were included
in the analysis. From patient charts we collected variables including gender, type of IBD,
age at diagnosis of IBD and CRC, date of diagnosis of IBD and CRC and extent of disease.
Results: Thus far we collected data in 5 of 8 university medical centers on 104 patients with
confirmed diagnoses of IBD and CRC, (male/female 65/39). Ulcerative colitis was diagnosed
in 64 cases and Crohn's disease in 40. Median ages at IBD and CRC diagnoses were 29
years [6-83] and 48 years [21-85] respectively. Using date of diagnosis as entry-point and
following the generally accepted guidelines, 26% of patients developed cancer before the
start of surveillance. This even increased to 33% of patients if surveillance would commence
at 10 or 20 years after diagnosis for extensive or left-sided disease respectively. Using onset
of symptoms to calculate the time between IBD-diagnosis and CRC, a total of 18% of patients
presented with cancer before 8 or 15 years of disease duration and 26% of patients before
10 or 20 years of disease duration, thus before the start of surveillance. Conclusions: These
results suggest that the diagnosis of CRC might be delayed or missed in a substantial number
of IBD patients (18-33%) when conducting surveillance strictly according to formal AGA
and BSG guidelines.
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Stool DNA Integrity Assay As a Marker of Colonic Inflammation in
Inflammatory Bowel Disease (IBD)
Steven H. Itzkowitz, Lina Jandorf, Carol Bodian, Joel Skoletsky, John M. Millholland,
Anthony Shuber
Background: A stool DNA panel, which includes an assay for DNA integrity (DIA), has
demonstrated effectiveness for colorectal cancer (CRC) screening in the general population.
DIA measures DNA mass and fragment length as genome equivalents (GEs) to assess DNA
integrity. Nothing is known about DIA performance in patients with ulcerative colitis (UC)
and Crohn's disease, with or without colonic neoplasia. Aim: To analyze DIA in IBD patients
undergoing colectomy for colonic neoplasia or medically refractory disease. Methods: After
informed consent, patients identified from gastroenterology and colorectal surgery practices
at Mount Sinai with extensive UC or Crohn's colitis (CC) of at least 8 years duration requiring
colectomy were enrolled. Subjects submitted a baseline stool sample prior to surgery and
another specimen several weeks post-operatively. Specimens were shipped on ice (without
stabilization buffer) and DNA was extracted from stool homogenates using a previously
validated technique, and analyzed for DIA by real-time PCR. Extremely high correlation
coefficients were observed between the four DIA markers (D, E, X, Y); therefore, only data
for marker Y are presented. Marker values were transformed to logarithms for statistical
tests. Results: Of 33 pts with IBD (29 UC; 4 CC); 8 were women. Worst dysplasia at
operation was: none (n=12), indefinite (n=3), LGD (n=9), HGD (n=1) and cancer (n=8).
There was no significant correlation between DIA score and patient age or gender. There
was also no significant correlation with the presence or grade of dysplasia/cancer, perhaps
due to lack of stabilizing buffer. A statistically significant increase in DNA mass (Y-200;
p<0.001) and long DNA (Y-2.4; p<0.001) was observed according to the degree of colonic
inflammation at surgery (Table). Curiously, all 4 CD patients had significantly lower Y-200
(p=0.002) and Y-2.4 (p=0.010) scores compared to UC pts. DIA scores dropped markedly
following colectomy (p<0.01 for Y-200 and for Y-24), indicating that the DIA values are
related to colonic disease. Conclusions: DIA is a novel, non-invasive marker of inflammation
in IBD. The low DIA values among CD patients (even those with neoplasia) suggests
differences in inflammation between CD and UC, and possible differences between colitis-
associated and sporadic CRC.
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Chromoendoscopy for Colonic Dysplasia Surveillance in Inflammatory Bowel
Disease
Ahmed E. Kandiel, Bret Lashner, Jean-paul Achkar, Aaron Brzezinski, Rocio Lopez,
Douglas L. Seidner, Bo Shen, John J. Vargo
Introduction: Current surveillance guidelines for dysplasia in patients with inflammatory
bowel disease (IBD) of the colon may be suboptimal. Studies from Europe and Japan have
shown a 3-4 fold increased yield of detection of precancerous lesions with chromoendoscopy
compared to conventional colonoscopy in ulcerative colitis. Aim: To determine if chromoen-
doscopy increases dysplasia detection when compared to conventional colonoscopy in a US
population of IBD patients that includes ulcerative colitis (UC), Crohn's colitis (CD), and
indeterminate colitis (IC). Methods: Patients with extensive UC or IC (extent proximal to
the splenic flexure) or CD involving at least 30% of colon undergoing routine dysplasia
screening were enrolled. Tandem colonoscopies were performed in each patient. The first
colonoscopy was a conventional colonoscopy and the second colonoscopy was performed
after spraying 0.1% indigo carmine dye. The number of dysplastic lesions identified with
each technique was compared. In addition, surveillance biopsies were obtained every 10
cm after chromoendoscopy to detect dysplasia in normal-appearing mucosa. Results: These
are preliminary data from a study designed to evaluate 100 UC patients. All identified
dysplastic lesions were adenoma-like masses (ALMs) with low grade dysplasia (LGD) with
the exception of one irregular looking dysplasia associated lesion (DALM) that was identified
with conventional colonoscopy in a 25 year old patient with severe UC. Chromoendoscopy
allowed identification of 2 additional ALMs in UC patients that were not seen with conven-
tional colonoscopy. No flat dysplastic lesions were seen with chromoendoscopy. 1293
random surveillance biopsies of normal-appearing flat mucosa were performed and identified
only one focus of LGD in a patient with CD. One patient with CD who had 2 ALMs was
the only patient with more than 1 dysplastic lesion. Conclusions: 1. Chromoendoscopy may
improve the identification of ALMs in UC patients. 2. In our population with a mean age
of 49-50 years, a higher frequency of ALMs was seen in CD (33%) than in UC (10%). 3.
The utility of random biopsies of normal-appearing flat mucosa should be re-evaluated.
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Methylene Blue Dye-Spray Targeted Biopsies Are Superior to Standard
Colonoscopic Surveillance Biopsies for Detecting Dysplasia in Patients with
Ulcerative and Crohn's Colitis: A Prospective Endoscopic Trial
James F. Marion, Jerome D. Waye, Daniel H. Present, Yuriy Israel, Carol Bodian, Noam
Harpaz, Mark Chapman, Maria T. Abreu, Thomas A. Ullman, James Aisenberg, Lloyd
Mayer
BACKGROUND: Patients with chronic ulcerative or Crohn's colitis (>8years) are at an
increased risk of developing colorectal cancer. Current standard surveillance relies on
detecting dysplasia using random sampling at colonoscopy but may fail to detect dysplasia
in many patients. Dye spraying aids in the detection of subtle mucosal abnormalities.
PURPOSE: To prospectively compare dye-spray technique using methylene blue to standard
colonoscopic surveillance in detecting dysplasia. METHODS: 115 patients were referred to
the Chomoendoscopy Study Group and prospectively screened for the study. 102 (64M,
38F) (79UC 23CC) patients meeting the inclusion criteria were enrolled. Following a standard
bowel prep each patient was examined using standard office endoscopic equipment by
Method A: standard surveillance colonoscopy with 4 random biopsies every 10 cm (for a
total of at least 32 samples) and Method B: a targeted biopsy protocol and finally Method
C: methylene blue (0.01%) dye spray was segmentally applied throughout the colon and
any pit-pattern abnormality or lesion rendered visible by the dye spray was targeted and
biopsied. Each patient had a single examination which included two passes of the colono-
scope. Specimens were reviewed in a blinded fashion by a pathologist. The three methods
were then compared with each patient acting as his or her own control. RESULTS: Method
C (targeted biopsies with dye spray) revealed significantly more dysplasia (16 patients with
low grade and 1 patient with high grade) than Method A (3 patients with low grade dysplasia)
(p=0.001) or Method B (targeted non-dye spray) (8 patients with low grade and 1 patient
with high grade dysplasia) (p=.057). Targeted biopsies with and without dye spray or “Max”
targeted biopsies detected dysplasia in 20 patients compared with 3 using Method A (p=
.0002)(Two-tailed exact McNemar's Test). There were no complications. CONCLUSION:
Methylene blue dye-spray targeted biopsies during surveillance colonoscopy are clearly
superior in the detection of dysplasia when compared to current standard techniques and
should become the standard of care in preventing colorectal cancer for patients with colitis.
Multiple random biopsies should be discontinued as a surveillance technique in favor of
dye-spray targeted biopsies.
Total Number of Patients with Dysplasia by Method
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Probability of Occult Cancer in Ulcerative Colitis with Dysplasia: A Modern
Assessment
Fernando Velayos, Jonathan P. Terdiman, Liyan Liu, Bernie Collins, James E. Allison, Lisa
J. Herrinton
Background: A landmark study published a decade ago reported a high probability of
finding occult colorectal cancer at colectomy in patients with ulcerative colitis (UC) and
dysplasia. (Bernstein et al., Lancet 1994;343:71). The probability of occult colorectal cancer
in a modern cohort of UC patients with dysplasia is unknown. Based on advances in
endoscopic imaging and sampling technique, we hypothesized that the probability of finding
cancer at colectomy would be lower in a modern cohort of UC patients with dysplasia
(1996-2005) compared to this historical report (1980-1993). Methods: We reviewed the
records of patients with UC who underwent colectomy within 4 months of a diagnosis of
colorectal dysplasia at a large integrated health care organization. As in the historical report,
dysplasia was dichotomized as polypoid “dysplasia-associated lesion or mass” (DALM) or
flat. The probability of finding cancer at immediate colectomy in the modern cohort was
compared with the earlier landmark report. We then explored the probability of cancer in
polypoid dysplasia based on the endoscopist's description of the lesion. Results: Dysplasia
was detected in 18 polypoid and 7 flat biopsies. The probability of occult cancer within flat
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dysplasia in the modern cohort was lower than the historical cohort; however the probability
of occult cancer within polypoid dysplasia was similar (50 vs. 43%). Interestingly, the
endoscopist's description of the polypoid lesion was useful in further refining the probability
of occult cancer in polypoid dysplasia. Conclusion: During a period of improved endoscopic
imaging and sampling technique, the probability of occult cancer at colectomy in a modern
cohort of patients with UC and flat dysplasia appears lower than in the past. Surpsingly the
probability of occult cancer in polypoid dysplasia remains high and has not changed much
over time. In counseling patients with polypoid dysplasia (particularly discrete polyps), the
endoscopist may have a previously unexplored and valuable role for refining the risk of
occult cancer and need for immediate colectomy.
*Categorized as DALM in the historical cohort. **NR: Not reported
390
Risk Factors Associated with Small Bowel Adenocarcinoma in Crohn's
Disease: A Case-Control Study
Gaël Piton, Jacques Cosnes, Elisabeth Monnet, Laurent Beaugerie, Philippe Seksik,
Guillaume Savoye, Guillaume Cadiot, Bernard Flourie, Philippe Marteau, Marc Lemann,
Jean-frederic Colombel, Elie Khouri, Bruno Bonaz, Franck Carbonnel
Background & Aims: Crohn's Disease (CD) is associated with an increased risk of small
bowel adenocarcinoma (SBA). SBA accounts for 30 to 50% of gastrointestinal cancer during
CD [1]. It affects young patients (median age 46 years), and carries a poor prognosis (median
survival 24 months) [2]. Several risk factors have been suggested in small series but the
subgroup of patients exposed to the highest increase of SBA remains ill-defined. The aim
of this study was to define risk factors of SBA during CD. Methods: In 11 French centres
affiliated to the GETAID, we identified 29 patients with CD and SBA. 87 controls with CD
without SBA, recruited in a single center were matched to the cases for sex, age, duration
and site of CD. Variables studied in cases and controls were professional status; tobacco;
cholecystectomy; appendectomy; familial history of IBD; Montreal Classification 5 years after
the diagnosis of CD, 3 years before the date of SBA, and at the time of SBA; extraintestinal
manifestations; granuloma. Variables of treatment (salicylates, steroids, immunosuppressive
; intestinal resection for CD before the diagnosis of SBA) were studied in the subgroup of
21 patients whose CD duration at diagnosis of SBA was longer than one year, and in their
63 matched controls. Quantitative variables were dichotomised at the median of cases and
controls and were compared by chi square and Fisher's exact test. Conditional logistic
regression, taking into account matching between cases and controls was performed. Results:
In univariate analysis, cases had had significantly less intestinal resection and had received
less salicylates (median duration 2 years) [respectively OR (IC 95%) 0.07 (0.02-0.33) and
0.32 (0.11-0.88)] than controls. In addition, median duration (min-max) of CD without
intestinal resection was significantly longer in cases [15,9 years (1,4-37,1)] than controls
[8,2 years (0,1-35,8), p=0,02]. All other variables studied did not reach statistical significance.
In multivariate analysis, two risk factors were associated with a lower risk of SBA : intestinal
resection and salicylates during more than 2 years [respectively OR=0.04 (0.01-0.31) and
OR=0.12 (0.02-0.69)]. These factors remained significant in the subgroup of cases (n=14)
and controls (n=42) who came from the center in which controls were recruited. Conclusions:
This study suggests that intestinal resection and salicylates therapy of more than 2 years
reduce the risk of SBA in patients with CD. [1] Jess T et al. Alim Pharmacol Ther 2004;19:287-
93. [2] Palascak-Juif V et al. Inflamm Bowel Dis 2005; 11(9):828-32
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Comparison of Phenotype By Mismatch Repair Gene Mutation Among
Probands Undergoing Clinical Genetic Testing for Mlh1 and Msh2
Elena M. Stoffel, Fay Kastrinos, Judith Balmana, David Stockwell, Ewout Steyerberg,
Rowena Mercado, Sapna Syngal
Introduction: The clinical phenotype expressed by patients with Lynch Syndrome may be
determined by the type of mismatch repair (MMR) gene mutation. Our aim was to compare
genotype-phenotype differences among probands undergoing testing for MLH1 and MSH2
gene mutations in a large clinical cohort. Methods: Clinical information was obtained from
the test request form of 1914 consecutive individuals submitting blood samples for MLH1
and MSH2 mutation analysis to Myriad Genetic Laboratories, Inc. Family history, age at
cancer diagnosis, and type of tumors were compared between individuals with MLH1 and
MSH2 gene mutations. Statistical significance of comparisons was assessed using chi-square
and Students t tests. Results: Two hundred and eighty-five of 1914 (15%) individuals who
underwent clinical genetic testing had detectable MMR mutations (112 MLH1, 173 MSH2).
Only 180 (63%) mutation carriers fulfilled Amsterdam criteria. The prevalence of colorectal
cancer (CRC) and endometrial cancer and did not differ among individuals with MLH1 or
MSH2 mutations. Mean age at CRC diagnosis was younger for MLH1 mutation carriers
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compared with MSH2 (41.4 years versus 44.7 years respectively, p=0.04), and MLH1
mutation carriers were more likely to be diagnosed with CRC at age < 50 years compared
with MSH2 mutation carriers (OR 2.3 p =0.02). Endometrial cancer was diagnosed in 67/
167 (40%) female carriers at mean age of 47.2 years versus 46.1 years for MLH1 and MSH2
carriers respectively. Overall, 42 (15%) mutation carriers reported a Lynch Syndrome-
associated cancer other than CRC or endometrial cancer, including tumors of the urinary
tract (17), ovary (14), stomach (3),intestine (3), brain (2), and cutaneous sebaceous neo-
plasms(16). The prevalence of these tumors was significantly higher among MSH2 mutation
carriers (36/173 (21%) affected), compared to MLH1 carriers (6/112 (6%) affected; p=
0.0003). The mean number of extracolonic (non-endometrial) cancers per family was also
significantly higher for those with MSH2 versus MSH1 mutations (p<0.001). Conclusion: This
large cohort undergoing clinical genetic testing demonstrates genotype-phenotype differences
among individuals with MLH1 and MSH2 mutations. MSH2 mutation carriers have more
Lynch Syndrome-associated cancers (other than endometrial cancer) and older age of CRC
diagnosis than MLH1 carriers. This may guide cancer surveillance recommendations for
extracolonic malignancies.
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The Efficacy of Adjuvant Chemotherapy with 5-Fluoruracil in Colorectal
Cancer Depends On the Mismatch Repair Status. Final Results from a 5-Years
Multicentric Prospective Cohorts Study
Rodrigo Jover, Pedro Zapater, Antoni Castells, Xavier Llor, Montserrat Andreu, Joaquin
Cubiella, Luis Bujanda, Josep maria Reñé, Juan Clofent, Juan diego Morillas, David
Nicolás-pérez, Artemio Payá, Cristina Alenda
Colorectal cancer (CRC) with mismatch repair (MMR) defective genes has a good prognosis.
However, several studies have shown a lack of efficacy of 5-fluorouracil (5-FU) based
chemotherapy in that kind of tumours. The aim of our study is to know if MMR defective
CRC has a better prognosis and a different response to adjuvant chemotherapy in a cohort
of patients followed during 5-years. METHODS: 754 surgically treated patients with CRC,
coming from 10 hospitals in the EPICOLON study were included, between October 2000
and November 2001. MMR defective status was diagnosed by immunohistochemistry staining
of MLH1, MSH2 and MSH6 proteins and microsatellite instability analysis performed using
microsatellite BAT-26. Patients have been followed during 1192±728 days (range: 1-2204
days) and 42 patients (5.6%) have been lost in the follow-up. 315 patients died (41.8%)
and 52 (6.9%) had a tumoral recidive at the end of the follow-up. At the inclusion in the
study 505 patients were diagnosed as TNM II or III stage, and adjuvant CT was applied to
248 patients (125 in the II stage and 135 in the III stage). Adjuvant CT was 5-FU based
in 98.2% of patients. The indication of adjuvant CT was done using clinical criteria without
knowing the MMR status of the tumors. Statistical analysis was performed with the Kaplan-
Meier method, log-rank test and Cox regression. RESULTS: MMR deficiency was found in
66 patients (8.8%). No differences were found in survival (SV) regarding MMR status (MMR
competent 1484 days; MMR-deficient 1557; log rank p=0.3). Similarly, no differences were
found in the Disease-Free Survival (MMR-competent 1332 days; MMR-deficient 1441 days;
log rank p=0.3). MSI-status did not influence SV or disease-free SV when patients were
analyzed separately according to the TNM stage. Adjuvant CT improves SV in patients in
the II or III stages, but this improvement is only evident in patients with MMR-competent
tumors. SV of patients with MMR-defective tumors does not improve with adjuvant CT.
Results of SV in the II and III stage are shown in the table. CONCLUSION: In a cohort of
CRC patients treated with 5-FU there are not differences in survival regarding MMR status
after a 5-years follow-up. Patients with MMR-deficient tumors do not obtain any benefit
from 5-FU based chemotherapy.
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Clinicopathological Characteristics and Chemoadjuvant Response of Rectal
Cancer Patients with Loss of IGF-2 Genomic Imprinting
Marcia R. Cruz-correa, Ronghua Zhao, Daniels Norma, Mariana Berho, Juan Nogueras,
Dana Sands, Weiss Eric, Francis M. Giardiello, Wexner Steven
[Background] Loss of genomic imprinting (LOI) of IGF-2 is an independent risk factor for
colorectal neoplasia (CRN), but its impact on the biological behavior of cancer remains
unclear. [Aim] This study determined if LOI of IGF-2 was associated with specific clinicopa-
thological characteristics and response to preoperative neoadjuvant therapy in patients with
rectal cancer (RC). [Patients and Methods] We performed PCR on gDNA and RT-PCR on
RNA extracted from normal peripheral blood lymphocytes (PBL) of prospectively recruited
RC patients, followed by Apa I digestion. Based on Apa I DNA polymorphism, the informative
(heterozygosity) and imprinting status of IGF2 gene were determined. Preoperative neoadjuv-
ant therapy was given to patients with T1/2N1/2M0 and T3/4N0/1/2M0 lesions. The baseline
(preoperative) TNM stage and tumor size were determined with colonoscopy, rectal ultra-
sound or MRI. TNM stage and tumor size were also determined by the pathologist postoperat-
ively. Statistical analysis was performed by using Spearman correlation, Mann-Whitney test,
and Fisher's exact test with SPSS software. [Results] Of ninety two RC patients recruited,
30 were informative based on Apa I DNA polymorphism and eligible for analysis. Eleven
patients (7 males; age: 60.36±11.18) were LOI-positive, and 19 patients (12 males, age:
60.63±14.22) were LOI-negative; The prevalence of LOI in RC was 36.67% (11/30). For
LOI-positive RC patients there was a significant positive correlation between tumor size and
TNM stage (r=0.64, p=0.037), which was not seen in LOI-negative patients. In 14 RC
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patients who underwent preoperative neoadjuvant chemoradiotherapy, the percentage of
tumor size reduction after preoperative neoadjuvant therapy was significantly higher in LOI-
positive patients (median: 100, 95%CI: 59.22-119.18) compared to LOI-negative patients
(median: 41.82, 95%CI: 15.18-71.10) (p=0.040). Furthermore, according to postoperative
TNM stage there was no disease progression in any of the LOI-positive RC patients (0/5),
while 30% (3/9) of LOI-negative patients had disease progression after neoadjuvant therapy.
[Conclusion] LOI-positive RC patients had larger tumors and enhanced response to preoper-
ative neoadjuvant therapy as defined by statistically significant tumor size reduction and no
disease progression compared to LOI-negative RC patients. LOI of IGF2 may mediate a
distinct carcinogenesis model with a less aggressive phenotype. [Support] NIH grants K07
CA092445 and P50 CA-62924-10, The John G. Rangos, Sr. Charitable Foundation, The
Cancer Research and Prevention Foundation, The Eleanor Naylor Dana Charitable Trust
and The Clayton Fund.
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Multiple Mechanisms for Disruption of Activin Signaling in Microsatellite
Stable (MSS) Colon Cancers
Barbara H. Jung, Jessica Gomez, Eddy Chau, Deena Ream-robinson, Christine M. Caro,
Temitope Keku, Robert S. Sandler, John M. Carethers
BACKGROUND: Activin is a growth-suppressive ligand from the transforming growth factor
beta (TGFβ) superfamily that exerts its cellular effects through binding to its primary receptor,
activin receptor 2 (ACVR2), leading to phosphorylation of activin receptor 1 (ACVR1) and
downstream signaling via phosphorylated SMAD2. We have previously shown that ACVR2
is mutated at one of its two coding polyadenine tracts in over 80% of microsatellite unstable
(MSI) primary colon cancers, resulting in loss of expression and increased local tumor
growth. Mutations in TGFβ receptor 2 (TGFBR2) have been identified in both microsatellite
unstable (MSI) and microsatellite stable (MSS) colon cancers. Here, we examined the preval-
ence and mechanism of ACVR2 loss in primary MSS colon cancers. METHODS: Fifty-one
MSS population-based colon cancers were tested for presence of ACVR1 and ACVR2 protein
followed by assessment of pSMAD2. The exon 10 coding polyadenine tract of ACVR2, which
is the prime site of inactivation in MSI colon cancers, as well as three kinase domain hotspots
implicated by homologous TGFBR2 mutations in MSS cancers, were sequenced for somatic
mutation. Markers flanking the ACVR2 gene locus and within the ACVR1 gene locus were
used to assess for loss of heterozygosity (LOH). RESULTS: While 43/51 (84%) of primary
MSS colon cancers expressed both ACVR2 and ACVR1, 7 (14%) lost ACVR2, 2 (4%) lost
ACVR1 and one lost expression in both. Overall, pSMAD2 was lost in 5 (10%) of tumors,
with 4 of these from tumors displaying wild type ACVR2, ACVR1, TGFBR2 and SMAD4.
All 51 tumors displayed the wild type ACVR2 exon 10 polyadenine tract. We found 3
distinct mutations in the kinase hotspots of ACVR2 within colon cancers with wild type
adjacent normal tissue. LOH at ACVR2 occurred in 2 of the 7 tumors with loss of ACVR2
expression, while no LOH was found at the ACVR1 locus. CONCLUSIONS: Activin signaling
is disrupted in MSS colon cancer but involves multiple members of the signaling cascade
including ACVR2, ACVR1, and pSMAD2. Several mechanisms, including but not limited
to somatic mutations at the kinase domain, and LOH, contribute to loss of ACVR2. This
implicates disruption of activin signaling as an important step in colon tumorigenesis as it
is selectively targeted by distinct mechanisms in both genetic subtypes of colon cancer.
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Cd8+ T Cell Infiltration Correlates with Microsatellite Instabillity (Msi) and
Female Gender in Colon Cancer
Monte Lee, Bing Yang, Kathleen Mcguire, Ming Ji, Katsumi Miyai, Betty Cabrera,
Temitope Keku, Robert S. Sandler, John M. Carethers
Background. The prognosis of patients with colon cancer is most dependent on tumor
staging, but recent evidence suggests that the adaptive immune response, represented by T
cells, is important in predicting clinical outcome. CD8 is a marker on cytotoxic T cells that
have the potential to respond to and kill altered cancer cells, and are hypothesized to
attenuate metastatic potential, protecting the patient. Colon cancers displaying MSI, which
confer a better overall survival, often display a “Crohns-like” lymphoid reaction surrounding
the tumor, the characteristics of which are not fully known. Here, we examined a population-
based, prospectively collected cohort of 503 patients from the North Carolina Colon Cancer
Study for genomic instability and CD8+ T cell intraepithelial infiltration. Methods. Archived,
formalin-fixed tissues were analyzed for MSI utilizing five, NCI-recommended microsatellite
markers, with MSI-H (typically associated with loss of DNA mismatch repair function)
defined as two or more markers with novel alleles. In a blinded fashion separate from the
MSI analysis, tumors were immunostained using an anti-CD8 antibody, and high-power
microscope images were taken from 3 independent areas of the tumor with CD8+ cells
counted by two observers in a blinded fashion. Tumors were called high infiltration if >150
CD8+ cells/HPF, low infiltration if <10 CD8+cells/HPF, and medium infiltration if >10 and
<150 CD8+ cells/HPF. ANOVA analysis was performed to determine correlation of CD8+
T cell infiltration with MSI status, gender, and race. Results. Of 503 colon tumors, 54
(11%) demonstrated MSI-H, which are statistically associated with mucinous histology, poor
differentiation, right colon location, and a Crohns-like lymphoid reaction. The first 194
tumor samples stained for CD8+ T cells were unblinded for statistical analysis. Thirty tumors
(15%) showed high CD8+ T cell infiltration, 128 (66%) medium, and 36 (19%) low
infiltration. There was a significant correlation between high CD8+ T cell infiltration and
MSI-H (p=0.00002) and interestingly, female gender regardless of MSI status (p=0.0054).
We found no correlation of infiltrating CD8+ T cells with race. Conclusions. There is a
strong correlation of infiltrating CD8+ T cells with colon tumors displaying MSI-H as well
as with female gender from a population-based cohort. The CD8+ T cell infiltration may
confer part of the improved survival observed for female colon cancer patients and patients
with MSI colon tumors.
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Cpg-Island-Methylation of the Estrogen Receptor Promoter in Sporadic
Colorectal Cancer: Analysis of Micrometastases in Lymph Nodes from Patients
with Stage Uicc II Disease
Verena Engelstaedter, Jan Harder, Mariya Varbanova, Silke Lassmann, Peter Baier,
Henning Usadel, Hubert E. Blum, Oliver G. Opitz
Introduction: To date patients with UICC stage II Colorectal Cancer (CRC) are not treated
with adjuvant chemotherapy because there is no proven survival benefit. Nevertheless,
approximately 20 percent of these patients develop distant metastases or local recurrence.
The clinical importance of lymph node micrometastases for local recurrence in patients,
lacking histopathological lymph node involvement, is undefined. Many molecular markers
have been studied for the detection of lymph node micrometastases facing problems of low
sensitivity and/or specifity. Issa et al. first described aberrant methylation of the estrogen
receptor (ESR) promoter in CRC. Because this epigenetic pattern was observed in 100 percent
of CRC, we reasoned methylation of the ESR promoter might be a good marker for the
detection of micrometastases. The aim of this study was to define the methylation of the
ESR promoter as a molecular marker in lymph nodes of patients with UICC stage I and II
CRC, in order to detect micrometastases causing local recurrence. Methods: Genomic DNA
of lymph nodes from paraffin-embedded tissue was isolated, followed by bisulfite treatment.
For the detection of methylated ESR promoter we established a sensitive real-time methylation
specific PCR (MSP) (Taqman). Results: In a pilot study of 14 patients with UICC stage III
disease (every T,N1/N2,M0) we demonstrated methylation of the ESR promoter in 14/14
tumors and in 13/14 histologically positive lymph nodes while no lymph node from a
control group without CRC was methylated for the ESR promoter. The study cohort consisted
of 49 CRC patients with available resected lymph nodes in which we analyzed the presence
of micrometastases (25 women, 24 men ; 11 stage I 38, stage II patients). The average
follow-up was 5,3 years (3,9-6,6). Correlation with clinical data revealed that only two
patients had local recurrence and both could be detected by MSP (sensitivity 100%). Another
11 patients showed positive ESR promoter methylation but remained disease free up to the
last follow-up (specifity 65%). Discussion: We demonstrated for the first time that the
methylation status of the ESR promoter analyzed by real time MSP is a promising marker
for the detection of micrometastases in lymph nodes of CRC patients. The number of
micrometastases in patients without recurrence might be explained by the short follow-up,
warranting a longer follow-up for these patients. The high sensitivity of MSP might also
have contributed, raising the question of the clinical significance of micrometastases for an
individual patient. This potential marker should now be determined prospectively in a larger
population with longer follow-up.
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Pre-Clinical Characterisation of a Novel, High Affinity, Orally-Active CCK-2
Receptor Antagonist, Z-360, in Gastrointestinal Malignancy
Anna M. Grabowska, Teresa M. Morris, Andrew J. Mckenzie, Rajendra Kumari, Kouji
Yoshinaga, Hiroki Hamano, Yutaka Emori, Susan A. Watson
Background: Gastrin has a role in gastrointestinal (GI) malignancy, leading to pro-proliferat-
ive, anti-apoptotic and pro-angiogenic activities. Anti-gastrin agents have been evaluated in
the clinic and some have generated encouraging trends. The aim of this study was to perform
pre-clinical evaluation of a novel, orally-active CCK-2 receptor (CCK-2R) antagonist, Z-360.
Methods: CCK-2R binding (125I gastrin-17 [G17] displacement assay), and G17-stimulated
calcium signalling, were measured in cells transfected with the classical or intron IV splice-
variant (I4sv) forms of the CCK-2R. The effect of Z-360 on basal and G17-stimulated
signalling was determined by evaluating PKB/Akt phosphorylation by Western blotting. Two
gastrin-sensitive human xenograft models, a colorectal hepatic metastasis model, C170HM2,
and an orthotopic pancreatic model, PAN-1, were used to evaluate Z-360 efficacy In Vivo.
CCK-2R expression was investigated using immunostaining. Apoptosis and microvessel
density (MVD) in the treated tumours were determined using TUNEL and CD34 immuno-
staining. Results: Z-360 inhibited 125I G17 binding to cells transfected with classical and
I4sv forms of the CCK-2R (Ki's of 0.098nM [EC50=0.10nM] and 0.83pM [EC50=2.2pM],
respectively) and G17-stimulated calcium signalling in cells transfected with the classical
receptor. Treatment of a GI cell line, with endogenous gastrin expression and constitutively
active PKB/Akt, using Z-360 led to reduced Akt phosphorylation which was partially reversed
by treatment with G17. In Vivo, Z-360 reduced liver tumour growth in a colorectal hepatic
metastasis xenograft model to the same level as that seen for 5FU/Leucovorin (81% reduction
in final liver size [p=0.02 at 30mg/kg Z-360] compared to 63% for 5FU/Leucovorin at 25mg/
kg [p=0.012]). In the pancreatic model, Z-360, combined with gemcitabine, significantly
decreased final tumour weight when compared to single agents (84% inhibition with 100mg/
kg Z-360 in combination, p=0.002 vs Z-360 alone) and this correlated with a significant
(p<0.01) increase in the proportion of apoptotic cells and decrease in MVD (p<0.01) within
the tumours. The reduction in MVD may relate to CCK-2R expression associated with blood
vessel-like structures in this model. Conclusions: These results show that an orally-active
CCK-2R antagonist has high sub-nM affinity for both the classical and I4sv forms of the
CCK-2R. It is well tolerated In Vivo and exerts an anti-tumour effect in colorectal hepatic
metastasis through effects partially mediated through de-activation of PKB/Akt pathways,
and has a beneficial effect when combined with gemcitabine in pancreatic cancer.
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Notch Inhibitors As Potential Therapeutics for Barrett's Esophagus and
Esophageal Cancer
V. Menke, M. Van den born, J. H. Van es, P. D. Siersema, A. Capello, R. W. De bruin, E.
J. Kuipers, H. C. Clevers, J. G. Kusters
Background: Signaling pathways, like Notch and Wnt determine the fate of intestinal
epithelium in the gut. Recent findings show that Notch inhibition converted proliferative
cells in the intestinal crypts, and Wnt deregulated neoplasia into post-mitotic goblet cells.
These data suggest that Notch inhibitors could be novel colon cancer therapeutics. Barrett's
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esophagus (BE) is intestinal metaplasia in a premalignant phase of the esophagus, but very
little is known of the involvement of the Wnt and/or Notch pathway in BE. Moreover,
treatment options for BE are presently not available. Aim: To determine whether Notch
inhibitors can be used as potential therapeutics for BE and esophageal cancer. Methods:
Esophageal biopsy specimens were collected from patients with reflux esophagitis (RE) (n=
7), BE (n=5), and healthy controls (n=5). The biopsies were stained for columnar epithelium
(CDX2), goblet cells (PAS), proliferation (Ki67), Wnt genes (TCF4, EphB2, β-catenin), and
Notch genes (Notch1, Math1, HES1). The functional role of Notch inhibition was determined
with an established animal model for BE. Gastrectomy with esophagojejunostomy (GEJ) was
performed in male Wistar rats, resulting in the development of BE after 6 months. Six GEJ
rats and 2 control rats were treated for 5 subsequent days with Notch inhibitor (30 µmol
2.5 ml/kg i.p.). Presence of metaplasia, proliferation, Wnt and Notch signaling were deter-
mined by HE staining and immunohistochemistry of the esophagus. Results: Squamous
epithelium presented low proliferation and tcf4 expression, that increased from RE to the
highest expression in BE. Notch1, Math1, and HES1 were expressed in RE, but Notch1 and
HES1 were much stronger in BE. EphB2, and β-catenin were only present throughout the
epithelium of BE. Inhibition of the Notch signaling pathway in the rat model showed a
dramatic decrease in proliferation of the BE segment, a down-regulation of HES1, and an
up-regulation of Math1, while the squamous epithelium remained intact. Conclusions: The
Wnt and Notch signaling pathways increasingly dominate the cascade of RE to BE. These
findings in BE equal the preceding data of the Notch and Wnt pathway in the colon.
Consequently, Notch inhibitors are also potential therapeutics for BE and esophageal cancer,
in which the multilayered squamous epithelium remains intact whereas neoplastic cells are
forced to differentiate.
399
EGF-Receptor Related Protein (ERRP) Causes Regression of Early and
Intermediate Stages of Colorectal Cancer
Eva M. Schmelz, Hu Xu, Jianhua Du, Sanjeev Banerjee, Fazlul Sarkar, Arun K. Rishi,
Adhip N. Majumdar
Selective anticancer therapies have been developed to suppress the activation of individual
member(s) of the EGFR family (EGFRs). Since most solid tumors express several members
of EGFR, this may not be sufficient to suppress all EGFR-activated signaling pathways and,
therefore, may not suppress tumor formation and/or progression. EGF-Receptor Related
Protein (ERRP), a 53-55 kDa protein that we isolated and characterized as a pan-erbB
inhibitor that targets multiple EGFRs. ERRP is highly effective in inhibiting growth of SCID
mice xenografts of colon and pancreatic cancer cells. Whether ERRP would be effective in
treating early (aberrant crypt foci, ACF) or intermediate colonic lesions (adenomas) remains
to be determined. In the present investigation, we examined the effect of ERRP on regression
of carcinogen (dimethylhydrazine)-induced ACF in CF1 mice, that represent the earliest
morphological changes in colon cancer. As a model for intermediate stages, we used the
C57Bl/6JMin+/- (Min) mice that carry mutations in the APC gene, which is also observed
in patients with FAB and a majority (up to 80%) of patients with sporadic colon cancer.
ERRP treatment began only after establishment of ACF in CF1 mice (after 6 wks) or adenoma
formation in Min mice (after 9 wks). Each mouse was injected daily with 50 μg ERRP or
vehicle (controls) for 10 days. This led to a 40-50% reduction of ACF (p<0.05) and their
size (P<0.05). In Min mice, we found a drastic reduction of tumor size throughout the
intestinal tract. These changes in both models were associated with a significant inhibition
(50-60%) of proliferation and stimulation (60-70%) of apoptosis in the intestinal mucosa.
Moreover, a marked reduction in activation (tyrosine phosphorylation) and expression of
EGFR, HER-2 and HER-3 as well as IGF-1R was noted. Additionally, DNA binding activity
of NF-kappa-B was attenuated. In contrast, the activity of intestinal alkaline phosphatase,
a marker of differentiation, was elevated following ERRP treatment. Taken together, the
results indicate that ERRP is effective in inducing regression of colorectal cancer at different
stages of progression. This could partly be attributed to inhibition of EGFRs and IGF-1R
signaling and induction of differentiation of intestinal mucosa. We suggest that ERRP could
be an effective therapeutic agent for colorectal cancer.
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Development of Progastrin (PG) Specific Monoclonal Antibodies (Mabs) and
PG Specific Vaccine for Attenuating Growth Factor Effects of Autocrine and
Endocrine PG-Like Peptides On Colon Cancer Cells and Colon
Carcinogenesis, Respectively
Pomila Singh, Gurpreet Singh
Background. The gastrin gene and PG peptides are expressed by > 70% colorectal carcinomas
(CRCs). Down-regulation of gastrin gene expression results in apoptotic death of gastrin
dependent CRCs. However, delivery of effective concentrations of anti-sense DNA to the
tumor cells, In Vivo, has proven to be a challenge. A vaccine, Gastrimmune, against gastrin
(G17) peptide is currently in clinical trials with mixed results. We recently reported that
Annexin II mediates anti-apoptotic effects of PG and G17-like peptides (Oncogene, 2006).
G17 also binds CCK2R with high affinity, and unlike Annexin II, CCK2R mediates several
biological effects on different cell types including differentiation and growth inhibition. This
may explain the mixed results obtained with Gastrimmune. In the current studies, we
targeted the colon cancer relevant peptide, PG, since elevated levels of PG, but not G17,
have been reported in patients with CRCs. Methods and Results. In the first set of studies,
we generated MAb, specific for PG, with <1% cross reactivity with Gly extended gastrin
and G17. The MAb, in a dose-dependent manner, attenuated growth of a human colon
cancer cell line, HCT-116, In Vitro. We are currently testing different fragments of this Ab
In Vivo. In the second set of studies, transgenic mice over-expressing PG (Fabp-PG) were
vaccinated with several antigens, and a pre-neoplastic marker of colon carcinogenesis, aber-
rant crypt foci (ACF), measured. We have previously reported a significant increase in colon
carcinogenesis in mice over-expressing PG (Gastro, 2000; Cancer, 2004). Of the various
antigens used for vaccination, a fusion protein containing thyroredoxin and full length PG
was most effective in completely attenuating colon carcinogenesis in Fabp-PG mice to control
levels measured in wild type littermates. Mice injected with the control peptides/proteins
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(including thyroredoxin or PG alone) did not demonstrate a similar loss in colon carcinogen-
esis. Balb/c mice, bearing xenografts of mouse colon cancer cells (CA), were similarly
vaccinated; mice with the highest titers of PG Abs demonstrated a significant loss in tumor
mass with an increase in necrosis. Conclusion. These studies confirm for the first time that
targeting the colon cancer relevant growth factor, PG, using either PG MAb or a vaccine
against PG represents a potent method of attenuating growth of gastrin dependent tumors.
Our studies further demonstrate that the fusion protein containing thyroredoxin and PG
can function as an effective vaccine for inducing apoptosis of PG-dependent tumors.
401
Immuno Monitoring of Combined DC Vaccination and Chemotherapy in a
Murine Pancreatic Carcinoma Model
Christian Bauer, Alexander Sterzik, Franz Bauernfeind, Maximilian Schnurr, Rosemarie
Kiefl, Stefan Endres, Andreas Eigler, Marc Dauer
Background: Multiple studies have shown that dendritic cell based vaccination can induce
antitumor immunity. However, clinical response is usually poor in patients with solid cancer.
Here, we investigated the interplay between DC vaccination and gemcitabine chemotherapy
in a murine pancreatic cancer model, correlating ex vivo immunomonitoring with clinical
efficacy. Material and methods: Murine Panc02 cells were transfected with an OVA vector
and the expression of MHCI restricted, OVA derived SIINFEKL peptide on the surface of
these cells was shown by stimulation of SIINFEKL-specific OT-1 cells. Bone marrow derived
DC were loaded with apoptotic Panc02-OVA cells, OVA protein or SIINFEKL peptide and
stimulated with LPS. Mice were vaccinated with 0.3 x 10E6 to 3 x 10E6 DC s.c. or i.p. For
immunomonitoring, an In Vivo cytotox assay based on detection of 15E-peptide-specific
CTL was established. 15E-peptide is derived from the MuLV env-protein, which is expressed
by Panc02. The possibility of MHCI-mediated lysis of Panc02 cells was tested using SIIN-
FEKL-specific OT-1 cells. Intracellular IFN-gamma staining of CD8 positive T cells and
SIINFEKL-streptamer staining were used to examine the induction of antigen specific T
cells. For tumor induction, 1 x 10E6 syngeneic Panc02 cells were injected s.c. into C57BL/
6 mice. Gemcitabine (50mg/kg) was given i.p. twice weekly. Results: Despite low MHCI-
expression, SIINFEKL-loaded Panc02-cells were lysed In Vitro by splenocytes derived from
OT-1 mice. In an In Vivo cytotox assay, p15E-specific CTL could be detected after vaccination
of C57BL/6 mice with Panc02 loaded DC, but not in untreated controls. Intraperitoneal
vaccination with OVA protein loaded DC did not only lead to a profound SIINFEKL specific
T cell response, but also to an increase in p15E specific T cells in tumor bearing animals.
Clinically, prophylactic vaccination with Panc02-loaded DC inhibited tumor growth not
only initially, but led to induction of a memory response suppressing tumor growth even
100 days after end of vaccination. In the therapeutic setting, DC vaccination and gemcitabine
showed synergistic efficacy. Conclusions: Induction of pE15-specific CTL and of a memory
response in a murine Panc02 carcinoma model indicate that DC vaccination is effective.
Epitope spreading could be demonstrated using an OVA transfection model. We currently
assess the immune response of vaccinated animals in tumor-bearing and tumor-free mice
with and without gemcitabine therapy. These results have implications for a clinical study
currently under way at our institution using tumor lysate pulsed DC to treat patients with
pancreatic carcinoma.
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A Monoclonal Anti-Plgf Antibody Inhibits Tumor Growth and Lymphatic
Metastasis Without Affecting Healthy Vessels
Christian Fischer, Bart Jonckx, Serena Zacchigna, Massimilano Mazzone, Emmanuel
Chorianopoulos, Marta Koch, Stephane Plaisance, Hoa Ngo, Maria Demol, Mieke
Dewerchin, Monica Autiero, Lieve Moons, Jean marie Stassen, Desire Collen, Peter
Carmeliet
Gene targeting studies in mice have elucidated a functional role of placental growth factor
PlGF, a homologue of VEGF, in pathological angiogenesis. Loss of PlGF, while not causing
any vascular defects during embryonic development, reproduction or normal adult life,
impaired angiogenesis in pathological conditions, such as cancer. Indeed, PlGF expression
correlates with tumor stage, vascularity, metastasis and survival in a variety of tumor entities,
and clinical trials revealed a 10-fold upregulation of plasma PlGF levels in cancer patients
who underwent anti-VEGF treatment. We generated a neutralizing anti-murine PlGF anti-
body, which inhibits PlGF binding to its receptor VEGFR-1, and report its efficacy to inhibit
primary tumor growth, tumor (lymph)-angiogenesis, and lymphatic metastasis in several
murine syngeneic tumor models. Compared to a control antibody, intraperitoneal administra-
tion of anti-mPlGF significantly suppressed the growth of established B16 melanoma, Panc02
pancreatic, CT26 colon, EL-4 lymphoma, and 4T1 breast tumors. Histological examination
revealed that anti-mPlGF impaired tumor vessel formation and maturation, and inhibited
intratumoral recruitment of myeloid and mobilization of endothelial progenitor cells. Further-
more, anti-mPlGF amplified the antitumor effect of the chemotherapeutics cyclophosphamide
in melanoma and gemcitabine in pancreatic tumors, respectively. Anti-mPlGF also inhibited
the growth of orthotopic pancreatic tumors, reduced the incidence of tumor invasion to
adjacent organs, common bile duct obstruction, and the generation of hemorrhagic ascites.
Moreover, anti-mPlGF impaired the formation of LYVE-1+ peritumoral lymphatics, and
inhibited lymphatic metastasis to regional and distant lymph nodes. Treatment with the
VEGFR-2 specific antibody DC101 increased plasma VEGF and PlGF levels in tumor bearing
mice, which may counteract antiangiogenic therapy. Notably, combined treatment with anti-
mPlGF and DC101 resulted in a more potent antitumor effect compared to either anti-mPlGF
or DC101 alone. Finally, unlike VEGF inhibitors, anti-mPlGF failed to affect pregnancy, did
not induce hypertension or pruning of quiescent vessels in the trachea and thyroid gland,
failed to elevate plasma levels of PAI-1, a marker of thrombotic risk, and did not enhance
doxorubicine induced cardiomyopathy. Thus, the use of antibodies against PlGF as an
antiangiogenic therapy for cancer may be a suitable and safe alternative or adjunct to VEGF
blockade offering the advantage of increased efficacy and reduced risk of resistance to
antiangiogenic treatment.
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Bombesin Receptor Subtype-3 Expression in Differentiated Human Visceral
Adipocytes Mediates Insulin-Independent Glucose Uptake
Anita Ratnasari, Dongmei Xiao, Sreenivas Garla, Richard Corkey, David H. Coy, Horst C.
Weber
Adipose tissue is a highly active endocrine organ and critical for proper regulation of energy
homeostasis. Disruption of glucose uptake results in insulin resistance, a hallmark of the
metabolic syndrome, diabetes mellitus type 2 and obesity. We hypothesized that the orphan
human bombesin receptor subtype-3 (hBRS-3) might regulate glucose uptake in human
adipocytes because BRS-3 k.o. mice are characterized by impaired glucose metabolism,
insulin resistance, and obesity. Cultured human undifferentiated and differentiated adipocytes
from subcutaneous, mesenteric and omental depots (provided by adipocyte core) were
examined for hBRS-3 expression. Subsequent to full differentiation in culture, glucose uptake
was measured in adipocytes with standard protocols using [3H]2-deoxy-D-glucose. AKT
(Ser473) and ERK1/2 phosphorylation was examined by immunoblotting with phospho-
specific antibodies. Using RT-PCR, we first demonstrated hBRS-3 expression in preadipocytes
and mature adipocytes isolated from all three fat depots. We subsequently detected intracellu-
lar calcium mobilization upon selective agonist stimulation of hBRS-3 by digital imaging in
fura-2 loaded adipocytes. In subcutaneous, mesenteric and omental adipocytes, stimulation
with insulin (100 nM), the positive control, resulted in two-fold increase of glucose uptake
(p<0.05 vs. control). HBRS-3 stimulation with a selective synthetic peptide agonist (100nM)
significantly (p<0.05) induced glucose uptake in omental (mean+/-SEM;1.8+/-0.4-fold) and
mesenteric adipocytes (2.6+/-0.1-fold) but not in subcutaneous adipocytes (1.0+/-0.6-fold).
Insulin plus hBRS-3 selective agonist resulted in glucose uptake levels in subcutaneous,
mesenteric and omental adipocytes similar to those with insulin alone. HBRS-3 agonist
stimulation of adipocytes caused time-dependent AKT and ERK1/2 phosphorylation, whereby
AKT phosphorylation was abolished in the presence of PI3 kinase inhibitor wortmannin and
MEK1 inhibitor PD98059. We conclude that hBRS-3 is expressed in human subcutaneous,
mesenteric and omental fat depots. However, only hBRS-3 expression in human visceral
adipocytes of mesenteric and omental origin facilitated insulin-independent glucose uptake
subsequent to ligand activation equipotent to insulin action. HBRS-3 dependent signaling
in human visceral fat cells involved PI3 kinase- and MEK1-dependent AKT activation thereby
communicating with insulin-dependent signal pathways. Thus, human fat depots possess
distinct biological characteristics and glucose homeostasis is regulated by hBRS-3 in visceral
fat depots. Human BRS-3 agonist might be a useful treatment option for insulin resistant states.
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Production of Adipokines from Gastric Fat Pad in Morbidly Obese Women
Rana Madani, Rahul Bhome, Nazar Miheisi, Vidya Mohamed-ali, Majid Hashemi
Background: The gastric fat pad (GFP) is distinct and morphologically dissimilar to other
visceral adipose tissue depots. Adipose tissue derived factors such as RANTES (Regulated
upon Activation Normal T-cell Expressed and Secreted), MCP-1 (Monocyte Chemo-attractant
Protein-1), adiponectin, leptin and Interleukin-6 (IL-6) are able to modulate susceptibility
to obesity associated pathology. We investigated the systemic and In Vitro release of these
adipokines from GFP and compared it to that from omental (Om) and subcutaneous (Sc)
human adipose tissue in relation to body fat and insulin sensitivity. Methods: Fourteen
obese female patients undergoing surgery were studied (n = 14, mean age 44 (7) years, BMI
48 (14) kg. m-2). Fasting glucose, insulin and circulating adipokines were measured. Sc,
Om and GFP adipose tissue were utilised for determining In Vitro adipokine release by organ
cultures. Insulin resistance was assessed by HOMA-R and body fat content by bioelectrical
impedance. Results: There was a significant interaction between % body fat and systemic
levels of leptin and IL-6 only. Production rates of adipokines In Vitro per gram tissue/ hr:
RANTES {median (IQR) Sc 31 (17-67), Om 36 (17-87), GFP 89 (60-128) pg/ml; MCP-1
Sc 5 (3-6), Om 5 (3-7), GFP 6 (4-8) ng/ml; leptin Sc 1068 (446-2299), Om 393 (205-
660), GFP 402 (123-680) pg/ml; adiponectin Sc 20 (11-23), Om 20 (13-25), GFP 17 (9-
22) ng/ml and IL-6 Sc 4 (2-12), Om 4 (0.5-38), GFP 4 (2-10) ng/ml}. There was a significant
difference between GFP RANTES release to that from Sc (p = 0.04) and Om (p = 0.02).
Depot specific differences in adipokine release were also apparent for leptin (mainly SC)
and IL-6 (mainly Om). % body fat and GFP adipokine release correlated negatively with
RANTES production and positively with MCP-1 and adiponectin release. SC leptin production
correlated positively with % body fat. Insulin resistance correlated negatively with adiponectin
release from all depots. It was also inversely related to GFP IL-6, Om MCP-1 and SC RANTES
release, but positively related to Om leptin production. Conclusion: The gastric fat pad
does not mimic omental adipokine production and is the primary depot for RANTES
production. Insulin sensitivity and % body fat differentially regulate systemic and tissue
production of adipokines.
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The Effects of Free Fatty Acids On Gastric Emptying, Plasma Cholecystokinin,
Appetite and Energy Intake Are More Potent Than Those of Triglycerides
Tanya J. Little, Antonietta Russo, Michael Horowitz, James H. Meyer, Douglas Smyth,
Chris Tsopelas, Karen L. Jones, Judith Wishart, Max Bellon, Christine Feinle-bisset
Introduction: The effects of fat on gastric emptying, gastrointestinal hormone release and
energy intake are dependent on the digestion of fat to free fatty acids (FFAs). There is limited
information about the comparative effects of FFAs and triglycerides (TGs) on these factors.
In animals, oleic acid inhibits energy intake more potently than an isocaloric infusion of its
TG, triolein. Aim: To compare the effects of FFAs and TGs on gastric emptying, cholecystoki-
nin (CCK) secretion, appetite and energy intake in healthy males. Methods: 9 healthy males
(23±2 years, BMI 22±1 kg/m2) were studied on three occasions to evaluate the effects of (i)
40 g of oleic acid (“FFA”) (1830 kJ), (ii) 40 g of macadamia oil (“TG”) (1856 kJ) (both as
600 ml oil-in-water emulsions stabilised with 4 % (w/v) powdered milk protein and labelled
with 15 MBq 123I), or (iii) 600 ml 4 % (w/v) powdered milk protein (“control”, 24 g skim
milk powder in 600 ml water, 352 kJ), administered intragastrically, on gastric emptying,
plasma CCK, appetite and energy intake. Results: Gastric emptying of FFA was much slower
than of TG (P<0.05, Figure A), with greater retention of FFA, than TG, in the proximal
stomach (P<0.001). Hunger was less (P<0.05), and fullness greater (P<0.05), following FFA
administration, when compared with both control and TG. Plasma CCK concentrations were
greater after FFA than after TG or control (P<0.05, Figure B). Energy intake was less after
FFA, when compared with TG (control: 4754±610 kJ, TG: 5463±662 kJ, FFA: 4199±410
kJ*; * P<0.05 vs TG). Conclusion: Free fatty acids empty from the stomach more slowly,
but stimulate CCK release and suppress appetite and energy intake much more potently,
than triglycerides.
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Successful Gastric Banding Surgery Lowers Serum Leptin But Not Ghrelin,
Gastrin, Or Pepsinogen I Levels
Joshua R. Shak, Jatin Roper, Guillermo I. Perez-perez, Fritz Francois, George A. Fielding,
Christine Ren, Martin J. Blaser
Background: Laparoscopic adjustable gastric banding (LAGB) is reported to be effective in
inducing weight loss in morbidly obese (BMI&;40) individuals. We determined changes in
serum leptin, ghrelin, gastrin, and pepsinogen I levels in patients before and after LAGB.
We hypothesized that LAGB induces weight loss but largely spares gastric function. Methods:
24 patients undergoing LAGB were prospectively enrolled. BMI was measured and blood
samples drawn at baseline, and 6 months and one year post-surgery. Serum leptin, ghrelin,
gastrin, and pepsinogen I levels were measured using immunoassays. Patients were considered
Helicobacter pylori positive if they were either H. pylori or CagA-seropositive. Results: BMI
decreased significantly from baseline (mean 45.1 ± SD 8.6) to 6 months (38.3 ± 8.8; p<0.01)
and to one year (34.8 ± 8.9; p<0.01) post-surgery. There was a significant fall in serum
leptin concentrations from baseline (median 19.7 ng/ml, IQR 15.1-23.4), to 6 months post-
surgery (11.4 ng/ml, IQR 7.7-16.1; p<0.01), and to one year post-surgery (6.9 ng/ml, IQR
5.8-13.2; p<0.01). In contrast, serum ghrelin levels at baseline (median 1298 pg/ml, IQR
749-1497) did not significantly change 6 months (1577 pg/ml, IQR 1077-1735) or one
year (1231 pg/ml, IQR 994-1544) post-surgery. Similarly, serum gastrin levels were similar
before (median 31.0 pg/ml, IQR 26.5-46.0) and one year post-surgery (28.5 pg/ml, IQR
20.8-34.0) and serum pepsinogen I levels were comparable before (49.2 ng/ml, IQR 38.7-
72.0) and one year post-surgery (49.7 ng/ml, IQR 40.4-79.3). BMI, leptin, ghrelin, gastrin,
and pepsinogen I were not significantly different between H. pylori positive (n=5) and H.
pylori negative (n=19) patients at any time point. Conclusions: In a setting in which LAGB
yielded ~23% weight loss over one year, serum leptin levels fell appropriately. The absence
of significant differences in ghrelin, gastrin, and pepsinogen I indicate BMI-independent
regulation and suggest that LAGB spares gastric function, which may be advantageous.
Changes in ghrelin dynamics may not play a role in gastric banding-induced weight loss. Lack
of differences between H. pylori positive and negative subjects may reflect small sample size.
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Exaggerated Postprandial GLP-2 Response After Roux-en-Y Gastric Bypass
Might Be Causative for Post Surgical Intestinal Adaptation
Katharina Wallis, Carel W. Le roux, Simon J. Aylwin, Ameet G. Patel, Richard Welbourn,
Steve R. Bloom, Alastair Forbes, Mohammad A. Ghatei, Julian R. Walters
Background: Weight loss after Roux-en-Y gastric bypass (RYGB) is largely attributed to
decreased appetite and calorie intake. Despite the loss of intestinal length, malabsorption
is rarely clinically relevant. This may be due to the morphological and functional adaptation
of the intestine that has been described following bariatric surgery. A change in intestinal
growth factor concentration has not yet been demonstrated in this context. Glucagon like
peptide 2 (GLP-2) is an intestinotrophic hormone, implicated in causing post-resection
intestinal adaptation. Aim: To examine changes in plasma concentration of GLP-2 following
RYGB. Methods: Meal related GLP-2 profiles were determined on plasma samples collected
prospectively in two study populations with ethical approval. In group A (n=16; 5 male,
11 female; mean age 48 y; mean preoperative BMI 49kg/m2), samples were obtained before
and at day 2, 4, 7 and 42 after RYGB; in group B (n= 6 females, mean age 47; mean
preoperative BMI 48kg/m2), before and at 1, 3, 6, 12 and 24 month after RYGB. Venous
blood was collected after a 12 h fast and following a mixed 400 kcal meal (30 min intervals
for 3 h). GLP-2 concentrations were determined by radioimmunoassay using antiserum FT-
17. Results: There was no significant change in fasting GLP-2 concentration at any time
point following RYGB surgery. However we found significant increases in the GLP-2 response
to nutrient stimulation (see table). This effect could be demonstrated as early as 2 days
following surgery and was still evident 24 month post surgery. Conclusion: An exaggerated
GLP-2 response to nutrient ingestion can be demonstrated as early as 2 days following
RYGB. Elevation of this growth factor may lead to adaptive changes in the intestinal mucosa
that account for the restoration of normal intestinal function within months after malabsorp-
tive bariatric surgery.
Percent increase of area under the curve for GLP-2 (0-180min)
Values in %; mean±SEM
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Endoincision Following Balloon Dilatation Is Superior to Dilatation Alone in
Managing Anastomotic Strictures in Gastric Bypass Patients
Charles W. Randall, Carlo M. Taboada, John Pilcher, Terive Duperier, Dana Reiss, Michael
Seger, Lloyd Stegemann
INTRODUCTION Gastric bypass surgery is growing exponentially. A recognized complica-
tion is anastomotic strictures that traditionally have been treated with balloon dilatation.
Our experience with dilatation is similar to other centers, where repetitive procedures are
required to provide long term success. Most anecdotal and published findings report the
average number of dilatations at 3-4. We applied our previous published technique of
endoscopic incision (treating Schatzki rings, pyloric stenosis and peptic duodenal strictures)
to this malady. METHODS 15 patients ranging in age from 22-54 (12 female; 3 male)
presented with symptomatic anastomotic strictures. None had prior experience with endos-
copic therapy. Balloon dilatation was carried out with a Microvasive CRE wire-guided TTS
balloon. Dilatation allowed the weak areas of the stricture to be identified. Our standard
endoscopic incision technique was then applied using the radial jaw forceps by Microvasive
(Boston Scientific) to remove scar tissue from the anastomosis, followed by directed incision
with the Microvasive Ultratome (Boston Scientific). Mean follow-up was 7 months with a
range of 4-24 months. RESULTS 9 patients had complete resolution of their symptoms after
the initial procedure. 4 patients had such a significant obstruction (lumen ≤ 2 mm) that a
second procedure was scheduled automatically. 2 patients had recurrences at 3 and 5 months
respectively but remained asymptomatic after a second procedure. All patients remain in
remission. No complications were observed. CONCLUSIONS 1.Endoscopic stricturotomy
is a safe and successful treatment of anastomotic strictures. 2.It provides greater long term
success than balloon dilatation. 3.Endoincision following dilatation reduces the total number
of procedures per patient.
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Differential Functioning of Pain Modulatory Networks in Men with and
Without Irritable Bowel Syndrome: A Central Role of the Parabrachial
Nucleus
Jennifer S. Labus, Bruce D. Naliboff, Kirsten Tillisch, Steve M. Berman, Brandall
Suyenobu, Lin Chang, Mark Mandelkern, Joshua Bueller, Emeran A. Mayer
Background: Alterations in endogenous pain modulating mechanisms have been suggested
as a plausible mechanism underlying visceral hypersensitivity in IBS patients{Mayer et al.
Gastroenterology, 2006}.This study aimed to test for an IBS-specific functional brain network
involved in such pain modulation. Methods: 20 men (10 non-constipated IBS patients, 10
healthy controls) received H215O PET scans during three conditions: resting baseline(BL),
rectal distension(INF) and anticipation(ANT). Multivariate partial least squares(PLS) tested
for distributed patterns of brain activity discriminating groups and conditions. Seed PLS was
used to identify a disease-related neural network functionally connected with the parabrachial
nucleus region(PBN), a pontine integration site for homeostatic afferent input, which also
plays a major role in pain modulation. Results: Task PLS revealed a significant pattern of
activations and deactivations(p<.001) that distinguished INF from BL in controls and IBS
patients and ANT from BL in IBS patients only. During INF, this network of regions
comprised activations in the PBN region, thalamus, insula, ventrolateral and medial prefrontal
cortex(PFC), and deactivations in somatosensory, arousal and attentional circuits. Seed PLS
identified a significant disease-specific network(p<.01) demonstrating strong between-group
differences in functional connectivity with PBN activity. Additionally, for the controls, this
network operated similarly across all tasks, but for IBS patients the network was only in
operation during BL and INF, but not ANT. The network included known pain processin-
g(thalamus, insula), limbic and paralimbic(hypothalamus, medial PFC, rostral ACC, middle
temporal gyrus) and cognitive(ventrolateral and dorsolateral PFC) regions. On average and
across tasks(except in ANT in IBS patients), thalamus, hypothalamus, and middle temporal
gyrus demonstrated positive correlations with the PBN in controls, but were negatively
correlated with the PBN in IBS patients. Similarly, insula, rostral ACC, medial, ventrolateral
and dorsolateral PFC were positively correlated with the PBN for IBS patients but negatively
correlated in controls. Conclusions: These results demonstrate significant differences in
brain responses between men with and without IBS to delivered and anticipated visceral
stimulation. These include differences ina) activation/deactivation of brain regions during
ANT; b) the functional connectivity between a PBN-centric network of brain regions; and
c) the engagement of this PBN brain network during the anticipation condition. Supported
by:DK 48351(EAM), P50 DK64539(EAM), R24AT002681(EAM), & K08DK071626(JSL).
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Cortical Mapping of Digestive Symptoms During Intracerebral Electrical
Stimulation
Agata Mulak, Philippe Kahane, Dominique Hoffmann, Lorella Minotti, Bruno Bonaz
Recently, the gut-to-brain sensorimotor pathways have been studied using noninvasive brain
imaging techniques. Interesting development is connected with the opportunity to study
the brain-to-gut pathways in human assessing the effects of cortical electrical stimulation.
Such electrical stimulation studies are routinely performed in medically intractable epileptic
patients having undergone chronic invasive recordings as a part of presurgical evaluation
of epileptogenic zones. Aim & Methods: To obtain a comprehensive map of the cortical
areas from where digestive symptoms during intracerebral electrical stimulation in epileptic
patients are elicited. Direct cortical electrical stimulations were performed in 339 medically
intractable epileptic patients (164 M, 175 F; mean age 27 years, range 5-54 years) selected
to presurgical evaluation using chronically stereotaxically implanted intracerebral electrodes
and audio-video-EEG monitoring system. Topography, modality and intensity of the analysed
digestive sensations were based on the patients' reports including detailed interview. Results:
Digestive symptoms were electrically induced on 723 different anatomical sites in 172
subjects (51%). According to the exclusion criteria, the final analysis includes 174 relevant
stimulations evoked in 87 selected patients. The reported sensations referred predominantly
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to the upper part of the digestive tract including the epigastria and area over the periumbilical
(n=83; 48%), retrosternal (n=17; 10%), pharyngeal (n=31; 18%), and oral (n=18; 10%)
regions. The temporal pole (BA38) (n=14), hippocampus (n=12), amygdala (n=8), and
anterior cingulate cortex (BA24/BA32) (n=9) were the typical anatomical locations connected
with the epigastric sensations. Oro-pharyngeal symptoms were frequently evoked by the
stimulation of the precentral gyrus, postcentral gyrus, and insula. Conclusion: Intracerebral
electrical stimulation is followed by a great variability of induced digestive and associated
symptoms corresponding to a widely distributed cortical network of visceral sensation
processing. A critical role of the limbic and paralimbic structures in this network, including
the temporal pole, hippocampus, amygdala, insula, and anterior cingulate cortex explain
emotional and autonomic input in responses to visceral stimulation.
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Heart Rate Variability As a Marker of Stress in Inflammatory Bowel Diseases
Sonia Pellissier, Cécile Dantzer, Sophie Fichou, Bruno Bonaz
Stress is an important factor of alteration of the autonomic nervous system (ANS) and can
induce long-term modifications of the sympatho-vagal balance. There is increasing evidence
that stress and autonomic abnormalities may play a role in the pathophysiology of inflammat-
ory bowel diseases (IBD). The vagus nerve and the sympathetic nervous system have an
anti-inflammatory and a pro-inflammatory effect respectively in experimental colitis. Stress
activates the sympathetic nervous system, inhibits the vagus nerve, and induces a relapse
of an experimental colitis. Aim: To explore the functional state of the ANS, as represented
by heart rate variability (HRV), and the psychological factors which could be associated to
stress in IBD patients during the period of flare and remission. Methods: 39 IBD patients
(15 ulcerative colitis, UC; 24 Crohn's disease, CD; age: 41±14 years, range: 21-63 years)
either in flare or in remission (determined by CDAI for CD and CAI for UC) were prospectively
included. Sixteen matched controls were studied. The sympatho-vagal balance was explored
by short term spectral analysis of the R-R interval. HRV was recorded over a resting period
of 10 minutes. High frequencies (HF) and low frequencies (LF) corresponded to the parasym-
pathetic and sympathetic tone respectively. After HRV recording, the subjects answered to
7 psychological questionnaires to evaluate their stress level. Results: No significant difference
was observed in HRV markers and psychological parameters between UC and CD so that
the two subgroups were pooled. During remission, the LF/HF ratio of IBD patients was not
different from controls (1.38±0.98 vs 1.14±0.44 respectively; P: NS) despite more depressive
symptoms (14.05±0.98 vs 8.39±4.29 in controls; p<0.01). IBD flare was associated with an
important rise in LF/HF ratio (3.47±1.89, p<0.001 vs remission and controls) due to the
combined reduction in HF (-50%) and increase in LF (+30%). Concomitantly, the score of
depressive symptoms, which was already high during remission, increased significantly
(20.80±10.05; p<0.05 vs remission and p<0.01 vs controls). Other psychological parameters
were also increased such as negative affect (27±6.2 vs 21.1±6.6 in remission; p<0.05),
anxiety state (46.8±15.4 vs 35.1±9.1 in remission, p<0.01) and perceived stress (43.2±10.4
vs 36.5±7.9 in remission, p<0.05). Conclusion: These results show that IBD flare represents
a state of real chronic stress. HRV seems to be a reliable marker of this physiopathological
state. This state is characterised by (1) an imbalance of the ANS with a sympathetic activation
and a parasympathetic depression and (2) an increase in stress vulnerability.
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Alterations of Emotional Modulation in Irritable Bowel Syndrome: An Fmri
Study
Joshua Bueller, Brandall Suyenobu, Joyce Reinholdt, Loretta So, Steve M. Berman, Bruce
D. Naliboff, Emeran A. Mayer
BACKGROUND: Converging evidence from preclinical, epidemiological, physiological and
brain imaging experiments supports the concept of enhanced responsiveness of brain circuits
concerned with emotional and stress reactivity in patients with Irritable Bowel Syndrome
(IBS). In addition, evidence suggests a reduced ability to regulate or cope with the stress
they experience, and a reduced ability to engage cortico-limbic pain modulation circuits.
In light of this, we aimed to test the emotional reactivity and emotional modulation of
females with IBS and control subjects. AIMS: Test the primary responsiveness of arousal/
stress circuits (Emotion Matching Task) as well as the ability of cortical influences to down-
regulate these circuits (Emotion Labeling Task) in subjects with IBS. METHODS: We used
fMRI (Siemens Allegra 3T MRI scanner) to study 14 healthy women (mean age = 27± 7)
and 10 female IBS patients (mean age = 33 ± 10) using validated emotional reactivity
(Emotional Matching) and modulation (Emotional Labeling) paradigms that involve the
viewing and labeling of negatively charged emotional faces to activate brain circuits involved
in emotional processing. RESULTS: Irrespective of group (Control or IBS), subjects showed
activation of brain regions previously reported in the literature during the emotional matching
including the left amygdala, insula and midcingulate cortices bilaterally, lateral prefrontal
cortices (PFC), and periaqueductal gray (PAG). As anticipated, the occipital cortex (OCC)
and face recognition areas (FFA) were also activated due to the inherent difference in the
experimental and control stimuli. No statistically significant group differences were found
in the reactivity of these regions. In contrast, during the labeling task, IBS subjects showed a
decreased ability to engage emotional modulatory regions, such as the ventrolateral prefrontal
cortex (bilaterally), and reduced activity of the infragenual cingulate, as compared to controls.
CONCLUSIONS: These results are consistent with a dysregulation of the cortico-limbic
emotional modulation system in in a female sample of IBS patients. Supported by: GlaxoS-
mithKline, NIH grants DK 48351(EAM) , P50 DK64539 (EAM), R24 AT002681(EAM)
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Alterations in Intestinal Serotonin Expression in Dyspepsia and Irritable
Bowel Syndrome
Amy E. Foxx-orenstein, Michael Camilleri, Michael D. Gershon, David R. Linden, Gary
M. Mawe, Jason T. Lewis, Kim L. Jensen, Nicholas J. Talley, Joseph H. Szurszewski, Alan
R. Zinsmeister
Background: Serotonin (5-HT) is a critical signaling molecule in the regulation of intestinal
motility, secretion and sensation. The role of 5-HT in the pathophysiology of functional
gastrointestinal disorders (FGID) is not well defined; however, studies have identified disturb-
ances in serotonin metabolism (e.g. reduced SERT expression) in patients with irritable
bowel syndrome (IBS) compared to control subjects. Regional differences in serotonin
metabolism may account for variation of symptoms in subjects with one or more FGID.
Hypothesis: Molecular elements of serotonin metabolism are altered in the GI mucosa of
female patients with dyspepsia, with or without IBS. Aims: To examine expression of
mRNA for the serotonin transporter (SERT [reuptake]) and tryptophan hydroxylase (TpH-
1 [synthesis]) from gastric, duodenal, and rectal mucosal biopsies from female patients with
constipation predominant IBS (C-IBS) alone, dyspepsia alone (DYS), C-IBS plus DYS, and
healthy volunteers. Methods: 48 female subjects with C-IBS, DYS, C-IBS plus DYS (as defined
by Rome II criteria) and healthy volunteers underwent EGD and flexible sigmoidoscopy with
biopsies obtained from the antrum, duodenum, and rectum. Transcript levels for SERT and
TpH-1 were quantified using real-time reverse transcription polymerase chain reaction relative
to expression levels of β-actin. Statistical analysis was with Kruskal-Wallis test. Results:
The data table below demonstrates median values of mRNA expression (fg/pg β-actin). SERT
expression was reduced in stomach in DYS (p=0.004), but not rectum of patients with IBS
or DYS. TpH-1 was elevated in both duodenal (p=0.002) and rectal (p=0.012) mucosa in
DYS. Conclusion: Expression of factors involved in 5-HT metabolism is altered in DYS but
not in IBS. Regional differences such as mucosal expression of TpH-1 in rectal mucosa of
DYS are of unclear significance. These results support the concept that FGID are associated
with altered serotonin signaling, but the cause and effect relationship remains to be deter-
mined.
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Stress-Induced Cortisol Response and Colonic Mucosal CRF-1 mRNA
Receptor Expression Correlate with Symptoms of Chronic Stress and Quality
of Life in Irritable Bowel Syndrome (IBS)
Elizabeth J. Videlock, Pu-qing Yuan, Yvette Tache, Arlene Licudine, Minou Mayer, Gordon
V. Ohning, Miyoshi Hirano, Emeran A. Mayer, Lin Chang
BACKGROUND: Evidence supports a prominent role of stress-induced alterations in brain-
gut interactions in IBS. CRF-1 receptors (CRF-1R) play an important role in the mediation
of enhanced stress-induced visceral pain and colonic motility responses in rodent models
of IBS, and an involvement of abnormal CRF signaling has been suggested in IBS patients
(Martinez & Taché, Curr Pharm Des 2006). AIMS: 1) To compare serial salivary cortisol
levels in response to a pelvic visceral stressor (flexible sigmoidoscopy) and CRF-1R expression
in colonic mucosal tissue collected in IBS patients and healthy controls, and 2) To determine
if these measures correlate with IBS symptoms and quality of life (QOLIBS). METHODS:
37 patients with IBS (26F, 11M, mean age 39 yrs) and 22 healthy controls (11F, 11M,
mean age 37 yrs) underwent sigmoidoscopy with colonic mucosal biopsies. Serial salivary
cortisol levels were collected at baseline and for 1 hr post stressor. Cortisol response was
corrected for body mass index and measured as % change from baseline to peak value.
Quantitative reverse-transcriptase PCR measured CRF-1R mRNA. Current (past 24 hr and
1 wk) and past (3 mos) IBS symptom severity, psychological symptoms (HAD), psychiatric
diagnoses, chronic stressors and QOLIBS were assessed using validated questionnaires and
interview. RESULTS: In the IBS patients (46% IBS-C, 27% IBS-D, 27% IBS-A), basal cortisol
levels positively correlated with symptoms of anxiety (r=0.40, p<0.05), depression (r=0.52,
p<0.01) and current lower abdominal discomfort (r=0.46, p<0.05). However, cortisol response
to the visceral stressor negatively correlated with symptoms of anxiety (r=-0.36, p=0.069),
depression (r=-0.40, p<0.05), chronic GI symptom severity (r=-0.41, p<0.05), current lower
abdominal discomfort (r=-0.53, p=0.01) and QOLIBS (r=-0.5, p=0.01). CRF-1R expression
positively correlated with anxiety scores (r=0.38, p<0.05). There were no significant group
differences between IBS and controls. CONCLUSION: Although there were no group
differences between IBS and controls in this sample size, there were significant relationships
between CRF-1R and cortisol levels with symptoms in IBS. Higher levels of colonic mucosal
CRF-1R gene expression and the pattern of higher basal but blunted lower cortisol responses
to a visceral stressor were seen in IBS patients with higher psychological and GI symptom
scores and poorer QOLIBS, consistent with allostatic load (McEwen, NEJM 1998). These
findings suggest that peripheral measures of CRF pathways may be markers of an altered
central stress response in IBS. Supported by NIH grants P50 DK64539 and R24 AT002681.
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Duodenal Eosinophilia and Mast Cell Infiltration in Functional Dyspepsia
(FD) and Irritable Bowel Syndrome (IBS): Duodenal Eosinophilia a Biomarker
for FD But Not IBS in Adults?
Nicholas J. Talley, Marjorie M. Walker, Pertti Aro, Jukka A. Ronkainen, Tom Storskrubb,
Laura A. Hindley, Coralie Pennaneach, William S. Harmsen, Alan R. Zinsmeister, Lars
Agreus
Background: In FD, duodenal hypersensitivity, sensitivity to duodenal acid infusion, duo-
denal acid hold up, and abnormal duodeno-gastric reflex responses have all been observed.
It is unknown if a subtle inflammatory process in the duodenum occurs in FD which may
account for these physiological alterations. We aimed to identify whether duodenal mucosal
eosinophils and mast cells are biomarkers for FD. Methods: A random sample of an adult
Swedish population (n = 1000; mean age 54 years; 51% female) underwent upper endoscopy
and biopsy. FD (n=51, Rome II, no IBS or heartburn), IBS (n=62; 35 with overlapping
dyspepsia) and randomly selected healthy controls (n=48) were identified in the population.
Two blinded independent observers assessed gastroduodenal eosinophil and mast cell counts.
Eosinophils were quantified by counting the number per high power field (HPF) in 5 HPFs
at each of 5 sites (cardia, body, antrum, D1 duodenal bulb, D2 second part duodenum),
and total counts summed over the 5 HPFs at each site. A subset of 16 FD subjects and 21
healthy controls had sections cut and stained by immunocytochemistry for mast cells (Dako
polyclonal rabbit anti-human CD117 and mast cell tryptase). Results: Cases and controls
were demographically similar. There was no association of IBS with duodenal eosinophil
counts regardless of overlapping dyspepsia or bowel habit status, but there was a strong
association in FD. Mean duodenal eosinophil counts in D1 and D2 in FD were 33.1 (SD
18.6) and 34.6 (16.9) compared with 18.4 (10.9) and 18.6 (10.5) in controls, respectively.
The odds ratio for FD (vs. healthy controls) in subjects with high D1 eosinophil counts
(≥median 22, relative to <22) was 11.7 (95% CI 3.9, 34.9), adjusting for age, gender and
H. pylori; similar results were observed in D2 (OR=7.3 [2.9, 18.1]). Gastric eosinophil counts
were overall not significantly increased in FD or IBS versus controls. Early satiety was
associated with eosinophilia in D1 (p=0.01) and D2 (p=0.02), adjusting for age, gender and
H. pylori. Retching and retrosternal pain were also significantly associated with duodenal
eosinophilia. No symptoms were associated with gastric eosinophil counts. There was a
modest correlation of eosinophil and mast cell counts in the duodenum (r=0.48 mast cell
tryptase, P<0.001), but there was no significant difference in the number of duodenal mast
cells in FD (mean D1 170.8) vs. controls (174.3). Conclusions: Duodenal eosinophilia may
characterize FD but not IBS in adults. However, duodenal mast cell infiltration and gastric
eosinophilia are not biomarkers in FD or IBS.
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Association of Postprandial Distress Syndrome and Epigastric Pain Syndrome
with Putative Pathophysiological Abnormalities in Functional Dyspepsia
Sebastien Kindt, Philip Caenepeel, Raf Bisschops, Rita Vos, Jan Tack
The Rome III committee proposed to distinguish postprandial distress syndrome (PDS) and
epigastric pain syndrome (EPS) as new sub-entities of functional dyspepsia (FD). The purpose
of this distinction is to identify subgroups which have a more homogeneous underlying
pathophysiology, and which are more likely to respond to specific therapy. The aim of this
study was to assess the association of EPS and PDS with pathophysiological mechanisms in
FD. Material and methods: A data set of 116 tertiary care FD patients (76 women, mean
age 39±1 year) who had filled out a questionnaire evaluating the presence of weight loss and
the severity (0=absent, 1=mild, 2=relevant, 3=severe) for each of eight dyspeptic symptoms
(epigastric pain, postprandial fullness, bloating, early satiety, nausea, vomiting, belching,
heartburn) was retrospectively analyzed to identify EPS, PDS or both, based on symptom
responses. For all patients, results of a 14C octanoic and 13C glycin breath test to assess
solid and liquid emptying respectively, and a gastric barostat to assess gastric sensitivity and
accommodation were available. H pylori status was known for 85 subjects. Data (mean±SEM)
were analyzed by t-tests and non-parametric tests. Results: EPS was present in 53% of
subjects and PDS in 84%, with overlap in 47%. Demographic features did not differ according
to subgroups. Meal-induced accommodation was significantly smaller in PDS (121±15 vs.
184±21 ml, p=0.039) with a higher prevalence of dysaccommodation (39 vs. 5%, p=0.004).
Discomfort thresholds were not significantly different in EPS compared to non-PDS (8.8±0.5
vs. 10.7±0.8 mmHg above MDP, NS) nor was the prevalence of gastric hypersensitivity to
distention (35 vs. 22%, NS). However, more subjects with both EPS and PDS had gastric
hypersensitivity as compared to patients with EPS or PDS alone or none (38 vs. 21%, p=
0.046). Weight loss was more pronounced in PDS (7.2±0.7 vs. 2.1±0.9 kg, p<0.001) and
EPS (7.3±0.9 vs. 5.2±0.9 kg, p=0.047) as compared to non-PDS and non-EPS respectively.
Gastric half-emptying time for solids or liquids didn't differ as compared to non-EPS or
non-PDS. H pylori showed a similar low prevalence in all subgroups. Conclusion: In this
retrospective analysis, PDS is associated with impaired gastric accommodation and weight
loss. Gastric hypersensitivity was more prevalent when subjects suffered from both EPS and
PDS. No specific pathophysiological anomaly was linked to EPS alone. The newly defined
entity PDS shows promise to identify a subgroup of FD patients with a higher prevalence
of impaired accommodation to a meal.
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Enterovirus Infection of the Stomach Is Associated with Dyspepsia: A Pilot
Controlled Study
Hashem El-serag, John Chia, Andew Y. Chia
Background Enteroviruses are common causes of gastrointestinal infections. Persistent entero-
virus infection has been reported in patients with chronic fatigue syndrome and fibromyalgia,
which are associated with chronic functional gut disorders. We examined the association
between dyspepsia and the presence of enterovirus viral capsid protein (EV VP1) in the
gastric antrum of subjects who underwent elective upper endoscopy. Methods We identified
a sample of volunteer subjects who previously underwent elective upper endoscopy with
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gastric biopsies and completed a GI symptom questionnaire. Dyspepsia was defined by the
presence of epigastric pain or discomfort more than 6 times during the past year in the
absence of organic lesions (gastric or duodenal ulcer or esophagitis grade B or greater).
Examination for the presence of EV VP1 was conducted by an investigator blinded to the
clinical information. Immunoperoxidase staining of the paraffin-embedded antrum tissue
was performed using enterovirus-specific monoclonal antibody (EV mAb) directed against
a conserve epitope of VP1 or a control mAb specific for cytomegalovirus (CMV mAb),
followed by standard staining protocol. The degree of staining was classified as: 0, no
staining; 1+, few to 10% cells stained with EV mAb; 2+, >10% and <50% cells stained; 3+,
> 50% cells stained. Specificity of antibody binding was assessed by inhibition study with
bovine serum albumin or with a synthetic peptide (15 amino acid) corresponding to the
VP1 binding epitope. The prevalence and score of EV VP1 staining were compared between
the two groups with and without dyspepsia using Chi square tests. Results We examined
gastric antrum biopsies from 41 subjects; mean age 44 years and 60% women. Of those,
19 reported dyspepsia and 22 had no dyspepsia. Enterovirus staining was present in 20
(49%) of all subjects. A greater proportion with dyspepsia (13/19, 68.4%) has enterovirus
staining (1+ and greater) than those without dyspepsia (7/22; 31.8%); p value =0.019, two
sided χ2 test. The staining was inhibited by low concentration of synthetic peptide (<100
ng), but not by bovine serum albumin (10 mg). Conclusion This preliminary study demon-
strates that enterovirus infection of the stomach antrum is significantly associated with
dyspepsia. Future prospective studies are warranted.
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A Cross-Sectional Survey to Assess the Usefulness of the Rome III Dyspepsia
Symptom Subgroups in a Large Community Sample
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: The Rome III classification of functional gastroduodenal disorders were pub-
lished earlier this year and recommended the subdivision of functional dyspepsia into two
distinct symptom subgroups: epigastric pain syndrome and postprandial distress syndrome.
As yet this classification has not been validated in a community sample of individuals with
dyspepsia. Methods: The authors examined dyspepsia symptom subgroups in a large number
of individuals originally randomly selected from the general population who were invited
to participate in a community screening program for Helicobacter pylori. All individuals
completed a validated 15-item dyspepsia questionnaire (the Leeds dyspepsia questionnaire
(LDQ)) at study entry, and the presence or absence of dyspepsia was assigned using these
data. Those reporting heartburn or regurgitation at a frequency of once a week or more
were classified as suffering from gastro-esophageal reflux disease, and excluded from further
analysis. Symptom subgroups were created using individual symptom items from the LDQ
(epigastric pain, early satiety, and nausea or vomiting). The degree of overlap between these
different subgroups was then examined. Results: 8407 individuals were originally recruited
of whom 3177 (38%) had dyspepsia according to the LDQ. However, 1290 described
heartburn or regurgitation at a frequency of once a week or more and were therefore
excluded, leaving 1887 (22%) individuals with Rome III dyspepsia with a mean age of 45
years, 1008 (53%) of whom were female. 1269 (67%) reported epigastric pain, of whom
730 (57.5%) described it as their predominant symptom. 684 (36%) reported nausea and /
or vomiting, of whom 126 (18%) described either as their predominant symptom. 609
(32%) reported early satiety, of whom 88 (14.5%) described it as their predominant symptom.
Furthermore 337 (18%) individuals were not classifiable into any of these three symptom
subgroups. Of the 1550 individuals who described symptoms compatible with one of the
three subgroups, 781 (50%) were in at least two subgroups, and 234 (15%) were in all
three. Conclusions: The new symptom subgroups recommended by the Rome III process
still led to considerable overlap of classification in this large population-based sample. In
addition, a significant minority of individuals with dyspepsia remained unclassifiable using
these criteria. Data are required from other population-based studies examining this issue
to assess the usefulness of these subgroups in clinical practice.
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Prolonged Recording of Duodenal Acid Exposure in Patients with Functional
Dyspepsia (FD) and Controls Using a Radiotelemetry pH Monitoring System
Jason Bratten, Michael P. Jones
Introduction: Abnormal duodenal acid exposure is linked with both DU and symptoms in
FD but our understanding has been limited by cumbersome recording methods. We have
previously shown that prolonged radiotelemetry pH monitoring (RpHM) in the duodenum
is feasible. The aim of this study was to compare duodenal acid exposure in healthy subjects
and patients with FD. Methods: Hp(-) patients with Rome II FD and controls underwent
EGD to place Bravo™ radiotelemetry capsules (RTC) in the distal duodenal bulb. RTC were
secured using endoclips. pH was recorded for 48 hrs. RTC retention was confirmed by
ultrasound after EGD and at 48hrs. Standardized test meals (1200 kcal/50gm fat/36 gm
protein) were eaten twice daily. FD completed a fifteen item dyspepsia symptom checklist.
Subjects were NPO other than sips of water between meals. Sleep periods were determined
from diaries. Meal periods were defined as the 3hr period following meal initiation. Results:
24 FD and 25 ctrls were studied. The FD group contained 5M/19F with a mean age(SDEV)
of 41(12) years. The control group included 12M/13F with a mean age(SDEV) of 30(8) years.
Prolonged recordings were obtained in 23/24 FD and 17/25 ctrls. Reasons for incomplete
recordings were RTC dislodgement (6), procedural complication (1) and suspected gastric
prolapse of RTC (2). Within groups, pH values for recording periods did not differ. Between
groups, FD had lower mean pH values during recording periods, which approached signific-
ance for daytime and reached significance for meals. Duodenal pH did not correlate with
dyspeptic symptoms with the exception of daytime pH and vomiting (r=-0.43; p=0.04).
Conclusions: Prolonged duodenal RpHM can be successfully performed using an RTC secured
with endoclips. Compared with controls, FD patients have greater duodenal acidification
particularly during daytime and meal periods. The relationship of duodenal pH with symp-
toms is poor but the significant correlation with vomiting supports previous studies demon-
strating nausea in association with acute duodenal acidification.
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Genome Wide Association Study for a Narrow Pediatric Phenotype - Early
Onset Colonic Crohn's Disease
Subra Kugathasan, Marla C. Dubinsky, Salvatore Cucchiara, Lee A. Denson, Vito Annese,
Gitit Tomer, Rachel Kraemer, Caroline Nievergelt, Dietrich Stephan, Jennifer Webster,
Howard Jacob, Nicholas J. Schork, Ulrich Broeckel
One of the most pressing issues in Crohn's disease (CD) genetics is the identification of genes
of early onset disease. In comparison to adult onset CD, pediatic-onset CD is characterized by
a more frequent colitis and less ileitis. Furthermore, this specific phenotype is less frequently
associated with CARD 15 mutations (less than 10% allele frequency) supporting the hypo-
thesis of a clinically and genetically independent, distinct disease subcategory. Colonic
disease was defined as macroscopic colonic involvement without any evidence of small
bowel disease, but may include perianal disease. In order to identify novel genetic factors
contributing to early CD, we perfomed a genomewide association study using the Affymetyrix
500k SNP chip. We included 121 colonic CD cases (age of onset less than 16 years. For
comparison, we used 100 age, and geographically matched pediatric controls. Since pediatric
controls are at risk of developing CD at a later point in life, we also performed the analysis
including 490 normal controls with an age of over 60 years where the risk of developing
CD is minimal. Using a single point analysis, we identified genome-wide significant (p<10-
7) and suggestive associations using the pediatric control group on chromosomes 3p14,
9q21, and 12q24. In addition, association signals were identified for the older normal
controls. We also compared allele frequency differences between the two different controls
groups. While a subset of association signals are present for both controls, a subset of SNPs
show association signals only for one control group. This analysis draws attention to study
design issues related to age of onset and the use of various control groups in case-control
studies. Replication studies are currently conducted in 300 well characterized pediatric onset
colonic Crohn's Disease using a family-based association design (TDT) in a multicenter
approach. In conclusion, we identified significant and suggestive association signals for a
unique pediatric CD phenotype. Our approach of various different control groups also
demonstrates some of the intricate issues related to the study design of case-control studies
in particular for early onset diseases.
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Different Haplotypes of the Il12b(P40) Gene Are Associated with Clinical
Crohn's Disease (CD) and with CD Patients Expressing Cbir1 Antibodies,
Respectively
Xiaowen Su, Kent D. Taylor, Charles O. Elson, Ling Mei, Carol J. Landers, Jerome I.
Rotter, Stephan R. Targan
Background: The IL12B gene codes for the p40 subunit shared in common by IL12 and
IL23, key cytokines that bridge innate and Th1/Th17 adaptive immune responses. CD has
been associated with increased secretion of IL12 and IL23, and treatment with p40 antibody
has been effective in certain CD patients. We have previously shown that the antibody
response to microbial antigens defines different groups of IBD patients, including those with
complicated disease. Aim: To investigate IL12B associations with CD and antibody expression.
Methods: Four IL12B SNPs: rs3212227 (previously associated with autoimmune disease),
F298V, rs2853694 (intron 4), and I33V were genotyped by Illumina GoldenGate Assay in
763 CD patients, and 254 controls. Serum antimicrobial antigens were measured by ELISA.
Chi-square was used to test for association of haplotypes with disease and presence of
antibody. Result: One haplotype block was found by Haploview 3.3. Individual haplotypes
were obtained by PHASE and ordered by frequency. Among three common haplotypes,
haplotype 1(H1:2212) was negatively associated with CD, i.e. protective (CD vs control:
68.3% vs 77.2%, p=0.007), with similar direction in both Jews and non-Jews. We also
observed an association between haplotype 3 (H3:1222) and anti-Cbir1 expression in these
CD patients, in that H3 frequency was significantly lower in the patients who were anti-
Cbir1 positive (31.8% vs 43.9%, p=0.001). This association was again observed in both
Jews and non-Jews. Conclusion: We have identified one IL12B gene haplotype protective
for clinical CD and a different protective haplotype in CD patients who expressed antibody
to CBir1. These results support the concept that IL12B variants, and therefore, IL12 and/
or IL23 are involved in the overall susceptibility to CD as well as the subtype of CD patients
defined by anti-CBir1 expression.
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An Interaction Between Il23r and Il17a and Between Il23r and Il17ra
Haplotypes Is Necessary for Susceptibility to Crohn's Disease
Konstantinos A. Papadakis, Jerome I. Rotter, Ling Mei, Xiaowen Su, Andrew F. Ippoliti,
Kent D. Taylor, Stephan R. Targan
Recent studies have identified an important role for the IL23/IL17 axis in the pathogenesis
of experimental IBD. IL23 receptor (IL23R) has recently been identified as a susceptibility
gene for Crohn's disease (CD). An association between IL17A and IL17RA genes and IBD
has recently been reported (Mei L, et al. DDW 2007). Aims: To determine whether an
interaction exists between IL23R and IL17A/IL17RA for conferring susceptibility to CD.
Methods: SNPs were selected to tag common haplotypes and genotyped in 763 CD and
254 controls using Illumina technology. Haplotype blocks were constructed using Haploview
3.3. Analysis was done in the total sample first, and then in Jewish and non-Jewish subjects
separately. Analysis for gene interaction was performed using the Breslow-Day test. Results:
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Two IL23R risk haplotypes were identified (IL23R block 3 H1 and block 2 H1) and one
each for IL17A (IL17A H2) and IL17RA (IL17RA H4) to confer increased risk for CD. IL23R
and IL17A interaction: while the risk haplotype for each gene contributed susceptibility
individually, there was no increased risk for disease if either of the two genes' risk haplotypes
were absent. IL23R absent/IL17A risk (OR 1.04, p=NS); IL23R risk/IL17A absent (OR 1.1,
p=NS); however, the combination of the risk haplotypes from IL23R with the risk haplotype
from IL17A dramatically increased risk for CD (30% in non-Jewish CD vs. 16% of controls,
OR 2.4; p for interaction 0.047). IL23R and IL17RA interaction: IL23R absent/IL17RA risk
(OR 1.1, p=NS); IL23R risk/IL17RA absent (OR 1.3, p=NS): i.e no increased risk if a risk
haplotype was absent. Yet again the combination dramatically increased risk in the total CD
sample (OR 3.0, p for interaction 0.036). IL17A and IL17RA interaction: In contrast, we
found no interaction between the IL17A and the IL17RA haplotypes in non-Jewish CD (P=
0.4). When all three haplotypes were examined sequentially for interaction, the OR for CD
in the non-Jewish population increased from 1 when neither haplotype was present to 3.7
(CI 1.3-10.1, P Mantel-Hanzel=0.0004) (Table). Conclusions: These data demonstrate the
multiple and likely complex interactions between the individual components of the IL23/
IL17 axis, which therefore appear to be playing a significant role in CD mucosal inflammation.
*One risk Haplotype present (of either IL23R, IL17RA or IL-17A), **Two risk Haplotypes
present (of either IL23R, IL17RA or IL-17A)
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Assessing Disease Penetrance of NOD2/CARD15 and Il23r Genes in
Inflammatory Bowel Disease Families and Case-Control Cohorts
Hui Shen, Richard H. Duerr, Steven R. Brant, John D. Rioux, Mark S. Silverberg, Kent D.
Taylor, Dan L. Nicolae, Judy H. Cho
BACKGROUND: Familial clustering in inflammatory bowel disease (IBD) reflects a complex
interplay of shared environmental and genetic factors. The Crohn's disease (CD) susceptibility
gene NOD2/CARD15 contains three major risk alleles. More recently, an uncommon coding
variant, Arg381Gln, in the IL23R gene was found to confer protection against IBD. Compar-
isons of familial and case-control disease penetrance of the NOD2/CARD15 and IL23R
variants provide insight into single gene effects in complex disorders such as IBD. METHODS:
A case-control cohort (765 CDs and 526 controls) and a cohort of 882 IBD families (including
599 CD families, each with both parents and IBD affected offspring) were genotyped for the
three NOD2 polymorphisms (Arg702Trp, Gly908Arg and Leu1007fsinsC) and Arg381Gln in
IL23R. Because each of the three NOD2 mutations occur on unique haplotypes, NOD2/
CARD15 genotype status were summarized as wild-type (WW), heterozygous (WM, carries
one NOD2 mutation), and homozygous (MM, homozygote or compound heterozygote).
Case-control disease penetrance was estimated as: P(D|G)=P(G|D)xP(D)/P(G), where P(D|G)
is the probability of developing disease conditional on a particular genotype, G. The disease
prevalence, P(D), was estimated as 0.0015 for CD and 0.0030 for IBD. The genotype
frequencies, P(G), were estimated from the controls. P(G|D) were counted from the patients.
Familial penetrance was estimated empirically based on genotype-dependent disease preval-
ence in parents of IBD probands. RESULTS: Despite the markedly increased genotype relative
risk of MM NOD2 genotypes (odd ratio=15.85, compared with subjects of WW), the
estimated case-control penetrance is only 1.78%. In CD families, compared with the overall
risk (5.93%) to parents, parents homozygous for NOD2 mutations demonstrated a signific-
antly higher disease penetrance (19.51%, p=0.0033). Of the 1764 parents of IBD probands,
140 (7.94%) had a confirmed IBD diagnosis. Strikingly, only 1 out of 137 parents heterozyg-
ous for the Arg381Gln allele had IBD (disease penetrance=0.73%), which is significantly
lower than the overall risk to parents (p = 5.0x10-4). CONCLUSION: IL23R and NOD2
genotype-dependent parental penetrance estimates can be applied to assess risk among first-
degree relatives of CD/IBD probands. The protective effect of Arg381Gln in IL23R is strongly
observed in parents of IBD probands, with a disease risk for heterozygotes >10 times lower
than that for all parents. This suggests that Arg381Gln, even in first-degree relatives enriched
for other IBD risk alleles, has a robust protective effect against IBD, highlighting the central
role of the IL23 pathway in disease pathogenesis.
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Candida Albicans Carriage and Asca in Familial Crohn's Disease
Annie Standaert-vitse, Mathias Chamaillard, Marie Joossens, Nadine Francois, Peggy
Vandewalle, Julien Branche, Herbert J. Van kruiningen, Christian Libersa, Corinne Gower-
rousseau, Antoine Cortot, Christel Neut, Boualem Sendid, Delphine Allorge, Franck Broly,
Severine Vermeire, Daniel Poulain, Jean-frédéric Colombel
Background & aims: Anti-Saccharomyces cerevisiae antibodies (ASCA) are present in about
60% of patients with Crohn's disease (CD), 20% of their first degree healthy relatives (HR),
while they are only present in 6% of controls. Recently, we have identified Candida albicans,
a commensal yeast of the human intestinal tract, as an immunogen for ASCA. The aims of
the study were to evaluate i) the prevalence and the diversity of yeasts recovered during
natural colonization of the digestive tract in multiplex CD patients, their HR and controls,
and ii) to correlate C. albicans carriage with ASCA, anti-C. albicans mannan antibodies
(referred as ACAMA) and CD-associated NOD2 mutations. Methods: Mouth swabs and stool
specimens were collected from 129 CD patients, 113 first degree healthy relatives from 45
multiplex families and 76 controls from 14 controls families for isolation, identification and
quantification of yeasts. Blood samples were collected for determination of NOD2 genotypes
and both ASCA and ACAMA serotypes. Results: C. albicans was the predominant yeast
specie isolated (80-89%) and its carriage was significantly increased in stools from CD
patients compared to control (45% vs 22%, P=0.003), without any influence of NOD2
mutations. Whereas the prevalence of ASCA was significantly increased in CD patients and
HR compared to controls (P<0.0001), the seroprevalence of ACAMA was similar between
the three groups (21%, 20% and 22% respectively, P=0.845). In natural conditions, ACAMA
levels correlated with increased C. albicans colonization in controls, HR and CD (P=0.032
P<0.0001; P<0.0001; respectively). Among HR, ASCA also correlated with C. albicans
colonization in both ACAMA seropositive and seronegative subjects. Similar results were
found when stratifying by the ASCA serotypes. However in CD, ASCA was not associated
with the carriage of C. albicans in the gastrointestinal tract, except in ACAMA seropositive
CD patients (P=0.003). Conclusions: Taken together, our results indicate that familial CD
patients are more colonized by C. albicans and ACAMA is dependent of the fluctuating
colonisation by C. albicans in controls, HR and CD. Furthermore, the ASCA seroprevalence
in HR is linked to their colonisation by C. albicans, confirming a possible role for this yeast
commensal as an immunogen for ASCA. Lastly, our results suggest a persistent susceptibility
to the colonization by C. albicans and/or a lack of modulation of ASCA response towards
this indigenous microbial agent in CD.
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Enhanced Expression of the Chemokine Cxcl16 in Intestinal Inflammation
and Association of the Cxcl16 P.Ala181val Polymorphism with Early Disease
Onset and Ileal Involvement in Patients with Crohn's Disease
Julia Seiderer, Julia Dambacher, Dorothea Leistner, Jan-hendrik Niess, Simone Pfennig,
Joachim Diebold, Dirk Haller, Burkhard Goeke, Thomas Ochsenkuehn, Peter Lohse,
Hans-christian Reinecker, Stephan Brand
Background/Aim: The recently identified CXCL16-CXCR6 chemokine-ligand receptor system
plays an important role in facilitating uptake of pathogens and chemotaxis of T cells implicat-
ing a potential function in inflammatory bowel disease (IBD). We therefore determined its
role in murine and human intestinal inflammation In Vivo. In addition, we initiated a large
genotype-phenotype study in 574 individuals, investigating whether the recently identified
CXCL16 p.Ala181Val polymorphism is associated with IBD. Methods: Expression studies
of CXCL16 and CXCR6 were performed by quantitative PCR, Northern Blot, immunohisto-
chemistry and ELISA. CXCL16 expression was determined in colonic biopsies and sera of
IBD patients and in two In Vivo models of murine intestinal inflammation (TNF DeltaARE
mice and murine cytomegalovirus (MCMV) infection). Genomic DNA from 201 patients
with CD, 164 with ulcerative colitis and 209 healthy controls was analyzed for the presence
of CXCL16 p.Ala181Val polymorphism and the CARD15 variants p.Arg702Trp, p.Gly908-
Arg, and p.Leu1007fsX1008. Results: The CXCR6 ligand-receptor system is expressed by
primary IEC and IEC cell lines with an inverse expression pattern along the cephalo-caudal
axis of the murine intestine. Upon CXCL16 stimulation several distinct signaling pathways
including ERK-MAP kinases and Akt are activated in IEC. Proinflammatory stimuli such as
LPS and TNF-α increase CXCL16 mRNA expression. Ileal CXCL16 mRNA expression is
3fold increased in TNF DeltaARE mice compared to wildtype controls (p=0.005). Similarly,
in C57BL/6 mice, colonic CXCL16 mRNA expression increased 1.8fold after 45 hours of
MCMV infection. CXCL16 mRNA expression is also increased in the inflamed colonic mucosa
of CD patients, in which we also found increased CXCL16 serum levels compared to a
control group (4.1 ng/mL vs. 3.5 ng/mL; p=0.006). The CXCL16 p.Ala181Val polymorphism
is associated with significant younger age at disease onset (p=0.016) in homozygous CD
patients and higher frequency of ileal involvement (p=0.024). Carriers of at least one Val
allele and one CARD15 variant had a higher frequency of a stricturing/penetrating phenotype
(p=0.030) and stenoses (p=0.014) compared to patients carrying CARD15 variants only.
Conclusion: CXCL16 expression is increased in murine intestinal inflammation In Vivo and
human IBD. The CXCL16 p.Ala181Val polymorphism is associated with a severe disease
phenotype in CD patients characterized by an early disease onset with ileal involvement.
Further functional studies are required to analyze if this polymorphism inhibits cleavage of
membrane-bound CXCL16 and decreases its antibacterial and chemotactic activity.
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Differences in Mechanisms of Oxidant Production in Esophageal Squamous
Cell Lines from Patients with and Without Barrett's Esophagus
Linda A. Feagins, Hui-ying Zhang, Xi Zhang, Deena Thomas, Lance S. Terada, Stuart J.
Spechler, Rhonda F. Souza
Introduction: Barrett's esophagus frequently is associated with duodenogastroesophageal
reflux (DGER), a condition that can increase the esophageal production of reactive oxygen
species (ROS). In human bronchial epithelial cells, ROS production has been linked to the
development of goblet cell metaplasia. It is not clear why only a minority of patients with
DGER develop Barrett's metaplasia, but phenotypic differences in the response of esophageal
squamous cells to DGER might play a role. We studied the effects of components of DGER
(acid and/or bile salts) on the generation of ROS in telomerase-immortalized, esophageal
squamous epithelial cell lines derived from patients who had GERD with (NES-B3) and
without (NES-G2) Barrett's esophagus. Methods: Equally seeded wells of esophageal squam-
ous cells were incubated with H2DCF-DA, a fluorescent probe activated by ROS, and then
exposed for 3 minutes to: 1) acidic pH 4 media, 2) neutral pH 7.2 bile media containing
200μM of glycochenodeoxycholic acid (GCDA, a conjugated bile salt), or 3) acidic pH 4
bile media containing 200μM of GCDA. Fluorescent intensity of the cells, measured as
relative light units (RLUs), was used for ROS quantification in the presence and absence of
DPI (inhibitor of NADPH oxidase), L-NMMA (inhibitor of NO synthase), and rotenone
(inhibitor of the mitochondrial electron transport chain). Results: After exposure to acidic
bile media, both NES-G2 and NES-B3 cells exhibited a significant increase in ROS production
(0.374±0.03 to 0.526±0.03 and 0.453±0.03 to 0.650±0.02 RLUs, respectively, p<0.05). In
contrast, neither cell line increased ROS production significantly after exposure to either
acidic media alone or neutral bile media. For NES-B3, incubation with DPI before exposure
to acidic bile media blocked the increase in ROS production (0.667±0.05 to 0.731±0.01
RLUs, p>0.05), whereas pretreatment with L-NMMA and rotenone had no significant effects.
For NES-G2, incubation with DPI and L-NMMA before exposure to acidic bile media blocked
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the increase in ROS production (0.260±0.01 to 0.259±0.02 and 0.374±0.03 to 0.370±0.03
RLUs, respectively), whereas pretreatment with rotenone had no significant effects. Conclu-
sions: Telomerase-immortalized esophageal squamous cells exposed to acid and conjugated
bile salts significantly increased their production of ROS. Cells derived from patients with
and without Barrett's esophagus produced ROS through different mechanisms, showing that
patients with and without Barrett's esophagus can have phenotypic differences in the response
of their esophageal squamous cells to DGER. Such differences might contribute to the
pathogenesis of Barrett's metaplasia.
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Stat5 Mediates Platelet-Activating Factor (PAF)-Induced NADPH Oxidase
Nox5s Expression in Barrett's Esophageal Adenocarcinoma Cells
Jin Si, Jose Behar, Jack R. Wands, David Beer, David Lambeth, Y.eugene Chin, Weibiao
Cao
A carcinogenic role of reactive oxygen species (ROS) has been demonstrated in several types
of human cancer. Elevated ROS levels have been reported in Barrett's esophagus (BE) and
in esophageal adenocarcinoma. We have shown that NADPH oxidase NOX5S (S stands for
short, that lacks EF-hand motifs at its N-terminal) is overexpressed in SEG1 esophageal
adenocarcinoma cells associated with BE and in BE with high-grade dysplasia, and that
NOX5S contributes to increased cell proliferation and decreased apoptosis in SEG1 cells.
We have also shown that PAF increases hydrogen peroxide (H2O2) production in SEG1
cells through activation of MAP kinases (ERK1/2, p38), cytosolic phospholipase A2 and
NADPH oxidase NOX5S. In the present study we examined the role of signal transducer
and activator of transcription 5 (STAT5) in PAF-induced NADPH oxidase NOX5S expression
in SEG1 esophageal adenocarcinoma cells. In SEG1 cells, acid treatment significantly
increased PAF production. 10-7M PAF significantly increased NOX5S mRNA expression
and H2O2 production. PAF significantly increased STAT5 but not STAT3 phosphorylation.
Knockdown of STAT5 by STAT5 siRNA in SEG1 cells abolished PAF-induced increase in
NOX5 expression and H2O2 production. The STAT5 binding element TTCTGGTAA (-
2249 to -2241 from ATG) of the NOX5S gene promoter was identified. In chromatin
immunoprecipitation assay NOX5 DNA was detectable in the immunoprecipitated chromatin
sample of SEG1 cell lysate by using a STAT5 antibody, suggesting that STAT5 binds to the
NOX5S promoter. In gel mobility shift assay we found a double-stranded 32P-labelled
oligonucleotide containing STAT5 binding element of NOX5S promoter bound to nuclear
extracts. Competition experiments with unlabelled oligonucleotide significantly reduced
binding, but addition of mutant oligonucleotide had less effect on binding. In the supershift
assay, a supershifted band was detected with a STAT5 antibody but not with c-Myc antibody.
These data suggest that STAT5 binds to the site TTCTGGTAA within the NOX5S promoter
region. To further confirm the role of STAT5 in the NOX5S expression, a NOX5S-promoter
reporter was generated by ligating a NOX5S promoter fragment (-2501 to -1 from ATG)
into the pGL3-basic vector. Overexpression of STAT5 caused 3.3-fold increase in activation
of this luciferase reporter, indicating STAT5 induced activation of NOX5S promoter. We
conclude that in SEG1 cells acid increases PAF production, which upregulates NOX5S
through activation of STAT5. Supported by NIDDK R21 DK073327-01.
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NADPH Oxidase Nox5s Mediates Acid-Induced Cox2 Expression in Barrett's
Esophageal Adenocarcinoma Cells
Jin Si, Xiaoying Fu, Jose Behar, Jack R. Wands, David Beer, Stuart J. Spechler, Rhonda F.
Souza, David Lambeth, Weibiao Cao
Cycloxygenase-2 (COX2) may play an important role in esophageal tumorigenesis since
COX2 is reported to be overexpressed in both metaplastic and adenocarcinoma cells in
Barrett's esophagus (BE) and selective COX2 inhibitors significantly decrease the incidence
of development of esophageal adenocarcinoma in a rat model of BE. How COX2 is upregulated
in BE, however, is unknown. We have shown that the NADPH oxidase NOX5S is overex-
pressed in esophageal adenocarcinoma cells and that acid treatment upregulates NOX5S
through an intracellular Ca2+ increase and activation of cAMP response element binding
protein. In this study we examine the role of NOX5S in the upregulation of COX2. Pulsed
acid treatment significantly increased prostaglandin E2 (PGE2) production and COX2 protein
expression in SEG1 esophageal adenocarcinoma cells. The PGE2 increase was inhibited by
the COX2 inhibitor NS-398, but not by the COX-1 inhibitor valeryl salicylate. The COX2
and PGE2 increases were blocked by removal extracellular calcium, suggesting that acid-
induced COX2 expression and PGE2 production depend on calcium influx. Knockdown of
NOX5S by NOX5 small interfering RNA significantly decreased COX2 expression and PGE2
production in basal condition as well as in response to acid treatment. Knockdown of NF-
κB1 p50 by p50 siRNA significantly reduced acid-induced PGE2 production in SEG1 cells.
Acid treatment significantly decreased IκBα and increased luciferase activity in SEG1 cells
transfected with a NF-κB In Vivo activation reporter plasmid pNF-κB-Luc. In a novel NOX5S
overexpressing stable cell line derived from telomerase-immortalized Barrett's cells, overexpr-
ession of NOX5S in Barrett's cells significantly increased hydrogen peroxide production,
COX2 expression, PGE2 production, and thymidine incorporation. The increase in thymidine
incorporation was significantly decreased by NS-398, but not by valeryl salicylate. Overexpr-
ession of NOX5S significantly reduced IκBα and increased luciferase activity in these Barrett
cells co-transfected with pNF-κB-Luc. We conclude that acid-induced COX2 expression
and PGE2 production depend on an increase in cytosolic calcium and sequential activation
of NADPH oxidase NOX5S and NF-κB. COX2-derived PGE2 production may contribute to
NOX5S-mediated cell proliferation. Supported by NIDDK R21 DK073327-01.
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Effects of Curcuma Aromatica with An Increased MnSOD in Esophageal
Submucosa in a Rat Model of Esophagoduodenal Anastomosis
Yan Li, John M. Wo, Qiaohong Liu, Ruifeng r Su, Mukunda b Ray, Robert c. G. Martin
Background: Gastroesophageal reflux disease (GERD) induces chronic oxidative stress. Accu-
mulating clinical and experimental evidences indicate that antioxidant capacity is depressed
and oxidative injury was increased during the transition from esophagitis to Barrett's eso-
phagus (BE) to esophageal adenocarcinoma (EAC). Curcuma aromatica, a traditional Chinese
herbal medicine, has been described as a potent antioxidant and the ingredients of Curcuma
aromatica have been also shown to display anti-carcinogenic properties in a wide variety of
cell lines and animals. Our previous studies have shown that there is a loss of manganese
superoxide dismutase (MnSOD) in both BE in humans and columnar esophageal epithelium
of rats after esophagoduodenal anastomosis (EDA). The aim of this study was to investigate
Curcuma aromatica effect MnSOD function and thereby prevention against BE and EAC in
a rat EDA model. Methods: EDA was performed on rats and curcuma aromatica oil was
administered (100mg/kg, i.p. every 3 day). Histological changes were determined after EDA
for 1 month, 3months and 6 months. MnSOD protein level and MnSOD enzymatic activity
were evaluated. Lipid peroxidation was determined by TBARs assay and 8-hydroxy-deoxygu-
anosine for DNA oxidative damage was measured by immunohistochemical staining. In
addition, the indexes of both apoptosis and proliferation were determined by PCNA staining
and TUNEL assay, respectively. Results: Severe esophagitis were seen in EDA rats, and
morphological transformation within the esophageal epithelium was observed with intestinal
metaplasia and cancer identified after 3 months. The EDA rats treated with Curcuma aromatica
showed that both MnSOD enzymatic activity and protein level were similar to sham controls.
Curcuma aromatica treated EDA rats demonstrated a significant decrease in oxidative damage,
decrease degree of esophagitis, and decreased incidence of BE and EAC when compared to
the saline treated EDA control. Decreased proliferation and apoptosis were also observed
in Curcuma aromatica treated EDA rats. Conclusions: 1) Curcuma aromatica preventes the
loss of MnSOD in the rat esophageal epithelium induced by oxidative damage. 2) Curcuma
aromatica may prevent the transformation of esophageal epithelial cell to BE to EAC by
preservation of MnSOD. 3) Further studies are underway to explore the potential anti-
carcinogenic mechanism of Curcuma aromatica.
Enzymatic activities of SOD (mean ± SD)
* P<0.05 VS sham.
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Th1 Immune Status in Patients Is Associated with An Increased Risk for
Barrett's Esophagus
V. Menke, A. Capello, J. G. Kusters, P. M. Van strien, L. M. Moons, R. R. Sital, R. W. De
bruin, E. J. Kuipers, P. D. Siersema
Background: The transition from reflux esophagitis (RE) to Barrett's esophagus (BE) is
associated with a shift of the cellular (Th1) towards the humoral (Th2) immune response.
These findings suggest that a Th1 response is involved in BE development, whereas a Th2
response is more important to maintain the chronic status of BE. Aim: To determine the
function of the immune responses (Th1 versus Th2) for the initiation and chronic phase of
BE. Methods: Duodenal reflux was induced by gastrectomy with esophagojejunostomy (GEJ)
in 7 week-old male Lewis rats (predisposition for a Th1 response; n=18), Brown Norway
(BN) (predisposition for a Th2 response; n=18), and Wistar rats (predisposition for Th1/
Th2 response; n=18). Rats were sacrificed at 6 time-intervals until 6 months after GEJ.
Metaplasia and inflammation in the esophagus were determined by HE staining and immuno-
histochemistry with the markers CD63 and CD168 (macrophages), CD3 (T cells), CD8
(cytotoxic T cells), CD45RA (B cells), CDX2 (intestinal epithelium), and PAS (goblet cells).
Results: At 2 wks post GEJ, histological examination revealed that all strains had developed
esophageal hyperplasia and severe esophagitis, characterized by the influx of macrophages
and CD8+ T cells. At 5 wks BE (PAS and CDX2 expression) was observed in the distal
esophagus of BN and Lewis rats. At 9 wks, all strains had developed BE in the distal esophagus,
and hyperplasia with ulceration was observed throughout the proximal esophagus. Lewis
rats contained the highest concentration of T and B cells. At 12 weeks, the BE segment was
enlarged in Lewis and BN rats. The acute and severe ulceration of the proximal esophagus
was characterized by the influx of large numbers of macrophages and T cells, while the
inflammation of the BE segment was more chronic involving many B cells. After 6 months,
all strains had developed a BE segment in the distal esophagus, but BE was most advanced
in the Th1 prone Lewis rats, where a patchy pattern of BE extended throughout the whole
length of the esophagus. Conclusions: Prior to BE development, even Th2 prone rats develop
a Th1 inflammatory response, and vice versa, Th1 prone rats display a Th2 type reaction
in the BE segment. The Th1 immune status of Lewis rats results in a faster development of
BE. This suggests that patients with a Th1 immune status are more susceptible for the
development of BE.
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Role of Klf in Neoplastic Progression in Barrett's Esophagus
Navtej Buttar, Cathrine Demars, Malini Madhavan, Vidu Mokkala, Martin E. Fernandez-
zapico, Kenneth K. Wang, Lori S. Lutzke, Raul A. Urrutia
BACKGROUND: Chronic reflux is implicated in the development of adenocarcinoma in
Barrett's mucosa. Contents of reflux activate PGE2 synthesis, which is closely associated
with neoplastic transformation. Cytosolic phospholipase A2α (cPLA2α) is the key regulatory
enzyme that provides substrate for prostaglandin E2 (PGE2) synthesis. The promoter region
of cPLA2α has GC-rich regions to which the members of SP/KLF (stimulatory protein/
Kruppel like factors) family of transcription factors can bind. AIM: 1) To examine the
expression, 2) effect on PGE2 synthesis & 3) functional relevance of SP/KLF in the process
of carcinogenesis in Barrett's mucosa. METHODS: RNA was extracted from mucosal biopsies
from patients with premalignant & malignant changes in Barrett's mucosa. SP/KLF expression
was assessed using PCR. The distinct members that showed altered expression during
neoplastic progression were selected for further analysis. Anti-cPLA2 antibody was used for
IHC on endoscopic mucosal resection specimens from patients with premalignant & malig-
nant changes in Barrett's mucosa. Molecular links between distinct SP/KLF family members
& The PGE2 synthesis pathway (& their functional relevance) were assessed by the following
methods using a gain or loss of function approach: cPLA2 promoter reporter constructs,
PGE2 levels & cell proliferation/apoptosis of Barrett's epithelial cells. RESULTS: There was
a profound loss of KLF11 expression in cancer samples compared to premalignant samples.
The expression of cPLA2, the key regulator of the PGE2 biosynthetic pathway, progressively
increased in Barrett's mucosa during neoplastic transformation. Restoring KLF11 expression
in malignant adenocarcinoma cells not only repressed the promoter activity of cPLA2α by
60% (p<0.05), but also down-regulated PGE2 production by 86% (p<0.05). KLF11 behaved
like a tumor suppressor since restoring its expression in malignant cells decreased prolifera-
tion by 50% (p<0.05) & increased apoptosis by 88% (p<0.05). It also up-regulated the
expression of novel growth regulatory genes, RANKL & MAD2L1. CONCLUSION: The loss
of KLF11 expression & The effect of KLF11 on the PGE2 synthesis pathway & cell growth
suggests that KLF11 behaves like a tumor suppressor. Further mechanistic & in-vivo studies
are underway to better understand the importance of KLF11 in Barrett's esophageal carcino-
genesis.
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Fusion of Proinsulin-Producing Bone Marrow-Derived Cells with Hepatocytes
in Diabetes
Mineko Fujimiya, Hideto Kojima, Lawrence Chan
We previously reported that diabetes in mice is associated with the appearance of proinsulin-
producing (Proins-P) cells in the liver (Proc Natl Acad Sci USA 101: 2458-2463, 2004). It
was unclear, however, whether these Proins-P bone marrow-derived cells (BMDC) merely
transit through the liver or undergo fusion with hepatocytes, an extremely rare event,
estimated that transplanted BMDC generate hepatocyte-like cells in the liver at a frequency
of <10-4. In this study, we found that in diabetes BMDC in the liver produce not only
Proins, but also Tnf-a, suggesting that diabetes reprograms gene expression in BMDC, turning
on “inappropriate” genes. Bone marrow transplantation (BMT) using genetically marked
donor and recipient mice showed that fusion occurs between Proins-P BMDC and hepato-
cytes. Cell fusion is further supported by the presence of the Y chromosome in Proins-P
cells in female mice that received male BMT cells. Morphologically, Proins-P fusion cells
are albumin-producing hepatocytes that constitute ~2.5% of the liver section area 5 months
after diabetes induction. We found that indeed fusion occurs between BMDC and hepatocytes
in diabetic mice with a frequency that is at least >100-1,000 fold higher than that in
nondiabetic controls. Thus, diabetes, a common pathological condition, produces major
perturbations in the behavior of BMDC that may have significant pathophysiological implica-
tions.
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Role of the Bhmt and Betaine System in Alcoholic and Non-Alcoholic
Hyperhomocysteinemia and Liver Steatosis
Cheng Ji, Masao Shinohara, John Kuhlenkamp, Christine Chan, Tin aung Than, Neil
Kaplowitz, Zhaoyu Li, Dennis e. Vance
BACKGROUND: The mechanisms by which the betaine and BHMT (betaine-homocysteine
methyltransferase) system protects against alcoholic or non-alcoholic hyperhomocysteinemia
and liver steatosis were investigated. METHODS: BHMT transgenic HepG2 and murine
models were generated. Comparisons were made between the transgenic and wild type in
their response to homocysteine, intragastric ethanol infusion, or feeding of a diet of high
methionine low folate (HMLF). RESULTS: The transgenic BHMT slightly increased apolipop-
rotein B (ApoB) expression in HepG2 cells and protected the cells from homocysteine (Hcy)-
induced ER stress and cell death. Suppression of BHMT by siRNA in mouse primary
hepatocytes worsened Hcy-induced cell injury. The BHMT transgenic mice appeared normal
in terms of ALT value, plasma Hcy and liver lipid. Ethanol feeding increased plasma Hcy
by 5 fold in wild type but by 3 fold in the transgenic mice. HMLF feeding increased the
Hcy by 21 fold in wild type but by 15 fold in the transgenic mice. In the presence of betaine
supplement, Hcy levels were normal in the transgenic mice fed HMLF or ethanol. Liver
triglycerides were increased in both HMLF fed (57±6 vs. control 23±2 mg/g liver) and
ethanol fed wild type (92±7 vs. control 23±3 mg/g liver). Transgenic BHMT reduced the
liver triglycerides by 30% and by more than 90% in the presence of betaine supplement.
Similar reduction of the liver cholesterol was observed. The ratios of S-adenosylmethionine
(SAM) to S-adenosylhomocysteine (SAH) and phosphatidylcholine (PC) to phosphatidyle-
thanolamine (PE) were reduced in both genotypes fed ethanol. Betaine supplement increased
SAM/SAH by 2 fold in the mice fed HMLF and by 4 fold in the mice fed ethanol, and
corrected the ethanol-induced reduction of PC/PE ratio. Liver glycine N-methyltransferase
(GNMT) mRNA was reduced in mice fed ethanol but not in mice fed HMLF. mRNA of
ApoB and LDL receptor 1 (LDLR1) was enhanced in the transgenic mice and betaine
supplement increased ApoB expression in the transgenic mice fed HMLF or ethanol. CON-
CLUSIONS: The BHMT and betaine system protects against diet or ethanol induced hyperho-
mocysteinemia and liver steatosis through multiple mechanisms including lowering Hcy,
increased SAM/SAH and PC/PE ratios as well as increased expression of ApoB which involves
in hepatic lipid secretion. (*Supported by NIDDK grant P30DK048522 and NIAAA grant
R01 AA014428).
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Unesterified Cholesterol Accumulation Within the Lysosomal Compartment
Dictates Liver Damage in Niemann Pick Type C Disease
Benny Liu, Eduardo P. Beltroy, Stephen D. Turley, John M. Dietschy
Introduction: Niemann Pick type C (NPC) disease is a disorder involving intracellular
cholesterol trafficking characterized by the accumulation of cholesterol within the lysosomal
compartment of every tissue. Significant liver dysfunction is frequently seen in patients with
this disease. Aim: To investigate the association between liver dysfunction and the lysosomal
accumulation of unesterified cholesterol using a NPC mutant mouse (npc1-/-) model by
manipulating the enterohepatic flux of cholesterol. Methods: In one study, npc1-/- and
control (npc1+/+) mice were fed chow diets containing 0.02% or 0.2% cholesterol, or 1%
cholesterol + 10% olive oil. In a parallel study npc1-/- mice on either the 0.02% cholesterol
or 1% cholesterol + 10% olive oil diet were also given ezetemibe (EZE) (20 mg/kg/day), a
potent inhibitor of intestinal sterol absorption. Mice were started on their respective diets
at 35 days of age and studied at 56 days at which time liver cholesterol content and liver
function tests were determined. Results: In npc1-/- mice fed 0.02% cholesterol, total liver
cholesterol content at 56 days was 31.1mg (vs 2.8 mg in npc1+/+controls) with ALT and
AST activities (u/L) of 308 and 580, respectively (vs ALT 26, AST 50 in npc1+/+ controls).
In npc1-/- mice fed 0.2% cholesterol, liver cholesterol content increased to 54.9 mg (ALT
436, AST 741). The 1% cholesterol + 10% olive oil diet further raised the total liver cholesterol
content in npc1-/- mice to 99.4 mg (ALT 1527, AST 1201). EZE lowered total hepatic
cholesterol content of npc1-/- mice on 0.02% cholesterol and 1% cholesterol + 10% olive
oil to 20.8 mg (ALT 224, AST 475) and 24.9 mg (ALT 301, AST 456), respectively. In
npc1-/- mice, the hepatic cholesterol accumulation was essentially all unesterified. In contrast,
npc1+/+ mice fed a 1% cholesterol + olive oil diet had total liver cholesterol contents similar
to npc1-/- fed a 0.02% cholesterol diet, however, essentially all was esterified and LFT's
were normal. Conclusion: In npc1-/- mice, the cholesterol accumulation occurs within the
lysosomal compartment and is almost entirely unesterified. In contrast, the cholesterol
accumulation in npc1+/+ occurs within the cytosolic compartment and is predominantly
esterified. These studies suggest it is the accumulation of unesterified cholesterol within the
lysosomal compartment that leads to hepatocyte damage and liver dysfunction in NPC
disease. Agents such as EZE which prevent intestinally derived cholesterol from reaching
and accumulating in the liver may prove therapeutic in treating NPC associated liver disease.
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Feeding Mice a High-Fat High-Caloric Diet Activates the Hepatic Endoplasmic
Reticulum (ER) Stress Response
Mohammad shadab Siddiqui, Richard Moseley, Richard M. Green
Non-alcoholic steatohepatitis (NASH) is associated with insulin-resistance, obesity, hepatic
steatosis and other components of the metabolic syndrome. These factors have recently been
shown to induce endoplasmic reticulum (ER) stress due to the accumulation of misfolded
proteins in the ER. The cellular response to ER stress includes the activation of a specific
cellular response known as the ER stress response or unfolded protein response (UPR). In
addition, we have shown that feeding mice a High-Fat, High-Caloric (HFHC) diet causes
obesity, hepatic steatosis and insulin-resistance. Aim: Thus, the purpose of this study is to
determine whether feeding mice a HFHC diet will activate the ER stress response. Methods:
Four inbred strains of mice (A/J, AKR/J, Balb/cJ, C57BL/6J) were fed a HFHC diet (60%
calories from fat) or chow for 16 weeks and the expression and phosphorylation status of
ER stress proteins were analyzed using Western immunoblotting. Results: The phosphorylated
(active) form of PERK (p-PERK) was increased approximately 10-fold in all murine strains
fed the HFHC diet, while non-phosphorylated PERK was essentially non-detectable. Non-
phosphorylated JNK was also essentially non-detectable in HFHC diet fed mice, while p-
JNK was abundantly expressed. The ER stress protein ATF-6 was highly expressed in HFHC
diet fed mice, compared to chow-fed mice. No increases of p-eIF2a were noted with HFHC
feeding, while non-phosphorylated e-IF2a was reduced. Conclusion: Mice fed the HFHC
diet have markedly increased expression of p-PERK, p-JNK and ATF-6, indicating activation
of the ER stress response. We speculate that this cellular stress pathway that is activated in
obesity and insulin-resistant models may be important in the pathogenesis and progression
of NASH.
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Apobec-1 Complementation Factor (ACF), An Au-Rich RNA Binding Protein
Member of the Hnrnp Family Is Required for Liver Regeneration
Valerie Blanc, Susan Kennedy, Nicholas O. Davidson
Apobec-1 complementation factor (ACF) is a high affinity AU-rich RNA binding protein
with homology to HuR and other members of the hnRNP multigene family. ACF is the RNA
binding subunit of the mammalian apoB mRNA editing enzyme with a wide tissue distribu-
tion. However while targeted deletion of the catalytic subunit apobec-1 is tolerated, germline
deletion of ACF results in embryonic lethality. ACF ko mutants developed only until E4
and isolated ACF ko blastocysts failed to proliferate In Vitro. siRNA knockdown of ACF in
hepatoma cells (HepG2) decreased cell growth and induced apoptosis. This suggests that
ACF regulates gene targets required for growth and development. We now examined whether
ACF expression is important for the adaptive response to 70% partial hepatectomy (PH) by
comparing ACF heterozygous (het) and littermate (WT) controls. There was a significant
decrease in hepatic proliferation (BrdU) in ACF het compared to WT at all time points.
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This reduced proliferation correlated with a delay in the liver mass recovery. WT livers
reached their original mass 36-to 48 hr post-PH, whereas, ACF het livers recovered their
original mass at 72 hr. This suggests that ACF is recruited early in liver regeneration. We
next sought to understand the possible range of RNA targets that might be involved in ACF-
mediated regulation of the response to PH. We first examined the induction of IL6 and
activation of downstream targets (JunB and STAT3), since activation of the tumor necrosis
factor-alpha-IL6 cytokine signaling pathway is required to induce hepatocyte proliferation.
These data showed increased IL6 mRNA expression in WT mice, maximal at 4-6 hr after
PH. In ACF hets IL6 mRNA fails to increase and was significantly reduced 4 hr post-PH,
resulting in the lack of induction of JunB and STAT3 mRNA expression. In addition, livers
from ACF hets failed to up-regulate p21 mRNA 4 hr post PH, preventing early assembly
of the cyclin /CDK complexes. p21 mRNA induction was abrogated in ACF hets and delayed
to 24hr. Since IL-6 and p21 mRNAs both contain AU-rich 3'UTRs, we examined RNA
binding to ACF. In Vitro cross-linking indicated that ACF binds IL-6 and p21 3'UTRs, with
localized high affinity regions suggesting that ACF participates in liver regeneration by
binding to and modulating the stability of RNAs encoding early recruited factors, particularly
IL-6 and p21. These two RNAs constitute the first identified targets recognized by ACF
beyond apoB mRNA editing. In addition, this is the first example of an RNA binding protein
that regulates the hepatic regenerative response to PH.
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High-Normal ALT Levels Are Associated with Long-Term Risks of Metabolic
Syndrome and Diabetes: The Framingham Heart Study
Wolfram Goessling, Joseph M. Massaro, Ramachandran S. Vasan, R. curtis Ellison,
Caroline S. Fox
Background: NAFLD has been increasingly recognized as the hepatic manifestation of the
metabolic syndrome (MetS), which is closely related to incident obesity, type 2 diabetes
(DM), and cardiovascular disease (CVD). Long-term data regarding the predictive value of
high-normal aminotransferase levels in the development of MetS, DM, CVD, and all-cause
mortality are limited. Methods: Participants from the Framingham Heart Study (n=2488,
mean age 44 years, 59% women) who attended an examination between 1978-1982, had
ALT and AST values < 40 U/L, and were free of excess alcohol use or incident conditions,
were followed for the 20-year development of obesity (n=197), MetS (n=242), DM (n=47),
CVD (n=113), or all cause-mortality (n=53) using logistic regression (MetS, DM) or Cox
proportional hazards models (CVD, all-cause mortality) comparing the risk of an event per
1 sex-specific standard deviation (SD) increase in AST or ALT; AST and ALT were log-
transformed prior to analysis. Obesity was defined as a BMI ≥ 30 kg/m2, MetS was based
on ATPIII criteria, DM defined by fasting plasma glucose ≥ 126 mg/dl or DM treatment.
CVD events were adjudicated by a 3-physician panel. Models were adjusted for age, sex,
smoking, menopause, and alcohol intake. DM models were additionally adjusted for BMI;
CVD models were adjusted for cardiovascular risk factors. Results: Mean (SD) AST was 18
(7) U/L and ALT was 21 (8). There was no association between AST and any of the outcomes
of interest (Table). Per 1 SD increase in ALT, there was a 1.17-fold increase in the odds of
MetS, and a 1.34 increase in the odds of DM. ALT was inversely associated with the
development of obesity. Significant associations were not observed with CVD or all-cause
mortality. Conclusion: ALT is associated with long-term development of multiple metabolic
abnormalities even within the normal range. These results suggest the need for reevaluation
of the upper limit of normal ALT values with respect to metabolic risk.
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Intestinal Alkaline Phosphatase: A Newly Recognized Gut Mucosal Defense
Factor
Ross F. Goldberg, Shaluk Biswas, Golam Mostafa, Xiao bo Zhang, Madhu S. Malo, Jose
Millan, Richard A. Hodin
Introduction: Intestinal alkaline phosphatase (IAP) is a small intestinal brush border enzyme
that has been reported to detoxify lipopolysaccharide (LPS). We explored the possible role
of IAP as a gut mucosal defense factor. Methods: In Vitro studies: HT-29 cells were stably
transfected with a human IAP expression plasmid and clones selected through a G418
selection process. IAP expression was confirmed by RT-PCR and enzyme assay. Wild-type
(WT) and IAP overexpressing cells (IAP cells) were examined under basal conditions, and
WT cells were also treated with sodium butyrate (NaBu), a short chain fatty acid that
induces endogenous IAP expression. Cell lysates and conditioned media were assayed for
LPS dephosphorylating activity using a malachite green-based phosphate detection kit. IAP
activity was assessed using pNPP as the substrate. In Vivo studies: IAP knockout (KO) and
WT mice were randomized to I/R (ischemia/reperfusion) (45-minutes gut ischemia by SMA
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clamping), sham (midline laparotomy with no ischemia) or control (no surgery performed)
group (n = 5), and reperfusion carried out for 48 h. After sacrifice, mesenteric lymph nodes
were harvested, homogenized in antibiotic-free broth, and assayed for bacterial growth.
Results: Sodium butyrate induced a time-dependent increase in alkaline phosphatase expres-
sion (18-fold increase at 24 h in cell lysates). Lysates of the IAP cells also showed a high
amount of AP activity (22-fold increase in IAP compared to parent cells). IAP was secreted
into the conditioned media in both cell lines, with an approximate 10-fold higher IAP
activity in the NaBu-treated HT-29 and IAP cells compared to parent cells. Lysates as
well as conditioned media obtained from NaBu-treated HT-29 and IAP cells effectively
dephosphorylated LPS. Following gut I/R injury, there was a dramatic increase in bacterial
translocation (CFU/g of tissue) at 48 h in IAP KO mice compared to their WT littermates
(46,849 vs. 17,276). Conclusions: We have shown for the first time that IAP made within
an intestinal cell is able to detoxify LPS. In addition, based upon our In Vivo data, it appears
that endogenous IAP is a critical and previously unrecognized component of the gut mucosal
defense system.
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A Novel Role for Defensins in Intestinal Homeostasis: Regulation of IL-1β
Secretion
Jishu Shi, Shelly Aono, Wuyuan Lu, Andre J. Ouellette, Xueyou Hu, Yingbiao Ji, Lei
Wang, Stephen Lenz, Christine Dykstra, Edward Morrison, Charles O. Elson
Impaired expression of antimicrobial peptidesα-defensins and over-production of proinflam-
matory cytokine IL-1β have been associated with inflammatory bowel disease (IBD). In this
study, we examine the interactions between defensins and IL-1β and the role of defensin-
deficiency in the pathogenesis of IBD. It was found that matrix metalloproteinase-7 deficient
(MMP-7 KO) mice, which produce procryptdins but not mature cryptdins (α-defensins)
in the intestine, were more susceptible to dextran sulfate sodium (DSS)-induced colitis.
Furthermore, the baseline and DSS-induced IL-1β production in the intestine are significantly
up-regulated in MMP-7 KO mice compared with that in WT mice. To elucidate the molecular
mechanism for the increased IL-1β production in defensin-deficiency In Vivo, we evaluated
the effect of defensins on IL-1β posttranslational processing and release. It was found that
α-defensins, including human neutrophil defensin HNP-1, human Paneth cell defensin HD-
5, and mouse Paneth cell defensins cryptdin-3 and cryptdin-4, can block the release of IL-
1β from LPS-activated monocytes. However, TNF-α expression and release from LPS-
activated monocytes are not affected by defensins. Unlike α-defensins, human α-defensins
and mouse procryptdins do not have any effect on IL-1β processing and release. Thus, α-
defensins may play an important role in intestinal homeostasis by controlling the production
of IL-1β.
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Toll-Like Receptor 2 Is Involved in Clostridium difficile Toxin a Signaling
Pathway in Colonic Epithelial Cells
Xi Na, Charalabos Pothoulakis, J. thomas Lamont
Background & Aims: C difficile, the causative organism of antibiotic-associated colitis,
produces a colitis characterized by an intense neutrophilic infiltrate and release of inflammat-
ory cytokines. We have recently shown that Gp96 serves as a receptor for C. difficile Toxin
A (TxA) on the cell surface of colonocytes where it facilitates toxin internalization and
subsequent cytotoxicity. Gp96 is a member of the Heat Shock Protein 90 family and interacts
with the Toll-like receptor (TLR) pathway. Intestinal epithelial cells express several TLRs,
including TLR2. Stimulation with TLR2 ligands led to activation of specific Protein Kinase
C isoforms (PKC-α and PKC-σ). Our group has reported the activation of PKC-α in response
to TxA exposure. In this study we further evaluated the role of TLR2 and activation of PKC-
σ following TxA exposure in human colonic HT29 cells. Methods: HT-29 cells were exposed
to TxA and the expression of TLR2 was examined by immunofluorescent staining. The
interaction between TLR2 and Gp96 was evaluated by co-immunoprecipitation, and phos-
phorylation status of PKC-σ was measured by Western-blot analyses. TLR2 neutralizing
antibody was used to determine the involvement of TLR2 in TxA-mediated signaling. TxA
mediated IL-8 secretion from colonocyte cultures was measured by enzyme-linked immuno-
sorbent assay. Results: TLR2 expression was markedly increased in HT 29 cells after 30
minutes of TxA (10 nM) exposure, and this increase was largely blocked by Gp96 antibody
(40 μg/ml), but not control IgG. TLR2 was found interacting with Gp96 in HT29 cells, and
more TLR2 was recruited into the Gp96 complex with TxA (10 nM) exposure. PKC-σ
phosphorylation levels increased after 1 hour of TxA (10 nM) exposure and remained
elevated for 4 hours, and this increase was blocked by neutralizing antibodies against TLR2
(20 ug/ml) but not control IgG. Increased secretion of IL-8 was detected 6 hours after TxA
exposure and peaked at approximately 18 hours. TLR2 neutralizing antibody inhibited TxA-
mediated IL-8 secretion in a similar fashion as rottlerin (a PKC-σ inhibitor). Conclusions:
We report that TLR2 is involved in C. difficile TxA mediated PKC-σ signaling cascade through
association with plasma membrane Gp96, a putative TxA receptor on the human colonocytes.
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Helicobacter pylori Effector Protein Caga Activates the Signal Transducer and
Activator of Transcription 3 (STAT3) Signaling Pathway: A Potential
Mechanism for Gastric Cancer Development
Dana Bronte-tinkew, Mauricio Terebiznik, Diane Ahn, Hitomi Mimuro, Chihiro Sasakawa,
Richard M. Peek, Nicola L. Jones
Infection with CagA positive Helicobacter pylori strains enhances the risk for gastric cancer
development. However the underlying mechanism(s) whereby this bacterium promotes
carcinogenesis remains unknown. Recent evidence indicates that aberrant activation of the
STAT3 signaling pathway may play a role in the development of gastric cancer. Therefore,
we hypothesized that H. pylori infection modulates STAT3 signaling. In epithelial cells,
H. pylori infection activated STAT3 as assessed by immunoblotting for phospho-STAT3,
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fluorescence recovery after photo-bleaching in STAT3-GFP transfected cells and luciferase
activation in cells transfected with a STAT3 reporter construct. Activation was dependent
on translocation of CagA into host cells since isogenic mutants of CagA or the type IV
secretion system, which are unable to inject CagA, failed to activate STAT3. However,
tyrosine phosphorylation of CagA was not required as infection with a CagA mutant (EPISA)
unable to undergo tyrosine phosphorylation still activated STAT3. Activation appeared to
occur at the receptor level since pre-incubation of cells with the superantagonist sant7
or gp130 mAb prevented H. pylori-mediated STAT3 activation. However, activation was
independent of IL-6 as pre-incubation with a neutralizing anti-IL-6 antibody failed to block
STAT3 activation. H. pylori also activated STAT3 In Vivo in a relevant animal model of H.
pylori-mediated gastric carcinogenesis. Gastric tissue lysates obtained from Mongolian gerbils
infected with the carcinogenic H. pylori strain 7.13, displayed increased phospho-STAT3.
In marked contrast, phospho-STAT3 was not detected in gastric tissue from uninfected
gerbils. Taken together, these results indicate that H. pylori activates the STAT3 signaling
pathway both In Vitro and In Vivoproviding a potential mechanism by which chronic H.
pylori infection promotes the development of gastric cancer.
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E. coli-Secreted Protein F/Sorting Nexin 9 Interaction Is Required for Efficient
Invasion of Epithelial Cells By Enteropathogenic E. coli
Andrew Weflen, Neal M. Alto, Athanasia Koutsouris, Cheri Lazar, Matthew J. Rardin, V.
K. Viswanathan, Gail A. Hecht
Diarrhea caused by enteropathogenic E. coli (EPEC) is a significant source of infantile
morbidity and mortality worldwide. Major events during EPEC pathogenesis include intimate
adherence to intestinal epithelial cells and subsequent injection of bacterial effector proteins
directly into the cytosol via a type three secretion system (T3SS). EPEC has also been shown
to invade epithelial cells. Several phenotypes, including tight junction disruption, have been
attributed to E. coli-secreted protein F (EspF). The C-terminus of EspF consists of three
nearly identical 44-48 amino acid repeats harboring proline-rich domains (PRDs). PRDs
within eukaryotic proteins interact with Src-homology 3 (SH3) domains. A yeast two-hybrid
screen confirmed a previous report that EspF interacts with the host cell protein sorting
nexin 9 (SNX9). SNX9 is involved in dynamin activation and clathrin-mediated endocytosis.
The interaction between the PRDs of EspF and the SH3 domain of SNX9 was confirmed
by co-immunoprecipitation and GST pull-down assays. To identify residues critical for this
interaction, 15aa peptides spanning the PRDs of EspF were synthesized and scanning Asp
point mutations introduced. Mutation of a critical Arg within EspF PRDs ablated the SNX9
interaction. Corresponding Arg to Asp point mutations were introduced into a full-length
EspF construct, which was transformed into an EspF-deficient strain (ΔespF). The resulting
strain (R3D3) was then exploited to determine if EspF/SNX9 interaction was required for
EPEC-induced loss of barrier function or invasion of epithelial cells. As measured by the
percentage drop in transepithelial electrical resistance of CaCoE monolayers over a six-
hour infection, loss of barrier function induced by R3D3 (-47.38+1.17%; n=13) was not
significantly different from wt (-47.74+2.40%; n=7; p=0.88) or pespF (-43.79+1.34%; n=4;
p=0.09). HeLa cells were subjected to gentamicin protection assays to test the invasiveness
of EPEC strains. Intracellular EPEC are represented as a percentage of total cell-associated
bacteria. As compared to wt (10.08+1.62%; n=9), both ΔespF (1.74+0.17%; n=9; p<0.0001)
and R3D3 (4.50+0.51%; n=9; p<0.005) were significantly attenuated for invasion. The
invasive rate of pespF was comparable to that of wt (10.39+1.71%; n=9; p=0.90). In summary,
our data show that the EPEC effector protein EspF interacts with the host protein SNX9
via a specific PRD/SH3 interaction. This interaction is dispensable for EspF-induced TER
loss, however, it enhances EPEC invasion of epithelial cells. To our knowledge, this is the
first report showing that EspF and SNX9 play a major role in bacterial invasion.
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Extracellular Matrix Proteoglycan Lumican Regulates Innate Immune
Response Via the CD 14-TLR4 Pathway
Shukti Chakravarti, Feng Wu, Luke Roberts
Aim: Lumican (Lum) is an extracellular matrix (ECM) keratan sulfate proteoglycan of the
LRR superfamily, found in barrier tissues such as the cornea, skin and intestinal submucosa.
Here we elucidated a mechanism of regulation of host innate immune response to the gram-
negative bacterial cell wall endotoxin, lipopolysaccharide (LPS) by ECM lumican. Methods:
Lum expression in Lum+/+ macrophages (MΦ)was tested by qRT-PCR and ELISA. Mice
were given intraperitoneal injections of E. coli LPS (16.7μg/g body weight) and survival
followed over 6 days. Serum cytokine levels were measured after 36 hrs with a Beadlyte®
Mouse Multi-Cytokine Flex Kit(Upstate Biotechnology). To test innate immune response in
culture eicited peritoneal MΦ were treated with LPS (0 to 10ng/ml) or a panel of other
PAMPS and tested for induction of TNFα and IL6. Activation of NF-κB in response to LPS was
tested in Lum+/+ and Lum-/-bone marrow-derived MΦ by EMSA. His-tagged recombinant
lumican (rLum) prepared in the pSecTag2 expression system in Hek293 cells (Invitrogen)
was used to test (1) binding with fluorescent FITC-LPS in solid phase, (2) binding with
CD14 in pull down assays, and (3) rescue of innate immune response in Lum-/- MΦ in
culture. Results: qRT-PCR and Elisa indicated induction of Lum transcript and protein in
Lum+/+ MΦ after LPS treatment. Compared to Lum+/+ mice, Lum-/- showed increased
survival in response to a systemic challenge of LPS with lower levels of TNFα, IL-1β, IL-
6, IL-12, GM-CSF and IL-10 in the serum. Lum-/- MΦ treated with a set of PAMPS, showed
lower than normal TNFα induction specifically in response to LPS. Activation of NF-κB in
response to LPS was delayed in Lum-/- MΦ while, LPS-mediated TNFα induction could be
partially rescued with rLum. In Vitro rLum bound FITC-LPS. To test the binding of lumican
to CD14, Hek 293 rLum were co-cultured with 293-mTLR4/MD2-CD14(Invivogen) cells.
The his-tagged rLum in the medium was purified on an affinity column, CD14 bound to
rlum was detected by western blotting. Immunohistology of Lum+/+ peritoneal MΦ indicated
the presence of lumican on the surface and in a cell adhesion assay exogenous rLum was
found to bind Lum-/- MΦ. Conclusion: Lumican-deficiency leads to poor LPS-sensing in
whole animals and primary MΦ. The results suggest that lumican is sequestered in the MΦ
pericellular ECM where it binds CD14 and LPS and facilitates it presentation to the LPS-
signaling pathway. Our study uncovers a novel role for an ECM protein in host response
to bacterial pathogen. Its role in host-pathogen interactions in the intestinal submucosa is
currently under investigation.
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Quantitative Involvement of Duodenal, Portal and Cerebral Nutrient Sensing
Towards Food Intake Control
Jihane Boubaker, Alain Chauvin, Sylvie Guérin, Charles-henri Malbert
Control of food intake originates primarily from three different areas including the brain,
the portal vein and the gut. Various nutrients have been shown to activate each of these
areas that in turn provide signals to reduce ingestion. The aim of our study is to evaluate
the quantitative role of these primary sensors towards eating behavior. To achieve our goal,
our strategy was to infuse glucose, lipids or amino-acids either in the brain blood supply,
the portal vein or the gut lumen while recording food intake pattern. Six 30 kg pigs were
surgically fitted with duodenal, carotid and portal catheters. Glucose (G, 20%), Intralipid
(IL, 20%), or a mixture of amino-acids (N, Nutrilamine 9S) were injected in either of these
three sites in an isocaloric manner (240 calories.kg-1.min-1) during 10 minutes before the
meal. This administration rate was selected based on a preliminary experiment (3 animals)
to avoid a significant increase in peripheral venous concentration of either glucose, triglycer-
ides and alpha-amino acids. The 2200g-test meal was presented for 30 minutes to evaluate
the microstructure of the meal. The trough is attached to a weighting strain gauge allowing
permanent tracking of the ingestion speed and number/duration of non-ingestion periods
within the meal. p<0.05 is considered as statistically significant The total amount of food
ingested was significantly reduced for IL administration within the duodenum (53 ± 8.6 vs
65 ± 2.5 g.kg-1BW) and for G administration either intra-portal (59 ± 3 vs 71 ± 0.2 g.kg-
1BW) or within the duodenum (61 ± 4.0 vs 69 ± 2.7 g.kg-1BW). This was related to a
significant decrease in ingestion speed during the first 10 minutes of the meal for IL and
G infusions. For G infusions only, this reduction persisted during the entire meal period.
Furthermore, duodenal IL significantly increased non-ingestion duration (18 ± 3.2 vs 13 ±
0.2 min); an effect not observed for G administration. Finally, no significant change in food
intake behavior was observed for N infusion irrespective of the administration route. In
conclusion, nutrient sensing for IL is probably located within the duodenum since intraduod-
enal but not carotid or portal infusions altered food intake. On the contrary, nutrient sensing
for G is likely within the portal vein since intraduodenal and intraportal infusions were
equally effective to reduce food intake. Finally, within the concentration limits used in our
study, N did not participate significantly to short-term control of food intake.
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Effect of Degree of Saturation of Triacylglycerols On Ileal Brake and Satiety
Jeroen Maljaars, Edward Haddeman, Harry Peters, Ad A. Masclee
It has previously been shown that ileal delivery of small amounts of fat decreases appetite
and food intake through activation of the ileal brake. The degree of saturation of triacylglycer-
ols, when administered in the duodenum influences cholecystokinin (CCK) secretion and
subsequent food intake. To assess whether the degree of saturation also influences the
potency of fat to activate the ileal brake, we performed a double-blind randomized cross-
over study in which the effect of varying degrees of saturation of triacylglycerols on ileal
brake and satiety was evaluated. Fifteen healthy subjects (mean age:24 yrs, mean BMI 22
kg/m2) were intubated with an oro-ileal catheter and participated in four experiments
performed in random order on 4 consecutive days. After consumption of a fat-free meal
(180 kcal) volunteers received 6 gram of fat in the ileum perfused over a 60 min period
scheduled at the time of regular activation of the ileal brake in the physiological postprandial
state, that is from 105-165 min after ingestion of the meal. Fat emulsions consisted of either
saline (control), shea (18:0), high-oleic rapeseed (18:1), or safflower (18:2) oil. Food intake
was measured during an ad-libitum lunch at t=240 min. Satiety scores were collected at
regular intervals by line scales. Blood was sampled for determination of CCK, and PYY, the
latter as an indicator for ileal brake-activity. Compared to control, scores for fullness were
significantly (p<0.05) higher versus control only after the 18:2 and 18:1 oils, while after
the 18:0 oil the difference was not significant (AUC fullness: control 32. mm/min, shea 37
mm/min, rapeseed 41 mm/min, safflower 42 mm/min, SE =2.3, p<0.05). Hunger scores
were significantly (p<0.05) decreased after 18:2 compared to the 18:0 oil and control. The
18:1 oil induced a significant decrease in hunger score compared to control (AUC hunger:
control 52 mm/min, shea 48 mm/min, rapeseed 44 mm/min, safflower 42 mm/min, SE =
1.7, p<0.05). Food intake did not differ between emulsions and control. CCK secretion was
significantly increased after 18:1 and 18:2 oils compared to control (AUC CCK after 18:0,
18:1 and 18:2 vs control resp.: 0.35 pM/min, 0.41 pM/min, 0.44 pM/min vs 0.27 pM/min,
SE=0.04, p<0.05). PYY-secretion was significantly increased after all emulsions compared
to control (p<0.05), pointing to ileal brake-activation. No significant differences in PYY
release were seen between the three emulsions. Conclusions: Ileal fat induces satiety through
activation of the ileal brake. This effect on satiety is influenced by the degree of saturation
of the triacylglycerols and is most pronounced after safflower and rapeseed oil.
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Butyrate Modulates Oxidative Stress in the Colonic Mucosa of Healthy
Humans
Henrike Hamer, Daisy Jonkers, Freddy J. Troost, Aalt Bast, Steven Vanhoutvin, Koen
Venema, Robert jan Brummer
Introduction: Butyrate, produced by colonic microbial fermentation, is the prime energy
substrate for colonocytes. In addition, it has an anti-carcinogenic potential and is suggested
to inhibit inflammation. Cancer and inflammation are associated with oxidative stress to the
mucosa. In Vitro studies showed that butyrate increased glutathione-S-transferase activity
and reduced H2O2-induced DNA damage, suggesting a role for butyrate on oxidative stress.
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Therefore, the effect of butyrate on several parameters of oxidative damage and anti-oxidant
defense were studied in the colon of healthy human volunteers. Methods: A randomized,
double blind, placebo controlled, crossover study was performed in 16 healthy volunteers
(age: 24(16-63)). Treatments consisted of daily rectal administration of a 60 ml enema
containing 100 mM sodium-butyrate or placebo (saline) for two weeks with a two weeks
wash-out period. After each treatment, biopsies were taken from the sigmoid colon. Non-
protein trolox equivalent antioxidant capacity (TEAC), uric acid (UA), reduced glutathione
(GSH) and oxidized glutathione (GSSG) levels and the enzyme activity of glutathione-S-
transferase (GST) were determined. Malondialdehyde (MDA) was measured as a parameter
of lipid peroxidation and the GSH/GSSG ratio was calculated as a marker of oxidative stress.
Results: Butyrate resulted in a higher (p<0.05) amount of GSH (26.5 (20.4-35.2) vs. 22.9
(12.0-31.5) nmol/mg protein), and in a significantly lower (p<0.01) amount of UA (2.4
(1.6-3.7) vs. 3.1 (1.9-3.3) nmol/mg protein) compared to placebo. Between butyrate and
placebo no statistical differences were found in TEAC (136.2 (116.2-207.6) vs. 137.2 (112.6-
210.7) nmol trolox Eq/mg protein), GST (0.3 (0.4-0.4) vs. 0.3 (0.2-0.5) U/mg protein),
GSSG (0.3 (0.1-2.7) vs. 0.4 (0.2-2.1) nmol/mg protein), MDA (0.8 (0.4-1.4) vs. 1.1 (0.7-
2.2) nmol/mg protein) and GSH/GSSG ratio (90.8 (7.6-333.9) vs. 70.1 (8.1-127.0)). In
addition, a significant positive correlation was found between MDA and GSSG (R2=0.35,
p<0.01), and a significant negative correlation between MDA and the GSH/GSSG ratio (R2=
0.27, p<0.01). Conclusion: Butyrate enhances the anti-oxidant defense capacity as indicated
by the increase in the amount of GSH. Also a decrease in the amounts of UA was found,
which might be due to an inhibitory effect of butyrate on xanthine oxidase, the enzyme
that catalyzes the production of UA. In addition, the correlations between the MDA and
the GSH/GSSG ratio and GSSG support the validity of these assessments in colonic biopsy
samples from healthy individuals.
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Effective Probiotic Therapy of the Irritable Bowel Syndrome (IBS): A Multi-
Center Clinical Trial with Primary Care Physicians
Paul Enck, Georg Menke, Kurt Zimmermann, Ute Martens, Sibylle Klosterhalfen
Probiotic therapy trials in IBS have produced conflicting results, partially due to high placebo
response rates and low “therapeutic gain” of the substance above the placebo response. It
is unknown whether therapeutic efficacy can be optimized when the study is conducted in
collaboration with primary care physicians. Methods: Two hundred ninety-seven patients
(117:180 males:females, 49.8 ± 14.4 years of age) with lower abdominal symptoms (abdom-
inal pain, diarrhea, constipation) diagnosed as IBS according to the WONCA criteria of
World Health Organization (WHO) primary care physicians (1983, 1998) were recruited
in 10 primary care centers, and were treated for 8 weeks by the probiotic compound Pro-
Symbioflor (R) (Symbiopharm GmbH, Herborn, Germany), (3 x 1.5 ml daily), an E-coli
prepapration containing 6 to 10 different bacterial clones, or placebo in a double-blinded,
randomized fashion. Patients were seen weekly by the physician, who assessed the presence
or absence of a total of 9 gastrointestinal and related symptoms. Responders were defined
as having at least a 50% decrease in overall symptom score as well as in abdominal pain
reports, to match current standards in IBS trial response definitions as set by FDA and
EMEA. Response rates were compared between groups by means of chisquare test or Fisher's
exakt test; in addition, the time course of responses was compared by means of Kaplan-
Meier analysis. Results: The overall symptom response to the drug was 68.5 % in comparison
to placebo with 37.8 %, the difference was statistically significant (p<0.001). The relative
benefit of the compound in comparison to placebo was 1.8, i.e. nearly double the number
of patients profited from verum than from placebo, and resulted in a low number-needed-
to-treat (NNT) of 3.3. The result was similar for the abdominal pain report (benefit: 1.7,
NNT: 3.5). While superiority of one center was noted (benefit: 1.2; NNT: 8.3), all other
centers also had significant results (benefit: 1.7; NNT: 8.1). No significant differences were
found between men and women. Kaplan-Meier analysis revealed a mean response time of
5.4 weeks for verum and 6.9 weeks for placebo (Kaplan estimator, p<.0001). Conclusion:
Probiotic treatment of IBS is effective, and superior to other treatment options because of
low NNT. The rather low placebo response in this trial may be due to the rather restrictive
response criterium on the one hand, and to involvement of primary care physicians on the
other: they may not promise their patients too much from the study, as they have to care
for these patients also after trial termination.
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Peroral Endoscopic Repair of Fistulae in Roux-en-Y Gastric Bypass Patients: A
Clinical Experience in 25 Patients
Reina D. Pai, Vladyslava Doktor, David B. Lautz, Christopher C. Thompson
Background: Roux-en-y gastric bypass is an effective treatment for severe obesity, however
there is significant associated morbidity. One prominent and often difficult to repair complica-
tion is staple line dehiscence with subsequent formation of gastro-gastric, jejuno-gastric or
other fistulae. Surgical repair is technically difficult and often carries prohibitive morbidity.
We report eighteen-month follow-up results of twenty-five patients who have undergone
endoscopic fistula repair. Methods: Twenty-five patients with history of Roux-en-y gastric
bypass with confirmed fistula on EGD or barium study underwent per-oral endoscopic
repair between 10/01/03 and 5/31/05. Endoscopic repair involved a combination of devices
including the Bard EndoCinch, LSI ESD, hemoclips and argon plasma coagulation. The goal
of the procedure was complete and durable fistula closure by mucosal ablation and tissue
apposition. Patients were seen or contacted for follow-up at one, six and eighteen month
intervals to assess for potential failure of repair based on symptoms or imaging suggestive
of recurrent fistula. Results: The average weight gain prior to procedure was 29.6 pounds.
Average fistula size was 1 cm and 9 patients had more than one fistula. Seventy-nine percent
of fistulae were gastro-gastric. An average of 3.6 plications and 1.6 hemoclips were used in
each procedure. Complete initial fistula closure was achieved in 24 of 25 patients. Immediately
post-op transient abdominal discomfort was experienced by all patients but no significant
complications were reported and minor complications consisting of nausea, vomiting and
diarrhea was present in only two patients. The average weight loss at one and six months
post-procedure was 10.8 and 14.2 pounds respectively and improvements in reflux and
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
weight related symptoms were also noted in most patients. At 18 months, 64% had undergone
either repeat endoscopic intervention or surgical revision, and 6 of 25 demonstrated durable
closure on radiographic imaging or repeat endoscopic evaluation. Conclusions: Peroral
endoscopic repair of post-bariatric fistulae is technically feasible but with poor durability.
However, this endoscopic route appears significantly less morbid then surgical alternatives.
We are currently evaluating fibrin glue and other tissue adhesives to improve long-term effect-
iveness.
519
First Annual AGA Fellows' Nutrition Training Course: Outcome of Nutrition
Support, Obesity and Basic and Clinical Nutrition Training
James S. Scolapio, Alan L. Buchman, Martin H. Floch
Background: Although it is widely agreed that the training of physicians should include a
focus on nutrition, the teaching of nutrition in medical schools and residency programs
generally remains inadequate. The degree of nutrition training in GI fellowship programs
has not been previously reported, but thought to be inadequate. A live education nutrition
course, targeted specifically for GI fellows, was recently completed. 19 faculty from across
the US and Canada participated. Pre and post course data was collected. Specific aims: To
determine the amount of nutrition exposure from a random sample of GI fellows attending
this course, to determine nutrition knowledge and practice behaviors pre and post course.
Hypothesis: There is a deficiency in nutrition education of GI fellows; this course curriculum
will positively change knowledge and practice behavior. Methods: Electronic surveys were
sent to each fellow pre and post course using a web based survey tool. The surveys asked
questions related to nutrition experience of fellows, nutrition knowledge and practice
behavior. The curriculum was comprised of 20-hours of live education delivered as didactic
lectures and workshops, included both basic and clinical topics. Lectures and workshops
were refocused when pre course survey identified a “gap” in medical knowledge or practice
behavior. Results: 56 fellows participated with a 100% response rate on surveys. 70%
reported no inpatient nutrition rotation despite 89% having an inpatient nutrition support
team managed predominately by allied health staff. 70% had never written an enteral or
parenteral order and only 12% had managed a home enteral or parenteral patient. 90%
responded they had no outpatient nutrition/obesity rotation and 59% had no core nutrition
lecture series. Only 43% responded that they had a M.D. nutrition expert in their GI division.
87% responded they had never been assessed for competency in nutrition. Only 9% had
ever completed a nutrition research project. Too few mentors, poor exposure, and a predom-
inant focus on endoscopy were the most frequent responses of why nutrition was not
pursued. Knowledge change was assessed using the same 20 questions pre and post course,
which corresponded to the curriculum. Mean correct response rates were 58% pre course
and 88% one week post course. Conclusion: There is a significant deficiency in nutrition
training in GI fellowship programs, and the established AGA nutrition curriculum guidelines
and core competencies are not being fulfilled in most programs. There is a need for increased
nutrition education in GI training programs and a need for ongoing educational courses for
our GI fellows.
520
A Comparison of Endoscopic Ultrasound (EUS) to Clinical, Endoscopic and
Pathologic (Cep) Factors in Classification of Esophageal Cancer (EC): More
Technology Is Not Always Better!
Gregory Zuccaro, Thomas W. Rice, John J. Vargo, Lisa A. Rybicki, John Goldblum, Rocio
Lopez, Tyler Stevens, John A. Dumot
Background. EUS is commonly used to guide therapy in EC by predicting dichotomized T
classification (pTim-T2 vs. pT3-T4), regional lymph node status (pN0 vs. pN1) and/or disease
extent (limited to wall: pTim-T2, pN0 vs. advanced beyond wall: pT3-T4 and/or pN1). Other
CEP (non-EUS) information always available to the endoscopist is typically ignored. Purpose.
Compare EUS to CEP (non-EUS) information in classifying EC. Methods. 314 pts with EC
underwent clinical evaluation with endoscopy, and EUS, followed by esophagectomy. No
patient received pre-operative chemoradiation. Post-operative pathologic classification was
the gold standard. Accuracy of prediction of pT3-T4, pN1, and advanced disease was
determined using: (1) EUS, (2) Logistic regression model using these CEP factors: age,
gender, weight loss, dysphagia, tumor traversibility, length, location, and morphology,
histopathologic type and grade. Receiver Operating Characteristic (ROC) curves were created
for EUS vs. CEP model, and Area Under Curve (AUC) calculated (AUC reflects discriminative
ability of a diagnostic test). Results. Pathologic classification at esophagectomy: 150 (48%)
pT3-pT4; 143 (45%) pN1, 176 (56%) advanced disease. CEP factors predictive of pT3-T4,
pN1 and advanced disease were: dysphagia, weight loss, increased tumor length, and poor
histologic grade. ROC curves for EUS and CEP model were indistinguishable (table and
figure). Conclusions. (1) EUS is an excellent test for classifying EC. (2) However, CEP
information available to any endoscopist taking a history and biopsy has similar predict-
ive accuracy.
Comparison of Predictive Accuracy as Measured by AUC: EUS vs. CEP model
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ROC curves: Plot of sensitivity vs 1-specificity for EC
521
15-Hydroxyprostaglandin Dehydrogenase Is An In Vivo Suppressor of Colon
Tumorigenesis
Seung-jae Myung, Ronald M. Rerko, Min Yan, Petra Platzer, Kishore Guda, Angela
Dotson, Earl Lawrence, Andrew Dannenberg, Alysia K. Lovgren, Guangbin Luo, Theresa
P. Pretlow, Robert Newman, Joseph Willis, Dawn Dawson, Sanford D. Markowitz
15-Prostaglandin dehydrogenase (15-PGDH), an enzyme catalyzing the rate limiting step in
prostaglandin degradation, is highly expressed in normal colon mucosa, but is ubiquitously
lost in human colon cancers. As 15-PGDH is metabolically poised to antagonize the prosta-
glandin synthetic activity of the COX-2 colon cancer oncogene, 15-PGDH has been hypothes-
ized to be a potential colon cancer suppressor gene. Here we report the In Vivo functional
demonstration of potent 15-PGDH activity in suppressing colon neoplasia development, by
showing that a murine 15-PGDH gene knockout induces marked susceptibility to colon
neoplasia development. We first demonstrate a 7.6-fold increase in colon tumors results
from 15-PGDH gene knockout in the APC mutant bearing Min mouse strain. We moreover
find that 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to
colon tumor induction by the carcinogen azoxymethane (AOM), and confers susceptibility
to AOM induction of both colonic adenomas and carcinoma in situ tumors. The mechanism
of colon neoplasia susceptibility induced by the loss of 15-PGDH involves a marked increase
in dysplasia, proliferation, and induction of cyclin D1 expression evidenced within the
microscopic aberrant crypt foci arising in 15-PGDH null colons. This is concomitant with
a doubling of mucosal PGE2 in 15-PGDH null versus wild-type colons. Examination of
lesions from humans with familial adenomatous polyposis demonstrates a parallel early
and universal loss of 15-PGDH expression within microscopic colon adenomas, including
dysplasias as small as a single crypt. These findings show that 15-PGDH is a potent In Vivo
suppressor of early colon neoplasia development and plays a significant physiologic role in
the normal negative regulation of the oncogenic activity of colonic prostaglandins. These
findings also have implication for the design of strategies for pharmacologic manipulation
of the intestinal COX-2 and prostaglandin biogenesis pathway.
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Role of Krüppel-Like Factor 4 in Wnt and Notch Signaling in the Intestinal
Tract
Amr M. Ghaleb, Beth B. Mcconnell, Mandayam O. Nandan, Jonathan P. Katz, Klaus
Kaestner, Vincent W. Yang
BACKGROUND: The zinc finger transcription factor, Krüppel-like factor 4 (KLF4), nega-
tively regulates cell proliferation. Previous work suggests that KLF4 is a tumor suppressor
in colorectal cancer. The expression of KLF4 has been shown to be regulated by the
tumor suppressor APC, and KLF4 itself may regulate colonic epithelial cell proliferation
by modulating APC activity. Studies also indicate that KLF4 is required for the terminal
differentiation of goblet cells in the mouse intestine. The Notch signaling pathway has been
shown to suppress goblet cell formation. Evidence also suggests that there is crosstalk
between the Notch and Wnt pathways. AIM: To determine whether KLF4 plays a role in
Wnt and Notch signaling in the intestinal tract. METHODS: C57BL/6 mice that are Klf4+/-
or ApcMin/+ were crossbred. At 10, 16 and 20 weeks of age, mice wild type (WT), heterozygous
for the Klf4 allele (Klf4+/-), heterozygous for the ApcMin allele (ApcMin/+), and heterozygous
for both alleles (Klf4+/-/ApcMin/+) were sacrificed and their intestines examined for adenoma
formation and stained for KLF4 and goblet cell markers. Klf4 mRNA levels were determined
by semi-quantitative RT-PCR. Human colon cancer cell line HT29 was treated or not with
a γ-secretase inhibitor, dibenzezpine (DBZ), to inhibit the Notch pathway. KLF4 and activated
Notch cytoplasmic domain (NotchCD) levels were determined by Western blotting.
RESULTS: At 10 weeks of age, Klf4+/-/ApcMin/+ mice developed on average 50% more
intestinal adenomas than ApcMin/+ mice (p<0.005). This increase was maintained at weeks
16 and 20. Neither WT nor Klf4+/- mice developed tumors. Immunohistochemical staining
showed a significant decrease in KLF4 levels in the normal-appearing intestinal tissues of
Klf4+/-/ApcMin/+ mice compared to WT, ApcMin/+ or Klf4+/- mice. KLF4 levels were further
decreased in adenomas from both ApcMin/+ and Klf4+/-/ApcMin/+ mice compared to their
adjacent normal-appearing tissues. RT-PCR showed an inverse correlation between adenoma
size and Klf4 mRNA levels in both Klf4+/-/ApcMin/+ and ApcMin/+ mice. The number of goblet
cells in both normal-appearing intestine and adenomas of Klf4+/-/ApcMin/+ mice was signific-
antly reduced compared to the other groups of mice. In HT29 cells, inhibition of Notch
signaling by DBZ resulted in a reduction in NotchCD and an increase in KLF4 levels.
CONCLUSIONS: Results from this study demonstrate that KLF4 plays an important role
in the early development of intestinal adenomas in the presence of ApcMin mutation. In
addition, Notch signaling may suppress KLF4 expression, resulting in reduced goblet cell
formation in the intestine and adenomas.
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Is Protection Against Colorectal Cancer Good Enough; A Comparison Between
Sigmoidoscopy and Colonoscopy in the General Population
Gurkirpal Singh, Ajitha Mannalithara, Huijian Wang, David J. Graham, Lauren B. Gerson,
George Triadafilopoulos
The optimal interval for colorectal cancer (CRC) and polyp surveillance after a negative
colonoscopy is controversial and ranges between 5-10 years. We aimed to determine the
risk and timing of developing CRC after a negative screening colonoscopy (C) or sigmoidos-
copy (S), and compared the two modalities. Methods: We conducted a retrospective, popula-
tion-based, time-matched, nested case-control study in the California MediCal program.
Cases with newly-diagnosed CRC (between 1/95-6/05) were identified, and age-, gender-
and time-matched with 10 controls who did not have CRC. All subjects had at least 5 years
of continuous eligibility before first diagnosis of CRC (cases) or matched index date (controls).
All C and S during these 5 years were identified by CPT codes; negative procedures were
classified by using previously-published criteria. The protective effects of negative C and S
were compared to no screening using conditional logistic regresion, adjusting for age, gender,
race, NSAID and aspirin use, and comorbidities. Patients with inflammatory bowel disease
and prior colorectal resection were excluded. Results: We identified 4,458 patients with
newly-diagnosed CRC and matched these to 43,815 controls without CRC (mean age 72.8
years, 62% women). Cases were significantly more likely to be white, have other comorbidities
(such as history of breast cancer) and less likely to take NSAIDs and aspirin. The adjusted
relative risk for CRC after a negative C (compared to no screening) was 0.55 (95% CI 0.46
- 0.65, p<0.0001). S was significantly less protective (RR for CRC 0.82, 95% CI 0.63 - 1.06,
p ns when compared to no screening, p<0.01 when compared to C). Both C and S were
significantly protective for left-sided tumors compared to no screening, but C was significantly
more so than S (CRC RR with C 0.16 vs. 0.53 with S, p<0.003). For the right-sided tumors,
however, only C showed a statistically significant protective effect (CRC RR 0.67, 95% CI
0.51-0.88) and was much better than S (CRC RR 0.86, 95% CI 0.55-1.35). The protective
efficacy of C improved from year 1 (RR of CRC 0.71) to year 2 (CRC RR 0.41), but slowly
and progressively lessened after that (CRC RR 0.55 at year 3, 0.56 yr 4 and 0.57 year 5),
presumably reflecting missed tumors at year 1 and subsequent year 2-5 rise presumably
due to new tumors. Nevertheless, for all years, C was better than S. Conclusions: C is better
than S in CRC protection and the only modality that is protective for right-sided lesions.
However, the benefit of C decreases during years 3-5 of f/u, suggesting that patients should
undergo repeat examination within 5 years of a negative index examination.
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The G-Beta Subunit of Heterotrimeric G Proteins Directly Links Gpcr
Activation with Transcriptional Regulation By Klf11, a Pancreatic Tumor
Suppressor and a Diabetes Gene
Jin-san Zhang, Gwen A. Lomberk, Shoichiro Tsuji, Mark J. Truty, Martin E. Fernandez-
zapico, Laurence J. Miller, Raul A. Urrutia
KLF11, together with KLF9, KLF10, KLF13, KLF14 and KLF16, forms a subfamily of Sp/
KLF proteins that mainly functions as transcriptional repressors. Our studies have shown
that KLF11 contains three distinct repressor domains, R1, R2, and R3. Interestingly, the R1
domain is structurally and functionally conserved among the members of this subfamily
and represents a defining biochemical feature for these repressor proteins that mediate
transcriptional repression via recruitment of Sin3/HDAC corepressor complex. Our functional
studies have shown that KLF11 is a candidate tumor suppressor for pancreatic cancer as
well as other malignancies including head and neck, leukemia, and esophageal cancer.
Analysis of the mechanism determined that KLF11 tumor suppressor properties require its
repression activity. Thus, identification of other coregulator proteins will be key for the
understanding of the transcriptional mechanisms used by KLF11 since the KRAS-MEK-ERK
pathway inactivates the R1 domain but not the R2 and R3 leaving the tumor suppressor
protein impaired but still active. More importantly, mutation and distinct polymorphic
variants within KLF11 transcriptional regulatory domains predispose to MODY type diabetes.
In an effort to identify protein(s) interact with KLF11 through the R2 or R3, we have used
the KLF11 cDNA fragment encoding this region of protein as bait for yeast two hybrid
screening. Intriguingly, the most frequently represented KLF11-interacting candidates were
the G-protein beta subunits (Gb1 and 2). Gb, a member of the large family of WD40 repeat
proteins, forms together with Ga and Gr the heterotrimeric G-proteins that are known to
transmit numerous and diverse extracellular stimuli via G-protein coupled receptors (GPCR)
to various intracellular effector molecules. The interaction of KLF11/Gb was further validated
in pancreatic cancer cells using both co-immunoprecipitation and biomolecular fluorescence
complementation assays. More importantly, activation of specific GPCR signaling triggered
the nuclear translocation of Gb and enhanced their interaction with KLF11. Using In Vitro
GST-pull down assays, we have mapped the Gb-interacting region to the R3 domain, which
contains identified human mutation/polymorphisms linked to the development of MODY
type diabetes. Our data suggest that the Gb may transmit the GPCR signaling message from
cell membrane to the nucleus in a direct manner through interaction with a sequence-
specific transcription factor, which is faster than previously anticipated. We are currently
investigating the role of Gb as a coregulator of KLF11-mediated transcriptional repression
and its significance in pancreatic disease.
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Netrin Biosynthesis By Enteric Neurons: Roles in Normal Guidance of Vagal
Sensory Axons and Their Mislocation in Aganglionic Gut
Elyanne M. Ratcliffe, Monique Anderson, Alcmene Chalazonitis, Michael D. Gershon
Vagal sensory innervation of the gut is established during fetal life. The guidance of vagal
sensory axons is, in part, mediated by netrins, which are located in the bowel wall, and by
their receptor, deleted in colorectal cancer (DCC), which is expressed by vagal fibers.
Application of DiI to fetal nodose ganglia permits descending vagal sensory axons to be
traced. Using this technique, we have demonstrated that vagal sensory axons fail to innervate
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aganglionic gut of mice that lack the tyrosine kinase receptor Ret, in which ganglia do not
form in the subdiaphragmatic bowel. Netrin-immunoreactivity is abundant in the mucosa,
vagus nerves, and around the presumptive myenteric plexus of the gut of wild-type mice
but is barely detectable in the aganglionic bowel of Ret -/- mice. We therefore tested the
hypothesis that developing enteric ganglia express netrin; an alternative is that nerves take
up netrin synthesized in the mesenchyme. Crest-derived and non-crest-derived cells of the
E15 rat gut were separated by positive and negative immunoselection with antibodies to
p75NTR, which is a marker for crest-derived cells in the fetal bowel. Transcripts encoding
netrin-1 were found by RT-PCR in the non-crest-derived cells but not in the crest-derived
precursors. The p75NTR-immunoreactive cells were cultured for 6 days in 3-dimensional
collagen gels with an extrinsic source of netrin-1 (stably transfected 293-EBNA cells
expressing c-Myc-tagged netrin-1 [to distinguish netrin that neurons might take up from
netrin they might produce]). Controls included crest-derived cells cultured alone or with
parental 293-EBNA cells. Media were supplemented with 10% fetal bovine serum and
with the Ret ligand, glial cell derived neurotrophic factor (10 ng/ml) to promote neuronal
differentiation. In all 3 types of culture, neurons (identified by their expression of PGP9.5)
were found to be netrin-immunoreactive. Cultures were further immunostained with antibod-
ies to c-Myc to identify netrin secreted by the transfected 293-EBNA cells. Although the
netrin-1-expressing 293-EBNA cells were c-Myc-immunoreactive, the neurons that developed
from the crest-derived cells were not. Neurons thus did not take up secreted c-Myc-tagged
netrin-1 and therefore must themselves express netrin. These results suggest that enteric
neurons, but not their crest-derived precursors, synthesize netrins. We propose that netrins,
produced by intrinsic neurons, enable vagal sensory axons to find their correct locations in
the myenteric plexus. This proposal would explain the mislocation of vagal axons in the
aganglionic gut. Supported by AGA RSA, CDHNF, DK58056, NS12969 and NS15547.
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Induced Trpc1 Expression in Intestinal Epithelial Cells Increases Protein
Phosphatase-2a Through Ca2+ Influx Leading to Inhibition of Nf-κB Activation
Bernard S. Marasa, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Jose Greenspon, Lan Xiao,
Ai-hong Zhang, Jie Chen, Douglas Turner, Jian-ying Wang
Apoptosis plays a critical role in maintenance of gut mucosal homeostasis and is highly
regulated by numerous factors including intracellular Ca2+. Transient receptor potential
canonical-1 (TRPC1) expresses in intestinal epithelial cells (IECs) and functions as Ca2+-
permeable channels activated by Ca2+ store depletion. We have demonstrated that ectopic
expression of the TRPC1 gene sensitizes IECs to apoptosis by inhibiting NF-κB activation,
but exact mechanisms by which induced TRPC1 represses NF-κB remain unknown. Serine/
threonine protein phosphatase-2A (PP2A) is implicated in a wide array of cellular functions
and shown to modulate anti- or pro-apoptotic signaling pathways. The current study tested
the hypothesis that induced TRPC1 expression inhibits NF-κB activation by increasing PP2A
through Ca2+ influx. Methods: Studies were conducted in IEC-6 cells. Levels of PP2A mRNA
and protein were measured by real-time PCR and Western blotting analysis. NF-κB activity
was examined by measuring its DNA-binding and NF-κB-dependent transcriptional activity,
while cytosolic free Ca2+ was measured by fluorescence digital imaging analysis. Functions
of PP2A were investigated by transfection with small interfering RNA targeting PP2A (siPP2A).
Apoptosis was induced by tumor necrosis factor-α plus cycloheximide. Results: Stable
TRPC1-transfected IEC-6 cells (IEC-TRPC1) highly expressed TRPC1 protein (~5-folds) and
displayed a sustained increase in Ca2+ influx after Ca2+ store depletion (~2-folds). Stable
IEC-TRPC1 cells also exhibited increased PP2A activity as indicated by increases in PP2A
mRNA and protein expression and its phosphatase enzyme activity. Levels of PP2A protein
and its phosphatase activity in stable IEC-TRPC1 cells were ~2-folds the value of parental
IEC-6 cells. This increased PP2A stabilized IκBα and induced the accumulation of cytoplasmic
IκBα, which was associated with an inactivation of NF-κB and increase in susceptibility to
apoptosis. Suppression of PP2A activity by its chemical inhibitor okadaic acid or specific
inhibition of PP2A expression by siPP2A transfection in stable IEC-TRPC1 cells decreased
levels of cytoplasmic IκBα, induced NF-κB-dependent transcriptional activity, and prevented
the increased sensitivity to apoptosis. Decreasing Ca2+ influx by exposure to a Ca2+ free
medium also decreased PP2A activity, activated NF-κB, and blocked the increased susceptibil-
ity to apoptosis of stable IEC-TRPC1 cells. Conclusions: These results indicate that 1) induced
TRPC1 increases PP2A expression through Ca2+ influx and 2) increased PP2A inhibits NF-
κB activation by stabilizing IκBα, thus sensitizing IECs to apoptosis.
529
The Basic Helix-Loop-Helix Transcription Factor Hand2 Is Required for
Terminal Differentiation of Enteric Neurons But Not for Colonization of the
Gut By Crest-Derived Precursors Or Their Initial Commitment to the
Neuronal Lineage
Fabien D'autreaux, Peter Cserjesi, Yuka Morikawa, Michael D. Gershon
The hand genes (1 and 2) encode basic helix-loop-helix transcription factors, which play
important roles in development of the heart, lateral mesenchyme, and autonomic nervous
system. These genes play roles in sympathetic ganglionic development and are critical in
noradrenergic specification. Both genes are expressed in the developing gut. Enteric and
sympathetic neurons, however, are different and the ENS lacks noradrenergic neurons. We
thus tested the hypotheses that the hand genes are differentially expressed in the fetal bowel
and that hand2 is necessary for terminal differentiation of enteric neurons. Expression of
hand genes was quantified as a function of developmental age, related to the expression of
other genes expressed by enteric crest-derived cells, and the cellular sites of expression were
determined. Hand2 expression was detected at E9.5 when crest-derived cells first enter the
bowel and, although developmentally regulated, persisted in the adult gut. Hand2 expression
was restricted to cells of crest origin; in contrast, hand1 was expressed only by smooth
muscle and interstitial cells of Cajal. Hand2 was intranuclear in precursor cells but was
excluded from the nuclei of mature neurons. Transgenic mice lacking hand2 die at E10.5,
prior to the formation of enteric neurons or glia but after crest-derived cells enter the gut.
Development of neurons and glia was thus compared in explants of wild-type and hand2
-/- bowel. The deletion of hand2 did not interfere with the normal colonization of the gut
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by crest-derived cells or with their In Vitro development as glia; it did, however, prevent
their development as neurons. Similarly, silencing of hand2 in crest-derived cells with siRNA
blocked neuronal development. Transgenic mice, in which the excision of a “floxed” hand2
was restricted to crest-derived cells by Cre recombinase under the control of the Wnt1
promoter survived to E12.5. Terminally differentiated neurons, marked by expression of
HuC/D or type-specific markers, such as nitric oxide synthase and dopamine β-hydroxylase,
failed to develop in the conditional knockout gut; nevertheless, precursors expressing earlier
neural traits, such as PGP9.5, were detected. These data suggest that hand2 expression is
required for enteric neuronal differentiation, but not for commitment of enteric neuronal
precursors to the neuronal lineage. Observations also support the idea that enteric neuronal
differentiation is not an all-or-none phenomenon, but occurs in stages and that defects in
specific regulatory genes can produce subtle abnormalities leading to as yet unexplained
disorders of GI motility. Supported by NIH grant NS15547.
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Erbb-4 Is Required for Cell Survival During Inflammation in the Intestinal
Epithelium
Mark R. Frey, D. brent Polk
The ErbB-4 receptor tyrosine kinase, the most recently described member of the epidermal
growth factor receptor-like ErbB family, regulates cell growth, survival, and differentiation
in several mammalian tissues. However, while ErbB-4 mRNA expression has been shown
in the gastrointestinal tract, no data are available on the receptor's function in the gut. In
this study, we tested the hypothesis that ErbB-4 promotes cell survival during epithelial
responses to injury and inflammation. METHODS: To assess ErbB-4 expression in injury
and repair, C57Bl/6 mice were given 3% dextran sulfate sodium (DSS) in drinking water
for 4 d to induce colitis, followed by 3 d recovery. ErbB-4 was detected by immunohistochem-
istry on paraffin-embedded tissue, and confirmed by Western blot of colon mucosal scrapings.
For cell culture assays, young adult mouse colon (YAMC) cells were transfected with non-
targeting or ErbB-4-specific siRNA and exposed to heregulin-1β or 100 ng/ml tumor necrosis
factor (TNF)-α, which is expressed at high levels early in DSS colitis, for various times.
Apoptosis was detected with the fluorescent caspase inhibitor SR-VAD-FMK. Western blot
analysis of cell lysates was performed for activation of cell death and survival pathways,
using phospho (P)-specific and total antibodies for ErbB-4, AKT, p38, ERK, and IkB-α.
RESULTS: DSS-induced injury stimulated a modest increase in ErbB-4 protein expression
throughout the colon epithelium. During the recovery phase, ErbB-4 levels increased dramat-
ically in regenerating regions. In our cell culture model, Western blot analysis for P-Y1162
ErbB-4, P-Y1188 ErbB-4, and total receptor showed that 24 h exposure to 100 ng/ml TNF-
α promotes ErbB-4 expression and phosphorylation by 10- and 7-fold, respectively (p values
< 0.001) in YAMC cells. We therefore asked whether ErbB-4 is required for cell survival in
the inflammatory milieu. Compared with non-targeting siRNA, ErbB-4 siRNA increased both
basal (7% vs. 12%, p < 0.0001) and TNF-stimulated (9% vs. 19%, p < 0.0001) YAMC cell
apoptosis after 24 h. With regard to the mechanism of ErbB-4-dependent cell survival,
Western blot analysis for P-AKT showed that the ErbB-4 ligand heregulin-1β stimulates this
pro-survival pathway in YAMC cells. Furthermore, ErbB-4 deletion by siRNA blocked AKT
phosphorylation in response to acute TNF exposure, while in contrast TNF-stimulated p38
activation and IkB-α degradation were not inhibited by ErbB-4 siRNA. CONCLUSIONS:
ErbB-4 promotes cell survival during regeneration and repair, possibly by activating the
AKT survival pathway. These data position ErbB-4 as a key regulator of the intestinal
epithelial response to injury.
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Real-Time Imaging of Cell Shedding from a Discrete Zone At the Surface of
the Human Colonic Epithelium
Alyson Parris, Amy Reynolds, Luke Evans, Cameron Jamieson, Alison Prior, Richard
Tighe, Mike Lewis, Mark Williams
The human intestine sheds approximately 10 billion cells every day. However, little is known
about the location and process of cell shedding in the human colon. In part this stems from
having to rely on analysis of static fixed mucosal sections. We have developed an ex-
vivo model of the human colonic epithelium that preserves cell-to-cell contacts between
neighbouring crypts and permits observation of dynamic cell shedding in real-time. AIMS:
To describe cellular and molecular features associated with cell shedding in the human
colon. METHODS: Colonic crypts were isolated from tissue biopsies obtained at sigmoidos-
copy from healthy-subjects (Ethical approval). Isolated crypts were attached to collagen-
coated coverslips and cultured for 24 hours - 3 days in serum-free DMEM (5%CO2/37oC).
Protein location was visualised by immunofluorescence and confocal microscopy. A range
of markers for cell viability (e.g. propidium iodide, PI; calcein-am; anti-active caspase 3),
cell polarity (e.g. anti-NKCC1), cell-to-cell contacts (e.g. mouse anti-Zona Occudens 1, ZO-
1; anti-E cadherin) and cytoskeleton elements (e.g. phalloidin-Alexa Fluor 568) were utilised.
Cell migration and cell shedding was assessed by DIC digital video time-lapse microscopy
using an oil immersion x63, 1.4 n.a., objective lens. Validatory experiments for protein
expression and cell morphology were performed on cryosections of colon biopsy samples.
RESULTS: Human colonic crypts maintained their gross morphological flask-like appearance
for a number of days in culture. Crypt cell migration was evident in the upper half of the
crypt structure (approx. 5 μm/h). On reaching the surface intercrypt region cells were shed
from a discrete zone at a rate of approx. one cell every 30 mins. Live cells located within
the discrete shedding zone remained calcein-positive and PI-negative. Shed cells became
calcein-negative and PI-positive over real-time. Immunocytochemical analysis revealed activ-
ated caspase 3 labelling within the discrete shedding zone. This was accompanied by
translocation of the nucleus from the basal to the apical pole of the cell. Expression of the
basolateral membrane transporter NKCC1 was dramatically reduced. Actin and ZO-1 label-
ling at apical tight junctions re-organised to form a co-localised band at the basal pole of
the cell under extrusion. These features were also evident in fixed cryosections cut from
the native human colon. CONCLUSIONS: Cell shedding occurs at a highly organised discrete
zone located at the surface intercrypt region. We now wish to study the cellular signals that
control the shedding process in health and disease.
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Effects of a Novel, First-in-Class Guanylate Cyclase-C Activator, Linaclotide
Acetate (Md-1100), On Gastrointestinal and Colonic Transit and Bowel Habits
in Patients with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)
Viola Andresen, Irene Busciglio, April Grudell, Duane Burton, Sanna Mckinzie, Amy
Foxx-orenstein, Alan R. Zinsmeister, Mark G. Currie, Caroline B. Kurtz, Michael Camilleri
Background: Linaclotide is a novel, first-in-class agonist of the human guanylate cyclase-C
(GC-C), a transmembrane protein located in the gut epithelium. GC-C activation induces
intestinal fluid secretion and inhibits colonic fluid absorption. In animal studies, linaclotide
accelerated gastrointestinal (GI) transit, and decreased surrogates of visceral pain. In human
phase I studies, linaclotide was safe and well tolerated, decreased stool consistency, increased
stool frequency and increased ease of passage of stool in healthy volunteers. Methods: This
randomized, double-blind, placebo-controlled study evaluated the effects of oral linaclotide,
100 and 1000 μg qd, in 36 women with C-IBS. Participants underwent 5-day baseline and
5-day treatment periods, during which GI transit (by validated scintigraphy) and bowel
function (by daily diaries, including Bristol Stool Form Scale) were assessed. Treatment
effects were compared using ANCOVA with pairwise comparisons of each dose versus
placebo. Baseline colonic transit was used as covariate. Results: Effects of linaclotide on
gastric emptying and orocecal transit times were not detected. There was a significant (p=
0.015) overall treatment effect on ascending colon (AC) emptying t1/2 with a significant
acceleration by linaclotide 1000 μg (p=0.004, left fig). Treatment effects on overall colonic
transit were also observed (p=0.020 for the geometric center (GC) at 48 hr) with a significant
acceleration by linaclotide 1000 μg qd vs. placebo (p=0.010). There were significant overall
treatment effects on stool frequency, stool consistency, ease of passage and time to first
bowel movement with a strong dose response for stool consistency (overall p<0.001, right
fig). No safety issues were identified. Conclusions: In women with C-IBS, linaclotide 1000
μg qd significantly accelerated AC emptying and colonic transit at 48 hr. Linaclotide also
improved stool consistency, stool frequency, ease of passage and time to first bowel move-
ment. The effect of loosening stool consistency was strongly dose dependent. Further studies
of clinical endpoints in randomized controlled trials are warranted.
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The HPA-Axis Function and Autonomic Response to Stress in Functional
Bowel Disorders in a Population Based Cohort
Tamira K. Klooker, Breg Braak, Susanne R. De rooij, Rebecca C. Painter, Ruurd M. Van
elburg, Rene M. Van den wijngaard, Guy E. Boeckxstaens, Tessa J. Roseboom
BACKGROUND/AIM: Stress is an important pathophysiological factor in the onset and
modulation of functional bowel disorders (FBD). Evidence, however, is conflicting whether
the autonomic response and / or the HPA-axis response to stress are altered in FBD. In the
current study we evaluated the presence of FBD and the autonomic and hormonal response
to stress in a large population based cohort. METHODS: The Dutch Famine Birth Cohort
consists of adults born as term singletons in the Netherlands between 1 November 1943
and 28 February 1947. These subjects were invited to fill out the Rome II questionnaire to
assess the presence of the FBD irritable bowel syndrome or functional dyspepsia. Participants
with abdominal pain, constipation or diarrhea, not fulfilling the Rome II criteria were
excluded. Anxiety and depression were scored using the Hospital Anxiety and Depression
Scale (HADS). Subjects underwent a standardized stress protocol consisting of a Stroop test,
a mirror-tracing test and a speech test. Blood pressure and heart rate were continuously
measured and salivary cortisol samples were collected. RESULTS: A total of 851 subjects
filled out the Rome II questionnaire. Subjects with abdominal complaints not fulfilling the
Rome II criteria were excluded (n=172), leaving 679 patients eligible for analysis (56-61yr).
18% (n=121, 80F) met the criteria for FBD and were compared to 558 controls (287F) free
of abdominal symptoms. Baseline cortisol concentrations (FBD: 4.8 ± 0.5 nmol/l, control:
4.6 ± 0.2, NS), blood pressure and heart rate were comparable between the two groups.
The peak cortisol response during the stress test, expressed as the maximal cortisol increase
from baseline, was higher in FBD patients compared to controls (3.6 ± 0.6 versus 2.8 ± 0.2
nmol/l, respectively, P=0.007; linear regression adjusted for baseline cortisol level, gender,
depression and anxiety). Peak values of systolic blood pressure (FBD: 45 ± 2, control: 49
± 1 mmHg), diastolic blood pressure (FBD: 21 ± 1, control: 22 ± 1 mmHg) and heart rate
(FBD: 16 ± 1, control: 15 ± 1 BPM) were not significantly different between the two groups.
CONCLUSIONS: This study shows that FBD patients have an increased cortisol release but
a normal cardiovascular response to psychological stress. These data suggest that patients
with FBD have an altered stress response reflected in an increased activation of the HPA-axis.
To what extent this finding contributes to symptom generation or changes in gastrointestinal
physiology requires further study.
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Impact of Serotonin Transporter Gene Polymorphism On Brain Activation By
Colorectal Distention in Healthy Subjects and Patients with Irritable Bowel
Syndrome
Shin Fukudo, Tomoko Mizuno, Toyohiro Hamaguchi, Michiko Kano, Satoshi Watanabe,
Yasuhiro Sagami, Tomotaka Shoji, Yuka Endo, Masashi Aoki, Yasuto Itoyama, Masatoshi
Ito, Kazuhiko Yanai, Michio Hongo, Motoyori Kanazawa
Background & Aims: Determining gene that plays a key role in brain-gut interactions is a
crucial step for clarifying pathophysiology of irritable bowel syndrome (IBS). We previously
reported that 5-hydroxytryptamine transporter gene-linked polymorphic region (5-HTTLPR)
relates anxiety in subjects including IBS (J Psychosom Res 2006;60:91-97). Amygdala is
more activated during the fearful face recognition in individuals with s allele of 5-HTTLPR
(Science 2002;297:400-403). We tested our hypothesis that 5-HTTLPR differentially activates
regional brain to the colorectal distention in normal subjects and IBS patients. Methods:
Subjects were 22 healthy subjects and 6 IBS patients. This study was approved by the Ethics
Committee and all subjects gave the written informed consent. DNA was extracted from
the peripheral blood. Using polymerase chain reaction, genotype of 5-HTTLPR was deter-
mined. Age, sex, diagnosis-matched individuals with s/s genotype (n = 14) and individuals
with l allele (genotype l/s, l/l, l/extra-l, n = 14) were compared. Barostat bag was inserted
to the colorectum. The bag was intermittently inflated with no (0 mmHg), mild (20 mmHg),
or intense (40 mmHg) stimulation with random order. Radioactive H2[15-O] saline was
injected at the bag inflation and positron emission tomography was performed. Changes in
rCBF were analyzed using statistical parametric mapping 2. Results: Individuals with s/s
genotype showed significantly more increase in rCBF by colorectal distention from 0 mmHg
to 40 mmHg than individuals with l allele. Significantly more activated brain regions in s/
s genotype were the left anterior cingulate cortex (ACC) and the right parahippocampal
gyrus (p < 0.0001). The increased rCBF by colorectal distention with 20 mmHg compared
to 0 mmHg was significantly greater in the left orbitofrontal cortex of individuals with s/s
genotype than that in individuals with l allele (p < 0.0001). Conclusion: These data suggest
that individuals with weak function of serotonin transporter respond to the gut signal more
in the emotion-regulating brain regions. Functional gene polymorphism may partially predict
the individual effect of selective serotonin reuptake inhibitor on IBS.
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Fecal Serine-Protease Activity: A Possible Pathophysiological Factor and
Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome
Krisztina Gecse, Richárd Róka, András Rosztóczy, Mathilde Leveque, Ferenc Izbéki, Jean
Fioramonti, Tibor Wittmann, Lionel Bueno
Background and aims: A recently detected high colonic luminal serine-protease activity
characterizing diarrhea-predominant irritable bowel syndrome (IBS-D) may be responsible
for commonly observed features in IBS, namely increased intestinal permeability and visceral
sensitivity, possibly through the activation of proteinase-activated 2 receptors. Thus the aim
of our present study was to investigate the possible origin of elevated serine-protease activity
and to evaluate if it may be a relevant pathophysiological marker in IBS-D. Methods: Fecal
samples of healthy subjects, of IBS (of all subgroups, fulfilling the Rome II criteria) and
ulcerative colitis (UC) patients and patients with acute infectious diarrhea (INF) were studied.
Fecal serine-protease, trypsin, mast-cell tryptase and myeloperoxidase (MPO) activity was
measured photometrically using specific substrates; fecal pancreatic elastase-1, human secret-
ory leukocyte protease inhibitor (SLPI), neutrophil elastase and calprotectin concentrations
were assayed by ELISA. Results: Serine-protease activity was significantly elevated in IBS-D
and UC patients compared to healthy controls (63.9±8.8 and 62.2±14.0 vs. 24.5±6.3 U/
mg protein; p<0.01 and p<0.05, respectively), meanwhile similar increase was not present
regarding INF and other subgroups of IBS patients. No significant difference was observed
in fecal trypsin and mast cell tryptase activity in UC, INF or in any subgroups of IBS patients
when compared to controls. Fecal pancreatic elastase-1 concentration showed no significant
difference between subgroups of IBS and UC patients compared with controls, it was however
decreased in the feces of INF patients (p<0.05). SLPI activity showed no significant difference
between any of the studied groups of patients when comparing them to control subjects.
Markers of intestinal inflammation, namely neutrophil-elastase, calprotectin concentration
and MPO activity were elevated only in stool samples of UC and INF patients, but not in
any subgroups of IBS patients. Conclusions: Our results indicate that elevated fecal serine-
protease activity in IBS-D patients is i) not due to increased intestinal transit, ii) not linked
to increased serine protease activity of epithelial origin, iii) not coupled with decreased
luminal anti-protease activity and iv) is not associated with mucosal inflammation, leading
us to assume a possible microbial origin. The present study also proves that elevated
serine-protease activity is a relevant pathophysiogical marker in IBS-D in the absence of
inflammatory markers.
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History of Trauma and the Risk of IBS Among Women Veterans
Hashem El-serag, Shirley laday Smith, Maria D. Wieman, David Graham, Donna White
Background There is little information regarding prevalence or determinants of IBS symptoms
among US military veterans. Previous studies in civilians have demonstrated an association
between the occurrence and severity of IBS and multiple psychosocial factors including a
history of sexual trauma. Our goal was to determine prevalence of IBS among women
veterans and to examine the association between a history of sexual, physical, or psychological
trauma and IBS within this population. Methods We conducted a cross-sectional study
among consecutive women veterans who use a Women's Clinic at a single large VA Medical
Center for primary medical care. The prevalence of IBS (according to Rome III criteria) and
several specific types of trauma were estimated using responses to self-administered Bowel
Disorder Questionnaire (BDQ) and Trauma History Questionnaire (THQ). We employed
logistic regression to examine the association between trauma history and IBS symptoms.
Models were adjusted for possible confounding by ethnicity and age-group. Results We
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enrolled 248 women veterans (86.9% participation rate). Almost half (47.6%) were between
ages 46 and 60, and most were either African-American (48.0%) or White (41.1%). Symptoms
consistent with IBS were reported by 93 veterans (37.5%), most (98.9%) with diarrhea as
a dominant symptom or alternating with constipation. There was a fairly consistent finding
of ~2- to 3-fold increase in relative risk of IBS among women veterans with a history of
trauma (Table). Conclusions Several types of physical, psychological and sexual trauma are
frequently reported by women military veterans. A history of trauma is associated with more
than doubling of the relative risk of IBS. Additional prospective research will be useful in
further defining the causal relationship between trauma and IBS as well as other functional
gut disorders.
IBS Symptoms
*By ethnic- and age-group
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Randomized Controlled Trial Shows Biofeedback to Be Superior to Alternative
Treatments for Patients with Fecal Incontinence
Steve Heymen, Yolanda V. Scarlett, Kenneth R. Jones, Yehuda Ringel, Douglas A.
Drossman, William E. Whitehead
Aim: To compare EMG biofeedback to an alternative treatment for patients with fecal
incontinence (FI). Methods: 168 patients participated in a 4-week run-in treatment consisting
of medication, education, and behavioral strategies to prevent FI. Thirty-five (21%) reported
adequate relief, precluding further participation, and 24 (14%) withdrew during run-in.
The remaining 108 patients (83 females) were included in the intent-to treat (ITT) analysis.
(One patient died during the treatment phase and was not included in the ITT analysis.)
All subjects were randomly assigned to one of two treatment groups: 1) EMG biofeedback,
n=44; 2) Kegel exercise control group, n=64. All patients in both groups were trained to
do Kegel exercises and behavioral strategies during 6 biweekly 1-hour sessions. Diary data
(incontinent episodes and compliance with Kegel exercises and behavioral strategies) were
reviewed in each session. The primary dependent measure was a report of adequate relief
(yes or no) three months post-treatment. Results: Chi-Square analysis demonstrated that
biofeedback for FI was superior to a Kegel exercise control group: 77% of biofeedback vs.
40.6% of controls were successful (X2 = 14.2, p < .001). Secondary analyses at 3-month
follow-up (ANCOVAs included baseline values as covariates) showed that biofeedback
patients had significantly lower scores on the Fecal Incontinence Severity Index (FISI)
compared to controls (p = .001), and a trend favoring biofeedback over controls (p = .07)
for FI frequency (from diary data). In a per-protocol analysis of diary data, biofeedback
subjects reported significantly fewer incontinent episodes (p = .042). In the biofeedback
group, 66% were completely continent vs. 48% in the control group at 3-month follow-
up. Prior to treatment, the groups did not differ (p >.05) on demographic variables [gender,
race, age (mean 59.6, range 23-85 years), physiological variables [rest, squeeze, or push
anal canal pressures (or EMG), first sensation threshold], psychological variables (depression,
anxiety, or QOL measures), symptom duration (mean 7.3 years), number of physician visits
in the previous 6 months (mean 3.6 visits), or symptom severity. In addition, there were
no significant differences between groups in expectation of benefit scores, measured at the
beginning of the second training session. Conclusion: This investigation provides definitive
support for the efficacy of biofeedback for FI: it is superior to education and conservative
management and also superior to Kegel exercises alone (for which patients reported a similar
expectation of benefit). [Supported by grants R01 DK57048, R24 DK67674, and RR00046]
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The International Consensus Guidelines for Management of Branch Duct
Intraductal Papillary Mucinous Neoplasm (BD-IPMN) Leads to Suboptimal
Management in a Selective Group of Patients
Samuel A. Giday, Jonathan M. Buscaglia, Sanjay B. Jagannath, Christopher L. Wolfgang,
Sergey V. Kantsevoy, Jason A. Daniels, Kurtis A. Campbell, Richard D. Schulick, John L.
Cameron, Ralph H. Hruban, Anthony N. Kalloo, Marcia I. Canto
The risk of BD-IPMNs for prevalent or incident malignancy is thought to be low. Hence, a
working group of The International Association of Pancreatology (IAP) has proposed guide-
lines for the management of BD-IPMNs (Tanaka et al, Pancreatology 2006). Resection is
recommended for all patients with symptomatic IPMNs and suspected main duct IPMNs
who are surgical candidates. Resection is not recommended if an asymptomatic BD-IPMN
is < 3 cm in size, if there are no high risk stigmata (main pancreatic duct dilation > 6 mm,
mural nodules), or is without malignant cytology. AIM: To apply IAP consensus guidelines
to a large cohort of patients with resected BD-IPMNs to determine (1) the proportion of
potentially missed malignancies and the (2) the frequency of surgery for asymptomatic non-
malignant BD-IPMNs, assuming the targets for resection were IPMN with carcinoma-in-situ
(CIS) or invasive cancer (CA). METHODS: Prospective EUS and pathology databases were
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queried for IPMNs that were evaluated and/or treated at Johns Hopkins Hospital from 1990-
2006. Main duct IPMNs without a cyst were excluded. Positive cytology was defined as
mucinous pancreatic ductal epithelium definitive or suspicious for malignancy. Univariate
and bivariate categorical analysis on the prevalence of malignancy (as CIS-situ or invasive
CA) was performed. RESULTS: 132 patients (52% men, 86% white, mean age=67 years)
with at least 1 BD-IPMN underwent surgery from 1990-2006. 44 patients (33%) also had
EUS in addition to multidetector CT and 43 of these had EUS-guided FNA. Mural nodules
were detected in 10 (22.7%) and positive cytology obtained in 6 (19.3%). Forty-five percent
(59/132) of BD-IPMNs had CIS (n=23) or CA (n=36) and 24% of these had no associated
symptoms. According to consensus guidelines, 24/59 (41%) malignant BD-IPMNs would
not have been resected if surgery was performed only on BD-IPMNs > 3 cm. Out of 48
patients without symptoms that underwent surgery, 9 (19%) of the cysts greater than 3cm
were without malignancy (IPMN-adenoma/-borderline). CONCLUSIONS: When applied to
a highly selected single center referral population, current consensus guidelines on the
management of BD-IPMNs would not recommend surgery in 43% of malignant BD-IPMNs
and would recommend unnecessary surgery in 19%. Adherence to IAP guideline recom-
mendations may lead to suboptimal management of BD-IPMNs. Development and validation
of a better model for prediction of prevalent malignancies in BD-IPMNs are needed.
539
Pancreatic Cancer Development During Follow-Up Among Intraductal
Papillary Mucinous Neoplasm with Or Without Indication for Resection By
International Guidelines
Minoru Tada, Takao Kawabe, Hiroshi Yagioka, Takashi Sasaki, Hirofumi Kogure, Yousuke
Nakai, Naoki Sasahira, Kenji Hirano, Takeshi Tsujino, Hiroyuki Isayama, Masao Omata
Background: By new international guidelines of intraductal papillary mucinous neoplasm
of the pancreas (IPMN) (Pancreatology 2006), indication for resection was proposed when
the following characteristics that predict malignancy were observed: existence of mural
nodules, a main pancreatic duct diameter larger than 10 mm, or a cystic lesion diameter
larger than 30 mm. In this study, we prospectively examined incidence and types of neoplasm
developing in the pancreas during follow-up of patients with IPMN with or without the
indication. Methods: Consecutive 395 patients with IPMN were divided into 45 that met
the criteria for resection (Group A) and the other 350 who did not (Group B). 14 of the
45 and 10 of the 350 were resected when the diagnosis was made. The remaining 371 were
followed-up as outpatients with imaging diagnosis up to 12 (average 4) years. Incidence of
pancreatic cancer was compared with expected number of pancreatic cancer death calculated
with age-gender matched population. In addition, factors contributing to the development
of pancreatic cancer were analyzed by Cox proportional hazard model. Results: For those
24 who were resected, cancer was found in 8 (57%) (Group A) and 1 (10%) (Group B),
proving significant difference (p=0.033). During follow-up, cancer was subsequently found
in 11, 1/31 (3%) from group A and 10/340 (3%) from Group B, with an annual incidence
rate of 0.77%, which was 20 times higher than the expected incidence. No significant
difference of the incidence was observed between two groups. Beside a case from Group A
consistent with malignant IPMN, most cases from Group B were ordinary ductal cancer and
at least two whose tumor was found in small size appeared arising in apart from the cystic
lesions. Cancer was more frequently detected in patients with smaller diameter of cystic
lesions although no significant differences were found except age by the Cox analysis.
Conclusion: The guidelines were useful for initial diagnosis of malignant IPMN, however,
were not predictive for development of ductal cancer during follow-up. For following-up
patients without indication of resection, the whole pancreas should be carefully examined
by imagings because ductal cancer could develop anywhere in the pancreas.
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Intraductal Papillary Mucinous Neoplasms of the Pancreas Consist of
Heterogenous Clinicopathological Groups: A Single Institution Experience of
157 Resected Cases
Mari Mino-kenudson, Cathy Richards, Stefano Crippa, Vikram Deshpande, Amitabh
Srivastava, Andrew L. Warshaw, Carlos Fernandez-del-castillo, Gregory Y. Lauwers
Premise: A recently proposed histologic classification of pancreatic intraductal papillary
mucinous neoplasms includes gastric (G-IPMN), intestinal (I-IPMN), pancreato-biliary (P-
IPMN) and oncocytic (O-IPMN) subtypes. G-IPMN is considered to be the precursor of
other subtypes often reported as a small cystic lesion with low-grade atypia involving branch
ducts, while the others commonly manifest as larger lesions of the main duct and main
branches with marked atypia. However, this concept has not been tested on a large series
of cases. Design: Our series consisted of 157 resected IPMNs proven to have a communication
with the duct system and no ovarian stroma (age 37-88 [mean 66.7] years, M:F=88:69).
Each case was graded according to the WHO criteria and classified as G, I, P or O-IPMN
based on the morphology of the highest grade, i.e., more biologically advanced component.
Cases with more than one subtype of similar grade were deemed as unclassifiable. IPMNs
histologically involving the main duct to any extent and irrespective of side branch involve-
ment were classified as main duct (MD) type and others as branch duct (BD) type. The results
were correlated with various clinicopathologic features. Results: 71 cases were classified as
G-IPMN, 59 as I-IPMN, 13 as O-IPMN, 4 as P-IPMN and 10 were unclassifiable. I and O-
IPMNs were seen in younger patients than G-IPMN (P<0.05). However, within each subtype,
patients with adenoma/borderline grade were younger than those with invasive carcinoma
by 7-8 years. 45% of G-IPMNs were confined to branch ducts while all other categories
were predominantly of main duct type. Of these, I-IPMNs preferentially involved the pancre-
atic head. Among invasive carcinomas, colloid type (n=14) and mixed colloid/ductal type
(n=2) were only associated with I-IPMN while all invasive carcinomas associated with G-
IPMN were of ductal type and 3 of those associated with O-IPMN showed an oncocytic
morphology. Conclusion: Each subtype of IPMN has unique characteristics. The younger
age of patients, location, and morphology of invasive components suggest that I-IPMN &
O-IPMN are truly distinctive neoplastic processes and may not arise through progression
of G-IPMN as currently believed.
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* ( ) indicates the number of cases located in the pancreatic head ** A: adenoma, BL:
borderline malignancy, ID: intraductal carcinoma, Inv: invasive carcinoma
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Surgical Vs. Conservative Approach to Intraductal Papillary Mucinous
Neoplasm: When to Intervene?
Mohammad A. Al-haddad, Frank G. Gress, Darren A. Pavey, Surakit Pungpapong, Feng
Li, Christopher D. Wells, Cuong C. Nguyen, Ananya Das, Peter V. Draganov, Dennis
Collins, Seth A. Gross, Massimo Raimondo, Timothy A. Woodward, Michael B. Wallace
Introduction: Intraductal papillary mucinous neoplasms of the pancreas (IPMN) are increas-
ingly recognized in clinical practice. They represent a unique clinicopathologic entity that
is characterized by mucin production, cystic dilation of the pancreatic ducts, and intraductal
papillary growth. Recent literature suggests that up to 45% of IPMN are malignant and
should be resected; however these data are based on larger, primarily symptomatic lesions.
The risk of malignancy and need for surgical resection in smaller, lower risk lesions is not
known. Aim: To identify predictors of a benign natural history in patients with IPMN.
Methods: Patients with cystic lesions of the pancreas suspicious for IPMN were evaluated
for potential clinical predictors of malignancy. Surgery was advised for those with a “high
risk” features (mass, mural nodule, malignant cytology or CEA > 200 on EUS-FNA or
pancreatic symptoms). Other patients were managed with serial imaging (CT, MRI) and
clinical follow up. Potential predictors were compared to a gold standard of surgical pathology
or long term clinical follow up without progression. Results: One hundred and seventy four
patients with IPMN were included. Ninety eight patients IPMN were followed conservatively
and were compared to seventy six patients who underwent surgical resection based on high-
risk features. Cancer or dysplasia was found in 27/76 (36%) of resected patients. None of
the conservative group developed cancer during a median follow up of 10 months (0-78
months). The presence of a mass/mural nodules on EUS, symptoms and younger age were
all predictors of malignancy based on univariate analysis (Table 1) with odds ratio of 8.77
and 2.74 for presence of mass/nodules and symptoms respectively using the multivariate
analysis model. None of the other factors were found to be significant in predicting malig-
nancy. Conclusions: 1- Our study confirms the previously described predictors for develop-
ment of malignancy in IPMN. We found an unexpected inverse association with age that
requires further studies to evaluate, 2- Conservative management of IPMN with no features
of malignancy is probably safe.
Table 1
* Median
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Accuracy of EUS in the Topographical Diagnosis and in Predicting Malignancy
in Patients with Intraductal Papillary Mucinous Tumours (IPMN):
Comparative Blind Study with Histology in 103 Operated Patients
Dermot O'toole, Anne Couvelard, Laurent Palazzo, Elize Chanteloup, Pascal C. Burtin,
Alain Aubert, Frédérique Maire, Marie-pierre Vullierme, Pascal Hammel, Alain Sauvanet,
Philippe Lévy, Philippe Ruszniewski
Introduction: Management of patients with IPMN is difficult due to the heterogeneous
presentation (involvement of the main pancreatic duct [MPD], branch ducts [BD] or mixed
types) and difficulties in predicting histological grades using preoperative morphology. To
date, factors suggestive of malignant transformation (MPD diameter >10 mm, BD >30 mm,
presence of mural nodules…) have not been universally accepted. Aim: Evaluate the dia-
gnostic precision of EUS in predicting the type and extent of involvement as well as the
histological grade of IMPN in a cohort of patients undergoing surgery in a single centre.
Patients & Methods: Between 2000 and 2005, 103 patients undergoing surgery for IPMN
(52 women; median age: 61 years [range: 21-76]) with preoperative EUS were included.
The types of lesion as well as topographical extension assessed at EUS were compared
with final macroscopic and histological results (in a blinded manner by two independent
physicians). Factors predictive of cancer were analysed by multifactorial logistic regression
(IC: 95%) including: age, sex, involvement of the MPD, BD or mixed; presence of dilated
MPD (>10mm) or DB (>20mm); parietal thickening (≥2mm), presence of parietal nodules,
duct communication, presence of a mass, number of dilated segments from 1 to 4: head,
isthmus, body, tail). Results: At histology, IMPN involved the MPD, BD or mixed in 3, 33
and 67 patients, respectively. MPD involvement was correctly predicted by EUS in 91% of
patients; EUS overestimated MPD involvement in 21% of isolated BD-type (passive dilatation
of MPD). The histological grades were: hyperplasia or low-grade dysplasia (n=26); moderate
or high-grade dysplasia (MD/HGD, n=54) and invasive cancer (n=23). The sensitivity of
EUS for predicting invasive cancer was 70%; 4 of 7 false negatives were found to be small
invasive foci along the MPD or BD. EUS overestimated cancer in 2 patients with HGD. At
multivariate analysis significant predictive factors of invasive cancer were the presence of a
mass at EUS (p<0.0001) and male sex (p=0.01); diagnostic precision: 88%. The extent of
MPD dilatation was the only factor predictive of MD/HGD (p<0.0001) with a PPV of
100% when greater than two segments are involved. Conclusion: In patients with IPMN,
preoperative EUS is good in predicting the topographical extent of ductal lesions. The
presence of a mass is the only morphological criterion predictive of invasive cancer and
these results questions the use of previously defined malignant criteria (diameter of duct
dilatation, intraductal masses/nodules, and parietal thickening). HGD can be accurately
predicted in the presence of > 2 dilated MPD segments.
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Long Term Follow Up of Patients with Incidentally Discovered Pancreatic
Cystic Neoplasm Evaluated By EUS
Nonthalee Pausawasdi, David Heidt, Diane Simeone, Richard S. Kwon, Sukanya
Subramanian, James Scheiman
Background: The management of incidental pancreatic cystic neoplasms is not well estab-
lished due to lack of adequate information on the natural history of these lesions. Aim: To
characterize clinical outcomes in a cohort of incidentally discovered asymptomatic pancreatic
cystic lesions undergoing EUS +/- FNA. Methods: Follow-up of patients with pancreatic cysts
imaged by EUS from 1995-2005. EUS findings, follow-up radiographic studies, cytology, and
pathology results were reviewed. Patients and referring physicians were contacted for long-
term outcomes. Results: 317 patients underwent EUS for evaluation of pancreatic cystic
lesions. 97/317 (31%) had asymptomatic, incidentally discovered pancreatic cysts; 220/317
(69%) were symptomatic. Of 97 asymptomatic patients, 93 were contacted. Among this
cohort, 71/93 (76%) had lesions smaller than 3 cm and 22/93 (24%) had larger lesions. All
71 patients with small lesions were followed without surgery. The median follow-up time
was 44 months (range 6-123 months). 69/71 (97%) are alive and free of symptoms of
pancreatic disease and 2 patients died of unrelated causes. Among the 71 patients with
small lesions, FNA was performed in 31 patients (44%). The fluid amylase, lipase, CEA,
(mean+/- sem) were 8603+/-2013 IU/L, 1841+/-377 IU/DL, 499+/-289 NG/ML. The fluid
cytology was negative for malignant cells. 28/71 patients (40%) had either a follow-up
radiographic study (CT, MRI), or EUS that was reviewed. Of 28 patients, 27 had stable
lesions and 1 had minimal enlargement on follow-up. All 22 patients with lesions larger
than 3 cm underwent surgical resection. Pathologic analysis of the 22 resected lesions
revealed that 2/22 had adenocarcinoma and ~ 50% had premalignant lesions. Summary: In
this study, 2 % (2/97) of patients underwent EUS for incidentally discovered pancreatic
cysts were found to have adenocarcinoma, and EUS predicted malignancy. Small incidental
pancreatic cysts without concerning EUS features are likely benign. Conclusions: EUS features
predict benign clinical outcomes in patients who have incidentally discovered asymptomatic
pancreatic cysts confirmed long term at median follow-up of 44 months. These individuals
can be followed without undergoing early surgical resection. Long-term follow-up studies
of well characterized patient cohorts with pancreatic cystic lesions are essential to provide
data for clinicians to appropriately select patients for surgical intervention.
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Aspirin Unlike NSAIDs Potentiates the Risk of Ulcer Gastrointestinal Bleeding
Among Helicobacter pylori Infected Individuals
Maite Arroyo, Luis alberto García-rodriguez, Sonia Hernandez-diaz, Pilar Roncales, Angel
Lanas
Background:Our current understanding of the effect of H. pylori on the risk of ulcer G-I
bleeding (UGIB) in patients taking NSAIDs or aspirin is derived from studies carried out
in Asian population. Interpretation of european studies has been hampered by important
methodological limitations. Goal:To determine the risk of ulcer bleeding associated with
the interaction of Hp infection and NSAIDs or low-dose aspirin use. Methods: Hospital-
based case-control study with prospective case ascertainment and retrospective data collec-
tion. Cases were consecutive patient hospitalized because of UGIB confirmed by endoscopy
in a general hospital. Age-matched controls (±5 years)(1:1) were chosen among those
attending the general outpatient clinics for reasons considered to be unrelated to NSAIDs
(either as an indication or contraindication). Drug use was considered to be current when
the drug was taken up to 7 days prior to the index date. The presence of Hp infection was
determined by western blot analysis of the presence of antibodies to CagA and/or to VacA
antigens in serum (Bioblot Helicobacter, Biokit SA. Barcelona, Spain), techniques previously
validated in our area. Relative risk of UGIB for the individual factors and the interaction
are provided and estimated by logistic regression. Results: 368 cases and 347 controls were
studied (mean age±SD was 61.7+17.1, 59.1% of males). The prevalence of NSAID and/or
low-dose ASA use was 32.9 % in cases and 20.5% in controls. The prevalence of Hp infection
was 85.5% in cases and 41.7% in controls (RR=8.5; 95%CI 5.8, 12.5). 37 cases and 2
controls did not have data on Hp infection and were excluded from all analyses. All results
are adjusted for age, sex, past ulcer history,smoking in addition to the studied drug exposures.
Table: Conclusion: NSAIDs present only a clinically significant effect in the absence of Hp.
Use of NSAIDs does not potentiate the risk conferred by Hp infection. This could explain
the different estimates of risk of NSAIDs observed in different populations when Hp status
is not considered. Aspirin increases the risk of UGIB independently of Hp and shows a
potentiation of the risk among Hp infected individuals.
Interaction NSAIDs/aspirin with Hp infection
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Adherence to Gastroprotection and the Risk of NSAID-Related Upper
Gastrointestinal Complications
E. M. Van soest, M. C. Sturkenboom, J. P. Dieleman, K. M. Verhamme, P. D. Siersema, E.
J. Kuipers
Objectives: Upper gastrointestinal (UGI) complications are a well recognized risk of NSAID
treatment, which requires prevention in high risk patients. Adherence to gastroprotective
agents (GPAs) in NSAID users is suboptimal, but little is known about the effect of non-
adherence on UGI risk. Aim: To investigate the association between the level of adherence
to GPAs and the risk of serious NSAID-related UGI complications in patients using non-
selective NSAIDs (nsNSAIDS). Methods: A nested case-control study was conducted within
a cohort of new nsNSAID users with at least one risk factor for a NSAID-related UGI
complication, identified within the Dutch Integrated Primary Care Information database
(IPCI) during 1996-2005. Cases with UGI ulcers or bleedings during NSAID use were
matched to controls on age and calendar time (same index date). Adherence to GPAs was
calculated as the proportion of NSAID treatment days covered (PDC) by a GPA prescription.
The primary risk window was the most recent episode of NSAID use prior to the index
date. The risk of a serious NSAID-related UGI complication was estimated by adjusted odds
ratios (OR) with 95% confidence intervals (95%CI) using multivariate conditional logistic
regression analysis. Results: Within the study cohort of 26,307 new nsNSAID users with at
least one risk factor, we identified 119 patients (0.45%) with a NSAID-related ulcer or
bleeding during or within 60 days after stopping the nsNSAID. Considering the most recent
episode of continuous nsNSAID use prior to the index date, 14.9% of the nsNSAID users
received GPAs (21 cases). Of these, 71.0% had a PDC ratio >80% (full adherence), 22.0%
had PDC ratios between 20-80% (partial adherence) and 7.0% was non-adherent (PDC
<20%). The risk of a serious NSAID-related UGI complication increased from 2.5 (95%CI:
1.0-6.7) in partially adherent persons to 4.0 (95%CI: 1.2-13.0) in those with a PDC <20%.
Considering the PDC level as a continuous measure (from high to low) the risk of a serious
NSAID-related UGI complication increased with 16% (95%CI: 3-32%) with every 10%
decrease in adherence. Excluding H2RA users that were not adequately dosed for the
prevention of NSAID-related UGI complications (i.e. less than double dose), the risk was
increased 2.7-fold in patients that were partially adherent and 4.5-fold in patients that were
non-adherent. Conclusion: There is a strong relationship between the level of adherence to
gastroprotective medication and the risk of serious UGI complications in high-risk nsNSAID
users. This underlines the need for proper patient instruction regarding adherence to GPAs
or further development of fixed combination strategies.
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Clinical Practice in the Prevention of NSAID-Associated GI Complications: An
Educational -Based Approach to Improve Non-Evidence Based Clinical Practice
Habits
Angel Lanas, Javier Ballina, Juan V. Esplugues, Eduardo Sobreviela, Javier Zapardiel
Background: Current guidelines in the prevention of NSAID-associated side effects are not
being followed in many countries. Objectives:1)To determine current clinical practice in
the prevention of GI side effects in Spain 2) To determine whether educational programmes
could modify non-evidence based clinical practice Methods: The data on demographics,
clinical history and treatments recorded from patients visited by 355 unselected rheumatolo-
gists or orthopedic surgeons randomly distributed across the country in Spain were evaluated
in two different phases. In Phase I, retrospective data from the last 5 patients visited by the
specialist were collected anonymously; 2-4 months later these specialists attended seminars
and received information regarding current scientific evidence on prevention strategies and
gastroprotection (GP)in the NSAID field; 3 months later, a Phase II was carried out under
the same circumstances with the same specialists. Inclusion criteria: patients>18 taking
NSAIDs either before/after being visited by a doctor who participated in both phases of the
study and attended the educational programme Results: Demographics of patients in both
phases (n=1563 and 1548 respectively) were homogeneous (61.8±13.7 y.o.,59%
females;61.1% OA patients) as were the type of NSAID prescribed or taken by patients
(3.8% coxibs). The length of NSAID prescription was similar in both phases as was the
proportion of patients who did not received any NSAID after the visit (12.8% vs 12.6%).
Conclusions: A high proportion of patients with musculoskeletal problems visited by the
specialist have at least 1 RF. GP is widely and probably overused both in patients being
prescribed or not prescribed with NSAIDs. The proportion of at -risk patients not receiving
appropriate GP is low. The educational programme had little impact on clinical practice
habits.
Patients on GP (PPI/misop)
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
High-risk=history of bleeding ulcer or taking anticoagulants;P-Value X2 Trend Cochran-
Armitage: Phase I:0.0519;Phase II:0.0043
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Risk Factors for NSAID-Associated Upper GI Clinical Events in a Long-Term
Double-Blind Study of 34,701 Arthritis Patients
Loren Laine, Sean P. Curtis, Byron L. Cryer, Yanqiong Zhang, Christopher P. Cannon
Precise GI risk assessment is key in the management of NSAID users. However, almost all
assessments of NSAID-associated GI risk factors are from observational studies, with potential
bias due to unknown or unmeasured factors. METHODS: Patients≥ 50 yrs with rheumatoid
arthritis or osteoarthritis were randomly assigned to diclofenac (150 mg qd) or etoricoxib
(60 or 90 mg qd). Low-dose aspirin and PPIs were allowed. Predefined endpoints of all
UGI clinical events (perforation, obstruction, bleeding or ulcer) and the subset of UGI
complicated events (perforation, obstruction, witnessed ulcer bleeding or significant bleeding)
were adjudicated by a blinded committee. Prespecified baseline clinical variables were
assessed with a Cox proportional hazard model. RESULTS: Baseline characteristics for
etoricoxib (N=17,412) vs. diclofenac (N=17,289) included age ≥ 65 (41.5 vs. 41.4%),
women (74.2 vs. 74.2%), prior UGI event (6.5 vs. 6.6%), low-dose aspirin use (34.6 vs.
34.6%), steroid use (15.8 vs. 16.0%), and PPI use (38.7 vs. 38.5%). Mean treatment duration
was 18 mos. UGI clinical events occurred in 422 patients (RR for etoricoxib vs diclofenac
0.69; 0.57-0.83); 160 had complicated events (RR = 0.91; 0.67-1.24). Significant predictors
are shown in Table 1 and subgroup results in Table 2 (no treatment by subgroup interaction
was significant). CONCLUSIONS: Age ≥ 65 yrs, prior UGI event, and baseline aspirin use
increase complications 3-4 fold. History of dyspepsia or CV disease may modestly increase
UGI clinical events. Baseline PPI use decreases risk∼50%. No risk factor, including baseline
PPI or aspirin use, significantly alters the relative risk between etoricoxib and diclofenac.
Table 1. Predictors at Baseline of UGI Events
Table 2. Rates of UGI Events Related to Baseline Characteristics
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Recent Advances in the Field of NSAID-Associated Side Effects Are Not
Appropriately Translated Into Clinical Practice
Angel Lanas, Javier Ballina, Eduardo Sobreviela, Javier Zapardiel
Background and Objectives: The new and recent data derived from studies focused on the
side effects associated both with NSAID and recommendations in prevention strategies have
received a wide display of attention in both scientific and non-scientific journals. It is unclear
whether the appropriate information has been translated into clinical practice. Methods: We
have conducted a nation-wide survey among 440 unselected specialists (rheumatologist and
orthopedic surgeons) distributed across the country and who represent the two specialties
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that most frequently prescribe NSAIDs. Doctors were questioned about issues with proven
scientific evidence that had been reported over the last 5 years. Results: 84.5% of doctors
were affiliated to some scientific society that had recently published guidelines regarding
the appropriate use of NSAIDs. Fifty per cent reported that the overall rate of upper
gastrointestinal (GI) complications in NSAID users was superior to 5 events per 100 patient-
years, 36% considered that NSAID use was not associated with damage to the lower GI
tract and 27% that low-dose aspirin did not induce damage to the upper GI tract. However,
most doctors (> 90%) correctly identified the 6 most important risk factors for NSAID-
associated GI complications. Regarding COX-2 selective inhibitors, 85% of doctors were
aware that these drugs were associated with a better GI profile than tNSAIDs, but 47% of
them did not know that low-dose ASA reduces the GI benefits of these drugs; Furthermore,
56% of the interviewed thought that COX-2 selective inhibitors were less safe than the
combination of a tNSAID+PPI for the GI tract. Most (95%) knew that COX-2 selective
NSAIDs were associated with increased cardiovascular risk; 54% considered that H2-RAs were
effective in the prevention of NSAID-induced GI complications and 40% that misoprostol was
effective in the prevention and treatment of NSAID-induced dyspepsia. Regarding their usual
clinical practice 52.4 % always prescribed some gastroprotectant (a PPI in 90% of cases)
with NSAIDs and 46% did so only when at least one risk factor was present. Conclusions:
A wide proportion of specialists that prescribe NSAIDs regularly in clinical practice over-
estimate the incidence of GI complications in NSAID users, are not aware that NSAID induce
damage to the lower GI tract, that low-dose aspirin reduces the GI benefits of COX-2
selective inhibitors, or that H2-RAs are not effective in the prevention of GI complications.
Although most doctors properly identify risk factors, they prescribe gastroprotectants ( PPIs)
regardless of the presence of risk factors.
585
Elevated Levels of Circulating Mesenchymal Stem Cells in Patients with
Chronic Hepatitis B and C
Julian A. Abrams, Vinita Jacob, John S. Manavalan, Timothy C. Wang, Sheng-wen Wang
BACKGROUND: Adult stem cells play a crucial role in the repair and maintenance of tissues.
There are three major populations of adult stem cells: mesenchymal stem cells (MSC),
endothelial progenitor cells (EPC), and hematopoietic stem cells (HSC). Mesenchymal stem
cells generate fibrous connective tissue, bone, cartilage, and the reticular network that
supports blood cell formation. The pathways that lead to hepatic fibrosis in chronic hepatitis
are not completely understood, and the recruitment of MSCs and other progenitor cells
may be involved in this process. We conducted an exploratory analysis of circulating
progenitor cells in patients with chronic viral hepatitis. METHODS: Peripheral blood monon-
uclear cells (PBMCs) were isolated from 7 patients with chronic hepatitis B or C without
cirrhosis and from 7 healthy controls. Data were collected regarding age, gender, and stage
of fibrosis on liver biopsy. Quantification of circulating progenitor cells was performed by
flow cytometry. PBMCs were labeled with fluorochrome conjugated monoclonal antibodies
against CD45, CD34, CD133, VEGFR2, CD117, and CD44, and incubated and washed
prior to 6-color analysis using a LSR II flow cytometer. EPCs were defined as CD34+ CD133+
VEGFR2+, HSCs as CD45+ CD34+ CD117+, and MSCs as CD45- CD44+. Counts were
expressed as number of progenitor cells per 10,000 mononuclear cells. RESULTS: Patients
with chronic hepatitis B or C had a significantly higher mean number of MSCs per 10,000
mononuclear cells than healthy controls (68.7 vs. 38.9, p=0.04) (Table 1). There was no
difference between patients with chronic viral hepatitis and controls with respect to number
of circulating EPCs (2.8 vs. 2.9, p=0.91) or HSCs (6.7 vs. 5.5, p=0.50). There was no
significant correlation between number of circulating MSCs and age, gender, or stage of
fibrosis on liver biopsy. CONCLUSIONS: Mesenchymal stem cells are present in significantly
higher levels in serum from patients with chronic hepatitis B and C than from healthy
controls. It is possible that recruitment of MSCs plays an important role in the development
of hepatic fibrosis. Further studies should be aimed at defining the role of MSCs in hepatic
fibrosis and identifying the signaling mechanisms that trigger their recruitment.
Table 1. Mean number of circulating progenitor cells per 10,000 mononuclear cells in
patients with hepatitis B or C and in healthy controls. Standard deviations in parentheses.
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Effect of Different Types of Liver Resection in Heamatopoetic Stem Cells
Mobilization
Maria assunta Zocco, Marialuisa Novi, Felice Giuliante, Emanuele Rinninella, Natalie
Saulnier, Maria ausilia Pugliesi, Carlo Rumi, Maria elena Ainora, Gennaro Nuzzo,
Giovanni Gasbarrini, Antonio Gasbarrini
Background: Bone marrow cells have been shown experimentally to participate in liver
regeneration after different kind of liver injuries, especially when the response of mature
hepatocytes is not sufficient. In particular, both In Vitro and In Vivo experiments suggested
that such cells might contribute to the regeneration after different kind of liver injuries,
even if it is difficult to quantify their effective contribution to liver growth response in
various experimental settings. As concerning patients submitted to partial hepatectomy, the
results of previous studies are not conclusive showing opposite results in different patients
populations. Aim: To investigate bone marrow stem cells mobilization in patients undergoing
hepatectomy according to type of resection and disease aetiology. Patients and methods:
Ten patients undergoing hepatectomy for different causes were enrolled. Patients were
divided into two groups according to the extent of liver resection: 5 patients undergoing
major liver resection (at least three segments: Group A) and 5 patients undergoing minor
resection (Group B). Mobilization of CD34+ cell was evaluated by cytofluorimetry on peri-
pheral blood samples at different time points: baseline, 1, 3, 7, 15 and 30 days after surgery.
Ten healthy subjects undergoing blood donation were also enrolled to evaluate the basal
value of CD34+ cells (Group C). Results: White blood cell counts remained in the normal
range (4.1-9.8 X 109/L) in all groups throughout the follow up even with significantly higher
values in patients undergoing surgery (at baseline 8.4 x 109 ± 3.0/L and 8.2 x 109 ± 2.5/
L) compared to healthy controls (6.2 x 109 ± 1.2/L) (p<0.01). The increase of CD34+ cells
was significantly higher in Group A as both absolute number and percentage at any time
point after resection compared to Group B ad C (day 7: 0,20% of WBC in group A vs 0.06%
in Group B and 0.05% in healthy controls; p<0.001). Among patient submitted to major
liver resection CD34+ mobilization was higher in patients with chronic liver disease compared
to patients with healthy liver. Conclusions: These results appear to confirm that the role of
extrahepatic progenitors in the normal, transiently injured liver repopulation is extremely
limited. However, major liver resection may represent a trigger for the mobilization of
haematopoietic stem cells thus suggesting that when the body endogenous repair mechanisms
are overwhelmed, extrahepatic progenitors may probably replace large amounts of the liver
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Significance of a Novel Biomarker for Hepatocellular Apoptosis (Caspase 3-
Cleaved Cytokeratin-18 Pruduct) in Acute and Fulminant Hepatic Injury
Yuki Yasumi, Yasuhiro Takikawa, Ryujin Endo, Kazuyuki Suzuki
Aim: Extensive hepatocyte injury and impaired liver regeneration are responsible for poor
prognosis of fulminant hepatic failure (FHF). Susceptibility of regenerating hepatocyte to
death receptor-mediated apoptosis is considered to be implicated in impaired liver regenera-
tion in FHF. Therefore, evaluation and control of hepatocellular apoptosis is critical for
improvement of prognosis in FHF. We experimentally and clinically evaluated the usefulness
of a novel biomarker of hepatocellular apoptosis, caspase 3-cleaved cytokeratin (CK)-18
pruduct. Method: 1. experimental study: Typical oncosis and apoptosis were induced by 3
mM H2O2 and 1 µM staurosporin (STS) in cultured HepG2 cells. The medium and cell
lysate ware serially obtained and provided for determination of CK-18 peptide 387-396
(M30Ag) using M30-Apoptosense ELISA kit (Peviva; Alexis, Grunwald, Germany). Apoptotic
index (AI: percentage of apoptotic cells in total cell), viable cell count (VC) and AST were
also determined by DAPI staining, MTT assay and automatic analyzer, respectively. 2. Clinical
study: Serum M30Ag was determined in 30 patients with acute hepatic injury, including
12 FHF patients. Results: 1. Experimental study: AI was 69% and VC was 8.0% at 20 hr
after STS administration. Intracellular M30Ag rapidly and markedly increased from 135 U/
L at prior STS administration up to 1502 U/L at 6 hr after STS and decreased again to 106
U/L at 20 hr after STS, whereas leaked M30Ag in medium was not increased until 20 hr
after STS. In contrast to apoptosis, no significant increase of M30Ag was seen in intracellular
nor in medium after H2O2 administration, although the VC decreased to 16% at 6 hr after
H2O2. 2. Clinical study: Serum M30Ag level markedly increased to 3495 [431-8431] (mean
[range]) U/L in AHI patients, significantly correlated to serum AST level (r=0.759, p<0.001)
but not associated with severity of the disease. Conclusion: M30Ag measurement clearly
distinguished apoptosis from oncosis in experimental study, but M30Ag increased in extracel-
lular fluid only after cell breakdown. Clinical study revealed that hepatocyte is damaged
through apoptotic mechanism in acute hepatic injury but that serum M30Ag elevation may
depend on leakage of hepatocyte membrane in consistent with the experimental findings.
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Correlation of Hepatic Fibrosis with Serum ALT and Viral Levels in Patient
with Chronic Hepatitis B
Ravi Vachhani, Dilip Moonka, Vijyamalini Pampati, Hetal Vachhani, Kimberly Brown,
Mary ann Sherbondy, Lois Lamerato, Stuart Gordon
Background: Current guidelines emphasize the importance of serum ALT and HBV DNA
levels when assessing the role of HBV treatment. Because of disease course fluctuation,
however, patients with normal ALT or low-level viremia may have significant fibrosis.
Objective: We sought to determine the relationship between hepatic fibrosis and serum
ALT values and baseline viral levels in a large cohort of US patients with chronic hepatitis
B Methods: We reviewed the charts of consecutively presenting treatment naïve chronic
HBV patients who underwent liver biopsy between 1997-2006. We recorded liver histology
and serum ALT/HBV DNA levels done at the time of liver biopsy. We used means for
patients with multiple values. We defined normal ALT as ≤40 U/L for men and ≤35 U/L
for women. Metavir scores (F0-F4) were used to grade fibrosis. Chi-square table was used
for statistical analysis. Results: We identified 105 HBV carriers (67% men), including 38%
Asian, 25% African American, and 30% Caucasian. The median age was 43, median ALT
was 55 and median HBV DNA was 214,000 copies/ml, including 13 patients with no
detectable viremia (≤300 copies/ml or 0.02 pg/ml). ALT values were not available for five
patients. Fifty-four percent were HBeAg negative. Serum ALT values strongly correlated with
degree of fibrosis (p < 0.001) but 19% of those with normal ALT had significant fibrosis
(F2 or F3). Increasing HBV DNA levels trended toward more advanced fibrosis (p=0.063).
HBV DNA levels >105 copies/ml correlated with more advanced fibrosis (p=0.007) although
34% (16/47) with viral loads≤105 copies/ml were≥F2. Age was not significantly correlated
with degree of fibrosis. The sensitivity, specificity, PPV and NPV of abnormal ALT and viral
load >105 copies/ml to detect fibrosis ≥F2 were 87,46,58,81 and 69,57,60,66 respectively.
Conclusion: Although higher ALT and higher HBV DNA levels were associated with more
advanced fibrosis, 34% of patients with viral levels ≤105 copies/ml at presentation and 19%
with normal ALT values had fibrosis grades of ≥F2. These findings validate the role of liver
biopsy to assess HBV disease severity, especially among those patients with a low suspicion
of significant fibrosis.
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Iron Increases HCV and Heme Oxygenase-1 (Ho-1) Expression in HCV-
Expressing Human Liver Cells
Herbert L. Bonkovsky, Lisa Rossi
University of Connecticut Health Center Background Chronic hepatitis C (CHC) is an
important cause of liver disease throughout the world. It has been shown that HCV increases
oxidative stress in the liver and that iron is a co-factor in this process. Studies have suggested
that reduction of iron in patients with CHC can slow fibrosis and decrease the risk of
hepatocellular carcinoma likely due to a decrease in oxidative stress. Until recently, there
were no cell culture models in which to study HCV infection. The recent development of
HCV replicon cell lines provide a unique opportunity to study the effects of oxidative stress,
including the effect of iron, on hepatocytes that express HCV. Heme oxygenase-1(HO-1),
the inducible isoform of the rate controlling enzyme of heme catabolism, is up-regulated
in cells expressing HCV proteins, as well as by other stressful stimuli. HO-1 plays a key
role as a protector against oxidative stress. The aim of this study is to investigate the effects
of oxidative stress in the form of iron on HO-1 and HCV expression in hepatoma cell lines
which express HCV proteins. Methods We investigated the effects of iron and oxidative
stress by exposing human hepatoma (Huh-7) cell lines expressing HCV proteins to varying
forms of iron, to H202 (an oxidative stressor) and to cobalt protoporphyrin (an inducer of
HO-1). We measured mRNA expression of HO-1 using RT-PCR. We investigated the effects
of iron on mRNA expression of HCV proteins in cell lines which either express core protein
to NS5, or non-structural proteins from NS3 to NS5B. Results Iron in the form of ferric
nitrilotriacetate (100 uM,) ferric citrate( 40 uM,) or TMH-ferrocene (100 uM), all resulted
in a 5 fold up-regulation of HO-1 mRNA levels. CNS3 cells, which express HCV core protein
to NS3, have increased expression of HO-1, even without exposure to iron or H2O2,
compared to 9-13 cell lines, which express NS3 to NS5B, or wild type (WT) Huh-7 cells.
There was a 4 fold increase in HCV mRNA in cells treated with iron. Conclusions Iron
increases HO-1 and HCV mRNA expression in human hepatoma cells expressing HCV. We
confirm recent findings that there is an increase in HCV and HO-1 gene expression in cells
expressing HCV viral proteins (J Hepatol 2006; 45: 5-12). We conclude that HCV results
in increased oxidative stress and up-regulation of HO-1 and that these effects are further
increased by iron. These results support the theory that iron is a co-factor in liver injury
in patients with underlying liver diseases, including HCV, and that this is likely due to an
increase in oxidative stress. Acknowledgment: Supported by a grant from NIH (RO1
DK38825).
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Age Greater That 40 Is a Stronger Predictor of Advanced Chronic Hepatitis B
(HBV) Than Current North American HBV Treatment Algorithms That
Demonstrate Low Predictive Value Regardless of HBeAg, Viral Load, Or
Alanine Aminotransferase (ALT)
Victor Araya, Ricardo Restrepo, Dennis Ng, Ramesh Koka, Kenneth D. Rothstein,
Mauricio Orrego, Santiago J. Munoz
Background: Little data exists linking treatment algorithms with histological severity. Aim:
Determine whether the North American HBV treatment algorithms and/or patient demo-
graphics correlate or predict the severity of chronic HBV. Method: Inclusion criteria: 1)
HBV-infected patients with at least two ALT's, detectable HBV DNA quantitative levels, and
eAg status obtained over a minimum of 6 months; 2) No prior antiviral therapy; 3) a
METAVIR scored liver biopsy within 2 years of the serological data. Peak ALT and HBV
DNA levels were used to define ALT and VL categorization. Exclusion criteria: 1) HIV or
HCV co-infection; 2) Iron overload; 3) hepatocellular carcinoma. Definitions: High viral
load (HVL): ≥104 copies/ml (c/ml) if eAg -, or ≥ 105 c/ml if eAg+; low viral load (LVL):
< 104 c/ml if eAg -, and < 105 c/ml if eAg+. For analysis, patients were distributed among
4 groups depending on their viral load and eAg status. Groups 0: eAg (-) and LVL; Group
1: eAg (-) and HVL; Group 2: eAg (+) and LVL; Group 3: eAg (+) and HVL. Spearman
correlation, Fisher's exact test, and logistic regression analysis were employed for statistical
modeling. Results: 425 patients seen between 2001 and 2006 were evaluated. 96 patients
met inclusion criteria. 61% were Asian, 59% males, mean age 47 (67% Age ≥ 40), 58%
had persistently normal ALT, 65% were eAg negative. No correlation existed between biopsy
grade or stage, and eAg status, ALT status, gender, or ethnicity. Groups 0 and 3 correlated
with biopsy grade (P=0.03 Fisher's Exact Test, FET), but not stage (P=0.46 FET). In Group
0, 37% had Stage≥ 3 and 18% had Grade≥ 3. The only variable demonstrating statistically
significant correlation with stage and grade was Age ≥ 40 (P=0.004 FET). Stage ≥ 3 was
seen in 20% age <40 and 51% age ≥ 40 and Grade ≥ 3 was seen in 17% age < 40, and
36% age ≥ 40. Logistic regression did not show that any Group, ALT status, Viral load
level, or eAg status was able to predict stage or grade ≥ 3. Age ≥ 40 had the highest area
under the ROC at 0.69 for advanced histological stages (3 or 4). Combining the variables
Age ≥ 40, Groups 1-3, and Abnormal ALT yielded an area under the ROC of 0.71 for Stage
≥ 3 and 0.77 for Grade ≥ 3. Conclusion: Current treatment algorithms for hepatitis B do
not correlate nor predict the severity of chronic HBV. Since available HBV treatment can
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improve HBV infection severity, accurate histological diagnosis is important for risk assess-
ment. Thus, patients age ≥ 40 may benefit most from a liver biopsy.
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Rectal Spectral Markers: A Novel, Accurate Modality to Risk-Stratify for
Colorectal Cancer (CRC)
Hemant K. Roy, Vladimir Turzhitsky, Young L. Kim, Michael J. Goldberg, Yang Liu,
Randall E. Brand, Nahla Hasabou, Mohammed Jameel, Vadim Backman
Introduction Finding an accurate, minimally invasive risk-stratification modality is critical
for devising cost-effective CRC screening strategies. Exploitation of the “field carcinogenesis”
through analysis of rectal/distal colonic mucosa is an attractive option; however previous
attempts (ACF, microarray, proteomic, apoptosis and proliferation), while validating the
concept, have not been sufficiently accurate or practical for clinical use. Our multidisciplinary
group has developed a number of optics technologies (Nature 2000, Nature Med 2001,
Gastroenterology2004) including most recently low-coherence enhanced backscattering spec-
troscopy (LEBS) which allows unprecedented quantitative information about epithelial nanos-
cale architecture. We have previously reported that LEBS markers were extraordinarily
sensitive to the colonic “field effect” in experimental models of CRC(Clin Cancer Res 2006).
In this study, we assessed the clinical utility of rectal LEBS markers. Methods: Two rectal
biopsies were taken from the endoscopically normal mucosa of 200 patients undergoing
colonoscopy. LEBS signals were obtained from these fresh (unfixed) tissues. Four previously
established LEBS markers were calculated by investigators blinded to endoscopic findings.
Results: The LEBS markers generally showed a progressive and highly statistically significant
alterations in patients who harbored adenomas and advanced adenomas (see table). The
performance characteristics for advanced adenomas were excellent (sens=100%, Spec=88%,
PPV=71%, NPV=100%). Two markers were altered in subjects with either a personal or
family history of colonic neoplasia but no current lesions. Thus, some markers represent
long term risk whereas others are more sensitive to the presence of current neoplasia. Given
that these markers represent <10% of the light scattering data, future algorithms are likely
to outperform these already remarkable results. Conclusions: We demonstrate that rectal
spectral markers could accurately risk stratify patients for the presence of adenomas throughout
the colon. Aside from screening for concurrent neoplasia, LEBS markers could provide long
term risk assessment for both sporadic and familial CRC. In the future, we envision that
primary care physicians may be able to determine need/timing of colonoscopy during the
annual rectal exam by using a recently developed minimally intrusive fiberoptic probe.
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A Population-Based Case Control Study of the Effectiveness of Colonoscopy
for Prevention of Death from CRC
Nancy N. Baxter, Meredith A. Goldwasser, Lawrence Paszat, Refik Saskin, David R.
Urbach, Linda Rabeneck
Introduction: Colonoscopy has been increasingly advocated as the preferred method for
screening the population for colorectal cancer (CRC) although no study has directly evaluated
effectiveness. We conducted a population-based case-control study to evaluate the effect-
iveness of colonoscopy for the prevention of death from CRC. Methods: We identified all
individuals diagnosed with CRC in Ontario age 52 to 90 from Jan 1996 through Dec 2001
who died of CRC by Dec 2003 using the Ontario Cancer Registry. These patients were our
cases. For each case, we randomly selected 5 controls from the Ontario population who
had not been diagnosed with CRC before the date of diagnosis in the case, matched according
to year of birth, sex, geographic location, and socioeconomic status. Controls were alive at
the date of death of the case and were assigned a referent date based on the date of CRC
diagnosis in the matched case. We determined medical care received by cases and controls
from Jan 1992 through the date of diagnosis (or referent date in controls) using information
from the Ontario Health Insurance Plan, and the Canadian Institute for Health Information
hospital discharge abstract database. We determined exposure to colonoscopy before the
date of diagnosis (or referent date) for our effectiveness analysis. We also evaluated the effect
of complete colonoscopy (colonoscopy to cecum or terminal ileum) for an efficacy analysis.
Because we were unable to reliably determine if colonoscopy was performed for screening
or diagnosis, we excluded colonoscopy occurring within 6 months prior to diagnosis. We
compared exposure to colonoscopy in the cases and controls using conditional logistic
regression controlling for comorbid conditions using the Charlson index. Results: We identi-
fied 10,292 cases and 51,460 matched controls. Median age of cases and controls was 73
years, and 45.7% were women. Colonoscopy data were available for cases and controls for
a median of 7.81 years prior to date of diagnosis (or referent date). 719 cases (6.99%)
underwent colonoscopy 6 or more months before diagnosis, vs. 5,031 controls (10.84%).
74.2% of colonoscopies were complete. Compared with controls, patients who died from
colorectal cancer were less likely to have undergone colonoscopy (adjusted conditional odds
ratio 0.69, 95% CI 0.63-0.74, p<0.0001), and less likely to have undergone a complete
colonoscopy (adjusted conditional odds ratio = 0.63, 95% CI 0.57-0.69, p<0.0001). Conclu-
sions: Colonoscopy is associated with a reduced risk of death from colorectal cancer, however
the magnitude of the effect of colonoscopy in the population may be lower than expected.
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Outcome of Surveillance Colonoscopy in the Community
Robert E. Schoen, Paul Pinsky, Joel Weissfeld, Lance Yokochi, Douglas J. Reding, Richard
B. Hayes, Paul Doria-rose, Susan Yurgalevich, John Gohagan, Christine for the plco
cancer screening trial Berg
The recommended timing for surveillance colonoscopy is not evidence based. Few studies
have examined the histologic outcomes of surveillance colonoscopy in a community setting.
Methods: A cohort of subjects from 9 U.S. screening centers in the PLCO trial with abnormal
screening flexible sigmoidoscopy and diagnostic colonoscopy within 1 year, and with ≥5
years of observation was queried regarding subsequent colonoscopy use. Medical records
to document colonoscopy outcomes were abstracted in a standardized fashion. Logistic
regression was used to estimate risk factors for advanced adenoma yield at initial surveillance.
Results: 2,795 subjects (61% male, mean age 63, median f/u 9.0 yrs) received a surveillance
colonoscopy within 10 years of their initial colonoscopy exam. Subjects with colonoscopy
follow up were classified by their initial colonoscopy as: Advanced adenoma (AA) (n=1099),
Non-advanced adenoma (AD) (n=819), and no adenoma (NA) (n=877). The overall yield
of AA on subsequent initial surveillance colonoscopy was 10.3% in AA group (mean f/u 42
± 23 months) vs. 6.8% in AD group (mean f/u 52 ± 23 months) vs. 4.3% in NA group
(mean f/u 55 ± 23 months) (p < 0.0001). In the AA group, the yield of a repeat AA on first
surveillance colonoscopy was not affected by timing of the first surveillance exam (0-23
months, 10.9% (n=275), 24-47 months, 10.0% (n=458), 48-71 months, 10.1% (n=248),
72-95 months, 10.0% (n=90), and 96-119 months, 10.7% (n=28)). Nor was there a trend
for increased yield of AA with later surveillance in the AD or NA groups. A logistic model
to identify factors associated with detection of AA during surveillance among subjects with
a baseline adenoma (n=1919) found increased risk among subjects with a large tubular
adenoma (OR 1.4 (95%CI 1.1-1.9)), villous histology (OR 2.2 (95%CI 1.5-3.1), and multiple
adenomas (OR 1.6 (95%CI 1.1-2.4)), but no association with timing of surveillance (OR
1.1 (95%CI 0.7-1.7)), gender, family history of CRC, or smoking. Conclusions: 1) Surveillance
colonoscopy in the community confirms that the yield of AA at the initial surveillance exam
is greater among subjects with a baseline AA, and the yield of AA follows a gradient from
AA to AD to NA, and 2) The absence of an increased yield of AA with later timing of
surveillance is notable, since one would have expected higher AA yields with a longer delay
in follow up. Further study is needed to identify and understand which subjects need early
vs. later surveillance.
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Risks of Serious Complications of Colonoscopy Among Four Canadian
Provinces: A Population-Based Cohort Study
Linda Rabeneck, Lawrence Paszat, Robert J. Hilsden, Refik Saskin, Des Leddin, Eva
Grunfeld, Elaine Wai, Meredith A. Goldwasser, Therese Stukel
Background: The most widely quoted complication rates for colonoscopy are from case
series performed by expert endoscopists. Objective: To conduct a population-based cohort
study of persons who underwent outpatient colonoscopy to estimate the rates of death,
bleeding, and perforation requiring admission to hospital within 30 d following the proced-
ure. Methods: We identified all individuals 50-75 yr old who underwent an outpatient
colonoscopy from April 1, 2002 to March 31, 2003 in British Columbia, Alberta, Ontario,
and Nova Scotia. The first colonoscopy was defined as the index colonoscopy. We excluded
those who, in the preceding 5 yr, had a colonoscopy, inflammatory bowel disease, colorectal
cancer, or a colonic resection. We also excluded those who had an upper endoscopy in the
7 d prior to or on the day of the index colonoscopy, and those who had endoscopic treatment
for a bleeding colonic lesion, or insertion of a colonic stent on the day of the index
colonoscopy. Using administrative data, we identified all individuals who were admitted to
hospital with bleeding or perforation within 30 d following the index colonoscopy in each
province. We pooled (Stukel TA et al. Statist Med 2001;20:2115-30) the rates of bleeding
and perforation from the 4 provinces. In Ontario we abstracted the hospital charts of all
individuals classified as having a bleed or perforation, and all deaths that occurred within
30 d following the procedure. We also abstracted the charts of a random sample of individuals
who were admitted to hospital within 7 d following the index colonoscopy who were not
classified as having a bleed or perforation. We calculated kappa for agreement between the
administrative and chart abstraction data. Administrative data were obtained from the Canad-
ian Institute for Health Information database, which has information on all hospital dis-
charges, and the physician claims database in each province. Results: We identified 97,204
persons who had an outpatient colonoscopy. The pooled rates of colonoscopy-related bleed-
ing and perforation were 1.64/1000 and 0.65/1000, respectively. In Ontario 3 deaths were
likely colonoscopy-related and 2 deaths were possibly colonoscopy-related, for a death rate
of 5/67,632 (0.074/1000). The kappas for agreement between chart abstraction-defined and
administrative data-defined bleeding and perforation were 0.76 (95%CI: 0.71-0.86) and
0.86 (95%CI: 0.77-0.95). Conclusions: The rates of bleeding and perforation requiring
hospitalization within 30 days following outpatient colonoscopy are 1.64/1000 and 0.65/
1000 in usual clinical practice. There is a clear - although low - risk of death (0.074/1000)
from the procedure.
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The Utilization of Colonoscopy As a Screening Method for Colorectal Cancer:
The Experience of Two U. S. Metropolitan Teaching Hospitals with Significant
Documented Racial Differences in the Prevalence and Distribution of
Advanced Neoplastic Lesions
Mohammad A. Wehbi, Jae W. Nam, Charles G. Nesmith, Julia M. Massaad, Minal Patel,
Kamil Obideen, Vincent W. Yang
BACKGROUD: Colorectal cancer (CRC) is the second leading cause of cancer death in the
United States. Current guidelines advise the screening for CRC in asymptomatic individuals
with average risk to begin at age 50. Several screening modalities are available although
there has been no consensus on the most appropriate method with which to screen indi-
viduals. Moreover, a limited number of studies examined the utilization of the screening
strategies in detecting the ethnic or gender differences in the prevalence and distribution
of colorectal neoplasia. AIM: The current study is designed to examine the utilization of
colonoscopy as a screening tool in asymptomatic individuals at average risk for CRC and
to assess gender and racial differences. METHODS: We conducted a retrospective review of
all colonoscopies performed between January 2000 and December 2005 in Emory University
Hospital (EUH) and Grady Memorial Hospital (GMH). The proximal colon was defined as
the segment from the cecum to splenic flexure. Advanced neoplasm was defined as tubular
adenomas > 10 mm, a polyp with tubulovillous or villous feature, and a polyp with high-
grade dysplasia or cancer. Statistical analysis was performed using Fisher's exact test. All
confidence limits and p values were two sided. RESULTS: A total of 16,737 colonoscopy
records were reviewed. Among these, 5,597 (33%) were performed to screen patients at
average risk for CRC. Among the 5,597 patients screened, 462 (8%) were found to have
advanced neoplasia, including 313 (67.8%) tubular adenoma > 10 mm, 100 (21.6%) tubulov-
illous adenoma, 7 (1.5%) high-grade dysplasia and 42 (9.1%) cancer. Two Hundred sixty
two (57%) advanced neoplasms were confined to the proximal colon. Caucasian patients
had an increased risk for proximal tubular adenoma > 10 mm with an odds ratio of 2.00(95%
CI 0.88 to 4.51). In contrast, African American patients had a higher risk for proximal
tubulovillous adenomas with an odds ratio of 6.00 (95% CI = 1.38 to 26.14) and proximal
adenocarcinoma with an odds ratio of 10.90(95% CI 1.37 to 86.42). The difference was
statistically significant with p values of 0.016 and 0.035 respectively. No differences were
detected in the pathology or in the regional distribution of advanced neoplasia between
genders. CONCLUSION: (1) Colonoscopy as a screening tool could detect a significant
number of advanced colorectal neoplasia in the proximal colon, which would have been
missed by flexible sigmoidoscopy. (2) The pathology of advanced neoplasia differs between
Caucasian and African American patients. The study results support an earlier and more
aggressive screening of African American patients.
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Race and Age Disparities in Colorectal Cancer (CRC) Screening: Stratification
By Prior Screening Status
Gregory S. Cooper, Doug Kou
Background: Previous cross-sectional studies suggest sociodemographic differences in the
use of CRC screening. However, as guidelines typically specify intervals between screening
tests, studies with longitudinal follow-up may be more informative. Methods: A 5% random
sample of Medicare beneficiaries in 1998 aged ≥ 70 was identified. Previous inpatient,
outpatient and physician claims from 1991-1997 were used to identify receipt of guideline-
recommended CRC screening (any colonoscopy, yearly FOBT and/or flexible sigmoidoscopy
or barium enema within 5 years). Diagnosis and procedure codes were used to exclude
patients at increased CRC risk - prior polyps or polypectomy, family history of CRC or IBD.
Claims from 1998-2003 were used to determine if patients met CRC screening guidelines
during this follow-up period - yearly FOBT, any sigmoidoscopy or barium enema or colonos-
copy if not previously performed. Univariate and multivariate analyses were used to compare
screening across age and racial groups. Results: A total of 166,603 average risk patients
were identified, including 51,982 (31.2%) with previous screening and 114,621 (68.8%)
with no previous screening. Previous screening was more common in whites (32.3%) than
in blacks (27.3%) or other racial groups (24.4%)(p<0.0001), and was less frequent in patients
aged 70-74 (29.4%) than other patients (75-84: 32.7%, 85+: 31.4%, p < 0.0001). During
follow up, complete screening occurred in 22.5% of patients and was more common in
those with previous screening (43.2%) than those previously unscreened (13.1%) (p <
0.0001). In both univariate analysis and logistic regression analysis adjusting for demo-
graphics and geographic region, subsequent screening was more common in whites and
younger age groups (Table). Conclusions: In this population-based cohort of average risk
individuals, regardless of previous screening status, nonwhites were less likely to undergo
longitudinal screening supporting racial disparities in CRC. Advanced age was also associated
with lower screening use, which may be justified given limited life expectancy.
* Referent group
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Estimating Non-Medical Costs Incurred By Individuals Undergoing Colorectal
Cancer Screening By Fecal Occult Blood Test Or Colonoscopy
Steven J. Heitman, Flora Au, Braden J. Manns, S elizabeth Mcgregor, Robert J. Hilsden
Objective: To determine the non-medical costs incurred by individuals undergoing colorectal
cancer screening by fecal occult blood test (FOBT) or colonoscopy (CLN). Methods: Consec-
utive individuals in the Calgary Health Region presenting for colorectal cancer screening
were recruited from four community laboratory collection sites (FOBT) and two endoscopy
units (CLN). We considered costs of travel, bowel preparation and time receiving care
for both the subject and an accompanying person when indicated. Subjects completed a
questionnaire with items on means of travel, bowel preparation (CLN group only) and time
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lost from work for both the subject and any accompanying person. Time costs were valued
at published age and sex-specific Government of Canada rates. Travel costs included estimated
costs for travel by car and actual costs reported for parking and cab or bus fares. Car users'
costs were estimated using the reported distance traveled and the Canadian Automobile
Association's estimate of motoring costs per kilometer. Results: The final sample included
590 FOBT (mean age 63, 55% men, 46% employed) and 451 CLN (mean age 57, 49%
men, 65% employed) with a response rate of 60% and 75%, respectively. Of the entire
sample, more than 90% of subjects traveled by car and 80% were accompanied when
undergoing a CLN. Average travel times were half an hour to pick-up and drop-off an FOBT
and one hour for a CLN. Average time lost (both work and receiving care) and non-medical
costs are shown in the Table. Conclusions: (1) Individuals undergoing colorectal cancer
screening by FOBT or CLN incur time costs. (2) The time off work and travel costs incurred
by people undergoing CLN are substantial. (3) These costs may influence the overall cost-
effectiveness of a screening program and may deter people from undergoing colorectal cancer
screening. Funding: Alberta Heritage Foundation for Medical Research
* only for those who were employed and reported time lost from work
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Cost-Effectiveness of Colon Cancer (CRC)Screening in Us Women
Cesare Hassan, Angelo Zullo, Sergio Morini
Background and Study Aim: Prevalence of advanced neoplasia in women has been recently
shown to be substantially lower than in men. Moreover, left-side neoplasia has been shown
to be poorly predictive of right-side associated neoplasia in women, rising some concern
on the cost-effectiveness of flexible sigmoidoscopy (FS). Aim of this analysis was to assess
the cost-effectiveness of endoscopy and CT colonography (CTC) in average-risk US women.
Methods: Cost-effectiveness of screening strategies was compared by using computer models
of a Markov process, in which a hypothetical population of 100 000 persons 50 years of
age undergoes CTC (with a 6 mm threshold), colonoscopy or FS once in life-time at 60
year of age. Advanced neoplasia distribution and FS accuracy were simulated to be equal
to those reported by Schoenfeld P et al. (N Engl J Med. 2005 May 19;352(20):2061-8.)
Results: Incremental cost-effectiveness as compared to no screening (ICER) of colonoscopy,
CTC, and FS was $2364, $1808 and $7404. FS appeared to be dominated by colonoscopy
and CTC, being more costly ($142,227,781 vs $135,866,971 and $129,794,819) and less
effective (CRC prevention rate: 19% vs 30% and 43%). Colonoscopy ICER as compared to
CTC was as low as $4181. Conclusions: FS is neither an effective nor a cost-effective option
for CRC screening in women. Although colonoscopy is slightly more expensive than CTC,
its higher efficacy supports its use as first-choice test in women. Among less invasive options,
CTC appears to be undoubtedly superior to FS, and a valid alternative to colonoscopy,
especially for those unwilling or at higher risk for endoscopic procedures.
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Optimal Colonoscopy Screening Interval After Inadequate Bowel Preparation:
A Decision Analysis
Kenneth Song, Uri Ladabaum, Jason A. Dominitz
BACKGROUND/AIMS: Inadequate bowel preparation (IBP) for colonoscopy may affect the
ability to detect adenomas. Wide variations exist in follow-up (f/u) intervals for colonoscopy
after an IBP. Our aims were to estimate the clinical and economic consequences of different
f/u intervals after an IBP. METHODS: We modified a previously validated Markov model
to estimate colorectal cancer (CRC) incidence and mortality, and discounted cost/life-yr
saved for people aged 50 to 80yrs at average CRC risk. For the base case, our inputs were:
IBP 25%, IBP detects 20% fewer adenomas but same number of cancers compared to an
adequate bowel preparation, and 10yr f/u interval for a false negative colonoscopy due to
IBP in those without a history of neoplasia. Shorter f/u intervals were compared to the base
case and 1-way sensitivity analyses on variables were performed. RESULTS: Initial analysis
showed all f/u intervals cost-effective compared to no screening, but the incremental cost-
effectiveness (ICE) for all shorter f/u intervals compared to the base case were >$100,000/
life-yr gained. In 1-way sensitivity analysis, only the 5yr f/u interval had an ICE <$100,000/
life-yr gained compared to the base case when colonoscopy cost was lower (base case: $820,
threshold: $740), colonoscopy death complication rate was lower (base case: 1/10,000,
threshold: 1/25,000), colonoscopy test performance was lower (base case: detection of cancer,
large adenoma, and small adenoma 95%, 90%, and 85%, threshold: 90%, 85%, and 80%),
or percentage of missed lesions due to IBP was higher (base case: 20%, threshold: 25%).
Varying the percentage of IBP in 1-way sensitivity analysis did not significantly affect ICE
results. CONCLUSIONS: A 5yr f/u interval, but not shorter, after an IBP may reduce CRC
cases at a reasonable incremental cost when compared to a 10yr f/u.
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Early 'Interim' Colonoscopy in An Adenoma Surveillance Population
Douglas J. Robertson, Lisa Sunwoo, Leila A. Mott, John A. Baron
BACKGROUND: After colonoscopy, recommendations for repeat exam are based on the
findings from the first exam. However, in some cases exams are completed prior to planned
repeat surveillance colonoscopy. AIM: Understand the frequency, cause and utility of interim
colonoscopy METHODS: We utilized patient data gathered as part of a large adenoma
chemoprevention trial. The study began in 1994, enrolling 1121 subjects all of whom
underwent clearing colonoscopy at baseline. Subjects were then randomized to study agent
or placebo with planned surveillance examinations to assess adenoma recurrence. We
searched the database associated with this trial for examinations flagged by coordinators as
'interim examinations'. These were exams performed prior to the planned assessment of
outcome at 3 years after the baseline exam and then at 3 or 5 years after the first surveillance
exam. Endoscopic reports for those 'interim' exams were reviewed by hand and abstracted
for information regarding the indication and findings. Simple descriptive statistics were used
to define the population and contingency tables were used to look for factors predicting
significant findings (advanced or multiple adenomas, cancer) on interim examination.
RESULTS: A total of 111 subjects (10%) underwent at least one interim endoscopic exam
(60 colonoscopies; 51 sigmoidoscopies) during the first two surveillance cycles (mean follow
up time = 6.3 years). Most commonly these exams were performed because of patient
symptoms (n=66), but nearly a third were driven by either the patient or the patient's
physician requesting an interim examination (n=41). Evidence of rectal bleeding (hematoch-
ezia or microscopic) was by far the most common symptomatic indication for repeat exams
(n =48). Overall, 10 subjects (9%) had significant findings on the interim examination.
Being symptomatic was not associated with significant findings on the exam. 2 cancers were
detected, but neither were in symptomatic patients. One exam detecting cancer was completed
early at patient request (diagnosed with another cancer outside the bowel) and the other
was performed early at physician discretion. CONCLUSIONS: In this population enrolled
in an adenoma chemoprevention trial, interim examinations occurred in 10% of the cases;
The majority driven by symptoms. As recommendations regarding surveillance intervals
lengthen such exams will become increasingly common and will utilize resources that might
be better focused on screening. Further work to define factors associated with significant
findings on such exams are warranted.
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Clinical and Economic Impact of Increased Colonoscopy Screening in the
United States: A Computer Simulation of a Markov Process
Won chan Lee, Yu-chen Yeh, Christopher B. Atzinger, Chris L. Pashos
Purpose: The colorectal cancer (CRC) screening rate (SR) remains well below the American
Cancer Society's goal for 2015 of 75% of the eligible population. This analysis sought to
ascertain the clinical and economic impact of increased CRC screening via colonoscopy
(COL). Methods: The long-term clinical and economic benefits of increased screening were
assessed using a computer-based Markov simulation model. Hypothetical cohorts of 10,000
individuals were modeled from age 50 until death, using the current published SR (~19%)
compared to potential increased SRs. Sensitivity parameters were varied to test robustness
of the model. An incremental cost effectiveness ratio (ICER) was calculated between improved
and current SRs as the additional cost per life year gained (LYG). Results: Increasing the
SR reduced CRC-related mortality and increased average life expectancy, regardless of changes
in most input parameters. With an increase in SR, detected early stage cancer cases increased
and costs related to diagnostic and therapeutic COL and treatment of early stage cancer
increased, while treatment costs related to late stage cancer decreased. A base case scenario
in which SR increased from 19% to 29% yielded an average of 118 LYG/10,000 population
and a lifetime cost of ~$1.3 million, and an incremental cost effectiveness ratio (ICER) of
$11,056 per LYG. The CRC-related mortality was reduced by 7%. With additional increases
in SR (Table 1) the ICER decreases, indicating consistently increasing economic value.
Conclusions: Increasing SR in the population recommended for CRC screening increases
early detection, enabling timely intervention to reduce treatment costs related to late stage
CRC. Ways to increase COL screening and reduce treatment cost should be a high public
health priority.
Table 1 ICER by incremental SR (per 10,000 population)
*Current SR = 19%
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The Clinical and Economic Effects of Falling Medicare Reimbursement Rates
for Colonoscopy: Is Pay-for-Performance the Answer?
Sameer D. Saini, Michael Volk, Sandeep Vijan
Background: Over the last decade, the demand for colonoscopy has steadily increased. At
the same time, the Medicare reimbursement rate for colonoscopy has steadily decreased. As
a result of these changes, gastroenterologists have a heightened incentive to increase the
number of colonoscopies that they perform. However, this increase in procedure volume
carries with it the risk of a decrease in colonoscopy quality. Recent studies have highlighted
an association between faster colonoscopy withdrawal times and lower polyp detection rates
(PDRs). The purpose of this study was to model the clinical and economic effects of a
“pay-for-performance” measure linking colonoscopy reimbursement to average colonoscopy
withdrawal time in a Medicare population. Methods: We developed a Markov model to
compare the clinical and economic effects of a pay-for-performance (PFP) surveillance strategy
(higher PDR) versus a standard reimbursement (SR) strategy (lower PDR). In the PFP strategy,
physicians received a $50 bonus per colonoscopy for maintaining an average withdrawal
time of ≥ 8 minutes. Published literature was used to estimate a 20% increase in PDR for
large polyps (≥ 1 cm) under this strategy. The target population was Medicare patients
with previously diagnosed colonic adenomas undergoing surveillance colonoscopy. Results:
In the base-case analysis, the PFP strategy was the more effective strategy, with a 20%
reduction in colorectal cancer (CRC) risk and a 22% reduction in CRC-related death compared
to the SR strategy. These lower rates of CRC translated into lower costs under the PFP
strategy, making PFP dominant over the SR strategy. These results were sensitive to the
reimbursement bonus and degree of improvement in polyp detection under the PFP strategy
as well as the malignant transformation rate of advanced adenomas. However, the incremental
cost-effectiveness ratio (ICER) of the PFP strategy remained under $50,000 per life-year
saved (LYS) even when the improvement in PDR under the PFP strategy was minimal (1%)
or when the PFP bonus per colonoscopy was greatly increased ($200). Conclusions: From
the perspective of a long-term payer, a pay-for-performance approach linking colonoscopic
withdrawal time to colonoscopy reimbursement is likely to be cost-saving or at least cost-
effective in an elderly surveillance population. These results were robust to a wide range of
assumptions in sensitivity analysis. The Centers for Medicare and Medicaid Services (CMS)
should consider implementing a pilot program to test the feasibility and cost-effectiveness
of this PFP strategy in a real-world setting.
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Translocation of Long Chain Fatty Acids Is Regulated By Dynamic Interaction
of Fat/Cd36 with Cholesterol/ Spingolipid Enriched Microdomains (Lipid
Rafts)
Robert Ehehalt, Joachim Fuellekrug, Wolfgang Stremmel
Background: Mechanisms of long chain fatty acid translocation across the plasma membrane
are important targets in treatment of human diseases like obesity or steatosis. Long chain
fatty acid translocation is achieved by a concert of co-existing mechanisms. These lipids can
passively diffuse, but certain membrane proteins can also accelerate the transport. However,
we now can provide further evidence that not only proteins but also the lipid microdomain
architecture plays an important part in the regulation of the facilitated uptake process.
Methods: Dynamic association of FAT/CD36, a candidate fatty acid transporter, with lipid
rafts were analysed by isolation of detergent resistant membranes (DRMs) and by clustering
of lipid rafts with antibodies on living cells. Lipid raft integrity was modulated by cholesterol
depletion using methyl-b-cyclodextrin and lovastatin. Functional analyses were performed
using an [3H]-oleate uptake assay. Results: Overexpression of FAT/CD36 increased long
chain fatty acid uptake. The uptake of long chain fatty acids was cholesterol and sphingolipid
dependent. Floating experiments showed that there are two pools of FAT/CD36, one found
in DRMs and the other outside of those domains. FAT/CD36 co-localized with the lipid raft
marker PLAP in antibody-clustered domains at the plasma membrane and segregated away
from non-raft markers. Antibody cross-linking increased DRM association of FAT/CD36 and
accelerated the overall fatty acid uptake in a cholesterol dependent manner. Another candidate
transporter, FATP4 was neither present in DRMs nor in the plasma membrane at all.
Discussion: Our observations suggest the existence of two pools of FAT/CD36 at the plasma
membrane. As increased raft association of FAT/CD36 leads to an increased fatty acid uptake,
dynamic association of FAT/CD36 with lipid rafts might regulate the process. There is no
direct interaction of FATP4 with lipid rafts or FAT/CD36. Lipid rafts have to be considered
as targets for the treatment of lipid disorders.
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Adaptations in Intestinal Lipid Absorption in Mttp-Iko Mice: Normalized
Cholesterol Absorption Despite Continued Triglyceride Malabsorption
Yan Xie, Jianyang Luo, Nicholas O. Davidson
Microsomal triglyceride transfer protein (Mttp) is absolutely required for mammalian intest-
inal and hepatic lipoprotein assembly and secretion. We previously generated conditional
intestinal Mttp deletor mice (Mttp-IKO) in which mice develop steatorrhea and lipid malab-
sorption. In these mice, triglyceride absorption was essentially eliminated while cholesterol
absorption was decreased by ~70%. Since Cre activation following tamoxifen (TAM) adminis-
tration is sustained up to 6 months, we examined whether any adaptive changes to intestinal
lipid absorption occur in Mttp-IKO mice at 6 weeks versus 3 weeks after TAM. Mttp-IKO
mice consuming a chow diet demonstrated comparable steatorrhea at 3 and 6 weeks (11.4
± 1.5 vs 15 ±1.6%) and decreased plasma cholesterol and triglyceride levels. Intestinal
lipid accumulation (mucosa or isolated enterocytes) demonstrated striking but comparable
accumulation of triglyceride and free fatty acids at both times, consistent with the block in
intestinal lipid secretion. Suprisingly, however, dual isotope cholesterol absorption studies
demonstrated that after 6 weeks Mttp-IKO mice absorbed comparable quantities of cholesterol
(48±2%) to control mice (54±3%). In order to examine the mechanisms underlying this
adaptation we examined mRNA expression (q-PCR) of genes related to intestinal cholesterol/
fatty acids transport. Mttp-IKO mice studied 3wks after TAM injection revealed decreases
in intestinal ABCA1 mRNA (70%), ABCG5 (55%), NPC1L1 (65%), CD36 (52%), and
increases in FATP4 mRNA (2 fold) and L-FABP (6 fold). By contrast, at 6wks after TAM
injection, intestinal ABCA1, ABCG5, FATP4 and L-FABP mRNA abundance were normalized
in Mttp-IKO mice, while NPC1L1 mRNA (the prime candidate cholesterol transporter) was
still decreased by 58% and CD36 (another candidate cholesterol transporter) was still
decreased by 50%. In addition, cellular cholesterol content in control and Mttp-IKO mice
was comparable at both 3 and 6 weeks, suggesting that cholesterol does not accumulate
despite a complete block in triglyceride and fatty acid export. Since compensatory upregul-
ation of the cholesterol efflux pump ABCA1 is known to be transcriptionally regulated by
changes in LXRa we examined intestinal LXRa mRNA, which was increased 3 fold in Mttp-
IKO mice at 6wks following TAM. These results suggest that genetic regulation of cholesterol
absorption can be compensated in Mttp-IKO mice through an alternate pathway, independent
of chylomicron formation. This alternate pathway is ABCA1 dependent and most likely
involves LXRa activation.
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The Peripheral Actions of the Des-Acyl and Octanoylated Ghrelin On Leptin
in Human Abdominal Subcutaneous Adipocytes
Steve J. Goodyear, Nancy F. Da silva, Katarina Kos, Alison L. Harte, Edmond Sung, Ling
S. Wong, Joseph P. O'hare, Sudhesh Kumar, Chuka U. Nwokolo, Philip G. Mcternan
INTRODUCTION:The anorexigenic leptin and orexigenic ghrelin, are peripheral signals that
control appetite via the hypothalamic neuropeptide Y (NPY) system. Ghrelin exists in an
inactive (des-acyl) and active (octanoylated) form which acts via the GHS-R1a. Whilst a
great deal is understood about central interaction of these peptides their peripheral pathways
remain uncertain. METHODS: Adipose tissue (AT) produces several neuropeptides. Due to
the importance of AT in the control of energy homeostasis we examined 1) AT expression
of ghrelin; 2) the effect of human recombinant (hr) octanoylated ghrelin (OctGhr) and des-
acyl ghrelin (DesGhr) on leptin secretion; 3) and the mechanism of action, involving NFκB
protein expression and activity studies. Ex vivo human abdominal and omental AT was
taken from women undergoing elective surgery (BMI:26.2(mean±SD)±1.6kg/m2,
Age:42.7±1.6yrs, n=38). Western blot analysis determined ghrelin protein expression. Isol-
ated AbdSc adipocytes were treated with 1, 10 and 100nM of des-acyl or octanoylated ghrelin.
Following 48 hours incubation, leptin secretion from conditioned media was measured by
ELISA. RESULTS: Ghrelin was expressed in AT and adipocytes in a depot-specific manner.
HrOctGhr (Control 5.2±1.4ng/mL; OctGhr 1nM:4.7±1.7ng/ml, OctGhr 10nM 5.0±1.6ng/
mL, OctGhr 100nM: 4.4±1.3ng/ml) as well as DesGhr (DesGhr1nM 5.3±1.7ng/mL; DesGhr
10nM 4.9±1.4; DesGhr 100nM: 4.1±1.5ng/ml) reduced leptin secretion and remained signi-
ficant after BMI adjustment for OctGhr (p=0.029, n=5). Further studies assessed translocation
of NFκB to the nucleus (expressed as a % of NFκB activity/protein expression). This showed
a dose dependent increase with octanoyl-ghrelin (OctGhr 1nM 21%, 100nM 66% p=0.01)
and des-acyl ghrelin (DesGhr: 1nM 29%, 100nM 113% p=0.03). DISCUSSION: Contrary
to the central feedback where leptin antagonises ghrelin action, our data suggests that both
forms of ghrelin, partly produced in the human fat itself, inhibit leptin production in the
human adipocyte as part of a feedback loop. This highlights AT as a site of neuropeptide
production and energy homeostatic regulation.
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Glucose-Dependent Insulinotropic Polypeptide Modulates Multiple Signaling
Targets in Adipocytes
Diane H. Song, Vera Kandror, M. michael Wolfe
Background: Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid regu-
latory peptide released from the upper small intestine in response to ingested nutrients.
Once released, it serves as the principal mediator of the enteroinsular axis that stimulates
pancreatic islet β-cells to secrete insulin. In addition to its incretin effects, GIP, like insulin,
appears to play a central role in the pathogenesis of obesity. Recent studies have suggested
that obesity may increase the risk of GI and other malignancies and that certain factors,
which are dysregulated in cancer, are also affected by nutrient-dependent intracellular
signaling. These factors, which mediate the effects of insulin and are components of the
mammalian targets of the rapamycin (mTOR) signaling pathway, include eukaryotic initiation
factor 4E binding protein (4EBP1) and ribosomal p70S6 kinase (p70S6K). Both are important
in promoting protein synthesis by enhancing translation, which thereby increases cell growth.
Purpose: To characterize GIP signaling pathways in adipocytes that may be involved in cell
growth. Methods and Results: 3T3-L1 cells were differentiated to adipocytes and serum
starved in low glucose medium overnight. On the following day, cells were treated with
insulin (10 nM) or GIP (0.02-20 nM) for 10 min and harvested for total protein extraction.
Equal amounts of protein were loaded onto a SDS-PAGE gel, and Western blot analysis was
performed for phospho-Akt (activated form), phospho-p70S6K (activated form), phospho-
4EBP1 (inactivated form), phospho-p38MAPK (activated form), and phospho-ERK1/2 (activ-
ated form). Insulin, a known factor that modulates these components, was used as a positive
control. Similar to insulin, GIP enhanced expression of activated forms of Akt and p70S6K,
and the inactivated form of 4EBP1. We also examined whether GIP may influence members
of the MAPK family members, which are associated with various cellular responses, including
proliferation, differentiation, and apoptosis. GIP enhanced activation of ERK1/2, which are
involved in promotion of cell growth, but not p38MAPK, which is involved in differentiation
and apoptosis. Summary and Conclusion: The results of these studies suggest that, in
addition to modulating glucose uptake, GIP, like insulin, activates Akt and modulates
downstream targets of Akt that are involved in enhanced protein translation. Furthermore,
GIP activates ERK1/2, which is important in promoting cell growth. These studies provide
further evidence for an important physiological role for GIP in fat cells and possibly in the
pathogenesis of obesity and obesity-related neoplasia.
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Host Metabolic Responses to Intestinal Parasitic Nematode Infections: A Novel
Explanation for the Evolutionary Conserved Obesity-Prone Phenotype
Tracie Wong, Marie A. Hildebrandt, Seana M. Thrasher, Judith A. Appleton, Rexford S.
Ahima, Gary D. Wu
Background: As descendents of hunter-gatherer societies, the current epidemic of diet-
induced obesity is the result of recent environmental changes, such as abundance of cal-
orically-rich food, combined with a normal physiological response to efficiently store energy
in order to survive during periods of famine, known as the “thrifty gene” response. Another
environmental factor that has undoubtedly shaped our metabolic response to stress through-
out evolution is parasitic nematode infection, which affects 1/5th of the world's population.
Methods and Results: Obesity-prone strains of mice are susceptible to chronic intestinal
nematode infections whereas lean mice are resistant. To test the hypothesis that the obesity-
prone, thrifty phenotype confers an advantage during the metabolic stress of nematode
infection, we compared the response to H. Polygyrus infection in two hosts: C57Bl/6 obesity-
prone mice and SWR obesity-resistant mice. Following infection, SWR mice showed a 60%
increase in food intake, whereas intake was unchanged in C57Bl/6 mice. Energy expenditure,
core body temperature, and stool triglyceride content did not differ between strains. Body
fat, measured by DEXA scan and hepatic triglyceride content, decreased significantly in
C57Bl/6, but not SWR mice. Infected SWR mice demonstrated severe weight loss when
their caloric intake was restricted to that of naïve mice in a pair-feeding study. In addition,
lean mass and body fat content, assessed by MRI and fat pad analysis, significantly decreased
in these pair-fed mice. Thus, SWR mice require an increase in calorie intake as a critical
adaptation to energy deficit during nematode infection. Profiling of intestinal cytokine
expression confirmed the known phenotype of SWR mice as rapid expellers of nematodes.
Conclusions: Our data suggest that parasitic nematode infection of the gut may underlie strain
differences in energy homeostasis. Obesity prone C57Bl/6 mice exhibit efficient utilization of
energy stores in fat during parasitic nematode infection, perhaps mediated through “thrifty
genes”. In contrast, obesity-resistant SWR mice require an increase in caloric intake to
maintain energy stores. Since mice are normally calorie-restricted in the wild, the obesity-
prone C57Bl/6 strain is better adapted to nematode infection. Teleologically, the strong
TH2-mediated immune response induced in SWR mice may have evolved to facilitate prompt
clearance of infection in order to maintain energy balance. Understanding the metabolic
response to parasitic nematode infection may lead to novel insights into intestinally-derived
mechanisms by which the immune response regulates host metabolism.
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Gastric/Intestinal Electrical Stimulation Modulates Appetite Regulatory
Peptide Hormones in the Stomach and Duodenum in Rats
Junying Xu, Terry Mcnearney, Jiande Chen
Background & Aim: Gut hormones have been identified as important signals for the regulation
of energy balance as well as gastrointestinal motility. Gastrointestinal electrical stimulation
(GIES) has been used for the treatment of obesity with promising results. However, the
mechanisms by which GIES benefits obese patients are complex and not completely under-
stood, especially the hormonal mechanism. The aim of this study was to investigate the
acute effects of GIES on some gut hormones related to satiety and/or appetite, including
ghrelin, obestatin, cholecystokinin-8 (CCK) and peptide YY3-36 (PYY3-36) in gut tissues
in rats. Methods: Thirty two adult male Sprague-Dawley® rats implanted with one pair of
electrodes in the antrum or duodenum were divided into 4 groups: 1) sham stimulation,
2) gastric electrical stimulation (GES) with pulse trains, 3) GES with long pulse and 4)
duodenal electrical stimulation (DES) with pulse trains. The rats were fasted at 4pm, and
electric stimulation was initiated at 8 am the next day for two hours. After electrical stimula-
tion, the rats were sacrificed immediately and gastric fundus, duodenum and distal colon
were harvested and extracted. Hormone levels of ghrelin; obestatin; CCK-8 and PYY3-36
were measured by radioimmunoassay (RIA). Results: (1) The mean gastric fundus ghrelin
level was 1789±362 pg/mg protein in the sham stimulation and significantly decreased with
GES of pulse trains (597±195 pg/mg, p=0.012), GES of long pulses (754±282 pg/mg p=
0.039) and DES (731±110pg/mg p=0.037). (2) The mean duodenal CCK-8 concentration
was 413±42pg/mg with sham stimulation and significantly increased with DES (762±98pg/
mg, p=0.013) but not with GES. (3) Neither gastric obestatin nor distal colonic PYY3-36
was altered by any of GIES. Conclusions: GIES significantly impacts appetite related peptide
hormones in gastric and duodenal tissues. Electrical stimulation with appropriate parameters
and locations increases anorexigenic hormone, CCK-8 and decreases orexigenic hormone,
ghrelin. These hormonal mechanisms suggest therapeutic potentials of GIES for obesity.
This study was partially supported by an NIH grant, DK063733.
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The Sensitivity of a the Aer-O-Scope™ - Results of a Prospective, Blind, Multi-
Center Study in Ex-Vivo Polyp Induction Pig Model
Nadir Arber, Roman Grinshphon, Jorge Pfeffer, Shimon Bar-meir
Background: The Aer-O-Scope™ (GI View) is a disposable, ultra-flexible, self-propelling
and self-navigating colonoscope (Gastro 130: 670-672, 2006). In addition to its innovative
pneumatic propulsion technology its optical system combines an omni multi-directional
module allowing for 360 degree viewing of the colon, behind, in front and to all sides of
the moving miniaturized camera. Used in combination with a standard front viewing channel
it eliminates the need for continuous tip manipulation and carries the potential for increased
sensitivity. Objective: To evaluate the ability of the Aer-O-Scope™ to detect polyps of varying
size simulated ex-vivo by beads sewn in a pig colon in alignment mimicking the human
anatomy. Materials and Methods: A two meter long unfolded pig colonic segment was
dissected, rinsed and closed distally with a clamp. Seven red metal beads ranging in size
(2.5, 3.5 and 9 mm) were randomly sewn. The Aer-O-Scope™ was prospectively tested
seven times. In each test a different number of beads were planted in the colon. A sealed
time map, indicating the true location and the size of each bead, served as the reference.
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Five well trained colonoscopists reviewed independently the Aer-O-Scopy videos for each
run (n=35) and scored the time and size of each bead they had observed. The colonoscopists
were blinded to the reference time map and had no access to the experimental model.
Results: The sensitivity of the Aer-O-Scope™ was 98.1% (95% CI 94.1%-100%) for any
polyp (any beads) and 97.1% (95% CI 87.1%-100%) for significant polyps (beads>6mm
in size). The false positive rate averaged 0.4 polyp per run (STD: 0.65; Min: 0.0; Max: 3.0).
The mean video assessment time was 8.0 minutes (STD: 4.0; Min: 3.5; Max: 20). Conclusion:
The Aer-O-Scope™ allows for direct visualization of the colonic mucosa. These remarkably
high detection rates, without any prior experience, suggest that its multi-directional optical
system is highly sensitive. Additional studies are warranted in order to establish its sensitivity
in-vivo.
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Natural History of Intermediate-Size Colorectal Polyps Assessed By Computed
Tomographic Colonography and Confirmed By Optical Colonoscopy
John T. Bassett, Cecilia Kim, Cathy Dykes, Priscilla Cullen, Tina Scott, Duncan Barlow,
Don Jensen, Brooks D. Cash
Background: Because prior colorectal cancer screening trials required the removal of all
identified polyps, the natural history of “intermediate” lesions is not known. Our study
seeks to determine the natural history of these lesions in a cohort of patients referred for
colorectal cancer screening at the National Naval Medical Center. Methods: Participants are
asymptomatic, average risk patients who had 1 or 2 polyps 6-9.9 mm in size on computed
tomographic colonography (CTC) at T0. Patients then underwent repeat CTC and clearing
optical colonoscopy (OC) after one year (T1) of observation. CTC exams are performed in
the department of radiology by staff radiologists who have read > 1000 CTC exams. Polyps
were considered matches if they were seen on CTC at both T0 and T1 and were in the
same anatomic portion of the colon. Any polyps that were not identified on CTC at both
time points were excluded since no size change could be calculated. Results: A total of 70
polyps 6-9.9 mm in size were seen on CTC at T0 and/or T1 in 41 patients. Thirty-two
matching polyps were seen on CTC in 28 patients at T0 and T1. Forty-one percent(29/
70)of the polyps were adenomatous and of these, 22 were matching non-advanced adenomas.
The mean size of these lesions was not statistically different at T0 and T1 (6.59 mm vs 6.79
mm; p=0.3052; Random Effects ANOVA). The mean growth rate of these polyps was 0.20
mm/year. Seven point one percent (5/70) of the polyps removed were advanced adenomas
(villous histology or high grade dysplasia) and 4 of these were observed on CTC at T0 and
T1. In contrast to non-advanced adenomas, the mean size of these lesions was significantly
different at T0 and T1 (7.81 mm vs 8.98 mm; p=0.0119). The mean growth rate of advanced
adenomas was 1.17 mm/year. Conclusions: Our findings demonstrate that 40-50% of inter-
mediate sized polyps are adenomatous and approximately 7% harbor advanced histologic
features. Some proponents of CTC have advocated observation of intermediate sized polyps
with serial CTC every 1-2 years and our results could be used to support this approach.
Among the neoplastic lesions, advanced adenomas have a significantly greater interval growth
rate than non-advanced adenomas, a feature that might be exploited to develop predictive
models based on polyp size change thresholds to indicate need for polypectomy, although
larger studies in different populations are needed to pursue this end.
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Extra-Colonic (EC) Findings Identified in Computed Tomographic
Colonography (CTC) Using CTC Reporting and Data System (C-Rads): Added
Benefit Or Cost?
Ganesh R. Veerappan, Mazer R. Ally, Jennifer S. Pak, Jung-ho R. Choi, Roy K. Wong
Introduction: CTC is a new technology being used for colorectal cancer(CRC) screening. In
addition to detecting polyps, CTC detects EC findings in 40-60% of all CTC studies.
Radiologists have recently standardized EC findings using C-RADs. With E1 = normal exam
or anatomic variants, E2 = clinically unimportant findings, such as simple cysts, E3 =
clinically unimportant findings requiring further work up, such as complex cysts, and E4 =
potentially important findings requiring an expedited work up, such as a mass. C-RADs
provides guidelines for following up EC findings to minimize the haphazard ordering of
unnecessary tests. Our study retrospectively explored the impact of C-RADs system on the
work up of EC findings. Method: We reviewed all CTC reports performed at our institution
from 6/03-6/06. All patients were retrospectively assigned a C-RADs score based on EC
findings. We searched our institution's database to review all subsequent radiology studies
done in pursuit of E3 and E4 findings. We determined the cost of all follow up radiologic
procedures based on Medicare 2006 reimbursement rates. All patients with E3, E4 lesions
had charts reviewed to determine the number of EC cancers detected. Results: 2277 patients
had a CTC from 6/03 to 6/06. 1094 patients (48.0%) were found to have a total of 1918
EC findings (287 significant findings and 1631 insignificant findings). 1183 patients (52.0%)
had no EC findings (E1). E2 findings were found in 882 patients (38.7%). 43 patients
(1.9%) had E4 findings and 169 patients (7.4%) had E3 findings. In these 212 patients, a
total of 170 CT scans, 45 Ultrasounds, 13 MRIs, and 13 PET scans were ordered to work-
up these EC findings. The estimated cost of these follow up studies was $100,000. A total
of 5 cancers (3 renal cell, 1 lymphoma, and 1 lung cancer) and 1 dangerous aortic aneurysm
(8cm) were found. 4/5 EC cancers were cured with resection. In comparison, 6 colorectal
adenocarcinomas and 3 adenomas with high grade dysplasia (HGD) were found on CTC
with curative resection in 6/9 patients. Discussion: This is the largest single-center study
assessing the prevalence of EC findings in CTC and the first done using CRADs. CTC
identified almost as many EC cancers as intra-colonic cancers. 10/14 lesions representing
cancer or HGD were detected early enough to be cured with resection. Using CRADs, only
9.3% of patients undergoing CTC required any further imaging. The subsequent radiological
studies for E3 and E4 lesions added an estimated $45 per CTC. CTC is a new screening
modality for CRC that may have the added advantage of discovering curable EC cancers
for minimal additional cost.
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Correlation of Narrow Band Imaging (NBI) Findings with Colon Polyp
Histology
Amit Rastogi, Sharad Mathur, Ajay Bansal, Sachin B. Wani, Peggy Callahan, Prashant K.
Pandya, Prateek Sharma
Background: Most colon cancers arise from adenomatous polyps (TA) while hyperplastic
polyps (HP) are thought not to have malignant potential. Differentiating the two is difficult
by standard colonoscopy, often leading to removal of HP (costs, time, etc). Magnifying and
high resolution chromoendoscopy shows details of pit patterns on polyp surface that correl-
ates well with histology. However, chromoendoscopy is cumbersome and not widely used.
NBI is novel technology that uses special narrow band filters allowing for more detailed
visualization of mucosal and capillary patterns. Aim: To test feasibility of NBI colonoscopy
in assessing the mucosal and vascular patterns of colon polyps and their correlation with
histology. Methods: Patients referred for screening colonoscopy were enrolled. High resolu-
tion colonoscope with capability of NBI was used (180 series, Olympus). After standard
colonic prep, colonoscope was advanced to cecum; during withdrawl, cecum and ascending
colon were visualized with standard white light and all polyps seen were removed. Then,
the endoscope was again advanced to cecum, and inspection performed during withdrawl
now with NBI. Additional polyps seen with NBI were recorded, photographed and removed.
The remainder of colon was examined sequentially in similar fashion, initially with white
light followed by NBI (15 to 20 cm increments). The size, location and morphology of
polyps were noted and photographed. Polyps were reviewed by pathologists blinded to NBI
finding. Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) of different
patterns in reference to histology were calculated. Results: Total of 40 patients enrolled
(mean age 62 yrs, all males, 80% caucasians). 51 polyps (29 TA, 22 HP) were detected by
NBI. Five surface patterns were visualized: fine capillary network with absent mucosal
pattern, circular pattern with dots, round/oval pattern, tubular pattern and gyrus pattern.
Sensitivity, specificity of round/oval, tubular or gyrus pattern for TA was 96.5% and 86.4%
respectively; PPV and NPV of 90% and 95% respectively. Sensitivity, specificity of fine
capillary network with absent mucosal pattern and circular pattern with dots for HP were
86.4% and 96.5% respectively; PPV and NPV of 95% and 90% respectively. Conclusions:
NBI colonoscopy provides clear and high resolution visualization of the surface patterns of
colon polyps. These patterns can help differentiate between TA and HP with high degree
of accuracy with potential to avoid unnecessary biopsies or polypectomies, thus saving
time and costs. Further validation of these surface patterns need to be performed in large
multicenter studies.
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Accuracy of Computed Tomographic Colonography for Colorectal Cancer
Screening in Asymptomatic Individuals
Brooks D. Cash, Cecelia Kim, Donald Jensen, Priscilla Cullen, James W. Kikendall, Tina
Scott, Scott L. Itzkowitz, Dong Lee, Jayde E. Kurland, Lawrence Goldkind, Duncan
Barlow
Background: Pickhardt et al. demonstrated that computed tomographic colonography (CTC)
was comparable to colonoscopy (OC) for the accurate detection of adenomas. Our study
seeks to validate Pickhardt's findings using similar technique for CTC. Methods: Participants
are asymptomatic, average-risk patients referred for screening who undergo CTC and are
categorized into one of three groups. Patients with polyps≥ 10 mm or≥ 3 polyps exceeding
6 mm proceed to OC during which all polyps identified are removed (Group A). Patients
with 1 or 2 polyps 6-9 mm in size undergo repeat CTC and clearing OC at 1 year (Group
B) and patients without any polyps ≥ 6 mm undergo OC in 5 years (Group C). Among
patients in groups B and C, 10% are randomly selected to undergo same-day OC. Standard
bowel purgative is used with oral contrast to tag fluid and stool for digital subtraction. CO2
is used for colon insufflation and 3-D flythrough serves as the primary mode of assessment
by an experienced (≥ 1000 CTC) radiologist. Results: 901 of a planned 3000 patients have
undergone CTC (mean age 56 years; 37.9% female; 80% Caucasian). Data is presented on
a per patient basis and OC results reflect segmental unblinding. 18.5% (167/901) patients
have proceeded to OC; 28.7% (48/167) for significant findings (group A) and 59.3% (99/
167) randomly selected or 1 year follow-up of intermediate sized polyps (groups B/C). For
adenomas ≥ 10 mm, CTC polyp detection sensitivity and specificity are 94.1% (95% CI:
80.3% to 99.3%) and 86.5% (95% CI: 79.5% to 91.8%). The positive predictive value (PPV)
and negative predictive value (NPV) of CTC for these lesions is 64.0% (49.2% to 77.1%)
and 98.3% (94.0% to 99.8%). The 94.1% sensitivity of CTC is comparable to OC (p=1.000,
McNemar's Test). Sensitivity of CTC for smaller adenomas remains equivalent to OC to a
threshold of 6 mm. For 6-9 mm adenomas, the sensitivity, specificity, PPV and NPV are
83.7% (95% CI:69.3% to 93.2%), 86.3% (95% CI:79.0% to 91.8%), 67.9% (95% CI:53.7%
to 80.1%), 93.9% (95% CI:87.8% to 97.5%), respectively, with an accuracy of 85.6% (95%
CI:75.4% to 90.6%). Conclusions: Our findings continue to demonstrate that CTC and OC
have similar accuracy for the detection of adenomas≥ 6 mm. CTC may be a viable alternative
to OC for primary CRC screening. We believe that contrast tagging and subtraction, CO2
insufflation, 3-D primary interpretation and the experienced interpreters are largely explain
our results. CTC continues to show promise as CRC test, but similar initiatives should be
undertaken with close collaboration between radiology and gastroenterology.
639
Gastroenterologist Interpretation of CTC: Pilot Study Demonstrating
Feasibility and Similar Accuracy Compared to Radiologists
Quentin Ray, Cecelia Kim, Tina Scott, Barlow Dunacn, Gary Brown, Donald Jensen,
Brooks D. Cash
Background: CT colonography (CTC) is an emerging colon cancer screening modality that
has the potential to increase adherence with current screening recommendations. Tradition-
ally, the interpretation of CTC has been limited to radiologists. As the technology of CTC
has progressed, 3-dimensional endoluminal fly-through images have largely replaced 2-
dimensional CT images as the primary reading modality. Such a display is a realistic corollary
to the endoscopic view obtained during colonoscopy. Our study sought to determine if
gastroenterologists can interpret the colonic display of CTC with similar accuracy as trained
radiologists. Methods: 2 board certified gastroenterologists and 4 gastroenterology fellows
in various stages of training interpreted a mean of 45 CTC (range 30-50) in which colonoscopy
had also been performed. Prior to reading any cases, each reader underwent CTC interpreta-
tion training with an experienced CTC radiologist. After interpreting each CTC, the gastroen-
terologist had access to both the original radiology interpretation of the CTC as well as the
corresponding colonoscopy results. Outcomes included accuracy of the gastroenterologist
interpretation, time required, evidence of learning, and the level of diagnostic agreement.
Results: Gastroenterologist readers identified patients with polyps ≥ 6 mm with a mean
sensitivity and specificity of 83.5% (67-100%) and 78.8% (69-100%), respectively. Corres-
ponding values for patients with polyps ≥ 8 mm were 83.8% (68-100%) and 74% (30-
93%), respectively, and for patients with polyps ≥10 mm were 87.8% (67-100%) and
85.2% (60-94%), respectively. 83% (5/6) of gastroenterologists achieved kappa scores ≥
0.60, suggesting good agreement with radiologists; 66% achieved kappa ≥ 0.75. There was
a direct relationship between diagnostic accuracy and level of gastroenterology training.
Average gastroenterologist reading time was 18.4 minutes (range: 11.2-25.6 minutes). Con-
clusions: Gastroenterologists are able to read CTC as accurately as radiologists. The level of
gastroenterology training affects the accuracy of CTC interpretation. Average gastroenterolo-
gist CTC interpretation times are similar to recommended colonoscopy times. Further studies
are warranted to determine if gastroenterologists are able to interpret CTC independently
in clinical practice.
640
Relationship Between Gastric Emptying Rate, Symptoms, Quality of Life
(QoL), and Response to Prokinetic Drugs in Patients with Postprandial
Distress Syndrome (PDS)
Fernando Macias-garcia, Manuel Barreiro-de acosta, Jose Larino-noia, Adolfo Figueiras,
Maria Vilarino-insua, Laura Nieto, Enrique Dominguez-munoz
A delayed gastric emptying (GE) is considered as one of the factors involved in the pathophysi-
ology of PDS. Prokinetic drugs have proved to be useful in this setting. Whether GE rate
is related to symptoms and QoL, and may predict response to therapy in PDS in unknown.
AIM: To evaluate a) the frequency of delayed GE, b) the relationship between GE rate and
the symptomatic response to prokinetic drugs, and c) the comparative efficacy of levosulpiride
vs domperidone in patients with PDS and severe postprandial fullness. METHODS: 60
consecutive patients (53 female, mean age 47 years, range 19-73 years) with PDS and severe
postprandial fullness as the main symptom were included in a randomized, open, comparative
crossover study of levosulpiride 25mg tid vs domperidone 10mg tid. Each drug was adminis-
tered for 14 days, with a 14 day-washing period between the two treatment periods. Dyspeptic
symptoms (0 to 54) and QoL (0 to 5) were scored (PAGI-QoL) and GE of solids (t½, phase
lag and GEC) was evaluated (13C-octanoic acid breath test) before and at the last day of
each treatment period. Sample size was calculated accepting an error type I of 5% and an
error type II of 10%, with an expected minimum difference between the two treatments of
5%. Multivariate analysis with multiple linear models was performed. RESULTS: GE was
delayed in 7 (12%) patients (t1/2 197.4±32.9min) and normal in the remaining 53 (88%)
cases (t½ 71.01±2.51min). Both levosulpiride and domperidone accelerated GE rate (mean
t½ reduction of 104.1min and 106.8min, respectively) in patients with delayed GE but not
in those with normal breath test result. Symptom score improved significantly under therapy
with both levosulpiride (reduction of 11.1±1.2 points) and domperidone (reduction of
9.2±1.2 points) (p<0.001 compared to basal) independently of whether GE was normal or
delayed. Similarly, QoL score improved significantly in all patients by 0.4±0.1 points with
both drugs (p<0.001 compared to basal). Adverse events were mild, and more frequently
related to levosulpiride (p<0.05). CONCLUSION: Severe postprandial fullness is not a
good indicator of delayed GE in patients with PDS. Prokinetic drugs, levosulpiride and
domperidone, are effective in these patients and lead to a significant improvement of symp-
toms and QoL. Response to prokinetic therapy is independent to GE rate.
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Efficacy and Safety of Itopride in Functional Dyspepsia: Results of Two Phase
III Multicentre, Randomized, Double-Blind, Placebo-Controlled Trials
Nicholas J. Talley, Jan Tack, Theadore Ptak, Rajendra Gupta, Monique Giguere
Background: Functional dyspepsia (FD) is a common disorder; there is little efficacious
drug therapy. Itopride, a prokinetic approved in several countries, showed promising efficacy
in FD in a Phase II trial (NEJM 2006; 23; 354: 832). We aimed to confirm the efficacy and
safety of itopride in FD. Methods: Two identical placebo-controlled clinical trials were
conducted in Europe and North America (NA). Males and females, 18 to 65 years, with a
diagnosis of FD (Rome II) and the absence (by upper endoscopy) of any relevant organic
disease were recruited. All were negative for H. pylori and, if present, heartburn could not
exceed one episode per week. Following screening, patients were randomized to itopride
100 mg tid or placebo. Co-primary outcome measures: 1) Leeds Dyspepsia Questionnaire
(LDQ); 2) Global Patient Assessment of efficacy (GPA). Symptoms were evaluated at weeks
2, 4 and 8. Secondary measures of efficacy included Nepean Dyspepsia Index (NDI) and
total LDQ score. Results: Primary efficacy endpoints were not reached, and no difference
in NDI scores was observed. A significant benefit of itopride over placebo was observed for
the LDQ responders in the International but not the NA trial (tables). The safety and
tolerability profiles were comparable to placebo, with the exception of prolactin elevations,
which occurred more frequently on itopride. Conclusion: Although itopride (vs placebo)
was well tolerated, and a higher response rate with respect to LDQ scores was observed
on active therapy, the primary efficacy endpoints were not reached. Sponsored by Axcan
Pharma inc.
International Trial ITT (Mostly EU sites)
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1LDQ Responder (pain and fullness)=improvement by at least 2 points on one symptom
without deterioration of the other
NA Trial ITT (Mostly NA sites)
1Same as International Trial
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Comparative Study of the Effects of Mitemcinal (GM-611), Erythromycin, and
Cisapride On Gastric Emptying in Rhesus Monkeys
Kenji Yogo, Ken-ichi Ozaki, Hisanori Takanashi, Masao Koto, Zen Itoh, Satoshi Omura
INTRODUCTION: Mitemcinal is an erythromycin (EM) derivative with high motor stimulat-
ing activity via motilin receptors but has no antibacterial activity. It showed symptom relief
after oral administration in patients with diabetic gastroparesis. Previously, we have reported
that the response to motilin in nonhuman primates is similar to in human. In the present
study, the effect of mitemcinal on the gastric emptying (GE) was investigated and compared
with those of EM and cisapride (5HT4 agonist). METHODS: Male Rhesus monkeys were
used in this study. The GE rate was determined using an acetaminophen (AAP) method
after overnight fasting. The monkeys were fed 10 mL/kg of liquid food thoroughly mixed
with 40 mg/mL of AAP. Blood samples were collected from the cubital vein every 15 min
after the liquid meal. The plasma AAP concentration at 45 min after the liquid meal (C45)
was measured as an index of gastric emptying. Test drugs were administered intravenously
(i.v.) 5 min after or orally (p.o.) 15 min before ingestion of the test meal. RESULTS: In
the vehicle group, plasma AAP concentration gradually increased after ingestion of the liquid
test meal. The average value of C45 for all vehicle groups was 4.80 ± 0.43 μg/mL (mean ±
SE, n=35). Mitemcinal increased C45 in a dose dependent manner (0.01-0.3 μmol/kg for
i.v. and 1-10 μmol/kg for p.o.). After administration of mitemcinal at the highest doses via
i.v. and p.o., C45 values were 23.8 ± 4.2 and 10.2 ± 2.1 μg/mL (each n=6), respectively.
EM (0.3-3 μmol/kg for i.v. and 10-100 μmol/kg for p.o.) also accelerated GE in a manner
similar to mitemcinal. However, EM required doses 10-30 times higher than mitemcinal to
increase C45 significantly. Cisapride (0.1-1 μmol/kg for i.v. and 3-30 μmol/kg for p.o.) also
accelerated GE; however, dose response for cisapride showed a bell-shaped curve after both
i.v. and p.o. administration. C45 values after i.v. and p.o. administration of the highest
doses of cisapride were only 9.5 ± 1.3 and 6.6 ± 1.1 μg/mL (each, n=6), respectively.
CONCLUSIONS: The present results demonstrate that mitemcinal and EM accelerated GE
in a dose-dependent manner in Rhesus monkeys after both i.v. and p.o. administration. In
contrast, cisapride showed a bell-shaped dose-response curve. It is known that well-coordin-
ated gastric and duodenum contractions may be important for GE. The results also suggest
motilin-like gastrointestinal contractile activity induced by mitemcinal is important for acce-
lerating GE dose-dependently.
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Tegaserod Significantly Improves Moderate−Severe Dysmotility Symptoms in
Patients with Functional Dyspepsia
Nimish Vakil, William D. Chey, Colin W. Howden, David L. Earnest, Gregory Ligozio,
Jeffrey Kralstein, Peter C. Rueegg
Background: There are no treatments (tx) with established efficacy for functional dyspepsia
dysmotility (D-FD) symptoms (sx). Patients (pts) with more severe sx have the greatest need
of relief and the greatest reduction in HRQOL and work productivity. We evaluated the
efficacy and safety of tegaserod (T) 6 mg bid in pts with D-FD and stratified the data by
baseline (BL) sx severity, using pooled data from 2 identical randomized, placebo (P)-
controlled trials. Methods: Women, ≥18 years, with at least mild D-FD (Rome II) were
recruited. Primary endpoints were % days with satisfactory sx relief, and composite average
daily severity score (CADSS) for postprandial fullness, bloating and early satiety. The severity
of postprandial fullness, bloating and early satiety for CADSS was self-rated by pts using a
7-point Likert scale. Pts were then grouped by CADSS: < moderate (score 1−<4), moderate
(score 4−<5),≥moderately severe (score 5−7). Additional variables included responder rates
for % days with satisfactory relief (≥50%), CADSS and individual sx (≥1.0 point improve-
ment from BL), as well as the Patients' Perception of Study Medication (PPSM) questionnaire.
Results: Increased BL sx severity was associated with greater tx differences between T and
P across the primary and secondary endpoints (table). Diarrhea, the most frequent adverse
event, occurred in more T (13.6%) than P (3.0%) pts, was typically mild, transient and did
not cause significant pt attrition. Conclusions: Tegaserod is safe and effective in women
with D-FD, with greater improvements seen in pts with increased baseline sx severity. Tx
effects are maintained for 6 weeks and improvements are seen in overall and individual
dyspeptic sxs. In the more severe subgroup the tx difference between tegaserod and placebo
across individual sxs averaged more than 10%.
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†with satisfactory relief, ‡≥1.0 point improvement
644
Work Productivity and Daily Activity Impairment in Patients with Functional
Dyspepsia: Double-Blind Comparison of Tegaserod Vs. Placebo
Loren Laine, Jan Tack, Colin W. Howden, Mohamed Omar, Gregory Ligozio, Jeffrey
Kralstein, David L. Earnest
Functional dyspepsia (FD) decreases quality of life and may impair work productivity and
daily activity. Therapy ideally should improve not only dyspeptic symptoms but also work
productivity and ability to carry out daily activities. METHODS: Women ≥ 18 yrs with
mid upper abdominal discomfort (≥ 2 of the following: postprandial fullness, early satiety
or bloating) and without IBS were randomly assigned to tegaserod 6 mg bid or placebo in
2 identical double-blind trials. The Work Productivity and Activity Impairment-Dyspepsia
(WPAI-D) questionnaire was used in the studies. WPAI is a validated tool to measure impact
of a disease on absenteeism (time absent from work), presenteeism (impaired productivity
at work), overall work productivity loss (absenteeism + presenteeism) and daily activity
impairment (non-work activities). Results were analyzed for all patients and for subgroups
divided by baseline dyspepsia symptom severity using a 7-point Likert scale: none-mild
(score 1-<4), moderate (4-<5) and moderately-very severe (5-7). RESULTS: Baseline severity
was none-mild in 1134 patients (774 employed), moderate in 990 (647 employed), and
moderately-very severe in 526 (363 employed). Table 1 shows the % of time for work
(employed patients) and daily activity impairment (all patients) at baseline. Table 2 shows
results at end of treatment for difference in mean improvement for tegaserod vs. placebo.
CONCLUSIONS: FD with dysmotility symptoms is associated with a large amount of missed
work, impaired work productivity and daily activities. Increasing symptom severity increases
this impairment. Tegaserod had larger effects in patients with more severe symptoms,
achieving statistical significance in improvement of daily activity impairment.
Work productivity and daily activity impairment at baseline in all patients and subgroups
by baseline symptom severity
Difference in change from baseline for tegaserod vs. placebo in work productivity and daily
activity impairment in all patients and subgroups by baseline symptom severity (negative
values indicate greater improvement with tegaserod)
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Effect of Placebo in Controlled Trials of Patients with Functional Dyspepsia: A
Meta-Analysis
Changcheng Wang, Yuhong Yuan, Richard H. Hunt
Backgrounds:Several treatments have been studied for functional dyspepsia (FD), but efficacy
is reported in only ~50% of patients while the placebo rate is as high as 20-30%, which
may be due to varied subjective outcome measures to assess response to FD. We aimed to
explore through meta-analysis the placebo effect in different FD trials including H. pylori
eradication, PPIs, H2RAs, prokinetics, and colloidal bismuth subcitrate (CBS). Methods:Engl-
ish-language MEDLINE, EMBASE and Cochrane searches for placebo-controlled RCTs in
adults were performed using keywords “functional dyspepsia” or “non-ulcer dyspepsia”
published to Nov 2006. Binary outcomes including symptom free or symptom improvement
were analyzed. Searches generated 272 citations and 39 met inclusion criteria: 4 RCTs for
H. pylori eradication with proportion dyspepsia symptom-free at 12 months, 8 RCTs for
PPIs and 12 for H2RAs with proportion with complete or improved symptom relief at 1-
12 weeks, 11 cisapride with proportion with symptom-free or improvement at 2-4 weeks
and 4 CBS with proportion with symptom-free or improvement at 4-8 weeks. Crossover
studies or studies without raw data and duplicate publications were excluded. Relative risk
(RR) (random effects model) with 95% CI was calculated with Review manager 4.2.8.
Results:3996 patients received active treatments and 4052 received placebo alone. The RRs
were 0.77 (95% CI 0.62-0.96, P=0.02) for H. pylori eradication, 0.68 (95% CI 0.53-0.86,
P=0.002) for PPIs, 0.79 (95% CI 0.70-0.90, P=0.0003) for H2RAs, 0.64 (95% CI 0.50-
0.83, P=0.0005) for cisapride and 0.51 (95% CI 0.22-1.15, P=0.10) for CBS. Overall, 30.5%
patients responded to placebo. Placebo response rates were 21.2% (H. pylori eradication),
23.5% (PPIs), 39.0% (H2RAs), 38.4% (cisapride) and 34.7% (CBS) in these 5 categories of
RCTs, respectively. Significant heterogeneity was seen between studies except in H. pylori
eradiation group. There were considerable variations in defining symptom improvement
and in observation time points in these studies. Conclusions:Although several treatment
strategies were effective in patients with FD, between 21% and 39% of the study population
reported symptom improvement on placebo alone. Placebo effect size varied among the
different trials, especially in H2RAs and cisapride trials, in which the placebo effect rate was
as high as 39.0%. Considering the high response to placebo and the unknown factors
influencing the placebo response, the variability of subjective symptom assessments may
result in the inconsistency of placebo effects with different treatments. Standardized objective
outcome measures are important for FD trials in the future.
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The Ubiquitin-Editing Enzyme A20 Restricts T Cell Receptor Signaling and T
Cell Mediated Intestinal Inflammation
Shigeru Oshima, Regina-celeste Ahmad, Rita Tavares, Emre Turer, Nataliya Shifrin, Bettina
Lee, Averil Ma
Background & Aims: Maintenance of mucosal immune homeostasis requires the collaboration
of multiple immune and stromal cells. One key immune cell type is T cells, which recognize
and respond to foreign antigens through antigen specific T cell receptors (TCRs). Chronic
stimulation of TCRs is required for the survival and maintenance of T cells, while activation
of T cells is triggered by more robust TCR stimulation. Thus, regulating the intensity and
duration of TCR signals plays a critical role in regulating the propensity of T cells to cause
inflammation. A20 is a novel ubiquity-modifying enzyme that regulates signal transduction
events in innate immune events. Thus, we have investigated whether A20 regulates TCR
signals and T lymphocyte function in the intestine. Methods: T cells were assayed for the
expression of A20 by immunoblotting. Thymocytes and peripheral T cells purified from
young A20-/- mice were assayed for their ability to cause intestinal inflammation after their
transfer into RAG-1-/- mice. Recipient mice were analyzed by histology, flow cytometry and
RPA analysis. A20-/- T cells were stimulated In Vitro via TCR and assayed for the production
of IL-2, as well as for TCR dependent signaling events. Finally, ubiquitylation of key TCR
signaling proteins was assayed by immunoprecipitation and immunoblotting. Results: We
find that A20 is dynamically regulated in purified thymocytes and mature T cells. A20-/- T
cells cause splenomegaly and intestinal inflammation after adoptive transfer into A20 compet-
ent RAG-1-/- mice. Purified A20-/- T cells exhibit prolonged NF-kB and JNK activity, and
increased expression of NF-kB-dependent genes, including pro-inflammatory cytokines after
TCR stimulation. A20-/- T cells more readily differentiate In Vitro into TH1 and TH17 type
T cells. A20-/- T cells also exhibit aberrant ubiquitylation of key TCR signaling proteins.
Conclusions: These data provide biochemical, cell biological and physiological evidence
demonstrating how A20 regulates ubiquitylation of TCR signaling proteins, restricts TCR
signaling and prevents T cell mediated intestinal inflammation.
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Induction of Colitis By Commensal Flagellin-Specific Th17 Cell Clones
Yingzi Cong, Wayne Duck, Lifang Li, Charles O. Elson
Purpose: We recently identified commensal flagellins as dominant antigens in animal models
of colitis and in patients with Crohn's disease. T cells reactive to the flagellin induced colitis
in SCID recipients, however the mechanisms involved are still undefined. Though Th1 cells
had been widely accepted playing a key role in colitis development, Th17 cells have recently
been identified as a lineage distinct from Th1 and Th2 cells that may play a pivotal role in
intestinal inflammation. In this report, we studied the role of flagellin- specific Th1 and
Th17 cells in the induction of colitis. Methods: Commensal flagellin Fla2, which is highly
homologous to previously identified FlaX, was cloned and recombinant full-length Fla2
flagellin was expressed in E.coli. Fla2 flagellin-specific T cell clones were established by
repeated stimulation of primed B6 CD4 T cells with Fla2 flagellin and then two rounds
cloned by limiting dilution. Th1 and Th17 clones were identified by intracellular cytokine
staining. Results: Among eleven Fla2 flagellin-specific T cell clones established, seven clones
produced IFNg but not IL-17 and four produced IL-17 but not IFNg, representing Th1 and
Th17 cells, respectively. These T cell clones used various TCBVbs independent of their
cytokine production. When stimulated with Fla2 flagellin, Th1 and Th17 clones produced
different cytokine profiles, in that Th1 clones produced IFNg and high amounts of GM-
CSF, but low levels of IL-6 and soluble CD40L, whereas Th17 clones produced IL-17 and
high levels of IL-6 and soluble CD40L, but low amounts of GM-CSF. When transferred into
normal C57BL/6 mice, then challenged with Fla2 flagellin in 40% ethanol intrarectally once
and anti-IL-10R antibody i.p. weekly, the Th17 clones induced severe colitis, whereas Th1
clones only induced mild colitis in the recipient mice. Anti-IL-10R treatment alone or transfer
by Th17 or Th1 clones alone without anti-IL-10R treatment did not cause colitis. Conclusion:
Taken all together, our data indicated that T cell clones reactive to a single commensal
bacterial flagellin are sufficient to induce colitis development and Th17 cells are crucial in
such disease induction. These T cell clones will allow dissection of the molecular events
downstream of these different effector cells.
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Bone Marrow Retaining Colitogenic Cd4+ T Cells May Be a Pathogenic
Reservoir for Chronic Colitis
Yasuhiro Nemoto, Takanori Kanai, Shin Makita, Ryuichi Okamoto, Teruji Totsuka,
Mamoru Watanabe
Background&Aims: Although the times when 'malignant' leukemia is completely cured by
bone marrow (BM) transplantation have come, 'benignant' inflammatory bowel diseases
(IBD) remain in a state of persistent diseases with lifelong recurrence. Surgery does not cure
IBD, even if regional lymph nodes and spleen are dissected, suggesting that colitogenic
memory CD4+ T cells might invade throughout the body, and other sites might act as
reservoirs for colitogenic memory CD4+ T cells. BM is known as a primary organ for lymphoid
hematopoiesis by the instrumentality of IL-7, but also known as a second lymphoid organ
to which harbor memory T cells. However, linking BM CD4+ memory T cells with a
pathological role in immune-mediated diseases is yet to be reported. We here report the
existence and the potential ability to induce colitis of the colitogenic BM CD4+ memory T
cells in murine colitis models.Methods: We isolated BM CD4+ T cells obtained from colitic
severe combined immunodeficient (SCID) mice induced by the adoptive transfer of
CD4+CD45RBhigh T cells, and analyzed the surface phenotype, cytokine production, and
potential activity to induce colitis. Furthermore, we assessed the role of IL-7 to maintain
the col i togenic BM CD4+ T ce l l s . Resul t s : We found that a high number of
CD4+CD44highCD62L-IL-7Rhigh effector-memory T (TEM) cells resided in the colitic BM,
and produced large amount of Th1 and Th17 cytokines.New SCID mice transferred with
the colitic BM CD4+ TEM cells induced colitis to a similar extent of mice transferred with
colitic LP CD4+ T cells. These colitogenic BM CD4+ TEM cells were mostly attached to IL-
7-producing stromal cells in colitic BM. IL-7-/-,Rag1-/- mice transferred with colitogenic BM
CD4+ TEM from colitic SCID mice didn't develop colitis, while IL-7+/+,Rag1-/- mice transferred
with colitic BM CD4+ TEM cells did develop severe colitis. Recovered cell number of TEM
cells from BM of IL-7-/-,Rag1-/- mice transferred with colitogenic BM CD4+ was markedly
and significantly reduced as compared with IL-7+/+,Rag1-/- mice transferred with colitic BM
CD4+ TEM cells.Conclusions:These findings suggest that BM is a reservoir for colitogenic
CD4+ TEM cells in IL-7-dependent manner. We suggest that IBD patients might need
systemic lymphoid reset treatment such as autologous BM transplantation for the cure rather
than just topical treatments.
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The Role of Invariant Natural Killer T Cells On a Mouse Colitis-Associated
Colon Cancer Model
Kyoko Yoshioka, Yoshitaka Ueno, Shinji Tanaka, Toshiko Onitake, Rie Hanaoka, Toru
Kawamura, Tsuyoshi Hatakeyama, Masaru Shimamoto, Masamoto Kanno, Hiromitsu
Watanabe, Kazuaki Chayama
BACKGROUND &AIM: A link between inflammation and cancer has long been suspected,
but its immune-dysregulation remains unknown. Invariant natural killer T (iNKT) cells are
a unique subset of T cells that provide anti-tumor immunity. However, the role of NKT
cells in inflammation-related tumorigenesis is still unclear. Here, we investigated the anti-
tumor immune response of iNKT cells in a mouse colitis-associated colorectal cancer model.
METHODS: Ten-week-old C57BL/6 (B6) and Jα18 NKT cell-deficient mice (KO) were
injected intraperitoneally (i.p.) with 9.6 mg/kg azoxymethane (AOM). After 7 days, 2.5%
dextran sodium sulfate (DSS) (ICN, MW 5000kDa) was given in the drinking water over
5 days, followed by 16 days of regular water. This cycle was repeated three times and mice
were sacrificed 16 days after the last cycle. Body weight, colon length, and histological score
were assessed for the evaluation of intestinal inflammation. Mononuclear cells were isolated
from the liver and labeled with a-galactosylceramide-loaded dimeric CD1d:Ig fusion protein
for the detection of iNKT cells. Activated CD4+T cells in the mesenteric lymph nodes and
colons were detected by staining with FITC-conjugated anti-CD69 or PE-conjugated anti-
CD25. The populations of these cells were all analyzed by flow cytometry. RESULTS: In
AOM/DSS model, iNKT cells in the B6 liver were selectively decreased. KO mice showed
increased number and size of colon tumors compared to B6 mice. KO mice exhibited
increased susceptibility to chronic colitis induced by DSS, as reflected by significantly higher
clinical and histological scores, and more severe colonic shortening. Flow cytometric analysis
revealed evidence of a significant increase in the percentage of mesenteric CD69+CD4+ and
CD25+CD4+T cells in KO mice. Both colonic CD25highCD4+ and CD25lowCD4+T cells
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were significantly increased in KO mice. CONCLUSION: Invariant NKT cells may play a
critical role on tumor immunosurveillance against colitis-associated colorectal cancer model
in mice.
650
IL-7 Is Essential for the Development and Persistence of Chronic Colitis
Teruji Totsuka, Takanori Kanai, Yasuhiro Nemoto, Takayuki Tomita, Shin Makita,
Mamoru Watanabe
Backgroud & Aims: Inflammatory bowel diseases (IBD) is caused by excessive and tissue
damaging chronic inflammatory responses by accumulating colitogenic effector or memory
CD4+ T cells in the gut wall, and commonly take persistent, disabling courses Although
interleukin-7 (IL-7) has recently emerged as a key cytokine involved in controlling the
survival of peripheral resting memory CD4+ T cells and their homeostatic turnover, its
potential to be sustained pathogenic memory T cells in immune-mediated diseases, such as
IBD, still remains unclear. Here we demonstrate that IL-7 is essential for the development
and persistence of chronic colitis induced by adoptive transfer of normal CD4+CD45RBhigh
T cells or colitogenic lamina propria (LP) CD4+ memory T cells. Methods & Results: Although
IL-7+/+ x RAG-1-/- recipients transferred with CD4+CD45RBhigh splenocytes developed mas-
sive inflammation of the large intestinal mucosa concurrent with massive expansion of Th1
cells, IL-7-/- x RAG-1-/- recipients did not. Furthermore, IL-7-/- x RAG-1-/-, but not IL-7+/+
x RAG-1-/-, mice transferred with LP CD4+CD44highCD62L-IL-7Rαhigh effector-memory T
cells (TEM) isolated from colitic CD4+CD45RBhigh-transferred mice, did not develop colitis.
Although rapid proliferation of transferred colitogenic LP CD4+ TEM cells was observed in
the in IL-7-/- x RAG-1-/- mice to a similar extent of those in IL-7+/+ x RAG-1-/- mice in CFSE
dilution assay, Bcl-2 expression was significantly down-modulated in the transferred CD4+
T cells in IL-7-/- x RAG-1-/- mice compared with those in IL-7+/+ x RAG-1-/- mice. The
average recovered numbers of LP CD4+ T cells from colitic IL-7+/+ x RAG-1-/- recipients
were markedly and significantly higher than those from the transferred IL-7-/- x RAG-1-/-
recipients. Conclusions: Taken together, IL-7 is essential for the development and the persist-
ence of chronic colitis as a critical survival factor for colitogenic CD4+ TEM cells, suggesting
that therapeutic approaches targeting IL-7/IL-7R signaling pathway to suppress the survival
of colitogenic CD4+ memory T cells may be feasible in the treatment of IBD.
651
Central Role of Pkcθ Signaling Cascade in Acquired Immune Mediated Colitis
Kiyotaka Nagahama, Atsuhiro Ogawa, Ken Sugimoto, Yasuyo Shimomura, Atul K. Bhan,
Atsushi Mizoguchi
Background & Aims: CD4 + T cells are activated through several signaling cascades that are
initiated mainly through immunological synapse (IS). A proximal signaling molecule associ-
ated with IS is T cell-specific protein kinase C (PKC), PKCθ that is required for the T cell
activation (proliferation) and survival through the activation of NFAT, NF-kB and AP-1. In
addition, PKCθ is involved in the induction of Th2 immune responses. Activated CD4+ T
cells have been well documented to participate in the induction of majority of acquired
immune mediated experimental colitis. However, the role of PKCθ in the CD4+ T cell-
mediated colitis has not yet been defined. Methods: Two colitis models were employed to
clarify the role of PKCθ in acquired immune mediated colitis, Th2-mediated colitis that
spontaneously develops in TCRα knockout (KO) mice and Th1-mediated colitis that is
induced in recipient RAG1 KO mice by transfer of CD4+ CD45RBhigh T cells. For Th2-
mediated colitis model, PKCθ-deficient TCRα double knockout (DKO) mice were generated.
In Th1-mediated colitis, CD4+ CD45RBhigh T cells from the spleen of WT or PKCθ KO mice
were transferred into RAG1 KO mice. Results: CD4+ T cells of PKCθ KO mice showed
significantly reduced expression of GATA-3, IL-4, and IL-5 but not T-bet or IFN-g as
compared to those of WT mice, suggesting an involvement of PKCθ in the induction of
Th2 immune responses. Indeed, deficiency of PKCθ resulted in the inhibition of Th2-
mediated colitis development; none of PKCθ-deficient TCRα DKO mice developed colitis
at 6 months of age, while 60% of TCRα KO mice developed colitis. Unexpectedly, deficiency
of PKCθ in CD4+ T cells contributed to the suppression of Th1-mediated colitis; transfer
of CD4+ CD45RBhigh T cells from PKCθ KO, but not WT, mice failed to induce colitis. This
suppression of colitis was associated with a significant decrease in colonic lamina propria
CD4+ T cells, suggesting a contribution of PKCθ-mediated CD4+ T cell expansion to the
pathogenesis of Th1-mediated colitis. This was further supported not only by In Vitro data
showing that naïve CD4+ T cells from PKCθ KO mice compared to WT mice weakly
proliferated in response to TCR ligation but also by In Vivo data that proliferative response
of colonic CD4+ T cells as judged by their incorporation of BrdU In Vivo was significantly
reduced in the recipient RAG1 KO mice reconstituted with PKCθ KO CD4+ T cells as
compared to those receiving WT CD4+ T cells. Conclusions: PKCθ is an indispensable
signaling molecule that activates CD4+ T cell-mediated several immune responses involved
in the pathogenesis of both Th1 and Th2 mediated colitis.
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Improving Colonoscopic Polyp Detection Through Microvascular Blood
Content Analysis with Four Dimensional Elastic Light Scattering
Fingerprinting (4d-Elf)
Hemant K. Roy, Vladimir Turzhitsky, Michael J. Goldberg, Young L. Kim, Randall E.
Brand, Alex Kromine, Mohammed Jameel, Bo Liu, Nahla Hasabou, Vadim Backman
Introduction: The adenoma miss rate of ~25% among expert endoscopists has major clinical
and medicolegal consequences. Current mitigation approaches (e.g. narrow band imaging)
have been suboptimal. Using a breakthrough spectroscopic technology, 4D-ELF (Gastro
2004), we observed that during colon carcinogenesis, there is early increase in blood supply
(EIBS) in the peri-cryptal capillary plexus from pre-dysplastic mucosa(Gut 2005). We wanted
to assess whether this extraordinarily sensitive “field effect” marker could be exploited for
polyp detection. Methods During colonoscopy, 196 subjects underwent 4D-ELF analysis
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from the visually normal mucosa with a fiberoptic probe via the biopsy channel. EIBS
(deoxygenated and total microvascular hemoglobin) was quantified by a previously validated
algorithm. Results: The 4D-ELF probe measured hemoglobin with >98% accuracy in tissue
models. EIBS was observed in the endoscopically normal mucosa at least 30 cm from
adenomas with the magnitude mirroring the proximity to the lesion (figure 1). EIBS was
more pronounced in association with large as opposed to small adenomas but was not seen
with hyperplastic polyps. An EIBS prediction rule for advanced adenomas had a sensitivity
and specificity of 100% and 97%, respectively. Conclusions: We demonstrate that in situ
EIBS reliably identified the presence of adenomas elsewhere in the colon. We envision that
if real-time measurement of EIBS is normal in a segment (~1/3 colon), the colonoscope
could be rapidly withdrawn even with a poor prep or incomplete cecal intubation. If EIBS
is elevated but a polyp is not readily visualized (e.g. behind a fold), then mapping the
gradient could lead to precise localization. Thus, EIBS detection could improve colonoscopic
accuracy without increasing procedure duration.
Fig 1 EIBS in Endoscopically Normal Mucosa. (p values vs. neoplasia-free subjects)
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In Vivo Identification of Colonic Dysplasia Using Peptide-Mediated Confocal
Fluorescence Microscopy
Pei-lin Hsiung, Jonathan Hardy, Christine B. Du, Peyman Sahbaie, Shai Friedland, Roy M.
Soetikno, Christopher H. Contag, Thomas D. Wang
Background: Patient morbidity and mortality associated with cancer originating from epithelia
of hollow organs may be reduced by early detection of pre-malignant (dysplastic) mucosa.
Phage display provides a highly complex library of peptides which can be screened to select
for high affinity ligands that preferentially bind to molecular markers of disease. These
peptides can be conjugated with fluorescent molecules and investigated as imaging agents
for targeting dysplasia In Vivo. Methods: Peptides were identified from a M13 phage library
by first clearing the libraries of those with non-specific binding by biopanning against a
non-malignant human intestinal cell line and fresh normal human colon biopsies. Unbound
phage were recovered and screened using freshly excised colonic polyps. Selected peptides
were sequenced, synthesized, tagged with fluorescein, and used for initial In Vivo testing in
patients undergoing routine colonoscopy. Approximately 3-6 mL of peptide at a concentration
of 100 μM was administered topically. After incubation for ~1 minute, imaging was performed
using a clinical fibered confocal fluorescence microscope (Cellvizio®-GI, Mauna Kea Techno-
logies, France) delivered through the working channel of a standard colonoscope. Imaging
of peptide binding was performed at tissue depths of up to 50 μm at 12 frames per second
with a resolution of 2.5 μm (transverse) x 20 μm (axial). Fluorescence target-to-background
ratios were calculated based on averaged fluorescence signal from colonocytes using 10
selected images of adenomatous polyp and 10 selected images of normal mucosa from each
patient. Subjects were monitored for peptide toxicity by CBC, LFTs, and BUN/Cr. Results:
In Vivo confocal fluorescence images were collected in 11 patients. Imaging of fluorescence
from fluorescein-conjugated peptide suggested binding to abnormal colonocytes. In contrast,
reduced fluorescence was observed from surrounding normal mucosa from the same patient.
Reduced fluorescence was also observed from fluorescein-conjugated scrambled peptide
used as a control. Target-to-background ratios between adenomatous and normal colonocytes
for 9 polyps was ~21 with an average signal-to-noise ratio of ~10. No fluorescence was
observed for non-peptide treated mucosa. Imaged polyps were removed by biopsy and In
Vivo observations were confirmed by histopathology. No toxicity associated with peptide
administration was found. Conclusions: Peptides with preferential binding to abnormal
tissues can enhance visualization of dysplastic lesions, demonstrating the potential to perform
real time histopathology and In Vivo optical imaging of molecular targets.
680
First Use of Integrated Elastic Scattering Optical Forceps for Real-Time
Histologic Classification of Colonic Polyps
Mark S. Amorosino, Ousama M. A'amar, Eladio Rodriguez-diaz, Lin lin Gao, Sara Gillers,
Rayhme Collins, Ashish Sharma, Qin Huang, Sandra Cerda, Michael J. O'brien, Irving J.
Bigio, Satish K. Singh
Purpose: To validate a newly-engineered medical device and system designed to co-register
Elastic Scattering Spectroscopy (ESS) readings with tissue biopsy for real-time in-vivo detec-
tion of dysplasia during lower gastrointestinal (GI) endoscopy. Methods: Patients were
enrolled from an extant pool referred for lower GI endoscopy. Two optical fibers were
integrated between the jaws of standard-type biopsy forceps as part of a simple, low-cost
system composed of a xenon light source, spectrometer, and laptop computer with custom
ESS software. The integrated forceps were used whenever polyp sampling was indicated
per current standards of care. The optical forceps were used to obtain ESS spectra from
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approximately 1 cubic mm of tissue exposed to pulsed broadband white light. The design
of our optical forceps permitted biopsy of the precise tissue measured by ESS. Physical
biopsies were reviewed independently by three GI pathologists. Optical biopsies were then
correlated to the consensus classification of the physical biopsies. The spectra obtained were
analyzed by support vector machines using features extracted by performing principle
component analysis. Results: A total of 200 colonic polyp biopsies (82 dysplastic and 118
non-dysplastic) from 58 patients were analyzed. Signal processing and a leave-one-out
analysis yielded a sensitivity of 80%, specificity of 80%, positive predictive value of 75%,
and negative predictive value of 85% for dysplastic vs. non-dysplastic tissue. Conclusion:
Our spectroscopically-guided forceps are able to co-register optical and physical biopsies.
Initial analysis is highly promising for the ability to differentiate dysplastic from non-
dysplastic colonic polyps in real-time with the use of fast signal processing. Applied to
current colon cancer screening recommendations, our device should increase adenoma yield
per biopsy by decreasing unnecessary sampling of nondysplastic polyps. Further benefits
of this simple, user-friendly device should be realized in greater screening efficiency, decreased
procedure time and reduced biopsy-associated risks and costs.
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Elastic Scattering Spectroscopy to Generate An Image of Patient Risk in
Barrett's Esophagus
Gary Mackenzie, M. Yong, B. Clark, M. Novelli, S. Thorpe, S. Bown, L. Lovat
Introduction: Elastic Scattering Spectroscopy (ESS) is a real-time In Vivo technique which
detects changes in the physical properties of cells. We have previously demonstrated a
sensitivity for detecting high grade dysplasia (HGD) in Barrett's esophagus of 92% and a
specificity of 60%. ESS is a point measurement but readings are extremely fast offering
clinicians the opportunity to virtually ‘scan' an area of Barrett's mucosa. Aims and Methods:
This was a preliminary study to prospectively test our previously published algorithm for
the detection of HGD and aneuploidy in Barrett's esophagus. Four measurements per site
and quadrantic sites every centimetre were measured throughout a patients Barrett's segment.
An optical image was created by interpolating the spectral scores following analysis to define
the risk of HGD and aneuploidy. This was then compared to quadrantic biopsies every 2cm
taken for histology. One biopsy at each level was processed for aneuploidy using image
cytometry. The time taken for the measurements to be collected was recorded in order to
assess practicality. Results: 40 Patients had their Barrett's Esophagus scanned. Twenty four
had HGD on subsequent biopsies and 16 had either low grade dysplasia or no dysplasia.
Of these 16 patients without HGD, 7 were found to have aneuploidy in all of their biopsies.
All 24 patients with HGD and all 7 with aneuploidy had positive scans and 4/9 low risk
patients with no dysplasia or aneuploidy had entirely negative scans. If biopsies were directed
only at suspicious areas on the scans, 17 instead of 80 biopsies would have been required
in the low risk patients and only 7 instead of 19 would have been necessary to exclude
aneuploidy. Scanning the oesophagus optically was performed by four different operators
and took an average of 4 minutes and 22 seconds for a 6cm segment of Barrett's, with no
significant difference between operators. Conclusions: Scanning patients Barrett's Esophagus
is fast without interobserver variability and can be used to identify high risk patients with
either HGD or aneuploidy. It could reduce the number of biopsies required to detect HGD
by over a half and reduce the number of biopsies processed for aneuploidy by over 60%
in a surveillance population. The findings also suggest that no biopsies would be needed
in a half of all patients undergoing endoscopic surveillance. In this series, no patients
with HGD or aneuploidy had negative scans. This study requires completion followed by
confirmation in multi-site testing on a surveillance population.
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Endoscopic Optical Coherence Tomography Reveals Barrett's Underneath
Squamous Neo-Epithelium After Radiofrequency Ablation
Hiroshi Mashimo, Yu Chen, Shu-wei Huang, Qin Huang, Aaron Aguirre, Joseph Schmitt,
James Fujimoto
BACKGROUND/AIMS: Radiofrequency ablation (RFA) is a promising treatment option for
patients with Barrett's esophagus (BE), but follow-up surveillance for potential changes
beneath the subsequent neo-epithelial layer is not possible by standard endoscopic visualiza-
tion. Endoscopic optical coherence tomography (EOCT) is an emerging medical imaging
technology which can generate real-time, high resolution, depth-resolved images in situ,
without removing tissue. We recently developed an EOCT system with 5 um axial resolution
and 15 um transverse resolution. Previous EOCT images acquired with this system demon-
strated distinct architectural features of normal esophagus, BE, and early cancer. The goal
of this study was to assess the subsurface tissue morphology over time after RFA treatment
of BE. METHODS: 15 patients with known BE were enrolled (5 with dysplasia). RFA was
performed using the bipolar radiofrequency balloon device (HALO 360, BARRX Medical,
Sunnyvale, CA). Patients were followed up with standard endoscopy and EOCT before, and
at two, four, and six months after the RFA treatment. When indicated, the patient received
focal RFA using HALO 90 system at 3 months. RESULTS: EOCT generally revealed squamous
neo-epithelium indistinguishable from normal esophagus, with underlying normal or (hea-
ling) architecture (consistent with edema and fibrosis). However, some cases revealed unique
morphology underneath a smooth-appearing, thin epithelium quite distinct from normal
untreated tissue regions. Disorganized glandular structures characteristic of BE could be
detected in these patients from two to six months post ablation. The depth the epithelium
varied during the healing process. Pinch biopsy and histology confirmed the subsurface
abnormality to be sub-squamous BE. CONCLUSIONS: EOCT allows real-time In Vivo imaging
of subsurface tissue morphology which is uniquely qualified for assessment and surveillance
of treatment efficacy after RFA of BE as an adjunct to standard endoscopy. This work suggests
that EOCT could be a promising non-invasive tool in evaluation of treatment effects, and
for real time guidance of focal ablation during follow-up endoscopy.
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Real-Time in-Vivo Histopathology for Detection of Neoplasia Using a Portable,
Confocal Miniprobe - A Blinded Analysis
Alexander Meining, Dieter Saur, Monther Bajbouj, Valentin Becker, Eric Peltier, Claus
Hann von weyhern, Heinz Höfler, Roland M. Schmid, Christian Prinz
Background and Aims: Confocal fluorescence microscopy (CFM) has been mentioned to be
a promising tool for in-vivo histology. Recently, a laser scanning microscope with a portable
miniprobe has been developed. Our aim was to evaluate the potential benefit of miniprobe-
based CFM for detection of neoplasia in a blinded manner. Methods: A total of 47 patients
with known or supected neoplasia in the upper (n= 34) or lower GI-tract (n= 13) were
examined with standard endoscopes. Chromoendoscopy with 2-5 ml cresyl violet 0.25%
was performed with the agent also being used as a fluorophore for CFM. Real time video
sequences were recorded and stored. Thereafter, biopsies were taken or mucosectomy was
performed from the same examined area. In addition, CFM was performed and biopsies
were taken from healthy mucosa. All digitally stored sequences were put into a random
order and assessed by a single examiner blinded. Results: A total of 119 CFM video sequences
were recorded of 85 benign or 34 neoplastic areas. Quality of CFM images was too low in
24 sequences, hence a presumptive endomicroscopic diagnosis could be established in 95
sequences. Accuracy of CFM for detection of neoplasia was 92.6% (sensitivity 92.3%,
specificity 92.8%). Agreement between CFM and histopathology was excellent (kappa: 0.821)
(see Figure for examples). On an intent-to-diagnose basis, accuracy of CFM was 73.9% (per-
biopsy) and 70.2% (per patient). Conclusions: We were able to show that cresyl-violet-
aided CFM using a miniprobe has the potential to diagnose neoplasia in real time during
ongoing endoscopy. This system has the advantage that it may be used with any standard
endoscope.
Endoscopy, CFM & histology
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Simultaneous Use of Smartpill pH and Pressure Capsule, Antroduodenal
Manometry, and Gastric Emptying Scintigraphy to Assess Gastric Emptying of
Digestible and Nondigestible Solids
Daniel Cassilly, Steve Kantor, Linda Knight, Alan Maurer, Robert S. Fisher, Henry P.
Parkman
Gastric emptying of digestible solids occurs after food is broken down to a few millimeters.
Nondigestible solids are thought to empty with phase III migrating motor complex (MMC).
Aim: To determine if a nondigestible solid empties from the stomach with the gastric phase
III MMC associated with the fasting period or with the triturated solid phase of the meal
during the fed period. Methods: 15 normal subjects underwent placement of an antroduod-
enal motility catheter using fluoroscopic guidance. Subjects ingested a standardized Eggbeat-
ers meal radiolabelled with Tc-99m, followed by ingestion of a SmartPill - a wireless pH
and pressure capsule measuring 13x26 mm. In 5 additional subjects, emptying of the
SmartPill was studied in the fasting period by having the subjects ingest the SmartPill with
only water. Gastric emptying scintigraphy was performed over 6 hours. Gastric emptying
of the SmartPill was indicated by a rapid rise of the SmartPill pH >3 pH units indicating
arrival in the alkaline small intestine. Pressure patterns of the antroduodenal manometry
recording were determined. Results: The SmartPill emptied from the stomach within 6
hours of meal ingestion in 14 of 15 subjects. In the 14 subjects, the SmartPill pressure
recordings showed high amplitude phasic contractions just prior to its emptying from the
stomach. The SmartPill gastric residence time (261±22 min [SEM]) significantly correlated
with the time to the first phase III MMC after meal ingestion (239±23 min; r=0.813; p<0.01).
In 9 of 14 (64%) subjects who emptied the SmartPill during the 6 hour postprandial
recording, the SmartPill emptied with a phase III MMC (first postprandial phase III in 4
and second phase III in 5). In 5 subjects, the SmartPill emptied with isolated distal antral
contractions and not with a phase III MMC. The SmartPill gastric residence time was
moderately correlated with gastric emptying of the solid meal (r=0.606 with T-50% and r=
0.404 with T-90%). In the 5 subjects ingesting only water, the SmartPill gastric residence
time (92±44 min) correlated with the time to the first Phase III MMC after water ingestion
(87±30 min; r=0.979; p<0.01). In 4 of 5 subjects, the SmartPill emptied with the first phase
III MMC, the other with the second phase III. Conclusions: This study demonstrates that
a nondigestible solid (SmartPill) empties from the stomach after meal ingestion in most
normal subjects with the return of the fasting phase III MMC rather than with the gastric
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emptying of a solid phase meal. However, in some subjects, the SmartPill emptied with
isolated antral contractions, a previously unappreciated mechanism for emptying of a nondi-
gestible solid.
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The Herbal Medication, Iberogast®, Relaxes the Proximal Stomach, Stimulates
Antral Motility, But Does Not Affect Pyloric and Duodenal Motility, and Slows
Gastric Emptying of Liquids in Healthy Men
Amelia N. Pilichiewicz, Michael Horowitz, Antonietta Russo, Anne F. Maddox, Karen L.
Jones, Michael Schemann, Gerald Holtmann, Christine Feinle-bisset
Introduction: The herbal medication, Iberogast® (“IBE”), improves symptoms in functional
dyspepsia. In Vitro (ie in muscle strips of guinea pig stomach), IBE has a dual action on
the gastrointestinal (GI) tract; it decreases fundic tone and increases antral motility in a
concentration-dependent manner (Hohenester et al. Neurogastroenterol Motil 2004;16:765-
73). In human gastric muscle preparations IBE relaxes the proximal stomach (Schemann et
al. Phytomedicine 2006; in press); The magnitude of this effect is comparable to that observed
in the guinea pig stomach. The effects of IBE on the intact human GI tract are currently
unknown. Hypothesis: IBE will relax the proximal stomach, stimulate phasic pressures in
the antrum and duodenum, decrease pyloric pressures, and have little or no effect on gastric
emptying, but increase meal retention in the proximal stomach. Protocol: We evaluated the
effects of oral IBE and control (“C”), each administered as a single dose (1.1 ml - as
recommended for IBE), in double-blind, randomized fashion, on (Part A) proximal gastric
volume, by barostat, (Part B) antropyloroduodenal motility, by high-resolution manometry,
and (Part C) gastric emptying and intragastric distribution of a solid/liquid meal, by scinti-
graphy, in 9 (Part A), 12 (Part B) and 8 (Part C) healthy males. Results: IBE increased
proximal gastric volume (maximum volume, C: 104±12 ml, IBE: 174±23 ml; P<0.05, Figure
A), and increased the motility index of antral pressure waves in the first 60 min (P<0.05,
Figure B), without affecting pyloric or duodenal pressures. IBE slightly increased the retention
of liquid in the total stomach between 10-50 min (P<0.01), although there was no significant
difference in the T50% for liquid (C: 20±3 min, IBE: 23±2 min), and no effect on gastric
emptying of solids (retention at 100 min; C: 40±4 %, IBE: 43±5 %) or intragastric meal
distribution. Conclusions: IBE has region-dependent effects on gastric motility in humans
by relaxing the proximal stomach and stimulating antral motility. These effects may contribute
to the reported therapeutic efficacy of IBE in functional dyspepsia.
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Incidence and Predictors of Small Intestinal Bacterial Overgrowth in
Gastroparesis
Savio Reddymasu, Irene Sarosiek, Sandra Sostarich, Richard Mccallum
Introduction: Gastroparesis (GP) is a common clinical condition characterized by often
disabling symptoms of abdominal pain, nausea, vomiting, bloating, and loss of weight. A
similar spectrum of symptoms are also present in small intestinal bacterial overgrowth
(SIBO). Aims of this study were to investigate the incidence and predictors of SIBO in GP.
Methods: 50 patients (41 females, 9 males) with GP underwent the glucose breath testing
(GBT) if they had an accompanying prominence of abdominal pain, gas and bloating.
Demographic data, information regarding the predominant bowel movement pattern, and
the use of tegaserod, dopamine antagonisits, opiate analgesics, and proton-pump inhibitors
was recorded. A diagnosis of SIBO was made on the basis of a positive GBT- which was
defined as a concentration of hydrogen or/and methane >20ppm (measured by Quintron
MicroLyzer DP; Milwaukee, WI) achieved during the first 90 minutes after ingestion of 50
grams of glucose in 148 cc of water. Logistic regression was used for statistical analysis and
odds ratios were calculated at 95% confidence levels. Results: 30 of the 50 (60%) subjects
with GP had a positive GBT, based on the hydrogen and/or methane criteria. Clinical
characteristics and medication profiles of patients are summarized in Table 1. Conclusions:
1.) SIBO is present in the majority of patients with gastroparesis secondary to diabetes, post
surgical, or idiopathic etiologies.2.). GP patients receiving opiate analgesics are more likely
and those on tegaserod less likely to develop SIBO in GP. 3.) Impaired motility underlying
GP can also extend into the small bowel-consistent with a neuropathic etiology explains the
SIBO. 4.) Appreciating the need to address and treat both GP and SIBO is an important
strategy in this challenging clinical setting.
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Acute Tryptophan Depletion Confirms Involvement of 5-Hydroxytryptamine in
the Control of Gastric Sensorimotor Function in Man
Brecht Geeraerts, Nele Dervaux, Lukas Van oudenhove, Rita Vos, Kostas Mimidis, Jan
Tack
BACKGROUND: Abnormalities of gastric sensitivity to distension and meal-induced accom-
modation have been implicated in the pathogenesis of functional dyspepsia (FD). Studies
in animals and in man have suggested involvement of 5-HT in the control of the sensorimotor
function of the proximal stomach, although the precise role of 5-HT remains to be elucidated.
Acute tryptophan depletion (ATD), which experimentally lowers 5-HT synthesis, has been
extensively used to study the role of 5-HT in anxiety and depression disorders. Our AIM
was to investigate the influence of ATD on gastric sensorimotor function, as well as anxiety
levels, in healthy volunteers. METHODS: 15 healthy subjects (28.8±1.5 years) underwent
a gastric barostat study twice to assess gastric compliance, perception to stepwise isobaric
distensions and postprandial gastric accommodation, after ingestion of an amino acid mixture
with or without tryptophan in a randomized, double-blind, cross-over design. Barostat
measurements started 5 hours after ingestion of the amino acid mixture. At different time
points, we assessed the severity of 9 epigastric symptoms on visual analogue scales (VAS),
plasma levels of tryptophan and 5-hydroxyindole acetic acid (5-HIAA), and STAI-state
anxiety scores. RESULTS: ATD significantly decreased plasma tryptophan (48.5±2.8 vs.
9.3±2.4 µmol/l, p<0.0001) and 5-HIAA concentrations (5.8±0.6 vs. 2.1±0.3 mg/l, p<0.0001)
after 5 hours. ATD did not influence gastric compliance (49.0±5.5 vs. 51.2±5.7 ml/mm Hg,
NS) and sensitivity to gastric distension compared to the control condition. Consequently,
the pressures needed to induce first perception or discomfort (respectively 11.4±0.6 vs.
11.2±0.9 and 20.1±1.1 vs. 19.7±0.8 mmHg, NS) and corresponding intra-balloon volumes
(respectively 222.1±25.8 vs. 231.4±38.8 and 643.7±56.7 vs. 645.8±51.0 ml, NS) did not
differ significantly between ATD and control condition. Anxiety scores were not elevated
by ATD (29.2±1.7 vs. 29.0±1.8, NS). However, during ATD, gastric accommodation was
significantly enhanced (higher postprandial volume increase up to 35 minutes postprandially:
AUC 3524±1409 vs. 7276±1298 ml*min, p<0.05; higher maximal intragastric volume within
30 minutes after meal ingestion: 204±43 vs. 316±40 ml, p<0.05). In addition, ATD was
associated with significantly decreased VAS scores for nausea during gastric distension (AUC
17.5±4.3 vs. 11.4±3.4 mm*mmHg, p<0.03). In CONCLUSION, these data suggest that
serotonin is involved in the control of the gastric accommodation reflex, and in the generation
of nausea during gastric distension.
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Plasma Glucose-Dependent Gastric Slow Wave Uncoupling and Loss of
Rhythmicity During Graded Hyperglycemic Clamping in Humans Measured By
Multichannel Mucosal Recording
Radoslav Coleski, William L. Hasler
Background: Gastric dysrhythmias are prevalent in diabetic gastropathy. Hyperglycemic
clamping mimics effects of diabetes in healthy humans, inducing tachygastria at threshold
plasma glucoses of 230 mg/dl. Effects of different degrees of hyperglycemia on regional
dysrhythmias and slow wave coupling are unexplored. Hypotheses: Using a mucosal map-
ping method we validated to characterize slow wave conduction, we hypothesized (i) hyperg-
lycemia elicits localized region-specific tachygastria, (ii) hyperglycemia evokes uncoupling
between adjacent regions when dysrhythmias are not present, and (iii) threshold plasma
glucoses causing tachygastria are different from those that induce uncoupling. Methods:
Catheters with bipolar mucosal electrodes were affixed 2, 6, and 10.5 cm from the pylorus
during endoscopy with midazolam in 10 healthy humans. After 1 hr control recordings,
graded hyperglycemic clamping was performed to targets of 250 mg/dl. Analysis was per-
formed on 5 min segments stratified to plasma glucoses from 150-275 mg/dl. Results: In
control recordings, slow wave frequencies proximally (2.91±0.05 cycles/min[cpm]) and
distally (2.81±0.09 cpm) were similar. Tachygastria (>3.6 cycles/min [cpm]) was present in
1.7±1.1% of recording time proximally and 3.3±1.8% distally and localized to one lead
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67% of the time. Coupling between adjacent sites was 76±2% with propagation velocities
of 1.1±0.3 cm/sec. 2±1% of segments showed >50% uncoupling. Maximal mean frequencies
proximally (3.26±0.19) and distally (3.59±0.22 cpm)(P<0.01) occurred at glucoses of 275
mg/dl. Maximal tachygastria proximally (16±6% of time) and distally (38±10%) occurred
at 275 mg/dl and was isolated to one lead 84% of the time. Threshold glucoses to increase
mean frequencies and induce tachygastria were 250 mg/dl proximally and 225 mg/dl distally
(both P<0.01). During periods of normal frequency (2.4-3.6 cpm), maximal uncoupling
proximally (51±8%) and distally (60±5%) occurred at 275 mg/dl (P<0.01) where 49±13%
of segments proximally and 74±6% distally showed >50% uncoupling (P<0.001). Threshold
glucoses to increase uncoupling were 175 mg/dl proximally and distally (P<0.01). Conclu-
sions: Under control conditions, gastric slow waves show stable, highly coupled rhythms.
Hyperglycemic clamping elicits plasma glucose-dependent isolated tachygastrias and uncoup-
ling of normal slow waves most prominent distally. Plasma glucose thresholds for inducing
uncoupling are lower than for evoking dysrhythmias suggesting that mechanisms for mainten-
ance of coupling and rhythm are distinct. These findings provide a foundation for studying
slow wave conduction defects in diabetic gastropathy.
689
Response of Diaphragm Biofeedback On Proximal Gastric Volume After Test
Meal
Xiaohong Sun, Zhao Yu, Meiyun Ke, Congxin Li, Yanli Zhang, Zhifeng Wang
Background and aim: Incompetence of the anti-reflux barrier and gastric fundus distension
are main factors of all mechanisms of gastroesophageal reflux, Our previous studies (AMS,
2002, DDW, 2005) showed that diaphragm biofeedback (DBF) could enhance tension of
crural diaphragm and pressure of gastroesophageal junction, and decreased or discontinued
acid suppression in patients with GERD. Recent study showed that postprandial DBF signific-
antly reduced esophageal acid exposure during 2 hrs postprandial period (DDW,2006). The
aim is to investigate the effect of DBF on the proximal gastric volume after a standard test
meal in health subjects (HS). Methods: Fifteen subjects (all male, 33.4±7.17) were enrolled
the study and each subject received twice studies. After fasting at least 6 hours, subjects
took a test meal within 10 min, contained 500 ml volume and 584 kcal of noodle with
500μCi 99mTC sulfur colloid labeled a fried egg. Then subject was standing in front of
dual-head SPECT and the abdomen was imaged at 0 min immediately after the test meal
and every 15 min for the first hour, then every 30 min for the second hour. One week
later, subjects need to repeat the study described above. The difference was subjects need
to have DBF for 10 min before ingesting the test meal, then 10 min DBF every 15 min for
2 hours. he measure of the proximal gastric volume indicated by interesting isotope counts
in the anterior and posterior position. Analysis parameter: the proximal gastric count in the
anterior and posterior position at each time point after the test meal, then geometric count
was calculated, and its difference between Non-DBF and DBF was analyzed. Result: Compared
with non-diaphragm biofeedback, the proximal gastric volume at every imaging point was
significantly reduced after training diaphragm biofeedback. Conclusion: Diaphragm biofeed-
back after test meal can significantly reduced the volume of the proximal stomach. Therefore,
our hypothesis is that diaphragm biofeedback training reduces gastroesophageal reflux par-
tially through reduced the volume of the proximal stomach. Further study needs to be
performed in patients with GERD.
Table 1. The proximal gastric volume in 15 health subjects
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Effect of Acid Suppressive Therapy On Narrow Band Imaging (NBI) Findings
in Gastoesophageal Reflux Disease (GERD)Patients
Prateek Sharma, Sachin B. Wani, Amit Rastogi, Sandy Hall, Sharad Mathur, April D.
Higbee, Ajay Bansal
Background NBI is a novel technology utilizing spectral narrow band filters that enhances
visualization of surface mucosal and capillary pattern of distal esophagus. Thus, microscopic
intrapapillary capillary loops (IPCLs) can be readily seen. Recent reports suggest that NBI
endoscopy may improve diagnosis of GERD over standard endoscopy. However, changes
in findings at NBI endoscopy in response to PPI therapy have not been assessed. Aim To
evaluate the effect of PPI therapy on findings observed at NBI endoscopy in GERD pts.
Methods Pts with GERD symptoms completed 2 validated GERD questionnaires [gastroeso-
phageal reflux questionnaire (GERQ) and reflux disease questionnaire (RDQ)] prior to
enrollment. Distal esophagus was examined by standard endoscopy followed by NBI. All
pts were treated with esomeprazole 40 mg QD; compliance confirmed by pill count. Features
seen only by NBI namely IPCL characteristics (increased number, dilatation, and tortuosity),
microerosions, increased vascularity at squamocolumnar junction (SCJ), columnar islands
and ridge/villous pattern below the SCJ were compared before and after PPI therapy. Kappa
(k) statistics were used to assess response to PPI therapy in the same patient with a value
of < 0.4 denoting a lack of agreement in the pre- and post-PPI NBI findings, representing
the highest likelihood of improvement. Wilcoxon sign rank test was used to compare the
maximum, minimum and average number of IPCLs/endoscopic field pre- and post-PPI
therapy. Results 21 GERD pts (90% males, 90% Caucasian, mean age 60 years) were evaluated
by NBI pre and post-PPI therapy. Mean duration of PPI therapy was 11.8 weeks (range: 8-
23 weeks). Pts responded to PPI therapy: reduction in the mean RDQ scores after PPI
therapy (13.3 vs. 2.9, p=0.0003). Complete healing of erosive esophagitis was achieved in
all but two patients. Features that improved with PPI therapy included: presence of increased
IPCLs (pre-PPI - 71% vs. post-PPI - 47%, k=0.02), tortuous IPCLs (90% vs. 9.5%, k=0.06),
dilated IPCLs (85% vs. 9.5%, k=0.05) and increased vascularity at the SCJ (42% vs. 9.5%,
k=0.24). All microerosions healed with PPI. Mean max (p=0.0013), min(p<0.0001) and
average (p<0.0001) number of IPCLs/endoscopic field also reduced significantly on PPI
therapy. Conclusions In GERD patients, features observed during NBI endoscopy not only
demonstrate reasonable sensitivity and specificity for diagnosing GERD but as shown in this
study, respond to PPI therapy as well. This suggests that these features are truly acid mediated
lesions. Large multicenter studies are needed to validate these findings, particularly in patients
with non-erosive reflux disease.
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Multichannel-Intraluminal-Impedance Guided Therapy for PPI-Resistant
Gastroesophageal Reflux
Monther Bajbouj, Valentin Becker, Roland M. Schmid, Alexander Meining
Background: Approximately 20% of GERD-patients do not respond completely to therapy
with protone pump inhibitors (PPI). The reason for this may be that treatment with PPIs
in standard dosage is not enough to decrease effectively gastroesophageal reflux. In alternative,
symptoms might reflect functional disorders where increasing the PPI dosage would be of
limited value. 24h-multichannel-intraluminal-impedance-measurement (MII) in combination
with pH-monitoring offers the possibility to objectively measure the quantity and quality
of gastroesophageal reflux. We therefore aimed to investigate whether this new device enables
a more tailored therapeutical approach to these patients. Methods: We enrolled 134 patients
(71 female, 63 male; mean-age 55 years), who reported persistent “reflux-associated” symp-
toms despite PPI-therapy in standard dosage of 40mg esomeprazole or 40mg pantoprazole
for at least 4 weeks. MII in combination with pH-monitoring was performed over a minimum
period of 22 hours. Stored data were analyzed with an integrated automatical software
(BioView, Sandhill Scientific, CO). If combined MII/ph-metry revealed pathological results
(pH<4 in more than 4% of the measured time and/or >73 non-/weakly-acidic reflux episodes)
PPI-dosage was doubled or surgery was recommended. Symptoms were assessed by using
a questionnaire before and at least 3 months after MII-recording. Results: Out of 134 patients,
53 (40%) had a pathological finding in combined MII/pH-metry despite ongoing PPI-therapy
(pathological MII: 25%, pathological pH-metry: 5%, both pathological: 10%). Among patients
with pathological findings in combined MII/pH-metry, four patients underwent surgery
whereas PPI dosage was doubled in the remaining 49 patients. Follow-up data were available
from 44/53 patients (83%). At follow-up, MII guided modification of treatment resulted in
a significant symptomatic improvement in 38/44 patients (86%). Conclusion: Multichannel
intraluminal impedance monitoring helps to objectively identify pathological gastroeso-
phageal reflux in symptomatic patients despite therapy with PPI in standard dosage. Thereby,
a more tailored approach for further treatment appears possible leading to a significant
improvement of symptoms in the majority of the patients.
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What Is the Optimal Duration of Oesophageal pH Measurement and Symptom
Assessment; A Prospective Study Using 96hr BRAVO™ Recordings
Mark R. Fox, Russell Canavan, Angela Anggiansah, Terry Wong
Introduction: The day-to-day variability of oesophageal acid exposure in patients with
suspected gastro-oesophageal reflux disease (GORD) is high with up to 1 in 3 patients
receiving a different diagnosis on repeated 24hr catheter based pH testing [Johnsson Gut88].
Early reports suggest that 48hr pH testing by the catheter-free Bravo™ system increase
measurement reliability; however these studies were retrospective and not designed to
determine the optimal duration of reflux investigation or diagnostic accuracy. Method:
Prospective study of 40 consecutive patients with typical reflux symptoms (18M:22F; 46
(21-70) years). Endoscopy followed by trans-oral delivery of the Bravo™ capsule 6cm above
the Z-line were performed. Patients returned after 48 and 96hr to download data. The day-
to-day variability of pH measurements was calculated. Patients were classified by acid
exposure (abnormal: >4.2% time pH<4) and symptom index (positive SI: >50% association
of reflux and symptoms) during each 24hr and 48hr test period. The reliability of 24hr vs.
48hr pH testing was assessed with 96hr results as the reference standard. Results: Four-day
recordings were available for 32/40 (80%) patients (n=4 detachment <96hr, n=4 consent
withdrawn due to symptoms off treatment). There was no difference in pH measurement
or SI over time (ANOVA p>0.1). Oesophageal acid exposure: Within patient variability was
higher for 24hr than 48hr test periods relative to the 96hr reference standard (p<0.01).
Pathological acid exposure was present in 18-19 patients on any test day and 13 patients
on every test day. Different diagnoses were reported in 11/32 (34%) and 3/32 (9%) patients
on repeated 24hr and 48hr pH testing respectively (p<0.01). Diagnostic reproducibility of
pH testing was improved by prolonged studies (kappa score, 24hr =0.32 (poor) vs. 48hr =
0.81 (very good)). Results were similar for alternative diagnostic classifications. Symptom
assessment: Different results were reported in 21/32 (76%) and 12/32 (37%) patients on
24hr and 48hr SI assessment (p=0.07). A positive 96hr SI was found in 2/15 (13%) and
13/17 (77%) patients in whom <2/4 days and 2/4 or more days had a significant association
between reflux events and symptoms respectively (p<0.01). Conclusion: Increasing the
duration of pH testing from 24hr to 48hr improves the reliability of pH testing and symptom
assessment (compared to a 96hr ‘reference standard'). Prolonging pH testing beyond 48hr
provides little improvement in diagnostic yield but may be justified in borderline cases and
to confirm the association between reflux events and symptoms in patients with inconsistent
results on the first two test days.
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96 Hours NO Better Than 24 Hours in Atypical GERD
Michael D. Gilles, Gregory D. Ayers, Michael F. Vaezi
Introduction: Studies suggest that long term esophageal pH monitoring may increase the
sensitivity for GERD diagnosis in patiens with typical symptoms. In atypical GERD, recent
data suggest the likelihood of abnormal 24-hour pH in symptomatic patients on therapy is
small (1-9%)(Charbel et al. Am J Gastroenterol 2005). Some have suggested the use of
prolonged pH monitoring in patients with atypical GERD. There are currently no studies
assessing the clinical yield and day to day variability of long term pH monitoring in this
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group of patients. Methods: Patients with atypical symptoms were studied off and on BID
PPI therapy for 96 hours using the wireless pH capsule (BRAVO). Atypical symptoms defined
as hoarseness, chest pain, chronic cough, asthma, shortness of breath, throat clearing, and
sore throat. Wireless pH capsule placed at 6-cm above the SQJ endoscopically. Mixed models
ANOVA on %time pH<4 assessed day-to-day variability and inter-group (off- vs on-therapy).
Day-to-day degree of variability based on two cutoff of normality (1.6% and 5.5%)was
measured by McNemar's Test. Results: 61 pts (mean age + SD = 47 + 14; 32 female) with
atypical symptoms unresponsive to therapy underwent 96 hour wirelss pH monitoring. 24
(40%) pts (mean age + SD = 50 + 15) were studied off and 37 (60%) pts (mean age + SD =
46 + 13) studied on therapy (p = 0.2). 83% pts off therapy and 97% pts on therapy had
pH < 5.5% on day 1. 78% pts on therapy had pH <1.6%. Higher degree of day to day
variability was present in pts off than those on therapy (p< 0.05) (Figure). However, within
the four days of the study there was no change in diagnostic yield for either groups (p=
0.2). Conclusions: Extended pH monitoring in atypical reflux not likely to significantly yield
a change in clinical diagnosis. Patients with atypical symptoms unresponsive to PPI's are likely
to have no increased esophageal acid exposure no matter what cut off of pH normality used.
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Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy?
Results from a Randomized, Double-Blind, Placebo-Controlled Trial (RCT)
Laura M. Iuga, Laura J. Orvidas, Ross A. Dierkhising, Alan R. Zinsmeister, Melissa M.
Westergren, Joseph A. Murray, Ramona Dejesus, Judith Mcelhiney, Yulia Khan, Andrew J.
Majka, Debra Geno, Kaiser G. Lim, Steven C. Adamson, Adil Abdalla, Mary Fredericksen,
Yvonne Romero, Group The pegg
Background: Gastroesophageal reflux disease (GERD) has been implicated as a cause of
laryngopharyngeal irritation leading to chronic upper airway symptoms. There is conflicting
evidence as to the response of these symptoms to potent acid suppression. Aims: To deter-
mine: 1) which chronic upper airway symptom(s) (dry cough, globus sensation, hoarseness,
nocturnal cough, sore throat, or throat clearing), if any, resolve with PPI therapy, and; 2)
which features of a patient's history predict a positive response to PPI therapy. Methods:
RCT of subjects recruited from the community, and primary and tertiary care clinics, with
at least 1 of 6 chronic (> 1 mo) and recurrent (> 2 /wk) symptoms identified by validated
symptom questionnaire. Persons using a PPI within 4 wks of starting the study were excluded.
Subjects were randomized in a 2.33:1 ratio to either bid esomeprazole 40 mg or placebo
for 6 months; completing monthly phone surveys. Primary outcome was “complete response”,
defined as complete resolution of a symptom present at baseline by the third month of
treatment, with continuing absence of that symptom throughout the rest of the study.
Results: 429 subjects were randomized to PPI (N=302, 46% males, mean age 56) or placebo
(N=127, 46% males, mean age 54). The overall frequency of non-exclusive symptoms
included: 214 dry cough, 148 globus sensation, 191 hoarseness, 109 nocturnal cough, 78
sore throat, 364 throat clearing, and 160 subjects with weekly GERD symptoms. Although
there was a difference in the proportion of subjects with throat clearing who experienced
complete resolution with PPI (7%) vs. placebo (<1%), [OR 9 (95%CI 1.1, 66), (p=0.04)],
the majority of subjects with throat clearing did not report either complete or partial
resolution. As expected, subjects with GERD symptoms improved with PPI [OR 15 (95%CI
3.3, 67), (p=0.003)]. There were no significant differences detected in complete response
(PPI vs placebo) for any other symptom. The presence of GERD increased the likelihood
of complete resolution of throat clearing [OR 4 (95%CI 1.3, 14)], and nocturnal cough [OR
4 (95%CI 1.4, 12)], regardless of treatment group assignment (PPI or placebo), suggesting
that so-called “silent refluxers” may be rare. Conclusions: A small subset of persons with
throat clearing improve with PPI therapy. Few people have complete resolution of dry cough,
globus sensation, hoarseness, or sore throat with twice daily PPI therapy, although those
with throat clearing and nocturnal cough may benefit, especially if they also have GERD
symptoms. This research was supported by a grant from the Investigator-Sponsored Study
Program of AstraZeneca.
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Evaluation of a Non-Invasive Pepsin Dipstick Test for the Diagnosis of Extra-
Oesophageal Reflux - Results of a Pilot Study
Vicki Strugala, Julian A. Mcglashan, Mark G. Watson, Alyn H. Morice, Giovanni
Calderone, Peter W. Dettmar
Background: Diagnosis of extra-oesophageal reflux (EOR) remains difficult. 24hr pHmetry
or impedance monitoring are invasive and insufficiently sensitive enough for use in EOR
and the laryngoscopic signs of EOR can be non-specific. An objective, non-invasive test for
the presence of EOR is warranted. Aim: Here we present data from a multi-centre pilot
study the primary outcome of which was to establish whether a non-invasive In Vitro test
was capable of diagnosing patients with EOR by detection of the presence of gastric enzyme
pepsin in sputum/saliva. The secondary outcome was to determine the appropriate time
frame in which to obtain samples from subjects either when attending clinic or when suffering
from symptoms. Methods: Ethical approval for this study was granted by MREC. Subjects
were recruited based on their score of the validated reflux symptom index (RSI). Controls
had RSI≤3 with no recent heartburn symptoms. Patients had RSI≥20 with visual evidence
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of reflux on laryngoscopy. Subjects gave written informed consent and were asked to provide
a sample of throat contents by coughing up and spitting into a collection vessel. Patients
were also asked to provide a sample at home when they were experiencing symptoms.
Samples were tested for the presence of pepsin using a lateral flow dipstick test incorporating
two unique monoclonal antibodies to human pepsin. Results: 20 subjects were recruited
into this pilot study. There were 10 control subjects (5M5F, mean (SD) age 36.9 (20.0)
yrs) with a mean RSI of 0.4. 9 out of 10 sputum samples obtained from control patients
were negative for pepsin. There were 10 patient subjects (7M3F, mean (SD) age 56.5 (19.7)
yrs (p=0.0402 compared to control)) with a mean RSI of 27. All provided a sample in clinic
of which 40% were positive for pepsin. 6 patients returned a second sample when sympto-
matic of which 67% were positive for pepsin. In total, at least one positive sample was seen
in 70% of patients compared to only 10% in controls (p=0.0062 Chi Squared test). Conclu-
sion: The results from this pilot study show that pepsin, as a marker for reflux, can be
detected in sputum/saliva obtained non-invasively from patients using a novel lateral flow
dipstick test. 90% of control patients were found not to have pepsin in their sample. 70%
of patients suspected of having EOR were found to have pepsin in their sample giving clear
objective evidence for the presence of reflux in the larynx, pharynx or upper airways.
Providing a sample when the patient was symptomatic was shown to improve the diagnostic
yield of the test compared to collection in clinic.
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Safety and Efficacy of Colonoscopy in the Elderly: Is the Juice Worth the
Squeeze? Experience in An Inner-City Community Hospital Serving African
American and Hispanic Patients
Abbasi J. Akhtar
Background & Aim: The elderly are among the most rapidly growing group of aging
population in the Unites States. The prevalence of gastrointestinal disorders including neo-
plasm is higher in the older adults. However, there is lack of enthusiasm and concern about
risk benefit ratio, amongst clinicians for colonoscopy in this population group in general,
and in our underserved minority population in particular. The aim of this study was to
evaluate the outcome of colonoscopy in our elderly patients in comparison to their younger
counterparts. Methods: Medical records of 1530 patients, who underwent colonoscopy over
a 9 year period, were reviewed retrospectively. Patients were stratified into over 65 years
of age (elderly group, n= 780, African American 435 and Hispanic 345) and under 65
years of age (control group, n=750, African American 413, Hispanic 337). The information
abstracted included: demographic details along with the indications for examination, colonos-
copic findings, complications, and completion rates and 30 day mortality. Results: The
median age was 77 years (range 66-101, 61% females) for the elderly group and 57 years
(range 18-65, 51% females) for controls. The elderly group required lower dose of medications
for conscious sedation (p<0.0001). The “crude” completion rate was lower for the elderly
group (79.5% v 89.7%), however “adjusted” completion rate was similar in both groups
(90.3% elderly v 90.9% control). There was no significant difference in outcome between
the two ethnic groups. On the whole diagnostic yield was higher in the elderly group (69%
v 49%, p<0.0001) with a significantly higher rate of cancer detection (7.9% v 1.8%,
p<0.0001). Of 62 elderly patients with colonic cancer, 38 (61%) had a curative resection.
There was no difference in complication rate between the two groups (0.35%). There were
two deaths within 30 days: one in the elderly group (post surgical sepsis), and one in the
control group (disseminated malignancy). Conclusions: Our study suggests that colonoscopy
in our elderly patients was safe and effective and resulted in a high diagnostic yield. Therefore
old age alone should not deter endoscopic evaluation when indicated.
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Attenuation of Regional Brain Activity Associated with Esophageal Acid
Exposure in Healthy Elderly
Mark K. Kern, Krisna Chai, Andrzej Jesmanowicz, Reza Shaker
It is believed that sensory deterioration contributes to the increase in prevalence and severity
of erosive esophagitis in elderly. Recent studies using fMRI in young individuals have
identified cortical regions responsive to esophageal acid perfusion. Our aim was to determine
and quantify the cortical response to esophageal acid exposure in the elderly and compare
the findings with the young. Methods: We studied 5 elderly (3 female, age range: 70-82
years) and 8 young (4 female, age range: 24-44 years), during two paradigm-driven, 21-
min. high spatial resolution fMRI scanning sequences. One scan alternated 2-minutes of
0.1N HCl perfusion with 5-minutes of saline perfusion and another scan alternated 5-
minutes of 0.1N HCl perfusion with 5-minutes of saline perfusion simulating short and
long duration acid reflux events. Perfusion of acid and saline was 1 ml/min. Results: Similar
to young healthy subjects described previously, a distributed network of cortical activity
including the anterior and posterior cingulate cortex (AC and PC, respectively), the insula
cortex (I), the prefrontal cortex (PF), the primary sensory/motor cortex (SM) as well as the
parieto-occipital (PO) cortex (Brodmann Area 7), was associated with esophageal acid perfu-
sion in the elderly subjects. (Table) With the exception of the PC, all tested cortical regions
showed significantly less activation for both perfusion durations in the elderly compared to
young. (Table) Maximum fMRI signal increase associated with esophageal acidification was
significantly affected by the duration of acid exposure in both elderly (2-min. acid perfusion:
3.5±0.3%, 5-min. acid perfusion: 6.5±0.6%) and young (2-min. acid perfusion: 3.9±0.5%,
5-min. acid perfusion: 7.7±1.3%). Conclusions: Esophageal acid sensitive neural afferent
function is deteriorated in the elderly. This deterioration can potentially result in a diminished
conscious response to acid exposure contributing to the observed increased prevalence and
severity of esophagitis in this age group.
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Oesophageal Motor Correlates of Dysphagia in Elderly Patients
Reme E. Mountifield, Helen Checklin, Robert Fraser, Jane M. Andrews, Richard Heddle,
Heather Ford, Geoff Hebbard
Background: Dysphagia is common in the elderly, however data on oesophageal motor
dysfunctions in these patients are limited. It is generally believed that peristaltic pressures
decline with age but recent data indicate that manometric diagnoses are similar in sympto-
matic old and young patients1. Aims: To determine the effects of advanced age on mechanical
correlates of dysphagia. Methods: Oesophageal manometry studies were reviewed from a
prospectively collected database containing 452 records between Dec 2003 and July 2005.
Recordings were analysed for all patients >80 years presenting with dysphagia and compared
with those from patients aged 18-45 yrs presenting with dysphagia. Manometry was per-
formed with a 16 channel perfused catheter with 8 sideholes (3cm intervals) along the
oesophageal body, and 8 sideholes (1cm intervals) spanning the lower oesophageal sphincter
(LOS). Ten wet swallows (5ml water) were performed in each of the left lateral and sitting
positions (20 total) and 5 solid swallows (bread) sitting. Data were analysed by two independ-
ent observers, blinded to patient age. Basal lower oesophageal sphincter pressure (LOSP)
and nadir pressures (at most complete LOS relaxation) were determined. Maximal intra-
swallow oesophageal body pressures were measured 6cm below the upper oesophageal
sphincter and 4cm above the LOS. A manometric diagnosis (normal, non-specific motor
disorder, low basal LOSP, ineffective peristalsis, achalasia and diffuse oesophageal spasm)
was determined for each study. Data are mean ± SEM. Comparisons by t-test. Results:
Tracings from 19 older (9M, 84.5±0.9 yr) and 20 young (10M, 33.2±2.1 yr) patients were
analysed. Basal LOSP were higher in older patients (see table). Nadir pressures for solids
but not water were also higher in older patients. Age did not significantly affect proximal
or distal oesophageal peristaltic pressures during either wet or solid swallows. Manometric
diagnoses were similar between the groups. Conclusions:Impairment of lower oesophageal
sphincter relaxation may contribute to dysphagia in older people. As oesophageal peristaltic
amplitudes were not reduced, the organization of oesophageal peristaltic sequences may
contribute to dysphagia in older people and requires further evaluation. 1 Andrews, J.M et
al. Audit of a Tertiary Hospital Clinical manometry Service: Age and Gender Affect Likely
Diagnosis. A305, ISDE 2006.
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Does Age Matter? Visceral Sensory Function As Assessed By a Standardized
Nutrient Challenge
Montri Gururatsakul, Tobias Liebregts, Birgit Adam, Guru Iyngkaran, Richard H.
Holloway, Dylan Bartholomeusz, Nicholas J. Talley, Gerald Holtmann
Background: Gastrointestinal disease is an important contributor to the overall morbidity
of the elderly. For example complicated ulcers (e.g. ulcers with life threatening bleeding)
appear to occur predominantly in elderly patients. A potential explanation could be age
related changes in sensory function that may explain why it is a common clinical observation
that patients with life threatening peptic ulcer bleeding are often asymptomatic until the
bleeding occurs. However, data on the effect of age on visceral sensory function are lacking.
Aim: To assess the role of age on visceral sensory function. Method: 33 healthy volunteers
were recruited (mean age 44.1, range 19 - 78, 19 female). After an 8 hr fast, they received
200 ml of a standardized enteral feeding solution (Ensure®) every 5 minutes up to a
cumulative volume of 800 ml. After each 200 ml drink, symptoms were assessed with the
Adelaide-Dyspepsia-Tool (ADT). This tool assesses 6 symptoms (fullness, abdominal pain,
retrosternal/abdominal burning, nausea, regurgitation, other) and determines peak and
cumulated symptom response. A cumulative symptom score across all symptoms was used
as the primary outcome variable. Data analysis: The association between the cumulative
symptom responses and the individual items with age was assessed by Spearman rank
correlations. The potential influence of height, weight and gender on symptom responses
was assessed by multiple stepwise regression analysis. Results: The mean cumulative symptom
response was 75.8+74. Fullness was the most important symptom reported (mean score
59.1+57 (SD)) followed by nausea (mean score 9.1+24) and pain (mean score 2.5+9). Thus,
these three items accounted for more than 90 % of the overall symptom load. The cumulative
pain and nausea scores were significantly and inversely correlated with age (r=-0.44, p=
0.01 and r=-0.42, p<0.02). The overall symptom response was significantly higher in females
compared to males (94 vs. 65, p<0.05), but the effect of age remained even after adjusting
for gender. Conclusions: The gastrointestinal symptom response to a standardized nutrient
challenge decreases with age. This age related change of sensory function may play an
important role for the GI morbidity and mortality in the elderly and provides a plausible
explanation for the high incidence of life threatening ulcer bleeding in the elderly that occurs
without preceding dyspeptic symptoms.
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Survival of Very Elderly Patients with Colorectal Cancer
Glen Doherty, Therese Cooney, Shane O'hanlon, Denise Keegan, Blathnaid Nolan, Anne
White, Kieran Sheahan, John M. Hyland, Diarmuid O'donoghue, Hugh Mulcahy
INTRODUCTION: The median age of onset of colorectal cancer (CRC) continues to increase
and operative treatments are increasingly being employed in the very elderly. Few data are
available on outcomes in this group. AIM: To determine initial and long term outcome in
CRC patients over 85 years. METHODS: The study included 2,237 CRC patients (≥85 years,
n=90; <85, n=2,147) admitted to a single institution. Clinical, operative and pathological data
were obtained from a prospectively maintained database and patients were followed up to
determine long term survival. RESULTS: There were more female patients (66% versus 47%,
p=0.001) and a greater proportion of right sided tumours (p=0.03) in the elderly group but
operative rates (91% elderly vs 94% younger, p=0.265) and resection rates (86% elderly vs
91% younger, p=0.09) were similar in both groups. No patient in the elderly group received
chemotherapy. Early (30 day) mortality was increased in the elderly (11% versus 4%, p=
0.004). Long term cancer related survival was also decreased in elderly patients (log rank,
p<0.0001). However, relative survival in the very elderly beyond the post-operative period
was more similar to the general population; overall 50% surviving at least 2 years. Multivariate
logistic regression demonstrated that tumour stage, chemotherapy and resection had highly
significant effects on survival (p<0.005) while age at diagnosis of 85 years or greater had
only a small independent influence on outcomes (p=0.05). CONCLUSION: Elderly patients
are more likely to die from CRC than their younger counterparts, but many have good
relative life expectancy following surgery. These results suggest that investigations to diagnose
CRC and aggressive operative therapies are justified in very elderly patients
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Novel Preliminary Findings of Mitochondrial DNA (mtDNA) Mutations in
Colonic Crypts of Patients with Diverticular Disease (the Boricc Study)
Ramesh P. Arasaradnam, Laura Greaves, Daniel Commane, Greetham Hazel, John
Mathers, Robert Taylor, Douglas Turnbull
Background: We have previously shown[1] that Mitochondrial DNA (mtDNA) mutations
may act as a putative biomarker for DNA damage. Oxidative damage which can occur as a
result of chronic inflammation, may cause mtDNA mutations which unlike nuclear DNA,
is not as well protected. MtDNA mutations have been shown to occur within colonic
crypt stem cells which clearly result in respiratory chain deficiency2. Aims & Method: To
characterise the presence of cytochrome c oxidase (COX) deficient crypts and the accumula-
tion of mtDNA mutations in colonic crypts of patients with Diverticular disease (DD).
Fresh frozen colorectal tissue from 35 patients; 25 age and sex-matched patients with
macroscopically normal colons as well as tissue from 10 patients with DD were analysed
histologically and histochemically. COX deficiency is the pathological hallmark of mtDNA
mutations. The percentage of COX deficient crypts were calculated from transverse sections
counted; only crypts that had more than 50% COX deficient cells were defined as COX
deficient. Results: Percentage COX deficient crypts were significantly higher in those with
DD (p=0.04). High sensitivity C Reactive Protein (hs CRP), was also higher in the DD group
but this did not reach statistical significance. (hs CRP was measured in 13 controls). (see
Table for details) Conclusions: This novel preliminary finding of higher COX deficiency within
colonic crypts in DD compared to controls suggests a further role of COX in characterising mt
DNA mutations. Further studies to correlate dietary intake with these mutations is underway.
This study is funded by the Food Standards Agency, UK (N12015) Reference: 1. Arasaradnam
RP, Greaves LC, Commane D et al. Mitochondrial DNA (mtDNA) mutations in human
colonic crypts: A novel biomarker of colon cancer risk? Gut 2006;55:11 A24
SD = Standard Deviation. Figures in brackets indicate 95% confidence intervals † indicates
statistical significance
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The Calcium-Sensing Receptor (CaSR) Mediates Meal Stimulated Gastrin
Secretion
Jianying Feng, Xinping Lu, Shari Anthony, Clark D. Petersen, Stephen A. Wank
BACKGROUND: The extracellular CaSR was first found to control calcium homeostasis by
regulating parathyroid hormone (PTH) secretion. Mice with homozygous deletion of the
CaSR succumb to hypercalcemia due to hyperparathyroidism. The CaSR has subsequently
been recognized as a multimodal sensor of multivalent cations, polyamines, L-amino acids
(a.a.) and pH in addition to Ca++ and Mg++. The CaSR is expressed in many tissues including
the gastrointestinal tract. The CaSR on human gastric antral G cells in short-term culture
mediates the release of gastrin in response to extracellular Ca++. While it has been long
recognized that peptone, L- aromatic A.a., and elevated pH stimulate the release of gastrin,
the mechanism for sensing these substances remains unknown. AIM: To determine whether
gastric CaSR is the physiologically relevant sensor for peptone, aromatic A.a. and pH stimu-
lated release of gastrin In Vivo. METHODS: CaSR and PTH gene deleted mice were provided
by Martin R. Pollak (JCI 111:1021-1028, 2003). Plasma gastrin response to peptone, phenyl-
alanine (Phe) and pH was assessed in littermates homozygous deleted (CaSR- /- /PTH- / -),
heterozygous (CaSR+ /- /PTH- / -) and wild type (WT) (CaSR+ /+/PTH- / -) for the CaSR
gene or WT C57/B6 mice. Brief anaesthesia with 5% isofluorane was used for retro-orbital
bleeds and gavage. Mice were fasted overnight and either fed ad libitum or gavaged with
either peptone (8%), Phe (100 mM), or Hepes (150 mM, pH 7.0) as a bolus equal to 1%
of body weight. Blood was sampled prior to and 30-45 minutes after gavage at the peak
gastrin response for each agent. Plasma gastrin was measured by RIA. Total plasma Ca++
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was determined using a SYNCHRON LX20. RESULTS: Total plasma Ca++ for CaSR - /- /
PTH- / -, CaSR+ /- /PTH- / - and CaSR+ /+/PTH- / - mice were 1.66±0.04, 1.83±0.18 mmol/
L, and 1.72±0.07 mmol/L, respectively. For ad libitum feeding and intragastric gavage of
peptone, L-Phe, Hepes pH 7.0, there was no significant gastrin response for CaSR- /- /PTH- /
-, while CaSR+ /- /PTH- / - and CaSR+ /+/PTH- / - mice responded with a 40-123% increase
in plasma gastrin over basal. The gastrin response for ad libitum and gavage feeding in the
heterozygous and WT littermates was similar to that observed for WT C57/B6 control mice.
High Ca++ dietary correction of plasma Ca++ in the CaSR- /- /PTH- / - mice did not
restore their gastrin response. CONCLUSION: Gastric CaSRs are necessary for intra-luminal
stimulation of gastrin release in response to rat chow, peptone, Phe and elevated pH. Whether
the sensing of these stimulants is directly mediated by CaSRs on gastric antral G cells awaits
further studies in isolated G cells.
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Extracellular Calcium-Sensing Receptor (CaSR) Mediates Wnt5a Secretion
from Colonic Myofibroblasts to Activate the Orphan Receptor Ror2 to Increase
Cdx2 and Sucrase-Isomaltase of Intestinal Epithelial Cells
Ivan Pacheco, R. john Macleod
Background: Little is known about the extracellular determinants of homeodomain transcrip-
tion factor CDX2 regulation. The Wnt family member Wnt5a may interact with Frizzled
2,4,7 or the orphan receptor Ror2 to signal in heterologous systems. Because stromal Wnt5a
transcripts are present in the small intestine, the current experiments determined whether
Wnt5a secretion was mediated by the CaSR on colonic myofibroblasts and determined if
this Wnt5a influenced expression of CDX2 and sucrase-isomaltase on model epithelial cells.
Methods: 18Co colonic myofibroblasts were challenged with low or high (0.5 vs 3 mM
Ca2+) for 18h and lysates and conditioned medium screened by Western blot. Interferring
RNA against the CaSR (siRNA duplex) was transfected into early passage cells. HT-29 and
Caco-2 cells were transiently transfected with Wnt5a (or Wnt3a) and 48h later CDX2 protein
and transcripts were assessed by Western blot and RT-PCR, respectively. Sucrase-isomaltase
(SI) expression was measured by luciferase reporter in cells transfected with wild type Ror2,
dominant negative Ror2 (Ror-GPI), with or without Wnt5a, and 48h later luciferase measured.
Results: Wnt5a secretion into medium was stimulated by CaSR activation. Levels of glycosyl-
ated Wnt5a were reduced to constitutive amounts of secretion by siRNA (20 nM) against
the CaSR. Other G-protein agonists, ADP or endothelin, did not stimulate Wnt5a secretion
from the myofibroblasts. Transient transfection of HT-29 adenocarcinoma cells with Wnt5a
but not Wnt3a increased CDX2 transcripts and protein. Comparable treatment of Caco-2
cells revealed substantial increases in CDX2 protein. The half-life of CDX2 protein was
increased in proliferative cells (12h vs 0.5h) after CaSR activation or transfection with Wnt5a.
SI-reporter activity was increased dose-responsively by Wnt5a but not Wnt3a or Wnt1 in
both cell types. Overexpression of wild type Ror2 increased Wnt5a stimulation of SI-reporter
(p<0.05). Dominant negative Ror2-GPI reduced Wnt5a stimulation of SI reporter. Increasing
Ror2 expression increased Wnt5a stimulation of CDX2 transcript which was blocked by
dominant negative Ror2. CaSR activation of both epithelial cell types increased Ror2 tran-
scripts. Conclusion: We conclude that the CaSR will stimulate Wnt5a secretion from colonic
myofibroblasts. Wnt5a interacts with endogenous Ror2 on epithelial cells to stimulate syn-
thesis of CDX2 and sucrase-isomaltase. Both CaSR and Wnt5a increase CDX2 protein half-
life. Our results suggest that CaSR/Wnt5a/Ror2 is a dynamic axis contributing to CDX2
homeostasis in the intestine.
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Return of Functional Parietal Cells in Patients with MéNéTrier's Disease
Treated with Cetuximab
Kevin Finnegan, Ki-taek Nam, James R. Goldenring, Robert J. Coffey
Background: Ménétrier's disease is a rare, acquired disorder of the stomach of uncertain
etiology characterized by giant, hypertrophic gastric folds in the body and fundus with
relative sparing of the antrum, decreased acid production, excess mucus secretion and
hypoalbuminemia. Histological findings include foveolar hyperplasia and glandular atrophy
with reduced numbers of parietal and chief cells. Increased signaling through the epidermal
growth factor receptor (EGFR) plays a critical role in the pathogenesis of Ménétrier's disease.
Case reports have demonstrated that the use of Cetuximab, a monoclonal antibody to the
EGFR, resulted in clinical and biochemical improvement in three patients with this disease.
However, a return of functional parietal cells has not been demonstrated in any of these
treated patients. Methods: Our two patients were admitted to our institution's clinical
research center for monitored therapy. Pretreatment testing included EGD with gastric pH
determination and biopsy of the gastric fundus and antrum as well as a contrasted CT scan
of the abdomen and pelvis. Parietal cell mass was determined by quantitative image analysis
of pre and post-treatment fundic biopsies immunostained for H+/K+-ATPase. Intravenous
infusion of Cetuximab was initiated at a loading dose of 490mg/m2 body surface area,
followed by three weekly treatments of 250mg/m2 BSA. Repeat EGD with biopsies and pH
determination was done the day after the initial loading dose and after the fourth treatment.
A repeat contrasted CT scan was also done after the fourth treatment. Results: Prior to
treatment, both patients had a thickened stomach wall by CT scan and, on endoscopy,
enlarged gastric folds with a gastric pH of 6. Pre-treatment fundic biopsies showed marked
foveolar hyperplasia with increased mucin staining and a marked reduction in parietal cell
mass at 23%. After 4 weeks of treatment with Cetuximab, one patient had a normal stomach
wall thickness by CT scan and normal appearing gastric folds on EGD with a gastric pH of
1-2. The second patient had improvement, but not normalization, in both stomach wall
thickness and size of the gastric folds. However, the post-treatment gastric pH was normal
at 1. Fundic biopsies in both patients after one month of treatment showed a near normal
appearing foveolar region as well as a significant increase in parietal cell mass at 65%.
Conclusion: We report here that two patients with Ménétrier's disease treated with Cetuximab
not only improved the biochemical and clinical features of the disease but also resulted in
the return of functional parietal cells.
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Evidence for C-Jun Protein Stabilization Induced By Direct Protein Kinase D-
Mediated Phosphorylation
Richard T. Waldron, Osvaldo Rey, Romeo Papazyan, Enrique Rozengurt
Background: Previous reports have indicated that protein kinase D (PKD) regulates Jun N-
terminal kinase (JNK) signaling to the transcription factor c-jun, but no mechanism has
been defined. Since c-jun is a central component of AP-1 transcription factor complexes, is
required for Ras-mediated cellular transformation in tumorigenicity assays, and has recently
been implicated in colorectal carcinoma, potentially novel forms of c-jun regulation warrant
investigation. We recently demonstrated that PKD, activated in intact cells by phorbol-12,
13 dibutyrate (PDB) or by GI hormones, directly phosphorylates c-jun at N-terminal sites
distinct from those modifed by JNK. We used isolated active PKD or JNK to phosphorylate
GST-jun(1-89) fusion protein, then generated tryptic phosphopeptides and analyzed them
by mass spectrometry (LC-MS/MS) to identify phosphorylation sites. Whereas JNK-phos-
phorylated GST-jun(1-89) produced peptides consistent with previously known sites Ser63
and Ser73, a PKD-phosphorylated peptide contained phospho-Ser58, a novel site in the c-
jun delta domain, a region with important implications for protein stability. Studies reported
here further substantiate our previous data and provide new evidence advancing the concept
that PKD-mediated phosphorylation modulates c-jun. Methods: We have undertaken assays
in transfected HEK293 cells to assess protein expression and Ser63 phosphorylation of wild-
type full-length c-jun and forms mutated at Ser58 to either block or mimic PKD-mediated
phosphorylation at this site. Protein expression of these c-jun forms was investigated by
Western blot analysis. We also assessed the transcriptional activation by these c-jun forms
using TRE-luciferase gene reporter induction in these cells. Results: Expression of transfected
c-jun-myc in HEK293 cells was detected by Western blot versus c-myc. Concomitantly, the
expressed c-jun-myc exhibited a constitutive level of Ser63 phosphorylation, as well as
significant induction of TRE-luciferase reporter gene expression. Interestingly, compared
with wild-type c-jun-myc, the levels of protein expression of both Ser58A and Ser58E were
elevated, consistent with a possible effect of direct phosphorylation by PKD within the delta
domain to modulate protein stability in these mutants. These data were substantiated by
the higher levels of specific TRE-luciferase induction by the mutants. Despite this, relative
levels of Ser63 phosphorylation were much less increased than the protein levels and the
luciferase gene induction. Taken together, these data suggest that PKD phosphorylation
modulates c-jun activities in part by stabilizing the protein against a degradative pathway.
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The Role of Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate
(Hrs) in the Post-Endocytic Trafficking of Protease-Activated Receptor 2
(PAR2)
Burcu Hasdemir, Graeme S. Cottrell, Nigel W. Bunnett
Activated PAR2 undergoes multi-monoubiquitination by the E3 ligase c-Cbl, which is required
for post-endocytic sorting of PAR2 to lysosomes, where degradation permanently arrests
signaling. The mechanisms of post-endocytic sorting of ubiquitinated receptors are incom-
pletely understood. The aim of this study was to investigate the role of the ubiquitin binding
protein Hrs, as part of the endosomal sorting machinery, in post-endocytic sorting of PAR2.
Living HEK-PAR2 cells were labeled with an antibody to an extracellular epitope of the
receptor, and were then challenged with PAR2 activating peptide (AP) (100 µM, 0-180 min).
Trafficking of antibody-labeled PAR2 from the cell-surface was studied by immunofluoresc-
ence and confocal microscopy. After 10-30 min, PAR2 was detected in endosomes, identified
by staining for early endosomal antigen 1 (EEA1), that also contained endogenous Hrs. After
120 min, PAR2 was detected in lysosomes, identified using an antibody to lysosome-associated
glycomembrane protein 1. Over-expression of Hrs, which disrupts function similar to Hrs
knockdown, resulted in formation of enlarged vesicles containing EEA1. Activated PAR2
and c-Cbl accumulated in these enlarged Hrs-positive vesicles, and PAR2 failed to traffic
to lysosomes. In HEK-PAR2 cells expressing Hrs vector without insert and treated with
cycloheximide (prevents new receptor synthesis), PAR2-AP induced almost complete degrada-
tion of PAR2 within 3 h, assessed by Western blotting. Over-expression of Hrs almost
abolished PAR2 degradation at 180 min (87.7±6.8% inhibition). Over-expression of an Hrs
mutant with a deleted ubiquitin interacting motif (HrsΔUIM) had the same effects on PAR2
trafficking as wild-type Hrs, suggesting that the interaction between PAR2 and Hrs is not
dependent on ubiquitination of the receptor. To investigate further the importance of receptor
ubiquitination, we expressed an ubiquitination-deficient PAR2 mutant (PAR2Δ14K/R). PAR2-
AP induced endocytosis of PAR2Δ14K/R, which recycled to the plasma membrane and
escaped trafficking to lysosomes. Over-expression of Hrs caused retention of PAR2Δ14K/R
in enlarged Hrs-containing vesicles, and prevented recycling. Thus, Hrs plays a critically
important role in the post-endocytic sorting of a single receptor, PAR2, to both degradative
and recycling pathways. This sorting role for Hrs is independent of its ubiquitin-interacting
motif and it can regulate trafficking of both ubiquitinated and non-ubiquitinated PAR2. The
sorting decision to degradative or recycling pathways appears to occur down-stream from
Hrs. Supported by NIH DK43207 and DK57840.
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PKD and Pkd2 Mediate Neurotensin-Induced Hsp27 Serine-82
Phosphorylation in PANC-1 Cells
Jingzhen Yuan, Enrique Rozengurt
BACKGROUND: Heat shock protein 27 (HSP27) belongs to the family of stress proteins.
Acting as a molecular chaperone, HSP27 exhibits various functions and has been implicated
in many physiological and pathological processes such as in gastric mucosal injury recovery,
motor neurone and nerve regeneration, tumor progress and resistance to chemotherapy.
The function of HSP27 is phosphorylation-dependent. Extensive studies have established
that stress-, heat shock, and UV radiation-induced HSP27 activation is mediated by the p38
MAPK cascade that results in HSP27 phosphorylation at serine 15, 78, and 82. A very recent
study identified HSP27 as a novel substrate for PKD and demonstrated that PKD stimulated
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HSP27 activation by phosphorylating its Ser-82 in cells stimulated with oxidative stress
(H2O2). However, it is unknown whether the phosphorylation of HSP27 can be induced
by neuropeptide GPCR signaling through a PKC/PKD-dependent pathway. Here, we elucid-
ated the signal pathways mediating neurotensin (NT)-stimulated HSP27 Ser-82 phosphoryl-
ation and the role of PKD family members in regulating HSP27 phosphorylation using
pancreatic cancer Panc-1 cells as a model system. RESULTS: NT induced a rapid HSP27
Ser-82 phosphorylation in a dose-dependent manner in Panc-1 cells, which was closely
correlated with NT-stimulated PKD activation loop phosphorylation and p38 MAPK Thr180/
Tyr182 phosphorylation. Treatment of Panc-1 cells with either the selective PKC inhibitor
GF-I or the p38 MAPK inhibitor SB202190 only partially (~50%) reduced NT-induced HSP27
Ser-82 phosphorylation. However, NT-induced HSP27 phosphorylation was abrogated by
treatment of the cells with a combination of both GF-I and SB 202190. Overexpression of
PKD in stably transfected Panc-1 cells increased the intensity and prolonged the duration
of NT-induced HSP27 Ser-82 phosphorylation. The enhanced HSP27 Ser-82 phosphorylation
was closely correlated to the increased expression of PKD protein. Either PKD or PKD2
gene silencing utilizing siRNAs targeting distinct PKD or PKD2 sequences reduced NT-
stimulated HSP27 Ser-82 phosphorylation, but cotransfection of siRNAs targeting both, PKD
and PKD2, virtually abrogated HSP27 Ser-82 phosphorylation in Panc-1 cells pretreated
with SB202190. CONCLUSION: Our results indicate that NT induces HSP27 Ser-82 phos-
phorylation through p38 MAPK- and PKD-dependent pathways in Panc-1 cells. These
findings demonstrate, for the first time, that the members of the PKD family, PKD and
PKD2, contribute to GPCR signaling-mediated HSP27 Ser-82 phosphorylation and thus,
demonstrate that HSP27 is a physiological downstream substrate of PKD and PKD2 in this
signaling pathway.
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Influence of Infliximab On Abdominal Fat Tissue and Metabolic Syndrome in
Crohn's Disease
Erika Parmentier-decrucq, Alain Duhamel, Laurent Peyrin-biroulet, Catherine Fermon,
Alexandre Louvet, Gwenola Vernier-massouille, Jean-frederic Colombel, Pierre
Desreumaux
Introduction: TNF-α is an adipocytokine playing a key role in the pathogenesis of chronic
inflammatory and metabolic disorders, such as Crohn's disease (CD), obesity and diabetes
mellitus. Since this cytokine has a well-established lipolytic effect, we hypothesized that
administration of an anti-TNF agent such as infliximab may result in visceral fat accumulation,
which is commonly associated to an increased risk for developing a metabolic syndrome.
Methods: 132 CD patients were investigated. In a first study, MRI quantification (cm3) of
total, intra-abdominal and subcutaneous abdominal fat tissue was performed systematically
before and 2 weeks after a first induction treatment of 3 perfusions of infliximab (0, 2, and
6 weeks) in 21 responding CD patients (13F, 8H, age 33 years) with perianal fistulas. In a
second prospective study, fasting glucose, HbA1c, HDL, LDL, total cholesterol and triglycer-
ide levels were assessed in 111 responding CD patients (46H, 65F, age 31 years) at baseline
and after maintenance treatment with infliximab until a maximal period of 26 months.
Patients with obesity, diabetes and metabolic syndrome were excluded. Results: First, a
significant homogeneous 18% increase of total abdominal fat tissue was observed in the 21
CD patients after three perfusions of infliximab (212±95 vs. 251±101, p=0.027). No correla-
tion was found between the variation of the body mass index and the enhancement of
abdominal fat tissue. Second, repeated administrations of infliximab in the 111 CD patients
were associated with a significant decrease of glycaemia (p<0.0001) and HbA1c concentra-
tions (p<0.0001), particularly in patients with high baseline values. Total, HDL, LDL choles-
terol and triglyceride values were not significantly modified and remain in the normal range
during the study. Conclusion: Infliximab treatment in patients with CD is associated with
a significant enhancement of abdominal fat tissue. Conversely, this morphological change
was accompanied by a decrease in glycaemia and HbA1c concentrations. Infliximab treatment
may reverse the impairment of insulin-mediated glucose uptake induced by TNF-α.
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Soluble Proteins Produced By Lactobacillus Rhamnosus Gg (LGG) Activate EGF
Receptor to Regulate the Anti-Apoptotic Response in Intestinal Epithelial
Cells
Fang Yan, Charlie Vanderpool, Hanwei Cao, D. brent Polk
Background. LGG has been used for treating and/or preventing several disorders, including
inflammatory bowel diseases. Our studies show that LGG and factors recovered from LGG
culture broth supernatant prevent cytokine-induced apoptosis in intestinal epithelial cells
trough activation of anti-apoptotic PI3-kinase dependent Akt. We have purified and cloned
two LGG soluble proteins (p75 and p40) that activate Akt and regulate intestinal epithelial
cell anti-apoptotic and proliferation responses. Because activation of EGF receptor (EGFR)
stimulates Akt activation and plays an anti-apoptotic role, these studies were designed to
test the hypothesis that p40 and/or p75 activate Akt and regulate the anti-apoptotic function
through EGFR-dependent mechanism. Methods. Human (T84 and HT29) and wild-type
(wt) and EGFR null young adult mouse colon (YAMC) epithelial cells were treated with
p75 and p40 in the presence or absence of EGFR kinase inhibitors (AG1478 or PD153035)
or metalloproteinase inhibitors (TAPI or GM6001) for 2 hours. Colon explants isolated from
6-8-week old C57BL/6 (wt) or Wav5 mice (C57BL/6Wav5), with kinase defective EGFR, were
cultured on the inserts in DMEM medium containing 0.5 % FBS and treated with p75 or
p40 for 2 or 6 hours in the presence or absence of tumor necrosis factor (TNF). Cellular and
total mucosal tissue lysates were collected to detect EGFR and Akt activation by immunoblot.
Paraffin-embedded sections were prepared to determine apoptosis by in situ oligo ligation
(ISOL) and active caspase-3 staining. Results. p75 and p40 stimulated EGFR phosphorylation
in YAMC, T84 and HT-29 cells, and EGFR kinase inhibitors blocked Akt activation by p75
and p40. p75 and p40 failed to activate Akt in EGFR-/- YAMC cells. Transfection of wt
EGFR, but not kinase inactive EGFR, restored LGG, p40 and p75 activation of PI3-kinase/
Akt. Co-culture of C57BL/6 colon tissue explants with p75 or p40 stimulated EGFR phos-
phorylation and Akt activation, which was not stimulated in C57BL/6Wav5 colon explants.
TNF induced colon epithelial apoptosis was decreased 3-fold by p75 or p40 co-treatment in
C57BL/6, but not in C57BL/6Wav5, colon explants. Furthermore, metalloproteinase inhibitors
decreased p75 and p40 activation of both EGFR and Akt. Conclusion. These studies
demonstrate: 1. EGFR kinase activity is required for p75 and p40 regulated intestinal
epithelial cell anti-apoptotic response; 2. p75 and p40 activation of EGFR may be through
metalloproteinase-dependent up-regulation of EGFR ligand production. These two novel
findings further elucidate the mechanism of soluble bacterial proteins regulating epithelial
cell homeostasis.
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Concomitant Immunosuppression Does Not Impact On the Outcome of
Maintenance Infliximab Therapy in Crohn's Disease: Final Results of the Imid
Trial
Gert Van assche, Gilles Paintaud, Charlotte Magdelaine, Geert D'haens, Filip Baert,
Severine Vermeire, Maja Noman, David Ternant, Hervé Watier, Paul Rutgeerts
Background. The benefit to risk ratio of concomitant immunosuppressives (IS) in addition
to infliximab (IFX) maintenance therapy for Crohn's disease (CD) is unclear and the efficacy
of IFX monotherapy beyond one year has not been explored. Aim. To study the benefit of
immunosuppression during maintenance therapy with IFX in a randomized controlled trial.
Methods. 80 CD patients in clinical remission were randomized to continue (CON, n=40)
or to interrupt (DIS, n=40) IS (AZA/6-MP/MTX) ≥6 months after the start of their combina-
tion with infliximab (5 mg/kg IV). Clinical efficacy, infliximab trough levels before a new
infusion and adverse events were assessed q8 wks for 104 wks. Primary endpoint was the
proportion in each arm who required a decrease in IFX dosing interval or stopped IFX
therapy. An end-of-study ileo-colonoscopy with SES-CD scoring was scheduled in patients
with ongoing IFX treatment. Results. 24/40 (CON) and 22/40 (DIS) patients needed a change
in IFX dosing interval within 104 weeks and 11/40 (CON) and 9/40 (DIS) stopped IFX,
mainly for loss of response (12/20) and intolerance (5/20). In the 41 patients undergoing
a 2-year ileo-colonoscopy, mucosal healing with absence of ulcers was observed in 61%
(CON) and 67% (DIS, p=0.7) of patients, respectively. Median endoscopic (SES-CD) score
was 1 (range 0-20) in both groups. 5/41 patients had a de novo (ileo)colonic stenosis. In
contrast to clinical and endoscopic responses, patients in the DIS group had lower overall
median serum IFX levels (Fig.). Initial IFX trough levels < 1 µg/mL were associated with
change in IFX dosing: OR:3.7 (95%CI: 1.3-10.6). Antibodies to infliximab (ATI) were rare
(CON: 2/40 and DIS 5/40) and most patients (74%) with IFX levels < 1 µg/mL were ATI
negative. Conclusion. Long-term continuation of immunosuppressives offers no clinical
benefit over IFX monotherapy, but is associated with higher IFX trough levels.
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Crucial Role of the Protein C Pathway in Governing Microvascular
Inflammation in Inflammatory Bowel Disease
Franco Scaldaferri, Miquel Sans, Cristina Graziani, Raimondo De cristofaro, Stefania
Vetrano, Bruce Gerlitz, Alessandro Repici, Antonio Gasbarrini, Alberto Malesci, Julian
Panes, Brian W. Grinnell, Silvio Danese
Endothelial protein C receptor (EPCR) and thrombomodulin (TM) are expressed at high
levels selectively in the microvasculature, and convert protein C (PC) to its activated form,
which is a potent anti-inflammatory molecule. In several chronic inflammatory conditions,
the protein C pathway is down regulated, leading to an impaired generation of activated
PC. The aim of this study was to explore the protein C pathway in inflammatory bowel
disease (IBD), and to assess the therapeutic implication of manipulating this system in
experimental colitis. The levels of TM and EPCR expression was evaluated by immunohisto-
chemistry in colonic sections from controls, Crohn's disease (CD) and ulcerative (UC)
subjects, and by flow cytometry in human intestinal microvasculature endothelial cells
(HIMEC), at baseline and after treatment with TNF-α, TGF-β and IL-10. The capacity to
generate activated PC by HIMEC was measured by colorimetric assay at baseline and after
treatment with TNF-α. The anti-inflammatory effect of recombinant activated PC was studied
on TNF-α stimulated HIMEC, and expression of VCAM-1 and ICAM-1 assessed by flow
cytometry, and ENA-78, MCP-1 and IL-8 measured by ELISA. Adhesion assays were used
to evaluate the capacity of activated PC to inhibit T-cell adhesion to HIMEC. In Vivo, the
anti-inflammatory effect of activated PC was tested in the dextran sodium sulphate (DSS)
model of colitis in mice and by intravital microscopy. Both CD and UC patients expressed
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lower levels of TM and EPCR in intestinal microvasculature than controls. In cell culture,
inflammatory cytokines down regulated HIMEC expression of EPCR and TM, leading to a
significant (p<0.05) impaired capacity to activate PC. Recombinant activated PC had a potent
anti-inflammatory effect, being able to down-regulate TNF-α-dependent VCAM-1 and ICAM-
1 expression (p<0.05), as well as chemokine production (p<0.05), and to inhibit T-cell
adhesion to HIMEC (p<0.05). Finally, administration of activated PC was very effective in
preventing experimental colitis as assessed by weight loss (p<0.05), disease activity index
(p<0.05), histological colitis (p<0.05) and inhibited leukocyte adhesion to the inflamed
intestinal vessels (p<0.05). The protein C pathway is strongly down regulated in the inflamed
intestine in IBD and represents a new system involved in microvascular inflammation in
the gut. Restoring the PC pathway may represent a new therapeutic approach to down play
intestinal inflammation by inhibiting endothelial cell adhesion molecule expression and
chemokine production in intestinal microvasculature, thus avoiding leukocyte recruitment
into the inflamed gut.
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TLR5-Deficient Mice Fail to Control Their Commensal Microflora and Develop
Spontaneous Colitis
Matam Vijay-kumar, Catherine Sanders, Shizuo Akira, Andrew S. Neish, Shanthi V.
Sitaraman, Ifor R. Williams, Andrew Gewirtz
BACKGROUND: Malfunctions in innate immunity (dysregulation and/or deficiency) may
play an important role in inflammatory bowel disease (IBD). Bacterial flagellin is thought
to be a dominant activator of innate immune signaling in epithelial cells and thus may be
a major activator of innate immunity in the gut. Consequently, we hypothesized that the
flagellin receptor, toll-like receptor 5 (TLR5), might play a role in driving immune responses
that underlie IBD. GOAL: To investigate the role of TLR5 by studying the phenotype of
mice engineered to lack this receptor. METHODS: Gene-targeting in ES cells was used to
make chimeric TLR5KO-deficient mice on an SL/J background, which were then backcrossed
to C57BL/6 mice for 6 generations to generate both TLR5KO mice and wild type (WT)
littermates (all experiments then compared the TLR5KO mice directly to their WT littermates).
The observation of spontaneous rectal prolapse (a suggestive indicator of colitis) in TLR5KO
mice but not in WT littermates, prompted us to analyze whether TLR5KO mice had spontan-
eous colitis and begin to decipher the potential underlying mechanisms. Specifically, we
measured body weight, fecal form/output, occult blood, hematologic parameters, organ
weights, cecum/colon morphology/histopathology, myeloperoxidase levels, serum acute
phase proteins (Serum amyloid A (SAA) and lipocalin-2), peripheral organ bacterial counts,
and cytokine secretion by colon organ culture. RESULTS: Spontaneous rectal prolapse was
exhibited by 11% (17/155) of TLR5KO mice and 0% (0/200) WT littermates. Complete
examination revealed that 41% of TLR5KO mice and 0% of WT littermates exhibited
spontaneous colitis as assessed by well-defined clinical, serologic, and histopathologic indic-
ators of this disorder (by 12-weeks age, p<0.0001). Compared to WT littermates, TLR5KO
mice that did not display evidence of colitis exhibited decreased intestinal expression of
TLR5-regulated host defense genes despite having an increased bacterial burden in the
colon and translocation of Staphylococci to the spleen/liver. CONCLUSIONS: Loss of TLR5
eventuates in the development of spontaneous colitis. Such colitis is likely due to their
innate immune deficiency rendering them unable to manage their commensal microflora
thus resulting in inflammation driven by other TLRs. That an engineered innate immune
deficiency ultimately results in spontaneous intestinal inflammation supports the notion that
an innate immune deficiency might underlie some cases of IBD.
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Efficacy and Safety of Sargramostim in Moderate to Severe Crohn's Disease:
Results of N.O.V.E.L. 4, a Phase III Multicenter Study
Brian G. Feagan, Frank Anderson, Graham L. Radford-smith, Oleg Solovyov, Sabine
Zurdel-dillinger
Background: Early clinical trials have shown that sargramostim, an activator of innate
immunity, may be effective in Crohn's Disease (CD). We report the results of a Phase III
trial that evaluated the efficacy and safety of sargramostim in patients with moderately to
severely active CD. Methods: This international (Argentina, Australia, Brazil, Canada, New
Zealand, Russia, Switzerland, Ukraine, United Kingdom), double-blind, placebo-controlled
trial randomly assigned 286 patients with active CD in a 2:1 ratio to receive sargramostim
6 μg/kg/day (n=193) or placebo (n=93) via subcutaneous injection for 56 days. Patients
were stratified by country and history of prior second-line therapy for CD. Moderate to
severe disease activity was defined as a Crohn's Disease Activity Index (CDAI) score of ≥
220 points and ≤ 475 points, and was confirmed by endoscopic or radiologic evaluation.
Patients had stable medical management of disease with 5-ASA compounds or antibiotics
for ≥ 4 weeks prior to receiving study drug. Other medical therapies for CD were not
allowed.The primary endpoint of clinical remission (CDAI score ≤150 points) and/or
response (≥ 100-point decrease from the baseline CDAI score) and safety were assessed at
Day 56 (End of Treatment - EOT), and 30 days after EOT. Results: The patient groups had
similar baseline demographics except that the placebo group had a higher mean age (43 vs.
36 yrs, P=0.048) and slightly lower mean CDAI score (291 vs. 303, P=0.032) than the
sargramostim group. No statistically significant clinical efficacy was seen for sargramostim
in comparison to placebo at EOT (remission-22.3% vs. 22.6%, response-41.1% vs. 33.3%).
However, considerable heterogeneity in the rate of placebo response was observed between
countries. A secondary composite remission/response analysis showed sargramostim to be
numerically better than placebo at EOT or at 30-day follow-up (48.2% vs. 36.6%, P=0.08)
and at anytime during the study (62.2% vs. 49.5%, P=0.06). The safety profile of sargramostim
was consistent with previous experience. Conclusions: Although the efficacy of sargramostim
to induce clinical response and clinical remission has been successfully demonstrated in
other clinical trials, this phase III trial failed to document clinical superiority over placebo.
The high placebo rate we observed may have been due to differences between countries in
patient populations and practice patterns that influenced the placebo response. In this short-
term experience, sargramostim treatment appeared safe. Overall efficacy awaits further con-
firmation.
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Albumin Versus Synthetic Colloid for Large Volume Paracentesis: A Meta-
Analysis of RCTs
Mohamed O. Othman, Archana Kaza, Ajitinder Grewal, Ayman Alzubi, Praveen K. Roy
PURPOSE: Albumin infusion for large volume paracentesis in cirrhotic patients has proven
to decrease the hypovolemia related complications. However, its use is limited by high cost
and a theoretical risk of transmission of infection. Several randomized controlled trials
(RCTs) have evaluated synthetic colloids as an alternative to albumin with conflicting results.
We conducted a Meta analysis to compare the efficacy of both interventions for large volume
paracentesis. METHODS: MEDLINE (from 1966-2006) and abstracts of gastroenterology
scientific meetings in the last 5 years were searched (search date October 2006). Only RCTs
enrolling adult subjects and comparing albumin versus synthetic colloids were included.
Studies were assigned a quality score. Two independent reviewers used standard forms to
extract data on study design, outcome measures, and adverse events. Fixed effects model
was used to compare morbidity, mortality and the cost of both interventions. Separate
analyses were performed for each main outcome by using Odds Ratios (OR). Heterogeneity
was assessed by calculating the I2 measure of inconsistency. RESULTS: 8 trials satisfied the
inclusion criteria (712 patients; 499 males, 213 females, mean age: 54-59). Albumin was
compared to Dextran 70 in 4 trials, Polygeline in 3 trials, Dextran 40 in 1 trial and to
Hydroxyethyl Starch in 1 trial. No significant heterogenity was present. Circulatory dysfunc-
tion or increase of Plasma Renin Activity was lower with the albumin infusion (OR 0.36;
95 % CI, 0.23-0.58). There was no statically significant difference between the two groups
regarding the risk of renal impairment (OR 1.03; 95 % CI, 0.57-1.84], hyponatremia (OR
0.64; 95 % CI, 0.41-1), encephalopathy (OR 0.84; 95 % CI, 0.46-1.53) or gastrointestinal
bleeding (OR 0.85; 95 % CI, 0.39-1.84). Mortality during hospitalization (OR 0.67; 95 %
CI, 0.29-1.56) and hospital readmission rates were similar in both groups (OR 1.14; 95 %
CI, 0.69-1.87). Synthetic colloids were cheaper than albumin in 4 studies. CONCLUSIONS:
Although albumin was associated with lower risk of circulatory dysfunction, the rate of
complications was similar in both groups. Synthetic colloids are a safe and cheap alternative
to albumin for large volume paracentesis.
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Turning a Gallbladder Into a Liver
Sum P. Lee, Christopher E. Savard, Rahul P. Kuver
Although transplanted hepatocytes have been used to repair damaged liver, obtaining suffi-
cient quantities of hepatocytes has proven difficult. A new source of donor cells to repopulate
a liver would be useful. The gallbladder shares developmental origins with the liver and
thus could serve as a source for donor cells. We have undertaken experiments to determine
if isolated gallbladder epithelial cells (GBEC) can survive in a damaged liver and can acquire
a hepatocyte phenotype. Methods: Epithelial cells were isolated from the gallbladders of
transgenic mice that constitutively express green fluorescent protein (GFP). Severe-combined
immunodeficiency (SCID) mice were used as recipients and had undergone retrorsine treat-
ment prior to surgery. Freshly isolated GBEC were injected into the spleens of recipient
mice, with or without partial hepatectomy (PH). Two weeks after recovery, the mice that
did not undergo PH were given three weekly doses of carbon tetrachloride (CCl4). Animals
were euthanized between one week and 6 months following surgery and the livers harvested.
The frozen livers were sectioned and examined for the presence of GFP-(+) cells. Morphology
was examined following H & E staining. Expression of biliary and hepatocyte markers (i.e.,
cytokeratin 19, carbonic anhydrase for the former; aldolase B, HNF-4a for the latter) was
determined by immunohistochemistry. Results: GFP-(+) cells were found in the liver of
recipient mice in scattered colonies. Either CCl4 treatment or PH led to successful transplanta-
tion. GFP-(+) cells were found one week after transplantation, and in larger colonies between
one and six months. Many of the GFP-(+) cells appeared to be morphologically consistent
with ductal epithelial cells, and expressed cytokeratin 19 and carbonic anhydrase IV. A
second notable population of GFP-(+) cells appeared morphologically consistent with hepato-
cytes, did not express cytokeratin 19 and carbonic anhydrase, but did express aldolase B
and HNF-4a. Discussion: GBEC can be transplanted into recipient SCID mouse liver.
Some of these transplanted cells developed a hepatocyte-like phenotype. Contamination by
hepatocytes and/or hepatic stem cells was precluded in this model since the transplanted
cells were isolated from the gallbladder. The conversion of GBEC into hepatocyte-like
cells supports the hypothesis that well-differentiated epithelial cells have the capability to
differentiate into another cell type under certain conditions In Vivo. Generating liver cells
from gallbladder cells may have clinical applications for the treatment of liver disease.
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Contribution of Common Variants in the Complement Factor H Gene to
Fibrogenesis in Chronic Hepatitis C Virus (HCV) Infection
Frank Grünhage, Hildegard Keppeler, Hermann e. Wasmuth, Margarete Odenthal, Uta
Drebber, Hans P. Dienes, Claus Hellerbrand, Tilman Sauerbruch, Frank Lammert
Background We recently showed that the complement factor 5 is a quantitative trait gene
that modifies liver fibrogenesis. We thus hypothesized that variations in other factors regulat-
ing the complement system might also influence fibrosis progression. Of note, common
variants of the CFH gene encoding the complement inhibitor factor H have been identified
as susceptibility loci for the development of age-related macular degeneration (Science
2005;308:385-9), which displays histo-pathological characteristics of organ fibrosis like
deposition of extracellular matrix proteins and progressive fibrotic tissue degeneration.
Hence, we tested the association of alleles for age-related macular degeneration in the CFH
gene (single nucleotide polymorphisms rs380390 and rs1061170 [Y402H]) with liver fibrosis
in patients with chronic hepatitis C virus (HCV) infection. Patients and methods Patients
with chronic HCV infection were recruited at three university hospitals (Aachen, Cologne,
Regensburg). Liver specimens were staged using the Desmet/Scheuer score and classified as
mild fibrosis (stages 0-2) or severe fibrosis (stages 3-4). CFH polymorphisms were genotyped
using fluorescent dye-marked reporter assays. Association tests were performed using the
software package developed by Strom and Wienker (http://ihg.gsf.de). Results A total of
467 patients were included in the study. Men were over-represented in our cohort (m:f
1.8:1.0), and mean age was 42 years (range 13-84). Heterozygous carriers (n=197/467) of
the rare allele of the rs380390 variant had an increased odds ratio (OR) for the development
of severe fibrosis (OR=1.70; 95% CI=[1.03-2.88]; p=0.034). Multiple logistic regression
analysis controlling for age and gender confirmed these results (OR=1.70; 95% CI=[1.05-
2.76]; p=0.033). There was only a trend for an increased OR in carriers of the risk allele
(p=0.062), probably due to the small number of homozygous patients (70/467). No associ-
ation was detected for the CFH variant rs1061170. Conclusion In our cohorts, the CFH
gene variant rs380390 and haplotypes without the Y402H coding variant were associated
with advanced fibrosis stages. We propose that genetic variation in this regulator of the
alternative complement pathway contributes to the complex individual predisposition to
rapid progression of liver fibrosis.
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Activation of Thioesterase Superfamily Member 2 (Them2) By
Phosphatidylcholine Transfer Protein (PC-TP): A Mechanistic Link Between
Membrane Lipid Composition and Hepatic Fatty Acid Metabolism
Keishi Kanno, Michele K. Wu, Brandon J. Fanelli, Erez F. Scapa, David E. Cohen
PC-TP is a liver-enriched intracellular lipid binding protein that promotes rapid exchange
of phosphatidylcholines between membranes In Vitro. We have demonstrated a key role for
PC-TP in regulating hepatic fatty acid metabolism, but the mechanism is not explained by
its phosphatidylcholine transfer activity. PC-TP is a steroidogenic acute regulatory protein
(StAR)-related lipid transfer (START) domain protein. Members of this superfamily all contain
lipid binding motifs of similar size as PC-TP (214 amino acids). Whereas START proteins
generally contain additional functional domains, the amino acid sequence of PC-TP comprises
only the lipid binding domain. The aim of this study was to test the hypothesis that PC-
TP might regulate lipid metabolism via interaction with another hepatocellular protein. PC-
TP was utilized as bait in a yeast two hybrid screen of a mouse liver cDNA library. This
identified Them2, an incompletely characterized thioesterase, as a PC-TP-interacting protein.
The interaction between PC-TP and Them2 was verified by a glutathione S-transferase pull-
down assay. The tissue distribution of Them2 was determined by Northern blot analysis,
which revealed high-level expression of Them2 in the liver. To determine whether PC-TP
colocalizes with Them2 intracellularly, HEK 293T cells were transfected with green (GFP)-
and red (RFP)-fluorescent PC-TP and Them2 fusion proteins, respectively. Confocal micro-
scopy revealed that RFP-Them2 expression was restricted to the cytoplasm, where it colocal-
ized with GFP-PC-TP. The influence of PC-TP on the enzymatic activity of Them2 was
quantified spectrophotometrically using purified recombinant His-tagged proteins and 5,5'-
dithiobis(nitrobenzoic acid) to detect the liberation of CoA from myristoyl-CoA. Them2
exhibited thioesterase activity, which was markedly increased by PC-TP as a function of
PC-TP/Them2 molar ratio (0.04-0.67). PC-TP is upregulated by activation of PPARα, a
transcription factor that controls fatty acid metabolism in the liver. To test for Them2
regulation by PPARα, mice (n=8/group) were fed 7d with chow or chow supplemented
0.2% (wt/wt) with the PPARα ligand fenofibrate. Them2 mRNA was upregulated by 2.5-
fold by fenofibrate in wild type mice. Fenofibrate-induced Them2 upregulation was not
observed in PPARα knockout mice. We conclude that PC-TP interacts with Them2 in liver
to promote acyl-CoA thioesterase activity. Because PC-TP preferentially binds phosphatidyl-
cholines with sn-2 polyunsaturated fatty acids, we speculate that PC-TP-Them2 interactions
provide a mechanistic link between membrane lipid composition and PPARα−regulated fatty
acid metabolism in the liver.
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Adipose Differentiation-Related Protein (Adrp) Is a Specific Histological
Marker for Hepatic Steatosis Caused By Alcohol Feeding
Ki M. Mak, Qi Cao, Chaoling Ren, Anatoly Ponomarenko, Charles S. Lieber
ADRP is a lipid-associated protein forming a surface coat on cytoplasmic lipid droplets,
thereby maintaining the lipid droplet structure. Immunohistochemical (IH) studies with
human tissues demonstrated that ADRP is a specific histopathological marker for diseases
characterized by lipid accumulation. Fatty change in hepatocytes is an early stage of alcoholic
liver injury. However, there are no specific histological markers for lipid droplets in these
fatty livers. The goals of this study were to evaluate whether ADRP could be used as a
histological marker for the assessment of steatosis after alcohol feeding in rats and, in the
affirmative, to evaluate the beneficial effects of medium-chain triglycerides (MCT) on the
ADRP expression, since it has been shown that MCT reduced triacylglycerol (TG) levels
after alcohol feeding. Accordingly, rats were fed 4 different isocaloric liquid diets. The control
group was given our standard dextrin-maltose diet. Its intake was paired to that of the 3
alcohol groups fed the alcohol-containing Lieber-DeCarli diet. The fat was either 32% of
cal as long-chain triglycerides (LCT), or 16% as LCT + 16% as MCT, or 32% as MCT only.
After 21 days of feeding, liver tissues were processed for paraffin embedding for IH staining
of ADRP using a monoclonal ADRP antibody. Tissues were also used for Western blot (WB)
determination of ADRP or chemical quantification of TG. Alcohol feeding resulted in intense
staining of ADRP in the centrilobular area with a diminution towards the perilobular area.
Both macrovesicular and microvesicular fats in hepatocytes were clearly coated by ADRP.
Quantification of ADRP by morphometric image analysis, expressed as % area stained,
revealed a 10-time increase of ADRP compared to controls (20.9±1.2 vs. 2.2±1.0, n=6,
p<0.001). MCT (16%) diminished the alcohol effect on ADRP by 33% (13.8±0.8, n=6,
p<0.001) while 32% MCT further reduced the change by 66% (6.6±1.0, n=6, p<0.001).
WB analysis showed an increase of ADRP after alcohol (2.7 relative units vs. control) and
the alcohol effect was reduced by 32% MCT (1.4 units vs. alcohol), substantiating the IH
analysis. Furthermore, the increase of ADRP expression reflected the rise of liver TG levels
after alcohol and its decrease reflected the lowered TG after MCT. In conclusion, the detection
by immunohistochemistry of ADRP offers a novel and sensitive method to assess fatty changes
in alcoholic disease. The protocol is applicable to detecting ADRP in archival human liver
tissues, because ADRP immuno-reactivity is preserved in paraffin-embedded tissues and the
ADRP antibody recognizes the human protein as well. Supported by NIH Grant AA014326.
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Does Obstructive Sleep Apnea Treatment Improve Levels of Adipocytokines
Associated with NAFLD?
Steve A. Keilin, Mary jo Atten, Bashar M. Attar, Sheela Channabasappa, Babak Mokhlesi,
Douglas Kimball, Aiman Tulaimat
Introduction: Obstructive sleep apnea (OSA) and NAFLD are closely associated with obesity,
insulin resistance and the metabolic syndrome (MS), and these patients often have derange-
ments in levels of the adipocytokines leptin and adiponectin. Obesity-related liver injury
can be attributed to leptin, tissue hypoxia and reactive oxygen production during apnea
episodes in OSA, and to cytotoxic advanced glycation end-products (AGEs) produced in
excess by diabetics. Leptin, a hepatic stellate cell activator, is elevated in obesity, while
adiponectin, the adipocytokine that maintains hepatic stellate cells in a quiescent state, is
decreased in obesity. Studies in OSA patients with BMI < 30 have shown that continuous
positive airway pressure (CPAP) use improves inflammatory and metabolic markers. We
selected a severely obese population to determine whether use of CPAP for OSA improves
inflammatory and metabolic markers and protects from liver injury in this population.
Methods: In addition to routine liver and metabolic chemistries, we measured weight/BMI,
fasting serum C-reactive protein (CRP), insulin, leptin, and adiponectin levels in 26 patients
with OSA before and after 30 days of CPAP use. Results: Our severely obese patients with
OSA (12M:14F) and baseline BMI of 45.8±2.0, had high insulin resistance (HOMA =
8.6±2.3, normal<3), elevated CRP (7.6±0.9, normal<3), and extremely elevated leptin (males:
20.9±8.2, normal=6; females: 52.1±6.4, normal=10). Thirty days of CPAP treatment imparted
a protective effect on non-diabetic OSA patients (n=17) as reflected by decrease in BMI
(p<0.02), decrease in triglycerides (pre =141.9±22.6, post =109.4±15.9, p<0.05), rise in
HDL ((pre =45.4±4.1, post =47.7±4.1, p<0.05), and rise in adiponectin (pre =11,350±1512,
post =12,800±1503, p<0.05). However, these parameters were not altered by CPAP use in
severely obese diabetic OSA patients (n=9). Conclusion: CPAP treatment improves metabolic
parameters and adipocytokine levels in overweight patients (BMI < 30), however, there is
limited information regarding similar efficacy in the severely obese. Our results indicate that
suppression of reactive oxygen production, via CPAP use, improves metabolic parameters
and adiponectin levels in severely obese non-diabetics, but does not impart similar protection
for those severely obese OSA patients with diabetes. This may, in part, result from inability
of CPAP use to modulate leptin levels in the severely obese OSA patient. Since free fatty
acids, tissue hypoxia, and AGEs contribute to the free radical insult and cytotoxic injury in
severely obese diabetics with OSA, these patients likely require a multimodal approach
to treatment.
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Impact of Hospital Volume On Outcomes of Acute Pancreatitis Neelima Reddy,
Mohamad Eloubeidi, Shyam Varadarajulu, Meredith Kilgore, University of
Alabama At Birmingham, Uab School of Public Health, Birmingham, Al
Neelima Reddy, Mohamad A. Eloubeidi, Shyam Varadarajulu, Meredith L. Kilgore
Aim: To evaluate the impact of hospital volume on health related outcomes of patients with
acute pancreatitis. Methods: Secondary analysis of 5-yr (1998-2003) data of inpatients with
acute pancreatitis obtained from the National Inpatient Sample database. Hospitals were
stratified into percentiles based on case (acute pancreatitis) volume. Logistic and multiple
regression models were used to estimate the association of hospital case volume with length
of stay (LOS) and patient mortality. Fixed effect models were used to adjust for all time
invariant hospital characteristics and comorbidity risk adjustment was performed using the
Elixhauser system. Results: Data from 5617 hospitals involving 269,329 inpatients (mean
age 52.6 years; 49% men) with acute pancreatitis was analyzed. The mean LOS for all
patients was 4 days and inpatient mortality rate was 1.7%. The median volume of cases in
the lowest 10th percentile of hospitals was < 26/yr compared to > 186/yr in the top 10th
percentile (range, 1-447/yr). Multivariate regressions with fixed effects found significant
trends in relationships between hospital case volume, LOS and mortality: the mean LOS
was lower in high-volume (> 186 case/yr) than low-volume (<26 case/yr) hospitals (4.3 vs.
6.4 days, p < 0.0001) and the mortality rate was lower in high-volume than low-volume
hospitals (0.7% vs. 1.9%; p < 0.001). Compared to direct admissions, patients transferred
from other institutions had a higher mortality rate (2.7%) and longer LOS (2.98 days).
Conclusion: Patients with acute pancreatitis managed at high volume centers have shorter
length of stay and lower mortality rates when compared to those managed at low-volume cen-
ters.
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Impact of Hospital Acquired Infection On Mortality in Acute Pancreatitis
Bechien Wu, Richard S. Johannes, Stephen Kurtz, Peter A. Banks
INTRODUCTION: Infection is believed to play a major role in the outcome of acute pancreat-
itis. No large studies have evaluated the impact of hospital acquired infection (HAI) on
mortality in acute pancreatitis (AP). Recently, Pennsylvania became the first state to issue
hospital-wide public reporting on HAI. This created an opportunity for a population based
assessment of the contribution of HAI to mortality in AP. AIMS: To study the independent
effect of HAI on in-hospital mortality in AP. METHODS: The Cardinal Health Research
Database is a large population dataset that has supported publicly reported hospital perform-
ance in Pennsylvania for 20 years. Cases with principal diagnosis ICD9-CM 577.0 (AP) from
the Cardinal database between Jan 2004 and Jan 2005 were identified. These cases were
linked with recently reported HAI data collected by the Pennsylvania Health Care Cost
Containment Council. Identification of HAI was based upon definitions set forth by the
National Nosocomial Infection Surveillance System. In order to determine the risk attributable
to HAI, a 5 to 1 propensity-matched cohort study was performed. Propensity scores were
calculated using a logistic regression model for AP mortality. This model contains 25 covari-
ates including vital signs, laboratory data, history and physical exam findings. In developing
this model, individual covariates were analyzed in a univariate manner then run in a fully
adjusted logistic regression model. The c-statistic for this model was 0.886. RESULTS: From
177 participating hospitals, there were 12,510 cases of pancreatitis reported during the
study period. Eighty-four patients with AP developed an HAI. After a 5-to-1 matching, the
study population of cases and controls consisted of 492 cases drawn from the AP population,
representing a 98% matching rate. The overall mortality odds ratio estimates for HAI with
95% confidence intervals are presented in the table below. The distribution of HAI sites
included 36% urinary tract infection, 35% blood-stream infections, 15.5% multiple sites
and 11% pneumonia. CONCLUSIONS: Through multivariate matching, a relatively unbiased
cohort was generated from a large population dataset. Given similar levels of disease severity,
patients with AP that developed HAI had a 9 fold greater risk of in-hospital mortality. The
vast majority of cases consisted of urinary and blood stream infections.
Mortality in Matched AP Cohort
OR=9.0 (4.5,17.9) p<.0001
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Prophylactic Antibiotic Use Is Protective in Patients with Severe Acute
Pancreatitis: A Systematic Review and Meta-Analysis
Nadim S. Jafri, Suhal S. Mahid, Spencer R. Idstein, Carlton A. Hornung, Susan
Galandiuk
INTRODUCTION: The management of patients with acute pancreatitis remains controversial
especially with respect to infection. Clinically it can present as mild self-limiting disease or
may rapidly progress to a severe life threatening condition. The use of prophylactic antibiotics
to prevent infection and reduce mortality remains a contentious issue. We assessed the
clinical outcome of patients with severe acute pancreatitis (SAP) treated with prophylactic
antibiotics compared to that of patients not treated with antibiotics. METHODS: We per-
formed a systematic search of Medline, EMBASE, and Cochrane Central Register of Controlled
Trials, using Pubmed, Google Scholar and Ovid as search engines without language restric-
tion. We also hand searched the references of original/review articles and evaluated symposia
proceedings, poster presentations, and abstracts from major gastrointestinal meetings. Relat-
ive risks were calculated for individual trials and data pooled using a fixed effects model.
Relative risk reduction (RRR), absolute risk reduction (ARR) and number needed to treat
(NNT) were calculated and are reported with 95% confidence intervals. Results were subjected
to sensitivity analysis in order to determine heterogeneity among studies. RESULTS: Seven
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studies from which we pooled 431 patients met eligibility criteria. Mean patient age ranged
from 43-59 years. Length of stay ranged from 17-44 days. Fifty six percent of patients had
alcoholic pancreatitis, the leading cause of SAP, followed by biliary pancreatitis (24%) and
other causes (20%). 219 patients with a proven diagnosis of SAP received prophylactic
antibiotics, while 212 were randomized to the placebo arm. Duration of antibiotic use ranged
from 5-21 days. Overall analysis showed a protective effect of antibiotic treatment with
respect to mortality with a RRR of 38 (95% CI, 6.0%-59%), ARR of 8% (95% CI, 1.0%-
15%) and NNT of 13 (95% CI, 7.0-100). With respect to morbidity, antibiotic prophylaxis
protected against infected necrosis with a RRR of 38 (95% CI, 14%-55%), an ARR of 12%
(95% CI, 4.0%-20%) and NNT of 8 (95% CI, 5-25) and surgical intervention with a RRR
of 26% (95% CI, 2%-45%), an ARR of 9% (95% CI, 1%-18%) and NNT of 11 (95% CI,
6-100). Sensitivity analysis indicated homogeneity among all subgroups. CONCLUSIONS:
Using strict pre-defined criteria, current guidelines, and a weighted method we demonstrate
that antibiotic prophylaxis of SAP is protective against infected necrosis, surgical intervention
and reduces mortality. These outcomes were consistently demonstrated across all types
of pancreatitis.
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Bedside Algorithm for Admission Mortality Risk in Acute Pancreatitis
Bechien Wu, Richard S. Johannes, Ying P. Tabak, Xiaowu Sun, Peter A. Banks
INTRODUCTION: Accurate identification and triage of patients at risk for mortality early
in the course of acute pancreatitis (AP) has important clinical implications. AIMS: To derive
and validate a bedside algorithm to be used on admission for rapid classification of in-
hospital mortality risk in AP. METHODS: Patient data was generated from the Cardinal
Health Research Database, a large population dataset that has supported public reporting
of hospital performance in Pennsylvania for 20 years. The derivation cohort consisted of all
cases from 2000-01 with principal diagnosis ICD9-CM 577.0 (AP). The validation cohorts
were admitted 2004-05. Candidate variables were obtained from an existing logistic risk
adjustment model. This model contains 25 covariates including vital signs, laboratory data,
history and physical exam findings. The classification and regression tree (CART) analysis
was performed to create a simplified algorithm for bedside application. Variables included
in the final classification and regression tree were then analyzed in a multivariate logistic
regression model for comparison. RESULTS: There were 17,992 cases from 212 hospitals
with 335 deaths in the derivation cohort. Mean age was 55.6 and 49.3% were males. CART
analysis consistently identified three variables (BUN>25, presence of SIRS, and age≥60) as
most efficient in stratifying patients' admission mortality risk. When applied to the validation
cohort, the stratification scheme achieved similar results. Figure 1 displays the algorithm.
BUN and SIRS alone were able to classify patients into low or intermediate-risk categories.
Age>60 further classified patients as high-risk. The c-statistics for the derivation and validation
cohorts were 0.802 and 0.786, respectively. CONCLUSIONS: Using large population-based
datasets we derived and validated a simple bedside decision analysis tool for estimating
admission mortality risk in the AP population. Three admission parameters (BUN, SIRS,
age) can stratify patients into high, intermediate, and low risk categories.
Classification algorithm in AP
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Percutaneous Pancreatic Necrosectomy (PPN) in the Management of Infected
Pancreatic Necrosis: Experience in 106 Patients
Colin Mckay, Clement Imrie, Ross Carter
Introduction Minimally-invasive techniques are increasingly used in the management of
patients with infected pancreatic necrosis. Early results are encouraging but selection bias
and small study size make it difficult to determine the place of these techniques in the
overall management of this complex illness. Here we describe our experience of PPN in a
large, consecutive cohort of patients and compare outcome over time, as the use of PPN
increased. Methods Consecutive patients with infected pancreatic necrosis admitted to a
single tertiary referral unit since the introduction of PPN in 1998 had prospective data
collection supplemented by case note review. Patients were grouped according to three time
intervals, 1998-2000; 2001-2003; 2004-2006. Mortality was compared. Results 131 patients
underwent pancreatic necrosectomy for infected pancreatic necrosis, of whom 106 had PPN.
The proportion of patients having PPN rose from 72% in 1998-2000 to 100% in 2004-
2006. Overall mortality was 19%. This compares to a pre-1998 mortality in our unit of
36%. The increase in use of PPN was not associated with a rise in mortality (17% in 1998-
2000; 22% in 2001-2003; 19.5% in 2004-2006). Conclusions With increasing experience,
the great majority of patients with infected pancreatic necrosis can be managed by PPN.
Adopting PPN as the preferred intervention in all patients does not increase mortality.
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Disconnected Pancreatic Duct Syndrome (DPDS) Requiring Distal
Pancreatectomy Is a New Indication for Pancreatic Islet Autotransplantation
(PIA): Initial Experience
Yogish Kudva, Santhi swaroop Vege, Michael B. Farnell, Suresh T. Chari, Michael L.
Kendrick, Florencia G. Que, Mark D. Topazian, Randall K. Pearson, Bret T. Petersen,
Michael J. Levy, Enrique Sabater, Haraldur Bjarnason, Matthew Callstrom, Michael Deeds,
Jarett Anderson, Adam Armstrong, Dennis Gastineau, Todd H. Baron
Background and Aim: DPDS after severe acute pancreatitis requires distal pancreatectomy
to remove the isolated pancreas, which may result in diabetes in nearly a third to half of
the patients. PIA, a recommended procedure after total or near total pancreatectomy in
specialist centers, prevents or ameliorates pancreatogenic diabetes. However, PIA has not
been reported for patients with DPDS undergoing distal or extended distal pancreatectomy
and hence we report here the initial experience of PIA with 5 patients. Methods: The clinical,
radiologic, endoscopic, and surgical details of 5 patients where PIA was attempted in 2006
have been abstracted to compare the 2 successful procedures with the other 3, where the
yield was too low for islet infusion. Results: The results are displayed in the table below.
The interval between the diagnosis of DPDS at ERCP and surgery was 12, 2, 4, 11, and 5
months respectively in the 5 patients. Both the patients who had successful PIA had the
continuity of pancreatic duct re-established on ERCP. Conclusions: In the first report of
PIA, in patients undergoing extended distal pancreatectomy for DPDS, post-operative diabetes
was not observed in one and one was stable on oral hypoglycemic agents during short term
follow-up. Low yield of islets was present in the 3 patients with firm pancreata at surgery.
PIA needs evaluation in larger group of patients with DPDS undergoing surgery with an
aim of preventing or ameliorating pancreatogenic diabetes. PIA may have to be considered
earlier during the course of DPDS to achieve better yield of islets.
Results: Details of the Five Patients With DPDS Undergoing PIA
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Fundoplication Reduces Gastroesophageal Reflux in a Refluxate-Dependent
Manner
Albert J. Bredenoord, Werner A. Draaisma, Bas L. Weusten, Hein G. Gooszen, André J.
Smout
Fundoplication almost abolishes acid reflux, but the effect on non-acid and gas reflux has
not been studied extensively. Symptoms after surgery are often attributed to the inability
of venting air from the stomach, but this has not been tested in an ambulatory setting.
Methods: Prior to surgery, stationary impedance-pH measurements were performed for 20-
min after reflux provocation by intragastric inflation of 600 mL of air. This was followed
by ambulatory 24-hr impedance-pH measurements. The incidence of air swallowing, gas
reflux, acidic and weakly acidic reflux was assessed. Both stationary and ambulatory measure-
ments were repeated 3 months after fundoplication. Results: In the stationary study fundoplic-
ation greatly reduced the occurrence of liquid (from 0.7±0.3 to 0.0±0.0, p<0.01), mixed
(from 1.4±0.5 to 0.0±0.0, p<0.01) and pure gas reflux events (from 2.6±0.5 to 0.8±0.4,
p<0.01) after air inflation. In the ambulatory study, there was a large decrease in the
prevalence of both acidic (-97%, from 47.7±6.2 to 1.6±0.5, p<0.01) and weakly acidic reflux
(-90%, from 24.7±9.9 to 2.6±1.0, p<0.01). The decrease in gas reflux was less pronounced,
albeit statistically significant (-51%, from 24.3±5.1 to 11.8±3.1, p<0.01). There was a larger
decrease in reflux events reaching the proximal esophagus (-99%, from 16.5±4.5 to 0.1±0.1,
p<0.01) than in events reaching the distal esophagus (-79%, from 11.4±1.6 to 2.4±0.8,
p<0.01). Fundoplication significantly decreased both volume and acid clearance time (from
18.1±1.5 to 15.6±1.4 s, p<0.05 and from 119.9±22.3 to 18.2±6.2 s, p<0.01). The numbers
of swallows and air-containing swallows were not affected by the operation (925±90 vs
912±88, NS; 322±34 vs 361±50, NS) . In 4 patients no acidic or weakly acidic reflux was
found at all after the operation and in 1 patient there was also a total inhibition of pure gas
reflux. Differences between patients of self-reported presence and severity of bloating, inability
to belch and inability to vomit were not related to differences in air swallowing or reflux
occurrence of gas and liquid during the stationary and ambulatory study. Conclusions: 1:
This is the first study showing that fundoplication reduces both acidic and weakly acidic
reflux and also pure gas reflux, in some patients reflux is blocked entirely. 2: The reduction
in liquid-containing (acidic and weakly acidic) reflux is larger than the reduction in pure
gas reflux. 3: The pronounced reduction in proximal reflux episodes and of acid and volume
clearance time suggests a reduction in volume of reflux episodes after surgery. 4: Symptoms
after fundoplication can not be predicted by objective findings.
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Mechanisms of Inhibition of Acidic and Weakly Acidic Reflux After
Fundoplication
Albert J. Bredenoord, Werner A. Draaisma, Bas L. Weusten, Hein G. Gooszen, André J.
Smout
Background and aim: Fundoplication effectively reduces the occurrence of gastroesophageal
reflux, although the exact mechanism of reflux inhibition is not known. High-resolution
manometry enables the identification of the two constituents of the esophagogastric junction
(LES and diaphragm) during spatial separation as occurs in a hiatal hernia. The aim of this
study was to investigate the effect of fundoplication on the mechanisms of acidic and weakly
acidic reflux. Methods: Reflux was measured with impedance and pH monitoring during a
postprandial 90-min recording period in 12 patients with GERD (7 with hiatal hernia of 3
cm on endoscopy) before and 3 months after laparoscopic Nissen fundoplication. Concomit-
antly, the occurrence of TLESRs and the morphology of the esophagogastric junction was
characterized with prolonged high-resolution manometry. Results: Fundoplication greatly
reduced the total (acidic and weakly acidic) number of reflux episodes (from 12.6±2.9 to
0.8±0.5, p<0.01). Before the operation 2 separate high-pressure zones (hernia profile) were
detected during 20.2 % of total time, during which there was a much higher reflux rate
compared to the periods with a single high-pressure zone (reduced hernia)(13.3±4.1 episodes
vs 7.8±1.3 /h). After fundoplication no double high-pressure zones were identified. Fundopl-
ication significantly decreased both the number of TLESRs (from 10.2±1.4 to 4.5±0.8,
p<0.01) and the percentage of TLESRs with acidic or weakly acidic reflux (from 73.5 to
4.4%, p<0.01). Nadir pressure during TLESRs increased after surgery (from 0 (0-0) to 2.5
(1-3), p<0.05). The duration of TLESRs was not affected (17.8±0.9 vs 16.5±0.8 s, NS).
Conclusions: Fundoplication greatly reduces gastroesophageal reflux by a complete abolition
of the double high-pressure zone profile (hernia profile) and reduction of both the number
of TLESRs as well as the percentage of TLESRs that is accompanied by reflux.
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Long-Term Outcome of Laparoscopic Fundoplication in 174 Children with
Gastro-Esophageal Reflux Disease (GERD)
Ilse Hoffman, Jan Tack, Antoon Lerut
Gastro-esophageal reflux (GER) is a common and mostly self-limiting problem in infants
and young children. In a subgroup of children, persistent GERD may require acid suppressive
and/or prokinetic therapy, and in those who remain refractory, surgical intervention may
be necessary. Although the Nissen fundoplication is the most widespread surgical procedure
for children with pathological gastroesophageal reflux disease, data on the long-term outcome
are scarce. Our aim was to assess the long-term outcome of children referred for antireflux
surgery in our hospital. Methods: All children who underwent antireflux surgery between
01/1995 and 11/2005 were prospectively followed up at 1 year after surgery and in case of
occurrence of gastrointestinal symptoms including dysphagia, diarrhoea or recurrent GERD.
Results: 174 children (108 boys, mean age of 7.2±5.6years), 72 of which had psychomotor
retardation (PMR), underwent a Nissen fundoplication, with a mean follow up time of
52±3 months. The fundoplication was completed laparoscopically in 96%, and short term
complications occurred in 8(4.6%) patients (1 haematoma, 4 herniations of the fundoplication
at barium swallow 24 hours post-surgery, and 3 local surgical complications), requiring
short-term reintervention in 7 patients (4%). At re-evaluation 13.2±10.7 months after surgery,
112 children (64.4%) were asymptomatic. In the 62 children (35.6%) with persisting or
new symptoms, additional investigations showed anatomical deformities in 4.6% (herniation
of the wrap in 8) and dysphagia without anatomical deformity in 15 children (8.6%). Eleven
patients (7.7%) reported symptoms suggestive of dumping with feeding-induced pallor (9),
abdominal pain (8), sweating (7) and diarrhea (5). Recurrence of GERD-like symptoms was
reported for 30 children (17.2%), but only 12 children had recurrent esophageal erosions.
Repeat pH monitoring was performed in 69 children (including those with recurrent symp-
toms or esophagitis), of which 7 (10%) were pathological. The cause of persisting symptoms
remained unclear in 14 children (8%); medical GERD therapy was prescribed to only 4.6%
of children. During follow-up, surgical reintervention was done in 2 children (1%) for GERD
recurrence and in 5 children (2.8%) for dysphagia. Conclusion: Anti-reflux surgery in
children with refractory GERD successfully controls reflux in close to 90%, but is not
devoid of complications. These include both short-term surgical complications and long-
term medical complications like dysphagia, recurrent GERD or dumping syndrome.
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The Lotus Trial - Comparing Esomeprazole to Laparoscopic Anti-Reflux
Surgery for the Management of Chronic Gastroesophageal Reflux Disease: A 3-
Year Interim Analysis
Lars R. Lundell, Jan G. Hatlebakk, Stephen Attwood, Christian Ell, Roberto Fiocca, Jean-
paul Galmiche, Tore Lind, Ola Junghard
Introduction: With the increasing efficacy of modern medical therapy for gastroesophageal
reflux disease (GERD), a direct long-term comparison with laparoscopic anti-reflux surgery
(LARS) is warranted. We report the 3-year interim results of a randomized study comparing
the efficacy and safety of esomeprazole (ESO) and LARS. Methods: LOTUS is an open,
parallel-group, multicenter, randomized, controlled trial conducted in eleven European
countries. LARS was completed according to a standardized protocol, always comprising a
total fundoplication and a posterior crural repair. Treatment comprized ESO 20 mg once
daily, which could be increased stepwise to 20 mg twice daily in cases of incomplete GERD
control. The primary outcome variable was time to treatment failure (Life table analysis).
Treatment failure was defined as insufficient control of GERD (ESO group: need for therapy
beyond ESO 40 mg; LARS group: need for medical therapy [antacids permitted] or additional
operation). Results: A total of 554 patients were randomized (ESO: n=266; LARS: n=288).
Baseline demographics and disease characteristics were similar between study arms. The
estimated proportion of patients who remained in remission was 93% for ESO and 90%
for LARS (figure). No major postoperative complications were experienced. ESO was well-
tolerated. Conclusions: Over the first 3 years of this long-term study, both continuous
esomeprazole treatment and laparoscopic total fundoplication were similarly effective and
well-tolerated therapeutic strategies for control of GERD.
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Anti-Reflux Surgery Compared with Maintenance OMEPRAZOLE for Reflux
Esophagitis. Results After 12 Years
Lars R. Lundell, Pekkra Miettinen, Helge E. Myrvold, Jan G. Hatlebakk, Lene Wallin,
Anders Malm, Anders Walan
Introduction: Proton pump inhibitor (PPI) therapy and anti-reflux surgery (ARS) are both
documented as being effective for management of gastroesophageal reflux disease (GERD),
but comparative controlled studies beyond 6 months are lacking. We now report the 12-
year follow-up results of the first such randomized study of safety and efficacy comparing
omeprazole (Ome) with ARS (ClinicalTrials.gov identifier: NCT00256737; SOPRAN).
Methods: This is an open, randomized, Nordic multicenter study. In total, 310 chronic
GERD patients with esophagitis and who were considered candidates for surgery were
randomized to either maintenance treatment with Ome or open ARS (fundoplication). The
primary variable was time to treatment failure (defined as recurrence of at least moderate
heartburn or recurrence of esophagitis [at least erosion] or need for other therapy [on the
initial and adjusted doses of Ome]). The profile and severity of post-fundoplication com-
plaints, as well as tolerability, were also reported. Results: The estimated proportions of
patients in sustained remission after 12 years were 53% and 45% in the ARS and Ome
groups, respectively (p=0.022) (figure). During the study, 38% of ARS patients required
maintenance PPI treatment and 15% of Ome patients were operated on. Seven patients in
the ARS group were re-operated on. The average daily dose in the Ome group after 1 and
10 years was 24 and 26 mg, respectively. Compared with the Ome group, more patients
in the ARS group complained of dysphagia, inability to belch and vomit, and rectal flatulence.
The prevalence of these symptoms remained similar over time. Both therapies were well-
tolerated. Conclusions: Both long-term PPI therapy and fundoplication are safe and effective
strategies for treatment of chronic GERD. Surgery was superior to omeprazole for keeping
patients in sustained remission over the observation period, but proportionally more operated
patients needed additional treatment. Post-fundoplication complaints remain a problem.
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Manometry and 24-Hour pH-Metry During 10 Years' Follow-Up in Patients
Randomized to Anti-Reflux Surgery Or OMEPRAZOLE
Jan G. Hatlebakk, Lars R. Lundell, Lene Wallin, Helge E. Myrvold, Pekka Miettinen,
Anders Malm, Anders Walan
Introduction: Abnormal lower esophageal sphincter (LES) characteristics and gastroeso-
phageal reflux play a major role in the development of gastroesophageal reflux disease
(GERD) as well as relapse of symptoms and development of complications. The long-term
effect of anti-reflux surgery or proton pump inhibitor therapy on LES and acid control,
however, is not well investigated. Methods: In a prospective, randomized, controlled multic-
enter study (ClinicalTrials.gov identifier: NCT00256737; SOPRAN), we compared LES
resting pressure, as well as distal esophageal exposure to acid, at baseline and 10 years after
randomization to either open anti-reflux surgery (ARS) or omeprazole 20-60mg daily (Ome).
Recordings in medically treated patients were made during treatment. Results: In total, 253
patients were investigated by manometry and 24-hour pH-metry before randomization. After
10 years, pH-metry data were available for 116 patients (ARS: 60, Ome: 56). In the Ome
arm, the mean dose of Ome was 26mg. Median percentage of time with esophageal pH <4
at baseline was 14.8% in ARS patients and 15.0% in Ome patients; after 10 years this was
reduced to 1.6% in ARS patients and 0.7% in Ome patients (10 years vs baseline, p<0.01;
ARS vs. Ome, not significant). Similarly, median number of reflux episodes was reduced
from 90 at baseline to 31 after 10 years in ARS patients, and from 79 at baseline to 11 after
10 years in Ome patients (10 years vs baseline, p<0.01; ARS vs. Ome, not significant). In
a subpopulation of patients with long-segment Barrett's esophagus (ARS=7, Ome=13), median
percentage of time with esophageal pH <4.0 after 10 years was 1.4% in ARS patients and
1.9% in Ome patients (not significant). Mean LES resting pressure increased significantly
from 11.8mmHg at baseline to 17.4mmHg after 10 years in ARS patients (p<0.01), whereas
in Ome patients the LES resting pressure remained stable (12.3mmHg at baseline vs.
13.5mmHg at 10 years). Conclusion: Both anti-reflux surgery and omeprazole were effective
for controlling esophageal acid exposure 10 years after randomization. Surgery significantly
increased lower esophageal sphincter pressure, which remained elevated after 10 years
compared with medically treated patients, in whom no change occurred.
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Reflux-Associated Symptom Probability from Preoperative Ambulatory pH
Monitoring Predicts Quality of Life (QoL) Following Laparoscopic Antireflux
Surgery (Lars)
Julie A. Holinga, Sonal Kumar, Chandra Prakash, Peggy Frisella, L. michael Brunt, Brent
D. Matthews, Ray E. Clouse
Both the symptom index (SI) and a test of reflux-associated symptom probability (RASP)
can be calculated from ambulatory pH monitoring (pHM) to provide evidence for a reflux
etiology to symptoms. We have recommended a hierarchical approach to the interpretation
of these tests (the SI only evaluated when the RASP test detects a significant reflux-symptom
relationship), but data supporting probability testing are limited. Outcome in QOL following
LARS was used to validate a RASP test as the more meaningful symptom association method.
Methods: 192 pts (48±1 yr; 106 female) prospectively completed a comprehensive question-
naire and underwent physiological testing (pHM, manometry) prior to LARS. The question-
naire included symptom measures, medication use, and the SF-36 for QOL; pHM results
included upright/supine acid exposure, DeMeester score, SI and a modification of the
previously described symptom association probability (mSAP); manometric results were
classified using a reported scheme. Outcome on QOL (total, physical health, mental health)
and symptom measures were averaged over the postoperative period using questionnaires
repeated at follow-up visits. Results: 83% of the pts had typical symptoms, 17% atypical.
mSAP probability averaged 0.1±0.02 and 67% of p values were <0.05; SI averaged 52±2%
and 61% had SI ≥50%. 91% of pts had elevated acid exposure time. Over a postoperative
period of 18±2 mo, total QOL significantly improved with LARS (62±2 vs 71±1), as did
physical health QOL (58±2 vs 67±2), mental health QOL (63±2 vs 71±1) and global
esophageal symptoms (GES: 5.5±0.2 vs 1.5±0.1 mm on a 10 mm line; p<0.001 for each).
Linear regression analyses were used to predict postoperative QOL controlling for baseline
QOL. Independent variables included pHM measures (mSAP, SI, DeMeester score), demo-
graphics (age, sex), and factors known or suspected to affect LARS outcomes (type of
operation, supine reflux, atypical symptoms, spastic motor disorders, resumption of PPIs).
mSAP trended toward predicting postoperative total QOL (p=0.08) and significantly pre-
dicted physical health QOL (p=0.01), the stronger the probability, the better the QOL. No
other variable was predictive. Mental-health QOL and GES were not independently predicted
by symptom association measures. Conclusions: RASP is a predictor of physical health QOL
following LARS, being superior to the SI and independent of other factors associated previ-
ously with LARS outcomes. These findings support the hierarchical importance of probability
testing in determining reflux-symptom associations and help validate its use in evaluating
patients with symptoms potentially attributable to reflux disease.
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Mapping Genes and Pathways Involved in Celiac Disease Pathogenesis
Alberto Rubio-tapia, Sreekumar Raghavakaimal, Yan W. Asmann, Michael R. Charlton,
Joseph A. Murray
Background/aim:The pathways responsible for celiac disease (CD) pathogenesis are only
partly defined. Oligonucleotide microarray technology can detect differential expression of
thousands of genes simultaneously. The aim of this study is to use oligonucleotide microarray-
derived gene expression profiles, “transcriptome”, from duodenal biopsies of celiac patients
and controls, to find novel molecular function pathways responsible for CD pathogenesis.
Methods: We included 51 subjects; 21 (13 female) treated CD (TC), 16 (10 female) untreated
CD (UC), and 14 (9 female) non-CD (NC). Fresh tissue samples of the duodenum were
snap frozen and stored in liquid nitrogen or RNA later. Total RNA was isolated, and the
quality of mRNA checked (Agilent Technologies, Palo Alto, CA). Oligonucleotide microarray
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technique using 54 K gene chip (Affymetrix HG-U133 plus 2.0 GeneChip Arrays platform)
was used to compare gene expression profiles in duodenal biopsies from UT (all Marsh 3);
TC in whom the mucosa was Marsh 0 (18), 1 (1), and 3a (2); and NC. Pathways analysis
(Ingenuity® Systems) was use to determine each involved pathway as well as changed gene
groups in function/disease categories. Unpaired t-test was performed for comparison. We
use p <0.05 as the threshold. Results: A total of 2,583 (NC vs. TC), 15,064 (UT vs. TC),
and 10,493 (NC vs. UT) genes were differentially expressed. The top significantly changed
functional pathways that had genes that were differentially expressed included (see table
1). The principal functions of the changed gene groups are: immune response, cell death,
proliferation, metabolism, cell-cycle, cell to cell signaling, tissue development, and inflamma-
tion (migration, chemotaxis, homing, and rolling). Conclusions: This study, using a large
number of healed TC and controls, suggest novel pathways involved in the pathogenesis of
CD. The pathways are persistently altered in treated healed CD and that changes are not
just secondary to inflammation.
Table 1. Differentially distributed non-metabolic pathways
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Receptor-Mediated Transcytosis of Iga/Gliadin Peptides Complexes in Celiac
Disease
Tamara Matysiak-budnik, Michelle Arcos-fajardo, Ivan Moura, Corinne Lebreton,
Christophe Dugave, Houda Tamouza, Dominique Lamarque, Stanislaw Chaussade,
Georgia Malamut, Christophe Cellier, Nadine Cerf-bensussan, Renato Monteiro, Martine
Heyman
Background: In celiac disease (CD), toxic or immunogenic gliadin peptides p31-49 and
p56-88 (33-mer) cross intestinal epithelium in intact or potentially active form along a
transcellular transport pathway. We tested hypothesis that this “protected” transport pathway
could involve a receptor-mediated transcytosis of IgA/gliadin peptide complexes, through
the abnormal expression of CD71, a newly described IgA receptor, in intestinal epithelial
cells. Methods: The expression of CD71 and its possible co-localization with IgA and gliadin
peptides were studied by confocal microscopy in duodenal biopsies from healthy individuals
and patients with treated or active celiac disease. Apical to basal transport of 3H-p31-49
and 3H-33-mer in intact form or in form of active fragments was measured ex-vivo in
duodenal biopsies mounted in adapted Ussing chambers. A possible inhibition of this
transport was tested in the presence of soluble transferrin receptor (sCD71) or non specific
monomeric, dimeric, polymeric or secretory IgA. Tritiated-gliadin peptides or fragments
collected in the basal compartment after 3 hour-incubation were analysed by radio-reverse
phase -high performance liquid chromatography. Results: As compared to control or treated
CD patients (TCD), active celiac patients (ACD) presented an overexpression of CD71 at
the apical pole of intestinal epithelial cells. In the duodenal mucosa of ACD patients, but
not of control- or TCD patients, a co-localization of IgA with CD71 and p31-49 was observed.
In biopsies from ACD patients studied in Ussing chambers, the addition of sCD71, dimeric,
polymeric and secretory IgA, but not of monomeric IgA, in the apical compartment, signific-
antly decreased the proportion of p31-49 and 33-mer crossing the mucosa in intact or
immunogenic form, as compared to biopsies incubated with peptides alone. Conclusions:
These results suggest that in active CD, the overexpression of CD71 at the apical pole of
intestinal epithelial cells opens a protected transcytosis of IgA/gliadin peptide complexes that
may establish a vicious circle perpetuating lymphocyte activation and intestinal inflammation.
These data may represent a novel therapeutic approach to CD, by blocking the first step of
a cascade triggering innate and adaptive immune responses to gluten.
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Universal and Grain-Specific T Cell Epitopes in Celiac Disease
Jason A. Tye-din, Jessica A. Stewart, Tim Beissbarth, Robert P. Anderson
A protease resistant wheat α-gliadin 33mer (Shan et al 2002) encompassing overlapping
epitopes (DQ2-α-I, II and III) is regarded as the most “important” T cell stimulatory peptide
in HLA DQ2 associated celiac disease (CD). Promiscuous recognition of barley and rye
peptides by T cells specific for wheat gluten peptides, for example DQ2-α-I, and II, is
thought to account for the toxicity of these grains (Vader et al 2003). We have screened a
library of 2,922 20mers encompassing over 18,000 T cell epitope candidate 12mer sequences
in wheat, rye, barley, and oat prolamins using IFN-γ ELISPOT assays with peripheral blood
T cells collected 6d after commencing 3d wheat, rye, barley or oats challenge (Anderson et
al 2000, 2005). Having defined immuno-dominance of wheat peptides after wheat challenge,
rye peptides after rye, and barley peptides after barley, we sought to determine whether T
cell stimulatory peptides are equally important after wheat, rye and barley ingestion.
METHODS: HLA-DQ2 CD subjects on strict gluten free diet consumed wheat (200g/d) (n=
10), barley (100 g/d) (n=8) or rye (100g/d) (n=6) for 3d. Immuno-dominant wheat gliadin
and glutenin, secalin, and hordein 16mer peptides were incubated with peripheral blood
mononuclear cells (PBMC) collected on day-6 after commencing gluten challenge in IFN-
γ ELISPOT assays. T cell stimulatory activity of peptides was quantified according to ELISPOT
response (SFU/million PBMC) expressed as a percentage of the most active peptide. RESULTS:
The ω−gliadin (DQ2-ω-I; QPEQPFPQPEQPFPWQP) or related sequences were dominant
following barley or rye ingestion and also active after wheat ingestion (mean response as %
of most active peptide response (± SEM) / % of subjects reacting: barley: 86±8% / 100%,
rye: 100% / 100%, wheat: 74±7% / 80%). In contrast certain sequences were recognised
by T cells selectively after a specific grain, for example: QLQPFPQPELPYPQPQL (DQ2-α-
I, II) which was dominant after wheat ingestion but only weakly recognised after barley or
rye ingestion (barley: 23±9% / 38%, rye: 27±7% / 33%, wheat: 91±5% / 90%). Additional
T cell stimulatory peptides were identified in rye (DQ2-sec-I) and barley (DQ2-hor-I) that
were commonly recognized and were occasionally dominant but only after either rye or
barley ingestion. CONCLUSION: Immuno-dominance of gluten peptides in CD is determined
by the toxic grain consumed. α-gliadin epitopes are important only after eating wheat. DQ2-
ω-I is important after eating wheat, rye or barley. Geographical/cultural variation in dietary
consumption of cereals may alter T cell epitope hierarchy in CD and be relevant to T cell-
based diagnostics and therapeutics.
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Small Intestinal Recovery Is Often Incomplete in Serum-Negative Celiacs
During Gluten-Free Diet
Alberto Lanzini, Francesco Lanzarotto, Alessandra Mora, Stefania Bertolazzi, Federica
Benini, Vincenzo Villanacci, Chiara Ricci
It has been suggested (Gastrointest Endosc 2003; 57: 187-91) that complete histopathologic
recovery may be the exception and not the rule in celiac patients during gluten free diet
(GFD), but the evidence is conflicting (Gastrointest Endosc 2004; 59: 158-9). Furthermore,
incomplete recovery with persistence of intraepithelial lymphocytosis during GFD is poten-
tially attributable to factors independent of celiac disease, i.e. Helicobacter pylori infection
(Arch Pathol Lab Med 2006; 130: 1020-5). The aim of our study was to review the effect
of GFD on duodenal histopathology in a large number of celiacs studied before and during
GFD, and to assess the role of Helicobacter pylori infection. We carried out follow-up duodenal
biopsy in 484 celiac patients 32 + 2 months (mean + SEM; median 18 months) after starting
gluten-free-diet (GFD). Prior to GFD 2%, 4% and 94% of patients were classified as Marsh
1, 2 and 3 at duodenal histopathology, respectively. At the time of follow-up biopsies 456
patients were tissue -transglutaminase (t-TG) and/or endomysial antibodies (EMA) negative
during GFD. Only 51 of these 456 seronegative patients had normal duodenal histopathology
during GFD, and the proportion changed slightly according to the length of GFD. Histopatho-
logy was normal in 11%, and Marsh 1, 2 and 3 lesions persisted in 14%, 53% and 22% of
332 patients on GFD for 12-24 months. The corresponding values were 10%, 15%, 57%
and 18% in 80 patients on GFD for 25 to 60 months, and 21%, 24%, 33%, 22% in 67
patients on GFD for longer than 60 months, respectively (p<0.004 by Chi-squared test for
independence). TTG/EMA were negative at the time of follow-up biopsy in 75/92 CD with
persistent Marsh 3 lesion during GFD. Gastric biopsies were obtained in addition to duodenal
biopsies in 432 patients at follow-up. The proportion of Marsh 1 and 2 lesion was similar
in patients with Helicobacter pylori infection (62%) as in those without infection (69%). We
conclude that (i) Marsh 1 and 2 lesions persist in the majority of CD patients during GFD
despite negative serology and clinical improvement; (ii) this persistence is independent of
Helicobacter pylori infection; (iii) there is a tendency for prevalence of abnormal histopathology
to decrease during prolonged dietary treatment; (iv) t-TG and EMA are poor predictors of
complete histopathologic recovery of duodenal mucosa during GFD.
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Protective Role of Anti-Idiotypic Network in Celiac Disease Prone Subjects
Fortunato Ferrara, Sara Dal bo, Sara Quaglia, Roberto Di niro, Roberto Marzari, Daniele
Sblattero, Stefano Martelossi, Tommasini Alberto, Alessandro Ventura, Tarcisio Not
The idiotypic-anti-idiotypic network seems to play an important role in the regulation of
the autoimmune response. Celiac disease (CD) is a gluten-dependent autoimmune disease
associated with circulating anti-transglutaminase antibodies (anti-tTG), which are synthesized
in the intestinal mucosa and are involved in the pathogenesis of CD. An idiotypic network
may be involved in sequestering the anti-tTG to modulate both the clinical manifestation
and the degree of the intestinal lesions. The anti-tTG belong to the restricted family of VH5
limiting the number of idiotypes so that the CD can be used as a model for studying the
role of idiotypic-anti-idiotypic network in autoimmune disorders. Aims: To investigate the
presence of anti-idiotypic network against the anti-tTG antibodies in CD and to evaluate
the role of this network in the pathogenesis of CD. Methods: We analyzed the anti-idiotypic
network in the sera and in the acid-eluted intestinal samples of two study groups, genetically
predisposed to gluten intolerance (all tested positive for HLA DQ2/DQ8), and with the same
risk for CD (first degree family of CD patients). The first group is composed of 12 biopsy-
proven CD patients (8F, mean age 16 y.) the second one is composed of 9 asymptomatic
subjects (6F, mean age 25y.) with normal intestinal mucosa. We measured the anti-idiotypic
(anti-anti-tTG) antibodies by an ELISA assay using our highly purified human anti-tTG
mini-body as target for the specific anti-idiotypic antibodies. The anti-tTG antibodies were
measured by ELISA assay using the human-recombinant transglutaminase as antigen. The
present study was approved by the independent ethical committee of our hospital. Results:
We found the IgA anti-idiotypic (anti-anti-tTG) antibodies in both the intestinal mucosa
and in sera samples of the 21 subjects. The ratio values between anti-anti-tTG antibodies
and anti-tTG in both serum and acid-eluted intestinal samples were significantly higher in
the 9 asymptomatic subjects than in 12 CD patients (mean ratio values in the sera: 13.78
for the asymptomatic subjects vs. 2.42 for CD patients; p<0.001; mean ratio values in eluted
samples: 7.29 vs. 0.522; p<0.001). Conclusions. In the contest of genetic predisposition to
gluten intolerance we measured the tTG-related idyotipic-anti-idyotipic network in the serum
samples and in the intestinal mucosa. Differences in the ratio values of anti-anti-tTG (anti-
idiotype) antibodies and of anti-tTG (idiotype) among the two study groups could represent
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an immune mechanism for suppression of the overt CD. High ratios of anti-idiotype to
idiotype could predict a lower risk for the development of CD.
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Live Cell Imaging of α2-Gliadin 33mer Transcytosis in Caco2 Cells
Michael Schumann, Jan F. Richter, Martin Zeitz, Michael Fromm, Joerg-dieter Schulzke
Introduction: Mechanisms of epithelial translocation of gliadin as the first step in antigen
presentation in celiac disease (CD) are poorly understood. Recent evidence points to a role
for epithelial transcytosis of gliadin peptides in this process. The α2-gliadin peptide p56-
89 (33mer) includes several epitopes that are recognized by CD-specific T cells and is
therefore a pivotal trigger of the adaptive immunologic response to CD. Aims: Analysis of
the transepithelial translocation of a 33 amino-acid α2-gliadin-peptide. Methods: The 33
amino acid α2-gliadin peptide was synthesized and tagged with the fluorescent dye Cy3.
Transcytosis of Cy3-33mer was analyzed in basal compartments of Caco2 cells growing on
PCF filters using RP-HPLC. FACS analysis of Caco2 cells was done using a FACSCalibur
flow cytometer. Caco2 cells were transfected with rab-pEGFPN1 constructs. Transfected
cells were analyzed by live cell imaging with confocal laser scanning microscopy. Results:
Inhibitors of endocytosis caused a 4-fold reduction of transepithelial translocation of the
33mer (methyl-β-cyclo dextrine 23±5%, nystatine 26%±6% relative to untreated control
cells). FACS analysis revealed that 33mer uptake was temperature-sensitive (2.9% 33mer-
positive Caco2 cells at 37°C versus 0.2% at 4°C). Imaging studies using confocal microscopy
showed colocalization of the Cy3-33mer and FITC-Dextran (a marker of fluid-phase endo-
cytosis) 30 min after apical addition of both to the cells. Furthermore, colocalisation was
seen with the 33mer and rab5GFP, but not with rab4- and rab7-GFP. Live cell imaging of
rab-transfected Caco2 cells allowed for real time analysis of the 33mer uptake by intestinal
epithelial cells. Conclusion: Transcytosis is identified as a mechanism for transepithelial α2-
gliadin-33mer translocation. Rab5, but not rab4 and rab7, is involved in this transcytosis
mechanism and possibly accounts for intracellular processing of the gliadin peptide.
764
Lower GI Clinical Events in a Double-Blind Randomized Comparison of a
COX-2 Selective Inhibitor (Etoricoxib) and a Traditional NSAID (Diclofenac)
in 34,701 Arthritis Patients
Loren A. Laine, Sean P. Curtis, Michael Langman, Dennis M. Jensen, Byron L. Cryer,
Haiyuan Zhu, Christopher P. Cannon
COX-2 selective inhibitors have lower rates of upper GI clinical events than traditional
NSAIDs, but no randomized trial has provided a pre-specified assessment of lower GI (LGI)
clinical events. METHODS: Patients ≥ 50 yrs with rheumatoid arthritis or osteoarthritis
were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd). Low-
dose aspirin was encouraged for patients with CV disease or diabetes. LGI was defined as
jejunum, ileum, or colon. Criteria for the predefined primary endpoint of LGI clinical events
(confirmed by a blinded adjudication committee) were perforation or obstruction requiring
hospitalization, or bleeding (gross or occult rectal bleeding without upper GI cause associated
with hypotension, orthostatic changes in HR (>20 bpm) or BP (>20 mm Hg systolic or >10
mm Hg diastolic), Hgb drop ≥ 2 g/dl, or transfusion; or observed intestinal active bleeding
or stigmata of hemorrhage). Hospitalizations for diverticulitis or LGI ulcer (adjudicated by
predefined criteria) and assessment of all investigator-reported LGI events were also pre-
specified exploratory endpoints. RESULTS: Baseline characteristics for etoricoxib vs. diclo-
fenac included age ≥ 65 yrs (41.5 vs. 41.4%), women (74.2 vs. 74.2%), prior LGI event
(2.4 vs. 2.3%), low-dose aspirin use (34.6 vs. 34.6%), steroid use (15.8 vs. 16.0%), and
PPI use (38.7 vs. 38.5%). Mean treatment duration was 18 mos. LGI events are shown in
Tables 1 and 2. Analysis of treatment-by-subgroup interaction revealed no significant differ-
ence in treatment effect related to age; steroid use; history of UGI event, LGI event, or colon
neoplasm; smoking; or concomitant aspirin or PPI use. CONCLUSIONS: A statistically
significant decrease in patients with confirmed LGI events was not seen with the COX-2
selective inhibitor etoricoxib vs. the traditional NSAID diclofenac in this large outcomes trial.
Table 1. Numbers of Patients with LGI Clinical Events and Rates per 100 Patient-Years
Table 2. Types of Confirmed LGI Clinical Events: Numbers of Patients and Rates per
100 Patient-Years
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Balancing Cardiovascular and GI Outcomes with Antiplatelet Therapy: A Cost-
Effectiveness Analysis of Competing Strategies
Martijn Van oijen, Robert J. Laheij, Laura E. Targownik, Jan B. Jansen, Verheugt W. Freek,
Brennan M. Spiegel
Background: The use of aspirin (ASA) and clopidogrel (Clop) has increased in response to
recent guidelines recommending low thresholds to start antiplatelet therapy in patients with
cardiovascular (CV) risk factors. Although these agents decrease the risk of CV disease, they
also increase the risk of GI complications. Proton pump inhibitors (PPI) reduce GI risk in
patients on antiplatelet therapy, but the cost-effectiveness of PPI co-therapy remains uncer-
tain. Therefore, we sought to appraise the cost-effectiveness of common CV prevention
strategies using combinations of ASA, Clop, and PPIs. Methods: We used decision analysis
with Markov modelling to calculate the cost-utility of 6 strategies for primary CV prevention
in a cohort of 60 y.o. patients with a 5-year myocardial infarction risk >3%: (1) low dose
ASA alone; (2) ASA+PPI; (3) Clop alone; (4) Clop+PPI; (5) ASA+Clop; and (6) ASA+Clop+PPI.
In the ASA and Clop strategies, PPIs were added if the patient developed dyspepsia or ulcer
complications. We derived 120 probability estimates for the model through systematic
literature review, and varied each estimate in sensitivity analysis. We adopted a third party
payer's perspective, and included cost estimates for a comprehensive list of related resources
(e.g. medications, physician visits, labs, hospitalizations, and procedures) as determined by
Medicare and the Red Book. The primary outcome was the incremental discounted cost per
quality adjusted life year (QALY) gained. Results: Of the 6 competing strategies, ASA alone
was least effective yet least expensive, and ASA+Clop+PPI was most effective yet most
expensive. When balancing cost and effectiveness, the ASA+PPI, ASA+Clop and Clop+PPI
strategies were dominated, leaving 3 viable options: ASA alone, Clop alone, and
ASA+Clop+PPI. Compared to ASA alone, Clop cost an incremental $125,700/QALY-gained.
Compared to Clop, ASA+Clop+PPI cost an incremental $181,290/QALY-gained. The
ASA+PPI strategy joined the cost-effectiveness frontier (i.e. became “viable”) when the cost
of PPI fell from $3.50 to $2.30 per tab, when PPI co-therapy increased ASA compliance by
10% over ASA alone, and when the risk reduction in GI complications afforded by PPIs
rose from 50% to 80% in ASA users. Conclusions: Low-dose ASA alone appears to optimize
the health economic balance between CV and GI outcomes. Using combination antiplatelets
or PPI co-therapy provides “diminishing returns” over ASA alone. However, ASA+PPI may
be cost-effective if PPI co-therapy is shown to increase compliance with ASA therapy (untested
to date), and in settings where PPIs can be purchased at a discount. (this study is unfunded)
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Sequential Therapy Versus Triple Therapy for Helicobacter pylori Eradication:
A Randomized-Controlled Trial
Dino Vaira, Angelo Zullo, Nimish Vakil, Luigi Gatta, Chiara Ricci, Federico Perna, Cesare
Hassan, Andrea Tampieri, Sergio Morini
Background: Antimicrobial resistance has decreased eradication rates for H. pylori worldwide.
To assess if a sequential treatment regimen eradicates H. pylori better than standard triple
drug therapy in adults with dyspepsia or peptic ulcer disease. Methods: Placebo-controlled
trial. Two Italian Hospitals between September 2003 and April 2006. 300 patients with
dyspepsia or peptic ulcer were studied. A 13C urea breath test, upper endoscopy, histology,
rapid urease test, bacterial culture, and antibiotic resistance assessment were performed at
baseline. Patients were classified as being infected with H. pylori if the UBT was positive
and if at least two of the following 3 tests were positive: rapid urease test, histology and
culture. Patients were randomized to a 10-day sequential regimen (pantoprazole 40 mg,
amoxicillin 1 g plus placebo for the first 5 days, followed by pantoprazole 40 mg, clarithromy-
cin 500 mg and tinidazole 500 mg for the remaining 5 days) in 150 patients or standard
10-day therapy (pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g) in 150
patients. All drugs were given twice daily. The UBT was repeated 4 and 8 weeks after
stopping the treatment. A patient was considered to have successful eradication when both
UBTs were negative. Results: There were 295 patients (Modified Intent to treat) of whom
91% (95% CI: 86.5-95.7) had successful eradication with sequential therapy compared to
78% (95% CI: 71.2-84.5) for standard therapy (difference: 13.3%; 95% CI: 5.1 to 21.4;
P = 0.0022). Clarithromycin resistance was found in 32 patients (12.5%). The sequential
therapy was significantly more effective in patients with clarithromycin resistant strains
(88.9% patients vs. 28.6%; P = 0.0034). The incidence of major and minor side effects did
not differ between therapy groups. Compliance with medication (>90% of medication taken)
was 94% in the sequential therapy group and 93% in the standard therapy group. Side-
effects led to the drop out of one patient in the sequential treatment group. Conclusions:
Sequential therapy is superior to conventional therapy for the eradication of H. pylori and
it is significantly more effective in patients harbouring clarithromycin resistant strains. The
incidence of side effects did not differ between therapy groups.
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Is Helicobacter pylori a Cause of Iron Deficiency Anemia and Treatment
Failure of Iron Supplementation in Children?
Shafiqul A. Sarker, George J. Fuchs, Hasan Mahmud, Nur H. Alam, Shamima Sultana,
Shamima Sattar, Tahmeed Ahmed, Mohammed A. Salam, Christoph Beglinger, Niklaus
Gyr
Background: Several studies have reported an association between H. pylori infection and
iron deficiency anemia (IDA), and labeled the infection as a cause of refractory IDA. Aim:
To investigate the role of H. pylori infection as a cause of IDA and/or treatment failure of iron
supplementation in children with IDA. Methods:The study was a prospective, randomized,
double-blind, placebo-controlled community-based trial and was conducted among four
groups (50 each) of children, aged 2-5 years with H. pylori infection (positive urea breath
test), and IDA(hemoglobin,Hb<110 g/l; serum ferritn, SF<12 µg/l; and soluble transferrin
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receptor,sTfR >8.3 mg/l). Group A received a 2-week course of anti-H. pylori(anti-Hp)therapy-
(Amoxicillin, clarithromycin, and omeprazole) plus a 90-day course of oral ferrous sulfate(-
anti-Hp plus iron); group B received a 2-week anti-Hp therapy plus placebo for iron for 90
days (anti-Hp therapy alone); group C received a 2-week course of placebo for anti-Hp
therapy plus iron for 90 days (iron alone); and group D received a 2-week course of placebo
for anti-Hp therapy and a 90-day course of placebo for iron (positive control). A fifth group
(n=60) with IDA but without H. pylori infection (group E) was treated with iron as negative
control. Hb, SF, and sTfR were repeated ar day 90. Children showing still IDA at day 90
were given a 3 month course of iron therapy. Results: Compared to the baseline, iron status
of most children improved at day 90 regardless of interventions. However, the change from
base line to day 90 was significantly higher among groups receiving either anti-Hp therapy
plus iron or iron alone in comparison with the group receiving placebo or anti-Hp therapy
alone. At day 90, IDA was corrected in significantly greater proportions of children receiving
anti-Hp therapy plus iron (68%) or iron alone (75%) compared to the other two groups
with anti-Hp therapy alone (36%) or placebo (25%); The results suggest no benefit from
anti-Hp therapy in correction of IDA. As regards to ID(Hb <110g/l and SF <12 µg/l or sTfR
>8.4 mg/l), iron therapy had the most pronounced effect; ID was corrected in 100% of
children receiving either anti-Hp therapy plus iron or iron alone as well as H. pylori negative
control children, compared to only 50% of children in the anti-Hp therapy alone or placebo
groups, suggesting again crucial role of iron but not of anti-Hp therapy in correcting iron
deficiency. Conclusions: The results of our study neither support a causal relationship
between H. pylori and IDA nor failure of iron supplementation in correcting iron deficiency
anemia in children.
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Obesity: A Risk Factor for Diverticulitis and Diverticular Bleeding
Lisa L. Strate, Yan L. Liu, Sapna Syngal, Edward L. Giovannucci
BACKGROUND AND AIM: Prior studies suggest that obesity may be a risk factor for
diverticulitis. The aim of this study was to examine prospectively the impact of body
mass index, waist circumference and waist-to-hip ratio on the development of complicated
diverticular disease. METHODS: Subjects included 47,454 US males in the Health Profes-
sionals Follow-up Study cohort who were aged 40-75 years and free of diverticular disease,
gastrointestinal cancer and inflammatory bowel disease at baseline in 1986. Men reporting
a new diagnosis of diverticulosis or its complications on biennial follow-up questionnaires
were sent supplemental questionnaires outlining details of diagnosis and treatment. Weight
and height were recorded every 2 years, and waist and hip circumference were collected in
1987. Study endpoints included diverticulitis and diverticular bleeding. For the analysis,
body mass index was divided into 6 categories, and waist circumference and waist-to-hip
ratio into 5 categories. Cox proportional hazards regression was used to adjust for age, study
year, dietary fat, fiber, and red meat, physical activity, and nonsteroidal anti-inflammatory
and acetaminophen use. RESULTS: We documented 865 incident cases of diverticulitis, and
445 incident cases of diverticular bleeding during 732,111 person-years of follow-up. In
the adjusted model, men with a body mass index of ≥30 kg/m2 had a hazard ratio of 1.76
(95% CI: 1.10, 2.84; P for trend =0.004) for diverticulitis, and 3.0 (1.50, 6.03; P for trend
<0.0001) for bleeding when compared with men with a body mass index of <21 kg/m2.
Men with a waist circumference of ≥40.25 inches had an adjusted hazard ratio of 1.50
(1.15, 1.96; P for trend 0.007) for diverticulitis, and 1.62 (1.10, 2.37; P for trend 0.004)
for bleeding when compared to men with a waist circumference of ≤34.25 inches. Waist-
to-hip ratio was also an independent predictor of diverticular complications: hazard ratio
1.63 (1.25, 2.13; P for trend 0.0002) for diverticulitis, and hazard ratio 1.94 (1.30, 2.88;
P for trend 0.001) for bleeding when comparing men with a waist-to-hip ratio of ≥0.98 to
men with a waist-to-hip ratio of ≤0.89. The effect of waist- to-hip ratio on diverticulitis
and bleeding appeared to be independent of body mass index. CONCLUSION: In this large
prospective study, body mass index and measures of central adiposity were associated with
an increased risk of both diverticulitis and diverticular bleeding.
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Can Patients with Diverticular Disease Eat Nuts, Corn and Popcorn?
Lisa L. Strate, Yan L. Liu, Sapna Syngal, Edward L. Giovannucci
BACKGROUND AND AIM: Patients with diverticular disease are frequently advised to avoid
nuts and seeds; however, there is no evidence to support this recommendation. The aim of
this study was to evaluate prospectively whether nut, corn and popcorn consumption are
associated with complications of diverticular disease. METHODS: Subjects included 47,454
US males in the Health Professionals Follow-up Study cohort who were aged 40-75 years
at baseline and free of diverticular disease, gastrointestinal cancer and inflammatory bowel
disease in 1986. Men reporting newly diagnosed diverticulosis or diverticular complications
on biennial follow-up questionnaires were sent supplemental questionnaires outlining details
of diagnosis and treatment. Recent nut, corn and popcorn consumption were ascertained
from a validated 131-item semiquantitative food frequency questionnaire mailed to all
participants every 4 years. Study endpoints included diverticular bleeding, symptomatic
uncomplicated diverticular disease and diverticulitis. Cox proportional hazards regression
was used to adjust for age, study year, body mass index, dietary fat, fiber, and red meat,
physical activity, and nonsteroidal anti-inflammatory and acetaminophen use. RESULTS:
During 18 years of follow-up (732,111 person-years), 445 incident cases of diverticular
bleeding, 651 incident cases of symptomatic uncomplicated diverticular disease, and 865
incident cases of diverticulitis were identified. For diverticular bleeding and symptomatic
uncomplicated diverticulosis, no multivariable associations were observed for consumption
of nuts, corn, popcorn, or combined consumption of the three. For diverticulitis, no associ-
ations were found for nut, corn, or combined nut, corn and popcorn consumption. However,
popcorn consumption alone appeared to be protective. After adjustment for other known
or potential risk factors for diverticular complications, men with the highest popcorn intake
(at least 2 times per week) had a hazards ratio of 0.71 (95% CI 0.56-0.90; P for trend
0.18) when compared to men with the lowest popcorn intake (less than once per month).
CONCLUSION: Data from this large, prospective cohort indicate that nut and corn consump-
tion do not increase the risk of diverticular complications. In fact, frequent popcorn consump-
tion was associated with a reduced risk of diverticulitis.
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Should We Test for Helicobacter pylori At the Time of Hospital Admission for
Patients with Upper Gastrointestinal Hemorrhage; A Cost-Minimization
Analysis
Ashish Atreja, Madhusudhan R. Sanaka, Alex Z. Fu, John J. Vargo
Background:An estimated 150 000 patients are hospitalized annually for peptic ulcer hemor-
rhage in USA and about two-thirds of these are associated with Helicobacter pylori (HP)
infection. National guidelines recommend routine screening for HP with CLO test or histology
in patients with peptic ulcer hemorrhage. However, compliance with HP screening remains
suboptimal. Furthermore, the sensitivity of CLO test and histology is reduced in the presence
of bleeding and antisecretory therapy. We hypothesized that screening with HP serology at
the time of hospital admission followed by endoscopy may lead to increased screening and
treatment of HP along with cost-savings compared to traditional approach. Methods: Decision
analysis was used to estimate the cost of “initial HP testing” arm (testing with serology
followed by endoscopy) versus traditional “initial endoscopy” arm (endoscopy followed by
CLO test) as shown in Figure.Clinical and costs estimates were derived from a systematic
review of the medical literature and sensitivity analyses were performed for important
variables. The principal outcome measured was cost savings per patient treated from third-
party payer perspective over the 2-year time course. Results: In the base case (50% likelihood
of peptic ulcer disease, 70% of ulcers due to recurrent hemorrhage, 100% compliance with
post endoscopy HP testing in traditional arm, 6% per year recurrent hemorrhage if HP not
eradicated, $10,000 cost of hospitalization visit), a strategy of initial serology followed by
endoscopy resulted in $130 savings per patient in two years. If compliance to HP testing
was reduced to 75% in “initial endoscopy” arm, the cost savings increased to $950 per
patient over the two years. The cost of increased serology testing was offset by the cost of
recurrent hemorrhages due to untreated HP in the “initial endoscopy” arm. Conclusion:
Initial testing with HP serology followed by endoscopy could prove to be a preferred strategy
for peptic ulcer bleeding especially in institutions where compliance to post endoscopy HP
testing is suboptimal.
Outline of decision tree comparing “initial endoscopy” arm with “initial HP testing” arm.
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Urea Breath Testing in Pediatrics: The Multicenter Usa Study
Yoram Elitsur, Vasundhara Tolia, Mark Gilger, Jesse Reeves-garcia, Eberhard Schmidt-
sommerfeld, Antone R. Opekun, Hala El-zimaity, David Graham, Kyoko Tsuchiya
Background: Urea breath testing (UBT) is widely used in adults for the diagnosis and
management of H. pylori infections. Its accuracy in children in the USA has remained unclear.
Aim: To evaluate the 13C-UBT in children with suspected H. pylori infection. Methods:
Children scheduled to undergo UGI endoscopy were invited to participate. Each underwent
a UBT using the US standard protocol for adults (BreathTek™ UBT) containing 75 mg 13C-
urea and 2 g of citric acid with breath sampling before and 15 min after urea ingestion. At
EGD, gastric biopsies were taken for RUT, culture and histology. H. pylori positivity was
defined as positive culture and/or positive RUT and histology. H. pylori negativity was defined
as all tests negative. Results were evaluated by delta over baseline (DOB) and urea hydrolysis
rate (UHR) which takes into account the low CO2 production by young children. Results:
205 children from 5 centers were entered including 22 in the age range 2-5, 100 between
6 and 12 and 83 between 13 and 17 including White, 146 (71%) White Hispanic, 43 (22),
Black 47 (23%), Asian 6 (3%) and other 3 (1%). There were 176 evaluate patients who
completed the endoscopy and had the appropriate samples taken. Compared to the defined
gold standard, the results with the UBT based on DOB cut-off value (pos ≥2.4‰) were 52
children were H. pylori positive and 124 H. pylori negative 47 children were H. pylori positive
with a sensitivity and specificity of 97.9% and 96.1%, respectively. Base on the UHR cut-
off value (pos≥10.0 mcg/min) 129 were H. pylori negative and 52 positive with a sensitivity
and specificity of 95.8% and 99.2%. In the age group 2-5 where the UHR has a theoretical
advantage over the DOB, the sensitivity and specificity using the DOB cut-off were 100%
and 92.9%, respectively vs. 100% and 100% using the UHR method. Conclusions: The US
standard 13C-UBT proved to be both simple and accurate for the diagnosis of H. pylori
infections in children. The UHR method to calculate of 13C-UBT result using a cut-off value
(pos = UHR ≥10.0 mcg/min) provided excellent results and is especially recommended to
confirm H. pylori infection status in small children.
A-111 AGA Abstracts
772
Sensitivity, Specificity and Predictive Values for Urea Breath and Stool Antigen
Tests for Helicobacter pylori (HP) in Children
John D. Snyder, Steven J. Czinn, Benjamin D. Gold, Yunn-yi Chen, Jeannette Guarner
Background. Validated and accurate non-invasive tests have long been sought to diagnose
Hp infection in children, especially for use as “tests for cure”. The urea breath (UBT) and
stool antigen (SAT) tests are the most promising to date but have not yet been evaluated
in tandem in large populations of U.S. children. This multi-center study was undertaken to
assess the sensitivity, specificity and predictive values of these tests in a pediatric population.
Methods. We enrolled children with abdominal discomfort who required diagnostic endos-
copy (EGD) and biopsy for evaluation. Hp infection was diagnosed by a GI pathologist
using the histologic criteria of the updated Sydney System and by a rapid diagnostic urease
test. The breath samples were collected and analyzed using the BreathTek system, including
gas isotope ratio mass spectrometry (Meretek Diagnostics, Lafayette, CO). Stool antigen
analysis was performed using the Premier-Platinum HpSA ELISA method (Meridian Diagnost-
ics, Cincinnati, OH). Results. 63 children have been evaluated over 2.5 years in this ongoing
study. The mean age of the patients was 12.9 + 3.7 years; 60% were female and 71% were
caucasian. Hp was identified in 5 patients (8%). All children enrolled succesfully completed
the urea breath test; 13 patients and their families were unable to provide a stool sample.
The senstiviity, specificity and predictive values of these 2 non-invasive tests are included
in the Table: Conclusions. Our preliminary results indicate that these two non-invasive tests
have promise but are limited by false positive (UBT) or false negative (SAT) results in
diagnosing H pylori infection in children. However, further refinements in these diagnostic
assays may improve their utility in pediatric populations. At present, our data support
previous North American guidelines recommending the use of histology as the gold standard
for diagnosis of Hp infection in children.
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Reinfection After Successful Eradication of Helicobacter pylori in Three
Different Populations in Alaska
Michael Bruce, Brian J. Mcmahon, Thomas Hennessy, Alisa Reasonover, Julie Morris,
Dana Bruden, Frank Sacco, Debby Hurlburt, Helen Peters, Jim Gove, Jim Williams, Alan
Parkinson
Introduction: H. pylori infection is common (75% antibody positive) among Alaska Native
persons, is a major cause of peptic ulcer disease, and may be associated with gastric cancer.
Scant information is available on the rates of reinfection after cure of H. pylori infection.
The goal of this study was to determine rates of reinfection in 3 groups: urban Alaska Native
persons (Group1), rural Alaska Native persons (Group2), and urban Alaska non-Native
persons (Group3) followed for two years. Methods: We enrolled adults diagnosed with H.
pylori infection based on a positive urea breath test (UBT) and/or one or more of the
following: culture, CLO test or histology. After successful treatment was documented at 2
months, we tested each patient by UBT at 4, 6, 12 and 24 months. At each visit, participants
were asked about medication use, illnesses and risk factors for reinfection. Results: 229
persons were followed for 2 years. The median age of participants at enrollment was 51
years; 55% were female. H. pylori reinfection occurred in 34 persons. Among Groups 1, 2
and 3, the cumulative reinfection rates at 2 years were 14.5%, 20.4%, & 12.0%, respectively.
Reinfection rates at each time point are shown in the Table. 282 household members
participated in the study; The percentage of H. pylori-positive household members differed
by group: Group 1: 46% (48/105), Group 2: 81% (91/112) and Group 3: 23% (15/65), p
< 0.0001. Overall, 45 of 58 (78%) household members of reinfected patients were positive
for H pylori by UBT compared to 109 of 224 (49%) of household members of persons not
reinfected (p=0.08). Among Group 2, 39 of 43 (91%) household members of reinfected
persons were H. pylori-positive compared to 52 of 69 (75%) of household members of
persons not reinfected (p=0.049). Conclusions: Among all 3 groups, reinfection after success-
ful treatment for H. pylori occurred at rates higher (15.6%) than those reported for other
US populations (< 5% at 2 years); rural Alaska Native persons appear to be at highest risk
for reinfection. Reinfected persons were more likely to reside in households with a higher
proportion of H. pylori-infected individuals than persons not found to be reinfected.
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Comparison of Different Second-Line Levofloxacin-Based Triple Schemes for
Helicobacter pylori Eradication
Simona Di caro, Dario Raimondo, Alberto Mariani, Enzo Masci, Pier A. Testoni, Ennio La
rocca
BACKGROUNG: The recommended second-line therapy for Helicobacter pylori (H. pylori)
eradication is the quadruple regimen that fails in up to 30% of patients (pts). Poor compliance
and antibiotic resistance are the main causes of treatment failure. Several recent studies
suggest levofloxacin-based triple therapy as an alternative rescue treatment to quadruple
scheme. However, a standard treatment (dosage and length) of levofloxacin-based regimens
have not been established. AIMS: To compare the efficacy and tolerability of 4 dosage and
duration different second-line levofloxacin-based schemes for eradication ofH. pylori infection
in the same population. METHODS: 160 consecutive patients (18-70 years aged, 72 males)
who failed H. pylori eradication with triple standard first-line therapies were randomized to
receive: esomeprazole 20 mg b.d., levofloxacin 500 mg o.d., amoxicillin 1 g b.d. for 7 days
or 10 days (GROUP A and GROUP B); esomeprazole 20 mg b.d., levofloxacin 500 mg b.d.,
amoxicillin 1 g b.d. for 7 days or 10 days (GROUP C and GROUP D). H. pylori status was
determined by 13-C Urea Breath Test (13C-UBT) or histology during endoscopy before
treatment and by 13C-UBT at least 6 weeks after end of therapy. Incidence of side effects
and compliance were also evaluated by a questionnaire. RESULTS: No dropouts were
observed. Eradication rates were: A: 26 pts (65%); B: 36 pts (90%); (A vs B; p<0.007); C:
28 pts (70%); D: 34 pts (85%); (C vs D; p > 0.05). In particular: A + C (7 days of treatment):
54 pts (67.5%) vs B + D (10 days of treatment): 70 pts (87.5%) (p<0.002). Mild side effects
were reported in 16% of pts (A: 6 pts; B: 8 pts; C: 12 pts; D: 14 pts). No severe adverse
events were observed. CONCLUSIONS: 10 days levofloxacin-based second-line regimens
are effective in curing the infection in more than 85% of pts (GROUP B and D) with a
lower but not statistically significant incidence of mild adverse effects in levofloxacin single-
dosage scheme (GROUP B). Eradication rates were similar between GROUP A and GROUP
C (levofloxacin 500 mg b.d. for 7 and 10 days). Duration of treatment appears to be the
crucial factor influencing eradication rate. Levofloxacin-based second-line triple scheme for
10 days can be proposed as a valid alternative to quadruple scheme.
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Effectiveness of a 10-Days Sequential Treatment for Helicobacter pylori
Eradication in Clinical Practice
Jordi Sánchez delgado, Luis Bujanda, Javier p. Gisbert, Llucia Titó, Xavier Calvet, Manuel
Castro
Introduction: Cure rates of Helicobacter pylori infection with standard triple therapy are
disappointingly low, often below 80%. A promising novel sequential treatment schedule
including five days of dual therapy followed by 5 days of triple therapy regimen has recently
been described. Cure rates of sequential therapy were significantly better than those of triple
therapy in a large randomized trial. All studies referring to sequential therapy published to
date were, however, performed in Italy. It is therefore mandatory to confirm these results
in other countries as well as to analyze sequential therapy effectiveness under routine clinical
practice conditions. Objective: 1) to assess the cure rate of a new sequential treatment
regimen in our area through a pilot study under clinical practice conditions and, 2) to
evaluate the tolerance to this therapeutic regime. Material and methods: 139 patients from
6 different centres were included in a pilot observational study in clinical practice situation.
H. pylori status was assessed by histology, urease test or urea breath test. The regime consists
of a 10-day treatment including a proton pump inhibitor (PPI) b.d. plus amoxicillin 1 g
b.d. for the first 5 days, and PPI b.d. clarithromycin 500 mg b.d. and metronidazol 500
mg b.d for the further 5 days. Eradication was determined at least 8 weeks after the end
of treatment by urea breath test or histology. Overall eradication rates of the treatment and
confidence intervals were obtained both per protocol and by intention-to-treat. Results: A
total of 139 patients with H. pylori infection were enrolled. Mean age was 49.6±15.7 years.
Sixty percent were men. Indications for eradication were uninvestigated dyspepsia (9.4%);
functional dyspepsia (24.5%); gastric ulcer (19.4 %) and duodenal ulcer (46.7%). H. pylori
infection at entry was determined by histology (45.3%), rapid urease test (37.4%) or urea
breath test (38.8%). Many patients had more than one diagnostic test. Eradication was
achieved in 117 out of 129 patients who returned for a follow-up test. Therefore, the
intention-to-treat eradication rate was 84.2% (95% CI, 76.8-89.6) and the per-protocol cure
rate 90.7% (95% CI, 83.9-94.8). The treatment was well tolerated and no major side effects
were reported. Only 14 patients complained of mild side effects (the most frequent being
metallic taste and diarrhoea). Conclusions: Sequential treatment seems highly effective to
eradicate Helicobacter pylori. The results of this pilot study substantiate the further realization
of a comparative study.
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Differences in Protein Expression Between Diabetic Nod Mice with and
Without Delayed Gastric Emptying
Kyoung M. Choi, Simon J. Gibbons, Dong ki Yang, Gary J. Stoltz, Alan R. Zinsmeister,
Joseph H. Szurszewski, Gianrico Farrugia
Background: Gastroparesis (defined as delayed gastric emptying [GE]) is a well recognized
complication of diabetes. Loss of interstitial cells of Cajal (ICC) and of nNOS expression
has been previously shown in diabetic gastroparesis. Changes in heme oxygenase-1 (HO-
1) expression and an increase in oxidative stress are also reported in diabetes. The temporal
association between changes in expression levels of these proteins and of oxidative stress
and the development of delayed GE is not known. Aims: Compare the expression of HO-
1, nNOS and c-Kit and the level of oxidative stress between diabetic NOD mice with and
without delayed gastric emptying and correlate the changes with GE. Methods: Group 1
mice (n=9) were non-diabetic, age matched controls for the other groups. Group 2 mice
(n=6) were diabetic (glucose > 250 mg/dl) for 10 weeks with normal GE. Group 3 mice
(n=6) were diabetic with delayed GE. GE was determined weekly using a [13C]-octanoic
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acid breath test. The expression of HO-1, nNOS and c-Kit was determined by immunoblots
on protein isolated from the muscle of the gastric body. Oxidative stress was determined
by measurement of serum malondialdehyde. Diabetic mice were insulin treated to keep
glucose between 400-500 mg/dl. Delayed GE was defined as T1/2 >130 min. Results: Median
(quartiles) blood glucose levels were 457 mg/dl (438-476) in Group 2 and 475 mg/dl (437-
531) in Group 3 (P>0.05). GE (mean T1/2 ±SEM) was 95±1, 98±5 and 98±4 min in Groups
1, 2, and 3 (before diabetes) respectively. After onset of diabetes, T1/2, measured during the
last week of the study, was 110±2 min in group 2 and 152±8 min in Group 3. Relative
HO-1 expression was increased in group 2 (median;quartiles: 2.05;1.98,2.18) compared to
Group 1 controls (0.56;0.44,0.63, P < 0.05) but was unchanged in Group 3 (0.54; 0.51,
0.57 vs 0.62; 0.48, 0.84, P> 0.05). Relative nNOS expression was decreased in both Groups
2 and 3 compared to Group 1 controls (0.4; 0.28, 0.43 and 0.26; 0.22, 0.31 vs 1.1; 1.06,
1.17 and 0.91; 0.75, 1.16, P<0.05). Relative c-Kit expression was unchanged in Group 2
(0.99; 0.92, 1.0 vs 1.17; 1.06, 1.22, P>0.05) and was decreased in Group 3 (0.24; 0.18,
0.27 vs 0.94; 0.85, 0.97, P<0.05). Mean (±SEM) serum malondialdehyde levels were increased
in Group 2 (51±4 nmol/ml vs 18±1 nmol/ml in Group 1, P<0.01) and markedly increased
in Group 3 (290±43 nmol/ml, P<0.005). Conclusion: Development of delayed GE appears
to be due to loss of ICC, loss of upregulation of HO-1 and increased oxidative stress rather
than changes in expression of nNOS. Supported by NIH grants DK68055 and DK57061.
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Preliminary Results of Multipoint Gastric Electrical Pacing for the Treatment
of Patients with Diabetic Gastroparesis
Richard Mccallum, Zhiyue Lin, Irene Sarosiek, Jameson Forster, Jiande Chen, Robert A.
Ross
The aim of this study was to determine how effective and safe multipoint gastric electrical
pacing is in the treatment of patients with diabetic gastroparesis. Methods: Three patients
(2F, 1M, mean age: 44 years, range: 35-58) with severe diabetic gastroparesis and delayed
gastric emptying were enrolled in this protocol thus far. Mean years of diabetes were 13
and mean years of gastroparesis were 4. During laparotomy for implantation of Enterra
device 4 pairs of temporary pacing wires were inserted on the serosa of the stomach along
the greater curvature with an inter-electrode distance of 1 cm. The most distal pair of
electrodes was 3-4 cm above the pylorus and the most proximal 15 -16 cm. The interval
between two pairs of electrodes was 4 cm. Electrodes at 15 to 16 cm and 7 to 8 cm proximal
to the pylorus were for stimulation and those at 3 to 4 cm and 11 to 12 cm for recording
the signals. After validation of pacing wires from 4 channel-serosal recordings, optimizing
pacing parameters for entrainment of gastric slow waves in each patient was achieved within
3 to 5 days after surgery. Two-channel gastric electrical stimulation (GES) was initiated for
1.5 months using an external multi-channel gastric pacemaker. Four-hour gastric emptying
time (GET), serosal electrical recordings and electrogastrogram (EGG), 7 upper GI symptoms
and a mean total symptom score (TSS) were assessed at baseline and after 1.5 months of
two-channel GES. Results: Tachygastria of 4.5 cpm was observed in one patient during
baseline serosal recordings. Two-channel Pacing at 1.1 times the intrinsic frequency (pulse
width of 10 to 200 ms and amplitude of 0.5 to 2 mA) entrained gastric slow waves and
normalized gastric dysrhythmia. Gastric empting improved in all 3 patients and 2 normalized
after 1.5 months. Mean 4-hour gastric retention decreased from 28% at baseline to 7%
(normal value <10% retention at 4 hours). All 3 patients had >50% symptom reduction
after GES. Mean TSS severity was reduced from 22 at baseline to 7 (maximum score: 28).
The mean postprandial EGG power (amplitude) was substantially increased from -1.4 to
2.5 dB. Mean HbA1c level (9.1 vs. 9.1%) and patients' mean weight were stable (155 lbs
vs. 143 lbs) during the study. Conclusions: Multipoint (two channels) and synchronized
gastric electrical pacing can be achieved in patients with diabetic gastroparesis and is able
to normalize and enhance gastric slow wave activity, accelerate gastric emptying and improve
upper-GI symptoms. This new approach advances electrical stimulation therapy for gastropar-
esis beyond the outcomes provided by the Enterra device currently available.
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Soy Germ-Enriched Pasta Containing Isoflavones Ameliorates Gastric
Emptying Time in Diabetic Patients
Carlo Clerici, Elisabetta Nardi, Danilo Castellani, Stefania Asciutti, Elisabetta Antonelli,
Gabriele Periello, Emanuela Floridi, Nadia Corazzi, Alessia Gherardi, Vittorio Giuliano,
Monia Baldoni, Olivia Morelli, Antonio Morelli, Kenneth Setchell
Background. It is well known that approximately 30% of patients with type 2 diabetes
develop delayed gastric emptying. Diabetic gastropathy is a condition of abnormal gastric
motility that may be associated with upper gastrointestinal symptoms, changes in oral drug
absorption and alterations in glycemic control. Isoflavones, a class of phytoestrogens found
in abundance in soybeans, are known to exert their biological actions by linking to estrogen
receptors, being the affinity for ER beta stronger than that for ER alpha. Both ER alpha and
ER beta receptors are localized into the enteric neurons and in the external muscolaris of
the stomach indicating a potential role of isoflavones in the control of gastric motility. Aim.
This study investigated in type 2 diabetic patients with delayed gastric emptying the influence
of isoflavones in gastric emptying rate. Methods. A double-blind, cross-over, placebo-con-
trolled study was undertaken. Ten type 2 diabetes patients (5 male and 5 postmenopausal
female) with delayed gastric emptying (t ½ > 120 min) and treated only with ADA standard
diet were enrolled in the study. History of gastrointestinal diseases or use of medication
affecting gastric emptying were considered exclusion criteria. Gastric emptying was assessed
using the [13C]octanoic acid breath test. The patients were randomized into two groups
and fed complete diets that included a daily 80g-portion of either soy germ-enriched pasta
(containing 33 mg of isoflavones) or conventional pasta for 8 weeks. Following a 4 week
wash-out period the patients were crossed-over and the other kind of pasta was administrated
for another 8 weeks. Gastric emptying time was determined before and after soy germ-
enriched pasta and conventional pasta administration. Results. In type 2 diabetes patients
with delayed gastric emptying a significant (p<0.05) reduction in gastric emptying time
(45%) was observed after soy germ-enriched pasta administration as compared to baseline
(161.2 ± 55.4 vs 112.6 ± 35.3 min). This effect was not achieved with conventional pasta
administration. Conclusion. Pasta enriched with isoflavones from soy germ improves gastric
emptying time in type 2 diabetes patients with delayed gastric emptying, therefore warranting
consideration as a potential therapeutic tool for the reduction or relieving of symptoms
associated with diabetic gastropathy.
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A Placebo-Controlled Cross-Over Study of Intrapyloric Injection of Botulinum
Toxin in Diabetic Or Postsurgical Gastroparesis
Joris Arts, Raf Bisschops, Philippe Caenepeel, Daniel Sifrim, Lieselot Holvoet, Kristin
Verbeke, Jozef Janssens, Jan F. Tack
Background: Recent open label studies suggest a potential benefit of intrapyloric injection
of botulinum toxin (botox) in the treatment of gastroparesis. A prospective randomised
study in idiopathic gastroparesis was unable to demonstrate benefit (Arts DDW 2006).
However, intrapyloric botox is most likely to be effective in patients with vagal dysfunction,
such as post-surgical or diabetic gastroparesis. Aim: To evaluate the efficacy of intrapyloric
botox in patients with gastroparesis after Nissen fundoplication or with diabetic gastroparesis.
Methods: Consecutive diabetic or post-Nissen gastroparesis patients were enrolled in a
double-blind, randomized, placebo-controlled cross-over study to assess the effects of intra-
pyloric botox 4x25U on gastric emptying rate for solids and liquids using the 14C octanoic
acid and 13C glycin breath test, and the Gastroparesis Cardinal Symptom Index (GCSI).
GCSI is the sum of severity scores (0-5) for 9 gastroparesis symptoms (nausea, regurgitation,
vomiting, fullness, early satiety, postprandial fullness, loss of appetite, bloating and bloating).
After baseline emptying and GCSI, patients underwent gastroscopy twice with intrapyloric
injection of botox or saline. One month after each endoscopy, emptying and GCSI was
repeated. Data (mean±SEM) were compared using paired Student's t test. Results: 18 patients
with diabetic (n=8) or postsurgical gastroparesis (6 men, mean age 42.3±2.7 years) particip-
ated in the study. Initial injection of botox did not significantly enhance gastric emptying
rates (solids 136±14 vs. 151±25 min; liquids 91±19 vs. 112±17 min; both NS), whereas
initial saline injection was associated with significant improvement of emptying for solids
(116±20 vs. 80±14 min, p=0.01), but not for liquids (94±16 vs. 61±8 min, NS). GCSI score
was significantly improved after initial injection of saline (31.3±2.0 vs. 22±3.6, p=0.03),
but not of botox (25.3±3.1 vs. 19.9±3.7, NS). When all data were pooled, saline injection
was associated with significantly improved gastric emptying rate (solids 133±16 vs. 96±14
min; liquids 103±12 vs. 80±15 min; both p<0.05) or GCSI (25.6±2.2 vs. 19.9±2.7, p=0.03)
compared to pre-treatment values. In contrast, pooled data for botox injection failed to
show improved gastric emptying rate (solids 113±12 vs. 142±19 min; liquids 79±12 vs.
98±11 min; both NS) or GCSI (23.8±2.3 vs. 21.3±2.5, NS) compared to pre-treatment
values. Conclusion: In this controlled randomized cross-overstudy, intra-pyloric injection
of botulinum toxin 4x25 units failed to improve gastric emptying rate or symptoms in
patients with diabetic or post-Nissen gastroparesis.
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Double Blinded Randomized Study of Temporary Gastric Electrical
Stimulation (GES): Preliminary Results of the Endostim Study (Endoscopic
Stimulation Temporarily Implanted Mucosally)
Thomas L. Abell, Janell Thompson, William D. Johnson, Anil Minocha
Introduction: Permanently implanted Gastric Electrical Stimulation has been shown to be
a successful therapy for many aspects of gastroparesis (GP). Recently endoscopic temporary
GES, (GIE 2005), has been advocated as a method to rapidly determine possible beneficial
effects of this therapy. However, temporary GES (Temp GES) has not been studied in a
blinded manner. Patients: We studied 58 patients, (11 males, 47 females, mean age 46
years) with the symptoms of GP and underlying diagnosis: (Idiopathic (ID), n=38 ; Diabetes
Mellitus (DM), n=13 ; Post-surgical (PS), n= 7) in a randomized placebo-controlled cross over
study of temp GES as two consecutive 4-day sessions. Methods: After baseline assessments of
symptoms (including vomiting), and health related quality of life (HRQOL), patients under-
went endoscopic placement of Temp GES on day 1 and then had devices turned ON/OFF
through day 4 when another assessment was done. Patients were crossed over to OFF/ON
days 5 through day 8 when final assessments were performed. Results were compared by
t-tests within and between groups and reported as mean +/- SE. Results: 28 patients had
ON-OFF and 30 patients had OFF-ON; 45 of 58 patients finished all 8 days. When analyzed
for all patients ON verses all patients OFF both vomiting frequency and HRQOL improved
significantly (p< 0.05). When analyzed for the first session, the results were even more
significant: the mean number of days vomiting decreased from 1.4 OFF to 0.4 ON (p=
0.001) and the mean number of days with nausea deceased from 1.6 OFF to 0.8 ON (p=
0.002). Conclusions: This blinded comparison of temporary endoscopic GES is the first
evidence based study of its effectiveness. Further stratification of results from the EndoSTIM
study should provide additional information about which gastroparesis patients may benefit
most from temporary GES.
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The Role of Advanced Glycation End Products (AGEs) in the Pathogenesis of
Diabetic Enteropathy
Raj Kumar, Prince Jeyabal, Pandu R. Gangula, Maria A. Micci, Pankaj J. Pasricha
Background: Gastric and enteric dysfunction is very common in diabetics, affecting up
to 50% of patients with serious adverse effects that include nausea, vomiting, diarrhea,
malabsoprtion and poor glycemic control. Loss of neuronal nitric oxide synthase (nNOS)
expression in the myenteric plexus has been postulated to be important in the pathogenesis
of diabetic enteropathy, but the underlying mechanisms remain unknown. Recently it has
been also postulated that several diabetic complications may be mediated by advanced
glycation end-products (AGEs), a class of modified protein adducts formed by non-enzymatic
glycation in diabetes that interact with the receptor for AGE (RAGE). Aim: We determined
the role of AGE in suppressing intestinal nNOS in a diabetic model, using two drugs: (1)
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aminoguanidine (AG) to prevent AGE formation and (2) ALT-711, an AGE cross-line breaker
(Alteon Inc.) Methods: Adult male Sprague Dawley Rats were rendered diabetic using STZ
and divided into four groups. Group A (“prophylactic”) receiving AG (1 g/L daily) in the
drinking water on day 2; Group B (“therapeutic”) receiving ALT-711 (3mg/kg ip) beginning
at the 6th week; Group C with no therapy and Group D (healthy controls). 12 weeks after
induction of diabetes, rats were sacrificed and duodenal nNOS expression analyzed by
immunohistochemistry, RT-PCR and Western blots. Results: The average body weight of
animals in all diabetic groups was lower by ~25-35% (p< 0.01) compared with controls,
and glucose levels were higher by ~6 fold (p < 0.01) under similar conditions. Diabetes by
itself (Group C) resulted in a significant elevation in both circulating (~20% higher in
diabetic animals compared with controls; p < 0.05) and tissue (~60% higher in diabetic
animals compared with controls; p < 0.05) levels of AGE, accompanied by a significant
reduction of myenteric nNOS as compared with healthy controls. The level of nNOS protein
was reduced by ~60% (p < 0.05) as judged by western blot analysis, whereas nNOS mRNA
level was reduced by ~40% (p < 0.05) in diabetic animals compared with controls. This
was completely reversed by both AG and ALT-711 treatment, despite the persistence of
hyperglycemia and weight loss. Both agents also prevented the rise in circulating and tissue
AGE levels. Conclusions: Advanced glycation end-products play a significant role in the
suppression of duodenal nNOS in the diabetic state and may contribute to the pathogenesis
of diabetic enteropathy. ALT-711, currently in clinical trials, has the potential for being a
useful therapeutic agent in this condition even in patients with poor glycemic control.
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Adenomatous Polyposis Coli (APC) Differentially Regulates β-Catenin
Phosphorylation and Ubiquitination in Colon Cancer Cells
Jun Yang, Chunming Liu
Background: Wnt/β-catenin signaling regulates the normal intestinal homeostasis, however
deregulation of the Wnt pathway results in tumorigenesis. More than 80% of colorectal
cancers are initiated by APC mutations, which stabilize β-catenin and activate Wnt/β-catenin
target genes. We previously found that β-catenin is sequentially phosphorylated by CKIα
and GSK3 in the Axin complex, and then degraded through ubiquitination-proteasome
pathway. Recently, we found that APC regulates β-catenin phosphorylation and ubiquitin-
ation by discrete steps and distinct mechanisms. We delineated the molecular mechanisms
of APC-regulated β-catenin degradation in this study. Methods: A GST fusion protein
containing the second and third 20aa repeats of APC (GST-APC2,3) was phosphorylated In
Vitro. The interaction between β-catenin and GST-APC2,3 was analyzed by GST pull-down
assay. The interaction between APC and β-catenin In Vivo was analyzed by immunoprecipit-
ation. Site-specific mutagenesis was performed to change the putative phosphorylation site
in APC2,3 from serine to alanine. Phosphorylation-specific antibodies against the second
and third 20aa repeat of APC were generated. Results: APC has two types of β-catenin
binding domains, three 15aa repeat domains and seven 20aa repeat domains. We found
that the 15aa repeats of APC may be required for β-catenin phosphorylation, but are
dispensable for β-catenin ubiquitination. The second and third 20aa repeats of APC is not
required for β-catenin phosphorylation but required for its ubiquitination and degradation.
It is important to note that the sequence around the second and third 20aa repeats is a “hot
spot” for APC truncations in colon cancer cells. CKI can phosphorylated GST-APC2,3 In
Vitro. Phosphorylated APC2,3 significantly increased β-catenin binding affinity. APC2,3 can
also be phosphorylated in HEK293T cells, and the phosphorylation sites were identified.
The kinase activity of CKIα, CKIε and GSK3 were inhibited by siRNAs and specific inhibitors
in HEK293T cells. APC phosphorylation and its interaction with β-catenin were analyzed
in these cells. Conclusions: APC regulates β-catenin phosphorylation by regulating the
assembly of the Axin complex, and then APC releases phosphorylated β-catenin from the
Axin complex for ubiquitination and degradation. Thus, APC truncations in colon cancer
cells inhibit β-catenin phosphorylation and ubiquitination, and stabilize β-catenin, ultimately
leading to cancer.
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Epigenetic Changes in the Components of the Wnt Pathway and Regression of
Hyperplasia In Vivo
Shahid Umar, Yu Wang, Joseph H. Sellin
Background: β-Catenin and APC proteins are components of the canonical Wnt signaling
pathway. Activation of β-catenin is recognized as critical early factor in tumorigenesis. We
previously described a novel mechanism of β-catenin activation In Vivo using the transmissible
murine colonic hyperplasia (TMCH) model: Ser9 phosphorylation and inactivation of GSK-
3β leading to stabilization, nuclear translocation and DNA binding of Ser45-phosphorylated
β-catenin (β-cat45; AJP-GI, 2006, in press). Aim: Determine correlation between epigenetic
changes in β-catenin and APC and hyperplasia during mucosal recovery from TMCH.
Methods: TMCH in Swiss-Webster mice was induced by Citrobacter rodentium. Histology
was performed in 5μm transverse sections while protein kinetics was measured in crypts
isolated from the distal colons of normal and 1-34 days' post-infected mice. Results: Sequential
measurement of H&E stained transverse sections revealed significant increases in crypt
length at 6 days' post-infection with continued hyperplasia till day 27 which finally declined
by day 34. β-Cat45, alongwith unphosphorylated β-catenin, increased by day 1 postinfection
preceding gross changes in crypt morphology, and persisted over the next 27 days before
declining by day 34 thereby correlating with regression of hyperplasia. Ser33,37/Thr41 residues
in β-catenin (β-cat33,37/41), however, failed to show early changes in phosphorylation at
days 6 and 12 TMCH, suggesting lack of GSK-3β action on β-cat45. Interestingly, β-cat33,37/
41 exhibited a gradual reciprocal increase in cellular abundance at day 20, peaking by day
27 before declining by day 34. β-Cat33,37/41 levels were, however, still lower than β-cat45
suggesting only partial recovery of GSK-3β activity at these time points. Indeed, GSK-3β
was still significantly phosphorylated at Ser9 at these time points indicating inhibition.
Cellular levels of total GSK-3β remained unchanged. Wild type APC (p312) expression
increased at day 6 followed by appearance of a 130 kDa band (p130) at day 12 TMCH.
p130 however, disappeared at day 20 with dramatic reappearance of p312 at day 27 before
levels returned to baseline at day 34. Conclusions: 1. Hyperplasia persists until day 27
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despite lack of bacterial presence. 2. Both Ser45-phosphorylated and unphosphorylated β-
catenin are critical for maintaining long-term proliferation during TMCH. 3. Reappearance
of p312 alongwith GSK-3β may facilitate β-catenin degradation coinciding with abrogation
of hyperplasia. Significance: Regression of hyperplasia parallels normalization of a distinct
pattern of epigenetic signaling of the Wnt pathway.
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Increased Expression of Krüppel-Like Factor 5 in Human Colon Cell Lines
with K-RAS Mutation and in Primary Human Colorectal Cancer
Mandayam O. Nandan, Agnieszka Bialkowska, Brian A. Babbin, Beth B. Mcconnell, Amr
M. Ghaleb, Vincent W. Yang
BACKGROUND AND AIMS: Our group previously reported that the pro-proliferative
transcription factor, Krüppel-like factor 5 (KLF5) mediates the transforming activity of
oncogenic H-Ras in NIH3T3 fibroblasts [Nandan et al. (2004) Oncogene 23, 3404; Nandan
et al. (2005) FEBS Lett. 579, 4757]. We also showed that KLF5 mediates the proliferative
effect of K-Ras in IEC-6 intestinal epithelial cells containing an inducible activated K-Ras
[Nandan et al. (2006) Gastroenterology 130, A20]. Both H-Ras and K-Ras activate KLF5
expression via mitogen-activated protein kinase kinase (MAPKK or MEK)/extracellular signal-
regulated kinase (ERK) in the MAPK pathway. In view that activating mutation of K-Ras is
present in up to 50% of colorectal cancer, we sought to determine whether expression of
KLF5 is increased in colorectal cancer cell lines and primary colorectal cancer tissues, and
whether the increased KLF5 expression may account for the proliferation of colorectal cancer
cells. METHODS: Human colon cancer cell lines SW480, DLD-1, HCT116, HT-29, and
RKO were examined for KLF5 levels, ERK activity and rate of proliferation. Small interfering
RNA (siRNA) and MEK inhibitors (PD98059 or U0126) were used to inhibit KLF5 expression.
K-Ras gene status was analyzed by sequencing. Eight human primary colorectal cancers with
paired adjacent normal tissues were stained for KLF5 by immunohistochemistry. RESULTS:
The levels of KLF5 protein in SW480, DLD-1, and HCT116 were significantly higher than
HT-29. RKO had no detectable KLF5. ERK activity was also elevated in SW480, DLD-1,
and HCT116. Suppression of KLF5 expression with KLF5-specific siRNA or MEK inhibitors
significantly reduced the rate of proliferation of the three cell lines with high KLF5 levels,
which contained an activated K-Ras. In contrast, HT29 and RKO contained wild type K-
Ras. Immunostaining of normal human colonic tissues showed that KLF5 was localized to
the nucleus of epithelial cells in the crypt region and absent from the surface epithelium.
The intensity of nuclear staining was increased in primary human colorectal cancer tissues
when compared to paired adjacent normal tissues. CONCLUSIONS: Human colon cancer
cell lines with activating K-Ras mutation contain high levels of KLF5 and ERK activity.
Suppression of KLF5 expression by siRNA or MEK inhibitors in these cell lines results in
reduced rates of proliferation, suggesting that KLF5 mediates the proliferative effects of K-
Ras. Moreover, elevated levels of KLF5 are observed in primary colorectal cancer when
compared to adjacent normal tissues. These results suggest that KLF5 plays an important
role in modulating proliferation of colorectal cancer cells.
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Role of Es Cell Specific RAS, Eras in Gastric Cancer
Eiji Kubota, Hiromi Kataoka, Makoto Sasaki, Kiyofumi Asai, Takashi Joh
Background and aims: ERas, ES cell specific Ras, was found to be expressed in ES cell only.
ERas is constitutive active without any mutation and plays a crucial role in the tumor-like
growth properties of ES cells (Nature 2003). We have previously reported that ERas is
expressed in gastric cancer cell lines and implicated in resistance to anti-cancer agents.
However, the role of ERas in gastric cancer has not been well elucidated. The aim of this
study is to investigate the mechanistic contribution of ERas to chemoresistance and the
possible target genes of ERas in gastric cancer. Material and Method: 1. We administrated
immunohistochemical staining to assess the expression of ERas in human gastric cancer
tissue. 2. To analyze the ERas function in gastric cancer, we established stable transfectants
using GCIY cells expressing the ERas gene, and PI3k/Akt and MAPK pathway were analyzed
by western blot. 3. We examined the effect of Rapamycin, inhibitor of mTOR which is
downstream of PI3k/Akt pathway, and the effect of U0126, inhibitor of MEK1/2, to the cell
survival under the exposure to CPT-11. 4. We also investigated the target genes of ERas
using human cDNA microarray and we assessed the anchorage-independent growth of ERas
transfectans using soft agar assay. Results: 1. ERas was expressed in about 30% in human
gastric cancer. 2. Overexpression of ERas did not induce the phosphorylation of MEK but
induced phosphorylation of Akt. 3. The ERas transfectants were significantly more resistant
to CPT-11 than control(IC50: control 83.5±8.6μM, ERas transfectant 166±20μM, p <0.01)
and administration of Rapamycin significantly reduced chemoresistance to CPT-11. In con-
trast, U0126 did not show any effect. 4. Microarray analysis revealed that ERas induced
down-regulation of E-cadherin and up-regulation of ABCG2, a member of the ATP binding
cassette transporter which is capable of extruding CPT-11 from cells. Gene set analyses of
microarray indicated that ERas induced activation of NFκB. E-cadherin inhibition was also
confirmed at protein levels by western blot and ERas significantly promoted colony-formation
in soft agar, with about a 4-fold number of colonies as compared with control. Conclusion:
ERas was expressed in human gastric cancer tissue and induced chemoresistance to CPT-
11 via phosphorylation of Akt and expression of ABCG2. ERas may be associated with
proliferation and metastasis of gastric cancer through inhibition of E-cadherin and activation
of NFκB.
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Expression of Fli-1 Leads to Increased Notch Activity Through Overexpression
of Fringe in Colorectal Cancer (CRC)
Luigi Ricciardiello, Lucia Fini, Hamed Khalili, Michael Selgrad, Erin Hotchkiss, Sung-
kwan Shin, Claudio Ceccarelli, Catia Giovannini, C. richard Boland
Background: The notch system is important in controlling cell fate, proliferation and apoptosis
in many cell lineages. Mammalians encode for 4 notch receptors and 2 types of ligands
named delta and jagged. Notch has gained attention because it is abnormally regulated in
several malignancies. Recently abrogation of the notch1 system in the APC Min mouse has
resulted in the reversion of adenomas to goblet cells. Proper notch activity is regulated by
O-fucosylation of the extracellular domain of both ligands and receptors by fringe proteins.
The FLI-1 gene, an ETS transcription factor, has been shown to directly regulate the expression
of fringe in murine models. However, its role in human CRC is unclear. Aims: To assess
the status of the notch system in CRC cells and its regulation. Methods: Expression studies
were performed in RKO, LoVo, HCT116, and SW480 cells on active notch (NICD) and
ligands; The fucosyltransferases: manic, lunatic, and radical fringe, and OFuc-T1; and the
transcription factors: Hes1, Hes5 and Fli-1. Plasmids encoding manic fringe, Fli-1, and
NICD were used for transfection. siRNA was performed on Fli-1, manic fringe, lunatic fringe
and notch1. Bisulfite sequencing was performed on the Fli-1 promoter. Immunohistochem-
istry (IHC) for NICD and Fli-1 was performed on clinical CRC samples. Results: SW480
showed the highest expression of NICD, while expression was undetectable in RKO. All
cells tested showed expression of the jagged1 ligand, while the expression of the ligand
DLL1 correlated with the expression of NICD. Hes1 was expressed in all cells, while Hes5
was expressed only in SW480. Manic fringe was undetectable in HCT116 and RKO, but
expressed in SW480. Transfection of manic fringe into RKO, LoVo and HCT116 resulted
in increased expression of Hes5 and NICD. siRNA inhibition of manic fringe in SW480
resulted in repression of HES5. Fli-1 was expressed only in SW480, and siRNA against Fli-
1 abrogated both manic fringe and Hes5. Transfection of Fli-1 into HCT116, LoVo and
RKO increased expression of both manic fringe and Hes5. The Fli-1 promoter was methylated
in the cells in which Fli-1 was absent. Treatment of RKO, HCT116 and LoVo with 5-aza-
2dC resulted in re-expression of Fli-1 and increased levels of manic fringe and Hes5.
Expression of Fli-1 was found only in cancer specimens showing increased NICD nuclear
expression. Conclusions: Fli-1 is responsible for increasing notch1 activity in SW480 cells
by increasing the expression of manic fringe and mediating the expression of HES5 and
overexpression of NICD. This supports the proposition that the notch system can function
as an oncogene in CRC.
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Klf4 Differentially Regulates Histone Acetylation in Colon Cancer Cells
Paul M. Evans, Wen Zhang, Xi Chen, Jun Yang, Chunming Liu
BACKGROUND/AIMS: Krüppel-like factor 4 (KLF4) is a zinc finger transcription factor that
is highly expressed in post-mitotic cells within the gut epithelium. KLF4 is a tumor suppressor,
inhibiting the expression of genes controlling the cell cycle such as Cyclin B and Cyclin E,
and simultaneously induces the expression of the cell cycle inhibitor p21Cip1/WAF1. In
previous studies using affinity purification, we identified p300/CBP in the KLF4 complex.
Since recruitment of co-activators such as p300 to the transcriptional apparatus is a common
method transcription factors use to activate gene expression, we decided to study what
effect p300/KLF4 interaction would have upon expression of known KLF4 target genes.
Furthermore, as several transcription factors are directly acetylated by p300, we decided to
investigate whether this was the case for KLF4. RESULTS: Via GST-labeled pull-down assays,
we confirmed that KLF4 and p300 do indeed interact. However, mutation of three key
residues in the N-terminal transactivation domain abolished this interaction. Western blotting
using an acetyl-lysine specific antibody confirmed that KLF4 is acetylated, and using a panel
of mutants we identified two key lysine residues. We then made several luciferase reporter
constructs containing the promoter sequence of KLF4 target genes IAP and Cyclin B1, and
tested the ability of p300 to synergize with KLF4 in transactivating these reporters. Via
Western blot and RT-PCR, we demonstrated the inability of the p300 binding mutant of
KLF4 to upregulate p21 and to downregulate Cyclin B1. Using ChIP assays, we demonstrated
that p21 and Cyclin B1 are direct targets of KLF4 regulation. Finally, via ChIP using an
acetyl-H3 specific antibody, we demonstrated that KLF4 promotes histone acetylation on
the p21 promoter, whereas KLF4 promotes histone deacetylation on the Cyclin B1 promoter.
CONCLUSIONS: We confirmed that KLF4 and p300 interact and found that this interaction
results in direct acetylation of KLF4, at two key lysines. p21 and Cyclin B1 are direct targets
of KLF4, and one mechanism by which KLF4 regulates their expression is by modulating
histone acetylation at the promoter.
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NOTES Distal Pancreatectomy Using Endoscopic Linear Stapler
Marvin Ryou, Derek G. Fong, Reina D. Pai, Ali Tavakkolizadeh, David W. Rattner,
Christopher C. Thompson
Background/Aim: To demonstrate the technical feasibility of a NOTES distal pancreatectomy
in an In Vivo porcine model. Methods: The procedure was performed in five pigs weighing
30 kg each (two pigs euthanized prior to procedure, one pig euthanized immediately
following procedure, and two pigs survived for 2 weeks). Following induction of anesthesia,
animals were placed in the supine position and a colon prep was performed. To facilitate
closure, 3-4 T-tag sutures were deployed across the anterior colonic wall 10 cm from the
anal verge using a modified Endocinch needle. A needle-knife incision was created in the
middle of the T-tag sutures, and a double-channel prototype R-scope (Olympus, Center
Valley, PA) was advanced into the abdominal cavity. The animal was then placed in the
prone position. The distal pancreas was easily identified, and its base was dissected using
a combination of air dissection with an injection needle and hook knife. A single-channel
endoscope was inserted into the prepped vagina, and a needle-knife incision was created.
The endoscope was replaced by a rigid linear stapler/cutter (Power Medical Interventions,
Langhorne, PA) which was guided into position across the base of the distal pancreas under
endoscopic guidance. After stapler firing, the resected pancreatic specimen was removed
transcolonically via a 2.8-cm Roth net (US Endoscopy, Mentor, OH). The colonic incision
was closed by deploying an Endoloop (Olympus) while gently pulling on the T-tag sutures
to provide counter traction. After 2 weeks, the animals were euthanized and necropsies
performed. Results: Distal pancreatectomy was successful in all animals. Prone positioning
was critical for proper exposure of retroperitoneal structures. The linear stapler/cutter func-
tioned flawlessly. The distal pancreas was resected easily, and the intact staple line achieved
hemostasis and avoidance of gross spillage of pancreatic secretions. The simultaneous trans-
colonic passage of both endoscope and linear stapler in the first non-survival animal caused
excessive shearing of the colonic wall, necessitating a combined transcolonic/transvaginal
approach in subsequent animals. This latter approach worked well, and the vaginal wall
was able to accommodate the linear stapler. Both survival animals thrived post-operatively.
Necropsies revealed clean staple lines, intact closed colonic incisions, and absence of infection,
hemorrhage, or gross spillage of pancreatic secretions. Conclusions: NOTES distal pancreatec-
tomy is technically feasible. Prone positioning in NOTES enhances exposure of retroperitoneal
structures. The trans-vaginal approach holds promise as a NOTES access site.
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Transgastric Miniprobe-Based Confocal Microscopy for In-Vivo Histopathology
in the Peritoneal Cavity
Alexander Meining, Stefan Von delius, Hubertus Feussner, Eckart Frimberger, Roland M.
Schmid
Background Natural Orifice Transluminal Endoscopic Surgery has been mentioned as an
emerging technology. Apart from the interventional approach we thought that such an access
might also be useful for targeted in-vivo histopathology by the means of confocal fluorescence
microscopy. Methods Transgastric in-vivo histopathology was evaluated in three domestic
pigs under general anesthesia. Following incision of the anterior gastric wall, a prototype
double channel videoendoscope (Karl Storz, Germany) was advanced into the peritoneal
cavity. 10ml of fluorescein 1% were subsequently injected intravenously and confocal micro-
scopy was performed using a flexible confocal miniprobe introduced through the instru-
mentation channel of the endoscope. Miniprobes were connected to a laser scanning unit
(Cellvizio, MKT, Paris) and real time video sequences were recorded and stored. The probes
applied had a field of view of 500 x 600 microns, confocal planes were 10 microns deep
(for examination of peritoneal layer) or 100 microns deep (for evaluation of liver/spleen).
Results Probes could easily be placed on the peritoneal layer, liver and spleen under direct
visualization with the endoscope (figure). Dynamic microscopic sequences with erythrocytes
flowing through blood vessels in the peritoneum could be seen. With the 100 microns deep
imaging probe, microstructures of organs such as liver-lobuli with central veins could
readily be identified (figure). Conclusions For the first time, we demonstrated that in-
vivo histopathology in the peritoneal cavity is feasible during natural orifice transluminal
endoscopy. Our method combines the minimally invasive approach to intraperitoneal organs
and the real time in-vivo acquisition of dynamic histopathologic images.
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NOTES Right Colectomy: A Feasibility Study
Tonia M. Young-fadok, Mark H. Whiteford, Peter M. Denk, Lee L. Swanstrom
Background: Early NOTES procedures have focused on appendectomy, cholecystectomy
and partial hysterectomy in porcine models. Methods have not illustrated surgical dissection
of critical structures. Aim: To employ a cadaver to determine feasibility of performing critical
steps of a right colectomy: dissection and control of ileocolic vessels; dissection of cecum
off the retroperitoneum; creation of an anastomosis; and transection of the bowel. Methods:
A female cadaver without abdominal scars was used. A bidirectional approach was employed,
with a gastroscope exiting the stomach, and a colonoscope exiting the rectosigmoid colon.
Both scopes were standard single channel instruments. Standard endoscopy forceps and
snares were used to achieve access, and dissection of the vascular pedicle and retroperitoneum.
A flexible laparoscopic stapler transected the vascular pedicle. An articulated laparoscopic
linear stapler was used to create an ileocolic anastomosis, and transect the bowel. Results:
The procedure was accomplished with the following steps. 1. A 10mm trocar was placed
in the left mid-abdomen and a pneumoperitoneum established. This eliminated issues of
illumination and insufflation, and permitted video documentation. 2. Via the laparoscope,
the gastroscope was visualized in the stomach. A gastrotomy was made anteriorly over the
most dependent portion of the greater curvature with the tip of the cautery snare and
balloon-dilated to allow exit of the gastroscope. 3. The colonoscope exited the colon at the
rectosigmoid after creating a colotomy with the tip of the cautery snare. 4. The ileocolic
junction was suspended from the anterior abdominal wall with a suture passed percutaneously
by a port closure device. 5. Mesenteric windows were opened at the base of the ileocolic
pedicle by scoring with the tip of the endoscopic cautery forceps. A flexible laparoscopic
linear stapling device was introduced via the colotomy and the vessels transected. 6. The
inferior and lateral peritoneal attachments were divided using the cautery forceps tip, mobiliz-
ing the cecum off the retroperitoneum. 7. The ascending colon and distal ileum were aligned,
and a colotomy and enterotomy made at the chosen resection margins. An articulated
laparoscopic linear stapler was introduced and used to create a side-to-side stapled anastom-
osis. 8. The stapler was reloaded and reintroduced to transect the bowel and complete the
resection. Conclusions: It was possible to complete critical surgical steps of a right colectomy
using a bidirectional transluminal approach. Multiple aspects remain to be addressed, includ-
ing sterile access, secure closure and improved instrumentation.
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The Use of Magnets in Natural Orifice Transluminal Endoscopic Surgery
(NOTES): Addressing the Problem of Traction and Counter-Traction
Marvin Ryou, Christopher C. Thompson
Background: Current NOTES procedures with the flexible endoscope are technically limited
by the inability to vigorously manipulate tissue and retract organs. The problem of distal
force exertion stems from two issues: (1) force is necessarily diminished over the course of
a long and floppy endoscope; (2) force are largely applied along the same axis as the visual
axis since the instrument channels are oriented in parallel fashion. Here we describe the
use of internal and external magnets that may potentially provide the multi-axial traction/
counter-traction required in more complicated NOTES procedures. Methods: An external
magnetic system was used , neodymium magnets were attached to an aluminum support
stand. Our internal magnetic system was small neodymium disk magnets / clips. The force-
distance relationship of our system was determined using digital tensiometer. This was
compared to maximal push/pull force generated by forceps The system was applied to 2
procedures: (1) In 3 non-survival transcolonic chole, magnet-conjugated clips were deployed
alonginferior edge of the hepatic lobes in order to lift the lobes. The procedure time
was compared to historical controls. (2) Transcolonic mesh implantation into the anterior
abdominal wall for ventral hernia repair in 3 survival pigs. Clips were affixed to the corners
of the mesh, which was then stabilized by the external magnet for implantation. Video logs
were kept for all facets of the study. Results: Over a separation distance of 5 cm to 0.25
cm, the magnetic force of our system (external magnet and a single magnet-conjugated clip)
increased exponentially from 3 to 90 Gramforce. Force did not diminish with intervening
soft tissue. The simultaneous use of several magnet-conjugated clips could lift heavy porcine
abdominal organs, such as a single hepatic lobe or a resected kidney. However, maximal
force generated by biopsy forceps at the endoscope tip ranged from 200 to 400 gramforces
and could easily overwhelm exteranl magnetic force. In Vivo, the magnet system facilitated
cholecystectomy by exposing the gallbladder during the duration of the operation. The
procedure time was shortened from a historical mean of 68 min (range 42 to 90; n=5) to
49.6 min (range 33 to 61; n=3). The magnet system also stabilized mesh for hernia mesh
fixation. Conclusions: Magnets can provide the traction and counter-traction through the
abdominal wall. This technique increased the efficiency of transcolonic cholecystectomy and
hernia mesh fixation and will likely be a useful component of complex NOTES procedures.
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Gastric Sleeve Resection Via NOTES
Marvin Ryou, Christopher C. Thompson
Background/Aim: The concept of performing gastric sleeve resection in the obese population
using a NOTES approach is appealing since the percutaneous route is avoided. We aimed
to demonstrate its technical feasibility of a NOTES gastric sleeve resection in ex vivo and
In Vivo animal studies (porcine model). Methods: Gastric sleeve resection was first performed
in 2 ex vivo porcine stomachs (from adult white pigs 40 kg) using a prototype flexible,
computer-guided, endoscopic linear stapler/cutter (Power Medical Interventions). The stapler
was 60-mm in length and used blue-loads (4 rows of staples; 1.3-mm bracket height after
firing). Standard laparoscopic technique was used: Stapling/resection commenced at the
pylorus and marched superiorly parallel to the lesser curvature in order to create a tubularized
stomach. Gastric volumes were measured before and after resection. The resected stomachs
were also bubble-leak tested using a digital pressure gauge. The procedure was then attempted
in two non-survival adult female pigs (30-40kg) using a rigid 60 mm power linear cutter/
stapler (Power Medical Interventions), again with blue-loads. A double-channel colonoscope
(Olympus) provided visualization and tissue retraction. The first procedure was performed
via a transcolonic approach. The second procedure was performed via a combined transco-
lonic and transvaginal approach. Results: The ex vivo stomachs required 7-8 60-mm cartridges
apiece to complete sleeve resection. Gastric volumes were reduced from 1100-1200 cc to
100 cc. Sleeve resections appeared intact upon visual inspection. Upon leak testing, the first
stomach leaked at 30 mm Hg at multiple sites along the staple line, particularly near the
pylorus and cardia where the gastric wall is thicker. The second stomach leaked at the staple
line prior to being able to obtain a pressure. Since blue loads are designed for much thinner
tissue, this was an expected observation. For the In Vivo portion of our study, the first
non-survival pig underwent a transcolonic procedure using a 30 mm rectal overtube to
accommodate both the rigid stapler and double-channel colonoscope. Given the shearing
effects of simultaneously introduced instruments, the second non-survival pig underwent a
sleeve resection whereby the colonoscope was introduced transcolonically, and the rigid
stapler was introduced transvaginally. The stapler/cutter was successfully fired twice in each
animal but complete sleeve resection was not completed. Conclusions: Successful NOTES
gastric sleeve resection awaits the advent of stapler cartridges meant for thicker tissue and
a steer-able endoscopic stapler/cutter—both currently in development.
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Prone Natural Orifice Transluminal Endoscopic Surgery (NOTES): Abdominal
Exploration and Nephrectomy in a Porcine Model
Reina D. Pai, Derek G. Fong, Ali Tavakkolizadeh, David W. Rattner, Christopher C.
Thompson
Background and Aim: In previous NOTES publications, the orientation of animals for
procedures has primarily been a supine position. In our lab's experience in trangastric
NOTES, supine positioning allowed adequate visualization of many lower organs, but the
kidneys and other retroperitoneal structures were not visualized. From the trancolonic
approach, the upper abdominal organs were easily accessible, however the lower abdominal
and retroperitoneal structures were rarely seen. The goal of this study was to evaluate the
benefits of prone positioning in NOTES procedures and determine feasibility of NOTES
nephrectomy. Methods: This study consisted of two arms: a transgastric arm with 4 animals
and a transcolonic arm with 7 animals. All procedures were done under general anesthesia
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with aseptic NOTES techniques. With the animal in the supine position, standard translu-
minal access methods using a needle knife and TTS balloon as necessary were used to
establish either transgastric or transcolonic entrance into the peritoneal cavity. The animal
was then repositioned into a prone position and front and hind legs were propped up with
soft padding to allow free space between the animal's abdomen and the operating table.
Exploration was conducted during which the animal was maneuvered into Trendelenberg
or reverse Trendelenberg as well as tilted right or left to obtain optimal exposure of the
retroperitoneal surfaces. In the final four animals, nephrectomy was attempted using a double
channel endoscope, hydro and air dissection, and hook knife cautery. Video logs were
maintained of each procedure. Results: From a prone transgastric and transcolonic approach,
visualization of all organs previously seen from these views remained intact, but additionally
the kidneys, distal pancreas and other retroperitoneal structures were identified. Dissection
and removal of the kidney was successfully completed in two animals and one of those
animals was survived for two weeks prior to necropsy. Although removal of the organ was
possible in both animals, extraction through the natural orifices in one piece resulted in
trauma to both the organ and the orifices. Conclusions: This study demonstrates the advant-
ages of prone NOTES procedures. In contrast to the supine method, prone NOTES provides
reliable access to retroperitoneal structures allowing for a more thorough abdominal explora-
tion and additional therapeutic procedures including NOTES nephrectomy.
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Role of Hp1 in Epigenetic Silencing of Members of TGFβ Signaling Pathway
Via Interaction with the Tumor Suppressor Klf11
Gwen A. Lomberk, Jinsan Zhang, Mark J. Truty, Raul A. Urrutia
KLF11/TIEG2 was isolated by our group in 1998 as a TGFβ-inducible transcription factor
that contains three distinct repressor domains, R1, R2, and R3. KLF11 acts as a tumor
suppressor for pancreatic cancer, at least in part, via the interaction of the R1 domain (also
called SID) and the corepressor Sin3a-Histone deacetylase complex (HDAC). Recent reports
indicate that KLF11 correlates with either the development or aggressiveness of additional
malignancies including head and neck, leukemia, and esophageal cancer. Moreover, families
carrying mutations in the R3 domain of this protein are predisposed to diabetes. Unfortu-
nately, however, the corepressor molecules for R2 and R3 domain have remained unknown.
Identifying these proteins is important for better understanding how oncogenic cascades
inactivate tumor suppressors since the K-ras-MEK-ERK pathway inactivates the R1 domain,
leaving the tumor suppressor protein KLF11 impaired but still active. Through sequence
analysis, we identified several PXVXL HP1-interacting domains within KLF11. HP1 proteins
are the “gatekeeper” of the epigenetic gene silencing that is mediated by histone H3 lysine-
9 methylation, and therefore a good candidate for involvement in KLF11-associated gene
repression. Indeed, we find that KLF11 interacts with HP1 In Vitro, and in particular, the
HP1α isoform. This is important since we observe that pancreatic cancer cell lines display
altered expression of this HP1 isoform. In addition, we observe an interaction between
KLF11 and HP1 proteins in Panc1 cells, using both immuno-precipitation and biomolecular
fluorescence complementation assays. In reporter assays, KLF11 and all three HP1 isoforms
mediate gene silencing in Panc1 cells. Finally, using ChIP assays, we find that both KLF11
and the HP1 proteins bind the same promoter regions of important TGFβ pathway genes,
such as BMP5, SMAD3, and TGFβRII, indicating that KLF11 and HP1 proteins interact to
regulate key promoters involved in pancreatic homeostasis and diseases. RU is supported
by Mayo Cancer Center and NIH Grants DK52913 andDK5662.
795
Knockdown of NFkB Activity By RNA Interference Enhances Gemcitabine and
Trail Mediated Apoptosis in Pancreatic Cancer Cells
Xue Pan, Temeyoshi Yamamoto, Thiru Arumugam, Baoan Ji, David J. Mcconkey, Craig D.
Logsdon
Background: Constitutive activation of the transcription factor nuclear factor kappa B (NFkB)
is a frequent molecular alteration in pancreatic cancer. Several previous studies have suggested
that NFkB activity is important for pancreatic cancer cell resistance to chemotherapies. The
aim of this study was to determine whether inhibition of NFkB by siRNA directed gene
silencing would increase the sensitivity of pancreatic cancer cell lines to either gemcitabine
or TNF related apoptosis inducing ligand (TRAIL) mediated apoptosis. Methods: Six human
pancreatic cancer cell lines (BxPc3, L3.6pl, CFPAC, Mpanc96, Panc1, Miapaca) were exam-
ined. The basal level of NFkB level was detected by electrophoretic mobility shift assay
(EMSA) and luciferase reporter assays. Silencing of the p65/relA subunit was confirmed by
western blotting as well as reporter assays. Sensitivity of the cell lines to gemcitabine and
TRAIL were examined before and after inhibition of NFkB by MTT and FACS assays. Results:
Gemcitabine concentration dependence studies indicated that three cell lines were relatively
sensitive (L3.6pl, BxPC3, CFPAC) and three lines were relatively resistant (Mpanc96, Panc1,
Miapaca). Similarly, Trail concentration dependence studies indicated that three of the cell
lines were relatively sensitive to TRAIL (L3.6pl, BxPC3, Miapaca) and three lines were
relatively resistant (Mpanc96, Panc1, CFPAC). Basal NFkB binding and activity were constitu-
tively high in all six pancreatic cancer cell lines compared to non-transformed human
pancreatic duct epithelial cells. Thus, NFkB basal activity did not correlate with either
gemcitabine or TRAIL resistance. Silencing of relA/p65 reduced cell numbers In Vitro of all
gemcitabine-sensitive pancreatic cell lines (BxPc3, L3.6pl, CFPAC) but none of the gemcitab-
ine-resistant cell lines (Mpanc96, Panc1, Miapaca). Silencing of relA/p65 also increased the
effectiveness of gemcitabine killing of all gemcitabine sensitive, but none of the gemcitabine
resistant cell lines. RelA/p65 silencing also sensitized two (Panc1 and CFPAC) of three TRAIL
resistant cell lines. Conclusions: There is no obvious relationship between NFkB basal activity
and chemoresistance of pancreatic cancer cells. RelA/p65 silencing improves responses to
cytotoxic treatments in some but not all pancreatic cell models. The combination of NFkB
inhibition with TRAIL may be more useful than with gemcitabine.
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Roles of Individual Nf-κB Proteins in Pathologic Responses of Experimental
Acute Pancreatitis
Gang Zhao, Christopher N. Reyes, Kip Hermann, Olga A. Mareninova, Kai-feng Sung,
Anna S. Gukovskaya, Alexander Hoffmann, Stephen J. Pandol, Ilya Gukovsky
Background and Aims: The pleiotropic transcription factor NF-κB is activated in all experi-
mental models of acute pancreatitis. One approach to determine its role in pancreatitis is
by using NF-κB knockout mice. We initiated a systematic investigation of the roles of
individual NF-κB proteins in various pathologic responses of acute pancreatitis by using
mice deficient in p65 (heterozygous deletion), p50 or c-Rel proteins, or their combinations.
Such data are also important for therapeutic strategies targeting specific NF-κB proteins in
pancreatitis. In this study, we measured the effects of the NF-κB genetic deletions in
cerulein (CR) pancreatitis, as well as the In Vitro model of acinar cells hyperstimulated with
cholecystokinin-8 (CCK). Because the role of NF-κB in the inflammatory response is well
established, we focused on its role in cell death responses and pathologic trypsinogen
activation. Methods: Pancreatitis was induced by i.p. injections of 50 μg/kg CR; isolated
acinar cells were treated with 100 nM CCK-8. We measured parameters of pancreatitis; The
expression of proteins controlled by NF-κB; NF-κB activity using electromobility shift assay
and Western blot; and apoptosis by TUNEL staining and caspase-3 activity. Results: NF-
κB genetic deletions attenuated CR-induced injury. For example, in p50-/- mice hyperamylase-
mia and necrosis decreased by 60% compared with the wild type responses. The extent of
apoptosis in CR-treated p50-/- mice increased by 50%; however, the major effector caspase-
3 was not activated, indicating the involvement of caspase-independent mechanisms. We
found that NF-κB regulates both pro-apoptotic Bad and anti-apoptotic Bcl-xL (but not Bcl-
2) proteins in pancreatitis. In particular, CR pancreatitis in wild type mice caused ~3-fold
increase in Bcl-xL, which was abolished in p50-/- and p65+/-p50-/- mice. Interestingly, NF-
κB also regulates the basal levels of pro- and anti-apoptotic proteins in pancreas. Unexpec-
tedly, we found an effect of NF-κB genetic deletions on the pathologic, intra-pancreatic
trypsinogen activation. For example, it was inhibited by 60% in p50-/- and c-Rel-/- mice.
However, the CCK-induced trypsinogen activation in isolated p50-/- or c-Rel-/- acinar cells
was the same as in the wild type. These data suggest that non-acinar (likely inflammatory)
cells regulate trypsinogen activation in pancreatitis via NF-κB dependent pathways. Conclu-
sions: The study elucidates the roles of individual NF-κB proteins in pathologic responses
of CR pancreatitis, in particular, the cell death response. The results further indicate NF-
κB dependent contribution of non-acinar cells to trypsinogen activation in pancreatitis.
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A Distinct Chromatin Modification Precedes p16 Methylation During the
Commitment to Pancreatic Cancer Development
Gwen A. Lomberk, Raul A. Urrutia
An important hypothesis of our laboratory is that epigenetic modifications in gene expression,
escaping detection by conventional genetic approaches, constitute early transformation “hits”
during the development of pancreatic cancer. According to this model, constitutive activation
of K-Ras would initiate signaling cascades leading to chromatin-mediated silencing of tumor
suppressor genes that, if maintained long-term, become as stable as any hereditable genetic hit
influencing the process of neoplastic transformation. DNA methylation is a well-established
mechanism for the epigenetic regulation of gene silencing. In particular, early methylation
of the p16 tumor suppressor gene is the step required for the development of pancreatic
cancer. However, DNA methylation of silenced genes, such as p16, is thought to first require
histone H3 lysine-9 hypermethylation. This phenomenon, directly implicates this chromatin
modification as the key step in the epigenetic gene silencing of tumor suppressor genes
during tumorigenesis. HP1 proteins are the “gatekeeper” of the epigenetic gene silencing
that is mediated by histone H3 lysine-9 methylation. We show that pancreatic cancer cells
express three HP1 proteins, HP1α, HP1β, HP1γ with an enrichment of the latter isoform.
While HP1α and β are both predominantly heterochromatin proteins, HP1γ localizes to
transcriptionally active euchromatin, as well as heterochromatin (silenced chromatin). In
order to begin testing our hypothesis that changes in chromatin play a significant role in
tumorigenesis, we took three pancreatic cell lines as a model, Hs776T, with normal p16
expression, PL45, with methylated p16 and subsequent loss of expression, and Panc1, with
deleted p16 and therefore loss of expression. We treated the methylated cell line, PL45,
with 5-azacytidine and obtained full re-expression of p16. Interestingly, performing ChIP
assays, we observed the presence of HP1γ only on the p16 promoter silenced by methylation.
HP1γ was neither present on the p16 promoter of the 5-azacytidine treated cell line nor on
that of normal expression (Hs766T) or that silenced through deletion (Panc1). These results
suggest that HP1 may be part of the earliest step that precedes and leads to the promoter
methylation of p16. To our knowledge, this is the earliest step found to occur immediately
after the mutation of K-ras during the formation of pancreatic cancer. RU is supported by
Mayo Cancer Center and NIH Grants DK52913 and DK5662.
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Activation of K-RAS in Pancreatic Acinar Cells Causes Chronic Pancreatitis in
Transgenic Mice
Baoan Ji, Jian Song, Lilian Tsou, Craig D. Logsdon
Background & Aims:K-ras mutations occur in more than 90% of pancreatic adenocarcinoma
and up to 40% of chronic pancreatitis.Transgenic models have been developed previously
to address these issues,but these models had intrinsic limitations.For example,the elastase
promoter previously utilized to drive K-ras expression in acinar cells is neither highly efficient
nor specific for adult acinar cells and would not be expected to remain functional in cells
after ras-mediated dedifferentiation.Another model utilized pdx1 promoter to drive the
expression of K-ras in the whole pancreas, but not specifically in acinar cells. In the current
study,we investigated the effect of active K-ras specifically in pancreatic acinar cells.
Methods:For highly specific and efficient expression of active mutant K-ras in pancreatic
acinar cells, two transgenic mice were created. One mouse utilized the CAG, a strong
universal promoter, followed by loxP-GFP-Stop-loxP and K-rasG12V (K-rasfloxedstop).This
construct expresses only GFP until a GFP-Stop cassette is removed by Cre mediated recomb-
ination which allows expression of active K-rasG12V.Activation of this cassette was achieved
by crossing this mouse with an acinar specific Cre-Er mouse developed using a full-length
elastase promoter in a BAC(BAC-El-Cre-Er).Results:GFP was expressed in nearly 100% of
the pancreatic acinar cells in K-ras floxedstop mice before cre recombination.K-rasG12V was
expressed in pancreatic acinar cells prepared from K-rasfloxedstop animals after, but not before,
infection with a Cre adenovirus. For detecting Cre-Er expression, the BAC-EL-Cre-Er mice
were crossed with a ROSA26 reporter mouse. The expression of Cre-Er was observed in
nearly 100% pancreatic acinar cells while no expression was found in duct and islet cells
by X-gal staining. Expression of active K-rasG12V by crossing K-rasfloxedstop with BAC-El-
Cre-Er led to dramatic decrease of pancreatic acinar cells,inflammatory cell infiltration and
significant fibrosis which mimics pathological changes observed in chronic pancreatitis.
Interestingly, acinar cell to duct cell metaplasia as well as signs of increased mitosis,apoptosis
and PanIn lesions in duct cells were also observed. Conclusions: Expression of the active
mutant of K-ras in pancreatic acinar cells caused a response very similar to chronic pancreat-
itis.This suggests the possibility that K-ras mutations observed in chronic pancreatitis might
contribute to the disease.This model will be useful for studies on the role of K-ras in acinar
cells, the mechanisms responsible for induction of acute and chronic pancreatitis, and the
relationship between inflammation and cancer in the pancreas.
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Pancreatic Acinar Cell Damage By Supra-Stimulation Is Regulated By Src-
Mediated Cortactin-Actin Dynamics
Vijay Singh, Mark A. Mcniven
Supra-stimulation (SS) of pancreatic acini leads to a block in zymogen secretion and induces
significant cell blebbing as well as vacuole formation, resulting in cell injury. The actin
cytoskeleton is thought to contribute to these aberrant processes, although the mechanisms
are poorly defined. We have observed that the non-receptor tyrosine kinase Src is activated
upon SS of rat pancreatic acini. Further, the localization of the actin-binding protein cortactin,
which is a Src substrate, is altered during cell injury. Therefore, the GOAL of this study
was to define the role of Src and cortactin in regulating actin dynamics in SS acini and test
whether preventing tyrosine phosphorylation of cortactin might reduce acinar cell injury
both In Vitro and In Vivo. We find that actin and cortactin are highly enriched at the apical
domain of acini stimulated with physiological concentrations of CCK (<0.1nM) as well as
resting acini, while SS with 10nM CCK induces a dramatic relocalization of these proteins
to the basolateral domain, from which large membrane blebs extend. Interestingly, Src was
activated up to 15-fold and cortactin was markedly tyrosine phosphorylated (3 fold in 2
minutes) in SS acini. In addition, a Src-cortactin complex, present in resting cells, was
completely dissociated within 2 minutes of SS. We next tested if preventing this phospho-
activation of the Src-cortactin complex could reduce SS-induced acinar cell blebbing. Pretreat-
ment of SS acini with the Src inhibitor PP2 (20uM) or SU6656 markedly reduced the
tyrosine phosphorylation of cortactin. Most importantly, drug treatment prevented the redis-
tribution of actin and cortactin to the basolateral domain of SS acini. We next tested whether
preventing cortactin phosphorylation might also exert a protective affect by transfecting acini
with a phospho-inhibitory mutant of cortactin (Y385,429,445F) prior to SS. Remarkably,
expression of this mutant protein mimicked the effects of treatment with the Src inhibitory
drugs, as noted by a lack of actin redistribution and a reduction in bleb formation by more
than 50%. In SUMMARY, these findings provide the first evidence that SS induces an
inappropriate activation of Src in pancreatic acini leading to tyrosine phosphorylation of
cortactin, which subsequently mediates an aberrant reorganization of actin at the cell base
and bleb formation. On going In Vivo studies suggest that inhibition of Src activity and
cortactin phosphorylation in rat models of arginine- or caerulein-induced pancreatitis signific-
antly reduces acinar cell damage.
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Regulation of Intestinal Epithelial Proliferation Through Beta 1 Integrin-
Dependent Paracrine Hedgehog Signaling in Intestinal Stromal Cells
Xiufen Li, Phillip Gray, Frederic Clayton, Wade S. Samowitz, Scott K. Kuwada
In Vitro studies support the role of the extracellular matrix in the regulation of intestinal
epithelial cell (IEC) proliferation but In Vivo mechanistic studies are lacking. We recently
published that conditional deletion of the beta 1 integrin gene in the intestinal epithelium
of mice caused intestinal epithelial hyperplasia, juvenile type polyps, and early postnatal
lethality (JCB 2006,175:505-14). These findings are found in mice with defective Hedgehog
(Hh) signaling, and both Sonic and Indian Hh expression were drastically reduced in the
IECs of the beta 1 integrin KO mice. AIM: To determine the mechanism by which the beta
1 integrin-dependent Hh signaling regulates IEC proliferation. METHODS: Villin-Cre / beta
1 integrin-flox/flox mice were bred to achieve homozygous deletion of beta 1 integrin in
the intestinal epithelium. IECs were isolated and used for Western blotting and quantitative
RT-PCR. RESULTS: The Hh receptor Patched is expressed only by intestinal stromal cells
and is activated in a paracrine fashion by Shh and Ihh, which are expressed by the IECs.
Decreased Hh signaling, evidenced by greatly reduced mRNA and protein expression of Gli-
1 and Bmp-4 (Hh pathway gene targets), was found in the intestinal stromal but not epithelial
cells of the KO mice vs control littermates. Indeed, exogenous SHH added to IECs and
intestinal myofibroblasts In Vitro increased Bmp-4 expression only in the latter. Bmp receptors
are expressed only by the IECs while Bmp-4 is expressed by the stromal cells. Bmp receptor
activation in IECs by stromal Bmp-4 causes Smad 1,5 and 8 phosphorylation in the IECs
and inhibits IEC proliferation. Western blotting confirmed that phospho-Smad 1,5, and 8
were all drastically decreased in the IECs of the KO but not control littermates. In addition,
protein expression of Id-1, a Bmp gene target, was markedly reduced in the IECs of the
KO but not control mice. The villous IECs of the KO mice demonstrated ectopic foci of
proliferation (Ki-67 positive), a hallmark of mice with defective Bmp signaling. CONCLU-
SIONS: Beta 1 integrin signaling generates Hh paracrine signaling from the IECs to the
stromal cells. Hh signaling in the stroma mediates Bmp-4 expression which then feeds back
to the IECs to regulate their proliferation. These studies provide novel insights into the
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strategic role of beta 1 integrins in regulating intestinal epithelial proliferation by mediating
epithelial-stromal crosstalk.
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Potentiation of Oxyntic Atrophy-Induced Gastric Metaplasia in Amphiregulin-
Deficient Mice
Ki taek Nam, Andrea Varro, Robert J. Coffey, James R. Goldenring
Background & Aims: The loss of parietal cells from the gastric mucosa (oxyntic atrophy)
is a critical step in the pathogenesis of chronic gastritis and gastric adenocarcinoma. Parietal
cells are known to secrete epidermal growth factor (EGF) receptor ligands that are critical
regulators of differentiation and epithelial cell function in the gastric mucosa. Although all
of the actions of EGF receptor ligands are mediated through a common EGF receptor protein,
individual ligands may produce different physiological responses. Previous investigations
have suggested that a deficit in EGF receptor signaling in waved-2 mice accelerates the
emergence of metaplasia following induction of acute oxyntic atrophy. We have now sought
to determine whether specific EGF receptor ligands regulate the metaplastic response to
oxyntic atrophy.Methods: To induce spasmolytic polypeptide-expressing metaplasia (SPEM),
Amphiregulin (AR) and transforming growth factor-α (TGF-α) deficient mice and their wild-
type littermates were treated with DMP-777 for 0 to 14 days as well as for 14 days followed
by 14 days of recovery off drug. We evaluated the gastric mucosal response to oxyntic
atrophy using cell lineage specific markers and also determined serum gastrin levels. Results:
While loss of TGF-α did not influence the induction of SPEM, loss of AR caused an
acceleration and amplification in the induction of SPEM following acute oxyntic atrophy.
DMP-777 treated AR deficient mice showed significantly less foveolar hyperplasia and a
lower gastrin level compared to wild type mice. In contrast, while DMP-777 treated TGF-
α deficient mice showed similar levels of hypergastrinemia as treated wild type mice, they
demonstrated an augmented level of foveolar hyperplasia. In AR-deficient mice the relatively
low level of gastrin appeared to be secondary to a significant increase in the number of
somatostatin expressing D-cells in mice treated with DMP-777 for greater than 7 days. Trefoil
factor family 2 (TFF2)/spasmolytic polypeptide (SP) and intrinsic factor dual-immunostaining
cells were significantly increased in the SPEM of AR deficient mice treated with DMP-777.
At the bases of glands of treated AR-deficient mice, IF immunoreactive cells were also co-
stained for BrdU and Ki-67, suggesting the re-entry of transdifferentiating chief cells into
the cell cycle. Conclusion: The absence of AR, but not of TGF-α, promoted the rapid
emergence of SPEM in response to oxyntic atrophy, likely from transdifferentiation of chief
cells. These findings suggest that AR is an important regulator of gastric lineage differentiation.
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Mechanisms of Post-Endocytic Sorting of Calcitonin Receptor-Like Receptor
(Clr) and Receptor Activity-Modifying Protein 1 (RAMP1), the Receptor for
Calcitonin Gene-Related Peptide (CGRP)
Graeme S. Cottrell, Benjamin Padilla, Stella Pikios, Dirk Roosterman, Martin Steinhoff,
Eileen F. Grady, Nigel W. Bunnett
The G-protein coupled receptor CLR and single transmembrane domain RAMP1 comprise
the receptor for CGRP. Although CGRP induces endocytosis of CLR/RAMP1 by established
mechanisms, little is known about post-endocytic sorting of these proteins to degradative
or recycling pathways. In HEK-CLR/RAMP1 cells, CGRP induced endocytosis CLR/RAMP1,
detected by immunofluorescence and confocal microscopy. CLR and RAMP1 colocalized in
endosomes with β-arrestin1 and 2 (GFP tagged), indicative of a “class B” receptor, which
has prolonged and high affinity interactions with β-arrestins. After sustained stimulation
(10-7 M CGRP, >2 h), CLR/RAMP1 trafficked to lysosomes, where both proteins were
degraded, determined by Western blotting. RAMP1 was degraded ~4-fold more rapidly than
CLR (RAMP1, 45±13% degradation, 5 h; CLR, 54±3% degradation, 16 h p<0.05). Inhibitors
of lysosomal, but not proteasomal, proteases prevented degradation of CLR and RAMP1.
Sustained stimulation with CGRP did not induce detectable mono- or poly-ubiquitination
of CLR or RAMP1, determined by receptor immunoprecipitation and Western blotting for
ubiquitin. A RAMP1 mutant lacking the only intracellular lysine (RAMP1K142R, a potential
site of ubiquitination) was internalized and degraded normally. In contrast, after transient
stimulation (10-7 M CGRP, 1 h), CLR and RAMP1 recycled with similar kinetics (2-6 h),
demonstrated by labeling receptors in living cells with antibodies to extracellular epitopes.
Transient stimulation desensitized CLR/RAMP1, assessed by measuring CGRP-induced
increases in [Ca2+]i. Bafilomycin A1 (inhibitor of vacuolar H+-ATPases) abolished resensitiza-
tion after transient stimulation, expression of dominant negative (GTPase-deficient) Rab4a
and Rab11a mutants inhibited resensitization (% resensitization compared to vehicle-treated
cells: vector control, 92±4; Rab4a, 93±3, Rab4aS22N, 77±4, Rab11a, 95±5, Rab11aS25N,
69±3), but cycloheximide (inhibitor of protein synthesis) did not affect resensitization. To
confirm this agonist-dependent post-endocytic trafficking of CLR and RAMP1, we expressed
epitope-tagged CLR and RAMP1 in SK-N-MC cells, which naturally express CLR and RAMP1.
Sustained stimulation with CGRP induced lysosomal trafficking of CLR and RAMP1, whereas
transient stimulation with CGRP induces recycling of CLR and RAMP1. Thus, after sustained
stimulation, CLR and RAMP1 traffic from early endosomes to lysosomes by an ubiquitin-
independent mechanism where they are degraded at different rates. After transient stimula-
tion, CLR and RAMP1 recycle by Rab4a and Rab11a-dependent pathways to mediate resensit-
ization. Supported by NIH DK39957, DK52388.
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Regulation of Gastric Ghrelin Secretion By Nitric Oxide (NO) Derived from
Neuronal Nitric Oxide Synthase (nNOS)
Tatsuhiro Masaoka, Hidekazu Suzuki, Yuriko Minegishi, Tetsufumi Takahashi, Eisuke
Iwasaki, Makoto Suematsu, Hiroshi Hosoda, Kenji Kangawa, Toshifumi Hibi
Background. Ghrelin is a gastrointestinal peptide with physiological roles of stimulating
food intake and gastric motility. We previously reported increased plasma ghrelin levels in
rats with streptozotocin-induced diabetes (FEBS Lett.541:64,2003),gerbils with H. pylori
infection(Gut 53:187, 2004). It has been suggested that insulin resistance, rather than a
high body mass is associated with reduction of the plasma ghrelin(J. Clin. Endocrinol.
Metab. 89:1630, 2004). Since nitric oxide (NO) induces adaptive relaxation of gastric
fundus, it is considered to be a conditioning factor for meal ingestion.Then, a relationship
between NO and the ghrelin dynamics is suggested. Using neuronal nitric-oxide-synthase-
deficient (nNOS-/-) mice, we evaluated whether NO derived from nNOS contributed to the
ghrelin production and secretion. Methods. Twelve week old male nNOS-/- mice(n=10)and
wild-type (WT) mice(n=10) were examined after 18 hours of food deprivation. The plasma
and gastric ghrelin levels were measured by radioimmunoassay, and the preproghrelin mRNA
expression level was measured by quantitative RT-PCR. Ghrelin expression in the stomach
was evaluated by immunohistochemistry. The plasma adiponectin, leptin and insulin levels
in sera were measured by ELISA. Results. In the nNOS-/- mice, the body weight(WT
22.2±0.6; nNOS-/- 26.3±0.5g, p <0.001), food intake, plasma levels of active(WT 75.5±6.5;
nNOS-/- 119.8±11.3fmol/ml, p <0.01) and total ghrelin(WT 827.5±24.1; nNOS-/-
1631.7±130.3fmol/ml, p <0.001), gastric levels of active(WT 984.8±61.6f; nNOS-/-
1446.4±234.3fmol/mg, p <0.05) and total ghrelin(WT 4677.4±237.4; nNOS-/-
5803.0±346.4fmol/mg, p <0.05), gastric preproghrelin mRNA expression levels(WT 0.7±0.1;
nNOS-/- 1.2±0.1, p <0.001), and the number of ghrelin-immunoreactive cells in the gastric
fundus(WT 124.0±9.9; nNOS-/- 152.1±8.5/mm2, p <0.05) were significantly increased as
compared with the corresponding values in the WT mice. Furthermore, while the serum
levels of adiponectin, which reflect the amount of visceral adipose tissue, were significantly
decreased in the nNOS-/-mice as compared with those in the WT mice(WT 26.4±1.6; nNOS-/-
19.2±1.0μg /ml, p <0.01), there were no significant differences between the two groups of
mice in the serum levels of insulin or leptin. Conclusion. The production and secretion of
ghrelin from the stomach were significantly increased in the nNOS-/- mice, which also
showed a significant increase in body weight, suggesting that NO derived from nNOS may
suppress the production and secretion of ghrelin from the stomach.
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Characterization of Gastrointestinal (GI) Enteroendocrine Ghrelin Producing
Cells
Shari Anthony, Xinping Lu, Weiping Chen, James M. Simone, Margaret Cam, Rafael
Villasmil, Stephen A. Wank
Background and Aims: Peptide hormones released from enteroendocrine cells along the GI
tract play a major role in the regulation of digestion, absorption and motility, as well as
appetite and satiety. Ghrelin is the only orexigenic peptide hormone reported to play a role
in short-term meal initiation and energy homeostasis. Ghrelin is produced in gastric X/A
cells, as well as enteroendocrine cells present throughout the intestinal tract. Despite intensive
study, the regulation of ghrelin remains unclear largely due to the relatively rare (<1% of
mucosal cells) and highly dispersed distribution of ghrelin cells within the mucosa of the
GI tract. Development of a practical method to isolate a pure population of ghrelin secreting
cells would greatly accelerate present efforts to understand it's regulation. Methods: FEB/N
transgenic mice were created using a construct containing a 5 Kb upstream promoter
sequence of the ghrelin gene fused with EGFP. Resected stomach, intestine and colon were
fixed in 4% paraformaldehyde, impregnated with 30% glucose and frozen for sectioning.
Ghrelin cells were stained with rabbit anti-ghrelin antibody, and detected by immunofluoresc-
ence using Alexa 594 goat anti-rabbit antibody. Dispersed single cells were obtained from
small intestinal digestion with collagenase and EDTA . Ghrelin-EGFP positive cells were
isolated by Fluorescence Activated Cell Sorting (FACS). Total RNA was extracted with
TRIzol and gene expression was assessed using an Affymetrix mouse genome 430-2.0 array
GeneChip. Results: Of three transgenic founders, two displaying higher EGFP expression
were analyzed. These mice were healthy, fertile and displayed no phenotype compared to
their WT littermates. Ghrelin-EGFP positive cells were present along the GI tract in a similar
expression pattern in both founders. Nearly 100% of the ghrelin-EGFP cells expressed ghrelin
immunoreactivity and nearly all ghrelin immunoreactive cells expressed EGFP fluorescence.
Consistent with our immunohistochemistry results, the gene expression profile of ghrelin-
EGFP positive cells resulted in a 527-fold increase compared to ghrelin-EGFP negative cells.
Conclusion: We have generated transgenic mice in which ghrelin cells along the GI tract
express EGFP in a sensitive and specific fashion. Using EGFP as a marker and FACS, we
were able to isolate a pure population of ghrelin cells from the small intestine that has
allowed us to complete a meaningful gene expression profile. Having a pure population of
ghrelin-positive cells should facilitate our ability to interrogate the gene expression profile
for potential candidates involved in the regulation of ghrelin secretion.
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Transgenic Expression of Pancreatic Secretory Trypsin Inhibitor (PSTI)
Increases Intestinal Cholecystokinin Cell Abundance and Causes Pancreatic
Hypertrophy
Yu Wang, Joelle Romac, Jay Hsu, Jinseok Heo, Rodger A. Liddle
Pancreatic secretory trypsin inhibitor (PSTI), also known as monitor peptide, is an endogen-
ous trypsin inhibitor produced by pancreatic acinar cells and is believed to protect against
prematurely activated trypsin within the pancreas. PSTI is stored in zymogen granules and
along with digestive enzymes is secreted into the duodenum. We previously have shown
that exogenous PSTI stimulates cholecystokinin (CCK) secretion In Vivo and from isolated
CCK cells In Vitro. In the current study we proposed that PSTI may have a physiological
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role in regulating CCK cell secretion and, therefore, may be an endogenous CCK releasing
factor. Methods: We recently created a transgenic mouse expressing a transgene comprised
of the mouse elastase I enhancer/promoter cloned upstream to a rat PSTI minigene. Pancreata
from PSTI transgenic and non-transgenic mice were compared by weight and morphometric
analysis of cell size. Duodenal CCK cell number was quantified following immunostaining
and plasma CCK levels were measured by our previously described bioassay using CCK-
stimulated amylase release from isolated pancreatic acini. Results: Western blot analysis and
immunostaining showed that PSTI expression was confined only to acinar cells of the
pancreas. Trypsin inhibitor activity was increased 1.9 fold in PSTI transgenic mice. By 4
weeks of age the pancreata of PSTI transgenic mice were 183% larger compared to non-
transgenic littermates. In addition, acinar cells were 18% larger by morphometric analysis
in PSTI transgenic compared to non-transgenic mice indicating cellular hypertrophy. Since
PSTI is a CCK secretagogue and CCK is known to exert trophic effects on the pancreas, we
examined CCK cell abundance in duodenum and CCK blood levels. Immunoreactive CCK
cells comprised only 0.6±0.1% of duodenal mucosal cells in non-transgenic mice but repres-
ented 1.3±0.2% of the mucosal cell population in PSTI transgenic mice (p<0.001, n=4-5).
Therefore, CCK cells were two-fold more abundant in intestine of PSTI transgenic mice.
Plasma CCK levels averaged 3.2±0.6pM in non-transgenic mice but were over four-fold
higher (14.8±0.5 pM) in PSTI transgenic mice. Conclusions: PSTI expression causes increased
intestinal CCK cell number, higher CCK blood levels and pancreatic hypertrophy. We
propose that PSTI secretion plays an important role in regulating CCK enteroendocrine cells
and the trophic effects of CCK may be responsible for the observed effects on pancreatic
growth.
832
Very High Prevalence of New-Onset Diabetes in Pancreatic Cancer- Results of
a Case-Control Study
Rahul Pannala, Jeffery B. Leirness, William Bamlet, Ananda M. Basu, Gloria M. Petersen,
Suresh T. Chari
Background/Aims: The association between diabetes mellitus (DM) and pancreatic cancer
(PaC) is complex because long-standing DM is a possible etiologic factor for PaC, and new-
onset DM is likely a manifestation of the cancer. However, the prevalence and clinical profile
of DM occurring in PaC remains poorly characterized. In a large case-control study, we
determined the prevalence of DM and impaired fasting glucose (IFG), estimated the propor-
tion of new onset DM (<2 years), and studied the clinical features of DM in PaC. Methods:
Newly diagnosed PaC patients from the Mayo Pancreas Clinic and age-matched controls
without a personal history of cancer attending our primary care clinic for routine physical
examination were prospectively recruited using ultra-rapid case ascertainment. Cases (n=
512) and controls (n=933) provided detailed demographic and clinical data through a
questionnaire and all had a fasting blood glucose (FBG) measurement within 30 days of
diagnosis (PaC) or enrollment (controls). Patients were classified as having DM (FBG > 126
mg/dl or on anti-diabetic treatment), IFG (FBG 100-125 mg/dl) or normal FG (<99 mg/dl).
Clinical and demographic data were abstracted from the questionnaire. Results: Cases and
controls were of similar age (66+10.5 vs.66+10.7 years) with a slight preponderance of men
among cases (57% vs. 47%, p<0.01). In cases, compared to controls, FBG was significantly
different (p<.001) and there was a higher prevalence of DM (47%vs 7%) and IFG (38% vs
34%), and a lower prevalence of normal FG (14% vs 59%). In multivariate analyses, PaC
patients, compared to controls, were at a 14-fold higher risk of DM (95% confidence intervals,
8.7, 21.5) after adjusting for age, gender, pre-morbid BMI and family history of DM. Among
diabetic patients, DM was previously undiagnosed in 24/67 (36%) of controls compared to
118/243 (49%) of PaC cases (p=0.06). Only 26% of diabetic PaC patients had DM of > 2
years duration vs. 47% of diabetic controls (p=0.002). PaC patients with DM were older
(67.9+9.5 vs. 64.4+11.5 years, p<0.001), had higher pre-morbid BMI (29.6+5.7 vs. 27.3+5.0,
p<0.001), were more likely to have weight loss >10 lbs (72% vs. 57%, p<.001) and a family
history of DM (47% vs. 31%, p<.001) as compared to PaC patients without DM. Conclusions:
PaC is a powerful diabetogenic state: only 14% of patients have a normal FG, and nearly
50% have DM which is not explained by differences in pre-morbid BMI and family history
of DM. Approximately 75% of DM in PaC patients is new-onset. The high prevalence of
DM and its temporal relationship to diagnosis of PaC suggests that in most patients the DM
is a consequence of the cancer.
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Association of New Onset Diabetes with Pancreatic Cancer
Marc Dorais, Raja Tamaz, Benoit Panzini, Jacques Le lorier
Background: Diabetes mellitus is generally considered to be associated with pancreatic cancer,
but the strength of this association is unclear. The relationship of diabetes with PC as a
cause versus consequence of the disease remains poorly defined, due in part to the lack of
accurate data on their temporal association. Objective: To examine the association of new
onset diabetes and PC in the period preceding the diagnosis of PC. Method: The Québec
Health Insurance Plan (Régie de l'Assurance Maladie du Québec, RAMQ) provides full
medical services and prescription drug coverage for nearly all individuals 65 years or older
living in a Canadian province of 7 million inhabitants in which they constitute a group of
approximately 850 000 individuals. Using this database, we performed a nested case-control
study, selecting a random sample of 75% of patients aged ≥ 70 who received a diagnosis
of PC between January 1993 and December 2003. Subjects receiving a first prescription of
oral hypoglycaemic agents or insulin were defined as new onset diabetic. Controls were
matched for age, sex and time period. Incidence of new onset diabetes was determined in
3 monthly intervals during the 5 years preceding the diagnosis of PC. Data were analysed
using conditional regression analysis adjusted for relevant variables. Results: A total of 3,030
cases of PC were analysed during the period of this study. Those were matched to 12,093
controls. Males represented 46 % of cases and controls. Subjects aged between 70 and 79
years represented 69% of cases and controls. The death rate for cases was 83% within 3
years after the diagnosis of PC compared to 16 % for controls. Diabetes was diagnosed in
23 % of cases and in 12 % of control subjects (odds ratio [OR], 2.04; 95% confidence
interval [CI]: 1.85-2.26) during the 5 years of observation. There was a significant and
gradually increasing association of new onset diabetes with PC at each 3 monthly period.
The OR of new onset diabetes for the period preceding PC, adjusted for medical resources
utilization was: 3 months before the diagnosis of PC, 8.50 (95% CI: 5.48-13.16); 6 months,
6.85 (CI: 5.03-9.33); 12 months, 5.97 (CI: 4.73-7.53); 18 months, 5.24 (CI: 4.27-6.43);
24 months, 4.58 (CI: 3.80-5.52); 36 months, 3.98 (CI: 3.38-4.69); 48 months, 3.45 (CI
2.98-3.99) and 60 months, 2.04 (CI: 1.85-2.26). Conclusion: Our results strongly suggest
that diabetes is a risk factor for PC in individuals aged ≥ 70. The marked increase in the
incidence of new onset diabetes within the 2 years preceding the diagnosis of PC may be
explained by detection bias or alternately may represent an early manifestation of the disease.
834
A Novel Highly Accurate Bio-Optical Approach for Improving the Cytologic
Diagnosis of Pancreatic Adenocarcinoma(PC)
Randall E. Brand, Hariharan Subranmanian, Charles Sturgis, Yang Liu, Vladimir
Turzhitsky, Nahla Hasabou, Debbie Polidoro, Hemant K. Roy, Vadim Backman
The suboptimal sensitivity rates for the cytologic diagnosis of PC are due in part to the
relative rarity of frankly malignant-appearing cells that can be identified by cytology. However,
cells that appear histologically normal may still have alterations in microscopically-invisible
detail, at the nanoscale. We have developed partial wave spectroscopic (PWS) microscopy
enabling the analysis of cell nanoarchitecture. To characterize cell nanoarchitecture we used
a PWS-derived parameter termed the disorder strength (Ld), which is proportional to the
variance of intracellular density of macromolecules (DNA, proteins, etc). We performed a
pilot study to test the hypothesis that epithelial cells considered to be nonmalignant (NM)
by conventional cytology in patients with PC possess nanoscale abnormalities. Methods: A
cytopathologist classified cells as either malignant (M) or NM from archived cytologic
specimens. PWS was performed on 26 groups of cells from 20 cases (13 PC). Of these
groups, 9 were M. The 17 NM groups were from the following clinical scenarios: 7 surgically
confirmed benign cases (B), 6 cases that also contained malignant cells and 4 cases interpreted
as nondiagnostic with PC confirmed subsequently. Results: As shown in the figure, the
intracellular standard deviation of Ld (SDLd) was significantly elevated in NM cells obtained
from PC patients, approximated the M cells and was different from the NM cells from B
cases. A prediction rule using Ld and SDLd had a sensitivity of 90% in the 10 NM cases
(one PC patient with nondiagnostic cytology was not detected) and 100% specificity. Overall
PWS improved the sensitivity of cytology from 69% to 92%. Conclusion: PWS can potentially
revolutionize the cytological diagnosis of PC through correct classification of cytologically
nonmalignant-appearing pancreatic cells as malignant. Large scale studies are currently
being conducted.
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Serum Tumor Antigen Reg4 in Pancreatic Cancer As a Useful Diagnostic
Biomarker
Reiko Takayama, Kenji Yamao, Akira Sawaki, Nobumasa Mizuno, Hidewaki Nakagawa,
Yusuke Nakamura
Background: Pancreatic cancer shows the worst mortality among the common malignancies,
because its detection at an early stage is difficult. So, one of the most realistic strategies to
improve the prognosis of this fatal disease is to screen pancreatic cancers at an early stage
or high-risk individuals of pancreatic cancer by non-invasive serological test. We focused
on a secreted protein REG4, which belongs to the REG (regenerating islet-derived) family,
and it's reported to be over-expressed in several gastrointestinal cancers. Earlier, we generated
precise expression profiles of pancreatic cancer cells using genome-wide cDNA microarrays
consisting of approximately 36,000 genes (Nakamura T. et al. Oncogene 23, 2385: 2004).
Pancreatic cancer tissues consist of large parts of non-cancer, stromal components. So, we
micro-dissected cancer cells from the tissues and purified them, then applied their amplified
RNA to the microarray analysis. Our precise microarray analysis on pancreatic cancer cells
identified several hundreds of over-expressing genes in pancreatic cancer cells. Among them,
we focused on one gene coding REG4 (Takehara A. et al. Cancer Science 97, 1191: 2006).
In this study, we evaluated the usefulness of REG4 in correlation with levels of tumor-
derived serum marker. Methods: We evaluated serum samples for the presence of REG4 in
healthy controls (n=48) and the patients (n=96), who had been confirmed to have pancreatic
disease between November 2004 and December 2005. Enrolled patients were 60 patients
with pancreatic cancer, 17 patients of intraductal papillary mucinous neoplasm (IPMN), 14
patients of pancreatitis, 2 patients with pancreatic cysts, 2 patients with fatty deposition, 1
patient with solid pseudopapillary tumor (SPT). Every patient was given written informed
consent. REG4 was quantified by ELISA (Enzyme Linked Immunosorbent Assay). We evalu-
ated the diagnostic value of REG4 by measuring antigen levels. Receiver operating character-
istic (ROC) plots were generated to determine the diagnostic accuracy. Results: The antigen
level of REG4 has different levels among pancreatic cancer, non-cancer, and healthy controls
(p<0.0001). We could discriminate the pancreatic cancer patients from controls with a
diagnostic power of 0.91 estimated by the area under ROC curve at a cutoff point of 3.53.
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At a cutoff point of 3.53, the specificity for pancreatic disease was 100% and the sensitivity
was 63.3%, the specificity is at 85.7%, and Accuracy is at 76.4%. Conclusion: Serum tumor
antigen, REG4 might be a promising serum tumor marker, when we distinguish pancreatic
cancer from healthy control.
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A Prospective Evaluation of the Systemic Inflammatory Response As a
Prognostic Indicator in Resectable Pancreatic Malignancy
Jennifer Logue, Simon Denley, Joanne Edwards, Donald Mcmillan, Clement Imrie, Ross
Carter, Colin Mckay
Introduction We have previously reported an association between the systemic inflammatory
response and survival following potentially curative resection for ductal adenocarcinoma of
the pancreas. The aim of this study was to prospectively evaluate the role of C-reactive protein
(CRP) as a prognostic indicator in resectable pancreatic cancer in addition to examining for
any association between serum levels of the regulatory cytokines intereukin-6 and interleukin-
8. Methods Pre-operative serum samples were collected prospectively from all patients
undergoing Whipple resection between 2003 and 2006. Routine laboratory measurements
of CRP were performed the day prior to surgery and recorded. Serum interleukin-6 and
interleukin-8 levels were measured by enzyme-linked immunosorbent assay (ELISA). Triplic-
ate analysis was performed and the mean value was used as the final concentration. Results
Sixty-four patients underwent Whipple resection for pancreatic or peri-ampullary tumours.
Thirty-six patients had completed a minimum of 14 months of follow-up at the time of
analysis. On follow-up, 20 patients had died of their disease. Elevated pre-operative CRP
was confirmed as a predictor of poor survival (p<0.05). Furthermore, Cox regression survival
analysis demonstrated that those patients with elevated serum interleukin-6 levels had
significantly worse survival (p<0.01). Serum interleukin-8 levels were not associated with
survival differences. There was a significant correlation between serum interleukin-6 levels
and CRP (r = 0.46, p<0.01). Conclusions The results of this prospective study demonstrate
that elevated pre-operative CRP predicts poor survival in patients undergoing Whipple
resection. This is associated with elevated interleukin-6 levels and suggests a relationship
between dysregulation of the innate immune response and an adverse prognosis with pancre-
atic cancer. Confirmation in a larger cohort of patients may enable pre-operative CRP to
aid in the selection of patients for potentially curative resection.
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A Pancreatic Cancer Screening Program for Familial High-Risk Individuals
Robert C. Kurtz, Jennifer Simon, Emmy Ludwig, Hans Gerdes, Michael House, Peter J.
Allen, Sara Olson
Patients (pts) with pancreatic adenocarcinoma (PC) have a median survival of 4-6 months.
No significant improvement in prognosis has occurred over the last 20 years. This dismal
outcome is likely due to advanced stage at initial presentation. Methods. In an attempt to
find early stage PC or its precursor lesions, we chose to screen healthy members of Familial
Pancreatic Cancer (FPC) families using non-invasive cross-sectional imaging (MRCP and/or
CT scan) and endoscopic ultrasonography (EUS). In 2002 we began a registry for FPC pts
and their healthy relatives. Healthy FPC relatives have MRCP or CT scans done initially,
followed by EUS when cross-sectional imaging reveals a pancreatic abnormality, by pt request
or when done at another center. To date, imaging studies have been performed in 66 of
103 consented relatives and these 66 participants represent the study group. Results. There
were 49 women, mean age 53.3 yrs, and 17 men, mean age 55.6 yrs who completed one
or more imaging studies. Twenty-five were Catholic, 19 were Jewish (17 of Ashkenazi
heritage), 9 were Protestant and there were 13 other. Twenty-six participants had 2 affected
relatives in their kindred, 14 had 3, 9 had 4, 2 had 5 relatives, and 3 had 1 affected relative
(PC before age 50). Forty-one participants had MRCP and/or CT without EUS, and 24 had
MRCP and/or CT plus EUS. Five asymptomatic participants (7.6%) were found to have
significant pancreatic lesions requiring intervention. All were women. Four had surgery: 3
had non-invasive intraductal papillary mucinous neoplasms (IPMNs) and 1 had an islet cell
tumor. One was found to have advanced PC diagnosed by imaging and biopsy. Those with
IPMNs included a 67 yo with 1 affected first degree relative (FDR) and 1 second degree
relative (SDR); A 72 yo with 3 affected FDRs (she was also in another screening study and
had surgery elsewhere); an 86 yo with 2 affected FDRs. Three of the women are Jewish (2
Ashkenazi, and 1 unknown). The pt with the pancreatic islet cell tumor is 63 yo with 1
affected FDR and 3 affected SDRs. The advanced PC was found in a 58 yo with 2 affected
FDRs. There were no adverse events related to the screening program. Conclusions. Our
study suggests that screening with MRCP/CT and EUS can detect early, asymptomatic
pancreatic neoplasms (mainly IPMNs) in presumed healthy FPC family members. We specu-
late that IPMNs might be the common PC precursor lesion in FPC patients. Whether or
not screening healthy FPC family members leads to improved PC survival will require further
investigation. Large, multi-institutional screening trials are needed to answer this question.
838
Immunisation with G17dt Can Slow Cancer Progression in the Insgas Mouse
Model
Amanda Tobias, Philip A. Clarke, Philip Kaye, Mohamad El-zaatari, Susan A. Watson
Introduction: Gastrin, a polypeptide hormone, secreted by G-cells in the stomach, is a
promoter of cancer cell growth In Vitro and In Vivo. Gastrin acts through cholecystokinin
type two receptors (CCK-2R) and the expression of both the gastrin gene and the CCK-2R
are closely linked to development, progression and invasion of cancer cells. Anti-gastrin
immunogen (G17DT) consists of a synthetic peptide from the N-terminal of human G17,
attached to a carrier protein, Dipheria Toxoid (DT). G17DT induces an antibody response
which neutralises the target hormone. Aim: This study examined the effect of G17DT on
development of pre-cancerous changes in stomachs of transgenic InsGas mice, which over-
express amidated gastrin (G17) under control of a rat insulin I promoter, and go on to
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develop glandular atrophy and invasive gastric cancer. Materials and Method: Mice were
given a course of either 250μg G17DT or DT at 0, 1 and 3 wks and then at 3-weekly
intervals thereafter. Mice were terminated at 10, 20 and 32wks, 1hr after administration of
bromodeoxyuridine. Stomach tissue was fixed, paraffin-embedded or snap frozen, and sec-
tioned for immunohistochemistry. A specific BrdU antibody was used to stain proliferating
cells and proliferating cells per gland and pre-cancerous lesion were counted. COX-2 antibody
was used to determine the protein level of COX-2, CD34 was used to stain blood vessels
and CCK-2R to stain the receptor. Results: In the fundus and antrum the levels of proliferation
were reduced at all time points in the G17DT groups compared to DT. A significant reduction
in proliferation was seen in the fundus of 32wks G17DT-treated mice in both normal tissue
and pre-cancerous lesions (p=0.005 and p=0.002, respectively). There was also a significant
decrease in COX-2 protein expression (p<0.001) in the 32wks G17DT group compared to
DT, but no significant decrease was seen at 10 and 20wks. Mean blood vessel density (BVD)
was reduced at all timepoints in the G17DT groups, although the reduction was only
significant in the 32wks G17DT group (p=0.006) compared to DT. At 32wks the pre-
cancerous lesions showed localisation of the CCK-2R. Conclusion: It has previously been
demonstrated that G17 is an important effector of tumour cell proliferation. As well as
increasing COX-2 expression, G17 has pro-angiogenic properties and the current study has
confirmed these activities in the InsGas mouse. This study has shown the downstream
pathways fuelled by gastrin in the development of pre-cancerous lesions as treatment with
G17DT reduces proliferation, COX-2 protein expression and BVD suggesting that gastrin
may promote gastric carcinogenesis through these mechanisms.
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H. pylori Eradication Prevents Progression of Gastric Cancer in
Hypergastrinemic Ins-Gas Mice
Chung wei Lee, Barry Rickman, Timothy C. Wang, James G. Fox
Helicobacter pylori infection causes chronic gastritis that may progress to gastric adenocarcin-
oma. In experimental H. pylori infection in cancer-prone, hypergastrinemic male INS-GAS
mice, we examined the efficacy of H. pylori eradication (omeprazole 400 µmol/kg/day,
metronidazole 14.2 mg/kg/day, and clarithromycin 7.15 mg/kg/day) in preventing gastric
carcinogenesis. Antimicrobial therapy was administered twice a day for 7 days during 3
timepoints postinfection; 8, 12, or 22 weeks (WPI). Mice were euthanized at 28 WPI.
H. pylori infection resulted in severe dysplasia manifested as high-grade gastrointestinal
intraepithelial neoplasia (GIN) in INS-GAS mice after 28 weeks of infection. Mice receiving
early eradication therapy had significantly attenuated gastric lesions when compared to
nontreated infected mice (p<0.001 and p<0.01, respectively). Although not as effective as
early treatment, progression to gastric cancer was ameliorated by H. pylori eradication at 22
WPI (p<0.01). Consistent with dysplasia scores, H. pylori eradication at 8, 12, and 22 WPI
significantly reduced the severity of gastritis (p<0.001) as well as gastric expression of IFNγ,
TNFα, and iNOS (all p<0.001), and glandular epithelia proliferation indices (p<0.01). We
conclude that H. pylori eradication is beneficial for attenuating the progression from severe
dysplasia to gastric cancer in H. pylori-infected INS-GAS mice. This study suggests the
potential benefit of eradication therapy of chronic H. pylori infection and prevention of
gastric cancer in humans.
840
Overexpression and Biological Function of Prion Protein in Gastric Cancer:
Promoting G1/S Phase Transition By Transcriptional Activation of Cyclind and
Inhibiting Apoptosis Through Bcl-2-Dependent Apoptotic Pathways
Jie Liang, Daiming Fan
Cellular prion protein (PrPC), the normal isoform of the pathogenic peptide (PrPSc) respons-
ible for the transmissible spongiform encephalopaties (TSEs), was previously found by our
lab to be widely expressed in gastric cancer cell lines, with a certain effect on drug accumula-
tion. In order to evaluate its biological significance in human gastric cancer, we investigated
its expression in a large series of gastric tissue samples (n = 124) by immunohistochemical
staining with the monoclonal antibody 3F4. Compared with normal tissues, gastric adenocar-
cinoma showed increased PrPC expression, correlated with the histopathological differenti-
ation (according to the WHO and Lauren classifications) and tumor progression (as docu-
mented by pTNM staging). To better understand the underlying mechanism, we introduced
the PrPC and two pairs of RNAi into both of gastric cancer cell lines AGS, SGC7901 and
found that overexpression of PrPC stimulated cell growth and the cycle progression, which
also significantly promoted SGC7901 cell growth in soft agar and its tumorigenicity in nude
mice. Meanwhile PrPC suppressed ROS and slowed down apoptosis in transfected cells.
PrPC was also found to be involved in cell cycle progress by promoting G1/S phase transition
dependent on overexpressed cyclinD and stimulated CDK4 activity analyzed by RT-PCR
and western blot in transfected cell models. However the apoptosis-related protein Bcl-2
was upregulated whereas p53 and Bax were downregulated in the PrPC-transfected cells.
A reverse effect was observed in PrPC siRNA-transfected cells. Then we cloned the CyclinD
gene (CCND) promoters containing PrPC binding sites and constructed the luciferase reporter
vectors. Luciferase reporter assay suggested that PrPC stimulated the promoter activity of
the CCND promoters higher than that of pcDNA3.1 vector, with CCND1 4.94-fold, CCND2
3.36-fold and CCND3 3.65-fold. These results strongly suggested that PrPC promoted G1/
S phase transition of gastric cancer cells by transcriptional activation of CyclinD, at the same
time it played a role as an effective anti-apoptotic protein through Bcl-2-dependent apoptotic
pathways in gastric cancer cells. Further study into the mechanism of these relationships
might enrich the knowledge of PrP, better our understanding of the nature of gastric
carcinoma, and further develop possible strategies to block or reverse the development of
gastric carcinoma.
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Enhancement of Development of N-Methyl-N-Nitrosourea-Induced Gastric
Malignant Lesions in C57blks/J- + LeprDb/+ LeprDb Mice
Nao Yoshizawa, Hirokazu Yamaguchi, Michio Kaminishi
Background: For many years, association between diabetes mellitus and malignant neoplasms
has been discussed. Studies have shown that diabetes mellitus is related to colon cancer,
breast cancer, pancreatic cancer and so on. In 2005, Yamagata et al. has shown in their
epidemiological study that a modest increase in fasting plasma glucose levels is a risk factor
for gastric cancer among H. pylori-seropositive subjects. However there is no animal model
showing association between diabetes mellitus and gastric cancer. Aim: To examine whether
occurrence of N-Methyl-N-Nitrosourea (MNU) - induced dysplastic and neoplastic lesions
of stomach is modulated in genetically diabetic db/db mice. Materials and Methods: A total
of 160 male 5-week-old mice were used. We assigned them into 5 groups. Group A; 40
db/db mice with treatment of MNU, Group B; 40 +/db mice with treatment of MNU, Group
C; 30 +/+ mice with treatment of MNU, Group D; 10 db/db mice without MNU, Group E;
40 db/db mice with treatment of MNU and H. pylori infection. MNU was given at 60 ppm
in drinking water for 20 weeks. Body weights and amount of water intake were measured
once a week. H. pylori were inoculated three times at week 1. The animals were sacrificed
at week 21 and 30 under anesthesia. At killing, blood samples were collected and glucose,
insulin, leptin, and adiponectin concentrations were measured by suspension array at Genetic
Lab Co., Ltd. The removed stomachs were fixed in 4% formaldehyde, embedded in paraffin,
and cut into 4-μm sections. Replicate sections were stained with hematoxylin and eosin.
Results: Until 30 weeks, 10 (25%) mice died in group A, 10 (25%) in group B, 9 (30%)
in group C, 3 (30%) in group D, 9 (23%) in group E, so 119 mice were investigated.
Average of body weights (g) was 25.5, 21.5, 16.3, 29.2 and 30.7 at week 1, 56.3, 22.5,
18.8, 36.5 and 53.7 at week 20, 61.7, 23.2, 18.9, 34.9 and 50.8 at week 30 in each group
respectively. Total intakes of MNU (mg) per mouse were 19.1, 16.7, 13.8, 0 and 17.4 for
each group. Body weights of db/db mice increased until week 15, so during week16-20
MNU per mouse weight in db/db mice was less than that in control mice. At week 21,
Enlarged or cystic glands were observed 79, 68, 42, 5 and 68 (%), epithelial hyperplasia
was observed 53, 50, 42, 0 and 76 (%), and epithelial dysplasia was observed 37, 6, 8, 0
and 59 (%), respectively. We observed carcinoma in 6% in Group E. Conclusion: Gastric
dysplasia induced by MNU was enhanced in db/db mice and cancer was obtained only in
db/db mice with H. pylori. Our data indicate that development of MNU - induced neoplastic
lesions is enhanced in db/db mice.
842
Inactivation of Secreted Frizzled-Related Protein 2 (Sfrp2) Gene in Gastric
Cancer and Its Potential Application
Wai K. Leung, Yuen y Cheng, Jun Yu, Christine Wong, Ellen Man, Julia Li, Wilson
Chong, Ka-fai To, Francis k L. Chan, Joseph J. Sung
Secreted frizzled related protein (SFRP) family genes are antagonists of the transmembrane
frizzled receptor, a component of the Wnt signaling pathway. Epigenetic inactivation of
SFRP1 is found to play a pivotal role on cancer development. However, the role of other
SFRP family genes on tumorigenesis remains largely unknown. Methods & Results: To
determine the frequency and functional significance of SFRP2 methylation in human gastric
cancer, we first screened the expression status of SFRP2 in 7 gastric cancer cell lines and
14 primary gastric cancer samples by RT-PCR. SFRP2 was silenced in all gastric cancer cells.
The mean expression level of SFRP2 was significantly lower in gastric cancer tissues as
compared to their adjacent normal tissues (P=0.008). Promoter hypermethylation of SFRP2
was detected in 73.3% primary gastric cancer as compared to 20% adjacent normal gastric
tissues (P<0.001) by methylation-specific PCR (MSP), which was associated with gene
downregulation. High resolution mapping of the promoter region by bisulfite sequencing
confirmed the densely methylated promoter region in MKN28 cell line, and 4 randomly
selected primary gastric cancer tissues and their adjacent normal tissues. Treatment with
demethylation agent, 5-aza-deoxycytidine, restored the expression of SFRP2 in all 7 cancer
cell lines. SFRP2 methylation was also detected in premalignant gastric lesions. Nine (37.5%)
endoscopic gastric biopsy samples obtained from non-cancer patients harboring intestinal
metaplasia also had methylated SFRP2 detected by MSP, suggesting their early involvement
in the multi-step gastric carcinogenesis process. We further tested the biological function
of SFRP2 in human gastric cancer cells. Transient transfection of SFRP2 in MKN45 cells
induced apoptosis (from 0.56% to 8.1%, P = 0.001) and inhibited cell proliferation (from
0.77% to 0.56%, P = 0.001). The In Vivo growth of MKN45 cells in nude mice was also
markedly inhibited by stable transfection with vector harboring SFRP2. At the end of 3-
week, there was negligible tumor growth in the transfected group as compared to control
(mean tumor size 97.87±18.15 mm3, P<0.0001). The feasibility of detecting methylated
SFRP2 DNA in the serum of gastric cancer patients was tested. Methylated SFRP2 was
detected in 12 (66.7%) serum samples from patients with gastric cancer but not in the 18
serum samples from normal controls (P<0.0001). Conclusion: Epigenetic inactivation of
SFRP2 is a common event in gastric carcinogenesis which may play a pivotal role on gastric
cancer development. Detection of methylated SFRP2 in serum may serve as a potential
biomarker for this cancer.
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The Effect of Sex Hormones On H. pylori-Induced Gastritis in Ins-Gas Mice
Masahiro Ohtani, Alexis Garcia, Arlin B. Rogers, Zhongming Ge, Nancy S. Taylor,
Koichiro Watanabe, Robert P. Marini, Mark T. Whary, Timothy C. Wang, James G. Fox
Background: The incidence of gastric cancer is higher in men than women. Helicobacter
pylori infection plays a crucial role in the pathogenesis of gastritis and gastric cancer; however
the effect of sex hormones on gastritis caused by H. pylori infection has not been fully
investigated. Aim: We investigated the effect castration of males and/or supplementation of
17β estradiol (E2) on progression of gastritis and gastric carcinogenesis caused by H. pylori
infection. Methods: Forty-two SPF male hypergastrinemic, INS-GAS mice on a FVB back-
ground were used. Castration or supplementation of E2 was performed at 8 weeks of the
age. The mice were then inoculated 3X per os with 108 cfu of H. pylori SS1 or broth at 10
weeks of age. Mice were euthanized at 16 weeks postinfection. Gastric histological evaluation
for inflammation, atrophy, hyperplasia, intestinal metaplasia, and dysplasia were graded on
a blinded basis by a pathologist and assigned a score from 0 to 4. A proliferative labeling
index using immunohistochemistry for Ki-67, was also tabulated. ELISA for anti-H. pylori
IgG2a (Th1 isotype) and IgG1 (Th2 isotype) was performed. Quantitative PCR for cyclin A
mRNA levels was also examined. Statistical analyses were performed using one way-ANOVA
followed by turkey's post tests or Dunn's multiple comparisons. Results: H. pylori infected
mice developed more severe corpus gastritis than uninfected mice. All gastric lesion scores
in infected E2-treated mice were significantly lower than those in intact infected male mice
(all p < 0.05), whereas gastric lesion scores in infected castrated mice were comparable to
that observed in intact infected males. Neither supplementation of E2 nor castration affected
H. pylori IgG2a antibody levels. However, IgG1 antibody levels in E2-treated infected mice
were significantly higher than that in the noncastrated infected group (p < 0.05). IgG1
antibody responses in castrated infected mice were similar with those recorded in the intact
group. Supplementation of E2 did not alter H. pylori colonization levels, whereas castration
decreased H. pylori colonization. Supplementation of E2 in infected mice significantly
decreased the Ki-67 labeling index and cyclin A mRNA levels (all p < 0.05), whereas castration
did not alter these indices. Conclusion: Supplementation of E2 provided a protective role
in reducing the severity of H. pylori-induced gastritis in INS-GAS male mice, but castration
did not suggesting that a potential protective mechanism by E2 in gastric carcinogenesis is
via modulation of epithelial cell proliferation and inducing a Th2-biased immune response.
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Obesity Is Associated with Increased Transient Lower Esophageal Sphincter
Relaxation
Justin Wu, Wilfred L. Mui, Yawen Chan, Joseph Sung
Aims: Obesity has been associated with GERD but the underlying mechanism is unclear.
We evaluated the association between obesity and function of gastroesophageal junction in
subjects without GERD. Methods: We prospectively recruited consecutive obese (BMI >30)
patients referred for weight reduction procedure and age-and-sex matched overweight (BMI:
25-30) and normal-weight (BMI >/=20 and <25) subjects. Exclusion criteria included erosive
esophagitis, reflux symptoms, need of PPI therapy for upper GI symptom, sliding hiatus hernia
>2 cm, and diabetes mellitus with established microvascular complication. All participants
underwent combined 2-hour postprandial esophageal manometry and pH monitoring after
a standard 400 kcal test meal followed by 24-hour ambulatory pH-metry. Results: 84 subjects
(Obese: 28, overweight: 28, normal-weight: 28) were studied. All 3 groups had comparable
mean lower esophageal sphincter (LES) pressure, LES length and peristaltic function. During
post-prandial period, both obese and overweight groups had substantial increase in gastro-
esophageal pressure gradient (GEPG)(Normal weight: 4.5+/-1.2 mmHg Vs Overweight: 7.1+/-
1.4 mmHg Vs Obese: 10.0+/-1.5 mmHg, p<0.001), 2-hour rate of TLESR (Normal weight:
2.1+/-1.2 Vs Overweight: 3.8+/-1.6 Vs Obese: 7.3+/-2.0, P<0.001) and proportion of TLESR
with acid reflux (Normal weight: 17.6+/-22.0% Vs Overweight 51.8+/-22.5% Vs Obese:
63.5+/-21.7%, p<0.001). Using multiple regression model adjusted for age, gender and
obstructive sleep apnea, BMI (r2: 0.70, B: 0.28, 95% C.I.: 0.24-0.33, p<0.001) and waist
circumference (r2: 0.65, B: 0.10, 95% C.I.: 0.08-0.11, p<0.001) were significantly correlated
with TLESR. Conclusion: Obesity is associated with increased GEPG, TLESR and acid reflux
during postprandial period in subjects without GERD. Abnormal postprandial LES function
may be an early event in the pathogenesis of obesity related GERD.
845
High Resolution Manometry of the EGJ: An Analysis of Crural Diaphragm
Function in GERD
Hyon Kim, John Pandolfino, Sudip Ghosh, John O. Clarke, Qing Zhang, Peter J. Kahrilas
Aim: High resolution manometry (HRM) provides a spatially enhanced, dynamic representa-
tion of the esophagogastric (EGJ) high-pressure zone making it possible to isolate the crural
diaphragm (CD) contraction from expiratory lower esophageal sphincter (LES) pressure.
This study compared CD function of subjects with and without gastroesophageal reflux
disease (GERD). Methods: 75 asymptomatic controls and 156 GERD patients (EGD or pH
monitoring positive) underwent HRM. The EGJ axial pressure profile was analyzed over 5
respiratory cycles to quantify the position and contractile vigor of the CD relative to the
LES. Correlations between EGJ HRM attributes and GERD status were examined. Results:
GERD patients had significantly greater CD-LES separation compared to either controls or
EGD-/pH- patients. GERD patients also had significantly less inspiratory augmentation of
EGJ pressure (EGD -/pH+, 11.5 ± 1.9 mmHg); EGD+, 10.0 ± 1.2 mmHg) compared to
A-121 AGA Abstracts
controls (16.9 ±1 mmHg) or EGD-/pH- patients (16.7± 0.2 mmHg). Using a logistic regression
model that simultaneously examined expiratory LES pressure, LES-CD separation and inspir-
atory EGJ augmentation while controlling for age and BMI, only inspiratory augmentation
had a significant independent association with GERD. The parameter estimate for inspiratory
augmentation was -0.07 (SE 0.03, p=0.001) while those for age and BMI were 0.08 (SE
0.04, p=0.04) and 0.13 (SE 0.03, p<0.001), respectively. The correlation between EGJ
component separation and crural diaphragm pressure augmentation was weak, but statistic-
ally significant (r=-0.3, p<0.0001). Conclusions: HRM characterization of EGJ morphology
correlates with the objective demonstration of GERD. Although both LES pressure and LES-
CD separation are associated with GERD, the strongest association and the only independent
predictor of GERD as a categorical outcome in a logistic regression analysis was impaired
CD function as indicated by reduced inspiratory augmentation of EGJ pressure.
EGJ pressure component separation and pressure profile amongst the subject groups
ANOVA, *p<0.05 vs controls, †p<0.05 vs EGD (+)
846
The Association Between Postmenopausal Hormone Use and Symptoms of
Gastroesophageal Reflux
Brian C. Jacobson, Beverly Moy, Graham A. Colditz, Charles S. Fuchs
Background: Estrogen and progesterone are thought to play a role in gastroesophageal
reflux in women. We sought to explore the relationship between symptoms of gastroeso-
phageal reflux disease (GERD) and postmenopausal hormone (PMH) therapy, including the
selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene, and over-the-
counter (OTC) hormone supplements. Methods: In 2002, we asked participants of the
Nurses' Health Study (n=121,700) how often during the prior year they experienced heart-
burn/acid-reflux. Women reporting GERD symptoms at least once a week were considered
cases, while those reporting no symptoms in the past year were considered non-cases for
comparison. Women were excluded if they failed to answer the question about GERD
symptoms (n=31,780), reported symptoms less than weekly (n=5,798), reported no symp-
toms but were using acid-suppression therapy (n=4,659), were premenopausal (n=661),
had a history of cancer (n=21,076), had missing data about PMH use (n=1,777), or had
other missing data (n=3,348). We used logistic regression models to study the association
between PMH therapy and GERD symptoms, controlling for potential confounding factors
such as body mass index (BMI), weight-change since menopause, physical activity, visits to
physicians, use of medications that decrease lower esophageal sphincter pressure, diabetes,
and dietary factors. Results: There were 11,993 eligible women who reported at least weekly
GERD symptoms and 40,608 who reported no symptoms during the prior year. Compared
to women who never used PMH (n=12,654), multivariate odds ratios (ORs) for the risk of
having GERD symptoms was 1.50 (95% CI 1.40-1.60) for former PMH users (n=20,810);
1.75 (95% CI 1.63-1.88) for current users of estrogens only (n=11,510); and 1.42 (95%
CI 1.30-1.55) for current users of estrogen plus progesterone (n=7,628). Significant trends
in increasing GERD symptom risk were observed among current estrogen users based upon
estrogen dose and duration of use (p for both trends <0.001). Compared to women who
never used PMH, women using SERMs and over-the-counter soy estrogen products were
significantly more likely to experience GERD symptoms (ORs 1.40, 95% CI 1.23-1.59; and
1.52, 95% CI 1.19-1.93, respectively). Findings were not significantly altered by controlling
for potential confounding factors, stratifying by BMI, or limiting the analysis to women with
symptoms several times a week or daily. Conclusion: Postmenopausal use of estrogens,
SERMs, and OTC estrogen supplements are associated with an increased risk of GERD
symptoms. This suggests there may be a hormonal component to the pathophysiology of
GERD among women.
847
Scintigraphic Imaging of Esophageal Shortening and the Acid Pocket in
Human
Hanneke Beaumont, Jan W. De jong, Roel Bennink, Guy E. Boeckxstaens
Introduction: Gastroesophageal reflux (GER) occurs twice as much during transient lower
esophageal sphincter relaxations (TLESR) in GERD patients compared to healthy volunteers
(HV). However, the mechanisms underlying this difference remain unclear. As the localisation
of the acid pocket floating on top of a meal and esophageal shortening could be important
determinants for reflux to occur, we developed a method allowing continuous visualisation
of these parameters. Methods: 10 HV (22-53, 7 M) without hiatal hernia were studied.
During upper endoscopy, the squamocolumnar junction (SCJ) was marked with a radio-
labelled clip. To visualize the acid pocket, 450 MBq 99mTc-pertechnetate was injected iv
and scintigraphic images were acquired up to 2 hrs postprandial in 480 15-secs frames. In
addition, subjects underwent manometry/pHmetry using a 8 channel sleeve catheter and a
4 channel pH probe with the most proximal sensor 2cm above the LES. At 15, 30, 45, 60,
90 and 120 minutes after a meal, pull through was performed to localize the position of
the acid pocket. Results: The acid pocket visualised by scintigraphy was located 2.0±0.1cm
distally of the SCJ. Pull through showed comparable results, with the proximal extent of
the acid pocket 1.8±0.7cm below the SCJ 15min, moving distally to 2.3±0.6cm below the
SCJ at 120min. The scintigraphic length of the pocket was 2.5±0.1cm and 2.6±0.2cm
measured by pull through. The length of the pocket was maximal at 60min (3.5±0.8cm).
109 TLESRs were recorded in the 2 hr postprandial period. 69% of the TLESRs were
accompanied by an upwards shift of the labelled SCJ clip, compatible with shortening of
the esophagus. This phenomenon was observed 83 times, with a mean upwards shift of
3.1±0.3cm, and related to a TLESR in 90%. In total, 16 acid reflux episodes were recorded
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with the acid pocket extending into the SCJ in 83%. Most reflux episodes (89%) occurred
during a TLESR. TLESRs with reflux were less frequently associated with esophageal
shortening than those without reflux (28% vs 77%). Conclusion: The position of the
postprandial acid pocket relative to the SCJ can be accurately visualized using scintigraphy.
This technique allows us to study possible differences in the localisation of the acid pocket
relative to the SCJ in GERD patients. In addition, we confirmed esophageal shortening
during TLESRs. Although the number of reflux episodes detected was rather small, reflux
occurred more frequently in the absence of esophageal shortening, possibly suggesting a
protective role of shortening against GER. Ongoing studies in GERD patients using this
experimental set-up are however crucial to confirm this hypothesis.
848
Sleep Deprivation Is Hyperalgesic in Patients with Gastroesophageal Reflux
Disease (GERD)
Ron Schey, Ram M. Dickman, Sairam Parthasarathy, Stuart F. Quan, Jonah Merchant,
Jeannette Powers, Bing Han, Daniel Vanhandel, Ronnie Fass
Background: Studies have demonstrated that GERD can cause sleep disturbances and sleep
deprivation due to nighttime heartburn or short, amnestic arousals during sleep. Thus far,
there are no studies evaluating the effect of sleep deprivation per se on GERD. Aim: To
determine if sleep deprivation enhances perception of intra-esophageal acid in patients with
GERD versus normal control. Methods: A total of ten healthy controls and ten GERD patients
with erosive esophagitis (Grades B-D) and history of heartburn at least three times a week
were included in the study. Subjects with medium to high risk for obstructive sleep apnea
and excessive daytime sleepiness were excluded from the study using the Berlin questionnaire
and Epworth Sleepiness Scale (score ≧ 10). Subjects were evaluated by demographic and
validated GERD symptom checklist questionnaires. Subjects were then randomized to either
sleep deprivation (one night with ≦ 3 hours of sleep) or good sleep (3 days with ≧ 7h
sleep/night). Patients crossed over to the other arm after 1 week. To ensure proper sleep
time, subjects were objectively monitored with an actigraph (a watch-like device worn on
the nondominant wrist that records motion with accelometers). The morning after good sleep
or sleep deprivation night, patients underwent stimulus response functions to esophageal acid
perfusion. Results: Ten healthy controls (mean age 36.9±5.4, M/F-5/5, BMI 28.6±2.5) and
ten GERD patients (mean age 49.5±4.7, M/F 8/2, BMI 29.2±2.0) completed all stages of the
study. The actigraph confirmed that all participants complied with the instructions for good
sleep and sleep deprivation time. GERD patients demonstrated a significant decrease in lag
time to symptom report (91±21.6 vs. 282.7±67, p=0.02), increase in intensity rating
(9.3+±1.4 vs. 4.4±0.9, p=0.02), and increase in acid perfusion sensitivity score (48.3±8.5
vs. 22.7±4.5, p=0.02) after sleep deprivation as compared to good sleep, respectively. In
contrast, normal subjects demonstrated lack of statistical difference in stimulus response
functions to acid after good sleep and sleep deprivation (493.8±60.3 vs. 578±16, 0.45±0.2
vs. 0.3±0.2 and 2.4±1.4 vs. 0.4±0.3, respectively, all p=NS). Conclusions: This is the first
study to demonstrate that sleep deprivation per se is hyperalgesic in patients with GERD.
The study supports a bidirectional relationship between GERD and sleep as a new concep-
tual model
849
Acid Suppression Normalizes the Expression of Mucosal Repair Associated
Genes in the Esophageal Epithelium of GERD Patients
Durk Vries, de, Jose Ter linde, Margot Van herwaarden, Pierre Shephard, Michael Geng,
Hans peter Hofmann, Thomas Klein, Stefan Postius, Matthijs P. Schwartz, Melvin Samsom
Background: Past studies aimed at addressing the effects of acid reflux and PPI therapy on
gene expression patterns in the esophageal epithelium concentrated on inflamed tissues.
Aims: Determine changes in gene expression in non-inflamed esophageal epithelium of
GERD patients. Address the role of acid by means of 1) acid suppression, and 2)collection
of biopsies at two levels in the esophagus. Materials and Methods: 20 GERD patients (10
M, mean age 52) with total 24-h acid exposure of 6-12% and SAP≥95% were selected from
pH-metry referrals. Ten patients discontinued PPI treatment, ten took pantoprazole 40mg
bid, both two weeks prior to sampling. History of severe esophagitis (C/D), Barrett's, or
other GI tract conditions was exclusion criteria. Ten age/sex-matched healthy controls (HCs)
were also recruited. Biopsies were taken during upper GI endoscopy from non-inflamed
mucosa 6 and 16 cm proximal to the squamocolumnar junction and used for gene expression
profiling or for histological evaluation. Profiling was performed on Human Genome U133
Plus 2.0 arrays (Affymetrix). Genes exhibiting a fold change >1.4 (t-test p-value <1E-4)
in patient groups compared to healthy controls were considered differentially expressed.
Differential expression was confirmed by real-time RT-PCR. Results: No endoscopic abnor-
malities were seen in HCs. Histology confirmed the absence of inflammation at all sites. In
GERD patients taken off PPIs, 52 genes were up-regulated in the distal esophagus epithelium
taking that of HCs as reference. Furthermore, 69 genes were up-regulated in proximal
esophagus. An overlap of 37 genes was observed between those two sets. The majority of
those genes was associated with cell-cell contacts and communication, cytoskeletal reorgan-
ization and repolarization, and suggested of an adaptation to a migratory phenotype. Genes
encoding proteins with anti-apoptotic functions or protective roles against oxidative stress
were also up-regulated in GERD patients off PPIs. However, strikingly, gene expression
profiles of GERD patients on PPIs and HCs were indistinguishable. Conclusions: Excessive
acid reflux causes superficial damage and stress response in non-inflamed areas of the
esophageal mucosa of GERD patients. Upon acid exposure, epithelial cells activate mechan-
isms globally known as epithelial restitution to increase their chance of survival, e.g. up-
regulation of anti-apoptotic, anti-oxidant and migration associated proteins. Acid suppression
therapy normalizes gene expression patterns in the epithelial cells of GERD patients under-
going PPI therapy to the point of them being indistinguishable from those of HC.
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Phosphorylation of Y398 and Y402 in Occludin Prevents Its Interaction with
ZO-1 and Attenuates Its Assembly Into Tight Junctions (TJ)
Bertha Elias, Gautam Kale, Anjaparavanda P. Naren, Takuya Suzuki, Ankur Seth,
Francesco Giorgianni, Dominic M. Desiderio, Le Shen, Jerrold R. Turner, Radhakrishna
(rk) Rao
Occludin, an integral 64 kD transmembrane protein of TJ, binds to ZO-1 at its C-terminal
domain. Oxidative stress-induced Tyr-phosphorylation of occludin and disruption of TJ is
mediated by a Tyr kinase, c-Src. Tyr-phosphorylation of GST-occludin-C (C-terminal 150
A.a) attenuates its binding to ZO-1. In this study, we identified the Tyr residues responsible
for this regulation. Methods: Non-phosphorylated and Tyr-phosphorylated GST-Occludin-
C (chicken and human) was generated in E. coli DH5α or E. coli TKX1 cells. Phosphorylation
sites were identified by Trypsin digestion and LC/MS/MS analysis. Y379 and Y383 (chicken)
or Y398 and Y402 (human) in GST-Occludin-C were singly or doubly mutated to A, F or
D by site directed mutagenesis. Phosphorylation of GST-Occludin-C and mutants was
induced by In Vitro incubation with c-Src, and analyzed by immunoblot analysis for p-Tyr.
ZO-1 binding of GST-Occludin-C was evaluated by GST pull down assay using Caco-2 cell
extracts. Similar mutations were induced in the human full length EGFP-occludin, and
transfected into Rat-1 fibroblasts (lack occludin) as well as MDCK cells. Localization of
EGFP-occludin and ZO-1 was analyzed by confocal microscopy. Results: LC/MS/MS analysis
of Tyr-phosphorylated chicken occludin showed that Y397 and Y383 are the major phos-
phorylated residues. These residues are located in a highly conserved sequence of occludin,
YETDYTT. Single mutation of Y379 or Y383 to A or F partially reduced phosphorylation
by c-Src, while double mutation abolished the phosphorylation. This demonstrates that
Y379 and Y383 are the Tyr-phosphorylation sites, which corresponds to Y398 and Y402 in
human occludin. Single or double mutations to either A or F did not significantly alter ZO-
1 binding. Unlike WT GST-Occludin-C, incubation of single and double mutants of occludin
(Y to A or Y to F) with c-Src failed to reduce the ZO-1 binding, suggesting that phosphorylation
of either Tyr reduces ZO-1 binding. Both single and double mutation of Y379 and Y383 to
D (mimics phosphorylation) resulted in a significant reduction in ZO-1 binding. Similar to
WT occludin, EGFP-occludin mutants, Y398A, Y398F, Y402A, Y402F and their double
mutants, localize to the membrane cell-cell contact points in Rat-1 cells or to intercellular
junctions in MDCK cells. However, Y398D, Y402D and Y398/402D mutants of occludin
failed to localize at the cell-cell contacts or intercellular junctions. Conclusion: We show
that phosphorylation of Y398 and Y402 in the C-terminal region of occludin prevents its
interaction with ZO-1, suggesting that such a mechanism may play a role in regulation of
TJ integrity. Support: DK55532 and AA12307.
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Dock5, a Novel Protein Related to Guanine Nucleotide Exchange Factor
Dock180, May Regulate Caco-2 Intestinal Epithelial Cell Spreading and
Migration Synergistically with Dock180
Matthew A. Sanders, Dinakar Ampasala, Marc D. Basson
Intestinal epithelial cell spreading, migration and lamellipodial extension require the adaptor
proteins Crk and CrkL and the small GTP binding protein Rac1, but the nature of the
interaction between these proteins is unclear. Although Crk regulates Rac1 in various cell
types via the guanine nucleotide exchange factor DOCK180, the mechanism of Rac1 regula-
tion by Crk in migrating intestinal epithelial cells is not known. We therefore sought to
elucidate the possible relationship between Crk and Rac1 in migrating intestinal epithelial
cells using human Caco-2 intestinal epithelial cell spreading and migration on basement
membrane type IV collagen as a model. siRNA knockdown of DOCK180 protein by greater
than 95% significantly inhibited Caco-2 cell spreading on collagen IV (18.6±3.4% inhibition,
n=11 independent experiments, p<0.001). Combined siRNA knockdown of Crk and the
related protein CrkL (54.2±3.5% inhibition of cell spreading, n=3, p<0.01) or Rac1
(44.2±2.7% inhibition, n=3, p<0.01), however, inhibited cell spreading much more strongly
than DOCK180 siRNA. Parallel studies demonstrated that DOCK180 siRNA knockdown
similarly inhibited Caco-2 sheet migration to a much lesser extent than siRNA reduction of
Crk and CrkL or Rac1(n≥3 independent experiments for each). These observations suggested
that although DOCK180 could play some role in this pathway, additional proteins probably
serve as intermediaries between Crk and Rac1 in Caco-2 cells. Two of the most closely
related proteins to DOCK180 are DOCK4 and the as yet functionally uncharacterized protein
DOCK5. We therefore verified expression of DOCK5 in Caco-2 cells by reverse transcriptase
(rt) PCR of Caco-2 RNA and cloning of the rtPCR fragment. We designed a specific siRNA that
reduced DOCK5 expression by 42.5±1.6% and did not affect DOCK180 protein expression.
Reducing DOCK5 expression inhibited Caco-2 spreading on collagen IV by 15.3±4.4% (n=
5, p<0.05) compared to control siRNA. Moreover, the combination of DOCK180 specific
and DOCK5 specific siRNA inhibited Caco-2 cell spreading significantly more than DOCK5
specific siRNA alone (30.9±3.8% inhibition, n=5, p<0.05 compared to control siRNA or
DOCK5 siRNA alone). siRNA targeting DOCK4, however, did not affect Caco-2 spreading
on collagen IV either alone or in combination with DOCK180 siRNA. These studies document
a previously uncharacterized biological function for DOCK5 and suggest that it acts syner-
gistically with DOCK180 to modulate intestinal epithelial migration. This novel protein may
be a potential target for pharmacologic or molecular interventions designed to promote
mucosal healing.
852
Repetitive Deformation Promotes Human Caco-2 Intestinal Epithelial
Migration Across Fibronectin Via Src-Dependent P38 Activation and Src-
Independent ERK Activation
Lakshmi S. Chaturvedi, Jianhu Zhang, Cheri Owen, Christopher Gayer, Harold M. Marsh,
Marc D. Basson
Repetitive deformation promotes wound closure in intestinal epithelial monolayers cultured
on substrates of tissue fibronectin, abundant in the extracellular matrix of the gut mucosa
during states of chronic inflammation. Little is known about the mechanism of this effect,
however, except that it requires activation of the mitogen activated protein kinase ERK1/2.
We therefore sought to identify other cell signals in the pathway that mediates this migration-
promoting (motogenic) effect. Human Caco-2 intestinal epithelial cell monolayers on
fibronectin-precoated deformable membranes were subjected to an average 10% repetitive
deformation at 10 cycles per minute, similar in frequency and amplitude to the deformation
experienced by the gut mucosa In Vivo during peristalsis or villous motility. Wound closure
was assessed by morphometry using microscopic imaging 12-24 hours after making circular
wounds. Strain-induced Src, ERK1/2 and p38 phosphorylation were assessed by Western
blot, and each signal was blocked by pre-treatment with specific inhibitors. Strain significantly
enhanced wound closure after 12 and 24 hours (p=0.012, n=17). Strain rapidly stimulated
Src phosphorylation (30±14%, p<0.05, n=5), and blocking Src by PP2 (10 uM) prevented
the motogenic effects of strain. Strain also promoted the phosphorylation of both ERK
(69±14%, p=0.015, n=4), and p38 (41±14%, p=0.015, n=4). The p38 inhibitor, SB203580
(20 uM) prevented the motogenic effects of strain, as did blocking ERK with PD98059 (20
uM). Although Src inhibition with PP2 abrogated p38 phosphorylation in response to strain,
it did not block, and indeed seemed to potentiate strain activation of ERK. These results
suggest that the motogenic effects of strain occur via Src-dependent p38 activation and Src-
independent ERK activation. These signals may be important potential targets for intervention
to promote mucosal wound healing in settings of inflammation or disease when peristalsis
and villous motility are abnormal.
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Loss of E-Cadherin Expression and Decreased Barrier Function in Intestinal
Epithelial Cells Expressing 15-Hydroxyprostaglandin Dehydrogenase
Hung Pham, Romina Vincenti, Lee W. Slice
Background.Prostaglandins (PGs) have a cytoprotective effect on the epithelial cells of the
intestinal mucosa. PG synthesis can be inhibited by NSAIDs, which can result in mucosal
injury. Also, PGs are biologically inactivated by oxidation by 15-hydroxyprostaglandin dehy-
drogenase (PGDH), which is expressed in intestinal epithelial cells. The aim of this study
is to determine the effect of decreased PG levels on barrier function of intestinal epithelial
cells. Methods.IEC-18 (from rat ileal crypts) and T84 (from human differentiated colonocytes)
cells were transduced with lentivirus that result in constitutive expression of PGDH and red
fluorescent protein. Western blot analysis and immunohistochemistry were used to measure
protein expression. PGs in cell culture media were measured by ELISA. Trans-epithelial
resistance was measured on cells grown on trans-well membrane inserts. Results. Serum-
starved (18 hr) IEC-18 cells produced both PGE2 (105±12 ng/ml) and PGI2 (153±30
ng/ml). IEC-18 cells that over-expressed PGDH (18.PGDH) had significantly decreased
production of PGE2 and PGI2 (20±5 ng/ml and 17±4 ng/ml, respectively). Western blot
analysis revealed that over-expression of PGDH in the 18.PGDH cells correlated with a
significant increase in the expression level of the E-cadherin transcriptional repressor, Snail,
and a loss of E-cadherin expression compared to wild type IEC-18 cells. Growing IEC-18 and
18.PGDH cells in co-culture revealed two distinct phenotypes. The IEC-18 cells established a
uniform monolayer and the 18.PGDH cells grew as multi-cell spheres. There was no mixing
of cell types between the monolayer and the spheres. IEC-18 cells in the monolayer showed
E-cadherin expression located at the cell membrane. In contrast, 18.PGDH cells in the multi-
cell spheres had no detectable E-cadherin expression. Because E-cadherin expression affects
intestinal epithelial barrier function, trans-epithelial resistance was measured in highly differ-
entiated colonocytes. Wild type T84 cells were grown in trans-well inserts. The trans-
epithelial resistance increased from 110±8 ohms (day 1) to 532±5 ohms (day 14). T84 cells
over-expressing PGDH showed a modest increase in trans-epithelial resistance from 96±10
ohms (day 1) to 176±9 ohms (day 14). Conclusions. PGDH over-expression significantly
decreased PG levels in intestinal epithelial cells with increased Snail expression and a
loss of E-cadherin expression. PGDH expression correlated with impaired trans-epithelial
resistance suggesting that PGs have a role in E-cadherin expression via Snail, providing a new
hypothesis for regulating intestinal epithelial resistance through PG catalysis. NIDDK061485
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Matrix Metalloproteinase-2 (Mmp-2) Regulates Paracellular Barrier in
Intestinal Epithelial Cells: Implications for the Role of Mmp-2 in Colitis
Pallavi Garg, Steve Epstein, Anupama Ravi, Hilary Robbins, Andrew Gewirtz, Didier
Merlin, Shanthi V. Sitaraman
Background and Significance: MMP-2 is upregulated during human as well as animal models
of inflammatory bowel disease. We recently demonstrated that epithelial-derived MMP2
mediates protective effect during inflammation and tissue damage in colitis. MMP-2 null
mice are highly susceptible to colitis. In this study, we examined the potential mechanism
by which MMP-2 exerts its protective effect. Methods: Permeability assays were done using
FITC-dextran in wild type and MMP-2 null mice. Stably transfected Caco2BBE cells with
pEGFP plasmid with and without MMP-2 gene, were used for permeability assay with FITC-
dextran and, to measure transepithelial resistance (TER). Western blot and confocal imaging
were used to examine distribution of tight junction proteins. Results: MMP-2 null mice
demonstrate increased permeability to FITC dextran. Overexpression of MMP-2 in epithelial
cells showed decreased paracellular flux of both 4 and 40 kD FITC dextran as well as
increased TER compared to vector transfected cells. There was a decrease in paracellular
flux by 70% and 50% of both 4 and 40 kD FITC dextran, respectively among overexpressed
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MMP-2 compared to vector, while the increase of TER was 34% compared to vector. Claudin-
1,-2 and -5 expression were significantly upregulated in cells overexpressing MMP-2, while
there was no change in the expression of claudin-4. Confocal study showed redistribution
of claudin-1 and -2 among MMP-2 overexpressed cells compared to vector, while there was
no change in the distribution of claudin-4. Summary and conclusions: Together, our data
demonstrate that MMP-2 modulates paracellular barrier likely through alteration in claudin
expression and thereby plays an important role in maintenance of epithelial barrier function.
Thus during inflammation, wherein MMP-2 protein and activity is highly upregulated,
epithelial-derived MMP-2 may be a critical host factor involved in protecting host from
luminal pathogens and toxins.
855
Role of Protease-Activated Receptor-1 in Neutrophil-Epithelial Signaling
Events and Neutrophil Transmigration
Alex Chin, Nathalie Vergnolle, Asma Nusrat, Charles A. Parkos
Epithelial pathophysiology during many inflammatory conditions of the gut is secondary to
neutrophil (PMN) infiltration of intestinal mucosa. Previously, we have demonstrated that
PMN contact with the basolateral aspect of the intestinal epithelium results in enhanced
permeability and epithelial signaling events prior to transmigration. However, the nature of
the epithelial cell surface receptors and PMN counter-ligands that mediate such responses
are unknown. Attractive candidate molecules include protease-activated receptors (PARs)
which, upon activation by proteases, regulate epithelial permeability and tight junctional
protein organization. We hypothesized that activation of epithelial PARs by subjacent PMN
serine proteases could activate signaling events that regulate epithelial barrier function. AIM:
To determine whether the increase in epithelial permeability induced by PMN contact is
dependent on PAR signaling and whether this event regulates PMN transepithelial migration.
METHODS: Inverted T84 intestinal monolayers cultured on the underside of 0.4μm (trans-
epithelial permeability) or 5.0μm (transepithelial migration) pore-sized transwell supports
were incubated with or without peripheral blood human PMNs in the presence or absence
of a chemotactic gradient of f-met-leu-phe (fMLP). Paracellular permeability (3h) was deter-
mined by measuring transepithelial resistance (TER) and PMN transmigration (2h) by measur-
ing myeloperoxidase activity. RESULTS: In the presence of a transepithelial fMLP gradient,
PMN contact with the basolateral aspect of T84 monolayers reduced baseline TER by 50%.
Pre-treatment of monolayers with 5μM SCH79797 (PAR-1 inhibitor), but not 5μM P4pal-
10 (PAR-4 inhibitor), prevented the decrease in TER induced by PMN contact and also
decreased the rate of PMN transepithelial migration by 50%. Basolateral, but not apical,
activation of PAR-1 with 100μM TFLLR decreased TER by 50% while incubation with
human PMN elastase (HNE) and proteinase-3, but not cathepsin G (CG), decreased TER
by 80%. PMNs pre-treated with: 1) 500μM AEBSF (serine protease inhibitor) were unable
to decrease TER and exhibited impaired transmigration by 60%, 2) 5μM SCH79797, P4pal-
10 or 100μM GM6001 still decreased TER by 50%, but exhibited impaired transmigration
by 80%, 60%, and 30% respectively, and 3) 100μM α1-ACT (CG inhibitor) or GW311616A
(HNE inhibitor) still decreased TER by 50% and did not exhibit impaired transmigration.
These results suggest that regulation of PMN transepithelial migration in the gut is mediated,
in part, by activation of epithelial PAR signaling events induced by PMN proteases.
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Commensal Flora Is Critical for the Normal Development of Regulatory T Cell
Function in Samp1/Yitfc Mice
Akira Okazawa, Giorgos Bamias, Jesus Rivera-nieves, Hiroshi Tamagawa, Brian K. Reuter,
Theresa T. Pizarro, Fabio Cominelli
Background & Aims: The commensal flora plays an important role in initiation and mainten-
ance of intestinal inflammation. Many studies have shown that intestinal inflammation does
not usually develop when mice are maintained under germ-free (GF) conditions. However,
we have recently reported that SAMP1/YitFc (SAMP) mice develop chronic ileitis in the
absence of commensal bacteria, as well as sporadic spontaneous colitis. The aim of this
study was to investigate the influence of the gnotobiotic conditions of the donor on the
development of intestinal inflammation using the adoptive transfer system. Methods: Histol-
ogical assessment of intestinal inflammation in GF-SAMP mice (>30 weeks of age), age-
matched, specific pathogen free SAMP (SPF-SAMP) mice and AKR mice was performed,
and intestinal expression of cytokine mRNAs was examined by real-time RT-PCR. Cells from
spleens and mesenteric lymph nodes (MLN) were assayed for CD4, CD25 and Foxp3 by
flow cytometry, and Foxp3 mRNA expression in isolated CD4+ MLN cells or splenocytes
was analyzed by real-time RT-PCR. Clinical course and histology were evaluated after adoptive
transfer of CD4+ MLN cells from GF- and/or SPF-SAMP donors into SCID recipients. Results:
GF-SAMP mice developed chronic ileitis comparable to that found in SPF-SAMP mice.
Intestinal expression of the mRNAs for IFN-γ and TNF-α was markedly increased in GF-
and SPF-SAMP mice compared with AKR mice. In comparison with SPF-SAMP mice, Th2
and regulatory cytokines were suppressed in GF-SAMP mice, with significant decreases in
the intestinal expression of the mRNAs for IL-5 (p<0.05), IL-13 (p<0.05), IL-10 (p<0.05)
and TGF-β (p<0.05). In GF-SAMP mice, Foxp3 expression in CD4+CD25+ MLN cells and
Foxp3 mRNA expression in CD4+ MLN cells were significantly decreased compared with
those from SPF-SAMP mice. Adoptive transfer of CD4+ MLN cells from GF- but not SPF-
SAMP mice induced severe colitis in SCID recipients. Interestingly, severe colitis was not
induced by co-transfer of CD4+ cells from GF- and SPF-SAMP mice. On the other hand,
adoptive transfer of CD4+ cells from GF- and/or SPF-SAMP mice induced ileitis, and there
was no difference in the extent of inflammation observed. Conclusion: These results indicate
that, in the absence of bacterial flora, the mucosal immune system has impaired regulatory
T cell function, and that this inability contributes to the induction of colitis but not ileitis
in the adoptive transfer system.
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The Protective Role of TLR4 Signaling in IL-10 Dependent Colitis
Sean Fine, Jose Gonzalez-navajas, Carol Shen, Eyal Raz
Inflammatory Bowel Disease is a chronic inflammatory disorder that has been attributed to
a dysregulated response towards the host colonic microflora. Activation of Toll-Like Receptors
by commensal bacteria has been shown to be essential for colonic homeostasis. In order to
investigate the roles of Toll-Like Receptors in spontaneous colitis in IL-10 deficient mice,
we generated mice deficient in IL10-/-/TLR4-/-or IL10-/-/TLR9-/-. IL10-/-/TLR4-/- mice
developed spontaneous colitis at 7 weeks while both IL10-/- and IL10-/-/TLR9-/- did not.
Consistent with this finding, the colons of IL10-/-/TLR4-/- mice expressed higher levels of
pro-inflammatory cytokines such as IL-17, IL-23p19, TNF-α, IL-6, and IL-27 in comparison
to IL10-/- and IL10-/-/TLR9-/- colons. Furthermore, the number of CD4 T cells in the
IL10-/-/TLR4-/- colon was significantly elevated compared to that of IL-10-/- or IL-10-/-/
TLR9-/- colon. Depletion of CD4 positive T cells in IL10-/-/TLR4-/- at 4 weeks of age
prevented spontaneous colitis. Finally, in a T-cell transfer model of colitis in RAG-/- mice,
transfer of CD4+CD45RBhigh from IL10-/-/TLR4-/- mice induced a significantly higher
degree of colitis than that of CD4+CD45RBhigh from IL10-/- mice. Taken together, this
data suggest TLR4 signaling suppresses the development of T-cell dependent spontaneous
colitis in IL10-deficient mice.
858
Helicobacter pylori Infection in Children Is Associated with a Mucosal T
Regulatory Cell Response and Less Severe Gastritis Than That of Adults
Shelton W. Wright, Lesley Smythies, Francisca Riera, Javiera Torres, Lea Novak, Julia
Schmitz, Robin G. Lorenz, Carolina Serrano, Paul R. Harris, Phillip D. Smith
Background: We previously reported that Helicobacter pylori infection is associated with a
gastric Th1-mediated inflammatory response. However, few studies have addressed gastric
immune responses in Helicobacter pylori-infected children, who typically have a reduced
incidence of Helicobacter pylori-associated gastroduodenal ulceration. Here we investigated
the hypothesis that T regulatory (Treg) cells, which down-regulate T cell-mediated inflamma-
tion, are present in association with reduced gastric inflammation and ulceration in Helicob-
acter pylori-infected children compared to infected adults. To address this hypothesis, we
characterized the gastric (1) inflammatory response and (2) Treg cell response in Helicobacter
pylori-infected children and adults. Methods: Gastric biopsies were obtained from 36 Helicob-
acter pylori-infected children <12 years of age (50% infected) and 79 adolescents and adults
>12 years of age (65% infected) residing in Santiago, Chile. Serial tissue sections were
evaluated histologically for gastric Helicobacter pylori and inflammation. Tissue specimens
also were analyzed for Treg (TGF-β, IL-10) and T helper 2 (IL-4, IL-13) cytokines. Results:
Helicobacter pylori-infected children displayed significantly less gastric inflammation and
ulceration than infected adults, despite equivalent levels of Helicobacter pylori colonization.
Gastric tissue levels of Treg cytokines, reflected in TGF-β and IL-10 protein and mRNA,
were markedly higher in infected children than in infected adults. In the infected children,
the TGF- β localized to lamina propria CD25+Foxp3+ cells, which were increased in number
compared to infected adults. The Th2 cytokine levels in the gastric tissue of children and
adults were equivalent, indicating the local IL-10 was not derived from Th2 cells and
implicating Treg cells as the source of the IL-10. Conclusion: The gastric mucosa of children
infected with Helicobacter pylori displays less inflammation and ulceration but increased Treg
cell activity compared to that of infected adults. These findings suggest that in children
a gastric Treg cell response down-modulates the inflammation induced by Helicobacter
pylori infection.
859
Role of Ctla-4 in Maintaining Regulatory Capacity of Cd4+Cd25+ T Cells
Against H. hepaticus-Triggered Inflammatory Bowel Disease in Mice
Koichiro Watanabe, Varada Rao, Theofilos Poutahidis, Shilu Xu, Masahiro Otani, Barry
Rickman, Arlin B. Rogers, Zhongming Ge, Susan E. Erdman, Toshio Fujioka, James G.
Fox
Background: Previously, we have shown that CD4+CD25+CD45RBlow regulatory T (Treg)
cells inhibit Helicobacter hepaticus (Hh)-induced colitis and colon cancer in Rag2-/- mice.
CTLA-4, a co-stimulatory molecule and negative regulator of cell proliferation and IL-2
production of T cells, is expressed on CD4+CD25+ Treg cells at high levels and is believed
to have important roles for their suppressive functions. However, it was not known whether
CTLA-4 signaling has a direct role in maintaining Treg suppressive capacity. Aim: We
examined the effect of CTLA-4 blockade on the protective ability of Treg cells against H.
hepaticus-induced inflammatory bowel disease (IBD) in mice. Materials and Methods: CD4+
CD45RBlow CD25+ cells were isolated from the spleens and mesenteric lymph nodes of
Hh -free 129/SvEv wild type mice and transferred i.v. into Rag2-/- 129/SvEv mice (3.0 x
105 cells/animal) 3 days before infection, as described previously. H. hepaticus (ATCC
51449) was administered per os every other day for three doses (2.0 x 107 bacteria/animal).
Some of the recipient mice underwent a 2-week administration of anti-mouse CTLA-4 Mab
or control Ig intraperitoneally, starting 1 day before or 6 weeks after Hh infection. Inflamma-
tion and epithelial dysplasia were evaluated histologically. Mice were euthanized 6 weeks
after the last dose of anti-CTLA-4. Quantitative PCR was performed using TaqMan Gene
Expression Assays kits to analyze mRNA expression of IFN-γ, IL-2, IL-10, Foxp3 and GAPDH.
Results: Hh infection induced moderate to severe inflammation and epithelial dysplasia
throughout the colon, whereas treatment with Treg cells ameliorated colitis development,
matching our earlier findings in this model. Hh-infected Treg recipient mice, administered
anti-CTLA-4, had poor body condition and wasting along with histological findings of
transmural inflammation and severe dysplasia. In addition, expression of IFN-gamma and
IL-2, but not IL-10, increased in the colon of those mice. Interestingly, despite the disrupted
Treg function, anti-CTLA-4 administration resulted in relative increase of colonic expression
of Foxp3, a functional marker of Treg cells, compared with Treg recipients dosed with
control Ig. In the absence of infection, anti-CTLA-4 itself did not induce any observable
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pathology in mice injected with Treg cells. Conclusion: CTLA-4 signaling appears to be
critical for Treg cells to inhibit Hh-associated IBD. Disrupted capacity of Treg cells following
anti-CTLA-4 administration is independent of Foxp3 expression, but is probably dependent
on dysregulation of proinflammatory cytokine responses to enteric bacteria.
860
Inducible IL-12-Producing B Cells Regulate Th2-Mediated Intestinal
Inflammation
Ken Sugimoto, Kiyotaka Nagahama, Yasuyo Shimomura, Atsushi Mizoguchi, Atul K. Bhan
BACKGROUND & AIMS: Our previous studies have identified a B cell subset that is
induced under inflammatory conditions in T cell receptor α knockout (TCRαKO) mice and
contributes to the attenuation of colitis by producing IL-10 (Immunity 2002, 16:219).
However, it is unclear whether the IL-10 produced by regulatory B cells directly or indirectly
contributes to the regulation of this colitis. METHODS: Cytokine production of purified
MLN B cells was examined by flow cytometric, ELISA, Q-PCR and RPA analyses. To investigate
the functional role of IL-12p70 in the pathogenesis of colitis in TCRαKO mice, IL-12p35
(a specific subunit of IL-12p70)-deficient TCRα double knockout mice were generated.
RESULTS: In the absence of B cells (B cell-deficient TCRα double KO mice, αμDKO)
or IL-10 (IL-10-deficient TCRα double KO mice, αIL10DKO), IL-12p35 expression was
significantly downregulated in the MLN of TCRαKO mice. Transfer of B cells from TCRαKO
but not αIL10DKO mice restored the IL-12p35 expression in the recipient αμDKO mice.
Unexpectedly, studies using purified MLN B cells, T cells, macrophages, DCs, neutrophils,
and NK cells demonstrated that B cells per se are responsible for the production of IL-
12p35 in the presence of IL-10. Flow cytometric and ELISA analyses revealed that the IL-
12p70 production by purified MLN B cell from TCRαKO mice but not WT mice is further
upregulated by the B cell receptor ligation in the presence, but not absence, of TLR9 ligand,
CpG. Interestingly, flow cytometric analysis clearly showed that IL-12p70-producing B cells
and IL-10-producing B cells represent different populations. To test the functional role of
p35 in the pathogenesis of colitis, IL-12 p35-deficient TCRα double knockout (αp35DKO)
mice were generated. Of note, the αp35DKO mice spontaneously developed much more
severe colitis compared to TCRαKO mice. QPCR analysis showed that the deficiency of p35
enhances the IL-17 production of CD4+ T cells. To further confirm whether IL-12p70-
producing B cells are actually involved in the regulation of colitis, B cells from TCRαKO
or αp35DKO mice were transferred into αμDKO mice. Transfer of B cells from TCRαKO
mice but not αp35DKO mice inhibited the progression of colitis in the recipient αμDKO
mice. In addition, the transfer of αp35DKO B cells enhanced IL-17 production of CD4+ T
cells. CONCLUSION: These results indicate that IL-12p70-producing B cells are induced
by IL-10-producing B cells and further enhance the regulation of a Th2-mediated colitis.
The deficiency of IL-12p70 is associated with an increase in IL-17 producing CD4+ T cells
(Th-17) in a Th2-mediated colitis model.
861
Cpg Motifs of Bacterial DNA Protect from Intestinal Inflammation By the
Induction of Antigen Unspecific Tolerance Against Bacterial Flora
Andre Bleich, Claudia Hofmann, Ulrike Strauch, Werner Falk, Hans J. Hedrich, Florian
Obermeier
Background & Aim: The pathogenesis of IBD is currently explained by a dysregulation of
the immune response towards the bacterial flora. We could previously demonstrate that
CpG motifs protect from intestinal inflammation in various animal models at least partly
by the induction of inhibitory T-cells indicating an induction of tolerance. To elucidate
whether these CpG motif induced regulatory properties observed in mice with a physiologic
bacterial flora are bacterial antigen specific or not we used germ-free mice in two different
models of colitis for CpG motif treatment. Material & Methods: Germfree BALB/c mice
were treated for two weeks twice weekly with 10 μg CpG-oligodeoxynucleotides (ODN),
control GpG-ODN, or PBS (sham-treated). These mice and untreated SPF BALB/c mice
served as donors for splenic CD4+CD62L+ cells that were transferred by i.p. injection
into CB17-Prkdcscid (scid) mice maintained under SPF conditions. After 8 weeks, colitis
development was evaluated histologically and cytokine production of mesenteric lymphnode
(mln) cells of recipients was determined by ELISA. Furthermore, germfree B6.129P2-
Il10tm1Cgn (Il10-/-) mice were CpG- or GpG-ODN treated and investigated for colitis develop-
ment under SPF conditions. Results: After transfer of CD4+CD62L+ cells from untreated or
GpG-treated but not CpG-ODN treated germfree mice, the severity of colitis was considerably
increased compared to animals that received cells from SPF mice. Histological observations
were corroborated by decreased IL-17, IL-6, and TNF levels and increased IL-10 secretion
by mln cells from scid-recipients which received cells from germ-free CpG-ODN treated
donors compared to controls. Further characterization of the transferred CD4+CD62L+ cell
population isolated from CpG-treated germfree animals revealed reduced IL-17, TNF, and
IFN-γ levels after anti-CD3 stimulation compared to GpG-treated controls, but not sham-
treated animals. To further elucidate the role of IL-10 in this context, germfree Il10-/- mice
were treated with CpG- or GpG-ODN, and transferred into a conventional SPF environment
thereafter. After 16 weeks, CpG-ODN treated mice developed significantly less colitis than
control GpG-treated mice. Conclusion: Even without the pre-existence of a bacterial flora
CpG motif exposition induces tolerance in germ-free mice and completely reverses the
detrimental effect of transferring T cells from germ-free mice into SPF housed scid recipients.
This indicates that the CpG-ODN induced regulatory T-cells are not bacterial antigen specific.
As this protective effect is also observed in germ-free Il10-/- mice IL-10 independent mechan-
isms seem to play an important role.
862
Direct Genetic Evidence for a Protective Role of Heat Shock Proteins Against
Irritant-Induced Gastric Lesions
Tomoaki Ishihara, Ken-ichiro Tanaka, Tohru Mizushima
Background & Aims: Gastric lesions result from an imbalance between aggressive and
defensive factors. Indirect lines of evidence suggest that heat shock proteins (HSPs) induced
by various aggressive factors provide a protective role against irritant-induced gastric lesions.
For example, geranylgeranylacetone (GGA), a clinically used anti-ulcer drug in Japan, was
shown to induce various HSPs both In Vitro and In Vivo. In this study, we compared gastric
ulcerogenic response and anti-ulcer activity of GGA in wild-type mice and null mice lacking
HSF1, a transcription factor for hsp genes. Methods: Gastric lesions were produced by oral
administration of ethanol or hydrochloric acid. Up-regulation of HSPs was monitored by
immuno-blotting, immunohistochemical analysis and real-time RT-PCR. Induction of
apoptosis In Vivo was assessed by TUNEL assay. Induction of cell death was assessed by
MTT assay In Vitro. Transfection of plasmid with HSP70 gene or small interfering RNA
(siRNA) for HSP70 gene was used to induce or suppress, respectively, the expression of the
gene. Results: The severity of gastric lesions induced by ethanol or hydrochloric acid was
worsened in HSF1-null mice. Ethanol administration up-regulated gastric mucosal HSPs, in
particular HSP70, in an HSF1-dependent manner, and more apoptotic cells were observed
in the gastric mucosa of HSF1-null mice than in wild-type mice. In Vitro, over-expression
of HSP70 suppressed ethanol-induced cell death, whereas suppression of HSP70 expression
drastically stimulated ethanol-induced cell death. Other parameters governing the gastric
ulcerogenic response In Vivo, including gastric acid secretion, gastric mucosal blood flow
and prostaglandin E2 levels, were not significantly affected in the absence of the hsf1 gene.
Orally administered GGA stimulated ethanol-induced up-regulation of HSP70 at gastric
mucosa in wild-type mice but not in HSF1-null mice. Furthermore, GGA suppressed ethanol-
induced gastric lesions in wild-type mice but not in HSF1-null mice. Conclusions: The
results suggest that the aggravation of irritant-induced gastric lesions in HSF1-null mice is
due to their inability to up-regulate HSPs, leading to apoptosis. It is also suggested that the
HSP-inducing activity of GGA contributes to the drug's anti-ulcer activity. This study provides
direct genetic evidence that HSPs, following their HSF1-dependent up-regulation, confer
gastric protection against the irritant-induced lesions.
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Angiogenesis and Vasculogenesis in Human Gastric Ulcers Is Regulated By
Coordinated Expression of Vegf, Angiopoietins and Cox2. Evidence for
Contribution of Bone Marrow Derived Endothelial Progenitor Cells
Andrzej S. Tarnawski, Zsuzsanna Sandor, Aihua Li, Jerald Jensen, Woo sung Moon
Background and Aims: Angiogenesis in granulation tissue leads to the restoration of microva-
scular network and is therefore essential for gastroduodenal ulcers healing. Granulation
tissue growth and generation of new vessels is stimulated by VEGF, a fundamental regulator
of angiogenesis. In animal models, gastric ulceration activates expression of VEGF, but the
clinical relevance of these findings and the roles of Angiopoietins-1, -2 (Ang1, Ang2), Cox2,
and bone marrow derived (BMD) endothelial progenitor cells in healing of human gastric
ulcer are uncertain. This study was aimed to determine expression and localization of VEGF,
Cox2, Ang1, Ang2 mRNAs and proteins in normal and ulcerated human gastric mucosa
and the presence of BMD endothelial progenitors. Methods: Biopsy specimens from normal
human gastric mucosa were obtained during endoscopy in 22 patients. Surgical specimens
of human gastric ulcers were retrieved from pathology archives. Studies: 1) Expression of
VEGF, Cox2, Ang1 and Ang2 mRNAs by RT/PCR and in-situ hybridization, 2) expression
of respective proteins by immunohistochemistry and Western blotting, 3) quantification of
signal intensity with video image system. 4) identification and localization of BMD endothelial
progenitors by immunostaining with CD34 antibody. Results: VEGF, Cox2 and Ang1
mRNAs and proteins are significantly upregulated in granulation tissue by 36-, 64- and 6-
folds, respectively (all p<0.001) and localized to endothelial cells, pericytes and smooth
muscle cells of blood microvessels and vessels, myofibroblasts and macrophages. VEGF and
Cox2 are co-localized in the majority of newly formed endothelial cells and are also strongly
expressed and co-localized to the epithelial cells of gastric ulcer margin. In the newly
generated microvessels and vessels, CD 34(+) cells were present and nested between CD
34(-) endothelial cells, indicating that in human gastric ulcer granulation tissue, sprouting
angiogenesis is complemented by BMD-derived endothelial progenitor cells. Conclusions:
1) Ulceration of human gastric mucosa triggers activation of VEGF, Cox2, Ang1 and Ang2
genes, which initiate angiogenesis. 2) Upregulation of VEGF, Ang1, and Cox2 in the endothel-
ial cells of regenerating microvessels promotes neovascularization in granulation tissue,
essential for the delivery of oxygen and nutrients to the healing site. 3) Co-localization of
VEGF and Cox2 in regenerating endothelial cells suggests their local interactions and autoc-
rine regulation. 4) This is the first demonstration that in human gastric ulcers BMD endothelial
progenitors contribute to and complement sprouting angiogenesis.
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Gastroprotective and Ulcer Healing Activities of Orexigenic Peptide, Orexin-a
(Ox-a) Are Mediated By Prostaglandins Derived from Cyclooxygenase-2, Vagal
and Sensory Nerves and Inhibition of Proinflammatory Cytokines
Tomasz Brzozowski, Peter C. Konturek, Slawomir Kwiecien, Danuta Drozodowicz, Michal
Pawlik, Atsukazu Kuwahara, Ikuo Kato, Grzegorz Burnat, Stanislaw J. Konturek, Wieslaw
W. Pawlik
OX-A, an orexigenic peptide detected in CNS, enteric nerves and endocrine cells of the gut,
is involved in the control of food intake, but its role in the mechanism of gastric mucosal
defense and ulcer healing has been little studied. We determined the effect of intraperitoneal
(i.p.) or intracerebroventricular (i.c.v.) administration of OX-A against gastric mucosal lesions
induced by application of 75% ethanol (1.5 ml i.g.) (series A) or healing of preexisting
gastric ulcers induced by serosal application of acetic acid (ulcer area=28 mm2) (series B)
without or with co-treatment with 1) the non-selective (indomethacin; 5 mg/kg i.p.) or
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selective COX-1 (SC-560, 5 mg/kg i.p.) and COX-2 inhibitors (rofecoxib 10 mg/kg i.g.),
and 2) cutting of vagal nerves (vagotomy) and blockade of sensory nerves by capsaicin (125
mg/kg s.c.) or inhibition of vanilloid receptor (VR-1) by capsazepine (10 mg/kg i.g.). The
area of gastric lesions was measured by planimetry, the gastric blood flow (GBF) determined
by H2-gas clearance technique and COX-1-, COX-2-, IL-1β-, and TNF-α mRNAs and
proteins were assessed RT-PCR and Western Blot. Ethanol produced a widespread mucosal
hemorrhagic lesions without affecting OX-A mRNA expression and its plasma level. OX-A
(1-40 μg/kg i.p.) or (50-2000 ng/rat i.c.v.) dose-dependently attenuated ethanol-induced
gastric lesions while producing a significant rise in GBF, plasma OX-A level and an increase
in mucosal RIA-PGE2 generation. In chronic study, 9-day administration of OX-A (5-60 μg/
kg-d i.p.) significantly reduced the area of gastric ulcers, the dose of OX-A inhibiting ulcer
area by 50% (ID50) being 20 μg/kg. The protective and ulcer healing effects of OX-A were
significantly attenuated by indomethacin and rofecoxib but not altered by SC-560. Co-
administration of 16,16 dm PGE2 (5 mg/kg-d i.p.) with OX-A, restored the protective and
ulcer healing activities of this peptide. Vagotomy, capsaicin denervation or capsazepine also
significantly reduced the gastroprotective and ulcer healing activities of OX-A and addition
of exogenous CGRP (10 mg/kg s.c.) restored the healing and mucosal hyperemia of this
peptide in capsaicin-denervated rats. COX-2 was upregulated at the ulcer margin and this
effect were further enhanced in OX-A treated rats. The IL-1β and TNF-α expression and
plasma levels of these cytokines were significantly elevated in rats with gastric ulcers and
these effects were significantly attenuated by treatment with OX-A. We conclude that OX-
A exerts gastroprotective and ulcer healing properties via mechanism involving activation
of PG-COX-2 system, vagal and sensory nerves and suppression of the proinflammatory cyto-
kines.
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Identification of Adult Stem Cell in the Gastric Mucosa Using Dcamkl1
Miho Adachi, Hiroshi Nagata, Hidekazu Suzuki, Toshifumi Hibi
Cell proliferation plays an important role in maintaining integrity of the gastric mucosa.
Adult stem cells are capable of maintaining, generating and replacing terminally differentiated
cells within their own specific tissue, as required by physiological cell turnover or tissue
damage. However, adult stem cells in the gastric mucosa have not yet been identified,
primarily due to the lack of distinct stem cell markers. Doublecortin calcium/calmodulin-
dependent protein kinase-like-1 (DCAMKL1) is essential for proper neurogenesis and neur-
onal migration. A recent study using gene expression profiling indicated that DCAMKL1
can be used to mark stem cells in the mouse gastrointestinal tract. The purpose of this study
was to identify stem cells in the rat gastric mucosa using DCAMKL1 as a marker. METHODS:
DCAMKL1 expression in the rat corpus was investigated by Western blots and immuno-
staining. Double-color immunostaining was performed to identify localization of DCAMKL1-
positive cells and other epithelial cell lineages. Changes in DCAMKL1 cells and proliferating
cell nuclear antigen (PCNA)-positive cells were determined following intragastric administra-
tion of absolute ethanol. RESULTS: In the Western blots, DCAMKL1 was expressed in the rat
stomach. Positive bands were also observed in the small intestine and colon. Immunostaining
demonstrated that in the small intestine, DCAMKL1- positive cells were found in the base
of crypts just above the lysozyme-positive paneth cells and just below the PCNA-positive
transit amplifying cells. In the stomach, small DCAMKL1 cells with a spindle-shaped morpho-
logy, were located in the mid-portion of each glandular epithelium, in a region called the
isthmus. DCAMKL1 cells were distant from the surface mucous cells. DCAMKL1 cells were
distinct from Muc6-stained mucous cells, histidine decarboxylase-stained ECL cell, ghrelin-
stained A-like cells or αSMA-stained myofibroblasts. DCAMKL1 cells was not coexpressed
with pepsinogen II-stained chief cells or H+/K+-ATPase-stained parietal cells in the isthmus.
DCAMKL1 cells were intermingled with PCNA cells, but did not co-stain with PCNA.
DCAMKL1 cells and PCNA cells disappeared 1h after ethanol administration. They reap-
peared at 6 to 24 hours, and retuned to the basal state on 7 days. CONCLUSIONS: Solitary
DCAMKL1-positive cells are present in the gastric isthmus and the small intestinal crypt,
where multi-potential stem cells are thought to reside. DCAMKL1 cells are distinct from
other cells of epithelial lineage, and their number changes after damage concomitantly with
proliferating cells. These findings suggest that DCAMKL1 is the marker of stem cells in the
gastric mucosa.
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Co-Localization of IGF-1 and EGFR in Epithelial Cells of Gastric Ulcer
Margin: IGF-1 Transactivates EGFR and Enhances EGF-Induced Re-
Epithelialization Through a Distinct from EGF Signaling Pathway
Thomas Nguyen, Aihua Li, Amrita Ahluwalia, Andrzej S. Tarnawski
Background: Gastric ulcer (GU) healing and re-epithelialization require cell proliferation,
migration and differentiation, which are controlled by growth factors. Previous studies
demonstrated that gastric ulceration induces EGF and its receptor (EGFR) expression in
epithelial cells of the ulcer margin and a recent study showed increased IGF-1 expression
in the same area. The precise role of IGF-1 in ulcer healing, its spatial and functional
relationship with EGF/EGFR in re-epithelialization process are unknown. Methods: GUs
were induced in rats by focal serosal application of acetic acid. Ulcerated and non-ulcerated
gastric mucosae were obtained sequentially following ulcer induction for expression of IGF-
1 and EGFR mRNAs and proteins by RT-PCR, Western blot and immunohistochemistry;
and cell proliferation with PCNA staining. In In Vitro studies using rat gastric epithelial
RGM1 cells, we examined whether IGF-1 transactivates EGFR; and determined the effect
of IGF-1, EGF and their combination on re-epithelialization of wounded RGM1 monolayer
and activation of MAPK and PI3K/AKT signaling pathways. Results: In non-ulcerated gastric
mucosa IGF-1 and EGFR were co-localized to the epithelial progenitor cells. Gastric ulceration
triggered increased expression of EGFR and IGF-1 mRNAs and proteins (>12- and >3-fold,
respectively; p<0.001) in epithelial cell of the ulcer margin (in ulcer associated cell lineage),
where EGFR and IGF were co-localized. In the same areas, cell proliferation was increased
by > 800% (p<0.001). In RGM1 cells, IGF-1 induced EGFR phosphorylation in a biphasic
mode with peaks at 15 and 120 min (2- and 2.7-fold; p<0.05, respectively) reflecting
EGFR transactivation. IGF-1 at 10 ng/ml enhanced re-epithelialization of wounded RGM1
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monolayers by 8-fold (p<0.001) compared to controls. This action was mostly (>80%)
dependent on PI3K/AKT and not MAPK. Treatment of wounded RGM1 monolayer with
IGF-1 plus EGF had an additive effect and significantly (>200%) enhanced cell migration
and re-epithelialization; EGF stimulated mainly MAPK, while IGF-1 stimulated PI3K/AKT
pathway. Conclusions: 1) Gastric ulceration induces EGFR and IGF-1 expression and co-
localization in epithelial cells of the ulcer margin. 2) IGF-1 transactivates EGFR. 3) Treatment
of wounded gastric epithelial monolayers with IGF-1 plus EGF has additive effect vs. either
growth factor alone, due to activation of different pathways. 4) These data demonstrate a
cross-talk and interactions between IGF-1 and EGF/ERFR in accelerating gastric ulcer re-
epithelialization and that increased EGF and IGF-1 expression represents a well coordinated
process rather than a redundancy.
867
TGF-Beta Stimulates Intestinal Epithelial FAK Synthesis Via Smad- and P-38
Dependent Mechanisms
Mary F. Walsh, Dinakar R. Ampasala, Arun K. Rishi, Marc D. Basson
Focal adhesion kinase (FAK) mediates processes as diverse as cell migration, proliferation
and apoptosis. Although FAK is regulated by phosphorylation, changes in FAK expression
also critically impact its signaling. FAK protein levels are reduced in the migrating front of
gut epithelial sheets In Vitro. We examined modulation of FAK protein in healing mucosa
In Vivo and postulated that TGF-βmodulates FAK protein. FAK and phospho-FAK immuno-
reactivity are each lower in epithelial cells immediately adjacent to human gastric and colonic
ulcers, but each is dramatically increased in epithelium near but not immediately adjacent
to ulcers. We hypothesized that the latter increase reflects stimulation by growth factors
near the ulcer In Vivo but absent In Vitro. TGF-β (0.1-2.0 ng/ml), but not FGF, PDGF or
VEGF increased FAK protein levels (p<0.003) in non-malignant human Caco-2 or rat IEC-
6 cells. TGF-β staining was also higher in the epithelium near the ulcers, and varied in
parallel with FAK among individual cells. We utilized a FAK promoter-luciferase construct
to investigate the mechanism of FAK regulation. TGF-β stimulated FAK promoter activity
in IEC-6 and Caco-2 cells in parallel with FAK protein. We quantitated FAK by immunoblot
or luciferase assay in subconfluent IEC-6 cells treated with 1.0 ng/ml TGF-β for 24 h and
studied the role of Smad2/3 and p38 using specific siRNA to Smad2/3 or p38-α, the TGF-
β receptor antagonist, SB431542, and the p38 inhibitor, SB203580. TGF-β stimulated
Smad2/3 and p38 activation/phosphorylation; SB431542 (0.5 uM) completely blocked TGF-
β stimulated phosphorylation of both. After 24 h, TGF-β increased FAK protein 58%
(p<0.008) over control and FAK transcription by 41% (p<0.007). TGF-β stimulation of
FAK was prevented by either SB431542 or SB203580 (10 uM). 70-75% reduction of Smad2/
3 or p38-α by specific siRNA each negated the TGF-β effect. Although gut epithelial motility
is associated with a direct inhibition of FAK protein levels immediately adjacent to mucosal
wounds, TGF-β may increase FAK protein in gut mucosal epithelial cells near but not
bordering upon mucosal ulcers via both Smad2/3 and p38 signals. Regulation of FAK
expression may be as important as FAK phosphorylation in influencing migrating gut epithe-
lial cells after mucosal injury.
868
Transient Receptor Potential Vanilloid-4 Activation in the Colon Causes
Visceral Hypersensitivity Symptoms
Nicolas Cenac, Christophe Altier, Nigel W. Bunnett, Wolfgang Liedtke, Gerald Zamponi,
Nathalie Vergnolle
The transient receptor potential vanilloid-4 (TRPV4) responds to osmotic and mechanical
stimuli. In TRPV4 deficient mice (trpv4-/-) mice, TRPV4 was found to be necessary for normal
thresholds in response to noxious mechanical stimuli. We hypothesized that TRPV4 is
implicated in visceral hyperalgesia and allodynia.Methods: The neuronal tracer fast-blue
was injected into the colonic wall of mice; 7 days after, dorsal root ganglia (DRG) neurons
were isolated in order to perform TRPV4 immunostaining, calcium signaling and patch-
clamping in fast-blue labeled neurons. In order to evaluate the effects of TRPV4 activation
on visceral nociception, groups of 8 mice received intracolonically (IC) the TRPV4 agonist
(4α-PDD, 10, 100 or 500μM) or its vehicle (40% ethanol), and abdominal muscle contrac-
tions in response to colorectal distention (CRD) were recorded 30 min, 1, 2, 4 and 6 hours
after TRPV4 agonist treatments. All experiments were reproduced three days after intrathecal
injection of TRPV4 silencer RNA (SiRNA) or control SiRNA. In addition, the response of
DRG neurons to capsaicin (1μM) was recorded, as well as the visceral nociceptive response
to IC capsaicin. The visceral nociceptive experiments were also performed in trpv4-/- mice.
Results: 50% of DRG neurons projecting from the colon (labeled with Fast-blue) expressed
TRPV4. On these DRG neurons, the TRPV4 agonist 4αPDD activated a non specific cationic
current and increased calcium flux. These current and increase in calcium signaling were
not observed in DRG neurons from mice treated with TRPV4 SiRNA. TRPV4 SiRNA treatment
did not modify calcium flux induced by capsaicin. Three days after intrathecal administration
of TRPV4 SiRNA nociceptive response to CRD was significantly decreased, compared to
control SiRNA-treated groups. Intracolonic administration of 4αPDD caused hyperalgesia
and allodynia from 30min to 4 hours after its administration in a dose dependant manner.
Hyperalgesia and allodynia induced by 4αPDD treatment were both inhibited by a pretreat-
ment with TRPV4 SiRNA. In trpv4-/- mice, the nociceptive response to CRD was significantly
lower than in wild type mice and hyperalgesia and allodynia induced by 4αPDD treatment
were both inhibited. However, TRPV4 SiRNA pretreatment had no effect on the hyperalgesia
and allodynia induced by capsaicin intracolonic administration. Conclusion: 4αPDD select-
ively activates TRPV4 in sensory neurons and in the colon of mice. TRPV4 activation is
implicated in the nociceptive response to CRD in basal conditions. TRPV4 activation caused
visceral hyperalgesia and allodynia. TRPV4 can be a new therapeutic target in visceral pain.
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Modulation of Visceral Afferents By Large Conductance KCA Channels
Jorgen Jensen, Lena Branden, Stuart M. Brierley, Nicole J. Cooper, Marie Green, Maria
Ahlefelt, Jan Mattsson, Malin Hulander, Stefan Pierrou, Anders E. Lehmann, L. ashley
Blackshaw
Background & Aim. Large conductance calcium activated potassium channels (BKCa) are
expressed in sensory structures including auditory hair cells, and are established modulators
of excitability. Here we show their expression in visceral sensory neurons and their effects
on mechanotransduction in vagal and spinal visceral afferents. Methods. Retrogradely-labelled
mouse gastric vagal (nodose ganglion) neurons were laser captured and compared with
randomly picked neurons by quantitative RT-PCR. Electrophysiological recordings were
made from gastric vagal afferents and from colonic splanchnic afferents using established
In Vitro preparations in mouse and rat (Page et al Gastroenterology 2004;127:1739-47,
Hicks et al J. Physiol. 2002; 544: 861-869). Results. Alpha and beta subunits of BKCa
channels were expressed at up to 4-fold higher levels in gastric vagal afferents compared
with other nodose neurons when compared against a housekeeper gene, suggesting an
increased role in gut-projecting afferents. Stimulus-response functions of gastric tension
receptors to circumferential stretch (0.5-5gm) were concentration-dependently reduced by
the BKCa opener NS1619 in 7 of 10 fibres tested by >50% at 1 microM. Three of 10 fibres
were unaffected. Probing responses of all 6 colonic serosal/mesenteric afferents tested were
reduced or abolished by NS1619 (1-100 microM). This effect could be reversed by the
selective BKCa channel blocker iberiotoxin (200nM). Administration of the non-selective
BKCa channel blocker charybdotoxin (100nM) in separate experiments increased activity
in colonic afferents. Conclusion. Our data show that BKCa channels are strongly expressed
in visceral afferents, and may have potent modulatory effects on their mechanosensitivity.
Funded by AstraZeneca
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P23 and Trypsin IV, Inhibitor-Resistant Trypsins, Induce Pancreatitis and
Activate Nociceptive Pathways in the Pancreas
Eugene P. Ceppa, Wolfgang Knecht, Anders Petersen, Eileen F. Grady, Nigel W. Bunnett,
Kimberly S. Kirkwood
Introduction The pancreas produces inhibitors of trypsin I/II to prevent damage by prema-
turely activated zymogens. However, during pancreatitis activated trypsins autodigest acinar
cells and cleave protease-activated receptor 2 (PAR2) on nociceptive neurons to induce
neurogenic inflammation and pain. The isozymes of trypsin that mediate these effects are
unknown. We hypothesized that rat p23 and human trypsin IV (mesotrypsin), inhibitor-
resistant trypsins that are upregulated and activated by lysosomal proteases during pancreat-
itis, activate PAR2 and induce pancreatic inflammation and pain. Methods Recombinant
prop23 and trypsinogen IV were activated using enterokinase and purified. To assess PAR2
activation, the effects of p23 and trypsin IV on [Ca2+]i were studied in KNRK-PAR2 cells.
To investigate pancreatitis and pancreatic pain, p23, trypsin IV, porcine trypsin II (10 µg/
ml) or vehicle were infused into the pancreatic duct of anesthetized rats (250 µl, 10 min).
After 2.5 h, inflammation was assessed by measurement of serum amylase and pancreatic
myeloperoxidase (MPO) activities, and pancreatic histology. To assess activation of nocicep-
tive pathways, sections of the dorsal horn of the spinal cord (T8-10) were stained for fos
by immunohistochemistry. Results p23 and trypsin IV increased [Ca2+]i in KNRK-PAR2
cells but not non-transfected KNRK cells, indicative of PAR2 activation. Intrapancreatic
infusion of proteases induced inflammation. However, p23 and trypsin IV produced more
pronounced inflammation than trypsin II: serum amylase (U/L): p23, *9953±1100; trypsin
IV, 6017±389; trypsin II, 6460±93; vehicle 4235±113; pancreatic MPO (U/mg): p23, *7±2;
trypsin IV, *11±3; trypsin II, 3±1; vehicle 2±1 (*p<0.05 compared to trypsin II). All isozymes
of trypsin caused injury of the pancreas, characterized by marked necrosis and infiltration
of neutrophils. All proteases increased the number of fos positive neurons in laminae I and
II of the dorsal horn at T8-T9 as compared to vehicle, indicative of activation of nociceptive
pathways. However, the effects of p23 and trypsin IV were greater than the effect of trypsin
II: fos positive nuclei: p23, *21±2; trypsin IV 20±3; trypsin II, *16±2; vehicle 12±2 (*p<0.05
compared to trypsin II). Conclusions p23 and trypsin IV, inhibitor-resistant trypsin isozymes,
induce a greater degree of pancreatic inflammation and activation of nociceptive neurons
than trypsin II, which is susceptible to endogenous inhibitors. Thus, p23 and trypsin IV
may be important mediators of pancreatic inflammatory pain in pancreatitis, when these
proteases are prematurely activated. Supported by DK39957, DK43207, DK07573.
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Electrophysiological and Molecular Signatures of Glucose Inhibited Neurons
in the Nodose Ganglia
Gintautas Grabauskas, Il Song, Chung Owyang
Animal studies demonstrate portal vein hypoglycemia induces feeding whereas hyperglycemia
in the same vessel evokes satiety. These actions are mediated by glucosensing neurons in
the nodose ganglia (NG). Glucose evoked excitation is mediated by closure of KATP channels
leading to membrane depolarization and neuronal firing. The mechanisms underlying the
ability of neurons to be inhibited by rises in glucose are not known. Whole cell patch clamp
recordings were performed on neurons isolated from rat NG. In 15% of NG neurons
examined, increase of glucose concentration from 5 to 15 mM decreased neuronal input
resistance and reduced the number of action potentials generated by a positive current
pulse. Increase of glucose concentration also inhibited generation of action potential and
hyperpolarized the recorded neuron. This inhibitory action was not attenuated by tolbutamide
(0.5 mM), a KATP channel inactivator, but was significantly blocked by a specific PLC
inhibitor U73122 (10 mM) and the adenylate cyclase inhibitor 2'5'-dideoxydenosine (DDA,
0.5 mM). This suggests the inhibitory action of high glucose is dependent on a cAMP driven
IP3 pathway that evokes calcium release and activate a Ca2+-dependent K+ current. We
investigated the hypothesis that this event is mediated by a novel cAMP-regulated guanine
nucleotide exchange factor (Epac) which stimulates PLC and participates in intracellular
Ca2+ homeostasis and regulation of K+ channel. In neurons dialyzed with the PKA and PKC
inhibitors H7 and calphostin C, application of DDA (0.5 mM) depolarized the neuron
whereas the PLC activator hyperpolarized the cell. DDA also prevented hyperpolarization
of these neurons in response to elevating glucose. Application of 8-Br-cAMP hyperpolarized
6/22 NG neurons. This inhibitory action was mimicked by application of an Epac-selective
cAMP analogue (10 μM, 2'-0-Me-cAMP, 5/23 neurons). To confirm the role of Epac in
glucosensing in glucose inhibited neurons, we transfected NG neurons with siRNA for Epac
1. Relative to untreated neurons, Epac 1 mRNA expression in treated neurons after 48 hrs
was reduced by 91+6%. These siRNA Epac treated neurons responded to 100 μM of 8 Br-
cAMP with membrane depolarization whereas untreated cells showed hyperpolarization.
Furthermore transfecting NG neurons with siRNA for Epac1 abolished the high glucose
evoked inhibitory responses (GluI) but did not change the fraction of glucose excited (GluE)
NG neuron. Our studies delineate a novel signal transduction system in GluI neurons in
which high glucose triggers cAMP synthesis which in turn acts via Epac-PLC pathway to
activate a Ca2+ sensitive K+ channel resulting in hyperpolarization.
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Cinnamaldehyde Sensitises and Activates Rat Vagal and Spinal Afferent
Neurones In Vitro and In Vivo
Anne-marie Coelho, Charlotte Booth, Martyn L. Evans, Catherine H. Frost, Stacey L.
Wood, Benson G. Bill, Natalie J. Tigue, Martin J. Gunthorpe, Kevin Lee, Wendy J.
Winchester
Background: TRPA1 is a member of the transient receptor potential channel family, activated
by pungent chemicals (allyl-isothiocyanate and cinnamaldehyde (TC)), present in sensory
neurones and implicated in pain sensations. The aim of this study was to evaluate TRPA1
channel expression in rat nodose (NG) and dorsal root (DRG) ganglia projecting to the gut,
and determine the effect of TC on rat vagal and spinal afferent neurone activity In Vitro and
In Vivo. Methods: For in situ hybridisation, male Sprague Dawley (CD) adult rats were
injected with fast blue (2% in saline) on the wall of stomach and descending colon to
identify NG and DRG neurones projecting to these tissues using specific riboprobes. TC
(300μM) was tested on NG and DRG neurones in culture, collected from adult male CD
rats and used for Ca2+-imaging or whole-cell patch-clamp techniques. For In Vitro colonic
afferent recordings, distal colon from male CD rats was removed and tied on to cannulae
and perfused internally and externally. Ramps of intracolonic fluid pressure (0-80mmHg
over 120-140sec) were repeated at 5min intervals, and multi-unit suction electrode recordings
were made from the splanchnic nerve proximal to the inferior mesenteric ganglion, in
response to TC applied intraluminal (300μM). For In Vivo jejunal afferent recordings,
extracellular recordings of jejunal afferent nerve discharge were obtained from pentobarbit-
one-anaesthetized male CD rats in response to isobaric balloon distension (2mmHg every
4sec, up to 60mmHg) before and after treatment with TC (300μM intraluminal). Results:
TRPA1 is expressed in vagal and spinal small diameter neurones, in about 26% of NG (15
out of 58) and 30% of DRG (22 out of 73) retrograde-labelled neurones, stomach- and
colon-specific respectively. TC induced increases of intracellular free Ca2+ levels in more
than 20% (11 out of 55) of rat NG neurones, and inward currents in approximately 24%
(10 out of 42) of rat DRG neurones. Applied into the lumen, TC also increased baseline
rat colonic afferent firing (453.4±131.7 vs 345.8±106.4 as control area under the curve
(AUC); n=5 p<0.05) and nerve response to ramp-induced distension (2375.0±929.5 vs
1930.0±923.8 as control AUC; n=5 p<0.05). Similarly, intraluminal TC increased baseline
jejunal afferent firing (65.0±18.1 vs 28.0±15.4 spikes/s as control; n=4 p<0.05) and afferent
response to low pressure (2-30mmHg) distension (n=6 p<0.05) in anesthetised rats. Conclu-
sion: These data provide evidences that TRPA1 is present and functionally active in vagal
and spinal afferent fibres innervating the gut and may contribute in the chemo- and mechano-
sensitivity of the gastrointestinal tract.
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Structure and Function of Mechanoreceptors Innervating the Internal Anal
Sphincter of the Guinea Pig
Penny Lynn, Marcello Costa, Simon Brookes
Sensory nerves to the internal anal sphincter (IAS) contribute to continence and normal
defecation, yet surprisingly little is known about their function or morphology. Here we
investigated the function and structure of mechanoreceptors to the guinea pig IAS. Methods.
Extracellular recordings In Vitro from rectal nerve branches to the IAS, combined with
anterograde labelling of recorded nerve trunks, were used to characterise extrinsic primary
afferent nerve endings activated by circumferential distension (Lynn et al, Gastro.
125(3):786). Results. Anterograde labelling of extrinsic nerves (n=8) show that filled axons
typically innervated the sparse irregular myenteric ganglia of the IAS, before ending in
extensive varicose arrays within the circular muscle and to a lesser extent, the longitudinal
muscle. Two types of novel specialised endings were observed with fan-like arrays of flattened
lamellae on the border between circular muscle and submucosa and the second were simple,
flattened bifurcated endings within the circular muscle. No intraganglionic laminar endings
were observed as have been described for the rectum. Extracellular recordings were made
from rectal nerves innervating the IAS. 5/5 single unit afferents from 4 preparations were
silent under basal conditions and responded to circumferential stretch with slowly-adapting
responses to maintained stretch. When probed with von Frey hairs, they had low thresholds
(0.3-0.5mN), and hotspots for a single unit were typically arrayed in elongated areas along
the circular muscle axis. In 10 units (n=4), there were 3.4 +/- 0.49 elongated fields per
unit and they were 62 +/- 16 mm long (mean +/- SEM). In eight preparations hotspots
(mechanosensitive) and coldspots (mechano -insensitive) were mapped and anterogradely
filled structures were identified. Hotspots were strongly associated with extensive fine varicose
arrays within the circular muscle (p<0.05). No association was seen between mechanosensi-
tive hotspots and fan-like arrays of flattened lamellae: their function remains unknown.
Conclusions. Mechanotransduction sites for low-threshold, slowly-adapting mechanorecep-
tors innervating the IAS are likely to be extensive fine varicose arrays within the circular
muscle. This contrasts with the specialised intraganglionic laminar endings of a similar
functional class of mechanoreceptors innervating the adjacent rectum (Lynn et al, Gastro.
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125(3):786). This suggests the internal anal sphincter receives different sensory innervation
compared to the rectum, presumably related to differences in physiological control of
the regions.
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Changes in Rat ECL Cell Gene Expression Due to 24 Hr Fasting
Nils W. Lambrecht, Iskandar Yakubov, George Sachs
Background: Gastric ECL cells respond to food intake by histamine release to stimulate
gastric acid secretion. Acid secretion returns to a basal level in the absence of food due to
decrease of ECL cell release of histamine. ECL cell histamine content is thought to be
regulated by histidine decarboxylase (HDC) activity. It could also depend on availability of
the HDC substrate, L-histidine and on histamine content in secretory vacuoles dependent
on the vesicular monoamine transporter 2. Generalized functional changes in ECL cells due
to fasting have not been examined in detail. Aims: To identify short-term changes in regulation
of ECL cell function between fasting and feeding. Methods: Alterations in rat ECL gene
expression during fasting were identified by comparative transcriptomal analysis of 95%
pure ECL cells from fed and 24hrs fasted rats eliminating mRNA contamination from
other gastric mucosal cell types. These data were compared to RT-qPCR of gastric mucosal
homogenates allowing assessment of ECL cell selective changes. Results: ECL cell HDC
expression was unchanged after 24 hr fasting. In contrast, there was increased gene expression
of histidine catabolizing enzymes (histidase, urocanase) and decreased expression of histidine
uptake transporters resulting in histidine depletion. Expression of the vesicular monoamine
transporter 2 was down-regulated decreasing histamine exocytosis. Expression of histamine
degrading enzymes, histamine N-methyl transferase and amine oxidase were up-regulated
in the mucosa. There was decreased gene expression of proteins with secretory functions
for synthesis and release of peptide hormones. There was increased gene expression of
proteins regulating transcriptional activity that results in increased cell survival, inhibition of
cell division, apoptosis and terminal neuroendocrine cell differentiation. There was decreased
expression of genes for cytoskeletal organization and gap junction formation, indicating
reduction of interaction with parietal cells. Conclusion: 24 hr fasting induces significant
changes in gene expression of enzymes other than HDC, resulting in histidine depletion in
ECL cells and histamine storage, decreasing the ability of ECL cells to secrete histamine.
The data provide an explanation of discrepancies in the effect of short-term fasting on HDC
gene expression compared to activity as well as insight into the regulation of ECL cell and
mucosal histamine content during fasting. In addition, ECL cells after 24 hr fasting not only
decrease their secretory function but also revert to a quiescent resting physiological state.
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Enhanced Aquaporin-4 Expression in the Gastric Fundic Parietal Cells After
the Pharmacological Acid Suppression
Hidekazu Suzuki, Yuriko Minegishi, Tetsufumi Takahashi, Toshihiro Nishizawa, Tatsuhiro
Masaoka, Masato Yasui, Toshifumi Hibi
Background. It had been believed that the water dynamics across cells was restricted by
virtue of the semipermeability of cell membrane, however, this belief has changed with the
discovery of the water channel, aquaporin (AQP). It has been reported that AQP4 is expressed
on the basolateral membrane of parietal cells, especially in the basal region of the gastric
fundic glands (FEBS Lett. 459:305, 1999). This indicates that parietal cells may have
different functions depending on their vertical localization (apical and basal parietal cells)
within a fundic gland. The present study was designed to investigate the expression of AQP4
in the mouse stomach after pharmacological acid suppression with a histamine type 2
receptor antagonist (H2RA) and proton pump inhibitor (PPI). Methods. Male 5-week-old
C57B/6 mice were prepared for this study, and an H2RA (Famotidine:FMT, 15mg/kg, 2x/
day, s.c.) or PPI (Lansoprasole:LPZ 30mg/kg, 1x/day, s.c.) was administered to the animals.
A 0.5% CMC solution was administered as control. Four or 8 weeks after the administration,
the stomachs of the mice were removed and examined by quantitative RT-PCR and immuno-
histochemistry for AQP4 expression. Results. The FMT group and LPZ group exhibited
higher AQP4 mRNA expression in the stomach than the control group (AQP4 mRNA/
GAPDH mRNA, 4 weeks: cont. 30.5±12.4, FMT 50.7±15.1, LPZ 156.1±59.2, cont. vs.
LPZ :p<0.05; 8 weeks: cont. 138.2±24.0, FMT 309.3±72.4, LPZ 788.2±295.6, cont. vs.
LPZ:p<0.001). AQP4 was specifically expressed on the basolateral membrane of the gastric
fundic parietal cells. A significant increase in the number of AQP4-positive parietal cells
(cell number/gland) in the gastric fundic glands was observed after the acid suppression,
especially in the LPZ group (4 weeks: cont. 6.2±0.7, LPZ 18.4±1.4, p<0.001; 8 weeks,
cont. 4.2±0.7, LPZ 16.8±1.7, p<0.001). Conclusion. AQP4 expression on the basolateral
membrane of parietal cells in the fundic glands was enhanced under the condition of
pharmacological acid suppression. AQP4-positive parietal cells, located in the basal portion
of the gastric fundic glands under normal conditions, may be involved in another as yet
unknown function besides acid secretion, that is possibly related to the water or gas transport
through the AQP.
876
Transport of Zn2+ Is Coupled to Secretion of H+ in Parietal Cells of the
Rabbit Gastric Gland
Haley B. Naik, Yoshiro Suzuki, Matthias A. Hediger, David I. Soybel
Aims: Recently we reported evidence that, within the gastric parietal cell, the content of
Zn2+ insulates the tubulovesicle (TV) compartment of the against leakage of its protons. In
this study, we identified a molecular mechanism of Zn2+ uptake by the TV compartment.
In addition, we tested the hypothesis that transport of Zn2+ from the cytoplasm to the TV
compartment is coupled to the secretory state of the parietal cell. Methods: Tubulovesicles
(TVs) were isolated from rabbit mucosa using cell fractionation and sucrose gradient separa-
tion. TV content of Zn2+ was monitored by measuring timed uptake of the Zn2+-specific
fluorescent reporter TSQ (33μM, 20 min exposure) in the presence of Zn2+ (25nM to
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250nM). Gastric glands were isolated using collagenase digestion and loaded with a Zn2+-
sensitive fluorescent dye, fluozin-3, to monitor [Zn2+] in the cytoplasm during intervals of
loading of Zn2+ across the basolateral membrane in the presence of 60μM Zn2+ in the
perfusing Ringer's solutions. RT-PCR and Western lot were used to probe preparations of
glands and TVs, respectively, for Zn transporters in the SLC30A family. Results: Using RT-
PCR and Western blot, we identified SLC30A-5 (ZNT5), as a candidate transporter for Zn2+
uptake by the TV compartment. Uptake of Zn2+ by isolated TVs, monitored by TSQ
fluorescence, was suppressed by >50% when proton gradients were equalized either by
acidification of the exterior solution (from pH 7.0 to pH 5.0, n= 3 expts, p<0.01) or by
alkalization of the interior using protonophores such as nigericin (7μM, n=3 expts, p<0.01).
In isolated gastric glands loaded with the reporter fluozin-3, stimulation of acid secretion
with forskolin (8μM) markedly accelerated the influx of Zn2+ to the cytoplasm (rate of
Zn2+ influx in fluorescence units 2.01±0.35 fold over control, n=17, p<0.001). Inhibition
of acid secretion arrested the flow of Zn2+ to the TV compartment, leading to accumulation
of Zn2+ in the cytoplasm (using omeprazole 100μM peak accumulation 6.7±1.8 fold over
control; SCH28080 10μM accumulation 2.2 ±. 0.1 fold over control, p<0.01 with n= 6
expts in inhibitor and control groups). Conclusions: Accumulation of Zn2+ in the TV/L
compartment is coupled to the trans-membrane proton gradient, consistent with Zn2+/H+
exchange that characterizes the SLC30A family of Zn2+ transporters. In addition, vectoral
flow of Zn2+ across the basolateral membrane into the cytoplasm and thence to the TV
compartment is regulated by secretory activity of the gastric parietal cell. A novel and
generalizable mechanism of acidity regulation in secretory compartments of epithelial cells
is thus suggested.
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Sulforaphane Modulates Gastric Oxyntic Cell Functions By Enhancing
Production of Radical Oxygen Speices
Akinori Yanaka, Hirofumi Matsui, Takeshi Shibahara, Akira Nakahara, Ichinosuke Hyodo,
Masayuki Yamamoto
Sulforaphane (SFN), a substance abundantly included in broccoli sprouts, affords chemoprev-
ention against cancer by a variety of mechanisms. SFN induces NF-E2 p45-related factor
2(nrf2)-dependent antioxidant enzymes, thereby protects normal cells from oxidative injury
(J Biol Chem 2002;277:3456-63). We have previously shown that SFN protects gastric
mucosa from oxidative injury via nrf2-depdendent mechanisms (Gastroenterology 2004;
126: A-47). On the other hand, SFN increases radical oxygen species (ROS) production by
cancer cells, thereby induces apoptosis of the cells (J Biol Chem 2005; 280: 19911-24). In
the present study, we decided to determine if SFN enhances ROS production by gastric
mucosa, and to determine if SFN-induced ROS modulates gastric oxyntic cell functions.
Methods: Study A: The effects of various doses of SFN, 1 μM- 10 mM, on isolated guinea
pig gastric glands (GG) were examined. 1)ROS production by GG was fluorometrically
measured using GG preloaded with a ROS-sensitive fluorescent dye, CM-H2-DCFDA. 2)
Histamine release was measured by histamine ELISA kit. 3) Acid production by GG was
estimated from 14C-aminopyrine(AP) accumulation. 4) Apoptosis and cell death of GG were
evaluated from oligonulceosome level and LDH release, respectively. Study B: Effects of
SFN on intact sheets of In Vitro gastric mucosa were compared between nrf2+/+ and nrf2-/-
C57/BL6 mice. Electrical resistance, acid secretion, histamine release, and LDH release were
measured. Mucosal expression of peroxyredoxin-1 (PRX-1) was evaluated by real time RT-
PCR. In some tissues, SIN-1, a peroxynitirite generator, was added to load oxidative stress.
Results: Study A: 1) SFN dose-dependently enhanced ROS production by GG. These effects
were prevented by a ROS scavenger, N-acetyl-l-cysteine (NAC). 2) SFN, 1-10 μM, stimulated
14C-AP accumulation. These effects were prevented by NAC or famotidine. 3) SFN dose-
dependently increased histamine release. This effect was prevented by NAC. 4) SFN, 100
μM-10 mM, inhibited 14C-AP accumulation, increased apoptosis and LDH release. These
effects were attenuated by NAC. Study B: 1) In nrf2+/+, but not in nrf2-/- mice, SFN up-
regulated PRX-1 expression and protected gastric mucosa from SIN-1-induced oxidative
injury. 2) In both nrf2+/+ and nrf2-/- mice, low doses of SFN stimulated histamine release
and acid secretion, while high doses of SFN decreased acid secretion, and increased LDH
release. Conclusions: SFN modulates acid secretion and viability of gastric oxyntic cells.
These effects of SFN are not mediated by nrf2-dependent mechanisms, but appear to be
related to SFN-induced stimulation of ROS production by the cells.
878
Pac1 Defecient Mice Have Increases in Basal Gastric Acid Output, An Effect
Mediated By Changes in Gastric Morphology
Yuxin Lu, David Oh, Gordon V. Ohning, Patrizia Germano, James Waschek, Joseph R.
Pisegna
Purpose: We and others have previously described the expression of the high affinity
receptor for Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), PAC1, on gastric
enterochromaffin-like (ECL) cells, and that PACAP stimulates gastric acid secretion in rats.
Conversely, PACAP has been shown to induce a decrease of gastric acid secretion in mice,
that it is presumed to be secondary to PACAP-mediated somatostatin release. To better
clearly define the role of PAC1 in the regulation of gastric acid output, a PAC1 knock-out
mouse model was developed. Methods: To develop PAC1 knock-out mice, the PAC1 gene
was disrupted by deletion of a 2.3 kb region containing exons 8-11, and replaced with a
neomycin selection cassette in the reverse direction (Brabet, et al. J. Clin. Invest. 2000). In
F1 crossbred mouse strain (129/Sv x C57BL6/J) heterozygous PAC +/- mice were bred to
develop homozygous PAC1 -/- mice on a C57BL6 mouse background. Mouse genotyping
was performed by triple primer PCR to confirm homozygosity and heterozygosity of the
PAC1 gene. Gastric acid measurements were performed in urethane anesthetized mice using
the pylorus ligation model. Acid output was determined by product of the titratable acidity
and gastric volume following sham-, or pentagastrin-, or PACAP infusions in both wild type
and PAC1 -/- mice. Results: During the observation period of 2 hours, the average basal
gastric acid secretion in urethane-anesthetized PAC 1 -/- was 0.29 ± 0.05 umol (10min) -1
(n=5), whereas for the WT the average basal acid output was 0.10 ± 0.01 umol (10min)
-1 (n=5). This translated to an approximately 3 fold higher basal stimulation in the PAC1
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-/-, compared to WT mice, a result that was statistically significant (p<0.001). As expected,
administration of PACAP did not result in an increase in gastric acid output, however
administration of pentagastrin showed maximal acid output in both the WT and PAC1-/-
mice suggesting that the gastrin stimulatory pathway was intact. Conclusion: The result
reported here is the first observation of gastric physiology in PAC1 deficient mice. The
expression of PAC1 is clearly important in the homeostatic mechanisms regulating gastric
acid secretion. Loss of PAC1 during development presumably may lead to compensatory
mechanisms via yet undiscovered mechanisms. Further morphometric analysis using
immunohistochemistry and measurement of gastrointestinal peptides in PAC1 -/- mice will
likely yield important physiological regulatory mechanisms for furthering our understanding
of the role of PACAP in gastric acid secretion.
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Identification of a Gastrin Response Element in the Vesicular Monoamine
Transporter Type 2 (VMAT2) Promoter and Requirement of the Proteasome
for Transcriptional Activity
Krista R. Catlow, Louise Ashurst, Andrea Varro, Rod Dimaline
Background: VMAT2 sequesters histamine into secretory vesicles of the enterochromaffin-
like (ECL) cell, a key requirement for gastric acid secretion. Its expression in ECL cells is
regulated by gastrin (G17) through binding of CREB and other unidentified proteins to the
proximal promoter. We sought to identify and characterize nuclear proteins required for
gastrin-mediated VMAT2 transcription. Methods: Binding proteins in nuclear extracts from
gastric epithelial cell lines were detected by electrophoretic mobility shift assays (EMSA),
and the significance of target DNA sequences assessed using VMAT2 promoter-reporter
constructs. Binding partners were characterized by yeast one-hybrid analysis and their
functional relevance assessed by RNA interference. Results: In EMSAs, nuclear proteins
from AGS-GR cells (that express the CCK2 receptor), formed several binding complexes
with the -65 to -37bp region of the rat VMAT2 promoter. G17 (10-10 to 5x10-9M) stimulation
of AGS-GR cells dose-dependently increased binding of a specific complex, that was maximal
after 1h. Mutation of the promoter showed the sequence -56ccgccccctc-47 was crucial for
binding. The same binding complex was identified in nuclear extracts from AR42J cells,
and was unaffected by incubation with antibodies to a range of transcription factors including
the SP and AP family. In luciferase reporter assays, the proximal 65bp of the VMAT2
promoter directed expression in AGS-GR cells that was increased by exposure to 10-9M G17
for 6h (control, 100±7.4%; G17, 278±11.9%, n=3, p<0.05,ANOVA). Mutation of either 5'
or 3' ends of the sequence ccgccccctc reduced the G17 response to 41.9±12.8% or 50.5±6.6%,
respectively, that of the wild type construct (p<0.001, n=3). Using the -65 to -37 VMAT2
promoter fragment as bait in a yeast one-hybrid assay, two of ten positive colonies identified
in an AR42J cell cDNA library contained the complete coding region of rat proteasome beta
subunit, PSMB1. Inclusion of PSMB subunit antibodies in EMSAs disrupted binding of the
gastrin-sensitive complex to the VMAT2 promoter. Transfection of AGS-GR cells with two
independent human PSMB1 siRNAs for 72h reduced VMAT2 promoter-reporter responses
to G17 (10-9M, 6h) to 37.1±4.2 and 56.9±4.4%, respectively, of that in cells transfected
with scrambled siRNA sequence (p<0.01, n=3). Conclusions: CCK2 receptor activation
induces nuclear protein binding to a C-rich response element in the VMAT2 proximal
promoter, and stimulates transcription. Protein binding and transcription is at least in part
dependent on nuclear expression of proteasome beta subunits.
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Endoscopy Nurse Experience Predicts Screening Colonoscopy Procedure
Times and Cecal Intubation Rates
Evan S. Dellon, Quinn K. Lippmann, Joseph Galanko, Nicholas J. Shaheen
Background: Though screening colonoscopy is felt to decrease the risk of colorectal cancer,
screening programs are time and resource intensive. The effect of nursing experience on
procedure duration and cecal intubation rates is unknown. Aim: To determine whether
endoscopy nurse experience level is associated with screening colonoscopy procedure length
or successfully reaching the cecum. Methods: We performed a retrospective analysis of
screening colonoscopies at the University of North Carolina Hospital between August 2003
and 2005. Procedures were limited to those performed by attendings without trainee involve-
ment. Nurse experience was measured in weeks from the initial start date to the procedure
date for each endoscopy nurse. The primary outcomes were time to cecum and cecal
intubation rate. The secondary outcome was total procedure time. Additional variables
related to both the procedure (preparation quality, medications administered, findings) and
the patients (age, gender, ASA score, BMI, comorbidities, and past surgical history) were
extracted from our electronic endoscopy database. Descriptive statistics, bivariate analysis,
and multivariate linear and logistic regression were performed. The study was approved by
the Institutional Review Board of UNC. Results: 3,631 screening colonoscopies were eligible
for analysis. Twenty-nine nurses were employed in our endoscopy unit during the study
period, 19 of whom were new to gastroenterological nursing. Mean time to cecum for
procedures involving nurses with 6 months of experience or less was 12.7 (± 6.8) minutes,
compared with 10.4 (± 8.5) minutes for nurses with more than 6 months of experience (p
< 0.001). For nurses with 6 months of experience or less, 18.1% of procedures had cecal
intubation times greater than one standard deviation from the mean, compared with 12.2%
of procedures for nurses with more than 6 months of experience (OR 1.6, 95% CI 1.3-2.0,
p < 0.001). Similar results were seen for total procedure duration. For nurses with 6 months
of experience or less, 9.3% of procedures did not reach the cecum, compared with 5.4%
of procedures for nurses with more than 6 months of experience (OR 1.8, 95% CI 1.4-2.4,
p < 0.0001). All relationships held after adjusting for potential confounding patient and
procedure variables. Conclusions: Nursing experience of six months or less is associated
with longer time to cecum, longer total procedure time, and a lower rate of cecal intubation
for screening colonoscopy. These findings may have implications for nurse training, procedure
scheduling, and endoscopy unit efficiency.
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Nurse Experience: A Strong and Previously Unidentified Predictor of
Screening Colonoscopy Complications
Evan S. Dellon, Quinn K. Lippmann, Joseph Galanko, Nicholas J. Shaheen
Background: While factors that predict screening colonoscopy complications have been
described, there are no published reports of the effect of nursing experience on colonoscopy
outcomes. Aim: To determine whether endoscopy nurse experience level is associated with
screening colonoscopy complications. Methods: We performed a retrospective analysis of
screening colonoscopies at the University of North Carolina Hospitals between August
2003 and 2005. Procedures were limited to those performed by attendings without trainee
involvement. Nurse experience was measured in weeks from the initial start date to the
procedure date for each endoscopy nurse. The primary outcome was any immediate complica-
tion defined as respiratory decompensation unresponsive to oxygen by nasal cannula, hypo-
tension requiring pharmacologic support, or cardiac arrhythmia, with or without use of
reversal agents. Additional variables related to both the procedure (preparation quality,
medications administered, findings) and the patients (age, gender, ASA score, BMI, comorbid-
ities, and past surgical history) were extracted from our electronic endoscopy database.
Descriptive statistics, bivariate analysis, and multivariate logistic regression were performed.
The study was approved by the Institutional Review Board of UNC. Results: Twenty-nine
nurses were employed in our endoscopy unit during the study period, 19 of whom were
new to gastroenterological nursing. 3,631 screening colonoscopies were eligible for analysis.
There were 16 immediate complications (0.4%) of respiratory depression (7), hypotension
(2), or bradycardia (7), 11 of which required medication reversal; there were no deaths.
Procedures with complications were associated with fewer weeks of nurse experience than
were uncomplicated procedures (98 weeks vs 157 weeks, p = 0.07), and 13 of the complica-
tions (81%) occurred during procedures staffed by nurses hired during the study period.
Eight of the complications (50%) occurred during procedures staffed by nurses with 6
months of experience or less (OR 2.4, 95% CI 0.9-6.4, p = 0.07), with 5 of the complications
(31%) occurring within the first two weeks of experience (OR 10.4, 95% CI 3.6-30.2, p <
0.001). These relationships held after adjusting for potential confounding patient and proced-
ure variables. Conclusions: Complications during screening colonoscopy were strongly
associated with nurse inexperience, particularly within the first two weeks of starting in our
endoscopy unit. This finding has implications for quality assurance, and also suggests
potential interventions to decrease immediate complications of screening colonoscopy.
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Is Nurse Administered Propofol Sedation (NAPS) Safe for Endoscopies in a
Gastroenterologist Ambulatory Practice?
Shajan Peter, Peter Wunderlich, Christoph Beglinger, Ludwig T. Heuss
Background: It has been shown that propofol can be safely administered by registered nurses
in specialized and hospital based endoscopy centres with experienced teams (Rex DK, Heuss
LT, Walker JA, Qi R. Gastroenterology 2005;129:1384-91). The use of NAPS in primary
Gastroenterology (GI) practice is still under debate. To address this, we analysed prospectively
collected data from a single GI physician ambulatory practice and compared them with data
from a University Hospital based tertiary endoscopy unit. Methodology: From 10/01 to 06/
06, all consecutive patients who underwent routine endoscopies under propofol sedation
at a single gastroenterologist - single trained nurse assisted GI practice in Biasca, Switzerland,
were prospectively enrolled in a database. Data were retrospectively analysed and compared
with the same number of similarly collected data during a 17-month period at the University
Hospital, Basel, Switzerland. In the private GI practice, all patients undergoing colonoscopy
received a single dose of fentanyl (50 μg) prior to the beginning of sedation (not done at
the University Hospital). Propofol was titrated according to the clinical response. Results:
A total of 3205 patients underwent NAPS for endoscopies at the GI practice. 443 procedures
were performed without sedation. Demographics are shown in the Table. There were no
cases requiring endotracheal intubation; no deaths occurred. The rate of respiratory events
requiring bag ventilation was less for the GI practice compared with the University (Table).
Conclusions: 1. Propofol can be safely administered for routine endoscopies in a single GI
physician - single nurse assisted centre. 2. Overall results are comparable and are independent
of the place of practice. 3. In the GI practice, the investigated patients had significantly
lower ASA scores. 4. The mean dosage of propofol was less in the primary practice.
**p = 0.02 between groups * p = < 0.001 between groups ASA = American Society of
Anaesthesia Classification
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Nurse Endoscopy: Preliminary Evaluation of the Groningen Colonoscopy
Training Program
Jan J. Koornstra, Hendrik M. Van dullemen
Background: Screening by colonoscopy is recommended in many countries to reduce the
risk of death from colorectal cancer. Given the limited supply of medical endoscopists, nurse
endoscopists may represent an economic alternative. Several studies are available that show
that non-medical endoscopists can be trained to perform flexible sigmoidoscopy as safely
and effectively as medical endoscopists. There are no such data on colonoscopy. We evaluated
the performance and safety of our colonoscopy training program for nurse endoscopists in
comparison with trainee medical endoscopists. Methods: Two gastrointestinal endoscopy
nurses were enrolled in a colonoscopy training program, including theoretical sessions and
computer-based colonoscopy simulation. Their first 100 colonoscopies in clinical practice
were evaluated and compared with results from 2 medical trainees during the same time
period. Only diagnostic procedures in patients with their entire colon in situ were included.
Objective criteria for competency were cecal intubation rate, cecal intubation time, need for
assistance and complications. Subjective criteria included pain and discomfort scores, were
assessed using a 10 point visual analogue scale (VAS; 0, none; 10 unbearable). Results: The
overall unassisted cecal intubation rate was 83 %. The median cecal intubation time for the
initial 25 procedures was 14 minutes (range 6-29), improving to 11 minutes (range 4-26)
for the last 25 procedures. Median patients' pain and discomfort scores gradually decreased
in the course of training from 3.1 to 2.0 and 1.7 to 0.2, respectively. Pathologic findings
were detected in 51 % of procedures, which in all cases were recognized by the nurse
endoscopists. No complications were observed. Cecal intubation rates and times and patient
satisfaction, pain and discomfort scores were similar between nurse endoscopists and medical
trainees. Conclusions: Endoscopy nurses can be trained to perform colonoscopy in a safe
and effective manner, with results similar to those for trainee medical endoscopists.
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Galectin-3 Mediates Nuclear β-Catenin Accumulation and Wnt Signaling in
Human Colon Cancer Cells Through Regulation of Gsk-3β Activity
Shumei Song, Nachman Mazurek, Chunming Liu, Kaifeng Liu, Robert S. Bresalier
Background: Wnt/beta-catenin signaling plays an essential role in both development and
carcinogenesis. More than 90% of colorectal cancers have an activating mutation in the
canonical Wnt signaling pathway. One of the hallmarks of activating Wnt signaling is the
accumulation of nuclear β-catenin. Galectin-3(gal3), a β-galactoside-binding protein, has
been recently implicated in Wnt signaling in breast cancer cells. Its role in regulating the
Wnt pathway in colon cancer is unknown. Methods: The human colon cancer cell line
LiM6, derivatives stably transfected with galectin-3 antisense, and AG1, a cell line containing
gal3-antisense under control of an inducible promoter were used as model systems. Total
β-catenin protein, its subcellular distribution, and the status of GSK-3β phosphorylation/
activation were determined by western blots. β-catenin/TCF transcriptional activity was
measured using pTOPFLASH and pFOPFLASH TCF reporter plasmids. The effects of gal3
on TCF activity were examined by co-transfection with a pCNC10 plasmid containing full
length gal3 cDNA. LiCl, an inhibitor of GSK-3β was used to define the mode of action of
gal3. Results: Down- regulation of gal3 by stable introduction or induction (by doxycycline
exposure) of gal3-antisense resulted in decreased total β-catenin protein levels and reduced
nuclear distribution with concomitant dephosphorylation/activation of GSK-3β. Basal β-
catenin/TCF transcriptional activity and the expression of one of its target genes cyclin D1
were suppressed as well. Transfection of gal3 into low-level expressing gal3 cells (LS174T)
augumented TCF luciferase reporter activity. Exposure of these cells or LiM6 gal3-antisense
clones to the GSK-3β inhibitor, LiCl, lead to β-catenin import into the nucleus and increased
β-catenin/TCF transcriptional activity, mimicking the effects of gal3. Conclusions: These
results suggest that gal3 mediates Wnt signaling, in part, by regulating the phosphorylation/
activity of GSK-3β and therefore the ubiquitination/signaling of β-catenin in colon cancer
cells.
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Cdx2 Promotes Anchorage Independent Growth By Transcriptional Repression
of Igfbp3
Sang Chun, Fang Chen, Joe Washburn, Jim Macdonald, Keri Innes, Marcia R. Cruz-
correa, Long H. Dang, Duyen Dang
BACKGROUND: CDX2 is a Drosophila caudal-related homeobox transcription factor that
is important for the establishment and maintenance of intestinal epithelial cells. CDX2 is a
marker of colorectal cancer (CRC), with strong staining in up to 90% of tumors. We have
reported that CDX2 promotes anchorage-independent growth in a subset of human CRC cell
lines. AIM: To determine the mechanisms by which CDX2 promotes anchorage-independent
growth. METHODS: Using Affymetrix U133A GeneChip, we identified that IGFBP3 expres-
sion was increased 3-fold in CDX2 knockout (KO) compared to parental LOVO cells. These
results were validated. To determine the effects of CDX2 on the IGFBP3 promoter, chromatin
immunoprecipitation (CHIP) and dual-luciferase promoter activity assays were performed
in 4 cell lines. To determine if increased IGFBP3 specifically mediated the effects of CDX2
on anchorage-independent colony formation, CDX2 KO and parental cells were treated with
monoclonal antibodies to IGFBP3 (mAb IGFBP3), recombinant human IGFBP3 (rhIGFBP3),
IGF1, and Long IGF1. RESULTS: Disruption of CDX2 was associated with a 3-fold increase
in IGFBP3 mRNA and protein expression, and IGFBP3 secretion. Using CHIP assays to
interrogate the proximal 2kb-IGFBP3 promoter, we found that CDX2 binds in the region
of nt -705 to nt -555 from initiation. Using dual luciferase assays, we found that CDX2
represses IGFBP3 promoter activity. Further deletion and site-directed mutagenesis analyses
identified two binding sites at nt -694 and nt -676 from initiation as being critical for CDX2
repression of the IGFBP3 promoter. These findings were consistent in LOVO, LOVO CDX2
KO, SW48 and LS174T cells. Finally, inhibition of IGFBP3 partially rescued the decreased
anchorage-independent growth phenotype observed in CDX2 KO cells. Treatment with
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mAbIGFBP-3 increased colony formation in CDX2 KO cells by 2-fold, but not LOVO cells.
Conversely, treatment with rhIGFBP3 decreased colony formation in LOVO cells by 2-fold.
Treatment with IGF1 increased colony formation in LOVO cells by ~2-fold, but not in
CDX2 KO. In contrast, LIGF1, which does not bind to IGFBP3, increased colony formation
by ~2-fold in both cell lines. Altogether, these data are consistent with a paradigm in which
CDX2 represses IGFBP3 expression, thus promoting IGF1 bioavailability and anchorage-
independent growth. CONCLUSIONS: These data demonstrate, for the first time, that in a
subset of colorectal cancer cell lines, 1) CDX2 can function as a transcriptional repressor
and 2) a mechanism by which CDX2 promotes anchorage-independent growth is by transcrip-
tional repression of IGFBP3.
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Vegf Mediates Endothelial-Epithelial Cross Talk in the Intestinal Mucosa
Rodrigo Jover, Tina Chen, Mariecka Pennings, Amelie Boquoi, Gregory H. Enders
Vascular endothelial growth factor (VEGF) is important in tumor angiogenesis and possibly
other aspects of tumorigenesis and is a new target in colon cancer therapy. Previous work
from our laboratory showed that targeted deletion of the p16Ink4a tumor suppressor gene
in Min mouse colon tumors causes increased tumor growth and vascularization associated
with higher levels of VEGF. To examine the mode of action of VEGF in the intestine, a
transgenic mouse was engineered to moderately overexpress VEGF overexpress from the
villin promoter. The principal aim of this study was to characterize the intestinal phenotype
of these transgenic mice. A second objective was to study In Vitro the interaction between
intestinal epithelial cells, endothelial cells and fibroblasts, using organotypic cultures.
METHODS: Haematoxylin-eosin and immunohistochemical staining was performed on form-
alin-fixed, paraffin-embedded or frozen samples from mouse intestine, using antibodies
against Claudin-7, CD34, CD31, alfa-smooth-muscle actin and Ki67. Organotypic cultures
were generated by embedding skin human fibroblasts and mouse endothelial cells in type
I collagen matrix. Proliferative and apoptotic indices were calculated respectively as the
percentage of Ki67 and caspase-3 positive cells. RESULTS: The intestinal mucosa of the
transgenic mice showed a dramatic phenotype with the presence of a striking mucosal
thickening and cysts. Surprisingly, there was no obvious increase in vascularization. The
cysts were comprised of epithelial cells, identified by claudin-7 staining and their contiguity
with crypts. The cysts were surrounded by a layer of CD34/CD31 positive cells and an outer
layer of alfa-smooth muscle actin positive myofibroblasts. Ki67 staining suggested an increase
in epithelial cell proliferation along the crypt-villus axis. In preliminary results from
organotypic cultures, proliferation of HCT-116 human colorectal carcinoma cells appeared
to be stimulated by the presence of endothelial cells. In contrast, endothelial cells did not
affect proliferation of p53-null mouse colonocytes, but appeared to inhibit their apoptosis.
CONCLUSION: Moderate VEGF overexpression causes a unique phenotype in the intestinal
mucosa characterized by altered crypt epithelial cell dynamics. The observed effects may
be secondary to direct cell-cell interaction between epithelial cells, endothelial cells and
myofibroblasts, in the absence of changes in blood flow. Organotypic co-cultures support
this notion by providing preliminary evidence for direct epithelial-endothelial cell cross-talk
affecting cell proliferation and cell fate.
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Gtpase Regulator Dock4 Is Required for Wnt Mediated Cell Migration
Geeta Upadhyay, Wolfram Goessling, Kenji Kawada, Ramnik Xavier, Leonard I. Zon, Vijay
Yajnik
Background & Aims: Small GTPase regulator, DOCK4, belongs to the CDM (Ced-5,
DOCK180 and Myoblast city) family of unconventional, Rac guanine nucleotide exchange
factors (GEFs). DOCK4 regulates localization of beta catenin at the cell-cell adherens junctions
but its function in wnt signaling remains to be elucidated. The focus of this study is to
understand the role of DOCK4 and small GTPases Rac and Rap1 in the regulation of beta
catenin by wnt signaling. Methods: Using the lentiviral system expressing DOCK4 SiRNA,
we established NIH3T3, 293 and IEC-6 cells with stable knockdown of DOCK4 expression.
Simulatneouly, we performed overexpression studies in these cell lines. Cells were stimulated
with either canonical ligand wnt-3a and non-canonical ligand wnt-5a and TCF transcription
was measured using luciferase assay (TOPFLASH). Functional studies on these cell lines
were performed, including transformation and migration assays. Moreover, to understand
the molecular basis of DOCK4's regulation of beta catenin, protein interaction studies along
with immunoflourescence microscopy were performed with members of the beta catenin
destruction complex. Zebrafish embryos were injected with DOCK4 morpholinos for 24
hours. Results: In NIH3T3 cells stimulation by wnt ligands 3a and 5a regulates GTP-Rac
levels in a DOCK4 dependent manner. DOCK4 does not bind to beta catenin but interacts
with beta catenin destruction complex. Silencing of DOCK4 expression leads to a dramatic
inhibition of wnt siganaling. However, as compared to vector alone, over-expression of
DOCK4 does not cause further enhancement in wnt signaling. Biochemical studies suggest
that during propagation of wnt signaling, DOCK4 is required for stabilization of free cytosolic,
transcriptionally active pool of beta catenin. The functional consequences of DOCK4 silencing
were also evident in wnt-induced cell transformation and migration invitro and zebrafish
embryogenesis invivo. Conclusion: We report a novel role of DOCK4-Rac pathway in
canonical wnt signaling. Since DOCK4 via Rap1 regulates beta catenin at cell-cell junctions
our novel findings suggest that DOCK4 may influence both adhesive and migratory function
of intestinal cells. These findings might have implications in intestinal homeostasis and colon
cancer progression.
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The Interaction Between Elf and Cdk4 and Cell Cycle Regulation in
Gastrointestinal Cancers
Michael Pishvaian, Tiffany M. Blake, Sangsoo Kim, Hye jung Baek, Anthony Kang, Yi
Tang, Pedro De brito, Varalakshmi Katuri, M. blair Marshall, Bibhuti Mishra, E. P. Reddy,
Lopa Mishra
Cancer cell proliferation is characterized by a short G1/S phase. The TGF-β signaling pathway
is a major inhibitor of G1/S progression through induction of CDK inhibitors and suppression
of myc and the CDKs, but the TGF-β pathway is inactivated in nearly all gastrointestinal
(GI) tumors. The Smad adaptor protein ELF is an essential component of the TGF-β signaling
pathway. Loss of ELF results in activation of oncogenes such as β-catenin and cyclin D1.
Interestingly, elf+/- transgenic mice develop spontaneous hepatocellular cancers (HCCs),
while elf-/- mice die, in utero. CDK4 is a major regulator of cell cycle progression and is
often overexpressed in a number of cancers. Recently Smad3 has been shown to be a
substrate of CDK4, suggesting that one mechanism by which CDK4 activity promotes
tumorigenesis is through the inhibition of TGF-β signaling. However, there is no clear
evidence from studies in humans and transgenic mice that mutations in Smad3 contribute
to tumorigenesis. Thus, our goal was to evaluate the potential role of ELF in CDK4 function
and cell cycle progression. Here we show that CDK4 and ELF expression are inversely
correlated in HCCs from elf+/- mutant mice. Furthermore, ELF interacts with CDK4 by
forming a complex that includes Smad3 in COS-7 and HepG2 cells. Mapping analysis
identified the N-terminal actin-binding domain of ELF to be responsible for its interactions
with CDK4. ELF is phosphorylated upon overexpression of CDK4, revealing a possible
mechanism by which CDK4 may inhibit ELF-dependent TGF-β signaling. Finally, we demon-
strate that upon rescuing normal ELF expression, we are able to significantly increase the
percentage of cells in G1 arrest and concurrently decrease the expression of CDK4. To
further assess the significance of the interaction between CDK4 and ELF in tumor formation,
we intercrossed elf+/- and CDK4+/R24C mice. CDK4R24C mutations abolish the ability of CDK4
to bind to p16INK4a thus rendering CDK4 constitutively active. Surprisingly, most of the
compound heterozygote elf and CDK4R24C mice showed embryonic lethality resembling
homozygote phenotypes of elf-/- mice with CNS and GI defects. We have also intercrossed
elf+/- and CDK4+/neo mice to determine whether haploinsufficiency of CDK4 can prevent the
HCCs seen in elf+/- mice. Conclusions: These results demonstrate the molecular interactions
between ELF and CDK4, and suggest a mechanism by which CDK4 may render cells
unresponsive to the growth inhibitory effects of TGF-β signaling. Furthermore, loss of ELF
expression, which occurs frequently in HCC, may enable uncontrolled CDK4-mediated cell
cycle progression and thus cellular proliferation.
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Development and Characterization of a Novel In Vivo Model for Carcinoid
Syndrome
Lindsey N. Jackson, L. andy Chen, Jing Li, Piotr G. Rychahou, Shawn D. Larson, Paul J.
Boor, Courtney M. Townsend, jr., B. mark Evers
Carcinoid tumors synthesize a variety of bioactive substances, including serotonin, chromog-
ranin A, and neurotensin, and have a predilection for the alimentary tract. Carcinoid syn-
drome, characterized by flushing, diarrhea, and valvular heart disease, can occur following
tumor metastasis to the liver, at which time bioactive hormones enter the systemic circulation.
Treatment of this disease is hampered by the lack of an In Vivo model that recapitulates the
clinical syndrome; therefore, the purpose of this study was to establish an In Vivo model of
carcinoid syndrome using the human carcinoid cell line, BON, which was developed in our
laboratory. METHODS. BON cells were stably transfected with the plasmid pEGFP-N1 and
selected in medium containing G418 (400 μg/ml); transfection was confirmed by assessment
of GFP expression. (i) Male athymic nude mice (n=22) were randomized to receive intraspl-
enic injection of parental BON cells (1 x 107) (n = 16), GFP-tagged BON cells (1 x 107)
(n = 4), or, as a control, HT29 colon cancer cells (1 x 107) (n = 2). Mice injected with
GFP-tagged BON cells were imaged once a week to follow tumor progression. All mice were
sacrificed 14 weeks following splenic injection. At sacrifice, spleen, liver, and heart were
harvested for H&E, Movat pentachrome staining, and immunohistochemistry (IHC), and
serum was assayed for serotonin by ELISA. RESULTS. Following BON cell splenic injections,
80% of the mice (n = 16/20) developed liver metastases; 20% (n = 4/20) developed lesions
of the tricuspid valve, mitral valve, or both as noted by H&E and Movat pentachrome
evaluation. Mesenteric fibrosis was noted in 30% of the mice by gross examination, and 8
of 20 mice developed gross diarrhea. Immunohistochemistry demonstrated heterogeneous,
strong positive staining for serotonin, neurotensin, and chromogranin A in the primary
tumor and tumor metastases. A significant elevation of plasma serotonin was noted in 45%
of the mice (mean = 482.3 ng/ml, range = 117-841 ng/ml). Neither mouse injected with
HT29 cells exhibited valvulopathy, mesenteric fibrosis, diarrhea, or elevation of plasma
serotonin. CONCLUSIONS. Intrasplenic injection of BON neuroendocrine cells leads to the
development of a carcinoid-like syndrome which mimics the clinical disease process. This
novel mouse model of carcinoid syndrome will be useful to further delineate the mechanisms
responsible for the clinical manifestations and sequelae and to evaluate new therapeutic
agents as treatment options.
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Once Daily Dosing of 3g mesalamine (Salofalk® Granules) Is Therapeutic
Equivalent to a Three-Times Daily Dosing of 1g mesalamine for the Treatment
of Active Ulcerative Colitis
Wolfgang Kruis, Aleksander Gorelov, Gediminas Kiudelis, István Rácz, Juris Pokrotnieks,
Marek Horynski, Marian Bátovský, Jan Kykal, Dan Keret, Roland Greinwald, Ralph
Mueller
AIM: To study the efficacy and tolerability of 3g OD mesalamine (Salofalk® granules) vs
1g TID mesalamine in patients with active ulcerative colitis. METHODS: Patients with active
ulcerative colitis (Clinical Activity Index [CAI] >4, Endoscopic Index [EI] ≥4) were elegible
for this double-blind, double-dummy, randomized, multicenter, phase III study. Patients
received once daily 3g mesalamine (n=191) or three-times daily 1g mesalamine granules
(n=189) for 8 weeks. Primary endpoint was clinical remission (CAI≤4) at the final/withdrawal
visit (per protocol [PP] population). RESULTS: 381 patients were randomized, 380 were
treated and evaluable for safety and intention-to-treat (ITT), 345 for PP analysis. EFFICACY
See tables below. Though not significant, the OD group showed slightly better efficacy rates
in nearly all endpoints. SAFETY Both treatment regimens were safe and no drug-related
serious adverse events were observed. CONCLUSION: In active ulcerative colitis once daily
treatment with 3g mesalamine is at least as effective and safe as three-times daily dosing of
1g mesalamine. Supported by Dr. Falk Pharma GmbH, Freiburg, Germany
Primary efficacy endpoint (final analysis):
*Non-inferiority margin: 15%; ** 3g mesalamine OD - 1g mesalamine TID; asymptotic
confidence interval
Secondary efficacy endpoints:
*At least marked improvement; ** At least slight improvement; *** Patients with baseline
DAImucosal≥2. DAI, Disease Activity Index; EI; Endoscopic Index; ITT, Intention-to-treat;
LOCF, Last observation carried forward; PGA, Physician's Global Assessment; PP, Per-pro-
tocol
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Erythrocytes-Mediated Delivery of Dexamethasone in Patients with Mild to
Moderate Ulcerative Colitis Refractory to mesalamine. A Randomised-
Controlled Study
Fabrizio Bossa, Anna Latiano, Luigia Rossi, Mauro Magnani, Orazio Palmieri, Nazario
Caruso, Grazia Napolitano, Ermelinda De santo, Angelo Andriulli, Vito Annese
BACKGROUND AND AIM - Up to one fourth of patients with Ulcerative Colitis (UC) on
steroids become steroid-dependent within 1 year, and virtually all patients report steroid-
related adverse events. We planned a controlled study to investigate the efficacy and safety
of low doses of dexamethasone encapsulated into erythrocytes (DEE) in UC patients refractory
to mesalamine. MATERIALS AND METHODS - Forty patients with mild to moderate UC
were randomly assigned to one of the following treatments: infusions of DEE (at inclusion
and after 14 days)(group A, n=20), oral prednisolone (0.5 mg/kg for 14 days and 6 mg/
weekly tapering )(group B, n=10), and sham infusions of DEE (group C, n=10). All patients
continued treatment with oral and topical mesalamine. Fifty milliliters of blood were drawn
from subjects of group A and C; dexamethasone 21-Phosphate (Dex 21-P) was encapsulated
into autologous erythrocytes (groups A) by means of specially designed equipment, and
subsequently infused into original donors. In the group C (sham), the blood was re-infused
after 2 hours without DEE loading. For all patients, clinical (Powell-Tuck), biohumoral
(ESR, CRP, cortisol) and endoscopic parameters (Baron) were recorded at study inclusion
and after 8 weeks. RESULTS - 7 patients (19%) had a pancolitis, 13 patients (31%) a left-
sided colitis, while the remaining 20 patients (50%) had a proctosigmoiditis. At study
inclusion, mean values of Powell-Tuck, ESR, CRP, and cortisol were not significantly different
between the three groups. A mean dose of 9.4+/-3.7 mg Dex 21-P was loaded into the
erythrocytes (group A) at each treatment. After 8 weeks, 3 patients in group A (15%), 2 in
group B (20%), and 8 in group C (80%)(p<0.01 vs A and B) had still an active disease.
Endoscopic remission (Baron 0 or 1) was reached in 24 patients, 15 in the group A (75%),
8 in the group B (80%) and only 1 in the group C (12%)(p<0.01 vs A and B). A significant
reduction of mean values of Powell-Tuck score, ESR and CRP was observed in groups A
and B compared to baseline (8.1 vs 3.6; p<0.05; 36.2 vs 22.5; p=0.01, and 1.4 vs 0.48;
p<0.01), but not in group C (9.1 vs 6.9; p=ns; 26 vs 30; p=ns; 3.7 vs 2.6; p=ns). No patient
treated with DEE developed steroid-related adverse events, compared to 8 out of 10 patients
of group B. CONCLUSION - Very low doses of Dex (mean total dose = 18.8 mg) encapsulated
into erythrocytes are as effective as oral prednisolone (mean total dose = 840 mg) in UC
patients with mild to moderate disease refractory to mesalamine without induction of
adverse events.
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Three-Antibiotic Combination Therapy in Patients with Active Ulcerative
Colitis: A Double-Blind Placebo-Controlled Multicenter Trial
Toshifumi Ohkusa, Kimitoshi Kato, Shuichi Terao, Toshimi Chiba, Katsuhiro Mabe,
Kazunari Murakami, Yuji Mizokami, Yoshiaki Takeuchi, Toshiro Sugiyama, Takahiko
Kudo, Akinori Yanaka, Shigeru Yamato, Tetsuji Yokoyama, Isao Okayasu, Nobuhiro Sato,
Sumio Watanabe
Background: We proposed that Fusobacterium varium might be one of the elusive pathogenic
factors in ulcerative colitis (UC). We developed an antibiotic combination therapy using
penicillin, tetracycline and metronidazole, to which F. varium is sensitive, and reported a
significant effect in active UC in a randomized, controlled pilot trial (Scand J Gastroenterol.
2005;40:1334-42). However, the study had a small number of patients and was a single-
blind study. In the present study, a double-blind placebo-controlled multicenter trial of the
antibiotic combination therapy was conducted to assess whether the therapy is effective for
the induction and maintenance of remission of active UC. Methods: A randomized, double-
blind, placebo-controlled, multicenter study evaluated the efficacy of three-antibiotic com-
bination therapy. Active UC patients were enrolled consecutively and randomly assigned to
receive amoxicillin, tetracycline and metronidazole per os for two weeks (treatment group;
n = 105) or placebo (control group; n = 105). F. varium was sensitive to the antibiotics.
The primary end points of the study were clinical response of Lichitiger's symptom score
(N Engl J Med 1994; 330: 1841), mucosal healing of Matts' grading score (Q J Med
1961;120:393), and clinical responses of the St. Marks index (Dig Dis Sci. 1982;27:533)
and Mayo score (N Engl J Med 1987;317:1625) at 3 months after treatment. Secondary end
points were clinically significant improvement in the clinical and endoscopic scores at 12
months. Results: The clinical activity and endoscopic scores in the treatment group decreased
significantly at 3 and 12 months after treatment, compared with those in the placebo group
(ITT, p=0.0007, 0.0004, and p=0.0013, 0.0008, respectively). Scores of frequency of watery
diarrhea, nocturnal diarrhea, fecal incontinence and general well-being were significantly
improved in the treatment group. The St. Marks index and Mayo score improved significantly
at 3 and 12 months after treatment compared to the placebo group (p=0.0002, <0.0001,
and p<0.0001, <0.0001, respectively). The cumulative remission rate for long-term follow-
up was significantly higher in the treatment group than in the control group (p = 0.042 by
Kaplan-Meier test). No serious drug-related toxicity was found during the trial. Conclusion:
Two-week antibiotic combination therapy against F. varium was effective and safe in patients
with active UC in this double-blind, placebo-controlled, long-term follow-up study.
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Pouchitis and Pouch Dysfunction After Ileal Pouch-Anal Anastomosis for
Ulcerative Colitis Or Indeterminate Colitis a Population-Based Study
Paul E. Evans, Darrell S. Pardi, William J. Sandborn, William J. Tremaine, Eric J. Dozois,
Robert R. Cima, David W. Larson, John H. Pemberton, Bruce G. Wolff, Scott Harmsen,
Alan R. Zinsmeister, Shamina Dhillon, Patricia P. Kammer, Edward V. Loftus
Purpose: The preferred operation for ulcerative colitis (UC) that is medically refractory or
complicated by dysplasia is a J ileal pouch-anal anastomosis (J-IPAA). A variety of pouch
dysfunction syndromes occur after J-IPAA including pouchitis, Crohn's disease (CD), cuffitis
in a pt with stapled anastomosis, and irritable pouch syndrome (IPS). The incidence and
natural hx of pouchitis and other forms of pouch dysfunction in a population-based cohort
of pts has not been studied. We report the incidence of pouch dysfunction syndromes in
all pts who had a J-IPAA who were living in Olmsted County, MN, when diagnosed with
UC or indeterminate colitis(IC). Methods: The Rochester Epidemiology Project, a medical
records linkage system providing data on all health care for the population of Olmsted
County was used to identify all county residents with a diagnosis of UC or IC from 1940-
2005 who had a J-IPAA from 1983-2005. Medical records were reviewed to characterize
clinical course following J-IPAA. Acute pouchitis was defined as an episode lasting < 4 wks
and < 4 episodes/yr. Chronic pouchitis was defined as any episode lasting > 4 wks, > 4
episodes/yr, or chronic treatment. Antibiotic-responsive disease was defined as rapid response
to antibiotics. Antibiotic-dependent disease required antibiotics to keep in remission. Antibi-
otic-refractory disease required immunosuppressive therapy. Results: Forty-five pts were
identified. Six pts (13%) had their diagnosis changed to CD. Three pts had pouch removal/
exclusion (all CD). Median follow-up after J-IPAA was 4 yrs (range 0-19). Of the remaining
39 pts without CD, 5 (13%) had IC. Nineteen (49%) had a stapled anastomosis. Sixteen
pts without CD had no pouch dysfunction after a median follow up of 1 yr (0-16); 22 pts
had >= 1 episode of pouchitis, and 1 developed IPS. 2/19 pts with a stapled anastamosis
(11%) developed cuffitis, both within 2 yrs of J-IPAA. The cumulative probability of pouchitis
at 1, 5, 10 and 15 yrs was 27%, 58%, 68% and 81%, respectively, using the Kaplan-Meier
method. Of the pouchitis pts, 17 pts had chronic pouchitis and 5 had acute pouchitis. Seven
were antibiotic-responsive, 9 were antibiotic-dependent and 6 were antibiotic-refractory.
Conclusions: Many pts with UC or IC who had a J-IPAA experienced some form of pouch
dysfunction. The most common form of pouch dysfunction was pouchitis, followed by CD.
Cuffitis and IPS were less frequent. Most pouchitis was chronic and required treatment with
continuous antibiotics or immunosuppressive agents. Although various pouch dysfunction
syndromes occur relatively commonly, they are generally treatable.
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Budesonide in Lymphocytic Colitis - A Randomized, Double-Blind, Placebo-
Controlled Trial
Stephan Miehlke, Ahmed Madisch, Birgit Bethke, Susann Wonschik, Eberhard Kuhlisch,
Renate Beckmann, Andrea Morgner, Ralph Mueller, Roland Greinwald, Gustavo Baretton,
Gerhard Seitz, Manfred Stolte
Background & Aims: Oral budesonide has been shown to be an effective treatment in
collagenous colitis. There is currently no established treatment for lymphocytic colitis. A
randomized, double-blind placebo-controlled was performed to evaluate the efficacy and
safety of budesonide in patients with lymphocytic colitis and chronic diarrhea. Methods: A
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total of 41 patients (27 females, median age 61 years) with lymphocytic colitis and chronic
diarrhea were randomized to receive oral budesonide 9 mg/d (Budenofalk®) or placebo for
6 weeks. Non-responder at week 6 were treated with open-label budesonide 9 mg/d for
further 6 weeks. Complete colonoscopy including histology and quality-of-life (SF-36) were
assessed at baseline and after 6 weeks. The primary endpoint was clinical remission (CR)
at 6 weeks pre-defined as no more than 3 non-watery stools/day on average. Results: The
rates of CR (ITT) at weeks 3 and 6 in the budesonide group versus placebo group were
68% versus 20% (p=0.004), and 86% versus 40% (p=0.004), respectively. With budesonide,
the median daily stool frequency decreased from 5 to 2 at 3 weeks and to 1 at 6 weeks (p=
0.01 and p=0.005 vs. placebo, respectively). Cross-over budesonide therapy induced CR in
further 9 of 10 patients. Only one patient discontinued budesonide therapy prematurely
(3.2%). At baseline, quality-of-life was considerably decreased, however SF-36 failed to
detect a significant improvement at 6 weeks. Conclusion: Budesonide is effective and safe
for induction of clinical remission in patients with lymphocytic colitis.
903
The Development of a Valid, Reliable and Responsive Pediatric Ulcerative
Colitis Activity Index (Pucai): A Prospective Multicenter Study
Dan Turner, Anthony Otley, David R. Mack, Krista Uusoue, Thomas Walters, Mary
Zachos, A. hillary Steinhart, Petar Mamula, Jeffrey Hyams, Anne M. Griffiths
BACKGROUND: No existing measure of ulcerative colitis (UC) activity has been rigorously
formulated for pediatric use. Repeated colonoscopy, the gold standard of activity assessment
in adults UC, is less acceptable to children. AIM: To develop and evaluate a non-invasive
index of pediatric UC activity. METHODS: A judgmental approach was used for item
generation, using a Delphi group of 36 pediatric IBD experts. Items were weighted by
regression analysis using a prospective cohort of 157 pediatric UC patients from 5 IBD
centers. The β estimates of the model served to guide the weighting, governed by maximizing
R2 and aided by a correlation matrix. Validation of the PUCAI was performed on a separate
prospective cohort of 48 UC children undergoing full colonoscopy. Colonoscopic appearance,
the invasive adult Mayo score and physician global assessment of disease activity (PGA)
served as the validation constructs. Each patient was assessed by two independent physicians
and reliability was determined by Intra-class Correlation Coefficient (ICC). Test-retest reliabil-
ity was established on 29 patients with unchanged disease activity at a repeated visit.
Responsiveness was evaluated at a follow-up visit of 41 active children using effect size
statistics (SRM, SES), correlational and diagnostic utility approaches. RESULTS: 41 items
were generated by the expert panel. Rank order was considered in item reduction, following
4 rounds of feedback to the group and 11 items were retained for the next phase. The
PUCAI was completed by two physicians assessing 157 UC children (age 12.7±3.8 yr; 77%
extensive; 34% moderate to severe, 19% mild, 47% quiescent). Six items were significant
in the regression analysis: stool number, consistency and blood content, abdominal pain,
activity level and nocturnal diarrhea. In the validation cohort (n=48), the weighted index
was highly correlated with both PGA (r=0.91, p<0.001) and colonoscopic appearance (r=0.76,
p<0.001), higher than two non-invasive adult indices, calculated simultaneously (Lichtiger (r=
0.71) and Seo index (r=0.69)). The PUCAI also showed excellent correlation (r=0.95,
p<0.001) with the reference invasive index (Mayo-score). The laboratory items did not
improve the PUCAI performance and thus were removed. Interobserver and test-retest
reliability were excellent (ICC=0.95; 95%CI 0.93-0.97). Serial ROC curves established the
cutoff points. Excellent responsiveness was found at repeated visits (SRM=2.1, SES=1.9,
AUC of ROC=0.97). CONCLUSION: The rigorously developed PUCAI is a non-invasive,
highly reliable, valid and very responsive measure of disease activity in pediatric UC and
may be used in clinical trials.
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EGFR-Overexpression Induces Telomerase Reactivation and Cell Cycle
Progression As Distinct Steps in a Cellular Model of Oral Esophageal
Carcinogenesis
Nina Hirt, Steffen Heeg, Angela Queisser, Michaela Doebele, Sarah Hauss, Heike Kunert,
Eva Egenter, Michael Quante, Alexander V. Werder, Hiroshi Nakagawa, Roderick
Beijersbergen, Hubert E. Blum, Oliver G. Opitz
Introduction: In our cellular model of oral-esophageal carcinogenesis EGFR-overexpression
plays a crucial role in In Vitro transformation, reactivation of telomerase and enhanced
proliferation of immortalized cyclin D1 overexpressing/p53 inactivated keratinocytes (OKF6
D1/d.n.p53). We previously demonstrated that this is mediated by the activation of the
PI3K/AKT pathway. The aim of this study was to further characterize the cellular mechanisms
involved in the reactivation of telomerase and acceleration of the proliferative capacity
induced by EGFR-overexpression leading to In Vitro transformation. Methods: We overex-
pressed EGFR in immortalized OKF6 D1/d.n.p53 cells by retroviral mediated gene transfer.
Expression levels and phosphorylation status of potential downstream targets of the PI3K-
AKT pathway as well as cell cycle regulating proteins were analyzed by western blotting
and RT-PCR. Protein-protein-interactions were demonstrated by co-immunoprecipitation.
Cellular localization of cell cycle regulators was demonstrated by immunofluorescence.
Furthermore, analysis of the hTERT promoter as well as the cyclin D1 promoter including
site directed mutagenesis was performed. Results: Co-immunoprecipitation showed a direct
phosphorylation of hTERT and Hif-1alpha by AKT. A detailed promoter analysis indicated
that hTERT expression is additionally regulated on a transcriptional level depending on the
presence of a Hif-1alpha binding site within the hTERT core promoter. Moreover, p21 is
phosphorylated by AKT and phospho-p21 is translocated to the cytosol as demonstrated
by immunofluorescence. Western blot analysis showed elevated levels of endogenous cyclin
D1 in EGFR-overexpressing cells. Preliminary data suggested that cyclin D1 is regulated
transcriptionally involving a cis-acting element between -770 and -558 bp of the cyclin D1
promoter. Conclusion: During malignant transformation EGFR-overexpression in immortal-
ized cyclin D1 overexpressing/p53 inactivated keratinocytes leads to reactivation of telomerase
and increased proliferation mediated through the PI3K/AKT pathway. hTERT is activated
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by AKT-mediated phosphorylation as well as through transcriptional regulation via Hif-
1alpha. Increased proliferation and activation of the cell cycle are mediated by phosphoryl-
ation and consecutive translocation of p21 from the nucleus. Furthermore, endogenous
cyclin D1 was transcriptionally upregulated. In this study we defined the cellular mechanisms
leading to telomerase activation, increased proliferation and ultimately In Vitro transformation
as distinct steps of carcinogenesis, induced by EGFR-overexpression.
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Her-2/Neu Amplification in Esophageal Adenocarcinoma As a Potent Target for
Cancer Immunotherapy
Francesca Milano, Agnieszka M. Rygiel, Jacques J. Bergman, Paul Fockens, Wilda D.
Rosmolen, Martien Kapsenberg, Anja Ten brinke, Marieke Van ham, Kausilia K.
Krishnadath
Her-2/neu is a 185KDa protein receptor which is largely overexpressed through gene ampli-
fication in several cancers. Her-2/neu protein has been proven to be an ideal Tumor Associated
Antigen (TAA) for immunotherapies. T-cell transfer therapies with anti Her-2/neu CTL
populations have confirmed significant tumor response for instance against breast cancer.
In previous studies we found that Her-2/neu is amplified and overexpressed in at least 50%
of esophageal adenocarcinomas. It is known that the outcome of esophageal cancer is poor
and novel treatment strategies are urgently requested. Developing Dendritic Cell (DCs) or
T-cell transfer immunotherapy by mediating CTL responses against Her-2/neu would be
attractive as an alternative treatment for esophageal adenocarcinomas. AIM: To assess whether
loading DCs with full length Her-2/neu mRNA is feasible to raise specific CTL populations
that can be used for future immunotherapeutic strategies. MATERIALS AND METHODS:
Her-2/neu mRNA was generated using the plasmid pSPJC1, with an insert coding for Her-
2 /neu which allows In Vitro transcription under the control of an SP6 promoter. Patient's
monocytes were electroporated with Her-2/neu mRNA and matured into DCs. Hereupon,
DCs were analysed for the expression of the Her-2/neu protein, for maturation markers and
for their potential to secrete IL-12 and IL-10. Mature DCs were subsequently used to
stimulate patient's lymphocytes in a Mixed Leukocyte Reaction (MLR) to assess lymphocyte
proliferation by measuring incorporation of [3H] thymidine using liquid scintillation count-
ing. Release of IFN-gamma by stimulated lymphocytes was measured by Cytometric Bead
Array. RESULTS: The mature DCs highly expressed maturation markers such as CD80,
CD86, CD83, CD209, and CCR7, and were able to release sufficient amounts of IL-12 but
low IL-10, features that demonstrate their high potential for inducing CTL reponses. Her-
2/neu expression was detected after one week of culture in the mature DCs. Stimulation of
the patient's lymphocytes by the Her-2/neu RNA loaded DCs resulted in high T-cell prolifera-
tion with significantly higher IFN-gamma production as compared to lymphocytes stimulated
by the not loaded DCs (control). CONCLUSION: This study demonstrates that the full
length Her-2/neu RNA can be used for generating DC mediated specific T-cell populations.
These CTL populations could be expanded ex vivo and employed for future T-cell transfer
therapies for esophageal cancer patients with Her2/neu amplification. Alternatively, DCs
loaded with full length Her2/neu RNA can be employed to treat esophageal adenocarcinomas
with DC vaccination immunotherapy.
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Insulin-Like Growth Factor Binding Protein-3 Regulates Esophageal Tumor
Formation and Growth Through Insulin-Like Growth Factor-Dependent and
Independent Mechanisms
Munenori Takaoka, Seokhyun Kim, Carmen Z. Michaylira, Doug Stairs, Takaomi Okawa,
Claudia D. Andl, Cameron N. Johnstone, Ben Rhoades, James Lee, Andres J. Klein-
szanto, Wafik S. El-deiry, Hiroshi Nakagawa
Introduction: Insulin-like growth factor binding protein (IGFBP)-3 exerts either proapoptotic
or growth stimulatory effects depending upon the cellular context. IGFBP-3 is overexpressed
frequently in esophageal cancer. Yet, the role of IGFBP-3 in esophageal tumor biology remains
elusive. Methods: To delineate the functional consequences of IGFBP-3 overexpression, Ha-
RasV12-transformed human esophageal cells (Kim SH et al. Cancer Research 2006; 66:10415-
424) were stably transduced with either wild-type or I56G/L80G/L81G mutant IGFBP-3,
the latter incapable of binding insulin-like growth factors (IGFs). Gene expression was
determined by enzyme-linked immunosorbent assay, Western blotting, and immunohisto-
chemistry. Western ligand blotting with 125I-IGFs determined the IGFBP-3 binding affinity.
Anchorage independent cell growth was assessed by soft agar colony formation assays.
Xenograft transplantation was done to monitor tumor growth by In Vivo bioluminescence
imaging. Results: Wild-type and mutant IGFBP-3 were highly expressed to a comparable
extent. Wild-type, but not mutant, IGFBP-3 bound IGF-1, prevented it from activating the
IGF-1 receptor and AKT, and greatly suppressed the anchorage-independent cell growth in
the presence of IGF-1. When xenografted in nude mice, In Vivo bioluminescence imaging
demonstrated that wild-type IGFBP-3 completely abrogated tumor formation (0%) by the
Ras-transformed cells with a rapid loss of the firefly luciferase activities and concurrent
induction of apoptosis, documented by caspase-3 cleavage as well as histology, and a marked
reduction in Ki67 positive cells. By contrast, empty vector transduced control (75%) and
mutant IGFBP-3 expressing cells (75%) formed tumors by six weeks after injection. Interest-
ingly, histology revealed more aggressive tumor growth by mutant IGFBP-3 than empty
vector control, without detectable caspase-3 cleavage in tumor tissues, which was further
corroborated by significant differences in Ki67 labeling index of 72% in mutant IGFBP-3
expressing tumors vs. 44% in empty vector control tumors (P<0.0001), indicating an IGF-
independent growth stimulatory effect of mutant IGFBP-3. Conclusions: Our innovative
approach reveals that xenografted tumors may require IGF-1 receptor signaling for adaptation
to the microenvironment in the host tissue, while IGFBP-3 may antagonize a prosurvival
effect of IGFs In Vivo. However, once tumors are adapted to the local microenvironment,
IGFBP-3 may confer a growth advantage to the Ras transformed esophageal cells in an IGF-
independent fashion. Thus, IGFBP-3 may contribute to esophageal tumor development and
progression, a novel mechanistic finding.
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Transcriptional Hotspots in Barrett's Related Adenocarcinomas
Mohammad Razvi, Altaf Dar, Kay Washington, Wael M. El-rifai
Serial analysis of gene expression (SAGE) provides a genome-wide analysis of gene expression
in a given cell population. In our efforts to define the gene expression alterations in Barrett's
related adenocarcinomas, four SAGE libraries were produced each from dissected neoplastic
and normal epithelia. Sequence analyses of 20,000 clones produced a total of 457,894
expressed tags with 67,200 unique tags. The four tumor libraries produced 287,219 tags
with an average of 71,804 tags per library. The normal samples produced 170,675 tags that
averaged 42,669 tags per library. These tags represent 16,040 known gene symbols. The
results demonstrated an up-regulation of 242 genes and a down-regulation of 153 genes
(two fold change, p<0.01). Ninety-three genes showed five fold or greater change in expres-
sion (p≤0.01) in at least two tumor samples as compared to all four normal libraries. In
order to identify potential oncogenomic transcriptional hot spots in the Barrett's genome,
we characterized the cytogenetic location of all altered genes. Interestingly, the distribution
of altered genes was not uniform across the human genome, nor did it correspond to
chromosome size. Overexpressed genes tended to cluster in well defined hotspots located
in certain chromosomes. Chromosome 19 had twenty-six overexpressed genes of which
eighteen mapped to 19q13. Similarly, thirty-five genes mapped to chromosome 1 of which
thirteen mapped to 1q21. We have also assigned each gene to a functional group based on
Gene Ontology information and found several groups that are highly relevant to cancer such
as cell cycle regulation, DNA regulation, and cell signaling. We validated the results of five
representative genes (ANPEP, ECGF1, PP1201, EIF5A1, and GKN) using quantitative real
time RT PCR on 31 tumor samples and 23 normal samples. In addition, we confirmed the
overexpression of ANPEP using immunohistochemistry on a tumor tissue array that contained
72 tumors. ANPEP is a secreted protein that may have diagnostic or prognostic significance
for Barrett's progression. Using SAGE analysis we have been able to identify and validate
several genes of functional importance that show changes in expression and may have
clinical significance.
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Pttg1 Is a Prognostic Factor and a Potential Therapeutic Target in Esophageal
Squamous Cell Carcinoma
Tetsuo Ito, Yutaka Shimada, Takatsugu Kan, Stefan David, John M. Abraham, Yuriko
Mori, Yulan Cheng, Bogdan C. Paun, Zhe Jin, Alexandru Olaru, Rachana Agarwal, James
P. Hamilton, Jian Yang, Christopher Bucci, Stephen J. Meltzer, Fumiaki Sato
Background: Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in various
human tumors and causes dysregulation of chromatid separation. PTTG1 was identified as
being expressed highly specifically in esophageal squamous cell carcinoma (ESCC) by our
previous microarray analysis (Sato et al., BBRC, 2006). The role of PTTG1 in ESCC is,
however, still unclear. The purpose of the current study was to examine the clinical signific-
ance of PTTG1 expression in ESCC and the effect of PTTG1 downregulation in potential
therapy of ESCC. Materials and Methods: PTTG1 expression in 113 surgically resected
primary ESCCs was evaluated by immunohistochemistry. Findings were compared with
clinicopathological data from patients. In addition, PTTG1 expression in 12 ESCC cell lines
was examined by quantitative RT-PCR and Western blotting. Two synthetic siRNAs directed
against PTTG1 and a non-targeting control siRNA were transfected into HT1080 and HSA/
c and PTTG1 mRNA expression was examined by quantitative RT-PCR. Transfection effici-
ency was accessed using a FAM-labeled siRNA. Cell proliferation was examined by both
WST-1 and cell counting assays. Cell cycle analysis was evaluated with flow cytometry.
Results: PTTG1 staining was observed primarily in the cytoplasm of tumor cells, but not in
normal esophageal epithelial cells. PTTG1 positivity (i.e., moderate to strong staining) was
observed in 68 (60.2%) of 113 tumors and associated with regional lymph node metastasis
(p=0.042), distant lymph node metastasis (p=0.005), pTNM stage (p=0.002), and poorer
patient survival (p=0.017). Multivariate analysis revealed that PTTG1 positivity showed a
trend toward being an independent prognostic factor in patients, although it did not reach
statistical significance (Cox Hazard model risk ratio 1.61, p=0.093). PTTG1 was expressed
in all 12 ESCC cell lines, and HSA/c was selected for further analysis because of its high PTTG1
expression level. PTTG1 mRNA expression in HT1080 and HSA/c cells was downregulated by
89% and 87% by the siRNAs directed against PTTG1 relative to the control siRNA. The two
siRNAs directed against PTTG1 showed almost identical effects on PTTG1 downregulation.
Transfected siRNA oligos were taken up by more than 90% of cells and were localized to
the cytoplasm. PTTG1 downregulation led to significant growth inhibition in both WST-1
(p<0.01) and cell counting (p<0.001) assays and induced G2/M cell cycle arrest in HSA/c
cells. Discussion: PTTG1 is a promising biomarker for predicting late progression of ESCC.
PTTG1 downregulation may inhibit the mitotic function of ESCC cells and shows potential
to serve as a molecular target for ESCC gene therapy.
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Role of FNA in the Accuracy of Endoscopic Ultrasound in Nodal Staging of
Esophageal Cancers: A Meta-Analysis and Systematic Review
Jyotsna Bk reddy, Srinivas R. Puli, Matthew L. Bechtold, Mainor R. Antillon, Jamal A.
Ibdah
Background: Therapeutic options for esophageal Cancers are influenced to a great extent
by the presence of nodal metastasis. Endoscopic ultrasound (EUS) is a valuable tool in
staging esophageal ca. The impact of Fine Needle Aspiration (EUS-FNA) in N staging of
patients with esophageal ca is unclear. Aim: To evaluate the accuracy of EUS alone versus
EUS with FNA in N staging of esophageal cancers. Methods: Study Selection Criteria: Only
EUS and EUS-FNA studies confirmed by surgery or with prolonged follow-up were selected.
EUS criteria used for nodal invasion were: > 1 cm, hypoechoic, and round instead of
elliptical. Only studies from which a 2 X 2 table could be constructed were included. Data
collection & extraction: Articles were searched in Medline, Pubmed, Ovid journals, CINH,
and Cochrane control trial registry. Two reviewers independently searched and extracted
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data. The differences were resolved by mutual agreement. Statistical Method: Meta-analysis
for the accuracy of EUS was analyzed by calculating pooled estimates of sensitivity, specificity,
likelihood ratios, and diagnostic odds ratios. Pooling was conducted by both Mantel-Haenszel
method (fixed effects model) and DerSimonian Laird method (random effects model). The
heterogeneity of studies was tested using Cochran's Q test based upon inverse variance
weights. Results: Initial search identified 2980 reference articles, in which 360 relevant
articles were selected and reviewed. Data was extracted from 48 studies (N= 4716) that met
the inclusion criteria. Of these, 44 studies used EUS alone and 4 studies used EUS-FNA.
The pooled estimates are shown in table 1. All the pooled estimates, calculated by fixed
and random effect models, were similar. The p for chi-squared heterogeneity for all the
pooled accuracy estimates was > 0.05. Conclusion: EUS is an important and accurate
diagnostic tool in the staging of esophageal cancers. The meta-analysis results show that
FNA substantially improves the diagnostic ability of EUS in nodal staging of esophageal
cancers. EUS with FNA should be the diagnostic test of choice in nodal staging of eso-
phageal cancers.
Table 1: Shows the pooled estimated for accuracy of EUS and EUS-FNA in nodal staging
of esophageal cancers with 95 % confidence intervals.
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Structured Patient Education Is Superior to a Self-Help Guidebook in Irritable
Bowel Syndrome (IBS) - A Randomized, Controlled Trial
Gisela Ringstrom, Stine Storsrud, Sara Lundqvist, Berndt Westman, Hasse Abrahamsson,
Magnus Simren
Background: IBS patients often feel that they are insufficiently informed about their condition,
despite frequent health care visits. Medical treatment options are limited. Structured educa-
tion is reported to be efficient (Saito et al Clin Gastroenterol Hepatol 2004), as well as
written information in the form of a self-help guidebook (Robinson et al Gut 2006). No
direct comparison between these treatment options exists. Methods: We included 158
patients (mean age 38 (18-68) years; 134 women) with IBS according to the Rome II criteria.
The patients were randomized to receive a structured education (‘IBS-school') (n=76) or a
self-help guidebook with thorough information about IBS (n=82). The ‘IBS-school' consisted
of six two-hour lessons, once per week, with ten patients in each group. Each lesson was
held by one out of five different health care professionals. All patients completed validated
questionnaires at baseline, and at three and six months after baseline, to evaluate GI symptom
severity (IBS Severity Scoring System, IBS-SSS), GI symptom-specific anxiety (Visceral Sensit-
ivity Index, VSI), health related quality of life (HRQOL) (IBS Quality of Life, IBSQOL),
psychological symptoms (Hospital Anxiety and Depression scale, HAD). The patients rated
their perceived level of IBS knowledge using a visual analogue scale. Results: The patients
in the education group experienced increased IBS knowledge (74±12 vs. 40±23 mm (mean
±SD); p=0.0001), reduced GI symptoms (IBS-SSS, 273±104 vs. 325±97; p=0.001), less GI
symptom-specific anxiety according to VSI (53±15 vs. 47±18; p=0.0001) and reduced anxiety
(HAD anxiety, 7.6±4.5 vs. 8.5±4.6; p=0.002) three months after the IBS-school. These results
were sustained at six months. Improved HRQOL was seen on several domains of IBSQOL
at both three and six months. The education group had sought less health care for GI related
symptoms six months after the education compared to six months before (0.6±1.5 vs.
1.5±1.8 visits; p=0.0001). No significant differences, except for improved HRQOL on a few
domains, were detected during the six months follow up in the guidebook group. Compar-
isons between the groups revealed significantly better results in the education group than
in the guidebook group for IBS knowledge (p=0.0001), GI symptom specific anxiety (p=
0.0001), GI symptom severity (p= 0.03) and health care consumption (p= 0.02). Conclusion:
Structured patient education in the form of an ‘IBS-school' is superior to a self -help guidebook
in IBS patients. The IBS-school increases the knowledge about IBS, reduces the psychological
and GI symptoms, improves HRQOL and diminishes health care consumption.
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Women Respond to Conditioning and Men to Suggestion of Nausea
Sibylle Klosterhalfen, Sandra Kellermann, Silke Braun, Axel Kowalski, Markus Schrauth,
Ursula Werz, Paul Enck
The placebo response (PR) is generated by two mechanisms, Pavlovian conditioning (PC)
and expectancies and suggestions (ES). Gender effects of the PR have rarely been dokumented
and were studied in two experiments using a motion-sickness paradigm here. Experiment
1 (PC): 48 healthy male and female volunteers were investigated on three days 1 week apart
using a standard rotations procedure (5 x 1 min, eyes closed, 120 degrees/s). PC subjects
received a salient oral stimulus (Cinnamon Listerine PocketPaks® breath strips, Pfizer,
Morris Plains, NJ, USA) immediately prior to rotation, subjects of the control group received
the stimulus 12 h after the rotation on day 1 and 2; on day 3, all subjects received the
stimulus prior to rotation. Experiment 2 (ES): 45 healthy male and female subjects were
randomised to a placebogroup (PG), a nocebo group (NG), and a control group (CG); all
were rotated once 5 x 1 min only. All subjects received the same oral stimulus immediately
prior to rotation; PG subjects were given the information, that a strong taste stimulus would
improve nausea symptoms, NG subjects were suggested a worsening of symptoms by the
stimulus, CG subjects did not receive additional information. In both experiments, rotation
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tolerance (RT) and symptom rating (SR) were determined as the main dependent measures.
Experiment 1 showed a significant interaction group x gender (F=3.67, p=.034), according
to which the conditioning occured predominantly in women (left Fig). In Experiment 2,
RT was significantly reduced in both PG and NG (F=4.06, p=.05), and men exhibited a
significant reduction in RT (F=4.1, p=.049 and responded stronger to rotation and suggestions
than women (right Fig) SR was less effective in PC and ES. We conclude that PC and ES
of nausea are both effective mechanisms of the PR, but PC is more effective in women,
while ES shows a higher efficacy in men. (Supported by DFG)
912
Differential Modulation of the Regional Brain By Hypnotic Suggestion Between
Patients with Irritable Bowel Syndrome and Healthy Subjects
Takahiro Terui, Satoshi Watanabe, Motoyori Kanazawa, Toyohiro Hamaguchi, Hirotaka
Mine, Kazuhiko Yanai, Masatoshi Itoh, Shin Fukudo
Background & Aims: Hypnotherapy is effective on intractable patients with irritable bowel
syndrome (IBS) when they do not respond to standard medical treatment. Hypnotic sugges-
tion changes somatosensory sensation via modifying activity of the anterior cingulate cortex
(ACC) (Science 1997; 277: 968-971). However, there is no study of the effect of hypnotic
suggestion on the brain in IBS patients. We hypothesized that hypnotic suggestion would
change the brain activity in IBS patients and that the modulation pattern would be different
from that of healthy controls. Methods: Subjects were 12 healthy subjects and 12 IBS patients.
This study was approved by the Ethics Committee and all subjects gave the written informed
consent. Barostat bag was inserted to the rectum. The bag was intermittently inflated with
no (0 mmHg), mild (20 mmHg), or intense (40 mmHg) stimulation with random order.
Hypnosis was induced by the Harvard Group Scale of Hypnotic Susceptibility form A.
Neutral, hyperalgesic, and analgesic suggestions were given with random order. Immediately
after the suggestion, the rectum was distended with 40 mmHg. Radioactive H2[15-O] saline
was injected at the bag inflation and positron emission tomography was performed. Changes
in rCBF were analyzed using Statistical Parametric Mapping 2. Results: In IBS patients, 40
mmHg-rectal distention induced significant activation of the thalamus, bilateral insula, and
periaqeductal gray (p < 0.001). Besides, left amygdala and right parietal cortex were more
activated at 40mmHg-rectal distention in IBS patients than in normal subjects (p < 0.005).
Analgesic suggestion significantly induced brain activation in some area including the right
dorsolateral prefrontal cortex (DLPFC) in IBS patients (p < 0.005). Significantly and differenti-
ally activated regions between IBS patients and controls were detected during analgesic
suggestion. Analgesic suggestion induced significantly more activation in the ACC, right
parahippocampal region, and right amygdala during 40 mmHg-rectal stimulation in controls
than in IBS patients (p < 0.005, p < 0.005, p < 0.001). In contrast, analgesic suggestion
induced significantly more activation in the left parahippocampal region during 40 mmHg-
rectal stimulation in IBS patients than in controls (p < 0.001). Conclusion: These data
suggest that hypnosis induces differential activation in the brain of IBS patients from those
of controls. More activation of DLPFC and ACC and less activation of left amygdala and
left parahippocampal region may be a key toward the new neurological therapy of IBS.
913
Gastrointestinal Symptom-Specific Anxiety: An Important Predictor for Health
Outcome and Symptom Severity in Patients with Irritable Bowel Syndrome
Magnus Simren, Gisela Ringstrom, Pia Agerforz, Per Jerndal, Martin Karpefors, Louis M.
Akkermans, Robert Spaziani, Markad V. Kamath, Stephen M. Collins, Alfred Bayati
Background: Gastrointestinal (GI) symptom-specific anxiety has been proposed to be of
importance for symptom severity and health outcome in patients with irritable bowel syn-
drome (IBS). Visceral Sensitivity Index (VSI) is a recently developed reliable and valid measure
of GI symptom-specific anxiety (Labus et al APT 2004). Aim: To assess the importance of
GI symptom-specific anxiety for symptom severity and health outcome in IBS in a large
database study. Methods: We included 171 healthy controls (108 females; mean age 36
years) and 334 patients fulfilling the Rome II criteria for IBS (243 females; mean age 41
years) at three centers. Demographic and disease-related factors were assessed using a
structured interview. Besides VSI, patients also completed a disease specific questionnaire,
the Gastrointestinal Symptom Rating Scale - IBS (GSRS-IBS) and two generic questionnaires,
the Hospital Anxiety and Depression scale (HAD) and the Short Form-36 (SF-36), as well
as the Rome II Modular Questionnaire. Results: Compared with the control subjects patients
with IBS had more severe GI symptom-specific anxiety, i.e. lower VSI scores (54±17 vs.
85±10 (mean±SD); p<0.0001). In the IBS group more severe GI symptom-specific anxiety
was seen in patients who were frequent health care consulters, both for GI (p<0.001) and
psychological symptoms (p<0.05). Lower VSI scores were also seen in patients with more
severe GI symptoms, as judged by the investigator (p<0.0001), who had chronic fatigue
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(p<0.05), who were on sick-leave or had early retirement (p<0.001) and who fulfilled the
Rome II criteria for more than three functional GI disorders (p<0.05). The VSI score was
correlated with GI symptom severity (GSRS total score, r=-0.41; p<0.0001), the mental (r=
0.47; p<0.0001) and physical component summaries of SF-36 (r=0.22; p<0.0001), as well
as general anxiety (r=-0.54; p<0.0001) and depression (r=-0.44; p<0.0001) measured by
the HAD scale. In a stepwise linear regression model assessing factors independently associ-
ated with the total gastrointestinal symptom severity (GSRS total score), VSI was included
together with bodily pain and role physical on SF-36, IBS subgroup, the number of Rome II
diagnoses and the presence of meal-related symptoms (R2=0.41). Conclusion: Gastrointestinal
symptom-specific anxiety is an important factor in explaining both perceived gastrointestinal
symptom severity and health outcome in patients with IBS. It seems likely that reduction
of GI symptom-specific anxiety in IBS could be a relevant treatment goal in order to achieve
general improvement in these patients.
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Hypnotherapy for Children with Functional Abdominal Pain Or Irritable
Bowel Syndrome: A Randomised Controlled Trial
Arine Vlieger, Carla Menko-frankenhuis, Simone C. Wolfkamp, Ellen Tromp, Marc A.
Benninga
Background: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) in child-
hood are among the most common reasons for consultation in pediatrics with reported
prevalences of 1 to 19%. Treatment usually consists of education, reassurance and dietary
advices such as extra fibres. Nevertheless, a significant proportion of 25 to 66% continues
to experience symptoms and efficient therapies for this group are lacking. Gut-directed
hypnotherapy (HT) has been shown to be highly effective in the treatment of adult patients
with IBS. Aim: To compare clinical effectiveness of gut directed hypnotherapy with standard
medical therapy (SMT) in children with FAP or IBS. Methods: 53 patients between 8 and
18 yrs with longstanding complaints of either FAP or IBS, were randomized to either HT
or the control group. HT consisted of 6 half hour sessions over a 3 month period; The
Manchester protocol of gut-directed hypnotherapy was used, adapted for children and
adolescents. Patients in the control group received standard medical care and 6 half hour
sessions of supportive therapy. Pain intensity, pain frequency and associated symptoms like
nausea, headache and appetite were scored in weekly standardized abdominal pain diaries
at baseline, 1,2, and 3 months after randomization and 6 and 12 months after therapy.
Cure was defined as > 80% improvement in pain scores; an improvement of < 30% was
regarded as no effect. Results: All but one patient completed therapy. Mean age was 13,3
yrs, 75% was female, 42% had IBS, mean duration of abdominal complaints was 3,4 yrs.
Hypnotherapy was highly superior to conventional therapy with 59% versus 12 % of the
patients cured after treatment and 85% versus 25% cured at one year follow-up (p <0.001;
see table). Mean pain intensity scores decreased in the HT group from 13.5 at baseline to
3.0 after treatment and 1.4 at one year follow-up. In the SMT group these figures were
14.2, 9.8 and 8.0 resp.In both groups also the associated symptoms decreased significantly,
but no difference was found between the two treatment groups. No difference in efficacy
of HT was found between children with IBS or FAP. Conclusion: Gut-directed hypnotherapy
is highly superior to conventional therapy in the treatment of children with longstanding
FAP or IBS. Further studies are warranted to confirm our findings.
p<0.001
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Impact of Serotonin Receptor-3 Gene Polymorphism On Irritable Bowel
Syndrome
Lisa Aibiki, Tomoko Mizuno, Norio Ozaki, Ryoko Ishihara, Masashi Aoki, Yasuto
Itoyama, Motoyori Kanazawa, Shin Fukudo
Objective: Serotonin (5-HT)-related genes are the candidates that regulate the sensitivity to
stress of Irritable bowel syndrome (IBS). We reported that a polymorphism in the promotor
region of the serotonin transporter gene associates with negative emotion in population
including IBS. Serotonin receptors are expressed abundantly in both the brain and the gut.
In particularly, the 5-HT3 receptor antagonist is used for the treatment of IBS. However,
its polymorphisms are not investigated. The objective of this study was to verify the hypothesis
that polymorphisms in the 5-HT3A (HTR3A) and 5-HT3B (HTR3B) genes are associated
with IBS. Methods: Subjects were 348 volunteers. Using Rome II criteria, 119 subjects with
IBS symptoms were identified. Remaining 229 subjects were control. Peripheral blood was
sampled from the forearm vein, and DNA was extracted from the lymphocytes. DNA was
amplyfied by polymerase chain reaction (PCR) method, then detected single nucleotide
polymorphisms (SNP) by restriction fragment length polymorphism (RFLP) method. Emo-
tional status and alexithymia tendency as endophenotype of IBS were assesed by Perceived-
Stress Scale (PSS), State-Trait Anxiety Inventory (STAI), Self-rating Depression Scale (SDS),
and Toronto Alexithymia Scale (TAS-20). Results: HTR3A did not associate with IBS. In
HTR3B, however, allele frequencies were significantly different between IBS and control
group in rs1176744 (A/C, p = 0.03) and rs10502180 (T/G, p = 0.02). C allele of rs1176744
and T allele of rs10502180 were more common in IBS. In rs1176744 polymorphism in the
HTR3B gene, significant associations of endophenotype were found. They are a significant
genotype×gender×IBS interaction in trait anxiety score (p = 0.015) and a significant
genotype×gender interaction in TAS-20 total score (p = 0.037). Conclusion: This study is
the first report that suggests the polymorphism of a targeted molecule of drugs used in the
treatment of IBS is associated with IBS. The rs1176744 is located in the exon 5 of HTR3B
and mutation from A to C causes replacement of tyrosine to serine, possibly modifying
function of ionic gate. Besides, our results suggest that the polymorphisms in the HTR3B
gene may also affect endophenotype of IBS including anxiety and alexithymia tendency.
Further studies to explore the function of the 5-HT3 receptor gene are promising in IBS
research.
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Prevalence and Prediction of Gastrointestinal Events in Patients Receiving a
Combination of Aspirin Plus Clopidogrel
Annie Chan, Fook hong Ng, Chee my Chang, Siu yin Wong, Wai ming Chu, Wai cheung
Yuen, Yuk kong Lau, T k Cheung, Benjamin c.y. Wong
Introduction: The efficacy of the addition of clopidogrel to aspirin has been established but
this was associated with gastrointestinal complications in 1.3% of patients in study situation.
However, this has not been documented in real life. Aim: This retrospective study aimed
to determine the prevalence of upper gastrointestinal complication in real life situation. The
treatment effect of H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) was
also analysed, as compared to the control. Method: From Jan 2002 to Sept 2005, records
of all patients receiving dual anti-platelet therapy were analysed. The end-point was the
occurrence of symptomatic peptic ulcers or its complications. The last date of censor was
15 June 2006. Results: The patient group consisted of 664 patients (age 66.6±12.0 years).
Prophylactic H2RA and PPI was prescribed to 148 (22.2%) and 160(24.1%) patients,
respectively. Prior gastrointestinal bleeding was significantly more common in the PPI group
(16.3%) or the H2RA group (4.1%) than the control group (2.0%). After a follow-up of
4.6±5.2 months, end-point was reached in 28 (4.2%) patients (gastrointestinal bleed 26,
dyspepsia 2). After adjustment for the confounding covariates, the hazard ratio (95% confid-
ence interval) for primary end-point was 0.053 (0.006-0.219) for PPI and 0.324 (0.113-
0.925) for H2RA, as compared to control. Conclusion: In real life, the incidence of peptic
ulcer disease and gastrointestinal bleeding associated with dual aspirin plus clopdiogrel
therapy was 4.2%. Co-prescription with PPI or H2RA can significantly reduce the risk.
Hazard ratio (95% confidence interval) for primary and secondary end points : control, H2-
receptor antagonist and proton pump inhibitor.
*adjusted for age, previous gastrointestinal bleeding, concomitant heparin, thrombolytic
or glycoprotein receptor IIb/IIIa inhibitor, poor cardiac status (inotropic or mechanical
ventilatory support)
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Upper Gastrointestinal Bleeding and the Changing Use of COX-2 Specific
Nonsteroidal Antiinflammatory Drugs
Ali S. Taha, Wilson J. Angerson, Rakesh Prasad, Caroline Mccloskey, Robin P. Knill-jones,
Oliver Blatchford
BACKGROUND With the concerns over the vascular side-effects of COX-2 specific nonster-
oidal antiinflammatory drugs (NSAIDs), rofecoxib was withdrawn, a study of celecoxib was
halted, and alternative therapies were recommended by the regulatory authorities. Given
the relative gastrointestinal safety of COX-2 NSAIDs and the greater ulcerogenic potential
of alternative conventional NSAIDs, we aimed to assess the incidence of upper gastrointestinal
bleeding in light of the changing use of these compounds. METHODS We examined the
numbers and clinical characteristics of patients developing haematemesis and/ or melaena
in Southwest of Scotland (population of 290,000). Comparisons were made between data
collected over one calendar year before and the year after rofecoxib was withdrawn. Drug
intake and prescriptions were documented including those for NSAIDs, low-dose aspirin
(75-mg) and other antithrombotic drugs (clopidogrel, dipyridamole, and warfarin). Other
clinical details, smoking, and excess alcohol intake (> 20 units/ week) were also noted.
RESULTS The following Table shows the incidence of upper gastrointestinal bleeding (num-
bers per 100,000 of the population) in one calendar year BEFORE as compared with the
year AFTER rofecoxib was withdrawn, in all patients and in relation to peptic ulcer risk
factors. The withdrawal of rofecoxib was associated with a drop in the use of celecoxib, a
rise in the use of other relatively mild NSAIDs (meloxicam, etodolac, and etoricoxib), and
continued rise in the use of low-dose aspirin and other anti-thrombotic drugs. CONCLUSION
The rise in the incidence of upper gastrointestinal bleeding is not related to the changing
use of NSAIDs. Instead, it reflects the increasing use of low-dose aspirin and other anti-
thrombotic drugs, and the rise in alcohol-related bleeding.
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Mortality Following NSAID-Related Gastrointestinal Or Cardiovascular Event
Neena S. Abraham, Christine Hartman, Walter E. Smalley
Background: Physician non-adherence to safer NSAID prescribing strategies is common,
increasing risk of upper gastrointestinal events (UGIE) among elderly patients, and use of
a highly COX-2 selective NSAID strategy contributes to increased risk of myocardial infarc-
tions (MI) and cerebrovascular accidents (CVA). This study aimed to quantify risk and
median time to mortality following an NSAID-related UGIE, MI or CVA and to examine
the effect of prescription strategy on subsequent mortality. Methods: Veterans > 65 years
prescribed an NSAID, coxib or salicylate (>325 mg/day) at a VA facility (01/01/00-12/31/
02) were identified from a national pharmacy database. Prescription fill data were linked in
longitudinal fashion to VA inpatient, outpatient and death files and merged with demographic,
inpatient, outpatient, provider and death data from Medicare. Each person-day of follow-
up was assessed for exposure to non-selective NSAIDs, COX-2 selective NSAIDs (coxibs)
and proton pump inhibitors (PPIs). Previously published validated algorithms were used
for assessing UGIE, MI and CVA. Cox Proportional Hazard Models assessed mortality in
the 365 days following index prescription, while adjusting for demographics, co-morbidity,
prescription channeling, geographic location and cumulative proportion of time spent on
NSAIDs, coxibs and PPIs. Patients were censored at event, end of follow-up, end of exposure
or death. Hazard Ratios (HR) and their 95% confidence intervals (CI) were calculated.
Results: Among 474,495 patients (97.8% male; 85.3% white; mean age, 73.9 [SD 5.6]),
2.9% died. 719 deaths (0.15%) followed NSAID-related events including 242 CVA, 335
MI, 9 patients with MI and CVA, 124 UGIE, 5 patients with UGIE and CVA and 4 with
UGIE and MI. Median time to death was shortest following NSAID-related cardiovascular
events (9 days following CVA [range, 0-316] and 10 days following MI [range, 0-338]) and
occurred 26 days following UGIE [range, 0-307]. NSAID-related CVA was associated with
greatest risk of death (HR=12.5; 95% CI: 11.0-14.3). MI and UGIE were also associated
with increased risk (HR=9.7; 95% CI: 8.6-10.9; HR=3.4; 95% CI: 2.9-4.0, respectively).
Also predictive of mortality were advancing age and co-morbidity, increased use of coxibs
and failure to ensure adequate gastroprotection. Conclusions: NSAID exposure increases
overall risk of mortality when adjusted for advancing age, co-morbidity, and proportion of
time spent on a traditional or COX-2 selective NSAID. NSAID-related CVA, MI and UGIE
should be considered herald events for subsequent mortality. Mortality can be reduced with
gastroprotection and by minimizing use of NSAIDs.
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Improving Adherence with PPI Prescribing Guidelines in High-Risk NSAID
Users: A Controlled “Before and After” Trial of An Electronic Medical Record
Reminder
Brennan M. Spiegel, Peter Glassman, Gareth S. Dulai, Paul Shekelle, Mary Farid, Inder
Singh, Dan Naim, Wayne Ho, Mark Mattar, Mark Makhani, Jennifer Talley, Lee
Ochotorena, Caroline Goldzweig
Background: Although guidelines recommend PPI co-therapy in high-risk NSAID users,
data consistently show that 70-90% of high-risk users do not receive gastroprotection. In
light of the guideline-practice disconnect, authorities have called for efforts to narrow this
persistent “gastroprotection gap.” Yet there have been few successful attempts to improve
provider compliance with guidelines. We developed and tested an electronic medical record
reminder to reduce “inappropriate underuse” of PPI co-therapy in high-risk NSAID users.
Methods: Using the Veteran's Administration (VA) Computerized Medical Record System
(CPRS) as a platform, we developed an e-reminder to identify patients on chronic (>30 day)
non-selective NSAID or ASA therapy with >1 independent risk factor(s) for a GI complication
(e.g. age>65, multiple NSAIDs, history of complicated ulcer, warfarin, prednisone) who were
not receiving PPIs. The reminder was based on “social influence theory,” and was designed
with clinical informatics experts to maximize point-of-care effectiveness. The primary out-
come was guideline adherence (adherence=reminder resolved by initiating PPI) during the
3-month period before vs after reminder deployment across a regional 14-center VA healthcare
network. The minimum calculated sample size was N=676. We conducted chi-squared and
survival analyses to measure guideline compliance between periods. Results: There were
363 and 324 patients in the baseline and reminder periods, respectively. 10% vs 25% of
patients were placed on PPIs in the baseline vs reminder periods, respectively (Δ=15%; 95%
CI=14-20%; p<0.01). In survival analysis, patients in the reminder period were 2.4 times
more likely to receive a PPI (HR=2.4; CI=1.6-3.6). In Cox regression adjusting for study
period and risk profiles, patients with >2 clinic visits were 70% more likely to receive a PPI
(HR=1.7; CI=1.1-2.4), and patients >65 yo were 50% less likely to receive a PPI compared to
younger patients (HR=0.5; CI=0.3-0.8). Among the 75% not placed on PPI in the intervention
period, 84% had unopened reminders (16% overridden, most for false positives or patient
refusal of PPI). Conclusions: This study indicates that the “gastroprotection gap” may be
narrowed in high-risk NSAID users through use of clinical informatics. The study is limited
by its lack of randomization and the high rate of unopened reminders. Further research
should measure the effectiveness and cost-effectiveness of similar interventions in varied
healthcare settings, and should also explore why older high-risk patients might inappropri-
ately receive less PPI co-therapy. Sponsored by AGA Outcomes Research Award
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Use of Physician Education and a Computer Alert to Improve Targeted Use of
GI Prophylaxis for NSAID-Related Peptic Ulcer Disease
Gregory A. Cote, John Rice, William J. Bulsiewicz, John Norvell, Keri Christensen, Anne
Bobb, Colin W. Howden
Background: GI hemorrhage accounts for 200-400,000 admissions in the US annually.
Around 50% of patients with bleeding ulcer have used aspirin and/or NSAIDs. Misoprostol
and PPIs may reduce NSAID-related upper GI tract complications in high risk patients, but
their targeted use may be suboptimal. Aim: To determine the impact of physician education,
a computer alert, or both on the targeted use of GI prophylaxis in high risk patients
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discharged from hospital. Methods: To target high risk patients, we studied cardiology
telemetry and CCU services. Every 4 weeks, 8 different residents manage these patients.
Over a 32-week period, residents were assigned to 1 of 4 8-week groups sequentially: Group
1: control; Group 2: physician education, consisting of a 10 minute tutorial on risk factors
for NSAID-related GI complications; Group 3: computer alert; Group 4: combination of
tutorial and computer alert. We reviewed all patients admitted to these cardiology services
during the study period. Exclusion criteria included discharge on no ulcerogenic medications,
incomplete discharge data, and in-patient death. Patients readmitted during the study period
were not re-counted. Medical records were reviewed for discharge medications, past medical
history, demographics, admission and discharge diagnoses, hospital days and Charlson co-
morbidity index. Other indications for acid suppression were documented. Between-group
comparisons were performed using Student's t-test. Chi-squared test was used to determine
independence among all 4 groups. Results: We enrolled 721 patients, of whom 118 (16%)
were excluded. The remaining 603 were divided by physician intervention group and risk
for NSAID-related GI complications. 428 of 603 (71%) patients met criteria for high risk:
120 in group 1, 99 in group 2, 104 in group 3, and 105 in group 4. 54.2% of high risk
patients received prophylaxis in the control group at the time of discharge, compared to
53.5% in group 2 (NS), 51.9% in group 3 (NS), and 69.5% in group 4 (p< 0.02). In patients
admitted without prophylaxis, the rate of new prescription at discharge was 29.5% in group
1, 35.2% in group 2 (NS), 35.1% in group 3 (NS), and 61.0% in group 4 (p<0.001).
Conclusion: The combination of a computer alert and brief physician education led to a
15.3% absolute increase in GI prophylaxis prescriptions among high risk patients at the
time of discharge from hospital. This intervention increased the absolute rate of new prescrip-
tions by 30.5% in high risk patients. This is a low cost method to improve the targeted use
of GI prophylaxis for high risk NSAID users. Funded by an investigator-initiated grant
from AstraZeneca
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Changing Perceptions and Practices Regarding Aspirin, NSAIDs, and Coxibs
Amongst Us Primary Care Providers (Pcps): A Tale of 2 Surveys
Najwa Elnachef, James Scheiman, A. M. Fendrick, Colin W. Howden, William D. Chey
Background: In 2003, we surveyed US PCPs about their perceptions and prescribing habits
regarding aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and Cox-2 selective
agents (COXIBs). In light of new data on indications and safety, we conducted a follow-up
survey to assess current thinking on these drugs. Methods: A 34 question survey was
developed by a group of academic physicians and administered via the internet to US PCPs.
PCPs who participated in the 2003 survey were first reinvited, followed by a new group of
PCPs to complete a final sample of 1000. Roughly half of the questions were present on
both surveys. Results: Of the current study cohort, 491 completed both surveys. 31% of
PCPs felt they prescribe NSAIDs more commonly now than in 2003 while 21% felt they
prescribe NSAIDs less commonly. 52% reported they are now more likely to recommend
a gastroprotective (GP) agent with an NSAID. 59% of PCPs report they now prescribe
COXIBs less frequently. In 2003, COXIBs accounted for 43% of NSAID prescriptions. In
2006, 25% of NSAID prescriptions are for COXIBs. 50% of PCPs felt that rofecoxib was
associated with increased cardiac risk while 50% did not believe this to be true or were not
sure. Fewer PCPs felt that celecoxib (32%) or traditional NSAIDs (35%) were associated
with increased cardiac risk. In hypothetical pt scenarios, 88% of PCPs recommended a
proton pump inhibitor (PPI) in a high risk pt with a recently healed NSAID ulcer requiring
NSAID for joint pain. However, only 54% recommended a PPI for a patient with a recently
healed ulcer who required ongoing low dose aspirin. 43% recommended a PPI and NSAID
while 41% recommended a PPI and COXIB for a pt with a remote history of ulcer-related
GI bleeding who needed both aspirin and an NSAID. 27% of PCPs recommend PPI co-
therapy while 16% suggested a COXIB instead of an NSAID for a pt with no GI history
who needed aspirin for cardioprotection and an NSAID for joint pain. When asked about
which agent they recommend for GP, the majority preferred prescription over OTC PPI.
However, 18-38% of PCPs recommended OTC PPI in our pt scenarios. Conclusion: This
follow-up survey found that a greater proportion of PCPs recognize the need for GP in pts
at increased risk for aspirin or NSAID associated GI complications. However, the pt scenarios
illustrate that this recognition does not always translate to clinical practice. OTC PPI has
captured a substantial proportion of the GP market. COXIBs still account for 25% of the
branded NSAID market and most PCPs feel that celecoxib and traditional NSAIDs are
associated with similar cardiac risk. Funded by a grant from TAP Pharmaceuticals.
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Efficient Knock-Down of RGS4 Expression in Colonic Smooth Muscle In Vitro
and In Vivo By Small Interfering RNA (Sirna)
Wenhui Hu, Fang Li, Sunila Mahavadi, Karnam S. Murthy
Regulator of G-protein Signaling 4 (RGS4) negatively modulates signaling via Gq-coupled
receptors by accelerating inactivation of Gαq. Stimulation of RGS4 expression by IL-1β and
in TNBS colitis is accompanied by decrease in PLC-β activity and initial contraction mediated
by Gαq. Direct evidence that increase in RGS4 expression is responsible for the decrease in
muscle contraction is lacking. One approach would be to develop a technique for blocking
the increase in RGS4 expression In Vitro and In Vivo. Aim. To establish the feasibility of
efficient silencing of endogenous RGS4 expression by siRNA both In Vitro and In Vivo in
rabbit smooth muscle cells. Methods. Two short hairpin RNAs (shRNAs) of rabbit RGS4
gene were designed, cloned into lentiviral pLL3.7 vector, and tested in cultured smooth
muscle cells 2-3 days after transient transfection with Lipofectamine 2000. Lentiviral vector
encoding RGS4 shRNA was packaged in HEK293T cells and the lentivirus was purified by
ultracentrifuge. Midline laporatomy was performed and 5 ml of lentivirus (transduction unit
at 109) was microinjected into the muscle layer of distal colon at multiple points. After 2
weeks, the distal (injection site) and proximal colons were removed and circular muscle
strips and dispersed muscle cells were prepared. Also, chemically synthesized RGS4 siRNA
was transfected with Lipofectamine 2000 into colonic circular muscle strips from normal
rabbit, and 2 days later single muscle cells were isolated. Expression levels of RGS4 mRNA
and protein were determined with Western blot and real-time RT-PCR. The consequences
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of RGS4 knockdown were examined by measurement of initial cell contraction and PLC-β
activity 30 seconds after acetylcholine stimulation. Results. RGS4 shRNA efficiently (>
90%) silenced expression of endogenous RGS4 in cultured muscle cells. In muscle strips,
synthesized RGS4 siRNA also efficiently silenced (> 90%) mRNA and protein expression of
endogenous RGS4. For the In Vivo studies, RGS4 expression in smooth muscle of distal
colon infected with RGS4 shRNA lentivirus was significantly reduced at both mRNA (60%)
and protein level (90%), as compared with distal colon infected with empty lentivirus or
uninfected proximal colon. In dispersed muscle cells derived from colonic muscle strips
treated with IL-1β, silencing of RGS4 restored the contractile response to control levels.
Similarly, silencing of RGS4 in cultured muscle cells treated with IL-1β restored PLC-β
activity. Conclusion. We have identified siRNA capable of silencing RGS4 in smooth muscle
In Vivo and In Vitro. Silencing of RGS4 restores PLC-β and contractile function in muscle
treated with IL-1β.
923
Citrobacter rodentium-Induced Alterations in Colonic Function Are Associated
with Upregulation of IL-17 Cytokines
Jennifer A. Stiltz, Aiping Zhao, Rex Sun, Allen Smith, Kathleen B. Madden, Joseph
Urban, Terez Shea-donohue
The pathogenesis of IBD is associated with dysregulated immune response to gut flora. Th17
is a newly identified T cell subtype that releases mainly IL-17A upon activation. Elevated
levels of circulating IL-17A are reported in IBD patients. Citrobacter rodentium (Cr) infection
of the colon is an emerging murine model of IBD with similarities to clinical disease. Aim:
To determine the changes in colonic smooth muscle and epithelial cell responses to Cr-
induced colitis and associated changes in Th17 cytokine expression. Methods: BALB/c mice
(n=5-9/group) were infected orally with live Cr (5x1010 cfu) or vehicle and studied 12 days
later. Microscopic damage was assessed blindly. Segments of colon were suspended in organ
baths and oriented in the longitudinal or circular direction to determine concentration-
dependent responses to acetylcholine (ACh). Segments of muscle-free colonic mucosae were
mounted in Ussing chambers to assess mucosal secretion in response to ACh and tissue
resistance (R), an index of mucosal permeability. mRNA expression of cytokines or their
receptors was determined by real-time PCR. Results: Cr colitis was characterized by submu-
cosal edema, marked mucosal hyperplasia, and lymphocyte infiltration. Infection induced
a significant inhibition of contractility to ACh in both longitudinal (8.8 ± 1.1 vs 5.1 ± 1.0
N/cm2) and circular (8.9 ± 1.5 vs 3.7 ± 0.6 N/cm2) smooth muscle. Cr also inhibited colonic
epithelial cell secretion to ACh (119±26 vs 39±1 µA/cm2), but did not alter mucosal R
(21±2 vs 18 ±2 Ω*cm2). The classical Th1 cytokines were upregulated in Cr -infected colon,
including IFN-γ and IL-12p40 (IL-23p40) (table), as well as TNF-α (not shown). Gene
expression studies on IL-17 cytokines and cytokine receptors showed thatCr also upregulated
IL-17A, IL-17C, IL-17F, and IL-17Ra (table). No significant differences were seen in the
mRNA expression of IL-17B and IL-17D (not shown). Conclusions: Cr infection induced
a colonic smooth muscle hypocontractility and epithelial cell hyposecretion. This dysregul-
ated gut function is associated with the upregulation of Th1 and the specific members of
IL-17 cytokines. These data indicate IL-17 cytokines could be a novel therapeutic target
for IBD.
mRNA expression of cytokines in Cr infection
*p<0.05, **p<0.01 vs Veh; n=5-9
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Evidence of Small Bowel Neuro-Muscular Abnormalities in a Rat Model of
Herpes Simplex Virus-1 (HSV1) Infection of the Enteric Nervous System
Roberto De giorgio, Paola Brun, Chiara Zoppellaro, Maria C. Giron, Cristina Felicani,
Giovanni Barbara, Vincenzo Stanghellini, Maddalena Bracceschi, Giorgio Palù, Giovanni
Zaninotto, Marcello Tonini, Roberto Corinaldesi, Rosa M. Gaion, Ignazio Castagliuolo
Digestive neuropathies are characterized by a wide array of enteric nervous system (ENS)
degenerative abnormalities leading to gut dysmotility. Although neurotropic viruses have
been implicated in the ENS degeneration, the mechanisms through which such viruses affect
the ENS are unknown. The aims of this study were to: a) establish an In Vivo model of
HSV1 infection in the rat ENS; b) assess whether HSV1 infection may cause functional
neuromuscular changes in the gut. Methods: Chronic HSV1 infection in the ENS was
established by inoculating rats intranasally (103 pfu) and after 4 weeks intragastrically (i.g.,
108 pfu), to elicit an appropriate immune response and reproduce the infection occurring
in humans. Six weeks after the i.g. inoculation HSV1 infected (n=12) or saline injected rats
(controls, n=6) were sacrificed and the presence and nature of HSV1 infection was determined
by PCR amplification of HSV1-tk gene, RT-PCR for HSV1 latency associated transcripts
(LATs) and early gene ICP-4, in situ hybridization and immunofluorescence for glycoprotein-
C (gC). In addition, ileum and duodenum segments (2 cm) were isolated and mounted
vertically into organ baths and changes in muscle tension, following exposure to KCl (60
mM) and 5-HT (10 μM) in the presence or absence of atropine (5 μM) were recorded by
isometric transducers. Results: Both controls and HSV1 infected rats did not show clinical
and histological abnormalities in the gastrointestinal tract. Viral tk-DNA and LAT mRNA,
but not ICP-4 mRNA transcripts, were detected in brain, full-thickness gut and isolated
enteric neurons indicating a latent HSV1 infection in these tissues. These findings were
confirmed by lack of HSV1gC immunoreactivity, whereas in situ hybridization showed HSV1
DNA in central nervous system and ENS. HSV1 infection significantly reduced KCl-evoked
tonic contraction by 50% in the ileum, without affecting duodenum responses. In duodenum
from control rats 5-HT-induced contraction was reduced by 44% after pre-treatment with
atropine, whereas HSV1 decreased by 72% 5-HT-induced contractions and atropine did not
alter this response. Conclusions: Following i.g. injection HSV1 establishes a latent infection
in the ENS. KCl and 5-HT-induced intestinal contractions are significantly reduced by HSV1
infection. The reduced contractility showed by HSV1 infected tissues indicates that the latent
infection may affect ileal neuro-muscular integrity and account per se for disturbed motility
and transit.
925
Inflammation of the Guinea Pig Distal Colon Is Associated with a Loss of
Intestinofugal Neurons
David R. Linden, Joseph H. Szurszewski
While several investigations have determined that hapten-induced colitis is associated with
a loss of myenteric neurons, they have not determined the functional classes of neurons
that are lost. We hypothesize that intestinofugal afferent neurons (IFANs) are among the
neurons that are lost during colitis. The cell bodies of IFANs reside in the myenteric plexus.
They project their axons to the prevertebral ganglia (PVG) where they provide ongoing
nicotinic cholinergic synaptic input to postganglionic sympathetic neurons. PVG neurons
provide ongoing inhibitory sympathetic tone to the entire gastrointestinal (GI) tract. To test
whether IFANs are lost during intestinal inflammation, the retrograde tracing dye, Fast
Blue, was injected into the inferior mesenteric ganglion (IMG) of guinea pigs that received
intracolonic administration of trinitrobenzene sulfonic acid (TNBS) and control animals.
Labeled IFANs in myenteric ganglia were quantified both as the proportion of ganglia
that contained at least one IFAN and the proportion of myenteric neurons (defined as
immunoreactive for Hu-D) that contained Fast Blue. In the region of ulceration, hyperemia
and edema, only 10 ± 1 % (N=4) of ganglia contained labeled neurons which is significantly
less than the same region in control animals (18 ± 2 %, N=4; P<0.05, two-way ANOVA).
The overall proportion of myenteric neurons identified as IFANs was also significantly
reduced in the inflamed preparations (0.19 ± 0.06 %; N=4) compared to control (0.42 ±
0.08 %; N=4; P<0.05, two-way ANOVA). Outside the area of inflammation, there was no
difference in either quantification of Fast Blue labeled neurons compared to controls (P>
0.05; two-way ANOVA). To assess the functional significance of the morphological data, we
investigated IMG neurons with an attached segment of colon using conventional intracellular
electrophysiology. The frequency of ongoing synaptic input that arose from colonic IFANs
was significantly reduced in guinea pigs 24 hours (8 ± 2 Hz; N=15), 6 days (7 ± 3 Hz; N=
7) or 56 days after TNBS treatment (6 ± 2 Hz; N=5) compared to controls (14 ± 2 Hz; N=
14; P<0.05, ANOVA). Both morphological and physiological data support the concept that
the reduction in myenteric neurons during hapten-induced colitis is, in part, due to a loss
of IFANs. Because IFANs form the afferent limb of reflexes that coordinate motor, secretory
and vasoactive activities throughout the GI tract, a loss of these myenteric neurons can
impact function of the entire GI tract. Supported by DK17632 and DK17238.
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CTLA-4 Haplotypes and Cd4+Cd25+Foxp3+ Regulatory T Cells in Irritable
Bowel Syndrome
Tobias Liebregts, Birgit Adam, Christoph Bredack, Susan Lester, Sarah Downie-doyle,
Stuart M. Brierley, Montri Gururatsakul, Kate R. Pilkington, Nicholas J. Talley, Gerald
Holtmann
Background: Immune activation may play a role in a subgroup of Irritable Bowel Syndrome
(IBS). We have recently shown that PBMC- mediated cytokine secretion is significantly
enhanced in IBS (Gastroenterology 2006; 130 (4):A51). This may reflect an impaired down-
regulation of immune function. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative
signal for regulatory T-cell activation and the +49GA and the CT60A/G polymorphisms are
known to be associated with autoimmune and inflammatory diseases. We hypothesized
that a CTLA-4 polymorphism is associated with enhanced T cell activation and symptom
patterns in IBS. Thus we aimed a) to investigate a possible association of CTLA-4 and IBS
symptoms, b) to characterize T cell mediated cytokine production and c) to compare
regulatory (CD4+CD25+FoxP3+) T cell (T reg) subsets in IBS to healthy controls. Methods:
CTLA-4 genotyping was performed on 100 IBS patients (Rome II) and 156 population based
controls by PCR-RFLP methods using the restriction enzymes BseXI (+49GA) and HpyCh4IV
(CT60). Patients were categorized based upon their symptoms assessed by the standardized
Bowel Disease Questionnaire. The following were considered key symptoms and pre-selected
prior to data analysis: pain associated with more or less bowel movements, >3 stools/day,
<3 stools/week, loose/watery stools, hard/lumpy stools, incomplete evacuation and urgency.
In a subset of 46 patients and 35 controls PBMC- derived CD4+ T cells were cultured for 24
hours and cytokine secretion (IFN-g, IL-10) was measured by enzyme-linked immunosorbent
assay. Cell surface expression of CD25 and the T reg cell transcript, FoxP3 was analyzed
by flow cytometry and quantitative RT-PCR. Results: CD4+ T cell mediated IL-10
(181.1±30pg/ml vs. 116.8±35.4pg/ml) and IFN-γ (78.4±8pg/ml vs. 40.8±7.1pg/ml) release
were significantly higher (p<0.05) in D-IBS patients compared to healthy subjects. No
significant differences were found for other IBS- subgroups. The number of circulating T
reg, CD25 and FoxP3 mRNA expression did not differ between subjects with IBS and
controls. The CTLA-4 AG haplotype was associated with the symptom urgency (OR 3.08,
95% CI 1.18-8, p=0.021), loose/watery stools (OR 2.07, 95% CI 0.88-4.89, p=0.038) and
>3 stools/day (OR 2.97, 95% CI 1.22-7.2, p=0.016). Summary and Conclusion: A CTLA-
4 AG haplotype is significantly associated with diarrhea-type IBS. These patients are character-
ized by enhanced T cell mediated cytokine production while circulating T reg are not
affected. Our data are consistent with the concept of a genetic susceptibility for impaired
down-regulation of T cell activation in a subset of patients with IBS.
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Inflammation-Induced Changes in the Electrical and Synaptic Properties of
Guinea-Pig Colonic Myenteric Neurons Persist Following Recovery from
Inflammation
Eric Krauter, David R. Linden, Elice M. Brooks, Derek S. Strong, Keith A. Sharkey, Gary
M. Mawe
It is becoming increasingly clear that persistent changes in gut function brought about by
infection and/or inflammation contribute to a large contingent of functional bowel disorders,
and these changes could involve altered neuronal function. In the inflamed colon, changes
in myenteric neuronal properties have been detected, including augmented fast excitatory
postsynaptic potentials (fEPSPs) of S neurons and hyperexcitability of AH neurons (Linden
et al., J Physiol 547:589-601, 2003; Krauter et al., DDW 2005). The goal of this investigation
was to determine if these changes persist following recovery from inflammation. Intracellular
electrophysiological recordings were obtained from colonic myenteric neurons of control
guinea pigs and 56 days post-trinitrobenzene sulfonic (TNBS) acid administration (inflamma-
tion resolves by post-TNBS day 21). Properties from a total of 13 S and 8 AH neurons from
the colonic myenteric plexus of 56 days post-TNBS animals were evaluated and compared
with neurons from control tissues. The resting electrical properties (resting membrane
potentials, RMP and input resistance, IR) of S neurons were comparable in both groups (IR:
control, 95.3 ± 48 MΩ, n = 47; 56 day, 83.6 ± 17 MΩ; RMP: control, -49 ± 7 mV, n =
47; 56 day, -50 ± 3 mV), but the resting membrane potential (RMP) of AH neurons was
depolarized (IR: control, 116 ±11 MΩ, n = 24, 56 day, 98 ± 15 MΩ, n = 8; RMP: control,
-69 ± 2 mV, n = 24; 56 day, -59 ± 3 mV, n = 8, p < 0.05). Furthermore, the amplitude of
the S neuron fEPSP was significantly larger in 56 day tissues than controls (control: 23 ±
1 mV, n = 93; 56 day: 32 ± 2 mV, n = 13; p < 0.005, unpaired t-test) and the excitability
of the AH neurons was higher in the 56 day animals than controls, as indicated by the
maximum number of action potentials per 500 millisecond depolarizing current pulse
(control, 1.6 ± 0.3; 56 day, n = 25; 6.3 ± 2 n = 8; p < 0.0001). During colitis, AH neuron
hyperexcitability is associated with a decrease in the magnitude of the afterhyperpolarization
(Linden et al., J Physiol 547:589-601, 2003), which appears to persist at the 56-day time
point (control, 22 ± 3 mV●s, n = 24; 56 day, 9.5 ± 3 mV●s, n = 7; p < 0.02, unpaired
t-test). These data indicate that the electrical and synaptic changes in S and AH neurons,
which are induced by colitis, are sustained following recovery from inflammation. Such
changes could contribute to the abnormal gut functions that are observe in post-infectious
irritable bowel syndrome. Supported by Supported by NIH grants DK62267, NS26995
(GMM), and Ruth L. Kirschstein National Research Service Award F31 NS055512-01 from
NINDS (EMK).
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Functional Coupling of ABC Transporters (CFTR and Mrp4) in the Gut
Chunying Li, Partha C. Krishnamurthy, Himabindu Penmatsa, Kevin L. Marrs, John D.
Schuetz, Anjaparavanda P. Naren
Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride
channel localized primarily at the apical or luminal surfaces of epithelial cells that line the
airway, gut, and exocrine glands. Recently, we demonstrated that a type 2 lysophosphatidic
acid receptor forms a macromolecular complex with CFTR mediated through a PDZ scaffold-
ing protein (NHERF2) in the apical surfaces of gut epithelial cells (J. Exp. Med. 2005; 202:
975). This physical association of multiprotein complex forms basis for the functional
coupling between lysophosphatidic acid signaling and CFTR-mediated chloride transport.
In the present study, we identified another CFTR interacting partner, the multidrug resistance
protein 4 (MRP4), which physically associates with CFTR through a different PDZ scaffolding
protein, PDZ domain containing 1 (PDZK1), forming a trimeric supramolecular complex
localized to the apical surfaces of gut epithelia. MRP4 is an organic anion transporter that
transports cyclic nucleotides (such as cAMP or cGMP) and some nucleoside monophosphate
analogs including nucleoside-based antiviral drugs. In the present study, we found that
adenosine-stimulated chloride currents mediated through CFTR channel in the apical surfaces
of HT29-CL19A gut epithelial cells are potentiated by the addition of MK571, an MRP4
inhibitor. Chloride current potentiation by MK571 is directly linked to reduced [3H]-cAMP
efflux through the apical membrane. As HT29-CL19A cells express the PDZ protein, PDZK1,
we tested if an MRP4 specific peptide that disrupts the complex formed between MRP4 and
PDZK1 affected MK571 potentiation of CFTR-mediated chloride channels. This MRP4 specific
peptide eliminated the MK571 potentiatiation of CFTR-mediated chloride currents when
these gut epithelial cells were activated by adenosine. These studies were extended In Vivo
to demonstrate that MK571 was incapable of potentiating the cholera toxin-induced CFTR-
dependent intestinal fluid secretion in MRP4 knock-out mice. Our present study demon-
strates, for the first time, the formation of a physical and functional complex consisting of
two ABC transporters and a PDZ scaffolding protein, which appears to have significant In
Vivo physiological or patho-physiological relevance and implications for diseases such as
secretory diarrhea, inflammatory bowel disease, and irritable bowel syndrome.
929
Regulation of the Interactions of Pp2a and Pp1 with Occludin During the
Assembly of Tight Junctions (TJ): Pp2a Dephosphorylates Occludin
Predominantly On Phospho-Threonine, While Pp1 Dephosphorylates Phospho-
Serine
Ankur Seth, Radhakrishna (rk) Rao
Occludin, a transmembrane protein of TJ, is phosphorylated on Ser/Thr residues. Our
previous study indicated that PP2A and PP1 negatively regulate the assembly of TJ in Caco-
2 cells. In this study we show that the interaction of PP2A and PP1 with occludin is regulated
during the assembly of TJ, and that PP2A and PP1 selectively dephosphorylate occludin on
Ser or Thr. Methods: Caco-2 cells were transfected with antisense oligos to PP2A (AS-
PP2A), PP1 (AS-PP1) or missense oligo (MS-oligo). TJ assembly was assessed by calcium
switch method, and monitored by measuring TER, FITC-inulin flux and confocal microscopy
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of occludin and ZO-1. Phosphorylation of occludin was evaluated by immunoprecipitation
of p-Ser and p-Thr and immunoblot analysis. Association of PP2A and PP1 with occludin
was determined by co-immunoprecipitation, and by pair wise binding using GST-occludin-
C (C-terminal 150 A.a.) and purified PP2A and PP1. Interaction of GST-Occludin-C with
PP2A, PP1 and PKCζ was evaluated by GST pull down assay using extracts from cells at
different stages of calcium switch. To evaluate occludin-dephosphorylation, immunocom-
plexes of phospho-occludin was incubated with PP2A or PP1 and immunoblotted for p-
Thr and p-Ser. Results: Calcium depletion by EGTA reduced TER, increased inulin flux,
and induced redistribution of occludin and ZO-1 from the junctions. Calcium gradually
increased TER, reduced inulin flux and organized occludin and ZO-1 at the junctions.
Calcium depletion dramatically reduced Thr-phosphorylation of occludin, while it was
elevated during calcium-induced reassembly of TJ. Co-immunoprecipitation of PP2A and
PP1 with occludin was greater in EGTA-treated cells, but it was gradually reduced during
the reassembly. GST pull down assay showed that the interaction of occludin with PP2A
and PP1, but not PKCζ, was greater in EGTA-treated cells, while it was reduced during the
assembly of TJ. Incubation of phospho-occludin with PP2A for 10 min reduced the level
of p-Thr without affecting p-Ser, while incubation with PP1 reduced p-Ser without affecting
p-Thr. Transfection of AS-PP2A or AS-PP1 accelerated the reassembly of TJ. In AS-PP2A-
transfected cells, the level of Thr-phosphorylated occludin during TJ-reassembly was signific-
antly greater compared to MS-oligo-transfected cells. In AS-PP1-transfeced cells however,
Ser-phosphorylated occludin was increased during the reassembly of TJ, while it was slightly
reduced in AS-PP2A or MS-oligo-transfected cells. Conclusion: These results suggest that
PP2A and PP1 may have distinct roles in regulating the phosphorylation of occludin on
Thr/Ser residues and TJ integrity. Support: DK55532 and AA12307
930
Gliadin-Dependent Neuromuscular and Epithelial Secretory Responses in the
Gut
Elena F. Verdu, Xian xi Huang, Jun Lu, Patricia Blennerhassett, Pinchang Yang, Chella S.
David, Derek Mckay, Joseph A. Murray
Background: Clinical studies suggest that gluten sensitivity, a state of abnormal immunity
to gluten, often associates with functional gut symptoms in the absence of chronic enteropa-
thy. Our aim was to investigate the role of gliadin sensitivity in the generation of gut
dysfunction in HLA-DQ8 transgenic mice. Methods: HLA-DQ8 mice were sensitized and
later gavaged with gliadin 3 times a week, for 3 weeks (G/G). Controls consisted of a) non-
sensitized mice gavaged with gliadin, or rice (C), b) gliadin-sensitized mice gavaged with
rice (G/R), c) Bovine serum albumin-sensitized mice gavaged with BSA (BSA/BSA). CD3+
intra-epithelial lymphocyte (IEL), macrophage counts, cytokines and intestinal morphology
by light (LM) and electron microscopy (EM) were investigated. Acetylocholine (ACh) release
by longitudinal myenteric plexus preparations, motility In Vivo, small intestinal contractility
In Vitro, and epithelial ion transport were measured. Results: Despite normal histology at
LM, G/G had a 50% reduction in microvilli height at EM, a 3-fold increase in ACh release
from the myenteric plexus, and a 20% increase in retroperistalsis occurence In Vivo vs C. This
was paralled by a decreased plasma IL-10/IFN-γ ratio in GG mice. Muscle hypercontractility In
Vitro after electric field stimulation or carbachol challenge, and an increase in active ion
transport after electric transmural stimulation was detected in G/G, but not in C, G/R or
BSA/BSA mice. Increased CD3+ IEL and macrophage counts were observed only in G/G
mice. Conclusions: Gliadin sensitivity in HLA-DQ8 mice leads to immune activation and
altered microvilli structure. Before the establishment of a chronic lesion, gliadin sensitivity
induces cholinergic dysfunction and a pro-secretory state that may lead to altered water
movements and dysmotility. These findings may provide a biological basis to explain why
gluten exclusion may be useful in a proportion of non-celiac patients with gluten sensitivity
and functional gut symptoms.
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PKA Independent Mechanism of Epithelial Cl Secretion Involving Epac-Rap2-
PLC-Ca2+ Signaling in T84 Cells
Mirajul H. Kazi, Damian B. Van rossum, Chung-ming Tse
Ca2+ and cAMP are second messengers that regulate intestinal epithelial Cl secretion. It has
been assumed that cAMP stimulated Cl secretion is mediated exclusively by PKA. However,
forskolin (FSK), the adenylate cyclase activator has been shown to increase intracellular Ca2+
([Ca2+]i) by unknown mechanisms. Epac is a recent discovered protein activated by cAMP
but its action is independent of PKA. Therefore, we studied the role of Epac in PKA
independent mechanism of FSK stimulated Cl secretion in T84 cells. Monolayers with
Resistance>2000Ω had Cl secretion measured via Ussing chamber under voltage clamp
condition. Addition of FSK caused an increase in Cl secretion measured as an increase in
short-circuit current (Isc). FSK stimulated Cl secretion was inhibited by PKC inhibitor, 5μM
GO6976 (ΔIsc 18 ± 3μA vs. 28 ± 5μA; P<0.05) and by the PKA inhibitor H-89(1μM) (ΔIsc
13 ± 2μA vs. 32 ± 2μA; P<0.01). Complete inhibition of Cl secretion was obtained either
by the combination of GO6976 plus H-89(1μM) or by 50μM H-89, at this concentration
H-89 inhibits both PKA & PKC. This suggested that FSK stimulated Cl secretion was both
PKA dependent and independent. FSK stimulated Cl secretion was also inhibited by BAPTA/
AM (Δ Isc 16 ± 2μA vs. 29 ± 4μA; P<0.001), an intracellular calcium chelator, the PLC
inhibitor U73122 (ΔIsc 20 ± 2μA vs. 32 ± 4μA; P<0.01) and the IP3 induced Ca2+ release
inhibitor 2-ABP (ΔIsc 11± 2μA vs. 28±2μA; P<0.01). [Ca2+]i measurement by Fura-2/AM
demonstrated that FSK caused a sustained elevation of [Ca2+]i (Δ[Ca2+]i 42 ± 15nM). In
the absence of extra-cellular Ca2+, FSK increased [Ca2+]i transiently but re-introduction of
1.8mM extra-cellular Ca2+ recovered the sustained phase. Both transient & sustained rise
of [Ca2+]i were inhibited by U73122. These findings suggested PLC mediated Ca2+ signaling
was involved in FSK stimulated Cl secretion. By western blot and RT-PCR, Epac1 was found
expressed in T84 cells. The Epac agonist, 8pCPT-2'-O-Me-cAMP stimulated Cl secretion,
and this was inhibited by BAPTA/AM but not by 1μM H-89. The PKA activator, Sp-8pCPT-
cAMP stimulated Cl secretion and the 8pCPT-2'-O-Me-cAMP's effect was additive with Sp-
8pCPT-cAMP. It has been shown that Rap2 activates PLCε/Ca2+ signaling. We further
demonstrated that, FSK and 8pCPT-2'-O-Me-cAMP activated Rap2; suggesting that Epac1
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and Rap2 linked cAMP into PLC/Ca2+ signaling in this secretory process. We conclude that
cAMP mediated intestinal Cl secretion is caused by the sum of PKA dependent & PKA
independent events and the latter are mediated through Epac1-Rap2-PLC-Ca2+ signaling.
932
Nkcc1, a Master Regulator of Intestinal Fluid Secretion,Is Regulated By
Acetylcholine Stimulated Cycles of Transporter Endocytosis, Degradation and
RE-Expression
Amy Reynolds, Alyson Parris, Luke Evans, Richard Tighe, Bill Stebbings, Kevin Sargent,
Mike Lewis, Mark Williams
Intestinal fluid secretion is driven by transcellular active transport of chloride. Signific-
antly,calcium mediated chloride secretion is transient in nature. NKCC1 mediates basolateral
uptake of chloride and is emerging as a master controller of fluid secretion. Observations
in our laboratory have recently demonstrated that cholinergic calcium signals stimulate
NKCC1 transporter internalisation. AIMS: To investigate the cellular signals for NKCC1
endocytosis and determine the fate of internalised transporter protein. METHODS: Crypts
were isolated from tissue biopsies obtained at sigmoidoscopy from healthy-subjects (Ethical
approval). Isolated crypts were attached to collagen-coated coverslips and cultured for 24
hours- 3 days in serum-free DMEM (5%CO2/37oC). NKCC1 expression was probed for
using a panel of polyclonal antibodies. Co-localisation with lysosomes was investigated by
co-labelling with a LAMP-1 monoclonal antibody. Labelling was visualised using appropriate
ALEXA conjugated secondary antibodies in conjunction with confocal microscopy. For
calcium imaging experiments colonic crypts were loaded with the calcium-sensitive dye
Fura2-AM. Transporter activity was assessed by monitoring the rate of plateau phase acid-
ification following addition of the ammonia ion (40 mM), a substrate for NKCC1. RESULTS:
NKCC1 was expressed on basolateral membranes along the crypt axis, with predominant
labelling at the crypt-base. Acetylcholine (ACh) stimulation (10μM, 30 mins) led to a loss
of membranous NKCC1 and a striking accumulation of NKCC1 at the apical pole of cells
lining the crypt-axis. Labelling of internalised NKCC1 protein and LAMP-1 was co-incident.
Cellular NKCC1 labelling was absent 1 hour post-stimulation. Transporter expression was
restored to resting levels after 5 hours stimulation with ACh. In the short-term, NKCC1
internalisation was inhibited by pre-incubation with the EGFR kinase inhibitor tyrphostin
AG1478 (1μM) or with an EGFR neutralising antibody. In the long-term, transporter re-
expression was inhibited by cyclohexamide (100μM) pre-treatment. Measurements of
NKCC1 activity were congruent with membrane transporter labelling. CONCLUSION:
NKCC1, a master regulator of intestinal fliud secretion, is regulated by acetylcholine stimu-
lated cycles of transporter endocytosis, degradation and re-expression. Transporter internalis-
ation is dependent on EGFR signalling, and protein synthesis is required for transporter re-
expression. The NKCC1 transporter life cycle phenomenon permits fluid secretion that is
commensurate with flushing of the crypt lumen, while providing a safety mechanism to
limit fluid loss.
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Jnk Mapk Downregulates Ca2+-Dependent Chloride Secretory Responses in
T84 Colonic Epithelial Cells
Fergal Donnellan, Brian J. Harvey, Frank E. Murray, Stephen J. Keely
Introduction: Neuroimmune agonists that act at G protein-coupled receptors (GPCRs) induce
Cl- secretion across colonic epithelia through elevations in intracellular Ca2+ or cAMP. Our
previous studies have demonstrated that GPCR agonists also induce transactivation of the
epidermal growth factor receptor (EGFr) and subsequent activation of ERK and p38 mitogen-
activated protein kinases (MAPKs). This pathway limits secretory responses to Ca2+, but not
cAMP-dependent agonists. c-Jun N-terminal kinase (JNK) is also a member of the MAPK
family but its role in regulating secretion is unknown. Aim: To examine the role of JNK in
regulating Ca2+ and cAMP dependent colonic Cl- secretion. Methods: Monolayers of T84
colonic epithelial cells were grown on permeable supports. Protein phosphorylation was
analyzed by Western blotting. Cl- secretion was measured as changes in short-circuit current
(Isc) across voltage-clamped T84 cells in Ussing chambers. Results: Western blot analysis
revealed that a prototypical Ca2+-dependent secretagogue, carbachol (CCh; 100 µM), induced
phosphorylation of both the 46kDa and 54kDa isoforms of JNK (n = 7; p < 0.01). Thapsigargin
(TG; 2µM), which specifically elevates intracellular Ca2+, mimicked the effects of CCh on
JNK phosphorylation (n = 5; p < 0.01). However forskolin (FSK; 10 µM), which elevates
cAMP, did not. CCh induced JNK phosphorylation was attenuated by the EGFR and ERK
inhibitors, tyrphostin AG1478 (1µM) and PD98059 (25µM), respectively. Pretreatment of
voltage-clamped T84 cells with SP600125 (2µM), a specific JNK inhibitor, but not an inactive
analog, potentiated Isc responses to both CCh and TG. Maximal responses to CCh in
SP600125-pretreated cells were 54.1± 5.8 µA/cm2 compared to 34.0 ± 3.5 µA/cm2 in control
cells (n = 6; p < 0.01), while responses to TG in SP600125-pretreated cells were 44.0 ±
5.5µA/cm2 compared to 28.5 ± 2.4 µA/cm2 in paired controls (n = 6; p < 0.05). SP600125
did not alter responses to FSK. Finally, following apical membrane permeabilization by
amphotericin (100 µM), SP600125 did not alter CCh-induced K+ currents across the basolat-
eral membrane. Conclusion: JNK MAPK limits the extent of Ca2+-, but not cAMP-dependent
Cl- secretion in colonic epithelia. JNK activation is mediated by transactivation of the EGFr
and ERK MAPK. The precise mechanisms by which JNK exerts its antisecretory effects
remain to be determined but do not appear to involve inhibition of K+ channels in the
basolateral membrane. These data increase our understanding of the molecular mechanisms
that regulate intestinal secretion and point to the MAPKs as potential targets for future
therapy of intestinal transport disorders.
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Claudin-1 Expression in Squamous Epithelium - A Molecular Marker for the
Differentiation Between Erosive and Non-Erosive Reflux Disease?
Thomas Wex, Dörthe Küster, Klaus Mönkemüller, Lucia Fry, Sven Kolfenbach, Antje
Stahr, Simone Völkel, Albert Roessner, Peter Malfertheiner
INTRODUCTION: Occludin, ZO-proteins and claudins are structural components of tight
junctions and regulate epithelial barrier function. There is limited knowledge about the
expression patterns of these proteins in relation to gastroesophageal reflux disease (GERD).
AIM: To investigate expression patterns of occludin, ZO-1, ZO-2, claudin-1 and -2 in cardia
and esophageal mucosa of patients with GERD. PATIENTS AND METHODS: 97 patients
with GERD-related symptoms and 31 subjects with dyspeptic symptoms excluding GERD
(reference group) were included. None of the subjects were treated with proton pump
inhibitors. The presence of Barrett's mucosa was an exclusion criterion. GERD comprised
45 and 52 patients with non-erosive (NERD) and erosive reflux disease (ERD, mostly Los
Angeles grade A and B), respectively. Multiple biopsies were taken from stomach and
squamous epithelium of each patient for histology and molecular analyses. The gene expres-
sion patterns of junctional proteins were analyzed by quantitative RT-PCR, semiquantitative
immunohistochemistry (IHC) and statistically evaluated by non-parametric Mann-Whitney
U test. RESULTS:Independent of the endoscopic appearance, expression levels of occludin,
ZO-1, ZO-2 were moderately upregulated (1.3 - 1.8 fold) in cardia and esophageal mucosa
of patients with GERD compared to reference group. Claudin-1 and -2 were distinctly
expressed with respect to location and the presence of GERD. Claudin-1 transcript levels were
about 10-fold higher in esophageal than cardia mucosa (P<0.0001). Claudin-1 expression was
2- and 3.1-fold upregulated in the esophageal mucosa of NERD and ERD, respectively
(P<0.02). IHC analysis demonstrated a significant upregulation of claudin-1 in the esophageal
mucosa of patients with ERD. Immunohistochemical score of claudin-1 staining in esophageal
mucosa were 1, 2 and 6 in reference, NERD and ERD, respectively (P<0.001). In contrast,
claudin-2 transcript level was 6.6-fold higher in cardia than esophageal mucosa (P<0.001),
and was found to be induced between 1.6- and 5-fold at both locations and similarly in
NERD and ERD (P-values: 0.005-0.25). CONCLUSIONS: GERD is associated with moderate
increase of junctional proteins such as occludin, ZO-1, ZO-2 and claudin-2 in cardia and
esophageal mucosa. Claudin-1 expression is specifically induced in squamous epithelium
of patients with erosive reflux disease and might represent a putative molecular marker for
differentiating NERD vs. ERD.
935
Dilated Intercellular Space Diameters of Esophageal Epithelium in Nerd
Patients with Typical Symptoms Resistant to PPI Therapy
Mentore Ribolsi, Renato Caviglia, Massimo Gentile, Sara Emerenziani, Carla Rabitti, Maria
chiara Addarii, Michele P. Guarino, Michele Cicala
Background and aim: Dilation of intercellular space diameters (ISD) of the esophageal
epithelium, assessed at electron microscopy, is likely to be an objective marker of GERD
symptoms in non erosive reflux disease (NERD) patients responder to proton pump inhibitor
(PPI) treatment. In these patients, it has been demonstrated a complete recovery of dilation
of ISD, together with heartburn resolution, following PPI therapy. Until now, no data are
available concerning the occurrence of ultrastructural alterations in NERD patients non
responder to PPI treatment and it represents the aim of the study. Methods: 10 NERD
patients (F6, mean age 48 years), presenting with typical symptoms resistant to PPI treatment
(<50% of symptom improvement following 4 week esomeprazole therapy at standard dose,
BID) underwent 24h pH-impedance (pH sensors placed at 5 cm above LES and 10 cm
below LES) and upper endoscopy while on PPI therapy. Patients filled out a standardized
questionnaire before and during therapy. Two biopsy specimens were taken, one at 5 cm
above LES and one at 10 cm below UES. From each specimen, 100 ISDs were measured,
in a blind fashion, by computer morphometry. Data concerning mean ISDs values were
compared with those obtained from 33 NERD patients off therapy and 12 asymptomatic
volunteers. Results: Acid exposure time of distal esophagus was within the normal range in
all 10 patients, analysis of gastric pH confirmed the compliance and effectiveness of treatment.
Symptom index was positive in 1 out of 10 patients. Weakly acid refluxes were prevalent
(83%). Mean ISD values are in Table. In all non responder patients ISDs were significantly
greater both at distal and proximal esophageal level compared to those of asymptomatic
volunteers and individual confidence intervals (CI) of ISD values were widely separated
from those in controls. Conclusions: Dilation of ISDs at distal and proximal esophagus
occurs in patients resistant to PPI therapy. Similar ISD values at proximal esophagus have
been observed in non responder patients on therapy and in symptomatic patients off therapy.
It can be hypothesized that in non-responder patients there is an “intrinsic” vulnerability
of the esophageal mucosal barrier accounting for the enhanced sensitivity to weakly acid
reflux and/or other chemical/mechanical stimuli. *p<.01 vs volunteers §p<.01 vs responders
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Clinical Course of Patients with Non-Erosive Gastroesophageal Reflux Disease
(NERD) On Step-Down Acid Suppressive Therapy: A Prospective Cohort
Study
Justin Wu, Jessica Ching, Kim Au, Sunny Chu, Cynthia Cheung, Yawen Chan, Francis k
L. Chan, Joseph Sung
Aim: The long-term clinical course of NERD patients after initial response to proton pump
inhibitor (PPI) therapy is unclear. We conducted a prospective cohort study to compare
the effectiveness of step-down therapy in patients with NERD and erosive esophagitis (EE).
Methods: Consecutive patients with weekly attacks of heartburn and/or acid regurgitation
were prospectively recruited for symptom evaluation and EGD. EE was defined by LA
classification. Hiatus hernia and H. pylori status were determined by EGD. Exclusion criteria
included gastric surgery, peptic ulcer, recent NSAID or PPI use. Patients with NERD and
grade A/B esophagitis at baseline EGD and complete symptom response to PPI were enrolled
to step-down therapy at 16-weeks intervals (in descending order: daily PPI, on-demand PPI,
daily H2-receptor antagonist (H2RA), on-demand H2RA, on-demand antacids) to maintain
patient-reported adequate relief of reflux by global symptom assessment. EGD was repeated
if there was alarm symptom or inadequate symptom relief by previous effective regimen.
Results: 376 NERD (mean age: 50.3±12.3) and 176 EE patients (mean age: 55.0±14.5, p=
0.002) were studied (mean follow-up: 45±25 months). NERD patients had more severe
baseline symptom (p=0.01), higher prevalence of female gender (68% Vs 36%, p<0.001),
dyspepsia (54% Vs 38%, p<0.001) and IBS (31% Vs 21%, p=0.02). 106 (28.6%) NERD
and 67 (38.7%) EE patients (p=0.02) failed step-down therapy and required regular PPI.
NERD patients also had adequate symptom relief with lower strength of step-down therapy
(p=0.04, see Table). Using multivariate analysis, baseline symptom severity was the only
predictor of failed step-down therapy in NERD patients (p=0.001). 38 (10.1%) NERD
patients Vs 32 (18.2%) EE patients required repeated EGD and grade A esophagitis was
found in 3 (0.8%) NERD Vs 22 (12.5%, p<0.001) EE patients, respectively. Conclusion:
Despite more severe baseline symptom and co-morbidities, NERD patients have higher
success rate of step-down therapy than EE patients in long-term management. Esophagitis
was uncommon and mild in NERD patients with symptom relapse on step-down therapy.
Percentages were presented in ( ).
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Increased Esophageal Muscle Thickness in Patients with Non-Erosive
Gastroesophageal Reflux Disease
Toshihiko Tomita, Takashi Kondo, Chizuko Hayashi, Junji Tanaka, Yongmin Kim,
Noriyasu Yamamoto, Nobuyuki Hida, Tadayuki Oshima, Kazutoshi Hori, Takashi
Sakagami, Takayuki Matsumoto, Hiroto Miwa
Background and Aim Non-erosive gastroesophageal reflux disease (NERD) is defined as
the presence of reflux symptoms in the absence of endoscopic mucosal damage. Pathophysiol-
ogical mechanism of NERD is heterogeneous and still unknown. Recently some investigators
reported that excessive esophageal muscle thickness has been reported to be associated with
heartburn. However, it is not yet clear the relationship between NERD and esophageal
muscle thickness. The aim of this study was to investigate the baseline esophageal muscle
thickness in both NERD patients and healthy volunteers, and to ascertain whether the
esophageal muscle thickness could be changed by acid perfusion in both groups. Materials
and Methods Six NERD patients and eight healthy volunteers underwent the acid perfusion
test. A double lumen gastric tube was inserted via the nasal route and placed at the middle
portion of the esophagus (15cm above the lower esophageal sphincter: LES). Acid (0.1M)
was applied at this location at a rate of 8 ml per minute for 12 minutes (after two minutes
application of saline). An ultrasonographic transducer was inserted into the second lumen
at a depth of 5 cm above LES, where thickness of the esophageal muscle was monitored
and measured. Heartburn intensity was evaluated in real-timely using a visual analogue
scale. Baseline esophageal muscle thickness was measured during the initial two minutes of
saline perfusion. Alteration of the esophageal muscle thickness after acid perfusion was also
measured in both NERD patients and healthy volunteers. Results Based on results from
acid perfusion test, six NERD patients had severe heartburn. In the eight healthy subjects,
four had moderate to severe heartburn while the remaining four subjects had zero to mild
symptoms. Baseline esophageal muscle thickness in the NERD patients (1.52±0.51 mm,
mean+SD) was significantly greater (p<0.05) than in the healthy volunteers (1.06±0.18 mm).
Esophageal muscle thickness after acid perfusion in the NERD patients (1.54±0.40 mm)
was also significantly greater (p<0.05) than in the healthy volunteers (1.05±0.18 mm).
However, in patients with NERD, esophageal muscle thickness was not significantly changed
by acid perfusion. Esophageal muscle thickness in healthy volunteers was also not significantly
altered by acid perfusion. Conclusions Baseline esophageal muscle thickness is increased
more in NERD patients than in healthy volunteers, yet acid perfusion did not thicken
esophageal muscle in both groups, suggesting that contraction of esophageal muscle is not
directly associated with symptom generation.
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24-Hour Ambulatory Intraluminal pH-Impedance in Patients with Non Erosive
Reflux Disease (NERD)
Patrizia Zentilin, Domenico Della casa, Michela Fanucchi, Pietro Dulbecco, Guido
Missale, Edoardo Savarino, Daniel Pohl, Andrea Parodi, Stefano De conca, Radu Tutuian,
Renzo Cestari, Vincenzo Savarino
Introduction: Is well recognized that NERD is the most common form of gastro-esophageal
reflux disease (GERD). While the role of acid reflux has been established the role of non-
acid reflux in generating symptoms in NERD patients is unknown. Aim: Aim of our study
was to evaluate the diagnostic role of 24-hour multichannel intraluminal impedance com-
bined with pH-metry (MII-pH) in patients with NERD studying the physical and chemical
properties of gastro-oesophageal refluxate. Methods: We evaluated 79 consecutive patients
with endoscopic NERD, (40 F, median age 49 years - range 20-74) and 27 control subjects
(14 F, median age 29 years - range 22-67) using MII-pH. Fifty-one patients had typical and
28 atypical reflux symptoms. At the time of the examination patients were off PPI therapy
for at least 30 days. During ambulatory impedance pH-metry refluxate presence was measured
at 3, 5, 7, 9, 15 and 17 cm above the LES and esophageal pH at 5 cm above the LES. We
calculated esophageal acid exposure (% time ph < 4), number of impedance detected reflux
episodes (acid, weakly acidic; liquid, mixed) and symptom association using the 5-min
window symptom index (SI). Results: All reflux episodes in the upright position contained
gas (i.e. gas only or mixed gas-liquid), while all reflux episodes in recumbent position
contained liquid (i.e. liquid only or mixed). Compared to healthy volunteers, NERD patients
with a positive SI had a higher number of non-acid reflux episodes (p=0.006) and a higher
number of reflux episodes extending into the proximal esophagus (p = 0.002). Thirty-eight
(48%) patients had an abnormal distal esophageal acid exposure (% time pH < 4) out of
whom 21 (55%) had a positive SI. In the group of NERD patients with a normal distal
esophageal acid exposure 17/41 (41%) had a positive SI. Out of these 9 (53%) NERD
patients with a normal acid exposure had a positive SI for weakly acidic reflux. In the group
of NERD patients with normal acid exposure and negative SI, 3/8 complained of heartburn
and 5/8 had atypical reflux symptoms. Conclusions: The liquid and gas composition of
gastroesophageal reflux episodes varies with the body position. Moreover, non-acid reflux is
common in NERD patients and would have been overlooked by conventional pH monitoring.
Monitoring for non-acid reflux in NERD patients increases the sensitivity of identifying
patients in whom symptoms are associated with reflux, thereby reducing the proportion of
patients labelled as having “functional heartburn”.
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Functional Heartburn and Non Erosive Reflux Disease: Different Patient
Profiles and Distinct Predictors of Symptoms
Tiberiu Hershcovici, Joseph Zimmerman
The mechanism(s) of symptoms in patients with functional heartburn (FH) are poorly
understood. We have analyzed the predictors of symptoms in such patients in relation to
patients with non-erosive reflux disease (NERD). Methods: Consecutive patients (n=330)
who completed a 24h esophageal pH monitoring for the evaluation of heartburn/regurgitation
were studied in a prospective, case-control design. Sources of referral were multiple and
unrelated to this research. All patients had had normal findings on upper endoscopy. Patients
with a Demeester score≤10 were classified as FH, while these with a score≥23 were defined
as NERD. (These scores correspond to the lower and upper 2 quartiles respectively). Reflux
symptoms were scored on a validated scale (1) and bowel symptoms-on 3 validated scales
(constipation, diarrhea and pain/gas symptoms) and on a weighted, composite score on
these scales (CBS) that was 89% sensitive and 93% specific in discrimination of IBS patients
from controls (2). The association between reflux symptoms, esophageal acid exposure and
other predictor variables was assessed by multivariate analysis. Results: FH (n=87) and
NERD patients (n=160) were similar in mean age (44.1±1.6 and 45.2±1.3) and % smokers
(14 and 21% respectively; p=0.34). However, 61% of FH patients were females compared
with 35% of NERD patients (p<0.001). The % of total monitoring time with a pH<4 in the
esophagus was 1.2±0.1 in FH and 13.4±0.6 in NERD. The scores of reflux symptoms in
the two groups were 49.6±2.3 and 62.7±1.7 respectively (p<0.001). By contrast, the scores
on the 3 bowel scales were similar. In both groups, reflux symptoms were independently
associated with CBS (p=0.011 and <0.001 for FH and NERD respectively). A significant
interaction was found in the effect of age on the relationship between esophageal acid
exposure and reflux symptoms (p<0.001). While in FH, reflux scores were inversely related
to age (p=0.002), the opposite was true for NERD (p=0.003). Smoking was independently
associated with reflux symptoms only in NERD (p=0.009). In both groups, gender and
esophageal acid exposure were not predictive of symptoms. Conclusions: 1: Disparate distri-
bution according to sex and an opposite relationship between reflux symptoms and age in
FH and NERD indicate that these two groups may be distinct. 2: In both FH and NERD,
bowel symptoms were the strongest predictors of reflux symptoms whilst esophageal acid
exposure was not related to these symptoms. References: 1: Scand J Gastroenterol, 2004;
39:212-216. 2: Dig Dis Sci, 2003; 48:743-749.
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Is Asking “How Are You Doing?” Enough to Capture Health Related Quality of
Life (HRQOL) and Overall Severity in Irritable Bowel Syndrome (IBS)?
Brennan M. Spiegel, Lin Chang, Fasiha Kanwal
Background: HRQOL and overall severity are key outcomes in the management of IBS.
Although several multidimensional scales have been developed to measure these outcomes,
these questionnaires are rarely used in everyday practice due to time and resource constraints.
Instead, most providers gauge overall HRQOL and severity by using the so-called “SF-1” -
namely, “How are you doing?” Although this approach is conceptually appealing, it remains
untested whether a single question can adequately capture HRQOL and severity in IBS. If
so, it would suggest that using validated instruments provides diminishing returns, as argued
by some skeptics, and is therefore unnecessary in clinical practice. Methods: We performed
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a cross-sectional analysis in a group of Rome II IBS patients recruited from a network of 8
geographically diverse centers throughout the U.S., including 5 universities, 2 community
practices, and 1 managed care practice. All patients completed standardized bowel symptom
and HRQOL questionnaires. We measured correlations between a single global health ques-
tion and 2 outcomes: HRQOL and severity. We measured global health with the SF-36
general health item: “In general, how would you say your health is?” (1-5 scale: “excellent” to
“poor”). We measured HRQOL with the IBS-QOL, a validated 34-item instrument (0-100;
100=best), and measured severity with a 10cm visual analog scale (VAS) and a previously
validated severity index, the “B.E.S.T.” questionnaire (0-100; 100=worst). We performed
univariate and multivariate models to measure the proportion of variance in each outcome
explained by the general health item. Results: 125 patients were enrolled. The average age
was 50, and 56% were women. The mean IBS-QOL, VAS, and BEST scores were 56+23,
5.9cm+2, and 41+22, respectively. The mean general health Likert response was 3.5+0.9.
In univariate analysis, the general health question explained 14% of the variance in HRQOL
(p<0.01). Similarly, it explained only 4% and 25% of the VAS and BEST scores, respectively
(both p<0.01). In a multivariable model adjusting for age, gender, IBS sub-type, and coping,
the general health item lost statistical significance in explaining IBS-QOL (p=0.18) and VAS
(p=0.91) scores, but remained significant for BEST (p=0.02). Conclusions: A single global
health question captures no more than 1/4th the information provided by validated HRQOL
and severity instruments in IBS. The “SF-1 approach” may be necessary, but not sufficient,
to fully understand the overall HRQOL and severity burden of illness. This highlights the
need to develop concise, rapidly completed, point-of-care HRQOL and severity indices in IBS.
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Global Measure of Adequate Relief Predicts Clinically Important Difference in
Pain and Is Independent of Baseline Pain Severity in Irritable Bowel
Syndrome (IBS)
Vanessa Z. Ameen, Amy T. Heath, David Mcsorley, Brennan M. Spiegel, Lin Chang
Background: IBS is characterized by multiple symptoms, e.g. abdominal pain and altered
bowel habits, and thus, a global outcome is widely used and accepted as the primary
endpoint in clinical trials. Adequate relief of abdominal pain and discomfort (AR) is sensitive
to treatment effects and has been validated in IBS as a global measure which differentiates
responders from nonresponders with regard to pain severity, urgency and stool frequency
(Mangel, J Int Med Res 1998). Recently, a global endpoint such as AR was reportedly
influenced by baseline overall IBS severity in a longitudinal observational study in an HMO
(Whitehead, AJG 2006). Aims: To determine if AR: 1) predicts clinically important differences
(CID) in pain severity, 2) varies by baseline pain severity, and 3) is a treatment response
measure which varies by baseline pain severity. Methods: We retrospectively analyzed data
from two 12-wk, multicenter, phase III trials comparing the efficacy of study drug (Med,
n=632) vs. placebo (Pbo, n=637) in 1269 female IBS patients (pts). Pain severity was self-
rated using a Likert scale (0-none, 4-severe). Baseline severity was assigned as: mild <1.5;
moderate 1.5-<2.5; severe ≧2.5. AR was defined as a “yes/no” response at wk 12 to the
question “In the past 7 days, have you had adequate relief of your IBS pain and discomfort?”
Main analyses were: 1) sensitivity (Sens), specificity (Spec), positive (PPV) and negative
predictive values (NPV) of AR on CID, defined at wk 12 as: a) ≧50% improvement in pain
score and b) an absolute improvement of ≧0.5, i.e. ≧½ standard deviation of change in
pain for all patients (½ SD)(Norman, Med Care 2003); 2) % of pts with AR by baseline
pain severity; and 3) treatment effects for AR by baseline pain severity. Significance was
assessed at α=0.01. Results: AR was a good predictor of CID in IBS pain severity (see table).
There were 342 (27%) pts with mild baseline pain severity, 662 (52%) moderate, and 265
(21%) severe. Pain severity did not affect % of pts who reported AR- mild: 50.3, moderate:
47.6, and severe: 42.3% (p=NS). Beneficial treatment effects for AR were similar across pain
severity levels (Med vs. Pbo)- mild: 58.4 vs. 42.6%, moderate: 52.8 vs. 42.0%, and severe:
52.0 vs. 33.8% (p=NS). Conclusions: Adequate relief is a good predictor of clinically
important improvement in pain severity in IBS. In clinical trials, the proportion of patients
who report AR, and the treatment effects for AR are comparable across baseline pain
severity levels.
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Women with Irritable Bowel Syndrome: Pelvic Floor Disorders and Associated
Quality of Life
Jennifer Y. Wang, Madhulika G. Varma, Jennifer Creasman, Leslee Subak, Jeanette Brown,
David Thom, Stephen Vandeneeden
Background: Patients with irritable bowel syndrome (IBS) have abdominal pain, bloating,
and variable bowel habits that may put them at risk for pelvic floor disorders, including
urinary incontinence (UI), pelvic organ prolapse (POP), and sexual dysfunction. We deter-
mined the independent association of IBS with these pelvic floor disorders and their related
quality of life. Methods: The Reproductive Risks for Incontinence Study at Kaiser Permanente
is a population-based study of 2109 randomly selected, racially diverse women (mean age
56 ± 9 years). All variables and potential risk factors were assessed by self-report, interview,
and/or physical exam. Participants responded either “yes” or “no” in a questionnaire as to
whether they ever had IBS. Factors known to be associated with pelvic floor disorders and
altered sexual function were determined a priori and examined for their association with IBS.
Next, multivariate regression analyses were used to determine the independent association of
IBS with the outcomes of various pelvic floor disorders or quality of life. Other predictors
used in these models in addition to IBS included factors that were associated with IBS at
p<0.2 level (white race, diabetes, >1 urinary tract infection in the last year, hysterectomy,
pelvic organ prolapse surgery, colon surgery, UI, and symptomatic POP). Results: The
prevalence of IBS in this cohort was 8% (n=204). Women with IBS had higher odds of
symptomatic POP (OR 2.5; 95% CI 1.5-4.2) and urinary urgency (OR 1.4, 95% CI 1.0-
2.0). Compared to women without IBS, women with IBS reported greater bother from
symptoms of POP (OR 7.6; 95% CI 2.2-25.6), UI (OR 2.1; 95% CI 1.3-3.4), and fecal
incontinence (OR 1.7; 95% CI, 1.0-2.9); and lower SF-36 mental and physical component
scores (p<0.01). Women with IBS were also more likely to report an inability to relax and
enjoy sexual activity and difficulty in having an orgasm (OR 1.9; 95% CI 1.2-2.8 and OR
1.5; 95% CI 1.0-2.3) and to give a low rating to their overall sexual satisfaction (OR 1.7;
95% CI 1.2-2.5). Conclusion: Women with IBS are more likely to have pelvic floor disorders
and are markedly more bothered by them. They also have sexual dysfunction and lower
quality of life. Therefore, it is important to address not only bowel symptoms, but also other
pelvic floor functions when assessing patients with IBS.
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Accelerated Small Bowel Transit and Contracted Transverse Colon in
Diarrhoea-Predominant Irritable Bowel Syndrome (IBS-D): Novel Insights from
Magnetic Resonance Imaging (MRI)
Luca Marciani, Steve Foley, Caroline L. Hoad, Eugene Campbell, John J. Totman, Eleanor
Cox, Penny A. Gowland, Robin C. Spiller
BACKGROUND: IBS-D patient's symptoms of urgent loose stools with bloating are often
exacerbated by meals but current techniques to objectively measure the underlying abnormal-
ities are difficult for patients to tolerate. Recent developments in MRI permit non-invasive,
patient-acceptable monitoring of small and large intestinal volumes and water signal before
and after meals under physiological conditions [1]. AIMS: To assess fasting colon volumes,
gastric emptying, postprandial small bowel water content (SBWC) and oro-cecal transit time
(OCTT) and response of the colon to a bran-containing meal known to provoke bloating
in IBS patients. METHODS: 18 IBS-D patients (8 male, 10 female) and 16 healthy controls
(8 male, 8 female) attended having fasted overnight. After fasting scans they ate a standard
331 kcal rice pudding with 15 g of coarse wheat bran. Serial MRI imaging was then performed
at 45 min intervals for 4.5 hours. Bowel water content was calculated by integrating all
image pixels containing water signal above a given threshold [1] as previously validated.
OCTT was assessed from the time of arrival of the head of the meal in the cecum. An
intestinal flow index (IFI) was calculated from SBWC at t=225min / OCTT. RESULTS:
(mean±SEM) The fasting transverse colon diameter (FTCD) was smaller for the patients
(24±1 mm) than for the controls (27.0±0.7 mm), p=0.055. Post-prandial, bran-stimulated
SBWC at 225 minutes was significantly higher than baseline (111±13 versus 70±10, p<0.009)
in the IBS patients but not in the controls (p<0.247). IBS-D showed significantly faster
OCTT of the meal which was 133±11 min versus control 239±15 min (p<0.001). The IFI
was higher in the patients (0.9±0.1 ml/min) than in the controls (0.58±0.07 ml/min), p<0.02.
10 patients showed marked increase in the transverse colon diameter (“mass movement”)
45 minutes postprandially. 7 IBS-D patients reported abnormal postprandial bloating (>
control's mean +2SD). 8 patients had contracted transverse colons with diameter ranging
from 15.5 to 21.9 mm, of which 5 reported abnormal bloating and 4 also showed a
“mass movement”. CONCLUSION: IBS-D patients show smaller fasting colonic diameter,
accelerated small bowel transit and increased postprandial SBWC, which when combined
with increased “mass movements” are likely to contribute to the postprandial urgency and
loose stools characteristic of such patients. MRI is a patient acceptable method which has
great potential for defining pathophysiology of symptoms and objectively evaluating treatment
efficacy. 1. Marciani L et al. Gastroenterology 130(4):A743, 2006.
944
Safety and Efficacy of Crofelemer in Patients with Diarrhea Predominant
Irritable Bowel Syndrome (D-IBS)
Anthony J. Lembo, David P. Rosenbaum, William D. Chey, Douglas A. Drossman
Background: Crofelemer is an oligomeric proanthocyanidin purified from the sap of the
plant species Croton lechleri. The red, viscous sap is known for its medicinal properties and
local health-healers from South America consider the crude sap orally therapeutic for the
relief of diarrhea among other diseases. Objectives: To evaluate the safety, and efficacy of
crofelemer in men and women with d-IBS. Methods: A randomized double-blind placebo-
controlled, dose-ranging (0, 125, 250, and 500 mg bid) 12-week treatment trial was per-
formed in 246 patients (male/female; average age 50 years old) with d-IBS (Rome II criteria).
IBS symptoms (pain, urgency, stool frequency and consistency, and adequate relief) were
self-reported by the patients via an interactive voice response system (IVRS). Patients needed
to exhibit active disease during the 2 week baseline period as defined by a mean daily stool
frequency ≥2/day, pain score ≥1 and stool consistency ≥3 (5-point Lickert scale for pain
and consistency) to be enrolled. Patients received treatment for 12 weeks followed by a 2
week treatment free period. Results: Crofelemer (125 mg bid) exhibited a consistent response
during each month among most efficacy endpoints in women with d-IBS (see table) reaching
statistical significance (p<0.05) for pain. Crofelemer had little effect on stool consistency
score though there was a trend toward reduced stool frequency. Treatment benefits were
not apparent in men although relatively few men enrolled in the trial (13-16/group). No
drug-related serious adverse events were reported. Adverse event rates were similar across
all dose groups although in the two highest doses (250 and 500 mg bid) there were a higher
percentage of dropouts. There were no drug- or dose-related differences in constipation.
During the 2 week treatment-free follow-up period symptoms approached baseline levels.
Conclusion: Crofelemer, 125 mg bid, was safe and led to significant improvement in pain,
and trends toward improvement in adequate relief, stool frequency, and urgency. These
results warrant further investigation of crofelemer for the treatment of women with d-IBS.
Efficacy of Crofelemer 125 mg bid in Females
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1Month 3 results; observed case analysis with disease outliers (mean baseline frequency >9
stools/day) removed from all groups. *statistically significant at p< 0.05
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The Safety Profile of Alosetron Since Reintroduction Under the Risk
Management Program
Eric Carter, Susan H. Gordon, Amy T. Heath, Neil E. Broadwell
Background: The 5HT3 receptor antagonist alosetron hydrochloride was reintroduced for
women with chronic, severe, diarrhea-predominant irritable bowel syndrome (dIBS) in
November 2002, under the auspices of a comprehensive risk management action plan
(RiskMAP). This followed withdrawal from the marketplace after the emergence of infrequent
but serious adverse events (SAEs) of ischemic colitis and severe constipation or complications
of constipation. We review the safety profile of alosetron (ALO) since reintroduction. Methods:
The safety data consist of adverse events (AEs) collected from 2 post-approval clinical trials,
and those reported from use of marketed product (MP) as of 30 June 06. Two multi-center,
randomized, double-blind, parallel studies evaluated the efficacy and tolerability of 12 weeks
treatment with 3 doses of ALO vs placebo (PBO) and ALO PRN and continuous dosing vs
PBO in women with severe dIBS. The MP reports include those spontaneously reported by
patients and physicians, as well as unsolicited reports received via the RiskMAP patient
tracking survey. SAE reporting is required by physicians under the RiskMAP. AEs of special
interest (ESI) include ischemic colitis, serious constipation, and complications of constipation.
Results: Clinical trials: 1,400 women received treatment. Non-serious constipation was the
most common AE (9-16% of ALO pts, 2-4% of PBO pts) and was dose-related. ESI were
not dose-related, and were self-limited and resolved without sequelae. MP: Approximately
21,600 pts have been prescribed ALO. 143 AE reports were medically confirmed and 50
of these were judged to be SAEs. ESI consisted of 15 reports of ischemic colitis with 14
medically confirmed, 6 reports of serious constipation with 2 medically confirmed, and 14
reports of complications of constipation with 5 medically confirmed. There were no reports
of mesenteric infarction or ischemia, and among the ESI, no confirmed surgeries, blood
transfusions or deaths. Conclusion: The safety profile of alosetron defined by medically
confirmed AE reports is now well characterized and has remained stable over the 3.5 years
following reintroduction into clinical practice. Ischemic colitis and severe constipation or
complications of constipation are rarely reported, resolved on prompt withdrawal of therapy,
and have not been associated with clinically significant sequelae.
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CD4+CD25+Foxp3+T Regulatory Cells Can Differentiate Into Th17 and
Induce CD4+CD25-Foxp3- T Cells to Become Th17 Without Exogenous TGF-
Beta
Lili Xu, Atsushi Kitani, Ivan J. Fuss, Warren Strober
Introduction: It has become increasingly apparent that IL-17 plays an active role in the
pathogenesis of inflammation involved in several models of autoimmune disease. Th17 T
cells comprise a distinct lineage of effector CD4+ T cells that have recently been shown by In
Vitro studies to be induced by the combined activity of TGF-β and IL-6. CD4+CD25+Foxp3+
“natural” regulatory T cells play a pivotal role in the suppression of inflammation through
their ability to express cell surface or secreted inhibitory molecules such as TGF-β. Since,
TGF-β is a key factor in IL-17 differentiation, this raises the question of whether regulatory
T cells by themselves can induce T cells to differentiate into IL-17-producing T cells in the
absence of exogenous TGF-β. Methods: In order to perform these studies a Foxp3-IRES-
GFP knockin mouse was fashioned. This animal allows the isolation of highly purified
populations of Foxp3+ T regulatory cells by FACS cell sorting isolation of GFP+/CD4+ cells.
Intracellular staining and secretion by ELISA determined generation of IL-17+ cells. Activation
of CD4+CD25+Foxp3+ was achieved by stimulation with anti-CD3/CD28 mAbs. Results:
In these studies, we demonstrate that upon activation ex vivo CD4+CD25+Foxp3+ produced
high amount of secreted TGF-β however, with the addition of IL-6 (20 ng/ml) In Vitro they
can induce CD4+CD25-Foxp3- T cells upon co-culture to differentiate into IL-17-producing
cells. In a positive control study, CD4+Foxp3- T cells stimulated with rTGF-β (3ng/ml) and
IL-6, 12% of the cell population were IL-17-producing cells whereas the former studies
produced 25% IL-17+ cells, indicating that CD4+CD25+Foxp3+ regulatory T cells were
even more efficient than exogenous TGF-β in the induction of IL-17+ cells. The induction
of IL-17 producing cells was TGF-β dependent since the blockade of TGF-β signaling by
a TGF-βRI inhibitor (ALK5) could block the generation of IL-17 producing cells. Strikingly,
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in the presence of IL-6, CD4+CD25+Foxp3+ T cells themselves could differentiate into IL-
17 producing cells without the addition of exogenous TGF-β, in contradistinction,
CD4+CD25+Foxp3+ T cells were resistant to Th1 polarization. Conclusion: These results
suggest CD4+CD25+Foxp3+ could be a source of IL-17 and that under inflammatory
circumstances (upon activation in the presence of IL-6) CD4+CD25+Foxp3+ could differenti-
ate CD4+ T cells into IL-17 effector cells. Our findings challenge the current therapeutic
role of CD4+CD25+Foxp3+ regulatory T cells in autoimmune diseases.
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Trans-Signaling Via the Soluble IL-6r Suppresses Oral Tolerance By Blocking
the Induction of Foxp3 in Naive CD4+ CD25- T Cells
Massimo C. Fantini, Sabine Hubner, Giovanni Monteleone, Christoph Becker, Markus F.
Neurath
Several lines of evidence sustain that the intestinal chronic inflammation observed in IBD
results from a loss of tolerance towards antigens normally contained in the gut lumen. The
emerging concept is that regulatory cells may be critical in the maintenance of tolerance
towards those antigens while guaranteeing an efficient immune response in case of infection
by pathogens. We have recently shown that the novel class of TGF-beta-induced regulatory
cells, which share many characteristics with the thymus-derived CD4+CD25+ regulatory
prevent colitis when transferred in SCID mice. We now show here that IL-6 produced by
activated DCs prevents the generation and suppressive capacity of TGF-beta-induced regu-
latory T cells In Vitro acting via the naturally occurring soluble IL-6 receptor alpha in a
process called IL-6 trans signalling. Moreover we have investigated the role of IL-6 trans
signaling in an In Vivo model of oral tolerance based on the oral administration of TNBS-
haptenized colonic proteins. Results from these experiments showed that the complex formed
by IL6 and the soluble IL6R alpha effectively prevents the induction of oral tolerance, thereby
promoting colitis after intrarectal rechallenge with TNBS. In further experiments we have
also demonstrated that IL-6 trans signalling prevents the induction of TGF-beta induced
regulatory T cells In Vitro and In Vivo during the homeostatic expansion occurring upon
the transfer of CD4+ naïve cells in immunocompromised Rag1-/- mice. Since TGF-beta
signaling has been shown to be necessary for the peripheral induction of regulatory T cells,
we have investigated the effect of IL-6 trans signaling on the expression of the TGF-
beta-pathway inhibitor Smad7. Indeed Smad7 resulted upregulated upon IL-6/IL6R-alpha
stimulation thus indicating that the inhibition of the peripheral induction of TGF-beta
induced regulatory cells may be at least in part mediated by the inhibition of the TGF-beta
signaling in naïve CD4+ T cells. The role of Smad7 in the modulation of the TGF-beta
mediated induction of regulatory cells was further confirmed by the generation of T cell-
specific Smad7 transgenic mice. IL-6 has been recently shown to be involved in the generation
of TH-17 cells which play a crucial role in the pathogenesis of IBDs. The present work
extends this concept demonstrating that IL-6 trans signaling prevents the peripheral induction
of regulatory T cells by blocking the TGF-beta pathway and that this mechanism may play
a key role in the loss of oral tolerance observed in IBD.
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Epigenetic Regulation of Foxp3 As a New Therapeutic Approach to
Experimental Colitis
Edwin F. Dezoeten, Ran Tao, Engin Ozkaynak, Wayne W. Hancock
Understanding the pathogenesis of inflammatory bowel disease (IBD) requires consideration
of the recently recognized population of naturally occurring CD4+CD25+ regulatory T cells
(Tregs) expressing the transcription factor, Foxp3; e.g. is Treg function impaired in patients
with IBD and how can the therapeutic potential of Tregs be exploited? We are studying the
epigenetic regulation of Foxp3 as therapy for experimental colitis, by inhibition of histone
deacetylase (HDAC) activity using HDACi compounds; inhibition of methylation using DNA
methyltransferase inhibitors (DNMTi); and blockade of ubiquitination and proteasomal
degradation. We report the In Vivo administration of HDACi such as trichostatin-A (TsA)
or valproic acid (VPA) increases the numbers of Foxp3+ Tregs in secondary lymphoid tissues,
and HDACi-treated Tregs have enhanced suppressive function In Vitro. Our biochemical
studies show Foxp3 protein itself is acetylated on multiple lysines in the forkhead domain
following Treg activation, and mutagenesis of those sites impairs Treg function; i.e. Foxp3
acetylation is required for optimal Treg function. We also find Foxp3 acetylation and
deacetylation in Tregs is controlled by recruitment of HDAC2 to Foxp3 via HDAC9, and
HDAC9 shuttles in and out of the nucleus as a result of TCR-dependent signals. Consistent
with these data, Tregs from HDAC2-/- or HDAC9-/- mice show markedly enhanced suppress-
ive function. Applying these molecular insights to IBD, we find HDACi use profoundly
suppresses development of DSS-induced colitis, and depletion of CD4+CD25+ (Treg) by
thymectomy plus CD25 mAb shows this effect is Treg-dependent. Similarly, adoptive transfer
of CD4+CD62L+ cells (containing ~5% CD4+ Foxp3+ cells) to SCID mice leads to colitis
at ~60 days, and compared with DMSO-treated controls, mice treated with TsA after their
development of colitis gained weight, and had negligible diarrhea and near normal histology.
In addition, flow cytometry showed increased CD4+ Foxp3+ cells in mesenteric LN and
increased expression of Foxp3, CTLA-4, PD-1, GITR and IL-10. Lastly, as HDAC9 inhibited
Foxp3-dependent Treg functions In Vitro, we tested HDAC9-/- mice in the DSS model.
Again, HDAC9-/- mice suffered less weight loss and recovered more quickly from colitis
than WT mice (p<0.05). In summary, HDACi use can regulate Foxp3-dependent functions
and enhance Treg suppression with biologically important consequences. Dissecting the
complex interactions of histone acetyltransferases and HDACs is but one of several potential
ways to pharmacologically manipulate Treg cells In Vitro and In Vivo, with likely future
beneficial consequences for the therapy of IBD.
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A Role for the Wiskott-Aldrich Syndrome Protein in the Recruitment and
Homing of CD4+CD25+Foxp3+ Regulatory T Cells to Peripheral Lymphoid
Organs
Michel H. Maillard, Vinicius Cotta-de-almeida, Deanna Nguyen, Pierre F. Michetti, Scott
B. Snapper
Background: Naturally occurring CD4+CD25+Foxp3+ regulatory T cells (nTreg) dysfunction
has been implicated in the pathogenesis of several murine models of inflammatory bowel
disease (IBD). The X-linked immunodeficiency Wiskott-Aldrich Syndrome (WAS) is caused
by mutations in the Wiskott-Aldrich Syndrome Protein (WASP) gene. The majority of WAS
patients develop autoimmunity, including, in some, an IBD-like illness. Likewise, WASP
knockout (WKO) mice spontaneously develop colitis. We recently demonstrated that WKO
mice have reduced numbers of nTregs. Employing the CD45RB transfer model as well as
In Vitro suppression assays, we showed that WKO nTregs are dysfunctional. Since WASP
modulates the actin cytoskeleton, we hypothesized that WKO nTreg dysfunction In Vivo
might be secondary to aberrant recruitment of WKO cells to secondary lymphoid organs
and target tissues. Methods: SCID mice were injected intraperitoneally with 400,000
WTCD45RBhi alone or in combination with 100,000 WT or WKO nTregs and followed
clinically for 8-10 weeks. At sacrifice, the number of nTregs in peripheral lymphoid organs
was determined by FACS. Dosing experiments were performed by varying the number of
WKO nTregs (100,000; low dose or 400,000; high dose) with WT CD45RBhi (400,000)
cells. To explore the relative ability of WKO nTregs to home to target organs, a competitive
homing assay was performed with fluorophor-labeled WKO (TRITC) or WT (CFSE) nTregs
or CD4+CD25- cells that were mixed at a 1:1 ratio and injected intravenously into WT
mice. The relative homing capacity of WKO nTregs or CD4+CD25- cells compared to WT
cells was determined in lymphoid organs of recipient mice by FACS after 12-15 hours.
Results: The numbers of CD4+Foxp3+ cells present in the spleen, mesenteric lymph nodes
and colonic lamina propria of SCID mice after cotransfer of WT CD45RBhi cells and WKO
nTregs was significantly lower than mice transferred with WT CD45RBhi cells and WT
nTregs. Furthermore, WKO nTregs were markedly impaired in their relative ability to home
to lymphoid organs in the competitive In Vivo homing assay. Finally, we observed that the
defects in suppression by WKO nTregs in the CD45RB transfer model of colitis could be
overcome by increasing the number of nTregs at the time of transfer. Conclusions: Defects
in migration and homing of WKO nTregs to target organs may play a role in the pathogenesis
of colitis in WKO mice.
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Interleukin 27 Regulates Immunity By Modulating the Balance Between
Inducible Regulatory T-Cells and Th-17 Cells Via Stat1
Clemens Neufert, Christoph Becker, Stefan Wirtz, Massimo C. Fantini, Benno Weigmann,
Peter R. Galle, Markus F. Neurath
Regulatory T cells (Tregs) play a crucial role in the maintenance of immune homeostasis in
the gut. Recently, we have shown that Tregs can be induced In Vitro from naïve T-cells by
TGFbeta and that these cells (iTregs) are efficient in protecting mice from the development
of experimental colitis. In contrast, the highly pro-inflammatory Th-17-lineage originates
from the same precursors in settings where IL-6 is present in addition to TGFbeta. To date,
factors influencing the balance between iTregs and Th-17 cells have been hardly characterized.
Here we show that IL-27 - upregulated at sites of gut inflammation - can exert pro- or anti-
inflammatory functions by modulating the balance between iTregs and Th-17 cells via
STAT1. CD4+CD25- naïve T-cells were polyclonally stimulated and grown in the presence
of TGFbeta or TGFbeta plus IL-6 for the induction of iTregs or Th-17 cells, respectively.
IL-27 was added at various conditions to clarify the role of this cytokine on these pathways
of T-cell differentiation. Flow cytometry was used to distinguish iTregs from Th-17 cells.
In order to investigate the functional level of iTregs, we performed co-culture proliferation
assays. Experiments addressing the signaling of IL-27 were done with knockout mice defective
in Stat1 and other proteins involved in IL-27 signaling. Our data show, that IL-27 can
strongly diminish the number of iTregs as measured by the expression of Foxp3. In addition,
this downregulation correlates with compromised suppressive activity. Interestingly, IL-27
is also a potent inhibitor of the highly pro-inflammatory Th-17 cell subset as demonstrated
by downregulation of IL-17A. Studies addressing the signaling of IL-27 reveal a STAT1
independent control of iTregs, in contrast to a STAT1 dependent suppression of Th-17 cells.
Thus, by utilizing different signaling pathways for the blockade of iTregs and Th-17 cells,
IL-27 could shape T-cell driven immune responses in gut inflammation and might play
opposing roles. We suggest a model in which STAT1 controls IL-27 mediated immune
responses by modulating the balance between iTregs and Th-17 cells; A balance that could
be of crucial relevance for autoimmune disorders such as inflammatory bowel diseases.
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Aberrant Thymic Selection in Hfut1 Mice Produces An Increased Percentage of
Foxp3+CD4+CD25+ T Cells That Do Not Possess Regulatory Function,
Resulting in Spontaneous Colitis
Gregory T. Moore, Steven J. Brown, Adam C. Winterhalter, Mark Lust, Sally J. Bell, Ross
Elliott, William Connell, Peter Cowan, Paul V. Desmond, Tony D'apice
Introduction: Human α1-2 fucosyltransferase (hFUT1) transgenic mice have widespread
glycosylation changes with decreased sialylation and increased fucosylation, an arrest in
thymocyte maturation at the corticomedullary junction, with lymphopenia and the develop-
ment of spontaneous colitis. We sought to determine how foxp3+CD4+CD25+ thymocyte
selection and regulatory foxp3+CD4+CD25+ T cell function was affected in hFUT1 mice.
Methods: CD4+ thymocytes and splenocytes were isolated from pre-colitic hFUT1 and wild
type (WT) BALB/c mice. TCR signal strength was measured by ZAP-70 phosphorylation
and Ca2+ flux, and apoptosis measured by Annexin V binding. Expression of CD25, L-
selectin, CD69, GITR and intracellular foxp3 and CTLA-4 was determined by flow cytometry.
CD4+ T cells were sorted into CD25+ and CD25- populations and proliferation to platebound
anti-CD3 determined as well as the ability to suppress division of CFSE-labelled WT
CD4+CD25- T cells. Sorted WT CD4+CD25+, CD4+CD25- and CD4+CD45RBhigh T cells
were adoptively transferred into 4 week old pre-colitic hFUT1 mice, which were then weighed
weekly and assessed at 12 weeks of age. Results: hFUT1 thymocytes have increased TCR
signal strength and increased apoptosis compared with WT mice. They have an increased
percentage of, but decreased number of, CD4+CD25+ thymocytes (19.6% vs 8.9%, 15-fold
reduction) and CD4+CD25+ lymphocytes (21.1% vs 8.3%, 16-fold reduction). hFUT1 and
WT CD4+CD25+ T cells have similar expression of foxp3 but the hFUT1 cells exhibit
increased CD69, GITR and CTLA-4, with decreased L-selectin expression. In Vitro, hFUT1
CD4+CD25+ T cells failed to exhibit anergy or suppress proliferation of WT CD4+CD25-
cells. Adoptive transfer of WT CD4+CD25+ and CD4+CD25- but not naive CD4+CD45RBhigh
T cells into hFUT1 mice improved weight gain and colitis. Conclusions: hFUT1 mice have
increased TCR signal strength and thymocyte apoptosis resulting in an increased percentage
of, but decreased number of, foxp3+CD4+CD25+ T cells that do not possess regulatory
properties. Transfer of WT regulatory but not naïve T cells into hFUT1 mice attenuates
colitis, suggesting that hFUT1 colitis develops due to impaired regulatory T cell function.
952
Beta2/Neurod Stabilizes Sp1 Binding to the Secretin Gene Promoter
Subir K. Ray, Andrew B. Leiter
The basic helix-loop-helix protein, BETA2/NeuroD1 activates transcription of genes encoding
several hormones including the gut hormone secretin and is required for expression of the
secretin gene in mice. Transfection assays show that BETA2 is a relatively weak transcriptional
activator by itself. BETA2 physically associates with Sp1 and forms a ternary DNA-protein
complex with Sp1 bound to an adjacent site to produce greater than additive transcriptional
activation. The amount of ternary complex formed was greater than predicted from the
DNA binding of each protein by itself. To characterize the mechanism of cooperative DNA
binding of BETA2 and Sp1, we examined the stability of DNA-protein complexes generated
by EMSA. We added purified Sp1, BETA2, and its dimerization partner E12 to a probe
containing the E-box and adjacent Sp1 binding site. After reaching equilibrium we added
a 500-fold molar excess of unlabeled competitor and measured the dissociation of Sp1-
DNA, BETA2/E12-DNA, and Sp1-BETA2/E12-DNA complexes at different time intervals.
The Sp1-DNA complex appeared to be much less stable than the other two complexes, with
only 22% remaining after 8 minutes versus 75-80% for the complexes generated by BETA2/
E12 and BETA2/E12-Sp1. The relative stability of the ternary complex suggests that Sp1
binding is stabilized in the presence of BETA2/NeuroD1 bound to the adjacent E box,
potentially accounting for the transcriptional synergy. We also compared Sp1 occupancy of
the endogenous secretin promoter in HeLa cells transfected with a BETA2 expression plasmid
to native HeLa cells that do not express BETA2 in order to determine whether BETA2
increases recruitment of Sp1 to the secretin promoter at the cellular level. Chromatin
immunoprecipitation (ChIP) assays revealed the presence of Sp1 at the secretin promoter
in BETA2-expressing HeLa cells but not in native HeLa cells. Sp1 occupancy of the DHFR
promoter of HeLa cells remained the same in the absence and presence of BETA2, indicating
that the observed differences were specific for the secretin gene. In conclusion, BETA2
stabilizes Sp1 binding to the secretin promoter leading to increased chromatin occupancy.
BETA2 is the only relatively tissue restricted transcription factor that binds to the secretin
enhancer yet it is a weak activator of transcription. Functional interactions with a widely
expressed transcription factor, Sp1 may be an important mechanism to potentiate the activity
of BETA2 in driving secretin gene expression in secretin-expressing cells, especially since
BETA2 appears to regulate binding of Sp1 to this promoter.
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Gastrin Regulates IL-8 and COX-2 Gene Expression in Gastric Epithelial Cells
At Both the Transcriptional and Posttranscriptional Level of mRNA Stability
Dharmalingam Subramaniam, Randal May, Timothy C. Wang, Courtney W. Houchen,
Shrikant Anant
Gastrin induces a pro-inflammatory response resulting in overexpression of cyclooxygenase-
2 (COX-2). It is also known to stimulate growth of malignant cells of colorectal, gastric and
pancreatic origin. However, the mechanism(s), especially in gastric cells is not completely
understood. To determine the effect of gastrin on gastric epithelial cells, we treated AGS-E
human gastric cancer cell line stably expressing the CCK-2 receptor with amidated gastrin-
17. Western blot analyses demonstrated that gastrin induced AKT, ERK and p38 phosphoryl-
ation. Real time RT-PCR, Western blot and ELISA analysis demonstrated a dose- and time-
course dependent induction of COX-2 and IL-8 mRNA and protein expression by gastrin.
Gastrin-mediated IL-8 and COX-2 mRNA and protein expression was inhibited by LY294002
(PI3K inhibitor) and SB203580 (p38 MAPK inhibitor). Luciferase reporter studies demon-
strated that gastrin induced COX-2 and IL-8 promoter activity, which was inhibited by PI-
3K inhibitor, but not the p38 MAPK inhibitor. Both IL-8 and COX-2 are regulated at the
transcriptional level by NF-κB. Electrophoretic mobility shift assays and luciferase reporter
assays demonstrated that gastrin induced NF-κB activity, which was suppressed by the PI-
3K inhibitor. IL-8 and COX-2 transcripts are also regulated at the posttranscriptional level
of mRNA stability. Gastrin increased the stability of both transcripts, the half-life increasing
from ~3 h to >8 h. However, addition of the p38 MAPK inhibitor abrogated gastrin-mediated
increased mRNA stability of both COX-2 and IL-8 mRNA. HuR is RNA binding protein
that regulates COX-2 and IL-8 expression in colon cancer cells. Western blot analysis
demonstrated that gastrin induced HuR protein expression in a dose- and time-dependent
increase manner. Furthermore, the p38 MAPK inhibitor, SB203580 suppressed the gastrin-
mediated induction of HuR expression. In addition, gastrin treatment resulted in relocaliz-
ation of HuR from the nucleus to the cytoplasm, which was decreased following treatment
with the p38 MAPK inhibitor. Immunoprecipitation-coupled RT-PCR analyses demonstrated
that gastrin enhanced HuR binding to the COX-2 mRNA. Taken together, these results
suggest that gastrin induces the expression of COX-2 and IL-8 expression at the transcriptional
and posttranscriptional levels by two independent pathways. Gastrin mediated transcriptional
regulation occurs through NF-κB activation and involves the PI-3kinase pathway, while
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posttranscriptional regulation occurs through HuR overexpression and cytoplasmic localiz-
ation involving the p38 MAPK pathway.
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Regulation of the Putative Growth Factor Reg-1 in the Gastric Epithelium By
Gastrin and Helicobacter pylori Via Distinct Promoter Elements
Islay Steele, Rod Dimaline, Graham J. Dockray, Richard M. Peek, Mark D. Pritchard,
Timothy C. Wang, Andrea Varro
Background: Helicobacter pylori infection produces moderately elevated plasma gastrin con-
centrations and is associated with gastric cancer. We previously identified increased gastric
mucosal expression of the putative growth factor, Reg-1, in patients and mice in response
to gastrin. Recent evidence suggests that in the intestine Reg-IIIγ might act as a defensive
host factor with antimicrobial activity after microbial colonisation in germ free mice. We
now report the transcriptional regulation of Reg-1 by Helicobacter in both humans and
mice and the promoter elements involved. Methods: In Helicobacter positive humans and
mice, mRNA abundance of Reg1 was determined by real time PCR; expression was studied
in primary mouse cultured gastric gland cells transiently transfected with 2.1kb or 104bp
of the Reg-1 promoter coupled to luciferase, and stimulated by gastrin (0.1-1nM) or infected
with H. felis or H. pylori (M.O.I. 1:50-200). Endogenous Reg-1 and cell specific targeting
of the constructs was determined by indirect immunofluorescence. Results In gastric corpus
from H. pylori infected patients, and in INS-GAS mice taken 3, 6 and 9 months post-
inoculation with H. felis, Reg-1 mRNA abundance was increased (p<0.05). Gastrin evoked
similar increases in expression of the 2.1 kb and 104bp Reg-1 luciferase constructs. A
rodent adapted H. pylori strain also stimulated both 2.1kb and 104bp constructs but H.felis
stimulated only the 2.1kb construct. Double labelling immunocytochemistry revealed expres-
sion of luciferase in pepsinogen-secreting chief cells and histamine-secreting enterochromaf-
fin-like cells, which corresponds to the normal expression pattern of human and mouse
Reg-1. Mutation of the sequence -79CCCC-76 within the 104bp sequence abolished the
response to gastrin but not to rodent adapted H. pylori. However, mutation of the sequence
-98GGCTTT-93 or -65CACC-58 in the same promoter construct virtually abolished responses
to H. pylori but not to gastrin. Interestingly, doses of gastrin (0.1nM) and Helicobacter (1:50)
that were sub-threshold when given separately, nevertheless acted synergistically on Reg
promoter expression in combination. Isogenic mutants of H. pylori lacking the VacA, CagA
or CagE virulence factors stimulated both promoter constructs comparable to that of the
wild type. Conclusion: Expression of Reg-1 in gastric epithelial cells is controlled by gastrin
and H. pylori through separate regulatory elements within the proximal 104bp of the pro-
moter.
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Sonic and Indian Hedgehog Direct the Development of Intestinal Villus
Smooth Muscle Through Activation of Myocardin and IGF-1
William Zacharias, Blair Madison, Xing Li, Asa Kolterud, Deborah L. Gumucio
Sonic (Shh) and Indian (Ihh) hedgehog (Hh) are secreted signaling molecules that are
expressed in the small intestinal epithelium during intestinal organogenesis. Loss or blockade
of either Shh or Ihh signaling results in marked developmental abnormalities involving both
the epithelial and mesenchymal compartments of the intestine. In order to further investigate
the impact of Hh modulation on intestinal development and homeostasis, we have developed
two transgenic animal models: a) A Villin-flox-βgal-flox-Hhip X Villin-Cre double transgenic
model that suppresses Hedgehog signals by expression of a soluble form of hedgehog
interacting protein (Hhip) that is activated by Cre recombinase; b) A Villin-Ihh transgenic
model that overexpresses Ihh in the intestinal epithelium. The Cre-activated Hhip model
exhibits a similar phenotype to previously reported Villin-Hhip animals, including a signific-
ant decrease in differentiated smooth muscle in the cores of the villi and disruption of the
muscularis mucosa, with eventual loss of villi during late adulthood. In contrast, the Villin-
Ihh model exhibits a progressive increase in villus smooth muscle throughout adult life.
Our results suggest that Hh signaling is crucial not only for the patterning of muscularis
externa, as previously demonstrated, but also for the development of smooth muscles within
the villus cores and muscularis mucosa. To identify the transcriptional targets of Hh signaling
that are responsible for these functions, we performed microarray analyses on isolated E18.5
mesenchyme treated In Vitro with Shh or Ihh. Two smooth muscle regulatory genes identified
as Hh targets by this array are Myocardin and IGF-1. Myocardin is a well-known transcription
factor directly implicated in smooth muscle differentiation, and IGF-1 has recently been
shown to increase the transcriptional activity of Myocardin. Studies on the regulation of
Myocardin and IGF-1 by Hh signaling are ongoing, and will provide a model for the
molecular regulation of smooth muscle by Shh and Ihh signaling throughout life.
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In Human Colon Cancer Cells, Acetylcholine-Induced Transactivation of
Epidermal Growth Factor Receptors (EGFR) Mediates Induction of Matrix
Metalloproteinase-7 (MMP-7) Gene Transcription
Guofeng Xie, Kunrong Cheng, Jean-pierre Raufman
Acetylcholine (ACh), and other cholinergic agonists, stimulate colon cancer cell proliferation.
Previously, we showed that ACh-induced proliferation of H508 human colon cancer cells,
which have high level expression of M3 muscarinic receptors, is mediated by transactivation
of EGFR (Cancer Res. 2003; 63: 6744). In the present study, we explored the mechanism
of ACh-induced EGFR activation. ACh-induced cell proliferation was attenuated by a specific
antibody to the EGFR ligand binding domain, by a broad spectrum MMP inhibitor (GM6001),
by more selective MMP-7 inhibitors, by a diphtheria toxin analogue (CRM197) that blocks
release of the EGFR ligand HB-EGF, and by HB-EGF antibody. Collectively, these finding
indicate that ACh-induced transactivation of EGFR is mediated by MMP-7-catalyzed release
of HB-EGF. To determine whether ACh alters MMP-7 expression, we performed quantitative
real-time PCR using primers spanning adjacent exons of MMP-7. Individual expression
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values were normalized by comparison with glyceraldehyde-3-phosphate dehydrogenase. In
H508 cells, but not SNU-C4 colon cancer cells that do not express muscarinic receptors,
ACh caused a striking 50-fold increase in MMP-7 mRNA levels. MMP-7 induction was
detected within 2 hr of incubation, maximal at 4-6 hrs and nearly back to basal levels by
24 hrs. Increased MMP-7 mRNA was detected with 1 μM ACh and maximal with 100 μM
ACh. ACh-induced MMP-7 mRNA expression was abolished by the muscarinic receptor
antagonist atropine, by antibodies to the ligand-binding domain of EGFR, and by EGFR
activation inhibitors (AG1478 and PD168393). These findings confirm that ACh-induced
MMP-7 induction is mediated via muscarinic receptors and transactivation of EGFR. p44/
42 MAP kinase (ERK 1/2) inhibitors (PD98059 and U0126) reduced MMP-7 induction by
80-90% (p<0.05), whereas phosphoinositol-3-kinase and NF-κB inhibitors (LY294002 and
SN50, respectively) had a negligible effect. In H508 but not SNU-C4 cells, ACh (100 μM)
also caused a > 50-fold increase in MMP-1 mRNA levels. However, whereas recombinant
MMP-7 (100 ng/ml) caused a > 50% increase in H508 cell proliferation (n=3; p<0.005),
up to 200 ng/ml MMP-1 did not alter basal cell proliferation. We conclude that (1) MMP-
7-catalyzed release of HB-EGF mediates ACh-induced transactivation of EGFR and stimula-
tion of H508 colon cancer cell proliferation; (2) ACh induces a striking increase in MMP-
7 and MMP-1 gene transcription; and (3) ACh-induced MMP-7 gene transcription is mediated
by transactivation of EGFR and post-receptor signaling via the ERK pathway. The functional
role of ACh-induced MMP-1 expression, if any, remains to be determined.
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Agonist-Dependent Phosphorylation of Threonine Residue 509 Regulates the
Kinetics of CCK2i4svR-Mediated Extracellular Signal Regulated Kinase (ERK)
Activation
Jeseong Park, Kirk L. Ives, Mark R. Hellmich
Introduction:The MEK/ERK pathway is involved in both receptor-mediated growth and
cellular differentiation. The precise cellular response is determined, in part, by the kinetics
(amplitude and duration) of ERK activation. Cancers of the GI tract express a splice variant
of the CCK2 receptor (CCK2R), called CCK2i4svR, which compared to CCK2R, contains 69
additional amino acid residues in its 3rd intracellular loop (3il) domain. HEK293 cells
expressing CCK2i4svR show increased tumorigenicity in nude mice and a rapid but transient
activation of the MEK/ERK signaling axis in response to agonist. By comparison, HEK293
cells expressing CCK2R are poorly tumorigenic and exhibit a slow, sustained agonist-induced
activation of ERK. G protein-coupled receptor signaling to the MEK/ERK pathway can be
regulated, in part, by agonist-induced receptor phosphorylation, which, in turn, regulates
receptor internalization and intracellular trafficking. The aim of this study was to determine
the role of agonist-induced receptor phosphorylation in the rapid-transient activation of
MEK/ERK by CCK2i4svR. Methods: HEK293 cells were stably transfected with either EGFP-
tagged wild-type (wt) CCK2i4svR or receptors containing point-mutations that disrupt pre-
dicted PKC phosphorylation sites in the 3il (S312A) and C-terminal tail (T509) domains.
Receptor subcellular localization was monitored using laser scanning confocal microscopy
(LSCM). Ca2+-dependent PKC isozymes (α, β1, β2, γ) were inhibited with Gö6976 (10
μM). Receptor phosphorylation was assessed by labeling cells with [32P]ortho-phosphate,
treating with agonist (gastrin1-17), and immunoprecipitating with a CCK2 receptor-specific
antibody. Western blotting was used to determine the levels of phospho-ERK (pERK).
Results: LSCM and immunoblotting revealed that Gö6976 treatment inhibited wt CCK2i4svR
internalization and prolonged the duration of ERK activation following agonist stimulation.
Additionally, Gö6976 treatment inhibited agonist-induced CCK2i4svR phosphorylation. Ana-
lysis of the CCK2i4svR-S312A and -T509A point-mutants revealed that the T509A mutant
was resistant to agonist-induced phosphorylation where as the S312A mutant was not.
Finally, cells expressing the CCK2i4svR-T509A mutant exhibited a prolonged activation of
pERK, which mimicked the activation kinetic in Gö6976 treated cells. Conclusion: These data
indicate that PKC-mediated phosphorylation of T509 regulates agonist-induced CCK2i4svR
internalization and the duration of ERK activation.
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Intentional Treatment with Infliximab During Pregnancy in Women with
Inflammatory Bowel Disease
Fabian Schnitzler, Herma H. Fidder, Marc Ferrante, Maja Noman, Gert A. Van assche,
Bernard Spitz, Severine Vermeire, Paul J. Rutgeerts
INTRODUCTION: Inflammatory bowel disease (IBD) is a disease which often occurs in
young women of childbearing potential, and physicians are confronted with treatment choices
in these patients. Infliximab (IFX) has proven to be very efficacious in IBD but there is still
limited data on the safety and foetal outcome of intentional use of IFX during pregnancy.
AIMS & METHODS: We identified 14 patients exposed to IFX within 3 months before
conception. In 12 of these women (9 CD, 2 UC and 1 IC), we judged that IFX was needed
to maintain remission and therefore, these patients were intentionally continued with IFX
in the first two trimesters. Because of the possibility of transplacental traffic of the drug in
the last trimester, it is our policy at present to stop IFX at month 6 of pregnancy. RESULTS:
The median number of infusions administered during pregnancy was 2 (range 1-5). So far,
there were 10 deliveries in a total of 9 women. Seven deliveries were healthy babies with
a gestational age between 38 and 40 weeks, 2 were premature deliveries (explained in detail
below), and one abortion occurred. One patient had 2 pregnancies under IFX exposure
(monotherapy): one leaded to abortion at 36 weeks and the second to a premature delivery
(boy, 2.020grams) at gestational age 34 weeks. Two women experienced a flare of their
disease during pregnancy. One occurred in a woman during her third pregnancy. The
previous pregnancies (not under IFX) in this female patient had resulted in 1 abortion and
1 delivery of a healthy girl. The flare during her third pregnancy occurred in the first
trimester and was managed until the second trimester with a total of 5 IFX infusions (one
time 10mg/kg). She finally delivered a healthy girl and IFX was restarted and maintained
q8 weeks after delivery. A further flare occurred in one female at 9 weeks and was treated
successfully with IFX 5 mg/kg. However, this pregnancy lead to a premature delivery at 28
weeks of a healthy boy (birth weight 980g). IFX was restarted in all women immediately
after delivery. All except two continued to show good response under q8 treatment and
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two patients lost response and were switched to adalimumab therapy. CONCLUSIONS:
Infliximab is a FDA class B drug. It is considered to be safe during pregnancy. In this cohort,
we report on the first 12 women who have been continued with IFX therapy during
pregnancy. Out of 10 deliveries, we report 2 premature deliveries with low birth weight (of
whom one woman had active CD during pregnancy) and one abortion.
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Infliximab Levels in Infants Born to Women with Inflammatory Bowel Disease
Uma Mahadevan, Jonathan P. Terdiman, Joseph Church, Eric Vasiliauskas, Albina Gitis,
Marla C. Dubinsky
Introduction: Infliximab (INF) is effective induction and maintenace therapy for patients
with inflammatory bowel disease (IBD). In utero exposure to INF has not been associated
with congenital anomalies or adverse fetal outcomes. However, a prior study had detected
INF levels in a newborn whose mother was treated with INF during pregnancy. The exact
mechanism of transfer of INF and the duration of detectable levels in the infant is not
known. Methods: In this prospective study, we collected INF levels in pregnant women
with IBD from the 6th month of gestation. At birth, cord blood samples and the mother
and newborn's INF levels were measured. The mother and infant's INF levels were then
followed until the levels were not detectable in the infant. All adverse events were documented.
Results: Five women were enrolled and completed their pregnancy. Four had Crohn's disease
and 1 had ulcerative colitis. The mean maternal age was 36 years (range 30-40). The mean
infusion interval during pregnancy was 8 weeks (6-12) and the mean time between birth
and last INF infusion was 30 days (2-91). The table documents INF levels (mcg/ml) in the
mothers and infants and adverse outcomes. Conclusions: Infliximab crosses the placenta
and is detectable in infants up to 6 months from birth. Low maternal infliximab levels at
birth are associated with shorter infliximab exposure times in the newborn. Adjustment of
dosing intervals should be considered in the third trimester to minimize exposure to the
infant. Further studies are needed to determine the implications of infant INF exposure on
vaccination status and immune system development.
Maternal and Newborn Infliximab (INF) Levels and Outcomes
INF concentrations in mcg/ml
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Colectomy Rates After Infliximab for Refractory Ulcerative Colitis and
Predictive Factors
Marc Ferrante, Severine Vermeire, Maja Noman, Fabian Schnitzler, Herma Fidder,
Godelieve Godefridis, Gert Van assche, Ilse Hoffman, Xavier Bossuyt, Paul Rutgeerts
BACKGROUND & AIMS: Infliximab (IFX) is efficacious for treatment of moderate to severe
ulcerative colitis (UC), but follow-up colectomy data are lacking. We studied colectomy
rates in our cohort of UC patients treated with IFX and tried to identify predictors of
colectomy. METHODS: The first 117 patients [median age 38 years and 43% female] with
moderate to severe refractory UC (n=109) or hospitalized for severe steroid-refractory UC
(n=8) treated with 5 mg/kg IFX were studied. At inclusion, 75 patients were on concomitant
immunomodulators, 8% were active smokers, 51% never smoked, 59% had CRP ≥ 5 mg/
L, 60% had extensive colitis and 51% were pANCA+. Thirty-four percent carried the MDR1
3435TT genotype, and 20% the 2677TT genotype. Short term clinical response was assessed
after 4 weeks (single infusion) or 10 weeks (induction). Kaplan-Meier curves were constructed
to identify predictors of colectomy. RESULTS: With a median (IQR) follow-up of 31 (10-
42) months, 22 patients (19%) needed colectomy (Figure). Patients who had never smoked
(LogRank p=0.040), with baseline CRP ≥ 5 mg/L (p=0.039), or carrying the MDR1 3435TT
genotype (p=0.039) had an increased risk and came to colectomy faster. Absence of short
term clinical response was significantly associated with early colectomy (p<0.001). Four
patients developed an infectious adverse event, 2 had a malignancy, 1 a cerebrovascular
accident and 1 auto-immune hemolytic anemia, 1 patient died (suicide). Five out of eight
patients with severe corticosteroid-refractory UC had a complete clinical response at week
4, 1 significantly improved after a second infusion and 2 needed a colectomy within 2
months. DISCUSSION: With a median follow-up of 2.5 years, 19% of patients treated with
IFX for moderate to severe UC needed colectomy. Never smoking, CRP ≥ 5 mg/L, MDR1
3435TT genotype and absence of short term clinical response were associated with early colec-
tomy.
961
Characterization of Molecular Responses to Infliximab Treatment in Ulcerative
Colitis By Expression Profiling
Xiao-yu R. Song, Katherine Li, Colleen Marano, Keying Ma, Allan Olson, Paul Rutgeerts
Background: The role of TNFα in IBD has been confirmed by the efficacy of infliximab
(IFX) in Crohn's disease and ulcerative colitis (UC).The ability to predict response by gene-
expression profiles has not been established. Method: Colonic biopsies were collected for
RNA extraction and hybridization to microarrays from 48 UC patients from ACT 1.Gene
expression profiles in samples from IFX responders were compared with samples obtained
at baseline (prior to treatment) and from IFX non-responders following treatment.Changes
in selected gene expression levels observed by microarray were verified by real-time poly-
merase chain reaction.Statistical analysis was conducted to identify significant treatment
effects and differences between responder and non-responder samples.ANOVA was con-
ducted with a false discovery rate of 5%.A gene expression signature at baseline was used
to classify clinical responders and non-responders post-IFX treatment.The classification was
performed with the 'K-Nearest Neighbors' algorithm in GeneSpringTM 7.2 and the signature
was evaluated by leave-one-out cross- validation. Results:When gene expression levels at
wk30 in 10 mg/kg IFX responder samples were compared with baseline samples,993 tran-
scripts showed a greater than 2-fold decreased expression.Upon further enrichment analysis
of functional annotations,most transcripts with decreased expression after IFX were predom-
inantly involved in signal transduction,immune and inflammatory responses,cell growth
regulation,and cell adhesion.Genes thought to mediate TNFα signaling had notably altered
expression profiles in IFX responders. We evaluated a baseline gene expression signature
consisting of 19 transcripts that showed significant differential expression between baseline
samples from patients who showed clinical response (n = 16) and no response (n = 6) in
both dose groups as assessed clinically at wk30 following treatment.Using the 19-transcripts
classifier, we correctly predicted the clinical outcomes for 21 patients including 16 of 16
clinical responders and 5 of 6 non-responders and misclassified one non-responder at wk30
as determined by Mayo scores giving rise to 100% of sensitivity and 83.3% specificity.
Conclusion:These data suggest that baseline gene expression profiles in patients with moder-
ately to severely active UC may be used as a tool to predict clinical response to IFX.The
utility of the classifier should be examined further with independent data sets. These data
further elaborate on IFX mechanism of action and suggest potential new pathways for
therapeutic intervention in UC.
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Long-Term Outcome of Treatment with Infliximab in 440 Crohn's Disease
Patients: Results from a Single Center Cohort
Fabian Schnitzler, Herma Fidder, Marc Ferrante, Maja Noman, Gert Van assche, Ilse
Hoffman, Severine Vermeire, Paul Rutgeerts
INTRODUCTION: Although infliximab (IFX) is used in clinical practice for >7 years, only
few data are available on the efficacy long-term. AIMS: To determine efficacy of IFX in
Crohn's disease (CD) long-term. METHODS: In the first 440 out of 562 CD patients treated
with IFX for luminal (n=359) or fistulizing (n=81) CD, long-term follow-up was completed
up to June 2006. Treatment was episodic in 213 (48%), scheduled in 108 (25%) and
episodic with switch to maintenance in 119 patients (27%). Concomitant medication was
AZA in 228 (52%), MTX in 46 (10.5%) and corticosteroids (CS) in 162 patients (37%).
Shortening of the interval between infusions or increase of dose of IFX were considered
therapeutic intervention. RESULTS: A total of 5.029 IFX infusions (median per patient 8,
IQR 3-16) were administered over a median of 41 months (IQR 21-69). Median disease
duration until 1st IFX was 7.7 years (IQR 3.1-14.7). A long-term benefit to IFX was observed
in 60% of patients (n=262), of whom 42% (n=186) had a sustained benefit on ongoing IFX
and in 17% (n=76) IFX could be stopped. Of the latter, 91% were still in remission at latest
follow-up (n=46 on AZA, n=11 on MTX and 12 no therapy). The majority (64%) did not
need interventions to maintain continued response, 28% needed 1 or 2 and only 7% needed
3 or more. Once patients started with IFX and responded initially, median duration of
continued response was 132 weeks (IQR 57-239). Of all patients on CS at 1st IFX, 73%
were weaned completely and did not need retreatment. Only 8% were judged primary non-
responders after a maximum of 3 infusions. 40 patients (9%) had to stop IFX definitely due
to side effects (19 severe infusion reactions, 20 delayed hypersensitivity, 14 other severe
adverse events). In 85 patients (19%), a definitive change in therapy was necessary primarily
due to loss of response. Of the 35 primary non-responders, 18 (51%) needed major abdominal
surgery, compared to 21% (87/405) of the responders (Odds ratio 3.87 (95%CI 1.91-7.83),
p<0.001). CONCLUSIONS: This is the largest single center experience on the long-term
outcome of IFX in patients with CD. With a median follow-up of 41 months, 60% of patients
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report a sustained benefit with IFX and 73% could completely stop steroids. Loss of response
is usually managed with therapeutic intervention with need for discontinuation in only 19%
of patients so far. Almost one third of patients with sustained benefit (29%) were able to
discontinue IFX, with sustained disease control for a median of 23.6 months after stop of IFX
(IQR 11-44). Primary non-response to IFX was associated with increased risk of abdominal
complications needing surgical intervention.
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Treatment Persistency in Infliximab-Treated Crohn's Disease Patients: A
Multicenter Retrospective Experience
Ali Keshavarazian, Lloyd Mayer, Bruce Salzberg, Michael Garone, Warren Finkelstein,
Joseph Cappa, Myron Brand, Jon Hain, David Zelinger, Ronald Hegedus, Robert
Diamond, Ulka Campbell, Christi Lane, Paul Stang, John Watson, Fabio Cominelli
Background: Existing reports of clinical experience with infliximab (IFX) are limited to
specific experiences over short time periods. Unlike certain medications used for the treatment
of chronic diseases, the long-term persistence of IFX use in Crohn's disease (CD) patients
has not been defined. Objectives: To determine IFX treatment persistence in CD patients
treated at gastroenterology centers that are “high prescribers” of IFX. Method: This retrospect-
ive, multicenter chart review analyzed data from adults younger than 90 yrs of age at the
time of their first IFX infusion on or before December 31, 2003 from 9 academic and
community-based gastroenterology practices. Data were collected from the initial infusion
until the date of data abstraction, or until treatment discontinuation or loss of follow up.
Persistency data were analyzed using survival analysis methods. Persistency was defined as
the cumulative proportion of patients remaining on treatment at a given time point throughout
the follow-up period. The incidence and type of infusion reactions were also captured in
this chart review. Results: A total of 447 CD patient charts from 9 gastroenterology centers
were reviewed.The mean patient age was 40.9 yrs, 88% of patients were Caucasian and
56.2% of patients were female.72% of patients received concomitant immunomodulator
therapy (e.g., AZA, 6 MP, or MTX).This value ranged from 59.4% to 88.9% across practices.Of
the 447 CD patient charts reviewed, 142 patients (31.8%) discontinued IFX; The most
common reason for discontinuation was due to adverse events (8.5%).Fewer patients discon-
tinued therapy due to lack of efficacy (6.5%) or infusion reactions (4.3%).The cumulative
proportion of CD patients continuing IFX at 2, 4, and 5 yrs was 73%, 58% and 54%,
respectively.IFX-treated patients who were receiving concomitant immunomodulators had
a greater probability of remaining on IFX therapy compared with those not receiving immuno-
modulator therapy at each time point (p<0.001).The total number of vials per patient-year
of treatment remained consistent from year 1 through year 4; A slight increase in the number
of vials used was observed at year 5.Infusion reactions occurred in 226 of 6468 (3.5%)
infusions, ranging from 0.3% to 7.7% across practices.There were two reports of serious
infusion reactions.The most common infusion reactions were flushing (1.4%), nausea (0.7%)
and chest pain (0.6%). Conclusions: In the overall experience observed in this actual clinical
practice retrospective cohort, the rate of long-term IFX treatment persistence was high and
is consistent with persistency rates of other therapies used to treat chronic diseases.
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Infliximab in Active Crohn's Disease Does Not Reactivate Latent Viruses (JCV,
CMV, EBV, HHV-6, -7 and -8)
Raffaello Sostegni, Alessandro Lavagna, Marco Daperno, Massimiliano Bergallo, Cristina
Costa, Rosalia Leto, Lucia Crocellà, Rodolfo Rocca, Rossana Cavallo, Angelo Pera
Background: Infliximab is commonly used for refractory Crohn's disease, although some
concerns on its long-term safety are present. Recently three cases of progressive multifocal
leukoencephalopathy (PML) after natalizumab treatment called out JC polyomavirus (JCV)
to a special attention. The aim of this study was to investigate the short term effects of
infliximab induction course on reactivation of several harmful latent viruses. Patients &
Methods: 60 consecutive patients scheduled for infliximab induction course were prospect-
ively enrolled. Blood samples were drawn before each visit prior to infliximab infusions (at
0, 2, 6 and 14 weeks). Specific PCR analyses were performed to detect JCV, EBV, HHV-6,
-7, -8 and CMV. Results: Infliximab was indicated for luminal and fistulizing disease in 49
and 15 cases, respectively. Clinical improvement and remission were achieved in 54 (90%)
and 39 (65%) patients, respectively, at 6 weeks. No patient was JCV-positive at any timepoint.
EBV serology was positive for 59/60 patients (98%), EBV DNAemaia was transiently positive
(>40 copies/100,000 PBMC) in 4 (7%) patients after infliximab, but in each case returned
to negative during the follow-up. All patients were always negative for HHV-6, -7 and -8.
CMV serology was positive in 42 patients (70%), but no CMV positive DNAemia was
observed at any time point. The results are detailed in the Table. There was no association
between concomitant treatments or clinical characteristics and viral status. During long-
term follow-up no case of PML was observed. Conclusions: Infliximab induction treatment
seems to be safe with respect to latent viruses reactivation. The long-term effects of infliximab,
particularly for the issue of lymphoproliferative disorders, warrants further studies with
larger populations, but so far data are reassuring.
DNAemia: positive DNAemia; Viral copies: median (95%CI); NA: Not Applicable
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Efficacy of Anti-TNF Agents in Luminal Crohn's Disease: A Meta-Analysis
Pierre Deltenre, Laurent Peyrin-biroulet, William J. Sandborn, Jean-frédéric Colombel
BACKGROUND AND AIM Infliximab, adalimumab and certolizumab have shown efficacy
for both induction and maintenance of clinical response and remission in luminal Crohn's
disease (CD). The aim of this study was to analyse the clinical efficacy of anti-TNF molecules
(infliximab, adalimumab, certolizumab, etanercept, onercept, CDP571) that have been evalu-
ated for the treatment of luminal CD using meta-analysis of randomized placebo controlled
trials. METHODS All randomized-controlled trials published between 1997 and 2006
(PUBMED, EMBASE, Cochrane database) and abstracts from Gastroenterology meetings
(DDW, UEGW) assessing the efficacy of anti-TNF agents vs placebo were included. The
key efficacy endpoints were clinical response (100-point response) and remission (CDAI <
150) at Week 4, Week 24-30, and Week 48-56. Steroid-free remission was also analysed
when available. Only trials with similar design were included in the analysis. The intention
to treat method was used. For each meta-analysis, the Peto and Der Simonian and Laird
methods were used. RESULTS The literature review identified 18 placebo-randomized-
controlled trials. Seven induction trials, 3 induction and maintenance trials, and 4 mainten-
ance trials with randomization after an open-label trial, involving a total of 3955 patients
were included. There were 2417 patients in the anti-TNF groups and 1538 patients in the
placebo groups. The results are summarized in the Table 1. CONCLUSION Among anti-
TNF agents, only infliximab, adalimumab and certolizumab are efficacious in treating active
luminal CD, with broadly similar results for induction and maintenance of clinical response
and remission.
Table 1. Overall analysis of each anti-TNF agent (IFX: infliximab, Ada:adalimumab, Certo:
certolizumab pegol, Eta:etanercept, Oner:onercept). Results expressed as mean difference
versus placebo (CI 95%). ND: not determined. NS: not significant.
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Infliximab Administered As 3-Dose Induction Followed By Scheduled
Maintenance Therapy in IBD: Comparable Clinical Outcomes with Or Without
Concomitant Immunomodulators
Gary R. Lichtenstein, R. H. Diamond, C. Wagner, A. Olson, R. Hegedus, M. Bala, William
J. Sandborn
Background and Methods: To assess whether concomitant immunomodulator therapy with
infliximab (IFX) is associated with better clinical outcomes when 3-dose induction followed
by scheduled maintenance therapy is used in inflammatory bowel disease (IBD), efficacy
data from pivotal trials in Crohn's disease and ulcerative colitis (ACCENT I & II, ACT I &
II) were compared. Results: As shown in the table below, response and remission rates did
not differ significantly when IFX was used with and without concomitant immunomodulators.
While there was a trend in favor of concomitant immunomodulators in some trials, there
was a trend against them in other trials. Three of the four trials showed a trend toward
fewer hospitalizations when concomitant immunomodulators were used, and this trend was
most pronounced in ACCENT I (luminal Crohn's disease (CD)). Conclusions: The use of
concomitant immunomodulators in patients receiving scheduled maintenance IFX therapy
for IBD does not improve clinical outcomes over 54 weeks. Whether concomitant immunom-
odulators would improve clinical outcomes in patients treated beyond 1 year is unknown.
Hospitalization rates may be lower with the use of concomitant immunomodulators, espe-
cially in CD. The benefits and risks of these agents in combination with IFX must be carefully
weighed. The use of concomitant immunomodulators in patients receiving scheduled main-
tenance IFX therapy for IBD should be considered optional, not mandatory.
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A 2-Year Follow-Up of the Swedish-Danish Infliximab/Placebo Trial in Steroid
Resistant Acute Ulcerative Colitis
Anders Gustavsson, Gunnar Järnerot, Erik Hertervig, Ingalill Friis-liby, Lars Blomquist,
Per Karlén, Christer Grännö, Mogens Vilien, Magnus Ström, åke Danielsson, Hans
Verbaan, Per m. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk
Background/Aim: Corticosteroids are a cornerstone in the treatment of a severe attack of
ulcerative colitis (UC). In unresponsive disease, cyclosporin (CsA) or infliximab (IFX) have
been used as rescue therapy. The long-term efficacy of CsA is questioned and not yet reported
for IFX. We present a 2-year follow-up of 45 patients given a single infusion of IFX 5mg/
kg or placebo in a previous trial, where 7/24 of IFX and 14/21 of placebo treated patients
had a colectomy within 3 months (1). Method: A 2-year follow-up regarding colectomy and
mortality. Results: During follow-up, another 6 patients had had a colectomy; IFX (n=4),
placebo (n=2) and totally 11/24 (46%) in the IFX-group and 16/21 (76%) in the placebo-
group were operated after 2 years (p<0.05) (Fig). Maintenance therapy consisted of azathiop-
rine ± 5-ASA (n=13) or solely 5-ASA (n=4) in IFX-treated patients, and azathioprine ± 5-
ASA (n=3) or solely 5-ASA (n=4) in placebo-treated patients. Colectomy proportions in the
azathioprine group were 3/16 and in the 5-ASA group 3/8. Additional IFX therapy was
given to 4 patients (single infusion, n=3; maintenance therapy, n=1), of which one had a
colectomy for unresponsive disease. There was no mortality. Conclusions: Using a single
infusion of IFX as rescue therapy in steroid resistant acute UC, a statistically significant
lower colectomy rate remained after 2 years compared to placebo. The distribution of
immunosuppressive therapy was unequal in the two groups, which may influence the
observed difference in long-term outcome. The optimal treatment strategy with IFX in
steroid-resistant acute UC needs further study. 1. Järnerot G, et al. Infliximab as rescue
therapy in severe to moderately severe ulcerative colitis. Gastroenterology 2005;128:1805-11.
Fig. Colectomy during 2 years follow-up after the original infliximab/placebo treatment
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Infliximab Is Effective As a Long-Term Treatment for Ulcerative Colitis:
Results of the Act Long Term Extension
Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel
Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J. De villiers, Allan
Olson, Hongyan Zhang, Jewel Johanns, Nicole Thorne, Jean-frederic Colombel, Daniel H.
Present, Bruce E. Sands
Purpose: To evaluate the long-term effect of infliximab (IFX) on disease activity, corticosteroid
use and health related quality of life (HRQL) in UC patients (pts) who completed ACT 1/
ACT 2, responded to IFX, and enrolled in the ACT extension. Methods:Pts with moderate-
to-severely active UC (baseline Mayo score ≥6 and ≤12) were enrolled in ACT 1 (n=364)
and ACT 2 (n=364). Pts were randomized (1:1:1) to PBO, IFX 5 or 10 mg/kg at baseline,
wks 2, 6, and q8 wks through wk 22 (ACT 2) and through wk 46 (ACT 1). Pts who had
responded to IFX during the trials could enroll in the extension; 118 pts entered the ACT
1 extension (at wk 54 or at the first infusion visit after wk 46 (E-0), and 111 pts entered
the ACT 2 extension (at wk 30 or at the first infusion visit after wk 22 (E-0). During the
extension, pts continued to receive IFX (5 or 10 mg/kg) q8 wk. Pts who had responded to
PBO also enrolled in the extension and continued to received PBO q8 wk but were discon-
tinued upon unblinding. Disease activity was assessed by a PGA. HRQL was assessed using
the IBDQ and the SF-36 PCS and MCS. Data snapshot of Nov 2006 indicated 229 pts
participated in the extension; 181 have been followed through 1 yr (E 56) and 92 through
2 yrs (E 104). Results below are from an observed analysis of IFX treatment; sensitivity
analyses, accounting for pts who discontinued, will be presented. Results:At Wks E0, E56
and E104, 76%, 92% and 97% of pts had little or no disease activity (PGA sof 0 or 1). Of
these, 41%, 61% and 75% had no disease activity (PGA of 0). Corticosteroid use was
progressively less during the extension with 80%, 88% and 98% of pts corticosteroid-free
at Wks E8, E56 and E104, respectively. HRQL, which was improved at the time of entry
into the ACT extension, improved further, with improvement from baseline in the ACT
trials in the IBDQ of 42, 53 and 57, in the PCS of 7.8, 8.6 and 11.2 and, in the MCS of
5.5, 6.3 and 6.4 at wks E0, E48 and E104, respectively. IFX was generally well tolerated
with <5% discontinuing therapy due to an AE. Notable SAEs included: prostate cancer, breast
cancer, pneumonia, sarcoidosis, abscess and death following Histoplasmosis pneumonia.
Conclusion: Pts with moderate-to-severely active UC who responded to IFX in the ACT
trials maintained their response to IFX through 2 yrs of IFX treatment in the ACT extension.
The proportions of pts with no clinical disease activity was 75% at 2 yrs and corticosteroid-
free was 98%. Improvement in HRQL observed in the ACT trials was maintained during
the extension. These data support IFX as an effective long-term treatment for UC.
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Early Crohn's Disease Shows High Levels of Remission to Therapy with
Adalimumab: Sub-Analysis of Charm
Stefan Schreiber, Walter Reinisch, Jean-frederic Colombel, William J. Sandborn, Daniel W.
Hommes, Ju Li, Jeffrey D. Kent, Paul F. Pollack
BACKGROUND: Adalimumab (ADA), a fully human anti-TNF monoclonal antibody, is
approved for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis,
and has shown efficacy in the induction and maintenance of remission in Crohn's disease
(CD) in patients (pts) naïve to and who have failed prior anti-TNF therapy. OBJECTIVE:
Increased duration of CD may negatively impact the outcome of therapeutic interventions
for a variety of reasons. We investigated the large population of the placebo (PBO)-controlled,
randomized CHARM trial for a relationship between duration of disease and response to 12-
month ADA therapy. METHODS: Of the 854 pts enrolled in CHARM, 778 were randomized at
Week (Wk) 4 to either PBO, 40 mg ADA every other week (EOW) or 40 mg weekly (W)
through Wk 56. 499 were responders at Wk 4 (CDAI decrease by ≥70 points [CR-70])
and formed the primary efficacy population of randomized responders (RR). RR pts were
divided into groups by disease duration (i) <2 years, (ii) 2 to <5 years, (iii) ≥5 years (post-
hoc). Remission (CDAI<150) was determined by disease duration groupings. Effect of disease
duration on remission was studied in a logistic regression model controlling for potential
confounders: sex, age, baseline (BL) CRP, concomitant therapies (steroids, immunosuppres-
sion), treatment, and presence of fistulae. RESULTS: No significant differences were noted
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in BL demographics (mean values: age 37 years, weight 70 kg, CRP 2.36 mg/dL, CDAI
317). A significant influence of disease duration on remission rates was found (Table), with
very high remission rates in ADA patients with <2 years since diagnosis. The logistic regression
model confirmed disease duration had a significant effect on remission when controlling
for all tested potential confounders (0.96 point estimate, 0.94-0.99 95% CI, p=0.002).
CONCLUSIONS: Therapy with ADA leads to sustained remission in approximately half of
CD RR pts on ADA with a CD duration of <2 years. Disease duration was a significant
contributor to the likelihood of attaining remission. The large remission rates in early CD
suggest a disease modification by early use of anti-TNF therapy with ADA and warrant a
prospective trial in early CD.
Table. Remission in RR, n/N (%)
*p<0.05 vs PBO.
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Screening for Celiac Sprue in Patients with Suspected Irritable Bowel
Syndrome: Results from a Prospective Us Multi-Center Trial
William D. Chey, Borko Nojkov, Richard J. Saad, Jennifer Rai, Cecilia H. Kim, Dong H.
Lee, A. H. Andrews, Brooks D. Cash
INTRODUCTION: The utility of screening for celiac disease (CD) in patients with suspected
IBS remains unclear. Further, the optimal means by which to screen for CD in IBS patients
has not be established. The goal of this study was to determine the performance characteristics
of serological tests for CD in patients with suspected IBS and controls. METHODS: Patients
meeting the Rome II criteria for non-constipated IBS with no alarm features and healthy
persons scheduled to undergo colonoscopy for colorectal cancer screening from 4 US sites
were invited to undergo serological screening for celiac disease. Subjects that agreed to
participate underwent testing for IgG and IgA anti-gliadin (AGA), anti-endomysial (EMA),
and anti-tissue transglutaminase (TTG) antibodies. Total serum IgA levels were also measured
(Prometheus laboratories, San Diego, CA). RESULTS: In this ongoing trial, 366 IBS patients
and 276 controls have been enrolled. Thirty-two (8.7%) IBS patients and 8 (2.9%) controls
had at least one abnormal antibody test result (p=0.005). IgG AGA was most commonly
positive (23 IBS pts and 3 controls). Biopsy-proven celiac disease has been confirmed in 4
(1.1%) IBS patients and 2 controls (0.7%, p=NS). Antibody test results for one IBS patient
with celiac disease were not available. Performance characteristics for the different antibody
tests are presented in the table. CONCLUSION: Though celiac antibodies were identified
significantly more commonly in IBS patients than controls, the prevalence of biopsy-proven
CD was similar between groups. Contrary to published literature, EMA and TTG yielded
marginal sensitivity and PPV for CD. The addition of IgG AGA identified patients with CD
missed by EMA and TTG but commonly yielded false positive test results. Our preliminary
results suggest that current recommendations to screen for CD with EMA or TTG alone
may not be adequate in clinical practice. Supported by a grant from Prometheus Laboratories
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Gastroenterologist (GE) Perceptions of Patient Anxiety (ANX) and Depression
(DEP): Is Poor Perception Misattribution?
Laurie Keefer, Gregory S. Sayuk, Michael Williams, Robert Rahimi, Jason Bratten, Tiffany
Havlicek, Michael P. Jones
Introduction: ANX and DEP are common and may initiate or exacerbate digestive symptoms.
Accurate recognition of ANX and DEP guides treatment and can improve outcomes. Studies
in primary care suggest that recognition of ANX and DEP is poor. Little is known about
GE ability to recognize ANX and DEP particularly in referral settings where these conditions
are more prevalent. Our aim was to determine the ability of GE to recognize ANX and DEP
during initial outpatient visits. Methods: New pt attendees of 3 university GE clinics and
their GE were evaluated. Pts were grouped by post-visit, GE-assigned diagnosis as FGID,
symptom-based diagnosis (abdominal pain, nausea, etc)(SB) or organic disorder (IBD, PUD,
etc)(OD). Pts completed the Hospital Anxiety & Depression Scale (HADS) and a measure
of GI symptom specific ANX (Visceral Sensitivity Index/VSI). GE rated ANX and DEP on
100mm VAS with anchors “not at all” and “severe.” GE also stated whether they felt that
pts were clinically anxious or depressed. Results: 20 GE evaluated 28 FGID, 45 SD & 86
OD pts. Groups did not differ by age or sex. No differences existed btwn groups for HADS-
ANX or HADS-DEP; however, FGID had higher symptom specific anxiety (VSI) than OD
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(Bonferroni p=0.04) but not SB (Bonferroni p=0.51). GE rated FGID as signif more ANX
than SB or OD pts (Bonferroni p=0.00 & 0.01 respectively) and were more likely to
characterize them as having an anxiety disorder even though there were no differences btwn
groups on this factor (χ2=8.7, p=0.01). Based on standard cutoffs for the HADS (>8), 64/
159 (13/28 FGID, 15/45 SB, 36/86 OD) pts met criteria for clinically signif ANX and 59/
159 (4/28 FGID, 9/45 SB, 21/86 OD) met criteria for clinically signif DEP. GE accurately
identified 6/64 patients with ANX and 2/59 DEP pts. There were no differences between
pt groups with respect to GE ability to accurately detect ANX or DEP. GE mislabeled 32%
of pts as clinically anxious & 11% as clinically depressed.Conclusions: GE ability to recognize
ANX and DEP is poor and pts are often misclassified. GE may misattribute symptom specific
ANX as generalized ANX. GE may also be more likely to diagnose pts with FGID rather
than SB if they regard them as more anxious. Further evaluation and education is warranted
regarding GE attitudes towards FGID and accurate recognition of ANX and DEP disorders.
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Is Intolerance to Drugs An Extra GI Somatic Manifestation of Irritable Bowel
Syndrome?
Alexandre Gougeon, Pierre Poitras, Muriel Binn, Mickael Bouin
Background: In clinical practice, patients with IBS frequently complain of medication side-
effects (an often discontinue treatment), but the prevalence of it has never been evaluated.
Aims: The first aim of this study was to assess the prevalence of drugs intolerance as an
extra GI manifestation in patients with IBS. The secondary aim was to verify the association
between drugs intolerance and psychological comorbidity. Methodology: 1) Female patients
followed in a tertiary care center completed questionnaires assessing the presence of drug
hypersensitivity as well as 11 somatic and 4 psychological extra GI conditions. IBS patients
(Rome II criteria; n=71) were compared to inflammatory bowel disease patients (IBD; n=
96) or to healthy controls (HC; n=67); 2) The relationship to psychological comorbidity
was verified in 2 different paradigms: a) by looking at the statistical correlation between
drugs intolerance and the psychological extra GI symptoms in our IBS patients, and b) by
comparing in a meta-analysis the side-effects to placebo (nocebo effect presumably increased
due to hypervigilance or amplification in psychological disorders) in 1305 IBS patients or
in 42 585 patients with comparable medical conditions included in various drug trials
approved by Health Canada (equivalent to FDA) between 1993 and 2003. Results: 1)
Prevalence of drugs intolerance was significantly more elevated in IBS (41% patients) than
in HC (7%) or in IBD (27%); as expected, biological and psychological extra GI symptoms
were also markedly increased in IBS; 2a) In our IBS patients, drugs intolerance was signific-
antly associated with somatic comorbidities such as fatigue (p<0.0001; OR 10.5), urinary
symptoms (p=0.015; OR 3.8), hypoglycemia (OR 3.5), but not with psychological factors
such as depression, anxiety, mood instability, or sleep disorder; 2b) The meta-analysis
revealed that nocebo effect was not different in patients with IBS than in patients with other
comparable medical conditions. Conclusions: Drugs intolerance or hypersensitivity is a
frequent extra GI manifestation of IBS, and it was not associated with psychological comorbid-
ity; A somatic origin must therefore be explored.
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Continuous 48-Hr Esophageal Acid Exposure in Normal Weight (NW),
Overweight (OW), and Obese (OB) Patients with GERD Symptoms
Michael D. Crowell, G. A. Decker, H. jae Kim, V. ann Schettler, Paula M. Dionisio, Angela
Bradley, John K. Dibaise, Virender K. Sharma
Obesity has been associated with GERD, but limited data have been reported on the relation-
ship between BMI and esophageal acid exposure (EAE). Most data were derived from catheter-
based testing that may cause discomfort and interfere with normal diet and activities.
BRAVO™ wireless pH-metry provides prolonged, continuous recording of pH and may
improve assessment of EAE in GERD. We tested the hypothesis that OW and OB patients
with complaints suggestive of GERD would have increased EAE compared with NW patients.
We also evaluated the variability in EAE over 48-hr in these BMI groups. Methods. 207
patients were studied over a 48h period off acid medications. Groups were NW (≤ 24.9
kg/m2;n = 80), OW (25.0-29.9 kg/m2;n = 76), and OB (≥ 30 kg/m2;n = 53). The pH
capsule was positioned orally 5-6 cm above the LES. A diary of daily activities was maintained
throughout the study. Data were evaluated using one- and two-way ANOVAs and are
presented as Mean ± SD with p-values set < 0.05. Results. Groups did not differ in age, but
more males were in the OW group. BMI was significantly different between groups (NW
21.7 ± 2.0 kg/m2; OW 27.2 ± 1.3 kg/m2; OB 36.0 ± 7.2 kg/m2). Total AET > 5.3% was
found more frequently in OB (77%) and OW (55%) patients compared NW (29%). Acid
exposure time was elevated (<0.05)in the OB (9.8% ± 6.4%) and the OW (7.5% ± 6.6%)
groups compared to NW (5.2% ± 5.3%). AET was highest in all groups during the upright
periods (NW 6.2% ± 6.4%; OW 9.6% ± 7.7%; OB 12.2% ± 8.0%). Supine AET was elevated
in the OB (6.9% ± 10.0%) group compared to OW (4.8% ± 7.9%) and NW (3.4% ± 5.7%).
The DeMeester score was higher in both the OB (35.5 ± 25.2) ant the OW (27.2 ± 22.6)
group compared to NW (18.6 ± 17.9) group. AET increased significantly from Day 1 (8.2%
± 6.3%) to Day 2 (11.3% ± 11.5%) in the OB group only. Conclusions. This is the first
study to report a positive relationship between BMI and esophageal acid exposure using
prolonged, continuous wireless esophageal pH-metry. Abnormal AET was more frequent in
OW and OB compared NW patients. Esophageal acid exposure was significantly greater in
OB and OW patients with GERD symptoms compared to NW patients. Variability in AET
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increased from the 1st to the 2nd 24h period in the OB group compared with the OW and
NW patients. Increased variability in esophageal acid exposure in obese patients supports
the use of more prolonged pH studies in subsets of GERD patients.
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G298s Mutation in NaV1.5 in a Patient with Irritable Bowel Syndrome
Reduces Sodium Current Density and Mechanosensitivity
Peter R. Strege, Yuri A. Saito loftus, David J. Tester, Giles R. Locke, Nicholas J. Talley,
Cheryl E. Bernard, Jonathan Makielski, Michael J. Ackerman, Gianrico Farrugia
Background: Human intestinal smooth muscle cells and interstitial cells of Cajal express
Nav1.5, a mechanosensitive Na+ channel encoded by SCN5A. Patients with heritable arrhy-
thmia syndromes due to mutations in SCN5A have increased gastrointestinal symptoms.
Comprehensive open reading frame/splice site analysis of the 27 translated exons of SCN5A
as a candidate gene for irritable bowel syndrome (IBS) revealed a missense mutation, G298S
(glycine to serine at amino acid 298), in one of 47 patients. G298S-SCN5A has been
reported previously in 2 patients with abnormal cardiac AV conduction. Due to a common
polymorphism at amino acid 558 and alternatively splicing that affects amino acid 1077,
there are 4 common genetic backgrounds for Nav1.5 that occur at various frequencies in
the human population: H558/Q1077del (45%), H558/Q1077 (25%), R558/Q1077del (20%),
and R558/Q1077 (10%). Aims: Determine the effect of the G298S mutation on Na+ current
density, kinetics and mechanosensitivity in each of the 4 Na+ channel backgrounds. Methods:
Na+ currents were recorded from HEK 293 cells separately transfected with H558/Q1077/
G298 (control) as well as the mutation expressed in the context of the 4 variants. Intracellular
solution contained Cs+. Extracellular solution was normal Ringer solution and episodically
perfused at 10ml/min to evoke shear stress. Results: Regardless of the background, Na+
current density was significantly reduced by 68 to 98% at holding voltages of -80, -70, or
-60 mV in cells with the G298S mutation as compared to control (P<0.05, n=5-33). Steady-
state activation of Na+ current was shifted by -6-8 mV in cells with the G298S mutation
compared to control (P<0.05, n=5-9). No shift was observed in steady-state inactivation
(P>0.05, n=5-9). Perfusion induced an increase of 20-29% in Na+ current in cells expressing
G298S, significantly less than the 50% mechanosensitive response observed in controls
(P<0.05 compared to no perfusion internal controls and P<0.05 to perfused controls, n=
11). Conclusion: The G298S mutation found in a patient with IBS is electrophysiologically
significant. The mutation results in a marked reduction in Na+ current and also loss of
Nav1.5 mechanosensitivity raising the possibility that the mutation may contribute to the
pathophysiology of IBS. Supported by NIH grant DK52766 and DK066271.
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Cluster Analysis Evidence That Irritable Bowel Syndrome Is Not a Single
Disorder But a Collection of Distinct Syndromes
William E. Whitehead, Olafur S. Palsson, Motoyori Kanazawa, Lisa M. Gangarosa, Syed
ismail M. Thiwan, Douglas A. Drossman, Miranda A. Van tilburg, Denesh K. Chitkara,
Spencer Dorn, Yehuda Ringel, Marsha Turner
Multiple physiological and psychological factors distinguish irritable bowel syndrome (IBS)
patients from controls. However, none of these potential markers is found in more than 2/
3 of IBS patients, and they are poorly correlated with each other. Aim: Test the hypothesis
that this diversity occurs because IBS is not a single disease entity but a group of distinct
disorders. Methods: 150 patients diagnosed IBS by their physicians and fulfilling Rome II
criteria underwent 8 physiological evaluations including pain sensitivity, colonic motility,
and stool consistency, and 6 psychosocial tests including somatization and neuroticism. In
addition to pain and urge thresholds, sensory decision theory analysis was used to calculate
a measure of neurosensory sensitivity (ability to discriminate between painful distentions),
which is independent of psychological influences on perception. Clinical outcomes (e.g.,
pain frequency and intensity, quality of life impact) were assessed but not used to identify
IBS-subtypes. Analysis steps: (1) Principal components analysis reduced the list of variables
to the smallest number of independent dimensions. (2) Cluster analysis of these factor scores
determined whether these combinations of variables separated the patients into distinct,
meaningful groups. (3) Groups defined by cluster analysis were compared on clinical out-
comes. Results: (1) Principal components analysis of 122 IBS patients with complete data
identified 6 independent dimensions accounting for 72% of variance: F1, sensory thresholds
and perceptual response bias in reporting pain and urge; F2, neurosensory sensitivity for
pain and urge; F3, somatization and life stress; F4, neuroticism and other psychological
symptoms; F5, colonic motility; and F6, stool consistency. (2) Cluster analysis showed that
combinations of these 6 factors separated IBS patients into 6 distinct groups: C1, a group
with low thresholds to report pain and urge; C2, a separate group high in neurosensory
sensitivity; C3, a group high in somatization and other psychological symptoms; C4, a group
high in colonic motility; C5, a constipation group; and C6, a diarrhea group. (3) Clinical
outcomes: Groups were significantly different on quality of life impact, psychological symp-
toms, and stool frequency. Conclusions: These data support the heterogeneity of IBS and
suggest that Rome II positive IBS patients can be separated into distinct groups. The specific
clusters await confirmation in an independent sample. Future research will test whether
these groups have distinct etiologies and whether they respond to different treatments.
[Supported by RO1 DK31369, R24 DK67674, and RR00046]
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The Impact of Obesity On Colon Cancer Screening
Deborah A. Fisher, William S. Yancy, Joseph Galanko, Christopher Martin, Robert S.
Sandler
Objective: Obesity is associated with an increased incidence of several cancers, including
colon cancer. The increase could be due to increased risk of disease and / or decreased
screening utilization. Evidence suggests that obese women are less likely to undergo breast
and cervical cancer screening. The purpose of this study was to determine if obesity is
associated with receipt of colon cancer screening using data from the North Carolina Colon
Cancer Study (NCCCS), a case-control population-based study. Methods: Using data from
928 controls from the NCCCS we performed logistic regression analyses using receipt of
any colon cancer screening test, regardless of indication, within the recommended time
interval as the primary outcome variable, and body mass index (BMI) classification as the
primary predictor variable. We adjusted the models for patient demographics, co-morbid
illnesses, and insurance status. The secondary endpoint was current receipt of a colon cancer
test for a screening indication only. Results: The sample was 50% men, 59% white, and
41% black with a mean age of 67 years. The BMI (kg/m2) distribution was: 18-24.9 (normal
weight)- 29%, 25-29.9 (overweight)- 39%, 30-34.9 (obese category 1)- 19%, 35-39.9 (obese
category 2)- 9% and >40 (obese category 3)- 4%. Across all BMI categories the proportion
of subjects who had undergone a screening test (for any indication) within the recommended
interval ranged from 54% to 67%. There was no association between current colon cancer
screening status and BMI in the unadjusted (p=0.09) or adjusted analyses (p=0.52). Age,
education, insurance status and having arthritis were significantly associated with screening
status in the adjusted model. There were also no significant differences across BMI categories
when only considering the tests performed for a screening indication. Gender had no impact
on screening status or the relationship between BMI and screening status. Conclusions: In
this large sample which was almost 40% overweight and over 20% obese, there was an
overall low rate of screening for colorectal cancer, but no differences across BMI categories.
The obesity disparities observed in screening for other cancers may not apply to colon
cancer. The increased colon cancer risk appears to be due to biology and not relatively
lower screening rates. The North Carolina Colon Cancer Study was supported by the NIH
P30 DK34987 R01CA 66635.
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Do Individuals with Suspected Higher Risk for Colorectal Cancer Show
Different Risk Profiles in Colonoscopy?
C. Adrion, Berndt R. Birkner, Ulrich Mansmann, A. Munte
Objective: Persons with a positive fecal occult blood test (FOBT) or with hematochezia are
suspected to have adenomas with higher risk profiles compared to persons undergoing
screening colonoscopy. The aim of the study is to prove this hypothesis within a larger
population to justify the ongoing colorectal screening paradigm. Materials and Methods:
The data are a near-total inventory of all outpatient colonoscopies in a population of about
12.5 million people. A state-wide electronic documentation of all outpatient colonoscopies
in persons with compulsory health insurance in Bavaria (Germany) in 2006 is used. Four
populations in comparison to the screening group were considered: (1) people with positive
FOBT (no hematochezia, no other indications), (2) people with hematochezia (no other
indications), (3) people with formerly removed adenoma or carcinoma, (4) people with no
FOBT or hematochezia, no formerly removed adenoma or carcinoma but other clinical
symptoms (i.e. diarrhea, unexplained anemia, obstipation, loss of weight, incomplete defeca-
tion, change in bowel habits). Logistic regression was used to assess age and sex adjusted
differences in risk profiles for these subgroups in comparison with screening subjects.
Advanced neoplasia (overall prevalence 7.65%) was defined as cancer or adenoma with at
least 10 mm in diameter, presence of high-grade dysplasia, or villous or tubulovillous
histology, or any combination thereof. Results:A higher risk of advanced neoplasia was found
for male gender (OR = 2.013, 95% CI 1.829 to 2.214) and for older age (65-74 vs. 55-64:
OR = 1.444, 95% CI 1.303 to 1.599; ≥75 vs. 55-64: OR = 1.941, 95% CI 1.678 to 2.245).
Patients with a positive FOBT (OR 3.094; 95% CI 2.623 to 3.650) or with hematochezia
(OR 2.141; 95% CI 1.787 to 2.563) or with follow-up after resection of colorectal adenoma
or carcinoma (OR 1.291; 95% CI 1.119 to 1.488) showed a higher risk for advanced
neoplasia than the screening subjects. However, patients with clinical symptoms showed a
lower risk (OR 0.767; 95% CI 0.681 to 0.863). There is evidence that these OR are slightly
modified by sex and age (LR-test: p < 0.0001). Conclusions:Patients with positive FOBT
and hematochezia are at higher risk for advanced colorectal neoplasia. Thus in these patients
colonoscopy has to be performed immediately. In patients under follow-up after adenomec-
tomy or carcinoma surgery the risk was only slightly higher than in screening subjects,
which is supportive for ongoing follow-up programs.
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Complications After Screening and Surveillance Colonoscopy
Cynthia W. Ko, Stacy Riffle, Cynthia Morris, Leann Michaels, Jennifer Holub, Jean A.
Shapiro, Laura Seeff, David A. Lieberman
Background and Aims: Colonoscopy is frequently performed on asymptomatic patients to
screen for colorectal cancer (CRC). The risk of serious complications after screening colonos-
copy is unclear, but has important implications for the overall benefits of a CRC screening
program. The aim of this study was to evaluate the incidence of serious complications within
30 days after screening or surveillance colonoscopy, and to identify potential risk factors
for complications. Methods: Patients age 40 and over undergoing colonoscopy for average
risk screening, surveillance, or evaluation of another abnormal screening test were prospect-
ively enrolled through the Clinical Outcomes Research Initiative (CORI). Patients were
contacted by telephone at approximately 7 and 30 days after the index exam and completed
a standard interview to detect complications. Follow-up data were linked to the colonoscopy
report entered into CORI. We estimated the incidence of serious complications within 30
days of colonoscopy in the overall population and in patient subgroups. We estimated
incidence by co-morbidity status by using the ASA classification. Results: A total of 18,271
patients were followed to 30 days. Gastrointestinal bleeding requiring hospitalization
occurred in 25 patients (incidence 1.4/1000 exams; 95% CI 0.9, 2.0). Perforations occurred
in 4 patients (incidence 0.2/1000 exams; 95%CI 0.1, 0.5), diverticulitis requiring hospitaliza-
tion in 5 patients (0.3/1000 exams; 95%CI 0.08, 0.6), and postpolypectomy syndrome in
2 patients (0.1/1000 exams; 95%CI 0.01, 0.3). Forty-five patients were hospitalized for
these and other serious complications related to the colonoscopy, including abdominal
pain, dehydration, adverse medication effects, and infection at the intravenous catheter site
(incidence 2.5/1000 exams; 95%CI 1.3, 3.3). The incidence of serious complications
increased with patient comorbidity (10.8/1000 for ASA class III vs. 1.6/1000 for ASA class
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I, p<0.001), pre-procedure warfarin use (8.8/1000 vs. 2.2/1000, p<0.001), and with use
of polypectomy with cautery (6.3/1000 with polypectomy/cautery vs. 1.2/1000 without
polypectomy/cautery, p<0.001). Conclusions: Complications after screening or surveillance
colonoscopy are not uncommon. Risk factors for complications may include comorbidity,
warfarin use, and polypectomy with cautery.
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Complications of Colonoscopy in the Medicare Population
Carrie Klabunde, Joan Warren, David F. Ransohoff, Martin L. Brown
Background: Colonoscopy is the most expensive and invasive of the colorectal cancer screen-
ing tests covered by Medicare, and carries the greatest risk of complications. Data docu-
menting complications associated with colonoscopy in individuals aged 65+ are very limited.
We address this gap by determining rates of complications following routine colonoscopy
in a large, population-based cohort of older Medicare beneficiaries. Methods: We used
Medicare claims for a 5% sample of Medicare beneficiaries to identify colonoscopies per-
formed between 7/1/2001 and 10/31/2004. The cohort included patients aged 66-95 who
completed procedures in an outpatient setting. We excluded patients who had more than
two colonoscopies, two colonoscopies less than 60 days apart, or a diagnosis of Crohn's,
inflammatory bowel disease, or diverticulitis. We classified colonoscopies by the type of
procedure: all procedures, screening only, diagnostic only, and procedures with biopsy/
polypectomy. Complications were classified as gastrointestinal-related, cardiovascular, and
emergency room visits occurring within 2, 7, 14, and 30 days following colonoscopy. We
compared complication rates against a control group of Medicare beneficiaries who had not
undergone colonoscopy; they were matched to cases on birth year, geographic region, race,
sex, and comorbidity. Information was obtained about the performing provider and included
physician specialty and volume and place the procedure was performed. Patient and provider
characteristics were examined in multinomial logistic regression models to identify predictors
of complications. Results: The case cohort was comprised of 51,373 colonoscopies, 2/3rds
of which were performed in hospital outpatient departments. Gastroenterologists performed
80% of the procedures, surgeons 16%, and primary care physicians 3%. Thirty-day complica-
tion rates for any colonoscopy ranged from a low of 0.7/1000 for perforation to a high of
26.2/1000 for emergency room visits. They were higher at 30 than at 2 days, and for
procedures involving biopsy/polypectomy than for screening only or diagnostic only proced-
ures. Complications increased with patient age and comorbidity. Rates of gastrointestinal-
related complications, emergency room visits, and arrhythmias were significantly higher in
cases than controls. Rates of other cardiovascular events were similar between the two
groups. Conclusions: Our study documents complications following routine colonoscopy
in a large cohort of Medicare beneficiaries. Results should be useful for patient-physician
discussions and decision-making about older adults' colorectal cancer screening options.
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Colorectal Cancers After a Negative Colonoscopy
Harminder Singh, Donna Turner, Lin Xue, Laura E. Targownik, Charles N. Bernstein
Background: In a recent study we determined that the risk of developing colorectal cancer
(CRC) after performance of a negative colonoscopy remains low even beyond ten years after
the index procedure (JAMA May 2006). Factors predisposing to the development of CRC
after a negative colonoscopy need to be further evaluated. Aim: To determine the risk
factors for development of CRC after a negative colonoscopy. Methods: We analyzed a) the
demographic features of individuals in our negative colonoscopy cohort that developed CRC
b) characteristics of the endoscopists performing the initial negative colonoscopy including
their specialty, rural vs. urban site of performance of the procedures and the annual volume
of colonoscopies performed. Results: 0.55% (72/13170) males and 0.48% (91/19,033)
females in the negative colonoscopy cohort developed CRC (p=0.4). Individuals who under-
went their initial endoscopy at a rural facility were twice as likely to be subsequently
diagnosed with CRC as compared to individuals who received their index colonoscopy in an
urban setting (0.8% vs. 0.4%; p<0.001). Those individuals who had their initial colonoscopies
performed by general practitioners in the rural facilities had the highest rate of subsequently
developing CRC [1% (13/1242)]. Otherwise specialty of the initial endoscopist did not
influence the subsequent rate of development of CRC (GP 0.7%, Internists 0.5%, Surgeons
0.5%; p=0.3). The annual volume of colonoscopies performed by the practitioner was not
predictive of CRC following a negative colonoscopy (<50/ year: 0.7%, 50-200/ yr: 0.5%, >
200/yr: 0.5%; p=0.7). Conclusion: Patients undergoing colonoscopy at rural facilities are
significantly more likely to develop CRC following an apparently negative colonoscopy than
subjects whose colonoscopies were performed in urban settings. This is possibly due to the
quality of endoscopy being performed by physicians practicing in rural settings. Further
research is required to ensure all persons undergoing colonoscopy are able to receive
equivalent quality of care.
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Long-Term Proton Pump Inhibitor Therapy and Colorectal Cancer
Alireza Sedarat, James D. Lewis, Sean Hennessy, Kathleen Propert, Wei-ting Hwang, Yu-
xiao Yang
Background: Proton Pump Inhibitor (PPI) therapy can lead to hypergastrinemia. Because
existing experimental and epidemiological evidence suggested an association between hyper-
gastrinemia and colorectal cancer (CRC), we examined whether long-term PPI use is associ-
ated with an increased risk of CRC in a large population-representative cohort. Patients &
Methods: We conducted a nested case-control study among patients ≥ 50 years of age and
with ≥ 5 years of colorectal cancer-free initial follow-up in the General Practice Research
Database (GRPD) (1987- 2003). The GPRD is a large outpatient electronic medical records
system from the United Kingdom with complete prescription records and validated diagnostic
codes for CRC. Cases consisted of all patients with an incident diagnosis of CRC. Using
incidence density sampling, up to 10 controls were matched with each case on practice site
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and both duration and calendar time of follow up prior to the index date. Mean follow up
prior to index date was 7.4 (±1.7) years. The primary exposure of interest was ≥5 years of
cumulative PPI therapy. We also assessed both duration-response and dose-response effects.
Daily dosage was calculated in units of defined daily dosage (DDD) per day. Confounders
adjusted for were age, sex, body mass index, alcohol use, tobacco use, prior colonoscopy
or sigmoidoscopy, hormone replacement therapy use, aspirin or non-steroidal anti-inflam-
matory drug use, and histamine-2 receptor antagonist use. Results: We identified 4,432
incident CRC cases and 44,292 controls. The adjusted odds ratio (AOR) for ≥5 years of
PPI exposure was 1.1 (95% CI 0.7-1.9) (Table). Among high dose PPI users (i.e., ≥1.5
DDD/day), there was a non-statistically significant trend towards an increased risk with
increasing duration of use (test for trend, p=0.17). Conclusion: Long-term PPI therapy at
regular dose is not associated with a significantly increased risk of colorectal cancer. We
could not exclude an increased CRC risk associated with long-term PPI use at high doses.
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Myofibroblast-Derived Wnt5a Regulates Epithelial Cell Heat Shock Protein 25
Expression and Proliferation
Kazuhiko Uchiyama, Mark W. Musch, Yasushi Nakagawa, Lev Lichtenstein, Vesta
Valuckaite, Tong-chuan He, Toshikazu Yoshikawa, Eugene B. Chang
BACKGROUND Pericypt myofibroblasts (MF) are believed to have an important role in
regulating colonic epithelial function, turnover, and neoplastic development. We have
observed that conditioned media (CM) from intestinal MF blocks butyrate induction of heat
shock protein (Hsp) 25 in cultured murine colonic epithelial YAMC colonic epithelial cells,
but promotes butyrate-induced cell proliferation. Because these data implicate the secretion
of a MF-derived bioactive factor, we sought to identify it and determine its mechanisms of
action. METHODS CM from murine pericrypt MFs (VUPF) was harvested 48 hrs after
adenovirus infection. YAMC cells were then incubated with CM in the presence of butyrate
(5 mM) and harvested 24 hrs later for Western blotting. In Vivo silencing of colonic Wnt5a
was performed by intramural injection of siRNA, whereas overexpression of colonic epithelial
Hsp25 was achieved through lentiviral luminal delivery of Hsp25 cDNA. Colonic specimens
were then harvest 2-3 days later and processes for Western and immunostaining for Ki67
(proliferation marker), Hsp25, and Wnt5a. RESULTS VUPF CM inhibited butyrate-induced
Hsp25 expression and promoted butyrate induced cell proliferation. Mass spectroscopy of
the active CM fraction implicated members of the Wnt family. In adenoviral-transfected
YAMC cells overexpressing FrzB, a dominant negative inhibitor of all members of the Wnt
family, CM inhibition of butyrate-induced Hsp25 induction was completely blocked. Real
time PCR revealed that VUPF mainly produce Wnt-5a. The biological actions of CM were
blocked with RNA silencing of MF Wnt5a. Lentiviral-induced overexpression of Hsp25
inhibited CM-augmentation of butyrate-induced YAMC proliferation, implicating Wnt5a
suppression of Hsp25 as critical factor for Wnt5a's pro-proliferative effects. This was sup-
ported by the finding that Hsp25 silencing in YAMC cells inhibited both basal and CM-
augmented butyrate-dependent proliferation. Wnt5a expression was silenced In Vivo by
intramural injection with Wnt5a siRNA. At the site of injection, Hsp25 expression was
increased along the entire length of the crypt in contrast to being only expressed by surface
colonocytes in mice injected with scrambled siRNA. These findings were associated with
decreased pericrypt MF Wnt-5a expression and decreased epithelial Ki-67 staining. When
colonic crypt Hsp25 expression was increased through luminal lentiviral infection, Ki-67
staining was nearly absent. CONCLUSION Pericrypt myofibroblast derived Wnt-5a regulates
colonic epithelial proliferation through a Hsp25-dependent pathway. This pathway may
play an important regulatory role in maintaining intestinal homeostasis.
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Role of PD-L1+PD-L2+ Colonic Myofibroblasts in the Regulation of Acute Th1
Mucosal Inflammatory Responses
Iryna V. Pinchuk, Jamal I. Saada, Ellen J. Beswick, Sumin M. Qiu, Gottumukkala S. Raju,
Victor E. Reyes, Don W. Powell
Background & Aim: T helper (Th) 1 cells are important effectors of the acute inflammatory
response in the gut. The intestinal inflammatory response to luminal antigens (Ag) requires
strict control (mucosal tolerance) to prevent undesirable responses to innocuous Ags.
Although the precise mechanism of peripheral tolerance remains unclear, it is established
that activation of Th cells is determined by their interaction with Ag presenting cells (APC)
which are characterized by their expression of class II MHC molecules and B7 family co-
stimulators. The phenotype of APCs in the human colonic mucosa and their involvement
in immunological responses are poorly characterized. We recently reported that human
colonic myofibroblasts (CMFs) are novel non professional APCs that represent important
cell phenotype in the normal colonic mucosa expressing class II MHC. These cells express
the B7-negative costimulators, PD-L1 and PD-L2, and suppress proliferation of CD3/CD28-
activated CD4+ T cells. We hypothesize that CMFs are local negative regulators of activated
T cell responses in normal colon and that basal expression of PD-Ls on CMFs is essential
for the suppression of acute inflammatory Th1 immune response during mucosal tolerance.
Methods: PD-L1 and PD-L2 expression on human CMFs was determined using Western
Blot and FACS analysis. Lymphoproliferation assays and cytokine ELISAs were used to
evaluate the role of PD-L1/2 expressed by CMFs with regard to the regulation of activated
T helper cell responses. Activated T cells were co-cultured with CMFs in presence/absence
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of blocking monoclonal antibody against PD-L1 and PD-L2. Results: Normal human CMFs
constitutively express PD-L1 and PD-L2 in situ and in primary culture. CMFs represented
60-80% of the PD-L1 and PD-L2 -expressing population of normal colonic lamina propria.
A unique observation was that PD-L2 was expressed by the cells (CMFs) other then DCs
and macrophages. Moreover, CMFs suppressed activated Th cell proliferation mainly via
cell contact dependent mechanism involving PD-L1 and PD-L2 signals. In contrast to this
results, CMF expression of PD-L1, but not PD-L2, was critical for the suppression of the
production of Th1 key cytokine, IFN-γ, by CD4+ effector T cells. Conclusion: These results
are consistent with the hypothesis that human CMFs expression of B7 negative co-stimulators
PD-L1 and PD-L2 are critical for the suppression of activated CD4+ effector T cell proliferation
upon inflammation and PD-L1 may control the Th1 acute inflammatory responses during
mucosal tolerance. Supported by NIDDK, GRIP and the Gulf Coast DDC,McLaughlin Endow-
ment.
1000
The Critical Role of Heat Shock Protein 47 in Intestinal Fibrosis Associated
with Inflammatory Bowel Diseases
Hiroshi Kitamura, Hiroshi Nakase, Yasuhiro Takeda, Takuya Yoshino, Katsuhiro Kasahara,
Satoru Ueno, Norimitsu Uza, Satoko Inoue, Sakae Mikami, Minoru Matsuura, Yoshihiro
Ishida, Kazuhiro Nagata, Tsutomu Chiba
Background: Fibrotic stricture and obstruction associated with chronic intestinal inflamma-
tion is one of the most important issues for patients with inflammatory bowel diseases (IBD).
Therefore, to elucidate the mechanism of intestinal fibrosis is essential for the development
of promising antifibrotic therapy in the future. Heat shock protein (HSP) 47, a collagen-
specific molecular chaperone, is believed to play an important role in the synthesis, processing
and secretion of collagens. Several laboratories have reported that HSP47 is associated with
various disorders such as liver fibrosis, renal fibrosis and so on. However, the association
between HSP47 and IBD-associated intestinal fibrosis remains unclear. Aim: To investigate
whether or not HSP47 is involved in intestinal fibrosis associated with chronic intestinal
inflammation. Method: C57BL/6 (wild type; WT) and IL10-KO mice at 4, 8, 12 and 16
weeks were used. Gene-expressions of both HSP47 and TGF-β in colonic tissue were
measured by semi-quantitative RT-PCR in the respective age groups. Protein levels were
measured by Western blot. The expression and localization of HSP47 were evaluated by
immunohistochemistry (IHC). In Vitro studies were conducted in NIH/3T3 cells. The effect
of HSP47 on procollagen α(I) was also investigated by transfection with small interfering
RNA-targeting HSP47 (siHSP47). Gene-expression of HSP47 and procollagen α(I) were
evaluated in NIH/3T3 cells with certain cytokine stimulations (TGF-β, TNF-α, IL-1β and
IL-10). Results: The following results were obtained: (1) Gene-expressions of both HSP47
and TGF-β in colonic tissue were significantly (p<0.05) increased in IL-10 KO mice compared
with WT mice in the same age group. Western blot findings showed similar results. Expres-
sions of these molecules coincided with severity of colonic inflammation in IL-10 KO
mice. IHC strongly revealed that HSP47 was mainly expressed in the mesenchymal cells of
subepithelial lesions. (2) In the In Vitro study, inhibition of HSP47 expression by siHSP47
in stable NIH/3T3 cells decreased gene-expressions of TGF-β-induced procollagen α(I). (3)
Gene-expressions of HSP47 and procollagen α(I) were up-regulated in NIH/3T3 cells after
stimulation with TGF-β, TNF-α and IL-1β. However, IL-10 inhibited gene-expressions of
HSP47 and procollagen α(I) in TGF-β-treated NIH/3T3 cells. Conclusion: Our findings
suggest that HSP47 is strongly involved in intestinal fibrosis associated with chronic intestinal
inflammation, and that IL-10 inhibits HSP47 expression of fibroblasts. In short, modulation
of HSP47 expressions by IL-10 may be one of therapeutic strategies for intestinal fibrosis.
1001
Fgf23 and Napi2a, Crucial Elements of Phosphate Homeostasis, Are Adversely
Affected By Acute and Chronic Colitis in Experimental Mice
Jennifer K. Uno, Claire B. Larmonier, Amanda T. Mah, James E. Tooley, Robert D.
Thurston, Kang moon Lee, R. balfour Sartor, Pawel R. Kiela, Fayez Ghishan
Background: Reduced bone mass is a common complication of IBD, although the mechanisms
contributing to osteopenia remain inconclusive. Skeletal integrity is the result of PO4- and Ca2+
accessibility and the balanced activity of osteoblasts and osteoclasts. Phosphate homeostasis is
maintained hormonally by PTH, vitamin D3 and phosphatonins that can affect phosphate
absorption and/ or excretion and therefore have a significant impact on the fate of bone
metabolism. While the effect of inflammation on osteoblasts and osteoclasts is well studied,
little is known about alterations in phosphate homeostasis in inflammatory states. To deter-
mine changes in phosphate handling which may contribute to the bone loss observed in
individuals with IBD, we studied the expression of renal sodium-phosphate cotransporter
NaPi-2a, as well as phosphatonin expression in chronic (IL-10-/-) and acute (TNBS) mouse
models of IBD. Methods: Acute colitis was induced with TNBS enema while chronic colitis
was generated with colonization of germ-free IL-10 knockout mice with SPF microbiota.
Renal mRNA expression was evaluated by real-time PCR. Protein was examined by immuno-
histochemistry (IHC), western blotting and ELISA. Results: In acute colitis, there was no
change in renal NaPi-2a mRNA expression, while IHC and western blotting revealed decreased
apical expression of NaPi-2a in the proximal tubules. This decrease was reversed in TNBS-
animals treated with neutralizing anti-TNF antibody. In chronic colitis, both mRNA and
Napi-2a protein expression were significantly reduced. Western blotting with total protein
from IL-10-/- mice showed a dramatic reduction of the typical 70 kDa duplex with a shift
to a higher molecular weight complex. In addition, FGF23, a phosphaturic hormone known
to down-regulate NaPi-2a, displayed a 4-fold increase in IL-10-/- mice. This increase in
mRNA corresponded with increased circulating levels of FGF23 relative to age-matched
wild-type control mice. Conversely, FGF23 mRNA levels remained unchanged in the TNBS-
treated mice indicating phosphatonin activity is altered only in chronic colitis. Conclusion:
Expression of renal transporter responsible for Pi reabsorption is adversely affected in both
acute and chronic colitis; however different mechanisms are utilized. Chronic inflammation
appears to involve transcriptional regulation of FGF23 and NaPi-2a while both acute and
chronic inflammation involves post-translational alterations of NaPi-2a. Collectively these
data suggest that intestinal inflammation alters renal phosphate handling and therefore, may
contribute to the abnormal bone metabolism associated with IBD. Supported by R01-DK33209
& R01-DK53347.
1002
TNF-α Is a Potent Activator for the Nox1-Based Oxidase System in Large
Intestinal Epithelial Cells
Kazuhito Rokutan, Yuki Kuwano, Kumiko Tominaga, Kiyoshi Masuda, Kensei Nishida,
Shigetada Teshima-kondo, Tomoko Kawai
Recently, several homologues of the catalytic, electron carrier component of the phagocyte
NADPH oxidase (gp91-phox) have been identified in a variety of non-phagocytic cells. Among
the NADPH oxidase (Nox)/dual oxidase (Duox) family members, Nox1 is predominantly
expressed in large intestinal epithelium and is suggested to regulate reactive oxygen species
(ROS)-dependent local innate immune response against pathogenic microbes. Several groups
including us have revealed that the Nox1-base oxidase is a multicomponent enzyme requiring
essential partner proteins: p22-phox, Nox organizer 1 (NOXO1), Nox activator protein 1
(NOXA1), and a small GTPase Rac1. In this study, we show that TNF-α acts as a potent
activator for the Nox1-based oxidase system. When T84 were treated with TLR5 ligand
flagellin, IL-1β, IFN-γ, or TNF-α, these stimulants similarly induced Nox1, while only TNF-
α activated transcription of the NOXO1 gene and up-regulated superoxide-producing activity
8-fold. T84 cells transfected with NOXO1 cDNA responded to flagellin, IL-1β, IFN-γ and
significantly increased superoxide generation, while TNF-α did not further up-regulated
superoxide production by the transfected cells. These results suggest that the NOXO1-
inducing capacity, rather than Nox1-inducing one, determine the respiratory burst activity
of T84 cells. The 3.8-kbp 5'-flank of the human NOXO1 gene was cloned by PCR amplifica-
tion of a human genomic DNA library. Using this fragment as template, serially truncated
fragments were constructed and transfected into T84 cells, and then promoter activities
were measured. We found that the region between -585 and -452 bp was crucial for both
basal and TNF-α-dependent promoter activities. This region contains putative binding
consensus elements for YY-1, AP-1, Ets, and the GC-rich region encoding three putative
binding sites for SP-1. Using the -585-bp reporter constructs carrying a mutation targeting
one of these elements, we confirmed that the AP-1 site (-561 to -551 bp) and SP-1 site 1
(-492 to -485 bp) exerted the TNF-α-mediated and basel transcription of the human NOXO1
gene, respectively. Furthermore, TNF-α, but not the other stimulants, activated p38 MAP
kinase and JNK1/2, and phosphorylated c-JUN and c-FOS. Consequently, only TNF-α
produced an AP-1-DNA complex. Finally, we confirmed that AP-1 decoy abolished the
TNF-α-stimulated induction of NOXO1 and up-regulation of superoxide generation. Since
the Nox1 transcript was reported to be up-regulated in Crohn's disease. Our results may
provide a novel pathway linking ROS-dependent innate immunity and development of
Crohn's disease.
1003
Multivesicular Late Endosomes - Compartments Responsible for MHC Class
II-Related Antigen Processing in Intestinal Epithelial Cells and Origin of Class
II-Bearing Exosomes
Juergen Buening, Dorthe Von smolinski, Kianush Tafazzoli, Stephan Strobel, Klaus-peter
Zimmer, Diether Ludwig, Andreas Gebert
Background and Aims: Intestinal epithelial cells (IECs) are suggested to present antigens to
CD4+ T cells and were shown to release immunocompetent MHC class II/peptide loaded
exosomes. Dependent on inflammatory stimuli, class II-related antigen presentation by IECs
might result in induction of regulatory or stimulation of pro-inflammatory T cells. The
underlying mechanisms remain inconclusive. Here we intended to identify the subcellular
compartments within IECs responsible for antigen processing and class II peptide loading.
Methods: Ovalbumin (OVA) was luminally injected into jejunal or ileal loops of Tnf(Del-
ta)(ARE) mice which spontaneously develop a Crohn′s like ileitis, and C57/129SvEv controls.
Specimens were taken from OVA-incubated loops at different times up to two hours. MHC
class II, invariant chain (Ii), A33 (a marker protein specific for intestinal epithelial cells)
and OVA were subcellularly visualised using fluorescence and cryo electron microscopy.
Tissue expression levels of IL-12 and IFN-gamma were assessed using quantitative real-time
RT-PCR. Results: MHC class II and Ii expression was found in the ileal epithelium of Tnf
and control mice, but not detected in the jejunal epithelium. In ileal IECs of Tnf and control
mice, MHC class II and Ii were seen throughout the endocytic tract. However the majority
of these two molecules was localised in multivesicular late endosomes (MVLE). OVA was
seen in these compartments 30 minutes after injection and accumulated at the one hour
period. Trafficking of OVA into MVLE was also seen in jejunal IECs, lacking MHC class II
and Ii. Internal vesicles of MVLE were labelled for A33, and A33/MHC class II-positive
exosomes were identified in the intercellular spaces of the epithelium. Compared to control
jejunum and ileum as well as Tnf jejunum, the inflamed ileum of Tnf mice showed significantly
increased levels of IL-12 and IFN-gamma. Conclusions: Our In Vivo findings indicate that
a certain subset of late endosomes, the MVLE, might be crucially involved in class II-
associated antigen processing and peptide loading within IECs. A33 labeling on internal
vesicles of MVLE further suggests that these compartments are most likely the origin of
MHC class II/peptide-loaded exosomes released from IECs. OVA targeting and accumulation
in MVLE seems to be a uniform process within the small bowel and independent of inflammat-
ory stimuli. Thus, future studies need to elucidate modulations of antigen processing and
petide loading onto MHC class II within MVLE which might be responsible for differences
in the IECs capacity to act as antigen presenting cells.
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Germline Variation of NOD1/CARD4 Does Not Determine Susceptibility to
Inflammatory Bowel Disease (IBD): Results of a Detailed Haplotype-Tagging
Investigation
Johan Van limbergen, Elaine R. Nimmo, Richard K. Russell, Hazel E. Drummond, Linda
Smith, Niall H. Anderson, Albert Tenesa, Charlie Lees, Ian D. Arnott, David C. Wilson,
Jack Satsangi
Background&Aims: NOD2/CARD15 variation has a weak effect on Crohn's disease susceptib-
ility in the Scottish and Scandinavian populations.(1) Both NOD1/CARD4 and NOD2/
CARD15 are intracellular pattern-recognition receptors involved in the innate immune
response. The NOD1/CARD4 gene lies within the putative 7p14.3 IBD locus. Data regarding
the role of a complex insertion/deletion (+32656) variant of NOD1/CARD4 in IBD from
groups in Germany, England and our own Scottish/Swedish data have shown no association
in contrast to the index study.(1-4) Our aim was to assess the influence of NOD1/CARD4
on IBD susceptibility and phenotype in the Scottish population using a gene wide association
approach. Subjects&Methods: 2296 subjects comprising of 1323 IBD patients (662 CD,
628 UC, 33 IBDU), 603 parents and 370 controls were genotyped for 9 single nucleotide
polymorphisms (SNPs) tagging the NOD1/CARD4 gene and the 3 common NOD2/CARD15
variants. Allelic, genotype and haplotype frequency comparisons between cases and controls
using χ2, multimarker transmission dysequilibrium testing (TDT) and a log-likelihood
analysis were used to assess association with IBD. Genotype-phenotype analyses (Montreal
classification, need for surgery - including stratification for NOD2/CARD15 variant carriage)
were also performed. Results: After correction for multiple testing, no significant associations
were observed between any of the NOD1/CARD4 SNPs studied and IBD, CD or UC (p≥
0.10 for all). Haplotype case-control analysis was also negative (p≥0.20 in IBD, CD and
UC). NOD2 variant carriage did not influence the effect of NOD1/CARD4 haplotype on CD
susceptibility. Multimarker TDT analysis was negative (p≥0.10 in IBD, CD and UC). Using
log-likelihood analysis (heterogeneity model - 1000 permutations), set χ2 statistics (degrees
of freedom=511) were reached 103, 396 and 35 times for IBD, CD and UC, respectively
(corresponding uncorrected p-values 0.10, 0.39 and 0.03). Genotype-phenotype analysis in
both adult and childhood onset CD did not show any significant influence of NOD1/CARD4.
We did not observe any significant effect of NOD2/CARD15 variant carriage on the influence
of NOD1/CARD4 on any of the phenotypes studied. Conclusion: This is the first study
using a gene wide haplotype-tagging approach to assess the contribution of NOD1/CARD4
in IBD. In the Scottish IBD population, germline NOD1/CARD4 variation does not represent
an important determinant of disease susceptibility. References: 1. Gaya et al. Lancet
2006;367(9518):1271-84 2. Franke A et al. Gut 2006;55:1679-80 3. Tremelling M et al.
Inflamm Bowel Dis 2006;12:967-71 4. Van Limbergen et al. Gastroenterology
2006;130(4):A64
1005
Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma
(Ppar-γ) Gene Are Associated with Inflammatory Bowel Disease (IBD)
John B. Beckly, Laura Hancock, Alessandra Geremia, Derek Jewell
Introduction: PPARγ is a nuclear receptor with inhibitory effects on NFκB, c-Jun and c-Fos
signalling. It is expressed in the colon and ileum but is impaired in inflammatory bowel
disease. Linkage to a region incorporating the PPARγ gene has been demonstrated in a
mouse model of ileitis and is syntenic to the 3p21-26 IBD susceptibility locus in humans.
A small case-control study has shown significant association between polymorphisms in this
gene and CD. Aim: To study these polymorphisms as well as the Pro12Ala substitution
and other haplotype tagging single nucleotide polymorphisms (SNPs) in cohorts of well
characterised CD and ulcerative colitis (UC) patients. Methods: A total of 7 SNPs from the
two major haplotype blocks (5 in block 1 and 2 in block 2) were genotyped in 608 CD
patients, 670 UC patients and 1131 controls using the MALDI-TOF iPLEX™ platform. All
patients and controls were unrelated, Caucasian, non-Jewish and from Oxfordshire. The
genotyping rate was >95% and the genotypes were all in Hardy-Weinberg equilibrium.
Results: There was an overall association between the block 1 SNP rs3892175 and IBD (p=
0.0066, OR 1.31, CI 1.08-1.60), CD (p=0.0095, OR 1.37, CI 1.08-1.73) and UC (p=0.048,
OR 1.27, CI 1.0-1.6). A common 5 SNP haplotype in block 1 was associated with IBD (p=
0.0073) and CD (p=0.01). For all the block 1 SNPs except rs3892175, sub-phenotype
analysis, showed a negative association of the minor allele of each SNP for ileal CD (p<0.005,
OR>0.59, CI 0.4-0.86), stricturing behaviour (p<0.006, OR>0.57, CI 0.37-0.87) and the
need for ileal resection (p<0.008, OR>0.46, CI 0.25-0.84) although these variables were
not independent of each other. Stratification of the cohort by known variants demonstrated
that the ileal association was seen in those carrying the IBD5 risk haplotype (p=0.001, OR
0.51, CI 0.32-0.78) with a protective effect seen in those negative for the common NOD2
variants (p=0.02, OR 0.60, CI 0.37-0.95). Conclusions: An association was found between
rs3892175 and IBD with a predominant contribution from the CD phenotype. The sub-
phenotypic associations were only seen for the block 1 SNPs in tight linkage disequilibrium
(LD) with the Pro12Ala variant which results in reduced transcriptional activity of the
PPARγ gene. However, these sub-phenotype associations were not seen for rs3892175 which
although was in the same block, was in much weaker LD. The overall associations with this
SNP and disease may be due to LD with another currently unidentified functional SNP.
1006
COX-2 and Mdr1 Gene Variants Are Associated with Both Crohns Disease and
Ulcerative Colitis in Danish Patients
Rodrigo Labouriau, Mette østergaard, Anja Ernst, Niels Thorsgaard, Henrik Krarup, Kim
Overvad, Herman Autrup, Vibeke Andersen
INTRODUCTION: An abnormal immune response on luminal constituents plays a role in
the pathogenesis of inflammatory bowel diseases. The mucosal uptake of potential pathogens
may be influenced by (a genetic predisposition to) an impaired mucosal barrier function
and/or dysregulation of mucosal immunity. Variants in genes involved in the intestinal
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“gatekeeper” function, i.e. intestinal xenobiotic transporters, and the inflammatory response
may predispose to inflammatory bowel diseases. MATERIALS AND METHODS. 585 patients
with ulcerative colitis, 388 patients with Crohns Disease and 796 healthy controls particip-
ated. All were Danish and of Caucasian ethnicity. The frequency of gene variants in Multidrug
Resistance 1 (MDR1, ABCB1) (G2677T/A, C3435T, intronic variant Grs3789243A), Breast
Cancer Related protein (BCRP, ABCG2) (C421A) and cyclo-oxygenase-2 (COX-2, G-765C)
were performed by real-time quantitative PCR using TaqMan chemistry on Mx3000P equip-
ment (Stratagene). The statistical analyses were based on chi-square asymptotic tests for
equality of distribution of the genotypes in patients and controls and the log-linear model
to test for epistasis . RESULTS: The relative frequencies of a single nucleotide polymorphisms
(SNP) marker for the COX-2 (G-765C) and the MDR1 (intronic variant Grs3789243A)
genes were significantly different in patients with Crohns Disease (p = 0.0009 and p =
0.001, respectively) and ulcerative colitis ( p = 0.0002 and p = 0.0003, respectively) as
compared to healthy controls. Both gene variants increased the risk for both Crohns Disease
and ulcerative colitis. The observed patterns of deviations from the hypothesis of non-
associations were compatible with a recessive effect for the COX-2 variant (i.e. the risk was
increased only when the individual was homozygous with respect to the COX-2 variant
gene) and a codominant effect for MDR1 variant (i.e. the risk was increased in individuals
that were heterozygous and homozygous with respect to the MDR1 variant gene). No
overdominans was found for MDR1, i.e. we found that the risk was higher in the homozygous
than the heterozygous individuals. No association was found for the SNP marker for BCRP
or the 2677 and 3435 marker for MDR1 neither for Crohns Disease nor for ulcerative colitis.
No epistasis between COX-2 and MDR1 variants were detected (p = 0.89), meaning that
we found no additive risk if both gene variants were present. CONCLUSION: Our data
indicates that genes involved in intestinal transport of xenobiotic agents (MDR1) and inflam-
matory response (COX-2) might predispose to both Crohns Disease and ulcerative colitis
in Danish subjects.
1007
Association of Runt-Related Transcription Factor 3 (Runx3) and Organic
Cation Transporters 1 and 2 (Octn1/2) with Inflammatory Bowel Disease
Rinse K. Weersma, Lu Zhou, Ilja M. Nolte, Gerrit Van der steege, Hendrik M. Van
dullemen, Elvira Oosterom, Klaas N. Faber, Maikel P. Peppelenbosch, Jan H. Kleibeuker,
Gerard Dijkstra
Introduction: RUNX3 is a member of the runt domain family of transcription factors. Loss
of RUNX3 function is associated with spontaneous colitis in knockout mice. RUNX3 resides
on chromosome 1p36, a susceptibility locus for IBD. Polymorphisms in OCTN1, resulting
in a disrupted binding site for RUNX are associated with Rheumatoid Arthritis. In a large
cohort of patients we looked for an association of RUNX3 and OCTN1/2 with IBD, also in
relation to CARD15 mutations. RUNX3 and OCTN mRNA expression was assessed in
inflamed and non-inflamed mucosa in patients and controls. Methods: 543 patients (309CD/
234UC) and 296 controls were included. 4 SNPs and 4 microsattelite markers were studied
for RUNX3. For OCTN1/2 SNPs 207 G→C, 1672 C→G and 4 additional SNPs, including
the polymorphism disrupting the RUNX binding site rs3792876 were analyzed. Results
were stratified for CARD15. RUNX3 and OCTN expression was determined by RT-QPCR
(ddCt) in mucosal tissue samples(14UC/16 CD and 6 controls) Results: RUNX3: SNP
rs2236851 is associated with UC (OR 1.61 CI 1.11-2.32), pancolitis (OR 1.86 CI 1.08-
3.21) and a borderline association with an early age of onset (OR 1.59 (CI 0.98-2.57)) and
leftsided colitis (OR 1.86 (CI 0.99-3.51)) This was confirmed by TDT and haplotype sharing
statistics. OCTN1/2: SNPs 207 G→C, 1672 C→G and rs3792876 were not associated with
IBD, CD or UC. SNPs rs272893 and rs273900 were associated with CD (OR 2.16 (1.21-
3.59) and 2.40 (1.43-4.05)) and subsets of CD. Interaction of RUNX3, OCTN1/2 and
CARD15 : Binary logistic regression analysis shows an OR of 3.83 (CI 1.26-11.67) for
carriership of a risk-associated allele in RUNX3 and OCTN1/2 for UC versus CD. No epistasis
with of CARD15 was found. Mucosal expression: RUNX3 mRNA expression is increased
(p<0.05) and OCTN expression is decreased (p<0.05) in inflamed colonic mucosa but not
in ileal mucosa in CD and UC compared to non-inflamed and controls. Conclusions: We
provide evidence for the genetic association of RUNX3 with UC and confirmed the association
for CD with OCTN1/2 although this involves other SNPs than previously described. In
addition, we showed an increased risk for UC in patients carrying both the RUNX3 and
OCTN risk-associated alleles. Finally, we showed upregulation of RUNX3 mRNA and down
regulation of OCTN mRNA in inflamed colonic mucosa compared to non-inflamed mucosa
of IBD patients or controls. Impaired activation of RUNX3 might result in decreased activity
of the TGF-B pathway, an important downregulator of mucosal inflammation. Further
functional studies concerning RUNX3 mutations are needed to clarify the role of RUNX3
in UC susceptibility.
1008
High Frequency Haplotypes in the X-Chromosome Locus Tlr8 Are Associated
with Both CD and UC in Females
Masayuki Saruta, Stephan R. Targan, Ling Mei, Dai Wang, Andrew F. Ippoliti, Kent D.
Taylor, Jerome I. Rotter
Background: TNF alpha and IL1 cytokines have been associated with mucosal inflammation
in both CD and UC. Innate immune defects have been associated with CD, including
CARD15. Recently Toll-like receptor TLR8 signalling has been shown to enhance generation
of both cytokines from LPS sensitized monocytes. Furthermore, the gene for TLR8 is on
the X-chromosome and IBD has been associated with abnormalities of X-chromosome number
and structure. Aim: To test whether TLR8 haplotypes are associated with IBD. Methods:
Subjects (763 CD, 351 UC, 254 control) were genotyped using Illumina technology. SNPs
were chosen to tag common Caucasian haplotypes using information from the Innate Immun-
ity PGA. Results: Both a “risk” and a “protective” TLR8 haplotype were associated with CD
in females (risk haplotype (H3): 18% of CD subjects had H3 compared with 8.9% of control
subjects; protective haplotype (H2): 59% of CD subjects had H2 compared to 72% of control
subjects). No significant association with TLR8 and CD in males was observed. H2 was also
associated with UC in females (59% of UC females had H2 compared with 72% of controls,
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p=0.024) as well as males (32% of CD males had H2 compared with 47% of controls, p=
0.009). The odds ratio for CD and UC in females increased progressively as a factor of
haplotype combinations from protective to risk: (table) Conclusions: TLR8 is an X-linked IBD
susceptibility gene, with common haplotypes predisposing and protecting. These associations
further emphasize the importance of gene variation in innate immunity as genetic determin-
ants, not only of CD, but of UC as well.
Odds Ratio
(*Mantel-Haenszel)
1009
Positional Candidate Gene Analysis in IBD2 Confirms Association Between
Ulcerative Colitis and Gli1 But Not Il23a
Mark Tremelling, Sneha John, Carlo Berzuini, Francesca Bredin, Catherine Price, Miles
Parkes
Background: IBD2 on chromosome 12 is a confirmed region of linkage for IBD which plays
a stronger role in susceptibility to ulcerative colitis (UC) than Crohn's disease (CD).1 A
recently reported genome-wide scan demonstrated strong association between the IL23R
gene and both CD and UC.2 The gene IL23A - encoding the cognate ligand of the IL23R
protein - lies within IBD2 and has 2 common haplotypes (>1%) both tagged by any one of
7 SNPs (http://www.hapmap.org) A recent report suggested association between IBD and
Gli1 which also maps to IBD2. In this study Gli1 was tagged using 4 SNPs, the strongest
association being with UC at tag SNP rs2228226.3 Aim: To test for association between UC
and tag SNPs within IL23A and Gli1 using a large IBD dataset from eastern England.
Methods: For IL23A 1000 UC cases and 1345 controls were genotyped for 2 SNPs (rs2643626
and rs2066808) tagging the entire gene using Illumina platforms. For Gli1 comparison was
made between this UC panel and a separate panel of 756 CD cases and 636 controls
genotyped for 4 SNPs (rs3187474, rs2228224, rs2228225 and rs2228226) using Taqman.
Statistical analysis was performed using logistic regression within STATA or R with routines
from (www-gene.cimr.cam.ac.uk/clayton/software/stata/) Results: For IL23A both SNPs were
in tight LD (r2=0.996) Allele and genotype frequencies were almost identical between cases
and controls. No association with UC was observed at either SNP (P=0.92 and P=0.98) For
Gli1 one SNP (rs2228224) failed genotyping (HWE P<0.05) and was excluded from analysis.
Remaining loci were in LD (D' 0.98-1.0 r2 0.71-0.88) Significant association with UC but
not CD was confirmed at one non-synonymous SNP (P=0.012) with an odds ratio similar
to the index study (1.22). (Table 1.) Regression analysis conditioning for the effect of
rs2228226 revealed no association at the remaining SNPs suggesting rs228226 may be
causally related to UC. Conclusion: UC is not associated with IL23A. Association was
confirmed between a coding SNP in Gli1 and UC. This SNP may be causally associated with
disease but further fine mapping is required. 1. Parkes Am J Hum Genet 2000;67(6):1605-10
2. Duerr Science 2006 3. Lees Gastroenterology 2006; 130(4): Suppl A52
Table 1.
1010
Il10 Is Required for Helminth Exposure to Regulate Lpmc and Mln Cell T-Bet
But Not Gata3 mRNA Expression
Jessica E. Stumphy, Sarah Winkler, Ahmed Metwali, M.nedim Ince, Arthur Blum, Tommy
Setiawan, Joseph F. Urban, Joel V. Weinstock, David E. Elliott
Inflammatory bowel disease is prevalent in locales were helminth infections are rare and is
rare where helminth infections are prevalent. Colonization with the helminth Trichuris suis
decreases disease activity in patients with Crohn's disease or ulcerative colitis. Exposure to
intestinal helminths such as Heligosomoides polygyrus inhibits colitis in several mouse models.
Helminth exposure is associated with inhibition of Th1 and promotion of Th2 responses.
Expression of the transcription factors T-bet and GATA3 are critical for the development
of Th1 and Th2 cells respectively. We tested the hypothesis that IL10 regulates T-bet
and GATA3 mRNA expression in gut-associated immune cells from mice colonized
with helminths compared to worm-free mice. Using real-time PCR, we analyzed mRNA
from freshly isolated unstimulated LPMC and MLN cells of wild type C57BL/6 mice that
were unexposed or colonized with H. polygyrus. We found that helminth exposure causes
a 2.6 fold (p<0.03) and 1.4 fold (p<0.04) decrease in T-bet expression by MLN and LPMC
with a 4.2 fold increase (p<0.003) in GATA3 expression by LPMC. We also analyzed mRNA
from C57BL/6 IL10-deficient mice with and without piroxicam-induced colitis and with
and without H. polygyrus exposure. LPMC and MLN cells from untreated IL10KO mice
express 20 (p<0.05) and 37 (p< 0.05) fold fewer GATA3 transcripts compared to untreated
wild type mice. Spontaneous T-bet and GATA3 mRNA expression by LPMC or MLN cells
from colitic IL10KO mice was not significantly different from that of non-colitic IL10KO
mice. Helminth exposure did not alter T-bet mRNA levels in IL10KO mice. However,
colonization with H. polygyrus caused a 27 fold (p<0.05) increase in GATA3 expression by
LPMC from non-colitic mice and a 6.6 fold (p<0.04) and 7.4 fold (p<0.08) increase in
GATA3 expression by MLN cells and LPMC from piroxicam-treated mice. This change is
associated with helminth-induced resolution of colitis. Conclusions: (1) Helminth-associated
reduction in T-bet expression requires intact IL10 circuitry. (2) Helminth-associated resolu-
tion of colitis does not require reduction in spontaneous T-bet mRNA expression. (3)
Helminth-associated augmentation of GATA3 expression does not require IL10. (4) Hel-
minth-associated resolution of colitis in IL10KO mice may be mediated in part by increased
GATA3 expression. Supported by AI49382, DK58755, CCFA, VAMC
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Granulocyte-Macrophage Colony-Stimulating Factor Improves Mucosal Repair
During Active Dextran Sulfate Sodium-Induced Colitis
Eric Bernasconi, Laurent Favre, Daniel Bachmann, Hanifa Bouzourene, Ed Croze,
Sharlene Velichko, John Parkinson, Pierre F. Michetti, Dominique Velin
Background and Aims: Early clinical trials have shown that sargramostim (GM-CSF), an
activator of innate immunity, may be effective in Crohn's Disease (CD). These preliminary
findings need to be confirmed in future studies. Since GM-CSF was previously reported to
improve wound healing, we tested whether GM-CSF promotes intestinal mucosal repair.
Methods: Recombinant mouse GM-CSF was expressed in yeast, purified to homogeneity
and pegylated using SPA 5000 (Nektar, Mountain View, CA). Mice treated with GM-CSF
(6 ug/mouse/day) or saline were exposed to 4% dextran sulfate sodium (DSS) for 7 days.
On day 5, 7 and 10, mice were examined by colonoscopy or sacrificed for evaluation of
inflammation and mucosal healing. Results: GM-CSF therapy prevented body weight loss,
diarrhea, and dampened mucosal inflammation. Mucosal repair was markedly improved in
GM-CSF-treated mice from day 7 on both by colonoscopy (ulceration score 1.2 ± 0.3 for
GM-CSF-treated vs 3.1 ± 0.5 untreated, p=0.01) and histological analysis (reepithelialized
ulcers 55% ± 4% for GM-CSF-treated vs 18% ± 13% untreated, p=0.01). On day 10, crypts
at ulcer edges in untreated mice exhibited a high cell proliferation index consistent with
active mucosal regeneration, while a weaker proliferation index at ulcer edges of GM-CSF-
treated mice suggested a later stage of mucosal regeneration (proliferative cell counts per
300 epithelial cells lining the ulcer edge 73 ± 3 untreated vs 26 ± 4 GM-CSF-treated, p=
0.0001). GM-CSF-mediated mucosal repair was accompanied on day 5 by increased mRNA
expression of factors implicated in mucosal healing: hepatocyte growth factor (1.7-fold, p=
0.03), regenerating gene III beta (3-fold, p=0.04), regenerating gene III gamma (2.7-fold,
p=0.03) and calgranulin B (13.4-fold, p=0.0001), as compared to untreated mice. Conclusion:
Our study shows that colon mucosal healing is improved by GM-CSF therapy and suggests
that enhanced ulcer healing may contribute to the mechanisms of action of GM-CSF in
Crohn's disease.
1012
Local IL-22 Gene Delivery Targeting Inflamed Mucosa Induces the Rapid
Attenuation with Goblet Cell Restitution
Ken Sugimoto, Kiyotaka Nagahama, Atsuhiro Ogawa, Yasuyo Shimomura, Akira Andoh,
Atul K. Bhan, Atsushi Mizoguchi
BACKGROUND & AIMS: Expression of IL-22 that specifically targets innate immunity is
induced by several inflammatory conditions including intestinal inflammation. However,
the role of IL-22 in intestinal inflammation has not yet been identified. METHODS: In Vitro
and ex vivo studies using human epithelial cancer cell lines and freshly isolated colonic
epithelial cells (CEC) from mice were performed to test the effect of IL-22 on the CEC
activation. In addition, In Vivo studies using experimental models of colitis were carried out
to define the role of IL-22 in the pathogenesis of colitis. RESULTS: IL-22 expression was
specifically elicited in the colonic CD4+ T cells under inflammatory conditions observed in
experimental colitis models as well as human IBD. Interestingly, expression levels of IL-22
were significantly lower in the inflamed colon of ulcerative colitis (UC) as compared to
Crohn's disease (CD) patients. Alternatively, IL-22 receptor complex was constitutively and
specifically expressed by the CEC of both UC and CD patients. To test the role of IL-22 in the
pathogenesis of colitis, IL-22 activity was neutralized in DSS colitis model by administration of
anti-IL-22 antibodies. Neutralization of IL-22 activity significantly delayed the recovery from
DSS-induced acute colitis. To explore the therapeutic potential of IL-22 to UC, we established
a new microinjection-based, lipid complex-mediated local gene delivery approach that
induces IL-22-overexpression that can specifically target the inflamed mucosa of T cell
receptor α knockout (TCRαKO) mice that share some features with human UC. This IL-
22 delivery enhanced the STAT3 activation in the CEC within the targeted, but not non-
targeted, mucosa and led to rapid attenuation of the local inflammation. Importantly, the
IL-22 supplement significantly restored the goblet cell differentiation that is characteristically
impaired in UC patients and TCRαKO mice with colitis. Indeed, IL-22 was capable of
inducing the expression of series of mucus-associated molecules such as MUC1 and MUC3
by human and mouse CEC. Notably, inhibition of STAT3 expression in T84 cell line by a
nucleofector-mediated transfection with STAT3 shRNA vectors resulted in a significant
decrease in the expression levels of these mucus-associated molecules. CONCLUSION:
These findings not only suggest a regulatory role of IL-22 in UC-like intestinal inflammation
but also provide novel insight into the involvement of IL-22 in goblet cell restitution through
STAT3 cascade. This study is supported by The Eli and Edythe L. Broad Foundation. K.S.
is supported by Research Fellowship Award of Crohn's and Colitis Foundation.
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Targeting T-Cell Co-Stimulation with Abatacept Is Effective in TNBS-Induced
Colitis
Xiaoxia Yang, Dawn Stetsko, Jenny Xie, Steve Nadler, Suzanne Suchard, Luisa Salter-cid
Abatacept is a recombinant, soluble fusion protein consisting of the extracellular domain of
human cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and a fragment of the Fc
domain of human immunoglobulin G1 (IgG1). It binds to B7-1 (CD80) and B7-2 (CD86)
on antigen presenting cells, thereby inhibiting their binding to the co-stimulatory molecule
CD28 on T cells. Evidence from preclinical studies suggests that the CD80/CD86 pathway
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is important in the pathogenesis of inflammatory bowel disease (IBD). Co-stimulation block-
ade and prevention of T-cell activation presents a rational approach in IBD, where increased
numbers of activated T cells and B7-expressing antigen presenting cells can be found. Here
we sought to determine if abatacept administration could abrogate trinitrobrenzene sulfonic
acid (TNBS) colitis, and to investigate its role in modulating the mucosal inflammatory
response. TNBS-induced colitis in SJL/J mice is a T helper1 (Th1) T cell-mediated colitis
that captures many of the features of Crohn's disease. Animals were administered 2.5 mg
TNBS intra-rectally and dosed with either abatacept or control chimeric IgG1. Prophylactic
administration of abatacept significantly improved (p>0.05 versus IgG-treated) body weight
loss, macroscopic disease endpoints such as colon length, and increased survival of the
colitic mice. The therapeutic effect was associated with decreased ex vivo production of a
wide-spectrum of pro-inflammatory Th1 cytokines by lamina propria mononuclear cells
including IL-12, IFN-γ and TNF-α. These findings suggest that abatacept has an impact on
the underlying mechanisms of disease induction in this model. Histological analysis of the
inflamed colons confirmed this protective effect. Compared with colons from chimeric IgG1-
treated mice, animals receiving 20 mg/kg abatacept showed a highly significant suppression
of inflammation, ulceration, glandular distortion, mucosal and submucosal hemorrhage and/
or edema. In all cases, administration of abatacept led to inflammation-clearing effects,
suggesting a therapeutic potential for IBD.
1014
Anti-Inflammatory Effects of a Novel Selective Adenosine Deaminase Inhibitor
in Experimental Colitis
Luca Antonioli, Matteo Fornai, Rocchina Colucci, Narcisa Ghisu, Federico Da settimo,
Gianfranco Natale, Emiliano Duranti, Agostino Virdis, Maria cristina Breschi, Corrado
Blandizzi, Mario Del tacca
Introduction. Adenosine plays a beneficial role as immuno-modulator in tissues subjected
to injurious stimuli, including inflammation. This nucleoside reduces the biosynthesis of
phlogistic cytokines and neutrophil functions, and prompts self-limiting immune responses.
On this basis, drugs able to promote the accumulation of endogenous adenosine, by blocking
its enzymatic breakdown, could represent a novel strategy to treat inflammatory bowel
diseases. Methods. The effects of 4-amine-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine
(APP, novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine hydro-
chloride (EHNA, reference adenosine deaminase inhibitor) and dexamethasone (DEX) were
tested in rats with colitis, induced by intrarectal dinitrobenzenesulfonic acid (DNBS, 15 mg/
rat), to assess systemic [food intake, body and spleen weight, tumour necrosis factor-
α (TNF-α) and interleukin-6 (IL-6) plasma levels] and colonic inflammatory parameters
[macroscopic and microscopic damage, TNF-α and myeloperoxidase (MPO) levels, cyclooxy-
genase isoforms (COX-1, COX-2) and inducible nitric oxide synthase (iNOS) mRNA expres-
sion]. DNBS-treated animals received APP (5 mg/kg), EHNA (10 mg/kg), DEX (0.1 mg/kg)
or vehicle intraperitoneally for 7 days, starting 1 day before DNBS. Results. DNBS caused
bowel inflammation and decreased food intake and body weight. Animals treated with APP
or EHNA, but not DEX, displayed greater food intake and body weight than inflamed rats.
Colitis was associated with an increase in spleen weight, which was counteracted by APP
or DEX. DNBS-induced colitis was characterized by macroscopic and microscopic tissue
alterations. Colonic MPO and TNF-α levels, as well as plasma TNF-α and IL-6 were increased.
These parameters were ameliorated by APP or DEX, while EHNA was less effective. Data
are summarized in table. An increment of iNOS expression was observed in inflamed tissues,
whereas COX-1 and COX-2 expression did not vary. These patterns were not affected by
test drugs. Conclusions. The novel adenosine deaminase inhibitor APP exerts significant
anti-inflammatory effects on intestinal inflammation through a reduction of pro-inflammatory
cytokines and local cellular infiltration. APP might provide the basis for the development
of a novel drug class active on adenosine pathways and effective against inflammatory
bowel disease.
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Crucial Role of Vegf in IBD: At the Cross-Road Between Immune-Driven
Angiogenesis and Inflammation
Franco Scaldaferri, Stefania Vetrano, Tommaso Stefanelli, Cristina Graziani, Vincenzo
Arena, Egidio Stigliano, Alessandro Repici, Alberto Malesci, Claudio Fiocchi, Silvio
Danese
We recently reported that pathological angiogenesis occurs in human IBD, where it represents
a novel pathogenic component. Because VEGF is an essential mediator of immune-driven
angiogenesis, we investigated the VEGF-VEGF-receptor (R) pathway and its modulation in
experimental IBD. The expression of VEGF-R1 and -R2 was assessed by immunohistochemes-
try in the colon of dextran sodium sulfate (DSS)-treated mice, and VEGF mucosal levels
were quantified by immunoblotting. The effect of VEGF overexpression and blockade was
assessed in colitic mice by adenoviral (Ad) transfer of VEGF-A and soluble (s) VEGFR-1.
Intestinal angiogenesis was measured by quantitative CD31 staining. The capacity of VEGF
to induce VCAM-1 and ICAM-1 expression by and T-cell adhesion to human intestinal
microvascular endothelial cell (HIMEC) was tested by flow cytometry and adhesion assays,
respectively. Control healthy mice displayed very low levels of VEGF-R1 and its expression
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did not change after induction of DSS colitis. In contrast, VEGF-R2 was strongly up-regulated
in colitic mice, particularly in newly formed submucosal vessels, and VEGF mucosal content
increased significantly (p<0.05). Compared to control-Ad-treated mice, Ad-VEGF-treated
mice displayed a significantly (p<0.05) worse colitis, while the colitis of sVEGFR-1-treated
mice improved significantly (p<0.05), as assessed by colitis activity index, weight loss and
histological scorE. colitic mice showed a significant (p<0.05) increase in mucosal angiogenesis
compared to healthy mice. Surprisingly, neither Ad-VEGF- or Ad-VEGFR1-treated mice
displayed a different degree of mucosal angiogenesis compared to Ad-control mice. VEGF-
treated HIMEC up-regulated surface VCAM-1 and ICAM-1 expression, and significantly
(p<0.01) bound more T-cells (5 fold increase) than resting HIMEC. The up-regulated
expression of VEGF and VEGF-R2 in experimental IBD suggests active angiogenesis. VEGF
manipulation improved colitis without significantly affecting mucosal angiogenesis. In the
DSS model, these results may be related to a more pronounced inflammatory activity of
VEGF rather than its angiogenic properties, as supported by HIMEC induction of VCAM-
1 and ICAM-1 up-regulation and promotion of T-cell adhesion. Thus, in addition to targeting
angiogenesis in chronic inflammatory disorders through VEGF blockade, disruption of the
VEGF-VEGFR-1 pathway may be beneficial because of the inhibition of its inflammatory
action on intestinal endothelium.
1016
Preferential Phosphorylation of Focal Adhesion Kinase (FAK) At Tyrosine-861
Is Critical for Mediating An Anti-Apoptotic Response to Hyperosmotic Stress
in GI Epithelial Cells
J. adrian Lunn, Rodrigo O. Jacamo, Enrique Rozengurt
Background and significance: FAK is a cytoplasmic tyrosine kinase that regulates focal
adhesion turnover, promotes tumor invasion, and protects epithelial cells from anoikis. We
have previously shown that FAK and c-Src protect cells from hyperosmotic stress (HS)-
mediated apoptosis. Studies show that anti-anoikis activity of FAK requires focal adhesion
localization, phosphorylation of FAK Tyr-397, and kinase activity. However, basic mechan-
isms underlying the anti-apoptotic activity of FAK in response to HS are unclear. We suggest
that FAK and c-Src activation by HS may provide a potential mechanistic explanation for
the tumor promoting effect of high salt diet on gastric cancer. In several GI epithelial cell
lines, we examined specific FAK tyrosine residues phosphorylated in response to HS and
tested the following hypotheses:1)c-Src kinase activity is necessary for specific FAK tyrosine
phosphorylation, 2)F-actin organization and intact cytoskeleton is necessary for this FAK
activation, and 3)specific FAK tyrosine phosphorylations are necessary for mammalian cells
to block HS-triggered apoptosis. Results: We demonstrated that FAK Tyr-861 is the predom-
inant tyrosine phosphorylation site stimulated by hyperosmotic stress (HS) in a variety of
cell types including epithelial cell lines (ileum-derived IEC-18, colon-derived Caco2, stom-
ach-derived NCI-N87), FAK null fibroblasts re-expressing FAK, Src-family kinase triple null
fibroblasts (SYF cells), and Src triple null fibroblasts in which c-Src has been restored (YF
cells). We showed that HS-stimulated FAK phosphorylation in epithelial cells is inhibited
by Src family kinase inhibitors PP2 and SU6656, and that it does not occur in SYF cells.
Unexpectedly, HS-induced phosphorylation of FAK at Tyr-397, Tyr-576, and most dramatic-
ally at Tyr-861, was completely insensitive to the F-actin-disrupting agents, latrunculin A
and cytochalasin D. Finally, we showed that in FAK null cells exposed to HS or growth
factor withdrawal, re-expression of wild type FAK restored cell survival, while re-expression
of FAKY861F did not. Conclusions: Our results indicate that FAK Tyr-861 phosphorylation
is required for mammalian cells to survival response to HS and suggest that FAK is an
upstream regulator of F-actin in response to HS. We propose that FAK/c-Src are sensors of
cytoplasmic shrinkage and through phosphorylation on FAK Tyr-861 by Src, initiate an
anti-apoptotic signaling pathway that protects cells from HS. We propose that in gastric
epithelial cells, repeated exposure to HS causes chronic FAK activation (and FAK Tyr-861
phosphorylation), which in turn leads to anti-apoptotic signaling and to gastric tumor promo-
tion.
1017
RNA Binding Protein Musashi-1 (Msi-1) Is An Important Regulator of Tumor
Growth
Sripathi Sureban, Robert George, Randal May, Brian K. Dieckgraefe, Shrikant Anant,
Courtney W. Houchen
The transformation of a normal mucosal epithelial cell to an invasive colorectal carcinoma
occurs via a well-coordinated accumulation of mutations in a series of critical genes. In the
gut, tumorigenesis arises specifically in the stem cell population located near the base of
intestinal and colonic crypts. The RNA binding protein, Musashi-1 (Msi-1) is a putative
intestinal progenitor/stem cell marker. The definitive role of Msi-1 in colon cancer and
cancer progression is currently unclear. In order to determine the effect of Msi-1 inhibition
on cell growth Msi-1 siRNA was transfected in to HCT116 cells and proliferation was assessed
by hexosaminidase proliferation assay. The siRNA-transfected cells were subjected to 12 Gy
γ-radiation and stained for capase-3 and TUNEL, to detect apoptotic cells. To further define
the role of Msi-1 in cancer progression, we administered Msi-1 siRNA as a liposomal
preparation to HCT116 colon adenocarcinoma xenografts in athymic nude mice and meas-
ured the tumor volume. Results: Following transfection of 30 nM Msi-1 siRNA to HCT116
cells, there was 30% reduction in cell proliferation. Furthermore, these cells demonstrated
2 fold increases in apoptosis as determined by caspase-3 and TUNEL assay. We observed
an increase in radiation-induced apoptosis in siRNA transfected cells. Furthermore, adminis-
tration of siRNA to Msi-1 arrested the HCT116 colon adenocarcinoma tumor xenograft
growth. Moreover, Msi-1 siRNA treated tumors (average tumor volume of (899.2 ± 517.4
mm3) were considerably smaller than the control untreated (4124.3 ± 1301.1 mm3) or
the scrambled treated tumors (6225.7 ± 638.18 mm3). The Msi-1 siRNA treated tumors
demonstrated a reduced staining for Msi-1 and CD31. However there was increased staining
for histone H3 (a marker for mitotic figures), caspase-3 and TUNEL staining suggestive of
mitotic catastrophe. Conclusions: Msi-1 is an important regulator of cancer cell proliferation
and tumor growth. These data provide strong evidence that Msi-1 is a novel target for tumor
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therapy, and that delivery of siRNA specifically against Msi-1 may be novel therapeutic
approach for cancer therapy.
1018
Bak-Null Mice Demonstrate Suppression of Epithelial Apoptosis, Crypt
Hyperplasia and Altered Differentiation in the Colon, and Are More
Susceptible to Colonic Carcinogenesis
Carrie A. Duckworth, D. M. Pritchard
Background: Apoptosis plays important roles in gastrointestinal homeostasis. Anti-apoptotic
members of the bcl-2 family, bcl-2 and bcl-w have previously been shown to regulate
intestinal apoptosis In Vivo. Although we have previously demonstrated that radiation-
induced small intestinal and colonic apoptosis is slightly suppressed in bax-null mice, pro-
apoptotic bcl-2 family members that play major roles in the regulation of intestinal apoptosis
have not been identified to date. We have therefore investigated the role of the pro-apoptotic
protein bak, using mice in which the bak gene has been deleted. Methods: Tissue sections
were prepared from formalin fixed small intestine and colon from adult female bak-null
mice and their wild-type (C57BL/6) counterparts. Apoptosis was induced by a single 10mg/
kg intra-peritoneal injection and aberrant crypt foci by 3 weekly injections of the carcinogen
azoxymethane (AOM). Cell number, apoptosis (by morphology and caspase 3 immunohisto-
chemistry) and proliferation (by mitotic index and BrdU incorporation) were assessed on a
cell positional basis. Goblet cell number was scored following alcian blue staining and
chromogranin A immunohistochemistry was performed to assess endocrine cell number.
Results: The colonic crypts of bak-null mice were significantly longer (1.6-fold) than C57BL/
6 and showed significantly increased colonic epithelial proliferation (2-fold). Significantly
fewer apoptotic cells (5-fold) were observed in the colonic table region of bak-null mice
relative to C57BL/6. However, no significant differences were observed in small intestinal
crypt or villus cell number or small intestinal apoptosis or mitosis between bak-null and
C57BL/6 mice. Colonic crypt apoptosis was significantly reduced in bak-null mice 8h follow-
ing AOM, but no differences were observed in small intestinal apoptosis following this
carcinogen. Mitosis was suppressed in C57BL/6 colon following AOM, whereas persistent
mitosis was observed in bak-null colon following this treatment. The number of aberrant
crypt foci following AOM was significantly increased in bak-null mice. Goblet cell number
was significantly increased in bak-null mice (3-fold) and chromogranin A positive cell number
was decreased (2.2-fold). Conclusions: (1) Bak-null mice demonstrate an altered colonic
phenotype with reduced apoptosis in the table region, increased epithelial proliferation,
altered differentiation patterns and crypt hyperplasia. (2) AOM-induced apoptosis is sup-
pressed in the colonic crypts of bak-null mice and this results in increased susceptibility to
colonic carcinogenesis. (3) Bak expression has little effect upon small intestinal homeostasis.
1019
Interactions of P73 and p63 Proteins Play Important Role in H. pylori
Infection
Jinxiong Wei, Daniel O’brien, Anna Vilgelm, Maria B. Piazuelo, Mary K. Washington,
Wael El-rifai, Richard Peek, Alexander I. Zaika
BACKGROUND: The p53 protein family includes p53, p73 and p63 proteins. Although
much has been written and studied about the p53 tumor suppressor, there is little known
about p73 and p63. Accumulating evidence suggests that both p73 and p63 play important
roles in apoptosis, epithelial cell differentiation, and therapeutic drug sensitivity in gastrointe-
stinal cells. p73 knockout mice display severe erosion of gastrointestinal epithelia accompan-
ied by gastrointestinal hemorrhages and deficiencies in their immune response (Nature,
2000). These animals die soon after birth because of high sensitivities to chronic infections
and inflammation. We explored the roles of p73 and p63 proteins in epithelial cell response
to Helicobacter pylori (H. pylori) infection. METHODS: AGS, MKN45 and KatoIII cells were
co-cultured with H. pylori (wild-type or its isogenic cag pathogenicity island mutants) at
various time intervals, and the roles of p53, p63 and p73 transcripts and proteins was
assessed by luciferase reporter, real-time PCR, Western blot and cell survival assays, and
fluorescent microscopy. We employed stable and transient transfections for ectopic expression
of p63 and p73 isoforms. siRNA and dominant-negative mutants were used to inhibit activity
of p73 and p63 isoforms. Human gastritis samples were analyzed by immunohistochemistry
and modified Steiner method. RESULTS: Using real-time PCR analysis and Western blotting,
we found that H. pylori causes rapid and strong elevation of p73 protein levels in a time-
dependent manner. Moreover, p73 levels were also increased In Vivo in human gastritis
associated with the H. pylori infection. We found that p73 (but not p53) up-regulation led
to transcriptional activation of pro-apoptotic genes, PUMA and NOXA, which triggered cell
death in epithelial cells. Down-regulation of p73 activity with a dominant-negative mutant
significantly suppressed apoptosis induced by H. pylori. In addition, p73 transcriptionally
up-regulated the FAS death receptor. Thus, p73 may contribute to H. pylori apoptosis
indirectly by sensitizing epithelia cells to FAS ligand. We also found that interaction between
bacterial Cag pathogenicity island and p73/p63 isoforms is an underlying mechanism for
p73 activation by H. pylori. CONCLUSION: We have demonstrated for the first time that
apoptosis associated with H. pylori infection in gastric epithelial cells is mediated by the
p73 protein. We also analyzed the underlying mechanism of p73 activation by H. pylori.
These results suggest that p73 is involved in the innate immune response, which could play
an important role in the pathogenesis of H. pylori infection.
1020
Mitochondrial Uncoupling Protein-2 Alters Chemoresistance By Decreasing
ROS Production and Apoptosis Rates in Colon Cancer Cells
Nicholas M. Mark, Zoltan Derdak, Jack R. Wands, Gyorgy Baffy
Background and Aims: Reactive oxygen species (ROS) have a complex role in cancer develop-
ment and growth. While excessive oxidative stress promotes senescence and apoptosis,
surviving cancer cells adapt and utilize mechanisms that limit intracellular ROS production.
We hypothesized that uncoupling protein-2 (UCP2), a negative regulator of mitochondrial
ROS production, supports this adaptive response and that inhibition of UCP2 is a feasible
target to restore chemosensitivity in cancer cells. Our hypothesis is based on previous
findings that many colon cancers overexpress UCP2 and furthermore that cells overexpressing
UCP2 display a more chemoresistant phenotype. Methods: We altered endogenous UCP2
levels in the human colon cancer cell line HCT116, either by overexpressing the full-
length human UCP2 or by RNAi-mediated silencing. We analyzed the effect of various
chemotherapeutic agents (ChemoRx) on cells that either overexpress the full-length human
UCP2 (HCT116UCP2) or have their endogenous UCP2 silenced. ChemoRx included campto-
thecin, etoposide, cisplatin, and doxorubicin. We monitored changes in the mitochondrial
membrane potential, O2 consumption, and intracellular levels of ATP and ROS. We detected
various phases of apoptosis by a number of assays. Results: Plasmid-encoded UCP2 was
properly targeted to the mitochondrial inner membrane of HCT116UCP2 cells, which dis-
played lower mitochondrial membrane potential and consumed more O2. ROS levels in
HCT116<UCP2 cells were consistently lower at baseline and in response to ChemoRx. More-
over, HCT116UCP2 cells treated with ChemoRx displayed decreased DNA laddering, annexin
V staining, and caspase-3 cleavage in addition to a shift from PUMA to Bcl-XL expression,
indicating diminished apoptosis. Pretreatment of HCT116 cells with the chemical uncoupler
FCCP, a pure protonophore, reproduced the protective effect of UCP2 overexpression,
confirming the primary role of proton leak in the anti-apoptotic action of UCP2. Finally, UCP2
silencing by siRNA and shRNA molecules in HCT116 cells resulted in higher mitochondrial
membrane potential, elevated ROS levels, and markedly increased rates of apoptosis in
response to ChemoRx. Conclusion: The results indicate that UCP2 is a major negative
determinant of ChemoRx-induced oxidative stress and apoptosis in HCT116 cells. Moreover,
inhibition of UCP2 is a potential novel target to reduce chemoresistance in cancer cells.
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Prostaglandin E2 Induces the Transcription of CD-55 in Colon Cancer Cells:
The Roles of Krüppel-Like Factor 4
Jinyi Shao, Vincent W. Yang, Hongmiao Sheng
Cyclooxygenase-2 (COX-2) and its derived prostaglandins (PGs) play key roles in colorectal
neoplasia. PGE2 promotes cell growth and inhibits tumor immunity. CD-55 is a complement
regulatory protein, which binds to C3 convertases and protects cells against bystander killing
by complement. Levels of CD-55 are increased in 75% of colorectal cancers. Previous studies
suggest that PGE2 regulates CD-55 expression at transcriptional level. Krüppel-like factors
(KLF) are zinc finger-containing transcription factor with diverse regulatory functions in
cell growth, differentiation, and embryogenesis. KLF4 is highly expressed in the differentiated
gut epithelial cells and inhibits intestinal epithelial proliferation. In the present study, we
demonstrate that PGE2-induced transcription of the CD-55 involves both the PKA/CREB
pathway and the KLF4 pathway. PGE2 rapidly increased the levels of both CD-55 mRNA
and protein in colon cancer LS-174T cells. PGE2 treatment resulted in a ~10-fold increase
in CD-55 transcription, as determined by transient transfection with CD-55 promoter
reporter. Either treatment with EP4 agonist or overexpression of active PKA reproduced the
similar effect of PGE2, suggesting that PGE2 induced CD-55 via the EP4/PKA/CREB pathway.
A CRE site within the CD-55 promoter was mapped between nt -72 and nt -65, which was
essential for PGE2 induction of CD-55 transcription. Additionally, progressively deleting of
CD-55 promoter sequence gradually reduced the basal activity of the CD-55 promoter and
the PGE2-induced CD-55 transcription as well. Since a number of CACCC elements which
is thought to be the KLF-binding element was identified within the CD-55 promoter, we
determined the functional role of KLF in CD-55 transcription. LS-174T cells were co-
transfected with both KLF4 expression vector and CD-55 promoter reporter plasmid. Ectopic
expression of KLF4 robustly increased the transcriptional activity of the CD-55 promoter.
In contrast, expression of either empty vector or KLF5 did not significantly alter CD-55
transcription. There are seven CACCC sites within the CD-55 promoter and removal of
these sites attenuated the induction of CD-55 transcription by KLF4. KLF4 protein was
expressed in LS-174T cells at relatively high levels. Exposure to PGE2 increased the transcrip-
tion of the KLF4 and levels of KLF4 protein. These results suggest that CD-55 is a KLF4
target gene and PGE2 induces CD-55 transcription through both CRE site and KLF-responsive
elements. The functional roles of PGE2 and KLF4 induction of CD-55 is not clear, since
both PGE2 and KLF4 play complex roles in biological and pathological processes of the gut.
1022
Role of Nitric Oxide in Peripheral Control of Vagal Afferent
Mechanosensitivity
Amanda J. Page, Tracey A. O'donnell, L.ashley Blackshaw
Background: In the nucleus tractus solitarius (NTS) nitric oxide (NO) modulates central
vagal neuronal circuits controlling autonomic functions. Many vagal afferents terminating
in NTS originating in the stomach and esophagus contain NOS (Neuroscience, 1998: 84;
549). In addition NO synthase has been found in nodose ganglia (J. Comp. Neurol. 1996:
364(1); 51-67). However, a role of NO at visceral peripheral afferent endings has not been
investigated. Aim: Determine the effect of inhibiting NO production on the mechanically
induced activity of gastroesophageal vagal afferent subtypes in the ferret. Methods: Single
fiber recordings of gastroesophageal vagal mechanoreceptors were made in ferret using
standard electrophysiological techniques (J. Physiol. 1998; 512: 907-916). L-NAME (0.1mM)
was applied to the peripheral afferent endings of ferret gastroesophageal vagal afferents and
their responses to graded mechanical stimuli investigated. These afferents have been previ-
ously characterized as tension, mucosal and tension/mucosal (TM) receptors according to
their responsiveness to circumferential tension or mucosal stroking or both (J.Physiol 1998;
512: 907-16). L-arginine (0.1mM) along with L-NAME (0.1mM) was then applied to the
peripheral ending to reverse the effects of L-NAME. Results: Inhibition of NOS with L-
NAME (0.1mM) increased the response of ferret mucosal receptors to mucosal stroking with
calibrated von Frey hairs (10-1000mg; n=5; p=0.0018). This enhancement of response was
reversed on addition of L-arginine (0.1mM) along with L-NAME (0.1mM). The ferret TM
receptor (n=13) responses to mucosal stroking and circular tension were unaffected by L-
NAME (0.1mM). The response of ferret tension receptors (n=10) to circular tension were also
A-155 AGA Abstracts
unaffected by L-NAME (0.1mM). Conclusion: These data indicate that L-NAME selectively
enhances mechanosensitivity of mucosal receptors suggesting that endogenous NO plays a
role in modulating mucosal receptor mechanosensitivity, and therefore potentially the percep-
tion of events in the gut. Supported by National Health and Medical Research Council of
Australia & AstraZeneca.
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Decreased Rat Voluntary Movement As a Measure of Chronic Visceral Pain - A
Study Using the Rat Chronic Acid Reflux Esophagitis Model
Hiroto Miwa, Tadayuki Oshima, Toshihiko Tomita, Jun Sakurai, Takayuki Matsumoto,
Junichi Koseki
Aim With increases in functional GI disorders, growing interest has arisen regarding the
mechanism of dyspeptic symptom generation. However, no animal models for assessment
of chronic visceral symptoms have been developed. In this study, we examined whether
voluntary movements of rats could be a measure to assess visceral symptoms of reflux
esophagitis. Methods A rat model for chronic acid reflux esophagitis (n=15) or a Sham
operation group (n=15) was made using 8-week-old male Wistar rats by a previously reported
method (Asaoka D, et al. J Gastroenterol 40(8); 781-790, 2005). In addition, omeprazole
(3 mg/kg/day, 10 mg/kg/day) was administered from the beginning (sc) to the esophagitis
rats (n=12). Voluntary movements were monitored for 10 days after operation using an
infrared sensor system and compared among these groups. Rats were sacrificed at day 10
to examine the size of erosions. Intracellular space of the esophageal mucosa at non-erosive
sites was also examined by emission electron microscopy. In addition, the expression of
tight junction proteins (Claudin-1, 3, 4, Occludin) in non-erosive esophageal mucosa was
examined using Western blot analysis. Results Voluntary movements (accumulation of total
counts of movement from day 2 to day 10, both day and night) of rats with reflux esophagitis
(59128+4622 counts/198h/cage) was significantly decreased compared to that in Sham-
operated rats (126433+6909). Total number of voluntary movements was not associated
with the size of erosions. In rats administered omeprazole treatment (10 mg/kg/day), total
counts of voluntary movements were significantly increased (74957+4908) and size of
esophageal erosions were significantly decreased compared to the rats with esophagitis. In
the reflux esophagitis rats, intracellular spaces were significantly enlarged and expressions
of tight junction proteins (Claudin-1, 3, 4, Occludin) were decreased. Conclusion Rats with
acid reflux esophagitis had significantly fewer voluntary movements, but the number of
movements was increased by administration of omeprazole. Decreased voluntary movement
in a rat reflux esophagitis model could be a measure of chronic visceral pain.
1024
Autonomic Responses to Distal Esophageal Acidification and Their
Relationship to Sensitization in a Human Model of Visceral Pain
Hypersensitivity
Abhishek Sharma, Peter Paine, Barbara Unsworth, Khuram Parvez, James Spibey, Yang C.
Chua, Qasim Aziz
Introduction Visceral Pain Hypersensitivity (VPH) is common in Functional Gastrointestinal
Disorders. Life stress has been associated with both the onset and exacerbation of these
disorders. How stress modulates visceral sensory perception is unknown, but may be medi-
ated in part by the Autonomic Nervous System. We have shown previously that distal
esophageal acidification induces a variable degree of VPH in the non-acid exposed proximal
esophagus (PE) due to the sensitization of spinal dorsal horn neurones [1]. Whether inter-
individual differences in autonomic reactivity explain this variability is unknown. Aim To
determine whether autonomic reactivity predicts the degree of VPH to esophageal acid-
ification. Methods In 13 healthy volunteers (8 female, age 22-58, mean 34.9 yrs) pain
thresholds (PT) to electrical stimulation (in milliamperes, mA) were determined in the PE
and foot (somatic control) pre- and post a randomized double-blind 30-minute esophageal
infusion of either 0.15M HCl or saline. All subjects had continuous ECG and blood pressure
(BP) monitoring. Results All subjects except two sensitized to acid infusion with a significant
fall in PT in the PE compared to saline [mean change in PT -5.4mA (4.4 mA SD) acid Vs
+2.0mA saline (3.6 mA SD) p=0.0012]. No significant change in pain thresholds was observed
on the foot with acid [baseline 54.2 mA (19.8 SD) Vs 52.3 mA (11.3 SD) at 2 hours, p=
0.68] or saline [baseline 45.8 mA (18.3 SD) Vs 51.6 mA (15.2 SD) at 2 hours, p=0.06].
Acid caused a greater rise in mean arterial pressure compared to saline [98.4mmHg
(16.0mmHg SD) Vs 92.4mmHg (15.5mmHg SD), (95% CI = 1.9 to 10.1), p=0.008], an
effect more pronounced in the 11 sensitizers (p=0.0036). Acid also caused a greater rise in
heart rate compared to saline [71.5 (10.4 SD) Vs 66.4 (7.9 SD), (95% CI = 0.6 to 9.6), p=
0.031], an effect again more pronounced in the 11 sensitizers (p=0.020). With simple linear
regression the degree of sensitization in the PE correlated with the change in mean arterial
pressure to acid, but not heart rate, suggesting that rising blood pressure was associated
with reducing sensitization (r = 0.68, 95% CI 0.14 to 0.91, p = 0.02). Conclusions Esophageal
acid infusion is associated with a rise in heart rate and BP. In addition, those that raised
their blood pressure to acid the most sensitized the least. Further work in larger numbers
incorporating selective autonomic measures is now warranted to identify whether inter-
individual differences in autonomic reactivity identify phenotypes with a greater tendency
to develop post-injury gut sensitization. References [1]Sarkar et al Lancet 2000;
356(9236):1154-9.
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Mice Lacking the TRPV4 Ion Channel Display Major Deficits in Spinal
Colonic But Not Vagal Gastroesophageal Mechanosensory Function
Stuart M. Brierley, Patrick A. Hughes, Amanda J. Page, Birgit Adam, Tobias Liebregts,
Gerald Holtmann, Wolfgang Liedtke, L.ashley Blackshaw
Background: Several candidate molecules exist as sensory mechanotransducers, including
TRPV4 - a transient receptor potential ion channel, recently proposed to transduce mechanical
stimuli(1). It is unknown whether TRPV4 contributes to the mechanosensory function of
visceral afferents. Aims: 1) To compare the localisation and relative expression of TRPV4
transcripts in whole spinal sensory dorsal root ganglia (DRG) with expression in identified
colonic DRG neurons. 2) To investigate and compare the role of TRPV4 in splanchnic &
pelvic colonic afferents with vagal gastroesophageal afferent mechanotransduction. Methods:
Cells expressing TRPV4 mRNA in T10-L1 and L6-S1 DRG were counted after fluorescence
in situ hybridisation (FISH). FISH combined with retrograde labelling determined which
colon-innervating cells express TRPV4. Quantitative RT-PCR determined TRPV4 mRNA
expression in whole DRG, and specifically in laser captured colonic DRG cells identified by
retrograde labelling. To determine the role of TRPV4 in mechanosensation, mouse vagal
gastroesophageal and colonic splanchnic or pelvic afferents were recorded In Vitro(2,3) from
TRPV4+/+ and -/- mice. Results: FISH revealed only 21±0.9% (N=6) of T10-L1 DRG neurons
and 18±0.8% (N=6) of L6-S1 DRG neurons expressed TRPV4, whereas TRPV4 was localised
in 64±4% (N=6) of colonic T10-L1 neurons and 58±2% (N=6) of colonic L6-S1 neurons
(both P<0.0001 vs non-colonic, n=6). Correspondingly, QRT-PCR showed greater TRPV4
mRNA expression in laser-captured colonic cells than in whole DRG. In response to graded
mechanical stimuli, colonic splanchnic afferents from TRPV4-/- mice had reduced stimulus-
response functions compared with TRPV4+/+, in serosal afferents by 50% (P<0.0001, 2-
way ANOVA, n=23), and in mesenteric afferents by 30% (P<0.001, n=23). TRPV4-/- also
had reduced mechanosensitivity of colonic pelvic serosal afferents by 50% (P<0.0001, n=
17). In contrast, in TRPV4-/- mice vagal gastroesophageal mucosal (n=46) & tension (n=
70) receptors displayed no deficits in mechanosensory function compared with TRPV4+/+.
Conclusions: Although TRPV4 is expressed at low abundance in whole DRG, it is highly
prevalent in cells innervating the colon. In keeping with these results, targeted deletion of
trpv4 decreases responsiveness of splanchnic and pelvic colonic afferents, implicating TRPV4
in colonic mechanosensation. Gene products of trpv4 may represent pathway-specific novel
targets to treat mechanical hypersensitivity such as occurs in IBS. 1) Liedke, Cell-Mol-Life-
Sci. 62 (2005) 2985-3001, 2) Page et al, Gut, 54 (2005) 1408-15. 3) Brierley et al, Gastro.
127, 1, 2004, 166-178. Supported by NHMRC Australia.
1026
Molecular and Behavioral Correlates of Chronic Gastric Hypersensitivity in a
Novel Model of Functional Dyspepsia Type Pain in Rats
Liansheng Liu, John Winston, Mohan M. Shenoy, Pankaj J. Pasricha
Although several pathophysiological abnormalities have been noted in functional dyspepsia
(FD), the pathogenesis of its clinical hallmark, epigastric pain or discomfort, is poorly
understood. We hypothesized that chronic gastric hypersensitivity, such as seen in FD
patients, can be modeled in rats by transient gastric irritation during the neonatal period,
a time of known neuronal vulnerability to long-term plasticity. Methods: 10 days old male
Sprague-Dawley rats received 0.2 ml 0.1% iodoacetamide (IA) in 2% sucrose daily by oral
gavage for either 3 or 6 days; controls (C) received 2% sucrose for the same duration. Rats
in all groups were then allowed to grow normally to adult age, 9-11 weeks at which point
behavioral and visceromotor responses (using acromiotrapezius EMG recordings) to graded
gastric balloon distention (GD, 20-80mmHg) were tested. In adult rats, mRNA levels of
genes involved in nociception were measured in DRGs T9-T12 serving the stomach by
quantitative RT-PCR, and gastric emptying of a solid nutrient meal was measured. Results:
Rats in both IA groups exhibited gastric hyperalgesia to 60 and 80 mm Hg distention in a dose-
dependent manner, as compared to the control groups (Table). Mild gastric inflammation was
seen in neonatal rats following 6 days of IA treatment. No significant gastric pathology was
seen in hypersensitive adult rats compared to controls. Increased expression of both CGRP(1.3
fold, p<0.05) and BDNF(1.7 fold, p<0.05) and decreased expression of ASIC3 (0.75 fold,
p<0.05) mRNA were observed in DRGs T9-T12 in the IA group compared to controls. The
rate of gastric emptying was not significantly different between IA and control groups.
Conclusions: These studies demonstrate that acute mild gastric inflammation in the neonatal
period can result in chronic gastric hypersensitivity that persists through adulthood, even
in the absence of significant gastric pathology. Further, this is accompanied by sustained
and specific alterations in key molecules involved in nociceptive signaling. Our results offer
insight into the pathogenesis of chronic functional epigastric pain and provide a potential
model for further study of this important clinical problem.
Behavior: On a scale of 0-4, as previously described EMG: Expressed as % increase over
baseline activity during distention *P < 0.05 compared to control; **p<0.001 compared
to control
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Cholecystokinin Induced Plasticity of Esophago-Gastric Vago-Vagal Reflexes
Gregory M. Holmes, Melissa Tong, R. alberto Travagli
It is well accepted that the actions of cholecystokinin (CCK) on gastrointestinal (GI) functions,
including a decrease in gastric tone and motility, occur via a paracrine action on peripheral
vagal afferent fibers; vagal sensory activation engages a vago-vagal brainstem circuit that
conveys effector functions back to the GI tract. Recent evidence suggests, however, that the
locus of CCK's action on the GI system is not restricted to peripheral afferent vagal fibers,
but also affects brainstem structures directly. The aims of the present study were to investigate
the effects of brainstem administration of CCK-8s on gastric tone and motility in basal
conditions and following the activation of esophago-gastric reflexes. Sprague-Dawley rats of
either sex were fasted overnight, anesthetized deeply with Inactin® (100-150mg/kg i.p.)
before implantation of an extraluminal force transducer on the serosal surface of either the
gastric fundus or corpus to record circular smooth muscle activity. An balloon was placed
orally approximately 1cm above the esophageal hiatus, to induce the esophago-gastric
inhibitory reflex (JPhysiol 1999). Rats were then placed in a stereotaxic frame and the dorsal
surface of the medulla exposed. Esophageal distention induced a reproducible decrease in
gastric tone (-22.5±6.5 mV), which was unaffected by 4th ventricular application of vehicle.
Application of CCK-8s (0.15-15nmol) on the floor of the 4th ventricle induced a dose-
dependent immediate and transient decrease in gastric tone and motility. Upon return of
the gastric tone to baseline values, however, the esophageal distention-induced decrease in
gastric tone was reversed, such that esophageal distention now induced an increase in
gastric tone (i.e., a contraction). This esophageal distention-induced contraction persisted
for approximately 2 hours following the administration of CCK-8s, after which esophageal
distention again induced a relaxation. These data indicate that 1) CCK-8s induces gastric
relaxation when applied to the floor of the 4th ventricle, suggesting a brainstem site of
action; and, 2) vago-vagal reflexes are not static but, rather, are plastic and open to modulation
by vagal afferent inputs, neurotransmitters as well as circulating hormones, such as CCK,
acting at the level of the brainstem. Supported by NIDDK 55530.
1028
Recurrence of Crohn's Disease (CD) Is Not Affected By Anastomotic Type
Following Ileocolic Resection (Icr): Results of a Multicenter Randomized
Controlled Trail (RCT)
Robin S. Mcleod, Bruce G. Wolff, Sue Ross, Robert Parkes, Marg Mckenzie, Scott A.
Strong, Donald Buie, Neil H. Hyman, P. terry Phang, David J. Schoetz, Carol Vasilevsky
Objective: There is evidence that stasis of the fecal stream may be important in the develop-
ment of postoperative CD and therefore a wide surgical anastomosis may decrease the risk
of recurrence. Thus, the objective of this RCT was to determine whether stapled side-to-
side anastomosis (SA) results in decreased recurrence compared to handsewn end-to-end
anastomosis (HSA) following ICR in patients with CD. Methods: Patients with CD who
underwent an ICR were randomized to SA or HSA. Colonoscopy was performed at 12
months. The primary outcome was endoscopic recurrence (ER) while the secondary outcome
was symptomatic recurrence (SR) (defined as symptoms plus endoscopic disease recurrence).
Leak rates (LR) were compared. A multivariate analysis was performed to determine factors
affecting recurrence of CD Results: Of 171 patients from 18 institutions in Canada, USA
and UK who were included in the study, 1 was excluded, 9 were lost to follow-up and 20
refused endoscopy. Thus, 170 subjects were included in the analysis of postoperative out-
comes and 139 in the efficacy analysis. There were no significant differences between the
groups with regards to smoking status, presence of a fistula or abscess, length of SB resected,
number of previous resections or proportion having a laparoscopic procedure. Four patients
(4.7%) in the HSA and 5 (6.0%) in the SA group developed a leak (p=0.62). After a mean
follow-up of 11.9 months, the ER rate was 43.1% in the HSA compared with 36.2% in the
SA group (-6.8% difference, 95% CI -23.1% -9.5%, p=0.92). The SR rate was 22.2% in the
HSA group compared with 21.7% in the SA group (-0.5% difference, 95% CI -14.5%-
13.5%). On multivariate logistic regression analysis, previous resections was predictive of
a higher risk of ER (OR 1.7, 95%CI 1.1-2.9) and SR (OR 2.0, 95%CI 1.1-3.6) and compliance
with post-operative imuran maintenance therapy was predictive of lower SR (0.1, 95% CI
0.006-0.784). Conclusion: This study shows that ER and SR rates are similar whether a
HSA or SA is performed. Both techniques can be performed safely. Post operative maintenance
imuran therapy may be effective in reducing the risk of SR.
1029
Pathological Features of Inflammatory Bowel Disease in Cgd Are
Indistinguishable from Those Observed in Crohn's Disease
Daniel Marks, Kana Miyagi, Farooq Rahman, Nicholas Grosvenor, Stuart L. Bloom, Tony
Segal
INTRODUCTION: Patients with chronic granulomatous disease (CGD), a rare congenital
disorder affecting 1/250,000 people and characterised by defective neutrophil function,
frequently develop an inflammatory bowel disease similar to Crohn's disease. Recently,
Crohn's patients have also been demonstrated to mount an unusually weak innate immune
response, which has been proposed to play a primary pathogenic role. The concordance
between the features of the bowel disease in these two conditions has never been formally
evaluated. METHODS: Retrospective case note analysis. RESULTS: 25 adult patients with
CGD were identified (11 X-linked, 12 autosomal recessive, 2 genotype unidentified). The
mean age of diagnosis was 13.6 years (range: 0-41 years). 14 patients (56%) had experienced
gastrointestinal symptoms in the preceding 3 years, most frequently diarrhoea (36%), abdom-
inal pain (32%), constipation (28%), and bleeding per rectum (24%). 11 patients (44%)
had documented gastrointestinal inflammation that was not secondary to infection. The
mean age of onset of gastrointestinal disease was 19.2 years (range: 4-55 years). Disease
manifested at all locations throughout the alimentary canal including the upper gastrointesti-
nal tract (45%), small intestine (27%), colon (73%) and rectum (73%). All these patients
had discontinuous inflammation and peri-anal involvement, and approximately half (45%)
demonstrated epithelioid granulomata on histology. In addition, some patients developed
intestinal fistulae (27%) or stenosis (9%). All 11 patients (100%) fulfilled the Lennard-Jones
criteria for the diagnosis of Crohn's disease, and 3 patients were originally misdiagnosed as
such prior to the recognition of the immunodeficiency phenotype. Partial therapeutic
responses (by clinical and biochemical criteria) were observed with 5-aminosalicylates (5
patients), thalidomide (1 patient) and interferon-γ (1 patient), and complete remission
achieved with azathioprine (1 patient), Infliximab (1 patient) and intestinal resection (1
patient). CONCLUSIONS: There are striking pathological similarities between the bowel
diseases observed in CGD and Crohn's disease. CGD patients appear particularly prone to
developing peri-anal complications. *DJB Marks & K Miyagi contributed equally to this work
1030
Negative Serologic Testing for Crohn's Disease Is Highly Predictive of Absence
of Small Intestinal Inflammation On Capsule Endoscopy: Results from a
Single Academic Center
Marvin M. Singh, Sameer Saini, Laurel Fisher, Mimi Takami
Background: The clinical presentation of Crohn's disease (CD) is often nonspecific. Further-
more, the disease is confined to the small bowel in up to 30% of patients, potentially
escaping detection with traditional endoscopic evaluation. In recent years, wireless capsule
endoscopy (WCE) has emerged as a technique for direct visualization of the small bowel,
and over 25% of WCEs are now performed to exclude occult Crohn's enteritis (CE). Though
WCE is a promising technique, it brings with it significant cost and potential resource
burden as well as some risk to the patient. An alternative, less invasive, and more widely
available technique for excluding occult CE is serologic testing. However, no study has
specifically evaluated whether negative serologic testing can predict absence of findings
consistent with CE on WCE, therefore precluding the need for WCE in these patients. The
purpose of this study was to address this gap in the literature. Methods: A retrospective
chart review was performed on 835 patients in the University of Michigan Health System
who underwent WCE between 2001 and 2006. Inclusion criteria were: (1) clinical suspicion
for Crohn's disease; (2) negative upper and lower endoscopies; (3) documented IBD serologic
panel; and, (4) documented WCE. Exclusion criteria were: (1) age < 18 at time of IBD
panel; (2) WCE performed prior to IBD panel; and, (3) known IBD. Findings considered
to be consistent with small bowel CD on WCE were: (1) any ulcer; (2) any stricture; or,
(3) deep mucosal erosions. The negative and positive predictive values (NPV and PPV) of
the IBD serologies for WCE findings consistent with CD were then calculated. 95% confidence
intervals were also calculated around these point estimates. Results: 67 patients met the
above described inclusion criteria. The mean age of the patients was 40 years and 57% were
female. Overall, 58% had negative IBD panels and 19% had WCE findings consistent with
CD. Of patients with negative IBD panels, 95% did not have findings consistent with CD
on WCE (NPV = 95% [95% CI: 81%-99%]). Of patients with positive IBD panels, 41% had
findings consistent with CD on WCE (PPV 41% [95% CI: 23%-61%]). Conclusions: In
patients with suspected CD and negative traditional endoscopic evaluation, a negative IBD
panel is highly predictive of a negative WCE. While a positive IBD panel should prompt
further evaluation for occult CD with WCE (PPV = 41%), a negative IBD panel in this
population may preclude the need for WCE (NPV = 95%). Future studies should validate
these results in a prospective fashion.
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Ccx282-B, An Orally Active Inhibitor of Chemokine Receptor Ccr9, Shows
Anti-Inflammatory & Clinical Activity in the Treatment of Crohn's Disease
Satish Keshav, Solomon Ungashe, Wei Zheng, Pirow Bekker, Kim Wright, Thomas J.
Schall
Background: CCX282-B is an oral, highly-specific antagonist of the chemokine receptor
CCR9, which is expressed by mucosa-homing intestinal leukocytes. CCR9 and its ligand
CCL25 are implicated in the pathogenesis of Crohn's Disease (CD). Inhibition of CCR9
offers a novel and selective therapeutic approach to the treatment of CD. CCX282-B has
been well-tolerated in Phase 1 studies involving healthy volunteers and was recently tested
in a safety and tolerability study in patients with CD. Methods: CCX282-B was investigated
in a 71-patient, randomized, double-blind, placebo-controlled Phase II trial. Adult patients
with moderate to severe CD, and a Crohn's Disease Activity Index (CDAI) score of 220 to
450, were randomized to receive CCX282-B or placebo in a 2:1 ratio. One capsule containing
250 mg of CCX282-B or placebo was administered once daily for 28 days. CDAI and CRP
levels were measured at baseline and study days 8, 15 and 29. To focus on patients most
likely to have definitively active disease1-2, we evaluated the effect of a baseline of CDAI ≥
250 and CRP > 7.5 mg/L on a 70-point reduction in CDAI, an important indicator of clinical
activity. In addition, rates of reduction in CDAI and CRP changes were assessed. Results:
CCX282-B was well tolerated and no clinically significant changes in serum chemistry or
hematological parameters were found. The incidence of adverse events was similar in placebo
and CCX282-B groups. Across the entire cohort, a 70-point decrease in CDAI was seen in
49% of patients on CCX282-B versus 45% on placebo. However, in the specified population
of 39 patients with more active disease (baseline CDAI ≥ 250 and CRP > 7.5 mg/L) a
reduction of 70 points in CDAI occurred in 58% on CCX282-B versus 31% on placebo.
Stepwise subpopulation analyses (table below) show increasing separation between active
and placebo in 70-point reductions in CDAI. These positive trends in efficacy are strongly
supported both by higher rates of reduction in CDAI in the active group (p=0.006) and a
CRP decrease of 11 mg/L in the CCX282-B group compared to placebo (p=0.07). Conclusion:
CCX282-B is a highly specific antagonist of CCR9, and the first chemokine-based inhibitor
of leukocyte trafficking to be tested in IBD. In a safety and tolerability study with CCX282-
B, specified subpopulation analyses demonstrate encouraging evidence for the clinical benefit
of its use in the treatment of Crohn's Disease. References: 1 Su et al., 2004, Gastro 126:1257;
2Will et al., 2005, DDW meeting; Abstr 338.
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Visilizumab Therapy in Subjects with Moderate-to-Severe, Refractory Crohn's
Disease
Daan W. Hommes, Stephan R. Targan, Axell Dignass, Daniel C. Baumgart, Lloyd Mayer,
Lili Zhang, Keith Wilson, Jim Lowder, Matthew Frankel
Purpose: We evaluated the safety and clinical activity of visilizumab, a humanized anti-CD3
monoclonal antibody in an open-label, phase I study in moderate-to-severe inflammatory
non-fistulizing Crohn's Disease (CD). Methods: Subjects with a CDAI > 250, a CRP > 4 mg/
L, and endoscopic evidence of active disease were administered i.v. bolus injections of
visilizumab 10 μg/kg on 2 consecutive days (Days 0 and 1). Clinical response was defined
as a decrease in the CDAI of >100 points below the subjects' baseline value, and remission
as a CDAI <150 at D59. Biopsies from a subset of 6 subjects were evaluated by immunohisto-
chemistry at pre-therapy and Day 59. Results: Seventeen of 18 enrolled subjects received
both doses (1 subject withdrew after the first dose); 13 treated subjects were followed
through to Day 89. The median baseline CDAI was 396 (271-516), and the median baseline
CRP was 28 mg/L (2-70). Nine subjects were oral or IV steroid-resistant, 6 were oral or IV
steroid-dependent, and 3 were steroid-independent. Seventeen subjects had received prior
infliximab (IFX); 5 were primary IFX non-responders, 2 had had intolerable infusion reac-
tions, and 10 had discontinued IFX due to loss of activity. By Day 29, responses were seen
in 11/18 subjects, clinical remission in 5/18. More than half (13/18) of the subjects had a
clinical response to visilizumab at Day 59, and 5 were responders at 6 months. Remission
by Day 59 was achieved in 6/18 subjects. The median D59 CDAI was 266 (69-570). On
average, in visilizumab responders, the CRP decreased by >/= 50% by or before Day 15. By
Day 59, all 6 subjects for whom paired biopsies were available showed evidence of mild to
moderate histological improvement. Mild to moderate cytokine release syndrome (CRS)
occurred in the majority of subjects. The adverse event (AE) profile, including their severity,
incidence, and drug relatedness were similar to that previously seen in IVSR-UC subjects
who had received an equivalent dose of visilizumab (10 μg/kg x 2). No lymphoproliferative,
malignant or life-threatening AEs were reported. Conclusion: Two 10 μg/kg visilizumab
doses administered as IV bolus injections on consecutive days were tolerated and produced
a rapid and sustained improvement in 11/18 subjects with moderate-to-severe, refractory CD.
1033
Extracorporeal Photoimmune Therapy (Ecp) for Refractory Moderately Active
Crohn's Disease (CD): A Multicenter, Open-Label Study
Maria T. Abreu, Christian Von tirpitz, Peter J. Mannon, William J. Sandborn, Thomas
Ochsenkuehn, Stephen B. Hanauer, Jim Wang, Walter Reinisch, Robert Hardi, Lloyd F.
Mayer, Emil Bisaccia, Robert Knobler, Sergij Goerdt, Martin Kaatz, Paul Williamson, Gert
A. Van assche
Background: ECP involves ex vivo treatment of peripheral blood leukocytes with 8-methoxyp-
soralen and UVA light causing apoptosis. Reinfusion of autologous apoptotic leukocytes has
been shown to be immunomodulatory and thought to be the basis for therapeutic activity
of ECP in immune-mediated inflammatory diseases. Aim: Evaluate the safety and efficacy
of ECP in patients (pts) with moderately active CD refractory or intolerant to immunosuppres-
sants (IS) and/or anti-TNF agents (anti-TNF). Methods: Treatment was twice-weekly with
ECP at Weeks (W) 0-4 then twice-weekly every other week from W6 to 12. Primary efficacy
assessment was a clinical response (CDAI decrease of ≥ 100 from baseline or CDAI < 150)
at W12. Inclusion criteria included CDAI from 220 to < 450, and evidence of inflammation
(CRP >10.0 mg/L or endoscopic evidence). Pts on concomitant IS, anti-TNF or corticosteroids
(CS) were permitted to continue them at stable doses during the study. Results: 28 pts
(mean age 38 years, 75% female, 100% Caucasian) participated. At baseline, 18/28 (64%)
were on CS, and 13/28 (46%) were on IS, of whom 3 (11%) were receiving anti-TNF. 5
pts discontinued due to active CD and one patient due to an increase in CRP. 14/28 (50%)
of pts achieved a clinical response. The response was rapid with 13/28 (46%) of patients
responding by W6. 7/28 pts (25%) went into remission and had a drop of over 200 points
in CDAI. 7/14 (50%) of anti-TNF refractory/intolerant pts responded. Median IBDQ improved
from 120 at baseline to 158 at W12. Median CRP decreased from 12.1 mg/L at baseline to
9.7 mg/L at W12. All 14 pts who achieved a clinical response by W12 continued in a 12W
extension phase; 71% maintained their response through W24. ECP was well-tolerated with
only 2 serious adverse events: general health deterioration and anemia. Conclusion: ECP is
safe and is beneficial in pts with moderately active CD refractory to IS and/or anti-TNF
agents. Future randomized trials of ECP are warranted.
1034
Myosin Light Chain Kinase-Mediated Increases in Tight Junction Permeability
Accelerate Onset and Intensify Severity of Experimental Inflammatory Bowel
Disease
Liping Su, Le Shen, Daniel R. Clayburgh, Jonathan B. Meddings, Clara Abraham, Jerrold
R. Turner
Increased epithelial tight junction permeability, measured as intestinal barrier loss, is an
established feature of human inflammatory bowel disease (IBD) and is present in some
unaffected relatives of IBD patients. Barrier dysfunction is also detected prior to disease in
experimental IBD, leading to proposals that barrier dysfunction may cause IBD. However,
since inflammatory cytokines that are elevated in IBD cause barrier dysfunction, the observed
changes may be secondary. The effect of primary barrier dysfunction has only been explored
experimentally by gross disruption of epithelial integrity; A condition not seen in humans.
We sought to test the hypothesis that, in an intact epithelium, permeability increases induced
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by physiologically-relevant mechanisms may predispose to IBD. METHODS: Transgenic
mice expressed constitutively-active myosin light chain kinase (CA-MLCK) from the villin
promoter in intestinal epithelia. Colonic and jejunal permeability were measured In Vivo by
urinary fractional recovery and perfusion, respectively. Transgenic RAG1-/- mice were used
for adoptive transfer. RESULTS: CA-MLCK mice grew and gained weight normally without
any apparent disease. CA-MLCK expression increased jejunal and colonic epithelial myosin
light chain phosphorylation. Corresponding elevation of colonic permeability was detected
as 54±7% and 70±9% increases in urinary recovery of creatinine and sucralose, respectively
(p<0.02). CA-MLCK expression increased jejunal permeability by 65±5% (p<0.01), while
the MLCK inhibitor PIK corrected permeability to that of control mice. Quantitative RT-
PCR showed a 165±18% increase in mucosal IFNγ (p=0.03), suggesting initiation of a
subclinical inflammatory process. Adoptive transfer of 5x105 CD4+CD45Rbhi lymphocytes
into RAG1-/- recipients caused weight loss within 19±1 days. In CA-MLCK RAG1-/- recipients
weight loss was apparent within 12±1 days (p=0.04). Moreover, CA-MLCK expression caused
more severe disease; 60% of CA-MLCK RAG1-/- recipients died within 6 weeks vs. 20% of
RAG1-/- recipients (p<0.01). Histological analysis showed that crypt abscesses and epithelial
hyperplasia developed earlier in CA-MLCK-expressing mice and that lymphoid infiltration,
crypt architectural distortion, and mucosal thickening were more extensive at later times.
CONCLUSION: Physiologically-relevant intestinal permeability increases induced by MLCK
are insufficient to cause disease. However, permeability increases accelerate onset and progres-
sion of experimental IBD. These data support the hypothesis that increased epithelial per-
meability is deleterious and suggest that restoring barrier function may be therapeutic in IBD.
1035
The Wnt Signaling Pathway Plays An Important Role in Intestinal Epithelial
Apoptosis During Inflammation
Mike G. Laukoetter, Porfirio Nava, Winston Lee, Matthias Bruewer, Jan M. Klapproth,
Brian A. Babbin, Charles A. Parkos, Asma Nusrat
Increased epithelial apoptosis induced by pro-inflammatory cytokines contributes to the
breakdown of the intestinal epithelial barrier, which plays a central role in the pathogenesis
of inflammatory bowel disease (IBD). While it is well known that interferon gamma (IFN-γ)
induce apoptosis in epithelial cells, the underlying mechanisms are incompletely understood.
Since the Wnt-signaling pathway has been implicated to play a role in epithelial proliferation
and differentiation we examined contribution of this pathway to IFN-γ-induced intestinal
epithelial apoptosis. For these studies we utilized complementary In Vitro cell culture and
In Vivo DSS-induced colitis models. We observed upregulation of an antagonist of the Wnt
signaling pathway referred to as Dickkopf Homolog 1 (DKK-1) in inflamed intestinal mucosa.
Since IFN-γ is upregulated in inflamed intestinal mucosa of IBD patients, we examined the
role of DKK-1 in IFN-γ- induced epithelial apoptosis. Apoptosis in intestinal epithelial cells
(IECs) incubated with human IFN-γ (100 U/mL) for 72hrs was confirmed by analysis of
caspase-3 and cleavage of PARP by western blotting and immunofluorescence labeling/
confocal microscopy. IECs undergoing apoptosis showed a 3 fold upregulation of DKK-1,
its receptor Kremen1, and a significant downregulation of its coreceptor LRP6 compared to
controls. Furthermore, INF-γ induced upregulation of p53 which is known to regulate DKK-
1 expression. Overexpression of p53 in IECs resulted in a significant upregulation of DKK-
1 expression compared to controls, and this effect was reversed by expression of dominant
negative p53. The ability of INF-γ to induce apoptosis was prevented by using a functional
inhibitory antibody to DKK-1 and a glycogen synthase kinase-3 (GSK-3β - downstream
target of DKK-1) inhibitor. As an In Vivo correlate, we observed significant upregulation of
DKK-1 in colonic mucosa and plasma from DSS-treated mice and in colonic mucosa from
Crohn's disease patients. These findings support a novel role for the Wnt pathway inhibitor,
DKK-1 in mediating IFN-γ induced IEC apoptosis. In conclusion, exposure to IFN-γ induces
p53 and DKK-1 secretion and engagement of DKK-1 to its cell surface receptors Kremen1
and LRP-6. Subsequently, the APC-axin-GSK-3-β complex is activated resulting in phos-
phorylation and degradation of β-catenin thereby inhibiting cell proliferation and stimulating
cell death. These findings represent the first report demonstrating participation of the Wnt
signaling pathway in apoptosis induced by a pro-inflammatory cytokine. (Supported by
grants from the German Research Foundation - La 2359/1-1 and the NIH - DK-55679, DK
- 61379).
1036
Van Gogh Like-1 Protein (Vangl1) a Downstream Effector of Intestinal Trefoil
Factor Mediates Protection Form Colitis
Jiri Kalabis, Ian M. Rosenberg, Daniel K. Podolsky
Introduction: Intestinal trefoil factor (ITF/TFF3) is important for mucosal homeostasis and
wound healing, but its signaling is incompletely understood. We previously reported Van
Gogh like-1 (Vangl1) protein as a downstream effector, required for ITF induced wound
healing of IEC's. siRNA mediated inhibition of Vangl1 blocked ITF and EGF induced wound
healing In Vitro. Vangl1 protein, a member of planar cell polarity pathway in Drosophila
was polarized in migrating IEC, where it selectively inhibited EGFR and CDC42 pathways
in the posterior pole of cell. Aim: To test the functional role of Vangl1 protein in dextran
sodium sulfate (DSS) induced colitis In Vivo. Material & Methods: Rabbit antibodies were
raised toward peptides derived from the extracellular domains of Vangl1 protein (α-VE1 &
2). Polyclonal antibodies were affinity purified and tested for their blocking ability a) on
ITF induced phosphorylation of Vangl1 protein using immunoprecipitation and western
blotting b) on ITF induced healing in the scratch wound-healing assay of IEC's; human
HT29 and rat IEC6 cells were used. Rabbit IgG (R-IgG) and rabbit polyclonal antibody
raised against the intracellular cytoplasmic tail of Vangl1 (α-VC1 & 2) were used as controls.
Female Sv129 mice, age 7-9 weeks were treated with 4% (w/v) DSS from day 0-6. Mice
were treated with control (R-IgG) orα-VE1 & 2 AB's (each 400μg /mouse/day on days 1,3 and
5; total 1.2mg/mouse). Weight, behavior, consistency of stool and bleeding were monitored
throughout the experiment and morphology of coecum and colon were examined on day
8. Results: Both α-VE1 & 2 antibodies, but not R-IgG inhibited ITF induced phosphorylation
of flag-Vangl1 protein in HCT116 epithelial cells. Further, both α-VE1 & 2, but not R-IgG,
α-VC1 & 2, inhibited ITF induced wound-healing of both human and rat IEC's. Mice treated
A-158AGA Abstracts
with α-VE1 & 2 antibodies lost significantly more weight during the course of DSS colitis.
This difference was significant from day 3 forward and was accompanied by increased
bleeding in stool. Differences in weight correlated with morphological findings on day 8.
There were signs of recovery with predominant complete epithelial coverage and local goblet
cell loses in control treated mice. α-VE1 & 2 treated mice had significantly increased damage,
with areas of complete loss of epithelium and complete goblet cell loss. These changes were
profound in the coecum, distal and proximal colon, while less pronounced in the medium
colon. Conclusions: Vangl1 protein has a protective function in DSS model of murine colitis.
1037
Phosphatidylinositol 3-Kinase Is Required for Immune-Mediated Intestinal
Epithelial Stem Cell Activation
Goo Lee, Navdha Mittal, Ramanarao Dirisina, Jennet Manjali, Terrence A. Barrett
PI3K is involved in signaling pathways that regulate cellular growth and survival. Recently,
we found that increased PI3K signaling promotes intestinal stem cell (ISC) activation (He
et al. Nat Genet, 2006). The gene for the major regulatory subunit of class IA PI3K, pik3r1,
encodes for three proteins (p85α, p55α and p50α). Mice deficient in p85α have increased
insulin sensitivity and hypoglycemia. To examine the role of PI3K on ISC activation specf-
ically, mice with loxP-flanked exon 7 of pik3r1 (p85αfl/fl) were used and mated with Mx1Cre
mice (Mx1Cre:p85αfl/fl). Inducible Mx1Cre system effectively targets Cre expression to stem
cells including those in intestinal crypt (He et al. Nat Genet, 2004). ISC activation was induced
by anti-CD3 and investigated using western blot (nuclear β-catenin in isolated crypt epithelial
cells), immunohistochemistry (IHC) of active (nuclear) β-catenin, BrdU and real time PCR
for β-catenin target genes. Upon Cre-mediated deletion by poly I:C injection, p85α becomes
truncated along with expression of p55α and p50α, referred as p85α KO (knockout) mice.
p85α protein levels from the cytoplasm of the crypt epithelial cells were reduced in p85α
KO mice as predicted. Consequently, Akt activation by anti-CD3 in p85α KO mice was
significantly reduced, as evidenced by attenuated phosphorylation at Ser-473 of Akt. Loss
of p85α attenuated Akt-induced cytoplasmic relocalization of FKHR. These findings suggested
that p85α KO mice expressed lower levels of epithelial class IA PI3K that reduced PI3K/
Akt signaling. Examination of ISC revealed that p85α KO mice reduced anti-CD3-induced
ISC activation, resulting in a decrease of nuclear β-catenin from intestinal crypts detected
by both western blot and IHC. Attenuated PI3K/Akt signaling (and FKHR nuclear retention)
reduced proliferation and increased apoptosis detected by BrdU and TUNEL stainings,
respectively. p85α deficiency failed to decrease iNOS, TNF, and IL-1β mRNA levels by anti-
CD3 from ileal mucosal scrapings in order to include lamina propia immune cells, consistent
with specificity of epithelial Cre expression. Analysis of crypt-specific mRNA detected by
laser capture microdissection showed decreased β-catenin target gene expressions (c-Myc
and CyclinD1). Taken together, these findings indicate that PI3K signaling is required for
immune-mediated Wnt/β-catenin signaling in ISC. This critical pathway may be an attractive
target for chemopreventative strategies in colitis-induced cancer. Supported by NIH RO1
grant AI61702-01A1
1038
Critical Role of Epithelial Junctional Adhesion Molecule-a in Experimental
Colitis
Stefania Vetrano, Francesca Tognoli, Elena Borroni, Nadia Polenterutti, Monica Corada,
Maria rosaria Cera, Vincenzo Arena, Alberto Malesci, Massimo Locati, Maria Rescigno,
Elisabetta Dejana, Silvio Danese
Junctional adhesion molecule -A (JAM-A) is a protein localized at the tight junctions of
epithelial and endothelial cells. JAM-A is involved in the control of leukocyte migration and
infiltration into the tissues. Aim of this study was to investigate the expression and functional
role of JAM-A in experimental colitis. C57BL6 JAM -A -/- , Tie-2 Cre JAM-A -/- (endothelial
specific JAM inactivation ) and matched control mice (wt) were treated with 2% dextran
sulphate sodium (DSS) for 7 days. Mice were monitored daily for weight loss, presence of
fecal blood and stool consistency. A disease activity index (DAI) was calculated. After 7
days, mice were sacrificed, colonic inflammation assessed using an histological score and
TNFα and chemokines measured in colonic organ culture by ELISA. JAM-A expression was
detected in the gut of healthy and DSS-colitic wt mice by immunohistochemistry at confocal
microscopy. JAM-A -/- mice were significantly more susceptible to experimental colitis as
assessed by body weight loss (p<0.001), DAI (p<0.001) and histological inflammation
(p<0.05) compared to Tie-2 Cre JAM-A -/- and wt mice. Notably, JAM-A -/- mice showed
severe and significant mortality (100%, p<0.001) upon administration of DSS compared to
Tie-2 Cre JAM-A -/- (0%) and wt mice (0%). JAM-A -/- mice produced significantly higher
TNFα, MIP-1α , MIP2 and KC-1 levels (all p<0,05) than Tie-2 Cre JAM-A -/- and wt mice.
Immunofluorescence analysis showed that in the healthy intestine, JAM-A was abundantly
expressed by epithelial and endothelial cells. However, in inflamed intestine, a down -regul-
ation of JAM-A in the epithelial layer was observed. Our results show that epithelial, but
not endothelial, JAM-A, has a strong protective effect against intestinal inflammation and
suggest that its expression is modulated by inflammatory conditions.
1039
Ksr Regulates Intestinal Epithelial Cell Proliferation and Apoptosis During
Chronic Inflammation in a Mouse Model of Colitis
Jeremy A. Goettel, Kay Washington, D. brent Polk
Background: The intestinal epithelium is a dynamic single cell layer providing selective
transport and barrier functions that protect the host from the outside world. Defects in
barrier function or ulcerations in the epithelium lead to an inflammatory response. While
acute inflammation is beneficial for bacterial clearance and cell survival, chronic inflammation
is associated with increased risk for developing cancer in diseases such as inflammatory
bowel diseases (IBD). While the etiology of these diseases is being actively investigated,
dysregulated immune function to luminal antigens and high levels of tumor necrosis factor
(TNF)-α are hallmarks. Our lab has previously shown kinase suppressor of Ras (KSR) to
be an important mediator of cell survival in response to TNF-α both In Vitro and In Vivo.
To investigate the role of KSR in the pathogenesis of IBD, we utilized the interleukin-10
(IL-10) deficient mice as a model of spontaneous colitis. Since IL-10-/- mice on a BALB/c
background develop spontaneous colitis, and we previously showed increase colitis in the
KSR+/-/ IL-10+/- mouse compared to IL-10-/- or KSR-/-, we wanted to test the hypothesis
that KSR protects epithelial cells from apoptosis within an inflammatory environment.
Methods and Results: Mice deficient for both IL-10 and KSR were bred and maintained on
a BALB/c background. At 10 weeks of age wild type (WT) BALB/c, KSR-/-, IL-10-/-, and
KSR-/-/IL-10-/- double knockout (DKO) mice were sacrificed and colon removed and scored
for intestinal injury, proliferation, apoptosis, and signaling proteins downstream of TNF-
Receptor 1. DKO mice have a 8-fold increase in colonic injury score, which is marked by
enterocyte loss, infiltrating mononuclear cells, and hyperplasia when compared to WT,
KSR-/-, or IL-10-/- mice of the same age. Mucosal scrapings of colonic epithelial cells show
that DKO mice have 30-fold higher levels of TNF, increased cyclooxygenase-2 (COX-2) and
IκB-α expression, and increased activation of extracellular signal-regulated kinase (ERK)
and AKT compared to WT and single gene knockout mice. Conclusion: These data suggest
that loss of KSR leads to early onset of colitis compared to IL-10-/- alone. The increase in
epithelial apoptosis in DKO mice may result from a marked increase in TNF expression
without an increase in NF-κB activation. The significant increase in epithelial cell proliferation
combined with enhanced apoptosis may alter barrier permeability and enhance mucosal
inflammation. Thus KSR appears to regulate both proliferative and apoptotic responses to
cytokine-mediated injury in the intestinal epithelium In Vivo with significant implications
for IBD.
S1034
Proton Pump Inhibitor Use Is Associated with An Increased Risk of Severe
Community Acquired Infections
Laura E. Targownik, Robert J. Laheij, Colleen Metge, Stella Leung
Background: Proton pump inhibitor (PPI) use has been associated with an increased risk
of community acquired pneumonia and C. difficile, presumably secondary to loss of the
natural antibacterial host defenses provided by gastric acid. Many severe systemic infections
may use the gut as an infectious reservoir, and PPIs have been shown to increase enteric
bacterial colonization. The relationship between PPI use and other serious infections remains
uncharacterized. Objective: To determine whether the use of proton pump inhibitors
increases the risk of severe community-acquired infections in a large population-based health
utilization dataset. Methods: We conducted a population-based case-control study using the
Manitoba Health Population Health Research Data Repository (MH-PHRDR) The MH-PHRDR
contains all health care contacts and pharmacy dispensations for all Manitobans from 1995
to 2004. We identified all individuals admitted to hospital with severe community-acquired
infections in subjects with either ongoing or previous use of proton pump inhibitors between
October 1995 and March 2004. A severe community acquired infection was defined as a
primary admission associated with an ICD-9 code for an infectious disease associated with
a secondary ICD-9 code for organ system dysfunction within 3 days of admission. Up to
10 controls were matched on sex, year of birth, and index date. Conditional logistic regression
was used to estimate the relationship between active use of PPIs and serious community
acquired infections and to adjust for multiple confounding variables, including the presence of
comorbid diseases, use of antibiotics, and immunosuppressive agents. Results: We identified
119,047 subjects with a history of PPI use, of whom 904 met our diagnostic criteria for
severe community acquired infection. Patients with severe infections were more likely than
controls to be actively using PPIs (adjusted OR 1.62, 95% CI 1.38-1.90). The association
was increased for high dose proton pump inhibitor users, (adjusted OR vs. standard dose
PPIs: 1.39, 95% CI: 1.02-1.88). Both respiratory (OR 1.78) and non-respiratory severe
infections (OR 1.52) were associated with active PPI use. Mortality in patients with severe
community acquired pneumonia was also increased among PPI users (OR 1.66 95% CI:
1.21-2.11) Conclusion: The use of proton pump inhibitors is associated with an increased
risk of severe community-acquired infections. This increased risk is seen both for respiratory
and non-respiratory infections, and is further pronounced in patients using high-doses of PPIs.
Further research is required to confirm the nature of this potentially significant relationship.
S1035
Does Technology Over Two Decades Affect the Diagnostic Accuracy of
Endoscopic Ultrasound with FNA in Evaluating Mediastinal
Lymphadenopathy? - A Meta-Analysis & Systematic Review
Jyotsna Bk reddy, Srinivas R. Puli, Shailender Singh, Mojtaba Olyaee
Purpose: Endoscopic ultrasounds technology has improved over the past two decades. The
affect of this technologic advancements on the diagnostic accuracy of Endoscopic Ultrasound
with FNA (EUS-FNA) in evaluating mediastinal lymphadenopathy is not known. Aim: To
evaluate the affect of technologic advancements on EUS-FNA's accuracy in diagnosing
mediastinal lymphadenopathy. Methods: Study Selection Criteria: Only EUS-FNA studies
confirmed by surgery or prolonged follow-up were selected. EUS criteria for nodal metastasis
were: > 1 cm, hypoechoic, and round instead of elliptical. Only studies from which a 2 X
2 table could be constructed for true positive, false negative, false positive and true negative
values were included. Data collection & extraction: Articles were searched in Medline,
Pubmed, Ovid journals, CINH, International pharmaceutical abstracts, old Medline, Medline
nonindexed citations, and Cochrane control trial registry. 2X2 tables were contructed from
the extracted data. Statistical Method: EUS studies were grouped into three time periods to
standardize the change in EUS technology and also to standardize the change in EUS criteria
for lymph node involvement. These time periods were 1990 to 1995, 1996 to 1999, and
2000 to 2006. Meta-analysis for the accuracy of EUS was found by calculating pooled
estimates of sensitivity, specificity, likelihood ratios, and diagnostic odds ratio. Pooling was
conducted by both Mantel-Haenszel (fixed effects model) and DerSimonian Laird method
(random effects model). The heterogeneity among studies was tested using Cochran's Q test
based upon inverse variance weights. Results: Initial search identified 2610 reference articles,
of which 360 relevant articles were selected and reviewed. Data was extracted from 32
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studies (N= 4912) which met the inclusion criteria. All the pooled estimates during the
three time periods are given in table 1. The p for chi-squared heterogeneity for all the pooled
accuracy estimates was > 0.05. Conclusion: EUS-FNA is the best available diagnostic tool
to evaluate mediastinal lymphadenopathy. There was a significant improvement in the
sensitivity over years with the change in technology and diagnostic criteria. The specificity
of EUS-FNA remains high over years. EUS-FNA should be the diagnostic modality of choice
to evaluate mediastinal lymphadenopathy.
Table 1: Pooled diagnostic accuracy estimates of EUS-FNA for different time periods with
95 % confidence intervals
S1036
Helicobacter pylori, Cag a and Pepsinogen Status in Esophageal
Adenocarcinoma, Barrett's Esophagus and Reflux Esophagitis Patients
Lesley A. Anderson, Brian T. Johnston, Peter Watson, Seamus J. Murphy, Kathy Bamford,
A. Ghazy, Heather R. Ferguson, Harry Comber, Jim Mcguigan, John V. Reynolds, Liam J.
Murray
Introduction: Several studies have demonstrated a protective effect against esophageal aden-
ocarcinoma (EAC) in H. pylori infected individuals. Infection with H. pylori or Cag A strains,
has also been shown to be associated with reduced risk of Barrett's esophagus (BE) and
reflux eosphagitis (RE), although there is substantial heterogeneity in findings between
studies. Several mechanisms of action have been suggested including gastric atrophy. We
investigated serological evidence of H. pylori infection, Cag A infection and gastric atrophy
within an Irish population-based study of RE, BE and EAC. Methods: This study utilised
data and samples collected in the FINBAR study. Four groups were recruited: 1)patients
with EAC,2)patients with long-segment BE,3)normal controls and 4)RE patients. Criteria
for designating H. pylori seropositivity were any of the following: 1.116KD (CagA) positive
w h e r e C a g A w a s p r e s e n t w i t h 1 o r m o r e o f t h e f o l l o w i n g b a n d s : 8 9 K D
(VacA),37KD,35KD,30KD (UreA) and 19.5KD or with the presence of the current infection
marker 2.Presence of any 1 band at 89KD, 37KD, 35KD with/without the current infection
marker 3.Presence of both 30 KD and 19.5 KD with/without current infection marker A
sample was designated Cag A positive if criterion 1 was met. Serum were tested for Pepsinogen
1 and 2 using a commercial enzyme immunoassay (Biohit PLc, Helsinki, Finland). A pep-
sinogen ratio (pepsinogen I divided by pepsinogen II) was calculated and the threshold for
gastric atrophy was set at 3 (a ratio <3 denoting atrophy). Analysis: Unconditional logistic
regression modelling was used to examine the associations between serological evidence of
H. pylori infection, Cag A infection and gastric atrophy and RE, BE and EAC (comparison
group, normal controls). Results: H. pylori infection appeared to be protective against all
three disease states with the odds of antibody positivity substantially reduced compared to
normal controls. Adjustment for potential confounders strengthened these associations and
fully adjusted odds ratios were similar across the disease states. When these analyses were
repeated for antibodies to the CagA antigen only, a similar pattern was seen although the
associations were weaker across the three diseases. There were strong inverse associations
between gastric atrophy and RE and BE. Ggastric atrophy appeared to protect against
esophageal but not junctional tumours. Conclusion: Our findings confirm that H. pylori and
Cag A infection protects against EAC and its precursors. Gastric atrophy most likely plays
a role in mediating this protection but other mechanisms of action may also be involved.
S1037
Respiratory Tract Infections with Acid-Suppressive Therapy: A Retrospective
Analysis of 31 Comparative Clinical Studies with Esomeprazole
Lennart Estborn, Svante Joelson
Introduction: There is debate over whether a causal association exists between decreased
gastric pH, such as that occurring with potent gastric acid-suppressive therapy, and an
increased risk of pulmonary infection, specifically pneumonia. Methods: This retrospective
analysis investigated the occurrence of respiratory tract infections (RTIs), including pneumo-
nia, with esomeprazole, placebo and comparator acid-suppressive agents. The AstraZeneca
ARIADNE safety database was searched for comparative, controlled phase II-IV clinical
studies with esomeprazole and standard reporting of all adverse events (AEs). Pooled adverse
event data were presented according to treatment comparison (esomeprazole vs placebo,
omeprazole, lansoprazole or ranitidine, respectively). Frequency and relative risk (RR), with
99% confidence interval (CI) and adjustment for time on treatment, were calculated for the
following four AE categories, based on MedDRA terms: all RTIs, signs and symptoms
potentially indicating RTI, lower RTI, and pneumonia. Results: A total of 16,583 patients
in 31 studies received esomeprazole for 2957.9 patient-years; 12,044 patients received either
placebo (n=3358) or comparator acid-suppressive drugs [omeprazole (n=4120), lansoprazole
(n=4234) or ranitidine (n=332)] for a total of 1923.2 patient-years. There were no significant
between-group differences with esomeprazole and placebo in the occurrence of RTI (9.2%
vs 8.5%; RR 0.93 [99% CI 0.78, 1.11]), signs and symptoms of RTI (1.8% vs 1.9%; RR
0.85 (99% CI 0.57, 1.27]), lower RTI (1.6% vs 1.5%; RR 0.92 [99% CI 0.59, 1.42]) or
pneumonia (0.2% in both groups; RR 0.94 [99% CI 0.29, 3.07]). The comparisons of
esomeprazole with the other comparator acid-suppressive drugs showed a similar pattern
with only minor between-group differences in the occurrence of any category of AE. The
occurrence of any of the four AE categories was also similar with esomeprazole 20 mg and
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40 mg, and with esomeprazole vs placebo according to treatment duration (4-8 weeks vs
16-26 weeks) and indication (GERD, NSAID, dyspepsia or reflux asthma). Conclusion:
This pooled analysis found no causal association between acid-suppressive therapy with
esomeprazole and increased risk of RTI, including pneumonia, in patients receiving this
agent for gastric acid-related disorders.
S1038
Smokeless Tobacco Use and Gastrointestinal Morbidity: An Endoscopic
Population-Based Survey. The Kalixanda study
Pertti Aro, Jukka A. Ronkainen, Tom Storskrubb, Gunilla Bolinder, Elisabeth Bolling-
sternevald, Michael Vieth, Manfred Stolte, Lars Engstrand, Kjell Alving, Sven-erik
Johansson, Nicholas J. Talley, Lars Agréus
Background and aims: Smokeless tobacco (moist snuff) is widely used in Scandinavia and
India, while the USA is the biggest market of smokeless tobacco in the world with approxim-
ately 12 million users. Nicotine intake is higher than in smokers and tobacco juice contamin-
ated saliva is swallowed. Little is known regarding the impact of smokeless tobacco on
gastrointestinal symptoms and pathological findings. We aimed to investigate whether expo-
sure to different forms of tobacco influences upper gastrointestinal symptomatology, histolog-
ical status and Helicobacter pylori (H. p.) infection. Method: A random sample (n=2,860) of
the adult population of two northern Swedish municipalities (n=21,610), was surveyed in the
Kalixanda study using a validated postal questionnaire assessing gastrointestinal symptoms. A
sub-sample of the responders was invited, in random order, to undergo an esophagogastrodu-
odenoscopy (EGD) including biopsies, H. p. culture and serology and symptom assessment.
The participants' present and past use of tobacco products was explored at the clinic visit.
Results: 2,122 individuals (participation rate 74.2%) completed the abdominal symptom
questionnaire; 1,001 (mean age 54.1 years, 48.8% males) of them participated in the EGD
part of the study (participation rate 73.3%). No symptom complexes were associated with
smokeless tobacco use, while cigarette smoking was a risk factor for dyspepsia (OR, 1.50; 95%
CI, 1.03-2.18). Smokeless tobacco users had a higher prevalence of esophagitis compared with
non-users (p=0.04) and a lower risk for peptic ulcer disease compared with smokers (OR,
0.12; 95% CI, 0.003-0.85). Use of smokeless tobacco was an independent risk factor for
thickening of the basal cell layer (OR, 1.84; 95% CI, 1.09-3.10) and for elongation of
papillae (OR, 1.75; 95% CI, 1.03-3.00) at the esophago-gastric junction, and for intestinal
metaplasia (a pre-neoplastic mucosal change) in the antrum (OR, 2.43; 95% CI, 1.10-5.38).
Current H. p. prevalences and seropositivity were not significantly associated to tobacco
use (table %, 95% CI). Conclusions: Smokeless tobacco is a risk factor for esophagitis and
antral intestinal metaplasia.
H. pylori split by tobacco user groups
S1039
Comparing Double Dose Versus Standard Dose Proton Pump Inhibitor
Therapy As Initial Management of Patients with Upper Gastrointestinal
Symptomatology
Laura E. Targownik, Colleen Metge, Stella Leung, Daniel F. Chateau
Background: Proton pump inhibitors are frequently used in patients presenting with a variety
of upper gastrointestinal symptoms. It is unclear whether prescribing a higher dose of PPIs
initially is associated with improved clinical and economic outcomes. Methods: We used
the Manitoba Health population based province-wide health care utilization database to
identify all patients between 1997-2002 with a new PPI prescription (no PPI prescription
in previous 12 months) associated with a physician visit for an upper gastrointestinal
symptom without a history of gastrointestinal bleeding or previous upper endoscopy. Patients
starting PPI therapy for treatment of H pylori were excluded. We then identified all persons
with new double-dose PPI prescriptions and matched them to up a standard dose using
control. All controls were matched on age, sex, socioeconomic status, presence of severe
comorbid illness, previous GI and non-GI hospital admissions, and prescription date. Cases
and controls were followed in the database for 12 months, tracking the use of GI-related
inpatient and outpatient resource utilization and prescription drug usage. Results: We identi-
fied 8,715 new double-dose prescriptions, of which 2,236 could be linked to an equivalent
number of tightly-matched standard dose controls. There were no significant differences in
health care utilization between the two groups in the twelve months leading up to enrollment.
In the year following initial prescription, there were no differences in overall duration of
PPI use between cases and controls (128 vs. 126 d, p>0.2), and subjects prescribed double
dose PPIs only ingested PPIs at double doses for a mean of 30 days. Subjects initially
prescribed double-dose PPIs had an equal number of GI-related ambulatory care visits (2.2
vs. 2.2 visits/yr, p>0.2), were not statistically more likely to undergo upper endoscopy
(21.8% vs. 20.8%, p>0.2), or to be admitted to hospital for upper gastrointestinal tract
disease (1.1% vs. 0.6%, p=0.090). There was a trend towards an increased likelihood of
hospital admission among subjects initially prescribed double-dose PPIs (4.7% vs. 3.6%,
p=0.072). 12-month GI related costs are higher for subjects initially prescribed double dose
PPIs ($680.60 vs. $510.52, p<0.001) Conclusion: Initial therapy with double-dose PPIs
does not appear to lead to any reduction in GI-related health care utilization, and may in
fact increase the costs of care. Furthermore, patients prescribed double-dose PPIs will often
step down to lower doses over time. The practice of prescribing double-dose PPIs as initial
therapy for upper gastrointestinal symptoms should be discouraged.
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Modifiable Episode-Specific Factors Increase the Risk of Chronic Unexplained
Gastrointestinal Symptoms
Smita Halder, Gary Macfarlane, David Thompson, Mahmoud Musleh, Sarah O'brien, John
Mcbeth
Background: Functional Gastrointestinal Disorders (FGID) are common in the community
yet risk factors for onset and chronicity are poorly defined. People with persistent symptoms
consume considerable healthcare resources and develop other functional symptoms. We
studied premorbid and episode-specific risk factors, at population level, for persistence of
FGID at six months. Methods: We followed up 11,000 adults aged 25-65 years selected
randomly from 3 primary care age/sex registers in the NW of England in a 36-month
population-based prospective cohort study. At baseline we collected data on demographics,
aspects of pain experience, sleep disturbance, anxiety, depression, illness behaviour, psycho-
logical status, adverse life events and GI symptoms in a postal health survey. We monitored
primary care consultations. We invited individuals consulting their doctor with unexplained
GI symptoms to participate. We captured current GI symptoms, past medical history, and
similar psychological measures to baseline in clinical interviews. Helicobacter pylori serology
was performed and stool samples obtained. We mailed follow-up questionnaires at 1 and
6 months post-consultation to determine symptom persistence, consultation behaviour, and
impact of symptoms on daily life. We used multivariate logistic regression modelling to
identify independent risk factors for persistence at six months . Results: 7784 (78.2%)
responded to the baseline survey; 610 consulted with GI symptoms. 368 GI consulters
agreed to participate and 280 (76%) completed six months follow up. 106 (38%) had
persistent symptoms. High levels of adverse psychological distress at time of consultation,
a negative impact of symptoms on daily life, symptoms present for more than 1 month and
episode duration of more than 2 hours all significantly increased the odds of persistence.
Changing one's diet at the time of symptom onset and associated gastroenteritis protected
against persistence. Conclusions: Potentially modifiable episode specific factors affect symp-
tom persistence. A predictive algorithm could be employed in primary care to identify
patients that will develop chronic unexplained GI symptoms, ensuring a holistic manage-
ment approach.
Combined episode specific and clinical factors model
*p<0.05; **age, gender, and practice adjusted
S1041
Proton Pump Inhibitors Do Not Decrease the Risk of Upper Gastrointestinal
Complications in Non-Steroidal Anti-Inflammatory Drug Users
Laura E. Targownik, Colleen Metge, Stella Leung, Daniel F. Chateau
Background: Proton pump inhibitors (PPIs) are commonly recommended for NSAID users
at increased risk of upper gastrointestinal (UGI) complications (perforation, bleeding, and
symptomatic ulcers). However, there have been no clinical trials in which PPIs prevent UGI
complications in non-aspirin NSAID users, as has been demonstrated with misoprostol and
COX-2 inhibitors. Epidemiologic data supporting the use of PPIs in this setting are also
limited. Methods: We used the Manitoba Health Population Health Research Data Repository
(MH-PHRDR) to perform a population based matched case-control analysis. The MH-PHRDR
contains all health care contacts and pharmacy dispensations for all Manitobans from 1995
to 2004. We identified all subjects who were using NSAIDs at the time of admission to
hospital with a primary diagnosis for an upper gastrointestinal complication, and matched
them to up to twenty age- and sex-matched NSAID-using controls who had not had a UGI
complication on the date of interest. The main predictor of interest was PPI use. We used
conditional logistic regression analysis to adjust for multiple covariates, including history
of previous UGI complications, comorbid illnesses and prior hospitalizations, use of corticos-
teroids, warfarin, and clopidogrel, and socioeconomic status. We also evaluated whether there
was additional benefit in high risk users (people with one of: age>65, multiple comorbidities,
warfarin/corticosteroid use, previous UGI complication). Results. We identified 1010 NSAID
users admitted with UGI complications, who were matched to 17,911 NSAID-using controls.
PPIs were actively used by 8.0% cases immediately prior to the GI event vs. 3.7% of controls
(P<0.001). Cases were also more likely to have severe comorbid illness or a history of UGI
complications, and were more likely to use medications associated with an increased risk
of UGI complications. After adjusting for multiple confounders, PPI use was associated with
a non-significantly decreased likelihood of developing a UGI complication when compared
with non PPI users (OR 0.95, 95% CI 0.71-1.27). There was also no significant reduction
in the odds of UGI complications in high-risk NSAID users (OR 0.89, 95% CI 0.67-1.21).
There was a trend towards a decreased likelihood of UGI complications in high-intensity
PPI users compared to standard dose PPI users (OR 0.79, 95% CI 0.40-1.56). Conclusions:
PPIs do not appear to significantly decrease the risk of UGI complications to the same degree
as COX-2 inhibitors or misoprostol in prescription NSAID users. Further study is required
to determine whether PPIs are equivalent to other gastroprotective strategies in NSAID users.
S1042
Symptom Profiles and Endoscopic Findings in African-American Patients with
Gastroesophageal Reflux Disease (GERD)
Sachin B. Wani, Amit Rastogi, Ajay Bansal, Sandy Hall, Sharad Mathur, Prateek Sharma
Background: The epidemiology of GERD in various ethnic groups is not well documented.
Identification of factors that vary by ethnicity may partially explain the marked demographic
differences in GERD complications. Aims: To study the differences in symptoms along with
demographic, clinical and endoscopic findings between African-American and Caucasian
patients with GERD. Methods: Consecutive patients presenting to our endoscopy unit for
their index endoscopy for evaluation of GERD symptoms were enrolled. Patients were
asked to complete a validated GERD questionnaire (GERQ) that documents onset of GERD
symptoms (heartburn, acid regurgitation), their frequency and severity. Additional informa-
tion recorded included demographics (age, gender, ethnicity), clinical data (smoking, PPI
use and duration, ASA/NSAIDs, BMI, family history) and endoscopic findings [erosive
esophagitis (EE), BE, hiatus hernia]. African-Americans were compared to age-matched
Caucasian using a univariate analysis (chi square and t-test). This served primarily to identify
risk factors that were then tested in a multivariate analysis using multiple logistic regression
analysis. Results: There were 840 patients that completed the study (91% males, mean age
57.5 yrs), including 108 African-Americans and 686 Caucasians. Mean age of study popula-
tion was 54.8 yrs (range: 24-84). On univariate analysis, African-Americans were less likely
(compared to Caucasians) to report a longer duration (> 5 years) of heartburn (39% vs.
59%, p=0.003) and regurgitation (33% vs. 51%, p=0.02) and were also less likely to
demonstrate BE on endoscopy (7% vs. 21%, p=0.01). There was no difference in prevalence
of smoking, obesity, use of acid suppressive therapies, ASA/NSAIDs, frequency or severity
of GERD symptoms, nocturnal reflux, hiatal hernia and EE between the two groups. Using
multivariate analysis, there were no differences between the two groups with exception of
BE prevalence which was significantly lower in African-Americans (OR 0.1, 95% CI 0.01-
0.85). Conclusions This study demonstrates that in GERD patients that are referred for
endoscopy, symptom profiles are very similar between African-Americans and Caucasians.
Despite the lack of differences in duration, severity, and frequency of reflux symptoms, BMI
and hernia prevalence, African-Americans were clearly at a much lower risk for development
of BE. The mechanisms responsible for the striking racial differences in the prevalence of
BE are unknown. Genetic predisposition is the most likely explanation and should be
explored in future studies to explain the lower frequency of BE and esophageal adenocarcin-
oma amongst African-Americans.
S1043
Risk Factors for Gastroesophageal Reflux Disease (GERD) in Children
Hoda M. Malaty, Danuta Celinska-cedro, G. Oracz, M. Lenarczyk, David Y. Graham,
Kennard Fraley
Background: Cross-sectional studies indicate a prevalence of 10-20% of GERD symptoms
among adults in Western countries. The prevalence among children remains unclear. Aim:
To investigate the incidence of GERD among children over the age of 2 years presenting to
a tertiary care center in Poland and to examine the correlation between pH monitoring and
risk factors for GERD. Methods: Children referred to the Department of Gastroenterology
at the Children's Memorial Health Institute, Warsaw, Poland during 2004 in whom a first
diagnosis of GERD was made, underwent 24-hour pH monitoring (abnormal versus normal
pH = reflux index >/< 4.2). The diagnosis of GERD was based on history and upon endoscopic
examination. The number of reflux episodes longer than 5 minutes during the 24 hour
observation as well as the children's weight and height were recorded. Using the growth
standards published by the National Polish Center for Health Statistics (M. Krawczynski,
2000), we calculated the gender/age specific weight-for-age Z-score (WAZ), height-for-age
Z-score (HAZ) (standard deviation score). Results: In one year (Jan 2004-to Jan 2005), 3,852
children between the ages of 2-18 visited the GI Department; 295 had a first diagnosis of
GERD (incidence 8% /year). Abnormal pH tests were present in 50%. The most common
symptoms were regurgitation/vomiting; 38% of patients. Abnormal pH studies and the
number of reflux episodes longer than 5 minutes were both significantly correlated with
Wt/Age Z-score (p=0.008) (P=0.001). Conclusion: GERD symptoms were a common cause
for referral to a tertiary care center in Poland. Obesity as assessed by a high Wt/Age Z-score
correlated with the presence of GERD in children.
S1044
Mortality from Peptic Ulcer and Inflammatory Bowel Disease Are
Characterized By Similar Geographic Variations
Amnon Sonnenberg
Background and Aims: The epidemiology of peptic ulcer and inflammatory bowel disease
show many similar patterns. The occurrence of a birth-cohort pattern with a pronounced
peak shortly before the turn of the 19th century is unique to ulcerative colitis, gastric and
duodenal ulcer, but affects no other gastrointestinal disease. The study was undertaken to
examine whether the epidemiology of peptic ulcer and inflammatory bowel disease would
reveal other similarities. Methods: Mortality data from 27 different countries between 1991
and 2004 were analyzed. Mortality from each diagnosis was expressed as deaths per year
and million living population. The relationships between the geographic distributions of
mortality from gastric ulcer (GU), duodenal ulcer (DU), Crohn's disease (CD), and ulcerative
colitis (UC) were compared using least square linear regression analyses. Results: For GU
and DU, mortality among different countries varied about 20- and 30-fold, respectively. For
CD and UC, mortality among different countries varied more than 60-fold. Mortality from
GU was common in Japan, Taiwan and most European countries. It was relatively rare in
Greece, the Asian city states of Singapore and Hong Kong, as well as Canada and the United
States. DU was most common in northern European countries. It was relatively rare in
countries from North and South America. CD and UC showed a geographic distribution
resembling that of duodenal ulcer. Both types of inflammatory bowel disease were particularly
common in England, Scotland and most northern European countries. Both diseases were
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relatively rare in countries from Asia and South America. There was a statistically significant
correlation between GU and DU with r=0.585 and p=0.00135. In comparison with peptic
ulcer, there was an even stronger and highly significant correlation between the two types
of inflammatory bowel disease with r=0.811 and p<0.0001. All four correlations between
each type of peptic ulcer and inflammatory bowel disease were statistically significant,
with r=0.449 (p=0.0188) for the CD-GU correlation, r=0.691 (p<0.0001) for the UC-GU
correlation, r=0.729 (p<0.0001) for the CD-DU correlation, and r=0.813 (p<0.0001) for
the UC-DU correlation. Even if two or three potential outliers were ignored, the correlations
remained statistically significant. Conclusions: The similarities in the geographic distributions
of gastric ulcer, duodenal ulcer, Crohn's disease, and ulcerative colitis suggest that these
four diseases may share a common set of environmental risk factors.
S1045
Adenocarcinoma of the Gastroesophageal Junction Region: A Critical
Appraisal
Benjamin L. Mitlyng, Kenneth P. Batts, Clinton Crowder, Lauralee Naslund, Robert A.
Ganz
Aim: Adenocarcinoma (AdCA) of the esophagus (E) and proximal stomach are both increasing
but controversy exists regarding the classification of tumor straddling the gastroesophageal
junction (GEJ), due to inconsistent definitions of the GEJ and cardia. Epidemiology, staging
and surgical approach make distinguishing these cancers important. The American Joint
Committee on Cancer (AJCC) offers staging guidelines for E and gastric (G) cancers but not
for cancers at the GEJ. We analyzed AdCAs involving the GEJ through a pathologic audit
of E and G cancers to compare the anatomic location of the tumor, likely pathogenesis, and
original ICD0/SNOMED codes. Methods: The pathology slides from the last 102 consecutive
resections for E and for G cancer at a tertiary care center were reviewed by expert GI
pathologists. For site, the tumors were reclassified as pure E, pure G, or if involving the
GEJ into esophageal predominant (E/GEJ), GEJ-centered (GEJ/C), and proximal stomach
predominant (G/GEJ). For etiology we reassessed if the tumors arose in Barrett's, chronic
gastritis, or neither (de novo cancers). Lastly, the previously assigned ICD0/SNOMED code
(E, cardia, or G) was compared with site and etiology. Results: 7 E squamous, 2 GIST, one
G carcinoid and five incompletely resected G cancers were excluded. Among 3 E/GEJ AdCA,
all arose in Barrett's (and had been initially coded as 3 E). Among 18 GEJ/C AdCA, 8 arose
in Barrett's (initially coded 8 E), 2 arose in chronic gastritis (initially coded 1 E, 1 cardia),
and 8 were de novo (initially coded 6 E, 2 cardia). Among 18 G/GEJ AdCAs, 4 arose in
Barrett's (initially coded 3 E, 1 cardia), 2 in chronic gastritis (initially coded 1 E, 1 cardia),
and 12 were de novo (initially coded 4 E, 7 cardia, 1 G). All 11 E AdCA (10 in Barrett's
and 1 de novo) and 35 gastric AdCA (24 in gastritis, 11 de novo) had been appropriately
coded as E or G respectively. Conclusion: AdCA involving the GEJ may arise in Barrett's
or gastritis but > 50% arise de novo. Regarding GEJ region AdCAs: of the 15 arising in
Barrett's only 1 had been “miscoded” as gastric, of the 4 associated with gastritis 2 were
coded as cardia but 2 were “miscoded” as esophageal, and of the 20 de novo AdCAs 10
were initially coded as cardia and 10 had been coded as E. An improved classification system
for GEJ-region tumors is needed in order to improve coding accuracy, and thus better
understand the evolving epidemiology of these cancers. This system should encompass both
the anatomy and the varied milieus within which the AdCAs may arise (Barrett's, de novo,
and gastritis). A solution to this problem would be detailed AJCC coding specific to the GEJ.
S1046
Female Gender and Young Age But Not Severity of Esophagitis Are Associated
with Greater Impairment of Health-Related Quality of Life in GERD
Gerald Holtmann, Juan Malagelada, Oliver Chassany, Peter Sander, Martina Bohuschke,
Kenneth R. Devault
PURPOSE: Health-related quality of life (HRQoL) is an important measure for assessing the
burden of disease from the patients' perspective. The aim of this study was to determine
factors that influence HRQoL in gastroesophageal reflux disease (GERD) patients. We specific-
ally aimed to assess the role of gender, age and severity of lesions for the impairment of
HRQoL. METHODS: GERDyzer™ is a validated questionnaire for the assessment of HRQoL
in GERD patients reflected in 10 dimensions of well-being. Each dimension is illustrated
with pictogram-like drawings and 100 mm visual analogue scales (VAS) are used for the
self-assessment of HRQoL in weekly intervals. Baseline data from trials using GERDyzer™ in
patients with endoscopically confirmed erosive esophagitis (EE) Grade A-D (LA-classification)
were included in the present analysis (n=1030; 478 females, 552 males). Mean GERDyzer™
sum scores were calculated separately for gender, EE grade and age classes (≤30 years;
>30≤50 years, >50≤65 years and >65 years). RESULTS: 491 patients (47.7%) suffered
from EE Grade A, 396 (38.5%) from EE Grade B, 107 (10.4%) from EE grade C and 28
(2.7%) from EE Grade D (missing values: n=8; 0.8%). The mean GERDyzer™ sum score
at baseline was significantly higher in females compared to males (34.35 vs 29.20; p<0.0001),
i.e. female patients felt more impairment due to the disease. Overall, the HRQoL of the
patients was significantly determined by the age class (p=0.025), with younger patients
being more impaired. By contrast, neither BMI (p=0.59) nor EE grade (p=0.22) showed a
significant influence on HRQoL. Interestingly, HRQoL of patients with EE grade D was
better compared to the other groups, however, this was not statistically significant. CONCLU-
SIONS: 1) Female gender and younger age are associated with more severely affected HRQoL
in GERD patients. 2) Severity of lesions does not predict the impact of GERD on HRQoL.
While the underlying mechanism for the discrepancy between severity of lesions and impair-
ment of HRQoL requires further studies, it is evident, that - at least in clinical trials -
assessment of severity of mucosal lesions is not sufficient to properly determine disease
severity.
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S1047
Bioptic Evaluation of Duodenal Mucosa in Adult Dyspeptic Patients (pts):
High Prevalence of Celiac Disease (CD). A Prospective Study
Salvatore Incarbone, Giuseppe Aprile, Lidia Puzzo, Giacomo Bonanno, Pietro Naso,
Cinzia D'agate, Carmelo Barbera, Carlo Puglisi, Giuseppe Trama, Antonio Russo
INTRODUCTION: CD is an autoimmune enteropathy of the small intestine characterized
by gluten intolerance in genetically susceptible subjects. Its prevalence in the general popula-
tion is reported about 1:100. At present the gold standard for diagnosis is the hystologic
evaluation of duodenal biopsies. AIMS & METHODS: Aim of our study is to evaluate the
prevalence of CD in pts referred to an open access Endoscopy Unit for dyspeptic disorders.
In this prospective series, we enrolled 626 consecutive pts (380 F, 246 M, mean age 39.1,
range 19-80 yrs) undergone upper endoscopy for dyspeptic disorders, from January 2004
to August 2005. Dyspepsia was defined according to Rome II criteria. Endoscopy was
performed by videoendoscopy and macroscopic appearance of duodenal folds and mucosa
was reported. In all pts 4 biopsies in the second duodenum were taken , oriented on paper
and processed by standard staining. Hystologic evaluation was done according to Marsh-
Hoberhuber criteria. Patients with family history or typical symptoms of CD, or presenting
heartburn with or without regurgitation as the only symptom, were excluded from our
investigation. RESULTS: 91 out of 626 pts evaluated (14.5%) had ulcer-like dyspepsia (UD),
297 (47,4%) dismotility-like dyspepsia (DD) and 238 (38,1%) indeterminate dyspepsia (ID).
The endoscopic findings were normal in 388 (62%), showed peptic lesions in 137 (21.7%),
malignances in 3 (0,5%), miscellaneous in 93 (14,8%) and were suggestive for CD in 5
(0,8%). Hystologic examination revealed CD in 12 pts (prevalence 1,9% - 1/52 pts). (Table
1). Seven out of 12 pts with CD had DD (OR 1,23; 95% CI 0.479-3.155; p<0,03); The
remaining 5 ID (OR 1,09; 95% CI 0.380-3.131; p<0,9 - Biostat Programm) CONCLUSION:
Our results show an higher prevalence of CD (1,9% - 1/52 pts) in a selected population of
adult dyspeptic pts. As reported as the type of dyspesia, we found a significant higher
prevalence in DD, related to ID. No patient with UD had CD. Furthermore, these data show
that if we had taken only duodenal biopsies in presence of macroscopic mucosa abnormalities,
we would have lost seven diagnosis of CD. In conclusion we suggest routinary use of
duodenal biopsy in all pts with DD and ID undergoing EGDS. Our investigation is a
preliminary one in Eastern Sicily, further observations on a larger number of patients
are needed.
table 1
S1048
Dysphagia: Prevalence, Risk Factors, and Impact On Quality of Life - A
Population-Based Study
Guy D. Eslick, Nicholas J. Talley
BACKGOUND: Data on the population epidemiology of dysphagia are scarce. Little is known
about the prevalence, risk factors and impact on quality of life of dysphagia in the general
community. This study aimed to determine the magnitude and impact of this problem.
METHODS: A random sample of 1,000 adult residents of Western Sydney, Australia, were
mailed a validated self-report questionnaire to assess dysphagia. Dysphagia was defined as
“a feeling that food sticks in your throat or chest.” Measured were dysphagia symptoms,
potential mechanisms, risk factors (heartburn, acid regurgitation), psychological distress
(anxiety, depression, neuroticism), quality of life (QoL), and demographics. RESULTS: The
response rate was 73% (n=672; mean age 46 years; 52% female). Dysphagia ever was
reported by 17% (n=110). Gastroesophageal reflux disease (GERD) defined as “at least
weekly heartburn and/or acid regurgitation” was associated with dysphagia (OR=4.20, 95%
CI: 1.56-11.32). Anxiety was also associated with dysphagia (OR=1.08, 95% CI: 1.03-1.13).
A reduction in the QoL sub-scales (SF-36) ‘role physical' (OR=0.99, 95% CI: 0.98-0.99)
and ‘general health' (OR=0.98, 95% CI: 0.97-0.99) were associated with dysphagia. Multiple
logistic regression analysis found that GERD was not independently associated with solid
food or progressive dysphagia (OR=0.68, 95% CI: 0.26-1.80), (OR=1.14, 95% CI: 0.26-
4.94), respectively. Odynophagia however was independently associated with GERD (OR=
3.41, 95% CI: 1.16-10.04). Intermittent dysphagia was independently associated with GERD
(OR=2.96, 95% CI: 1.76-4.98) and anxiety (OR=1.09, 95% CI: 1.01-1.19). The presence
of progressive dysphagia was independently associated with depression (OR=1.34, 95% CI:
1.07-1.67). Progressive dysphagia was independently associated with reduced ‘general health'
(OR=0.95, 95% CI: 0.90-0.99), while intermittent dysphagia was independently associated
with a reduction in the ‘role physical' sub-scale (OR=0.98, 95% CI: 0.97-0.99). CONCLU-
SIONS: Dysphagia is remarkably common in the general population. GERD is a risk factor
for dysphagia as well as odynophagia. The presence of intermittent dysphagia was associated
with anxiety, while progressive dysphagia was associated with depression. Dysphagia has a
negative impact on quality of life.
S1049
The Relationship Between Gastroesophageal Reflux Disease and Irritable
Bowel Syndrome in Primary Care
Ana Ruigomez, Luis A. García rodríguez, Mari-ann Wallander, Saga Johannson
Background and aim: Gastroesophageal reflux disease (GERD) and irritable bowel syndrome
(IBS) co-exist more commonly than would be expected by chance alone, yet the correlation
between the two morbidities is unclear. We aimed to investigate the relationship between
GERD and IBS in primary care. Methods: A population-based cohort study was conducted
using the General Practice Research Database. To evaluate the risk of IBS following a GERD
diagnosis, we identified patients with a first diagnosis of GERD (n = 6606), and compared
them with an age- and sex-matched comparison cohort free of GERD (n = 9650). Similarly,
to evaluate the risk of GERD following an IBS diagnosis, we identified patients with a first
A-162AGA Abstracts
diagnosis of IBS (n = 2932), and compared them with a cohort free of IBS (n = 4968).
Information was obtained on patient demographics, and on morbidity and drug use in the
12 months before diagnosis. Patients were followed up for 12 months after diagnosis. Logistic
regression analysis was used to compute odds ratios (ORs) and 95% confidence intervals
(CIs). Results: The incidence of IBS per 1000 person-years was 14.5 (95% CI: 11.9-17.7)
in the GERD cohort and 3.5 (95% CI: 2.5-4.9) in the comparison cohort. The adjusted
relative risk of developing IBS was 3.2 (95% CI: 2.1-4.8) in the GERD cohort compared
with controls. The incidence of GERD per 1000 person-years was 15.0 (95% CI: 11.2-20.1)
in the IBS cohort and 4.4 (95% CI: 2.9-6.7) in the comparison cohort. The adjusted relative
risk of developing GERD was 2.8 (95% CI: 1.7-4.9) in the IBS cohort compared with
controls. In the GERD cohort, stress (OR: 3.1; 95% CI: 1.2-7.9), and use of hormone
replacement therapy (OR: 2.2; 95% CI 1.1-4.3) and other over-the-counter ovarian hormone
drugs (OR: 3.3; 95% CI: 1.1-9.5), were associated with a greater risk of developing IBS,
but gender, and a prior record of general pain, sleep disorders, anxiety or depression, were
not. In the IBS cohort, a prior record of general pain (OR: 3.1; 95% CI: 1.4-6.9) and cough
(OR: 2.8; 95% CI: 1.1-7.6) were associated with a greater risk of developing GERD, but
gender, and a prior record of stress, sleep disorders, anxiety, depression, asthma and laryngitis
were not. The use of hormone replacement therapy and other over-the-counter ovarian
hormone drugs did not affect the risk of developing GERD in patients with IBS. Conclusion:
The approximately threefold increase in the risk of developing IBS in the year following a
GERD diagnosis and vice versa suggests that there is a link between the two morbidities
which warrants further research.
S1050
The Relation Between Gastroesophageal Reflux and Respiratory Symptoms in
General Practice
Toshiyasu Watanabe, Yoshihisa Urita, Kaoru Domon, Susumu Ishihara, Hiroki Ota,
Motohide Iwata, Kazushige Nakanishi, Motonobu Sugimoto, Kazumasa Miki
Background: Gastroesophageal reflux disease (GERD) and respiratory disease are common
causes for consultation in primary care, but the two remains unclear. Many previous studies of
the association between the two had selection bias, since data were obtained in a retrospective
manner. Studies addressing the correlation between respiratory disorders and GERD symp-
toms in an unselected group of persons are sparse. The aim of this study was to evaluate
the relationship between GERD and respiratory symptoms in general practise. Patients and
Methods: Between September 2005 and March 2006, 1022 consecutive patients (485 men
and 537 women with a mean age of 42 years) who first attended the Outpatient Department
of General Medicine and Emergency Care of Toho University Omori Hospital were enrolled
in the present study. They were asked to respond the F-scale questionnaire regardless of
their chief complaints. This questionnaire was devised from 12 questions, which were scored
to indicate the frequency of symptoms, as follows: never = 0; occasionally = 1; sometimes =
2; often = 3; and always = 4. If the patient has a score of more than 7 point, GERD is
considered as positive. Results: Over all, 390 (38%) patients were diagnosed as GERD and
134 (13%) had respiratory symptoms including cough, sputum, and/or dyspnea. Patients
with respiratory symptoms had GERD symptoms more frequently than patients without
respiratory symptoms (46% v.s. 22%, p<0.05). Among 329 current smokers, 159 (46%)
had GERD symptoms regardless of the presence of respiratory symptoms. Conclusions:
Patients with respiratory symptoms are at a significantly increased risk of developing GERD.
Whether or not treatment for GERD or respiratory diseases is useful for the prevention of
respiratory symptoms and GERD, respectively, should not be driving management decisions
in primary care. It is more important that the association between these conditions be
more widely recognized so that the primary care physicians are alert to their possible
comorbid occurrence.
S1051
Prevalence and Clinical Characteristics of Endoscopic Reflux Esophagitis in
Routine Check-Up Subjects in Korea: A Prospective Multicenter Study
Cheol hee Park, Kyoung oh Kim, Yong woo Chung, Il hyun Baek, Kwang ho Baik, Hyun
joo Jang, Sea hyub Kae, Woon geon Shin, Kyung ho Kim, Hak yang Kim
Background/Aims: The prevalence of reflux esophagitis (RE) in Korea was believed to be
low until now, but epidemiological data on RE in Korea are rare. The aims of this study
were to evaluate the epidemiologic and clinicopathologic characteristics of RE patients
who were diagnosed by endoscopy in a routine health check-up program. Methods: We
prospectively recruited the subjects who had RE among those who visited a health promotion
center for routine check-up at Hallym Medical Center (5 institutions) between July 2005
and June 2006. RE was defined on the four level scale of the Los Angeles classification.
Subjects were given a validated self-reported questionnaire, which measured the presence
of typical reflux symptoms (heartburn, acid regurgitation). Results: The enrolled study
participants comprised 785 subjects with RE and 11869 healthy controls. Overall prevalence
of RE was determined to be 6.2%, and when stratified by age, prevalence was 2.7%, 5.4%,
7.1%, 6.3%, and 9.6% for those in their 30s or younger, 40s, 50s, 60s, and 70s or older,
respectively. RE was more common in male (male; 548. female; 237)(p< 0.05). All subjects
with RE had LA grade A (76%), B (22%), and C (2%). This suggests the mild nature of RE
in Korea. Twenty-four (188/785) percent of all subjects with RE did not have typical reflux
symptoms. Using a multiple logistic regression analysis, RE was associated with coffee (odds
ratio (OR), 1.3; 95% confidence interval (CI), 1.1-1.4), BMI (OR, 1.4; 95% CI, 1.2-1.6),
smoking (OR, 2.8; 95% CI, 1.7-4.4), and hiatal hernia (OR, 5.6; 95% CI, 4.9-7.2). Among
the patients with RE, two hundred twelve (27%) were 60 or more than 60 years old. The
frequency of accompanying hiatal hernia in the elderly group (age≥60) was significantly
higher than the younger group (age<60) (25%, 53/212 vs. 8%, 46/573, p<0.05), while other
factors such as smoking, coffee, BMI, and peptic ulcer disease were not different between
the two groups. Conclusions: The prevalence of RE is 6.2% in routine check-up subjects
in Korea. Hiatal hernia, smoking, coffee, and high BMI are most likely the risk factors of
RE in routine check-up subjects. The existence of hiatal hernia seems to be suggested more
relevant to the development of RE in the elderly group.
S1052
Low Acid Secretion Is a Risk of Resistant to Proton Pump Inhibitor Treatment
On Gastroesophageal Reflux Disease
Tsuneya Wada, Makoto Sasaki, Hiromi Kataoka, Naotaka Ogasawara, Eiji Kubota,
Yoshinori Mori, Takaya Shimura, Tsutomu Mizoshita, Takashi Mizushima, Yasuyuki
Okamoto, Takeshi Kamiya, Takashi Joh
Background: The Japanese is low gastric acid secretion compared to U.S. populations.
Furthermore, many Japanese are progressing in gastric hypoacidity, because continuance
infection rate of Helicobacter pylori is high and atrophy of gastric mucosa is progressing.
Gastric acid secretion influences reflux symptoms of gastroesophageal reflux disease (GERD),
and therefore epidemiology and treatment of GERD in Japanese may be different from in
U.S. populations. From the viewpoint of gastric acid secretion, we evaluated the conditions
of Japanese GERD patients. Method: Eighty GERD patients who had endoscopic negative
GERD or grade A to B esophagitis of Los Angeles classification were studied. We made use
of serum pepsinogen I & II and evaluated atrophy of gastric mucosa. We divided subjects
in two groups; low acidity group which has a gastric mucosal atrophy (pepsinogen I≦70
and I/II≦3.0) and high acidity group which does not have (pepsinogen I&;70 or I/II >3.0).
The subjects were randomly assigned to proton pump inhibitor (PPI) treatment (Omeprazole
20mg or Rabeprazole 10 mg) or H2 receptor antagonist (Famotidine 40mg) and we examined
SF-36 and the reflux, abdominal pain, indigestion scale of Gastrointestinal Symptom Rating
Scale (GSRS) before and after treatment. Result: Twenty-five subjects (31.3%) were classified
in low acidity group and 55 (68.7%) were high acidity group. SF-36 before treatment
revealed that QOL of both groups significantly decreased than that of Japanese general
populations (p<0.05), but there was no difference between the two groups. GSRS before
treatment showed that the scale score of both groups significantly increased in reflux
(2.88±1.05, 3.22±1.43 respectively), abdominal pain (2.52±0.96, 2.25±1.22 respectively)
and indigestion (2.31±0.86, 2.38±1.09 respectively), but there was no significant difference
between the two groups. In comparison with SF-36 before and after treatment, QOL of
high acidity group was significantly improved in vitality (from 52.9±22.0 to 59.6±20.7,
p<0.05) and mental health (from 61.9±20.0 to 70.3±20.7, p<0.05), but not any scales in
low acidity group. In high acidity group, all scales of GSRS was significantly improved after
treatment (reflux scale; from 3.22±1.43 to 1.87±1.16, abdominal pain scale; from 2.25±1.22
to 1.57±0.75, indigestion scale; from 2.31±0.86.43 to 1.81±1.73) (p<0.05), but not in the
low acidity group. Furthermore there was no difference in the effect of three treatments
(Omeprazole, Rabeprazole, and Famotidine). Conclusion: The GERD patients were not
affected by acid secretion property in the impairment of QOL, but low acid secretion is a
risk of resistant to PPI treatment.
S1053
Is There An Association Between Helicobacter pylori and Obesity?
Nisha K. Lassi, G. richard Locke, Michael Camilleri, Cathy Schleck, Alan R. Zinsmeister,
Nicholas J. Talley
Background:Obesity has become a public health epidemic in many developed countries;
The prevalence continues to increase at an astounding rate. Of interest, the prevalence of
Helicobacter pylori (HP) decreased dramatically during the decades preceding the obesity
epidemic in the United States. Since HP is a chronic infection of the stomach and a difference
of just a few calories per day leads to significant changes in weight over a longer period,
we hypothesized that HP infection is inversely related to obesity. Methods: A modified, valid
Bowel Disease Questionnaire was mailed to a random sample of residents in Olmsted County,
MN utilizing the Rochester Epidemiology Project medical records linkage system. Two nested
case control studies were performed in which subjects with symptoms of dyspepsia and
IBS and asymptomatic controls were invited for further evaluation. During these studies,
participants were weighed and serum was tested for HP by a valid ELISA. Using logistic
regression analysis, the association between body mass index (BMI) and HP was assessed,
adjusting for age, gender, alcohol and tobacco use. Results: The overall response rate to the
mailed surveys was 62%. For the nested case control studies, the response rate was 60%.
Among the 218 subjects with both an HP and BMI assessment, the mean age was 44 ± 15
and 47% were female. Of these, 17% were HP seropositive and 83% were seronegative.
The mean BMI was 27 ± 6; 33% had a BMI greater than or equal to 25 but less than 30,
and 23% had a BMI greater than or equal to 30. The mean BMI in the HP seropositive
group was 27 (SD ± 7), and 27 (SD± 6) in the HP seronegative group. The table provides
the % of subjects by HP status in each of three BMI categories (the odds ratios are adjusted
for the potential confounders listed above) Conclusion: Although the direction of the odds
ratios fit the hypothesis, no significant association between body mass index and H. pylori
seropositivity was detected. Other factors such as dietary habits, socioeconomic status, or
living conditions may explain the contrasting patterns of these two major health issues in
the US.
S1054
A Population-Based Study of Dyspepsia in Rural Malaysia: Epidemiology,
Health-Care Seeking Behaviour and Economic Impact
Sanjiv Mahadeva, Hematrav Yadav, Khean-lee Goh
INTRODUCTION Dyspepsia is a global health problem. However, population-based data
from Asian countries, particularly in rural areas, is lacking. AIMS To determine the prevalence,
epidemiological risk factors, health-care seeking behaviour and economic impact of dyspepsia
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in a representative rural population in Malaysia. METHODS A cross-sectional survey using
a door-to-door direct interview technique with a validated GI symptom questionnaire was
conducted in Banting district, Selangor, between January and March 2006. Subjects were
identified using a population-based stratified sampling method. RESULTS A total of 2000
adults (mean ± SD age: 40.4 ± 15.3 years, males 37.2%) were interviewed. The demographics
of the population were as follows: Ethnicity- Malays 79%, Chinese 7.6% and Indians 12.6%,
level of primary or no education 31.6%, level of skilled or professional employment 34.6%,
median residents per household 5 (range 1-16) and median monthly income USD 150.00.
Dyspepsia was prevalent in 554 (27.7%) adults and was associated with female gender
(29.5% vs 24.5% males, p=0.056), Malay race (29.1% vs 22.4% non-Malay, p=0.006), regular
analgesia intake (48.1% vs 24.5%, p<0.0001), co-morbidity (42% vs 23.5%, p<0.0001) and
excessive chili intake (35.8% vs 26.9%, p=0.009). Regression analysis revealed that regular
analgesia intake (OR 0.41, 95%CI=0.31-0.54), Malay race (OR 1.57, 95%CI=1.20-2.60),
and excessive chilli intake (OR 1.62, 95%CI=1.17-2.28) were independent risk factors for
dyspepsia. Over the preceding 3 months, 162 (29.8%) adults with dyspepsia had required
medication, with 51.6% using over the counter drugs and 26.7% requiring medical consulta-
tion. Work absenteeism amongst dyspeptics was only 9.8%, with a cumulative loss of
earnings over the preceding 3 months of USD1266.95. CONCLUSION Dyspepsia is common
in rural Malaysian adults but is associated with a low medical consultation rate and work
absenteeism. .
S1055
Comorbid Medical and Psychiatric Illness and Substance Abuse in HCV-
Infected and Uninfected Veterans
Uzma A. Khan, Kathleen Mcginnis, Melissa Skanderson, Adeel Butt
Background: We undertook this study to determine the prevalence of comorbidities in HCV
infected and uninfected persons. Methods: Demographic/comorbidity data for HCV infected
persons and age, race and gender matched HCV uninfected controls were retrieved from
the VA National Patient Care Database using ICD-9 codes. We used logistic regression to
determine the odds of comorbidities in HCV infected subjects. Results: We identified 126,926
HCV infected subjects and 126,926 controls. HCV infected subjects had a higher prevalence
of diabetes, anemia, hypertension, COPD/asthma, cirrhosis, HBV, cancer, psychiatric comor-
bidities and substance abuse but a lower prevalence of coronary artery disease (CAD) and
stroke. In HCV infected persons, the odds of being diagnosed with congestive heart failure,
diabetes, anemia, hypertension, COPD/asthma, cirrhosis, HBV and cancer were higher, but
lower for CAD and stroke. After adjusting for substance abuse, the odds of psychiatric
comorbidities were not higher in HCV infected persons. (Table) Conclusions: The prevalence
of comorbidities differs in HCV infected and uninfected veterans. The association between
HCV and psychiatric diagnoses is partially attributable to substance abuse. These factors
should be considered when evaluating patients for treatment and designing new interven-
tion strategies.
Odds of co-morbid diagnoses in HCV-infected veterans compared with HCV uninfected vet-
erans.
*The two groups were matched for age (5 year blocks), race and gender. â€Adjusted for
age, race, gender, drug use and alcohol use.
S1056
The Cost-Effectiveness of Endoscopic Surveillance of Gastric Ulcers: Results
of a Decision Analysis
Wendy W. Ho, G scott Gazelle, Chin Hur
BACKGROUND: The goal of following a benign-appearing gastric ulcer (GU) with upper
endoscopy (EGD) until complete healing is to diagnose gastric cancer (CA) at an earlier
stage in those ulcers that are caused by an underlying malignancy. However, the prevalence
of CA in these patients is relatively low and there is a cost associated with repeat EGDs.
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The purpose of this study was to evaluate the cost-effectiveness of endoscopic surveillance
of GUs. METHODS: A Markov model of GUs in a hypothetical cohort of 70 year old men
was constructed to compare two strategies: 1) repeat surveillance EGDs until complete ulcer
healing (SURV) or 2) no endoscopic surveillance (No SURV). A GU was defined as a gastric
ulcer found on index EGD with no pathologic evidence of malignancy. The base estimate
for the prevalence of CA in GUs was 2% (range 0-4.3%). The stage distribution of CA in
patients diagnosed by surveillance EGD and those diagnosed at symptomatic presentation,
as well as CA survival by stage, were based on published data. On average, patients undergoing
endoscopic surveillance had 2.7 EGDs. The model had a time-horizon (follow-up) until
death. Extensive sensitivity analysis was performed. RESULTS: In the base case, the SURV
strategy was superior and resulted in 12.2877 life-years (LY), while the No SURV strategy
resulted in 12.2621 LY, for a net difference of 0.0256 LY and an incremental cost-effectiveness
ratio (ICER) of $53,120/LY. Sensitivity analysis showed that age had a significant impact
on the cost-effectiveness of the SURV strategy, with younger age leading to increased cost-
effectiveness (Table 1). Using $80,000 as an ICER acceptability ceiling, the SURV strategy
was cost-effective below age 78. A higher prevalence of CA in GU patients also improved the
cost-effectiveness of the SURV strategy (Table 2). CONCLUSIONS: Endoscopic surveillance of
gastric ulcers until complete ulcer healing is a cost-effective strategy. This strategy should
be pursued, especially in young populations with a high prevalence of gastric cancer.
Table 1: Sensitivity Analysis: Age
Table 2: Sensitivity Analysis: Prevalence of Gastric Cancer in Gastric Ulcers
S1057
Evaluating Obscure Gastrointestinal Bleeding (OGIB): A Cost-Benefit Analysis
of Alternative Strategies
Ma Somsouk, Ian M. Gralnek, John M. Inadomi
Background & Aims: The most cost-efficient approach in the evaluation of OGIB is uncertain.
Emerging technologies (e.g., capsule endoscopy (CE) & double-balloon enteroscopy (DBE)),
allow examination of the entire small bowel but consume healthcare resources. Thus it is
unclear where to incorporate these technologies into clinical practice. We performed a cost-
benefit analysis to determine the optimal strategy for patients with OGIB in whom standard
upper endoscopy and colonoscopy were negative. Methods: We compared 5 strategies: initial
small bowel follow through (SBFT), enteroclysis (EN), push enteroscopy (PE), CE, or DBE.
The diagnostic yield of tests for polyps/neoplasia, inflammatory lesions/ulcers, vascular
ectasias, or no lesion found was based on a systematic review of the published literature,
including meta-analyses where available. The endpoint of each strategy was treatment or
biopsy to confirm diagnosis. Positive findings at SBFT, EN, or CE were followed up with
PE or DBE depending on estimated lesion location. Negative SBFT, EN, or PE was followed
up with CE, then by upper and/or lower DBE depending on estimated lesion location. If
no lesion was found and DBE was incomplete, intra-operative enteroscopy was performed.
Differences in yield between competing strategies were accounted for in a cost-benefit analysis
where missed lesions incurred additional costs for recurrent OGIB. Costs were taken from
a third-party payer perspective. Sensitivity analysis identified the thresholds at which strategy
preferences were altered. Results: The optimal strategy was initial DBE with a cost of $3,802.
Initial CE costs an incremental $554. Initial DBE was sensitive to the cost of DBE with a
threshold of $2,263 above which CE became the preferred initial strategy. If DBE were
unavailable, initial CE was preferred to PE unless the cost of CE exceeded $1,450, the
prevalence of vascular ectasia or ulcer exceeded 55% or 50% respectively, or >70% of lesions
were located within reach of PE. Variation in other model assumptions did not change
the order of preferred strategies. Conclusions: Following negative upper endoscopy and
colonoscopy in the evaluation of OGIB, DBE may be the least expensive approach. However,
given DBE's limited availability, technical rigors, extended procedure time and sedation use,
CE may likely be the more reasonable initial clinical strategy with use of DBE as a complement-
ary tool. PE is the preferred initial strategy only if the current cost of CE were to exceed
$1,450 or if the vast majority (>70%) of lesions are within reach of PE.
S1058
The Cost-Effectiveness of Continuous Infusion Intravenous Proton Pump
Inhibitors (IV PPI) Administered Prior to Endoscopy in the Treatment of
Patients Presenting with Suspected Upper GI Bleeding (UGIB)
Salman Alsabah, Alan N. Barkun, Karl Herba, Viviane Adam, Wendy Kennedy, Gilles
Pomier layrargues
Background: Recent randomized trials have shown that IV PPI pre-endoscopic therapy in
patients with UGIB downstage bleeding ulcer stigmata; no analyses have since incorporated
these data into a cost-effectiveness analysis. Aim: To assess the cost-effectiveness of high
dose IV PPI infusion administered to patients with suspected UGIB prior to gastroscopy in
American and Canadian settings. Methods: A decision tree was created, using Tree Age Pro
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2005, comparing two approaches for the use of IV pantoprazole 8mg/hr in UGIB patients
(all patients received an 80mg IV bolus on presentation). Either the infusion was initiated
while awaiting endoscopy or it was started only post- endoscopy, after endoscopic therapy.
The PPI infusion was not continued post-endoscopy if it showed a low risk ulcer or non
ulcer lesion; it was given for 72 hours if endoscopic hemostasis was performed. The model
considered outcomes of patients found to be bleeding from ulcers and non-ulcer lesions.
Assumptions of probabilities were derived from recent randomized trial evidence. In-patient,
pharmacological costs, and lengths of stay were derived from national US or Canadian
databases. The unit of effectiveness was the proportion of patients without an episode of
re-bleeding over a 30-day time horizon. We tested the robustness of results using threshold
and sensitivity analyses, guided by Tornado diagrams. We adopted a third-party payer
perspective. Results: Hospitalization costs were higher in Canada than the USA because of
longer hospitalization for comparable patients. In both the USA and Canada, administering
IV PPI pre-endoscopy was both slightly more costly and effective with greater mean cost-
effectiveness ratios (US$4,928 versus 4,808 per episode of rebleeding in the USA, and
CAN$6,059 versus 6,020 in Canada). IV PPI pre-endoscopy cost US$47,567 to prevent one
additional rebleeding episode in the USA (CAN$19,967 in Canada). Sensitivity analysis
showed robust results in the USA across wide clinically relevant ranges of assumptions. In
Canada, IV PPI pre-endoscopy became the dominant strategy if the mean uncomplicated
stay of patients with bleeding ulcers exhibiting high risk stigmata rose above 6.1 days, or
if that of patients with low risk stigmata decreased below 3.4 days. Conclusion: The routine
administration of IV PPI bolus and infusion before urgent endoscopy, in the USA, is slightly
more effective, but at a high incremental cost. In Canada, it is a dominant cost-effective
approach when the duration of hospitalization for high risk ulcer patients rises or that of
low-risk ulcer patients decreases. Guideline recommendations need to take into account
such considerations.
S1059
High Dose Intravenous Proton Pump Inhibitor Prior to Endoscopy in Patients
with Acute Upper Gastrointestinal Bleeding Is Cost-Effective
Kelvin K. Tsoi, James Y. Lau, Joseph J. Sung
Background. We recently reported a randomized study in which high-dose intravenous
omeprazole or placebo was administered to patients presenting with acute upper gastrointesti-
nal bleeding prior to endoscopy [Lau et al Gastroenteorl 2005;128 supple 2:347]. Early use
of omeprazole led to reduced endoscopic therapy and shortened hospital stay. The cost-
effectiveness of the pre-emptive approach has not been determined. Method. A decision
analysis model was structured over 30-day outcomes. Probabilities were derived from a total
of 631 patients in the original trial and health cost figures were obtained from Hong Kong
SAR Government. All cases of rebleeding and surgical procedures were included in the
calcuation. The primary measurement was Incremental Cost Effectiveness Ratio (ICER) to
avert endoscopic therapy. This is a ratio between the difference in average cost in the two
patient groups to the difference in percentage of patients who did not require endoscopic
therapy, i.e. a measurement of cost saved or spent to avert an endoscopic therapy by using
high-dose intravenous omeprazole. A range of active bleeding rate from index endoscopy,
cost for hospital stay and endoscopic therapy were tested in sensitivity analysis. Results.
The need for endoscopic therapy was reduced from 28.4% to 19.1% when omeprazole was
used instead of placebo. ICER per endoscopic therapy saved was USD1,843. The use of
omeprazole was cost-effective when endoscopy cost from USD1,000 to 10,000, and daily
hospital stay cost from USD200 to 1,000. Sensitivity analysis showed that results were robust
over a wide range (10% to 50%) of active bleeding (during index endoscopy). Based on
two-way (cost of hospital stay and rate of active bleeding on index endoscopy) sensitivity
analysis, when the rate of active bleeding was low and the cost of hospital stay was also
low, this might not be a cost-effective strategy. Conclusion. Early use of high-dose intravenous
omeprazole prior to endoscopy is effective in reducing need for endoscopic therapy and is
cost-saving.
S1060
Can Eradication of Helicobacter pylori Inhibit the Development of Gastric
Cancer? Observation Based On a 10-Year Follow-Up for the Development of
Gastric Cancer in Subjects with Helicobacter pylori Infection
Kimihiko Yanaoka, Chidu Mukoubayashi, Hisanobu Deguchi, Izumi Inoue, Hirohito
Magari, Hiroshi Ohata, Mikitaka Iguchi, Hideyuki Tamai, Kenji Arii, Masashi Oka,
Osamu Mohara, Masao Ichinose
[Objective] Although chronic atrophic gastritis(CAG) was previously considered to be age-
related due to external environmental factors, it was revealed in the 1980s that Helicobacter
pylori (HP) infection is the most important responsible factor for the disease. Many investi-
gations have since reported the correlation between the development of gastric cancer and
gastritis caused by HP infection. Furthermore, even after eradication of HP gastric cancer
may still develop. We performed a 10-year longitudinal cohort study on the development
of gastric cancer in subjects with HP infection to elucidate the preventive effects of HP
eradication on the development of gastric cancer. [Methods] A comparative study was
performed based on the annual incidence rate of development of gastric cancer between an
HP infected group (3,656 male subjects), whose natural course had been followed for 10
years (a mean of 9.6 years), and an eradication group (591 male subjects) who had been
followed for 10 years (a mean of 9.0 years) after successful eradication. Individual groups
with and without gastric mucosal atrophy were categorized, based on serum pepsinogen
(PG) levels ( PG1≤70 and PG1/2≤3: positive) to evaluate the preventive effects of eradication
on the development of gastric cancer. [Results] Among 3,656 HP-infected subjects, the
development of gastric cancer was confirmed in 55 subjects during the study period (annual
incidence rate = 0.16%), while 5 subjects developed gastric cancer among 591 subjects
cured of infection (annual incidence rate = 0.10%), indicating no significant reduction in
the cancer development by HP eradication (p=0.11; log-rank test). Among the HP-infected
subjects, 1329 subjects were PG testing-positive and 2327 subjects were the testing-negative,
and the development of gastric cancer was confirmed in 30 and 25 subjects, respectively
(annual incidence rate = 0.24 % and 0.11 %). Among the HP-eradicated subjects, 224
subjects were PG testing-positive and 367 subjects the testing-negative, and the development
of gastric cancer was confirmed in 4 and 1 subjects, respectively (annual incidence rate =
0.19% and 0.03 %). Significant reduction in the cancer development by HP eradication was
observed only in PG testing-negative subjects (p=0.01), but not in PG testing-positive
subjects (p = 0.06). [Conclusion] The results of the present study strongly indicate that the
development of gastric cancer after HP eradication depends on whether a subject has an
extensive CAG prior to eradication. It is highly probable that the benefit of HP eradication
diminished in most of subjects defined by PG testing-positive criteria of PG1≤70 and
PG1/2≤3.
S1061
Difference Between Depressed and Flat Type Early Colorectal Tumors
Kohei Kuroda, Hiroo Yamano, Kenjiro Yoshikawa, Kentaro Sato, Masahito Nomoto,
Minoru Fujita, Toshihisa Hosoya
[Purpose] Recently, the number of superficial type colorectal tumors has been increasingly
detected. It has become clear that these superficial lesions contain two subtypes: flat and
depressed lesions. However, their clininopathological features in colorectal carcinogenesis
remain obscure. The purpose of this study was to clarify the importance of the classification
of superficial type. [Materials and Methods] We analyzed clinicopathological findings for
2667 colorectal superficial tumors resected endoscopically or surgically (2597 adenomas
and 70 submucosal invasive carcinomas). We classified superficial tumors into two subtypes
according to their morphology: flat and depressed types. These tumors were divided into
2540 cases of the flat type and 127cases of the depressed type. [Results] The rates of
submucosal invasive carcinomas were 1.1% and 33.9% in the flat and depressed types,
respectively. In the flat type tumors under 9mm in diameter, all cases were intramucosal
lesions and there was no case of submucosal invasive carcinomas. Also, the flat types with
larger sizes were associated with higher rates of submucosal invasion (4.1% between 10 and
19mm, and 17.3% over 20mm in diameter, respectively). On the other hand, the rates of
submucosal invasive carcinomas in the depressed type were always high regardless of size
(8.1% under 9mm in diameter, 87.9% between 10 and 19mm, and 100% over 20mm in
diameter, respectively). In submucosal invasive carcinomas, the depressed lesions (14.3 ±
5.0mm in diameter) were significantly smaller than the flat lesions (21.0 ± 10.1mm; p<0.01).
[Conclusion] We suggest that the flat and depressed types are similar in that they are both
morphologically superficial, but that they differ from one another in their clinicopathological
features. Especially, depressed type lesions tend to invade the submucosal layer even when
they are small and they may have more malignant potential than flat type lesions. Therefore,
we should always be aware of this type of lesion during colonoscopic examnination.
S1062
A Double Blind, Randomized, Placebo-Controlled Study of the Efficacy and
Safety of short-Term Duration Use of Sodium Picosulfate in the Treatment of
Constipation
Chris Schuijt, Michael A. Kamm, Chris C. Jordan, Jean-michel Vix, Ursula Koehler,
Kenneth G. Mandel
BACKGROUND & AIM: While laxatives are commonly recommended as first line pharmaco-
logical treatments, few studies support their safety and efficacy in treating constipation. This
study examined safety and efficacy of sodium picosulfate (SPS), a laxative with similar
pharmacological action to bisacodyl, in the short-term treatment of constipation. METHODS:
This multicenter study randomized 57 subjects having ≥3 months history of chronic con-
stipation, defined as reported stool frequency of <3 bowel movements (BM) per week and/
or straining on ≥25% of defecations, to 3 days treatment with 7mg SPS (n=29) or matching
placebo (PL; n=28). Daily diaries recorded medication use, number of BMs, straining, stool
consistency, bloating, and abdominal pain for 5 days. Treatment responders were defined
as achieving an increase of ≥1 BM/day and having straining reduced to “rarely” or “never”.
Baseline and end-of-treatment comparisons of BM frequency, straining, stool consistency,
abdominal pain, and bloating were secondary outcome measures. Vital signs, hematocrit,
serum creatinine and serum electrolytes, were measured at entry and end of study. RESULTS:
All 57 subjects took at least 1 dose of assigned study medication and completed the study.
Mean age was 54.8 (range 19-85) and 54.1 (19-89) and there were 26 and 20 females in
the SPS and PL groups respectively. Baseline ratings for stool frequency and form, straining,
bloating, and abdominal pain were well matched between the SPS and PL groups. 82.8%
and 50% of subjects responded to SPS and PL, respectively (p = 0.01). 24/29 subjects
receiving SPS reported an increase of ≥1 BM/day and rated straining as “never” or “rarely”;
17/28 and 14/28 subjects treated with PL reported an increase of ≥1 BM/day and reduced
straining. Assessments of secondary endpoints of stool consistency, bloating and abdominal
pain reinforced the observation of a favourable clinical response to SPS.41% and 18% of
subjects reported pasty or liquid stool, 93% and 71% reported bloating as rare/never, and
55% and 43% reported having no abdominal pain with SPS and PL treatment, respectively.
2 and 5 subjects treated with PL and SPS reported at total of 2 and 7 adverse events. None
were serious. One case of diarrhoea and of abdominal pain was reported in each group.
There were no changes in serum hematocrit, creatinine or electrolytes. CONCLUSIONS:
This study confirms SPS to be effective, well tolerated and safe in the acute treatment of
constipation. As a liquid formulation, SPS offers an advantage of being easily titrated to
optimize efficacy and minimize side effects.
S1063
Satisfaction with Healthcare in Inflammatory Bowel Disease: Influence of
Patient Characteristics
Carlvin Luces, Elizabeth Brown, Keith Bodger
INTRODUCTION Interest in measuring satisfaction with healthcare (SwH) is growing. Better
information about factors affecting SwH should help providers and planners to improve
service quality. Factors that may affect SwH include those that relate to patient characteristics
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and those that relate to features of the healthcare system itself. If ratings of SwH are to be
used as a measure of healthcare quality we need to understand the confounding influence
of measurable patient factors. There is poor knowledge of the factors that determine SwH
in IBD. AIMS & METHODS We aimed to identify patient factors associated with variation
in SwH among subjects with ulcerative colitis (UC) and Crohn's disease (CD) attending GI
clinics at a university hospital. SUBJECTS Out-patients attending for follow-up. PRIMARY
OUTCOME: Global SwH measured using a visual analogue scale (‘feeling thermometer')
consisting of a 100mm scale anchored between 0 (completed dissatisfied) and 100 (completely
satisfied) [‘SwH%']. DATA COLLECTED: Age, sex, occupation, educational level, disease
history (IBD type, duration, complications, surgery, drugs), activity score (Harvey Bradshaw
Index [HBI] or Simple Colitis Activity Index [SCAI]), global health state (‘utilities', using
Time Trade Off [TTO] and EQ5D), health-related QoL [IBD-Q], Hospital Anxiety & Depres-
sion Scale [HADS], IBD knowledge questionnaire [CCKNOW], membership of national
patient association. RESULTS: Data for the first 149 patients (CD, n=70;UC, n=79): Mean
(SD) SwH%: 79 (19.8); Range: 10-100. SwH% was independent of age, disease type, disease
duration, immunosuppressant use, surgery, recent hospitalisation and HADS scores. Mean
SwH% was lower in those who ‘Stayed on at School' (74.5 v 81.8; p=0.09) or had ‘Higher
Qualifications' (62.5 v 82.0; p=0.019) and showed a negative correlation with level of disease
knowledge (CCKNOW score; Pearson r = -0.24; p=0.045). SwH% was correlated negatively
with colitis activity score (SCAI, Pearson r = -0.47; p=0.001) and positively with utility
score (TTO, Pearson r = 0.29; p=0.007). CONCLUSION: Overall, SwH was high among
IBD patients but SwH rating was influenced by global state of health (utility) and disease
activity. ‘Better' educated patients and those with higher levels of disease knowledge appear
to report lower SwH, probably reflecting higher expectations of care (as reported in other
disease areas). SwH is a potentially useful outcome measure but absolute scores are influenced
by patient factors that appear unrelated to service quality.
S1064
Variables Predictive of Early Mortality and Urgent ERCP in Patients with
Acute Cholangitis
Jefrey Salek, Elayne Livote, Kostas Sideridis, Simmy Bank
Introduction: Acute cholangitis is a disease that presents with varying severity. Unlike in
pancreatitis, a well-accepted multifactoral prognostic scoring system is still lacking for acute
cholangitis. We report a scoring system that can be used to identify patients at high risk of
early mortality and those that may benefit from earlier ERCP. Methods: The diagnosis of
acute cholangitis was made if subjects had abdominal pain, jaundice, fever, and elevated
liver function tests. Ultrasound or abdominal CT was performed to support the diagnosis
in all subjects. If an ERCP was performed in the first 24 hours it was defined as urgent and
after 24 hours it was considered late. Approximately sixty variables were recorded and
analyzed against hospital mortality, urgent ERCP, and late ERCP. Chi-square test, Fisher's
exact test, and logistic regression analyses were used when appropriate. Results: A total of
108 patients, with an average age of 69.6 years, were studied. Overall mortality rate was
24.1%. Among the subjects who had an ERCP, 35% were performed urgently. Univariate
analysis identified 18 and 15 variables significantly (p<0.05) associated with mortality and
having an urgent ERCP, respectively. Using step-wise logistic regression three factors were
found to be significant in predicting mortality: total bilirubin (p<0.01), PTT (p<0.01), and
presence of a liver abscess (p<0.01). Two factors were found to be significant in predicting
urgent ERCP: ALT (p<0.01) and WBC (p<0.01). The parameter estimates for predicting
mortality and need for urgent ERCP are shown: mortality = (16.9 X associated liver abscess)
+ (4.2 X total bilirubin) + (0.88 X PTT). A score above 100 (n=26) was associated with a
100% mortality (sens=93.9, spec=80.7). Urgent ERCP = (0.95 X ALT) + (37 X WBC). A score
above 900 (n=29) was associated with an urgent ERCP (sen=0.98, spec=0.91). Summary: We
have developed a prognostic scoring system for predicting mortality and need for urgent
ERCP in patients with acute cholangitis using common clinical and biochemical variables.
Our scoring system allows for the identification of high-risk patients soon after admission
to a hospital, a time when the outcome of the disease is difficult to predict solely on
clinical impression.
S1065
Does Age, Ethnicity, and Gender Have a Role in Post-Polypectomy
Colonoscopic Surveillance Intervals?
Mihir Bakhru, Carol A. Burke, Rocio Lopez
Purpose: Post polypectomy (PP) colonoscopic surveillance intervals vary based upon risk
of recurrent neoplasia. Risk factors associated with recurrent advanced adenomas include
number of adenomas, size, and pathology. Age, gender, and ethnicity as risk factors have
been less studied and not utilized in surveillance guidelines. We compared the effect of age,
gender and ethnicity on the risk of recurrent and advanced neoplasia 3 years after baseline
colonoscopy. Methods: We reviewed prospective data from subjects who underwent PP
surveillance 3 after adenomas were cleared from their colorectum. Presence of neoplasia
was defined as having at least one adenoma found during either procedure. Advanced
neoplasia was defined as any villous pathology, high grade dysplasia, or >1 cm in size.
Subjects were classified based on age (+/- 5 yrs), ethnicity (Caucasian versus non-Caucasian),
and gender. Both univariable and multivariable logistic regression analysis were performed
to determine if age, gender, or ethnicity are associated with recurrent or advanced neoplasia.
Results: 825 subjects with mean age 63.5 yrs, 72.2% male, 15.7% non-Caucasian ethnicity
were included. By univariable analysis, older age was associated with presence of neoplasia
on follow-up colonoscopy, with median age of 62.8 yrs versus 60.8 yrs (P=0.009) and
recurrent advanced neoplasia, with median age 65.5 yrs versus 61.5 (P=0.026). Non-Cauca-
sian ethnicity was also significant with 69.2% with recurrent neoplasia (P=0.021) but not
advanced neoplasia (P=0.17). Gender was not associated with recurrent neoplasia or advanced
neoplasia (P=0.082; P=0.39). On multivariable analysis, non-Caucasian [OR (95% CI): 1.74
(1.14, 2.66); P=0.01] was a significant predictor of recurrent neoplasia but not age [OR
(95% CI): 1.07 (0.99,1.15); P=0.07] or gender (OR (95% CI): 1.30 (0.94, 1.80);P=0.11].
However, age [OR (95% CI): 1.14 (1.01, 1.28); P=0.03] but not ethnicity [OR (95% CI):
1.39 (0.78,2.45) P=0.26] or gender [OR (95% CI): 0.83 (0.50,1.35); P=0.44] was associated
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with risk of recurrent advanced neoplasia. Conclusion: Older age is a predictor of having
both recurrent neoplasia and advanced neoplasia. Non-Caucasian ethnicity has a higher risk
of having recurrent neoplasia but not with advanced features. Gender does not favor a
certain outcome of follow-up colonoscopic evaluation. It may reasonable to consider older
age and non-Caucasian when assessing surveillance intervals with already established guide-
lines of adenoma characteristics.
S1066
Adjuvant Therapy in Patients with Pancreatic Cancer: A Population-Based
Study
Yasser H. Shaib, Jessica A. Davila
Background: We conducted a population-based study to examine the utilization and the
outcomes of adjuvant therapy following curative surgery for pancreatic cancer. Methods:
Using the SEER-Medicare linked database we identified patients with local or regional stage
pancreatic cancer who received curative surgery between 1992 and 1999. Inpatient and
outpatient claims files were searched for treatment codes indicating receipt of chemotherapy
or radiation therapy. Multiple logistic regression models were developed to examine factors
associated with the utilization of adjuvant chemotherapy with or without radiation following
curative surgery. Unadjusted and adjusted hazard ratios were calculated in Cox Proportional
Hazards models to examine the effect of therapy on survival. Results: We identified 554
patients diagnosed with local or regional pancreatic cancer who received curative surgery.
The majority of these patients were younger, male (52% vs. 48%) and white (84% white,
7% black, 4% Hispanic, and 5% other). Of those 52% received surgery only followed by
chemotherapy with radiation (37%), and chemotherapy without radiation (11%). Factors
associated with receipt of adjuvant chemotherapy with or without radiation following curative
surgery included younger age and regional stage of disease. In the multivariable model, the
association between receipt of adjuvant chemotherapy with or without radiation and age
and stage remained significant. In the Cox proportional hazard model that examined the
risk of one-year mortality, the receipt of chemotherapy with radiation was associated with
a 30% reduction in mortality compared to surgery alone (HR=0.7; 95% CI:0.5-0.9. Age,
gender, race and period of diagnosis had no impact on mortality. In the model examining
the overall risk of mortality at any time following diagnosis, receipt of chemotherapy with
or without radiation was not associated with an improvement in mortality (HR=0.9;
95%CI:0.7-1.0). Conclusions: Approximately 48% of patients in our cohort received surgery
and chemotherapy with or without radiation. Patients who were younger or had regional
stage disease were more likely to receive adjuvant chemotherapy with or without radiation.
Receipt of chemotherapy with radiation following curative surgery for pancreatic cancer is
associated with short-term improvements in mortality but not overall mortality.
S1067
The Alosetron Hydrochloride Patient Survey Program: 3 1/2 Years of
Experience with 6,232 Patients
Suzanne Cook, Amy T. Heath, Susan H. Gordon, Pat Tennis, David Miller, Kelly Hollis,
Elizabeth Andrews
Background: An important aspect of post-marketing risk management for alosetron is the
risk management program (RMP), which was mutually agreed upon by the US Food and
Drug Administration and GlaxoSmithKline. Two of the goals of the RMP are: 1) educating
patients about the benefits and risks of alosetron and 2) ongoing evaluation of the impact
of risk minimization interventions on appropriate product use at the prescriber and patient
level. To evaluate the effectiveness of the RMP, a patient follow-up survey is being conducted.
The survey was designed to assess patient knowledge of the benefits and potential risks of
alosetron use, physician counseling and prescribing in relation to recommendations in the
RMP, and the extent to which patients satisfy the labeling guidelines for treatment with
alosetron. Methods: The survey program is a prospective study of patients who are prescribed
alosetron. Participants voluntarily enroll at the time of treatment initiation by completing
the pre-enrollment card found in every medication package, or obtained from the prescribing
physician. Participants complete baseline and quarterly surveys. Data on irritable bowel
syndrome history, symptoms, interaction between the patient and prescribing physician,
and patient knowledge are collected. Results: As of June 30, 2006, the study included
completed baseline questionnaires from 6,232 patients; this is approximately 30% of all
patients prescribed alosetron since re-introduction. The majority of participants were female
(93.2%). Of participants, 48% were aged 45-65, 76% were prescribed alosetron by a gastroen-
terologist, and 89% of females met clinical criteria for treatment with alosetron as described
in the package insert. Patient compliance with the RMP at baseline was high. Nearly all
patients discussed with their physician how alosetron can help their symptoms (97%), the
possible risks of alosetron (96%), reasons to stop taking alosetron (94%), and when to call
their physician (94%). Among participants, 89% received the Medication Guide from their
physician and 88% from the pharmacist; 98% reported reading the Medication Guide. More
than 85% reported receiving their prescription with the blue sticker and 91% reported
signing the physician-patient agreement. Conclusions: Results from the patients surveyed
indicate high compliance with the RMP in terms of patient education and physician coun-
seling, and concordance between patient characteristics and clinical treatment criteria for alo-
setron.
S1068
Hydrogen Breath Testing Does Not Predict Response to Antibiotics in Patients
with Or Without IBS
Rana Abraham, Kelly Cushing, Ali Keshavarzian, Mary Kwasny, Ece A. Mutlu
Background: Hydrogen breath testing (HBT) has long been used to identify patients with
small intestinal bacterial overgrowth (SIBO). HBT is now being promoted to identify a subset
of patients with irritable bowel syndrome (IBS) who may respond to antibiotic therapy.
Aim: To define a clinical patient characteristic or HBT parameter that predicts response to
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antibiotic treatment in patients with SIBO with or without IBS. Methods: All subjects who
underwent HBT from 2003 to 2006 at Rush University Medical Center were identified using
the HBT database cross referenced to a billing database. IBS was defined by the Rome II
criteria and the absence of other GI related illnesses and predisposing factors to SIBO such
as diabetes. Subjects were excluded if they had HIV, immunosuppresion,or widespread
malignancy or terminal illness. For HBT, 25 gm of lactose or 20 gm of lactulose were used.
Two baseline samples & samples every 15 mins were taken up to 165 mins. Breath samples
were then analyzed using the Quinton Microlyzer for hydrogen, methane & carbon dioxide.
The clinical patient characteristics & The HBT results were obtained with chart review and
were analyzed with chi- square, Fisher exact tests for categorical data, & Kruskal-Wallis
tests for continuous variables, using SPSS v. 11.5 & S+7.0. HBT were considered positive
for SIBO if there was a double peak in hydrogen or methane in lactose or lactulose HBT;
or the hydrogen level was > 20 ppm before 90 min in lactulose HBT. The tests were read
by a single gastroenterologist with experience. Results: 72/190 (38%) had SIBO based on
HBT; 94 (49%) were treated with antibiotics; data on treatment response was available on
76 (81 %), without any baseline differences in those with missing data. 51 (67%) had IBS.
Subjects responding to antibiotics were older (mean age 39 vs 59, p=0.04) and were less
likely on IBS treatment (p=0.038). There was no correlation between treatment response
and HBT test results in general and in the IBS subset. Other patient related variables such
as gender, pre-test symptoms or diagnosis, post-test symptoms or diagnosis, past medical
or surgical history, medications, endoscopic or histological findings from EGD and/or colon-
oscopy, hemoglobin and albumin, did not differ between the responders and non responders.
Among the IBS subset, no difference existed among the non-responders (n=18) vs. the
partial responders (n=38) vs. the complete responders (n=20) in frequency of SIBO, clinical
characteristics, or HBT parameters. Conclusion: HBT does not predict response to antibiotic
treatment in patients with suspected SIBO with or without IBS.
S1069
Marked Variability in Editor and Author Conflicts of Interest and Funding
Disclosures in Gastroenterology Journals
Nikhil Bhargava, Jamal Qureshi, Nimish Vakil
Background: Conflict of interest has gained prominence and several recent cases of non-
disclosure have been widely reported in the lay press. Standards for conflicts of interest
reporting have been published for authors (JAMA 2005;294:110-1) and editors. Aim: To
evaluate the conflict of interest policies for clinical gastroenterology journals with the highest
impact factors and to measure compliance with these policies. Methods: We examined six
consecutive issues of 11 journals devoted to gastroenterology with the highest Science
Citation Index (impact factor). We evaluated original contributions and editorial articles but
excluded review articles and case reports. Each article was evaluated for (a) declaration of
a funding source and (b) declaration of the presence or absence of a conflict of interest. In
addition, each journal's published conflict of interest policy for authors and editors were
reviewed. If these policies were not readily available in the journal or its website, journals
were individually contacted to obtain this information. Results: 8 of 11 journals (73%) had
a formal policy regarding an author's disclosure of conflict of interest. 1,133 articles were
evaluated amongst the selected journals. Disclosure of the presence or absence of a conflict
of interest ranged from 2-100%. Gut and Hepatology had the highest rates of disclosure
(100%). A potential conflict of interest was present in 0-12.7% of articles with the highest
rates (12.7% and 11.2%) being reported by the journals that had the highest disclosure rate
(Gut and Hepatology, respectively). The source of funding for a study was disclosed in
29-99% of the articles examined with only one journal (Alimentary Pharmacology and
Therapeutics) scoring above 90% (99%). Only 2 of 11 journals publicly disclosed the
conflicts of interest of the editors to the reader (American Journal of Gastroenterology and
Gastrointestinal Endoscopy) and only 3 had a formal method for handling editor's conflict
of interest. The journals with the highest disclosure rates for authors (Gut and Hepatology)
did not disclose the conflicts of interest of the editors. Conclusions: 1. The standards of
disclosure for authors are extremely variable in leading gastroenterology journals. 2. Editors
rarely disclose their own conflicts of interest and formal procedures to handle their conflicts
do not exist for most journals. 3. Disclosure of funding sources is incomplete in the majority
of gastroenterology journals. 4. This data may help the practitioner in evaluating the source
and content of the material they choose to adopt in their practices.
S1070
The Utilization of and Adherence to the Gastroenterology Core Curriculum
On Hepatology Training During a Gastroenterology Fellowship: A Nationwide
Survey Among Fellows and Program Directors
Jason Guardino, Deborah D. Proctor, Rocio Lopez, William D. Carey
The Gastroenterology Core Curriculum (GCC) represents a consensus of 4 major societies:
AGA, AASLD, ACG, ASGE. First published in 1996 (Gastroenterology) and updated in
2003, it describes knowledge and skills desired at the completion of fellowship training in
Gastroenterology. The hepatology subset of the GCC (H-GCC) forms a large portion of the
document and the focus of this research. Compliance with GCC has never been previously
assessed. AIMS: 1. Measure adherence of the H-GCC within GI Training Programs (GITP).
2. Compare the perceptions of the H-GCC compliance by fellows (F) and program directors
(PD). 3. Provide comparative information to assist PD in improving GITP. METHODS: A
questionnaire was designed to assess the general and hepatology components of the GCC.
F (2005 & 2006 graduates) and PD were invited to participate by means of 3 sequential
mailings (asking for answers representative of their own situation) between March - April
2006. Pearson's chi-square and Fisher's Exact tests were used to analyze the data. RESULTS:
Of 971 potential respondents, the questionnaire was returned by 42% of PD and 33% of
F. More than 90% compliance with guidelines was declared by both F and PD for: 3 yr IM
residency prerequisite, PD board certification in GI, minimum 3 fulltime faculty (including
> 1 fully trained hepatologist), longitudinal outpatient experience and teaching supervision.
There was less than 70% agreement by either F or PD for the following: minimum > 18
months of clinical training (with minimum > 30% hepatology), minimum > 20 paracentesis
and liver biopsies. Outcomes did not vary by program size, geographical location and NIH
funding. Most hepatology core topics were covered according to F; however > 10% claimed
their program was deficient in: liver physiology, acute fatty liver of pregnancy, angiography,
immunosuppressant use, and congenital hepatobiliary disorders. F in non-liver transplant
intuitions more often reported a lack of training in fulminant hepatic failure, appropriate
selection of transplant patients, and diagnosis/management of rejection (p<0.001). CONCLU-
SIONS: 1. A non-evaluative mailed questionnaire to F and PD is a practical means to measure
compliance with the H-GCC. 2. F and PD assessment of GITP are highly concordant. 3.
Most H-GCC criteria are being met by GITP. 4. Attention is required in many programs to
provide adequate time for clinical and hepatology training and prescribed number of proced-
ures. 5. Improved instruction in several hepatology topics seems warranted. 6. Future
studies measuring compliance with other components of the GCC using this methodology
seems feasible.
S1071
A Computer-Based Decision Support Tool to Determine Colonoscopy
Preparation
Thomas F. Imperiale, Jon Cardwell, Mubashir Khan, Jennifer S. Stuart, Peter Castelluccio,
Jason Sutherland
BACKGROUND: In many open access endoscopy units, polyethylene glycol (PEG) is used
for colonoscopy (CY) preparation (prep) despite clinical trials demonstrating that sodium
phosphate (NaP) is better tolerated, costs less, and results in an equivalent or better quality
prep. A decision support tool (DST) might be useful in open access systems if it accurately
and reliably selected patients who could safely use NaP instead of PEG. OBJECTIVE: To
design and pilot test a computer-based DST that determines the prep for patients undergoing
CY. METHODS: We designed the DST using Boolean logic to examine the VA's electronic
medical record (EMR) for CY indication, medications, ICD-9-CM diagnoses, and laboratory
data. The DST was designed to determine whether patients could safely receive NaP instead
of PEG, and who might benefit from a stimulant laxative prior to the prep; and to identify
patients with renal insufficiency, ascites, advanced CHF, and MI within 6 months, conditions
that preclude safe NaP use. We examined a 6-month sample of patients scheduled for
outpatient CY (all of whom actually received PEG, as this was a pilot test of the DST) to
determine DST performance as compared with that of a trained research assistant (RA), who
was blinded to the DST results. Disagreements between the DST and RA were adjudicated
by a board-eligible internist (MD), who was blinded to DST and RA decisions. RESULTS:
Of 1201 patients (mean age 61.5 +/- 10 years, 95% men), the DST and RA identified 939
(73%) and 944 (74%), respectively, who could receive NaP instead of PEG. There was
agreement between DST and RA for 1187 of 1201 (98.8%) patients. Of the 14 disagreements,
the DST disallowed NaP in 9 and allowed it in 5. Of these 5 cases, the MD agreed with the
DST in 3. The DST missed an indication of chronic diarrhea, but detected a normal creatinine
that both RA and MD missed. For the second decision, the DST and RA identified 398
(33%) and 393 (33%) patients, respectively, who had an indication for a stimulant laxative,
with agreement of 99.4% (1195 of 1201). Of 6 disagreements between DST and RA, the
DST allowed a stimulant laxative in 6 cases with MD agreement for all 6; The RA missed
3 patients with diabetes, 2 patients on narcotics, and 1 with quadriplegia. CONCLUSION:
The DST identifed a substantial proportion of patients who could take NaP instead of PEG,
while accurately identifying patients with conditions that preclude its safe use. It also
identified patients who might benefit by adding a stimulant laxative to the prep. We are
planning a clinical trial to determine whether the DST improves both patient-centered and
system outcomes.
S1072
Longitudinal Direct Medical Costs Associated with Constipation in Women
Denesh K. Chitkara, Nicholas J. Talley, Nilay Shah, H. Van houten, Amy Weaver, Miranda
A. Van tilburg, S. Katusic, William E. Whitehead, G. richard Locke
Background: Constipation affects 12-17% of the general population. Although direct medical
costs for constipation related medical visits are thought to be high, to date there have been
no studies examining longitudinal resource utilization in adults with constipation. Aim: To
estimate the incremental direct medical costs associated with constipation in women.
Methods: This is a nested case-control retrospective study. The sample consists of all mothers
of 5,718 children in the population-based birth cohorts who were born during 1976-1982
in Rochester, MN and did not migrate from the area prior to 5 years of age. All medical
visits for providers were available for research review through the Rochester Epidemiology
Project. The cases included mothers who presented to Olmsted county medical facilities
with constipation. Controls were randomly selected among all non-cases in the sample (i.e.
no diagnosis for constipation). The controls were matched to cases in a 2:1 ratio, matching
on DOB for the mother and child, and years of follow-up. Direct medical costs for cases
and controls were collected for the years 1987-2003 or until the subject emigrated from
the community. The medical costs and utilization were obtained from administrative data
(excluding outpatient pharmaceutical costs). Results: We identified 135 women among the
birth-cohort mothers with a diagnosis of constipation. We observed a median follow-up of
13.2 years for the cases and 12.2 years for the controls. The median annual direct medical
costs for cases were more than double those of controls ($2193 vs. $1034; p<0.001). The
median annual inpatient costs for cases were $580 compared to $2 for controls (p<0.001),
while the median outpatient costs for cases were $379 compared to $225 for control
(p<0.001). The median annual emergency department costs for cases were $99 compared
to $44 for controls (p<0.05). Cases were more than twice as likely to have at least one
surgical procedure over the observation period (25.2% vs. 11.9%; p<0.001). The median
number of annual outpatient visits for cases were 3.3 compared to 1.8 for controls. Cases
also had a significantly higher annual inpatient admissions and emergency room visits
compared to controls. Women with constipation were also significantly more likely to have
the following comorbid conditions compared to controls: depression, headache, back pain,
limb pain, and anxiety. Conclusion: Women with constipation have significantly higher
medical care utilization and expenditures compared to women without constipation.
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Post-Resection Endoscopic Surveillance in Colorectal Cancer Patients
Mehul Vora, Marwan Fakih, Kelli Bullarddunn, Michael D. Schiff, Ashwani Rajput, Judy
Smith, Hector R. Nava, Annette Sunga
BACKGROUND and SIGNIFICANCE: Appropriate colonoscopy surveillance in patients with
history of resected colorectal cancer (CRC) and a complete pre- or perioperative colonoscopy
is controversial. The American Gastroenterology Association, American Society of Colon and
Rectal Surgeons, and the American Society of Clinical Oncology recommend colonoscopy
3 years after resection, then every 5 years thereafter given the studies are normal. The
National Comprehensive Cancer Network, recommends a 1 year post operative colonoscopy
followed by 2-3 year intervals thereafter. We conducted a retrospective single institute study
in patient (pts) with resected CRC to investigate rate of high risk polyps and invasive CRC
in pts with resected CRC at 1 year after curative intent surgery and at 3 years after having
normal or low risk polyp findings on their year 1 colonoscopy. METHODS: The records of
CRC pts who had undergone curative intent resection at our institution between 1/1996 to
11/2005 were reviewed. Patient demographics, colonoscopy findings and treatment histories
were collected. Colonoscopy findings were classified into one of 3 groups: CRC, High risk
adenomatous polyps (≥1cm in size, more than 3 in number, villous component or high
grade dysplasia) and Normal colonoscopy or low risk polyps. Influence of age, race, gender,
family history, and chemotherapy on colonoscopy findings was sought. RESULTS: 198 pts
(median age 68, 57% males, 90% Caucasian) with resected CRC who had at least a docu-
mented 1-year post resection colonoscopy were evaluable for this study. 187 (94.4%) had
normal findings or low risk polyps, 8 (4%) had high-risk polyps, and 3 (1.5%) had CRC
1-year post resection colonoscopy. The majority of the year 1 post-surgery high-risk polyps
occurred in pts with full preoperative colonoscopies (80%) with fair to good bowel prepara-
tions. The 3 CRCs included 2 anastomotic recurrences and a second primary in pts who
had undergone a full a preoperative colonoscopy. Similarly, on the 4th year post-op colonos-
copy: 103 pts out of the 187 with a normal/low risk polyps at 1-year colonoscopy had a
repeat colonoscopy 3 years later; 98 pts (95.1%) had normal or low risk polyps, 3 (2.9%)
had high-risk polyps, and 2 (1.9%) had CRC (1 anastomotic recurrence and 1 a second
primary). In multiple logistic regression analysis, only age was predictive of detecting high-
risk polyps or cancer (p=0.015). CONCLUSION: Our data shows that over 5% of pts who
have undergone curative intent surgery will have high-risk polyps or cancer detectable at
1 year after resection. This suggests that colonoscopic surveillance at 1 year is appropriate
in this patient population.
S1074
Impact of a Diagnosis of Dysplastic Barrett Esophagus On Quality of Life
Parameters and Willingness to Enroll in a Randomized Sham-Controlled Trial
of Ablation (U.S. Aim Dysplasia Trial)
Nicholas J. Shaheen
Aims: On behalf of the AIM Dysplasia Trial Investigator Group, we assessed the impact of
a diagnosis of Barrett esophagus (BE) with low-grade dysplasia (LGD) or high-grade dysplasia
(HGD) on quality of life (QOL) and willingness to enroll in a randomized, sham-controlled
trial of ablation. Methods: The U.S. AIM Dysplasia Trial commenced in March 2006 at 20
centers. Eligibility requires a diagnosis of BE with LGD or HGD (max 8 cm) and confirmation
by an expert pathology service (Cleveland Clinic Foundation). If confirmed, patients are
randomized according to: LGD vs. HGD and BE length (<4cm vs. 4-8 cm). Randomization
(2:1, treatment vs. sham) occurs at time of endoscopy. Treatment group: EGD, balloon
inflation, and circumferential ablation of BE tissue with HALO360 System (BÂRRX Medical,
Sunnyvale, CA). Sham group: EGD, balloon inflation only. Follow-up: surveillance EGD/bx
and additional ablation, as needed (treatment group only), comparison of BE and dysplasia
eradication at 1 year (treatment v. sham.) At enrollment, patients complete a questionnaire
assessing impact of BE-dysplasia diagnosis on QOL (visual analog responses, 0-100 mm)
Results: Enrollment status: screened (n=320), consented/slides reviewed/QOL completed
(n=194), pathology confirmed (n=85), randomized (n=62). QOL results available for 51
patients (37 LGD, 14 HGD). Once initial eligibility confirmed, >90% of patients have agreed
to consent, indicating a high motivation to undergo ablative therapy. The majority of LGD
(54%) and HGD (71%) patients reported “worry regarding a future need for esophagectomy.”
The majority of LGD (65%) and HGD (79%) patients also reported “worry about development
of esophageal adenocarcinoma.” Conclusion: The majority of patients with BE containing
dysplasia express concern about the development of esophageal cancer, and those with HGD
express significant concern about the possibility of death from cancer. Patients with BE
containing dysplasia had high motivation to participate in a randomized trial of ablative
therapy.
QOL Questionnaire: Patient Responses
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Values are median (IQR) “0” indicates no impact or best state “100” indicates most severe
or worse state
S1075
A Single Serum Albumin On Admission to the Surgical High Dependency Unit
Predicts Mortality in Critically Ill Patients with Gastrointestinal Pathology
Fiona Leitch, Euan J. Dickson, Angela Mcbain, Simon Robertson, Clement W. Imrie
AIMS Pre-operative hypoalbuminaemia is well established as a marker of poor outcome in
surgical patients with gastrointestinal pathology. Albumin in this context functions as a
marker of nutritional status and the inflammatory response. However, in the critically ill
surgical patient it is the pro-inflammatory state and subsequent endothelial dysfunction with
capillary leak which results in low serum albumin. Current markers of outcome in critically
ill patients, such as organ failure scores, require serial measurements and complex calculations
to predict mortality. This results in delayed identification of the high risk patients who are
most likely to benefit from early intervention. Our aim was to evaluate a single albumin
measurement on admission to the Surgical High Dependency Unit as a marker of the
magnitude of endothelial injury, and correlate this with mortality. METHODS In a prospective
study conducted in a Surgical High Dependency Unit (SHDU), 66 consecutive emergency
patients were evaluated. Full Ethics Committee approval was obtained. Serum albumin was
measured on admission to the HDU and was evaluated with respect to in-hospital mortality.
RESULTS Serum albumin on admission to SHDU discriminated survivors from non-survivors
(p=0.013, ANOVA). The mortality in patients with an albumin of less than or equal to 25g/
dl (n=50) was 24%. All of the patients with an albumin of greater than 25g/dl (n=16)
survived (p=0.030, Chi-Square). The mean albumin in survivors was 21.3 g/dl, and 16.0
g/dl in those who died (p=0.013, Student's T Test). CONCLUSIONS Albumin is a significant
predictor of mortality (p=0.013) in critically ill surgical patients with gastrointestinal patho-
logy. This is probably related to the degree of inflammatory insult and subsequent endothelial
failure. A single serum albumin measurement on admission to the critical care facility
may be used to identify the high risk patient and allow earlier intervention to restore
physiological stability.
S1076
Specificity and Sensitivity of Esophageal pH Drops for Classical Acidic,
Weakly Acidic and Superimposed Reflux Episodes
Marissa C. Aanen, Albert J. Bredenoord, Melvin Samsom, Andre J. Smout
Introduction Ambulatory 24-h pH recording is a commonly used technique in patients
with symptoms of GERD. Classically, reflux events are identified as drops in pH from above
to below pH 4 (C). In addition, drops of ≥1 pH unit with nadir pH>4 are regarded as
weakly acidic gastroesophageal reflux (WA) while pH drops with nadir pH <4 are thought
to represent superimposed reflux (S). The threshold values for these drops as well as their
specificity and sensitivity for gastroesophageal reflux have never been investigated. Our aim
was to determine the specificity, sensitivity and threshold values for the three types of reflux
events. Methods Impedance-pH monitoring was performed in 10 patients (6♂; mean age
53±8 yr) with severe GERD symptoms who were off acid-suppressive medication for 1 wk.
Drops in pH of at least a 0.5 pH unit within 5 sec were identified and categorized as C,
WA and S reflux. Impedance monitoring was used as reference standard for reflux detection.
A receiver operating curve (ROC) was made to determine the area under the curve (AUC)
and the optimal cut-off point. Results Of the 2104 pH drops in total, 31% were C, 60%
WA, and 8% S. Seventy-one percent of the pH drops were associated with one or more of
the 1345 reflux events detected by impedance. This was the case in 79% of the C, 32% of
the WA and 47% of the S pH drops. Forty-eight percent of the pH drops that were not
detected with impedance monitoring were found to be swallow-associated. The ROC analysis
results are listed in the table. Discussion Esophageal pH monitoring was found not to be
a reliable detector of reflux when compared to impedance as reference standard. Optimal
threshold values for classical acidic, weakly acidic and superimposed reflux events are 1.5,
0.7 and 0.6 units, respectively.
Outcomes ROC curves
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Investigating Central Pain Processing Involved in Anxiety-Induced Colonic
Hypersensitivity Using Functional Magnetic Resonance Imaging (Fmri) in the
Rat
Anthony C. Johnson, Brent Myers, Jelena Zinnanti, Yasvir Tesiram, Rheal A. Towner,
Beverley Greenwood
Background: Imaging studies suggest that abnormalities in central processing of visceral
events are a major contributing factor in the development of irritable bowel syndrome (IBS)
symptomatology. Our previous studies in rodents demonstrated that stereotaxic implantation
of corticosterone (CORT) onto the amygdala induced anxiety and colonic hypersensitivity.
Goal: To identify, using functional magnetic resonance imaging (fMRI), the specific brain
nuclei involved in the induction of anxiety-induced colonic hypersensitivity in a rodent
model. Methods: In anesthetized (10 mg/kg xylazine and 100 mg/kg ketamine i.p.) rats,
micropellets of either CORT (30 µg, n = 6), or cholesterol (30 µg, n = 6) to serve as a
control, were stereotaxically implanted bilaterally on the dorsal margin of the central amydala
(CeA). Seven days after the surgery, rats were anesthetized with chloral hydrate (400 mg/
kg i.p.) and placed in the fMRI magnet (7 T). A series of isobaric colonic balloon distensions
(90s off, 30s on, 8 replicates) at two pressures (40 and 60 mmHg) were performed in a
standard block-design. Cross-correlation statistical analysis was used to determine significant
differences between distended and non-distended states in CORT and cholesterol treated
animals. Results: In rats with CORT implants, colonic distension induced significantly
greater overall brain activation (40mmHg = 1291; 60 mmHg = 2022 total pixels, p < 0.05,
Fisher exact test.) when compared to cholesterol controls (40mmHg = 196; 60 mmHg =
1080 total pixels). Additionally, the CORT-implanted rats showed greater activation of
specific nuclei that are known to be involved in anxiety and pain perception (Table).
Summary and Conclusion: This is the first study to show that differences in brain activation
which represent major characteristics of IBS, exist in a rodent model of anxiety-induced
colonic hypersensitivity.
Table
P calculated with Fisher's exact test.
S1078
A Prospective Comparative Study of Narrow-Band Imaging, Lugol's
Chromoendoscopy and Conventional Endoscopy for the Detection of
Esophageal Cancer in Patients with Head and Neck Cancer
I-lin Lee, Cheng-shyong Wu, Tzer-zen Hwang,, Wen-cheng Chen, Shui-yi Tung, Chia-
sheng Chuang, Kuo-ling Wei
Background: Patients with head and neck cancer have a high prevalence of second primary
squamous cell carcinoma in esophagus. However, the detection of an early esophageal cancer
by standard endoscopy is difficult due to its minute mucosal change. Lugol dye staining
during endoscopy was reported to improve the detection rate of esophageal cancers. But it
was time-consuming and of risk of iodine toxicity. Narrow band imaging (NBI), enhancing
the mucosal capillary loops, was valuable for the differential diagnosis of Barrett's esophagus.
It was seldom to be utilized for the observation of esophageal squamous cell carcinoma
(SCC). This study aims to compare conventional endoscopy, lugol's chromoendoscopy, and
NBI for the detection of esophageal SCC and dysplasia in patients with head and neck
cancers. Methods: A total one hundred and two patients with primary head and neck cancers
were enrolled for the prospective study from January to October 2006. None of those
patients had any esophageal symptoms occurred. A standard endoscopy (GIF Q260, Olympus
Optical, Tokyo, Japan) was performed, followed by a NBI (CV260SL, Olympus) observation,
and 2 % lugol's dye spray chromoendoscopy. Biopsy was taken from the abnormal lesion
site for histopathological diagnosis. The results of the three endoscopic methods were
recorded and analyzed. Results: Overall fifteen lesions in 13 patients with esophageal cancer
or dysplasia (7 advanced SCC, 6 high grade dysplasia, 2 low grade dysplasia) were proved
by histopathological results and the prevalence rate is 12.7 %. Hypopharyngeal cancer
appeared to be the highest prevalence of secondary primary esophageal SCC (7/30, 23.3
%). Most lesions detected were at the middle third of esophagus (3 in upper, 8 in middle,
4 in lower third). Three out of 6 lesions with high grade dysplasia and none with low grade
dysplasia could be visualized by standard endoscopy (detection rate 37.5 %). All the dysplastic
lesions could be identified by NBI with presenting typically as brownish change of mucosa.
The detection rate of using NBI and lugol's chromoendoscopy for esophageal carcinoma or
dysplasia were equivalent. Conclusions: The prevalence of esophageal SCC is extremely high
in patients with primary head and neck cancers. The use of NBI is equal to the use of lugol's
chromoendoscopy in the detection of early esophageal cancer, and superior to standard
endoscopy. Therefore, using NBI as endoscopic surveillance is highly-recommended in this
high risk group.
S1079
A Novel Class of Vanadium-Based Magnetic Resonance Imaging Contrast
Agents for Targeting Colon Cancer Cells with High Glycolitic Activity
Devkumar Mustafi, Walter J. Liszewski, Reba Mustafi, Anusara Chumsangsri, Marc
Bissonnette, Elizabeth Peng, Gregory S. Karczmar, John W. Ejnik, Heather Martin
Introduction: We have developed a novel class of contrast agents that contain VO2+-chelated
organic ligands for magnetic resonance imaging (MRI). These compounds provided excellent
contrasts in high-resolution MR images of rodent tumors. The main objectives were to
demonstrate that these contrast agents were taken up by highly glycolitically active colon
cancer cells and specifically targeted intracellular protein kinases. Such VO2+-chelates could
thereby provide high-resolution functional MR images of tumors that cannot be achieved by
conventional, non-specific contrast agents. Methods: For these experiments we chose HCA-
7 and Caco-2 cells derived from human colonic adenocarcinomas. Cells were plated on 6-
well plates at 250,000 cells/well. Each of the three VO2+-chelates, including VO(acetylaceton-
ato)2, was added to final concentrations ranging from 100-500 μM and cells incubated for
5 min. To demonstrate the uptake of VO2+-chelates in cancer cells, we carried out In Vitro
MRI at 4.7 Tesla and atomic absorption (AA) studies with intracellular extracts. The cytosolic
fraction of cell extracts was collected for MRI and AA studies. To assess if VO2+-chelates
activate intracellular protein kinases, we measured phospho-(active) AKT and phospho-
(active) ERK by Western blotting. In addition, MR images of tumors implanted in the hind-
limbs of rats were obtained before and after I.V. injection of contrast media. Results: MR
images, and the amount of intracellular vanadyl in HCA-7 cells as measured by AA of
soluble extracts after cell treatment with vehicle or VO2+-chelates, showed significant vanadyl
concentrations in the cytosolic fraction of cell extracts. These results clearly demonstrate
there is intracellular uptake of vanadyl into colon cancer cells exposed to VO2+-chelates.
VO2+-chelates at 100, 250, and 500 μM significantly increased p-AKT and p-ERK in HCA-
7 and Caco-2 colon cancer cells by 2-fold, 5-fold, and 12-fold, respectively, compared to
controls (p<0.05). Moreover, MRI of rodent tumors demonstrated preferential and persistent
uptake of VO2+-chelates in tumors. Conclusions: Results from In Vitro MRI and AA studies
provided direct experimental evidence that VO2+-chelates accumulate within colon cancer
cells. Cell signaling experiments indicated that VO2+-chelates activated key intracellular
protein kinases involved in glycolysis. MRI studies In Vivo demonstrated preferential accumu-
lation of VO2+-chelates in rodent tumors. This is a novel approach to cancer detection with
the potential to produce easily tolerated MRI contrast agents that are sensitive to cancer
metabolism. [Supported by the American Cancer Society, Illinois Division: 06-18].
S1080
Highly Specific in-Vivo Molecular Imaging of Early-Stage Pancreatic Cancer By
Fibered Fluorescence Endomicroscopy in Mice
Johannes Von burstin, Barbara Seidler, Günther Schneider, Alexander Meining, Roland M.
Schmid, Dieter Saur
Background: One reason for the bad outcome of pancreatic cancer (PC) is the lack of a
highly specific diagnostic tool for early-stage PC. Molecular near infrared fluorescence (NIRF)
imaging of tumor specific proteases could be a promising tool for detection of early-stage
PC. Aim: To evaluate protease activatable NIRF-probes and in-vivo fibered fluorescence
endomicrosopy in early-stage PC in an orthotopic mouse model using various PC cell
lines. Methods: PC cell lines TD-2 (murine), MiaPaCa-2 and BxPC-3 (human) were stably
transfected with enhanced green fluorescent protein (EGFP)/firefly luciferase and implanted
into the pancreata of nude mice. 3 weeks later, MMP- or Cathepsin acitvatable NIRF probe
was injected i.v. 24 hours after injection, non-invasive bioluminescence imaging (BLI) and
whole-body fluorescence detection were performed. In a second step, mice were subjected
to laparotomy, followed by minimal-invasive fibered fluorescence endomicroscopy (Cellvizio,
MaunaKeaTechnologies). Third, mice were sacrified and tumors were veryfied by ex-vivo
EGFP-detection and NIRF-imaging of explanted organs. In another approach, mice were
subjected to laparotomy and NIRF-probes were topically applied to the tumor. After 24
hours, BLI and fluorescence signals were taken as described above. A non-acitivatable probe
and injection of NIRF-probes into mice with acute pancreatitis served as control in each
experiment. Results: Tumor growth was verified by BLI. Following i.v.-injection of the
Cathepsin sensitive probe, all PC were detectable by whole-body fluorescence measurement
and by fibered fluorescence endomicroscopy at cellular level in-vivo, respectivley. In contrast,
injection of the MMP sensitive probe resulted in NIRF signals in mice bearing PC derived
from TD-2 and BxPC-3 cell lines, but not from MMP-2/9 negative MiaPaCa-2 cells. Ex-vivo
detction of EGFP showed tumor sizes of only few millimeters in all mice. Topical application
of NIRF-probes resulted in a signal intentsity equal to i.v.-application in tumors, but markedly
reduced background. Conclusions: Via activatable NIRF-probes, PC can be detected by
whole-body fluorescence imaging and at cellular level using a fibered fluorescence endomicro-
scope in-vivo. This method is highly specific and allows discrimmination between normal
pancreatic tissue, inflammation and PC. However, topical application of NIRF-probes resulted
in strong signal intensity and minmal background and possible reduction of toxic side
effects. Thus, endoscopic molecular imaging with protease activatable NIRF-probes is a
powerful tool for imaging of early-stage PC.
S1081
Detection of the Colorectal Cancer (CRC) Field Effect Through Partial Wave
Spectroscopic Microscopy (Pws)
Hemant K. Roy, Yang Liu, Hariharan Subramanian, Dhananjay Kunte, Prabhakar Pradhan,
Ramesh K. Wali, Jennifer Koetsier, Michael J. Goldberg, Zvezdana Bogojevic, Vadim
Backman
Background Profound genetic, epigenetic and proteomic alterations in the histologically-
normal colonic mucosa characterizes field carcinogenesis in CRC patients. However, current
modalities to detect these field changes have either been insensitive or clincally impractical.
Our group has developed a number of light scattering technologies (Nature 2000, Gastro
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2004) including most recently PWS, a powerful technology that allows heretofore unattain-
able accuracy at quantifying the nanoscale architecture in a single cell. The present study
aimed to assess whether PWS could detect the field effect of CRC. Methods: 1.Fisher 344
rats were treated with the colon-specific carcinogen, azoxymethane (AOM) or saline and
euthanized at pre-neoplastic time points (weeks 2, 4, or 8 post injection). Colonocytes were
isolated using a modified Weiser technique 2.HT-29 cells were stably transfected with SiRNA
plasmid or empty vector that targeted either c-terminus src kinase (CSK) or the epidermal
growth factor receptor (EGFR). 3. The PWS parameter disorder strength (Ld) was calculated.
Ld reflects the intracellular density of solid molecules (e.g. DNA, proteins, membranes).
Both mean and Ld variability (SDLd) can represent nanoscale structural perturbations.
Results: 1. There was a highly significant and progressive increase in Ld corresponding to
more “stochastic” cell nanoarchitecture (Table). These events are pre-dysplastic since ~20 and
~35 weeks are required after AOM-treatment to develop adenomas and CRCs, respectively.
2.Knockdown of the tumor suppressor gene CSK (by ~40%) resulted in increased Ld, whereas
reduction in the proto-oncogene EGFR (by ~30%) was noted to decrease Ld values. As
expected, there was a clear gradient of aggressiveness (CSK-RNAi construct >empty vector>
EGFR RNAi construct) as assessed by standard molecular markers (e.g. PCNA). Conclusions:
This is the first demonstration of a practical and robust means of detecting the subtle
genetic/epigenetic changes of field carcinogenesis. This ability to accurately detect single cell
nanoarchitectural changes may have a variety of applications including markedly improving
cytological brushings accuracy or CRC risk-stratification through analysis of exfoliated cells
from the rectum.
Data expressed as % control (age matched saline-treated rats or HT-29 transfected with
empty vector, respectively).
S1082
Randomized Controlled Study On Diagnostic Accuracy and Tolerability of
Transnasal Upper Digestive Endoscopy (Egds) with a New 4.9 Mm Endoscope
Vs a 5.9 Mm Endoscope and Transoral Egds in Unsedated Dyspeptic Patients
Italo Stroppa, Enrico Grasso, Alessandro O. Paoluzi, Giampiero Palmieri, Claudio Tosti,
Fabio Andrei, Francesco Pallone
Background and aim: Olympus GIF-N180 is a new 4.9 mm endoscope with only “up-down”
movement for upper digestive endoscopy (EGDS). Aim of the study was to assess accuracy
and tolerability of transnasal EGDS (T-EGDS) with the 4.9 mm endoscope compared with
a 5.9 mm endoscope and transoral EGDS (C-EGDS) with a standard 9.8 mm endoscope.
Patients & Methods: After pre-endoscopy assessment of anxiety, 300 consecutive patients
comparable for age, gender and residence were randomized to three groups: 4.9 mm T-EGDS
(N=100), 5.9 mm T-EGDS (n=100) and C-EGDS (N=100). Endoscopies were performed with
local xylocaine only and under continuous monitoring of cardio-respiratory parameters
(oxygen saturation, one-lead ECG). Endoscopy accuracy was established taking into account
the possibility to examine esophagus, entire stomach and duodenum, and to obtain reliable
histology of gastric biopsy specimens. Quality of images was also evaluated by the operator.
After endoscopy, patients graded discomfort at insertion and during examination by a 5-
point Likert scale. Patients examined by T-EGDS and already submitted to C-EGDS in a
recent (<2 years) past were also asked to express their preference between T-EGDS and C-
EGDS. Results: Pre-endoscopy anxiety level was comparable in the three patient groups
(p>0.05). Endoscopy was successfully performed in all patients in the 4.9 mm T-EGDS and
the C-EGDS groups, while in 12 patients in the 5.9 mm T-EGDS group transnasal insertion
of the endoscope failed due to anatomical reasons. Of these 12 patients, 8 patients accepted
to undergo examination with the 4.9 mm endoscope, and T-EGDS was possible in 6/8
patients but failed upon insertion in 2. In all investigated patients, T-EGDS with the 4.9
mm endoscope offered possibility to examine esophagus, entire stomach and duodenum as
far as the second portion, with excellent images, and without complications. No differences
were found between the three types of endoscopy, including discomfort, but duration of
T-EGDS (7.28 ± 2.36 minutes with 4.9 mm endoscope; 7.08 ± 2.35 minutes with 5.9 mm
endoscope) was longer (p<0.0001) than that of C-EGDS (5.5 ± 2.05 minutes). Reliable
histology was possible in all patients who underwent T-EGDS and C-EGDS. All patients
expressed high level of satisfaction, and 79/89 (89%) patients preferred T-EGDS. No signific-
ant changes in oxygen saturation, blood pressure and heart function were recorded during
EGDS. Conclusions: The two movements Olympus GIF-N180 endoscope offers possibility
to perform an accurate, safe and well-tolerated EGDS. The smaller size of the instrument
greatly reduces the failure rate at insertion and risk of complications.
S1083
Pinhole SPECT Imaging and Quantification of Intestinal Cd4+ T Cells in the
Dextran Sulfate Sodium Model of Murine Colitis
Bittoo Kanwar, Dong-wei Gao, Mei-hsiu Pan, Benjamin Franc, Joseph M. Mccune
Background: Comprehensive analysis of the extent of inflammatory bowel disease (IBD)
requires characterization of the phenotype and disposition of immune cells within involved
regions of intestine. The aim of this study was to evaluate a non-invasive scintigraphic
technique to quantify colonic CD4+ T cells in a dextran sulfate sodium (DSS) model of
murine colitis. Methods: Groups of BALB/c mice were treated with 0%, 3%, or 5% DSS
dissolved in drinking water for a period of 7 days. Mice were then injected with 350 μg of
indium 111- labeled rat anti-mouse antibody. Pinhole SPECT and CT imaging of the abdomen
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were performed 48 hours after antibody injection. Following imaging, mouse colons were
harvested and digested and lymphocytes were quantified with enrichment of the CD4+
fraction. Immunohistochemistry confirmed the presence of anti-CD4+ antibody. Histopathol-
ogic analysis was performed to grade the severity of inflammation. Results: Colonic CD4+
T cell uptake of the injected anti-CD4 antibody, as determined with small animal pinhole
SPECT, correlated with the histopathologic score and total CD4+ T cell numbers. Group
differences in CD4+ T cell count (P<0.01), total lymphocyte number (P<0.01), and histopa-
thologic score (P<0.01) confirmed the degree and extent of colitis severity as a function of
increasing doses of DSS. Conclusions: Small animal pinhole SPECT, utilizing a monoclonal,
non-depleting, anti-CD4+ indium 111-labeled antibody appears to be a useful modality to
image the degree of colitis In Vivo in a non-invasive manner.
SPECT/CT overlay of mouse treated with 5% DSS
S1084
Clinical Trial of “Miro” Capsule Endoscope Using Novel Transmission
Technology, “E-Field Propagation” for the Evaluation of Safety and Diagnostic
Feasibility
Seungmin Bang, Jeong youp Park, Seung woo Park, Jae bock Chung, Suck Chung, Won
Cho, Jung jin Hwang, Han bo Shim, Tae song Kim, Don haeng Lee, Si young Song
Backgrounds & Aims We developed novel capsule endoscope (CE) named “MiRo” based
on the completely new transmission technology, named “Electric-field propagation” by the
cooperative works of Intelligent Microsystem Center of KIST, IntroMedic Co., Ltd, and
Yonsei University College of Medicine under Frontier 21 project of Korea. Specifications of
“MiRo” are real-time image receiving, 10.8x24mm, 3.3 g, 1500 field of view, 320x320 pixel
formats, 1.4-2.8 frame/sec, and 9-11 hours battery time. To evaluate the clinical safety and
diagnostic feasibility of the prototype “MiRo”, we performed multicenter clinical trial. Methods
All volunteers received the base line studies including EGD, ECG etc. for the screening
cardiovascular and GI obstructive diseases. 24-hour holter monitoring in first 10 cases and
ECG with rhythm strip in remaining subjects were performed to evaluate its effect on cardiac
conduction system. All volunteers filled up the questionnaires for self-assessment of any
adverse events during the test. We analyzed transmission rate of captured images, the
inspection rate of entire small bowel, and the quality of transmitted images, which was
graded as outstanding, excellent, good at average, below average, and poor. The trial was
approved by IRB and KFDA. Results Among the 49 healthy volunteers, 45 were included
in the clinical trials and the remaining 4 excluded due to abnormalities on base-line study.
Any subjective symptoms related on CE were not found except mild chest discomfort of
one case during the passage of MiRo in distal jejunum. Any adverse effects on neuromuscular
system were not noticed. No abnormalities in the cardiac conduction system were found.
All CE were expelled through the anus within 3 days. The entire small bowel could be
explored in all cases. The transmission rate of captured image in stomach, small bowel and
colon were higher than 97% (99.5%, 99.6% and 97.2%, respectively). The mean total
duration of image transmission was 9 hour and 51 minute. The mean transit time of entire
small bowel was 4 hour and 33 minute. The quality of images was graded more than good
at average in 41 cases (91.1%). The details of villi and vascular structures of small bowel
were clearly visualized in 31 cases (68.9%). With this superb quality of image, unexpected
abnormal findings of small bowel were noticed in 13 cases (4 of polyps, 4 of lymphangiectasia,
and 4 of lymphoid hyperplasia). Conclusions The novel CE, “MiRo” is safe and effective for
exploring the entire small bowel with good quality of image and real-time feasibility. This
novel transmission technology will go beyond the field of small bowel capsule endoscopy
in the near future.
S1085
EUS-FNA Versus PET for Detection of Local Recurrence in Rectal Cancer
Darren A. Pavey, Katherine S. Garman, Frank G. Gress
BACKGROUND: Accurate detection of local recurrence in rectal cancer is important to
guide clinical management. Imaging options include pelvic CT, MRI, PET and Endoscopic
Ultrasound (EUS). Currently the optimal imaging technique is not known and there are no
previously reported comparisons of rectal EUS versus PET scan. AIM: To evaluate the
accuracy of PET and rectal EUS for the detection of local recurrence following surgery for
rectal cancer. METHODS: All patients who underwent both PET scan and rectal EUS between
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January 2001 and November 2005 were identified from an endoscopic database. Results of
PET and rectal EUS findings were compared to the gold standard of surgical histopathology
or long term clinical follow-up. RESULTS: Patients were referred following onset of lower
GI symptoms or abnormal pelvic CT findings during follow-up after surgery. Twenty-one
patients (14 M, 7F) with a mean age 54 years (range 16-75) who had undergone both PET
and rectal EUS were identified. PET scan suggested local recurrence in 15/21 (71%) and
was negative in 6/21 (29%) of cases. Surgical histopathology or long term follow-up confirmed
local recurrence in 6/15 (40%) patients with positive PET and excluded local recurrence in
5/6 (83%) patients with negative PET. Overall the sensitivity, specificity, positive predictive
value, negative predictive value and accuracy of PET scan for detection of local recurrence
were 86%, 36%, 40%, 83% and 52%. Rectal EUS reported local recurrence in 7/21 (33%)
cases and was negative in 14/21 (67%) cases. Surgical histopathology or long term follow-
up confirmed local recurrence in all 7 positive cases and excluded local recurrence in all
14 negative cases. The sensitivity, specificity, positive predictive value, negative predictive
value and accuracy of rectal EUS for detection of local recurrence were 100%. EUS-FNA
was performed in 12/21 (57%) cases and was diagnostic of malignancy in 5/12 and atypical
in 1/12 cases. All cases with EUS-FNA cytology diagnostic of malignancy were confirmed
to have local recurrence by surgery or long term follow-up. The case with atypical cytology
and one case with negative cytology both had EUS evidence of a mass consistent with local
recurrence. The mean duration of follow-up was 26 months. There were no complications
associated with rectal EUS. CONCLUSIONS: Rectal EUS is more accurate than PET for the
diagnosis of local recurrence following surgery for rectal cancer. PET is susceptible to a high
rate of false positives, resulting in relatively low specificity. In addition, rectal EUS-FNA has
the ability to obtain cytology to confirm the diagnosis of recurrence and thereby guide
further management.
S1086
In Vitro and In Vivo Imaging of Colon Cancer with Cetuximab Conjugated
Fluorescent Magnetic Nanoparticles
Young-seok Cho, Kiyuk Chang, Hyung-keun Kim, Tae-jong Yoon
Background/Aims: Magnetic nanocrystals have potential to bring dramatic improvements to
biomedical sciences, including detection, diagnosis, and therapeutic systems. We recently
synthesized biocompatible silica-overcoated iron oxide nanoparticles containing organic dye
(rhodamine B isothiocyanate, RITC) within a silica shell of controllable thickness. The
purpose of this study was to develop sensitive colon cancer imaging system with colon
cancer targeting antibody, cetuximab (Erbitux®) conjugated FMN. Methods: Nine nm sized
iron oxide was chosen and FMN was synthesized. FMN with PEG modification was conjugated
to humanized anti-EGFR monoclonal antibody, cetuximab (Erbitux®). Association of FMN-
Erbitux® probe conjugates was assessed using confocal laser scanning microscopy (CLSM)
on two different cell lines: target HT-29 colon cancer cell lines with weak expression of
EGFR and control HL60 lung cancer cell lines without EGFR expression. Dynamic In Vivo
observation of tumor targeting events of FMP-Erbitux® probe conjugates on 4.7 T research
imager. MR images of cancer cell implanted (HT-29) nude mouse before and after the
intravenous injection of control conjugates and probe conjugates. Also, we performed fluores-
cence immunohistochemical studies of excised tumor slice. Results: CLSM imaging provided
spatial distribution of EGFR expressions in which red fluorescence is only detected in the
membrane regions of the HT-29 cells. In the dynamic In Vivo observation of tumor targeting
events of FMP-Erbitux® probe conjugates, significant MR signal change of the tumor site
were observed after 30 min of the probe conjugate injection (Fig. 1A), whereas no difference
was detected after the control conjugate injection. MR signal change of the tumor site was
disappearing after 20 hrs (Fig. 1D). On the histological analysis, the region of high vascular
density showed greater deposition of probe conjugates than that of low vascular density.
Conclusion: Our FMN-Erbitux® probe conjugates might function as an effective multimodal
imaging agent.
S1087
Diamagnetically-Stabilized Levitation Control of An Intraluminal Magnetic
Capsule
Michael Lam, Martin P. Mintchev
Background. Controlled navigation promotes full utilization of capsule endoscopy for reliable
real-time diagnosis in the gastrointestinal (GI) tract [1], but intermittent spontaneous peristal-
sis can disturb the navigational control, destabilize the capsule and take it out of levitation.
Aim. The focus of the present work was to develop an economic and effective real-time
magnetic capsule-guiding system that can operate in the presence of GI peristalsis while
retaining navigational control. Methods. An experimental setup implemented a magnetic
capsule navigation system consisting of a pair of 11-cm, 5,000-turns copper electromagnets,
a position sensor and a feedback control unit, and was utilized to levitate a real-size capsule
containing a 7-mm in diameter, NdFeB magnet. Known lateral forces were applied to the
capsule mimicking the peristalsis of the GI tract. System requirements to maintain levitation
control over the capsule were recorded. Based on these experimental measurements, advanced
computer simulations using the computer-aided design (CAD) system Maxwell 3D (Ansoft,
Pittsburgh, PA) confirmed the validity of the modeling approach. Once the modeling was
verified, a real-size system that could handle peristaltic forces of up to 1.5 N was designed
utilizing the same CAD system. The addition of a 2-mm thick Bismuth diamagnetic [2]
casing for stabilizing the levitating capsule was also studied. Results. From the Maxwell 3D
simulations of a peristaltic force of 1.5N, a real-size system containing 50-cm in diameter,
10,000-turns copper electromagnets driven by currents of up to 300 Amperes was shown
to successfully maintain control over the levitating capsule at a 15 cm distance. The proposed
magnetic capsule guidance system with added diamagnetic capsule-casing was also shown
to be complying with the required mathematical conditions for diamagnetic stabilization
[2]. The modeled magnetic field around the diamagnetically-shelled permanent magnet was
shown to be redistributed aligning its interaction with the external electromagnets, thus
stabilizing the levitating capsule. Conclusion. A custom-designed diamagnetically-facilitated
capsule navigation system can successfully steer an intraluminal magnet-carrying capsule in
both experimental and computer-aided models. Real-size capsule guidance system using
diamagnetic stabilization is a feasible diagnostic modality that could be implemented in the
near future. References. [1] Fireman Z et al. (2004). Future of capsule endoscopy. Gastrointest
Endoscopy Clin N Am 14, 219-227. [2] A. K. Geim et al. (2001). Diamagnetically stabilized
magnet levitation. The American Journal of Physics, 69 (6), 702-713.
S1088
High Resolution 3d Reconstruction of the Human Gastroesophageal Junction
Rita Yassi, Leo K. Cheng, Dane Gerneke, Ian Legrice, Greg B. Sands, John A. Windsor,
Andrew J. Pullan
BACKGROUND: Little is known about the microstructure of the GEJ and contributing
structures such as the phrenoesophageal ligament (PEL) and their affect on swallowing.
AIM: To obtain detailed 3D representation of the human GEJ by combining high resolution
cross sectional images (comparable to histological sections) at 50µm intervals. This virtual
reconstruction can be resectioned at arbitrary planes and will improve the understanding
of muscle distribution and fiber orientation. Ultimately, this information will be used to
construct an anatomically accurate functional computer model of the GEJ. METHODS AND
RESULTS: An en-bloc harvest of the GEJ from a cadaver was excised 10 hrs postmortem
and suspended in a specially designed jig to maintain anatomical relations. The sample was
fixed in 3% formalin for 1 week before wax embedding resulting in a 75x75x55mm sample
block. A custom built extended-volume imaging system comprising a digital camera
(Canon1D MarkII) and Ultramill (Leica SP2600) mounted over a precision (0.1µm step)
XYZ stage (Aerotech) was used to obtain detailed microstructural information using Surface
Imaging Microscopy. The surface of the block was milled flat, etched, stained with May-
Grunwald and a 6x6 overlapping matrix of images was captured to cover the entire surface
at 8.22µm pixel resolution. This cycle was then repeated at 50µm Z steps for 650 steps. The
stained tissue was segmented out from the image with resolution comparable to conventional
histological thin sections. A 3D representation of the GEJ region was constructed (Fig. 1).
CONCLUSIONS: We have successfully imaged a normal human GEJ at high resolution
(8.2x8.2x50µm) that allows us to examine this region in new ways. These data are suitable
for use in a 3D computer model, which is currently being constructed. The model will
provide opportunities to examine the relationship between anatomy and physiology in health
and disease states.
Fig. 1: High resolution 3D reconstruction of the human GEJ (32.55 mm high).
S1089
Incidental Extracolonic Findings in Asymptomatic Screening Population
Undergoing Contrast-Enhanced CT Colonography
Young sun Kim, Nayoung Kim, Soo young Kim, Kyoung soo Cho, Min jung Park, Jeong
yoon Yim, Seon hee Lim, Kyung ran Cho, Dong hee Kim, Chung hyeon Kim, In sung
Song, Chan soo Shin, Sang-heon Cho, Byung-hee Oh
Background and Aims: CT colonography (CTC) without using contrast material might have
a great difficulty in characterizing extracolonic lesions, thus leading to unnecessary further
evaluation. The purpose of this study is to evaluate incidental extracolonic findings that
may be encountered with CTC using contrast material and to evaluate clinical implications
in the detection of potential abnormalities in an asymptomatic screening population. Methods:
Intravenous (IV) contrast medium-enhanced CTC was performed in 2,230 asymptomatic
adults (mean age, 57.5 years). Axial images were prospectively examined for extracolonic
lesions, and subjects with radiologically confirmed diagnoses were followed up. Extracolonic
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findings were recorded and classified into the following categories: findings of highly import-
ance, those of moderate importance, and those of little importance. Findings of highly
importance were defined as those which required immediate further diagnostic studies and
medical or surgical treatment. Clinical and radiologic follow-up, missed lesions, and clinical
outcomes were assessed using medical records (mean duration of follow-up, 1.6 years).
Results: A total of 2,186 extracolonic findings were detected in 66.5% (1,484/2,230) of the
subjects: 121 findings of highly importance in 121 subjects, 358 findings of moderate
importance in 305 subjects, and 1,707 findings of little importance in 1,058 subjects.
Subsequent medical or surgical intervention resulted from these findings in 2.0% (45/2,230)
of the subjects. New extracolonic cancer was detected in 0.5% (12/2,230) of the subjects,
including renal cell cancer (n=5), hepatocellular carcinoma (n=3), pancreatic cancer (n=1),
lung cancer (n=1), cervix cancer (n=1), and stomach cancer (n=1). Of these subjects, 83.3
% had N0M0 cancer, and most of them (83.3%) needed no additional staging workup.
CTC missed 8 extracolonic findings of highly importance including 1 early-stage prostatic
cancer. Of 115 subjects with highly important findings, 15 (7.7%) underwent additional
radiological imaging studies for indeterminate lesions. There were no severe life-threatening
complications related to contrast medium. Conclusions: IV contrast-enhanced CTC could
safely detect asymptomatic early-stage malignant diseases, thus reducing their morbidity or
mortality. In addition, it might be helpful in making one-stop staging work-up for extracolonic
cancer and to reduce unnecessary follow-up for indeterminate lesions.
S1090
Is Endoscopic Ultrasonography Useful in Follow Up of Gastric Lymphoma ?
Giacomo Bonanno, Francesco Di raimondo, Pietro Naso, Rosario Giustolisi, Francesco
paolo Russo, Carmelo Barbera, Salvatore Incarbone, Antonio Russo
Background. Endoscopic Ultrasound (EUS) is considered the best technique for locoregional
staging at diagnosis but its role in the follow up of patients with gastric lymphoma after
organ conserving strategies has not been established. Aim. We conducted a retrospective
study in order to evaluate if EUS is a reliable tool in the follow up of patients with
gastric lymphoma treated with a conservative stomach approach. Materials and methods.
We retrospectively studied 23 patients with primary gastric lymphoma. Sixteen of them
were affected by MALT Lymphoma and 7 by Diffuse Large B Cell Lymphoma (DLBCL).
Five patients were treated with H. pylori eradication therapy alone (omeprazole + Amoxicillin
+ clarithromycin); 8 patients received a treatment including HP eradication and chemotherapy
and the remaining 10 patients were treated with chemotherapy alone. Results. At the end
of initial treatment a CR (Complete Remission) was documented in 15 (65%) patients by
using endoscopy with biopsy (E-Bx). At the same time only 2 patients showed normalization
of EUS. Patients were then evaluated with E-Bx and EUS every 3/6 months and, at the last
evaluation, the number of patients in CR by E-Bx increased to 21 (91%). At the same time,
although EUS showed a reduction of median value of thickness of gastric wall, from 1 to
0.6 cm (p= .0031), only 7 patients (30%) had a normal EUS. A total of 99 evaluations with
both EUS and E-Bx were evaluated and we found concordance between the two methods
in only 33 cases (33%). No significant difference on the percentage of concordance was
recorded between MALT and DLBCL. After a median follow up of 36 months we have not
observed any relapse in 13 pts (6 DLBCL and 7 MALT) with a persistent positive EUS but
negative E-Bx. Conclusions. Although the length of follow up cannot exclude late relapse,
we think that in gastric lymphoma EUS tends to over-stage residual disease. Therefore, in
these patients conventional gastroscopy with biopsy remains the gold standard for follow up.
S1091
Dysplasia Detection in Barrett's Patients Using the Optical Biopsy™ System
Robert A. Ganz, Kenneth K. Wang, Mary L. Krinsky, Satish K. Singh, Chet Sievert
BACKGROUND: Detection of dysplasia within Barrett's esophagus is often difficult, yet early
detection of dysplasia may result in improved outcomes. Random biopsy methods, as
suggested by guidelines, are not often practiced due to their lack of sensitivity and their
time consuming nature. Although optical methods have been previously described using
laboratory equipment, we assessed the use of the Optical Biopsy™ System which employs a
robust commercial laser-induced fluorescence (LIF) spectrophotometry system to distinguish
between Barrett's metaplasia and low or high-grade dysplasia in Barrett's patients. METHODS:
Using a standardized biopsy protocol of 4 quadrant biopsies every 2 cm of visible columnar
mucosa, multiple tissue samples were taken in established Barrett's patients. Immediately
prior to physical biopsy, the SpectraScience Optical Biopsy™ System was used to collect
spectral data. The Optical Biopsy™ Forceps used in this study combines a novel fiberoptic
probe coaxially placed within the jaws of a standard biopsy forceps to facilitate both the
collection of spectral data and the physical biopsy from the identical piece of tissue without
the need for instrument exchange. The spectral data collected was correlated with the results
of the pathologist's interpretation of the physical biopsy sample. A statistical tissue recognition
algorithm was developed based on the spectral data/pathology correlation. The clinical data
(excluding the training set) was retrospectively analyzed using the algorithm to determine
the sensitivity and specificity of the Optical Biopsy™ System. RESULTS: A total of 78
patients, with any length Barrett's esophagus, were enrolled into the trial with 774 optical
biopsies taken. Physical biopsies revealed 268 specimens of Barrett's mucosa without dyspla-
sia, 59 with low-grade dysplasia, and 11 with high-grade dysplasia. Applying the algorithm
to the data set retrospectively, demonstrated a sensitivity of 90% and a specificity of 80%
in distinguishing between low or high-grade dysplasia and non-dysplastic Barrett's epithe-
lium. The algorithm will be further refined by numerous reruns through the data set to
achieve spectral discriminator enhancements and subsequent improvement in sensitivity
and specificity prior to further study. CONCLUSION: The Optical Biopsy™ LIF System can
distinguish dysplastic Barrett's epithelium from Barrett's metaplasia with a high degree of
sensitivity and specificity. Based upon these results, a prospective trial is scheduled to
determine the clinical utility of using the Optical Biopsy™ System in surveillance endoscopy
of Barrett's patients.
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
S1092
Elastic Scattering Spectroscopy (Ess) for the Detection of Aneuploidy in
Barrett's Esophagus
Gary Mackenzie, D. Oukrif, S. Green, M. Novelli, S. Bown, L. Lovat
Introduction: Aneuploidy (altered DNA copy number) is an independent marker of future
cancer risk in patients with Barrett's Esophagus without high grade dysplasia (HGD). Such
a patient has a five year adenocarcinoma risk of 28% if they have aneuploidy compared to
0% in the absence of aneuploidy in a cohort study of 322 patients. Elastic Scattering
Spectroscopy is a real-time In Vivo technique which detects changes in the physical properties
of cells. We have already demonstrated a sensitivity for detecting HGD in Barrett's oesophagus
of 92%. The measurement of aneuploidy by either image or flow cytometry is labour intensive
and therefore at present is not deliverable in routine clinical practice. If a fast, reliable, In
Vivo method such as ESS could detect aneuploidy during routine surveillance endoscopy,
biopsies could be targeted to high risk patients. Aims and Methods: Can ESS detect aneuploidy
In Vivo in Barrett's Esophagus in the absence of HGD? Matched optical and conventional
biopsies were taken from patients with Barrett's Esophagus. Biopsies demonstrating HGD
were excluded. The biopsies were then processed for aneuploidy using image cytometry
analysis. Paraffin was removed from a 40 micrometre section, and nuclei were liberated
with protease. The nuclei were spun onto a slide and stained with Feulgen for automated
image analysis and histogram generation. Results: 976 spectra from 258 Sites were collected
from 60 patients with Barrett's esophagus. Histograms were blindly analysed by two observers
and consensus was reached in all cases. 205 sites were classified as diploid and 53 sites
were classified as having image abnormalities. No sites contained HGD. We constructed a
new statistical algorithm using both jacknife and bootstrap training techniques to discriminate
between aneuploid and diploid sites without HGD. The results were almost identical using
both statistical techniques. ESS correctly identifying aneuploid sites using both statistical
methods with a sensitivity of 83% and specificity of 78% and the area under the ROC curve
was 0.86 displaying ‘good' discrimination. Conclusions: ESS can detect aneuploidy in Barrett's
Esophagus In Vivo in the absence of HGD. Over 85% of patients undergoing surveillance
do not have aneuploidy in their Barrett's esophagus so if ESS could successfully exclude
aneuploidy, these patients would not require a further endoscopy for at least five years.
Resources could then be focused on the surveillance or even treatment of patients with
aneuploidy. This ESS algorithm for the detection of aneuploidy requires prospective testing.
S1093
Is Clinical Response Followed By Mucosal Healing in Patients with Crohn's
Disease of the Small Bowel; A Prospective, Multicenter Study Using Wireless
Capsule Endoscopy
Alkiviadis Efthymiou, Nikos Viazis, Gerassimos J. Mantzaris, Nikos Papadimitriou,
Dimitrios Tzourmakliotis, Sotirios A. Raptis, Dimitrios G. Karamanolis
BACKGROUND-AIM: So far, there are no published studies assessing mucosal healing of
the small bowel in patients with Crohn's disease (CD) receiving medical therapy for the
induction of clinical remission. Previous studies have shown that steroids do not induce
mucosal healing of the large bowel, in contrast to biologic therapies which achieve both
clinical remission and mucosal healing. The aim of our study was to assess the correlation
between clinical response and mucosal healing of the small bowel, using wireless capsule
endoscopy (WCE). For these purposes, we designed a new endoscopic score for CD of the
small bowel, the simple capsule endoscopic score for Crohn's disease (SCES-CD). MATERIAL-
METHODS: We included in the study 40 patients with known CD or patients with suspected
CD in whom diagnosis was established for the first time. Patients were included if they had
all of the following: acute flare-up of their disease documented by a CD activity index (CDAI)
>150, involvement of the small bowel, age>18 and the non-stricturing, non-penetrating type
of the disease. For our score's calculation, 4 endoscopic variables were collected: ulcers and
their size, period of time that ulcers were visible (expressed as percentage of the small bowel
transit time), period of time that any other lesion was visible (erythema, oedema) and
stenoses. Each variable was scored from 0 to 3 for the whole small bowel and the values
were added to a total score, the SCES-CD. All patients that met the inclusion criteria had
WCE and calculation of the SCES-CD, prior to the initiation of any treatment. Treatment
varied according to the treating physician. Patients were then evaluated again, after a month
of treatment. If they had not achieved clinical response (CDAI<150, or decrease of CDAI
of >100), they were re-evaluated every 15 days until clinical response was achieved. When
this happened, they had a second WCE with calculation of the SCES-CD. RESULTS: The
mean SCES-CD scores before and after treatment were 4.35±0.38 and 3.73±0.37 respectively
(mean±SEM). t-test analysis showed a difference between the two scores, but not at a
significant level, (mean difference 0.625, 95% confidence intervals -0.026 - 1.276, p=0.59).
The SCES-CD correlation with CDAI was also poor (r=0.27, p=0.08). CONCLUSIONS:
WCE is a valuable tool in the evaluation of mucosal healing in CD. SCES-CD is a useful
endoscopic index of disease severity in CD of the small bowel, which we found easy to
calculate and practical in use. However, there was no correlation between clinical response
and mucosal healing in CD of the small bowel.
S1094
Validation of the Work Productivity and Activity Impairment Questionnaire -
Crohn's Disease Version. (WPAI:CD)
Mercedes Vergara, Francesc Casellas, Antonia Montserrat, Michael Maudsley, Olga
Gallardo, Elena Ricart, Xavier Calvet
Background: Although Crohn's disease (CD) is a frequent cause of work disability, there
are no validated instruments to measure work impairment in CD. The Work Productivity
and Activity Impairment Questionnaire (WPAI) has recently been described as a valid tool
for determining work disability. However, it has not been validated for CD patients. Objective:
To validate the WPAI questionnaire for use in CD patients. Methods: A validated Spanish
translation of the WPAI test was evaluated. The WPAI-CD measures; Work time missed
(WTM) - hours missed because of CD: Work impairment while working (IWW) - degree
A-172AGA Abstracts
of reduction in productivity while working due to CD and overall work impairment (OWI).
The following properties of the questionnaire were measured for their validation: a) Discrimin-
ant validity: comparing WPAI in CD patients with active versus inactive disease and CD
patients versus healthy controls. b) Convergent validity: comparing WPAI with a Quality
of Life questionnaire (IBDQ-9) and WPAI with CD activity (measured by Harvey index). c)
Responsiveness was determined by comparing WPAI-CD values in the same patient during
a flare of CD and when patients were in remission. d) Reproducibility: comparing two
WPAI-CD measures obtained two weeks apart in stable patients. The Wilcoxon test for
paired data and the Mann-Whitney U test for unpaired data were used for comparisons.
Results: One hundred and six patients were included in the different analysis. A) Discriminant
validity: WTM in active patients versus inactive patients was 25% vs. 3%; IWW 32% vs.
1%, OWI 47 % vs. 5% (p<0.01). WTM in patients versus controls (n=24) was 16% vs. 1%,
IWW 21% vs. 7% and OWI 30%vs 7% (p<0.01). b) Convergent validity: Correlation between
WPAI and IBDQ-9 was r=0.6 and between WPAI and disease activity was also r=0.6. c)
Responsiveness: Eighteen patients presented a WTM= 32% in remission vs. 60% during a
flare; IWW= 18% vs. 71%; OWI= 45% vs. 88% (p<0.05). d) Reproductibility: In fifty-four
stable patients, WTM= 6.1% vs. 6.4%. Reproducibility of IWW was, however, limited IWW=
20% vs. 42%. Conclusion: WPAI is a valid and responsive questionnaire for measuring
absenteism of CD patients at work. Changes will be necessary to improve reproducibility
in the evaluation of presenteism
S1095
Novel Autoantibodies Against Ubiquitination Factor E4a (Ube4a) Are Potential
Biomarkers for Detection and Prediction of Clinical Activity and Outcome in
Patients with Crohn's Disease
Toshio Sakiyama, Hiroshi Fujita, Hirohito Tsubouchi
Background: Identification of a disease- and organ-specific autoantigen can potentially con-
tribute to understanding molecular mechanisms involved in Crohn's disease (CD) and
lead to development of clinically useful biomarkers. Aim: To identify potential intestinal
autoantigens specific to patients with CD and evaluate their diagnostic value. Methods: A
cDNA expression library from normal terminal ileum was created and screened with pooled
sera from three randomly selected patients with CD. For evaluation of the diagnostic value
of antibody screening, serum samples obtained from 39 patients with CD, 28 patients with
UC and 60 healthy controls were examined for IgG against the strongest clone. Results: We
identified an intestinal cDNA clone encoding ubiquitination factor E4A (UBE4A), a U-box-
type ubiquitin-protein ligase. The prevalence of anti-UBE4A IgG in patients with CD was
significantly higher than that in patients with UC or healthy controls (46.2% vs, respectively,
7.1%, P = 0.0006; 3.3%, P < 0.0001). Anti-UBE4A positive patients with CD were more
likely to require surgery (P = 0.0013). The level of anti-UBE4A IgG was correlated with
disease activity (r = 0.777, P < 0.0001) and associated with stricturing or penetrating
disease (P = 0.0028). Immunohistochemical studies showed up-regulation of UBE4A in
enteroendocrine cells of inflamed ileal mucosa with CD. Conclusions: Anti-UBE4A antibodies
are potentially useful biomarkers to diagnose and predict disease severity in patients with
CD. Whether UBE4A plays a role in the etiopathogenesis of CD remains to be determined.
S1096
Mycobacterium avium Ssp Paratuberculosis (MAP): A Blinded Detection Study
(Epru 99-01) Does Not Support An Association of MAP with Crohn's Disease
(CD)
Edgar Boedeker, Noam Harpaz, Saleh Naser, William Blackwelder, Carol Tacket, Michele
Trucksis, Daniel Frank, Norman Pace
To examine a role for Mycobacterium avium ssp paratuberculosis (MAP)in the pathogenesis
of Crohn's Disease (CD), adjacent aliquots of 219 samples of surgically resected tissues from
139 well-characterized patients with Crohn's disease (n = 43), ulcerative colitis (n = 38),
or controls without IBD (n = 58) were cultured for Mycobacteria by identical methods in
two laboratories (UCF, UMD). Three media (BACTEC, BACTEC+egg, and MGIT) were
inoculated. The MGIT media was designed to increase the recognition of cell wall-free forms
of MAP. When cultures registered positive for growth, polymerase chain reaction (PCR)
analysis was performed on DNA extracts to identify the mycobacterial species. 112 samples
were positive for MAP in any medium (38 BACTEC, 40 BACTEC + egg, 91 MGIT), however
there proved to be no correlation between the results obtained in the two microbiology
labs. Concordance for positivity in any medium was only 22% (25/112), for Bactec 2.6%
(1/38), for Bactec+Egg 5% (2/40) and for MGIT 11% (10/91). The Kappa reliability test for
agreement was essentially 0 for all 4 measures of positivity. This lack of correlation under-
mined the ability to determine predictable associations of culture positivity with disease.
Additional analysis examined the association of culture positivity with disease in the individual
labs. Culture results from neither lab yielded a significant association with diseased tissue,
either for any positive test (Table 1), or for any culture method (MIGIT Table 2). Direct
analysis of tissue by Mycobacteria-specific PCR analysis of rRNA (a less sensitive method)
did not detect MAP in any of the samples. These results do not support an association
between MAP and Crohn's disease.
Table 1. Rate of MAP Culture Positivity in Any Specimen from Each Individual on Any
Medium by Lab
*Chi square comparing all three groups simultaneously
Table 2. Rate of MAP Culture Positivity in Any Specimen on MGIT Medium by Lab
*Chi square comparing all three groups simultaneously
S1097
Defining and Validating Cut-Off's for the Simple Endoscopic Score for Crohn's
Disease
David N. Moskovitz, Marco Daperno, Gert A. Van assche, Filip Baert, Annemie Gevers,
Raffaello Sostegni, Jean-frederic Colombel, Geert D'haens, Paul Rutgeerts
Introduction. A new goal in Crohn's disease treatment is to aim for endoscopic healing,
since improved clinical outcomes were shown in patients attaining endoscopic remission.
The Simple Endoscopic Score for Crohn's Disease (SES-CD) was developed as an easier
measure for endoscopic activity. Our aim was to further advance the SES-CD by defining
cut-off values for disease activity, therefore better objectifying these scores. We then validate
our findings in a new group of patients. Methods. 191 consecutive patients with an established
diagnosis of Crohn's disease who underwent colonoscopy had CDEIS, SES-CD, CDAI, and
CRP calculated. For the SES-CD, four endoscopic variables were defined according to the
original paper (SES-CD-1=ulcer size, SES-CD-2= proportion of the surface covered by ulcers,
SES-CD-3= proportion of the surface with any other lesions, and SES-CD-4=stenosis).
Endoscopic remission was defined as SES-CD-1 =0 in every explored segment. Endoscopically
severe was defined as either ulcer size greater than 2 cm (SES-CD-1 =3) or ulcer size within
0.5-2 cm (SES-CD=2) in greater than 30% of the explored segment (SES-CD-2=3) or
narrowing that could not be passed (SES-CD-4=3). Endoscopically moderate was divided
into two categories, mild and moderate. The sensitivity and specificity for different cut-off
values for determining endoscopic remission and endoscopic severity were calculated for
both the SES-CD and CDEIS using ROC curves. Cut-offs were then validated in a separate
cohort of 112 patients. Results. There were 27 (14%) of patients in remission, 36 (19%)
with mild score, 58(30%) moderate, and 70 (37%) severe. Optimal cut-off's and sensitivity
and specificity are illustrate in table 1. Differences in CDAI, IBDQ, and CRP levels were
significant (p<0.05) when comparing the endoscopic classes of remission vs mild-to-moderate
vs severe endoscopic activity. We confirmed our results in the 112 additional patients
achieving similar cut-offs and statistically significant differences for CDAI, CRP, and IBDQ
between groups. Discussion. We are able to define and validate cut-off's for the SES-CD.
In addition we are able to prove the clinical relevance of the defined cut-off's.
S1098
Young Children with Crohn Disease Demonstrate Different Serologic Profiles
Than Those Who Present At An Older Age
James Markowitz, Joel R. Rosh, Marian D. Pfefferkorn, Anthony Otley, Maria M. Oliva-
hemker, M. susan Moyer, David R. Mack, Neal S. Leleiko, Subra Kugathasan, Jonathan S.
Evans, Wallace V. Crandall, Christine Langton, Jeffrey Hyams
Background: Determining serologic profiles to cellular and microbial antigens has become
an important means of characterizing patients with IBD. While detectable antibodies occur
in ~60% of patients with Crohn disease (CD), children often lack detectable serologic
responses. Recently, a serologic marker to a novel flagellin antigen, anti-cBir1, has been
reported to identify IBD patients with CD and identify those ANCA+ patients who have
“UC-like” CD. AIM: To evaluate the frequency of anti-cBir1 responses in a group of children
with CD, with particular emphasis on the role of age in the development of serologic
responses. METHODS: Data were drawn from the Pediatric IBD Collaborative Research
Group Registry, a multicenter observational inception cohort begun in 2002. At or shortly
after diagnosis of IBD, subjects had a serologic assessment for neutrophil specific ANCA,
ASCA IgA, ASCA IgG and anti-ompC (Prometheus Labs). Banked sera were subsequently
tested for anti-cBir1 (Prometheus). RESULTS: 172 children with CD (mean age 11.6±3.0
yrs, 68% male) were evaluated. 12 were <6 yrs old, 44 were 6-10 yrs, and 116 were 11-
16 yrs at diagnosis. As there were no differences in the frequencies of serologic markers
between the older two age groups, comparisons are made between the youngest children
(<6 yrs) and those ≥6 yrs. Rates of positive serologic markers are noted in the Table. ASCA
IgA, ompC and ANCA rates were similar between groups. ASCA IgG was more common
in older children, and anti-cBir1 in those <6 yrs (p=0.0088). 100% of the children <6 yrs
of age were cBir1+, compared to only 63% of those ≥6 yrs. These differences were not
explained by the frequencies of NOD2/CARD15 variants in the different age groups, which
ranged from 32-37%. 8/12 (67%) children <6 yrs old lacked ANCA, ompC and ASCA,
compared to 60/160 (37.5%) of those ≥6 yrs (p=NS). All 8 of those <6 yrs who lacked
ASCA, ompC and ANCA were cBir1+, compared to 34/60 (57%) of the children≥6 yrs who
lacked these markers (p=0.0199). Conclusions: The anti-cBir1 assay identifies a subgroup of
children with CD who would otherwise not be characterized serologically. This appears
especially important in the youngest children with CD, in whom anti-cBir1 appears to be
particularly common. These differences suggest that there may be different, and as yet
unrecognized, genetic, immunologic or microbial factors leading to CD in the youngest chil-
dren.
Rates of Positive Serologic Markers
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S1099
A Cross-Sectional Study to Determine If C-Reactive Protein (Crp) Normal
Range Phenotype Varies According to Genotype
Jennifer Jones, Li-sheng Chen, William J. Tremaine, Sandra Peterson, Edward V. Loftus,
Leanna Beaudhuin, Scott Harmsen, Joseph Mcconnell, Allan Zinsmeister, William J.
Sandborn
Background: C-reactive protein (CRP) is a sensitive and early marker of acute inflammation.
The relationship between CRP concentration and clinical disease activity in inflammatory
bowel disease is inconsistent. This may be explained in part by recently described polymorph-
isms (PMs) of the CRP gene which have been shown to alter baseline and stimulated CRP
concentrations. An improved understanding of the relationship between these genotypes
and their CRP concentration phenotype may have significant implications for detecting
inflammatory processes and for monitoring therapy. Objectives: We sought to determine
whether median CRP concentrations in normal subjects differed according to CRP, tumor
necrosis factor-alpha (TNFα), and Interleukin 6 (IL-6) genotype. Methods: De-identified
medical records of adult subjects presenting for blood collection at the Mayo Clinic, Rochester,
Minnesota were reviewed. Patients with active infectious and inflammatory conditions were
excluded. Demographic information including age, body mass index (BMI), smoking status
and medications were recorded. High-sensitivity CRP assays were performed on all blood
samples. Samples were evaluated using a luminex-based method for multiplex analysis of
inflammatory marker gene polymorphisms. Results: A total of 521 charts were reviewed for
this study, and 432 samples were successfully collected and assayed. The median CRP value
was 0.96 mg/dL. CRP concentrations ranged from ranged from 0.03 to 40.15 mg/dL.
Significantly higher median CRP concentrations were observed in association with CRP 1444
mutant type (MT) homozygote and heterozygote status as well as CRP 286 heterozygote
TMT status. These associations were persistent after multivariate analysis controlling for age,
gender, body mass index (BMI), hypertension, dyslipidemia and obstructive sleep apnea.
1444 MT homozygote and heterozygote status as well as 238 MT genotype TMT were also
associated with higher CRP concentrations by quintile analysis (p<0.03). Conclusion: There
appears to be a meaningful association between select genetic PMs of the CRP gene and
basal hs-CRP concentrations in healthy individuals. These results may have implications for
the interpretation of hs-CRP concentrations used for risk-stratification in cardiovascular
disease and detection of mild inflammatory disease. Stratification by genotype should be
considered when using hs-CRP for the detection of sub-clinical inflammatory disease. Larger
studies are needed to perform haplotype analyses and to adequately evaluate the relationship
between hs-CRP and genetic polymorphisms with lower allelic frequencies.
S1100
The Pharmacogenetics of Methotrexate Therapy in Inflammatory Bowel
Disease
Bijay Baburajan, Natalie Prescott, Monica Arenas, Su yang Soon, Azhar Ansari, Klaus
Herrlinger, Fraser Cummings, Mark Tremelling, Miles Parkes, Derek P. Jewell, Chris
Mathew, Anthony M. Marinaki, Jeremy D. Sanderson
Introduction. Methotrexate (MTX) acts by inhibiting dihydrofolate reductase and the purine
and pyrimidine biosynthetic pathway. Response in inflammatory bowel disease can be
limited by side effects leading to drug withdrawal (10% of patients) or non-response (45%).
Polymorphisms in enzymes involved in folate metabolism and transport have been shown
to predict clinical outcome. In this retrospective study, clinical outcome and tolerance to
MTX were correlated to genetic variation in MTHFR, ATIC (purine synthesis), and TS
(pyrimidine synthesis). Methods. Data was available on 203 patients with Inflammatory
Bowel Disease . 171 were treated with methotrexate for more than 12 weeks. Response was
defined as a withdrawal of steroids with a Harvey- Bradshaw Index < 4. Hepatotoxicity
(ALT > 3 times the upper limit of normal); neutropaenia, nausea and other less frequent
side effects were recorded. Patients were genotyped for the, ATIC 347C>G, TSER*2/*3 and
TYMS 3'-UTR 6 bp in/del , MTHFR 1298 A>C and MTHFR 677 C>T genotypes. Genotypes
were tested for association with clinical outcomes and side effects using recessive and
dominant models Results. 49(24%) patients suffered side effects predominantly as nausea
during initiation of therapy. 5 patients experienced leucopenia and 12 developed abnormal
Liver function tests during therapy. 66 /163 (40%) of patients responded to therapy. The
ATIC 347C>G mutation correlated with side effects as a dominant and a recessive trait. 14/
47 (29%) of homozygous mutants developed side effects compared with 58/139 (42%)
(two-sided P value = 0.0344, RR = 2.176, 95% CI : 1.136 to 4.169). No other associations
were found in recessive or dominant models with either response to therapy or occurrence
of side effects. Conclusions: These findings suggest that genetic variation in folate metabolism
does influence tolerance to MTX. Further studies may define those loci which are of true
clinical importance or which might have an additive effect as part of a pharmacogenetic
index as proposed for MTX use in Rheumatoid arthritis.
S1101
Fecal Calprotectin Levels As a Predictive Marker of Steroid-Resistance/
Responsiveness in Acute Crohn's Disease
Caitlin O'mahony, Liam O'mahony, Fergus Shanahan
Background: The role of fecal calprotectin as a non-invasive surrogate marker of gastrointesti-
nal inflammation has been well studied. However, the use of calprotectin levels as a predictive
marker of therapeutic response has not been well studied. Aims: To determine whether the
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level of fecal calprotectin relates to likelihood of response or resistance to steroid therapy
in patients with acute Crohn's disease. Methods: 68 consecutive patients with acute Crohn's
disease were assessed prospectively before, during, and after steroid-induced remission.
Steroid treatment was standardised for all, beginning with oral prednisolone 40mg/day with
a non-linear tapering schedule over 12 weeks. Steroid-induced remission was defined in
advance as CDAI <150, ability to get off steroids after 12 weeks and remain off steroids for
≥6 months following induction. Failure to respond was defined as the inability to taper off
steroids within 12 weeks or the need to intervene with infliximab or surgery. Fecal calprotectin
was quantified by ELISA as were serum cytokines IL2, sIL-6R, IL-6 and IL-8. Results Fecal
calprotectin levels (1085 mg/kg +/-129; mean +/- SEM) were on average x20 times the
normal (<60 mg/kg). Levels amongst those who responded to steroids (715 +/- 157; n=20)
were significantly lower than those who failed to respond (1239 +/-167; n=48; p=0.045).
More importantly, patients with a calprotectin level >250 mg/kg only had a 1:5 chance of
responding, and the likelihood of response diminishes at greater levels, whereas those with
values less than that had a >50% chance of responding. Mean CDAI in the responders (210
+/-21) was not significantly different from non-responders (250 +/-12). Serum cytokines
and CRP levels were not predictive of response to steroids. Conclusions: Calprotectin is a
better predictor of response to steroids than systemic biomarkers in patients with acute
Crohn's disease. For the subset of patients with highly elevated levels of calprotectin (>250),
clinicians should consider an alternative to corticosteroids for remission-induction, because
of the low likelihood of response to a standardized regimen.
S1102
Characteristics of Patients with CDAI-Defined Active Crohn's Disease (CD)
and Low C-Reactive Protein (Crp)
Patrick Chamouard, Alain Ledit, Michel Patris, René Baumann
Rational: CDAI better predicts clinical symptom severity than CD inflammatory activity. In
some randomized clinical trials, placebo response is more frequent in patients with CRP <
10 mg/L. The aim of this study was to investigate factors liable to act upon CRP level in a
CD cohort and to describe clinical characteristics of patients with active CD and CRP < 10
mg/L. Methods: CRP and CDAI was measured in 143 consecutive patients with CD. The
Montreal classification was used to define CD phenotype. A CDAI threshold of 220 was
adopted to separate inactive or mildly active from highly active CD. ROC curve was used
to assess diagnostic value of CRP to predict a CDAI ≥ 220. Results: CRP (mean (m) = 24.3
± 3.8 mg/L) was correlated to CDAI (m = 196.9 ± 12.0) (r = 0.638: p = 0.0001). CRP level
was not different according to the site of disease (L) or age at diagnosis (A) but was lower
in stricturing disease (B2) by comparison with nonstricturing disease (B1) or penetrating
disease (B3) (15.5 ± 2.9 mg/L) versus 31.5 ± 6.3 mg/L: p = 0.035) and in case of previous
intestinal resection (IR) (13.5 ± 2.6 mg/L versus 31.7 ± 6.0 mg/L: p = 0.017). CRP was not
correlated to BMI or age, but was negatively correlated to disease duration (r = -0.264: p =
0.033) although this correlation was not significant after control of IR and B factors. ROC
curve confirmed the diagnostic value of CRP to predict a CDAI ≥ 220 (AUC220ROC =
0.814; CI: 0.776-0.852, p = 0.0001). The optimal threshold maximizing sensibility (SE)
and specificity (SPE) was 10.3 mg/L: α risk (1-SPE) = 0.269 and β risk (1-SE) = 0.300.
Fifty patients had CDAI ≥ 220 ; of these 15 had CRP < 10 mg/L. Among these 15 patients,
5 (30%; CI: 6.8-53.2%) presented with slight or moderate depression assessed by a validated
scale that increased and biased CDAI score. L, A, IR, and BMI were not different in these
two subgroups respectively of 15 and 10 patients by comparison with other patients -CDAI
≥ 220 and CRP ≥ 10 mg/L- or with all patients taken together. However B2 behavior
seemed to be more frequent among patients without depression and -CDAI ≥ 220 and CRP
< 10 mg/L- (60.0%; CI: 29.6-90.3%, n = 10) by comparison with patients with -CDAI ≥
220 and CRP ≥ 10 mg/L- (37.1%; CI: 21.1-53.1%, n = 35) (p = 0.177). Conclusion: CRP
level was lower in CD patients with previous IR and/or with B2 behavior. A CDAI-defined
active CD and low CRP level could reflect in some patients the weight of subjective items
of this index. Higher B2 frequency in this subgroup could deserve additional investigations.
S1103
Kinetics of 6-Thioguanine Nucleotides During Infliximab Treatement in IBD
Patients: A Predictive Value of short Term But Not Long Term Response
Xavier Roblin, Jean marc Phelip, Johana Pofelski, Xavier Coulaud, B. Bonaz, Philippe
Bichard
A significant increase of 6-TGN (> 400 pmoles/8x108 erythrocytes) one to three weeks after
the first infusion of Infliximab is a predictive factor of short term response to Infliximab in
CD (1). There is no data about the evolution of 6-TGN kinetics during Infliximab at mean
term and about their predictive value of response during CD and UC. Aim of the study :1)
analyse the kinetics of azathioprine (AZA) metabolites (6 TG, methylated metabolites : 6-
MMP et 6-MeTIMP) during induction and maintenance treatment withInfliximab, 2) research
correlation with these metabolites levels and response to treatment during IBD. Patients and
Methods : Eighty six patients (60 CD et 26 UC), mean age 41,4 years, have been included
prospectively. All these patients have AZA treatment at the same dose during the follow up
of the study and are treated with Infliximab (5mg/kg iv) at W0, W2, W6 and then every
8 weeks. The follow up was at least 12 month. Before each Infliximab infusion, a CDAI
score or analysis of number of fistulas for CD and CAI for UD were calculated. A clinical
remission was definated by: CDAI<150 or closing of all fistulas for CD; CAI<2 for UC. A
clinical response was definated by: a decrease of CDAI > 100 and/or closing of at least 50%
of fistulas for CD; A decrease of CAI of 50% UC. 6 TG and total methylated metabolites
(HPLC) dosage have been realised at W0, W2, W6, W14 and W30. Results : 1) There was
a strong correlation between clinical response at W14 and increase of 6 TG between W0
and W2 (increase of at least 1,5 times the baseline) with VPP at 91% and also in CD than
in UC. On the other hand, there was no correlation between the rate of methylated metabolites
at W2 and clinical response at W14, 2) The increase of 6 TG at W2 in patients with clinical
response was transitory. The rates of 6-TGN at W14 and W 30 become equivalent to W0.
3) There were no correlation between 6 TG or methylated metabolites kinetics and the
persistence of clinical response for mean term with infliximab, also in CD than in UC.
Conclusions : This study confirms a forward interaction between Infliximab and AZA also
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in CD than in UC with a significant increase of 6 TG but not methylated metabolites. This
increase of 6 TG is transitory and has a predictive value only for clinical response to induction
treatment with Infliximab. 1- Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B
Drug interaction between infliximab and azathioprine in patients with Crohn's disease.
Aliment Pharmacol Ther. 2003 Nov 1;18(9):917-25.
S1104
Gene Expression Profiling to Predict the Response of Infliximab in Patients
with UC
Ingrid Arijs, Leentje Van lommel, Kristel Van steen, Gert De hertogh, Frans Schuit, Karel
Geboes, Gert Van assche, Séverine Vermeire, Paul J. Rutgeerts
Introduction and aim: Infliximab (IFX), the chimeric monoclonal antibody against tumor
necrosis factor-α, has been recently shown to be effective for maintaining clinical remission
and mucosal healing in patients with moderate to severe, active ulcerative colitis (UC) whom
have had an inadequate response to standard therapy. However, a subset of patients showed
no effect to this agent. The aim of this study is to identify gene signatures predictive of
response to IFX in patients with UC using high-density oligonucleotide arrays. Methods:
Colonic mucosal biopsies were obtained from 11 CU patients before and 4 weeks after
treatment. The patients were classified as (non)-responders based on clinical, endoscopic,
histological and laboratory findings. Total RNA was isolated, labelled and hybridized to
Affymetrix HGU133plus2.0 array. Data was analyzed using R software. Probe level analysis
was performed using robust multichip average methods. Wilcoxon's test, Mann-Whitney
test, moderated t test (Limma) and significance analysis of microarrays (SAM) were used
for statistical data analyses. Hierarchical clustering was performed to visualize transcript/
sample relationship. The EASE application on the DAVID homepage was used for Gene
Ontology analysis. Results: For treatment effect, we analyzed the change in expression of 5
responders before and after treatment. By SAM analysis (FDR<0.05), 195 probesets were
upregulated and 130 were downregulated after treatment. The downregulated probesets
included genes that were predominantly involved in immunity, inflammatory response,
signal transduction, cell communication and apoptosis. For predicting response to IFX
treatment, expression profiles of responders and non-responders before treatment were
compared. In 5 responders and 6 non-responders, 31 probesets identified by SAM analysis
(FDR<0.22) were differentially expressed and an unsupervised hierarchical clustering per-
fectly separated these responders from non-responders. Five probesets were downregulated
in non-responders with a fold change > 2. The genes represented by these probesets were
Transcription factor 7-like (TCF7L2), Rho GTPase activating protein 5 (ARGHAP5), PH
domain and leucine rich repeat protein phosphatase-like (PHLPPL), MAX interactor 1 (MXI1)
and FXYD domain containing ion transport regulator 3 (FXYD3). All the results were
comparable with the other statistical tests. Conclusion: We showed that transcriptional
profiling of pre-treatment biopsies may be used as a tool to predict likely responders to
IFX treatment.
S1105
Mucosal Inflammation in Inflammatory Bowel Disease Can Reliably Be
Predicted with the Fecal Calprotectin Test
Geert R. D'haens, Filip Baert, Severine Vermeire, Marc Ferrante, Gert A. Van assche, Maja
Noman, August Van olmen, Liesbeth Moortgat, Leen Stuyven, Patrick J. Hanaway, Paul J.
Rutgeerts
Introduction: Fecal calprotectin has been proposed as a marker of inflammatory activity in
inflammatory bowel disease (IBD). We addressed the question whether this test can reliably
replace colonoscopy in the assessment of disease activity in IBD and whether certain ‘cut-
off' levels could be used to determine the presence of active mucosal disease. This is
particularly important since mucosal healing has become an important endpoint in the
management of IBD. Methods: 155 IBD patients (pts)(112 Crohn's disease (CD), age 39.5
+/-13, 43 ulcerative colitis (UC)(age 49.3+/-15.4) and 41 IBS controls (age 37.0 +/- 13.5)
who were scheduled for colonoscopy at 3 referral hospitals delivered a sample of feces prior
to the start of their bowel cleansing for colonoscopy. Indications for this procedure were
assessment of IBD activity and functional bowel disease. In CD pts the following parameters
were collected: endoscopic scores CDEIS and SES-CD, Crohn's disease activity index CDAI
and quality of life measure IBDQ. In UC pts the Mayo score and the extent of inflammation
were recorded. All patients had a blood test for serum CRP, albumin, Hct and thrombocytes.
Stool samples were frozen and sent to Genova Diagnostics for measurement of calprotectin
with PhiCal Assay (ELISA). Correlation analysis was done with Pearson tests. Results: Median
Calpro levels were 465 (61-1128)μg/g in UC, 175 (44-938) μg/g in CD and 54 (16-139)
µg/g in controls. In UC, the Calpro values correlated highly with the colitis activity index
CAI (r=0.56), the Mayo endoscopic subscore (r=0.62), the extent of disease (r=0.56), the
product of extent x severity (r=0.75))(all p<0.001), but not with CRP (r=0.32,NS). In CD,
Calpro correlated in decreasing order with: SES-CD (r=0.63), CDEIS (r=0.55), CRP (r=0.52)
and thrombocytes (r=0.41)(all p<0.001). Poor correlations were seen with the clinical scores
CDAI (r=0.13)(NS) and IBDQ in CD (r=-0.22,NS). ROC-curve analysis revealed a cut-off
Calpro value of 450 to distinguish IBD from controls (specificity 91%, sensitivity 39%). In
UC, a cut-off level of 200 μg/g gave a sensitivity of 71% and a specificity of 100% for any
mucosal disease activity (Mayo>0); A cut-off of 700 gave 67% sensitivity and 89% specificity
for Mayo>1 (more severe disease). In CD, a cut-off value of 750 indicated large ulcers
anywhere in the colon with sensitivity of 40% and specificity of 87%. Conclusion: fecal
calprotectin levels correlate significantly with endoscopic disease acticity in IBD. Cut-off
levels to reveal active mucosal disease can be determined. The Calpro test could replace
endoscopic evaluation to assess active mucosal inflammation in IBD.
S1106
Validation of a Computer-Aided Analysis of Inflammatory Bowel Disease
(IBD) Serologic Markers: A Novel Method to Improve the Accuracy of
Predicting IBD, Crohn's Disease (CD), and Ulcerative Colitis (UC)
Gary R. Lichtenstein, Susan Carroll, Leonard Eggleston, Bruce Neri, Augusto Lois
Background/Aims: Serologic testing can help physicians diagnose IBD and classify the disease
as CD or UC. Tests include assays for the anti-Saccharomyces cerevisiae antibody (ASCA),
anti-Escherichia coli outer membrane protein C (anti-OmpC), anti-CBir1 flagellin (anti-CBir1),
and perinuclear antineutrophil cytoplasmic antibodies (pANCA), and their results generally
are categorized as positive or negative relative to a cutoff value. Methods: Prometheus
Laboratories has developed a novel algorithmic approach to IBD serologic marker analysis,
in which assay results are compared not to cutoff values but to specific disease and non-
disease patterns detected by the algorithm. Since pattern recognition is the method used to
differentiate IBD from other conditions, the complete range of values for each assay is
incorporated. The algorithm is a sophisticated computation developed from the sequential
analysis of a series of serologic assay results using two statistical classifiers including a neural
network. We used serologic data from a cohort of 1813 patients with confirmed diagnoses,
including CD (n = 646), UC (n = 431), irritable bowel syndrome (n = 366), and no disease
(n = 370). The algorithm was then validated using serologic data from a second cohort;
none of the assay results used in the development of the algorithm was used for its validation.
Results: The validation cohort consisted of 500 patients with known diagnoses, including
CD (n = 188), UC (n = 105), and no confirmed disease (n = 207). The prevalence of IBD
in this cohort was 59%, which is equal to the proportion of IBD-positive serologic values
analyzed annually at Prometheus. Overall the accuracy (number of predictions that correctly
identified the known diagnosis) of the algorithm was 92%. Additional performance character-
istics of the algorithm are shown below: Validation cohort IBD UC CD Sensitivity 93% 93%
88% Specificity 95% 97% 98% Positive Predictive Value (PPV) 96% 89% 96% Negative
Predictive Value (NPV) 90% 98% 93% Since PPVs and NPVs vary with prevalence (sensitivity
and specificity remain constant regardless of prevalence), they were determined for a second
validation cohort, consisting of 243 patients with a 15% prevalence of IBD, including CD
(n = 18), UC (n = 18), and no confirmed disease (n = 207). PPVs for IBD, CD, and UC
were 75%, 74%, and 73%, respectively; NPVs for IBD, CD, and UC were 99%, 100%, and
99%, respectively. Conclusion: Algorithmic analysis of serologic data results in accurate
predictions of IBD and classification of IBD into CD and UC.
S1107
Magnetization Transfer (Mt) MRI: A Non-Invasive Method to Identify and
Quantitate Intestinal Fibrosis
Jeremy Adler, Scott D. Swanson, Phylissa Schmiedlin-ren, Peter D. Higgins, Trevor M.
Verrot, Ellen M. Zimmermann
The natural history of Crohn's disease (CD) is characterized by chronic intestinal inflammation
leading to fibrosis. There are no non-invasive methods of identifying fibrosis, or monitoring
fibrosis over time. MT-MRI uses molecular characteristics of macromolecules like collagen
to differentiate between water in edematous and inflamed tissue vs. water in fibrotic tissue.
We hypothesize that MT-MRI will identify intestinal fibrosis, and correlate with tissue
collagen. METHODS: Peptidoglycan-polysaccharide (PG-PS) was injected intramurally into
cecum and distal ileum of Lewis rats at laparotomy. Control animals were injected with
Human Serum Albumin (HSA). PG-PS rats developed chronic inflammation, granulomas
and intense fibrosis beginning day 14 post-injection. Rats were scanned in a Varian Inova
2.0 T, 31 cm clear bore system equipped with Acustar S-180 actively shielded gradients.
For ex vivo tissue, a series of MT profiles were obtained in logarithmic intervals from 100
Hz to 100 kHz off-resonance. In Vivo MT-MRI images were obtained at 10 kHz (Msat) and
100 kHz off-resonance (M0). The MT ratio was calculated in the cecal wall as 100*(1-Msat/
M0). Upon dissection, gross gut score was determined in a blinded manner. Histologic
intestinal wall thickness was measured. Cecal tissue was homogenized and subjected to
SDS-PAGE; blots were probed with an anti-collagen type I antibody. RESULTS: Ex vivo
tissue from PG-PS and HSA injected rats demonstrated different MT profile curves at the
off resonance frequencies tested, consistent with the ability of MT-MRI to differentiate control
vs. fibrotic tissue. In Vivo MT-MRI performed 28 days after injection, demonstrated a
significant difference in MT ratio between the PG-PS (n=17) and HSA (n=11) injected rats
(22.0 ± 1.6 vs. 13.0 ± 1.3; p=0.0006). There was good correlation between the MT ratio
and cecal thickness as determined by gross assessment of cecal thickness (R2=0.697), and
histologic tissue thickness in mm (R2=0.318). MT ratio from In Vivo scans correlated well
with tissue collagen as determined by Western Blot (n=17; R2=0.639). Finally, when PG-
PS rats were scanned at weekly intervals, there was a progressive increase in MT ratio after
2 weeks, coincident with the development of fibrosis. CONCLUSION: MT-MRI was able
to identify fibrotic tissue, and the MT ratio correlated with tissue collagen. MT-MRI detected
changes in tissue fibrosis over time. This supports our hypothesis that MT-MRI can be used
to differentiate intestinal fibrosis from non-fibrotic tissue, and to quantify the degree of
fibrosis. This could be a useful tool for monitoring the natural history of CD.
S1108
Thiopurine-Induced Liver Injury in Patients with Inflammatory Bowel Disease
(IBD): A Systematic Review
Javier P. Gisbert, Yago Gonzalez-lama, Jose Mate
AIM: The frequency of azathioprine (AZA) or mercaptopurine (MP)-induced hepatotoxicity
markedly varies among different series and data are sometimes contradictory. Our aim was
to conduct a systematic review of studies evaluating incidence of thiopurine-induced liver
injury in patients with IBD. METHODS: Bibliographical searches were performed in MED-
LINE electronic database up to 2006 looking for the following words (all fields): (“inflammat-
ory bowel disease” OR “Crohn's disease” OR “ulcerative colitis”) AND (azathioprine OR 6-
mercaptopurine) AND (liver OR hepatotoxicity OR hepatocelular OR cholestatic). Studies
evaluating incidence of thiopurine-induced liver injury in patients with IBD were specifically
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reviewed. The mean percentage of patients with liver injury was calculated and expressed
as weighted mean. As the follow-up time markedly varies among studies, the risk of liver
injury is better expressed as the incidence of hepatotoxicity per patient-years of follow-up,
and therefore the annual hepatotoxicity rate (per patient-year), was also calculated. RESULTS:
34 studies, including a total of 3,485 patients, evaluated the incidence of thiopurine-induced
liver injury in patients with IBD. The mean overall incidence of AZA/MP-induced liver
disorders (abnormal liver tests, without taking into account the follow-up period) was 3.4%
(95% CI from 2.9 to 4.1%). When only studies where the follow-up time was specifically
stated were considered, 2,992 patients received AZA/MP treatment during a total of 6,952
years of follow up, and mean annual drug-induced liver disorder rate (per patient-year) was
only 1.4% (95% CI from 1.1 to 1.7%). However, this low figure calculated from retrospective
studies contrasts with a much higher incidence (>10%) reported by the first and only
prospective epidemiological study specifically addressing the incidence of thiopurine-induced
hepatotoxicity in IBD patients. CONCLUSION: When published studies evaluating thiopur-
ine-induced liver injury in patients with IBD are considered, the mean overall incidence of
AZA/MP-induced disorders was approximately 3%. When only studies where the follow-
up time was specifically stated, mean annual drug-induced liver disorder rate was only
1.4%. However, this low figure calculated from retrospective studies contrasts with a much
higher incidence (>10%) reported by the first and only prospective epidemiological study
specifically addressing the incidence of thiopurine-induced hepatotoxicity in IBD patients,
which underlines the fact that more prospective studies are necessary to accurately evaluate
the precise incidence of AZA/MP-induced liver injury.
S1109
A New “Calprotectin POC Device” Correlates with ELISA and Separates
Between Endoscopic Assessed Mucosal Healing and Active Ulcerative Colitis
Arne Roseth, Magne K. Fagerhol, Janus Wasiluk, Inge Dale
Calprotectin (Cpt) is a neutrophil marker protein that is stable in stools for 7 days at ambient
temperature and can be sent by ordinary mail by the pts to the local laboratory. It correlates
with the 3 days excretion of 111-In labeled leucocytes as well as with histology in IBD;
normalization of Cpt is a strong indicator of mucosal healing in such pts. Furthermore,
determination of Cpt in stools by ELISA is accepted by the FDA for the diagnosis of IBD
and to separate between IBD and IBS. Being based upon an ELISA, a more extensive use
of this marker in clinical practice has been hampered due to logistics; time from sampling
to a result can often exceed 7 days. We have therefore designed a rapid POC device, making
it possible for the physician to obtain a reliable result in less than 15 minutes. Aim of the
study: Evaluation of this Cpt-POC device in a relevant clinical material. Method: 66 consecut-
ive patients referred for colonoscopy were included. 41 had previous known UC, 25 were
referred due to chronic diarrhea. Of these, 30 was diagnosed with endoscopic active UC,
11 had mucosal healing. All endoscopic procedures were done by one physician (AR) and
in all pts, biopsies were collected from the t.ileum (when relevant) and all parts of the colon
in separate containers. Endoscopic activity was assessed according to accepted criteria, using
the Mayo Clinic scoring system. All pts were asked to send in a stool sample 3-4 days after
colonoscopy and before starting treatment. Cpt was assessed both by ELISA and the POC
device but at two different times, in two separate stool extracts. Results: The correlation
between the two methods was excellent (r= 0.92, p< 0.001). In pts with diarrhea and normal
histology, all except three had Cpt <50mg/kg (71,85,220). Among UC pts with mucosal
healing, all had normal Cpt levels except 3 (67,75,97) All but two pts with active disease
had Cpt > 100 (median 600, range 48-2150) Conclusion: This POC device is a quantitative
rapid format test for the determination of fecal calprotectin; it correlates strongly with the
ELISA method previously used in clinical studies. It will soon be available for clinical use
and may be useful in medical decision-making since it is an objective marker of intestinal
inflammation.
S1110
A Meta-Analysis of Studies On Itpa Polymorphisms and Thiopurine Toxicity
Jolanda M. Van dieren, Ernst J. Kuipers, Bettina E. Hansen, Edward E. Nieuwenhuis,
Janneke Van der woude
Background Thiopurine is an immunosuppressant widely used in the treatment of Inflammat-
ory Bowel Disease (IBD). Thiopurine treatment is associated with the development of side
effects. It has been suggested that the enzyme inosine triphosphate pyrophosphatase (ITPase)
plays a role in the digestion of thiopurines and that defective ITPase activity resulting from
polymorphisms in the ITPase encoding genes may be associated with azathioprine-induced
side effects. However, current studies are controversive on this hypothesis. Aim This meta-
analysis was performed to gain more insight into a possible relationship between thiopurine-
induced side effects and ITPA polymorphisms. Methods Medline was explored for published
articles on ITPA polymorphisms and thiopurine toxicity. Studies that compared the ITPA
94C>A and/ or the IVS 21A>C polymorphism frequencies among thiopurine tolerant and
intolerant adult IBD patients were included in this meta-analysis. Odds ratios for the develop-
ment of “all side-effects”, “bone-marrow toxicity”, “hepatotoxicity” and “pancreatitis” were
calculated from each of the included studies and were processed in a meta-analysis with
random effects. Results Nine published studies investigated ITPA polymorphisms and azathi-
oprine toxicity. Six studies (with a total of 751 patients) met our inclusion criteria and
were processed in the meta-analysis. This meta-analysis shows that none of the studied
polymorphisms, either the ITPA 94 C>A or the IVS 21A>C polymorphism, is significantly
associated with any of the studied side-effect parameters, e.g. “all side-effects”(OR 1.5 (0.62-
3.5)), “bone-marrow toxicity”(OR 1.32 (0.4-4.36)), “hepatotoxicity” (OR 0.98 (0.38-2.49))or
“pancreatitis” (OR 1.72 (0.61-4.86)). Conclusions This meta-analysis indicates that there is
no correlation between the development of thiopurine toxicity and ITPA polymorphisms
and that there is no relevance of determining these ITPA polymorphisms in patients treated
with thiopurines.
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Effect of 5-Aminosalicylates (5-ASAS) On Renal Function in Patients with
Inflammatory Bowel Disease (IBD): 4-Year Follow-Up Study
Javier P. Gisbert, M. Luna, Y. Gonzalez-lama, J. Mate
AIM: Nephrotoxicity, which may be potentially irreversible, has been described in some
patients with IBD treated with 5-ASA. Some authors have recommended regular monitoring
of renal function for the duration of 5-ASA therapy. Our aim was to conduct a retrospective
survey of IBD patients, both with and without 5-ASA treatment, evaluating renal function
regularly during 4 years. METHODS: Consecutive patients with IBD were retrospectively
evaluated. Serum creatinine was measured before starting 5-ASA therapy, and thereafter
yearly up to 4 years. Creatinine clearance (ClCr) was estimated from serum creatinine with
the Cockroft and Gault formula. Based on the estimated glomerular filtration rate, patients
were classified as having: normal renal function (ClCr>60 ml/min), moderate impairment
(ClCr 30-59), severe impairment (ClCr 15-29), and advanced renal failure (ClCr <15). The
influence of 5-ASA treatment on renal function was assessed by univariate and multivariate
analysis. RESULTS: 150 IBD patients (42% ulcerative colitis, 55% Crohn's disease, and 3
indeterminate colitis) were included. Mean age was 45 years, 45% males, and 30% smokers.
62 patients were receiving 5-ASA treatment (95% coated mesalazine, 1.6% prolonged release
mesalazine, and 3.2% sulfasalazine). Mean dose of mesalazine was 1.9 +/- 0.8 g/day (range,
0.5-4), and most patients were receiving between 1 and 3 g/day. Serum creatinine levels at
0, 1, 2, 3, and 4 years in patients taking 5-ASAs remained stable (0.93, 0.93, 0.94, 0.96,
and 0.83 mg/100ml). Similarly, ClCr did not change for the 4-year follow-up in 5-ASA
treated patients (92, 91, 90, 88, and 102 ml/min). Furthermore, values of both serum
creatinine and ClCr were similar in patient with and without 5-ASA treatment (non-statistic-
ally significant differences at any time from 1 to 4 years). The percentage of patients with
moderate impairment of the estimated glomerular filtration rate at 0, 1, 2, 3, and 4 years
was: 6.5%, 6.5%, 4.8%, 8.1%, and 3.2%; while corresponding figure for severe impairment
of the estimated glomerular filtration rate was 0% at all control times. Finally, in the
multivariate analysis, 5-ASA treatment (yes/no) was not correlated with serum creatinine
levels or ClCr. Dose of 5-ASA was not predictive for change in renal function. No interstitial
nephritis was reported during follow-up. CONCLUSION: 5-ASA-related renal disease was
not reported in our series, which suggests that the incidence of renal impairment in IBD
patients receiving these drugs is exceptional. Our results do not support the recommendation
of monitoring of serum creatinine in patients receiving 5-ASA treatment.
S1112
The Diagnostic Value of Combined Noninvasive Fluorine-18 Labeled-Fluoro-2-
Deoxy-D-Glucose - Positron Emission Tomography CT Enterography for
Evaluation of Active Crohn's Disease
Anis A. Ahmadi, Dennis Collins, John F. Valentine, Walt Drane, Steven F. Polyak
BACKGROUND: CT enterography (CTe) is an important tool in the evaluation of small
bowel Crohn's disease. Potential limitations of CTe exist, including inadequate small bowel
distention and non-inflammatory mucosal enhancement. This study describes a cohort of
adults who had combined CTe with localized positron emission tomography (LPET) using
fluorine-18 labeled-fluoro-2-deoxy-D-glucose (FDG) to better delineate disease activity. We
hypothesize that FDG activity correlates with CTe findings in areas of active inflammation,
and FDG uptake in abnormal CTe segments predicts response to therapy. PATIENTS &
METHODS: Twelve consecutive patients that underwent combined CTe-LPET after evalu-
ation at the University of Florida Inflammatory Bowel Diseases Clinics were studied. Data
analyzed included CTe findings, FDG uptake, C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), short Inflammatory Bowel Disease questionnaire (SIBDQ), and Harvey-
Bradshaw index (HBI). Abnormal CTe segments were scored (mural enhancement and mural
thickness). FDG activity was scored by normalized standardized uptake value (SUV). Results
of CTe-LPET were compared to medical outcome by Fisher's exact test. Correlations of CTe
and SUV scores with CRP, ESR, SIBDQ, and HBI were estimated using Spearman's rank
analysis. RESULTS: Among the 12 patients studied, CTe identified 16 abnormal segments
of small bowel. 12 of 16 (75%) abnormal CTe segments demonstrated increased FDG uptake
with mean normalized SUV of 3.8 (SD +/- 2.16). 4 of 16 (25%) abnormal CTe segments
lacked FDG accumulation, with a mean normalized SUV of 0.14 (SD +/- 0.39). All 4 of
these patients failed medical therapy and required surgical resection. LPET did not identify
additional segments as compared to CTe. Thus, abnormal CTe segments that lacked significant
FDG uptake was associated with failed medical therapy (p<0.0006). There was no correlation
between CTe scores and CRP (r=0.09, p=0.76), ESR (r=0.07, p=0.82), SIBDQ (r=0.02, p=
0.95), or HBI (r=-0.01, p=0.98). However, there was a significant correlation between CTe
score and SUV score (r=0.51, p=0.04). CONCLUSIONS: All inflamed segments of small
bowel identified by FDG accumulation correlated with abnormal segments noted by CTe.
Failure to accumulate FDG in abnormal segments identified by CTe correlates strongly with
medical failure. These lesions likely represent non-inflamed fibrotic strictures. No correlation
was identified amongst biochemical and clinical markers, and CTe and FDG scores. Further
investigation of the value of combined CTe-LPET in stricturing Crohn's disease is warranted.
S1113
Mucosal Pathology of the Pelvic Ileal Reservoir: Relationship of
Histopathological Features to the Diagnosis of Pouchitis
Gerald Bailey, John Gao, Victor E. Pricolo, Murray B. Resnick, Baishali Bhattacharya
Background:The significance of mucosal inflammation of the ileal reservoir (pouch) following
total proctocolectomy for ulcerative colitis (UC) is not well understood. There is considerable
controversy over the nature of the pathologic changes observed in the ileal pouch, and
pouchitis continues to be an ill-described entity. Histologically, pouchitis is a gradable
phenomenon based on mucosal inflammation and epithelial metaplasia. We examined the
ileal pouch from patients with UC to determine the frequency and histopathologic character-
istics present in patients with pouchitis. Design: H&E sections of 149 mucosal biopsies
from the ileal pouch of 130 patients with UC after total proctocolectomy were studied. The
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specimens were scored according to grade of inflammation in the lamina propria, presence
or absence of epithelial activity (cryptitis, crypt abscess), ulceration, villous blunting (VB),
crypt distortion (CD), pyloric metaplasia, granulomas and dysplasia. Results were compared
to the clinical data. Clinical and histopathological parameters were compared using Fishers
exact test. Result:Mucosal inflammation was present in 140 (94%) biopsies, including 15
(10.1%) with acute neutrophilic inflammation only in the lamina propria, 5 (3.4%) with
chronic changes (plasmacytosis and/or VB, CD), and 120 ( 80.5%) with chronic active
inflammation. There were 9 (6%) normal biopsies. Biopsies with chronic active inflammation
were significantly (P<0.001) associated with increased grade of inflammation, VB, CD,
epithelial activity, ulceration, and pyloric metaplasia. Pyloric metaplasia was present in 20
biopsies in the chronic active group (16.7%). Biopsies that were normal or only had acute
inflammation or chronic changes were associated with no clinical symptoms. No granulomas
or dysplasia were present in any of the biopsies. Conclusion: Based on our study, granulomas,
dysplasia and malignancy was not present in any of the pouch biopsies. The majority of
the ileal pouch biopsies contained chronic active inflammation. Pyloric metaplasia, often
seen in Crohn's disease, should not be a cause of alarm as we found it in 16% of the pouch
biopsies and seems to be a common phenomenon. Lack of clinical symptoms with only
acute or chronic mucosal inflammation should not be termed pouchitis by the pathologist.
The diagnosis of pouchitis should be reserved for those cases with chronic and active
inflammation in concert with the clinical symptoms.
S1114
PYLORIC Gland Metaplasia- A Novel Histological Marker for Refractory
Pouchitis and Crohn's Disease of the Pouch
Revital Kariv, Thomas P. Plesec, Feza H. Remzi, Rocio Lopez, Bret A. Lashner, Victor W.
Fazio, John R. Goldblum, Bo Shen
Background: Chronic antibiotic-refractory pouchitis (CARP) and Crohn's disease (CD) of
the pouch are challenging complications in ulcerative colitis (UC) patients who underwent
proctocolectomy with ileal pouch-anal anastomosis (IPAA). There are no sensitive and specific
markers for the diagnosis and prediction of CARP and CD. Pyloric gland metaplasia (PGM)
is considered histological marker for chronic small bowel inflammation and particularly for
CD. However, the role of PGM in the diagnosis and prognosis of pouch conditions has not
been investigated. Aim: To assess 1) the accuracy of PGM in the diagnosis and prediction
of CARP and CD of the pouch 2) risk factors for PGM in pouch mucosa. 3) association
between PGM and pouch failure. Patients and methods: Pouch and neo-terminal ileum
biopsies reports were reviewed for PGM presence/absence among patients from our Pouchitis
Clinic. All biopsies and matching surgical specimens of identified patients were reviewed
by 2 expert GI pathologists for PGM, Pouchitis Disease Activity Index histology score for acute
inflammation, Heidelberg histology score for chronic inflammation and semi quantitative
eosinophil score. 34 demographic, clinical, endoscopic, and radiographic parameters were
reviewed from a prospectively maintained database and analyzed with univariable and
multivariable analyses. CARP and CD (clinical outcome) were diagnosed according to previ-
ously published criteria by our group. Results: Of 111 patients, 39 (35.1%) were found to
have PGM. Sensitivity, specificity and likelihood ratio for PGM as a diagnostic marker for
CARP or CD were 63.8%, 96.2% and 16.8, respectively. The table shows risk factors for
PGM by multivariable analysis. Adjusting for all factors in the model, subjects with CARP
or CD were 53.5 times more likely to have PGM than those with other diagnoses. In
univariable analysis patients with PGM had a higher frequency of pouch failure than those
with no PGM (12.8% vs.1.4%, P = 0.02). Conclusions: PGM is a specific marker for CARP
or CD of the pouch with a high likelihood ratio and is an indicator for adverse clinical
outcomes. The presence of PGM in the pouch is associated with eosinophilic infiltration.
Table 1. Risk factors for Pyloric Gland Metaplasia: Multivariable logistic regression analysis.
S1115
Lymphocytopenia Does Not Correlate with Metabolite Levels in IBD Patients
Treated with Immunosuppressives
Bincy P. Abraham, Darrel Finlay, Joseph H. Sellin
BACKGROUND & AIMS: Azathioprine and 6-mercaptopurine (aza/6mp) are effective immu-
nosuppressives commonly used for treatment of IBD. The mechanism of action of these
drugs has not been fully delineated, although apoptosis of T lymphocytes may play an
important role. We have previously shown that significant lymphocytopenia occurs com-
monly in IBD patients on aza/6mp. 6mp metabolites, including 6TG and 6 MMP, have been
suggested as surrogate markers of the safety and efficacy of immunosuppressive therapy.
We therefore sought to correlate metabolite levels with leukocyte, lymphocyte and CD4
levels in patients treated with aza/6mp. METHODS: Data from patients in a single IBD
practice were extracted for WBC, absolute lymphocyte counts, metabolite levels, and CD4
levels. Correlations were made by comparison of metabolite levels with WBC levels and its
subsets. RESULTS: Of 123 IBD patients, 51% (63/123) were lymphocytopenic (abs lympho-
cyte count <1500), and 28% (35/123) were significantly lymphocytopenic (abs lymphocyte
count <1000). 71% of the mildly lymphocytopenic patients (45/63) were on aza/6mp.
80% of the patients with significant lymphocytopenia (28/35) were on immunosuppressive
therapy. In assessing the 65 patients on immunosuppressive therapy, 18 were mildly lymph-
ocytopenic, and 28 were significantly lymphocytopenic. Only 8 patients were leukopenic
(WBC <4,000/mm3). These eight were also lymphocytopenic. However, the vast majority
of patients with lymphocytopenia (55/63) had normal WBC counts. We compared lympho-
cyte and WBC counts to the commonly measured metabolites (6TG & 6MMP). There was
no significant correlation between either lymphocyte count to 6TG & 6MMP (correlation
of -0.05 and -0.06 respectively) or WBC counts to 6TG & 6MMP (correlation of -0.30 &
-0.31 respectively). In a select group of patients with severe lymphocytopenia, we measured
CD4 counts and found them to be significantly depressed (84 to 361). One of these patients
developed an opportunistic infection (herpes zoster). There was no positive correlation
between CD4 counts and metabolite concentrations. Lymphocytopenia was sometimes pro-
longed and persisted even with undetectable metabolite levels. CONCLUSIONS & SIGNIFIC-
ANCE: Significant lymphocytopenia and depressed CD4 counts can occur in the presence
of normal WBC counts and metabolite (6TG/6MMP) levels. The clinical significance remains
to be fully defined, but monitoring of IBD patients on immunosuppressive therapy should
include regular measurement of lymphocyte count as well as WBC.
S1116
Sexual Function Among Women with Crohn's Disease: A Need for
Sympathetic Investigation?
Patrick Borentain, Valerie Seyfried, Mireille Bonierbale, Jean-charles Grimaud
Crohn's disease (CD) affects all aspect of quality of life (QoL), including professional, social,
and sexual function. In validated QoL scores used in CD, little attention has been paid to
sexual functioning. Indeed, in CD, several factors may interfere with sexuality, fertility and
pregnancy. The aim of this study was to compare level of sexual functioning amongst women
with CD with healthy women. Twenty consecutive women with CD who have a regular
partner since at least 1 month were compared to a population of twenty healthy women,
of similar age. A sexologist doctor interviewed patients and controls. We used the ASEX
questionnaire, items from the sexual function questionnaire that is used in the Cleveland
Clinic's Department of Urology and a structured questionnaire use in a previous study
(Cleeveland). For patients, a questionnaire of CD-related factors was completed. Sexual
dysfunction was more frequent in patients compared with controls. We found that all the
compartments of coital sexual life were impaired: sexual desire (χ2 = 10.1, p<0.005), vaginal
lubrication (χ2 = 4.33, p<0.05), facility to reach orgasm (χ2 = 6.14, p<0.05), and satisfaction
procured by orgasm (χ2 = 8.49, p<0.005). Patients' overall sexual satisfaction was more
disappointing compared with controls (χ2 = 12.91, p<0.005). In our study, presence of
perineal localization was associated with an aggravation of the sexual disorders (χ2 = 12.18,
p<0.005). Dyspareunia (χ2 = 5.05, p<0.05), probably in connection with vaginal infections,
and the perception of a deterioration of the sexual life were worse (χ2 = 5.80, p<0.05). The
major factors limiting the sexual activity were tiredness, abdominal and pelvic pains, dia-
rrhoea, and fear of incontinence. This study shows that women with Crohn's disease have
significantly more sexual problems than controls. There is a need for sympathetic investigation
and specialized management of this aspect of social life.
S1117
Histologic Features Predictive of Crohn's Disease of the Pouch Following Ileal
Pouch-Anal Anastomosis for Ulcerative Colitis
R. Wilcox, C. Weber, C. Mcbride, R. Hurst, A. Noffsinger, J. Hart
Background: We retrospectively studied resection specimens from Ulcerative Colitis(UC)
patients who underwent ileal pouch-anal anastomosis(IPAA) and subsequently developed
both clinical and histologic evidence that changed their diagnosis to Crohn s disease(CD)
( Delta patients ). Our objective was to determine whether any specific morphologic features
could decrease the error rate in diagnosis. Design: From 1989-2003, 18 Delta patients were
identified based on severe pouch disease plus: pouch removal with histologic evidence of
CD(n=4), fistulas (n=9), upper GI disease(n=2), extra-intestinal disease with abscess(n=1)
or severe, supra-pouch disease with biopsy confirmation(n=2). For each Delta case, 10 UC
colectomy cases (5 immediate prior and post each Delta patient) which remained UC after
IPAA served as controls. Two GI pathologists blindly reviewed 241 cases (Delta=18,Control=
223) and independently graded multiple, distinguishing histologic variables. An overall
gestalt impression was also determined by each pathologist as follows:(1) Definitely UC (2)
S/O UC (3) Indeterminate Colitis (4) S/O CD (5)Definitely CD. Result: Deepest extent of
inflammation was significantly associated with Delta cases for both pathologists( 2=18.45,
p=0.002 and 2=13.64, p=0.018). Neural hyperplasia was significantly associated for one(
2=6.23, p=0.044). However, the gestalt impression for UC vs. CD was not associated with
Delta cases for either pathologist. Significant agreement existed between pathologists gestalt
impression(Spearman s rho, r = 0.43, p<0.01) and for all tested parameters(except lymphoid
aggregates). Only 10% of all cases with deep inflammatory changes were Delta cases. By
logistic regression only neural hyperplasia was significantly associated with the identification
of Delta cases (Pathologist 1; O.R.=3.27, p <0.05). Conclusion: Although deepest extent of
inflammation and neural hyperplasia were significantly correlated with Delta patients, no
single histologic feature or combination of features allowed for identification of patients that
ultimately developed CD of the pouch.
S1118
Teduglutide Augments Plasma Citrulline, a Marker of Enterocyte Mass in
Patients with Crohn's Disease
Alan L. Buchman, Roxanne Kapikian, Lidia L. Demchyshyn
Plasma citrulline (CT), a nonprotein amino acid produced by intestinal mucosa, is a marker
of functional absorptive bowel length and enterocyte mass. Glucagon-like peptide-2 (GLP-
2) is produced by the intestinal L-cells and is involved in regeneration, maintenance and
repair of the intestine. Teduglutide (TD) is an analog of naturally-occurring GLP-2 with
single amino acid substitution at the second position (Ala - Gly) and may be effective for
the treatment of intestinal diseases characterized by physical, chemical or surgical damage
or disease of the intestine, including Crohn's Disease (CD). The data presented is from a
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study with 8 weeks of treatment in patients with CD. One of the exploratory objectives of
this study is to assess the changes in citrulline concentration after 8 week treatment with
TD. METHODS AND RESULTS: In a double-blind pilot study, 100 patients with moderate-
to-severe CD were randomized and treated with a daily, SQ dose of placebo, or TD 0.05,
0.10 or 0.20 mg/kg. Plasma CT was measured at -2 (screening), 0 (baseline), 2, 4, and 8
weeks of treatment. A repeated measures model was fit to the CT data for change from
baseline. There were statistically significant differences in the least squares means between
placebo and each of the teduglutide groups at all dosing weeks. CONCLUSIONS: There is
an early and sustained increase of CT throughout the course of treatment with TD regardless
of dose. This data suggests that TD may augment the total enterocyte mass in patients with
previous intestinal lesions and measurement of plasma CT may represent an appropriate
measure for mucosal healing with novel growth factors such as TD.
S1119
Thiopurine Methyltransferase (Tpmt) Activity and Adverse Effects of
Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of
394 Patients
Javier P. Gisbert, Pilar Nino, Luis Rodrigo, Carlos Cara, Luis G. Guijarro
Aim: To prospectively evaluate whether a relationship between thiopurine methyltransferase
(TPMT) activity and incidence of adverse effects (especially myelotoxicity) exists, in a long-
term follow-up study of a large group of patients with inflammatory bowel disease treated
with azathioprine. Methods: TPMT activity in red blood cells (RBCs) was measured by a
radiochemical method in 394 consecutive patients with Crohn's disease (238) or ulcerative
colitis (156) starting treatment with azathioprine. The relationship between several variables
and TPMT values was assessed, and the correlation between such levels and the incidence
of adverse effects was evaluated. Results: Mean TPMT value was 18.6±4 U/mL RBCs (range=
9.4-33.7). No patient had low TPMT levels (<5), 7.1% had intermediate levels (5-13.7),
and 92.9% had high levels (>13.8). Differences (p<0.001) were demonstrated in TPMT
activity depending on the type of inflammatory bowel disease, but not on the remaining
variables (including treatment with 5-aminosalycilates). Adverse effects were reported in 74
patients (18.8%), the most frequent being gastrointestinal intolerance (9.1%), and myelotox-
icity (4.3%). No patient having adverse effects had low TPMT levels. However, mean TPMT
activity was lower in those with adverse effects (16.6±3 vs. 19.1±4U/mL; p<0.001). Moreover,
the probability of suffering myelotoxicity in the high TPMT group was only 3.5%, compared
with 14.3% in the TPMT intermediate group (OR=4.5; 95% CI=1.37-14.9). Conclusion:
The strategy of determining TPMT activity in all patients prior to initiating treatment with
azathioprine could help to minimize the risk of myelotoxicity, as patients with intermediate
TPMT activity had 4 fold more risk than high TPMT activity patients.
S1120
Long-Term Prediction of Relapse By Using a Magnifying Colonoscope for
Patients with Quiescent Ulcerative Colitis
Takafumi Ando, Osamu Watanabe, Osamu Maeda, Kazuhiro Ishiguro, Daisuke Ishikawa,
Motofusa Hasegawa, Shinichi Kondo, Naoki Ohmiya, Yasumasa Niwa, Yuji Nishio,
Hidemi Goto
Background: A relapse of ulcerative colitis (UC) is difficult to predict by routine colonoscopy.
We reported that pit patterns in rectal mucosa assessed using a magnifying colonoscope are
predictive of relapse for 1 year in patients with quiescent ulcerative colitis (Gut, 2006).
Aims: We investigated the usefulness of a high-resolution video-magnifying colonoscope
with chromoscopy to predict exacerbations over a long term (5 years). Methods: Magnifying
colonoscopy was performed in 25 UC patients in remission. Pit patterns in the rectal mucosa
were classified into three magnifying-colonoscopy (MCS) grades on the basis of size, shape,
and arrangement. Mucosal macrophage inflammatory protein (MIP)-1α activity in biopsy
specimens of rectal mucosa was measured and the specimens were microscopically graded
according to the system of Riley. The patients were followed until relapse or for a maximum
of 5 years. Multivariate survival analysis was performed to determine independent predictors
of clinical relapse. Results: Of the 25 patients, 4 were MSC grade 1, 10 were grade 2, and
11 were grade 3. Follow-up for at least 5 years after the start of the study was possible in
all patients. During the study 20 (80%) patients relapsed (grade 1: 50%, grade 2: 80%,
grade 3: 91% ). After magnifying colonoscopy, the patients with MSC grade 1 relapsed later
than 2 years, and the patients with MSC grade 3 relapsed within 2 years. A positive
correlation was identified among MCS grade, histological grade and mucosal MIP-1α activity.
Multivariate proportional hazard model analysis showed that the MCS grade was a significant
predictor of relapse. The Kaplan-Meier estimate of relapse during the 5 year follow-up was
observed to increase with increasing MCS grade. Conclusion: MCS grading is associated
with the degree of histological inflammation and mucosal MIP-1α activity in quiescent UC
patients, and may predict the probability of subsequent disease relapse in UC patients in
remission over a long term.
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S1121
Clinical Significance of Serum P53 Antibodies in Patients with Ulcerative
Colitis and Its Carcinogenesis
Nagamu Inoue, Shigeo Yoshizawa, Katsuyoshi Matsuoka, Hiromasa Takaishi, Haruhiko
Ogata, Yasushi Iwao, Makio Mukai, Tomonobu Fujita, Yutaka Kawakami, Toshifumi Hibi
Objective: Mutation of p53 gene and cellular accumulation of p53 protein are frequently
detected early in the progression of ulcerative colitis (UC)-associated colorectal cancer (CRC)
and considered to play an important role in carcinogenesis of UC. For early detection of
UC-associated CRC, surveillance colonoscopy is recommended in UC patients at high risk.
However, poor acceptability deteriorates its effectiveness and suitable marker for selecting
patients at high risk is needed. Here, we evaluated clinical usefulness of the measurement
of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera
samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with
sporadic CRC and 63 healthy controls (HC) were obtained. Serum anti-p53 antibodies
were detected in duplicate with ELISA method. Immunohistochemical detection was also
performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive
in 15.0% (43/286) of UC patients while only one subjects (1.6%) was positive for p53 Ab
(p=0.0014). In sporadic CRCs, 52.4% of 82 patients were positive. In UC patients with
disease duration equal to or longer than 8 years, positivity of serum p53Ab (20.8%) was
significantly higher than those in patients with shorter duration (9.2%) (p=0.0063). Eight
of 13 (61.5%) UC patients with neoplasia (6 of 8 (75.0%) patients with CRC, 2 of 5 (40.0%)
patients with dysplasia) were positive for serum p53Abs, which was significantly higher
than that in patients without neoplasia. The sensitivity and specificity of serum p53 Ab test
for neoplasia in UC patients were 61.5% and 87.2% (238/273), respectively, and positive
predictive value for neoplasia was calculated at 18.6% (8/43). All UC patients with CRC
were positive for p53 staining while two of which were negative for serum p53 Ab. Finally,
levels of serum p53 Ab in 4 patients with CRC we could monitor had fallen after resection
of the tumor. Conclusions: Screening for serum p53 Ab by ELISA seems to have too low
positive predictive value and sensitivity to take place of colonoscopy as the initial screen or
to soften current surveillance recommendation for patients with UC. However, it deserves
further evaluation to determine whether it might be used to identify patients who could
safely be left for a longer interval before repeat colonoscopy. In addition, it could be helpful
for improving the effectiveness of surveillance program by salvaging the patients at high
risk who drop from the program or refuse surveillance colonoscopy.
S1122
Expert Algorithms Based On Common Laboratory Tests Outperform
Thiopurine Metabolites in the Prediction of Thiopurine Treatment Success in
Inflammatory Bowel Disease
Akbar K. Waljee, Joel C. Joyce, Sijian Wang, Ji Zhu, Peter D. Higgins
Background: Patients with IBD often require thiopurine therapy to achieve remission. Physi-
cians traditionally monitor blood counts and chemistries during thiopurine use. More
recently, monitoring of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-
MMP) levels has become popular, despite increased cost and only fair test characteristics
(sensitivity 62%, specificity 72% in Osterman's 2006 meta-analysis). Metabolite monitoring
does provide additional value by detecting noncompliant patients and patients who shunt
thiopurines away from 6-TGN toward production of 6-MMP. Aims: 1) To determine whether
components of the blood counts, blood chemistries, and age can: a) predict clinical response,
b) identify thiopurine non-compliance, and c) identify patients (shunters) who produce a
low (<15) 6-TGN/6-MMP ratio when they metabolize thiopurines; and 2) to compare the
test characteristics of algorithms based on common laboratory tests with the test characteristics
of 6-TGN. Methods: Laboratory values were pulled from the University of Michigan Clinical
Data Warehouse. Subjects were required to have had a complete blood count, comprehensive
panel, and thiopurine metabolites drawn in a 24 hour window between 2004 and 2006.
774 patient charts were abstracted (by two authors blinded to 6-TGN values) for clinical
response. Clinical response was defined by the criteria of Dubinsky (2002). Machine learning
methods, including boosted CART trees and random forests, were used to develop predictive
algorithms from laboratory values in a training set of 70% of the observations. The resulting
algorithms were then tested in the remaining 30% of the observations. Results: All of the
methods of machine learning used produced similar algorithms and performance. In this
sample, an algorithm using laboratory values and age predicted clinical response in the test
set with an area under the ROC curve (AuROC) of 0.84. In comparison, 6TGN levels
predicted clinical response with an AuROC of 0.61. Laboratory algorithms were able to
predict thiopurine noncompliance with an AuROC of 0.79, and to identify thiopurine
shunters with an AuROC of 0.75. Conclusions: Novel algorithms that use age and laboratory
values from the blood count and the comprehensive chemistry panel can predict clinical
response, noncompliance, and shunting of thiopurine metabolism in patients on thiopurines.
This approach is less costly and appears more accurate than 6-TGN metabolite measurement
for clinical response in our sample. If this algorithm can perform as well in other populations,
this approach may provide a low cost, rapid alternative to metabolite testing for monitoring
thiopurine use.
S1123
Greater Exposure to Infliximab Is Not Associated with Increase in Mortality
and Serious Infections - Treat™ Registry Data with Nearly 20,000 Patient-
Years of Follow-Up
Gary R. Lichtenstein, R. D. Cohen, Brian G. Feagan, William J. Sandborn, B. A. Salzberg,
D. M. Chen, M. P. Turner, D. R. Mink, D. L. Broussard, R. H. Diamond
Background and Methods:TREAT,a prospective registry, was established to study the long-
term safety of infliximab (IFX) and other therapies in Crohn's disease (CD). Patients (pts)
who received an average of ≥5 infusions/yr were defined as ‘continuous' treatment; pts
received an average <5 infusions/yr were defined as ‘intermittent' treatment. Pts who contrib-
uted ≥ 1-yr of follow-up were eligible for analysis. Risks of serious infection (SI) and
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mortality for intermittent and continuous IFX were evaluated. Results:6273 pts were enrolled
as of 8/06, of whom 3334 received IFX (10,796 pt-yrs (py)) (n= 873 with continuous IFX
for ≥2 yrs, n = 958 with intermittent IFX for ≥2 yrs) and 2939 received other therapies
only (8277 py) with a mean follow-up of 3.4 yrs. There was a significant difference in CD
severity at enrollment between both treatment groups (p<.0001).More IFX-treated pts had
moderate-to-severe (31.1% vs 10.7%, p<.0001) or severe-fulminant (2.6% vs 0.6%, p<.0001)
CD at enrollment. More IFX-treated pts were hospitalized (27.3% vs. 19.0%, p<.0001) the
yr prior to enrollment, and more were taking prednisone (27.1% vs. 15.9%, p<.0001) or
immunomodulators (49.1% vs. 31.6%, p<.0001) at enrollment. All of these factors may
contribute to an increased risk of infection and mortality. Mortality was similar for continuous
IFX- and non-IFX-treated pts (.22 per 100 py vs .37; RR = .59, 95% CI = .29 - 1.22).Mortality
was also similar for intermittent IFX- and non-IFX-treated pts (.44 per 100 py vs 0.37; RR=
1.20, 95% CI= 0.73 - 1.99). The unadjusted rate of SI for continuous IFX was higher than
the rate for non-IFX-treated pts (1.38 per 100 py vs .63; RR = 2.18, 95% CI = 1.36 - 3.49),
and similar to that of intermittent IFX-treated pts (1.56 per 100 py; RR = 2.47 vs. non-
IFX-treated, 95% CI = 1.47 - 4.14). When multivariate Cox proportional hazards analysis
was conducted to adjust for increased severity of CD and increased use of concomitant
prednisone and immunomodulators in pts on IFX therapy, neither continuous nor intermit-
tent IFX remained statistically significant predictors of an increased risk of SI relative to
other treatments (HR = 1.40 for continuous vs. no-IFX, 95% CI = .87 - 2.26; HR = 1.35
for intermittent vs. no-IFX, 95% CI = .75 - 2.44). Conclusions:Greater IFX exposure was
not associated with an increased risk of mortality or SI.Despite more severe CD, continuous
and intermittent-IFX-treated pts have similar rates of mortality as pts not treated with
IFX.IFX-treated pts have an increased risk of SI but multivariate Cox proportional hazard
analysis suggests that this increased risk is associated with prednisone and narcotic use, and
not IFX.
S1124
Safety of Infliximab and Other Crohn's Disease Therapies - Treat™ Registry
Data with Nearly 20,000 Patient-Years of Follow-Up
Gary R. Lichtenstein, R. D. Cohen, Brian G. Feagan, William J. Sandborn, B. A. Salzberg,
D. M. Chen, M. P. Turner, D. R. Mink, D. L. Broussard, R. H. Diamond
Background and Methods: TREAT, a prospective registry, was established to study the long-
term safety of infliximab (IFX) and other therapies in Crohn's disease (CD). Results: 6273
pts were enrolled as of 8/06, of whom 3334 received IFX (10,796 pt-yrs (py)) (86.5% ≥2
infusions) and 2939 received other therapies only (8277 py) with a mean follow-up of 3.4
yrs. More IFX-treated pts had moderate-to-severe (31.1% vs 10.7%, p<0.0001) or severe-
fulminant (2.6% vs 0.6%, p<0.0001) CD. Also, more IFX-treated pts had been hospitalized
(27.3% vs. 19.0%, p<0.0001) in the year prior to enrollment, and more were taking prednis-
one (27.1% vs. 15.9%, p<0.0001) or immunomodulators (49.1% vs. 31.6%, p<0.0001) at
enrollment. Infusion reactions occurred in 3.7% of 35,189 infusions; severe reactions in
0.09%. Mortality was similar for both IFX- and non-IFX-treated pts (0.52 per 100 py vs
0.50; RR=1.02, 95% CI=0.70-1.50). In an adjusted Cox proportional hazards analysis, the
use of prednisone (HR=1.96, CI=1.28-3.00, p=0.002) and narcotics (HR=2.06, CI=1.33-
3.21, p<0.001) were the only medications associated with increased risk of mortality. The
incidence of malignancies in the two groups was similar (0.39 per 100 py in IFX pts vs
0.53 in non-IFX pts; RR=0.74, 95% CI=0.49-1.12), as was the incidence of lymphoma (0.04
per 100 py in IFX pts vs 0.05 in non-IFX pts; RR=0.8, 95% CI=0.22-2.99). The incidence
of serious infections (SI) was 1.19 per 100 py within 3 months of an IFX infusion and 0.67
not within 3 months of an IFX infusion (RR=1.77, 95% CI =1.27-2.46, p=<0.001). However,
an adjusted Cox analysis showed IFX was not a predictor of SI (HR=1.28, 95% CI=0.87-
1.90). The only medications associated with SI were prednisone (HR=2.04, CI=1.42-2.93,
p<0.001) and narcotics (HR=2.17, 95% CI=1.51-3.14, p<0.001). To date, one IFX-treated
pt with known latent TB, who did not receive adequate prophylaxis, developed active TB.
Conclusions: IFX safety is similar to that of conventional immunomodulators. Despite having
more severe CD, IFX pts had similar rates of mortality, neoplasm and lymphoma as pts not
treated with IFX. IFX-treated pts have an increased risk of serious infection but Cox propor-
tional hazard analysis suggests that this increased risk is independently associated with
prednisone and narcotic use, and not IFX therapy.
S1125
Antibodies to Complex Microbial Mixtures Are a Better Diagnostic for Crohn's
Disease
Rachel J. Adams, Sharise P. Heazlewood, Mark O'brien, Michael A. Mcguckin, Timothy
H. Florin
Antibodies (Ab) to mannan (ASCA) are used to aid diagnosis of Crohn's disease (CD).
Recently, Ab to specific bacterial antigens (Ag) have been studied, e.g. a flagellin (CBir1)
from Clostridium coccoides subphylum. It has been suggested that combining Ab tests may
improve diagnostic utility[1].We hypothesised that current diagnostic Ag tests including
mannan and CBir1 are surrogate markers for increased mucosal IgG to intestinal microbiota
in CD. We compared the diagnostic utility of Ab to F2 (a homologue of CBir1) and
mannan with two complex surface Ag preparations from: Bacteroides vulgatus (Bv), a common
gastrointestinal (GI) bacterium and an in-proportion multibacterial preparation of faecal
microbiota (MBP). Sera Ab was measured in two age and sex-matched cohorts. (A) 40 CD,
40 ulcerative colitis (UC) and 40 GI controls; (B) 80 CD and 80 non-GI controls. IgG was
elevated against each Ag preparation in CD but receiver operator characteristic (ROC) plot
analysis showed IgG to complex Ag preparations were better than ASCA (P<0.04) or F2
(P<0.05) at differentiating CD from UC or controls in both cohorts. Combining F2 and
ASCA data did not improve ROC. This supports our hypothesis that increased IgG to
individual Ag is indicative of a humoral immune response to all microbiota in CD, rather
than measuring responses important for pathogenesis. Increased IgG to microbiota is consist-
ent with a mucosal defect facilitating increased exposure to microbial Ag or an altered
immune response in CD. There is little diagnostically unique about mannan or CBir1.
Combining them may improve sensitivity but at the expense of specificity, which is why
the ROC was not improved. 1. Abreu. 2006. Gastro. 131: 664
S1126
Mucosal Ulcers and Disease Extent in the Simple Endoscopic Score for
Crohn's Disease (Ses-CD) Correlate with Clinical and Biological Disease
Indices: Further Simplification of the Endoscopic Score
Marco Daperno, David N. Moskowitz, Gert A. Van assche, Filip Baert, Annemie Gevers,
Raffaello Sostegni, Jean-frédéric Colombel, Geert R. D'haens, Paul J. Rutgeerts
Introduction. The Crohn's Disease Endoscopic Index of Severity (CDEIS), is used as a
measure for endoscopic activity, its use in routine practice is hampered by the fact that it
is complicated and time-consuming. More recently, the Simple Endoscopic Score for Crohn's
Disease (SES-CD) was proposed. In recent trials infliximab, natalizumab, and adalibumab
have been associated with ulcer healing. Moreover, there is a correlation between those who
have achieved ulcer healing and clinical improvement. We aim to further simplify the SES-
CD to make it even easier in clinical practice, with a focus on ulcer healing. Method. For
the SES-CD, 4 endoscopic variables included ‘ulcers', ‘proportion of the surface covered by
ulcers', ‘proportion of the surface with any other lesions', and ‘stenosis'. Each variable was
scored from 0 to 3 in each segment: ulcers were scored according to size, proportion of
ulcerated surface and of affected surface according to extent, and stenosis as single or
multiple, and whether the colonoscope could be passed through. The new SES-CD score
was calculated excluding the category ‘proportion of the surface with any lesions'. We
correlated SES-CD new and SES-CD old to CDAI, CRP, and IBDQ. Results. There were 191
patients belonging to the original SES-CD study. Correlations of SES-CD new and old with
CDAI, CRP, and IBDQ are illustrated in table 1. Discussion. We show good correlation of
a new SES-CD score with clinically relevant variables of disease. Our study suggests that
scores involving ulcer size and extent, as suggested by recent studies are likely the most
clinically relevant when scoring response to drugs and should be used in the future as
clinically relevant end-points.
Correlation of new and old SES-CD to clinical activity indices
S1127
Multi-Gene Approach to Discriminate for Ulcerative Colitis, Crohn's Disease
and Irritable Bowel Syndrome
Petra Von stein, Nikolai Kouznetsov, Alexander Gielen, åke öst, Oliver Von stein, Robert
Löfberg
Background & Aims: Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
are heterogeneous disorders of the gastrointestinal tract and can profoundly affect the quality
of life. Because many of the symptoms of IBD are similar to those of IBS, the former is often
misdiagnosed. Additionally, the two major forms of IBD, ulcerative colitis and Crohn's
disease show characteristic, but mostly non-specific, pathological features that may overlap
and result in a long delay of a final diagnosis or a diagnosis of “indeterminate colitis”. Our
aim was to identify and confirm the usability of special markers which could help to clinically
distinguish IBS from IBD and to discriminate UC from CD. Methods: We used a subtractive
hybridization method to identify IBD specific genes from colonoscopic biopsies. In quantitat-
ive PCR experiments, the differential expression of seven identified marker genes were
analyzed and the possible clinical utility of these markers was evaluated in 280 patients
using a special algorithm. Results: The data obtained from three independent studies could
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confirm the clinical diagnosis in 86%-92% of all cases. The specificity of having IBD ranged
from 94%-95% with a sensitivity of 85%-95%, and the specificity of having UC from 77%-
94% with a sensitivity of 91%-95%. Conclusions: The use of expression profiling of certain
marker genes from biopsies of patients with IBD/IBS-like symptoms would enable quick
and reliable diagnosis ultimately improving disease management.
S1128
Adequately Dosed 6-TG Use in Chronic Intestinal Inflammation Is Not
Associated with Nodular Regenerative Hyperplasia: A Series of 73 Liver
Biopsies
Bindia Jharap, Chris J. Mulder, Gijsbertus Den hartog, Berend D. Westerveld, Leopold G.
Engels, Dirk J. De jong, Adriaan A. Van bodegraven, Nanne K. De boer
Background The use of 6-thioguanine (6-TG) has been proposed as a rescue drug in patients
with chronic inflammatory intestinal conditions, such as inflammatory bowel disease (IBD)
and celiac disease, failing to tolerate or refractory to standard thiopurines. However, the use
of 6-TG in IBD patients has been discarded due to previous reported hepatotoxicity, in
particular nodular regenerative hyperplasia (NRH), associated with high dose 6-TG. Pathohis-
tological data of 73 liver biopsy specimens acquired from patients using long-term and
adequately (low-)dosed 6-TG are presented here. Methods: All liver biopsy specimens from
patients with chronic inflammatory intestinal diseases treated with 6-TG for three months
or longer in five hospitals in the Netherlands were examined. The specimens were classified by
experienced liver pathologists and subdivided into 1. normal histology, 2. NRH, inconclusive
pathohistological changes potentially NRH- related or aspecific regeneration, 3. sinusoidal
dilatation or veno-occlusive disease (VOD), 4. PSC, or 5. fibrosis. Results: 73 liver biopsy
specimens were analyzed; 68 (93.2%) and 5 (6.8%) biopsy specimens were from patients
with IBD and celiac disease, respectively. Of these specimens, 46.6% were acquired from
male patients with a median age of 49.5 years (range 28-72 years); female patients had a
median age of 41.0 years (range 22-65 years) (P= 0.026, Mann-Whitney test). The median
6-TG dosage was 20 mg daily (range 18-24 mg). The median duration of 6-TG use was 2.8
yrs (range 4-57 months). Normal histology was seen in 47/73 liver biopsy specimens (64.4%).
None of the patients had a definitive diagnosis of NRH. Potentially NRH-related findings,
although inconclusive, were found in 3/73 (4.1%) liver specimens, whereas aspecific regen-
eration was observed in 9.6%. Characteristics of pathological sinusoidal structure was
detected in eight slides (11.0%). No VOD was found. Three liver slides showed PSC or
inconclusive PSC. Fibrosis, but no cirrhosis, was observed in six liver biopsy specimens
(8.2%). Conclusion: Although previous reports suggested NRH to be a common finding in
patients treated with 6-TG in high dosages, no NRH could be found in 73 liver biopsy
specimens from patients with IBD or celiac disease with long-term and adequately (low-
)dosed 6-TG therapy. Hepatotoxicity, particularly NRH, is a dose-dependent adverse event
of thiopurine use, and is not associated with adequately dosed 6-TG.
S1129
Dose-Dependent Influence of 5-ASA On Thiopurine Metabolism
Nanne De boer, Dennis Wong, Piet Hooymans, Bindia Jharap, Peer De graaf, Chris J.
Mulder, Leopold G. Engels, Adriaan A. Van bodegraven
Introduction Thiopurines are frequently administered immunosuppressive drugs in the
treatment of inflammatory bowel disease (IBD). A substantial number of patients is unable
to benefit from thiopurine therapy due to the development of inadequate metabolites levels.
Several studies indicated that 5-aminosalicylates (5-ASA) may influence the metabolism of
thiopurines but conclusions were restricted due to the number of patients or study design.
Aims & Methods We prospectively investigated the influence of two different 5-ASA (Pen-
tasa®) dosages (2 gr/day followed by 4 gr/day) on thiopurine metabolism. IBD patients on
mono-therapy thiopurines were included and received consecutively the 2 different 5-ASA
regimes. 6-Thioguaninenucleotide (6-TGN), 6-methylmercaptopurine (6-MMP), 5-ASA and
N-acetyl-5-aminosalicylic acid (N-5-ASA) levels were determined before 5-ASA therapy (t=
1), after 4 weeks of 2 gr/day (t=2), after 4 weeks of 4 gr/day (t=3) and after at least 4 weeks
after cessation of 5-ASA therapy (t=4). In addition, routine laboratory parameters were
determined. Results Twenty-six IBD patients (42% male and 69% CD) on steady state
thiopurine mono-therapy were included. Mean 6-TGN levels during the different regimes
were 243 (t=1), 326 (t=2), 396 (t=3) and 286 (t=4) pmol/8x10E8 RBC, respectively. Mean
6-MMP levels were 3023 (t=1), 3516 (t=2), 2896 (t=3) and 2899 (t=4) pmol/8x10E8 RBC,
respectively. Mean 5-ASA levels were 0 (t=1), 1055 (t=2), 2422 (t=3) and 0 (t=4) ng/ml
serum. Mean N-5-ASA levels were 0 (t=1), 2287 (t=2), 3822 (t=3) and 0 (t=4) ng/ml serum.
A rise in 6-TGN level was observed in 92% (t=2) and 100% (t=3) of patients. Individual
6-TGN levels increased with 45% (t=2) and 70% (t=3), respectively. No significant variations
in 6-MMP levels were observed. No correlations were established between the different 5-
ASA and thiopurine metabolites. Two patients (8%) developed a leucopenia (both 2.4 x10E9/
l) that resolved spontaneously. Conclusion This pharmacodynamic study shows that 6-TGN
levels increase in a dose-dependent manner during 5-ASA co-administration. However, 5-
ASA has no influence on 6-MMP levels which reflect TPMT activity. Our results warrant
further studies on 5-ASA use in IBD patients who develop inadequate 6-TGN levels during
thiopurine therapy.
S1130
Myelotoxicity Is a Late Event in Azathioprine-Treated Tpmt Heterozygotes:
Lessons for Monitoring
Melissa Smith, Anthony M. Marinaki, Monica Arenas, Greenfield Simon, Azhar Ansari,
Jeremy Sanderson
INTRODUCTION: Heterozygous TPMT deficiency has been reported to be associated with
side effects to azathioprine, particularly myelotoxicity. However, the extent and timing of
toxicity when treated with azathioprine at standard dose is not clearly established and, as
a result, take up of TPMT testing pre-treatment remains low. AIMS & METHODS: We
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undertook a subgroup analysis of TPMT heterozygous patients identified in a prospective
cohort of 216 Inflammatory Bowel Disease (IBD) patients treated with 2mg/kg azathioprine.
Monitoring included FBC, renal & liver profile, ESR & CRP, (at weeks 2, 4, 6, 12, 18 &
24) and thioguanine nucleotide (TGN) levels and clinical assessment (at weeks 4, 12 & 24).
RESULTS: 19 (9%) of the cohort were TPMT heterozygous (12 CD, 7 UC). All were prescribed
azathioprine as a steroid sparing agent. There was 100% concordance between TPMT
genotype and phenotype. By 36 weeks, 17/19 patients had withdrawn due to: myelotoxicity
(6), gastrointestinal disturbance (6), nausea (4), and rash (1). Myelotoxicity occurred from
12 weeks [mode 12wks, range 12-36wks] & all episodes occurred off steroids. In 4 patients
myelotoxicity occurred within 4 weeks of steroid withdrawal. In those with normal TPMT,
the incidence of myelotoxicity was 1%. The single patient who appeared to tolerate long
term azathioprine was non-compliant [multiple low TGN blood levels (75pmol/8x108 RBC)
& urinary 6-thiouric acid]. The average TGN level in the remainder was high (566 pmol/
8x108 RBC). CONCLUSION: TPMT heterozygous patients do not tolerate full dose azathiop-
rine and in the majority of cases treatment is withdrawn within 6 weeks due to gastrointestinal
side effects. This early effect may protect this group from later-occurring myelotoxicity.
Steroids appear to have a protective effect. The implications for therapy are: 1. TPMT
heterozygous patients will not tolerate standard dose azathioprine therapy. 2. Conventional
early intensive blood monitoring regimens will not detect myelotoxicity in this group.
3. Close FBC monitoring when withdrawing concurrent steroids is important to detect
late myelotoxicity.
S1131
Sargramostim Treatment of Pediatric Crohn's Disease: Preliminary Results of a
Phase 1-2 Safety and Pharmacokinetic Study
Robert Baldassano, Stanley A. Cohen, George D. Ferry, Melvin B. Heyman, Joel R. Rosh,
Sona Grossova-garie, Catherine Scholz, Harland S. Winter
Background: Effective, low-risk therapies for the initial and long-term management of
pediatric patients with Crohn's disease (CD) remain an unmet need. Sargramostim (SRG),
an innate immunity activator, has shown clinical efficacy in inducing steroid-free remission
in adults with CD and thus may have clinical value in pediatric patients as well. The objective
of this study was to evaluate the safety and pharmacokinetics (PK) of SRG in pediatric
patients with active CD with and without concomitant corticosteroid (CS) therapy. Methods:
A phase 1-2 US multicenter, open-label, safety and pharmacokinetic study was conducted
in pediatric patients 6 to 16 yrs old with active CD. Patients received either 4μg/kg or 6μg/
kg SRG subcutaneously QD for 8 weeks (End of Treatment-EOT) and were followed for 4
weeks post-treatment(end of study). Efficacy measures included the Pediatric CD Activity
Index (PCDAI) and the Physician's Global Assessment. Remission was defined as absolute
PCDAI of ≤10 and response as a decrease from baseline of ≥12.5 points. Patients were
stratified by age and CS use. Blood samples for PK analysis were collected on days 1, 8,
and 15. Results: Of the 22 patients enrolled, data are now available for 18. 11 patients
received 4 μg/kg (5 on CS) and 7 received 6 μg/kg (3 on CS). 15/18 (83%) achieved
remission or response at EOT. Rapid improvement in PCDAI was noted after 1 week, with
a mean decrease in PCDAI of 30.25±9.43 points in the non-CS group by EOT. This response
was sustained for ≥ 4 wks post-EOT. In the CS group, reduction of PCDAI was less
pronounced, likely due to rapid CS withdrawal prior to EOT. SRG was well tolerated. Mild
injection-site reactions occurred in 90%. Back pain occurred in 39%, mostly within the first
2 wks of therapy. 3 patients required dose reductions due to elevated absolute neutrophil
counts. 18 patients were evaluated for PK. Following 4 μg/kg, mean (SD,n) AUC(0-tlast)
was 3.89(3.3,5) and 2.83(0.44,6) ng*h/mL for 6-11 and 12-16 yr old groups, respectively;
Cmax was 1.62(1.4) and 0.799(0.19) ng/mL. Following 6μg/kg, AUC(0-tlast) was 5.22(1.6,
7) ng*h/mL and Cmax was 1.48(0.59) for the 12-16 yr old group. The mean t1/2 ranged
from 1.41h to 1.88h, suggesting no apparent differences in elimination with respect to dose
or age. Concomitant CS use did not appear to affect SRG exposure. Conclusion: In this
preliminary analysis, sargramostim produced response or remission in the majority of
pediatric CD patients studied and demonstrated linear PK. The elimination was unaffected
by dose, age or CS stratification. The safety profile was similar to that seen in adults with
CD. Overall efficacy awaits further confirmation.
S1132
Cyclosporine (CsA) and Infliximab (Inf) As Acute Salvage Therapies for Each
Other, in Severe Steroid Refractory Ulcerative Colitis (UC)
Elana A. Maser, Deepthi Deconda, Simon Lichtiger, Daniel Present, Asher Kornbluth
Introduction: In patients with severe UC refractory to steroids, either CSA or INF may be
added to attempt remission. If the patient then fails either CSA, or INF, it is unknown
whether success can be achieved acutely with the alternative drug. The objective of this
study was to assess outcomes in patients using CSA after the failure of INF, and vice versa,
in patients with severe steroid refractory UC. Methods: We reviewed the charts of 20 patients
with severe, steroid refractory UC who failed CSA first (CSA-FIRST), and received INF as
acute salvage therapy (n=14), or who failed INF first (INF-FIRST), and then received CSA
as acute salvage therapy (n=6). We defined acute salvage therapy as receiving the alternative
drug within 4 weeks of discontinuing the first drug. Remission was defined as normal
number of bowel movements and absence of rectal bleeding; clinical response was defined
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as improvement of symptoms. Results: CSA-FIRST and INF-FIRST patients were comparable
for age (µ=34 vs. 37 years) and disease duration (µ=8.4 vs.9.4 years); 6 of 6 patients in the
INF-FIRST group had pancolitis vs. 6 of 14 in the CSA-FIRST group (p=.06). 14 patients
who failed CSA-FIRST were treated with INF as acute salvage therapy; 6 patients who failed
INF-FIRST received CSA as acute salvage therapy. The acute salvage rates are shown in
Table 1. CSA-FIRST patients received a mean of 3.8 months (mos) of CSA (range 0.5-12.2
mos) and then a mean of 3.4 (range 1-6) INF infusions. INF-FIRST patients received a
mean of 2 infusions of INF (range 1-3) and then were treated with CSA for a mean of 8.7
mos (range 0.5-37.5 mos). Of the patients who achieved remission in either group, none
have gone to colectomy during a mean follow-up 15.1 months. Severe adverse events (SAE)
occurred in 3 patients: 1 CSA-FIRST patient developed jaundice, 1 CSA-FIRST patient
developed E. coli sepsis and died; and 1 INF-FIRST patient developed herpetic esophagitis.
Conclusions: Our data does not address whether CSA or INF is the preferred initial therapy
in severe steroid refractory UC. However, in patients with severe steroid refractory UC who
fail treatment with either CSA or INF, remission is achieved in only 1/3 of patients with
acute salvage therapy with the other drug. Acute salvage rates are comparable whether CSA
or INF is used first, and serious drug-related adverse events occurred in 15% of all patients,
including 1 death.
Table 1.
S1133
Role of Demographic Factors On Azathioprine (AZA) Responsiveness: Impact
of Body Mass Index (BMI)
Martin H. Holtmann, Frank Krummenauer, Dirk Lorenz, Christina Claas, Kristina
Kremeyer, Olivia Rainer, Iris Vogel, Ulrich Böcker, Stephan Boehm, Guido Gerken,
Carsten Buning, Rainer Duchmann, Wolfgang Kruis, Max Reinshagen, Jan Schmidt,
Andreas Stallmach, Andreas Sturm, Peter R. Galle, Daan Hommes, Geert D'haens, Paul
Rutgeerts, Markus Neurath
Introduction: AZA is the gold standard for maintenance therapy in IBD. Predictive factors
for azathioprine responsiveness are poorly characterized, however, due to the limited study
sizes. We thus performed an analysis of such factors in a large European multicenter
population. This study population allowed for the first time a detailed analysis of the role
of demographic factors for AZA responsiveness. Methods: Data from 818 CD patients and
358 UC patients from 14 european centers on long-term AZA therapy were included.
Endpoints were changes in flare frequency and steroid need between the time periods prior
to, under and after AZA intake. Changes of flares/year (y) or prednisolone equivalent/month
(m)were indicated as medians and quartils. P<0.05 in the T-test indicated statistic significance.
Results: Prior to AZA, males (n=270) had a higher flare incidence of 0,125/y (0,0457-
0,3233), than females with 0,1/y (0,0284-0,2793 (n=364) (p=0,048) associated with a strong
trend to a higher steroid need (p=0,055). Under AZA treatment these differences disappeared.
Patients with a BMI < 25 or >25, had similar flare incidences and steroid intake prior to
and under AZA treatment. Interestingly, when AZA was discontinued after < 3 years, CD
patients but not UC patients with a BMI > 25 had more flares than those with a BMI < 25,
although in both disease groups, patients with a BMI < 25 consumed more steroids than
patients with a BMI > 25. However, when AZA was taken > 3 years, there were no more
differences between patients with a BMI < 25 and > 25. Starting AZA earlier than the average
duration since disease onset (71 m for CD and 45 m for UC) most likely indicates more
severe disease activity. And in fact, flare incidences and steroid need were higher in these
patients before AZA (p=0.000). Responsiveness to AZA was less (p= 0.0006 for CD and p=
0.048 for UC). However, when AZA was taken > 3 y, these differences disappeared. Discus-
sion: For the first time, sex differences in disease behaviour in CD, but not in UC were
identified. In addition, the different BMI dependent disease behaviour after AZA discontinu-
ation supports a diverget role of nutrition in CD and UC. The approximation of disease
activity between patients with less severe and more severe disease, when AZA is taken for
more than 3 years, further supports the clinical benefit of long term treatment.
S1134
Infliximab Dose in Real-Life Remains Stable Over 30 Months with Favourable
Benefit:Risk Profile in CD
Richard Fedorak, Alain Bitton, Philip Hassard, Andrew Vargo, Edith Garon
INTRODUCTION: Infliximab (IFX) has been shown to be effective for the induction and
maintenance of remission in moderately severe Crohn's disease in Phase 3 clinical trials. It
is well described that the dose of agents used outside of clinical trials is frequently altered
by clinical assessment and patient (pt) compliance. OBJECTIVE: This registry evaluates the
use of IFX in clinical practice and compares its use to results seen in clinical trials. METHODS:
Data collected from an ongoing, prospective, Canadian multi-centre registry of Crohn's pts
on IFX was analyzed. Among the parameters collected are: demographics, concomitant
medications, adverse events and IFX dose over time. Data is collected at: baseline, 2 Months
(M), 6M and every 6M thereafter. Eligible pts must be naïve to IFX and eligible for IFX
therapy as per the Canadian Product Monograph. RESULTS: As of today 488 pts have been
enrolled, 218 men and 270 women. Target enrolment: 2000 pts. Mean age: 37 years; mean
weight: 70kg. 69% of pts were on immunosuppressants at baseline. Thus far, the IFX dose
remains stable over time (M30) (Figure 1). Mean Crohn's Disease Activity Index (CDAI)
decreased from 339.9 at baseline to 102.6 at M30 (p < 0.0001 by ANOVA). 63% and 88%
of pts demonstrated a clinical response at M2 and M30 respectively. No cases of TB,
lymphoma or death occurred. CONCLUSION: The registry shows that the dose of IFX in
Crohn's pts remains stable over 30M of observation. This dose yields efficacy and safety results
in line with the favourable benefit:risk profile for IFX as demonstrated in clinical studies.
Figure 1
S1135
Infliximab Usage in Crohn's Disease 2002-05: A Retrospective Cohort Study
Brian G. Feagan, Robert Sederman, Patricia R. Grossman, Edward Loftus
Background: No large-scale studies have evaluated infliximab (IFX) use for Crohn's disease
(CD) in clinical practice. Expert panels have recommended IFX as a tertiary therapy for
patients who have failed immunosuppressive (IS) therapy (azathioprine, mercaptopurine,
or methotrexate), and have endorsed continuous, scheduled maintenance therapy with co-
administration of an IS to minimize sensitization. To better understand implementation of
these recommendations, we evaluated patterns of IFX use in a retrospective cohort of
CD patients. Methods: PharMetrics, a US healthcare claims database of nearly 25 million
commercially insured patients, was used. Patient selection criteria included: continuous
enrollment during a 3-year period, at least one claim for CD (ICD-9 555.x), and a first IFX
claim in 2003 or 2004. Patients were followed for 12 months prior to first infusion and for
up to 2 years of therapy. Time between infusions and usage of CD drugs was calculated. Drug
classes analyzed were IS, low-dose corticosteroids (<10mg/day), high-dose corticosteroids
(≥10mg/day), and 5-aminosalicylic acid/sulfasalazine (5-ASA). Results: Sixty-seven percent
of patients were aged between 30 and 64 years and 56% were female. A total of 621 newly
treated IFX CD patients were identified. Of these, 558 (90%) received ≥2 infusions. Of the
558, 172 (31%) had ≥1 ‘gaps' between infusions exceeding 16 weeks during the first 1-2
years of therapy. The mean length of these gaps was 31 weeks. Of those with gaps, 79%
had 1 gap, 17% had 2 gaps, and 4% had 3-4 gaps. Additionally, 266 (43%) discontinued
IFX within 1 year. During the year prior to IFX use, 54% of patients were treated with IS.
After the first infusion, IS were used concomitantly by 56% of patients (95% CI: 52-60%)
(Table). Conclusions: Expert recommendations regarding the optimum use of IFX have not
been widely implemented. Intermittent IFX use was common, 44% of patients did not
receive concomitant IS therapy, and many received IFX as primary therapy. Concomitant
5-ASA and corticosteroid use remains common. Factors responsible for these findings have
not been identified, but likely include the cost of continuous infusions, fear of toxicity with
combined therapy, and lack of awareness of the risk of immunogenicity.
Percent of patients with CD prescriptions prior to and during IFX therapy
S1136
Infliximab As Rescue Therapy in Acute Severe UC: A Survey of the Scottish
Society of Gastroenterology (Ssg)
Charlie Lees, Deborah Heys, Alan G. Shand, Ian D. Penman, Kelvin R. Palmer, Colin L.
Noble, Craig Mowat, Hasnain Jafferbhoy, Rob Boulton-jones, Andrew Williams, Helen
Gillett, Chris Evans, John Todd, Nicholas Church, K. Vaidya, James Rose, Ian D. Arnott,
Jack Satsangi
Introduction. As many as 40% of patients with acute severe ulcerative colitis (UC) will fail
to respond to first-line medical therapy. Treatment of these patients has been limited to
surgery or cyclosporine. Doubts remain about the efficacy of cyclosporine and concerns
over its toxicity. Jarnerot et al demonstrated in a randomised controlled trial that infliximab
as “rescue” therapy for severe UC was effective with emergency colectomy rates of 29% vs.
67% for placebo (p=0.017, NNT<3). Aims. We aimed to complete a pan-Scotland retrospect-
ive audit of infliximab use as rescue therapy for patients with acute severe UC failing first
line intensive medical therapy, and determine factors predicting short and long-term outcome.
Methods. All members of the SSG were invited by e-mail to participate in this survey.
Responses from 12 hospitals in Scotland were received of which 8 provided sufficient data
on 39 patients for inclusion in the study at the time of abstract writing. All data were
collected retrospectively by case-note review. All 39 patients met Truelove and Witts criteria
for disease severity at admission. There were 23 male and 16 female patients with a median
age at diagnosis of 30.7 years (IQR 21.9-43.3). The timing of infliximab therapy was at the
discretion of the clinicians involved. Results. 26/39 (66.6%) of patients avoided urgent
colectomy following infliximab rescue therapy. The median duration from admission to
infliximab therapy was 9 days (IQR 5.5-12 days). Patients treated within 5 days of admission
were significantly more likely to undergo colectomy than those treated after 6 or more days
(55.5% vs. 26.7%, p=0.05). Colectomy was predicted by low serum albumin at admission
and at day 3 of iv steroids (p=0.03), but not by stool frequency or CRP. 13/39 (33.3%) of
patients underwent urgent colectomy at a median of 5 days (range 1-8 days) following
infliximab. Following hospital discharge, only 1 additional colectomy was reported during
a median of 130.5 days follow-up (IQR 89.5-303.0). 3 months follow-up was available on
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21/26 (80.8%); of these 15/21 (71.4%) had successfully tapered their oral steroid therapy.
One patient, who responded to infliximab and was discharged from hospital, died of septic
shock from broncho-pulmonary pneumonia 3 weeks following infliximab therapy. One
patient had severe post-operative sepsis resistant to anti-bacterial therapy and only responding
to intensive anti-fungal treatment. Conclusions. Infliximab may be an effective rescue therapy
in acute severe UC, but safety concerns remain paramount and appropriate patient selection
is critical.
S1137
Effect of Infliximab On Small Bowel Stenoses in Crohn's Disease. A
Prospective Long-Term Follow-Up Study
Nadia Pallotta, Fausto Barberani, Naima Abdulkadir hassan, Danila Guagnozzi,
Alessandro Gigliozzi, Sandro Boschetto, Giuseppina Vincoli, Enrico Corazziari
The effect of Infliximab on intestinal stenoses in Crohn's Disease(CD) is not known since
previous studies reported conflicting results based on retrospective observations (1,2) or
assessment of obstructive symptoms rather than of the stenotic lesion itself (3). Small intestine
contrast ultrasonography (SICUS) accurately assesses presence, number, extension, and sites
of the small bowel transmural alterations and luminal stenoses (4). Aim. To assess prospect-
ively with SICUS the evolution of small bowel stenoses in CD patients treated with Infliximab.
Methods and Patients. Within a long-term prospective follow-up study of CD, 21 patients
(M13, Age: M±SD, 47±14 yrs), 12 of whom with one or more stenoses of the small bowel,
were treated with Infliximab (5mg/Kg at week 0,2,6 and 10mg/Kg every 8 weeks thereafter)
for steroid refractoriness, fistulizing disease, or to avoid high risk surgery. Concomitant
therapy was azathioprine in 4 patients and 5-ASA in 10. Follow-up visits and SICUS were
performed at least yearly (range 4-12 months) for 17-52 months. SICUS was performed
during distension of small bowel lumen following ingestion of 375 ml of polyethylene
contrast solution. Stenosis was defined at SICUS as lumen diameter <1cm of the maximally
distended loop, confirmed in at least two consecutive follow-up observations, and at endos-
copy if located in the terminal ileum. Results. After Infliximab treatment in no case there
was progression of the preexisting strictures or the appearance of new ones. After the first
3 induction doses of Infliximab there was complete regression of the stenosis in one patient
and no disease variation in 5 patients who were operated upon, 3 of whom with preexisting
stenosis. During Infliximab maintenance treatment in the 15 remaining patients there was
no need of surgery, and complete regression of 5 stenoses (1 single stenosis in 3 patients,
and 1 stenosis in 2 patients, each with 3 stenoses) after 8-24 cycles of Infliximab administra-
tions. In 2 additional patients there was partial regression of the extension, respectively 3
cm and 1 cm, of 2 stenoses. Conclusions. In this prospective follow-up study in CD patients
treated with Infliximab there was (a) complete or partial regression of 36.8% of small bowel
stenoses that were very likely of inflammatory nature, and (b) no appearance of new, and
no progression of preexisting, small bowel stenoses. Infliximab treatment does not appear
to be contraindicated, and may be of benefit, in CD patients with stenotic lesions of the small
bowel. (1)Toy et al.Gastroenterology 2000; (2)Vasilopoulos et al AJG.2000; (3)Lichtenstein et
al. AJG.2006; (4)Pallotta et al. Inflamm Bowel Dis 2005
S1138
Maintenance Treatment with Azathioprine in Ulcerative Colitis: Outcomes
After Drug Withdrawal in Patients with Sustained Remission
Sandro Ardizzone, Andrea Cassinotti, Giovanni Actis, Piergiorgio Duca, Giuseppe
D'albasio, Elisa Gai, Alessandro Massari, Matteo Bosani, Elisabetta Colombo, Gianpiero
Manes, Giovanni Maconi, Gabriele Bianchi porro
Background: Azathioprine (AZA) has proven to be effective in the treatment and maintenance
of remission of ulcerative colitis (UC). Aims: To investigate, in an Italian multicentre retro-
spective study, the clinical outcome of ulcerative colitis after withdrawal of maintenance
treatment with AZA in patients with sustained remission at the time of withdrawal. Methods:
From our database we found 94 UC patients (M/F 58/36, mean age 34 yr) who stopped
AZA electively or because of drug-related toxicity, and were in sustained remission at the
time of withdrawal. The patients were followed-up until a relapse occurred or until the end
of follow-up (mean 61 months). The incidence of clinical relapse and/or colectomy after AZA
withdrawal were analysed according to the duration of treatment and any other demographic,
clinical and endoscopic variables. Results: Treatment duration was < 24 months in 26
patients, 24-48 months in 31 patients and > 48 months in 37. After drug withdrawal, 80.8%
of patients relapsed (mean time to relapse 16 months, range 1-119) and the colectomy rate
was 10.6%. While no significant differences in relapse rate were observed between duration
24-48 months and > 48 months (74.2% vs 78.4% respectively), patients treated for <24
months had significantly higher relapse rate than the other two classes (92.3%; p=0.003).
Cox models showed that higher relapse rates were also significantly correlated to pancolitis
(p=0.038) and younger age at diagnosis (p=0.042). Conclusion: Discontinuation of treatment
with AZA while UC is in remission leads to a high relapse rate. Prospective controlled trials
are warranted to establish whether treatment should continue indefinitely.
S1139
The Use of Complementary Medicine in Pediatric Patients with Inflammatory
Bowel Disease: Results from a Multi-Center Survey
Anthony P. Wong, Ann Clark, Elizabeth Garnett, Michael Acree, Stanley A. Cohen,
George D. Ferry, Melvin B. Heyman
OBJECTIVES: Few data exist on the use of complementary alternative medicine (CAM)
ipediatric patients with inflammatory bowel disease (IBD). We examined the use of CAM
at three pediatric medical centers in the United States, comparing a group of children
suffering from IBD with children presenting with chronic constipation. METHODS: Surveys
were administered by postal mail and at Pediatric IBD Centers in San Francisco, Houston,
and Atlanta during regular clinic visits from 2001 to 2003. A comparison group consisting
of pediatric patients with chronic constipation for greater than six months and who were
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followed by a pediatric gastrointestinal specialist was also surveyed. Data were analyzed by
t-test and Chi-square analysis. RESULTS: 236 surveys were collected from the IBD group
(San Francisco, n=69; Houston, n=100; Atlanta, n=67). 126 questionnaires were collected
from the chronic constipation comparison group (San Francisco, n=24; Houston, n=97;
Atlanta, n=5). In the IBD group, 62% had Crohn's disease, 37% had ulcerative colitis, and
1% had indeterminate colitis. The overall use of CAM was 50% in the IBD group and 23%
in the chronic constipation group. Regional breakdown of CAM use in IBD revealed no
differences. Survey-takers specified over 45 different CAM therapies, and these therapies
were coded and categorized (Table 1). The most commonly used CAM therapies in the
IBD group were spiritual interventions (25%) and nutritional supplements (25%). Positive
predictors for CAM use in IBD include the patient's self-reported overall health (p=0.012),
an increase in the number of side effects associated with allopathic medications (p=0.004),
Caucasian (p=0.039), and parental education beyond high school (p=0.044). CONCLU-
SIONS: CAM use was twice as common in pediatric patients with IBD compared with
chronic constipation. Spiritual interventions and nutritional supplements were the most
common modalities, which differs from one previous US study (Heuschkel et al, 2002).
Practitioners need to accept that half of their pediatric IBD patients may be using CAM in
addition to conventional therapy and can begin employing some predictors to help identify
patients and families who will turn to alternative therapies. Supported in part by grants
from the NIH (DK 060617 and DK 007762), by the Mt Zion Health Fund/Osher Center
for Integrative Medicine, and the Marcus Foudation
Table 1: CAM Use
S1140
An Open Label Series of Rifaximin for Long Term Maintenance Therapy for
Patients with Refractory Pouchitis
Asher Kornbluth, Michelle Hunt, James George, Peter Legnani
Introduction: Patients who undergo the ileoanal anastamosis procedure for ulcerative colitis
are at risk for the development of idiopathic inflammation of the pouch, termed pouchitis.
Although there is limited randomized controlled trial data for the use of the antibiotics
metronidazole and ciprofloxacin, they are the mainstay of therapy for patients with pouchitis,
with approximately 80-90% success rates. Approximately 5-10% of patients are refractory,
or require chronic suppressive antibiotic therapy. We have previously reported that 13 of
16 (81%) patients with pouchitis refractory to at least 2 antibiotics, in addition to probiotics
and/or budesonide, had significant clinical improvement with rifaximin in doses of 600-
800 mg/day. Objective: The aim of this study was to determine the duration of efficacy and
safety of rifaximin as maintenance therapy in this group of patients with refractory pouchitis,
responsive to rifaximin acutely. Methods: The diagnosis of pouchitis was confirmed in all
(16) patients with pouchoscopy, prior to starting rifaximin treatment, and severity was
defined as moderate-severe using the Pouchitis Disease Activity Index. All 13 patients with
previously medically refractory pouchitis who responded to rifaximin, continued mainten-
ance therapy with a mean dose of 400mg/day (range 200-800 mg/day). Maintenance of
clinical response was defined as the absence of new symptoms, and the avoidance of any
new pouchitis treatment. Patients were censored at either failure as described above, or time
at last follow-up (last observation carried forward). Results: Overall, the mean duration of
maintenance of response was 13.6 months. Ten of 13 patients (77%) successfully maintained
their response on rifaximin for a mean of 16.7 months, at time of last follow-up. Three of
the 13 patients had a recurrence of pouchitis at a mean of 3.3 months; 2 improved with
budesonide 9 mg/day, and one improved with ciprofloxacin 500 mg BID. No drug-related
toxicity was observed. Conclusions: In this open-label series of 13 patients maintained on
rifaximin after successful acute therapy for refractory pouchitis, the maintenance of response
with rifaximin was achieved in 77% of patients for a mean of 16.7 months, with excellent
safety. Prospective randomized controlled trials are warranted to define the role of rifaximin
in the long-term maintenance management of patients with pouchitis.
S1141
β Catenin Target Gene Expression Is Increased in Ulcerative Colitis (UC) and
Links UC to Activated Intestinal Epithelial Stem Cells: Abrogation By 5asa
Identifies a Potential Mechanism of 5asa Related Cancer Prevention
Elizabeth Managlia, Terrence A. Barrett
Background and Aims: Ulcerative Colitis (UC) correlates to an increased risk of colorectal
cancer (CRC) with many CRCs displaying aberrant wnt/β catenin signaling. Murine models
demonstrate elevated nuclear β catenin (a reliable marker for activated intestinal epithelial
stem cells (IESC)) as well as increased β catenin target gene expression in mice with colitis
or cancer. We evaluated β catenin target genes and inflammatory genes in UC patients. We
also examined the impact of 5ASA on gene expression, due to reports indicating a role in
decreased risk of CRC. This study aims to elucidating the mechanism of aberrant IESC
signaling which may result from chronic inflammation and potentially lead to CRC. Methods
and Results: Biopsies were collected during routine colonoscopies for UC or normal screening.
Biopsies from untreated (UT) patients showed mRNA of CD44 and COX2 was increased
an average of 5.6- and 12-fold in areas of active UC compared to normal tissue. mRNA
levels decreased to 3-fold for CD44 and 8.6-fold for COX2 in patients on 5ASA. The fold
increase of mmp7 in UT patients varied, increasing between 300- and 7000-fold over normal
tissue, while in patients on 5ASA therapy the increase averaged 1600-fold. mRNA of iNOS,
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IL10 and IL6 were elevated 77-, 68-, and 15-fold respectively in UT samples, and 21-,12-
, and 3-fold in patients on 5ASA, while levels of IP10 and IL8 were elevated 5- and 31-
fold but did not decrease significantly with 5ASA. Comparisons of active disease with
uninvolved tissue from the same patient revealed that COX2 was expressed at normal levels
in uninvolved tissue, while CD44 and mmp7 remained increased at 2- and 50-fold over
normal tissue despite iNOS, IL10, IL6, IP10, and IL8 all being expressed at near normal
levels. Epithelial gene expression was evaluated separately from that of the stroma by using
LCM material. IL10 and inos were expressed strongly in the stroma and confirmed the
findings of the whole biopsies. Increased COX2 expression was detected in both the epithelial
and stromal compartments. Additionally, while increases in CD44 and mmp7 in epithelial
cells yielded similar results to the whole biopsies, LCM captured epithelial cells also revealed
a 3-fold increase in cmyc expression and a 2.8-fold increase in cdx1 in UT patients. cmyc
and cdx1 had normal gene expression in 5ASA treated patients. Conclusions: These data
describe dysregulation of βcatenin genes in UC that can be partially remedied by 5ASA.
These findings highlight the importance of further exploration into this pathway in the
epithelium and surrounding stroma ultimately determining the link of UC to dysfunctional
IESC and CRC.
S1142
Clinical Efficacy of “Top-Down” Intravenous Cyclosporin Therapy in Patients
with Severe Ulcerative Colitis
Naoki Yoshimura, Yasuo Suzuki, Masakazu Takazoe
BACKGROUND & OBJECTIVE: Cyclosporin (CsA) has shown efficacy in patients with
steroid refractory ulcerative colitis (UC). However, until now, the management of severe
UC has been by a “step-up” algorithm in which the treatment is first initiated with steroids
and CsA is introduced when patients have become refractory to steroids. This strategy has
been associated with a high relapse rate due to inadequate mucosal healing which in part
might be attributable to long-term exposure to steroids. We felt that a strategy of introducing
CsA as a monotherapy immediately after an exacerbation of UC (aggressive “top-down”
approach) might be superior to the routine “step-up” strategy. METHODS: Between January
1997 and April 2006, 114 patients with UC received intravenous (iv) CsA, 3-4mg/kg/day.
Twenty-one patients received CsA as monotherapy (“top-down” group). Thirty-four patients
who failed to respond to iv steroid (40-60mg/day) received CsA within 14 days of concurrent
iv steroid (early CsA group). Fifty-nine patients received CsA after they failed to respond
to more than 14 days of iv steroid (late CsA group). The last 2 groups were defined as
“step-up” groups. Patients who did not improve within 14 days of iv CsA underwent
colectomy. Patients who responded to CsA were discharged on a regimen of oral CsA or
oral CsA plus steroid (both were tapered) with 5-aminosalicylate and were followed clinically
and endoscopically for at least 6 months. Long-term outcome was evaluated by the Kaplan-
Meier survival analysis. RESULTS: In November 2006, patients were retrospectively evalu-
ated. The clinical activity and endoscopic indices on admission were similar in the 3 groups.
Overall, 89 of 114 patients (78.1.%) had a response within 14 days of CsA therapy. Further,
20 of 21 patients (95.2%) in the “top-down” CsA group achieved remission compared with
31 of 34 patients (91.28%) in the early CsA group and 38 of 59 patients (64.4%) in the
late CsA group. The endoscopic index fell from 11.5±1.0 to 4.1±1.8 in the “top-down”
group and from 11.7±1.1 to 6.0±1.2 in the “step-up” groups (P<0.05). Of the 89 responders,
55 patients did not receive immunomodulators like azathioprine and were observed for 6
to 87 months. At 6 months, 1 of 16 patients (6.3%) in the “top-down” group relapsed
compared to 16 of 39 patients (41.0%) together with 6 of these undergoing colectomy in
the “step-up” groups (P<0.01). CONCLUSIONS: The present study shows for the first time
that in the management of patients with severe UC, for both induction of remissions and
the sustainability of the response, an aggressive “top-down” CsA therapy is significantly
superior to the routine “step-up” approach.
S1143
Infliximab in Pediatric Crohn's Disease: Long-Term Follow-Up of An
Unselected Cohort
Lissy D. Ridder, Edmond Rings, Marc A. Benninga, Jan Taminiau, Frank Kneepkens,
Johanna Escher
Objective: The purpose of this study was to describe the clinical experience with the anti-
tumor necrosis factor chimeric monoclonal antibody, infliximab, in paediatric patients with
Crohn's disease (CD) in The Netherlands. The early stages of immune-mediated disease may
be more susceptible to immunomodulation and the natural history of CD may be altered.
Therefore, we examined if children had prolonged duration of response when infliximab
was initiated early in the disease course. Methods: Clinical response and adverse events
were recorded for all Dutch paediatric CD patients treated with infliximab from October
1992 to June 2006. Results: Sixty-two CD patients (36 boys) in 9 hospitals were treated
with infliximab. Mean age at the start of infliximab therapy was 14.2 years (range, 7.1-18.2
years). Mean follow-up since the start of infliximab was 32 months. In total, 744 infliximab
infusions were administered. Analysis of the entire cohort demonstrates that 14.5% of
patients had prolonged response, while 59.7% were infliximab dependent and 22.6% lost
response. In patients with fistulizing disease prolonged response to infliximab therapy was
seen in 50%. In total, 8 patients (12.9%) developed an infection during infliximab therapy
and 7 of the 62 patients (11.3%) had an immediate allergic reaction during infusion. There
was no statistical difference regarding response to infliximab therapy in the entire cohort
when started within 1 or within 2 years after CD was diagnosed as compared to after 1 or
after 2 years. Conclusions: This study describes the longest follow-up of a large, unselected
pediatric CD cohort receiving repeated infusions of infliximab. Infliximab is a very effective
therapy in these children not responding to standard therapies. Clinical response to infliximab
therapy is seen in 75% of patients, which is even higher than the response in adult CD
patients. It is important to note, however, that 60% of this cohort is dependent on repeated
infliximab infusions. Infliximab maintenance therapy seems very effective and safe in paediat-
ric CD. Long-term safety however, is still of major concern. There was no difference in
response between early and late disease for more or less than both 1 and 2 years interval
between diagnosis and start of infliximab.
S1144
Efficacy of 6-Mercatopurine (6-MP)in the Treatment of Ulcerative Colitis (UC)
Alicia M. Sambuelli, Anibal H. Gil, Silvia M. Negreira, Silvina A. Goncalves, Segio P.
Huernos, Pablo Tirado, Toro A. Martin, Ivan Doldan, Andres Roca, Andrea Czech, Ana
Cabanne
BACKGROUND: 6-mp is a purine analogue extensively used in Crohn's disease management;
however, there is limited information concerning its use in UC. AIM: to evaluate efficacy
and safety of 6-mp UC treatment. MATERIAL AND METHODS: records of UC patients
receiving 6-mp from Jan 2000 to Dec 2006 attending a single center were reviewed to assess
clinical response, mucosal healing, steroid discontinuation, colectomy rates, and safety.
Indication was steroid-dependent UC defined as difficulty to withdraw steroids during
previous 6 mo. with two discontinuation attempts. We included 80 patients (40 males),
mean age 31 yrs (range 3-68), extensive UC: 39 patients, left-sided: 36, distal: 5, mean time
from UC onset until 6-mp treatment 6.8 yrs (6mo-28 yrs). Tentative 6-mp dose was 1 mg/
kg. An 8 wk course of meprednisone started at 40 mg/d was used as a bridge. Efficacy was
categorized as global response (Mayo score≦ 3 with rectal bleeding subscore≦1, endoscopic
improvement and steroid free intervals > 1 yr) and remission (Mayo score≦ 2 with mucosal
healing as defined by a Mayo endoscopic subscore ≦ 1, plus sustained steroid discontinu-
ation). RESULTS: Global response rates at 6 mo, 1, 2, 3 yrs were 89% (n=72), 82% (n=69),
76% (n=51), 71 % (n=40) and remission rates 89%, 80%, 68%, 59%. Surgical requirement at
the same times was 7%, 12%, 15%, 17% (Kaplan Meier Life Table); 44% of colectomized
were 6-mp intolerant. Steroids were discontinued in 4.7±0.4 mo., 12% of cases needed
sporadic courses. Mean 6-mp dose for achieving efficacy was 0.94±0.03 mg/kg. A significant
increase in mean cell volume in responders vs. no responders (p<0.00001, Wilcoxon signed
test) was observed. Responders had lower final mean WBC values, although significant
difference compared with non-responders was not reached. WBC helped select non-
responder patients to treat with higher dose (>1mg/kg) to achieve efficacy (11% of cases).
Side effects, observed in 30% of patients, were: raised liver enzymes (10%) is normalized
by stopping 6-mp, 3 of them continued with lower dose), leucopenia (7.5%, 2/3 of them
reverted by decreasing dose), fever (2.7%), pancreatitis (2.5%), nauseas (2.5%) and infections
(6.3%: pneumonia, varicella, herpes zoster). Thirteen (16%) patients discontinued 6-mp.
Hospitalization was only required in non-responders. CONCLUSION: 6-mp has shown to
be effective in steroid dependent UC treatment, exhibiting a suitable rate of endoscopic
response and low rate of colectomy in long-term follow up. Routine analyses were useful
in monitoring safety and to improve efficacy. Benefits of 6-mp seem to outweigh potential
risks of other therapies and surgical procedures.
S1145
Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease
Alessandro Armuzzi, Barbara De pascalis, Italia Roberto, Sara Ennas, Fabio De vincentis,
Simona Guglielmo, Paolo Fedeli, Alfredo Papa, Italo De vitis, Giovanni Gasbarrini,
Domenico Melina, Giuseppe Fedeli, Antonio Gasbarrini, Luisa Guidi
Background & Aim: Infliximab has been shown to maintain remission through one year in
about 40% of Crohn's disease (CD) and ulcerative colitis (UC) patients refractory or intolerant
to non-biologic therapy. There are few data on infliximab therapy beyond one year in CD
and no data on long-term scheduled therapy in UC. Aim of this study was to analyze the
clinical efficacy of long-term (>1 year) scheduled infliximab therapy in IBD patients. Methods:
Medical records of IBD patients treated with infliximab scheduled therapy for at least one
year (>8 infusions) at our Unit were retrospectively reviewed and details on demographic,
clinical and endoscopic characteristics and adverse events recorded. Response, remission
and mucosal healing were assessed by CDAI or fistula drainage (CD) and Mayo score (UC),
according to the definitions used in the ACCENT and ACT trials. Results: A total of 73 IBD
patients (46 CD, 27 UC) was treated with infliximab for at least one year on an 8-weekly
scheduled regimen. CD patients (luminal/perianal, 32/14) received a mean±SD number of
infusions/patient of 13±4 (range 9-26). 78.2% were also receiving azathioprine or methotrex-
ate. 10/46 patients (21.7%) required a decrease in the interval between infusions and/or an
increase in dosage to maintain response. 8/46 patients suspended infliximab treatment
because of prolonged remission (n=6), pregnancy (n=1), worsening intestinal stricture (n=
1), side effects (n=1). 5/8 are still in remission after a median follow up of 40 months,
whereas two have been operated because of intestinal stricture. Thirty-eight patients are
currently in prolonged response (n=10) or remission (n=28) on scheduled infliximab regimen.
22/32 luminal CD patients (68%) also showed sustained mucosal healing. UC patients
received a mean±SD number of infusions per patient of 13.6±5 (range 9-25). 70% were on
concomitant azathioprine or methotrexate. Dose flexibility was required in 7/27 patients
(26%). Two patients underwent elective colectomy. Twenty-five patients are currently in
prolonged response (n=9) or remission (n=16) with scheduled infliximab therapy. Mucosal
healing was observed in 16/25 patients (64%). Notably, all 73 IBD patients were able to
discontinue corticosteroids. Adverse events occurred in 8/73 IBD patients, leading to inflixi-
mab discontinuation in one of them. Conclusions: long-term (>1 year) scheduled treatment
with infliximab appears to be efficacious and safe and resulted in prolonged response,
remission and mucosal healing in a majority of our IBD patients receiving 8-weekly infusions.
A positive steroid-sparing effects was also observed. Dose flexibility was needed in 23% of
the patients.
S1146
Autologous Stem Cell Transplantation in Moderate-Severe Refractory Crohn's
Disease: The Milan Experience Without CD 34+ Cells Selection
Sandro Ardizzone, Andrea Cassinotti, Claudio Annaloro, Francesco Onida, Daria
Trabattoni, Aldo Della volpe, Claudia Vener, Giovanni Maconi, Salvatore Greco, Mario
Clerici, Giorgio Lambertenghi deliliers, Gabriele Bianchi porro
Background and aims: Autologous haematopoietic stem cell transplantation (aHSCT) with
CD34+ cell selection has recently been used to treat refractory Crohn's disease (CD), showing
good safety and promising efficacy. We investigate the safety and efficacy of aHSCT without
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CD34+ cell selection in refractory CD. Patients and methods: Four patients (3 males, 1
female; age 26-45 years) with active moderate-severe CD (median CDAI 316), refractory or
intolerant to multiple drugs including infliximab, were enrolled. Unselected PBSCs were
collected after mobilisation with CTX 1.5 g/m2 and G-CSF 10 mcg/kg. The conditioning
regimen included CTX 50 mg/kg on days -5 to -2 and rabbit ATG 2.5 mg/kg on days -4
to -2. Primary end point were toxicity and clinical remission (CDAI < 150) at 3 months.
Secondary end point were endoscopic response (SES-CD) at 3 months and modulation of
T reg (CD4/CD25/Foxp3) cells, a subset of lymphocyte with inhibitory actions, measured
at baseline, 3 and 6 months. Results: No improvement or slight worsening was observed
after mobilisation (median CDAI 335, range 258-404). At the third month, the primary
end-point was reached in all patients, with a median CDAI of 85 (range 56-102) despite
discontinuation of all medication, apart from antibiotics in two patients with perianal fistula.
Endoscopic scores improved in 3/4 patients. No unexpected serious adverse events were
observed, except for a new perianal abscess after mobilisation in one patient, idiopathic
pericarditis in another and hemorrhagic cistitis by Staph aureus in an other patient, all
quickly treated with conservative therapy. At 6 months CD4/CD25/Foxp3 cells were lesser
in the unique patient that didn't reach also endoscopic remission. Conclusion: Unselected
CD34+ cells transplantation is safe overall and can induce remission in previous refractory
patients. Interesting immunomodulatory effects are suggested. Further recruitment and long-
term results are ongoing.
S1147
Cannabis Use By Patients with Inflammatory Bowel Disease
Simon Lal, Manijeh Ryan, Sabrena Tangri, Mark S. Silverberg, Allan Gordon, A H.
Steinhart
Background: Medicinal use of cannabis has been reported in a number of conditions, such
as multiple sclerosis and chemotherapy-induced nausea: 8.9% of Canadian adults reported
using cannabis in the previous year, including 1.9% for ‘medicinal reasons'.1 Experimental
evidence suggests that the endogenous cannabinoid system may be protective against colonic
inflammation, leading to the possibility that activation of this system has a pathogenic or
even therapeutic role inflammatory bowel disease (IBD).2 There are,however,no data on the
use of cannabis by IBD patients. Methods: 100 patients with ulcerative colitis (UC;mean
age 33 (range 18-80); 66 female) and 191 patients with Crohn's disease (CD; mean age
33.5 (range 18-71);105 female) attending the outpatient clinic of Mount Sinai Hospital IBD
centre (Toronto) completed a questionnaire concerning current and previous cannabis use,
socio-economic factors, disease history, and medication use. Quality of life was assessed
using the short IBDQ.3 The study was approved by the Research Ethics Board of Mount
Sinai Hospital. Categorical data were compared using chi-squared, IBDQ scores are displayed
as mean +/- SEM and compared using ANOVA. Results: A comparable proportion of UC
and CD patients reported lifetime (48/95 (51%) UC vs. 91/189 (48%) CD) or current (11/
95 (12%) UC vs. 30/189 (16%) CD) use of cannabis. Of lifetime cannabis users, 14/43
(33%) UC and 40/80 (50%) CD patients had used it to relieve IBD-related symptoms (p=
0.06 UC vs. CD), including abdominal pain (13/14 (93%) UC vs. 38/40 (95%) CD), diarrhea
(9/14 (64%) UC vs. (9/40 (23%) CD) and reduced appetite (12/14 (86%) UC vs. 28/40
(70%) CD). Patients were more likely to use cannabis for symptom relief if they had a
history of abdominal surgery (29/48 (60%) vs. 24/74 (32%); p=0.002), chronic analgesic
use (29/41 (71%) vs. 25/81 (31%); p<0.001), alternative/complimentary medicine use (36/
66 (55%) vs. 18/56 (32%); p=0.01) and a lower IBDQ score (45.1+/-2.1 vs. 50.3+/-1.5; p=
0.03). Patients who had used cannabis (60/139 (43%)) were more likely than non-users
(13/133 (10%); p<0.001 vs. users) to express an interest in participating in a hypothetical
therapeutic trial of cannabis for IBD. Conclusions: Cannabis use is common amongst patients
with IBD, particularly amongst those with a history of abdominal surgery, chronic abdominal
pain and/or a low quality of life index. The therapeutic benefits of cannabinoid derivatives
in IBD may warrant explorat ion. 1. Ogborne AC, Smart RG, Adlaf EM. Cmaj
2000;162(12):1685-6. 2. Massa F, Storr M, Lutz B. J Mol Med 2005;83(12):944-54. 3.
Irvine EJ, Zhou Q, Thompson AK. Am J Gastroenterol 1996;91(8):1571-8.
S1148
The Dietary Management of Orofacial Granulomatosis / Oral Crohn'S
Carlo Nunes, Miranda C. Lomer, Michael Escudier, Pepe J. Shirlaw, Stephen J.
Challacombe, Jeremy D. Sanderson
Background: Orofacial granulomatosis (OFG) is a rare chronic inflammatory disease of
unknown aetiology that typically presents with lip swelling in young adulthood. Management
of OFG remains a challenge but recent evidence implicates dietary antigens, in particular
cinnamon and benzoate, as a possible trigger of the chronic inflammatory process. At our
institution dietary manipulation, in the form of a cinnamon and benzoate free diet (CB-
free), is used as a standard first line treatment. Failing a CB-free diet, a more formal dietary
approach with liquid enteral diet as a sole source of nutrition is offered. In this study we
review the impact of a dietary approach to OFG. Aim: A retrospective case note review to
determine the utilisation and efficacy of dietary manipulation in patients with OFG. Methods:
Patients attending a combined Oral Medicine/ Gastroenterology clinic with a diagnosis of
OFG confirmed by typical clinical and histological features were advised on a CB-free diet
(n=57) for 12 weeks. Following treatment with a CB-free diet those patients who required
further symptomatic control were assessed for suitability of liquid enteral diet (elemental
E028 or Modulen IBD) as a sole source of nutrition for 6 weeks followed by low fat, fibre
limited, exclusion (LOFFLEX) reintroduction regimen. A standardised oral disease chart was
used to objectively assess the oral features pre- and post all dietary treatments. Results: Data
was available on 57 patients who followed a CB-free diet. The median age was 22yrs and
29 patients were male. Improvement in oral activity scores were seen in 39/57 (68.4%)
patients following a CB-free diet after 12 weeks. Of the 57 patients, 15 patients with an
incomplete or absent response to the CB-free diet were assessed for liquid enteral nutrition.
Data was available for 12 of these patients. Three patients could not comply with the diet
within the first week and one had no response after six weeks of Modulen IBD. On an
intention to treat basis, 8/12 (66.7%) patients had improvement in their oral disease activity
scores, two were taking Modulen IBD and 6 were taking elemental E028. Conclusion: A
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dietary approach as management for patients with OFG is an effective form of treatment
and supports the view that the disease is driven by a dietary antigen(s). The disease typically
affects teenagers and young adults making dietary therapy particularly appropriate. In a
majority, this avoids the need to consider corticosteroids and immunosuppression.
S1149
Colonic Segmental Resection for Crohn's Disease: Clinical and Surgical
Recurrence Rates and Recurrence Risk Factors
Anne-carole Caldera, Philippe Seksik, Isabelle Nion-larmurier, Virginie Sebbagh, Laurent
Beaugerie, Jean-pierre Gendre, Emmanuel Tiret, Jacques Cosnes
Introduction: Although colonic segmental resection has been proposed for surgical treatment
of local complications of Crohn's disease (CD), extent of resection in Crohn's colitis is still
debated. The aims of the study were to determine clinical and surgical recurrence rates after
colonic segmental resection for CD and to identify recurrence risk factors. Patients and
methods: In a cohort of CD patients evaluated in a tertiary referral center, patients who
underwent colonic segmental resection for CD lesions between 1978 and 2005 were enrolled.
Patients with either ileo-colonic or rectal resection or length of colonic resection > 50 cm
were excluded. Patients were compared to a control group of patients who underwent total
or subtotal colectomy for CD, matched for age, gender and age at diagnosis of CD. Clinical
and surgical outcomes were collected and compared in the two groups and risk factors for
clinical and surgical recurrence were assessed using log rank test and multivariate Cox
analysis. Results: Sixty-six patients were included with a mean follow-up (+/- SD) of 9.7 +/-
6.3 years after colonic segmental resection. In this group, 48 patients (72.7%) had clinical
recurrence after a mean of 2.2 +/- 2.4 years and 30 patients (45.5%) underwent colonic re-
resection after a mean of 4.9 +/- 4.7 years since the colonic segmental resection. Clinical
recurrence rates were not different between CD patients with colonic segmental resection
and controls with 5-year and 10-year clinical recurrence rates of 68.5% and 86%, respectively,
in the colonic segmental resection group and 63.9% versus 84.9% respectively, in the control
group (NS). Five-year and 10-year surgical recurrence rates were also not different with
25.4% and 54.6% respectively, in the colonic segmental resection group versus 23.5% and
42.7% respectively, in the control group (NS). In multivariate analysis, stricturing disease
was associated with a higher clinical recurrence rate compared to fistulizing disease (OR=
2.3 ; 95% CI 1.4-2.5), and distal resection (below the splenic flexure) was associated with
a very increased risk of re-resection (OR=5.0 ; 95% CI 2.4-11.1). Conclusion: The best
results of colonic segmental resection for CD are observed in proximal fistulizing colonic
disease. Patients requiring colonic segmental resection below the splenic flexure have a
higher risk of clinical recurrence.
S1150
Further Experience with the Use of 6-Thioguanine As An Alternative
Immunosuppressant in Patients with Crohn's Disease
Tim Elliott, Azhar Ansari, Su yang Soon, Farina Fong, Bijay Baburajan, Anthony
Marinaki, Monica Arenas-hernandez, Jeremy Sanderson
INTRODUCTION: 6-Thioguanine (6-TG) has been used as an alternative thiopurine in
patients with Crohn's Disease (CD) resistant to, or intolerant of conventional immunosuppres-
sion, with evidence of good clinical efficacy. However, recent reports have questioned its
safety with respect to hepatotoxicity but experience remains limited. In this study we report
our experience of the safety and efficacy of 6-TG in a series of patients with Crohn's Disease.
AIMS & METHODS: A retrospective study of 29 patients with CD who had failed thiopurines
+/- methotrexate between 2001 and 2006 was performed. Indications for treatment with 6-
TG were active disease (n=15), ability to withdraw infliximab (n=8), steroid sparing (n=3)
and fistula closure (n=3). All patients underwent regular clinical review, liver function tests
(LFTs) and full blood counts (FBC). 20/29 patients underwent imaging of the liver and
those on treatment for longer than 1 year were advised to undergo liver biopsy. RESULTS:
The median dose of 6-TG used was 40mg daily (range 20-60mg). Median duration of 6-
TG treatment was 22 months (range 0 - 60 months). Initial clinical response was achieved
in 17/29 (59%). Of these, 12 (41%) remained in remission at a median of 44 months follow-
up. 6 of 29 (21%) patients discontinued 6-TG due to adverse effects [hepatotoxicity (n=3),
gastrointestinal upset (n=2), and rash (n=1)]. In total, 9/29 (31%) patients developed abnor-
mal LFT's during thioguanine therapy. These were mostly transient and mild (up to 2x
normal). One patient developed a sinusoidal syndrome with splenomegaly and pancytopenia
resolving on cessation of 6-TG. FBC's were normal in all other patients. MRI and US imaging
showed mild splenomegaly in one other patient. All other liver images were normal. Of 11
liver biopsies, none showed evidence of nodular regenerative hyperplasia. Positive findings
at liver biopsy were focal areas of thickened liver cell plates (but no fibrosis) (n=1), granuloma
(n=1), mild portal tract inflammation (n=2) and mild steatosis (n=6). CONCLUSION: 6-
TG is moderately well tolerated with acceptable clinical efficacy for third line immunosuppres-
sion in CD. Hepatotoxicity remains a concern and the occurrence of an acute sinusoidal
syndrome emphasises the need for vigilance. Mild LFT abnormalities are common and of
uncertain significance. However, reports of significant NRH as summarised by a recent
European 6-TG Working Party have not been substantiated by this well-studied UK cohort.
S1151
Mesalamine Use Is Protective Against Small Bowel Bacterial Overgrowth in
Patients with Crohn's Disease Who Have Undergone Ileocecal Resection
Joshua E. Stern, Andrew Rhim, Mical Campbell, Monina Pascua, Lalkrushna Malaviya,
Vinay Nair, Thomas Henry, Gary R. Lichtenstein
Background: Patients with Crohn's disease (CD), especially patients with a history of ileoco-
lonic resection, are predisposed to the development of small bowel bacterial overgrowth
(SBBO). Mesalamine has demonstrated antibacterial properties and could potentially protect
against SBBO. We retrospectively investigated whether use of mesalamine was associated
with decreased risk of SBBO in patients with CD. Methods: We included all patients with
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a history of CD and an ileocecal resection who had a lactulose breath test (LBT) between
March 2006 and November 2006 at the University of Pennsylvania Medical Center. LBT
was performed for evaluation of abdominal symptoms not believed to be due to active CD,
after performance of small bowel follow-through and/or colonoscopy. LBT was performed
in typical fashion with hydrogen levels recorded before and after lactulose administration.
Nonfermenters were excluded from analysis. Fisher's exact tests and logistic regression
analysis were used to evaluate the association between mesalamine use and a positive LBT.
Effects of potential confounders were considered using multivariate logistic regression Results:
34 patients underwent LBT. 9 (26%) were nonfermenters and were excluded from further
consideration. 16 (47%) had a positive LBT, and 9 (26%) had a negative LBT. Mean age
was 46.0 +/- 13.7 years and 39.8 +/- 8.5 years, respectively in patients with and without a
positive LBT (p=0.22). 9 (64%) and 4 (57%) patients in the positive and negative LBT
groups, respectively (p=1.00), had intestinal strictures. Of the 16 patients with SBBO, 1
(6%) was taking mesalamine, while 6 of the 9 (67%) patients without SBBO were taking
mesalamine, p<0.003, OR 0.03 (CI: 0.003-0.388). We did not find any confounding effects
from the following clinical variables: age, gender, smoking status, duration of disease, and
presence of active disease, intestinal strictures, diabetes mellitus, and hypertension, and
use of azathioprine, 6-mercaptopurine, infliximab, steroids, and proton pump inhibitors.
Conclusion: There is a high prevalence of SBBO in symptomatic CD patients who have
undergone ileocecal resection for evaluation of abdominal symptoms not believed to be due
to active CD. Our data suggest that administration of mesalamine may protect against SBBO.
Future, prospective studies should be undertaken to confirm our initial findings.
S1152
Do Statins Reduce Inflammatory Bowel Disease Exacerbations?
Kishore Maganty, Mei C. Huang
BACKGROUND: Statins are lipid-lowering and cardioprotective drugs that also have anti-
inflammatory and immunomodulator properties. Statins have been suggested to reduce
colonic inflammation in experimental animals and short term clinical trials in humans with
inflammatory bowel disease (IBD). AIM: The objective of the study is to evaluate the role
of statins in the maintenance of remission and in reducing exacerbations of IBD. METHODS:
All patients older than 18 years of age, who were diagnosed with Crohn's disease (CD) and
Ulceratve colitis (UC) and followed in the outpatient gastroenterology clinic in the last 3.6
years, were included. Patients with diagnoses of indeterminate and non-IBD colitis were
excluded. Clinical characteristics of the severity and extent of the disease were reviewed.
Flare-up was defined as exacerbation of disease resulting in hospitalization or outpatient
initiation or an increase in the systemic steroid dosage. Hazard ratio of IBD flare-ups was
compared between patients not on statins and those on statins for lipid-lowering benefits.
RESULTS: A total of 238 charts were retrieved. 175 patients met the inclusion criteria. The
selected population was predominantly female (60.5%) and white (97%). The mean age
was 49.2. More patients had CD (56%) than UC (44%). A total of 20 statin users were
identified and were matched individually with 20 controls. The average number of flares
per patient in the last 3.6 years in the statin group was 0.55 compared with 0.95 in the
control group (Hazard ratio: - 0.57 and p = 0.0085). Subgroup analysis revealed that the
mean number of flares in CD patients was 0.87 in the non-statin users and 0.42 in the
statin group. Similar data was seen in the UC groups. The mean number of flare-ups was
1.0 in the non-statin group and 0.61 in the statin group of UC patients. Escalation of the
treatment during a flare (surgery and/or Infliximab) was required in 3 of the 20 patients in
the statins group versus 1 of the 20 patients in the control group. CONCLUSION: Statins
show beneficial effects on decreasing the number of flare-ups and thus maintaining disease
remission in our retrospective study. Our study confirmed the previous clinical trial of short
term benefits of statins in maintenance of IBD remission. Large-scale prospective clinical
studies should substantiate the results.
S1153
Ciclosporin Enemas in Refractory Distal Colitis
Yogananda Reddy, Navneet K. Ahluwalia
BACKGROUND: Distal colitis refractory to standard therapy is a complex problem but the
optimum management remains unclear. Treatment options have been limited to topical or
oral corticosteroids, 5-aminosalicylates and oral immunomodulator therapy. Uncontrolled
studies suggest that ciclosporin administered as enema may be of benefit in distal and left
sided colitis and is safer than intravenous or oral administration. The side effects reported
in the literature are negligible and blood ciclosporin levels are very low. OBJECTIVES: The
aim of this study was to evaluate the efficacy of ciclosporin enemas in patients with proctitis,
distal and left sided colitis where the conventional medical treatment has failed to control
the symptoms. Patients were made aware of the unlicensed indication of the ciclosporin
enemas. Response was monitored by improvement in the symptoms of diarrhoea, bleeding
and general well being. PATIENTS / METHODS: 19 patients treated with ciclosporin enemas
of whom 10 had distal colitis, four patients with left sided colitis and four had proctitis
whilst one patient initially diagnosed as distal colitis subsequently turned out to have pan
colitis. All patients underwent flexible sigmoidoscopy and had objective evidence of active
disease prior to treatment with ciclosporin. The average duration of the diagnosed disease
was 6.74 years (range1-22). The mean age of the patients was 40.4 years (range 20-73) and
13 out of 19 were females. The dose of ciclosporin used was 250 mg once daily at night
for 2-4 months as an induction regimen. Patients continued on their oral 5-ASA and
immunomodulators whilst on ciclosporin enema treatment. RESULTS: 9 patients are in
complete remission after the induction regimen, 4 patients had relapse of their symptoms
after the induction regimen and currently in remission following the maintenance therapy
of 250 mg on alternate days, 3 patients failed to improve of which one had extensive disease
than previously diagnosed, two patients discontinued treatment and one patient died of end
stage chronic obstructive airway disease. The average duration of treatment with ciclosporin
enemas was 7.4 months (range 1-36 months). One patient experienced headache, two had
difficulty in retaining the enema and one patient felt generally unwell. Majority of patients
reported subjective improvement in their bowel symptoms within 4 weeks of ciclosporin
enema. CONCLUSIONS: Two third of our patients responded to the ciclosporin enemas
when the conventional treatment failed to control their symptoms. Ciclosporin enemas are
safe and are useful in the treatment of refractory distal or left sided colitis.
S1154
Patients with Colonic IBD Exhibit High Serum Bile Acid Concentrations: A
Comprehensive Study Using Tandem Mass Spectrometry
Philippe Seksik, Dominique Rainteau, Claude Wolf, Harry Sokol, Lydie Humbert,
Germain Trugnan, Olivier Chazouilleres, Jacques Cosnes, Laurent Beaugerie, Raoul
Poupon
Background & Aims: Chronic inflammation of intestinal mucosa and increased concentration
in fecal bile acids are involved in carcinogenesis of inflammatory bowel diseases (IBD)-
associated colon cancer. Bile acids (BAs) biosynthesis and enterohepatic transport depends
on various factors, including gut microflora composition, ileal BA transporters, unconjugated
BAs colonic facilitated transport, bacterial conversion to 7-dehydroxylated (secondary)
unconjugated BAs, bacteria and activity of nuclear receptors. However, little is known about
enterohepatic circulation of BAs in IBD. The aim of our study was to seek quantitative and
qualitative abnormalities in serum BAs in colonic IBD patients. In order not to interfere
with altered BAs absorption by injured mucosa in ileal Crohn's disease (CD), we focused
our study on pure colonic CD and ulcerative colitis (UC). Methods: Fasting blood samples
from 27 active colonic IBD patients (10 CD, 8 distal UC, 9 extensive UC), with no hepatic
or biliary abnormalities, and 36 healthy controls were collected. Tandem mass spectrometry
coupled with HPLC analysis was achieved to characterize in serum 40 different BAs and
by-derivatives. Addition to serum of calibrated internal standard allowed quantification for
27 Bas. Ratio to total BAs level of the different subtypes of BAs was used to assess BAs relative
proportions. Results: In IBD patients, absolute total, primary, secondary and conjugated BAs
levels were higher than in controls (total BAs 7.5 µM vs 2.2 µM, p<0.001). BAs proportions
showed no difference for primary, secondary or unconjugated BAs, however an increase in
tauro-, and sulfo-conjugated BAs proportions were observed in IBD patients. The increase
in total BAs levels was superior in CD than in UC (9.0 µM vs 6.7 µM, p=0.04). The same
was true for the increase in primary BAs proportion (0.58 in CD vs 0.43 in UC, p=0.04).
Extensive involvement of the colon, both in CD and UC, was associated with higher levels
of cholate acid (1.4 vs 0.9 µM, p=0.02), higher primary BAs proportions, and lower secondary
BAs, lithocholate acid and sulfo-conjugated proportions than in distal diseases. Conclusion:
In this exploratory study, we report an increase in serum BAs levels, mostly of primary BAs,
in IBD patients with pure colonic disease, particularly in patients with extensive colonic
diseases. Whether these changes result from inflammation-induced cholestasis or altered
bacterial microflora should be investigated.
S1155
Tolerability of 6-Mercaptopurine in Azathioprine Intolerant Patients with
Inflammatory Bowel Disease
Charlie Lees, Ajeet Maan, Bhakti Hansoti, Ian D. Penman, Alan G. Shand, Kelvin R.
Palmer, Ian D. Arnott, Jack Satsangi
Introduction. Azathioprine (AZA) and 6-mercaptopurine (6-MP) are both effective immunos-
uppressive agents for the induction and maintenance of remission in both Crohn's disease
(CD) and ulcerative colitis (UC). At present, AZA therapy is prescribed in preference in
Europe, whilst 6-MP is favoured as first-line therapy in N America. Azathioprine intolerance
(AZAINTOL) is a common clinical problem, requiring drug withdrawal in up to 30% of
patients. The subsequent use of 6-MP in these patients is described, but data to support
this are lacking. Aims. The aim of this study was to assess the tolerability of 6-MP therapy
in IBD patients previously intolerant of AZA, and determine factors that predict tolerability.
Methods. 61 AZAINTOL patients who were subsequently treated with 6-MP at a single tertiary
referral centre for IBD between 1993 and 2005 were identified. Data were extracted by
retrospective case-note review. Phenotypes were analysed by the Montreal classification. The
median age at diagnosis was 34.9 years (IQR 24.7-46.8). There were equal numbers of each
sex (male 31/61, 50.8%), and disease type (CD 31/61, 50.8%; UC 30/61, 49.2%). The
median duration of 6-MP treatment was 733 days (IQR 328-1127) in AZAINTOL6-MPTOL,
and 54 days (IQR 13.5-105) in AZAINTOL6-MPINTOL patients. Results. 6-MP was tolerated
by 59% (36/61) of AZAINTOL patients overall, 60.7% (17/28) in patients in whom nausea
and vomiting was the primary reason for AZA withdrawal, 61.1% (11/18) for flu-like illness,
33.3% (3/9) with hepatotoxicity, 100% (1/1) with neutropenia, 100% (3/3) with rash and
0% (0/1) with pancreatitis. It was noteworthy that the primary intolerance of 6-MP was
frequently different to that for AZA. The median age at diagnosis was significantly younger
in the AZAINTOL6-MPINTOL group (28.4; IQR 22.5-38.1) compared with AZAINTOL6-MPTOL
(37.0; IQR 27.8-56.5; p=0.014). 6-MP was tolerated more frequently in males (22/31;
71.0%) than in females (14/30; 46.7%; p=0.048, OR=2.79, C.I.=0.97-8.04). The maximum
AZA dose in the two groups was equivalent (AZAINTOL6-MPTOL 1.48mg/kg vs. AZAINTOL6-
MPINTOL 1.39 mg/kg, p=0.80), as was the median duration of AZA treatment (50.0 days
(IQR 24.0-157.0) vs. 76.0 days (IQR 26.5-197.0), p=0.93). 6-MP tolerance was not affected
by diagnosis, disease location, disease behaviour, surgery, smoking status, family history,
extra-intestinal manifestations, or TPMT activity. Conclusions. 6-MP should be considered
in AZAINTOL patients, particularly those in whom nausea and vomiting, flu-like illness or
rash was the major reason for AZA withdrawal.
S1156
6-Thioguanine Therapy in Crohn's Disease - A Swedish Experience
Sven H. Almer, Henrik Hjortswang, Curt Peterson, Ulf Hindorf
Aims: To evaluate the tolerance to 6-thioguanine (6-TG) in patients with Crohn's disease
(CD) and prior intolerance or resistance to azathioprine (AZA) and/or 6-mercaptopurine (6-
MP). Methods: 23 CD patients (13 men, median age 41 (19-65) years) treated with 6-TG
at a single center due to prior intolerance (n=18) or resistance (n=5) to the thiopurine drugs
AZA and/or 6-MP were prospectively followed. Adverse events (AE) and clinical efficacy
A-185 AGA Abstracts
were recorded. TPMT activity and thioguanine nucleotide (TGN) metabolites were measured.
Results are expressed as median (range). Results: The patients were treated with 40 (20-
60) mg 6-TG for 259 (15-1428) days. All had normal TPMT activity (9.9-19.1 U/ml RBC),
except one (6.6 U/ml RBC). Sixteen patients (70%) experienced AE that lead to discontinu-
ation (n=10) after 85 (15-451) days or dose reduction (n=6) after 78 (10-853) days. AE
were pain (n=5), GI-intolerance (n=4), hepatotoxicity (n=2) and other (n=5). Ten of 18
patients (56%) with prior thiopurine intolerance (AZA n=10; AZA and 6-MP n=8) discon-
tinued 6-TG treatment due to AE as compared to none of the 5 patients with AZA/6-MP
resistance (p=0.046). Of the 13 patients that tolerated 6-TG, eight discontinued treatment
due to therapeutic failure (n=5) or safety concerns (n=3). There was no difference in maximum
TGN levels between patients with AE leading to discontinuation/dose reduction when com-
pared to patients without AE, 652 (99-2488) vs. 551 (392-1574) pmol/8x10^8 RBC; p=
0.80. Nor was there a difference in maximum TGN levels between patients with therapeutic
failure (n=5) and patients that benefited from treatment (n=5), 645 (551-1852) vs. 1155
(466-2488); p=0.73. The three patients that stopped medication due to safety concerns had
maximum TGN levels of 392, 983 and 1574 pmol/8x10^8 RBC, respectively. Conclusions:
In this cohort, a modest fraction (22%) of CD patients with traditional thiopurine failure
had longterm benefit of 6-TG-treatment. Patients with prior intolerance to AZA and 6-MP
were more likely to discontinue 6-TG treatment due to AE than patients tolerant to these
drugs. 6-TG therapy seems to offer no evident benefit for these intolerant patients and other
treatment options should be considered.
S1157
Longterm Methotrexate Maintenance Immunomodulator Therapy in Ulcerative
Colitis
Amar Naik, Lydia R. Weber, Joshua F. Knox, Jeanne Emmons, Susan Skaros, Mazen Issa,
David G. Binion
Background: Longterm immunosuppressive therapy with methotrexate (MTX) is efficacious
in chronic inflammatory diseases including rheumatoid arthritis, psoriasis, and Crohn's
Disease. There is limited data regarding MTX use in ulcerative colitis (UC). We characterized
the longterm efficacy of MTX in UC pts focusing on safety, hospitalizations, and colectomy
in a routine clinical setting. Methods: This was a retrospective observational study of UC
pts treated at an IBD center between 1998-2006. Pt demographics, history of drug intolerance,
MTX dose, duration, adverse reactions, and reasons for cessation of MTX therapy were
recorded. Outcome variables included quality of life, hospitalization, and colectomy. Pts
were divided between those on > 6 months of therapy and those on < 6 months of MTX
prior to discontinuing. Results: Among 325 UC pts (49% male, 51% female), there were
54 pts who were treated with MTX (46% male, 54% female). Mean age of the pts was 45
± 14.6y and mean disease duration was 9 ± 6.5y. Active tobacco use was identified in 7%.
Drug intolerance to purine analogs was 84%, and 10% were steroid dependent prior to
initiation of MTX. Among 54 pts who were initiated on MTX, 57% (n=31) remained on
therapy for >6 months. Average oral dose was 15±6 mg/week and average sq dose was 18±8
mg/week. 84% benefited from long-term maintenance therapy (>6mo; range 6-73 months).
There were 7 hospitalizations and 5 colectomies in this group (1 dysplasia, 4 refractory
colitis; 10%). In MTX pts treated for <6 months prior to discontinuation (n=23), there were
4 hospitalizations and 11 colectomies (11 refractory colitis; 48%; p<0.001). Avg duration
of therapy was 2±1.2 months prior to MTX discontinuation/colectomy. Infliximab use was
42% in pts on MTX >6 months and 57% in pts <6 months. Among UC pts treated for >6
months, MTX monotherapy was used in 65%, while the remaining 35% required combination
treatment with maintenance infliximab. There were 16 adverse reactions among both groups,
which led to cessation of therapy (1-MTX pneumonitis, 5-infections (4-C. difficile, 1-pneumo-
nia), 1-rash, 8-nausea, 1-dizziness). Among patients on longterm therapy, 2 discontinued
drug transiently due to desired pregnancy. Conclusion: Longterm immunomodulator therapy
with MTX was effective in a subset of moderate to severe UC pts, with monotherapy benefiting
22% at one year of treatment and combination therapy with infliximab benefiting an addi-
tional 26%. UC MTX non-responders either underwent colectomy or discontinued treatment
after 2 months on average, suggesting a short-term trial in refractory UC pts is warranted.
S1158
Predictors of Long Term Response to Infliximab Beyond the First Year
Alla Grigorian, Houssam E. Mardini, Lisbeth A. Selby, Razvan I. Arsenescu, Trevor A.
Winter, Willem J. De villiers
BACKGROUND: Infliximab is effective in maintaining remission in patients with Crohn's
disease (CD). Current evidence is available mainly for the first year of therapy. Little is known
about maintenance therapy efficacy and its predictors beyond the first year. METHODS:
Demographic, disease characteristics (age at onset; location and behavior), concomitant
therapy, and surgeries were recorded on all CD pts who have been on infliximab maintenance
therapy for more than one year. Failure was defined as recurrent / active disease despite
maximizing dose and intervals. Active disease was defined as symptomatic disease requiring
systemic steroids and / or resective surgery. Multivariate survival analysis was used to identify
factors that independently affected long term response. RESULTS: 33 pts (17F and 16M)
were identified. Median age was 27 yrs and median disease duration 6 yrs (range <1-14).
26 pts (79%) were on concomitant immunomodulators and 14 (42%) were current smokers.
15 had inflammatory, 14 had perforating and 4 had stricturing phenotypes and 12 had
perianal disease. Infliximab was initiated within the first 2 yrs of dx in 17 (52%). Smoking
(median time to failure was 32 mos among non-smokers compared to 20 mos among
smokers; hazard ratio [HR] 0.57; p=0.03) and earlier initiation of infliximab after diagnosis
(p=0.01) were the only independent predictors of longer response. The median time to
failure was 37 mos among pts with earlier infliximab initiation (within the first 2 yrs of dx)
compared to 25 mos among pts with later initiation (HR 0.49; p=0.02). Immunomodulator
use was associated with a trend towards longer time to failure (p=0.08) CONCLUSIONS:
Earlier initiation of infliximab maintenance therapy after diagnosis of Crohn's disease is
associated with a significant longer response while smoking is associated with a shorter
duration of response.
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S1159
Infliximab in Crohn's Disease: Step-Up Or Top-Down?
Garret Cullen, Denise Keegan, John M. Hyland, Diarmuid P. O'donoghue
Aims: High rates of corticosteroid dependency and low remission rates are quoted as justifica-
tion for early introduction of biological agents (top-down treatment) in moderate to severe
Crohn's disease (CD). Concerns regarding corticosteroid dependency are heightened by data
from the Crohn's Therapy Resource Evaluation and Assessment Tool (TREAT) registry. The
aims of this report were to review outcomes and corticosteroid dependency rates in a group
of moderate/severe CD patients treated with a standard (step-up) regimen and assess the
potential benefit a top-down strategy. Methods: One hundred and three consecutive patients
newly diagnosed with CD in 2000-2002 were identified from a prospectively maintained
database. Severity of disease at presentation was scored using the Harvey-Bradshaw Index
(HBI). Disease was classified using the Montreal classification. Results: Seventy-two patients
had moderate/severe CD at diagnosis (HBI > 8). Fifty-four had non-stricturing, non-penetrat-
ing disease (B1). Sixty-four (89%) received corticosteroids while 44 (61%) were treated with
immunomodulatory agents. Twenty-one patients received infliximab (median time from
diagnosis to treatment: 1.3 years), 8 of whom remain in remission. Fifty-one patients did
not receive infliximab, 11 of whom underwent surgery for stricturing disease or internal
fistulae. Thirty-nine of the remaining 40 patients are in remission without receiving infliximab
(1 unrelated death). Fifteen have had resection surgery - 10 for limited ileocaecal disease
Four patients were identified who may well have benefited from top-down treatment. Three
had B1 colonic disease one of whom progressed to B3 behaviour. The fourth had B1 small
bowel disease. All had surgery. At a median follow up of 5 years, 66 of 72 (92%) patients
with moderate/severe CD are in remission (median HBI: 1). Thirty-four (47%) are on
immunomodulatory agents. One patient is on low-dose corticosteroids. Conclusions: The
judicious use of corticosteroids, immunomodulators and surgery for limited disease resulted
in high remission rates and low morbidity at 5 years in our study. Until markers of disease
progression can be identified at diagnosis, it is difficult to justify the early use of biologic
agents in all patients with moderate/severe CD.
S1160
Open-Label Infliximab Therapy in Ulcerative Colitis: A Multicenter Survey of
Results and Predictors of Response
Yago Gonzalez-lama, I. Fernandez-blanco, A. Lopez-sanroman, C. Taxonera, B. Casis, S.
Tabernero, F. Bermejo, F. Martinez-silva, J. L. Mendoza, P. Martinez-montiel, F. Sanchez, J.
A. Carneros, J. Mate, Javier P. Gisbert, Inflammatory bowel diseases from madrid On
behalf of the group for the study of
AIM: Results of randomized controlled trials showing efficacy of infliximab in ulcerative
colitis (UC) must be confirmed in clinical practice. Our aim was to evaluate the efficacy
and safety of infliximab in UC patients of the Madrid area, looking for clinical predictors
of response. METHODS: Multicenter retrospective survey of all UC patients treated with
infliximab in Madrid (Spain) followed up for at least 2 weeks. RESULTS: 47 UC patients
were included (45% males, mean age 44±15 years), with a mean follow up of 4.7 months
(range 0.5-21), and a total number of 211 infliximab infusions. Infliximab was prescribed
for steroid-resistance in 34% of the patients, and for steroid-dependence in 66%. Response
and remission rates were, respectively, 97% and 42% at the 2nd week, 93% and 69% at
the 6th week, and 80% and 65% at the long-term follow up (mean 8.2 months, range 3.5-
21). Overall, 85% of the patients were considered to achieve a favourable outcome, and
15% did not respond or lose the response. Age, gender, disease duration, indication for
infliximab (steroid-resistance/dependence), disease severity, C-reactive protein, concomitant
thiopurinic therapy, or smoking habit, did not influence on efficacy. Extent of the disease
was the only predictive factor: patients with pancolitis had better response than those with
left sided colitis (p=0.02). Adverse events were reported in only 4 cases (8.5%), all of them
mild. CONCLUSION: Infliximab is safe and effective for UC. Short and long term response
rates of this large multicenter study are better than those reported in randomized controlled
trials. Extent of the disease was the only predictive factor for clinical response.
S1161
Hyperhomocysteinemia Is a Risk Factor of Stenosis in Crohn's Disease
Patients
Philippe Bichard, Jean marc Phelip, Joanna Pokelski, Xavier Roblin
No data report any association between Crohn's disease (CD) and hyperhomocysteinemia
but all the studies are transversal and can't conclude about a link. In Vitro, hyperhomocysteine-
mia is associate with an overexpression of procollagen alpha and TIMP-1 increasing the risk
of fibrosis (1). Aim of the study : appreciate if hyperhomocysteinemia is associated with an
increase risk of stenosis in CD. Patients and methods : Patients with CD without stenosis
at time of inclusion are included prospectively. All the patients had a follow-up of at least
two years. At the inclusion, all patients had blood samples including: ANCA, ASCA, Vitamin
B12, folate and plasmatic homocysteinemia levels. Results : 67 patients (mean age : 41.4
+/- 7.6 years, sex ratio M/F 0.9) were included. 32 patients have pancolitis, 25 ileocolitis
and 10 ileitis CD. The mean follow-up was 2.9 years. We observed a stenosis in 28 patients
during the follow up. Fifteen patients had a surgical resection and five a treatment by
dilatation. In univariate analysis, the associated factors with stenosis were: an ileal localisation
(p: 0.01), hyperhomocysteinemia (p:0.03), the presence of ASCA (p:0.04) and a duration
of disease up to 5 years (p:0.05). After logistic regression, only two independent factors
were associated with stenosis : ileitis OR : 12.5 : 95%CI : 2-250 ; p :0,001 ; hyperhomocystei-
nemia OR : 9,7 ; 95%CI : 1.7-125 : p : 0,03). In the subgroup of 36 patients presenting
at inclusion an hyperhomocysteinemia, 15 patients have been treated with folate. During
the follow-up, the frequency of stenosis was equal in the two groups. Conclusion : Hyperhom-
ocysteinemia is associated with a increase risk of stenosis in Crohn's disease during the
follow-up. In our study, folate treatment doesn't decrease this risk factor. 1- Garcia-Tevijano
ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martin-Duce A, Caballeria J, Mato JM,
A-186AGA Abstracts
Avila MA Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and
hepatic fibrosis. Hypertension. 2001;38:1217-21.
S1162
Expression Profiling of Monocytes After Granulocyte and Monocyte
Adsorption Apheresis in Patients with Ulcerative Colitis
Hermann Schulze, Dirk Koczan, änne Glass, Gisela Sparmann, Robert Jaster, Stefan Liebe,
Wolfgang Ramlow, Jörg Emmrich
Background and aims: The efficiency of granulocyte and monocyte adsorption apheresis
(GMCAP, Adacolumn®, Otsuka Pharmaceuticals Co., Japan) in the treatment of ulcerative
colitis has been successfully demonstrated by previously published studies. The aim of this
study was the analysis of the expression profile in peripheral blood monocytes before and
after GMCAP therapy. Methods: Monocytes were isolated from 40 ml of peripheral blood
using MACS® depletion (Miltenyi Biotec, USA) before and one week after the treatment
cycle (weekly apheresis over 5 weeks). After 8 hours of cultivation monocytes were lysed
and the RNA was isolated using standard procedures. RNA from 5 patients with active UC
(CAI 6-10) successfully treated with GMCAP (CAI ≤6) were used for gene expression
profiling with an Affymetrix® microarray system (GeneChip Human Genome U133 Plus
2.0 Array). Gene expression changes of a subset of genes were verified by real time PCR
(ABI 7000 Real Time PCR System®, Applied Biosystems, USA) in 10 patients responding
to GMCAP therapy with reduction of CAI. Results: 261 transcripts were identified to be
differentially expressed in response to GMCAP. Expression changes ranged from 5.14-fold
decrease to 6.21-fold increase (159 weaker/102 stronger expressed). The attributed molecular
function of differentially expressed transcripts included elements of the immune response
e.g. chemokine (C-C motif) receptor 5 (CCR5), chemokine (C-C motif) receptor 7 (CCR7),
allograft inflammatory factor 1 (AIF1), signal transduction (e.g. STAT1) and cell motility
and adhesion (e.g. selectin L (lymphocyte adhesion molecule 1)). Conclusion: GMCAP
induces gene expression changes in peripheral blood monocytes. The observed changes
of gene expression patterns affected important elements of the immune response, signal
transduction, and cell adhesion. These results may improve the understanding of the complex
mechanisms of GMCAP therapy in UC.
S1163
A Randomized, Multi-Center, Placebo-Controlled Trial of Polyethylene Glycol
Laxative for Chronic Treatment of Chronic Constipation
Jack A. Di palma, Mark V. Cleveland, John Mcgowan, Jorge L. Herrera
OBJECTIVES: Polyethylene glycol(PEG)3350is currently approved for the short-term treat-
ment of occasional constipation. This study was designed to compare the safety and efficacy
of PEG laxative versus placebo over a 6 month treatment period in patients with chronic
constipation. METHODS: Study subjects who met defined criteria for chronic constipation
were randomized in this double-blind, placebo-controlled, parallel, multi-center study to
receive PEG laxative as a single daily dose of 17g or placebo for 6 months. Baseline constipa-
tion status was confirmed during a 14 day observation period. As a primary efficacy variable,
treatment success was defined as relief of modified ROME criteria for constipation for 50%
or more of their treatment weeks. Various secondary measures were assessed. An Interactive
Voice Response System (IVRS) recorded daily bowel movement experience and study efficacy
and safety information. Laboratory testing at baseline and monthly for the study duration
was analyzed for hematology, blood chemistry including amylase, GGT, uric acid, lipids,
and urinalysis. RESULTS: 304 patients were enrolled and received treatment at one of 50
centers. Successful treatment according to the primary efficacy variable was seen in 52.0%
of PEG and 11% of placebo subjects (p<0.001). Similar efficacy was seen in a subgroup of 75
elderly subjects. According to the primary efficacy definition (based on individual treatment
weeks), 61% of PEG treatment weeks versus 22% of the placebo weeks were successful
(p<0.001). There were no significant differences in laboratory findings or adverse events
except for the gastrointestinal category where diarrhea, flatulence and nausea were the most
frequent with PEG although they were not individually statistically significant compared to
placebo. Similar results were observed when analyzed for differences due to gender, race,
or age. CONCLUSIONS: PEG laxative is safe and effective for use in patients with chronic
constipation for 6 months.
S1164
A Randomized, Multi-Center Comparison of Polyethylene Glycol Laxative and
Tegaserod in Treatment of Patients with Chronic Constipation
Jack A. Di palma, Mark V. Cleveland, John Mcgowan, Jorge L. Herrera
OBJECTIVES: Polyethylene glycol (PEG) 3350 and tegaserod, a serotonin subtype 4 receptor
partial agonist are currently approved for treatment of constipation. This study was designed
to compare the safety and efficacy of each product over a 4 week treatment period. METHODS:
Study subjects who met defined criteria for chronic constipation were randomized in this
open-labeled, parallel, multi-center study to receive the PEG laxative as a single daily dose
of 17g or tegaserod tablets 6mg BID, for 28 days. As a primary variable, treatment success
was defined for each patient as relief of modified ROME criteria for constipation for 50%
or more of their treatment weeks. Various secondary measures were also assessed. An
Interactive Voice Response System (IVRS) recorded daily bowel movement experience and
study efficacy and safety information. RESULTS: 237 patients were enrolled and received
treatment at one of 25 centers. Successful treatment according to the primary variable was
seen in 50.0% of the PEG and 30.8% of tegaserod subjects (p=0.003). The PEG subjects
also had more bowel movements per week (p=0.019), more weeks with no ROME symptoms
(“super efficacy”), and less lumpy/hard stools (p=0.001). Tegaserod subjects experienced
more severe cramping (p=0.048) and straining at stool (p=0.013). Tegaserod patients experi-
enced a significantly higher incidence of headaches. Otherwise, there were no significant
differences in adverse events. CONCLUSIONS: While PEG laxative and tegaserod are safe
for their intended use in chronic constipation, PEG had superior efficacy, less headache and
cramps, and superior ratings for stool consistency.
S1165
Rifaximin Versus Systemic Antibiotics for the Treatment of Small Bowel
Bacterial Overgrowth
Maurizio Gabrielli, Cristiano ernesto Lauritano, Emidio Scarpellini, Andrea Lupascu,
Davide Roccarina, Lucia Sparano, Carlo Petruzzellis, Maria elena Ainora, Giovanni
Cammarota, Giovanni Gasbarrini, Antonio Gasbarrini
Objectives: Few controlled studies concerning choice and duration of antibiotic therapy for
small intestinal bacterial overgrowth (SIBO) are available. Aim of the present study was to
investigate the efficacy, safety and tolerability of rifaximin with respect to two different
systemic antibiotics (metronidazole and levofloxacin) for SIBO decontamination. Methods:
We enrolled 120 consecutive SIBO patients. Diagnosis of SIBO based on clinical history
and positivity to glucose breath test (GBT). All patients were randomised in 3 seven-
days treatment groups: rifaximin 1200 mg (R group); metronidazole 750 mg (M group),
levofloxacin 500 mg (L group). Glucose breath test was reassessed 1 month after. Compliance
to the treatment and incidence of adverse events were also evaluated. Results: No significant
differences were observed in the GBT normalization rate among the three groups in both
intention-to-treat and per protocol analysis, although a trend toward an higher decontamina-
tion rate was observed in the rifaximin and levofloxacin groups with respect to metronidazole
one (R group: 62.5% in ITT and PP analysis; L group: 60% in ITT and 63% in PP analysis;
M group: 45% in ITT and 49% in PP analysis). On the other hand, the overall prevalence
of adverse events was significantly lower in the rifaximin group with respect to the other 2
groups. Conclusions: Rifaximin shows a similar efficacy compared to systemic antibiotics
both with a significant gain in terms of tolerability. Since SIBO often require life-long
management and recurrent treatment courses, rifaximin could represent the best choice for
SIBO decontamination.
S1166
Proton Pump Inhibitor Therapy: A Major Independent Risk Factor for the
Development of Clostridium difficile-Associated Disease
Sam Yoselevitz, Vivek Kumar, Sudhir K. Dutta
Background & Aims: Clostridium difficile accounts for approximately 3,000,000 cases of
diarrhea and colitis each year (Clostridium difficile-associated disease or CDAD). The preval-
ence of CDAD seems to be rising and the causative organism is becoming increasingly
refractory to standard antibiotic therapy. Major risk factors for the development of CDAD
have traditionally included: antibiotic therapy, increasing age, and hospitalization. More
recently, marked inhibition of gastric acid secretion has been implicated as an important
factor in the development of CDAD. We postulated that proton pump inhibitors (PPI's)
may constitute a major independent risk factor in the development of CDAD in hospitalized
patients. Methods: To examine this issue further, we conducted an IRB-approved retrospect-
ive study of hospitalized patients in an inner-city tertiary-care hospital. We identified 410
patients with Clostridium difficile toxin assay positivity and clinical signs of disease (ICD-9
code 008.45) admitted to the hospital between Jan 2000 and Dec 2005, of which 300 were
available for final analysis after application of exclusion criteria. Patients without evidence
of CDAD who were admitted during the same time period (n=720) were identified as
controls. 500 of these patients were utilized in the final analysis after application of exclusion
criteria. The study population was then grouped according to the following criteria: Proton
pump inhibitor (PPI) use alone, antibiotic use alone, H-2 antagonists alone, and the various
combinations of the above. Also recorded were co-variables, such as age, gender, ethnicity,
length of hospital stay and presence of other co-morbidities. Data was recorded using
Microsoft Office Access 2003 and analyzed for significance of difference among the various
groups using SPSS version 12.0.1. Results: Of the CDAD-positive cases (300), 92 patients
(30.7%) had disease associated with the use of antibiotics alone, 71 patients (23.7%) with
the use of PPIs alone, and 113 patients (37.7%) with the combination of antibiotics and
PPIs. The percentage of patients on PPI therapy was found to be far greater in the CDAD
population as compared to the control group (23.7% vs. 8.8% respectively). Furthermore,
the use of PPIs for at least 7 days was associated with a greater than 3-fold likelihood of
developing CDAD with an OR of 3.21 (95% CI 2.13-4.83). We also observed a statistically
significant increase in CDAD (p<0.05) among females and Caucasians in this study popula-
tion. Conclusion: These observations suggest that PPI therapy may constitute a major
independent risk factor for the development of CDAD in hospitalized patients.
S1167
Prevention of Clostridium difficile (C. difficile) Diarrhea with Probiotic in
Hospitalized Patients Treated with Antibiotics
Rehan Rafiq, Damodar Pandey, Safa Mahgoub osman, Raja Masood, Indira Donepudi,
Edward Norkus, Nejat Kiyici, Hilary I. Hertan
Purpose: C. difficile diarrhea is a common health problem justifying treatment efforts to
reduce its occurrence. Because of the relatively poor response to current therapy, additional
approaches for prevention and/or treatment are warranted. There is no support for primary
prophylaxis for C. difficile infection, but Saccharomyces boulardii can be used to decrease
recurrences. (Surawicz et al, Clin Infect Dis. 2000; 31:1012-1017).The aim of this study
was to determine the efficacy of probiotic (Lactobacillus acidophilus 80%, Lactobacillus
bulgaricus 10%, Bifidobacterium Biffidum 5%, S. Thermophilus 5%) to prevent C. difficile
diarrhea in hospitalized patients who were receiving antibiotics. Methods: 100 in-patients,
receiving oral or intravenous antibiotics, were enrolled in a prospective randomized trial
with two groups; A control group and a treatment group, with similar age and sex distribution.
The treatment group was started on daily probiotic therapy (Lactobacillus 500mg- 2 caplets
tid) from the start of antibiotic therapy until hospital discharge. Data were collected on age,
sex, class of antibiotic used, CBC, CMP, and proton pump inhibitor (PPI) use. Patients
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were monitored for fever, leukocytosis, development of diarrhea, abdominal distension,
constipation and abdominal pain. Stool specimens from patients with these symptoms were
sent for C. difficile toxin assay. Student t-tests and chi-square analysis compared differences
in means or proportions between both groups. Additional logistic regression analyses tested
for risk factors related to C. difficile infection. Results: We observed that 22/55 patients
without probiotic and 5/45 patients with probiotic developed C. difficile diarrhea (P=.001).
Regardless of treatment, it occurred more frequently in older patients (71 ± 17(sd) yrs vs.
59 ± 19 yrs; P=.0062). Occurrence was higher among patients using PPI(45% of PPI users
vs. 15% of PPI non-users; P=.001). Both admission Hematocrit and albumin were significantly
lower in C. difficile patients; P=.0341 & P=.0010, respectively). Logistic regression analysis
further determined 83% decreased risk with probiotic use (P=.012), plus an independent
5% increased risks for every 1-year increase in age of the patient starting with age 19 years
(P=.011), 6.8-fold increased risk among PPI users (P=.005) plus a 6.6-fold increased risk
among patients diagnosed with sepsis (P=.021). Conclusion: Probiotic significantly reduced
C.difficile diarrhea in hospitalized patients receiving antibiotics. Increasing age, sepsis and
use of PPI were associated with increased risk of C. difficile diarrhea.
S1168
Clostridium difficile Infection of the Small Bowel: New Threat from An Old
Friend
Mushal Naqvi, Sarah Addison, Michael Hallissey, Phillipe Taniere, Jason Goh, Chris Keh,
John Fielding
Introduction: Clostridium difficile is a major causative agent of colitis. Risk factors are age,
pre-existing inflammatory bowel disease, recent surgery and antibiotic use. The distribution
of pseudomembrane formation is generally restricted to the colon. Only 14 cases of C.
difficile ileitis have been reported. We present a series of 10 cases of small bowel C. difficile
infection. Methods: Patients from our institution suffering with small bowel C. difficile were
identified between Dec 05 and Dec 06 from a prospectively collected data base. Clinical
data and outcomes were recorded. Small bowel C. difficile was diagnosed by the following
criteria: 1) A small bowel histopathological specimen showing pseudomembranous ileitis
2) Ileostomy effluent found to be positive for C. difficile toxin. Results: Mean age of patient
was 54.4 years (34-76). M:F ratio was 2:3. Three patients suffered with chronic Ulcerative
Colitis and 6 had an underlying abdominal neoplasm. All patients had under gone abdominal
surgery. Nine received antibiotics during the same inpatient episode, prior to developing
their small bowel C. difficile infection. Five patients were diagnosed on histology and 5 on
microbiology. Mean length of time from onset of symptoms to diagnosis was 4.8 days (0-
14). Presenting complaints varied from localized symptoms such as high stoma output,
abdominal pain and distension with vomiting, through to systemic signs of sepsis including
pyrexia, tachycardia and hypotension, with metabolic acidosis. Three patients had non
systemic symptoms. Seven presented with systemic upset without diarrhoea or flux, 5
diagnosed on histopathology alone, in contrast to the non-systemic group, where all 3 were
confirmed on microbiology. Four patients died as a result of their small bowel C. difficile,
all of these had presented with systemic upset. Conclusion: The finding of 10 cases of small
bowel C. difficile infection from our hospital in 12 months may reflect either an increase in
incidence of this rare disease or enhanced vigilance in its detection. This condition carries
a very high mortality. The low rate of positive microbiological evidence in cases of C. difficile
ileitis emphasizes the need for a high index of suspicion in high risk individuals with
abdominal symptoms and systemic signs of sepsis.
S1169
Characterization of Clostridium difficile Strains Isolated from Patients with
Hospital-Associated Diarrhea, October 2005-September 2006
Zhi-dong Jiang, Mark Larocco, Herbert L. Dupont
At a large tertiary care university hospital in Houston that routinely diagnosis hospital-
associated Clostridium difficile (CD) diarrhea with the cell culture cytotoxin-B assay, we
attempted to culture for CD 214 using consecutive toxin-B positive stools obtained by the
laboratory, October 2005-September 2006. All samples were stored at -80*C immediately
until examined. The recovery of CD was performed using alcohol shock followed by inocula-
tion onto cycloserine-cefoxitin fructose agar. Culture isolates were screened for the genes
coding for toxin A (tcdA), toxin B (tcdB) and binary toxin genes (cdtA and cdtB) and partial
deletions in the tcdC gene. Toxin genes were amplified and the PCR products are being
sequenced to confirm identification. Antimicrobial susceptibility was evaluated for the isolates
for vancomycin and metronidazole. CD was recovered from 166 (78%) of the fecal samples.
The storage time between sample collection and culture were 1 to 12 months. There was
no decline in the rate of CD recovery over time. All culture positive isolates were further
confirmed as CD by 16s ribosomal DNA. We eliminated from study 17 isolates found to
be negative for tcdA, tcdB and cdtA/cdtB genes (A-B- Binary toxin-). Of the 149 CD isolates,
31 (21%) produced the expected bands for cdtA/cdtB genes (binary toxin+), 97 (65%)
possessed both tcdA and tcdB genes for toxin A and B, and 28 (19%) were positive for
toxin B (tcdB) and binary toxin (cdtA/cdtB). Distribution of CD toxin type remained relatively
constant over the study time period. High-level resistance was not seen for any of the strains
tested against the antibacterial drugs (Table). The study provides evidence that CD binary
toxin is endemic in our hospital. We are currently looking for the partial deletion of the
tcdC gene to determine presence of the more virulent variant NAP1 strain. Antimicrobial
resistance does not appear to be a limiting factor in the management of CD diarrhea cases
in our hospital. Other studies underway, molecular fingerprinting of strains for clonal pattern
of transmission, the association of CD toxin pattern with host genotype, presence of fecal
inflammatory markers and In Vitro susceptibility of strains to rifaximin and nitazoxanide.
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S1170
Gastrointestinal Side Effects of Drugs - Is It a Problem; A Population Based
Study
Gunvor S. Fosnes, Per G. Farup
Aim and background: Clinical trials demonstrate a high prevalence of gastrointestinal (g-i)
side effects of drugs. Because patients with side effects probably reduce the dose or change
to other drugs, side effects might be less prevalent in daily practice. This study evaluates
the prevalence of g-i side effects of drugs in an adult general population. Methods: In 2001
The Norwegian Institute of Public Health invited 11078 subjects in Oppland county to
participate in a cross-sectional population based survey. They completed questionnaires
concerning past and present diseases with emphasis on g-i disorders (classified according
to the Rome II criteria), use of drugs, anxiety/depression (Hopkins Symptom Check List-
10) and musculo-skeletal pain (scored 0-12). G-i symptoms were classified in three groups
and defined as follows: 1: Abdominal pain/discomfort = any abdominal pain/discomfort
appearing at least 3 weeks last 3 months. 2: Diarrhoea = Diarrhoea predominant irritable
bowel syndrome (D-IBS) plus functional diarrhoea. 3: Constipation = Constipation predomin-
ant IBS plus functional constipation. The impact of drugs on g-i symptoms was explored
by stepwise logistic regression with correction for variables with p<0.2 in the bivariate
analyses. Drugs for g-i disorders are excluded because the symptoms in subjects using these
drugs might be due to insufficient effect or g-i co-morbidity. Results: 4522 (42%) subjects
participated in the study. The population prevalence of abdominal pain/discomfort, diarrhoea
and constipation were 18.5%, 14.0%, and 13.9% respectively. G i symptoms were in bivariate
analyses significantly correlated with sex, age, formal education, smoking habits, coffee,
physical activity, anxiety/depression, musculo-skeletal pain, several past and present diseases,
use of drugs in general, and with 22 specified drugs. After corrections for other dependent
variables, g-i symptoms were statistically significantly (p < 0.05) correlated with the following
drugs (results are given as OR with 95% CI). Abdominal pain/discomfort was correlated
with insulin (OR 4.0 [1.6;10.0]) and non opioid analgesics and antipyretics (OR 1.2 [1.0;1.5]);
diarrhoea with lithium (OR 5.1 [1.4;18.5]) and antidepressants (mianserin and venlafaxine)
(OR 2.6 [1.2;5.7]); constipation with high-ceiling diuretics (OR 2.4 [1.3;4.4]), nitrates (OR
1.8 [1.0;3.2]), antithrombotic agents (OR 1.6 [1.1;2.2]), l-thyroxin-Na (OR 1.6 [1.1;2.4])
and NSAIDs (OR 1.4 [1.1;1.7]) Conclusions: Several drugs were significantly correlated with
g-i symptoms. Although significant correlations do not prove causal relationships, g-i side
effects seem to be prevalent in subjects using these drugs.
S1171
Colonic Mucosal Lesions Associated with Low-Dose Aspirin: A Case-Control
Study
Tomoyoshi Shibuya, Toshifumi Ohkusa, Akira Harada, Kazuko Beppu, Naoto Sakamoto,
Akihiko Kurosawa, Taro Osada, Akihiro Namihisa, Mariko Hojo, Akihito Nagahara,
Tatsuo Ogihara, Sumio Watanabe
Background: We have reported that long-term NSAID users had a significantly higher
incidence of colonic lesions than that of non NSAIDs-users (Gastroenterology
2006;130:A316). In recent years, there has been a substantial increase in prescriptions of
low-dose aspirin, which have broadened to include the prevention of thrombosis in ischemic
coronary disease. In the present case-control study, we analyzed colonoscopic findings to
investigate the incidence of adverse events in the colon following the long-term use of low-
dose aspirin. Methods: The study included 4298 patients who underwent colonoscopy
between January 2004 and December 2005. They were divided into the two groups; 418
patients treated for over six months with low-dose aspirin and 3879 patients not treated
with NSAIDs as a control group. A case-control study was performed by medical record review
for endoscopic findings, underlying diseases, pre-endoscopic symptoms, and durations of
use. Results: Colonic lesions were found in 17 of the 418 patients (4.1%) with low-dose
aspirin. Among these, the duration of use ranged from 0.5 to 20 years (mean 6.5 years).
The most frequent features of colitis were ulcers seen in 10 patients (58.8%). In the 10
patients with ulcers, the longitudinal linear ulcers were seen in 6 patients. The sigmoid
colon (8 patients), and descending colon (7 patients) were commonly involved. In the
control group, 99 of the 3879 patients (2.6%) had colonic ulcers or colitis. Odds ratio were
2.06 (95%CI: 1.19-3.57) calculated using logistic regression for prevalence of colitis according
to the low-dose aspirin use. In the differences between the sexes, odds ratio of aspirin-
induced colitis in women was significantly increased (3.72; 95%CI; 1.76-7.86, p = 0.001),
but odds ratio of aspirin-induced colitis in men was not significantly increased (1.27; 95%CI;
0.56-2.91, p > 0.2). Conclusion: The prevalence of colonic lesions in low-dose aspirin users
was found to be about 4.7%. It was shown that long-term usage of low-dose aspirin had a
statistically significant increased incidence of colonic ulcers or colitis, especially in women.
It will be necessary to be aware of not only gastro-duodenal ulcers but also colonic lesions
in the long-term use of low-dose aspirin.
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S1172
Microscopic Colitis: A Large Retrospective Analysis from a Health
Maintenance Organization Experience
Kevin T. Kao, Benito Pedraza, Amy C. Mcclune, David Rios, Joan Mao, Sony
Wiriosuparto, Nayereh Khankhanian, Robert Zuch, Michael Kanter, Julia Phillipson,
Kevin Godfrey, Chris N. Conteas
Background and Aims: Recently published data suggests that the incidence and prevalence
of microscopic colitis (MC) are rising. Relatively few of these studies establish a relationship
between microscopic colitis and associated diseases or cancers. The aim of this study was
to examine the demographic data on a large multi-ethnic population of patients with MC
in Southern California and to determine the association of MC with inflammatory bowel
disease (IBD), colorectal cancer and other diseases. Methods: All patients diagnosed with
MC by colonic biopsy from 1996-2005 were identified utilizing a pathology database. All
biopsies were reviewed by experienced pathologists utilizing standard histologic criteria.
Patient's medical records were reviewed and data regarding patient age, co-morbidities, sex,
ethnicity, and medications taken within 1 year of diagnosis were analyzed. An age and sex
match standard control group was also generated.Χ2 test was used to evaluate the associations
of co-morbidities between lymphocytic colitis (LC), collagenous colitis (CC) and the control
group. Results: A total of 547 cases of MC were identified, 376 patients with LC and 171
patients with CC. Patients were predominantly female, comprising 73% of the subjects. The
female/male ratio was 3:1 in CC and 2.7:1 in LC. The age range at time of diagnosis was
19 years to 98 years. The ethnic distribution of our patients was 72.4% Caucasian, 6.9%
Hispanic, 2.6% Asian, 2.9% African American and 0.2% from the Middle East. Gastroeso-
phageal reflux disease (p<0.001), Celiac disease (p<0.001), irritable bowel syndrome
(p<0.001), thyroid diseases (p<0.001) and rheumatologic diseases such as rheumatoid arth-
ritis (p<0.001) and CREST syndrome (p<0.001) were found to have a higher occurrence in
MC compared to control group. Concurrent use of rantidine or Non-steroidal anti-inflammat-
ory drugs was also associated with MC. Occurrence of colorectal cancer, diabetes and
inflammatory bowel disease was found to have no statistical differences between the MC
group and the control group Conclusions: This is the largest group of patients with MC
known to the authors that has been studied to date. MC was found in predominately female
patients. LC was more common than CC among non-Caucasian populations. Previously
found association between biopsy proven Celiac disease and MC was also reported here,
but only about 3%. Conditions such as IBS, thyroid disease and GERD were also found to
be related to MC which was not consistently reported previously. Furthermore, neither an
increased risk of colorectal cancer nor IBD was associated with MC in this study.
S1173
A Randomized Controlled Trial of Octeotride for the Treatment of Severe
Acute Lower Gastrointestinal Bleeding
Esther Fort, Meritxell Casas, Alan Colomo, Ingrid Ordas, Carlos Guarner, Begoña
Gonzalez, Carles Aracil, Xavier Torras, Adolfo Gallego, German Soriano, Sergio Sainz,
Candid Villanueva, Joaquin Balanzo
Acute lower gastrointestinal bleeding (GIB) is a common cause of hospitalization. Although
it is self-limited in majority of cases, without treatment further bleeding may occur in >10%
of cases and mortality in >3-5%. Emergency colonoscopy may be useful in the management
of lower GIB. However, no drug therapy has shown efficacy in this setting. Octreotide is a
safe medication, which induces splanchnic arteriolar vasoconstriction and has been effective
in some studies for the treatment of upper-GIB. The aim of this study was to assess the
efficacy and safety of octreotide, in addition to emergency colonoscopy, for the treatment
of lower-GIB. METHODS: Patients admitted with severe hematochezia or fresh melena and
with hypotension (systolic BP < 100mmHg) or hemoglobin <10 G/dL were eligible. Emer-
gency gastroscopy was performed within 4 hours and when upper-GIB was excluded, patients
without suspicion of ischemic colitis were randomized to receive or not receive a continuous
octreotide iv infusion. Urgent colonoscopy within the first 24 hours of admission was
performed in all patients after bowel cleansing lavage. RESULTS: 82 patients were randomized
to received octreotide and 80 to a control group, with 1 and 4 exclusions respectively.
Baseline data were similar in both groups. Lower GIB was due to diverticula in 74 cases
(46%), to colonic angiodisplasia in 22 (14%), the cause was not identified in 10 (6%) and
was due to other causes in the remaining. Emergency endoscopic treatment was performed
in 23 (28%) patients in the octreotide group and in 26 (34%) in the control group. Further
bleeding occurred in 4 of 81 patients (5%) in the octreotide group and in 16 of 76 (21%)
in the control group (P= 0.003). Emergency surgery to control bleeding was required in 4
(5%) and 10 (13%) patients respectively (P=0.09). Transfusional requirement were higher
in the control group (3.34.5 vs 2.12.8, P= 0.03). Complications related to bleeding occurred
in 27 (31%) patients treated with octreotide vs 33 (61%) in the control group (P NS) and
complications related to treatment in 16 (20%) vs 6 (8%) (P=0.04) which were severe only
in 2 vs 1 cases (P NS). Three (6%) in the octreotide group and 2 (4%) in the control group
died (P NS). CONCLUSIONS: Octreotide may reduce significantly the rate of further bleeding
in patients with severe acute lower gastrointestinal hemorrhage, although it also increases
the incidence of minor complications and has no effect on survival.
S1174
Coxibs Induce Acute Lethality Independent of Their Ability to Inhibit
Eicosanoid Production
David C. Montrose, Sierra Seaman, Jillian N. Ilsley, Thiruchandurai V. Rajan, Manish
Ramesh, Frank C. Nichols, Dmitry Sonin, Bruce Liang, Daniel W. Rosenberg
Introduction: An important adverse effect associated with long-term use of non-steroidal
anti-inflammatory drugs (NSAIDs) is gastrointestinal (GI) toxicity. A number of COX-2
selective inhibitors have been developed to circumvent this toxicity while retaining thera-
peutic efficacy. Recent clinical trials examining the reduced GI toxicity, however, have
revealed cardiovascular toxicity associated with these agents, attributable to loss of key
prostaglandins associated with maintenance of blood pressure and thrombotic activity.
Materials and Methods: In the present study, we sought to determine the non-prostanoid
related effects of selective COX-2 inhibitors by using mice that are compromised in their ability
to generate prostaglandins (PGs) as a result of a genetic deletion of cytosolic phospholipase A2
(cPLA2). We administered both specific (celecoxib, rofecoxib and sulindac) and non-specific
(aspirin) COX inhibitors, each incorporated into laboratory chow, to cPLA2 nullizygous
mice and wild-type littermates. Results: There was a rapid onset of lethality (3 to 16 days),
preceded by weight loss, dehydration and lethargy, in the cPLA2 nullizygous mice, an effect
that was limited to those animals treated with COX-2 specific inhibitors. No effect was
found in the wild-type littermates, or in mice receiving aspirin alone. No evidence for drug-
related alterations in cardiac function was found. However, upon necropsy, severe damage
to the GI tract was observed (distension, ulceration, fragility and perforation), occurring in
the cPLA2-null mice treated with celecoxib. Damage was associated with acute peritonitis
and bacteremia resulting in severe sepsis. PG levels (PGD2, PGE2, PGF2α, 6-keto F1α) in
the small intestine were reduced in the cPLA2-/- mice compared to cPLA2+/+ littermates
(up to 3-fold) on control chow. However, PG levels were reduced to a comparable extent
by celecoxib. Conclusion: The absence of cPLA2-/- sensitizes mice to coxib-induced intestinal
injury independent of PG levels. This indicates a directly toxic effect of coxibs on intestinal
epithelium and a protective role for cPLA2 under these conditions.
S1175
Chronic Heart Failure Causes Bowel Wall Edema, Increased Intestinal
Permeability, Bacterial Adherence and Activation of the Local and Systemic
Immune System
Juergen Bauditz, Anja Sandek, Alexander Swidsinski, Sabine Buhner, Birgit Rudolf,
Wieland Schroedl, Tim Karhausen, Wolfram Doehner, Matthias Rauchhaus, Hans-dieter
Volk, Stephan Von haehling, Stefan D. Anker, Herbert Lochs
Background and Aim: Case observations suggest that acute heart failure causes bowel wall
edema. However, the effects of chronic hart failure on intestinal morphology and function
have not yet been systematically investigated. The aim of our study was therefore to investigate
whether chronic heart failure (CHF) is associated with alterations of the bowel wall, a
disturbed intestinal barrier and activation of the immune system. Methods: We studied 22
CHF patients (age 67±2 years, LVEF 31±1%, NYHA class 2.3±0.1, peak VO2 15.0±1.0 mL/
kg/min) and 22 age matched controls (62±1 years, LVEF 68±2%, peak VO2 24.7±1.3 mL/
kg/min). Sigmoidal wall thickness was assessed by transcutaneous ultrasound. Intestinal
permeability was investigated by lactulose-mannitol and sucralose test, passive carrier-medi-
ated transport by D-xylose test. Sigmoidal biopsies were assessed for edema, inflammation
and mucosal bacterial biofilm by Fluorescence in situ hybridisation (FISH). High-sensitivity-
C reactive protein (hs-CrP), serum Tumor necrosis factor (TNF), Interleukin 6 (IL-6) and
immunoglobulin (Ig) anti-LPS were measured by ELISA. Whole blood was incubated ex
vivo with LPS for 24 hours and cytokine release was assessed. Results: Ultrasound demon-
strated swelling of the sigmoid in CHF patients compared to controls [2.9±0.2 vs. 1.5±0.2
mm, (p<0.002)]. Wall thickening corresponded to histologic edema (57% vs. 12%, p<0.02)
and inflammation (50% vs. 6%, p<0.003) in CHF patients. CHF patients compared to controls
showed increased small intestinal permeability (lactulose/mannitol ratio: 0.023±0.001 vs
0.017±0.001, p=0.006), increased large intestinal permeability (sucralose excretion:
0.62±0.17% vs 0.20±0.06%, p=0.03) and decreased D-xylose absorption (27±3% vs 37±1%,
p=0.003). FISH demonstrated a higher number of bacteria within the mucus of CHF patients
(10.4x108/ml vs 0.01x108/ml, p=0.007) and a higher number of bacteria adherent to the
sigmoidal mucosa (p=0.03). Hs-CrP-serum levels in CHF patients correlated to sigmoidal
wall thickness (p<0.005). Patients compared to controls showed similar serum concentrations
of IgM- and IgG-anti-LPS (p>0.3). Patients had higher serum concentrations of TNF (3.0±0.2
vs 2.5±0.1 pg/mL, p=0.04), IgA-anti-LPS (128 [96; 368] vs 78 [41; 129] relative ELISA
units/mL), IL-6 (3.0 [1.6; 3.4] vs 1.0 [0.8; 1.7] pg/mL) and higher whole blood LPS stimulated
TNF release (919±80 vs 563±59 pg/mL) (all p<0.006). Conclusion: Chronic heart failure
causes bowel wall edema. This bowel wall edema is associated with intense bacterial coloniza-
tion of the colonic mucosa, inflammation within the mucosa, an increased intestinal permeab-
ility and a systemic immune response.
S1176
Plasma Citrulline Is a Biomarker of Intestinal Function in HIV Infected
Patients with Infectious Enteritis: A Prospective Study in 88 Patients
Pascal Crenn, De truchis Pierre, Neveux Nathalie, Cynober Luc, Jean-claude Melchior
Plasma/serum citrulline (Cit), specific product of enterocyte metabolism, is a surrogate
marker of functional enterocyte mass that evaluate the global intestinal absorption (Crenn,
Gastroenterology 2003). Cit was studied in gastrointestinal diseases, but never in HIV
infection despite the reemergence of infectious digestive diseases. Objective: to define Cit
and its evolution in HIV patients with HIV-related infections or ARV (antiretroviral) therapy.
Methods: 88 HIV patients (71M, 17W; 43(24-68)yrs) were prospectively studied (chromato-
graphy), and stratified in 6 subgroups: ARV treated with VL (viral load) <200 and CD4>200,
without digestive symptoms (group1,n=29), or with ARV-related diarrhea (group2,n=16);
detectable VL but CD4>200, with diarrhea (group3,n=8) or without (group4,n=5); low
CD4(<200) and high VL, without digestive symptoms (group5,n=9) or with diarrhea
(group6,n=21) related to documented opportunistic protozoa(n=8), intestinal mycobacter-
ia(n=7), CMV infection(n=2), HIV-related enteropathy(n=4). Patients with previous intestinal
resection or severe renal failure (n=4) were not included. Results: 39/43 patients without
diarrhea (groups 1,4,5) had Cit within normal values (30-50µM/l). Cit was moderately low
(20-30µM/l) in 22/24 patients of groups 2,3. All patients of group 6 but 1 had Cit<20µM/
l; 7 of these patients had Cit<10µM/l, highly predictive for the need of parenteral nutrition
(7/7 vs 1/14 with Cit>10, Fisher test, p<0,01). A positive correlation was established between
Cit and albuminemia (p<0,05), but not with weight or inflammatory status (CRP). Clinical
improvement under specific therapy in 18/21 patients was associated to Cit improvement
in a few weeks. Conclusions: Cit plasma concentration confirms as a biomarker of enterocyte
function in HIV patients, with moderate (<30µM/l, ARV related diarrhea) or severe (<20µM/
l, infectious diarrhea) decrease. Normalization of Cit is associated with clinical improvement
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of digestive disease. Cit could be a valuable test for indication of nutrition support in small
bowel immuno/infectious related diseases.
S1177
Familial Constipation Is Associated with α2 Adrenoceptor Polymorphism
Annie on on Chan, Camy Huang, Gigi Leung, Wai mo Hui, Shiu kum Lam, Benjamin C.
Wong
Background: We have previously showed the presence of familial aggregation in patients
with functional constipation. Genetic factors may be an underlying etiology. It has been
reported that α2a and α2c adrenoceptor polymorphisms were associated with irritable bowel
syndrome with predominant constipation. Aim: to investigate if α2a and α2c adrenoceptor
polymorphisms are associated with familial constipation. Methods: Patients with functional
constipation satisfying the Rome II criteria were recruited. The presence of functional con-
stipation in their family members were enquired as described in our previous study. Poly-
morphisms for α2 adrenoceptor were detected by polymerase chain reaction amplification,
and sequencing. Familial constipation was arbitrarily defined as the presence of ≥3 first
degree relatives with functional constipation. Results: There were 46 patients with familial
constipation and 151 without. The two groups did not differ in age (48 ± 12 vs 47 ± 12
years, p=0.45), but more female were observed in the familial group (93.5% vs 79.5%, p=
0.017). The prevalence of α2A-1291 (C→G) wild-type was 10.7%, heterozygous 46.2%
and homozygous polymorphism 43.1%, and α2CDel 322-325 wild-type 77.2%, heterozyg-
ous 16.8% and homozygous polymorphism 6.1%. There was no association between α2A
polymorphism and familial constipation, or between α2C polymorphism and familial con-
stipation. However, there were more patients with familial constipation having the combined
genotype ofα2CDel 322-325 homozygous andα2A-1291 (C→G) heterozygous/homozygous
polymorphism (10.9% vs 3.3%, p=0.041). Conclusion: Familial constipation is associated
with α2 adrenoceptor polymorphism. Genetic factor may play an important etiological role
in familial constipation.
S1178
Prevalence of Colonic Lesions After a Negative Screening Colonoscopy in a
Population with Rapidly Rising Colorectal Cancer Incidence: A Prospective
Multi-Center Analysis
Annie on on Chan, Ching kong Loo, Chi man Leung, Siu yin Wong, Fook hong Ng, Ka
wah michael Li, Kong ming Lam, Shiu kum Lam, Benjamin C. Wong
Background: Colorectal cancer (CRC) incidence is rapidly rising in Hong Kong. Limited
evidence exists to guide the optimal frequency of repeat endoscopic examination for CRC
screening after a negative colonoscopy. Despite a decrease in risk was observed for ten years
after a negative colonoscopy, CRC was detected in a minority after an initial negative
colonoscopy and the prevalence was unknown. Aim: to identify the prevalence of colonic
lesions after an initial negative screening colonoscopy. Methods: Patients with an initial
negative colonoscopy done for screening, abdominal pain, or altered bowel habit at 5 to 7
years ago, from four regional hospitals in Hong Kong, were invited to have a second
colonoscopy. Indications and results for those who had a colonoscopy repeated prior to
this study were ascertained. The cause of death for the deceased was identified either through
the computer registry or from history by the relatives. Results: There were 406 patients with
an initial negative colonoscopy. 11 patients had colonoscopy repeated before this study for
various symptoms. 143 patients were available for the second colonoscopy, 28.6% (41)
had colonic polyps, 4% (6) of them were advanced lesion, including one intramucosal
adenocarcinoma at sigmoid colon. 63 patients died during this period, including one died
of CRC at the ascending colon. The rest of patients either refused the examination or we
had loss their contact. Conclusion: Four percent of the patients developed advanced colonic
lesion after an initial negative colonoscopy at 5 to 7 years. These advanced lesions might
have or have already evolved into malignancy if the screening interval was 10 years. The
10-year interval for an initial negative screening colonoscopy may not be applicable to a
population with rapidly rising CRC incidence.
S1179
Intestinal Inflammation in Irritable Bowel Syndrome (IBS) Patients Seems Not
Dependent On Human Protease-Activated Receptors (Hpar) Overexpression in
Colonic Mucosa
Romain Gloro, Moise Coeffier, Stéphane Allouche, Pierre Dechelotte, Eric Lerebours,
Stephane Lecleire, Jean-marie Reimund, Philippe Ducrotte
Background: Recent years have witnessed tremendous progress in our understanding of
IBS. Several authors [1], provided direct and compelling evidence for a role of intestinal
inflammation, leading to the “(micro) inflammation hypothesis” in IBS pathogenesis. Never-
theless, the mechanisms by which inflammation contributes to IBS have not yet been
extensively explored or definitively established. Due to their potential roles in gut motility,
sensory function and inflammatory and immune response, protease-activated receptors
(hPAR-1 to hPAR-4) appear as potential contributors to IBS pathophysiology [2,3]. Aim:
Therefore, we analyzed gut inflammation by measuring fecal calprotectin concentrations and
measured hPARs mRNA expression in colonic mucosa from IBS patients, active inflammatory
bowel disease (IBD) patients, and healthy controls (HC). Patients and Methods: Colonic
biopsies have been obtained in 23 subjects: 5 IBS (positive for Rome II criteria), 13 with
active IBD (8 Crohn's disease and 5 ulcerative colitis patients), and 5 HC. Colonic mucosal
specimens were immediately frozen after biopsy was performed, and stored at -80 °C until
hPAR-1 to -4 mRNA expression levels were determined (real-time quantitative PCR). In IBD
patients biopsies were taken in inflamed colonic mucosa. Fecal calprotectin concentrations
were measured by ELISA, the day before colonoscopy was performed (i.e. before colon
cleansing). Results: In all IBS patients, fecal calprotectin was increased compared to normal
levels (< 25 mg / kg of stool) but significantly lower than in IBD patients (p < 0.05). In
IBD, colonic hPAR-1 and hPAR-3 mRNA levels were significantly increased compared to
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hPAR-1 and hPAR-3 mRNA in colonic mucosa from IBS patients (p < 0.05 and p < 0.01
respectively) or HC (p < 0.01 for both). No statistical difference in hPAR-1 and hPAR-3
mRNA expression was observed between IBS patients and HC. Colonic hPAR-2 and -4
mRNA levels did not differ between IBS patients, HC and patients with IBD. Conclusions:
The reported increase in fecal calprotectin concentrations strengthen the putative role of
inflammation in IBS pathogenesis. However, lack of increased hPARs mRNA expression in
colonic mucosa compared to high hPAR-1 and hPAR-3 mRNA levels in IBD patients indicates
that inflammatory pathways involved in IBS and IBD pathogenesis may be different. [1]
Chadwick et al. Gastroenterology 2002;122:1778 [2] Vergnolle et al. Gut 2005;54:867 [3]
Gloro et al. Expert Opin Ther Target 2005;9:1079 Acknowledgements: This study has been
supported by a grant from IRMAD (sponsored by AstraZeneca, France) to JMR, and from
IPSEN BEAUFOUR France to RG.
S1180
Cellular Localization of Corticotropin-Releasing Factor (CRF) Receptor 1
(CRF1) in Human Colon and Its Expression in the Jejunum and Colon of
Irritable Bowel Syndrome (IBS) Female and Male Patients
Pu-qing Yuan, Vincent Wu, Lin Chang, Javier Santos, Esteban Saperas, Juan R.
Malagelada, Yvette Tache
Background: CRF signaling pathways are responsible for mediating the gut response to stress
via binding to two distinct receptor types, CRF1 and CRF2. Experimental studies support
a role of central and peripheral CRF1 receptors in the colonic motor and hyperalgesic
responses to stress. Patients with irritable bowel syndromes (IBS) have a greater colonic
motility response to intravenous CRF compared to healthy volunteers and IBS is more
prevalent in female. Aims: To examine the cellular localization of CRF1 in the colon of
healthy subject and to compare changes in CRF1 mRNA in jejunal and sigmoid colonic
biopsies of healthy subjects and IBS patients and between men and women. Methods: CRF1
expression was detected in ascending colon, descending colon, transverse colon, sigmoid
colon with whole thickness tissues from 4 male healthy subjects (24-29 yrs). CRF1 immuno-
histochemistry, double labeling of CRF1/ED2, a marker for macrophage, and CRF1/RMCP
II, a marker for mast cells, were performed on both whole thickness tissue and the sigmoid
colonic biopsies of healthy subjects. 14 jejunal biopsies from healthy control (3 females, F,
3 males, M) and diarrhea-IBS patients (IBS-D) (4 F, 4 M), 54 sigmoid colonic biopsies from
20 control (10 F, 10 M) and 34 IBS patients with predominantly constipation (IBS-C) or
alternating (IBS-A) (24 F, 10 M) were processed for real-time quantitative PCR for CRF1.
Results: CRF1 mRNA was present in each investigated segments of colon. CRF1 immunoreac-
tivity was located in the cells in the lamina propria and in submucosal and myenteric
neurons. The double-labeled CRF1/ED2 cells and CRF1/RMCP II cells represent 79% or 13
% of total CRF1 IR positive cells in lamina propria respectively. Less than 8% of CRF1 IR
positive cells were not labeled either by ED2 1 or by RMCP II. Real time PCR showed that
CRF1 mRNA level in the jejunal mucosa of the control group is significantly higher in male
than in female and tends to be increased (38%) in female IBS patients compared to control.
In contrast, a decreased tendency was found in jejunal (23%) in male IBS patients. In the
colonic biopsies, CRF1 mRNA expression tends to be decreased in both female and male
IBS patients. Conclusions: The findings support the existence of a CRF1 regulatory system
in human colon and suggest a significant role for CRF1 signaling pathways in the regulation
of colonic function and local inflammation through a direct action on the macrophages and
mast cells in lamina propria . A sex-based difference in jejunum and a decreased tendency
in the colon of IBS patients in CRF1 expression may contribute to the gender differences
and pathophysiology in IBS.
S1181
Interobserver Variability of Wireless Capsule Endoscopy (WCE) in Patients
with Crohn's Disease and NSAID Enteropathy
Winfried A. Voderholzer, Laurence Maiden, Samuel N. Adler, Bjarni Thjodleifsson,
Herbert Lochs, Ingvar Bjarnason
Background and Aim: WCE is an emerging method for diagnosing small bowel disease.
However it is not clear if it is possible to distinguish between the damage seen in Crohn's
disease and NSAID-enteropathy. We assessed this along with an assessment on the interobser-
ver differences of interpretation of lesions. Methods: Forty capsule videos from patients
with either Crohn's disease (CD) or NSAID enteropathy were examined by an experienced
investigator and lesions were marked as thumbnails (Rapid 4 software, GivenImaging).
Copies of all videos were sent to three other independent investigators which were blinded
with respect to the patients' diagnosis and all thumbnails were classified by using a standard-
ized evaluation form. Lesions were classified as reddened folds, denuded area, red spot,
mucosal break without blood, mucosal break with blood, blood without mucosal break,
and strictures. Each investigator made a diagnosis as i) definite NSAID enteropathy ii) NSAID
enteropathy likely iii) uncertain iv) CD likely and v) definite CD. Results: 546 lesions in 40
patients were evaluated. 176 (32.2%) lesions were classified the same by all 3 investigators.
Another 253 lesions (46.3 %) were classified the same by at least two investigators. A fifths
of lesions (n=117, 21.4 %) were classified differently by all investigators. Diagnosis of definite
or likely NSAID enteropathy, uncertain diagnosis and definite or likely CD was made by
investigator I (34.2 %, 15.8 %, 47.5%), by examiner II (64.9 %, 10.8%, 22.5 %), and by
investigator III (55 %, 15 %, 30 %), respectively. The respective Kappa values were 0.21
(I vs. II), 0.15 (I vs. III), 0.32 (II vs. III). With respect to final diagnosis all 3 investigators
agreed in 45 % of videos and at least to investigators in 43 %. Different diagnosis by all
investigators happened in 12.5 %. Conclusions: There is not only considerable interobserver
variation with respect to small intestinal lesions seen by WCE in Crohn's disease and NSAID
enteropathy, but the investigators made the wrong diagnosis in 25 % of patients making
diagnosis of both diseases difficult in the small intestine. There is considerable overlap in
the WCE appearances between Crohn's and NSAID-enteropathy. This study emphasises that
WCE images need to be interpretated along with clinical details.
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S1182
COX-2 Enteropathy in Man
Laurence P. Maiden, Ann Seigal, Ingi Bjarnason, David Scott, Bjarni Thjodleifsson, S.
Birgisson, Ingvar Bjarnason
Background: NSAID-gastropathy is sufficiently important as to warrant co-administration
of misoprostol or proton pump inhibitors or alternatively prescribe cyclo-oxygenase 2 (COX-
2) selective inhibitors. However the “serious ulcer outcome studies” suggest that 40% of
the clinically significant gastrointestinal bleeding originate more distally, presumably from
NSAID-enteropathy. We used capsule enteroscopy to study small bowel damage in patients
on long-term NSAIDs and COX-2 selective agents. Methods: 120 patients on long-term
NSAIDs and 40 on COX-2 selective agents underwent a capsule enteroscopy study. Sixty
healthy volunteers acted as controls. Small bowel damage was categorised and quantitated.
Results: 62% of patients on conventional NSAIDs had abnormal investigations which differed
significantly (p < 0.001) from controls. The main pathology related to reddened folds (13%),
denuded areas (39%) and mucosal breaks (29%). 2% had diaphragm-like strictures and 3%
had bleeding without an identifiable lesion. The damage, seen in 50% of patients on COX-
2 selective inhibitors (reddened folds (8%), denuded areas (18%) and mucosal breaks (22%))
did not differ significantly (p > 0.5) from that seen with NSAIDs. Conclusion: Long-term
NSAIDs and COX-2 selective agents cause comparable small bowel damage. This suggests
an important role for COX-2 in maintenance of small bowel integrity. The results have
implications for strategies that aim to minimise the gastrointestinal damage in patients
requiring anti-inflammatory analgesics.
Quantification of pathology detected
S1183
Functional Gastrointestinal Disorders and Functional Polymorphism in a
Norwegian Population Based Study
Carl G. Platou, Frank Skorpen, Pål R. Romundstad, Kristian Hveem
Background: The aetiology of functional gastrointestinal disorders (FGID) is still unclear.
Studies have indicated that inheritance plays an important role for people who develop
FGID. The functional polymorphism of the G-protein beta-3 subunit (GNB3-C825T) has
been reported to be associated with functional dyspepsia (FD). The A118G polymorphism
of the µ opioid receptor (OPRM1) influences opioid efficacy in pain treatment, and could
possibly play a role in modulation of GI functions (i.e. sensory and motor function, immuno-
modulation). Aim: To determine the prevalence of FD and irritable bowel syndrome (IBS) in
an unselected Norwegian population and investigate possible association with the functional
polymorphisms of GNB3-C825T and OPRM1-A118G. Methods: In 2004, 2000 persons,
aged 20 or more, were randomly selected from the population in Verdal municipality, Nord-
Trøndelag County, Norway. They were invited to a screening survey including a research
diagnostic questionnaire for functional gastrointestinal disorders. 1118 attended; mean age
59.9 years (21-91), 54.4% women. 807 (371 men and 436 women) had also participated
in a previous health survey (HUNT 2) in 1995-1997 in which extracted DNA was available.
FD and IBS were identified according to Rome II criteria. Genotyping was carried out using
allele-specific hybridization probes on a LightCycler Real Time PCR system (Roche). Results:
The observed prevalence of FD was 5.6% (4.6% men/6.4% women) and IBS 10.4% (7.7%
men/12.7%women). The genotype distribution of GNB3-C825T was: 8.7% TT, 51.0% CC
and 40.2% CT; likewise for the OPRM1-A118G genotypes: 1.2% GG, 77.9% AA and 20.8%
AG. The distribution of the polymorphisms in the cohort was tested according to the Hardy-
Weinberg principle and the Chi-square test did not detect any significant deviation. Logistic
regression analysis did not reveal any significant association (p< 0.05) between FD/IBS and
the GNB3-C825T/ OPRM1-A118G genotypes. Conclusions: No significant associations were
observed between FD/IBS and the GNB3-C825T/OPRM1-A11G genotypes. The lack of
significant associations may in part be due to low power.
S1184
OMEPRAZOLE Treatment Leads to Bacterial Overgrowth with Increased
Levels of the Secondary Bile Acid Deoxycholic Acid in Rats
R. R. Sital, I. A. Boere, L. H. Van damme, F. W. De rooij, J. L. Wattimena, R. W. De
bruin, A. H. Van vliet, H. P. Endtz, E. J. Kuipers, J. G. Kusters, P. D. Siersema
Background: Proton pump inhibitors (PPIs) are prescribed for the treatment of acid-related
disorders. Although PPIs are known for their safety and efficacy, bacterial overgrowth in
the upper gastro-intestinal tract as a consequence of acid suppression can be a drawback.
Some overgrowing bacterial species are capable of metabolizing primary bile acids into
secondary bile acids, i.e., deoxycholic acid (DCA), which has been demonstrated to have a
tumor promoting capacity. Aim: 1) To determine whether administration of PPIs to rats is
associated with bacterial overgrowth in the small intestine. 2) To determine bile acid composi-
tion in PPI-treated rats. Methods: Ten Wistar rats were treated with 400 μmol/kg omeprazole
(PPI-treated), daily administered by gavage for a period of 6 weeks, which is equivalent to
a dose of approximately 80 mg omeprazole in humans. In addition, 10 rats underwent
gastrectomy with esophagojejunostomy (GEJ-treated) to mimic total achlorhydria, and 10
served as normal controls (non-treated). After 6 weeks, the jejunum, ileum, and colon of
all rats were cultured. Rat bile was collected by cannulating the common bile duct and the
composition was determined by high performance liquid chromatography. Results: The
anaerobic bacteria Clostridium perfringens and/or Bacteroides spp, which are capable of
dehydroxylating primary into secondary bile acids, were present in the jejunum of 10/10
GEJ-treated rats, in 6/10 PPI-treated rats and in 0/10 of the non-treated rats. Of the primary
bile acids, only glycine-conjugated cholic acid (GCA) was higher in GEJ-treated and PPI-
treated rats compared to non-treated rats (GCA: 3203 (p=0.009), 6541 (p=0.043) and 895
mmol/L, respectively). Of the secondary bile acids, both taurine-conjugated DCA (TDCA)
and glycine-conjugated DCA (GDCA) were increased in GEJ-treated and PPI-treated rats
compared to non-treated rats (TDCA: 4645 (p<0.001), 5651 (p=0.006) and 468 mmol/L,
respectively and GDCA: 821 (p=0.002), 1597 (p=0.028) and 67 mmol/L, respectively).
Finally, the total sum of secondary bile acids was also higher in the GEJ-treated and PPI-
treated rats compared to non-treated rats (7835 (p<0.001), and 9017 (p=0.022) versus 1850
mmol/L, respectively). Conclusions: Use of PPIs in rats is associated with overgrowth of
anaerobic bacteria in the small bowel and increased biliary levels of DCA. This implies that
long term use of high-dose PPIs may have the unwanted side-effect of contributing to
exposure of the upper gastro-intestinal tract to potentially toxic secondary bile acids with
a tumor-promoting capacity.
S1185
Antioxidant Vitamins and Plasma Fatty Acids in Inactive and Active
Inflammatory Bowel Disease (IBD) Patients
Susanne Hengstermann, Luzia Valentini, Lennart Schaper, Thomas Koernicke, Carsten
Buning, Sabine Buhner, Wolfgang Tillinger, Francesco W. Guglielmi, Brigitte M.
Winklhofer-roob, Herbert Lochs
Background Only few data are available about the plasma fatty acid (FA) profile as well as
antioxidant vitamins in inactive IBD compared with active IBD patients and healthy controls
(HC). Methods To obtain a detailed overview of antioxidant vitamins and FA we analysed
vitamin C, vitamin E, carotenoids (lycopene, lutein/zeaxanthin, β-cryptoxanthin, a-/β-carot-
ene), saturated (SFA, C14:0, C15:0, C16:0, C18:0, C20:0, C22:0), mono-unsaturated (MUFA,
C16:1n7, C18:1n7, C18:1n9, C22:1n9) and poly-unsaturated FA (PUFA, C18:2n6, C18:3n6,
C20:3n6, C20:4n6, C22:4n6, C18:3n3, C20:5n3, C20:6n3, C22:5n3, C22:6n3) in plasma.
Inflammatory parameters (CRP; a-1-acid glycoprotein, AAG; faecal calprotectin, FC) as well
as clinical disease activity (CDAI, CAI) were determined in 167 IBD patients and 45 sex,
age and BMI matched HC. The IBD study groups consisted of 138 inactive IBD (83 Crohn's
disease, CD, 49 ulcerative colitis, UC) and 35 active IBD patients (17 CD, 18 UC). Results
Overall nutritional status was normal in inactive (BMI 23.9±4.7 kg/m2), active (22.7±4.2
kg/m2) IBD patients and HC (22.3±1.9 kg/m2). Inflammatory parameters (CRP, AAG, FC)
were significantly increased in inactive and active IBD in comparison to HC. Plasma levels
of carotenoids differed significantly between inactive and active IBD as well as between
inactive/active IBD and HC (table). Significantly decreased plasma levels of vitamin C,
increased levels of MUFA and comparable levels of vitamin E, SFA and PUFA have been
found between inactive/active IBD and HC. FA inversely correlated with FC, vitamin C and
total carotenoids were found to inversely correlate with FC, CRP and AAG in IBD patients.
Discussion This study showed for the first time that antioxidant status and FA profile in a
large population of inactive and active IBD patients are disturbed independently from
disease activity as compared to matched HC, despite normal overall nutritional status. The
compromised status of antioxidant vitamins might offer a therapeutic opportunity to improve
antioxidant and inflammatory status.
Antioxidant vitamins and fatty acids of inactive and active IBD patients and HC
P1Inactive vs active IBD, P2active IBD vs HC, P3inactive IBD vs HC, NS non significant
S1186
Comparison of Mucosal Reparative Responses of Lubiprostone and
Polyethylene Glycol (PEG) Laxative in Ischemia-Injured Porcine Ileum
Adam J. Moeser, Prashant K. Nighot, Birgit Roerig, Ryuji Ueno, Anthony T. Blikslager
Lubiprostone is a novel type-2 chloride channel (ClC-2) activator approved for treatment
of chronic idiopathic constipation in adults. The mechanism of action of lubiprostone is
unique in that it stimulates fluid secretion via activation of ClC-2 expressed in intestinal
epithelia, as compared with traditional osmotic laxative agents which trigger electrolyte and
fluid movement by inducing luminal-directed osmotic gradients. Recent studies demonstrate
that lubiprostone also has mucosal barrier reparative properties, although prior studies by
our laboratory indicate that mucosal osmotic agents may have a similar effect. Application
of lubiprostone to ischemia-injured porcine ileum mounted in Ussing chambers stimulated
rapid recovery of intestinal barrier function, a mechanism involving targeted activation of
ClC-2 Cl- channels and reorganization of interepithelial tight junctions (Moeser et al., 2006).
To further differentiate their mechanisms of action, this study was performed to compare
mucosal reparative responses of lubiprostone with those of a PEG laxative agent in ischemic
intestines. Porcine ileum from n=6 piglets (~5kg body weight) was subjected to ischemic
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conditions by occluding the local mesenteric circulation for 45 minutes In Vivo. Ileal tissues
from each pig were then harvested and mounted in Ussing chambers and bathed in Ringer's
containing indomethacin (5μM) to prevent endogenous prostanoid stimulation of Cl- secret-
ory channels. Intestinal barrier repair in response to lubiprostone or a PEG laxative was
assessed by measuring transepithelial electrical resistance [TER]. Statistical analyses of data
collected over a 180-minute time course included 2-way ANOVA for the effects of time and
treatment on indices of barrier function. Forty-five minutes intestinal ischemia resulted in
significant reductions in TER in the porcine ileum (TER = 38±3 Ω.cm2 and 12±4 Ω.cm2
in non-ischemic and ischemic tissues, respectively P<0.01). Application of 1μM lubiprostone
to the mucosal surface of ischemia-injured ileum induced significant elevations in TER
compared with non-treated ischemic tissues (peak TER=34±7Ω.cm2 and 12±1.3 Ω.cm2 in
lubiprostone and non-treated ischemic tissues, respectively, P<0.05) Application of a PEG
laxative (20mM) to the mucosal surface of ischemic tissues had no effect on recovery of
TER (P>0.05). This experiment demonstrates that lubiprostone stimulates recovery of TER
in ischemic intestinal tissues whereas the PEG laxative did not. These results suggest that,
unlike osmotic laxatives, lubiprostone stimulates repair of the injured intestinal barrier.
S1187
Treatment of Painful Diverticular Disease of the Colon with mesalamine. A
Placebo-Controlled Study
Wolfgang Kruis, Eberhard Meier, Michael Schumacher, Oliver Mickisch, Werner
Schneider, Roland Greinwald, Ralph Mueller
AIM: To study the pain alleviating efficacy and safety of mesalamine pellets in patients with
lower abdominal pain as a symptom of uncomplicated diverticular disease. METHODS:
Patients with moderate to severe lower abdominal pain caused by diverticular disease were
enrolled into this double-blind, randomised, placebo-controlled multicenter study. Patients
were treated by mesalamine pellets (3x1g 5-ASA/day) or placebo over 6 weeks. The endpoint,
assessed after 28 days, was the cumulative difference of the daily pain scores to baseline.
Pain intensity scores (PIS) were documented in diaries. Baseline score was defined as the
median of the last 7 pre-treatment days. RESULTS: 123 patients were randomised, 117
patients were treated. All 117 patients were evaluable for safety and intention-to-treat (ITT),
91 for per-protocol-analysis (PP). EFFICACY See tables below. SAFETY The administration
of mesalamine pellets was safe and the tolerability was comparable to that of placebo. 18
adverse events (AEs) occurred in 13 patients of the mesalamine group, 17 AEs in 11 patients
of the placebo group. Two serious AEs were observed in the placebo group, none in the
mesalamine group. CONCLUSION: Although a confirmatory proof of efficacy could not
be shown, the data suggest some beneficial effect of mesalamine in diverticular disease.
Mesalamine was safe and well tolerated.
Primary efficacy endpoint:
Secondary efficacy endpoints:
S1188
Lubiprostone, a Novel Type-2 Chloride Channel (Clc-2) Activator, Does Not
Affect Serum Electrolyte Balance in Elderly and Non-Elderly Patients with
Chronic Idiopathic Constipation
Edwin Rivera, Aimee Wahle, Taryn R. Joswick, Ryuji Ueno
Chronic constipation is a common condition in the general population, with increased
prevalence among elderly patients. Lubiprostone, a novel ClC-2 activator, is approved for
the treatment of chronic idiopathic constipation in adults. Lubiprostone enhances intestinal
fluid secretion via activation of ClC-2. To determine whether lubiprostone affects serum
electrolyte balance, pooled data from three well-controlled trials of 3 to 4 weeks' duration and
three open-labeled, long-term trials of 24 to 48 weeks' duration were examined. Electrolyte
concentrations (sodium, potassium, chloride, calcium, phosphorus, and magnesium) were
determined from venous blood samples obtained at baseline, end of treatment, and (in long-
term trials) at various times throughout the studies. In the placebo-controlled trials, actual
values, as well as changes from baseline at end of treatment, for electrolyte concentration
measurements were compared across treatment groups. In the open-labeled studies, electro-
lyte concentrations at baseline were compared with end-of-treatment values. Electrolyte
levels were examined in the overall study population, as well as in elderly patients (≥65
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years of age). The pooled, well-controlled studies included 258 patients treated with lubipro-
stone (24 mcg BID) and 266 patients who received placebo (10.5% elderly and 10.8% male,
overall). In the open-labeled, long-term studies, 878 patients (18.6% elderly; 13.8% male)
were treated with lubiprostone (24 mcg BID). In the placebo-controlled studies, no significant
difference was seen in any serum electrolyte concentration between treatment groups at
baseline or at end of treatment. Furthermore, no statistically significant differences were
observed between groups for change from baseline values in any electrolyte measurement.
These findings were consistent for both the overall study population as well as for the elderly
study population. At the end of the open-labeled, long-term trials, electrolyte levels in the
overall study population and in elderly patients remained within the normal range and
showed no clinically relevant changes from baseline. Lubiprostone (24 mcg BID) did not
affect serum electrolyte balance in elderly patients. In addition, pooled analysis demonstrated
no clinically significant changes in electrolytes in the overall study population. The data
support the safety of lubiprostone in adults, including elderly patients, with chronic idio-
pathic constipation.
S1189
High Dosage Rifaximin for the Treatment of Small Intestinal Bacterial
Overgrowth
Emidio Scarpellini, Maurizio Gabrielli, Cristiano ernesto Lauritano, Andrea Lupascu,
Maria elena Ainora, Giovanni Cammarota, Immacolata alessia Cazzato, Davide Roccarina,
Giovanni Gasbarrini, Antonio Gasbarrini
Background: Rifaximin is a broad spectrum non absorbable antibiotic used for treatment
of small intestinal bacterial overgrowth (SIBO). Doses of 1200 mg per day showed an
decontamination rate of 60% with low side effects incidence. Aims: to assess efficacy, safety
and tolerability of rifaximin 1600 mg with respect to 1200 mg per day for SIBO treatment.
Methods: Eighty consecutive SIBO patients were enrolled. Diagnosis of SIBO based on
clinical history and positivity to H2/CH4 glucose breath test. Patients were randomised in
two 7-days treatment groups: rifaximin 1600 mg (group 1); rifaximin 1200 mg (group 2).
Glucose breath test was reassessed 1 month after. Compliance and side effects incidence
were also evaluated. Results: One drop-out were observed in group 1 and two in group 2.
Glucose breath test normalization rate was significantly higher in group 1 with respect to
group 2 both in intention-to-treat (80% versus 57.5%; p < 0.05) and per protocol analysis
(82% versus 60.5%; p < 0.05). No significant differences in patient compliance and incidence
of side-effects were found between groups. Conclusions: Rifaximin 1600 mg per day showed
a significantly higher efficacy for SIBO treatment with respect to 1200 mg with similar
compliance and side-effect profile.
S1190
Instituting Tegaserod to Prevent Postoperative Ileus in Patients Undergoing
Elective Cardiothoracic Surgery PD Allegretti D.O., G Mercogliano M.D., Jj
Verrecchio D.O., K Wolov D.O., S Goldman M.D., F Sutter D.O., M Morgan
D.O
Paul D. Allegretti, Giancarlo Mercogliano, Jonathan J. Verrecchio, Kevin Wolov, Scott
Goldman, Francis Sutter, Melissa Morgan
Purpose: The purpose of our study is to use the medication tegaserod to help promote normal
bowel function, decrease time to discharge from the hospital, and prevent postoperative ileus
after elective cardiothoracic surgery. Methods: After approval by our institutional review
board and informed consent of the patients, we conducted a pilot study of 20 male patients
whom have undergone recent elective cardiothoracic surgery and 10 male postoperative
controls. The tegaserod group consisted of seventeen Caucasian males and three African
American males with an average age of 67.4 years. The control group consisted of eight
Caucasian males, one African American, and one Asian male with an average age of 69.2
years. All subjects had normal baseline renal function and no history of abdominal surgery.
The study group received tegaserod, 6mg, one half hour before breakfast and dinner on
postoperative day 1 and thereafter. The control group received the current standard of care
which may include the use of metoclopramide, nasogastric tube decompression, minimizing
opioid analgesia, and early postoperative feeding. Results: The median number of postoperat-
ive days before a bowel movement was 3 days in the tegaserod group versus 4 days in the
standard care group (p= 0.013 by Wilcoxon Rank Sum Procedure). The median number of
postoperative days before discharge was 4 days in the tegaserod group versus 6 days in the
standard care group (p= 0.0005 by Wilcoxon Rank Sum Procedure). Two patients in the
standard care group developed an ileus on postoperative days 2 and 3 respectively, while
we had no patients develop an ileus in the tegaserod group. Three patients in the tegaserod
group developed diarrhea postoperatively with subsequent formed bowel movements before
discharge. One patient in the tegaserod group had nausea on postoperative day 1 resolving
within 24 hours. No patients withdrew from the study. Conclusion: Our pilot study demon-
strated a more rapid return to normal bowel function, fewer postoperative inpatient days,
and much lower risk of an ileus with institution of tegaserod on postoperative day 1 versus
standard care. Tegaserod can be safely used in this subset of postoperative patients with
potentially great clinical and economical benefits including near elimination of postoperative
ileus. Further randomized, double-blinded studies will be needed to better characterize these
results. Key Words: Tegaserod, Ileus Subject area: Intestinal Disorders
S1191
Small Bowel and Multivisceral Transplantation: Indications and Graft Survival
Hossam Kandil, G. Bond, C. Harris, L. Martin, D. Koritsky, Toby Graham, Stephen
O'keefe, G. Mazariegos, Kareem Abu-elmagd
Introduction: Intestinal and multivisceral transplantation has become an acceptable treatment
for patients with irreversible intestinal failure who cannot be maintained on total parenteral
nutrition (TPN). The recent cumulative improvement in patient and graft survival has been
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attributed to technical innovations and better management strategies including immunopro-
phylaxis. However, the underlying etiology of the end-stage intestinal failure and indications
for transplantation may influence survival outcome. Methods: Clinical data were collected
on patients who underwent small bowel and multivisceral transplantation at UPMC between
May 1990 and March 2004. Survival rates were calculated according to primary etiologies
for intestinal failure utilizing Kaplan-Meier method. Results: 135 adult patients underwent
primary intestinal transplant. All donors were cadaveric and ABO-identical. Lymphocytotoxic
cross-match was positive in 23% of patients. 39% received donor bone marrow cell infusion
and the intestinal component of 33% was irradiated ex vivo. Baseline immunosuppression
was tacrolimus plus steroids until anti-lymphocyte (rATG) immunoprophylaxis protocol
initiated after which tacrolimus monotherapy with weaning protocol was used. Patient
demographics and survival data are summarized below. Visceral vascular thrombosis, Crohn's
disease, abdominal trauma, and gastrointestinal tumors are the most common indications
for visceral transplantation in adults. Most of the multivisceral transplantations were needed
for patients with vascular thrombosis and gastrointestinal tumors. Intestine-only allograft
was performed more commonly in patients with vascular thrombosis and Crohn's disease.
Combined liver and intestinal transplantation was required with similar frequency for the
4 different common indications. The one and 3-year survival rates were similar among the
different disease categories with better long-term survival among the rATG group. Conclusion:
The etiology of the intestinal failure influences the type of the needed visceral graft with
similar survival rates. The rATG pretreatment improved the long-term survival rates.
Survival Rate for the common indications for each intestinal transplant procedure
S1192
Small Intestinal Bacterial Overgrowth in Acromegalic Patients
Andrea Parodi, Eugenia Resmini, Alfredo Greco, Diego Ferone, Vincenzo Savarino
Background Gastrointestinal abnormalities in acromegaly include dolichomegacolon, slow
colonic transit and increased prevalence of colonic polyps. However, in clinical practice
acromegalic patients often present intestinal symptoms such as meteorism and flatulence.
Aim The aims of this study were to investigate orocecal transit time (OCTT) and the presence
of small intestinal bacterial overgrowth in acromegaly as cause of intestinal symptoms.
Methods 41 acromegalic patients, and 30 healthy subjects, sex and age-matched entered
the study. Disease activity was evaluated by means of oral glucose tolerance test. For
subsequent statistical analysis, the patients were classified according to whether they were
on medical treatment with somatostatin analogs at the beginning of the study “treated” and
“untreated” and according to clinical control, that is “controlled” and “uncontrolled” and
“partially controlled”. Acromegalics and controls completed a questionnaire for IBS-like
symptoms to check clinical status and were submitted to a 10 g standardized lactulose H2
breath test (LH-BT) in order to determine the OCTT and presence of SIBO. The patients
positive for SIBO were treated with rifaximin 1200 mg /die for 10 days and a second LH-
BT was performed after 1 month from the end of therapy. Results Our data showed an
increased prevalence of SIBO in acromegalic patients compared with healthy controls (18/
41 vs 1/30, p=0.000). OCTT was significantly slower in acromegalic patients compared with
healthy controls (169.53±8.15 vs 107.25±6.56, p=0.000). There was a significantly lower
OCTT in treated compared with untreated patients (183.21±9.01 vs 158.89±6.38, p=0.02)
and between these two groups and healthy controls (105.75±6.34, p=0.00 in both groups).
There was no statistically significant difference for OCTT between controlled and uncontrolled
patients. Thirteen acromegalic patients, positive for SIBO, were treated with rifaximin. Seven
had a complete eradication of SIBO after therapy (54%) and 66% had symptom improvement.
Conclusions These data demonstrate for the first time that SIBO occurs more frequently in
acromegalic patients than in normal subjects. OCTT is significantly delayed in acromegalic
patients and this suggests that acromegaly determines impairment of intestinal motility, wich
represents a risk factor for the development of SIBO.
S1193
May Breath Test Be Useful in Diagnosis of IBS Patients? An Italian Study
Andrea Parodi, Alfredo Greco, Edoardo Savarino, Giorgia Bodini, Marina Corbo, Virna
Segalla, Sara Milazzo, Stefano De conca, Elisa Marabotto, Luca Isola, Pietro Dulbecco,
Edoardo giovanni Giannini, Patrizia Zentilin, Carlo Mansi, Vincenzo Savarino
Background Irritable bowel syndrome (IBS) is one of the most common diagnoses in gastroen-
terology. In many cases small bowel bacterial overgrowth (SIBO) and food intolerance may
mimic an irritable bowel syndrome. The role of H2/CH4 breath test (BT) is still uncertain
in diagnostic algorithm of IBS patients. Aim The aim of this study was to determine the
utility of lactulose, glucose and lactose H2/CH4 breath tests in the diagnosis of IBS patients.
Methods Consecutive 132 IBS patients, and 30 healthy subjects, sex and age-matched,
entered the study. We used Rome II criteria to diagnose IBS in our patients. Patients and
controls underwent a lactulose BT in order to assess the presence of SIBO and to determine
oro-cecal transit time (OCTT). Subjects with a non significant increase of H2/CH4 concentra-
tion performed a glucose BT in order to optimize the diagnosis of SIBO. Patients which
referred intestinal symptoms associated with milk or dairy food intake underwent also a
lactose BT. Patients completed a symptom questionnaire in order to check clinical status.
Patients positive for SIBO were treated with rifaximin 1200mg/die for 10 days and after one
month from the end of therapy, they performed a second lactulose or glucose BT and they
completed a second symptom questionnaire. Patients positive for lactose BT received a
lactose free diet for one month and then they completed a second symptom questionnaire.
Results Our data showed an increased prevalence of SIBO in IBS patients compared with
healthy controls (50% vs 5%, p=0.000). Glucose BT was useful to identify further 26%
patients positive for SIBO. OCTT was significantly slower in IBS patients compared with
healthy controls (149.61±8.23 vs 107.25±6.56, p=0.000). There was a significantly slower
OCTT in IBS SIBO positive patients compared with IBS SIBO negative patients (161.19±
8.01 vs 135.84 ±7.48, p<0.05). Twenty patients had a lactose positive BT, but 10 of them
were also positive for SIBO. There was no difference in symptom assessment between SIBO
positive and negative patients. After antibiotic treatment, eradication rate was about 75%
and 85% of treated patients had improvement of symptoms. Conclusions These data demon-
strate that H2/CH4 breath tests are useful to categorize IBS patients better than clinical
features alone and so they should be performed in diagnostic algorithm of these patients.
Therapy with rifaximin is safe and seems to be suitable for eradication of SIBO.
S1194
Sensitivity and Specificity of Lactulose Breath Test (Lbt) in a Rat Model of
Small Intestinal Bacterial Overgrowth (SIBO)
Koorosh Moezardalan, Eileen O. Taschereau, Justin H. Barad, Lynne Hamilton, Mark Lyte,
Henry C. Lin
Background: LBT is used to diagnose SIBO by detecting abnormal bacterial fermentation
with a change in profile of breath hydrogen (H2). Controversies exist in interpreting the
H2 profile since culture is often used as the gold standard despite access in patients being
limited to the duodenum. An animal model of SIBO has no access limitations. In rats, a
validated model of SIBO is feeding raw red kidney bean (RKB) containing phytohemagglutinin
which promotes bacterial adherence (Banwell. Appl Environ Microbiol 1985;50:68-80). The
aim of this study was to test the hypothesis that LBT has high sensitivity and specificity in
a rat model of SIBO. Methods: 36 male rats age 9-12 weeks were used. Control rats (n=
18) ate regular chow, and RKB rats (n=18) ate chow enriched with 24% powdered raw RKB
for 2 weeks. LBT was performed on day 0, 7 and 14 of feeding by sampling air every 15
minutes for 3 hours from an airtight chamber used to house the rat. H2 was measured by
gas chromatography. Intestinal tissue (duodenum, mid-jejunum, terminal ileum, and colon)
was collected for bacterial culture from 8 control and 8 RKB rats after 2 weeks of feeding.
Tissue was ground in sterile PBS and spiral plated on CNA agar for gram+ and on MacConkey
agar for gram- organisms. Results were expressed as colony forming units per gram of tissue
(CFU/g). Comparisons were by Mann-Whitney and Friedman tests (data shown as mean±SD).
Results: On day 0 no difference in LBT was seen between RKB and control. Peak H2
concentrations (ppm) on days 7 (RKB 104.6±136.6, Control 28.4±29.1) and 14 (RKB
98.3±70.6, Control 24.7±19.6) were significantly higher in the RKB group (P<0.01). Time
(minutes) to first H2 rise of ≥20 ppm above baseline on days 7 (RKB 112.9±42.3, Control
147.5±43.4) and 14 (RKB 125±37.8, Control 162±29.2) occurred significantly earlier in the
RKB group (P<0.05). Culture results showed significantly more gram+ organisms (CNA
agar) in the duodenum and mid-jejunum in RKB rats vs. control (P<0.01). CNA culture
from duodenum using a threshold of≥70000 CFU/g was the most effective for differentiating
RKB from control group (area under ROC curve = 0.97). Using this criteria as the gold
standard for SIBO, an LBT result of ≤120 minutes to first H2 rise of ≥10 ppm above
baseline had a sensitivity/specificity of 86%/67%, and an LBT result of ≤135 minutes to
first H2 rise of ≥20 ppm above baseline had a sensitivity/specificity of 71%/76% to detect
SIBO. Conclusion: Higher and earlier peaks of H2 were detected in response to lactulose
in the RKB fed rats, suggesting SIBO after one and two weeks of RKB feeding. When
compared to culture results, LBT has high sensitivity and specificity.
S1195
Microscopic Colitis Not Otherwise Specified (NOS) in Patients with Diarrhoea
Predominant IBS in a Tropical Setting
Arjuna P. De silva, Anuradha Dassanayake, Janake Hewavisenthi, Chathurika Munasingha,
Manohari N. Liyanage, Mihiri P. Karunanayaka, Janaka De silva
Introduction: Colonoscopy is not routinely recommended in IBS unless there are alarm
symptoms. However, studies have shown that microscopic colitis and low grade inflammatory
bowel disease (IBD) can mimic IBS. Microscopic colitis not otherwise specified (MNOS) is
a distinct but poorly studied entity, especially in the tropics. Aims: To investigate the presence
of colonic and ileal inflammation in patients with diarrhoea predominant IBS (IBS-D) in a
tropical setting. Methods: In a prospective study over one year, we selected 30 patients aged
between 18 and 60 years (mean age 37.5yrs) M: F-19:11 with IBS (using Rome II) and no
alarm symptoms. Alarm symptoms were defined as unintentional significant loss of weight,
bleeding per rectum or melaena. All patients had normal ESR, CRP, TSH and stools reports.
None of the patients were on NSAIDS or proton pump inhibitors. There were 11 controls
(patients with a family history of colon cancer) (Mean age 42.5) yrs M:F -5:6. Serial biopsies
were obtained from the ileum, caecum, right colon, transverse colon, descending, and
rectum. MNOS was defined as; The presence of acute (aggregates of polymorphs in the
lamina propria) and chronic (basal plasmacytosis in more than two foci) inflammation
with or without intraepithelial lymphocytosis in the absence of crypt distortion. Results:
Colonoscopy was macroscopically normal in both cases and controls. 17 (57 %) of cases
had MNOS, 1(5%) ileal inflammation only, and 12 (38%) had normal histology. None of
the cases had IBD, lymphocytic colitis or collogenus colitis. Histology was normal in 9(82%)
of controls and 2(18%)had MNOS.MNOS was significantly commoner in cases than in
controls P = 0.02. The right side of the colon was the commonest site of involvement in
patients with MNOS (72%). 64% of patients with MNOS had a history suggestive of post
infective IBS as compared to 40% of patients without MNOS who had a similar history
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(P>0.05). Conclusion: Microscopic colitis NOS seems common in patients with diarrhoea
predominant IBS (using ROME II) in a tropical setting. Post infectious IBS seemed commoner
in patients with MNOS compared to patients without MNOS although this did not reach
statistical significance. Colonoscopy with ileoscopy and serial biopsies seems useful to detect
mucosal inflammation in IBS-D. However, the significance of this mucosal inflammation
needs further investigation.
S1196
Concentration and Spectrum of Bile Acids in Normal Human Cecal Contents
James P. Hamilton, Guofeng Xie, Jean-pierre Raufman, Susan Hogan, Terrance L. Griffin,
Christine A. Packard, Dale A. Chatfield, Lee R. Hagey, Joseph H. Steinbach, Alan F.
Hofmann
Based on several lines of In Vivo and In Vitro evidence, the aqueous concentration of bile
acids in the colon may have physiological significance, including stimulation of colonic
electrolyte and water secretion. Nonetheless, because access to the proximal colon is difficult
without cleansing, limited information is available regarding the bile acid composition of
normal human cecal contents. To determine the concentration and spectrum of bile acids
in the human cecum, immediate postmortem (< 24 hr) cecal stool samples were obtained
from 19 otherwise healthy persons dying an unnatural death (e.g. trauma, homicide, suicide,
or drug overdose). Bile acid concentration was measured using an enzymatic assay for
3α-hydroxy bile acids; bile acid classes were determined by electrospray ionization mass
spectrometry (ESI-MS); and individual bile acids by gas-chromatography-mass spectrometry
(GC-MS) and liquid chromatography (LC)-MS. The 3α-hydroxy bile acid concentration
(µmol bile acid/ml cecal content) was 0.4 ± 0.2 mM (mean ± SD); The total 3-hydroxy bile
acid concentration was 0.6 ± 0.3 mM. The aqueous concentration of bile acids (supernatant
after centrifugation) was identical, indicating that most bile acids were in solution. By LC-
MS, bile acids were mostly in unconjugated form (90 ± 9%, mean ± SD); sulfated, non-
amidated bile acids were 7 ± 5% (range, 0 - 40%), and non-sulfated amidated bile acids
(glycine or taurine conjugates), were 3 ± 7% (range, 0 - 26%). By GC-MS, ten bile acids
were identified: deoxycholic (34 ± 16%), lithocholic (26 ± 10%), ursodeoxycholic (6 ± 9%),
as well as their primary bile acid precursors cholic (6 ± 9%) and chenodeoxycholic acid (7
± 8%). In addition, 3β-hydroxy derivatives of some or all of these bile acids were present
and averaged 27 ± 18% of total bile acids, indicating that 3β-hydroxy bile acids are normal
constituents of cecal content. We conclude that in the human cecum: (1) deconjugation
and dehydroxylation of bile acids are nearly complete, (2) most bile acids are in solution,
(3) bile acid concentration is less than critical micellar concentration, and (4) chenodeoxych-
olic and deoxycholic acid concentrations are below those reported to induce secretion in
experimental models. The present data provide approximate values for healthy persons
and may be useful for comparison with the bile acid spectrum in persons with bile acid
malabsorption, inflammatory bowel disease or colon cancer.
S1197
GVHD of the GI Tract After Bmt: Are Both Upper and Lower Endoscopies
Necessary to Make the Diagnosis?
Hazem Hammad, Nolan E. Perez, Tarek Dahche, Murray N. Ehrinpreis
Purpose: Graft versus host disease (GVHD) is a frequent complication of bone marrow
transplant (BMT), occurring in approximately 50% of patients after allogeneic BMT. In both
the acute or chronic forms of GVHD, the donor's bone marrow attacks the patient's organs
and tissues, impairing their ability to function and increasing the patient's susceptibility to
infection. GVHD usually affects the skin, mucous membranes, liver and gastrointestinal tract
(GIT). GIT involvement typically presents with watery diarrhea, abdominal pain, nausea
and vomiting, and gastroenterologists are usually consulted to perform endoscopy, often
both upper and lower, in patients suspected of having GVHD of the GIT. After the diagnosis
is confirmed by intestinal biopsies, steroids are administered for treatment. Previously,
biopsies of the upper GIT were purported to underestimate the severity of GVHD. The
purpose of our study was to identify the characteristics of GVHD of the GIT and to determine
if both upper and lower endoscopies are necessary for histologic confirmation. Method: We
retrospectively reviewed the medical records of patients who had biopsy-proven GVHD of
the GIT after BMT from 2000-2005 at Karmanos Cancer Institute in Detroit, Michigan.
Demographics, clinical presentations, co-morbidities, type of BMT, endoscopic findings and
histology results were recorded. Herein, we present the results of the histological analysis.
Results: We identified 57 patients with GVHD of the GIT diagnosed by upper and/or lower
endoscopy. The mean age was 39 and 53% of patients were male. 44 patients underwent
upper endoscopy, of which 93% (41) had confirmatory biopsies. 50 patients underwent
lower endoscopy, of which 88% (44) had confirmatory biopsies. Of the 34 patients who
underwent both upper and lower endoscopies, 26 (76%) had similar histology (within one
histologic grade) between the upper and lower intestinal tract; of the 8 patients who had
discrepant histology, 4 had more severe involvement of the upper GIT. In patients who had
biopsies from the stomach and duodenum, 29 out of 32 (90%) had similar or more severe
involvement of the duodenum. Conclusions: Upper endoscopy is associated with a higher
diagnostic yield than lower endoscopy (93% vs. 88%) for GVHD. The great majority (88%
or 30/34) of patients who underwent upper and lower endoscopies had similar or more
severe involvement in the upper GIT, with the duodenal biopsies giving the highest yield.
Therefore, upper endoscopy alone (i.e. EGD with duodenal biopsies) is usually sufficient
to make the diagnosis and guide therapy for GVHD of the GIT, and automatic bidirectional
endoscopy is not warranted.
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S1198
Better Efficacy of Tegaserod in Constipated Patients with Slow Colonic
Transit, Absent Pelvic Floor Dyssynergy and Absent Impaired Rectal Sensation
Annie on on Chan, Wai mo Hui, Gigi Leung, Nina yh Wong, Pierre Chan, Ivan fh Hung,
Axel Hsu, David But, Shiu kum Lam, Benjamin cy Wong
Objective: Functional constipation comprises of slow transit and pelvic floor dyssynergy.
Tegaserod has been shown to be effective in patients with functional constipation. We aimed
at identifying the subgroup of constipated patients who responded the best to tegaserod
treatment. Design: 250 patients were randomized for tegaserod or placebo treatment. Colonic
transit time and anorectal manometry were performed and available for analysis in 216 and
75 patients, respectively before the randomization period. Responders were defined as a
mean increase of complete spontaneous bowel motion≥1/week compared with the baseline.
Slow colonic transit was defined as >67 hours, pelvic floor dyssynergy defined as paradoxical
contraction or a failure to relax during anorectal manometry together with the feeling of
outlet blockade and/or digital evacuation, impaired rectal sensation defined arbitrarily as
greater than or equal to the mean balloon volume of the first sensation. Results: Demographic
data were comparable in the treatment and placebo groups. The responder rate was 41%
vs 20.9% (p=0.048) in slow transit, 51.4% vs 34.4% (p=0.047) in normal transit; 50% vs
30% (p=0.22) with pelvic floor dyssynergy, 54.2% vs 26.7% (p=0.087) without; 40% vs
22.2% (p=0.26) with impaired rectal sensation, 60% vs 35.3% (p=0.11) without; for the
treatment and placebo groups respectively. The improvement in responder rate comparing
the treatment to placebo group was best seen in those with absent pelvic floor dyssynergy,
absent impaired rectal sensation, but in slow transit instead of normal transit. Conclusion:
Tegaserod treatment is useful in constipated patients with slow colonic transit.
S1199
Efficacy of Tegaserod for Functional Constipation in Chinese Subjects: A
Randomized Double Blind Controlled Trial in a Single Center
Annie on on Chan, Wai mo Hui, Gigi Leung, Wayne hc Hu, Shiu kum Lam, Benjamin cy
Wong
Background: Tegaserod has been shown to be effective in chronic constipation in western
population. Aim: We investigated if Tegaserod is equally effective in Chinese population.
Materials and methods: 250 patients were randomized to a double-blinded 8-week treatment
of Tegaserod 6mg b.i.d or placebo. Response during weeks 1-4 was defined as an increase in
complete spontaneous bowl motion (CSBM)≥1/ week. Secondary efficacy included response
during weeks 1-8, individual symptoms and scores, quality of life and global assessment of
bowel habits and constipation. Results: 109 patients from the treatment group and 107
from the placebo group completed the 8-week treatment. Responder rates was 47.7% vs
29% for the treatment and placebo groups (p=0.005). The sustained CSBM rate was 29.4%
vs 15.7% in the two groups (p=0.016). The response rate was higher than that reported
previously in the Caucasian studies. There was improvement in the scores for stool form
scale, bothersomeness of constipation, abdominal distension/bloating, and satisfaction of
bowel habit (ps<0.05). The mental score was higher in the treatment group (46.8±9 vs
43.6±10, p=0.01). Conclusions: Tegaserod is effective in relieving chronic constipation in
Chinese population. The efficacy observed may be higher than that in western population.
S1200
Tegaserod Accelerates Small Bowel Transit Gregg Valenzuela MD,
Richmond,Virginia
Gregg A. Valenzuela
INTRODUCTION: Tegaserod is known to accelerate colon transit. It is unknown as to
whether tegaserod can effect small bowel transit and facilitate capsule endscopy small bowel
studies. METHOD: Capsule endoscopy transit times from consecutive studies were reviewed
in a case control series in patients given no premedication(NRx) or 12 mg tegaserod(Tg12)
2 hours before the study. All patients had fasted over night. Mouth to pyloris(M-P), pyloris
to ileocecal valve(P-IVC), mouth to IVC(M-IVC), and completed, mouth to cecum, studies(-
COMPLETE) were compared. Patients were of similar age. CONCLUSIONS: Tegaserod
accelerates small bowel transit in the fasted state. In this study tegaserod did not accelerate
gastric emptying or provide more complete studies for evaluation. Tegaserod may be helpful
in clinical situations characterized by impaired small bowel motility.
RESULTS
Times given in minutes; results given as the mean.
S1201
Aspirin Does Not Prevent Recurrence of Colorectal Adenomas in Patients with
Coronary Artery Disease
Annie on on Chan, Man hong Jim, Kwok fai Lam, David cw Siu, Teresa Tong, Fook hong
Ng, Siu yin Wong, Wai mo Hui, Shiu kum Lam, Benjamin C. Wong
Background: Aspirin has been reported to prevent colorectal adenoma recurrence. In contrast,
we observed a high prevalence of colorectal adenomas in patients with coronary artery
disease (CAD) in our previous study. Aims: To investigate whether aspirin prevents colorectal
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adenomas recurrence in patients with CAD. Methods: Patients scheduled for coronary angiog-
raphy as workup for CAD were enrolled for screening colonoscopy as described in our
previous study. Patients with colorectal adenoma after a clearance colonoscopy were recruited
for follow up study. Surveillance colonoscopy was performed at the end of first year. Aspirin
was prescribed to patients with CAD (aspirin group) as part of the routine management,
but not to those without (control group). Results: There were 46 patients with coronary
artery disease (aspirin group) and 51 without (control). There was no difference in sex
(91.3% male vs 82.4%, p=0.19), age (66 ± 7 vs 64 ± 8 yrs, p=0.18) or advanced colorectal
lesion (23.9% vs 17.6%, p=0.44) at screening colonoscopy in the two groups. In the
surveillance colonoscopy, the aspirin group, did not have a lower colorectal adenoma
recurrence rate (32.6% vs 27.5%, p=0.58) nor advanced lesion (15.2% vs 7.8%, p=0.25)
than the control. However, the presence of advanced lesion in the first screening colonoscopy
predicted the subsequent recurrence of colorectal adenoma (50% vs 24.7%, p=0.028).
Conclusion: Aspirin does not reduce colorectal adenoma recurrence rate at 1-year in those
with CAD. This may be secondary to the multiple concomitant risk factors.
S1202
Biofeedback Is Equally Effective in Patients with short Or Long Duration of
Functional Constipation
Annie on on Chan, Rany Chow, Wai mo Hui, Gigi Leung, Teresa Tong, Shiu kum Lam,
Benjamin C. Wong
Background: We have previously showed that biofeedback was effective in patients with
functional constipation. Aim: to investigate if biofeedback is more effective in patients
with short or long duration of functional constipation. Methods: Patients with functional
constipation satisfying the Rome II criteria were recruited. Short duration of constipation
was defined arbitrarily as ≤5 years, and long duration as >5 years. Patients were asked to
stop all laxative medication for two weeks and record daily bowel habits on a diary card,
as well as complete a constipation symptom severity questionnaire. Use of rescue laxatives
was recorded. Biofeedback consisted of teaching of proper defecation posture, abdominal
muscle exercise, pelvic floor retraining with pressure and biofeedback and also training of
balloon expulsion from the rectum. Each session lasted 30-60 minutes and was repeated
weekly for six sessions. Bowel symptoms, defecation frequency were assessed at baseline
and after six weeks. Severity of bowel symptoms were assessed in a 5 point Likert scale.
Changes in symptom severity from baseline were compared in the long and short duration
groups using Mann-Whitney U test. Results: There were 16 patients with short duration
and 39 with long duration. The two groups did not differ in age (44 ± 14 vs 49 ± 12 years,
p=0.16) or sex (female: 75% vs 89.7%, p=0.15). After completion of treatment, the number
of complete spontaneous bowel movements increased similarly in both groups (3.0 vs 2.5,
p=0.32), and constipation symptoms decrease in both groups: bloating (-1.1 vs -0.89, p=
0.43), incomplete evacuation (-1.7 vs -1.7, p=0.65), straining (-1.0 vs -1.0, p=0.99) and
laxative use (-3.2 vs -5.0, p=0.45). Conclusion: Biofeedback is equally effective in those
with long and short duration constipation.
S1203
High Recurrence of Small Intestinal Bacterial Overgrowth After Antibiotic
Treatment
Ernesto cristiano Lauritano, Maurizio Gabrielli, Emidio Scarpellini, Andrea Lupascu,
Carlo Petruzzellis, Davide Roccarina, Sandra Sottili, Giovanni Cammarota, Giovanni
Gasbarrini, Antonio Gasbarrini
SUMMARY Objectives: Small intestinal bacterial overgrowth (SIBO) is defined as an abnor-
mally high bacterial population level in the upper small intestine. Current SIBO treatment
is based on empirical courses of broad spectrum antibiotics but no data concerning SIBO
recurrence after antibiotic decontamination are available. Aim of the present study was to
investigate SIBO recurrence at 3, 6 and 9 months after antibiotic treatment and SIBO
recurrence predisposing condition. Methods: Sixty-one (61) consecutive patients affected
by SIBO and decontaminated by rifaximin (1200 mg per day for a week) were enrolled.
Diagnosis of SIBO was based on hydrogen glucose breath test (GBT). GBT was reassessed
at 3, 6 and 9 months after antibiotic treatment. Results: Eight (8) patients (8/61, 13%), 17
patients (27/61, 28%) and 26 patients (26/61, 46%) resulted to be positive to GBT at 3, 6
and 9 months after antibiotic decontamination, respectively. Older age (median age, 41.62
vs 35.60 years, p=0.03), use of protonic pump inhibitors and history of appendicectomy
(OR 4.4, IC 95%: 1.3-15.0, p<0.03) were significantly associated to SIBO recurrence.
Conclusions: Incidence of SIBO recurrence is high after antibiotic decontamination. Older
age, history of appendicectomy and use of protonic pump inhibitors are predisposing
conditions to small bowel recontamination. Cyclic courses of non-absorbable antibiotics
could be needed to prevent SIBO recurrence in patients with predisposing conditions.
S1204
Methane Breath Excretion Is Not Accompanied By a Different Pattern of
Clinical Presentation in IBS Patients
Michele Di stefano, Francesca Moroni, Paola Tana, Claudio Londoni, Samanta Mazzocchi,
Emanuela Miceli, Gino roberto Corazza
Background and Aims: Colonic methane (CH4) production is an effective consumption
pathway for hydrogen, but its clinical role in the pathophysiology of symptoms is still
unknown. In small samples of IBS patients, intestinal CH4 production correlates with clinical
presentation (1) and slows colonic transit time (2). However these data have not yet been
confirmed and the aim of this study was to verify the role of methane on both clinical
presentation and motility in a large cohort of IBS patients. Patients and Methods: A group
of 78 IBS (Rome II) patients (19 males, mean age 39 yrs ±12) underwent the lactulose
breath test to evaluate breath excretion of intestinal gases. Ten grams of lactulose in 250
ml of water were given orally after fasting breath sampling, and breath samples were then
collected every 15 minutes for 4 hours for hydrogen (H2) and CH4 detection. Cumulative
gas production was evaluated by the area under the time-concentration curve calculation
(AUC). Thirty-one patients were H2 and CH4 excretors and 47 H2 excretors. We subdivided
the CH4 excretors into 4 different patterns: type 1= constant, unmodified excretion through-
out the breath test; type 2= parallel increase of CH4 and H2 excretion; type 3= reduction
of CH4 excretion when H2 increases; type 4= increase in CH4 excretion without H2
modification. Presence and severity of bloating, flatulence, abdominal pain and borborygmi
were evaluated by a semiquantitative scale where 0=no symptom, 3= severe symptom. We also
estimated mouth-to-cecum transit time by the lactulose breath test. Results: The prevalence of
methane excretors was similar between IBS-C and IBS-D patients (37% vs 36%, respectively,
chi-square=NS). Methane excretors in comparison with methane non-excretors showed no
difference in the prevalence of bloating (87% vs 80%), flatulence, (81% vs 79%), abdominal
pain (81% vs 81%), borborygmi (74% vs 68%); in the severity of bloating (2±1 vs 2±1),
flatulence, (1.5±1 vs 1.4±0.9), abdominal pain (1.7±1 vs 1.7±0.9), borborygmi (1.3±1 vs
1.4±1); in mouth-to-cecum tansit time (128±23 min vs 111±39 min). There was no correla-
tion between severity of each symptom and CH4 excretion. Similarly, there was no difference
in prevalence and severity of symptoms and in mouth-to-cecum transit time between the
four subgroups of CH4 excretors (ANOVA). Conclusions: In a large sample of IBS patients
there is no evidence of association between methane excretion, pattern of clinical presentation
and intestinal motility.
S1205
Irritable Bowel Syndrome After Intestinal Infection: A Systematic Review and
Meta-Analyses
Marroon Thabane, Dan T. Kottachchi, John K. Marshall
Background and Aim: Post-infectious irritable bowel syndrome (PI-IBS) denotes the onset
of symptoms of IBS after an episode of enteric infection. Individual studies suggest that
symptoms of PI-IBS persist for years in most patients but gradually improve. A systematic
review was undertaken to define the incidence and natural history of PI-IBS. Methods: The
MEDLINE database (1966- ), Cochrane trial registries, and publication bibliographies were
searched to identify studies of PI-IBS. Data were extracted by two independent reviewers,
with inter-rater agreement assessed using Cohen's kappa and disagreements resolved by
consensus. Methodological quality was assessed by the modified Newcastle-Ottawa Scale
for assessing quality of non randomized studies. Pooled odds ratios and corresponding 95%
confidence intervals (CI) for prevalence of IBS were estimated by patients at risk using a
fixed effect (Mantel-Haenstzel), or random effect model if significant heterogeneity existed
(p<0.10) using RevMan 4.2 MetaView software for comparative studies. Precision weighted
pooled proportions were estimated from both controlled and uncontrolled studies. Results:
17 of 25 studies identified met our inclusion criteria (K=0.90); 16 were prospective cohort
studies (9 controlled, 7 uncontrolled) and 1 was a follow-up for one of the eligible studies.
Gastroenteritis was self reported in 7 studies and clinically or laboratory confirmed in 9.
Follow-up ranged from 3 months to 6 years. Among controlled cohort studies, intestinal
infection was associated with increased risk of IBS at study end (POR=6.05; 95% CI 3.28,
11.16). In subgroup analysis, the risk of developing IBS was increased at 3 months (POR=
7.61; 95%CI 4.28, 13.51), 6 months (POR=4.92; 95%CI 2.88, 8.42), 12 months (POR=6.64;
95%CI 2.54, 17.37) and 24-36 months (OR=3.87; 95%CI 2.98, 5.02). Among controlled and
uncontrolled studies, the pooled proportion estimate of IBS risk at study end was 98.3 per
1000 persons (95% CI 90.5, 880.0). Subjects with PI-IBS were more anxious and depressed
than those without PI-IBS, with mean score differences 2.72 (95%CI 1.75, 3.68) and 1.77
(95%CI 0.04, 3.50). Subjects with PI-IBS were younger than those without PI-IBS group
[mean age difference -3.31(95%CI: -4.69, -1.93)] and had a longer duration of fever [mean
difference 0.77 days (95%CI: 0.32, 1.22)]. Conclusion: The risk of IBS is increased six-fold
after acute gastrointestinal infection, with a pooled risk of 99 per 1000 infected persons.
Young age, prolonged fever, anxiety and depression are associated with PI-IBS.
S1206
The Oral Nonsystemic Antibiotic Rifaximin Prevents Symptom Recurrence in
Patients with Recurrent Clostridium difficile-Associated Diarrhea
Herbert L. Dupont, Zhi-dong Jiang, Kevin Garey
The prevalence and severity of Clostridium difficile-associated diarrhea (CDAD) are increasing
due to the poor response to standard therapy and to the emergence of an epidemic strain
of C difficile. Up to 25% of patients experience CDAD recurrence after first-line therapy,
and 3% to 5% of patients have >6 relapses. Treatment failure rates of 22% have been
reported with use of metronidazole, and the appropriate treatment for CDAD recurrence is
not well defined. Rifaximin is a nonsystemic antibiotic with a placebo-like tolerability profile
and robust In Vitro activity against multiple strains of C difficile. Preclinical data support a
beneficial role of rifaximin in the treatment of CDAD. This was an open-label evaluation of
rifaximin efficacy in patients with recurrent CDAD. Five adult patients (mean age, 69 y;
range, 56-75 y) with recurrent CDAD and unresponsiveness to first-line therapy were
administered rifaximin after providing a pretreatment stool that was positive for C difficile
cytotoxin B. Clinical response was assessed by resolution of diarrhea. These patients had
previously received therapy with metronidazole (n=3) or vancomycin (n=4) and had experi-
enced at least 2 CDAD relapses. Two patients also had received nitazoxanide during a
separate clinical study. One patient had received rifaximin 400 mg/d for 6 days in the
previous month. All patients received rifaximin 1200 mg/d for 2 weeks followed by 600
mg/d for 2 weeks. During treatment, all 5 of these patients achieved complete resolution
of diarrhea, with an average time to symptom relief of 7.6 days. Recurrence of CDAD
symptoms was not observed at 1 month follow-up, which is currently ongoing. A sixth
patient included in this report (age, 56 y) with persistent diarrhea and multiple underlying
comorbidities was treated by a physician on our staff with rifaximin 1200 mg/d for 36 days.
After treatment, the patient passed C difficile toxin-positive diarrheal stools; however, 4
different fecal cultures were negative for C difficile. The patient died from underlying illness.
In summary, rifaximin 1200 mg/d for 2 weeks followed by 600 mg/d for 2 weeks effectively
resolved clinical symptoms of CDAD and prevented CDAD recurrence in 5 of 6 patients,
with 1 patient showing probable microbiologic cure without opportunity for follow-up.
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Randomized, placebo-controlled studies are warranted to further investigate the role of
rifaximin in the treatment and prevention of CDAD.
S1207
Increased in Prevalence of Advanced Colonic Polyps in Young Patients Over
the Past Eight Years in Hong Kong
Tze jui Lam, Chris jj Mulder, Salvador a Peña, Benjamin C. Wong, Wai mo Hui, Shiu
kum Lam, Annie on on Chan
Background: In Hong Kong, CRC is ranked as the second most common cancer regarding
to incidence. Previous studies have shown a change in the distribution of CRC as well as
the age of onset. Aim: This study investigated the distribution of advanced polyps, in
increasing time, with regard to the prevalence, the histopathological features, such as histo-
logy. Methods: During the study period 1998 to 2005, 6424 colonoscopies have been
reviewed. Advanced polyp was defined as a polyp ≥ 10 mm in diameter, an adenoma with
villous component, or an adenoma with moderate to severe dysplasia. Polyps are considered
right sided if they occurred proximal to the splenic flexure and left sided if they occurred
distal to the splenic flexure. All the polyps were divided into two groups based upon the
year of the examination: period I is from 1998 to 2001 and period II from 2002-2005.
Results: 1856 polyps were detected from 6424 colonoscopies. Among them, 613 (33.0%)
were advanced polyps. The male to female ratio of advanced polyps was 1.74. The ages of
the 359 patients with advanced polyps during the 8 years ranged from 22 to 91 year, with
a mean of 69.21 year. Advanced polyps were mainly left sided (59.5%) in the whole study
period. The proportion of advanced polyps of age ≤ 60 years increased from 17.7% in
period I to 26.3% in period II (P=0.014). The proportion of advanced tubulovillous polyps
rose from 21.5% in period I to 29.5% in period II (P= 0.031). Conclusions: These data
confirm an increase of advanced polyps in the younger age group in time, which suggest that
the importance of screening by colonoscopy for advanced polyps increases in younger people.
S1208
Chronic Intestinal Pseudo-Obstruction: Familial Visceral Myopathy in Three
Generations with Alpha Actin Positive Inclusion Bodies in Intestinal Smooth
Muscle
Taina Sipponen, Riitta Karikoski, Hannu Nuutinen, Antti Markkola, Ilkka Kaitila
Familial visceral myopathy is a rare disease presenting as chronic intestinal pseudo-obstruc-
tion. Both autosomal dominant and recessive conditions have been described. In autosominal
dominant forms there are often signs of megacystis or megaduodenum and esophageal
motility disorders together with bowel dilatation. The disease affects usually the longitudinal
intestinal smooth muscle layer. Inclusion bodies in the intestinal smooth muscle have been
reported in sporadic forms. We report the clinical and histopathological findings on a three
generation family with seven affected members suffering from autosomal dominant visceral
myopathy. All patients presented with chronic intestinal pseudo-obstruction affecting particu-
larly entire small bowel which was markedly dilated in radiographic studies. Patients became
symptomatic in childhood or in adolescence and suffered from intermittent abdominal pain,
distension and vomiting. There were no signs of megacystis or megaduodenum. Two of the
patients died of the disease complications and one is on home parenteral nutrition. Specimens
for histopathological studies were available from three of the family members. Histologic
abnormalities involved intestinal smooth muscle with intracellular alpha-actin positive and
in more advanced stages also PAS-positive inclusion bodies mostly in the inner circular
layer of the muscularis propria. There was also degeneration and fibrosis of the muscularis
propria. The inclusions were not visible in routine hematoxylin-eosine-stained sections, but
were found in immunohistochemical stainings for smooth muscle alpha actin. There was
no abnormality in muscularis mucosae or in blood vessels and the findings were not identified
in mucosal biopsy specimens. To our knowledge this is the first described alpha smooth
muscle actin positive inclusion body finding in familial visceral myopathy.
Alpha actin positive inclusion bodies in small bowel inner smooth muscle layer
S1209
Gross Lower Gastrointestinal Bleeding in Patients On Anticoagulant and/Or
Antiplatelet Therapy: Endoscopic Findings and Clinical Outcomes
Jana G. Hashash, Assaad Skoury, Nathalie Aoun, Wael Shamseddeen, Kassem Barada
BACKGROUND & AIMS: Acute gastrointestinal bleeding is a severe complication of antico-
agulant and antiplatelet therapy. The aim of this study was to compare the frequency of
abnormal findings at endoscopy and the clinical outcomes in patients hospitalized with
gross lower gastrointestinal bleeding and using anticoagulant and/or antiplatelet drugs to
those in patients not using them. METHODS: A retrospective review of the medical records
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of 780 patients admitted to the American University of Beirut Medical Center with gross
gastrointestinal bleeding between January 1994 and August 2006 was conducted. Of those,
21.5% had lower gastrointestinal bleeding. The endoscopic findings, transfusion requirement,
length of hospital stay, need for surgery or embolization, and mortality rates were compared
between two groups, group A comprising patients on aspirin, clopidogrel, warfarin, heparin,
or a combination, and group B those not receiving any such drugs. Categorical variables
are presented as number and frequency, and continuous variables as mean ± standard
deviation. Pearson Chi square and independent sample t-test were used to test for association
between taking antiplatelet/anticoagulant on one hand and the other variables on the other
hand. P-value<0.05 was considered significant. RESULTS: Of 168 patients, 99(59%) were
in group A and 69(41%) in group B. Patients in group A were older(71±12 vs 62±20 years)
and more likely to have hypertension, diabetes, and vascular disease. Endoscopic data were
available for 86.3% of patients. The frequency of colorectal abnormalities is shown in the
table below. Subgroup analysis showed that the frequency of colon cancer was higher in
patients using warfarin compared to that in group B(17.2% vs 1.7%, p<0.05). Patients in
group A were more likely to require transfusions(38.4% vs 20.3%, p<0.05), but length of
hospital stay, need for surgery or embolization, and mortality rates(7.1% vs 4.3%) were
similar in both groups. CONCLUSION: The vast majority of patients with lower gastrointesti-
nal bleeding in the setting of anticoagulant or antiplatelet therapy have pathologic lesions,
and in those using warfarin, colon cancer is a common finding, supporting endoscopic
evaluation of all such patients. Apart from an increased likelihood of requiring transfusion,
clinical outcome in bleeding patients is not adversely affected by such therapy.
S1210
History of Hypothyroidism Is Associated to Small Intestinal Bacterial
Overgrowth
Ernesto cristiano Lauritano, Anna lisa Bilotta, Maurizio Gabrielli, Emidio Scarpellini,
Andrea Lupascu, Immacolata alessia Cazzato, Carlo Petruzzellis, Sandra Sottili, Giovanni
Cammarota, Giovanni Gasbarrini, Alfredo Pontecorvi, Antonio Gasbarrini
SUMMARY Objectives: Small intestinal bacterial overgrowth (SIBO) is defined as an abnor-
mally high bacterial population level in the upper small intestine. Intestinal motor disfunction
associated to hypothyroidism could predispose to SIBO. Luminal bacteria could modulate
gastrointestinal symptoms and interfere with levothyroxine absorption. Aims of present study
was to assess the prevalence and the clinical pattern of SIBO in patients with history of
hypothyroidism and the effects of SIBO decontamination on thyroxine absorption. Methods:
Fifty (50) consecutive patients with history of hypothyroidism due to autoimmune thyroiditis
were enrolled. Diagnosis of SIBO was based on positivity to H2 glucose breath test. SIBO
positive patients were treated with one-week rifaximin 1200 mg per day. Glucose breath
test, gastrointestinal symptoms and thyroid hormones plasma levels were reassessed 1 month
after treatment. Results: Twenty-seven (27) patients with history of hypothyroidism resulted
to be positive to GBT (27/50, 54%) with respect to 2 in the control group (2/40, 5%). The
difference was statistically significant (p < 0.001). Abdominal discomfort, flatulence and
bloating were significantly more prevalent in SIBO positive group. These symptoms signific-
antly improve after antibiotic decontamination. Thyroid hormones plasma levels were not
affected by successful SIBO decontamination. Conclusions: History of hypothyroidism is
associated to SIBO development. Bacteria in excess could influence gastro-intestinal clinical
manifestations in patients with history of hypothyroidism. SIBO decontamination is associated
with gastrointestinal symptoms improvement; however luminal carbohydrate fermenting
bacteria don't interfere with thyroxine absorption.
S1211
Clostridium difficile-Associated Disease Severity Grading Scale
Leticia P. Luz, Kimberly A. Reske, Erik R. Dubberke
Background: The incidence and severity of Clostridium difficile-associated disease (CDAD)
are increasing. Aggressive management of severe disease is recommended. There are currently
no validated methods for early identification of patients at increased risk for adverse events
due to CDAD. Aim: To test the ability of a CDAD severity grading scale based on presenting
symptoms in predicting adverse outcomes due to CDAD. Methods: Retrospective cohort of
adult patients with CDAD treated at a tertiary hospital between January and March, 2003.
CDAD definition was positive toxin assay or pseudo-membranes seen on colonoscopy. The
CDAD severity grading scale was based on the National Cancer Institute Common Termino-
logy Criteria for Adverse Events v3.0 criteria for grading colitis and diarrhea. Cases were
classified as follows: grade 1 diarrhea/colitis = mild; grade 2 diarrhea/colitis = moderate; >=
grade 3 diarrhea/colitis = severe. Only symptoms present within 48 hours of CDAD diagnosis
were included. Adverse outcomes evaluated included: death at 180 days, recurrent CDAD,
surgery due to CDAD, surgical consult, toxic megacolon, colonic perforation, lower GI bleed,
admission to an ICU for CDAD, vasopressors for hypotension, time from treatment to
symptoms resolution, composite adverse event including endpoints stated above, duration
of symptoms / diarrhea, and bloodstream infection due to enteric organism. Univariate
analyses (t-test, Mann-Whitney U, chi-square) and Kaplan-Meier analysis were performed,
and p <=0.05 was considered significant. Results: 78 patients with CDAD were included.
19 (24%) cases were classified as mild/moderate and 59 (76%) were classified as severe.
There was no difference in survival between mild/moderate and severe cases at 180 days.
Severe cases had a significantly longer duration of CDAD symptoms when compared to
mild/moderate cases (median=10 days vs. 5 days; p=0.02). Severe cases had a significantly
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higher occurrence of the composite adverse outcome variable when compared to mild/
moderate cases (44 [75%] vs. 6 [32%]; p<0.01). 7 (12%) of severe cases had a blood stream
infection due to an enteric organism compared to 1 (5%) mild/moderate case, but the
difference was not significant (p=0.6). Conclusion: The severity grading scale was able to
identify patients at increased risk for some adverse outcomes, especially when combined in
a composite variable. These findings suggest that this severity grading scale might be able
to predict CDAD related adverse events when studied in a larger population of patients.
S1212
Epidermal Growth Factor Prevents Hydrogen Peroxide-Induced Disruption of
Tight Junctions in Cholangiocyte Monolayers
Sreekar Guntaka, Ankur Seth, Nicholas F. Larusso, Radhakrishna (rk) Rao
The tight junctions (TJ) of bile duct epithelium form a barrier to the diffusion of bile
components across the duct into the liver parenchyma. Disruption of bile duct epithelial TJ
may play a role in the pathogenesis of liver diseases such as primary sclerosing cholangitis.
Our previous study showed that oxidative stress by Hydrogen peroxide (H2O2) disrupts the
TJ in intestinal epithelial monolayers. Therefore, we hypothesized that hydrogen peroxide
disrupts bile duct epithelial TJ. Epidermal growth factor (EGF), a gastrointestinal mucosal
protective factor, protects the TJ of intestinal epithelium from a variety of insults. Therefore,
in the present study we also investigated the protective effect of EGF on TJ of H2O2-
treated NRC1 cell monolayers. Methods: NRC1 cell monolayers, on Transwell inserts, were
incubated with 50-500 μM of H2O2 in the absence or presence of 10-30 nM EGF (adminis-
tered 10 min prior to LPS). Paracellular permeability was evaluated by measuring transepithe-
lial electrical resistance (TER) and FITC-inulin flux. TJ integrity was assessed by confocal
immunofluorescence microscopy of occludin and ZO-1. Organization of actin cytoskeleton
was visualized by staining cells with Alexafluor-488 conjugated phalloidin and confocal
microscopy. Results: Incubation of NRC-1 cell monolayers with H2O2 induced a time and
dose-dependent decrease in TER and increase in inulin permeability, suggesting that H2O2
increases the paracellular permeability in NRC1 cell monolayer. H2O2-induced increase in
permeability was associated with a redistribution of occludin and ZO-1 from the intercellular
junctions and disruption of actin cytoskeleton. Pretreatment of cell monolayers with EGF
significantly prevented H2O2-induced decrease in TER and increase in inulin permeability
and redistribution of occludin and ZO-1 from the intercellular junctions. EGF also prevented
H2O2-induced disruption of actin cytoskeleton. Conclusion: These results demonstrate that
EGF protects bile duct epithelial TJ from LPS. Support: DK55532; Mussette and Allen
Morgan Research Foundation.
S1213
Blockade of Bradykinin (Bk-2) Receptors Protects the Liver in Concanavalin a
Model of Hepatic Tissue Injury
Jaroslaw Biernat, Ryszard Sendur, Rafal Obuchowicz, Artur Dembinski, Teresa Pawlik,
Wieslaw Pawlik
Bradykinin (BK) is a potent arterial hypotensive peptide, but in the liver it induces a portal
hypertensive response observed not only in the liver cirrhosis but in different models of
acute liver injury as well. Portal hypertensive action of bradykinin is mediated by B2 receptors
located on sinusoidal cells of the periportal region. Using a model of immune-mediated
liver injury we performed the experiments on concanavalin A (ConA) pre-treated rats to
explore the role BK-1 and BK-2 receptors in this model of hepatic injury. In addition we
examined the effects of BK-1 and BK-2 receptors in sensory denervated animals. Experiments
were performed on Wistar rats weighing 200-220 under pentobarbital anesthesia. Mean
arterial blood pressures (AP), portal blood flow (PBF) and microcirculatory hepatic blood
flow (HBF) using laser-Doppler flowmetry were measured. At the end of each experiment
the venous blood samples were taken to establish the levels of hepatic tissue injury markers
(ALT, AST). Experimental groups: control group, ConA alone pre-treated animals, Con A
+ sensory denervation (capsaicin), ConA +BK-1 receptor antagonist, ConA + BK-2 receptor
antagonist, ConA + BK-1 + sensory denervation, ConA+BK-2 + sensory denervation. In
ConA alone pre-treated animals ALT and AST serum levels raised to 4233 ± 1540 and 2578
± 980 U/L whilst HBF were reduced by 12% (NS) in comparison to the values in the control
group. In BK-1 receptor- blocked rats HBF and both ALT and AST serum levels were not
statistically different to those observed in ConA alone pre-treated rats. In contrast BK-2
receptor blockade decreased ALT and AST serum levels by 34% and 32% respectively. In
addition HBF increased by 21% in this group. In capsaicin-denervated rats ALT and AST
levels were increased by 42% and 32% respectively while HBF values were reduced by 32%
(p< 0,05) versus ConA alone pre-treated rats. However when Con A was given to BK-2
receptor antagonist + capsaicin pre-treated animals, the observed reduction of both ALT
and AST was similar to the reduction of ALT and AST in BK-2 alone pre-treated rats.
Blockade of BK-2 (but not BK-1) receptors has a potent protective effect in Con A model
of hepatic tissue injury. The protective effect BK-2 receptor blockade is strictly correlated with
the observed vasodilation and seems not to be related to the activation of sensory neurons.
S1214
The Prevalence of PBC-Specific Autoantibodies in Patients with Systemic
Sclerosis
Andrzej P. Bialek, Susan Encabo, Beata Butkiewicz, Kozlowska Anna, Marek Brzosko,
Gary Norman, Piotr Milkiewicz
Background. The prevalence of clinically significant primary biliary cirrhosis (PBC) in patients
with systemic sclerosis (SS) is estimated to be 2.5%. It has also been shown that more than
90% of clinically and biochemically asymptomatic subjects who are positive for AMA express
histological features compatible with PBC. Early detection of PBC is of clinical importance
as timely introduction of the treatment with ursodeoxycholic acid (UDCA) makes the pro-
gnosis in this condition comparable to the general population. Detection of AMA has been
recently improved by introduction of a new assay utilizing the Gershwin-Leung recombinant
MIT3 antigen containing the 3 major epitopes for AMA autoantibodies. ELISA tests for
detection of 2 other PBC-specific autoantibodies (AAB), gp210 and sp100 have also recently
become available. Study aims: (i) assess the prevalence of PBC-specific MIT3 IgG-AMA, gp-
210 and sp100 AAB as well as SS-associated centromere and Scl-70 AAB in SS patients; (ii)
compare clinical and biochemical parameters in AMA positive and negative SS patients.
Materials and Methods. Fifty-two consecutive patients with SS referred to the Rheumatology
Dept were included. Thirty one suffered from limited skin SS (lcSS) and 20 from diffuse
SS(dcSS). Only one patient in this cohort was diagnosed with PBC before inclusion into the
study. MIT3 AMA, gp210, sp100, centromere A&B, Scl-70, and Jo-1 AAB were detected
by ELISA (INOVA Diagnostics, San Diego). Appropriate statistical tests were used for the
comparison between analyzed groups. Results. Eight (15%) patients with SS tested positive
for PBC specific AAB (7 were MIT3 IgG and 1 sp100 positive). No statistically significant
differences were observed between PBC-specific AAB positive and negative subjects in terms
of gender, age at the diagnosis, SS presentation (lcSS vs dcSS), prevalence of pruritus or
liver biochemistry. A clear, but not statistically significant trend towards increased prevalence
of chronic fatigue in PBC-specific AAB positive patients was observed (63% vs 37%). AAB
to centromere or Scl-70 were detected in 57.7% of the SS patients. No patients were positive
for both. Of the 8 SS patients positive for PBC-specific AAB, 2 were also positive for
centromere and 3 were positive for Scl-70 AAB. Conclusions. In patients with systemic
sclerosis, PBC-specific AAB are detected in 15% of subjects and thus occur 6 times more
commonly than clinically recognized PBC. As it is very likely that these patients indeed
suffer from PBC and early treatment with UDCA may improve their prognosis, screening
for these autoantibodies should be considered as a part of their routine assessment.
S1215
Gender Differences in Autoimmune Hepatitis; Histocompatibility Leukocyte
Antigens, Long Term Outcome and Survival
Thawab Al-chalabi, James Underhill, Bernard C. Portmann, Ian G. Mcfarlane, Michael A.
Heneghan
Introduction: Autoimmune hepatitis (AIH) is predominantly a disease of women. Reasons
for this gender bias are unclear and few series exist that have assessed clinical characteristics,
treatment responses and long-term outcomes of men with AIH. Aims and Methods: To
evaluate the clinical course and outcomes of a cohort of 51 men from a total of 238
consecutive patients with definite AIH from a single centre between 1971 and 2005. The
primary outcome measure was death or liver transplantation. Median follow up was 14
years (range 1-35y) in men and 11 years (range 0.1-30 y) in women Results: Median age
at diagnosis was 39y in men and 49y in women (p= 0.0589). HLA A1, B8 and DR3 allotypes
and the HLA A1-B8-DR3 haplotype, were more frequently expressed in male patients than
female patients with AIH (63% vs. 45%, p=0.049; 74% vs. 38%, p<0.001; 62% vs. 44%,
p=0.058; and 50% vs. 23%, p=0.003; respectively). There were no significant differences
with respect to clinical manifestations at presentation, time to diagnosis, prevalence of
concurrent or family history of autoimmune diseases. The presence of cirrhosis at initial
liver biopsy was similar in the two groups. Induction and maintenance therapies were similar
in both patient groups; 98% of male patients and 96% of female patients demonstrated a
complete initial response to treatment. A greater number of men experienced at least one
relapse compared to women (71% vs 55%, p=0.0591). Despite this, during long-term follow-
up, female patients were significantly more likely to die or require liver transplantation than
male patients (Log rank test p=0.0363). Multivariate analysis demonstrated absence of
jaundice at presentation, presence of ascites, haematemesis and low necroinflammatory grade
at presentation to be factors associated with reduced survival in both groups of patients.
Conclusions: Men with AIH appear to have a higher relapse rate and younger age of disease
onset compared to women, which may relate to the increased prevalence of the HLA A1-
B8-DR3 haplotype. Despite this, male patients with AIH have significantly better long-term
survival and outcome. Low disease activity and manifestations of portal hypertension at
presentation appear to be associated with reduced survival.
S1216
Biliary Involvement in Patients with Autoimmune Pancreatitis: Clinical
Features and Response to Treatment
Amaar H. Ghazale, Suresh T. Chari, Naoki Takahashi, Thomas C. Smyrk, Michael J. Levy,
Mark D. Topazian, Jonathan E. Clain, Randall K. Pearson, Bret Petersen, Santhi S. Vege,
Keith D. Lindor, Michael B. Farnell
Introduction: The biliary tree is the most common extra-pancreatic organ involved in Autoim-
mune Pancreatitis (AIP). In this study, we evaluated clinical characteristics and treatment
response of AIP patients with biliary involvement. Methods: From a prospectively maintained
database of AIP patients, 41 patients with evidence of biliary strictures on cholangiography
were identified. AIP was diagnosed by HISORt criteria; diagnostic pancreatic histology was
available in 25 patients. Imaging, laboratory, and clinical characteristics as well as treatment
response was assessed. Results: Mean patient age was 62 +/- 2 yrs, 83% males. Obstructive
jaundice was a presenting symptom in 35/41 (85%). Serum IgG4 was >140 mg/dl in 77%,
and >280 mg/dl in 48% of patients. Alkaline phosphatase was elevated (>142 U/L) in 78%,
AST >31 U/L in 83% and ALT >45 U/L in 87%. Distal intra-pancreatic biliary strictures
(resembling pancreatic cancer) were found in 28/41 (68%), proximal extra-hepatic strictures
(mimicking cholangiocarcinoma) in 14/41 (34%) and intra-hepatic strictures (similar to
primary sclerosing cholangitis) in 18/41 (44%). Only 2/41 (5%) had inflammatory bowel
disease. Thirty one patients were treated with steroids, all initially with prednisone. Starting
dose ranged from 30-60 mg and length of treatment 4-16 weeks, most common regimen
being prednisone 40 mg for 1 month with taper over 2 months. Response, defined as
improvement/resolution of strictures and/or improvement/normalization of liver enzymes,
was achieved in 30/31 (97%) patients. Seven patients had complete resolution of strictures,
and 17 normalized liver tests. In patients with biliary stents (n=20), stent removal after
therapy was possible in 95%. Symptomatic and/or biochemical relapse (↑ liver enzymes)
occurred in 12/31 (39%). The sole factor predicting relapse was presence of intra-hepatic
(PSC-like) strictures (9/12 relapsers vs. 7/19 non-relapsers, p=0.03). Relapses were treated
with slow steroid taper alone in 6 patients and with short steroid courses in addition to
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immunomodulatory drugs in 5 (4 azathioprine, 1 mycophenolate mofetil). Second relapses
occurred only in the slow steroid taper group (n=4) either during or after taper. No relapses
occurred in the immunomodulatory group and all remained on these drugs at the time of
study. Conclusions: Biliary strictures in AIP commonly involve the distal bile duct; however
they can also frequently occur in the proximal and intrahepatic ducts. Initial steroid response
is excellent, however relapses are common. Intrahepatic strictures resembling PSC are more
likely to relapse. Role of immunomodulatory drugs to prevent relapse needs further study.
S1217
Posttraumatic Sclerosing Cholangitis (PTSC): Unexpectedly High Incidence in
Certain Groups of ICU Patients
Dorothee Dorlars, Jenny Gebhardt, Jürgen Pausch
Background: Previously, we described a new entity of severe progressive cholestasis syndrome
mimicking post-traumatic sclerosing cholangitis (PTSC), manifesting in trauma patients with
thoracic or craniocerebral injury. New data shows that this disease is increasing in frequency
and has a poor prognosis. Patients and methods: From 5/2001 to 11/2006, we observed
18 patients (male:female=17:1; ages 21 to 67 yrs.) with PTSC. More than 80% of the patients
were treated in the ICU for more than 3 weeks (13-164 days, mean 44) with long-term
mechanical ventilation (10-74 days, n=8 for more than 4 weeks). 11/18 patients had suffered
polytrauma, 8 of these with thoracic trauma. 7/18 patients had a 2nd degree craniocerebral
injury. Of these, 5 also suffered thoracic trauma (lung contusion, hematopneumothorax).
Of the 3 patients without thoracic injury, one had severe COPD, while another developed
ARDS during the course of treatment. We analyzed risk factors and the natural history of
PTSC. Results: Upon admission, the liver function tests were normal in all but 2 patients.
17/18 patients showed a typical elevation in cholestatis parameters between day 4 and 10
of their ICU stay. AP values peaked at 492-5799 U/l (mean 2323), GGT values at 360-2509
U/l (mean 1181), bilirubin values at 0.8-31 mg% (mean 10). ERC findings were consistent
with sclerosing cholangitis or vanishing bile ducts. 9/18 patients were treated endoscopically
(4 bouginations, 7 sludge/stone extractions), with no significant effect on laboratory para-
meters. Follow-up: All patients are being treated with UDCA 20-25 mg/kg. To date, 3
patients have improved clinically (incl. laboratory parameters), while 3 patients are stable,
2 having cirrhosis. 2 patients have undergone liver transplant. Both required a re-transplanta-
tion and now have normal laboratory values. 4 patients are listed for transplant. In 5 patients
the disease is progressively worsening, 3 of these are ineligible for transplant. Complications
were variceal bleeding (n=1) and iterative cholangitis (n=2). 1 patient was lost to follow-
up. Conclusions: PTSC is a more common condition than previously thought. Risk factors
include male gender, severe lung disorders (thoracic trauma, ARDS, COPD) and craniocereb-
ral injury. Typical laboratory findings are an elevated AP and GGT (AP>GGT;17/18 patients).
ERC findings suggest an etiological role for ischemic-type biliary lesions (ITBL). Treatment
includes regular endoscopic interventions, high-dose UDCA therapy and early assessment
for liver transplant. The prognosis is poor, making further research on the pathogenesis of
this condition critical to developing a causal treatment or prophylaxis.
S1218
Role of HIDA Scan in Chronic Cholecystitis in Ambulatory Setting: A
Retrospective Study
Kishore Maganty, Meenalochani Narayanan, Larry Hughes, Howard B. Chodash
BACKGROUND: Cholescintigraphy (HIDA scan) is commonly used to diagnose cholecystitis.
Unlike acute cholecystitis which presents with acute RUQ pain and is diagnosed with clinical
and radiological findings on ultrasound or HIDA scan; chronic cholecystitis is a pathological
diagnosis and frequently occurs in an ambulatory setting, presenting with non-specific
symptoms such as vague RUQ abdominal pain and dyspepsia. Ultrasound has not been very
useful in the diagnosis. The value of HIDA +/- CCK in patients with chronic cholecystitis
in an ambulatory setting has not been well defined. Cholecystokinin (CCK) given after a
negative HIDA scan can reveal gallbladder (GB) dysfunction. AIM: To evaluate the efficacy
of HIDA +/- CCK in patients with chronic cholecystitis in an ambulatory setting. METHODS:
Setting: A retrospective study of an outpatient population. Inclusion criteria: All outpatients
over 18 years who underwent HIDA +/- CCK for any indication during a 5-year period
were reviewed. Those with acute cholecystitis or gallbladder diseases other than chronic
cholecystitis were excluded. Outcome: histological diagnoses of chronic cholecystitis after
HIDA + CCK scan vs. HIDA scan. Statistical method: Fisher exact test. RESULTS: A total
of 1600 patients who had a HIDA scan from 2000-2005 were analyzed, 568 patients met
inclusion criteria. The patients were 76.6% female with a mean age of 50.6 years. Chronic
cholecystitis was diagnosed in 145 patients, 20 patients had a positive HIDA scan (Delayed
or non-visualization of the GB), 93 patients had a positive HIDA + CCK (GB dysmotility—
ejection fraction < 35%), and 32 patients had a negative HIDA +/- CCK. Sensitivity of a
HIDA scan for diagnosis of chronic cholecystitis was 13.8% (20/145) vs HIDA+CCK 82.3%
(93/113) (p=.001). Specificity of a HIDA scan for diagnosis of chronic cholecystitis was 75%
(12/16) vs. HIDA + CCK 36.6%(4/11) (p=0.061). False negative rate is 17.6 % (20/113)
with HIDA + CCK vs. 37.5% (12/32) with a HIDA scan (p=0.028). Positive predictive value
in HIDA + CCK 93% (93 of 100) vs. HIDA 81% (17 of 21)(p= 0.0976). CONCLUSION:
The results indicate that HIDA + CCK is significantly more sensitive than HIDA scan in
diagnosing chronic cholecystitis. Patients with chronic and non-acute RUQ abdominal pain
and dyspeptic symptoms should be evaluated for GB dysmotility by HIDA + CCK.
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S1219
Sex-Based Differences in Gallbladder Cancer Associated with
Pancreaticobiliary Maljunction
Wataru Munakata, Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta,
Atutake Okamoto
Background/Aims: Gallbladder cancer predominantly affects women; this sex-based differ-
ence is influenced by factors such as gallstones, sex hormones, and genetic susceptibility.
On the other hand, pancreaticobiliary maljunction (PBM) is also significantly more common
in women. PBM is a congenital anomaly that occurs when the pancreatic and bile ducts are
united outside of the duodenal wall. In patients with PBM, the action of the sphincter of
Oddi cannot functionally affect the union of the two ducts, and pancreatic juice can reflux
into the bile duct. This frequently results in biliary cancer. In particular, PBM without biliary
dilatation is a strong risk factor for gallbladder cancer. We examined sex-based differences
in gallbladder cancer associated with PBM. Methodology: With a particular focus on gender
differences, we retrospectively compared clinicopathological findings between 44 patients
(9 men, 35 women) with gallbladder cancer associated with PBM (without biliary dilatation)
and 232 patients (60 men, 172 women) with gallbladder cancer that was not associated
with PBM. Results: Gallbladder cancer was detected in 75% of patients with PBM without
biliary dilatation. Among PBM patients, gallbladder cancer was significantly more common
in women than in men (29/35 (83%) vs. 4/9 (44%), p<0.05). Both men and women with
gallbladder cancer associated with PBM were significantly younger at the time of diagnosis
than patients with gallbladder cancer without PBM (p<0.01). Gallstones were detected in
only 10% of women with gallbladder cancer associated with PBM, while gallstones were
detected in 63% of women with gallbladder cancer without PBM (p<0.01). There were no
significant sex-based differences between cases of gallbladder cancer associated with and
without PBM in the location and histology of cancer, incidence of multiple biliary cancers,
and resectability. Conclusions: Gallbladder cancer occurs very frequently in patients with
PBM without biliary dilatation, and women appear to be at significantly higher risk than
men. The age at diagnosis of patients with gallbladder cancer associated with PBM was
significantly younger than of patients with gallbladder cancer without PBM. Gallstones were
rarely detected in gallbladder cancer associated with PBM compared with gallbladder cancer
without PBM.
S1220
The Usefulness of Percutaneous Cholecystostomy with Gbit-Catheter for
Acute Cholecystitis
Kei Ito, Naotaka Fujita, Yutaka Noda, Go Kobayashi, Jun Horaguchi, Osamu Takasawa,
Takashi Obana, Takuro Endo, Kazunari Nakahara
Background: Although early cholecystectomy is the standard treatment in case of acute
cholecystitis, the morbidity and mortality in patients at high risk for surgery from comorbid
diseases is high. The aim of this study was to evaluate percutaneous cholecystostomy (PC)
for treatment of acute cholecystitis. Patients and methods: Between Jan. 2002 and Dec.
2005, 118 consecutive patients with acute cholecystitis who underwent PC (male, 39; female,
20; mean age, 73; range, 44-92) were enrolled in this study. Percutaneous cholecystostomy
was performed by puncturing the gallbladder with an 18-gauge needle under US-guidance,
followed by deployment of a GBit-catheter (Cathex, Co., Ltd., Tokyo, Japan) with the
Seldinger technique. The GBit-catheter employed is a single pigtail catheter with side-holes
for sufficient drainage. Indications for PC were as follows: peritonitis, pericholecystic abscess
or no improvement with antibiotics and factors precluding immediate performance of chole-
cystectomy. PC was regarded as technically successful when a pigtail catheter was adequately
placed in the gallbladder. A positive clinical response was defined as normalization of at
least two of the three clinical parameters of acute cholecystitis (abdominal pain, fever, and
leukocytosis) within 72 hours. The technical success rate, clinical response rate, and incidence
of early complications were evaluated in each group. Results: PC was technically successful
in all patients. Good clinical response was obtained in 106 patients (90%). Three patients
who did not show clinical response died of comorbid diseases. Dislodgment of catheter was
observed in three patients (2.5%). After improvement of inflammation, cholecystectomy was
performed in 84 patients (laparoscopic cholecystectomy, 55; open cholecystectomy, 29).
The incidence of conversion to open procedure was 16% (9 patients) in the laparoscopic
group. No surgery-related complications were encountered. Conclusions: Percutaneous cho-
lecystostomy is a safe, effective procedure for selected patients with acute cholecystitis who
cannot immediately undergo cholecystectomy.
S1221
On the Value of Percutaneous Transhepatic Cholangiodrainage (PTCD) in the
Therapy of Benign Biliary Duct Stenosis: Our Current Data
Dorothee Dorlars, Ralf Hünerbein, Jürgen Pausch
Background: Percutaneous transhepatic cholangiodrainage (PTCD) has become a reliable
and safe method in treating benign diseases of the biliary tract, if these are not suited to
endoscopic treatment. However, data pertaining to percutaneous treatment techniques are
still rare. The recent data confirm our earlier findings. Patients and methods: Between March
2000 and November 2006, 26 patients were treated by PTCD (13 male, 13 female; age
range 30-84 yrs, mean age 61 yrs; polyurethane PTCD drains produced by Pflugbeil,
Germany, “Münchner Drainage”). The biliary stenoses were variously (post)inflammatory
stenoses of extra- or intrahepatic bile ducts (n=7; 5 of them combined with bile duct stones),
or strictured anastomoses after biliodigestive anastomosis (n=11) or after hemihepatectomy
(n=3). 4/26 evolved after cholecystectomy. One patient had a long-segment bile duct stenosis
after complicated acute pancreatitis. 4/26 patients had bilateral stenting, 2 received a PTCD
of the left liver lobe. After initial placement of the PTCD (8 F), bougienage up to 20 F was
carried out. We replaced the drains, on average, every 2-3 months. The final drain calibers
were 12, 14 F, 16 F, 18 F and 20 F. The treatment took 4 to 17 months (mean 12,1
months). The drains were all internalised and were flushed twice per week. Results: Of the
26 patients, 13 experienced no complications. Only one patient had a severe complication
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involving bleeding and requiring transfusions. The remaining 12 patients suffered only one
or more mild complications: cholangitis (7), PTCD-blockage (5), leaks (3) and local skin
irritation (3). 8 patients are still being treated. Of the 18 patients who completed treatment,
one did not respond sufficiently to percutaneous drainage and received a metal stent. 17
patients had a follow up of up to 5 years and are actually doing well without signs of relapse.
Conclusions: With more than six years of performing PTCD in benign biliary duct stenoses
we found an effective alternative to surgery with a high success rate (of at least 90 %) and
few side effects (serious complications less than 8%). The modern large-caliber polyurethane
drains are safe and well tolerated.
S1222
Incidence and Risk Factors for Hepatic and Extrahepatic Malignancies in
Primary Biliary Cirrhosis in Japan
Ken Sato, Kenichi Hosonuma, Masatosi Yanagisawa, Takeshi Itikawa, Naondo Sohara,
Satoru Kakizaki, Hitoshi Takagi, Masatomo Mori
Background: Hepatocellular carcinoma (HCC) have been increasingly reported as a complica-
tion of primary bliliary cirrhosis (PBC). However, no large case studies have focused on the
detailed analysis of the incidence ratio and risk factors for hepatic and extrahepatic malignanc-
ies in PBC in Japan. Methods: Our aim was to analyze the incidence of malignancies in a
large series of PBC patients in Japan; to compare the incidence with those obtained in the
general population, as derived from the general cancer registry; and to clarify any possible
adjunctive risk factors for malignancy. The comparison of the incidence of malignancies
between the study group and the general population was obtained by the standardized
incidence ratio (SIR), which is the ratio between the cases observed and the expected number
of cases in the study group. A logistic regression analysis was performed to clarify the risk
factors for hepatic or extrahepatic malignancies using laboratory data and questionnaires
about hereditary predisposition and lifestyle habit. Results: The overall sample included 239
patients (29 males, 210 females). The mean age was 57 years (range 24-86); Liver biopsy
was performed in 168 patients. One hundred and eight patients had Scheuer's stage 1, 33
had stage 2, 16 had stage 3, and 11 had stage 4. The follow-up period was average 89
months per person. Extrahepatic malignancies developed in 14 cases (5.9%), and HCC in
eleven cases (5.2%) which were not always associated with cirrhosis. One case of HCC had
positive HCV-RNA test but the non-cancerous liver tissue was consistent with PBC. The
SIR for HCC was 6.0 (95%CI 3.0-10.7), whereas the SIR for top four extrahepatic malignanc-
ies, the colon, gastric, lung and breast cancer were 0.7 (95%CI 0.1-2), 0.6 (95%CI 0.1-
1.7), 0.7 (95%CI 0.1-2.4), 1.2 (95%CI 0.1-4.3), respectively. Symptomatic PBC showing
icterus, ascites, varices, or hepatic coma was an independent risk factor for HCC in overall
PBC patients. When multivariate analysis was restricted to female patients, Age, HCV-RNA,
symptomatic PBC or family history of HCC were independent risk factors for HCC. Diabetes
mellitus, hyperlipidemia, symptomatic PBC, or preexistence of HCC were independent risk
factors for extrahepatic malignancies in not only overall but also female patients. Conclusions:
The incidence of HCC but not extrahepatic malignancies was significantly higher in PBC
than those in the general population in Japan. We advocate that symptomatic PBC has to
be regularly monitored for HCC and extrahepatic malignancies, and lifestyle-related diseases
may play an important role on incidence of extrahepatic malignancies in PBC.
S1223
Trans-Abdominal Ultrasound Is Less Sensitive for the Diagnosis of Acute
Cholecystitis in Case of a Early Clinical Presentation
Marie Pierik, Chris Verslype, Baki Topal, Raymond Aerts, Martin Hiele
INTRODUCTION & AIM The challenge in the diagnosis of early acute cholecystitis with
gallstones is distinguishing it from uncomplicated biliary colic. Misclassification may result
in delay of adequate therapy. Differential diagnosis is made by combination of clinical
findings, inflammation parameters and trans-abdominal ultrasound (US). Sensitivity of ultra-
sonography (US) for acute cholecystitis is reported to be between 60 and 88 percent. We
were interested in the sensitivity of US to detect acute cholecystitis in patients presenting
early (<24 hours) after the first symptoms. MATERIALS & METHODS The clinical records
were reviewed of 331 consecutive patients who underwent a cholecystectomy in our hospital
between January 2004 and December 2004. In this cohort, we identified 110 patients who
were admitted for acute cholecystitis. Clinical, US and laboratory findings at presentation
were recorded for all patients. Furthermore we registered if patients had undergone primary
cholecystectomy or initial treatment with antibiotics and delayed cholecystectomy (after six
weeks). RESULTS Patients presenting at the emergency department within 24 hours after
the first onset of symptoms more often had an negative US (19 out of 41 versus 5 out of
69, p<0.01 OR 0.154 95%CI{0.047-0.506}) and had lower CRP values (p<0.01 OR 0.984
95%CI{0.972-0.996}) compared to patients presenting later. The sensitivity of US was 53.7%
and 92.8% for patients examined within or after 24 hours respectively. All the patients with
a negative ultrasound presented with prolonged upper abdominal pain (>6 hours) and
cholecystolithiase or sludge in the gallbladder. In the subgroup of patients presenting at the
emergency department within 36 hours after the first symptoms, 43.4% of the patients with
a negative ultrasound compared to only 24.7% with a positive ultrasound were initially
treated with antibiotics. CONCLUSION Ultrasound examination is less sensitive for the
diagnosis of acute cholecystitis in case of early clinical presentation. In patients with suggestive
symptoms and a negative US, the latter can be repeated to avoid delay in appropriate treat-
ment.
S1224
Cholecystectomy Or Wait-and-See Policy After Endoscopic Removal of Cbd
Stone: Compare with Silent GB Stone
Jin hong Kim, Jai hak Jeung, Byung moo Yoo, Sung jae Shin, Jae youn Cheong, Kee
myung Lee
Background: Endoscopic sphincterotomy(EST) is an effective method of managing common
bile duct stones. But after endoscopic removal of common bile duct stones, the need for
cholecystectomy in patients with concominant gall stones is controversial. The aims of this
study were to evaluate the recurrence rate of biliary complications and to assess the require-
ment for subsequent cholecystectomy by comparing silent gallstone patients. We also investig-
ated the risk factors of biliary complications. Method: We reviewed retrospectively 57
patients with common bile duct stones with concominant gallstones treated by EST without
subsequent chlecystectomy from May 2003 to December 2005 as a patient group. The
Control group was composed of 171 patients with silent gallstone diagnosed by abdominal
ultrasound during the same period. We defined the biliary complications as biliary colic,
acute cholecystitis, recurrence of common bile duct stones. The following factors were
considered while evaluating risk factors for the developing of biliary complication: age,
gender, CBD stone size, CBD stone number, periampullary diverticulum, lithotripsy, a
presenting illness of pancreatitis or jaundice, low lying cystic duct, cystic duct patency, GB
wall thickening, Gallstone number, GB sandy stone, EST site. Following up the both groups
was done by medical records or phone calls. Result: No significant difference was noted
concerning both group characteristics (table1). During a mean 22-month follow-up, 57
patients allocated to patient group, 6 (10.5%) had biliary complications(acute cholecystitis,
n = 1, biliary colic, n = 2, recurrence of common bile duct stone, n = 3) compared with 4
(2.5%) of the 171 in the control group(acute cholecystitis, n = 4) (p=0.004). The mean
time elapse to biliary complication was 9.3 months in patient group and 18.5months in
control group. By Cox regression analysis, low lying cystic duct(p=0.008) and GB wall
thickening(p=0.012) was found as a risk factor of biliary complication. Conclusion: After
common bile duct stone removal by EST, subsequent cholecystectomy is warranted in
patients with low lying cystic duct and GB wall thickening at the time of CBD stone removal,
although in asymptomatic state
. Patients Characteristics.
S1225
Serum Hepatocyte Growth Factor Activator Inhibitor Type 1 Is Positively
Associated with Hepatic Fibrosis in Patients with Chronic Hepatitis C Virus
Infection
Akihiro Moriuchi, Hirofumi Uto, Susumu Hasegawa, Makoto Oketani, Yoichiro Takami,
Kazunori Kusumoto, Katsuhiro Hayashi, Akio Ido, Toshiya Yamagishi, Sherri O. Stuver,
Hirohito Tsubouchi
[Purpose] Liver cirrhosis/fibrosis is characterized by excess production and deposition of
extracellular matrix components, leading to tissue scarring and destruction of normal hepatic
parenchyma. Hepatocyte growth factor (HGF) activator inhibitor type 1 (HAI-1) is a serine
protease inhibitor that proteolytically cleaves and activates HGF. The mature membrane-
form of HAI-1 can be proteolytically cleaved and released into the extracellular environment.
Although several studies have investigated the anti-fibrotic effect of HGF, how the HGF/
HAI-1 system is involved in hepatocyte repair and hepatic fibrosis has not been fully clarified.
The aim of this study is to elucidate the clinical significance of serum HAI-1 in patients
with chronic hepatitis C virus (HCV) infection. [Methods] A total of 454 subjects with
chronic HCV infection were included in this study. Chronic HCV infection was confirmed
by the presence of HCV antibodies and HCV RNA. An additional 89 chronic hepatitis C
(CHC) patients who underwent liver biopsy were also analyzed. Serum HAI-1 levels (ng/
ml) were assessed by enzyme-linked immunosorbent assay (ELISA). In addition to HAI-1,
serum levels of total HGF, activated HGF, platelet count, AST, HCV core protein and hepatic
fibrosis marker, type IV collagen 7S (IVcol7s) and hyarulonic acid (HA) were also evaluated.
[Results] Mean HAI-1 serum levels were 7.5±2.3 in the healthy donors (n=52). In the 454
HCV-infected subjects, serum HAI-1 levels were positively correlated with IVcol7s (r=0.73,
p<0.001) and HA (r=0.42, p<0.001). However, there was no correlation between HAI-1
levels and total HGF, activated HGF, AST, or HCV core protein levels. In the 89 patients
with CHC, serum HAI-1 levels significantly increased with the severity of liver fibrosis
[F1:12.5±7.6 (n=38); F2:18.2±9.6 (n=28); F3:26.4±11.0 (n=11); F4:30.1±13.0 (n=12)]
(p<0.001). In addition, the nine patients who remained responsive to interferon therapy
had significantly decreased mean HAI-1 levels (-7.6±2.0) over the seven-year follow-up
period, whereas in the 11 untreated patients, mean HAI-1 levels increased during this
observation period (18.0±3.9) (p<0.001). [Conclusions] HAI-1 is associated with hepatic
fibrosis but not with HGF levels. Serum HAI-1 levels may serve as a non-invasive, clinical
marker for hepatic fibrosis in HCV-infected patients. HAI-1 levels could also serve as a
surrogate marker for the antifibrotic effects of HCV treatment.
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S1226
Diagnostic Value of Biochemical Markers for Prediction of Liver Fibrosis and
Inflammation in Pediatric Patients
Yoram Bujanover, Rachel Klar, Michal Kori, Esther Granot, Ron Shoul, Vered Nachmias
Background: In the past several noninvasive laboratory methods were suggested as an
alternative to liver biopsy .Recently a panel of six serum markers -Fibro test(FT) - Actitest(AT)
was validated in the prediction of liver fibrosis and inflammatory activity in adult patients
with liver disease. Aim: The aim of the present study was to assess the diagnostic utility of
the Fibrotest - Actitest in pediatric patients with viral and autoimmune hepatitis. Subjects
and methods: Twenty four patients were studied, 14 female, 10 male, age range 2-18 yr
(m-12.4yr). Diagnosis : HCV-13; HBV-3;HCV+HBV-1; HCV+HIV-1;Autoimmune hepatitis-
4. Liver biopsy was performed in 23 patients. Six biochemical markers were evaluated using
commercial kits : Total bilirubin, GGT, alfa2 macroglobulin, haptoglobin, apolipoprotein
A1, ALT. Those parameters were used for the calculation of the FT-AT scores according to
the patent algorithm of Biopredictive (France) ranging from 0-1. Liver biopsy was compared
to the results of the FT and AT using AUROC statistical analysis. Results: FT- 75% of the
patients were F0; F0-F1 12%, F1- 4%, F1-F2- 8%, AT-A0 41%, A0- A1 -20%, A1- 12%,
A1-A2 -20%, A3 - 4%. The AUROC comparing FT with the liver biopsy results were 0.85
for F0 , 0.87 for F0-F1, 0.88 for F1-F2. FT yielded a higher AUROC than AT .85 VS .70
respectively. Conclusions: Fibrotest - Actitest is a simple and effective method to assess
fibrosis and inflammation in pediatric patients with liver disease. The correlation with liver
histology was high. The biochemical markers may serve as an alternative to liver biopsy in
pediatric patients
S1227
Prevalence and Risk Factors Associated with Hepatitis B and Hepatitis C Virus
Infections Among Healthy Population in An Urban Community in Dhaka,
Bangladesh
Hasan Ashraf, Christian Rothermundt, Nur H. Alam, Pradip K. Bardhan, Abdullah
Brooks, Sawkat Hassan, Niklaus Gyr
Introduction: Prevalence data of Hepatitis B virus (HBV) and Hepatitis C virus (HCV)
infections among healthy population in Bangladesh is rare. However, chronic HBV and HCV
infected individuals remain asymptomatic for many years. A population-based study was
conducted to estimate the prevalence of HBV and HCV infections including their risk
factors, which might eventually guide the development of prevention strategies. Methods:
Asymptomatic subjects of either gender of all ages residing at an urban community of
Kamalapur, Dhaka were randomly enrolled into the study after written consent. Information
was collected on demographic, occupational and behavioural characteristics including their
education, marital status, previous surgical and dental procedures and receiving injections
and blood transfusions. HBV infection was diagnosed by performing HBsAg and Anti-HBc
by ELISA and HCV was diagnosed by Anti-HCV screening test (ELISA-3). Results: From
June 2005-April 2006, 1844 healthy subjects were enrolled, 37% males, 22% gave previous
history of jaundice. HBsAg was positive in 121 (6.6%) subjects: 14 (0.8%) were only HBsAg
positive and 107 (5.8%) were both HBsAg and Anti-HBc positive. Only Anti-HBc was positive
in 420 (23%) subjects and HCV was positive in 9 (0.5%) subjects: 4 (0.2%) were only Anti-
HCV positive and 5 (0.3%) were both Anti-HCV and Anti-HBc positive. About half of the
HBV positive subjects were between ages 20-40 years, which was rare (4%) among under-
5 children. Some factors such as previous jaundice (OR 1.33; p=0.01), exposure to a
community barber for shaving (OR 2.29; p=0.00), received treatment from unregistered
health care providers (OR 1.44; p=0.005), received treatment for sexually transmitted diseases
(OR 1.77; p=0.002), being married (OR 2.23; p=0.00), and multiple sex partners (OR 2.57;
p=0.00) were significantly associated with HBV infection. Similarly, receiving illicit drug
injections (OR 11.86; p=0.01), needle-stick injuries (OR 2.11; p=0.001), needle piercing of
ear, nose and body (OR 1.3; p=0.01), surgical operation (OR 1.3; p=0.02), circumcision
(OR 1.47; p=0.00) and animal bites (OR 1.68; p=0.00) like dog, cat, monkey-bites were
associated with HBV infection. Conclusion: The finding of the study demonstrates a high
endemicity of HBV infection in an urban community in Dhaka, Bangladesh. However, HCV
infection is rare. Prevention of HBV infection in Bangladesh is urgently necessary by hepatitis
B vaccination and creating public awareness for practicing one-time-use-only needles and
syringes and ensuring safe blood transfusions and maintaining strict aseptic precautions
during surgical and dental procedures.
S1228
Ultrasound Guided Versus ‘Blind' Day Case Liver Biopsy: What Would You
Choose?
Karen M. Forrest, Christine M. Welch, Devina Mallon, Howard Smart, Ian T. Gilmore,
Martin Lombard
Introduction: Percutaneous liver biopsy is associated with a morbidity rate of 6%. Death is
rare. At our centre the outpatient liver biopsy service is provided by doctors from Gastroenter-
ology, Infectious Diseases and Radiology. Obese patients, those with an abnormal liver
ultrasound (US), a targeted lesion or a previous liver transplant are classified as higher risk.
These procedures are done under US guidance by either a Radiologist or a Gastroenterologist.
We audited our practice to identify the local complication rates, to compare US guided
(non-plugged) and blind biopsy and to assess how practice could be improved. Methods:
All outpatient liver biopsies from Jan 2000 and Dec 2005 were traced from the biopsy request.
Data for procedure indication, pathology and radiology results, possible complications and
death were collected. If a possible complication was identified the notes were obtained for
further analysis. Results: Over the 6 year period there were 640 biopsies on 608 patients.
No patient had died within 30 days. We found 33 complications (5.2%). Eighteen patients
were admitted within 30 days (2.8%) including 4 pre-planned. Of the 378 unguided biopsies
there were 25 complications: 1 transfusion-dependent haemorrhage, 1 pneumothorax , 1
haemoptysis, 6 samples contained viscera, 11 patients had pain (6 requiring admission) and
a further 6 patients attended hospital within 30 days, some for unrelated reasons. Of the
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262 US guided biopsies there were 8 complications: 2 patients had pain and a further 6
patients attended hospital within 30 days, some for unrelated reasons. Forty-three attempts
were recorded as having failed. 37 of these were to be undertaken blindly: 4 procedures
were felt to be unsafe and were abandoned, 7 failed to obtain an adequate specimen, 10
samples contained inadequate liver tissue for histological diagnosis and 16 samples did not
contain any liver tissue. The remaining 6 were performed with US guidance: 5 were not
adequate for diagnosis and 1 sample was lost. Conclusion: Day case liver biopsy appears
to be a safe procedure at our centre. The higher risk US guided biopsies are less likely to
fail (2.7% v 9.5%) and less likely to be complicated (3.1% v 6.6%) and this supports the
argument for US-guided biopsy.
S1230
Sequential Treatment with Lamivudine and Alpha-Interferon in Chronic
Hepatitis B: A Pilot Study
Grazia A. Niro, Rosanna Fontana, Domenica Gioffreda, Serafina Fiorella, Angelo
Iacobellis, Pasquale Conoscitore, Angelo Andriulli
Background: Monotherapy with alpha interferon (α-IFN), effective in a small subset of
patients with chronic hepatitis B (CHB), is limited by relevant side effects. Long-term
treatment with nucleosides/nucleotides analogues is burdened by drug-resistant mutants
occurrence. Sequential therapy of IFN with nucleos(t)ide analogues might represent a strategy
to delay emergence of drug resistance. Aim: To evaluate the efficacy of sequential lamivudine
and IFNα 2b monotherapies in preventing the occurrence of YMDD mutants and in achieving
a virologic and biochemical response at the end of therapy and at the end of 12-month
follow up. Methods: Fifteen patients with HBsAg, anti-HBe positive chronic hepatitis, HBV-
DNA > 100.000 copies/ml, and ALT > 2x ULN received 4 consecutive courses, each lasting
for 6 months, of monotherapy with lamivudine (100 mg/day), followed by IFN α 2b (5
MU/tiw), lamivudine (100 mg/day) and IFNα 2b (5 MU/tiw). At the end of the 24 months
of therapy patients were followed up for 12 months. Quantitative HBV-DNA was evaluated
during and off treatment, and, whenever positive, HBV polymerase and precore/core regions
sequenced. Results: All patients completed the 24 month treatment period. End of treatment
response was achieved in 10 patients (67%). One pt did not respond to therapy although
viremia levels declined in respect to baseline, and a second pt with undetectable viremia at
week 16 experienced a genotypic resistance at week 24 and a phenotypic resistance at week
72. A rebound of viremia occurred in the remaining three pts at week 48, that was followed
by self-limiting acute hepatitis in a single pt. At the end of follow up six pts (40%) remained
sustained responders. At baseline the precore stop codon mutation (G1896A) was found in
80% of patients and was equally distributed between responders and non responders. The
A1762T mutation was observed in 8 patients (53%), 4 responders (40%) and 4 (80%) non
responders, while the G1764A mutation was detected in 9 patients (60%), 5 responders
(50%) and 4 non responders (80%). When taken collectively, the group of triple promoter
mutations at nucleotide 1762-1764-1896 prevailed in non responders (60% vs 20%). Muta-
tions L180M and M204V were identified in the single pt with breakthrough. Conclusion:
Sequential therapy with lamivudine/interferon was efficacious in maintaining virological
response in 40% of patients and capable of inhibiting the emergence of resistance to lamivud-
ine. Genetic alterations of the HBV genome within the basic core promoter influenced
response to therapy.
S1231
Peginterferon Alfa 2a / Ribavirin Versus Peginterferon Alfa 2b / Ribavirin
Combination Therapy in Chronic Hepatitis C Genotype 3
Arif Q. Khan, Ali Awan, Sultan Shahbuddin, Qamar Iqbal
Hepatitis C virus (HCV) genotype 3 account for upto 80% of HCV infection in Pakistan.
The purpose of the present study was to compare the efficacy and safety of Peginterferon
Alfa 2a / Ribavirin combination therapy with Peginterferon Alfa 2b / Ribavirin combination
therapy in Chronic Hepatitis C genotype 3 patients. Material and Methods: In an open
randomized controlled trial 66 naïve Chronic Hepatitis C genotype 3 patients were random-
ized to receive Peginterferon Alfa 2a 180 ug/weekly plus Ribavirin 800 mg/day (33 pt group
I) or Peginterferon Alfa 2b 1ug/kg/body wt/weekly plus Ribavirin 800 mg/day (33 pt group
II) for 24 weeks. Both groups were comparable for age, sex, baseline ALT level, albumin
level, viral load, and genotype 3 subtypes. Primary end point was loss of HCV RNA at 24
weeks after stopping the treatment (SVR). Results: Of these 66 patients. 60 patients (30 in
each group) completed the trial as 2 patients (1 in each group) were lost to follow up, 1
patient in group I developed hyperthyroidism, 2 patients (1 in each group) developed severe
thrombocytopenia and one patient in group II developed severe neutropenia. Reduction of
peginterferon dosage were required in 4 patient (2 in each group) and reduction of ribavirin
dosage were required in 3 patients (2 in group I and 1 in group II). End of treatment
response (ETR) in group I and II was 26 (86.6%) and 27 (90%) patients respectively.
Sustained virologic response (SVR) in group I and II was 26 (86.6%) and 27(90%) patients
respectively. Conclusion: Both Peginterferon Alfa 2a / Ribavirin and Peginterferon Alfa 2b /
Ribavirin regimens were similar in efficacy and safety in Chronic HCV genotype 3 patients.
S1232
Efficacy of a 72-Week Course of Treatment for Previous Relapsers to PEG/
Ribavirin Therapy
Jeffrey Mcmahon, Stuart C. Gordon
Background/Aims: Patients who relapse after 48 weeks of PEG/ribavirin treatment represent
a difficult therapeutic challenge. No guidelines exist concerning the proper management of
these individuals. Two recent studies showed lower relapse rates following 72 vs. 48 weeks
of therapy among treatment naïve candidates. It is unknown, however, whether a longer
duration of re-treatment will achieve SVR among previous relapsers. We assessed our prelim-
inary experience using a repeat course of extended PEG/ribavirin in patients who previously
relapsed after 48 weeks of PEG/ribavirin. Methods: Four consecutively evaluated HCV
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patients (3 genotype 1, 1 genotype 2), who relapsed following an initial 48-week course of
PEG/ribavirin, underwent re-treatment for 72 weeks. During their initial therapy, 3 of 4
patients became negative within the first 16 weeks, and all four patients maintained >80/
80/80 adherence. None of the patients required growth factors at any time. Following initial
therapy, all 4 relapsed within 12 weeks of their last dose. Each was then re-treated with
PEG-IFN alfa 2a 180 mcg once weekly plus ribavirin (>13.3 mg/kg/day) for 72 weeks. We
assessed HCV RNA using Amplicor 2.0 quantitative and reflex TMA qualitative testing.
Results: During re-treatment, each patient became HCV RNA negative by treatment week
12, and maintained viral negativity for the duration of treatment. Six months after completing
re-treatment, each patient remained HCV RNA negative, thus now achieving a recognized
SVR. Extended duration therapy was well tolerated; 2 of the 4 patients received higher doses
of ribavirin based on weight, and no patient required dose reductions due to adverse events.
Conclusions: 1) SVR is attainable among patients who relapse following 48 weeks of PEG/
ribavirin therapy. 2) 72 weeks of re-treatment was well tolerated in this group of motivated
patients. 3) Two of these patients received higher doses of ribavirin during re-treatment,
thus ribavirin dosing may affect the ability to achieve SVR. 4) Each patient remained adherent
during both regimens, thus the duration of viral negativity appears to represent a pivotal
goal. 5) Patients who relapse after 48 weeks of PEG/ribavirin should be considered for re-
treatment with a longer duration regimen.
S1233
Factors Associated with Adherence to Combination Therapy of Interferon and
Ribavirin for Patients with Chronic Hepatitis C: Importance of Patient
Selection and Treatment Experience
Daisuke Tanioka, Yoshiaki Iwasaki, Kouichi Takaguchi, Hiroshi Ikeda, Ryoichi Okamoto,
Yasuyuki Araki, Masaharu Ando, Toshinari Shimoe, Noriaki Hashimoto, Keiji Kita,
Minoru Tomita, Yasuhiro Makino, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi
Shiratori
BACKGROUND/AIMS: A combination therapy of interferon (IFN) or pegylated IFN plus
ribavirin achieves higher rate of sustained virologic response than IFN monotherapy. How-
ever, poor adherence is one of the most important problems, especially in older patients.
In this study, we analyzed factors that might have effect on adherence to therapy in patients
who had initial or re-treatment of IFN therapy. PATIENTS AND METHODS: We consecut-
ively enrolled 363 patients (221 were IFN naïve and 142 were undergoing re-treatment)
with chronic hepatitis C. Mean age of naïve and re-treatment groups were 54.8 and 55.7
years, respectively. IFN alpha-2b was administered daily for two weeks, followed by three
times per week for 22 weeks, while ribavirin was administered daily. We evaluated tolerability
in terms of treatment adherence to the 80/80/80 rule. Logistic regression analysis was
performed to analyze the factors associated with adherence to combination therapy. RESULTS:
Of 363 patients, 189 (52%) achieved 80% adherence. Multivariate logistic regression analysis
revealed that re-treatment, center with more patients (>=30 cases) enrolled, patients age
(<55 years), body weight (<60 kg), genotype 2, hemoglobin concentration (>=14 g/dL), and
dosage of IFN per weight (<0.13 MIU/kg) were associated with achievement of 80% adherence
to combination therapy. Accordingly, the achievement of 80% adherence was more frequent
in re-treatment (61%) than in naïve group (46%) (p<0.01), in centers with more patients
enrolled (57%) than in less patients enrolled (46%) (p=0.03). CONCLUSION: The present
data suggest that patient selection and treatment experience are important for better adherence
to combination therapy for patients with chronic hepatitis C.
S1234
Antiviral Therapy with Peginterferon Alfa-2a and Ribavirin Does Not Reduce
Bone Mineral Density in Patients with Chronic Viral Hepatitis C Genotype 1
Infection
Dietmar M. Klass, Christoph Hartmann, Simone Braig, Guido Adler, Michael Fuchs
One single study has suggested that bone mineral density (BMD) is reduced in patients with
non-cirrhotic chronic viral hepatitis C. Antiviral combination therapy with standard interferon
and ribavirin may further decrease BMD. The aim of our study was to systematically investigate
the effect chronic hepatitis C genotype 1 infection alone and current standard therapy with
peginterferon alfa-2a/ribavirin on BMD and bone metabolism. 26 consecutive male patients
with biopsy proven absent advanced fibrosis (Desmet <2) agreed to participate in this
prospective non-randomized study. 21 patients were put on peginterferon alfa-2a (180µg
weekly) and ribavirin 1000-1200 mg daily for 48 weeks and followed for another 24 weeks.
The other 5 patients did not want therapy and were observed for 72 weeks (controls).
Biochemical markers of bone turnover (calcium, phosphate, PTH, 25-hydroxycholecalciferol,
1,25-dihydroxycholecalciferol, leptin) were measured with standard assays and BMD was
measured employing dual energy X-ray absorptiometry of the femoral neck and the lumbar
spine (L1-L4), all at baseline, during therapy and at weeks 48 and 72, respectively. Treatment
was stopped in 5 patients due to non-response or depression. The mean age of treated
patients was 36.8±7.7 vs. 41.6±7.8 of controls and the mean body mass index was 26.6±2.8
vs. 25.4±1.1, respectively. Baseline viral load (kIU/ml) was 1049±1574 in treated patients
and 1191±863 in controls with an end-of-treatment (EOT) response of 69%. All biochemical
markers of bone turnover measured as well as BMD were not significantly different among
both groups at baseline and there was no evidence of osteopenia. During the 48 weeks of
treatment no significant (p>0.05) change was observed for serum calcium (2.31±0.06 vs.
2.27±0.06 mmol/l), phosphate (0.99±0.14 vs. 0.95±0.14 mmol/l), PTH (26.2±9.8 vs.
38.5±21.4 pg/ml), 25-hydroxycholecalciferol (22.2±11.6 vs. 24.0±13.2 ng/ml), respectively.
Interestingly 1,25-dihydroxycholecalciferol (45.9±12.3 vs. 35.5±15.9 pg/ml) and leptin
(6.5±2.8 vs. 5.0±2.8 ng/ml) decreased significantly (p<0.05). Antiviral treatment had no
impact on the t-score (baseline: -0.06±1.67 vs. EOT: 0.31±1.64; p>0.05). In untreated
patients the t-score was stable over time (baseline: -1.1±0.8 vs. week 48: -0.64±1.06).
We conclude that neither chronic viral hepatitis C infection nor antiviral treatment with
peginterferon alfa-2a and ribavirin reduces BMD in non-cirrhotic patients. Therefore routine
measurements of BMD are not required in these patients.
S1235
Bile Duct Proliferation (Bdp) Is Associated with Intrapulmonary Shunts (Ips)
in Patients with Cirrhosis
David Koch, Megan Malone, David N. Lewin, Joseph Romagnuolo, Adrian Reuben
Background: The basis of the hepatopulmonary syndrome is intrapulmonary vasodilatation
and resultant shunt formation. The rat common bile duct ligation model provides a mechan-
ism for the development of IPS- proliferating cholangiocytes produce endothelin-1, which
induces intrapulmonary nitric oxide production. However, it is unknown whether BDP and/
or cholestasis are associated with IPS in humans. Aim: To determine if IPS in patients with
cirrhosis are associated with BDP and/or cholestasis. Methods: We performed a retrospective
cohort study of 62 liver transplant patients who had a transthoracic echocardiogram to look
for IPS during pre-transplant evaluation. The patients' liver biopsy slides were reviewed for
evidence of BDP. Simultaneous laboratory and clinical data were used to determine the
severity of liver disease and degree of cholestasis. Results: Of the 62 patients studied, 46
(74%) had IPS while 16 (26%) did not. In patients with IPS, 39/46 (85%) had BDP, whereas
in patients without IPS, BDP was present in 8/16 (50%, p=0.005). Median values are
summarized in Table 1. Compared to non-IPS patients, those with IPS were younger, had
higher serum levels of bilirubin and alkaline phosphatase, and more advanced liver disease
as evidenced by higher MELD and Child-Turcotte-Pugh (CTP) scores. Multivariate analysis
via logistic regression model was performed and 4 variables remained significant: BDP,
bilirubin, ascites, and age (see Table 2). Variables that were not significant in this model
but were on univariate analysis were: MELD,CTP, alkaline phosphatase, AST, and ALT.
Three IPS patients (7%) had respiratory complications after transplantation and 2 died
(mortality rate 4%); there were no complications in the non-IPS patients. Conclusion: In
patients with cirrhosis, IPS are associated with an increased prevalence of BDP and laboratory
evidence of worse liver disease and cholestasis than in patients without IPS.
Table 1. Univariate Analysis
Table 2. Multivariate Analysis
S1236
A Comparative Study of MELD Versus Child Pugh C Score As a Prognostic
Factors for Rebleeding and Death in Patients with Esophageal Variceal
Bleeding
Ricardo Flores-rendon, Rafael Castañeda-sepulveda, Jorge Leal-salazar, Eduardo Mendoza-
fuerte, Hector Maldonado-garza, Miguel Mar-ruiz, Reyna Elizondo-rivera, Jose A.
Gonzalez
INTRODUCTION The MELD and Child Pugh (CP) scores are good predictive models for
mortality in patients (pts) with chronic liver disease. A few studies have compared the utility
of these scores as predictive models for rebleeding and death in pts with esophageal variceal
bleeding (EVB). OBJECTIVE To evaluate the utility of MELD versus CP C scores to predict
rebleeding and mortality in pts with EVB. MATERIALS AND METHODS From a prospective
collected data base, we studied all pts with diagnosis of EVB admitted to our institution
between years 2003 to 2006. We studied age, gender, etiology, MELD and CP score at
admission, rebleding (Baveno IV criteria) and mortality were recorded. Statistical analysis:
The variables are expressed as mean, range and standard deviation. Chi square and Fisher
exact test were used for comparisons. ROC curves (significant if an area under the curve
(AUC) >0.80, p < 0.05) were done to determined the predictive value of MELD score for
rebleeding and mortality. All pts were treated with band ligation. The sensitivity (S), specificity
(Sp), Accuracy (Ac), positive predictive value (PPV) and negative predictive value (NPV) for
the MELD and CP C score are reported. RESULTS We found 212 pts with EVB; 145 males/
67 females, mean age of 53 years. Etiology: alcoholic 72 %, Hepatitis B/C 3/4 %, Autoimmune
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3 % and unknown 18 %. CP score A: 38 pts, B: 108 pts, and C: 66 pts. Fifteen pts re-
bleed (7%) and their CP score was A: 1 pts, B: 7 pts, C: 7 pts, and 9/15 pts die. The ROC
curve for MELD score and rebleeding showed a best cut-off value of > 20 with AUC of 0.67
(CI95% 0.48-0.87) (p=0.022). The MELD score > 20 versus the CP C score results were
S: 67/46 %, Sp: 88/70 %, Ac: 79/68 % PPV: 20/11 %, NPV: 97/94 % respectively. A total
of 17 (8%) died their CP score was A: 0 pts, B: 3 pts and C: 14 pts. The ROC curve for
MELD score and mortality showed a best cut-off value of > 23 with AUC of 0.88 (CI95%
0.77-0.99) (p=<0.001). The MELD > 23 (26 pts) versus CP C (66 pts) score showed S: 88/
82 %, Sp: 89/73%, Ac: 89/74 %, PPV: 41/21 % and NPV: 99/98 % respectively. CONCLU-
SIONS The MELD score > 23 is a better score than Child Pugh C to predict mortality. Any
scores were found to be useful to predict rebleeding.
S1237
Cardiovascular Disease in Liver Cirrhosis: A Case-Control Study
Evangelos Kalaitzakis, Tomas Jonsson, Annika Rosengren, Einar Bjornsson
The prevalence of coronary heart disease(CHD) in patients with liver cirrhosis(LC) has been
reported to be low despite the frequent presence of diabetes(mostly LC due to hepatitis C,
Marchesini et al, Am J Gastro 99). However data on the prevalence of CHD in cirrhotics
with other etiologies are scarce. We aimed to determine the occurrence of CHD in a cohort
of consecutive patients with LC. Methods:127 consecutive cirrhotics(mean(SD)age 57(11);
Child-Pugh 8.6(2.3); MELD 13.2(5.6);50F;55 with alcoholic LC;36 HepC) were evaluated for
a history of CHD(previous myocardial infarction(MI), stable or unstable angina pectoris(AP),
diabetes and hypertension. Arterial blood pressure(BP) and total serum cholesterol were
measured. Available elecrocardiograms(ECG) were coded according to the Minnesota criteria.
Patients were considered to have CHD if they had a positive history and/or compatible ECG
findings. 203 subjects matched with the cirrhotics for age, gender and smoking status
randomly selected from the general population served as controls. Results: 26/127(20.5%)
cirrhotics vs 21/203(10.3%) controls (p=0.01) had CHD. History of AP was more common
in cirrhotics vs controls (6.3% vs 1.9%,p=0.037) whereas previous MI or ECG findings
compatible with CHD did not differ between groups. Cirrhotics compared to controls had
lower systolic BP (126mmHg(18) vs 136mmHg(19),p<0.001), diastolic BP (74mmHg(11)
vs 84mmHg(10),p<0.01), and total cholesterol (4.2mmol/l(1.6) vs 5.6mmol/l(1.0),p<0.001),
and higher prevalence of diabetes (33/127(26%) vs 12/203(6%),p<0.001), but did not differ
significantly in the occurrence of hypertension or family CHD history. In multivariate analysis
(dependent variable:CHD, both cirrhotics and controls) only diabetes was found to be
independently related to CHD(beta= 7.12, p<0.001) but not having LC. In the LC group,
patients with vs without CHD were older (65yr(9) vs 54yr(11),p<0.001) and had more
often alcoholic LC (65.4% vs 34.3%, p=0.007), diabetes (46.2% vs 19.4%, p=0.009), previous
diagnosis of hypertension (50% vs 12.8%, p=0.002) and family CHD history (15.4% vs 0%,
p<0.001) but less often cholestatic cirrhosis (3.8% vs 20.9%, p=0.045) and hepatitis C
(11.5% vs 32.8%, p=0.038). Gender, smoking habits, LC severity or complications were
not related to CHD in cirrhotics. In multivariate analysis (dependent variable:CHD, LC
group only), only age (beta=1.2, p=0.006) and alcoholic LC (beta=9.5, p=0.042) were
independently related to CHD. Conclusion: Liver cirrhosis per se does not seem to confer
a protective effect against coronary heart disease. In cirrhotics, older age and alcoholic
etiology seem to be related to coronary heart disease.
S1238
The Utility of Low Serum Albumin Ascites in Patients with Cirrhosis
Yemi M. Fasakin, Hashem El-serag
Background: Serum-albumin ascites gradient (SAAG) is extensively used in the diagnostic
workup of ascites. High SAAG (defined as SAAG ≥ 1.1) has been shown to have a high
sensitivity (>97%) in diagnosing ascites related to portal hypertension. However, in patients
with known cirrhosis in whom the pretest likelihood of portal hypertension related ascites
is very high, the yield of a low SAAG (<1.1) in detecting additional non-portal hypertension
causes of ascites is unclear. To our knowledge, no study has specifically evaluated low SAAG
in patients with cirrhosis and ascites. Methods: We identified all patients who received
paracentesis over a 5-year period at a single large Veteran Affairs center. Cirrhosis was
defined based on clinical, histological, and radiological features. Non-portal hypertension
causes of ascites were identified including carcinomatosis, tuberculosis, renal causes, and
pancreatic or chylous ascites. We calculated the positive and negative predictive values
associated with low SAAG. Results: We identified 98 patients with low SAAG ascites of
whom 80 patients had cirrhosis. Of patients with cirrhosis and low SAAG, only 22 (27.5%)
of these patients received additional diagnoses of which spontaneous bacterial peritonitis
was the most common additional diagnosis (10, 14.5%). Other non-portal hypertension
causes were present only in 11 (13.8%): malignant ascites in 4, tuberculous peritonitis in
3, nephrotic syndrome in 2, chylous ascites in 1, and perforated viscus in 1. The mean
SAAG of malignant ascites was the lowest in comparison to all other causes of low SAAG.
The overall positive predictive value for a low SAAG in identifying non-portal hypertension
causes of ascites was 13.8%. On the other hand, of the 18 patients without cirrhosis who
had a low SAAG ascites, 11 (61.1%) patients received specific diagnoses: 7 peritoneal
carcinomatosis, 2 perforated viscus, 1 chylous ascites, and 1 nephrotic syndrome. Conclusion:
Low SAAG (<1.1) is not useful in identifying additional non-portal hypertension causes of
ascites among patients with cirrhosis. In these patients, the high pretest likelihood of portal
hypertension-related ascites overrides low SAAG.
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S1239
Small Intestinal Bacterial Overgrowth in Cirrhotics Is Related to Severity of
Liver Disease
Chandana Pande, Ashish Kumar, Barjesh C. Sharma, Shiv kumar Sarin
Background: Small-intestinal bacterial overgrowth (SIBO) has been considered a predisposing
factor of spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhotic patients.
There is scanty data in literature about the prevalence of bacterial overgrowth in cirrhotics
and its relationship to severity of liver disease. This information would help in prevention
of these serious complications by targeting therapy against bacterial overgrowth in high risk
population. Aims and Objectives: To assess the prevalence of SIBO and its relationship with
the severity of liver dysfunction. Methods: Consecutive patients of cirrhosis of liver were
included. Patients were excluded if: (i) on probiotics, (ii) bled in past 4 wk, (iii) grade III/
IV encephalopathy. Antibiotics, if any, were stopped 7 days prior and lactulose was stopped
2 days prior to study. Bacterial overgrowth was measured by the glucose hydrogen breath
test. A baseline value of ≥20 ppm or a rise of ≥12 ppm over baseline within 2 hr of
ingestion of 75 g of glucose was considered positive for SIBO. Prevalence of SIBO in cirrhotics
was compared with healthy controls. Additionally prevalence of SIBO was compared among
Child-Pugh class A, B and C. Results: Sixty two cirrhotics (mean age 42±15 yrs, males 81%)
and 15 healthy controls were studied. The etiology of cirrhosis was: Hepatitis B (35%),
alcoholic liver disease (26%), Hepatitis C (21%), cryptogenic cirrhosis (16%) and autoim-
mune liver disease (2%). Thirty nine percent patients had ascites, 9% had past history of
spontaneous bacterial peritonitis and 40% were bleeders. The Child's status of the patients
was: A 29%, B 45%, C 26%. Nine (14%) patients and 2 (13%) healthy controls were non
hydrogen producers (p=ns). Of the remaining 53 cirrhotics, 26 (49%) were positive for
SIBO, compared to only one (8%) control (p<0.05). Prevalence of SIBO increased with
severity of liver disease (Child-Pugh A 17%, B 43%, C 69%; p<0.05). There was no difference
in prevalence of SIBO among different etiologies of cirrhosis. Conclusions: Nearly 49%
cirrhotics have SIBO. The prevalence correlates with the severity of liver disease. Efficacy
of probiotics and antibiotics may be better evaluated in reference to breath test results
in cirrhotics.
S1240
Sustained Virologic Response to Previous Interferon Treatment May Reduce
the Risk for the Recurrence of hepatocellular carcinoma in Patients with
Hepatitis C
Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Ryo
Terada, Kenji Miyoshi, Hideki Ohnishi, Shouta Iwadou, Bon Shoji, Kenji Kuwaki, Junichi
Toshimori, Tetsuya Yasunaka, Hiroaki Hagihara, Kohsaku Sakaguchi
BACKGROUND and AIMS; It has been reported that interferon (IFN) treatment for chronic
hepatitis C could prevent the development of hepatocellular carcinoma (HCC). HCC are liable
to recur frequently even after curative therapy mainly because of multicentric occurrence. The
purpose of this study was to clarify the effect of previous IFN treatment before the develop-
ment of HCC on the recurrence and survival of HCC patients. METHODS; Three hundred
and eighty-two out of 897 patients with HCC diagnosed at Okayama University Hospital
between 1995 and 2005, had underwent curative treatment for HCV-related HCC. One
hundred and eighteen who had received IFN treatment before the development of HCC
were compared with the other 264 patients (IFN untreated group). Seventeen of IFN treated
group were sustained virologic responders (SVR), and the other 101 patients were non-
SVR. Twelve out of 101 patients were sustained biochemical responders (SBR). Survival rate
and the 1st and 2nd recurrence rate after curative treatment for HCC were statistically
analyzed. Risk factors for HCC recurrence were analyzed by Cox proportional hazards model.
RESULTS; Mean follow-up period of all patients was 6.2 years. IFN treated group comprised
70 men and 48 women, and mean age at IFN therapy and development of HCC was 58
and 65 years old, respectively. One hundred out of 118 patients (85 %) were classified into
Child-Pugh classification A. IFN untreated group comprised 182 men and 82 women, and
mean age at development of HCC was 67 years old. Survival rate of SVR was higher than
that of non-SVR and IFN untreated patients (p=.010). The 1st HCC recurrence rate was
similar between SVR and non-SVR. However, the 2nd HCC recurrence rate in SVR at 2
years was significantly lower than that in non-SVR (0% vs. 68%, p=.006). There were no
significant difference in the survival rate and the 1st and 2nd recurrence rate between SBR
and non-SVR. In multivariate analysis, the age at the time of IFN therapy (p=.043) and
tumor number at HCC development (p=.044) were independent factors related to 1st HCC
recurrence, while sustained virologic response (p=.057) were related to 2nd HCC recurrence.
CONCLUSIONS: Sustained virologic response to previous interferon treatment in patients
with hepatitis C may reduce the risk for the second recurrence of HCC and improve survival.
S1241
Gemcitabine Treatment for Advanced Biliary Tract Cancers
Tsunenori Fujita, Tetsuo Ajiki, Ippei Matsumoto, Kenro Hirata, Shiro Takase, Takashi
Kamigaki, Makoto Shinzeki, Yasuhiro Fujino, Yoshikazu Kuroda, Yonson Ku
Background: Although surgery is the most effective therapy for biliary tract cancers, many
cases are unresectable and show high recurrence rates even when curative surgical resection
was initially thought to have been achieved. Therefore, the role of chemotherapy for biliary
tract cancers is necessarily important. Objective: To evaluate the efficacy and safety of
chemotherapy with gemcitabine for advanced biliary tract cancers retrospectively. Methods:
Between February 2002 and October 2006, 66 patients (28 gallbladder carcinoma, 37
bile duct carcinoma, 1 ampullary carcinoma) received gemcitabine treatment (1000mg/m2)
weekly for three weeks followed by a week of rest. Results: Forty-eight (73%) out of 66
patients had received gemcitabine treatment more than 2 cycles. Twenty four patients
demonstrated grade 1-2 neutropenia and 8 patients demonstrated grade 3 neutropenia.
About half patients demonstrated neutropenia, but they recoverd from neutropenia only by
skipping gemcitabine treatment of one week. Thirteen patients demonstrated grade 1-2
anemia and 5 patients demonstrated grade 3 anemia. Thirteen patients demonstrated grade
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1-2 thrombocytopenia and 4 patients demonstrated grade 3. However, nineteen patients
(29%) received biliary stenting (insertion of expandable metallic stent or endoscopic retro-
grade biliary drainage tube) for biliary obstruction. Six patients underwent biliary stenting
more than 2 times due to stent occlusion. After biliary re-stenting, these 6 patients could
continue to receive gemcitabine treatment.Twelve patients withdrew from the study due to
various reasons (liver dysfunction, poor general condition, etc.). Nine patients received
gemcitabine treatment as postoperative adjuvant without lesions to evaluate and 6 patients
microscopically remained cancer cells at the cut end of bile duct. The remaining 39 patients
were possible to be evaluated for the efficacy of gemcitabine chemotherapy. In these 39
patients, no patient showed complete response (0%), 6 patients showed partial response
(15%), 15 patients showed stable disease (38%)and 13 patients showed progressive disease
(33%). Median survival time was 10 months, and the one-year survival rate was 49%. These
results were better outcome compared to conventional chemotherapy reports of another
chemotherapeutic agents (median survival rate from 4 to 10 months). Conclusion: Gemcitab-
ine chemotherapy was well tolerated and effective for advanced biliary tract cancers. Relieving
biliary obstruction is essential for continuation of gemcitabine treatment.
S1242
Impact of Transarterial Chemoembolization On the Outcome of hepatocellular
carcinoma
Mohamed O. Amer, Lisa M. Richards, Fatma Barakat, Yuko Kono, Steven Rose, Marquis
Hart, Elliot Alpert, Tarek Hassanein
Transarterial Chemoembolization (TACE) has become and increasingly popular modality
for controlling the growth of Hepatocellular Carcinoma (HCC) in patients with cirrhosis.
Aim: To assess the efficacy of TACE in treating patients with HCC. Method: We performed
a retrospective review of all the patients who had HCC and were treated before a liver
transplantation and had an explant pathology available. Results: Between 2001 and 2006,
39 consecutive patients had TACE before liver transplantation. More than 90% necrosis was
achieved in 18 patients (46%) among them 13 patients (33%) had complete necrosis without
evidence of malignancy in the explant. Comparing patients with >90% necrosis (group A)
and those with < 90% necrosis (group B) there was no significant difference in age, sex,
etiology of liver disease, CTP, MELD score, or CLIP. The median duration of follow-up was
26 (3-72) and 20 (6-128) months for both groups respectively groups A and B. The post
transplantation follow-up duration was 23 (1-56) and 8 (1-45) months for groups A and B
respectively. The median size of the largest lesion was 2.8 (1-6) and 2 (0.3-4.5) cm in both
groups and multifocality was detected in 8 (44%) and 15 (71%) of patients respectively (p=
0.88). Vascular invasion was detected in 2 (12%) patients in group A and 2 (9%) patients
in group B. In those lesions with residual viable tumor, 80% of tumors in group A were
well differentiated versus 57% in group B (p=0.35). Recurrence of HCC post liver transplanta-
tion was detected in only 1 patient in group A. During the follow-up period 3 patients died
in group A and 2 patients died in group B (p=0.51). The cause of death in group A was
due to recurrence of HCC in 1 patient and complications of liver transplantation in 2 patients.
In group B both patients died due to complications of liver transplantation. Conclusion: TACE
achieved complete necrosis in nearly 46% of HCC patients. Criteria for poor response
to TACE include elevated serum AFP levels, the number of lesions and the poor tumor
differentiation. It is interesting to find that there was no significant difference in the outcome
after liver transplantation between both groups regarding the recurrence if HCC or the mor-
tality.
S1243
Risk Factors for Local Recurrence and Complications After Percutaneous
Radio-Frequency Ablation of hepatocellular carcinoma
Shinichiro Nakamura, Yoshiyuki Kobayashi, Hirokazu Miyatake, Bon Shoji, Kenji
Miyoshi, Hironori Tanaka, Kazuhiro Nouso, Kohsaku Sakaguchi
[Purpose] The purpose of this study was to investigate the risk factors for local recurrence and
complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma
(HCC). [Study design] Retrospective cohort study. [Methods] RFA was performed percutan-
eously using a 17-gauge internally cooled-tip electrode under real-time US guidance. When
the targeted nodule was adjacent to diaphragm, we used the artificial pleural effusion
technique to avoid lung injury. If the targeted nodule was close to the gastrointestinal tract,
we used the artificial ascites technique. Parameters for univariate and multivariate analyses
of patient and tumor characteristics were as follows; age, gender, Child-Pugh grade, number
of tumor, tumor size, hypervascular tumor, tumor location (adjacent to large vessels such
as hepatic vein, major portal vein, or inferior vena cava; adjacent to extrahepatic organs
such as diaphragm, heart, kidney, stomach, small intestine, colon, pancreas, or gall bladder),
tumor markers, and safety margin. Variables associated with local recurrence and complica-
tions were assessed by Cox proportional hazard model and logistic regression model, respect-
ively. [Results] Between April 2001 and May 2006, we performed RFA on 825 HCC nodules
in 537 patients. Among them, 310 nodules (38%) in 226 patients were primary HCC and
cumulative 5-year survival rate of these patients was 81%. The mean tumor diameter was
16 ± 6 mm, 145 nodules were adjacent to large vessels and 405 nodules were adjacent to
extrahepatic organs (ex. diaphragm, 283; gastro-intestine, 59; heart, 48; kidney, 26; gall
bladder, 22). Cumulative 1-, 3-, and 5-year local recurrence rate were 4%, 9% and 11%,
respectively. As a result of multivariate Cox proportional hazard model, hazard ratio of
significant risk factors for local recurrence were; safety margin < 5mm, 12.9 (95% C.I.: 2.8-
228.9); tumor adjacent to major portal vein, 2.9 (95% C.I.: 1.6-5.1); hypervascular tumor,
2.4 (95% C.I.: 1.2-5.4). The complications after RFA occurred in 58 tumors (7%). Multivariate
logistic regression model revealed that odds ratio of significant risk factors for complications
were; tumor adjacent to hepatic duct, 12.1 (95% C.I.: 3.8-35.6); RFA of recurrent HCC,
2.0 (95% C.I.: 1.1-4.1). [Conclusion] HCC adjacent to major portal vein or hepatic duct
has higher risk for local recurrence and complications.
S1244
Neoplastic Seeding After Radiofrequency Ablation for hepatocellular
carcinoma
Jun Imamura, Ryosuke Tateishi, Ryota Masuzaki, Takamasa Oki, Noriyo Yamashiki,
Tadashi Goto, Hideo Yoshida, Shuichiro Shiina, Haruhiko Yoshida, Takao Kawabe, Masao
Omata
Background: Neoplastic seeding after radiofrequency ablation (RFA) for hepatocellular carcin-
oma (HCC) occur in 0 - 12.5% of treated cases. Previous studies reported that tumor seeding
was associated with subcapsular tumor location, poorly differentiated tumors, a high alfa-
fetoprotein (AFP) level and biopsy prior RFA. The aim of the present study is to assess the
rate and the risk factor of neoplastic seeding after RFA in a large number of patients who
had a long follow-up. Method: From February 1999 to December 2004, total of 1840
patients with 3828 nodules were treated by RFA in our hospital. The influence of age, sex,
liver function, tumor size, number of tumors, number of sessions , tumor location , biopsy
prior RFA and differentiation degree were assessed. Results: Neoplastic seeding was identified
in 30 patients (1.6%). Only poor differentiation degree was associated with the presence of
neoplastic seeding (p = 0.01). 1-year survival rate after the diagnosis of neoplastic seeding
was 86% and 2-year survival rate was 47% (Median survival was 2.1 year). Conclusion:
Only poor differentiation degree was the risk factor of neoplastic seeding after RFA.
S1245
Efficacy of Radiofrequency Ablation Therapy and Surgical Resection As Well
As Complications in 130 Patients in Japan with Single hepatocellular
carcinoma Smaller Than 3 CM
Atsushi Hiraoka, Yoshimasa Yamashita, Kazuhiro Uesugi, Yohiei Koizumi, Yasunori
Yamamoto, Aki Hasebe, Soichi Ichikawa, Makoto Yano, Yasunao Miyamoto, Tomoyuki
Ninomiya, Kenichi Kashihara, Saburo Nishiura, Masashi Hirooka, Bunzo Matsuura, Norio
Horiike, Kojiro Michitaka, Morikazu Onji
Aim/background: Although surgical resection is recognized as a curative therapy for hepato-
cellular carcinoma (HCC), radiofrequency ablation therapy (RFA) has also become widely
used throughout the world, mainly because of its ease of use, lower level of invasiveness,
and effectiveness. To compare the efficacy and safety of RFA with surgery, we investigated
relevant patient clinical data. Materials and Methods: We retrospectively analyzed clinical
data including complications for 130 patients with HCC who were treated with RFA or
surgical resection at Ehime Prefectural Central Hospital from January 2000 to July 2006.
Patients with a single HCC smaller than 3 cm and a Child-Pugh classification of A or B
were studied. Results: None of the patients had a past history of HCC. Seventy-eight were
treated with RFA (RFA group) and 52 underwent surgical resection (surgery group). In the
RFA group, 5 patients were treated using artificial effusion, 1 with a percutaneous ethanol
injection, and 10 with a laparoscope or thoracoscope. The average age of the patients in
the RFA group was older (69.3±9.4 years vs. 62.4±10.6 years, p<0.01). In addition, the
percentage of Child-Pugh class B patients in the RFA group was greater (24.3% vs. 3.8%)
and the size of their tumors was smaller (2.0±0.5 cm vs. 2.2±0.6 cm, p<0.01). There were
no significant differences in the survival rates after 1, 3, and 5 years (RFA group: 94%,
87%, and 70%, respectively; surgery group: 95%, 93%, 60%, respectively) or no-recurrence
survival rates after 1, 3, and 5 years (RFA group: 87%, 58%, 29%, respectively; surgery
group: 98%, 66%, 18%, respectively). One case of biloma, 1 of inflammation of the organs
near the tumor, and 3 of dermatitis combustionis were observed as complications in the
RFA group, while there was 1 case of postoperative hepatic failure and 2 of postoperative
abscesses in the surgery group. Other postoperative changes (ascites and pleural effusions)
did not have an effect to prolong the hospital period. In both groups, a reduction in Child-
Pugh score was not observed at the first instance of recurrence. Conclusion: In individual
cases, RFA or surgical resection are appropriate therapy choices for HCC, after considering
the localization in the liver and liver reserve function. In the present study, patients with a
single HCC smaller than 3 cm who underwent the former procedure had a lower frequency
of severe complications, and RFA was thought to be equal to surgical resection.
S1246
Radio-Frequency Ablation for Unresectable Liver Metastases from Colo-Rectal
Cancer
Yukihiro Koike, Shuichiro Shiina, Haruhiko Yoshida, Kazuhiro Watanabe, Tateo Kawase,
Masao Omata
Background: This study was conducted to clarify the safety and efficacy of percutaneous
radiofrequency ablation (RFA) for unresectable liver meatstases of colorectal cancer. Methods:
From 2002 to 2006, 74 patients with unresectable liver metastases from colorectal cancer
were treated by RFA. At the initial ablation, the mean number and size of tumor foci were
6.8+-8.0 and 50+-36 mm, respectively. Patients were not considered for surgical resection
due to the presence of extrahepatic metastases (34 patients), prior hepatic resection (12),
extent of tumor involvement of the liver (more than 5 lesions, 26), and age (over 75 y.o.,
19). 35 patients had failed in previous chemotherapy. Survival rates were compared with
those of the 18 historical controls who had not received RFA for liver metastases. Prognostic
factors were evaluated by univariate Cox proportional hazard model. Results: Until May
2006, patients have received a total of 324 RFA procedures. There were no procedure-
related mortality. Nine complications (3.4%) of 3 live abscess , 2 peritoneal metastases, 2
liver abscess, and 2 others were observed. 1- and 2-year survival rates of the patients who
received radiofrequency ablation for liver metastases were 72 % and 52 %, while those of
the historical control were only 50% and 0% (P<0.01, log rank test). Prior administration
of anticancer agents, co-existence of extrahepatic metastases at the time of 1st RFA , and
tumor size of hepatic metastastatic lesions were the significant negative prognostic factor.
Conclusion: This study indicated that RFA may safely improve the prognosis of patients
with unresectable liver metastases from colorectal cancer.
A-203 AGA Abstracts
S1247
Application of Radiofrequency Ablation Therapy for the Treatment of
Metastatic Liver Cancers
Kazuhiro Nouso, Shuji Uematsu, Kunihiro Shiraga, Ryoichi Okamoto, Shota Iwado,
Hiromitsu Kanzaki, Koji Miyahara, Sayo Kobayashi, Ichiro Sakakihara, Naoko Kajikawa,
Hironori Tanaka, Shin-ichiro Nakamura, Yoshiyuki Kobayashi, Kohsaku Sakaguchi,
Yasuyuki Araki
Background: Radiofrequency ablation therapy (RFA) has been frequently used for the therapy
of hepatocellular carcinoma. Metastatic liver cancers are also candidates for RFA; however,
the outcomes of the patients treated by RFA have not been well studied. The purpose of
this study is to analyze the usefulness of RFA for the treatment of metastatic liver cancers.
Patients and Methods: Among 41 consecutive patients with metastatic liver cancers treated
by RFA in our department and affiliated hospitals between June 2001and September 2006,
36 patients who received curative surgical resection of primary cancers were enrolled in
this study. The primary tumors consisted of 24 colon cancers and 12 cancers with other
origins including 3 gastrointestinal stromal tumors. All patients were confirmed for the
complete ablation of the metastatic liver lesions by contrast-enhanced CT. None of the
patients had severe complications of RFA. Informed consent was obtained from all patients
for the use of their clinical data. Results: Mean age of the patients was 62.4 years, 23 (64%)
were male, 15 patients (42%) had single metestatic liver tumor and the mean tumor size
of the maximum tumor was 2.6cm in diameter. Mean observation time was 511 days and
median survival time was 1,134days. The recurrence of the tumor was observed in 26 (72%)
patients and 50% recurrence free survival was 306 days. Of the 26 patients, 9 patients
(35%) had extra-hepatic recurrence and 21 (81%) had intra-hepatic recurrence. The recur-
rence patterns of the intra-hepatic metastasis were as follows; local recurrence (recurrence
at the same segment of the liver, 5 cases, 24%), distant recurrence (recurrence at the other
segments of the liver, 10 cases, 48%), and simultaneous recurrence at local and distant (6
cases, 29%). Only 6 patients (29%) had single recurrent tumor; however, the numbers were
less than or equal to 3 in 11 patients (52%), and 11 patients (52%) including the cases
were re-treated by RFA. In 24 colon cancers, 16 (67%) showed recurrence. The rate of extra-
hepatic and intra-hepatic recurrence were 38% (6 cases) and 75% (12 cases), respectively. The
intra-hepatic tumor numbers were less than or equal to 3 in 8 patients (67%), and 7 patients
(58%) were re-treated by RFA. Conclusions: High rate of intra-hepatic distant recurrence
as well as extra-hepatic recurrence indicates that curative treatment of metastatic liver cancers
is difficult by RFA alone. Approximately half of the recurrent tumors in the liver could be
re-treated by RFA without severe complications, indicating the usefulness of RFA for the
treatment of metastatic liver cancers.
S1248
Repeat Hepatic Resections for Colorectal Metastases
Masami Minagawa, Masatoshi Makuuchi
Objective To determine the value of repeat resection for recurrent colorectal metastases to
the liver. Background Liver resection represents the best and a potentially curative treatment
for metastatic colorectal cancer to the liver. After resection, however, most patients develop
recurrent disease, often isolated to the liver. Methods From 1980 to 2005, a total of 503
patients received curative hepatic resection for metastases from colorectal cancer. Among
them, 132, 28, 11, 2, and 1 patients underwent second, third, 4-, 5-, and 6-times hepatic
resection respectively for recurrent liver metastases. In this paper, the factors which will
influence the survival after second hepatectomy were analyzed. Results Overall 5-year sur-
vivals were 43%, 34%, 53%, 58%, and 100% respectively after a first, second, third, 4-,
and 5-times hepatic resection. There was no operative mortality. Prognostic indicators of
reduced survival after second hepatectomy were fewer than 4 months intervals between first
and second hepatectomy (P=0.0003), 4 or more lymph nodes metastases around colorectal
cancer (P=0.0034), and number of metastases at second hepatectomy (P=0.0294). Numbers
of metastasis at 1st hepatectomy, CEA at first or second hepatotomy, size of metastases were
not significant factors. Conclusions Repeat liver resection for colorectal liver metastasis is
safe. Patients, who had been resected pN0 or pN1 primary cancer, experienced 3 or fewer
recurrent liver nodules after 4 or more months after first hepatectomy were the best candidate
for a repeat resection.
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S1249
Antitumor Effect of Ts-1 On Inoculated Human Biliary Cancer Cells in Nude
Mice
Haruki Morimoto, Tetsuo Ajiki, Tsunenori Fujita, Taku Matsumoto, Yoshiyasu Mita,
Hiroshige Hori, Yonson Ku, Hirokazu Fukui, Takahiro Fujimori, Yoshikazu Kuroda
Background: Since the prognosis of biliary carcinoma is poor, investigating the efficacy of
new chemotherapeutic agents is essential for the development of new treatments for this
tumor. TS-1 is a newly developed oral fluorinated pyrimidine and the antitumor effect of
TS-1 has been already demonstrated in a variety of solid tumors. However, few clinical
studies have reported using TS-1 to treat biliary cancers. Methods: We examined the effect
of TS-1 on biliary cancers resulting from subcutaneously inoculation of NOZ, SK-ChA-1,
MZ-1, TGBC-2TKB biliary tumor cells in nude mice. For orthotopic inoculation at the
gallbladder, we selected an NOZ cell line from among the 4 cell lines in the present study
because NOZ cells reliably yielded high frequency of tumor formation at the gallbladder
and showed a high potential for tumor growth and metastasis. Two weeks after subcutaneous
(S) or one week after orthotopic(O) inoculation, the mice were randomized into two groups:
Group A(S) and Group C(O), mice were administered 0.9% sodium chloride solution by
gavage for three weeks after inoculation (control). Group B (S) and Group D (O), mice were
administered TS-1 (10mg/kg) by gavage for three weeks. Six weeks after subcutaneous or
four weeks after orthotopic inoculation, all mice were sacrificed, and macroscopic and
histological findings were evaluated. For tumor materials obtained from Groups A-D, the
expression levels of proliferating-cell nuclear antigen (PCNA) and vascular endothelial growth
factor (VEGF) were examined using immunohistochemical methods to investigate cellular
proliferation activity and tumor angiogenic activity. Tunnel assays were performed to deter-
mine apoptotic status. Results: In the subcutaneously inoculation model, TS-1 significantly
inhibited tumor growth of NOZ and TGBC-2TKB biliary tumor cells. For NOZ biliary tumor
cells, the mean percent of PCNA-positive tumor cells was significantly higher in tumors
from mice in Group A (34.1%) compared to those of Group B (15.1%) as well as in Group
C (71.9%) compared to those of Group D (34.0%). The mean percent of Tunnel-positive
tumor cells was significantly lower in Group A (1.5%) compared to Group B (3.5%), while
those of Group C (2.0%) and Group D (2.7%) did not differ. In the orthotopic inoculation
model, metastases to the lung, mediastinal lymph nodes and peritoneum significantly
decreased in mice from Group D compared to those in Group C. There was no significant
difference in VEGF expression among these groups. Conclusions: TS-1 treatment may inhibit
tumor progression in some biliary cancer cells by inhibiting cell proliferation and indu-
cing apoptosis.
S1250
Photodynamic Therapy of Hilar Cholangiocarcinoma: Long Term Results
Guido Schachschal, Maria-anna Ortner, Jochen Liebetruth, Marek Mazan, Winfried
Voderholzer, Herbert Lochs
Background: Survival of patients with nonresectable hilar cholangiocarcinoma is about 3
to 5 month. Randomized controlled studies of photodynamic therapy (PDT) have shown
significant improvement of survival time. However, long term outcome has not yet been
adequately investigated.Aim: To present long-term outcome in patients undergoing photody-
namic therapy of nonresectable advanced hilar cholangiocarcinoma in a single centre study.
Methods: Sixtyfive patients with nonresectable hiliar cholangiocarcinoma were treated with
PDT between 1996 and 2006. Diagnosis was established by typical morphology in ERCP
and diagnosis of a tumour with ultrasound and CT. In 42 patients diagnosis was additionally
confirmed by histology. Sixty carcinomas were classified Bismuth IV, 3 as Bismuth III, 2 as
Bismuth II and 1 as Bismuth I. All patients were initially treated with plastic stents and
received 1 to 5 PDT (mean 1.75). PDT was performed 48 hours after intravenous application
of 2 mg/kg body weight Photofrin®. Restenting was performed 3 monthly and repeated
PDT was performed in patients with intraluminal tumour recurrence. Results: Tolerance
of PDT was excellent with few side effects. There was no significant decrease of bilirubin
within the first week after PDT [6.37 mg/dl (SD 8.31 mg/dl) vs. 6.28 mg/dl (SD 8.01 mg/
dl). Cholangitis occurred in 17 %, severe photosensitivity in 2.5%. No other side effects
were noted. Overall 1-year survival was 77%. Mean survival time was 612 days (95% CI
466 d; 758 d), median survival time was 493 d (95% CI 409 d; 576d) (See fig.) Conclusion:
PDT is a well tolerated palliative therapy of hilar cholangiocarcinoma which increases survival
time approximately 2.5 fold increase as compared to other conservative therapies.
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S1251
Efficacy and Safety of Covered Wallstents for Unresectable Malignant
Extrahepatic Biliary Obstruction
Cristina Gómez, Francisco javier Jimenez, Sarbelio Rodriguez, Ferran Gonzalez-huix,
Fernando Mugica, Jose luis Cabriada, Cándido Villanueva, Claudio Rodriguez, Carlos De
la serna, Carlos Guarner, Cobiwa Collaborating group
INTRODUCTION: Endoscopic biliary stenting is a well-established palliative treatment in
patients with unresectable malignant biliary stricture. Obstruction of uncovered self-expand-
able metal stents, due to tumor ingrowth, is the most frequent late complication,. A covered
self-expandable metal stent might increase stent patency, but could favour possible complica-
tions related to stent covering (pancreatitis, cholecystitis, migration). OBJECTIVES: To evalu-
ate the efficacy and safety of covered Wallstents in patients with unresectable malignant
extrahepatic biliary obstruction. PATIENTS AND METHODS: Multi-center, national, pro-
spective and non-randomized register of patients with extrahepatic biliary obstruction treated
with endoscopic covered self-expandable metal stent between January and December 2005.
RESULTS: One hundred and ninety-nine patients treated with prosthesis were included in
32 hospitals. Initial clinical success rate (decrease of bilirubin level and clinical improvement)
was observed in 96% of cases. Early complications occurred in 4.5% of patients (3 pancreatitis,
2 cholangitis, 1 haemorrhage, 1 perforation, 1 cholecystitis). Late complications occurred
in 18.9% (obstruction 8.5%, migration 5% and cholangitis without obstruction 3%), without
detecting tumour ingrowth in any case. Median stent patency was 138.9 days (+ 112,6).
One year actuarial probability of patency was 70%. Complementary treatment was identify
in a multivariate analysis as the only independent predictive factor of patency. One year
actuarial probability of non-migration was 86%. A previous insertion of a prosthesis was
the only predictive factor of migration. Actuarial probability of survival at 6 months of
follow-up was 42%. In a multivariate analysis, complementary treatment and low bilirubin
level were independent predictive factors of a better prognosis (> 4 months). CONCLUSIONS:
Covered Wallstent is an effective treatment in patients with nonresectable malignant extrahep-
atic biliary obstruction, prevents ingrowth tumour and does not seem favour possible
complications related to stent covering.
S1252
Antitumor Activity of Paclitaxel-Eluting Polyurethane Membrane As a Stent-
Covering Material: In Vivo Preliminary Results in Animal Model
Seok Jeong, Don haeng Lee, Jin-hee Maeng, Soon-sun Hong, In suh Park, Yong sun Jeon,
Sang-soo Park, Sung-gwon Kang, Jung il Lee, Jin-woo Lee, Kye sook Kwon, Hyung gil
Kim, Yong woon Shin, Young soo Kim
Background/Aim: Primary bile duct cancer has characteristic biological behaviors that are,
locally growing at the primary lesion and seldom metastasizing to distant sites. An efficient
local therapy is demanding. We evaluated the antitumor effect, systemic toxicity and the
degree of tumor cell apoptosis of local and controlled-releasing membrane for various amount
of paclitaxel in a tumor model. We also tried to identify the local effect of this releasing
system by measuring the paclitaxel concentration in tumor and other various organs. Materials
and Methods: We made an animal tumor model by injecting CT26 cell suspension containing
1x106 cells in a volume of 0.1 ml into the dorsal skin of three BALB/c mice. The different
amount of paclitaxel-containing (100, 300, 600, 1200 μg) or non-containing polyurethane
membranes were inserted into the subcutaneous layer beneath the pre-formed tumor mass
on the day 7 after the cell inoculation. The tumor size was measured repeatedly using
caliper, and the body weight of the tumor model was monitored until 28 days after insertion
of membrane. The tumor mass was harvested on day 35 of the membrane treatment. Terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) assay was
performed for in situ detection of apoptotic cells in the extracted tumor tissues. High
performance liquid chromatography was done to measure paclitaxel concentration in tumor,
as well as in various peripheral tissues and serum. Results: The concentrations of paclitaxel,
measured in two mice which were treated with 100 μg paclitaxel-contained membrane,
were higher in tumor tissue than in other tissues or serum. Conclusion: In current preliminary
animal study, we found out that the local and controlled-releasing polyurethane membrane
for paclitaxel had significant and dose-dependent antitumor activity, and did not exert
systemic toxicity on the tumor model. We suggest that the paclitaxel-releasing membrane
would be applied for the development of the drug-eluting stent as a local therapy of bile
duct cancer.
Antitumor activity, systemic toxicity and degree of apoptosis according to the amount of
paclitaxel in the polyurethane membrane
S1253
The Role of MAP Kinase (ERK) Nitration in the Gastric Mucosa of Rats with
Portal Hypertension: Therapeutic Implications
Hirofumi Kawanaka, Nao Kinjo, Daisuke Yoshida, Go Anegawa, Kozou Konishi, Shohei
Yamaguchi, Andrzej S. Tarnawski, Yoshihiko Maehara
Background & Aims: Portal hypertensive (PHT) gastric mucosa has increased susceptibility
to injury and delayed mucosal healing. Since excessive nitric oxide production is implicated
in PHT gastric mucosa, and since MAPK (ERK) signaling induces cell proliferation and leads
to gastric mucosal healing in response to injury, we postulated that nitration of ERK by
peroxynitrite might alter ERK signaling in PHT gastric mucosa, leading to delayed mucosal
healing. Methods: Portal hypertension was produced by staged portal vein ligation and
sham-operation (SO) rats served as controls. (1) In gastric mucosa of PHT and SO rats at
14 day, we studied: (a) lipid peroxide (LPO) and expressions of nitrotyrosine-containing
proteins by Western blotting; (b) ERK activation, phosphorylation of MEK, an upstream
molecule of ERK, and epithelial proliferation by PCNA labeling index in response to 50 %
ethanol injury; and (c) the ratio of nitrated/total ERK by Western blotting and direct binding
of ERK and peroxynitrite by co-immunoprecipitation. (2) In a separate experiment, PHT
and SO rats were received either rebamipide (30 mg/kg/day), an antiulcer drug that acts as
a free radical scavenger, or vehicle intragastrically daily for 13 days afte the operation. We
studied; (a) LPO and nitrotyrosine-containing proteins; (b) nitration of ERK; and (c) ERK
activation and mucosal healing in response to ethanol injury. Results: (1) (a) In PHT gastric
mucosa, LPO and nitrotyrosine-containing proteins were significantly increased by 36% and
32%, respectively, vs. in SO. (b) Following ethanol injury, ERK activation was significantly
increased by 109% and 127%, at 6 and 24 hours, respectively, vs. in non-injured gastric
mucosa (baseline). In contrast, ERK activation in PHT gastric mucosa was not significantly
increased from baseline. However, there was no significant difference in phosphorylation
of MEK, an upstream of ERK, between PHT and SO rats. (c) Western blotting showed that
the ratio of nitrated/total ERK was significantly increased in PHT gastric mucosa by 132%
vs. in SO. Co-immunoprecipitation showed that direct binding of ERK and peroxynitrite was
significantly enhanced in PHT gastric mucosa. (2) Treatment with rebamipide significantly
decreased LPO and nitrotyrosine-containing proteins as well as nitration of ERK by peroxyn-
itrite in PHT gastric mucosa, thus normalizing ERK activation and reversing mucosal healing
to ethanol injury. Conclusions: Enhanced nitration of ERK by peroxynitrite is involved in
the impaired MAPK (ERK) signaling in PHT gastric mucosa. Our findings provide a new
molecular mechanism, which predisposes PHT gastric mucosa to injury and impairs healing.
S1254
The Effect of Selective Intestinal Decontamination On Liver Hemodynamics in
Patients with Alcohol Related Decompensated Cirrhosis
Adamos Saveriadis, John Vlachogiannakos, Ioannis Theodoropoulos, Nikos Viazis, Kimon
Fundulis, Costas Markoglou, Sotirios A. Raptis, Dimitrios G. Karamanolis
Background: Endotoxemia following intestinal bacterial overgrowth and translocation is
commonly seen in cirrhotic patients with ascites. Both endotoxin itself and cytokines release
in response to it are potent stimuli for the production of endothelin-1 which may act in
combination with cyclooxygenase products to increase portal venous pressure. Aim: The
aim of the study was to investigate the effect of selective intestinal decontamination on
regional hemodynamics (hepatic venous pressure gradient, HVPG) in alcohol related cirrhotic
patients with ascites. Patients/Methods: Patients with decompensated cirrhosis (Child-Pugh
>7) and ascites who were abstinent from alcohol for the previous 6 months were eligible
for the study. A standard screening protocol was used for bacterial infection at admission
with clinical examination, blood analysis, chest radiograph, blood, urine and ascitic cultures.
Patients received selective intestinal decontamination for 28 days with non-absorbable antibi-
otic rifaximin (1200 mg/day). Plasma endotoxin levels were determined in day 0 and day
29. All patients underwent HVPG measurement through femoral vein catheterization before
starting antibiotics and the measurement was repeated after stopping rifaximin (day 29).
Results: Forty eight patients fulfilled the inclusion criteria. Eighteen patients excluded because
of infection (n=6), refusing informed consent (n=5), HCC (n=3), portal vein thrombosis (n=
2) and known allergy to rifaximin (n=2). Thirty patients (25 men-5 women) included in
the study. Median (range) age was 59.5 (42-75) years. Twelve were Child-Pugh B and 18
Child-Pugh C. Mean (SD) plasma endotoxin levels decreased significantly after rifaximin
administration (1.58±0.84 vs 0.84±0.71, p=0.0005). Twenty five patients had lower endo-
toxin levels on day 29 as compared to day 0. HVPG measurement achieved in 28 patients.
Mean (SD) HVPG values were 17.59±2.75mmHg on day 0 vs 14.47±2.38 on day 29 and
the difference was statistically significant (p<0.0001). Mean (SD) change was -3.1±2.4 (95%
CI: -4.037 to -2.170). HVPG decreased after rifaximin in 23 patients, remained stable in
two and increased in 3 patients. Conclusion: HVPG values decreased significantly after
selective intestinal decontamination with rifaximin in patients with alcohol related decom-
pensated cirrhosis and this might have been achieved through significant reduction of plasma
endotoxin levels.
S1255
The Therapeutic Effect of Cyanoacrylate On Gastric Variceal Bleeding and
Factors Related to Clinical Outcome
Sang woo Kim, Chang nyol Paik, In seok Lee, Jae myung Park, Yu kyung Cho, Jae kwang
Kim, Sok won Han, Myung-gyu Choi, In sik Chung, Kyu yong Choi
Background: Cyanoacrylate has been recommended for the treatment of gastric variceal
bleeding. The purpose of this study was to evaluate the efficacy and safety of cyanoacrylate
injection therapy in patients with gastric variceal bleeding, and to identify the factors
predictive of failure, rebleeding and survival after therapy. Patients and methods: One
hundred twenty-one patients with gastric variceal bleeding that received cyanoacrylate injec-
tion were retrospectively reviewed. Results: Initial hemostasis was achieved in 96.9% of
patients that were actively bleeding during endoscopy. Success of therapy was achieved in
110 patients (90.9%). Rebleeding and mortality rate during 4-week were 13.2% and 11.6%.
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A stepwise logistic regression analysis including age, sex, cause of cirrhosis, Child-Pugh
class, variceal form, bleeding site (cardia or fundus), initial hemoglobin, ICU treatment,
kidney failure and presence of hepatocellular carcinoma as variables indicated that only the
Child-Pugh class was an independent predictive factor of treatment failure (Child-Pugh C
vs. Child-Pugh A and B, Odds ratio, 5.0; 95% CI, 1.2-19.4; P = 0.025). The actuarial
probability of a four-week absence of rebleeding and survival after the initial therapy was
86.8% and 85.1%, respectively. A stepwise logistic regression analysis showed that a Child-
Pugh class C and hepatocellular carcinoma (HCC) were independent predictive factors for
rebleeding (Odds ratio, 7.4; 95% CI, 2.0-27.0; P = 0.003 and Odds ratio, 3.3; 95% CI, 1.0-
11.1; P = 0.05, respectively) and mortality (Odds ratio, 7.4; 95% CI, 2.0-27.0; P = 0.003
and Odds ratio, 3.3; 95% CI, 1.0-11.1; P = 0.05, respectively). Only two cases (2.7%)
with serious complications, noted as cyanoacrylate embolisms, were observed. Conclusion:
Cyanoacrylate injection is an effective treatment method for gastric variceal bleeding. The
Child-Pugh class was only independent predictive factors of treatment failure. The Child-
Pugh class and the HCC were risk factors for rebleeding and survival.
S1256
Reduced Portal Flow-Rate As Predictive Factor of Portal Vein Thrombosis
Development in Patients with Liver Cirrhosis
Maria assunta Zocco, Marialuisa Novi, E. Di stasio, L. Riccardi, A. Forgione, R. De
cristofaro, Maria elena Ainora, Emanuele Rinninella, Giuseppe Merra, M. Santoro, S.
Lancellotti, Antonio Grieco, G. Landolfi, Giovanni Gasbarrini, Gian ludovico Rapaccini,
Antonio Gasbarrini
Background. Portal vein thrombosis (PVT) is a negative prognostic factor in patients with
advanced liver disease. This complication has been related to liver dysfunction, neoplasms,
hemodynamic factors and hypercoagulability states but its exact pathogenesis is yet not
known. Aim. To find the role of coagulation parameters, prothrombotic factors, portal flow
rate and disease aetiology as predictors of liver disease progression and PVT development
in patients with different stages liver cirrhosis. Patients and methods. Seventy-five consecutive
patients with liver cirrhosis stratified according to disease aetiology were included in the
study. Coagulation parameters, prothrombotic factors (platelets count, PT, proteins C and
S, antithrombin III, antiphospholipid antibodies), Child-Pugh and MELD score were evalu-
ated in all subjects at the enrolment and every six months for 1 year. Ultrasound examination
was used to evaluate portal vein patency and flow rate at the same time points. We performed
multiple logistic regression selecting significant correlating variables at univariate analysis
and was used to determine clinical factors as independent predictors of thrombosis incidence
after 1 years. Results. 9 out of 75 cirrhotic patients enrolled in the study were found to
develop portal vein thrombosis in one year (12%). Most patients were in class Child-Pugh
B and C. Serum levels of prothombotic factors resulted lower in patients with advanced
cirrhosis compared to patients with Child-Pugh class A. The multivariate analysis, show
that only the decrease of portal vein flow-rate has a significant influence on portal vein
thrombosis development onset within one years (OR=2183; p=0.019). Conclusion. Reduced
portal flow rate has a major role in the PVT development in patients with liver cirrhosis.
These results suggest the need of a more strict follow up in this group of patients
S1257
Prognostic Role of the Initial Portal Pressure Gradient Reduction After TIPS in
Patients with Cirrhosis
Erwin Biecker, Felix Roth, Jörg Heller, Hans H. Schild, Tilman Sauerbruch, Michael
Schepke
Background/Aims: Both, baseline portal pressure and portal hemodynamic response to drug
treatment are important predictors of survival in patients with portal hypertension. Aim of
the present study was to determine the prognostic relevance of the portal pressure gradient
prior to and after TIPS insertion in patients with liver cirrhosis and recurrent esophageal
variceal bleeding. Methods: 118 cirrhotic patients (Child A/B/C: 41/56/21; baseline bilirubin
1.9 ± 2.2 mg/dl; Child-score 7.7 ± 2.0; baseline portal pressure gradient 21.8 ± 4.7 mmHg;
50 died during follow-up of 25.7 ± 24.1 months) underwent TIPS for the prevention of
variceal rebleeding. A multivariate logistic regression analysis (Cox model) was applied to
identify independent determinants of rebleeding and survival. The estimated respective
rebleeding rate and the estimated survival (Kaplan-Meier) were compared by log-rank testing.
Results: TIPS insertion reduced the portal pressure gradient by 53.2 ± 17.7%. During follow-
up 21 patients suffered significant rebleeding (17.8%), bleeding related mortality in the
entire cohort was 3.4% (4 patients). The median survival (95% CI) was 48.2 (39.8; 60.8)
months. The multivariate Cox model identified creatinine as the only independent predictor
of survival and the initial decrease of the portal pressure gradient after TIPS insertion as
the only independent predictor of rebleeding. Portal pressure gradient prior TIPS insertion
(21.8 ± 4.7 mmHg) and the gradient at the time of rebleeding (22.0 ± 2.9 mmHg) did not
differ significantly. Patients with an initial decrease of the portal pressure gradient after TIPS
insertion <30% were at highest risk for rebleeding. Patients with an initial decrease of the
portal gradient >60% rarely suffered from rebleeding. Conclusions: The initial decrease in
the portal pressure gradient after TIPS insertion is a predictor for the risk of rebleeding but
not a predictor for survival after TIPS placement.
S1258
Portal Biliopathy in Extra-Hepatic Portal Vein Obstruction (EHPVO): A
Progressive Biliary Disease!
Ashish Kumar, Barjesh C. Sharma, Shiv kumar Sarin
Background: Bile duct anomalies with or without gall bladder changes in patients with portal
hypertension are termed as portal biliopathy. It is caused by venous collaterals pressing on
the bile duct or ischemic injury and is seen in upto 90% pts with EHPVO. The severity
and natural history of biliopathy has not been studied. Aims: To know the presentation,
nature and progression of portal biliopathy. Patients & Methods: Endoscopic retrograde
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cholangiography (ERC) was performed in consenting pts of EHPVO who were being prospect-
ively followed since 1992. Biliopathy was classified according to Sarin et al, based on the
site and extent of involvement as: only extra-hepatic bile duct involvement, type 1; only
intra-hepatic, type 2; both intra and extra-hepatic, type 3 (left hepatic duct 3 a, right hepatic
duct 3 b). A second ERC was performed when clinically indicated or after about 2 yrs.
Results: Seventy nine pts with EHPVO (median age 20 yr, range 5 to 62 yr, males 67%)
were studied. 87% pts had presented with UGI bleed with median gr 3 esophageal varices.
History of jaundice was seen in 24% and pain abdomen 9%. On ERC, 92% had changes
of portal biliopathy. Most frequent type of involvement was type 3 b (51%) followed by
type 1 (42%). The nature of involvement was indentations in 49% and strictures in 36%.
20% pts had stones in bile ducts and 9% had history of cholangitis. The median bilirubin
was 1.1 (range 0.3 to 15.9) mg/dl and median serum alkaline phosphatase was 171 (range
42 to 617) IU/L. All patients were successfully managed by endoscopic stone extractions
and biliary dilations with or without stenting. Twenty-four (30%) patients underwent a 2nd
ERC after a median interval of 21 (range 1 to 111) months. On 2nd ERC, the type of
involvement had progressed to 75% pts having type 3 involvement compared to 54% in
1st (p=ns). Indentations progressed to strictures, increasing its frequency to 71% from 46%.
Frequency of stones also increased from 25% to 33% (p=ns). Conclusions: Portal biliopathy
is very common in patients with EHPVO. It usually remains asymptomatic; however it is a
progressive disease leading to biliary strictures. Bile duct stone formation is its common com-
plication.
(p = ns in all)
S1259
Effect of Porto-Systemic Shunting On Postprandial Energy Expenditure and
Substrate Metabolism in Cirrhosis
Tatjana Schuetz, Silja Mueller, Ajmal Omar, Esmatollah Kasim, Thomas Kroencke,
Herbert Lochs, Johann Ockenga
Background: The effect of porto-venous shunting on postprandial metabolism is unclear.
Therefore, we compared postprandial energy metabolism in patients with a transjugular
intrahepatic porto-systemic shunt (TIPSS), patients with liver cirrhosis without shunt (LCI)
and healthy controls. Methods: We investigated 9 male patients with established LCI (CHILD
A: 8, CHILD B: 1) and an average BMI of 26 ± 2.8 kg/m2, who had already been treated
by TIPSS. In addition 8 matched controls and 5 patients with LCI but without TIPSS were
investigated. Energy expenditure was measured before and after ingestion of a standardized
oral supplement (300 kcal; 55% carbohydrates, 30% lipids; 15% protein) using indirect
calorimetry (DATEX Ohmeda, Freiburg, FRG). In addition, blood samples were taken at
points 0 (=basal), 15, 30, and 60 minutes after 200 ml had been administered. Plasma levels
of glucose, insulin, leptin, CCK, resistin, and adiponectin were measured. Results: Resting
energy expenditure (REE_basal) was significantly higher in TIPSS patients compared to LCI
(1766±50 vs. 1425±125 kcal/d; p<0.03) but didn't differ to controls (1694±75 kcal/d;n.s.).
In parallel, the cumulative total diet induced energy expenditure (REE_diet) over 60 min
postprandially (REE_AUC60min) was highest in TIPSS (10595±1777 kcal), followed by
controls (9752±3872 kcal) and LCI (6928±2117 kcal). However, the mean relative postpran-
dial change of REE did not differ (d_REE_TIPS: 7.85±1.7%; d_REE_control: 8.45±3.4%;
d_REE_LCI: 7.07±3.4%; n.s.). Further analysis revealed, that the degree of insulin resistance
(expressed as insulin levels or HOMA index) was associated with REE_AUC60min (r=0.665
and r=0.643; p<0.005). No association was found with basal levels of further hormones like
leptin, CCK, resistin, adiponectin or with body weight and body composition. Conclusion:
Although in patients with porto-systemic shunts the fuel absorbed postprandially appears
in the systemic circulation without passing the metabolically active liver, this does not seem
to influence the diet induced energy expenditure. In addition, the association between insulin
resistance and REE_diet indicates, that the peripheral substrate utilisation is the determining
factor for the extent of REE_diet.
S1260
Correlation Between Lactose Absorption and Lactase-Phlorizin Hydrolase
Gene (LCT) Polimorphisms in Brazilian Subjects
Andrea C. Bulhoes, Helena A. Goldani, Fernanda S. Oliveira, Ursula S. Matte, Rafael B.
Mazzuca, Themis R. Silveira
Introduction: Adult type hypolactasia is characterized by the fall of lactase activity levels to
5% to 10% of birth levels that occurs during childhood and adolescence. It has been
recognized that C/T-13910 mutation is the major responsible for lactase-phlorizin hydrolase
gene (LCT) persistence and mutation G/A-22018 appears to be only in cosegregation with
C/T-13910. This study aimed to assess the presence of these two mutations in Brazilian
individuals with and without lactose malabsorption diagnosed by hydrogen breath test (HBT)
Subjects and Methods: Lactose intolerant individual (n=10) was defined as not able to drink
any quantity of milk due to presence of symptoms (nausea, abdominal pain, flatulence) or
those able to drink up to 2 glasses of milk (approximately 500ml) a day. Tolerant individuals
(n=10) were those reporting being able to drink more than 3 glasses of milk a day without
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symptoms. All individuals underwent hydrogen breath test (HBT) after oral ingestion of 50g
lactose (equivalent to 1 liter of milk). Molecular analysis for C/T-13910 and G/A-22018
mutations was performed using a PCR-based method. Primers were designed for this study
based on GeneBank sequence. Results: Out of the 20 individuals enrolled in this study, 18
(90%) were female. All were caucasians, except for one Asian descendent. Overall mean age
was 32.7 ± 7.3 years. All of lactose tolerant subjects had negative HBT and 90% of intolerants
had positive HBT. The genotypes CT/GA, CT/AA e TT/AA (lactase persistence) were found
in 10 individuals, all of them with negative HBT. The genotype CC/GG (lactase non-
persistence) was found in 10 individuals, 9 of them with positive HBT results. There was
significant agreement between the presence of mutations in the LCT gene promoter and
HBT results (kappa= -0,9, p < 0,001). Genotype CT/AA has not been described previously,
and was related to lactase persistence. Conclusions: The present study showed a significant
agreement between the two mutations G/A-22018 and C/T-13910 and lactose absorption
in Brazilian subjects, suggesting that the molecular test could be used for the diagnosis for
adult type primary hypolactasia.
S1261
Exogeneous Glucose Oxidation: Comparison Between [1-13c], [2-13c], and [3-
13c]Glucose
Yoshihisa Urita, Toshiyasu Watanabe, Kaoru Domon, Susumu Ishihara, Hiroki Ota,
Kazushige Nakanishi, Motonobu Sugimoto, Kazumasa Miki
Background: In normal individuals, in the presence of insulin, glucose is taken up by a
variety of cells, where it undergoes glycosis and then enters the tricarboxylic acid (TCA)
cycle or is shunted to fat synthesis. In either case, CO2 is produced as a metabolic byproduct.
This CO2 enters the circulation and is eliminated in the lung, and is excreted in expired
air. Recently, stable isotope, 13C-substrate, is used for the diagnosis of gastric emptying,
malabsorption, or metabolic disorder. However, [13CO2] recovery in the form of labeled
CO2 at the mouth of 13C provided in the form of glucose could depend on the site of
labeling. Carbons 3 and 4 released as CO2 upstream acetate, do not enter the TCA cycle.
Carbons 2 and 5 entering the TCA cycle in position 1 on [1-13C]acetate, provide CO2 at
the second turn of the cycle. Carbons 1 and 6 entering the TCA cycle in position 2 on [2-
13C]acetate, provide CO2 beginning at the third turn. The aim of the present study is to
compare the oxidation rate of exogenous glucose between the three sites of labeling. Further-
more, breath 13CO2 recovery from an oral glucose ingestion is evaluated in diabetic patients
and normal volunteers. Patients and Methods: Thirteen healthy volunteer (five men, eight
women) with a mean age of 21 (range 20-23) years and five diabetic patients (two were
treated with insulin) were studied three times. The subjects received a 100ml of water
containing 100mg of either [1-13C], [2-13C], or [3-13C]glucose, in the sitting position after
an overnight fast with one-week intervals. Breath samples were collected at 10 min-intervals
for 150 min. 13C was measured as the 13CO2/12CO2 isotope ratio and was expressed as
delta over baseline per mil (‰). Results: The maximal value of 13CO2 excreted in the expired
air (Cmax) was higher after administration of [3-13C]glucose than after administration of
[1-13C] and [2-13C]glucose in healthy volunteers (Figure).13CO2 excretion was lower in
all [13C]substrates in diabetic patients treated with insulin injection, whereas 13CO2 excre-
tion was greater in all [13C]substrates in diabetic patients with diet therapy alone than in
healthy volunteers. Conclusions: When a small amount of [13C]glucose is ingested, breath
13CO2 excretion reflects the rate of glucose entry in the TCA cycle. The results of [1-13C],
[2-13C], and [3-13C]glucose breath test may reflect the function of glycolysis and TCA cycle.
S1262
The 13carbon-Mixed Triglyceride Breath Test (13C-MTGBT) Is Not a
Repeatable Test in Children with Cystic Fibrosis (CF) and Exocrine Pancreatic
Insufficiency (EPI, Despite of Simultaneous Measurement of Total Co2-
Production By Indirect Calorimetry
Denise Herzog, Edgard Delvin, Caroline Albert, Claire Dupuis, Jacques E. Marcotte,
Véronique Pelletier, Ernest Seidman
There is no tool to monitor dose requirements of pancreatic enzyme supplements in cystic
fibrosis patients with exocrine pancreatic insufficiency. The 13C-MTGBT estimates the hydro-
lysis of triacylglycerols by pancreatic lipase and could be used for such an evaluation. Aim:
to assess the repeatability of the 13C-MTGBT in patients with CF and EPI. Method: After
an overnight fast nine patients with CF took a standardized test emulsion containing 5mg/
kg 13C-2octanoyl-1,3-distearin, plus a standardized breakfast with pancreatic enzyme sup-
plements. Before and during 6h after the test meal, end-expiratory breath samples were
collected in duplicates, at intervals of 30 minutes. After 3h of test, indirect calorimetry for
total CO2 measurement was performed. The BT was carried out twice at 1 month's interval.
A 72h stool collection for fecal fat analysis, including a 72h food diary was begun immediately
after the first BT. Finally, fecal elastase 1 was tested once in all patients. Results: All patients
had EPI as for fecal elastase 1 test results. Baseline 13C-enrichment was similar in both tests
for all nine patients (mean -23.9 (SE 0.44), and -23.6 (SE 0.44) DOB (delta over baseline.
The mean coefficient of variation (CV) of duplicate breath samples was 0.73% (0.1) and
0.67% (0.16), respectively. Figure: Percent dose recovery (PDR) of two BTs of 6h duration
each, at 1 month interval, in 9 CF patients. When using PDR curves for comparison, BTs
were not repeatable in any of the 9 patients. Fecal fat excretion was increased in 3 patients
with low cPDR. In 3 patients the PDR curves were graphically similar. For these, mean CV
of each of the 13 measurements, taken twice at one month interval, were: 11% (SE 2.8),
22% (SE 7.0) and 32.6% (SE 15.6), respectively. The coefficient of repeatability (CR)
according to Bland was > 2 standard deviations (SD) from the mean difference of PDR values
in these 3 patients. CR > 2SD means that results are not identical. Conclusion: The 13C-
MTGBT is not repeatable in pediatric CF patients and therefore not suitable for monitoring
efficacy of exogenous lipase supplements.
S1263
Low Glycemic Sucrose-Isomer Isomaltulose (Palatinose) Enhances Glucose
Oxidation
Yoshihisa Urita, Toshiyasu Watanabe, Kaoru Domon, Susumu Ishihara, Kazushige
Nakanishi, Masayuki Uchida, Taketo Yamaji, Hajime Sasaki, Jun Suzuki, Koji Kashimura,
Motonobu Sugimoto, Kazumasa Miki
Background: Isomaltulose is a disaccharide, alpha-1,6-linked glucose and fructose, which
has been found in honey and sugar cane extract. It is favorable in products for diabetics
because the hydrolysis of isomaltulose by a homogenate of human intestinal mucosa is one
fourth that of scrose. It has been unclear whether isomaltulose affects the metabolism of
glucose coexisting in the meal. The aim of the present study is to evaluate the influence of
isomaltulose on glucose metabolism. Materials and Methods: Seven healthy volunteer, five
women and two men, aged 20-22 years, were recruited. First, the subjects received 100mg
of [1-13C]glucose solution (100mL) in the sitting position after an overnight fast. Breath
samples were collected at baseline and at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100,
110, 120, 130, 140, and 150 min after ingestion. After one week, the same breath test
after ingestion of 100mL water containing [1-13C]glucose and 100mg of isomaltulose was
performed in all subjects. In the next study, an isomaltulose-based formula (INSLOW; Meiji
Dairies Corporation) and a dextrin-based standard formula (MEIBALANCE 200; Meiji Dairies
Corporation) were used as a test meals instead of water and 100mg of [1-13C]glucose was
added to these two liquid test meals (200mL, 200kcal). After oral administration of the test
meal with [1-13C]glucose, breath samples were collected at the same time course. The
pattern of breath 13CO2 excretion was compared between using two test meals. Results:
The breath 13CO2 levels rise gradually from the beginning and reached a plateau at 110
min after administration of glucose solution with isomaltulose, whereas those after administra-
tion of glucose alone continued to increase until 130 min-time point. Higher values of breath
13CO2 excretion after administration of glucose solution with isomaltulose were found at
10 to 110 min. After oral administration of an isomaltulose-based formula with [1-13C]glu-
cose, the breath 13CO2 levels increased much more rapidly than after a dextrin-based
standard formula. Significant differences were found at 60 min (3.82 +/- 1.34 per mil v.s.
2.98 +/- 0.84 per mil) and later. Conclusions: Due to the slower digestion of isomaltulose
and its lower oxidation rate, isomaltulose enhances glucose oxidation. Replacing high-
glycemic-index forms of carbohydrates with low-glycemic index carbohydrates may have
advantages in the management of diabetic mellitus by the mechanism of enhanced glucose
oxidation as well as slower digestion.
S1264
13c-Breath Test of Glucose and Fructose for Evaluating Acute Fuel Selection
in Response to Ingestion of Carbohydrate and Apple Juice
Yoshihisa Urita, Toshiyasu Watanabe, Kaoru Domon, Susumu Ishihara, Kazushige
Nakanishi, Motonobu Sugimoto, Kazumasa Miki
Background: The advantages fructose offers for diabetics are that it produces a smaller
increase in blood glucose than do other sugars, and it is metabolized largely independent
of insulin. These effects are based on the fact that fructose in absorbed across the small
intestine more slowly than glucose in man. However, the acute metabolism of fructose is
not completely understood when fructose is taken with glucose. Our objective was to
investigate acute fuel selection in response to ingestion of carbohydrate and apple juice.
Patients and Methods: Two test meals (Trelan G 225mL and apple juice 250mL) containing
100mg of [1-13C]glucose or [1-13C]fructose were consumed in a randomized, crossover
design by eight healthy subjects, six women and two men, aged 30-46 years. Breath samples
were collected at baseline and at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120,
130, 140, and 150 min after oral ingestion of test meals. Results: The breath 13CO2 levels
increased much more rapidly from the beginning and throughout the study period when
[1-13C]fructose accompanied the carbohydrate meal (Trelan G). There was no significant
difference of 13CO2 excretion between after [1-13C]glucose and [1-13C]fructose when the
substrate was taken with apple juice. Conclusions: In conclusion, fructose is preferentially
oxidized and that glucose is oxidized more slowly when taken with carbohydrate, whereas
the two sugars are utilized with the same speed when taken with apple juice despite of the
different metabolic pathway.
S1265
A Novel Strategy for Oligosaccharide Generation in the Digestive Tract Using
Transglucosidase; Good Heath Promotion and Disease Prevention
Makoto Sasaki, Hiromi Kataoka, Naotaka Ogasawara, Eiji Kubota, Tsuneya Wada,
Yoshinori Mori, Takaya Shimura, Tsutomu Mizoshita, Takashi Mizushima, Yasuyuki
Okamoto, Takeshi Kamiya, Satoshi Koikeda, Takashi Joh
Background: Dietary fiber, which includes oligosaccharides, is known to be a factor that
promotes good health and prevents disease; it not only normalizes blood glucose but also
lowers blood cholesterol and improves the microflora in the large intestine, which in turn
promotes normal laxation. Aims: The aim of this study was to evaluate a novel strategy for
generation of oligosaccharide in the digestive tract using transglucosidase (TG) and estimate
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the effects of oral administration of TG on postprandial glucose concentrations in healthy
subjects. Methods: First, the oligosaccharide synthase was examined in a gastric ligation rat
by high-performance liquid chromatography (HPLC). Secondary, to evaluate the effect of
oligosaccharide synthesizing enzyme (TG) on postprandial hyperglycemia, a randomized
placebo-controlled three-way crossover trial was separated by a washout period of more
than 3 days. Twenty-four normal healthy volunteers, aged 30-61 y (17 males and 4 females)
were selected for this study. The subjects' health was assessed as normal by prestudy
screening. All subjects received 3 types of test meals (3 rice balls: protein, 14.4 g; fat, 2.1
g; and carbohydrate, 111 g: total energy, 522 kcal) with 200 ml water in which 0 mg, 150
mg, or 300 mg of TG was dissolved. Blood samples for estimating plasma glucose and
insulin concentrations were collected before and every 30 min after the experiment. Results:
Oligosaccharide was generated in the stomach enzyme-doze dependently .As compared to
no TG treatment, administration of 150mg TG prevented a postprandial increase in plasma
glucose (P = 0.069) but not 300mg of TG. Insulin concentrations did not changed by TG
administration. With regard to the 17 subjects who were suggested to have impaired glucose
tolerance, TG significantly decreased the postprandial blood glucose (P < 0.05: 150 mg of
TG vs. control, P < 0.05: 300 mg of TG vs. control) and marginally insulin concentrations
(P = 0.099: 600 mg of TG vs. control). Conclusions: We evaluated a novel strategy for
oligosaccharide generation in the alimentary tract and a novel effect on prevention of
postprandial hyperglycemia, suggesting that oligosaccharide synthesizing enzyme may be
useful for good health promotion and disease prevention such as type 2 diabetes mellitus.
S1265a
Characterization of Mucosal Redox Status in Human Intestine
Menghua Luo, Lorraine M. Leader, Li H. Gu, Mohammad Wehbi, Mahmoud Barrie,
Kamil Obideen, Shanthi Srinivasan, Jones P. Dean, Thomas R. Ziegler
Background: Previous studies suggest that malnutrition is associated with oxidative stress,
characterized by low antioxidant levels in blood and decreased gut mucosal concentrations
of glutathione (GSH), the major intracellular low-molecular weight thiol antioxidant. Cyto-
solic and nuclear thioredoxin 1 (Trx1) and mitochondrial Trx2 are also important antioxidant
proteins critical for cell redox signaling. However, little data on redox status in human gut
mucosa are available and no data have been published on the redox potentials (Eh in mV)
of the GSH/glutathione disulfide (GSSG) pool, Trx1 or Trx2 in human intestinal mucosa.
Our primary aim was to characterize the redox status of mucosal GSH/GSSG, Trx1 and
Trx2 in small bowel and colon in adults. The secondary aim was to evaluate whether Eh
of the plasma cysteine (Cys)/cystine (CySS) couple (the major extracellular low-molecular
weight thiol disulfide pool) was indicative of gut mucosal GSH/GSSG redox. Methods: Gut
mucosal biopsies were obtained from 61 well-nourished male subjects during surveillance
endoscopy (mean age 60±1 years, range 43-76 yr). GSH and GSSG levels were determined
by HPLC in biopsies from duodenum (DUO; n=14), terminal ileum (TI, n=22), ascending
colon (AC, n=25) and descending colon (DC, n=27) and GSH/GSSG Eh calculated by Nernst
Equation. Trx1 redox potential (Eh) was determined in DUO (n=8) and TI (n=4) and Trx2
Eh was determined in DUO (n=8) and DC (n=7) by redox Western blot. Concomitant
plasma for Cys/CySS Eh was obtained in 31 subjects in whom gut mucosal redox was
characterized [DUO (n=7), TI (n=15), AC (n=21) and DC (n=12). Data (mean±SE) were
analyzed by t-test, ANOVA and Pearson's correlation. Results: A significant gradient was
present for GSH/GSSG Eh in gut mucosa: DUO -221±6, TI -232±3, AC -239±2, DC -227±3
mV, respectively, with TI and AC exhibiting the most reducing Eh (DUO vs TI and AC,
P<0.05). GSH/GSSG Eh in DC was significantly more oxidized than in AC (P<0.05). Trx1
Eh was -273±2 and -267±4 mV in DUO and TI, respectively (NS). Trx2 Eh was -312±9
and -326±3 mV in DUO and DC, respectively (NS). Mitochrondrial Trx2 was considerably
more reduced than cyosolic and nuclear Trx1 in DUO (P<0.05), consistent with previous
In Vitro findings. Plasma Cys/CySS Eh was significantly, and negatively, correlated with
cellular GSH/GSSG Eh in DUO (r= -0.91; P<0.001) and was not correlated with GSH/GSSG
Eh in TI, AC and DC. Conclusions: The human intestinal mucosa exhibits a significant
proximal-distal GSH/GSSG redox gradient and detectable Trx1 and Trx2. These data provide
a basis for comparison to gut mucosal redox changes as affected by nutritional status, disease
and therapy.
S1265b
Comparison of Ileal and Duodenal Brake Mechanisms On Satiety and
Gastrointestinal Transport
Jeroen Maljaars, Edward Haddeman, Harry Peters, Ad A. Masclee
Background: In both the duodenum and ileum, exposure of the luminal wall to nutrients
activates a negative feedback mechanism. This duodenal and ileal brake are known to reduce
food intake and hunger, and to inhibit gastric emptying and small bowel transit. In order
to compare the ileal and the duodenal brake mechanisms, we performed a single-blind
crossover study to compare the effects of fat emulsions infused either in the ileum or in the
duodenum on satiety, food intake and gastrointestinal motor transport. Methods: Fifteen
healthy female normal weight volunteers (mean age 23yrs, mean BMI 22 kg/m2) were
intubated with a 270-cm naso-ileal tube, and participated in two experiments performed
in random order on two consecutive days. Each test day after consumption of a fat-free
liquid meal (180 kcal) at t=0 min, a emulsion consisting of 6g fat was administrated either
into the duodenum or into the ileum from t=30-90 min after meal ingestion. Satiety para-
meters (visual analogue scales), blood samples (plasma CCK, PYY), gastric emptying with
13C-acetate breath test and small bowel transit time (SBTT) with lactulose H2 breath test
were assessed at regular intervals. Food intake was assessed during an ad-libitum meal at
t=240 min. Results: Ileal fat induced a significantly stronger inhibition in appetite and
hunger compared to duodenal fat (Appetite: 41.6 vs 49.9 mm/min, SE=2.0, p=0.004, Hunger:
39.0 vs 44.0 mm/min, SE=2.1, p=0.08). However, no significant differences were foud
between ileal and duodenal fat with respect to food intake. Ileal infusion of fat caused a
significant delay in gastric emptying (206 vs 138 min, SE=10.3, p<0.05) and in small bowel
transit time (ileum vs duodenum 144 vs 85 min, SE= 13.7, p=0.005) compared to duodenal
fat. No significant differences were seen in CCK and in PYY-secretion (CCK AUC 0.56 vs
0.51 pM/min, SE= 0.05, PYY AUC: 22.7 vs 25.4 pM/min, SE=1.04) between the duodenal
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and ileal infusion. However, the pattern of CCK- and PYY-secretion was different with
significantly higher levels in the early phase of the test day in response to duodenal fat, and
significant higher levels in the late phase in response to ileal fat. Conclusions: Ileal fat more
potently inhibits hunger, gastric emptying and small bowel transit compared to duodenal
fat. Thus, the ileal brake appears to be more potent compared to the duodenal brake.
S1265c
Novel Technique for Mucus Sampling and Proteomic Analysis of Human
Colonic Mucus
Henrike Hamer, Daisy Jonkers, Raymond Schipper, Arnoud Loof, Steven Vanhoutvin,
Freddy J. Troost, Ger Koek, Andrea Kodde, Koen Venema, Robert jan Brummer
Introduction: The colonic mucus layer is an important dynamic component of the epithelial
barrier, which can be affected by dietary intake and intestinal disorders. The mucus layer
contains mucin glycoproteins, intestinal trefoil factor (ITF) and many other compounds
secreted by the intestinal epithelium, such as secretory IgA (sIgA). To determine changes
in the human mucus layer, standardized In Vivo sampling is required. In this study, mucus was
collected with a cytology brush during sigmoidoscopy in order to assess the reproducibility of
the sampling technique and the inter-individual variability of mucus composition. In addition,
attention was paid to standardization of mucus sampling and feasibility of proteomic analysis.
Method: From 11 healthy volunteers triplicate colonic mucus samples were collected from
the same region during sigmoidoscopy using cytology brushes. The total mucin concentration
was determined by measuring the amount of liberated oligosaccharide side chains and
monosaccharides (galactosamine, glucosamine, fucose, galactose). Also sIgA and total protein
concentration were determined and proteomic analysis was performed using SELDI-TOF
MS. Results: The amount of oligosaccharide side chains correlated significantly with both
the galactosamine concentration (R2= 0.91; p<0.001) and the sum of monosaccharides (R2=
0.97; p<0.001). A significant correlation was also found between total protein concentration
and the amount of oligosaccharide side chains (R2= 0.12; p<0.05), but the correlation between
the galactosamine concentration and total protein did not reach statistical significance (R2=
0.11; p=0.06). Mean triplicate values of sIgA ranged from 0.16 to 1.81 gram sIgA/mmol
oligosaccharide side chains. The mean variation coefficient of triplicate samples per subject
was 41.3 ±17.9%. Duplicate proteomic analyses of one mucus sample resulted in highly
reproducible profiles. Using a hierarchical cluster analysis, it was shown that all three replicate
samples clustered in five out of 11 subjects, and two out of three replicate samples clustered
in another five different subjects. Conclusion: The liberated oligosaccharide side chain
concentration can be used to standardize the amount of mucus obtained with cytology
brushes during endoscopy. Secretory IgA concentrations can be measured in the mucus
samples. Proteomic analysis of intestinal mucus is feasible and yields information on many
proteins. The cluster analysis showed that subject specific profiles can be obtained. However,
the differences between some triplicates indicate that analyzing only one mucus sample can
result in an observation bias.
S1265d
Prospective Evaluation of H. pylori Eradication Effects On Meal-Induced
Changes in Plasma Ghrelin and Leptin
Aditi Kinkhabwala, Jatin Roper, Joshua R. Shak, Asalia Z. Olivares, Chi-hong Tseng,
Guillermo I. Perez-perez, Martin J. Blaser, Fritz Francois
BACKGROUND: Appetite and energy expenditure are regulated in part by ghrelin and leptin
produced by gastric mucosa. Although H. pylori (HP) colonization may be associated with
reduced levels of ghrelin, the effects of eradication on energy homeostasis have not been
described. The aim was to prospectively evaluate the effect of HP eradication on meal-
induced changes in serum ghrelin and leptin levels. METHODS: Patients referred for clinically
indicated upper endoscopy were enrolled and a detailed evaluation including body mass index
(BMI) was obtained at baseline and ≥ 8 weeks after endoscopy. Patients were categorized as
HP+ if ≥ 2 tests (rapid urease, histology, culture, HP serology) were positive. During the
first visit in all subjects, and during subsequent visits in the initially HP+ subjects, blood
was collected the morning after an overnight fast, and 1 h after a standard high protein
meal. After receiving an antibiotic regimen, HP eradication was confirmed by urea breath
test. Levels of plasma ghrelin and leptin were determined by specific ELISAs, and results
compared with the Wilcoxon signed rank test using the patients as their own controls.
RESULTS: Among 31 enrolled patients, 13 (42%) were HP+ (Mean age of 61 ± 13 y and
mean BMI of 33 ± 6). HP was eradicated in 12 (92%) subjects, who were included in further
analyses. After Mean of 8 ± 3 months BMI was not significantly changed in those who were
HP- at baseline; p=0.83. In contrast after Mean of 7 ± 4 months post-eradication, BMI
significantly increased in the initially HP+ individuals by Mean 0.8 ± 0.3; p=0.009. Median
ghrelin (pg/ml) increased significantly from baseline (2069, IQR 1746-2709) to post-HP
eradication (3587, IQR 2359-4859); p=0.034. Post-prandial ghrelin levels post-eradication
were Mean 137% higher than pre-eradication; p=0.007. Consistent with these findings,
median leptin levels (pg/ml) pre-eradication (5544, IQR 3432-9046) increased significantly
after HP eradication (18507, IQR 7356-29598); p=0.0005. Compared to baseline, post-
eradication fasting leptin rose significantly; p=0.034. Similarly for post-prandial levels, com-
pared to baseline, post-eradication leptin was significantly elevated; p=0.001. CONCLU-
SIONS: H. pylori eradication resulted in increased BMI, and circulating fasting and post-
prandial leptin, perhaps by raising ghrelin levels. These studies provide direct evidence that
HP gastric colonization is involved in the regulation of systemic ghrelin and leptin levels.
These findings are consistent with the hypothesis that the declining incidence of HP coloniza-
tion in developed countries is associated with the observed increases in metabolic diseases.
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S1265e
Consumption of a High-Fat Diet for 3 Weeks Increases Fasting Plasma
Cholecystokinin (CCK) Concentrations, But Does Not Diminish the Effects of
Exogenous CCK-8 On Antropyloroduodenal (Apd) Motility, Appetite and
Energy Intake in Healthy Lean Men
Tanya J. Little, Kate L. Feltrin, Michael Horowitz, James H. Meyer, Judith Wishart,
Christine Feinle-bisset
Introduction: There is evidence from rodent studies that the effects of both fat and CCK
on gastrointestinal function and food intake are attenuated by a high-fat (HF) diet. For
example, suppression of gastric emptying and food intake by exogenous CCK-8 was dimin-
ished following 34 or 54% fat diets when compared with a 5% fat diet (Am J Physiol
278:R166-70,2000). In humans, following a HF diet gastric emptying of fat is accelerated (Gut
32:483-6,1991); moreover, the pyloric motor response to intraduodenal lipid is decreased
following a 40%, when compared with a 10%, fat diet, despite similar increases in plasma
CCK concentrations (Am J Physiol 285:G188-96,2003), suggesting that the sensitivity to
CCK is reduced by a HF diet. Hypothesis: The effects of exogenous CCK-8 on APD motility,
appetite and energy intake will be attenuated by a HF diet. Protocol: 10 healthy lean males
(age: 22±1 yr, BMI: 22±1 kg/m2) consumed isocaloric diets (~15,400 kJ per day), containing
either 44% (HF) or 10% (low-fat; LF) fat, for 21 days in single-blind, randomised, cross-
over fashion. The protein content of the diets was matched. Immediately following each
diet, the effects of a 45-min intravenous infusion of CCK-8 (2 ng/kg/min) on APD motility,
hunger and fullness and plasma CCK were assessed. At t=30 min during the infusion,
subjects were offered a buffet-style meal, from which energy intake (kJ) was quantified.
Results: Body weight was not affected by the diets (HF: 69.5±22 kg, LF: 69.3±22 kg).
Baseline CCK levels were greater following the HF (4.3±0.4 pmol/l), when compared with
the LF (3.1±0.3 pmol/l, P < 0.05), diet. Intravenous CCK-8 suppressed antral and duodenal,
and stimulated tonic and phasic pyloric (Fig A), pressures (P<0.05 for all), with no difference
between the two diets. Hunger, fullness and energy intake (Fig B) also did not differ.
Conclusions: Consumption of a HF diet for three weeks increases fasting plasma CCK, but
the effects of exogenous CCK-8 on APD motility and energy intake do not appear to be
affected. This latter observation suggests that, in healthy lean men, sensitivity to exogenous
CCK-8 is unchanged following a short period on a HF diet.
S1265f
Evidence for Homeostatic Disorder of Active-Ghrelin Levels, PYY 3-36, CCK,
and Asp in Morbidly Obese Pregnant Women
Krzysztof Sodowski, Krystyna Zwirska-korczala, Dorota Kuka, Michal Kukla, Wojciech
Cnota, Ryszard Zdun, Paulina Budziszewska, Bartlomiej Czuba, Anna Wloch, Tomasz
Brzozowski, Stanislaw J. Konturek
Background: The peripheral signals produced within the gastrointestinal tract such as ghrelin
and peptide YY are results of nutritional status. While food intake is stimulated by ghrelin,
it is inhibited by peptide YY. Therefore, alteration in hormone physiology may play an
important role in increased food consumption resulting in supraphysiological weight gain
during pregnancy. This study aims to evaluate active ghrelin, PYY3-36, CCK, acylation-
stimulating protein (ASP), insulin, glucose, lipid profile (cholesterol, HDL, LDL, triglycer-
ydes), basic gastrin and postprandial concentrations, in order to answer the question whether
or not a relationship exists between these peptide levels in pregnant women and varying
body mass gains in the second trimester of physiological pregnancy. Methods: Accordingly,
the examined pregnant women were divided into 4 groups: control pregnancy and weight
gain below 500 gram, overweight low weight gain < 1kg / week, overweight high weight
gain >1kg / week, morbidly obese pregnant, weight gain above 1.5 kg/week. Results: For
the first time we noticed that pregnant women with excessive,-but not morbid, body mass
growth-during the second trimester of pregnancy, displayed no disorders in secretion of the
hormones such as active-ghrelin, PYY 3-36, CCK, gastrin and ASP. However, as far as active-
ghrelin is concerned, the concentration at the baseline was considerably higher in morbidly
obese pregnant women than in the remaining groups. A relative hyperghrelinaemia was
found in those pregnant women, remaining even after the meal, so we observed an abnormal
active-ghrelin response with a minimal postprandial drop. Interestingly, in morbidly obese
pregnant patients, despite the increased general estrogen concentration, we did not observe
the typical postprandial PYY 3-36 increase. We have demonstrated that maternal CRP serum
levels correlate significantly with pregnancy obesity and that CRP levels are higher in morbidly
obese pregnant women than in lean pregnant women. In conclusion, we have shown that
with pregnant women displaying excessive, but not morbid body weight growth in the
second trimester of pregnancy, homeostasis in the secretion of hormones such as active-
ghrelin, PYY 3-36, CKK, ASP, gastrin is maintained and we have demonstrated that maternal
serum CRP levels correlate significantly with pregnancy obesity and that CRP levels are
higher in morbidly obese pregnant women than in lean pregnant women.
S1265g
Utility of An In Vitro Model to Study the Bioaccessibility of Protein and
Carbohydrate Using a Novel Pancreatic Enzyme Replacement Therapy (Altu-
135)
Bhami Shenoy, Robert Havenaar, Miriam Verwei, Alexey L. Margolin
Introduction: TNO's In Vitro gastrointestinal (GI) model systems simulate the successive
dynamic processes in the stomach and the small intestine [TNO's gastro- Intestinal Model-
1 (TIM-1 system)], allowing for the study of the stability, release, dissolution, absorption
and bioconversion of nutrients and pharmaceuticals in the GI tract. In the model systems,
digested and water-dissolved low molecular weight compounds are dialyzed continuously
from the jejunum and ileum compartments of the model via hollow-fiber semi-permeable
membrane systems. We tested the utility of the TIM-1 system by simulating the conditions
in the GI tract of human adults with cystic fibrosis (CF)-related pancreatic insufficiency (PI)
for the study of ALTU-135, an investigational pancreatic enzyme replacement therapy (PERT)
to aid in the digestion of fats, protein and carbohydrate. Data on amylase activity of PERTs
in PI has not been previously presented. Methods: The TIM-1 system was used to mimic
CF conditions by maintaining pH 5.0 in the duodenal compartment throughout the digestion
period and lack of secretion of pancreatic enzymes. The efficacy of the protease and amylase
components of ALTU-135 was examined by running the model under a “fed state” using a
breakfast meal (30% fat; 15% protein; 55% carbohydrate) in the presence and absence of
ALTU-135. The digestion of protein was monitored by measuring and analyzing α-amino
nitrogen or total nitrogen, and that of carbohydrate by glucose in the dialysate. These
analyses provided data on the timing and rate of protein and carbohydrate digestion, and
the potential availability for absorption (bioaccessibility) of amino acids, small peptides, and
glucose. Results: The model was shown to be useful to study the digestion of protein by
ALTU-135 in CF conditions of the GI tract. The highest amounts of the protein and
carbohydrate were digested and absorbed between 90 and 120 minutes after intake. The
dialysate from the jejunum compartment contained more nitrogen and glucose than that of
the ileum compartment, thus showing that maximum digestion and absorption took place
in the jejunum compartment, as in humans. Calculations of mass balance showed more
than 90% digestibility of proteins and bioaccessibility of (α-amino) nitrogen. Similarly,
more than 80% digestibility of carbohydrates and bioaccessibility of glucose was observed.
Conclusions: 1) The TIM systems are excellent tools to study the functionality of food
components under various physiological conditions 2) ALTU-135 facilitated digestibility of
protein and carbohydrate and the bioaccessibility of (α-amino) nitrogen and glucose in the
GI tract.
S1265h
Digestive and Absorptive Functions in the Elderly
Yoshihisa Urita, Toshiyasu Watanabe, Kaoru Domon, Susumu Ishihara, Kazushige
Nakanishi, Motonobu Sugimoto, Kazumasa Miki
Background: Aging is the factor affecting malabsorption of nutrients including glucose,
amino acid, and short-chain fatty acid. The aim of this study is to evaluate changes in
digestive and absorptive functions in the elderly. Patients and Methods: (1) A standard 75
g oral glucose tolerance test (GTT) was performed in 99 subjects (25 aged >70 yrs). The
patients received 75g (225 ml) of glucose solution in the sitting position after an overnight
fast. Breath samples were collected at baseline and at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80,
90, 100, 110, and 120min after ingestion. (2) Consecutive 198subjects presenting diagnostic
upper endoscopy were recruited in this study. 13C-acetate was administrated intraduodenally
in 66, 13C-glycine in 65, and 13C-glucose in 67 patients. At the end of endoscopy, a tip
of endoscope was placed to the second part of the duodenum and 20 ml of water containing
100 mg of 13C-substrate was sprayed onto the duodenal mucosa. Breath samples were
taken at baseline and at 10-min interval. (3) After ingestion of liquid test meal, breath H2
gas levels were measured at 10-min interval. (4) At endoscopy, we intubated the stomach
without inflation by air, and 20 ml of intragastric gas was collected through the biopsy.
Intragastric hydrogen and methane concentrations were immediately measured by gaschrom-
atography (5) An increase in intragastric H2 level after spraying 20ml of liquid test meal
and milk. Results: (1) 13CO2 recovery rate is lower in the aged group after 13C-glucose
administration. (2) Absorption values in 13C-glycine breath test absorption and oxidation
of glycine was enhanced in obese subjects. No significant differences between older and
younger people were found after ingestion of 13C-glucose, 13C-acetate, 13C-glycine, and
13C-leucine. (3) There was no difference in breath H2 elevation after administration of
liquid test meal between older and younger people. (4) An intraduodenal H2 level is similar
in two groups. (5) A ratio of increased H2 level in the stomach after spraying liquid test
meal and milk is not higher in the elderly. .Conclusions: A decreased carbohydrate absorption
and an increased intraduodenal H2 level were found in the elderly.
S1266
Amoxycillin and Multispecies Probiotic Intake Affect Cytokine Production in
Healthy Volunteers
Catherina Koning, Daisy Jonkers, Ellen Stobberingh, Theo Out, Reinhold Stockbrugger
Introduction Antibiotics can affect cytokine production via direct effects on immune compet-
ent cells or indirectly through a disturbance of the intestinal microbiota. There is also
increasing evidence that probiotics influence host immune function directly or indirectly.
Most evidence, however, comes from In Vitro studies and effects in healthy individuals are not
clear. Aim and Methods The possible immunomodulatory effect of a multispecies probiotic on
induced cytokine production was studied in forty-one healthy volunteers treated with 500
mg amoxycillin twice daily from day 1-7. In addition, five gram of a multispecies probiotic
(5 lactobacilli, 3 bifidobacteria, 1 enterococcus) (109 cfu/gr) or placebo was given twice
daily from day 1-14. From each subject blood samples were collected at 0, 7, 14 and 63
days. Monocyte and T-helper type 1 (Th1), type 2 (Th2), and regulatory cell cytokines were
assessed in supernatant of stimulated whole blood cultures by multiplex assay. Results Forty
volunteers completed the study, 19 in the probiotic (mean age 25.5 (10.2) years) and 21
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in the placebo group (mean age 28.2 (11.5) years). Cytokine levels of IL-4, IL-13, IFN-γ
and IL-10 are shown in table 1. Conclusion Amoxycillin intake results in a decrease of IL-
4, IL-13 and IFN-γ and an increase of IL-10 protein production upon in-vitro induced
stimulation in healthy volunteers. The intake of a multispecies probiotic resulted in a further
decrease of IL-4 and Il-13 and less pronounced increase of IL-10 protein production. These
findings suggest that the intake of a multispecies probiotic modulates some of the effects
of amoxycilin in that it dampens the effects of amoxycillin on the ex-vivo cytokine production.
Table 1: Cytokine production in supernatant of stimulated (CD3/CD28 for IL-4, IL-13 and
IFN-γ; LPS for IL-10) whole blood cultures in picogram/ml (mean (sd)).
Within group differences, p<0.05 1) t=14 vs t=0/7, 2) t=14/63 vs t=0 and t=63 vs t =7 3
t=63 vs t=14 4) t=7 vs t=0 5) t=63 vs t=0 6) t=63 vs t=0/7/14
S1267
Modulation of the Commensal Flora By Probiotic Feeding Delays the Onset
and Decreases the Severity of Disease in the Collagen-Induced Arthritis (CIA)
Model in a Strain-Dependent Manner
Barbara Sheil, John Macsharry, Liam O'mahony, Fergus Shanahan, Barry Kiely
Background and aims: We have previously demonstrated that consumption of specific
probiotic bacterial strains can modulate mucosal inflammatory disease. We hypothesized
that this anti-inflammatory activity could also impact extra-intestinal inflammatory disease.
The aim of this study was (i) To determine the effect of oral administration of probiotic
bifidobacterial and lactobacilli strains in a murine arthritis model, (ii) To determine if this
effect is strain-dependent. Methods: DBA/1 mice were fed Bifidobacterium infantis 35624(n=
20), Bifidobacterium breve (n=10), Bifidobacterium longum (n=10), Lactobacillus salivarius (n=
10) or placebo (n=20) for at least 2 weeks prior to arthritis induction with bovine type II
collagen. Following arthritis induction a visual assessment of arthritis severity (VAAS) was
undertaken. Mice were sacrificed; paw swelling measured and joints scored histologically
at the end of the study period. Results: Consumption of B. infantis but not B. breve, B.
longum or L. salivarius resulted in significant improvements in the visual assessment of
arthritis (p< 0.05) and paw thickness measurements (p=0.005) when compared to placebo
fed animals. No significant change in histology was observed at the end of the study which
is not surprising as this measurement was obtained following onset of end-stage disease.
Conclusions: Oral feeding with B. infantis 35624 but not L. salivarius, B. breve or B. longum
delayed the onset and attenuated the severity of arthritis in the collagen-induced arthritis
model. This study demonstrates that the anti-inflammatory effects of specific probiotic strains
is not restricted to the gastrointestinal tract.
S1268
Probiotics Prevent Alcohol-Induced Hepatic Damage in a Mouse Model of
Liver Disease
Denny D. Demeria, Julia Ewaschuk, Dave Thiel, Kevin St. arnaud, Marie-claire Arrieta,
Thomas A. Churchill, Karen Madsen
Gut-derived bacterial products and toxins play an important role in the initiation and
progression of alcohol-induced liver disease. Ethanol increases gut permeability and allows
enhanced microbial translocation through the portal vein into the liver. The subsequent
activation of the hepatic innate immune system results in increased levels of TNFα secretion
and hepatic damage. Probiotics have been shown to decrease intestinal permeability and
also to down-regulate pro-inflammatory cytokine secretion in several models of colitis. Aim:
The aim of this study was to determine if orally administered probiotics would maintain
intestinal barrier function and prevent the development of alcohol-induced liver disease in
a mouse model. Methods: Adult male 129 Sv/Ev mice were fed an ethanol-containing
(EtOH) or control (C) liquid diet (BioServ) for 30 days. A separate group was fed VSL3
probiotics (2.8 x 108 CFU/day) (Streptococcus thermophilus, Bifidobacterium breve, B. longum,
B. infantis, Lactobacillus acidophilus, L. plantarum, L. casei, L. bulgaricus) for 1 week prior to
the initiation of the ethanol diet. In Vivogastric and intestinal permeability was assessed by
administering a sucrose-lactulose-mannitol solution followed by HPLC analysis of urine
prior to and after the study. At the time of sacrifice, blood, gut and liver tissue samples were
obtained for enzyme and cytokine analysis. As a measurement of neutrophilic infiltration,
myeloperoxidase (MPO) levels in the small intestine were measured by ELISA. Results: All
mice consumed equal caloric amounts of the liquid diets. However, over the duration of
the study, control mice gained weight (1.4±0.5g) while EtOH mice lost weight (-6.7±2.6g).
In addition, EtOH mice exhibited elevated serum AST and ALT, increased hepatic levels of
TNFα and IFNγ, mild hepatic steatosis, and increased MPO levels in the small intestine. In
contrast, probiotic-treated mice (EtPro) had normal ALT and AST levels, liver histology,
and hepatic TNFα and IFNγ levels. Small intestinal MPO levels and weight loss were
attenuated in the probiotic group. However, gastric and small intestinal permeability did
not differ between the EtOH and EtPro groups, suggesting that the beneficial effects of
probiotics were not mediated through a maintenance of intestinal permeability. Conclusion:
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Oral probiotics are effective in protecting against liver damage induced by alcohol consump-
tion and may be useful as adjunctive therapy in patients with chronic liver disease.
S1269
Effect of Yoghurt Containing Three Probiotic Bacteria in Patients with Irritable
Bowel Syndrome (IBS) - A Randomized, Double-Blind, Controlled Trial
Magnus Simren, Anette Lindh, Linda Samuelsson, Johan Olsson, Iris Posserud, Hans
Strid, Hasse Abrahamsson
The effects of probiotic bacteria on symptoms in IBS patients remain controversial. The
majority of studies published so far are small and the effects of the different bacteria tested
have varied. METHODS: We included 118 IBS patients fulfilling the Rome II criteria (80
females; mean age 44 years). After a screening period of two weeks eligible patients were
randomized to receive eight weeks of daily treatment with 400 ml of yoghurt containing at
least 5 x 107 cfu/ml of Lactaobacillus paracasei, ssp. paracasei, Lactobacuillus acidophilus
and Bifidobacterium lactis (active), or acidified milk without these bacteria (control), compar-
able in colour, texture, and taste. Symptoms were assessed at baseline and weekly during
the treatment period with the IBS severity scoring system (IBS-SSS), as well as asking the
patients if they had had adequate relief of their IBS symptoms during the previous week.
Health related quality of life (HRQOL) was assessed using a generic (Short-Form 36) and
a disease-specific (IBSQOL) questionnaire, and psychological symptom severity was evaluated
with the Hospital Anxiety and Depression scale. RESULTS: Thirty-three patients in the active
group and 34 in the control group completed the trial; 44 patients were screening failures
and 7 dropped out prematurely during the treatment phase, due to lack of effect of the
treatment or to factors unrelated to the study. The yoghurt was well tolerated and no serious
adverse events occurred. The overall GI symptom severity, assessed by IBS-SSS, improved
in both groups during the treatment period, but the improvement did not differ statistically
between the groups (p=0.24). The IBS-SSS score was reduced at the last week of treatment
compared with baseline in both the active group (256±81 vs. 206±113 (mean±SD); p=
0.006) and in the control group (302±106 vs. 228±125; p=0.0001). The mean proportion
of weeks with adequate relief tended to be greater in the active than in the placebo group
during the first four weeks of the treatment period (33 vs. 20%; p=0.11), whereas no such
trend could be seen during the last four weeks (38 vs 35%; p=0.87). No differences between
the groups could be detected regarding HRQOL and psychological symptom severity. CON-
CLUSION: In this eight-week trial we could detect a positive effect on GI symptoms in IBS
patients of both yoghurt containing three probiotic bacteria and acidified milk without any
bacteria. However, the effectiveness of probiotics in IBS still remains uncertain, since the
results indicate that the milk matrix may have influenced the results and/or the presence
of a large placebo effect. This study was supported by a grant from Arla Foods AB.
S1270
Immunostimulatory Effect of Ingesting Lactobacillus- and Bifidobacterium-
Containing Yogurt in Helicobacter pylori-Infected Subjects
Kuan-yuan Wang, Shui-nin Li, Jui-yen Huang, Wen-ming Wang
Background: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress
Helicobacter pylori. Supplementing with AB-yogurt has been shown to improve the rate of
eradication of H. pylori in humans. Objective: We administered AB-yogurt to subjects with
asymptomatic H. pylori to investigate its immunoregulatory action. Methods: Forty-three
adults voluteers infected with H. pylori consumed 230 ml of AB-yogurt (10(7) colony-
forming units of both Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12/mL) twice
daily for 8 weeks. Serum interleukin-4 (IL-4), IL-10 and interferon-gamma (IFN-γ) were
determined before and after the intervention. Gastric biopsy samples obtained from fourteen
randomly selected subjects were sent for immunohistochemical staining. In addition, peri-
pheral blood mononuclear cells (PBMCs) were isolated from the two groups of donors
(twelve H. pylori-infected subjects treated with AB-yogurt and eleven subjects with milk
placebo for 4 weeks respectively). We quantified IFN-γ production by PBMCs after stimula-
tion of cultured live H. pylori. Results: The serum level of IFN-γ dramatically increased after
the 8-wk ingestion of AB-yogurt. The gastric mucosal and serum levels of IL-10 were not
changed. PBMCs of subjects who consumed AB-yogurt showed enhanced capacity to produce
IFN-γ from 0.9 fold to 2.9 fold after 4 wk of therapy. Conclusion: Regular intake of AB-
yogurt in subjects with colonized H. pylori can potentiate the production of IFN-γ at the
systemic level. This immunostimulatory effect might explain howH. pylori loads are decreased
by the AB-yogurt.
Table 1. Levels of cytokines in serum of H. pylori-colonized subjects before (week 0) and
after (week 8) ingestion of AB-yogurt
Table 2. Expression of cytokines in gastric mucosal biopsies of H. pylori-colonized subjects
before and after ingestion of AB-yogurt
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Biopsies were performed twice at each site. Each value is the sum of the scores of the 2 biopsies.
S1507
Down Regulation of Baba Expression Has a Survival Advantage for
Helicobacter pylori in Mongolian Gerbil Stomach
Tomoyuki Ohno, Saori Fujimoto, Hiroaki Ogiwara, Massimo Rugge, Stefan Odenbreit,
Rainer Haas, Ellen J. Beswick, Victor E. Reyes, Anna Arnqvist, Hiroyoshi Ota, David Y.
Graham, Yoshio Yamaoka
Background: We previously reported that phase variations of BabA (positive to negative)
occurred in infected Mongolian gerbils at 3 months, the time when inflammation reached
maximal levels (2006 DDW); however it is unknown whether phase variations played a role
in gastric damage. Methods: Mongolian gerbils were inoculated with H. pylori TN2GF4
strain (input: BabA positive) and sacrificed after 3 months (n = 5). At least 5 single colonies
were picked up (output) from each gerbil and the expression of BabA was determined by
immunoblot and Lewis b (Leb) binding was measured by the ability to bind to 125I-labeled
fucosylated Leb antigen. Output strains which were different in BabA/Leb status were used
to inoculate gerbils (n = 5) and the colonies were picked up after 3 months. The whole
babA gene and its promoter lesions were analyzed by sequencing. Leb expression in the
gastric mucosa was checked by immunohistochemistry. The attachment of H. pylori to AGS
cells and IL-8 production from AGS cells was measured by flowcytometry and ELISA,
respectively. Results: Leb was expressed in the gastric mucosa of gerbils of uninfected and
infected gerbils. As expected, phase variations occurred compared to the input strain in
94% (32/34 colonies). Phase variations of BabA were identical to the Leb binding ability
(ie, BabA-negative = Leb binding negative). However, no genetic changes were detected in
the babA coding or promoter regions which clearly differ from previous report of phase
variations in infected rhesus monkeys. Following inoculation of gerbils with BabA(+) output
strains, phase variations occurred in 89% of recovered colonies. In contrast, BabA remained
negative in gerbils inoculated with output BabA(-) strains. Inflammations and antral mucosal
thickness were the highest in gerbils infected with output BabA(+) strains, followed by those
infected with the original BabA(+) input strains. Gerbils infected with output BabA(-) strains
showed only mild inflammation in the antrum (eg, thickness = 1.1, 0.7 and 0.3 mm,
respectively: P <0.01). In Vitro experiments showed that attachment to gastric epithelial cells
and IL-8 induction were independent of BabA status, although attachment correlated with
IL-8 levels. Conclusions: BabA expression was disappeared or was markedly reduced in
most gerbils. Strains with low or no BabA gene expression caused only mild inflammation.
It appears that the continued expression of BabA possibly confers a survival disadvantage
in gerbil stomachs. The mechanism of down regulation of babA remains unclear.
S1508
The Antimicrobial and Antiprotease Peptide Elafin Is Induced By H. pylori
Infection and May Protect the Mucosa Against Neutrophil Elastase
Yoshio Hosaka, Maureen Koslowski, Guoxing Wang, Christian Schäfer, Klaus Fellermann,
Peter Fritz, Eduard Stange, Jan Wehkamp
Background/Aim: Epithelial-derived antimicrobial molecules are key effectors of mucosal
innate immunity. We and others have recently reported that Helicobacter pylori infection
induces the mucosal antibiotic peptide human beta defensin 2 (HBD-2). The aim of the current
study was to systematically assess the distribution and quantity of different antimicrobial host
factors including the antiprotease elafin in the normal and diseased upper gastrointestinal
tract, as dependent on Helicobacter pylori (H.p.) status. Materials/Methods: For real time
PCR and assessment of histological inflammation, we investigated biopsy samples from the
esophagus, different locations in the stomach (fundus, corpus and antrum) as well as the
duodenum in a total of 11 healthy controls and a 41 macroscopically inflamed patients
(H.p negative and positive). Using quantitative real-time PCR with external standards, we
compared expression levels of mRNA encoding antimicrobial peptides including defensins
(HBD1, HBD2, HBD3, HD5, HD6) cathelicidin (LL37), psoriasin, the antimicrobial antipro-
tease elafin, proinflammatory cytokine IL-8 as well as two housekeeping genes (GAPDH
and HPRT). The degree of histological inflammation as well as Helicobacter pylori status by
methylene blue staining and biochemical analysis of urease activity was assessed in all
samples. In addition we performed immunostaining for elafin in helicobacter positive and
negative samples with comparable degree of inflammation. Results: In the normal upper GI
tract there was significant expression of elefin in the esophagus > stomach (p<0.05) whereas
that of LL-37 was very low. Gastric H.p. colonisation was associated with an increased
expression (p=0.027) and positive staining (p=0.002) of elafin, in parallel with IL-8. Further-
more, both elafin and HBD-2 could be found overexpressed in samples with chronic active
compared to chronic inactive gastritis (elafin p=0.019, HBD2 p= 0.046). Other peptides
like HD-5 and HD-6 as well as LL-37 were not affected by inflammation status. Conclusion:
In addition to HBD2, the antimicrobial antiprotease elafin seems to be another important
host molecule which is induced by H.p. infection. Thus, the deleterious proteolytic activity
of neutrophils could in part be antagonized by epithelial antiproteases like elafin. As antimi-
crobial peptides can significantly inhibit growth of H. pylori In Vitro it remains to be clarified
in future studies how H. pylori succeeds in escaping these defense mechanisms.
S1509
Increased Adhesion of Helicobacter pylori to Laminin Under Iron Reduced
Conditions
D. Finn, S. Hearty, R. O'kennedy, D. Kelleher, H. Windle
Background & Aim: H. pylori (HP) adhesins are required by the pathogen for efficient
colonisation. These include the sialic acid-binding adhesin (SabA) which has been shown
to bind laminin- an extracellular matrix (ECM) glycoprotein that plays an important role
in cell differentiation and maintenance of cell integrity. Earlier studies with P.aeruginosa and
C.diphtheria demonstrated an increase in adhesion to glycoproteins by the bacteria when
grown under iron reduced (Fe-) conditions. The aim of this study was to determine if HP's
ability to bind laminin was modulated when grown under Fe- conditions. Materials &
Methods: HP strain NCTC 11638 (WT), SabA mutant (ΔSabA) & Ferric Untake Regulator
mutant (ΔFUR) were grown in normal or Fe- media (BHI+6.5% FCS) for 48 hours. Bacteria
were harvested and re-suspended in 50mM Tris buffer. HP binding to laminin (Lam) and
fibronectin (Fib) was measured by Surface Plasmon Resonance using a Biacore system. Each
ligand was covalently attached to a sensor chip and the bacteria were passed over the ligand.
Changes in the refractive index corresponding to a bacteria-ligand interaction was recorded.
Data was combined from repeat experiments and analysed by mean comparison and Stu-
dent's(paired) t-test. Results: HP WT grown under Fe- conditions showed a significant
increase in binding to both Lam [80.04 +/- SEM 7.9 vs 136.49 +/-SEM 19.3, p<0.009] and
Fib, [85.43 +/- SEM 10.8 vs 101.94 +/- SEM 12, p<0.013]. However the increase in Lam
binding was markedly higher than for Fib, 71% vs 19%. This binding pattern was similar
for ΔFUR [Lam: 57.1 +/-SEM 6.3 vs 113.03 +/- SEM 27, p<0.038 and Fib: 83.1 +/- SEM
11.6 vs 95.14 +/- SEM 13.4, p<0.029]. Lam binding by ΔSabA under normal conditions
was reduced by 47% when compared to the WT with no further change when grown under
Fe- conditions [42.19 +/- SEM 2 vs 47.24 +/- SEM 2.2, p<0.085]. The binding of ΔSabA
to Fib showed an increase [61.4 +/- SEM 1.9 vs 65.09 +/- SEM 2.3, p<0.038] when grown
under Fe- conditions of 6%. Again, the level of binding, under normal conditions, was
reduced by 28% when compared to the WT. Conclusions: HP shows increased binding to
Lam and Fib when grown under Fe- conditions. This increase appears to be independent
of the FUR protein (which controls iron homeostasis in HP) and, in the case of Lam, involves
SabA. The residual binding of ΔSabA indicates that other adhesins must be involved in
binding to the ECM. The increased binding of HP to ECM under Fe- conditions may have
physiological relevance particularly when acute infection is accompanied by hypochlorhydria,
as reduced gastric acid secretion results in a decrease in bio-available iron.
S1510
Role of Two Independent Tonb Systems in Iron Acquisition of Helicobacter
Mustelae
J. Stoof, A. H. Van vliet, J. G. Kusters, E. J. Kuipers
Background: Helicobacter mustelae is a gastric pathogen of ferrets, and its pathogenesis
mimics many aspects of human infection with H. pylori. However, relatively little is known
about the virulence factors of H. mustelae and their regulation. Iron-restriction at mucosal
surfaces by host is a non-specific defense mechanism against bacterial pathogens, and hence
iron acquisition is considered to be an important virulence factor. Iron-acquisition in Gram-
negative bacteria is mediated by specific outer membrane proteins (OMPs), which require
energy transduced by the TonB complex. Aim: To characterize the mechanisms of TonB-
dependent iron uptake in H. mustelae. Methods: The H. mustelae genome sequence (available
as non-annotated sequence from www.sanger.ac.uk) was screened for genes encoding putat-
ive iron-aquisition proteins. Isogenic mutants were created by insertional mutagenesis in
H. mustelae strain ATCC43772. Strains were grown in iron-restricted and iron-sufficient
conditions, and gene expression was monitored by Northern hybridization and SDS-PAGE.
Strains were plated under iron-limited conditions, and hemoglobin, hemin or ferric citrate
were supplemented as sole iron source. The growth promotion zone was measured after
48h. Results: Wild-type H. mustelae was able to utilize hemoglobin, hemin and ferric citrate
as sole iron source. The H. mustelae genome contained several genes encoding putative outer
membrane receptors for iron uptake, as well as two tonB genes. Transcription of the OMP-
encoding genes fecA, frpB1b and cfrA was repressed by iron, whereas expression of the frpB1a
gene was iron-independent. Iron-responsive expression of the FecA, FrpB1B and CfrA
proteins was confirmed at the protein level. A tonB1 mutant was unable to grow with hemin
as sole iron source, but was not affected in growth on the other tested iron sources. In
contrast, mutation of the tonB2 gene resulted in reduced growth with ferric citrate and
hemoglobin. Discussion: The H. mustelae genome encodes several putative iron acquisition
genes, and most but not all these genes display iron-responsive transciption in line with
their predicted function. The two TonB orthologs of H. mustelae have differential roles in
iron acquisition, with TonB1 functioning in hemin uptake. These iron acquisition systems
are predicted to play an important role in allowing H. mustelae to overcome host-mediated
iron restriction at the gastric mucosal surface.
S1511
Role of the Inva Invasin Gene in H. pylori Entry Into Ags Cells
Hui Liu, Cristina Semino-mora, Douglas Berg, Andre Dubois
Background. Although most H. pylori reside on gastric epithelial cell surfaces and in the
overlying mucus, many studies have reported finding them within host epithelial and immune
cells. The H. pylori invA (invasin homolog, also called nudA) gene is well expressed only
when H. pylori is attached to or inside host cells (Semino-Mora et al, Gastroenterol 2005;
128: 112). Aims and methods. To explore the role of invA in host cell entry, an invA-cam
deletion derivative of strain J99 was constructed by PCR and DNA transformation, and
transformants were verified by PCR and by fluorescence in situ hybridization. AGS cells
were inoculated with either wild type strain J99 or its invA mutant (multiplicity of 140 H.
pylori cfu/AGS cell) and separate chambers of each culture were fixed in glutaraldehyde for
electron microscopy. A gentamycin protection viability assay was used to estimate the fraction
of intracellular vs. inoculated bacteria. Transmission electron microscopy (TEM) was used
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to count intracellular and membrane bound H. pylori. Results. The gentamycin protection
assay indicated marked reduction in cell entry of the invA mutant relative to J99 wild-type
(3.1±0.2% vs 12.7±3.8% resistant fraction). Transmission electron microscopy demonstrated
many pseudopodia emerging from cell surfaces in J99 wild type- and invA-cam-infected
AGS cell cultures, often intimately embracing H. pylori. The number of intracellular H. pylori/
cell was 0.2±0.1 after inoculation with the invA-cam mutant compared to 1.4±0.2 after
inoculation with J99 wild type. In addition, the number of membrane-bound H. pylori/cell
was 2.5±0.3 using the invA-cam mutant vs. 0.1±0.1 using J99 wild type. Conclusions. The
invA gene is important for the rare (but we propose potentially biologically significant)
uptake of H. pylori by host cells. Deletion of invA limits H. pylori to the AGS cell surface,
where, even if partially protected by pseudopodial embrace, it may remain more vulnerable
to host defense or therapeutic intervention, or less prone to trigger normal immune. carcino-
genic, or other developmental response pathways.
S1512
Isolated H. pylori Duodenal Colonization Is the Cause of Several Idiopathic
Duodenal Ulcers
Antonio Pietroiusti, Antonio Forlini, Andrea Magrini, Alberto Galante, Antonio
Bergamaschi
Background. The prevalence of H. pylori negative (idiopathic) duodenal ulcers is raising. A
negative search for the organism in the stomach, sometimes associated to a negative urea
C13 breath test, is generally performed to exclude its presence. We hypothesized that in
some cases H. pylori may disappear from the stomach, but may survive in the duodenum,
causing an ulcer, erroneusly classified as idiopathic. We therefore evaluated whether isolated
duodenal colonization is present in some duodenal ulcers, and whether they respond to
eradication therapy. Metodhs. This was a prospective study on consecutive ambulatory
patients undergoing upper gastrointestinal endoscopy in secondary care setting. Gastric and
duodenal biopsies were taken from all patients with a duodenal ulcer (DU).The presence
of H. pylori was evaluated by means of rapid urease testing, histology, and culture. At each
site, H. pylori was considered to be absent if all tests were negative, whereas it was considered
to be present if culture and/or histology plus urease tested positive. Independently from the
findings of duodenal biopsies, patients without gastric infection (i.e. with gastric biopsies
negative at all tests) were classified as having idiopathic ulcers, and underwent urea C13
breath test. At this time, all patients without gastric infection underwent eradication therapy,
independently from the findings of urea C13 breath test. Control endoscopy was performed
six months after eradication treatment, with the same modalities as the basal one. Results.
Among 608 included DU patients, 42 (6.9%) were classified as idiopathic: 24 (3.9%) were
free from gastric and duodenal infection (Group A), and 18 (3.0%) (Group B) had isolated
duodenal colonization. Urea C13 breath test was positive in one (4.2%) Group A patient,
and 3 (16.7%) Group B patients. After eradication therapy, DU were detected in 14 out of
20 Group A patients (70%) (four patients did not perform control endoscopy) and in 2
group B patients (11.1%) (OR: 18.66, 95% CI: 3.23 to 107.82, p=0.002 ) The difference
was still detectable at multivariate analysis taking into account possible confounding factors,
such as age, sex, smoking and DU familial history (OR 15.79, 95% CI :2.48 to 100.53, p=
0.001). Conclusions. 1)H. pylori is detectable in the duodenum of a substantial proportion
of patients with so called idiopathic duodenal ulcers; 2)Urea C13 breath test is of limited
help in these patients; 3)Eradication therapy is effective in these patients, whereas it is
ineffective in patients with duodenal ulcers in whom the organism is not detectable both
in the stomach and duodenum.
S1513
Novel Diversity Site of Helicobacter pylori Vaca Is Critical for Cytotoxin
Activity and Clinical Outcome
Tomoko Inagaki, Yoshiyuki Ito, Takashi Ohno, Shinsuke Matsunaga, Ryuho Masaki,
Masahiro Ohtani, Sousyoku Lee, Hiroyuki Suto, Masaru Kuriyama, Yoshihide Keida,
Takeshi Azuma, Akihiro Wada, Toshiya Hirayama, Yukinao Yamazaki
[Background] Helicobacter pylori (H. pylori) vacuolating cytotoxin (VacA) plays an important
role in the pathogenesis of gastroduodenal diseases. VacA undergoes cleavage into a N-
terminal 37kDa (p37) and a C-terminal 58kDa (p58) fragments. This cleavage occurs between
alanine and lysine (Ala-Lys; aa344-345) and is required for the activation of VacA. About
400 amino acids consisting of full-length p37 and partial p58 are essential for vacuole
formation. [Aim] The aim of this study is to examine whether diversity in the VacA cleavage
site affects the vacuolating cytotoxin activity and clinical outcome. [Methods] One hundred
and nineteen clinical isolates from four different areas in Asia (Fukui (53 strains) and
Okinawa (52 strains), Japan, China (7 strains), Vietnam (7 strains)) were included in this
study. Strains from Fukui and Okinawa were isolated from patients with gastric cancer (23,
24), duodenal ulcer (10, 11) and chronic gastritis (20, 17), respectively. All strains from
China and Vietnam were from patients with gastric cancer. The amino acid sequence of
cleavage site was determined by DNA sequencing of vacA gene. VacA was extracted from
liquid culture supernatant of H. pylori, and quantitative vacuolating cytotoxin activity was
measured by neutral red uptake assay using human gastric cancer cell lines (AZ521). [Results]
We found a novel diversity of amino acid sequence at the VacA cleavage site (alanine and
lysine; Ala-Lys type or proline and lysine; Pro-Lys type). All strains were divided into two
groups (Ala-Lys or Pro-Lys). VacA from strains in Fukui, China, and Vietnam contained
Ala-Lys type cleavage site. Whereas, strains in Okinawa were more diverse, 80% and 45%
of strains from patients with duodenal ulcer and chronic gastritis possessed Pro-Lys type
VacA, respectively. Furthermore, all strains with Pro-Lys type VacA were m2 type in the
middle region. In contrast, all Okinawa strains from patients with gastric cancer showed
Ala-Lys and m1 VacA. Pro-Lys type strains showed significantly lower cytotoxin activity
than Ala-Lys type strains regardless of vacA m-region type (p<0.01). [Conclusion] We found
a novel diversity site of VacA affecting cytotoxin activity. This diversity may reflect the
clinical outcome and geographic partitioning or genetic evolution of vacA.
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S1514
Role of Bacterial Strain Diversity of Helicobacter pylori in Gastric
Carcinogenesis Induced By N-Metyl-N-Nitrosourea in Mongolian Gerbils
Tomotaro Kawazoe, Takashi Sakagami, Kazuhiko Nakajima, Kazutoshi Hori, Yoshihiro
Fukuda, Takayuki Matsumoto, Hiroto Miwa
Aim H. pylori is known to enhance gastric carcinogenesis induced by chemical carcinogens.
We previously demonstrated that infection with H. pylori strain SS1 did not enhance carcino-
genesis induced by N-methyl-N- nitrosourea (MNU) in C57BL/6 mice. Whether this result
was due to the bacterial strain SS1 or the experimental host, C57BL/6 mice, should be
addressed. Therefore, we examined whether H. pylori strains introduced to the same host
(Mongolian gerbils) differed in carcinogenicity. Results should help us to better understand
the role of bacterial factors in gastric carcinogenesis. Materials and Methods Six-week-old
male SPF Mongolian gerbils (n=126) were used. H. pylori TN2GF4 strain (CagA(+), VacA(+))
and SS1 strain (CagA functionally(-), VacA(-)) were selected as infectious bacteria. Two
experiments were performed. In the first experiment (induction of gastritis), histological
change in gastric mucosa of gerbils infected by H. pylori (TN2GF4, SS1, vehicle) without
MNU at 1 month or 6 months was assessed. In the second experiment (experimental
carcinogenesis), after completion of administration of MNU 30 ppm for 10 weeks, H. pylori
(TN2GF4, SS1, vehicle) was inoculated to the gerbils. The number of gastric cancers and
histopathological changes at week 54 were assessed. Results With regard to induction of
gastritis, activity and inflammation in the TN2GF4 group were significantly greater than in
the SS1 group at 1 month, while no significant difference was noted at 6 months. On the
other hand, intestinal metaplasia and atrophy were significantly greater with TN2GF4 than
with SS1 at 6 months but not at 1 month. Six in the TN2GF4 group (75%) had a gastric
ulcer at 6 months, while no ulcer developed in the SS1 group. The BrdU labeling index
was significantly higher in the TN2GF4 group than in the SS1 group at 1 and 6 months.
In studies on experimental carcinogenesis, macroscopically, 47.8% (11/23), 26% (7/26) and
0% (0/26) of animals had gastric adenocarcinoma in the MNU+TN2GF4 group, MNU+SS1
group and MNU alone group, respectively. No gerbil had multiple tumors. Histologically,
9 of 11 cancers in the MNU+ TN2GF4 group, and all the cancers in the MNU+SS1 group
were well differentiated adenocarcinoma. All carcinomas penetrated into the muscular layer.
Conclusion Both H. pylori strains, TN2GF4 and SS1, promoted carcinogenesis in Mongolian
gerbils. The severity of gastritis and destruction and restoration of gastric mucosa may be
related to gastric carcinogenesis. That the SS1 strain significantly accelerated carcinogenesis
only in Mongolian gerbils and not in C57BL/6 mice suggests the crucial role of host factors
in carcinogenesis by H. pylori infection.
S1515
Helicobacter Species Colonizing the Carnivore Stomach Contain Two
Independent Urease Gene Clusters
J. Stoof, R. G. Pot, S. Breijer, D. Van der neut, E. J. Kuipers, J. G. Kusters, A. H. Van vliet
Background: The enzyme urease is an important virulence factor of Helicobacter species
colonizing the gastric environment, as it plays an essential role in allowing survival of the
acidic conditions of the gastric environment. The urease enzyme consists of UreA and UreB
subunits, and is activated via the UreEFGH accessory proteins, while urea enters the cell
via the UreI urea channel. All gastric Helicobacter species characterized to date contain a
gene cluster containing the ureABIEFGH genes. Recently we described a gene cluster encoding
a putative second urease (UreA2B2) in Helicobacter felis. Aim: To investigate the prevalence of
this second urease gene cluster in other Helicobacter species.Methods: Southern hybridization
analysis was used to study the prevalence of ureB genes in gastric and enterohepatic Helicob-
acter species. Urease expression was monitored using immunoblotting with antibodies raised
to the H. felis UreA2 and UreB2 proteins. The Helicobacter mustelae genome sequence was
obtained from the Sanger Institute Pathogen Sequencing Unit at http://www.sanger.ac.uk/
Projects/H_mustelae, whereas the Helicobacter acinonychis genome sequence was described
recently (PLoS Genet. 2006;2(7):e120). Results: Genomic DNA of H. mustelae, H. felis and
H. acinonychis contained multiple restriction fragments hybridising at low stringency to a
H. pylori ureB-specific probe, suggesting the presence of additional urease genes. Expression
of two UreB-like proteins was confirmed in H. mustelae strain ATCC43772, H. felis strain
2301 and H. acinonychis strain Sheeba using immunoblotting. Analysis of the H. mustelae
and H. acinonychis genome sequences allowed identification of a gene cluster encoding the
UreA2 and UreB2 proteins. This gene cluster did not contain genes encoding urease accessory
proteins. The H. mustelae and H. acinonychis UreB2 proteins are ~70% identical and ~90%
homologous to the UreB1 proteins from the same species. Phylogenetically, H. mustelae and
H. acinonychis UreB2 form a cluster together with H. felis UreB2, separately but close
to Helicobacter UreB(1) proteins. Discussion: The urease-positive Helicobacter species H.
mustelae, H. acinonychis and H. felis contain a ureA2B2 gene cluster potentially encoding a
second urease enzyme. Such a second urease gene cluster seems to be absent in H. pylori
and enterohepatic Helicobacter species, and is thusfar only present in Helicobacter species
colonizing the stomach of carnivores. This suggests a link between diet and genetic properties
of the colonizing Helicobacter species.
S1516
Obesity and Helicobacter pylori Infection: A Random Endoscopic Population-
Based Study. The Kalixanda Study
Pertti Aro, Tom Storskrubb, Jukka A. Ronkainen, Lars Engstrand, Michael Vieth, Nicholas
J. Talley, Lars Agréus
Background and aims: The incidence of obesity continues to rise. Non-ulcer dyspepsia has
been linked to being underweight and is associated with H. pylori. H. pylori is disappearing,
representing one cause of dyspepsia, and hence might be a protective factor for obesity.
Obesity on the other hand may be a risk factor for peptic ulcer. We aimed to define the
relationship between obesity and H. pylori infection in a randomly selected adult population
evaluated by esophagogastroduodenoscopy (EGD). Methods: A representative randomly
selected sample (n=2,860) of the adult Swedish population (n=21,610, mean age 50.4
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years) was surveyed. The individuals completed a validated questionnaire on gastrointestinal
symptoms and a sub-sample of them, who did answer the questionnaire, were then randomly
selected for the EGD part of the study with biopsies, H. pylori culture and serology and
symptom assessment. Body mass index (BMI) was categorized according to the WHO
recommendations. Results: 2,122 individuals (participation rate 74.2%) completed symptom
questionnaires; 1,001 of them (mean age 54.1 years, 48.8% male) participated in the EGD
part of the study (participation rate 73.3%). BMI data were available from 991 and biopsies
from 1,000 individuals. The prevalence ofH. pylori by culture and/or histology, the proportion
of cag-A positive strains and the prevalence of positive H. pylori serology by BMI categories
are presented in the table. Obesity was an independent risk factor for cag-A positive H.
pylori infection (OR=4.6, 95% CI 1.7- 12.8) analyzed by multivariate logistic regression
model including socioeconomic status, use of alcohol, smoking, use of aspirin and dyspepsia,
and adjusting for age and gender. Conclusions: Obesity is an independent risk factor for
having cag-A positive H. pylori infection. H. pylori is not a protective factor for obesity.
H. pylori status by BMI category
*significantly higher compared with normal weight (p=0.0007)
S1517
The Virulence Factor Vaca from Helicobacter pylori Induces a G0/G1 Cell
Cycle Arrest in T-Cells
Martin Schenk, Roland A. Klaffschenkel, Kehlbach Rainer, Bettina Gebert, Alfred
Koenigsrainer, Rainer Haas, Michael J. Sessler
By the release of soluble virulence factors Helicobacter pylori interacts with stomach infiltrating
leukocytes and thereby inhibits total eradication. Targets of t-cell inhibition may be activation
or proliferation. Therefore an interaction with the cell cycle of t-cells may be plausible.
1x106 Jurkat cells in RPMI (10% FCS) were stimulated with supernatants from H. pylori
p12 (wild type) and p12DVacA (knock out) at various concentrations for 1, 24 and 48
hours. For some experiments supernatants were activated by acidification (pH 2, 1 h, 37°C).
After 1 hour the cells were pulse-labeled by adding 20 µM 5-bromo-2'-deoxyuridine (BrdU).
After two wash-steps with PBS cells were fixed with 70% ethanol and stored for at least 24
h at -20°C. Thawed and fixed cells were incubated with 0.1 mg/ml cold RNase A at 37°C
for 10 min and with pepsin for further 10 min at 37°C. DNA was made single-stranded by
adding 2 N HCL at room temperature for 10 min. Thereafter cells were labeled with anti-
BrdU mouse IgG1 antibody and the (FITC)-labeled secondary F(ab')2 rabbit anti mouse
antibody and 10 µg/ml Propidiumiodid/RNase. Analysis was performed by flow cytometry.
During the incubation with supernatant from H. pylori (p12) the portion of cells in the G0/
G1-phase decreased from 37,9% (1h), to 6,5% (24h) whereas in the control (Co) and the
knock-out group (ΔVacA) the portion of G0/G1 arrested cells was only 2,7% and 2,6%.
This effect was enhanced by an pre-activation of VacA to a five-fold portion of arrested cells
(8,8% versus 1,6% and 1,9%). Synchronization of cells by serum starvation ( 0,5% for 72
h) showed a decrease of cells in the G0/G1-phase from 37,1% to 19,4% after 24h (p12) .
In the control (Co) and knock-out group (ΔVacA) they decreased to 12% and 7,9%. This
effect was clearly enhanced by the acid activated form of VacA (p12 25,4%, Co 10,6%,
11,7% ΔVacA). Longer observation periods (48h), incorporation of BrdU for only 1h and
experiments in the absence of FCS showed similar results. Unspecific stimulation with
Concanavalin A 0,1mg/ml resulted in an increase of arrested cells using p12 (16,2% versus
10,8% and 12,5 %) and the activated form of p12 (15,8% versus 11,1% and 11,6%).
Stimulation with Ionomycin/PMA, 3µM, 150ng/ml showed only an increase of arrested cells
using the activated form of VacA (33.6% versus 15% and 16,6%). It is concluded that the
interaction of VacA with t-cells caused a cell cycle inhibition from G1- to S-phase within a
period up to 48 hours. This was independent of other proteins and was not effected by an
unspecific extra-cellular stimulation. These were indicators of a very robust mechanism
of inhibition.
S1518
Comh: Isolation, Purification and Characterisation of a Unique H. pylori
Protein
K. Kostidis, K. D. Bardhan, C. W. Potter, J. R. Sayers
Introduction Many organisms, including H. pylori, share the property of DNA uptake from
their environment (competence) which is used as an energy source and occasionally for
genetic transformation. This is enabled by a complex network of ComB proteins located
close to and within the bacterial cell membrane. H. pylori alone possesses the comH gene
and when deleted, the organism loses competence (Smeets et al, 20001). We were able to
express the ComH protein in our earlier work (Kostidis et al2). Here we report on its
purification and partial characterisation. Aim & Methods To determine if ComH protein
is a nuclease and to identify its location within the cell. The H. pylori laboratory strain 26695
was cultured and its DNA isolated. The comH gene was amplified by PCR, and cloned and
expressed in various expression vectors. Antibodies against ComH were raised in rabbits
and the antisera used to detect the location of the protein In Vivo. Results (1) As reported
earlier, high-level expression was achieved with the pGEX-KG system but the GST-ComH
fusion protein proved insoluble. (2) The comH gene was cloned in a pET21-histidine (his),
an expression vector. The his-tagged ComH protein expressed was purified using affinity
and anion exchange chromatography. (3) ComH was tested for nuclease activity in liquid
assays, and under various conditions. No nuclease activity was detected. (4) Nevertheless,
ComH was able to bind single-stranded (ss) DNA in electrophoretic mobility assays, with
a binding constant (Kd) of 36 nM at pH 7. (5) Antibody against GST-Com H protein was
raised in rabbits and then purified. Western Blotting and FACS showed that the purified
antibody adhered to the cells, indicating that the ComH against which it is directed is located
in the outer membrane and that its surface is exposed. Conclusion This is the first time
the ComH protein, the product of the unique H. pylori competence gene comH, has been
expressed, purified and partially characterised. Against expectation, it is not a nuclease but
it is able to bind ssDNA with high efficiency. Its function remains unknown but we presume
is in some way essential in making H. pylori competent. Acknowledgement Konstantinos
Kostidis is a Research Fellow of the Bardhan Research and Education Trust (Registered
Charity No. 328452) References (1) Smeets et al. comH, a Novel Gene Essential for Natural
Transformation of Helicobacter pylori. Journal of Bacteriology 2000;182:3948-3945 (2) Kos-
tidis et al. ComH: Purification of a unique H. pylori protein. Gut 2005;54(Suppl 2): A86
S1519
A Comparison Between Iraqi and Iranian Helicobacter pylori Strains
Nawfal Hussein, Richard Argent, Darren Letley, Marjan Mohammadi, Merdan
Muhammad, John Atherton
Introduction: Helicobacter pylori causes peptic ulceration and gastric cancer. Virulence factors
include 1) the cag pathogenicity island (cag+ strains are associated with gastric ulceration
and cancer and strains with more CagA EPIYA motifs are associated with cancer), 2) VacA
(s1, i1, and m1 types are associated with gastric cancer) and 3) dupA (dupA+ strains are
associated with duodenal ulcer). Although pangastritis is common in Iraq, gastric atrophy
is rare. Additionally, the incidence of gastric cancer in Iraq appears lower than that of Iran.
In this project, virulence determinants of both Iraqi and Iranian strains were studied and
compared. Methods: 49 and 60 strains from patients with different clinical outcomes were
collected from Iraq and Iran, respectively (DU Iraq 15, Iran 8; GU 5, 9; non-ulcer 29, 43).
We specifically excluded strains from cancer patients, and we have reported those separately.
PCR was performed to determine the presence of cagA and its EPIYA motif number, the
status of dupA genotype, and allelic variation of vacA. Results: The rate of cagA positivity
was similar among strains from Iraq and Iran (35/49 (71%) and 46/60 (77%), respectively)
and its presence was significantly associated with PUD in Iraq (P <0.005) but not Iran. The
presence of cagA alleles with > 3 EPIYA motifs was significantly higher among Iranian strains
than those from Iraq (P <0.01). There was no association between vacA signal and mid
region and PUD in either population. In Iraq, there was a significant association between
i1 genotype and GU (P <0.01) (4/5 (80%) of GU compared with 7/35(20%) of non-GU
patients), but not in Iran. Finally, 16/49 (33%) and 23/60 (38%) of Iraqi and Iranian strains
respectively typed positive for dupA. While a significant association between infection with
dupA-positive strains and DU was observed for Iraqi patients (P < 0.01), there was no
association for Iranian subjects. Conclusion: Virulence factors present in both Iraqi and
Iranian H. pylori strains are similar to those in Western strains. The presence of cagA with
more EPIYA motifs in Iran may help explain the high cancer incidence rate. A novel
association was found between i1 genotype and GU in Iraqi strains. Despite the similarity
of virulence factors between Western countries and Iraq, the cancer rate in Iraq is still low
which may indicate the presence of an enigma in the region.
S1520
Study of the Serum Antibody Response Against the Vacuolating Cytotoxin
(Vaca) from Helicobacter pylori in a Mexican Population
Francisco Aviles, Humberto Santamaria, Margarita Camorlinga, Javier Torres, Lourdes
Flores, Darren Letley, John Atherton
VacA activity differs among isolates due to polymorphism in its gene. Its p58 subunit may
be type m1 or m2. Type m1 binds more extensively to cells and has been associated more
closely with gastric adenocarcinoma than type m2. We aimed to study the antibody response
against p58 in a Mexican population. Methods: Serum and gastric biopsies were obtained
from 198 infected individuals. These included 118 cases with chronic gastritis only, 39 with
pre-cancerous lesions (intestinal metaplasia, atrophy, or dysplasia), 25 cases with duodenal
ulcer and 16 with gastric cancer. 27 non-infected individuals were used as controls. Strains
were vacA genotyped by PCR and recombinant m1 and m2 p58 subunits were used in
ELISA for serology. Results: Of 198 infected individuals, 105 were seropositive for VacA;
sera from 34 of these recognized both m1 and m2 antigens and sera from 71 recognized
one only. From these 71, 63 (89%) had ELISA results that correctly identified the genotype
found in isolates (P<0.01 χ2) and in 26/34 isolates with a positive response toward both
toxin types (P<0.01 FET). Levels of antibodies against m1 protein were higher than for m2
in all three groups with more severe disease: LP (P<0.02), DU (P<0.02), and GC (P<0.05).
Conclusion: In Mexico the m1 genotype is prevalent (75%) among H. pylori clinical isolates;
although the anti-VacA serum antibody response is poor in infected individuals (47%).
Mixed serological response to both m1 and m2 antigens is frequent (17%). The m1 genotype
induce a stronger response than m2. The vacA type of the infecting strain can be predicted
with the ELISA test in a significant number of cases particularly when there is a serological
response to only one toxin type (P< 0.001 χ2 test).
S1521
Possible Role of Helicobacter pylori Caga On Gastric Epithelial Cell
Carcinogenesis
Osamu Handa, Yuji Naito, Satoshi Kokura, Ikuhiro Hirata, Tatsushi Omatsu, Tetsuya
Okayama, Satoko Adachi, Satomi Akagiri, Hitomi Okada, Katsura Mizushima, Takahiro
Suzuki, Tomohisa Takagi, Hiroshi Ichikawa, Norimasa Yoshida, Hirofumi Matsui, Takeshi
Azuma, Sunao Kawano, Toshikazu Yoshikawa
Background: Although epidemiological studies have clearly shown that Helicobacter pylori
(H. pylori) is a definite carcinogen and the positivity of cytotoxin associated gene product
A (CagA) of H. pylori is strongly associated with gastric carcinogenesis. Recently, two types
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of CagA has been defined based on its amino acid sequence; East-Asian CagA and Western
CagA. Strong correlation between East-Asian CagA and the higher mortality rate by gastric
cancer in East-Asian countries have also been reported. However, the mechanism by which
CagA itself causes gastric cancer is not known. Aim: In the present study, we investigated
the effect of CagA protein on the factors that are closely related to gastric carcinogenesis
using CagA expressed gastric epithelial cells. Materials and Methods: To this end, we used
cagA gene- and a Tet-off system- stably transfected rat normal gastric epithelial cell line
(RGM1), in which CagA expression could be controlled by tetracycline concentration in the
cell culture medium. Transfected cagA gene was obtained from both East-Asian type strain
and Western type strain. The effect of CagA expression on 1) the production of reactive
oxygen species (ROS), 2) 1% fetal bovine serum- induced cell growth, and 3) apoptotic
stimuli- reduced cell viability were evaluated. The effect of H2O2 -induced inhibition of
proteasome activity on CagA expression was also assessed. Results: We found that expressed
CagA, after removal of tetracycline, localized to the mitochondria where it induced significant
ROS production, increased cell growth via accelerated cyclinD1 expression and acquired
the resistance against apoptotic stimuli. In addition, moderate amount of H2O2 -induced
inhibition of proteasome activity increased the expression of CagA protein in RGM1. Conclu-
sion: Taken together, CagA itself has a potential to promote gastric
S1522
Atherosclerotic Burden in Patients with Infection Sustained By Caga-Positive
Strains of H. pylori
Francesco Franceschi, Davide Roccarina, Giovanni Gigante, Giampaolo Niccoli, Luigi
Carbone, Stefano Ursella, Valentina Fiore, Gaetano A. Lanza, Gregory A. Sgueglia, Luca
Altamura, Micaela Conte, Giuseppe Ferrante, Italo Porto, Antonello Leone, Giovanni
Gasbarrini, Antonio Gasbarrini, Filippo Crea, Nicolò Gentiloni silveri
Background: The role of bacterial infection in atherosclerosis has been studied extensively
in the past few years. H. pylori infection, and in particular CagA-positive strains, emerged
as a possible atherosclerotic stimulus. Nevertheless, whether CagA-positivity is associated
with more extensive or severe atherosclerotic coronary burden is still unknown. To clarify
this point we evaluated angiographic atherosclerotic disease severity and extent in patients
affected by coronary artery disease (CAD) based on the prevalence and the titre of antibodies
anti- Urease B and anti-CagA. Methods: 40 consecutive patients (33 males, mean age 63.3±11
years) admitted to our Cardiology Department between February 2005 and March 2006,
with the diagnosis of ischemic heart disease, were enrolled. All patients underwent coronary
angiography after hospital admission. Moreover, the prevalence of classical atherogenic risk
factors as well as the prevalence and the titre of antibodies anti-Urease B and -CagA were
assessed in all patients. Finally either the degree of coronary stenosis or the extent of coronary
atherosclerotic disease was evaluated in all patients using a validated score system. Results:
A significant correlation was found between anti-CagA antibody titre and extent score (p=
0.03), while stenosis score was similar (p=0.114). On the contrary, no significant correlation
was found between anti-Urease B antibody titre and either extent or stenosis score. Moreover,
patients who were seropositive for CagA had a more extensive CAD (p=0.029) when compared
to seronegative. Interestingly, while serum glucose, LDL levels, anti-Urease B and anti-CagA
antibodies were univariate predictors of extent score, at multivariate analysis only anti-CagA
antibody titre was an independent predictor of the extent of coronary atherosclerotic disease
(p=0.04). Conclusions: The results of this study supports the association between CagA-
positive H. pylori infection and coronary atherosclerotic burden. Further studies are now
needed to better elucidate the mechanism by which CagA-positive strains may promote ath-
erosclerosis.
S1523
Helicobacter pylori Genotyping from Paraffin-Embedded Gastric Biopsies in
Contrasting Gastric Cancer Risk Colombian Areas
Liviu A. Sicinschi, Pelayo Correa, Richard M. Peek, Maria C. Camargo, Alberto Delgado,
Maria B. Piazuelo, Luis E. Bravo, Barbara G. Schneider
Background: Helicobacter pylori cagA and vacA s1 and m1 genotypes are associated with
elevated gastric cancer (GC) risk. To identify risk factors for gastric cancer in two regions
of Colombia that differ in GC risk, we genotyped H. pylori from paraffin-embedded gastric
biopsies. Methods: Gastric biopsies were taken from 107 adults with dyspeptic symptoms,
from areas of high and low risk for GC. Genomic DNA was amplified using primers specific
for the cagA gene and for the s and m alleles of the vacA gene. The s and m segments were
amplified using two different primer sets designed from different portions of the gene, both
sets being used in simplex and multiplex PCR. Amplified PCR products were analyzed on
agarose gels. Results: Infection with H. pylori was detected by 16S rDNA assay in 97 (90.7%)
of the 107 biopsies. Complete genotyping was achieved in 87 (89.6%) of the samples from
infected subjects. Ten samples were incompletely genotyped (10.4%). Ten samples were
confirmed as lacking H. pylori DNA by 16S rDNA assay. Seventy-eight H. pylori strains
(73%) were identified as cagA positive. No association was found between cagA status and
GC risk (P=0.153). The s1 genotype was predominant (93.6% of all subjects) over s2 (6.4%)
and an s1:s2 ratio of 24:1 was present in high risk areas and 10:1 was present in low risk
areas. No association of vacA s fragment distribution by area was found. In contrast, the
m1 to m2 vacA ratios were 7:1 in high and 2:1 in low risk areas. The m1 allele was found
more frequently in the high risk area, and the m2 allele was more prevalent in the low risk
area (P=0.037). The s1m1 genotypes were more common in the high risk area, and the
s2m2 genotypes were more common in the low risk area (88% versus 67%, P=0.044). The
prevalence of s1m1 genotypes and cagA positivity was 84% and 61% for high and low risk
areas, respectively (P=0.011). Only 54% of the m vacA signals were detected by both simplex
and multiplex PCR; 22% of m signals were found by simplex only and 24% by multiplex
PCR only (P=0.001), suggesting that the number of false negative results increases when
using only one primer set. In contrast, the majority of s genotypes (86%) amplified equally
with both primer sets. Conclusions: Overall, H. pylori cagA and vacA genotyping from
paraffin-embedded gastric biopsies permitted high typability and discrimination. The more
virulent cagA positive s1m1 strains were more prevalent in high risk than in low risk areas.
This may partially explain the difference in GC risk between them. Use of dual primer sets
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improved genotyping, especially for the m region, which may be highly diverse in Colombian
H. pylori strains.
S1524
Effect of Helicobacter pylori On Hepatocytes
Kyoko Ito, Yoshio Yamaoka, Boris Yoffe, Giovanni Suarez, Victor E. Reyes, David Graham
BACKGROUND & AIMS: Helicobacter DNA has been detected in human hepatocellular
carcinoma (HCC) tissues. Our aim was to determine the effect of H. pylori infection on
hepatocyte replication as a potential role in the procarcinogenic process. METHODS: Huh7
human HCC cells were co-cultured with H. pylori NCTC11637 (CagA+, VacA+, OipA+ and
BabA+). Cell morphology was observed by light microscopy. Apoptosis was assessed using
a quantitative apoptosis ELISA, Western blot analysis to detect pro- and activate caspase-3
and toluidine blue stain to count apoptotic bodies. Cell proliferation was assessed using the
BrdU assay to quantify DNA synthesis and MTT assay to measure metabolic activity. DNA
fragmentation and DNA synthesis were measured after passages of hepatocyte subcultures
to assess the effect of intracellular and persistent H. pylori infection. RESULTS: Huh7 cells
infected by H. pylori strain 11637 displayed morphological changes. Caspase-3 was also
activated and DNA fragmentation increased 3.4 ± 0.3 and 6.1 ± 1.2 fold at MOI of 30 and
300, respectively (P <0.01). Toluidine blue assay confirmed augmentation of apoptosis. DNA
synthesis increased to 139 ± 6% of control at an MOI of 30 (P <0.05) and decreased to 16
± 7% of control (P = 0.146) at an MOI of 300 (P <0.01). The overall metabolic activity of
hepatocytes was decreased 70 ± 11% at an MOI of 30 and 64 ± 8% at an MOI of 300 (P
<0.01). Intracellular H. pylori 11637 increased DNA fragmentation 3.0 ± 0.4 fold (P <0.01).
Persistent H. pylori inside hepatocytes also increased DNA fragmentations 1.5 ± 0.1 fold
greater than control (P <0.01) but did not significantly affect hepatocyte DNA synthesis (P
>0.152). CONCLUSIONS: H. pylori infection altered the regulation of hepatocyte replication.
The overall effect was related to inoculum size suggesting a threshold effect beyond which
the cells were unable to compensate for increased cell death. In the low MOI infection
analogous to an In Vivo situation, it appears that H. pylori may promote an increase in cell
cycle. Intracellular H. pylori also promoted hepatocyte apoptosis. Together, these results
suggest H. pylori could play a role in chronic liver diseases.
S1525
Are Caga-Positive Strains of Helicobacter pylori Associated with Increased Risk
of Ischemic Heart Disease; A Meta-Analysis
Francesco Franceschi, Davide Roccarina, Giovanni Gigante, Giampaolo Niccoli, Giuseppe
Ferrante, Luigi Carbone, Stefano Ursella, Valentina Fiore, B. Fusco, Micaela Conte,
Antonello Leone, Giovanni Gasbarrini, Antonio Gasbarrini, Filippo Crea, Gentiloni silveri
Nicolò
Background: Several previous studies and meta-analyses aimed at determining a possible
association between ischemic heart disease (IHD) and seropositivity to H. pylori, in general,
reported conflicting results. On the other hand, some pilot studies have shown that the
association between IHD and H. pylori may result stronger after stratifying the data for the
prevalence of CagA-positive strains. Despite those findings, the association between CagA-
positive strains of H. pylori and IHD is still debated. To clarify this issue we designed a
study aimed at analysing the effect of CagA-positive strains of H. pylori on the occurrence
of acute coronary syndromes. Methods: We performed a meta-analysis including 13 epidemi-
ological studies (3 prospective and 10 retrospective), involving a total of 5503 patients on
the association between seropositivity to CagA and IHD. We only selected studies including
patients admitted to the hospital for the occurrence of an acute coronary syndrome, while
studies including patients with stable angina or other chronic coronary disease were excluded.
Results: Seropositivity to CagA was significantly associated with the occurrence of acute
coronary syndromes: 1.49 (1.21-1.82) [random odds ratio (OR), 95% confidence interval
(CI)], p=0.0001. Heterogeneity was found, χ2 =19.5, p= 0.08. A sensitivity analysis, excluding
studies that gave the individual strongest positive association and with a large CI and a
small sample size, confirmed the main result. A pre-specified subgroup analysis according
to the type of study, retrospective or prospective, confirmed the global meta-analysis results
in both subgroups. Moreover, the association remained significant even after the adjustment
for potential confounding factors. Conclusions: This meta-analysis shows the presence of a
significant association between seropositivity to CagA-positive strains of H. pylori and the
occurrence of acute coronary syndromes. Further studies are needed to better elucidate the
mechanisms by which CagA-positive strains of H. pylori may affect coronary atheroscler-
otic disease.
S1526
The Role of Vamp7 On Vaca-Induced Vacuolation
Hirosato Mashima, Junko Suzuki, Yukako Yoshikumi, Hideki Ohno, Masao Omata
[Background] Helicobacter pylori-produced cytotoxin VacA induces intracellular vacuolation.
The VacA-induced vacuole is assumed to represent the pathological status of intracellular
trafficking. The fusion mechanism of endosomes requires the formation of a tight complex
between Q-SNAREs and R-SNAREs. We reported syntaxin7, a family member of Q-SNARE
protein, to be involved in the VacA-induced vacuolar formation. We herein report the
identification of its SNARE partner based on the findings of immunocytochemistry, co-
immunoprecipitation studies, and a knock-down experiment. [Methodology] We stained
VacA-intoxicated AGS cells with anti-VAMP7 and anti-VAMP8 antibody. Next, we analyzed
the time course of the mRNA level of VAMP7 and VAMP8 in VacA-intoxicated AGS cells.
We then transiently transfected EGFP-tagged wild-type VAMP7 vector to AGS cells with or
without VacA toxin, immunoprecipitated the cellular extract using anti-GFP antibody, and
blotted the protein with anti-syntaxin7 antibody. Conversely, we transiently transfected
EGFP-tagged wild-type syntaxin7 vector, immunoprecipitated the cellular extract using anti-
GFP antibody, and then blotted the protein with anti-VAMP7 antibody. We knocked down
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the expression of VAMP7 using siRNA and measured neutral red dye uptake under VacA-
exposure condition. [Results] An immunocytochemical analysis of AGS cells revealed endo-
genous VAMP7, a member of R-SNARE protein, and not VAMP8, to be localized to the
vacuoles induced by VacA. A Northern blot analysis revealed that VacA intoxication increased
the expression of VAMP7 mRNA in a time-dependent manner, however, the expression
level of VAMP8 showed no change. These findings suggested that VAMP7, and not VAMP8,
participated in VacA-induced vacuolar formation. In an immunoprecipitation study, syn-
taxin7 was co-immunoprecipitated with EGFP-VAMP7 and the intensity of the band of
syntaxin7 was much stronger in VacA-intoxicated cells than in non-toxicated cells. VAMP7
was also co-immunoprecipitated with EGFP-syntaxin7 and the band of VAMP7 was stronger
in intoxicated cells. Reduced expression of VAMP7 lowered neutral red dye uptake into
VacA-treated cells compared to the control. [Conclusion] We therefore conclude that R-
SNARE VAMP7 plays an important role of VacA-induced vacuolation as a partner of Q-
SNARE syntaxin7.
S1527
Proinflammatory Interaction Between H. pylori and Gastric Epithelial Cells Via
Protease-Activated Receptor
Ikuhiro Hirata, Norimasa Yoshida, Hirokazu Kajikawa, Kazuhiro Katada, Osamu Handa,
Tomohisa Takagi, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Takeshi Okanoue,
Toshikazu Yoshikawa, Fumihiro Hirayama
[Background and Aims] H. pylori can secrete some kinds of proteases including trypsin-like
serine protease. Recently, some serine proteases have been proposed to play important roles
in the inflammatory and immunological reaction via protease-activated receptors (PAR) in
various cells. Activation of PAR results in proinflammatory reactions via cytokine production
such as IL-8. Therefore, in the present study, we evaluated the kinetics of PAR expression
in H. pylori-infected gastric epithelial cells and investigated involvement of PAR in the IL-
8 production by H. pylori-infected gastric epithelial cells. [Materials and Methods]1) We
assessed expression of PAR1 and PAR2 in the gastric mucosa by real time-PCR using biopsy
specimens taken from H. pylori-positive patients or H. pylori-negative patients. 2) We used
human gastric epithelial cell line MKN45 cells. Expression of PAR1 and PAR2 on MKN45
cells was assessed by real time-PCR and immunocytochemistry. After MKN45 cells were
stimulated with H. pylori live bacteria (ATCC43504), we evaluated expression of PAR1 and
PAR2 by real time-PCR and IL-8 protein production by ELISA. Then we evaluated the effects
of nafamostat mesilate (a serine protease inhibitor), blocking antibody to PAR1 or PAR2,
and transfection with siRNA for PAR1 or PAR2 on IL-8 production from MKN45 cells
stimulated by H. pylori. [Results] 1) Expression level for PAR1 and PAR-2 mRNA was
significantly higher in the gastric mucosa of H. pylori-positive patients than in the gastric
mucosa of H. pylori-negative patients. Especially, PAR mRNA expression in the antrum was
high compared to that in the gastric body. 2) PAR1 and PAR2 mRNA, and its protein were
constitutively expressed on unstimulated MKN45 cells. Treatment of cells with H. pylori
resulted in significant increase in PAR1 or PAR2 expression. H. pylori live bacteria induced
IL-8 production from MKN45 cells. H. pylori-mediated IL-8 production was significantly
inhibited by nafamostat mesilate, blocking antibody to PAR and in PAR1 or PAR2 deficient
cells treated with siRNA. [Conclusions]These results indicate that H. pylori infection induces
increased expression of PAR in the gastric epithelial cells and promotes IL-8 production
through PAR, suggesting an important role for PAR in the modulation of gastric inflammation
associated with H. pylori.
S1528
Cpg Methylation of O6-Methylguanine DNA Methyltransferase (Mgmt) During
H. pylori Gastritis Is Associated with H. pylori Caga Status
Antonia R. Sepulveda, Yuan Yao, Dong I. Park, Jae J. Kim, David Graham
Background: Previous studies have shown an increased number of DNA mutations, including
base substitutions, associated with H. pylori (Hp) gastritis. The DNA repair protein MGMT
can prevent G to A mutations and has been shown to be down-regulated by CpG methylation
of its promoter region. DNA repair may be impaired during H. pylori gastritis, suggesting
the possibility of epigenetic regulation of the MGMT DNA repair gene during Hp gastritis.
Aims: To determine the methylation levels of MGMT in the gastric mucosa during Hp
gastritis and the effect of Hp eradication on MGMT methylation in the mucosa as well as
to determine whether Hp CagA status is associated with MGMT methylation. Methods:
Gastric antral biopsies from 33 patients with Hp gastritis (one biopsy at baseline and one
biopsy taken from the same patient at 6-8 weeks after Hp eradication were studied. Hp
eradication was done by triple therapy. There were 27 men and 6 women, mean age 56.7
years. Hp was confirmed histologically and by PCR for the Hp 16S rRNA and CagA genes.
Gastric inflammation scores were determined. Extracted DNA was subjected to sodium
bisulfite modification. Quantitative SYBR GREEN Methylation specific PCR (QS-MSP) and
bisulfite sequence analysis for CpG islands in the promoter of MGMT were performed. CpG
methylation levels were determined by comparison with a standard curve to represent a
range of CpG methylation from 0% to 100%. Results: QS-MSP demonstrated that the levels
of MGMT CpG methylation in the mucosa of Hp positive gastritis were (11%, SD=3.2), and
after Hp eradication the levels decreased (4.2%, SD=2.6), P=0.027. MSP amplified DNA
products were sequenced confirming CpG methylation of CpGs within the MGMT amplified
fragment. The inflammation score (combined neutrophils and mononuclear inflammation)
of cases with positive CpG methylation vs. cases negative for CpG methylation were: mean
1.95 and 1.55, respectively, P=0.09. Among the cases of active gastritis (before eradication)
with positive MGMT CpG methylation (21 cases) there were 83% with CagA-positive Hp
strains, and 4% with CagA-negative Hp strains; in active gastritis with negative MGMT CpG
methylation (10 cases) there were 4 cases with CagA-positive and 6 with CagA-negative Hp
(p=0.035). Conclusions: H. pylori gastritis leads to increased CpG island methylation of the
MGMT DNA repair gene. CpG methylation of MGMT was more frequent in gastritis associated
with CagA positive strains. The levels of MGMT CpG methylation declined but remained
at low levels 6-8 weeks after H. pylori eradication, suggesting a role of inflammatory products
in the activation of cellular factors involved in CpG methylation.
S1529
Helicobacter pylori Alters the Subcellular Localization of P120-Catenin in
Gastric Epithelial Cells
Seth Ogden, Daniel O'brien, Judith Romero-gallo, Uma Krishna, Dawn Israel, Al
Reynolds, Richard M. Peek
Background & Aims: Helicobacter pylori is a Gram-negative bacterial species that specifically
colonizes gastric epithelium, and infection with this bacterium is the strongest known risk
factor for distal gastric cancer. H. pylori dysregulates several components of intercellular
junctions, including ZO-1 and β-catenin. p120-catenin (p120) is typically found at the
adherens junction, where it regulates cadherin turnover and membrane localization. p120
also coordinately regulates the expression of Wnt/β-catenin target genes by relieving transcrip-
tional repression. Aberrant expression of p120 has been demonstrated in a number of
epithelial malignancies, including gastric cancer. Since H. pylori can activate β-catenin, we
determined the effect of this pathogen on p120 localization and investigated the role of
p120 in the induction of matrix metalloproteinase-7 (MMP-7), a Wnt/β-catenin target gene
with carcinogenic potential. Methods: MKN28 gastric epithelial cells were co-cultured with
the β-catenin-activating H. pylori strain 7.13. Immunofluorescence and subcellular fractiona-
tion/immunoblotting were performed to examine alterations in p120 localization. Endogen-
ous p120 expression was inhibited using retroviral transduction with a sequence coding for
human-specific p120 siRNA. MMP-7 induction was determined by real time RT-PCR.
Results: Infection with H. pylori strain 7.13 induced a significant decrease in levels of
cytoplasmic p120 and a concomitant increase in membranous p120. Immunofluorescent
laser scanning microscopy revealed that p120 accumulates in perinuclear aggregations in
response to H. pylori infection. H. pylori co-culture increased MMP-7 mRNA levels In Vitro;
however, knockdown of p120 completely attenuated H. pylori-mediated MMP-7 expression.
Conclusions: H. pylori infection of MKN28 cells alters the subcellular localization of p120.
Expression of p120 is required for induction of MMP-7 by H. pylori, revealing a novel role
for p120 in the H. pylori-mediated induction of a Wnt/β-catenin target gene.
S1530
The E-Cadherin/Catenin Complex Suppresses Helicobacter pylori-Mediated
Cancer Cell Invasion
Maria J. Oliveira, Angela M. Costa, Ana C. Costa, Gianpaolo Suriano, Jose C. Machado,
Raquel Seruca, Marc Mareel, Ceu Figueiredo
Helicobacter pylori interacts with gastric epithelial cells, activating signaling pathways import-
ant for carcinogenesis. We have recently shown that H. pylori strains with a functional type
IV secretion system stimulate gastric cancer cell invasion through a c-Met-dependent pathway.
Because E-cadherin/catenin complex is a key component of the adherens junctions, as well
as an invasion suppressor, we investigated the role of the complex in H. pylori-mediated
cancer cell invasion. AGS cells lacking E-cadherin expression were stably transfected with
E-cadherin using a lentivirus transfection system. The expression, cellular localization, and
molecular interactions between proteins of the E-cadherin/catenin complex were evaluated
by immunocytochemistry and immunoprecipitation using specific antibodies. The effect of
H. pylori on cell invasion was evaluated using the Matrigel invasion assay. In E-cadherin-
transfected AGS cells, we observed that E-cadherin was expressed at the cell membrane,
and the cellular localization of the other proteins of the complex was reorganized: alpha-
catenin and p120-catenin were recruited from the cytoplasm to the membrane, and beta-
catenin was partially delocalized from the nucleus to the membrane. Functional aggregation
assays and coimmunoprecipitation between E-cadherin, p120- and beta-catenin confirmed
the molecular integrity and functionality of the complex. After infection of E-cadherin-
transfected cells with H. pylori, we have found that H. pylori was no longer able to stimulate
cell invasion into extracellular matrix components. Furthermore, in these cells H. pylori led
to decreased c-Met tyrosine phosphorylation. In addition, we observed an interaction between
E-cadherin and the bacterial protein CagA. These results raise the possibility that the E-
cadherin/catenin complex may compete with c-Met for CagA interaction, therefore preventing
H. pylori-mediated cancer cell invasion.
S1531
Helicobacter pylori-Induced Paxillin Phosphorylation and Cytoskeletal RE-
Organization Require Src Dependent Signaling
Fazal Tabassam, David Y. Graham, Yoshio Yamaoka
Background: Paxillin, a non-receptor tyrosine kinase is a multi domain adopter protein that
localizes at focal adhesion sites. Paxillin, phosphorylated by focal adhesion kinase (FAK)
and Src, serves as a scaffolding protein for cytoskeletal proteins to mediate signaling pathways
to regulate actin cytoskeletal organization, cell motility and migration. H. pylori injects CagA
which is tyrosine phosphorylated by Src family kinases and interacts with host proteins to
modulate cytoskeletal reorganization, motility and elongation of gastric epithelial cells In
Vitro. The sequence of events leading to these phenotypic changes remains unclear. Aim:
To identify the sequence of early signaling events involved in H. pylori-mediated regulation
of Src and its involvement in mediating paxillin phosphorylation responsible for phenotypic
changes of AGS cells. Methods: AGS cells were co-cultured with live H. pylori or its isogenic
cag pathogenicity island (PAI) or oipA mutants and the phosphorylation status of Src, Erk1/
2 and paxillin were evaluated using immunoblot and fluorescence microscopy. Results: H.
pylori induced transient tyrosine phosphorylation of Src Y418, followed by autophosphoryl-
ation of FAK Y397. The presence of a FAK-Src signaling complex (confirmed by immunoprec-
ipitation experiments) resulted in tyrosine phosphorylation of Src Y527 inH. pylori concentra-
tion-and time-dependent manner. Activation of Src resulted in tyrosine phosphorylation of
Erk1/2 at T202/Y204 and paxillin Y31 and Y118. Activation of these signaling pathways
subsequently resulted in actin stress fiber formation indicating a requirement for Src in H.
pylori-mediated phenotypic changes. Inhibiting FAK expression by FAK-specific siRNA or
chemical inhibitor of Src resulted in inhibition of H. pylori-mediated paxillin phosphorylation
and actin stress fiber formation indicating the requirement for both FAK and Src in regulating
intracellular signaling and actin stress fiber formation. Both cag PAI and oipA mutants were
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involved in activation of Src. Interestingly, oipA mutants had significantly reduced site specific
tyrosine phosphorylation of paxillin Y31 which resulted in inhibition of actin stress fiber
formation while cag PAI mutants markedly reduced activation of paxillin Y118 and had less
effect on actin stress fiber formation. Conclusion: The involvement of OipA with FAK plays
a crucial role in signaling events controlling activation of Src and paxillin and is likely
responsible for initiation of cytoskeletal reorganization, cellular motility and phenotypic
changes.
S1532
Regulation of the Urokinase Plasminogen Activator System in the Gastric
Epithelium By Helicobacter pylori
Susan Kenny, Cedric Duval, Rod Dimaline, Graham J. Dockray, Mark D. Pritchard, John
Atherton, Andrea Varro
Background: Gastric cancer is associated with Helicobacter pylori infection but while preneo-
plastic changes are recognised to involve remodelling of both epithelial and subepithelial
compartments, the relevant signalling mechanisms are poorly understood. We previously
identified increased gastric expression of plasminogen activator inhibitor (PAI)-2, a member
of the urokinase plasminogen activator (uPA) system, in patients infected with H. pylori. We
have now studied the expression of other key members of the system and their contribution to
signalling between the epithelium and a key sub-epithelial cell type, the myofibroblast.
Methods: In infected humans, mRNA abundance of uPA, its receptor (uPAR) and PAI-1 was
determined by real time PCR; expression was studied in human cultured gastric glands
using promoter-reporter (luciferase) constructs. Endogenous expression and cell specific
targeting of the constructs was determined by indirect immunofluorescence; uPA enzyme
activity was separately measured in cultured human gastric epithelium and myofibroblasts
before and after PAI-1 knockdown. Proliferation was determined by [3H]-thymidine incorp-
oration. Results: uPA, uPAR and PAI-1 were all up-regulated in the stomach in Helicobacter
pylori infected patents. The increases were mainly localised to epithelial cells. Endogenous
uPA, uPAR and PAI-1, and their respective promoter-reporter constructs, showed distinct
patterns of cell-restricted expression in cultured human gastric glands. There was increased
luciferase activity in all three constructs after H. pylori stimulation that was attributable to
the cag pathogenecity island since a cag- strain had no effect. Soluble uPA enzyme activity
in the medium of cultured human glands was increased by H. pylori and stimulated still
further by knockdown of the inhibitor, PAI-1. In samples that responded to H. pylori with
high uPA activity, PAI-1 knockdown only marginally increased proteolytic activity, while
low responders had significantly higher uPA activity after knockdown suggesting individual
variation in the relative abundance of uPA and PAI-1. Exogenous uPA stimulated further
proliferation of both primary human gastric epithelial cells and myofibroblasts after PAI-1
knockdown. Conclusions: 1. H. pylori infection up-regulates expression of all members of
the uPA system in stomach. 2. Increased uPA activity may act as a growth factor to both
epithelial cells and myofibroblasts. 3. Changes in expression of different members of this
system may contribute to the preneoplastic changes that lead to gastric cancer.
S1533
Early H. pylori Eradication and Additional Rebamipide Treatment Evoke
Effective Restoration of Sonic Hedgehog Expression in the Gastric Fundus of
Mongolian Gerbils
Hidekazu Suzuki, Toshihiro Nishizawa, Yuriko Minegishi, Tatsuhiro Masaoka, Tetsufumi
Takahashi, Eisuke Iwasaki, Toshifumi Hibi
Background. Early-phase H. pylori (Hp) eradication, before the formation of gastric preneo-
plastic lesions in the fundus, could be beneficial to prevent gastric cancer development (N.
Eng. J. Med. 345:784, 2001; JAMA 291:187, 2004). Expression of sonic hedgehog (Shh),
a morphogen involved in the gastric fundic homeostasis, has been shown to be reduced not
only in intestinal metaplasia, but also in Hp-associated atrophic gastritis (Gut 51:628, 2002;
J. Pathol. 206:186, 2005); furthermore, its expression has been restored after Hp eradication.
However, the optimum time point for Hp eradication to perform gastric mucosal reversal
and prevent cancer development still remains uncertain. Also, effects of regenerative agents
after Hp eradication have not been fully explored. Rebamipide, a gastroprotective agent,
promotes ulcer healing by scavenging oxygen free radicals. The present study was designed
to investigate the restoration of gastric mucosal Shh expression after Hp eradication and the
additional effect of rebamipide in promoting gastric mucosal regeneration. Methods. Male
Mongolian gerbils (5 weeks) were inoculated with Hp. Eradication was carried out 12, 24
and 48 weeks after Hp inoculation. Gerbils were then examined 10 weeks after the eradication.
Control, Hp-infected and Hp-eradicated gerbils were further subdivided into the normal
diet and the rebamipide-containing diet groups. Gastric myeloperoxidase (MPO) activity
and histological scores based upon the updated Sydney system were evaluated. In-situ
hybridization and immunohistochemistry were performed for Shh expression. Results. With
time after Hp inoculation, MPO activity, Shh mRNA expression and inflammation and
atrophy scores increased. In the Hp-eradicated gerbils at 12 weeks, most cohorts showed
almost complete regeneration, in terms of both regression of inflammation and restoration
of Shh expression. Rebamipide treatment started at 12 weeks further promoted gastric
mucosal regeneration. In the Hp-eradicated gerbils at 24 weeks, although gerbils without
fundic nodules showed significant mucosal regeneration, gerbils with fundic nodules showed
less regeneration. Rebamipide initiated at 24 weeks promoted the regeneration only in
gerbils without nodular formation. Hp-eradicated gerbils at 48 weeks showed no significant
regeneration, and no effects of rebamipide. Conclusion. Early Hp eradication induced
regression of the gastric mucosal inflammation with restoration of Shh expression. Rebamip-
ide significantly promoted Shh restoration and gastric mucosal regeneration, especially in
the earlier stage after Hp eradication, before the formation of irreversible lesions.
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S1534
Roles of Syndecan-1 and Syndecan-4 in H. pylori Pathogenesis
Virginia Carl, Steven G. Black, Laurey Comeau, Michael F. Smith
The syndecans are a family of four type I transmembrane heparan sulfate proteoglycans
(HSPG) which represent the major source of heparan sulfate on the cell surface. The proteins
represent four distinct gene products organized such that the heparan sulfate chains are
placed distal to the cell surface and contain a conserved cytoplasmic COOH-terminal with
characteristic serine and tyrosine phosphorylation sites. The syndecans bind to a wide
variety of soluble and insoluble extracellular effector molecules such as extracellular matrix
components, growth factors, cytokines, and microbial pathogens. These HSPGs have variably
been demonstrated to play important roles in facilitating the formation of active signaling
complexes by acting as coreceptors to concentrate and present ligands to the cell surface
receptors or in fact actively participate in the enhancement of cell signaling. Several studies
have indicated pivotal roles for the syndecans in bacterial pathogenesis, tissue homeostasis,
and cell migration, while loss of syndecan-1 expression has been associated with a poor
prognosis in a number of cancers. Recent studies from our lab have demonstrated that
syndecan-4 expression can be enhanced in MKN45 gastric epithelial cells in response to
Helicobacter pylori infection and purified Toll-like receptor (TLR) 2 or 5 ligands, PAM3CSK4
or flagellin, respectively. In order to determine if syndecans participate in the host response
toH. pylori infection, we have examined the effects of syndecan deficiency on the inflammatory
response In Vitro and In Vivo. In Vitro, knockdown of syndecan-1 or syndecan-4 expression
in IMGE5 mouse gastric epithelial cells using siRNA resulted in a significant decrease in H.
pylori -induced expression of IL-6 and chemokine expression. Additionally, H. pylori infection
or TLR stimulation resulted in syndecan-4, but not syndecan-1, shedding from the surface
of MKN45 cells. Shedding, like IL-8 expression, was dependent on an intact Cag PAI.
Furthermore, in an In Vivo infection model with H. pylori (strain SS1), syndecan-1 deficient
mice displayed significantly increased bacterial burden and decreased cytokine expression
relative to wild type mice at 12 weeks post-infection. These data thus suggest that the
syndecans play an important role in the regulation of the host response to H. pylori infection.
S1535
Negative Regulation of Bax Gene in H. pylori-Infected Human Gastric
Epithelial Cells By Apurinic/Apyrimidinic Endonuclease-1/Redox Factor-1
(Ape-1/Ref-1)
Asima Bhattacharyya, Kishor K. Bhakat, Sankar Mitra, Sheila e. Crowe
Background: APE-1/Ref-1 repairs oxidative DNA damage and reductively activates transcrip-
tion factors. A third, less known function is negative gene regulation by lysine-acetylated APE-
1/Ref-1 (ac-Ref-1). APE-1/Ref-1 is acetylated by transcriptional co-activator p300 activated by
calcium. ac-Ref-1 downregulates parathyroid hormone and renin expression by interaction
with negative calcium response elements (nCAREs) in their promoters. Our previous data
indicate that H. pylori infection increases expression of APE-1/Ref-1 in gastric epithelium.
It is also known that infection alters gastric epithelial growth and survival with altered
expression of various genes regulating cell cycle and apoptosis such as bax. This study
assesses the effect of H. pylori-mediated increase of intracellular calcium ion concentration
[Ca2+]i on acetylation of APE-1/Ref-1 in AGS cells and its interaction with an nCARE in the
bax promoter. Methods: The effect of H. pylori-induced increased [Ca2+]i (measured by
fluorescent dye) on ac-Ref-1 and total APE-1/Ref-1 was determined by western blotting.
p300's role in APE-1/Ref-1 acetylation was assessed by immunoprecipitation. APE-1/Ref-1
stably suppressed AGS via shRNA were transiently transfected with empty vector, wild
type APE-1/Ref-1 or ac-deficient construct and cotransfected with a bax-luciferase reporter
containing the nCARE. Results: H. pylori-induced [Ca2+]i increase caused APE-1/Ref-1
acetylation involving p300 which was suppressed by cytosolic Ca2+-chelator BAPTA-AM.
Both wild type and ac-deficient APE-1/Ref-1 enhanced bax-luciferase activity. H. pylori
infection reduced luciferase activity in cells with basal ARE-1/Ref-1 and to an even greater
extent in cells overexpressing wild type APE-1/Ref-1. However, infection did not have a
significant inhibitory effect in cells expressing mutant APE-1/Ref-1 suggesting that H. pylori-
mediated repression of transcription is due to acetylation of APE-1/Ref-1. Conclusion: Our
data indicate that H. pylori infection induces acetylation of APE-1/Ref-1 which represses bax
transcription via nCaRE. These novel results further implicate APE-1/Ref-1 in mediating the
effects of H. pylori in gastric epithelial cells. (Supported by RO1 DK61769)
S1536
Gastric Carcinogenesis in Rhesus Monkeys. Role of a Carcinogen and
Intracellular H. pylori in Stem Cells
Cristina Semino-mora, Hui Liu, Steven Mog, Andre Dubois
Helicobacter pylori is recognized as a cause of gastric cancer, but only a fraction of infected
subjects develop gastric cancer. The present studies were undertaken to study the co-
carcinogenic effects of the nitrosating carcinogen ethyl-nitro-nitrosoguanidine (ENNG) given
orally and H. pylori infection, and to examine the presence of H. pylori within gastric
progenitor cells. Gastroscopies were performed in 23 Rhesus monkeys naturally infected
with H. pylori and were cured using quadruple therapy. Biopsies were cultured for H. pylori
or fixed for histology to study the pathology of the gastric mucosa. The mRNA expression
ofH. pylori 16S rRNA and of rhesus monkey SOX2 and CDX2 were determined by fluorescence
in situ hybridization to localize and quantify H. pylori infection, progenitor cells, and molecu-
lar intestinal metaplasia respectively. After cure of the infection, H. pylori-negative monkeys
were assigned to one of four groups: controls (C); inoculation of a virulent H. pylori strain
isolated from a patient with gastric cancer (H); ENNG (E); and H. pylori inoculation +
ENNG (started 6 months post-inoculation; H+E). Follow-up gastroscopies and biopsies were
performed at regular intervals. Post inoculation, both H and H+E groups had antral gastritis
and H. pylori were present in the gastric lumen, attached to, and within gastric epithelial
cells (including progenitor cells), and in the lamina propria. Starting at 21-month of ENNG
administration, gastric body biopsies of 3 H+E animals demonstrated atrophy and inflamma-
tion with loss of parietal cells and conserved chief cells. At 31-month, gastric antrum biopsies
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of one H+E animal showed intestinal metaplasia, small intestinal type, with marked epithelial
hyperplasia and regeneration. Expression of CDX2 became consistently positive both inte
antrum and in the body of these 3 H+E at 31 months. At 52 months, one of these animals
had an antral biopsy with focal epithelial dysplasia characterized by epithelial tubules in
cribriform-like pattern with overlying erosions. The other antral biopsy showed marked
glandular atrophy with an intramucosal cyst. The dysplastic cells had nuclear stratification
and prominent nucleoli. Intracellular H. pylori were observed inside SOX2-positive progenitor
cells located in the neck region in both H+E and H animals. This observation demonstrates
that H. pylori can be present within gastric epithelial progenitor cells and that precancerous
lesions appear in persistent H. pylori infection associated with administration of a carcinogen.
Repeat endoscopies continue to be performed at 2-month intervals and surveillance for early
gastric neoplasia is investigated.
S1537
Concurrent Helicobacter bilis Infection in C57bl/6 Mice Modulates Systemic
and Gastric Immune Responses and Attenuates Gastric Pathology Associated
with H. pylori Infection
Laura B. Lemke, Mark T. Whary, Arlin B. Rogers, Zhongming Ge, Yan Feng, James G.
Fox
Introduction: Studies examining experimental Helicobacter pylori (Hp) infection in mice fail
to consider the potential effects of enzootic enterohepatic Helicobacter spp., despite the ability
of some co-pathogens to alter the pathogenesis of gastric helicobacter infections (Fox et al,
Nat Med, 2000). The current study investigates the ability of the enterohepatic H. bilis (Hb)
to modulate the pathogenesis of experimental Hp infection in mice.Methods: Female C57BL/
6 mice were divided into four groups of 30: uninfected, orally inoculated with Hp (Hp),
orally inoculated with Hb (Hb), or orally inoculated with Hb followed 2 weeks later by Hp
infection (HpHb). Mice were analyzed at 6 and 11 months post infection (pi). Gastric
histological evaluation for inflammation, atrophy, hyperplasia, intestinal metaplasia and
dysplasia were graded on a blinded basis by a pathologist, and assigned a score from 0 to
4. ELISA for anti-Hp IgG2a (Th1 isotype) and IgG1 (Th2 isotype), and quantitative PCR
for IL-1β, TNFα, IFNγ, IL-10 and IL-13 gastric mRNA were also performed. Results: HpHb
mice had significantly less severe gastric inflammation at 6 and 11mos pi compared to Hp
mice (P<0.05). Atrophy, mucous metaplasia and hyperplasia were also significantly reduced
in HpHb mice at 6mos pi (P<0.05), while intestinal metaplasia and dysplasia were less
severe at 11mos pi (P<0.05). Serologic analysis of IgG2c and IgG1 titers to Hp was predictive
of gastritis scores. Hp mice had significantly higher Th1 associated IgG2c and a trend towards
higher Th2 associated IgG1 responses to Hp compared to HpHb mice (P<0.002, P=0.10
respectively). Consistent with serologic data, the Th1-associated cytokines IFNγ and TNFα
were upregulated in gastric tissue of Hp mice compared to HpHb mice at 6mos pi (P<0.05),
with significant upregulation of IFNγ, TNFα and IL-1β occurring at 11mos pi (P<0.05).
The Th2-associated cytokine IL-10 was upregulated in Hp mice compared to HpHb mice
at 11mos pi (P<0.05). Conclusions: These data suggest that pre-existent enterohepatic
helicobacter infection can ameliorate gastric helicobacter pathology and modulate the Hp
Th1-associated gastric and systemic immune responses. Further studies determining the
mechanisms for the protective effects of apparent heterologous immunity are warranted.
S1538
Helicobacter pylori Induces Mislocalization of Occludin in Gastric Epithelial
Cells
Lydia Wroblewski, Judith Romero-gallo, Le Shen, Jerrold Turner, Dawn Israel, Aime
Franco, Uma Krishna, Richard M. Peek
Background and Aims: Infection with Helicobacter pylori predisposes to gastric cancer, yet
carcinogenic epithelial responses to this pathogen are incompletely defined. Tight junctions
are critical regulators of transepithelial transport, cell adhesion, and cell migration, and
alterations in apical-junctional complexes by H. pylori may increase the risk of developing
cancer. Therefore, we examined alterations in the topography and expression of occludin,
a major component of the epithelial tight junction, in response to H. pylori infection.
Methods: Mice with a genetic susceptibility for gastric cancer (INS-GAS) were infected with
the carcinogenic H. pylori cag+ strain 7.13 for 8 weeks and occludin localization was
determined by immunohistochemistry. In Vitro, H. pylori-infected (48h, bacteria to cell ratio
100:1) and uninfected MKN28 gastric epithelial cells were separated into membrane and
cytosolic fractions and probed for occludin expression by Western blot. Occludin localization
in MKN28 cells was also investigated by immunohistochemistry. Results: H. pylori infection
focally decreased gastric epithelial cell membrane occludin and induced the formation of
occludin-laden cytoplasmic vesicles in INS-GAS mice compared to medium-treated mice.
Concordant with these In Vivo findings, Western blot analysis demonstrated that co-culture
of MKN28 cells with H. pylori strain 7.13 and the cag+ strains J166 and 60190 significantly
decreased occludin in the membrane and increased occludin in the cytosol. Immunohistoch-
emical analysis of infected MKN28 cells verified Western blot data by demonstrating an
accumulation of occludin in cytosolic vesicles in response to H. pylori. Inactivation of cagE
had no effect on occludin mislocalization compared to wild type H. pylori. Conclusions:
1. H. pylori infection leads to a focal and marked redistribution of occludin in gastric
epithelial cells In Vivo. 2. Redistribution of occludin In Vitro mirrored the pattern of occludin
mislocalization induced in mouse gastric mucosa, but was independent of the H. pylori
virulence factor CagE.
S1539
A COX-2 Gene Polymorphism Increases Risk of Non-Cardia Gastric Cancer
and Esophageal Squamous Cancer in a Us Population
Malcolm G. Smith, Georgina Hold, Charles Rabkin, Wong-ho Chow, Joe Fraumeni,
Ashley Mowat, Emad M. El-omar
Background: Cyclooxygenase-2 (COX-2) is an important mediator of carcinogenesis, with
roles in cellular proliferation, angiogenesis and apoptosis. COX-2 expression is upregulated
in pre-malignant gastric lesions and adenocarcinomas and this increased expression has
been correlated with poor clinicopathological variables. We have previously shown that a
single nucleotide polymorphism at position -765 in the COX-2 gene (COX-2 -765 G>C)
influences the development of pre-malignant changes in the stomach in H. pylori infected
subjects. Carriage of the COX-2-765 G allele is associated with higher COX-2 expression
and increased risk of hypochlorhydria and gastric atrophy. Aim: To evaluate the effect of
the COX-2 -765 G>C polymorphism on the risk of developing gastric and esophageal cancers.
Methods: We used PCR-RFLP to genotype the COX-2 -765 G>C polymorphism in a largely
Caucasian US case-control study comprising 184 cases of non-cardia gastric cancer, 122 cardia
gastric cancer, 107 esophageal adenocarcinoma, 50 esophageal squamous cell carcinoma and
209 population controls. Odds ratios and 95% confidence intervals (CI) were calculated
and logistic regression was used to adjust for age, race and gender. Genotyping was confirmed
by direct sequencing. Results: Carriage of the COX-2 -765 G allele was associated with an
increased risk of non-cardia gastric cancer, compared to subjects homozygous for the C
allele (adjusted OR = 1.6 95% CI 1.0 - 2.6). The odds ratio was higher for intestinal type
gastric carcinoma (adjusted OR 2.0 95% CI 1.0 - 3.9). Carriage was also associated with
increased risk of esophageal squamous cell carcinoma (adjusted OR 2.0 95% CI 1.0 - 3.9).
However, no association was found between the polymorphism and risks of cardia gastric
cancer or esophageal adenocarcinoma. Conclusion: The COX-2 -765 G>C polymorphism
influences the development of pre-malignant changes in the stomach in H. pylori infected
subjects, and this study now confirms those with the high expressing G allele are at increased
risk of developing non-cardia gastric cancer and esophageal squamous cell cancer. These
two cancers appear to share similarities in risk perhaps mediated by a shared gastric pheno-
type. This polymorphism is a candidate for further study in relation to gastric and eso-
phageal cancers.
S1540
Association of Anemia and Helicobacter pylori Infection in Asymptomatic
Young Bangladeshi Children
Pradip K. Bardhan, Shafiqul A. Sarker, Christoph Beglinger, Niklaus Gyr
Background: Gastric acid is considered to be one of the most important luminal factors
necessary for optimal absorption of non-heme iron. In the developing countries, H. pylori
(HP) infection occurs very early in the life, and the resulting gastritis may lead to achlorhydria
or hypochlorhydria, which in turn may decrease iron absorption in the young children
already nutritionally compromised, leading to anemia. Studies examining the relationship
between HP infection and anemia have reported conflicting results. Aim: To examine the
association between HP infection and hemoglobin (Hb) levels in young asymptomatic Bangla-
deshi children. Methods: This was a community-based cross-sectional study. Hb levels (g/
dL) were determined from asymptomatic children (aged 6 months to 2 years) selected
randomly from rural and peri-urban Bangladeshi communities. None received any antibiotic
in the preceding 3 months. Status of HP infection was determined by 13C-urea breath test
(UBT) and HP fecal antigen (FA) test. Only children with concordant results from both UBT
and FA were included. Anthropometric, fecal microscopic, nutritional, socioeconomic, and
dietary data were also collected. Data are expressed as mean ± SD, and were analyzed by
Student's t test, χ2 test and logistic regression. Results: Out of 110 children enrolled in the
study, 101 children were included in the final analysis based upon the concordance of UBT
and FA. 41 children (40.6%) were HP positive (+) and 60 (59.4%)were HP negative (-).
Malnutrition (wt./age <75% of NCHS median) was noted in 68 (67%) children. The Hb
levels in the HP (+) group were significantly lower compared to those of the HP (-) group
(8.7 ± 1.5 and 9.5 ± 1.5, respectively, p=0.006). 42 (41%)children had significant anemia
(Hb <9 g/dL). The number of children distributed according to hemoglobin levels showed
a significant difference between the HP (+) and HP (-) groups (Table). In logistic regression,
HP infection appeared to be a significant risk factor for anemia (Odds ratio 1.68, 95% CI
1.12-2.52, p=0.038). The covariates in the regression equation were age, gender, nutritional
status, socioeconomic status, fecal pathogens, breast-feeding, immunization, and mother's
education. Conclusion: A significant association was noted between HP Infection and anemia
in asymptomatic young Bangladeshi children. Intervention of HP infection may decrease
the incidence of anemia in this vulnerable population.
Number of children according to Hb levels and HP status
χ2=8.48, p=0.0369
S1541
Stronger Caga-Shp-2 Bindings in Western Helicobacter pylori Strains
Compared with East Asian Strains Using Live Clinical Isolates
Hiroaki Ogiwara, David Y. Graham, Yoshio Yamaoka
Background: CagA protein of Helicobacter pylori has been reported to inject into host cells
where it is phosphorylated and binds to SHP-2. The ability of CagA to bind to SHP-2 was
reported to be greater in East Asian than in Western strains. However, these results were
based on the techniques using transfection of CagA plasmids and not injection by type IV
secretion. We therefore investigated CagA-SHP-2 bindings using live H. pylori. Methods:
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We used 52 clinical isolates (26 from East Asia and 26 from Western countries) from patients
with either gastric cancer or duodenal ulcer. CagA production from cultured H. pylori was
measured by immunoblot. Gastric epithelial AGS cells were co-cultured with H. pylori and
the cell lysates were subject to immunoblot for CagA and phosphorylation status of CagA
and to immunoprecipitation for SHP-2 followed by immunoblot for CagA to detect CagA-
SHP-2 binding complexes. The intensity of the bands was evaluated by grading from 0
(none) to 5 (strongest). Results: CagA levels among clinical isolates were slightly higher in
Western than in East Asian strains (mean 3.7 vs. 3.1; P = 0.08). CagA levels in cell lysates
co-cultured with AGS cells were significantly higher in Western than in East Asian strains
(4.3 vs. 2.5; P <0.001). The number of H. pylori attached to AGS cells (quantitative culture)
did not differ between Western and East Asian strains. However, the levels of CagA-SHP-
2 binding complexes were significantly higher with Western than with East Asian strains
(3.5 vs. 1.7; P <0.001) and were strongly correlated with CagA levels in cell lysates (R =
0.83, P <0.001) but not with phospho-CagA levels (R = 0.24). CagA levels and CagA-SHP-
2 binding complexes levels were also independent of clinical outcomes. The levels of
phosphorylated CagA levels were also independent of the origin or outcome. In East Asian
strains, the number of EPIYA motifs in the 3' 2nd repeat region of the cagA was one in all
strains except for 1 strain with 2 repeats. In Western strains, number of EPIYA motifs was
1 in 3 strains, 2 in 18 strains and 3 or more in 6 strains. Strains with 3 or more motifs
showed the strongest phosphorylation of CagA (score = 5). Conclusion: In contrast to
previous studies using CagA plasmid transfection systems, live clinical isolates showed that
CagA-SHP-2 binding was stronger in Western strains than in East Asian strains and this is
likely related to the higher number of EPIYA motifs and greater production of CagA in
Western strains.
S1542
Interaction of Vegf and Its Receptors to Expansion of Gastric MALT
Lymphoma By Helicobacter Heilmannii Infection
Masahiko Nakamura, Shinichi Takahashi, Hidenori Matsui, Kaori Nishikawa, Hiroshi
Serizawa, Toshifumi Hibi, Kanji Tsuchimoto
Our recent study has revealed that Helicobacter heilmannii (Hh) peroral infection brought
about the gastric low-grade MALT lymphoma in almost all C57BL/6 mice after a period of six
months (Infect Immun, in press), while the pathophysiological mechanism of this lymphoma
formation remains to be clarified. Thus, the present study was undertaken to elucidate the
interaction of this lesion with angiogenesis. C57BL/6 female mice, infected with Hh for
more than 6 months were used in the following experiments. Microvascular alteration was
investigated by intravenous injection of FITC-dextran (MW 50, 000), followed by the confocal
microscopic observation. The electron microscopic observation was also performed. The
localization of the VEGF-A, C, Flt-1 and Flk-1 immunoreactivities was observed by the
indirect immunohistochemical methods. In addition, the effect of monoclonal antibodies
against Flt-1 and Flk-1 was estimated by the size of the protrusive lesion in the fundic
portion of the gastric mucosa. As a result, the MALT lymphoma tissue was shown to have
rich microvascular network consisting of the immature capillaries and venules, revealed by
electron microscopy. By the immunohistochemical analysis, very much enhanced VEGF-
A immunoreactivity was observed in the whole MALT lymphoma tissue, while VEGF-C
immunoreactivity was observed only in the marginal area of the lymphoma. Both Flt-1 and
Flk-1 were expressed in the lymphoma tissues. Flk-1 were mainly expressed in the immature
endothelial cells, while Flt-1 were observed in the accumulated lymphocytes. The treatment
with VEGF receptor monoclonal antibody significantly decreased the size of the protrusive
lesion. In conclusion, VEGF-mediated mechanism was shown to play an important role in
the expansion of the MALT lymphoma tissue induced by Hh infection in C57BL/6 mice.
S1543
Effect of the TLR4 Asp299gly Polymorphism On LPS-Induced Cytokine
Production and Nf-κB Activation in Mononuclear Cells
Georgina Hold, Susan Berry, Guillermo I. Perez-perez, Emad M. El-omar
Background: Toll-like receptor 4 (TLR4)-mediated recognition of lipopolysaccharide (LPS)
is required for efficient handling of Gram-negative bacterial infections including H. pylori.
A common mutation in TLR4, Asp299Gly, has been shown to be associated with increased
risk of developing gastric cancer and its precursors of hypochlorhydria and atrophy. However
the functional consequences of the polymorphism remain unclear with conflicting evidence
concerning its effect on downstream cytokine production. Aim: To evaluate the effect of
the TLR4 Asp299Gly polymorphism on NF-κB activation and cytokine production following
LPS stimulation. Subjects and Methods: Venous blood was collected from 18 individuals,
9 wildtype and 9 heterozygous for the Asp299Gly polymorphism. PBMCs were isolated
using density centrifugation, and monocytes were seeded onto microtitre plates at 106
monocytes per ml and incubated for 90 mins at 37oC/5%CO2 with non-adherent cells
removed by PBS washing. Highly purified LPS (1ng/ml) from E. coli (EC, serotype 0111:B4)
and H. pylori (HP, ATCC 26695) were added to cells and incubated for up to 24 hrs. Control
cultures were incubated in medium alone. Supernatants were assayed at various time points
up to 24 hrs for cytokine production (IL-1β, IL-6, IL-8, IL-10, IL-12 and TNF-α) using the
cytometric bead array (BD Biosciences). Cells were also assessed for NF-κB activation using
antibody to NF-κB (p65) and fluorescence microscopy. Results: Following 24 hrs of H.
pylori LPS stimulation, carriers of the polymorphism had significantly higher levels of IL-
1β, TNF-α, IL-6 and IL-10, but lower levels of IL-8 (Table). E. coli LPS stimulation showed
similar patterns but were not significant for TNF-α. Assessment of NF-κB activation indicated
that subjects with the TLR4 polymorphism showed delayed translocation of NF-κB from
the cell cytoplasm to the nucleus compared to wild-type subjects. Conclusion: Our findings
clearly show that the TLR4 Asp299Gly polymorphism affects downstream signalling and
subsequent cytokine production in mononuclear cells. In particular, carriers of the poly-
morphism produce higher levels of IL-1β and TNF-α, which are powerful pro-inflammatory
cytokines and potent gastric acid inhibitors. This may explain the relevance of this polymorph-
ism in gastric cancer and its precursors.
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S1544
Dietary Glutamine Supplementation Reduces Inflammation and Hyperplasia
During Helicobacter pylori Infection in the Mouse
Susan J. Hagen, Masahiro Ohtani, Jin-rong Zhou, Nancy S. Taylor, Barry Rickman, James
G. Fox
We recently showed that L-glutamine (GLN) protects gastric mucosal RGM-1 cells from
ammonia-induced cell death and predicted that GLN may also protect surface cells during
Helicobacter pylori (HP) infection. GLN is a widely-used supplemental amino acid in human
intestinal disorders but little information exists as to its efficacy in the stomach. The aim of
the current study was to test whether GLN supplementation is protective against HP-
associated pathology in a mouse model. METHODS: Mice (C57BL/6) were fed a diet
consisting of 20.3% protein, 66% carbohydrate, 5% fat with a total of 3.9 kcal/gm or with
a diet consisting of 20.3% protein and 5% GLN (25.3% total protein), 61% carbohydrate,
5% fat with a total of 3.9 kcal/gm. The diet compositions were identical save for the addition
of GLN and were prepared from purified components by Research Diets, Inc. Mice had a
2 week pre-feeding period after which they were divided into control (sham-infected) or
HP (SS1) infected groups. Weights and food consumption were recorded weekly. Tissues
were analyzed for inflammation, atrophy, foveolar hyperplasia, and mucous metaplasia at
6, 12, and 20 weeks post-infection (WPI). The degree of HP colonization in tissues was
determined by quantitative RT-PCR as were the levels of TNF-α, IFN-γ, IL-1β, IL-4, IL-10,
and TGF-β. Serum levels of IgG2c and IgG1 were determined by ELISA. RESULTS: Food
consumption between groups was not different, but mice fed the GLN diet had a lower
body weight overall. Colonization by HP was not different in mice fed the GLN diet nor
was there a significant change in atrophy or metaplasia scores. GLN supplementation resulted
in an early (6 WPI) and robust inflammatory response to HP followed by a significant
(p<0.05) reduction in inflammation by 20 WPI. Hyperplasia was notable by 12 WPI on
either diet but decreased significantly (p<0.05) with GLN by 20 WPI. The expression of
IL-1β was significantly higher at 6 WPI; however no other changes in pro-inflammatory
cytokine levels were detected over time nor was there a Th1 to Th2 cytokine profile
switch with GLN. There was a robust anti-inflammatory response with GLN, consisting of
a significant increase in IL-4, IL-10, and TGF-α at 6 WPI. After this initial response, there
was a reduction or no change in anti-inflammatory mRNA levels over time. CONCLUSIONS:
Our data demonstrate that supplemental GLN reduces inflammation and hyperplasia in
mice infected with HP and suggest that GLN protects gastric surface epithelial cells during
HP infection, In Vivo. We propose that GLN supplementation may prove to be a feasible
alternative therapy for reducing HP-associated pathology in humans.
S1545
Transactivation of EGFR By TNF Modulates TNF-Stimulated COX-2
Expression
Stuart Hobbs, Uma Krishna, Richard Peek, Robert H. Whitehead, D. brent Polk
Background: Tumor Necrosis Factor (TNF) regulates complex cellular responses during
injury and repair such as apoptosis and survival through signaling by TNF Receptors 1 and
2. Deregulated signaling by TNF plays an important role in the pathogenesis of a number
of gastrointestinal diseases. Previous observations suggest that TNF-stimulated signaling may
additionally be important in the pathogenesis of gastritis and gastric cancer induced by
the Gram-negative bacteria Helicobacter pylori. We have previously observed that H. pylori
stimulates Epidermal Growth Factor Receptor (EGFR) phosphorylation and that TNF may
be a possible mediator of this transactivation. Cyclo-oxygenase-2 (COX-2) may be an import-
ant target of H. pylori, TNF, and EGF-stimulated signaling since it regulates diverse biological
responses, including migration, proliferation, and apoptosis, that are involved in gastric
carcinogenesis. Here we hypothesize that TNF-stimulated transactivation of EGFR regulates
induction of COX-2 expression by TNF and H. pylori. Since TNF may be a possible mediator of
H. pylori-stimulated EGFR transactivation, we determined the significance of TNF-stimulated
EGFR transactivation in the induction of COX-2 expression by TNF in mouse gastric epithelial
cells (MGECs). Methods and Results: MGECs were treated with TNF for 1, 3, 6, 16, and
24 hours or H. pylori at a multiplicity of infection of 100:1 for 1, 3, 6, and 24 hours. Both
TNF and H. pylori increased COX-2 expression after 3 hours of treatment which continues
to increase up to 24 hours of treatment. Next, MGECs were transfected with small interfering
RNA (siRNA) specific for EGFR or pretreated with the EGFR kinase inhibitor AG1478 and
then treated with TNF for 24 hours. EGFR siRNA inhibits EGFR expression by approximately
50% and inhibits TNF-stimulated COX-2 expression at 24 hours of TNF treatment by
approximately 30%. AG1478 similarly reduces TNF-stimulated COX-2 expression 30% at
24 hours of TNF treatment. Finally, MGECs were pretreated with either the MMP inhibitor
GM6001 or the ADAM17-specific inhibitor TAPI-1 and then treated with TNF for 24 hours.
Neither GM6001 nor TAPI-1 inhibited TNF-stimulated COX-2 expression. Conclusions:
TNF and H. pylori stimulate COX-2 expression in MGECs, and full TNF induction of COX-
2 expression requires EGFR expression and kinase activity; however the induction does not
require MMP activity. This suggests that the EGFR transactivation that regulates TNF-
stimulated COX-2 expression occurs through an MMP-independent mechanism.
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S1546
The Roles of Sp1, AP-1 and Nf-κB in Helicobacter pylori-Mediated Down-
Regulation of H,K-ATPase α Subunit Transcription
Arindam Saha, Charles E. Hammond, Maria Trojanowska, Adam J. Smolka
H. pylori infection of human gastric mucosa perturbs normal acid secretory mechanisms,
inducing hypochlorhydria, gastritis and increased risk of gastric carcinoma. Gastric acid
secretion is mediated by H,K-ATPase, a proton-translocating ATPase in parietal cell apical
membranes. We showed previously that H. pylori down-regulates H,K-ATPase α subunit
(HKα) gene transcription In Vitro, providing a partial mechanistic basis for hypochlorhydria.
Given previous reports of Sp1 activation of HKα promoter, and the roles of NF-κB and AP-
1 in H. pylori-mediated inflammatory responses, we hypothesized these transcription factors
participate in H. pylori inhibition of HKα gene expression. To identify putative binding sites
for these transcription factors in human HKα promoter, we performed DNase I footprinting
assays with 206 bp HKα 5'-flanking sequence and recombinant human Sp1, c-jun and p50
NF-κB. Positive HKα footprints revealed Sp1 binding at -56 to -39 bp, c-jun binding at
-98 to -73 bp, and p50 NF-κB binding at -117 to -170 bp. Expression of the transcription
factors in gastric epithelial AGS cells and their interaction with consensus oligonucleotides
or with HKα promoter was confirmed by gel shift analysis. The mobility and intensity of
Sp1 and AP-1 oligonucleotide:protein complexes in AGS cell nuclear extracts, and positive
super-shifts of these complexes with Sp1 and c-jun antibodies, were unaffected by H. pylori
infection. In contrast, gel shift banding patterns with both NF-κB consensus oligonucleotide
and with 20 bp HKα sequence (-150 to -170 bp) probes were altered and intensified after
H. pylori infection, and specific NF-κB interaction with the probes was confirmed by p50
NF-κB antibody super-shifts. Participation of AP-1 and NF-κB binding sites in HKα gene
expression and inhibition by H. pylori was assessed in AGS cells transfected with HKα
deletion-Luc promoter constructs. The activity of an HKα 102 bp construct encompassing
the AP-1 response element deduced from footprinting and gel shifts was reduced by 80%
by deleting the AP-1 binding sequence. In the case of a 206 bp HKα construct encompassing
the NF-κB response element, H. pylori infection of the transfected AGS cells decreased HKα
activity by 54%. Functional involvement of NF-κB in this inhibition was confirmed by AGS
cell pre-treatment with p105 NF-κB siRNA which relieved H. pylori-induced HKα promoter
inhibition. We conclude that 1) Sp1 and AP-1 participate in constitutive activation of human
HKα but do not mediate H. pylori inhibition of HKα gene expression, and 2) H. pylori induces
p50 NF-κB binding to HKα promoter causing down-regulation of HKα gene transcription.
S1547
Tlr9 -1237t/C Promoter Polymorphism and Risk of Gastric Cancer in
Caucasian and Japanese Populations
Georgina Hold, Susan Berry, Charles Rabkin, Wong-ho Chow, Joe Fraumeni, Ashley
Mowat, Takafumi Ando, Hidemi Goto, Emad M. El-omar
Background: Pattern-recognition receptors, most notably Toll-like receptors (TLRs), are
crucial sensors of microbial infections including H. pylori. We have previously shown that
a single nucleotide polymorphism in the LPS receptor - TLR4 (+896A/G) is a risk factor for
the development of non cardia gastric cancer. More recently we have also demonstrated
that carriage of the TLR9 -1237T/C polymorphism predisposes H. pylori infected subjects
to a severe phenotype characterized by hypochlorhydria and gastric atrophy. Aim: To
evaluate the effect of the TLR9 -1237T/C polymorphism on the risk of developing gastric
carcinoma. Subjects and Methods: We used a 5' nuclease assay to genotype the TLR9
-1237T/C polymorphism in two Western and one Asian gastric cancer case control studies:
Study 1) a population based case control study conducted in Poland, comprising 326 GC
cases and 406 controls, Study 2) a largely Caucasian gastric cancer case control study
conducted in the U.S., consisting of 298 GC cases (120 cardia and 178 non-cardia subsites)
and 210 controls and Study 3) a Japanese gastric cancer case control study comprising 242
gastric cancer cases and 98 controls. Serum antibody to Helicobacter pylori whole cell antigen
was detected by enzyme-linked immunosorbent assay. Odds ratios and 95% confidence
intervals (CI) were calculated and logistic regression was used to adjust for age, race, and
sex. Results: Carriage of the pro-inflammatory TLR9 -1237 C allele in the Caucasian case-
control studies was not associated with an increased risk of developing gastric carcinoma -
Study 1 (OR = 0.9, 95% CI 0.6 - 1.2) and Study 2 (OR = 0.8, 95% CI 0.5 - 1.2). Results
were similar for Study 2 cases subdivided into cardia (OR = 1.1, 95% CI 0.7 - 1.8) and
non cardia gastric cancers (OR 0.6, 95% CI 0.4 - 1.0). Among controls in both studies,
carriers were no more likely to be H. pylori antibody positive (Study 1 OR = 1.2, 95% CI
0.6 - 2.4; Study 2 OR = 1.4, 95% CI 0.7 - 2.7). The TLR9 -1237T/C polymorphism was
not detected in the Japanese population. Conclusion: Although carriage of the TLR9 -1237
C allele is associated with a more pronounced inflammatory response in the gastric mucosa
of H. pylori infected subjects and an increased risk of developing pre-malignant changes, it
does not appear to alter the risk of acquiring H. pylori infection nor of developing the
eventual outcome of gastric cancer. We postulate that this polymorphism is important at
an early stage in the inflammatory response to H. pylori and may facilitate the action of
other mediators in the development of gastric cancer.
S1548
Course of Pangastritis and Serum Markers Pepsinogen I(PepI), Pepsinogen
II(PepII) and Gastrin17 (G17)in First-Degree Relatives (FDR) of Gastric
Cancer Patients, 2 Years After H. pylori Eradication in a Double-Blind
Randomized Placebo Controlled Study
Sadegh Massarrat, Arghavan Hajsheykholeslami, Sm Shahidi, N. Rakhshani, R. Rafiee, K.
Azimi, N. Mohammadi, M. Tavazoee, R. Fakhar, M. Babaei, Sm Tabib, M. Saliminejhad,
H. Nobakht, J. Nasiri, M. Dooghaie moghadam, S. Saeidi, R. Didehvar, N. Zendehdel
Background:gastric cancer(GC) is the commonest cancer in male Iranians.The aim of this
study was to evaluate the impact of H. pylori eradication on course of precancerous lesions&
serum markers PepI,PepII and G17 in FDR of GC patients with different types of gastritis.
Material&Method: FDR of GC patients treated in Tehran hospitals, aged 40-65 years under-
went gastroscopy and histologic examination of gastric mucosa & RUT. Biopsies from 5
sites (2 from Antrum, 2 from corpus & 1 from fornix) were obtained & evaluated according
to modified Sydney classification. The severity of inflammatory cell infiltration, atrophy (AT)
& intestinal metaplasia (IM) was categorized in 4 groups ( normal=1 , mild=2 ,moderate=
3 , marked=4 ) for each biopsy sample.Mean score of AT & IM in 2 antrum biopsies as
change in antrum & 2 corpus biopsies as change in corpus were calculated. Those H. pylori
positive patients, who had antrum predominant pangastritis (APG) or Corpus predominant
pangastritis (CPG), were selected & enrolled randomly & blindly in 2 eradication group&
placebo group. Control endoscopy was performed 2 years later . Biopsies from the same 5
initial sites were obtained & histologically examined. Serum markers PepI,PepII& G17 were
measured in patients sera before & 2 years after treatment.The before & after treatment
scores were compared. Eradication was considered successful when urease test & histology
for H. pylori in all antral biopsies were negative. Results:467 out of 903 with both types of
pangastritis were enrolled into the study. Up to now, 151 of them (91 with APG & 50 with
CPG) have reached the second endoscopy.H. pylori was eradicated in 53 of the patients.The
mean score of AT & IM & serum markers PepI , II & G17 in before & 2years after treatment
sampling in both groups are shown in table 1. normal mucosa in all areas was found 2
years later in 11 patients;6 with initial CPG & 5 with APG. H. pylori was eradicated in 10
of them. Conclusion: the preliminary results show that only atrophy in antrum & corpus
is reversible in both APG & CPG . Both types of gastritis can be reversed to normal mucosa.
Pepsinogen I&II significantly decrease in eradicated subjects, but Pep II is a better marker
for the regression of pangastritis.
Table 1:
S1549
Curcumin Blocks Vegf Synthesis and NF-kB Activation On Prevention of
Gastric Microcirculatory Albumin Leakage in Helicobacter pylori Infected Rats
Duangporn Thong-ngam
Abstract Background: H. pylori infection causes gastric inflammation and peptic ulcers.
Curcumin, a polyphenolic chemical constituent derived from turmeric (Curcuma longa),
has pharmacological activity including anti-inflammatory, anti-cancer, anti-oxidant, and anti-
microbial effects. Aims: To investigate the effects of Curcumin on prevention of gastric
microcirculatory albumin leakage by blocking VEGF synthesis and NF-kB activation in
chronic H. pylori infected rats. Method & Material: Fifteen male Spraque-Dawley rats were
divided into 3 groups: control group, H. pylori infection group, and Curcumin treated group.
The rats were inoculated with H. pylori suspension (108 -1010 CFU/ml) by gavage twice
daily, for three consecutive days. Two weeks after H. pylori inoculation, the animals were
treated with DMSO in group 2 or Curcumin 200 mg/kg in group 3 once daily for 1 week.
H. pylori infected was determined by positive rapid urease test and histopathology. Intravital
fluorescence microscopic technique was performed to examine albumin leakage on stomach
postcapillary venules. VEGF levels were analyzed using ELISA and NF-kB activities using
immunohistochemistry. Results: In H. pylori infection groups, the albumin leakages were
found at 30 min after FITC-Dextran injection, VEGF levels were 619.4±65.1 pg/ml, and
NF-kB activities were 44.2±2.3% those were significantly (p<0.001) increased when com-
pared with the control groups (VEGF 228.6±18.1 pg/ml and NF-kB 28.6±1.3%, respectively).
Treatment with Curcumin could significantly (p<0.05) reduce the albumin leakages, VEGF
(476.6±81.1 pg/ml), and also significantly (p=0.013) reduce NF-kB (34.0±2.2%). Conclu-
sions: Curcumin could prevent gastric microcirculatory albumin leakage by blocking VEGF
synthesis and NF-kB activation in chronic H. pylori infected rats. KEY WORDS: H. pylori,
albumin leakage, VEGF, NK-kB, Curcumin
S1550
IL-23 Enhances IL-17 Production in Helicobacter pylori-Infected Gastric
Mucosa
Roberta Caruso, Daniele Fina, Alessandro O. Paoluzi, Giovanna Del vecchio blanco,
Carmine Stolfi, Massimo C. Fantini, Angelamaria Rizzo, Fabio Andrei, Ilaria Peluso,
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Background & Aim. Helicobacter pylori (Hp) infection causes a chronic inflammation of
the stomach. Locally-produced cytokines are supposed to sustain the Hp-driven gastric
inflammation, and this is in part due to the ability of such molecules to enhance the mucosal
recruitment of inflammatory cells. We previously showed that IL-17 is highly produced in
Hp-infected mucosa where it contributes to enhance the synthesis of the chemoattractant,
IL-8. How IL-17 production is regulated in Hp-infected stomach remains however unknown.
IL-17 is produced by several cell types, including the recently characterized Th17 cell type.
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The factors driving the differentiation of human Th17 cells remain unclear, even though
IL-23 seems to play a key role in expanding/amplifying Th17 cell responses. The aim of
this study was to characterize the expression and the role of IL-23 in Hp-infected gastric
mucosa. Methods. Gastric biopsies taken from Hp-infected and uninfected patients were
analyzed for IL-17, IL-23/p40, and IL-23/p19 RNA content by real time PCR. IL-23 protein
was analysed by ELISA. To examine whether IL-23 controls IL-17 production, lamina propria
mononuclear cells (LPMC) isolated from gastric biopsies of patients with Hp-infection were
treated with a neutralizing IL-23/p19 or control IgG in the presence of anti-CD3, while
LPMC isolated from Hp-uninfected biopsies were treated with rhIL-23 and/or anti-CD3.
After 48 hours culture, IL-17 RNA and protein were analysed by real time PCR and ELISA,
respectively. Results. Expression of IL-17, IL-23/p19, and IL-23/p40 RNA was more pro-
nounced in the Hp-infected biopsies in comparison to Hp-uninfected samples. Consistently,
IL-23 protein levels were higher in Hp-infected biopsies than controls. Treatment of normal
gastric LPMC with rhIL-23 enhanced the synthesis of IL-17, and this effect was evident at
both the RNA and protein level. Additionally, blockade of IL-23 in cultures of LPMC isolated
from Hp-infected biopsies diminished IL-17 production. Conclusions. Data show that IL-
23 is up-regulated in Hp-infected gastric mucosa, where it contributes to enhance IL-
17 production.
S1551
Infiltrating Gastric Macrophages Are Highly Susceptible to Apoptosis and
Exhibit Attenuated Nitric Oxide Production in Helicobacter pylori Infection
Rupesh Chaturvedi, Nuruddeen D. Lewis, Kshipra Singh, Mohammad Asim, Daniel P.
Barry, Holly M. Scott algood, Timothy L. Cover, Keith T. Wilson
Background: Macrophage cell lines activated by H. pylori (Hp) In Vitro produce nitric oxide
(NO), which can kill Hp. However, Hp also induces ornithine decarboxylase (ODC) that
produces spermine, causing macrophage apoptosis and inhibition of iNOS translation. Our
aim was to assess apoptosis and NO generation in macrophages from Hp-infected gastric
mucosa. Methods: C57BL/6 mice were infected with Hp SS1 and assessed between day 1
and 60 post-inoculation (p.i.). Following enzymatic digestion of the glandular stomach and
positive selection of leukocytes with antibody to CD11b, macrophage levels were assessed
by flow cytometry using an antibody to the macrophage marker F4/80. Apoptosis was
measured by staining with annexin V/7-AAD and flow cytometry. For functional studies
macrophages were directly isolated by F4/80 positive selection. The NO metabolite, NO2-,
was assessed by the Griess reaction. mRNA and protein expression was measured by real-
time PCR and flow cytometry, respectively. Results: Inoculation of mice with Hp induced
a rapid influx in macrophages during the first 2 days p.i. (Table), followed by an immediate
decrease in the number of these cells and only partial recovery by day 60. Apoptosis peaked
initially at day 2 p.i., with high levels also at day 60 (Table). While iNOS mRNA increased
7-fold at day 2, there were only 2- and 1.8-fold increases in iNOS protein and NO2- levels,
respectively. Similarly, at day 60 p.i., there was a 4-fold increase in iNOS mRNA, but only
1.5-fold increases in iNOS protein and NO2- levels. At days 2 and 60 p.i., macrophage ODC
levels were increased 5-fold. When cells from chronically infected mice (day 60 p.i.) were
stimulated with Hp ex vivo, there was a 50-fold increase in iNOS mRNA levels, but only
1.1-fold and 1.6-fold increases in iNOS protein and NO2-, respectively. In contrast, macro-
phages from naïve mice lacking ODC expression exhibited 4-fold increases in iNOS protein
and NO2- with ex vivo Hp stimulation. Conclusions: Apoptosis of infiltrating macrophages
results in a net loss of cells in acute Hp infection. In chronic infection, there is also a high
level of apoptosis. iNOS protein expression and NO production are reduced relative to iNOS
mRNA levels in acute and chronic infection, which may be due to high ODC levels. Deficient
NO production and loss of macrophages in the gastric mucosa are likely to contribute to
the survival of Hp in the stomach.
*p < 0.05, **p < 0.01 vs. day 0 (naïve); §p < 0.05, §§p < 0.01 vs. day 2 p.i.
S1552
Toll-Like Receptor-Dependent Activation of Dendritic Cells Affects Adaptive
Immunity to Helicobacter pylori
Roland Rad, Lena Brenner, Roland M. Schmid, Christian Prinz
Background: Recognition of infection leads to the induction of adaptive immunity through
activation of dendritic cells (DCs), which have the unique capacity to capture antigen in
the periphery and deliver it to T cells in secondary lymphoid organs. Methods: We analyzed
the molecular mechanisms of DC activation by H. pylori In Vitro and its consequences In
Vivo. Results: The adaptor protein Myd88 mediates Toll-like receptor (TLR), IL-1 and IL-
18 signalling. Whereas DCs from wild-type, IL-1R-/- and IL-18-/- mice responded to H.
pylori with the secretion of proinflammatory cytokines and the upregulation of MHC-II
and costimulatory molecules, these microbe-induced maturation processes were profoundly
impaired in Myd88-/- DCs, demonstrating that TLR-dependent H. pylori-sensing mediates
DC activation. Analysis of the microbe-specific DC-transcriptome revealed that a large part
of the H. pylori-induced transcriptional changes depended on Myd88-signalling, comprising
large sets of genes involved in crucial steps of immune regulation, such as dendritic cell
maturation/differentiation, antigen uptake/presentation, effector cell recruitment and T cell
activation. The impaired ability of Myd88-deficient DCs to mount a proinflammatory gene
expression profile in response to H. pylori In Vitro was reflected In Vivo by reduced gastric
inflammation and increased bacterial colonisation. Furthermore, H. pylori infected Myd88-
deficient mice showed reduced Helicobacter-specific IgG2c/IgG1 ratios compared to wild-
type mice, suggesting that TLR-mediated H. pylori-sensing instructs polarisation of adaptive
immunity toward a Th1 phenotype. Conclusion: The principal pathway by which DCs sense
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H. pylori and become activated is the TLR-dependent signalling cascade. In Vivo, TLR-
mediated recognition of infection affects adaptive immunity to the microbe.
S1553
Targeted PCR Confirmation of Vaccine Components Conserved Between
Human and Mouse-Adapted Strains of H. pylori
Leonard Moise, Daniel Rivera, Julie Mcmurry, Woojin Kim, Dong-soo Lee, Jacques Pappo,
Emilia M. Sordillo, Steven F. Moss, William Martin, Annie Degroot
Background: Despite considerable effort, an effective Helicobacter pylori vaccine remains
elusive. Advances in predictive in silico modeling and epitope-based vaccination afford novel
approaches to H. pylori vaccine development. Our aim is to develop a T-cell epitope-based,
therapeutic vaccine against H. pylori and to first demonstrate its efficacy in a mouse model
of H. pylori disease. Because the strains of H. pylori that infect humans do not generally
infect mice, and the sequence of the mouse-adapted “Sydney” SS1 strain is not publicly
available, we therefore used targeted PCR to confirm that the putative epitopes we selected
from human H. pyloriisolates (J99 and 26695) were conserved in the mouse-adapted (SS1)
H. pylori strain. Methods: J99 and 26695 open reading frames (ORFs) were aligned and
compared. Putative T-cell epitopes were identified by computational analysis from highly
conserved ORFs using an epitope mapping algorithm (EpiMatrix). Clustered epitopes con-
taining multiple HLA-binding motifs and bearing low human sequence homology were
identified. PCR was performed using primers designed to anneal to J99 epitope sequences,
in order to identify comparable regions in SS1. Results: Of 1,491 ORFs in the J99 genome,
1,107 were conserved in 26695 (95% identity on average). The EpiMatrix algorithm selected
1,152 sequences from these ORFs that were predicted to be highly immunogenic. Of these,
150 epitope clusters, with no more than 25.9% human homology, were selected as vaccine
candidates. The selected epitope clusters originate from 130 distinct ORFs, of which 128
(98%) are novel antigens. PCR products equivalent in size to those of the epitope clusters
from J99 were detected for 136 (91%) of these epitope clusters in the SS1 genome. Conclu-
sion: This study illustrates the use of targeted PCR analysis to rapidly select epitope clusters
conserved across mouse and human H. pylori strains in a high-throughput manner. Confirma-
tion and selection of these T-cell epitopes identifies novel vaccine candidates for multi-
epitope vaccine development.
S1554
Serum Titer of Anti-Helicobacter pylori Caga Hot Spot Correlates with the
Grade of Histological Gastritis in Japanese Patients
Shunsuke Takata, Masanori Ito, Tsuyoshi Kuroda, Shosuke Kitamura, Akemi Takamura,
Masana Tatsugami, Yoshihiro Wada, Shinobu Imagawa, Yoshiaki Matsumoto, Hiroshi
Masuda, Xue fei Xie, Shinji Tanaka, Masaharu Yoshihara, Ken Haruma, Kazuaki Chayama
Background and Aim: Helicobacter pylori(H. pylori) causes chronic inflammation that is
frequently associated with atrophic gastritis, peptic ulcer disease, and gastric carcinomas.
CagA(+) H. pylori strains are more virulent than cagA(-) strains and are associated with
gastric carcinoma. The translocated CagA undergoes tyrosine phosphorylation in the host
cells and induces hummingbird phenotype. Recent reports clarified that tyrosine phosphoryl-
ation of Glu-Pro-Ile-Tyr-Ala (EPIYA) motif in CagA plays critical role in the morphological
transformation of cells, and that East Asian CagA have stronger toxicity than Western CagA.
We synthesized an oligopeptide (CEPIY(P)ATIDF; CagA-P) designed from East Asian CagA-
specific EPIYA-D site (Higashi et al. Proc Natl Acad Sci, 2002) as an antigen and examined
the titer of anti-CagA-P antibody by ELISA in Japanese patients. Further we investigated
the relationship between its titer and clinical status of patients. Method: Fasting sera were
collected from 132 patients with dyspesia (80 men, 112 H. pylori positive). Status of H.
pylori infection was evaluated by anti-H. pylori antibody titer (E-plate, Eiken, Japan). Diluted
sera (1:200) were subjected to ELISA, in which we used CagA-P oligopeptide as an antigen.
In 90 patients withH. pylori infection (64 Men; mean age, 65.0y.o.), we underwent endoscopic
examination and took five biopsy specimens. Histological gastritis was evaluated by the
updated Sydney System. We subclassified all patients into two groups (CagA-P positive and
negative) by the serum titer determined by our ELISA system. We examined that relationship
between the serum titer of anti-CagA-P antibody and degrees of histological gastritis between
two groups. Results: The titers of anti-CagA-P antibodies in sera of H. pylori (+) patients
were significantly higher than those of H. pylori (-) patients (p<0.05). There was no correlation
between titers of anti-H. pylori and anti-CagA-P antibodies. When we set a cut-off for the
maximum titer in H. pylori (-) patients, 60.7% of H. pylori (+) patients showed high titers
of anti-CagA-P antibodies. Of 90 patients with H. pylori infection, 61 cases were classified
as CagA-P positive by ELISA test. In the gastric corpus, the level of mononuclear cell
infiltration was significantly higher CagA-P positive cases compared to that in CagA-P negative
cases (P<0.05). Conclusions: CagA-P is an antigen-peptide against the host and there is a
relationship between the titer of anti-CagA-P antibody and histological findings of gastritis.
Using our ELISA system, it may be possible to quantitatively evaluate tyrosine phosphoryl-
ation of the CagA protein.
S1555
Use of Recombinant Aphc As a Potential Vaccine Against Helicobacter pylori
Infection
Avril A. O'riordan, Linda Mulligan, Veronica Athie-morales, Henry J. Windle, Dermot P.
Kelleher
Helicobacter pylori (H. pylori) is a Gram-negative spiral bacterium infecting human gastric
mucosa with worldwide prevalence. It affects 30-50% of the population in developed coun-
tries and 50-90% in developing countries. It is the most important etiological agent of
chronic active gastritis, peptic ulcer disease and has also been associated with the development
of gastric carcinogenesis. The infection can be cleared by antibiotic therapy. However, with
the emergence of antibiotic resistant strains of the pathogen, it is well recognized that
vaccines must be developed against this organism. AphC is an alkyl hydroperoxide reductase
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from H. pylori. Previous work in our laboratory demonstrated that H. pylori-negative indi-
viduals had evidence of anti-AphC and anti-NapA antibodies and stronger T cell responses
to these proteins as compared to H. pylori-infected patients. NapA is an efficacious therapeutic
and prophylactic vaccine against H. pylori in animal models. The aim of this project is to
evaluate the efficacy of recombinant AphC for use as a therapeutic vaccine to protect against
H. pylori infection in the C57BL6J mouse model. To enhance immunogenicity, an adjuvant,
Alum, was employed. Animals were vaccinated prior to challenge with H. pylori SS1 strain
and sacrificed after 4 weeks. The results demonstrate viable count colonisation levels in
stomachs of mice vaccinated with AphC alone were reduced by 2.3 fold (3.1 x106 cfu/g
vs. 7.3 x106 cfu/g, p=0.05) with respect to controls. Adjuvanted vaccine resulted in significant
colonisation reduction of 3.3 fold (2.4 x106 cfu/g vs. 8.1 x106 cfu/g, p=0.015) with respect
to controls. Correlation with these results was seen by histologic analysis. The group average
histologic colonisation score was 0.2 ± 0.12 AphC alone vs. 0.6 ± 0.21 Control and 0.2 ±
0.12 Alum/AphC vs. 1 ± 0.28 Alum. Serum IgG titres to the vaccine alone were in the range
of 1:50,000 following boost and in the range of 1:200,000 following boost when vaccinated
with AphC/Alum adjuvant. This successful immune response may have contributed in
reducing the numbers of bacteria in the stomach. We would conclude that AphC when
used with Alum adjuvant may be an effective therapeutic and prophylactic vaccine against
H. pylori in animal models.
S1556
Attenuated Salmonella Typhimurium Encoding the Hpaa Antigen of
Helicobacter pylori Elicit a Th1 and Th2 Immune Response
Carolina Serrano, Marco Olmos, Elsa Bruce, Patricio Martinez, Javiera Torres, Alejandro
Venegas, Paul R. Harris
Background: The development of a vaccine for Helicobacter pylori is a key strategy for reducing
the worldwide prevalence of the infection. Although immunization with recombinant H.
pylori antigens (i.e., urease, ureB) has yielded promising results, most of these studies relied
on the use of the adjuvant cholera toxin, precluding its use in humans. Thus, the development
of new vaccine strategies for H. pylori is essential. Aim: To evaluate the ability of a novel
HpaA Salmonella typhimurium vaccine to induce a mucosal immune response in mice.
Methods: HpaA gene was amplified by PCR and ligated into a pET27b expression vector
containing an auto-transporter domain. The plasmid vector was modified by inserting a
kanamycin resistance gene to obtain a lethal-balanced vector. This plasmid construction was
electroporated into Salmonella typhimurium χ4550/pGP1-2 vaccine strain. BALB/c mice were
immunized (3 doses of 1x107cfu over 6 days) with the experimental vaccine (HpaA, n=4),
pET strain (vaccine without HpaA gene, n=6) or medium alone (PBS, n=9). A similar booster
dose was applied 7 weeks later. Then, vaccinated mice were challenged with H. pylori strain
SS1 (CagA-/VacA+ phenotype) (1x107 cfu) at week 11. Seven weeks after challenge, mice
were sacrificed and the mucosal immune responses (TNF-α, IL-1β, IL-4, IL-10, IFN-γ, IL-
12) were measured by immunoassays in homogenized gastric tissue. HpaA IgG was measured
at baseline and at sacrifice. Results: After H. pylori challenge, HpaA-vaccinated mice had
higher levels of serum IgG anti-H. pylori HpaA (52.7+/-9.2 AU/ml) compared to pET-
vaccinated mice (30.7+/-18.6 AU/ml (p<0.05) and PBS control mice (23.5+/-8.7 AU/ml)
(p<0.01). Gastric tissue from HpaA-vaccinated mice had higher levels of IFN-γ and TNF-
α than PBS control mice (p<0.05). In addition, gastric tissue from pET-immunized mice
had higher levels of IL-4, IL-10, IFN-γ than PBS control mice (p<0.05). However, gastric
tissue from HpaA-vaccinated pET-immunized mice had similar cytokine levels. Conclusions:
HpaA vaccination of mice induced highly protective anti-H. pylori HpaA antibody levels,
and H. pylori challenge boosted seroconversion but not local cytokine production. Mice
exhibited a mucosal cytokine (Th1 and Th2) response to an attenuated S. typhimurium
vaccine vector that did not increase with the addition of the H. pylori gene HpaA to the
vaccine. Funded by FONDEF DO2I-1067 (Chile) and FONDECYT 1030894 (Chile).
S1557
The Effects of Interleukin (IL)-13 On NF-kB-Related Cytokine Profile and Cell
Viability in “In Vitro” Model
Brunella Marotti, Patrizia De colibus, Germana De nucci, Debora Compare, Giovanni
Autiero, Alba Rocco, Gerardo Nardone
Helicobacter pylori (H. pylori)-related immune response may play a key role in the outcome
of infection. Indeed, the immunoregulatory and proinflammatory cytokine profile may influ-
ence the nature of the local T-cell response. Furthermore, recently, it has been reported a
shift from an IFN-gamma mediated Th1 response to IL-4/IL13 mediated Th2 response
in metaplastic and neoplastic areas. It has been demonstrated that IL-13 possesses anti-
inflammatory and anti-apoptotic properties, even if the mechanisms underling these actions
are yet unclear. Finally, mounting evidences suggest that IL-13 may regulate NF-kB, an
important factor implicated in the immuno regulation of inflammatory response. The aim
of this study was to evaluate the effects of IL-13 on NF-kB-related cytokine profile and cell
viability in gastric cancer cell lines. Gastric cancer epithelial cell lines (AGS low differentiated,
MKN28 well differentiated), preincubated for 24 h with 10 ng/ml of IL-13, were stimulated
with TNF-alfa, LPS and broth culture filtrates by different H. pylori strains VacA+/CagA+,
VacA-/CagA-, VacA-/CagA+, VacA+/CagA-. The activation of NF-kB was evaluated by Electro-
phoretic Mobility Shift Assay (EMSA). The effects on NF-kB related cytokine profile (IL-10,
IL-6 and IL-8) and cell viability were analyzed by RT-PCR and the MTT Cell Proliferation
Assay, respectively. In AGS and MKN28 cell lines, pre-treated with IL-13, a decrease of NF-
kB induced by TNF-alfa, LPS and H. pylori filtrates was observed. In MKN28 cell lines we
found that IL-13 also affected NF-kB-dependent gene transcription i.e. decrease of IL-6, IL-
8 mRNA and an increase of IL-10 mRNA. Furthermore, cell lines pre-treated with IL-13
were preserved from apoptosis. In conclusion, our study showes that IL-13 induces a
modulation of NF-kB-related cytokine profile and an increase of cell viability.
S1558
Role of Akap (a Kinase Anchoring Protein) in Phosphorylation of PLC-β3 and
Inhibition of PLC-β3 Activity By cAMP-Dependent Protein Kinase in Smooth
Muscle
Karnam S. Murthy, Sunila Mahavadi, Wimolpak Sriwai
Stimulation of IP3 formation by contractile agonists is dependent on activation of phospholi-
pase C-β1 (PLC-β1) via Gαq or PLC-β3 via Gβγi. Cyclic AMP- and cGMP-dependent protein
kinase (PKA and PKG) inhibit PLC-β3 activity via direct phosphorylation of the enzyme,
and PLC-β1 activity via stimulatory phosphorylation of RGS4 (Regulator of G protein
Signaling), leading to rapid inactivation of Gαq-GTP. Aim. To determine the role of AKAP
in phosphorylation of PLC-β3 and inhibition of its activity by PKA and PKG in smooth
muscle cells. Methods. PLC-β3 activity stimulated by Gi3-coupled adenosine A1 receptors
was measured in cells labeled with [3H]myo-inositol. Phosphorylation of PLC-β3 was meas-
ured using phospho-specific (Ser1105) antibody, and in cells labeled with 32P. The role of
PKA anchoring protein AKAP was examined using the cell-permeable AKAP-PKA competing
peptide Ht-31. The association of AKAP with PLC-β3 and protein phosphatase 2B (PP2B)
was determined by immunoprecipitation. Results. Activators of PKA (cBIMPS) and PKG
(8-pCPT-cGMP) induced phosphorylation of PLC-β3 but not PLC-β1, and inhibited PI
hydrolysis stimulated by the A1 receptor agonist, cyclopentyl adenosine (CPA). Treatment
of dispersed muscle cells with Ht-31 blocked PLC-β3 phosphorylation and reversed the
inhibition mediated by PKA, but not by PKG, suggesting that association of PKA with AKAP
is necessary for PKA-mediated phosphorylation of PLC-β3 and inhibition of PI hydrolysis
mediated via Gβγi. Immunoprecipitation studies demonstrated that AKAP79 was associated
with the regulatory subunit of PKA, PLC-β3, and the Ca2+/calmodulin-dependent protein
phosphatase PP2B. Treatment with Ht-31 disrupted the association of AKAP with PKA, but
not that with PLC-β3 or PP2B. The association of PKA, PLC-β3 and PP2B with AKAP79
suggests that AKAP79 acts as scaffolding protein, and raises the possibility that AKAP
anchors PKA and PP2B close to the PLC-β3 isoform to facilitate its phosphorylation and
dephosphorylation. In support to this notion, blockade of PP2B activity by the PP2B inhibitor
(calcineurin) or the calmodulin antagonist (calmidazolium) significantly increased PLC-β3
phosphorylation induced by PKA and PKG. Conclusion. The PKA-anchoring protein
AKAP79 anchors PLC-β3 and PP2B. PLC-β3 phosphorylation and inhibition of PI hydrolysis
by PKA, but not by PKG require the association of PKA with AKAP79. The association of
PP2B within the same complex provides a mechanism for rapid dephosphorylation of PLC-
β3, and restoration of its activity.
S1559
High Serum Bile Acids Cause Hyperthyroidism and Goiter in Duodenal
Contents Reflux Model
Ken-ichi Mukaisho, Yoshio Araki, Hiroyuki Sugihara, Chen Kuan hao, Takanori Hattori
Background/aims: Watanabe et al. recently reported (Nature, 2006) that BAs play a role in
the regulation of thyroid hormone signaling and energy homeostasis; BAs bind to TGR5
and regulate the expression of type 2 iodothyronine deiodinase (D2), which convert less
active thyroxine (T4) into active 3'5'3'-tri-iodothyronine (T3). They also reported that BAs
may selectively increase T3 levels in tissues where T3 promotes energy expenditure, and
thereby enables us to make a therapeutic approach for fighting obesity. On the other hand,
in the duodenal contents reflux model of rats, we noted an elevation of serum bile acid and
swelling of the thyroid gland. This study was designed to elucidate whether bile acids
(BAs) also enhance thyroid function. Methods: In varying lengths of period after esophago-
jejunostomy without gastrectomy, which causes duodenal content reflux, rats were sacrificed
after scaling of body weight, and blood samples were taken from the heart for analyses of
BAs and triiodothyronine (T3), thyroxine (T4), free T3 (fT3), free T4 (fT4) and thyroid
stimulating hormone (TSH) in the serum. The histological features of thyroid samples were
examined. The thyroid body weight ratio was also calculated as a relative thyroid weight.
Results: Macroscopically, at 10 and 30 weeks after operation, thyroid glands in the reflux
model showed a symmetric enlargement because of the presence of diffuse hypertrophy of
thyroid follicular epithelium. At 10 weeks after operation, the animals with the reflux showed
significantly lower serum TSH levels and greater thyroid weight than those in the control.
An inverse correlation between serum BAs and TSH levels was noted in the reflux model
but not in the control. At both 10 and 30 weeks after operation, the absolute and relative
thyroid weights were greater in the reflux model than in the control (unpaired t-test, p<0.05).
And, microscopically, thyroid follicles were greater in size and number with paler colloid
in the reflux model than the control. Conclusions: High serum BAs cause hyperplasia of
thyroid follicles and reduction of TSH. In the duodenal contents reflux model, passive
absorption of BAs occurs from gastric mucosa and esophageal mucosa in rats (we have
succeeded in detecting BAs in esophageal tissues by high-performance liquid chromato-
graphy). Probably, the resultant continuously elevated levels of BAs activate the thyroid
gland as well as skeletal tissues with a receptor for BAs (probably TGR5). The effects of BAs
on thyroid hormones thus include induction of overall hyperthyroidism. Therefore, strict
monitoring of serum TSH levels is of vital importance if BAs are used for the treatment
of obesity.
S1560
Protein Tyrosine Phosphatase 1b Governs Differential Epidermal Growth
Factor Receptor Phosphorylation and Signaling Induced By EGFR Vs. GPCR
Ligands
Declan F. Mccole, Michael Bunz, Kim E. Barrett
Background/Aims: We have previously shown that the G protein-coupled receptor (GPCR)
agonist, carbachol (CCh), activates the EGFr via release of the EGFr ligand, transforming
growth factor-α (TGF-α), and limits the extent of CCh-induced epithelial chloride secretion
by activating extracellular signal-regulated kinase (ERK) but not phosphatidylinositol 3-
kinase (PI3-K). In contrast, inhibition of chloride secretion by EGF involves PI3-K. CCh
also induces a different pattern of EGFr tyrosine phosphorylation than native ligands do
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and this appears to reflect protein tyrosine phosphatase (PTP) activity. In the presence, but
not the absence of PTP inhibitors, CCh induced phosphorylation of EGFr residues Y992 or
Y1068 that serve as binding sites for SH2 domains and the adaptor molecule, Grb2, respect-
ively, and also phosphorylated AKT1, a downstream target of PI3-K activation. However,
the identity of the specific phosphatase(s) targeted by these inhibitors in this system was
unknown. The aim of this study was thus to determine whether a major EGFr regulatory
phosphatase, PTP-1B, accounts for divergent recruitment of signals that mediate inhibition
of chloride secretion by EGF vs. CCh. Methods: All experiments were conducted with T84
colonic epithelial cells grown on permeable supports. Protein phosphorylation was deter-
mined by Western blotting. Small interfering RNA (siRNA) transfection was performed using
the Amaxa nucleofector system. Results: We have previously shown that treatment of T84
monolayers with CCh (100 μM) does not cause phosphorylation of the EGFr residues Y992
and Y1068. Since PTP-1B has been shown to play a key role in dephosphorylating EGFr
tyrosine residues, including Y992 and Y1068, following EGF stimulation, we investigated if
siRNA-mediated knockdown of PTP-1B would alter CCh-induced EGFr activation. PTP-1B
expression was maximally reduced by 87 ± 6 % (n=4) in T84 cells. siRNA knockdown of
PTP-1B significantly facilitated CCh-induced phosphorylation of EGFr residues Y992 (3.2 ±
0.6 fold increase; p<0.05, n=4), and Y1068 (11 ± 7 fold increase; p<0.01, n=4) vs. CCh-
treated control siRNA transfected cells. Moreover, CCh-induced AKT1 phosphorylation was
also significantly increased in PTP-1B deficient cells (3.6 ± 1.8 fold; p<0.05; n=3). Conclu-
sions: EGF and CCh induce different EGFr tyrosine phosphorylation patterns and thereby
recruit different downstream signals to regulate epithelial chloride secretion. These differences
are likely due, at least in part, to dephosphorylation of EGFr tyrosines by PTP-1B as
pharmacological and molecular inhibition of PTP-1B permits CCh to mimic the effects of
EGF on EGFr signaling events.
S1561
Inhibition of Mlc20 Phosphorylation Downstream of Ca2+ and RHOA: A Novel
Mechanism Involving Phosphorylation of RHoa-INteracting PRotein (P116RIP)
By PKA and PKG and Stimulation of Mlc Phosphatase Activity
Sunila Mahavadi, Wenhui Hu, Karnam S. Murthy
Contraction of smooth muscle consists of a transient Ca2+-dependent phase mediated by
Ca2+/calmodulin-dependent activation of MLC kinase and phosphorylation of MLC20, and
a sustained Ca2+-independent phase mediated by inhibition of MLC phosphatase and stimula-
tion of MLC20 phosphorylation via RhoA-dependent pathways. Relaxation of contracted
smooth muscle is mediated by cAMP- or cGMP-dependent protein kinase (PKA or PKG).
We have previously shown that PKA and PKG act on several targets in the cascades to
reduce intracellular Ca2+ and/or augment MLC phosphatase activity via phosphorylation of
RhoA at Ser188. It is also possible that PKA and PKG act downstream of Ca2+ and RhoA
to stimulate MLC phosphatase activity and dephosphorylate MLC20. Recent studies have
identified a novel protein p116Rip that associates with MYPT1, the regulatory subunit of
MLC phosphatase. MYPT1 binds to, and targets the catalytic subunit of MLC phosphatase
to MLC20. Phosphorylation of p116Rip by c-Src augmented p116Rip association with MYPT1
and enhanced MLC phosphatase activity. Aim. To determine whether PKA and PKG phos-
phorylate p116Rip and enhance its association with MYPT1, and whether the association
enhances MLC phosphatase activity and MLC20 dephosphorylation. Methods. Studies were
done in freshly dispersed muscle cells, and in cultured muscle cells expressing PKA/PKG
phosphorylation site-deficient RhoA(S188A). p116Rip phosphorylation was measured in cells
labeled with 32P. MLC20 phosphorylation was measured using phospho-specific (Ser19)
antibody and association of p116Rip with MYPT1 was determined by immunoprecipitation.
Results. Activators of PKA (cBIMPS) or PKG (8-pCPT-cGMP) induced phosphorylation of
p116Rip; The phosphorylation was accompanied by an increase in the association of p116Rip
with MYPT1. In permeabilized muscle cells, both PKA and PKG activators decreased MLC20
phosphorylation and contraction induced by a fixed concentration of Ca2+, implying the
existence of a mechanism that does not involve inhibition of intracellular Ca2+ mobilization.
In cells expressing RhoA(S188A), PKA and PKG had no effect on acetylcholine-induced
RhoA or Rho kinase activities, but significantly decreased sustained MLC20 phosphorylation
suggesting the existence of inhibitory mechanism(s) downstream of RhoA. The results implied
that PKA and PKG enhance the association of p116Rip and MYPT1, and augment MLC20
phosphatase activity and MLC20 dephosphorylation downstream of Ca2+- or RhoA-dependent
pathways. Conclusion. Phosphorylation of p116Rip by PKA and PKG increases association of
p116Rip with MYPT1 and enhances MLC phosphatase activity and MLC20 dephosphorylation.
S1562
Deleterious Effects of Leptin On Intestinal Epithelial Permeability
Laurent Ferrier, Pierre De coppet, Helene Eutamene, Aurelie Rouaud, Gilles Chaumaz,
Christian Bonnet, Lionel Bueno, Jean Fioramonti, Philippe Valet, Vassilia Theodorou,
Jean-pierre Segain
Background & Aims. Increased intestinal permeability is observed in patients with inflam-
matory bowel diseases (IBD). Intestinal inflammation is also associated with the development
of mesenteric adipose tissue surrounding the gut. However, the cross-talk between this
adipose tissue and the intestinal epithelial barrier has been poorly characterized. Con-
sequently, the aim of this study was to investigate whether an adipokine, leptin could affect
the paracellular permeability of intestinal epithelial cells (IEC) In Vivo and In Vitro. Methods.
After an overnight fast, individually housed Wistar rats (225-250g) received intra-peritoneal
administration of leptin (50 µg) or its vehicle. Then, animals were given 0.7 µCi of 51Cr-
EDTA by gavage, and urine was collected for 6 hours. Gut paracellular permeability (GPP)
was calculated as the percentage of radioactivity recovered in urine. In Vitro, HT29 IEC
lines were cultured on permeable Transwell membranes for 15 days to obtain differentiated
confluent monolayers. At this time (T0h), leptin (0, 1, 10 and 100 ng/mL), or IL-6 as a
positive control (0, 1, 10 and 50 ng/mL), were added to the basal compartment of the
Transwell. The transepithelial resistance (TER) was measured at T0h, T3h and T6h with a
voltohm-meter and expressed as the mean variation (ΔOhm.cm-2) from the initial value
observed at T0h. In addition, the expression of mRNA encoding the leptin receptor (ObR)
was investigated by RT-PCR in differentiated HT29 cells. Results. In control animals, GPP
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was 0.7±0.3 % (n=8). Leptin administration significantly increased GPP over a 6-hour period
(1.6±0.3 %, P<0.05, n=8). ObR was expressed in HT29 cells. Similarly to IL-6, leptin
decreased the TER of HT29 monolayers in a time- and dose-dependent manner (2-way
ANOVA, P<0.05). Leptin was active from 1 ng/mL, and its maximal effect was achieved at
10 ng/mL and maintained over the 3-6h period (-85±7 Ohm.cm-2, P<0.05, n=5). Conclu-
sions. The present data show for the first time, that an adipokine, leptin, increases gut
paracellular permeability In Vivo in rats, and In Vitro in differentiated human epithelial cell
lines. This effect is likely directly mediated through ObR activation in IEC. These results
point out a putative new role for adipose tissue-derived mediators in IBD pathophysiology.
S1563
Enhancement of Intestinal Epithelial Cell Barrier Function By Sphingosine-1-
Phosphate
Jose Greenspon, Jaladanki N. Rao, Ruiyun Li, Eric D. Strauch, Bernard S. Marasa, Jian-
ying Wang, Douglas Turner
Introduction: The intestinal epithelial cell layer acts as a semipermeable barrier and is
essential for its protective and absorptive qualities. Loss of barrier integrity however, is
implicated in a vast array of pathologic conditions such as ischemia and sepsis. Evidence
implicates disruption of junctional paracellular proteins as the primary pathway by which
these conditions affect permeability. An increasing body of evidence has shown that sphingos-
ine-1-phophate (S1P) is an important protective mediator of vascular and pulmonary barrier
function, and that its protective effects are mediated by alterations of the paracellular protein
levels. Moreover, the intestinal epithelium has been found to express several of the receptors
by which S1P has mediated its protective response in other tissues and the intestinal mucosa
is abundant with S1P. However, the role of S1P in the regulation of intestinal epithelial
barrier function is unknown. This study tested the hypothesis that S1P regulates intestinal
mucosal barrier function by altering paracellular protein expression. Methods: Differentiated
intestinal epithelial cells (IEC-Cdx2L1 line) were exposed to S1P at varied concentrations
(0.5 to 50 μM) for 1 to 24 hours. Western blot analysis, real-time PCR, paracellular permeabil-
ity assays using 14C-labeled mannitol, and intracellular Ca2+ concentration ([Ca2+]i) using
digital fura-2 imaging were performed. Results: [Ca2+]i was increased by ~three-fold when
IEC-Cdx2L1 cells were exposed to S1P at the concentration of 0.5 μM with a gradual
increase, peaking at ~90 seconds. Real-time PCR analysis and Western blotting revealed that
protein levels of occludin as well as E-cadherin mRNA and protein were significantly increased
after treatment with S1P at the same concentration. Exposure to S1P [0.5 μM] also improved
epithelial barrier function as indicated by a decrease in paracellular permeability (~23%).
Additionally, treatment with LPS [50 mg/mL] for 18 hours decreased levels of E-cadherin
and thus increased paracellular permeability, both of which were prevented by co-incubation
with S1P. Conclusions: These results indicate that S1P promotes intestinal epithelial barrier
function by modulation of adherens and tight junction as a result of increased [Ca2+]i.
S1564
Role of Exogenous and Endogenous Lipoxins (LX) in Gastroprotection and
Gastric Adaptation to Aspirin. Involvement of Nitric Oxide (NO)
Tomasz Brzozowski, Peter C. Konturek, Robert Pajdo, Slawomir Kwiecien, Michal Pawlik,
Aneta Targosz, Grzegorz Burnat, Stanislaw J. Konturek, Wieslaw W. Pawlik
LX and recently identified COX-2 derived “aspirin-triggered lipoxin LXA4” (ATL) are unique
lipid mediators with a potent antiinflammatory properties. ALT were shown to enhance the
resistance of the gastric mucosa to damage induced by aspirin (ASA) and to contribute to
ASA-induced gastric adaptation to but the involvement of NO in the mechanism of LX-
induced protective actions in the stomach has been little studied. This study was designed
to determine the effect of exogenous administration of LXA4 against the formation of ASA-
induced gastric damage (125 mg/kg in 0.1 N HCl applied i.g. once) and in gastric adaptation
to acidified ASA (100 mg/kg-d) given p.o. for 5 days without or with concurrent daily
treatment with 1) NOS inhibitor, L-NNA (20 mg/kg i.p.), 2) a selective COX-1 (SC-560; 5
mg/kg i.g.) and COX-2 inhibitors (rofecoxib; 10 mg/kg i.g.), and 3) a potent 5-lipoxygenase
inhibitors, baicalein (20 mg/kg i.p.) and AA-861 (5 mg/kg i.p.). Area of gastric lesions was
determined by planimetry, the gastric blood flow (GBF) was measured by H2-gas clearance
method, mucosal ALT levels (ELISA) and malondialdehyde (MDA) concentration as an index
of lipid peroxidation were assessed and expression of mRNA for cNOS, iNOS, COX-1 and
COX-2, in the gastric mucosa was analyzed by RT-PCR. Single exposure to ASA produced
gastric lesions and decreased GBF while significantly raising mucosal ATL and MDA contents.
Pretreatment with LXA4 (0.1-20 μg/kg i.g.) dose-dependently reduced the area of ASA lesions
and significantly raised the GBF; The dose of LXA4 inhibiting lesion area by 50% (ID50)
being 7 μg/kg. These protective and hyperemic effects of LXA4 was completely abolished
by L-NNA. COX-2, cNOS and iNOS mRNAs were strongly upregulated in ASA-treated
gastric mucosa with or without LXA4 while COX-1 mRNA remained unchanged. After 5
repeated exposures to ASA, the lesion area was reduced by 85%, and an increase in the
GBF and a further rise in mucosal ATL levels and a signifcant fall in mucosal contents of
MDA from from the initial values (at day 0) were observed. These effects were significantly
attenuated by the concomitant treatment with baicalein, AA-861, L-NNA and rofecoxib but
not significantly influenced by SC-560. The strong signals for COX-2-, cNOS- and iNOS
mRNAs expression were detected ASA-adapted gastric mucosa. We conclude that: 1) LXA4
attenuates ASA-induced gastric lesions via an increase in the GBF mediated by NO derived
from cNOS and iNOS expression and activity; 2) COX-2 derived ATL induced by ASA are
involved in the mechanism of gastric adaptation to this NSAID, possibly due to activation
of NO-NOS system and inhibition of lipid peroxidation.
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S1565
Up-Regulation of Rgs4 and Down-Regulation of Cpi-17 in Rabbit Colonic
Smooth Muscle from TNBS-Induced Colitis Mediate the Decrease in Muscle
Contractility
Wenhui Hu, Fang Li, Jiean Huang, Sunila Mahavadi, Karnam S. Murthy
The contractility of smooth muscle in inflammatory bowel disease and experimental colitis
is reduced due to inhibition of neurotransmitter release and a decrease in the response of
smooth muscle to contractile agonists. The mechanism of the latter has not been fully
elucidated. Several cytokines, including IL-1β and TNFα are elevated in mucosa and smooth
muscle during experimental colitis. We have recently shown that exposure of circular colonic
muscle strips, and freshly isolated or cultured colonic muscle cells to IL-1β alters the
expression of specific targets in the signaling pathways that mediate initial (RGS4) and
sustained (CPI-17) contraction. The increase in RGS4 expression accelerates inactivation of
Gαq, whereas the decrease in the expression of the endogenous phosphatase inhibitor, CPI-
17, maintains MLC phosphatase activity, reducing sustained MLC20 phosphorylation and
contraction. Signaling targets proximal to RGS4 or CPI-17 (receptors, G proteins, PLC-β,
RhoA, Rho kinase) were not affected. Aim. To determine whether the changes in RGS4 and
CPI-17 expression also occur In Vivo in colonic smooth muscle from rabbit colitis induced
by TNBS (trinitrobenzene sulfonic acid). Methods. TNBS (150 mg in 1 ml of 50% ethanol)
was instilled into the colon of rabbits ~15 centimeters from the anus. As a control, the same
volume of 50% ethanol was instilled. The animals were euthanized on day 5 (the time of
maximal inflammation) and a 5-cm segment of inflamed distal colon was removed. Circular
muscle strips were dissected for Western blot and real-time RT-PCR analysis; contraction
was measured by scanning micrometry in cells isolated from the muscle strips. Results.
Initial (30 sec) and sustained (5 min) contraction in response to acetylcholine in muscle
cells isolated from colonic muscle strips derived from rabbit with TNBS colitis was signific-
antly inhibited (50% and 44%, respectively) compared with the response of cells derived
from untreated colon or colon treated with ethanol. Expression of RGS4 mRNA in muscle
strips from TNBS colitis was increased to 5-fold, whereas expression of CPI-17 mRNA was
decreased by 74%. Similarly, expression of RGS4 protein as determined by Western blot
was increased to 3-fold, whereas CPI-17 protein was decreased by 79%. There was no
significant change in RGS4 or CPI-17 expression in colonic muscle strips derived from
colon treated with ethanol. Conclusion. RGS4 expression is up-regulated whereas CPI-17
expression is down-regulated in colonic circular smooth muscle from TNBS colitis. The
changes in expression are accompanied by corresponding decreases in initial and sus-
tained contraction.
S1566
Expression of PDGF and Their Receptors in Rat Cholangiocytes and Bile Duct
Fibroblasts: Effects of LPS
Tae hyun Kim, Rahul P. Kuver, Christopher E. Savard, Sum P. Lee
PDGF is a potent mitogen and chemoattractant for fibroblasts at sites of tissue injury in
various tissues. The role of PDGF in promoting fibrosis around proliferating bile ducts in
chronic hepato-biliary diseases is not clear. We investigated the expression of PDGF and
its receptors by normal rat cholangiocytes (NRC) and bile duct fibroblasts before and after
treatment with lipopolysaccharide (LPS). Methods: Rat NRC and bile duct fibroblasts were
isolated and cultured. Cells in serum-free media were treated with E. coli LPS for 24 or 48
hrs. PDGF-A, B, and PDGF-Receptor α and β (PDGF-Rα and PDGF-Rβ) mRNA levels were
measured by relative quantitative real-time PCR. We measured PDGF-AA, AB and BB protein
levels by ELISA; and PDGF-C, PDGF-Rα and PDGF-Rβ protein levels by western blot.
Results: LPS treatment was associated with small (1.5-2.5-fold) increases in PDGF-A, B,
and C mRNA levels in NRC and fibroblasts. PDGF-Rα and PDGF-Rβ mRNA was only
expressed in fibroblasts, and LPS increased mRNA of these receptors up to 4-fold in those
cells. LPS increased PDGF-AA production in NRC significantly from 123.4 ± 5.2 to 171.2
± 12 pg/µl (p<0.01), but an increase in fibroblasts from 554.3 ± 111.1 to 649.7 ± 83 pg/
µl was not statistically significant (p>0.05). PDGF-BB and AB were detected in both cell
lysates, but not in their media. PDGF-BB and AB were significantly increased only in NRC
cell lysates treated by LPS, but not in fibroblast cell lysates. LPS induced up-regulation of
fibroblast PDGF-C and PDGF-Rα, but did not alter PDGF-Rβ expression levels.Conclusions:
Our data demonstrate, for the first time that NRC and bile duct fibroblasts produce PDGF-
AA, BB, and AB, and these may act on PDGF-R expressed in fibroblasts. LPS enhances
fibroblast PDGF-C and PDGF-Rα levels, but not levels of PDGF-Rβ. PDGF secreted by NRC
thus may promote the proliferation and activation of fibroblasts, thereby facilitating the
formation of collagen found in peribiliary fibrosis.
S1567
Modulation of Adherent Junction Complexes By CRF Receptor Type 2 (CRF2)
Activation: A Good Or Bad Mediator of Stress in Inflammatory Bowel
Diseases?
Monica Pampillonia, Michèle Lainé, Christiane Oddou, Nadine Cristina, Sonia Pellissier,
Frédéric Canini, Muriel Jacquier-sarlin, Bruno Bonaz
Recent data suggest that stressful life events participate in the development or relapse of
inflammatory bowel diseases (IBD). Activation of corticotrophin-releasing factor (CRF) or
urocortin (Ucn) signalling pathways plays a key role in the body's response to stress. CRF
receptors are expressed in the gastrointestinal tract and considered to participate in the
intestinal inflammatory responses but underlying mechanisms remain unclear. Aim: To
determine the signalling pathways through which stress and the subsequent production of
CRF peptides modulate expression and function of adherent junction proteins and regulate
the intestinal epithelial barrier function, a key step in intestinal inflammatory response.
Methods: HT-29 cells exposed or not to inflammatory mediators (H202) or neuropeptides
(UcnII, CRF and CRF2) were used for morphological, biochemical and confocal microscopy
analyses (In Vitro model). Similar experiments were performed in epithelial cells collected
from control rats or rats with dextran sulfate sodium (DSS)-induced colitis (In Vivo model).
Results: While HT-29 cells express membranous variants of CRF2 (40 to 50kDa) we also
detected a soluble variant in the cytosol (18-20kDa). An advanced characterization of these
variants is under investigation by PCR approaches. Furthermore, the expression of the 40
kDa variant was up regulated by both oxidative stress (H2O2) and CRF2 ligands such as
CRF2 and UcnII. The ligand-mediated activation of CRF2 induced a dose dependant increase
of total E-cadherin expression. However, E-cadherin molecules were not expressed at the
cell membrane but rather found in cytoplasmic vesicles, a process associated with a decrease
in cell-cell contacts and an increase in cell permeability. Studies on the In Vivo model also
showed an increase in the expression of the 40 kDa variant of CRF2 and E-cadherin in
epithelial cells collected from distal colon compared to proximal colon of most DSS-treated
rats. Discussion: This work indicates that inflammatory mediators up regulate the expression
of CRF2. Its activation by specific ligands such as UcnII and CRF2 modulates E-cadherin
expression and alters E-cadherin-mediated cell adhesion. It thus appeared that, on one hand,
the local release of CRF after stress may trigger as well exacerbate an inflammatory response
by disrupting epithelial barrier thus contributing to the pathophysiology of IBD. On the
other hand, changes in E-cadherin mediated adhesion are essential for cell migration, a
process occurring during the reparative mechanism of epithelial restitution.
S1568
Loss of SSTR2 Expression By Thymocytes Increases Natural T Regulatory Cell
Development Offsetting An Otherwise Pro-Inflammatory Bias in SSTR2-
Deficient Mice
Ahmed Metwali, Sarah Winkler, Arthur Blum, Khurram Qadir, David E. Elliott
Somatostatin (SST) is a 14aa peptide that suppresses inflammation. Macrophages make SST
which directly inhibits T cell IFNγ secretion. SST also is made by epithelial and dendritic
cells in the thymic medulla. T cells (including thymocytes) express SSTR2, one of five known
SST receptors. T cells from SSTR2-deficient mice do not express any SST receptors. SSTR2
-/- C57BL/6 mice develop normally and do not spontaneously develop aberrant inflammation
though they are more susceptible to TNBS colitis than wild type (WT) C57BL/6 mice.
Thymus from SSTR2 -/- mice express twice as much SST mRNA (p=0.003), four times as
much SST peptide (p=0.004), and have five times more SST-positive cells (p=0.015) than
WT mice. Thymus from SSTR2 -/- mice contain normal numbers of T cells with normal
CD4/CD8 ratio. Expression of most activation markers is normal but CD4+CD25+ cells are
increased in SSTR2 -/- (3.7 + 0.4%) compared to WT (2.8 + 0.2%, p=0.05) mice. Foxp3
is a transcription factor expressed by regulatory T cells. Thymocytes from SSTR2 -/- mice
express 2.9 fold more FoxP3 mRNA (p=0.04) than WT. To determine if natural T regulatory
cell function in SSTR2 -/- mice helped to offset loss of SST-mediated regulation, we transferred
splenic CD25-depleted CD4+T cells from either WT or SSTR2 -/- mice into Rag -/- mice.
Rag mice that received CD25-depleted T cells from SSTR2 -/- mice developed much more
severe colitis (3.9 + 0.06, measured on a 4 point scale) compared to mice that received
equal numbers of CD25-depleted T cells from WT (2.85 + 0.21, p<0.001) mice. Mesenteric
lymph node cells from SSTR2 -/- RAG-reconstituted mice spontaneously produced more
IL17 (0.23 + 0.08 ng) than MLN cells from WT RAG-reconstituted mice (0.06 + 0.03 ng,
p<0.05). Conclusions: Loss of thymic T cell SSTR2 expression increases natural T regulatory
cells. Removal of these regulatory cells uncovers a greater inflammatory capacity in T cells
that lack SSTR2. Grant Support: AI49382, VAMC.
S1569
Aberrant Responses to TLR (Toll-Like-Receptor) Agonists and Common
Luminal Antigens (Ags) in Patients with Inflammatory Bowel Diseases (IBD);
Difference Between Crohn's Disease (CD) and Ulcerative Colitis (UC)
Harumi Jyonouchi, Iona M. Monteiro, Lee Geng, Agnes Cushing-ruby
IBD are generally regarded as autoimmune diseases triggered by aberrant inflammatory
responses to benign luminal antigens (Ags). Evidence indicates that TNF-α and IL-17 play
major roles in gut inflammation associated with IBD. The gut mucosal immune responses
are initially triggered by innate immunity sensing bacterial byproducts via pattern recognition
receptors such as toll like receptors (TLRs) and nucleotide oligomerization domain (Nod)
proteins. The mutation of the ligand binding domain of Nod2 is frequently associated with
CD in Caucasians. However, the prevalence of this Nod2 mutation is less marked in other
ethnicities. TLR responses are also implicated with the disease development of IBD. This
study assessed responses to common luminal Ags and stimulants of innate immunity (TLR
agonists) in our IBD patients, most of them are African Americans and Hispanics. In this
study, we examined 15 IBD patients (CD; N=8 median 10.8 yr, UC; N=7, median 14.1 yr)
all of whom were not taking systemic corticosteroids for at least 4 weeks prior to sample
obtainment. Controls include healthy children (N=11, median 6.5 yr) and children with
non-IgE mediated food allergy (NFA; N=9, median 5.1 yr). Responses to luminal Ags [dietary
proteins (DPs; cow's milk, soy, and gliadin) and microbial Ag (candida)] were assessed by
measuring production of cytokines (IFN-γ, IL-1β,L-5, TNF-α, IL-10, IL-12, and IL-17) by
peripheral blood mononuclear cells (PBMCs). We also assessed responses to TLR 2/3/4
agonists by measuring production of inflammatory (TNF-α, IL-1, IL-6, and IL-12) and
counter-regulatory (IL-10 and sTNFRII) cytokines by PBMCs. PBMCs from CD patients
produced higher amounts of TNF-α, IL-1β, IL-6, and IL-10 with a TLR4 agonist (LPS) and
sTNFRII and IL-10 with TLR2 agonist (zymosan) than cells from healthy controls (p<0.05).
PBMCs from NFA children produced higher amounts of TNF-α and IL-12 with DPs than
controls consistent to our previous results. In contrast, CD children revealed higher produc-
tion of IFN-γ (p<0.05) and IL-17 (p<0.02) by PBMCs against candida Ag than healthy
controls without significant reactivity to DPs. UC patients revealed equivalent responses to
luminal Ags and TLR agonists as did healthy controls. Neither IL-17 production with control
polyclonal T cell stimulants nor TLR 3 responses differed among the study groups. Our
results thus indicate the presence of aberrant responses to TLR2/4 agonists and luminal Ags
in CD but not in UC patients in our IBD study subjects. Increase in IL-17 production against
luminal Ag may also indicate pathological importance of Th-17 cells in CD patients.
A-223 AGA Abstracts
S1570
TGF-Alpha Mediates Autocrine EGF Receptor Trans-Activation Following
TNF-Alpha Stimulation in Human Intestinal Epithelial Cells
Humberto Jijon, S. Mokashi, Andre G. Buret, M. Hollenberg, H. Parsons, Paul L. Beck
Background: Tumor Necrosis Factor-alpha (TNF-α) is a key inflammatory mediator in the
pathogenesis of Inflammatory Bowel Diseases. In addition to its proinflammatory effects on
intestinal epithelial cells (IECs), TNF-α has also been shown to stimulate IEC proliferation
and migration. We have previously demonstrated that TNF-α activates multiple mitogen
activated protein kinase (MAPK) cascades in intestinal epithelial cells. As the EGFR is a
potent activator of MAPKs, we hypothesized that the EGFR may participate in TNF-dependent
MAPK activation leading to epithelial restitution. Aims: In this study we examined the
possible interaction between the TNF and EGFR's in HT-29 cells. Methods and Results:
Immunoprecipitation of the EGFR and subsequent immunoblotting revealed that the EGF
receptor is phosphorylated on tyrosine following a 15 minute treatment of intestinal epithelial
cells (HT-29) with 10 ng/ml TNF-α. This event is dependent on the intrinsic kinase activity
of the EGFR as tyrosine phosphorylation of the EGFR was blocked by the EGFR kinase
inhibitor AG1478 (200nM-1μM) but not by the platelet-derived growth factor (PDGF)
receptor kinase inhibitor AG1298 (10 μM). Autophosphorylation of the EGFR was also
inhibited by both the Src-kinase inhibitor PP2 (10 μM), suggesting a role for a Src-family
kinase in EGFR phosphorylation. In addition, EGFR autophosphorylation was inhibited by
the matrix metalloproteinase (MMP) inhibitor BB94 (10 μM) and the TNF-α-converting
enzyme-specific inhibitor (TACE) TAPI-1 (1 μM). Interestingly, immunoneutralization of
TGF-α also abrogated EGFR autophosphorylation. Conclusions: These results suggest that
activation of the TNF receptor leads to the activation of a Src-related kinase, leading to the
activation of TACE, leading to the release of membrane bound TGF-α. TGF-α is then free
to activate the EGFR tyrosine kinase in a manner similar to what has been described for G
protein-coupled receptor-mediated transactivation of the EGFR. These results reveal a previ-
ously unrecognized interaction between the TNF receptor and the EGFR in IECs and suggest
that the latter may act to relay signals emanating from TNF receptors.
S1571
Prokineticin-1 Receptor Mediates Intestinal Secretory and Contractile Activity
Paul R. Wade, John R. Mabus, Jeffrey M. Palmer, Stephen M. Prouty, Paul R. Saunders,
Sandra L. Mckenney, Kristen M. Chevalier, Pamela J. Hornby
Background: Prokineticin-1 (PK1) is a novel peptide acting via a G-protein coupled receptor
(Gpr73; PK1R) that has contractile effects in guinea pig ileum. Our initial studies on the
effects of exogenous PK1 in rats revealed that it evoked an accumulation of fluid in the
intestine and enhanced propulsive motility. Aim: Thus, the aim of this study was to test
the hypothesis that PK1 is pro-secretory and modulates intestinal epithelial ion transport
either directly or via activation of intrinsic secretomotor reflex pathways; additional aims
were to determine the effects of PK1 on intestinal contractility and motility, and to localize
PK1R and its gene expression. Methods: Effects of PK1 on transit and fluid accumulation
were studied in rats In Vivo; Ussing-type flux chambers were used to measure short-circuit
current (Isc) in ileal tissues; A myobath apparatus was used to measure contraction in
segments of ileum; RT-PCR was used to determine PK1R expression and fluorescence
microscopy was used to determine its immunohistochemical localization. Results: Human
recombinant PK1 (hPK1; 100 μg/kg, p.o.) stimulated fluid accumulation in the small intestine
(340 ± 90% of vehicle-treated controls at 30 min) and in separate studies accelerated transit
of a carmine marker (11.6 ± 4.1% at 30 min, P<0.05 vs controls). Serosal application of
hPK1 stimulated a concentration-dependent (EC50 = 8 nM) secretory response (Isc = 47.6
± 3.5 μA/cm2) that was inhibited by >90% in the presence of bumetanide (500 µM) or in
Cl--free buffer, and was inhibited by piroxicam (10 µM), but not tetrodotoxin (Ttx). Pretreat-
ment with a prostaglandin (PG) EP4 receptor antagonist, AH23848 (30 µM), or a cyclooxy-
genase-1 inhibitor, FR122047 (10 µM), reduced the hPK1 response (70% and 50% of
control, respectively). hPK1 evoked concentration-dependent, biphasic contractions of ileum
consisting of early and late (EC50=87.8 and 72.4 nM) components. The early, but not the
late contraction was Ttx- and atropine-sensitive and the late contraction was inhibited by
80% when the mucosa and submucosal plexus were removed. Levels of PK1R (normalized
to Gapd) mRNA were 6-7 fold higher in ileum than in gastric fundus, pylorus, or duodenum
and 2-fold higher than in jejunum; with equivalent expression in ileal mucosa as in muscularis
externa. PK1R-immunoreactivity was observed in ileal submucosal and myenteric neurons.
Conclusions: We demonstrate for the first time that PK1 is a potent intestinal secretogogue
acting via PG EP4 receptors on enterocytes; moreover, PK1 increases contractility and
enhances propulsive motility via neuronal and non-neuronal pathways in the rat small bowel.
S1572
Evidence for the Involvement of Sur1-Type KATP Channels in the Glucose-
Responsive Mechanism Modulating Peristalsis in the Mouse Proximal Colon
Bishwa R. Tuladhar, Abdelrazzag A. El-majdoub, Robert J. Naylor
INTRODUCTION: SUR1-type KATP channels have been shown to be present in both glucose-
responsive enteric neurons (Liu et al., 1999, J NeuroSci, 19, 10305-10317) and interstitial
cells of Cajal (Nakayama et al., 2005, J Cell Sci, 118, 4163-4173) and are implicated in
glucose evoked responses in the gut. The aim of this study was to investigate the effect of
glucose removal and the role of SUR1-type KATP channels on peristalsis in the mouse isolated
colon. METHODS: Segments of the proximal colon (3 cm in length and next to the caecum)
were obtained from BKW mice (38-42 g), cannulated at the oral and anal ends and secured
horizontally in water-jacketed baths containing Krebs solution at 37°C and gassed with 95%
O2 and 5% CO2. A regular peristalsis was achieved with an intraluminal pressure of 3-6
cm of water. Peristalsis was recorded and measured as described previously (Tuladhar &
Naylor, 2002, Gastroenterol, 122 T1077 Suppl). All drugs were added to the serosal side
and concentration-response curves to diazoxide were constructed by cumulative addition
of diazoxide at 6-8 minute intervals once regular peristalsis was obtained. To examine the
effect of glucose removal, the Krebs solution containing 11.1mM glucose was replaced with
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the solution containing mannitol at the same concentration and the effect on peristalsis was
recorded for a 20 min period. RESULTS: Replacement of glucose with mannitol resulted in
inhibition of peristalsis, with peristalsis becoming highly irregular, in all control tissues (n=
6) but no such effect was observed in any of the tissues in the presence of 3 µM glibenclamide
(n=6). The KATP channel opener diazoxide (10-100 μM) did not alter the tone of the
tissues but inhibited peristalsis in a concentration-dependent manner with a pEC50 value
of 4.84±0.16 (N=7) and abolished peristalsis in all tissues by 100 μM. Glibenclamide had
no significant effect on the diazoxide concentration-response curve at 0.01 μM (pEC50 value
4.48±0.18, N=6, P>0.05) but produced a significant antagonism of the diazoxide responses
at 0.1 μM (pEC50 value 3.98±0.11, N=6, P<0.01) and 1 μM (pEC50 value 3.73±0.08, N=
8, P<0.001). CONCLUSIONS: The inhibition of peristalsis observed on removal of glucose
indicates that there is a glucose-responsive mechanism modulating peristalsis in the mouse
colon. This glucose-responsive mechanism is likely to involve SUR1-type KATP channels as
glibenclamide, at a low concentration, antagonised both the effects of glucose removal and
diazoxide on peristalsis. The findings may provide a link between gastrointestinal motility
and metabolic diseases.
S1573
Involvement of 5-Ht2a Receptors in Motor and Inflammatory Disorders
Induced By Mesenteric Ischemia Reperfusion in Mice
Fiore Cattaruzza, Paola Ghizzardi, Simona Bertoni, Vigilio Ballabeni, Mariannina
Impicciatore, Catia Sternini, Elisabetta Barocelli
Background and Aims: In physiological conditions, 5-HT released from enterochromaffin
cells in response to mechanical or chemical stimuli initiates peristaltic and secretory reflexes
participating in visceral sensation and intestinal blood flow modulation. Following mesenteric
ischemia/reperfusion (I/R), large amount of 5-HT is detected in the intestinal lumen and
plasma. Discrepant findings suggest that 5-HT either aggravates or prevents intestinal I/R
damage. Hence, the aim of the study was to investigate the effects of blockade of different
5-HT receptors on gastrointestinal transit (GIT) delay and inflammation caused by mesenteric
I/R in mice. Methods: Mesenteric ischemia (45 min), induced by occlusion of the superior
mesenteric artery, was followed by 24 hrs reperfusion in mice. Sham operated (SO) animals
served as controls. 5-HT2A receptor antagonist, ketanserin (0.5 mg/kg i.v.), 5-HT3 receptor
antagonist, ondansetron (0.2 mg/kg i.v.) or 5-HT1A receptor antagonist/partial agonist buspi-
rone (10 mg/kg i.v.) was administered before and 8 hrs after ischemia in I/R or in SO mice.
GIT was measured by charcoal gavage and expressed as % of the distance travelled by the
charcoal in the small bowel. Leukocytes infiltration, as index of tissue inflammation, was
evaluated by measuring myeloperoxidase activity (MPO) of jejunal tissue and expressed as
mU/mg tissue. Vascular permeability was assessed by measuring Evans Blue dye extravasation
into the intestinal tissue and expressed as mcg EB/100 mg tissue. Results: Among the 5-HT
antagonists tested, only ketanserin significantly reduced the prolongation of GIT in I/R mice
(58±4% vs. vehicle I/R 40±3%; P<0.01) at a dose that did not modify GIT in SO. The
increase of MPO activity induced by I/R was prevented by the administration of ketanserin
(0.95±0.52 vs. vehicle I/R 3.04±0.79 mU/mg; P<0.05) but not by ondansetron or buspirone
(1.42±0.47 and 3.05±0.78, respectively vs. vehicle I/R 3.04±0.79 mU/mg). The blockade
of 5-HT2A receptors also prevented the enhancement of Evans Blue extravasation caused
by I/R in the intestinal tissue (10.84±1.52 vs. vehicle I/R 34.41±9.09 mcgEB/100mg; P<0.01).
Conclusions: This study supports the hypothesis that 5-HT2A receptor stimulation by
endogenous 5-HT contributes to the motor, vascular and inflammatory responses induced
by mesenteric I/R. Supported by PRIN (MIUR2004) grants
S1574
Corticotropin-Releasing Factor (CRF) Is Expressed in Sheep and Rat Duodenal
Enterochromaffin Cells and CRF Receptor Type 2 and Its Ligand Increase
Intracellular Calcium in Hbon Cells
Lauraine Rivier, Helen Raybould
CRF, localized to the central nervous system, mediates the body's response to stress. However,
CRF, CRF receptor type 1 (CRF1R) and type 2 (CRF2R) and other endogenous ligands
(urocortin 1, UCN1) have also been localized to the GI tract and regulate function. Enteroch-
romaffin cells (EC) in the colon have been shown to produce and secrete 5-HT and CRF.
The aim of the present study was to determine (1) localization of CRF, and its receptors to
EC cells in the small intestine and (2) the functional response of EC cells to activation of
CRF1R and CRF2R, using hBON cells (model for EC cells). Methods: Immunohistochemistry
for CRF, 5-HT, and the CRF ligand, UCN1, was performed on sheep and rat duodenum.
Changes in intracellular calcium [Ca++]i were measured using FURA-2 in hBON cells in
response to CRF (CRF1R and CRF2R ligand), 5-HT, 2-Me-5-HT (agonist for 5-HT3R),
ML10302 (agonist for 5-HT4R), UCN1 (CRF1R and CRF2R ligand), UCN2 and 3 (CRF2R
specific ligands). Results: CRF and 5-HT colocalized in sheep and rat duodenum and hBON
cells. hBON cells were also immunopositive for UCN1, 5-HT3R, and CRF2R. Ligands for
the CRF2R and 5-HT3R significantly (P<0.01) increased [Ca++]i ; CRF 500 nM (0.636 ±
0.098 ), 5-HT 100µM (0.445 ± 0.056), 2-Me-5-HT 9.8 µM (0.495 ± 0.074), UCN1 484
nM (0.344 ± 0.030), UCN2 545 nM (0.346 ± 0.039), UCN3 500 nM (0.331 ± 0.070) (data
expressed as mean ± SEM increase in [Ca++]i as bound/unbound ratio; n = 4-23). The
CRF1R/CRF2R antagonist, Astressin (AB, 8.5 µM), and CRFR2 antagonist, Astressin2B (A2B,
9 µM) significantly (P<0.01) reduced the changes in [Ca++]i induced by CRF (AB:81%
reduction, A2B:74%), UCN1 (AB:69%, A2B:84%), and UCN2 (AB:98%, A2B:87%). Ondan-
setron (>100 µM), a 5-HT3R antagonist, significantly (P<0.05) reduced the 2-Me-5-HT
response (49%), but not that of 5-HT. 5-HT3R blockade had no effect on the response to
CRF; similarly CRF2R blockade had no significant effect on response to 5-HT or 2-Me-5-
HT. A 5-HT4R agonist (ML10302, 50-100 µM) and antagonist (LY-278,584, 100 uM) had
no effect on the response to 5-HT or 2-Me-5-HT. Removal of extracellular Ca++ significantly
(P<0.05) attenuated the CRF-mediated responses (61% reduction), but not that of 5-HT
(47%), or 2-Me-5-HT (30%). BAPTA-AM, an intracellular Ca++ chelator, significantly
(P<0.01) reduced the response of CRF (81%), 5-HT (73%), and 2-Me-5-HT (78%). Conclu-
sions: In hBON cells, activation of CRF2R and 5-HT3R increases [Ca++]i . The colocalization
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of CRF and 5-HT in EC cells suggests the possibility that activation of EC cells may produce
changes in GI function via paracrine or autocrine pathways.
S1575
Localisation of Pre-Synaptic Cholinergic Muscarinic Receptor Subytpe 2 (M2r)
in the Guinea Pig Enteric Nervous System
Andrea M. Harrington, John M. Hutson, Bridget R. Southwell
Purpose: The cholinergic muscarinic 2 receptor (M2r) is one of four subytpes of muscarinic
receptors that mediate acetylcholine activity in the enteric nervous system (ENS). Localisation
studies describe abundant M2rs and M3rs, on smooth muscle cells across a range of species.
Pharmacological studies also suggest that M2rs regulate acetylcholine release from cholinergic
nerves in guinea pig colon. This study localised M2rs in the guinea pig ileum using fluores-
cence immunohistochemistry. Double labelling using antibodies for neurochemical markers
was used to determine the type of nerve fibers bearing M2r. Methods: Segments of guinea
pig ileum (n = 3) were fixed, prepared for sections and wholemounts and incubated with
antisera against the rat M2r sequence, followed by a fluorescent secondary antibody. Tissue
was double labelled using antibodies to nitric oxide synthase (NOS), common choline
acetyltransferase (cChAT), substance P (SP), synaptophysin and vesicular acetylcholine trans-
porter (VAChT). Immunoflourescence was viewed using confocal microscopy Results: In
guinea pig ileum, abundant M2r-IR was present on the surface of circular and longitudinal
smooth muscle cells. M2r-IR was also present on nerve fibres in the circular muscle and
myenteric and submucosal ganglia. M2r-IR was present in many but not all nerve fibres.
M2r-IR was present in VAChT-IR and cChAT-IR cholinergic nerve fibres and SP-IR nerve
fibres in the myenteric ganglia. M2r-IR was also present on a small number of nerve fibres
that contained NOS-IR in the myenteric ganglia, with M2r-IR present on NOS-IR nerve
fibres around cell bodies that are not NOS-IR. M2r-IR (NOS negative) varicosities were also
present around NOS-IR nerve cell bodies. Conclusions: M2rs are not only present on muscle
cells in the intestine, but also on nerve fibres. Therefore M2rs mediate muscle reflexes
directly via their presence on muscle and also via neural transmission. These finding support
pharmacological studies that suggest M2rs act presynaptically to mediate neurotransmitter
release from nerve fibres onto nerve cell bodies and muscle. The presence of M2rs on VAChT
and NOS containing nerve fibres and around cChAT-IR and NOS-IR cell bodies suggests
M2rs regulate the release of acetylcholine and nitric oxide onto nerve cell bodies.
S1576
Induction of Gastrin/Cholecystokinin Receptor (CCK2R) Expression in
Response to Cellular Stress In Vitro and In Vivo
Louise Ashurst, Andrea Varro, Rod Dimaline
Background. Important physiological roles of CCK2R include regulation of gastric acid
secretion, and maintenance of normal proliferation and migration within gastric epithelium.
Recent evidence suggests increased CCK2R expression following mucosal injury or inflamma-
tion e.g. in Barrett's Oesophagus, in response to radiation-induced intestinal damage, or in
experimentally induced gastric cryo-ulcers. However, little is known about mechanisms that
regulate CCK2R expression. We used In Vivo and In Vitro models to study CCK2R expression
during cellular stress, and tissue injury and regeneration. Methods. We measured CCK2R
transcription in the gastric cell lines AGS, AR42J and RGM1 using reporter constructs
containing 0.1 to 5kb of the human CCK2R promoter. Endogenous CCK2R mRNA was
measured by real time PCR. Ulcers were generated in mouse gastric corpus mucosa using
cryoprobes, and CCK2R expression visualized by immunohistochemistry (IHC). Results.
Deletion analysis showed that the proximal 196bp of the CCK2R promoter sustained basal
expression in the gastric epithelial cell lines AGS and RGM1. Expression was reduced by
>70% in promoter constructs shorter than -196bp, and was dependent upon the integrity
of SP1, GATA and C/EBP binding sites. When AR42J cells that endogenously express the
CCK2R were serum starved for 24h, CCK2R mRNA abundance increased 3.5-fold (Control
100±7.5%, Serum Free(SF) 358±10.5%, n=4, p<0.001, t-test). Moreover AR42J cells trans-
fected with a 1.7kb promoter-reporter construct had increased luciferase expression on
serum starvation (Control 100±2.6%, SF 220%±13.9, n=3, p<0.01). Serum withdrawal from
RGM1 cells that express low levels of CCK2R, also increased CCK2R mRNA abundance
(2.7-fold) and receptor protein expression determined by immunocytochemistry was also
increased. In mice with single cryo-ulcers (~2mm diameter) in gastric corpus mucosa IHC
revealed a time dependent increase in CCK2R expression in regenerating mucosa at the ulcer
crater margins that was maximal after 9 days. In addition, there was novel expression of
the receptor on sub-mucosal cells and cells within the smooth muscle layers beneath the
healing ulcer crater, noticeable at day 6 and maximal at day 9. Expression of CCK2R in
these layers was not seen in undamaged stomach, or within 2 days of ulceration, and was
confined to the region close to the ulcer crater. Conclusions Data from both In Vitro and
In Vivo models suggest that the CCK2R may play a role in cellular responses to stress and
the mucosal response to injury. Expression of the receptor within the sub-mucosal and
smooth muscle layers may be important in the later stages of the repair process.
S1577
IFNγ Activates Stat Signaling in Gastrin-Producing Cells
Tamara Tucker, Juanita L. Merchant
Background: The hormone gastrin is a growth factor for the gastric mucosa and is the
primary hormonal regulator of acid secretion. In Vivo, gastrin expression and secretion are
regulated by fasting, feeding, and changes in gastric pH.Helicobacter pylori (H. pylori) infection
causes gastritis, hypergastrinemia, and subsequently increased acid production. H. pylori
infection initiates a Th1 inflammatory response and IFNγ is one of the major cytokines
produced. We have previously shown that IFNγ infusion into mice for 7 days induces
gastritis, hypergastrinemia, and increased gastrin mRNA levels. Although these results suggest
a significant effect of IFNγ on the gastrin-producing G cell, whether the effect is direct is
not known. Therefore, we set out to test whether IFNγ signaling directly stimulates gastrin
gene expression in a homogeneous cell line. Methods: The human gastric cell line, AGS,
was cultured in serum free media for 24-48 hrs prior to treatment with 100ng/ml of human
IFNγ. Gastrin mRNA was measured by quantitative PCR. Immunofluorescent staining and
western blot analysis were used to quantify the levels of IFNγ receptor (IFNγR) and Stat1
proteins. Results: Immunostaining for the IFNγRα chain was punctate and predominantly
within the cytoplasm of both untreated and IFNγ treated AGS cells. In addition, there
appeared to be an increase in staining in the IFNγ-treated cells. We confirmed that IFNγ
stimulated an increase in the levels of IFNγRα and IFNγRβ chains by immunoblot. We
tested whether IFNγ treatment activated Jak-Stat signaling pathways in AGS cells. Indeed
we observed an increase in Stat1 phosphorylation as early as 5 min and nuclear localization
of phosphorylated Stat1 30 min after treatment with IFNγ. Increased levels of gastrin mRNA
were seen in AGS cells 3 hrs after IFNγ treatment. Through in silico mapping, we have
identified a consensus IFN-γ-activating sequence (GAS), which is known to bind Stat1 at
-402bp in the proximal gastrin promoter. Conclusion: We have shown that IFNγ activates
Stat1 and increases gastrin mRNA levels in AGS cells. The presence of a GAS element within
the gastrin promoter supports a direct role for a Th1 inflammatory cytokine in the induction
of gastrin gene expression.
S1578
Interactions of Cubilin with Megalin and the Product of Amnionless Gene
(AMN) - Effect On Its Stability
Rajiv Ahuja, Raghunatha R. Yammani, Seema Kalra, Bellur Seetharam
Background: Cubilin is a 460 kDa multidomain, multiple purpose receptor expressed in
ileal and renal epithelial cells. It functions in the uptake of cobalamin (Vitamin B12) bound
to gastric intrinsic-factor in the intestine and in tubular reabsorption of many structurally
distinct ligands (albumin, transferrin, lipids, and other vitamin binding proteins) in the
kidney. Cubilin functions with two accessory proteins, one, AMN, a 50 kDa cystein rich
protein and two, megalin, a large endocytic receptor implicated in Hyman nephritis. The
purpose of this study was to identify the interactive regions of cubilin that bind to megalin
and to examine whether all three proteins interact with each other in native membranes.
Methods: Various cubilin fragments covering the entire molecule were generated by RT-
PCR, translated In Vitro, and allowed to bind to megalin-Sepharose matrix. The radioactivity
bound in the presence of Ca++ or EDTA was evaluated by SDS-PAGE. Cubilin, megalin
and AMN protein levels were determined by immunoblotting (IB) using their respective
antiserum in total and apical brush border membranes isolated from normal and megalin
antibody producing rabbits and in opossum kidney (OK) cells following silencing of the
AMN gene by small interfering RNA technique. Pulse-chase labeling of OK cells was carried
out to determine half-life of cubilin in AMN or megalin silenced cells. Results: In Vitro,
binding to megalin occurred with 100 residue N-terminus and CUB domains 12-17 and
22-27 of cubilin. Functional inactivation of megalin by its antibody in rabbits producing
high titer antiserum to rat megalin resulted in drastic reduction of cubilin and AMN protein
levels in both total and apical BBM of the kidney and intestine. Cubilin and megalin
could be detected by IB using immunoprecipitated material obtained using rat kidney total
membrane extracts and antibodies to AMN or megalin and cubilin or AMN, respectively.
Silencing of AMN gene by siRNA technique resulted in reduction of both cubilin and megalin
protein levels. Furthermore, half-life of cubilin was appreciably decreased in both AMN and
megalin gene silenced cells. Conclusions: i) megalin interacts with specific regions of cubilin
In Vitro ii) in native membranes, megalin and cubilin also interact with AMN, iii) mutual
interactions of cubilin with both AMN and megalin are required for its intracellular stability.
S1579
Induction of P21 WAF1/CIP1 Via the Ep4 Receptor Mediates the Regulation of
Cell Cycle Progression By Cyclooxygenase-2 in Colorectal Cancer
Glen A. Doherty, Sinead M. Byrne, Eamonn S. Molloy, Clare M. Cox, Noelle M. Griffin,
Sandra C. Austin, Elaine W. Kay, Frank E. Murray, Desmond J. Fitzgerald
BACKGROUND/AIMS - Cyclooxygenase-2 (COX-2) expression is elevated in colorectal
cancer (CRC) and is associated with poor survival for reasons which are not well characterised.
Prostaglandin E2 (PGE2) is the major end product of COX-2 activity in colorectal cancer
cells, signalling through a number of subtypes of cell surface receptors (EP 1-4). We assessed
the mechanisms by which COX-2 activity leading to PGE2 generation might regulate cell
cycle progression. RESULTS - EP4 was the most abundant subtype of PGE2 receptor in HT-
29 and HCA7 cells; colorectal cancer cell lines which show COX-2 dependent generation
of PGE2. The expression pattern in human cancer was similar. All four EP receptor subtypes
were detectable by quantitative RT-PCR on template from human colorectal cancers (n=10).
The EP4 receptor was consistently the most abundant transcript in these samples (ANOVA,
p=0.01). HT-29 colon cancer cells produced PGE2 in a COX-2 dependent manner. An
accumulation of cells in G0/G1 phase of the cell cycle was observed in HT-29 cells treated
with SC-236 5μM (selective COX-2 inhibitor) for 24 hours (p=0.02). The effects of the
COX-2 inhibitor were abrogated by co-incubation with PGE2 (1μM). G0/G1 arrest was also
seen with a specific antagonist of the EP4 receptor (EP4A, L-161982) (p=0.01). Treatment
of HT-29 cells with either SC-236 or EP4A caused an early reduction in intracellular cAMP
(ANOVA, p=0.01) as detected by enzyme immunoassay. The ability of selective inhibition
of the EP4 receptor to modulate changes in the expression of cell cycle genes (Cyclin D1,
the cyclin dependent kinases CDK4 and CDK6 and CDK inhibitors p21 WAF1/CIP1 and
p27 KIP1) was evaluated by qRT-PCR. A dramatic induction in p21 WAF1/CIP1 expression
was seen after 4 hours with treatment with EP4A (mean fold increase 4.4, p=0.04) while
the expression of the other cell cycle regulation genes remained unchanged. A similar early
induction in p21 WAF1/CIP1 was also seen with PD153025 (1μM), an EGFR tyrosine kinase
inhibitor, suggesting EGFR transactivation via the EP4 receptor as a potential mechanism.
CONCLUSION - COX-2 regulates cell cycle transition in HT-29 colorectal cancer cells via
signalling through the EP4 receptor; The most abundant PGE2 receptor in colorectal tumours.
The observed cell cycle arrest is associated with early induction in expression of p21 WAF1/
CIP1 suggesting that this is the likely mechanism. Specific targeting of the EP4 receptor or
downstream targets may offer a safer alternative to COX-2 inhibition in the prevention and
treatment of CRC.
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Deoxycholyltaurine (DCT)-Induced Survival and Proliferation of Human Colon
Cancer Cells Is Regulated By Activation and Nuclear Translocation of Nf-κB
Jasleen Shant, Kunrong Cheng, Jean-pierre Raufman
Fecal bile acids are implicated in the progression of colon cancer. DCT, a conjugated
secondary bile acid, stimulates proliferation of human colon cancer cell lines by activating
post-epidermal growth factor receptor (EGFR) signaling, including activation of both the
p44/42 MAP kinase and phosphoinositol-3-kinase(PI3K)/Akt pathways (Biochem Pharmacol
70:1035, 2005; Gastroenterology 130:A119, 2006). In the present study, we tested the
hypothesis that activation of NF-κB, downstream of PI3K/Akt, is an important regulator of
colon cancer cell survival and proliferation. In H508 and HT-29 human colon cancer cells,
adding 100 μM DCT (2 hr at 37oC) rescued cells from apoptosis (~60% reduction in
apoptotic cells after additional 4-hr incubation determined by DAPI nuclear staining, p <
0.005). Adding 30 μM LY294002, a PI3K inhibitor, attenuated the protective effects of DCT.
To determine the role of NF-κB in mediating bile acid actions we: (1) used immunoblotting
and immunofluorescence microscopy to examine nuclear translocation of the p65 subunit
of NF-κB and (2) used an ELISA-based transcription factor assay in nuclear extracts to
measure the binding of activated NF-κB to its consensus sequence. In both cell lines, DCT
(100 μM)-induced nuclear translocation of NF-κB was detected within 10 min of incubation
and was maximal by 2-3 hr. In HT-29 cells an increase in nuclear p65 NF-κB was still
evident at 24 hr, whereas in H508 cells levels had returned to basal by 6 hr. In HT-29 cells,
with 10 μM DCT, prolonged activation of NF-κB was abolished by pre-incubation with
antibody to IL-1α, an agent previously implicated in the prolonged activity of NF-κB (Cell
124:1225, 2006). DCT was a more potent inducer of NF-κB nuclear translocation in H508
cells compared to HT-29 cells (DCT dose-response: 0.1-100 μM vs. 10-300 μM, respectively).
In H508 cells, DCT-induced cell proliferation and NF-κB nuclear translocation (immunoblot-
ting) were attenuated by adding EGFR, PI3K activation, proteosome, NF-κB nuclear localiz-
ation, and IκBα kinase inhibitors. NF-κB nuclear translocation was not blocked by inhibitors
of p44/42 MAPK activation. Likewise, DCT-induced NF-κB activation (ELISA) was attenuated
by proteosome, NF-κB nuclear localization, and IκBα kinase inhibitors. We conclude that
DCT-induced stimulation of colon cancer cell proliferation is mediated by at least two major
post-EGFR signaling pathways. DCT-induced activation of PI3K/Akt signaling causes nuclear
translocation and activation of NF-κB, thereby promoting cell survival and proliferation.
The NF-κB signaling cascade provides a novel therapeutic target to block bile acid-induced
colon cancer cell proliferation.
S1581
Reciprocal Relationship Between Circulating Gastrin and Iron Status in Mice
and Humans
Kelly Smith, Suzana Kovac, Gregory J. Anderson, John Burgess, Arthur Shulkes, Graham
S. Baldwin
Background and aim: Gastric acid production is important in intestinal iron absorption.
The peptide hormone gastrin exists in amidated (Gamide) and non-amidated (Ggly) forms,
which stimulate gastric acid secretion, and colorectal proliferation and cancer development,
respectively. Our previous observation that non-amidated gastrins require ferric ions for
biological activity In Vitro (1), and that circulating gastrin concentrations are increased in
mice and humans with hemochromatosis (2), suggests a possible link between gastrin and
iron homeostasis. The aim of this study was to investigate the connection between gastrin
and iron status in mice and humans. Methods: Gastrin concentrations were measured by
radioimmunoassay in mice with iron homeostasis altered by feeding diets with low, normal
and high iron contents. Iron status of mice under- and over-expressing gastrin, and of
humans with multiple endocrine neoplasia, was measured by standard methods. Results:
Ggly concentrations in the plasma (low Fe, 63 ± 3 pM; normal Fe, 49 ± 3 pM; p < 0.01),
and Gamide concentrations in antral mucosal extracts (low Fe, 930 ± 120 pmol/gm; normal
Fe, 560 ± 70 pmol/gm; p < 0.05), are significantly increased in mice on diets low in iron
compared to mice on diets containing normal iron. Transferrin saturation is significantly
increased in CCK2 receptor-deficient mice which overexpress gastrin (CCK2R-/-, 81.3 ± 4.6
%; wildtype C57BL/6J, 54.1 ± 3.6 %; p < 0.001), and significantly decreased in gastrin-
deficient mice (Gastrin-/-, 71.4 ± 4.1 %; wildtype Balb/c, 94.4 ± 1.8 %; p < 0.001). Hypergastri-
nemia in patients with multiple endocrine neoplasia correlates with an increased serum
transferrin saturation. Conclusions: Our data reveal a reciprocal relationship between circu-
lating and antral gastrin concentrations and iron status. These findings open new perspectives
on the mechanisms of iron homeostasis and have implications for the treatment of diseases
associated with changes in gastrin production, such as peptic ulcer and gastric and colorectal
cancers. References: 1. Pannequin, J., Barnham, K., Hollande, F., Shulkes, A., Norton, R.S.
and Baldwin, G.S. (2002) Ferric ions are essential for the biological activity of the hormone
glycine-extended gastrin. J. Biol. Chem. 277: 48602-48609. 2. Smith, K., Kovac, S., Anderson,
G.J., Shulkes, A. and Baldwin, G.S. (2006) Circulating gastrin is increased in hemochrom-
atosis. F.E.B.S. Letters. 580:6195-6198.
S1582
Vitamin D Positively Regulates Intestinal Alkaline Phosphatase Expression
Golam Mostafa, Premraj Pushpakaran, Shaluk Biswas, Madhu S. Malo, Richard A. Hodin
BACKGROUND: Vitamin D3 (VD, cholecalciferol) and its analogues play a significant role
against inflammation and colorectal cancers, and appear to promote gut mucosal defense.
We investigated the role of vitamin D in the regulation of intestinal alkaline phosphatase (IAP),
a putative gut mucosal defense factor that detoxifies lipopolysaccharides (LPS). METHODS: In
Vitro: Caco-2 cells were transiently transfected with a vitamin D receptor (VDR) expression
plasmid, and the cells were then treated -/+ VD (100 nM) for 24 h. RNA was extracted
from transfected cells and quantitative real-time PCR performed. In Vivo: Sprague-Dawley
rats were starved for 3 days in order to silence IAP expression. The animals were then
injected (i.p.) with VD (1 μg/kg) or the saline control, sacrificed after 12 hours, and small
intestinal mucosal cells collected by scraping. Cell lysates were prepared and assayed for
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total alkaline phosphatase (AP) activity. IAP contribution to total AP activity was determined
in the presence of phenylalanine (10 mM), which selectively inhibits IAP activity. RESULTS:
Real-time RT-PCR on RNAs extracted from Caco-2 cells demonstrated low levels of IAP
expression at baseline and minimal induction with either VD treatment or VDR transfection
alone. However, when combined, VDR transfection and VD treatment caused an 8-fold
increase in IAP mRNA expression. These results corroborate our previously reported transfec-
tion data showing that VD transactivates the IAP-luciferase reporter plasmid through an
upstream response element located within the 5' flanking region of human IAP gene. Lysates
prepared from VD-treated Caco-2 cells showed significant endogenous IAP activity. Animals
treated with VD showed an approximate 2.5-fold increase in AP activity (mostly IAP) in the
duodenal and jejunal cell lysates. CONCLUSION: The anti-inflammatory effects of Vitamin
D in the gut may be mediated via IAP, a newly recognized mucosal defense factor.
S1583
Endothelin-Converting Enzyme-1 (ECE1) Degrades Internalized Calcitonin
Gene-Related Peptide (CGRP) in Acidified Endosomes to Regulate Recycling
and Resensitization of Calcitonin-Like Receptor (Clr) and Receptor Activity-
Modifying Protein 1 (RAMP1)
Benjamin Padilla, Graeme S. Cottrell, Dirk Roosterman, Stella Pikios, Martin Steinhoff,
Nigel W. Bunnett
Cell-surface peptidases, such as neutral endopeptidase, degrade neuropeptides in extracellular
fluid and thereby terminate signaling. The role of peptidases in endosomes is unknown.
We hypothesized that the membrane peptidase ECE1 degrades internalized CGRP in early
endosomes to promote recycling and resensitization of CLR and RAMP1, the CGRP receptor.
To examine expression and localization of ECE1 in HEK cells, we used RT-PCR and immuno-
fluorescence. All ECE1 isozymes (a, b, c, d) were detected by RT-PCR. Endogenous ECE1
and expressed ECE1a, b, c and d-GFP were localized in endosomes containing early endoso-
mal antigen 1. When HEK-CLR/RAMP1 cells were incubated with fluorescent Alexa-CGRP,
Alexa-CGRP bound to the plasma membrane and internalized into early endosomes con-
taining ECE1a-d. To determine if ECE1 hydrolyzes CGRP at endosomal pH (5.5), CGRP
(0.25 mM) was incubated with recombinant human ECE1 (83 nM, 6h, 37°C, pH 5.5) and
fragments were analyzed by HPLC and mass spectrometry. CGRP was 42±4% degraded by
cleavage at G14-L15, K24-D25 and N26-F27, consistent with inactivation. The ECE1 inhibitor
SM-19712 prevented this degradation. There was no degradation at extracellular pH 7.4.
To examine the role of ECE1 in regulating CLR/RAMP1 trafficking and interaction with β-
arrestins, which regulate recycling, live HEK-CLR/RAMP1 cells expressing β-arrestin2-GFP
were labeled with antibodies to extracellular epitopes of CLR and RAMP1, and then incubated
with CGRP (100 nM, 60 min, 37°C). CLR, RAMP1 and β-arrestin2-GFP were localized by
confocal microscopy. In vehicle-treated cells, CGRP induced trafficking of CLR, RAMP1 and
β-arrestin2 to endosomes. After 2-6 h, CLR and RAMP1 recycled to the plasma membrane
and β-arrestin2 returned to the cytosol. SM-19712 caused retention of CLR and RAMP1 in
endosomes containing β-arrestin2, and prevented CLR/RAMP1 recycling and the return of
β-arrestin2 to the cytosol. To determine if ECE1 regulates resensitization of CGRP-induced
Ca2+ signaling, HEK-CLR/RAMP1 cells were incubated with CGRP (100 nM, 1 h) or vehicle,
washed and challenged with CGRP (30 nM) after 2 h. In cells expressing ECE1 empty
vector, CGRP responses were resensitized by 33±2% at 2 h, compared to vehicle. Expression of
ECE1a, b, c or d accelerated resensitization to 58±5%, 69±4%, 75±5% or 70±5% respectively
(p<0.05). Conversely, SM-19712 reduced resensitization by >50%. Similar results were
obtained in SK-N-MC cells, which naturally express CLR/RAMP1 and ECE1. Thus, ECE1
degrades CGRP in acidified endosomes to promote dissociation of CLR/RAMP1 from β-
arrestins, and thereby control receptor recycling and resensitization. Supported by NIH
DK39957, DK43207.
S1584
P38 Mitogen-Activated Protein Kinase Regulates Cbl Activity and Epidermal
Growth Factor Receptor Downregulation
Mark R. Frey, D. brent Polk
We have previously shown that p38 mitogen-activated protein kinase (MAPK) is required
for epidermal growth factor (EGF)-stimulated young adult mouse colon (YAMC) cell restitu-
tion. In this model, p38 is a molecular switch determining whether EGF exposure results
in cell migration or proliferation. This study tests the hypothesis that p38 promotes cell
migration via downregulation of EGF receptor (R). METHODS: YAMC cells were treated
with EGF and/or p38-specific pharmacological inhibitor (SB202190) or siRNA. EGFR and
the EGFR-directed ubiquitin ligase Cbl were immunoprecipitated and subjected to Western
blot analysis for tyrosine phosphorylation and ubiquitinylation. EGFR internalization was
assayed by immunofluorescence localization or cellular uptake of biotin-EGF. To translate
cell culture results to intact tissue, sections of colon from C57Bl/6 mice were dissected and
cultured on mesh inserts. Tissue pieces were treated with EGF and/or SB202190 and
homogenized for Western blot analysis. RESULTS: Western blot analysis for phospho-p38
and -Cbl in YAMC cell lysates showed that EGF rapidly (<1 min) stimulates p38 activity,
preceding phosphorylation/activation of Cbl. Consistent with these data, pretreatment with
SB202190 or p38α siRNA blocked EGF-induced Cbl phosphorylation and EGFR ubiquitinyl-
ation, as well as EGFR degradation induced by sustained (4-24 h) EGF exposure. Further-
more, phosphosite-specific antibodies showed that p38 blockade selectively inhibits EGF-
stimulated EGFR Y1045 phosphorylation, a key site for Cbl activation, without affecting
other phosphotyrosine residues on the receptor. The effects of p38 blockade are dynamic
and independent of receptor endocytosis in that addition of SB202190 up to 1 h after EGF
exposure, when EGFR is fully endocytosed as shown by immunofluorescence or biochemical
internalization assay, reversed Cbl activation and blocked EGFR degradation. In our organ
culture model, acute exposure of mouse colon samples to 100 ng/ml EGF promoted Cbl
phosphorylation. Cbl activation was reversed by preincubation with p38 inhibitor, confirming
the relevance of our cell culture data to EGFR function in colonic tissue. CONCLUSIONS:
Downregulation of EGFR is a dynamic process requiring sustained Cbl activity to maintain
internalized receptor in a degradation-competent form. p38 is a key regulator of EGFR
phosphorylation on Y1045 and thus of Cbl activation and EGFR ubiquitinylation. As both
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p38 inhibition and EGFR activation are being investigated as therapeutic targets in a number
of disorders including inflammatory bowel diseases, these findings have important implica-
tions for both normal homeostasis and disease pathogenesis.
S1585
A-Kinase Anchoring Protein (Akap) Assembles a PKA/AC/Pde4/Pp2a Signaling
Module to Regulate cAMP Formation and PKA-Mediated Function in Smooth
Muscle
Karnam S. Murthy, Sunila Mahavadi
PKA regulates cAMP levels in smooth muscle cells via phosphorylation of phosphodiesterase
(PDE4D5) and adenylyl cyclase (AC V/VI). Phosphorylation of PDE4D5 and AC V/VI stimu-
lates degradation and inhibits synthesis of cAMP, respectively. AKAPs provide a molecular
scaffold that orients PKA and other signaling molecules toward selected substrates. Aim.
To examine whether the enzymes that regulate cAMP formation (AC V/VI, PDE4D5, and
PP2A) are regulated by PKA via their association with the AKAP. Methods. AC V/VI and
PDE4D5 activities were measured using [α-32P]ATP and [3H]cAMP as substrates, respectively.
Phosphorylation of AC V/VI and PDE4D5 was measured in cells labeled with 32P. Association
of AKAP79 with PKA, AC V/VI, PDE4D5 and protein phosphatase 2A (PP2A) was measured
by immunoprecipitation. The role of AKAP was examined using the cell-permeable AKAP-
PKA competing peptide Ht-31. Results. As previously shown, VIP stimulated AC V/VI and
PKA activities and induced PKA-dependent feedback of phosphorylation of AC V/VI and
PDE4D5 in gastric smooth muscle cells. Blockade of PKA with myristoylated PKI augmented
AC V/VI and attenuated PDE4D5 activities, implying that phosphorylation by PKA attenuated
the synthetic activity of AC V/VI and enhanced the degradative activity of PDE4D5. Similarly,
treatment of dispersed muscle cells with Ht-31 to disrupt the association of PKA and AKAP,
blocked phosphorylation of both AC V/VI and PDE4D5, and augmented the activity of AC
V/VI and attenuated the activity of PDE4D5. The results imply that association of PKA with
AKAP is necessary for PKA-induced phosphorylation AC V/VI and PDE4D5 and for the
feedback regulation of their activities. Co-immunoprecipitation studies demonstrated that
AKAP79 was associated with AC V/VI, PDE4D5, the regulatory subunit of PKA, and the
catalytic subunit of PP2A suggesting that AKAP79 acts as a scaffolding protein for PKA, AC
V/VI, PDE4D5 and PP2A. The results also suggest that the phosphatase necessary to reset
the activities of AC V/VI and PDE4D5 is localized to the same complex tethered by AKAP.
Treatment of cells with Ht-31 disrupted the association of AKAP79 with the regulatory
subunit of PKA and with PDE4D5, but had no effect on the association of AKAP79 with
AC V/VI or PP2A. Both Ht-31 and PKI decreased the association of AKAP and PDE4D5,
suggesting that phosphorylation of PDE4D5 augmented its association with AKAP. Conclu-
sion. AKAP79 anchors PKA, AC V/VI, PDE4D5, and PP2A into a molecular scaffold that
fosters feedback regulation of cyclase and phosphodiesterase activities by PKA, leading to
rapid termination of the cAMP signal in smooth muscle cells.
S1586
Dock4 Regulates PDGF-Dependent Chemotaxis By Internalization of the
Growth Factor Receptor Via Adaptor Protein Grb2
Kenji Kawada, Geeta Upadhyay, Sailajah Janarthanan, Matthew Hall, Vijay Yajnik
Background & Aims: We previously isolated DOCK4 in a screen for novel tumor suppressor
genes, and have recently identified its isoform resulting from alternate splicing of exon49.
DOCK4 belongs to the CDM proteins (Ced-5, DOCK180 and Myoblast city), unconventional
Rac guanine nucleotide exchange factors (GEFs). However, the function and the regulatory
mechanism of DOCK4 remain to be elucidated. The focus of this study is to understand
the cellular and molecular mechanisms of DOCK4 in chemotaxis initiated by platelet derived
growth factor receptor beta (PDGFRβ), a member of the receptor tyrosine kinases (RTKs).
Methods: To examine the binding properties of DOCK4, GST pull down and immunoprecipit-
ation assays were performed. Using the pBabe-puro retroviral expression system, we estab-
lished the NIH3T3 cells stably expressing various DOCK4 constructs. We examined the
PDGF-dependent chemotaxis using Boyden chamber assays. Ligand-induced PDGFRβ endo-
cytosis was evaluated by flow cytometry and confocal immunofluorescence microscopy.
Results: In NIH3T3 cells, DOCK4 is required for PDGF-dependant chemotaxis and it regulates
both GTP-Rac levels and PDGFRβ endocytosis without altering MAP kinase and PI-3 kinase
function. The adaptor protein Grb2 SH3 domains bind to DOCK4 via the high affinity motif
PPVPPR, which is excluded in a naturally occurring splice variant. This splice variant is
unable to bind Grb2 and disrupts receptor internalization and chemotaxis. PDGF stimulation
results in the recruitment of the Grb2-DOCK4 complex to the phosphorylated PDGFRβ.
Moreover, DOCK4 Rac GEF function is not required for PDGFRβ internalization, but is
necessary for PDGF-dependent chemotaxis. DOCK4 binds to ELMO and CrkII through its
SH3 domain and C-terminal proline-rich domains, respectively, but silencing DOCK4 or
Grb2, but not CrkII, effectively reduced the PDGF-dependent migratory response. Finally,
we show that DOCK4 restores PDGF-dependant chemotaxis in K-Ras transformed cells by
induction of PDGFRβ endocytosis and is over-expressed in sporadic human colon tumors.
Conclusion: We report a novel intracellular signaling pathway linking PDGFRβ to the CDM
Rac exchange factor DOCK4 via adaptor protein Grb2. These novel observations on PDGFRβ
regulation underscore a key role of receptor endocytosis in directional cell migration.
S1587
Immunolocalization of Histamine H4 Receptor in the Rat Gastrointestinal
Tract
Giuseppina Morini, Fiona C. Shenton, Paul L. Chazot, Daniela Grandi
The recently characterized histamine H4receptor (H4R) subtype is undetectable in the rat
stomach and small intestine by Northern analyses. Present study is aimed to investigate the
expression of histamine H4R along the entire gastrointestinal tract in the rat, using sensitive
immunohistochemical methods. Groups of rats were either fed ad libitum or fasted for 24
h before the sacrifice. Tissue samples were taken from stomach, small intestine and colon,
fixed in 10% formalin, and prepared for immunohistochemistry. Anti-H4R (374-390) anti-
bodies were raised in rabbits, affinity purified and validated as previously described (Van
Rijn, Chazot et al. Mol. Pharmacol. 70: 604, 2006). Immunoreactivity to H4R (H4R-IR) was
differently distributed in the various regions of the gastrointestinal tract. H4R-IR was observed
in the epithelium of gastric fundus, where the number of positive cells per gland was 0.75
± 0.03 in fed rats and 0.90 ± 0.05 in fasted rats. Almost all the H4R-IR cells were immunoreac-
tive for chromogranin A, demonstrating that in the fundic mucosa H4R-IR is exclusively
localized to endocrine cells. Endocrine cells in the fundus were found to express also the
histamine H3 receptor (H3R). However double-labeling for H3 and H4 receptor revealed that
all the H4R-IR cells were negative for H3R antibody, suggesting that the two histamine
receptors are localized on distinct endocrine cell types. H4R-IR was extremely rare in the
epithelium from gastric antrum and duodenum and absent in the epithelium from distal
ileum and colon both in fed and in fasted rats. H4R-IR was also present in the myenteric
plexus of all regions of the gastrointestinal tract examined, with no apparent difference
between fed and fasted animals. Staining for H4R was particularly strong in ganglion cell
bodies and present, although to a lesser degree, in fibers. By contrast the submucosal plexus
was negative for H4R. This suggests a role for H4R in rhythmic peristalsis. No H4R-IR was
found in mast cells, vessels and leucocytes. This study provided new evidence for the
existence of H3R and H4R in distinct subpopulations of gastrointestinal endocrine cells.
Furthermore, we have identified, for the first time, the H4R in the mammalian enteric
nervous system.
S1588
E6007: An Orally Active Inhibitor of Integrin Activation for Inflammatory
Bowel Disease
Masayoshi Ohkuro, Yoshikazu Kuboi, Hiroko Kuramochi, Toru Sakairi, Kenzo Muramoto,
Hiroyuki Sasaki, Makoto Kotake, Tetsuya Kawahara, Naoki Yoneda, Shinsuke Hirota,
Hiroshi Azuma, Nobuko Komura, Yoshiaki Ohashi, Takao Saeki, Ieharu Hishinuma,
Hironobu Hiyoshi, Osamu Asano
Background: Infiltration of various types of leukocytes is commonly observed at the inflam-
mation site in inflammatory bowel disease (IBD). These cells are chemotactily recruited via
a series of processes involving adhesion molecules such as integrins expressed on its cell
surface. Anti-alpha 4 integrin mAb, which inhibits lymphocyte invasion, has shown clinical
benefits in Crohn's disease (CD). Additionally, apheresis therapy with neutrophils and
lymphocytes is known to be effective for the treatment of ulcerative colitis (UC) and CD.
These evidence suggest that inhibition of infiltration/migration of multiple types of leukocytes
may provide clinical benefits in IBD patients. Herein we describe E6007, which inhibits cell
adhesion/invasion of both lymphocytes and neutrophils, and disease-related parameters in
animal IBD models. These inhibitory effects may be due to inhibition of integrin activation
through preventing the interaction between integrin and calreticulin. Methods & Results:
E6007 inhibited adhesion of phorbol myristate ascetate-induced Jurkat lymphoid cells to
fibronectin and human neutrophils to endothelial cells, with IC50s of 3.0 and 1.2 μM,
respectively. In an In Vitro cell migration assay, E6007 inhibited migration of SDF-1-induced
lymphocytes and IL-8-induced neutrophils, with IC50s of 409 nM and 160 nM, respectively.
In an In Vivo mouse model, oral administration of E6007 suppressed oxazolone-induced
lymphocyte and neutrophil infiltration into the colon with a minimum effective dose of 1
mg/kg. Furthermore, in the dextran sulfate sodium (DSS)-induced mouse colitis model, oral
administration of E6007 for 7 days resulted in significant prophylactic effects on disease
activity index, neutrophil infiltration into the colon, and shortening of colon at oral doses
of 0.3-1 mg/kg. In the mouse CD4+CD45RB high T cell-transferred colitis model, oral
administration of E6007 showed significant prophylactic effects on stool consistency and
thickness of colon, with a minimum effective dose of 1-3 mg/kg. Conclusion: E6007, an
integrin activation inhibitor suppresses cell adhesion/migration in both lymphocytes and
neutrophils. Orally-administered E6007 shows ameliorative effects in both DSS-induced and
T cell-transferred mouse colitis models. These results suggest that E6007 may provide a
novel mechanism of action potentially for the treatment of both UC and CD.
S1589
Inhibition of Cell Traffic with Orally Active Integrin α4 Antagonist
Ameliorates Murine Colitis Induced By Adoptive Transfer of Cd4+Cd45rbhi T
Cells; Role of Dendritic Cells and Macrophages
Chieko Ejima, Yuji Tanaka, Yasuyo Suga, Yuka Ikenoue, Masaki Hashimoto, Hideaki
Kihara, Masahiro Murata, Rei Kawashima, Yuki I. Kawamura, Taeko Dohi, Manabu
Suzuki
BACKGROUND AND AIM: Inhibition of accumulation of α4 integrin positive cells in gut
inflamed tissue is the promising approach for treatment of inflammatory bowel diseases
(IBD), although it's exact action mechanism is still unclear. The aim of this study is to clarify
the therapeutic potential of α4 integrin antagonist which might inhibit dendritic cells (DCs)
and macrophages as well as α4 integrin positive T cells. METHODS: An aliquot containing
0.25X10^5 CD4+CD45RBhigh T cells (RBhi T cells) purified by cell sorting using FACS
Vantage™ (purity>99%) in 200μl of phosphate-buffered saline was injected intravenously
into SCID mice. Anti-α4 integrin antibody PS/2 (10mg/kg, i.p.) or a small molecule α4
integrin antagonist, AJM300 (2% dietary administration) were administered to recipient
mice. The administration was initiated on the next day of cells transfer. In our previous
studies, AJM300 had been proved to inhibit not only the interaction between α4β7 integrin
and mucosal addressin cell adhesion molecule-1 (MAdCAM-1, IC50; 1.5nM), but also
between α4β1 integrin and vascular cell adhesion molecule-1 (VCAM-1, IC50; 6.3nM).
Mice were euthanized 3 weeks later, peripheral blood mononuclear cells and plasma were
collected. The colon was removed for histopathological examination, immunohistochemical
analysis and isolation of lamina propria mononuclear cells. Expression of cell adhesion
molecules (α4, MAdCAM-1), cell surface molecules (CD4, CD11c, F4/80) and MHC class
II was assessed by flow cytometry. RESULTS: Accumulation of CD4-positive cells, CD11c-
positive DCs and F4/80-positive macrophages were observed in the inflamed colon of this
model and these cells proved to express α4 integrin. Administration of anti-α4 integrin
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antibody and AJM300 suppressed the increment of colon weight and improved the patholo-
gical scores. In addition, anti-α4 integrin antibody prevented the accumulation and activation
of DCs and macrophages in inflamed sites, as well as activated T cells. Antibody also
ameliorated IBD symptoms of this colitis model. CONCLUSIONS: Anti-α4 integrin antibody
and AJM300 might exert their efficacy by preventing the accumulation of DCs and macro-
phages at the inflamed site, in addition to RBhi T cells, and also by inhibiting the interaction
between DCs/macrophages and T cells.
S1590
Efficacy of Abatacept, a Selective Co-Stimulation Modulator, in Oxazolone-
Induced Colitis
Xiaoxia Yang, Dawn Stetsko, Jenny Xie, Steve Nadler, Suzanne Suchard, Luisa Salter-cid
Abatacept is the first in a class of therapeutic agents that selectively modulates T-cell co-
stimulation via the CD28:CD80/CD86 pathway. It binds to B7-1 (CD80) and B7-2 (CD86)
on antigen presenting cells, and prevents their interaction with CD28 on T cells. Induction
of CD86 on the intestinal mucosa is thought to be one of the key events responsible for
the inflammatory reaction in inflammatory bowel disease (IBD). Furthermore, by blocking
co-stimulation of mucosal activated T cells as well as naive T cells present in the lymph
nodes and Peyer's Patches, abatacept has the potential to interfere with both the induction
and maintenance phases of the pathological immune response. We sought to determine the
efficacy of abatacept in a T-cell dependent experimental murine colitis model and to investig-
ate its mode of action in colonic inflammation. Oxazolone-induced colitis is a T helper2
(Th2) colitis model that has a histological and cytokine-pattern resemblance to human
ulcerative colitis (UC). To induce disease, SJL/J mice were pre-sensitized by epicutaneous
application of 3% oxazolone in 100% ethanol on Day 0, and challenged 5 days later by intra-
rectal administration with 1% oxazolone in 50% ethanol. Here we show that intraperitoneal
administration of abatacept prior to oxazolone challenge ameliorated colitis in a dose-
dependent manner. Body weight, survival rate and colon length were examined, and signific-
ant protection was observed at doses ≥10 mg/kg. Histopathological assessment of colitis
activity showed a marked suppression of inflammation and associated mucosal ulceration,
as well as mucosal and submucosal edema and necrosis, in mice treated with abatacept
compared with chimeric IgG1-treated controls. Ex vivo CD3/CD28-mediated release by
lamina propria T cells of several pro-inflammatory cytokines, including IL-4, IL-5, IL-13
and IL-17, was markedly inhibited in oxazolone-challenged animals treated with abatacept
(p<0.01 versus IgG-treated). In further studies, a significant therapeutic effect, as assessed
by clinical course and inhibition of cytokine production, was also observed when abatacept
was dosed after disease initiation. Mice treated with abatacept had a 100% survival rate.
The immunomodulatory effects of abatacept in this model of experimental colitis suggest that
it may be an attractive therapeutic approach for human IBD in general and UC in particular.
S1591
Blockade of TNF-α Inhibits Tumor Progression in Colitis-Associated Cancer
Michio Onizawa, Takanori Kanai, Yasuhiro Nemoto, Shigeru Oshima, Shin Makita,
Ryuichi Okamoto, Teruji Totsuka, Hideo Yagita, Mamoru Watanabe
Background & Aim: Crohn's disease (CD) and ulcerative colitis (UC) are two major forms of
inflammatory bowel diseases (IBD) characterized by massive infiltration of pro-inflammatory
mediator-producing CD4+ T cells and macrophages in the intestine. It is well known that
one of the serious complications of long-standing IBD at increasing risk during the course
is an intestinal carcinoma developed through IKKβ/NF-κB pathway activated by pro-inflam-
matory mediators including TNF-α. At present, anti-TNF-α treatment for IBD are the most
advanced in use and development, but there are no reports in terms of the possible effect
on the prevention of colitis-associated intestinal carcinoma. We here assess whether anti-
TNF-α therapy modulates the incidence and development of colitis-associated intestinal
carcinoma using a murine model of colitis-associated colon cancer. Methods: C57BL/6 mice
were randomized into 7 groups as followed, (1) no treatments; injected i.p. with azoxyme-
thane (AOM, 1mg/body) at day 1 and treated with (2) control Ab (1mg/body) or (3) anti-
TNF-α mAb (MP6-XT22, 1mg/body) weekly starting at day 12; administered with three
cycles of 3.0 % DSS for 5 days and normal water for 16 days starting at day 7, and treated
with (4) control Ab or (5) anti-TNF-α mAb weekly starting at day 12; injected i.p. with
AOM, followed by three cycles of 3.0% DSS, and treated with (6) control Ab or (7) anti-
TNF-α mAb. At 11 wks after the start of experiment, all mice were analyzed. Results: In
preliminary assessment, TNF-α mRNA and protein were significantly increased in the colon
at 5 days after DSS administration as compared with normal mice with no DSS treatment.
Furthermore, our anti-TNF-α mAb did not affect the severity of colitis compared with
control Ab during the experimental period. No neoplastic lesions were detected in mice
treated with AOM alone groups (2, 3) and DSS alone group (4, 5). Although 13±4.37/
mouse of colon tumors was observed mainly in anal side in a group of AOM+DSS (6), anti-
TNF-α mAb treatment significantly reduced the incidence to average of 7.8±3.04/mouse
(P<0.05). Conclusions: Our study suggests scheduled anti-TNF-α mAb therapy has a benefit
to decrease the incidence and development of the IBD-associated intestinal cancer.
S1592
Optimization of Beta Glycolipids for Alleviation of Immune Mediated Colitis:
A Role for Different Combinations in Altering Nkt Lymphocyte-Associated
Immune Modulatory Effect
Gadi Lalazar, Lydia Zolotarovya, Orit Pappo, Yaron Ilan
NKT cells are a subset of regulatory lymphocytes which recognize glycolipid ligands presented
by the MHC class I-like molecule CD1d. Beta-glycolipids have been shown to modulate
NKT cell function and alleviate immune mediated disorders. Aim: To determine the immune
mechanism and immune modulatory effect of different combinations of beta-glycolipids on
NKT cells and alleviation of immune mediated colitis. Methods: Immune-mediated colitis
was induced in 8 groups of mice (n=10) by intra-colonic instillation of Trinitrobenzene
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Sulfonate (TNBS) on days 1 and 5. Mice in groups B-H were treated with daily intraperitoneal
injections of different combinations of beta-glucosylceramide (GC) and beta-lactosylceramide
(LC). Group B-H received 15µg GC + 15µg LC; 150µg GC + 15µg LC; 15µg GC + 150µg
LC, 1.5µg GC + 150µg LC, 150µg GC + 1.5µg LC, 15µg LC, 15µg GC respectively.
The immunological effect was assessed by FACS analysis of intrahepatic and intrasplenic
lymphocytes for NK, CD4 and CD8 markers and by measurement of serum cytokines. The
clinical effect of beta glycolipids on immune-mediated colitis was assessed by survival,
macroscopic and microscopic scores. Results: The 1:1 combination of GC and LC (group
B) had the most profound immunological and clinical effect. Treatment with beta glycolipids
was associated with an increase in the liver/spleen NKT ratio (3,10,9,10,13,15,7 vs. 1.5,
groups B-H compared with A, p<0.05) and a decrease in the spleen/liver CD4/CD8 ratio
(0.4,0.5,0.3,0.6,0.5,0.9,0.3 vs. 1, groups B-H compared with A), suggesting an increased
intrahepatic CD8 cell trapping. These alterations were associated with increased survival
and reduced macroscopic and microscopic colitis scores in groups B-H compared to control
group A (43,14,43,14,14,43,43%, and 92,65,88,78,64,57,82% respectively, p<0.003). In
groups B-H, serum IFNγ (pg/nl) levels as well the IFN/IL-4 and IFN/IL-10 ratios were
reduced compared to control group A (184,9,103,14,320,140,83 vs. 437; 55,0,72,14,38,1,26
vs. 153; 6,0.09,1.8,2,0.3,12,7 vs. 14 respectively, p<0.05). Conclusions: Altering the com-
bination of beta-glycolipids changed the redistribution of NKT cells and increased CD8 T
cell trapping in the liver. These effects were associated with alleviation of immune mediated
colitis and a Th1 to Th2 cytokine shift. The 1:1 combination of GC and LC showed the greatest
clinical effect along with the most profound immunological changes. This combination was
superior to combinations with other ratios or administration of either glycolipid alone.
Optimization of beta-glycolipid immune modulatory effect can be achieved via administration
of specific glycolipid combinations.
S1593
The Effects of Dietary Curcumin in Th-1 Driven Colitis in IL-10 Knockout
Mice
Claire B. Larmonier, Jennifer K. Uno, Kang moon Lee, Thomas Karrasch, Christian Jobin,
R. balfour Sartor, Fayez K. Ghishan, Pawel R. Kiela
Background: Crohn's disease (CD) involves an aberrant and persistent immune response
against non-pathogenic intestinal bacteria, with Th1 and Th17 lymphocytes playing a key
role in the development and determination of the immune response mediated by IFNγ,
IL17, IL12, and IL23. Curcumin (diferulolylmethane) exhibits a protective role in mouse
models of chemically induced colitis, with its presumed primary mechanism of action
mediated through inhibition of NFκB. Curcumin demonstrates profound anti-inflammatory
effects in intestinal epithelial and in immune cells In Vitro. However, it's effectiveness In
Vivo in T-cell mediated experimental colitis has not been described. Aim: To investigate the
effects of dietary curcumin on development of colitis, immune activation and In Vivo NFκB
activity in IL10 knockout mice, an established model of Crohn's disease, which develop
spontaneous immune- mediated colitis when transferred from germ-free (GF) to specific
pathogen-free (SPF) conditions. Methods: GF wild-type (WT) or IL10-/- mice were colonized
with SPF bacteria while fed control diet or diets supplemented with 0.1, 0.5, or 1% curcumin
and sacrificed 14 days post-colonization. NFκBEGFP transgenic (TG) mice on WT or IL10-/-
background were similarly colonized, fed control or 1% curcumin diet and sacrificed 28-
days post-colonization. We evaluated colonic morphology, expression of IL12p40 and IFNγ
mRNA by real-time PCR, and IL-12p40 and IFNγ secretion by colonic explants and by
mesenteric lymph node cells stimulated with cecal bacterial antigen. Activation of NFκB
was evaluated in IL10wt/wt;NFκBEGFP and IL-10-/-;NFκBEGFP mice by whole colon fluorescence
and confocal microscopy. Results: Proximal and distal colon morphology showed a mild
protective effect of curcumin in IL-10 KO mice at 0.1% with much less prominent effects
at higher concentrations. Colonic IFNγ and IL-12p40 mRNA expression followed a similar
pattern. By ELISA, secretion of IL-12p40 and IFNγ in colonic explant and mesenteric lymph
nodes cell cultures significantly increased in colitic mice, but was not affected by dietary
curcumin. Surprisingly, despite known In Vitro effects of curcumin, activation of NFκB as
evaluated in situ in IL10-/-NFκBEGFP TG mice, was not inhibited by 1% dietary curcumin.
Conclusion: In the setting of Th1 mediated colitis, curcumin demonstrated limited potency,
with partially improved colonic morphology, but with no effect on pathogenic T-cell
responses. Moreover, in situ functional assay for NFκB activity indicates limited effects of
dietary curcumin on the activation of this transcription factor in the IL10-/- model of Crohn's
disease. Support:R01DK67286 & R01DK53347
S1594
22-Ene-25-Oxa-Vitamin D (Zk156979) Affects the IL-23/IL-17-/IL-6 Axis to
Treat Th1-Mediated Experimental Colitis in Mice
Carolin Daniel, Heinfried H. Radeke, Ulrich Zuegel, Juergen M. Stein
Background & Aims: We described 22-ene-25-oxa vitamin D (ZK156979) as a representative
of a novel class of low calcemic vitamin D analogs with a well preserved immunosuppressive
activity in Th1-mediated colitis in mice (Daniel C et al. 2006, JPET 319:622-31). Recently,
the IL-23/IL-17/IL-6 axis was shown to play a pivotal role in as yet classical Th1-mediated
diseases. Very recently a genome wide association study identified IL23R as an inflammatory
bowel disease gene (Duerr RH et al. 2006, Science Express 26 Oct). The object of the
following study was to investigate the impact of ZK156979 on IL-23, IL-17 and IL-6
expression in TNBS-colitis in mice. Methods: A rectal enema of TNBS [100 mg/kg body
weight (BW)] was applied to male Balb/c mice, and calcitriol [0.2 µg/kg] or ZK156979 [0.2
or 2.0 µg/kg] were administered intraperitoneally from day 0-3 or 3-5 following the instillation
of the haptenating agent. The study is conforming to the Guiding principles in the care and
use of animals and was performed under approval of the ethical committee of Darmstadt/
Germany (F134/03). Body mass and clinical activity score of colitis were determined daily.
CD4+ T-cells were isolated from the Lamina Propria using the method of van der Heijden
and Stok with slight modifications. IL-23, IL-17 and IL-6 protein expression in CD4+ T
cells was analyzed by Western Blot. Results & Conclusion: Treatment with ZK156979
significantly reduced the severity of TNBS-colitis without exhibiting calcemic effects. Both,
early and late treatment abrogated body weight loss, diarrhea, and macroscopic intestinal
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inflammation with a potency comparable to calcitriol. The therapeutic effect of ZK156979
was accompanied by a significant inhibition of IL-23 (FTY720 [3 mg/kg]: 36.67±9.11% of
TNBS-group; p<0.01), IL-17 (FTY720 [3 mg/kg]: 41.77±6.31% of TNBS-group; p<0.01)
and IL-6 protein expression (FTY720 [3 mg/kg]: 26.85% of TNBS-group; p<0.001). To
conclude, our data provide first clear evidence that the beneficial prophylactic as well as
therapeutic profile of ZK156979 in Th1-like experimental colitis is also due to a significant
impact on the IL-23/IL-17/IL-6 axis further supporting the concept that ZK156979 may offer
a new auspicious therapeutic option for the treatment of human inflammatory bowel diseases.
S1595
Interaction of Cyanide with Sulfide Detoxification in the Colonic Mucosa: An
Explanation for the Beneficial Effect of Smoking On Ulcerative Colitis?
Daniel Kraft, Julie Furne, Michael Levitt
Background and objective: Cigarette smoking benefits ulcerative colitis (UC), but the nature
of the anti-inflammatory component of smoke and why this effect is limited to the colon
remain speculative. We propose that the protective effect of smoking results from an interac-
tion between a detoxification product of H2S (a major metabolite of colonic bacteria) and
cyanide in cigarette smoke. Methods: In Vitro studies: the metabolic products resulting from
incubation of rat cecal mucosa with H235S and varying cyanide concentrations were identified
via separation of S35-reaction products by HPLC followed by scintillation counting. In Vivo
studies: rats received intracecal H235S along with either intraluminal or intravenous cyanide.
Blood simultaneously sampled from a cecal and jugular vein was assayed for H235S metabol-
ites. Results: In Vitro studies: in the absence of cyanide, thiosulfate was the predominant
sulfide metabolite. However, in the presence of cyanide the major sulfide detoxification
product shifted from thiosulfate to thiocyanate. In Vivo studies: in the absence of cyanide,
thiosulfate was the primary detoxification product, but cyanide availability (intraluminal or
intravenous) shifted the detoxification product to thiocyanate. The much higher concentration
of thiocyanate observed in cecal versus systemic blood demonstrated that thiocyanate produc-
tion took place in the mucosa rather than systemically. Conclusions: In the absence of cyanide,
H2S is detoxified by colonic mucosa to thiosulfate. However, when cyanide is available,
colonic rhodanese converts thiosulfate to thiocyante. The significance of thiocyanate is that
this compound has a roughly 750-fold greater affinity for myeloperoxidase (MPO) and
eosinophil peroxidase (EPO) than the usual substrates of these enzymes, chloride and
bromine. Thus, thiocyanate blocks the ability of MPO and EPO to produce highly toxic
hypochlorite and hypobromite, which are injurious to local tissues. Cigarette smoke is the
major source of cyanide exposure and the colonic mucosa is the only tissue with very
high concentrations of thiosulfate. Thus, smoking results in uniquely high thiocyanate
concentrations in colonic mucosa, explaining why the anti-inflammatory effect of smoking
is limited to the colon. Confirmation of the anti-inflammatory effect of cyanide/thiocyante
in animal models of colitis could provide the basis for novel therapies for UC such as topical
or systemic administration of thiocyanate and/or cyanide.
S1596
Cannabinoid Receptor 2 Is Required for Homeostatic Control of Intestinal
Inflammation
Xavier Thuru, Mathias Chamaillard, Meliha Karsak, Emilie Gantier, Edmone Erdual,
Caroline Dubuquoy, David Philippe, Christel Rousseaux, Yung-chi Wang, Pierre Dubus,
Jacek Stalewski, Frederique Menzaghi, Claudio Schteingart, Andreas Zimmer, Pierre
Riviere, Pierre Desreumaux
Introduction: The phytocannabinoids from Cannabis sativa showed various medicinal proper-
ties, including in chronic pain disorders and cancer. Broad cellular and immunocyte respons-
iveness to cannabinoids are conferred by the cannabinoid receptor 1 (CB1) and 2 (CB2), which
are two members of the G-protein coupled receptors (GPCRs). However, their respective
physiological role in the gut remains elusive. Aim: Given the regulatory role of endocannabi-
noids in inflammatory and nociceptive disorders, we hypothesized that abnormal enteric
sensing by the cannabinoid receptors, CB1 and/or CB2, might predispose to inflammatory
bowel diseases (IBD). Methods: Expression of cannabinoid receptors in colonic resection
specimens of IBD patients (40 Crohn Disease (CD), 30 Ulcerative Colitis (UC) and 30 non-
IBD subjects) was evaluated by RT-PCR and immunohistochemistry. The effect of Fe 200859,
a specific CB2 ligand, was investigated in different models of acute or chronic induced colitis
(Trinitrobenzene sulfonic acid (TNBS), Dextran sodium sulfate (DSS)). The mechanism of
action of this compound was assessed In Vitro in two murine cell lines (RAW macrophage
and MEF myofibroblast cell lines). Results: We found abnormal expression of cannabinoid
receptors expression in both colonic resection specimens of IBD patients. CB2 was signific-
antly more expressed in non-inflammed resection specimens of CD patients, but not in
UC. Consistently, by using pharmacological and genetic inhibition of Cnr2, we unraveled
physiological anti-inflammatory and anti-fibrotic properties of CB2 in three preclinical models
of IBD. These beneficial effects were reflected by increased survival rates, an improvement
of macroscopic and histologic scores, a decrease in colon TNF-alpha and IL-1beta mRNA
levels. Furthermore, CB2 blockade inhibited cell proliferation in a p65- and ERK-dependent
manner, indicating that CB2 controls cell proliferation through NF-kB and MAPK signaling
pathways. Conclusion:CB2 was also required to limit immunocytes recruitment In Vivo and
chemokine production, providing an explanation for its anti-inflammatory and anti-fibrotic
function in the intestine. Hence, since CB2 is required for homeostasis of intestinal inflamma-
tion, CB2-targeting compound should be considered to treat intestinal inflammation and
visceral pain.
S1597
Protective Effects of Dietary Curcumin in Trinitrobenzene Sulfonic Acid
(TNBS)-Induced Colitis Are Mouse Strain-Dependent
Claire B. Larmonier, Jennifer K. Uno, Maciej A. Lipko, Nicolas Larmonier, Fayez Ghishan,
Pawel R. Kiela
Inflammatory Bowel Disease (IBD) is a chronic disorder influenced by environmental factors
and genetic predisposition. The two main forms of IBD, Ulcerative Colitis (UC) and Crohn's
Disease (CD) involve an inappropriate and persistent immune response against the non-
pathogenic intestinal flora. Mucosal T cells play a key role in the development of the immune
response and the cytokine environment defines the orientation of Th1, Th2 or Th17 T cells
subsets. CD has been characterized by a Th1 type response (IFNγ, IL12, IL17, IL23)
and UC seems to be mediated by Th2 cytokines such as IL4, IL5, and IL13. Curcumin
(diferulolylmethane) has been shown to display a protective role in mouse models of IBD,
and to reduce relapse rate in human UC. TNBS colitis in NKT-deficient SJL/J mice has been
described as a Th1-mediated inflammation, while BALB/c mice are believed to have a mixed
response. We therefore investigated the effect of curcumin (2% in diet) in colitis induced
in these two strains of mice. Mortality and body weight were monitored daily. Mice were
sacrificed 7 days post-induction and colons were harvested for morphological evaluation
and RNA extraction. Spleens from naïve BALB/c and SJL/J mice were also harvested to
evaluate the effect of curcumin on proliferative responses and cytokine secretion In Vitro.
In BALB/c mice, curcumin significantly increased survival, protected from weight lost, and
normalized the indices of the disease. However, in TNBS-treated SJL/J mice, curcumin did
not show any protective effect. Genome-wide microarray analysis of colonic gene expression
was employed to define the differential effect of curcumin in these two strains. This analysis
not only confirmed the disparate reaction of these two strains to curcumin, but also indicated
different response to TNBS. In Vitro, curcumin in concentrations ranging from 0 to 5μM
dose-dependently inhibited proliferation of splenocytes from naïve BALB/c but not SJL/J
mice, when non-specifically stimulated with a mitogenic agent, Concanavalin A (ConA). In
similar experimental settings, proliferation of CD4+ splenocytes was inhibited in both strains,
albeit with 2-fold higher IC50 in SJL/J mice. Secretion of IL4 and IL5 by CD4+ lymphocytes
of BALB/c, but not SJL/J mice, was significantly augmented by ConA and reduced to control
levels by 5μM curcumin. Conclusion: The efficacy of dietary curcumin in chemically induced
models of colitis varies in BALB/c and SJL/J mouse strains. While the exact mechanism
underlying these differences is unclear, the results suggest that dietary curcumin may be of
different value depending on the immune predisposition in CD and in UC. Supported
by R01DK067286
S1598
An Orally Active Alpha4 Integrin Antagonist Ajm300 Attenuates Inflammatory
Cell Infiltration and Exacerbation of DSS-Induced Chronic Colitis in Rats
Satoko Maruyama, Shunsuke Kageyama, Toshihiko Sugiura, Manabu Suzuki
Background & Aims: Although the humanized antibody to α4 or α4β7 integrin has
demonstrated the clinical benefit for the patients with inflammatory bowel disease (IBD),
the orally effective α4 integrin therapy may be preferable. AJM300 is an orally active small
molecule α4 integrin antagonist and Phase II study for active Crohn's disease is currently
ongoing in Japan. The aim of this study was to evaluate the efficacy of AJM300 in a rat
model of dextran sodium sulfate (DSS)-induced chronic colitis. Methods: Chronic colitis
was induced in male Wistar rats by the repetitive treatment with 3%DSS (mol.wt. 5,000);
each cycle consisted of 7-day consumption of 3%DSS followed by 7-day consumption of
tap water. After completion of 2 cycles, AJM300 was orally administered at 100 mg/kg b.i.d.
for 7 days during the third treatment of 3%DSS. The disease activity index (DAI), which is
combined scores of stool consistency and rectal bleeding, was recorded daily. Seven days
after the initiation of the third DSS consumption (day 8), animals were euthanized after
blood sampling for measurement of hemoglobin count and the distal colon was removed
for the histological and immunohistochemical analysis. Results: A cyclic administration of
3%DSS/water induced a chronic colitis with the histological features with crypt destruction,
inflammatory cell infiltration and mucosal ulceration in rats. Increased expression of MAd-
CAM-1 was also observed. AJM300 significantly attenuated the increase in DAI scores as
well as the decrease in hemoglobin counts at 100 mg/kg b.i.d. In addition, AJM300 signific-
antly reduced the number of CD3+ cells (T lymphocytes) and granulocytes in the lamina
propria mucosa of the distal colon on day 8. Conclusions: These results suggested that the
daily oral treatment with AJM300 was effective in a rat model of DSS-induced chronic colitis
and that this efficacy was accompanied with the reduction of inflammatory cell infiltration
to the colonic mucosa. AJM300 might be beneficial for the treatment of patients with IBD.
S1599
Elemental Diet Feeding Prevents the Development of Ileitis in the Samp1/Yitfc
Model of Crohn's Disease in Association with Marked Changes in Intestinal
Flora
Miho Hanai, Kazuhiko Sugawara, Christopher A. Moskaluk, Alda Vidrich, Steven M.
Cohn, Fabio Cominelli, Marcia Mcduffie
BACKGROUND & AIMS Elemental diets (ED) have been used successfully as both induction
and maintenance therapy in Crohn's disease, but the precise mechanisms of action are still
unclear. SAMP1/YitFc (SAMP) mice spontaneously develop ileitis with histologic features of
Crohn's disease. We tested an ED in current clinical use (Elental, Ajinomoto Co., Japan) in
SAMP mice to determine its effects on intestinal inflammation, immunological parameters,
epithelial cell morphology, and intestinal microbial flora. METHODS SAMP mice were treated
with ED beginning at either 10 weeks or >30 weeks of age (treatment study), or at 6 weeks
(prevention study). Control (Ctr) groups received a standard chow diet. Calorie intake was
matched, and growth parameters were carefully monitored. After a 4- or 8-week treatment
period, the ileum was scored for intestinal inflammation and epithelial cell morphology by
light microscopy. Selected cytokine (TNFα, INFγ, IL-10) and defensin-related cryptdin
(CRS1C, CRS4C) mRNA levels in the distal small intestine were determined by real-time
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PCR, and lymphocyte populations in spleen and mesenteric lymph node were examined
for CD4, CD8, CD44 and CD62L expression by flow cytometry. Finally, microbial contents
of both ileum and cecum were characterized using bacterial 16S rRNA fingerprinting (T-
RFLP). RESULTS Mice with established ileitis (≥10 weeks of age), given ED for a 4- or 8-
week treatment period, showed no improvement in histological scores. In contrast, ED
significantly decreased intestinal inflammation when treatment was begun before the develop-
ment of ileitis (N=12 per group, p<0.001). The greatest improvement was seen in the severity
of active inflammation and abormalities in epithelial architecture. Weight gain was slightly
increased in the ED cohorts, primarily due to enhanced caloric utilization, but we found
no significant differences in lymphocyte subsets or cytokine levels between the groups. We
did find, however, an increase in cryptdin expression in ED-fed mice which was associated
with marked differences both in colonization with specific bacterial species and in the
diversity of intestinal microbial flora. CONCLUSIONS ED prevents ileitis in the SAMP1/
YitFc model of Crohn's disease. This protection is associated with increased local expression
of antibacterial peptides and significant differences in the bacteria flora. Our findings suggest
that ED suppresses bacterial species capable of initiating intestinal inflammation, either
directly through actions on luminal bacteria or indirectly through increased expression of
epithelial “innate” immune responses.
S1600
Therapeutic Potential of Antigens of Ancylostoma Caninum and Schistosoma
Mansoni in TNBS-Induced Colitis in Mice
Nathalie E. Ruyssers, Joris G. De man, Benedicte Y. De winter, Alex Loukas, Rita M. Van
den bossche, Arnold G. Herman, Paul A. Pelckmans, Tom G. Moreels
Background: The hygiene hypothesis suggests an inverse relation between parasitic infections
and the frequency of chronic inflammatory bowel diseases. Our previous results indeed
showed a beneficial effect of concurrent parasitic infection on trinitrobenzene sulfonic acid
(TNBS) colitis in rats (Moreels et al, Gut, 2004). However, therapeutic treatment with living
helminths has serious drawbacks. These may be overcome by using helminth antigens instead
of living worms. Aim: We investigated whether isolated antigens of Ancylostoma caninum
and Schistosoma mansoni can improve the course of TNBS-induced colitis in mice. Methods:
For each antigen mixture (A. caninum and S. mansoni) male OF1 mice were divided in 5
groups: control-phosphate buffered saline (PBS), control-antigen, TNBS-PBS, TNBS-antigen
25μg, TNBS-antigen 50μg. Colitis was induced by intrarectal administration of 10mg TNBS
in 30% ethanol. Control mice were injected intrarectally with saline. Six hours after TNBS
or saline injection, mice were treated i.p. with 25μg or 50μg antigens or PBS. Mice were
sacrificed 3 days later and inflammation was scored based on 5 parameters: clinical disease
activity (CDA; range 0-8), macroscopic (MaS; range 0-12) and microscopic (MiS; range 0-
12) inflammation score, extent of colonic inflammation (ExtInf; cm), and myeloperoxidase
(MPO; units MPO/g tissue) concentration. Results (Table 1): Treatment of control mice
with the different antigens showed no signs of inflammation on all parameters tested (data
not shown). In the TNBS-PBS group all inflammatory parameters were significantly increased
compared to controls. Treatment of TNBS colitis mice with helminth antigens (TNBS-Ag)
significantly decreased MaS, ExtInf and MPO whereas CDA and MiS only tended to decrease.
Conclusions: Injection of antigens of A. caninum and S. mansoni reduced TNBS-induced
colitis in mice suggesting a therapeutic potential for helminth antigens in IBD.
Table 1
Data are shown as median (25% and 75% percentiles, non-parametric data) and mean±sem
(parametric data). *p≤0.05, significantly different from control-PBS; #p≤0.05, significantly
different from TNBS-PBS; Kruskal-Wallis for non-parametric data, Two way ANOVA for
parametric data; N=7-10
S1601
Reduction of Rat Colitis and Colonic TNF-α and IL-6 Levels, and
Augmentation of the Beneficial Actions of Sulfasalazine By
Dehydroepiandrosterone (Dhea)
Brendan J. Whittle, Csaba Varga, John Gebhard
Dehydorepiandrosterone (DHEA), an abundant endogenous steroid hormone with antioxid-
ant properties, can influence the activity of the nuclear factor, NF-κB, a key transcription
factor for the production of pro-inflammatory cytokines found in colitis. The effects of DHEA
in a 3 day rat colitis model and on colonic tumour necrosis factor-α (TNF-α) and interleukin
6 (IL-6) levels have been investigated and its interactions with the well-established therapy
for colitis, sulfasalazine, now explored. Colitis was induced in the rat by the intracolonic
instillation of trinitrobenzene sulfonic acid (TNBS;10 mg) and the extent of colonic inflamma-
tion assessed after 3 days in terms of macroscopic injury and colonic inflammatory biomarkers
and cytokines, myleoperoxidase (MPO), TNF-α and IL-6. Administration of DHEA (20-40
mg/kg, p.o. b.i.d.) obtained from InflablocCap™ capsules, commencing 48h prior to TNBS
challenge, caused a dose-dependent reduction in the area of macroscopic colonic injury
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(from 42 ± 4% to 19 ± 3% of the total area measured, at the higher dose; n=9; P<0.001)
and also significantly (P<0.05) reduced the macroscopic clinical score. The TNBS-provoked
5-fold increase in colonic MPO levels, an index of neutrophil infiltration, was also dose-
dependently inhibited by DHEA (by 64% at the higher dose, P<0.01), as was the 5-fold
increase in colonic levels of TNF-α and IL-6 as determined by ELISA (reduced by 79% and
50% respectively, P<0.01). Using a comparable protocol, administration of low doses of
sulfasalazine (12.5 mg/kg, p.o., b.i.d) or DHEA (10 mg/kg, p.o., b.i.d) alone had no significant
effect on TNBS-provoked macroscopic colonic damage or the elevated colonic levels of the
biomarker, MPO, determined after 3 days. In contrast, combination of these low doses of
DHEA and sulfasalazine substantially attenuated the colitis, reducing the macroscopic area
of injury by 51% (P<0.01), and reducing the elevated MPO by 66% (P<0.01). This combina-
tion also significantly reduced the elevated TNF-α and IL-6 levels in the colonic tissue by 80%
and 73% respectively (P<0.01 for both). These findings demonstrate that this formulation of
DHEA can reduce the macroscopic injury and the elevated inflammatory biomarkers, MPO,
TNF-α and IL-6 in this rat model of colitis. The beneficial therapeutic interaction observed
between low doses of DHEA and sulfasalazine on all colitis parameters determined may
indicate a potential clinical utility for this combination.
S1602
The Tripeptide Kdpt Proves Effective for Treatment of Murine Models of
Inflammatory Bowel Disease
Christian Maaser, Dominik Bettenworth, Klaus Kannengiesser, Andreas Luegering,
Thomas Brzoska, Christof Von eiff, Wolfram Domschke, Torsten Kucharzik
Background and Aims: As the tripeptide KDPT, H-Lys-D-Pro-Thr-OH, shows high structural
similarities to the C-terminal three amino acids of α-MSH, which are thought to mediate
the anti-inflammatory properties of this hormone e.g. in animal models of colitis, we aimed
to evaluate the anti-inflammatory potential of KDPT in murine models of IBD. Methods:
Experimental colitis was induced in C57BL/6 WT mice by addition of 2% w/v dextrane
sodium sulphate (DSS) in drinking water for five days. KDPT was applied intraperitoneal
in a prophylactic (daily application starting one day before DSS) and therapeutic setting
(KDPT daily from day 3 after DSS start). Furthermore the anti-inflammatory potential of
locally applied KDPT was tested by rectal installation of KDPT. In addition, the therapeutic
effect of KDPT was examined in the CD45RBhigh transfercolitis model. In both models, the
course of inflammation was monitored by weight loss, histological scoring of colonic changes
as well as MPO-activity and mucosal IL-1β mRNA expression. Results: In the prophylactic
(i.p.) as well as therapeutic setting, KDPT-treated animals showed a significantly reduced
overall weight loss in comparison with the control groups (p<0.05). Affirmatively, blinded
histological scoring revealed significantly reduced signs of colonic inflammation in treated
animals of both groups (p<0.05), prophylactic and therapeutic. These changes were paralleled
by a reduced mucosal MPO-activity and IL-1β mRNA-expression. In further experiments
with the DSS-colitis model, locally applied KDPT by rectal gavage led to a significantly
reduced weight loss, a significantly improved histological score in the distal colon and
significantly decreased mucosal expression of Il-1β mRNA. The anti-inflammatory potential
of KDPT was confirmed in the CD45RBhigh transfercolitis model, in which daily i.p. adminis-
tration of KDPT starting from day 26 after cell transfer ameliorated the course of disease
leading to a significant gain of weight (p<0.05) while animals of the control group continued
to loose weight. These changes were confirmed by histological analysis. Conclusions: Our
findings suggest KDPT as a potential, inexpensive and most likely less side effect causing
option for treatment of inflammatory bowel disease. Pharmacological testing is currently
performed with the aim of clinical trials in the near future.
S1603
A Selective Cxcr2 Receptor Antagonist, Sb656933-Aaa Reduces Disease
Symptomology and Ulceration in a Dnbs Rat Model of Colitis
Lisa A. Lione, Scott Mccleary, Laurens Kruidenier, Martin P. Vidgeon-hart, Jennifer L.
Stretton, Tracey E. Ashmeade, Kevin Lee, Jakob Busch-petersen, Sheila I. Schwartz, Peter
G. Mclean
Background: Neutrophil recruitment into the colon is believed to play a key pathogenic role
in Ulcerative Colitis and experimental colitis models. Increased levels of the potent neutrophil
chemoattractant NAP-2 (selective for the CXCR2 chemokine receptor) have been reported
in active UC (Kruidenier et al., 2006). We have previously observed that a selective CXCR2
antagonist is effective in murine DSS and rabbit formalin-immune complex colitis models
suggesting that selective antagonists of CXCR2 may have clinical utility in inflammatory
diseases, particularly where neutrophilic recruitment is a component. Aim/Methods: The
selective CXCR2 antagonist SB656933-AAA has previously been shown to inhibit CXCL1
(GRO-α) and IL-8-mediated activation and chemotaxis of human neutrophils. In the present
study we investigated the preventative effects of SB656933-AAA (10, 30, 100 mgkg po bid)
and Sulfasalazine (300 mgkg po qd) in the dinitrobenzenesulphonic acid (DNBS) model of
rat colitis, given for up to 10 days starting 1 day before colitis. Colitis was induced in rats
by intracolonic administration of 20mg of DNBS in 0.5ml of 50% ethanol. Results: SB656933-
AAA at 10 and 30 mgkg significantly reduced the disease symptomology (diarrhea, faecal
blood and body weight loss) and ulceration/inflammation (macroscopic score) in DNBS 7-
day rat model of colitis, with efficacy equivalent to sulfasalazine. Furthermore, inflammation
was evaluated histologically and SB656933-AAA at 30 and 100 mgkg showed a trend for
inhibiting cell infiltration similar to sulfasalazine. The time course effect of SB656933-AAA
(10 mgkg po bid) was also evaluated at 4, 7 and 10 days post colitis. Disease symptomology
was significantly reduced from as early as day 2 up to day 7 of colitis, whilst inflammation
and macroscopic damage was significantly reduced only at day 7 of colitis, with the early
(day 4) and later phases (day 10) being unaffected. Again the efficacy of SB6569333-AAA
was comparable to that of sulfasalazine. Colon MPO activity and cytokine levels were similarly
altered. Conclusions: Our data identify SB656933-AAA as anti-inflammatory in a rat model
of colitis, highlighting the opportunity for development of CXCR2 antagonists for the treat-
ment of inflammatory bowel diseases.
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S1605
Partial Replacement of Dietary Fat with MCT Improves the Course of the
Disease and Enhances the Apoptosis of Colonic Cd3+ Cells in IL-10(-/-)
Colitic Mice
Elisabet E. Pedrosa, Josep Manye, Violeta V. Lorén, Isabel I. Ojanguren, Lurdes L. Fluvià,
José maría J. Hernández, Gerhard Rogler, Eduard E. Cabré, Fernando F. Fernández-
bañares, Miquel angel Gassull
Rationale: Standard rodent diets mostly contain n6 fatty acids (n6), which are proinflammat-
ory and may contribute to perpetuate the experimental colitis in these animals. We previously
found that dietary MCT may down-regulate some inflammatory mediators in rats. We aimed
to assess 1) the effect of replacing 50% of dietary fat by MCT on the course of colitis in
IL10(-/-) mice, and 2) the molecular/cellular mechanisms involved. Methods: IL10(-/-) mice,
housed on pathogen-free environment, were fed diets with 18% of energy as fat, with 100%
sunflower oil (n6; n=12) or 50% sunflower oil/50% coconut oil (n6/MCT; n=12)for 8 weeks.
Then mice were sacrificed and the colon harvested to assess 1)macro and microscopic
damage (score 0-12), 2)intraepithelial (IEL) and lamina propria (LPL)lymphocyte (CD3+)
apoptosis, 3)cytokine production in culture, 4)expression of toll-like receptor 2 (TLR2), and
5)fatty acid profile. Results: Weight loss was milder in the n6/MCT group. Colitis incidence
(8% vs 66%) and microscopic score [0(0-0) vs 3.5(2-5)] were lower in this group. The
percent of colonic CD3+ cells was decreased in n6/MCT mice as compared to n6 group
[%IEL: 0.9(0.6-1.1) vs 12.3(9.7-14.5)*; %LPL: 2.7(1.8-3) vs 5.6(4.6-6.4)*]. This effect was
associated to increased IEL CD3+ cell apoptosis [52(37.3-58.8)% vs 8.7(7.9-12.4)%*]. n6/
MCT mice showed a markedly reduced IL6 [0.8(0.2-3.3) pg/ml vs 150(75-320)* pg/ml]
and IFN [0(0-1.1) pg/ml vs 110(29.4-275)* pg/ml] production, and a non-significant increase
in TLR2 expression [0.15(0.09-0.45) vs 0.004(0.002-0.1)]. Fatty acid profile was similar in
both groups. (*p<0.05). Conclusions: Partial replacement of dietary fat with MCT decreases
the incidence and severity of colitis in IL10(-/-) mice. This is associated to milder CD3+
cell infiltrate and lower proinflammatory cytokine production. CD3+ cell apoptosis might
regulate inflammation in this model.
S1606
Activity of Spleen Tyrosine Kinase (Syk) Is Required for Development of
Colitis in Mice
Aletta Kraneveld, Anneke Rijnierse, Ellen Herlaar, Rajinder Singh, Donald Payan, Jochen
Schmitz, Nigel W. Bunnett
Introduction Mast cells mediate allergic diseases and contribute to inflammatory bowel
disease and irritable bowel syndrome, where there is increased influx of mast cells and
release of mast cell products. In the intestine, mast cell products are proinflammatory and
signal to intrinsic and extrinsic neurons, resulting in functional disorders. The non-receptor
tyrosine kinase syk is essential for immunoreceptor signaling, including mast cell Fc receptors
and B and T cell receptors. We hypothesized that inhibition of syk suppresses mast cell-
dependent intestinal inflammation and functional disorders. Methods Mice were sensitized
with protein (ovalbumin, ip) or chemical (dinitro-fluorobenzene, DNFB, skin sensitization)
antigens, and challenged with antigen orally (ovalbumin) or intrarectally (dinitrobenzene
sulfonic acid, DNS). Mast cell activation was assessed by measuring mouse mast cell protease
1 (MMCP1) in plasma. Inflammation was evaluated macroscopically and microscopically
and by myeloperoxidase (MPO) assays. Stool consistency was used as an index of altered
function. Mice were treated the Syk inhibitor R788, which suppress IgE- and IgG-mediated
activation of Fc receptors and degranulation of mast cells, or vehicle (control). Results
Challenge of ovalbumin-sensitized mice caused mast cell degranulation, indicated by >50-
fold increase in MMCP1 compared to challenged, non-sensitized mice (p<0.05). R788
reduced MMCP1 levels in sensitized, challenged mice to levels of sensitized, non-challenged
mice, indicating inhibition of mast cell activation. In ovalbumin-sensitized mice, ovalbumin-
challenge induced widespread mucosal inflammation, characterized by increased MPO in
ileum (3.8-fold) and proximal colon (11-fold), indicative of granulocyte infiltration. R788
reduced MPO in ileum (2.6-fold) and colon (1.6-fold) (p<0.05). In DNFB-sensitized animals,
DNS-challenge induced accumulation of lymphoid follicles in the colonic mucosa (per colon:
9.8±1.6 vs. 4.0±1.1 in control), indicative of lymphocyte proliferation and recruitment.
R788 reduced follicle number to control levels (5.1±1.1). DNS challenge of sensitized animals
caused altered stool consistency (30% diarrhea, 60% loose stool). R788 prevented this effect
(0% diarrhea, 10% loose stool). Conclusions Antigen challenge of sensitized mice results
in degranulation of mast cells, inflammation (granulocytes and lymphocytes infiltration),
and functional disturbances (diarrhea). Syk inhibition prevents mast cell degranulation,
suppresses inflammation, and reduces functional disturbances. Thus, syk inhibitors are a
potential novel therapy for inflammatory and functional disorders of the intestine.
S1607
Cholinergic Anti-Inflammatory Pathway in Experimental Colitis
Aiping Bai, Xianmin Fan, Nonghua Lu
Background and aims: Recent studies have reported that neuroimmune interaction can affect
the process of intestinal inflammation. The cholinergic anti-inflammatory pathway is a neural
mechanism that is controlled by the vagus nerve, and inhibits proinflammatory cytokine
overproduction in inflammatory response. Inflammatory bowel diseases (IBD) are character-
ized by proinflammatory cytokines, tissue damage, and loss of neurons in inflamed mucosa,
which implies the cholinergic anti-inflammatory pathway is impaired during the process of
inflammation. To investigate the potential therapeutic effect of the cholinergic anti-inflammat-
ory pathway on IBD, we studied the effect of cholinergic agonist anabaseine, and a nicotinic
receptor antagonist chlorisondamine diiodide in TNBS-induced colitis. Methods: Trinitroben-
zene sulfonic acid (TNBS)-induced colitis was induced on day 0, 10μg anabaseine or 1.5μg
chlorisondamine diiodide was administrated i.p to each mouse right after the induction of
colitis, and repeated daily till the mice were sacrificed on day 7. Inflammation was examined
by histological analysis, myeloperoxidase (MPO) activity, and the production of proinflam-
matory cytokines such as TNF-α and IL-1β in colonic tissue. The expression of neuronal
marker as S100 protein and neurofilament protein was determined by immunohistochem-
istry. Results: The mice with colitis treated by anabaseine showed less tissue damage, lower
MPO activity, and lower proinflammatory cytokine levels, compared with mice with untreated
colitis, whereas mice treated by chlorisondamine diiodide showed exacerbated tissue damage,
the highest MPO activity, and the highest proinflammatory cytokine levels. The expression
of S100 protein and neurofilament protein was absent in inflamed mucosa of mice with
TNBS-induced colitis or those treated by chlorisondamine diiodide. However, administration
with anabaseine restored the expression of those neuronal markers in the mucosa of mice
with TNBS-induced colitis, and prevented the loss of mucosal neurons. Conclusion: The
agonist of the cholinergic anti-inflammatory pathway inhibits colonic inflammatory response
by down-regulating the production of proinflammatory cytokines, and by inhibiting loss of
mucosal neurons, which suggests that the cholinergic anti-inflammatory pathway may be a
new potential target for management of IBD.
S1608
The Cannabinoid-2 (Cb2) Receptor Mediates Protection Against TNBS Colitis
in Mice
Martin Storr, Cathy M. Keenan, Kamela D. Patel, Keith A. Sharkey
Background: The endocannabinoid-system has been reported to be involved in intestinal
inflammation. Activation of cannabinoid-1 (CB1) receptors results in attenuation of experi-
mental colitis. However, little is known about the possible influence of the CB2 receptor in
intestinal inflammation. Aim: Our aim was to describe the effects of a CB2 receptor agonist
(JWH 133) and a CB2 receptor antagonist (AM630) in experimentally induced, trinitroben-
zene sulfonic acid (TNBS), colitis in mice. Methods: Colitis was induced in male C57BL/6
mice by intra-rectal installation of 100 μl 4% TNBS in 30% ethanol. Weight changes were
observed for 3 days. At day 3 the mice were sacrificed and the colon was removed for
macroscopic scoring and the evaluation of myeloperoxidase (MPO) activity. 6-10 mice in
each group were treated with intraperitoneal injections of the CB2 receptor agonist JWH
133 (20mg/kg) once daily or twice daily, the CB2 antagonist AM630 (10mg/kg) once daily
or vehicle. Results: Intrarectal installation of TNBS caused marked colonic inflammation.
TNBS treated mice had a macroscopic score of 7.2 ± 2.2 compared to 1.2 ± 1.1 in the
vehicle (ethanol) treated control mice. TNBS treated mice showed a MPO level of 5.5 ±
2.1U/mg compared to 1.2 ± 1.1 U/mg in the vehicle control mice. The CB2 receptor agonist
JWH 133 reduced the macroscopic score and MPO levels in a dose dependent manner
(macroscopic score: 5.4 ± 2.8 once daily; 5.4 ± 2.2 twice daily; MPO: 1.2 ± 0.8 U/mg and
0.6 ± 1.0 U/mg). In contrast, the CB2 receptor antagonist AM630 caused no significant
change in inflammation (macroscopic score: 9.2 ± 1.7; MPO: 4.9 ± 1.7). Body weight changes
and survival rates were not significantly different amongst treatment groups. Conclusion:
This study provides evidence that activation of the CB2 receptor reduces colonic inflammation
under experimental conditions suggesting that the CB2 receptor may be a possible therapeutic
target in inflammatory bowel disease.
S1609
Stoichiometry of Binding to and Complex Formation with TNF By
Certolizumab Pegol, Adalimumab, and Infliximab and the Biologic Effects of
These Complexes
Alistair J. Henry, Jeff Kennedy, Gianluca Fossati, Andrew M. Nesbitt
Background: Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF
antibody. Due to its unique structure, it may have different stoichiometry and complex
formation properties to the bivalent antibodies adalimumab and infliximab. Immune com-
plexes can be a destructive immunologic feature with various unwanted consequences. We
determined the stoichiometry of binding of the 3 anti-TNFs to the TNF trimer, and the
size and In Vitro biologic consequences of the immune complexes they form. Methods:
Stoichiometry of binding was determined by isothermal titration calorimetry, which relies
on the production of small, measurable amounts of heat whenever a binding event occurs.
Small amounts of anti-TNF were added to TNF until no more heat of binding was measured,
and the number of anti-TNF molecules bound to a TNF trimer was determined. Dynamic
light scatter determined the size of the complexes formed by the anti-TNFs over a range of
antigen:antibody ratios. The approximate molecular weight was determined from the complex
size. The effect of the complexes on peripheral blood neutrophils was assessed by measuring
degranulation (myeloperoxidase release) and superoxide production (oxidation of cyto-
chrome c).Results: Dynamic light scattering studies showed that, at the optimum antigen:an-
tibody ratio, adalimumab and infliximab formed huge complexes >30 nm diameter. This
suggests that these bivalent antibodies readily crosslink TNF trimers by binding to monomers
in different trimers. Certolizumab pegol complexes were <20 nm, consistent with the theory
that due to certolizumab pegol's univalent structure it cannot crosslink TNF trimers to form
large complexes. Isothermal titration calorimetry showed that certolizumab pegol bound to
2.9 monomers in a trimer at saturation. Infliximab and adalimumab bound 2.46 and 2.48
monomers, respectively. This suggests that the bivalent antibodies have difficulty binding
to all monomers in a trimer, presumably because of steric or allosteric effects. The large
immune complexes formed by adalimumab and infliximab caused degranulation and
superoxide production by neutrophils, whereas those formed by certolizumab pegol caused
only marginal effects. Conclusions: Certolizumab pegol does not form large complexes with
TNF trimers due to its unique univalent structure preventing crosslinking. Infliximab and
adalimumab form enormous complexes with TNF due to their bivalent structure, which
have proinflammatory effects on neutrophils In Vitro causing them to degranulate and
produce superoxide. These results show that certolizumab pegol has a unique mode of
action in this regard due to its fundamentally different structure.
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S1610
Induction of Antigen-Specific Tolerance By Oral Administration of Lactococcus
Lactis Delivered Antigen
Inge L. Huibregtse, Veerle Snoeck, Henri Braat, Esther C. De jong, Sander J. Van
deventer, Pieter Rottiers
Introduction: Antigen-specific immune suppression is an attractive therapeutic goal for the
treatment of autoimmune and allergic inflammatory diseases of the gastro-intestinal tract.
Active delivery of recombinant autoantigens or allergens at the intestinal mucosa by genetically
modified Lactococcus lactis (LL) provides a novel therapeutic approach for the induction
of tolerance. For this purpose we genetically engineered ovalbumin (OVA) secreting LL (LL-
OVA) and evaluated the local and systemic immune response in OVA-TCR transgenic mice
(DO11.10) after oral supplementation. Methods: A PCR amplified OVA cDNA fragment was
ligated in the erythromycin resistant pT1NX vector. LL and LL-OVA were grown overnight
at 30 C in erythromycin supplemented medium. In Vitro and In Vivo quantification of the
secreted OVA was evaluated by ELISA. Mice were sensitized with 10 μg OVA s.c. and fed
for 10 days with BM9 (control), OVA 1ug, LL or LL-OVA (1x10 9 CFU)/day. Tolerance
induction was assessed by DTH responses, IL-10 and IFN-γ measurements after ex vivo
restimulation, proliferation assays with neutralizing IL-10 and TGF-β antibodies and adoptive
transfer experiments using different CD4+CD25 subsets. Results: Daily intragastric adminis-
tration of LL-OVA in DO11.10 mice led to a significant decrease in DTH response compared
to the sensitized BM9 treated mice (1x10 -2 mm vs 15x10 -2 mm). Furthermore a significant
increased IL-10 production of OVA-restimulated cervical lymph nodes, splenocytes and
GALT cells was seen in LL-OVA treated mice compared to the control groups and this was
accompanied by significant decreased proliferative capacity of the splenocytes and a reduction
of splenic IFN-γ production. Interestingly, suppression was mediated by an atypical popula-
tion of CD4+CD25- ‘adaptive' regulatory T cells that function through a TGF-β dependent
mechanism. Conclusion: Mucosal delivery of OVA by genetically modified LL induces
suppression of local and systemic inflammatory OVA specific T-cell responses in DO11.10
mice, by the induction of TGF-β dependent regulatory T-cells. These data suggest that the
mode of mucosal delivery of an antigen to the mucosal immune system critically determines
immune activation. Furthermore our data provide promise for the development of effective
therapeutics for treatment of several common autoimmune, inflammatory and/or allergic
diseases by autoantigen- and/or allergen-secreting L.lactis.
S1611
Oral Administration of Alkaline Phosphatase Ameliorates Colitis
Annemarie Tuin, Alie De jager-krikken, Lisette Bok, Raaben Willem, Markwin P. Velders,
Dirk K. Meijer, Klaas Poelstra, Gerard Dijkstra
Crohn's disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory
bowel diseases with unknown etiology, but a dysregulated mucosal immune response to
gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands, especially
lipopolysaccharide (LPS), seem to contribute in the maintenance of the disease. Previously,
we showed that the enzyme alkaline phosphatase (AP) is able to detoxify LPS and the aim
of this study was therefore to examine its role in inflammatory bowel diseases.Methods:We
examined intestinal AP (iAP) mRNA expression and LPS-dephosphorylation in intestinal
biopsies of control persons and IBD patients, and we studied the effect of orally administered
iAP-tablets on the progression of dextran sodium sulphate-induced colitis in rats.Results:
In healthy persons, iAP mRNA and protein expression was high in the ileum relative to the
colon. iAP mRNA expression was not altered in CD patients, but it was markedly reduced
in UC patients when inflamed tissue was compared to non-inflamed tissue. Oral administra-
tion of iAP-tablets to colitic rats resulted in a significant attenuation of colonic inflammation
as reflected by reduced mRNA levels for TNF-α, IL-1β, IL-6 and iNOS, a reduced iNOS-
staining and inflammatory cell influx, and a significantly improved morphology of the
intestinal wall. Conclusions: The present study shows that epithelial iAP mRNA expression
is reduced in UC patients. The rat model indicates that oral administration of iAP can
replenish the intestinal tract with active AP-enzymes, resulting in a significant reduction of
inflammation. This may provide new opportunities for the treatment of IBD.
S1612
Inhibition of Cathepsins As a Therapeutical Option for Inflammatory Bowel
Diseases (IBD)
Heidi Piberger, Martin Hausmann, Katrin Menzel, Florian Obermeier, Werner Falk,
Juergen Schoelmerich, Gerhard Rogler
Introduction: Cathepsins (CTS) are lysosomal cystein proteases which have intra- and
extracellular functions. During IBD they are secreted by macrophages and contribute to
tissue destruction in the mucosa. CTS represent an interesting therapeutical target as it may
be possible to eliminate only the extracellular tissue damaging part, but not the physiological
essential intracellular protein. Previous studies showed a high expression of cathepsin D
(CTSD) in intestinal macrophages of inflamed mucosa from patients with IBD. Inhibition of
CTSD and combined inhibition of cathepsins B- and L led to an amelioration of experimental
dextrane sodium sulphate (DSS) colitis in mice. Aim of this study was to identify the CTS,
which has the most prominent influence on colitis. Methods: DSS colitis was induced and
cathepsin B (CTSB) was inhibited by CA074 and cathepsin L (CTSL) by Z-Phe-Tyr-aldehyde
respectively. Inhibitors were applicated intraperitoneally at a dose of 7 mg/kg each. The
control group was treated with PBS. Read out parameters were course of weight loss,
inflammatory reduction of colon length and the histological degree of inflammation and
epithelial damage (histological score). Results: Inhibition of CTSB during acute DSS colitis
resulted in elongated colon length, while the CTSL inhibitor had no influence on this
parameter compared to control mice. Accordingly, DSS-induced weight loss was reduced
by 37% after CTSB inhibition compared to the PBS-treated group. In contrast, inhibition
of CTSL had no impact on weight loss. Furthermore inhibition of CTSB led to an improvement
of the histological scores, while the CTSL inhibitor could not reduce the degree of inflamma-
tion. Conclusion: Inhibition of CTSB caused an amelioration of inflammation, while CTSL
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inhibition did not affect parameters of DSS colitis. CTSB therefore seems to be a promising
therapeutical target for treatment of colitis.
S1613
Intravenously Administered Bone Marrow-Derived Mesenchymal Stem Cells
Gather Into Inflamed Tissues to Prevent Focal Inflammation in Dextran
Sulfate Sodium-Induced Acute Colitis in Rats
Fumio Tanaka, Kazunari Tominaga, Masahiro Ochi, Tetsuya Tanigawa, Masatsugu Shiba,
Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi, Tetsuo
Arakawa
Background: Bone marrow transplantation significantly affects the systemic immune system
as well as showing therapeutic efficacy for leukemia. Bone marrow cells (BMCs) can differenti-
ate into intestinal subepithelial myofibroblasts (SEMFs) which have proinflammatory effects.
In contrast, BMCs containing mesenchymal stem cells (MSCs) have both therapeutic effects
for clinical human colitis via partly mediated by mucosal regeneration and anti-inflammatory
function under the particular conditions. We examined the therapeutic efficacy and distribu-
tion of MSCs for dextran sulfate sodium (DSS)-induced acute colitis in rats regarding
with anti-inflammatory or regenerative effects such as various cytokines or growth factors
expressions. Materials & Methods: Experimental colitis was produced by 4% DSS in drinking
water for 7 days in inbred male Lewis rats. Bone marrow was extruded from tibias and
femurs. Then, its mononuclear cells were isolated and cultured in low-glucose DMEM
containing 10% fetal bovine serum for MSCs outgrowth. On day 0, 2, and 4, MSCs labeled
with PKH67, green fluorescent cell-linker dye, were injected via tail vein. We checked the
volumes of food and water intake, stool condition, and body weight everyday. Distribution
of PKH67-labeled MSCs in injured tissues was evaluated by histological analysis using
indirect immunofluorescence assay. On day 7, total colon was excised and each colonic
mRNA expression of various cytokines (TNF-α, IL-1β, IL-10, COX-2) and growth factors
(VEGF, HGF, b-FGF) were measured by real time RT-PCR method. Results: MSC treatment
improved the bloody stool and body weight loss, and significantly inhibited the shortening
of colon length. PKH67-labeled MSCs were mainly distributed to subepithelial tissue of
injured rectum. At the rectum of MSC-treated rats, mRNA expressions of TNF-α, IL-1β,
COX-2 were markedly decreased to about 40, 15 and 15%. IL-10 was also decreased to 25%.
VEGF, HGF and b-FGF were also significantly suppressed to 40, 25 and 25%, respectively. At
the distal colon site, similar tendency was observed. Conclusion: These findings suggested
that intravenously administered MSCs gathered into inflamed tissues to prevent focal inflam-
mation rather than induction of tissue regeneration mediated by SEMF-derived growth
factors in DSS-induced acute colitis in rats.
S1614
Am1241, a Cb2-Specific Agonist Protects Against Immune But Not Acute
Colitis
David A. Ziring, Jonathan Braun
Background: Cannabinoid agonists play important biologic and potential therapeutic roles on
cell types involved in inflammation and inflammatory pain. While the CB1 (endocannabinoid)
receptor predominates in the CNS, CB2 receptors are found primarily in cells of the immune
system. The capacity of cannabinoids to pharmacologically alter immune function is well
established, particularly on the production and responsiveness to certain cytokines by macro-
phages and dendritic cells. We have previously shown the requirement of the CB2 receptor
on immune cells for the development of specific immunoregulatory B and T cell subsets.
These findings indicated that CB2-specific agonists may modulate the activity of immunoregu-
latory cell subsets. Inflammatory bowel disease results from dysregulation of immune
homeostasis and an inappropriate response to commensal bacteria. We were prompted to
determine whether agonists at the CB2 receptor could augment protection against murine
modeled colitis. To test this, we modeled both acute and immune colitis via DSS and
Galphai2 -/- T cell transfer, respectively. Methods: We administered 3.5% DSS in drinking
water to groups of 6 C3H/HeJ mice with contemporaneous administration of CB2 agonist,
AM1241 1 mg/kg or vehicle control (DMSO) intraperitoneally (IP). We monitored the mice
for weight loss and hematochezia. We withdrew the DSS after 5 days and sacrificed the
mice on day 8 for the collection of colonic tissue for histologic colitis scoring. In a separate
experiment, we isolated splenic T cells from sick Galphai2 -/- mice and administered them
IP to 12 Rag 1 -/- mice and similarly administered AM1241 or DMSO. Results: We found
that mice injected with AM1241 were not protected against acute colitis modeled by DSS.
AM1241 was protective against the development of immune Galphai2 -/- mediated T cell
colitis as measured by both weight loss and histology. Conclusion: AM1241, a CB2 receptor-
specific agonist, protects against immune but not acute colitis. DSS injury models acute, T
cell-independent colitis, mimicking the initiating events in chronic intestinal inflammation.
The therapeutic role of CB2 specific agonists appears to augment the activity of cells engaged
in the immunoregulation of gut inflammation, rather than by attenuating effector function.
DSS colitis is largely dependent on interferon gamma and STAT3-mediated IL-6 production,
while the colitis caused by Galphai2 -/- T cell transfer is mediated in part by IL-17. Further
investigation of CB2 agonists will be useful in resolving cell types and molecules that serve
as decision points in intestinal inflammation with potential therapeutic utility in human IBD.
S1615
Decoy Oligodeoxynucleotides Targeting AP-1 and Nf-κB Attenuate Intestinal
Inflammation in Murine Experimental Colitis
Ichiro Moriyama, Shunji Ishihara, Mohammad Rumi, Md Aziz, Yoshiyuki Mishima,
Chikara Kadota, Naoki Oshima, Norihisa Ishimura, Hideaki Kazumori, Yasunori
Kadowaki, Yuji Amano, Yoshikazu Kinoshita
(Background & Aim) A variety of therapeutic strategies are used for inflammatory bowel
diseases (IBD), though none have been shown to be extremely effective. AP-1 and NF-κB
are the major transcription factors that upregulate genes involved in immune as well as
A-232AGA Abstracts
proinflammatory responses in the gut in the pathogenesis of IBD. We investigated the
therapeutic efficacy of decoy oligodeoxynucleotides (ODNs) targeting AP-1 and NF-κB to
prevent dextran sulfate sodium (DSS)-induced colitis in mice. (Materials & Methods)
Double-strand decoy ODNs were generated by annealing equimolar amounts of single
stranded sense and anti-sense phosphorothioate-modified ODNs containing consensus AP-
1 or NF-κB binding sequences. Scrambled ODNs were also generated as controls for the
decoy ODNs. The In Vitro functional effects of the decoy ODNs were examined using reporter
gene luciferase assays with specific AP-1 and NF-κB promoter constructs. Experimental
acute colitis was induced in 7-week-old male BALB/c mice by administering a 2.5% DSS
solution in drinking water for 7 days. AP-1 or NF-κB decoy ODNs or scrambled ODNs
were intraperitoneally injected from days 2 to 5 during the DSS-administration period, after
which the mice were killed and their colon sections examined to evaluate the therapeutic
effects of the decoy ODNs. Colitis was assessed by weight loss, colon length, histopathology,
and myeloperoxidase (MPO) and interleukin (IL) -1β in the colonic tissue contents. (Results)
Transfection with decoy ODNs clearly inhibited the transcriptional activities of the AP-1
and NF-κB promoter constructs in cells from the HEK293 cell line. In the experimental
colitis model mice, treatment with AP-1 or NF-κB decoy ODNs, but not the scrambled
ODNs, significantly inhibited weight loss and shortening of the colon induced by DSS
administration. Further, histological examinations showed that lamina propria infiltration
by both polymorphonuclear and mononuclear cells as well as crypt epithelial damage were
markedly decreased in the decoy ODN-treated mice. Decoy ODN treatment also decreased
the colonic tissue contents of MPO and IL-1β in mice with DSS-induced colitis. (Conclusion)
Double-strand decoy ODNs targeting AP-1 and NF-κB effectively attenuated intestinal inflam-
mation associated with experimental colitis in mice, indicating the potential of targeting
proinflammatory transcription factors in the development of new therapies for IBD.
S1616
Fty720 Ameliorates Oxazolone Colitis in Mice By Affecting T Helper Type 2
Functions Via the IL-1 Receptor Related Protein T1/St2 Running Title: Fty720
Affects Th2 Functions in Oxazolone Colitis in Mice
Carolin Daniel, Nico A. Sartory, Gerd Geisslinger, Heinfried H. Radeke, Juergen M. Stein
Background & Aims: The sphingosine-1-phosphate analogue FTY720 is known to alter
migration and homing of lymphocytes via sphingosine1-phosphate receptors. However,
several studies indicate that its mode of action is more complex and that FTY720 may also
directly influence cytokine effector functions. The object of this study was to investigate the
effect of FTY720 in T helper type (Th2)-mediated oxazolone-induced colitis in mice. Methods:
A rectal enema of oxazolone [90 mg/kg body weight] was applied to Balb/c mice. FTY720
was administered i.p. from day 0-3 or from day 3-5 following the instillation of the haptenating
agent. Assessment of severity of colitis was performed daily. FTY720 plasma levels were
detected using LC-MS/MS-analysis. Colon tissue was analyzed macroscopically and micro-
scopically, myeloperoxidase activity as well as cytokine levels of lamina propria CD4+ T-
cells and T1/ST2- as well as GATA3-expression were determined. Results & Conclusions:
Treatment with FTY720 prominently reduced the clinical and histopathologic severity of
oxazolone-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and
microscopic intestinal inflammation. The therapeutic effects of FTY720 were associated with
a prominent reduction of the key effector Th2-cytokines IL-13, IL-4 and IL-5. Strikingly,
FTY720 also distinctly inhibited T1/ST2-expression (FTY720 [3 mg/kg]: 38.73±7.33% of
Oxazolone-group; p<0.001), a member of the IL-1 receptor family, which is involved in
Th2 effector functions. In addition, we observed a significant reduction of GATA3 protein
expression following treatment with FTY720. To further support this concept, In Vivo
blockade of IL-13 significantly abrogated the immunomodulatory potential of FTY720 in
Th2-mediated colitis. In conclusion, our data provide the first evidence that FTY720 exhibits
beneficial prophylactic as well as therapeutic effects in Th2-mediated experimental colitis
by directly affecting Th2 cytokine profiles probably by reducing T1/ST2 and GATA3, thus
offering a new auspicious therapeutic instrument for the treatment of human ulcerative colitis.
S1617
Neutrophil Elastase Inhibitor Ameliorates Experimental Murine Colitis
Yasuo Shioya, Kyoko Katakura, Kaori Kanno, Keietsu Saito, Ryoma Suzuki, Hiromasa
Ohira
Background: Neutrophil elastase is a proteinase which exists in granulocytes and plays an
important role in the pathogenesis of inflammatory disorders. It has been reported that
neutrophil elastase activity is increased in both colonic mucosa and blood of inflammatory
bowel disease (IBD) patients, and also that becomes an aggravation factor of IBD. To develop
a new therapy for IBD, we examined the effect of a neutrophil elastase inhibitor, Sivelestat
sodium hydrate, on experimental murine colitis. Methods: Acute colitis was induced to
BALB/c mice by giving dextran sulfate sodium (DSS) to their drinking water for 7 days.
Sivelestat sodium hydrate was administered subcutaneously to mice prior to and during the
induction of colitis. Disease activity index (DAI), colonic myeloperoxidase (MPO) activity,
luminal neutrophil elastase activity, and mRNA expression in colon were investigated. Results:
Subcutaneous administration of Sivelestat sodium hydrate ameliorated the severity of DSS-
induced colitis. Neutrophil elastase activity was increased in inflamed colon and which
was reduced by Sivelestat sodium hydrate administration. Even KC, mature granulocyte
chemotactic factor, was decreased in mRNA expression level in the colon of Sivelestat sodium
hydrate prescribing mice. Conclusion: These results suggested Sivelestat sodium hydrate
ameliorated colonic inflammation by decreasing not only the activity of neutrophil elastase
but also the effect of chemotactic factor. Clinicaly, Sivelestat sodium hydrate improves the
injury that is associated with systemic inflammatory response syndrome. Same as this, clinical
use of this inhibitor would further clarify the usefulness in clinical colonic inflammation.
S1618
Resveratrol Does Not Reduce the Severity of Experimental Colotis in Mice
Petr Protiva, Michael E. Hopkins, Kan Yang, Peter R. Holt, Martin Lipkin
Background: Resveratrol (RES) is a natural polyphenolic phytoalexin that generally is consid-
ered an anti-inflammatory compound due to its ability to inhibit NFkappaB activation. RES
has been shown to reduce the severity of TNBS-induced colitis in rats. Hypothesis: Using
the mouse model of dextran sulfate (DSS)-induced experimental colitis we tested the hypo-
thesis that RES administration reduces the severity of colitis in - vivo. Methods: Young male
C57BL/6J mice were fed an AIN76A diet ± resveratrol 0.1% or 1% and colitis was induced
by DSS 1 or 2% (w/v) in drinking water. The severity of colitis was evaluated by clinical and
histological parameters including weight loss, survival, severity of diarrhea, and histological
changes in colon. Total RNA also was extracted from colons of the DSS 1% group and used to
create cDNA to measure mRNA levels of TNF alpha, IFN gamma, IL6 and IL10 inflammatory
cytokines. The protocol was approved by The Laboratory Animal Research Center at the
Rockefeller University. IACUC Results: DSS loads were 12.2 mg/g in the 1% group and
27.1 mg/g in the 2% group and resulted in weight loss of -4.2% in the DSS 1% and -10.6%
with the DSS 2% group. DSS 1 or 2% induced significant clinical and histological colitis
(P<0.001, DSS 1% or 2% vs controls) and induced all measured inflammatory cytokines
mRNAs when compared to controls (P<0.05). Mice fed the AIN76A diet alone vs
AIN76A+RES 0.1 or 1% showed no significant differences in levels of cytokine mRNAs or
clinical or histological colitis score. Adding RES 0.1% to the diet did not significantly reduce
the severity of colitis. Adding RES 1% to the diet of mice with colitis induced by DSS 2%
actually resulted in increased mortality not present in animals fed control diets. Conclusion:
The results of these 2 independent experiments indicate that RES does not reduce the
severity of inflammation in experimental DSS colitis in mice and it may actually worsen the
clinical outcome. Recent rodent studies showed that high dose RES supplementation may
offer some health benefits such as reduction of the negative impacts of high fat diet but our
study clearly demonstrated that RES also has a proinflammatory potential that may result
in harmful consequences.
S1619
Pretreatment with Lactobacillus Fermentum (Lf) Decreases the short-Term
Severity of Experimental Colitis in Balb/C Mice
Lorén Violeta, Josep Manye, Elisabet E. Pedrosa, Isabel I. Ojanguren, Eduard E. Cabré,
Ramon Bartolí, Jordi Xaus, Miquel angel Gassull
Rationale: Imbalance in gut microbiota is a potential pathogenic mechanism for IBD. Probi-
otics prevent bowel colonization by pathogens, may be immunomodulatory, and improve
the gut barrier function. Also, LF has a high antioxidant capacity that may cope with the
oxidative stress of IBD. We aimed 1) to assess the effect of pretreatment with LF on
TNB-induced colitis in Balb/c mice, and 2) to evaluate the possible associated changes
in inflammatory mediators. Methods: 30 Balb/c mice, housed in specific pathogen-free
environment, received either LF (109 CFU/day, n=15) or vehicle (30% PBS, n=15) in drinking
water for 2 w. Then, therapy was discontinued and TNB (a single 0.5 mg TNB/50% ethanol
enema) or sham colitis (a single saline enema) were induced to 10 and 5 animals per group,
respectively. Mice were sacrificed 72 h after colitis induction, and the colon harvested for
macro- and microscopic scoring (0-12), and myeloperoxidase (MPO) activity. Colon tissue
was cultured and eicosanoid and cytokine levels measured in the supernatant. Results: In
TNB colitis mice, the colonic weight/length ratio (median [IQR]) was lower in the LF than
in vehicle group (24[22-28] vs 29[26-35] mg/cm; p=0.02). Also, the histological score was
lower in LF than in vehicle group (5.6[5.2-5.9] vs 6.8[6.1-7.7]; p=0.04). The MPO activity
trend to increase in the vehicle group. Surprisingly, the production of the proinflammatory
cytokine IL-2 was greater in the LF group. Despite this fact, levels of PGE2 and IL-4 -both
with cytoprotective and regulatory actions- were higher on the LF group [8.5±1.0/4.9±0.5
pg/ml, p=0,017 and 0.8(0.5-0.88)/0.3(0.25-0.45) pg/ml, p=0.05; respectively]. LF did not
have any effect on sham colitis. Conclusions: Pretreatment with LF attenuates the severity
of colonic damage in TNB colitis. This effect is associated with apparently antagonic changes
in immulogical markers, which deserve further research.
S1620
Therapeutic Effect of Shi-219, a Novel Water-Soluble Prodrug of Eg626
(Phthalazinol), On Mouse Dextran Sodium Sulfate-Induced Colitis
Naoko Murano, Mitsuyuki Murano, Takuya Inoue, Kuramoto Takanori, Kumi Ishida, Ken
Kawakami, Yousuke Abe,, Eijiro Morita, Takashi Nishikawa, Ken Toshina, Shigeru Ito,
Ichiro Hirata, Ken-ichi Katsu
BACKGROUND: Increased cytokines, such as IL-1b, TNF-a, and IL-6, and the eicosanoids,
LTB4, TXB2 and PGE2, participate in inflamed colonic mucosa of patients with inflammatory
bowel disease (IBD) as part of the local inflammatory response. Clinical trials of EG626
(Phthalazinol), a platelet aggregation inhibitor, were conducted in patients with arterioscler-
osis in the 1980's and its effectiveness was confirmed. EG626 has also been reported to
inhibit the activity of cyclic AMP and eicosanoids, and thus exhibits an anti-inflammatory
effect. In this study, we sought to elucidate the cytoprotective mechanisms of intraperitoneal
SHI-219, a novel water-soluble prodrug of EG626, in a mouse dextran sodium sulfate (DSS)-
induced colitis, which resembles human ulcerative colitis. METHODS: Mice were randomized
into four groups: 1) a normal group that received tap water for 7 days, 2) a control group
that received 5% DSS for 7 days and 0.3 ml of distilled water/day i.p., 3) a SHI-219 (2mg)
group that received 5% DSS for 7 days and SHI-219 (2mg) in 0.3ml of distilled water/day
i.p., and 4) the SHI-219 (0.5mg) group that received 5% DSS for 7 days and SHI-219
(0.5mg) in 0.3ml of distilled water/day i.p.. Mice were sacrificed under anesthesia on day
7. The effects of SHI-219 were evaluated by Disease Activity Index (DAI), Histological
Damage Score (HDS). The local expression and secretion of proinflammatory mediators
including proinflammatory cytokines (i.e., IL-1b, IL-6, TNF-a) and eicosanoids (i.e., PGE2,
LTB4, TXB2, and COX-2) were measured by ELISA. RESULTS: DAIs and HDSs were
significantly lower in mice treated with SHI-219 (2mg) compared with the Control group
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(p<0.01). The mucosal concentrations of IL-1b, IL-6, and TNF-a were significantly lower
in the SHI-219 treated groups compared with the Control group (p<0.01). TXB2 and LTB4
concentrations were significantly lower SHI-219 treated groups(p<0.01, p<0.05)), but PGE2
concentrations were not inhibited. COX-2 expression also correlated with the degree of
inflammation in the intestinal mucosa in the SHI-219 treated group, indicating that SHI-
219 did not inhibit COX-2 expression by immunohistochemical staining. CONCLUSIONS:
In this study, treatment with SHI-219 was able to ameliorate the pathological, and clinical
damage of DSS-induced colitis. The compound inhibited both TXB2 and LTB4 production
in DSS-induced colitis in mice, but did not inhibit COX-2 or PGE2, which are important
for cytoprotection in the colonic mucosa. These results suggest that administration of SHI-
219 is effective in ulcerative colitis. The properties of SHI-219 may make it a potential new
therapeutic drug for IBD.
S1621
High Throughput Screening of a 3000 Member Secreted Protein Library Leads
to the Identification of Proteins That Promote Epithelial Restitution in Animal
Models of IBD
Kristen L. Pierce, Thomas Brennan, Aileen Zhou, Shannon A. Marshall, Dirk Behrens,
Ariel Pios, Robert Dean, William Roscoe, Thomas L. Bray, Scott J. Giese, Thadd Reeder,
Stephen K. Doberstein
FivePrime Therapeutics has developed a unique, genome-wide library of human secreted
proteins which we screen in high-content cell-based assays to determine the most potent
and specific factors for a given human disease. To discover the best protein drug candidates
for protection and regeneration of the intestinal epithelium, we assayed our comprehensive
human secreted protein library (approximately 3,000 unique proteins) for molecules with
the ability to activate cell survival pathways by phosphorylation of Akt. We screened primary
rat intestinal epithelial cells and the adenocarcinoma cell line, HT-29, using high-throughput
antibody-based detection of phospho-Akt. Initial hits from these assays were further tested
in secondary assays to determine their relative potency and specificity. Based on these In
Vitro assays, we have identified the two most promising compounds (FPT042 and FPT046).
In Vitro, both FPT042 and FPT046 are highly potent stimulators of Akt phosphorylation
(Ec50=2.7 ng/ml and Ec50=3.2 ng/ml, respectively). As expected, FPT042 and FPT046 also
stimulate intestinal epithelial cell survival and proliferation, with Ec50s = 6.25 ng/ml and
6.4 ng/ml, respectively. In addition, both FPT042 and FPT046 potently stimulate phosphoryl-
ation and activation of a second intracellular kinase, ERK (Ec50s =15.1 ng/ ml and 0.43
ng/ ml, respectively), which also drives intestinal cell survival and proliferation. Both molec-
ules have demonstrated efficacy in the dextran sodium sulfate (DSS) model of IBD. In this
model, hydrodynamic tail vein transfection was used to deliver continuous levels of FPT042
and FPT046 to mice that were exposed to 5% DSS in the drinking water for 7 days. By 12
days after the start of DSS, both FPT042 and FPT046 led to a statistically significant decrease
in DSS-induced loss of body weight and colon shortening, a quantitative measure of intestinal
damage. Additional experiments are underway to examine the pathology of the intestine in
the FPT042 and FPT046 groups, to assess the reduction in intestinal damage in animals
treated with purified FPT042 and FPT046 protein, as well as experiments to test the feasibility
of luminal delivery of these potential therapeutic agents.
S1622
Protective Role of Interleukin-10-Producing Regulatory Dendritic Cells Against
Murine Autoimmune Gastritis
Masamoto Torisu, Hidehiro Murakami, Akbar Fazle, Hirohumi Yamanishi, Naoyuki
Higaki, Naozumi Shibata, Tomoyuki Yokota, Bunzo Matsuura, Hidetaka Matsui, Morikazu
Onji
Background/Aims: Antigen-pulsed regulatory dendritic cells (DCs) that induce and produce
interleukin (IL)-10 In Vitro are capable of inducing immunogenic tolerance In Vivo. In this
study, we assessed the capacity of regulatory DCs to inhibit inflammation and autoantibodies
in a murine model of autoimmune gastritis (AIG). Methods: A murine model of AIG was
produced by neonatal thymectomry (3-day old) in BALB/c mice and by administrating
polyinosinic:polycytidylic acid (poly I:C,5 mg/kg). Parietal cell (PC)-pulsed regulatory DCs
(PC-pulsed DCregs) were produced by culturing bone marrow DCs with IL-10, lipopolysac-
charide and PC antigen for 48 hours. PC-DCregs were administered into mice with AIG,
intraperitoneal, 4 times (once in every two weeks). Results: Administration of poly I:C in
neonatal thymectomized mice resulted in development of AIG in almost all mice. The stages
of gastritis and the titers of autoantibody to PC were significantly lower in PC-pulsed DCregs-
treated AIG mice compared to phosphate-buffered saline (PBS)-treated control mice (p<0.05).
The levels of IL-10 in the culture supernatant of spleen cells were significantly higher in
PC-pulsed DCregs administered AIG mice compared to PBS-treated control mice (p<0.05).
The frequencies of CD4+CD25+ regulatory T cells in the spleen were significantly increased
in AIG mice treated with PC-pulsed DCregs compared to PBS-treated control mice (p<0.01).
Intracellular cytokine staining revealed that IL-10 was produced by CD4+CD25+ T cells
from AIG mice treated with PC-pulsed DCregs. Conclusion: PC-pulsed DCregs inhibited
the levels of gastric inflammation in AIG mice indicating a possible usage of this approach
for treatment and controlling autoimmune disease.
S1623
Coppix Protects Against TNBS Induced Colitis Through Ho-1 Induction
Sang wook Kim, In hee Kim, Seong hun Kim, Seung ok Lee, Hey jin Jeong, Geom seog
Seo, Soo teik Lee, Dae ghon Kim, Yong sung Kim
Heme oxygenage-1 (HO-1), rate-limiting enzyme in heme catabolism, has been known to
show strong immune-suppressive properties although its mechanisms are not completely
understood. In this study, the authors investigated the mechanism whereby HO-1 has anti-
inflammatory properties in trinitrobenzene sulfonic acid (TNBS)-induced colitis. Body weight
was evaluated and tumor necrosis factor (TNF-α), interleukin (IL)-1β and intercellular
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adhesion molecule-1 (ICAM-1) were detected by immunohistochemical staining. Heme
oxygenase-1 (HO-1) expression was analyzed by Western blot and immunohistochemical
staining. In a mouse model, HO-1 inducer, cobalt-protoporphyrin IX (CoPPIX) administra-
tion significantly improved the clinical symptoms and histopathologic changes of trinitroben-
zene sulfonic acid (TNBS) colitis as well as significantly suppressed the expression of several
inflammatory mediators such as TNF-α, IL-1β and ICAM-1 induced by TNBS. Furthermore
CoPPIX suppressed NF-κB activation that is an important transcription factor for expression
of pro-inflammatory mediators in TNBS colitis while HO-1 activity inhibitor, zinc protopor-
phyrinIX (ZnPPIX) reversed the protective effects of CoPPIX in TNBS colitis. Collectively,
these results suggest that HO-1 exerts anti-inflammatory effects by down-regulation of NF-
κB activity via induction of HO-1 during pathogenesis of TNBS-induced colitis.
S1624
Effect of Sulfasalazine On the Colonic Transcriptome in Rat TNBS Colitis
Olga Martinez-augustin, Trinidad Montero, Antonio Suarez, Xavier Llor, Jose maria
Vieites, Maria dolores Suarez, Antonio Zarzuelo, Miguel A. Gassull, Fermin Sanchez de
medina
Sulfasalazine (SAZ) is a widely used intestinal antiinflammatory drug, yet its mechanism of
action is incompletely understood. We tried to characterize the antiinflammatory effect of
SAZ by analyzing its impact on the colonic transcriptome in the rat model of inflammatory
bowel disease induced by trinitrobenzenesulfonic acid (TNBS). SAZ (500 mg/kg) was admin-
istered starting 2 days before colitis induction and daily thereafter and animals were sacrificed
at 7 days of colitis. SAZ exerted antiinflammatory effects as expected, assessed by lower
body weight loss, colonic weight to length ratio and myeloperoxidase. Total RNA was isolated
from the distal colon (full thickness, necrosis excluded) and subjected to genomic analysis
using Affymetrix Rat Genome 230 2.0 microarrays. 3 SAZ treated animals were compared
to 3 TNBS vehicle treated animals and 6 uninflamed rats using analysis of variance followed
by Benjamini correction and Tukey posthoc tests. Selected genes were re-examined by real
time PCR as independent verification. 2077 transcripts were differentially expressed in the
TNBS and control groups, but only 675 genes were affected in the SAZ group, consistent
with its antiinflammatory effect. 1125 inflammatory (TNBS regulated) genes were affected
by SAZ, while 311 were classified as SAZ unresponsive. In addition, 11 genes not affected
by inflammation were regulated by SAZ. The quantitative impact of SAZ on TNBS regulated
genes was highly variable, ranging from 8.2 fold (Aqp8) to 0.1 fold (Lilrb3_predicted)
changes in gene expression. The effect of SAZ on inflammatory genes was almost invariably
one of normalization, i.e. downregulation of upregulated genes and viceversa. The normaliza-
tion was either complete or partial depending on the gene considered. SAZ unresponsive
transcripts include immunologically relevant genes such as Lnk, Cd74, Lyn, Cd14, Tacr2
and antigen presentation genes. On the other hand, the SAZ responsive genes were highly
varied and did not conform to any specific pattern or pathway, such as NF-kB inhibition
or antioxidative activity. Extracellular matrix genes were preferentially affected by SAZ
treatment; in particular, SAZ tended to normalize the upregulation of several collagen isoforms
as well as related enzymes that are involved in collagen processing and extracellular protein
crosslinking. Thus SAZ is likely to act via a number of different mechanisms.
S1625
Intestinal Epithelial Cell-Derived IL-7 in the Alteration of Intraepithelial
Lymphocytes in a TPN Mouse Model
Hua Yang, Hiroyuki Koga, Xiaoyi Sun, Blair Madison, Deborah L. Gumucio, Daniel H.
Teitelbaum
Background: Total parenteral nutrition (TPN) results in profound changes in intraepithelial
lymphocytes (IEL), and such changes may result in a loss of mucosal barrier function. We
have previously shown that TPN is associated with a marked decline in intestinal epithelial
cell (EC)-derived IL-7 expression. Because IL-7 is vital for IEL development and maintenance,
we hypothesized this decrease in EC-derived IL-7 after TPN administration may contribute
to the observed neighboring IEL changes. Methods: Six groups of mice were used: 1) Wild
type (WT) TPN (n=5); 2) WT enterally-fed (Control, n=5); 3) WT enterally-fed treated with
anti-IL-7 receptor (IL-7R) antibody (n=5); 4) TPN treated with IL-7(TPN+IL-7, n=5); 5) IL-
7vill mice enterally-fed (IL-7vill C, n=5); 6) IL-7vill mice given TPN (IL-7vill+TPN, n=4). The
latter two study groups consisted of transgenic mice with specific intestinal EC over-expres-
sion of IL-7, and were developed in our laboratory for this purpose using an EC-specific
villin promoter (P12.4 KVill). Mice were studied after 7 days of TPN. IEL phenotype and
IL-7R expression were studied with flow cytometry. IEL cell cycle was detected used propid-
ium iodide DNA staining. Results: IL-7R expression was observed in CD4+,CD8+ and TCR-
αβ+, as well as TCR-γδ+ IEL. Significant changes in IEL were noted after TPN administration
(Table). IEL proliferation significantly decreased with TPN. TPN+IL-7 mice showed an
attenuation in TPN-associated IEL changes, including a smaller decline in IEL proliferation,
and a prevention of TPN-associated IEL phenotypic changes. Blocking IL-7R on normal
healthy mice, resulted in several similar changes in the IEL as those observed in TPN mice.
Furthermore, numbers of IEL in IL-7vill mice were significantly higher than WT mice. IEL
proliferation, CD8αβ+, CD4+ and TCR-αβ+ subtypes of IEL significantly increased in IL-
7vill mice compared to WT mice. Finally, IL-7vill+TPN mice maintained IEL proliferation,
and had high levels CD4+, CD8αβ+ and αβ-TCR+ IEL, which were not significantly different
from Control mice. Conclusion: These results offer further insight into the role of EC-
derived IL-7 on IEL development and function. They suggest that a decrease in EC-derived
IL-7 expression may be a contributing mechanism to account for the observed TPN-associated
IEL changes.
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Results are mean±SD. *P<0.05, using ANOVA compared to TPN group.
S1626
Activated Notch Signaling Suppresses Generation of Goblet Cells in the
Human Intestinal Mucosa
Ryuichi Okamoto, Kiichiro Tsuchiya, Mamoru Watanabe
Background & Aims: The intestinal epithelia consists of four main lineages of differentiated
epithelial cells; Absorptive, goblet, endocrine and paneth cells. Among these lineages, goblet
cells represent the dominant lineage within the colonic mucosa, secreting wide variety of
indispensable molecules such as mucins, cytokines or trefoil factors. However, “depletion”
of goblets cells is frequently observed in the inflamed mucosal lesion of inflammatory bowel
diseases, suggesting a yet unknown dysregulation of mature goblet cell generation in such
regions. Notch signaling is one of the signaling pathways that are known to have indispensable
role in mammalian development. Recent studies have shown that Notch signaling also
regulates cell fate decision of progenitor cells in tissues such as brain, blood, lung or skin.
To determine whether Notch signaling also regulates cell differentiation within the human
intestinal epithelia, we employed immunohistochemical and cell-based functional assays and
analyzed the functional role of Notch signaling in both normal and inflamed mucosa of the
human intestine. Methods: Immunohistochemical analysis using surgically ressected human
intestinal tissues was performed to determine expression and localization of cleaved Notch1
and Hes1, a known target gene of Notch signaling. Cell-based functional assays were per-
formed using human IEC-derived cells in which forced expression of constitutively activated
Notch1 could be induced by Tet-on system. Results: Immunohistochemical examination of
normal human intestinal tissues showed nuclear localization of cleaved Notch1 and its target
gene Hes1 protein in the epithelial cells within the crypt region. Immunohistochemical
analysis compared to Ki-67 expression suggested that Notch1 is activated in the stem/
progenitor of the epithelial cell population.Transient activation of Notch1 in LS174T cells
significantly up-regulated Hes1 transcription, but conversely down-regulated E-box depend-
ent transcription. Furthermore, continuous activation of Notch1 significantly down-regulated
both MUC2 gene expression and mucin production in LS174T cells. Consistently, Notch1
was broadly activated in distorted crypts of the inflamed regions of ulcerative colitis patients,
where goblet cells were depleted. Conclusions: These results suggest that Notch1 activation
within human intestinal epithelial cells function as a repressor of goblet cell generation,
which may have a central role for the appearance of goblet cell “depletion” in the inflamed
mucosa of inflammatory bowel diseases.
S1627
The Role of Anti-TNF Therapy in Colitis-Induced Cancer
Goo Lee, Navdha Mittal, Guang-yu Yang, Gery Grimm, David J. Shealy, Terrence A.
Barrett
Ulcerative colitis (UC) increases the risk for the development of colitis-induced cancer (CIC).
Thus, reducing cancer risk in patients with UC carries significant clinical implications. It is
speculated that aberrant activation of intestinal stem cell (ISC) contributes to CIC. Anti-
TNF is an established therapy of Crohn's disease and UC. In prior studies, we found T cell-
induced ISC activation was dependent on TNF. In this study, we examined whether treatment
of severe, chronic colitis with anti-TNF reduces the risk for CIC by blocking ISC activation.
We utilized IL10-/- mice fed with piroxicam (Px)-chow to induce severe colitis and cancer.
In this model, mice develop a severe transmural colitis (day 28 after Px feeding) that leads
to predictable onset of multiple dysplasia (d42), and focal but invasive cancer (d80). Anti-
TNF (rat/mouse chimeric monoclonal IgG) or control IgG was administered ip weekly from
d14 and mice were sacrificed at four time points (d28, d42, d84, and d130 after Px feeding).
Stem cell activation was detected using western blot (nuclear β-catenin in isolated crypt
epithelial cells), real time PCR for β-catenin target genes and immunohistochemistry (IHC)
of (active) nuclear β-catenin and BrdU. In control IgG-treated groups, colitis indices were
9.3 (out of 13) at d28, 9.5 at d42, and 9 at d84. 100% of colitic mice and at d42 and d84
had dysplasia (No. of dysplatic lesions/colon;2.7-2.8). Treatment with anti-TNF reduced
dysplasia (d84) by 85% and carcinoma by 73%. Chemopreventative effects anti-TNF con-
nected with reduction of ISC activation as indicated by 40% decrease of β-catenin expression
detected by western blot, 60% of decrease epithelial proliferation and 52% decrease of
Cyclin D1 mRNA compared to corresponding IgG-treated groups. Mice treated with anti-
TNF between d14-84 were then followed to determine the recurrence off treatment at d130.
Interestingly, 25% of anti-TNF-treated mice (d14-d84) at d130 had carcinoma compared
to 75% of IgG-treated group. Thus, prolonged tumor-suppressive effect was observed. In
conclusion, anti-TNF therapy reduced colitis-induced stem cell activation, dysplasia and
cancer, suggesting that early anti-TNF treatment of patients with severe UC may reduce
subsequent CIC risk. Supported by research grant from Centocor Research and Develop-
ment Inc.
S1628
Basolateral Ige-Antigen Complexes Trigger An Epithelial Chemokine Response
Via Cd23 and Activation of ERK/Jnk Pathways
Hongxing Li, Huabao Xiong, Lloyd F. Mayer, M. cecilia Berin
Background: Human intestinal epithelial cells express the IgE receptor CD23. CD23 can be
detected in stool of patients with food allergy but not controls, and participates in allergic
reactions by transcytosis of allergen-IgE complexes. The impact of signaling through CD23
on the function of the epithelial cell has not yet been determined. Objective: To determine
if CD23 has a function in addition to transport in intestinal epithelial cells. Specifically, our
aim was to determine if CD23 on intestinal epithelial cells can respond to antigen-IgE complex
binding with a triggering of epithelial pro-inflammatory chemokine release. Methods: Human
Caco-2 cells were polarized on transwells. Cells were stimulated with immune complexes
formed by humanized IgE (anti-NP) and its antigen NP(14)-BSA Biotin. Chemokine mRNA
expression was assessed by real-time PCR, and chemokine protein secretion by ELISA.
Signaling pathway activation was assessed by immunoblotting. ERK and JNK were inhibited
with U0126 and JNK inhibitor II (both 10 microM), respectively, or with their matched
negative controls. Endogenous CD23 expression was knocked down by stable transfection
with CD23 shRNA retroviral plasmid and compared to a control shRNA retroviral plasmid.
CD23 silencing was confirmed by RT-PCR and western blotting. Results: IL-8 and CCL20
were measured as representative pro-inflammatory chemokines known to be produced by
epithelial cells. Basolateral, but not apical, antigen-IgE complexes induced a significant
upregulation of IL-8 and CCL20 mRNA expression and basolateral chemokine secretion.
IgE or antigen alone had no effect. IgE-antigen complexes induced activation of MAPK/ERK
and SAPK/JNK, but not p38 or the NF-kappaB pathway. The downstream transcription
factor AP1 was activated as measured by transBinding assay. Pharmacologic inhibition of
ERK or JNK each inhibited IL-8 and CCL20 secretion significantly (by >70%). IgE-antigen
complex-induced ERK and JNK signaling, AP-1 activation, and chemokine release were all
abrogated by silencing of CD23. Conclusion: These studies show that basolateral IgE-antigen
complexes trigger a pro-inflammatory chemokine release that is dependent on CD23 and
signaling via ERK and JNK pathways. We speculate that epithelial activation by these immune
complexes, subsequent to transcytosis, may play a critical role in late phase inflammatory
responses to food allergen exposure.
S1629
The Dec-205 Receptor in Intestinal Epithelial Cells - Receptor-Mediated
Antigen Targeting Into MHC Class II-Enriched Compartments
Juergen Buening, Werner Nicklas, Karsten Mahnke, Diether Ludwig, Andreas Gebert
Background and Aims: In dendritic cells, DEC-205 receptor-mediated antigen trafficking
was shown to target MHC class II-enriched compartments and to increase the efficiency in
antigen presentation. The DEC-205 receptor has additionally been identified on intestinal
epithelial cells (IECs). However its subcellular localisation in IECs and function remains
unknown. Here we investigated the modulation of DEC-205 expression in IECs during
bacterial colonisation of the gut and intestinal inflammation. Its subcellular expression was
analysed particularly in view of associations with compartments relevant for antigen pro-
cessing and presentation. Methods: We used NMRI mice, either kept germ free or convention-
ally colonised, Tnf (DELTA)(ARE) mice, which spontaneously develop an Crohn's like ileitis,
and C57/SvEv129 controls. In jejunal and ileal specimen the DEC-205 expression was
studied at the ultrastructural level by fluorescence and cryo electron microscopy. Results:
DEC-205 was not detected in the small bowel epithelium of germ free mice. In contrast,
in colonised mice, DEC-205 was found in IECs of jejunal and ileal villi. While crypt IECs
showed faint expression or lacked DEC-205 under constitutive conditions, expression was
induced in ileitis. Cell surface labelling of DEC-205 in IECs was restricted to the basolateral
membrane. DEC-205 was intracellularly localised in vesicles, late endosomes and lysosomes.
Of note, the majority of DEC-205 was detected in multivesicular late endosomes, containing
abundant MHC class II and invariant chain molecules. The subcellular distribution of DEC-
205 was similarly seen in jejunal and ileal IECs and not affected by inflammation. Conclusions:
Our findings suggest that the DEC-205 receptor in IECs mediates antigen delivery from
basolateral membranes into MHC class II-enriched compartments, as previously described
in dendritic cells. Antigen targeting via DEC-205 might enhance the antigen presenting
capacity of IECs to CD4+ T cells. Future studies will need to address functional consequences
of DEC-205-related antigen uptake and processing in IECs.
S1630
Proteomic Analysis Distinctively Separates Ulcerative Colitis and Colorectal
Cancer from Healthy Controls By Distinct T Cell Populations
Uta Berndt, Sebastian Bartsch, Lars Philipsen, Bertram H. Wiedenmann, Axel U. Dignass,
Andreas Sturm
BACKGROUND: Patients with UC are at increased risk for colorectal cancer (CRC). In the
pathogenesis of ulcerative colitis (UC), a disturbed T cell function is critically involved,
prompting us to investigate and compare mucosal protein expression patterns in both
diseases. Respecting that the cellular function depends upon the complex protein network
that constitutes the cellular environment as a whole, we performed a Multi-Epitope-Ligand-
Cartography (MELC). MELC is an unique robotic whole-cell imaging technology which can
visualize dozens of proteins simultaneously in a structurally intact single cell or tissue, thus
allowing to identify disease specific protein expression patterns. METHODS: Endoscopic
biopsies were taken during colonoscopy from CRC, UC, and non-inflamed tissue (n=10
each group). After fixation and embedding, MELC microscopy with more than 30 different
FITC-conjugated antibodies and subsequent bleaching steps was performed. RESULTS:
When the significance level was set to p<0.0005 (t-test) and the search depth to mostly five
antibody combinations, controls and CRC can be differentiated by 1930, controls and UC
by 531, and CRC from UC by 539 distinct protein combinations including extracellular,
cell surface and intracellular target structures. For example, compared to controls, the number
of CD56+NfkB+p53- cells was significantly increased in both, CRC and UC, uncovering a
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shared role of natural killer cells in both diseases. Confirming common pathways in CRC
and UC, the expression of the adhesion molecules CD18, CD29, and CD11a on activated
T cells as well as the number of activated CD8+, CD45R0+, CD56+, or CD44+ T cell
subpopulations was comparably increased in both entities compared to control tissues. In
contrast, in CRC, but not in UC tissue, the number of epithelial cells expressing ICAM-1
but deficient for caspase-3, -8, and bax was significantly increased compared to controls,
probably explaining an increased cell adhesion in CRC. On the other side, mucosal T cells
and natural killer cells expressing NfκB, but lacking caspase-8, have increased bcl-2 expres-
sion levels in CRC compared to UC and control tissue. CONCLUSION: The results of this
study show that several combinatorial molecular protein patterns which are critically involved
in the mucosal immune system, are distinct in UC and CRC whereas others are comparably
changed in both diseases, suggesting that many pathogenic events might be shared by UC
and CRC. Thus, topological proteomic analysis may help to reveal the molecular mechanisms
of UC and CRC and understand the different pathogenic events in the underlying disease path-
ways.
S1631
Luminal Antigens Access Not Only MHC II But Also MHC I Pathways in Late
Endosomes of Intestinal Epithelial Cells- In Vivo Study in Crohn's Ileitis
Gheorghe Hundorfean, Stephan Strobel, Klaus-peter Zimmer, Andreas Gebert, Diether
Ludwig, Jürgen Büning
Background and Aims: In contrast to healthy conditions, intestinal epithelial cells (IECs)
are thought to stimulate pro-inflammatory CD4+ and CD8+ T cells during Crohn's disease
(CD). However, the underlying mechanisms in antigen processing and presentation, particu-
larly with regard to the presentation of exogenous antigens via MHC I, remain unclear. Here
we investigated the epithelial expression of MHC I and MHC II and its interference with
endocytic pathways of luminal antigens, In Vivo. Methods: During ileoscopy, ovalbumin
(OVA) was sprayed onto ileal mucosa of CD patients (active ileitis and ileitis in remission)
and controls. The epithelial traffic of OVA and MHC I/II pathways were subsequently studied
in mucosal biopsies using fluorescence and cryo electron microscopy. Results: Beside its
expression at the basolateral membranes, MHC I was detected throughout the endocytic
tract of IECs. Of note, MHC I molecules were found to accumulate intracellularly within
MHC II-enriched multivesicular late endosomes of IECs. This compartment was efficiently
accessed by internalized OVA already 10 minutes after endoscopic application. Vesicles,
likewise those enclosed in multivesicular late endosomes, were consistently detected in the
intercellular spaces of the epithelium and carried MHC I, MHC II and OVA at later periods.
OVA trafficking and the subcellular distribution of MHC I and MHC II in IECs showed no
difference between CD patients and controls. Conclusions: We suggest that multivesicular
late endosomes are responsible for MHC I- and MHC II-related processing of exogenous
antigens in IECs. The intercellularly detected vesicles might represent immunocompetent
exosomes released by IECs and originate from multivesicular late endosomes. Thus, presenta-
tion of exogenous antigens by IECs is most likely not restricted to MHC II, but also occurs
as “cross presentation” via MHC I. The distinct capacity of IECs in antigen presentation
might depend on differential antigen processing and production of immunostimulatory
exosomes within the subset of late endosomes identified in our study.
S1632
Protein Kinase C Isoform ζ Is Involved in IFN-γ Stimulated Secretion of IL-
18bp By Human Intestinal Epithelial Cells
Stephan Haas, Melanie Gruber, Peter Feick, Frank Herweck, Jutta Gundt, Manfred V.
Singer, Ulrich Böcker
Background: Interleukin (IL)-18 binding proteins (bp) counterbalance biological effects of
IL-18. Both agonist and antagonist are expressed in human intestinal epithelial cells. A better
understanding of the regulatory pathways involved may foster the development of specific
anti-cytokine strategies in chronic IL-18-mediated intestinal inflammation. Aim: To determine
signal transduction events involved in interferon (IFN)-γ-mediated expression of IL-18bp
in human intestinal epithelial cells. Methods: Cultivated intestinal epithelial cell lines HT-
29 and Caco-2 were exposed to IFN-γ In Vitro in the presence or absence of specific inhibitors
of signal transduction. Expression of IL-18bp was assessed by Western blot analysis or
ELISA. Total cell lysates and nuclear extracts were obtained from stimulated cells and
unstimulated controls. Phosphorylation of extracellular signal regulated kinase (ERK) 1/2,
signal transducer and activator of transcription (STAT) 1, p65 and of classical, novel, and
atypical protein kinase C isoenzymes was investigated by Western blot analysis. Results: IL-
18bp was constitutively and stably expressed in intestinal epithelial cells as demonstrated
in the presence of actinomycin D or cycloheximide. IFN-γ dose-dependently increased the
intracellular content and extracellular secretion of IL-18bp. Concomitantly, phosporylation
of STAT1 occurred. By contrast, phosphorylation of p65 and ERK1/2 remained unchanged.
Ro 31-8220, an inhibitor of classical and novel protein kinase C isoforms, abrogated induction
of IL-18bp, while Gö6976, an inhibitor of classical protein kinase c-α and β1, did not. A
subsequent analysis identified that phosphorylated atypical protein kinase c isoform ζ was
selectively present in nuclei of IFN-γ stimulated cells. However, selective inhibition of
protein kinase c isoform ζ diminished IFN-γ dependent secretion of IL-18bp only, while
the augmentation of intracellular IL-18bp remained unaffected. Furthermore, the protein
kinase c activator phorbol 12-myristate-13-acetate did not induce IL-18bp. Conclusions:
Selective activation of the protein kinase c isoform ζ is involved in IFN-γ dependent regulation
of IL-18bp secretion. However, additional signaling events induced by IFN-γ independently
of protein kinase c activity are required for intracellular accumulation of IL-18bp.
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S1633
Epithelial: Lamina Propria Lymphocyte Interactions Promote Epithelial Cell
Differentiation
Stephanie Dahan, Giulia Roda, David Pinn, Franziska Roth-walter, Okebugwu Kamalu,
Lloyd Mayer
INTRODUCTION: Lymphoepithelial interactions in the gut occur in the epithelial layer as
well as in the sub-epithelial space. We have previously described that normal (NL) LPL
could induce IEC differentiation (promoting intestinal alkaline phosphatase (IAP) activity)
in T84 cells, and that this was even greater upon exposure to CD LPL. We confirmed this
finding ex vivo, in colonic tissue sections. Crypt epithelial cells were positive for IAP and
the dysregulation of IEC differentiation was due to an increase in MAPK and Akt activation.
The localization of SOX9, a transcription factor associated with IEC differentiation, was also
dysregulated in IBD mucosa. AIM: To define the mechanism involved in the dysregulation
of IEC differentiation in CD. METHODS: T84 crypt-like cells were co-cultured with freshly
isolated LPL (NL, CD or UC) for 4 days. After removal of LPL, T84 cells were lysed and
subjected to i) Real Time-PCR to assess CDX2, SOX9, and CEA family member mRNA
levels, and ii) Western blot analysis of SOX9 and the CEA family members. CDX2 mRNA
expression was also assessed on freshly isolated IECs derived from human colonic biopsies.
Human colonic tissue sections were immunostained for cyclin D1 and CDX2. RESULTS:
The level of CDX2 mRNA in T84 cells co-cultured with NL LPL was slightly increased
(2.28±0.58 fold over untreated controls), and increased significantly when T84 cells were
co-cultured with CD LPL (3.98±1.45 fold, p<0.01). In contrast, a decrease in CDX2 mRNA
was seen in surface IECs from CD and UC tissues. In active UC, this decrease was highly
significant (0.07±0.03 fold versus 0.39±0.18 in normal IECs, p<0.05). There was an increase
in CDX2 staining in the nuclei of crypt epithelial cells in IBD tissues and a decrease in
surface epithelium staining in active UC mucosa. Cyclin D1, a nuclear target downstream
of Akt, was assessed. Interestingly, normal mucosa exhibited surface epithelial staining. This
staining tended to become more nuclear in the crypt of inactive and active CD. CEA family
members (markers of differentiation) were upregulated at the mRNA and protein level in
T84 cells co-cultured with NL or CD LPL, whereas SOX9 was downregulated at the protein
level in T84 cells co-cultured with NL or CD LPL. CONCLUSION: Our observations indicate
that the crosstalk between LPL and IECs activates CDX2, and downregulates SOX9, two
transcription factors involved in IEC differentiation. These two factors appear to be involved
in the acceleration of IEC differentiation in CD mucosa providing new insights into the
dysfunction of the epithelial barrier in CD versus UC.
S1634
Cyclooxygenase-2 Regulates Toll-Like Receptor(TLR) 2 Expression and Tlr2-
Mediated Chemokine Production in Intestinal Epithelial Cells
Shinichiro Shinzaki, Hideki Iijima, Satoshi Egawa, Sachiko Nakajima, Shuji Ishii,
Toshiyuki Yoshio, Takanobu Irie, Yoshimi Kakiuchi, Tsutomu Nishida, Masakazu
Yasumaru, Tatsuya Kanto, Masahiko Tsujii, Shingo Tsuji, Norio Hayashi
Background and aim: Toll-like receptors (TLRs) on the intestinal epithelial cells are involved
in the first line of defense by producing cytokines and chemokines. Cyclooxygenase(COX)-
2 and its downstream prostaglandin(PG) E2 are suggested to have a protective effect in the
mucosal surface. In this study, we investigated the possibility that COX-2 regulates the TLR
expression and TLR-mediated chemokine production in intestinal epithelial cells. Method:
The expression of TLR mRNA was determined by quantitative RT-PCR in two intestinal cell
lines, Caco-2 cells which express low level of COX-2 and HT-29 cells which express large
amount of COX-2. Caco-2 cells were transfected with COX-2 (Caco-2-COX-2) and the levels
of TLR2 expression and interleukin(IL)-8 production after the stimulation with Pam3CSK4,
a selective ligand for TLR2, were compared between the Caco-2-COX-2 cells and mock
transfected cells. In addition, the effect of suppressing COX-2 in HT-29 cells by COX-2
RNA interference (RNAi) was analyzed. The effects of PGE2 or a selective COX-2 inhibitor,
etodolac, in these cells were also analyzed. Chemokines produced from Caco-2 cells with/
without Pam3CSK4 stimulation in the presence and the absence of PGE2 were analyzed by
chemokine array. Results: The level of TLR2 expression was significantly higher in Caco-2-
COX-2 cells than in Caco-2-mock cells. On the other hand, TLR2 expression was significantly
decreased when COX-2 was knocked down by RNAi in HT-29 cells in comparison to the
original HT-29 cells. Treatment of Caco-2 cells with PGE2 increased TLR2 expression,
whereas treatment of Caco-2-COX-2 cells with etodolac resulted in decrease of TLR2 expres-
sion. Stimulation of TLR2 by Pam3CSK4 significantly increased IL-8 production in Caco-
2-COX-2 cells as compared to Caco-2-mock cells. Stimulation of TLR2 in the presence of
PGE2 increased the production of CXC chemokines including IL-8 and IFN-gamma inducible
protein(IP)-10, whereas the levels of CC chemokines, e.g., macrophage inflammatory pro-
tein(MIP)-1beta and monocyte chemoattractant protein(MCP)-3, were decreased by PGE2
and Pam3CSK4. Conclusion: COX-2 and PGE2 regulate innate immune system by modifying
TLR2 expression and its downstream chemokine production. Controlling the expression of
COX-2 may contribute to protect from the disorders of mucosal immune system including
inflammatory bowel diseases.
S1635
Activation of Intestinal Epithelial Cell-Associated P2y Nucleotide Receptors
Stimulates Cytokines Expression and Increase Macrophages Adhesion
Christine Langlois, Djordje Grbic, émilie Degagné, Fernand-pierre Gendron
Introduction: Intestinal epithelial cells (IECs) express multiple cytokines and adhesion
molecules required for the recruitment and adhesion of immune cells to the epithelium
monolayer. Extracellular nucleotides, such as adenosine 5'-triphosphate (ATP) and uridine
5'-triphosphate (UTP), are a new class of immune-active molecules that activate specific
receptors known as P2Y G-protein-coupled receptors and P2X ligand-gated ion channels.
We thus investigated the role of extracellular nucleotides and associated P2Y receptors in
the inflammatory responses of IECs and more particularly at the upregulation of macrophages
adhesion to IECs. Methods: Human colon adenocarcinoma Caco-2/15 and HT-29 cells and
A-236AGA Abstracts
untransformed rat intestinal epithelial IEC-6 cells were stimulated with 100µM ATP, ADP,
UTP or UDP in a time-dependent manner. Cytokines expression was measured by RT-PCR
and cytokine antibody array. Effect of an inflammatory insult on P2Y receptor expression
was measured In Vivo by RT-PCR from colonic tissues obtained from DSS-induced colitis
in mice and In Vitro by RT-PCR and western blot following stimulation of IECs with IL-
1β. Monocytic U-937 cells were differentiated to macrophages-like cells by an 18h treatment
with 100ng/ml of PMA, labeled with the green fluorescent dye PKH2 and added (1x106
cells/well) to a monolayer of IECs previously stimulated for 3 to 8h with 100µM of ATP,
ADP, UTP or UDP. The cells were washed in PBS, and adherent U-937 cell numbers
were determined by microscopy using fluorescein isothiocyanate illumination. Results:
Pro-inflammatory insult increase P2Y2 receptor expression. Increase in P2Y2 expression is
regulated at the transcriptional level. Stimulation of IECs by extracellular nucleotides resulted
in an increase expression of pro-inflammatory cytokines, namely: TNF-α, GM-CSF, IL-8
and IL-12. Adhesion of macrophage-like U-937 cells to a monolayer of IECs stimulated by
extracellular nucleotides is increased by more than a 3 fold factor as compared to control.
The increase adhesion of U-937 to IECs correlates with increase expression of ICAM-1
and CD47 following nucleotide. Conclusion: These results are clearly demonstrating the
implication of extracellular nucleotides and P2Y receptors in the recruitment of immune
cells, such as macrophages, to the epithelial barrier and the importance of extracellular
nucleotide signaling in the modulation of IECs immune response in inflammatory bowel dis-
eases.
S1636
Immunomodulatory Effect of Flavonoids On Iec18 Cells - A Structure-Activity
Relationship Study
Rocio Lopez-posadas, Isabel Ballester, Raquel Gonzalez, Isabel Romero, Maria dolores
Suarez, Antonio Zarzuelo, Olga Martinez-augustin, Fermin Sanchez de medina
Flavonoids are polyphenolic compounds of natural origin that are normally ingested as part
of the human diet. Some flavonoids exert intestinal antiinflammatory effects In Vivo but
their structure-activity relationship is insufficiently characterized, particularly regarding their
effects on the intestinal epithelium. Thus we have assessed the immunomodulatory activity
of 9 different flavonoids in the IEC18 rat epithelial cell line. These included different
structural families such as flavonols (quercetin, kaempferol), flavones (chrysin, luteolin,
apigenin, diosmetin), isoflavones (genistein, daidzein) and flavanones (hesperetin). IEC18
cells, which produce IL6 in response to LPS (1 µg/ml), were pretreated for 1 h with the
flavonoids (50 µM) or vehicle (DMSO). Apigenin (43.0±4.9%), chrysin (48.1±5.5%), daidzein
(79.2±8.5%), genistein (41.8±2.1%) and kaempferol (60.4±7.4%) inhibit IL6 secretion. None
of the compounds tested was toxic to IEC18 cells, based on lactate dehydrogenase, crystal
violet and WST assays. The effect of LPS was almost completely inhibited by SB203580 and
Bay11-7082 but only modestly by SP600125 and PD98059, suggesting that it involves p38
as well as the NF-kB pathway, with a minor role of ERK and JNK. All inhibitors were used
at 10 µM. Western blot analysis confirmed that LPS induced p38 and IkB phosphorylation
as well as both RelA and p50 translocation to the nucleus. This was confirmed in IEC18
cells transfected with an NF-kB driven luciferase reporter plasmid. Western blot analysis
indicated that the mechanism of flavonoid inhibition involves a combination of actions on
p38 and NF-kB. Additional experiments are needed to clarify the molecular basis of this
inhibition. Based on these findings the structural requirements for immunomodulatory
activity in the intestinal epithelium are the presence of a 2-3 double bond and the absence
of a 4'-OH group. On the other hand, the 3'-OH group and the iso position of the B ring
seem to be irrelevant. Our results suggest that there may be better flavonoid alternatives to
quercetin heterosides (which are the most active in preclinical inflammatory bowel disease
models so far) as intestinal antiinflammatory agents, specially considering that some of them
have additional immunomodulatory effects in macrophages (Biochem Pharmacol 2006;
72:1010).
S1637
Downregulation of Metallothioneins (MTS) in Intestinal Epithelial Cells
(IECs) Is Associated with Impaired Chemoattractant Activity
Anouk Waeytens, Debby Laukens, Sylvie Janssens, Harald Peeters, Pieter Rottiers, Claude
A. Cuvelier, Martine De vos
Background: MTs are highly conserved metal-binding proteins that play a role in metal
and radical detoxification, metal homeostasis and cell proliferation. We previously showed
a decreased basal mRNA expression of MTs in samples of Crohn's disease (CD) patients with
colitis, correlating with protein expression. Since MTs are mainly expressed in enterocytes, we
investigated functional consequences of a deficient MT expression in IECs. Methods: We
constructed a MT knockdown (MTkd) HT-29 cell line using siRNA and evaluated MT
expression with Q-PCR and immunofluorescence. We infected MTkd as well as wild type
(WT) monolayers with invasive bacteria (S typhimurium, S enteritidis, and the CD-associated
adherent-invasive E coli strain LF82), with non-pathogenic Lactococcus lactis, and with lipo-
polysaccharide and peptidoglycan. To evaluate chemoattractant properties of MTkd cells,
interleukin (IL)-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion
were measured with ELISA. In addition, chemotaxis of neutrophils was assessed after 1 hour
using a chemotaxis microchamber and supernatans of lipopolysaccharide-stimulated cells.
Results: A twofold downregulation of MT mRNA and protein in MTkd cells was demon-
strated. Stimulation with invasive bacteria and with bacterial cell wall constituents induced
IL-8 and GM-CSF secretion in both WT and MTkd cells, albeit significantly lower for MTkd
cells (p<0.001). Lactococcus lactis bacteria were not able to induce IL-8 or GM-CSF secretion.
Chemoattractant activity of MTkd cell supernatans was significantly weaker compared with
WT cell supernatans (20% versus 36% migrated neutrophils, p<0.001). Conclusion: We
demonstrated that chemoattractant activity is impaired in MT deficient IECs. Together with
previous findings of a decreased MT expression in CD patients with colitis, these results
suggest that CD is associated with a disturbed cell migration which could lead to a defective
acute inflammatory response. Furthermore, these data provide a molecular background for
treatment stimulating innate immunity such as GM-CSF (sargramostim).
S1638
Replication of Crohn's Disease Mucosal E. coli Isolates Within Macrophages
and Their Susceptibility to Antibiotics
Sreedhar Subramanian, Carol L. Roberts, C. A. Hart, Steve W. Edwards, Barry J.
Campbell, Jonathan M. Rhodes
Background & Aims: There is increasing evidence that E. coli may have a pathogenic role
in Crohn's disease(CD).1 They can be found in increased numbers adherent to the mucosa1
and within tissue macrophages2. This study investigates replication of CD mucosal E. coli
within macrophages and their susceptibility to antibiotics. Methods: Replication of CD E.
coli isolates within J774-A1 murine macrophages and human monocyte-derived macrophages
(HMDM) was assessed by culture and lysis after gentamicin killing of non-internalised
bacteria and verified by transmission electron microscopy (TEM). Results: All three CD
mucosal adherent isolates studied: HM580, HM605 and HM615, replicated within J774-
A1 cells (170.8±6.8%, 230.3±15.9% and 274.3±33.8% respectively by 3h) more than E.
coli K12 (127±16.3%; P<0.05). HM605 replication within HMDM (395.2±74.3% by 3h)
also exceeded that for K12 (138.8 ±20.0%, P=0.03). TEM showed replicating HM605 within
macrophage phagolysosomes. Killing of HM605 within J774-A1 macrophages following 3h
incubation with antibiotics tested at their published peak serum concentrations (Cmax) was:
ciprofloxacin (100 ± 0%, mean ± SD%, P=0.04), rifampicin (76 ± 19.9%, P=0.02), tetracycline
(69.3 ± 19.9%, P=0.02), trimethoprim (57.2 ± 8.5%, P=0.01), clarithromycin (50.8 ± 7.5%,
P=0.0004) and azithromycin (41 ± 18%, P=0.03 (see table). Ampicillin was not effective
against intra-cellular HM605. Triple antibiotic combinations were also assessed at 10% Cmax.
The combination of ciprofloxacin, tetracycline and trimethoprim was particularly effective
causing 97 ± 0.0% killing at 10% Cmax versus 86 ± 2.0% for ciprofloxacin alone. Conclusions:
Clinical trials are indicated to assess the efficacy in CD of combination antibiotic therapy
targeted at killing E. coli within macrophages. References: 1. Martin HM, Campbell BJ, Hart
CA, Mpofu C, Nayar M, Singh R et al. (2004) Enhanced E. coli adherence and invasion in
Crohn's disease and colon cancer. Gastroenterology 127: 80-93. 2. Liu Y, van Kruiningen
HJ, West AB, Cartun RW, Cortot A and Colombel JF. (1995) Immunocytochemical evidence
of Listeria, E. coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108:
1396-404.
*P<0.05, **P<0.01, ***P<0.001
S1639
Critical Role of MAP Kinases in Governing Lymphocyte Adhesion to and
Migration Across Microvasculature in Inflammatory Bowel Disease
Miquel Sans, Franco Scaldaferri, Stefania Vetrano, Tommaso Stefanelli, Cristina Graziani,
Vincenzo Arena, Angelo eugenio Potenza, Alessandro Repici, Alberto Malesci, Silvio
Danese
BACKGROUND: Lymphocyte adhesion to and migration across the endothelium is a key
pathogenic event in inflammatory bowel disease (IBD). We have previously demonstrated
that adhesion of T-cells to human intestinal microvascular endothelial cells (HIMEC) is
mediated by VCAM-1 and fractalkine, but the signaling molecules that orchestrate this
process remain unknown. MAP kinases (MAPK) are signaling enzymes critically involved
in multiple inflammatory processes. However, their role in regulating lymphocyte recruitment
in the inflamed intestine has never been explored. AIMS: To study the functional role of
the MAPK p38, p42/44 and JNK in regulating lymphocyte adhesion to and chemotaxis
across the microvasculature in IBD. METHODS: Expression of the active, phosphorylated
forms of p38, 42/44 and JNK was studied by immunostaining in tissue sections of 10 Crohn's
disease (CD) and 10 ulcerative colitis (UC) patients, and 10 controls. Phosphorylation of
p38, p42/44 and JNK was assessed by western blot in HIMEC and human intestinal fibroblasts
(HIF). HIMEC and HIF were stimulated with TNF-α and the effect of specific MAPK blocking
peptides was studied. Expression of VCAM-1, fractalkine, and ICAM-1 was measured by
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flow cytometry, and IL-8 and MCP-1 production by ELISA. T-cell-HIMEC adhesion and
migration assays were used to evaluate the functional impact of each MAPK blockade.
RESULTS: Significant phosphorylation of all MAPK was demonstrated in the bowel microvas-
culature and fibroblasts of IBD patients, but not of healthy subjects. In Vitro, stimulation of
HIMEC with TNF-α triggered the phosphorylation of all MAPK as well as VCAM-1, fractalk-
ine, and ICAM-1 upregulation. Specific blockade of p38 by SB203580 decreased by 50%
(p<0.01) the expression of all MAPK, whereas the p42/44 inhibitor PD 98059 decreased
by 50% (p<0.01) the expression of ICAM-1 and fractalkine, and the JNK inhibitor SP600125
failed to inhibit MAPK expression. Treatment of HIF with TNF-α elicited IL-8 and MCP-1
production, which was significantly (p<0.05) reduced by specific p38 and p42/44 blockade.
Finally, p38 and p42/44 blockade, but not JNK blockade, significantly reduced lymphocyte
adhesion to (p<0.05) and transmigration across (p<0.05) HIMEC monolayers. CONCLU-
SIONS: The active forms of MAPK are upregulated in the bowel mucosa of IBD patients.
In Vitro, MAPK p38 and p42/44 regulate expression of adhesion molecules and production
of chemokines and are required for lymphocyte adhesion and migration. Taken together,
these observations suggest a critical role for MAPK in governing lymphocyte influx into the
gut in IBD patients and may represent a novel target to dampen intestinal inflammation.
S1640
Substance P (SP) Stimulates Expression of the Pro-Angiogenic Factor Cyr61 in
Colonic Epithelial Cells. Evidence for a SP-Cyr61 Communication During
Experimental Colitis
Hon wai Koon, Dezheng Zhao, Hua Xu, You sun Kim, Yanai Zhan, Mary P. Moyer,
Charalabos Pothoulakis
Background and Objectives: Substance P (SP) participates in intestinal inflammation via
binding to the G-protein coupled neurokinin-1 receptor (NK-1R). Previous reports showed
that vascularization and expression of angiogenic factors are evident in the colonic mucosa
of rats with colitis and patients with inflammatory bowel disease (IBD). Cyr61 is a cysteine-
rich extracellular matrix-associated protein of the CCN family that promotes angiogenesis.
Although increased expression of Cyr61 is associated with breast cancer, wound healing,
and vascular diseases, there is no evidence indicating its expression and role in colitis. We
determined whether SP is associated with cyr61 in colonocytes and the dextran sulfate (DSS)
models of colonic inflammation. Methods: Human NCM460 colonocytes stably transfected
with the human NK-1R (NCM460-NK-1R cells) and mice with DSS (5%)-induced colitis
were used. Results: SP (10 nM) stimulated cyr61 expression and cyr61 promoter activity
(~2-fold) in NCM460-NK-1R colonocytes that was evident at 4 hrs. Histone deacetylase
(HDAC) modifies histone proteins and chromatin structure, events associated with gene
regulation. Pretreatment of colonocytes with the HDAC inhibitors trichostatin (TSA) and
sodium butyrate (SBT) diminished SP-induced cyr61 protein expression and cyr61 promoter
activity. Likewise, cyr61 promoter activity was up-regulated by transient transfection of
colonocytes with a HDAC-overexpressing construct. Thus, SP mediates cyr61 by stimulating
HDAC activation. Moreover, SP enhanced HDAC1 protein expression and HDAC enzymatic
activity in a time- and dose-dependent manner that was sensitive to HDAC inhibitors (TSA/
SBT). Pharmacologic inhibition of de novo HDAC gene transcription (by actinomycin D)
and translation (by cycloheximide), as well as RNA interference of HDAC1, but not HDAC3,
blocked SP- induced HDAC activity in colonocytes. Colonic tissues from mice exposed to
5% DSS for 5 days, showed increased HDAC1 protein levels (Western blot), enhanced HDAC
tissue activity (HDAC activity assay), and increased cyr61 expression and vascularization
(immunohistochemistry). Compared to vehicle, i.p. injection of the specific SP, NK-1R
antagonist CJ-12255 to mice reduced colonic inflammation, HDAC1 expression and HDAC
activity, cyr61 protein expression and blood vessel density. Conclusion: These are the first
results indicating that SP induces cyr61 expression and possibly angiogenesis via HDAC1
activation. We speculate that this pathway might participate in the regulation of colonic
inflammation and tissue recovery mediated by SP and NK-1R. Supported by a Research
Fellowship from CCFA to HWK and a NIH grant DK47343 to CP.
S1641
Stat5b Regulates Colon Epithelial Cell Survival in Crohn's Disease and
Murine Colitis
Xiaonan Han, Ingrid Jurickova, Huan Xu, Rebecca Carey, Lee Denson
Current evidence suggests that mucosal barrier dysfunction contributes to the exaggerated
adaptive immune response to the enteric flora which characterizes Crohn's disease (CD).
Increased colon epithelial cell (CEC) apoptosis may cause barrier dysfunction via induction
of an “apoptotic leak”. We have reported that STAT5b activation is reduced in affected
pediatric CD colon, and that STAT5b deficient mice exhibit increased sensitivity to colitis
due to TNBS administration. Growth hormone (GH) administration has activated STAT5b
and reduced mucosal inflammation in experimental colitis. We hypothesized that STAT5b
influences susceptibility to colitis in part by regulating CEC survival. Methods: Colon biopsies
were obtained from pediatric patients with newly diagnosed CD and Ulcerative Colitis (UC),
chronic refractory CD, and healthy controls. Colon tissues were from STAT5b deficient and
wild type (WT) mice. STAT5b and NFkB activation in CEC was determined by immunohisto-
chemistry, immunofluorescence, and flow cytometry. Expression and/or activation of pro-
apoptotic (caspase-3/Bax/Bid/Trail) and anti-apoptotic genes (Bcl-2/Bcl-xl) were determined
by microarray, real time PCR, and Western Blot. RNA interference was used to knock down
STAT5b expression in the T84 human CEC line and the effect upon expression of pro- and
anti-apoptotic genes and TNF dependent NFkB and caspase-3 activation was determined.
Results: Microarray analysis demonstrated up regulation of BID/FAS expression in CD and
UC colon. STAT5b deficient mice exhibited reduced colonic expression of anti-apoptotic
genes including Bcl-2 and Bcl-xl, and increased expression of pro-apoptotic genes including
Bid, Bax, and Trail. Consistent with this, the abundance of cleaved caspase 3 and the
frequency of apoptotic CEC were increased in STAT5b deficient mice. This was associated
with mucosal edema and increased NFkB serine phosphorylation in CEC at baseline. GH
administration reduced mucosal inflammation in WT, but not STAT5b deficient, mice. RNAi
knock down of STAT5b expression in T84 cells led to a significant increase in TNF dependent
NFkB activation, and cleaved caspase-3 and Bax abundance. GH reduced TNF dependent
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NFkB activation, and cleaved caspase-3 and Bax abundance, in T84 cells; this effect was
abrogated by STAT5b knock down. Conclusions: STAT5b regulates CEC survival via up
regulation of an anti-apoptotic gene program. Impaired CEC STAT5b activation in IBD may
promote barrier dysfunction via induction of an “apoptotic leak”. STAT5b activation may
therefore represent a novel therapeutic target for promoting mucosal healing and restoring
barrier function in IBD.
S1642
The IGF-Iea (IGF-I) and IGF-IEC (Mgf) Splice Variants of the IGF-I Gene
Selectively Mediate Hyperplasia and Hypertrophy of Human Intestinal Smooth
Muscle
Krystina M. Berg, Jennifer Bowers, John F. Kuemmerle
The Insulin-like Growth Factor-I (IGF-I) gene is alternatively spliced with the main isoform,
IGF-I, encoded by the IGF-IEa splice variant. We recently showed that a second isoform,
Mechano-Growth Factor (MGF), encoded by the IGF-IEc splice variant, is also expressed
in human intestinal muscle. Expression of both MGF and IGF-I by intestinal muscle is
increased in the setting of active Crohn's Disease. Crohn's Disease is accompanied by both
hypertrophy and hyperplasia of intestinal muscle. Aim: To determine the effect of MGF
and IGF-I on human intestinal muscle hypertrophy and hyperplasia. Methods: Normal
human intestinal smooth muscle cells were isolated and placed into primary culture on glass
coverslips in Dulbecco's Modified Eagles Medium (DMEM) with 10% added serum. Cells
were serum starved for 24 h and treated for an additional 24 h with either 10 nM MGF,
10 nM IGF-I or serum free DMEM (DMEM-0). Hypertrophy was measured from mean cell
volume in the same 25 cells on each coverslip using confocal microscopy in cells loaded
with 10 μM Vybrant CFDA SE cell tracer™. Hyperplasia was measured from DNA synthesis
in cells using [3H]thymidine incorporation. MGF protein levels were measured in muscle
isolated from regions of active stricturing Crohn's Disease with stricturing and normal
resection margins. Results were quantitated using immunofluorescent staining with a specific
MGF antibody (1:250 dilution) and analyzed using confocal microscopy and Volocity™
Image Analysis Software. Results: Basal mean cell volume in untreated muscle cells was
9900 ± 1400 μm3 and was similar for all three groups. Mean cell volume in untreated
muscle cells (DMEM-0) remained constant for 24 h. In cells treated with MGF for 24 h
mean cell volume increased by 85 ± 14% above basal. Treatment of cells with IGF-I for 24
h did not affect cell volume (1 ± 10% above basal). In untreated muscle cells, basal
[3H]thymidine incorporation was 150 ± 20 cpm/μg protein. In contrast to its effects of
volume, treatment of cells with MGF did not affect DNA levels (3 ± 5% above basal).
Treatment of muscle cells with IGF-I increased DNA levels by 76 ± 8% above basal.
Immunoreactive MGF protein in smooth muscle from regions of active inflammation was
increasd by 54 ± 4% over smooth muscle from uninflamed regions. Conclusions: Increased
expression of the IGF-IEc (MGF) and IGF-IEa (IGF-I) splice variants of IGF-I in Crohn's
Disease selectively mediates the response of muscle to chronic inflammation. MGF protein
levels are increased in Crohn's Disease mediating muscle hypertrophy, whereas IGF-I medi-
ates muscle hyperplasia, both are components of stricture formation.
S1643
Lipopolysaccharide-Induced Activation of IL-8 and Phospho-IκBα in Human
Intestinal Epithelial Cells Is Mediated By Bcl10
Sumit Bhattacharyya, Alip Borthakur, Nitika Pant, Pradeep K. Dudeja, Joanne K.
Tobacman
Bcl10 (B-cell CLL/lymphoma 10) is a caspase recruitment domain (CARD)-containing protein
that is associated with constitutive activation of NFκB in MALT (mucosa-associated lymphoid
tissue) lymphomas. Like NOD2/CARD15, which is associated with genetic predisposition
to Crohn's disease, BCL10 has a CARD domain at its N-terminal. In lymphocytes, Bcl10 is
a key mediator of a pathway of inflammation from toll-like receptor 4 (TLR4) to IL-8. Using
RNA silencing, ELISA, Western blot, and cell culture, we have identified a Bcl10-mediated
mechanism of IL-8, NFκB, and phospho-IκBα activation by lipopolysaccharide (LPS;Sigma)
in human intestinal epithelial cells (IEC). With full-length, recombinant Bcl10 protein (233
amino acids, MW 31K; Chemicon), we developed an ELISA to quantify changes in Bcl10
following exposure to LPS. Treatment of the normal human IEC NCM460 (InCell) with 1-
20 ng/ml of LPS (Sigma) for 6 hours resulted in marked increases in IL-8, IL-8 promoter,
phospho-IκBα, NFκB, and Bcl10. Increases in IL-8 and phospho-IκBα were significantly
reduced following knockdown of Bcl10 by siRNA. LPS 10 ng/ml for 6 hours increased IL-
8 from a baseline value of 0.63 (±0.01) ng/ml to 2.56 (±0.18) ng/ml. Following knockdown
by Bcl10 siRNA for 24 hours, IL-8 response to LPS (10 ng/ml for 6 hours) declined to 1.38
(±0.13) ng/ml, less than the IL-8 value resulting from exposure to LPS 1 ng/ml for six hours
(1.55±0.02 ng/ml). Phospho-IκBα increased to 4.2 times the baseline value following LPS
(10 ng/ml for 6 hours). Following Bcl10 knockdown, the LPS-induced increase in phospho-
IκBα declined to only 2.1 times the baseline value. Increasing concentrations of LPS were
associated with higher concentrations of Bcl10 protein in the NCM460 cells (LPS: 0, 1, 10,
20 ng/ml → Bcl10: 1.02, 2.16, 4.3, 6.20 ng/mg protein). These results demonstrate a novel
and important pathway of LPS induction of IL-8 through Bcl10. Identification of Bcl10 as
a mediator of LPS-induced IL-8 and phospho-IκBα activation in normal human intestinal
epithelial cells provides new insight into mechanisms of intestinal cell inflammation and
new opportunities for therapeutic interventions.
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S1644
Effect of Rebamipide On Disruption of Tight Junctional Protein, Claudin-1,
and Trans-Epithelial Electrical Resistance Induced By Oxidative Stress in
Intestinal Inflammation
Haruhiko Ogata, Nobuhiko Kamada, Nagamu Inoue, Toshifumi Hibi
Background and Aim Disruption of intestinal mucosal barrier established by the formation
of junctional complex composed of junctional proteins, adjacent proteins and desmosome
is considered to be one of the major factors in the pathophysiology of inflammatory bowel
disease. Rebamipide has a broad spectrum of pharmacological actions that include suppres-
sion of neutrophil functions and stimulation of mucosal epithelial cell regeneration. We
have previously reported the efficacy and safety of topical treatment of rebamipide in patients
with active ulcerative colitis (UC) by randomized control study. Aim of this study is to
elucidate the mechanism of the effect of rebamipide in intestinal inflammation In Vivo and
vitro. Materials and Methods 1) In Vivo analysis; Immunostaining using monoclonal antibody
against claudin-1 was performed on colonic biopsied specimen from active UC patients (n=
19) before and after 4-week treatment with rebamipide enema. 2) In Vitro analysis; Claudin-
1 mRNA expression in conventionally cultured CaCo-2 cells with 200 micromole of rebamip-
ide was analyzed by RT-PCR. Changes in trans-epithelial electrical resistance (TEER) in
confluent CaCo-2 cells were measured by using trans-well chamber under the condition of
1-4 hours after addition of 0.5mM hydrogen peroxide (H2O2). Furthermore, the effect of
rebamipide on TEER was also analysed. Results 1) By immunohistochemical analysis, few
claudin-1 protein expressions were observed in colonic mucosal epithelial cells from active
UC patients, and 4-week treatment with rebamipide enema showed remarkable restoration
of claudin-1 expression. 2) In conventionally cultured CaCo-2 cells, claudin-1 mRNA expres-
sion was significantly increased by addition of rebamipide into culture medium. Administra-
tion of H2O2 caused marked decrease of TEER in CaCo-2 cells cultured in trans-well
chamber. However, rebamipide strongly suppressed the effect of H2O2 on TEER in CaCo-
2 cells. Conclusions One of the mechanisms of mucosal damage in UC is likely to be caused
by increased oxidative stress due to loss of cellular tight junctions, which in turn leads to
increased permeation of antigens or microorganisms. The efficacy of rebamipide in active
UC may be due to suppression of oxidative stress and improvement of mucosal integrity
measured by TEER. Increased expression of claudin-1 in CaCo-2 cell line also suggests that
rebamipide could improve the resistance of mucosal epithelial cell to colonic antigens.
S1645
Changes in the Innervation of Human Colonic Blood Vessels in Inflammatory
Bowel Disease: An Immunohistochemical Study
Dayan De fontgalland, David A. Wattchow, Marcello Costa, Simon Brookes
Purpose: In inflammatory bowel disease there is reduced mucosal vascular perfusion, resulting
in ulceration. Neuropeptides that control vascular tone have been implicated in the perpetu-
ation of the disease process. The aim of this study was to compare the chemical coding
of the innervation of colonic mesenteric and submucosal blood vessels in patients with
inflammatory bowel disease to control subjects. Methodology: Specimens of colonic bowel
wall and mesentery were obtained from patients undergoing segmental resection for colonic
cancer (control) and inflammatory bowel disease (ulcerative colitis). Mesenteric and submu-
cosal arteries and veins were dissected and prepared for double labelling immunohistochem-
istry. The following markers were examined: Tyrosine Hydroxylase(TH), Neuropeptide
Y(NPY), Substance P(SP), Calcitonin Gene related Peptide(CGRP), Nitric Oxide Synthas-
e(NOS), Vasoactive Intestinal Polypeptide(VIP), Somatostatin(SOM), Vesicular Acetylcholine
Transporter (VaChT). All nerve fibres were labelled with PGP 9.5. A transect method was
employed for detailed quantification of markers. Results and Discussion: TH and NPY were
the predominant markers present in perivascular nerves and were 100% colocalised within
varicosities.They accounted for approximately 90% of the total nerve population (sympath-
etic). CGRP IR nerve fibres were scarce (<3%) and did not localise with SP (approximately
12%) unlike small animal models. SP is the likely neurotransmitter for extrinsic sensory
neurons in humans. SP is not colocalised with NPY or VAChT. In normal bowel, the
submucosal vessels have significantly more SOM IR nerve fibres compared to mesenteric
vessels raising the possibility that these nerve fibres originated from the submucous plexus.
The mesenteric vessels from the left hemicolon show VAChT -IR nerve fibres in greater
abundance compared to the rest of the colon (7% cf 2%) p<0.0005. This describes a
parasympathetic vasodilator innervation to the distal colonic mesenteric vessels. In inflammat-
ory bowel disease, there was a significant increase in SP-IR nerve fibres and a significant
reduction in SOM -IR nerve fibres, on the submucous arteries in ulcerative colitis compared
to normal bowel (SP: 11+/-7% cf 25+/-3%, SOM: 23 +/-4% cf 3+/-2%: p<0.05). Conclusions:
This study shows significant differences in the chemical coding of blood vessels in ulcerative
colitis, as well as small animal models when compared to normal controls. The changes in
SP and SOM-IR nerve fibres may contribute to the altered vascular perfusion seen in
Ulcerative Colitis
S1646
Spironolactone Inhibits Transforming Growth Factor Beta(TGFβ)-Induced and
Methylpredisolone-Augmented Fibrogenesis in Human Colonic Myofibroblasts
Laura Johnson, Ellen M. Zimmermann, Peter D. Higgins
Background: TGFβ has been implicated in the post-inflammatory fibrosis of Crohn's disease.
In Vitro fibrogenesis can be induced in human colonic myofibroblasts by recombinant TGFβ1.
Corticosteroid use has been associated with increased stenosis, stricture, and obstruction
(SSO) in a large epidemiologic study of Crohn's disease. Spironolactone has been shown to
inhibit fibrosis of the myocardium in congestive heart failure. Aims: 1) To determine whether
methylprednisolone (MP) can augment TFGβ1-induced fibrogenesis (as measured by collagen
and α-Smooth Muscle Actin [αSMA] expression) in an In Vitro human colonic myofibroblast
model of intestinal fibrosis; 2) to determine whether spironolactone (SPIR) can inhibit
TGFβ1-driven fibrogenesis in this model; and 3) to determine whether spironolactone can
inhibit corticosteroid-augmented fibrogenesis in this model. Methods: CCD-18co human
colonic myofibroblasts were serum starved, treated with 1 nM TGFβ1 for 48 hours, and
harvested for protein or RNA. Physiologic doses of 100 μM SPIR and/or 1 nM MP were
added to cells concurrently with TGFβ1. Collagen, αSMA, and GAPDH expression were
detected by Westerns and real time PCR. Results: TGFβ1 induces a fibrogenic phenotype
in CCD-18co cells, increasing collagen and αSMA mRNA (2x, 26x) and protein (2.7x, 6.6x)
expression with altered cell morphology and adhesion. Concurrent treatment with MP
augmented protein expression of αSMA by an additional 25%. The fibrogenic phenotype
induced by TGFβ1 is inhibited by concomitant treatment of SPIR (αSMA protein decreased
2.4x, p<0.001, collagen by 13x, p<0.001). Similarly, the augmented fibrogenic phenotype
induced by TGFβ1 and MP is inhibited by concomitant treatment of SPIR (αSMA protein
decreased 2.6x, p=0.019, collagen by 29x, p<0.001). Conclusions: The corticosteroid methyl-
prednisolone augments the fibrogenic state induced in human intestinal myofibroblasts by
TGFβ1. This finding may help to explain the epidemiologic finding that corticosteroids
increase the incidence of SSO. Spironolactone inhibits the fibrogenic state induced in human
intestinal myofibroblasts by TGFβ1, even when augmented by corticosteroids. Spironolactone
might offer a protective benefit during corticosteroid use or in patients at high risk for SSO.
Further mechanistic studies and evaluation of spironolactone in rodent intestinal fibrosis
models are underway.
S1647
Endogenous IGF-I Regulates the Inflammatory Response of Murine Colonic
Smooth Muscle to TNBS-Induced Chronic Inflammation
Krystina M. Berg, Jennifer Bowers, Liya Qiao, John F. Kuemmerle
We have shown that endogenous Insulin-like Growth Factor-I (IGF-I) and IGF Binding
Protein-5 (IGFBP-5) act individually and jointly to regulate the growth of intestinal smooth
muscle by stimulating proliferation and that Mechano-Growth Factor (MGF) stimulates
muscle cell hypertrophy. IGF-I, MGF and IGFBP-5 expression in colonic smooth muscle
are all increased in Crohn's Disease and in TNBS-induced colitis. Aim: To determine whether
endogenous IGF-I regulates the response of colonic muscle to chronic inflammation induced
by TNBS and whether this is associated with alterations in levels of MGF or IGFBP-5 in the
smooth msucle cells. Methods: Transgenic mice, Igf1tm2Ts/ImJ, which have a 70% reduction
in IGF-I levels and B6129SF2 control mice were used to determine the role of endogenous
IGF-I in the response of colonic smooth muscle to chronic inflammation. Mice were adminis-
tered 2.5 mg of TNBS in 50% ethanol by intrarectal administration or vehicle alone. After
7 days, when chronic inflammation is present, the colons were harvested and used to prepare
tissue sections for histology. Smooth muscle cells were isolated to prepare RNA and protein
lysates. Semi-quantitative histologic scoring of extent of muscle thickening (0-3) and cellular
infiltration (0-3) was used to grade muscle inflammation. Levels of IGF-I, MGF, and IGFBP-
5 RNA were quantitated using real-time PCR using the ΔCt method with β-actin as control.
Results: In untreated Igf1tm2Ts/ImJ mice, IGF-I RNA levels were 1.1 fold lower than in
B6129SF2 control mice. TNBS treatment in control mice elicited a 1.5 fold increase in IGF-
I RNA that was decreased by 60% in Igf1tm2Ts/ImJ mice. The increase in IGFBP-5 and MGF
RNA levels elicited by TNBS in control mice (1.3 and 1.7 fold increase, respectively) were
also inhibited in Igf1tm2Ts/ImJ mice (50% and 80%, respectively). Both groups of mice had
mean histologic scores of 0 following vehicle treatment. Control mice treated with TNBS
developed significant muscle inflammation compared to vehicle treated mice with mean
histologic scores of 5. The effects on the muscle, induced by TNBS, were ameliorated in
Igf1tm2Ts/ImJ mice compared to control mice with mean histologic scores of 2. Conclusions:
Endogenous IGF-I is required for development of the full chronic inflammatory response
in murine colonic smooth muscle to TNBS-induced colitis. IGF-I also regulates the expression
of IGFBP-5 and MGF, both of which are increased in chronically inflamed muscle and in
turn mediate smooth muscle cell hyperplasia and hypertrophy.
S1648
Endoglin Is a Novel Regulator of Fibroblast Function in Crohn's Disease
Associated Fibrostenosis
John P. Burke, R. william G. Watson, Jurgen J. Mulsow, Neil G. Docherty, J. calvin Coffey,
P. ronan O'connell
Introduction: The intestinal fibroblast is the key cell mediating Crohn`s disease (CD) associ-
ated fibrostenosis and the cytokine transforming growth factor (TGF)-β1 is critical to this
process promoting growth factor production and collagen contraction. However, we have
previously demonstrated that fibroblasts isolated from CD strictures exhibit reduced respon-
sivity to stimulation with TGF-β1 (1). Endoglin is a membrane glycoprotein which acts as
a negative regulator of TGF-β1. Methods: following the acquisition of institutional ethical
approval human intestinal fibroblasts were cultured using a primary explant technique from
serosal biopsies of patients undergoing intestinal resection for CD strictures (n=6) or controls
undergoing resection for colorectal cancer (n=8). Endoglin expression was assessed using
confocal microscopy, flow cytometry, immunohistochemistry and western blot. The effect
of small interference (si)RNA-mediated knockdown of endoglin on fibroblast responsivity
to TGF-β1 (1ng/ml; 24 hr) in terms of connective tissue growth factor (CTGF) expression
(determined by western blot) and ability to contract collagen in-vitro was assessed. *P<0.05
was significant using students t-test. Results: Human intestinal fibroblasts express endoglin.
Crohn's stricture fibroblasts express increased constitutive endoglin relative to control
fibroblasts (*P=0.002). Treatment of fibroblasts with TGF-β1 resulted in endoglin upregul-
ation. SiRNA mediated endoglin knockdown resulted in enhanced responsivity to TGF-β1
in terms of CTGF production. Endoglin deficient cells exhibit enhanced basal and TGF-β1
stimulated collagen contraction. Conclusions: This is the first reported association of endoglin
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with stricturing Crohn's disease. Fibroblasts deficient in endoglin exhibit enhanced responsiv-
ity to TGF-β1. We propose endoglin over-expression by the fibroblast is part of an autoregula-
tory mechanism in response to stimulation with TGF-β1 and represents a novel therapeutic
entry point for fibrotic Crohn's disease. References: Mulsow JJ, Watson RW, Fitzpatrick JM,
O'Connell PR. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal
fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg.
2005 Dec;242(6):880-7.
S1649
T Cell-Derived Microparticles from Crohn's Disease Patients Induce Vascular
Hyporeactivity Through a Ppar-Gamma-Dependent Pathway
Jean-marie Reimund, Mostefai hadj Ahmed, Bernard Duclos, René Baumann, Christian D.
Muller, Ramaroson Andriantsitohaina
Background: Several anatomical, pathological and physiological [1,2] studies suggest that
vascular reactivity is impaired in Crohn's disease (CD), and may participate to its pathophysi-
ology. On the other hand, circulating cell-derived microparticles (MP) have been described
to be increased in active CD patients and returned to normal values after infliximab treatment
[3]. Aim: Therefore, considering the potential role of circulating MP in regulating endothelial
function and vascular reactivity, the main objective of this study was to investigate the effects
of T lymphocyte-derived MP (TLMP) from CD patients on vascular reactivity, compared to
TLMP from healthy subjects. Methods: Circulating TLMP were obtained from peripheral
blood in 8 active CD patients (CDAI > 220) and 6 healthy subjects. Their effect on vascular
reactivity of male Swiss mice aortic rings (with endothelium or after endothelial removal)
mounted on a wired myograph was studied in the presence or not of a 30 nmol/L concentra-
tion of TLMP from CD patients or healthy subjects after application of acetylcholine or
serotonine, with or without rosiglitazone, a PPAR-gamma agonist. Results: (i) Compared to
TLMP from healthy subjects, TLMP from CD patients induce a significant vascular hyporeac-
tivity of acetylcholine-activated aortic rings (p < 0.001. (ii) This is also the case after activation
by serotonine in intact aortic rings (p < 0.001) or after endothelium removal (p < 0.01).
(iii) These effects are associated to an increase in arterial cyclooxygenase 2 (COX2) expression,
but not nitric oxide expression (immunohistochemistry). (iv) In presence of rosiglitazone, the
effects of CD-derived TLMP on vascular reactivity are abolished. Conclusion: T lymphocyte-
derived MP obtained in active CD patients induce a significant vascular hyporeactivity
which may participate in CD pathophysiology. This suggest an important deleterious role
of inflammation-induced TLMP in active CD. Increased COX2 expression in presence of
CD-derived TLMP can be interpreted as a defence mechanism in order to protect from
vascular hyporeactivity and its consequences. Correction of vascular reactivity by rosiglitazone
indicates, in addition to previous studies suggesting a role of PPAR-gamma in CD pathophysi-
ology, that PPAR-gamma agonists may be considered of potential interest in CD treatment.
Acknoweledgement: This work was supported by a grant from Association François Aupetit
(AFA), France [1] Lebuffe et al. Aliment Pharmacol Ther 2000;14:1279 [2] Tabernero et
al. Circulation 2003;107:1407 [3] Chamouard et al. Dig Dis Sci 2005;50:574
S1650
Identification of Differentially Expressed Proteins in Biopsies of IBD Patients
Using Zoom 2d Gel Coupled with Dige and Lc-MS/Ms
Xuhang Li, Sean Sullivan, Laurie Conklin, Robert Diez, Mark Donowitz, Carmen Cuffari,
Themos Dassapoulos, Steven Brant, Robert Cole, Theodore Bayless, Yueping Chen
Background: Although intensive studies, the pathogenesis of inflammatory bowel disease
(IBD) is still poorly understood. Considering proteins are principle functional units for
phenotypic determination of IBD, we began to apply proteomic approaches to identify and
characterize differentially expressed or post-translationally modified proteins in the mucosa
of Crohns disease (CD) patients compared with that in normal subjects. Methods: We
developed a highly reproducible Zoom 2D/DIGE approach to separate and compare expres-
sion of mucosal proteins between pinch biopsies. Fluorescent dye Cy3 and Cy5 were used
to label proteins from normal subjects and CD, respectively, while Cy2 was used to label
equal amount of proteins from normal and CD as an internal control. A 24-cm IPG strip,
pH 4-7, was used for each IEF separation. Each IEF strip was then equally divided into
three portions and each portion was subjected to a second dimensional SDS-PAGE. Proteins
of interest were picked for identification by LC-MS/MS analysis. Results: Up to 3,000 protein
spots were highly reproducibly and well resolved on our 2D gel. Based on the analysis of
three independent normal-CD pairs, 40 spots of differentially displayed proteins with similar
changes (≥1.0 fold changes) were picked for identification, including 27 up-regulated and
13 down-regulated. The differentially expressed proteins identified can be categorized as
following groups: 7 known to be involved in inflammation, 4 involved in cytoskeleton
structuring and remodeling, 4 metabolic enzymes or kinases, 3 involved in protein degrada-
tion pathways, 3 in protein translation and modifications, 2 G-protein kinases, 2 involved
in cell proliferation, 2 members of peroxiredoxin family, one heat shock protein (Heat shock
protein gp96 precursor), and 2 proteins with little known function. 5 pairs of proteins (each
pair has similar molecular weight but different PI) were identified as the same proteins with
presumably different degrees of phosphorylation. An interesting example of those is the
lymphocyte specific protein 1, which is minimally phosphorylated in normal condition, but
heavily phosphorylated in CD. Conclusion: The Zoom 2D-gel/DIGE approach we employed
is a highly reproducible approach for proteomic study of IBD. Most differentially expressed
proteins identified are involved in the regulation of either inflammation, or cell growth/
proliferation, disregulation of which is the characteristics of intestinal mucosal pathophysiol-
ogy of CD. Identification of these proteins provides potential targets for further characteriza-
tion of pathogenic proteins, and thereby leading to better understanding of IBD pathogenesis
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S1651
Increased Expression of Human Protease-Activated Receptor 1 and 3 (HPAR-1
and -3) mRNA in Inflammatory Bowel Disease (IBD) Patients Colonic Mucosa
Romain Gloro, Moise Coeffier, Stephane Allouche, Spyros Sophos, Guillaume Savoye,
Stephane Lecleire, Eric Lerebours, Pierre Dechelotte, Philippe Ducrotte, Jean-marie
Reimund
Rationale: Protease-activated receptors (PARs) (which belong to the G protein-coupled recep-
tors family) play a role in regulating intestinal inflammatory/immune response [1]. In humans,
four PARs (hPAR-1 to -4) have been identified. In the digestive tract, they are expressed by
epithelial cells, neurons, smooth muscle as well as mast cells. Until now, only two groups
reported hPAR overexpression in IBD, i.e. increased hPAR-1 mRNA expression in Crohn's
disease (CD) [2], and, enhanced hPAR-2 expression (immunohistochemistry) in ulcerative
colitis (UC) [3]. Aim: Our objective was to study hPAR-1 to -4 mRNA expression in colonic
mucosa from active IBD patients, compared to colonic mucosa from healthy controls (HC),
and to examine their potential relationship to fecal calprotectin concentrations. Patients and
Methods: Colonic biopsies were obtained in 22 subjects (CD: n = 8, UC: n = 9, HC: n =
5), immediately frozen and stored at -80 °C until hPAR-1 to -4 mRNA expression levels
were determined (real-time quantitative PCR). In 11 IBD patients (CD: n = 6, UC: n = 5)
biopsies have been taken in both inflamed and non-inflamed mucosa. In all subject, fecal
calprotectine was measured by ELISA, the day before colonoscopy was performed (i.e. before
colon cleansing). Results: In IBD patients, hPAR-1 and hPAR-3 mRNA levels were significantly
increased in inflamed mucosa compared to non-inflamed mucosa (p < 0.05 and p = 0.001
respectively), and compared to HC colonic mucosa (p < 0.01 and p = 0.001 respectively).
hPAR-2 and -4 mRNA levels did not differ between IBD patients (inflamed or non-inflamed
colonic mucosa) and HC. Fecal calprotectin concentrations were higher in IBD patients than
in HC (1224 mg/kg vs 21.5 mg/kg, p < 0.05) and positively correlated to hPAR-1 (r = 0.63,
p < 0.01) and hPAR-3 (r = 0,70, p < 0.001) mRNA levels. Conclusion: This study, confirming
the increase in hPAR-1 mRNA levels in inflamed IBD colonic mucosa, is the first to report
an increased hPAR-3 mRNA expression (correlated to fecal calprotectin) in inflamed colonic
mucosa from IBD patients. It strongly suggest that both hPAR-3 and -1 play a role in IBD
pathogenesis and could be considered as potential therapeutic targets. Forthcoming studies
are needed to understand more precisely the mechanisms by which hPAR-3 and -1 modulate
inflammatory/immune response in IBD. [1] Gloro et al. Expert Opin Ther Target
2005;9:1079-95 [2] Vergnolle et al. J Clin Invest 2004;114:1444-56 [3] Kim et al. Inflamm
Bowel Dis 2003;9 :224-9 Acknowledgements: This study has been supported by a grant
from IRMAD (sponsored by AstraZeneca, France) to JMR, and from IPSEN BEAUFOUR
France to RG.
S1652
Galectin-1 and Galectin-2 - New Activators of Colonic Lamina Propria
Fibroblasts
Elisabeth Lippert, Manuela Gunckel, Juergen Schoelmerich, Werner Falk, Florian
Obermeier, Gerhard Rogler
Background: We recently have identified galectin-3 (gal-3) as a new and extremly strong
fibroblast activator from colonic epithelial cells. Our aim was to identify other factors of
this lectin family that could induce fibroblast activation. Additionally we aimed to clarify
the role of the structurally closely related galectin-1 (gal-1) and galectin-2 (gal-2) in intestinal
fibroblast activation. Material and Methods: Colonic lamina propria fibroblasts (CLPF) were
isolated from surgical specimens from colonic carcinoma or diverticulitis as well as from
biopsies of healthy controls. Recombinant gal-3 expression was performed by the pET vector
system. Gal-3 was purified using avidin affinity chromatography. Gal-1 and gal-2 were
purchased from R&D Systems, Wiesbaden, Germany. Fibroblast stimulations were performed
in 6-well plates for 24 h, the galectins were used in increasing concentrations between 10
µg/ml to 1 ng/ml. IL-8 was quantified in the supernatant of the cells as read out for fibroblast
activation. Results: Both gal-1 (10 µg/ml) and gal-2 (10 µg/ml) induced a strong fibroblast
activation with increased IL-8 secretion compared to controls (9.35 fold and 3.0 fold
increase vs controls). Gal-1 costimulation with gal-3 in different concentrations induced a
concentration dependent fibroblast activation that significantly exceeded the additive effects
of both lectins. Gal-1 and gal-2 costimulation resulted in a notable fibroblast activation.
Discussion: With gal-1 and gal-2 we identified two further fibroblast activators. These factors
may play an important role in persisting fibroblast activation in inflammatory bowel disease
with formation of strictures and stenosis. The role of both factors in IBD tissue and fibroblasts
is under further investigation.
S1653
Persistent Oxidative Stress Damage and Inhibition of Catalase (Cat) in
Peripheral White Mononuclear Cells (PWMC) of Patients with Crohns Disease
(CD): Implications in Physiopathology
Belen Beltran, Pilar Nos, Francisco Dasi, Marisa Iborra, Isabel Conde, Guillermo Bastida,
Vicente Garrigues, Julio Ponce
Background: Active CD patients have an increased ROS peripheral leukocyte damage and
decreased plasma antioxidants. We have previously shown that PWMC of active CD patients
have an increased oxidative stress, which depends on H2O2 production. Aims: 1) To study
whether the oxidative stress detected in CD patients has an impact on the cell by measuring
oxidative damage on lipids and DNA. 2) To characterize whether the oxidative stress damage
is recovered in remission. 3) To analyze antioxidant enzymes activities in active and inactive
CD in order to clarify the origin of the oxidative stress damage. Methods: Blood samples
from healthy subjects (n=20, mean age 32 ± 8 y) and from patients at first flare of CD or
when being in remission (n=20, mean age 36.9 ± 9.2 y) were obtained. PWBC were isolated
by Ficoll-Histopaque sedimentation. Lipid peroxidation was detected by measuring the
malondialdehyde (MDA) concentration in the cells. DNA oxidative damage was measured
detecting the amount of 8-oxodeoxyguanosine (8-oxo) incorporated in the DNA strain. MDA
and 8-oxo were detected by HPLC. Superoxide (SOD) and catalase (CAT) activity were
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measured spectrophotometrically by enzymatic assays. Statistical analysis was performed
with the Mann-Whitney test. Results: C Reactive Protein (CRP) values were: controls (1.2
± 0.24), active CD (78.57 ± 12.3), inactive CD (5.7 ± 2.6). Inactive patients had the
experiment performed when they were a mean time of 4.3 ±1 months in remission. Table
1 shows the oxidative damage on lipids and DNA and Table 2 shows SOD and CAT activities
Conclusions: PWMC from active CD patients have a significant oxidative stress damage,
which affects both the lipids and the DNA. This damage is not recovered in remission.
During active disease, PWMC have an increase of SOD activity, which will help to metabolize
the O2- production. However, catalase activity is inhibited and will help to the generation
of H2O2 in the cells. Inactive CD patients recover normal activity of SOD enzyme, however the
inhibition of catalase is not recovered. This event could contribute to PWMC immunological
functioning and thus could have an impact on the physiopathology of CD.
S1654
IFNγ Sensitizes T84 Cells to Flagellin-Induced Apoptosis Through Down-
Regulating Anti-Apoptosis Protein Expression
Yimin Yu, Zixian Lu
Background: Vertebrate digestive tracts are colonized by hundreds of different kinds of
microbes. These microbes are restrained in luminal cavity by intra-epithelium tight junction.
The integrity of intestinal epithelium is critical to maintain intestinal tolerance to commensal
microbes. Disruption of intestinal epithelial integrity results in the leaks of microbes and/
or microbial components that may lead to inflammatory disorder such as inflammatory
bowel disease (IBD). Interferon γ (IFNγ) is a pro-inflammatory cytokine and considered as
a driving factor in IBD development. One of the possible detrimental effects of IFNγ might
be enhancing epithelial cell death. However, the molecular mechanism by which IFNγ
promote intestinal epithelial cell death is not known. In the present work, we investigated the
effect of IFNγ on T84 cell apoptosis in responding to flagellin and its molecular mechanism.
Methods: T84 cells were cultured in DMEM/F12 medium. Apoptosis was determined by
TUNEL staining. Biochemical analysis of apoptosis cascade and expression of anti-apoptosis
proteins were studied by western blotting. Results: 1) Extended pretreatment with IFNγ
(500 units/ml) sensitized T84 cells to apoptotic effect of flagellin. Flagellin alone or IFNγ
alone could not induce T84 cell apoptosis. The effect of IFNγ was suppressed if flagellin
was present during IFNγ pretreatment. 2) IFNγ pretreatment resulted in the down-regulation
of anti-apoptosis proteins XIAP and cIAP1. IFNγ pretreatment also abolished flagellin-
induced expression of cIAP2. 3) After IFNγ pretreatment, flagellin-induced NFκB signaling
activation was suppressed while flagellin-induced MAPK activation was enhanced. 4)
Knocking-down anti-apoptosis protein expression by siRNAs rendered Hela cells to apoptosis.
Conclusions: Both anti- and pro-apoptosis signaling pathways are initiated by flagellin in
intestinal epithelial cells. This balanced response is altered by IFNγ through suppressing
NFκB activation which results in decreased levels of anti-apoptosis proteins and excessive
cell death.
S1655
Early Epithelial Cell Alterations in a Population At Risk for Celiac Disease
with Normal Histology
Mala Setty, Jerrold R. Turner, Govind Bhagat, Kamalika Nag, Emily Kistner, Riccardo
Troncone, Peter H. Green, Stefano Guandalini, Joseph A. Murray, Bana Jabri
Background: Celiac disease (CD) is an intestinal inflammatory disease induced in genetically
susceptible people by the ingestion of gluten, a wheat protein. A known mechanism is the
adaptive immune response to immunodominant peptides of α-gliadin recognized by gliadin
specific CD4+ T cells in the lamina propria(LP) driving the anti-tissue transglutaminase
(TTG) antibody response. Mucosal damage, however, is mediated by CD8+ intraepithelial
lymphocytes(IEL) activated by IL-15. These IEL recognize the stress-inducible non-classical
MHC class I molecule, MIC expressed on epithelial cells. The α-gliadin p31-49 peptide,
unrecognized by CD4+ T cells, has been shown to trigger both IL-15 and MIC in epithelial
cells. We hypothesize that the innate and adaptive immune responses can occur independ-
ently, but are both required to induce overt CD. Methods: 183 patients underwent duodenal
biopsies for GI symptoms, family history(FH) of CD or presence of anti-TTG ab. Those with
normal histology were divided into controls(n=51) or latent/at risk CD(n=85) based on
presence of anti-TTG ab, 1st or 2nd-degree FH, or gluten sensitivity. Active celiacs(n=47)
were identified by histological diagnosis. Controls had neither FH of CD nor anti-TTG ab.
Biopsies stained for IL-15, Hsp70 and MIC were interpreted by a GI pathologist(JRT) in a
blinded manner scoring IL-15 from 0-4, and Hsp70 and MIC, from 0-3. Results: Significantly
increased IL-15 and Hsp70 expression was seen in the at-risk group versus controls. A
subset of at risk patients had increased expression of both markers as compared to controls.
HLA type made no significant difference in expression of either marker. When analyzed
based on TTG ab, 17% of TTG+ at risk patients expressed both markers and, surprisingly,
27% of TTG- at risk patients shared both markers. In contrast, MIC, required for IEL
activation, was not significantly increased among either TTG+ or TTG- latent patients.
Conclusions: These results indicate latent CD patients with apparent normal histology and
CD4+ response can be separated into patients with and without epithelial stress markers.
Conversely, these observations suggest that innate epithelial alterations can exist in absence
of an anti-gluten CD4+ T cell response. Altogether our study supports the hypothesis that
gluten can trigger an innate immune response in absence of an adaptive anti-gluten immune
response. Furthermore, they suggest that IL-15 and Hsp70 may allow to identify latent
patients with a higher risk towards overt CD.
S1656
Gliadin Elicits Cxcr3-Dependent Intestinal Zonulin Release, Increased
Intestinal Permeability and Myd88 Recruitment
Karen Lammers, Ruliang Lu, Julie Brownley, Anna Sapone, Craig Gerard, Stefanie N.
Vogel, Alessio Fasano
Ingestion of gliadin, the toxic component of gluten, triggers celiac disease (CD). Apical but
not basolateral intestinal epithelial exposure to gliadin induces the release of zonulin and
subsequent increase in intestinal permeability, suggesting that gliadin interacts with a luminal
receptor. Recently, we identified the chemokine receptor, CXCR3, as the receptor for gliadin.
Aim: to explore the function of CXCR3 after gliadin binding. Methods: In Vitro experiments
with CXCR3-transfected HEK293T cells and intestinal epithelial cell lines were performed
to study gliadin binding to the receptor; CXCR3 protein and gene expression on intestinal
epithelial cells; and, signaling pathways activated by CXCR3-gliadin binding by immunofluo-
rescence (IF) microscopy, real time RT-PCR, and, western blot analysis/immunoprecipitation.
Ex vivo experiments were performed to study the role of CXCR3 in zonulin release and
intestinal transepithelial electrical resistance (TEER) changes in response to gliadin exposure
using C57BL/6 wild type- and CXCR3-/—mouse small intestine in microsnapwell chamber
experiments; to localize CXCR3 expression in intestinal tissues by laser capture microdissec-
tion; and, to study CXCR3 gene and protein expression in human intestinal biopsy specimens
from non-celiac disease and celiac disease patients by real time RT-PCR and IF. Results: In Vitro
experiments showed specific colocalization of gliadin with CXCR3. CXCR3 was expressed in
human and mouse intestinal epithelium and lamina propria. Mucosal CXCR3 expression
was elevated in active CD but turned to baseline level during gluten-free diet. Gliadin
exposure led to physical association of CXCR3 and MyD88. Ex vivo experiments revealed
that gliadin exposure to intestinal segments from WT mice increased zonulin release (0.33+/-
0.06 (baseline) vs. 0.61+/-0.13 ng/mg protein (post-gliadin exposure, p<0.04) and decreased
TEER (24.1+/-3.5 (baseline) vs. 14.3+/-2.4 Ω.cm2 (post-gliadin exposure, p=0.0004)). Con-
versely, CXCR3-/- intestinal segments failed to respond to gliadin (zonulin: 0.33+/-0.15
(baseline) vs. 0.25+/-0.06 ng/mg protein (post-gliadin exposure, p=NS), and TEER: 18.2+/-
4.1 (baseline) vs. 16.5+/-3.9Ω.cm2 (post-gliadin exposure, p=NS). Conclusions: We show
that gliadin binds to CXCR3 and leads to the activation of the zonulin pathway and increase
in intestinal permeability in a MyD88-dependent fashion. The intestinal expression of this
receptor was observed at epithelial and lamina propria level. Its expression is up-regulated
during the acute phase of celiac disease and returns to baseline expression following the
implementation of a gluten free diet.
S1657
Lack of Organ Pathology in a Mouse Model of Tissue Transglutaminase
Autoimmunity
Tobias Freitag, Daniele Sblattero, Gerry Melino, Detlef Schuppan
Introduction: In celiac disease (cd) patients, tissue transglutaminase (TGase2) autoantibody
titers correlate with disease severity. While deposits of IgA directed against TGase2 have
been demonstrated in the small intestine in cd patients, the role of autoantibodies and T
cell immunity to TGase 2 in the development of organ pathology in cd remains unclear. A
model to study the effects of autoimmunity against TGase2 In Vivo is missing. Methods:
TGase2-/- mice (11th backcross to C57BL/6, gluten-free diet from birth) were immunized
with 80 μg recombinant mouse TGase2 or ovalbumin (control) in complete Freund's adjuvant
(CFA) and received one boost with 40 μg antigen in incomplete Freund's adjuvant. Rag1-/-
recipients of adoptive transfers of 66 x 10^6 splenocytes i.p. from TGase2- or ovalbumin-
immunized TGase2-/- donors were immunized once with corresponding antigen in CFA
immediately post-transfer. After 10 and 16 weeks, serum TGase2 autoantibody titers (ELISA),
total serum IgA (ELISA) and anti-endomysial antibodies (IF) were analysed. At 16 weeks,
organs were collected for histology (H/E). Results: Rag1-/- recipients of splenocytes from
TGase2 immunized donor mice developed high titers of TGase2 IgG autoantibodies (1:2468
+/- 655 serum dilution at week 10 (mean +/- SD); 1:2122 +/- 304 week 16) as well as anti-
endomysial antibodies, while control sera were negative. TGase2 IgG levels in this group
were comparable to levels reached in TGase2-immunized TGase2-/- mice (1:3020 +/- 973).
TGase2 IgG autoantibodies included IgG1 and complement-activating IgG2c subtypes. While
total IgA levels had recovered in recipients, there was no production of TGase2 IgA. Intraepi-
thelial lymphocytes and, occasionally, Peyer's patches were present in the small intestine,
consistent with reconstitution with T and B lymphocytes. Spleen weights had recovered.
No tissue defects were seen in the small intestine, colon, liver, pancreas and skin. (Immuno-
) histological studies are ongoing. Clinically, mice remained normal. Conclusions: In experi-
mental mice, systemic tolerance to TGase 2 is broken and high levels of TGase2 IgG
autoantibodies (including complement-activating IgG2c subtype) are sustained for at least
16 weeks post-treatment. However, no organ pathology was detected in the small intestine,
colon, liver, pancreas and skin. The study of long-term effects of autoimmunity against
TGase2 In Vivo is in process.
S1658
Glucagon-Like Peptide-2 (GLP-2) Increases Mesenteric Blood Flow in Humans
Lasse Bremholm, Mads Hornum, Birthe Henriksen, Steen Larsen, Jens J. Holst
Background : Mesenteric blood flow is thought to vary depending on the digestion and
absorption of various ingested macronutrients. We hypothesized that the intestinotrophic
hormone, GLP-2, may be involved in the regulation. Changes in mesenteric blood flow can
be measured by duplex ultrasound scanning of the superior mesenteric artery and expressed
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as resistance index (RI). The aim of this study was to demonstrate the influence of GLP-2
on the flow, expressed by change in RI. Methods: A homogeneous group of ten healthy
volunteers completed a two day trial. On day 1 a standard meal was given, and RI measured
in the mesenteric artery. On day 2 (fasting) GLP-2 was infused intravenously at rates of 0.5
pmol/kg/min, 1,0 pmol/kg/min and 2,0 pmol/kg/min over 3 x 45 min. After a 60 min rest
450 nmol synthetic GLP-2 was given subcutaneously (SC). RI in the mesenteric artery was
measured continuously. Results: After IV infusion the following changes in RI were observed:
0.5 pmol/kg/min: 2,7 % (range 0-6,3 %), 1,0 pmol/kg/min: 6,7 % (range 0,4-15,9 %), 2,0
pmol/kg/min: 15,3 % (range 9,6-22,7 %). p < 0.00802 (Friedmann ANOVA). When giving
SC GLP-2, elicited a maximum average change in RI of 15,6 % (range 5,0-28,1 %). The
standard meal elicited a 14,7 % (range 8,8-21,6 %) change, p<0.020 (Wilcoxon). There is
a similar change over time (0-90 min) after a standard meal and after subcutaneous adminis-
tration of synthetic GLP-2. Conclusion: Our study shows a significant association between
IV and SC infusion of synthetic GLP-2 and change in mesenteric blood flow. A linear
dose- response relationship was observed after i.v. infusion. The meal induced changes in
mesenteric blood flow over time were reproduced by SC GLP-2. Thus our results support
the hypothesis that GLP-2 is an important regulator of mesenteric blood flow.
S1659
A Novel Model of Ischemic Enteritis Induced By Stenosis of Superior
Mesenteric Artery in Rats
Tohru Kotani, Yuka Takahira, Yoshino Komatsu, Kikuko Amagase, Koji Takeuchi
Background/Aims: Ischemic enteritis, the disease of which onset is rapid, followed by exten-
sion progressively and resulting in a high mortality rate, is caused either by interruption or
decrease of the arterial inflow to the small intestine. At present, however, an animal model
of ischemic enteritis that has a high clinical predictability is not available. In the present
study, we aimed to establish a new model of ischemic enteritis in rats and evaluated the
usefulness of this model by examining the prophylactic effects of various agents. Methods:
Male SD rats were used after 18 h fasting. Ischemic enteritis was induced by partial ligation
of the superior mesenteric artery (SMA). Under ether anesthesia, SMA was isolated, and a
stenosis was produced by placing a needle (20~23 guage) on the vessel and then ligature
of both the vessel and needle, and then a needle was removed from the ligature, resulting
in a calibrated constriction of SMA. After the operation, the animals were fed normally and
killed various days later up to 7 days. Enterobacterial count was measured 7 days after the
stenosis of SMA. Gene expression of inducible nitric oxide (NO) synthase (iNOS) in the
mucosa was examined by RT-PCR. Ampicillin (antibiotics; 800 mg/kg/day), aminoguanidine
(a selective inhibitor of iNOS; 20 mg/kg/day) or indomethacin (3 mg/kg/day) was given PO
or SC, respectively, after the operation. Results: The stenosis of SMA caused mucosal ischemia
and resulted in damage in the small intestine, especially the ileum, 3~7 days after the
operation, and the severity of damage increased dependent on the guage of needle. No
damage occurred in the small intestine by inducing the stenosis with a needle of 20~21
gauge, while a few lesions were observed when a 22 gauge needle was used. When a needle
of 23 guage was used, although some of the animals died within 24 h, multiple hemorrhagic
lesions occurred in the small intestine at the incidence of 100%, the survival rate being
about 80%. Both aerobic and anaerobic bacterial counts were significantly increased 7 days
after the operation, together with the up-regulation of iNOS mRNA expression in the mucosa.
The repeated administration of ampicillin as well as aminoguanidine significantly prevented
the development of intestinal lesions caused by ischemia, while indometacin treatment
markedly increased the severity of these lesions. Conclusions: The present study demonstrated
a novel rat model of ischemic enteritis that may be useful for screening the drugs against
ischemic enteritis. It is assumed that the pathogenic mechanism of this model involves
enterobacteria and iNOS/NO as well as prostaglandins.
S1660
Hypertonic Saline and Its Effect On Intestinal Lymphatic Flow in the Setting
of Acute Intestinal Edema
Ravi S. Radhakrishnan, Lindsey Villarubia, Hasen Xue, Glen A. Laine, Randolph H.
Stewart, Norman W. Weisbrodt, Charles S. Cox
Introduction: We have shown that acute edema induced by resuscitation and mesenteric
venous hypertension (MV-HTN) impairs intestinal transit and contractility and is reversed
by 7.5% hypertonic saline (HS). Also, prior studies have shown that HS redistributes fluid
to the intravascular, intraluminal, and peritoneal spaces and is associated with increased
water channel expression suggesting that HS induces intestinal filtration secretion. However,
the effect of acute intestinal edema and HS on microvascular fluid balance is unknown. We
sought to examine the changes in mesenteric venous fluid balance in the setting of acute
intestinal edema, treated with HS. Methods: Rats were randomized to four groups: sham,
MV-HTN with 80 cc/kg NS (NS 80), HS alone, and NS 80 with HS administration after 30
minutes. Mesenteric veins and lymphatic vessels were cannulated to measure pressure. In
addition, pressure transducers were placed in the bowel wall to measure interstitial pressure.
After 30 minutes, central venous pressure (CVP), lymphatic pressure, and interstitial pressure
were measured. Also, mesenteric lymphatic flow was measured and lymphatic resistance
was calculated. Intestinal edema was measured by wet to dry tissue weight ratio (W/D).
Results: Acute intestinal edema causes a significant increase in CVP, lymphatic pressure,
interstitial pressure, and lymphatic flow. There is also a significant decrease in lymphatic
resistance. HS administration results in similar values to sham. Conclusions: Acute intestinal
edema causes a significant change in mesenteric lymphatic fluid dynamics, suggesting that
there is a significant movement of interstitial fluid through the lymphatic vessels, without
resolution of interstitial edema. HS improves tissue edema without significantly increasing
lymphatic flow. These data, along with the fluid redistribution and water channel data from
previous studies suggest that HS does not improve tissue edema through increased lymphatic
function alone, but rather by other mechanisms, possibly via filtration secretion through
increased water channel expression.
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S1661
Prophylactic Enrichment of Ileal Enterocyte Phospholipids with
Polyunsaturated Fatty Acids Facilitates Acute Repair Following Ischemic
Injury in Suckling Piglets
Sheila Jacobi, Adam J. Moeser, Ben Corl, Kathleen A. Ryan, Anthony T. Blikslager, Robert
J. Harrell, Jack Odle
Infant formula companies began fortifying formulas with long-chain polyunsaturated fatty
acids (PUFA) in 2002, including arachidonic acid (AA) at ∼ 0.5% of total fatty acids. Long-
chain PUFAs, in particular AA, are precursors for the synthesis of prostanoids which have
been shown to stimulate recovery of intestinal barrier function in ischemic injured porcine
ileum. We have demonstrated that supplementation of milk with PUFA increases the content
of AA in enterocyte membranes of piglets, however, the effect of enterocyte membrane
enrichment of AA on intestinal repair is not known. The objective of these experiments was
to investigate the effect of higher supplementation of AA on intestinal barrier repair in
ischemic-injured porcine ileum. One day-old pigs (n=24) were fed a milk-based formula
for 10 d. Diets contained either no PUFA (0%AA), 0.5%AA, 5%AA, or 5% eicosapentaenoic
acid (EPA) of total fatty acids. Following dietary enrichment of intestinal phospholipids,
ileum from piglets were subjected to in vivo ischemia injury by clamping the local mesenteric
blood supply for 45 min. Following the ischemic period control (non-ischemic) and ischemic
intestinal loops were harvested, stripped from their seromuscular layer, and mounted on
Ussing chambers. Transepithelial electrical resistance (TER) was measured as an index of
intestinal barrier function over a 240 min recovery period. Ischemia-injured ileal tissues
from piglets fed the 5% AA diet and 5% EPA exhibited enhanced recovery of TER compared
with other treatments (% increase in TER = 13±13, 21.6±12 59.1±12, 50.8±13, for 0%AA,
0.5%AA, 5%AA, and 5%EPA, respectively, p<0.05). Enhanced TER recovery response
observed with 5% AA supplementation was attenuated by in vitro application of indomethacin
suggesting that recovery responses in these tissues was mediated by endogenous prosta-
glandins. Histological evaluation of ischemic ileal tissues from piglets fed the 5% AA formula
showed reduced histological lesions as indicated by a reduction in the percentage of denuded
villi surface area measured immediately after ischemia compared to other dietary treatments
(P<0.05). These data demonstrate feeding elevated levels of long-chain PUFAs enhance
recovery of TER in ischemic injured porcine ileum and this mechanism is mediated via
endogenous prostaglandin synthesis.
S1662
Therapeutic Expectation of Proteinase-Activated Receptor-2 Antagonism in
Intestinal Ischemia-Reperfusion Injury in Rats
Hiroshi Ichikawa, Norimasa Yoshida, Tomohisa Takagi, Takahiro Suzuki, Tetsuya
Okayama, Tatsushi Omatsu, Ikuhiro Hirata, Osamu Handa, Satoshi Kokura, Yuji Naito,
Takeshi Okanoue, Toshikazu Yoshikawa
Proteinase-activated receptors (PARs), which are cell surface membrane receptors activated
by the serine proteases thrombin and trypsin, constitute a recent described family of 7-
transmembrane G protein-coupled receptors that are activated by proteolysis. To date, four
proteinase-activated receptors (PARs) have been identified, with distinct N-terminal cleavage
sites and tethered ligand pharmacology. Especially, PAR2 is an integral component of the
inflammatory process, and its expression by human endothelium is upregulated by cytokines.
In recent years several evidence have been accumulated for an involvement of this receptor
in the response to endothelial injury In Vitro and In Vivo experimental settings suggesting
a role for PAR2 in the pathophysiology of gastrointestinal system. The aim of this study is
to prove the usefulness of anti-PAR2 blocking antibody using the reperfusion-induced rat
intestinal mucosal injury model In Vivo. Intestinal ischemia was induced for 30 min by
applying a small clamp to the superior mesenteric artery after ligating the celiac artery in
rats. Reoxygenation was produced by removal of the clamp. Sixty minutes after reperfusion,
the rats were killed by exsanguinations via the abdominal aorta. A blocking antibody to
PAR2 at a dose of 1mg/kg was injected intraperitonealy 2 hours before ischemia. Both intra-
luminal hemoglobin and protein levels, as indexes of mucosal damage, significantly increased
from mean basal levels after 60 min of reperfusion. These increases in intra-luminal hemo-
globin and protein levels were significantly inhibited by treatment with anti-PAR2 antibody.
The concentration of thiobarbituric acid-reactive substances (TBA-RS), myeloperoxidase
(MPO) activity and the content of mucosal CINC-2β in the intestinal mucosa were signific-
antly higher than the basal level after reperfusion. These increases were all significantly
inhibited by the treatment with anti-PAR2 antibody. Reverse transcription polymerase chain
reaction revealed that PAR2 mRNA was constitutively expressed in intestinal mucosa and
that this expression was markedly enhanced in mucosal cells exposed to ischemia-reperfusion.
The results of the present study indicate that a blocking antibody to PAR2 inhibited lipid
peroxidation and reduced development of the intestinal mucosal inflammation induced by
ischemia-reperfusion in rats. This investigation suggests that anti-PAR2 blocking antibody
has potential as a new therapeutic agent for reperfusion injury.
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S1663
Treatment of Neonatal Rats with Probiotics Normalizes Hpa-Axis Activity and
Produces Long-Lasting Beneficial Effects On Colonic Barrier Dysfunction
Induced By Early Life Stress
Mélanie G. Gareau, Jennifer Jury, Glenda Macqueen, Philip M. Sherman, Mary H. Perdue
BACKGROUND: We previously showed that neonatal maternal separation (MS) of Sprague-
Dawley rat pups causes immediate and long-term changes in intestinal physiology. AIM: To
examine if administration of probiotics can prevent MS-induced gut dysfunction. METHODS:
MS pups were individually separated from the dam for 3h/day from days 4-19; non-separated
(NS) pups served as controls. Twice per day during the separation period, 109 probiotic
organisms (two strains of Lactobacillus species) were administered to MS (MS-probiotics;
MS-P) and NS pups (NS-probiotics; NS-P); vehicle-treated pups received saline. Studies
were conducted on day 20, when blood was collected for corticosterone (CORT) measurement
as an indication of hypothalamic-pituitary-adrenal (HPA) axis activity, and colonic function
was studied in tissues mounted in Ussing chambers. Ion transport was indicated by baseline
and stimulated short-circuit current (Isc); macromolecular permeability was measured by
the flux of horseradish peroxidase (HRP) across colonic tissues; bacterial adherence/penetra-
tion into the mucosa was quantified by culturing tissues in selective media. Colonic function
and host defense were also evaluated at day 60. RESULTS: Colonic Isc (NS 145 ± 2; MS
175 ± 5 μA/cm2) and HRP flux (NS 7 ± 1; MS 25 ± 6 pmol/cm2/h) were significantly higher
in MS vs NS pups, as was serum CORT (NS: 125 ± 13; MS: 215 ± 23 ng/mL). There was
increased adhesion/penetration of total bacteria in MS pups (NS 37 ± 15; MS 146 ± 45
CFU(x103)/g tissue, but a significant reduction in Lactobacillus species (NS 17 ± 6; MS 2 ±
1 CFU(x103)/g tissue). Probiotic administration ameliorated the MS-induced gut functional
abnormalities compared to vehicle (MS-P: Isc 123 ± 11 μA/cm2; HRP 7 ± 2 pmol/cm2/h).
Unexpectedly, probiotics also significantly reduced the elevated CORT levels (MS-P: 140 ±
6 ng/mL). Similarly, long term gut pathophysiology at 60 days in MS rats was inhibited by
neonatal administration of probiotics. No effects of probiotic treatment were observed in
NS-P animals. CONCLUSIONS: Our results indicate that MS reduces beneficial commensal
bacteria and this contributes to colonic pathophysiology. Probiotics restore the balance
of bacterial flora and improve gut physiology, at least in part by normalization of HPA
axis activity.
S1664
Mechanosensitive Release of Calcium Or 5-HT: P2Y1 Receptor Over-
Expression in Human Bon Cells
Jianjing Xue, Fievos L. Christofi, Helen J. Cooke
Background:.Mechanical stimulation releases 5-HT from enterochromaffin cells and stimu-
lates afferent nerves to initiate secretory and motility reflexes. One of the steps in the
mechanosensitive pathway may be ATP/ADP activation of P2Y1 receptors (Rs). The human
enterochromaffin derived carcinoid BON cell is an established model to study release of 5-
HT in enterochromaffin cells. Aim: To determine if mechanical stimulation involves P2Y1R
mediated activation of the Gαq signaling pathway for 5-HT release. Methods: The full
sequence of the human P2Y1R was over-expressed in BON cells with native P2YRs or
expressed in heterologous 1321N1 cells deficient in P2YRs. A P2Y1R silencing RNA was
used to knock down protein expression in Western blots. Fluo-4 imaging was used to detect
calcium. ATP and 5-HT release were measured by kits. Results/Discussion: Gene transcripts
for P2Y1, 2, 4, 6, 11, 12, 13 receptors were detected in BON cells. Basal 5-HT release
(1.1±0.2 pmole/well/20 min) increased 5-7 fold with ATP or ADP (n=7; p<0.001). Mechanical
stimulation evoked an increase in ATP that was amplified by ARL67156 known to prevent
ectonucleotidase degradation. To establish a link between the P2Y1R upstream of Gαq and
downstream mobilization of calcium and 5-HT, cells were treated with the phospholipase
C inhibitor U73122 or its control U73343. Mechanically-evoked release of calcium through
the Gαq pathway was verified by blockade of mechanically evoked 5-HT release in native
or over-expressed BON cells treated with U73122. Mechanical stimulation of P2Y1R deficient
cells had no effect on basal calcium release compared to controls; however, mechanical
stimulation caused a peak calcium response in 1321N1 cells transfected with P2Y1Rs com-
pared to controls. The P2Y1R agonist, 2MeSADP, mimicked and the P2Y1R antagonists,
MRS2179 and A3P5P, abolished the calcium response. A silencing P2Y1R RNA knocked
down P2Y1R mRNA > 50% and reduced basal 5-HT in BON cells Conclusions: The results
suggest P2Y1Rs are the missing link that connects the release of ATP/ADP upstream of Gαq
with downstream changes in calcium mobilization and 5-HT release. Therefore, understand-
ing the complex signaling pathway for regulation of 5-HT release from a human enterochrom-
affin cell model may lead to discovery of new targets for drug development (R01 DK37420).
S1665
Role of A2a Adenosine Receptors in the Regulation of Colonic Motility in
Normal Human Colon
Matteo Fornai, Luca Antonioli, Rocchina Colucci, Narcisa Ghisu, Marco Tuccori, Piero
Buccianti, Massimo Chiarugi, Antonio Marioni, Corrado Blandizzi, Mario Del tacca
Introduction. Adenosine is thought to be involved in the regulation of gastrointestinal motor
and secretive functions through the activation of specific purinergic receptors. However, the
role played by this nucleoside in the control of human intestinal motility remains unknown.
The present study examines the influence of adenosine A2a receptors on motor activity in
isolated human colon. Methods. Circular muscle preparations were obtained from normal
regions of colonic tissues excised from patients undergoing surgery for uncomplicated
neoplastic conditions. Colonic muscle strips were set up in organ baths containing Krebs
solution and connected to isotonic transducers (constant tension = 1 g) to determine the
effects of ZM 241385 (selective adenosine A2a receptor antagonist, 0.01 µM) and CGS
21680 (selective adenosine A2a receptor agonist, 0.1 µM) on contractile responses evoked
by transmural electrical stimulation (TES: 0.5 ms, 30 mA, 10 Hz, 100 pulses) or carbachol
(1 µM), either in the absence or in the presence of guanethidine (10 µM), Nω-nitro-L-
arginine methylester (L-NAME, nitric oxide synthase inhibitor, 100 µM), atropine (1 µM),
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, nitric oxide-sensitive guanylyl cyclase
inhibitor, 10 µM) or alpha-chimotrypsin (2 U/ml). Five to 7 preparations were included in
each set of experiments. Results. Application of TES to colonic preparations evoked atropine-
sensitive contractile responses which were significantly enhanced by ZM 241385
(+56.2±9.4%). In the presence of guanethidine and alpha-chimotrypsin, the increasing effects
of ZM 241385 on TES-evoked contractions were unaffected (+51.6±9.9%), while they were
prevented by L-NAME (+16.1±2.1%) or ODQ (+11.2±4%). Upon incubation of colonic
muscle with atropine, guanetidine and alpha-chimotrypsin, TES evoked L-NAME-sensitive
relaxant responses which were partly prevented by ZM 241385 (-45.8±4.8%). In the presence
of tetrodotoxin (1 µM), carbachol elicited atropine-sensitive contractions, which were unaf-
fected by ZM 241385 (+9.3±2.6%). When colonic strips were incubated with dipyridamole
plus adenosine deaminase, to abate endogenous adenosine levels, CGS 21680 caused a
significant reduction of TES-evoked contractions (-46.2±8.9%), but did not modify carbachol-
induced contractile responses (-2.8±1.1%). Conclusions. The present results indicate that:
1) adenosine is involved in the inhibitory control of colonic motility in humans through
activation of A2a receptor subtypes; 2) this receptor pathway is likely to operate at neural
level and to act via the recruitment of inhibitory nitrergic mechanisms.
S1666
Species Dependent Differences in the Actions of Sympathetic Nerves and
Norepinephrine in the Internal Anal Sphincter
Caroline A. Cobine, Miranda Fong, Ross Hamilton, Kathleen Keef
The role of sympathetic nerves as excitatory motor nerves in the internal anal sphincter
(IAS) is still uncertain. We have previously shown that the excitatory motor innervation to
the canine IAS is sympathetic (Tichenor et al, 2002). However, others have suggested that
sympathetic nerves play little if any role in the control of motility in the IAS (for review
see Rattan, 2005). We reasoned that this discrepancy may arise in part because of species
differences in the actions of sympathetic nerves in the IAS. To address this hypothesis we
compared the motor responses of the Cynomolgus monkey, the New Zealand white rabbit
and the BalbC mouse under the same conditions as those previously used to characterize
sympathetic motor responses in the canine IAS. Isolated strips of IAS in each species
developed spontaneous contractions which consisted of tone with superimposed phasic
activity. Spontaneous activity in each case was less than 50% of the maximum ability of the
muscle to contract. When nerves were stimulated with electrical field stimulation (EFS, 1-
30 Hz) in the presence of atropine (1 μM) and L-NA (100 μM) frequency dependent
contraction was observed in the monkey IAS which increased tone to at least twice the
spontaneous amplitude (n=6). Neural contractions were abolished by guanethidine (10 μM,
n=3) or phentolamine (3 μM n=3). In contrast, only nerve induced inhibition was observed
in the mouse (n=4) and rabbit IAS (n=4). The sympathetic neurotransmitter NE also caused
concentration-dependent (0.01-100 μM) contraction in the monkey IAS (n=5). This response
was abolished by phentolamine (3 μM n=4) revealing a small relaxation which in turn was
abolished by propranolol (3 μM, n=4). In contrast, NE caused only relaxation in both the
rabbit (n=4) and mouse IAS (n=4). These inhibitory effects were not blocked by TTX but
were partially reduced by either phentolamine or propranolol and abolished by combined
phentolamine and propranolol. These data suggest that the monkey IAS, like the canine
IAS, contains functional sympathetic motor innervation which is largely due to stimulation
of excitatory adrenergic receptors. In contrast, sympathetic nerves do not play the same
excitatory role in either the rabbit or mouse IAS. These data suggests caution in extrapolating
too vigorously about the role of sympathetic nerves in human IAS based upon more distantly
related species.
S1667
Postnatal Maturation of 5-Hydroxytrypamine Signaling in the Mucosa of the
Guinea Pig Ileum
Xiaochun Bian, Bhavik Patel, Xiaoling Dai, Gregory Swain, James J. Galligan
5-Hydroxytryptamine (5-HT) is released from enterochromaffin (EC) cells in response to
chemical or mechanical stimulation of the intestinal mucosa. 5-HT activates enteric neural
circuitry to initiate secretory and motor reflexes. While EC cells are present in the neonatal
intestine it is not known if mucosal 5-HT signaling mechanisms are fully developed at birth.
Therefore, we investigated 5-HT handling in the ileal mucosa of newborn (<48 h postnatal)
and adult (~4 months postnatal) guinea pigs. We used amperometry for real time detection
of 5-HT in the mucosa of ileal segments In Vitro. Amperometry measured currents caused
by oxidation of 5-HT on the surface of diamond microelectrodes positioned near the mucosal
surface. We also used: HPLC to measure mucosal 5-HT and 5-hydroxyindole acetic acid
(5-HIAA, 5-HT metabolite) content and immunohistochemistry (IHC) and Western blot
methods to localize 5-HT and the 5-HT transporter (SERT). In adult tissues, the basal 5-
HT current was 0.8 ± 0.03 nA; this increased by 0.2 ± 0.02 nA when the mucosa was
stimulated mechanically with a glass probe; these levels were significantly lower than those
in neonatal tissues (basal = 4.2 ± 0.2 nA; stimulated = 1.6 ± 0.1 nA, P < 0.05). All oxidation
currents were blocked in low calcium solutions indicating that currents were associated
with regulated 5-HT release. In adult tissues, fluoxetine (1 μM), a SERT inhibitor, increased
basal currents to 3.0 ± 0.3 nA and stimulated currents to 0.7 ± 0.1 nA. Fluoxetine did not
change oxidation currents in neonatal tissues. 5-HT IHC revealed that the number of EC
cells in longitudinal sections of adult tissues (627 ± 32) was not different from the number
in neonatal tissues (578 ± 22, P > 0.05). SERT immunoreactivity was localized to enterocytes
in the mucosa of adult tissues but SERT was absent from the neonatal mucosa. Western
blot analysis revealed that SERT protein was present in higher levels in adult compared to
neonatal tissues. Mucosal levels (ng/mg protein) of 5-HT and 5-HIAA were 2.3 ± 0.3 and
0.2 ± 0.04 in adult tissues and 2.5 ± 0.3 and 0.1 ± 0.02 in neonatal tissues. The 5-HIAA/
5-HT ratio (a measure of 5-HT turnover) was lower (P < 0.05) in neonatal tissues. These
data indicate that 5-HT released from EC cells was not recovered and metabolized by
enterocytes in neonatal tissues. We conclude that 5-HT signaling is not fully developed in
the neonatal intestine as SERT, the primary determinant of 5-HT clearance, is not expressed.
As EC cells are functional in the neonatal intestine, secretory and motor reflexes in newborns
may be more strongly influenced by mucosal 5-HT than in adults.
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S1668
Activation of Enteric Neurons of the Myenteric Plexus in Response to Luminal
Fat in the Dog
Eileen O. Taschereau, Winnie Ho, Keith A. Sharkey, Anna Hui, Henry C. Lin
Background: Perfusion of fat in the distal small intestine slows transit of buffer in the
proximal small intestine: the fat-induced ileal brake (Gastro 1996;110:1491). The afferent
limb of this inhibitory reflex must contain neurons that are activated by luminal fat, since
the ileal brake is abolished when the distal gut is treated with mucosal anesthetic. While
extrinsic sensory nerves have been shown to respond to fat (J Auton Nerv Syst 1986;17:231-
241), it is not known whether intrinsic primary afferent neurons, the afferent neurons of
the enteric nervous system, are activated by luminal fat. Aim: The aim of this study was to
test the hypothesis that enteric afferent neurons may be activated by luminal fat using
detection of activated neurons by c-Fos expression with immunohistochemistry. Methods:
Duodenal and midgut fistulas divided the small intestine into the proximal and distal ½ of
gut in 8 dogs. The ileal brake was demonstrated in 3 conscious dogs by perfusing 60 mM
oleate in the distal gut (afferent limb of the reflex) while buffer was perfused in the proximal
gut (efferent limb of the reflex), and measuring transit across the proximal gut as cumulative
% recovery (mean±SE) of a radioactive marker. Buffer alone was perfused in both sections
as the control. For the acute experiment, 6 dogs were perfused with oleate in the distal gut
and buffer in the proximal gut, and 2 dogs were perfused with buffer in both sections,
under isoflurane anesthesia. Immediately after perfusion, laparotomy was performed and
the proximal and distal sections of small intestine were removed. We compared Fos immuno-
reactive (IR) cells in the myenteric plexus of the fat-exposed distal gut with that of the
buffer-exposed proximal gut (control). Results: Intestinal transit was slowed by fat in the
distal gut (buffer control 68.9± 11.4% vs. ileal brake 23.5± 9.7%, p<.05, paired t-test). The
number of Fos-IR cells in the myenteric plexus (nuclei/mm) was significantly greater in the
fat-exposed distal section than in the buffer-exposed proximal section (4.2± 1.7 vs. 1.3±
0.9; p< .01, paired t-test, n=6). The number of Fos-IR cells was low in both sections of the
2 dogs perfused with buffer alone (0.2±0.1 proximal, 0.9± 0.8 distal). Double-labeling
revealed that some of the Fos-IR cells were also labeled with a marker of cholinergic neurons.
Conclusion: In response to fat vs. buffer, a greater number of myenteric neurons were
activated. This difference in Fos expression between the fat-exposed distal gut and the buffer-
exposed proximal gut may be explained by the specific activation of enteric neurons by
luminal fat. This study is support by NIH R01 DK059983.
S1669
Endocannabinoids Dampen Enteric Network Activity and Modulate
Mitochondrial Transport Via CB1 Receptors
Pieter Vanden berghe, Koen Ameloot, Werend Boesmans, Priya Gomes, Jozef Janssens, Jan
Tack
The interest in cannabinoid modulation of gut function has grown over the last decades.
Using immunohistochemical and pharmacological tools, it was shown that cannabinoid 1
(CB1) receptors were present in the enteric nervous system (ENS) and that CB1 activation
slows motility and delays gastric emptying. CB1 receptors are negatively coupled to several
Ca2+ channel subtypes whereby they modulate presynaptic neurotransmitter release (Pertwee
1997, 2000). Here we investigated whether exogenous CB1 ligands and antagonists affect
ongoing activity in enteric neuron networks and whether mitochondrial transport in nerve
fibers is modulated by CB1 activity. We used primary cultures of guinea-pig myenteric
neurons, which we loaded with Fluo-4 AM (10 μM) to measure network activity, or with
Mitotracker Green (50 nM) to monitor mitochondrial transport. The Fluo-4 signals were
normalized and spontaneous changes, as well as all transport phenomena were analyzed
using Igor Pro®. Cultured neurons, kept at 35oC, displayed spontaneous activity, which
was quantified by measuring frequency of signaling events in the network fibers (up to 0.3
Hz). The CB1 receptor antagonist AM-251 (10 μM, ANOVA, p<0.001, n=120 regions from
N=3 dishes) significantly increased signaling frequency, comparable to the increase in activity
induced by mild network depolarization (K+ from 5 to 6.5 mM). Conversely, CB1 activation
(methanandamide, MA, 10μM) abolished spontaneous network firing. We also calculated
the proportion of mitochondria (compared to the number of stationary mitochondria) that
was transported in individual enteric nerve fibers. In control HEPES buffered solution about
21.4 ± 0.8 % was transported. After incubation (48 hours) with CB1 agonists, MA (10 μM,
n=10) and WIN55,212 (10 μM, n=4) the transport was reduced to 12.5 ± 1 % and 7 ± 0.5
% respectively. On the contrary, incubation with AM-251 (10 μM, n=15) increased the
transport to 30.6 ± 5% (ANOVA, p<0.05). The velocity, at which the organelles were
transported, did not differ in any of the drug conditions. Conclusion: These data suggest
an important role for CB1 receptors in regulating the activity state of the ENS: activation of
CB1 receptors dampens network activity, while receptor inhibition releases a break for nerve
signaling. The transport of mitochondria, necessary for energy supply at distant loci (eg.
synaptic contacts) is correspondingly suppressed or enhanced. The opposite effects of agonists
and antagonists suggest that enteric nerve signaling is under continuous control of CB1
receptor activity, either via endogenous release of a CB1 receptor ligand or due to constitutive
activity of the CB1 receptor.
S1670
Opiate Dependence Manifests in the Murine Ileum But Not Distal Colon
Gracious R. Ross, Forrest Smith, William Dewey, Hamid I. Akbarali
Opiate induced constipation is a major side-effect in the treatment of chronic pain and
opioid withdrawal develops the clinical syndrome of increased motility and intense diarrhea.
The continuous administration of morphine is well known to result in physical dependence
and tolerance. However, clinical evidence largely indicates that constipation remains a severe
effect in spite of analgesic tolerance development. This contrasts with findings in the guinea-
pig ileum-myenteric plexus preparations since the early 70's of both opiate dependence and
tolerance development In Vitro. The objective of the present study was to determine if
opiate dependence was also evident in the distal colon. Naloxone-precipitated withdrawal
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contractures were used to establish opiate dependence. Longitudinal muscle strips of ileum
and distal colon from male Balb/C mice were set up for isometric contraction recordings.
Electrical field stimulation (EFS) was applied through concentric electrodes. Morphine inhib-
ited EFS (50 V, 7.5 Hz) in a dose-dependent fashion both in ileum (pD2 7.1, n=7) and
distal colon (pD2 7.8). Following 1 hr incubation with morphine, addition of naloxone
precipitated a withdrawal contracture in the ileum (44 % of ACh (3 µM) contraction, n=8)
but not the distal colon. Naloxone induced contractions were blocked by TTX and were
atropine sensitive. In morphine-pelleted mice (75 mg), tolerance to analgesia was evident
at 3 day as measured by the tail-flick assay. The pD2 for morphine induced effects from
these mice on the ileum EFS was shifted to the right to 5.1 from 7.1 for placebo but not
in the colon (7.8 vs. 6.9, n=7). EFS was dose-dependently inhibited by specific agonists,
DAMGO (μ), DPDPE (δ) and U69593 (κ) in both ileum and distal colon. However, the
colon was more sensitive to DAMGO (pD2 8.6 vs. 7.7) and less sensitive to DPDPE (pD2
6.4 vs 8.3) compared to the ileum. There were no differences in response to U69593 (pD2
8.6 vs 8.7). The present data show that morphine-induced dependence, as measured by
naloxone precipitated withdrawal, occurs in the ileum but not the distal colon. The findings
also suggest that the cellular mechanisms of morphine-receptor desensitization differ between
the colon and ileum
S1671
Regulation of the Neurochemical Phenotype of the Enteric Nervous System By
Intestinal Epithelial Cells
Raphael Moriez, Philippe Aubert, Julien Chevalier, Jean paul Galmiche, Stanislas Bruley
des varannes, Christine Cherbut, Michel Neunlist
INTRODUCTION : The neurochemical phenotype of enteric neurons is influenced by the
enteric environment. For instance, in inflammatory conditions such as IBD, changes in
neuromediators content have been observed. However, the role of intestinal epithelial cells
(IEC) in the regulation of the neurochemical phenotype of enteric neurons remains unknown.
Therefore, our study aims at identifying, In Vitro, the role of IEC in the control of neuromedia-
tors expression in the enteric nervous system (ENS). METHODS : Intestine of rat embryos
(E15) were removed and finely diced. Tissue fragments were digested with trypsin and
DNAse I and the cell supension was seeded in 12-well plates. The primary ENS culture was
used at day 13. Rats IEC (IEC-6) were seeded on Transwell filters and cultured for 10 days.
In some conditions, IEC-6 were incubated for 24 hours with a cytomix of IFN-g (100 U/
mL) and TNF-a (10 ng/mL) prior to the coculture with ENS. Coculture experiments were
performed by maintaining primary culture of ENS in presence or absence of IEC-6 (inflamed
and non-inflamed) for 3 days. At the end of the culture, the ENS was processed for either
immunohistochemical or Q-PCR studies. Immunohistochemical studies were performed with
antibodies against PGP 9.5 (a general neuronal marker), VIP, nNOS and GFAP (a marker
of glial cells). RESULTS : Compared with primary ENS cultured alone, coculturing primary
ENS with IEC did not modify the number of neurons/ganglia (27±4 vs. 21±1, P>0.05, n=
4). However, the coculture significantly increased the population of VIP immunoreactive (-
IR) neurons (6±2% (of PGP 9.5-IR neurons) in control conditions vs. 17±4% in coculture
conditions, P<0.05, n=4) without modifying the population of nNOS neurons (61±1% in
control conditions vs. 67±6% in coculture conditions, P>0.05, n=4). This increase in the
proportion of VI-IR neurons was associated with an increase in VIP mRNA expression (2.2
fold, P<0.05, n=4). Compared with the coculture with IEC-6, coculturing inflamed IEC did
not alter the number nor the phenotype of enteric neurons. Finally, coculturing the ENS
with IEC induced a significant increase in GFAP expression. CONCLUSION: In conclusion,
this study suggests that IEC modulate the phenotype of enteric neurons and glial cells. The
mechanisms and factors involved remain to be identified.
S1672
Morphological and Functional Recovery of the Pylorus After Complete
Denervation: Evidence of the Regenerative Ability of Enteric Neurons
Maria A. Micci, Kristen M. Kahrig, Pankaj J. Pasricha
Introduction: Application of the cationic detergent BAC to the serosal surface of gastrointesti-
nal tract leads to degeneration and death of neuronal, muscular and other cellular elements
in the outer layers. Until recently, it was thought that this was followed by rapid regrowth
of muscle, leading to a completely denervated region of the gut. Recent reports suggest that
myenteric ganglia eventually reform in such regions. However, it is not known whether this
is a true regeneration in that it results in restoration of neural function. We therefore studied
temporal changes in morphology and function of the pylorus after BAC administration.
Methods: Adult male C57BL/6J mice were anesthetized, the pyloric region identified and
0.05% BAC in saline was brushed on the serosal side using a cotton-tip applicator every 5
minutes for 30 minutes. Control mice were treated with saline. At 2 and 4 weeks post-
treatment, pyloric function was assessed by measuring the relaxation of pyloric strips in an
organ bath in response to electrical field stimulation (EFS). Immunofluorescence analysis
of pyloric sections using specific antibodies for neuronal and glia phenotype (βIII-tubulin,
nNOS and GFAP) was performed in order to identify enteric neurons and glia. Results:
Serosal application of BAC to the mouse pylorus produces a complete loss of recognizable
enteric neurons and glia in the myenteric plexus 2 weeks post-treatment and this is associated
with a significant functional impairment of the pyloric muscle as compared to saline-treated
controls (Figure 1). Despite the extent of this injury, at 4 weeks post-BAC treatment
myenteric neurons and glia have repopulated the pylorus in a normally appearing fashion
and pyloric function is completely restored (Figure 2). Conclusions: Our data show that
the enteric nervous system is capable of complete morphological and functional regeneration
despite significant injury. A study of the underlying mechanisms is of critical importance
to the understanding of many neuromuscular disorders of the gut.
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S1673
5-Hydroxyindalpine, the Putative 5-HT1P Receptor Agonist, Accelerates
Peristalsis in Mouse Isolated Colon, But Has NO Effect On the Activity of
Known 5-HT Receptors
Natalie Mitchell, Emma P. Pepperell, Jason D. Brown, Sandrine Ociepka, Jason
Witherington, Bishwa R. Tuladhar, Gareth J. Sanger, Kevin Lee, Selim Cellek
Current knowledge on the putative 5-HT1P receptor, which is suggested to be involved in
peristaltic reflex, is derived from electrophysiology and binding studies; experiments on
peristalsis have been limited to flat-bed preparations. We therefore investigated the effect
of the putative 5-HT1P receptor agonist, 5-hydroxyindalpine (5-OHIP) on distension-induced
peristalsis in mouse isolated intact colon. The effect of 5-OHIP on activity of some of the
receptors in the gut was also investigated. The proximal colon from male CB57BL6/J mice
was perfused at the oral end. The perfusate was collected from the caudal end into a reservoir.
Peristalsis was initiated by increasing the intraluminal pressure by raising the reservoir. The
pressure was recorded by transducers at both oral and caudal ends. The effect of 5-OHIP
given serosally on frequency of peristaltic contractions, maximum pressure and basal pressure
were recorded in the absence or presence of putative 5-HT1P receptor antagonist, N-acetyl-
5-hydroxytrytophy-5-hydroxytryptophan (5-HTP-DP). The correlation between distension
pressure and frequency was also studied in the absence or presence of 5-OHIP. The activity
of 5-OHIP on 5-HT1B, 1D, 2A, 2B, 2C, 4, 6, 7, α1A, α1B, D2, D3, H1 and H2 was
studied using recombinant receptor expression systems. A regular peristalsis was achieved
by increasing the intraluminal pressure. The average frequency, maximum pressure and
basal pressure of peristaltic strokes were 0.012±0.0001 Hz, 5207.9±42.8 mmH2O and
35±0.1 mmH2O respectively at 35 mmH2O distension pressure. Peristaltic activity was
abolished by scopolamine (10 µM), hexamethonium (100 µM) or tetrodotoxin (1 µM). 5-
OHIP (0.1 nM-1 µM) caused acceleration of peristalsis; observed as a significant increase
in frequency. Maximum effect was observed at 1µM (46.2±16.1% increase in frequency,
P<0.05). At high concentrations (10 µM), 5-OHIP caused 32.5±8.1% decrease in the fre-
quency (P<0.05). 5-OHIP (0.1 nM-10 µM) did not alter maximum pressure or basal pressure.
The potentiating effect of 5-OHIP on peristaltic frequency was reduced by 1µM 5-HTP-DP.
Distension pressure-frequency curve was not altered by 5-OHIP (0.1 and 1 µM). 5-OHIP
(up to 10 µM) showed no activity on any of the receptors studied. These results demonstrate
that mouse isolated colon is a reproducible model for distension-induced peristalsis. The
accelerating effect of 5-OHIP supports a key role for the putative 5-HT1P receptor in
regulation of peristalsis. However the lack of activity of 5-OHIP on the known receptors
highlights the need of identification of the receptor(s) targeted by this compound.
S1674
Activating of ATP-Dependent K+ Channels Comprised of Kir 6.2 and Sur 2b
By Pge2 Through Ep2 Receptor in Cultured Interstitial Cells of Cajal from
Murine Small Intestine
Chan-guk Park, Young dae Kim, Man woo Kim, Seok Choi, Jae yeoul Jun
Background/Aims: The interstitial cells of Cajal (ICC) are pacemaker cells in gastrointestinal
tract and generate an electrical rhythm in gastrointestinal muscles. Also, previous studies
have shown that PGE2 influences motility in the small intestine and that it also modulates
ATP-dependent K+ channels in ICC. Therefore, in this study, we investigated the possibility
that PGE2 affects the electrical properties of cultured ICC by activating ATP-dependent K+
channels and the action of PGE2 involves the mobilization of intracellular Ca2+ oscillation
in ICC. In addition, EP receptor subtypes and subunits of the ATP-dependent of K+ channels
involved in these effects were investigated. Methods: For our study, we performed the
patch clamp experiments, RT-PCR, cAMP assay, and measurement of intracellular Ca2+
concentration with confocal microscope. Results: Treatments of ICC with PGE2 inhibited
electrical pacemaker activities in the same manner as pinacidil, an ATP-dependent K+ channel
opener and PGE2 had only a dose-dependent effect. Using RT-PCR technique, we found
that ATP-dependent K+ channels exist in ICC and that these are composed of Kir 6.2 and
SUR 2B subunits. To characterize the specific membrane EP receptor subtypes in ICC, EP
receptor agonists and RT-PCR were used: Butaprost (an EP2 receptor agonist) showed the
actions on pacemaker currents in the same manner as PGE2. However sulprostone (a mixed
EP1 and EP3 agonist) had no effects. In addition, RT-PCR results indicated the presence of
the EP2 receptor in ICC. To investigate cAMP involvement in the effects of PGE2 on ICCs,
SQ-22536 (an inhibitor of adenylate cyclase) and cAMP assays were used. SQ-22536 did
not affect the effect of PGE2 on pacemaker currents, and PGE2 did not stimulate cAMP
production. Also, we found PGE2 inhibited the spontaneous [Ca2+]i oscillations in cultured
ICC. Conclusions: These observations indicate that PGE2 alters pacemaker currents by
activating the ATP-dependent K+ channels comprised of Kir 6.2-SUR 2B in ICC and this
action of PGE2 are through EP2 receptor subtype and also the activation of ATP-dependent
K+ channels involves intracellular Ca2+ mobilization.
S1675
Dynamic Imaging of Myenteric Neurons and Muscle During the Murine
Colonic MMC
Peter O. Bayguinov, Grant W. Hennig, Dante Heredia, Nick J. Spencer, Terence K. Smith
Background: Spontaneous, colonic migrating motor complexes (CMMCs) propagate every
2-3 mins along the isolated murine large bowel and appear to underlie pellet propulsion. A
CMMC consists of a hyperpolarization followed by cholinergic rapid oscillations in membrane
potential superimposed upon a sustained depolarization of circular muscle.1 There have
been no recordings from myenteric neurons and muscle during this important motor
behavior. Aims: To determine: 1) if stretch and mucosal stimulation can activate a CMMC;
2)the sequence of activation of myenteric neurons and muscle during an evoked CMMC.
Methods: 1) Reflex responses: tension recordings were made along an opened segment of
the murine large bowel that was pinned to expose the muscosa. 2) The large bowel was
pinned mucosal side down, the ends were rolled over to expose the mucosa. Strips of
longitudinal muscle were removed to expose myenteric ganglia. Neurons and smooth muscle
were loaded with Fluo-4 and the Ca2+ activity recorded with a CCD camera. Brushing the
mucosa, evoked a controlled CMMC. All tissues were perfused with Krebs' solution at 37oC.
Ganglia were marked and neurons later identified using immunohistochemistry. Results: 1)
Mucosal stimulation evoked a premature CMMC, which was an all-or-none response, regard-
less of the intensity of the stimulus. The evoked and spontaneous CMMCs were blocked
by atropine (1 µM), hexamethonium (1 µM) and ondansetron (1 µM). In contrast, circumfer-
ential stretch was without effect. 2) The responses of myenteric neurons, longitudinal and
circular muscle during a CMMC evoked by mucosal stimulation were complex. During the
CMMC both muscle layers were activated at the same time. A high percentage (~60%) of
myenteric neurons didn't appear to change their activity throughout a CMMC, whereas,
others either increased or decreased their activity immediately prior to or during the CMMC.
Conclusions: We found no evidence for a classic peristaltic reflex in the murine colon, since
mucosal stimulation (but not stretch) evoked an all-or-none CMMC. In addition, we have,
for the first time, developed a method that allows us to begin to unravel the complex neural
activity in different functional classes of myenteric neurons and its relation to muscle activity
during a physiological motor behavior whose timing can be accurately controlled. Support:
NIDDK RO1 DK45713 (TKS and NJS). 1: Spencer et al. 2005 J Physiol. 564:829-47].
S1676
Endothelin Receptor B (Ednrb) Mutation Affects Small Intestinal Smooth
Muscle Contractility Independent of Neuronal Activity
Kent C. Williams, D. brent Polk
Ednrb signaling regulates development of the enteric nervous system (ENS). Mutation of
Ednrb results in Hirschsprung disease where myenteric ganglia do not develop in the distal
colon. While surgical resection of the aganglionic segment allows survival, most still suffer
dysmotility symptoms, such as reflux and abdominal discomfort. We hypothesize that
Ednrb mutation affects the regulation of small intestinal motor patterns regardless whether
aganglionosis develops in the distal colon. Smooth muscle response to Ednrb signaling was
studied in segments of proximal small intestine in mice that possess an engineered Ednrb
mutation (Ednrbtm1Ywa). Ednrb tm1Ywa/tm1Ywa mice develop aganglionosis of the distal colon
while Ednrb+/+ and Ednrbtm1Ywa/+ mice display indistinguishable normal phenotypes. The
presence of myenteric ganglia in the proximal small intestine and distal colon of 15 day old
mouse pup littermates was determined by PGP 9.5 and anti-Hu immunostaining. Ednrb
regulation of smooth muscle activity in whole segments of proximal small intestine was
studied in 30 ml organ baths by recording changes in smooth muscle tension after giving
a dose (10-7M) of STX-6c, an Ednrb agonist. To determine whether the Ednrb signaling
that changed smooth muscle activity was mediated via enteric neurons, STX-6c was added
to intestinal segments from Ednrb+/+ mice where neuronal activity was inhibited with the
neurotoxin, tetrodotoxin (TTX). Electrical field stimulation (EFS) was used to verify TTX
inhibited ENS regulation of smooth muscle activity. As expected myenteric ganglia were
detected in the proximal small intestine, but not the distal colon in Ednrbtm1Ywa/tm1Ywa mice.
Myenteric ganglia were present in both locations in Ednrb+/+ and Ednrbtm1Ywa/+ mice. STX-
6c did not alter smooth muscle contractility in Ednrbtm1Ywa/tm1Ywa intestinal segments. In
Ednrbtm1Ywa/+ segments the smooth muscle response to Endrb signaling was reduced nearly
2 fold as compared to Ednrb+/+ segments (n=13, p=.0002) EFS stimulation of the ENS
increased smooth muscle contractility in all segments studied, including Ednrb tm1Ywa/tm1Ywa
segments, except the Ednrb+/+ segments where TTX inhibited the ENS. Ednrb induced
changes of smooth muscle were not significantly affected by inhibition of enteric neurons
(n=13, p=0.08). These findings support the hypothesis that mutation of a single Ednrb allele
affects regulation of smooth muscle activity in proximal intestinal tract regardless of whether
a distal aganglionic segment develops. Although Ednrb signaling regulates the development
of the ENS, Ednrb regulation of intestinal smooth muscle contractility is independent of
neuronal activity.
S1677
Enteric Neurons Signal to Glial Cells Via Purinergic Pathways
Priya Gomes, Werend Boesmans, Jozef Janssens, Michel Neunlist, Jan Tack, Pieter Vanden
berghe
Appreciation and understanding of the role of enteric glial cells has increased over the last
decade. Although the possibility for glial cells to respond to a number of signaling molecules
including neurotransmitters has been shown, so far, evidence for direct neuron-glia commun-
ication is lacking. In this study we investigate signaling from enteric neurons to glia.Methods:
In a primary cell culture model derived from embryonic mouse gut, we used the fluorescent
dye Fluo-4 AM to monitor intracellular Ca2+-changes. Enteric neuron to glia communication
was examined by activation of neurons either by exposure of cultures to high K+ (25mM)
or more selectively by a nicotinic cholinergic receptor agonist (DMPP, 20µM). Results: Upon
activation, neurons responded with a Ca2+-rise, followed by a Ca2+-rise in the neighboring glia
about 3-5 seconds later (1.27 ± 0.02, n=205 and 1.31 ± 0.03, n=270 for high K+ and DMPP
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respectively), while in the absence of neurons no such glial response was observed. In a
continuous perfusion (1ml/min), neuronal activation did not result in a response in glial
cells suggesting involvement of a paracrine mechanism. Since enteric glia express P2 receptors
and respond to purinergic agonists with an increase in Ca2+, we hypothesized that ATP is
involved in the signaling from neurons to glia. Neuronal activation in cultures treated with
the P2 receptor antagonist suramin (200µM) indeed resulted in a significant reduction of
the Ca2+-rise in glial cells indicating an involvement of the purinergic pathway (1.18 ± 0.02,
n=137 vs. 1.27 ± 0.02, n=205 in control, p<0.05). To further elucidate the messenger
molecules involved, we modulated the purinergic pathway by controlling the availability of
extracellular ATP and ADP. We used an ecto-nucleotidase inhibitor (ARL-67156, 100µM) and
enzymes that enhance nucleotide hydrolysis (apyrase VI and apyrase VII, which preferentially
hydrolyze ATP and ADP respectively, 10U/ml) to increase or decrease the amount of nucleot-
ides in the extracellular space. Application of ARL enhanced the Ca2+-rise in glial cells (1.61
± 0.05, n=102 vs. 1.31 ± 0.03 in control, p<0.05). Exposure to apyrase VI reduced the glial
Ca2+-rise (1.22 ± 0.01, n=119, p<0.05), and a combination of apyrase VI and apyrase VII
(5U/ml each) resulted in a further reduction of the glial Ca2+-rise (1.1 ± 0.01, n=85, p<0.05)
suggesting that both ATP and ADP are involved. Conclusions: Enteric neuron activation
evokes Ca2+-transients in glial cells. Suramin, ARL and apyrase data suggest the involvement
of a purinergic pathway which is mediated to a significant extent by ATP-dependent paracrine
intercellular communication.
S1678
Opiate Tolerance Develops in the Mouse Ileum But Not Distal Colon Circular
Muscle
Gracious R. Ross, Forrest Smith, William Dewey, Hamid I. Akbarali
The analgesic effects of morphine result in development of tolerance upon repeated adminis-
tration. However, clinical evidence indicates that similar tolerance does not develop to
morphine-induced constipation. Indeed, opioid-induced bowel dysfunction can severely
hamper the management of pain. In the guinea-pig ileal longitudinal muscle- myenteric
plexus, both morphine- tolerance and dependence have been demonstrated for the presyn-
aptic opioid receptors. However, morphine tolerance in smooth muscle are not known. In
the present study we examined the development of tolerance in the circular muscle of the
ileum and distal colon. Circular muscle rings from Balb/C mice were mounted in organ
bath for isometric tension recordings. Morphine produced concentration -dependent contrac-
tions in both ileum and colonic preparations. The potency and efficacy of morphine were
greater in distal colon (pD2, 7.2; Emax, 0.05 g/mg) compared to ileum (pD2, 6.8; Emax, 0.02
g/mg). These contractions were not blocked by TTX (100 nM) or atropine (100 nM) but
were inhibited by nifedipine (10 µM) and naloxone (10 µM). Repeated administration of
single concentration of morphine (3 µM) every 30 mins with in-between washes, resulted
in tolerance only in the ileum but not the distal colon. Morphine-induced contractions were
reduced by 41% by the 4th administration in the ileum but remained constant in the colon.
A tonic contraction was maintained in the colon in the presence of morphine (60 mins)
while the ileum relaxed to baseline under the same conditions. Neither the PKC inhibitor,
bisindolylmaleimide (10 µM), nor the PKC activator, Phorbol-12,13-dibutyrate (1 µM),
affected the tolerance in the ileum. Of the specific agonists, DAMGO (µ), DPDPE (δ) and
U69593 (κ), only µ- and δ -agonists produced contractions while the κ -agonist was
ineffective. DPDPE was more potent than DAMGO in both ileum (pD2: DPDPE, 8.7 ± 0.1,
DAMGO, 7.1 ± 0.08) and colon (pD2: DPDPE, 8.7 ± 0.1, DAMGO, 6.8 ± 0.1). Interestingly,
repeated administration of DAMGO (1 µM) or DPDPE (30 nM) did not develop tolerance
in ileum or colon. These data demonstrate a) the presence of functional opioid receptors
on circular smooth muscle in the ileum and colon, b) morphine-induced contractions are
dependent on calcium entry, c) the ileum but not the colon develops tolerance to morphine
and d) protein kinase C is not involved in the development of tolerance in the gut. These
direct contractile effects in the distal colon may explain the segmental phasic contractions
associated with morphine-induced constipation
S1679
Platelet Serotoninergic Kinetic Parameters Suggest Altered SERT Function in
Patients with Irritable Bowel Syndrome
Marco Schmidtmann, Ivo R. Van der voort, Leonora Franke, Andrea Riedl, Ralf
Uebelhack, Burghard F. Klapp, Hubert Mönnikes
Background and aim: Serotonin (5-HT) is a neurotransmitter playing a key role in the
regulation of gastrointestinal (GI) function, in particular GI motility, secretion, and sensitivity.
There is considerable evidence suggesting that alterations in serotoninergic mechanisms are
involved in the pathopysiology of irritable bowel syndrome (IBS). According to current
knowledge, the serotonin transporter (SERT) is identical in all organs of the body. Con-
sequently, the observation of changes in 5-HT metabolism parameters resulting from studies
in platelets (plat.) suggests the presence of altered function in serotonergic mechanisms also
in other parts of the organisms, like the gut or the brain. Therefore, the aim of the present
study was to investigate serotonergic functional parameters of plat. in patients (pat.) with
irritable bowel syndrome (IBS) and healthy controls (HC) and to recognize differences in
the 5-HT kinetic parameters between both populations. Methods: Measurement of 5-HT
metabolic parameters (5-HT-concentration (ng 5-HT/109 plat.), 5-HT-uptake (pMol 14C-5-
HT/109 plat. x 5min.), Vmax (pMol 5-HT/109 plat. x min), and Km (µMol)) in plat. under
fasting condition of 118 pat. with IBS (IBS+D=57, IBS+C=28, IBS+A=33) and 52 HC.
Statistical analyses were performed with t-test and Mann-Whitney rank sum test
(median±SEM). Results: Serotonin uptake (48.1±2.8 vs. 59.5±19.7), Vmax (1.6±29.0 vs.
2.1±0.3), and Km (0.3±0.03 vs. 0.4±0.05) were significantly reduced in IBS pat. compared
to HC. Subgroup analyses revealed a significant reduction of serotonin uptake (43.6±4.2
vs. 59.5±19.7) and of Vmax (1.6±61.5 vs. 2.1±0.3) in IBS-D pat. compared to HC. IBS+C
pat. had significantly reduced values of Vmax (1.5±0.2 vs. 2.1±0.3) and Km (0.35±0.05 vs.
0.43±0.05). IBS+A pat. showed significantly reduced values for serotonin uptake (48.7±4.8
vs. 59.5±19.7), Vmax (1.7±0.2 vs. 2.1±0.3), and Km (0.3±0.05 vs. 0.43±0.05) compared
to HC. No significant differences could be observed in the serotonin concentration of plat.
between IBS pat. and HC or between the different subgroups of IBS pat. compared to HC.
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Furthermore, no significant differences in 5-HT kinetic parameters could be observed between
the IBS-subgroups. In all parameters investigated no significant gender difference was
observed in IBS pat. and HC. Conclusion: IBS patients differ from HC in 5-HT kinetic
parameters of plat. which indicates a dysfunction of SERT in the pat. group. It could be
concluded from this observation that similar changes in SERT function are also present in
the GI tract and/or the brain of IBS pat. The clinical relevance of this observation has to be
verified further.
S1680
Role of Purinergic Inhibitory Neuromuscular Transmission in the Mouse IAS
Ross Hamilton, Bronagh Mcdonnell, Miranda Fong, Sean Ward, Kathleen Keef
There is still controversy regarding the neurotransmitter(s)underlying NOS-independent
inhibitory motor innervation to the internal anal sphincter (IAS). In addition, few studies
have examined the electrical events that underlie inhibitory neuromuscular transmission.
The present study investigated the role of the purinergic neural pathway in the mouse IAS
and its relationship to changes in membrane potential (Em). Contractile activity and Em
were measured in isolated muscle strips. Electrical field stimulation of nerves (EFS 0.1-5
Hz; 1 min, 10V, 1 ms dur pulses) gave rise to frequency dependent inhibition of contraction
which was maximum at 2.5 Hz (atropine and guanethidine present throughout). Individual
stimuli generated inhibitory junction potentials (IJPs) which averaged 27 mV in amplitude
(n=15). Each IJP was associated with a transient inhibition of contraction whereas higher
frequency EFS (2.5-5 Hz) gave rise to a more sustained hyperpolarization (SH) and sustained
inhibition of contraction. Blockade of NOS activity with N-nitro-L-arginine (L-NA 100 μM,
n=4) reduced the duration of the IJP by approximately 15% but did not reduce IJP amplitude.
L-NA caused a small but significant reduction in contractile inhibition at 1 Hz EFS (n=7)
but not at other frequencies. All remaining experiments were carried out in the presence
of L-NA. NOS-independent contractile inhibition (2.5 and 5 Hz), IJPs and SH (2.5 Hz) were
significantly reduced or abolished by the P2 receptor antagonists PPADS (100 μM, n=4)
and suramin (250 μM, n=6). These neural events were also significanty reduced by P2Y
receptor desensitization with ADPβS (10 μM, n=4) and to a lesser extent by the selective
P2Y1 blocker MRS2179 (1 0 uM, n=7). Contractile inhibition, IJPs and SH were also
significantly reduced by the small conductance calcium activated potassium channel (SK)
blocker apamin (1μM, n=7). Removal of potassium (K+) from the bathing medium increased
IJP amplitude to 205% of control (n=3) whereas return of K+ 30 min later hyperpolarized
Em by 18 mV (due to sodium pump stimulation) and reduced IJP amplitude to 50% of
control (n=3). These changes are commensurate with potassium channels underlying the
IJP. ATP (1 mM, n=4) inhibited contraction on average by 74% and this effect was not
blocked by either TTX (1 μM) or the adenosine receptor antagonist 8-sulfuphenyltheophylline
(100 μM). In conclusion, NOS-independent pathways significantly contribute to neural
inhibition in the mouse IAS. Our results suggest a significant role for a purinergic neural
pathway involving P2Y receptors and the activation of SK potassium channels leading to
membrane hyperpolarization.
S1681
Timing and Force of the Ascending Myenteric Reflex Contraction in Rat Ileum
Is Modulated By the Orl1 Receptor
Birol Yuece, Andrei Sibaev, Andreas Haaken, Dieter Saur, Burkhard Goke, Hans peter
Allescher, Martin Storr
Background: Nociceptin (Orphanin FQ) is the endogenous agonist of the newly cloned
“orphan” opioid receptor (ORL1). Aim: The aim of the present study was to investigate
the possible influence of the ORL1 receptor on smooth muscle contractility, cholinergic
neurotransmission and the myenteric reflex of rat ileum. Methods: Isolated ileum strips were
studied in organ bath experiments. Contractions of the smooth muscle were induced by
electrical stimulation or by pharmacological stimulation (carbachol; 5-HT). The ascending
part of the myenteric reflex was studied in an ileum segment (10cm) in an organ bath
separated into three chambers to discriminate possible drug influence in different parts of
the myenteric reflex. Postulating an cholingergic transmission immunhistochemical stainings
with Chat-positive neurons were performed. Results: Neither nociceptin nor the ORL1-
receptor antagonist [Nphe1]nociceptin(1-13) had an influence on basal tonus, spontaneous
activity or on pharmacologically prestimulated smooth muscle. Electrical stimulation caused
a cholinergic mediated contractile responses which were reduced by Nociceptin in a concen-
tration dependent manner. In the presence of the antagonist, the nociceptin effect was
abolished whereas in the presence of the opioid receptor antagonist naloxone the nociceptin
effect was unchanged. The antagonist when given alone did not influence the electrically
induced contractions. Myenteric reflex responses were induced by electrical stimulation and
caused an ascending contraction. Nociceptin significantly reduced this ascending contraction
and prolonged the latency from stimulation to contraction, independently of the chamber
where nociceptin was applied. These effects of nociceptin were antagonized by [Nphe1]noc-
iceptin(1-13). This results were confirmed by immunhistochemical stainings were Chat-
positive neurons were colocolized with ORL-1 receptors. Conclusions: The results indicate
that the endogenous peptide nociceptin modulates excitatory cholinergic neurotransmission
in the rat ileum by a mechanism that involves the ORL1-receptor but not other opioid recep-
tors.
S1682
Bone Marrow Stromal Cells Survive Transplantation and Rescue Neurons in
the Gastrointestinal Tract Denervation
Lin Rong, Yuanjun Gao, Zheng Ding, Wei Qian, Xiaohua Hou
Aims: Transplantation of bone marrow stromal cells (bMSCs) has been shown to be successful
in a variety of experimental models of nongastrointestinal diseases. The aim of this study
is to assess the potential of transplantation of allogenic bone marrow stromal stem cells as
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a therapheutic straegy for disorders of the enteric nervous system. Methods: 0.5% Benzalkon-
ium chloride (BAC) was applied to the serosal surface of pylori in adult rat to make myentric
plexus ablation model and saline was as control. BMSCs isolated from bone marrow were
cultured, identified In Vitro and labeled by bis-benzimide before transplantation. In bMSCs
grafted rats, the marked bMSCs were transplanted in rats which had been treated by BAC
three days ago, but in controls, the same volume of 1640 culture media was injected.
Immunofluorescence and RT-PCR of gastroduodenal specimens were dissected at 28 days
after cell transplantation. Results: Many live transplanted cells could be detected in submucosa
without enteric neuro- markers or neurotransmitters expression. We could detect PGP9.5
positive neural structure regenerated in ablated myoenteric plexus near bMSCs mustered
region. Subpopulation of PGP9.5 positive neurons were also weakly express neural specific
endolase (NSE). While there was no VIP, NOs positive cells could be detected. In gastric
wall of bMSCs grafted rats, glial cell line derived neurotrophic factor (GDNF) gene expression
kept a continuous, stable higher level comparing with BAC treated animals. In Vitro, we've
found that the endogenous expression of GDNF in BMSCs would be significantly enhanced
if we use GDNF induced them. Conclusions: Allogenic bMSCs can survive in microsurround-
ing of gastrointestinal tract at least 28 days. Regenerated neuron can be detected while most
of them are still immature. BMSCs' this GDNF positive feedback character may play a very
important role in this processing.
S1683
Differential Dysregulation of ADORA3, ADORA2A, ADORA2B, and P2RY14
Expression Profiles from 34 Purine-Genes in Mucosal Biopsies and Peripheral
Blood Mononuclear Cells in Inflammatory Bowel Diseases
Leszek Rybaczyk, Jacqueline E. Wunderlich, Bradley Needleman, Scott Melvin, Iveta
Grants, Kun Huang, Fievos L. Christofi
Background and aim: Adenosine (ADO), ADO A3 or A2 receptor (R) agonists are protective
in experimental IBD by suppressing free radicals,inflammation,immune modulation or neural
protection. Dysregulation of purinergic P2XR(1,2,4,7), P2YR(1,2,4,6) or ADOA2R(A,B)
involved in gut reflexes is prevented by oral A3R agonists in experimental colitis
(IBD,12(8):766-789,2006). We hypothesized that purinergic pathways are sensitive to gene
dysregulation in human IBD. Methods: Raw datasets for 34 purine genes were extracted
from NCBI gene expression omnibus (NCBI GEO, http://www.ncbi.nlm.nih.gov/projects/
geo/) and analyzed (first time) by NCI BRB array tools for sigmoid colon mucosal biopsies
of Crohn's (CD,N=11), ulcerative colitis (UC,N=10) and controls (N=10,GSE#1710), as
well as for peripheral blood mononuclear cells (PBMCs) (CD,N=59;UC,N=26;control,N=
42,GSE#3365). Differential expression of genes was assessed by a random variance- and
Bonferroni Holm correction of multiple tests (see table). Results: In CD biopsies, only
ADORA3 (↓30%) and P2RY14 (↓31%) gene products are down regulated by disease. A
negative correlation exists between CD duration (2-20 yrs) or severity and ADORA3 expres-
sion; negative correlation exists for P2RY14 and disease severity. In UC, P2RY14 was down-
regulated 33%. In PBMCs, ADORA2A and ADORA2B are upregulated by disease. Functional
ADORA3 were identified by imaging Ca2+ neural activity in submucosa from Roux-en-Y
patients (N=6) loaded with 30µM Fluo-4/AM using a laser confocal system. A 3 s fiber tract
stimulation (FTS) evokes a TTX-sensitive frequency-dependent (0.1-100Hz) Ca2+ response
that is reduced 60% by an ADORA3 agonist Cl-IB MECA (5µM) after ADORA1 knock-
down with FSCPX (N=84,p<0.001). In TNBS colitis, neural ADORA3 immunoreactivity is
reduced 20-30% (N=3). Conclusions: ADOA3R expression distinguishes between CD and
UC. In CD, down-regulation of ADORA3 may get worse with longer duration and severity
of IBD. Purine-gene changes occur more sparingly in human IBD compared to experimental
IBD. Dysregulation of A3, A2A, A2B, and P2Y14Rs of 34 purine genes is relevant in mucosal
reflexes and therapeutic targeting (DK44179, NCRR 1S10RR11434).
S1684
Effects of GDNF and Ret Haploinsufficiency On Motility in the Colon of
Developing and Adult Mice
Rachael Roberts, Joel C. Bornstein, Heather Young
Mutations in the genes encoding members of the Ret signaling pathway account for around
30% of the cases of Hirschsprung's disease. Ret is a receptor tyrosine kinase that is expressed
by enteric neuron precursors. The ligand, glial cell line-derived neurotrophic factor (GDNF),
is expressed by the gut mesenchyme and forms a complex with a GPI-linked protein, GFRa1,
before binding to and activating Ret. Mice with null mutations in Ret or Gdnf lack enteric
neurons from the small and large intestines. Previous studies have shown that adult Gdnf+/-
mice have about a 40% reduction in the number of enteric neurons, but Ret+/- mice do
not have any significant differences in enteric neuron number from wild-type mice. The
effects of Gdnf and Ret haploinsufficiency on propagating motility patterns in adult and
developing mice have not previously been investigated. Colonic migrating motor complexes
(CMMCs) are a well characterized pattern of spontaneous, propagating contractions observed
in the mouse colon In Vitro. We used In Vitro preparations of colon from developing
and adult Ret+/-, Gdnf+/- and wild-type mice to examine the effects of Gdnf and Ret
haploinsufficiency on CMMCs. Video recordings of mouse colon In Vitro were used to
construct spatiotemporal maps of spontaneous contractile patterns. Properties of CMMCs
in adult, P6 and P10 Ret+/- mice were not significantly different from those in wild-type
mice of similar age. In adult Gdnf+/- mice, the frequency, distance propagated along the
colon and change in diameter of CMMCs were significantly lower than in wild-type and
Ret+/- mice. Furthermore, in P6 wild-type and Ret+/- mice, CMMCs were not present under
control conditions, but could be induced by inhibition of nitric oxide synthase (NOS)
activity. In P6 Gdnf+/- mice, CMMCs could not be revealed by NOS inhibition. We conclude
that the decreased density of enteric neurons in adult Gdnf+/- mice reported previously is
correlated with deficits in spontaneous motility patterns. Furthermore, CMMCs appear later
during development in Gdnf+/- mice than in wild-type or Ret+/- mice.
S1685
Gastric Electrical Stimulation and Sacral Electrical Stimulation: Are Two
Devices Better Than One?
Thomas L. Abell, Shailey Jain, Paige White
Introduction: Gastric Electrical Stimulation (GES) is available as a Humanitarian Use Device
for patients with the symptoms of gastroparesis and is effective in reducing gastrointestinal
symptoms. We have previously shown that patients with gastric motor disorders often have
co-existing abnormalities of the genitourinary system (Gastroenterol 112: A737, 1997),
which may now be treated with sacral electrical stimulation (SES), resulting in similar
improvements in genitourinary symptoms. Patients: We compared the results of therapy
with GES and SES in 14 patients who were implanted with both devices. Patients were 12
f, 2 m, mean age of 41 years, who had documented gastroparesis as well as bladder or other
pelvic floor dysfunction. All 14 patients had received their GES before the SES. Methods:
Patients were evaluated at baseline and latest follow up (median 4 years for GES and 2 years
for SES), according to previously standardized scores of GI (GI: 0-4, TSS max 20) and GU
(GU: 0-3, UTSS, max 12) function. Results were compared by paired t-tests and reported
as mean ± SE. Results: All 14 patients improved both GI and GU symptoms and the
improvement in all parameters as nausea, vomiting, anorexia, bloating, abdominal pain and
gastric total symptom score (TSS), leakage, urgency, voiding difficulty, number of pads used
and urinary total symptom score (UTSS) were statistically significant (see table below).
Conclusions: Combinations of GES & SES appear to be safe and effective for patients with
both gastroparesis and bladder dysfunction and the existence of a stimulator for one disorder
does not preclude another stimulator.
S1686
Establishment and Characterization of Embryonic and Post Natal Enteric
Neuronal Cell Lines from Immorto-Mice
Mallappa Anitha, Irene Joseph, Randy D. Blakely, Shanthi Srinivasan
Background The isolation and culture of primary enteric neurons is a difficult process and
yields a small number of neurons. We developed embryonic and post-natal enteric neuronal
cell lines using the H-2Kb-tsA58 (Immortomouse) transgenic mice. This mouse harbors the
thermolabile mutation (tsA58) under the control of an interferon γ-inducible H-2Kb promoter
element in every cell of the body. The functional expression of the SV40 large T antigen
can be turned on by culturing the cells in a medium containing interferon γ at a permissive
temperature (33°C) and at higher temperatures it gets rapidly inactivated and results in
differentiation of the cells. Methods Intestines of E13-mouse embryos and second day
post natal mice were digested and enteric neuronal precursors isolated using magnetic
immunoselection with a p75NTR antibody. The cells were maintained at the permissive
temperature, 33°C in the presence of IFN-γ. All experiments were performed between
passages 5-30. To further differentiate into neuronal cells they were transferred to 37°C and
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cultured in the presence of GDNF for 2-7 days. PCR amplification of cRet, Peripherin, Tau,
SERT, Nestin, GFAP and α-smooth muscle actin (α-SMA) and Western blotting using specific
antibodies for Peripherin, PGP9.5, HuD, GFAP and α-SMA was performed. Immunocytoch-
emistry was performed using specific antibodies for Peripherin, PGP9.5, Ret, Tau, HuD,
SERT, Nestin, GFAP and α-SMA. For pAkt analysis cells were exposed to GDNF for 30
minutes, cell lysates were obtained and Western blot analysis performed. Results Expression
analysis of cells at 33°C showed the presence of neuronal markers peripherin, PGP9.5, HuD
and Tau. Few of these cells expressed Nestin, GFAP or α-SMA. When transferred to 37°C
in the presence of GDNF for 2 and 7 days, both cell lines further differentiated into neurons
(95% of cells are PGP9.5 positive). Western blot analysis showed increased expression of
peripherin, PGP9.5 and tau (3 fold increase, p<0.001). At 37°C there was minimal expression
of Nestin (5%), GFAP or α-SMA (< 2%). These neurons expressed the characteristic markers
of enteric neurons including Ret and the transporter SERT. Exposure of these cells to GDNF
resulted in increased phosphorylation of Akt, similar to what has been demonstrated in
primary enteric neuronal cultures. Conclusions We have developed an embryonic and post
natal enteric neuronal cell lines that has neuronal characteristics similar to primary enteric
neurons. These cells lines can be used to study diseases affecting the enteric nervous system
and may be beneficial for transplantation therapy in diseases such as Hirshsprungs disease.
S1687
Enteric Glial Protein S100b Up-Regulation Stimulates Nitric Oxide Production
in Ulcerative Colitis
Carla Cirillo, Giovanni Sarnelli, Giuseppe Esposito, Raffaella Petruzzelli, Michela Grosso,
Teresa Iuvone, Rosario Cuomo
Background: In the central nervous system increased expression of astroglial derived S100B
protein has been associated with inflammation, via nitric oxide (NO) production. In animals,
enteric glia participates to gastrointestinal inflammation. The role of enteroglial-S100B protein
in gut inflammation has been poorly investigated in humans. Aim: To evaluate the role of
S100B protein and its association with NO production in ulcerative colitis (UC). Methods:
S100B mRNA and protein expression, iNOS protein expression and NO production were
evaluated in rectal biopsies from 30 patients with UC and 40 controls. To test enteroglial
activation in experimental inflammation, S100B levels and nitrite production were evaluated
after a 24 hours incubation of control rectal biopsies with 100 μg/ml lipopolysaccharide
(LPS). In addition, to verify whether S100B increase was associated with NO production,
control biopsies were stimulated for 24 hours with exogenous S100B (0.005-5 μM), either
alone or in the presence of the antibody against receptor for advanced glycation endproducts
(RAGE; 1:1000 dil. v/v), which mediates S100B-induced inflammatory responses. Results:
In rectal mucosal biopsies from patients with UC, a stronger and diffuse S100B immunoreac-
tivity was present in the submucosa, together with a marked S100B immunopositivity in
the mucosa, while, in control biopsies, S100B immunohistochemistry was confined within
the submucosa. In patients with UC, S100B mRNA and protein expression, iNOS protein
expression and nitrites levels were significantly higher than in controls (2600±35%, 1360±10,
1035±12 and 266±13%, respectively). In control biopsies incubation with LPS significantly
increased S100B mRNA and protein expression (1600±26% and 501±52, respectively).
Moreover, addition of exogenous S100B (4 concentrations from 0.005 to 5 μM) induced a
significant and concentration-dependent increase of both iNOS expression (174±4%; 672±7;
914±14 and 1438±12, respectively) and nitrite production (90.3±2.5; 228±4; 412±10 and
766±10.7%, respectively). S100B-induced iNOS protein expression and nitrite production
were significantly inhibited in the presence of the specific anti RAGE antibody (-65±4.2%
and -61.3±2.5, respectively). Conclusions: We showed that enteroglial cells activation stimu-
lates nitric oxide production in ulcerative colitis via S100B up-regulation. Our data highlight
the involvement of enteroglial cells in gut inflammation.
S1688
A Polarized Intrinsic Occult Reflex Underlies Accommodation and Slow
Transit in the Large Bowel
Eamonn J. Dickson, Jim Ren, Grant Hennig, Nick Spencer, Terence K. Smith
Background: We have recently reported that colonic elongation inhibits ongoing peristaltic
reflex activity in the guinea-pig distal colon. We have referred to this intrinsic reflex, which
appears to underlie storage and slow transit, as an occult reflex (hidden from view) since
it withdraws ongoing motor activity from the muscle. Aims: To determine whether this occult
reflex activated by longitudinal stretch involves: 1) ascending or descending interneuronal
pathways, and 2) the mechanism underlying this inhibition. Methods: Simultaneous
intracellular recordings were made from the circular muscle (CM) at either end of a circumfer-
entially stretched opened portion in the middle of the segment, and from myenteric neurons
in a circumferentially stretched segment of guinea-pig distal colon. Nicardipine (1 µM ) was
added to paralyze the muscle. Results: Ongoing, coordinated oral excitatory (EJPs) and anal
inhibitory (IJPs) junction potentials occurred in the CM at the ends of the stretched portion
of colon. The addition of longitudinal stretch (LS) to the oral, intact flaccid segment reduced
the amplitude and coordination of oral EJPs and anal IJPs in a graded manner (Control
EJPs=11.65 ± 0.65mV, plus 60% oral LS =3.42 ± 0.32s; p<0.01, n=6), without changing
resting membrane potential. In contrast, stretching the flaccid anal segment had no effect
(Control EJPs=11.65 ± 0.65mV, plus 60% anal LS =10.86 ± 0.83s ; p>0.01, n=6). L-NA
(100 µM) completely reversed the inhibitory effects of oral LS. Transmural stimulation
applied ~15mm oral of the recording site evoked inhibitory postsynaptic potentials (IPSPs)
(6-7mV) in “spontaneously” active interneurons, which were blocked by L-NA, and fast
excitatory post synaptic potentials (FEPSPs) in motor neurons. Conclusions: Our data sup-
ports the novel hypothesis that slow transit and accommodation in the large bowel are
generated by release of NO from mechanosensitive descending NOS +ve interneurons that
are activated by colonic elongation. These descending interneurons release NO to hyperpolar-
ize and thereby inhibit spontaneous firing in other mechanosensitive interneurons underlying
peristalsis. Support: NIDDK RO1 DK45713 (TKS and NJS).
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S1688a
A Genetic Predisposition to Develop Diet-Induced Obesity Correlates with
Altered Glucose Transport and Secretomotor Function in a Rat Model
Niall P. Hyland, Joanna Rybicka, Wallace K. Macnaughton, Quentin J. Pittman, Keith A.
Sharkey
The diet-induced obese (DIO) model in rodents shares many similarities with human obesity.
Both display a persistent obese phenotype that is accompanied by insulin resistance and
appears to be due to a polygenic pattern of inheritance. Several studies suggest that hormones
derived from the small intestine contribute to the development of obesity, but few studies
have investigated intestinal function in obese rodents. Our aim was to investigate whether
the regulation of glucose transport or secretomotor function differed in DIO compared to
diet-resistant (DR) rat jejunum, and whether this was dependent on a genetic predisposition
to develop DIO. Male inbred and outbred (5-7 wks old) Sprague-Dawley rats were maintained
on a medium high fat diet (32 Kcal %fat) for 9-10 weeks and split into DIO and DR groups
based on weight (inbred DR vs DIO, 33% weight difference; outbred DR vs DIO, 15-22%
weight difference). Rats were fasted overnight before euthanasia. Segments of proximal
jejunum were removed, overlying smooth muscle stripped away by blunt dissection, and
tissues were mounted in Ussing chambers and voltage-clamped at 0mV. Luminal glucose
(10mM), but not non-transportable 2-deoxy-D-glucose (10mM), significantly increased
short-circuit current (Isc) in both inbred and outbred DR tissues. The glucose-induced
response was significantly increased in inbred DIO jejunum compared to DR animals (inbred
DR, 20.8±7.3μA.cm-2, n=5, inbred DIO, 61.4±8.1μA.cm-2, n=4, P<0.01). In contrast,
responses in outbred DIO jejunum were significantly decreased compared to DR tissues
(outbred DR, 26.6±5.9μA.cm-2, n=7, outbred DIO, 6.3±2.1μA.cm-2, n=7, P<0.01). Basolat-
eral addition of veratridine (30µM), which prevents inactivation of voltage-dependent Na+
channels, resulted in a tri-phasic change in Isc, the third phase of which was both secretory
and prolonged. In inbred DR and DIO jejunum, veratridine responses were not significantly
altered. However, the third phase was significantly decreased in outbred DIO compared to DR
small intestine (DR, 38.7±6.0μA.cm-2; DIO, 17.9±4.4μA.cm-2, n=9-11, P<0.05). Responses to
both forskolin (10μM) and bethanechol (100μM) were the same in inbred and outbred DIO
and DR tissues. These data suggest that submucosal nerve function is significantly altered
in outbred DIO rats. Decreased glucose responses likely represent an adaptive response
to limit nutrient absorption in outbred DIO jejunum. However, in inbred animals this
compensatory response is lost, possibly contributing to the development of obesity in
genetically predisposed DIO rats. Supported by Canadian Institutes of Health Research and
Canadian Association of Gastroenterology
S1688b
The Relation Between Childhood Obesity and Gastroesophageal Reflux
Disease
Nirav Patel, Aliza Solomon, Susanna Cunningham-rundles, Eleanor Tripp, Robbyn E.
Sockolow, Aeri Moon
Background: The growing prevalence of obesity among children in the United States is a
significant health concern, and it puts children at risk for obesity-related medical conditions.
In adults, obesity and overweight are independent risk factors for gastroesophageal reflux
disease (GERD) and endoscopy-proven esophageal erosions. As childhood GERD is a risk
factor for GERD in adolescence and adulthood, the relationship between childhood obesity
and GERD should be determined. Methods: All children between the ages of 2 to 20 years,
referred for upper endoscopy with biopsies at New York Weill-Cornell Medical Center
between January 2000 and April 2006 were eligible for the retrospective study. Procedures
that were excluded from the study include those with absence of esophageal biopsies, repeated
upper endoscopies on each patient during the time period, and those with unavailability of
all required information (e.g. height and/or weight at time of procedure). 264 procedures
were reviewed for age of the patient, gender, weight, height, presence of reflux esophagitis
(RE), and usage of anti-reflux medications (proton pump inhibitors or H2 blockers). RE
was diagnosed based on histologic findings of basal cell hyperplasia and exocytosis. There
were 127 males and 137 females, ranging from 2 to 20 years of age (mean, 11.1 years).
Weight and height were used to obtain body mass index (BMI) percentiles on sex-specific
BMI-for-age growth charts. Results: Overall, 38 children (15%) were found to be overweight
(BMI >95 percentile), of which 37% had histologic evidence of GERD. Comparatively, 25%
of the 131 children in the normal BMI group (BMI 15 to 85 percentile) were found to have
GERD. The secondary analysis based on usage of anti-reflux medications revealed a 44%
prevalence (11 of 25 patients) of GERD in the overweight group on anti-reflux medications
versus 23% (17 of 74 patients) with GERD in the normal BMI group on medications. In
contrast, the analysis of patients not using anti-reflux medications indicated a lower preval-
ence of GERD (23% versus 28%) in the overweight group as compared to the normal BMI
group. Conclusions: These data largely suggest that there is a correlation between childhood
GERD and overweight. Early intervention in overweight children may help to prevent GERD
and its sequelae. These implications may provide yet another piece of evidence in the battle
against obesity and its associated morbidities.
S1688c
Validation of Dual Excitation X-Ray Absorptiometry (Dexa) Scanning for
Determination of Visceral and Subcutaneous Fat Distribution and
Demonstration of Involvement of Angiotensin II in the Visceral Fat
Vasoconstriction Induced By Stimulation of Intestinal Mucosal Afferent Nerves
Felix W. Leung, Samuel Murray, Elsa Murray, Peter Eggena, Vay liang Go
Background: Disruption of intestinal mucosal afferent nerve function by intragastric capsaicin
treatment redistributes fat from visceral to subcutaneous sites in obese rats. I. Existing DEXA
data in small animals show total fat as % body weight, but DEXA determination of % body
fat in the visceral (%VF) and subcutaneous (%SF) compartments has not been described.
II. The mechanism of visceral fat vasoconstriction induced by stimulation of intestinal
mucosal afferent nerves has not been reported. Hypotheses: I. DEXA data coupled with
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visceral fat dissection allow %VF and %SF to be determined accurately. II. Angiotensin II
mediates the above mentioned vasoconstriction. Method: I. In 5 mice, DEXA scan was
obtained before and after visceral fat dissection. The dissected fat (VF) weight (gm) was
determined by DEXA and by direct weighing. II. In 4 anesthetized rat preparations, visceral
(mesenteric) adipose tissue blood flow (ATBF) was monitored by laser Doppler flowmetry
(LDF). After baseline, vehicle [V] or 3 mg/kg enalapril [E] (angiotensin converting enzyme
inhibitor) was administered intravenously followed by 2 ml/kg of 640 µM capsaicin intradu-
odenally (ID). Results: Tables 1 & 2. Conclusion: These pilot data suggest DEXA results
combined with visceral fat dissection permit determination of %VF and %SF. The visceral
fat vasoconstriction induced by stimulation of intestinal mucosal afferent nerves is mediated
in part by angiotensin II. These tools will permit the vascular mechanism of intragastric
capsaicin-induced redistribution of fat from visceral to subcutaneous sites to be studied.
There is agreement in VF weight determined by DEXA and by direct weighing; with a
maximum discrepancy of 9% (# 2). Based on this agreement, DEXA recorded SF weight
after VF dissection was used for calculation of body fat distribution.
The LDF signals showed an instantaneous decline suggesting that the reduction in ATBF is
a neural- rather than a hormone-mediated event. The changes at its maximum are tabulated
in Table 2. After enalapril treatment, the reductions consistently appeared to be smaller
than those after vehicle treatment.
S1688d
Overweight and Chronic Constipation in Children: A Primary Care
Perspective
Sudipta Misra, Andrew Liaw
Objective: We have reported an association between constipation and overweight in children
seen at subspecialty clinic. This study was designed to test the relationship at primary care
setting. Methods: Retrospective chart review of children between the ages of 5 and 18 years
from primary care clinic. There were two distinct groups. Prevalence group: Charts of
children seen for general pediatric care were reviewed for anthropometry, incidences of
overweight, constipation and frequency of overweight recognition. Constipation group:
Children diagnosed with constipation (identified by ICD-9 code) at the same facility were
reviewed for anthropometry, incidence of overweight and referral to subspecialty clinic for
further management. Children with organic causes of constipation and growth abnormalities
were excluded. Body mass index (BMI) was calculated in all children in both groups. A
BMI of >85 percentile for age and sex from the NIH 2000 growth chart was classified as
overweight. Chi-square and odds ratio were used for analysis. Results: Twenty-eight of 955
children in the prevalence group (2.93%) had constipation and 319 (33.4%) of them were
overweight. There was no difference in the incidence of constipation between overweight
children (n=9, 2.8%) and the rest (n=19, 2.98%, p>.05). Incidence of overweight in children
with constipation (28/9, 32.1%) was not more than those without (927/310, 33.4%, p>.05).
There was no significant difference in the incidence of overweight between children in the
prevalence (33.4%) and constipation (66/20; 30.3%) groups. Twenty-four of the 66 children
diagnosed with constipation at primary care clinic were referred to subspecialty clinic for
further management. Eleven of these children were overweight. An overweight child was
3.1 times more likely to be referred to subspecialty clinic for further management (p<. 05).
Children in the constipation group were younger than those in the prevalence group (mean
age 9.68 and 12.54 years respectively), but were otherwise comparable to the prevalence
group. Conclusion: There was no relationship between overweight and constipation in
primary care setting. However, overweight children were more likely to be referred to
subspecialty clinic for treatment failure. This may explain the reported increased incidence
of overweight among constipated children treated at subspecialty clinic. Overweight children
are more likely to have resistant constipation.
S1688e
Evidence of Peripheral Neural Plasticity in Diet-Induced Obese (Dio) Rats:
Expression of Immunoreactive NPY in Lumbar Drgs and Dorsal Horn of
Spinal Cord Evidence of Peripheral Neural Plasticity in Diet-Induced Obese
(Dio) Rats: Expression of Immunoreactive NPY in Lumbar Drgs and Dorsal
Horn of Spina Cord
Jihong Chen, Junying Xu, Jiande Chen
Background & Aims: Evidence of brain neurochemical changes in diet-induced obesity
(DIO) rats suggests that neural plasticity may be an important contributor to the perpetuation
of obesity during both development and adulthood. The metabolic imprintings in lumbar
dorsal root ganglions (DRGs) and spinal cord may help to find some clues of the special
state of energy homeostasis in DIO rats. Neuropeptide tyrosine Y (NPY) is one of the meal-
related neuropeptides which is present in both central nervous system and peripheral nervous
system and is suppressed after the meal. It is hypothesized that the expression of NPY in
the spinal cord and/or the L1-3 DRGs is altered in DIO rats. The aim of the study was
therefore to study the expression of NPY in the spinal cord and the L1-3 DRGs in fasted
and fed DIO rats and regular rats. Methods: DIO (n=10) and regular (n=10) rats were
purchased at 8 weeks and fed with high-fat diet or regular chows, respectively, until 17
weeks. After being shifted to a standard diet for 5 days they were fasted for a period of 24
hrs. Then after, five in each group were sacrificed immediate and the other five in each
group were sacrificed after a 2-hrs re-feeding. The expression of NPY in the spinal cord and
L1-3 DRGs in each rat was investigated using immunofluorescence. Results: No changes
were noted in the expression of NYP in the spinal cord or the L1-3 DRGs between fasted
and fed rats, neither in DIO rats nor the regular rats (see table 1) except that there was a
trend of increase in the expression of NPY in the L1-3 DGRs in the fed state between the
regular rats and DIO rats (7.91±3.30 Vs 1.45±0.64 , P=0.069). Conclusions: The trend of
increase in the postprandial expression of NPY in the L1-3 DRGs in the DIO rats compared
with the control rats may suggest an impaired suppression of appetite after the meal in DIO
rats. These preliminary findings may also suggest that alterations in NPY expression in DIO
rats are less prominent in the fasting state compared with the fed state and less prominent
in the spinal cord compared with the L1-3 DGRs.
Expression of NPY in Spinal cord and L1-3 DRGs
* p=0.069 compared with regular (re-fed)
S1689
Steatopancreatitis in Obesity: Leptin Or Adiponectin?
Nicholas J. Zyromski, Abhishek Mathur, Kyle W. Yancey, John T. Gripe, Julia J. Walker,
Debao Lu, Deborah A. Swartz-basile, Keith D. Lillemoe, Henry A. Pitt
Introduction: Obesity is epidemic in the United States and leads to fat infiltration of visceral
organs. Adipose tissue has recently been characterized as an endocrine organ which modulates
the inflammatory response in part through the adipokines leptin and adiponectin. We have
recently shown that obese mice have increased pancreatic fat and pro-inflammatory cytokines.
Additionally, Lepdb (leptin-resistant) obese mice develop more severe pancreatitis than their
lean counterparts. However, the influence of adipokines on the evolution of pancreatitis is
unclear. Therefore, we tested the hypothesis that leptin and adiponectin modulate the severity
of pancreatitis. Methods: Sixteen lean C57BL/6J, and 16 obese Lepdb (hyperleptinemic,
hypoadiponectinemic) female mice were studied at 12 weeks of age. In the experimental
group edematous pancreatits was induced by intraperitoneal injection of caerulein (50 µg/
kg hourly for six hours). The control group were similarly injected with vehicle. Three hours
after the last injection, blood and pancreata were collected. Pancreatitis severity was scored
histologically using a validated method: the degree of edema, inflammation, and vacuolization
were added for a total score. Serum leptin, adiponectin and pancreatic tissue levels of
interleukin (IL)-1β, interleukin (IL)-6, myeloperoxidase (MPO), and monocyte chemotactic
protein-1 (MCP-1) were measured by ELISA. Data were analyzed by ANOVA and Tukey
tests. Results: Results for body weight, serum leptin and adiponectin, histologic pancreatitis
score, and pancreatic IL-6 are presented in the table. Pancreata from obese mice with
pancreatitis had significantly (p<0.001) more IL-1β, IL-6, MPO, and MCP-1 than their lean
counterparts and the obese controls. Conclusions: These data suggest that 1) obese mice
develop more severe pancreatitis than lean controls and 2) hyperleptinemia and hypoadi-
ponectinemia correlate with an increased severity of pancreatitis. Therefore, we conclude
that the adipokine milieu may modulate steatopancreatitis in obese mice.
*p<0.001 vs Lean-Control, †p<0.001 vs Lean-Pancreatitis, §p<0.05 vs Obese-Control
S1690
The Influence of Leukocytes Infiltration On Protease Activation in the Course
of Experimental Pancreatitis
Julia Mayerle, Matthias Sendler, Annegret Dummer, Barbara Brandt-nedelev, Karin
Scharffetter-kochanek, Frank U. Weiss, Walter Halangk, Markus M. Lerch
Premature intracellular protease activation is thought to be responsible for the onset, the
propagation and the severity of acute pancreatitis. Transmigration of leukocytes into the
pancreas influences the severity of acute pancreatitis. Trypsin activation in acute pancreatitis
was previously reported to follow a biphasic time course peaking at 1h and 8h after the
onset of the disease. Since the underlying mechanism for the second trypsin peak could be
independent of CCK-receptor activation, we investigated the impact of leukocytes on protease
activation in CD18 null mice, which lack the ability of leukocyte transmigration into the
pancreas. CD-18 deficient mice were generated by targeted disruption of the CD18 gene (J
Clin Invest. 2002; 109: 183-92.). Acute pancreatitis was induced by caerulein(50µg/h, i.p.).
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Activities of amylase, lipase, myeloperoxidase(MPO), cytokine secretion (TNFα, IFNγ, IL-
6, IL-10, IL-12, IL-2, IL-5 and MCP-1), trypsin, trypsinogen, elastase and pro-elastase were
enzymatically measured with specific substrates. Histological evaluation of pancreatic injury
and lung injury was performed after H&E staining. CCK-induced trypsin and elastase
activation as well as necrosis in isolated acinar cells was measured by specific fluorogenic
substrates and propidium iodide exclusion. Wild type animals and CD-18 ko animals
developed acute pancreatitis after supramaximal caerulein stimulation, with a greater severity
in the wild type animals as indicated by significantly increased markers of local and systemic
damage. Wild type animals showed a biphasic pattern of trypsin and elastase activation
peaking at 1h and 8h, both of which were abolished in CD18 null mice. Stimulation of isolated
pancreatic acini from wild type and CD18 null mice with supramaximal concentrations of
CCK did not result in altered trypsin or elastase activation or a different rate of necrosis.
In CD-18 null mice serum levels of pro-inflammatory cytokines such as MCP-1 were
significantly increased already 1h after the first caerulein injection. Leukocytes greatly contrib-
ute to local and systemic damage in acute pancreatitis. Moreover, they not only influence
the systemic inflammatory response, but have a direct impact on protease activation. Surpris-
ingly, they not only contribute to the second peak of protease activation, but influence the
very early phase of premature protease activation, of which the underlying mechanism
needs to be elucidated. Our data question the hypothesis that leukocytes contribute to the
pathogenesis of acute pancreatitis solely as a consequence of premature zymogen activation,
but point to a direct involvement in the earliest disease phase.
S1691
Ghrelin Accelerates Pancreatic Recovery in the Course of Acute Edematous
Pancreatitis in Rats
Artur Dembinski, Zygmunt Warzecha, Piotr Ceranowicz, Stanislaw J. Konturek, Jaroslaw
Biernat, Beata Kusnierz-cabala, Jerzy W. Naskalski, Romana Tomaszewska, Wieslaw W.
Pawlik, Atsukazu Kuwahara, Ikuo Kato, Peter C. Konturek
Introduction: Ghrelin, a 28-amino-acid polypeptide was originally isolated from the stomach.
Recent studies have shown that pretreatment with ghrelin exhibits protective effects in the
gut. Administration of ghrelin reduces gastric mucosal damage evoked by ethanol, stress or
ischemia followed by reperfusion, as well as inhibits the development of experimental
acute pancreatitis. However, these protective effects require administration of ghrelin before
exposure to damaging factor and for this reason have a limited clinical value. The aim of
present study was to examine the influence of ghrelin administration after development of
acute pancreatitis on the severity of this disease and pancreatic regeneration. Methods: Acute
pancreatitis was induced by caerulein given i.p. 5 times at a dose 50 μg/kg/dose in 1 h
intervals. Ghrelin was administered twice a day at the dose 8 nmol/kg/dose, starting 24 h
after last injection of caerulein. Rats were sacrificed 0 h or 1, 2, 3, 5, 7 and 10 days after
cessation of caerulein administration. The severity of acute pancreatitis was assessed by
histological examination of pancreases and measurement of serum activity of pancreatic
enzymes and serum concentration of pro-inflammatory interleukin-1β. Moreover, pancreatic
cell proliferation was examined by incorporation of labeled thymidine into pancreatic DNA;
whereas pancreatic blood flow was measured by laser Doppler flowmetry. Results: Adminis-
tration of caerulein led to the development of acute edematous pancreatitis and maximal
severity of this disease was observed 24 h after induction of pancreatitis. Treatment with
ghrelin reduced morphological signs of pancreatic damage such as pancreatic edema, leuko-
cyte infiltration and vacuolization of acinar cells, and administration of ghrelin led to complete
regeneration of the pancreas at the 7th day from acute pancreatitis development. In contrast,
in control rats, a slight pancreatic edema and inflammatory infiltration was still observed
at the 10th day of acute pancreatitis. Also ghrelin administration reduced biochemical indexes
of the severity of acute pancreatitis such as serum activity of lipase, amylase and poly-
C ribonuclease, and led to earlier normalization of these parameters. These effects were
accompanied with an increase in pancreatic DNA synthesis and a decrease in serum level
of pro-inflammatory IL-1β. Moreover administration of ghrelin caused an improvement of
pancreatic blood flow. Conclusions: Treatment with ghrelin exhibits therapeutic effect in
the course of experimental acute pancreatitis by reduction of inflammatory process and
stimulation of post-inflammatory pancreatic regeneration.
S1692
The Impact of Pancreatic Phospholipase A2 On the Severity of Experimental
Pancreatitis
Manuel Ruthenbürger, Julia Mayerle, Barbara Brandt-nedelev, Thomas Wartmann, David
Y. Hui, Walter Halangk, Markus M. Lerch
Premature intracellular activation of digestive zymogens is regarded as an initial and initiating
event for acute pancreatitis. While activation of proteolytic zymogens has been shown in
numerous studies, the role of other digestive enzymes is much less clear. Several authors
have suggested that Phosholipase A2 is responsible for the cellular injury of pancreatic acini.
These earlier studies have, however, not distinguished between different members of the
PLA2 family and generally investigated leukocyte PLA2 type 2a rather than pancreatic
secretory PLA-2 type 1b. Pancreatic secretory-PLA2-deficient mice were generated by targeted
disruption of the PLA2 gene (Gastroenterology 2001; 120:1193-1202). Acute pancreatitis
was induced by 7 hourly injections of caerulein (50µg/h, i.p.). Control mice received i.p.
saline. Activities of amylase, lipase, myeloperoxidase, trypsin and PLA2 were enzymatically
measured with specific substrates. Histological evaluation of pancreatic injury was performed
after H&E staining, and apoptosis was analysed by 3-OH nick-end labelling. Pancreatic
edema was calculated as ratio of pancreatic wet weight to body mass. CCK-induced necrosis
in isolated acinar cells was measured by propidium iodide exclusion. PLA2 expression and
PLA2 activity was absent in PLA2-KO animals. In wild type animals we detected a high
PLA2 basal activity with a 3-fold increase after supramaximal caerulein stimulation. As an
endogenous activator of PLA2 we identified Cathepsin L in addition to trypsin. Supramaximal
caerulein stimulation induced early pancreatic injury as indicated by high levels of serum
amylase and lipase in wild-type mice as well as knock-out animals. The pancreatic inflammat-
ory reaction indicated by myeloperoxidase levels and CD45 staining was reduced in the
latter; in parallel we detected a 7 fold increase in the rate of apoptosis in PLA2 KO animals.
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Isolated acinar cells from both animal groups showed no difference in CCK-induced necrosis
or trypsin activity. Our data clearly indicate that activation of the secretory pancreatic pro-
PLA2 plays a role in mediating the systemic inflammatory response, but has little or no impact
on the initiation or propagation of the digestive enzyme activation cascade in pancreatic acini.
The deletion of PLA2 leads to a shift of cell death from predominantly necrosis to apoptosis
for which the underlying signalling pathway remains unknown.
S1693
Evidence for the Role of Specific Tumor Necrosis Alpha Inhibition in
Modulating Experimental Acute Pancreatitis: Amelioration of Injury By
Etanercept, a Soluble Antagonist of the P75 TNF Receptor
Giuseppe Malleo, Emanuela Mazzon, Tiziana Genovese, Rosanna Di paola, Carmelo Muia,
Tomasso Centorrino, Ajith K. Siriwardena, Salvatore Cuzzocrea
Introduction:Tumor necrosis factor TNF-α plays a pivotal role in the pathogenesis of acute
pancreatitis (AP). Recent studies have shown that inhibition of TNF-α ameliorates experi-
mental AP but the mechanisms of this effect are not fully elucidated. This study evaluates
the action of the potent TNF antagonist etanercept, a fully humanized dimeric soluble form
of the p75 TNF receptor on cerulein-induced severe-AP in wild type and selective TNF-α
gene deletion mice. Methods: Mice [4-5 weeks old; median (range) weight 20 (18-22)g]
with a targeted disruption of the TNF-α gene (TNF-α KO) and littermate wild-type controls
(TNF-αWT) were cared for in compliance with European animal welfare regulations and
randomly allocated to one of 6 groups (10 animals per group) as follows: (i) TNF-αWT +
cerulein[cerulein hourly (x 5) (50 μg/kg intra-peritoneal)](ii) TNF-αKO + cerulein, (iii)
TNF-αWT + saline, (iv) TNF-αKO + saline,(v) TNF-αWT + cerulein + etanercept 10 mg/
kg 1h after the first cerulein; (vi) TNF-αWT Sham + etanercept. Mice were killed by
exsanguination at 24 hours after induction of AP. End-points: pancreatic wet:dry weight,
serum amylase, lipase, immunohistochemical localisation of FAS ligand, BAX, BCL2, TNF-
alpha, myeloperoxidase and Terminal Deoxynucleotidyltransferase-Mediated UTP nick-end
Labeling (TUNEL) Assay. Results: Intraperitoneal injection of cerulein in WT mice was
associated with significant rises in the serum levels of lipase and amylase and resulted in
characteristic acute necrotizing pancreatitis. A substantial increase of TNF-α formation was
found in pancreas samples collected from WT mice at 24 hours after cerulein administration.
In contrast, pancreas levels of TNF-alpha together with features of acute pancreatitis were
significantly lower in TNF-α deficient mice in comparison to those of WT animals. After
the administration of etanercept a marked reduction of TNF-α levels and features of AP in
cerulein-treated WT mice was observed. At 24 hours after cerulein administration, TUNEL
assay confirmed the presence of apoptotic cells in sections obtained from cerulein-treated
WT mice. In contrast, no positive staining for TUNEL assay was found in tissue sections
of cerulein-treated TNF-αKO mice as well as in WT mice that had been previously treated
with Etanercept. Discussion: This study provides the first evidence that TNF-α gene deletion
and pharmacological treatment with etanercept, a recombinant fully humanized sTNFR2
(p75) fusion protein, significantly reduced the development of cerulein-induced pancreatitis,
pancreas injury and TNF-α production and suggests that etanercept ameliorates injury by
a TNF-α-dependent mechanism
S1694
Administration of IL-12 and IL-18 Which Induces Severe Pancreatic Damage
in Obese, Leptin-Deficient OB/OB Mice Can Be Used As a Pathologically
Relevant Model of Acute Pancreatitis
Joseph A. Sennello, Maria Pini, Melissa E. Gove, Raja Fayad, Giamila Fantuzzi
Obesity is associated with increased risk of developing severe acute pancreatitis (AP), although
the mechanisms of this association are not clear. Serum, peritoneal and pancreatic levels of
IL-12 and IL-18, two macrophage-derived cytokines important for induction of IFN-gamma,
are elevated in AP and correlate with severity of disease in human patients. IL-18 is also
elevated in obese compared to normal-weight subjects. We investigated the effect of adminis-
tration of IL-12 and IL-18 on pancreatic inflammation in lean WT and in obese leptin-
deficient ob/ob mice. Two daily IP injections of IL-12 (200 ng/mouse) and IL 18 (500 ng/
mouse) lead to development of pancreatic edema as well as increases in serum amylase
and lipase in WT mice. Disease was self-limiting and resolved in 48-72 hours. However,
administration of the cytokine combination to ob/ob mice lead to death of pancreatic acinar
cells, as evaluated by histological examination and TUNEL staining, without development
of significant pancreatic edema. Serum amylase and lipase levels were 3-fold higher in ob/
ob compared to WT mice injected with IL-12 and IL-18. Ob/ob mice also developed marked
hypocalcaemia (5.6+/-0.8 mg/dl) and extensive adipose tissue necrosis with saponification
as seen in human patients. In contrast to WT mice in which no lethality was present, 100%
lethality was observed in ob/ob mice 48 hours after receiving IL-12 and IL-18. Furthermore,
the cytokine combination induced a significant increase in serum IL-6 levels in ob/ob but
not in WT mice. Serum levels of the acute-phase protein SAA were 100-fold higher in ob/
ob compared to WT mice treated with IL-12 and IL-18. To clarify whether the increased
AP severity of ob/ob mice was due to leptin deficiency or to obesity, two approaches were
taken. Reconstitution of ob/ob mice with leptin for 5 days prior to and during injections
of IL-12 and IL-18 did not significantly alter hypocalcaemia, IL-6 or SAA levels and led to
a minor but significant increase in serum amylase and lipase. Administration of leptin to
ob/ob mice for one month followed by pair feeding to WT mice for 2 weeks allowed us to
generate “lean” ob/ob mice. Compared to obese ob/ob mice, lean ob/ob did not develop
hypocalcaemia and had significantly reduced levels of IL-6 and SAA in response to IL-12
and IL-18. However, serum amylase and lipase reached levels comparable to those observed
in ob/ob mice. This suggests that the lean ob/ob mice had a similar initiation of disease
without the secondary complications associated with obesity. In conclusion, administration
of IL-12 and IL-18 is a pathologically relevant model of AP in which severity is associated
with obesity.
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Galanin Knockout Mice Are Less Susceptible to Caerulein-Induced Acute
Pancreatitis
Mayank Bhandari, Masahiko Kawamoto, Anthony Thomas, Colin Carati, C. J. Ormandy,
James Toouli, Gino T. Saccone
Acute pancreatitis (AP) is a painful, sometimes lethal condition, for which there is no specific
treatment. We have shown that galanin, a vasoactive neuropeptide, regulates pancreatic
vascular perfusion; its non-selective antagonist galantide, can ameliorate AP in mouse and
possum models. Aims: To determine if administration of galantide in a mouse model would
ameliorate AP and if mice lacking the galanin gene are more susceptible to caerulein-induced
AP. Methods: Female Balb C, galanin knockout (KO) and their wild-type littermates, were
used in the study. AP was induced in mice by 7 hourly intraperitoneal injections of caerulein
(50µg/kg). Galanin (10nmol/kg) or galantide (10, 20 and 40nmol/kg) were individually
administered intraperitoneally with each caerulein injection (n=6-9/group). Balb C mice
control groups (n=3-4) received galanin, galantide or saline injections only. Galanin KO
and wild-type littermate groups (n=3-4/group) received saline injections. Pancreata were
harvested 6 hours after the final caerulein injection for histological examination and estimation
of myeloperoxidase (MPO) activity. Pre- and post-AP plasma amylase and lipase activities
were measured. Data were analyzed by ANOVA. Results: In Balb C mice treated with galantide
(40nmol/kg), plasma amylase and lipase activity was reduced to 62% and 59% respectively
of the levels in the AP alone group (P<0.05). Administration of galanin or galantide alone
did not significantly alter the activity of plasma amylase or lipase. Importantly galantide
treatment significantly reduced the mean pancreatic MPO activity by 50% and the number
of necrotic pancreatic acinar cells by 25% compared with the AP alone group (both P<0.05).
In galanin KO mice the mean plasma amylase and lipase activities were 72% and 48% of
the levels in wild-type littermate following the induction of AP respectively (P<0.05). Pancre-
atic MPO activity in the galanin KO group was 5% of that in the wild-type following the
induction of AP (P<0.05). The necrosis and vacuolization scores in the pancreata of galanin
KO group was 26% and 73% respectively of that observed in wild-type following induction
of AP (P<0.05). Conclusion: These data indicate that mice lacking the galanin gene are less
susceptible to caerulein-induced AP and the severity of AP in Balb C mice is ameliorated
by treatment with the galantide. These findings are consistent with galanin playing a major
role in AP. Galanin antagonists may be useful in decreasing the severity of AP. The support
of Flinders Technologies and Bio Innovation SA are acknowledged.
S1696
The Inflammatory Response of Acute Pancreatitis Promotes Necrosis Through
Effects On the Pi3 Kinase System
Jae hyuk Do, Olga Mareninova, Alex Paik, Chris Reyes, Aurelia Lugea, Lars Fischer, Ilya
Gukovsky, Anna Gukovskaya, Stephen J. Pandol
Background: Infiltration of the inflammatory cells into pancreas and acinar cell death are
major pathologic responses of acute pancreatitis (AP). We showed that these responses are
interrelated because neutrophils infiltration results in a marked inhibition of apoptosis and
stimulation of necrosis in experimental AP. The present study was to determine signaling
mechanisms underlying effects of neutrophils on death responses in cerulein (CR)-induced
AP. Based on our previous data the lipid phosphatase, PTEN, is a key negative regulator of
PI3K-induced Akt activation in pancreas. We found that reactive oxygen species (ROS)
increase activity of pancreatic Akt by inhibiting PTEN. In the present study we hypothesized
that ROS produced by activated neutrophils cause PTEN inhibition resulting in an increase
in PI3K-induced Akt activation, which inhibits acinar cells apoptosis. Methods: AP was
induced in rats, wild type and PI3K-gamma deficient mice by i.p. injection of 50 mg/kg
CR. Neutrophil depletion was achieved by i.p. injection of anti-neutrophil serum (ANS) for
4 hrs, and verified by measuring neutrophil level in blood. Apoptosis in pancreatic tissue
was measured by TUNEL; and caspase activities were determined with a fluorogenic assay;
Akt activity and phosphorylation by In Vitro kinase and Western blot; PTEN oxidation and
activity by electromobility shift and enzymatic assays. Results: CR-induced pancreatitis in
PI3K-gamma deficient mice displayed 2-times more apoptosis and 50% less necrosis, than
that in wild type mice. CR-induced pancreatitis in rats markedly increased pancreatic Akt
activity and phosphorylation suggesting the role of Akt in the effects of the PI3K system in
CR-induced pancreatitis. Neutrophil depletion increased apoptosis in pancreatitis in rats by
5 fold, activities of caspases-3 and -9 by 2 and 4 fold, respectively, and inhibited necrosis
by 80%. Neutrophil depletion in rats also markedly decreased PI3K-induced Akt activation
in pancreatitis. The effect of neutrophils on Akt activity is mediated by PTEN inhibition.
Indeed, we found that neutrophil depletion decreased PTEN oxidation and stimulated its
activity in pancreatitis. These results suggest that ROS produced by the inflammatory cells
inactivate PTEN through oxidation resulting in an increased Akt-phosphorylation and activity.
Increases in Akt activity in turn worsen pancreatitis by inhibiting apoptosis. Conclusion:
This mechanism likely explains at least some of the beneficial effects that PI3K inhibition
has in AP models.
S1697
Interrelationship Between Autophagy and Apoptosis in Cerulein Pancreatitis
Olga A. Mareninova, Kip Herman, Stephen J. Pandol, Samuel W. French, Fred S.
Gorelick, Ilya Gukovsky, Anna S. Gukovskaya
Background and Aims: Autophagy is an adaptive process through which the cell degrades
unneeded or defective cytoplasmic organelles. Organelles to be degraded are sequestered
within double-membrane vacuoles called autophagosomes, which then fuse with late endo-
somes and lysosomes, forming autolysosomes. The material within autolysosomes is degraded
by hydrolases. Defective or excessive autophagy causes both apoptotic (type 1) and autophagic
(type 2) programmed cell death. The role of autophagy in the regulation of pancreatic acinar
cell death is not known. We studied the interrelationship between autophagic and apoptotic
death responses in cerulein (CR) pancreatitis and in the In Vitro model of acinar cells
hyperstimulated with CCK-8. Methods: We characterized autophagy in rat CR pancreatitis
and in rat pancreatic acinar cells stimulated with 100 nM cholecystokinin-8 (CCK) by using
electron and immunofluorescence microscopy, and Western blot to measure LC3 protein,
a specific autophagy marker. Apoptosis was quantified with TUNEL assay, and caspase-3
activation, with a fluorogenic assay. Results: Pancreatic tissue from rats with CR pancreatitis
displayed an increase in double-membrane structures characteristic of autophagosomes. Both
Western blot and immunofluorescence showed increase in LC3-II, a form of LC3 that uniquely
localizes to autophagosomes. Similarly, CCK hyperstimulation of acinar cells resulted in
accumulation of autophagic vacuoles, as manifested by increase in LC3 punctate staining.
These data demonstrate autophagy activation in CR pancreatitis. The commonly used auto-
phagy inhibitor 3-methyladenine (3-MA; 10 mM) prevented CCK-induced increase in LC3-
II as well as the formation of autophagic vacuoles. 3-MA greatly inhibited apoptosis (by
~50%) and caspase-3 activation (by ~80%) in CCK-treated acinar cells. These results indicate
that autophagy activation is necessary for apoptosis in acinar cells. General caspase inhibitors
zVAD-fmk and Q-VD-OPH markedly increased accumulation of autophagic vacuoles both
in CR pancreatitis and in acinar cells hyperstimulated with CCK, suggesting a negative feed
back from apoptosis to autophagy. Conclusions: Autophagy is activated in both In Vivo and
In Vitro models of CR pancreatitis. Our results suggest a mediatory role for autophagy in
apoptotic death of acinar cells. On the other hand, the results demonstrate that caspases
negatively regulate autophagy in pancreatitis.
S1698
Alcohols Enhance Zymogen Activation and Vacuolar ATPase Translocation in
Caerulein-Stimulated Pancreatic Acinar Cells
Martine Alexandre, Madhavi Bhoomagoud, Thomas R. Kolodecik, Fred S. Gorelick,
Edwin C. Thrower
Premature zymogen activation in the acinar cell initiates acute pancreatitis. Alcohols can
sensitize the acinar cell to this activation but the mechanism is not well understood. We
have shown that zymogen activation requires a proton-transporting vacuolar ATPase (vAT-
Pase). For vATPase activation, the soluble peripheral domain (V1) must translocate to, and
assemble with, the integral membrane domain (V0). Stimulation of acini with caerulein has
been shown to effect translocation of soluble vATPase V1 subunits to membranes. Alcohols
can sensitize the acinar cell to caerulein-induced zymogen activation. We propose that the
sensitizing effects of alcohols might be mediated by the vATPase. To investigate this hypo-
thesis, isolated rat pancreatic acini were treated with 10-7M caerulein either alone or in the
presence of ethanol [50mM] or butanol [20 mM] for 15 minutes (to measure translocation
by immunoblot) or 60 minutes (to measure zymogen activation by fluorogenic assays).
Caerulein (10-7M) increased translocation of V1 compared to unstimulated controls. This
translocation was further increased in the presence of ethanol or butanol, demonstrating
that alcohols enhance caerulein-induced translocation of V1 to membranes. Ethanol and
butanol increased caerulein-induced trypsinogen activation compared to caerulein alone;
The vATPase inhibitors bafilomycin A1 and concanamycin (100mM) reduced this enhanced
activation to control levels. A similar trend was seen for chymotrypsinogen activation.
Caerulein-stimulated amylase release was identical for all treatment groups indicating cell
viability. From these studies we suggest that alcohols may sensitize the acinar cell to caerulein-
induced zymogen activation by enhancing vATPase assembly and activity.
S1699
Mechanisms of Pancreatic Akt Activation in Cerulein Pancreatitis and By
Ethanol Feeding. Role of Pten
Olga A. Mareninova, Aurelia Lugea, Irina Odinokova, Ilya Gukovsky, Stephen J. Pandol,
Anna S. Gukovskaya
Background and Aims: Phosphatidylinositide 3-kinase (PI3K) is a key signaling molecule.
The effects of inducible (class I) PI3K are mostly mediated through the Akt/PKB kinase,
which is negatively regulated by the phosphatase PTEN. We have recently shown that the
class I PI3K gamma isoform mediates key pathologic responses of cerulein (CR) pancreatitis,
such as trypsinogen and NF-κB activation. Alcohol abuse is a major etiologic factor in
pancreatitis; however, ethanol's effects on the PI3K/Akt pathway in pancreas have not been
investigated. In this study, we investigated the effects of CR pancreatitis and ethanol feeding
on the PI3K-Akt-PTEN system. Methods: Rats were pair-fed for 6 weeks either control or
ethanol-containing Lieber-DeCarli liquid diet. Pancreatitis was induced in rats by 4 hourly
i.p. injections of 50 μg/kg CR. In pancreatic tissue, we measured Akt phosphorylation by
Western blot; Akt activity with In Vitro kinase assay and ELISA; and PTEN activity, oxidation
and phosphorylation with enzymatic assay, electromobility shift assay and Western blot,
respectively. Results: We found that CR pancreatitis caused a ~50% decrease in pancreatic
PTEN activity. Both mechanisms that can mediate PTEN inactivation, namely, its oxidation
and phosphorylation, were activated in pancreatitis. Ethanol feeding also inhibited PTEN
activity (by ~30%). However, ethanol-induced PTEN inhibition was solely due to increased
PTEN oxidation, whereas PTEN phosphorylation was not affected by ethanol. PTEN inhibi-
tion, both in CR- and ethanol-treated rats, was associated with a marked increase in pancreatic
Akt activity and phosphorylation. These data suggest that PTEN inhibition is a major
mechanism of Akt activation induced in rats by CR pancreatitis or ethanol feeding. Conclu-
sions: CR pancreatitis and ethanol feeding both inactivate PTEN (through its oxidation and
phosphorylation), resulting in Akt activation. In turn, persistent Akt activation in pancreas
could be a factor predisposing to alcoholic pancreatitis. The results show that PTEN inhibition
is a common effect of both CR pancreatitis and ethanol feeding, and provide a possible
mechanism underlying the effects of PI3K, in particular PI3K gamma, in pancreatitis.
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Blockage of the T-Cell Co-Inhibitory Surface Molecule Ctla-4 (Cd152) in
Necrotising Pancreatitis Increases Mortality
Julia Mayerle, Annegret Dummer, Cathleen Sünder, Janine Kalkowski, Frank U. Weiss,
Mandy Busse, Matthias Sendler, Barbara M. Bröker, Markus M. Lerch
Patients with severe acute pancreatitis often die from bacterial infection arising in pancreatic
necrosis. Severe pancreatitis is characterised by an overwhelming inflammatory immune
response syndrome (SIRS). This could be followed by a compensatory anti-inflammatory
response syndrome (CARS)which may facilitate infection of the pancreatic necrosis. Since
the role, if any, of T cells in acute pancreatitis has not been defined, we have determined
the expression and impact of the inhibitory T cell surface molecule CTLA-4(CD152)in
murine models of acute pancreatitis. Pancreatitis was induced in C57BL6 mice either by
caerulein (50µg/h, i.p.) or retrograde taurocholate (TC 2%) injections into the pancreatic
duct and animals were sacrificed after 6h, 24h, 48h and 72h. Serum was evaluated for
amylase levels and cytokine secretion. Flow cytometry was employed to evaluate T-cell
response. Granulocyte infiltration was detected by MPO activity and staining for GR-1.
Apoptosis was detected by 3-OH-nick-end-labelling of the thymus. Splenic CTLA-4 expres-
sion was either determined by FACS analysis or antibody labelling. In taurocholate-induced
pancreatitis the bacterial load of the liver and pancreas was determined. Blockage of CTLA-
4 was achieved using a monospecific inhibitory antibody and pancreatitis subsequently
induced with 2% taurocholate. Bacterial translocation from the gut was not observed until
48 hours after induction of pancreatitis. Pro-inflammatory cytokines, as well as granulocyte
activation and tissue infiltration were significantly higher in taurocholate pancreatitis com-
pared to caerulein pancreatitis. Thymus cell apoptosis was also found to be significantly
increased in taurocholate pancreatitis compared to caerulein pancreatitis. There was a linear
correlation between increased CTLA-4 levels and increased mortality from pancreatitis.
Blockage of CTLA-4 with inhibitory antibody before induction of pancreatitis significantly
decreased animal survival. In contrast to mild pancreatitis (caerulein model) taurocholate-
induced pancreatitis involves T-cells. T-cell activity parallels mortality in this model sug-
gesting a possible shift from SIRS to CARS as supported by increased expression of the
inhibitory surface molecule CTLA-4 and bacterial translocation from the gut. Blockage of
CTLA-4 with an inhibitory antibody, which results in a decrease of T cell activity and
increased systemic pro-inflammatory response, greatly increases the severity and mortality
of the disease. Our data indicate that T-cells are - even in the absence of a known pathogen
- critically involved in the pathogenesis and especially immune modulation of severe
acute pancreatitis.
S1701
Pharmacologic But Not Genetic Deletion of TRPV1 Protects Mice Against
Caerulein-Induced Pancreatitis
Joelle Romac, Shannon J. Mccall, John E. Humphrey, Jay Hsu, Jinseok Heo, Rodger A.
Liddle
We have previously demonstrated that destruction of primary sensory nerves or blockade
of the capsaicin receptor (transient receptor potential vanilloid type 1, TRPV1) reduces the
severity of experimental pancreatitis. In the current study, we examined the effects of TRPV1
gene deletion in TRPV1 knockout (TRPV1 -/-) mice during neurogenic activation of pancreatic
inflammation using a secretagogue-induced model. Methods: In this model, a supramaximal
dose of caerulein (50 µg/kg) was injected hourly for 12 hours. TRPV1 -/- mice were compared
to wild type (TRPV1 +/+) animals. Pancreatitis was assessed by measuring serum amylase,
pancreatic edema, myeloperoxidase (MPO) activity, and histological scoring. Substance P
released from primary sensory nerve endings binds to NK1 receptors (NK1R) on pancreatic
acinar cells resulting in internalization of the receptor-ligand complex. NK1R endocytosis
has been used as a measure of endogenous substance P release. Results: Caerulein treatment
caused significant elevations in amylase levels in both TRPV1 +/+ (4.4 fold increase) and
TRPV1-/- (5 fold increase) mice compared with non-caerulein-treated control mice. MPO
levels were undetectable in untreated mice but increased to 405 µU/mg protein in TRPV1
+/+ mice and 869 µU/mg protein in TRPV1 -/- mice (p<0.05). Caerulein caused pancreatic
edema with a 1.7 fold increase in the pancreas/body weight ratio in TRPV1 +/+ mice and
a 1.3 fold increase in TRPV1 -/- animals; and produced histologically indistinguishable
changes of pancreatitis in both TRPV1 +/+ and -/- mice. Interestingly, NK1R endocytosis
was increased to a similar extent in both groups of mice following caerulein treatment. We
then confirmed the importance of neurogenic inflammation in pancreatitis by ablating
primary sensory nerves with high doses of the TRPV1 agonist resiniferatoxin (RTX). Pancreat-
itis was ameliorated by RTX treatment in wild type mice but not in TRPV1 -/- mice. Moreover,
RTX abolished NK1R endocytosis in TRPV1 +/+ mice but had no effect in TRPV1 -/- mice
indicating that substance P release still occurred in TRPV1 -/- mice. Conclusions: These
findings demonstrate that TRPV1 is involved in the pathogenesis of pancreatic inflammation
and pharmacologic destruction of TRPV1 neurons protects against pancreatitis. However,
genetic deletion of TRPV1 -/- l results in developmental gene compensation that adjusts for
the absence of TRPV1 expression so that neurogenic inflammatory pathways are preserved.
S1702
Role of High Mobility Group Box Chromosomal Protein 1 in Experimental
Severe Acute Pancreatitis
Takeo Yasuda, Takashi Ueda, Yoshifumi Takeyama, Takahiro Nakajima, Hidehiro Sawa,
Makoto Shinzeki, Kozo Takase, Yoshikazu Kuroda
Background:High mobility group box chromosomal protein 1 (HMGB1) was identified to
have the capacity to induce cytokines and activate inflammatory cells when it is applied
extracellularly, and increases in patients with sepsis, hemorrhagic shock, and disseminated
intravascular coagulation. Recently we disclosed the significant elevation of serum HMGB1
in patients with severe acute pancreatitis (SAP). The aim of this study was to clarify the
contributions of HMGB1 in SAP, using rat and mice model. Methods:Experiment 1; male
Wistar rats were used. Mild acute pancreatitis was induced by intravenous administration
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of caerulein (5 μg/kg/h for 4 h) (Cn pancreatitis). SAP was induced by retrograde injection
of 3% or 20% sodium deoxycholate into the biliopancreatic duct (DCA pancreatitis). We
measured serum HMGB1 concentrations by ELISA in these models. In 3% DCA pancreatitis,
serum HMGB1 concentrations were measured 6, 12, 18, and 24 h after the induction of
SAP. Moreover, the expressions of HMGB1 protein in pancreas, liver, kidney, lung and small
intestine were analyzed by western blotting. Experiment 2; female C3H/HeN mice were
employed. SAP was induced by creating closed duodenal loop (CDL pancreatitis). Anti-
HMGB1 neutralizing antibody (200 μg) was injected intraperitonealy just before SAP was
induced. Severity of pancreatitis and organ injury (liver, kidney, and lung) was examined
12 h after induction of SAP. Results:Experiment 1; serum HMGB1 levels were increased in
rat acute pancreatitis. Serum HMGB1 levels in Cn pancreatitis, 3% DCA pancreatitis, and
20% DCA pancreatitis were 5.7 ± 0.5 ng/ml, 9.0 ± 1.5 ng/ml, and 29.4 ± 7.0 ng/ml
respectively, and were correlated with the disease severity. In 3% DCA pancreatitis, serum
HMGB1 level was significantly increased 6 h after the induction and thereafter decreased.
The expressions of HMGB1 protein in pancreas, liver, kidney, and lung were increased 12
h after the induction. Experiment 2; anti-HMGB1 neutralizing antibody significantly
improved the elevation of serum amylase level and histological alterations of pancreas and
lung in CDL pancreatitis. Anti-HMGB1 antibody also significantly ameliorated the elevations
of serum alanine aminotransferase and creatinine in CDL pancreatitis. Conclusions:The
serum HMGB1 levels were significantly increased in rat SAP, and the expressions of HMGB1
protein were increased in major injured organs. Blockade of HMGB1 attenuated the develop-
ment of mice SAP and associated organ dysfunction. These results suggest that HMGB1 may
play a pivotal role in the pathogenesis of SAP, and that HMGB1 may act as a key mediator
for inflammation and organ failure in this disease.
S1703
The Role of Protein Kinase C Isoforms in Pancreatic Zymogen Activation
Sara E. Osgood, Thomas R. Kolodecik, Joseph R. Reeve, Stephen J. Pandol, Fred S.
Gorelick, Edwin C. Thrower
Premature zymogen activation within the pancreatic acinar cell is a key event in the initiation
of acute pancreatitis. To investigate the mechanisms of this activation, we have developed
a cell-free reconstitution system (Thrower, AJP 2006). It demonstrated that zymogen granule-
enriched and microsomal fractions from the pancreas can support cytosol-dependent zym-
ogen activation. Activation of some zymogens, such as chymotrypsinogen, may further
depend on ATP. Protein kinase C (PKC) has been shown to have multiple roles in the
regulation of both physiology and pathophysiology of the pancreas. We proposed that it
may participate in cytosol and ATP-dependent zymogen activation. The reconstituted system
and a series of isoform-specific PKC inhibitors were used to examine this hypothesis. In the
presence of inhibitors for PKC δ, PKC ε and PKC ζ, little inhibition of cytosol-dependent
trypsin activity was seen in either particulate fraction. However, cytosol and ATP-dependent
chymotrypsin activity in the zymogen granule-enriched fraction were inhibited by approxim-
ately 30%, 40% and 80% of maximal following incubation with PKC δ, ε and ζ inhibitors,
respectively. Similar results were seen under identical conditions in the microsomal fraction,
chymotrypsin activity being reduced by about 20%, 20% and 30% of maximal with PKC
δ, ε and ζ inhibitors respectively. These results indicate that different PKC isoforms play a
greater role in cytosol and ATP-dependent chymotrypsin activation, than trypsin activation.
Further, PKC ζ appears to be the predominant isoform in mediating this effect and more
so in the zymogen granule-enriched fraction. This implies that different isoforms of PKC
can mediate zymogen activation in varying degrees and at differing cellular locations.
S1704
Protection of Hsp27 By Inhibition of Pkcδ and Induction of Bcl-2 Expression
in Acute Pancreatitis
Antje Malo, Bettina Ziehe, Constanze Kubisch, Burkhard Goeke, Claus Schaefer
Introduction: We have recently shown that overexpression and phosphorylation of the small
heat shock protein Hsp27 in exocrine acini protects against cerulein-induced pancreatitis.
Beside the development of necrosis, the magnitude of apoptosis seems to be crucial for the
severity of pancreatitis. So far, only little is known about the induction and regulation of
apoptosis during acute experimental pancreatitis. Most recently, a new study showed a role
of Hsp27 in inhibiting the extrinsic apoptotic pathway in an In Vivo cell culture model. The
aim of our study was to determine the molecular mechanisms how Hsp27 protects against
cerulein-induced pancreatitis. Material and Methods: Transgenic mice overexpressing human
Hsp27 (hu-Hsp27) in the pancreas were developed using a construct containing Hsp27
under control of the CMV promoter as described previously. Pancreatitis was induced by six
hourly intraperitoneal injections of cerulein (50µg/kg bw) in wildtype C57/bl and huHsp27
overexpressing transgenic mice. Pancreatic lysates were investigated by western blotting and
immunoprecipitation (i.p.) using specific antibodies against caspase 3, 9, Bcl-2, Bad and
PKCδ. Results: No significant expression or activation for caspase 3 and 9 were detectable
in wildtype mice compared to transgenic mice overexpressing human Hsp27 in exocrine
acinar cells. Interestingly, western blot analysis revealed a strong increase of the anti-apoptotic
Bcl-2 expression in huHsp27 mice after cerulein injections while non transgenic mice showed
decreased levels of Bcl-2. Expression of pro-apoptotic Bad was in both, transgenic and
wildtype mice, increased. Co-immunoprecipitation with PKCδ and Akt showed a direct
interaction with Hsp27, both, in wildtype and huHsp27 transgenic animals. However, after
induction of pancreatitis with cerulein, PKCδ phosphorylation and thereby its kinase activity
was decreased in transgenic animals. In addition, western blotting and immunofluorescent
studies showed a translocation from the cytosol to the plasma membrane for the activated
PKCδ isoform. Conclusion: Overexpression of the small heat shock protein Hsp27 in exocrine
acinar cells protects against cerulein-induced pancreatitis. One possible mechanism is to
reduce the expression and activity of PKCδ on one hand and to increase the expression of
Bcl-2 as a anti-apoptotic protein on the other hand.
A-252AGA Abstracts
S1705
Early Feeding in Acute Pancreatitis in Rats
Ryan T. Hurt, Paul J. Matheson, Chester J. Mays, El rasheid Zakaria, Stephen A. Mcclave,
Richard N. Garrison
Introduction: Patients with acute onset pancreatitis (AP) often have long hospital stays
complicated by infection, multiple organ failure and death with a mortality rate nearing
30%. Clinical studies show that early enteral feeding in AP improves clinical outcome. We
investigated whether these benefits might be related to enhanced gastrointestinal blood flow
from enteral feeding with control diet (CD) and whether immune-enhancing diet (IED)
might amplify this effect. Methods: AP was initiated in male Sprague-Dawley rats (200-
220g) via intraperitoneal injection of cerulein (50 microg/kg BW X2, 1 hr apart, total volume
1 cc NS). Whole organ blood flow was measured by the colorimetric microsphere technique
with phantom organ control at 20 and 24 hours after the onset of pancreatitis in three
groups (n=8/group): 1) AP with no feeding (NPO); 2) AP + intrajejunal (IJ) placement of
CD (10 cc/4 hours, Pro-Balance, Nestle, Glendale, CA); and 3) AP + IED (10 cc/4 hours IJ,
Crucial, Nestle). Results: The effect of AP was decreased blood flow to the splanchnic
circulation as evidenced by significant decreases in splenic and small intestinal (1st third)
blood flow, with a compensatory hyperemia in the antrum. The CD reversed this effect as
evidenced by maintained blood flow throughout the splanchnic circulation. Conversely, IED
exacerbated this effect of AP as evidenced by decreased blood flow in the first and last thirds
of the small intestine, the spleen and the pancreas. Conclusions: These results show that
AP might jeopardize gut integrity by reducing blood flow to the splanchnic circulation (with
the exception of a compensatory hyperemia to the stomach or reverse steal effect). While
the CD appeared to reverse this effect by maintaining blood flow to all segments of the GI
tract, the IED amplified the effect of AP with further reduction of splanchnic blood flow.
These data suggest that early feeding of the gut during AP might be protective via modulation
of organ blood flow and this blood flow effect depends on the diet's nutrient composition.
S1706
Effects of Toll-Like Receptor 4-Deficiency in the Pathophysiology of
Experimental Severe Acute Pancreatitis
Hidehiro Sawa, Takashi Ueda, Yoshifumi Takeyama, Takeo Yasuda, Makoto Shinzeki,
Takahiro Nakajima, Kozo Takase, Yoshikazu Kuroda
Purpose. In severe acute pancreatitis (SAP), multiple organ dysfunction syndrome in the
early phase and infectious complications (infected pancreatic necrosis and sepsis) in the late
phase are two major contributors to the high mortality. Toll-like receptor 4 (TLR4) recognizes
lipopolysaccharide of gram-negative bacilli, and is involved in inflammatory response and
host defense mechanism. We reported that expressions of TLR2 and TLR4 on alveolar
macrophages were diminished in experimental SAP in DDW 2004. Then, we demonstrated
that expressions of TLR2 and TLR4 in intestinal mucosa were increased in the early phase
and thereafter were decreased in experimental SAP in DDW 2006. This study aimed to
examine the effects of TLR4-deficiency in mice SAP. Methods. Female C3H/HeN (wild-type)
and C3H/HeJ (TLR4-deficeient) mice (weighing 20-22g, 9 weeks old) were used. SAP was
induced by creating closed duodenal loop (2 cm in length). Severity of pancreatitis (HE
staining of pancreas and serum amylase level), organ dysfunction (liver and kidney), and
bacterial translocation to pancreas were evaluated 12 hours after induction of SAP, and were
compared between two types of mice. Results. HE staining of the pancreas showed edema,
hemorrhage, leukocyte infiltration, and necrosis in both wild-type and TLR4-deficient mice,
but there was no significant difference in the histopathological findings. Serum amylase
levels were elevated in both wild type mice (52,155 ± 14,449 IU/L) and TLR4-deficient
mice (49,912 ± 3,877 IU/L), but significant difference was not observed. Serum AST, ALT,
BUN and creatinine were significantly elevated in both wild-type and TLR4-deficient mice
SAP compared with sham group, buy they were significantly lower in TLR4-deficient mice
SAP than those in wild-type mice SAP. Bacterial translocation to pancreas could be detected
12 hours after the induction of SAP. In wild-type mice SAP, 55% of mice exhibited positive
bacterial culture. Whereas 80% of mice showed positive bacterial culture in TLR4-deficient
in mice SAP. In particular, positive rate of gram-negative bacterial culture in TLR4-deficient
mice SAP (80%) was significantly higher than that in wild-type mice SAP (35%). Conclusions.
We demonstrated that TLR4 deficiency attenuated the hepatic and renal dysfunction, and
aggravated the gram-negative bacterial translocation in SAP. These results suggest that TLR4
is implicated in the mechanism of organ dysfunction and bacterial translocation in SAP, and
that TLR4 may facilitate the inflammatory response and function defensively against infection.
S1707
Deactivation of LPS/Toll-Like Receptor 4 (TLR4) Signaling in Patients with
Severe Acute Pancreatitis
Akihiko Satoh, Tooru Shimosegawa
Background and Aims: Infectious complication in severe acute pancreatitis is associated with
significant morbidity and mortality. Although the reduced responsiveness in peripheral blood
mononuclear cells (PBMC) toward bacteria during pancreatitis may be linked to subsequent
development of sepsis, the signaling mechanism mediating the deactivation is poorly under-
stood. Toll-like receptor 4 (TLR4) is involved in the recognition of bacterial products and
thus participates in the induction of the immune and inflammatory cascade. The aim of the
present study was to determine the underlying signaling mechanisms by which TLR4 mediat-
ing pathway modulates the immune responses of PBMC in pancreatitis. Methods: Patients
with acute pancreatitis were prospectively enrolled. At admission, the PBMC were freshly
isolated from patients with mild pancreatitis (n = 13), severe pancreatitis (n= 12) or healthy
controls (n=13). We determined the expression of TLR4 in monocytes by FACS after staining
with specific antibodies. The other set of experiments, PBMC were incubated with or without
a TLR4 ligand (LPS 100 ng/mL), and the TNF-α release and the NF-κB activation were
assayed by ELISA and by immunoblotting, respectively. Expression of myeloid differentiation
factor 88 (MyD88), a critical adaptor protein in mediating TLR4 signaling was also assayed by
immunoblotting. Results: PBMC from patients with severe pancreatitis exhibited significantly
(P<0.05) lower TNF-α release in response to LPS stimulation (1.6 fold increase over LPS
untreated) than healthy controls (3.2 fold increase). Immunoblotting revealed that LPS
induced degradation of IκBα in PBMC from both controls and mild pancreatitis patients in
a time dependent manner whereas no significant changes in IκBα were observed in cells
from severe pancreatitis. Notably, the expression of TLR4 and MyD88 level in the cells from
severe pancreatitis were indistinguishable from those in controls. Conclusion: These results
demonstrate that the deactivation of PBMC occurs in patients with severe pancreatitis but
not mild pancreatitis. The impaired responses to LPS occur at the level of neither TLR4
expression nor MyD88, and other mechanisms must be involved.
S1708
Calcium and Reactive Oxygen Species Regulate Mitochondrial Mediators of
Acinar Cell Death in Experimental Pancreatitis
Irina Odinokova, Olga A. Mareninova, Kip Herman, Yuri V. Evtodienko, Aleksander
Andreyev, Anna S. Gukovskaya
Background and Aims: Acinar cell death is a key pathologic response of pancreatitis; however,
its mechanism remains poorly understood. We recently showed that mitochondrial permeabi-
lization associated with cytochrome c release is an early event mediating death responses
of pancreatitis. Cytochrome c release mediates apoptosis, whereas mitochondrial depolariza-
tion may lead to necrosis. In this study we determined the regulation of cytochrome c release
and the mitochondrial membrane potential (DYm) by Ca2+ and reactive oxygen species
(ROS), both in isolated pancreatic mitochondria and in pancreatic acinar cells hyperstimulated
with CCK-8 (CCK). Methods: In isolated rat pancreatic mitochondria we measured DYm
with TPP+ electrode and TMRM fluorescence; respiration, with Clark electrode; and ROS
levels, with Amplex-Red. In rat acinar cells stimulated with 100 nM CCK-8 we measured
apoptosis, necrosis, and mitochondria ROS using TUNEL assay, LDH release, and confocal
microscopy of DHR 123 labeled cells, respectively. Cytochrome c release was measured by
Western blot. Results: Exogenous superoxide producer KO2 or exogenous H2O2 (up to 1
mM) had little effect on DYm. In contrast, Ca2+ dose-dependently (0 to 6 µM) depolarized
pancreatic mitochondria. Cytochrome c release from mitochondria was stimulated by KO2
and blocked by mitochondrial ROS inhibitors (DPI, rotenone, and CCCP), indicating a
mediatory role of ROS. Ca2+ had a dual effect on cytochrome c release from isolated
pancreatic mitochondria: it was stimulated at Ca2+ concentrations up to ~1.3 mM and
inhibited at higher Ca2+ concentrations. We found that the inhibition is due to the loss of
DYm at higher Ca2+ concentrations, which blocked the mitochondrial ROS production
required for cytochrome c release. Consistent with the results on isolated mitochondria, the
sustained increase in cytosolic Ca2+ in acinar cells hyperstimulated with CCK mediates
mitochondrial depolarization. In turn, the Ca2+ induced loss of DYm leads to acinar cell
necrosis. On the other hand, increases in Ca2+ and ROS are both required for cytochrome
c release and subsequent apoptosis in CCK-treated cells. Conclusions: The results indicate
that mitochondria are major targets for the pathologic Ca2+ response and oxidative stress,
key events in pancreatitis. The interplay between Ca2+-induced mitochondrial depolarization
and ROS is a critical determinant of the pattern of death responses in pancreatitis. Ca2+
and ROS stimulate cytochrome c release leading to apoptosis, whereas Ca2+-induced depolar-
ization counteracts apoptosis by inhibiting cytochrome c release, and shifts the death response
towards necrosis.
S1709
Galanin Receptor Antagonist M35: A Potential Pharmacological Treatment for
Acute Pancreatitis
Masahiko Kawamoto, Mayank Bhandari, Anthony C. Thomas, Colin J. Carati, James
Toouli, Gino T. Saccone
Acute pancreatitis (AP) is characterized by microcirculatory and secretory disturbances which
contribute to ischemia and necrosis of the pancreas. To date, there is no specific treatment
for AP. We have provided evidence that galanin plays a role in AP-induced hyperenzymemia
and vascular perfusion changes in a possum model 1. Aim: Given that ischemia is the key
event in AP, we determined if administration of the galanin antagonists M35 and M40 would
ameliorate AP in a caerulein mouse model. Methods: AP was induced in male Swiss mice
by 7 hourly intraperitoneal (i.p.) injections of caerulein (50µg/kg). M35 or M40 (20 or
40nmol/kg in saline) were administered i.p. with each caerulein injection (n=4-6/group).
Mice in control groups (n=3-4/group) received either M35 or M40 (40nmol/kg) or saline.
The pancreata were harvested at 12 hours for histological examination and estimation of
myeloperoxidase (MPO) activity. Pre- and post-treatment plasma amylase and lipase activities
were measured. Data were statistically analyzed by ANOVA. Results: M35 (40nmol/kg)
reduced plasma amylase and lipase activities in AP mice to 53% and 34% of the levels in
the AP alone group, respectively (P<0.05) whereas M40 was without effect. Administration
of M35 or M40 alone did not significantly alter the activity of plasma amylase or lipase
above baseline values. M35 (40nmol/kg) but not M40 reduced MPO activity to 57% of the
level in the AP alone group (P<0.05). Importantly only M35 treatment in AP mice significantly
reduced the necrosis score by 29% compared with the AP alone group (P<0.05). Conclusion:
Treatment with the galanin antagonist M35 reduced pancreatic hyperenzymemia, MPO
activity and pancreatic necrosis induced by AP. These data support our contention that the
galanin antagonist M35 may offer a new therapeutic approach to AP. The support of
Flinders Technologies and Bio Innovation SA are acknowledged. 1 Bhandari M et al., Galanin
antagonism, modifies acute pancreatitis(AP)-induced hyperenzymemia and pancreatic vascu-
lar perfusion changes in a possum model. J Gastroenterol Heptol 21 (suppl: 4), A354, 2006.
A-253 AGA Abstracts
S1710
Possible Role of Peroxisome Proliferator-Activated Receptor Alpha (Ppar-α) in
Anti-Inflammatory Actions of Perfluorooctanoid Acid (Pfoa) in Experimental
Acute Pancreatitis
Thomas Griesbacher, Beate Tiran, Bernhard A. Peskar
Perfluorooctanoic acid (PFOA) has been shown to exert anti-inflammatory effects in models
of cutaneous inflammation. It has also been suggested that activation by PFOA of peroxisome
proliferator-activated receptor alpha (PPAR-α) provides the explanation for the effects of
PFOA at least in these models. We have therefore investigated whether PFOA would also
exert similar effects in a model of acute edematous pancreatitis and whether an agonism at
PPAR-α could be involved in these effects. Acute pancreatitis was induced in anesthetized
rats by i.v. infusion of the CCK analogue, cerulein (4 nmol/kg/h for 2 h). PFOA (150 mg/
kg) or the PPAR-α agonist clofibrate (10-100 mg/kg) were injected s.c. 30 min before the
cerulein infusion. Rats were sacrificed 2 h after the end of the infusion and tissue samples
were excised for the determination of pancreatic oedema, leukocyte activation and release
of prostaglandin (PG) E2, 6-keto-PGF1α and thromboxane (TX) B2. Pancreatic-type amylase
and lipase were measured both in the blood serum and in the pancretic tissue. Cerulein
induced acute edematous inflammation of the pancreas, associated with a significant accumu-
lation of activated leukocytes in the tissue (160,310 ± 47,910/mg protein) and a stimulation
of the synthesis of PGE2 (13.5 ± 4.1 pg/mg dry wt/10 min), 6-keto-PGF1α (113.9 ± 16.9
pg/mg d.w./10 min) and TXB2 (38.5 ± 9.0 pg/mg d.w./10 min). PFOA had no effect on the
inflammatory edema but significantly (p<0.05) reduced activated leukocytes (41,330 ± 9,970/
mg protein), PGE2 (4.8 ± 0.3 pg/mg d.w./10 min), 6-keto-PGF1α (46.6 ± 13.7 pg/mg d.w./
10 min) and TXB2 (12.9 ± 1.7 pg/mg d.w./10 min). In comparison, clofibrate had no effect
on edema formation or leukocyte activation, but significantly (p<0.05) and almost completely
inhibited prostanoid synthesis when administered at a dose of 100 mg/kg (PGE2: 3.8 ± 0.9
pg/mg d.w./10 min; 6 keto-PGF1α: 8.3 ± 3.9 pg/mg d.w./10 min); The lower dose of
clofibrate, however, had no significant effects. Neither PFOA nor clofibrate had significant
effects on amylase or lipase activities in the blood serum or in the pancreatic tissue. In
summary, PFOA attenuates the accumulation of activated leukocytes in the pancreatic tissue
and reduces the synthesis of prostanoids in cerulein-induced acute pancreatitis. However,
unlike its action in cutaneous inflammation, PFOA does not affect edema formation. An
activation of PPAR-α seems to be involved in the stimulation of prostanoid synthesis during
acute pancreatitis, but does not seem to be involved in the other parameters that were investig-
ated.
S1711
Acute Pancreatitis Increases the Excitability of Brainstem Vagal Circuits
Shuxia Wan, Kirsteen N. Browning, R. alberto Travagli
Recent evidence suggest that inflammatory states increases the excitability of gastrointestinal
sympathetic (dorsal root ganglia) and parasympathetic (nodose ganglia) sensory neurons.
We hypothesize that this increase in excitability may also affect the responsiveness of
vagal brainstem circuits to neurotransmitters/neuromodulators. Cholecystokinin (CCK-8s)
is involved in pancreatic vago-vagal circuits and we have shown recently (AmJPhysiol. 2005
and 2006; JNeurophysiol. 2005) that CCK-8s also acts directly at the level of gastrointestinal
related brainstem neurocircuitry. The aims of this study were to investigate whether the
response of vagal motoneurons to CCK-8s was altered following caerulein-induced acute
pancreatic inflammation. Whole cell patch clamp recordings were made from 110 identified
pancreas-projecting vagal motoneurons from control and rats in which acute pancreatitis
was induced by intraperitoneal injections of 100μg/kg caerulein. In the current clamp
configuration, CCK-8s induced a concentration-dependent increase in firing rate (threshold
1nM, EC50=50nM); following acute pancreatitis, there was a leftward shift in the response
to CCK-8s such that the response threshold to CCK-8s administration was 0.1nM and the
EC50 was 3nM. In both control and acute pancreatitis, the CCK-8s mediated excitation was
mediated via actions at the CCK-A receptors on DMV neuronal membrane since the effects
were antagonized by pretreatment with lorglumide (1μM), not mimicked by perfusion with
CCK-non sulfated (1μM). CCK-8s increased excitatory synaptic transmission between the
NTS and the DMV in both control and acute pancreatitis rats; however, the percentage of
presynaptically responding cells (40% in control vs 83% following pancreas inflammation)
was significantly increased as was the magnitude of the response (200±19% in control, N=
8, vs 567±187% in acute pancreatitis, N=10, rats). These data indicate that the acute
inflammation induced by caerulein increases the responsiveness of brainstem pancreatic
vagal circuits to CCK-8s and suggests that the brainstem may have a role in the visceral
responses to acute inflammatory states. Supported by PBRC foundation
S1712
The Role of Acinar Cell AMP-Dependent Protein Kinase (AMPK) in Acute
Pancreatitis
Alexander P. Diaz de villalvilla, Edwin C. Thrower, Thomas R. Kolodecik, Fred S.
Gorelick
Premature activation of digestive enzyme proteases (zymogens) in the acinar cell is a hallmark
of acute pancreatitis. Acidification of cellular compartments is required for this activation
and appears to be mediated by a multisubunit vacuolar ATPase (V-ATPase). Activation of
the V-ATPase requires assembly of its soluble V1 subunits on its membrane V0 subunits.
Factors that regulate this assembly and V-ATPase activation are poorly understood. Acute
pancreatitis involves ischemia, causing ATP consumption and increasing the AMP:ATP
ratio. AMP-dependent protein kinase (AMPK) is activated by increases in AMP:ATP. We
hypothesize that AMPK is involved in the assembly/activation of the V-ATPase under the
conditions seen in acute pancreatitis. To examine this issue, isolated rat pancreatic acini
were hyperstimulated with 10-7M caerulein to cause zymogen activation. V-ATPase assembly
was assayed using cell fractionation and immunoblot analysis. Trypsin and chymotrypsin
activity were measured using fluorogenic substrates. Caerulein hyperstimulation was observed
to cause both protease activation and V-ATPase assembly. When treated with Compound
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C, a specific AMPK inhibitor, caerulein-dependent protease activation increased two-fold.
AMPK inhibition was associated with enhanced assembly of the V-ATPase. Finally, stimulation
of AMPK activity by an exogenous agonist, AICAR, caused a decrease in V-ATPase assembly.
These results suggest that AMPK may have a protective role in acute pancreatitis by inhibiting
the assembly of the V-ATPase, and decreasing the potential extent of zymogen activation.
S1713
Extracellular pH Modulates Cerulein-Induced Zymogen Activation Through a
Vacuolar ATPase in Pancreatic Acinar Cells
Madhavi Bhoomagoud, Thomas R. Kolodecik, Christine A. Shugrue, Edwin C. Thrower,
Fred S. Gorelick
An early step in acute pancreatitis (AP) is premature zymogen (protease) activation. Data
published from our laboratory suggest that zymogen activation is mediated via a vacuolar
ATPase (vATPase). Activation of vATPase involves translocation of the soluble peripheral
domain (V1) to the integral membrane domain (V0), whereupon assembly occurs. We
hypothesize that zymogen activation occurs within the same compartment where vATPase
is located. Given that clinical studies have shown a correlation between decreased extracellular
pH (pHe) and AP, we further hypothesize that pHe effects on zymogen activation are
dependent on vATPase activity. We induced aberrant zymogen activation in isolated pancre-
atic acinar cells with hyperstimulatory concentrations [10-7M] of the cholecystokinin ana-
logue cerulein (CER). After CER stimulation In Vivo, immunofluorescence studies show a
redistribution of the membrane bound vATPase (V0) toward the apical pole of the cell where
it co-localizes with cellular compartments containing trypsinogen activation peptide (TAP),
a marker of zymogen activation. Chymotrypsin and trypsin activity was measured In Vitro
using spectrophotometric assays with specific fluorogenic peptide substrates. Medium acid-
ification (pHe from 7.6 to 6.8) dramatically sensitizes cells to CER-induced protease activa-
tion, but does not affect basal protease activation. Changes in pHe did not affect CER-
stimulated secretion in acinar cells. Additionally, induction of intracellular acidosis (low
pHi) by the addition of sodium propionate to CER-stimulated acinar cells caused a much
greater activation of both trypsin and chymotrypsin compared to changing pHe alone.
Inhibition of the vATPase using bafilomycin or concanamycin (100nM) is most pronounced
at low pHe (pH 6.5-7.0). At more alkaline pHe, the vATPase inhibitors either have no
significant effect (pHe 7.5), or cause an increase in protease activation at pHe 8.0. In
conclusion, these studies suggest that zymogen activation occurs in compartments containing
assembled vATPase. Zymogen activation is enhanced considerably at both low pHe and pHi,
conditions mimicking metabolic acidosis, and appears to be mediated by the vATPase. These
findings may be relevant to the pathogenesis of AP.
S1802
The Prevalence of Barrett's Esophagus in Children and Adolescents: A
Prospective Multi-Center Study
Mark A. Gilger, Hashem B. El-serag, Kenn W. Fairly, Mitchell D. Shub, Mark J. Integlia,
Peter A. Richardson, Nina Tatevian
The prevalence of Barrett's esophagus (BE) in children is unclear. There have been no
prospective studies that have examined this issue. An estimate of the prevalence of suspected
BE in children and adolescents obtained from retrospective studies is approximately 2.5/
1000. Purpose: To estimate the prevalence of suspected and proven BE in children and
adolescents undergoing upper endoscopy. Methods: A prospective, multi-center study using
the Pediatric Endoscopy Database System - Clinical Outcomes Research Initiative (PEDS-
CORI). All children 0 to 18 years undergoing diagnostic upper endoscopy for any reason
were asked to enroll. We collected information on several potential risk factors. Endoscopic
procedures were standardized by (1) measuring the distance from the upper incisors to the
Z-line, (2) measuring the distance from the upper incisors to the proximal lesion, (3)
determining the Los Angeles Classification of esophageal erosions, (4) photographing the
lesion (if any) and the gastroesophageal junction. Live case orientation sessions were held
prior to initiating the study with all participating endoscopists (24) in all three children's
hospitals (Texas Children's Hospital, Phoenix Children's Hospital, Barbara Bush Children's
Hospital). 4 quadrant biopsies were obtained from each centimeter of suspected BE. Two
pathologists blinded to the endoscopic findings or risk factors independently evaluated all
biopsies. All slides were triple stained with hematoxylin & eosin, alcian blue and a modified
silver stain. Confirmed BE was defined as the presence of goblet cells characteristic of
intestinal metaplasia. Results: Most (91%) of children undergoing diagnostic endoscopy
agreed to participate. To date, 393 children aged 9.9 +/- 4.9 have been enrolled. Only 1.5%
had cerebral palsy and 4.3% had mental retardation. The main complaints were heartburn
(27%), regurgitation (30%), vomiting (37%), and poor weight gain (29%); multiple com-
plaints may have been present in the same person. Three cases of suspected BE have been
identified (3/393=8/1000, 95% CI 2/100 to 3/1000). One case of suspected BE had intestinal
metaplasia (1/393, 2.5/1000, 95% CI 1% to 4/1000). Conclusions: Endoscopically suspected
BE is rare in children and adolescents (8/1000). Intestinal metaplasia in these areas is unusual
(overall 2.5/1000). These preliminary results suggest that vigorous standardization for the
identification and recording of endoscopic landmarks does not appreciably alter recent
retrospective prevalence estimates of BE in children.
S1803
The Prevalence, Incidence, and Cost of Diagnosing Dysplasia in Patients with
Barrett's Esophagus in a Community Practice
Anne M. Breitinger, Nitesh Ratnakar, Nalini Guda, Ahmad B. Shughoury, Nimish Vakil
Introduction: Studies on the cost of diagnosing dysplasia or cancer in Barrett's esophagus
are sparse and biased towards tertiary centers. The available data may be skewed towards
more severe patients. The aim of this study was to determine the yield of a surveillance
program for Barrett's esophagus in community practice and to estimate the cost of diagnosing
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dysplasia or cancer. Methods: The computerized databases of all operative procedures per-
formed at two large community-based teaching hospitals in Milwaukee, WI were ana-
lyzed(1000 beds combined). Patients with a diagnosis of Barrett's esophagus from 1996 to
2005 were identified using ICD codes. Both the endoscopic report and histopathological
findings were reviewed individually to confirm the endoscopic picture and the presence of
intestinal metplasia. The prevalence of dysplasia at the first endoscopy and the incidence
of endoscopy over follow-up were determined. Assuming a cost for endoscopy plus biopsy
to be $500(based on Wisconsin Medicare costs for physician and facility), costs were
calculated for every diagnosis of cancer and dysplasia. Results: A total of 1299 endoscopies
were performed over the 10 year study period in patients with biopsy confirmed Barrett's
esophagus(i.e. with specialized intestinal metaplasia). There were 667 patients undergoing
their first endoscopy at which a diagnosis of Barrett's esophagus was made. 21 had low
grade dysplasia, 5 had high grade dysplasia and 2 had esophageal adenocarcinoma. 305
patients underwent a second(surveillance) endoscopy and a total of 14 new low grade
dysplasias and 1 new adenocarcinoma were found. No high grade dysplasias or cancers
were found at surveillance endoscopy #3(n=148), endoscopy #4(n=99), endoscopy #5(n=
40) and endoscopies #6-8(n=40). The total estimated cost of these procedures in patients
with Barrett's esophagus was $649,500 and the cost to diagnose one case of high grade
dysplasia was $129,900 and one adenocarcinoma was $216,500. Conclusions: 1. Adenocarci-
noma and high grade dysplasia are usually diagnosed at the index endoscopy or at the first
surveillance endoscopy. 2. The yield of continued endoscopic surveillance is low beyond
the second surveillance endoscopy. 3. The cost per diagnosed case is very high and would
be higher if the costs of screened patients with chronic GERD who did not have Barrett's
esophagus were added to these costs. 4. As with colonoscopy, the yield at the first endoscopy
may exceed the yield at later time-points and reallocation of resources to the initial endoscopy
may be a better use of them.
S1804
Assessment of Fluorescence in Situ Hybridization, Digital Image Analysis and
Routine Cytology for Cytologic Barrett's Esophagus Specimens
Shannon Brankley, Emily G. Barr-fritcher, Michael B. Campion, Mona Legator, Lori S.
Lutzke, Jesse S. Voss, Benjamin R. Kipp, Larry E. Morrison, Thomas J. Sebo, Kenneth K.
Wang, Kevin C. Halling
Background: The goal of this study was to assess the relative sensitivity and specificity of
fluorescence in situ hybridization (FISH), digital image analysis (DIA) and routine cytology
(RC) of endoscopic brushing specimens obtained from patients being evaluated for Barrett's
esophagus (BE). Patients with BE are 30 to 125 times more likely than the general population
to develop esophageal cancer. Methods: One hundred nine esophageal brushing specimens
were taken at the time of biopsy from 97 males and 12 females (Mean age: 65 years; Range:
34-87) with a history of biopsy-proven BE. FISH was performed using probes for 8q24 (C-
MYC), 9p21 (p16), 17q11 (HER2), and 20q13. One hundred consecutive non-inflammatory,
non-squamous cells were analyzed per specimen. All observed signal patterns were recorded
and a percentage of abnormal cells was calculated. Specimens exceeding the previously
determined thresholds for polysomy, tetrasomy, single locus gain, or 9p21 loss were inter-
preted as positive. DIA slides were Feulgen-stained and analyzed by collecting the 50 most
abnormal appearing cells. DIA histograms were interpreted for ploidy status (diploid, near-
diploid, aneuploid, or tetraploid). RC slides were prepared with the ThinPrep method,
stained with a PAP stain, and interpreted as negative, atypical, suspicious, or positive for
cancer by an experienced cytopathologist. Histologic classification of the tissue was used as
the gold standard for determining sensitivity and specificity.Results: See Table.Conclusions:
FISH was shown to be more sensitive than DIA and RC while maintaining comparable
specificity. These data suggests that FISH, using probes for 8q24 (C-MYC), 9p21 (p16),
17q11 (HER2), and 20q13 may be a useful method for the detection of esophageal dysplasia
and adenocarcinoma in patients with BE. Further studies will be needed to evaluate its
utility for the detection of BE associated neoplasia.
1Aneuploid and tetraploid results were considered positive for cancer 2Suspicious and positive
results were considered positive for cancer *Statistical difference (P<0.01) between FISH
and DIA/RC **No statistical difference (P>0.05) between FISH and DIA/RC
S1805
Large-Scale Prospective Study Reveals Novel Risk Factors for Barrett's
Oesophagus
Angela Wong, Laurence B. Lovat, Rodney Burnham, Allan Hackshaw, Rebecca Fitzgerald
Introduction: Barrett's esophagus (BE) is the precursor lesion for esophageal adenocarcinoma
(AC), which is rapidly rising in incidence. Most AC patients present de novo without the
opportunity for surveillance as their BE has not been diagnosed. Hence the epidemiological
risk factors associated with BE would be clinically useful in determining a Barrett's predictor
model, with the utility for determining which patient group to screen by endoscopy and
biopsy. To date symptom nomograms have not been sensitive or specific enough for clinical
use. Methods: A modified validated questionnaire was used to investigate the epidemiological
factors that may be associated with BE in consecutive patients attending upper gastrointestinal
endoscopy for all indications. Unselected patients between 18-75 years were recruited
prospectively in 3 UK centers: Addenbrooke's Hospital, Cambridge, Oldchurch Hospital,
Essex and University College London Hospital, London following Multi centre Research
Ethics Committee approval (MREC 01/5/51). Results: 1823 patients were recruited, 904
were male (M) and 919 female (F). 119/1823 (6.5%) patients were found to have a new
diagnosis of BE, 78M and 41F. The significant findings on univariate and multivariate logistic
regression analysis are summarized in Table 1. Smoking at various time points was not
associated with BE. Conclusion: In this large prospective epidemiological study, multivariate
analysis has shown that increasing age, male sex, duration of reflux symptoms and nocturnal
symptoms are associated with a diagnosis of BE. Although current alcohol consumption was
not associated with BE, at age thirty, drinking >10 units was associated with an astonishing
OR of 30.32 on univariate analysis, supporting the hypothesis that this may act as an initiator
of BE. Interestingly, eating smaller meals more often was associated with a reduced OR of
BE, suggesting that adopting this lifestyle measure may be efficacious in reducing reflux and
BE prevention. BE risk factors are multi-factorial and large patient numbers are required to
demonstrate factors with relatively small ORs.
Table1: Significant risk factors on uni- and multivariate analysis
S1806
Patient Preferences for Chemoprevention in Barrett's Esophagus
Chin Hur, Darcy E. Broughton, Elissa Ozanne, Norman S. Nishioka, G scott Gazelle
BACKGROUND: Although evidence suggests that aspirin and celecoxib may diminish the
risk of esophageal adenocarcinoma (ECA) in patients with Barrett's esophagus (BE), the
potential benefit of these drugs come at the cost of potential harms, most notably the
increased risk of cardiovascular events associated with celecoxib. The purpose of this study
was to determine and characterize patient preferences for the use of these two chemopreven-
tive agents in patients with BE. METHODS: Patients with Barrett's esophagus were recruited
in a large urban hospital prior to a clinic or endoscopy appointment. Data on individual
preferences were collected using a specialized questionnaire administered by an investigator.
The questionnaire incorporated standard risk communication techniques to create a prefer-
ence-threshold elicitation procedure. Participants were provided summary profiles outlining
the lifetime benefits and harms of celecoxib and aspirin (presented anonymously as Drug
A and B). Both celecoxib and aspirin were portrayed as reducing the risk of ECA and
increasing the risk of GI events. However, taking celecoxib would increase the risk of heart
attack (HA) while aspirin would reduce this risk. Participants were then asked if they would
be willing to take each drug. Depending upon the original choice, subjects responded to a
series of binary, follow-up questions where the harm-benefit ratios were altered in a ‘ping-
pong' fashion to determine conditions under which a patient might be willing to take the
two drugs. RESULTS: 109 were asked to participate and 100 subjects (92%) completed the
survey. The mean age was 64 with 28% female and 72% male. Under base conditions, 15%
stated that they would take celecoxib and 76% would take aspirin. Acceptability threshold
exploration found that participants, on average, would be willing to take celecoxib if it
would reduce the future risk of ECA by >83% or if it did not increase the risk of HA by
>16%. Patients would take aspirin if it reduced the future risk of ECA by >33% or if it
decreased the risk of HA by >23%. The most important factor regarding celecoxib use was
the increased risk of HA, and for aspirin, the reduced risk of ECA. CONCLUSIONS: A
majority of those surveyed stated that they would take aspirin but would not take celecoxib.
The increased risk of HA and the decreased risk of ECA were the most important factors
determining celecoxib and aspirin use, respectively. These data can serve to inform physicians
regarding the variability of patient preferences contemplating these drugs for ECA chemoprev-
ention in Barrett's esophagus.
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S1807
Preservation of the Functional Integrity of the Distal Esophagus After
Circumferential Ablation of Barrett's Esophagus
Hanneke Beaumont, Jacques J. Bergman, Roos E. Pouw, Joep J. Gondrie, Carine
Sondermeijer, Hans Gregersen, Barry P. Mcmahon, Guy E. Boeckxstaens
Background: Balloon-based circumferential ablation (CA) and endoscope-mounted focal
ablation (FA) are promising new ablative modalities for Barrett esophagus (BE) with high-
grade dysplasia (HGD). Previous studies suggest that CA and FA, contrary to other ablative
techniques, do not result in significant scarring or stricture formation. Aims: Measure
esophageal inner diameter (E-ID) and perform manometry and impedance planimetry (IP)
to assess esophageal motility and compliance before and after CA plus FA for BE-HGD.
Methods: Ten patients (8 male, median age 72 yrs) with BE-HGD (median length 7 cm
(IQR 6-10)) were included. A balloon-based electrode (HALO360 System, BÂRRX Medical,
Sunnyvale, CA, USA) was used for primary CA and an endoscope-mounted electrode
(HALO90 System) for secondary FA of residual BE. Measurement of E-ID, manometry and
IP were performed at baseline and 2 months after final ablation session. E-ID measurement
was obtained every 1 cm of the distal 10 cm of esophagus with a non-compliant balloon
(HALO360 System) and an automated pressure/volume system. Manometry was performed
using a 10 channel water perfused sleeve catheter. IP was performed using a functional
lumen imaging probe (FLIP) that measures 8 cross sectional areas (CSA) at 4-mm intervals
inside a saline-filled bag with 2 pressure side holes; one proximal to and one inside the
bag. The FLIP was positioned with the bag straddling the gastroesophageal junction (GEJ).
The bag was filled with saline (25 ml/min, max 60 ml). Bag pressure and CSA were recorded
at a rate of 10Hz. Results: All patients had complete eradication of dysplasia and 9 had
complete eradication of IM. There were no strictures or narrowing noted on final endoscopy.
E-ID did not change; pre 31.5mm (IQR 25-33 mm), post 31.3mm (IQR 29-33 mm)(p=NS,
paired Student t-test). LES pressure did not change (pre 4.0 ± 0.4 mm Hg; post 5.5 ± 1.2
mm Hg, p=NS), nor did the amplitude of peristaltic contractions per measured segment
(pre 41.2 ± 11.1 mmHg; post 46.2 ± 9.9 mmHg, p=NS). IP showed no significant change
in compliance; narrowest CSA pre 147 ± 12.4 mm2 with a mean bag pressure of 16.0 ±
0.7mmHg; narrowest CSA post 118 ± 5.6 mm2 (p=0.08) with a mean bag pressure of 15.7
± 0.9mmHg (p=0.93). Conclusion: This is the first report on the effects of CA and FA
indicated for BE-HGD on the functional integrity of the treated esophagus. No difference
was seen in the esophageal inner diameter, motility function or compliance between baseline
and post-ablation measurements, suggesting that this method of ablation not only effectively
removes dysplasia and BE but also preserves the functional integrity of the esophagus.
S1808
Evaluation of Esophageal Capsule Endoscopy (Ece) Findings in
Gastroesophageal Reflux Disease (GERD) and Barrett's Esophagus (BE)
Patients: Are There Differences Between Experienced Gastroenterologists and
Trainees?
John A. Bonino, Amit Rastogi, Sachin B. Wani, Richard E. Sampliner, Ajay Bansal, Rashmi
A. Tadiparthi, Shailender Singh, Jason M. Sugar, Prateek Sharma
Background ECE is a novel technique that is being evaluated for screening GERD pts for
BE and erosive esophagitis (EE). Studies using ECE have reported variable accuracy rates
and the diagnostic skills or lack of experience of the examiner may be responsible. Aims
(1) To evaluate the sensitivity and specificity for detection of BE, EE and hiatal hernia (HH)
by experienced gastroenterologist (GI-A) and trainees (GI-T) using ECE (2) To investigate
whether accuracy rates improve as the number of procedures assessed increases. Methods
ECE procedures (PillCam ESO, Given Imaging, 14 frames/sec) performed at 2 centers were
utilized. All pts underwent standard upper endoscopy (EGD)following ECE; findings at EGD
considered as gold standard. ECE video clips were divided in 4 groups (Gp 1 to 4) with
an equal number of pts with BE, EE and HH in each group. GI-A (n=3,>2 yrs experience)
and GI-T (n=3,>150 EGDs) blinded to EGD results viewed the ECE clips in the 4 gps in a
sequential fashion. In a training session, representative clips were discussed and agreed upon.
Results 92 ECE procedures performed in pts for chronic GERD (n=40) or BE surveillance (n=
52) were utilized. The mean age was years 59.7 years and majority were males (91%). At
EGD, BE was confirmed in 45 patients with a mean length of 3.5 cm (range 0.5-11). EE
was diagnosed in 18 pts and HH in 70. There was no difference between GI-A and GI-T
in the mean sensitivity (70% vs. 65%) and specificity (84% vs. 85%) for the detection of
BE. Mean sensitivity and specificity for EE and HH detection is shown in the Table. The
mean sensitivity and specificity for detection of BE in the 4 groups for GI-A were 83% &
70% (Gp 1), 67% & 80% (Gp 2), 53% & 87% (Gp 3), and 77% & 92% (Gp 4). Similarly,
the mean sensitivity and specificity for detection of BE in the 4 groups for the GI-T were
66% & 92% (Gp 1), 72% & 87% (Gp 2), 56% & 77% (Gp 3) and 67% & 85% (Gp 4).
No significant improvement in detection of BE, EE or HH was identified as evaluations
progressed from Group 1-4. Conclusions This study demonstrates no significant difference
in sensitivity and specificity of ECE for detection of BE, EE and HH between GI-A and GI-
T. Also, there did not appear to be an improvement as the number of ECE studies reviewed
increased. Improvements in the ECE technology and ingestion protocol may further improve
the accuracy rates of ECE for BE and EE.
Values expressed as mean %
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S1809
Surveillance Using EMR and Biomarkers in Barrett's Esophagus with High
Grade Dysplasia: A Prospective Study
Ganapathy A. Prasad, Kenneth K. Wang, Navtej Buttar, Kevin C. Halling, Shannon
Brankley, Lynn S. Borkenhagen, Lori S. Lutzke
Rationale: Estimates of progression to carcinoma in HGD and BE vary, when using standard
surveillance protocols. Rates of progression in protocols utilizing EMR are unknown. The
role of biomarkers using FISH, in predicting progression has also not been investigated.
Aims: To define outcomes (incident carcinoma and persistent HGD) following endoscopic
surveillance with EMR and biomarkers in a prospective cohort. Methods: Patients with HGD
presenting to the BE Unit at Mayo Clinic and opting for endoscopic surveillance were
prospectively followed. All patients underwent protocol assessment with EGD, 4 quadrant
biopsies every centimeter, endoscopic mucosal resection (EMR) of visible nodules and EUS.
Patients subsequently underwent endoscopic surveillance every 3 months. Biomarkers were
assessed using FISH. Biomarkers assessed included: loss of 9p21 (p16 gene) and 17p13.1
(p53 gene) loci; gains of 8q24(c-myc), 17q (HER2-neu) and 20q13 loci. Respective centrom-
eric probes were also used to assess chromosome 9, 17, 20, and 8. Cells were also assessed
for loss or gain of chromosomes (aneusomy and polysomy). Demographic and clinical
variables were prospectively collected. Pathology was confirmed by two gastrointestinal
pathologists. Statistical analysis was performed using standard statistical tests to determine
rates and potential predictors of persistent HGD/progression to carcinoma. Results: 56
patients were followed for a mean duration of 22.6 months (SEM 1.55). 49 (88%) were
males, with a mean age of 67.5 years (SEM 1.6). Median BE length was 4 cm (IQR 2-7)
and 3 cm (IQR 0-6) at end of follow up. 51 patients (91%) underwent a median of 2 (IQR
2-5) EMRs. 13 (23%) of patients had persistent HGD. 5 patients developed carcinoma (4
intramucosal and 1 submucosal) during follow up: leading to a cumulative incidence of
8.9% over 22 months. The mean time to progression to cancer was 25 months (SEM
5.1; range 14 to 42 months). 2 patients underwent esophagectomy and 3 were treated
endoscopically (EMR and PDT in one patient). Patients developing cancer had statistically
significantly higher rates of loss of p53 (LOH) (p = 0.04), polysomy (p= 0.04) and loss of
the Y chromosome (p<0.01) when compared to those who did not develop cancer. Other
biomarkers (loss of p16 and gains of other loci) did not predict progression to cancer.
Conclusions: In this study, progression to carcinoma (defined by incident cancers) in patients
with HGD using a surveillance protocol including EMR appears to be lower than that
reported in the literature. Loss of p53, polysomy and loss of the Y chromosome when
detected by FISH may help to risk stratify patients with HGD.
S1810
Laser Confocal Microscopy (Lcm) As a Guide for Endoscopic Mucosal
Resection (EMR) in Barrett's Esophagus
Kenneth K. Wang, Michel Wongkeesong, Navtej Buttar, Ganapathy A. Prasad, Lori S.
Lutzke, Lynn S. Borkenhagen, Kelly Dungan
Laser confocal microscopy in an endoscope-based system with variable depth adjustment
and limited frame rate (2 per second) has been shown to be of value in diagnosis of dysplasia
in Barrett's esophagus. We evaluated a probe-based system with fixed depth resolution to
identify areas of Barrett's esophagus and dysplasia in a prospective study. Aim: To determine
the ability of a LCM probe to detect Barrett's mucosa and dysplasia for EMR in Barrett's
esophagus. Methods: This is a prospective cohort study of patients with Barrett's esophagus
who were referred to the Barrett's esophagus unit for endoscopic mucosal resection for
potential neoplasia in Barrett's esophagus. The mucosa surface of the Barrett's esophagus
was first cleansed with 20 milliliters of 10% acetic acid. Patients were given 10% fluorescein
5.0 milliliters intravenously approximately a minute prior to imaging with LCM (Mauna
Kea Technologies). A laser LCM probe was placed through the biopsy port and opposed to
the mucosa of interest. The LCM system scanned with a 488 nm laser at 14 frames per
second. After identification of areas of Barrett's esophagus with dysplasia, neoplastic areas
were removed using endoscopic mucosal resection using the cap technique (Olympus EMR-
001) while non-dysplastic areas were extensively biopsied with standard forceps in 4 quad-
rants every one centimeter. Results: 40 patients, mean age 69+2 years, with a Barrett's length
of 4+1 cm were studied. The LCM probe identified no Barrett's mucosa in 5 patients, 10
with Barrett's mucosa without dysplasia, 11 with low-grade dysplasia, 13 with high-grade
dysplasia, and 1 with cancer. A total of 14 mucosal resections were performed based on
the LCM. The histology revealed no evidence of Barrett's mucosa in 13, 5 with intestinal
metaplasia, 9 with low-grade dysplasia. 12 with high-grade dysplasia, and 1 with cancer.
The LCM agreed with histology in 29 cases (73%). LCM overstated dysplasia as compared
with histology (p<0.05). Sensitivity of LCM was 100% as no patient with intestinal metaplasia
was not diagnosed. Specificity for intestinal metaplasia was 77%. For dysplasia LCM was
81% sensitive and 74% specific. Conclusions: A probe based LCM system has reasonable
sensitivity and sensitivity to guide EMR. This system allows LCM to be applied through any
standard endoscope with real-time diagnostic capabilities.
S1811
Absence of Na+/Sugar Cotransport Activity in Barrett's Metaplasia
James M. Mullin, Lisa J. Murray, Mary carmen Valenzano, Marysue Whitby, Owen Tully,
David Rudolph, Giancarlo Mercogliano, James J. Thornton
The well documented, morphological intestinal phenotype and especially the presence of
sucrase-isomaltase on the apical surface of true (Alcian blue positive) Barrett's epithelia,
prompted our group to test for the presence of Na+-dependent, active sugar transport (SGLT
family) in Barrett's as a potential biomarker. Sodium-dependent sugar transport is a classic
biomarker of the small intestinal enterocyte. Our approach was to examine cellular uptake
of the nonmetabolizable glucose analog, alpha-methyl-D-glucoside (AMG), a substrate for
the entire SGLT family of transport proteins. Under an IRB-approved protocol, patients
known to have Barrett's esophagus, and presenting for upper endoscopy for screening
purposes, provided written informed consent for additional biopsies to be taken during the
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upper endoscopy. These biopsies, three each from duodenum, gastric fundus, and Barrett's
metaplasia or normal esophagus, were incubated in bicarbonate-buffered saline (KRB) con-
taining 0.1 mM 14C-AMG at 22oC for 60 minutes. Duodenum is known to have abundant
SGLT, and served as a positive control. Gastric fundus and normal esophagus served as
negative controls, these tissues known not to exhibit Na+/glucose cotransport activity. Biopsies
were copiously rinsed with 4oC KRB at the end of incubation to remove extracellular 14C-
AMG, then a wet weight was measured followed by addition of biopsy to 0.4M perchloric
acid for release of intracellular radioactivity, and precipitation (and later measurement) of
total DNA. Results were 24.98 picomoles/µg DNA +/- 3.55 picomoles/µg (SEM) for duodenum
(n = 12), 3.62 +/- 0.66 for gastric fundus (n = 12), 1.21 +/- 0.06 for normal esophagus
(n = 3) and 2.99 +/- 0.58 for biopsies of Barrett's metaplasia (n = 8). There was statistical
difference (P < 0.01) between duodenum and each other biopsy site but there was no
statistically significant difference between normal esophagus and Barrett's esophagus biopsies
(paired Student's t test). Relative results were the same when expressed as cpm/µg wet
weight. Additional biopsies were homogenized and sonicated in a detergent-free buffer,
pelleted and resuspended in a Triton-containing buffer or an SDS-containing buffer to
solubilize membrane-associated and cytoskeletal-associated proteins respectively. A poly-
clonal antisera to SGLT1 did not evidence any presence of SGLT in Barrett's tissue, supporting
the 14C-AMG uptake results. We conclude that in spite of the intestinal enterocyte phenotype
of certain Barrett's cell types, SGLT is not present in these cells. Supported in part by grants
from the Pa. Dept. of Heath and the Oncologic Fndn. of Buffalo.
S1812
High Fidelity DNA Histograms in Neoplastic Progression in Barrett's
Esophagus
Chenggong Yu, Xiaoqi Zhang, Qin Huang, Michael Klein, Raj K. Goyal
Background: This study describes the high fidelity DNA histograms in different stages of
neoplastic progression to Barrett's adenocarcinoma (BAC). Methods: High fidelity DNA
histograms were obtained with image cytometry on sections (ICS) and were classified based
on DNA index (DI) values of the peaks into diploid (DI=0.9-1.1), mild aneuploid (DI=1.1-
1.3), moderate aneuploid (DI=1.3-1.8), and severe aneuploid (DI&;1.8). Heterogeneity index
(HI) representing cells with different DNA content and the 5N exceeding cell fraction were
determined. Results: 187 cases, including 34 normal gastrointestinal mucosa (control), 66
Barrett's specialized intestinal metaplasia (SIM), 22 low grade dysplasia, 22 high grade
dysplasia and 43 BAC were investigated. Controls showed sharp diploid peaks with HI
values less than 13 and no 5N exceeding nuclei. SIM showed a spectrum of histograms
including diploid, mild aneuploid, and moderate aneuploid histograms. The frequency and
severity of aneuploidy increased with worsening histological grades of dysplasia. All BAC
cases were aneuploid, with moderate or severe aneuploidy. Marked elevated HI values (>20)
and 5N exceeding fractions (>5%) were found in 5%, 32%, 50% and 88% of cases with
SIM, low grade dysplasia, high grade dysplasia and BAC, respectively. The patterns of DNA
histograms seen on ICS in Barrett's associated mucosal lesions are shown in Figure 1.
Conclusions: The high fidelity DNA histograms suggest that: 1) Barrett's SIM may already
be dysplastic in nature, and all BAC may be markedly aneuploid; 2) Elevated cellular DNA
heterogeneity and 5N fractions may be markers of progressive chromosomal changes and
‘unstable aneuploidy' that identifies progressive lesions.
S1813
High Detection Rate of Neoplasia in Barrett Esophagus Is a Result of Referral
Bias
Heiko Pohl, Jens Aschenbeck, Ralf Drossel, Andreas Schroeder, Michael Mayr, Martin
Koch, Thomas Roesch, Bertram H. Wiedenmann
Background: Estimation of annual neoplasia risk in Barrett esophagus is primarily based on
data collected at referral centers. Whether such data accurately represent the risk profile for
neoplasia in the entire group of Barrett patients, especially those who are seen in primary
care setting, is not known. Objective: To compare the proportion of high grade intraepithelial
neoplasia (HGIN) and esophageal adenocarcinoma detected in Barrett patients at tertiary
referral centers and private practice setting. Methods: We retrospectively collected data from
all patients with histologically confirmed Barrett esophagus seen in six academic medical
centers and 19 private gastroenterological practices in Berlin, Germany, between 2003 and
2005. The primary outcome measure was the prevalence of HGIN and adenocarcinoma in
tertiary referral centers compared to private practices. Further outcome measures included
demographic characteristics, proportions of patients with long and short segment Barrett,
and number of biopsies per 2cm Barrett segment. Results: We identified 1337 Barrett patients,
32.5% (n=433) in academic medical centers and 67.5% (n=904) in private practices with
a similar proportion of men (68.6% and 68.7). Patients at medical centers were older (63
versus 59 years, p<0.001), had a longer mean Barrett segment (3.7cm versus 2.6cm, p<0.001),
a higher proportion of long segment Barrett (46.1% versus 29.9%, p<0.001). HGIN and
cancer were detected in 7.2% (n=31) of patients in academic medical centers compared to
0.8% (n=6) in private practice setting (p<0.001). Of 31 patients with HG-IN or cancer
detected at academic medical centers 18 were referred from private practice and 7 admitted
with an acute illness, and only 3 patients (0.8%) were detected through screening or
surveillance. The mean number of biopsies from a Barrett segment ≤2cm and ≤4cm were
4.1 and 4.9 in academic medical centers and 2.5 and 2.8 in private practice setting (p<0.001).
Conclusions: Academic medical centers detect HGIN or esophageal adenocarcioma almost
ten times more often than private practices. Referral bias primarily explains this difference.
In the Barrett population advanced neoplasia may develop less frequently, than previ-
ously thought.
S1814
The Relationship Between Body Mass Index (BMI) and Barrett's Esophagus
(BE)
Sachin B. Wani, Ajay Bansal, Amit Rastogi, Sandy Hall, Prateek Sharma
Background: Prevalence of obesity in Western countries is increasing in epidemic proportions.
Obesity has been linked to gastroesophageal reflux disease (GERD) symptoms, erosive
esophagitis and esophageal adenocarcinoma (EAC). However, the association between obesity
and BE is unclear. Aim: To prospectively evaluate the association of BMI with BE in GERD
patients undergoing their initial screening endoscopy. Methods: Consecutive patients pre-
senting to endoscopy unit for their index endoscopy for evaluation of GERD symptoms
were enrolled. Patients were asked to complete a validated GERD questionnaire (GERQ)
and additional information such as demographics, family history, smoking, medications,
and BMI were recorded. Diagnosis of BE was based on presence of columnar-lined mucosa
in distal esophagus at endoscopy with intestinal metaplasia in biopsy specimens. BMI was
calculated as weight in kilograms / square of body weight in meters (kg/m2). Univariate
analysis (chi-square and t-test) followed by multivariate logistic regression analyses were
performed to examine the association of BMI with BE adjusting for age and race. This was
compared to the group with GERD symptoms without BE. BMI was examined both as a
continuous and categorical variable (<25, 25-30, >30). Results: There were 119 patients
with a new diagnosis of BE and 510 non-BE patients that completed the study (91% males,
mean age 57.5 yrs). The mean ages of BE and non-BE patients were similar (58.7 vs. 57.5
yrs, p=0.36). Mean BE length was 2.38 cm (range 0.5-12) with majority (74%) demonstrating
short-segment BE (<3cms). Mean BMI was lower in the BE group than in the non-BE group
(28.3 vs. 29.5, p=0.03). There was no difference in the number of BE patients with BMI
<25 (29% vs. 28%), 25-30 (43% vs. 35%) and >30 (28% vs. 37%) than those without BE
(p=0.13). Similar results were noted when the association between BE length and BMI was
assessed. In the multivariate analysis, adjusting for race and age, when compared with BMI
<25, patients with BMI >30 were less likely to demonstrate BE (OR 0.4, 95% CI 0.2-0.7)
but with no difference in BE prevalence for patients with BMI 25-30. Conclusions: This
study contradicts recent suggestions that increasing BMI is associated with an increased risk
for BE development. Although obesity may be an important risk factor for BE; The distribution
of adipose tissue may be more important than the overall BMI. Future studies should
investigate the role of visceral adiposity measured by waist circumference in BE and EAC
development. On the other hand, it is also possible that obesity plays an important role in
GERD and EAC development rather than in BE.
S1815
Assessment of Response of Barrett's Esophagus to Ablative Therapy Using
Biomarkers: A Prospective Study
Ganapathy A. Prasad, Kenneth K. Wang, Kevin C. Halling, Shannon Brankley, Lori S.
Lutzke, Navtej Buttar, Louis-michel Wong kee song, Lynn S. Borkenhagen, Kelly T.
Dunagan
Rationale: It is known that histological response alone is unreliable to assess ablative therapy
in HGD. Biomarkers are proposed as an alternative to help define response to therapy. Aims:
1. To assess status of biomarkers in patients with HGD/mucosal cancer before and after
PDT 2. To correlate biomarker status post PDT with histology. Methods: Patients undergoing
PDT for HGD/mucosal cancer at Mayo Clinic, Rochester were prospectively studied. All
patients underwent a protocol assessment with EGD, 4 quadrant biopsies every centimeter,-
EMR of visible nodules and EUS. Cytology samples were obtained using standard cytology
brushes. Biomarkers were assessed using FISH for locus specific and centromeric probes.
Biomarkers assessed included: loss of 9p21 (p16) and 17p13.1 (p53); gains of the 8q24(c-
myc), 17q (HER2-neu) and 20q13 loci and polysomy. Patients received intravenous Sodium
Porfimer followed by photoradiation with cylindrical diffusing fibers (630 nm light;200
Joules/cm fiber energy). Demographic and clinical variables were prospectively collect-
ed.McNemar's test was used to compare pre and post PDT proportions. Results: 31 patients
were studied. Median age was 66 years (IQR 56-73). 28 (88%) were males. 25 (78%) had
HGD and the rest had mucosal cancer. Mean BE length was 5 cm (SEM 0.5). Distribution
of biomarkers pre and post PDT is shown in Figure 1. Post PDT biomarkers were obtained
after a median duration of 9 months (IQR 3-12m). 26 patients (84%) had no evidence of
HGD at the time of repeat sampling for biomarkers. There was a statistically significant
improvement in biomarkers post-PDT (loss of the p16 locus, gain of c-myc locus and
polysomy or gain of any locus). In the subgroup (n=26) with no HGD following PDT, 8
remained FISH positive for one or more biomarkers : Of which 2 (25%) had recurrent HGD
at the last follow up (mean follow up after PDT 16.6 months). Conclusions: Histological
downgrading of dysplasia following PDT appears to be also associated with the loss of
biomarkers which have been associated with progression of neoplasia in BE. This may predict
a lower risk of future neoplasia in these patients.
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S1816
An Analysis of the Oesophageal Proteome By 2-Dimensional Gel
Electrophoresis Before and After Dietary Intervention with Eicosapentaenoic
Acid (EPA) in Patients with Barrett's Esophagus
Abigael C. Polley, Sam Mehta, Michael Rhodes, Elizabeth K. Lund, Lynda C. Olivier,
Francis Mulholland, Carmen Pin, Ian Johnson
Introduction: Polyunsaturated fatty acids of the n-3 series exert anti-inflammatory effects in
many tissues. Fish oils suppress mitosis and increase apoptosis in intestinal epithelia, and
there is epidemiological evidence for anticarcinogenic effects of fish consumption in both
colon and esophagus. Here we describe effects of prolonged dietary supplementation with
the n-3 PUFA eicosapentaenoic acid (EPA) on the proteome in volunteers undergoing regular
clinical screening of Barrett's esophagus (BE). Methods: Endoscopic biopsies were taken at
a recorded level from squamous (Sm) and Barrett's (BE) mucosa (confirmed histologically)
of five individuals who were part of a randomised trial of the effects of n-3 fatty acids in
Barrett's esophagus. Participants then consumed three 500mg capsules of unesterified EPA
(99%; SLA Pharma, UK) daily for 6 months. They then underwent a second endoscopy
with biopsies at the same level. Additional biopsies were taken to confirm incorporation of
EPA in the lower esophagus. Proteins were extracted from biopsies and separated using 2-
D gel electrophoresis. Gels were imaged and compared using ProteomWeaver™ software.
Patterns of protein expression, both between tissues and before and after supplementation,
were compared using multivariate statistics. Individual protein spots were picked and ana-
lysed by MALDI-ToF mass-spectrometry. Results: Principal components analysis revealed
major differences in global patterns of protein expression, both between tissues and after
supplementation. Cytokeratin (CK) expression differed markedly between Sm and BE. For
example, CK4 and CK13 were strongly expressed in Sm but virtually absent in BE, whereas
CK8 and CK19 showed the reverse pattern. Similarly the calcium-dependent signalling
proteins S100A2 and S100A9 (calgranulin) were much more strongly expressed in Sm than
BE (p<0.05) but S100A6 (calcyclin) levels were higher in BE (p<0.05). Relatively few
individual proteins underwent statistically significant changes in expression after EPA supple-
mentation but calpain was up-regulated in Sm (p<0.05) whereas heat shock protein 27
(HSP27) was down-regulated in both Sm and BE (p<0.05). Conclusions: This study demon-
strates very extensive changes in protein expression associated with the transition from
squamous to Barrett's esophagus. Proteomics provides a powerful tool for assessing effects
of dietary or pharmaceutical interventions in the GI tract. Increased EPA levels were associated
with subtle changes in protein expression; down-regulation of the anti-apoptotic protein
HSP27, consistent perhaps with reduced inflammatory stress, may be potentially anticarcin-
ogenic.
S1817
Interobserver Variation in the Diagnosis of Dysplasia in Barrett's Oesophagus
Using the Vienna Criteria- A Pilot Study
Sunil Sonwalkar, Olorunda Rotimi, Nigel Scott, Mike Dixon, Anthony Axon, Simon
Everett
INTRODUCTION: Six studies have assessed the interobserver variation in the diagnosis of
dysplasia in Barrett's oesophagus (BO), mostly based on Riddell's method of classification
in IBD. There are no studies based on the accepted Vienna system. AIMS & METHODS:
To assess the interobserver variation in the diagnosis of dysplasia (in particular-Indefinite
for dysplasia (IND)) in BO using the revised Vienna classification. Histology database was
searched for cases with BO (SIM on histology), dysplasia and adenocarcinoma (ADO) in
the time period 1st April 1984 to 31st December 2004. 42 cases with a diagnosis of IND
and 15 time matched controls, each with a diagnosis of BO without dysplasia, low grade,
high grade dysplasia and ADO were identified & 137 slides retrieved. 3 GI histopathologists
(P1, P2 and P3) reassessed the slides independently based on the revised Vienna classification.
Interobserver agreement between individual GI pathologists was determined by Cohen's
Kappa statistics. RESULTS: 21 of 42 cases (50%) were reclassified as IND by at-least one
of the three histopathologists-14 by pathologist 1 (P1), 3 by pathologist 2 (P2) and 12 by
pathologist 3 (P3). Thus P1, P2 and P3 were in agreement with the original diagnosis of
IND in 14/42(33%), 3/42(7%) and 12/42(29%) cases respectively. P1 and P2 agreed on the
diagnosis of IND in a single case, P2 and P3 in none and P1 and P3 in 7 cases. The kappa
for the cases with an initial diagnosis of IND (n=42) between P1 and P2 was 0.15 (poor),
between P2 and P3 was 0.03 (poor) and between P1 and P3 was 0.35 (fair). The kappa on
all cases between P1 and P2 was 0.26 (fair), between P2 and P3 was 0.13(poor) and between
P1 and P3 was 0.36 (fair). CONCLUSION: This is the first study looking at interobserver
variation in the diagnosis of IND in Barrett's Oesophagus using the revised Vienna criteria.
The kappa for the diagnosis of IND was fair at the best in this study (0.15, 0.03 and
0.35 respectively).
Kappa values for the diagnosis of dysplasia on an eight-tier system based on the Vienna criteria:
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s The agreement between the three GI histopathologists (P1, P2 & P3) for the diagnosis of
Indefinite for dysplasia (n=42) was poor(k=0.18). The agreement for all cases (n=102) was
fair (k=0.29) and on removing the cases with Indefinite for dysplasia, the agreement remained
fair (k=0.34)
S1818
Semi-Automated Image Cytometry in Barrett's Oesophagus Using Cytospin
Preparations Extracted from Routine Biopsy Material
Jonathan P. Bury, Sally Roberts, Roy Stewart, Chandu Bardhan
INTRODUCTION: There is ongoing interest in the potential clinical utility of DNA ploidy
measurement in identifying those patients with Barrett's oesophagus with highest risk of
progression to malignancy. However, the optimal method for assessing DNA aneuploidy in
routinely acquired biopsies has yet to be established. Flow cytometry has been used in many
studies, whilst others have used image cytometry on tissue sections, requiring the manual
selection of nuclei of interest. Here we describe the application of an image cytometry
method which is semi-automated and can be applied to routinely acquired formalin-fixed
paraffin embedded tissue samples. AIMS & METHODS: 20 samples were studied - 4 each
of normal squamous mucosa, columnar lined oesophagus, low- and high- grade dysplasia,
and Barrett's adenocarcinoma. Thick (50 micron) sections were cut from tissue blocks, and
nuclei extracted ezymatically. Suspensions of nuclei were then centrifuged directly onto a
slide which was then stained by the Feulgen technique. The Fairfield Imaging System
(Medical Solutions, Nottingham, UK) was used to automatically acquire digitised images of
individual nuclei at 400x magnification. Distorted and overlapping nuclei were then manually
disgarded. The integrated optical density (IOD) of individual nuclei was automatically
calculated, and histograms of IOD (and hence DNA content) produced. RESULTS: Typically
around 1000 nuclei were available for analysis after automated acquisition and deslection
of unsuitable nuclei. IOD / DNA content histograms for each of the 4 samples of normal
oesophagus showed a clean diploid peak. One of the 4 samples of columnar lined oesophaghus
showed DNA aneuploidy, as did one sample with low grade dysplasia, whilst 3 of the 4
samples with high grade dysplasia showed aneuploidy, as did all four of the samples of
Barrett's adenocarcinoma (p=0.002; Linear-by-linear association test). CONCLUSION: This
study demonstrates the feasibility of using this approach to assess DNA ploidy in archival
samples of Barrett's mucosa. Our results are consistent with data derived using other tech-
niques for assessing ploidy. The cytospin technique has the advantage that a large numbers
of nuclei can be assessed, without the the requirement histopathological expertise to select
nuclei of interest. Direct comparitive studies warrented to assess the specificity and sensitivity
of this approach in comparison to more established methods such as flow cytometry and
image analysis using manually selected nuclei.
S1819
Effectiveness of Barrett's Esophagus Surveillance in the Detection of
Esophageal Adenocarcinoma and High Grade Dysplasia
James H. Yeung, Ross Mclean, John Hanson, Clarence K. Wong
Background and Aim: The incidence of esophageal adenocarcinoma (EA) has been growing
faster than that of any other cancer since the 1970s. Endoscopic surveillance is recommended
for all patients with Barrett's Esophagus (BE), the most important risk factor for development
of EA. Recent studies have shown that EA detected through surveillance of BE are associated
with lower disease staging and improved survival. Unfortunately, it appears that most EAs
are still diagnosed by symptoms. Our aim was to evaluate the effectiveness of BE surveillance
at detecting EAs in our region. Methods: We analyzed all patients who had been diagnosed
with either high grade dysplasia (HGD) or adenocarcinoma of the gastroesophageal junction
or esophagus in our health region between 2001 and 2006. Cases where esophageal cancer
was a result of caustic ingestion, a recurrent cancer, or secondary to metastatic spread were
excluded. As well, patients with gastric cardia adenocarcinoma, squamous cell carcinoma,
lymphomas, leiomyosarcomas, or benign tumors were also excluded. Patients were further
stratified as either being diagnosed through a BE-surveillance program, or through endoscopy
as a result of investigating presenting symptoms. Data that was obtained include presence,
frequency and duration of dysphagia, hemoptysis, as well as heartburn. A history of BE and
all screening endoscopies performed prior to the cancer diagnosis were also recorded. Results:
We identified 227 patients with HGD or esophageal adenocarcinoma. In this cohort, there
were 26 females and 201 males with an average age of 64.9 years. Twenty of the 227 patients
(8.8 ± 5.3% 95% confidence interval) were detected to have HGD or adenocarcinoma
through BE surveillance. Patients with HGD were also more likely to be detected through
surveillance (47.9%) than patients with adenocarcinoma (4.4%). The difference in propor-
tions is statistically significant (p<0.001). Patients were diagnosed with HGD and EA a
median of 1.39 and 1.86 years respectively after initial diagnosis of BE. Conclusions: BE
surveillance detected 8.8% of the total number of HGD and esophageal adenocarcinoma
cases diagnosed in our 5 year review. Surveillance of known BE was effective at detecting
HGD. However, a large majority of patients with EA or HGD are still diagnosed via presenting
symptoms. It is alarming that patients were diagnosed with HGD and adenocarcinoma much
earlier than the current American College of Gastroenterology guidelines, which recommend
a 3-year BE surveillance endoscopy interval if lacking dysplasia on two consecutive biopsies.
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S1820
Is the Risk of Invasive Esophageal Adenocarcinoma in High Grade Dysplasia
in Barrett's Esophagus Overestimated; A Meta-Analysis of the Published
Literature
Vani Konda, Andrew S. Ross, Keith Naylor, Shang Lin, Barbara Cislo, Lynne Stearns,
Charles E. Dye, Amy Noffsinger, John A. Hart, Mitchell C. Posner, Mark K. Ferguson,
Irving Waxman
BACKGROUND: The need for esophagectomy in patients with Barrett's esophagus (BE) with
high grade dysplasia (HGD) is controversial. The literature reports varying prevalence of
esophageal adenocarcinoma in patients with BE with HGD. As new endoscopic treatments
emerge for BE with HGD and intramucosal carcinoma (IMC), appropriately estimating the
risk of invasive esophageal adenocarcinoma (IEAC) is critical in order to evaluate different
treatment options. AIM: To understand the prevalence of reported IEAC patients with
Barrett's esophagus with HGD who underwent esophagectomy. METHODS: A MEDLINE
search was done using the terms “Barrett's esophagus”, “esophageal adenocarcinoma”, “high
grade dysplasia”. Articles that reported esophagectomy pathology results for patients that
had BE with HGD by endoscopic biopsy were included. Articles with insufficient preoperative
or postoperative information were excluded. We define “invasive esophageal adenocarcin-
oma” or IEAC as tumor with submucosal invasion or beyond. Carcinoma in situ (CIS) and
IMC are not considered as IEAC in this analysis. RESULTS: Sixteen articles were selected
for analysis of prevalence of IEAC with publication dates ranging from 1987 to 2003. Among
the 263 patients who underwent esophagectomy for HGD, 41.8% of these patients had in
the esophagectomy resection specimen undiagnosed invasive esophageal adenocarcinoma
by the original authors'definitions. Reported rates varied from 0% to 73%. By the AJCC
staging, 152 patients had HGD or Stage 0 postoperatively, 85 had Stage I, 15 had stage IIa,
5 had stage IIb, and 6 had Stage III. The prevalence of IEAC is established by examination of
the eight studies (n=120) that provided differentiation between intramucosal and submucosal
invasion. Only 10.5% had IEAC (submucosal invasion or beyond) while 89.5% had only
either HGD or IMC. CONCLUSION: Utilizing strict pathologic definitions of invasive disease,
the true prevalence of IEAC in BE and HGD may be significantly overestimated. To separate
CIS and IMC from true invasive disease is clinically relevant because CIS and IMC may
potentially be treated with endoscopic techniques, such as endoscopic mucosal resection.
This information may prove invaluable when considering treatment options for HGD or
IMC in BE.
S1821
Prospective Testing of the Effectiveness of Screening Recommendations for
Barrett's Esophagus: A Population Community Based Study
Houssam E. Mardini, Alla Grigorian, Sarah Turner, Nicholas J. Nickl
BACKGROUND: Currently, screening for Barrett's esophagus is recommended for patients
with long-standing GERD symptoms, particularly those > 50 yr of age. These recommenda-
tions have not been tested in a population based setting. The aim of this study was to
evaluate the effectiveness of current recommendations. METHODS: Public advertisement
(newspaper and radio) was carried out in 3 counties in Kentucky with higher than average
esophageal adenocarcinoma incident. People who met the inclusion criteria for screening
(as determined by a phone interview) were invited to attend an educational session about
reflux disease, BE and dysplasia and cancer. They were advised to undergo a screening
endoscopy by a local community based endoscopist. Follow up contact was made 3 months
later to determine if endoscopy has been performed and obtain findings, results and treatment
recommendations. RESULTS: Between January 2006 and September 2006, 124 subjects (77
F and 57 M; mean age 52 yrs) who met the inclusion criteria attended an educational
session. 87 subjects (70 %; 52 F and 35 M; mean age 49 yrs) followed recommendations
and underwent EGD within 3 months of the educational session. BE was confirmed in 21
subjects (24%; 12 M and 9 F). Short segment BE was found in 5 (25%). Low grade dysplasia
was identified in 4 subjects (20% of pts with BE and 4.6% of the entire cohort). 3 (75%)
of the low grade dysplasia subjects were male. No high grade dysplasia or cancer cases were
found. Because of the community based setting, in 3/4 cases with dysplasia the biopsies
were sent to a gastrointestinal pathology specialist for confirmation. There were no reported
complications in any of the procedures. CONCLUSIONS: Screening for BE based on current
recommendations detects BE in 25% of subjects who meet screening criteria. It appears to
be more effective in men than in women. Low grade dysplasia is frequently found in
this group.
S1822
Clinical Outcome of Cases with Indefinite for Dysplasia in Barrett's
Oesophagus Over Two Decades
Sunil Sonwalkar, Olorunda Rotimi, Nigel Scott, Mike Dixon, Anthony Axon, Simon
Everett
INTRODUCTION:Two yearly surveillance is recommended for non dysplastic BO, more
often for cases with dysplasia. No study has looked at clinical outcome of cases with the
diagnosis of Indefinite (IND) for dysplasia in BO AIMS & METHODS: We studied the
clinical outcome of the cases diagnosed as IND over the last 20 years at our institution.
This was a cohort analytical study. Histology database was searched to generate lists of cases
diagnosed with Barrett's Oesophagus (SIM on histology) & dysplasia in the time period 1st
April 1984 to 31st December 2004. All cases had slides reviewed by three GI histopathologists.
Progression was defined as a diagnosis of LGD, HGD or ADO while regression was defined
as a diagnosis of BO. RESULTS:42 cases originally diagnosed as IND were followed up for
a median of 38.7 months (range 6-122 months). 31 cases (73%) did not progress but 11
cases (27%) progressed after a median follow-up of 31.4 months (range 6-104 months): 5
(45%) to LGD, 3 (28%) to HGD, 2 (18%) to suspicious for invasive carcinoma and 1 (9%)
developed intramucosal cancer. All three histopathologists agreed on a common diagnosis
of BO in 2 of these 11 cases but in neither of these did they all agree on a common diagnosis
of IND. However, P1 and P3 agreed on a diagnosis of IND in 3 of the 11 cases. The 9 cases
that progressed and had no consensus diagnosis were reclassified by P1 as BO (2), IND (3),
LGD (2), HGD (1) and CIS (1) by P2 as BO (1), LGD (2), HGD (4) and IMCA (2) and by
P3 as BO (1), LGD (3) and HGD (5)respectively.There was a non-significant negative
correlation with progression and a consensus diagnosis of IND [8 cases (7 between P1&P3
and 1 between P1&P2) (rho= -0.308, p=0.809)], but a significant positive correlation between
a diagnosis of IND by at least one histopathologist (21 cases) and progression (rho=0.485,
p=0.01). On Kaplan-Meier analysis, there was no significant association between a consensus
diagnosis of IND, or a re-diagnosis of IND with progression. CONCLUSION: A second
opinion from an experienced histopathologist does not necessarily predict cases with an
initial diagnosis of IND, which might progress. Patients with this diagnosis should be offered
surveillance similar to other grades.
S1823
Racial and Ethnic Differences in the Prevalence of Barrett's Esophagus Among
Patients Who Undergo Upper Endoscopy
Julian A. Abrams, Sydney Fields, Charles J. Lightdale, Alfred I. Neugut
BACKGROUND: The prevalence of Barrett's esophagus (BE) in minority populations is
assumed to be the same as for esophageal adenocarcinoma (EAC), but this has not been
well studied. The incidence of EAC is significantly higher in whites and males than in non-
whites and females. Males are also at increased risk for progression from BE to EAC. It is
not known whether various races/ethnicities have different risks for progression from BE to
EAC, and it is important to determine the risk of BE in minorities so that it can be compared
to EAC. METHODS: We performed a retrospective cross-sectional analysis of all patients
who underwent upper endoscopy at Columbia University Medical Center over a one year
period. Patients with a prior endoscopy within five years or a previous diagnosis of BE or
esophageal adenocarcinoma were excluded. All suspected cases of BE were confirmed by
pathology reports. Data was collected and analyzed with regards to patient race/ethnicity
(self-reported), various demographic factors, indication for endoscopy, and endoscopic and
histologic findings. RESULTS: A total of 2,158 patients met criteria for analysis. The mean
age was 56.0 (SD 17.6), and 39.8% were male. Whites (37.7%), blacks (11.7%), and
Hispanics (22.1%) comprised the majority of patients. Among all subjects, 4.3% had histolog-
ically confirmed Barrett's esophagus. The prevalence of BE was significantly higher in whites
than in Hispanics (6.0% vs. 1.7%, p=0.0001) and in blacks (6.0% vs. 1.6%, p=0.003). The
prevalence was also higher in males than in females (5.6% vs. 3.4%, p=0.01). In multivariable
regression analysis, factors associated with a decreased risk of BE were black race (OR 0.31,
95%CI 0.11-0.88) and Hispanic ethnicity (OR 0.35, 95%CI 0.16-0.75). Male gender (OR
1.65, 95%CI 1.07-2.53), the presence of reflux symptoms (OR 3.10, 95%CI 2.01-4.79), and
older age had a significantly increased association with Barrett's esophagus. CONCLUSIONS:
Hispanics and blacks have a significantly lower prevalence of Barrett's esophagus as compared
to whites. These differences in prevalence are comparable to the differences in incidence
seen with esophageal adenocarcinoma, which implies that race/ethnicity is a risk factor in
the initial steps of the metaplasia-neoplasia sequence. Reasons for lower rates of Barrett's
esophagus in Hispanics and blacks need further investigation.
S1824
A Multidisciplinary Assessment of 49 Cases of Barrett's Esophagus with High-
Grade Dysplasia - Prior and Post Surgical Resection
Alberto Ruffato, Nabil Rizk, Ippolito Modica, Valerie W. Rusch, Manjit S. Bains, John K.
Tsai, Hans Gerdes, Arnold J. Markowitz, Jinru Shia, David S. Klimstra, Laura H. Tang
Introduction: Both the diagnosis and the management of patients with high grade dysplasia
(HGD) in Barrett's esophagus (BE) are controversial. The endoscopic assessment and the
pathological evaluation on biopsies are essential in guiding the management. We performed
a retrospective evaluation of 49 patients who underwent surgery at our institution (1996-
2006) based on biopsy diagnoses of HGD. Methods: We blindly reviewed all the available
biopsy material to confirm the diagnoses of HGD. The clinical data and records of endoscopy
were collected. AJCC Cancer Staging was used for pathological assessment. Results: Table
1 summarizes the clinical, endoscopic history and the pathological status in resections. There
was no difference in duration of symptoms between patients with or without carcinoma in
resections, 5 ys (2-15) and 4 ys (0.2-35). The average total biopsies were 3/patient (1-11).
The diagnosis of carcinoma in resections had no correlation with the duration of BE, >6
mons 13/33(39%) and < 6 mons 6/16(38%). Most patients remained with the status of
dysplasia; and carcinoma was detected in >1/3 cases. Table 2 reveals the correlation between
the number of procedures, biopsies and the detection of carcinoma. There were no surgery
related deaths or disease recurrence (47 mons). The 5-year disease specific survival (DSS)
for both HGD and carcinoma was 100%. Conclusion: In the absence of contraindications,
esophagectomy is the treatment for cure of BE with HGD; and this is supported by the
following: 1)an unlikelihood of regression of HGD and a likelihood of progression to
carcinoma; 2)a high rate of undetected carcinoma on biopsies; 3)an unpredictable long term
outcome of non-surgical management of HGD; 4)low morbidity and mortality rates associated
with surgical expertise; 5)excellent DSS in early stage carcinomas. For patient safety, it is
imperative to establish a multidisciplinary assessment, including extensive endoscopic and
pathological evaluation, of individual situations before proceeding for surgery.
Table 1
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Table 2: Correlation of Pre-resection Evaluations and the Detection of Carcinoma in Resections
S1825
Biological Characteristics of Cardia Type Epithelium in Patients with Barrett's
Esophagus
Angela Sefah, Daphne Ang, Kelly Walton, Xin Geng, Kiron M. Das
Introduction: Barrett's epithelium (BE) is an intestinal metaplasia at the esophago-gastric
junction, and the presence of goblet cells is a hallmark in the diagnosis of BE. BE is recognized
as a pre-cancerous condition and the majority of adenocarcinoma (AC) with BE develop in
the intestinalized mucosa. However, in the largest study reported thus far, about 30% of
AC was considered to arise from non-BE epithelium (N Engl J Med 1999;340:825). Cardia-
type epithelium (CE) (“non-intestinalized” without goblet cells) is commonly found in BE.
Biological behaviour of CE is unknown. It is unclear if AC may develop from CE as well.
We developed a monoclonal antibody (mAb Das-1, IgM isotype) specific against colon
epithelium that reacts with BE with 100% sensitivity and specificity, suggesting that BE is
a colonic type of metaplasia. mAb Das-1 does not react with epithelium of the small
intestine, stomach or esophagus. Objective: The aim of this study was to evaluate the
immunophenotypic features of CE using mAb Das-1 and other markers. Materials and
Methods: Twenty-five tissue blocks from 15 patients with BE containing normal squamous
epithelium, CE and BE were retrieved from the archives. All 25 specimens were histologically
evaluated by two pathologists, independently, prior to immunophenotypic characterization.
Serial tissue sections were examined by mmunoperoxidase assay, and evaluated by a third
person without knowledge of histology. Immunophenotypic markers included mAb Das-1,
and mAbs against CDX-2 (differentiation marker for intestinal-type epithelium), villin (brush
border marker), and Heppar-1 (hepatocyte antigen-1 reported in BE). Results: mAb Das-
1 was positive in 6 of 6 (100%) BE tissue, in 13/16 (81%) cardia-type epithelium and 2 of
3 tissue with focal intestinal metaplasia (IM). There was no mAb Das-1 reactivity with
squamous epithelium. CDX-2 was positive in 3 of 6 (50%) BE tissue and in 8 of 16 (50%)
cardia-type epithelium and 1 of 3 IM. CDX-2 did not react with squamous epithelium.
Antibody against villin reacted with 1 of 6 (16.6%) BE, in 5/16 (31%) Cardia-type epithelium,
and in 2 of 3 IM. Squamous epithelium was villin negative. mAb Das-1 positivity in BE was
significantly higher than CDX-2 (p<0.05) and villin (p<0.01) reactivity. Heppar-1 did not
react with BE and squamous epithelium, but reacted with 1 of 16 (6%) cardia-type epithelium
and 1 of 3 IM. Conclusion: Cardia-type epithelium (“non-intestinalized epithelium”) bears
colonic phenotype marker similar to BE. Immunophenotyping with mAb Das-1 and CDX-
2 suggests cardia-type epithelium may be an early form of metaplastic process of intestinaliz-
ation.
S1826
Can the Presence of Intestinal Metaplasia and Dysplasia in Columnar-Lined
Esophagus Be Predicted? - A Multivariable Analysis
Marjon Kerkhof, Ewout Steyerberg, Johannes G. Kusters, Ernst J. Kuipers, Peter D.
Siersema
Background: The histopathological presence of intestinal metaplasia (IM) and the grade of
dysplasia in the columnar-lined esophagus (CLE) determine the frequency of endoscopic
follow-up, but are both prone to sampling error and interobserver variability. Aim: To
determine clinical risk factors and to develop a simple model which is able to predict
histology, i.e. the presence of IM or low-grade dysplasia (LGD) in IM in biopsies taken from
CLE. Methods: We collected clinical (age, gender, body mass index, use of tobacco and
alcohol and medication use) and endoscopic findings at index upper GI endoscopy of 908
consecutive incident and prevalent patients with a CLE of ≥ 2. Multivariable logistic regres-
sion analysis was performed, and a prediction model for histological results was developed
with internal validation by bootstrapping. Results: In 127/908 (14%) patients, biopsies of
CLE did not contain IM (No IM). Of the 781 (86%) patients with IM, 663 (85%) patients
had no dysplasia (ND), and 118 (15%) LGD. The most important predictors for the presence
of IM were a longer segment CLE, a larger hiatal hernia (HH) and male gender, while among
those with IM older age and male gender were most important for the presence of LGD.
Multivariable combination of predictors yielded reliable models (goodness-of-fit tests:
p>0.20), which were able to discriminate IM from no IM (area under ROC curve: 0.82),
but only reasonably discriminated LGD from ND (area: 0.65). Internal validation confirmed
these findings. Conclusions: A simple score based on clinical and endoscopic findings is
able to accurately predict the presence of IM in biopsies from CLE. In contrast, predicting
the presence of LGD versus ND in IM is more difficult. Predictions from these models may
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help in the decision-making on whether surveillance should be performed in view of the
known sampling error at endoscopy and interobserver variability at histology.
S1827
Silent Heartburn and a Phenomenon of Lack of Recall of Heartburn in Patients
with Barrett's Esophagus
David J. Desilets, Brian H. Nathanson, Farhad Navab
Introduction: Classic reflux symptoms, heartburn and regurgitation are the most common
presenting symptoms of patients with Barrett's Esophagus (BE). Previous studies suggest
that a proportion of patients with BE do not have classic symptoms (Gastroenterol 2005;
129:1825) and BE may be found at endoscopy in asymptomatic patients (Gastroenterol
2003;125:1670). In this study we provide data on the frequency of silent heartburn and a
phenomenon of lack of recall of heartburn in patients with BE in a tertiary care center.
Methods: 148 patients with BE were studied over 6 yr (1999-2005). 113 (76.4%) were
male. Median age and range in LSBE 51.5 yr (29-91) and SSBE 54.5 yr (24-91). Diagnosis
was made endoscopically and confirmed on histology as presence of intestinal metaplasia.
The cohort was divided into long-segment BE (LSBE), defined as BE >= 3 cm (n=72), and
Short-segment BE (SSBE), BE < 3 cm (n=76). In silent heartburn, patients consistently denied
having this symptom. We defined lack of recall as patients who did not admit to classic
reflux symptoms prior diagnosis of BE, but did so after diagnosis. Results: A total of
90.3%, 87.5%, and 80.6% of LSBE had heartburn, regurgitation and night-time symptoms,
respectively. A total of 82.9%, 77.6%, and 52.6% of SSBE had heartburn, regurgitation and
night-time symptoms. LSBE patients had significantly more night-time symptoms compared
with SSBE (p<0.001), and reported more regurgitation (p< 0.048). Frequency of absence
of heartburn did not vary by BE length 9.7% of LSBE vs 11.8% of SSBE. Lack of recall also
did not vary by BE length 16.7% of LSBE vs 11.8% of SSBE (p=0.401) but was significantly
not zero, as was silent heartburn (p <0.01). Acute gastrointestinal bleeding was a presenting
symptom in 15.3% of LSBE and in 0% of SSBE (p<0.001). LSBE patients had heartburn
much longer than SSBE patients (117.7 (106.8) months vs. 67.0 (88.9), p = 0.002). More
dysphagia was present in LSBE patients (23.6% vs. 13.2%, p = 0.100). None of other
manifestations: dyspepsia, chest pain, cough, hoarseness, asthma and chronic gastrointestinal
bleeding were significantly different in the two groups. Conclusions: While classic reflux
symptoms are most common, patients with BE have diverse presenting manifestations. Night-
time symptoms, regurgitation and a long duration of heartburn are significantly more common
in patients with LSBE. Approximately one in ten patients with BE do not have heartburn.
Other patients only recall that they had heartburn after the diagnosis has been established,
regardless of BE length.
S1828
Adenovirus-Mediated Ectopic Cdx2 Expression Provokes Intestinal Markers in
Embryonic Mouse Esophagus and Stomach
Jonathan M. Quinlan, John M. Farrant, David Tosh, Jonathan M. Slack
Background: Barrett's esophagus is characterised by transformation of stratified squamous
to intestinal type columnar epithelium, which predisposes to esophageal adenocarcinoma.
Recent reports suggest that cdx2, encoding a homeodomain transcription factor which is a
key regulator of intestinal differentiation, is important in the development of Barrett's meta-
plasia. Cdx2 has been demonstrated in Barrett's metaplasia and ectopic gastric expression
in transgenic mice provokes intestinal metaplasia. cdx2+/- mice show focal loss of function
in the colon, which provokes transformation to forestomach epithelium, bordered by regions
of small intestinal epithelium, a process ascribed to intercalary regeneration. Methods: To
investigate the role of cdx2 in the development of Barrett's metaplasia, we have developed
an ex vivo culture system for embryonic mouse esophagus, stomach and intestine. Using
replication-defective recombinant adenovirus as a gene delivery method to the epithelium
of E14.5 upper gastrointestinal organ cultures, we examined the effect of cdx2 and VP16cdx2
expression using immunohistochemistry and confocal microscopy. To examine the stability
of epithelial character between adjacent tissues, we set up co-cultures of esophagus, stomach
and intestine where one tissue comes from a ROSA26 embryo (ubiquitously labelled with
β-galactosidase) and the other from CD1. The cultures were analysed using immunohisto-
chemistry and Xgal staining to determine whether the boundary of tissue type stays with
β-galactosidase expression or slips away from it. Results: Epithelial transgene expression
was confirmed by co-staining with E-cadherin. cdx2 or VP16cdx2 expression in the esophagus
and stomach provoked the intestinal markers Muc-2 and sucrase-isomaltase 7 days after
adenoviral infection, with co-localisation of Cdx2 and Muc-2. Recombinations of CD1
esophagus and ROSA26 intestine appear to show anterior reprogramming with p63 expres-
sion in ROSA26-derived tissue. Co-cultures of CD1 stomach and ROSA26 intestine demon-
strated co-localisation of H/K/ATPase and β-galactosidase, suggesting anterior reprogramming
of the ROSA26-derived intestine to adopt a gastric phenotype. Conclusion: We have
developed a method of gene delivery to the epithelium of ex vivo upper gastrointestinal
organ cultures. Ectopic expression of cdx2 constructs in esophagus and stomach leads to
induction of intestinal markers. This implies that cdx2 has a key role in the initial metaplastic
transformation of Barrett's esophagus. The co-culture system provides evidence that adjacent
tissues can be re-programmed, with 'horizontal spread' between adjacent epithelia.
S1829
High Fat Intake Plays a Crucial Role in the Development of Barrett's
Esophagus and Esophageal Adenocarcinoma Through Elevated Bile Acids in
Duodenal Contents Reflux
Chen Kuan-hao, Ken-ichi Mukaisho, Yoshio Araki, Hiroyuki Sugihara, Takanori Hattori
Background: The incidence of Barrett's esophagus (BE) and esophageal adenocarcinoma
(EAC) has risen since the 1970s in the United States. Although it has been noticed that diet
is related to gastro-esophageal reflux disease, which is a strong severity-dependent risk factor
for the above-mentioned esophageal lesions, what dietary components are responsible for
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the development of the esophageal lesions remains unclear. Materials and Methods: Eight-
week-old male Wistar rats were divided into two groups according to diet as follows: the
control group, fed a standard diet (CE-2, containing 4.88% soybean oil) and the high fat
group, fed a high fat diet (Quick Fat, containing 14.1% cow fat). First, the effect of high
fat intake on the metabolism of bile acids (BAs) was examined by evaluating free and
conjugated BAs with high-performance liquid chromatography in the bile juice that was
aspirated directly from the common bile duct of animals in the groups without operation.
Next, we used reflux animals, which underwent esophagojejunostomy without gastrectomy.
Sequential morphological changes in these animals fed with or without the high fat diet
were then studied for up to 30 weeks after surgery. We also measured the pH of esophageal
contents in reflux animals of both groups. Results: A significant increase in the concentration
of bile acids, in particular of taurocholic acid (TCA) and taurodeoxycholic acid (TDCA),
was detected in animals fed with the high fat diet (median concentration of TCA, 9.8 mmol/
l; TDCA, 4.2 mmol/l) compared with animals fed with the standard diet (7.5 mmol/l; 0.77
mmol/l respectively). There was no significant difference in the pH of esophageal contents
between the high fat group (median 6.91; range 5.5-7.2) and the control group (6.49; 5.5-
7.2). The inflammation and mucosal changes (esophagitis with erosion and/or ulcers) in
the high fat group were much severer compared with those in the control group throughout
the duration of the experiment. At 30 weeks postoperatively, the reflux animals in the high
fat group showed an increased incidence of BE and EAC (100.0% and 42.8%, respectively,)
compared to those in the control group (50.0% and 12.5%, respectively). Conclusion: High
fat intake plays a crucial role in the development of BE leading to EAC. The assumed
mechanism of this process is as follows: The concentrations of BAs and taurine conjugates,
which are reportedly present in significantly greater proportions in patients with erosive
esophagitis and Barrett's esophagus/stricture, are increased in bile juice by high dietary fat
intake. These BAs then promote the development of BE and EAC in both acidic and neutral
pH environments.
S1830
Mapping Clonality in Individual Glands in Human Barrett's Esophagus
Simon Leedham, Stuart Macdonald, David Poller, Rebecca Harrison, Janusz A. Jankowski,
Nick Wright
INTRODUCTION: Barrett's oesophagus is an important pre-malignant condition. Work on
clonal expansion in Barrett's suggests that in some patients a single clone can expand to
populate an entire Barrett's segment. This work was largely completed on lysate obtained
from whole biopsies. Neosquamous islands can sometimes be seen in the midst of a Barrett's
segment. The origin of these islands is not clear. We aimed to examine the clonality of
individual Barretts glands and neosquamous islands using p53 gene mutations and microsa-
tellite markers to assess for loss of heterozygosity (LOH). METHODS. Individual glands
from across dysplastic patches from paraffin embedded Barretts tissue were isolated by laser
capture microdissection. Gland lysate underwent microsatellite marker analysis for 3 tumour
suppressor genes (APC, p53, p16), and nested PCR amplification to allow p53 gene sequenc-
ing. Individual gland mutations were compared with the results obtained from whole biopsy
lysates RESULTS.Dissected tissue was classified histologically. LOH patterns for the 3 different
markers were analysed for each of the histological tissue grades present in oesophagectomy
and biopsy blocks. p53 gene mutations and LOH patterns showed a great deal of clonal
diversity between individual glands in oesophagectomy blocks, suggesting a greater degree
of clonal heterogeneity than expected. No LOH or gene mutations were found in neo-
squamous islands, and these new clones appeared to be arising from oesophageal gland
ducts. Individual gland dissection also allowed detection of LOH not detectable from whole
biopsy analysis. CONCLUSIONS. Individual gland dissection and analysis reveals clonal
diversity within Barretts segments not detectable by whole biopsy analysis. Gland to gland
clonal heterogeneity suggests that previous models of mutational selective sweeps across
entire Barretts segments may be over simplifications. Wild-type neo-squamous islands have
a different clonal origin from the surrounding mucosa and may originate from oesophageal
gland ducts.
S1831
Proliferation and Epigenetic Changes in Human Esophageal Keratinocytes Are
Necessary for Cdx2 Induction of Intestinalization
Jianping Kong, Brandon Isariyawongse, Toshihiko Ezaki, Hirotoshi Nakagawa, Debra
Silberg, John P. Lynch
INTRODUCTION: Barrett's esophagus (BE) is characterized by the replacement of normal
squamous esophageal mucosa with an intestinalized columnar epithelium. The molecular
mechanisms underlying the development of Barrett's metaplasia are not understood due to
the absence of experimental models. Cdx2 (Caudal-related homeobox 2) is ectopically
expressed in BE, but its role in this process is unclear. Herein we describe a novel cell-
culture model for human esophageal keratinocyte intestinalization. METHODS: Retroviral-
mediated Cdx2 expression in immortalized human EPC2 keratinocytes. The effect of Cdx2 on
cell proliferation and morphology by H3-thymidine incorporation, WST-1 assay, quantitative
Real-Time PCR analysis, and transmission-electron microscopy (TEM). Cdx2-expressing and
control cells were treated with a DNA demethylation agent, 5-aza-2'-deoxycytidine (5AzaC).
RESULTS: Cdx2 expression in immortalized human EPC2 keratinocytes could be transiently
established, but the expression was not maintained for more than 1 or 2 passages, and was
associated with a significant reduction in H3 tritiated thymidine incorporation. Co-expression
of human cyclin D1 in EPC2 cell (EPC2.D1) rescued the cells expressing Cdx2 for further
studies. Ectopic expression of Cdx2 in the EPC2.D1 cells resulted in a decrease in cell
proliferation but did not induce an intestinal ultrastructure on TEM. Nor was there a
significant induction of intestine-specific or Cdx2 target genes. Epigenetic gene alterations
have been reported in Barrett's epithelial cells, and this may enhance intestinalization. To
enhance Cdx2 activation of transcriptional targets, we treated Cdx2 expressing and control
EPC2.D1 cells with 5AzaC to demethylate epigenetically silenced genes. Compared to the
EPC2.D1 cells, several known Cdx2 target genes and intestinal differentiation and Barrett's
markers were significantly induced by 5AzaC treatment in a dose- and time-dependent
manner. Several previously unexpressed (SLC26a3-DRA, LPH, Alk Phos) and poorly expre-
ssed genes (Villin, CAI, NHE2) had significant increases in their mRNA expression levels
with 5AzaC. More interestingly, the mRNA expression level of several of these genes
(SLC26a3, NHE2, CAI, cytokeratin 20) was greatly enhanced in the EPC2.D1-Cdx2 cells
over the control EPC2.D1 cells. Enhanced expression of SLC26a3, NHE2, and CAI in human
Barrett's epithelium was confirmed by quantitative RT-PCR and immunohistochemistry.
CONCLUSION: Ectopic proliferation signals and alterations in epigenetic gene regulation
are necessary for Cdx2-medicated intestinalization of human esophageal keratinocytes.
S1832
Contrasting Serum Antioxidant Profiles in Reflux Esophagitis and Barrett's
Esophagus
Heather R. Ferguson, Brian T. Johnston, Jayne V. Woodside, Marie Cantwell, Lesley A.
Anderson, Seamus J. Murphy, Peter Watson, Jim Mcguigan, John V. Reynolds, Harry
Comber, Liam J. Murray
Introduction There is evidence from animal studies that oxidative stress plays a key role in
the development of reflux esophagitis (RE) and Barrett's esophagus (BE). Tissue culture
experiments have reported similar findings in humans. However, whilst some have reported
higher levels of oxidative stress in BE compared to RE, others have suggested that the reverse
is true. The aim of this study was to compare serum levels of antioxidants between RE
patients, BE patients and normal controls. Methods In a case-control study, patients with
RE (n=215), BE (n=197) and population controls (n=226) were recruited from throughout
Ireland. Vitamin C was measured by automated fluorimetric analysis, using metaphosphoric
acid stabilised serum samples. Lipid soluble antioxidants, including alpha-tocopherol,
gamma-tocopherol, retinol and carotenoids (alpha-carotene, beta-carotene, beta-cryptoxan-
thin, lycopene, lutein, zeaxanthin) were measured using a high performance liquid chromato-
graphy assay with diode array detection. One way analysis of variance was used to test for
differences among the mean serum antioxidant concentrations by case status. Serum antioxid-
ant variables were categorised as tertiles, based on the distribution among the control group.
Logistic regression analysis was used to test for association between tertiles and disease,
whilst adjusting for potential confounding factors. Results Mean serum levels of gamma-
tocopherol, retinol, alpha-carotene and beta-cryptoxanthin were significantly lower in RE
subjects compared to controls (p< 0.001). The highest tertile groups for gamma-tocopherol,
retinol, alpha-carotene and beta-cryptoxanthin were associated with significantly reduced
risks of RE (OR= 0.05, 95% CI 0.02-0.10; OR= 0.21, 95% CI 0.12-0.37; OR= 0.28, 95%
CI 0.16-0.50; OR= 0.38, 95% CI 0.22-0.64 respectively). No significant differences were
noted between BE subjects and controls in mean serum levels or serum tertile levels for
these antioxidants. Mean serum levels of vitamin C and lycopene were significantly lower
in BE subjects compared to controls (p=0.003 and p=0.009 respectively). However, there
were no significant differences in serum tertile levels between these groups. Conclusion These
findings would suggest that antioxidant status may be more important in the pathogenesis of
RE than BE, however further investigation of these preliminary findings in larger population-
based studies will be necessary to validate these results. Future studies may also assess the
role of antioxidant therapy, as an adjunct to acid suppressant therapy, particularly in the
treatment of RE.
S1833
Does Claudin Expression Play a Role in the Acid Resistance of Barrett's
Esophagus?
Biljana Jovov, Christina M. Van itallie, John L. Carson, Nicholas J. Shaheen, James M.
Anderson, Roy C. Orlando
Backgraund & Aims: Barrett's esophagus (BE) is a lesion characterized by specialized colum-
nar epithelium lining the distal esophagus. It develops in subjects with acid reflux disease
as replacement for destroyed esophageal stratified squamous epithelium (SqE) - presumably
because it is more acid resistant than SqE. How BE resists acid injury is complex but one
means may involve alteration in the structure and function of its tight junctions. Methods:
To address this question, expression profiles were performed for 21 claudin genes by
quantitative RT-PCR and the highly expressed claudins were detected by western blot and
immunolocalized by fluorescence microscopy in endoscopic biopsies from both BE and
healthy SqE from subjects without esophageal disease. In addition the structure of the tight
junction in BE was determined using freeze fracture electron microscopy. Results: The results
showed that all 21 claudins were expressed in BE while 19 claudins were expressed in SqE.
Further, claudins 3, 4, 12, 15, 18 and 23 were overexpressed in BE compared to SqE, with
claudin 18 notable for being both the most highly expressed in BE and absent in SqE.
Immunolocalization studies in BE revealed that all tested claudins (except claudin 1) were
localized to the tight junctions, including claudin 18. Given the uniqueness of claudin 18
in BE, this claudin was expressed in MDCK II cells and shown to selectively increase
junctional resistance to cations (Na+) compared to standard MDCK II cells. Elaborate strands
observed on freeze fracture of BE support a complex tight junctional structure suggested
by the claudin expression profile and immunolocalization findings. Conclusions: These
results suggest that alterations in tight junction structure and function in BE is one means
for its greater acid resistance than SqE. Support: NIH grants DK036013, DK063669, and
DK45134.
S1834
The Role of the Xenobiotic Sensor Pxr in the Development of Barrett's
Esophagus
A. Van de winkel, L. M. Moons, V. Menke, A. Capello, R. G. Pot, H. Van dekken, E. J.
Kuipers, P. D. Siersema, J. G. Kusters
Introduction: Reflux of gastroduodenal contents containing xenobiotic compounds such as
bile acids is thought to play an important role in the pathogenesis of Barrett's esophagus
(BE). The xenobiotic sensor Pregnane X Receptor (PXR) is one of the factors involved in
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the metabolism of these compounds. Therefore, the expression of PXR is likely to contribute
to the manifestation of BE. As PXR activity is in part determined at a genetic level by
single nucleotide polymorphisms (SNPs) in the PXR gene, these SNPs may play a role in
susceptibility to BE. Aim: To investigate the association between PXR expression levels and
BE development. Methods: DNA was obtained from a total of 683 Caucasian subjects
comprised of 249 patients with BE, 233 patients with reflux esophagitis (RE), and 201
healthy controls. PXR haplotypes were based on the gene polymorphisms at -25358C/T,
7635A/G, and 8055C/T as determined by competitive allele specific PCR. PXR mRNA and
protein levels in biopsies from squamous epithelium (SE) and columnar epithelium (CE)
of patients with BE (n=8), SE of RE patients (n=8), and SE of controls (n=3) were determined
by quantitative Real-Time PCR and immunohistochemistry. Results: In RE biopsies, PXR
mRNA was expressed 26 fold higher than in SE of controls. In addition, a 70 fold increase
in PXR expression was found in CE compared to SE of BE patients. Immunohistochemical
staining of BE showed PXR-positivity in the cytoplasm of a fraction of intestinal-like columnar
epithelial cells, which was more frequent in the villi than in the crypts. Furthermore, the
PXR 7635G allele was more frequently observed in BE patients (39%) than in RE patients
(36%) and controls (33%) (BE vs controls: OR 1.36; CI 1.03-1.80 (p=0.03)). The same
trend was observed in allele distribution of the -25358 C/T and 8055C/T polymorphisms,
but there was no significant difference between the groups. Conclusions: PXR genotypes
associated with elevated PXR activity are associated with an increased risk of developing
BE. Additionally, increase in mRNA and protein levels of PXR correspond with a development
of healthy esophagus towards RE and BE. Thus, PXR levels may be involved in progression
towards a more advanced disease stage in the esophagus.
S1835
Abdominal Obesity and Body Mass Index As Risk Factors for Barrett's
Esophagus
Douglas A. Corley, Ai Kubo, Theodore R. Levin, Gladys Block, Laurel Habel, Charles
Quesenberry, Greg Rumore, Patricia A. Buffler
BACKGROUND: Barrett's esophagus is a strong risk factor for esophageal adenocarcinoma,
but little is known about its associations with body mass index (BMI) or abdominal obesity.
METHODS: We conducted a case-control study within the Kaiser Permanente Northern
California population. Persons with a new Barrett's esophagus diagnosis were matched to
subjects with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to
population controls. Subjects completed detailed questionnaires and a standardized anthro-
pometric examination. RESULTS: We interviewed 320 cases, 316 GERD patients, and 317
controls. There was an association between Barrett's esophagus and abdominal circumference
(independent of BMI) compared with population controls (OR=2.24 95% confidence interval
[CI] 1.21-4.15; circumference >80cm vs. <80cm); there was a threshold effect, with most
of the increased risk evident at circumferences above 80cm and no significant trend for
further increases in circumference. There was also a trend for association compared with
GERD patients (test for trend, p=0.03). There was no association between Barrett's esophagus
and BMI. Abdominal circumference was strongly associated with GERD symptoms (severe
weekly GERD symptoms, per 10cm increase in circumference OR=1.86 (1.03 - 3.38));
adjustment for GERD substantially attenuated the association between Barrett's esophagus
and abdominal circumference. CONCLUSIONS: Waist circumference, but not BMI, had
independent associations with the risk of Barrett's esophagus compared with both population
controls and GERD patients. The attenuation of the association after adjustment for GERD
supports the hypothesis that abdominal obesity is associated with Barrett's esophagus through
GERD. The threshold for increased risk may start at relatively small increases in abdom-
inal circumference.
S1836
Comparative Cytokine and Transcriptomic Profiling of Oesophageal Squamous
and Cancer Cells Exposed to Deoxycholate Reveals Cell Type Specific
Responses
Shane P. Duggan, Fiona Behan, Aideen Long, John V. Reynolds, Dermot Kelleher
Oesophageal adenocarcinoma (OAC) commonly arises from the presence of a premalignant
lesion known as Barrett's Oesophagus (BO). This condition most frequently occurs in the
setting of Gastro-Oesophageal Reflux Disease (GORD) in conjunction with as yet unidentified
genetic and environmental factors. The presence of abnormal concentrations of bile acids
in the reflux aspirates of GORD patients supported by various animal models has implicated
bile acids such as deoxycholate (DCA) in the promotion of oesophageal injury and meta-
plasticity. Previously we have reported the DCA-mediated activation of transcription factors
AP-1 and NF-kB through PKC and MAPK pathways in oesophageal cancer cells. Recently,
comparative cytokine and gene expression profiling of DCA mediated responses in oesopha-
geal squamous (HET-1A) and Adenocarcinoma (SKGT4) cell lines has been performed. This
method has highlighted important pathways de-regulated in oesophageal carcinogenesis.
Cytokine profiling of oesophageal cells exposed to DCA revealed extensive differences in
the secretion and expression of such key cytokines as IL-1A, IL-1B, IL-8, IL6, VEGF and
MCP1 between the two cell types. Transcriptomic approaches further outlined the differences
in pathway activation in response to DCA between HET 1A and SKGT-4 cells. In this
context, 3 main gene lists were generated, common transcript inductions (eg. DDIT3, VEGF,
SUI1, LATS2, KLF4, GDF15, MAFF), squamous specific (eg. NGFB, RAB45, CXCL14, TRIB3,
TIEG, RORA, SMAD7, DIAPH3) and adenocarcinoma cell-specific transcript inductions
(eg.CCL20, RGS3, DNAJB9, UHRF1, COX-2, IL-1B, IL-1A, ESM1). Many of these genes
were validated in separate experiments using real time RT-PCR. An additional layer of
bioinformatic analysis has compared the DCA-induced transcriptome with microarray data
sets charting oesophageal metaplastic progression (Kimchi et al 2005. GEO record:-
GDS1321). We have demonstrated that over 30% of the genes previously identified as
altered in the oesophageal carcinogenic sequence are involved in DCA signalling (eg. RORA,
DUSP1, NR4A1,2,3 LIF, GDF15 DAF, ATF3 and ESM1). “In silico” gene promoter site
analysis of the microarray data sets has identified key transcription factors, such as RORA,
involved in the regulation of DCA-signalling and carcinogenesis. This study has identified
numerous gene sets responsive to DCA with involvements in oesophageal carcinogenesis.
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Further functional analysis of the genes identified in this study will shed light on the
involvement of bile acids in oesophageal carcinogenesis and will hopefully provide new
targets for treatment of GORD, BO and ultimately OAC.
S1837
Is NSAID Use Associated with a Lower Risk of Barrett's Esophagus in Patients
with GERD Symptoms; A Case-Control Study
David L. Glenn, Ryan D. Madanick, Joseph Galanko, Ginny Sharpless, Nicholas J.
Shaheen
Background: Several studies have demonstrated a decreased risk of esophageal adenocarcin-
oma among subjects who chronically take NSAIDs. The impact of NSAID use on Barrett's
esophagus (BE) is less well understood. Aim: To compare NSAID history in subjects with
reflux symptoms and BE to those with reflux symptoms but no BE. Methods: We performed
a case-control study comparing subjects aged 18 and 80 with BE to those with reflux
symptoms but no BE. Cases had BE, defined as endoscopically visible tongues of any
size with histologic confirmation of intestinalized epithelium. Controls had classic GERD
symptoms. To minimize misclassification, we required controls to have had EGD in the last
year documenting the absence of BE. Subjects who had undergone ablative therapy and those
with previous esophageal resection were excluded. Subjects underwent upper endoscopy to
confirm histology. They then completed a series of questionnaires, assessing demographics,
GERD severity, and quality of life. Subjects also completed an extensive coordinator-per-
formed interview assessing both over-the-counter and prescription NSAID use. NSAID use
was classified into current, former, sporadic and never. Current and former users had at
least once/week use for at least 6 continuous months, either ongoing (current) or in the
past (former). Use was further quantified using “dose-years” of exposure, defined as the
recommended daily dose multiplied by no. years of exposure. Bivariate analysis was per-
formed assessing NSAID use by case-control status. Logistic regression was then performed
with case/control status as the outcome variable, NSAID use as the predictor variable, and
sex, age, tobacco use, and drinking as covariates. Results: To date, 360 subjects have been
enrolled. Seventy-six percent of cases were male, compared to 49% of controls (p=0.0002).
The mean age of cases was 55.8 (SD 8.6), and of controls 49.3 (SD 12.2) (p=0.0001).
Bivariate analysis demonstrated that NSAID use did not differ between cases and controls,
with 58% of cases reporting current or former NSAID use, compared to 57% of controls
(p=0.92). When assessed in separate strata, or grouped as current vs. former/sporadic/never,
no differences were found. The multivariate analysis demonstrated no differences in NSAID
use in cases and controls. Older age and male gender were risk factors for BE. Conclusions:
In contrast to a recent report, our large ongoing study found no differences in NSAID use
between cases and controls. Elucidation of the relationship between NSAIDs and BE is
important for understanding the pathogenesis of BE, and may impact chemopreventive strat-
egies.
S1838
Unlike Esophageal Squamous Cells, Metaplastic Barrett's Cells Resist UV-B-
Induced Apoptosis By Activating Nf-κB
Kathy Hormi-carver, Stuart J. Spechler, Rhonda F. Souza
Introduction: Apoptosis is an important mechanism for eliminating cells that have sustained
extensive, and potentially carcinogenetic, DNA injuries. To become malignant, cells must
acquire the ability to resist apoptosis. NF-κB is a transcription factor that plays a key role
in effecting resistance to apoptosis by enhancing the expression of survival pathway proteins
including Bcl2, XIAP, cIAP1, and survivin. In earlier studies, we showed that the metaplastic
cells of Barrett's esophagus are more resistant to apoptosis than esophageal squamous
epithelial cells. In this study, we tested our hypothesis that NF-κB activation mediates the
resistance to apoptosis in Barrett's cells. Methods: Non-neoplastic, telomerase-immortalized
esophageal squamous cells (NES-G2 and NES-B3) and Barrett's epithelial cells (Bar-T) were
exposed to 50 and 100 J/m2 of UV-B irradiation, which is known to cause DNA damage
that induces apoptosis in normal cells via enhanced expression of p53 and caspase. Apoptosis
was determined quantitatively by Annexin V staining; Western blotting was used to determine
the expression of NF-κB, p53, caspase-3, Bcl2, XIAP, cIAP1, and survivin. Results: Baseline
apoptosis rates determined by Annexin V staining were low in all 3 cell lines (Bar-T 4.21
± .04% SEM; NES-G2 4.91 ± .10%; NES-B3 4.41 ± .19%). Exposure to UV-B did not induce
apoptosis in Bar-T cells (4.19 ± .20% after 50 J/m2, 4.07 ± .21% after 100 J/m2), but
significantly increased apoptosis in NES-G2T cells (35 ± 1.9% after 50 J/m2, 58 ± 2.5%
after 100 J/m2) and NES-B3T cells (36 ± .21% after 50 J/m2, 60 ± .50% after 100 J/m2). In
the esophageal squamous cell lines, the UV-B-induced increase in apoptosis was accompanied
by a dose-dependent increase in p53 and cleaved caspase-3 proteins. UV-B irradiation
increased expression of NF-κB, Bcl2, XIAP, cIAP, and survivin proteins in a dose-dependent
fashion in Bar-T cells, but decreased the expression of those proteins in the squamous cell
lines. Resistance to UV-B-induced apoptosis in Bar-T cells was abolished by treatment with
a specific NF-κB inhibitor (Bay 117085) and by siRNA against NF-κB/p65. Conclusions:
Unlike esophageal squamous cells, Barrett's epithelial cells are resistant to apoptosis induced
by low-dose UV-B irradiation. This resistance to apoptosis is mediated by the activation of
NF-κB and by increased expression of survival pathway proteins including Bcl2, XIAP,
cIAP1, and survivin. This study elucidates molecular pathways whereby metaplastic Barrett's
cells are more resistant to apoptosis than native esophageal cells, a feature that may underlie
the persistence and malignant predisposition of Barrett's metaplasia.
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S1839
Role of Farnesoid-X-Receptor in Esophageal Carcinogenesis
Vidu Mokkala, Cathrine Demars, Kenneth K. Wang, Marlys Anderson, Lori S. Lutzke,
Raul A. Urrutia, Navtej Buttar
Background: Barrett's esophagus (BE) is a premalignant condition resulting from chronic
reflux injury. Bile salts contained in the refluxate are considered to promote carcinogenesis
and activate pro-carcinogenic pathways in BE. Contrary to this, some bile salts also act as
ligands which activate the farnesoid-X-receptor (FXR), with different bile salts having different
affinities for FXR. FXR activation has been shown to promote pro-apoptotic and anti-
proliferation genes and could potentially prevent the development of adenocarcinoma in
BE. Aims: 1) To assess for FXR expression in premalignant Barrett's, malignant esophageal
tissue and their respective cell cultures. 2) To examine the functional role of FXR in the
survival of adenocarcinoma cell line (SEG) transfected with retroviral vector carrying FXR
vs empty vector (EV). Methods: RNA was extracted from snap-frozen mucosal biopsies from
patients including squamous, premalignant BE, and adenocarcinoma of the esophagus, as
well as respective cell cultures. PCR was used for the initial screening of FXR expression
and confirmed by quantitative real-time PCR. Cell lines were treated with the selective FXR
agonist, chenodeoxycholic acid (CDCA), to see if FXR expression could be induced. SEG
cell line, which lacked FXR, was transfected with a retroviral vector carrying FXR or EV
alone, and expression of FXR was verified by PCR. Proliferation and apoptosis were examined
via BrdU and TUNEL immunostaining with Hoechst counterstain, Cell Death ELISA and
MTT assay. Results: In patients with adenocarcinoma, FXR expression is not seen in squam-
ous, Barrett's or adenocarcinoma; yet in patients who have not progressed to cancer FXR
expression is present in squamous and Barrett's tissue. FXR expression is lost in SEG.
Although the expression of FXR in SEG does not increase with addition of FXR agonist
CDCA or with EV alone, it can be restored via retroviral transfection of FXR. When FXR
is restored to SEG via retroviral transduction, cell survival is reduced by 23% (p<0.05) as
compared to EV only transfected cells. SEG shows 33% (p<0.05) increase in apoptosis with
the restoration of FXR when compared to EV alone. However, proliferation does not change
significantly. Conclusions: During the progression from premalignant to malignant condition
in Barrett's mucosa there is a loss of FXR expression. This loss of FXR expression is of
functional relevance as restoration of FXR expression in SEG via retroviral vector carrying
FXR decreases their survival by making them more prone to apoptosis. Further mechanistic
and in-vivo studies are underway to better understand the importance of FXR in carcinogen-
esis in BE.
S1840
Heterogeneity of Telomerase Immortalized Benign Barrett's Cells: Selective
Response of Columnar Cells to Colonic Metaplasia By Acid and Bile
Manisha Bajpai, Rhonda F. Souza, Kiron M. Das
Introduction: Barrett's epithelium (BE) is a metaplastic process at the distal esophagus, due
to a chronic gastroesophageal reflux disorder. The origin of these metaplastic cells is unclear.
A telomerase (hTERT) immortalized cell line derived from endoscopic biopsies from a patient
with long segment BE was utilized to investigate cellular phenotypes and the reactivity to
a novel monoclonal antibody, mAb Das-1 (IgM isotype). mAb Das-1 reacts with BE tissue
with 100% sensitivity and specificity. mAb Das-1, developed against a colon epithelial
protein, reacts with the epithelium of colon but not with the small intestine, stomach or
esophagus, suggesting that BE is a colonic phenotype of metaplasia. Materials and Methods:
The immortalized cells were examined systematically, with and without exposure to acid
(pH4) and bile (100mM chenodeoxycholic acid) for up to 2 weeks, utilizing monoclonal
antibodies, mAbs (all IgG), against several cytokeratin (CK) markers, CK8&7 (columnar
cells), CK4 (squamous cells), and mAb Das-1 (colonic phenotype). The cells were incubated
with primary mAbs, followed by fluorescent conjugated anti-mouse IgG or IgM and analyzed
by FACS and immunohistochemistry. Additional marker included p75NTR (esophageal stem
cells). Results: Thirty-five-50% of these immortalized cells reacted with mAb Das-1, sug-
gesting the presence of both colonic and non-colonic phenotypes. Forty-50% of the cells
reacted with CK8 and CK7, only 7% against CK4, and 4-7% reacted with p75NTR. To
identify the phenotype of cells that react with mAb Das-1, double color immunofluorescence
was performed utilizing FITC-anti-mouse IgG and PE-anti-mouse IgM. This assay demon-
strated that mAb Das-1 positivity distinctively co-localized with the CK8 and CK7+ cells.
None of the CK4+ cells reacted with mAb Das-1. Exposure to acid and bile for 2 weeks
showed 40-50% increase in the reactivity of CK8 and mAb Das-1 positive cells but not
CK4+ cells, suggesting preferential response of the columnar/colonic metaplastic cells by
acid and bile salt. Some of the p75NTR+ cells (untreated) also reacted with mAb Das-1,
suggesting a possible origin of metaplastic cells. Conclusion: Telomerase-immortalized
benign “BE cells” contain populations of cells that react with markers of a colonic phenotype,
of a columnar phenotype, of a squamous cell phenotype, and of stem cells. While acid and
bile amplified proliferation of CK8/mAb Das-1 positive cells, cells expressing squamous cell
marker were not influenced in the short-term culture. These immortalized cells may provide
a novel approach to investigate, further, the effects of environmental factors and the origin
of BE.
S1841
Exposure to Radiation Increases the Risk of Barrett's and Multilayered
Epithelium
Helen M. Shields, Abram Recht, Helen H. Wang
The relationship between radiation and the development of Barrett's (goblet cell metaplasia)
and/or multilayered epithelium has not been previously investigated. Aim: We compared
the presence of Barrett's and/or multilayered epithelium in endoscopic biopsy specimens
between a group of patients potentially exposed to chest radiation and a control group.
Methods: Six hundred and seventeen charts over a period of 23 years from one gastroenterolo-
gist's practice (HMS) were reviewed for patients with a history of radiation therapy. Thirty
such patients were identified. Of these, fifteen (14 women, 1 man; age: 37 to 78 years with
a mean of 58 years) had an endoscopic biopsy of the gastroesophageal junction (GEJ)
performed six months to 21 years after irradiation. Radiation therapy was given for breast
cancer (9), Hodgkin's disease (2), lymphoma (1), malignant thymoma (1), a brain tumor
with subsequent high-dose chemotherapy and bone marrow transplant for leukemia (1),
and an adenoid cystic carcinoma of the submandibular gland (1). Only endoscopic biopsies
from the GEJ that contained both squamous and columnar mucosa were evaluated. The
control group consisted of 30 patients who were individually gender- and age-matched (age:
39 to 82 years with a mean of 58 years), and who had an endoscopic biopsy specimen
taken from the GEJ within 2 months of the biopsy of the exposed patient. None of the
controls had a history of radiation therapy, or known Barrett's or multilayered epithelium
at the time of biopsy. Results: Eight of the 15 irradiated patients (53%) had Barrett's (goblet
cell metaplasia) in contrast to 6 of 30 (20%) of the control patients (odds ratio: 3.5, 95%
confidence interval [CI] of 1.0 - 12; P=0.03). In addition, in the irradiated group, 6 of the
15 patients (40%) had multilayered epithelium, in contrast to 3 of 30 (10%) of control
patients (odds ratio: 5.5, 95% CI of 1.0 - 29; P=0.02). In the radiation therapy group, 10
of 15 (67%) irradiated patients had Barrett's and/or multilayered epithelium, in contrast to
7 of 30 (23%) control patients (odds ratio: 4.3, 95% CI of 1.2 - 14; P=0.01). The interval
from radiation to the diagnosis of Barrett's ranged from 1 to 21 years. Conclusions: Our
study shows a significant association of Barrett's and/or multilayered epithelium with prior
radiation therapy. The underlying mechanisms, including the potential contribution from
the chemotherapy many of these patients received, need to be determined. Further studies
of the association of radiation therapy and esophageal metaplastic changes are needed.
S1842
Role of the Immune Response in the Development of Barrett's Esophagus
Astrid Capello, Vivianda Menke, Rebecca C. Kiekens, Paulina M. Van strien, Ernst J.
Kuipers, Johannes G. Kusters, Peter D. Siersema
Barrett's esophagus (BE) is a chronic inflammatory condition resulting in an increased risk
of developing esophageal adenocarcinoma. Little is known about the initial stages of the
inflammatory processes associated with BE development. In this study, we investigated the
role of the immune response in the initial stages towards the development of BE in a mouse
model. Since esophagitis is characterized by a Th1 and BE with a Th2 type immune response,
two different mouse strains, i.e. a Th1 prone (C57Bl/6) and a Th2 prone (Swiss Webster) strain
were used. Methods: Esophagojejunostomy and gastrectomy (GEJ-model) was performed in
8-week old male mice; 30 C57Bl/6 and 30 Swiss Webster (SW). Mice were sacrificed at 4,
8 and 16 weeks. Mucosal thickness of the esophagus, and distance to the anastomosis was
determined with Nikon EclipseNet software in HE stained slides of the esophagus. The
immune response was characterized using immunohistochemistry (IHC) with specific anti-
bodies against macrophages, dendritic cells (DC's), B cells (B220), and T cells (CD3), T
helper (Th, CD4) cells and cytotoxic T (Tc, CD8) cells. Results: In SHAM operated mice,
no inflammation was found in the esophagus, resulting in a mean mucosal thickness of
0.035 mm in both strains. Over time, an increase in the inflammatory reaction was observed
in the esophagus, which was associated with an increase of the mucosal thickness. At 16
weeks post GEJ, the mean longitudinal length of the inflamed tissue was significantly longer
in SW mice than in C57Bl/6 mice (17.64±1.4 mm vs. 6.40±2.1 mm, respectively, p=0.002).
IHC revealed that in SHAM operated SW mice more Tc (CD8) cells and Th (CD4) cells
were found in comparison with C576Bl/6 mice. While both mouse strains displayed a
pronounced increase in the number of immune cells, the predominant cell types clearly
differed between the two strains, i.e., more eosinophils, B cells, T (CD3) cells and Th (CD4)
cells were found in SW mice compared to C57Bl/6 mice at all time points. However, in
C57Bl/6 mice, an increase in Th (CD4) cells was detected over time, which was not observed
in SW mice. Conclusions: The GEJ model applied in different strains of mice is suitable
to study the immune response in the initial stages towards the development of BE, with
SW mice showing a more pronounced humoral type immune response (Th2) indicated by
an increased number of eosinophils and B cells. It remains to be established whether this
would translate into some mice strains being more sensitive to the development of BE.
S1843
Metaplastic & Neoplastic Coculture Model for Barrett's Esophagus
Cathrine Demars, Vidu Mokkala, Kenneth K. Wang, Marlys Anderson, Lori S. Lutzke,
Navtej Buttar
BACKGROUND: Current In Vitro methods of studying carcinogenesis in Barrett's esophagus
(BE) involve the use of either metaplastic or neoplastic cell culture. However, in reality,
metaplastic, dysplastic & neoplastic cells are often all found in a single biopsy specimen of
BE. These cells likely influence the growth dynamics of each other. Moreover, growth
modulatory agents released from underlying stromal cells may exert differential effects on
the metaplastic & neoplastic cells when they are present together. AIM: To develop &
characterize a novel coculture model of metaplastic & neoplastic cells from BE & examine
if pathophysiological agents differentially affect cell growth in coculture. METHOD: Primary
Barrett's epithelial cultures, metaplastic cell line (BAR: immortalized Barrett's) & neoplastic
cell lines (SEG, FLO, BIC: esophageal adenocarcinoma) were cultured in varying ratios &
maintained in Barrett's Plus media. Cells were labeled with red or green membrane dye
prior to coculture to distinguish cell type. Doubling time was calculated to test the effect
of the labeling dyes on cell growth. Cocultures were treated with 1 or 2 ng/mL PGE2, 200
uM bile acid mix (for 15 minutes), or vehicle every 48 hours for 7 days. Single cell type
cultures were included as controls. Proliferation & apoptosis were determined by BrdU
immunostaining & TUNEL. Cells were counterstained with Hoechst & total cell numbers
counted in a blinded manner via microscopy. RESULTS: Metaplastic & neoplastic cells grew
well together in coculture. The most optimal results were obtained by growing benign &
malignant cells in a 1:5 ratio. Membrane dyes did not affect the doubling time. When grown
individually, PGE2 increased proliferation of both malignant & benign cells by 80% & 75%,
respectively (p<0.05). PGE2 decreased apoptosis of malignant cells by 25% (p<0.05) & had
no effect on apoptosis of benign cells. In coculture, PGE2 treatment increased survival of
malignant SEG cells by 70% compared to control, but reduced survival of benign primary
Barrett's cells by 18% (p<0.05). Individual treatment of benign & malignant cells with bile
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resulted in a 48% decrease in survival of SEG cells compared to control, but had no effect
on BAR cell survival. However, treatment of cocultures with bile resulted in 24% decline
in BAR cells & 52% decline in SEG cells survival (p<0.05, compared to control). CONCLU-
SION: This novel metaplastic-neoplastic coculture model provides an innovative way to
assess the effect of various pathophysiological agents that can influence cell growth in
BE. We are currently exploring how metaplastic & neoplastic cells influence each others
growth dynamics.
S1844
Bile Acid Stimulated Expression of the Farnesoid X Receptor Enhances the
Immune Response in Barrett Esophagus
Astrid Capello, Leon M. Moons, Ernst J. Kuipers, Peter D. Siersema, Johannes G. Kusters
Introduction: Barrett esophagus (BE) is a chronic inflammatory condition resulting in an
increased risk for the development of esophageal adenocarcinoma. Exposure to acid and
bile containing reflux may play an important role in the induction and maintenance of the
chronic inflammation in BE. The exact role of bile acids in this process remains however
unclear. The Farnesoid X Receptor (FXR) is a nuclear receptor involved in the regulation
of synthesis, as well as in transport and absorption of bile acids. It also plays a role in the
activation of the innate immune response. Deoxycholid acid (DCA) is a potent activator of
FXR, whereas guggulsterone acts as an FXR inhibitor. Aim: To investigate the relationship
between DCA and FXR and the induction of the chemokines IL-8 and MIP3α. Methods:
In Vivo expression levels of FXR, IL-8, and MIP3α proteins were determined by immunohisto-
chemistry in biopsy specimens taken from Barrett's epithelium and squamous epithelium
of 15 patients with BE. mRNA levels were determined by semi-quantitative RT-PCR. The
effect of DCA exposure on mRNA levels of FXR, IL-8 and MIP3α were investigated in the
esophageal adenocarcinoma cell line TE7, with or without pre-treatment of the FXR inhibitor
guggulsterone. Results: FXR expression was found in biopsy specimens of patients with BE
on both a transcriptional level and immunohistochemically. A 2.3-fold (p=0.02) increase in
FXR expression was found in Barrett's epithelium compared to squamous epithelium of the
same patient. Similarly, a 1.5-fold increase (p=0.04) in IL-8 expression, and a 1.7-fold
increase (p=0.019) in MIP3α expression was found in biopsies from Barrett's epithelium.
In Vivo experiments revealed that after exposure of TE7 cells to 200 µM DCA, FXR (4.7-
fold; p=0.002), IL-8 (3.3-fold; p=0.007) and MIP3α (19.2-fold; p<0.0001) were increased
compared to untreated cells. This increase in FXR levels was reduced to almost zero if cells
had been pre-treated with guggulsterone (p<0.0001). In addition, a dose-dependent decrease
of IL-8 (2.9-fold; p=0.007), and MIP3α (3.0-fold; p=0.002) was observed if cells were pre-
treated with guggulsterone. Conclusions: The bile acid receptor FXR and the chemokines
IL-8 and MIP3α are increased in Barrett's epithelium compared to squamous epithelium of
BE patients. The In Vivo induction by DCA suggests that bile acids actively may induce the
inflammatory response in BE by recruiting cells that are involved in this process.
S1845
Helicobacter pylori and Caga+ Infection Status As Risk Factors for Barrett's
Esophagus and Gastroesophageal Reflux Disease
Douglas A. Corley, Ai Kubo, Theodore R. Levin, Gladys Block, Laurel Habel, Greg
Rumore, Charles Quesenberry, Patricia A. Buffler, Julie Parsonnet
BACKGROUND: Gastric colonization with Helicobacter pylori is a proposed protective factor
against esophageal adenocarcinoma but little is known about its associations with Barrett's
esophagus (a metaplastic change of the esophagus that is a strong cancer risk factor), and
its possible association with gastroesophageal reflux (GERD) is controversial. METHODS:
We conducted a case-control study within the Kaiser Permanente Northern California popula-
tion. We identified all persons with an incident diagnosis of Barrett's esophagus (cases);
cases were matched to persons with GERD (without Barrett's esophagus) and to controls.
Subjects completed anthropometric examinations, interviews and antibody testing forHelicob-
acter pylori and its cagA protein. GERD symptoms were graded using a validated question-
naire. RESULTS: We evaluated 318 cases, 312 GERD patients, and 299 population controls.
Helicobacter pylori prevalence was similar among cases and GERD controls. Compared with
population controls, patients with Barrett's esophagus were substantially less likely to have
antibodies for Helicobacter pylori (odds ratio [OR]=0.40, 95% confidence interval [CI]0.24-
0.65); The association was stronger among those with lower body mass indexes (BMI<25
OR=0.02, 95%CI 0.00-0.16) and those with cagA+ strains (OR=0.07, 95%CI 0.02-0.34).
There was also a strong inverse association between Helicobacter pylori and GERD symptom
severity (OR=0.17, 95%CI 0.07-0.39; severe symptoms) or frequency (OR=0.15, 95%CI
0.07-0.32; symptoms >weekly). CONCLUSIONS: Helicobacter pylori infection and cagA+
status were inversely associated with both Barrett's esophagus and GERD symptoms. The
findings are consistent with the hypothesis that Helicobacter pylori colonization protects
against GERD and the subsequent development of Barrett's esophagus.
S1846
Risk Factors for Barrett's Oesophagus Among Middle-Aged Men with Reflux
Disease: A Case-Control Study
Nicholas Stern, Keith Bodger
INTRODUCTION: In a minority of reflux patients, mucosal inflammation (reflux oeso-
phagitis, RO) is associated with the development of Barrett's metaplasia (BM). Each year,
about 0.5% of people with BM develop adenocarcinoma (AdC). The factors that determine
why a patient with RO develops BM are incompletely understood. AIMS & METHODS:
The present case-control study aimed to explore risk factors associated with the presence
of BM in middle-aged men with reflux disease. A consecutive series of male, caucasian,
middle-aged patients (Born: 1945-1965) were identified from endoscopy records. Cases of
BM included those with at least 3cm of columnar mucosa (confirmed histologically) and
the control group included those with RO (LA Grade A-B), identified in a ratio of 1:2
(BM n=203:RO, n=401). Each individual was sent a locally-piloted postal questionnaire,
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incorporating a validated reflux score, lifestyle questions and items regarding present and
past weight (at age 20), waist measurement and height. RESULTS: The response rate was
39.4% (BO, n=90; RO, n=148), with respondents closely age-matched (Mean [SD] yrs: BO
51.2 [6.1]; RO 50.7 [5.9]). Compared to controls, BM patients reported: (i) Longer duration
of heartburn symptoms (>12 yrs, p=0.003; >20 yrs, p=0.005); (ii) A higher Body Mass Index
at age 20 years (23 vs 22, p=0.047); but (iii) A lower frequency of eating within an hour
of bedtime (9% vs 18.5%, p=0.047). No significant differences in frequency of nocturnal
symptoms, current BMI, aspirin or NSAID use, smoking, alcohol, frequency of exercise or
‘fast-food' consumption. CONCLUSION: Among middle-aged, caucasian males with reflux
disease, the presence of BM was associated with a longer history of reflux symptoms and a
higher reported BMI in early adult life. Overweight young adults with reflux may be at
particular risk of developing BM. This is consistent with epidemiological data suggesting
that reflux symptoms and obesity are independent risk factors for AdC. The mechanisms
whereby obesity might enhance the risk of malignant progression remain unclear.
S1847
Regulation of Intracellular pH By Na+/H+ Exchange in a Non-Neoplastic,
Telomerase-Immortalized, Barrett's Cell Line
Nelia A. Tobey, Karen Brown, Roy C. Orlando
AIM: Barrett's esophagus (BE) refers to a metaplastic specialized columnar epithelium that
replaces acid reflux-damaged stratified squamous epithelium in the distal esophagus. This
suggests that Barrett's is a form of adaptive protection against further reflux injury. Since
extrusion of hydrogen ions (H+) from the cytoplasm by Na+/H+ exchange (NHE) is one
means by which all epithelia defend against acid injury, we sought to identify and characterize
this process in a non-neoplastic, telomerase-immortalized Barrett's cell line (BCL).
METHODS: BCL (courtesy of R. Souza, Southwestern University, Dallas, TX) were grown
on glass coverslips and loaded with the pH-sensitive dye, BCECF, for recording of intracellular
pH (pHi) by fluorescence microscopy using a ratio imaging technique. RESULTS: In HEPES
solution at 25oC, basal pHi of BCL was 7.41 ± 0.03 (n=25); and when exposed to amiloride,
1mM, or Na+-free HEPES, n=4-5, resting pHi declined at a rate of 0.08 ± 0.03 and 0.12 ±
0.06 units/min with pHi falling to 7.18 ± 0.05 and 7.06 ± 0.12, respectively. Acidification
of BCL by exposure to NH4Cl, 20 mM, or HCl, pH 6.0, for 3 min, n=6-10, resulted in
declines in pHi by 0.54 ± 0.05 and 0.41 ± 0.03, with recovery rates of 0.15 ± 0.04 and
0.16 ± 0.02 pH units/min, respectively; however, recovery from acidification after NH4Cl
was completely abolished by amiloride or Na+-free solution, n=8-10. CONCLUSIONS: The
BCL possesses a Na+-dependent, amiloride-sensitive, acid-extruding mechanism consistent
with NHE. NHE in BCL is active in both resting and acid-challenged states and as such
contributes to the capacity of BE to resist damage upon exposure to acid reflux. Support:
NIH DK 063669.
S1848
The Relationship Between Obesity with Hiatal Hernia and Barrett's Esophagus
David J. Desilets, Brian H. Nathanson, Farhad Navab
Introduction: Recent studies suggest that obesity may disrupt the esophago-gastric junction
leading to hiatal hernia (Gastroenterol 2006;130:639). There is a relationship between obesity
and Barrett's esophagus (BE) and esophageal adenocarcinoma (Dis Esoph 2006;19:321).
Because of the increasing incidence of obesity more information is needed on the relationship
between weight gain and other lifestyle risk factors with BE. Methods: 148 patients with
BE were studied over 1999-2005. Diagnosis was made endoscopically and confirmed on
histology as presence of intestinal metaplasia. Hiatal hernia (HH) was measured endoscopicaly
as cm above the squamocolumnar junction. The cohort was divided into those with long-
segment BE (LSBE, defined as BE >= 3 cm (n=72), and those with Short-segment BE (SSBE),
BE < 3 cm (n=76). 113 (76.4%) were males. Median age and range in LSBE 51.5 yr (29-
91); and SSBE 54.5 yr (24-91). Body weights and heights were measured at time of diagnosis.
Hiatal hernia length, BE length, and an increase in weight of > 5 lb (2.3kg) over 5 years
prior to diagnosis were recorded as were duration of reflux symptoms, current or past
tobacco smokers and present or past alcohol users (> 5 drinks per day). Results: There was
no difference in BMI by BE length (SSBE, BMI 28.8 (6.2) vs. 29.9 (10.1), p =0.48) but both
groups were significantly overweight (BMI&; 25; p <0.001), with 74.3% in LSBE and 79.0%
in SSBE. Obese patients (BMI > 30) showed no difference in gender, HH or BE length
compared with those with BMI < 30. However, obese patients had a younger presentation
50.2 (13.8) yr vs. 56.7 (14.4), p < 0.008. Patients who admitted to a weight gain of 5 lb
(2.3kg) (n = 90) had a longer HH (3.5 (2.1) cm vs. 2.8 (1.9) cm, p < 0.026) but did not
have longer BE lengths. However, longer HH lengths were correlated to longer BE lengths
(0.68, p<0.001). Patients who had a history of all three negative lifestyle risk factors (n=
34): weight gain, tobacco use, smoking and alcohol use, presented at a younger age than
those with no risk factors (n =11); 50.3 (12.3) yr vs. 59.7 (16), p < 0.027 and were more
likely to be male (87.2% vs. 0%, p< 0.001) but had no difference in BE length. Conclusions:
A large proportion (76.7%) of patients with BE are overweight (BMI > 25). BMI is not
correlated with BE length. A weight gain over the 5 yr prior to diagnosis increases HH
length, but does not affect the length of BE. The results support the concept that the length
of BE remains stable. A high BMI and the 3 lifestyle factors (smoking, drinking, weight
gain) appear to cause an earlier onset of BE, and may provide more time for mucosal injury.
S1849
Patterns of Aneuploidy in Long Segment Barrett's Esophagus
Christian G. Peyre, Steven R. Demeester, Andrew L. Tang, Shahin Ayazi, Jessica M. Leers,
Nuttha Ungnapatanin, Michael F. Press, John C. Lipham, Jeffrey A. Hagen, Tom R.
Demeester
BACKGROUND & AIMS: Aneuploidy has been shown to be an important risk factor for
the progression of Barrett's esophagus (BE), and it is known that most cancers occur in the
distal portion of a long-segment of Barrett's esophagus. However, little is known about the
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distribution of aneuploid cells within long-segment Barrett's esophagus. Previously, most
studies used flow cytometry to evaluate for aneuploidy, but it is now possible to detect
aneuploidy using fluorescent in-situ hybridization (FISH). The aim of this study was to
determine the distribution of aneuploid cells within long segment Barrett's esophagus.
METHODS: Standard 4 quadrant biopsies were taken from the gastroesophageal junction
and every 2 cm throughout the columnar mucosa in patients undergoing evaluation for
reflux symptoms. The presence of intestinal metaplasia was confirmed with H&E staining.
Formalin fixed, paraffin embedded biopsy samples from each level were then analyzed using
FISH. Samples were sectioned, deparaffinized, treated with a protease solution, denatured
and hybridized overnight with selected probes (Vysis, Downers Grove, Il). For each biopsy
level, 100 Barrett's cells were enumerated using probes for chromosomes 4 and 8. Each cell
was classified as diploid (2 fluorescent probes per nucleus) or aneuploid. Results were
clustered by presence or absence of dysplasia and by distance from gastroesophageal junction
(distal: 0-3 cm, mid: 4-8 cm, proximal: >8 cm) for analysis. RESULTS: Eleven patients with
long segment BE were randomly selected for this study. Median length of BE was 10 cm.
The study population consisted of 5 patients with non-dysplastic BE and 6 with both
dysplastic and non-dysplastic segments on routine histology. There was a significant increase
in the percentage of aneuploid cells from non-dysplastic to dysplastic Barrett's (24.1% vs
36.1%, p<0.0001). Additionally, aneuploid cells were uniformly distributed within long
segments of nondysplastic Barrett's esophagus (distal esophagus 25%, mid-esophagus 24%,
proximal esophagus 25%, p=NS). CONCLUSIONS: These findings suggest that FISH may
be a useful technique to detect and follow the presence of aneuploidy in patients with Barrett's
esophagus. Importantly, in non-dysplastic long-segment Barrett's esophagus aneuploid cells
appear to be uniformly distributed through the length of columnar mucosa. Thus, aneuploidy
alone can not explain the observed preference for cancer development distally in long-
segment Barrett's esophagus.
S1850
Differences in Inhibitory Phosphorylation of Mek1/2 in Benign Esophageal
Squamous Cell Lines from Patients Who Have GERD with and Without
Barrett's Esophagus
Deena Thomas, Hui ying Zhang, Xi Chen, Xi Zhang, Kathy Hormi-carver, Robert M.
Genta, Stuart J. Spechler, Rhonda F. Souza
Introduction: Acid exposure is known to activate a number of signal transduction pathways
that can affect cell growth. It is not known why only a minority of patients who have
pathological acid reflux develop Barrett's metaplasia, but it is possible that differences among
patients in the esophageal squamous cell signaling pathways that are triggered by acid reflux
might play a role. We have shown that acid exposure activates ERK1/2 (a pro-proliferative
member of the mitogen activated protein kinase family) in the squamous epithelium of
patients who have GERD without Barrett's esophagus, but not in those with Barrett's eso-
phagus. To explore the mechanisms underlying this difference in acid-induced signaling,
we studied the phosphorylation of MEK1/2, an upstream kinase for ERK1/2, at baseline and
after acid exposure in benign, telomerase-immortalized, esophageal squamous epithelial cell
lines derived from patients who had GERD with Barrett's esophagus (NES-B3) and without
Barrett's esophagus (NES-G2). Methods: NES-G2 and NES-B3 cells were exposed to acidic
media (pH 4.0) for 3, 5 or 10 minutes; cells in pH-neutral media alone served as a control.
Western blotting was used to determine MEK1/2 phosphorylation at two activating sites
(serines 218/222) and at one inhibitory site (threonine 286); β-tubulin was used as a loading
control. Results: There were no apparent differences in the levels of phospho-MEK1/2 at
the two activating sites between NES-G2 and NES-B3 cells, either at baseline or after acid
exposure. In contrast, we detected a strong signal for phosphorylation of MEK1/2 at the
inhibitory site in NES-B3 cells, but we detected no such signal in NES-G2 cells. Acid exposure
had no apparent effect on the expression levels of phospho-MEK1/2 at the inhibitory site
in NES-B3 cells, and acid exposure did not induce inhibitory MEK1/2 phosphorylation in
NES-G2 cells. Conclusions: In esophageal squamous cell lines derived from patients with
GERD, we found inhibitory phosphorylation of MEK1/2 in those from a patient with Barrett's
esophagus, but not in those from a patient without Barrett's esophagus. In patients with
GERD who develop Barrett's esophagus, we speculate that inhibitory phosphorylation of
MEK1/2 may prevent acid-induced ERK1/2 activation in esophageal squamous cells, thereby
predisposing to mucosal repair through metaplasia rather than regeneration.
S1851
In Benign Barrett's Epithelial (Bar-T) Cells, Acid Exerts Anti-Proliferative
Effects Through Activation of the Chk2 Pathway
Hui ying Zhang, Xi Zhang, Linda A. Feagins, Deena Thomas, Stuart J. Spechler, Rhonda
F. Souza
Introduction: In Barrett's cancer cell lines, acid exposure has been found to induce prolifera-
tion. In a benign, telomerase-immortalized Barrett's cell line, in contrast, we have shown
that acid has anti-proliferative effects that are mediated in part by p53. Cell proliferation
also can be mediated by Cdc25A, a phosphatase that activates the Cyclin E-cdk2 complex,
which promotes progression through the cell cycle. Cdc25A is degraded through activation
of the Chk1/Chk2 kinases. Thus, Chk1/Chk2 activation can cause cell cycle arrest because
the degraded Cdc25A cannot activate Cyclin E-cdk2. To elucidate mechanisms underlying
the anti-proliferative effects of acid on Barrett's epithelial cells, we exposed those cells to
acid and studied their proliferation, Chk1/Chk2 and Cdc25A levels, and Cyclin E-cdk2
activity. Methods: Telomerase-immortalized, benign Barrett's epithelial (BAR-T) cells were
exposed to acidic media (pH 4.0) for 10 minutes, and proliferation was determined by cell
counting, by BRDU incorporation, and by entry into S phase on flow cytometry. At multiple
time points after the acid exposure, we determined expression levels of phospho/total Chk1/
Chk2 and Cdc25A by Western blotting, and we determined Cyclin E-cdk2 activity by an
immunoprecipitation-kinase assay. In addition, the effect of acid on entry into S phase was
determined in the presence and absence of a Chk2 inhibitor (caffeine).Results: Acid exposure
caused a significant decrease in cell number (1234 ± 13 to 899 ± 16 SEM), in BRDU
incorporation [1.9 ± .05 to 1.5 ± .04 relative intensity units (RIUs)], and in S phase entry
(82 ± 3.7% of control). The level of phospho-Chk2 had increased by 15 minutes after acid
exposure, but no phospho-Chk1 was detected at any of the time points. By 30 minutes,
the Cdc25A level had decreased, as had cyclin E-cdk2 activity. The delay in S phase entry
was abolished by treatment with a Chk2 inhibitor. Conclusions: In non-neoplastic Barrett's
epithelial (BAR-T) cells, acid exposure exerts an anti-proliferative effect by activating the
Chk2 pathway, which decreases Cdc25A levels and Cyclin E-cdk2 activity. This study
elucidates molecular pathways whereby acid exposure exerts potentially beneficial, anti-
proliferative effects on benign Barrett's epithelial cells.
S1852
High Fidelity DNA Histograms of Surface and Crypt Cells in Barrett's
Intestinal Metaplasia and Dysplasia
Xiaoqi Zhang, Qin Huang, Raj K. Goyal, Robert D. Odze
The histopathological diagnosis of dysplasia in Barrett's esophagus traditionally requires the
presence of dysplastic change in surface as well as crypt cells. It was recently shown that
biopsies of Barrett's epithelium with crypt dysplasia and surface maturation show molecular
abnormalities similar to conventional dysplasia suggesting that it may represent a form of
true dysplasia (Lomo et al, 2006). It has also been shown that high fidelity DNA histograms
(HFDH) using image cytometry on tissue sections can provide highly reproducible DNA
content analysis of pre-selected groups of cells (Huang et al, 2005). In present study, HFDH
were obtained on surface epithelium and crypt cells in biopsies histologically diagnosed as
Barrett's intestinal metaplasia (IM) (n=15), IM with crypt dysplasia (IM-CD) (n=15), low
grade dysplasia (LGD)- (n=15) and high grade dysplasia (HGD) (n=6), which were kept
blinded to the operator. The DNA content measurement parameters including values of
DNA index (DI) of the peaks, DNA heterogeneity index (HI, representing cell populations
with different DNA contents) and 5N exceeding fractions (percent of cells with DNA content
greater than 5N) were calculated. Elevation of 5N exceeding rate has been suggested to
indicate severe chromosomal instability and a maker of neoplastic progression and poor
outcome. The surface cells in IM and IM-CD had normal DI values of peaks and HI. However,
the DNA content parameters were significantly elevated in the crypts of IM and IM-CD
(p<0.05). Moreover, the DNA content parameters were all significantly higher in the crypts
of IM-CD than those in IM (p<0.05), but similar with that of LGD (p>0.05), suggesting
that the DNA content abnormalities in IM-CD were more like that in LGD, rather than in
SIM. The DI values, HI and 5N exceeding fractions were significantly elevated in the surface
cells of LGD and HGD, compared to IM or IM-CD (p <0.05). However, there was no
significant difference in the mean DI values, HI or 5N exceeding rate between surface and
crypt cells in LGD or HGD. All DNA ploidy values in HGD were significantly worse than
LGD (p<0.05). These studies show that: 1) Elevation of HI is an early abnormality followed
by increase in DI of the main peak (aneuploidy); 2) DNA abnormalities start in the crypts
of IM at an early stage of disease; 3) DNA abnormalities in the crypts of IM-CD are similar
to those of conventional full crypt histologically defined dysplasia. We suggest that Barrett's IM
may, in itself represent a neoplastic epithelium and IM-CD is an early form of true dysplasia.
S1853
Differential Effects of Deoxycholic Acid and Ursodeoxycholic Acid On
Apoptosis, NfκB Activation, Expression of COX-2 and Release of Vascular
Endothelial Growth Factor (Vegf) in Barrett's Carcinoma Cell Line
Gregor Burnat, Matthias Engel, Matthias Ocker, Eckhart G. Hahn, Peter C. Konturek
Background and Aims: Bile acids have been suggested to play an important role in the
progression of Barrett's epithelium into adenocarcinoma. Ursodeoxycholic acid (UDCA)
significantly reduces the risk of colorectal cancer, while, deoxycholic acid (DCA) has been
implicated in the promotion of carcinogenesis in gastrointestinal tract. The molecular effects
of these bile acids on carcinogenesis in the Barrett's epithelium are poorly understood.
Therefore, we compared the effects of UDCA with that of DCA on apoptosis rate, activation
of NFκB, synthesis and release of vascular endothelial growth factor and expression of COX-
2 and release of PGE2 in Barrett's carcinoma cell line (OE-19). Methods: OE-19 cell line
was incubated with UDCA or DCA (100-300 µM) for 24 h at neutral or acidic pH. The
apoptosis rate was analyzed by FACS method and the expression of p21 was assessed by
Western blot. The mRNA expression for COX-2, VEGF and DNA-repair enzymes (MUTYH,
OGG1) was measured in OE-19 cells by quantitative RT-PCR, whereas the release of VEGF
and PGE2 in culture medium by ELISA. In addition, activation of NFκB (NFκB-p65) was
analyzed in nuclear extracts by Western blot and OE-19 cells were incubated in the presence
or absence of NFκB inhibitor (MG-132). Result: In contrast to UDCA, DCA induced higher
apoptotic rate and caused a deregulation of cell cycle with acceleration of S/G2 phase
transition and inhibition of p21 expression. In addition, DCA caused stronger downregulation
of mRNA expression for DNA repair enzymes (MUTYH and OGG1) and higher expression
and release of VEGF. DCA induced higher NFκB activation than UDCA and the blockade
of NFκB activity attenuated the stimulatory effect of DCA on COX-2 expression. In acidic
pH (pH=5), the stimulatory effect of both bile acids on COX-2 was stronger than in neutral
pH (pH=7). Conclusions: UDCA has a lower carcinogenic effect on Barrett's cells than DCA.
This is due to its weaker stimulatory effect on NFκB activation, VEGF and COX-2 expressions
with consecutive VEGF and PGE2 release. Low pH enhances the carcinogenic potential of
bile acids.
S1854
The Roles of Caudal-Related Homeobox Gene Cdx1 and Cdx2 in Esophageal
Epithelial Cells in Barrett's Epithelium
Hideaki Kazumori, Mika Yuki, Yoshinori Komazawa, Toshihiro Shizuku, Yoshikazu
Kinoshita
Background & Aims: The mechanism of transformation to intestinal metaplasia in Barrett's
esophagus has not been clarified. We have recently showed that bile acids activate Cdx2
promoter via NF-kB, and stimulate the production of Cdx2 protein in esophageal ker-
atinocytes with a resulting production of intestinal type mucin. In addition to Cdx2, Cdx1
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plays major roles in the development of intestinal epithelium. Therefore, we investigated
the direct effects of bile acids on the expression of Cdx1 in cultured esophageal squamous
epithelial cells. Further, we investigated the relation between Cdx1 and Cdx2 expressions
in cultured esophageal squamous epithelial cells. Methods: A rat model of Barrett's esophagus
was produced by anastomosing the esophagus and jejunum. The expressions of Cdx1 and
Cdx2 were investigated by immunohistochemistry. The response of bile acids on Cdx1 gene
expression was studied in using a Cdx1 promoter luciferase assay. Further, esophageal
squamous epithelial cells were transfected with Cdx1 or Cdx2 expression vector, and their
possible transformation to intestinal-type epithelial cells was investigated. Results: Esophago-
jejunal anastomoses formed intestinal goblet cell metaplasia in rat esophagus specimens.
The metaplastic epithelium strongly expressed both Cdx1 and Cdx2. When the effects of
bile acids mixture on the expression of Cdx1 were examined, the bile acids mixture dose-
dependently increased Cdx1 promoter activity. Transfection of the Cdx1 expression vector
in cultured esophageal epithelial cells induced production of Cdx2 protein. In addition,
transfection of the Cdx2 expression vector induced production of Cdx1 protein. Conclusions:
We showed that bile acids stimulate the expressions of both Cdx1 and Cdx2 in the esophageal
epithelial cells. The expressions of Cdx1 and Cdx2 are important mechanisms in the develop-
ment of Barrett's epithelium.
S1855
Gene Expression in Barrett's Esophagus: Laser Capture Vs. Whole Tissue
Hashem El-serag, Zhannat Z. Nurgalieva, Toni-ann Mistretta, Milton J. Finegold, Susan G.
Hilsenbeck, Chad Shaw, Gretchen J. Darlington
Background: Diagnosis of Barrett's esophagus (BE) is typically done through morphologic
analysis of esophageal biopsy tissue. Such samples often contain several cell types, including
squamous, columnar, and goblet cell epithelia as well as stromal cells, which can confound
the use of global gene expression profiling for studies of diagnostic markers as well as
pathogenesis. Laser capture microdissection (LCM) allows the isolation of specific cells from
heterogeneous cell populations. We aimed to determine whether careful LCM of biopsies
could be used to identify a pattern of gene expression diagnostic of BE. Methods: We
obtained biopsies from BE and normal esophagus (E) from 9 subjects with long segment
BE. Samples from 5 subjects were examined as whole tissue, and in 4 subjects the glandular
epithelium of BE was isolated using LCM (BE_LCM) and compared to both basal cell and
squamous cell epithelium (E_LCM). RNA extracted from these samples was subjected to
cDNA microarrays using Human Affymetrix HG_U133A GeneChip® for whole tissue and
Hgu133plus2 for LCM isolated specimens. Probe sets that were in common on these two
arrays (22,278) were constructed using an indexing method in Bioconductor (http://www.bi-
oconductor.org/) package of R. Results: Differential gene expression using whole tissue
specimens revealed 1797 differentially expressed probe sets between BE and E (fold change
> 2.0; p<.001). Most (74%) were also differentially expressed between BE_LCM and a
combined basal and squamous cell epithelium (E_LCM), showing that there was high
concordance between the two sampling methods with respect to genes whose expression
might be specific to the Barrett's cells. However, LCM provided additional information (3443
genes) about the alterations in gene expression that may represent the BE phenotype.
Functional gene groups differed between whole biopsy and the LCM BE samples. Immune
response genes, particularly for immunoglobulins were increased in the BE whole sample
(19 of 317), while none for immunoglobulins were found in the 1,018 differentially expressed
genes in the BE_LCM samples. Insulin like growth factor binding proteins (IGFBP 3,4,6,
and 7) were highly expressed in the whole biopsy but only was also elevated in expression
in the BE_LCM sample. Conclusions: The differences in gene expression profiles depend
on whether specimens are whole tissue biopsies or LCM dissected. Only the latter can be
regarded as specific to Barrett's cells as distinct from surrounding cell types. However, for
diagnostic markers studies, additional information can be obtained by examining genes
expressed in whole as well as LCM specimens.
S1856
A Novel Dietary-Related Model of Esophagitis and Barrett's Esophagus
Katerina Dvorak, Naihsuan Guy, Hana Holubec, Claire M. Payne, Harris Bernstein, Carol
Bernstein, Achyut K. Bhattacharyya, Harinder S. Garewal
Background: Barrett's esophagus (BE) is a premalignant lesion of the distal esophagus where
normal squamous epithelium is replaced by metaplastic columnar epithelium containing
goblet cells. Hydrophobic bile acids are speculated to play a major role in BE development.
It has been reported that BE lesions occur in p53-/- mice fed a zinc-deficient diet, or in
transgenic mice overexpressing cyclin D1 that were on a zinc-deficient diet. Thus, we
hypothesized that BE lesions will develop in mice fed a zinc-deficient diet containing the
hydrophobic bile acid, deoxycholic acid (DCA). Methods: To test this hypothesis, thirty-
two wild-type C57BL/6 mice were divided into four experimental groups and fed (a) a
control diet, (b) a zinc-deficient diet, (c) a diet supplemented with 0.2% DCA, and (d) a
zinc-deficient diet supplemented with 0.2% DCA. Mice were sacrificed between 10-13 weeks
and tissues taken from the esophagus. MUC2, β-catenin, the p65 subunit of NF-κB, and
markers of proliferation and oxidative and nitrosative stress were evaluated using standard
immunohistochemical techniques. Results: Esophageal changes, consistent with esophagitis
were detected in all mice fed the zinc-deficient diet supplemented with DCA, while BE-like
lesions were detected in 50% of the mice fed this diet. Marked thickening of the esophageal
mucosa, an increase in proliferation, and an increase in expression of markers associated
with oxidative and nitrosative stress were detected in these areas. The newly formed BE-like
lesions expressed MUC2, a marker of columnar differentiation. Furthermore, translocation of
the p65 subunit of NF-κB and β-catenin to the nucleus was detected in these tissues.
Conclusion: This mouse model of esophagitis and BE is expected to contribute to a deeper
understanding of BE pathogenesis and to prevention strategies to help eradicate this disease.
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S1857
Analysis of Candidate Gene Polymorphisms Associated with Dyspepsia in
Japanese Population
Tomomitsu Tahara, Tomiyasu Arisawa, Tomoyuki Shibata, Masakatsu Nakamura, Mikijyu
Sakata, Fangyu Wang, Ichiro Hirata, Hiroshi Nakano
[Background] The role of genetics to the development of functional dyspepsia (FD) is unclear.
Recently, a significant association was reported between FD and G-protein beta3 (GNB3)
subunit gene polymorphism. [Aim] We aimed to clarify the association between candidate
gene polymorphisms altering serotonergic and CCKergic receptor functions, G protein trans-
lation, and regulation of the brain-gut axis, and dyspepsia in a Japanese population. [Subjects
and methods] 153 dyspeptics and 152 non-dyspeptic subjects enrolled in this study. All
subjects underwent gastroscopy and patients who have significant upper gastrointestinal
findings were excluded. Other diseases were also excluded by face-to-face history and
physical examination. 5-HT2A T102C, CCK-1 intron 1 T779C, GNB3 protein C825T and
COMT Val158Met polymorphisms were determined by polymerase chain reaction-restriction
fragment length polymorphism. H. pylori infection status was examined by histology or
antibody against H. pylori. [Results] DNA was available from 91 patients with unexplained
dyspepsia and 96 healthy controls. Non-significant correlation was found between GNB3
protein homozygous 825T and unexplained dyspepsia (OR=1.65, 95%CI=0.87-3.13).Among
H. pylori negatives, the homozygous GNB3 protein 825T significantly increased the risk of
dyspepsia (16.7% vs. 40.5%; OR=3.40, 95%CI=1.16-9.93, p=0.026). Among dyspeptics,
frequency of the same genotype was highly prevalent among patients with meal-unrelated
upper abdominal pain (36%), heart burn (38%) and belching (40%). Any other polymorph-
isms of candidate genes were not associated with dyspepsia when considered as single
factors. Combined analysis of candidate genotypes showed that weak correlation was found
between GNB3 protein 825T+COMT 158Met+5-HT2A 102C carriers and decreased risk of
dyspepsia (OR=0.52, 95%CI=0.26-1.06, p=0.08). [Conclusion] The homozygous 825T allele
of GNB3 protein is associated with dyspepsia in H. pylori-negatives. Although candidate
genes controlling serotonergic and CCKergic receptor functions and regulation of the brain-
gut axis do not appear to be associated with dyspepsia as single factors, genetic interaction
of these genotype may modify the risk of developing dyspepsia.
S1858
Abdominal Symptoms in Patients with the Brugada Syndrome and a “Loss of
Function” Mutation in the Nav1.5 Sodium Channel
Breg Braak, Tamira K. Klooker, Niran Al kassab, Nynke Hofman, Arthur A. Wilde, Guy
E. Boeckxstaens
Background & Aims: The Nav1.5 sodium channel is expressed in the interstitial cells of
Cajal and in the intestinal circular smooth muscle. Recently, patients with long QT syndrome
type 3 (LQTS3) with “gain of function” mutations in the SCN5A gene, encoding for the
Nav1.5 sodium channel, were shown to have increased gastrointestinal symptoms. In the
present study, we evaluated whether SCN5A “loss in function” mutations are also associated
with increased gastrointestinal symptoms, further underscoring a role for Nav1.5 sodium
channels in gastrointestinal function. Therefore, the prevalence of gastrointestinal symptoms
was evaluated in patients with Brugada syndrome type 1 (BrS1) with a proven SCN5A “loss
of function” mutation. Methods: BrS1 patients with (M+) and without (M-) an SCN5A
mutation, recruited from a prospective database of the outpatient clinic of the department
of Cardiology, were invited to participate. Patients were asked to fill out the Gastrointestinal
Symptom Rating Scale (GSRS), the Rome Criteria Questionnaire and the Gastrointestinal
Quality of Life Index (GIQLI) questionnaire. Results: Eighty seven of the 121 patients (72%)
with BrS1 completed the questionnaires (39% female, age 49 ± 14 yr). Forty four patients
had an SCN5A mutation. 23 % and 16 % of the M+ patients met the Rome III criteria for
functional dyspepsia or IBS respectively, compared to 16 % and 12 % of the M- patients
(NS). According to the GSRS, no significant differences were found in the occurrence of
abdominal pain, epigastric pain, reflux, or loose and hard stools. Similarly, no differences
in bowel related quality of life were detected using the GIQLI questionnaire (mean 113 ±
12 vs 115 ± 14 for M+ vs M- patients respectively, NS). Conclusion: No differences were
found in the prevalence of gastrointestinal symptoms between M+ and M- patients, suggesting
that “loss of function” mutations do not affect GI function, in contrast to “gain of function”
mutations in SCN5A (LQTS3).
S1859
Safety and Tolerability of Long-Term Therapy with Tegaserod in Patients with
Functional Dyspepsia and Dysmotility Symptoms: Results of Multicenter
Extension Studies
William D. Chey, Jan Tack, Colin W. Howden, Salam F. Zakko, Peter C. Rueegg, Seleshi
Demissie, David L. Earnest, Jeffrey Kralstein
Background: Safety of long term tegaserod use has been well documented in IBS-C and
chronic constipation patients (pts). Recently, two large trials showed tegaserod to be effective,
safe and well tolerated for 6 weeks in women with functional dyspepsia (FD) with dysmotility
symptoms. Subjects who completed these trials were invited to participate in 12-month
extension studies (E1, E2) evaluating safety and tolerability of tegaserod therapy. Methods:
Participants were English-speaking women, ≥18 years of age, with Rome II dysmotility-
type FD who had completed one of the core 6-weeks trials. Pts with ulcer-like dyspepsia,
GERD and active IBS were excluded. The objective was to evaluate the safety and tolerability
of tegaserod for up to 12 months (M12). Results: The total safety population included 780
pts (359 in E1; 421 in E2). Adverse event (AE) frequencies over the entire 12 months are
reported for the pooled safety population of both E1 and E2 (table). Diarrhea generally
occurred early in treatment as a single episode and of short duration (median duration E1
5.0 days, E2 7.5 days). Most cases (144 of the 158) of diarrhea were classified as mild or
moderate. Importantly, diarrhea during tegaserod treatment seldom led to discontinuation.
The most common serious AEs were abdominal pain, costochondritis, and dizziness (2 cases
each in E1 [0.6%]). Only one case of diarrhea was reported as a SAE at Month 6 (E1, 0.3%)
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and no additional cases occurred by M12. Conclusions: Tegaserod 6 mg b.i.d. was well
tolerated during 12 months' treatment of women with FD and dysmotility symptoms. Mild
diarrhea is an anticipated AE and may be related to the motility-enhancing mechanism of
action of tegaserod. Diarrhea tended to occur early in treatment and infrequently led to
discontinuation. This safety profile is consistent with that demonstrated across other indica-
tions.
S1860
Hospital Admissions and Primary Care Attendances for Non-Ulcer Dyspepsia,
Reflux Esophagitis, and Peptic Ulcer in Scotland 1981-2004
J. H. Baron, Amnon Sonnenberg
Aims: The past decades have witnessed a fall in the occurrence of peptic ulcer and a rise
in the occurrence of gastroesophageal reflux disease. Acid-related diseases of the upper
gastrointestinal tract have been more common in Scotland than most other countries. The
study was aimed to assess the recent time trends of esophageal disorders, non-ulcer dyspepsia,
gastric and duodenal ulcer in Scotland. Methods: The Scottish National Health Service
provided diagnostic data on admissions to all Scottish hospitals from 1981 to 2004 and
patient visits to general practitioners (GP) from 1998 to 2004. Data were broken down by
state of deprivation, urban versus rural residence, and geographic location. Results: In the
last quarter-century in Scotland, there were seven-fold increases in annual hospitalizations
for dyspepsia (from 900 to 6000 per million population) and for esophageal disorders (from
500 to 3700). Annual hospitalizations for gastric and duodenal ulcer changed from 590 to
1100 and from 1400 to 1130 per million population, respectively. The variation of hospital
admissions for dyspepsia among various Scottish regions closely matched the variation of
deprivation among them with r = 0.99 (p = 0.0074) and a relative risk of RR = 3.48. No
such correlation existed for any of the other three diagnostic groups. The relative risk of
3.48 and the 18% prevalence of deprivation in Scotland yielded an attributable risk of AR =
31%. GP contacts for dyspepsia (27,600 per million population) and esophageal disorders
(10,000) were common compared with relatively infrequent contacts for gastric ulcer (500)
and duodenal ulcer (1,200). Dyspepsia showed a statistically significant rise of GP contacts
with increasing scores of deprivation. This rise occurred similarly among urban and rural
residents and applied to data for each individual year between 1998 until 2004. None of
the other diagnoses showed any clear-cut correlation with score of deprivation. Conclusions:
Gastric and duodenal ulcer have become relatively rare causes for hospital admission, as
well as outpatient physician visits. Their former predominant role in upper gastrointestinal
disease has been replaced by gastroesophageal reflux disease and non-ulcer dyspepsia, both
increasing sevenfold in the last quarter-century. Deprivation may affect the occurrence of
dyspepsia itself or the likelihood of physician encounters for this disorder.
S1861
Psychometric Validation of the Gastrointestinal Symptom Rating Scale and
Quality of Life in Reflux and Dyspepsia Questionnaire in Dyspepsia: A Six-
Country Study
Károly Kulich, Ahmed Madisch, Franco Pacini, Jose m Pique, Jaroslaw Regula, Christo j
Van rensburg, László újszászy, Jonas Carlsson, Katarina Halling, Ingela Wiklund
Background and Purpose: Measuring the impact of dyspepsia symptoms on patients' daily
lives can be problematic in international clinical trials. Our study aimed to document the
psychometric characteristics of the Afrikaans, German, Hungarian, Italian, Polish and Spanish
translations of two patient-reported outcomes questionnaires in patients with dyspepsia.
Methods: Patients with a history of dyspepsia (defined as persistent and/or recurrent pain
or discomfort centred in the upper abdomen) for ≥ 6 months, and episodes of dyspepsia
on ≥ 1 day during the previous 7 days, were included in the study. Patients completed the
Gastrointestinal Symptom Rating Scale (GSRS), the dyspepsia version of the Quality of Life
in Reflux and Dyspepsia (QOLRAD), the Short-Form 36 (SF-36) and the Hospital Anxiety
and Depression (HAD) scale. Patients with stable symptoms (n = 441) completed the GSRS
and the QOLRAD again 1 week later. Results: In total, 853 patients were included in the study
(mean age: 42-48 years; 61-72% female). All language versions of the GSRS demonstrated
high internal consistency (range: 0.72-0.87) in the Indigestion, Diarrhoea and Constipation
domains. Consistency was lower in the Abdominal pain domain, probably reflecting the
difficulty of measuring this often fluctuating symptom. In the QOLRAD, internal consistency
was high (range: 0.79-0.95) in all domains for all language versions. Intraclass correlation
coefficients ranged from 0.36 to 0.75 for the GSRS, and from 0.41 to 0.82 for the QOLRAD.
The GSRS Abdominal pain domain correlated significantly with all QOLRAD domains in
most language versions, and with SF-36 Bodily pain in all versions. QOLRAD domains
correlated significantly with the majority of SF-36 domains in most versions. The GSRS
Abdominal pain and Indigestion domains correlated with the HAD anxiety score in most
of the language versions assessed, and most of the QOLRAD domains correlated with the
HAD anxiety score in all language versions assessed. Both questionnaires were able to
differentiate between patients whose health status differed according to symptom frequency
and severity. Conclusion: The psychometric characteristics of the six different language
versions of the GSRS and QOLRAD were found to be good, with acceptable reliability and
validity. The GSRS and QOLRAD will be useful for evaluating dyspepsia symptoms and
their impact on patients' daily lives in multinational clinical trials.
S1862
An International Comparison of Burden of Illness in Patients with Dyspepsia
Katarina Halling, Ingela Wiklund, Jonas Carlsson, Karoly Kulich
Background and Purpose: Dyspepsia is a common reason for individuals to consult a
physician. Yet relatively few studies have evaluated the impact of dyspepsia symptoms on
patients' lives. Our study aimed to assess and compare the burden of illness in patients with
dyspepsia in South Africa, Germany, Hungary, Italy, Poland and Spain. Methods: Consecutive
patients who presented with upper gastrointestinal symptoms and whose predominant
symptoms were those of dyspepsia (defined as pain or discomfort centred in the upper
abdomen) were recruited from primary care and gastroenterology clinics. Investigators
assessed the severity and frequency of symptoms. Patients completed the following question-
naires in an electronic diary: the Gastrointestinal Symptom Rating Scale (GSRS), the Quality of
Life in Reflux and Dyspepsia (QOLRAD) questionnaire, the Hospital Anxiety and Depression
(HAD) scale and the Medical Outcomes Study Short-Form 36 (SF-36). High GSRS scores
indicate more severe symptoms, while low QOLRAD scores indicate a more severe impact
on daily functioning. Results: In total, 853 dyspepsia patients were included, with between
111 and 175 recruited from each country (mean age: 42-48 years; 61-72% female). Mean
GSRS scores showed that patients were most troubled by indigestion and abdominal pain.
QOLRAD scores indicated that symptoms of dyspepsia caused emotional distress, problems
with food and drink, and reduced vitality. Symptoms also, but less frequently, caused
problems with sleep and physical functioning. Patients with severe symptoms and those
with more frequent symptoms had higher GSRS scores and lower QOLRAD scores than
subjects with mild or less frequent symptoms. Mean SF-36 scores showed that the health
of patients with dyspepsia was impaired compared with the general population. South
African patients had the most frequent and severe symptoms, which had the greatest effect
on health-related quality of life, according to QOLRAD and SF-36 scores. Italian patients
had the least frequent and severe symptoms, with the lowest impact. According to the HAD
scale, 27-58% of patients involved in the study were anxious and 15-36% were depressed.
Conclusion: The health-related quality of life of patients with dyspepsia is reduced because
their symptoms cause emotional distress, problems with food and drink, and impaired
vitality. The impact on health-related quality of life increased with increasing severity and
frequency of symptoms. A better appreciation of the impact of dyspepsia symptoms on
patients' lives should aid patient management.
S1863
Impact and Risk Factors for Dyspepsia in Urban South East Asians: A
Population-Based Study
Sanjiv Mahadeva, Hematrav Yadav, Khean-lee Goh
INTRODUCTION Population-based studies of dyspepsia in South East Asia, a rapidly devel-
oping region, is lacking. AIMS To determine the prevalence, epidemiological risk factors,
health-care seeking behaviour and economic impact of dyspepsia in a representative urban
population in Malaysia. METHODS A cross-sectional survey using a door-to-door direct
interview technique was conducted in a representative residential area in Kuala Lumpur
between April and October 2006. Subjects were identified using a population-based stratified
sampling method and GI symptoms were assessed using a validated questionnaire . RESULTS
A total of 2039 adults (mean ± SD age: 40.5 ± 11.8 years, males 44.2%) were interviewed.
Population demographics were as follows: Ethnicity- Malays 45.3%, Chinese 38.0% and
Indians 13.1%, tertiary education level 62%, professional employment 47.7% and median
monthly income USD 850.00. Dyspepsia was prevalent in 723 (35.5%) adults and associated
with age < 50 years (37.5% vs 26.4%, p<0.0001), female gender (39.6% vs 30.4% males,
p=<0.0001), Malay race (42.6% vs 29.6%, p=<0.0001), Indian race (41% vs 34.6%, p=
0.044) , tertiary education (37.2% vs 32.6%, p=0.032), regular coffee intake (36.8% vs
32.8%), smoking > 10 per day (40.9% vs 34.9%), regular analgesia intake (60.4% vs 30.7%,
p<0.0001), co-morbidity (46.5% vs 32.4%, p<0.0001), excessive chili intake (46.5% vs
34.8%, p=0.011) and low income group (39.8% vs 33.2%, p=0.013). Regression analysis
revealed that female gender (OR 1.40), Malay race (OR 2.65), Indian race (OR 1.75), low
income (OR 0.73), smoking (OR 1.63), regular analgesia (OR 0.27) and co-morbidity (OR=
0.50) remained as independent risk factors for dyspepsia. Over the preceding 3 months,
287 (40.0%) adults with dyspepsia had required medication, with 52.3% using over the
counter drugs and 21.8 % requiring medical consultation. Work absenteeism amongst
dyspeptics was 15.9%, with a total of 368 working days lost due to dyspepsia. CONCLUSION
Dyspepsia prevalence is high in urban Malaysian adults and is associated with a significant
medical consultation rate and work absenteeism. .
S1864
Reasons for Over-the-Counter Acid Inhibiting Drug Or Antacid Use in the
Netherlands
E. P. Van vliet, E. J. Kuipers, E. W. Steyerberg, P. D. Siersema
Introduction: General practitioners (GPs) in The Netherlands are often the first-line physicians
consulted for symptoms of dyspepsia. Symptomatic persons may however prefer to buy
acid-inhibiting drugs or antacids in a drugstore or pharmacy and bypass a GP. In the United
States, it was recently found that persons who buy over-the-counter (OTC) acid inhibitors
did so because of a lack of health insurance, lack of time to visit a physician, and the belief
that buying OTC acid inhibitors was cheaper than visiting a physician. Aim: To investigate
how often persons in The Netherlands substitute consultation of a GP by use of OTC acid
inhibitors or antacids and to determine reasons for substitution. Methods: From April 2005
to February 2006, persons buying OTC acid inhibitors or antacids in 10 pharmacies and
6 drugstores were asked to fill out a questionnaire on general characteristics, health status
and drug use. Persons who participated were over 18 years old and used OTC acid inhibitors
or antacids for personal use. A total of 82/160 (51%) questionnaires were returned. Results:
Sixty-three persons used antacids, 14 acid inhibitors, and for 5 persons it was unknown
what type of medication was bought. Seventy-one (87%) persons substituted GP consultation
by OTC acid inhibitor or antacid use, whereas 11 (13%) persons did both, i.e., bought
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these medications and visited a GP. Reasons for substitution were the belief that symptoms
were not serious enough to seek medical care in 56 (79%) persons, the belief that OTC
acid inhibitor or antacid use was cheaper than visiting a physician in 5 (7%), and lack of
time to visit a physician in 2 (3%). Other reasons (n=14) included among others temporary
OTC antacid use for upper gastrointestinal (GI) symptoms associated with pregnancy or a
favorable medical response on OTC acid inhibitors or antacids in the past (some persons
gave more than one reason). Substitution was more common in persons without comorbidity,
without a previous history of a disorder affecting the upper GI tract, without a previous
prescription of an acid-inhibiting drug or antacid by a GP or medical specialist, without
alarm symptoms, and with less than 4 days per week symptoms prior to OTC acid inhibitor
or antacid use. Conclusion: Substitution of physician consultation by OTC acid inhibitor
or antacid use is common in The Netherlands. Although the reasons for OTC acid inhibitor
or antacid use do not suggest an a priori increased risk for underlying serious disorders, such
as malignancy, it is advisable that staff in drugstores and pharmacies provides information on
the appropriate use of OTC acid inhibitors or antacids and on when to consult a GP.
S1865
What Is the Placebo Effect in Eradication Trials of H. pylori-Positive Functional
Dyspepsia?
Changcheng Wang, Yuhong Yuan, Richard H. Hunt
Backgrounds: About 50% of patients with functional dyspepsia (FD) have co-existent H.
pylori gastritis and evidence suggests that eradication reduces dyspepsia symptoms compared
to controls. However, some of these patients also benefit from placebo and the absolute
benefit of eradication over placebo alone is not known. We aimed to explore through meta-
analysis the effects of H. pylori eradication on dyspepsia symptoms compared with placebo
alone. Methods: English-language searches for RCTs in adults were performed using key-
words “functional dyspepsia” or “non-ulcer dyspepsia” published to Nov 2006 in MEDLINE,
EMBASE and Cochrane databases. RCTs with placebo alone as control were included.
Searches generated 272 citations and 4 met inclusion criteria: RCTs with raw data on
proportion of patients symptom-free at 12 months in H. pylori-positive FD patients. Studies
using active drugs plus placebo and duplicate publications were excluded. Review manager
4.2.8 was used and relative risk (RR) (fixed effects model) with 95% CI was calculated.
Results: 487 patients receiving H. pylori eradication therapy and 491 receiving placebo
alone were identified. The proportion with complete relief of dyspepsia symptoms at 12
months, a subjective measure, in the eradication group (27.3%, 133/487) was significantly
higher than that in the placebo group (21.2%, 104/491) (RR=0.78, 95% CI 0.63-0.97, P=
0.02) and homogeneity was seen (P=0.93). Successful H. pylori eradication rate at 12 months,
an objective measure, was markedly higher in the eradication group (79.4%, 312/393) than
in the placebo group (7.6%, 32/422) (RR=0.10, 95% CI 0.07-0.14) but with heterogeneity
(P=0.0001). Conclusions: Eradication of H. pylori infection in patients with functional
dyspepsia shows benefit over placebo but ~20% of placebo-treated patients became symptom-
free after 12 months. Considering the small proportion with H. pylori eradicated (~8%) in
the placebo group, the significant difference in those becoming symptom-free between the
eradication and placebo groups cannot be fully explained by the eradication of H. pylori
alone. The placebo effect involves psychological and other factors but is also higher with
subjective endpoints such as symptom scores. The difference between the eradication rate
and symptom relief in placebo group may be attributed to the difference between the
objective and subjective outcome measures.
S1866
Effect of Placebo in PPIs Or H2ras Controlled Trials of Patients with
Functional Dyspepsia: A Meta-Analysis
Changcheng Wang, Yuhong Yuan, Richard H. Hunt
Objective: Treatment of patients with functional dyspepsia (FD) is controversial. Acid
suppression produces symptom relief in a proportion of dyspepsia patients but this has not
been reported consistently. Moreover, placebo response rates in clinical trials for FD are
reported to be ~20- 30%. We aimed to explore the placebo effect in trials of PPIs/H2RAs
for FD through meta-analysis.Methods: MEDLINE, EMBASE and Cochrane English language
searches for RCTs in adults were performed using keywords “functional dyspepsia” or “non-
ulcer dyspepsia” published to Nov 2006. Searches generated 272 citations, and 20 met
inclusion criteria: RCTs comparing PPIs or H2RAs with placebo alone, with raw data on
the proportion FD patients with complete relief or improved symptoms at 1-12 weeks.
Crossover studies without washout period and duplicate publications were excluded. Review
manager 4.2.8 was used and relative risk (RR) (random effects model) with 95% CI was
calculated. Results: In total, 2815 patients received PPIs (8 studies) or H2RAs (12 studies)
and 2823 received placebo alone. The proportion of complete relief of dyspepsia symptoms
at 2-12 weeks in PPIs arms (33.6%, 534/1590) was significantly higher than that in placebo
alone (23.5%, 378/1606) (RR=0.68, 95% CI 0.53-0.86). At 1-6 weeks, H2RAs were (50.0%,
613/1225) significantly more effective than placebo alone (39%, 475/1217) (RR=0.79, 95%
CI 0.70-0.90), although as many as 39% placebo users had symptom relief. Significant
heterogeneity was seen in both comparisons which could not be resolved by sensitivity
analyses. Quality of included studies varied from 2 to 5 by Jadad scores. Due to the quality
and the reporting of included studies, we could not further explore whether a subset of FD
patients was more likely to benefit from antisecretory therapy. Conclusions: In published
RCTs, 30-50% of FD patients reported symptoms improved after short-term use of PPIs or
H2RAs, but placebo response rates were high in these studies and reached 39% in the
H2RAs trials, which was higher than the rate in PPI users (23.5%). The characteristics of
placebo responders are not known and merit further study. The significant heterogeneity
between studies may be caused by the differences in symptom assessment criteria, different
endpoints, and different subtypes of FD patients. To properly evaluate the efficacy of
an active drug, we need not only good quality RCTs, but also standard and objective
outcome measures.
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S1867
A Population Based Comparison of Concurrent Medical Illnesses in African
American Versus Caucasian American Patients with Functional Dyspepsia
Anil Minocha, William Johnson, William Wigington
BACKGROUND: There is paucity of literature on racial differences in the concurrent illnesses
encountered by patients suffering from functional dyspepsia (FD). In addition to psychosocial
stresses encountered in life, the lifestyle and dietary factors that could impact the gut and
extra-gastrointestinal system are different between African Americans (AA) and Caucasian
Americans (CA). HYPOTHESIS: AA patients with FD are likely to have greater prevalence
and different pattern of co-morbidities as compared to CA. METHODS: We conducted a
survey of population at 9 different sites. Subjects filled a questionnaire which included
Rome II criteria for FD. Subjects were also asked about demographic as well as clinical
characteristics. Subjects with prior history of chronic inflammatory bowel disease and gastro-
intestinal cancer were excluded. RESULTS: 1099 out of 1303 questionnaires were returned.
The response rate was 84 percent. Analysis was carried out after eliminating 109 incomplete
forms yielding 990 subjects. FD v non-FD: As compared to non-FD subjects, FD patients
had an increased prevalence of hypertension (34.4% v 27.7%), stroke, (3.6% v 1.5%),
migraine (27.5% v 14.9%), arthritis (23% v 15.2%), chronic back pain, (23% v 11.2%),
chronic fatigue syndrome (2.8% v 0.9%), asthma (13% v 7.1%), endometriosis (4.5% v
1.6%), restless leg syndrome (4.1% v 1.1%), palpitations (8.1% v 2.6%), urinary problems
(9.3% v 3.2%), PTSD (4.1% v 0.8%), anxiety (17.4% v 7.5%), and depression (25.9% v
12.1%). However, there was no difference in prevalence of diabetes mellitus (10.1% v 8.6%)
and fibromyalgia (2.8% v 1.4%). Racial differences in FD patients: Comparing AA patients
with FD to their CA counterparts, the prevalence of several conditions in the two races was
significantly different as shown in Table 1. However, no difference was seen between the
FD patients of the two races with respect to hypertension, diabetes mellitus, arthritis, chronic
back pain, fibromyalgia, asthma, endometriosis, restless leg syndrome, heart palpitations,
urinary problems, PTSD. CONCLUSION: There is an increased prevalence of medical and
psychiatric conditions in patients with functional dyspepsia. Caucasian Americans with FD
have greater higher prevalence of many concurrent co-illnesses than their African Amer-
icans counterparts.
Racial differences in prevalence of medical conditions in patients with functional dyspepsia
S1868
Predicting Symptom Improvement to PPIs in Functional Dyspepsia (FD):
Influence of Duodenal Acid Profile, Symptoms and Psychosocial Factors
Michael P. Jones, Jason Bratten
Introduction: PPIs are widely used to treat FD although available literature suggests limited
efficacy. PPI responders have often been felt to have either occult PUD or GERD. To better
identify pts likely to respond to PPI, we evaluated carefully screened FD pts using clinical
variables that might predict PPI response. Methods: Rome II FD pts enrolled in a study of
prolonged duodenal pH measurement were offered a 2-week open label trial of bid PPI. Pts
completed Nepean Dyspepsia Index (NDI), a 15-item dyspepsia symptom assessment, SF-
36, HADS, Visceral Sensitivity Index, Life Events Questionnaire and the Vital Exhaustion
Inventory. 48hr duodenal pH monitoring was accomplished using endoscopically-placed
radiotelemetry pH capsules. Results: 24 pts (5M/19F) with a mean(SDEV) age of 41(12)
yrs were studied. NDI scores decreased signif following PPI (BL=178±56; PPI=156± 49; t=
2.47; p=0.02)(Figure). 8/24 pts experienced ≥25% reduction in NDI score following PPI.
Signif correlations existed between a decrease in NDI score and symptoms of fullness/slow
digestion (r=0.46; p=0.02) and bloating (r=0.40; p=0.05). Duodenal pH monitoring did not
correlate with baseline NDI score or predict response to PPI. For the symptom and psychoso-
cial measures administered, only baseline NDI score predicted subsequent decrease in NDI
score with PPI (r=0.53; p=0.008). Conclusions: Dyspepsia severity, measured by NDI,
decreases with bid PPI therapy. Only sxs of fullness/ slow digestion and bloating were signif
associated with treatment response. Duodenal pH is not predictive. Psychosocial factors
were also not predictive. Higher NDI scores at BL were associated with greatest reduction in
NDI scores during PPI treatment. Whether this represents a statistical or clinical phenomenon
requires further investigation.
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S1869
Postprandial Motility Index Is Significantly Reduced in Patients with Migraine
and Dyspepsia
Michele Di stefano, Ennio Pucci, Emanuela Miceli, Paola Tana, Samanta Mazzocchi,
Giorgio Sandrini, Giuseppe Nappi, Gino roberto Corazza
Backround and Aims: We have recently shown that in patients with migraine and dyspepsia
the intake of a low-caloric low-fat meal induce a significant reduction of post-prandial
discomfort thresholds. This abnormality is not evident in patients with functional dyspepsia,
thus suggesting that post-prandial reduction of discomfort thresholds may characterize
migraine patients. As variations of gastric motility index (MI) were described in a subset of
dyspeptic patients, the aim of this study was to evaluate whether abnormalities of this
parameter may have a role in the pathophysiology of dyspeptic symptoms in migraine
patients. Patients and methods: Eighteen patients with migraine without aura, diagnosed
according to ICHD-II criteria and dyspeptic symptoms (32±5 yrs, 11 female), 16 patients
with functional dyspepsia, diagnosed according to Rome II criteria (39±5 yrs, 10 female)
and 16 healthy volunteers (28±6 yrs, 9 female) underwent gastric barostat test, which
monitors gastric motor activity (contraction or relaxation) as changes in intraballoon volume
(reduction or increase, respectively) at a constant intrabag pressure. After an overnight fast,
a double lumen polyvinyl tube with an adherent, infinitely compliant plastic bag (1200 ml
capacity), finely folded, was inserted in the stomach through the mounth. The polyvininyl
tube was connected to a computer-driven programmable volume-displacement barostat
device. During the test we evaluated gastric accommodation reflex and phasic contractility,
quantified using a motility index (MI) during three 30-min periods: fasting and first and
second 30-min period after the administration of a low-caloric liquid meal. A baseline
reconstruction was performed using a computerised algorithm and a MI was calculated as
the area between the signal and the baseline normalised over time. Results: Both dyspeptic
patients with migraine and without migraine showed a physiological gastric accommodation.
Fasting MI was similar in pts and HV. Postprandial MI was significantly reduced in patients
with migraine (13.4±4.8 mLxmin) than in healthy volunteers (19.6±6.6 mLxmin) and in
dyspeptic patients (22.6±7.4 mLxmin) during the first post-prandial 30-min period. In
particular the difference was more evident considering MI when the first 30-min postprand
period was considered. Conclusions:Our results show that pts with migraine and dyspeptic
symptoms suffer from an alteration of postprandial gastric motor function. Besides the
previously shown post-prandial hypersensitivity, a more pronounced reduction of postpran-
dial Mi characterises migraine pts with respect to dyspeptic pts.
S1870
Baseline Health-Related Quality of Life Is Correlated with Baseline Symptom
Severity and Is Improved By Tegaserod in Patients with Moderate to Severe
Functional Dyspepsia Dysmotility Symptoms
Nicholas J. Talley, William D. Chey, Nimish Vakil, Mohamed Omar, Gregory Ligozio,
Jeffrey Kralstein
Background: The clinical relevance of disease severity levels is unknown in functional
dyspepsia (FD). We aimed to examine HRQoL in patients (pts) with FD and predominant
dysmotility symptoms (D-FD) from 2 large tegaserod (T) trials. Methods: Pooled data from
2 identical, 6-week (wk), randomized, double-blind, placebo-controlled studies (T 6 mg
b.i.d.). Women, ≥18 years, who met Rome II criteria for D-FD were included. Pts with
ulcer-like dyspepsia, GERD or active IBS were excluded. During a 2-wk baseline (BL) phase,
severity of postprandial fullness, bloating and early satiety (composite average daily symptom
severity score; CADSS) was self-rated by pts using a 7-point scale. CADSS was then grouped
by severity: < moderate (score 1−<4), moderate (score 4−<5), and≥moderately severe (score
5-7). HRQoL was assessed using Short-Form Nepean Dyspepsia Index (SF-NDI). Results:
Similar proportions of pts had < moderate (42.8%) and moderate (37.3%) symptoms, while
fewer had ≥moderately severe dyspepsia symptoms (19.9%). Mean CADSS was positively
correlated with HRQoL. Pts with ≥moderately severe symptoms at BL reported the highest
scores in all SF-NDI domains indicating greatest impairment (table 1). At the end of 6-wks'
treatment, significant improvements in all SF-NDI domains were observed with T vs placebo
in the ≥moderately severe subgroup and for most domains in the moderate subgroup (table
2). Conclusions: Patients with more severe FD dysmotility symptoms have greater impairment
of HRQoL. There is an association of increased baseline symptom severity with greater
impairment of HRQoL, and with a significantly greater treatment difference between tegaserod
versus placebo.
S1871
Influence of Acid Suppressive Effects On Symptom Improvement in Dyspepsia
Junichi Akiyama, Takeichi Yoshida, Akahiko Sako, Masao Kobayakawa, Ryosuke Shoda,
Naohiko Masaki, Naomi Uemura
Backgrounds and Aims: Acid suppressive therapy is commonly used for treating dyspeptic
symptoms, but whether acid suppression is truly effective in dyspepsia is controversial. Acid
suppressive effects of proton pump inhibitor (PPI) is reported to vary among individuals,
which could explain the discrepancies between studies regarding the effects of PPI on
dyspepsia. The aims of this study were to evaluate the effects of PPI both on dyspeptic
symptoms and esophageal/gastric acidity, and determine if the improvements of various
dyspeptic symptoms are dependent on the degree of acid suppression. Methods: Thirty-
two patients with dyspeptic symptoms were included to the study. Before and after a 8
weeks course of omeprazole (OPZ) 20mg daily, dyspeptic symptoms were assessed by
Gastrointestinal Symptom Rating Scale (GSRS) and 24-hour esophageal and gastric ambulat-
ory pH recordings were performed. The esophageal and gastric acidity were expressed as
percentage of the time with pH<4 (%T). Results: 1) At baseline, the percentage of patients
who reported symptoms of reflux, abdominal pain, indigestion, diarrhea and constipation
were 84%, 63%, 91%, 59% and 72%, respectively. 2) After 8 weeks of OPZ treatment,
esophageal and gastric %T were significantly lower than baseline (9.5% vs. 1.5%; p<0.01,
90.5% vs. 36.7%; p<0.01, respectively). Gastric %T after OPZ therapy varied widely, ranging
from 0 to 79.1%. All patients who achieved gastric %T < 36.7% (L group; n=16) had normal
esophageal acid exposure whereas those with pathological acid exposure showed gastric %T
> 36.7% (H group; n=16). 3) After OPZ therapy, GSRS domains of reflux, abdominal pain
and indigestion were also significantly lower than baseline (3.0 vs.1.0; p<0.01, 1.3 vs. 1.0;
p<0.05, 1.8 vs.1.5; p<0.05, respectively), but diarrhea and constipation domains did not
differ. Stratified by acid suppressive effect, reflux domain were significantly decreased in
both L and H groups (p<0.01), abdominal pain domain tended to be lowered only in L group
(p=0.06) and indigestion domain were significantly decreased only in H group (p<0.05).
Conclusions: Acid suppressive therapy improved not only reflux symptom, but also abdom-
inal pain and indigestion, while these improvement patterns differed with respect to the
degree of acid suppression. This implies underlying mechanism of symptom improvement
may be different among each symptom subgroups.
S1872
Does Rome III Criteria Apply to Japanese Dyspeptic Patients ?
Noriaki Manabe, Ken Haruma, Hiroaki Kusunoki, Tomoari Kamada, Jiro Hata
Background and Aims: A subset of dyspeptic patients responds to acid suppressive therapy,
but the prevalence of non-erosive reflux disease (NERD) has never been established in Japan.
A classification based on the latest literature on functional dyspepsia was recently proposed
at the Third Rome Conference (Rome III). While this classification seems logical, there might
be some problems needing evaluation. The aim of this study was to evaluate the prevalence
of NERD patients among Japanese dyspeptic patients and to evaluate whether the criteria of
Rome III could also apply to them. Subjects and Methods: One hundred eighteen consecutive
patients (53 males, 65 females; mean age 45.5 years) complaining of chronic symptoms
occurring at least several times per week that could be attributed to the upper gastrointestinal
region, were recruited. Blood examination, ultrasonography and endoscopy revealed no
organic, systemic, or metabolic diseases. The patients also answered a questionnaire about
their symptoms related to the gastrointestinal region. Results: There were 36 NERD patients
(30.5%) among the 118 subjects. The NERD patients were excluded from among these
subjects. The subjects were then divided into three groups according to main symptoms,
meal-induced dyspeptic symptoms (PDS group) (24 males, 27 females; mean age 48.8 years),
epigastric pain symptoms (EPS group) (17 males, 22 females; mean age 43.6 years) and
chronic idiopathic nausea symptoms (CIN group) (11 males, 13 females; mean age 42.6
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years). Time frames from when the symptoms occurred were 5.6+/- 0.8 months in the PDS
group, 5.7+/- 0.9 months in the EPS group and 3.8 +/- 1.0 months in the CIN group. The
criteria of Rome III could not be applied to 23 patients (54.1%) in the PDS group, 20
patients (54.1%) in the EPS group, and 16 patients (66.7%) in the CIN group, because the
time frame was a little shorter than that of the Rome III criteria. There were 16 patients
(21.1%) whose symptoms overlapped between PDS and EPS, 12 patients (18.5%) who
overlapped between PDS and CIN, and 11 patients (20.4%) who overlapped between PDS
and CIN. Conclusions: NERD patients comprise about 30% of Japanese dyspeptic patients.
The time frame defined by Rome III (six months) could not always be applied to Japanese
FD patients, because they consulted the hospital sooner than indicated by the Rome III
criteria. There was a considerable overlap among the three groups (PDS, EPS, CIN) into
which patients were divided.
S1873
The Effects of Tegaserod 6 Mg Bid On Gastrointestinal Symptoms in Patients
with Functional Dyspepsia and Accompanying Heartburn
Sheila Rodriguez-stanley, Ivan Bottoli, Howard M. Proskin, Sattar Zubaidi, Susan Riley,
Tisha Adams, Maggie Wolff, Philip B. Miner
Background: In a study of 42 functional heartburn subjects, (CGH 2006; 4:442-450) that
were sensitive to mechanical balloon distention of the esophagus, a large percentage of them
also had accompanying dyspeptic complaints. Tegaserod 6 mg BID appeared to improve
many of these upper and lower GI symptoms. Aims: To determine prospectively if Tegaserod
6 mg BID improves occurrence, frequency, severity and bothersomeness of 10 upper and 2
lower gastrointestinal symptoms in patients with documented functional dyspepsia-heartburn
overlap. Methods: This was a double blind, placebo controlled, randomized crossover study.
25 patients (3 M, 22 F; Age range 19-54 years) underwent all screening procedures after
informed consent, and met enrollment criteria: no esophageal, gastric or duodenal erosions
or ulcers, normal 24 h esophageal pH, and sensitivity to mechanical distention of the
esophagus and stomach. Patients were randomized to Tegaserod 6 mg bid or placebo for
14 days, separated by a 14-day washout. Patients completed a symptom questionnaire after
completing each treatment phase. Comparisons with respect to symptom variables were
performed using crossover ANOVA's. Results: Tegaserod resulted in a significant improve-
ment in 4 of the 10 upper gastrointestinal symptoms (heartburn, regurgitation, early satiety
and postmeal abdominal bloating) as demonstrated by the decreased overall scores for the
following variables (Table 1). No change in scores was observed for epigastric pain, epigastric
discomfort, chest pain, difficulty swallowing, nausea or vomiting. Conclusions: Tegaserod
6 mg BID improves many of the individual components of functional dyspepsia-heartburn
overlap: heartburn, regurgitation, early satiety and postmeal abdominal bloating. These data
support the use of Tegaserod for patients with dyspepsia and heartburn overlap. Study
funded by Novartis Pharmaceuticals
Table 1: Symptoms improved by Tegaserod
S1874
Racial Differences in Prevalence of Abdominal and Extra-Abdominal Surgeries
Among Patients with Functional Dyspepsia
Anil Minocha, William D. Johnson, William Wigington
BACKGROUND: Literature suggests that there is an increase in prevalence of surgeries
among patients with IBS; however is paucity data on patients with functional dyspepsia
(FD). To our knowledge, there is no published data on the differences in the prevalence of
surgeries between Caucasian Americans (CA) and African Americans (AA) patients with FD.
METHODS: We randomly approached potential subjects at several sites in our metropolitan
area over a period of 12 months. The subjects filled a questionnaire which included Rome
II criteria for functional dyspepsia. In addition to the demographic characteristics, subjects
were asked about their surgical history. Subjects with h/o IBD and GI cancer were excluded.
RESULTS: One thousand ninety nine or 84% of those distributed were returned. On checking
the exclusion and inclusion criteria, we eliminated 109 subjects. The reasons for elimination
included incomplete questionnaires and incorrect marking of questionnaires that resulted
in invalid data. FD v Non-FD: 32.8% of FD patients (n=247) had undergone some type of
abdominal or pelvic surgery compared to 26.2% of those without FD (n=743). The prevalence
of appendectomy and tonsillectomy among FD patients (n=247) versus non-FD subjects
(n=743) was also not significant (9.7% v 7.9% and 12.5% v 13.3%; p=NS). However,
considering female patients with FD, there was an increased prevalence of hysterectomy as
compared to females without FD (25.1% vs 16.3%; p=0.02). CA v AA patients with FD:
Considering only the patients with FD based on race, we found significant racial differences
in prevalence of various surgeries. Table 1 shows that there was a greater prevalence of all
types of surgeries among Caucasian Americans as compared to African Americans. FD v
Non-FD within each race: There was trend towards an increased “any” abdominal surgery
for CA with FD (48.8% v 37.29%; p=0.06); however, no such difference was seen for AA
subjects. There was no significant increase in appendectomy or hysterectomy in AA patients
with FD. In contrast, among Caucasian Americans with FD, there was a significantly increase
in rate of appendectomy (23.8% v 12.3%; p<0.01) and hysterectomy (31.3% v 17%; p=0.01)
as compared to Caucasian Americans without FD. CONCLUSION: Functional dyspepsia is
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associated with an increased frequency of surgeries and there is greater impact among
Caucasian Americans as compared to African Americans.
Racial differences in FD patients
S1875
Toll-Like Receptor (TLR) 2- and TLR4-Mediated Signals Delay Healing of
Gastric Ulcer in Mice
Toshio Watanabe, Kazuhide Higuchi, Atsushi Kobata, Tetsuya Tanigawa, Masatsugu Shiba,
Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Tetsuo Arakawa
Background: We previously reported that inflammatory mediators such as tumor necrosis
factor-α (TNF-α) and neutrophils delay experimental gastric ulcer healing. Toll-like receptors
(TLRs) recognize specific molecular patterns found in a broad range of microbial pathogens
such as bacteria and viruses, triggering inflammatory responses. It has recently been reported
that certain TLRs family members also respond to endogenous molecules released from
stressed or damaged tissues. Aim: To investigate expression and roles of TLR2 and TLR4
in gastric ulcer healing in mice.Methods:Male wild-type, TLR2-deficient, and TLR4-deficient
mice were used. Gastric ulcers were induced by serosal application of acetic acid. Mice were
sacrificed on day 4 or 9 of ulcer induction, and ulcerous tissues were subjected to measure-
ments of ulcer size, immunohistochemical examination, and assay of mRNA levels by real-
time RT-PCR. Results: At day 4 after ulcer induction, mean ulcer sizes did not differ among
the three groups. By day 9, TLR2- and TLR4-deficiency each significantly enhanced healing
of gastric ulcers; The mean ulcer sizes (mm2) in wild-type, TLR2-decicient, and TLR4-
deficient mice were12.8 ± 2.1, 7.0 ± 0.8, and 5.8 ± 0.6, respectively. In wild-type mice,
ulceration increased the levels of mRNAs of TNF-α and interleukin-1β (IL-1β) by 23.1-fold
and 354.3-fold by day 4, respectively, and 20.6-fold and 198.7-fold by day 9, respectively.
Deficiency of TLR2 and TLR4 markedly inhibited the increase in levels of mRNAs of TNF-
α and IL-1β with reduction of the number of neutrophils infiltrating ulcerous areas by day
4, but had no inhibitory effect on expression of mRNAs of inflammatory cytokines or
neutrophil infiltration by day 9. Ulceration also increased levels of TLR2 mRNA by 10.8-
fold and 9.9-fold by day 4 and 9, respectively, but did not affect TLR4 mRNA level. Both
TLR2 and TLR4 proteins were detected in endothelial cells and inflammatory cells such as
macrophages in ulcerous areas, though no immunostaining for these TLRs was observed in
epithelial cells. Conclusion: These findings suggest that endogenous molecules in ulcerated
tissue may trigger inflammatory responses in the early phase of ulcer healing via both TLR2-
and TLR4-mediated signaling pathways, leading to delay of healing of gastric ulcer.
S1876
Possibility of Trefoil Factor Family 3 (TFF3) As a Therapeutic Agent for Post-
EMR Gastric Ulceration
Shinya Ohashi, Michiyuki Kanai, Motohide Kimura, Eriko Hayashi, Arimichi Takabayashi
Background & Aims: Endoscopic mucosal resection (EMR) is a prevailing procedure for the
treatment of early gastric cancers. Following the procedure, patients need a limited diet or
medications such as antacid or mucoprotective drugs to protect the denuded area and
facilitate healing of the artificial ulceration. The Trefoil Factor Family 3 (TFF3) is abundantly
secreted onto the mucosal surface by specialized mucus-secreting cells of the gut, and plays
a critical role in epithelial restitution. The aim of this study was to evaluate the possibilities
of TFF3 as a therapeutic agent for treatment of post-EMR gastric ulceration. Methods: Gastric
mucosal resection, a model of EMR in the rat, was established as follows. Following gastrotomy
of the anterior wall of the rat stomach, the mucosal layer of the posterior wall of the stomach
was lifted using pipette tips and stripped using a razor blade (approximate diameter, 5 mm).
Recombinant TFF3 (rTFF3; 10 or 100 mg/ml) dissolved in Pluronic F-127 gel, which is
fluid at refrigerator temperatures but is a soft gel at body temperature, was sprayed onto
the denuded area just after mucosal resection. Animals were sacrificed on postoperative days
1, 3, 5, 7, and 14. The process of ulcer healing was evaluated macroscopically as well as
histologically. TFF3 expression of the gastric mucosa during the same postoperative periods
was examined by RT-PCR. Results: The basal level of TFF3 expression in the gastric mucosa
was very low. Increased expression was observed at postoperative day 1 and maximal
expression was detected at day 3. Although the exogenous rTFF3 sprayed onto the ulcer
surface stayed only up to postoperative day 1, rTFF3 significantly accelerated mucosal
healing and attenuated the rate of ulcer healing macroscopically. Histological examination
demonstrated that reepithelization, the initial process of epithelial wound healing, was
significantly promoted in the group treated with rTFF3 compared with an untreated group.
In addition, rTFF3 reduced surface necrosis, inflammation extension, and fibrosis. Conclu-
sions: This study demonstrated the clinical importance of restitution, an initial phase of
epithelial wound healing, which was promoted by exogenous administration of rTFF3.
Therefore, TFF3 might be a new therapeutic agent for use against post-EMR gastric ulceration.
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S1877
Changes in Activity of the Zeta (ζ) Isoform of Pkc Is An Important
Determinant of the Inflammatory Pathways: Unique Protective & Modulatory
Mechanisms in Gut Epithelium
Ali C. Banan, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth, Yueming Tang,
Ashkan Farhadi, Ali Keshavarzian
NF-kB alterations are key events in the pathogenesis of inflammatory GI disorders. Using
GI cells, we found that NF-kB activation & IkB degradation cause cytoskeletal & barrier
disruption during oxidative conditions. Suppressing NF-kB leads to protection. But, the
molecular events underlying these processes are still unclear. The 78 kDa -ζ isoform of PKC
modulates cell maintenance, we therefore determined whether activation of PKCζ is required
for protection against oxidant-induced I-kK activation and consequent NF-kB & IkB-α
alterations and barrier disruption in gut epithelium. Methods: We used multiple transgenic
cell clones over-expressing PKCζ or under-expressing it. These new transgenic clones were
then incubated with various PKC activators or inhibitors ± oxidant/H2O2. Wild type (WT)
cells were treated similarly. We then assessed monolayer barrier integrity {LIVE/DEAD,
fluorometry}, barrier & cytoskeletal protein stability {laser confocal microscopy, SDS-PAGE
fractionation}, PKCζ subcellular activity & distribution {immunoprecipitation, In Vitro
kinase}, I-kK activity (immunecomplex kinase assay), IκBα levels {PAGE}, NF-κB (p50/
p65) subunit activities {ELISA, EMSA}, n=6/grp. Results: {A} Transfected clones ectopically-
expressing full-length PKCζ or the WT cells pretreated with EGF were protected against
oxidant injury. In these cells we found: PKCζ activation, I-kK isotypes inhibition, IkBα
stabilization; NF-kB (p50/p65 subunits) inactivation; occludin assembly (increased mem-
brane fraction, decreased cytosolic fraction), occludin cytoarchitectural integrity, & mono-
layer barrier stability. All measures of protection induced by expression of PKCζ were
synergized by added growth factor, EGF. {B} During ectopic-expression, most of PKCζ
resided in membrane & cytoskeletal fractions, showing constitutive activity. In these over-
expressing clones or EGF pretreated WT cells, PKCζ (78 kDa) was found with both IkK
(87 kDa) and IκB (37 kDa), forming novel endogenous, signalosomes of PKCζ — IkK —
IkB. {C} Anti-sense transfection to induce underexpression of endogenous PKCζ prevented
measures of EGF-mediated protection (including on IkK isotypes, IkB-α & NF-kB) and led
to monolayer occludin & barrier instability. Conclusions: We report for the first time that:
1) Activation of PKC-ζ isoform is necessary for cellular & barrier protection under stress
of IkK — I-kB — NF-kB pathway activation; 2) PKC-ζ appears to be a new intracellular
modulator of both IkK & IkB in gut cells; 3) We have identified a new anti-inflammatory
mechanism - protection of barrier integrity through the activation of PKC-ζ — IkK/ I-kB
signalosome & inactivation of NF-kB — in cells.
S1878
Cyr61 Induces Epithelial-Mesenchymal Transition in Gastric Mucosal
Epithelial Cells - A New Approach to Gastric Ulcer Healing
Jianyuan Chai, Manith Norng, Jasmine Chai, Justine Chow
Background & Aims: The integrity of gastric epithelium is maintained by cell-cell junctions
involving E-cadherin in complexes with β-catenin. Ulceration disrupts this structure and
activates epithelial-mesenchymal transition (EMT), in which epithelial cells at ulcer margin
reversibly develop mesenchymal cell phenotype and become migratory to cover the denuded
area. Cyr61 is a matricellular protein with features intermediate between conventional growth
factors and extracellular matrix molecules. Cyr61 functions through its integrin receptor
and is known for supporting angiogenesis and matrix remodeling in the context of cutaneous
wound healing. The aims of this study were to determine the roles of Cyr61 in EMT and
gastric mucosal restoration during ulcer healing. Methods: Rat gastric mucosal epithelial
cells (RGM1) were treated with recombinant Cyr61 at 100ng/ml for 2 and 6 hours and 1,
4 and 8 days (In Vitro). E-cadherin and vimentin were used as markers for epithelial and
mesenchymal cells respectively. For In Vivo study, gastric ulcers were induced in rats using
acetic acid and treated by injection of recombinant Cyr61 at 100ng/ulcer. The effect of
Cyr61 on ulcer healing was examined at 3 and 7 days after treatment. Results: Cyr61
reversibly induced vimentin expression in RGM1 cells, meantime, significantly reduced the
amount of E-cadherin protein by 72.3% and 87.4% after 4- and 8-day treatment respectively
(P < 0.001). However, the loss of E-cadherin did not seem to be caused by inhibition
of its expression as E-cadherin mRNA level remained unchanged after Cyr61 treatment.
Immunocytochemistry showed that Cyr61 activated nuclear translocation of β-catenin in
RGM1 cells, which is normally suppressed by Glycogen Synthesis Kinase (GSK3β) phos-
phorylation. Kinase assays demonstrated that Cyr61 significantly knocked down GSK3β
kinase activity by 91.2% and 95.1% after 4- and 8-day treatment respectively (P < 0.001).
We also found that Cyr61 activated integrin-linked kinase (ILK) and inactivation of ILK by
expression of a kinase-dead ILK cDNA in RGM1 cells completely abolished Cyr61-induced
EMT. Finally, injection of recombinant Cyr61 into ulcerated gastric mucosa induced vimentin
expression in the epithelial cells of regenerating gastric glands and promoted ulcer closure.
Conclusions: 1) Cyr61 induces reversible EMT in gastric epithelial cells; 2) Cyr61-induced
E-cadherin down-regulation is due to β-catenin translocation rather than suppression of its
expression; 3) Cyr61-induced EMT is mediated by ILK; and 4) Injection of Cyr61 into rat
gastric ulcers promotes EMT and re-epithelialization.
S1879
Delayed Gastric Mucosal Repair After Ethanol Intoxication in Musashi-1 Null
Mice
Tetsufumi Takahashi, Hidekazu Suzuki, Yuriko Minegishi, Tatsuhiro Masaoka, Hiroshi
Nagata, Yumi Matsuzaki, Hideyuki Okano, Toshifumi Hibi
In the process of gastric mucosal healing after injury, regeneration of the injured tissue is
important. In this connection, it has been shown that expression of Musashi1 (Msi1), an
RNA-binding protein, is increased in the rat gastric mucosa after acute ethanol intoxication
(FEBS Lett. 580:27-33, 2006), suggesting the importance of Msi1 during the repair process.
In the present study, the process of tissue repair after ethanol-induced acute gastric mucosal
injury was investigated in Msi1-knockout mouse (Msi1-KO; PNAS 99:15194-9, 2002), to
clarify the role of Msi1 in gastric mucosal regeneration. Methods. Msi1-KO and control
wild-type ICR mice (male, 20 weeks old) were administered absolute ethanol (0.3 ml) via
gavage into the stomach after 18 hours of food deprivation, and the stomachs were resected
5 or 24 hours after the ethanol intoxication. Mice were intraperitoneally injected with 5-
bromo-2'-deoxyuridine (BrdU; 50 mg/kg) 60 min prior to the gastric resection. Gastric erosion
and ulceration was histologically evaluated based upon the Sydney system. Localization of
parietal cells and the cellular proliferative activity were evaluated by immunohistochemistry
using anti- H+-K+-ATPase alpha subunit antibody and anti-BrdU antibody, respectively.
Results. At the examination conducted 5 hours after the ethanol administration, it was
found that the severity of the mucosal erosive and ulcerative lesions was greater in the Msi1-
KO mice than those in the wild-type mice. Furthermore, a significant decrease in the number
of the parietal cells was found in the gastric fundus of Msi1-KO mice at this time-point,
even in areas with maintained epithelial layers. Furthermore, in the border area positive for
the parietal cells in the gastric fundus of these mice, an increase in the number of cells
showing positive staining for desmin, an intermediate filament, and decrease in the number
of BrdU-positive cells were shown. At the examination conducted 24 hours after the ethanol
administration, an increase in the number of cells with clear vacuolation was found in the
basal portion of the gastric fundus in the Msi1-KO mice, whereas no such severe lesions
were detected in either the Msi1-KO mice without ethanol intoxication or in the wild type
mice with ethanol intoxication. Conclusion. Msi1 plays an important role in the restoration
of the foveolar epithelium of the gastric fundus after ethanol-induced gastric mucosal injury,
possibly through regulation of the functions of desmin-positive cells, which is recently
reported to be originated from bone marrow mesenchymal stem cells (BMSCs) (J. Mol.
Cell. Cardiol. Epub. Aug. 21, 2006).
S1880
Monocarboxylate Transporter -1 and Sodium Bicarbonate Co-Tranport
Cooperate in the Regulation of Gastric Epithelial Restitution By Influencing
Cell Viability
Regina Ragasa, Songhua Zhang, Sin hwee Ong, Susan J. Hagen
Current studies suggest that the major pH regulatory transporters in gastric surface epithelial
cells are the sodium hydrogen exchanger and the sodium bicarbonate transporter (NBC).
Although expression of the monocarboxylate transporter (MCT-1), a hydrogen lactate co-
transporter, is very high at the basolateral membrane of surface cells and in rat gastric
mucosal (RGM-1) cells, little is known about its role in pH regulation or in other functions.
Here we show that MCT-1 is essential for restitution and that it cooperates with NBC in
regulating the survival of gastric surface cells. METHODS: We used a specific MCT-1
antagonist, α-cyano-4-hydroxycinnimate (CHC), in ex vivo frog studies and In Vitro studies
with RGM-1 cells. To determine the effects of CHC in the frog stomach, recovery of
transepithelial resistance (TER) after injury was measured in the presence or absence of 0.5-
5 mM CHC with a luminal pH (pHL) of 4.0 or 7.4. To accompany TER data, mannitol flux
experiments were performed. In RGM-1 cells, wound repair was measured in the presence
or absence of 1-5 mM CHC in standard or bicarbonate-free buffer at pH 7.4. RGM-1 cells
were also incubated with 1-10 mM lactate, which was used as a competitive inhibitor of
MCT-1 activity. The viability of RGM-1 cells with CHC or lactate was determined using the
crystal violet assay. RESULTS: CHC significantly and dose-dependently inhibited restitution
of the frog gastric mucosa, where the TER was 97%, 62%, and 16% of control at pHL 4.0
in 0.5, 1, and 5 mM CHC, respectively. Experiments with CHC at pHL 7.4 showed similar
results. These data are further supported by mannitol flux experiments, where the flux rate
remained high for CHC treated stomachs. In RGM-1 cells, CHC also significantly (P<0.01)
and dose-dependently inhibited wound repair. However, viability was also reduced with 3
and 5 mM CHC to 63% and 46% of control, respectively. This reduction in viability was
further exacerbated under bicarbonate-free conditions so the viability with 5 mM CHC was
29% of control. Because bicarbonate-free conditions alone did not affect cell viability, the
result with CHC suggests cooperation of the transporters. Lactate significantly (P<0.01)
inhibited wound repair with no effect on viability, further supporting a role for MCT-1 in
restitution. CONCLUSIONS: Our results demonstrate that MCT-1 and NBC play a key
role in gastric epithelial cell restitution. Because MCT-1 exports hydrogen and NBC imports
bicarbonate, we propose both transporters regulate intracellular pH. Our results support
the notion that MCT-1 is a major pH regulatory transporter during restitution, with NBC
playing a more minor role.
S1881
A New Pathophysiological Mechanism for Epithelial Migration & Monolayer
Healing: Pkc-Lambda (Pkc-λ) Isoform Activity Is Required for Oxidant-
Induced Reduction of Cellular Migration and Remodeling in Gut
Ali C. Banan, Lijuan Zhang, Maliha Shaikh, Yueming Tang, Christopher B. Forsyth, Ali
Keshavarzian
Despite many previous studies on cell migration, the molecular events that accelerate wound
healing during gut disorders remains unclear. Because the lambda (-λ) isoform of PKC, an
atypical DAG-independent isozyme, is abundant in parental gut cells & is translocated to
the membrane fractions upon oxidative stress, we hypothesized that PKC-λ is critical in
oxidative stress-induced disruption of cell migration & cytoskeletal remodeling in gut cells.
Methods: Cells were transfected with an inducible plasmid to create novel transgenic clones
stably overexpressing native PKC-λ or with a dominant negative plasmid to stably inhibit
the native PKC-λ. Multiple clones were exposed to oxidant (H2O2) ± PKC modulators.
Parental cells were treated similarly. We monitored cell migration/ monolayer repair {3D
imaging of migrating cells}, barrier function {fluorometry}, cytoskeletal stability {confocal
microscopy, SDS-PAGE fractionation}, PKC-λ activity/ subcellular distribution {In Vitro
kinase, immunofluorescence}, oxidative stress (quenchable fluorescence), tubulin & actin
assembly (depolymerization of subunits of cytoskeleton, SDS-PAGE), n=6/grp. Results: {A}
In parental cells, oxidative stress caused: translocation of PKC-λ from cytosol to particulate
(membrane + cytoskeletal) fractions, activation of native PKC-λ, instability of tubulin/ actin
(↑monomeric & ↓polymerized pools), disruption of cytoskeletal architecture, reduced cell
A-271 AGA Abstracts
migration, & monolayer dysfunction. {B} In transgenic clones, over-expression of the (74
kDa) PKC-λ isoform (~3.2 fold) led to large disruptive effects on cell migration, including
cytoskeletal remodeling and monolayer instability. Over-expressed PKC-λ was mostly found
at the leading migration front (i.e., membrane & cytoskeletal fractions with a smaller cytosolic
distribution), indicating its activity. Here, PKC-λ(74 kDa) was active & endogenously com-
plexed with actin (43 kDa) &/or tubulin (50 kDa) pools. Disruption of migration induced
by PKC-λ expression was synergized by added oxidants. {C} Stable inactivation of endogenous
PKC-λ (-99.9%) by a dominant negative prevented all measures of oxidant induced reduction
of cell migration & monolayer repair. Conclusions: We show new pathophysiological pro-
cesses in gut epithelium (1) oxidative stress disrupts epithelial migration by disassembling
the cytoskeleton, in part, through the activation of PKC-λ isoform; (2) Activation of PKC-
λ by itself appears to be sufficient for reduced cellular migration and monolayer healing.
(3) The unique ability of PKC-λ to alter dynamics of repair and wound healing under
inflammatory conditions is a novel mechanism not previously described in cells.
S1882
Relationship Between the Bile Acid Concentration in Gastric Juice and the
Histological Gastritis in Japanese Patients: A Large Scaled Cross-Sectional
Study
Masana Tatsugami, Masanori Ito, Hiroshi Masuda, Shosuke Kitamura, Akemi Takamura,
Yoshihiro Wada, Yoshiaki Matsumoto, Shinobu Imagawa, Xue Fei xie, Shunsuke Takata,
Mitsuhiro Mihara, Masaru Nakamura, Shinji Tanaka, Masaharu Yoshihara, Ken Haruma,
Kazuaki Chayama
Background and Aim: Chronic inflammation in the gastric mucosa is mainly caused by
Helicobacter pylori (H. pylori) infection. However, the bile acid is another important toxic
factor for the injury of gastric mucosa. Previously, we reported the close relationship between
the bile acid concentration in gastric juice and the gastric carcinogeneis (Nakamura et al.
Gastrointest Endosc 2001). We examined the relation between the bile acid concentration
in gastric juice and the histological gastritis in Japanese patients by a large scaled cross-
sectional study. Methods: A total of 900 patients (673 men, mean age 50.7 y.o.) were
studied. Gastric juice was collected by gastro-endoscopic examination without enzyme
treatment. We examined the total volume of gastric juice, pH and total bile acid concentration
by enzymatic method. In all patients, we took four gastric biopsy specimens from the gastric
corpus and antrum. The grade of gastritis was assessed using the updated Sydney system.
H. pylori infection was examined by 13C-urea breath test, histological examination and
antibody titer. Moreover, in all patients, fasting sera were collected and the serum levels of
pepsinogens and gastrin were examined. Results: Out of 900, 733 were diagnosed as H.
pylori positive. The total bile acid concentration was significantly higher in H. pylori-positive
patients than in H. pylori-negative patients ( 451.2 vs 98.2 mmol/l ), In H. pylori-positive
patients, there were significant positive associations between the bile acid concentration
and the grades of histological atrophy/intestinal metaplasia in the gastric antrum (P<0.01).
However, we found significant negative associations between the bile acid concentrations
and the histological scores of mononuclear cell/neutrophil infiltrations (P<0.01). The same
results were obtained when we selected and analyzed the patients with none or mild atrophy.
Although, we obtained the same results in the examination of the gastric corpus, we found
no statistical relationship between pepsinogen/gastrin levels and the bile acid concentration.
Conclusions: The bile acid in gastric juice contributes to the progression of histological
atrophy and intestinal metaplasia in H. pylori-positive patients. However, these processes
were not associated with the mononuclear cell/neutrophi inflammations in the lamina propria.
S1883
Increased Esophageal Intraepithelial Lymphocytes (IELs) Reflect Active
Esophagitis Or Gluten Sensitivity, But Do Not Imply a Diagnosis of
“Lymphocytic Esophagitis”
Emily J. Loyd, Rhonda K. Yantiss
Background: Data regarding the importance of IELs in esophageal biopsies are conflicting,
but most suggest they are not reliably increased in disease states compared to control patients
(CP). However, a recent report described a form of chronic esophagitis termed lymphocytic
esophagitis, characterized by numerous IELs in the papillary epithelium (PE). In this study,
we evaluated esophageal IELs in patients with reflux (RE) and allergic (AE) esophagitis, H.
pylori gastritis (HP), and gluten sensitivity (GS) in order to determine they are a marker of
a previously unrecognized entity or merely an epiphenomenon related to other inflammatory
processes. Design: Esophageal mucosal biopsies from 40 patients (9 RE, 10 AE, 10 HP, 11
GS) with clinically, pathologically, and serologically (when appropriate) documented disease
and 10 CP with normal endoscopic and pathologic findings were immunostained with CD3
antibodies using the ABC technique. Blinded to the diagnostic category, four 600x fields
with the greatest cellularity were selected and the IELs were counted. IELs in the interpapillary
mucosa (IPM) and PE were separately recorded and the results were compared between
groups. Result: Overall, mean IELs were highest in RE (131), AE (133), and GS (96), which
were statistically similar. IELs were significantly more numerous in each of these groups
compared to both HP and CP (p<0.04 all comparisons). All groups, except AE, showed
greater numbers of IELs in the PE compared to the IPM (p<0.02 for all comparisons). In
fact, most of the increase in IEL numbers seen in GS reflected increased IELs in the PE.
The mean numbers and distribution of IELs in HP and CP were similar. Conclusion:
Esophageal IELs are a normal component of the eosinophil-rich inflammatory infiltrate
typical of RE and AE. Interestingly, increased IELs in the papillary epithelium may be a
marker of GS, particularly in the absence of active esophagitis. Esophageal IELs are present
in healthy patients and those with gastritis, indicating that their presence in low numbers,
particularly near the papillae, is a normal finding and does not imply a diagnosis of
lymphocytic or chronic esophagitis.
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S1884
Nitric Oxide Generated Luminally At the Gastro-Esophageal Junction Disrupts
the Tight Junction of the Adjacent Epithelium
Nobuyuki Ara, Katsunori Iijima, Kiyotaka Asanuma, Jun Yoshitake, Shuichi Ohara,
Tetsuhiko Yoshimura, Tooru Shimosegawa
We have recently demonstrated that high concentrations of nitric oxide (NO) are generated
luminally at the GE (gastro-esophageal) junction through entero-salivary recirculation of
dietary nitrate in human, and that NO thus formed actually diffuses into the adjacent gastric
tissue (Gastroenterology 2002, Gut 2005). However, the potential mechanism how NO
generated luminally can disturb the surrounding epithelium remains unknown. NO has
been known to play various roles in the physiology and pathophysiology of gastrointestinal
tract, and at higher concentration as generated by inducible form of nitric oxide synthase,
it impairs intestinal barrier function by disrupting the tight junction. <Aim> To investigate
whether NO generated luminally diffuses into the adjacent tissue sufficiently to disturb the
tight junction of the epithelium. <Methods> We designed an In Vitro Ussing chamber model,
in which gastric mucosal membrane was mounted between the two halves of a chamber,
to reproduce a microenvironment of the human GE junction and its adjacent mucosa. The
mucosal side of the chamber was bathed with physiologic concentrations of sodium nitrite
(0.1 - 5.0 mM) dissolved in pH 2.5 to generate nitric oxide, while the serosal side was
bathed with pH 7.4 Krebs buffer. The transmembrane resistance (R) was measured with
Ag-AgCl electrodes as an index of electrophysiological injury, and the 3H-mannitol flux
from mucosal side to serosal side was measured to evaluate the permeability of the membrane.
The sections of the mounted mucosa were stained immunohistochemicaly with occludin,
one of the major tight junction related proteins. In addition, dinitrosyl dithiolato iron
complex (DNIC), which is a paramagnetic marker for assessing the interaction of NO
with iron-sulfur proteins, was measured by means of electron paramagnetic resonance
spectroscopy to confirm the diffusion of nitric oxide into the mounted mucosa. <Results>
The R was significantly decreased dose-dependently, by 60 % during 3-hour exposure to
0.1 mM nitrite compared with the nitrite-free controls. Meanwhile, the mucosal permeability
was significantly increased by 160 %. Occludin was fragmented or not detected in the
superficial epithelium by the 0.1 mM nitrite exposure compared with controls. High signal
intensity of DNIC was observed dose-dependently in the nitrite-exposed mucosa. <Conclu-
sions> This study suggests that NO generated luminally could disturb the mucosal barrier
function of the adjacent epithelium by disrupting the tight junction. The mechanism may
represent an early effect of NO-derived stress on the epithelium at human GE junction.
S1885
Morphological and Immunohistochemical Evaluation of the Esophageal
Mucosa in Health and Gastroesophageal Reflux Disease
Ann-cathrine Jönsson-rylander, Kerstin Carlson, Magnus Ruth, Madeleine Pettersson,
Christina Abrahamsson, Thomas Hedner
Background and Aim: The morphological characteristics of the mucosa in relation to disease
and symptom expression are as yet not fully understood. The aim of the present study was
therefore to characterize the microscopic appearance and distribution of proteins involved
in the epithelial barrier in health as compared to erosive and non-erosive reflux disease,
both after normal acid exposure and after a 6-week treatment with PPI. Methods and Material:
Subjects with heartburn/reflux as predominant symptom, on average weekly basis over a
minimum 3-months period, were recruited via advertising. Healthy volunteers (HV) who
had previously undergone endoscopy served as controls. A total of 42 of 56 recruited subjects
completed the study and were possible to evaluate. Both subjects with reflux symptoms (n=
32, 19 males, age 44.7 years, range 19-61) and HV (n=10, 5 males, mean age 31.7 years,
range 23-40) were randomized, in a double blind, crossover fashion to treatment with
esomeprazole 40mg twice daily and placebo during 6 weeks respectively. 24-hour pH
recordings were registered after 4 weeks and endoscopies were performed at the end of
each treatment period. Biopsies, one from each quadrant of the esophageal epithelium were
taken (Cook ADFS-2.2-160) 2 cm above the LES, fixed in 4% buffered formalin and
embedded in paraffin. The biopsies were cut to 4 mm thick sections and used for both IHC
and HTX&Eo staining. The morphological changes from each biopsy were evaluated in the
HTX & Eo stained sections according to Ismail-Beigi (Gastroenterology 1970;58:163). IHC
was performed after antigen retrieval with antibodies against cell cycle markers, tight junc-
tions, adherence junctions, desmosomes, gap junctions and keratin markers. Results The
10 HV had no morphological changes. Endoscopic esophagitis (grade A, B) was detected
in 15 while 17 had non-erosive disease (NERD), 12 with positive and 5 negative histology.
Immunorectivity (IR) was found with Ki67, cyclin D1, claudin -3, -4, occludin, Zo-1, -3,
JAM-1, a-,b-,g-catenin, e-cadherin, desmoglein-3, desmoplakin-1, -1+2, cytokeratin-4, -8/
18, -13, filaggrin, loricrin. IR was found both after placebo and esomeprazole in all groups,
some minor changes in IR were detected although non-significant. On the other hand, there
was no IR detected with antibodies against Claudin-2, claudin-7, symplekin, cingulin,
envoplakin, connexin 43, pan-cytokeratin, and involucrin. Conclusions Differences between
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HV and patients with NERD in barrier function of the epithelium could not be detected by
comparing the presence and distribution of barrier related proteins
S1886
Isothiocyanate-Related Compounds Inhibit the Recovery of Wounds Induced
in Gastric Epithelial Cells: Mediation By Trpa1?
Shusaku Hayashi, Eiji Nakamura, Yoshikazu Kubo, Masato Suzuki, Susan J. Hagen, Koji
Takeuchi
Background/Aims: During the early healing process of gastric mucosal lesions, the intact
epithelial cells migrate to promptly reseal the wounded area, the phenomenon termed as
restitution. This process has been shown to depend on actin filament, Ca2+ and growth
factors, yet the detailed mechanism remains still unclear. We previously reported that DIDS,
a stilbene compound, completely abolished the recovery of wound in the rat gastric epithelial
cells. Recent study showed that allyl isothiocyanate activates transient receptor potential
subtype A1 (TRPA1), a member of TRP ion channel family. Since DIDS contains the isothiocy-
anate moiety, it is possible that the inhibitory effect of this compound on the epithelial
wound healing is mediated by the activation of TRPA1. In the present study, we examined
the effect of TRPA1 agonists on the repair process of epithelial cells after injury, using the
rat gastric epithelial cell line RGM1 monolayer, and investigated the possible participation
of TRPA1 in the mechanism of epithelial restitution of the stomach. Methods: RGM1 cells
were inoculated in 24-well plates cultured at 37°C under 5% CO2 in air. After obtaining
a confluent RGM1 cell monolayer, a round artificial wound of constant size was induced
in the center of the cell monolayer using a pencil-type mixer with a rotating silicon tip. The
repair process was monitored 0, 4, and 8 h after the induction of wound. We also examined
the expression of TRPA1 mRNA and protein in RGM1 cells. Results: Immediately after the
wound induction, cells at the edge of wound started to form lamellipodia, migrating toward
the center of wound, and by so doing the cell-free area was decreased over time. The addition
of icilin, the TRPA1 agonist, dose-dependently suppressed the recovery of the epithelial
wound. Likewise, another TRPA1 agonist, ally isothiocyanate, also significantly inhibited
the epithelial wound repair. The recovery of the epithelial wound was also potently inhibited
when the ambient temperature was lowered to 17°C, the threshold temperature where
TRPA1 is thought to be activated. However, neither the TRPM8 agonist menthol nor the
TRPV1 agonist capsaicin significantly affected the wound healing. The expressions of TRPA1
mRNA and protein were confirmed in the rat stomach but not in RGM1 cells. Conclusions:
We confirmed the potent inhibition by the isothiocyanate compounds of the epithelial
restitution in the rat stomach, probably through the suppression of cell migration, and
further suggested that the mechanism of this action does not result from the interaction
with TRPA1 but may be due to other unidentified effects unrelated to TRPA1.
S1887
Ethanol Induced Nf-κB Activation Protects Against Cell Injury in Cultured Rat
Gastric Mucosal Epithelium
Harri Mustonen, Tuula Kiviluoto, Pauli Puolakkainen, Eero Kivilaakso
This study investigates NF-κB activation in gastric mucosal cells by ethanol and the effects
of inhibition of NF-κB signaling pathway with siRNA technique in this ulcerogenic situation.
NF-κB is a transcription factor family regulating gene transcription of many important
mediators of inflammatory response. METHODS: Rat gastric mucosal cells (RGM-1) were
grown in cell culture flasks to confluent monolayers at 37o C in humidified atmosphere
containing 5% CO2 in air. The cells were exposed for different time periods to the ulcerogenic
agent ethanol. For evaluation of NF-κB activation nuclear and cytoplasmic protein extracts
were prepared. The nuclear fraction was analyzed with electrophoretic mobility shift assay
(EMSA) or with ELISA based transcription factor assays. Caspase-3 (promoter of apoptosis)
activity was measured with time resolved fluorescence based assay and cell viability with
tetrazolium based assay. Inhibition of NF-κB signaling pathway was done either by using
NEMO binding peptide or by decreasing RelA expression with siRNA techniques. NEMO
binding peptide blocks the association of NEMO/IKKγ with IKK complex and thereby
prevents the dissociation of IκB from the NF-κB complex, leading thus to inhibition of NF-
κB activation RESULTS: Ethanol (1-5%) induced dose dependently NF-κB activation, which
was inhibited with BAPTA (intracellular calcium chelator). Ethanol also induced caspase-3
activity (2.5±0.1 fold control), which was further potentiated by inhibiting ethanol induced
NF-κB activation either with NEMO binding peptide (3.5±0.3, p<0.05, N=12) or by reducing
RelA (NF-κB p65) expression (4.0±0.4, p<0.05, N=12) and thereby affecting the NF-κB
signaling pathway. Inhibition of NF-κB activity with NEMO binding peptide decreased cell
viability significantly during 5% ethanol exposure (0.90±0.015, fold control, N=11) as
compared to ethanol exposure either alone (0.96±0.01, p<0.05, N=11) or with negative
control NEMO binding peptide (0.96±0.02, p<0.05, N=11). Reducing relA expression
reduced cell viability in epithelia exposed to 5% ethanol (0.86±0.02, fold control) as compared
with non transfected (0.93±0.01, p<0.05, N=23) or non-functional siRNA transfected epithe-
lia (0.94±0.01, p<0.05, N=23) exposed to 5% ethanol. CONCLUSION: In conclusion,
ethanol induces NF-κB activation via a calcium dependent pathway and inhibition of the
NF-κB activation either with NEMO binding peptide or by reducing RelA expression with
siRNA technique potentates apoptosis and cell damage induced by ethanol, suggesting a
protective role for ethanol induced NF-kB activation in ethanol exposed gastric mucosal epi-
thelium.
S1888
Taurocholate Inhibits Caspase-3 Activity in Ethanol Exposed Cultured Rat
Gastric Epithelium
Harri Mustonen, Tuula Kiviluoto, Pauli Puolakkainen, Eero Kivilaakso
We have previously shown that ethanol induces NFκB activation and apoptosis in rat gastric
epithelium and that concomitant exposure to taurocholate with ethanol further enhances
NFκB activation. This study investigates the ethanol and taurocholate induced NFκB activa-
tion and apoptosis in cultured gastric epithelium using siRNA technique to inhibit NFκB
signaling pathway. METHODS: Rat gastric mucosal cells (RGM-1) were grown in cell culture
flasks to confluent monolayers at 37o C in humidified atmosphere containing 5% CO2 in
air. The cells were exposed for different time periods to ethanol and taurocholate. For
assessment of NFκB activation nuclear protein extracts were analyzed with ELISA based
transcription factor assay. Inhibition of NFκB signaling pathway was done by decreasing
RelA expression with siRNA techniques. Caspase-3 (promoter of apoptosis) enzyme activity
was measured with time resolved fluorescence based assay and cell viability was measured
with tetrazolium salt based assay. RESULTS. Ethanol induced dose dependently NFκB
activation and simultaneous exposure to taurocholate further enhanced this activation. Simul-
taneous exposure to ethanol and taurocholate decreased ethanol induced caspase-3 activation
and increased cell viability. Taurocholate (5mM) alone inhibited caspase-3 enzyme activity
in gastric epithelial cells, decreasing caspase-3 activity from 1.0±0.1 to 0.48±0.1 fold control
(p<0.01, N=12). Inhibition of NFkB activation with siRNA technique increased further the
caspase-3 activation (from 2.7±0.2 to 4.1±0.3, N=20, p<0.01) in ethanol exposed epithelia,
but this NFκB inhibition did not affect caspase-3 activation in epithelia simultaneously
exposed to ethanol and taurocholate (from 1.3±0.2 to 1.0±0.1, N=20, NS). However, cell
viability was lowered by inhibition of NFκB signaling in both ethanol (from 0.84±0.01 to
0.81±0.01, N=13, p<0.05) or ethanol and taurocholate exposed epithelia (from 0.89±0.01
to 0.74±0.03, N=13, p<0.01). Larger concentrations than 10 mM of taurocholate with
ethanol resulted gradually in severe decrease in cell viability. CONCLUSIONS. Taurocholate
inhibits casapase-3 activity and potentiates ethanol induced NFκB activation thereby enhan-
cing cell viability in ethanol exposed tissues. Inhibition of NFκB pathway with siRNA
technique decreases cell viability in ethanol and taurocholate exposed tissues, even though
caspase-3 activity is still inhibited by taurocholate suggesting that the NFκB signaling is
essential in this ulcerogenic situation for cell survival.
S1889
Central Administration of Glucagon Like Peptide-2 (GLP-2) Alleviates
Ethanol-Induced Oxidative Gastric Damage in Rats
Mustafa Deniz, Sema Tekin, Gözde Cakirsoy, Merve Pehlivancik, Tugba Ocek, Hatice
Caglioz, Nilay Orak, Nertila Poci, Hasan H. Sahin, Serap Arbak, Berrak Yegen
Background: Acute ulcer formation is known to be associated with excessive acid secretion
in the stomach, reduction in gastric mucosal blood flow, constant intake of non-steroid
anti-inflammatory drugs, ethanol and stress. Glucagon like peptide 2 (GLP-2), which is an
intestinotrophic growth hormone produced in endocrine L-cells of the intestinal mucosa,
can rapidly improve intestinal epithelial barrier function. However, the role of GLP-2 in
gastric ulcerogenesis was not thoroughly studied. The present study was designed to assess
the possible protective effects of central and systemic GLP-2 administration on ethanol-
induced gastric injury in rats. Materials and Methods:Sprague Dawley rats of both sexes
were fitted with stainless steel cerebroventricular cannulas inserted into left lateral cerebral
ventricles. Following a recovery period of 5-7 days, a group of rats were administered
intracerebroventricularly (icv) either with saline or GLP-2 (5μg/5 μl), while another group
of rats received GLP-2 subcutaneously (5 μg/ rat; sc). Five minutes after the injections,
gastric mucosal injury was induced by orogastric administration of ethanol (99 %, 5 ml/
kg). Half an hour after the gastric ulcer induction, a holeboard test was performed for the
evaluation of anxiety level by recording the freezing time in 5-min period. At the 3rd hour
of ulcer induction, rats were decapitated and ulcer index was calculated and gastric samples
were obtained for light and scanning microscopical evaluations, along with the determinations
of gastric myeloperoxidase (MPO), lipid peroxidation (LP) and glutathione (GSH) levels to
demonstrate the extent of oxidative injury. Results:Increased macroscopic and microscopic
damage scores induced by ethanol administration were significantly decreased in rats treated
with GLP-2, either icv or sc (p<0.05-0.01). Gastric MDA and MPO activity, which were
increased in saline-treated ulcer group, were decreased when GLP-2 was centrally adminis-
tered (p<0.05-0.01), while decreased GSH level in ulcer group was not altered with the
treatments. On the other hand, increased freezing time due to ulcer induction, representing
increased anxiety, was reduced significantly when the rats were administered icv GLP-2
(p<0.01). Conclusion: The results demonstrate that intracerebroventricularly injected GLP-
2 improved gastric injury more dominantly than its systemic administration by reducing
the extent of oxidative stress and by suppressing the anxiogenic effect of ulcer development.
Thus, these data suggest a potential therapeutic role for GLP-2 in the prevention of gastric
mucosal lesions.
S1890
All-Trans Retinoic Acid Up-Regulates Tff Expression in Gastric Epithelial
Cells
Tadahito Shimada, Takero Koike, Michiko Yamagata, Akihiro Tajima, Kyoko Tabei,
Masashi Yoneda, Akira Terano, Hideyuki Hiraishi
Background and Aim: All-trans retinoic acid (ATRA) is a ligand for retinoid acid receptor
(RAR), a member of the nuclear receptor superfamily. Although RARs are known to have
important functions in the development and differentiation of a variety of organs, it is not
known whether the expression of tissue-specific genes is regulated by ATRA and other
ligands for RARs in adult stomach. Among three trefoil factor family (TFF) peptides identified
so far (TFF1, TFF2, and TFF3), TFF1 and TFF2 are specifically expressed in gastric epithelial
cells and play critical roles in the defense of the gastric mucosa. In this study, we examined
the effects of ATRA on the expression of TFF genes in gastric epithelial cells. Methods:
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MKN45, a cell line derived from human gastric carcinoma, was used. Endogenous TFF1
and TFF2 mRNA expression was analyzed by real-time quantitative RT-PCR. The promoter
sequences of human TFF1 (-953 to +36) and TFF2 (-912 to +24) genes were cloned into
the SmaI site of pGL3-basic vector (Promega) and reporter gene assays were performed.
Activation of RAR was assessed with pRARE-TA-SEAP vector (Clonetech), which contained
multiple copies of retinoic acid response element upstream of the SEAP gene. phRL-TK
vector (Promega) was always co-transfected for standardization. Results: (1) ATRA stimulated
the transcription of RARE-driven SEAP genes in a dose-dependent manner, suggesting that
MKN45 cells possess functional RARs. Maximum effects were observed with 20 microM
ATRA. (2) ATRA up-regulated the transcription of TFF1 and TFF2 reporter genes in a dose-
dependent manner, and incubation with 20 microM ATRA for 40 h caused about 3-fold
and 6-fold increases in the transcription of TFF1 and TFF2 reporter genes, respectively. (3)
13-cis retinoic acid, another RAR ligand, also up-regulated the transcription of TFF1 and
TFF2 reporter genes. (4) In the case of TFF2, a series of deletion analysis showed that ATRA
responsive region is localized between -661 and -262 of the TFF2 gene promoter, although
apparent RAR binding sites are not present within this region. (5) We confirmed the up-
regulation of endogenous TFF1 and TFF2 mRNA expression by ATRA treatment. Conclusion:
These results suggest that RAR is involved in the regulation of TFF expression in gastric
epithelial cells.
S1891
Does Lactation Exert Beneficial Or Deleterious Influences On Healing
Processes of Gastric Ulcers in Rats?
Kaoru Nishikawa, Kikuko Amagase, Koji Takeuchi
Background/Aims: It is known that various changes in gastric function and morphology
occur in rats during lactation, including acid hypersecretion and hypergastrinemia as well
as mucosal hypertrophy/hyperplasia, although the mechanism responsible for these changes
remains unknown. These changes are thought to exert both beneficial and deleterious
influences on the healing of gastric ulcers. Indeed, previous studies examined the influence
of lactation on the healing of gastric ulcers, yet the results were not without controversy.
In the present study, we re-examined whether lactation exerts beneficial or deleterious effects
on the healing of acetic acid-induced gastric ulcers in rats. Methods: Female SD rats were
used. Three days after delivery, gastric ulcers were induced by serosal application of acetic
acid (99%, 100 µl) for 60 sec. Lactating rats were housed individually in cages with pups.
In some cases, lactating rats were pair-fed for 12 days starting from the day before the acid
application. Omeprazole (60 mg/kg) was given PO once daily for 7 days, starting 3 days
after the acid application. Mucosal levels of Prostaglandin E2 (PGE2) were measured by
EIA. The expression of COX-2 mRNA was examined by RT-PCR, while that of growth factor
protein (VEGF and bFGF) was determined by western blotting. Acid secretion was measured
in pylorus-ligated rats (4 h). Results: Serosal application of acetic acid produced a well-
defined ulcer in the stomach; The ulcer score reached the maximum at 3 days later and
healed spontaneously thereafter, with the up-regulation of COX-2/PGE2 production as well
as the expression of growth factors in the ulcerated mucosa. The healing of these ulcers was
significantly impaired in lactating rats, and the ulcer score on day 10 being about 3.5 times
greater as compared to that of normal rats. In lactating rats, both gastric acid secretion as
well as food intake were markedly increased as compared to normal rats, while the up-
regulated expression of COX-2 and growth factors as well as the increased PGE2 production
in the ulcerated mucosa remained unchanged. Omeprazole given once daily for 7 days did
not affect the delayed healing observed in lactating rats. Of interest, the delayed healing of
gastric ulcers during lactation was totally antagonized when the rats were pair-fed. Conclu-
sions: These results suggest that the healing of acetic acid-induced gastric ulcers were
delayed in lactating rats, and the mechanism of the impaired healing is not related to acid
hypersecetion and may be accounted for by inhibition of the tissue contraction at the ulcer
base caused by the increase of food intake.
S1892
Isothiocyanate Blocks Restitution and Wound Repair in the Mammalian
Stomach By Inhibiting Both Monocarboxylate and Bicarbonate Transport
Activity
Regina Ragasa, Eiji Nakamura, Lisa M. Marrone, Saeko Yanaka, Shusaku Hayashi, Koji
Takeuchi, Susan J. Hagen
Restitution is essential for reformation of the gastric mucosal barrier after injury. We recently
showed that DIDS, a stilbene compound and bicarbonate transport inhibitor, blocks restitu-
tion but the mechanism is still undefined. Because stilbenes are also reactive toward puri-
no(ATP) receptors, certain K+-channels, and the monocarboxylate transporter (MCT) via
one or more isothiocyanate (ITC) “R” groups, we aimed to determine whether restitution is
blocked by isothiocyanate and which of the isothiocyanate-binding transporters are involved.
METHODS: recovery of transepithelial resistance and morphology after injury in guinea
pig stomachs, ex vivo, was evaluated in the presence or absence of DIDS (2 ITC groups),
SITS (1 ITC group), or DNDS (0 ITC groups). Likewise, the repair of round wounds in
gastric mucosal (RGM-1) monolayers was evaluated in the presence of DIDS, SITS, or DNDS.
RGM-1 cells were also incubated with bicarbonate-free buffer, ATP or analogues of ATP to
determine the role of purinoreceptors, barium to determine the role of K+-channels, or
phloretin to test the role of MCT in wound repair. Because phloretin also potently blocks
glucose transport, wound repair was evaluated in glucose-free buffer. RT-PCR was used to
examine the expression of MCT isoforms in RGM-1 cells. Viability was determined using
the crystal violet assay. RESULTS: DIDS dose-dependently blocked restitution and wound
repair without reducing viability. At 300 μM, DIDS blocked restitution and wound repair
by 100%, SITS blocked by 50%, and DNDS blocked by 0%. These results demonstrate the
dependence of restitution on ITC. ATP, analogues of ATP, or barium did not affect wound
repair, suggesting that purino(ATP) receptors and barium-sensitive K+-channels, like Kir6.2/
SUR2A, are not the target of DIDS. Phloretin dose-dependently inhibited wound repair and
this result was exacerbated in bicarbonate-free conditions, where there was 100% blockade
of wound repair with no reduction in viability when both transporters were blocked simultan-
eously. Results with glucose-free buffer suggest that the effects of phloretin are not related
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to inhibition of glucose transport. Like in native surface cells, MCT-1 is the isoform expressed
in RGM-1 cells. CONCLUSIONS: Our results demonstrate that isothiocyanate compounds
like DIDS and SITS block bicarbonate and monocarboxylate transport, which seem to work
cooperatively to facilitate restitution. That isothiocyanates block gastric mucosal repair is of
particular importance in light of new data implicating isothiocyanate-containing broccoli
sprouts as a potential therapy against Helicobacter pylori-associated pathology in humans.
S1893
Role of Nociceptors/Neuropeptides Pathway in the Pathogenesis of Heartburn
in Nonerosive Reflux Disease
Norimasa Yoshida, Takahiro Suzuki, Masaaki Kuroda, Kazuhiro Kamata, Osamu Handa,
Tomohisa Takagi, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Hiroshi Kuramoto,
Toshikazu Yoshikawa, Takeshi Okanoue
Background and Aims: Esophageal visceral hypersensitivity has been proposed to be a
pathogenesis of heartburn in nonerosive reflux disease (NERD), but its further mechanisms
are unclear. In general, nociceptors and neuropeptides are involved in the pain perception
in various organs. Therefore, the objective of the present study was to estimate expression
of acid-sensing nociceptors (a transient receptor potential vanilloid receptor subtype 1
(TRPV1), acid-sensing ion channel 3 (ASIC3), protease-activated receptor 2 (PAR2) for
trypsin/tryptase, and neuropeptides (substance P and CGRP) released from nerve ending,
and their receptors (neurokinin 1 receptor (NK1R) for substance P and RAMP1 for CGRP)
in the esophageal mucosa of NERD patients. Materials and Methods: Biopsy samples were
taken from NERD patients and normal subjects without heartburn to examine nociceptor/
neuropeptide expression in the esophageal mucosa. The expression level of nociceptors,
neuropeptides and their receptors were assessed by real-time RT-PCR and enzyme immuno-
assay. Localization of substance P and CGRP in the esophageal mucosa was determined by
immunohistochemical staining. Level of reflux-related symptoms (heartburn and regurgita-
tion) was expressed using GSRS score. Results: Expression of mRNA for TRPV1 and PAR2,
but not ASIC3, was significantly elevated in the esophageal mucosa of NERD patients
compared to normal subjects. Substance P protein level and its receptor NK1R mRNA also
increased in NERD patients. A positive correlation between the substance P protein level
and the GSRS score was observed. Immunohistochemical study revealed the presence of
substance P-positive nerves in the just below basal layer of the esophageal mucosa. There
were no significant differences in the expression level of CGRP protein and its receptor
RAMP1 mRNA between NERD patients and normal subjects. Conclusions: These findings
suggest that the occurrence of heartburn in NERD patients may involve the increase in
both substance P release and NK1R receptor expression associated with the activation of
nociceptors, TRPV1 and PAR2.
S1894
Persistent Administration of Exogenous Luminal Nitric Oxide Exacerbates
Tissue Damage in the Esophagus of Chronic Reflux Esophagitis Model of Rats
Fumitake Isiyama, Katsunori Iijima, Kiyotaka Asanuma, Nobuyuki Ara, Jun Yositake,
Tetuhiko Yosimura, Tooru Shimosegawa
High concentrations of nitric oxide (NO) are generated luminally at the gastro-esophageal
(GE) junction through entero-salivary recirculation of dietary nitrate in human (Gastroenter-
ology 2002). Using an animal model whose GE junction was exposed to exogenous luminal
NO for a few hours, we recently demonstrated that NO thus formed actually diffuses into
the adjacent gastric tissue and could cause nitrosative stress at that site (Gut 2005). However,
whether persistent administration of exogenous NO could lead to histological damage in
the adjacent tissue remains unknown. When gastric acid refluxed into the esophagus, the
site of luminal NO generation shifts to the lower esophagus (Gut 2005). Therefore, NO
thus generated in the lower esophagus could affect tissue damage at that site. Aim. To
investigate the influence of persistent administration of exogenous NO on tissue damage in
the esophagus using chronic acid reflux esophagitis (RE) model in rats. Methods. According
to Omura et at (SJG 1998), RE model of rats was produced by ligating the transitional
region between the forestomach and the glandular portion with a 2-0 silk thread and covering
the duodenum near the pylorus ring with a small piece of an 18Fr Nelaton catheter. RE
rats were divided into three groups; rats in Group A were given 0.1% nitrite in drinking
water and 1% ascorbic acid in diet, group B were given 0.1% nitrite and normal diet, and
group C were given water and normal feed as controls. In this model, NO is supposed to
generate luminally in the esophagus by the chemical reaction of nitrite solution with refluxed
gastric acid (group B) or gastric acid plus ascorbic acid (group A). One week after, rats
were sacrificed and the esophagus was removed. The excised esophagus was assessed by
macroscopic and histological analysis and myeloperoxidase (MPO) activity was measured.
Results. Macroscopically, erosions and hyperplasia were observed more prevalently in the
esophageal mucosa of group A and B compared with controls. Histologically, there were
defect of epithelium and marked infiltration of inflammatory cells in the lamina propia and
submucosal layer in group A and B. MPO activity (mean+/-SD) of esophageal mucosa was
82.7+/-67.5 in group A and 31.4+/-20.7 in group B, both being significantly higher than
controls (9.6+/-4.9) (P < 0.05). Conclusion. Persistent administration of exogenous luminal
NO exacerbated tissue damage in the esophagus of RE rat model. Peroxynitrite (ONOO-)
formed by the reaction of diffused NO and superoxide produced at the injury site in RE
may be involved in the tissue exacerbation.
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S1895
Melatonin (Mt) Attenuates the Experimentally-Induced Esophagitis Through
Increased Generation of Mucosal Prostaglandins and Nitric Oxide, Enhanced
Activation of Sensory Nerves and Elevation of Esophageal Blood Flow
Roxana O. Zayachkivska, Tomasz Brzozowski, Peter C. Konturek, Zbigniew Sliwowski,
Michal Pawlik, Danuta Drozdowicz, Mieczyslaw Gzhegotsky, Stanislaw J. Konturek,
Wieslaw W. Pawlik
Background and Aims: MT, a potent antioxidant hormone produced by pineal glands and
gastrointestinal mucosa was shown to exert gastroprotective activity, but its influence on
the esophageal mucosa has not been evaluated. The aims of the study were 1) to examine
the effects of exogenous MT on rat model of esophagitis, 2) to determine the influence of
this indole on esophageal blood flow (EBF), and 3) to assess the involvement of prostaglandins
(PG) and nitric oxide (NO) in MT-induced protection against esophagitis. Methods: Esophag-
itis was induced in rats by esophageal perfusion (2 h per day for 7 days under anaesthesia)
with vehicle (control), HCl and pepsin (HCl/P) or HCL/P + bile acids (HCL/P/BA). Vehicle
(Veh) or MT (5 and 20 mg/kg i.p.) was administered 30 min prior to esophageal perfusion
without or with pretreatment with indomethacin (INDO) (2 mg/kg i.p.), L-NNA (20 mg/
kg i.p.) or capsaicin (CAP) (125 mg/kg s.c.). The macroscopic lesion score (range 0 - 3)
was assessed and EBF was determined by H2-gas clearance method. Esophageal biopsies
were collected for assessment of COX-2 and inducible NO synthase (iNOS) expression by
quantitative RT-PCR. Results: Following esophageal perfusion with HCl/P or HCl/P/BA, the
esophageal lesions score reached the values of 1.9±02 and 1.1±0.1, respectively, being
accompanied by the decrease of EBF by 20% and 35% of that in vehicle-perfused esophagus.
Pretreatment with MT reduced dose-dependently lesions score in HCl/P or HCl/P/BA-induced
esophagitis and caused significant increase in EBF accompanied by the rise in mucosal
generation of PGE2 and luminal NO release. Pretreatment with INDO and L-NNA, that
reduced mucosal formation of PGE2 and NO by 80% and 60%, respectively, aggravated
lesions score caused by HCl/P to 2.8 ± 0.3 and 3.0 ± 0.3, while reducing the EBF by 45%
and 30%. Also CAP-induced deactivation of sensory nerves enhanced HCl/P-induced score
up to 3.0 ± 0.3 and reduced EBF by 30% without affecting PGE2 or NO formation.
Pretreatment with MT (20 mg/kg i.p.) significantly reduced HCl/P lesion score caused by
INDO, L-NNA and CAP in HCl/P perfused rats and alleviated the fall in EBF without affecting
mucosal generation of PGE2 or luminal NO level. The mRNAs for COX-2 and iNOS mRNA
were upregulated in the gastric mucosa of MT-treated rats as compared to vehicle. Conclu-
sions: MT represents a potent protective factor for the esophageal mucosa and its beneficial
effects depend upon an enhancement in EBF possibly mediated by endogenous PG and NO
derived from COX-2 and iNOS expression and activation of sensory nerves.
S1896
Differences in Salivary Secretory Function Between Patients with Reflux
Esophagitis and Those with Non-Erosive Reflux Disease
Noriaki Manabe, Ken Haruma, Jiro Hata, Hiroaki Kusunoki, Tomoari Kamada
Background and Aims: It has been speculated that impaired salivary flow contributes to
abnormal acid clearance in patients with reflux esophagitis (RE), but, some points remain
unclear. To assess salivary function easily and objectively, we have developed a method for
assessing salivary gland blood flow using Doppler ultrasonography, and evaluate the salivary
secretory function in patients with RE and those with non-erosive reflux disease (NERD)
using this method. Study 1: Establishment of a method for assessing salivary gland blood
flow using Doppler ultrasonography. Subjects and Methods: Doppler waveform analysis was
performed on the facial artery to assess blood inflow to the submandibular gland of 10
healthy subjects (5 men, 5 women; mean age, 24.5 years). Blood flows were compared
before and after secretory stimulation with 1mL of lemon juice (1 mL). At the same time,
saliva was collected and weighed before and after stimulation. Results: The submandibular
gland blood flow increased after stimulation in all subjects. Both the within-day reproducibil-
ity and day-to-day reproducibility were good. There was a significant correlation between
the increased maximum velocity and that of salivary secretion (correlation coefficient, 0.510;
p < 0.05) and between the increased mean velocity and that of salivary secretion (correlation
coefficient, 0.371; p < 0.05). Study 2. Differences in the responsiveness of salivary gland
blood flow between patients with RE and those with NERD. Subjects and Methods: In
addition to the measurements performed in study 1, the size of the submandibular gland
was measured in 26 patients with RE (11 men, 15 women; mean age, 63.7 years), 41
patients with NERD (14 men, 27 women; mean age, 62.6 years), and 86 healthy subjects
(39 men, 47 women; mean age, 42.0 years). Results: There were no significant differences
in the salivary gland blood flow among the three groups before stimulation of salivary
secretion. There were also no significant differences in the size of the submandibular gland
among the three groups. After stimulation, the percentage changes in maximum velocity
and mean velocity decreased more significantly in the RE group than in the healthy subjects
(17.1±5.2% in the RE group vs. 52.8±5.2% in the healthy subjects; p<0.05), while there were
no significant differences between the NERD group and the healthy subjects (34.2±11.2% in
the NERD group vs. 52.8±5.2% in the healthy subjects; not significant). Conclusions: We
have established a new method for assessing salivary function for easy use in daily practice,
and found that a decrease in salivary secretory function was involved in the pathology of RE.
S1897
Weakly Acidic Solutions Containing Pepsin and Bile Acids Can Increase
Significantly Esophageal Mucosa Permeability
Ricard Farré, Hannah Van malenstein, Rita De vos, Karel Geboes, Pieter Vanden berghe,
Inge Depoortere, Jan Tack, Daniel Sifrim
In patients with non erosive reflux disease (NERD) or patients with refractory GERD in
spite of adequate PPI therapy, symptoms can be associated with weakly acidic gastroeso-
phageal reflux (pH 7-4). Symptoms are thought to occur if acid reaches sensory nerve
endings due to increased mucosal permeability through mucosal dilated intercellular spaces.
In human and rabbit, esophageal perfusion of acid (pH 1-2) and pepsin induces DIS and
increases mucosa permeability. We hypothesized that less acidic solutions containing pepsin
and bile acids (similar to weakly acidic reflux detected in patients “on” PPI) might also
increase esophageal mucosa permeability and thereby, contribute to esophageal symptoms.
Aim: To evaluate the effect of weakly acidic solutions on esophageal mucosa permeability.
Methods: Six male Sprague-Dawley rats and 4 New Zealand rabbits were euthanized and
segments from the esophagus were removed and mounted in diffusion chambers. Mucosa
permeability was assessed by measuring the mucosa-to-serosa passage of fluorescein (Fl)
(375 Dalton). The tissues were first pre-incubated for 30 min with Krebs pH 7.2 or HCl
pH 5.0 + pepsin 1 mg/mL + taurodeoxycholic acid (TDA) 2.6 mg/mL in the mucosal side.
Thereafter, tissues were exposed to Fl and permeability was calculated and expressed in
µmols/cm2 of Fl obtained at the serosal side after incubation for 30, 60, 90 and 120 min.
Results: Weakly acidic solutions did not provoke visible erosions on light microscopy but
increased significantly the esophageal mucosa permeability in both species. Compared to
incubation with control solutions, incubation with HCl pH 5.0 + pepsin + TDA, increased
the permeability to FL at 120 min from 0.35 ± 0.07 µmols/cm2 to 0.62 ± 0.16 in rats (p=
0.014) and from 0.69 ± 0.22 µmols/cm2 to 4.91 ± 2.79 µmols/cm2 in rabbits (p=0.035).
Conclusion: In 2 different species, exposure of the esophageal mucosa to a weakly acidic
solution containing pepsin and bile acids increased significantly the permeability of the
mucosa to small molecules. This mechanism may contribute to the association between
symptoms and weakly acidic gastroesophageal reflux in patients with NERD or refractory
GERD.
S1898
NOD1 Gene Polymorphism Influences the Susceptibility to Gastroesophageal
Reflux Disease and Progression of Gastric Atrophy in Helicobacter pylori
Infection
Tomoyuki Oikawa, Akira Imatani, Sho Asonuma, Naoki Asano, Tomoyuki Koike,
Katsunori Iijima, Shuichi Ohara, Tooru Shimosegawa
Background & Aim: Gastroesophageal reflux disease (GERD) is an acid-related disorder,
and gastric mucosal atrophy induced by Helicobacter pylori (Hp) infection generally inhibits
the development of GERD by reduction of acid secretion. Contradictory to the idea, even
a part of Hp-infected patients develop GERD, and this may be due to the influence of the
host genetic factors such as gene polymorphism. NOD1 as an intracellular sensor of Hp
initiates the host innate immune signaling and NFκB response. It was reported that an
insertion-deletion polymorphism (ND1+32656[T-/GG]) in intron 9 of NOD1 is associated
with inflammatory bowel disease. Therefore, we investigated the effect of ND1+32656 [T-/
GG] polymorphism on susceptibility to GERD, degree of Hp-induced gastritis, and gastric
mucosal atrophy in Japanese people. Subjects & Methods: In this hospital based case-
reference study, genomic DNA was prepared from the group of 101 Hp infected healthy
subjects and from the case group of 195 GERD patients with reflux esophagitis and/or
Barrett's esophagus. In these GERD patients, 96 were Hp-positive and 99 were Hp-negative.
ND1+32656[T-/GG] biallelic polymorphism was genotyped by direct sequence analysis. We
also measured serum pepsinogen (PG) and assessed gastritis score according to the updated
Sydney system with biopsy specimens. In addition, we performed electrophoretic mobility
shift assay (EMSA) to assess the difference of DNA-binding activity between ND1+32656 T
and GG In Vitro. Results: Allele frequency of ND1+32656 was 0.80 for T and 0.20 for GG
in the control group. The Hp-infected patients carrying ND1+32656 GG (GG carrier group)
showed an increased risk of GERD with odds ratio (OR) 2.13[95% confidence interval (CI),
1.20-3.78] compared with Hp-infected control subjects, and also with OR 2.36[95% CI,
1.32-4.22] compared with Hp-negative GERD patients. In histological assessments, inflam-
mation score in the body was significantly lower in the GG carrier group than the T/T group
(p=0.05). Similarly, a PG I/II ratio that decreases as greater the severity of atrophy showed
a tendency to be higher in the GG carrier group than the T/T group (p=0.06). EMSA
using synthetic allele-specific oligonucleotides showed the differential DNA binding patterns
between ND1+32656 T and GG in the nuclear protein prepared from AGS and GCIY, gastric
epithelial cell lines. Conclusions: ND1+32656 GG allele may mitigate corpus gastritis induced
by the innate immune response to Hp infection, and may inhibit the progression to gastric
atrophy. In addition, this polymorphism may increase the risk of GERD even in Hp-
positive patients.
S1899
The Gastroesophageal Pressure Gradient in GERD, Relationships with Obesity
and Hiatal Hernia
Durk Vries, de, Margot Van herwaarden, André Smout, Melvin Samsom
Background: From previous studies it is clear that hiatal hernia (HH) and the gastroesophageal
pressure gradient (GEPG) both play a role in the pathophysiology of gastroesophageal reflux
disease (GERD). Transient sphincter relaxations during which acid reflux occurs exhibit an
increased GEPG. Obese patients have increased GEPG and more HH. However, until now
no data of the combined effect of BMI, GEPG and HH is available for large groups of GERD
patients. Materials and methods: 154 symptomatic patients with pathologic reflux (pH<4
≥ 6% time) and/or positive symptom association (SI≥50;SAP≥95) on 24-hour pH-metry
were included. All patients underwent stationary esophageal manometry. Mean intragastric
and distal intra-esophageal pressures were determined both during peak inspiration and mid-
expiration. GEPG was defined as mean intragastric pressure minus mean intra-esophageal
pressure. Presence or absence of hiatal hernia (HH) or esophagitis was assessed endoscop-
ically. Associations were tested with Chi-square, means compared with T-tests, correlation
coefficients are Pearson's. Results: Presence of HH was strongly associated with being over-
weight (BMI&;25) (P=.009) and the presence of esophagitis (P<.0005). Patients with HH
had higher inspiratory intra-gastric pressure (1.79 vs. 1.58 kPa; P=.016) and inspiratory
and expiratory GEPG (1.59 vs. 1.19 kPa; P<.0005 and 0.41 vs. 0.11 kPa; P=.001, respectively).
In patients without HH, BMI was correlated with inspiratory and expiratory intra-gastric
pressure (r 0.45 and r 0.46, respectively, P≤.002). In the presence of HH these correlations
were weaker (r 0.29 and r 0.33, respectively, P≤.002) but in this group BMI correlated
with expiratory intra-esophageal pressure (r 0.28, P=.003) and inspiratory GEPG (r 0.20,
P=.036). In both groups inspiratory GEPGs correlated with intra-gastric pressure (no HH r
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0.38, HH r 0.43; P≤.01) but a much stronger correlation was seen with intra-esophageal
pressure; in the group with HH this was less pronounced (r-0.81 vs. r-0.59; all P<.0005).
Expiratory GEPGs were strongly correlated with intra-esophageal pressure, less pronounced,
again, in the HH group (r-0.80 vs. r-0.69; all P<.0005); intra-gastric pressure and GEPG
did not correlate at all. Conclusion: Overweight GERD patients more often have HH and
have increased intra-gastric pressure. In the absence of HH, GEPG variance is determined
almost exclusively by the intra-esophageal pressure, but in the presence of HH both intra-
gastric and intra-esophageal pressure are determinants of the GEPG. It stands to reason that
the effects of HH and elevated intra-gastric pressure act synergistically in the etiology of
GERD in the obese.
S1900
short Exposure of Non-Erosioned Esophageal Mucosa to Bile Acids Is
Associated with Strong Increase of Esophageal Mucosa Permeability and
Dilated Intercellular Spaces (Dis)
Ricard Farré, Hannah Van malenstein, Pieter Vanden berghe, Rita De vos, Karel Geboes,
Inge Depoortere, Jan Tack, Daniel Sifrim
Prolonged exposure of esophageal mucosa to acid and bile acids, due to duodeno-gastro-
esophageal reflux, is very important in the pathogenesis of severe esophagitis and Barrett's
esophagus. In contrast, patients with non-erosive reflux disease (NERD) may have normal
or increased acid exposure but usually short exposure to bile acids as indirectly measured
with Bilitec. In these patients, heartburn is believe to occur if acid reaches sensory nerve
endings due to increased mucosal permeability through dilated intercellular spaces (DIS).
We hypothesized that even a short exposure to bile acids may contribute to the increased
esophageal mucosal permeability observed in NERD. Aim: To evaluate the effect of bile
acids on esophageal mucosa permeability.Methods: Six New Zealand rabbits were euthanized
and segments from the esophagus were removed and mounted in diffusion chambers. Mucosa
permeability was assessed by measuring the mucosa-to-serosa passage of fluorescein (Fl)
(375 Dalton). The tissues were first pre-incubated for 30 min with Krebs pH 7.2 or HCl
pH 2.0 + pepsin 1 mg/mL with and without taurodeoxycholic acid (TDA) 2.6 mg/mL in
the mucosal side. Thereafter, tissues were exposed to Fl and permeability was calculated
and expressed in µmols/cm2 of Fl obtained at the serosal side after incubation for 30, 60,
90 and 120 min. Presence of erosions and diameter of intercellular spaces were assessed
using light (LM) and transmission electron microscopy (EM). In each EM microphotograph
the intercellular space area was measured and a ratio area/perimeter of the corresponding
cells was calculated to obtain a relative measure of DIS. Results: Exposure of esophageal
mucosa to test solutions did not provoke erosions (LM). Compared to control solution,
incubation with HCl pH 2.0 + pepsin did not increase mucosal permeability. In contrast,
the acid-pepsin-TDA solution increased significantly (65 times) the permeability to Fl. The
increase at 120 min was from 0.69 ± 2.2 µmols/cm2 to 45.2 ± 1.4 µmols/cm2. Incubation
with acid-pepsin alone did not enlarge intercellular spaces. Adding TDA to the test solution
significantly enlarged intercellular spaces in the prickle and the basal layers (0.093 ± 0.005
µm) compared to control (0.013 ± 0.005 µm). Conclusion: Experimental short exposure
of non-erosioned esophageal mucosa to bile acids (similar situation to that observed in
NERD) is associated with strong increase of esophageal mucosa permeability and dilated
intercellular spaces (DIS). These results suggest that bile acids in the refluxate may play a
significant role in the mechanisms of symptoms generation in patients with NERD.
S1901
Prevention of Gastroesophageal Reflux-Induced Ulceration By Selective TRPV1
Receptor Antagonist in Rats
Yue Zheng, Bidyut K. Medda, Banani Banerjee, Richard Komorowski, Jyoti N. Sengupta,
Reza Shaker
Biology of esophageal squamous mucosa as it relates to injury induced by gastroesophageal
reflux disease remains incompletely understood. Existing data suggests different degrees of
injury by similar acid exposure. Emerging information suggests a critical role for biological
components at the cellular level such as epithelial TRPV1 receptors in the development of
tissue injury by acid (Fujino et al., Gut 2006; 55: 34-40). Our aim was to determine the
effect of selective TRPV1 receptor antagonist (AMG9810) on development of esophageal
mucosal injury in a rat reflux model. Method: We studied a total of 20 rats after a previously
described reflux-promoting surgery (RPS) (as described by Omura et al. Scand J Gastroenterol
1999. 34: 948-953). Of these, 5 received AMG9810 and 5 received placebo beginning on
the day of surgery (10 micromol/kg for 7 days). Both groups were sacrificed at day 7. Of
the remaining, 5 received placebo and 5 AMG9810 seven days after surgery for the ensuing
7 days and sacrificed at day 14 following surgery. Investigator performing the RPS was
different from whom administering the compounds. Esophageal tissue was removed in its
entirety and photographed and examined macroscopically and subsequently histologically.
Examiners were blinded to the groups. Results: In 6 of 10 rats that did not receive AMG
9810, RPS resulted in ulcerations at different levels of the esophagus. Histological examination
confirmed 4 of these 6 macroscopically observed ulcerations. In contrast, both macroscopic
and histologic examinations showed no evidence of ulcer formation in rats treated with
AMG 9810. Histological examination, however, showed acute and/or chronic inflammation
in both controls (4 of 10) and AMG9810-treated rats (6 of 10). Conclusion: AMG9810
prevents development of reflux-induced ulcerations pre- and post-emptively possibly though
blockade of epithelial TRPV1 receptors. The TRPV1 receptor antagonist does not seem to
prevent reflux-induced inflammatory changes. Supported in part by R01 DK025731 and
R01 DK062312-01A2.
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S1902
Brain Activation Response to Esophageal Acid Stimuli and to Psychological
Stimuli in Subgroups of Gastroesophageal Reflux Disease
Liping Duan, Kun Wang, Xiangzhu Zeng, Jianyu Liu
AIM: To assess brain activition response to esophageal acid stimuli and to psychological
stimuli in subgroups of gastroesophageal reflux disease (GERD) by functional magnetic
resonance imaging (fMRI). METHODs: 12 health volunteers (5 males, 29±10yrs) and 28
GERD patients were enrolled in the study. All of them are right-handed. The study protocol
was approved by the Human Research Review Committee of PUHSC and all subjects gave
written informed consent before the study. According to the results of gastroscopy and 24-
h pH monitoring, GERD patients were divided into four subgroups as reflux esophagitis
(RE) (f/m=2/4,61±14yrs), non-erosive reflux disease+ (NERD+) (no RE but the pH monitoring
result was positive, f/m=3/7, 36±12yrs), NERD-SI+ (gastroscopy and pH monitoring were
negative, while symptom index-SI was positive, f/m=3/2, 57±9yrs) and NERD-SI- (no RE,
pH monitoring and SI were negative, while being favorable response to PPI trial, f/m=3/4,
50±7yrs). fMRI images were obtained during the following four procedure: baseline, 0.1N
HCl esophageal perfusion (10ml/min), 0.9% NaCl esophageal perfusion (10ml/min) and
psychological stimuli (patients were told that acid would be perfused into their esophagus
which might induce heartburn or acid regurgitation) accompanied with 0.9% NaCl eso-
phageal perfusion. Statistical parametric mapping (SPM2) analysis identified brain activation
between baseline and stimulation amone each of the subgroups. The anterior cingulated
cortex (ACC), prefrontal cortex (PFC), insular cortex (IC) and thalamus were chosen as
region of interests (ROI). MarsBaR and Xjview analysis were used to get datas of ROI voxels
(1voxel=2*2*2mm3). Median (Quartile) was used to test the differences. RESULTS 1.To
the psychological stimulation, thalamus and PFC were significantly activated in NERD-SI-
patients than in controls {[24(0-95) vs. 0(0-0.75)] and [40(15-161) vs. 3(0-16.5)]}(p<0.05).
2. To acid stimulation, thalamus and a part of PFC (BA10) were activated more in NERD-
SI- patients than in controls {[15(14-40) vs. 0(0-5.25)] and [14(10-83) vs. 4.5(0-20)]}, p=
0.261 and p=0.277. 3. There were no ROI activation differences among controls, NERD-
SI+, NERD+ and RE groups to both stimulations. CONCLUSION: 1. NERD-SI- patients
presented the hyperreactivity in thalamus and PFC brain regions either to psychological
stimuli or to acid stimuli, suggests that altered sensory processing in this subgroup may
play an important role in the pathegenesis of their symptoms. 2. There is no obvious
relationship between the cerebral activation and the erosive extent of esophagus. Funded
by Research Fund for the Doctoral Program of Higher Education of China.
S1903
Correlation of GERD Symptom Scores with Macroscopic and Microscopic
Inflammation in the Distal Esophagus
Ajay Bansal, Sandy Hall, Sachin B. Wani, Sharad Mathur, Amit Rastogi, April D. Higbee,
Prateek Sharma
Background: It has been reported that in GERD patients, the frequency and severity of
symptoms have a poor correlation with macroscopic esophageal injury i.e. erosive esophagitis.
However, correlation between reflux symptoms (using a validated scoring system) and
macroscopic/microscopic inflammation has not been performed. Aim: To correlate GERD
symptom scores with both macroscopic and microscopic esophageal inflammation. Methods:
Consecutive GERD patients completed a validated questionnaire (reflux disease questionnaire
- RDQ) prior to enrollment in the study. RDQ scores for heartburn and regurgitation were
compiled to obtain a total RDQ score (range 0-24). All patients then underwent upper
endoscopy with distal esophageal biopsies, 1 cm above the normal squamocolumnar junction
(SCJ). The presence of macroscopic erosive esophagitis was graded using the LA classification.
Esophageal biopsies were examined in a blinded manner by a single pathologist for basal
cell hyperplasia, papillary elongation, dilated intercellular spaces (DIS), necrosis or erosion,
eosinophils and neutrophils. All components were graded 0 to 2 as previously described
with a maximum possible score of 12. Additionally, the presence of lymphocytes (chronic
inflammation) was also evaluated. All correlations were performed by the Spearman's correla-
tion method. Results: 53 GERD patients, mean age 57.4 yrs (92% males, 87% Caucasians)
were enrolled. Twenty one pts had non erosive reflux disease (NERD) and 32 had erosive
esophagitis (EE)(7 grade A, 15 grade B, 9 grade C, 1 grade D). The mean RDQ scores were
not significantly different between the EE and NERD patient groups (10.7 vs. 8.8, p=0.35).
There was a significant positive correlation between the RDQ scores and the composite
histology scores (r=0.37, p<0.007). On further analysis of all the individual histologic
parameters within the composite histologic score, the presence of DIS was significantly
associated with the RDQ scores (p<0.002). Also, patients with RDQ scores > 14 had a higher
degree of lymphocytes and eosinophils but not neutrophils (p<0.01) when compared to
those with RDQ < 14. Conclusion: GERD symptoms (using a scoring system) do not correlate
with macroscopic esophageal injury i.e. erosive esophagitis. However, symptom scores (RDQ)
correlate significantly with abnormal esophageal histopathology, specifically with the pres-
ence of DIS and chronic inflammation (lymphocytes)(but not acute inflammation: neutro-
phils). This suggests that both DIS and chronic inflammation may play a role in symptom
perception in GERD patients.
S1904
Acid Suppression Therapy with Proton Pump Inhibitors Does Not Improve
Inflammation in Barrett's Esophagus
Ajay Bansal, Sharad Mathur, Jyotsna Talapaneni, Shailender Singh, Sachin B. Wani, Amit
Rastogi, Srinivas R. Puli, Prateek Sharma
Background: Chronic inflammation has been linked to carcinogenesis in numerous cancer
models. In BE, inflammatory cytokines have been shown to be elevated and case control
studies have shown ASA and NSAID to decrease the risk of adenocarcinoma suggesting a
role for inflammation in BE cancer progression. We studied the effect of pharmacologic acid
suppression on inflammatory scores in BE patients. Methods: A detailed analysis of biopsy
specimens from BE patients at baseline (pre-) and post- proton pump inhibitor (PPI) therapy
A-276AGA Abstracts
was systematically performed. The inflammatory scores at baseline were compared to scores
after at least 3 months of PPI therapy at three different levels within the BE segment. A
group of BE patients who were not on acid suppressive therapy and had 2 sets of biopsies
at least 3 months apart were used as controls (untreated group). All biopsies were reviewed
by a single pathologist. The presence of inflammation in all biopsies was scored based on
the updated Sydney Classification (normal, mild, moderate and marked scored as 0, 1, 2
or 3). The paired statistical analysis was done with Wilcoxon signed ranks test. Results: The
PPI treated group included 27 patients (mean age 61 years, 26 males, 90% Caucasians)
with a mean BE length of 4.7cm (range 1-15 cm) and the untreated group included 16
patients (mean age 66 years, all males, all Caucasians) with a mean BE length of 7.2 cm
(range 1.5-14 cm). The mean duration of acid suppression in the PPI group was 17 months
(range 3 to 44 months). The mean baseline scores for monocytes, neutrophils and eosinophils
were 1.43, 0.53 and 0.72 in the PPI treated group and 1.52, 0.53, 0.74 in the untreated group
respectively. Post treatment, the mean scores for monocytes, neutrophils and eosinophils were
1.47, 0.61 and 0.66 in the PPI treated group and 1.41, 0.59, 0.79 in the untreated group
respectively. Thus, at follow up, no significant changes were observed in the inflammatory
scores either in the PPI treated or untreated group. There were no differences when the
results were analyzed separately for each biopsy level. Conclusions: In this detailed analysis
of BE biopsies, acid suppression did not improve inflammatory scores. In view of link of
inflammation to carcinogenesis, this persistence of inflammation on PPI therapy suggests
that acid suppression as sole therapy may not be adequate for neoplasia prevention in BE.
S1905
Serotonin Receptor 3a Polymorphism C178t Is Associated with Visceral
Hypersensitivity in GERD
Durk Vries, de, Jose Ter linde, Margot Van herwaarden, André Smout, Melvin Samsom
Background: Familial clustering and twin studies show that susceptibility to GERD has a
hereditary component. Visceral hypersensitivity plays an important role in GERD symptom
generation. Serotonin (5-HT) modulates visceral sensitivity of the GI tract. Moreover, 5-HT
reuptake inhibiting drugs diminish esophageal hypersensitivity, possibly by increasing 5-
HT availability to descending serotonergic antinociceptive pathways. The 5-HT3 receptor
has been reported to function in both pro- and antinociceptive pathways depending on
receptor location. The T-allele of the C178T SNP in the 5-HT3 receptor A subunit encoding
gene (HTR3A) is related to an increased protein level of the 5-HT3A subunit via enhancement
of translation. Increased incorporation of the 5-HT3A subunit in the pentameric 5-HT3
receptor decreases 5-HT affinity and enhances the rate of receptor desensitization. Notably,
5-HT-driven activity in the amygdala and prefrontal cortices differed in subjects with CC
and CT genotype. Aim: Evaluate the association of the HTR3A C178T genotype with disease
susceptibility and visceral hypersensitivity in GERD. Methods: GERD was defined by 24-
hour esophageal pH-monitoring and symptom association scores (total time pH<4 ≥6%
and/or SI≥50% or SAP≥95%). DNA was extracted from blood of 320 GERD patients (189
male, mean age 48.7, mean BMI 26) and 339 symptom-free controls (95 male, mean age
41.5, mean BMI 24). Genotyping was performed by molecular beacon assay. Results: For
the entire GERD group no association with the HTR3A C178T genotype was observed. Yet
the GERD subgroup characterized by physiological acid exposure (total time pH<4 <6%)
and positive symptom association score showed a higher frequency of T allele carriers relative
to controls. Logistic regression with age, sex and BMI as covariates yielded an odds ratio of
1.86 (95%CI 1.05 - 3.28; P = 0.033). Dichotomizing the GERD subgroup with pathological
acid exposure according to positive symptom association score did not affect the genotype
distribution. Conclusions: The higher prevalence of T-allele carriers in the GERD subgroup
that constitutes the more sensitive extremity of a spectrum of visceral sensitivity in GERD,
suggests that HTR3A is a genetic determinant of visceral hypersensitivity in GERD. A
decreased response to 5-HT of the 5-HT3 receptor involved in one of the descending
serotonergic antinociceptive pathways may underlie the association.
S1906
Dynamics of Unbuffered Postprandial Acid Pocket and Role in Acidic
Gastroesophageal Reflux
Alan T. Clarke, Angela A. Wirz, John P. Seenan, Jonathan J. Manning, Derek Gillen,
Kenneth E. Mccoll
Background: An unbuffered pocket of highly acidic juice is observed in the proximal stomach
after a meal in healthy subjects using pull-through pH studies. Aims: i) To confirm that
postprandial acidification of the proximal stomach occurs simultaneously to distal gastric
buffering using a novel static high resolution pH catheter ii) to establish whether discrete
episodes of esophageal acid reflux originate from the postprandial acid pocket. Methods:
15 healthy subjects were studied. A custom made high resolution 12 sensor pH catheter
(sensors 1 to 12 located 172, 138, 127, 116, 105, 94, 83, 72, 61, 50, 30 and 0 mm from
the distal tip) was then attached to the esophageal mucosa at the proximal margin of the
gastric folds. The catheter was fixed in place using endoscopic clips through prolene loops
tied on between sensors 4 and 5. After a 2 hour rest period following endoscopy, fasting
pH was recorded for 30 minutes, during a standardized meal and for 90 minutes after
completion of the meal. The % time pH < 4 for the 90 minute postprandial period was
calculated for each subject. Reflux events were defined as a recorded fall in pH to less than
4 in one or more of the esophageal sensors and simultaneous intragastric pH was recorded
Results: There was a significant variation in the %time pH<4 over the 90 minute postprandial
period measured by the 12 sensors (Kruskal-Wallis analysis of variance p<0.001). The
greatest %time pH<4 was seen in the three sensors 5.5 (median 20.1%), 16.5 (median
58.1%) and 27.5mm (median 44.2%) distal to the proximal margin of the gastric folds
(Table 1.). The reason for the difference in buffering was due to differing duration of
buffering following completion of the meal with the cardia having the least duration of
buffering after completion of the meal. The duration of buffering progressively increased
on moving distal to the cardia. 60 reflux events (esophageal pH<4) were recorded in the
postprandial period in the 15 subjects. Simultaneous intragastric pH monitoring demon-
strated that in 71.7% (n=43) of these events, the only source of the refluxate was the region
of high acidity in the proximal stomach Conclusion:Postprandial buffering is of shorter
duration in the proximal stomach and this provides a source of highly acidic gastric juice
available for reflux into the esophagus
Median %time pH<4 over 90 minute postprandial period
Table 1
S1907
Nociceptors-Mediated Neuropeptides Release in the Esophageal Mucosa
Exposed to Acid
Takahiro Suzuki, Norimasa Yoshida, Kazuhiro Kamada, Ikuhiro Hirata, Tatsuji Omatsu,
Osamu Handa, Tomohisa Takagi, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Takeshi
Okanoue, Toshikazu Yoshikawa
<Background and Aims>Heart burn in patients with non-erosive reflux disease (NERD) may
be partially dependent on the esophageal visceral hypersensitivity, which mechanisms are
unclear. Recently, acid-sensing receptors such as a transient receptor potential vanilloid
receptor subtype 1 (TRPV1) have been proposed to contribute to the occurrence of acid-
related symptoms in gastroesophageal reflux disease including NERD. In addition, neuropep-
tides such as substance P and CGRP are well known to be involved in the pain perception
in various organs. The objective of the present study was to determine interaction between
acid-sensing nociceptors and neuropeptides in the rats esophageal mucosa exposed to acid
<Materials and Methods> Exp1. Seven weeks old male Wister rats were used in this study.
Under pentobarbital anesthesia, we orally inserted 6 Fr catheter with balloon into the
esophagus in rat, and injected hydrochloric acid (HCl, pH1.0) or physiological saline into
the esophagus through the lateral hole of catheter. Infusion fluid was pooled into the lower
esophagus by inflating balloon at cardia for ten minutes. Subsequently, HCl or physiological
saline was sucked in and balloon was deflated. One hour later, esophageal mucosa was
exfoliated and substance P and CGRP contents in the mucosa were assessed by EIA. Exp2.
Rats were intravenously pretreated with TRPV1 antagonist (capsazepine) or acid-sensing ion
channels (ASICs) blocker (amiloride) ten minutes before HCl injection through the catheter.
In the same manner as Exp1, substance P and CGRP contents were evaluated. <Results>
There were no significant differences in macroscopic and microscopic findings between the
HCl group and the physiological saline group (control group). There were no significant
differences in CGRP protein level. Substance P protein level was significantly increased in
HCl group compared with control group. Pretreatment with TRPV1 antagonist or ASICs
blocker had no significant effects on mucosal CGRP protein level in both HCl and control
group. On the other hand, substance P protein level was significantly decreased in HCl
group by the pretreatment with TRPV1 antagonist or ASICs blocker compared with control
group. <Conclusions>These results indicate that acid exposure to the esophageal mucosa
induces substance P release via acid-sensing nociceptors such as TRPV1 and ASICs, suggesting
the importance of nociceptors/ neuropeptides pathway in the esophageal visceral hypersensit-
ivity.
S1908
Narrow Band Imaging (NBI) Findings Correlate with Histologic Changes in
Gastroesophageal Reflux Disease (GERD) Patients
Amit Rastogi, Sharad Mathur, Sachin B. Wani, Ajay Bansal, Sandy Hall, April D. Higbee,
Prateek Sharma
Background: NBI is a novel endoscopic technique that accentuates mucosal and capillary
patterns of distal esophagus by spectral narrow band optical filters. Features like microscopic
intrapapillary capillary loops (IPCLs) are readily identified and have been shown to be
present in significantly higher numbers in GERD patients compared to controls. However,
the correlation of findings on NBI with histopathological changes is not known. Aim: To
correlate findings at NBI endoscopy to histological changes in the distal esophagus of GERD
patients. Methods: Patients diagnosed with GERD on basis of 2 validated GERD questionnaires
[gastroesophageal reflux questionnaire (GERQ) and reflux disease questionnaire (RDQ)]
were enrolled. The distal esophagus was examined by standard endoscopy followed by NBI.
Features seen only by NBI - IPCL characteristics (increased number, dilatation, and tortuos-
ity), microerosions, increased vascularity at squamocolumnar junction (SCJ), columnar
islands and ridge/villous pattern below the SCJ were recorded. The max and min number
of IPCLs/endoscopy field was counted manually. Biopsies were obtained 1 cm above SCJ
and all specimens were reviewed by pathologist blinded to clinical and NBI findings. A
histological scoring system that accounts for necrosis/erosion, neutrophil/eosinophil infiltra-
tion, basal cell hyperplasia, papillary elongation, and dilatation of intercellular spaces was
utilized (score 0-2 given for each lesion). Findings at NBI were correlated with the histological
score using Pearson correlation coefficient and Wilcoxon two sample tests. Results: 52 GERD
patients [32 erosive esophagitis and 20 non-erosive reflux disease ] were prospectively
evaluated. The mean age was 56.7 yrs and majority of the patients were males (92%) and
Caucasians (88%). The mean histological score was 4.1 (range 0-12). Patients with dilated
IPCLs (n=39) and tortuous IPCLs (n=39) demonstrated a significantly higher histological
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scores than those without these findings (4.5 vs. 2.5, p=0.01) and (4.5 vs. 2.8, p=0.03)
respectively. The average IPCLs/endoscopic field correlated best with the total histological
score (r=0.29, p=0.03). However, there was no difference in the histological score between
patients with and without microerosions, increased vascularity at SCJ, columnar islands and
ridge/villous pattern below SCJ. Conclusions: These results show that NBI findings in
distal esophagus of GERD patients; IPCL features in particular, correlate significantly with
histological changes observed in distal esophageal biopsies. NBI endoscopy may be a reliable
objective parameter in correlating changes in distal esophagus to acid reflux.
S1909
The Effects of Obesity On Oesophageal Function and Acid Exposure in
Patients Referred for Investigation of Reflux Symptoms
Roy Anggiansah, Angela Anggiansah, Mark R. Fox
Introduction: The increasing prevalence of obesity and gastro-oesophageal reflux disease
(GORD) suggests an association between these two conditions. A recent study using station-
ary, high resolution manometry demonstrated that obese subjects have a raised gastro-
esophageal pressure gradient and are more likely to have disruption of the oesophago-gastric
junction (leading to hiatal hernia); A ‘perfect scenario' for reflux.[Pandolfino Gastro06] This
study aimed to establish whether these demographic and manometric changes are associated
with increased oesophageal acid exposure in clinical practice. Method: A prospective study
of 574 patients referred for oesophageal investigation. Height, weight and waist circumference
were measured. Body mass index (BMI kg/m2) was calculated. Reflux symptoms were
assessed by a validated questionnaire. Conventional manometry assessed lower oesophageal
sphincter (LOS) pressure, total and abdominal LOS length and peristalsis (gastric reference).
24hr ambulatory catheter based pH studies were performed. Multivariate regression identified
associations of oesophageal acid exposure (%time pH<4/24hr) with demographic and mano-
metric variables. Results: Patients without reflux symptoms were excluded (n=90). Complete
manometry and pH data was available for 407/484 (84%); M:F 45%:55%. Oesophageal acid
exposure was positively associated with reflux symptoms (p<0.001). The prevalence of
obesity and reflux was similar in both sexes; however females reported more severe symptoms
(p<0.01). Obesity and reflux increased with age (p<0.01); however symptoms were
unchanged. Increasing BMI and waist circumference were associated with more severe
oesophageal acid exposure (both p<0.002) but not reflux symptoms (p=0.1). Increasing
oesophageal acid exposure was associated with shorter abdominal LOS length (p<0.001),
lower LOS pressure (p<0.002), and peristaltic contractile pressures (p<0.04). Increasing
waist circumference was also associated with shorter abdominal LOS length (p<0.001),
lower LOS pressure (p<0.004), and peristaltic contractile pressures (p<0.05). None of these
associations were present when a correction for height (BMI)was included in the regression
analysis. The magnitude of the effect on LOS and contractile pressure across the observed
range was similar to that expected from increasing intra-gastric pressure with central obesity
(~5mmHg). Conclusion: In patients referred for investigation of reflux symptoms obesity is
associated with increasing oesophageal acid exposure. Analysis suggests that this is due to
a rise in intra-gastric pressure and gastro-esophageal pressure gradient related to central adip-
osity.
S1910
The Natural History of Non-Erosive Gastroesophageal Reflux Disease (NERD)
in Japan: A Prospective Study
Takane Azumi, Kyoichi Adachi, Noriyuki Arima, Shino Tanaka, Junko Yagi, Kenji
Koshino, Masaharu Miki, Kenji Furuta, Yoshikazu Kinoshita
Background and Aim: We have recently clarified that 60% of Japanese patients with gastro-
esophageal reflux disease (GERD) are diagnosed as having non-erosive gastro-esophageal
reflux disease (NERD). This study was performed to clarify the natural history of patients
with NERD and tried to find possible risk factors for the development of NERD and reflux
esophagitis (RE) within a period of several years. Subjects and Methods: After obtaining
written informed consent, 1845 patients, who were examined by upper gastrointestinal
endoscopy for annual check-ups and answered a GERD symptom by Japanese version of
the Carlsson-Dent self-administered questionnaire (scores of more than 6 as positive for
reflux symptoms), were prospectively enrolled between April 2000 and March 2001. Five
hundred and fifty-five individuals returned between April 2005 and March 2006. Individuals
with a history of gastric surgery or eradication therapy for H. pylori infection were excluded,
and Patients who had regularly taken proton pump inhibitors, H2 receptor antagonists and
prokinetics during the 5-year follow-up period were also excluded. Thus, 542 individuals
(male: 411, female: 131, mean age 47.3 yr in 2000) were analyzed in this study. Patients
with reflux symptoms but without erosive esophagitis were diagnosed as having NERD.
Results: At enrollment, 73 cases were diagnosed as NERD, 47 as RE and 422 as normal.
After 5 years, 6% and 5% of normal subjects showed progression to NERD and RE, respect-
ively. Only 19% of the 73 NERD patients showed unchanged status, and 11% showed
progression to RE; reflux symptoms in the remaining 70% disappeared in 5 years. Forty-
seven percent of RE cases showed no change of disease status. Presence of NERD at enrollment
was the only significant risk factor for presence of NERD after 5 years by multiple logistic
regression analysis. On the other hand, the presence of RE and hiatal hernia, increase of
BMI and habitual drinking were significant predictive factors for the presence of reflux
esophagitis after 5 years. Conclusion: Reflux symptoms of patients with NERD frequently
disappear after 5 years. Unlike RE, it is difficult to identify patients with NERD who will
still have the disease 5 years later on the basis of clinical characteristics.
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S1911
Gastroesophageal Reflux Occurs After Arousals and Awakenings in Patients
with Obstructive Sleep Apnea
Geoffrey Spencer, Sharon Schutte-rodin, Brensinger Colleen, Steve Stache, David A.
Katzka, David C. Metz
Background: There is an increased prevalence of gastroesophageal reflux (GER) in patients
with obstructive sleep apnea (OSA). We aimed to study the association of sleep events and
GER. Methods: Subjects with OSA and GER were recruited to assess the temporal relationship
of sleep and reflux events. Prior to testing, GER medications were held for ≥7 days and
CPAP for ≥2 days. A standard diagnostic sleep study with pH probe placed 5cm above the
LES was conducted. Sleep and pH data were recorded simultaneously. Data from this study
was used in a case-crossover design to calculate the symptom association probability between
sleep and GER events. GER was defined as a drop in pH<4 for ≥4 seconds and events were
combined if they were separated by ≤15 seconds. Case periods were defined by one of the
following outcomes: GER event, apnea, arousal, or awakening. Exposure to the remaining
variables was sampled for a time preceding the outcome. Control periods were defined by
times excluding the outcome variable and were randomly sampled for the exposure variable.
Conditional logistic regression, conditioning on the patient, was used to calculate odds ratios
for event association, comparing exposed and unexposed periods. Sensitivity analysis was
performed varying the exposure window from 60 to 180 seconds and the criteria of combining
repeated GER events at 5, 15, and 30 seconds. Results: We enrolled 17 subjects; 3 mild, 5
moderate, and 9 with severe OSA. Baseline analysis using an exposure window of 60 seconds
and combining GER events occurring within 15 seconds showed a significant association
of both awakenings (OR 4.95, p<0.001) and arousals (OR 2.50, P<0.0001) preceding GER
events. The association of both awakening and arousal preceding GER remained significant
(p<0.0001) when the exposure window was varied to 60, 120, and 180 seconds and when
varying the criteria for combining GER events at 5, 15, and 30 seconds. Using this model,
associations were not significant for apneas preceding reflux or for reflux preceding apneas,
arousals, or awakenings. Conclusion: In patients with GER and OSA, GER events follow
arousals and awakenings. However, GER does not appear to lead to apnea, arousal or
awakening. We postulate that arousals or awakening may restore reflexes such as transient
LES relaxations precipitating GER.
S1912
Is Dilated Intercellular Space Also Significant in Korean GERD Patients ?
Sang woo Lee, Hoon jai Chun, Bora Keum, Yong dae Kwon, Du rang Kim, Sanghoon
Park, Yeon seok Seo, Yong sik Kim, Yoon-tae Jeen, Hong sik Lee, Soon ho Um, Jai hyun
Choi, Chang duck Kim, Ho sang Ryu, Chang sub Uhm
Backgrounds/Aims: It is evident that dilated intercellular spaces (DIS) is a marker of epithelial
cell damage in GERD, and DIS is reversible after proton pump inhibitor (PPI) therapy at
transmission electron microscopy (TEM) in western studies. Recently, It has been reported
that there are some different characters between western and Asian GERD patients. And,
the study of DIS on Asian patients is rare. So we tried to verify DIS in Korean GERD patients
and to evaluate the reversibility of DIS after PPI therapy. Methods: 10 asymptomatic controls
and 16 symptomatic GERD patients (8 with nonerosive reflux disease (NERD) and 8 with
erosive esophagitis (EE)) were enrolled. During endocopy, four biopsies were taken from
macroscopically normal mucosa at 5 cm above squamocolumnar junction for TEM. 100
intercellular spaces were measured on TEM photographs in each patient. After 2 months
of PPI therapy, endoscopic biopsies were repeated for evaluating DIS reversibility. Results:
Mean DIS of GERD was increased significantly about two times greater than that of controls
(control vs. NERD vs. EE; 0.53±0.34, 1.11±0.64, and 1.26±0.55 μm, respectively, p<0.001).
Mean value of maximum DIS in GERD were also two times greater than controls (1.51±0.12,
2.95±0.41, and 2.91±0.54 μm, p<0.001). Conclusions: Intercellular spaces of esophageal
epithelium in Korean EE and NERD patients were significantly dilated and DIS was recovered
after PPI therapy as shown in the western studies. DIS can be considered as a reliable marker
of epithelial damage and a healing parameter of GERD in Korea.
S1913
The Rat Model with Chronic Acid Reflux Esophagitis Is Useful for
Investigation of Extra-Esophageal Manifestation of GERD
Yuko Izumi, Akihito Nagahara, Daisuke Asaoka, Yuji Shimada, Miho Yoshimura, Akihiko
Kurosawa, Taro Osada, Masato Kawabe, Takashi Yoshizawa, Mariko Hojo, Sumio
Watanabe
Aim Gastro Esophageal Reflux Disease: GERD is classified into two groups, one is esophagus
symptom-complex e.g. reflux esophagitis and another is extra-esophageal symptom-complex
e.g. chronic cough and bronchial asthma, however mechanisms of extra-esophageal symptom
is still obscure. We previously reported the pathophysiology of esophagitis in the rat chronic
acid reflux esophagitis model (Asaoka et al. J of Gastroenterology40:781,2005). In this study,
we investigated that whether our model would appropriate to investigate the extra-esophageal
manifestation of GERD. Methods Four control rats underwent sham operation and 9 rats
with chronic acid reflux esophagitis made by previously reported procedure were employed
in this study. Lungs and esophagus were obtained one week after the operation then lungs
and esophagus were stained by hematoxylin and eosin staining in both group. About lungs,
parameters below were measured and compared between two groups. The ratio of total
cross section area of blood vessel to total cross section area of the lung was measured as
an evaluation of degree of the vasodilatation and congestion. The degrees of inflammatory
cell (neutrophile) infiltration in three fixed points in each lung (upper, middle, and lower
lung field) were measured and convert them to the labeling index. About esophagus, survival
rate and incident rate of esophagitis at one week was investigated in esophagitis group.
Student T test was used to statistical analysis. Results Pulmonary bronchial vasodilation and
congestion was significantly higher in esophagitis group than controls (8.3 ± 3.3 vs 3.1 ±
1.4, p<0.05). The labeling index of inflammatory cell infiltration was found to be significantly
higher in esophagitis group than controls (14.7 ± 4.1 vs 7.7 ± 2.9, p<0.01). In esophagitis
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group, survival rate was 77.8%, incident rate of esophagitis was 100%. Conclusions This
model showed a pulmonary bronchial lesion as well as esophagitis, suggesting that this
model is useful as a model for investigation of extra-esophageal manifestation of GERD.
S1914
Enhanced NADPH Oxidase (Nox) Expression in Rat Esophageal Mucosa After
the Acid Exposure
Eisuke Iwasaki, Hidekazu Suzuki, Toshihiro Nishizawa, Tatsuhiro Masaoka, Tetsufumi
Takahashi, Yuriko Minegishi, Toshifumi Hibi
Background. Reactive oxygen species (ROS) may play a critical role in the inflammation of
esophageal mucosa such as gastroesophageal reflux disease. NADPH oxidase is a major
source of ROS in phagocytic cells. Although it has been considered that low levels of
ROS seen in nonphagocytic cells is by-product of aerobic metabolism, recently superoxide
generating homologues of phagocytic NADPH oxidase (Nox) have been found in several
cell types (Nature. 1999, 401: 2002, 79-82). However, the role of Nox family members in
acid-induced esophagitis has not been fully investigated. The aim of the present study is to
examine the expression of Nox homologues in the esophageal mucosa after acidic liquid
loading by using new experimental rat model. Materials and Methods. Specific-pathogen-
free 7-week-old male Sprague-Dawley rats were used. After 24 hours' fasting, operation was
performed under the general anesthesia. A 2-cm midline incision was made in the lower
neck to expose the esophagus. The esophagus was ligated with attention to avoid injuring
the vagal nerve and carotid artery. The rats were laparotomized and inserted catheter to
esophagus through the forestomach to inject reagents. Immediately esophago-gastric junction
was ligated. The rats were divided into four groups by contents of loading reagent, as follows;
Group A (n=6; control group with no reagent), Group B (n=6; 0.3 ml saline), Group C (n=
6; 0.3 ml 0.001N HCl), Group D (n=6; 0.3 ml 1N HCl). The rats were sacrificed 4 hours
after the operation. Esophageal mucosa was removed and expression of Nox1, Nox3, Nox4
and Nox5 mRNA was evaluated by quantitative RT-PCR. Results. The mRNA expression
of Nox3 and Nox5 were not amplified in esophageal mucosal tissue among the four groups.
In rats of group B, C and D, significant increase in the Nox1 and Nox4 mRNA were found
(Nox1/GAPDH mRNA; A 0.005, B 0.114, C 0.119, D 0.260, A vs D p <0.05, A vs B p<
0.05; Nox4/GAPDH mRNA; A 0.34, B 1.11, C 1.18, D 1.37, A vs D p <0.05, A vs B p<0.05).
Conclusion. Enhanced levels of Nox1 and Nox4 mRNA expression were found in esophagus
not only acidic liquid loading, but also with neutral liquid loading. To our knowledge we
are the first to report that NADPH oxidase expression in esophageal injury model with acidic
or non-acidic liquid loading.
S1915
Functional and Molecular Analysis of Distal Esophageal Mucosa. Correlations
with Acidic and Non Acidic Reflux
Stanislas Bruley des varannes, Tanguy Chaumette, Julien Geay, Jan Hatlebakk, Jean paul
Galmiche, Michel Neunlist
The esophageal squamous mucosa exerts an important barrier function which limits the back
diffusion of potentially harmful components of the refluxate material either in physiological or
pathological conditions (GERD). In humans, however, the mechanisms underlying this
function remain poorly known. Our aims were therefore a) to better characterize some key
parameters of both structural and functional integrity, and b) to correlate changes in these
parameters and characteristics of the reflux material (acid, weakly acidic or biliary). Patients
and methods. Sixteen patients (4 men, age ; 51.4 [18-71] yrs) with symptoms suggestive
of GERD had an upper GI endoscopy with 6 distal esophageal biopsies, a 24-h esophageal
impedance-pHmonitoring (Sleuth Recorder, Sandhill) and a 24-h esophageal bilirubin mon-
itoring (Bilitec 2000, Medtronic). Esophageal biopsies of 13 asymptomatic controls (8 men,
50.9 yrs [33-62]) with a normal upper GI endoscopy served as controls. Esophageal permeab-
ility to fluorescent markers of different weights [dextran (4.4 kD), inulin (2-5 kD) and
sulfonic acid (478 D, 0.1 mg/ml)] was assessed on biopsies using mini-Ussing chambers at
37°C (diameter 1.7 mm). mRNAs expression of junctional proteins (ZO-1 and occludin)
and of IL-8 were determined using real time PCR. Results. Esophageal acid exposure was
pathological in 9 (out of 14) patients, and bilirubin exposure was abnormal in 6 (out of
16) patients. Impedance reflux were mainly non acidic reflux in 8 (out of 14) patients.
Changes in esophageal permeability to sulfonic acid were correlated to impedance reflux
(r=0.739 ; n=7 ; p=0.0384) as well as to acidic reflux (r=0.919, p<0.001) but not to bilirubin
exposure (r=0.679; n=7; p=0.07). Acid sulfonic permeability was increased (> 75th percentile)
in 2 of the 5 patients with non erosive reflux disease and in the two patients with esophagitis.
However the esophageal mucosa was not permeable to dextran or inulin-FITC. ZO-1 and
IL-8 mRNAs were significantly increased in patients with excessive bilirubin exposure (p=
0.048 and 0.012 respectively), but not in patients with pure abnormal esophageal acid
exposure. Conclusions. Sulfonic acid is a sensitive marker for the detection of subtle changes
in esophageal permeability. Our study provides evidences of both structural and functional
abnormalities in GERD, even in patients without mucosal breaks at endoscopy. The abnormal-
ities detected depend on the physical characteristics of the reflux material.These observations
could set the basis for an increased sensitivity in patients with GERD.
S1916
Relationship Between Postprandial Acid and Bile Pocket At the Gastro-
Esophageal Junction and the Lower Oesophageal Sphincter
Dominiek De wulf, Raf Bisschops, Daniel Sifrim, Rita Vos, Jan Tack
The presence of a pocket of highly acidic unbuffered gastric juice was demonstrated at the
level of the gastro-oesophageal junction (GOJ) after ingestion of a meal (Fletcher 2001).
The upper limit of this acid pocket was located about 2 cm more proximal to the preprandial
level of the GOJ, suggesting extension within the sphincter. The aim of the current study
was to provide a detailed study of the relationship between the lower oesophageal sphincter
(LES) and the acid pocket. Methods: 16 healthy volunteers, mean age 27.8 years, underwent
an orally placed triple catheter (pH electrode, Bilitec® and manometry) stepwise pull-
through (1 cm/min, LES -10cm to LES +5 cm) before and 10, 30 and 50 minutes after a
liquid meal (Nutridrink® 200 ml). Values are shown as mean±SEM and compared by
student's t-test. Results: After ingestion of the meal, pH in the gastric body increased from
1.44±0.1 to 4.20±0.33 (p<0.05). Intragastric bilirubin absorbance rose from 0.06±0.02
preprandially to respectively 0.12±0.01, 0.14±0.01 and 0.17±0.01 at 10, 30 and 50 min
postprandially. Ten, 30 and 50 min postprandially, pH probe pull-through showed a pH
drop of on average 1.29±0.38, 2.35±0.34 and 2.31±0.35 units in an area located between
-2 cm and +2 cm of the distal margin of the LES (preprandial location) (nadir pH values
respectively 2.7±0.3, 2.1±0.2 and 2.7±0.3). The pull-through confirmed that the lower limit
of the LES was found at the same level before and after the meal (respectively 4.8±1.0;
4.4±0.8, 4.3±1.0 and 4.4±0.9 cm). Compared to preprandially, LES sphincter length was
also not significantly decreased at 10, 30 and 50 minutes postprandially (respectively 4.8±1.0;
4.4±0.8, 4.3±1.0 and 4.4±0.9 cm). The acid pocket extended respectively 1.3±0.6, 1.8±0.6
and 2.4±0.6 cm from the lower end of the LES at 10, 30 and 50 min postprandially, as
determined by simultaneous manometry Gastric bilirubin absorbance rose gradually during
the postprandial measurement phase, and this rise included the GOJ region. Bilirubin
absorbance levels above 0.14 were absent at the GOJ before the meal, but were found in
respectively 6, 7 and 11 subjects at 10, 30 and 50 min postprandially. In all but one subject,
these elevated bilirubine absorbance levels extended within the distal 2 cm of the LES.
Conclusion: We confirmed the presence of a postprandial acid pocket at the GOJ-level. This
acid pocket contains bile and extends within the distal 2 cm of the LES in healthy volunteers.
S1917
Netgerd Or Helicobacter pylori: Which Is Responsible for Carditis?; The Parsi
Database
Siavosh Nasseri-moghaddam, Hadi Razjouyan, Seyed mehdi Nouraie, Azadeh Mofid,
Mansoureh Mamarabadi, Maysam Alimohamadi, Hamed Ghotbi, Shahnaz Tofangchiha,
Reza Malekzadeh
Introduction: The etiology of chronic inflammation at the cardia (carditis) is controversial.
It has been linked to GERD, H Pylori, or neither of them. It has even been proposed that
independent localized carditis could serve as an objective marker for GERD. We assessed
contributing factors to carditis in a cohort of GERD patients. Methods: The “Prospective
Acid Reflux Study of Iran, (PARSI)” is established to follow 1000 GERD patients over 10
years. Case recruitment is ongoing. To be eligible, patients should have at least one of the
following symptoms for at least 4 weeks over the past 3 months: acid regurgitation, heartburn,
dysphagia, or non cardiac chest pain. All undergo upper GI endoscopy with protocol biopsies
from the antrum, body, cardia, the Z-line, and the lower esophagus. HP infection is confirmed
with rapid urease test and histology. Patients with and without histologic carditis were
compared for the presence of HP at different sites, erosive esophagitis, concomitant gastric/
duodenal erosions/ulcers, sex, age and smoking. Chi-square and student t-test were used
for statistical analysis. Multivariable analysis was also performed. Results: Five hundred
twenty two patients (56.6% female, mean age: 40.2 years) were studied. Carditis was detected
in 368 (70.5%). There was no sex difference between the two groups. Patients with carditis
were older (mean age 41.7 vs. 36.5 y, P< 0.001). Duodenal erosions/ulcers were more
common among patients with carditis (P: 0.02 and 0.08, respectively). Gastric erosions/
ulcers were not different between the 2 groups. Intestinal metaplasia at the cardia was found
in 15 (4.0%) patients with carditis vs. none of those without carditis (p<0.02). HP was
found at the cardia of 59.2% of patients with carditis and 1.9% of those without it (P
<0.001), while it was present (any site) in 69.6% of patients with carditis vs 12.4% of those
without carditis (p<0.001). On univariate analysis carditis was found to be protective against
erosive esophagitis (OR: 0.57; 95%CI: 0.37-0.88). On multivariate analysis HP (OR: 69.8;
95%CI: 21.7-224.1; P <0.001) and age (OR: 1.02; 95% CI: 1.01-1.04; P=0.003) were the
only independent risk factors for carditis, while erosive esophagitis had an inverse correlation
with it (OR: 0.52; 95%CI: 0.31-0.87; P=0.014). Conclusions: In a cohort of GERD patients,
H Pylori is independently associated with inflammation at the cardia while the presence of
carditis seems to be protective for erosive esophagitis.
S1918
The Pro-Inflammatory Cytokines IL-1b and IL-8 Are Increased in the Gastric
and Esophageal Mucosa of Patients with Both Non-Erosive (NERD) and
Erosive Gastroesophageal Reflux Disease (Erd)
Klaus E. Monkemuller, Doerthe Kuester, Thomas Wex, Ulrich Peitz, Sven Kolfenbach,
Mike Beyer, Peter Malfertheiner
Introduction: ERD is characterized by inflammatory changes of the esophagus. NERD patients
have similar clinical presentation as patients with ERD, but endoscopy is negative for erosions.
# Aims: To determine the gene expression of the proinflammatory cytokines IL-1b and IL-
8 in antral, cardia and esophageal mucosa in patients with NERD and ERD and asymptomatic
controls. Patients and Methods: Hundred-eight patients with GERD symptoms, no PPI-
treatment (n=98) or on PPI-treatment (n=20) were included. Of those, 35 and 38 (no PPI)
and 15 and 5 (on PPI) were diagnosed with ERD and NERD, respectively. Asymptomatic
controls (n=17). Exclusion criteria: autoimmune gastritis, corpus-predominant H. pylori
(Hp)-gastritis and Barrett's mucosa. Endoscopic characterization of esophagitis: Los Angeles
classification. Histological classification of esophagus mucosa: Ismeil-Beigi criteria; Gastritis:
Sydney criteria. In addition to gastric biopsies for histology and rapid urease test (RUT),
additional biopsies for molecular studies were taken from antrum, cardia and esophageal
squamous epithelium (2 cm above the GEJ) from each patient. Hp-infection: histology and
RUT. The gene expression levels of IL-1b and IL-8 were analyzed by quantitative RT-PCR.
Statistics: non-parametric Mann-Whitney U test. Results: ERD and NERD patients revealed
significant higher levels of IL-1b and IL-8 transcript levels in their antral, cardia and eso-
phageal mucosa than controls. When compared to controls, IL-1b expression was about
10-fold upregulated for all locations irrespective of the endoscopic appearance of GERD (p-
values: 0.001 to 0.0001). The IL-1b expression was similar in patients with ERD and NERD.
IL-8 induction was different with respect to endoscopic diagnosis and location. Patients
with NERD vs controls revealed an induction of IL-8 by factor 4, 8 and 4 for antrum, cardia
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and esophageal mucosa, respectively (p-values: 0.13 to 0.02). The upregulation of IL-8 was
also significantly higher in ERD vs controls reaching 8-, 12- and 9-fold for antrum, cardia
and esophagus (P values: 0.001 to 0.0006). The up-regulation of IL-1b and IL-8 in the
stomach and esophagus was similarly present irrespective of an existing PPI-treatment in
15 NERD and 5 ERD patients. Conclusions: Both, ERD and NERD, are associated with an
induction of the pro-inflammatory cytokines IL-1b and IL-8. IL-1b is similarly up-regulated
in both endoscopic forms, while IL-8 is stronger induced in ERD than NERD.
S1919
Is Abdominal Obesity a Risk Factor for Erosive Esophagitis?
Ja seol Koo, Sang woo Lee, Sung woo Jung, Dong il Kim, Hyung joon Yim, Yong sik
Kim, Hong sik Lee, Hoon jai Chun, Jai hyun Choi, Chang duck Kim, Ho sang Ryu
Background & Aims: An association between obesity according to body mass index (BMI)
and gastroesophageal reflux disease (GERD) has been reported, although study results have
been inconsistent. Recently, abdominal obesity has been concerned as an important risk
factor of various diseases. However, it is not known whether abdominal obesity is associated
with GERD. Therefore, we carried out a cross sectional study to determine the association
between abdominal obesity and erosive esophagitis. Methods: We consecutively enrolled
3801 subjects (mean age 45yr, 42% women) who underwent upper endoscopy for routine
health evaluation. After examination of upper endoscopy, the severity of erosive esophagitis
was graded from A to D according the LA classification. BMI, waist circumference (WC)
and waist-hip ratio (WHR) were measured to classify overweight, obesity and abdominal
obesity. According to BMI and WC, subjects were divided to 4 groups (overweight without
abdominal obesity (Group 1), overweight with abdominal obesity (Group 2), obesity without
abdominal obesity (Group 3), and obesity with abdominal obesity (Group 4)). Results:
Among total subjects, 376 (9.9%) had esophageal erosions (338, mild erosive esophagitis
(LA-A, B) and 38, severe erosive esophagitis (LA-C, D)). BMI was significantly higher in
those with esophageal erosions (EE) than those without EE (24.6±3.2 vs 23.7±3.0 kg/m2
p<0.01). WC was also significantly higher in those with EE than those without EE (84.1±9.5
vs 81.1±9.3 cm p<0.01), but WHR had no significant difference between those with EE
and those without EE (0.89±0.06 vs 0.87±0.16, p=0.059). When subjects were divided to
4 groups according to BMI and WC, the groups with abdominal obesity had more frequent
prevalence of EE than the groups without abdominal obesity (9.0% in Group 1, 10.4% in
Group 2, 12.8% in Group 3 and 13.4% in Group 4, p<0.01). Conclusion: The results in
this study suggest that abdominal obesity, measured by waist circumference is a risk factor
of erosive esophagitis. Further study will be necessary to prove the influence of abdominal
obesity in causing the erosive esophagitis.
S1920
Utility of Proximal Versus Distal pH Monitoring for the Diagnosis of GERD
Ajay Bansal, Sachin B. Wani, Amit Rastogi, Sandy Hall, April D. Higbee, Prateek Sharma
Background: Traditional 24 hr ambulatory pH monitoring is performed with the catheter
placed 5 cm above the upper border of LES. This method has been reported to have a
sensitivity of only 50-60% for diagnosis of GERD, especially in patients with either milder
grades of erosive esophagitis (EE) or non erosive reflux disease (NERD). It is unclear if
measuring acid exposure (with the availability of wireless capsule) closer to GEJ may increase
the accuracy of pH monitoring in the diagnosis of GERD. We performed dual (proximal
and distal) wireless pH monitoring in pts with reflux symptoms to define its clinical utility
in GERD patients. Methods: GERD pts and controls (no reflux symptoms) as defined by 2
validated questionnaires (GERQ and RDQ) were prospectively enrolled in the study. GERD
patients had a score of >2 using the reflux disease questionnaire (RDQ)(range 0-36) and
were off PPI therapy for at least 7 days prior to pH monitoring. In both patients and controls,
upper endoscopy was performed and under direct endoscopic vision, two pH capsules were
placed 1 cm (distal) and 6 cm (proximal) above the GEJ. All patients and controls were
encouraged to continue their usual activities and there were no dietary restrictions. ROC
curves were constructed using data from the proximal and distal capsules and sensitivity
and specificity were compared. Results: 26 GERD patients (90% Caucasians, 90% males)
and 17 controls (65% Caucasians, all males) were enrolled in the study. The mean ages for
GERD and controls were 55 and 59 years respectively. Of 26 GERD pts, 11 had NERD and
15 had EE (3 grades A, 7 grade B, 5 grade C). Data was evaluable in 25 patients. Median
acid exposure time (AET)(% time pH < 4) along with ranges are shown in the table. In EE
patients, the sensitivity and specificity using the AET at 6 cm level (proximal) for the
diagnosis of GERD were 92% and 71% and at 1 cm level (distal) were 62% and 38%
respectively. For the NERD group, the sensitivity and specificity of the proximal AET were
45% and 64% and at the distal level were 45% and 76% respectively. Conclusion: In both
the proximal (6 cm) and distal (1 cm) esophagus, there is an increment increase in AET
from controls to NERD to EE patients. However, pH monitoring in the distal esophagus, 1
cm above GEJ, does not help improve the diagnostic accuracy of GERD. Distal esophageal
pH monitoring cannot be recommended for the diagnosis of GERD at this time.
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S1921
The Role of Hiatus Hernia in Pediatric GERD
Wikrom Karnsakul, Stacey Gillespiel, Mary D. Cannon, Robert C. Byrd
Objectives: To study the relationship between the size of HH and age, gender, histologic
findings on esophageal biopsies, body mass index (BMI), and requirement of medical and
surgical treatment. Methods: Outpatient records of children diagnosed with GERD were
reviewed. GERD was diagnosed based on history, 24 h pH monitoring, upper endoscopy
(EGD), upper gastrointestinal study (UGI), and/or an exclusion of other conditions causing
their GI symptoms. Children who had secondary causes of GERD such food allergy, inflam-
matory bowel disease, post-Nissen fundoplication, GI obstruction were excluded from this
study. The diagnostic criteria of small sliding HH is presence of the lower esophageal ring
between 2 and 4 cm above the level of diaphragmatic hiatus and for large HH it is 4 cm
and greater above the level of diaphragmatic hiatus. Results: From May 2004 to November
2006, GERD was diagnosed in 258 children (98% Caucasians, mean age 8.2 years (1 mo
-19 y, 125 female, 143 male) at GI service of West Virginia University Hospitals. UGI was
done in 111 children without evidence of gastrointestinal obstruction. Sliding HH was
detected in 58 children (mean age 7.0 y, 21 female, 37 male). Fifty-eight percent had family
history of GERD and 15 % with HH. A small and large HH were observed in 40 (mean age
7.2 y, 14 female, 26 male) and 18 (mean age 7.2 y, 8 female, 10 male) and BMI in these
two groups was 21.9 and 22.4 respectively. EGD detected HH in only 3 of 39 children who
both had UGI and EGD performed. Erosive esophagitis was observed in 2 children with
large HH, one of which developed iron deficiency anemia. Mild esophagitis was present in
21 of 31(68%) and 8 of 8 (100%) children with small and large HH respectively. Prolonged
combined use of prokinetics and acid therapy was required in 13 children (32%) with small
HH and 6 children (33%) with large HH. When medical therapy failed, Nissen fundoplication
improved reflux symptoms in 3 children with large HH and one infant with small HH.
Conclusion: The frequency of HH detected by radiography is high (22%) in our series.
There were no differences in demographic characteristics, histologic findings on esophageal
biopsies, BMI, requirement of medical or surgical treatment between children with small
and large HH. The discrepancy in the endoscopic and radiographic indicates an underestim-
ated report of HH in pediatric endoscopy. A long-term study in children with HH and an
accurate, minimally invasive method to detect HH are required to clarify its significance,
the progression of HH size, correlation with reflux symptoms, and its significant complications
in their adulthood.
S1922
Nocturnal Gastroesophageal Reflux (Nger) Revisited with Impedance-pH
Monitoring
Fernando Fornari, Kathleen Blondeau, Jan Tack, Daniel Sifrim
Nocturnal acid GER has been characterized with pH-metry and poly-somnography. Arousal
periods may occur preceding reflux (before TLESRs) and/or after reflux during acid clearance.
Impedance-pHmetry not only can assess acidic and weakly acidic reflux but also allows
evaluation of esophageal flow events (swallow-related or secondary) preceding and following
reflux. We aimed to assess the prevalence and characteristics of nocturnal weakly acidic
reflux and to evaluate esophageal flow events preceding reflux and during the clearance
process. Methods: We analyzed supine-nocturnal periods (median 8h, 23m) of impedance-
pH studies from 15 healthy subjects and 76 unselected GERD patients (“off” PPI). Patients
had normal acid exposure (n=24), increased upright acid exposure (n=15) or increased bi-
positional acid exposure (n=37). Acid and weakly acidic reflux (nadir pH 7-4) were identified
and 2 min pre-reflux and 2 min post-reflux intervals were scanned for: a) aboral flow, b)
another reflux, c) nonspecific (no-flow), d) silent. Results: Healthy subjects had few nGER
[2 (0.5-5)] and 70% of them were weakly acidic. GERD patients with normal, upright and
bi-positional increased acid exposure had more nGER: 4.5(2-8.5), 7(5.5-12) and 10(7-
13) nGER with 76(50-100%), 77(59-100%) and 43(16.5-57%) of weakly acidic reflux
respectively. Acid reflux concentrated in the first half whereas weakly acidic reflux increased
in the second half of the nocturnal period. Most nGER (90%) was pure liquid with 49%
and 25% of acid and weakly acidic reflux reaching proximal esophagus respectively
(p<0.001). Bolus clearance time was similar in all groups. Acid clearance was significantly
prolonged in patients with bi-positional increased acid exposure. In the 2 min pre-reflux
interval most nGER [82% (66-100)] showed impedance aboral flow. In the 2 min post-
reflux interval, aboral flow was the most common pattern, but it was less frequent [66%
(50-86%)] than in the pre-reflux interval. This was true for acid and weakly acidic reflux
without differences between controls and GERD patients. Conclusions: Impedance-pH
monitoring has higher sensitivity than pHmetry in detection of nocturnal reflux. Weakly
acidic reflux is common during the second half of supine nocturnal periods. Most nocturnal
reflux is preceded by esophageal activity and transit, suggesting pre-reflux arousals. Compared
to controls, post-reflux aboral flow events are not decreased and volume clearance is not
prolonged in most patients with GERD. However, chemical clearance and acid exposure is
prolonged in patients with severe GERD, suggesting differences in the refluxate composition.
S1923
Determinants of Gastro-Esophageal (GER) Reflux Perception in Patients with
Persistent Symptoms Despite Proton Pump Inhibitors (PPIs)
Arnaud Duriez, Maylis Capdepont, Frank Zerbib
Introduction - Approximately 20% of GERD patients have persistent symptoms despite PPI
therapy. The aim of this study was to assess the determinants of reflux perception in patients
on PPI therapy. Patients and methods - Twenty patients with symptoms suggestive of GER
despite double dose PPIs (bid) were included in this study. Ambulatory 24-hour pH-
impedance studies (Sandhill, CO, USA) were performed in all patients: reflux events (RE)
were detected visually using impedance and then characterized by pHmetry as acid, or non
acid reflux, i.e. weakly acidic, or weakly alkaline (Gut 2004;53:1024-31). Symptoms were
considered as being related to reflux if they occurred within a 2-min time window after the
onset of the reflux episode. To analyze reflux parameters associated with perception, both
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univariate (χ2 test) and multivariate logistic regression analyses were performed. Symptoms
were considered globally and separately for heartburn, regurgitation and cough. Results. A
total of 986 RE were detected, 283 (28.7%) of which were symptomatic. There were 136
acid RE (41.9% symptomatic), and 850 non acid RE (26.6% symptomatic). Multivariate
analysis showed that independent factors associated with symptoms (overall) were: proximal
extent (15 cm above LES) (OR 3.85 (2.78 , 5.34) p<0.001), upright position (OR 2.52
(1.56 , 4.08), p<0.001), short bolus clearance time (OR 1.98 (1.45 , 2.72); p<0.001), low
cumulative (1 hour before RE) esophageal bolus exposure (OR 1.63 (1.18 , 2.26); p=
0.003), and occurrence of at least one AR during the hour preceding RE (OR 1.82 (1.29 ,
2.56),p<0.001). Factors associated with heartburn were nadir pH <5.3 (p<0.001), cumulative
(1 hour before RE) esophageal acid exposure (acid burden) (p<0.001) and liquid only reflux
(p<0.05). Factors associated with regurgitation were upright position (p<0.001), proximal
extent (p<0.001), presence of gas within the refluxate (mixed reflux) (p=0.011), and short
bolus clearance time (p<0.001). Factors associated with cough were upright position (OR
p<0.001), liquid only reflux (p<0.001), acid reflux (p=0.021), nadir pH < 5.3 (p<0.001),
short bolus clearance time (p<0.001) and preceding AR (p=0.002). Conclusions - In patients
with persistent symptoms on bid PPI, symptoms are more likely to be evoked by reflux
episodes in upright position and when proximal extent occurs. Surprisingly, short bolus
clearance and low esophageal bolus exposure are associated with symptom occurrence.
Proximal extent and presence of gas within the refluxate are more likely to be associated
with regurgitation while pH of the refluxate seems to play a role in occurrence of heartburn
and cough.
S1924
Refluxate Characteristics Leading to Symptoms in Acid Suppressed Patients
Marcelo F. Vela, Elizabeth G. Hill, Neeraj Sharma, Wojciech Blonski, Gonzalo Torres-
villalobos, Donald O. Castell
Background: Studies of refluxate characteristics leading to symptoms have been performed
mainly in untreated patients and through 24-hour pHmetry. Multichannel Intraluminal
Impedance and pH (MII-pH) enables detection of nonacid reflux and provides very detailed
characterization of each reflux episode including height, acidity, composition (liquid, mixed
liquid+gas), and refluxate clearance time. Aim: Determine characteristics of reflux episodes
associated with symptoms in acid suppressed patients. Methods: 30 GERD patients with
persistent symptoms (heartburn, regurgitation, chest pain, cough) despite maximal acid
suppression (PPI BID +/- H2-blocker HS) underwent 24-h MII-pH on medication. Reflux
episodes were considered symptomatic if symptom occurred within 2 minutes of episode.
A repeated measures multivariable regression analysis was performed using generalized
estimating equations (GEEs) to assess the odds of a symptomatic episode as a function of
age (years), gender, and each of the following reflux characteristics: acidity (acid/minor-
acid/nonacid), height above LES (cm), composition (liquid/liquid+gas), and volume clearance
time (sec). Among those episodes that were symptomatic, we conducted an additional
analysis using the same predictors and modeling strategy to identify those risk factors
associated specifically with heartburn. Results: 711 reflux episodes (135 symptomatic) were
recorded in 30 patients (33% male, mean age 56). Based on the multivariable GEE analysis
of all episodes, refluxate height was the only variable significantly associated with producing
symptoms (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 1.02 to 1.11; p = 0.0025).
Thus a 1 cm increase in refluxate height results in a 7% increase in the odds of the episode
being symptomatic, while a 5 cm increase in height results in a 38% increase in the odds
of producing symptoms (OR = 1.38, 95% CI = 1.12 to 1.70). Among symptomatic episodes
(56 episodes associated with heartburn and 79 with other symptoms), there is a 64% increase
in the odds of heartburn as opposed to any other symptom when the reflux composition
is mixed rather than liquid, although these results are not statistically significant (OR =
1.64, 95% CI = 0.87 to 3.10; p = 0.13). Conclusion: Refluxate height appears to be the
most important factor leading to symptoms in patients taking maximal acid suppression. A
mixed refluxate composition (liquid+gas) may be associated with heartburn. Therapies for
these patients should aim to limit proximal extension of refluxate and possibly diminish
gas content.
S1925
Mechanisms of Excessive Esophageal Acid Exposure in Patients with Reflux
Esophagitis
Katsuhiko Iwakiri, Yuriko Tanaka, Noriyuki Kawami, Hirohito Sano, Yoshinori Hayashi,
Makoto Kotoyori, Choitsu Sakamoto
Background: It is evident that reflux esophagitis (RE) is characterized by excessive esophageal
acid exposure. The number of acid reflux episodes, the way acid comes up after reflux and
the delay of acid bolus clearance cause excessive esophageal acid exposure, however, the
pathophysiology of excessive esophageal acid exposure, including the way acid comes up
after reflux, is not yet clear. Methods: 14 patients with severe RE of LA-grade C, 15 patients
with mild RE of LA-grade A or B and 15 healthy subjects (HS) underwent esophageal
manometry with a 21-lumen perfused assembly which monitored pressure in the pharynx,
the upper esophageal sphincter, the esophageal body, the LES and the proximal stomach.
Esophageal pH was monitored at 2 and 7cm above the LES and recordings were taken for
3 hrs in a sitting position after a meal. Results: In HS and patients with mild RE, more than
95 % of acid reflux episodes were transient LES relaxations (TLESRs). In patients with severe
RE, 62% of acid reflux episodes were TLESRs, 18% were strain reflux and 14% were free
reflux. There was no difference in the rate of TLESRs or the rate of acid reflux during TLESRs
at 2 cm above the LES between the 3 groups, however the incidence of acid reflux at 7 cm
above the LES during TLESRs in patients with severe RE (50.9% (27.2-71.4), median
(interquartile range)) was significantly higher than that of patients with mild RE (35.7 (17.1-
47.3)) (p=.0217) and HS (15.4 (5.3-21.0)) (p<.0001). In addition, the rate of acid reflux
during TLESRs in patients with mild RE was significantly (p=.0072) higher than that of HS.
The amplitude and the success rate of primary peristalsis in patients with severe RE (25.5
mmHg (14.0-40.0), 30.0 % (5.0-55.0)) were significantly lower than those of HS (47.0
(33.0-64.0) p<.0001, 80.0 (60.0-85.0) p<.0001) and patients with mild RE (44.0 (30.0-
63.0) p<.0001, 70 (50.0-80.0) p=.001) but there was no difference in the amplitude and
the success rate of primary peristalsis between HS and patients with mild RE. Conclusions:
The pattern of acid reflux is very different in the 3 groups. In patients with severe RE,
refluxed acid at 2cm above the LES rises more easily to the proximal esophagus, but it does
not clear easily from the esophagus, compared with HS and patients with mild RE. In
patients with mild RE, and in HS, refluxed acid clears quickly but in patients with mild
RE, refluxed acid at 2cm above the LES comes up easily to the proximal esophagus, compared
with HS. This is the reason that patients with mild and severe RE have excessive esophageal
acid exposure.
S1926
The Comparison of Risk Factors for the Erosive Esophagitis and Nerd in
Korea: A Nationwide Multi-Center Prospective Study
Nayoung Kim, Sang woo Lee, Sung il Cho, Chan-guk Park, Chang-hun Yang, Hyun soo
Kim, Jong sun Rew, Jeong seop Moon, Sung kook Kim, Joon yong Park, Geun am Song,
Hwoon yong Jung, Yong chan Lee, Jae gyu Kim, Jae j. Kim, Soo-heon Park, Hyun chae
Jung, In-sik Chung
Background & Aims: The prevalence of gastroesophageal reflux disease (GERD) is increasing
in Korea. This study was performed to compare the prevalence rates, symptom spectrum
and risk factors between erosive esophagitis(ERD) and non-erosive reflux disease (NERD)
in Koreans in 2006. Methods: Upper gastrointestinal endoscopic examinations as a health
check-up were performed for 25,536 patients in individuals visiting 40 nationwide general
hospitals for routine health check-up. The gastroesophageal reflux questionnaire was designed
to evaluate multiple factors which can affect GERD. Endoscopic findings of erosive esophagitis
were classified according to LA classification. NERD was defined when heartburn and or
acid regurgitation symptom occur at least once per week among the subjects without erosive
esophagitis and Barrett's esophagus. Multivariate analysis was performed for the risk factors
of ERD and NERD. Results: A total of 23,517 subjects (92.09%) were classified as normal,
1498 (5.87%) as minimal change and 2,019 patients (7.91%) as erosive esophagitis including
5.87% in LA-A, 1.84% in LA-B, 0.18% in LA-C, and 0.02% in LA-D. Among 2,019 ERD
patients 48 (0.19%) were found to be Barrett's esophagus by biopsy. The NERD subjects
were 1,012 (3.96%). The 61.4% of ERD felt the reflux symptoms in the previous 1 year
but 100% in NERD. Not only heartburn or acid regurgitation but also extraesophageal
symptoms were more frequently found in the NERD than in the ERD. The risk factors for
ERD were male (OR 2.92, 95% CI 2.20-3.87), Kyungsang providence (OR 1.56, 95% CI
1.03-2.37), eradication history of H. pylori (OR 2.20, 95% CI 1.67-2.91), alcohol (OR 1.51,
95% CI 1.23-1.85), body mass index (BMI)≥25 (OR 1.09, 95% CI 1.05-1.12), and hiatal
hernia (OR 5.43, 95% CI 3.76-7.84). The protective factor for ERD was H. pylori infection
(OR 0.46, 95% CI 0.37-0.56). In contrast, the risk factors for NERD were male (OR 1.38,
95% CI 1.18-1.60), antibiotics (OR 2.08, 95% CI 1.29-3.35), diabetes mellitus (OR 1.34,
95% CI 1.04-1.73), and eradication history of H. pylori (OR 1.28, 95% CI 1.03-1.61). The
protective factors were age group of 40-59 yrs than below 40 (OR 0.84, 95% CI 0.72-0.98),
BMI below 25 (OR 0.95, 95% CI 0.93-0.98), and monthly income more than $1000 (OR
0.56, 95% CI 0.43-0.74). Conclusions: The prevalence of erosive esophagitis without Barrett's
esophagus was 7.71% and that of NERD was 3.96%, resulting in the prevalence of GERD
in 2006 in Korea was 11.67%. The risk factors for ERD and NERD were different, suggesting
the underlying pathogenesis could be different between these two disease entities.
S1927
Different Degrees of Ineffective Esophageal Motility in Patients with GERD:
Impact On Esophageal Acid Exposure and Pharmacological Reversibility
Fernando Fornari, Kathleen Blondeau, Luis Durand, Enrique Rey, Manuel Diaz rubio, Jan
Tack, Daniel Sifrim
Several studies have shown high prevalence of ineffective esophageal motility (IEM) in GERD
and suggested an important role of IEM in delayed esophageal acid clearance. Recent studies
using impedance-manometry proposed that only severe IEM is associated with abnormal
esophageal volume clearance. Aims: 1) to assess the impact of severity of IEM on esophageal
acid clearance and acid exposure; 2) to test the reversibility of severe IEM. Methods: 216
GERD patients underwent ambulatory esophageal pH-metry and stationary manometry.
Esophageal motility was characterized in 186 patients with increased esophageal acid expo-
sure: 99 patients without IEM; 55 with mild IEM (30-80% ineffective contractions) and 32
patients with severe IEM (>80% ineffective contractions). We assessed the relationship
between severity of IEM, acid clearance time and esophageal acid exposure. In 30 patients
with esophagitis, we evaluated the reversibility of severe IEM with edrophonium 80 µg/kg
(IV). Results: Acid clearance time was similar in patients with mild IEM (83.4 ± 6.5 sec)
and those without IEM (75.8 ± 3.7 sec) but was significantly longer in patients with severe
IEM (112.7 ± 16.8 sec; p < 0.05). Esophageal acid exposure was similar in patients with
mild IEM (13.3 ± 0.9%) and those without IEM (12.8 ± 0.6%) but was significantly higher
in patients with severe IEM (16.8 ± 2.4%, p < 0.05). Severe IEM could be reverted with
edrophonium in 55% of patients. Conclusions: Mild IEM (30-80% of ineffective contrac-
tions) is not associated with prolonged acid exposure. Only severe IEM is associated with
prolonged acid clearance time and increased acid exposure, particularly in supine periods.
Strong cholinergic stimulation can reverse severe IEM and might be useful to predict the
patient's response to prokinetic medication.
S1928
The Changes of Esophageal Epithelium Intercellular Spaces Before and After
OMEPRAZOLE Treatment in GERD Patients
Yan Xue, Liya Zhou, Sanren Lin
Objectives: to observe the changes of esophageal epithelium ultrastructure of patients with
erosive esophagitis before and after Omeprazole treatment. Methods: 20 patients with erosive
esophagitis diagnosed by gastroscopy were enrolled. All of them were treated with Omepra-
zole (Losec, 20mg bid) for 4 weeks. Then they underwent gastroscopy again. Biopsy specimen
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was taken from 2cm above Z-line for electronic microscopy. All the patients completed the
questionnaire about reflux symptoms before and after treatment and scored. The cutoff
value of dilated intercellular spaces was defined more than 0.79μm. This study was approved
by the Ethics Committee of the Peking University Health Science Center. Results:1. 20
patients (9 females and 11 males) were enrolled. The mean age was 50.80±12.58 years.
According to the LA classification, A, B and C grade of EE were 3, 16, and 1 cases respectively.
After 4 weeks' treatment, the esophageal erosions were completely healed in all the patients.
2. The mean symptom scores before and after treatment were 6.95±3.20 and 1.40±2.98
respectively. The reflux symptoms were completely relieved in 14 patients, and mostly
relieved in 4 cases, but there were 2 cases whose symptoms relief was less than 50%. 3.Before
treatment the mean, maximum and minimum intercellular spaces of esophageal epithelium
were 1.14±0.15μm, 1.47±0.15μm and 0.85±0.17μm respectively; after treatment the mean,
maximum and minimum intercellular spaces of esophageal epithelium were 0.51±0.18μm,
0.72±0.25μm, 0.36±0.15μm respectively, with significant differences comparing with before
treatment (P<0.001). Conclusion: The dilated intercellular spaces of esophageal epithelium
in erosive esophagitis patients could be recovered after a short time treatment with PPI.
DIS before and after PPI treatment
S1929
Predictive Value of Pre-Operative Oesophageal Impedance the Assessment of
Dysphagia After Fundoplication
Nam Q. Nguyen, Katrina Ching, Marcus Tippett, Jenny Myers, Glyn Jamieson, Richard
H. Holloway
Dysphagia after fundoplication is common and relates to impaired esophageal clearance.
Pre-operative manometry does not reliably predict post-fundoplication dysphagia. Direct
assessment of clearance by fluoroscopy is useful but clinically limited by exposure to radiation.
Intra-luminal impedance (MII) allows detailed assessment of oesophageal clearance without
radiation. Aim. To assess the value of pre-operative oesophageal manometry-impedance
monitoring in predicting the occurrence of post-fundoplication dysphagia. Methods. 16
patients with reflux disease (8M:8F; 54±4yrs) underwent (i) symptom score assessment and
(ii) oesophageal function testing by combined manometry-MII technique, before and after
laparoscopic fundoplication. Oesophageal body motility and impedance were measured
concurrently at 4 sites 5-cm apart starting 2cm above the lower oesophageal sphincter (LES).
LES pressure was recorded with a sleeve sensor. Impaired clearance was defined by either
prolonged bolus presence time (BPT) and/or total bolus transit time (TBTT). An individual
was judged to have abnormal oesophageal clearance function if there were > 2/10 liquid or
> 3/10 viscous responses with impaired clearance. Results. Fundoplication increased nadir
LOS pressure, distal oesophageal wave amplitude, propagation time, distal oesophageal
BPT, and TBTT. The number of impaired clearance responses increased significantly post-
operatively (liquid: 81/160 vs. 43/160, P<0.01; viscous: 67/160 vs. 25/160, P<0.01). Pre-
operatively, clearance was impaired in 5 (31%)patients and persisted in all post-operatively,
4 of whom had dysphagia. Of 11 (69%) patients with normal clearance pre-operatively, 6
patients developed impaired clearance post-operatively, 5 of whom had dysphagia; whilst
dysphagia occurred in only 1 of 5 patients in whom clearance remained normal post-
operatively. Thus, of the 10 patients with post-operative dysphagia, only 4 had impaired
clearance pre-operatively. The sensitivity and specificity of pre-operative impedance for post-
operative dysphagia were 40% and 83% respectively, identical to those of manometry
alone. Combined pre-operative manometry-MII technique had a 50% sensitivity and a 83%
specificity for post-operative dysphagia. Conclusions. Whilst most patients with impaired
clearance pre-operatively have post-operative dysphagia, impedance monitoring is an insens-
itive predictor of post-operative dysphagia as 60% of these patients have normal pre-operative
clearance. The addition of impedance monitoring to manometry does not improve the pre-
operative prediction rate for post-operative dysphagia.
S1930
Can Pathologists Agree in the Assessment of Microscopic Esophagitis?
Roberto Fiocca, Paula Fernström, Stefan Franzen, Robert H. Riddell, Magnus Ruth, Hans
Rydholm, Prateek Sharma, Kaiyo Takubo, Michael Vieth, Lisa M. Yerian
Background and aims. A recently published systematic review suggests that at least two
thirds of patients with non-erosive gastroesophageal reflux disease (GERD) have microscopic
esophageal lesions. We aimed to develop and validate clear, consensus-driven criteria for
the recognition and grading of microscopic esophagitis in patients with GERD. Methods.
Criteria were developed for assessing the thickness of the basal cell layer, length of the
papillae, severity of intercellular space dilations and presence of intraepithelial eosinophils,
neutrophils and mononuclear cells. The draft criteria were tested in an independent evaluation
by five pathologists from Europe, North America and Asia, using 167 histological slides (4
biopsies, one in each quadrant, from 2 cm above the gastroesophageal junction) from 15
patients with reflux esophagitis, 17 patients with non-erosive reflux disease and 10 healthy
controls. The draft criteria were refined and reassessed using 250 photographic images
selected by an independent pathologist, and encompassing previously assessed markers with
different degrees of change. The area to be assessed was indicated on each image. Results.
Applying the draft criteria on histological biopsy slides, we obtained mean pairwise kappa
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estimates (± standard deviations [SD]) of 0.34 (±0.25) for basal cell thickness, 0.59 (±0.24)
for length of papillae, 0.31 (±0.15) for intercellular space dilation, 0.74 (±0.14) for eosino-
phils, 0.56 (±0.36) for neutrophils and 0.38 (±0.15) for mononuclear cells. The estimated
intraclass correlation coefficients were 0.38 for basal cell thickness and 0.56 for length of
papillae. Assessing the absence or presence of necrosis/erosion and healed erosion was judged
as important, leading to the addition of these variables to the criteria. When using the
refined criteria in the annotated photographic images, the mean pairwise kappa estimates
(± SD) were 0.49 (±0.16) for basal cell thickness, 0.81 (±0.05) for length of papillae,
0.61 (±0.08) for intercellular space dilation, 0.87 (±0.05) for eosinophils, 0.84 (±0.09) for
neutrophils, 0.60 (±0.09) for mononuclear cells, 0.90 (±0.04) for necrosis/erosion and 0.73
(±0.14) for healed erosion. The pairwise agreements for these markers were 74%, 89%,
74%, 93%, 97%, 81%, 97% and 94%, respectively. The estimated intraclass correlation
coefficients were 0.69 for basal cell thickness and 0.95 for length of papillae. Conclusions.
The draft consensus criteria achieved promising levels of agreement when assessed independ-
ently by five pathologists. Further evaluation is needed using histological images without
indicating the area that is to be assessed.
S1931
Applying Computational Fluid Dynamics to the Oesophago-Gastric Junction
Barry Mcmahon, Karl Odie, Kenneth W. Moloney, Hans Gregersen
Whilst methods exist to indirectly measure the effects of increased flow for refluxing, they
cannot quantitatively measure the amount of acid travelling back up into the oesophagus
during reflux, nor can they indicate the flow rate through the oesophago-gastric junction
(OGJ). As OGJ dysfunction is a flow effect it seems most appropriate to describe the effect
as a measure of this flow. A device known as the functional lumen imaging probe (FLIP)
has been shown to reliably measure geometry and pressure changes in the OGJ. FLIP cannot
directly measure flow, but the data gathered from the probe can be used to model flow
through the junction precisely using a technique know as computational fluid dynamics
(CFD). CFD uses a set of equations to predict flow patterns and is widely used in engineering
to predict the flow over vehicles. These equations require appropriate assumptions to provide
simplifications before useful data can be obtained. Assuming that the cross-sectional areas
obtained via FLIP are circular then the radii of these circles can be obtained. A cubic
interpolation scheme can then be applied to give a high-resolution geometry for the OGJ
walls. Assuming that the operating fluid within the OGJ is water, that the walls have a
roughness length of 120nm, and that the pressures proximal and distal to the OGJ can be
obtained via manometric readings, CFD simulations can be conducted. For this case which
modelled a reflux scenario, it can be seen that at the narrowest section, a jet of fluid squirts
into the oesophagus at a higher velocity than the fluid surrounding it. This jet has a maximum
velocity of almost 2ms-1, which occurs where the OGJ is at its narrowest diameter (1.46mm),
and extends 4cm into the oesophagus. The trajectory of the jet is deflected from vertical
due to the bend in the cardia below. This simple prediction of acid ‘squirting' into the
oesophagus illustrates how the use of numerical methods can be used to improve understand-
ing of the OGJ in ways that current methods cannot. This initial work using CFD, never
before used in the OGJ, shows some considerable promise for the future.
S1932
The Clinical Course of Patients with Non-Cardiac Chest Pain (NCCP) After
Empirical Proton Pump Inhibitor (PPI) Test: A Prospective Cohort Study
Justin Wu, Yawen Chan, Vincent Wong, Grace Wong, Larry Lai, Dorothy Chow, Francis k
L. Chan, Joseph Sung
Background: PPI test has been recommended for initial management of NCCP. However,
the impact of PPI test on long-term management of NCCP is unclear. Aim: To study the
clinical course of NCCP patients undergoing empirical PPI test in a prospective cohort study.
Methods: Consecutive patients with monthly attacks of angina-like chest pain but negative
cardiac investigations were prospectively recruited for upper GI symptom assessment, fol-
lowed by empirical open-label Esomeprazole (Eso) 20 mg daily. Initial response of symptom
was evaluated at 13 weeks post-treatment using patient-reported global symptom assessment
and subsequent follow-up visits were arranged at 13 weeks interval. Patients with inadequate
or no initial response of chest pain underwent EGD, esophageal manometry and 24-hour
esophageal pH monitoring after withdrawal of PPI for 4 weeks. The rate of adequate relief
of chest pain, need of GI investigations and use of antidepressant were evaluated at 52
weeks. Results: 142 NCCP patients (Mean age: 54±12; male: 63) were studied. 32 patients
(22%) had concomitant weekly reflux symptoms (GERD+) and the remaining 110 patients
had no reflux (GERD-). 34 (24%) patients had initial adequate relief of chest pain by Eso
at 13 weeks. In GERD+ group, all 32 patients had complete resolution of reflux symptom
but only 20 (63%) of them had initial adequate relief of chest pain by Eso. In GERD- group,
only 14 (13%) had initial adequate relief of chest pain. Among the 34 initial responders,
only 19 (56%, 9 GERD+ and 10 GERD-) still had adequate relief of chest pain on maintenance
Eso. During the 52-week period, antidepressant therapy was used in 42 (30%) patients and
16 (12%) had adequate relief of chest pain. 90 (63%) patients underwent EGD, which
detected erosive esophagitis in 5 (4%) patients. 56 (39%) patients underwent manometry,
which detected nutcracker esophagus in 4 (3%), hypertensive LES in 3 (2%), hypotensive
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LES in 12 (9%) and ineffective esophageal motility in 24 (17%) patients. 64 (45%) patients
underwent pH monitoring, which detected abnormal acid exposure (acid exposure time
>4%) in 10 (7%) and positive symptom-reflux association in 4 (3%), respectively. Conclusion:
Empirical PPI is neither effective nor durable for treatment of chest pain in a significant
proportion of NCCP patients despite relief of concomitant reflux. Use of antidepressant and
GI investigations are still common practice for long-term management of NCCP but their
benefits are limited.
S1933
Characterization of “pH Only” Acid Gastroesophageal Reflux Episodes in
Infants
Frederick W. Woodley, Parul Gulatti, Soledad Fernandez, Hayat M. Mousa
Background: Combined esophageal pH monitoring (EPM) and multichannel intraluminal
impedance (MII) analysis (EPM/MII) in infants demonstrates that total esophageal acid
exposure (TEAE) is primarily the consequence of two types of acid gastroesophageal reflux
(AGER) events: 1) classic events that are detectable by combined EPM/MII, and 2) enigmatic
events that are detectable only by EPM (“pH only events” [POEs]). Aims: 1) To characterize
POEs on the basis of frequency, duration, and nadir pH, and 2) to examine the extent to
which POEs contribute to TEAE by comparing both AGER event types on the basis of these
3 variables. Methods: EPM/MII tracings, from 12 symptomatic infants (< 12 mos, median
3.5 mos), were retrospectively examined. Mean frequency (events/hr), duration, and pH
values were calculated for both AGER event types during each phase of the feeding cycle
(feeding, 1st hour post-prandial [1stPP], 2nd hour PP [2ndPP], and fasting). Mean values
were compared using a mixed model with repeated measures with significance established
at alpha = .05. Subjects were enrolled following written parental consent. The study protocol
was approved by the Columbus Childrens Hospital Institutional Review Board. Results: In
the 281 hr of combined recording time, 205 EPM/MII events (median 23/pt, range 4-56/
pt) and 640 POEs (median 38/pt, range 4-207/pt) were recorded. The frequency of EPM/
MII and POE events, across all subjects and phases of the feeding cycle, was 0.66±0.32/hr
and 2.2±0.32/hr, respectively (p=.001). The frequency of POEs was remarkably (but not
significantly) higher during 2ndPP (3.42±0.64 vs 0.72±0.64, p=.0724) and fasting (3.24±0.64
vs 0.99±0.64, p=.2238). Mean durations of EPM/MII events were significantly longer than
POEs during 1stPP (113.3±18.1s vs 38.3±12.8s, p=.0164), 2ndPP (147.1±18.9s vs 48.8±9.5s,
p=.0001), and fasting (191±15s vs 42.2±10.4s, p<.0001). Mean nadir pH values were similar
between AGER event types during feeding and 1stPP, but significantly lower for EPM/MII
events during 2ndPP (1.9±0.15 vs 2.6±0.07, p=.0005) and fasting (1.5±0.12 vs 2.9±0.07,
p<.0001). Compared to EPM/MII events, POEs comprise almost one half (49.7%) of the
TEAE and the majority of EAE during 2ndPP (62%). Linear regression showed that POEs
are 2.6-times more likely to occur during 2ndPP compared to feeding (p=.04). Conclusions:
POEs comprise a significant fraction of TEAE in infants. Differences in nadir pH values
between EPM/MII events and POEs during 2ndPP and fasting periods suggest likely differ-
ences in chemical clearance efficiency of these two AGER event types, particularly during
later phases of the feeding cycle.
S1934
Induced Transient Lower Esophageal Sphincter Relaxation (TLESR) in Normal
Control Subjects and Patients with Hiatal Hernia
Amit Kalra, Anil K. Vegesna, Ramashesai Besetty, Muhammad Y. Haroon, Chuang Keng_
yu, Umar Farooq, Robert S. Fisher, Henry P. Parkman, Barry Levitt, Annapurna Korrimili,
Larry S. Miller
Background: Transient lower esophageal sphincter relaxations (TLESRs) are difficult to study
because they are infrequent isolated events. Purpose: To develop a new method to induce
TLESR. To determine the intragastric pressure and volume threshold for inducing TLESR
in normal control subjects and patients with hiatal hernia in order to study the physiology
of TLESR. Methods: 13 normal volunteers and 5 patients with hiatal hernia underwent
endoscopy. During the endoscopy a water perfused pressure transducer was placed through
the biopsy channel of the endoscope. Air was removed from the stomach in a retroflexed
position and a gastric baseline pressure was measured. Air was then insufflated into the
stomach through the endoscope until the gastroesophageal junction (GEJ)opened or until
the subject complained of discomfort. The volume of air and the pressure above the baseline
were measured at the time of GEJ opening on endoscopic view. Results: There were two
patterns of GEJ opening. In pattern I (10 normal subjects) the hiatus slowly stretches and
deforms, however the hiatus (gastric sling fiber/ clasp fiber complex) and distal esophagus
(the intrinsic LES) opened simultaneously, allowing expulsion of air from the stomach into
the esophagus. The mean pressure and volume at the point of distal esophageal opening in
pattern I was 11.5 ± 8.6mmHg and 1284.15 ± 570.23mL. In pattern II (5 normal subjects,
2 of the normal subjects had overlap between patterns I and II) the hiatus of the GEJ opened
rapidly (gastric sling fiber/ clasp fiber complex) after insufflation of air into the stomach.
Then, at some time point later and at a higher pressure and volume, the distal esophagus
opened (the intrinsic LES) allowing expulsion of air into the esophagus. The mean pressure
and volume for hiatus opening and distal esophageal opening in pattern II in the normal
subjects was 12.6 ± 6.1mmHg and 1228.59 ± 763.97mL for the hiatus and 19.7 ± 1.9mmHg
and 1728.83 ± 660.34mL for the LES. In the patients with hiatal hernia the gastroesophageal
junction opened at a mean pressure and volume of 3.12mmHg and 221mL above the
baseline, significantly lower than in the normal control subjects (p<0.0001). In all cases
there was endoscopic evidence of esophageal body contractions after the distal body opened
in the absence of swallows. Conclusions: A new technique was developed and normative
data for intragastric pressure and volume was collected for inducing TLESR. Two endoscopic
patterns of TLESR were described in normal subjects. The gastroesophageal junction opens
at a significantly lower pressure and volume in patients with hiatal hernias compared to
normal control subjects.
S1936
Regardless of Helicobacter pylori Status, Erosive GERD Does Not Occur in
Patients with Serum Pepsinogen I ≦ 30 Ng/Ml and I/II Ratio ≦ 2.0
Tomohiko Shimatani, Ayumi Furukawa, Jing Xu, Susumu Tazuma, Masaki Inoue
Background: Studies have indicated that serum pepsinogen (PG) concentrations correlate
with the extension of gastric mucosal atrophy. However, except as a screening test for high-
risk subjects for gastric cancer, this marker is not widely used. Gastric acid secretion is an
essential element in the pathogenesis of erosive gastroesophageal reflux disease (GERD);
therefore, the PG test method appears a useful tool for screening erosive GERD. Aims: With
consideration given to Helicobacter pylori (H. pylori) status, to investigate correlations between
serum PG concentrations and intragastric pH. Also, to compare PG concentrations between
normal subjects and erosive GERD patients. Methods: Study-1: H. pylori status, serum PG
I and II concentrations, and intragastric pH were investigated in 229 subjects without any
tumorous and/or ulcerous lesions in the stomach and duodenum. Intragastric pH monitoring
was performed for 24-h and intragastric % time pH > 3.0 was calculated as a parameter
representing the degree of gastric acid secretion. Study-2: H. pylori status and serum PG I
and II concentrations were investigated in 732 normal subjects and 260 erosive GERD
patients. Results: Study-1: In the 126 H. pylori-positive subjects, PG I and I/II ratio were
significantly correlated with % time pH > 3.0 for 24-h (r = -0.21 and -0.53, P = 0.017 and
< 0.0001, respectively). On the other hand, in the 103 H. pylori-negative subjects, PG
concentrations were not correlated with % time pH > 3.0 in any time period and regardless
of PG concentrations, % time pH > 3.0 for 24-h was lower than 40% in 99 subjects (96.1%).
Study-2: Of the 512 H. pylori-positive normal subjects, 193 (37.7%) were compatible with
PG I ≦ 70 ng/ml and I/II ratio ≦ 3.0, 129 (25.2%) were compatible with PG I ≦ 50 ng/
ml and I/II ratio ≦ 3.0, and 44 (8.6%) were compatible with PG I ≦ 30 ng/ml and I/II
ratio ≦ 2.0. However, of the 131 H. pylori-positive erosive GERD patients, 29 (22.1%), 18
(13.7%), and none (0.0%) were compatible with each of the three criteria. Significant
differences were observed between the two groups in respect to prevalence (P = 0.00083,
0.0053, and 0.00050, respectively). On the other hand, of the 220 normal subjects and
129 erosive GERD patients without H. pylori infection, 13 (5.9%) and 5 (3.9%), 11 (5.0%)
and 5 (3.9%), and only 3 (1.4%) and none (0.0%) were compatible with each of the three
respective criteria. Conclusions: Serum PG I and I/II ratio well predict intragastric % time
pH > 3.0 for 24-h. Erosive GERD does not occur in patients with serum PG I ≦ 30 ng/ml
and I/II ratio ≦ 2.0, regardless of H. pylori status.
S1937
Symptom Correlation in GERD Patients Using the Wireless pH Capsule
(BRAVO) in the Distal Esophagus
Ajay Bansal, Sandy Hall, Sachin B. Wani, Amit Rastogi, April D. Higbee, Prateek Sharma
Background: The traditional method of pH monitoring focuses on acid exposure 5 cm above
the upper border of LES. In contrast, the Bravo pH system affixes a pH sensing capsule
onto the esophageal mucosa thereby allowing accurate pH monitoring closer to the gastroeso-
phageal junction (GEJ). It is unclear whether this distal pH monitoring has added value in
symptom correlation in GERD patients. Aim: To correlate acid exposure as measured by
the wireless pH monitoring capsule 6 cm and 1 cm above the GEJ with GERD symptoms.
Methods: Subjects with reflux symptoms and controls (no reflux symptoms) as documented
by 2 validated GERD questionnaires [gastroesophageal reflux questionnaire (GERQ) and
reflux disease questionnaire (RDQ)] were prospectively enrolled. Acid suppressive therapy
was withheld for 1 week prior to an upper endoscopy and then, under direct endoscopic
vision, two wireless pH capsules were placed; 1 cm (distal) and 6 cm (proximal) above the
GEJ. At least 16 hours of recorded pH data was required for the patient to be included in
the analysis. Abnormal acid exposure time values were obtained using ROC curves. Symptom
associated probability (SAP) was computed from pH tracings and a SAP value >95% for
either heartburn or regurgitation was considered to be positive. The RDQ scores were
compared with the degree of acid exposure at the proximal (6 cm) and the distal (1 cm)
levels. Results: 26 GERD patients (mean age 55 yrs, 90% Caucasians, 90% males) and 17
controls (mean age 59 yrs, 65% Caucasians, all males) were enrolled in the study. Eleven
patients were diagnosed with NERD and 15 with EE. Twenty-five tracings had analyzable
data. Using data from the proximal capsule, SAP was positive in 43% of EE and 36% of
NERD patients. For the distal capsule, SAP was positive in 36% of EE and 37% of NERD
patients. Four patients (3 EE and 1 NERD) had a normal SAP at the proximal level but an
abnormal SAP with the distal capsule whereas the reverse was true in 1 patient (i.e. normal
SAP distally, abnormal proximally). The mean RDQ scores were significantly different
between patients with normal and abnormal acid exposure at the proximal capsule (9.8 vs.
17.6 respectively, p<0.04, Wilcoxon summed rank test) but not at the distal capsule (14
vs. 16.7 respectively, p=NS). Conclusion: Increased acid exposure in the proximal esophagus
(6 cm) but not in the distal esophagus (1 cm) correlated with reflux symptoms (RDQ scores).
Distal esophageal pH monitoring improved the SAP to >95% in 1 additional NERD patient.
Addition of distal pH monitoring does not improve symptom correlation in GERD and
cannot be recommended for improving symptom evaluation.
S1938
PH Monitoring in Asymptomatic Individuals and Its Endoscopic Correlates,
An Update
Ruben D. Acosta, Patrick E. Young, Craig M. Womeldorph, Marjorie R. Piorkowski,
Cecilia H. Kim, Brooks D. Cash
Background: While the symptoms of gastroesophageal reflux (GERD) occur regularly in
much of the population, the prevalence of pathologic esophageal acid exposure in patients
without GERD is unknown. Current pHmetry standards were established with naso-eso-
phageal sensors in GERD patients and may not be the ideal standard. Using an implantable
esophageal pH monitoring probe, we measured esophageal acid exposure and correlated
this exposure to the endoscopic and histologic appearance of the esophagus in individuals
without GERD. Methods: Patients referred for colonoscopy were asked to complete a validated
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questionnaire (modified GERQ) designed to determine the presence of symptomatic GERD.
Patients without GERD or GERD symptoms undergo an EGD including photographs of the
gastroesophageal junction and measurement of the lower esophageal sphincter (LES) location.
Biopsies of the distal esophagus and any abnormal appearing tissue are obtained. A catheter-
free pH- probe is placed 6 cm above the LES and pH is monitored for 48 hours. Patients
return the monitor and an activity diary within 2-5 days. Results: 39 asymptomatic individuals
have undergone EGD (mean age is 52.6; 34% female; 18% African-American). There were
4 failed probe deployments. pH data is available for 90% of subjects. 67% (24/35) had
significant acid exposure, defined by a Johnson-DeMeester (JD) score of 14.72, on either
day 1 (18), day 2 (13), or both (10). Of these patients, 29% (7/24) had endoscopic and/
or histologic evidence of reflux. Five patients with either a normal JD score or no JD score
due to failed deployment also had evidence of acid reflux changes. Thus, 30.8% (12/39)
patients without GERD symptoms had evidence of significant esophageal acid exposure.
The positive and negative predictive values for JD score from day 2 were 46.2% (6/13) and
63.6% (14/22) respectively. The prevalence of esophagitis and Barrett's esophagus were
25.7% (9/35) and 17.1% (6/35), respectively. No statistically significant relationships were
seen between acid exposure and BMI, sex, race, age, ETOH/wk or coffee/day intake. An
elevated JD score on day 1 or day 2 increased the odds of having reflux by 31%, but the
correlation with esophageal symptoms or physiologic changes was sporadic. Conclusions:
Our interim analysis indicates that significant esophageal acid exposure, as well as endoscopic
and/or histologic changes attributable to acid reflux, is common in an asymptomatic popula-
tion. Reassessment of our current standards for pHmetry may be warranted.
S1939
Esophageal and Gastric pH Profiles in Patients with Refractory
Gastroesophageal Reflux Disease Treated with Twice Daily Proton Pump
Inhibitors
Vandana Boparai, Andrew K. Roorda, Samuel N. Marcus, George Triadafilopoulos
Background: It is generally assumed that acid suppressive therapy with proton pump inhib-
itors (PPIs) improves or eliminates symptoms of gastro-esophageal reflux disease (GERD)
by suppressing intra-gastric acidity and normalizing intra-esophageal pH. “Refractory GERD”
has been questioned and failure to inhibit acid production with adequately dosed, twice
daily PPIs is considered uncommon. Continued symptoms despite such therapy would
suggest that symptoms are “functional”, not due to acid reflux and therefore may not be
relieved even after antireflux surgery or endotherapy. Performing ambulatory pH monitoring
while on PPI therapy may guide the clinician to the correct diagnosis, but this has not been
adequately studied. Aims: To assess the efficacy of twice daily (bid) PPI therapy in normalizing
intra-esophageal and intra-gastric pH in patients with refractory GERD seeking endoscopic
or surgical therapy. Methods: Patients with refractory GERD were prospectively evaluated
by endoscopy with biopsy, esophageal motility, and dual-sensor 24-hr ambulatory pH
monitoring while receiving twice daily PPI therapy (before breakfast and before dinner) for
GERD symptom control. Analyses and comparisons of intra-esophageal and intra-gastric pH
profiles while on bid PPI therapy were then made. Results: Fifty-six patients, 26 men and
30 women, with symptomatically refractory GERD (30 non-erosive; 11 erosive) and/or
Barrett's esophagus (15, 7 long-segment), were studied. All were symptomatic (mean compos-
ite score 0.97, range 0-3, despite bid PPI therapy which was well-tolerated. PPIs used (all
bid, ac) were: Omeprazole 20mg (n=6), esomeprazole 40mg (n=29), lansoprazole 30mg (n=
10), pantoprazole 40mg (n=4) and rabeprazole 20mg (n=7). Mean hiatal hernia length
was 1.5cm (range 0-6cm); mean LESP was 10mmHg; 23 patients had moderate to severe
dysmotility. Only 19 (34%) of patients normalized their intra-esophageal pH profiles while
on bid PPI therapy with a mean percent time with intra-esophageal pH<4.0 of 9.3% (95%
CI 7.2-11.4; range 0-34%). All 5 PPIs used accomplished similar degree of intra-gastric acid
suppression, particularly nocturnal, with a mean percent time with intra-gastric pH<4.0 of
35.4% (95% CI 29.3-41.5; range 0.3-89%); The mean percent with nocturnal (supine)
pH<4.0 was 42.6 (95% CI 34.9-50.3). Conclusions: The majority of symptomatically-
refractory GERD patients with or without Barrett's esophagus are not “functional” as they
continue to exhibit pathologic GERD and low intra-gastric pH, particularly nocturnal, despite
twice-daily PPI therapy. These findings may have significant therapeutic implications.
S1940
Continuing Reflux On PPI Therapy Is Similar in Adults and Children
Amit Agrawal, Neeraj Sharma, Amine Hila, Radu Tutuian, Marcelo F. Vela, Donald O.
Castell
Background: 24 hour multichannel intraluminal impedance and pH (MII-pH) esophageal
monitoring allows detection of both acid and non-acid gastroesophageal reflux (GER) epis-
odes. Both pediatric and adult patients may have persistent symptoms despite PPI therapy.
Aim: To identify and compare characteristics of continuing GER on PPI therapy in pediatric
versus adult patients. Method: 192 consecutive MII-pH studies performed on PPI therapy
in our laboratory were analyzed. The total number of reflux episodes and symptom index
(SI) were measured. Positive SI defined as >50% (i.e. at least half of the symptoms associated
with reflux). 2 groups were identified: adults ( > 18 years) and pediatrics ( < 18 years).
Results: There were 154 (80%) adults and 38 (20%) pediatric patients. Of the 154 adults,
the mean age was 52 years and 121 (79%) were females.The mean number of total, non-
acid and acid reflux episodes were 36, 28, and 8 respectively. 78 (51%) had a positive SI
during MII-pH study. 39 (50%) were positive for non-acid reflux, 13 (17%) for acid reflux,
and 2 (3%) for both acid and non-acid reflux. 49 (63%) had an abnormal number of reflux
episodes of which 25 (51%) also had a positive symptom association with GER. Of the 38
pediatric patients, the mean age was 4 years and 21 (55%) were males. The mean number
of total, non-acid, and acid reflux episodes were 33, 23 and 12. 18 (47%) had a positive
SI during MII-pH study. 9 (50%) were positive for non-acid reflux, 2 (11%) for acid reflux,
and 1 (6%) for both acid and non-acid reflux. 9 (50%) also had an abnormal number of
reflux episodes of which 3 (33%) also had a positive symptom association with GER.
Conclusions: Many pediatric and adult patients experience symptomatic GER despite PPI
therapy. The characteristics of GER are similar on PPI therapy in adults and children.
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
S1941
Pillcam™ Eso Capsule Endoscopy Accurately Detects Abnormalities of the
Esophagus and Is Highly Preferred By Patients with Symptomatic
Gastroesophageal Reflux Disease
P. J. De jonge, B. C. Van eijck, H. Geldof, F. C. Bekkering, E. J. Kuipers, P. D. Siersema
Background: The invasiveness of esophagogastroduodenoscopy (EGD) limits its utilization
in patients with suspected or established esophageal disease. PillCam ESO capsule endoscopy
(Given Imaging Ltd.,Yogneam, Israel) offers an alternative non-invasive approach to visualize
the esophagus. Aim: To assess the accuracy and acceptability of capsule endoscopy (CE) in
evaluating patients with suspected gastro-esophageal reflux disease (GERD). Methods:
Patients with suspected GERD underwent CE within 1 week following EGD. Swallowing of
the capsule followed a standardized CE ingestion protocol. The CE videos were reviewed
by two investigators who were blinded to the EGD findings. The EGD results were considered
to be the gold standard. Exclusion criteria were a known gastrointestinal obstruction, a
cardiac pacemaker and dysphagia. Sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV). were evaluated. In addition, patient preference, pain,
discomfort, and physical symptoms after both procedures were compared using validated
questionnaires. Results: A total of 31 consecutive patients underwent both EGD and CE of
the esophagus (78% male, mean age ± SD: 51 ± 13 yr), of whom 14 patients had EGD for
GERD symptoms and 17 for Barrett's esophagus (BE) surveillance. In addition, 9 healthy
controls without symptoms were included for CE only. Mean esophageal transit time was
188s (range: 6-622s). A complete study of the Z-line was possible in 37/40 (92%) patients.
Incomplete visualization of the Z-line was due to the presence of bubbles in 3/38 (7%)
patients or a fast passage through the distal third of the esophagus (1/38 [2%]). This CE
study could not be analysed. CE accurately assessed the presence of esophagitis in 12 of
14 patients (sensitivity, 86%; specificity, 96%; PPV, 92%; NPV, 93%). BE was detected in
16 of 17 patients (sensitivity, 94%; specificity, 96%; PPV, 94%; NPV, 96%). Of all patients,
11/31 [35%] experienced EGD as painful, while only one patient experienced pain during
ingestion of the capsule. Discomfort was experienced during EGD in 22/31 [71%] patients,
and in 5/31 [16%] during CE (p<0.05). Apart from an increase in throat ache (47% after
EGD versus 19% before, p<0.01), both procedures did not cause physical symptoms. There
were no adverse events related to CE. All patients preferred capsule endoscopy to EGD.
Conclusion: CE is a convenient and sensitive method for the study of esophageal abnormalities
and may provide an effective method to screen patients with symptomatic GERD. Nonethe-
less, EGD is still required in BE patients to histological confirm the diagnosis.
S1942
Limitations of Ambulatory Pharyngeal pH Monitoring - A Cause for Concern
Yue Zheng, Shiko Kuribayashi, Linda Tatro, Candy Hofmann, Reza Shaker
Despite recent enthusiasm, pharyngeal ambulatory pH monitoring poses significant chal-
lenges in terms of correct identification of both reflux events and their pH. Sampling
frequency and more importantly response rate of the pH sensor to both liquid as well as
mist acidic events can influence the result. The aim of this study was to test and compare
the performance of the three available pH probes under controlled experimental conditions
simulating pharyngeal liquid and mist acid reflux event. Methods: Three pH probes (pHer-
saflex (Alpine Biomed, Fountain Valley, CA, USA), COMFORTEC (SANDHILL SCIENTIFIC,
Highlands Ranch, CO, USA) and Dx-pH (Respiratory Technology Corporation, Poway, CA,
USA)) were wrapped together and immersed into 0.001N, 0.01N and 0.1N HCl respectively
(pH 3.4, 2.4 and 1.2 respectively) in room or body temperature for 1 minute. After each
acid immersion, the probes were rinsed with water and then dipped in baking powder
solution for 1 minute. A total of 40 repetitions were performed for each pH solution. In
addition an atomizer was used to spray the pH sensors with acidic mist (0.001N, 0.01N
and 0.1N HCl) from a 2cm distance. These tests were done with probes inside swine
intestine, room air or inside a plastic tube. Results: Although all three probes eventually
reached similar pH nadir comparable to that measured by standard pH meter, the time
interval for reaching this nadir was significantly different among probes (p<0.001, Table).
The time intervals from acid contact to onset of pH change, however, were similar among
probes and ranged within one second. Temperature change didn't affect performance of any
probe significantly. In spray test, detection of pH change varied between 90-100% for Dx-
pH probe, 80-100% for COMFORTEC probe and 60-90% for pHersaflex probe. The recorded
pH, however, did not always reflect the accurate pH of the solution. Response time and
time to nadir was similar to that of the immersion test. Conclusion: Response rate of the
available ambulatory pH probes differ significantly. Given the rapidity of pharyngeal events,
those probes with slower response rate may overestimate the occurrence of minimally acid/
non-acid reflux events to the determent of highly acidic events. Supported in part by R01
DK025731-25.
Time to pH nadir
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The Diagnostic Value of Dilated Intercellular Spaces for GERD Is Strongly
Affected By the Presence of Helicobacter pylori Infection
Nathan D. Johnston, David Graham, Hala M. El-zimaity
BACKGROUND: Routine histology is of limited value in the diagnosis of gastroesophageal
reflux disease (GERD). However, variables such as dilation of intercellular spaces are thought
to provide a more accurate measure of disease presence. AIM: To evaluate the diagnostic
role of histological alterations in GERD while controlling for the presence of H. pylori infection
in the stomach. METHODS: Esophagogastroduodenoscopy was performed in patients with
clinical symptoms suggestive of GERD. The Los Angeles classification was used to grade
esophagitis. Multiple biopsies were obtained from the antrum, corpus, cardia, at the Z line
and 2 cm above it. Esophageal biopsies were evaluated for dilation of intercellular spaces,
elevation of rete ridges, basal cell hyperplasia, intestinal metaplasia, and intraepithelial
infiltration with neutrophils, eosinophils, and/or lymphocytes. Gastric biopsies were evalu-
ated for density of Helicobacter pylori, polymorphonuclear cells, mononuclear cells, intestinal
metaplasia, foveolar hyperplasia and smooth muscle hyperplasia. RESULTS: The study
included 38 patients (14 had normal mucosa-nonerosive reflux disease or NERD-Grade 0).
H. pylori infection was identified in 15 and 10 of these (67%) had the bacteria identified
in a cardia biopsy. Dilated intercellular spaces were observed in all patients. In erosive GERD
patients, the presence and extent (height and width) of dilated intercellular spaces was
greater in H. pylori negative patients at both the Z-line and more proximal biopsies. In
NERD patients, the extent of dilated intercellular spaces was found in proximal esophageal
biopsies irrespective of H. pylori status. In contrast, at the Z line some patients with H. pylori
infections and NERD did not show dilated intercellular spaces but they were present in the
biopsies taken 2 cm proximal to the Z-line. The presence of intra-epithelial eosinophils and
intra-epithelial lymphocytes was predictive of erosive GERD irrespective of the presence or
absence of dilatation of the intercellular spaces (p <0.001). CONCLUSIONS: Histopathology
has a useful role in the evaluation of patients with reflux esophagitis. Esophageal biopsies
should always be taken approximately 2 cm proximal to the Z-line to avoid the presence
of H. pylori-associated absence of dilated intercellular spaces and the false impression that
the patient's symptoms are not related to reflux disease.
S1944
Differences in the Recognition of Heartburn Symptoms Among GERD Patients,
Doctors, Nurses, and Normal Healthy Subjects in Japan
Noriaki Manabe, Ken Haruma, Jiro Hata, Hiroaki Kusunoki, Tomoari Kamada
Background and Aims: “Heartburn” is defined as a burning sensation in the retrosternal
area, and is strongly suggestive of GERD. We have found that patients complaining of
heartburn in general clinical practice actually refer to various symptoms as “heartburn”. The
aim of this study was to investigate possible differences in the recognition of “heartburn”
among normal healthy subjects (HS), GERD patients, nurses, and doctors, as well as between
patients with non-erosive reflux disease (NERD) and those with reflux esophagitis (RE).
Subjects and Methods: We conducted an anonymous questionnaire survey on “heartburn”
among a total of 481 people including 96 GERD patients (68 NERD patients [32 men, 36
women; mean age 58.8 years]: 28 RE patients [18 men, 10 women; mean age 68.9 years])
who visited Kawasaki Medical School Hospital and affiliated facilities, 170 HS (113 men,
57 women; mean age, 30.6 years), 111 nurses (111 women: mean age, 33.0 years), and
104 doctors (59 specialists in gastroenterology and 45 non-specialists; 98 men, 6 women;
mean age, 49.4 years). The subjects were asked to choose the option closest to the symptom
that they would recognize as heartburn. If the options did not match their answer, the
subjects were asked to describe it themselves. Results: Comparison of the recognition of
“heartburn” revealed that there were no differences in the recognition between RE patients
and doctors, while it was found that NERD patients did not recognize “regurgitation” or
“burning sensation in the chest” as heartburn as much as doctors did (P<0.05), but recognized
“stomachache” as heartburn (P<0.05). HS recognized “anorexia” as heartburn (P<0.05).
Nurses recognized “queasy feeling” as heartburn (P<0.05). Assessment of possible differences
between NERD patients and those with RE revealed that significantly more NERD patients
chose “stomachache” (P<0.05), while significantly more RE patients chose “regurgitation”
(P<0.05)(Table). Conclusions: There were some differences in the recognition of “heartburn”
among HS, GERD patients, nurses, and doctors. Doctors and RE patients had a common
recognition of “heartburn”, but there were differences in the recognition of “heartburn”
between NERD patients and doctors or RE patients.
Differences in the recognition of heartburn
NERD: non-erosive reflux disease, RE: reflux esophagitis, HS: normal healthy subject
S1945
A New Questionnaire FSSG, Frequency Scale for the Symptoms of GERD,
Better Correlates with Endoscopic Severity Than Quest Questionnaire, and Is
Capable to Evaluate Dyspeptic Symptoms in GERD Patients. Japan FSSG
Committee Multi Center Trial
Motoyasu Kusano, Kanako Yamaguchi, Toshihito Saitoh, Masahiko Inamori, Takashi
Ando, Tomoiko Shimatani, Kyoichi Adachi, Yasuyuki Shimoyama, Fukunori Kinjo, Shiko
Kuribayasi, Shoji Mitsufuji, Kazuhide Higuchi, Shigeki Koyama, Junichi Akiyama, Atsushi
Takagi, Hiroto Miwa, Kazuma Fujimoto
Aim: FSSG was developed by Kusano et al.(J Gastroenterol, 2004). They selected 12 questions
from 50 questions about most common symptoms experienced by GERD patients with a
score for the frequency of each symptoms (never=0, occasionally=1, sometimes=2, often=
3, and always=4). Twelve questions in FSSG consist of 7 reflux symptoms (RS) such as
heartburn and regurgitation, and 5 other dysmotility-like dyspeptic symptoms (DS) such
as bloating or postprandial fullness. We compared the efficiency of FSSG and Dent's question-
naire for GERD (QUEST), and also investigated the relation between RS and DS scores in
FSSG. Subjects and Methods:A total of 362 patients (age:51.8±18.2, M/F:207/155) at the
first visit of gastroenterology department of 15 hospitals were enrolled. All patients answered
completely both FSSG and QUEST questionnaires, and underwent an upper GI endoscopy.
The patients were diagnosed as 94 erosive GERD (eGERD, LA Grade A, B, C and D), 39
non-erosive GERD (NERD), 34 gastric ulcers (GU), 31 duodenal ulcers (DU), and 164
functional dyspepsia(FD). eGERD was further classified as mild (mGERD, Grade A and B)
and severe(sGERD, Grade C and D). Results: Table shows sensitivity of each questionnaire
for each group of diseases with cut off point of 8 for FSSG and 4 for QUEST. There was
no significant difference between both questionnaires in sensitivity, nor in specificity. There
were significant (p<0.01 ANOVA) differences in FSSG scores among NERD(10.2±1.1),
mGERD (10.8±0.8)and sGERD (17.3±3.4). Contrary, QUEST scores showed no significant
difference among the groups of GERD. RS scores among the groups were higher in the
order of eGERD>NERD>GU≒DU&;FD. RS score in eGERD was significantly (p<0.001)
higher than those of GU, DU, and FD. DS scores were higher in the order of GU&;eGERD>-
DU≒NERD>FD. DS scores in GU, eGERD and sGERD were significantly (p<0.05) higher
than that of FD. Conclusions: FSSG showed equal initial diagnostic ability for GERD to that
of QUEST. However, FSSG score significantly correlated with the severity of endoscopic
gradings. FSSG is capable to evaluate not only reflux symptoms but also dysmotility-like
dyspeptic symptoms. Therefore, FSSG could be a useful questionnaire to investigate how
important of dyspeptic symptoms in each group of GERD patients, and also to evaluate the
therapeutic efficacy of medical treatments.
Sensitivity and Specificity for FSSG and QUEST
S1946
Measurement of Gastroesophageal Reflux in the Pharynx: A New Technology
Colleen B. Gaughan, Andrew Tang, John C. Lipham, Christian G. Peyre, Christian
Rizzetto, Brendan Boland, Nuttha Ungnapatanin, Jeffrey A. Hagen, Steven R. Demeester,
Cedric G. Bremner, Tom R. Demeester
Introduction: Causal relationships between gastroesophageal reflux disease and laryngeal/
respiratory complaints have been difficult to confirm due to lack of a reliable method of
measuring pH in the pharynx. The purpose of this study was to evaluate a new device for
measuring pharyngeal pH, characterize the pH environment of the pharynx and provide
normative data for the use of the ResTech Dx probe. Methods: Subjects were prospectively
enrolled as they presented to the USC Esophageal Laboratory with laryngeal/respiratory
complaints and/or GERD symptoms. Asymptomatic volunteers were recruited as controls
and were excluded if they had any laryngeal/respiratory complaints, GERD symptoms,
esophageal motility disorders, a structurally defective LES, or hiatal hernia. Subjects were
studied simultaneously with a dual channel pH probe (distal probe 5 cm>LES, proximal
probe 1cm < UES) and a ResTech Dx pH probe (pharynx). pH events in the pharynx were
characterized as weak acid (pH 4-6) or acid (pH <4) that coincided with a pH events in
the distal esophagus. Average pH at the probe positions, number of total pH events and
percentage of time for pharyngeal pH events was compared between patients and controls.
Results: 30 subjects participated in the study (20 patients, 10 controls). There were no
significant differences between groups. All had successful ResTech Dx probe placement and
24 hour pH monitoring. There was a significant pH gradient between the probe positions
observed for patients, but not normal controls. The lowest pH was observed at the distal
esophageal probe (6.23), and became less acidic proximally, [(6.35), 1cm < UES], and
neutral (7.68) in the pharynx (p<0.01). Most pH events observed were weak acid events
(99%) in both normal controls and patients. There was no significant difference in the mean
number of pharyngeal pH events between normal controls and patients. The percentage of
time of pharyngeal pH events was significantly different for normal controls (1.8%) compared
to patients with increased distal esophageal acid exposure (15.9%; p=0.03) but not signific-
antly different compared to patients with normal distal esophageal acid exposure (5.2%).
Conclusions: The ResTech Dx Upper Airway pH probe provides reliable pH monitoring in
symptomatic patients normal controls. There is a significant pH gradient in the esophagus,
related to dilutional effects of saliva. The majority of pharyngeal pH events are weak acid
events (pH 4-6). The percentage of time of pharyngeal pH events is useful in distinguishing
symptomatic patients with increased distal esophageal acid exposure from those with normal
distal esophageal acid exposure.
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S1947
Increasing Prevalence of Reflux Esophagitis But Not Typical GERD Symptoms
in Apparently Healthy Adults Between Two Time Periods in Taiwan- An
Evidence of Increasing Silent GERD
Han-chung Lien, Chi-sen Chang, Hong-zen Yeh
Background: The prevalence of GERD is increasing in Asia, however, comparisons among
epidemiological studies are hampered by using different definitions and among different
ethics or populations. We compared the prevalence of reflux esophagitis and GERD symptoms
among apparently healthy adults in Taiwan between 2 cross-sectional studies conducted in
year 2002 and 1995. Materials and methods: A total of 3946 out of 5112 consecutive mostly
asymptomatic adults receiving self-paid routine check-up including panendoscopy and a
validated GERD questionnaire were compared for the presence of reflux esophagitis and
symptoms between 2 time periods. (N = 2044 in 1995; N = 1902 in 2002 with sex- and
age-match) The endoscopy was performed in the same unit, by the same group of experienced
endoscopists using the modified Savary-Miller classification. The inter-observer agreement
of the presence of esophagitis among endoscopists was good with a kappa of 0.6 tested by
80 endoscopic pictures. The GERD symptom was defined as any one(s) of heartburn, acid
regurgitation, and belching at least once a week in the last 3 months. Results: The prevalence
of reflux esophagitis increased in 2002 compared to that in 1995 (12.5% vs. 5%, p<0.001),
while the majority was grade 1 in severity in both time periods (82.9% vs. 86.3%, p = 0.3).
The age (49.9± 12.0 vs. 49.7± 12.1), male ratio (60.1% vs. 61.9%), and BMI (24.1± 3.3
vs. 24.1± 3.6) were no difference between 2 time periods, however, BMI was higher in both
time periods among the patients with esophagitis compared to those without esophagitis
(25.5± 3.4 vs. 23.9± 3.2, p<0.001, and 25.7± 3.1 vs. 24.0± 3.6, p<0.001). There was also
an increase of hiatal hernia (3.8% vs. 2.2%, p<0.001), and was equally associated with
esophagitis in both time periods (45.8% vs. 45.4%). Males had a higher risk of esophagitis
in both time periods (OR 3.2(2.3-4.4) vs. OR 6.4(3.3-12.5)) though both genders had an
increase risk of esophagitis along the time. There was an increase of esophagitis in subjects
older than 40 but not in subjects younger than 40. The prevalence of GERD symptoms was
similar between 2 time periods (17.4% vs. 16.9%, p=0.7). In patients with reflux symptoms,
the risk of esophagitis was no difference between 2 time periods (15.8% vs. 18.5%, RR
0.8(0.5-1.2)), while in patients with no reflux symptoms, the risk of esophagtis increased
along the time (12.0% vs. 2.2%, RR 5.9(4.2-8.5)). Conclusions: The increase in prevalence
of asymptomatic reflux esophagitis among apparently healthy adults older than 40 in Taiwan
implicates an increase of silent GERD, which may possess a future risk of developing GERD
symptoms and complications.
S1948
Acid Exposure of MID-Proximal Esophagus: A Better Tool for Excessive Reflux
in Nerd?
Sara Emerenziani, Mentore Ribolsi, Marina Rizzi, Renato Caviglia, Michele P. Guarino,
Michele Cicala
Background: Sensitivity of 24 hour pH monitoring is poor (50-60%) in non erosive reflux
disease (NERD) patients. In these patients, it has been demonstrated that proximal extent
of acid reflux is a main determinant of reflux perception. AIM of this study was to evaluate
the diagnostic accuracy of the AET values at middle and proximal esophagus as well as the
reproducibility of these parameters. Methods: Following 3-week washout from proton pump
inhibitors (PPI), 83 consecutive NERD patients, responsive to PPI treatment, underwent
esophageal manometry and multi-channel 24-hour pH test. 13 patients underwent the same
study on two occasions (2 to 5 weeks interval). According to the manometric findings, the
four sensors were placed at gastric level, 5 cm above the LES, 10 and 3 cm below the UES.
Clinical data were obtained using a standardized questionnaire. AET at 5 cm above LES
>5% of total recording time, and AET at 10 cm and 3 cm below UES >95th percentile
values (1.1% and 0.7%, respectively) of 20 asymptomatic volunteers (control group) were
considered as pathological. Symptom Association Probability (SAP) values were evaluated
at each esophageal level. AET parameters were considered reproducible if remain in the
same category on both occasions. To assess time-related intra-subject variability Student's
t test for paired samples and Bland-Altman test were also used Results: AET in asymptomatic
controls was (mean, [95% Confidence Intervals, CI]) 1.7% [1.1-2.2] at distal esophagus,
0.63% [0.2-1.0] at 10 cm below UES and 0.4% [0.1-0.7] at 3 cm below UES. AET values
and percentage of patients with a positive pH test are shown in the Table. Only two patients
with a positive test at distal became negative at middle and proximal levels. Intra-subject
reproducibility was 56% at distal, 77% at middle and 46% at proximal esophagus. No
significant difference between the two observations was found in AET values at distal and
middle levels. SAP test detected at the distal sensor was positive in 33 out of 83 patients
and slightly improved at 10 cm below UES. Conclusions: In NERD patients, the diagnostic
yield of the pH test is significantly improved by the assessment of AET at middle esophagus.
As this variable seems to be highly reproducible, it could be considered a reliable and useful
tool in non erosive reflux disease.
AET and percentage of patients with positive test
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S1949
“pH Only” Acid Gastroesophageal Reflux Episodes Are Not Temporally
Correlated with Respiratory Symptoms in Infants
Hayat M. Mousa, Frederick W. Woodley, Christina Conklin, Christopher Rupert, Erica
Cowoski
Background: Analysis of combined esophageal pH monitoring (EPM) and multichannel
intraluminal impedance (MII) tracings reveals a dubious type of acid gastroesophageal reflux
(GER) event that is detectable by EPM but does not correspond to a pattern of MII that is
characteristic of retrograde bolus movement within the esophagus. We have shown that
these “pH only events” (POEs) contribute significantly to total acid GER in infants. The
clinical significance of POEs in infants has not been tested. Aim: To test the clinical importance
of POEs by attempting to temporally correlate POEs with respiratory symptom events (RSEs)
that are suggestive of GER as an etiology. Methods: Combined EPM/MII tracings, from 12
symptomatic infants (< 12 mo, median 3.5 mos) who were oral feeders and had not received
a fundoplication prior to testing, were retrospectively examined for POEs and RSEs (coughs
[Cs], gagging [Gs], choking [Chs], wheezing [Ws], and apnea [As]). POEs that occurred 2
min before, during, or 2 min after an RSE were all tagged as being temporally correlated
with an RSE. Symptom indices (SI) and symptom sensitivity indices (SSI) were calculated
across all RSEs for each subject. SI and SSI were considered significant when they exceeded
50% and 10%, respectively. All subjects were enrolled following written parental consent.
The study protocol was approved by the Columbus Childrens Hospital Institutional Review
Board. Results: Across all subjects, 640 total POEs (median 38, range 4-207/pt) and 544
total RSEs (348 Cs, 7 Gs, 21 Chs, 24 Ws, and 144 As; median 37, range 1-119/pt) were
detected and recorded. Of the total POEs, 59 (9.0 %) were temporally correlated with an
RSE (31 Cs [52.6%], 0 Gs [0%], 2 Chs [3.4%], 13 Ws [22.0%], and 13 As [22.0%]). Of
the total RSEs, 40 (7.4 %) (23 Cs [57.5 %], 0 Gs [0%], 2 Chs [5 %], 6 Ws [15%], and 9
As [22.5%]) were temporally correlated with a POE. Across all RSEs, none of the subjects
had a positive SI and 2 (16.7%) had a positive SSI. Across all subjects and all RSEs, the
mean SI and SSI was 9.2 ± 3.6% and 7.0 ± 2.2%, respectively. Conclusions: While POEs
can be temporally correlated in a few subjects using the current method of analysis, they
are not strongly associated with the RSEs that have been linked previously with GER. This
result should be interpreted carefully and in full consideration of the patient population
and the frequency of their respective RSEs.
S1950
24 Hour Combined pH-Impedance Reflux Monitoring (MII-pH) in
Symptomatic GERD Patients On Or Off PPI: Symptom Association Analysis
Anthony A. Starpoli, David L. Ulrich, Nicholas M. Gualtieri, Ramani Rangavajhula, Vasco
Eguia
Introduction: MII-pH reflux monitoring detects non-acid reflux and strengthens symptom
association analysis. The aim of this study was to further characterize typical symptoms of
esophageal reflux in reflux patients tested on and off medications and compare Symptom
Index and Symptom Associated Probability Scores. Methods: 24 hour MII-pH transnasal
intraesophageal monitoring was performed on 74 patients complaining of suspected GERD
related symptoms either on or off PPI therapy. All reflux events were identified by intraluminal
impedance and characterized as acid or nonacid. Symptom Index ( SI positive ≧50%)and
Symptom Associated Probability (SAP positive ≧95%)scores were calculated and a bivariate
analysis was performed. Results: Seventy-four patients (38 (52%) females and 34 (47%)
males with 38 patients on daily PPI therapy and 34 patients off daily anti-acid treatment)
underwent 24 hour combined MII-pH monitoring. Seventy-two patients recorded symptoms
during the study day and 2 patients had no symptoms during testing. Forty-four patients
complained of heartburn during testing and 41 regurgitation, which were considered typical
symptoms. SAP and SI correlated >80%( p<.01)when testing was performed on PPI therapy.
SAP and SI correlated poorly in off-PPI testing. See Table. Conclusion: Nonacid reflux was
detected in both on and off PPI therapy groups. On PPI testing yielded a greater percentage
symptom related nonacid reflux for regurgitation. Detecting heartburn related nonacid reflux
was less than that for regurgitation despite PPI therapy. SAP and SI correlate significantly
when testing is performed on acid suppression therapy.
SAP and SI On and Off PPI therapy
S1951
Impedance-pH Monitoring in Patients with Ent Symptoms Suspected Due to
GERD: Results from a Single Practice
Girish Anand, Matthew Gideon, Philip Katz
Introduction: Patients with ENT symptoms suspected due to GERD refractory to antireflux
therapy present a diagnostic challenge. Non-acid reflux is thought to play a role in some
of these patients. Combined multichannel intraluminal impedance and pH (MII-pH) mon-
itoring has the ability to detect gastro-esophageal reflux (GER) episodes independent of their
pH and evaluate the relationship between symptoms and all types of GER. Current reports
address multiple extra-esophageal symptoms. Aim: Review impedance/pH studies in patients
referred for ENT symptoms. Methods: Retrospective review of MII-pH studies between 07/
2003 - 11/2006. All patients referred by a single ENT specialist were included and MII-pH
studies reviewed for percent time pH <4 in the upright and supine positions, total number
of acid/non acid reflux episodes. Studies were included if performed on or off medications.
Symptom correlation was assessed by symptom index. Symptoms reviewed by manual
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reading of the study. Normal values for the variables were based on the established reference
ranges in the literature and followed in our laboratory. A positive symptom index (SI) was
declared if at least half of each specific symptom events were preceded by reflux episodes
within five minutes. Results: A total of 117 patient studies were reviewed. Symptoms included
voice change (40%), chronic cough or throat clearing (30%), heartburn (20%) as well as a
variety of other ENT symptoms. 79 patients were studied on therapy- twice daily PPI with
or without ranitidine at bed time. 38 patients were studied off therapy. 103/117 patients
(88%) had normal acid control, whether on or off therapy.11/38 (29%) off therapy patients
had abnormal esophageal acid exposure while 76/79 (96%) on therapy patients had normal
acid control. Only 18/117 (15%) patients had an abnormal number of total acid/non-acid
reflux episodes (>73), 6 of which occurred in the off therapy group. However 20/79 (25%)
patients studied on therapy had positive SI despite normal reflux frequency. Summary:
Overall abnormal acid reflux is uncommon in this subset of patients. Abnormal non-acid
reflux particularly on therapy is also uncommon. Conclusion: The subset of patients with
positive SI require further investigation to determine if this is a manifestation of visceral
sensitivity or a complete chance phenomenon.
S1952
Obesity Is a Risk Factor for Non-Acid Reflux
Courtney Barancin, Kevin D. Halsey, Eric A. Gaumnitz, Arnold Wald
Introduction: Gastroesophageal reflux and obesity cause significant morbidity in the United
States. Studies are conflicting as to the impact of obesity on acid reflux. Little is known
about the relationship between obesity and non-acid reflux. The aim of this study is to
examine the affects of obesity on reflux characteristics as defined by impedance-pH. Methods:
Impedance-pH results of 88 subjects referred for reflux symptoms were analyzed. Subjects
on acid suppression or post- anti-reflux surgery were excluded. Body mass index (BMI) was
stratified into 3 groups: normal weight (BMI 18.5-25), overweight (BMI 25.1-29.9) or obese
(BMI >30). Twenty-four hour impedance-pH studies were analyzed for total number of
reflux events, total number of proximal esophageal reflux events, and proximal bolus contact
time (PBCT) for acid and non-acid events. Linear regression analysis was used to determine
a relationship between impedance parameters and BMI. Manometry studies were done in
75 subjects who were analyzed in regard to motility and impedance findings. Results: Subject
population included 67 females, 21 males; average age 65.2 years; average BMI 28.7. No
relationship was seen between BMI and total acid reflux events and PBCT. A non-significant
trend was seen between increasing BMI and increasing total number of reflux events (acid
+ non-acid events). A significant relationship was seen between increasing BMI and increasing
number of non-acid reflux events (F=0.02, P= 0.02). When obese subjects with dysmotility
(n=20) were compared to those with normal motility (n=9), there were no differences in
PBCT (mean 47.3 vs 33.9, P=0.279) or total number of proximal reflux events (PRE)
(mean 21.1 vs 27.4, P=0.249). Obese subjects with normal motility (n=20) however had a
significantly higher PBCT (mean 33.9 vs 27.9, P=0.002) and total number of PRE (mean
27.4 vs 19.8, P=0.0004) when compared to normal weight, normal motility subjects (n=
35). In non-obese subjects there was a higher PBCT (mean 53.4 vs 27.9,P=0.034) and total
number of PRE (mean 25.6 vs 19.8, p=0.002) in those with abnormal motility compared
to those with normal motility. There was no difference between obese and non-obese subjects
with dysmotility (n=9) in PBCT (mean 47.3 vs 53.4, P=0.35) and total number of PRE
(mean 21.1 vs 25.6, P=0.8). Conclusions: 1) Increasing BMI significantly correlates to
increased non-acid reflux events. 2) Obesity correlates with increased PBCT and number
of proximal reflux events irrespective of motility. Therefore, we conclude obesity is a risk
factor for non-acid reflux disease and is independent of esophageal motility.
S1953
Tolerability and Utility of the BRAVO Capsule in Children Younger Than Ten
Years
Wahaj Zaidi, Cary M. Qualia, Thomas Rossi
Background: The Bravo capsule is a wireless pH recording device attached to the esophageal
mucosa used to evaluate patients for gastroesophageal reflux. The fear of complications and
negative side effects may preclude pediatric gastroenterologists from implementing this
technology in small children. Methods: The parents of children younger than ten years who
had undergone a Bravo capsule study were contacted by phone and asked a series of
questions. The age and weight for each of these children at the time of the study were
recorded and the results of each of the studies were documented. Results: Between March,
2006 and November, 2006 eight children younger than age ten years had a Bravo capsule
placed. The mean age of the children was 7.1 years (range - 5 years to 9 years) and the
mean weight was 23.3 kg (range - 18.4 to 36.6 kg). One of the patients complained of
dysphagia for solid foods and none complained of dysphagia for liquids during the two
days following insertion of the capsule. Five children experienced some discomfort during
this time period, but none of these children experienced difficulty sleeping. The parent of
all eight children said he or she would be willing to have the study repeated if it was
clinically indicated. Five children had previously undergone a pH study using a nasal catheter,
and the parent of all of these children said he or she preferred the wireless capsule to the
nasal catheter. There were no esophageal perforations as a result of capsule placement. The
capsule documented acid reflux in all of the patients. Four were determined to have clinically
significant acid reflux (mean number of episodes = 73; mean percentage of time pH < 4 =
4.3% in these patients). Conclusion: The Bravo capsule is a safe, effective, and extremely
well-tolerated means of diagnosing acid reflux in children younger than age ten years.
S1954
Demographic Features of PPI Failures: Are There Differences Between Those
with a Positive Versus Negative Symptom Index (SI)?
Neeraj Sharma, Amit Agrawal, Marcelo F. Vela, Donald O. Castell
Background: Gastroesophageal reflux disease (GERD) causes a wide variety of symptoms,
even in patients on PPI therapy. Whether atypical or typical, these symptoms may or may
not be associated with ongoing reflux, as determined by combined multichannel intraluminal
impedance (MII-pH) testing. The demographic characteristics of patients with a positive
versus negative SI have not been established. Aim: To determine the demographic differences
in patients with a positive versus negative SI. Methods: Retrospective review of the last 200
consecutive adult patients having MII-pH testing on twice daily PPI therapy (between January
2005 and October 2006) was performed. Studies were analyzed to determine the symptom
index (SI) for each complaint. A patient was categorized as overall positive SI if any symptom
had a SI > 50%. Charts were reviewed to determine the gender, race, and age of each patient
and compared for those with a positive or negative SI. Results: Table 1 shows the number
and mean age of the patients in each category. Conclusions: In our patient population who
have had undergone MII-pH testing to evaluate PPI failure, there is no significant gender,
racial, or age difference in those with a positive versus negative SI.
Table 1
* chi-square test † t-test
S1955
Catheter Free pH Monitoring Is Well Tolerated and Often Positive in Patients
Intolerant of Nasal Catheterisation
Russell Canavan, Mark Fox, Roy Anggiansah, Angela Anggiansah, Terry Wong
Introduction Patient tolerance is a limiting factor in the use of conventional catheter based
esophageal pH studies. The catheter free pH monitoring Bravo® system is an alternative
approach. It is not established whether those patients intolerant of nasal catheters will tolerate
catheter free pH monitoring. Secondarily, it is unclear what proportion of these patients
have pathological oesophageal acid exposure. Method Prospective assessment of patients
referred to a tertiary centre for oesophageal studies between 03/03/2003 and 01/10/2006.
Details were recorded on a database and on paper records. Patients with major motility
disorders on manometry were excluded from the study (achalasia, diffuse esophageal spasm).
The remainder proceeded to catheter based 24 hour pH studies (C-pH). Those intolerant
of nasal catheterisation were offered catheter free pH studies by the Bravo® system, (B-pH).
Patients who underwent both procedures were asked to fill in a satisfaction survey of their
experience of both procedures. Results A total of 2578 patients were referred for oesophageal
studies. Manometry revealed major motility disorders in 140 (5.4%) of patients. 1691 patients
(66%) proceeded to C-pH with 58% of these patients had significant gastro-esophageal
reflux assessed as a DeMeester Score >14.72. 143 (8.5%) patient did not tolerated nasal
catheterisation (age range, male:female). 90 patients intolerant of nasal catheter (F:M=43:47,
age range 25- 69) underwent B-pH with 71% having a DeMeester score >14.72. Those who
underwent both procedures showed a significant preference for the B-pH with an overall
satisfaction of 4.6/5 and all patients would recommended the catheter-free pH system to a
friend in preference to conventional catheter based pH studies (p<0.01). Conclusion A small
proportion of patients are intolerant of catheter based pH monitoring systems. Patients
intolerant of catheter based systems have a high incidence of significant gastro-esophageal
reflux and tolerate catheter free systems with a high degree of satisfaction.
S1956
The Proton-Pump Inhibitor Test in Identifying Gastroesophageal Reflux
Disease-Related Globus
Dong hyun Sinn, Poong-lyul Rhee, Jun haeng Lee, Hee jung Son, Dong kyung Chang,
Young-ho Kim, Jae j. Kim, Jong chul Rhee
Background: Studies suggest an association between globus sensation and gastroesophageal
reflux disease (GERD). Empirical trial with high-dose proton-pump inhibitors (PPIs) has
been shown to be a effective tool for diagnosing patients with GERD. However, this diagnostic
strategy has not been well established in patients with GERD-related globus patients. Methods:
Patients with globus sensation as predominant symptom were enrolled into the study. GERD
was determined by upper endoscopy and by 24-h esophageal pH monitoring. Patients
received high-dose PPIs for 14 days. Daily diary assessing severity and frequency of globus
sensation, typical reflux symptoms (heartburn, acid regurgitation) and other symptoms (chest
pain, chronic cough, epigastric soreness, etc) was used for analysis. Patients completed a
daily diary throughout the study periods. The PPIs empirical trial was considered diagnostic
if globus sensation improved ≥50% than baseline. Institutional review board at Samsung
medical center approved this study for human study. Results: Of the 56 patients with globus
sensation that were enrolled, 15 (27%) had erosive esophagitis and/or abnormal pH test
(GERD-related globus) and 41 (73%) had both tests negative (GERD negative globus). Of
the GERD-related globus patients, 8 patients (53.3%) had improvement in globus sensation
over two weeks of PPI trial. Of the GERD negative globus patients, 18 (43.9%) had improve-
ment in globus sensation over two weeks of PPI trial. The sensitivity and specificity of the
PPIs empirical trial was 53% and 56%, respectively. Of the 56 enrolled patients, 41 patients
(73%) experienced typical symptoms and 15 patients (27%) did not experience typical
symptoms. There was no significant difference in improvement of globus sensation over
two weeks of PPI trial in GERD-relate globus vs. GERD negative globus in patients who
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experienced typical symptoms (40% vs. 64%, p>0.05, chi-square test, n=41), and who did
not have typical symptoms (54% vs. 25%, p>0.05, Fisher's exact test, n=15). Conclusion: The
PPIs empirical trial is not sensitive or specific for diagnosing GERD-related globus patients.
S1957
The Added Value of Esophageal Balloon Distention and Bernstein Acid
Infusion to High Resolution Manometry in a Clinical Practice Setting
Sheila Rodriguez-stanley, Susan Riley, Sattar Zubaidi, Philip B. Miner
Background: Limited diagnostic tools are available for assessment of patients with swallowing
disorders. Esophagogastroduodenoscopy is the most commonly performed test, which pro-
vides little information about esophageal function. High Resolution Manometry (HRM) is a
new technique for assessing motor abnormalities of the esophagus using a 32-sensor probe,
with greater accuracy in detection of LES abnormalities. Esophageal manometry, however,
is done infrequently. Sensory testing with chemical stimulation (Bernstein) and mechanical
stimulation (Barostat) is rarely performed. Obvious abnormalities can be overlooked without
a comprehensive approach to potential esophageal abnormalities. Aims: 1) To compare
assessment of esophageal motility, acid sensitivity and mechanical sensitivity in all patients
evaluated in our GI diagnostic laboratory, 2) To evaluate the diagnostic value of our functional
esophageal battery of tests which include HRM, Bernstein and Barostat balloon distention.
Methods: It is our GI Laboratory's practice to perform HRM as well as esophageal barostat
and Bernstein tests, where tolerated, for all patients referred for upper GI complaints. Charts
for 54 consecutive patients were reviewed for patients who received HRM (Sierra Scientific
Instruments) plus provocative tests. Presenting symptoms, HRM results, and mechanical
and chemical sensitivity results are summarized. Results: Patients presented to the GI Lab
with one or more symptoms: Chest pain (54%), Heartburn (30%), Reflux (26%), Regurgita-
tion (26%), dysphagia (24%) and cough (22%). All patients underwent HRM: 69% of
patients were able to tolerate esophageal barostat balloon distention and 70% tolerated
Bernstein acid infusion. Results are summarized in Table 1. Summary and Conclusions: 1)
Enhanced sensitivity of HRM allowed detection of a large percentage of patients with an
LES abnormality (57%); 2) 44% had esophageal sensitivity to balloon distention, acid
perfusion or both; 3) Of the 22% of patients with a normal HRM, 83% of these were sensitive
to chemical and/or mechanical stimuli; 4) Sensitivity testing reveals sensory abnormalities
that are relevant to the patient's esophageal complaints.
Table 1: HRM and Sensitivity Results
S1958
Ineffective Oesophageal Body Motility and Transit and Symptom Perception in
Gastroesophageal Reflux Disease Patients
Upendra Marreddy, Etsuro Yazaki, David F. Evans, Keshava Mannur, Andrew Jenkinson
Introduction: Non-specific motility abnormalities of oesophagus has been claimed to underlie
prolonged acid clearance by affecting oesophageal emptying. Patients perceive only a minority
of the reflux episodes detected by intraluminal monitoring. Aims and Methods: 36 patients
with typical symptoms of gastro-esophageal reflux underwent standard manometry and 24-
hour impedance-pH, monitoring. 21 patients who had at least one symptomatic reflux
episode, presence of non-specific manometric abnormalities, volume clearance and acid
clearance and the characteristics of symptomatic and asymptomatic reflux episodes were
compared. Results: Manometry revealed no characteristic pathological motility patterns;
however, 7 of the 21 patients had non-specific body motility abnormalities. Repetitive
contractions in two, low and high amplitude of contractions in three each, and six patients
had of incomplete propagation of the peristaltic wave with simultaneous contractions. The
mean bolus transit time was normal in both supine and erect posture but the acid clearance
time however, was prolonged in both supine and erect postures in 5 of the 7 patients who
had nonspecific abnormalities.1501 reflux episodes were detected in these 36 patients; they
reported 292 symptoms, of those 141 symptoms correlated to reflux events. Symptoms,
which correlated with reflux episodes, were predominantly Heartburn and regurgitation,
chest pain correlated with reflux episodes only on twelve occasions. Compared with asympto-
matic episodes, symptomatic episodes were associated with a larger pH drop (p<0.001),
lower nadir pH (p<0.05), and higher proximal extent (p<0.001). Symptomatic reflux episodes
had a relatively longer volume and acid clearance time (p<0.05 and p<0.002). Symptomatic
episodes were preceded by a higher oesophageal cumulative acid exposure time (p<0.05).
Purely gas reflux episodes were symptomatic only in minority of cases, half of them had a
recoded drop in pH by <0.5 units. Conclusion: GORD patients who had Non-specific
manometric abnormalities had delayed chemical but not bolus clearance. Heartburn and
regurgitation are more likely to be experienced by the patients when the pH drop is large,
proximal migration of the refluxate is high, and bolus and acid clearance from the oesophagus
is delayed. References : Sifrim et al; Relevance of ineffective oesophageal motility during
oesophageal acid clearance. Gut. 2003 Jun;52(6):784-90 Shay S, et al. 24 hr MII-pH mon-
itoring: A multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol
2004. doi: 10.1111/j.1572-0241.2004.04172.x
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S1959
PPI Therapy Does Not Decrease Postprandial Reflux: An Analysis of Two
Hour Postprandial Impedance and pH Recordings
Wojciech Blonski, Marcelo F. Vela, Donald O. Castell
Background: Combined multichannel intraluminal impedance and pH (MII-pH) identifies
acid and non-acid reflux episodes. Postprandially, particularly during treatment with PPI,
reflux becomes predominantly non-acid. The aim of this study was to assess and compare
reflux frequency between prolonged MII-pH (18-20 hrs) and the 2-hr postprandial interval
in patients on and off PPI therapy. Materials and methods: We analyzed MII-pH studies
performed in 110 patients (48 women, mean age 49.9 yrs) monitored on (n=70) or off (n=
40) PPI therapy. Analyzed parameters included number of acid (AR), non-acid (NAR) and
total (AR and NAR) reflux episodes per hour (ep/hr), shown in Table below. Results: Table
below provides the mean numbers (± SE) of reflux episodes per hour in analyzed groups.
Patients on PPI therapy had significantly higher (p<0.0001) mean number of NAR ep/hr
during the total monitoring and 2-hr postprandial interval than those off PPI therapy. On
the other hand, patients off PPI therapy had a significantly higher mean number of AR ep/
hr during the total monitoring (p<0.0001) and 2-hr postprandial interval (p=0.0002)than
those on PPI therapy. The total number of reflux ep/hr did not differ between patients on
and off therapy. Conslusions: The total number of reflux episodes increases during postpran-
dial period irrespective of gastric acid suppressive therapy. In patients on PPI therapy
postprandial reflux is predominantly non-acid. PPI therapy does not decrease postprandial
reflux; it simply changes the acid content and pH level.
Table: The distribution of mean numbers of reflux episodes per hour in patients on and off
PPI therapy.
* p-value: comparisons total monitoring vs. 2- hr postprandial **p-value: comparisons acid
vs. non-acid reflux ep/hr
S1960
24 Hour MII-pH Testing On Patients Both On and Off PPI Therapy with
Atypical GERD Symptoms of Cough and Throat Clearing: 24 Hour pH-
Impedance Monitoring in Reflux Realted Cough: Characterization and
Symptom Association Analysis
Anthony A. Starpoli, David Ulrich, Ramani Rangavajhula, Vasco Eguia, Nicholas Gualtieri
Introduction: The role of acid versus non-acid reflux and its relation to atypical symptoms
such as cough and throat clearing in patients on or off PPI medications is not well character-
ized. The aim of this study was to further characterize and compare atypical symptoms of
cough and throat clearing suspected related to esophageal reflux in a patient population
both on and off medications. Methods: Concurrent pH and impedance recordings (MII pH
Sleuth, Sandhill) were performed on 74 patients complaining of suspected GERD related
symptoms either on or off PPI therapy. Reflux events were detected by intraluminal impedance
monitor and characterized as acid or nonacid and correlated to patient symptom diary using
both Symptom Index and Symptom Associated Probability scores. Results: Seventy-four
patients (38 (52%) females and 34 (47%) males with 38 patients on daily PPI therapy and
34 patients off daily anti-acid treatment) underwent 24 hour combined MII-pH monitoring.
Seventy-two patients recorded symptoms during the study day and 2 patients had no
symptoms during testing. Twenty-six patients complained of atypical symptoms of cough
or throat clearing. In the 38 patients on PPI therapy 17 had symptoms of cough or throat
clearing. Conclusions: Nonacid reflux plays a significant role in reflux related cough and
should be pursued.
SAP and SI for Cough/Throat Clearing
S1961
Wireless 48-Hr pH Monitoring Is Not Superior to 24-Hr pH Monitoring
Combined with Upper Endoscopy for the Detection of Gastro-Esophageal
Reflux Disease
P. J. De jonge, D. J. Bac, I. Leeuwenburgh, R. J. Ouwendijk, A. J. Van tilburg, M. E. Van
leerdam, E. J. Kuipers, P. D. Siersema
Background: One of the limitations of conventional 24-hr pH monitoring is the risk of false-
negative results due to day-to-day variability in gastro-esophageal reflux patterns. Wireless
48-hr pH recording (BRAVO; Medtronic, Minneapolis, MN) may improve the detection of
gastro-esophageal reflux disease (GERD). Objective: To study day-to-day variability in acid
reflux patterns using the BRAVO pH system. Methods: Patients with symptomatic gastroeso-
phageal reflux disease (GERD) underwent upper endoscopy and subsequent placement of
a BRAVO pH capsule. During endoscopy the presence of reflux esophagitis (RE) was graded
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according to the LA classification. The pH capsule was deployed 6 cm above the squamo-
columnar junction. All antisecretory medications were stopped at least 7 days prior to
placement. During monitoring, patients were encouraged to resume their daily routine of
meals and activity. Day-to-day variation in abnormal gastro-esophageal acid exposure was
studied using the DeMeester score (DMS) (threshold: >14.7) and total % of time pH<4
(threshold: >4.2%). Results: A total of 34 patients underwent pH monitoring (54% male,
mean age ± SD: 45 ± 13 yr). Successful 48-hr pH monitoring was performed in 28 (83%)
patients, while early capsule dislodgement occurred in 6 (17%) patients. In the first 48
hours after capsule attachment, some patients experienced minor symptoms of foreign body
sensation (n=20 [71%]) and chest discomfort (n=2 [7%]), whereas 1 patient had severe
chest pain (4%). Symptoms disappeared over a period of maximum 5 days in all patients.
Of the 28 studies performed, 22 (79%) patients had a positive DMS, of whom 4 (14%)
were positive on day 1 only, 2 (7%) on day 2 only and 16 (57%) on both days. With regard
to the % of time that pH was <4, 23 (82%) patients were positive. Three (11%) patients
were positive on day 1 only, 4 (14%) on day 2 only and 16 (57%) on both days. All 4
patients who were positive on day 2 only also had endoscopic evidence of RE. In 7/18
(38%) patients with RE, pathologic reflux was detected on both days, 4/18 (22%) were
positive on day 1 only and 3/18 (16%) were negative on both days. Of all patients with
GERD symptoms but without RE, 6/10 (60%) were positive on both days, 2/10 (20%) were
positive on day 1 only and 2/10 (20%) were negative on both days. Conclusion: Wireless
48-hr pH monitoring may not increase the detection rate of pathologic reflux in this group
of patients with GERD as compared to 24-hr pH monitoring combined with upper endoscopy.
Nonetheless, comfort for patients may be an argument to perform wireless 48-hr pH mon-
itoring and not conventional 24-hr pH monitoring.
S1962
Presentation and Outcomes of Patients with Non-Acid Reflux Disease
Diagnosed By MII-pH Testing
Ashish Malhotra, James W. Freston, Khalid Aziz
Background: The role of acid in the pathophysiology of gastroesophageal reflux disease is
well accepted. The role, if any, of non-acid reflux disease (NARD) is much debated. To
date, little is published on the outcomes of patients diagnosed with NARD. We present a
case series to report outcomes of patients diagnosed with NARD on Combined pH-Impedance
testing (MII-pH). Setting: John Dempsey Hospital is a university-based referral center serving
a large suburban area of central Connecticut. Methods: Fifty consecutive patients referred
for evaluation of atypical manifestations presumed to be due to GERD were studied. All
had failed to respond to standard anti-secretory therapy. The MII-pH technique confirmed
or rejected the diagnosis of NARD. MII-pH criteria for acid, non-acid or gas reflux were
those of Sifrim, Castell et al; Gastro-oesophageal reflux monitoring: review and consensus
report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024-
1031. Patients were studied on or off PPI therapy depending upon the question posed by
the referring physician. If the question was “Does the patient have GERD?” testing was done
while off medication. Medication was continued during testing if the question was “Why is
there an incomplete response to PPI in this patient with GERD?” or “Is the extra-esophageal
symptom due to GERD? Results: Out of 50 patients studied 10/50 (20%) had NARD and
1/50 (2%) had both acid and non-acid reflux. Of these, 5/11 (45.4%) patients presented
with upper aero-digestive symptoms like hoarseness, wheezing, cough etc., 1/11 (9.1%)
presented with non-cardiac chest pain, and 5/11 (45.4%) presented with miscellaneous
symptoms like epigastric pain, throat or facial pain, tongue burning etc. Only, 2/11 (18.2%)
were found to have a motility disorder yet 5/11 (45.4%) showed at least a partial subjective
response to prokinetic agents. 4/11 (27.3%) were referred for surgery. Of these, 2 patients
had improvement in symptoms after modified Nissen fundoplication and jejunostomy
respectively, 1 declined surgery and 1 was lost to follow-up. Interestingly, 2/11 (18.2%)
improved with non-pharmacologic, non-surgical interventions like voice counseling and
speech therapy. Of note, 8/11 (72.7%) had undergone prior upper endoscopy which was
normal in 3/11 (27.3%) and 5/11 (45.4%) had had prior ENT evaluations which was normal
in 2/11 (18.2%). Conclusions: MII-pH testing helps establish the diagnosis of NARD in
these referral patients. Though the management gold standard for NARD is yet to be
discovered; some of these patients may benefit from prokinetic agents and others from voice
counseling, speech therapy or surgery.
S1963
Persistent Symptoms On PPI Therapy: A Comparison of Patients with Only
Non-Acid Reflux Versus Those with Combined Acid and Non-Acid Reflux
Neeraj Sharma, Amit Agrawal, Marcelo F. Vela, Donald O. Castell
Background: Combined multichannel intraluminal impedance-pH (MII-pH) testing allows
for the identification of non-acid reflux. Persistent symptoms despite PPI therapy may be
due to non-acid or acid reflux, or may not be due to reflux at all. Aim: To compare symptom
profiles of patients with non-acid reflux alone versus patients with both acid and non-acid
reflux. Methods: A retrospective review of the last 200 consecutive patients undergoing
MII-pH on PPI therapy was performed. Patients were divided into 2 groups based on the
acidity of their reflux episodes: non-acid alone and mixed reflux (acid and non-acid). Chi-
square was used to compare the two groups for (a) percentage of patients with each symptom
and (b) percentage of patients with a positive symptom index (SI) for each symptom. Results:
Of 200 consecutive patients, 100 had only non-acid reflux episodes, and 100 had mixed
acid and non-acid reflux episodes. Figures 1&2 summarize group comparisons.Conclusions:
In patients with persistent symptoms on twice daily PPI therapy, 50% had non-acid reflux
alone and 50% had mixed reflux. Symptom profiles and SI positivity were similar for both
groups, except for heartburn, which was experienced less frequently and with a lower
percentage of SI positivity in patients with non-acid reflux alone.
S1964
Newly-Designed PCR Study Has Revealed One Third of MALT Lymphoma
Cases Doubly Positive to Helicobacter Heilmannii-Like Organism and HP in
Japan
Masahiko Nakamura, Hidenori Matsui, Somay Y. Murayama, Chihiro Aikawa, Yukie
Sekiya, Hiroshi Serizawa, Hidekazu Suzuki, Masayuki Suzuki, Shinichi Takahashi,
Toshifumi Hibi, Kanji Tsuchimoto
As to the pathogenesis of the MALT lymphoma, not only Helicobacter pylori (Hp) but H.
heilmannii (Hh) infection has been reported to be closely related mainly from the pathological
analysis of human cases, while recent PCR method has become very sensitive and the results
should be reexamined. Thus, the present study was undertaken to clarify the infection of
H. heilmannii-like organism (HHLO), which includes Hh and H. suis (Hs), and Hp in 233
cases suffering from various kinds of upper gastrointestinal diseases including gastritis,
gastric ulcer, duodenal ulcer, gastric polyp and MALT lymphoma. The PCR analysis was
performed using extracted DNA and newly designed 16S rDNA for Hp and HHLO. In
addition, the selective PCR analysis of Hp, Hh, Hs and H. felis (Hf) was also performed to
the HHLO positive cases by the urease gene. The localization of the Hh and Hp bacilli was
identified by the in situ hybridization. As a result, out of 12 MALT lymphoma cases 4 cases
were positive to Hp, 5 positive to HHLO and among them 4 cases were doubly positive to
HHLO and Hp. By Fisher's exact test, HHLO infection as well as Hp and HHLO co-nfection
was significantly related to the MALT lymphoma. By the analysis of urease gene, 4 cases
were found to belong to Hs infection among 9 HHLO positive patients, while other cases
were not identified to either Hh, Hs or Hf. By the in situ hybridization method, the Hh was
recognized near the surface epithelial cells and fundic glandular cells including parietal cells,
which coincided well with our previous infection study using C57BL/6 mice. On the other
hand, 129 cases were positive to Hp and only 4 cases were positive to HHLO out of 221
non-MALT lymphoma cases. In conclusion, HHLO and Hp coinfection has shown to be
closely related to MALT lymphoma in Japanese cases.
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A Simple and Novel Virulence Genes Based Multiplex PCR Assay for
Diagnosing and Molecular Typing Helicobacter pylori Infection from Human
Gastric Biopsies
Santosh K. Tiwari, Aleem A. Khan, Manoj Gopi, Shakeel Ahmed, Mohammed A. Habeeb,
Chittor M. Habibullah
Aim Gastric injury among the H. pylori infected largely depends upon combination of host
and bacterial factors. Virulence factors identified as markers of ulcerogenic/carcinogenic
strains such as the genes of the cag-PAI, vacuolating associated cytotoxin gene A (vacA),
and Helicobacter pylori restriction Endonuclease-replacing gene A (hrgA) are not present in
all strains/show different allelic variations. Determination of the specific genotypes of H.
pylori associated with each disease type would enable the physicians to identify patients at
increased risk of developing one or the other form of overt diseases at an early stage. Herein,
we describe a novel, fast, specific, multiplex PCR assay by which the presence or absence
of five potential virulence genes viz., cagA, cagE, and cagT, signal sequence (s1 and s2) of
vacA, and presence or absence of a hrgA gene can be detected in a single reaction. Methods
Fresh gastric biopsy samples 1 from the antrum, 1 from incisura, and 1 from the body of
the stomach were collected during endoscopy from 82 patients [duodenal ulcers (n=28),
pre-pyloric ulcers (n=12), peptic ulcers (n=2), GERD (n=2) gastric adenocarcinoma (n=14)
and non-ulcer dyspepsia (n=24)] for rapid urease test, DNA analysis, and histologic examina-
tion respectively. Chromosomal DNA was extracted directly from the gastric biopsies of all
the subjects by method described by Chattopadhyay S et al J Clin Microbiol 2004. 1microlitre
of the supernatant was used for the amplification of the cagA, cagE, cagT, vacA, hrgA was
carried out in a single tube using an optimized thermal reaction. Results Genotypic data
showed presence of all the five target genes in 81.7% and deletions in one or more loci
among 18.3% cases. Genotype cagT+ve/hrgA+ve/cagA+ve/cagE+ve/vacAs1+ve was more pre-
dominant in our study population (67.07%). hrgA, cagT, cagE, and cagA genes were present
in 100%, 92.7%, 85.4%, 81.7% of the subjects respectively. The vacAs1 subtype had higher
prevalence frequency in patients with overt gastrointestinal disease (78.57%) than with
GERD and NUD (50%). Conclusion This study showed that combinations of cagT+ve/
hrgA+ve/cagA+ve/cagE+ve/vacAs1+ve genotype have a higher differentiating and predictive
value for the development of severe form of disease manifestations, compared to single
virulence factor alone. The multiplex PCR assay developed herein can serve as an effective
tool for genotyping H. pylori from large population and can be explored to gain insights at
the genotypic variability exhibited by this pathogen.
S1966
NO Relationship Between the Regional Prevalence of Helicobacter pylori
Infection and the Incidence of Esophageal Adenocarcinoma
Mark Van blankenstein, Caspar W. Looman, Anneke J. Van vuuren, Martine Ouwendijk,
Peter D. Siersema, Jan W. Coebergh, Ernst J. Kuipers
Case-control studies have suggested that colonization with H. pylori may provide protection
against the incidence of adenocarcinoma of the esophagus (ACE). We investigated whether
an inverse relationship between the prevalence of H. pylori colonization and the incidence
rates of ACE could be demonstrated in the populations of 4 of 9 cancer registry regions of
The Netherlands with significantly differing ACE incidence rates, see table. The prevalence
of H. pylori colonization was tested serologically in 1600 blood donors, 400 from each of
the 4 cancer registry regions, divided into five 10-year age-groups of 80 donors between
the ages of 18 to 68 years. Although immigrants comprise about 10% of the population,
both donors and ACE patients are only found amongst the native born Dutch population.
There were clear age specific gradients in the prevalence of H. pylori colonization, compatible
with a cohort effect; however, there were neither significant differences in the overall H.
pylori colonization rates between the 4 regions (p=0.87), nor between the wide variations
(between 4.6 and 13.8% per year) in the observed rising trends in the incidence rates of
ACE in the four regions and their practically identical age specific declining H. pylori
colonization rates (p=0.14). This population based study calls into question the presumed
protective effect of H. pylori colonization against the incidence of ACO.
S1967
Identification of a Highly Immunoreactive 100-Kda Antigen in Jhm-Cap
Enzyme Immunoassay Kit Recognized in Sera of Japanese Patients
Kazuki Yamada, Takahiko Kudo, Tadahiro Orihara, Masumi Okuda, Teruko Nakazawa,
Toshiro Sugiyama
Background and Aims: It has been reported that commercial enzyme immunoassay (EIA)
tests for the infection diagnosis of Helicobacter pylori (H. pylori) have high diagnostic perform-
ances in Western countries. However, their accuracy is greatly reduced when sera from
developing countries, East Asia, and younger subjects are evaluated, and there is little
knowledge about this phenomenon. A serum-based EIA test of Japanese strain-derived high-
molecular-weight proteins (JHM-CAP), prepared by exactly the same procedure as for HM-
CAP EIA, has been developed. We have previously reported that in Japanese children, the
performance of JHM-CAP EIA was statistically better than that of HM-CAP EIA, and the
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high sensitivity of JHM-CAP EIA was due to the presence of a highly immunoreactive 100-
kDa protein, which was absent in HM-CAP EIA. The aim of this study was to identify this 100-
kDa protein contained in the JHM-CAP EIA. Methods: JHM-CAP antigens were separated by
SDS-PAGE, and the gel piece containing 100kDa protein was excised. The 100kDa protein
was in-gel digested by trypsin, and the extracted peptides were analyzed by matrix-associated
laser deposition-ionization time-of-flight (MALDI-TOF) mass spectrometer. We identified
this 100kDa protein by peptide mass fingerprinting (PMF) method. Immunoblotting of the
JHM-CAP and HM-CAP was carried out with diluted serum (from a JHM-CAP-positive adult
patient) before the anti-CagA antibody reaction. Another immunoblotting was also carried
out with the anti-CagA antibody before the diluted serum reaction. Immunoblotting of the
JHM-CAP antigen and the proteins extracted from four H. pylori strains (JHM-CAP EIA kit
was derived from these strains) with anti-CagA antibody were also carried out. Results: By
PMF method, and immunoblot analysis, we identified this highly immunoreactive 100kDa
protein as a part of the CagA protein. The diluted serum almost completely inhibited anti-
CagA antibody binding. However, immunoblottng with diluted serum was slightly inhibited
by anti-CagA antibody. In the immunoblotting of the JHM-CAP antigen and clinically isolated
H. pylori strains, anti-CagA antibody recognized a 100-kDa band in the JHM-CAP antigen,
but it recognized an about 120 kDa band in all the four strains. Conclusions: We identified
this highly immunoreactive 100-kDa protein in JHM-CAP as a part of the H. pylori CagA
protein. And we also presumed that it is cut during the process of protein refinement for
ELISA kit making.
S1968
Seroprevalence of Helicobacter pylori in South Korea
Jeong Y. Yim, Nayoung Kim, Seung H. Choi, Young S. Kim, Kyung R. Cho, Sun S. Kim,
Geom S. Seo, Heung U. Kim, Gwang H. Baik, Chan S. Sin, Sang H. Cho, Byung H. Oh
Background:Helicobacter pylori (H. pylori)-associated gastrointestinal diseases have been
widely recognized. The aims of this study were to investigate the interval change of seroposi-
tivity of H. pylori between 1998 and 2005 in Korea and to find the factors related to H.
pylori infection. Methods: Between January and December of 2005, a total of 15,916 health
check-up subjects (aged≥16 years) from all parts of South Korea responded to the question-
naire, and the prevalence of H. pylori was investigated by measuring anti-H. pylori IgG
antibodies. Subjects were categorized into 3 education levels: low (middle school graduates),
middle (high school graduates or university dropouts), and high (university graduates or
graduates of a postgraduate course). Monthly family income was categorized into 3 groups:
low income (< 3,000 US dollars per month), middle income (3,000 to 10,000 US dollars
per month), and high income (>10,000 US dollars per month). The seropositivity in asympto-
matic subjects (aged ≥ 16 years) was compared with that of 1998, which was surveyed by
the Korean H. pylori Study Group. Results: The overall seropositivity rate (aged ≥ 16 years)
was 56.0%, and 13.9% of seropositive subjects were found to have a history of H. pylori
eradication therapy. Males, subjects from Seoul, and subjects with high education or high
income showed a significantly higher frequency of eradication therapy. Multiple logistic
regression model for relative risk factors for H. pylori in subjects without history of H.
pylori eradication revealed significant associations with gender (male gender), age (old age),
geographic area (province), and economic status (low income).With the exclusion of subjects
who had a history of H. pylori eradication and current gastrointestinal symptoms, the
seropositivity rate of H. pylori became 59.6% in 8,020 subjects. Seroprevalence of H. pylori
was significantly higher in subjects aged 50-59 years, males, low income group, and subjects
from provinces. The seroprevalence in 2005 (59.6%) significantly decreased compared with
that of 1998 (66.9%), and the decrease was significant in subjects aged < 70 years, Seoul
and Gyeonggi province (which is close to Seoul). Conclusions: The seroprevalence of H.
pylori in asymptomatic health check-up subjects in 2005 decreased to 59.6% from 66.9%
in 1998, probably due to the improvement of socioeconomic status and hygiene.
S1969
Prevalence and Risk Factors for Helicobacter pylori Infection in Jiangsu
Province
Shi R. Hua
Ruihua Shi, Shunfu Xu, Hongjie Zhang, Hong Zhu, Xiayue Huang, Xiaoxing Chen, Xueliang
Li, Zhigang Yan, Guoxin Zhang, Yanbing Ding, Guiqian Sun Department of Gastroenterology,
the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China This
work was supported by Grants from 135 Key Disciplines and Lab projection of Jiangsu
Province, China Aims: To investigate the epidemiology and risk factors of H. pylori infection
in areas with high prevalence of gastric cancer in Jiangsu province in China. Methods: We
performed a prospective epidemiological survey of H. pylori infection status in natural
population conducted in Xiangshui and Gaoyou county, Jiangsu Province, China. 1457
individuals were enrolled by random cluster-sampling. Data were collected by face-to-face
interviews using a standard questionnaire. Infection with H. pylori was assessed by 13C-
urea breath test and detection of serum IgG antibodies to mixed H. pylori antigens. Results:
1371 subjects completed questionnaires and H. pylori detection. In total, the prevalence of
H. pylori infection in this cohort was 62.07% (95% confidence interval,). The rate of H.
pylori infection was the highest (67.25%) in persons aged 30~40 years old, and the infection
rate was not related to gender. People with annual family income at 1000~4999 RMB had
the lowest risk of H. pylori infection (53.49%), compared with those people whose annual
family income was below or above that level. Prevalence of H. pylori infection was high in
big size of family. Infection rate of H. pylori was associated with dietary-related factors, such
as times of eating cooked rice and potatoes per week. H. pylori infection rate was associated
with the symptom of vomiting (P=0.0274) and family history of stomach diseases. Surpris-
ingly, compared to non-symptomatic individuals, those people with dyspeptic symptoms
presented a low rate of H. pylori infection. A high rate of H. pylori infection was found in
individuals who washed hands with soap. In addition, no association of H. pylori prevalence
and smoking, drinking was found in the study. By multivariate logistic regression analysis,
family income was independent predictors for H. pylori infection. Conclusions: H. pylori
infection rate in high gastric cancer prevalent areas was correlated with age, size of family,
family income, frequency of eating cooked rice/potatoes, the symptom of vomiting and
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family history of stomach diseases. The relationship between H. pylori infection and source
of drinking water, personal hygiene and eating habits, needs to be further investigated.
S1970
Evaluation and Comparison of Different Non-Invasive New and Well
Established Diagnostic Tests for Diagnosis of H. pylori Infection: How Reliable
Are They in Clinical Practice?
Andreas Leodolter, Osman Amani, Dietmar Zielinski, Michael Vieth, Joachim Labenz
Recent innovation in the field of non-invasive diagnosis of H. pylori included the rapid stool
antigen testing, several new commercial available test systems became available. Conflicting
results about accuracy have inspired us to perform a prospective study to investigate the
major non-invasive testing methods for diagnosis of H. pylori infection. Methods: Prospective
single-centre trail including 110 patients of a general medical department designated for
routine upper GI-endoscopy with collection of biopsies. Patients with previous PPI/antibiotic
treatment or eradication therapy were excluded. Diagnosis of H. pylori infection was based
on histology and RUT. Stool samples of all patients were analyzed using 3 different mono-
clonal rapid stool antigen tests (ImmunoCardSTAT! HpSA, Rapid Hp StAR, helicoCARE
direct) and monoclonal EIA (FemtoLab). Serum antibodies against H. pylori (RIDASCREEN
IgG and IgA) were analyzed and 13C-UBT performed in 73 patients of the included patients.
Results: 39 patients were infected with H. pylori. Discrepancy between histology and RUT
was observed in 6 cases (5%). All three rapid stool antigen tests provided a comparable
accuracy (sensitivity 85%, specificity 94-97%), the EIA provided a higher sensitivity (90%).
Even the sensitivity of the IgG antibody test was comparable (86%) with a lack of specificity
(83%, all positive in the western blot indicating a previous infection). IgA determination
was insufficient (sensitivity 70%, specificity 72%). Sensitivity of the 13C-UBT was unexpected
low (75%). Conclusion: Unlike several previously performed trials non of the non-invasive
tests could provide a sensitivity higher than 90% for diagnosis of H. pylori in our trial,
performed under clinical routine care in a large medical department. The laboratory based
EIA stool antigen test has a the highest accuracy. Unspecified use of medications like PPI
or antibiotics, a common problem in daily practice, might be in part responsible and explain
the difference of a 10% lesser sensitivity compared to other trials.
S1971
Gastric Juice for the Diagnosis of Helicobacter pylori Infection in Patients On
Proton Pump Inhibitors
Javed Yakoob, Shahid Rasool, Zaigham Abbas, Wasim Jafri, Muhammad Islam, Zubair
Ahmad
Background: Proton pump inhibitors (PPI) decrease the diagnostic efficacy of most of the
diagnostic tests for Helicobacter pylori (H. pylori). The aim of this study was to determine
the efficiency of gastric juice polymerase chain reaction (PCR) method for the detection of
H. pylori infection in patients on PPI. Methods: Eighty five consecutive patients with dyspeptic
symptoms attending the endoscopy suite were enrolled in this study. Antrum biopsy speci-
mens were collected at endoscopy for the histology and gastric juice for H. pylori 16S rRNA
PCR. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)
and positive likelihood ratio for gastric juice 16 rRNA PCR were compared against histology
in patients with and without PPI. Results: There were 58 (68%) males and 27(32%) females.
The age range was 17-70 years with a mean age of 36.8 ± 11. 37 (43.5%) patients were
taking PPI. Gastric juice 16S PCR was positive in 53 (62%) patients. Histology showed H.
pylori associated gastritis in 57 (67%) patients. In patients not taking PPI, the sensitivity,
specificity, positive predictive value, negative predictive value, accuracy and positive likeli-
hood ratio for gastric juice PCR were 76%, 93%, 96%, 62%, 81% and 25%, respectively.
In patients on PPI these values were 75%, 64%, 81%, 56%, 62% and 27.1, respectively.
Conclusion: Gastric juice PCR for H. pylori has a low specificity for the diagnosis ofHelicobacter
pylori in patients on PPI, however sensitivity is unaffected.
S1972
Esophageal Bolus Presence During Meals Evaluated By Impedance Manometry:
Normal Values and Inter-Observer Reliability
Daniel Pohl, Mentore Ribolsi, Edoardo Savarino, Bernadette Stutz, Michael Fried, Radu
Tutuian
Introduction: Impedance manometry (MII-EM) is a clinically available tool to evaluate
esophageal function by measuring intraesophageal pressure changes and bolus transit. Tradi-
tionally, the assessment of esophageal function has been based on evaluating esophageal
peristalsis and bolus transit using standardized small amounts liquids in 20-30 seconds time
intervals. This approach though is not a good reproduction of physiologic swallowing during
eating. Aim: To evaluate esophageal bolus presence during a meal in healthy volunteers
using combined MII-EM and to test the reliability of these measurements. Methods: Healthy
volunteers (HV) were evaluated using solid state combined MII-EM catheter with 5 pressure
channels and 5 impedance segments. Bolus presence data were recorded 2, 5, 10, 15 and
20 cm above the lower esophageal sphincter (LES). All volunteers were asked to eat 2 slices
of bread and 200 ml of orange juice in sitting position at their normal pace. Tracings were
reviewed independently by 4 investigators who manually summated, at each impedance
level, the time elapsed between bolus entry and bolus exit (bolus presence time) for each
swallow. The hereby obtained esophageal bolus presence time (EBPT) at each level was
expressed as percentage of total meal duration (MD). Results: Bolus presence data in each
impedance segment recorded from 20 HV (8 f, mean age 28, range 20-44) are summarized
in table 1. We found a very good correlation between the readings of all 4 raters for EBPT
per segment (ICC 0.92-0.95). Females ate the meal slower (meal duration 14.1 ± 6.2 min
vs. 6.9 ± 2.0 min; p<0.002) and had longer total BPT compared to males (total BPT 3.5 ±
1.8 min vs. 2.4 ± 1.0 min; p<0.001). Conclusion: 1. In healthy subjects meal boluses are
present less than 50% of total meal duration in the esophagus. 2. There is a good reliability
between raters in quantifying bolus presence based on MII-EM readings. 3. Gender differences
should be considered when interpreting data from patients with esophageal symptoms.
Esophageal bolus presence time (EBPT) expressed as % of meal duration and Crohnbach
alpha intra-class correlation (ICC) coefficients of the 4 raters
S1973
The Comparision of Intense Sucralfate Therapy with Standard Therapy in
Patients Having Recent Stage Corosive Esophagitis
Yuksel Gumurdulu, A.taner Sunbul, Burhan Ozdil, Banu Kara, Cem kaan Parsak, Gurhan
Sakman, Salih Colakoglu, Hikmet Akkiz
Aim: In recent stage corosive esophagitis, the persentage of strictures is 70-100% by the
standard therapy. Present therapies don not decrease the risk of stricture formation. In this
study we aimed to research the effect of intense sucralfate therapy in stage 3 corosive
esophagitis patients and compare with the standart therapy. Materials and Methods: We
studied 13 patients from endoscopy and general surgery departments between 2004,2006
years in whom stage 2B and 3 corosive esophagitis were diagnosed endoscopically. If there
was a perforation suspition, the patient was asked to drink the mixture of low molecular
weighted opaque substance and sterile isotonic solution and imagined under scopy. The
ones having desertion to diaghrapmatic space were not included to study and followed by
surgically.We grouped the patients as one with 7 patients (3men, 4 woman) and the
other with 6 patients (3 men, 3 woman).The second group received antibiyotics (ampisilin
sulbactam 4x1.5 gr 7 days), high dose proton pump inhibitors (omeprazole 2x40gr) and
steroids and additionally were parenterally hydrated and oral food stopped. The first group
received sucralfate 12x10cc for 3 days additional to the medication of the second group.
After 3 days, between 8 and 24 o'clock 10cc for 2 hours, between 24, 8 o'clock 10 cc for
4 hours sucralfate was given till 21 days completed. Then these patients continue to receive
sucralfate 4x10cc till 45 days. No side effect of sucralfate was seen in the patients.Panendos-
copy was done to all the patients at submission and 21. day, 45. day, 3. mounth, 6. mounth
respectively. The patients were followed between 6 and 12 months in the study. (Table 1)
Results:During the following period only in one patient, narrowness which allowes the
penetration of 9.2 mm endoscopy and did not narrowed more at 3 and 6 months further
was determined. The other 6 patients did not have esophagial strictures. In the second
group narrowness related to strictures was seen in the 5 patients. In 2 ones at one location,
in 2 ones at two different locations and in 2 patients at multiple locations esophagial
narrowness were seen. The patients whose narrowness were formed, were followed by
dilatation therapy. The two patients who did not respond to dilatation therapy, had operated.
Sucralfate was not beneficial to the severe gastric lesions of the patients. All the ones having
gastric lesions fom two groups were operated.
Table 1 :Our patients features
S1974
Dysphagia and Thyroid Disease
Hassan Borghei, Renjy Vattasseril, Ambreen Siddiquie, Vishal Datta, Vincent Notar-
francesco, Jonathan T. Simon, Farida Khan, Maurice A. Cerulli
Background-Thyroid disorders are known to be associated with GI tract dysfunction. The
role of thyroid function tests (TFTs) is well established in chronic diarrhea and constipation
however, the effect of thyroid malfunction on esophageal motility is not well known nor
has it been extensively studied. On review of medical literature in English language/ Human
subjects/ on esophageal motor dysfunction and thyroid disorders from 1966 to 2006 only
case reports were found. We hypothesize that if thyroid function plays an important role
in intestinal motility then it may be important in esophageal motility disorders as well.
Material & Methods-Adult patients (pts) with established thyroid disease (hypo or hyper
thyroidism without obstructing goiters or tumors), along with matched controls, in an
Endocrine practice and in a medical clinic were consented and given an IRB approved
questionnaire to evaluate the prevalence of subjective esophageal motility disorder symptoms
of dysphagia, heart burn and non-cardiac chest pain (ncCP). Consented patients charts were
reviewed for TFTs, other medical history and medications. Pts with history of neuro-muscular
disorders and stroke were excluded. Results -70 pts (46 with thyroid disease and 24 controls)
agreed to participate in the study.19 out of 46 pts in the thyroid group had more than 2
episodes of dysphagia per week verses (vs.) 1 out of 24 controls (p<0.009). 10 out of 26
hypothyroid pts had more than 2 episodes of dysphagia per week vs. 1 out of 24 controls
(p<0.006). 9 out of 20 hyperthyroid pts experienced dysphagia more than twice a week vs.
1 out of 24 controls (p<0.003). 10 out of 26 hypothyroid pts had heartburn vs. 8 out of
24 controls (p<0.8). 8 out of 20 hyperthyroid pts had heartburn vs. 8 out of 24 controls
(p<0.8). 7 out of 26 hypothyroid pts had ncCP vs. 4 out of 24 controls (p<0.5). 4 out of
20 hyperthyroid pts had ncCP vs. 4 out of 24 controls (p<1.0). The combination of ncCP
and heartburn did not produce a significant difference among the groups. 70% of Hispanic
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pts with thyroid disease reported dysphagia compared to 38% of blacks and 16% of whites.
Conclusion- A significantly higher percentage of thyroid pts experience dysphagia compared
to the control group. As there was no significant difference in the incidence of heartburn
and ncCP between the groups, the higher prevalence of dysphagia in pts with thyroid disease
does not seem to be related to gastroesophageal reflux disease. In addition race and ethnicity
may play a role in the perception of dysphagia. Our research warrants further evaluation
of esophageal motility in pts with thyroid disease, which is part of our ongoing project.
S1975
Oral Fluticasone Proprionate for the Treatment of Symptomatic Esophageal
Lichen Planus: A Case Series
Samir C. Grover, Jennifer Shin, Ramasamy Saravanan, Sarah Cho, Patarapong
Kamalaporn, Gary R. May, Gabor Kandel, Paul P. Kortan, Norman Marcon
BACKGROUND: Lichen planus, a disorder of the squamous epithelium of unknown etiology,
rarely involves the esophagus symptomatically, but can be a difficult to treat cause of
dysphagia and odynophagia. The literature describes treatment of esophageal lichen planus
with proton pump inhibitors, systemic and intralesional corticosteroids, systemic immunos-
uppressants and periodic dilatation of strictures. Fluticasone proprionate, when administered
orally, has found a role in the management of esophageal inflammatory disorders such as
eosinophilic esophagitis, but has not been described previously in the treatment of lichen
planus esophagitis. METHODS: We report our center's experience in the treatment of
esophageal lichen planus with fluticasone proprionate delivered orally. Three patients with
esophageal lichen planus were identified from a chart review. All three patients were female
and had evidence of concomitant oral lichen planus; one patient had evidence of vulvar
lichen planus, and none had evidence of dermal involvement. The mean age at presentation
was 59.7 years. All three patients were symptomatic for dysphagia to solids and one patient
had presented to hospital with a food bolus obstruction. All three patients had pathology
showing features of lichen planus in the esophagus including a lymphocytic inflitrate with
basal epithelium degeneration. On endoscopy, all three patients had evidence of proximal
erosive esophagitis. Two patients had narrow strictures of the proximal esophagus. All three
patients had been tried on oral steroids prior to referral. RESULTS: Patients were treated
with fluticasone proprionate at a dose of 1000 micrograms daily administered orally in two
divided doses. Two patients developed complete resolution of dysphagia and the third
patient noted an improvement in dysphagia symptoms after only two weeks of therapy.
One patient had complete endoscopic remission that persisted after eight months of therapy.
One patient was managed with bougie dilation of the esophagus at the time of diagnosis,
but remained asymptomatic after. CONCLUSIONS: Symptomatic lichen planus esophagitis
can be effectively treated with oral fluticasone proprionate. As fluticasone carries a lesser
side effect profile than alternative therapy, including systemic corticosteroids and immunos-
uppressants, it may be a useful management option in these patients.
S1976
Fatal Complications of Paraesophageal Hiatal Hernias Are Rare: A Population
Based Analysis
Jarmo A. Salo, Tuomo K. Rantanen, Jari V. Räsänen, Eero I. Sihvo
Background: Due to classical assumption most paraesophageal hiatal hernias (PEHH) are
considered to be linked with life-threatening complications making surgical treatment almost
invariably necessary. Previous conception is based on smaller patient series and no population
based analysis about fatal outcome of PEHH exists. Methods: All death certificates in which
esophagitis, esophageal ulcer, stricture, or hiatus hernia were mentioned between 1987 and
2001 in Finland (population ca. 5 million) were obtained from administrative databases.
The medical records of these 333 possible patients were analyzed. Results: Hospitals had
782 conservative or operative treatment periods (633 patients) (annually mean 52, 36-79)
for PEHH. Of these, 563 (89%) had 512 open, 51 laparoscopic procedures. Twenty eight
patients died (annual mortality: 0.3/1 000 000) 17 after conservative treatment and 11 after
emergency operation (operative mortality 2.0%). The most common agonal symptoms were
vomiting, abdominal pain, and hematemesis. In the conservatively treated group the cause
of death was incarceration in 24, gastric ulcer in 2, and volvolus in 2 patients. The diagnosis
of complicated PEHH was made during lifetime in 23 patients (82%). No asymptomatic
patients or patients who underwent elective surgery died. Conclusions: Contrary to earlier
assumption fatal nonreflux complications of PEHH are rare and directed to symptomatic
patients The operative mortality is much lower than earlier estimated and connected with
emergency operations on symptomatic patients. This should be taken into account in operat-
ive indications and patient clarification.
S1977
Peeling Esophageal Mucosa: Causes and Management
Vijay Poreddy, Johanne Rigaux, Firas H. Al-kawas
INTRODUCTION: Peeling esophageal mucosa (PEM) is endoscopically defined as esophageal
mucosa peeling away when biopsies are performed. It is rarely observed during evaluation
of chronic dysphagia. CASES: We report three cases of PEM. All were females with dysphagia
and previous dilations. Endoscopic findings were similar; PEM, multiple webs, and proximal
strictures. Immunofluorescence confirmed cicatricial pemphigoid in one case. Histopathology
suggested a bullous disease in another case. No biopsies showed viral infection or eosinophilic
infiltration. Two patients responded to steroids. One patient had dilation alone using Savary
dilator up to 33F. DISCUSSION: PEM is rare and can be puzzling to the endoscopist. In
our patients, it was associated with proximal strictures and multiple webs. Differential
diagnosis includes pemphigus vulgaris, cicatricial pemphigoid, lichen planus, and chronic
esophagitis dissecans. Esophageal involvement is rare and is predominantly seen in women.
Mucocutaneous lesions can be absent. PEM with “crepe-paper” appearance has been described
in eosinophilic esophagitis. Diagnosis is usually obtained by histopathology and/or immuno-
fluorescence. Repeat biopsies, as in two of our patients may be necessary for diagnosis.
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CONCLUSIONS: PEM is rare and may represent autoimmune disease. Other yet “undefined”
etiologies may also be a cause. All patients were women with dysphagia and associated
proximal strictures and multiple webs. Definitive diagnosis can be difficult and may require
repeated samplings. Steroids are effective and should be tried when a high index of suspicion
for an autoimmune disease is present. Careful dilation may be performed due to higher risk
of perforation.
S1978
Dysphagia-Causing Versus Incidental Inlet Patch in the Proximal Esophagus
Deborah Giusto, David Cimbaluk, Shriram Jakate
Background: Heterotopic gastric mucosa in the proximal esophagus or inlet patch is consid-
ered to be a common congenital anomaly occurring in up to 10% of the population. Its
true prevalence on upper endoscopy is difficult to determine as it is entirely bypassed during
entry and often overlooked and ignored during withdrawal of the scope. Furthermore, when
endoscopically noticed, it is rarely systematically described or adequately biopsied with the
presumption that these lesions are incidental and asymptomatic. We describe three patients
with progressive dysphagia where an inlet patch appeared to be the only symptom-causing
abnormality. These dysphagia-causing inlet patches are endoscopically and histologically
compared with incidental lesions. Design: Three patients (males, ages 10, 11 and 13), being
investigated for gradually increasing dysphagia, underwent upper endoscopy (EGD) and
biopsies of the duodenum, stomach, distal esophagus and inlet patch in the upper esophagus.
EGD and histological features were reviewed to determine the cause of dysphagia. A control
population of fourteen other patients (ages 3-66, 11 males and 3 females) with incidental
inlet patches who had EGD for various gastrointestinal symptoms were also reviewed.
Dysphagia-causing and incidental inlet patches were compared. Results: All three patients
with dysphagia had endoscopically large (between 2.0 and 3.5 cm) inlet patches (one had
two separate patches, 2.0 and 1.0 cm); mixed gastric fundal and antral type mucosa and
moderate to severe chronic inflammation. None had H. pylori, intestinal metaplasia or
dysplasia in the inlet patches. There were no strictures or webs and no other causes for
dysphagia were found such as eosinophilic or reflux esophagitis. The duodenal, gastric and
distal esophageal biopsies were unremarkable. The control population showed smaller (<2
cm) sized inlet patches, often single-type mucosa (7/14 cardia, 3/14 antrum, 1/14 fundus
and mixed cardia and antrum 3/14) and either none (4/14) or mild inflammation (10/
14). Conclusions: Inlet patches can occasionally cause dysphagia in young patients. These
dysphagia-causing lesions are >2 cm, sometimes multiple, usually contain mixed gastric
type mucosa including gastric fundus and show moderate to severe chronic inflammation.
In symptomatic patients, it is recommended that the endoscopists look for an inlet patch,
carefully describe its endoscopic features, document the size, and adequately sample the
lesion. Other causes of dysphagia should be excluded before associating the symptom with
an inlet patch.
S1979
Hydraulic Dilatation in the Treatment of Achalasia- A 5 Year Tertiary Referral
Centre Experience
Neil Rajoriya, Jennifer Crichton, Shona Thomson, Cate Buchanan, Ruth Gillespie, Robert
C. Heading, John F. Mackenzie
BACKGROUND: Achalasia is a neuromuscular disorder of the esophagus characterized by:
reduced peristalsis, the inability of Lower Esophageal sphincter to relax in response to
swallowing. Treatment options include: Dilatation, Myotomy & Botulinum toxin. AIM: The
aim of the study was to assess the efficacy and complication rates in patients receiving
hydraulic Rigiflex dilatations for Achalasia in our centre. METHODS: A retrospective case-
note analysis was carried out over a 5 year period (January 2000-2005). Investigations
including: Endoscopy, Manometry, 24hr pH studies and Gastrograffin swallows were
reviewed. RESULTS: N=23. The mean age was 49(+/-16). PRE-DILATATION: 18 had weight
loss, 16 dysphagia, 5 regurgitation, 4 food bolus obstruction and 2 chest pain. The median
duration of illness was 14 months (range 1 month-15 years). 21% had previous Myotomy
and 26% had previous dilatation. 82% had an Endoscopy (95% having Cardial biopsies).
The mean LES pressure was 26(+/-10.2) mmHg and 11% had a raised DeMeester Score.
80% had “aperistalsis” on manometry. The mean diameter of oesophagus was 4.6cm (+/-
1.2cm) on imaging. 26 % of patients had a documented history of Auto-Immune diseases.
DILATATION: The median number of dilatations was 1 (range 1-2). 9% needed Endoscopic
guidance. 44% were dilated to 30cm, 52% to 35mm and 4% to 40mm. 13% had a step-
wise approach (1 session of 30mm then repeat session in 4-6 weeks later to 35mm). 17%
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had complications (1 respiratory arrest post-sedation, 3 perforations settling with in-patient
conservative treatment). 83% of patients were discharged within 12 hours. POST DILATA-
TION: 78% reported symptom improvement. 61 % had full resolution of symptoms with
no relapse. 86% of patient's weight increased at 2 months (median weight increase 3kg
(range 2-20kg). 39% had a relapse in symptoms (of the relapsing patients: 45% relapsed
within 2 months and 100% within 6 months). Of the relapsing patients (n=9), 2 had repeat
dilatations (median time to rpt dilatation 5.5 months (range 5-6 months), and 7 were referred
for Heller's Myotomy. 14% of patients reported an increase in symptoms of GORD. 52%
of patients were started on PPI post-dilatation. The mean size of oesophagus post dilatation
was 4.4cm (+/-1.4cm). The mean follow-up of patients has been 16 months (+/-14.8).
CONCLUSION: Hydraulic dilatation offers a high rate of symptom improvement and weight
gain. In our cohort, size of oesophagus pre-dilatation did not affect symptom response,
relapse rate or outcome post-procedure. Dilatations above 35mm should not be attempted
due to high risk of perforation.
S1980
Hypermethylation of Tachykinin-1 Is a Common and Early Event in Human
Esophageal Cancer, and Associated with Poor Prognosis in Esophageal
Squamous Cell Carcinoma
Zhe Jin, Yulan Cheng, Yuriko Mori, Jian Yang, Carmit Mantzur, Bogdan C. Paun, James P.
Hamilton, Fumiaki Sato, Tetsuo Ito, Takatsugu Kan, Suna Wang, Stefan David, Alexandru
Olaru, Rachana Agarwal, John M. Abraham, Stephen J. Meltzer
The tachykinin-1 (TAC1) gene has been mapped to chromosome 7q21-22, which frequently
shows loss of heterozygosity in esophageal adenocarcinoma (EAC). Our aim was to investigate
whether and at what stage promoter hypermethylation of TAC1 is involved in human
esophageal carcinogenesis. Hypermethylation of the TAC1 promoter was examined by real-
time methylation-specific PCR (MSP) in 260 human esophageal tissues of differing histologies.
Real-time RT-PCR and MSP were also performed on esophageal cancer cell lines before and
after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC). Hypermethylation of TAC1 showed
highly discriminative receiver-operator characteristic curve profiles, which clearly distingu-
ished esophageal squamous cell carcinoma (ESCC) and EAC from normal esophagi (NE)
(p<0.0001). Both the frequency and the quantitative normalized methylation value (NMV)
of TAC1 methylation were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's
(D), EAC, and ESCC than in NE (p<0.01). The frequency of TAC1 hypermethylation
increased early and incrementally in the neoplastic progression cascade, from 7.5% in NE
to55.6% in BE from patients with Barrett's alone to57.5% in D and finally to 61.2% in patients
with frank adenocarcinoma. Twelve (50%) of 24 ESCCs exhibited TAC1 hypermethylation.
Overall patient survival correlated with TAC1 methylation status in ESCC patients (mean
22 months vs. 110 months, p=0.0102, Log-rank test), but not in EAC patients. Treatment
of KYSE220 ESCC and BIC EAC cells with 5-Aza-dC In Vitro reduced TAC1 methylation
and increased TAC1 mRNA expression. Promoter hypermethylation of TAC1 is a common
event in human esophageal carcinomas and occurs early during Barrett's-associated eso-
phageal neoplastic progression, and is associated with a poor prognosis in ESCC.
S1981
Genomic Instability in Single Non-Dysplastic Biopsies Distinguishes Crohn's
Disease Progressors from Nonprogressors
Bo-in Lee, Megan Settle, Lisa M. Yerian, Teresa A. Brentnall, Peter S. Rabinovitch, Mary P.
Bronner
Background: Patients with Crohn's disease (CD) are at increased risk of intestinal cancer,
requiring life-long surveillance. Our previous studies have identified widespread genomic
biomarkers of cancer risk in ulcerative colitis (UC). Based on the parallels in UC and CD
tumorigenesis, we now extend these studies to CD, to determine if a FISH biomarker panel
will distinguish long-term, dysplasia-free CD nonprogressors from the small minority of CD
progressors with neoplasia. Methods: Epithelial isolates from fresh frozen biopsies were
prepared from 10 CD nonprogressors with long-term benign followup and 5 CD progressors
(3 with cancer, 2 with dysplasia). Dual-color FISH was performed for 2 arm/centromere
probe sets: p53/cep17 & cyclin D1/cep11. A total of 10 and 12 sites were available for
testing from nonprogressors (5 ileal, 5 colorectal) and progressors (2 ileal, 7 colorectal [all
nondysplastic], 3 cancers), respectively. Nondysplastic progressor samples were located a
mean distance of 33.7+/-12.1 cm from the CD neoplasms. Results: The mean % of any
FISH abnormality (both arm and centromeric losses and gains) for both probe sets was
significantly different between CD non-progressors, nondysplastic CD progressor samples,
and CD cancers (p53/cep17, 10.9% vs. 18.6% vs. 24.0%, p=0.007; cyclin D1/cep11, 9.1%
vs. 15.1% vs. 16.3%, p=0.003). Importantly, nondysplastic samples from CD nonprogressors
vs. progressors were significantly different for mean % any FISH abnormality in each probe
set (p53/cep17, p = 0.016; cyclin D1/cep11, p = 0.003). There were no significant differences
in genomic instability comparing inflamed CD bowel versus skip lesions (p>.05). The sum
of % any abnormality for both probe sets was always below a threshold of 26% in CD non-
progressors (range 14-25%), and was consistently higher than a 29% threshold in non-
dysplastic tissues of progressors (range 30-39%), with the exception of 1 skip lesion in a
CD progressor. Receiver operator characteristic (ROC) analysis for the sum of % any FISH
abnormality for both probe sets yields an optimal sensitivity of 89% and specificity of 100%
with an area under the curve of 0.94. Conclusions: These data indicate for the first time
that genomic alterations in CD are not limited to neoplastic tissue itself, but instead appear
to be widespread within the nondysplastic bowel of these patients. Further, CD nonpro-
gressors are separable from CD progressors on the basis of this FISH panel, parallel to our
data in UC. As such, the results show promise for improving CD cancer surveillance by
reducing unnecessary screening of nonprogressors, and focusing surveillance onto the
patients most likely to benefit.
S1982
Novel Alterations in Barrett'S-Related Adenocarcinomas
Dunfa Peng, Essam Sheta, Steven M. Powell, Kay Washington, Christopher A. Moskaluk,
Ira Goldknopf, Wael M. El-rifai
In this study, we applied high-resolution, two-dimensional, gel electrophoresis as a proteom-
ics approach to identify novel proteins that may be involved in the carcinogenesis of Barrett's
related adenocarcinomas (BA). We analyzed 12 primary tissue samples that included 8 BAs
and 4 normal mucosa samples. We selected twenty-three spots, that were consistently altered
(≥ 3 fold) in at least 4/8 tumor as compared to all normal samples, for MALDI TOF mass
spectra analysis. The MALDI TOF MS analysis demonstrated biologically interesting up-
regulated proteins such as; several members of the zinc finger proteins (Znf146, Znf212),
Cyclin D1, Dr5, Erbb3, Triobp, and Fhl3. Examples of down-regulated proteins included
Klf6 and Lgi2. We selected four over-expressed proteins for pre-validation at the mRNA
and protein levels. Using quantitative real-time reverse-transcription PCR on 39 BA tissue
samples, we demonstrated mRNA up-regulation of ZNF146 (12/39, 30.7%), ZNF212 (8/
39, 20.5%), DR5 (16/39, 41%) and ErbB3 (19/37, 51.3%), as compared to 10 normal tissue
samples. Using antibodies against these proteins, Western blot analysis confirmed moderate-
to-strong expression in three esophageal adenocarcinoma cell lines (TE7, BIC1, and SEG1).
We performed immunohistochemical (IHC) analysis of Znf146, Dr5 and Erbb3 on a tissue
microarray that contained 75 Barrett's-related adenocarcinomas. Normal tissue samples
showed absent IHC staining intensity for Znf146 and Dr5 and absent to weak intensity for
Erbb2. Conversely, BA tissue samples demonstrated over-expression of Znf146 (29%), Dr5
(90%), and Erbb3 (84%), as compared to normal tissues. Interestingly, Barrett's-related
dysplasia samples showed overexpression of Dr5 (3/6, 50.0%) and Erbb3 (5/8, 62.5%).
Our results reveal novel proteins for Barrett's-related adenocarcinomas and suggest that
dysfunction of their related signaling pathways may be involved in Barrett's carcinogenesis.
S1983
Amplification of Topoisomerase IIα Occurs in Colorectal Cancer and Its
Expression Is Associated with Aggressive Disease
Alan Coss, Kieran Sheahan, Shane Sullivan, Edward Fox, John Hyland, Diarmuid
O'donoghue, Dermot Leahy, Hugh Mulcahy, Jacintha O'sullivan
Topoisomerase IIα (TOP2A) codes for a key enzyme (topoIIα) involved in DNA replication,
which may be an important prognostic and therapeutic marker in cancer. However, limited
data are available on its role in colorectal cancer (CRC), and TOP2A gene copy number
alterations in this disease have not been investigated. METHODS. Using microarray comparat-
ive genomic hybridisation (array CGH), we examined TOP2A copy number alterations in
tissue from 39 sporadic CRC cases. Two-color fluorescent in-situ hybridisation (FISH) was
used to confirm and localise amplification of TOP2A in the same tumors. Using immunohisto-
chemistry and tissue microarrays, we examined percentage positivity and intensity levels of
topoIIα in 228 CRC cases, representing all four tumor stages. Results were correlated with
extensive clinical, pathological and survival data. Tumor proliferation was assessed by staining
for Ki67. RESULTS. TOP2A amplification was identified using array CGH and discriminated
between non-metastatic and metastatic disease. Amplification was confirmed and quantified
using FISH and localised specifically to tumor epithelial cells. No significant amplification
was seen in stromal cells or in normal colonic tissue. Significant associations were detected
between topoIIα expression and advancing tumor stage (p=0.02), poor differentiation (p=
0.001) and lymphovascular invasion (p=0.006). Multivariate analysis confirmed this associ-
ation to be independent of tumor proliferation (p=0.007). CONCLUSIONS. TopoIIα expres-
sion in CRC is associated with a more aggressive tumor phenotype and appears to be
associated with TOP2A gene amplification. Identification of TOP2A/topoIIα alterations in
clinical practice may allow for targeted chemotherapy with etoposide or anthracyclines
(which target topoIIα) in a subset of CRC patients.
S1984
A Comparative Analysis By Sage of Gene Expression Profiles of Esophageal
Adenocarcinoma and Barrett's Esophagus
Jantine Van baal, Francesca Milano, Agnieszka M. Rygiel, Carine Sondermeijer, Jacques J.
Bergman, Maikel Peppelenbosch, Kausilia K. Krishnadath
BACKGROUND: Esophageal adenocarcinoma (EA) is a major type of esophageal cancer. EA
is associated with Barrett's esophagus (BE), a metaplastic condition of the distal esophagus,
in which through longstanding gastro-esophageal reflux disease, the normal squamous
epithelium is replaced by columnar epithelium. Research has been done concerning the
pathophysiology, however, the exact molecular basis of this cancer remains unclear. Therefore
we evaluated the transcriptome of EA in comparison to non-dysplastic BE, the metaplastic
epithelium that predisposes for EA. MATERIAL AND METHODS: The SAGE technique was
used for obtaining transcriptomes of biopsies taken from an EA and a BE patient. Validation
of results by RT-PCR and immunoblotting was performed using tissue samples of 12 extra
EA and BE patients. RESULTS: Almost 80,000 tags were sequenced. Between EA and BE
1,013 tags were significantly differentially expressed (p<0.05). The most up-regulated genes
in EA compared to BE were SRY-box-4 and Lipocalin2, whereas the most down-regulated
genes in EA were Trefoil factors and Annexin A10. Cluster analysis of these tags in groups
of biological processes shows that genes situated in the clusters cell division, cell growth
and signal transduction play a major role in EA. CONCLUSIONS: The comparison of the
gene expression profiles of EA with BE shows that the tissues have their own definite
characteristics. The detection of genes exclusively expressed in EA compared to metaplastic
BE may have significant clinical implications, as these may be valuable as tumor markers.
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Secreted Protein Acidic and Rich in Cysteine (SPARC) As a Prognostic Marker
in Colonic and Rectal Cancer
Anneli Robbshaw, Frances Lloyd, Amber Appelbee, Ian C. Lawrance
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers. Patient
outcome is often dependent on the clinical staging of the primary tumor at diagnosis. The
ACPS system considers physical aspects of the primary tumor and correlates with the long-
term outcome for patients with stage A and D disease. It does not, however, accurately
predict the long-term outcomes of patients with intermediate stage disease (B and C). The
levels of TGF-β1, COX-2, PGE2 and the MMPs -2 and -9 are associated with a worse
prognosis in CRC. SPARC regulates TGF-β1 expression and enhances MMP-9 levels via the
induction of COX-2 and PGE2. It may thus be a key molecule in the mediation of the
biological aspects associated with poor prognosis in CRC. METHODS: SPARC expression
was determined immunohistochemcally in paired samples of normal intestinal and colorectal
cancer tissue collected from patients undergoing surgery. Patients with ACPS stage B and
C colon and rectal tumors with and without disease recurrence at 5 years were selected
from the Fremantle hospital CRC database. Patients were matched for age at diagnosis, sex
and tumor histology. SPARC was stained immunohistochemcally and levels determined by
morphometric assessment, total cell count and percentage of positive cells. RESULTS: Cellular
expression of SPARC was significantly greater in colorectal cancers compared to normal
intestine by each method (p=0.004, p=0.002 and p=0.002 respectively; correlation between
methods r2=0.82). SPARC staining was very low in ACPS stage A and very high in stage D
colorectal tumors. SPARC levels were assessed by morphometric assessment and cell counts
in the stage B colon cancer from patients with a poor outcome were markedly greater than
those from stage B patients with a good outcome. No differences were found between the
stage B rectal cancers with good orpoor outcome, nor between any of the stage C cancer
groups. The percentage of cells positive for SPARC was not different between any of the
groups. CONCLUSION: The findings suggest that SPARC is expressed in cancer as opposed
to normal intestine and this expression is greater in more advanced tumors with a worse
prognosis. The findings also suggest that SPARC could potentially be used as a prognositc
marker in ACPS stage B colon cancer patients, as a greater SPARC expression was associated
with a worse prognosis. Correlation of the SPARC levels with the expression of other markers
such as TGF-β1, COX-2, PGE2 and the MMPs, however, needs to be undertaken to determine
a prognostic link between these markers.
S1986
DNA Promoter Hypermethylation of p16 Or APC Predicts Progression to
Cancer in Barrett's Esophagus
Jean S. Wang, Mingzhou Guo, Elizabeth A. Montgomery, Lisa Hicks, Hilary Cosby, James
Herman, Marcia I. Canto
Introduction: Although Barrett's esophagus is associated with an increased risk of esophageal
adenocarcinoma, it is difficult to predict which patients are most likely to progress to cancer
using current techniques. Aim: To determine whether DNA promoter hypermethylation of
p16 or APC in esophageal biopsies is a biomarker that will predict which patients with
Barrett's esophagus are likely to progress to esophageal adenocarcinoma. Methods: We
performed a nested case-control study in Barrett's esophagus patients who later progressed
to high-grade dysplasia or adenocarcinoma and patients who did not progress pathologically
from 1998-2004. The mean follow-up time was 2.2 years and all patients underwent
endoscopic surveillance using the Seattle biopsy protocol. After DNA extraction and sodium
bisulfite modification, we performed methylation-specific PCR for p16 and APC on initial
esophageal biopsies at presentation and compared the results to subsequent clinical outcomes.
Results: There were 12 patients with Barrett's esophagus who subsequently progressed from
baseline pathology to high-grade dysplasia or adenocarcinoma, and 53 patients who did
not progress from their baseline pathology. The mean age was 61.2 years, and 81.7% were
male. Patients had baseline diagnoses of Barrett's esophagus with no dysplasia (40%), low-
grade dysplasia (30%), and high-grade dysplasia (30%). Higher baseline dysplasia grade
was associated with more progression as would be expected: 6.4% of those with no dysplasia
progressed, 17.3% of those with low-grade dysplasia progressed, and 34.8% of those with
high-grade dysplasia progressed. Patients with Barrett's esophagus who subsequently pro-
gressed had a significantly higher prevalence of hypermethylation in their initial esophagus
biopsies compared to those who did not progress with respect to both p16 (90.0% vs.
33.3%, p<0.001; OR=18) and APC (90.9% vs. 47.1%, p=0.008; OR=11.2). Conclusions:
The presence of DNA promoter hypermethylation of p16 or APC is a strong predictor of
subsequent progression to esophageal adenocarcinoma in patients with Barrett's esophagus
with a 2 year follow-up period.
S1987
The Association of Elevated C-Reactive Protein Levels with Synchronous and
Advanced Colorectal Adenoma
Han-mo Chiu, Jaw-town Lin, Yi-chia Lee, Ming-shiang Wu
Background: Chronic inflammation has been implicated in the development of colorectal
cancer (CRC). The presence of low-grade systemic inflammation determined by elevation
of high-sensitivity C-reactive protein (CRP) has been associated with the risk of cardiovascular
diseases and cancers. However, previous studies of CRP and CRC in cohorts with enrollment
of different genders were controversial and little is known about CRP levels in colorectal
adenoma, the precursor lesion of CRC. This study aims to clarify the relationship between
CRP and colorectal adenoma and whether there are any gender differences. Methods: Plasma
CRP levels were cross-sectionally examined in consecutive 6,695 ethnic Chinese who received
complete total colonoscopy and thorough health check-ups. Logistic regression was used
to relate the risk of colorectal adenoma to CRP levels. Findings: Plasma CRP levels were
significantly higher in subjects with colorectal neoplasia than those without neoplasia (1.84
mg/L vs. 1.47 mg/L, p=0.0472). Presence of synchronous neoplasia (OR=1.92, 95% CI=
1.26 - 2.92 in third quartile), advanced neoplasia (OR=2.10, 95% CI=1.35 - 3.26 in third
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quartile and OR=2.00, 95% CI=1.25 - 3.19 in fourth quartile), and concurrent synchronous
and advanced neoplasia (OR=3.33, 95% CI=1.5 - 7.24 in third quartile and OR=2.63, 95%
CI=1.16 - 5.96 in fourth quartile) were associated with elevated levels of plasma CRP, after
adjustment of other risk factors. Gender stratification showed positive association of high
CRP levels with risk of colorectal neoplasia in men but no corresponding association was
noted in women. Interpretation: Elevated plasma CRP levels are independently associated
with the increased risk of colorectal adenoma in men but not in women. These data support
the crucial role of chronic inflammation in the development of CRC and provide new
mechanistic insights that warrant further investigations.
Adjusted for age, gender, history of colon polyp, aspirin/NSAIDs use, physical activity,
alcohol intake, smoking, cardiovascular disease, WBC and BMI
S1988
Her2/Neu Oncogene Amplification and Overexpression in the Transformation
of Barrett's Esophagus
Agnieszka M. Rygiel, Francesca Milano, Fiebo J. Ten kate, Jantine W. Van baal, Paul
Fockens, Wilda Rosmolen, Jacques J. Bergman, Maikel P. Peppelenbosh, Kausilia K.
Krishnadath
BACKGROUND: The amplification and overexpression of a Her2/neu proto-oncogene correl-
ates with poor survival of patients with Barrett's esophageal adenocarcinoma (EAC). However,
the studies examining the occurrence of Her2/neu amplifications together with the protein
overexpression in a BE patients with different stages of dysplasia are lacking. AIM: To
evaluate the frequency of Her2/neu (17q21) gene amplification and Her-2/neu protein
overexpression in BE without dysplasia (ND)-low grade dysplasia (LGD)-high grade dysplasia
(HGD)-esophageal adenocarcinoma (EAC) sequence. MATERIAL and METHODS: Fluores-
cent in situ hybridization (FISH) using a centromeric probe for chromosome 17 and a Her2/
neu (17q11.2) locus-specific probe were applied on 167 brush cytology specimens taken
from BE patients (118 ND, 24 LGD, 15 HGD, 10 EAC). Tissue sections of all cases that
presented with Her2/neu amplification and/or polysomy of chromosome 17 were investigated
for Her-2/neu overexpression by immunohistochemistry (IHC) with the HercepTest.
RESULTS: The Her2/neu amplification was not seen in ND but was detected in 4% (1/24)
of LGD, 46% (7/15) of HGD, and 30% (3/10) of EAC. Of the 11 cases having Her2/neu
amplification, 36% (4/11) showed 3+ IHC positivity, 18% (2/11) showed 2+ positivity, and
45% (5/11) cases were negative for protein overexpression assessed by IHC. CONCLUSIONS:
Her2/neu amplification is an important marker for malignant progression of BE. Evaluation
of Her2/neu status by FISH is a more sensitive technique then IHC, since a significant
number of cases with Her2/neu gene amplification do not show protein overexpression
by IHC.
S1989
Gene Expression Profile Comparison of Barrett's Esophagus Epithelial Cell
Cultures and Biopsies
Jantine W. Van baal, Agnieszka M. Rygiel, Francesca Milano, Marley Anderson, Jacques J.
Bergman, Maikel Peppelenbosch, Kenneth K. Wang, Kausilia K. Krishnadath
BACKGROUND: Barrett's esophagus (BE) is a metaplastic process in which the normal
squamous epithelium of the distal esophagus is replaced by columnar lined epithelium. To
gain more insight in the process of metaplasia and to identify which genes are specifically
expressed by the epithelial cells and the surrounding tissue, the aim was to define and
analyze the gene expression profile of a BE primary cell culture and compare with a BE
biopsy. MATERIAL AND METHODS: To specifically obtain the epithelial cell layer, epithelial
cells from biopsies of BE were cultured using a Barrett specific culturing medium. Serial
analysis of gene expression (SAGE) was applied to obtain a transcription library of a BE
primary epithelial cell culture. The transcriptome was analyzed and compared with the
transcriptome of a BE biopsy. Validation of results by RT-PCR was performed using tissue
samples of 16 BE patients and 16 primary cell cultures. RESULTS: Over 80,000 tags were
sequenced. Statistical analysis revealed 1,228 significantly differentially expressed tags when
comparing the Barrett primary cell culture SAGE library with that of the BE biopsy. Genes
significantly higher expressed by the Barrett epithelial cells were for instance Lipocalin 2,
A-294AGA Abstracts
SOX 4, Cytokeratin 7, Galectin 7 and Cyclin D1, whereas Annexin A10, TFF1 and TFF2
were specifically expressed in the BE biopsies and therefore are more likely to be stromal
factors. CONCLUSIONS: This study efficiently revealed a subset of genes specifically expre-
ssed by BE epithelial cells or genes that are more likely expressed by the stroma. These
valuable data sets will have important implications for future analyses that for instance look
into the specific effects of epithelial and stromal factors in the development of Barrett's
metaplasia and progression into esophageal adenocarcinoma.
S1990
Plasma MMP-9 Level Is Better Than Serum MMP-9 Level to Predict Gastric
Cancer Evolution
Chun-ying Wu, Ming-shiang Wu, En-pei Chiang, Chien-jen Chen, Nai-hui Chi, Ying-ting
Shih, Gran-hum Chen, Jaw-town Lin
Background: Matrix metalloproteinase-9 (MMP-9) in blood is a promising new tumor
marker. The aims of the present study are to compare the usefulness of plasma and serum
MMP-9 levels for predicting gastric cancer development, invasion and survival. Material
and Method: In this nested case-control study, 114 gastric cancer patients and 87 healthy
controls were enrolled. MMP-9 levels and activities were quantitatively measured by ELISA
assay and zymography. The results were compared with the occurrence, clinicopathological
features and outcomes of gastric cancer patients. The follow-up time for all patients was at
least 5 years. RESULTS: Serum MMP-9 levels were significantly higher than plasma MMP-
9 levels. Both plasma and serum MMP-9 levels correlated significantly with active MMP-9
identified by zymography (P=0.002 and P=0.048 respectively). Plasma MMP-9 level was
significantly elevated in gastric cancer patients when compared with control subjects
(P<0.001). Serum MMP-9 levels did not differ between the groups. Receiver-operator charac-
teristics (ROC) analysis showed the values of sensitivity (82.5%) and specificity (65.5%) at
the maximum accuracy for plasma MMP-9 at ≥60 ng/mL (P<0.001). Elevated plasma
MMP-9 correlated significantly with lymph node metastasis (OR=3.43, P=0.019), lymphatic
invasion (OR = 7.58, p=0.009) and venous invasion (OR = 4.14, p=0.033). Patients with
elevated plasma MMP-9 levels had poorer survival rates than those with normal plasma
MMP-9 levels (P=0.038). Serum MMP-9 level did not correlate well with gastric cancer
invasive phenotypes or survival. CONCLUSION: Our results suggest plasma MMP-9 level
is a better marker than serum MMP-9 level for predicting gastric cancer development
and progression.
Receiver-operator curves for plasma and serum MMP-9 levels.
S1991
Improvement of Atrophic Gastritis Related with Helicobacter pylori Infection
in the Patients with Gastric Cancer RE-Expression of Sonic Hedgehog and
Reduction of Cdx2 After Helicobacter pylori Eradication
Akiko Shiotani, Noriya Uedo, Hiroyasu Iishi, Masaharu Tatsuta, Shingo Ishiguro, Noriaki
Manabe, Tomoari Kamada, Hiroaki Kusunoki, Ken Haruma
Background: Loss of Sonic Hedgehog (Shh) and aberrant CDX2 expression are early changes
that occurs in the mucosa prior to neoplastic transformation correlating with the presence
of intestinal metaplasia (IM). Aim: To reverse atrophic gastritis correlated with the changes
in Shh and CDX2 expression in the non-cancerous mucosa of patients with gastric cancer
after H. pylori eradication. Methods: Seventy patients with endoscopic resection for early
gastric cancer and 30 controls were studied. Specimens were obtained from the corpus
greater and lesser curves and the antrum greater curve before eradication and one year after
eradication. Expression of Shh and CDX2 were evaluated by immunostaining. Serum levels
of gastrin 17 and pepsinogen were measured by RIA and ELISA. Results: Serum levels of
pepsinogen I before and after eradication were correlates inversely with corpus atrophy.
The scores of inflammation at each site and atrophy at the corpus greater curve were
improved after eradication in the both groups. Serum levels of pepsinogen I before eradication
in the patients with improvement of corpus atrophy were significantly higher (<0.01) than
those in the patients without. Shh expression at the corpus greater and lesser curves were
significantly increased (p<0.001)and CDX2 expression at the corpus lesser curve was signific-
antly decreased (p=0.001) after eradication. The difference between the control and the
cancer groups became remarkable after eradication in not only corpus gastritis (<0.01), but
also in Shh (p=0.001) and CDX2 expression (p<0.001). The atrophy and expression of Shh
and CDX2 at the corpus lesser curve significantly improved in mucosa without incomplete
IM (<0.01), but not in the mucosa with incomplete IM. Conclusions: H. pylori eradication
prior to incomplete IM improves atrophic gastritis and may prevent gastric cancer by recovery
of Shh expression and reduction of CDX2. To detect patients with residual high risk of gastric
cancer after eradication, serum pepsinogen I may be useful as a predictor of improvement of
atrophy by eradication.
S1992
Role of Interleukin-6 Gene Promoter Polymorphism -634g/C and Serum
Interleukin-6 Level in Gastric Adenocarcinoma
Jaw-town Lin, Wei-chih Liao, Ming-shiang Wu
Background: In gastric adenocarcinoma, an increase in serum interleukin-6 (IL-6) level with
disease progression has been reported, and a single nucleotide polymorphism (SNP) at
position -634 (C>G) in the promoter of IL-6 gene was discovered in Asian populations. The
-634G allele has been associated with an increased production of IL-6 by mononuclear cells
In Vitro and reported as a risk factor for diabetic nephropathy and lung cancer. However,
its role in gastric cancer is unclear. This study aims to study the effect of this SNP on serum
IL-6 level and overall survival after surgery in gastric cancer. Methods: Genotyping was
performed in 155 patients who underwent resection for gastric adenocarcinoma and 211
healthy controls. Serum IL-6 level was analyzed in all gastric cancer patients and in a sub-
sample of 63 controls (31 CC, 23 GC, and 9 GG). The effects of various factors on serum
IL-6 level were analyzed with linear regression. The relative importance of various factors
with regard to overall survival was analyzed with Cox proportional hazard regression model
in 147 patients who underwent intent to cure surgery. Findings: In controls, there were no
significant differences in IL-6 levels between CC and GC/GG genotypes (p =0.429). In gastric
cancer patients, an incremental increase in the proportion of high IL-6 level (>13pg/mL)
with advancing stages was noted (trend p<0.001). The effect of SNP on IL-6 level was
not statistically significant (p=0.555). Multivariate analysis identified high IL-6 level as an
independent factor associated with a lower likelihood of survival (hazard ratio for survival
0.67, 95% CI =0.51-0.87, p=0.002) in addition to depth of invasion (T), lymph node
invasion (N), and distant metastasis (M). In stage 3 patients, median survival was significantly
shorter in the high IL-6 group than in the low IL-6 group (618 vs. 1854 days, p=0.040).
Interpretation: -634C/G has no effect on serum IL-6 level in controls and gastric cancer
patients, and it is not associated with survival after surgery. However, serum IL-6 level greater
than 13pg/mL is an independent risk factor for decreased survival. Significant differences in
survival exist between high and low IL-6 group in stage 3 patients. Further study is necessary
to compare perioperative chemotherapy with surgery alone in treating gastric cancer patients
with high or low serum IL-6 levels.
S1993
Gene Expression Profile Analysis of Esophageal Squamous Cell Carcinoma
and Normal Squamous Esophagus
Jantine Van baal, Francesca Milano, Agnieszka M. Rygiel, Wilda D. Rosmolen, Jacques J.
Bergman, Maikel P. Peppelenbosch, Kausilia K. Krishnadath
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) develops in a multi-step,
progressive process, as the result of a sequence of histopathological changes that typically
involves esophagitis, atrophy, mild to severe dysplasia, carcinoma in situ and finally, invasive
cancer. Worldwide ESCC is the predominant esophageal cancer and has a high mortality
rate. For understanding and optimizing future treatments it is important to understand the
specific biology of this cancer. We hypothesized that by generating a large molecular data
set of ESCC and by quantitatively comparing this with normal squamous epithelium, we
will accurately classify the different phenotypes of these tissues and improve our insight in
the biological pathways and mechanisms involved in this malignancy. MATERIAL AND
METHODS: In this study gene expression profiles were obtained using the technique serial
analysis of gene expression (SAGE). By using tissue samples of 10 extra ESCC patients, RT-
PCR and immunoblotting was performed for validation of results. RESULTS: Over 75,000
tags were sequenced. Between ESCC and normal squamous epithelium 1,235 tags were
significantly differentially expressed (p<0.05). The most up-regulated genes in ESCC com-
pared to normal squamous epithelium were BMP4, E-Cadherin and TFF3. Clustering analysis
of significantly differentially expressed genes in groups of biological processes showed that
cell-cell signalling is five fold decreased in ESCC compared to normal squamous epithelium.
In contrast, the clusters cell cycle, metabolism, cell division and cell communication were
important in ESCC, all these clusters were more than 10 fold increased. In more detail, 13
main clusters of biological processes were more than 5 fold increased in ESCC in contrast
to 1 cluster in normal squamous epithelium. CONCLUSIONS: Clustering analysis indicated
that ESCC is a highly active epithelium in several types of processes, like cell adhesion,
signal transduction, cell death, immune response and cell growth. Genes identified as
specifically expressed in ESCC compared to normal squamous esophagus could be useful
as tissue biomarkers and could have important clinical implications.
S1994
Prediction of Gastric Cancer By Analysis Ob Aberrant DNA Methylation in
Non-Neoplastic Gastric Epithelium
Tomomitsu Tahara, Tomiyasu Arisawa, Tomoyuki Shibata, Fangyu Wang, Masakatsu
Nakamura, Makoto Kuroda, Ichiro Hirata, Hiroshi Nakano
(Backgaround) Aberrant DNA methylation is one of the major events in carcinogenesis.
Promoter DNA methylation is also present in various non-neoplastic tissues including gastric
epithelium as age-related phenomenon, suggesting that it occurs early in the process of
tumorgenesis. (Aim) We aimed to clarify the relationship of aberrant DNA methylation in
non-neoplastic gastric epithelia with the risk of gastric cancer, H. pylori infection, the degree
of H. pylori induced gastritis. (Subjects) 89 patients enrolled in this study. The status of
aberrant DNA methylation was compared in patients divided into two groups: Gastric cancer
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(GC) cases (n=43,mean age 65.9 [29-91], F:M=0.30, intestinal type[n=25], diffuse type[n=
18]) and 46 age, sex matched patients without evidence of GC(peptic ulcer diseases[n=15],
gastritis[n=31]) as a control group. (Method) Genomic DNA was extracted directly from
non-neoplastic epithelia of antral biopsies obtained by endoscopy. The promoter methylation
status of the p14 and p21 genes were determined by Methylation-Specific-Polymerase Chain
Reaction (MSP). The promoter methylation status of the p16 gene was quantified by digital
densitographic analysis following to MSP. The degree of gastritis in antrum was assessed
according to the updated Sydney system. The PG I/ II ratio was calculated based on the
data of serum PG I and PG II levels measured by radioimmunoassay. (Results) Among H.
pylori positives, The mean methylation level of the p16 gene in non-neoplastic gastric
epithelia was significantly higher in GC patients than in controls (0.45±0.31vs 0.20±0.17,
P=0.016). The methylation level of the p16 gene was also associated with the risk of intestinal
type histopathology (0.38±0.24vs 0.20±0.17, P=0.017). The methylation level of the p16
gene was significantly higher in patients with intestinal metaplasia(IM) than in patients
without IM (0.31±0.25vs 0.19±0.16, P=0.04). Furthermore, the methylation level of the
p16 gene was correlated with lower PG l/ll ratio (R=-0.33, P=0.04). There were no significant
differences between p16 methylation level and inflammatory activity of gastritis. Among
controls, The methylation frequency of the p14 gene was significantly higher in H. pylori
positives than in H. pylori negatives (38.5%vs.10.0%, P=0.03) The methylation of the p21gene
was found in only one case with GC. (Conclusion) Our data suggest that aberrant DNA
methylation is potently induced by H. pylori infection and analysis of methylation in non-
neoplastic gastric epithelia may be useful for screening patients who may be at risk of
developing gastric cancer in H. pylori positive patients.
S1995
Could the Plasma Ghrelin Level Be a Novel and Non-Invasive Marker for
Gastric Cancer ?
Tatsuhiro Masaoka, Hidekazu Suzuki, Toshihiro Nishizawa, Eisuke Iwasaki, Hiroshi
Hosoda, Kenji Kangawa, Toshifumi Hibi
Background. Although serum levels of pepsinogen (PG) has gained attention as a screening
test to detect patients with atrophic gastritis, a risk factor for gastric cancer, the serum levels
of PG are affected by Helicobacter pylori (H. pylori) eradication therapy (Aliment. Pharmacol.
Ther. S1:25, 2004). We previously reported that the plasma ghrelin levels were correlated
with the serum levels of PGI and the PGI/II ratio (Hepatogastroenterol. 51:1249, 2004).
Recently, low plasma adiponectin levels have been reported to be associated with an increased
risk of gastric cancer (Clin. Cancer Res. 11:466, 2005). The present study was designed
to elucidate the possibility of using plasma ghrelin level as a novel and non-invasive marker
for gastric cancer. Methods.1. Twenty five patients with H. pylori-positive chronic gastritis
were enrolled for the study. Before and after H. pylori eradication therapy (mean interval:
10 month), blood samples were collected. The plasma levels of ghrelin were measured by
radioimmunoassay. The serum levels of PGI and PGII were measured by EIA. 2. Thirty
three patients with chronic gastritis were enrolled, and the plasma ghrelin and serum
adiponectin levels were measured. The serum levels of adiponectin were measured by ELISA.
3. Seven patients with gastric cancer and 197 patients with chronic gastritis were enrolled,
and the plasma levels of ghrelin, serum PGI and PGII were measured. Results. 1. In the
patients with low serum PG levels (PGI<70μg/l and PGI/II ratio<3; low PG group), although
the PGI/II ratio was significantly increased (2.3±0.2 to 4.6±0.4, p<0.001), no significant
changes in the plasma ghrelin levels were noted during the present observation period. In
the patients with high PG levels (high PG group), no significant changes were noted in
either the PGI/II ratio or the plasma ghrelin levels. In both groups, the serum PGI levels(pg/
ml) were significantly decreased (low PG group: 49.2±4.8 to 27.6±2.8, p<0.001; high PG
group: 120.3±24.2 to 58.0±7.5, p<0.001). 2. A significant correlation was found between
the plasma ghrelin and serum adiponectin levels (r = 0.36, p<0.05). 3. The serum PGI levels
and PGI/II ratio were significantly decreased in patients with gastric cancer as compared
with those in patients with chronic gastritis. The plasma ghrelin levels tended to be decreased
(p=0.07) in the gastric cancer group. Conclusion. Since plasma ghrelin levels were lower
in the gastric cancer group, were not affected by H. pylorieradication therapy in the short
term, and were correlated with the serum levels of adiponectin, the plasma ghrelin level is
suggested as a potential novel and stable marker for gastric cancer.
S1996
Peripheral Blood Gene Expression Markers of Local and Progressive
Colorectal Diseases Determined By Whole Genome mRNA Array Analysis
Bela Molnar, Orsolya Galamb, Barnabas Galamb, Norbert Solymosi, Ferenc Sipos, Sandor
Spisak, Kinga Toth, Pál Miheller, Tamas Zagoni, László Herszényi, Zsolt Tulassay
Background and Aims: Gene expression analysis of peripheral blood using high-density
oligonucleotide microarray can contribute to the determination of distant blood markers of
local pathophysiological alterations in colorectal diseases. With the help of whole genomic
microarrays circulating tumor cell related mRNA markers can be detected and verified , as
well. Methods: 8 ml peripheral blood was collected, immediately lysed, stabilised in Paxgene
tubes then total RNA was extracted, amplified after β-globin reduction and biotinylated
from 8 patients with colorectal cancer, 8 with villous adenoma (>1 cm), 8 with active IBD
and 8 healthy normal controls. Genome-wide gene expression profile was evaluated by
HGU133 Plus2.0 microarrays. RMA background correction, quantile normalization and
median polish summarization were used. Kendall's rank correlation was performed for
quantification of association between the expression level and the disease stages. Results:
Cytokeratin 20 was elavated in IBD samples as compared to normal ones (2.63+1.01/2-
42+1.15). Classification of benign and malignant tumor markers in comparison with IBD
and normals could be performed using downregulated genes like albumin, coeruloplasmin,
doublesex and mab-3 related transcription factor 2 (DMRT2), SNF2 histone linker PHD
RING helicase, SWI/SNF related reugulator of chromatin , and upregulated like C7 open
reading frame 38, CYP2C18, Chemikone receptor 8, CD36. Carcinoma cases could be
classified from adenomas by upregulated specrin beta 4, translocase pf inner mitochondrial
membrane, synapsin 1, microtubule associated monooxygenase, max-associated gene and
downregulated CDC20 cell division cycle 20 homolog b, solute carrier family 34, CYP11A1,
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
tropomyosion 1. CRC could be classified fromm all of the other observed groups by upregul-
ated Tropomyosin 3, Adaptor related protein complex1, E2F7 transcription factor, Amyloid
precursor, MADS box transcription factor 2, and downregulated EP400N terminal like
protein, Nudix type motif 4 pseudogen1, Spouty related EVH1 domain. Albumin, CCDC7
colied-coil domain containing 7, DMRT2, SHB showed sequential changes in normal, aden-
oma and CRC. Fold changes were at all of these genes in significant difference to the reference
normal group by (p<0.001). Conclusions: CK20 circulating tumor cell marker proved to
be elevated in IBD patients. New multivariate expression markers were identified using
mRNA while genomic expression arrays and peripheral blood . These markers and technology
can lead to alternative screening procedures.
S1997
Microsomal Prostaglandin E-2 Expression Correlates with Clinicopathological
Factors and Prognosis in Patients with Diffuse-Type Gastric Adenocarcinoma
Katya Gudis, Atsushi Tatsuguchi, Ken Wada, Tetsuro Hiratsuka, Seiji Futagami, Yuh
Fukuda, Teruo Kiyama, Takashi Tajiri, Kazumasa Miyake, Choitsu Sakamoto
Background: Cyclooxygenase (COX-2)-derived PGE2 has been shown to modulate cancer
progression. Microrosomal prostaglandin E synthase-1 (mPGES-1) functions downstream
of COX-2 for PGE2 biosynthesis and its overexpression has been associated with various
cancers including gastric adenocarcinoma. Studies have shown that another PGE synthase,
mPGES-2, can also couple with COX-2, however, the relationship between this isomer and
clinicopathological factors and patient prognosis has yet to be explored in gastric cancer.
Aim: To investigate mPGES-2 protein expression in human gastric cancer and determine
the relationship between mPGES-2 expression and clinicopathological factors, patient pro-
gnosis and COX-2 expression. Methods: We examined 129 surgical resections from gastrec-
tomy patients and 16 paired biopsies from endoscopy patients. mPGES-2 protein expression
was analyzed in gastric biopsies by Western blot (WB) and its cellular localization in gastric
cancer surgical resections by immunohistochemistry. Immunohistochemical results were
compared with clinicopathological factors, patient prognosis and COX-2 expression. Results:
mPGES-2 protein expression was found in neoplastic and paired non-neoplastic biopsy
samples. mPGES-2 immunoreactivity localized in the cytoplasm of glandular epithelial cells
of non-neoplastic mucosa and ranged from negative to moderate. It was also found in
epithelial cells with intestinal metaplasia and in lamina propria inflammatory cells. In neo-
plastic tissue, mPGES-2 protein localized with apparent uniformity in the cytoplasm of
cancer cells. However, in 29% (38/129) of cases, mPGES-2 immunoreactivity was significantly
more pronounced in cancer cells than in the adjacent glandular epithelium and these cases
were defined as positive. mPGES-2 expression correlated with histology, depth, lymphatic
invasion, vascular invasion, lymph node metastasis, TNM stage, and tumor recurrence . It
also correlated with mPGES-1 and COX-2 expression. In multivariate analysis, only stage,
mPGES-2 and mPGES-1 expression retained independent prognostic significance. However,
only stage and mPGES-2 expression were found to have independent prognostic value in
diffuse type cancer. Conclusions: mPGES-2 protein may play an important role in tumor
progression in conjunction with COX-2 and may be a useful biologic marker of prognostic
significance in gastric cancer, especially in cancers with diffuse type histology.
S1998
Glut-1 Determines Radiation Response in Rectal Cancer
Sarah . Brophy, Kathy Sheehan, David Bouchier-hayes, Deborah Mcnamara, Elaine Kay
Introduction Neoadjuvant chemoradiotherapy is optimal treatment for T3/T4 or node-
positive rectal cancers, however 15-30% of tumours have a poor response. Early identification
of non-responders would prevent unnecessary treatment and reduce morbidity. Aim The
aim was to determine the relationship between expression of Glucose Transporter- 1 (GLUT-
1), a hypoxia marker, and response to neoadjuvant chemoradiotherapy in rectal cancer.
Methods All patients receiving neoadjuvant chemoradiotherapy for rectal cancer in a single
institution from 1998 -2005 were included. Pre-treatment biopsies were immunohistochem-
ically stained for GLUT-1 expression and scored by proportion of tumour cells positive.
Response to treatment was scored in the resected specimens using the tumour regression
(TRG) grading system. Statistical analysis was performed using the chi-squared test. Results
69 patients were eligible for inclusion. 43.5% had a good response to chemoradiotherapy,
with 14% complete pathological response rate. 56.5% had poor or no response. 72% of
tumours expressed GLUT-1. GLUT-1 expression was significantly associated with poorer
response to treatment (p=0.014). GLUT-1 negative tumours had 80% probability of good
response compared to 32% probability of good response in GLUT-1 positive tumours. GLUT-
1 positivity did not correlate with pre-treatment T-stage but was significantly associated
with a higher pathological T-stage (p=0.03). GLUT-1 expression did not correlate with
pathological N-stage, tumour grade or circumferential margin involvement. Discussion
GLUT-1 expression is associated with poor response to radiotherapy and high pathological
T-stage in rectal cancer. GLUT-1 has potential to identify patients at high risk of non-
response and may facilitate selection of patients for novel therapies.
S1999
Micrornas As Potential Marker in Pancreatic Malignancy - Pilot Translational
Study Using EUS-FNA Samples
Shiro Urayama
Background: Pancreatic cancer remains as the most lethal of malignant diseases. With limited
therapy, enhanced understanding of the cancer is needed to formulate improved outcome.
As newly recognized molecular signals involved in post-transcriptional regulation of gene
expression, microRNA (miRNA) has been acknowledged as significantly involved in cancer.
In this study, we have selected a subset of mature miRNA potentially involved in human
pancreatic cancer from cultured cells. We have then profiled the presence of the set of
miRNA in tissue from patients with possible pancreatic disease obtained during EUS to
investigate the feasibility of acquiring such information from individual patients. Materials
A-296AGA Abstracts
& Methods: Total RNAs were harvested using small-RNA-sensitive technique from three
human pancreatic cancer cell lines (Panc-1, MiaPaCa-2, BxPC-3). From this set, along with
total RNA of normal human pancreas, small RNA populations (<40nt long) were isolated
by electrophoresis. Spotted-arrays with 328 mature human miRNAs with control probes
were hybridized to the labeled small RNAs. The fluorescence signals were then scanned
with GenePix 4000B and log-normalized data were analyzed for significant gain or loss of
miRNA signals in malignant pancreatic cancer cells versus normal pancreas. Based on the
result, we have chosen 5 gainers of miRNA signals. Then, using RNA-preserved EUS-
FNA specimen obtained from pancreatic cases (10 pancreatic adenocarcinoma, 5 chronic
pancreatitis, 3 normal) we have applied our immunoconcentration technique to concentrate
pancreatic ductal cells and isolate total RNA. We have then tested for presence of the select
miRNAs with semiquantitative RT-PCR, using specific primers for each of the five miRNAs
against control (5S rRNA). Results: Focusing on gainers of miRNA in cancer, we have chosen
the following 5 miRNAs from the cancer cell-lines versus normal pancreas from array
study: hsa-miR-23a, hsa-miR-29a, hsa-miR-191, hsa-miR-221, hsa-miR-222. Using the cell-
concentration method, RT-PCR protocol performed on the isolated total RNAs from each
patient sample showed presence of significantly upregulated miRNA of the above in majority,
but heterogeneously, of pancreatic cancer cases and variably in the chronic pancreatitis and
the normal samples. Conclusion: miRNA detection is possible from concentrated EUS-FNA
specimen. Heterogeneity of the individual miRNA signals suggests potential benefit from
marker identification based on patient data and identification of subgroups of the cancer
patients based on miRNA markers. Application in larger patient population with correlated
clinical indicators would be needed in future studies.
S2000
The Expression of EGFR in H. pylori Infected Intestinal Metaplasia and
Gastric Cancer
Noriko Nakajima, Yoko Ito, Shigeaki Mizuno, Kimitoshi Kato, Noriko Kinukawa,
Norimichi Nemoto, Eric R. Lacy
H. pylori(HP) infection causes chronic gastritis(CG), and gastroduodenal ulceration and
gastric cancer(GC). The model of GC is proposed in which superficial gastritis is followed
by CG, intestinal metaplasia(IM) and GC. EGFR is a receptor as a transmembrane glycoprotein
with tyrosine kinase activity. It is thought to play a central role in cancer growth and
progression. The inhibitors of EGFR have recently shown antitumor activity and an overall
survival benefit in patients. IL-16 is involved in the pathophysiological process of chronic
inflammatory diseases. The aim of this study is to determine the changes in the expression
of EGFR in IM and GC as well as the effect of HP infection and IL-16 on epithelial cell
proliferation and EGFR expression in gastric cells In Vitro. Methods:Gastric biopsies were
classified by histological findings as CG without HP(CG-), CG with HP(CG+), IM without
HP(IM-), IM with HP(IM+) and GC with HP(GC+). For In Vitro studies, AGS cells were
incubated with combinations of IL-16 and HP. Gastric epithelial cell proliferation was studied
by BrdU uptake. The expression of EGFR was studied by ABC, ELISA and RT-PCR.Results:IL-
16 expression was detected in all HP infected gastric mucosa. In CG, EGFR protein was
significantly increased by HP infection (CG-:7.30±1.38% vs. CG+:19.22±2.79%, p<0.01).
In HP infected mucosa, there was no significant difference on the EGFR protein levels
between CG+ and IM+ (CG+:19.22±2.79% vs. IM+:13.53±4.11%), but EGFR expression
increased in GC+(29.43±3.53%, p<0.01) than CG+ and IM+. In Vitro studies:HP infection
significantly decreased cell proliferation and EGFR protein levels. Administration of IL-16
increased BrdU uptake and EGFR protein on AGS cells which was decreased by HP. Co-
incubation with IL-16 increased the expression of EGFR mRNA on HP infected AGS cells.
Conclusions:The expression of EGFR in long-term HP infected gastric mucosa may indicate
an early stage in carcinogenesis, because it appears before the histologically evident tumor.
The expression of IL-16 by HP infection can be a trigger for the expression of EGFR on
gastric mucosa, and it may also be a factor for gastric carcinogenesis. The combination of
chemotherapy drugs with the inhibitors of EGFR may be one of the potential treatments
for gastric cancers.
*= significant difference from AGS cells only **=significant difference between with and
without IL-16 on AGS cells p<0.05 was taken as statistically significant.
S2001
Interphase Fluorescence in Situ Hybridization (FISH); A Biomarker of Gastric
Cancer Risk in H. pylori-Multifocal Intestinalized Pangastritis
Byung wook Kim, Mary P. Bronner, Mee-yon Cho, Bo-in Lee
Background and aim: Intestinal metaplasia (IM) of gastric mucosa is the only known marker
of increased cancer risk in H. pylori-gastritis. The aim of this study is to identify better
biomarkers of gastric cancer in patients with H. pylori-multifocal intestinalized pangastritis.
Method: Thirty patients without gastric cancer (non-progressor; NP) and forty one patients
with gastric cancer (progressor; P) were enrolled in this study. Single endoscopic antral
biopsies were perfored after methylene blue chromoscopy and epithelial cells were isolated
from the biopsied specimen with epishake-off method. Interphase fluorescence in situ
hybridization (FISH) using bacterial artificial chromosome (BAC) probes (4q32.2, 10q22.1,
18q21.1 and 19q22) and a commercially available 9p21 probe was performed. Results: Loss
of 4q32.2, 18q21.1, and 19q12 was significantly high in P than in NP (p<0.05). Gain of
10q22.1 was significantly high in P than in NP (p<0.05) (Figure). Conclusion: Interphase
FISH with 4q32.2, 10q22.1, 18q21.1 and 19q22 BAC probes offers promise as a biomarker
of cancer risk in H. pylori-multifocal intestinalized pangastritis.
S2002
Gene Expression Aspects of Adenoma-Dysplasia-Carcinoma Sequence - Results
of a Whole Genomic Expression Profiling Study
Orsolya Galamb, Barnabas Galamb, Norbert Solymosi, Ferenc Sipos, Sandor Spisak, Zsolt
Tulassay, Bela Molnar
Background and Aims: Gene expression analysis of colon biopsies using high-density oligonu-
cleotide microarray can contribute to the understanding of local pathophysiological alterations
and to functional classification of precancerous adenoma, different stage colorectal carcinomas
(CRC). As the most CRC develop on the basis of villous adenomas, we focused on the gene
expression aspects of adenoma-dysplasia-carcinoma sequence. Methods: Total RNA was
extracted, amplified and biotinylated from frozen colonic biopsies of 15 patients with CRC,
15 with villuos adenoma (9 dysplastic, 6 non-dysplastic) and 8 healthy normal controls.
Genome-wide gene expression profile was evaluated by HGU133 Plus2.0 microarrays. Gene
expression was also measured by Taqman real-time PCR. RMA background correction,
quantile normalization and median polish summarization were used. Kendall's rank correla-
tion was performed for quantification of association between the expression level and the
disease stages. Results: Seventeen genes were identified which shows significantly increasing
gene expression tendency both in microarray and RT-PCR analysis (p<0.05), according to
the normal-adenoma-dysplasia-carcinoma sequence. The top increasing tendency showing
genes are melanoma cell adhesion molecule, collagen type IV alpha 1, biglycan, interleukin-
8, matrix GLA protein, thrombospondin-2, von Willebrandt factor, and osteopontin. Five
genes showed significantly decreasing expression pattern both in microarray and RT-PCR
analysis (p<0.05), including prostaglandin D2 receptor, ATP-binding cassette, sub-family
A, member 8, chemokine (C-X-C motif) ligand 12, amnionless homolog and brain creatine
kinase. Conclusions: The genes which were identified as an increasing or decreasing tendency
showing genes according to the adenoma-dysplasia-carcinoma sequence, can be the progres-
sion markers of the colorectal carcinogenesis and tumor progression. Tissue microarray
analysis of the potential markers at protein level on expanded set of samples is planned.
Furthermore, our whole genomic microarray analysis of biopsy samples provides discriminat-
ive signatures, data warehouse, and an insight into pathophysiological background of
colonic diseases.
S2003
Progression Markers of Early and Late Stage Colorectal Cancer Determined By
Protein Arrays
Sandor Spisak, Orsolya Galamb, Norbert Solymosi, Barnabas Galamb, Balazs Nemes,
Ferenc Sipos, Tamas Zagoni, Zsolt Tulassay, Bela Molnar
Background and aims: Colorectal cancer progression markers could be important diagnostic
and therapeutic targets. The protein chip technology could be utilised for the parallel
evaluation of large number of proteins at the same time. Patient and methods: From 10
Dukes B and 6 Dukes stage D colorectal cancer patient, malignant and normal specimen
were collected and fresh frozen immediately after surgery. Proteins were purified by Alumina
(Sigma) from homogenized collected tissue and were labelled by monoreactive Cy3 and
Cy5 fluorescent die (Amersham). The labelled samples were hybridized by die swap labelled
technique on AB500 antibody array (BD) and scanned by a Genepix scanner (Molecular
Devices). R statistical software and Bioconductor limma and marray programme packages
were used for data analysis. The background reduction was performed by RMA and normexp
normalization methods. Quantile normalisation method was applied. Significantly differently
expressed genes were identified by T test. The MA value or fold change of differentially
expressed proteins was determined. Results: The normal and CRC samples could be distingu-
ished according to protein expression markers. Examining these two groups we found 53
differentially expressed genes, from which 23 (tumor protein p73, caldesmon 1, heat shock
90kDa protein 1, alpha) was down regulated and 30 (DNA topoisomerase I, cyclin A1) was
up regulated in tumour samples. To separate normal and Dukes 'B group 74 genes were
applicable, from which 27 (interleukin 13, syntaxin 8) was down regulated and 47 (heat
shock 60kDa protein, nuclear mitotic apparatus protein 1) was up regulated at protein level.
Examining normal and Dukes'D groups we found 68 differentially expressed protein, where
27 (TNF receptor-associated factor 2, B-cell CLL/lymphoma 2) was down regulated and 41
(tyrosine kinase 2, cyclin D3) was up regulated. We managed to separate the two groups
of tumour with the evaluation of 12 differentially expressed genes, where 5 was down
regulated (syntaxin 8, sequestosome 1) and 7 was up regulated (cyclin A1 CDC-like kinase
1). In some cases we found signs of HPV 16 infection in tumour samples. The expression
in cases of C-myc oncogene, Caveolin 1, HPV 16, COX-2, TGF-B was confirmed on tissue
microarrays composed from the paraffin embedded surgical samples by immunhistochemis-
try. Discussion: Protein arrays can identify progression and diagnostic markers colorectal
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surgical specimen. The found new markers can be introduced into immunhistochemical
protocols and evaluated by further therapeutic studies as potential targets.
S2004
Clinical Significance of Microsomal Prostaglandin E Synthase Expression in
Colorectal Cancer
Atsushi Tatsuguchi, Tsuguhiko Seo, Keigo Mitsui, Masaoki Yonezawa, Shu Tanaka, Shunji
Fujimori, Katya Gudis, Seiichi Shinji, Takashi Tajiri, Teruyuki Kishida, Choitsu Sakamoto
Background: Cyclooxygenase (COX)-2-derived PGE2 has been shown to modulate cancer
progression. Microsomal prostaglandin E synthase (mPGES)-1 functions downstream of
COX-2 for PGE2 biosynthesis and its overexpression has been associated with colorectal
adenocarcinoma. Studies have shown that another PGE synthase, mPGES-2, can also couple
with COX-2; however, the relationship between this isomer and clinicopathological factors
and patient prognosis has yet to be explored in colorectal cancer. Aim: To investigate mPGES-
1 and mPGES-2 protein expression in human colorectal cancer and determine the relationship
between their expression and clinicopathological factors, patient prognosis and COX-2
expression. Methods: We examined 96 surgical resections from colorectomy patients and
10 paired biopsies from endoscopy patients. mPGES-1 and mPGES-2 protein expression
were analyzed in colorectal biopsies by Western blot and their cellular localization in
colorectal cancer surgical resections by immunohistochemistry. Immunohistochemical results
were compared with clinicopathological factors, patient prognosis and COX-2 expression.
Results: Western blot analysis showed that mPGES-1 protein expression was significantly
higher in neoplastic than in paired non-neoplastic biopsy samples. mPGES-2 protein expres-
sion was found in neoplastic and paired non-neoplastic biopsies. mPGES-1 immunoreactivity
was predominantly observed in the cytoplasm of cancer cells in 50 cases (52%). mPGES-2
immunoreactivity localized in the cytoplasm of glandular epithelial cells of non-neoplastic
mucosa and ranged from negative to moderate. In neoplastic tissue, mPGES-2 protein
localized with apparent uniformity in the cytoplasm of cancer cells. However, in 44% (42/
96) of cases, mPGES-2 immunoreactivity was significantly more pronounced in cancer cells
than in adjacent glandular epithelium and these cases were defined as positive. Both mPGES-
1 and mPGES-2 expression correlated with tumor recurrence but no other clinicopathological
factors including depth of invasion, lymph node metastasis, and stage. Statistically, the two
protein expressions did not correlate with each other. In univariate analysis, mPGES-1 and
mPGES-2, but not COX-2, correlated with worse prognosis in stage II and III patients (N=54).
In multivariate analysis, mPGES-1, mPGES-2 expression retained independent prognostic
significance. Conclusions: mPGES-1 and mPGES-2 protein expression may be regulated
differently, and may play important roles in colorectal tumor progression. In addition, these
proteins may be useful biologic markers of prognostic significance in stage II-III colorectal
cancer patients.
S2005
Altered Gene Expression Levels in Formalin-Fixed, Paraffin-Embedded Tumor
Biopsies Are Molecular Markers of Gastric Cancer
Timothy P. Millar, Charles E. Hammond, Arindam Saha, Adam J. Smolka
Gastric cancer (GC) is the second leading cause of global cancer-related death, accounting
for 3% of U.S. cancer mortality. When diagnosed, only patients with local neoplasms (25%)
are candidates for curative resection, with 30% 5-year survival; The rest show locoregional
lymph node metastases (50%) and distant metastases (25%) with <1 year survival. As part
of an effort to identify molecular markers for early detection of GC, we sought to detect
differences in selected gene expression levels in archived normal and neoplastic gastric
mucosal biopsies. Gene-specific intron-spanning forward and reverse PCR primers were
designed to amplify 11 genes associated in the literature with GC (aldh3A1, anxa1, cdh1,
ddx1, igfbp3, met, pck1, cerbB2, egfr, nqo1, and pgc). Amplicon specificity was confirmed by
dissociation profile analysis, gel electrophoresis, and DNA sequencing. RNA was isolated
from formalin-fixed, paraffin-embedded tissue (FF-PET, 20 µm sections) from tumor and
histologically-normal marginal tissue gastric biopsies from 20 patients diagnosed with GC
(MUSC Tumor Bank). RNA samples were reverse-transcribed using truncated gene-specific
reverse primers, and SYBR Green real-time RT-PCR analyses were performed on a BioRad
iCycler iQ. Negative controls confirmed >10 Ct difference (210-fold less product) in reactions
lacking reverse transcriptase. Three separate RNA preparations were analyzed for each pair
of biopsy sections for each patient. Raw Ct data for each target gene were quantified as ΔCt
by normalization to Ct values for an internal control gene (glyceraldehyde-3-phosphate
dehydrogenase). All 11 target genes were reproducibly detected in both normal and tumor
gastric biopsy sections at ΔCt values ranging from 1.07 to 5.30. Differences in gene expression
levels for aldh3A1, anxa1, cdh1, ddx1, igfbp3, met, and pck1 were not significantly different
when tumor RNA was compared to normal marginal tissue RNA. In contrast, ΔCt values
for 4 genes were significantly different (P ≤0.05) between tumor and normal tissue as
shown. Receiver operator characteristic curve analysis showed cerbB2, egfr, nqo1, and pgc
were moderately accurate in discriminating tumor from normal tissues (AUC values from
0.864 to 0.733). We conclude that real-time RT-PCR analysis of archived gastric FF-PET
biopsies may be a valuable resource for retrospective studies evaluating putative GC molecu-
lar markers.
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S2006
Glycosphingolipid Globotriaosylceramide (Gb3) and the Colorectal Adenoma-
Carcinoma Sequence
Olga Kovbasnjuk, Linda M. Hylind, Oksana Gutsal, Christine Iacobuzio-donahue, Francis
M. Giardiello
Background: Glycospingolipid is abundant in the outer leaflet of plasma membranes of
eukaryotic cells. Globotriaosylcermide (Gb3) is an abnormal glycosylation found in an
invasive phenotype of colorectal cancer cells and thought to be a marker of metastatic disease
in human colorectal cancer. However, the presence of this marker in adenomatous polyps,
primary colorectal cancer and metastatic lesions has not been well studied. Methods: The
presence of Gb3 in normal colorectal mucosa, adenomatous polyps, primary colorectal
cancers and metastatic liver implants was studied by fluorescence microscopy. The amount
of Gb3 staining (the relative amount of Gb3 per each cell) was calculated per 5x5 um area
of epithelial cells labeled by pan-keratin antibody and expressed as the average of Gb3 per
unit area of epithelial cell. Results: Gb3 was present in the normal mucosa of 0/8 (0%)
healthy controls, in 7/9 (78%) tubular adenomas, 7/12 (58%) primary colorectal cancers
and 4/4 (100%) of hepatic metastatic lesions. There was a statistically significant difference
in the frequency of the presence of Gb3 between controls and: 1) tubular adenomas (p<0.01),
2) malignant disease (primary cancers and metastasis) (p<0.01), and 3) colorectal neoplasia
(adenomas, primary cancers and metastasis) (p<0.001). There was no statistically significant
difference in intensity of Gb3 between tubular adenomas (108+/-35.6 (SD)), primary colorec-
tal cancers (123+/-67) or hepatic metastasis (110+/-43). Conclusion: GB3 is found in prema-
lignant colorectal lesions (tubular adenomas) as well as malignancy (primary colorectal
cancer and metastasis) suggesting abnormal glycosylation is an early event in the adenoma-
carcinoma sequence occurring at the junction of normal and neoplastic tissue. Gb3 may be
a useful marker for colorectal cancer screening. Supported by: The John G. Rangos, Sr.
Charitable Foundation, The Clayton Fund, NIH grants K07 CA092445, CA 53801, and P50
CA 62924-10.
S2007
Validity and Reliability of the Endoscopic Diagnosis of Aberrant Crypt Foci
Akshay K. Gupta, Paul Pinsky, Christopher Rall, Matthew G. Mutch, Robert E. Schoen
Introduction: Aberrant crypt foci (ACF) have emerged as a potential biomarker for colorectal
carcinoma. High magnification chromoscopic colonoscopy (HMCC) can identify ACF In
Vivo. However, there are a number of criteria used to describe ACF endoscopically, resulting
in wide variability in the reported prevalence rates of ACF. Studies of the validity of
ACF assessment in relation to histologic diagnosis and studies of reproducibility across
endoscopists are lacking. Methods: Validity: Step 1: 50 photos of purported ACF, obtained
prospectively via HMCC in the Prostate Lung Colorectal and Ovarian Cancer screening trial
ancillary study of ACF, whose histological diagnosis was known, were shown to 5 endoscop-
ists blinded to the histology results. On histology, 29 out of the 50 were confirmed ACF.
The sensitivity and specificity of HMCC was calculated for each endoscopist using histology
as the gold standard. Step 2: Because of variability across endoscopists, each photo was
assessed by a single independent observer for endoscopic criteria that have been used to
define ACF in the literature. The criteria used were the number of crypts in the lesion,
distinctness of margin, deeper color staining, outer and luminal diameter of the crypts,
shape of the crypt lumen, and epithelial thickness. Each of these criteria was assessed for
its predictive value towards histological confirmation of an ACF. Reliability: A panel of 4
endoscopists examined 3 sets of 10 images suspected to be ACF on HMCC sequentially,
over time. Each assessment involved rendering an endoscopic diagnosis (i.e., is it an ACF?)
and scoring each image on a set of endoscopic criteria used in step 2 above. Results: Validity:
Step 1: The sensitivity and specificity of endoscopic ACF diagnosis using HMCC was on
average 70% (range 55 - 90) and 59% (range 38 - 76) respectively across the 5 endoscopists.
Step 2: On regression analysis, only the epithelial thickness of the crypts in the lesion could
significantly predict the results of histology (P = .033). Number of crypts in the lesion and
the diameter of the entire crypt were of borderline significance. Reliability: Agreement was
> 70% for the endoscopic diagnosis of an ACF, and for each of the individual criteria in
all 3 sets, but agreement did not appreciably improve over time. Conclusions: HMCC for
diagnosis of ACF has wide variability in sensitivity and specificity across endoscopists. Of
the multiple endoscopic criteria evaluated to diagnose ACF, only increased epithelial thickness
was significantly associated with histologic confirmation. Inter - rater agreement rates of
endoscopic criteria describing ACF are acceptable.
S2008
Clinical Significance of Cystatin Sn As a Novel Biomarker for Colorectal
Cancer
Kyoko Yonemitsu, Hiroki Endo, Hirokazu Takahashi, Yasushi Ichikawa, Hiroshi Shimada,
Hiroshi Uozaki, Masahisa Fukayama, Hiroyuki Aburatani, Tatsuhiko Kodama, Yukio Ito,
Mina Sagara, Chihiro Miyazawa, Atsushi Nakajima
BACKGROUND: Cystatin SN is a molecular which was identified by comprehensive gene
analysis of colorectal cancer. Cystatin SN is secretory protein, inhibitor of cysteine proteinases,
expressed in normal salivary gland and highly expressed in colorectal cancer. We investigated
the utility of cystatin SN as a novel biomarker for colorectal cancer. METHODS: Monoclonal
antibody to Cystatin SN and enzyme-linked immunosorbent assay (ELISA) system was
developed. We investigated correlation between serum Cystatin SN concentration and the
lesion, and compared to carcinoembryonic antigen (CEA) and carbohydrateantigen 19-9
(CA19-9). The study was performed on 121 patients who underwent colonoscopy and/or
operation for colorectal cancer. And histopathological examination using monoclonal anti-
body to Cystatin SN was performed. RESULTS: 121 patients are 15 patients with advanced
colorectal cancer, 7 patients with early colorectal cancer, 41 patients with adenoma, and
58 patients without colorectal lesion as control. Serum cystation SN concentration is signific-
antly high in colorectal cancer patients in comparison with non-cancer patients (p<0.0001).
Serum cystation SN concentration is significantly high in colorectal cancer patients in
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comparison with adenoma patients (p=0.0005), and with control (p<0.0001). The data
showed good correlations between presence of cancer and serum cystation SN concentration
than CEA and CA19-9. Histopathological examination revealed that the cancer and the
adenoma are immunostained in part by Cystatin SN antibody, suggesting that the cancer
and the adenoma express Cystatin SN. CONCLUSION: Cystatin SN is increased in advanced
colorectal cancer. Serum cystation SN concentration is significantly high in colorectal cancer
patients in comparison with non-cancer patients. Concerning the existence of cancer, Cystatin
SN showed good correlations than CEA and CA19-9 as frequent used biomarkers. Our
results suggest that Cystatin SN is a novel biomarker for colorectal cancer, and that sensitivity
and specificity is better than conventional biomarkers.
S2009
Identification of Serum Biomarkers of Pancreatic Cancer Using Stable Isotope
Labeled Proteome Standard and Extensive Multidimensional Liquid
Chromatography Mass Spectrometry
Kenneth H. Yu, Colin G. Barry, David Austin, Anil K. Rustgi, Ian A. Blair
The purpose of this study was to identify biomarkers of pancreatic cancer in human serum.
Two major obstacles to this goal are the high abundance of many nonspecific proteins and
the low abundance of proteins of interest. These obstacles were addressed by developing a
labeled proteome internal standard, extensive sample separation, followed by ultra-high
resolution and mass accurate mass spectrometry (MS). Levels of many acute-phase proteins
are elevated in pancreatic cancer. These proteins lack the sensitivity and specificity of clinically
useful biomarkers. The use of a stable isotope labeled proteome derived from the secreted
proteins produced by a pancreatic cancer cell line as an internal standard makes it possible
to focus only on proteins derived from pancreatic cancers, and to accurately quantitate their
relative levels in human serum. CAPAN-2 cells were grown to near confluence in DMEM
containing [13C6,15N1]leucine and [13C6,15N2]lysine (Cambridge Isotopes) and 10%
dialyzed FBS. The cells were passaged at least five times, and subsequently grown in ITS
supplemented serum-free media. Conditioned media was collected, pooled and aliquoted.
Proteins were separated by 1-D gel electrophoresis and trypsin digested. In parallel, proteins
were trypsin digested and separated by strong cation exchange (SCX). Peptides were analyzed
by reversed-phase LC/MS/MS using a Finnigan LTQ-FT mass spectrometer. Raw spectra
were searched against the RefSeq Human database, and protein identifications determined
with Peptide Prophet and Protein Prophet (Institute for Systems Biology). 696 unique proteins
were identified. Analysis of the mass spectra revealed that incorporation of [13C6,15N1]leuc-
ine and [13C6,15N2]lysine into the proteome was > 99%. 1 mg of the labeled proteome
was added as an internal standard to either pooled serum from 6 patients with early stage
pancreatic cancer or serum from 6 patients with benign pancreatic disease. Extensive sample
separation was performed beginning with immunodepletion of the top-12 serum proteins
and isoelectric focusing along IPG gel strips. Gel strips were divided into 9 sections, proteins
were trypsin digested and further separated by SCX prior to analysis by reversed-phase LC/
MS/MS as previously described. A number of proteins identified in the conditioned media
were increased in sera from patients with pancreatic cancer. A larger set of serum samples
will be analyzed to determine the clinical utility of these potential biomarkers. Supported
by NIH grants P30 CA16520, RO195586, R25 CA101871, ITMAT Research Fellowship and
AGA/FDHN Bernard L. Schwartz Designated Research Award in Pancreatic Cancer.
S2010
The Cyclin Dependent Kinase Inhibitor, P27Kip1, Has NO Correlation with the
Malignant Potential of Gastrointestinal Stromal Tumors (GISTs)
Haim Shirin, Vladimir Kravtsov, Mark Shahmurov, Vered Sheyak-shabat, Ivgeni
Krinshpon, Avi Alin, Ilana Avinoach, Yona Avni
BACKGROUND: Tumor size and mitotic activity are characteristically associated with the
malignant potential and prognosis of gastrointestinal stromal tumors (GISTs). However,
since neither small tumor size nor low mitotic activity can rule out malignancy, additional
factors that may predict malignant behavior have been suggested. AIM: To evaluate the
correlation between the cyclin dependent kinase inhibitor (CDI), p27kip1 expression and
the malignant potential of GIST. METHODS: Serial sections were evaluated by immunohisto-
chemistry after staining with antibodies against p27/Kip1 and Ki-67 in surgical material
obtained from 36 patients with GIST, mean age 68.7. GISTs were classified as suggested
by the National Institutes of Health into four groups: very low, low, intermediate and high
risk GISTs. p27kip1 staining intensity and the percentage of positive cells were investigated
for association with different groups, pathological features, overall survival, and disease-free
survival. Histologic grade was assigned by spindle vs. epithelioid cell histology, the presence
of mucosal invasion, tumor cell necrosis or atypia and the number of mitoses per 50 high-
power fields. RESULTS: One patient was classified as very low risk, five as low risk, fourteen
as intermediate and sixteen as high risk. Clinically, twenty six patients were defined as
benign and ten patients as malignant GIST. p27kip1 did not differ by sex, clinical presentation
or location of the tumor. Regarding size, p27kip1 values did not differ between subjects with
small (<5cm), medium (5-10 cm) or large diameter (>10 cm) of tumors. p27kip1 also did
not differ by predominant spindle cell or epitheloid cell types of GIST, but subjects with
atypia had significantly higher p27kip1 values (1.7±0.9 vs. 0.96±0.9, p=0.03). p27 did not
differ across low, intermediate and high risk groups. Among the thirty six patients who
underwent surgery, five died perioperatively and five patients died during the follow up
(1992-2003) because of unrelated diseases to GIST. Only one patient died because of
recurrancy of his GIST. However, comparative evaluation of p27kip1 expression in GIST
cells revealed higher levels of p27kip1 in patients who died compared to those who survived
(2.04±0.54 vs. 1.3±0.99,p=0.1). In the multivariate model, the expression of p27kip1 was
not significantly associated with any of the variables examined except Kit protein-CD117,
(r=0.37,p=0.03). CONCLUSION: The cyclin dependent kinase inhibitor p27kip1, was not
associated with the malignant potential of GISTs and did not serve as a predictor of survival.
S2011
MMP-9 -1562 C/T Promoter Polymorphism Associated with Gastric Cancer
Development in Female
Chun-ying Wu, Ming-shiang Wu, Hsiao-ping Chen, Chien-jen Chen, Gran-hum Chen,
Jaw-town Lin
Background&Aims: Matrix metalloproteinase-9 (MMP-9) plays an important role in cancer
invasion and metastasis. Enhanced expression of MMP-9 in tumor tissues or plasma has
been reported to correlate with invasiveness of a variety of cancer, including gastric cancer.
However, how MMP-9 genetic polymorphisms influence the occurrence and outcome of
tumors is less investigated. Methods: The present study was based on previously stored
peripheral blood samples from 263 gastric cancer patients and 354 healthy controls. MMP-
9 genotyping was done using PCR-RFLP method. Logistic regression analyses and Cox
proportional hazards analyses were used to evaluate the associations between polymorphisms
and gastric cancer susceptibility, clinicopathological features, and survival. Results: We did
not find statistically significant difference in MMP-9 -1562 genotype frequencies between
cases and controls. However, female patients had higher C/T or T/T genotypes compared
with female controls (OR=2.12, 95% CI: 1.13-3.96, P=0.02), especially in the older age
subjects (OR=2.64, 95% CI: 1.02-6.84, P=0.04). This polymorphism did not correlate
well with clinicopathological characteristics of gastric cancer. On Cox proportional hazards
analyses, serosal invasion and lymph node metastasis, not MMP-9 polymorphism, were
independent prognostic factors for survival. Conclusions: MMP-9 -1562 C/T polymorphism
may be used as a marker to predict gastric cancer development in female subjects, especially
in the elderly.
S2012
Hmlh1, Hmsh2 and Cyclooxygenase-2 (COX-2) in Sporadic Colorectal Polyps:
Immunohistochemical Study and Its Importance in the Colorectal
Carcinogenesis
Raul A. Balbinotti, Adriana V. Safatle-ribeiro, Ulysses Ribeiro, Paulo Sakai, Cristovam
Scapulatempo, Regina M. Catarino, Carlos E. Corbett, Venâncio A. Alves
Colorectal adenomatous polyps are known as premalignant lesions. Mutations in the mis-
match repair (MMR) enzymes hMLH1, hMSH2 and hMSH6 are recognized causes of heredit-
ary nonpolyposis colorectal cancer and act by inducing a mutator phenotype characterized
by microsatellite instability (MSI). MSI is also detected in sporadic colorectal cancers. COX-
2 is an inducible enzyme that regulates prostaglandin synthesis and is overexpressed at
sites of inflammation, in colorectal adenomatous polyps and cancer. Aims: To evaluate the
immunoexpression of hMLH1, hMSH2 and Cox-2 in polyps resected through colonoscopy,
and to associate to the clinicopathologic characteristics (age, gender, location, size, histology
and grade of dysplasia). Methods: 167 patients with colonic polyps, 6 normal colonic mucosa,
and 23 patients with colorectal adenocarcinoma were enrolled in this study. All patients
had no familial history of colorectal cancer. The samples were prospectively collected and
immunostained for hMLH1, hMSH2 and Cox-2 using the ABC-immunohistochemistry tech-
nique and amplification by biotinylated tyramide. Results: The mean age was 60.2 + 13.8
(varying from 21 to 90 years-old) and 77 (55.8%) were men. Tubular adenomas were
present in 81.4%, tubulous-villous in 15.9%, serrated in 1.8%, and villous in 0.9%. The
majority of the adenomas were located in the retossigmoid region (63.5%), followed by
ascendent in 14.2%, cecum in 7.5%, descendent in 8.2%, and transverse in 6.7%. High-
grade dysplasia was detected in 59.6% of the adenomas. Loss of hMLH1 and hMLH2
immunoexpression was observed in 20% and 15.5% of the adenomas, respectively. Cox-2
was positive in 9% of the adenomas, and in 40% of the adenocarcinomas. Moreover, Cox-
2 immunoexpression was associated to the multiplicity of adenomas in the same patient,
p=0.001. There was no association between marker immunoexpression and gender, age,
location, size, histology or grade of dysplasia. Conclusions: 1. Loss of hMLH1 and hMLH2
immunoexpression in adenomas is relatively frequent in patients without colorectal cancer
familial history; 2. Cox-2 is overexpressed in colorectal adenomatous polyps and adenocarcin-
omas, and its positivity in adenomas may indicate higher risk for multiple lesions.
S2013
Mass Spectrometry-Based Biomarker Discovery in Mouse Models of Intestinal
Tumor
Kenneth Hung, Samuel Volchenboum, Alvin Kho, David Sarracino, Larissa Georgeon
richard, Bryan Krastins, Raju Kucherlapati
Early detection of colorectal cancer (CRC) can greatly improve prognosis. However, screening
is limited by current colonoscopy resources and patient compliance. One attractive discovery
approach utilizes mass spectrometry to identify disease-associated plasma proteins. Once
identified, these biomarkers can then be detected in the clinic using standard ELISA tests.
As a prelude to human studies, we have focused on the Apc D580 model for CRC. For
these studies, plasma was obtained from intestinal tumor-bearing and control animals.
Samples were reduced, alkylated, and digested with trypsin. The resulting peptides were
fractionated using a strong cation exchange (SCX) column. The samples were analyzed by
LC-MS/MS using a Thermo LTQ-FT hybrid mass spectrometer. The resulting spectra were
analyzed by both Bioworks 3.2 (SEQUEST) and the Computational Proteomics Analysis
System (CPAS). Over 500 proteins were identified using this approach. Some of the differenti-
ally expressed proteins were noted to be involved in processes such as cell adhesion, cell
growth, and Wnt signaling. Principal component analysis and agglomerative clustering
analysis demonstrated that these protein profiles were able to distinguish between tumor-
bearing and control animals. A greedy search algorithm was used to identify small subsets of
proteins that were able to predict the presence of tumor. We are currently using commercially
available antibodies to validate candidate biomarkers by immunoblot of plasma and immuno-
histochemistry of tumor tissue. These studies illustrate the potential of combining mass
spectrometry with mouse cancer models for human biomarker discovery. Ultimately, these
efforts might lead to the detection of cancer from a single drop of blood.
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Genotype-Phenotype Characterization of Loss of Genomic Imprinting of IGF2-
Positive Colorectal Cancer
Marcia R. Cruz-correa, Ronghua Zhao, Myrian Oviedo, Norma Daniel, Linda M. Hylind,
Chenhua Luo, Juan Nogueras, Dana Sands, Eric G. Weiss, Steven D. Wexner, Frank
Giardiello
Background. Loss of genomic imprinting (LOI) of IGF-2 is an independent risk factor for
colorectal cancer (CRC), however the LOI-positive CRC phenotype has not been previously
characterized. Aim. This study determined the clinicopathological characteristics of LOI-
positive CRC patients compared to the LOI-negative CRC individuals. Patients andMethods.
We performed PCR on gDNA and RT-PCR on RNA extracted from normal peripheral blood
lymphocytes (PBL) of prospectively recruited RC patients, followed by Apa I digestion. Based
on Apa I DNA polymorphism, the informative (heterozygosity) and imprinting status of
IGF2 gene were determined. Several clinical and pathological characteristics were evaluated
including: age at diagnosis, gender, family history of CRC, tumor stage, differentiation, size,
lymph node involvement, and size. Statistical analysis was performed by using logistic
regression, Mann Whitney test, Kruskal-Wallis test using STATA 9.0. Results. Of 239
patients recruited, 82 were informative based on Apa I DNA polymorphism and eligible for
analysis. Fifty-six patients (22 males; age: 55.7±12.7) were LOI-negative, and 26 patients
(13 males, age: 61.6±15.3) were LOI-positive; 39 patients had rectal and 43 patients had
colon cancer. The odds ratio for the association of LOI of IGF2 with CRC was 5.3 (95%
CI 2.3-11.7), 6.04 (95% CI 2.27-16.3), and 3.94 (95% CI 1.36 - 11.4) for all CRC, rectal,
and colon cancer, respectively. Evaluation of the clinicopathological characteristics was
performed for all CRC cases, and separately for rectal and colon cancer. No statistically
significant difference for any of the characteristics evaluated was found in patients with rectal
cancer. However, among patients with colon cancer, LOI-positive patients were diagnosed at
a younger age (64.9±11.6 vs. 56.1±11.4, p = 0.04), and had significantly advanced cancer
stage (Dukes D: 57% vs. 10%, p= 0.03). Conclusion. LOI-positive colon cancer patients
present at a younger age and with an advance stage of disease, compared to LOI-negative
patients. Moreover, LOI-positive colon cancer patients appear to have distinct genotype-
phenotype characteristics compared to LOI-positive rectal cancer patients. These findings
suggest a distinct carcinogenic pathway for LOI-positive patients, which may have implica-
tions in screening and risk assessment. [Support]. NIH grants K07 CA092445 and P50
CA-62924-10, The John G. Rangos, Sr. Charitable Foundation, The Cancer Research and
Prevention Foundation, The Eleanor Naylor Dana Charitable Trust and The Clayton Fund.
S2015
High Frequency of Chromosome 14 Deletion in Early-Onset Colorectal Cancer
Najat Mourra, Guy Zeitoun, Bruno Buecher, Pascal Finetti, Arnaud Lagarde, José
Adélaïde, Daniel Birnbaum, Gilles Thomas, Sylviane Olschwang
Introduction Several genes have been recognized, when mutated in the germ line, to highly
predispose to colorectal cancer, impairing the DNA mismatch repair system in HNPCC
syndrome, or APC or MYH in adenomatous polyposes. However, 10 to 15% of MSS colorectal
cancer is reported to develop in a context of genetic predisposition, leading to a large
proportion of unexplained early-onset MSS cancers. Material and methods Three independent
series of patients undergoing surgical resection for colorectal carcinoma under 50 years were
selected prospectively between 1993 and 2003. The first series of samples has been allelotyped
using 361 poly-CA polymorphisms distributed on the 39 autosomal arms within a larger
set of 166 sporadic tumours. The second series has been genotyped using 30 poly-CA
polymorphisms distributed on the 8 chromosomes exhibiting allelic losses in more than
30% of the previous cases. The third series has been genotyped on chromosome 14 only.
Results Comparison of genomic profile from patients younger and older than 50 years at
the 8 most frequently lost chromosomes allowed to identify chromosome 14 as showing a
significant difference between the 2 groups. Dense chromosome 14 genotyping was able to
detect 2 partial deletions in a general background of 55% allelic loss, pointing at a region
located between D14S63 and D14S292. Conclusion These observation suggest that a tumour
suppressor gene located on chromosome 14 might play an important role in MSS colorectal
carcinogenesis. As it appears to be more frequently involved in early-onset cases, it could
be also a good candidate in inherited conditions.
Allelic loss frequency of colorectal cancer according to age at diagnosis
* of the eight most frequently lost chromosomes in sporadic colon cancer
S2016
Germline Hypermethylation of the Mlh1 Promoter Region As the Cause of
Lynch Syndrome
Renée C. Niessen, Robert M. Hofstra, Krista Kooi, Jianghua Ou, Ana Ferreira, Maran J.
Berends, Harry Hollema, Jan H. Kleibeuker, Rolf Sijmons
Background: Hypermethylation of the MLH1 promoter region is most often a somatic event
and associated with a high degree of microsatellite instability (MSI-H) in sporadic colorectal
cancer (CRC). Recently several CRC cases with germline hypermethylation of the MLH1
promoter region were reported. In this study we studied the prevalence of MLH1 promoter
hypermethylation in a large group of Lynch syndrome (HNPCC) suspected patients. Methods:
From a group of 344 patients, that had (1) CRC < 50 yrs, and/or (2) endometrial cancer <
50 yrs, and/or (3) two or more Lynch syndrome associated cancers, irrespective of age, we
selected those, who had no MLH1, MSH2 and MSH6 germline mutation and had absent
MLH1 protein staining in the tumor or, if staining was unavailable, had MSI-H in the tumor.
In these patients DNA from lymphocytes was tested for MLH1 promoter hypermethylation
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using methylation specific PCR (and sequencing) after sodium bisulphite modification and
subsequently by denaturing gradient gel electrophoresis of the PCR products. Results: 59/
344 patients were selected. Two (2/59=3.3%, 2/344=0.6%) had MLH1 promoter hyperme-
thylation in lymphocytes. In both patients the family history for Lynch syndrome associated
tumors was negative. Patient 1 had CRC at 37 yrs. The tumor showed MSI-H, loss of MLH1
protein staining and LOH for MLH1. DNA, isolated from skin fibroblasts, a mouth wash
and the tumor also showed MLH1 promoter hypermethylation. DNA of the father, the
mother and 7 siblings showed no MLH1 promoter hypermethylation. Patient 2 had five
CRCs (48-60 yrs), endometrial cancer (52 yrs) and ureteral cancer (62 yrs). The tested
tumors showed MSI-H. Conclusion: Germline MLH1 promoter hypermethylation causes
Lynch syndrome in a small percentage of Lynch syndrome suspected patients. This possibility
should be considered in the evaluation of such patients. Supported by the Dutch Cancer
Society RUG 2002-2678
S2017
The Characterization of a French Cohort of Multiple Polyposis Patients
Reveals a Very High Frequency of Myh Mutation Carriers: A Phenotypic and
Genotypic Prospective Study
Yvan Graber, Stephane Pinson, Driffa Moussata, Bénédicte Gelas-dore, Claude Barthelemy,
Michel Pelletier, Didier Pillon, Henri Moindrot, Bernard Nallet, Lapalus Marie-georges,
Dominique Leroux, Fabienne Prieur, Jean-christophe Saurin
Aim : Multiple colorectal polyposis (MP) is defined by the presence of 1-100 adenomas
excluding classical familial adenomatous polyposis (FAP). Several studies have shown that
atypical APC germline mutations were responsible for a small fraction of cases with MP.
We performed this prospective study to characterize the phenotype, epidemiology and
genetics of a french cohort of MP patients. Methods : One hundred fifty consecutive patients
with at least 3 synchronous colorectal adenomas, excluding known FAP or HNPCC cases,
were included in 8 gastroenterology units of the Rhône-Alpes region. Patients were submitted
to a standardized upper and lower endoscopy (indigo-carmin, lateral viewing in the duo-
denum), an epidemiological questionnaire, and genetic counselling. We report the clinical
and genetic data of the first 53 patients with complete analysis (denaturating high performance
liquid chromatography) of the MYH gene. Results : The 53 patients (mean age 63 years,
range 41-81) had a mean of 6 (1-21) adenomas. APC gene screening was negative in the
first 20 cases. In contrast, 27 cases (51 %) were at least heterozygous for a mutation in the
MYH gene (23 heterozygous, 4 homozygous). A diffuse colonic polyposis (defined by the
presence of at least 10 lesions after indigo carmine dye) was observed in only 2 patients (1
heterozygous MYH, one without mutation), and duodenal adenomas were reported in only
2 patients. None of the 4 MYH homozygous patients had a phenotype compatible with
classical nor attenuated FAP, and the number of colorectal adenomas was not increased in
cases with as compared to those without germline MYH mutation. A family history (presence
in one first degree relative, or involving 2 generations) of adenomatous polyps or colon
cancer was present in 35 % versus 58 % and 26 % versus 50 %, in patients without or
with MYH germline mutation, respectively. Conclusion : This phenotypic and genotypic
study in a French PM cohort reveals the highest ever reported frequency of MYH mutations
in a defined population. Interestingly, the colonic phenotype of MP polyposis patients
appears independent on the MYH mutation status, and far from attenuated FAP cases, but
the family history of colon adenomas and cancer appears stronger in MYH mutation carriers.
This study has important implications for the clinical management of what seems to be the
most frequent genetic predisposition to colon cancer.
S2018
Peroxisome Proliferator- Activated Receptor Gamma (Pparγ) Plo12ala
Polymorphism Influences the Susceptibility of Japanese to Gastric Cancer
Tomomitsu Tahara, Tomiyasu Arisawa, Mikijyu Sakata, Tomoyuki Shibata, Masakatsu
Nakamura, Ichiro Hirata, Hiroshi Nakano
(BACKGROUND) Genetic factors may play important roles in gastric carcinogenesis, but
all the mechanism is not clearly demonstrated. Activation of peroxisome proliferator- activated
receptorγ (PPARγ) has been shown to inhibit the proliferation of gastric cancer cells and
suppress gastric mucosal inflammation induced by H. pylori. Plo12Ala polymorphism affects
codon12 of the PPARγgene and alters its promoter activity. (AIM) We aimed to clarify the
relationship of PPARγ gene Pro12Ala polymorphism with the risk of gastric cancer, the
degree of H. pylori induced gastritis in Japanese population. (SUBJECTS) The study was
performed on 215 with gastric cancer (GC) patients (mean age 65.0 [29-91], F:M=0.29) and
201 patients without GC (mean age 64.0 [29-92],F:M=0.32) as a control group. (METHODS)
Plo12Ala polymorphism of PPARγ was investigated by polymerase chain reaction-restriction
fragment length polymorphism in all of the subjects. The odds ratio (OR) and 95% confidence
interval (CI) were calculated by logistic regression with adjusment for age, sex, and H. pylori
infection status. The gastritis score of noncancerous antral mucosa was calculated by the
updated Sydney system. (RESULTS) Plo12Ala genotype of PPARγ showed a significantly
higher frequency in GC patients than in controls (OR=2.43; 95%CI=1.04-5.67). The Plo12Ala
genotype was associated with an increased risk of non-cardiac gastric cancer (OR=2.39;
95%CI=1.02-5.65), lower third gastric cancer (OR=3.56; 95%CI=1.31-9.71), advanced can-
cer (OR=2.93; 95%CI=1.13-7.58), and Lauren's intestinal cancer (OR=2.94; 95%CI=1.13-
7.66). We also found that the Ala12 allele tended to increase the risk of venous invasion
(OR=3.12; 95%CI=0.98-9.93) and lymph node metastasis (OR=2.38; 95%CI=0.89-6.40).
Among H. pylori-positive subjects, the atrophy and metaplasia scores of the antral mucosa
were significantly higher in those with the12Ala allele. (CONCLUSION) Our data suggest
that the 12Ala allele of PPARγ may be associated with gastric mucosal atrophy in H. pylori-
infected patients, and may increase the risk of gastric cancer in the Japanese population.
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S2019
Identification of Mlh1 and Msh2 Mutations By Means of a Predictive Model in
Colorectal Cancer Patients
Xavier Bessa, Lucía Marquez, Francesc Balaguer, Xavier Llor, Rodrigo Jover, Antoni
Castells, Montserrat Andreu
Identification of mutations in germ-line DNA mismatch repair genes in CRC patients has
important implications in their management. Different predictive models had been published
recently Objective To develop a predictive model for detection of deleterious mutations in
MLH1 and MSH2 genes in CRC patients Aims and methods The study population was 1222
patients with newly diagnosed CRC from a prospective, multicenter, nationwide study in
20 hospitals in the general community in Spain (JAMA 2005;293:1986-1994). Demographic,
clinical, pathological, molecular, and familial characteristics were analyzed. Patients whose
tumors exhibited microsatellite instability and/or lack of protein expression underwent
MSH2/MLH1 germline testing. Germline testing identified 11 mutations (0.9%) in either
MSH2 (7 cases) or MLH1 (4 cases) genes. A multivariate predictive model was developed
by means of a logistic regression model. Results Univariate analysis identified as predictive
variables gender, age less than 50 years, personal history of HNPCC-associated neoplasia,
differentiation degree, a first-degree family history with CRC and a first-degree family history
with CRC before the age of 50 years. Multivariable analysis identified as independently
variable gender (OR 13.9;IC95%:1.6-121.5), age less than 50 years (OR 19.9;IC95%:3.7-
108.9), personal history of HNPCC-associated neoplasia (OR 30.9;IC95%:6.0-159.6) and a
first-degree family history with CRC before the age of 50 years (OR 10.9;IC95%:2.1-57.1).
The discrimination value of the predictive model was established by means of a ROC curve,
with the area under the curve 0.88 (IC95%: 0.75-1.01). Conclusion A complete personal
and familial history in CRC patients may be useful in predicting the risk for germline
mutations in the DNA mismatch repair genes
S2020
Higher Incidence of Rectal Cancers and Frequent Loss of Hpms2 and Hmsh6
Expression Are Seen in Young, Non-Familial Colorectal Cancer Patients
Ajay Goel, Jennifer Spiegel, Takeshi Nagasaka, Sheryl Livingston, Richard Meyer, Warren
E. Lichliter, C. richard Boland
Colorectal cancer (CRC) occurs rarely in individuals <50 years, and is a heterogeneous group
including patients with Lynch syndrome, and those with other non-familial, sporadic cancers.
Lynch syndrome is a genetic disorder caused by germline mutations in DNA mismatch
repair (MMR) genes. Aim: This study examined the patterns of DNA MMR protein expression
and microsatellite instability (MSI) in patients <50 years old with sporadic, apparently non-
familial CRC. Methods: Paraffin embedded tissue sections were obtained from 82 patients
with CRC, all <50 years old, who did not come from a familial cluster of CRC. Immunohisto-
chemical (IHC) staining was performed for hMLH1, hMSH2, hMSH6, and hPMS2 proteins.
MSI analyses were performed using a panel of 5 mononucleotide markers in a pentaplex
PCR, and used consensus criteria for MSI (>2 mutations=MSI-H). Results: The mean age of
the patient cohort was 34.4 years (range 16-47 years); 52% were female. Only 26% (22/
78) of the tumors were located in the right colon, while 74% (56/78) were located in the
left colon. Unexpectedly, 61% (34/56) of the tumors were in the recto-sigmoid or rectum.
Overall, 17% (14 of 82) of the CRCs were MMR-deficient, based upon loss of expression
of MMR proteins at IHC. Unlike typical Lynch syndrome, only 43% (6/14) of these MMR-
deficient CRCs (by IHC) demonstrated loss of expression of one of the two major DNA
MMR proteins, hMLH1 or hMSH2 (3 each for hMLH1 and hMSH2), together with the
associated loss of hPMS2 or hMSH6. Importantly, 8/14 (57%) of the MMR-deficient CRCs
exhibited the exclusive loss of either hPMS2 (n = 3) or hMSH6 (n = 5), without the respective
loss of expression of hMLH1 or hMSH2. While all 6 tumors with hMLH1 or hMSH2 loss
were MSI-H, only 4/8 tumors with an isolated loss of hMSH6 (1/4) or hPMS2 (3/3) were
MSI-H. Conclusions: We found isolated loss of hMSH6 and hPMS2 proteins in 10% of 82
young patients with non-familial CRC, and the majority of these patients (61%) had tumors
in the rectum. Our findings raise the possibility that some patients may have germline
mutations in hMSH6 associated with a low level of MSI-H, and that some of these apparently
non-familial patients may have germline mutations in hPMS2. More importantly, the observa-
tion that tumors associated with isolated loss of hMSH6 or hPMS2 develop without loss of
hMSH2 and hMLH1 or MSI-H raises new questions about the molecular pathways through
which these tumors develop.
S2021
Natural Occurrence of Colorectal Adenomas in Younger Adults
Cheryl J. Pendergrass, Daniel L. Edelstein, Linda M. Hylind, Blaine T. Phillips, Christine
Iacobuzio-donahue, Marcia R. Cruz-correa, Katharine Romans, Constance A. Griffin, G.
johan A. Offerhaus, Francis M. Giardiello
Background: The colorectal adenoma is the precursor lesion in virtually all cases of colorectal
adenocarcinoma. The occurrence of colorectal adenomas has been studied in older adults
(>50 years old), but not in younger adults (18-49 years old). Methods: The prevalence by
age, gender, race and location (left vs. right-proximal to splenic flexure) and the number
of colorectal adenomas detected was investigated using the study design of epidemiologic
necropsy in 3578 persons (1993 whites and 904 African Americans) aged 18-89 autopsied
from January 1, 1985 to December 31, 2004 at the Johns Hopkins Hospital. Autopsies with
evidence or suspicion of colorectal adenomas or colorectal cancer before death and colorectal
cancer after death were excluded (607). Affected young adults were compared to affected
older adults. Results: The prevalence of adenomas per decade was: 20-29 yrs- 1.4%; 30-39
yrs- 2.4%; 40-49 yrs- 3.8%; 50-59 yrs- 10.2%; 60-69 yrs- 11.2%; 70-79 yrs- 10.9%; 80-
89 yrs- 11.9%. The relative risk for adenomas in older compared to younger adults was 3.4
(p= 0.001). Colorectal adenomas in younger adults occurred more commonly in males
(62%) and were left-sided (right/left ratio = 0.73) similar to older adults (62% and R/L =
0.96 respectively, p=ns). The mean number of adenomas in younger adults affected was
1.06+ 0.25 (SD) (95% Cl .99 to 1.13). Subgroup analysis revealed no statistical difference
in polyp occurrence between white and African American (AA) younger adults, but older adult
African Americans had statistically significantly increased occurrence of polyps compared to
whites (14.0% vs. 10.0%, respectively; P<0.05). Also, in both younger and older adult
African Americans adenomas occurred more frequently in the right colon (R/L ratio 2.0 and
1.5, respectively) compared to the left colon in younger and older adult whites (0.66
and 0.67, respectively) (p=<0.01). Conclusions: Colorectal adenomas infrequently occur in
younger adults and are, in general, more likely left-sided and in males. In younger adults
the frequency of adenomas does not differ by race, but older adult African Americans have
greater occurrence of adenomas than whites. Irrespective of age, whites have predominately
left-sided and African Americans right-sided adenomas. More than 1 colorectal adenoma in
a younger adult is statistically greater than 3 standard deviations from the mean and should
raise the suspicion for a familial predisposition to colorectal neoplasia. Supported by: The
John G Rangos Sr. Charitable Foundation, The Clayton Fund, NIH grants P50 CA 62924-10.
S2022
Decreased Cytotoxicity of Bile After Intervention with Ursodeoxycholic Acid
in Patients with Familial Adenomatous Polyposis : A Pilot Study
Marloes Berkhout, Hennie Roelofs, Pieter Friederich, Annie Van schaik, Marleen J.
Gosens, Brigitte Marian, Beatrice L. Pool-zobel, J. han J. Van krieken, Wilbert H. Peters,
Fokko M. Nagengast
Background: Duodenal adenomas, especially those clustered in the peri-ampullary region, are
the main pre-malignant extra-colonic manifestations in patients with Familial Adenomatous
Polyposis (FAP), which suggests a role of bile in this adenomatosis. Ursodeoxycholic acid
(UDCA), a bile acid with chemopreventive properties was tested in patients with FAP to
find out whether UDCA is able to reduce cytotoxicity or genotoxicity of bile or to reduce
the cyclooxygenase-2 expression in the duodenum. Materials and methods: A three-month's
unblinded intervention with UDCA (25 mg/kg body weight daily) was performed in 5
patients with FAP. Bile acids were determined by gas chromatography. Cytotoxicity of bile
was quantified by the WST-1 assay. Genotoxicity was determined using the comet assay.
COX-2 expression was determined immunohistochemically. Results: UDC was well tolerated
and was highly enriched in bile. Cytotoxicity of the bile was 3-fold lower as compared to
the pre-intervention bile (p = 0.043), whereas no difference in genotoxicity was observed
. In 4 of the 5 patients, the duodenal COX-2 expression was reduced (p = 0.125) after the
intervention. Conclusions: UDCA enrichment of bile in patients with FAP did lower the
cytotoxicity of bile whereas duodenal COX-2 expression was non-significantly reduced. The
results of this small pilot study warrants a more extensive study on chemoprevention of
UDCA in patients with FAP
5 Immunohistochemical staining for COX-2 in normal duodenal mucosa of patients with
FAP, sampled before and after the intervention with ursodeoxycholic acid. A & C, Before
intervention (x200) B & D, After intervention (x400)
S2023
Prevalence of Muir-Torre Syndrome in a Lynch Syndrome Database
Christopher D. South, Heather Hampel, Ilene Comeras, Judith Westman, Albert De la
chapelle
Background: The Lynch syndrome (LS) is the predisposition to malignancy associated with
germ-line mutations in the mismatch-repair (MMR) genes MLH1, MSH2, MSH6, and PMS2.
In addition to colorectal cancer, the LS spectrum of tumors includes sebaceous gland tumors
and keratoacanthomas. Muir-Torre syndrome (MTS), a clinical variant of LS, is the association
of these skin neoplasms with visceral malignancies and felt to be rare. We sought to specifically
look for these lesions and the associated molecular abnormality in a database of Lynch
syndrome families to determine their frequency and genotype-phenotype correlation.
Methods: Probands were identified through a new diagnosis of colorectal or endometrial
carcinoma at 6 participating hospitals in metropolitan Columbus, Ohio (pop. 1.5 million)
regardless of age or the presence or absence of a family history of cancer as outlined in previous
reports. Personal and family histories of sebaceous gland tumors and keratoacanthomas were
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documented during proband questioning at the time of accrual and subsequent genetic
counseling sessions of family members at risk. Results: Of 50 Lynch syndrome families in
our registry, 15 families (30%) were found to have a history of MTS related tumor in at
least 1 family member. All of these tumors were verified by pathology reports, clinical
records, or personal confirmation. There were no MTS associated skin lesions in families
with germline MSH6 or PMS2 mutations. 5 of 9 families with an MLH1 mutation had at
least one family member with a skin lesion consistent with MTS. 10 of 24 families with
MSH2 mutations were found to have a family member with a MTS associated tumor. Of
the 15 MTS families 6 were found to have an A-&;T mutation at nt942+3 in the MSH2
gene. A total of 8 LS families in our registry had this specific mutation. 6 of the families
(75%) with this mutation had at least 1 member with a MTS associated tumor. 53% of the
skin lesions were found prior to the detection of colorectal cancer. Conclusions: MTS
associated skin tumors are much more common in families with LS than previously believed
likely due to previous inattention by patients and clinicians towards non-melanoma skin
cancers and benign skin lesions when obtaining personal and family histories. Despite earlier
reports suggesting a preponderance of MSH2 mutations among families with MTS we found
a similar incidence of MTS skin lesions in families with MLH1 mutations. Patients with
known LS, and perhaps especially those with a 942+3A>T mutation of the MSH2 gene
should receive dermatologic screening for these lesions.
S2024
The Incidence of Hereditary Non-Polyposis Colorectal Carcinoma Related
Cancer in Clinically Ascertained Mlh1, Msh2 and Msh6 Families
D. Ramsoekh, M. E. Leerdam van, A. Wagner, D. Dooijes, E. J. Kuipers
Background: Hereditary non-polyposis colorectal carcinoma (HNPCC) is caused by mutations
in the mismatch repair genes (MLH1, MSH2, MSH6) and is responsible for 2-5% of all
colorectal cancer (CRC) cases. Few series have suggested that MSH6 mutation carriers
develop CRC at a higher age and have a higher incidence of endometrial cancers (EC)
compared with MLH1 or MSH2 mutation carriers, however, data are limited. The aim of
the present study therefore was to evaluate the phenotypic manifestations of MSH6 families
compared to MLH1 and MSH2 families. Methods: Data were collected from medical records
and family pedigrees of HNPCC families with a proven mutation in the MLH1, MSH2 or
MSH6 gene, who visited the department of Clinical Genetics of the Erasmus Medical Center
between 1995 and 2005. Affected subjects were only included if the tumor diagnosis was
confirmed by histology or clinical reports. Clinical data of MSH6 families were compared
with data from families with MLH1 and MSH2 mutations. Results: A total of 68 HNPCC
families with a mutation in MLH1 (n=25 families, including 1361 individuals), MSH2 (n=
23, including 1579 individuals) or MSH6 (n=20, including 2023 individuals) were identified.
CRC was less frequently observed in MSH6 families (mean: 2.5 cases CRC/family) compared
to MLH1 (mean: 3.1 CRC/family), and MSH2 families (mean: 2.8 cases CRC/family), p<
0.01. The mean age of CRC onset was significantly higher in MSH6 families (mean 58 ±
14 years) compared to MLH1 (mean 48 ± 13 years) and MSH2 families (mean 47 ± 13
years), p < 0.01. Endometrial cancer developed more often in MSH6 families than in MLH1
or MSH2 families (mean 1.6 cases/family vs. 0.7 cases/family, p=0.2). The age of EC onset
was significantly higher in MSH6 families (mean age: 55 ± 9 yrs) compared to MSH2 (mean
45 ± 10 yrs, p<0.01), but not to MLH1 families (mean age: 51 ± 14 yrs). Small bowel
tumors were significantly more frequently observed in MSH2 families than in MSH6 families
(6% vs. 0%, p<0.01). Urothelial cell carcinoma was more often diagnosed in both MSH2
(5%) and MSH6 (5%) families compared to MLH1 (1%, ns). There was no difference in
frequency of ovarian, brain and skin tumors among the HNPCC families. Conclusion: MSH6
mutation carriers develop both CRC and EC at a later age than to MLH1 or MSH2 mutation
carriers. EC is more frequently observed in MSH6 families, while small bowel tumors were
more frequently observed in MSH2 families. This finding emphasizes the importance of
individualized programs (i.e. colonoscopy and periodical gynaecological examination) in
MSH6 families as well as in MLH1 and MSH2 families.
S2025
In Primary Sclerosing Cholangitis the Long-Term Risk for Colorectal Cancer Is
More Than Twofold Higher Than the Risk for Cholangiocarcinoma. Results of
a Long-Term Cohort Study
Marian M. Claessen, Frank P. Vleggaar, Kristien Tytgat, Melvin Samsom, Henk R. Van
buuren
Background & Aim: Although it has been well established that patients with primary
sclerosing cholangitis (PSC) carry a high life time risk for cholangiocarcinoma (CCA) and
colorectal cancer (CRC), relatively few long-term studies have quantified these risks. The
aim of this study was to determine the actuarial incidence of malignancies in a cohort of
PSC patients followed for up to 25 years. Methods: Analysis of all patients who were
diagnosed with PSC between 1980-2006 in two university medical centres in the Netherlands
(Utrecht, Rotterdam). Relevant data were retrieved from medical charts. The cumulative risk
of cancer and survival was calculated with the actuarial method (Kaplan-Meier). Results: A
total of 211 patients were included of which 143 (67.8%) patients were male. The median
age at diagnosis was 35 years (range 11-75). Altogether 126 (59.7%) patients had concurrent
IBD (ulcerative colitis, n=93; Crohn's disease, n=23; indeterminate colitis, n=10). Patients
were followed for a mean period of 9.6 years. Estimated median transplantation-free survival
was 13.1 years. During follow-up 45 (21.3%) patients died and in 42% this was cancer
related. Thirty-nine patients developed malignancies of which 15 (7.1%) were CCA. In five
cases CCA was diagnosed within one year of diagnosing PSC. The estimated risk of CCA
after 10/20 years was 8.6/8.6%. No significant difference in CCA-incidence between patients
with or without concurrent IBD was found. Sixteen (7.6%) patients developed CRC. The
overall estimated risk of CRC after 10/20 years was 9.0/19.3%. In patients with concurrent
IBD the 10/20 years risk for CRC was 13.2/26.4% and without IBD 2.3/2.3% (p=0.0126
log-rank test). The 10/20 years risk of CRC or CCA was 15.2/26.7%. Other malignancies
diagnosed during follow-up included gallbladder carcinoma in two patients, pancreatic
cancer in one, lymphomas in three and melanoma and gastric cancer in one case each.
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Conclusion: Patients with PSC have a highly increased risk of developing cancer, in particular
IBD-associated CRC.
S2026
Incidence of Pancreatic Adenocarcinoma Is Increased in Young Individuals
with Metachronous Syndromic Cancers. Ravi Sharaf, Russell Mcbride, Jennie
Kline, Alfred Neugut, Harold Frucht. Columbia University Medical Center
Ravi Sharaf, Russell Mcbride, Jennie Kline, Alfred I. Neugut, Harold Frucht
BACKGROUND: Pancreatic cancer is curable only if detected at an early stage. One third
of pancreatic cancers are related to cigarette smoking. Up to 15% of pancreatic cancers have
a genetic predisposition such as familial breast and ovarian cancer (BRCA1/BRCA2) syndrome,
familial atypical multiple mole melanoma (FAMMM) syndrome, hereditary non-polyposis
colorectal cancer (HNPCC), and Peutz-Jeghers Syndrome (PJS). The aim of this study was
to determine whether a knowledge of the genetic and environmental risk factors common
to pancreatic cancer and metachronous malignancies in young individuals could be used
to identify individuals for early detection of pancreatic cancer. METHODS: Data from the
Surveillance, Epidemiology, and End-Results (SEER) registries was used from 1973 through
2003 for individuals aged 20-49 years. The observed and expected incidence of malignancies
metachronous for pancreatic cancer was calculated. Similar analysis was performed with
lung cancer as a control. Results were expressed as a relative risk (RR) with 95% confidence
interval. RESULTS: Pancreatic cancer in young individuals was associated with a higher
incidence of subsequent cancer of the kidney (RR 6.48) and ovary (RR 5.97). The risk of
pancreatic cancer was increased after cancer of the gallbladder (RR 20.67), stomach (RR
7.5), ascending colon (RR 5.45), cervix uteri (RR 1.69), trachea/mediastinum (RR 14.58),
and lung and bronchus (RR 2.92) in young individuals. Testicular cancer (RR 3.07) and
lymphoma (RR 2.55-3.10) also predisposed to future pancreatic malignancy. Using lung
cancer as the incident tumor, tobacco-related malignancy was increased. CONCLUSION:
Pancreas cancer frequently occurs with tobacco-related malignancies (trachea/mediastinum,
lung and bronchus), supporting the etiologic role of smoking. An increased incidence of
pancreatic neoplasia after testicular cancer and lymphoma, suggests a causative role of
therapeutic radiation. Pancreatic cancer is increased with malignancies associated with familial
cancer syndromes, such as HNPCC (ascending colon, stomach, gallbladder, endometrial,
kidney). Significant association of pancreatic cancer was found with ovarian but not breast
cancer, raising the possibility that genetic carriers of the BRCA1/BRCA2 mutations elect
prophylactic mastectomy. Significant association was not found with melanoma, perhaps
indicating early removal of dysplastic lesions in those with known FAMMM syndrome. PJS
may be so infrequent as to not affect the incidence of small bowel cancer. Individuals
younger than age 50 with a syndromic malignancy should be considered for screening and
early detection of pancreatic neoplasia.
S2027
Rectal Mucosa Gene Expression Profile in First-Degree Relatives of Rectal
Cancer Patients
Federico Sopena, Lydia Gutierrez, Mark Strunk, Angel Ferrandez, Dietmar Fernandez,
Angel Lanas
Up to 30% of colorectal cancer (CRC) cases exhibit familial clustering, which means that
this disease has a potentially definable genetic component. However, the specific genetic
defects involved in most moderate-risk familial colon cancers have not yet been elucidated.
Aim. To determine the genetic expression profile of rectal mucosa in first-degree relatives
of patients with rectal cancer. Methods. Rectal mucosa biopsies were endoscopically taken
in: Group A, five patients (mean age 60.2, 80% male) with adenocarcinoma of the rectum
including tumor tissue and normal rectal appearance mucosa samples; Group B, five indi-
viduals (mean age 52.6, 40% male) with normal colonoscopy who had a first-degree relative
diagnosed of rectal cancer under 60 year old; Group C, five controls (mean age 62.0, 20%
male) with normal colonoscopy and no personal or familial history of CRC or polyps. In
addition, biopsies from sigmoid colon and cecum were taken in all groups. Informed consent
was obtained and the study was approved by the local IRB. Biopsies were placed in RNAlater
until tRNA was isolated with a commercial kit (RNeasy, Qiagen). cRNA was then synthesized,
hybridized and scanned with the Human Genome U133 Plus 2.0 array from Affymetrix.
Statistical analysis of the data was performed using appropriate software (GeneSpring GX 7.3).
Results. A total of 44 samples underwent microarray analysis. Non-supervised hierarchical
clustering of a total of 6,270 valid sequences clearly differentiated tumor from non-tumor
rectal samples and non-tumor rectal samples from sigmoid and cecum samples. Microarray
analysis of rectal samples revealed a number of expressed genes that were significantly
different (false detection rate <0.05) between: group A (tumor tissue) and B, 1492 genes;
group A (normal mucosa) and group B, 263 genes; and group B and C, 126 genes. In tumor
tissue, Wnt signaling pathway (axin 2), proliferation (MYC) and anti-apoptotic (BIRC5=
survivin) genes were overexpressed. In normal mucosa from first-degree relatives (Group
B), BIRC5 was underexpressed when compared to normal mucosa from controls (Group C)
(fold change 0.79±0.11). This finding could reflect a down-regulation pro-apoptotic effect
in normal epithelium prior to the development of dysplasia in some individuals with familial
rectal cancer. Conclusions. Rectal tumors show a unique gene expression profile that differs
from normal rectal mucosa. Some of these overexpressed genes could be involved in early
steps of colorectal carcinogenesis. Microarray analysis separates rectal samples of first-degree
relatives of rectal cancer patients from rectal mucosa of average risk CCR population.
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S2028
A Polymorphism of Microrna 27a Genome Region Is Associated with Gastric
Mucosal Atrophy in Male Subjects
Tomiyasu Arisawa, Tomomitsu Tahara, Tomoyuki Shibata, Masakatsu Nakamura, Yoshio
Kamiya, Ichiro Hirata, Hiroshi Nakano
[Background] Non coding microRNAs regulate the expression of various mRNAs. Although
the mechanisms underlying miRNA gene regulation in human disorders are not well under-
stood, they have certainly the potential to bind to 3' UTRs of mRNAs via sequence
complementarity and regulate gene expression at the post-transcriptional level. The human
miR-27a locates in chromosome 19. There have been few previous studies of the human
miR-27a, despite 861 targets were registered in miRBase Target Database of www.sanger.a-
c.uk/ web site. We attempted to clarify the relationship between miR-27a genome polymorph-
ism and chronic gastritis. [Methods] The study was performed in 179 patients with no
evidence of gastric malignancy. The severity of histological chronic gastritis was classified
according to the updated Sydney system. According to the severity of gastric mucosal atrophy,
the subjects were divided into the following 3 groups: the non-atrophy (NA) group (atrophy
score=0 and metaplasia score=0), the severe atrophy (SA) group (atrophy score=3 or meta-
plasia score=3), and the mild atrophy (MA) group (all others). [Results] The frequency of
miR-27a G allele was 34.6% at position 40 of MIRN27A (GenBank). Although the frequencies
of miR-27a G allele were increased in subjects with peptic ulcer or severe mucosal atrophy,
no significant differences were seen. The miR-27a polymorphism showed an interaction
with gender in relation to gastric mucosal atrophy (p=0.090). In only male subjects, the
miR-27a polymorphism was associated with the gastric mucosal atrophy (p=0.039) and both
atrophy and metaplasia scores in G/G group were significantly higher than those in the
other groups. [Conclusions] The miR-27a genome region polymorphism may be an important
definitive factor to develop the gastric mucosal atrophy in Japanese male subjects.
S2029
Hepatic Adenomas Caused By Tcf1 Mutations in Patients with Biallelic
Germline Mismatch Repair Gene Mutations
Spring Holter, Aaron Pollett, George Zogopoulos, Hyeja Kim, Kym Boycott, Carl-christian
Jackson, Shirley Chou, Leigha Senter, Mark Clendenning, Albert De la chapelle, Steven
Gallinger
Heterozygous germline mismatch repair (MMR) gene mutations in MLH1, MSH2, MSH6 or
PMS2 cause Lynch syndrome, a condition associated with an increased risk of colorectal,
endometrial and other gastrointestinal, gynecologic and urinary tract cancers. However, a
different and distinct clinical syndrome is associated with biallelic germline MMR gene
mutations which predisposes to features of neurofibromatosis, childhood-onset hematologic,
brain and gastrointestinal cancers. Inactivation of the MMR pathway leads to the expansion
or contraction of primarily intronic microsatellite sequences resulting in a characteristic
somatic molecular phenotype known as microsatellite instability. Additionally, genes con-
taining repetitive sequences (such as TGFβRII) are targets for somatic mutation in the
presence of impaired MMR. In this report, we provide the first description of a unique
clinical phenotype (hepatic adenomas) caused by a specific somatic mutational mechanism
(TCF1 mutations) in germline biallelic MMR mutation carriers. Two unrelated individuals
diagnosed with colon cancer at ages 9 and 14 were found to have homozygous MLH1
mutations and compound heterozygous PMS2 mutations, respectively. Liver metastases were
suspected in both individuals based on preoperative imaging studies; however, subsequent
biopsies and/or resection of these solid liver lesions resulted in a diagnosis of multiple
hepatic adenomas in each case. Importantly, hepatic adenomas have been associated with
biallelic inactivation of the TCF1 gene and TCF1 contains a coding poly-cytosine (C8) repeat
at nucleotide 873 in codon 291. We hypothesized that susceptibility to hepatic adenomas
in these children with biallelic MMR gene mutations is caused by somatic TCF1 mutations
at the C8-tract. Genomic DNA from the hepatic adenomas and matched normal liver from
the two patients were screened by automated sequencing for mutations in the TCF1 C8-
tract. In both cases, we identified an insertion of a cytosine at codon 291, which causes a
frameshift and leads to a truncated protein at codon 316 (P291fsX316). These results show
that the TCF1 C8-tract is a target for somatic mutations in individuals with biallelic MMR
mutations and predisposes to the development of hepatic adenomas. This novel association
should be considered in the investigation of liver lesions in this uncommon genetic condition.
S2030
Extracellular Calcium-Sensing Receptor (CaSR) Stimulates Wnt5a Secretion
Which Inhibits Beta-Catenin Signaling of Intestinal Epithelial Cells
Independent of the Orphan Receptor Ror2
Ivan Pacheco, Madeline Hayes, R. john Macleod
Background: Molecular determinants of chemoprotection by calcium supplementation against
colon cancer are currently unknown. Wnt5a, a Wnt family member, will signal through
Frizzeleds 2,4,7 or Ror2. It is not known which receptors Wnt5a interacts with in the
intestine. Wnt5a protein expression in primary Dukes B colon cancer identified a subgroup
of patients with good prognosis (Cancer Res. 2005; 65(20): 9142-6). Methods: Western
blots of Wnt5a protein from HT-29 or sub-confluent Caco-2 lysates and conditioned medium
after CaSR activation (by 3 mM Ca2+) was performed. Interfering RNA (siRNA duplex) and
dominant negative (R185Q) CaSR used to determine involvement of CaSR. Tcf signaling
was measured by TOPFLASH luciferase in cells transiently transfected with wild type or
dominant negative Ror2. The involvement of Siah-2 on the inhibitory effect of Wnt5a on
Tcf/TOPFLASH was assessed by transfection of DN-Siah2 in both cell types. Role of APC
integrity on Wnt5a induction of Siah2 assessed by RT-PCR and Western blot of inducible
full length APC compared with truncated APC cell lines. Results: Extracellular Ca2+ activation
of CaSR stimulated Wnt5a secretion. CaSR activation or Wnt5a transfection of these cells
inhibited Tcf/TOPFLASH reporter equivalently and reduced cellular beta-catenin. Cells trans-
fected with siRNA against CaSR reduced CaSR transcripts and protein, blocked Ca2+-
stimulated Wnt5a secretion, and reversed Ca2+-mediated inhibition of Tcf/TOPFLASH
reporter. Dominant negative CaSR R185Q also reversed Ca2+-mediated inhibition of Tcf/
TOPFLASH reporter. Wnt5a inhibition of Tcf/TOPFLASH reporter was not increased by
overexpression of Ror2 or reversed by dominant negative Ror2-GPI constructs. CaSR and
Wnt5a inhibition of Tcf/TOPFLASH reporter was reversed by dominant negative E-ubiquitin
ligase Siah2. CaSR activation or Wnt5a transient transfection of truncated APC cells increased
Siah2 transcripts and protein. CaSR activation of cells overexpressing full length APC did
not produce Wnt5a. Conclusion: We conclude that CaSR-mediates secretion of Wnt5a from
intestinal epithelia with a truncated APC. This secreted Wnt5a acts in an autocrine manner
to inhibit beta-catenin signaling in intestinal cells. The Wnt5a inhibition of beta-catenin
signaling is independent of endogenous Ror2 by requires substantial increases of the E-
ubiquitin ligase, Siah2.
S2031
Novel Carbohydrate Recognition-Based Drug Delivery System to
Intraperitoneal Metastases
Yuzuru Ikehara, Toru Niwa, Le Biao, Sanae K. Ikehara, Norifumi Ohashi, Takeshi
Kobayashi, Yoshitaka Shimizu, Masao Ichinose, Naoya Kojima, Hayao Nakanishi
Gastric cancer killed 50557 people in Japan in 2004. The abdominal cavity of these patients
is usually involved with peritoneal carcinomatosis, a common manifestation of this cancer,
and thought to have a short median survival. The lymphoid tissue in the omentum, at the
so-called milky spots, is known as an initial place for disseminated cancer cells to develop
into solid tumours. In the present study, we developed a new drug delivery method so as
to control tumour development at the milky spots. Intraperitoneal macrophages significantly
took up oligomannose-coated-liposomes (OML) that were injected into the peritoneal cavity,
and then gradually accumulated in the omentum and the other lymphoid tissues within 24
h of intraperitoneal injection of OMLs. When 5-FU was encapsulated in the OMLs, more
than 60% of administered 5-FU accumulated in the omentum. Treatment of macrophages
at 39°C for 30 min led to the release of 5-FU from the macrophages, suggesting that
controlled release from macrophages could be achieved by mild hyperthermia. We encased
magnetic nanoparticles, which are known to convert electromagnetic energy to heat, in the
OMLs to achieve In Vivo hyperthermia at the site. Using this system in a mouse intraperitoneal
metastasis model, we successfully controlled tumour development by co-administration of
OML-encased 5-FU and OML-encased magnetic nanoparticles, followed by treatment with
an alternating magnetic field. No apparent reduction was seen in tumour growth with the
administration of OML-encased magnetic nanoparticles or OML-encased 5-FU alone. Thus,
we have established the use of intraperitoneal macrophages as a novel drug-delivery system
for the control of cancer metastatic to milky spots.( This work was funded primarily by
Industrial Technology Research Grant Program in '04 from NEDO, and in part by Program
for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN) )
S2032
The Effects of P53 and K-RAS Mutation On Development of Preneoplastic
Conditions in Helicobacter Felis Infected Mouse Stomach
Tomoyuki Okumura, Shigeo Takaishi, Govind Bhagat, Sheng-wen Wang, Melitta Penz-
oesterreicher, Jacqueline Baumgartner, Kelly Betz, Tyler Jacks, Anil K. Rustgi, Timothy C.
Wang
Background: The p53 tumor suppressor gene and K-ras oncogene are frequently altered in
gastric cancer. The K19- K-ras V12 transgenic mice develop gastric mucous neck cell
hyperplasia, a precursor to gastric adenocarcinoma. In contrast, no abnormalities of the
stomach have been reported in p53 mutant mice. In this study, we examined the effects of
p53 and K-ras mutation in Helicobacter felis (H felis) infected mouse stomach. Methods:
The K19- K-ras V12 transgenic mice were crossed with p53 R172H mutant mice. Half of
the littermates (K-ras /p53 mutant, p53 mutant, K-ras mutant, and wild type) were infected
with H. felis at 3 months of age, while the other half served as uninfected controls. Gastric
histology was assessed 3 months after infection and mRNA expression of cytokines (such
as IL-1beta, IFN-gamma, TNF-alpha, IL-4) and EGF family growth factors (such as amphireg-
ulin, HB-EGF) were examined by real time RT-PCR. Results: H. felis infection resulted in
severe chronic inflammation in K-ras mutant mice, moderate inflammation in wild type
mice, and only mild inflammation in K-ras /p53 mutant and p53 mutant mice. Gastric
glandular hyperplasia was observed in K-ras mutant and wild type mice with H. felis infection.
Cytokine expression was increased with H. felis infection but showed no significant difference
among uninfected controls. With H. felis infection, IL-1beta was 2-4- fold increased in all
mice compared to corresponding uninfected controls. IFN-gamma and TNF-alpha were
more than 20-fold increased in K-ras mutant mice, while less than 5-fold increased in K-
ras /p53mutant, p53 mutant, and wild type mice. IL-4 was decreased in all mice with H.
felis infection. In the uninfected cohorts, amphiregulin was 6-fold increased in K-ras /
p53mutant and K-ras mutant mice compared to wild type mice, while no significant change
was detected in p53 mutant mice. With H. felis infection, amphiregulin was significantly
increased in K-ras mutant and wild type mice, but not in K-ras /p53mutant and p53 mutant
mice. HB-EGF was significantly increased after H. felis infection in K-ras /p53 mutant, K-
ras mutant, and wild type mice but not in p53 mutant mice. Conclusion: Our results
suggested that the K-ras mutation in K19 positive gastric neck cells strongly induces Th1-
dominant host immune responses with upregulation of growth factors after H. felis infection,
resulting in severe chronic inflammation and early onset of gastric glandular hyperplasia.
In contrast, a germline p53 mutation inhibited these responses, reduced inflammation and
inhibited development of hyperplasia.
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A Modulation of Iron Transport Proteins in Oeosphageal Adenocarcinoma
Keith Roberts, Matthew J. Brookes, Jessica Boult, Gregory J. Anderson, Robert Spychal,
Tariq Iqbal, Chris Tselepis
Introduction and Aims: There is accumulating evidence that iron is important in oesophageal
adenocarcinoma. However, how iron mediates carcinogenesis at the cellular and molecular
level remain unclear. The aims of this study were to investigate in human oesophagus
the expression of the iron transport proteins implicated in cellular iron import; duodenal
cytochrome C (DCYTB), divalent metal-ion transporter 1 (DMT1) and transferrin receptor
1 (TfR1), iron export; hephaestin (HEPH) and ferroportin (FPN) and storage (ferritin) in
the pre-malignant lesion Barrett's metaplasia and in oesophageal adenocarcinoma. Methods:
Perls staining was used to examine iron deposition. Real-Time PCR was used to examine
mRNA expression in samples of Barrett's metaplasia matched with oesophageal adenocarcin-
oma (n=11) and samples of Barrett's metaplasia without oesophageal adenocarcinoma (n=
13). Semi-quantitative immunohistochemistry was used to examine cellular localisation. The
effect of cellular iron loading on cellular proliferation and the expression on iron transport
proteins was determined in oesophageal cell lines OE33 and SEG-1 utilising a BrdU assay
and Real-Time PCR respectively. Results: In the progression of Barrett's metaplasia to aden-
ocarcinoma there was an overexpression of DMT1, TfR1, DCYTB, FPN and ferritin at both
the mRNA and protein level. These changes in expression were associated with increased
iron deposition. Localisation studies revealed that DMT1, TfR1 and DCYTB were all localised
on the luminal surface of Barrett's metaplasia samples as predicted by their functions.
However, in adenocarcinoma these proteins were also abundantly localised to the cytoplasm.
Interestingly, FPN immunoreactivity was largely cytoplasmic in both Barrett's metaplasia
and adenocarcinoma specimens. Overexpression of DMT1, TfR1, ferritin and a repression
in HEPH was further associated with adenocarcinoma with positive nodal involvement.
Challenging OE33 and SEG-1 cells with iron resulted in increased cellular proliferation
which was associated with decreased expression in TfR1 and DMT1 mRNA and increased
ferritin protein expression. Conclusions: Progression to oesophageal adenocarcinoma is
associated with increased expression in iron import proteins. The apparent cytoplasmic
localisation of the iron exporter protein FPN implies an early defect in iron export in the
neoplastic process. A repression in the iron export protein HEPH was only associated with
metastasised tumours. These events culminate in increased intracellular iron which mediates
cellular proliferation and represents a further mechanism of carcinogenesis.
S2034
Rock II Mediates Colon Cancer Invasion in a 3d In Vitro Model
Ramana Vishnubhotla, Marinka Bulic, Jameela Huq, Shan Sun, Michael Cho, Sarah C.
Glover
Cells in the colonic crypt follows a strict 2-D axis as stem cells differentiate into enterocytes
and migrate up the crypt-villus axis. In colon cancer, this axis is disrupted and tumor cells
undergo migratory reversal allowing them to invade into the submucosa and beyond. One
major pathway that has been shown to be critically influenced by the tumor microenvironment
is the Rho/ROCK pathway. Evaluation of these proteins in resected human colon cancers
revealed up-regulation of ROCK II, a downstream effector of Rho, at the invasion front.
ROCK II has been linked with other greater invasion and metastasis in other solid tumors
but its role in colon cancer invasion has yet to the fully defined. The goal of this study was
to evaluate the behavior of ROCK II in non-malignant (NCM460) and malignant (Caco-2
E and SW620) colonic epithelial cell lines grown in 3-D type 1 collagen scaffolds. Scaffolds
were evaluated at 1 and 3 days post invasion for phenotypic appearance of cells, depth of
invasion, ROCK II expression and localization, proliferation, collagen degradation, and
overall ROCK activity. Multiphoton images revealed that both NCM460 and Caco-2 E cells
invaded the tissue scaffolds and formed “crypt-like” structures. SW620 cells invaded into
the scaffold to a depth that was nearly two-fold greater than that of either the NCM460 or
Caco-2 E cells, more readily degraded collagen, and were the least proliferative. When
probed with antibodies specific for ROCK II, “plaque-like” structures were noted in both
Caco-2 E and SW620 cells but not in NCM460 cells. ROCK activity was three fold higher
in the SW620 cells 24 hours post invasion as compared with the other cell lines evaluated.
Finally, silencing ROCK II via siRNA decreased SW620 cell invasion depth by half but had
little effect on the invasion of Caco-2 E cells. In both Caco-2 E and SW620 cells, silencing
ROCK II substantially decreased cell proliferation. Taken together, this data suggests that
ROCK II plays a significant role in colon cancer invasion in the least proliferative, most
invasive tumor cells.
S2035
The Apc1323t/+ Mouse: A Novel Murine Model Analagous to the APC-1309
Mutation Causing Severe Intestinal Polyposis in Humans
Maesha G. Deheragoda, Patrick Pollard, Emma Nye, Nikki Mandir, Pooja Seedhar,
Rosemary Jeffery, Nicholas A. Wright, Ian Tomlinson
Introduction: Mutations in both alleles of the Adenomatous Polyposis Coli (APC) gene result
in initiation of intestinal tumorigenesis in patients with Familial Adenomatous Polyposis
Coli (FAP). In the intestine, the Wnt signalling pathway controls proliferation and differenti-
ation. The APC protein regulates Wnt activity through interaction with beta catenin. The
APC-1309 mutation is associated with a severe disease phenotype in humans. Commonly
used murine models of FAP, such as the ApcMin/+ mouse, carry germline mutations in Apc
in sites which are not analogous to those found in humans. Aims: To develop a murine
model containing an Apc mutation in a site equivalent to that causing severe FAP disease
in humans, and compare this with the ApcMin/+ mouse in order to investigate the functional
effects of different apc proteins on Wnt signalling and tumorigenesis. Methods: We used
embryonic stem cell targeting and homologous recombination to create a novel murine
model, Apc1323T/+. Molecular characterisation of the Apc1323T/+ was performed with
Western and Southern blotting. The phenotype of Apc1323T/+ mice was compared with
the ApcMin/+ mouse, which carries an Apc allele truncated at codon 850. Both mouse lines
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were assessed for tumour burden, site, size and composition. The Wnt signalling pathway
was assessed with immunohistochemistry, in situ hybridisation and gene expression arrays.
Crypt fission and proliferation analysis was performed on microdissected adenomas to assess
tumour development. Results: Compared with the ApcMin/+, the Apc1323T/+ demonstrates
a higher tumour burden (mean number of gastric adenomas=2; mean number of small bowel
adenomas=186; mean number of large bowel adenomas=3). Apc1323T/+ adenomas are
larger with many tumours showing high grade dysplasia. Tumours develop approximately
20 days earlier than a comparable burden in the ApcMin/+ mouse. Study of early tumorigen-
esis shows differential activation of the Wnt signalling pathway, differences in cellular
composition and crypt fission rates between the two models. Conclusion: The Apc1323T/
+ mouse allows study of intestinal tumorigenesis consequent to germline mutations in Apc
that are equivalent to those in humans. Our data suggests this phenotype is analogous to
the severe intestinal polyposis seen in FAP patients with APC-1309 germline mutations.
Dysregulation of the Wnt signalling pathway and crypt fission appear to play a central role
in producing this more severe phenotype. It is an excellent In Vivo model for a comparative
study of Wnt signalling control by different portions of the apc protein.
S2036
Smad4-Mediated Reversal of EMT Is Associated with Activation of Autocrine
BMP Signaling in Colorectal Cancer Cells
Jesse J. Smith, Sheng-ru Shiou, Punita Dhawan, R. daniel Beauchamp
Background: Epithelial to mesenchymal transition (EMT) is a critical and potentially reversible
event in the acquisition of the metastatic phenotype in cancer progression. The transforming
growth factor-β family of cytokines (including TGF-β and bone morphogenetic proteins
(BMPs)) and their universal intracellular mediator, Smad4, play an important role in the
regulation of EMT. Clinically, loss of Smad4 expression is associated with loss of E-cadherin
expression, liver metastasis (Losi et al, Oncol Rep 2004) and poor prognosis in colorectal
cancer (Alazzouzi et al Clin Can Res 2005). Recently, expression of Smad4 in Smad4-
deficient SW480 human colon cancer cells was found to be sufficient to induce reversal of
EMT, including induction of E-cadherin expression and loss of tumorigenicity, but did not
restore TGF- β growth inhibitory responses (Muller et al Oncogene 2002). Purpose: To
determine the mechanism by which Smad4 expression reverses EMT in the SW480 cells.
Results: We observed that in Smad4-deficient SW480 colon carcinoma cells, expression of
Smad4 leading to the reversal of EMT, re-expression of E-cadherin, and loss of tumorigenicity
did not restore TGF-β signaling due to low levels of endogenous TGF-β type II receptor.
Interestingly, when expressed in SW480 cells, Smad4 was in an ‘active state' represented
by its nuclear immunofluorescent staining. This suggests that expression of Smad4 enables
the SW480 cells to respond to the TGF-β family of cytokines other than TGF-β in an
autocrine manner. We next sought to determine the activation of BMP signaling. When co-
transfected with a BMP-specific reporter construct (BRE2-Luc), Smad4 significantly increased
the promoter activity of BRE2-Luc in SW480 cells in the absence of exogenously added
ligand. This effect was reversed by addition of the BMP ligand antagonist, Noggin, indicating
specific activation of BMP signaling by Smad4 expression. We also observed increases in
nuclear phospho-Smads1, 5, and 8 (activated BMP Smads) in our Smad4 expressing SW480
clones as compared with the parental and vector control cells, supporting the notion that
expression of Smad4 establishes autocrine BMP signaling. Conclusion: These data indicate
that Smad4 can act as a tumor suppressor despite the absence of functional TGF-β signaling.
Expression of Smad4 appears to unmask autocrine BMP signaling in the Smad4 deficient
SW480 cells. These data support the hypothesis that BMP signaling has an important tumor
suppressor function in colonic epithelial cells. Supported by USPHS grants CA 69457 and
DK 52334
S2037
The Effect of Helicobacter pylori Infection On Sonic Hedgehog Signal Pathways
in Gastric Epithelial Cells
Yeun jung Choi, Jie-hyun Kim, In ohk Lee, Hoguen Kim, Woo ick Yang, Yong chan Lee
Background/Aims: Aberrant activation of hedgehog (Hh) signaling pathway leads to patholo-
gical consequences in a variety of human tumors, such as gastric cancer and pancreatic
cancer. Sonic hedgehog (Shh) is implicated in stem/progenitor cell restitution of damaged
gastric mucosa during chronic infection with Helicobacter pylori (H. pylori). H. pylori with
various virulence factors causes mucosal damage and may participate in gastric carcinogenesis.
The aims of this study were to examine the changes in Shh signal pathways in gastric
epithelial cells in response to H. pylori infection. We also assessed the influence of various
virulence genes of H. pylori implicated in gastroduodenal pathogenesis such as cagA, cagE
and vacA Shh expression by gastric epithelial cells. Methods: Real time RT-PCR, western
blot and immunohistochemistry were utilized to analyze the expression, localization and
transcriptional regulation of the Shh, Ptch and Gli1. 60190 (cagPAI positive), 8822 (cagPAI
negative), and various gene knock-out mutant H. pylori strains of cagA, cagE and vacA
respectively were used. AGS, MKN74, and MKN45 cells were used as for gastric epithelial
cells. Paraffin-embedded tissues from resected human gastric cancer were used to evaluate
the expression of Shh and related signal proteins In Vivo. Results: Expression of Shh in
gastric epithelial cells infected with H. pylori were increased confirmed by immunoblot and
real time RT-PCR. Furthermore, cagA positive strains showed higher level of Shh expression.
Gli1mRNA, the transcriptional target of the Hh pathway, were increased in expression in
cells infected with H. pylori compare to uninfected control implying that H. pylori infection
might lead to enhanced Hh pathway activation in gastric cancer cells. The Shh positive
immunoexpression in H. pylori-infected gastric cancer tissue were higher than the ratio of
uninfected gastric cancer tissue. Immunostaining of Shh correlated with tumor differentiaion
apart from the status of H. pylori infection. Conclusion: Shh expression correlates with the
status of H. pylori infection and H. pylori may activate the Hh signal pathways through up-
regulation of Shh in gastric epithelial cells. CagA may influence the expression of Shh in
gastric epithelial cells.
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S2038
Characterization of Candidate Genes Influencing Migration, Invasion and
Metastasis in Genetically Generated Oral-Esophageal Cancer Cells
Heike Kunert, Sarah Hauss, Claus W. Franzke, Eva Egenter, Nina Hirt, Angela Queisser,
Michaela Doebele, Steffen Heeg, Gitta Goessel, Thomas Reinheckel, Leena Bruckner-
tudermann, Christoph Peters, Hubert E. Blum, Oliver G. Opitz
Introduction: The ability of a tumor cell to migrate across the extracellular matrix (ECM)
is a prerequisite for metastasis. In our cellular model of human oral-esophageal carcinogenesis
we were able to recapitulate tumor development in a stepwise fashion. Cyclin D1 overexpres-
sion and p53 inactivation led to immortalization, additional EGFR overexpression induced
an In Vitro transformed phenotype, whereas additional c-myc overexpression resulted in
invasive cancer cells. To study the ability of these different cells to migrate, we analyzed
the expression and localization of different candidates thought to be involved in tumor
invasion and metastasis: 1. Collagen XVII a hemidesmosomal epithelial adhesion protein,
mediating the adhesion of cells to the ECM, 2. E-Cadherin a cell adhesion molecule of
adherens junctions, mediating homophilic cell-cell contacts, 3. the cell surface protein CD24
and 4. the cysteine protease Cathepsin B involved in the degradation of proteins. Methods:
The expression of these candidate genes was assayed in immortalized oral keratinocytes
(OKF6D1/d.n.p53), in In Vitro transformed OKF6D1/d.n.p53/EGFR and OKF6D1/d.n.p53/
EGFR/c-myc cancer cells by real-time PCR and western blot analysis. The cellular distribution
of these proteins was studied by immunofluorescence. Furthermore, we analyzed the migra-
tion behavior in our cellular model using a matrigel assay. To eventually increase the
metastatic potential we additionally knocked down the E-Cadherin gene via siRNA. Results:
RT-PCR revealed a downregulation of collagen XVII expression in transformed cells followed
by an upregulation in cancer cells. Immunofluorescence demonstrated that the cellular
localization of collagen XVII, E-Cadherin and Cathepsin B is influenced by malignant trans-
formation, i.e. collagen XVII is first translocated to the cytoplasm and relocated to the cell
membrane in cancer cells, whereas E-Cadherin is accumulated to the cell membrane in
nonmetastatic transformed cells. Cathepsin B is recruited from the lysosomes to the membrane
during malignant transformation. Migration and invasion appears to be increased only in
the genetically generated cancer cells overexpressing c-myc. Conclusions: In our human
cellular model of oral-esophageal carcinogenesis we demonstrated that only collagen XVII
is differentially expressed during carcinogenesis. Nevertheless, cellular localization of collagen
XVII, E-Cadherin and Cathepsin B is defined by the distinct steps of tumor development.
Finally, these different findings lead to the conclusion, that In Vitro generated cancer cells
acquire features, potentially allowing to migrate through the ECM and ultimately to metast-
asize.
S2039
Transient EPEC Infection of Colon Cancer Cells in 3d Scaffolds Increases Cell
Invasion Via the Influence of the T3ss On Rock Signaling
Marinka Bulic, Ramana Vishnubhotla, Jennifer L. Roxas, Jameela Huq, Shan Sun, Michael
Cho, V. K. Viswanathan, Sarah C. Glover
Although the role of Helicobacter pylori in the development of gastric cancer has been
well established, the involvement of other bacteria in the development and post-neoplastic
transformation of colon cancer is less clear. Other studies have shown that bacterial proteins,
such as the β-casein derived peptides of Listeria monocytogenes. are potential mediators of
colon cancer invasion (The EMBO Journal (2003) 22:6161). However, the contribution of
other more common enteric pathogens such as enteropathogenic E. coli (EPEC) to colon
caner cancer invasion is yet to be determined. We have recently shown that ROCK II is an
important mediator in colon cancer invasion. In addition, some bacterial effector proteins
such as IpGB1, IpGB2, and Map have also been shown to demonstrate G protein mimicry
function (Cell (2006) 124:133). Thus, the specific goals of this study were to: (1) to determine
if transient infection with EPEC would lead to increased colon cancer invasion, (2) to
determine if invasion is dependent on the type 3 secretion system (T3SS), and (3) to evaluate
the effect of transient EPEC infection on Rho kinase (ROCK) activity. Caco-2 BBE (C2BBE)
intestinal epithelial cell were grown on top of 500 μm think type 1 collagen scaffolds for
three days. C2BBE cells were then transiently infected with EPEC or the T3SS-deficient
ΔescN mutant at MOI=40 for two hours followed by treatment by 1 μg/ml gentamicin.
Scaffolds were evaluated at one day post-infection for phenotypic appearance of cells, depth
of invasion, proliferation, and overall ROCK activity. NCM 460 cells, a non-malignant colon
epithelial cell line, were used as controls. Multi-photon images revealed that C2BBE cells
invaded the tissue scaffolds and formed “crypt-like” structures. EPEC-infected cells invaded
at a depth that was nearly 8-fold greater than that of untreated cells. Proliferation of infected
cells were also 2-fold greater and had ROCK activity 2.5-fold greater than the control cells.
ROCK activity in cells infected with ΔescN mutant dropped nearly five-fold lower than
uninfected control cells. When these experiments were performed with NCM 460 cells,
there was significant change in depth of invasion between control cells and cells infected
with EPEC. This study demonstrates for the first time that EPEC can modulate colon cancer
cell invasion through ROCK signaling and that this appears to be, in part, due to effectors
injected into the cell by the T3SS. Further study will be required to elucidate the precise
mechanism(s) involved in the modulation of colon cancer cell invasion by EPEC.
S2040
P130cas Facilitates Pressure-Stimulated Colon Cancer Cell Adhesion Through
Interactions with Paxillin and Crk
Christina Downey, David H. Craig, Marc D. Basson
Cancer adhesion and metastasis are critically regulated by focal adhesion kinase (FAK) and
stimulated by extracellular pressure. p130Cas is a tyrosine phosphorylated protein that
regulates diverse aspects of cell biology including proliferation, motility and survival. One
mechanism of p130Cas action involves localization of FAK to the focal adhesion complex
where phosphorylated FAK promotes paxillin tyrosine phosphorylation, creating a binding
site for Crk, which then binds directly to p130Cas, facilitating p130Cas activation of down-
stream targets. We hypothesized that p130Cas influences pressure-stimulated cancer cell
adhesion via this pathway, and tested this hypothesis using human SW620 colon cancer
cells adhering to type I collagen under ambient or 15 mm Hg increased pressure for 30
minutes. Signal studies were performed in suspended cells prior to adhesion. SW620 cells
were initially transfected with paxillin mutants that are unable to be phosphorylated at Y31,
Y118, Y181, or at both Y31 and Y118. All cells displayed increased adhesion in response
to extracellular pressure except those transfected with the Y31Y118 double mutant (n=4,
p<.01). Coprecipitation studies in SW620 cells exposed to ambient or 15 mmHg increased
pressure conditions for 30 minutes demonstrated that increased pressure stimulates paxillin
association with both p130Cas and Crk. Moreover, reducing the levels of either Crk or
p130Cas by specific siRNA prevented the stimulation of SW620 cell adhesion by extracellular
pressure (n=3, p<.05). Finally, SW620 transfection with the paxillin Y31Y118 double mutant
prevented Crk association with paxillin in either ambient pressure controls or pressure-
stimulated cells. These data indicate that p130Cas mediates pressure stimulated cancer cell
adhesion through interactions with Crk and paxillin, and that paxillin phosphorylations at
Y31 and Y118 are each necessary for these interactions. This novel pathway may be a useful
target for pharmacologic or molecular approaches to inhibit cancer metastasis.
S2041
Regulation of Intestinal Cell Migration: Phosphorylation and
Dephosphorylation of Villin
Seema Khurana, Sijo Mathew, Yaohong Wang, Srinivasan Kamalakkannan, Sudeep P.
George
Most human cancers originate from epithelial cells and include the major killers such as
colon cancer. Metastasis is the most lethal property of cancer cells and critical to this property
is the increased migratory state of tumor cells. Epithelial cell migrate by a complex process
with a poorly understood molecular basis. Epithelial cell maintain cell-cell contact as they
move and undergo epithelial to mesenchymal transition to become motile. Previously we
have demonstrated that villin, an epithelial cell specific actin binding protein regulates cell
migration, apoptosis and epithelial to mesenchymal transition, underscoring the significance
of this protein to epithelial cell function. We have also demonstrated that tyrosine phosphoryl-
ation of villin is required for its role in cell migration. In this study we characterize the
specific kinases and phosphatases that determine the tyrosine phosphorylation of villin as
well as villin's function in cell migration. Using the c-src, c-yes and c-fyn null fibroblasts
(SYF null), we demonstrate that tyrosine phosphorylation of villin by any of these three Src
family tyrosine kinases is required for villin's function in cell migration. Expression of the
villin phosphorylation site mutant, VIL/AYFM, confirmed our observation that tyrosine
phosphorylation of villin was required for its effects on cell migration. Other kinases that
were also examined but had no effect on either villin phoshorylation or villin-induced cell
migration include Jak-2, Jak-3 and Syk-2. Overexpression of the tyrosine phosphatases SHP-
2 and PTP-PEST individually inhibited phosphorylation of villin and villin-induced increase
in cell migration. Expression of both phosphatases together had a synergistic effect. It may
be noted that overexpression of Src family kinases and down-regulation of SHP-2 and PTP-
PEST in colon carcinomas is well documented. Our study identifies the non-receptor tyrosine
kinases, the phosphatases as well as the substrates of these enzymes that regulate epithelial
cell migration, thus providing a molecular mechanism for the increased cell migration noted
in wounded epithelia as well as metastatic tumor cells.
S2042
P-Glycoprotein Influences Beta-Catenin Cellular Localization and Nuclear
Translocation
Jayshree Mishra, Qiuye Zhang, Brien L. Neudeck
Introduction: P-glycoprotein (Pgp) is important for chemotherapy resistance in colon cancer.
Strategies to transcriptionally inhibit Pgp are therefore desirable. Membrane dissociation and
subsequent nuclear translocation of beta-catenin is important in colorectal carcinogenesis.
We hypothesized that the downregulation of Pgp may have untoward affects on beta-catenin
cellular localization. Methods: A1C6-HeLa Tet OFF cells where Pgp expression was under
the control of a tetracycline repressible vector (either PgpON or PgpOFF) and Caco-2 cells
were employed. Confocal microscopy was used to determine cellular localization of beta-
catenin and co-localization with Pgp. Immunoblotting and immunoprecipitation were
employed to determine total beta-catenin amounts, degree of beta-catenin nuclear transloca-
tion and co-immunoprecipitation with Pgp. Real-time RT-PCR was performed to compare
beta-catenin expression levels between PgpON and PgpOFF cells. Efflux of rhodamine 123
(10 μM) was measured to characterize Pgp transport function. Transepithelial resistance
(TEER) was measured in PgpON and OFF cells. Results: Beta-catenin was strongly localized
in cell to cell membrane junctions in PgpON cells. Conversely, beta-catenin exhibited
significantly less staining at membrane junctions with more cytosolic and nuclear localization
in PgpOFF cells. Pgp and beta-catenin co-localized in both PgpON and Caco-2 cells. No
difference in total beta-catenin protein or mRNA expression were detected between PgpON
and OFF cells. There was no significant difference in TEER between PgpON and OFF cell
lines (564 +/- 41 vs 496 +/- 28 ohms cm2). Conclusions: Loss of P-glycoprotein from the
apical membrane results in beta-catenin dissociation from the adherens junction and nuclear
translocation. Strategies targeting Pgp may adversely affect the cytoskeleton architecture.
S2043
Expression of Hcp-1 in Oesophageal Carcinogenesis
Keith Roberts, Matthew J. Brookes, Jessica Boult, Andrew T. Mckie, Tariq Iqbal, Robert
Spychal, Chris Tselepis
Background and Aims The incidence of oesophageal adenocarcinoma is currently rising
faster than any other cancer in the western world. Comparable to other cancers the incidence
of oesophageal adenocarcinoma is influenced by diet, and, in particular red meat has been
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linked to increased risk. One potential mechanism to explain this could involve heme which
is found in red meat. Haem is thought to be transported into enterocytes via the transporter
Haem carrier protein 1 (HCP-1). The aims of this study were i) to determine HCP-1
expression in human oesophagus and in the malignant progression to adenocarcinoma (ADC)
ii) to investigate if oesophageal cell lines were able to import haem and whether this
modulated cell behaviour and iron transport protein expression. Methods Real-Time PCR
was employed to examine mRNA expression in samples of Barrett's metaplasia (BM) matched
with ADC and samples of BM without evidence of ADC. Semi-quantitative immunohisto-
chemistry was used to examine localisation and protein levels in human oesophagus, BM
and ADC. The effect of hemin on cellular proliferation and migration was assessed by hemin
loading oesophageal lines OE33 and SEG-1; followed by BrdU and wound healing assays
respectively. The effect of hemin loading on the expression of the iron transport proteins
was determined by Real-Time PCR and western blotting. Results When comparing ADC
with matched internal BM obtained from the same resection specimen we observed an 8
fold increase in HCP-1 mRNA expression. However, comparing BM with matched gastric
mucosa revealed no difference in HCP-1 mRNA expression. Localisation studies demonstrated
HCP-1 in BM where it was localised on the surface epithelium whilst in ADC HCP-1 was
cytoplasmic. Utilising a tissue microarray HCP-1 expression was statistically increased by
1.4 fold in ADC associated with vascular invasion compared to ADC with no vascular
invasion (P<0.02). Culturing OE33 and SEG-1 cells with hemin for 24 hrs resulted in
increased cellular iron which induced cellular proliferation and migration. Additionally
hemin loading resulted in decreased TfR1 and DMT-1 mRNA expression and increased
ferritin protein expression. Hemin loading did not change HCP-1 mRNA or protein expression
levels but did increase haem oxygenase mRNA expression. Conclusions Our data suggests
that from BM to ADC there is an over expression of HCP-1 and that this is associated with
vascular invasion. We also provide evidence that HCP-1 is expressed in oesophageal lines
and that culture with hemin caused increased cellular proliferation and migration. We thus
conclude that HCP-1 and heme are likely to have a role in oesophageal carcinogenesis.
S2044
Expression and Potential Role of Apurinic/Apyrimidinic Endonuclease-1 (Ape-
1) in Mongolian Gerbil Model of Gastric Carcinogenesis
Seiji Futagami, Tetsuro Hiratsuka, Tomotaka Shindo, Tatsuhiko Hamamoto, Kenji Suzuki,
Nobue Ueki, Masafumi Kusunoki, Kazumasa Miyake, Katya Gudis, Sheila e. Crowe,
Choitsu Sakamoto
Background&Aims: Apurinic/apyrimidinic endonuclease-1 (APE-1) is a multifunctional pro-
tein and a key enzyme involved in DNA base excision repair (BER), which has been linked
to chemosensitivity in certain cancers. H. pylori infection has been shown to upregulate
APE-1 expression in native and cultured gastric epithelial cells (Gastroenterology. 127:845-
858;2004). However, little is known about the expression and role of APE-1 in the develop-
ment of gastric cancer. Therefore, in our study, we investigated APE-1 expression and
localization in short-term and long-termH. pylori infected-Mongolian gerbil models. Methods:
42 Mongolian gerbils were divided into four groups. 10 Mongolian gerbils were given five
biweekly 30ppm doses of MNU (N-Methyl-N-nitrosourea) (Group 1 gerbils). 6 short-term
H. pylori infected-Mongolian gerbils were sacrificed after 8 weeks H. pylori infection (Group
2 gerbils). 20 Mongolian gerbils were given five biweekly 30ppm doses of MNU pretreated
and long-term H. pylori infection ( 44-weeks) (Group 3 gerbils). Group 4 gerbils served as
control (n=6). Groups 1, 3, and 4 gerbils were sacrificed at week 54. Incidence of gastric
adenocarcinoma was determined at week 54 by histological analysis. APE-1 expression
and localization in gastric tissues of Mongolian gerbils was evaluated by western blot and
immunohistological analysis. Results: APE-1 was localized in gastric epithelial cells and
mesenchymal cells including macrophages in H. pylori infected-Mongolian gerbils. APE-1
localization was predominantly nuclear in epithelial cells, and cytoplasmic in mesenchymal
cells. The number of APE-1 positive cells in group 1 and group 2 gerbils were significantly
increased compared to the control group. In addition, the number of APE-1 positive cells
in group 3 gerbils were synergistically increased compared to those in group 1 and group
2 gerbils. In western blot analysis, levels of APE-1 protein in gastric tissues from each group
showed the same relative differences in expression as observed in the immunohistochemical
studies. However, although the incidence of gastric adenocarcinoma in group 3 gerbils was
high, at 65% (13/20), APE-1 positivity in gastric cancer cells was low in this group, at 15%
(2/13). Conclusion: Our results demonstrate that H. pylori infection and MNU treatment
synergistically increased APE-1 expression in gastric tissues of Mongolian gerbils. The
observed reduction of APE-1 expression in gastric cancer tissues may provide insight into
the progression of these conditions and warrants further investigation.
S2045
Role of Chronic Inflammation in Sporadic Colorectal Neoplasia
Mairi H. Mclean, Graeme I. Murray, Keith N. Stewart, Georgina L. Hold, Nicky Fyfe, N
ashley G. Mowat, Emad M. El-omar
Background: Chronic inflammation is a risk factor for many cancers but its role in sporadic
colorectal neoplasia has not been studied. Most cancers arise from adenomatous polyps,
which are exposed to physical, chemical, microbial and hypoxic stress. We hypothesise
that chronic inflammatory activity within benign precancerous polyp tissue is key to cell
transformation. Aim: The aims of this study were to investigate inflammatory cell phenotype
of adenomatous polyps of varying sizes and degrees of dysplasia, compared to adjacent
normal mucosa, and to assess the phenotype of stromal macrophage infiltration. Methods:
Paraffin embedded tissue from 65 colonic polyps and 35 paired normal mucosal biopsies
were assessed. In addition, 40 polyps with low grade dysplasia (LGD), 40 with high grade
dysplasia (HGD) and 40 with a focus of adenocarcinoma (CaP) were studied. Immunohisto-
chemistry with antibodies against CD3, CD4, CD8, CD25, CD20, CD38, CD56, CD68, mast
cell tryptase and neutrophil elastase was used to assess the presence of T cells (helper,
cytotoxic and activated subsets), B cells, plasma cells, NK cells, macrophages, mast cells
and neutrophils, respectively. Macrophage phenotype was investigated using an immunohis-
tochemical double staining technique in a representative subset of the paired adenoma and
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normal mucosa specimens. Classically and alternatively activated macrophages were identi-
fied by expression of iNOS or arginase I, respectively. Results: In small polyps, neutrophil
and T helper cell infiltrate was increased compared to normal mucosa (p=0.001 & 0.014).
Macrophage infiltrate was significantly increased in large polyps compared to paired normal
mucosa (p=0.002). There was also a significantly increased neutrophil and activated T cell
infiltrate in large polyps compared to paired normal mucosa (p= 0.001 & 0.001). Neutrophil
and macrophage infiltrates increased along with increasing degrees of cell dysplasia towards
overt neoplasia (LGD vs. HGD p=0.01, HGD vs. CaP p=0.001, LGD vs. HGD p=0.035 and
HGD vs. CaP p=0.001, respectively). In adenomas, there was a significant increase in the
number of iNOS +ve macrophages compared to adjacent normal mucosa (p=0.001). 91%
of the CD68 +ve cells expressed iNOS within the polyps, compared to 20% within normal
mucosa (p=0.001). Conclusion: Inflammatory cell infiltrates are a key feature of adenomatous
polyps, increasing along with increasing degree of cell dysplasia. Macrophages predominantly
express iNOS, suggesting classical activation with pro-inflammatory function. These findings
are likely to be relevant to the pathogenesis of sporadic colorectal cancer.
S2046
Mechanism of Colon Carcinogenesis Induced By Dietary Fatty Acid and
Accelerating Wnt Signaling
Ryosuke Shiraishi, Takehiro Fujise, Takashi Kakimoto, Tsukasa Kuroki, Kanako
Yamaguchi, Kenichiro Watanabe, Hibiki Ootani, Ryo Shimoda, Seiji Tsunada, Hiroyuki
Sakata, Ryuichi Iwakiri, Kazuma Fujimoto
Background and Aim Incidence and mortality rate of colon cancer are increasing every
year, and that is mainly attributable to Westernization of Japanese food habits. There are
epidemiologic data that showed positive associations between dietary fat intake and colon
cancer. Many studies demonstrated that colon tumor-promoting effect of a high fat diet
depends not only on the amount of fatty acid consumed but also on the fatty acid composition.
Wnt signaling pathway is integrally associated with colon carcinogenesis. The aim of this
study is to investigate the effect of different dietary fat on colon carcinogenesis using rats
pretreated with azoxymethane (AOM). Materials and Methods Fifteen mg/kg body weight
of AOM dissolved in 1 ml saline was i.p injected to male SD rats once a week for 2 weeks.
Rats were fed with a basal diet or supplemented with 10% corn oil, 10% olive oil, 10%
fish oil and 10% beef tallow for 44 weeks. Colonic tumors, including adenomas and
carcinomas, were examined at 44 weeks. Colon proliferation was evaluated by BrdU uptake.
COX-2, Beta-catenin, cyclinD1, Wnt2 and Wnt5a were analyzed by Western blotting. Results
At 44 weeks, dietary olive and fish oil decreased colon cancer incidence and multiplicity
in rats treated with AOM. In contrast, both corn oil and beef tallow promoted colon cancer
incidence and multiplicity. These two dietary oils increased BrdU uptake and expression of
cytosolic beta-catenin, cyclin D1 in colonic mucosa. In rats fed with beef tallow without
AOM treatment, more BrdU uptook cells presented in upper area of crypt than middle and
lower area. Wnt2 and COX-2 expression increased regardless of AOM treatment in rats fed
with dietary beef tallow. Wnt5a expression was increased in rats fed with dietary corn oil.
Conclusion In AOM treated rat, long term feeding of dietary corn oil and beef oil increased
cell proliferation via Wnt signaling pathway in colonic mucosa, which lead to promotion
of colon cancer with AOM treatment. Furthermore, upper localization of BrdU uptook cells
in dietary beef tallow without AOM indicated that the composition of dietary fatty acid itself
play an important role in colonic carcinogenicity.
S2047
Galectin-3-Muc1 Interaction Promotes Epithelial Cancer Cell Aggregation:
Potential Role of Circulating Galectin-3 in Colon Cancer Metastasis
Qicheng Zhao, Monica Barclay, Jonathan M. Rhodes, Lu-gang Yu
Background & Aims: Homotypic aggregation of circulating cancer cells results in formation
of tumour microemboli and is one of the key elements that determine metastatic behaviour.
Galectin-3 is an endogenous galactoside-binding protein which shows up to 5-fold increased
concentration in the blood of cancer patients and this is closely correlated with cancer
progression. We have investigated the effect of extracellular galectin-3 on homotypic aggrega-
tion of cancer cells. Methods: Recombinant galectin-3 was incubated with HT29 colon
cancer cells 50% of which were pre-labelled with DiI and 50% with DiO fluorescent dyes.
Aggregation was assessed by FACS analysis. Results: Recombinant galectin-3 at concentrations
(0.1 - 1μg/ml) similar to those found in the sera of metastatic cancer patients induced dose-
dependent increase of cell aggregation of MUC1-expressing HT29-5F7 cells but not that of
the parental HT29 cells which express less MUC1. At 0.25 μg/ml recombinant galectin-3
increased cell aggregation by 95% (95± 43%, Mean± SD, P<0.0001,ANOVA) .Recombinant
galectin-3, 1 μg/ml, also increased by 26% (26 ±5% ,P<0.0001) aggregation of MUC1
transfected breast epithelial HCA1.7+ cells but not of HCA1.7- (MUC1 negative) cells. The
effects of galectin-3 on cell aggregation were inhibited by the presence of 50 mM lactose.
Treatment of HCA1.7+ cells with recombinant galectin-3 induced clustering and focal loss
of cell surface MUC1 and MUC1 was absent at the cell-cell contacts of aggregates. Conclusions:
Galectin-3, at concentrations found in the blood of cancer patients, induces cancer cell
aggregation by interaction with glycans expressed on cancer-associated MUC1, possibly by
revealing cell adhesion molecules which otherwise are concealed by the massive size of the
MUC1 transmembrane mucin molecule. This suggests a critical role for circulating galectin-
3 in cancer metastasis.
S2048
Sulindac and Gefitinib Inhibit Muc2 and Muc5ac Mucin Expression Via Akt
and Mapk Pathways in Human Colon Cancer Cells
Elizabeth Half, Shumei Song, Yunjie Sun, Robert S. Bresalier
Background. Alterations in the expression of the mucin genes MUC2 and MUC5AC have
been associated with colorectal tumor progression. Both epidermal growth factor (EGF) and
PGE2 have been shown to induce mucin expression in bronchogenic cancers . We therefore
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sought to determine the effect of gefitinib, an EGF receptor (EGF-R) tyrosine kinase inhibitor,
and sulindac, a non selective cyclooxygenase (COX) inhibitor, on mucin expression in
human colon cancer cells. Methods: LS174T colon cancer cells which express EGF-R, COX-
2, MUC2 and MUC5AC, were stimulated with PGE2 and/or EGF then treated with Gefitinib
(‘Iressa', AstraZeneca), sulindac sulfide or a combination of the two agents for 12 hours.
The PI3K inhibitor, LY294002 and the MEK1/2 inhibitor UO126 were also utilized. MUC2,
MUC5AC, total and posphorylated AKT and ERK1/2 protein expression were determined
by Western analysis. Transient transfection with MUC2 and MUC5AC promoter constructs
was used to monitor MUC2 and MUC5AC transcriptional activity. Results: Treatment of
colon cancer cells with PGE2 or EGF resulted in stimulation of MUC2 and MUC5AC protein
expression in a dose dependent manner. The combination of both agents had a synergistic
effect. Both PGE2 and EGF resulted in phosphorylation of AKT and ERK1/2. Use of corres-
ponding inhibitors resulted in inhibition of MUC2 and MUC5AC. Gefitinib or sulindac
inhibited MUC2 and MUC5AC proteins in a dose dependent manner through inhibition of
both AKT and ERK1/2 phosphorylation. Gefitinib (10μM) inhibited MUC2 expression by
2- fold and MUC5AC by 3 -fold. The addition of sulindac (80μM) to gefitinib caused a
greater reduction in protein levels relative to gefitinib alone (9-fold decrease in MUC2, 10-
fold decrease in MUC5AC). PGE2 and EGF also stimulated MUC2 and MUC5AC promotor
activity significantly. Gefitinib inhibited EGF stimulated MUC2 (2.35 fold, p< 0.005) and
MUC5AC (2.69 fold, p< 0.05) promotor activity while sulindac significantely inhibited only
MUC2 promotor activity (p<0.005). Combining these agents resulted in a greater reduction
in MUC2 promotor activity relative to gifitinib alone (2-fold decrease, p=0.008). Conclusion:
MUC2 and MUC5AC production by human colon cancer cells is inhibited by the COX
inhibitor sulindac and by inhibition of EGF-R through modulation of AKT and MAPK
pathways. MUC2 inhibition occurs at the transcription level with both agents as does
inhibition of MUC5AC by gefitinib. These data provide a rationale for combination strategies
which may inhibit colorectal tumor progression.
S2049
A High Fat Western Style Diet Induces Early Genetic and Inflammatory
Changes in a Mouse Colorectal Cancer Model
Ildiko Erdelyi, Thomas C. Liu, Sussana Cunningham-rundles, Martin Lipkin, Peter R.
Holt
Background: A well established mouse model of diet induced colorectal cancer has been
developed by feeding wild type C57Bl/6 mice a high fat ‘western style' diet (WD). This diet
is characterized by high caloric fat percentage along with low calcium, low vitamin D and
high folate. The mice develop aberrant crypt foci in 3 months and adenomas and carcinomas
after 12-24 months. Our preliminary data shows a significantly increased number of CD3+
T-cells in the flat mucosa of the colon after 12 months suggesting an early inflammatory
mechanism. Aims: To determine whether a WD induces colorectal cancer in a mouse model
through early inflammatory and immunological changes. Methods: Groups of 10 C57BL/6
mice were fed either a WD or a control AIN 76 diet ad libitum for 3 and 6 months. Colonic
specimens were taken for analysis by microarray gene expression analysis (Sentrix Mouse
Ref 8 expression Bead Chip, Illumina) and a selected quantitative panel of 69 proteins
associated with inflammatory pathways. Results: After 3 months the WD significantly
increased the levels of several pro-inflammatory proteins (CRP, fibrinogen IgA, MCP-5,
MIP1γ, leptin and myeloperoxidase) compared to the control diets. Glutathione S-transferase
(GST), a crucial detoxifying enzyme was 8 fold increased. Gene expression microarray
demonstrated alterations in 1407 genes (p<0.05). Changes in several of these pathways have
been implicated in early cancer initiation and progression. Significant pathways included
inflammatory pathways (interleukin 7, CD28, FADD), cell cycle regulators (cyclin D2, cyclin
A1, retinoblastoma 1), and apoptosis (caspase 9, cradd). Gene expression related to oxidative
stress such as the GST family and metallothionein 1 and 2 were upregulated in the WD
group. As expected several genes related to fat metabolism were also upregulated. Conclusion:
A high fat western style diet induces significant early changes at both the protein and gene
expression level in a mouse colorectal cancer model. These changes are detected prior to
the development of polyps and cancer. Characterization of these changes may lead to further
understanding of the mechanisms involved in initiation and progression of diet-induced
colonic neoplasia Such changes may also provide novel targets for chemopreventive strategies.
S2050
Melatonin and Colon Carcinogenesis: Inhibitory Effect of Melatonin On
Oxidant (H2O2 )-Induced β-Catenin Accumulation
Yueming Tang, Ali Banan, Christopher B. Forsyth, Hani P. Nissan, Maliha Shaikh, Zhang
Lijuan, Jayanthi Rangan, Phillip A. Engen, Ali Keshavarzian
Background: Colon cancer is the second most common cause of cancer-related death. Wnt/β-
catenin signaling pathway plays an important role in the mechanism of colon cancinogenesis.
Cancer cells often have high levels of reactive oxygen species intermediates. Oxidative stress
can modulate the function of β-catenin. Melatonin as a free radical scavenger can protect
DNA from free radical damage. The concentration of melatonin in gastrointestinal tissues
is 10-100 folds higher than blood levels, and at least 400 folds higher than the pineal gland.
Human colon mucosa has high affinity binding receptors for melatonin. During the night
time, melatonin concentration in colon cancer patients was significantly lower than in control.
Evidence has accumulated that melatonin, as antioxidant, has anti-carcinogenesis effect on
colon cancer In Vivo and In Vitro, however the mechanism is unclear. We hypothesize that
melatonin may effect the wnt/β-catenin signaling pathway to inhibit colon carcinogenesis.
The aims of the studies are: 1. to determine whether oxidant induced β-catenin activation;
2. to determine the effect of melatonin on oxidative stress. Methods: Human colon cancer
cell line, Caco-2 cells were preincubated with melatonin (0.1-1μM) for 30 min, then,
incubated with oxidant (H2O2, 0 to 0.5mM) for another 30 min. The phospho-β-catenin
levels in the cell extracts were analyzed by western blot. The β-catenin target gene, c-myc
mRNA expression were measured using real time RT-PCR. Results: H2O2 decreased β-
catenin phosphorylation in Caco-2 cells in a dose-related fashion, resulted in accumulation
of β-catenin in cytoplasm and nucleus, and inappropriate activation of the target gene, c-myc.
H2O2 increased c-myc mRNA expression 2.5-fold higher than control group. Pretreatment of
the Caco-2 cells with melatonin inhibited H2O2-induced β-catenin accumulation (85%) and
c-myc mRNA expression (83%).Conclusion:Our results demonstrate that melatonin inhibits
oxidant-induced β-catenin accumulation and its target gene expression in Caco-2 cell line.
Since Oxidant-induced wnt/β-catenin activation plays important role in colon carcinogenesis,
our findings suggest that melatonin may prevent colon cancer through wnt/β-catenin sig-
naling pathway. Thus, melatonin has potential for prevention and treatment of colon cancer.
S2051
Swedish Smokeless Tobacco (Snus) Accelerates Gastric Cancer in a
Helicobacter pylori Mouse Model
Björn Stenström, Chun-mei Zhao, Arlin B. Rogers, Hans-olof Nilsson, Erik Sturegård,
Steinar Lundgren, James G. Fox, Timothy C. Wang, Torkel Wandström, Duan Chen
Background and aim: Snus (the Swedish variant of moist oral smokeless tobacco) has been
popular in Sweden and Norway, and is being introduced to the rest of Europe and the US.
The aim of the present study was to examine if snus is carcinogenic to the stomach,
particularly in Helicobacter pylori (H.p.) infected hosts at increased risk for gastric cancer
development. Methods: Snus (General™; Swedish Match, Sweden) was mixed with powdered
standard mouse food to a concentration of 5-9% (w/w) and given to wild-type (WT) and
gastrin transgenic (INS-GAS) mice (6 months old) with or without concurrent H. p. infection.
A H. p. strain 67:21, containing the entire Cag pathogenicity island, was used for infecting
mice 6 weeks prior to snus exposure. Snus intake was assessed by measurement of cotinine
concentration in the kidney. H. p. infection was determined by culture and conventional
bacteriological methods. Results: After 6 months of snus exposure, the cotinine levels were
724.6±88.0 µg/µL in WT and 665.7±60.3 µg/µL in INS-GAS mice (p>0.05) with or without
H. p. infection. Persistent H. p. colonization was documented 7.5 months after the inoculation
in 17 of 22 WT mice and in 12 of 22 INS-GAS mice. Serum gastrin-17 concentration was
not elevated by snus ingestion. Pathological evaluation of the stomach revealed that when
snus was given to uninfected mice, WT mice showed mild morphological changes, while
4 of 8 INS-GAS mice had carcinoma in situ (CIS), compared to 2 of 8 without snus
exposure. When snus was given to H. p.-infected mice, 9 of 17 WT mice developed CIS
with intramucosal invasion, the remaining 8 of 17 WT mice had high grade dysplasia (score
>1.5), associated with increased gastritis, epithelial defects, oxyntic atrophy, hyperplasia,
and intestinal metaplasia, and 12 of 12 INS-GAS mice developed CIS with intramusocal
invasion and submucosal herniation. An increase in the proliferation rate (determined by
PCNA immunostaining) was associated with the increased incidence of CIS in both WT and
INS-GAS mice. The apoptosis rate (caspase-3 immunostaining) in WT mice was increased
by snus alone and further elevated in combination with H. p. infection. The apoptosis rate
in INS-GAS mice was higher than that in WT mice, but was not further increased by snus
alone and reduced by snus + H. p. infection. In addition, the ECL cell density was reduced
in both strains of mice subjected to snus alone or snus + H.p. infection. Conclusions: Snus
appears to be a gastric carcinogen in mice. The development of CIS was associated with
the increased rates of the epithelial cell proliferation and apoptosis, common features of
gastric carcinogenesis.
S2052
Eomesodermin in Human Cd8+ T Cells: Regulation of Cytolytic T Cell
Activity and of Lymph Node Metastasis in Colorectal Cancer
Imke Atreya, Christoph C. Schimanski, Christoph Becker, Stefan J. Wirtz, Heike
Dornhoff, Elke Schnürer, Martin R. Berger, Dennis Strand, Wolfgang Herr, Peter R. Galle,
Markus Neurath
Introduction: An efficient cytolytic T cell function is essential for immune-mediated rejection
of colorectal cancer. However, the molecular mechanisms driving T cell-mediated cancer
rejection are still poorly understood. Here, we assessed the relevance of the T-box transcrip-
tion factor Eomesodermin in colorectal cancer. Results: By analysing tissue probes from 88
different colorectal tumors, a significant inverse correlation between Eomesodermin expres-
sion in colorectal cancers and the presence of lymph node metastases could be shown,
whereas no such correlation was noted for the master transcription factor of regulatory T
cells, FoxP3. To evaluate whether this effect might be due to effects of Eomesodermin on
tumor infiltrating CD8+ T cells, we subsequently analyzed the regulated expression and
function of this transcription factor in human T cells. Whereas overexpression of this factor
induced perforin but not granzyme expression, siRNA mediated suppression of Eomesoder-
min expression led to significantly reduced IFN-gamma production, perforin levels and
cytolytic activity of CD8+ T cells. Furthermore, TGF-beta and IL-4 could be identified as
important inducers of Eomesodermin expression. These data define for the first time a
regulatory role of Eomesodermin for CD8+ T cell activity in humans. Conclusion: Our
findings suggest that Eomesodermin controls lymph node metastasis in human colorectal
cancer by direct effects on CD8+ T cell activity.
S2053
Epidermal Growth Factor Receptor (EGFR) Nuclear Import Is Linked to
Activation of DNA-Depending Protein Kinase (DNA-PK) in the Carcinogenesis
of Barrett Adenocarcinoma
Alexander Braun, Klaus Dittmann, Ingmar Königsrainer, Alfred Königsrainer
Background: Barrett's esophagus (BE) is a premalignant lesion characterized by replacement
of normal squamous epithelium with columnar epithelium. EGFR has been detected in the
nucleus of various tissues and cell lines and there is a physical interaction between the EGFR
and DNA-PK. Nuclear DNA-PK is essential for repair of DNA. This study was undertaken to
examine nuclear EGFR and the nuclear kinase activity of DNA-PK in the carcinogenesis of
Barett adenocarcinoma. Methods: A total of 42 patients with adenocarcinoma (n = 25) and
intraepithelial neoplasia (n = 12) in BE were included. Finally, as control group, we selected
5 patients without intraepithelial neoplasia in BE. Samples of invasive adenocarcinoma
derived from 25 oesophagectomy specimens. Endoscopic mucosal resection (EMR) was used
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in 17 patients (104 samples) with (84 samples) and without (20 samples) intraepithelial
neoplasia. The nuclear EGFR was shown by confocal microscopy. The DNA-PK protein was
detected with help of a specific antibody after Western blotting. Results: 84% (21/25) of
Barrett adenocarcinoma and 58% (7/12) of intraepithelial neoplasia showed a nuclear EGFR
whilst 20% (1/5) was found in BE without intraepithelial neoplasia. 88% (22/25) of Barrett
adenocarcinoma and 75% (9/12) of intraepithelial neoplasia showed nuclear DNA-PK. There
was no DNA-PK in BE without intraepithelial neoplasia Conclusions: Complex formation
between EGFR and DNA-PK was observed inside the nucleus, these are common events in
Barrett adenocarcinoma and in BE with intraepithelial neoplasia. These data adress that
nuclear EGFR and nuclear DNA-PK may be a novel biomarker for BE and that its expression
may help to predict the prognosis of this pathology. In the future, the use of this procedure
could play an important role in the evaluation of patients with BE.
S2054
Helicobacter pylori Infection: Protection for Esophageal Squamous Cell
Carcinoma But Risk for Gastric Cardia Adenocarcinoma in Taiwan
I-chen Wu, Yu-kuei Chen, Jang-ming Lee, Shah-hwa Chou, Yih-gang Goan, Deng-chyang
Wu, Ming-tsang Wu
AIMS: This study aims to clarify the role of Helicobacter pylori (Hp) infection on the risk
of oral squamous-cell carcinoma (SCC), esophageal SCC, gastric cardia and non-cardia
adenocarcinoma and colon adenocarcinoma. METHODS: 199 oral SCC (188 males and 11
females), 271 esophageal SCC (258 males and 13 females), 196 gastric adenocarcinoma
(123 males and 73 females) and 240 colon adenocarcinoma (139 males and 101 females)
patients were completed for serum tests of Hp infection. Two hospital- and one community-
based controls (n=305, 403 and 395, respectively) were used for the comparisons. Hp
seropositivity was determined by an ELISA method against Hp IgG. Hp CagA antibody was
also checked in subjects with positive Hp IgG. In In Vitro study, one esophageal SCC (CE
81T/VGH) cell line was co-cultured with Hp, using one gastric adenocarcinoma (AGS) cell
line as the control. Hp-induced cell apoptosis was determined by flow cytometry with PI
and annexin-V-FITC staining as well as TUNEL assay. RESULTS: In Table 1, presence of
Hp infection was found to be a significantly protective factor for developing esophageal SCC
(adjusted odds ratio (AOR): 0.259-0.449; all p-value < 0.05) but a risk factor for gastric
adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060; all p-value < 0.05) in
comparison to the three control groups. The similar results were not found in cancers of
oral cavity and colon. Flow cytometric analysis (Figure 1) showed increased apoptosis from
0.95% to 14.05% in CE 81T/VGH, but not in AGS cells, after co-cultured with Hp at a
concentration ratio of 1 Hp and 100 cancer cells for 36 hrs. TUNEL assay revealed similar
result (data not shown). CONCLUSIONS: Our findings support that Hp infection protects
from the development of esophageal SCC, but increases the risk of gastric cardia adenocarci-
noma.
Association between Hp infection and cancer risks
* adjusting for age, gender, educational levels, cigarette smoking, alcohol and betel nut con-
sumption
S2055
Evidence for Distinct Pathways Leading to P53 Stabilization in Adenomas of
Patients with Familial Adenomatous Polyposis
Willemijn A. Van dop, Guy E. Boeckxstaens, Daniel W. Hommes, G. johan A. Offerhaus,
Gijs R. Van den brink
Background: Patients with Familial Adenomatous Polyposis (FAP) carry a germline mutation
in the APC-gene and develop hundreds of colorectal adenomas in adolescence for which
they undergo a colectomy. The majority of sporadic colonic cancers also result from a
mutation in the APC-gene. As a multitude of very small adenomatous lesions can be found
in colonic resection specimens of patients with FAP, this disease serves as an excellent model
to study the earliest stages of colorectal carcinogenesis. A mutation in the APC-gene leads
to diminished degradation and nuclear accumulation of β-catenin. In Vitro studies have
shown that overexpression of β-catenin enhances the transcriptional activity of the tumor
suppressor protein 53 (TP53 or p53). P53 can be activated in response to diverse cellular
stresses, including overexpression of oncogenes and DNA damage, and is an important
suppressor of colorectal carcinogenesis. In Vitro p53 activity has been shown to be augmented
by an induction of the expression of p14ARF, which stabilizes p53 by sequestering MDM2,
a major regulator of p53 proteolysis. Another pathway that leads to p53 stabilization, the DNA
damage response pathway, was recently suggested to act as an early barrier to tumorigenesis by
Bartkova et al. (Nature 2005). In this pathway p53 is stabilized by phosphorylation of the
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N-terminal domain on Ser15 by the upstream stress response kinases ATM and DNA-PK.
This phosphorylation stabilizes p53 by interfering with the ability to bind MDM2. The
mechanisms that lead to p53 stabilization in early colorectal adenomas has not yet been
examined In Vivo. Material and Methods: We therefore examined early adenomas in resection
specimens from 5 different patients with FAP using antibodies against p53, serine15 phos-
phorylated p53, phosphorylated ATM, phosphorylated DNA-PK and p14ARF. Adenocarcin-
omas were used as a positive control. Results: We observed accumulation of nuclear p53
in all adenomas. P14ARF was similarly upregulated in all adenomas. We also observed an
increase of DNA-PK, ATM and p53 phosphorylation. However, p53 phosphorylation was
dependent on adenoma size and was lost in the larger adenomas. Conclusions: These results
show In Vivo that in adenomatous lesions of patients with FAP there is an evident stabilization
of p53. Our results suggest that the main mechanism of p53 stabilization is by β-catenin
induced upregulation of p14ARF. Activation of the DNA damage response pathway may
also play a role but this is mainly observed in the smallest adenomas and therefore at the
earliest stages of carcinogenesis.
S2056
Dietary Fatty Acid Composition and GSH Affect Rat Colon Carcionogenesis
Ryosuke Shiraishi, Takehiro Fujise, Takashi Kakimoto, Tsukasa Kuroki, Kanako
Yamaguchi, Kenichiro Watanabe, Hibiki Ootani, Ryo Shimoda, Seiji Tsunada, Hiroyuki
Sakata, Ryuichi Iwakiri, Kazuma Fujimoto
Background and Aim Incidence and mortality rate of colon cancer are increasing every
year, which are mainly attributable to Westernization of Japanese food habits. There are
epidemiologic data that showed positive associations between dietary fat intake and colon
cancer. Many studies demonstrated that the colon cancer-promoting effect of a high fat diet
depends not only on the amount of fatty acid consumed but also on the fatty acid composition.
Furthermore many food which indicated to have cancer preventive effect, showed antioxidat-
ive properties. Oxidative stress was integrally associated with colon carcinogenesis. The aim
of this study is to investigate the effect of different dietary fat and oxidative stress on colon
carcinogenesis in rats pretreated with azoxymethane (AOM). Materials and Methods Fifteen
mg/kg body weight of AOM dissolved in 1 ml saline was i.p injected to male SD rats once
a week for 2 weeks. Rats were fed with a basal diet or supplemented with 10% corn oil,
10% olive oil, 10% fish oil and 10% beef tallow for 12 weeks. Colonic aberrant crypt foci
(ACF) was examined at 12 weeks. Additionally rats fed with basal diet with 10% beef tallow
and 1% reduced glutathione (GSH) in vehicle were studied. Among rats fed with 10% beef
tallow diet with GSH, lipid peroxide of serum was evaluated by thiobarbituric acid-reactive
substance (TBARS). Results At 12 weeks, dietary olive and fish oil decreased the number
of ACFs, which is a biological precursor of colon cancer in rodent and human. In contrast,
both corn oil and beef tallow increased the number of ACFs among rats treated with AOM.
Rats fed with beef tallow showed the largest number of ACFs, in contrast 1% GSH in vehicle
decreased to the same level as olive oil. Lipid peroxide level of rats fed with beef tallow
and GSH was lower than that of rats without GSH. Conclusion Long term feeding of dietary
corn oil and beef tallow were suggested to increase colorectal cancer in AOM treated rat,
in contrast olive and fish oil had preventive effect. Ingested antioxidative was suggested to
suppress carcinogenesis, which indicated that oxidative stress had an important role during
carcinogenic process.
S2057
Malignant Transformation of Rat Gastric Epithelial Rgm-1 Cell Line Induced
By Carcinogen Mnng Accompanied with Increased Expressions of Anti-
Oxidative Stress Enzymes By Carcinogen N-Methyl-N'-Nitro-N-
Nitrosoguanidine (Mnng) Treatment
Osamu Shimokawa, Hirofumi Matsui, Yumiko Nagano, Tsuyoshi Kaneko, Jumpei Udo,
Takeshi Shibahara, Akinori Yanaka, Akira Nakahara, Ichinosuke Hyodo
[Background and Aim]: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment induces
gastric cancer in animal model. DNA methylation and oxidative stresses derived from MNNG
are reported to involve in carcinogenesis. We aimed to establish an In Vitro model of MNNG-
induced cancer. [Methods]: RGM-1, a rat gastric mucosa-derived cell line, was incubated
in a medium containing MNNG for 28 days. Cells were first examined morphologically. In
order to examine the tumorgenesis, cells were incubated within soft agar, and were injected
subcutanenously into the thighs of nude mice. In order to investigate cellular migration
ability, RGK-1 cells were incubated in a 12 well plate, above of which mounted 44 micro-
meter pore filters. The number of cells migrated above each filter were counted. RNA extract
of the cells were examined by RNA micro-array. [Results]: MNNG-treated RGM-1 cells
showed morphological changes with reproducibility. We named this transformed cells RGK-
1. RGK-1 proliferated in soft agar, and subcutanenously injected RGK-1 formed tumors in
mice thighs. RGK-1 cells migrated above the filters. RNA micro-array analysis demonstrated
mRNA which involved anti-oxidant responsible enzymes such as superoxide dismutase
(SOD) were increased. [Conclusion]: We established a MNNG-induced transformed cell
line, RGK-1, from a gastric mucosa-derived cell line In Vitro. RGK-1 demonstrated tumor
genesis and migration ability. We propose that RGM-1/RGK-1 system is a desired In Vitro
model of gastric cancer carcinogenesis. Increased mRNA expressions related to anti-oxidant
responsible enzymes suggested the involvement of oxidative stresses in this transformation.
S2058
Molecular Biological Study for Diffuse Type Gastric Cancer - A View of Runx3
Expression-
Takayuki Motoyoshi, Hideyuki Konishi, Shunji Tachibana, Chohei Sakakura, Naoki
Wakabayashi, Shoji Mitsufuji, Keisho Kataoka, Takeshi Okanoue
Background: Human runt-related transcription factor gene 3 (RUNX3) is known to be a
growth regulation factor of gastric epithelial cells. We have previously shown that in the
majority of gastric cancers RUNX3 expression is reduced by hypermethylation not only at
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the tumor region but also at the surrounding intestinal metaplasia. We have also shown
that RUNX3 expression was begun to be reduced at early stage of almost all diffuse type
gastric carcinomas. Aim: To explore the mechanism how RUNX3 is related to carcinogenesis
and progression of diffuse type gastric carcinoma in comparison with those of intestinal
type gastric carcinoma. Materials and Methods: A retrospective review of 105 cases of gastric
cancer (75 cases of intestinal type and 30 cases of diffuse type gastric carcinoma) was
performed. Immunohistochemical analysis was performed on paraffin-embedded tissue
samples of 56 early stage gastric cancers (40 cases of intestinal type and 16 cases of diffuse
type gastric carcinoma) using RUNX3 monoclonal antibody gifted from Prof. YOSHIAKI
ITOH in Institute of Molecular and Cell Biology, National University of Singapore. And then
methylation status of promoter region of RUNX3 gene is studied in 49 cases of peritoneally
disseminated gastric cancer (35 cases of intestinal type and 14 cases of diffuse type gastric
carcinoma) using methylation specific PCR. Results: RUNX3 expression in the tumor region
is reduced in 12 out of 16 cases (80%) of diffuse type early gastric carcinoma and half (20
out of 40 cases) of intestinal type early gastric carcinoma. While RUNX3 expression in the
surrounding mucosa is reduced in 18 out of 40 cases (45%) of intestinal type early gastric
carcinoma but no diffuse type early gastric carcinoma. RUNX3 gene is hypermethylated in
all cases of peritoneal dissemination of diffuse type gastric carcinoma. Conclusions: The
reduction of RUNX3 expression showed more obviously in diffuse type gastric carcinoma than
in intestinal type. An inactivation of RUNX3 appeared from the early stage of carcinogenesis of
diffuse type gastric carcinoma, and have closely related to its progression. These results
indicate that RUNX3 expression analyses imply a potential for an earlier diagnosis of minute
cancer and peritoneal dissemination of diffuse type gastric carcinoma.
S2059
5-Aminosalicylic Acid Interferes with Cell Cycle Progression and Induces
Apoptosis of Colorectal Cancer Cells
Pim J. Koelink, Marij A. Mieremet-ooms, Wim E. Corver, Mieke Mommaas, Gerrit
Griffioen, Cornelis B. Lamers, Daan W. Hommes, Hein W. Verspaget
Epidemiological studies suggest that 5-aminosalicylic acid (5-ASA) has cancer-chemopreven-
tive properties In Vivo, e.g., 5-ASA medication in ulcerative colitis is associated with a
reduced colorectal cancer incidence. Due to its few and relative mild side-effects 5-ASA is
therefore an attractive candidate in a chemopreventive/treatment strategy for colorectal
cancer. Inhibition of proliferation and induction of apoptosis are two widely recognized
mechanisms of action of chemopreventive agents. Our studies aimed to evaluate 5-ASA's
potential on these features to colorectal cancer cells In Vitro, within a physiological achievable
range. 5-ASA was found to inhibit cell growth at low concentrations (<35mM), and reduced
cell numbers to even below starting values at higher concentrations (>35 mM) in HT29,
Colo205, Caco2 and HCT116 cells (IC50 range 17-34 mM). Flow cytometry analysis,
including cyclin A/B1 and phospho-histone H3 (a marker of chromosomal condensation),
showed that 5-ASA induced cell cycle arrest in the S and G2/M phase of HT29 cells.
Microscopic analysis confirmed the mitotic arrest. Aberrant mitotic spindles, leading to
features of “mitotic catastrophe” or “mitotic death”, i.e., giant cells containing multiple
micronuclei, were found, confirming that 5-ASA interferes in cell cycle progression. In
contrast to HT29 cells, Caco2 cells were arrested in the G0/G1 phase. In both cell lines a
dose-dependent increase in apoptosis by 5-ASA was found, as assessed by Annexin V flow
cytometry and immunohistochemical detection of a caspase-cleavage product of cytokeratin
18 (M30), in addition to the classical morphological features of apoptosis. Western-blot
analysis showed increased levels of active caspase-3 by 5-ASA. The survivin and p21 pathways
were found to be unaffected by 5-ASA treatment. 5-ASA's anti-inflammatory actions have
been reported to be dependent on activation of the peroxisome proliferator-activated receptor-
gamma (PPAR-gamma). GW9662, a specific PPAR-gamma antagonist, was not able to antag-
onize the effects on HT29 cell proliferation, indicating that the growth inhibitory effects of
5-ASA are PPAR-gamma independent. Thus, these observations indicate that 5-ASA interferes
in the cell cycle progression of colorectal cancer cells In Vitro and induces epithelial cell
apoptosis, which illustrate its chemopreventive properties. These responses are time, concen-
tration/dosage and cell-type dependent and PPAR-gamma independent.
S2060
5-Aminosalycilic Acid (5-ASA)-Mediated Block of Colon Cancer Cell Growth
Is Associated with Degradation of Cdc25a and Accumulation of Cells in S-
Phase
Carmine Stolfi, Daniele Fina, Roberta Caruso, Flavio Caprioli, Massimo C. Fantini, Ilaria
Peluso, Angelamaria Rizzo, Fabio Andrei, Salvatore Bellinvia, Francesco Pallone, Giovanni
Monteleone
Background & Aim. Epidemiological observations indicate that 5-aminosalicylic acid (5-
ASA) reduces the risk of developing CRC in patients with ulcerative colitis. However,
the molecular mechanism underlying the antineoplastic effect of 5-ASA remains poorly
characterized. In this study we have examined whether 5-ASA modulates CRC cell growth
and analyzed its effects on cell cycle checkpoints. Methods. CRC cell lines (i.e. HCT-116,
HT-29 and CT-26) were treated with graded doses of 5-ASA (5-30 mM) for 48 hrs, and
then cell cycle and proliferation were evaluated by FACS. Both phosphorylated and total
CDC25A, CHK1 and CHK2 were evaluated in total extracts of 5-ASA-treated cells by Western
blotting. Moreover, we evaluated the effect of 5-ASA on the development of CT-26-derived
xenografts in mice. Results. 5-ASA dose dependently inhibited CRC cell growth. The 5-
ASA-mediated anti-mitogenic effect was reversible and associated with no change in CRC
cell survival, and accumulation of cells in S-phase. Consistently, 5-ASA enhanced phosphoryl-
ation and degradation of CDC25A, a phosphatase necessary for promoting the G1-S phase
transition and S-phase progression. Time-course analysis showed that CDC25A phosphoryl-
ation was preceded by activation of the upstream kinase CHK2. Finally we showed that
administration of 5-ASA to Balb/c mice markedly reduced the development of CT-26-derived
colon cancers. Conclusions. These data support further the notion that 5-ASA negatively
regulates CRC cell growth, thus bringing new insights into the molecular mechanism underly-
ing the antineoplastic action of this drug.
S2061
Proteinase-Activated Receptor 2 (PAR2) Increase Cell Proliferation Through
Cyclin D1
Hongying Wang, Tyron Harrison, Wallace K. Macnaughton
Proteinase-activated receptor (PAR)-2 is a G-protein coupled receptor that is activated by
the proteolytic activity of serine proteinases such as trypsin and tryptase. PAR2 plays import-
ant roles in physiological and pathophysiological processes, and has recently been shown
to promote colon cancer cell proliferation. However, the mechanisms whereby this occurs
are still unknown. Cyclin D1 is an important regulator of DNA synthesis in the cell cycle.
We aimed to test whether cyclin D1 is involved in PAR2-induced cell proliferation. We
used the human epithelial cell line, A549, which was treated with the selective PAR2
activating peptide (PAR2-AP), SLIGRL-NH2 (50 µM). RT-PCR showed that exposure of cells
to the PAR2-AP significantly increased cyclin D1 mRNA expression by 100% by 3 hours
after treatment (p<0.05). Using the TOP-FLASH luciferase reporter assay for the transcrip-
tional activity of beta-catenin, which is elevated in many forms of colon cancer and is a
known regulator of cyclin D1, we also showed that beta-catenin activity was elevated 4-fold
(p<0.01) with PAR2-AP treatment. Cell cycle analysis by flow cytometry showed a slight
increase of the G2/M phase by 12 hours after the stimulation with PAR2-AP. Moreover,
using the BrdU-labeling method, we found that exposure of cells to the PAR2-AP significantly
increased DNA synthesis 12 hours after treatment. In conclusion, we have shown that
activation of PAR2 in epithelial cells increased cyclin D1 and DNA synthesis by stimulating
the transcriptional activity of beta-catenin. Thus, our study provides evidence of a new role
for PAR2 and PAR2-activating proteinases in cell proliferation and tumorigenesis. (H. Wang
is supported by a CAG-CCFC Fellowship.)
S2062
Generation of a Novel Mouse Model for Treatment of Liver Metastases from
Neuroendocrine Tumors
Daniel Benten, Jorg Schrader, Harald Ittrich, Katharina Fradrich, Andrea Pace, Andreas
De weerth, Ansgar Lohse, Michael Blaker
Therapeutic options for liver metastases of gastroenteropancreatic-neuroendocrine tumors
(NET) are unsatisfactory. Recent in-vitro studies using NET cell lines discovered new signal-
ling pathways and indicated antiproliferative effects of various drugs. Whether these mechan-
isms are also effective in-vivo is unknown. Therefore, to investigate suitable drugs in-vivo,
we developed a mouse model for the treatment of NET liver metastases. 5x10e5 cells of an
established human pancreatic NET cell line (BON-1) were transplanted intraspenically or
via the portal vein in immunodeficient NOD-SCID mice. Serum analysis of transplanted
mice showed an early increase of the biochemical NET marker, chromogranin A. Macroscopic
and microscopic examination of excised livers 4 weeks following cell transplantation showed
multiple tumor nodules, comprised of small cells. The human origin of these cells in murine
liver lobes was determined by PCR as well as DNA-in-situ-hybridization using human specific
primers and probes. Tissue analysis using chromogranin A and Ki67 immunohistochemistry
showed that cells kept their original property and proliferated in-vivo. To study quantitative
growth of NET liver metastases over time, we used magnetic resonance imaging (MRI) of
transplanted mice, followed by volumetric analysis. Since many tumor cells were retained
in the spleen after intrasplenic injection, only the intraportal administration route was used
for these studies. Two weeks following cell transplantation, all animals developed liver
metastases with an average tumor volume of 164±70 mm3 (n=6). Weekly MRI showed near
exponential tumor growth thereafter, resulting in an up to 40-fold volume increase at week
five after transplantation. At this time, malignant ascites or illness due to liver insufficiency
developed, and experimental animals were sacrificed. Pulmonary metastases were not
detected by MRI or PCR analysis. Although therapeutic studies comparing the in-vivo
effectiveness of pharmaceuticals on growth inhibition of BON-1 cells require further examina-
tion, our findings indicate the potential of this mouse model to investigate antiproliferative
effects of new drugs for improving the unfavourable outcome of NET liver metastases.
S2063
Long Term Followup of Patients with Malignant Carcinoid Syndromw
Receiving Sandostatin Lar
Joanne Garland, Cathy Bouvier, Philippa Davies, Christos Toumpanakis, John Buscombe,
Martyn Caplin
INTRODUCTION: Somatostatin analogues are used for symptomatic and therapeutic treat-
ment of malignant carcinoid sydrome. Use of long-acting preparations has major implications
in terms of convenience. There is little long term data regarding the use of somatostatin
analogues. AIMS & METHODS: To assess the long term effect of Sandostatin LAR on the
management of patients with malignant carcinoid sydrome. Case notes of 60 consecutive
patients (age range 30-78 yrs; 40 male and 20 female) treated with Sandostatin LAR attending
a specialist neuroendocrine clinic were reviewed. 35 patients had primary tumour in the
midgut, 12 in the foregut and 13 had unknown primary tumour sites. Patients had 3 - 6
monthly evaluation of symptoms, biochemical markers and CT imaging. 28 (47%) patients
did not require any other therapy, however 32 (53%) patients required additional therapeutic
modalities including chemotherapy, interferon and radionuclide targeted therapy. RESULTS:
55 of the 60 patients (92%) were commenced on a dose of 20mg monthly, 5 (8 %) on 30
mg. Of the 28 patients treated with Sandostatin LAR alone, median follow up time is 25
months. 18 of these 28 (64%) improved and remained stable in terms of symptoms although
10 had deterioration of symptoms after an average of 12.4 months. 5 of 28 patients (18%)had
progressive disease on CT scans after an average time of 27 months. Increased symptoms
or disease progression was an indication to increase the Sandostatin LAR dose. Of 32 patients
requiring additional therapies, 21 were on Sandostatin LAR alone for an average of 18
months before beginning other treatments. 15 of the 32 patients (47%) had radiological
progression; The remaining 17 were treated in view of biochemical progression or sympto-
matic deterioration. Side effects: Of the total 60 patients, 6 (10%) were noted to have
gallstones on CT imaging. 3 patients (5%) had abdominal pain after the injection, 6 (10%)
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had increased diarrhoea for up to 5 days following the injection. CONCLUSION: Sandostatin
LAR is a well tolerated long term treatment. Somatostatin analogues are good at controlling
malignant carcinoid syndrome. A significant proportion of patients maintained stable disease
whilst on Sandostatin LAR. The anti tumour / stabilization effect of somatostatin analogues
need to be assessed in randomised studies.
S2064
Encouraging Results with the Somatostatin Analogue 90yttrium-Dota-
Octreotate for the Treatment of Metastatic Neuroendocrine Tumors: A Series
of 47 Patients
Christos Toumpanakis, Ann-marie Quigley, Victoria Warbey, Rajaventhan Srirajaskanthan,
Tim Meyer, John Buscombe, Martyn E. Caplin
Background :Radiolabelled somatostatin analogues are used not only for tumor visualization,
but also for treatment of metastatic neuroendocrine tumors. Previous studies have assessed
radiolabelled octreotide, but recent evidence suggests that radiolabelled octreotate has even
higher binding to type II SSTR. Aim: To estimate efficacy and tolerability of a new radiolabelled
somatostatin analogue,90Yttrium-Tyr3-DOTA-octreotate(90Y-DOTA-octreotate), in patients
with metastatic neuroendocrine tumors which progressed, despite the administration of
other treatments. Patients & Methods: Forty seven patients (mean age was 60.4 years,range:
34-85 years) with metastatic neuroendocrine tumors were studied. In most patients the
tumours were either low or intermediate-grade, whilst eleven patients had high-grade
tumours. The latter had received chemotherapy in the past. All patients received 1-3 cycles
of the 90Y-DOTA-octreotate every 2-3 months, either intravenously(19/47,40.4%) or intra-
arterialy (28/47,59.6%). In 8 patients of the latter group the intrarterial administration was
combined with particle embolization of hepatic metastases. Intravenous aminoacids were
also administered for protection of renal function. Clinical and/or radiological response to
treatment was defined as the improvement of symptoms and/or either stabilization or reduc-
tion of tumor growth, respectively. Mean follow-up period was 10.1 months (range:2-21
months). Results: In all patients the post treatment scintigraphic scan demonstrated uptake
and localization by the tumour. Clinical improvement was noted in 28/47 (59.5% patients)
after 1-3 treatments. Stabilization of tumor growth was achieved in 11/17 (64.7%) patients,
who had completed the 3 cycles of treatment, and in 7/13 (53.8%) in those who had 2
cycles so far. Radiological response, even lower (4/11,36.3%), was noted also, in the high-
grade group of patients who had progressed despite chemotherapy. Bone marrow toxicity
(WHO grade II) was noted in 6/47 (12.7%) ,persisting at 3 months in two patients with
significant bone metastases. One of them who had chemotherapy in the past, developed
also irreversible mild renal failure (WHO grade II), despite prophylactic aminoacids. Conclu-
sion: 90Y-DOTA-octreotate seems to be a well-tolerated and safe treatment for patients with
progressive neuroendocrine tumors, despite a risk for bone marrow toxicity in patients with
large-volume bone metastases. Early results, regarding efficacy were promising. Longer
follow-up and more pts are required for better evaluation of tumor response.
S2065
Neuroendocrine Tumors (Nets) of the Colon Differ from Sporadic Colorectal
Cancers (Crcs) in Molecular Pathogenesis, and Foregut and Midgut Nets in
Methylation Patterns and Survival
Christian N. Arnold, Ajay Goel, Iris Scharf, Andrea Sosnowski, Patricia Grabowski,
Takeshi Nagasaka, Annette Schmitt-gräff, Rudolf Arnold, C. richard Boland, Hubert E.
Blum
Introduction: Colonic NETs (c-NETs) are characterized by rapid tumor growth and poor
differentiation. Compared to foregut and midgut NETs (f/m-NETS), c-NETs have a worse
prognosis. The molecular pathogenesis of these tumors is unexplained. Aims: To investigate
the molecular and clinical characteristics of NETs, and to compare these with sporadic
CRCs. Methods: Tumors were analyzed for microsatellite instability (MSI) and the CpG
island methylator phenotype (CIMP). MSI was determined using consensus (Bethesda)
criteria. CIMP was determined by methylation-specific PCR or combined bisulfite restriction
analysis. CRCs were CIMP+ when >2/6 genes were methylated; NETs were CIMP+ when
≥3/8 genes were methylated. The NETs were scored for proliferation using Ki-67, and
patient survival. Results: A total of 34 c-NETs, 38 f/m-NETs, and 150 sporadic CRCs with
known MSI status (9% MSI-H, 29% MSI-L, 63% MSS) were investigated. Among the sporadic
CRCs, 10/13 (77%) of the MSI-H, 10/43 (23%) of the MSI-L, and 24/94 (26%) of the MSS
CRCs were CIMP+ (p<0.001). Of the 34 c-NETs analyzed, 1 was MSI-H, 5 were MSI-L,
and 19 were MSS; 0/1 of the MSI-H, 3/5 (60%) of the MSI-L, and 13/19 (68%) of the MSS
c-NET tumors were CIMP+ (p=0.17). Of the f/m-NETS, 4/38 (11%) were MSI-L and the
remainder MSS. 20/34 (59%) c-NETs vs 13/38 (34%) f/m-NETs were CIMP+ (p=0.036).
The proliferation index was significantly higher in c-NETs compared with f/m-NETs, in
which 28/34 (82%) of c-NETs had an index >30% vs 0/38 (0%) of the f/m-NETs (p<0.001),
but there were no significant associations between the Ki-67 index and CIMP status in
either. Median survival for the c-NETs was 13.8 months vs. 67 months for the f/m-NETs.
Median survival for CIMP+ (20/34) vs. CIMP- (14/34) c-NETs was 16.9 vs. 10.7 months
(p=0.4). The survival of CIMP+ (13/38) vs. CIMP- (25/38) f/m-NETs was 71.1 vs. 62.8
months (p=0.266). The survival of patients with c-NETs did not correlate with Ki-67 index,
but the median survival for f/m-NETs with a Ki-67 index <2% vs 2-29% was 84.3 and 38.3
months, respectively (p<0.001). CIMP+/- status did not affect survival in any subgroup.
Conclusions: CIMP is a common feature both in c-NETs and in sporadic CRC, but is less
common in f/m-NETs. CIMP is associated with MSI-H in sporadic CRC, but not in either
type of NET. f/m-NETs have lower Ki-67 scores than c-NETs, and survival is significantly
better for f/m-NETs than c-NETs, but Ki-67 scores influenced survival only in the f/m-NETs.
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S2066
Validation of Prognostic Relevance of the New TNM-Classification System for
Neuroendocrine Tumors of Foregut Origin
Ulrich-frank Pape, Henning Jann, Uta Berndt, Bertram H. Wiedenmann
Neuroendocrine tumors (NET) of the gastroenteropancreatic system are rare and thus only
recently a new TNM-classification system has been proposed (Rindi et al. Virchows Arch
2006;449:395ff). However, validation of this TNM-system is pending. In this study prognostic
significance of the new TNM-classification was tested in a cohort from a referral center. We
retrospectively studied 176 patients with histologically proven foregut NET according to
primary tumor localization, presence or absence of hormone hypersecretion or of metastasis
at initial diagnosis and performed survival analyses. Statistical significance was calculated
using the log-rank test. In 156 NET cases primary tumor localization was in the stomach
(37), duodenum (20) and pancreas (99). Observed hypersecretion syndromes at initial
diagnosis were Zollinger-Ellison`s (16; duodenal 10, pancreatic 6), carcinoid (15; pancreatic
11, duodenal 2, bronchial 2), insulinoma (7), glucagonoma (2) and Werner-Morrison`s
syndromes (1, all pancreatic). Hormone hypersecretion at initial diagnosis had no effect on
survival (p=0,583). However, presence versus absence of metastatasis was associated with
a significantly poorer outcome (5-year survival rate YSR 58 vs. 91%, 10 YSR 50 vs. 90%;
p=0,0003). Previous classification systems by Capella from 1995 and the WHO from 2000
were able to significantly discriminate between low and high grade malignant NET (p=
0,0015 and 0,0092 resp.), but did not allow further prognostic differentiation according to
extent of tumor disease (stage) or differentiation of tumor cells (grade). In contrast, the
newly proposed TNM-classification system was able to significantly differentiate stage IV
NET from all other stages (I vs. IV p=0,0006; II vs. IV p=0,0005; III vs. IV p=0,0045) as
well as stage III from stage I NET (p=0,0227). Furthermore, the new classification system
which includes a grading system according to mitotic index of proliferating cell fraction
(Ki67-index; G1 <3%, G2 3-20%, G3 >20%) was also able to singnificantly seperate all
three groups from each other (5-YSR G1 93%, G2 72%, G3 27%; G1 vs. G2 p=0,040; G1
vs. G3 p<0,0001; G2 vs. G3 p<0,0001). Further analyses revealed prognostic relevance even
when staging and grading criteria were combined. In conclusion, this is the first study to
independently demonstrate prognostic relevance of the newly proposed TNM-classification
system for NET with statistical significance. This TNM-system therefore provides a new and
powerful tool for future classification of NET in both routine clinical work and in urgently
needed international clinical trials.
S2067
Performance of Morphological Examinations in the Preoperative Detection of
Pancreatic and Duodenal Gastrinomas
Dermot O'toole, Colm Murphy, Thomas Aparicio, Laurent Palazzo, Anne Couvelard,
Laurence Choudat, Alain Aubert, Rachida Lebtahi, Frédérique Maire, Marie-pierre
Vullierme, Jean-claude Soulé, Philippe Ruszniewski
Introduction: The preoperative detection of gastrinomas using CT-scan and somatostatin
receptor scintigraphy (SRS) is often difficult due to their small size and duodenal localisation
in about two thirds of patients. In data published before 1995 the mean sensitivity of
endosonography (EUS) for the detection of duodenal tumours was 39%. Aim: Evaluate the
diagnostic precision of EUS, CT and SRS in the preoperative detection of gastrinomas in
relation to their localisation (duodenal or pancreatic) in a cohort of patients followed since
1995. Patients and methods: Retrospective study of 23 patients undergoing surgery for
gastrinoma between 1995 and 2005. The diagnosis of gastrinoma was made on the basis
of the presence of the Zollinger-Ellison syndrome in all patients and at least one specific
biological criterion (hypergastrinemia and/or high hourly acid output, at basal state or
post-secretin stimulation) using levels previously defined and published. The reference
examination was histopathology. Results: Thirty five tumours were found in 23 patients (1
patient with MEN-1 syndrome had 9 pancreatic and 3 duodenal tumours). The median
tumour size was 11 mm (range: 5-110) with the following localisations: duodenal (n=12),
pancreatic (n=9) and 2 patients had primary lymph node tumours (confirmed when surgical
exploration of the pancreas and open duodenotomy failed to identify another primary site).
The overall diagnostic precision for preoperative examinations was: EUS, 75%; CT, 54%;
SRS, 65%; and EUS+SRS, 79% (NS). The diagnostic precision for the preoperative detection
of pancreatic gastrinomas and lymph node primaries was as follows: EUS (100%), SRS
(90%) and CT (82%), (NS). In the patient with multiple tumours all three examinations
corrected identified the tumours. The diagnostic precision of EUS, SRS, CT and EUS+SRS
for identifying duodenal tumours (median size 9 mm) was 54%, 46%, 31%, and 61%,
respectively. All duodenal tumours not detected using EUS were < 10 mm (4 were < 5
mm). Conclusion: Pancreatic gastrinomas (or primaries involving lymph nodes) are easily
identified using CT, SRS and EUS. Small duodenal gastrinomas (<10 mm) remain difficult
to detect even though the performance of EUS has increased with time.
S2068
Small Bowel Carcinoid (ECCell) Neoplasia Exhibits TGF B1-Mediated
Regulatory Abnormalities Including Up-Regulation of C-Myc and Mta1
Mark Kidd, Irvin M. Modlin, Roswitha Pfragner, Geeta N. Eick, Manish C. Champaneria,
Anthony K. Chan, Robert L. Camp, Shrikant M. Mane
Introduction: While it is known that small intestinal carcinoids are derived from enterochrom-
affin (EC) cells, these cells remain poorly characterized and little is known of their growth
regulatory mechanisms of these neuroendocrine cells. Down-regulation or loss of the TGFb1
cytostatic program and activation of TGFb-mediated transcriptional networks is associated
with uncontrolled growth, and metastasis in other neural tumors, glioblastomas. We investig-
ated whether this phenomenon was common to small intestinal carcinoid tumors. Methods:
We assessed the effects of TGFb1 on cultured normal EC cells (isolated by FACS sorting)
and the neoplastic EC cell line, KRJ-I, using the MTT assay. TGFbRII transcript and protein
were identified in tumor cells and the effects of TGFb1 on SMAD2 phosphorylation and
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nuclear translocation quantified. The time-dependent response of SMAD4, SMAD7 and c-
Myc protein expression and P21WAF1/CIP1 transcript was measured in response to TGFb1
and transcript expression of candidate downstream targets, MTA1 and E-cadherin, were
assessed. Results: TGFb1 inhibited normal EC cell proliferation (IC50 = 17pM) but stimulated
neoplastic EC cell proliferation (EC50 = 22pM). In tumor cells, significantly decreased
transcript (p<0.01) of TGFbRII was identified, but no receptor mutations were identified
and protein expression was evident. TGFb1 (1ng/ml) resulted in SMAD2 phosphorylation
and <7% nuclear expression compared to 93% in normal EC cells. In neoplastic cells, TGFb1
(1ng/ml) caused a decrease in SMAD4 (>16%, p<0.05) while SMAD7 and c Myc transcript
and protein were respectively increased >21% (p<0.05) and ~40% (p<0.002). TGFb1 (1ng/
ml) also decreased p21WAF1/CIP1 transcript by 60% (p<0.001). Expression of the down-
stream targets of the c-Myc pathway, MTA1, was increased (20%) and E-cadherin decreased
(30%). Conclusion: The neoplastic EC cell is characterized by loss of TGFb-1 mediated
growth inhibition and, like glioblastomas, utilizes the TGFb system to induce gene responses
associated with growth promotion (c-Myc and the ERK pathway), invasion (E-cadherin) and
metastasis (MTA1).
S2069
Secretin Receptor and Secretin Receptor Variant Expression in Gastrinomas:
Correlation with Clinical and Tumoral Features and Secretin and Calcium
Provocative Test Results
Marc J. Berna, Tapas K. Pradhan, Scott H. Long, Andrea Pace, Karl M. Hoffmann, Jose
Serrano, Robert T. Jensen
Background and Aims: Because fasting serum gastrin levels of patients with the Zollinger-
Ellison syndrome (ZES) frequently overlap with results seen in other conditions causing
hypergastrinemia, 60% of these patients require secretin testing. However, the response to
secretin shows a marked variability (4000-fold difference in gastrin increase) in ZES patients
and 6-30% of ZES patients have a negative secretin test. The molecular basis for this variability
or negative response is unclear. It is unknown if the density of secretin receptors on
gastrinomas could partly explain this variability. Furthermore, a secretin receptor variant,
which lacks 36 amino acids in the amino terminus, has been reported to be able to act as
a dominant negative has been described, but it is unclear, if expression of this variant can
explain secretin test variability or negative secretin tests in ZES patients. The aim of this
study was to investigate these possibilities. Methods: Secretin receptor and variant receptor
mRNA expression was determined by real time-PCR in gastrinomas from 54 ZES patients.
Results were correlated with gastrin-provocative test results and tumoral/clinical/laboratory
features. Results: Secretin receptor mRNA was detectible in all gastrinomas but varied 132-
fold with a mean value of 0.89±0.12 receptor molecules/β-actin molecule. The variant was
detected in all gastrinomas but levels varied 102-fold and were 72-fold lower than the total
secretin receptor. Secretin receptor levels correlated with variant secretin receptor levels,
with secretin test results and with tumor size/location but did not correlate with calcium
test results, with tumor growth/extent or with clinical variables and acid secretory responses.
Secretin receptor variant levels did not correlate with secretin test results. Detailed analysis
provides no evidence the variant expression modified the secretin test response or accounted
for negative secretin tests. Conclusions: Secretin and secretin receptor variant expression
occur in all gastrinomas. Because the expression of the total secretin receptor correlated
with the secretin test results, our results suggest the total secretin receptor density is an
important determinant of the secretin test response. However, we found no evidence that
secretin receptor variant density can influence secretin test results or explain the negative
secretin tests seen in some ZES patients.
S2070
Presentation and Diagnostic Features of Pancreatic Endocrine Tumours
Amy Krepska, Alexandra Davidson, Christos Toumpanakis, Rajaventhan Srirajaskanthan,
Tim Meyer, Astrid Mayer, Martyn Caplin
Introduction: Pancreatic neuroendocrine tumours are uncommon tumours, with a reported
incidence of 1 in 100 000 in the general population. We report on the nature of presentation
and diagnostic features in a case series of patients. Methods: The notes of 121 consecutive
patients with Pancreatic Endocrine tumours seen in our unit since the year 2000 were
reviewed. This cohort of patients was comprised of 57 men and 64 women. Age range from
16 to 79, mean age 44 years. Results: Principle presenting features were abdominal pain
57% (69 cases), diarrhoea 25% (30 cases), jaundice 8% (10), weight loss 5% (6) and
hypoglycaemic episodes 3% (4); incidental findings accounted for the remaining patients.
Of the 121 patients 70% (85 cases) had metastases at initial presentation, and liver metastases
were present in 65%. The majority of these tumours are non functioning (62%), however,
12% are gastrinomas, 5% insulinomas, 4% VIPomas, 2% PTHrp secreting tumours, 2%
somatostatinoma, 1% carcinoid tumour of the pancreas and 1 case of a glucagonoma. The
histology assessed thus far n=63, shows that the majority are well or moderately differentiated
tumours, with 8% poorly differentiated tumours. The Ki67 proliferation index was <10%
(lower grade) in 65% (41/63) of cases; The remaining 35% of cases being >10% (high
grade). Of the 113 patients that underwent octreotide scans, 76% (86 cases) showed positive
uptake and 24% (27) showed no uptake. In addition MIBG scans were performed in 18
patients of which only 8 (44%) were positive. The pancreastatin fragment of chromogranin
A was raised in 54% of cases. Conclusions: The most common presenting symptoms of
pancreatic endocrine tumours appear to be abdominal pain, diarrhoea and jaundice. The
majority of tumours are well or moderately differentiated neuroendocrine tumours. Octreo-
tide scans are positive in 79% of cases; however, MIBG scans are of little help in making
the initial diagnosis. The pancreastatin fragment of chromogranin A is not a good marker for
pancreatic endocrine tumours. We are currently assessing predictive markers for pancreatic
neuroendocrine tumour outcome.
S2071
Is Adjuvant Therapy Useful After Resection of Liver Metastases of Digestive
Endocrine Tumors ?
Frédérique Maire, Pascal Hammel, Olivia Hentic, Reza Kianmanesh, Anne Couvelard,
Dermot O'toole, Anne-laure Pelletier, Vinciane Rebours, Alain Sauvanet, Philippe Lévy,
Philippe Ruszniewski
In patients with gastroenteropancreatic endocrine tumors (GEP) and liver metastases (LM),
surgical resection is the only treatment with curative intent. Five-year recurrences are docu-
mented in 59-70 % of the patients. The effect of adjuvant chemotherapy on relapse-free
survival (RFS) and overall survival (OS) is unknown. Aim of the study : Assess the feasibility,
tolerance and efficacy of systemic adjuvant chemotherapy following LM resection in patients
with GEP. Patients and methods : Between 1996 and 2006, 35 patients (17 male, median
age 52 [range: 21-69] years) undergoing surgery for LM of GEP were planned to receive
adjuvant chemotherapy. Primary tumor, mainly located in the pancreas (n=18) or small
bowel (n=10), was resected in 31 patients. No primary tumor was found in 4 patients. Prior
to surgery, no extrahepatic lesion was identified in any patient (thoraco-abdominal CT and
somatostatin receptor scintigraphy). Seven patients had received systemic or intrahepatic
chemotherapy/chemoembolization before liver surgery. Adjuvant chemotherapy consisted
of 4 postoperative courses of i.v. streptozotocin-5 FU (500 and 400 mg/m2, respectively,
daily for 5 days every 42 days). Feasibility, tolerance, RFS and OS were evaluated. Results
: Liver surgery consisted of metastasectomies, major hepactectomies (at least one lobe) or
liver transplantation in 6, 25 (including 15 2-stage hepatectomies) and 4 patients, respectively.
Median post-operative follow-up was 36 months. Four patients did not receive chemotherapy
due to postoperative complications. The 31 remaining patients received 4 [range: 1-4] cycles.
Proteinuria > 0.2 g/day occurred in 2 patients. Two patients had grade 3-4 toxicity (1 aplasia
leading to death, 1 non febrile neutropenia). Recurrence of the disease was observed in 21
of 31 treated patients (68%), and occurred in the liver, lymph nodes, bone and lung in 15, 5,
1 and/or 1 patients, respectively (median delay : 24 months). Recurrence was not significantly
correlated to primary tumor location, functional status, type of surgery or Ki-67 index. RFS
at 1, 3 and 5 years was 86, 37 and 19 %, respectively. OS at 1, 3 and 5 years was 93, 89
and 59 %, respectively. Conclusion : Adjuvant chemotherapy with streptozotocin-5 FU is
generally well-tolerated in patients with GEP following resection of LM ; however, serious
complications can occur. Disease recurrence in 68% of the patients, after a median follow-
up of 36 months, is similar to the figure reported in historical cohorts without adjuvant
chemotherapy. Thus, administration of streptozotocin-5 FU seems of limited value in this
indication.
S2072
High Incidence of Immunoglobulin Heavy Chain Gene Involved Translocation
in Gastric Diffuse Large B-Cell Lymphoma: Potential Value in Prognosis
Shotaro Nakamura
Background: Several chromosomal translocations involving MALT1, BCL10, FOXP1 and
BCL6 have been described in gastric B-cell lymphomas at variable frequencies. However,
comprehensive studies for these translocations have not been done in Japanese cases, in
particular for translocation involving immunoglobulin heavy chain gene (IGH). Methods:
204 Japanese cases of primary gastric B-cell lymphoma (90 MALT lymphomas, 54 diffuse
large B-cell lymphomas [DLBCL] plus MALT lymphoma [DLBCL+MALT] and 60 DLBCL
without MALT lymphoma) were enrolled. Translocations involving MALT1 and/or IGH were
investigated using interphase fluorescence in situ hybridization (FISH). In cases positive for
MALT1, additional FISH for API2-MALT1 was performed, while in those positive for IGH,
further FISH was carried out with probes for BCL10, BCL6, BCL2, FOXP1, cyclinD1 and c-
myc. Cases of DLBCL were further classified as either germinal center B-cell-like (GCB) or
non-GCB subgroups based on the immunophenotyping with CD10, BCL6 and MUM1.
Results: t(11;18)/API2-MALT1 was detected in 18 (21%) of 87 cases of MALT lymphoma
and 1 (2%) of 45 cases of DLBCL+MALT, but none of DLBCL without MALT lymphoma.
Among MALT lymphoma cases, t(11;18) was significantly associated with H. pylori-negative
cases, resistance to H. pylori eradication, and BCL10 nuclear expression. Translocation
involving IGH was detected in 28 (33%) of 85 cases of DLBCL with or without MALT
lymphoma, while only in 3 (5%) of 63 cases of MALT lymphoma. Partner genes for IGH
translocation included BCL6 (5 DLBCL+MALT, 2 DLBCL), FOXP1 (1 MALT lymphoma, 2
DLBCL+MALT), c-myc (1 DLBCL+MALT, 1 DLBCL) and BCL2 (1 MALT lymphoma), being
unknown in the remaining 18 cases (1 MALT lymphoma, 9 DLBCL+MALT, 8 DLBCL).
Among cases of DLBCL with or without MALT lymphoma, IGH translocation was significantly
associated with favorable prognosis, but not with any other clinicopathologic factors including
immunophenotyping into GCB/non-GCB subgroups. Cox multivariate analysis revealed
younger age, early stage and IGH translocation to be independent prognostic factors for better
overall and event-free survivals. Conclusions: t(11;18)/API2-MALT is relatively common in
Japanese cases with gastric MALT lymphoma, predominantly associated with H. pylori-
negative cases. The results also revealed a high incidence of IGH involved translocation in
DLBCL with or without MALT lymphoma. Although the partner genes were unknown, the
IGH translocation appeared to identify cases with better prognosis.
S2073
Long-Term Clinical Outcome of Patients with Gastric Low-Grade Mucosa
Associated Lymphoid Tissue Lymphoma After H. pylori Eradication Therapy
Shiho Terai, Katsunori Iijima, Katsuaki Kato, Naohiro Dairaku, Tatsuhiko Suzuki,
Masayoshi Yoshida, Tomoyuki Koike, Yasushi Kitagawa, Akira Imatani, Hitoshi Sekine,
Shuichi Ohara, Tooru Shimosegawa
Background: H. pylori eradication therapy is recognized as an effective primary treatment
for gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, there is little
information about the long-term outcome after eradication therapy. Aim: To elucidate the
long-term outcome of gastric MALT lymphoma after H. pylori eradication treatment in a
large prospective series of our patient, with a special attention to how the states of remission
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evaluated at a time of 12 months after eradication are modified during further long-term
follow-up. Patients and Methods: From April 1995 to August 2006, 85 consecutive patients,
including 9 H. pylori-negative patients, with localized gastric MALT lymphoma without a
diffuse, large B-cell lymphoma component received H. pylori eradication therapy regardless
of H. pylori infection status. Patients were followed by means of endoscopic examinations
with biopsies, computer tomography, and blood tests. Results: The median follow-up period
after eradication was 44 months. Sixty-five of 76 (86%) H. pylori-positive patients and only
1 of 9 H. pylori-negative patients achieved complete remission (CR) and all remained in CR
except for a few cases with transient histological relapse for a median period of 43 months.
Although histologically observed residual lymphoma was found in 14 patients at 12 months
after eradication despite normalized endoscopic findings, the majority of the patients eventu-
ally achieved late CR. Eight patients, including 6 H. pylori-negative patients, did not response
to eradication therapy. Of these, 4 patients received radiotherapy (30 Gy) and achieved CR.
None of enrolled patients showed progressive disease during the follow-up. Conclusion:
The long-term outcome of localized gastric MALT lymphoma after H. pylori eradication
therapy was favorable. Although histologically observed residual lymphoma despite normal-
ized endoscopic findings was found in some patients, a watch and wait strategy could be
applied for these cases since the majority of them were in the process of achieving late CR.
S2074
Translocation T(11;18)(Q21;Q21) in High- and Low-Grade Gastric MALT
Lymphoma
Sonia Toracchio, Teresa G. Hayes, Maurice Moffett, Hiroyoshi Ota, Daphne De jong, Jan
paul De boer, Andrew Wotherspoon, Massimo Rugge, David Graham, Hala M. El-zimaity
Background: Translocation t(11;18)(q21;q21) is the most frequent chromosomal aberration
in extranodal marginal zone lymphoma of the MALT type. This translocation has been
associated with an aggressive course but has not been described in high-grade gastric MALT
lymphoma. As some authors propose that tumors with this translocation rarely or never
progress to high-grade lymphomas, this translocation is not regularly examined in the clinical
setting. However, these conclusions were based on examining few specimens. Aim: This
study examined the frequency of chromosomal translocation t(11;18)(q21;q21) in low-grade
and high-grade marginal zone lymphoma of the MALT type as well as the incremental cost-
effectiveness ratio of testing for the translocation at initial presentation vs. forgoing genetic
testing. Methods: We examined paraffin-embedded tissue of patients with gastric marginal
lymphoma of the MALT type. The presence of the t(11;18)(q21;q21) was determined using
reverse transcription-polymerase chain reaction (RT-PCR). A decision tree was designed to
compare screening vs. no screening of t(11;18) in low-grade gastric MALT lymphoma.
Results: We examined 64 paraffin-embedded gastric lymphomas (41 high-grade MALT
lymphomas and 23 low-grade MALT lymphomas) from Italy, USA and Japan. beta-actin
transcript was amplified in 61 of 64 cases. The t(11;18) translocation was detected in 21%
(8 of 39) cases with high-grade MALT lymphoma vs. 18% (4 of 22) with low-grade MALT
lymphoma [odds ratio 0.861, 95% CI 0.227-3.267]. Taking high grade lymphoma risk with
its associated expenses, over a ten year follow up, the screening cost was $6,485 to $12,531
per patient compared to $27,657 in the absence of screening. Conclusion: Translocation
t(11;18)(q21;q21) occurs at an approximately equivalent frequency in both low-grade and
high-grade gastric lymphomas of the MALT type. These results challenge the assumption
that this translocation is absent in high-grade lymphoma or that the translocation precludes
its progression to high-grade lymphoma. Screening studies appear both clinically desirable
and cost effective. Acknowledgments: Dr. Sonia Toracchio was supported by a fellowship
from Fondazione Italiana per la Ricerca sul Cancro (FIRC), Milan, Italy.
S2075
Cases of Gastric MALT Lymphoma and Diffuse Large B-Cell Lymphoma
Associated with Okadaella Gastrococcus-Like Organism
Takayuki Okada, Kazutoshi Hori, Kazuhiko Nakajima, Akira Yamamoto, Adkins Graham,
Hiroto Miwa
Background Diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue
(MALT) lymphoma are B-cell related primary gastric lymphomas, occurring about 2% of
gastric malignant neoplasms. The regression of gastric MALT lymphoma following antibiotic
treatments, suggests the possible involvement of Helicobacter pylori (Hp) and/or other micro-
organisms in the development of the lymphoma. Okadaella gastrococcus (Og) that has been
discovered by one of the authors (T.O.), is an intracellular gram-negative coccoid bacterium
and co-exists with Hp. The aim of this study was to examine the presence of Og in the
gastric lymphoma by a newly developed Og immunohistochemistry. Method Two cases of
Hp-negative gastric MALT lymphoma and one case of Hp-positive DLBCL were examined.
The latter case was examined by transmission electron microscopy (TEM). A rabbit polyclonal
antibody against Og was raised by a standard method by Japan Biotest laboratory. Immunohis-
tochemical detection of Og was performed on formalin-fixed, paraffin-embedded sections
using an avidin biotin peroxidase complex method. Results No binding was detected in
the absence of the primary antibody. Heavily stained Og-like immunoreactivities (OGLIR)
were seen in the gastric mucosa of all specimens examined. Intracellular and extracellular
OGLIR were observed in the mucus, epithelia, and lamina propria. Some OGLIR were
associated with lymphocytes. TEM detected Og-like micro organisms in the lymphoma cells,
but not Hp. Conclusions Og might be associated with the development of gastric lymphoma,
as OGLIR were seen in all these cases, and Og-like bacteria were found in the lymphoma
cells. Further studies are warranted to examine the association of gastric lymphoma and
Og infection.
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S2077
Experience with Laparoendoscopic Resection of Gastrointestinal Stromal
Tumors
William J. Bulsiewicz, Dalia Ibrahim, Caren S. Palese, Mohammed Kalan, Nadim G.
Haddad
Background: This case series examines the authors' experience regarding the techniques and
outcomes of endoscopic assisted laparoscopic resection of gastrointestinal stromal tumors
(GISTs). Methods: A retrospective chart review was performed of all patients at Georgetown
University Medical Center from Jan 2002-April 2006 who underwent laparoendoscopic
surgery of a GIST. All patients had GISTs which were resected via direct localization of the
tumor via endoscopy allowing for the least amount of gastric tissue to be resected while
achieving negative margins. EGD with endoscopic US was performed to assess the gastric
layer of origin, size, and location. In all cases, FNA of the lesion was performed with an
on-site cytologist to confirm an adequate sample. Patients were considered candidates for
the operation if they had a FNA confirmed GIST in an anatomic location amenable to
laparoscopic resection. Location and size of tumor dictated whether a gastric sleeve resection,
wedge resection, or partial gastrectomy was performed. Results: We performed combined
laparoscopic-endoscopic resection in 4 patients successfully. In two other patients the opera-
tions were converted to the open technique because of the friability of the tumor, and in
the second case, tumor position. The 4 patients who successfully underwent the combined
procedure (2 males, 2 females) were a mean age of 68 years (46 yrs to 81 yrs). 3 of the
tumors were located in the body/posterior wall of the stomach and 1 tumor was located in
the cardia. Op-time was a mean of 81 min (49 min to 123 min). Blood loss was estimated
at <200 cc in all 4 patients. Tumor size was a mean diameter of 52.3 mm (35 mm-70 mm).
The larger tumors (70 mm and 60 mm) had an intermediate malignant potential and the
two smaller tumors (35 and 45 mm) had a low malignant potential. All margins were
pathologically negative. Hospital stay was 3 days for all 4 patients. There were no intra- or
post-op complications and no mortalities. Patients have been recurrence free and followed
out for a mean of 13.5 months (5 to 32 months). Conclusion: Through pre-surgical evaluation
of the gastric walls through EUS/FNA and subsequent direct endoscopic localization of
tumor, laparoscopy-endoscopy allows for minimal tissue resection while ensuring negative
margins. Simultaneous evaluation with endoscopy can also prove to be beneficial in alerting
the surgeon when the procedure might be more safely performed in the open fashion as
was noted in two cases at our institution. In summary, the main benefit of the endoscopy
is tumor localization which ultimately dictates the optimal surgical approach in terms of
safety and efficacy.
S2078
Diagnostic Yield of Fecal Occult Blood Testing for Significant Neoplasia After
Clearing Colonoscopy
Robert H. Lee, Benjamin Brichler, John M. Carethers, Samuel B. Ho
Background: Fecal Occult Blood Testing (FOBT) is an accepted form of colorectal cancer
(CRC) screening, but is not recommended for CRC detection within 10 years of a clearing
colonoscopy. Despite this, an automated reminder for annual guaiac-based FOBT appears
on a patient's electronic chart at our Veterans Affairs (VA) Hospital even if a clearing
colonoscopy has recently been performed. Consequently, a subset of veterans receive FOBT
After Clearing Colonoscopy (FOBT-ACC). Aims: (1) To determine the extent of the practice
of FOBT-ACC, and (2) To compare the diagnostic yield for significant colonic neoplasia of
FOBT-ACC versus clearing colonoscopy alone. Methods: A review of colonoscopy reports
at our VA Hospital from 1996-2006 identified patients who underwent a baseline clearing
colonoscopy and a 2nd colonoscopy within a 10-year time span. Patients were then divided
into two groups: (1) patients who received clearing colonoscopy followed by FOBT (FOBT-
ACC), and (2) patients who received clearing colonoscopy (CC) alone. The rates for advanced
adenomatous polyps (>2 adenomas, >9mm adenoma, villous histology, or CRC) found on
2nd colonoscopy were calculated. P-values using a two-tailed Fisher's exact test were used
to determine the significance of difference in rates for CRC and advanced adenomatous
polyps between the groups. Results: There were 5091 clearing colonoscopies performed for
surveillance or screening. 1437/5091 (28%) patients received FOBT-ACC. The mean interval
between clearing colonoscopy and the first FOBT-ACC was 1.9 years with a mean of two
FOBTs checked per patient. 631/5091 (12.4%) patients had a 2nd colonoscopy. The detection
rate of advanced adenomatous polyps (Table 1) was lower in the FOBT-ACC group than
in the CC group (12.4% vs 22%, p=0.002) as was the overall rate for significant neoplasia
(14.4% vs 22%, p=0.016). There was no difference in the diagnostic yield for CRC between
the two groups. In those patients who underwent FOBT-ACC, there was no significant
difference in diagnostic yield for significant neoplasia between FOBT positive and FOBT
negative patients (14.9% vs 14.3%, p=0.92). Conclusions: FOBT-ACC is a common practice
at our VA Hospital that does not improve the diagnostic yield for colonic neoplasia within
10 years of a clearing colonoscopy. Prospective studies should be considered to further
assess the utility of interval FOBT for detecting neoplasia that are potentially missed on
clearing colonoscopy.
Table 1.
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S2079
Colonoscopic Screening in Average Risk Individuals Ages 40 to 49 Vs. 50 to
59 Years
Benjamin Lebwohl, Andrew Rundle, Robert Vogel, Stephen Levine, Susan Spear, Alfred I.
Neugut
Background: Screening guidelines for colorectal cancer include colonoscopy starting at age
50 based on the prevalence of adenomas and the incidence of colon cancer at that age. Only
one prior study, however, has investigated the prevalence of colorectal neoplasia with
colonoscopic screening in asymptomatic average-risk individuals aged 40-49 (Imperiale,
NEJM 2002; 346:1781). Aim: To determine the prevalence with colonoscopy of colorectal
adenomas and cancer in asymptomatic, average-risk persons aged 40-49. Patients & Methods:
Screening colonoscopies were offered to participants of Executive Health Exams, a healthcare
provider that offers screening services as part of employer-provided wellness programs to
U.S. employees of multiple corporations starting at age 40 for those at average risk for colon
cancer. Measured outcomes included the presence of one or more adenomas and the size,
number and location of each adenoma. Adenomas considered advanced were those that
were≥1 cm in diameter or that contained villous or dysplastic features. Results: We analyzed
553 screening colonoscopies for patients aged 40-49 and 352 screening colonoscopies for
patients aged 50-59. The mean age was 45.4 (40.1-49.9) in the 40-49 age group, and 53.7
(50.0-59.7) in the 50-59 group. Males accounted for 75% of the population aged 40-49
and 77% of the population aged 50-59. Of the 553 patients in the 40-49 age group, 79
(14%) had one or more adenomas. Twenty-one of these patients (3.8% of the total screened)
had two or more adenomas, and 11 of these patients (2%) had an advanced neoplasm. No
cancers were identified in this group. Of the 352 patients in the 50-59 age group, 57 patients
(16%) had one or more adenomas detected. Eleven of these patients (3.1% of the total
screened) had two or more adenomas, and 10 of these patients (2.8%) had an advanced
neoplasm. One cancer (0.3%) was identified on colonoscopy in the 50-59 group. Conclusion:
Similar to Imperiale, et al, we found on colonoscopic screening that the prevalence of total
adenomas, advanced neoplasms, and cancers was the same in individuals ages 40-49 as in
those 50-59 yrs (see Table). Based on these findings, the justification for screening average-
risk individuals for colorectal cancer starting at age 40 is as strong as starting at age 50, the
currently-recommended starting age.
Prevalence of adenomas, advanced neoplasms, and colorectal cancer among patient groups
aged 40-49 and 50-59
S2080
Missed Upper Gastrointestinal Cancer Within 3 Years of Previous Endoscopy
Andrew N. Milestone, Alex J. Kent, Rob D. Goldin, Jonathan M. Hoare
Introduction: Esophagogastric cancer is detected in less than 2% of upper endoscopy referrals.
However, despite increasing “Early Access Endoscopy” services, early detection does not
appear to be improving. Furthermore, evidence in the literature suggests a significant number
of upper gastrointestinal cancers (UGIC) may be missed at previous endoscopy. However,
there are very few studies specifically addressing this issue. The aim of this study was to
identify potentially missed UGIC in patients undergoing upper endoscopy within 3 years
of subsequent UGIC cancer diagnosis. Methods: A retrospective analysis of all 18604 upper
endoscopies performed over a 5.5 year period. 163 (0.9%) gastric and 85 (0.5%) esophageal
cancers were identified by cross-referencing endoscopy and histology databases. 28 (17.2%)
gastric and 11 (12.9%) esophageal cancers were identified in patients who had undergone
previous endoscopy within 3 years of cancer diagnosis. The 3 year “miss” period is based
on mucosal tumor doubling time and to allow comparison with the few studies addressing
this subject. Results: 10.5% (17/163) gastric and 10.6% (9/85) esophageal cancers were
potentially missed at previous endoscopy with 6.8% and 8.2% deemed “Definitely missed”
(see table 1). The overall potential UGIC miss rate was 10.5% (26/248). 11 gastric and 2
esophageal cancers diagnosed at repeat endoscopy during a single patient admission were
categorised as a “delayed” diagnosis rather than a missed diagnosis. No misses were related
to pathologist errors on review of histological samples. 45-50% of “definitely” UGICs had
sinister symptoms at initial endoscopy. Conclusions: Our data suggests a significant number
of UGIC lesions are missed at initial endoscopy. It can be seen in our study, that the
endoscopist played a role in the majority of missed diagnoses. These findings are consistent
with a 9.8% overall UGIC missed diagnosis at prior endoscopy in a recent UK study of
similar sample size. The need to ensure good endoscopic technique with thorough mucosal
examination, adequate biopsies and recognition of abnormal mucosa, particularly in patients
with alarm symptoms, is highlighted.
Table 1: Categories and reason for missed UGIC
S2081
Can a Quantitative Fecal Occult Blood Test Determine the Need for
Colonoscopy in Patients At High-Risk for Colorectal Neoplasia?
Paul Rozen, Rachel Hazazi, Zohar Levi, Alex Vilkin, Amal Waked, Eran Maoz, Shlomo
Birkenfeld, Yaron Niv
Background: High-risk patients, with family or personal history of colorectal neoplasia,
undergo colonoscopy screening/follow-up at intervals predetermined by clinical experience.
Aim: To examine if a specific, sensitive & quantified immunochemical test for fecal hemo-
globin (Hb) (I-FOBT) could indicate need for colonoscopy. Methods: 1000 asymptomatic
high-risk patients, undergoing elective colonoscopy after preparing 3 I-FOBTs, are being
prospectively studied & we analyzed the first 500. I-FOBTs were analyzed & quantified by
the OC-MICROTM automated instrument (Eiken, Japan), results given as ngHb/mL buffer
&≥75ngHb threshold was used for determining positivity. Diagnostic endpoint was “signific-
ant” neoplasia: cancer (CRC) & advanced adenoma (AP) (size≥1cm,≥20% villous histology,
any HGD). Data given as means ± SD, 95% CI, positive & negative predictive values (PPV
& NPV). Results: See Table. Conclusions: I-FOBT detected 100% of CRC & 50% AP. With
a PPV of 46%, all cancers & A significant neoplasm would have been detected every 2.2
follow-up colonoscopies, the assumption being that systematically repeated I-FOBT will
identify further significant neoplasia. If confirmed by the completed study & A further
prospective trial of interval I-FOBT screening, this could significantly decrease the colonos-
copy burden on these patients & on the medical services.
S2082
Evolution of the Screening Algorithm for a National Bowel Cancer Screening
Programme
Joy C. Gordon, Callum G. Fraser, Robert J. Steele
The UK bowel cancer screening pilot began in 2000. A complex screening algorithm was
mandated. Results for the 188318 kits tested in Scotland over 2000-2002 were as follows.
Participants who had five or six positive ovals on the first non dietary restricted guaiac
faecal occult blood test [FOBT] were classed as strong positive [0.39%] and were offered
colonoscopy without further testing. Participants with one to four ovals positive were classed
as weak positive [4.67%] and asked to do a second FOBT [with dietary restriction]. If any
oval was positive on this second test [1.03%], colonoscopy was offered; however, if all six
ovals were negative [3.29%], a third FOBT [again dietary restricted] was requested. If any
oval was positive on the third test [0.38%], colonoscopy was offered. In the second screening
round [2002-2005], the need for dietary restriction seemed of less importance because of
documented changes in the diet of the population, the conclusions of a published meta-
analysis, and the FOBT were dry before analysis thus eliminating false positive results due
to plant peroxidase activity. Dietary restriction was therefore eliminated making the screening
algorithm simpler for participants. There were 0.23% strong positive, 4.38% weak positive,
and 0.47% positive on the third test in the 180322 kits tested. Most positive results come
from repeat testing and and this caused long screening histories for some. In consequence,
we examined the yield of disease in those who had undergone three FOBT. In the first
round, the 596 strong positive participants had 112 cancers and 244 adenomas, the 1669
weak positive had 146 cancers and 795 adenomas, but of the 625 who required a third
FOBT, only 25 had cancer and 229 adenomas. Second round results were similar. We
eliminated the third FOBT to simplify the third screening round [2005-2007], in part because
many colonoscopies [over 20%] would be saved but only a small amount of disease missed,
and also because the pilot was to be a national programme with screening offered every
two years. For the Scottish Bowel Screening Programme to roll out in 2007, further algorithm
refinement has been done. All participants will initially be sent a FOBT. Participants who
hve strong positive results are more likely to have bowel disease and thus will be offered
colonoscopy immediately. Participants who are weakly positive will be asked to do a faecal
immunochemical test [FIT] rather than a FOBT since this strategy directs colonoscopy to
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those with significant disease. Negative individuals will be invited for screening again after
two years.
S2083
Methylated Genes As Candidate Markers for Colorectal Cancer Screening
Linked to Cpg Island Methylator Phenotype
Hongzhi Zou, Jonathan J. Harrington, Abdirashid M. Shire, Rafaela L. Rego, Liang Wang,
Megan E. Campbell, Ann L. Oberg, David A. Ahlquist
Background: Methylated genes have been detected in the blood and stool of patients
with colorectal cancer. Discriminant methylation markers are required to achieve optimal
performance in a potential colorectal cancer screening application. However, it is not clear
to what extent the tumor CpG island methylator phenotype (CIMP) affects screen detection
by such markers. Aim: To select genes frequently methylated in colorectal neoplasia, and
to evaluate the impact of CIMP on the sensitivity of a methylation marker panel. Methods:
Four genes, EYA2, BMP3, ALX4, and vimentin, specifically methylated in colorectal cancer
were hierarchally-selected from 41 candidate genes. They were further evaluated in two
pilot studies on a total of 206 colorectal tissues, including 74 cancers, 62 adenomas, and
70 normal epithelia. In studies I and II, gene methylation status was analyzed in blinded
fashion by methylation specific PCR (MSP) and real-time quantitative MSP, respectively,
and further confirmed by bisulfite genomic sequencing. All subject groups were age matched.
Results: In study I, methylation of EYA2, BMP3, ALX4, and vimentin was detected in 51%,
60%, 74% and 77% of 43 cancers; 44%, 72%, 91% and 91% of 32 adenomas; and 3%,
7%, 17% and 17% of 29 normal epithelia, respectively (P< 0.05, cancer or adenoma vs
normal for each gene). In study II, at a specificity of 93%, methylation of EYA2, BMP3,
ALX4, and vimentin was found in 87%, 74%, 58% and 65% of 31 cancers and 53%, 77%,
93% and 77% of 30 adenomas (P<0.05 for each gene). Assay sensitivity was not significantly
improved by combining any or all markers compared to the best single marker (P>0.05).
If CIMP is defined as methylation of ≥2 markers, then 72% (53/74) of cancers and 84%
(52/62) of adenomas exhibited CIMP. Neoplasms associated with methylated markers were
more likely to be located in the proximal colon (P<0.01). Conclusions: EYA2, BMP3, ALX4,
and vimentin genes are commonly methylated in colorectal cancers and adenomas but rarely
in normal epithelia. While the large majority of colorectal neoplasms appears to exhibit
CIMP, an important minority does not and would be missed by tests that target methylated
genes only. Complementary use of markers that detect CIMP-negative neoplasms is a biologic-
ally rational approach to optimize screening sensitivity.
S2084
Prevention of Colorectal Cancer By Early Colonoscopy: A Feasible
Perspective, Deduced from Autopsy Data
Kaspar Geul, J.dik.f. Habbema, Ching.w. Ting, J.h.paul Wilson, Fred t. Bosman, Ernst j.
Kuipers
Background- Modelling of life time colorectal adenoma incidences enables the development
of optimal scenarios for colorectal screening. Adenoma recurrence rates after polypectomy
suggest that a large proportion of adenomas and subsequent colorectal cancers may concen-
trate in a small fraction of the population, found adenoma positive at a single screening
procedure. In the absence of life time longitudinal observations, quantative assessments can
only be based on autopsy data. Aims- To predict which proportion of the colorectal cancer
incidence up to 80 years could be prevented by a single colonoscopy at 50 years and
surveillance of adenoma-positive cases only. Methods- 490 autopsy cases without previous
symptoms of colorectal neoplasia, were studied for the presence of colorectal adenomas.
Model parameters shaping adenoma incidence as a function of age and preexisting number
of adenomas were fitted to the observed adenoma prevalences in 1000 bootstrapped samples
drawn from the material. Subsequently, a simulation model rendering adenoma “birth years”
in a 90 year life span was combined with a time dependent probability function to seek the
rate of malignant transformation, which reproduced the incidence of colorectal cancer in
our population. Accurate statistics involved over 107 simulated lives, at least 10.000 for
each sample. Close reproductions were obtained using a power function, relating the rate
of malignant transformation to either the age of the adenoma or the age of the patient. The
latter variant yielded the most conservative outcomes, which are presented here. It was
assumed that all colorectal cancers stem from adenomatous polyps. Results- At 50 years
24% of an average-risk population is adenoma positive. This subset contributes 76% to the
adenoma incidence expected until 80 yrs (95% confidence interval 65-86%). According to
the model these adenomas are associated with 81% of the incidence of colorectal cancer
between 50 and 80 years. (95% confidence interval 69-90%). Metachronous adenomas
developing after the age of 70 years are responsible for an average of only 4% of this
incidence. The goodness of fit (R2) for predicted and observed numbers of neoplasms at
various ages averaged 0.98 (one sided 95% lower confidence bound: 0.95). Conclusion- A
major proportion of colorectal cancers, causing loss of life expectancy, appears potentially
preventable by a single colonoscopy performed at 50 years and subsequent surveillance of
the 24% adenoma positive subset of the population until 70 years. Assuming follow-up at
5 year intervals this would involve on a population basis an average of less then two
colonoscopies in a life time.
S2085
Predictors of Screening Colonoscopy Completion Among Urban Minorities
Lea ann Chen, Lina Jandorf, Jennifer A. Christie, Anabella Castillo, Gary Winkel, Steven
H. Itzkowitz
Background: Colonoscopy is increasingly recommended as the most efficacious test to screen
average risk individuals for colorectal cancer. However, factors that contribute to the success
of screening colonoscopy (SC) completion are not well understood. In an attempt to optimize
SC rates among urban minority subjects, we established a direct referral/open access endos-
copy (OAE) program whereby patients were assisted by a patient navigator (PN) to arrange
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for their colonoscopy. Aims: To determine the success of navigating subjects to obtain their
SC and to explore demographic factors associated with completing SC. Methods: Participants
were predominantly ethnic minorities with Medicaid health insurance referred for SC by
primary care clinics of an urban teaching hospital. Once referred, a bilingual Hispanic female
PN informed patients about the procedure and preparation, arranged transportation, and
provided other support. Demographic factors were analyzed as independent predictors using
univariate and multivariable methods. Results: Of 1169 initial referrals, 688 patients qualified
for navigation and 532 (77%) patients underwent navigation. Of those navigated, 353 (67%)
completed SC. Completion was not related to age or family history of colon cancer. However,
women were 1.31 times more likely to complete than men (95% CI 1.11-2.63, p=0.014).
Hispanics were 1.67 times more likely to complete than African Americans (95% CI 1.11-
2.50, p=0.013). Hispanic females were 1.5 times more likely to complete than Hispanic
males (95% CI 1.23-4.21, p=0.009), whereas there were no gender differences in completion
rates among African Americans. Conclusions: Urban minority subjects can be successfully
navigated into SC, and two-thirds of subjects completed SC. However, despite systems
designed to minimize barriers to SC in insured patients, one-third of minority subjects still
did not complete SC. Future research will attempt to understand why patients might resist
colonoscopy and how we can further increase screening rates.
S2086
Increasing Incidence of Right-Sided Colorectal Cancers: Implications for
Sigmoidoscopy in CRC Screening
Harminder Singh, Alain Demers, Lin Xue, Donna Turner, Charles N. Bernstein
Although flexible sigmoidoscopy (FS) has been proposed as an option for population-based
colorectal cancer (CRC) screening in Canada, several studies suggest it may have limited
value in protecting against right-sided CRC. However, there are limited data on recent trends
of right-sided CRC incidence and utilization of lower gastrointestinal endoscopy, including
FS in Canada. Aim: To determine concurrent longitudinal trends of right-sided CRC incidence
and utilization of lower gastrointestinal endoscopy in Manitoba, Canada. Methods: Cases of
CRC diagnosed between January 1, 1964 and December 31, 2004 were identified from
the population-based Manitoba Cancer Registry. Lower gastrointestinal endoscopies were
identified from Manitoba Health's population-based Physician Claims database. Trends of
age-standardized (standardized to the 1991 Canadian population) incidence rates were
determined using Joinpoint analyses. Results: Overall incidence rates of CRC increased from
42/100,000 in 1964 to 56/100,000 in 1978 (average annual change (APC) 1.89%, p<0.001)
and have since remained stable (54/100,000 in 2004). Right-sided (cecum, appendix,
ascending colon and hepatic flexure) CRC rates showed a monotonic increase in both men
and women (figure) (APC both sexes combined 6.3%, p<0.001). The most rapid (200%)
increase occurred in individuals over 70 years of age. While rates of diagnostic colonoscopies
quadrupled between 1985 (257/100,000) and 2003 (1,083/ 100,000; APC 8.89%, p<0.001),
rates of colonoscopies with polypectomies increased gradually from 35/100,000 in 1985 to
110/100,000 in 1998 and then more than doubled in the subsequent five years (233/
100,000; APC17.4 %, p<0.001). Rates of FS declined since 1998 (APC -6.77%, p=0.01;
258/100,000 in 2003). Conclusions: Increasing rates of right-sided CRC especially in older
individuals may limit the value of FS based CRC screening in Canada. Reasons for increasing
incidence of right-sided CRC despite increasing rates of colonoscopy over the last twenty
years need to be further explored.
Right-sided CRC Incidence Rates (Males-open squares; Females-triangles)
S2087
Heterogeneity of Colorectal Adenoma Epidemiology An International
Comparison
Berndt R. Birkner, A. Munte, Ulrich Mansmann, C. Adrion
Objective: Detailed knowledge of colorectal adenoma in large populations is crucial for
better understanding of adenoma epidemiology and secondly in designing effective preventive
strategies to reduce the incidence of colorectal cancer. Materials and Methods: The data
represent a population-based sample of 12.5 million Bavarians based on an ongoing online
documentation (January to Sept. 2006) of all colonoscopies of out-patients with compulsory
health insurance. Six populations were compared with respect to adenoma prevalence,
gender, age, size, number and histological type of findings: BS - Bavarians with screening
colonoscopy (33,965); BD - Bavarians with diagnostic colonoscopy (109,317); PO - Polish
screening population (43,042) (NEJM, 2006, 355); ZI - official German report on screening
colonoscopy 2006 (506,519). Additionally, the National Polyp Study (NPS, US) and the
Funen study (FU, Denmark) report on adenoma bearing persons. Five populations of
adenoma bearing persons were studied: 8,311 (BS), 6,011 (PO), 21,514 (BD), 2,632 (NPS),
and 1,734 (FU). Results: Mean age (standard deviation) in the BS [BD] population is 64.8
(SD 6.7) [57.1 (14.7)] for men and 64.3 (6.8) [56.1 (15.3)] for women. For specific
subpopulations the following proportions were reported: Females: 55.4% (BS), 64.3% (PO),
56.7% (BD); 55.6% (ZI); Persons free of adenoma/carcinoma: 74.6% (BS), 85.2% (PO),
79.2% (BD); 78.8% (ZI); Low grade adenoma: 16.8% (BS), 8.9% (PO), 13.4% (BD); 13.7%
(ZI); Advanced adenoma (no carcinoma): 7.4% (BS), 5.0% (PO), 5.8% (BD); 6.6% (ZI);
Carcinoma: 1.2% (BS), 0.9% (PO), 1.5% (BD); 0.9% (ZI). Proportions in the adenoma
bearing subpopulations are: Females: 43.2% (BS), 51.6% (PO), 45% (BD); 38.4% (NPS),
37.1% (FU); Multiple adenoma: 50.1% (BS), N.A. (PO), 48.6% (BD); 40.6% (NPS), N.A.
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(FU); Tubular adenoma: 81.5% (BS), 75.1% (PO), 80.1% (BD); 52.6% (NPS), 80% (FU);
Large adenoma (1 cm): 22.4% (BS), 23.7% (PO), 21.8% (BD); N.A.% (NPS), 47.8% (FU).
Conclusions: International comparisons show distinct differences in key variables of adenoma
epidemiology and demography of screening as well as adenoma bearing populations. There-
fore, screening models can not be uncritically transferred between different health care
systems. The numbers needed to screen (to detect one advanced neoplasia in the large
bowel) differ strongly between populations: PO 17 (95% CI 16 to 18); BS 12 (95% CI 11
to 13).
S2088
Is Single Stool Sampling As Effective As Two Stool Sampling in Fecal
Immunochemical Test Based Screening for Colorectal Cancer?
Stephen Cole, Alicia Smith, Jane Upton, Graeme Young
Background: Fecal occult blood tests (FOBT) usually require sampling from multiple bowel
movements to optimize test sensitivity as colorectal neoplasms appear to bleed intermittently.
Newer fecal immunochemical tests (FIT) for hemoglobin are more sensitive and might
perform adequately with sampling from a single bowel movement. This greater simplicity
might improve population participation in screening programs but compromise lesion detec-
tion. Aim: To compare relative lesion detection of brush-sampling FIT in single- and 2-
bowel movement mode in people undergoing diagnostic colonoscopy. Methods: Instructions
were developed for using InSure™ (Enterix Inc, New Jersey) in single-stool mode so that
text and cartoons closely resembled the manufacturer's standard instructions for 2-stool
mode. The InSure™ 2-stool sample collection card was used for both test modes. Single-
stool sampling was achieved by applying 2 samples collected from the same bowel movement
to the sample card, one sample to each window using a new brush each time. Study
participants scheduled for diagnostic colonoscopy were asked to complete a standard 2-
stool sample collection card and 2 single-stool cards from 2 serial bowel movements prior
to commencing bowel preparation. Results: Complete sets of 3 FIT sample cards, colonoscopy
reports and, as appropriate, pathology reports were obtained for 326 people undergoing
colonoscopy (Table 1). Specificities deduced from false-positive rates were: 2-stool: 94.3%,
1st stool: 91.8%, 2nd stool: 92.6% (not significant). Conclusions: These initial results suggest
that InSure™ detects cancer or adenomas approximately equally well in both 2-stool and
single-stool mode and thus neoplasia detection is not compromised by sampling a single
bowel movement. There is no obvious specificity advantage in single-stool mode, perhaps
because 2 samples were taken in the single-stool mode. Large screening studies should now
be undertaken with FIT to determine if sampling from a single bowel movement achieves
similar lesion detection to when 2 movements are sampled.
Numbers (and proportion) with a positive FIT for most severe diagnosis. P=NS for all compar-
isons.
†From colonoscopy, confirmed by histopathology report. ‡Advanced adenoma: >9mm or
high grade dysplasia or >2 adenomas or villous component, or serrated.
S2089
Predictive Risk Factors Associated with Intestinal Metaplasia in a Prospective
Chinese Cohort Under Surveillance for Gastric Cancer
Khay-guan Yeoh, Feng Zhu, Khek-yu Ho, Christopher Khor, Andrea Rajnakova, Wee-
chian Lim, Wan-cheng Chow, Choon-jin Ooi, Chek-siang Foo, Heng-yu Wong, Kwong-
ming Fock, Yoshiaki Ito
Background: The Gastric Cancer Epidemiology and Molecular Genetics Programme (GCEP)
Cohort Study in Singapore aims to enroll 4000 Chinese subjects age > 50 years, offering
screening by endoscopy with systematic prospective follow-up over a minimum of 5 years.
A prior study established that Chinese age >50 years had higher risk of gastric cancer,
compared to the general population. The main objective is to establish predictive risk factors
associated with gastric cancer, by using molecular and genetic approaches. A key question
is to determine the true malignant potential of intestinal metaplasia (IM), recognized as a
gastric pre-malignant lesion. Aim: To perform a preliminary analysis of factors associated
with IM in this cohort of subjects Methods: Informed consent was obtained from all subjects
and the study approved by the institutional review boards of 4 major public hospitals.
The study captures comprehensive clinical information on a state-of the-art database, and
prospectively collects and stores sera, white cell DNA, gastric biopsies from antrum(3),
body(2) and cardia(2), and gastric juice specimens according to a standardized protocol.
Subjects at higher risk (IM, family history, H. pylori) undergo screening annually, while
others are screened at 3 and 5 years. One antral biopsy is used for Helicobacter pylori (H.
pylori) culture and genotyping. Histological assesment of H. pylori , serum gastrin and
pepsinogen levels and IL-1β genotyping are also performed. Cox regression was performed
to identify factors associated with IM. Results: In 456 consecutive Chinese subjects (mean
age 60±8 years; male 53%), 54% have documented H. pylori infection from medical records
(37%) or histology (24%) or serology (20%). By histology, chronic gastritis was diagnosed
in 72%, IM in 38%, gastric atrophy in 18%. Cox Regression showed that age, history of H.
pylori infection and chronic gastritis were highly associated with IM with odds ratios (95%CI)
of 1.6 (1.1-2.2), 1.4 (1.0-2.8) and 5.5 (3.0-10.0) respectively. Sex, alcohol, smoking and
family history of gastric cancer were not significantly associated with IM. Results on H. pylori
serology, IL-1β host genotypes are pending. Conclusions: Age >60 years, past history of H
pylori infection, and presence of chronic gastritis were predictive of intestinal metaplasia in
this high risk cohort. If validated, this could aid risk stratification of subjects that require
surveillance. Further results from this project will provide quantitative estimate of the true
malignant potential of IM and its subtypes.
S2090
Undiagnosed Advanced Lesions in Colonoscopy: A Real Problem
Angel Ferrandez, Monica Navarro, Pilar Roncales, Marcos Diez, Federico Sopena, Angel
Lanas, Ricardo Sainz
Background: Colonoscopy is considered the gold standard for diagnosis of colonic polyps
and colorectal cancer (CRC). However, adenoma miss rates in tandem colonoscopy studies
varies from 2% for adenomas ≥10 mm to 13% for adenomas 5-10 mm and to 26% for
adenomas 1-5 mm. Aim: To investigate the rates of undiagnosed advanced neoplasia:
advanced adenomas (AA) or CRC in a “real-setting” endoscopy unit Methods: We reviewed
the colonoscopy reports from 2000 to 2005 performed in our Endoscopy Unit, the only
available public facility for 260,000 people in a specific area in Zaragoza, Spain. In Spain,
more than 80% of the people are attended by the public Health Care System. Undiagnosed
lesions were defined as follows: An AA (≥10 mm, villous architecture or severe dysplasia)
not reported in a colonoscopy performed in the previous two years, or a CRC not diagnosed
in a colonoscopy performed in the previous 3 years. We excluded patients with HNPCC
or FAP and performed a per-patient analyses. Results: A total of 7646 colonoscopies were
performed from 2003 to 2005 in which 912 patients were diagnosed with at least one AA
and 403 with CRC. Twenty eight (6.94%) patients with CRC had a CRC-free colonoscopy
in the previous 3 years and 70 (7.67%) patients had a colonoscopy without an AA performed
during the previous 2 years. In 7 (25%) patients with undiagnosed CRC the location area
for the cancer was not reached in the previous colonoscopy, thus the real miss-rate of CRC
was 5.3% (21/396). Missed CRCs were located in 10 (47.62%) patients in the rectum, in
8 (38.1%) in the left colon an in 3 (14.28%) patients in the right colon. In 5 (23.81%)
patients the preparation was reported as poor. In 11 (15.71%) patients with undiagnosed
AA the endoscopist did not reach the colon area where such AA was found, thus the real
miss-rate of AA was 6.92% (59/853). Six (0.7%) patients had a missed AA < 10 mm (3
severe dysplasia and 3 villous) and 53 (6.21%) had a missed AA > 10 mm independent of
their histology. Missed AA were found in the rectum in 11 (18.64%) patients, in the left
colon in 28 (47.46%) patients and in the right colon in 20 (33.89%) patients. In 12 (20.33%)
patients the bowel preparation was poor. Conclusions: Undiagnosed advanced neoplasia is
common in a real setting. Missed advanced lesions are more frequently found in the left
colon. Ways to avoid such miss-rates include careful exploration of the entire mucosa,
adequate withdrawal time and good bowel-prep, which could have avoided about 40% of
missed CRC and 20% of missed AA. Lowering miss rates is crucial for correct follow-up
recommendations. Patients should be aware of miss rates in a colonoscopy procedure.
S2091
A Method for High-Yield Retrieval of Colonocytes from Naturally Evacuated
Stool
Victoria White, Cinzia G. Scarpini, Nuno Barbosa-morais, Richard Miller, Nick Coleman
Introduction Screening for colorectal cancer (CRC) is hampered by the lack of a non-invasive
test that provides the high sensitivity and specificity of invasive tests. The aim of this study
was to develop a novel method of isolating large numbers of well preserved colonocytes
from naturally evacuated faeces to use in screening assays based on the detection of proteins,
such as minichromosome maintenance proteins, or on faecal DNA testing. Experimental
Procedure Fourteen naturally evacuated stools from patients with symptoms of CRC were
washed with various reagents and three fractions of the wash fluid isolated by filtration and
centrifugation. These fractions were (i) the solids retained by a filter (F-fraction), (ii) the
pellet of the filtrate (P-fraction) and (iii) the supernatant of the filtrate (S-fraction). For each
stool, the cell yield in 100µl of each fraction (i.e. the volume that could be placed on a
standard microscope slide) was counted by a single observer. Each counted cell was also
categorised by morphology into either a normal colonocyte or ‘other' cell. This latter group
principally represented malignant colonocytes and/or apoptotic colonocytes, a small number
of macrophages may also have been included. Recognisable inflammatory cells e.g. neutro-
phils were excluded from the cell counts. Results A median of 317, 122 and 87 cells counted/
100µl were obtained from the F, P and S fractions respectively (14 stools, ≥2 slides per
fraction per stool). The F-fraction had a higher cell yield compared with the P-fraction (p=
0.03) and S-fraction (p=0.004). The yield of normal colonocytes in each fraction was not
significantly different, but the yield of ‘other' cells in the F-fraction was higher than in either
the P or the S-fraction (p=0.03 for both). On average, over 1500 cells per stool were obtained
in the F fraction. Cell yield in the F fraction varied with stool consistency, with soft stools
yielding less cells than firm stools (p=0.01) and hard stools (p=0.02). Background debris
on the slides was equivalent for each of the three fractions. Colonocytes could be retrieved
in the F fraction from stools that had been stored on ice for 12 hours. Conclusion We have
developed a simple, novel method of isolating large numbers of colonocytes from faeces.
Solids retained by the filter (F-fraction) yield the highest number of cells and significantly
enrich for ‘other' cells. We are currently confirming that colonocytes isolated by this method
can be used for immunocytochemistry and for DNA extraction. We anticipate that this
approach will substantially increase the sensitivity of non-invasive CRC screening methods.
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Are Participants of the Colorectal Cancer Screening Program in the
Netherlands Well Informed?
Anne F. Van rijn, Marije Deutekom, Paul Fockens, P. Bossuyt, Leo G. Van rossum, Robert
J. Laheij, J. Jansen, Evelien Dekker
Adequate knowledge of a disease is crucial in making an informed decision on participation
in screening programs and might raise participation rates. The level of knowledge and
awareness on colorectal cancer (CRC) in the Netherlands was earlier shown to be low. In
the Dutch pilot study on CRC screening with fecal occult blood testing (FOBT), which is
currently being conducted, a detailed information leaflet is provided aiming to increase
knowledge. Aim: To evaluate whether participants of the CRC screening program are
adequately informed by a detailed information leaflet. Method: A screening package consisting
of an invitation letter, an information leaflet, and a FOBT was sent by mail to all those
invited for screening. The information leaflet was comparable to leaflets from other European
CRC screening programs and included information on CRC in general and the risk factors
associated with CRC (e.g. positive family history and age above 50). The benefits and
limitations of the FOBT were also discussed, explaining the risk of false negative and false
positive results. In the leaflet participants with recent rectal blood loss were advised not to
perform the FOBT and to contact their general practitioner (GP). Two weeks after sending
the package, a questionnaire was sent to the first 1000 invited individuals. The questionnaire
was designed to collect data on the level of knowledge and awareness of CRC with items
corresponding to the information provided in the leaflet. It also investigated clarity and
readability of the information leaflet. Results: The response rate to the questionnaire was
599 (60%). These were all participants that had sent in the FOBT. In total 581 (97%)
participants found the information brochure clear and readable. Of all participants 302
(50%) believed that a negative FOBT excluded the presence of CRC. Age older than 50
years and a positive family history for CRC were identified as risk factors by only 216 (36%)
and 194 (32%) respectively. The percentage of participants who had rectal bleeding in the
last three months was 75 (13%). The majority of these participants did not follow the advice
of the leaflet as only 9 (12%) went to their GP. Conclusion: Although 97% of the participants
found the information brochure clear and readable, the average knowledge of the participants
was disappointing, as half of the participants believed that a negative FOBT excluded CRC.
More than 10% of all participants reported rectal bleeding and thus did not follow the
advice not to perform the FOBT and to consult their GP. Following these data in a population
over time seems to be crucial in optimizing preventive educational programs for CRC.
S2093
Impact of Quality of Bowel Preparation On the Detection of Colonic Polyps
During Colonoscopy: A Prospective Study
Shaily Jain, William D. Johnson, Anil Minocha
Background: The diagnostic yield of colonoscopy is dependent on the quality of the bowel
preparation. To our knowledge this has not been evaluated in an American population
prospectively. Our study assessed the impact of the quality of bowel preparation on the
presence and size of colon polyps detected. Methods: Data were collected in a large US
tertiary care university hospital. Patients presenting for colonoscopy were prospectively
enrolled and the parameters for bowel preparation collected included the stool score and
the preparation quality (excellent, good, fair or poor). The stool score was calculated using
Aronchick stool scale which includes amount and consistency of stool and percent of bowel
wall visualized. These parameters were recorded by the endoscopy nurse to avoid any
physician bias. Results: A total of 922 patients, 59.4% (543) African Americans and 40.6%
(370) Caucasian Whites were enrolled. Patients were stratified according to the stool score
and the bowel preparation quality. Demographics were analyzed and no statistically significant
difference was observed in age, sex, race and education with respect to the quality of
preparation. The presence of polyps was adjusted to the above variables. Logistic regression
was performed. The detection of polyps was dependent on the quality of bowel preparation
determined by stool score (<5 vs.≥5, p= .0037). The detection of polyps was also positively
dependent on the quality of preparation (poor vs. fair or better, p=.0117). Advanced aden-
omas (≥ 1 cm or villous histology) were also more likely to be found if the bowel preparation
was fair or better (p=.0114). Conclusions: The quality of bowel preparation is a major
determinant of polyp detection as a better preparation is associated with higher rate of polyp
detection. Documentation of bowel preparation quality is important to validate the results
of colonoscopy and determining the surveillance interval. This also emphasizes the need to
improve current preparation practice.
Detection of polyps, stool score
Detection of polyps, quality of prep
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S2094
Gastric Cancer Patients Present High Levels of Serum Gastrin, a Hormone
That Modifies the Activity of Some Enzymes with a Role in Keeping the
Acide-Base Equilibrium
Ioan Puscas, Adrian Maghiar, Marcela Coltau, Gheorghe Mermeze, Paula Mare, Gabriela
Domuta
It has been described the association of certain gastric and colorectal carcinomas to the high
levels of gastrin.Our research has proved that In Vitro and In Vivo gastrin is a carbonic
anhydrase (CA) II activator.The same research showed that gastric carcinoma patients serum
activates purified CA II. AIM: Starting from these observations we followed the gastrinemia
and the effect of serum gastrin on CA II in gastric carcinoma patients and we also studied
the effect of proglumid association to the serum (proglumid being a specific antagonist of
gastrin). MATERIAL AND METHOD: we selected a group of 115 patients with hystopatholog-
ical confirmed gastric carcinoma and a group of 119 healthy volunteers. Blood was collected
from both groups and the serum was separated. We measured the gastrinemia levels by
HPLC method. After that, we followed the direct activation of serum at 1/50 dilution on
purified CA II and also the effect of its association to proglumid at 10(-4) M. CA II activity
was assessed by stopped-flow method. DISCUSSION AND CONCLUSIONS: Serum gastrin
levels are very high in carcinoma patients as compared to controls. The serum of gastric
carcinomas powerfully activates CA II, but not that of controls. By associating proglumid
(a specific gastrin antagonist), this activating effect is reduced by over 50% in all carcinoma
patients and it is not modified in control group. The results confirme the existence of high
levels of gastrin in gastric carcinoma patients and show the involvement of carcinogenic
mechanism in acid-base equilibrium, because the serum of carcinoma patients activates
carbonic anhydrase - an enzyme whose basic physiological role is to catalyse the interconver-
sion of carbon dioxide and bicarbonate in order to maintain the acid-base equilibrium. This
method might constitute a simple and rapid screening test for diagnosing gastric cancer and
for detecting the serum gastrin levels.
RESULTS
S2095
Performance Characteristics of Faecal Occult Blood Tests: Which Test to Use
for Colorectal Cancer Screening?
Jochim S. Terhaar sive droste, Michael E. Craanen, Rene W. Van der hulst, Pleun Snel,
Annekatrien Depla, Ruud J. Loffeld, Laura De baaij, Liesbeth Mutsaers, Roy Van wanrooy,
Suzanne Van der reijt, Chris J. Mulder
Introduction: Guaiac-based faecal occult blood tests (FOBT's) in a colorectal cancer screening
setting are commonly hampered by a poor specificity and positive predictive value, resulting
in many (futile) follow-up colonoscopies. Hence, immunochemical FOBT's with apparently
better clinical performance, absence of dietary restrictions and only one faecal sample required
have been proposed as a more efficient screening tool. Aim: To compare an immunology-
based (OC sensor®, Eiken Chemical Co, Japan) and a guaiac-based (hemoccult®, Beckman
Coulter, Inc. USA) FOBT in consecutive patients undergoing colonoscopy in terms of clinical
yield of colorectal cancer and advanced adenomas. Methods: All patients aged > 18 years
and scheduled for a colonoscopy in participating hospitals (N=3) were asked to perform
both FOBT's in the week prior to colonoscopy. A haemoglobin concentration of > 100 ng/
ml in the test sample was considered a positive result. The McNemar's test was used for
the comparison of correlated proportions. P<0,05 was considered statistically significant
Results: After excluding 70 patients, in whom the caecum was not visualized and/or bowel
cleansing was insufficient, the total number of eligible patients was 446. The overall positivity
rates were 7,4% and 10,3% for the hemoccult® test and OC sensor® test, respectively.
Colorectal carcinoma and advanced adenomas (i.e., > 1 cm in diameter and/or villous
architecture and/or high-grade dysplasia) were found in 2,5% and 9,6% of the patients,
respectively. Small adenomas, colitis and other lesions were identified in 57% of the patients.
No lesions were found in 31% of the patients. Test characteristics for both FOBT's are
shown in Table 1. Non of the differences observed were statistically significant. Conclusions:
Although the sensitivity and specificity of both tests in detecting colorectal cancer were
rather high in this patient group, the sensitivities were only modest/poor in detecting high-
risk, pre-cancerous lesions. Moreover, the low positive predictive values might hamper the
introduction of either one of these tests in a screening setting. Particularly, the immunological
FOBT did not improve the overall positive predictive value. A larger cohort is currently
being investigated to confirm these preliminary findings.
Test characterisitcs
advanced neoplasias consist of advanced adenomas and cancers
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S2096
Preferences for Colorectal Cancer Screening: Are Primary Care Physicians and
the Public On the Same PAGE?
Seija K. Kromm, Gillian Currie, Steven J. Heitman, Robert J. Hilsden, Antony Irving, June
Bergman, Daniel C. Sadowski, Deborah Marshall, S elizabeth Mcgregor
Background: Physician recommendation strongly predicts compliance with cancer screening.
Guidelines for colorectal cancer (CRC) screening recommend that the choice of screening
test be a joint decision between physicians and patients that incorporates patient preferences.
Our previous research found that the general public preferred screening over no screening
and that test accuracy, followed by ability to find polyps were the most important attributes
affecting CRC test preferences. Prior screening experience appeared to influence preferences
for procedure among the general public: people with no prior experience of screening
preferred a procedure whose description matched a virtual colonoscopy, all else equal.
People with screening experience preferred a procedure whose description matched a colon-
oscopy, all else equal. Purpose: To determine the attributes of CRC screening tests that
influence test choices among physicians when recommending a screening test to patients
and compare them to the general public. Methods: A discrete choice experiment involving
a series of 8 choices between two hypothetical CRC screening tests and not being screened
was completed by 156 Alberta primary care physicians via a mailed survey. Each test was
described by 7 attributes: accuracy, need to travel for test, waiting time, test procedure,
ability to find polyps, need for follow-up test and frequency of the test. Physicians were
asked to indicate which screening test (if any) they would recommend to a hypothetical 55
year-old patient with no family or personal history and no symptoms of polyps or CRC.
Responses were analyzed using multinomial logit regression. Results: Physicians preferred
screening over no screening regardless of the test characteristics. Test accuracy followed by
ability to find polyps were the most important attributes for physicians. Physicians took all
test attributes into account when recommending screening except for the frequency of the
test. The order of importance of the remaining attributes was need for travel, need for follow-
up test, test preparation and procedure, and waiting time. All else being equal, the type of
test preparation and procedure physicians preferred to recommend patients closely resembled
FOBT. Conclusion: Test accuracy and ability to detect polyps are the most important
attributes for both physicians and the general public. However, preferences for the type
of procedure differ between physicians and the general public and physicians value test
characteristics which were not important to the public. Resources to assist physicians and
patients in making choices for CRC may help to resolve these discrepancies.
S2097
Prevalence of Advanced Pathology in Small and Diminutive Polyps
David M. Chaletsky, Sheetal Sharma, G. patricia Ayala, Cindy Huang, Amee Mapara-shah,
Gregg Brodsky, Khoa Vu, Yinghong Wang, Tanya Needham, Ashar Ata, Seth Richter
Background and Aims: With the increasing availability of CT colonography, the clinical
significance of small polyps, and their potential for malignant transformation, will become
an increasingly important issue with regard to colorectal cancer screening and surveillance.
We sought to evaluate the prevalence of advanced pathology in small and diminutive
polyps removed at colonoscopy. Methods: A retrospective review of all colonoscopies from
September, 2001 through June, 2006 was performed. Polyp size and pathology were recorded.
Advanced pathology was defined as high grade dysplasia, carcinoma, and polyps with >25%
villous component. Results: A total of 5788 polyps were recorded and 4465 had complete
data on size and pathology. Of these, 3017 (67.57%) were 1-5mm, 1090 (24.41%) were
6-10mm, and 358 (8.02%) were >10mm. The rate of advanced pathology was 1.89% in
the 1-5mm group, 7.52% in the 6-10mm group, and 39.66% in the >10mm group. Conclu-
sions: In our study, polyps ≤10mm contained significant rates of advanced pathology.
Strategies to address small and diminutive polyps must be developed in light of the ever
increasing availability of CT colonography.
Pathology vs. Polyp Size
S2098
Impact of Sex, Age, and Region On Acceptance of Screening Colonoscopy in
Bavaria (Germany)
V. Henschel, Berndt R. Birkner, Ulrich Mansmann, A. Munte
Objective: The effectiveness of screening colonoscopy in preventing colorectal carcinoma
(CRC) depends on its acceptance within the target population. There are neither detailed
data on age and sex effects nor on regional heterogeneities in age and sex adjusted user
rates. These figures are needed to target campaigns and public health related interventions
to improve compliance with CRC prevention programs. Materials and Methods: An ongoing
Bavarian (Germany) wide electronic documentation of all outpatient colonoscopies in persons
with compulsory health insurance in 2006 is used. There were 33,445 screening colonoscop-
ies in 3,665,530 persons older than 55 years. The individual's age, sex and home region
(area code) were documented. Official regional sex- and age-stratified population data was
used to calculate acceptance rates. The unadjusted acceptance rate for women of age 55-
65 is 1.37% (9,953 colonoscopies/ 725,260 persons), of age 65-75: 1.04% (6,899/ 666,481),
older than 75: 0.25% (1,637/ 645,358) and for men of age 55-65: 1.05% (7,548/ 716,910),
of age 65-75: 1.03% (5,995/ 581,292), older than 75: 0.42% (1,413/ 330,229). A Poisson
model with sex and age-group as main effects and their interaction as well as random effects
for the 99 identified regions were used with the strata specific total population as offset.
Results: The acceptance of screening colonoscopy is highest in persons between 55 and 65
years of age. It decreases with age, in men between 65 and 75 years by 8% and for men
older than 75 years by 61%. There are interaction effects between age and sex. Acceptance
among women is 30% higher in the age group between 55 and 65 years, nearly the same
level between 65 and 75 years, and 39% lower above 75 years. There are marked regional
effects. Screening colonoscopy is less accepted in specific rural regions and better in the
commuter belts of larger towns. The acceptance varies by a factor of 3 between regions with
the lowest 10% and regions with the highest 10% adjusted user rates. Conclusions: The
data represents a complete inventory of all screening colonoscopies in persons with compuls-
ory health insurance in Bavaria (population 12 million). There is evidence that the acceptance
of screening colonoscopy decreases with age, which is more pronounced in women. In
people aged 75 years and older the low attendance on screening colonoscopy contrasts with
the high CRC incidence. Whether acceptance rates for this age group should be increased
is an issue of ongoing debate. There are remarkable regional differences in user rates. This
information can help to target educational advertising of screening programs.
S2099
Colon Screening in African Americans (AA) Versus Caucasians in a Large
Endoscopic Database: AA Women and Men Have a High Risk of Advanced
Neoplasia Compared to Caucasians
David A. Lieberman, Jennifer Holub, Glenn M. Eisen, Matthew Moravec
Colorectal cancer (CRC) mortality is higher in African Americans (AA) compared to Caucasi-
ans (C). Prior work has suggested that AA develop cancers at a younger age than C and are
more likely to have cancer in the proximal colon. Few studies have examined racial differences
in rates and location of premalignant advanced neoplasia in asymptomatic individuals receiv-
ing screening colonoscopy. The purpose of this study was to compare results of colonoscopy
screening in AA and C in diverse clinical practices who participate in the Clinical Outcomes
Research Initiative (CORI). The key endpoint was one of more polyps > 9mm, as a surrogate
of advanced neoplasia. The specific aims were to determine if there were racial differences
in age, gender, and location (proximal vs. distal) of polyps > 9mm. Methods: CORI receives
endoscopy reports from 68 diverse adult practice sites in the United States. We analyzed
colonoscopy reports from 2004-2005 in asymptomatic patients undergoing colonoscopy for
1) average-risk screening or 2) family history of CRC/polyps. The endpoint was prevalence
of polyps/masses > 9mm. Prior work has shown that 80-90% of such polyps are adenomas.
Results: 80,061 C, and 5464 AA had screening colonoscopy during the study period. Overall,
6.2% of C, and 7.7% of AA had an endpoint defined as polyp(s) >9mm (p < 0.0001).
Among subjects < 60 years, the prevalence of endpoint was 5.2% in C and 6.1% in AA
(p = .02). Multivariate analysis (shown in the table) reveals that AA women have a risk of
the endpoint similar to C and AA men, and significantly higher than C women. Proximal
location of the endpoint was more common in females, (+) FHx and age > 60 years. There
was no significant difference in the prevalence of proximal location for AA and C (OR
1.13;95% CI 0.93,1.38. Conclusions: This is the largest study of screening colonoscopy to
examine racial differences in a key outcome: polyp(s) >9mm. These results demonstrate
that both AA women and men, < 60 years old, have a higher risk of polyp >9mm compared
to C. The age-adjusted risk of the endpoint in AA women is significantly greater than C
women and similar to AA and C men. These results suggest that intensive screening efforts
should be targeted at both AA men and women before age 60 years.
Odds Ratio for Polyp(s) > 9mm: Multivariate Analysis
S2100
Use of Aberrant Crypt Foci (ACF) As a Biomarker to Assess Colorectal
Cancer (CRC) Risk As a Function of Race and Socioeconomic Status
Jenny Ng, Ahsan Arozullah, Ronald Ewing, Robert E. Carroll, Richard V. Benya
ACFs are the earliest histopathological lesion associated with malignant transformation in
the colon, and are commonly used as a surrogate marker in animal models of CRC. Because
of their small size, magnification and the use of vital stains are typically needed to visualize
these microscopic structures. ACF enumeration studies that have been performed to date
in humans have been restricted to selected populations. However, nothing is known as to
the prevalence of ACF's in an unselected population of patients undergoing routine screening,
nor is anything known as to the relationship of ACF# with race, environment, or socio-
economic status. Methods: We recently devised a novel approach to rapidly enumerate
ACF# during endoscopy called magnification chromo-colonoscopy (MCC, Endoscopy 2004;
36: 609). Because magnification chromoscopy provides enhanced ability for visualizing
otherwise difficult to appreciate lesions such as flat adenomas (Hurlstone, et.al. Gut 2004;
53: 376), all patients seen in the UIC CRC Screening Clinic are evaluated by MCC. Results:
The UIC Medical Center serves as a community hospital to an economically depressed
adjacent population (median 1999 household income: $25,143 vs. US average $41,994).
Over the last 12 months 542 MCC were performed for CRC screening (accounting for 48%
of all screening exams at UIC). Of these, 329 (61%) agreed to participate in our ACF
Database. The average age of those screened was 58.6±0.4 (mean±SE), of whom 58% were
female. The racial distribution was 57% African American, 17% Caucasian, and 12% Latino;
with 25% covered by Public Aid or Medicaid. Overall, 12% had no ACF; 28% had 1-5
ACF, 20% had 5-9 ACF, and 40% had 10 or more ACF; with mean ACF# being 12.6±0.7.
ACF# increased with advancing age in patients not found to have polyps (r=0.25, p<0.003);
in contrast, there was no association with age for patients with polyps (r=0.09, p=0.3).
ACF# correlated with the number of polyps located distally (p<0.001), but not proximally
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(p=0.33), to the splenic flexure. Increased ACF# was observed in active (p=0.03) and prior
(p=0.009) smokers as compared to non-smokers. In contrast, there was no difference in
ACF# between Caucasians (13.5±2.6), African Americans (12.6±1.1) or Latinos (9.7±1.7).
There also was no association for ACF# with body mass index, aspirin or multivitamin
consumption. There was also no difference in ACF# in patients covered by HMO/PPO and
commercial insurance as compared to those covered by Medicaid/public aid. Conclusions:
ACF#—and by extension CRC risk—does not differ by race or by insurance status, but
does with smoking.
S2101
Upper GI Cancer: How Reassuring Is a Negative Endoscopy in the Last 3
Years?
Benjamin Colleypriest, Peter F. Marden, Sarah Bailey, Aram Fard, Amrutha Ramu, John
Linehan
Introduction Oesophageal and Gastric cancer carry a grave prognosis with 5 year survival
less than 15%. Symptoms of early upper gastrointestinal cancer are non-specific and many
patients may be referred for endoscopy at this stage. The aim of this study was to look at
the current frequency of normal investigations during a 3 year period prior to a diagnosis
of oesophageal or gastric carcinoma in a hospital that serves a population of 500 000 people.
Methods All patients with a new diagnosis of oesophageal or gastric cancer during a 3.5
year period (2001-2004) were identified. Records were examined to find patients who,
during the 3 years prior to diagnosis, had had either a barium investigation or endoscopy.
Results 180 patients, 67% males and 33% females, were found with a new diagnosis of
oesophageal cancer. The majority of tumours found were adenocarcinoma on histology. 17
patients had been investigated with a barium swallow. Of these tests 15 were abnormal and
prompted an endoscopy.. 33 patients were found to have had endoscopies in the 3 years
prior to diagnosis. Of these 18 prompted repeat endoscopy, 6 were part of a Barrett's
surveillance program and 7 were normal (6-36 months prior to diagnosis). 114 patients
were identified with a new diagnosis of gastric cancer during the study period, of which
62 % were male and 38% female. Again the vast majority of cases were adenocarcinoma.
Twenty patients had been investigated with endoscopy in the 3 years prior to their diagnosis.
Of these, 15 endoscopies were abnormal and prompted repeat endoscopy. Only 2 patient
were investigated previously with a barium meal yielding abnormal results Conclusion This
study sought to answer the question, ‘How reassuring is a normal investigation within the
last three years?' We found a low but significant miss rate for upper gastrointestinal investi-
gations in a three year period prior to diagnosis. 5% (3.9% endoscopy 1.1% barium) of
patients presenting with oesophageal cancer and 4.4% with gastric cancer had been investig-
ated . The rates of diagnosis of early cancer in the UK are lower than is other countries.
Does this represent differences in techniques or lack of a screening program for upper GI
cancer? This low but significant miss rate indicates that patients developing new symptoms
require repeat investigation.
S2102
Prospective Comparative Evaluation of Fecal Tumor Pyruvate Kinase Type
M2(M2-PK) with a Rapid Bedside Immunological Test for Screening of
Colorectal Neoplasia
Yogesh Shastri, Nada Povse, Nicolas Hoepffner, Stefan Loitsch, Wolfgang Caspary, Oliver
Schröder, Jürgen Stein
BACKGROUND: Immunological fecal occult blood (IFOB) testing has established itself as
the new tool for colorectal cancer (CRC) screening. Also the simpler,cheaper and more
convenient newer bedside IFOBTs have been validated for mass CRC screening. Dimeric
isoenzyme of pyruvate kinase, termed M2-PK expressed by tumor cells,a direct target of
several oncoproteins, has as well been proposed as a new screening tool for the same. Newer
bedside IFOBT has not yet been compared in sufficiently large sample of population with
fecal (F.) M2-PK. AIM: To compare the performance characteristics of fecal M2-PK as a
screening biomarker for colorectal neoplasia against a validated bedside IFOBT and colonos-
copy. METHODS: 200 consecutive patients who were referred for colonoscopy also provided
the stool samples for performance of M2-PK and an immunochemical strip test. The kits
used were: for bedside F. IFOBT -Prevent ID® CC,Preventis GmbH, Germany and for F.
M2-PK - a commercially available sandwich ELISA (ScheBo Biotech AG, Germany). Each
F. M2-PK test costs about 30 €, need 6 hrs while for the bedside test,patient has to pay
about 5 € & results can be read in just 10 min. RESULTS: Patient and performance
characteristics are as depicted in Table 1 and 2. CONCLUSIONS: : This bedside immunoch-
emical strip test was found to have significantly higher specificity, which is the most important
performance characteristic of any cancer screening test, as compared to that of F. M2-PK.
Not only this it proved to be a convenient, non cumbersome, cheap and accurate tool for
detection of CR neoplasia.
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Table 2: Performance Characteristics of two tests
Values in bracket indicate confidence interval
S2103
Why Do Subjects Decline Colorectal Cancer Screening By FOBT?
Anne F. Van rijn, Marije Deutekom, Paul Fockens, P. Bossuyt, Leo G. Van rossum, Robert
J. Laheij, Jan B. Jansen, Evelien Dekker
Background: The colorectal cancer screening pilot-study in the Netherlands will invite 20.000
individuals by sending them a fecal occult blood test (FOBT). Overall, participation rates
for CRC are low (30-60%). To increase participation it is important to identify the reasons why
individuals do not participate. Targeting specific subgroups could lead to higher participation
levels. Most studies on adherence to screening were conducted in populations that had
different screening options available. Aim: Our primary aim was to identify motivations of
non-participants to the Dutch FOBT screening program. The second aim was to identify
which motivations could be targeted for increasing adherence. Methods: We randomly
selected 1000 invited individuals of the Dutch screening program. In the group of non-
participants, telephone interviews were conducted with all those that had a listed telephone
number, 3 to 6 months after the initial invitation. In the interview we asked for the main
reason for non-participation. The answers were divided in two groups: Group A reasons
that could possibly be influenced by extra attention or education; Group B seemingly
non-reversible motivation. Results: Of the first 1000 invited individuals 49.6% were non-
participants. Of the non-participants 215 had a listed telephone number. In total 131 non-
participants were reached and within this group a telephone interview was conducted. In
this group 20 non-participants, when called, stated they were reminded by the phone call
and were planning to perform the FOBT soon. Thus, an increase in participation of 15%
could be seen by a single telephone call. The main reasons of the remaining 111 non-
participants were divided in A and B. Group A (seemingly possible to influence, 60%): no
reason to participate because of absence of complaints (11%), did not read information
(11%), disgust of performing FOBT (9%), not interested (9%), too busy (5%), anxiety (2%),
on vacation (2%), too much information (2%), concern about privacy (2%), no reason (7%).
Group B (seemingly non-reversible, 40%): too ill to perform FOBT (11%), family problems
(e.g. ill spouse) (9%), fatalism (6%), recently received colonoscopy (6%), rectal blood loss
(consulted GP) (4%), and others (4%). Conclusion: In this preliminary study 60% of non-
responders declined screening because of reasons that could possibly be influenced by
supplying more or better information. Targeting these factors predicting non-compliance
with specific measures could lead to an increased participation rate. Further research will be
necessary to see whether adherence increases indeed once specific measures have been taken.
S2104
Cyp1a1 Polymorphisms Predict Estrogen Metabolism But Not Colorectal
Neoplasia Risk in Post Menopausal Women
Dayna S. Early, Reina Villareal, Elisabeth Cole, Anne Nagler, Nicola Napoli, Feng Gao,
Ellen Li
Introduction: The impact of estrogen on risk of colorectal neoplasia is uncertain. Premeno-
pausal women have a reduced incidence of colorectal cancer (CRC), suggesting that estrogen
status may be a component of the gender-related prevalence rate. The Women's Health
Initiative estrogen only arm, however, did not show a protective effect against CRC. Published
data has shown that carriers of the AA/CA alleles of the C4887A polymorphism of the
CYP1A1 gene have enhanced estrogen metabolism relative to carriers of the CC alleles. This
study examined whether this genetic marker of enhanced estrogen metabolism segregated
with of colorectal neoplasia in postmenopausal women. Methods: We enrolled postmenopau-
sal women not taking HRT who presented to our endoscopy center for screening colonoscopy.
Informed consent was obtained and demographic, medical, family and dietary information
was gathered via survey. Blood and urine samples were collected during the endoscopy
center encounter. Ultrasensitive estradiol was measured using radioimmunoassay, sex hor-
mone binding globulin was measured by ELISA (DSL Inc.), urinary estrogen metabolites
will be determined by ELISA (ESTRAMET 2/16 kit , Immunacare Corp.) and CYP1A1
polymorphisms of the C4887A allele were determined via PCR-RFLP. Results: 93 eligible
women were identified from a convenience sample over a 6 month period. 4 were excluded (3
declined to participate, phlebotomy unsuccessful in 1). Thus the study population consisted of
89 women (mean age 61.5 ± 8.3 yrs). 54 were Caucasian, 33 African American and 1
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Japanese. 76 (85.4%) were homozygous for the C allele (CC) of the CYP1A1 C4887A
polymorphism and 13 (14.6%) were carriers of the A allele (CA or AA allele). 43 (48.3%)
had neoplasia found at colonoscopy or had a history of colorectal neoplasia. Among carriers
of the A allele 65% (8/13) had neoplasia compared to 45% (35/76) for non-carriers. Although
there appears to be a higher prevalence of neoplasia among carriers of the A allele this
association was not statistically significant (p=0.37). There was no statistical association
between race and polymorphism status (African American =2 “A” allele, 31 “CC” allele,
Caucasian = 11 “A” allele, 44 “CC” allele, p=.12). Neither race nor BMI predicted neoplasia
status. Conclusions: Carriers of the A allele of the C4887A polymorphism have enhanced
estrogen metabolism and lower free estradiol. Our study showed a trend toward segregation
of neoplasia with carriers of the A allele, although the results were not statistically significant.
Validation in a larger sample may support the hypothesis that carriers of the A allele are at
greater risk of colorectal neoplasia.
S2105
The Implication of Hedgehog-Interacting Protein in Human hepatocellular
carcinoma
Motohisa Tada, Fumihiko Kanai, Yasuo Tanaka, Keisuke Tateishi, Miki Ohta, Yoshinari
Asaoka, Motoko Seto, Fumio Imazeki, Takao Kawabe, Osamu Yokosuka, Masao Omata
(Background and Aims) Hedgehog (Hh) signaling is normally active only in the embryo.
Recently, the activation of Hedgehog signaling in hepatocellular carcinoma (HCC) has been
reported, as was shown in gastric and pancreatic carcinoma. Hedgehog-interacting protein
(HHIP), which is a receptor of Hh ligands, functions to negatively regulate Hh signaling.
Previous report showed down-regulation of HHIP in gastric and colorectal carcinoma. The
implication of HHIP in HCC, however, is not well known. In this study, we investigated
the involvement of HHIP in HCC. (Methods) We analyzed HHIP mRNA expression in six
hepatoma and hepatoblastoma cell lines by RT-PCR. The methylation status of 5' CpG island
of HHIP gene in these cells with or without the demethylating agent, 5-aza-2'-deoxycitidine
(5-Aza-CdR), was investigated by sodium bisulfite sequencing and methylation-specific PCR
(MSP). After establishing HuH7 cells stably expressing HHIP gene, we investigated Gli
reporter activity, the viability of the cells and mRNA expression of transcriptional target
genes of Hh signaling by luciferase assay, MTS assay and quantitative real-time PCR, respect-
ively. The methylation status of HHIP and HHIP mRNA expression in 36 HCC cases were
analyzed by MSP and quantitative real-time PCR. Loss of heterozygosity (LOH) of HHIP
was also investigated. (Results) HHIP mRNA expression was not detected in HepG2, HuH6,
HuH7 or Hep3B cells. HHIP DNA was hypermethylated in HepG2 and HuH6 cells. By
treating with 5-Aza-CdR, HHIP DNA was demethylated and HHIP mRNA expression was
restored in HepG2 and HuH6 cells. Gli reporter activity and the viability of the cell were
reduced by the transfection of HHIP (42.3% and 62.3%, respectively, relative to control).The
mRNA expression of Patched, Gli1, Bcl2 and CyclinD2 were decreased in HHIP-transfected
cells (64.2, 66.8, 68.2 and 70.5%, relative to control, respectively). HHIP mRNA expression
of HCC tissues was lower than those of corresponding non-tumorous tissues in 31/36 of
HCC cases. MSP analysis revealed that HHIP hypermethylation occurred in 21/36 of HCC
tissues, while no methylation was detected in corresponding non-tumorous tissues. HHIP
mRNA expression level of HHIP hypermethylation cases was significantly lower than that of
unmethylation cases (p < 0.0001) and all of the tumors that exhibited HHIP hypermethylation
showed lesser amounts of HHIP mRNA expression than that of corresponding non-tumorous
tissues. LOH of HHIP was detected in 10/36 of HCC cases. (Conclusions) The activation
of Hh signaling via down-regulation of HHIP, which is caused by DNA hypermethylation,
might be involved in the pathogenesis and progression of HCC.
S2106
Role of p16 Immunohistochemistry in the Differentiation of Sporadic Versus
Familial Cases in Mlh1-Deficient Colorectal Carcinomas
Artemio Payá, Cristina Alenda, Gloria Peiró, Susana Benlloch, Laura Sempere, Rodrigo
Jover
Background. Colorectal carcinoma (CRC) with loss of MLH1 expression can be sporadic or
familial. Sporadic cases show promoter hypermethylation of MLH1, which are frequently
associated with hypermethylation of other genes and regions, such as p16 and MINTs. There
are some genetic differences between sporadic and familial mismatch repair (MMR) defective
CRC, as for example the existence of BRAF mutations. These differences could be associated
with a distinctive immunohistochemical profile. The aim of our study was to evaluate the
role of p16 immunohistochemistry in the distinction between sporadic and familial cases
in MLH1-defective CRC. Design. We selected 67 CRC with loss of MLH1 protein expression.
There were 15 (22%) HNPCC cases, defined by the presence of MLH1 germline-mutation
and/or accomplishment of Amsterdam II criteria. MMR status was studied by microsatellite
instability (MSI) analysis using BAT26, and immunohistochemistry for MLH1, MSH2, MSH6
and PMS2 proteins. BRAF-V600E mutation detection was performed in a ABIPRISM 7500
based on the design of two TaqMan probes labelled with a different fluorescent tag specific
for the wild-type and the mutant allele. P16 immunohistochemistry (IHC) (Santa Cruz,
California, USA) was classified as negative (<1% of positive nuclei) or positive. Results. Loss
of p16 immunohistochemical expression was observed in 29% (15/52) of sporadic tumors
and in 0% (0/15) MLH1-deficient HNPCC cases (p=0,018). BRAF mutations were observed
in 43% of sporadic and in 0% MLH1-deficient HNPCC cases (p=0,005). 19% of cases
without BRAF mutation, showed lack of p16 staining, and all of them were sporadic cases.
Combination of p16 IHC and BRAF mutation increase sensitivity and negative predictive
value for the diagnosis of sporadic MLH1-deficient CRC. Sensitivity, specificity and positive
and negative predictive value for the detection of sporadic cases are showed in the table.
Conclusions. Our results suggest that MLH1-deficient CRCs with loss of p16 expression are
sporadic. p16 immunohistochemistry may be an useful tool in the diagnosis of sporadic
MMR defective tumours.
S2107
Epigenetic Downregulation of the Receptor Tyrosine Kinase Epha6 in Human
Colorectal Cancers
Tadateru Maehata, Hiroyuki Yamamoto, Ken Okamoto, Yoshiyuki Watanabe, Chihiro
Okuse, Hiroaki Taniguchi, Katsuhiko Nosho, Yasushi Adachi, Kohzoh Imai, Yasuhisa
Shinomura, Fumio Itoh
Altered expression of the genes for Eph receptors and ephrins has been recognized to play
an important role in human colorectal cancer. Among the EphA family genes, the potential
role of EphA6 in human colorectal cancer has not been investigated. We analyzed the
expression profiles and epigenetic alterations of EphA6 gene in colorectal cancer cell lines
and cancer tissues. Downregulation of EphA6 mRNA expression analyzed by RT-PCR was
observed in 31 (47%) of 66 colorectal cancer tissues. Downregulation of EphA6 expression
analyzed by immunohistochemistry on tissue microarray was observed in 62 (63%) of 98
colorectal cancer tissues, of which 22 (22%) and 40 (41%) showed low and no expression,
respectively. No significant association between EphA6 downregulation at protein level and
clinicopathological characteristics was found, suggesting that downregulation of EphA6
expression play an important role in the relatively early stage of colorectal carcinogenesis.
To examine the role of methylation and/or histone deacetylation in silencing of EphA6,
colorectal cancer cells were treated with demethylating agent, 5-aza-2'-deoxycytidine (5-
aza-dC), and/or histone deacetylase inhibitor, trichostatin A (TSA). TSA but not 5-aza-dC
restored EphA6 expression. Chromatin immunoprecipitation analysis revealed that histone
of EphA6 promoter was deacetylated and treatment with TSA restored the histone acetylation
of EphA6, indicating the role of histone deacetylation in the silencing of the EphA6 gene.
A heterochromatic structure characterized by neither acetylated H3 nor acetylated H4, and
histone H3 lysine 9 hypermethylation and histone H3 lysine 4 hypomethylation was observed
in cancer cells of which EphA6 gene was aberrantly silenced. Downregulation of EphA6
expression by siRNA resulted in a significant increase in colon cancer cell growth In Vitro.
Our results suggest that downregulation of EphA6 expression due to histone deacetylation
plays an important role in colorectal carcinogenesis. Furthermore, reversal of EphA6 silencing
may be a potential target for treatment and/or prevention of colorectal cancers.
S2108
Characterization of Immune Escape Phenotype of Human Gastric Cancers
with and Those Without High-Frequency Microsatellite Instability
Tamaki Hirata, Hiroyuki Yamamoto, Hiroaki Taniguchi, Nobuki Miyamoto, Chie
Miyamoto, Katsuhiko Nosho, Tadateru Maehata, Yasushi Adachi, Fumio Itoh, Kohzoh
Imai, Yasuhisa Shinomura
Gastric cancers with and those without high-frequency microsatellite instability (MSI-H)
represent distinctive pathways of carcinogenesis. The aim of this study was to clarify if
human leukocyte antigen (HLA) class I antigen subunits and antigen processing machinery
(APM) components is differentially downregulated between these cancers. Using reverse
transcription PCR (RT-PCR), loss of heterozygosity (LOH) analysis, methylation-specific PCR
(MSP), DNA sequencing, immunohistochemistry, flow cytometry, we analysed expression
and/or alteration of HLA class I antigen subunits and APM components, including low
molecular weight polypeptide proteasome subunit (LMP)2, LMP7, LMP10, transporter associ-
ated with antigen processing (TAP)1, TAP2, tapasin, proteasome activator (PA) 28α, and
PA28β in stage-matched two panels of 30 MSI-H and 30 microsatellite stable (MSS) gastric
cancers. Mutations at coding microsatellites (cMS) located within β2-microglobulin (β2m)
and genes encoding APM components, including endoplasmic reticulum (ER) chaperone
protein genes, such as calnexin, SEC63, SEC31, and P4HB (p55), were also analysed.
HLA class Ia transcript was totally downregulated in 18.3% of cancer cases. Locus-specific
downexpression of HLA-A, -B, and -C was detected in 41.6%, 45.0%, and 31.7% of cases.
Loss of HLA-A was significantly more frequent in MSI-H cancers. The LOH ratios of the
HLA-A, -B, and -C loci microsatellite markers were relatively low: 5/32 (15.6%) for D6S306,
4/32 (12.5%) for D6S258, 4/33 (12.1%) for D6S273, and 4/30 (13.3%) for D6S1666.
Methylation of HLA-A, -B, and -C was detected in 38.3%, 40.0%, and 28.3% of cases.
Methylation of HLA-A was significantly more frequent in MSI-H cancers. A significant
association between methylation and downexpression was observed in gastric cancer tissues.
Mutations at cMS of β2m and APM components were detected in 3.3~46.7% of MSI-H
cancers but in none of MSS cancers. Our data show that gastric cancers have various defects
in HLA class I antigen subunits and APM components and that MSI phenotype is associated
with a frequent HLA-A inactivation and frameshift mutations of the APM genes.
S2109
DNA Damage-Related Hypomethylation Induced Not Senescence Nor
Apoptosis, But Aberrant Hypermethylation in Cpg Island Methylator
Phenotype-High Colon Cancer Cells Via Aberrant ERK / Akt Activation and
Enhanced DNA Methyltransferase Activity
Masahiko Tsujii, Shingo Tsuji, Shusaku Tsutsui, Hideki Iijima, Masakazu Yasumaru,
Tsutomu Nishida, Takanobu Irie, Satoshi Egawa, Shinichiro Shinzaki, Shuji Ishii, Sachiko
Nakajima, Toshiyuki Yoshio, Jumpei Kondo, Hiroshi Eguchi, Sunao Kawano, Norio
Hayashi
[Background & aim] Aberrant methylation contributes to colon cancer formation and progres-
sion through a hypermethylator phenotype termed CpG island methylator phenotype (CIMP),
which appears to be a defining event in approximately half of all sporadic tumors. The
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mechanism by which aberrant methylation in epithelial cells of the colon is initiated and
propagated, is currently under intense scrutiny. DNA damage is a well-known factor involved
in carcinogenesis. In the present study, we investigated the effect of DNA damage on histone
and DNA methylation status using colon cancer cell lines. [Materials & Methods] DNA
damage was induced by an alkylating agent (melphalan) , H2O2, UVA radiation, or ionizing
radiation. Seven colon cancer cell lines were evaluated by methylation-specific polymerase
chain reaction of CpG islands in hMLH1, methylated in tumors (MINT) 1, MINT 2, MINT
31, and CDKN2A (p16), p14 (ARF), and hMLH1. CIMP high was defined as methylation
at 2 or more of these loci. Acetylation and methylation status of histone H4, ERK/Akt
activation and extent of DNA repair enzymes binding to DNA were evaluated. Using an
arbitrarily primed methylation sensitive PCR screening method, alterations in the methylation
profile were demonstrated. DNA methyltransferase activity was investigated by EpiQuik
Methyl transferase activity Assay kit. [Results] DNA damage induced by the treatment of
melphalan, H2O2, UVA, or ionizing radiation was detected for 48 hours. A loss of monoacetyl-
ated and trimethylated histone, global DNA-hypomethylation and gene-specific hypomethyl-
ation in 6 genes were detected after DNA damage induction and continued for more than
96 hours. After induction of hypomethylation, binding of DNA repair enzymes to DNA was
increased in all seven-cell lines. Twelve hours after hypomethylation was induced, ERK/Akt
activation, DNA methyltransferase activity and gene-specific hypermethylation in 4 genes
were enhanced only in CIMP-high 3 cell lines, whilst these changes were not detected and
premature senescence and apoptosis were observed in the other 4 CIMP-negative cell lines.
[Conclusion] DNA damage induced aberrant hypomethylation in colon cancer cells, which
was followed by aberrant gene-specific hypermethylation detected only in CIMP-high cancer
cells. Aberrant ERK/Akt activation during DNA damage-related hypomethylation and
enhanced DNA methyltransferase activity appeared to be involved in induction of aber-
rant hypermethylation.
S2110
Epigenetic and Genomic Alteration in Sporadic Colorectal Cancer in African
Americans
Hassan Ashktorab, Mohammad Daremipouran, Hassan Brim, Edward L. Lee, Francis M.
Giardiello, Duane T. Smoot
Background: A possible alternative pathway of tumorigenesis has been identified in the
colorectal cancers (CRC). This pathway is associated with serrated precursor lesions, variable
levels of microsatellite instability (MSI), driven partly by epigenetic inactivation linked to
methylation of CpG island in human colon cancer and often coupled to associated changes
in histone state (i.e acetylation, histonedeactylase (HDAC)), chromatin structure and gene
silencing. We postulate that epigenetic changes are associated with genetic alteration in
colon cancer. Therefore, we studied sporadic CRCs in African Americans (AA) (at higher
risk for sporadic CRC) for the expression and methylation status of mismatch repair genes
(hMLH1, hMSH2), acetylation of histone 3 (H3K9), genetic changes including MSI, BRAF
(V600E) mutation and Genome-Wide Array Comparative Genomic Hybridization (CGH).
Methods: MSI experiments were conducted on sporadic CRC in AA (N=95; 56F/39M) using
the five markers recommended by the Bethesda guidelines. H3K9, MLH1 and MSH2 gene
expression was checked using an immunohistochemical (IHC) and MSP technique. Genome-
wide method including CGH microarray (44K) used for chromosome aberration analysis
and the BRAF V600E mutation was determined by sequencing. Results: The mean age for
carcinomas was 65.7 years in AA. In AA samples 30% of the cancers demonstrated MSI-H.
Most (71.5%) of MSI-H CRC in AA were proximal, moderate differentiated, and highly
mucinous. Defects in hMLH1 gene were found in 68% CRCs, while this rate was 29% for
hMSH2. BRAF mutation was observed in 9.7% (8/82) cancers. Of MSI-H tumors 20% (7/
29) had BRAF V600E mutations and this rate was 12.5% (1/8) for MSI-L. Of AA with BRAF
V600E mutations, (43%) expressed (by IHC) hMLH1. Of interest in CGH microarray was
amplification of HDAC within chromosome 17 region q21.2-q21.32 that has been implicated
in the progression of cancer. H3 K9 acethylation nuclear expression was observed in 71%
and 12% of the cancer cases and normal, respectively. Conclusion: We identified epigenetic
and genomic changes in sporadic CRCs from AA patients. HADCs could be important in
sporadic tumors where the effect of epigenetic changes may lead to genetic alteration in
progression of CRC in African Americans. MSI is high in our series of patients and acethylation
nuclear expression H3 K9 was correlated with various clinicopathological factors, including
stage of the disease. Our results and analysis strategy will be helpful to elucidate pathogenesis
of colorectal carcinogenesis.
S2111
Base Excision Repair Genes Alkyl Adenine DNA Glycosylase (Aag) and O6-
Methylguanine DNA Methyltransferase (Mgmt) Suppresses Helicobacter pylori-
Associated Inflammation and Progression to Cancer
Chung wei Lee, Barry Rickman, Lisiane B. Meira, Leona Samson, James G. Fox
Dysfunction and polymorphisms of DNA repair enzymes have been associated with higher
risk of gastric cancer. Because Helicobacter pylori causes gastritis, oxidation and alkylation
DNA damage, and promotes progression to gastric cancer, we designed studies to examine
whether the Aag or Mgmt DNA alkylation repair proteins would have a protective effect on
H. pylori-associated gastritis and gastric cancer. C57BL/6 background lacking Aag (Aag-/-)
or Mgmt (Mgmt-/-) function were used in an experimental infection with H. pylori (Sydney
strain). Aag-/- mice infected with H. pylori for 32 weeks developed more severe gastric
pathology including foveolar hyperplasia (p<0.05 for male), mucus metaplasia (p<0.05 for
both genders), hyalinosis (p<0.05 for both genders), and oxyntic atrophy (p<0.05 for both
genders) relative to wild type (wt) infected mice. Infected female Mgmt-/- mice (n=9)
developed significantly higher mucus metaplasia (p<0.01), hyalinosis (p<0.05), and oxyntic
atrophy (p<0.05) than female infected wt mice. Both Aag-/- and Mgmt-/- mice developed
similar Th1-associated IgG2c titers and had comparable levels of H. pylori colonization
relative to wt mice. We conclude that Aag or Mgmt mediated DNA repair is protective
against the development of H. pylori-associated premalignant gastric lesions.
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S2112
E-Cadherin Promoter Hypermethylation Induced By Interleukin-1β in Human
Gastric Cancer Cell Lines
Xuemin Qian, Chi hin Cho, Camy Huang, Wai mo Hui, Shiu kum Lam, Annie on on
Chan
Background: Interleukin-1 beta (IL-1β) is upregulated in the present of Helicobacter pylori
(H. pylori) and is important for initiating and amplifying the chronic inflammatory response
in the stomach. We observed previously that the H. pylori infection was associated with E-
cadherin methylation and that H. pylori eradication was associated with disappearing of E-
cadherin methylation. We postulated that E-cadherin methylation was mediated through
IL-1β. Aim: To examine if IL-1β could induce promotor methylation at E-cadherin in in-
vitro cultured human gastric cancer cell lines: TMK-1 (diffuse type), MKN-74 and MKN-7
(intestinal type), none of which has E-cadherin gene mutation or promoter methylation.
Methods: The cell lines TMK-1, MKN-74 and MKN-7 were treated with different concentra-
tions of IL-1β (0.025, 0.1, 0.25, 1.0, 2.5ng/mL) for 6, 12 and 24 hours, respectively.
Methylation status of the E-cadherin promoter was determined by using methylation specific
polymerase chain reaction followed by sequencing of PCR products. The effects of IL-1β
on the cells, after blockade with interleukin 1-receptor antagonist (IL-1ra) at 10, 20, 50,
100ng/ml for 1h, were also tested. Results: Promoter methylation at E-cadherin was detected
when TMK-1 cells were treated with 2.5ng/mL IL-1β for 6h, MKN-74 cells with 0.025ng/
mL IL-1β for 6h and MKN-7 cells with 2.5ng/mL IL-1β for 24h, respectively. Sequencing
analysis showed cytosine-guanosine (CpG) sites within E-cadherin promoter region were
partially methylated. The methylation of IL-1β in different cell lines were dose- and time-
dependent. No methylation at E-cadherin was observed when IL-1β was blocked by pretreat-
ment of IL-1ra at 20ng/ml for 1h. Conclusion: Our study indicated that IL-1β plays an
important role in E-cadherin methylation. We hypothesize that H. pylori induces methylation
of E-cadherin through the action of IL-1β. Our present results will serve as a valuable
evidence for further studies.
S2113
Epigenetic Regulation of Microrna Expression in Pancreatic Cancer
Kwang hyuck Lee, Oliver Kent, Michael G. Goggins, Seung-mo Hong, Noriyuki Omura,
Joshua Mendell, Anirban Maitra
Bakground: Aberrant expression of microRNA (miRNA) is considered as an important
mechanism of carcinogenesis. The targets of miRs have been studied extensively. However,
regulatory mechanisms that control the expression of miRNA per se are only partially known.
It has been well studied that many nuclear genes in human cancers are regulated by epigenetic
mechanisms - hypermethylation and histone deacetylation. In this study, we investigated if
epigenetic mechanisms regulate miR expression in pancreatic cancer cell lines. Method:
Pancreatic cancer cell lines - MiaPaCa and Panc1 - were treated with the demethylating
agent, 5-aza-2'-deoxycytidine (5-Aza-dC) or the histone deacetylase inhibitor, trichostatin
A (TSA), as well as the combination. Re-expression of known epigenetically silenced genes
- NPTx and UCHL1 - was used as a positive control to confirm efficacy of treatment.
Expression of 326 human miRs in control and treated cell lines was assessed using a
microarray-based approach (Combimatrix, Mukilteo, WA). Differential re-expression of miRs
was confirmed by Northern blot analysis. Result: Eighteen miRNAs in the MiaPaCa cell
line and 17 miRNAs in the Panc1 cell line were two-fold or greater differentially upregulated
following exposure to either agent, or the combination. The differential overexpression of
miRNAs-22, -16 and -193a was confirmed by Northern blot analysis in the MiaPaca cell
line. Of interest, the 5' upstream regions of all three miRNAs contain evolutionary conserved
sequences that harbor CpG islands. Genomic sequencing is currently underway to confirm
methylation of 5' CpG dinucelotides in the control cell lines, and their demethylation
following 5-Aza-dC exposure. Conclusion: Our studies confirm that, akin to nuclear genes,
miRNAs are also epigenetically regulated in human neoplasia. Future studies will reveal
whether the epigenetically silenced miRs represent the non-coding variant of tumor sup-
pressor genes, and whether miR epigenetic tags in neoplastic cells can be useful as a
cancer biomarker.
S2114
H. pylori Eradication Reverses Cpg Island Hypermethylation of Tumor-Related
Genes in Gastric Ulcer Patient, But Not in Gastric Carcinoma Patient
Takuji Yamasaki, Mitsuru Kaise, Hisao Tajiri
(Background and aim) CpG island hypermethylation (CIHM) of tumor suppressor and
tumor-related genes involves gastric carcinogenesis. We have demonstrated that H. pylori
eradication significantly reverse CIHM of tumor-related genes in H. pylori-infected gastric
mucosa of non-cancerous patients (Gastroenterology. 128 suppl2;A134, 2005). The aim of
this study is to compare the status of CIHM and its reversibility by H. pylori eradication
between patients with gastric cancer and gastric ulcer. (Methods) The subjects consisted of
21 H. pylori-infected patients with gastric ulcer and 7 H. pylori-infected patients with early
stage gastric carcinoma resected by EMR. Biopsy samples were obtained from non-cancerous
corpus mucosa before and one-month after successful H. pylori eradication. Using genomic
DNAs retrieved from the samples and treated with sodium bisulfite, we performed methyl-
ation-specific PCR to examine CIHM of DAP-kinase and E-cadherin. ((A specimen was
assessed as positive for methylation if a expected size of PCR product was visualized by
electrophoresis using primer sets specific for promoter methylation.)) (Result) In gastric
ulcer patients, methylation rates of DAP-kinase and E-cadherin genes in the gastric mucosa
were 55% and 50% before H. pylori eradication, respectively. The rates significantly (P>0.01)
reduced to 5% and 0% one-month after eradication, respectively. In gastric cancer patients,
methylation rates of DAP-kinase (86%) and E-cadherin genes (100%) before eradication
were significantly higher (P>0.01) than those in gastric ulcer patients. H. pylori eradication
did not change methylation rates of DAP-kinase (86%) and E-cadherin genes (100%) at all
in gastric cancer patients by contrast to gastric ulcer patients. (Conclusion) H. pylori is
considered as a potent inducer of CIHM because its eradication could apparently reverse
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CIHM of tumor-related genes in the gastric mucosa of gastric ulcer patients. However, the
epigenetic alterations frequently observed in non-cancerous corpus mucosa of gastric cancer
patients were so profound that H. pylori eradication could not reverse CIHM at least within
one month. The evidence suggests that the status of CIHM in non-cancerous gastric mucosa
bearing gastric cancer is adamant and related with carcinogenic ‘field effect' induced by
H. pylori.
S2115
Uneven Locational Distribution of Colorectal Adenomas Carrying K-RAS/Braf
Mutation and Rassf2 Methylation
Keita Harada, Jun Kato, Sakiko Hiraoka, Joichiro Horii, Hideyuki Fujuta, Yasushi
Shiratori
Background & aims: Activation of Ras signaling caused by K-ras/BRAF mutation is a hallmark
of colorectal tumors. In addition, RASSF2, the negative regulator of K-ras oncogene, is often
inactivated by methylation of the promoter region in those tumors. However, relationship
between these genetic and epigenetic Ras-associated alterations has not yet been clearly
elucidated. In particular, whether these alterations are likely to coexist or to be mutually
exclusive is still controversial. In the current study, we analyzed K-ras/BRAF mutation and
the methylation status of RASSF2 promoter region in colorectal adenomas, and the locational
distribution of tumors that carried these alterations were examined. Methods: Tissues of
adenomas larger than 10 mm were consecutively collected from patients who underwent
endoscopic polypectomy in our hospital. DNA was extracted from the tissues, and K-ras
codon 12 and 13, and BRAF codon 600 point mutations were analyzed by direct sequencing
analysis. RASSF2 methylation status was analyzed by combined bisulfite restriction analysis.
The anatomical distribution was described as follows; proximal colon (including cecum,
ascending colon, and transverse colon), distal colon (including descending colon and sigmoid
colon), and rectum. Results: A total of 120 adenomas were examined. K-ras/BRAF mutations
were relatively frequently observed in adenomas in the proximal colon (22/48, 46%) and
the rectum (13/23, 57%), compared to in those in the distal colon (15/49, 31%) (rectum
vs. distal colon, p = 0.04). RASSF2 methylation was also prevalent in adenomas in the
proximal colon (14/48, 29%) and the rectum (9/23, 39%), compared to in those in the
distal colon (7/49, 14%) (rectum vs. distal colon, p = 0.03). Coexistence of K-ras/BRAF
mutations and RASSF2 methylation was observed in 12/48 (25%) of adenomas in the
proximal colon and 6/23 (26%) of adenomas in the rectum, but only 3/49 (6%) of adenomas
in the distal colon (proximal vs. distal colon; p = 0.01, and rectum vs. distal colon; p =
0.03). Multivariate analysis using parameters including patient age, gender, adenoma location,
size, and histology revealed that adenoma location (proximal colon or rectum) was a signific-
ant predictor of carrying both K-ras/BRAF mutations and RASSF2 methylation (OR, 4.70;
95%CI, 1.27-17.37). Conclusions: Adenomas in the proximal colon and those in the rectum
exhibited a similar pattern of disorder of Ras signaling pathway. Meanwhile, adenomas in
descending or sigmoid colon were distinctive due to rare coexistence of K-ras/BRAF mutations
and RASSF2 methylation.
S2116
Concordant Methylation and Braf Mutations in Synchronous Colorectal
Carcinomas
Kazuo Konishi, Lanlan Shen, Nicole Sieffert, Kazuhiro Kaneko, Toshinori Kurahashi,
Michio Imawari, Stanley R. Hamilton, Jean-pierre J. Issa
Backgrounds & Aim: Field defect or field cancerization is thought to underlie multicentricity
of cancer in patients who have multiple tumors in the same tissue type. The field defect in
colorectal cancers (CRCs) is characterized by occurrence of synchronous or metachronous
multiple tumors. Epigenetic changes have been proposed as mediators of this field defect
in some cases. The aim of this study is to determine epigenetic and genetic characteristics
in synchronous colorectal neoplasias (Sy-CRNs). Methods: We evaluated the methylation
status of eight genes (MINT1, 2, 31, hMLH1, p16, p14, MGMT and ERα) using a quantitative
bisulfite-pyrosequencing analysis and genetic alterations of BRAF and KRAS using pyrosequ-
encing analysis and mutant allele-specific amplification, respectively, in 39 Sy-CRNs (10
cancer pairs and 9 cancer/adenoma pairs) and 69 sporadic colorectal cancers (S-CRCs).
Results: Methylation levels of MGMT were significantly higher in Sy-CRNs than S-CRCs
(30.3 % vs. 17.3%, P = .010). MINT31 methylation was significantly lower in Sy-CRNs
than S-CRCs (5.5% vs. 12.2%, P = .016). However, there was no significant difference in
methylation levels for the other genes between Sy-CRNs and S-CRCs. Methylation levels of
MGMT with a sensitive assay tended to be higher in normal colonic samples with MGMT
methylation in both tumors than samples without MGMT methylation in both tumors (26.7
% and 15.2 %, respectively; P = .334). There was no significant difference in the incidence
of CIMP, KRAS and BRAF mutations between Sy-CRNs and S-CRCs. Nevertheless, we found
significant correlations between tumor pairs for MGMT, MINT1, p16 and hMLH1 methylation
(r = .640, P = .002; r = .732, P < .001; r = .614, P = .003; r = 979, P < .001, respectively),
as well as for BRAF mutations (r = 0.840, P < .001). In paired samples of Sy-CRNs, the
relative risk (RR) of finding concordant patterns of BRAF mutations was 8-fold higher than
that of discordant patterns (1.35 vs 0.17, P = .092). Conclusions: Synchronous colorectal
tumors are highly concordant for methylation of MGMT, MINT1, p16 and MLH1 as well
as BRAF mutations, consistent with a molecular field defect that predisposes to specific sub-
types of cancers. It remains to be determined whether this field defect is acquired or inherited.
S2117
Preference of Aberrant Methylation of Promoter Region in Multiple Genes
Indicates Presence of Cpg Island Methylator Phenotype in Colorectal Cancers
Koji Hokazono, Takashi Ueki, Hiroyuki Konomi, Ryuichi Mibu, Masao Tanaka
Purpose: The presence of CpG island methylator phenotype (CIMP) in colorectal cancers
(CRCs) was recently proposed, but the definition of CIMP has not been clear. In this study,
we examined the methylation status of a large panel of cancer-related genes in CRCs to provide
the evidence of presence of this phenotype. Materials and Methods: Aberrant methylation in
the promoter region of 24 tumor-suppressor and cancer-related genes in extracted DNA
from 68 CRCs had been proved by methylation-specific polymerase chain reaction (MSP).
We defined CIMP according to the number of methylated genes and investigated the clinic-
opathological features of CIMP including survival of the patients with CRCs. Results: MSP
demonsterated that 7 genes were methylated in 6.7% to 86.7% of 15 CRCs and in 6.7%
to 86.7% of normal colonic mucosae, and no methylated templates of the other 17 genes
emerged in any 15 normal colonic mucosae. We excluded the 7 genes that were methylated
at some rate in histologically normal colonic mucosae and used the 17 genes aberrantly
methylated in CRCs for further investigation of CIMP status in 68 CRCs. The frequency of
aberrant methylation of the 17 genes ranged from 1.5% to 72.1% in 68 CRCs. The frequency
of aberrant methylation in each CRCs did not distribute at random and the number of CRC
with each methylated genes showed three peaks of frequency of carcinomas having no, three
and seven methylated genes. We classified carcinomas harboring methylation at seven or
more of these genes as CIMP-high (CIMP-H) and carcinomas having no methylated genes
as CIMP-negative (CIMP-N) while carcinomas with one to six methylated genes were classified
CIMP-low (CIMP-L). The observed number of CRCs in each group is significantly different
from the expected distribution (p<.0001). CIMP-H CRCs were frequently in proximal colon
and the patients with CIMP-H CRCs had a better 5-year disease free survival than those
with CIMP-N and -L (p<.05). Conclusion: The subset of CRCs may harbor CIMP-H and
the patients with CIMP-H CRCs could have good prognosis compared with those with
CIMP-N or -L CRCs.
S2118
Homeodomain Transcription Factors Cdx1 and Cdx2 Bind to Ku70/Ku80,
Regulators of Double Strand DNA Break Repair
Hoeun Lee, Rong J. Guo, John P. Lynch
Introduction: Caudal-Related homeobox proteins, Cdx1 and Cdx2 are structurally and
functionally conserved intestine-specific transcription factors. Their functional roles include
development and differentiation of intestinal epithelium, and modulation of proliferation,
apoptosis, and cell-adhesion. In a previously published study (Aoki et al. Nature Genetics
35, 323-330 (2003)) reduction of Cdx2 gene expression was associated with mTOR-mediated
chromosomal instability. However, the complete mechanism in this effect has not been fully
elucidated. In the present study we characterize a strong interaction between Cdx1 and
Cdx2 and the DNA Double Strand break repair factor Ku70/Ku80. Methods: Flag-tagged
Cdx1 and Cdx2 were immunoprecipitated and the products were analyzed by electrophoresis
and Comassie staining. Bands were cut out for identification by mass spectrometry. Interac-
tions were confirmed by GST pulldown assays. Results: Several reproducible Comassie
staining bands common to both Cdx1 and Cdx2, were cut out and sequenced by mass
spectrometry. Identified proteins included a number of ribosomal proteins, such as L7, L7a,
L8, S2, S3a, and S4. Two higher molecular weight bands were identified as Ku70 and Ku80,
respectively. Ku70/Ku80 is a heterodimeric nuclear protein that functions in the DNA double-
stand break repair. The Ku70/80-Cdx2 interaction was confirmed by immunoprecipitation
and western blotting. GST pulldown studies with Cdx2 truncation mutants identified the
Cdx2 N-terminus as the critical region for Ku70/Ku80 binding. Functional studies are
ongoing to determine the effect of this interaction on Ku70/Ku80 function In Vivo. Conclusion:
Intestinal specific transcription factors Cdx1 and Cdx2 interact with Ku70/Ku80, key elements
of double strand DNA break repair. Studies of the functional significance for this interaction
are ongoing.
S2119
Age-Related Methylation of Normal Colon Mucosa, and Risk of Colorectal
Neoplasia; The Difference Between Proximal and Distal Colon
Joichiro Horii, Sakiko Hiraoka, Jun Kato, Keita Harada, Hideyuki Fujita, Yasushi Shiratori
Background and Aim: DNA methylation is closely correlated with the development of
colorectal neoplasia. Although a part of DNA regions are methylated in cells of normal colon
mucosa in an age-dependent manner, clinical significance of the age-related methylation is
still unknown. Meanwhile, clinical and biological differences between colorectal neoplasia
in the proximal and distal colon has been demonstrated. In this study, we aimed to investigate
the methylation status of age-related methylation loci in normal colon mucosa, with special
attention paid to the difference between the proximal and distal colon. Moreover, relationship
between the methylation status and clinical risk factors of neoplasia was examined. Methods:
A pair of biopsy specimens of normal mucosa of proximal and distal colon were collected
from each patient who underwent polypectomy at our hospital. DNA was extracted from the
biopsy specimens, and the methylation status was determined by MethyLight, a fluorescence-
based, real-time PCR assay. Methylation status was measured as the percentage of methylated
reference (PMR). PMR at a specific locus was calculated by dividing the GENE:ACTB ratio
of a sample by the GENE:ACTB ratio of RKO (colorectal cancer cell line, fully methylated),
and multiplying by 100. Examined age-related loci were the promoter region of ESR1 and
MYOD1, and exon 1 of p16 (INK4A). Results: A total of 85 paired samples of normal colon
mucosa were collected. Methylation of ESR1 and MYOD1 loci in normal colon mucosa
could be detected by the Methylight assay, while methylation of p16 locus could not be
detected. Comparison of the PMR between the distal and proximal colon of each patient
revealed that normal mucosa of the distal colon was more highly methylated than that of
the proximal colon in both of ESR1 and MYOD1 loci. (p<0.0001 and p=0.0009, respectively).
Next, we analyzed the relationship between the PMR of these loci and the clinical risk factors
of neoplasia, including gender, smoking and drinking habits, patient history of malignancy,
and family history of colorectal cancer. Patients with a history of malignancy were likely to
show high PMR of ESR1 in the distal colon (p=0.03, comparison among tertiles according
to PMR), while those with drinking habit were likely to show low PMR of ESR1 in the distal
colon (p=0.003). In addition, patients with family history of colorectal cancer tend to show
low PMR of MYOD1 in the distal colon (p=0.01). Conclusions: Methylation levels of age-
related loci were different between the distal and proximal colon. Moreover, some of clinical
risk factors of neoplasia were correlated with the status of methylation of these loci.
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S2120
Extracellular Superoxide from Enterococcus Faecalis Induces Aneuploidy and
Modulates Cell Cycle in Chromosomally Stable Human Colonic Epithelial
Cells Via a Bystander Effect
Xingmin Wang, Mark M. Huycke
Commensal microbiota has been implicated in the etiology of sporadic colorectal cancer.
Enterococcus faecalis is an intestinal commensal that produces copious extracellular superox-
ide. We previously showed that superoxide anion from E. faecalis promotes chromosomal
instability (CIN) in human-hamster hybrid cells (ALN) through activation of cyclooxygenase-
2 in macrophages. To determine whether extracellular superoxide from E. faecalis can induce
CIN in chromosomally stable colonic epithelial cells, we exposed HCT116 cells to E. faecalis
OG1RF. By counting chromosomes on metaphase plates, we noted a high degree of aneuplo-
idy. The frequency of aneuploidy was significantly less for cells exposed to OG1RF with
MnSOD (31 of 107 metaphase plates having hypo- or hyperdiploidy [29%]) compared to
OG1RF alone (46 of 102 [45%], P = 0.02). To increase throughput, aneuploidy in mitotic
cells was quantified by FACS analysis. After a 2 hr incubation with OG1RF, the average
percentage of aneuploid HCT116 cells (± SD) was 37.0 ± 4.5, 51.2 ± 7.4, 54.6 ± 5.3, and
28.2 ± 2.9 at 24, 48, 72, and 96 hrs post-exposure, respectively. MnSOD significantly
decreased the percentage of aneuploid cells at 48 (34.4 ± 7.8, P = 0.05) and 72 hrs
(29.3 ± 9.5, P = 0.01) suggesting that extracellular superoxide from OG1RF substantially
contributed to the induction of aneuploidy in these cells. Tocopherols, as lipid radical chain
terminators, also significantly protected against induction of aneuploidy. Addition of 200
μM α- or γ-tocopherol decreased the percentage of aneuploid cells (30.4 ± 0.8 and 19.9 ±
1.8, respectively) compared to OG1RF alone (38.8 ± 4.7, P < 0.001). To address the
hypothesis that E. faecalis activates innate immune cells to produce diffusible factors that
induce CIN in colonic cells, HCT116 cells were exposed to murine macrophages (RAW264.7)
infected with E. faecalis using a dual-chamber tissue culture system. The percent of aneuploid
cells significantly increased for HCT116 cells exposed to RAW264.7 cells treated at a
multiplicity of infection of 1,000 compared to co-culture with uninfected cells (20.2 ± 4.3
vs. 13.4 ± 0.4, P < 0.001). Moreover, HCT116 cells developed a remarkable G2/M cell cycle
arrest after exposure to RAW264.7 cells that had been infected with OG1RF, suggesting
that DNA damage occurred in HCT116 cells mediated by diffusible factors produced by
OG1RF infected macrophages. These findings show extracellular superoxide from E. faecalis
strongly induces aneuploidy in chromosomally stable human intestinal epithelial cells and
suggest a novel role for redox-active commensal bacteria in colorectal carcinogenesis.
S2121
Histology Is of Value in Identifying Lynch Syndrome Among Colorectal Cancer
Patients
Brindusa Truta, Yunn yi Chen, Peggy G. Conrad, Amie M. Blanco, Yong ho Kim, Eun
taek Park, Guoren Deng, Sanjay Kakar, Young Kim, Marvin H. Sleisenger, Jonathan P.
Terdiman
Background: The revised Bethesda guidelines recommend the testing of colorectal cancers
(CRC) for either microsatellite instability (MSI) or expression of the mismatch repair proteins
(MMR), if the patient is diagnosed before 60 years of age, and if the tumor demonstrates any
of the histological features suggestive of high-frequency MSI (tumor infiltrating lymphocytes
(TILs), Crohn's like inflammatory reaction, mucinous/signet ring differentiation or medullary
growth pattern). The value of histology in identifying Lynch syndrome, especially among
CRC patients diagnosed between 50 and 60 years of age has not been studied. Methods:
All CRC patients diagnosed before the age of 60 years and treated at our institution from
1997 to 2005 were identified. Patients with polyposis or inflammatory bowel disease were
excluded. After informed consent, demographic, clinical and family history data were col-
lected. Two pathologists reviewed the tumors to determine if any of the histological features
suggestive of MSI were present. The tumors were then tested for MSI and expression of MSH2
and MLH1 by immunostaining. Results: Sixty-five patients with CRC could be contacted and
included in the study. Thirty-five patients were between 50 and 60 years of age and 30
patients were younger at diagnosis. The mean age was 48 +/- 9.86. Overall, 28 patients
(43%), including 13 of 35 diagnosed between age 50-60, had a cancer demonstrating one
or more of the histological features suggestive of MSI : 15 with mucinous differentiation, 7
with mix histology (mucinous, TILs, Crohn's like pattern), 1 with a medullary growth
pattern, 3 with TILs and 1 with a Crohn's like inflammatory response. Patients with tumors
demonstrating histological features were younger at diagnosis (45 vs 50 yrs, p = 0.02), but
did not differ with respect to sex, family history of CRC or other HNPCC related cancers,
tumor location or stage from those without MSI histology. Importantly, the tumors with
MSI histology were much more likely to be MSI-H (11/25 vs 1/29, P<0.0001). Imunochemis-
try done on 58/65(89%) cases was concordant with MSI results. Conclusions: Among patients
with CRC diagnosed prior to 60 years of age a significant percentage has tumors with
histological features suggestive of MSI and nearly 50% were found to be MSI-H. In all cases
but one (sensitivity = 92%), tumors with MSI-H were found to have one or more of these
histological features. Limiting MSI analysis to only tumors with suggestive histology would
have reduced the need for MSI testing by nearly 60%. Final assessment of the utility of
histology in detecting Lynch syndrome awaits results of germline MMR gene analysis of
the cohort.
S2122
Methylation Profile As a Prognostic Factor in Advanced Gallbladder Cancer
Juan carlos Roa, Leonardo Anabalon, Johnatan Castillo, Angelica Melo, Patricia Garcia,
Manterola Carlos, Antonio Sanhueza, Ivan Roa, Juan carlos Araya, Miguel Villaseca
Advanced gall bladder cancer (GBC) presents a high mortality rate; nevertheless, within the
group of subserous tumors, 2 patient groups with a different prognosis are recognized that
are potentially curable. Hypermethylation in gene promoter areas is a frequent epigenetic
mechanism of the carcinogenic process involved in tumor suppressor genes inactivation.
Their presence has been used as a prognostic tumor marker and for selecting specific
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therapies. Objective: To obtain the methylation profile of advanced gallbladder tumors and
its relation to follow-up and clinical-morphological characteristics. Materials and Methods:
109 patients with advanced GBC were chosen from archive material. The methylation profile
was determined by PCR (MSP) in 15 genes from different metabolic cellular pathways related
to the carcinogenic process (p15, CDKN2A, p73, DAPK-1, RASSF1, APC, FHIT, CDH1,
CDH13, TIMP3, DCL-1, MGMT, GSTPi, RARB2 and MLH1). Results: The gene methylation
frequency found in decreasing order was: DAPK1 46.8%, CDH1 45%, CDH13 42%, FHIT
34.8%, CDKN2A 33%, p15 31%, MGMT 29.4%, DCL-1 22%, RASSF1 21%, APC 20%,
TIMP3 20% GSTPi 19.3%, p73 19%, MLH1 18.3% and RARB2 16%. The bivariate analysis
showed a significant relation to survival for p73 (p<0.006), MGMT (p< 0.006), DCL1
(p<0.044), CDH13 (p<0.001) and p15 (p=0.04) while APC (p= 0.06) and FHIT (p=0.1)
presented a non significant tendency. The subserous tumors with a methylation index equal
to or greater than 0.4 were associated with the worst survival rate (p<0.001). The multivariate
analysis found the MGMT gene to be an independent prognostic factor (p<0.01). Conclusions:
The high frequency of aberrant methylation in advanced GBC proves the important role that
this epigenetic process plays in gallbladder carcinogenesis. The differences in the methylation
profile and their association with patient survival for p73, MGMT,p15, CDH13 and DCL-
1 proves the usefulness of epigenetic studies in prognosis and potential selection of therapeutic
alternatives in GBC. Financed by Fondecyt 1050603 and DIUFRO 120537.
S2123
The Neuroendocrine Peptide Precursor Genes Somatostatin and Tachykinin-1
Are Hypermehylated in Gastric Cancers
Yuriko Mori, Yulan Cheng, Zhe Jin, Stefan David, Alexandru Olaru, Takatsugu Kan,
Bogdan C. Paun, Fumiaki Sato, Tetsuo Ito, Rachana Agarwal, James P. Hamilton, John M.
Abraham, Stephen J. Meltzer
Background and Aim: Neuroendocrin peptides play essential roles in the regulation of
gastrointestinal secretion, motility, and mucosal immunity. Furthermore, some of these
peptides have been implicated in the direct and indirect modulation of human tumorigenesis.
Recently, we found that two gastrointestinal neuroendocrine peptide precursor genes, somato-
statin (SST) and tachykinin-1 (TAC1), demonstrated frequent promoter hypermethylation in
human colon cancers. Promoter hypermethylation is a major mechanism for gene inactivation
in human cancer. Therefore, our finding indicates that SST and TAC1 may play tumor-
suppressive roles in the human gastrointestinal tract. To further investigate this hypothesis,
we analyzed the epigenetic abnormality of SST and TAC1 in gastric cancer, presented here.
Methods: Forty-seven primary gastric tumors and 41 normal gastric mucosae were analyzed
for SST and TAC1 promoter methylation status. Methylation status was assessed using the
real-time quantitative methylation specific PCR (MSP) method. The association of promoter
hypermethylation and mRNA downregulation was evaluated in gastric cancer cell lines that
underwent 5-aza-deoxycitidine induced global genomic DNA demethylation using the real-
time quantitative RT-PCR and MSP methods. Results: SST demonstrated promoter methyl-
ation in 25 (53%) of 47 primary gastric cancers and in 11 (27%) of 41 normal gastric
mucosae (p=0.01). TAC1 demonstrated promoter methylation in 20 (42%) of 47 primary
gastric cancers and in 7 (17%) of 41 normal gastric mucosae (p=0.01). No significant
association was observed between promoter methylation status in tissues and age, gender,
tumor stage, or histological subtype for either SST or TAC1. Interestingly, SST methylation
was much more prevalent in microsatellite-unstable (MSI-H) cancers (6 of 7, 86%) than in
microsatelite-stable cancers (20 of 40, 50%; p=0.01). We also confirmed that a decrease
in promoter methylation level was associated with an upregulated mRNA level in 5-aza-
deoxycitidien treated gastric cancer cell lines. Conclusion: Our data demonstrate that both
SST and TAC1 are abnormally inactivated via promoter methylation in a subset of human
gastric cancers. This abnormal methylation appears to occur in an early stage of gastric
carcinogenesis, because SST and TAC1 methylation prevalence was independent of tumor
stage. Further studies are now indicated to elucidate mechanisms underlying their involve-
ment in gastric cancer.
S2124
Detection of Mlh1 Germline Methylation in Hereditary Non-Polyposis
Colorectal Cancer Syndrome (HNPCC)
Matthias Ebert, Heike Görgens, Juliane Hoffmann, Hans Schackert
The present model of colorectal carcinogenesis includes the step-wise progression of adenoma
to invasive cancer. It is now widely accepted that sporadic colorectal cancers frequently arise
from preneoplastic lesions through the activation of oncogenes (k-ras), and the inactivation of
tumor suppressor genes (APC, p53, DCC) and mismatch repair genes. Defects in mismatch
repair genes are present both in sporadic colorectal cancers and in Lynch syndrome. The
germline mutations underlying Lynch syndrome include the inactivation of the genes MSH2,
MLH1, MSH6 or PMS2. Recent studies indicate that the inactivation of MLH1 may also
result from DNA hypermethylation which was analysed in our series of patients with Lynch
syndrome. In 443 index patients with Lynch syndrome alterations of mismatch repair genes
were observed in 205 patients. In 122 of these 205 patients a germline mutation of either
MSH2, MLH1, MSH6 or PMS2 was identified. In addition, we analysed 19 individuals
without MLH1 expression and germline mutation with regard to the presence of germline
MLH1 methylation. After informed consent DNA was extracted from blood leukocytes and
was analysed by Methylight assay and bisulfite seuquencing. In two individuals who fulfilled
Bethesda-criteria 2 and 4 without MLH1 germline mutation, we found promoter methylation
of the MLH1 gene. Neither of these two individuals reported first-degree relatives with
cancer. Our data indicate that MLH1 methylation is present in patients with Lynch syndrome
without MLH1 germline mutation and, thus, may contribute to the pathogenesis of this
disease in the absence of germline mutations.
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S2125
Novel Aberrantly Methylated Genes in Esophageal Adenocracinoma
Eric Smith, Neville J. De young, Andrew Ruszkiewicz, Peter G. Devitt, Glyn Jamieson,
Paul A. Drew
Background: The incidence of esophageal adenocarcinoma (EAC) in the Western world has
risen dramatically over the last three decades, such that it has the greatest increase of any
malignancy and is the most common cancer of the esophagus. EAC is one of the most lethal
cancers, with a five year survival of less than twenty percent. The only known risk factor
is the premalignant Barrett's metaplasia (BE). Aberrant DNA methylation is frequently
observed in BE and EAC, and is thought to contribute to the disease progression and to
influence outcome. Knowledge of gene methylation may assist in diagnosis, treatment, and
understanding the biology of the disease. Aim: To discover genes which have expression
altered by methylation in EAC. Materials and Methods: The EAC cell line OE33 was
demethylated with 5-aza-2'-deoxycytidine (aza-dC). Gene expression was compared between
cells grown with and without aza-dC using Affymetrix Human Genome U133 Plus 2.0
Array. The relationship between DNA methylation and gene expression was determined in
four esophageal cancer cell lines (TE7, OE19, OE21 and OE33) by melt curve analysis and
quantitative real time RT-PCR respectively. Methylation was measured in tumors, Barrett's
and squamous mucosa from the resection margin of 25 patients with EAC. Results: Eleven
genes, selected from the array screen, were methylated in one or more esophageal cancer
cell lines, but unmethylated in lymphocytes from patients with no known disease. All of
these genes were frequently methylated in EAC. Seven of these genes (BNIP3, FBN2, MLF1,
PRDM2, RBP4, RARRES1, TFAP2C) have been reported methylated in other cancers, but
not BE or EAC. Four genes (CLDN6, DCBLD2, FNBP1 and MGC16824) have not previously
been reported as methylated in any cancer. CLDN6 encodes a calcium-independent cell-
cell adhesion molecule. DCBLD2, an intracellular cell adhesion molecule, is involved in
receptor-mediated signaling, and negative regulation of cell growth. FNBP1 is involved in
protein biosynthesis and MGC16824 is an esophageal cancer associated protein. Conclusion:
This study reports significant DNA methylation of four novel genes in EAC and BE. Methyl-
ation of these genes has not been reported before in any cancer. Their role in tumorogeneis
is unknown and warrants further investigation. (Supported by the NIH as part of the Study
of Digestive Health)
Frequency of DNA methylation in tumor, Barrett's and squamous mucosa from patients
with esophageal adenocarcinoma
S2126
Effects of Helicobacter pylori Infection On Genetic Instability and Cellular
Phenotype in Intestinal Metaplasia in Japanese Patients with Barrett's
Esophagus: A Prospective 1-Year Follow-Up Study
Kentaro Moriichi, Jiro Watari, Kiron M. Das, Hiroki Tanabe, Ryu Satoh, Amen H. Zaky,
Youkou Konno, Chisato Ishikawa, Yuhei Inaba, Kotaro Okamoto, Atsuo Maemoto,
Mikihiro Fujiya, Toshifumi Ashida, Yutaka Kohgo
Background/Aims: Intestinal metaplasia (IM) has been widely recognized as an associated
risk factor and a probable precursor of Barrett esophagus-associated adenocarcinoma (BEAd).
Although many studies have found no association between Helicobacter pylori (H. pylori)
infection and Barrett's esophagus (BE), there is evidence to the contrary. Genetic instabilities
(GINs), i.e. microsatellite instability (MSI) and loss of heterozygosity (LOH), have been
documented in some malignancies. Therefore, these genetic variations may be involved in
BE carcinogenesis. We developed a monoclonal antibody, mAb Das-1, which highly reacted
against BE and adenocarcinoma arising in BE. Here, we investigated the effects of H. pylori
infection on GIN and the mAb Das-1 reactivity in IM in patients with BE in a 1 yr prospective
study. Materials and Methods: From 2004 to 2006, one thousand eighty-one consecutive
Japanese individuals who underwent endoscopy were enrolled. Out of these cases, 181
(16.7%) had BE, including short segment in 167 and long segment BE in 14 cases. In cases
of 29 samples from 25 patients with IM shown by biopsy specimens from BE, H. pylori
infection showed positive in 18 and negative in 11. DNA was extracted from IM by using
laser capture microdissection and we evaluated MSI or LOH at 5 microsatellite loci based
on the Bethesda panel. Serial sections were immunostained with mAb Das-1. We also
analyzed 7 early stage BEAd cases in the same manner. Results: 1) GINs in IM were observed
in 51.7% (15 of 29), comprised of 41.4% (n=12) in MSI and 10.3% (n=3) in LOH. In
contrast, those in non-IM from BE and BEAd were 11.1% (1 of 9) and 100% (6 of 6, no
DNA in 1 case), respectively. 2) GIN showed significantly higher in patients with H. pylori
infection (66.7%, 12 of 18) than in those without H. pylori infection (27.3%, 3 of 11)
(p<0.05). 3) The mAb Das-1 reactivity in IM and BEAd is detected in 89.7% and in 85.7%,
respectively. However, there was no correlation with H. pylori infection. 4) Interestingly, of
four patients with both GINs and H. pylori infection, two showed no MSI or LOH after
eradication. Conclusions: These results indicate that GINs in IM from BE may be associated
with carcinogenesis of BEAd in early phase. Patients without H. pylori showed significantly
lower in the incidence of GINs than those with H. pylori. In addition, H. pylori eradication
reduced GINs during the one year period post treatment, although cellular phenotype, as
identified by mAb Das-1 was not altered. Thus, H. pylori eradication therapy may prevent
carcinogenesis in BE as well as gastric carcinogenesis in Japanese population.
S2127
Distinct Tpef/HPP1 Gene Methylation Patterns in Gastric Cancer Indicates a
Field Effect in Gastric Carcinogenesis
Audrius Ivanauskas, Juliane Hoffmann, Laimas Jonaitis, Rytis Markelis, Elona Juozaityte,
Limas Kupcinskas, Peter Malfertheiner, Cathy Lofton-day, Christoph Röcken, Matthias
Ebert
Background. Aberrant methylation of the TPEF/HPP1 gene was recently reported in hyperpl-
astic colon polyps, colorectal adenomas and carcinomas. Recent studies confirmed that
TPEF/HPP1 methylation is a frequent event in other human cancers as well, such as bladder
and gallbladder cancers. However, there are only limited data on significance of TPEF/HPP1
gene methylation in gastric adenocarcinomas. Methods. Using the Methylight assay, TPEF/
HPP1 gene methylation was assessed in fresh frozen cancer tissue and matched normal
gastric mucosa of patients with gastric cancer (n=48), and in the gastric mucosa of tumor-
free dyspeptic patients (n=11). Results. TPEF/HPP1 promoter gene methylation was observed
in 35 of 48 (73 %) gastric adenocarcinomas, and in 27 of 48 (56 %) matched normal gastric
mucosa cases (P = 0.087). In contrast, the occurrence of TPEF/HPP1 methylation was much
lower in gastric mucosa of dyspeptics (1 of 11; 9%) and the difference was significant in
comparison with both tumor tissue (P=0.0001) and normal mucosa (P=0.0047) of cancer
patients. TPEF/HPP1 gene expression was significantly reduced in adenocarcinomas in
comparison with matched normal gastric mucosa (P=0.022). Conclusion. Our data suggest
that methylation of TPEF/HPP1 is present in the majority of gastric adenocarcinomas and
in the surrounding tumor-free gastric tissue, indicating that this epigenetic change may
point to a field effect in the gastric mucosa. The assessment of TPEF/HPP1 promoter gene
methylation in the gastric mucosa could potentially offer a biomarker in the early detection
of gastric adenocarcinomas.
Distribution of TPEF/HPP1 methylation according to the tumor characteristics in gastric
cancer patients
* - statistically significant difference (P= 0.022) between cancer and non-neoplastic tissue
# - statistically significant difference (P= 0.018) between 0+1 and 2+3 TNM pN category
S2128
Expression of Fhit, Mlh1, p16Ink4a, and E-Cadherin in Early Multiple Gastric
Carcinomas
Akihito Hara, Kazuo Yashima, Yoshikazu Murawaki
Objective: The frequency of synchronous or metachronous multiple gastric carcinomas has
been reported to be approximately 15%. An increasing number of methylation-related tumor
suppressor genes (MTSGs) are inactivated hypermethylation of CpG islands in the promoter
have been reported in gastric carcinomas. However, the role of MTSGs is not well understood
in multiple gastric carcinogenesis. The aim of this study is to evaluate the clinical significance
of MTSGs expression, during the early stages of synchronous or metachronous multiple
gastric carcinogenesis. Methods: The protein expression of 4 MTSGs including Fhit, Mlh1,
p16INK4A, and E-cadherin was examined using immunohistochemical methods in 75 early
gastric carcinomas, comprising 42 single carcinomas and 33 synchronous or metachronous
multiple carcinomas. These samples were obtained by endoscopic mucosal resection.Results:
The expression of Fhit, Mlh1, p16, and E-cadherin was lost or reduced in 31.0%, 21.4%,
23.8%, and 35.7% of the single gastric carcinomas and in 42.4%, 42.4%, 45.5%, and 25.0%
of the multiple gastric carcinomas, respectively. The rate of the absent expressions of p16
was significantly higher in the multiple gastric carcinomas than in the single gastric carcinomas
(p=0.048). The frequency of the lost or reduced expression of Mlh1 was tend to be higher
in the multiple gastric carcinomas than in the single gastric carcinomas (p=0.088). No
significant differences of these MTSG expressions were found between in synchronous and
the metachronous gastric carcinomas. Furthermore, the average number per sample of the
lost or reduced proteins of 3 MTSGs (Fhit, Mlh1, and p16) was significantly higher in the
multiple (1.30) than in the single gastric carcinomas (0.76) (p=0.014). Conclusion: We
found that the accumulation of lost or reduced MTSG protein expressions was closely
associated with synchronous or metachronous multile gastric carcinomas, compared with
single gastric carcinomas. Analyses of MTSGs expression using immunohistochemistry could
be useful for evaluating the potential of multiple gastric carcinogenesis.
S2129
The Clinical and Immunohistochemical Characteristics of Signet Ring Cell
Carcinoma of the Stomach
Donghun Lee, Dong ho Lee, Chang kyu Choi, Young soo Park, Jin wook Kim, Na young
Kim, Sook-hyang Jeong, Jin-hyeok Hwang
Background : Reports of clinical and immunohistochemical characteristics in patients with
signet ring cell carcinoma(SRC) of the stomach are conflicting. The aim of this study was
to clarify the clinical and immunohistochemical characteristics of signet ring cell carcinoma.
Methods: A retrospective study was conducted in 653 patients with gastric cancer who had
undergone gastrectomy or endoscopic mucosal resection from May, 2003 to April 2006.
Clinical and immunohistochemical features in patients with SRC and non-SRC were com-
pared. Results: Of 653 patients, 91(13.9%) were in SRC and 562(86.1%) were in non-SRC.
399 (61.1%) were in early gastric cancer and 254(38.9%) were in advanced gastric cancer.
A-323 AGA Abstracts
SRC more frequent in young age, female gender than non-SRC. Significant difference were
noted in mean patient age(SRC in 54.9 vs non-SRC in 62.9), patients gender(M:F in 1.1:1
vs 2.3:1), expression of p53(12.2% vs 43.2%) and c-erb B2(36.0% vs 58.3%)(p<0.05).
hMLH1, hMSH2 and MSI were immunopositive in 86.5%(SRC in 88.3% vs non-SRC in
86.9%), 88.7%(75.0% vs 90.5%) and 8.1%(4.2% vs 8.8%) of total stomach cancer patients,
respectively. The high thymidylate synthase level was 22/48(45.8%) in SRC and 157/
259(60.6%) in non-SRC. There were no statistically significant differences in tumor location,
stage. depth of invasion, nodal involvement. Conclusion: SRC was frequent in comparative
young age and more in woman relatively. Expression of p53, c-erb B2 and thymidylate
synthase were less frequent in SRC. These results suggest that SRC may have difference
genetic background of carcinogenesis.
S2130
The Colonic Field Effect in the Elderly: Support for the Age-Based
Predilection to Colorectal Cancer Proceeding Via the Adenoma-Carcinoma
Sequence
Pragnesh Patel, Rasna Gupta, James Hatfield, Yi Xu, Mary ann Rambus, Adhip Majumdar,
Michael Lawson, Martin Tobi
A colonic field effect is known in colorectal carcinogenesis but field effects in the elderly
has not been shown. We used Adnab-9 anti-adenoma monoclonal antibody to define the
field effect (Tobi et al.,Dig Dis Sci 47:317,2002) in a group of elderly patients compared
to a younger control group. Methods: Random regional colonoscopic biopsies were taken
from 3 right colonic segments (cecum, ascending, transverse) and 3 from the left (descending
sigmoid and rectum). 4μ sections were labeled with Adnab-9 using the standard ABC
technique (Vectostain). A field effect was defined as any labeling in 2 or more contiguous
regions as referenced above. Patients were categorized as elderly if age was >65 (group 1;n=
75) and controls were <65 years of age (group 2; n=138). Only asymptomatic average-risk
patients were included in the analysis to avoid bias. The results of this cross-sectional analysis
of study patients at baseline are presented with a longitudinal follow-up for development
of neoplasia still in progress. Results: Mean age of group 1 was 72.0+5.9 versus 53.7+7.1
years for group 2 patients. 32% of group 1 as compared to 13% of group 2 patients had
evidence of a field effect (Odds ratio 9.865; Confidence intervals 3 to 13; p=0.002 by Chi-
square). Distribution of staining was either “golgi” or luminal. 10/75(13%) group1 and 8/
138(6%) group2 had adenomatous polyps (p<0.05) but no cancers were found in either
group at baseline. Most of these lesions were left-sided (57% for Group 1 and 63% for
Group 2). Left field effects tended to be more prevalent in Group 1 patients (46% vs 33%).
No effect of race and gender, and medications with anti-inflammatory effect on the presence
of the field effect was observed. Conclusions: This study shows that in asymptomatic patients,
a significantly greater proportion of elderly patients show evidence of a field effect of
carcinogenesis as defined by Adnab-9 labeling of fixed biopsy tissue. More adenomas were
found on the left than on the right side of the colon in both groups, consistent with the
distribution in the general population. This was associated with a greater tendency to a left
sided field effect in Group 1 patients. These data suggest that the field effect associated with
the adenoma-carcinoma sequence increases with age and may provide a mechanism for the
observed age-dependent development of neoplasia. This methodology may also provide an
objective, convenient means of defining regionality of risk within the individual colon if
data from follow-up studies are confirmatory. Supported by a Merit Review Grant from the
Department of Veterans Affairs. Dr. M. Tobi is a past licensor of Adnab-9 to Dako Inc.
S2131
Risk Analysis of Gastrointestinal Surgery in Elderly Patients Over 75 Years
Old
Tsuneo Tanaka, Yasuhiro Matsugu, Naoki Kagawa, Hideki Nakahara
Aim: It is known well that the function of various organs is compromised at advanced ages.
However, since the degree of dysfunction varies among different organs, preoperative and
precise evaluation of the reserved capabilities of individual organs is difficult. The present
study was undertaken to evaluate the operative risk of elderly patients (over 75 years old)
scheduled to undergo surgery. Materials & Methods: The subjects of this study were 1,573
patients with gastrointestinal disease who underwent surgery between January 2002 and
December 2005. The underlying disease was benign in 581 (37%) cases and malignant in
992 cases (63%). Emergency operation was performed on 269 cases (17%) and laparoscopic
surgery on 278 cases (18%). They were divided by age into two groups: control group
(below 74 years, n=1231) and the aged group (over 75 years, n=342). The presence/absence
of preoperative complications, hematological parameters and operative parameters were
compared both groups. For risk assessment using the Physiological and Operative Severity
Score in the enUmeration of Mortality and morbidity (POSSUM), data on 12 parameters
related to physiological score (PS) and 6 parameters related to operative severity score (OS)
were derived from the database or individual patients. The risk of individual patients was
rated on a three-category scale (low-risk: 12-19, moderate-risk: 20-24 and high-risk: more
than 25) on the basis of PS scores. Results: The percentage of patients having preoperative
complications of the respiratory, cardiac, renal, neurological systems was significantly higher
in the aged group than in control. Hemoglobin, albumin, cholinesterase, sodium and urea
levels were significantly lower in the aged group than in control. The PS was 16.2±4.0
(mean±SD) in control and 21.7±4.8 in the aged group (p<0.001), the OS was no difference
in both groups. The percentage of patients rated as having high-risk increased as age
advanced. Postoperative complications were seen in 399 cases (25.4%), and death during
hospital stay occurred in 27 cases (1.7%). The morbidity rate was significantly higher
(p<0.001) in the aged group (33.9%) than in control (23.0%), however, the mortality rate
was no difference in both groups.Conclusion: Elderly patients over 75 years old often have
preoperative complications and compromised organ function. The PS score as assessed using
the POSSUM is useful for evaluation of operative risk in elderly patients.
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S2132
Real Time Dynamic Movement of Caveolin 1 During Smooth Muscle
Contraction of Human Colon and Aged Rat Colon Transfected with Caveolin 1
cDNA
Sita Somara, Robert R. Gilmont, Paul M. Jenkins, Jeffrey R. Martens, Khalil N. Bitar
Background: Caveolae are essential caveolin-rich lipid rafts microdomains in the membrane
for the docking of signaling molecules modulating excitation-contraction in smooth muscle.
Objective: Real time monitoring of the dynamic movement of caveolin and to study the
effect of aging on its essential characteristics. Methods: 1. Colonic smooth muscle cells
(CSMC) were isolated from human sigmoid colon and aged rat colon. Isolated CSMC were
transfected either with YFP-tagged wild type caveolin 1 cDNA (YFP-WT-cav1) or with
YFP tagged TFT-mutant caveolin-1 cDNA (YFP-TFT-cav1; dominant negative cav1). 2.
Transfected CSMC were grown on a cover slip. The movement of cav1 in response to
acetylcholine (Ach) was monitored real time under confocal microscope. 3. Fluorescence
Recovery after Photobleaching (FRAP): FRAP was used to determine if cav1 protein was
able to move within a membrane. Results: A. Caveolin 1 movement: 1) In human CSMC
transfected with YFP-WT-cav1 cDNA, a rapid cyclic movement of fluorescent cav1 was
observed on the membrane in response to Ach stimulation. The movement was localized
and characterized by rapid cycling of cav1 between the cytosol and the membrane. The
movement of cav1 was also observed to be synchronized and organized along the whole
length of the cell. 2) In human CSMC transfected with YFP-TFT-cav1 dominant negative
cDNA, blotch of fluorescence was observed in the cytosol of the CSMC. No movement of
fluorescent cav1 was observed in these CSMC in response to Ach. 3) Transfection of CSMC
from aged rat with YFP-WT-cav1 cDNA restored the physiological contractile response to
Ach as well as the dynamic movement of cav1 along the organized cytoskeletal path observed
in normal adult CSMC. B. FRAP: A significant high percent recovery with fast mobility was
observed in the bleached section of the cells. Summary: Real-time monitoring of live human
colonic SMC transfected with YFP-WT-cav1 cDNA suggests that caveolin cycles within and
along the membrane in a synchronized and highly organized cytoskeletal path. These studies
provides for the first time, the advantage of the real time monitoring of the dynamic movement
of caveolin in living cells without fixing the cells. Conclusions: Rapid movement of cav1
in response to Ach suggests that cav1 plays a dynamic role in CSMC contraction. In line
with previous studies, present analysis suggests that cav1 is essential for maintenance of
caveolae on the membrane. Supported by Grant NIH RO1 DK 042876
S2133
Effect of Aging On Cortical Neural and Neurocognitive Central Processing of
Rectal Mechanosensory Signals
Mark K. Kern, Venelin Kounev, Patrick Sanvanson, Adeyemi Lawal, Candy Hofmann, B
douglas Ward, Reza Shaker
Disorders of colonic funtion are common among elderly. These dysfunctions are attributed
to abnormalities of motor funtion. Effect of aging on cortical neural and neurocognitive
processing of afferent signals originating from the colon is poorly understood and their role
in clinical syndromes in the elderly has not been systematically studied. Aims: 1) To
characterize and quantify the cerebral cortical fMRI activity associated with subliminal
(neural) and perceived (neurocognitive) rectal distension in healthy elderly subjects. 2)
Compare the findings to those of young subjects. Methods: 11 healthy elderly (7 F, age
range: 71-85 years) and 9 healthy young (5 F, age range: 20-28 years) subjects were
studied using a barostat controlled fMRI whole brain scanning (high spatial resolution MRI,
2.5x2.5mm within slice resolution, TR=6 s, TE=40 ms) during two levels of phasic subliminal
(5 and 10mmHg) distension pressures and barely perceived (liminal) distensions of the
rectum. Results: For equivalent subliminal rectal distensions, elderly subjects showed signific-
antly smaller numbers of activated voxels. (Figure A) The average percent maximum signal
change in both groups increased significantly from subliminal to liminal distension (*p<0.05)
The time interval between the onsets of distension and fMRI signal increase in the elderly
were significantly longer (Δp<0.001) than that of the young. (Figure B) Conclusions: Aging
negatively affects neural and neurocognitive processing of rectal mechanosensory signals.
These effects are manifested by diminished cortical recruitment and prolonged cortical fMRI
activation latency in elderly compared to young healthy subjects.
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S2134
Gastric Distension Attenuates the Hypotensive Response to Intraduodenal
Glucose in Healthy Older Subjects
Diana Gentilcore, James H. Meyer, Michael Horowitz, Karen L. Jones
Postprandial hypotension (PPH) is an important clinical problem, particularly in the elderly,
and is associated with an increased incidence of falls, stroke and angina. We have established
that the magnitude of the fall in blood pressure (BP) is related to the rate of gastric emptying
(GE) so that the reduction in BP and rise in heart rate (HR) are greater when GE is relatively
more rapid (1). In contrast, gastric distension may attenuate the postprandial fall in BP
(2,3). The aims of this study were to evaluate the effects of gastric distension, with intragastric
(IG) water, on the BP and HR responses to intraduodenal (ID) glucose in healthy older
subjects. Eight subjects (5M, 3F; age 65-76 yr) were studied on 3 separate days. BP and
HR (automated device) were measured, during a 60min ID infusion at 5ml/min of (i) 50g
glucose in 300ml saline (‘ID glucose'), (ii) 50g glucose in 300ml saline with an intragastric
(IG) infusion (t=7-10min) of 500ml water (‘IG water and ID glucose') or (iii) ID saline
infusion with an IG infusion (t=7-10min) of 500ml water (‘IG water and ID saline'). Between
t=60-120min, ID saline was infused at 5ml/min. GE of the IG water was measured by
ultrasound. Results are shown in the figures (mean ± SEM). Systolic BP was greater (P<0.05)
with ‘IG water and ID saline' when compared with ‘IG water and ID glucose' and less
(P<0.05) with ‘ID glucose' when compared with ‘IG water and ID glucose' ie IG water
prevented the fall in BP induced by ID glucose. HR was higher (P<0.01) with both ‘IG water
and ID glucose' and ‘ID glucose' when compared with ‘IG water and ID saline'. GE was
faster (P<0.01) with ‘IG water and ID saline' when compared with ‘IG water and ID glucose'
(T50: 41.0 ± 4.0min vs 77.7 ± 8.3min; P=0.006). We conclude that gastric distension
induced by water markedly attenuates the hypotensive response to ID glucose in healthy
older subjects. The consumption of water before a meal, accordingly, represents a simple
approach to the management of PPH. 1. Jones et al, 2001; J Am Geriatr Soc; 49:162-7. 2.
Shannon et al, 2002; Am J Med; 112:355-60. 3. Jones et al, 2005; Am J Physiol; 289:G240-8.
Effects of water-induced gastric distension on a) Systolic BP, b) HR and c) gastric emptying
in healthy older subjects. Data are mean values ± SEM.
S2135
Segmental Distribution of Nhe8 and Its Sensitivity to Nhe Specific Inhibitors
Hua Xu, Huacong Chen, Jiali Dong, Ronald Lynch, Fayez Ghishan
Introduction: NHE8 is a newly identified Na+-H+ Exchanger (NHE) isoform. Our previous
work has shown that NHE8 is located at the apical membrane of intestinal epithelial cells,
and it is highly expressed in suckling rats. These studies indicate a role for NHE8 in intestinal
Na+ absorption during early post-neonatal development. Further functional analysis of NHE8
in PS120 cells indicates that NHE8 mediates sodium-dependent proton exchange, and its
activity may be stimulated by acidic intracellular pH. However, the segmental distribution
of NHE8 along the intestine and its sensitivity to known NHE specific inhibitors remains
unknown. This study was performed to determine the segmental distribution of NHE8, and
its sensitivity to NHE2 and NHE3 specific inhibitors. Method: Northern blot analysis was
performed using NHE8 specific probes from human, rat and mouse. To evaluate the functional
properties of NHE8, a rat NHE8 cDNA construct was transfected into PS120 cells. Transfected
cells were treated with NH4Cl to produce an acid load. Non-transfected cells were killed
by the acid load, while NHE8 expressing cells survived. Recovery of Intracellular pH (pHi)
from an acid load was evaluated to characterize NHE8 function using the pH indicator
SNARF-4. Results: Northern blot analysis indicated that in human, higher NHE8 expression
was seen in stomach, duodenum, and ascending colon. In mouse, higher NHE8 expression
was seen in jejunum, ileum and colon. The expression level of NHE8 is much higher in
the stomach and jejunum in young mice compared with adult mice. In NHE8 transfected
PS120 cells, the rate of recovery from an acid load was not influenced by 1 μM HOE694,
a NHE2 specific inhibitor. In the presence of 10 μM HOE694, NHE8 function is significantly
reduced compared with control. In the presence of 20 μM S3226, a NHE3 specific inhibitor,
NHE8 activity was also reduced. Conclusion: our results suggest that NHE8 is expressed
along the gastrointestinal tract in human and mouse, and its expression pattern is altered
by development. Though inhibitors of both NHE2 and NHE3 can influence NHE8 functional
activity, the concentration dependence of these inhibitors is significantly less, indicating
some differences in functional properties. This investigation was supported by NIH grant
R01-DK073638 (Ghishan and Xu).
S2136
Effect of Lubiprostone, a Unique Agent for the Treatment of Chronic
Idiopathic Constipation, On Clinical Electrocardiographic Results
Craig Sprenger, Alan Copa, Joel Morganroth, Raymond Panas, Ryuji Ueno
Some drugs have been shown to unexpectedly delay cardiac repolarization, causing docu-
mented cases of torsade de pointes (TdP) in humans. Delayed cardiac repolarization may
result in cardiac arrhythmias, most clearly TdP, which can degenerate into ventricular
fibrillation and sudden death. Lubiprostone was evaluated in a thorough QT/QTc study in
healthy volunteers, in which 177 healthy males and females received a single dose of either
lubiprostone (at a 24 mcg [clinical] or 144 mcg [supratherapeutic] dose), an active control
(moxifloxacin, 400 mg), or placebo. Sixty-nine digital ECGs were obtained over the 24-
hour period before dosing and for 24 hours post-dosing, and were manually analyzed at a
central ECG laboratory blinded to treatment. The primary endpoint used the individualized
correction formula for QT duration (QTcI; placebo-corrected mean change from baseline).
The QTcI result for the clinical dose was 0 ms and for the supratherapeutic lubiprostone
dose was +2 ms. No signal of any QTc outlier was seen with lubiprostone as compared to
control. Lubiprostone showed a placebo-corrected increase in heart rate of 4 and 11 beats
per minute, respectively, but no changes in PR or QRS interval duration. A retrospective
analysis of ECGs collected during a separate Phase 2 trial consisted of a 3-week oral treatment
period in 129 constipated patients. Patients received placebo or lubiprostone 24 mcg QD,
BID, or TID. ECGs were obtained at baseline and at the end of the study and were evaluated
with manual digital measurements at the same central ECG laboratory. The placebo-corrected
change from baseline in the Fridericia-corrected QT duration with lubiprostone 24, 48, and
72 mcg was -4, -3, and -5 ms, respectively. The outlier analyses revealed that 1 subject in
each active treatment group met the nonspecific outlier criterion of a 30-60 ms-change from
baseline, and no subject met the specific criteria of a new >500 ms, new abnormal U waves,
or a >60 ms change from baseline. The results of the QT/QTc trial in healthy volunteers
support this result. When healthy humans were dosed with lubiprostone at a single 24 or
144 mcg dose, and constipated patients were dosed chronically with lubiprostone at varying
doses, no QTc prolongation was observed. This indicates that lubiprostone treatment does
not increase the risk of TdP caused by QTc prolongation. These results are consistent with
the current cumulative safety information for lubiprostone when administered to patients
with irritable bowel syndrome or chronic constipation, with no serious cardiac adverse
events reported to date that were attributed to lubiprostone administration.
S2137
Heterogeneity of Lower Esophageal Sphincter Function in Children with
Achalasia
Claudio Morera, Samuel Nurko
Achalasia is a rare esophageal motor disorder in children. The manometric hallmarks are
esophageal body aperistalsis, lack of lower esophageal sphincter (LES) relaxation, and high
LES pressure. However LES relaxation has been occasionally described in adults with achala-
sia, making the diagnosis difficult. A systematic evaluation of LES function in children with
achalasia has not been performed. AIM: To describe LES function in children with achalasia
METHODS:We performed a retrospective review of manometric tracings of pediatric patients
with achalasia (all had lack of esophageal peristalsis and classic barium study) and compared
them with control patients. The average resting pressure and relaxation characteristics of
the LES in each patient and for each individual swallow were evaluated. RESULTS: There
were 29 achalasia and 16 control patients. The main characteristics are shown in the table.
All control patients had normal peristalsis, LES pressure and relaxation in all wet swallows.
In the achalasia group the LES relaxation was evaluated in 181 swallows. Some LES relaxation
was present in 76.8% (139/181) of swallows and 20% (29/139) had normal relaxation. Only
5/29 patients (17%) had a lack of LES relaxation in all swallows. No single patient in which
there was some LES relaxation (24/29) after swallows had more than 30% of normal LES
relaxations. The LES pressure was normotensive (<35 mmHg) in 11/29 patients (37.9 %).
CONCLUSION: The LES function after swallows in pediatric patients with achalasia shows
heterogeneity. The classic description of a non-relaxing high pressure LES in patients with
achalasia is rarely found in children. LES pressure was normal in 40% of patients. A complete
lack of LES relaxation after swallows in children with achalasia is rare, partial relaxations
are very common, and normal relaxations may be present in up to 30% of swallows. The
presence of some LES relaxations after swallowing in patients where there is lack of esophageal
peristalsis should not exclude the diagnosis of achalasia.
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S2138
An Epidemiological Study of Common GI Symptoms in School-Age Children
Miguel Saps, Carlo Dilorenzo
Aims: To assess the prevalence and impact of common GI symptoms in school-age children.
Methods: All 3rd to 8th grade students attending 2 Chicago Public Schools were invited to
a prospective cohort study. Over the course of 6 months, participating students completed
weekly surveys, including validated, age-appropriate questions assessing the presence and
severity of abdominal pain, constipation, diarrhea, nausea, vomiting, and chest pain during
the previous week along with 2 questions on headaches and limb pain to examine co-
morbidities and somatization. At baseline (week 1), questionnaires on anxiety, depression,
coping, quality of life (QOL) and somatization were also completed. Missed days of school,
parental work absenteeism, childcare arrangements and medical consultations were reported
by parents. Results: 237 students ages 8-15 (134 girls, 35% Black, 22% Latino, 21%
Caucasian, 9% Asian), out of 495, were enrolled. A mean of 89% (77-98) responded each
week for a total of 3,287 completed questionnaires. 72% reported ≥1 symptom per week
(median 1.72 +/- 1.54). 48% (35-70) reported ≥1 GI symptom per week. Prevalence of GI
symptoms: AP 38% (25-54), nausea 26% (16-41), diarrhea 10% (5-20), constipation 9%
(4-19), and vomiting 8% (5-13). 24% reported AP for≥8 consecutive weeks. Those reporting
AP were more likely to have other GI symptoms (P < 0.001). Girls reported nausea more
often (P = 0.0025). The prevalence of symptoms was similar in all ages and races. Children
with <8 weeks of AP had lower depression scores than in those with >12 weeks of pain (P
< 0.01). Those with impaired QOL were more likely to have≥4 weeks of pain (P < 0.0008).
28% missed ≥1 days of school because of AP (mean 2.35, range 1-13 days). 10% of parents
missed ≥1 days of work to care for a child with AP (mean 1.89, range 1-5 days). Only 3
students sought medical attention for AP during the course of the study. Conclusions: AP
is common among school-age children and is associated with higher scores of depression
and anxiety, worse quality of life, school absenteeism, and parental missed work. Office
based studies result in under diagnosis.
S2139
Autonomic Response to Stress in Children with Functional Abdominal Pain
(FAP)
Martina Puzanovova, Andre Diedrich, Warren Lambert, Grace Shelby, Lynn S. Walker
Alterations in autonomic nervous system (ANS) activity have been found in adults with
functional gastrointestinal disorders and children with psychosomatic symptoms and anxiety.
Heart rate variability (HRV) is a noninvasive index of spontaneous changes in ANS activity
and can be evaluated via power spectral analysis of the ECG signal. Aims: To investigate
the differences in HRV indices before, during and after a mental stressor in pediatric patients
with FAP and controls. Materials and methods: Subjects were 8 -16 years of age (M=12.3)
(n=49 FAP; n=22 well). Heart rate (sitting, awake) was continuously recorded on a dual-lead
ECG system (Biopac). HRV parameters were calculated (using Fast Fourier Transformation)
directly from electrode tracings after customized peak detection (HRVAnalyzer©, Diedrich).
Time (mean heart rate, mean RR) and frequency domains were analyzed with special attention
to high frequency (HF) 0.15-0.4 Hz; low frequency (LF) 0.04-0.15 Hz; and sympathovagal
balance (SVB), a ratio of LF/HF that reflects ANS modulations on HRV. Subjects were
exposed to 3 differentt validated laboratory mental stressors. 7 time periods were evaluated
(mean length ~5min) including 5 minute pre-stressor baseline. Results: FAP patients differed
from controls in the LF/HF ratio, the LF and HF correlation, and other frequency domain
indices, suggesting that atypical baseline characteristics may be present in FAP children.
The correlation between LF and HF differed significantly for the FAP vs well groups for
each of the 3 stress periods (correlation coefficients were 0.82 in well vs. 0.54 in FAP, p=
0.007; 0.85 vs 0.58, p=0.01; and 0.92 vs 0.67, p=0.01). These findings suggest increased
sympathetic response in FAP children that was not followed by the increase in vagal response
seen in the well group. The ANS reactivity was highest in both groups during the last mental
stressor (Woodcock-Johnson III Diagnostic Reading Battery). Most HRV indices were age
and gender dependent at p < .05. Conclusion: FAP and well children differ in their ANS
response to mental stress. Laboratory mental stressors differed in their ability to elicit
significantly different responses between groups. Because of developmental differences in
maturation of ANS, age-matching of subjects should be considered in pediatric studies.
Further study of differences in HRV variability indices between FAP and well children
is warranted.
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S2141
Childhood Abuse and Neglect Predicts Subsequent Gastrointestinal Symptoms
in Children: A Prospective Study
Miranda A. Van tilburg, Denesh K. Chitkara, Adam Zolotor, J. chirstopher Graham,
Howard Dubowitz, Alan Litrownik, Emalee Flaherty, William E. Whitehead, Des Runyan
One third to more than half of women in Gastroenterology clinics report some type of abuse
and the prevalence is highest among functional GI patients [Ann Int Med 1995; 123:782-
94]. These women often report neglect or abuse during childhood. However, no study to
date has prospectively evaluated the association between childhood maltreatment and func-
tional GI symptoms. Methods: The LONGitudinal Studies of Child Abuse and Neglect
database is a consortium of five research studies examining the antecedents and consequences
of maltreatment in samples of children who are at high risk for abuse and neglect. Beginning
at age 4, children are assessed every 2 years. Reports to Child Protective Services (age 0-
12) were coded for 5 types of maltreatment (Emotional Maltreatment, Lack of Supervision,
Failure to Provide, Sexual abuse, and Physical Abuse) using a Modified Maltreatment Classi-
fication Scheme (MMCS). At age 12 children provided a retrospective self-report of physical,
psychological, and sexual abuse. Gastrointestinal symptoms (Sx) were derived from the
Child Behavior Check List. Endorsement by both parent and child of GI Sx were assumed
to be suggestive of abdominal pain or nausea/vomiting of functional origin. Children with
GI Sx were compared to children without GI Sx. Results: Two thirds of the sample had at
least one MMCS report of abuse and half reported history of abuse at the age 12 interview.
Nausea/vomiting was associated with MMCS maltreatment (see Table) and this was mainly
explained by the relation with sexual abuse (OR 2.4; p < .01). Abdominal pain was weakly
associated with MMCS maltreatment. Retrospective self-reports of any maltreatment signific-
antly predicted both abdominal pain and nausea/vomiting. These associations were stronger
in girls than boys. No differences were found between African American and Caucasian
children. Conclusions: Functional GI Sx are more common in maltreated children than
non-maltreated children. There is a longitudinal relation between sexual abuse and upper
GI symptoms. Self-reported maltreatment history of any type is associated with both nausea/
vomiting and abdominal pain. These associations are stronger for girls than for boys. Abuse
and neglect should be considered in children presenting with functional GI Sx especially
in girls who report unexplained nausea/vomiting. [Supported by 90CA1676, 90CA1677,
90CA1678, 90CA1679, 90CA1680, 90CA1681 and R24 DK67674].
Odds Ratios (95% CI) for GI Sx by Maltreatment
S2142
Safety and Efficacy of Tegaserod in Children
Olivia Liem, Hayat M. Mousa, Marc A. Benninga, Carlo Di lorenzo
Background: Tegaserod is increasingly prescribed by pediatric gastroenterologists although
there are very few published data concerning its use in children. Aim: To assess the efficacy
and safety of tegaserod in children. Methods: Patients treated with tegaserod in our Division
from 2004 to 2006 were retrospectively evaluated and interviewed. Defecation and fecal
incontinence frequency, and global assessment score of relief of symptoms were assessed.
Results: 72 children (44 girls) were evaluated. Median age at initiation of tegaserod was 9.6
(range, 1.1-18.3) yrs, median duration of symptoms 5.4 (range, 0.1-15.6) yrs and median
follow up time after initiation of tegaserod 10.6 (range, 0.1-45.2) months. Indications to
prescribe tegaserod were constipation (61%) and functional abdominal pain syndromes such
as functional dyspepsia or IBS (39%). Defecation frequency was lower in the constipated
group than in the non constipated group (1 vs. 5/wk, p=0.04) and increased after tegaserod
use (1 vs.7/wk, p<0.001) whereas it did not change in the other group. Fecal incontinence
decreased during treatment (45% vs. 23%, p<0.001). Parents rated global assessment score
of relief of constipation after tegaserod use as moderate or significant in 73% of the constipated
group and 72% in the other group. Relief of abdominal pain and bloating symptoms after
tegaserod was rated as moderate or significant in 66% and 62% of all cases in the constipated
group, respectively. In the group with functional abdominal pain syndromes moderate or
significant relief for abdominal pain and bloating symptoms was seen in 62% and 68% of
the patients, respectively. In children older than 8 yrs, 81% experienced moderate or
significant relief for their main complaint after tegaserod vs. 57% of the younger group (p=
0.03).The median dose of tegaserod prescribed was 0.22 (range, 0.05-0.87) mg/kg/day.
Adverse events were observed in 34% of the patients. The most common side effects consisted
of mild, self-limiting diarrhea (20%) and abdominal pain (10%). Tegaserod had been discon-
tinued by 14 (19%) of the study children, 7 in the constipated group and 7 in the other
group, at time of the interview. Poor therapeutic response was the main reason (8.3%),
followed by no longer needing the medication in 5.6% of all cases. Only one patient
discontinued tegaserod because of side effects; she experienced pain at the cecostomy site.
Conclusion: Tegaserod can be safely used in children of different ages and effectively relieves
a variety of functional gastrointestinal symptoms. Further randomized placebo-controlled
studies are needed to support evidence-based pediatric prescribing of tegaserod.
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S2143
The Role of Rectal Compliance in Recovery from Severe Childhood
Constipation
Maartje M. Van den berg, Marloes E. Bongers, Wieger P. Voskuijl, Guy E. Boeckxstaens,
Marc A. Benninga
Introduction: A relative large group of children with functional constipation (FC) does not
respond to conventional treatment. Increased rectal compliance is a predominant finding
in children with FC and has been proposed as an important pathophysiological mechanism.
We hypothesized that children with increased rectal compliance are less likely to achieve
good clinical outcome. The aim of this study was to determine the influence of increased
rectal compliance on recovery from severe FC. Methods: Children (age: 8-18 years) with
functional constipation for >2 years were studied. Constipation was defined by the classic
Iowa criteria. A pressure-controlled distension protocol (barostat) was performed before and
after 1 year of standardized treatment. Thresholds for rectal sensation were assessed using
an ordinal scale ranging from no sensation to pain (0-5). Rectal compliance was calculated
using a non-linear mixed-effect model for pressure-volume curves. Clinical success was
defined as ≥3 bowel movements per week and <1 fecal incontinence episode per week
irrespective of laxative use. Results: Baseline measurements were performed in 101 children,
65% male, mean age: 11.0±2.1 years. Mean duration of symptoms was 7.1±3.0 years. After
1 year of standardized treatment, 87 children completed clinical follow-up and a second
barostat study was performed in 79 children. Five patients (5.0%) showed abnormal sensation
for urge to defecate at baseline and 2 (2.6%) after 1 year (p=0.66). At baseline, mean rectal
compliance was 24.8±9.8 ml/mmHg and rectal compliance was divided in 3 categories, 1)
normal (<20 ml/mmHg, based on previous studies in healthy children), 2) moderate increased
compliance (20-31 ml/mmHg) and 3) severe increased compliance (>31 ml/mmHg, >75th
percentile). Compliance was normal in 36%, moderate increased in 40% and severe increased
in 24% of the patients. The different rectal compliance categories showed similar success
percentages after 1 year: 1) 42%, 2) 41% and 3) 40%. No difference was found in the time
to first clinical success between the 3 categories (p=0.19, log rank). Rectal compliance had
not changed significantly after 1 year compared to baseline in children with successful
outcome, neither in children with unsuccessful outcome. Conclusion: Although increased
rectal compliance is found in the majority of children with long-lasting functional constipation
it has no relation to treatment failure. Other, yet unknown, factors might play a more
significant role in the persistence of functional constipation.
S2144
Symptom Reporting, EGD Referral and Biopsy Results in Children with
Chronic Abdominal Pain
Martina Puzanovova, Erin Rudzinski, Kezia Shirkey, Sari A. Acra, Lynn Walker
Presentation of upper abdominal symptoms as well as the need to reassure the patient,
parent or clinician may influence the decision to recommend EGD in children with chronic
abdominal pain (CAP). Aims: To identify symptoms and psychosocial factors that (1) pre-
dicted referral for EGD and (2) discriminated between patients with positive vs negative
biopsy findings. Methods: The sample was consecutive new patients referred to the tertiary
care center for evaluation of abdominal pain of at least 3 months' duration, without chronic
illness or GI disease. Children and parents completed validated questionnaires including the
Children's Somatization Inventory, Questionnaire on Pediatric Gastrointestinal Symptoms,
Children's Depression Inventory, Functional Disability Inventory and Family Inventory of
Life Events. The physician was blind to questionnaire results. EGDs were done at physicians'
discretion. Biopsy results were reviewed by two pathologists blinded to the child's condition
and were graded using Sydney-Houston criteria. Biopsies of esophagus, stomach, and duo-
denum were scored as negative, equivocal, or positive. Results: From the total sample of
461 children (mean age 11.87 years; 62% girls) 127 (28%) underwent EGD with biopsy
(mean age 12.1 years; 57% girls). Among girls, symptoms that significantly predicted EGD
performance included vomiting (53%, p< .01), nausea (84%, p< .01), and “food making
you sick” (27%, p< .02). Among boys, symptoms that predicted EGD performance included
lump in the throat (22%, p< .03) and difficulty swallowing (22%, p< .01). Psychosocial
variables did not predict EGD performance. From the total of 127 patients who underwent
EGD, 3 were excluded for incomplete data, leaving 124 with biopsy results. Biopsy scores
were negative at all sites for 34.68% (n = 43) and positive at one or more sites for 45.16%
(n = 56). In the remaining 20.16%, biopsy results were equivocal at one or more sites but
not positive at any site. Boys were significantly more likely than girls to have a positive
biopsy at one or more sites (56.6% vs 36.62%, p< .03); this gender difference was due to
the higher rate of positive esophageal biopsy for boys (47.17%) compared to girls (26.76%),
p< .04). We compared the frequency of each GI symptom by biopsy result and gender.
Among boys only, vomiting by both child and parental report predicted positive esophageal
biopsy findings (p< .02 for child report; p< .03 for parent report). Conclusion: Among CAP
patients, positive EGD biopsy is more common for boys than girls. In boys but not girls,
the complaint of vomiting predicts positive biopsy and should raise clinical suspicion and
lead to EGD referral.
S2145
Rectal Function in Adolescents Recovered from Functional Constipation - A
Barostat Study
Maartje M. Van den berg, Wieger P. Voskuijl, Guy E. Boeckxstaens, Marc A. Benninga
Introduction: Inconclusive data exist regarding the relation between anorectal function
parameters and the outcome of functional constipation (FC) in children. Abnormal rectal
function due to increased distensibility (compliance) has been reported in children with
FC. In this study, rectal function was evaluated in adolescents recovered from constipation
(RC) to determine whether good clinical outcome is associated with normal rectal compliance.
Methods: A pressure-controlled intermittent distension protocol (barostat) was performed
in healthy volunteers (HV), FC patients and RC subjects, free of symptoms for at least 4
years. FC was defined by the classic Iowa criteria. Thresholds for rectal sensation were
assessed using an ordinal scale ranging from no sensation to pain (0-5). Rectal compliance
was calculated using a non-linear mixed-effect model for pressure-volume curves. Results:
Forty-seven FC patients, median (range) age of 12 (11-17) years, and 20 RC subjects, 15
(11-18) years, were studied and compared to 22 HV, 14 (8-16) years. Pressure thresholds
for first sensation, urge to defecate and rectal pain were not significantly different between
the 3 groups. To trigger urge to defecate, significant higher intra-balloon volumes were
required in FC and RC patients when compared to controls (p=0.001 and p=0.02). The
median (5th-95th percentile) rectal compliance in HV was 16 (12-20) ml/mmHg. FC patients
had a rectal compliance of 25 ml/mmHg (13-47) and RC 20 ml/mmHg (12-35). FC and
RC patients had a significantly higher rectal compliance when compared to HV, (p<0.001
and p=0.003). RC had lower rectal compliance when compared to FC (p=0.02). Significantly
more FC patients had a rectal compliance above the upper limit of normal (>95th percentile
of HV) when compared to RC subjects, 75% vs. 45% (p=0.02). Conclusion: Rectal compliance
is disturbed in the vast majority of adolescents with functional constipation and is not
completely normal in adolescents recovered from constipation. The clinical relevance of
rectal compliance in childhood constipation needs to be further investigated with prospective
longitudinal studies.
S2146
Pureed Diet Via Gastrostomy Tube Reduces Retching and Gagging and
Promotes Increased Oral Intake
Kathy B. Santoro, Therese O'flaherty, Ajay Kaul
BACKGROUND: Use of pureed foods by gastrostomy tube (PBGT) is an alternative to using
commercial formulas .We have shown this to be of benefit in children experiencing retching
and gagging on g tube feeds (abstract DDW, 2005). AIM: To determine, by parental reporting,
the degree of improvement of gagging and retching, and oral intake on a PBGT diet. Weight
gain was also evaluated on this diet. SUBJECTS: A total of 43 children, attending the
Interdisciplinary Feeding Team clinic, were determined to fulfill entry criteria for the study.
95% of the children had a fundoplication. The children ranged in age from 9 months to
9.75 years, with the mean age of 31 months. 83% of the study group were less than 3 years
of age. METHODS:Once the decision was made to trial pureed feedings via gastrostomy
tube, the components of the formula were designed by a Registered Dietitian, using a
combination of pureed meats, fruits, vegetables, cereals, and oils. Additional ingredients
were added on a case by case basis, tailoring the diet to meet the child's calorie and
protein goals, avoiding foods to which the child had known allergies. Vitamin/mineral
supplementation was then completed, as well as calculation of additional required fluids.
A phone survey was conducted 2 months to 2 years after being on PBGT diet. Follow up
weights were obtained and average weight gain was calculated. RESULTS: Please see tables
below. 1. 76.8% of children had 51-100% reduction in intolerance symptoms on PBGT
diet. 2. 56% reported improvement in the child's oral intake. 3. Average weight gain was
7.5 gm/day on the PBGT diet. 4. Some children had some weight loss during the intial phases
of transition to PBGT diet but subsequently showed appropriate weight gain. CONSLUSION:
Transition to a PBGT diet should be considered in children with intolerance to gastrostomy
tube feedings and poor oral intake. In our experience PBGT is well tolerated and greatly
improves the quality of life for the children and their caregivers.
DECREASE IN GAGGING AND RETCHING AFTER PBGT
CHANGE IN ORAL INTAKE ON PBGT
S2147
Behavioral Therapy in Childhood Constipation: A Randomized Controlled
Trial
Marieke Van dijk, Marloes E. Bongers, Giel-jan De vries, Martha A. Grootenhuis, Bob F.
Last, Marc A. Benninga
Introduction: Stool withholding behavior plays most likely an important role in development
and persistence of childhood constipation. Behavioral therapy focusing on stool withholding
behavior in combination with oral laxative treatment might be more successful than oral
laxatives alone. Aim of this study: To compare clinical effectiveness of additional behavioral
therapy (BT) to conventional therapy (CT) alone in constipated children. Methods: 129
children (73 male) aged 4-18 years with constipation defined by the classic Iowa criteria
were included and randomized to CT (n=64) or BT (n=65). Intervention periods for CT
and BT consisted of 12 visits to our outpatient clinic during 22 weeks. BT consisted of
standardized intervention focusing on various behavioral components in child and parents.
Defecation and fecal incontinence (FI) frequency and behavioral profiles measured by the
Child Behavior Checklist were assessed at baseline, after 22-weeks therapy and at 6-month
follow-up (FU). Intention-to-treat analyses were used to assess differences between CT and
BT in defecation, FI, success, behavioral scores in clinical range and stool withholding
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behavior. Success was defined as defecation frequency ≥3/wk and FI frequency ≤0.5/wk
irrespectively of laxative use. Results: A total of 118 patients completed therapy, 114 patients
completed FU. Improvement in defecation frequency was higher with CT compared to BT
post treatment (CT: 2.0 to 7.3/wk vs BT: 2.0 to 5.3/wk, p=.003) and at FU (CT: 2.0 to 6.0/
wk vs BT: 2.0 to 5.5/wk, p=.02). No difference in decrease of FI frequency was found
between CT and BT post treatment (CT: 15.3 to 1.4/wk vs BT: 15.2 to 1.5/wk) and at FU
(CT: 15.3 to 2.5/wk vs BT: 15.2 to 3.1/wk). Success was not significantly different between
CT and BT post treatment and at FU, 61% vs 50% and 62% vs 49% respectively. Behavioral
scores in clinical range were present in 40% of children in CT group and 34% of children
in BT group at baseline. More children with behavioral scores in clinical range changed to
normal scores with BT compared to CT (BT: 16% vs CT: 12% post treatment and BT: 13%
vs CT:2% at FU, p=.01). Stool withholding behavior was present in 86% of children in CT
group and 75% of children in BT group at baseline. More children with stool withholding
behavior changed this behavior with BT (BT: 69% vs CT: 64% post treatment and BT: 22%
vs CT:10% at FU p=.02). Conclusion: Behavioral therapy in combination with conventional
therapy is equally successful in treating childhood constipation compared to conventional
therapy alone. BT addresses behavioral problems and stool withholding behavior in constip-
ated children more effectively.
S2148
Biofeedback for Childhood Functional Abdominal Pain Improves Symptoms
and Decreases Healthcare Utilization
Nader N. Youssef, Warren L. Shapiro, Erik Sowder, Richard Gevirtz
BACKGROUND: Limited effective treatment options exist for the treatment of childhood
functional abdominal pain (FAP). FAP is also associated with increased healthcare utilization
later in life. Biofeedback (BF) through paced breathing exercises and its effects on the
autonomic nervous system attempts to change behavioral response to chronic pain including
decreased need for ongoing medical care. OBJECTIVE: To determine symptom relief and
healthcare utilization in children with FAP after completing a course of biofeedback. SUB-
JECTS & METHODS: A database of a large health maintenance organization was queried
to identify all children from 2003—2006 who were diagnosed with FAP by a pediatric
gastroenterologist and who then completed Heart Rate Variability BF treatment. BF sessions
were 1 hour long and held weekly. Autonomic regulation measures were collected in the
form of peak-valley differences of Respiratory Sinus Arrhythmia. Data were collected over
the 2-year period prior to BF treatment and 2-year post treatment. Outcome measures used
included: pain intensity measured on a visual analog scale (1-10), frequency of pain episodes
per week, number of health care visits, prescriptions, emergency room visits, and diagnostic
evaluations. RESULTS: 39 children (55% female, aged 13.4 years, range 8 to 19 years)
diagnosed with FAP underwent BF treatments (4.9 sessions, range 1-12). Pain symptoms
and healthcare utilization was significantly reduced for all outcome measures (see Table).
CONCLUSIONS: In this cohort of children with FAP treated with biofeedback, there was
a marked decrease in pain intensity and healthcare utilization. Biofeedback should be consid-
ered as a cost effective first line therapy for childhood FAP. Long-term studies need to be
performed to see if early and effective interventions for childhood FAP have long lasting
positive effects into adulthood.
Effects on Pain and Healthcare Utilization with Biofeedback for Childhood FAP
S2149
Recollection of Childhood Abdominal Pain Is Associated with IBS in Adults:
Results from a Population Based Survey
Denesh Chitkara, Nicholas Talley, Nilay Shah, Cathy Schleck, Alan R. Zinsmeister, G.
richard Locke
Background: Adults who present for medical care for functional gastrointestinal disorders
(FGIDs) frequently recall experiencing gastrointestinal symptoms as a child. However, it is
unclear if the recollection of childhood abdominal pain (AP) is a specific risk for any one
of the functional gastrointestinal disorders (FGID), and if the recollection of AP as a child
occurs in a population based sample of subjects with FGIDs. Aim: Evaluate the association
between experiencing a FGID and recollecting AP as a child in a population based sample
of adults. Methods: A valid self report questionnaire of gastrointestinal symptoms (BDQ),
which includes queries about patient demographics, current and previous gastrointestinal
symptoms, and a screen for somatization was mailed to an age and sex stratified random
sample in Olmsted County, MN. Logistic regression models that adjusted for age, gender,
BMI, somatization, and other factors were used to estimate the odds ratios (OR) of recalling
bouts of stomach or belly pain as a child (before age 15) for each of the FGID as defined
by the Rome II criteria. Results: 2298 (55%) of a total of 4194 eligible subjects returned a
completed questionnaire. A total of 56% of respondents were females, with the mean (±SD)
age of respondents being 62 (±12) years. Of the respondents, 212 (9%) recalled experiencing
abdominal pain as a child. Individuals who recalled experienced AP as a child were more
likely to currently have a FGID (Table). Recalling AP as a child was significantly associated
with IBS but not GERD, dyspepsia, constipation or diarrhea. Conclusion: Recollecting AP
as a child is specifically associated with IBS in adults. This suggests that a proportion of
adults who meet the specific symptom criteria for IBS experience the onset of abdominal
pain during childhood. This is not true for other functional gastrointestinal disorders.
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[This study was supported by a research grant from the Department of Pediatrics at UNC
Chapel Hill].
The association of the recollection of childhood AP and functional GI disorders
S2150
Colonic Caliber and Manometry Findings in Children with Chronic
Constipation
Ajay Kaul, Sachin Batra
BACKGROUND: There is currently no evidence-based consensus on the indication for
colonic manometry study in children with chronic constipation. HYPOTHESIS: Children
with chronic constipation and a non-dilated colon on a contrast enema (CE) have a normal
colonic manometry (CM) study. METHODS: CM tracings and contrast enemas (CE) of 42
children (27 males; mean age 6.8 years) with chronic constipation on laxative therapy for
at least 6 consecutive months were reviewed. All subjects had normal rectal biopies to rule
out Hirschsprung's disease. All subjects underwent CM using water-perfused catheters and
the protocol complied with published standards. CM was categorized as abnormal if there
was lack of high amplitude propagating contractions in a dilated sigmoid, absence of gastroco-
lonic reflex (GCR) or colonic inertia. RESULTS: The probability of a normal CM in children
with chronic constipation and a non-dilated colon(NPV) is 85%. Only 15% of subjects with
a non-dilated colon had an abnormal CM while 41% of those with an abnormal CE had
an abnormal CM (p=0.08).(See table below). CONCLUSION: This pilot study suggests a
correlation between colonic caliber and motor activity in children with chronic constipation.
This finding will need to be confirmed in a larger cohort as it may have an impact on patient
selection for referral to a motility center for colonic manometry studies.
RESULTS:
2 additional subjects with a dilated rectosigmoid had no HAPCs in the dilated segment.
S2151
Duration of Meconium Passage in Premature and Full Term Infants
Noor Bekkali, Sofie L. Hamers, Marijke R. Schipperus, Paolo G. Valerio, Marc A.
Benninga
Background Meconium is the first stool passed after birth. The passage of meconium is
delayed in premature infants compared to full term infants. The difference in duration of
meconium passage until transition to normal stools has however never been assessed in
preterm and full term infants. Hypothesis Premature infants have a prolonged duration of
passage of meconium compared to full term infants. Methods Between August and November
2006 all infants born in an academic and non-academic hospital with a postmenstrual age
(PMA) between 25 - 42 weeks and without metabolic, congenital diseases or gastrointestinal
disorders requiring surgery were eligible for this study. The infants were divided into 4
groups: 1) PMA ≤ 30 wks; 2) PMA between 31 - 34 wks; 3) PMA between 35 - 37 wks;
4) PMA ≥ 38 wks (full term). Bowel habits were evaluated using standardized daily bowel
diaries. Stools were classified as meconium or normal, based on consistency and color.
Results A total of 169 infants (86 males) were included in the study; 21, 52, 39 and 57
infants in group 1, 2, 3 and 4, respectively. In 93% of full term infants meconium passage
started within 24 hours. Compared to full term infants, significant less children had a passage
of first stool within 24 hours; group 1 (52%, p<0.001), 2 (69%, p=0.001) and 3 (74%, p=
0.005). First meconium passage within 48 hours occurred in 98% of full term infants and
97% of infants from group 3. This percentage was significantly lower in group 1 (86%, p=
0.03) and 2 (88%, P=0.04) compared to full term infants. No difference was found in the
duration of meconium passage between full term infants and infants with a PMA 35 -37
weeks; median (range) 2 days (1-5) and 2 days (1-6), respectively. The duration of the
passage of meconium was significantly prolonged in group 1 (7 days (4-13), p<0.001) and
2 (4 days (1-11), p<0.005) when compared to full term infants. Lower PMA was correlated
with prolonged duration of meconium passage (r=-0.67, P<0.005). Conclusion The passage
of meconium is not only delayed but also prolonged in premature infants with PMA ≤ 34
weeks. Factors influencing duration of meconium passage should be further evaluated.
S2152
Additional Use of Enemas Versus Conventional Treatment in Children with
Severe Constipation: A Randomized Controlled Trial
Marloes E. Bongers, Maartje M. Van den berg, Wieger P. Voskuijl, Marc A. Benninga
Introduction: Treatment of constipated children is often long-lasting since up to 30% of
these children show unsuccessful outcome after 5 years. Conventional treatment consists
generally of oral laxatives. Children refractory to oral laxatives may benefit from regular
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rectal evacuation by enemas. Aim of this study: To compare clinical effectiveness of additional
treatment with enemas (ATE) to conventional treatment (CT) alone in constipated children.
Methods: Children aged 8-18 years with at least 2 years symptoms of constipation, as defined
by the classic Iowa criteria, were included. Polyethylene glycol was administrated orally to
both treatment groups. Children randomized to ATE received additionally 3 enemas/week
and this frequency was reduced by 1 enema every 3 months. Defecation pattern was assessed
at baseline and after one year of treatment. Success was defined as defecation frequency
≥3/week and fecal incontinence frequency <1/week irrespectively of laxative use. Results:
A total of 102 children, 66 male, with a mean age of 11.1±2.1 years, were included and
randomized to ATE (n=52) or CT (n=50). Mean duration of symptoms was 7.1±3.0 years.
A total of 87 patients completed the study; ATE: n= 44 (85%), CT: n= 43 (86%). After one
year of treatment a significant increase in median defecation frequency (ATE: 1.5 vs 5.0/
week, p<.001; CT: 1.0 vs 4.5/week, p<.001) and a significant decrease in median fecal
incontinence frequency (ATE: 8.0 vs 0.8/week, p<.001; CT: 6.5 vs 0.5/week, p<.001) was
found and was not different between treatment groups. Similar success rates after one year
of treatment were found for ATE and CT, 41% versus 44%. Time to first success was not
different between ATE and CT (p=0.72, log-rank test). Conclusion: There is no additional
effect of enemas compared to oral laxatives alone in the treatment of severely constipated
children. Low success rates after one year of treatment indicate that both oral and rectal
laxatives are insufficient in treating severe constipation. Development of new compounds
for childhood constipation is needed.
S2153
Diagnoses, Therapies, and Outcomes Following a Systematic Algorithm for
Symptomatic Children with Hirschsprung's Disease After Corrective Surgery
Bruno P. Chumpitazi, Samuel Nurko
Over half of children with Hirschsprung's disease (HD) after corrective surgery (CS) will
develop bowel symptoms (BS) such as constipation, fecal incontinence and/or enterocolitis.
Strategies for the evaluation and management of these children have been proposed but not
evaluated. Aim To determine the diagnoses, therapies, and clinical outcomes when using a
systematic algorithm to address BS in children with HD after CS. Methods A diagnostic
algorithm that excludes anatomic etiologies and then evaluates anorectal and colonic function
as needed was followed. Records were retrospectively reviewed. Management was based on
evaluation findings. Clinical outcome was classified into four groups (excellent, good, fair,
poor) based on symptoms, incontinence, laxatives, and rectal therapies. Results 60 children
were evaluated. 54(90%) presented with obstructive symptoms and/or enterocolitis and
6(10%) with non-overflow fecal incontinence. Initial aganglionosis was rectosigmoid in
42(70%),long segment in 8(14%) and total colonic in 10(16%). Initial corrective surgeries
were Soave in 38(63%),Duhamel in 12(20%),Swenson in 6(10%),and unknown in 3(5%).
7(12%) had Down's syndrome. Evaluation Diagnostic studies included barium enema in
49(82%),anorectal manometry (ARM) in 48(80%),rectal suction biopsy in 40(67%),endos-
copy and mucosal biopsy in 39(65%), full-thickness rectal biopsy in 13(22%), and colonic
manometry in 5(8%). Residual aganglionosis was identified in 9(15%) and colonic/anastom-
otic strictures in 7(12%). 3(5%) had rapid transit. All children undergoing ARM had non-
relaxing anal sphincters. Colonic dysmotility was found in 3/5(60%). Management Five(8%)
children responded to an initial bowel regimen and did not undergo further evaluation.
Anal sphincter C. botulinum toxin A was given in 38 (63%), with 33/38 (87%) having an
improvement. 23(38%) underwent surgical therapy with re-do pull-through in 9(15%),myec-
tomy in 5(8%),cecostomy placement in 2(3%),permanent ileostomy/colostomy in 2(3%),
stricturoplasty in 2(3%),and anal dilatation in 4(6%). Outcome Mean follow-up was 39 ±
4 months. 3 children were lost to follow-up. Outcomes were excellent in 16(28%),good in
22(39%),fair in 1(2%), and poor in 18(31%). Children with enterocolitis were more likely
to have an excellent or good clinical outcome (p<0.05). Other factors such as sex, initial
aganglionsis extent, type of corrective surgery, Down's syndrome, and need for surgery did
not influence outcome. Conclusion Following a systematic algorithm often identifies etiolog-
ies that require specific therapies in children with HD following CS, and may allow a majority
of these children to have a favorable outcome.
S2154
Alcohol-Induced Liver Injury in Female Rats Differs with Sex Hormone Status
Patricia K. Eagon, Mary S. Elm, Frank D. Houghton, Heidi Sapp, Beverley A. Moore,
Amin A. Nanji
Women are more susceptible than men to alcohol-induced liver injury, suggesting that
estrogen may be a major factor in pathogenesis of this disease. Our AIM was to determine
if sex hormone status influenced degree of alcohol-induced injury in female rats fed alcohol.
METHODS: Female Wistar rat groups (n=6-7) used in this study were normal cycling females
(NCF), ovariectomized (OVX), and OVX treated with physiological levels of estradiol (EOVX).
These groups mimic premenopausal, postmenopausal, and postmenopausal estrogen replace-
ment status, respectively. For 8 weeks and beginning at 43 days of age, rats received voluntary
oral paired feedings containing either no alcohol (isocaloric control, IC) or alcohol (AF)
with fish oil as fatty acid source. This diet was shown previously to induce significantly
more severe injury in female than male rats (Gastroenterology 128 (4, suppl 2), A-685,
abstract #182, 2005). Liver injury was assessed by histopathology, scored for degree of fatty
liver (0-4) and number of inflammatory cells, and by serum enzymes. RESULTS: All AF
rats showed elevated serum AST and ALT levels, with highest levels in NCF (2.6 fold over
IC). Livers of all AF rats demonstrated some degree of fatty change, with NCF having the
most marked change (mean scores, NCF, 2.4; OVX, 1.9; EOVX, 1.3, p<0.02 compared to
IC). Numbers of inflammatory cells were evident in all AF rats, but highest in NCF group
(NCF, 106; OVX, 48; EOVX 49 cells per sq mm; p<0.02 versus IC). Liver-to-body weight
ratios in AF rats were elevated significantly only in NCF and OVX groups. With respect to
hormone status, AF rats in the NCF group, the group most injured, had equivalent estradiol
levels that were not changed by alcohol. The estradiol levels in AF OVX rats were significantly
lower than in either the NCF or EOVX groups. However, the NCF group was distinguished
by progesterone levels; while NCF AF rats had reduced progesterone (50% of IC group),
the levels were higher than that in either OVX or EOVX group (p<.05). CONCLUSIONS:
Normal cycling female rats fed alcohol in a fish oil-containing diet had significantly more
severe liver injury than either OVX or EOVX females on the same diet. These findings
suggest that while estrogen may be a major factor in alcohol-induced liver injury in females,
it is not the sole factor, since estrogen repletion in the EOVX group did not result in the
same degree of injury seen in the NCF group. Further, this study suggests that progesterone
may be a cofactor in liver injury as well. Thus, premenopausal women may be at greater risk
for alcohol-induced injury than postmenopausal women, even when estrogen replacement
therapy is used.
S2155
Loss of Platelet-Activating Factor Acetylhydrolase, An Enzyme That Selectively
Hydrolyzes Oxidatively Damaged Phospholipids, in the Liver of Patients with
Nonalcoholic Steatohepatitis
Kadakkal R. Radhakrishnan, Lisa M. Yerian, Rocio Lopez, Thomas Mcintyre, Ariel E.
Feldstein
Oxidative stress and lipid peroxidation play a central role in disease progression in nonalco-
holic fatty liver disease (NAFLD). Recently, oxidized phospholipids were shown to accumulate
in hepatocytes from patients with NAFLD and to correlate with disease severity (Hepatology.
2006;43:506). Platelet-activating factor acetylhydrolase (PAF-AH) is an enzyme produced and
secreted by liver cells that is uniquely positioned to inactivate these deleterious phospholipids.
However, the expression and clinical significance of PAF-AH in human NAFLD has not
been examined. Thus, the aims of this study were to ascertain the occurrence and significance
of PAF-AH expression in the liver in human NAFLD. METHODS: PAF-AH expression
was assessed by immunohistochemistry (IHC) using a monoclonal antibody in 44 patients
undergoing liver biopsy for suspected NAFLD. Histology was graded using the NAFLD
NIDDK activity score. IHC was semiquantitated blindly by an experienced hepatopathologist
using two scoring systems for extent (0 to 100%) and intensity (0 to 3) of staining. Wilcoxon
rank sum tests were used in order to assess whether extent and intensity were significantly
different between subjects with NASH and those without. Spearman's correlation coefficients
were used to study correlations of extent, intensity and several factors of interest. RESULTS:
The extent of PAF-AH expression was significantly lower in the livers of patients with NASH
(n = 20) as compared to patients with simple steatosis (n = 14) or normal biopsies (n =
10) (p = 0.05). Moreover, a significant negative correlation was observed between extent of
PAF-AH expression and degree of lobular inflammation (r = -0.43; p = 0.004; 95% CI
-0.71,-0.14). A significant but weak negative correlation was also found between extent of
PAF-AH expression and stage of fibrosis (r = -0.43; p = 0.004; 95% CI -0.71,-0.14). There
was no evidence to suggest intensity of PAF-AH expression was significantly different between
subjects with and without NASH (p = 0.54). CONCLUSIONS: The present study shows
that PAF-AH expression is decreased in patients with NASH. Loss of this protective enzyme
may be implicated in disease progression in NAFLD suggesting a potential new therapeutic
strategy for NASH.
S2156
Evaluation of Small Intestinal Bacterial Overgrowth in Nonalcoholic
Steatohepatitis By Jejunal Aspirate and Quantitative Culture
Sreenivasa B. Chalamalasetty, Ujjala Ghoshal, Uday C. Ghoshal, George Alexander, Asha
Misra, Gourdas Choudhuri
Background : Pathogenesis of non-alcoholic steatohepatitis (NASH) is still unclear. NASH
in jejuno-ileal bypass surgery seems to be associated with small intestinal bacterial overgrowth
(SIBO). A single human study using breath tests has shown increased prevalence of SIBO
in patients with NASH. We did this study to evaluate frequency of SIBO in NASH using
quantitative culture of jejunal aspirate (currently the gold standard method) and hydrogen
breath tests. Methods : NASH was diagnosed based on presence of fatty liver on ultrasonogra-
phy and alanine aminotransferase (ALT) 1.5 times above upper limit of normal for a period
of more than 6 months. Other causes of chronic hepatitis have been excluded by viral and
autoimmune markers, copper and iron studies. Historical controls with no clinical evidence
of fatty liver were taken as controls. Jejunal aspirate was collected using a standard technique,
with a catheter assembly during esophago-gastro duodenoscopy, was cultured for aerobic
and anaerobic bacteria and colony count was determined using serial dilution technique.
Glucose and lactulose hydrogen breath tests (GHBT and LHBT) were also performed in a
subset of patients. SIBO was diagnosed if aspirate grew >105 colony forming unit/ml (CFU/
ml) of bacteria in the aspirate or breath H2 rise > 14 ppm on GHBT. Results : Jejunal
aspirate could be obtained in 35 of 38 patients with NASH. Culture was sterile in 14 (40%)
and bacteria were isolated in 21 (60%), one of whom also grew anaerobes. In contrast,
bacteria were isolated in 3/12 historical controls (25%) (p=ns). The median colony counts
in patients whose culture was positive was 103-105 CFU/ml. SIBO was present in 7/35
(20%) patients with NASH (5 by jejunal aspirate culture and 2 on GHBT) in contrast to
none of the controls (p=ns). On culture of the aspirate in patients with SIBO, 2 patients
had 2 types of organisms and 3 had one organism isolated. The various organisms grown
in SIBO were Streptococcus in 2, Acinetobacter baumanii in 2, Enterococcus fecalis, Enterobacter
aerogenes and Proteus mirabilis in one each. On comparison of patients with and without
SIBO, no significant difference in their age, anthropometric measurements or ALT was found.
Conclusion : Small intestinal bacterial overgrowth as diagnosed using quantitative jejunal
aspirate culture is uncommon in patients with NASH. Therefore, it is unlikely to play major
role in pathogenesis of this disorder.
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S2157
Upper Normal Range of Alanine Aminotranfearase (ALT) Can Be Associated
with Features of Metabolic Syndrome in Patients with Nonalcoholic Fatty
Liver Disease (NAFLD)
Chang-il Kwon, So young Lee, Gi chul Han, Kyeh dong Shi, Soo kyoung Kim, Kwang
hyun Ko, Sung pyo Hong, Seong gyu Hwang, Pil won Park, Kyu sung Rim
Aims : The purpose of this study was to evaluate the prevalence of ultrasonographic fatty
liver and metabolic syndrome with upper normal range of liver function test in apparently
healthy Korean adults. Methods : We examined 538 men and women, aged 30-80years,
who participated in health screening test. Those with history of viral hepatitis, alcohol abuse,
and oral hypoglycemic agent or insulin use were excluded from the study. A standard
interview, anthropometrics, biochemical studies, and abdominal ultrasonography were con-
ducted for each participant. Among the people with normal ALT level, we first compared
clinical characteristics and prevalence of metabolic disorders according to the presence of
nonalcoholic fatty liver, and then they were further divided into upper normal ALT level (
> 20 IU/L) and lower normal ALT level( < 20 IU/L). Results : The prevalences of untrasono-
graphic nonalcoholic fatty liver and metabolic syndrome in the enrolled subjects were 18%
and 21.9%. Compared to the people without fatty liver, people with ultrasonographic fatty
liver and normal ALT level had odds ratios for metabolic syndrome of 4.53 (95% CI, 2.35-
8.75), insulin resistance of 4.83 (2.71-8.59), hypertension of 2.69 (1.44-5.02), dyslipidemia
of 6.90 (3.56-13.39), and obesity of 5.39 (3.12-9.33), respectively. Furthermore, the preval-
ences of metabolic syndrome and other metabolic disorders were increased in both ultrasono-
graphic fatty liver group or ultrasonographic normal liver group with upper normal ALT
level compared to the lower normal ALT level (p<0.01). Conclusions : The ultrasonographic
fatty liver was strongly associated with metabolic syndrome and common metabolic abnor-
malities even with normal liver function test. In patients with upper normal ALT level, the
prevalence of metabolic syndrome increased parallel to the increment of ALT level.
S2158
Prevalence and Associated Factors of Nonalcoholic Liver Fatty Disease and
Metabolic Syndrome: Results from a Cross-Sectional Study
Antonio Colecchia, Amanda Vestito, Elisabetta Petracci, Maria letizia Bacchi-reggiani,
Antonio maria Morselli-labate, Anna rita Di biase, Giuseppe Mazzella, Francesca Lodato,
Marco Montagnani, Francesca Pasqui, Davide Festi
Nonalcoholic fatty liver disease ( NAFLD) and metabolic syndrome ( MS) are considered
closely related diseases, having insulin resistance as common pathogenetic mechianism. A
few studies, however, have simultaneously assessed NAFLD and MS prevalence and associated
factors in a general population. Aim: to evaluate by means of a cross-sectional study prevalence
and associate factors of NAFLD and MS. Material and Methods: The cross sectional study
was performed on a general population ,aged 28-84 yrs; 1534 out of 1646 ( 93%) subjects
agreed to participate to the study. All subjects underwent abdominal ultrasound (US),
physical examination, fasting blood specimen collection, seven day dietetic diary. NAFLD
was evaluated by US and MS was defined according to ATP III criteria (presence of 3, or
more, of the following parameters: waist circumference, fasting glucose, HDL-cholesterol,
triglycerides, blood pressure). Insulin resistance was evaluated using the triglycerides/HDL-
Cholesterol ratio ( Tg/Hdl ratio) ( n.v.< 3.5). Results: 479 out of 1534 ( 31.2%) subjects
were excluded because they presented other liver diseases (391 alcohol, 20 HBV, 63 HCV
and 5 autoimmune). 382 out of 1055 subjects ( 36.1%) ( males 57.8%, mean age: 52.1 ±
12.7) had NAFLD, while 240 out of 1055 ( 22.7%) subjects had MS ( males 45.8%,mean
age 55.5 ± 12.6). In NAFLD, MS prevalence was 41.6% (159 out of 382 subjects); at
multivariate analysis, associate factors resulted: sex male (OR:1.89), systolic hypertension
(OR:1.9), hyperglicemia (OR:1.9), visceral obesity (OR:4.9), Tg/HDL ratio (OR:2.9), ALT
(OR:2,5), gGT (OR:1.8). NAFLD was present in 66.2% (159 out 240 subjects) of MS subjects:
at multivariate analysis associated factors resulted: increasing age (OR:1.5); female sex
(OR:1.05); fatty liver ( OR:5.22); Tg/Hdl ratio ( OR: 23.04). Conclusions: the present study
confirm the strong association between NAFLD and MS; although NAFLD prevalence is
higher. Subjects with NAFLD had higher risk (OR: 13.5) to have MS than vice-versa (OR:
5.22); this observation suggest that NAFLD could plays an early role in the development
of M.S. Further epidemiologiocal and pathophysiological studies are needed to better define
which is the killer or the victim.
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S2159
Usefulness of a Scintigraphic Analysis for Discriminating Nonalcoholic
Steatohepatitis (NASH) from Non-NASH By Technetium-99m-2-Methoxy-Iso-
Butyl-Isonitrile (99mtc-Mibi)
Masafumi Ono, Kosei Masuda, Mitustaka Fukumoto, Toshiji Saibara, Akira Hirose,
Yasuko Nozaki, Masaya Takahashi, Naoaki Akisawa, Shinji Iwasaki, Saburo Onishi
Background/Aims: It is considered to be important to distinguish nonalcoholic steatohepatitis
(NASH) from simple steatosis. Technetium-99m-2-methoxy-iso-butyl-isonitrile (99mTc-
MIBI) is a lipophilic cation initially designed for the scintigraphic evaluation of myocardial
perfusion related to the mitochondrial function. We examined the clinical usefulness of
99mTc-MIBI scintigraphy for detecting the presence of NASH in patients with biopsy-proven
NAFLD. Methods: Twenty-six patients with biopsy-proven NAFLD and 5 healthy controls
were enrolled in this study. According to the NAFLD Activity Score (NAS), 11 patients were
diagnosed to have NASH and 4 patients were determined to have non-NASH. Laboratory
examinations, and 99mTc-MIBI scintigraphy were performed in all patients and healthy
subjects. Results: The liver/heart (L/H) ratio in comparison to the hepatic uptake on 99m
Tc-MIBI scintigraphy were obviously lower in the patients with NASH, in comparison to
either the non-NASH patients (p<0.05) or the healthy controls (p<0.01), respectively. In
addition, the L/H values were significantly correlated with NAS in the 26 NAFLD patients
(r= -0.413, p= 0.038). Furthermore, the L/H values in 4 NASH patients after treatment were
increased in comparison to the pre-treatment levels (p<0.02). Conclusions: In this study,
we showed for the first time that the retention of 99mTc-MIBI in the liver of NASH patients
decreased, therefore the liver imaging of 99mTc-MIBI could be a useful tool for discriminating
NASH from non-NASH.
S2160
Variablility in the Histologic Interpretation of Non-Alcoholic Fatty Liver
Disease
Charles P. Katopes, Sri N. Surapaneni, Richard Komorowski, Behnaz Behmaram, James R.
Wallace, Peter Nuttleman, Jose Franco, Rajiv Varma, Omar Massoud, Kia Saeian, Samer
Gawrieh
Limited data exist regarding the robustness of pathological evaluation of different histological
features of non-alcoholic fatty liver disease (NAFLD), as well as delineating its diagnostic
categories [fatty liver (FL), or nonalcoholic steatohepatitis (NASH)]. Aim: Determine the
intra and inter-observer variability in both diagnosis of and in grading different histological
features of NAFLD by two academic pathologists.Methods: The biopsy database of the
Hepatology Clinic at the Medical College of Wisconsin was reviewed and patients who
underwent liver biopsy for idiopathic abnormal liver tests, suspected NAFLD,or cryptogenic
cirrhosis between 1/2003 and 4/2006 were identified. Two academic pathologists blinded
to prior diagnosis independently reviewed all biopsies twice and provided a score for
individual features of NAFLD according to the NAS scoring system and a diagnosis [FL,
possible NASH, NASH, or 'others' (<5% fat or isolated minimal inflammation]). Weighted
kappa statistics were calculated to determine degree of intra and inter-observer agreement
for individual features and diagnosis. Results: 66 liver biopsy samples were reviewed. The
histological feature scores with corresponding intra and inter-observer weighted kappa
statitistics are summarized in the table.The intra and inter-observer agreement (weighted k)
was poor for hepatocellular ballooning (0.07 and -0.09) and lobular inflammation (0.18
and 0.06), fair for fibrosis stage (0.4 and 0.32) and diagnostic category (0.27 and 0.29) ,
fair to moderate for the total NAS score (0.40 and 0.43), and moderate to good for steatosis
grade (0.61 and 0.60). Conclusions: Agreement between 2 academic pathologists was good
only when evaluating steatosis grade but was poor to fair with other major histological
features of NAFLD. This resulted in a fair agreement on the diagnostic category and NAS
scores. These results suggest that the distinction of NASH from FL remains challenging even
for academic pathologists. With the epidemic expansion of NAFLD, better methods to
identify and score histological features are needed for accurate diagnosis of different NAFLD
phenotypes and reproducible measurement of outcomes in clinical trials of NASH.
Inter & Intra-Observer Agreement on Histology of NAFLD
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S2161
Pentoxifylline for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): A
Randomized, Placebo-Controlled Study
Warawuti Buranawuti, Panida Thong-u-thaisri, Chutima Pramoolsinsap, Naruemon
Wisedopas, Kalayanee Atamasirikul, Umaporn Udomsubpayakul
INTRODUCTION: Insulin resistance plays an important role in pathogenesis of NAFLD.
Adiponectin has antilipogenic and anti-inflammatory effects, while TNFα reduces insulin
sensitivity and has proinflammatory effects. The aims of this study are to determine the
efficacy and safety of pentoxifylline, a TNFα inhibitor, compare with placebo METHODS:
Thirty two patients had biopsy-confirmed NASH and NAFLD with other causes of liver
disease and secondary causes of NASH excluded. All patients had persistently elevated ALT
(> 1.5 times for more than 6 months, after dietary treatment for 2months) were randomized
into 2 groups. The first group was given pentoxifylline at a dosage of 400 mg t.i.d. plus
dietary treatment and the second group was given placebo with dietary treatment for 6
months. The changes in ALT, AST, insulin resistance index (homeostatic metabolic assess-
ment- HOMA IR, Waist/Hip ratio), TNFα and adiponectin level from baseline to at the end
of treatment were compared between 2 groups. RESULTS: The 32 patients had a mean age
of 48.94+11.66 yr. 19(59%) were male, 5 (15.6%) were obese( BMI > 30 kg/m2) with mean
BMI 26.49+ 3.22 kg/m2, 5 (15.6% ) were type II DM, 12 (37.5%) were hypertension and
27 (84.4%) were dyslipidemia. No baseline demographic differences between 2 groups. The
mean serum alanine, aspartate aminotransferase and serum fasting glucose levels decreased
significantly from baseline in the pentoxifylline group compared to the placebo group. (
ALT decreased 68.25 +40.76 vs. 18.19 +34.24, p =0.001; AST decreased 27.31 +20.42
vs.7.94 + 19.78 , p=0.008; FBS decreased 9.13 + 10.71 vs. increased 0.75 + 5.74, p=0.003)
The pentoxifylline groups showed more improvement in BMI, HOMA IR index and serum
TNFα, compared with the placebo groups, but no statistically significant. Adinopectin levels
were not changing significantly between 2 groups. Only one patient in the pentoxifylline
groups withdrew from the study, primarily because of nausea. No serious adverse events
occurred. CONCLUSIONS: Pentoxifylline therapy had effectively achieved significant
improvement in aminotransferase level among patients with NAFLD when compared to pla-
cebo.
S2162
Bradykinin-Induced Cyclooxygenase-2 Expression and Prostaglandin E2
Release in the Enteric Nervous System of Guinea-Pig Small Intestine
Mei-hua Qu, Xiyu Wang, Sumei Liu, Guo-du Wang, Guijun Fei, Fie Zou, Yougin Du, Yun
Xia, Jackie D. Wood
Bradykinin (BK) is an inflammatory mediator of documented importance in the small and
large bowel. It is derived from kininogen during tissue injury, anoxia or inflammation. We
reported earlier that BK acts at B2 receptors on myenteric and submucosal neurons to elevate
excitability, suppress release of neuro-transmitters and stimulate the neuronal synthesis
and release of prostaglandins (Br J Pharmacol 2003; 138:1221; J Exp Pharmacol Exp Ther
2004;309:320). These actions are suppressed by agents that inhibit cyclooxygenase (COX).
This study examined induction of COX2 expression and release of prostaglandin E2 (PGE2)
by BK in primary cultures of the myenteric and submucosal plexuses. BK-induced COX2
mRNA expression was determined with real-time quantitative RT-PCR and COX2 protein
expression was examined with Western blot analysis and immunohistochemistry. ELISA
assay was used to measure BK-induced prostaglandin release. Incubation of myenteric
plexus preparations with BK (1nM - 1µM) for 4 hr increased COX2 mRNA expression in
a concentration-dependent manner. Expression was greatest at 100 nM with a 4.35±0.61-
fold increase relative to control. COX2 (100nM) stimulation of mRNA expression was time-
dependent and increased by 1.34±0.33, 5.64±1.92, 4.76±0.51, 4.90±1.24 and 2.82±1.54-
fold after incubation for 2, 4, 6, 8 and 24hr respectively (n=3). Western blot analysis
found BK-induced COX2 protein expression patterns to be similar to mRNA expression.
Immunoreactivity for COX2 protein was expressed by myenteric and submucosal neurons
after 4hr incubation with BK (300nM). Incubation of both plexus preparations with BK
significantly stimulated the release of PGE2. BK-induced release of PGE2 in the myenteric
plexus was reduced to 17% of control by the COX2 inhibitor, NS398, and to 60.6% by the
COX1 inhibitor, FR122047. In the submucosal plexus, BK-induced release of PGE2 was
reduced to 37.5% of control by the COX2 inhibitor, NS398, and to 66.1% by the COX1
inhibitor, FR122047. The results supplement our earlier electrophysiological, molecular
biology and immunohistochemical evidence that bradykinin acts at B2 bradykinin receptors
on myenteric and submucosal neurons to stimulate COX1 and COX2 and the formation of
prostaglandins. Once formed and released, the prostaglandins feedback onto the same
neurons to elevate excitability and suppress the synaptic release of norepinephrine and other
neurotransmitters. Elevated secretomotor neuronal activity underlies stimulated mucosal
secretion and the secretory diarrhea associated with intestinal inflammatory states. (Supported
by NIH RO1 DK57075)
S2163
IL-25 Is a Novel Player in Th2-Mediated Protective Immunity Against
Nematode Infection
Aiping Zhao, Rex Sun, Jennifer Stiltz, Kathleen B. Madden, Fred D. Finkelman, Joseph
Urban, Terez Shea-donohue
IL-25 (IL-17E) is a newly-identified member of the IL-17 family. IL-25 is proposed to have
an important role in protective immunity as mice that lack IL-25 have delayed worm
expulsion and delayed upregulation of Th2 cytokines. Exogenous IL-25 induces a typical
Th2 immune response and accelerates worm clearance. The immune regulation of IL-25
expression during infection and the effect of IL-25 on gut function, however, are unknown.
Aim: To investigate the immune regulation of IL-25 expression during nematode infection
and determine the role of exogenously-administrated IL-25 on murine intestinal smooth
muscle function. Methods: BALB/c (WT), or mice deficient in Stat6 (Stat6-/-), IL-4 (IL-4-/-
), or IL-13 (IL-13-/-) were inoculated with Nippostrongylus brasiliensis (Nb) and studied 9
days later. Separate groups of WT mice were injected daily with IL-25 (0.7 μg/mouse iv)
or vehicle and studied 7 days later. Segments of jejunum were suspended longitudinally in
organ baths for smooth muscle function studies. Total RNA was isolated from intestine and
the mRNA expression of cytokines and cytokine receptors (R) was measured by real-time
PCR. Results: Nb infection upregulated both IL-25 (19±5 fold) and IL-25R (7.7±1.2 fold)
in WT mice. In contrast, infection-induced upregulation of both IL-25 and IL-25R was
abrogated in Stat6-/- mice (data not shown). In IL-4-/- mice, Nb-induced upregulation of IL-
25 (6.6±1.4 fold) and IL-25R (3.2±0.8 fold) persisted. In IL-13-/- mice, IL-25 expression
was unchanged afterNb, but IL-25R remained elevated (3.8±1.2 fold). In WT mice, exogenous
IL-25 induced an intestinal smooth muscle hypercontractility (table), including elevated
amplitude of spontaneous contractions (SC) and increased responses to acetylcholine (ACH)
and electric field stimulation (EFS) that were similar to that observed in response to IL-13.
Exogenous IL-25 also upregulated IL-13, IL-25R, and GATA-3, downregulated IL-12/IL-
23p40 (table), but did not alter IL-4, IFN-γ, IL-17A, or T-bet expression (data not shown).
Conclusions: Nematode infection upregulated IL-25 and IL-25R by a mechanism that is
dependent on IL-4/IL-13 activation of Stat6 signaling. These data suggest that Th2-induced
upregulation of IL-25 plays a role in the hypercontractile effects of Th2 cytokines that
facilitate worm expulsion. The inhibition of Th1 immune responses implicates IL-25 as a
novel therapeutic target in Th1-mediated gut inflammation.
*p<0.05 vs WT-vehicle; n=5
S2164
Changes in Synaptic Transmission and Neuronal Excitability in Ileal
Submucosal Neurons During TNBS-Induced Colitis
Ian M. Hons, Gary M. Mawe, Keith A. Sharkey
Gastrointestinal dysfunction occurs throughout the gut in inflammatory bowel diseases, even
in cases where inflammation is localized to a single region. Previous studies have demonstrated
altered signaling in the enteric nervous system at the site of inflammation (colitis) and in
the colon of animals with active ileitis. We therefore examined whether the properties of
enteric neurons in the terminal ileum were altered during colitis. Intracolonic TNBS (0.3-
0.5ml, 20-25mg/ml in 25% ethanol) or saline was administered to male albino guinea pigs,
and the ileum and colon were removed 7 days later. The severity of colitis was assessed by
body weight change and a macroscopic damage score. The distal ileum was maintained in
oxygenated Krebs solution containing nicardipine and scopolamine. The submucosal nerve
plexus was dissected from a segment of ileum and S and AH type neurons were evaluated
by intracellular voltage recordings. Passive and active electrical properties were evaluated
as well as synaptic events evoked by focal stimulation of adjacent ganglia. The mean colonic
damage score following TNBS treatment was 6.7 ± 0.9 (n=10), while no damage was observed
in colons of saline treated animals, nor in the ileums of either group. Neurons where assigned
to 3 groups using electrophysiological criteria: Dogiel type I S neurons with inhibitory
postsynaptic potentials (IPSPs), which are known to contain VIP (S-VIP) or S neurons
without IPSPs, which express ChAT (S-ChAT), and AH neurons which posses a characteristic
action potential shape, prolonged afterhyperpolarization, and Dogiel type II morphology.
In S-ChAT neurons, Colitis increased the maximum action potential firing frequency follow-
ing an intracellular depolarizing step (saline 25.6 ± 2.5 Hz, n=5; TNBS 42.3 ± 7.2 Hz, n=
4; P < 0.05). In S-VIP neurons, the amplitude of the slow excitatory synaptic potential was
decreased in animals with colitis (saline 9.8 ± 1.8 mV, n=5; TNBS 3.8 ± 0.8 mV, n=4; P <
0.05). In the AH neurons, TNBS treatment resulted in a prolongation of the action potential
at half maximum amplitude (saline 1.63 ± 0.16 ms, n=5; TNBS 2.47 ± 0.23 ms, n=5; P <
0.05) and a delay in the time to peak amplitude (saline 0.90 ± 0.06 ms, n=5; TNBS 1.45
± 0.13 ms, n=5; P < 0.01). We have demonstrated changes to enteric signaling in the
terminal ileum during (or in response to) colitis. These changes may underlie widespread
gastrointestinal dysfunction following a localized inflammatory insult. This is the first demon-
stration of alterations in neuronal plasticity at distant sites oral to an active site of inflamma-
tion.
S2165
Polysialylated Neuronal Cell Adhesion Molecule (PSA-NCAM) Is Re-expressed
in a Subpopulation of Myenteric Neurons Following Experimental Colitis in
Adult Rats
Philippe Ouellet, Catherine Rhéaume, Cindy Gauthier, Dorothée Dal soglio, Christophe
Faure
Background: The enteric nervous system (ENS) plays a critical role in inflammatory bowel
diseases. PSA-NCAM expression in enteric neurons is developmentally regulated with a high
expression during embryogenesis and a complete absence in adults. In the adult brain, PSA-
NCAM is reexpressed after injury (ischemia, seizures) and is involved in neuronal networks
repair. We therefore hypothesized that PSA-NCAM could be reexpressed in the ENS following
a TNBS (2,4,6 trinitrobenzene sulfonic acid)-induced colitis in adult rats. Our objectives
were (1) to study the reexpression of PSA-NCAM in adult rat ENS in TNBS-induced colitis
and (2) to determine the phenotype of the cells reexpressing PSA-NCAM. Methods: Colitis
was induced in adult Sprague Dawley rats by intra-colonic administration of 20 mg of TNBS
diluted in ethanol. Control animals were injected with ethanol or saline. Colons were
collected 1, 3, 7 and 21 days after induction of colitis (T1, T3, T7 and T21). The intestinal
specimens were assessed for macroscopic (Macro, max=14) and histological (Histo, max=
13) severity of colitis. Double immunofluorescences were performed on wholemount prepara-
tions. A neuronal marker (PGP9.5), a glial marker (s100b), a marker for neuronal nitric
oxide synthase (nNOS), choline acetyltransferase (ChAT) and calbindin, a marker for intrinsic
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primary afferent neurons (IPANs), were used in combination with an antibody for PSA-
NCAM. Three animals were used for each stage. Results: Severe colonic inflammation was
present early after induction at T1 (Macro=11.2, Histo=11) and decreased at T3 (Macro=
7.2, Histo=8.2) and T7 (Macro=2.6, Histo=5.9) until T21 (Macro=0.7, Histo=4.2). Control
animals injected with saline had a normal colon. At T3, 2.22%±0.28 (p<0.01 vs. saline
controls) of the PGP9.5+ neurons reexpressed PSA-NCAM. Saline controls were virtually
all negative for PSA-NCAM immunoreactivity. PSA-NCAM was not reexpressed in any s100b+
cells. 92%±2 and 86%±1.5 of PSA-NCAM+ cells were positive for calbindin and ChAT,
respectively. PSA-NCAM+ neurons were not significantly labelled with nNOS. Conclusion:
We demonstrate that a subpopulation of adult rat myenteric neurons reexpresses PSA-NCAM
in the TNBS-induced colitis model. The vast majority of PSA-NCAM reexpressing neurons
also express calbindin and ChAT. This suggests that these PSA-NCAM+ neurons exhibit an
IPAN phenotype. Because IPANs are the first neurons in the pathway of the intrinsic reflex
that controls motility, blood flow and trans-epithelial movement of fluid in the intestine,
PSA-NCAM expression in these neurons may lead to mechanisms that enhance intrinsic
sensory reflex activity during intestinal inflammation.
S2166
Molecular Signatures for Altered Mucosal Immunity in Colon in Irritable
Bowel Syndrome
Jeroen Aerssens, Michael Camilleri, Willem Talloen, Leen Thielemans, Hinrich W.
Göhlmann, Ilse Van den wyngaert, Theo Thielemans, Christopher N. Andrews, Adil E.
Bharucha, Paula J. Carlson, Irene Busciglio, Duane D. Burton, Thomas Smyrk, Raul A.
Urrutia, Bernard Coulie
Background: Irritable bowel syndrome (IBS) has been associated with increased mucosal
permeability, mild inflammation, and altered colonic bacteria. We used microarray expression
profiling of sigmoid colon mucosa from IBS patients and healthy controls to identify molecular
mechanisms that may contribute to pathogenesis of IBS. Methods: Gene expression profiling
was performed using Affymetrix U133-Plus2.0 GeneChips with RNA from sigmoid colon
mucosal biopsies from 36 IBS patients and 25 healthy control subjects. Statistical methods
for microarray data were applied to search for differentially expressed genes and molecular
signatures that correctly classify IBS patients and healthy controls. Results: Gene expression
profiles were consistent across 2 sites within the sigmoid and were stable on repeat biopsy
over ~3 months. Differentially expressed genes suggest functional alterations of the host
mucosal immune response. Names of genes with q<0.1 in the statistical analysis for microarray
and fold change (ratio of mean gene expression in IBS compared to health) are given in
parentheses. Three genes (LRAP [Leukocyte-derived arginine aminopeptidase; 0.39] , PSME2
[Proteasome activator subunit 2 {PA28 beta}; 0.84], TAP2 [Transporter 2, ATP-binding
cassette, sub-family B (MDR/TAP); 0.71]) are involved in antigen processing. Six genes (VSIG2
[V-set and immunoglobulin domain containing, 2; 1.20], VSIG4 [V-set and immunoglobulin
domain containing, 4; 0.66], FCGR2A [Fc fragment of IgG, low affinity IIa, receptor {CD32};
0.77], MS4A4A [Membrane-spanning 4-domains, subfamily A, member 4; 0.74], M160
[Scavenger receptor cysteine-rich type 1 protein M160 {CD163 antigen-like 1}; 0.69], MUC20
[Mucin 20; 1.52]) participate in the immune response. Three genes (LYZ [Lysozyme; 0.48],
CASP1 [Caspase 1, apoptosis-related cysteine peptidase {interleukin 1, beta, convertase};
0.76], COP1 [Caspase 1 dominant-negative inhibitor pseudo-ICE; 0.81]) are involved in
host defense. NOX/DUOX oxidase genes [NCF4; 0.70, DUOX2; 3.8] are involved in oxidative,
non-specific host defense. The most strikingly increased expression involved a yet uncharac-
terized gene, DKFZP564O0823, which we propose to re-name IBS1 (1.41-fold). We identified
32 gene probe sets which constitute a molecular signature that enabled distinction of a
separate group of IBS patients from healthy controls with ~70% accuracy. Conclusions:
Mucosal expression studies suggest there are alterations in colonic mucosal immunity in
IBS, which might identify IBS subsets. These molecular alterations may provide a signature
or biomarkers to aid the objective diagnosis or develop novel therapies for IBS subtypes.
S2167
Effects of cAMP and cGMP Activation On Serotonin-Selective Reuptake
Transporter (SERT) Expression and Function in Caco-2 Cells
Brigitte Lavoie, Cristen Pantano, Kevin F. Foley, Gary M. Mawe
Serotonin (5-hydroxytryptamine; 5-HT) released by enterochromaffin cells activates motor,
secretory and vasodilator reflexes and is involved in intestinal sensation. 5-HT is removed
from the mucosal interstitial space by SERT. Mucosal SERT is decreased in ulcerative colitis
and in animal models of intestinal inflammation leading to increased 5-HT availability and
possibly contributing to altered gut function and sensation. In cells of neuronal and placental
origin such as JAR cells, SERT function is increased by the second messengers cAMP and
cGMP; however, the regulation of SERT in intestinal epithelial cells has not been determined.
The goal of this study was to establish whether the cAMP and cGMP signaling pathways
regulate intestinal SERT expression and function. Caco2 cells, an immortalized human
intestinal epithelial cell line natively expressing SERT and JAR cells were treated with 100
µM forskolin for 8, 24, and 48 hours and SERT mRNA levels were assessed by Taqman
real-time PCR. Interestingly, a significant decrease in SERT mRNA was detected at all time
points in Caco2 cells, whereas expression of neuronal SERT in JAR cells was upregulated
by cAMP activation as previously reported. Additionally, treatment of Caco2 cells with
100uM cGMP did not yield and significant effect on SERT mRNA expression. Treatment of
Caco2 cells with forskolin also led to a decrease in SERT function as determined by the
ability of SERT to take up [3H] 5-HT, however an increase in SERT function was observed
in JAR cells under the same conditions. Furthermore cGMP did not significantly affect SERT
function. Interestingly, SERT function in Caco-2 cells was upregulated by an agonist of the
cAMP-EPAC pathway. EPACs (exchange protein directly activated by cAMP) are newly
discovered intracellular signaling proteins that are activated by cAMP independent of protein
kinase A. Stimulation of Caco-2 cells with 8 CPT-2'O-Me-cAMP (10 µM), a cAMP analog
that activates the EPAC pathway, but not PKA, for 24 and 48 hours enhanced SERT function.
In conclusion, these findings indicate that expression and function are regulated differently
in intestinal SERT as compared to cells of neuronal or placental origin, and they suggest
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that cAMP-induced changes in SERT function involve transcriptional changes. *BL and CP
contributed equally. Supported by Novartis Pharmaceuticals.
S2168
Enteric Mast Cells in Experimental Allergic and Non-Allergic Enterocolitis in
Guinea Pigs
Xiyu Wang, Guo-du Wang, Yun Xia, Sumei Liu, Guijun Fei, Fie Zou, Yougin Du, Mei-hua
Qu, Jackie D. Wood
This study compared enteric mast cell biology in a food allergy model induced by ingestion
of cow's milk with a non-allergic enterocolitis model induced by ingestion of dextran sulfate-
Na+ (DSS). Immunofluorescence, immunoblotting and ELISA were methods used. Ingestion
of 3% DSS for 3-5 days induced enterocolitis marked by mucosal inflammation, diarrhea,
bloody feces and body-weight loss. Mast cell numbers were increased by 4.3 fold to 64.3±8.4
mast cells/mm2 relative to control numbers of 14.8±2.5 mast cells/mm2 in the DDS-treated
ileum. Mast cells in the DDS-treated colon were elevated 6.6 fold to 37.2±7.4 mast cells/
mm2 relative to control values of 5.6±1.2 mast cells/mm2. Numbers of mast cells in the
ileum and colon of milk-sensitized guinea pigs were not elevated. Data were obtained from
6 preparations removed from each of 6 animals. Immunoreactivity (IR) for the NK1 receptor
subtype co-localized with mast cell tryptase-IR and chymase-IR in all preparations. Histamine
levels of 1273.2±58.1 ng/g were present in DDS-treated preparations and 985.5±45.9 ng/g
in milk-sensitized preparations and were higher (P<0.05) than control values of 640.0±123.4
ng/g. Bath application of capsaicin (1µM), substance P (SP, 0.5-2µM) or calcitonin gene-
related peptide (CGRP, 0.2µM) stimulated histamine release from all preparations. Capsaicin,
SP and CGRP-evoked histamine release from milk-sensitized and DDS-treated preparation
was elevated (P<0.05) relative to controls. Bath application of DDS (1-30µM) did not evoke
histamine release in any of the preparations. Bath application of compound 48/80 (C48/80,
200µg/ml) did not stimulate histamine release from untreated controls or milk-sensitized
preparations. Identical concentrations of C48/80 did evoke histamine release from DSS-
treated preparations from 5 guinea pigs. Electrical stimulation, applied to mesenteric nerve
trunks, interganglionic fiber tracts in the myenteric or submucosal plexus or transmurally
enhanced histamine release from DDS-treated preparations, but not from milk-sensitized
preparations. Bath application of 20-µM beta-lactoglobulin evoked histamine release from
milk-sensitized preparations and not from non-sensitized controls. Mast cell stabilization
with doxantrazole (30µM) or cromolyn (5-10 µM), but not ketotifen (20-200µM), suppressed
the action of capsaicin, SP and electrical stimulation to evoke the release of histamine. These
results support the hypothesis that enteric mast cells are a key to understanding the underlying
pathophysiology for symptoms associated with mucosal inflammation and food allergies.
(Supported by NIH RO1 DK37238, RO1 DK57075 and KO8 06468)
S2169
Synaptic Behavior in the Enteric Nervous System (ENS) of Guinea Pigs with
Experimentally-Induced Enterocolitis Or Food Allergy
Guo-du Wang, Xiyu Wang, Guijun Fei, Sumei Liu, Fie Zou, Yougin Du, Mei-hua Qu, Yun
Xia, Jackie D. Wood
Neuronal excitability and neurotransmission in the ENS of a food allergy model, induced
by ingestion of cow's milk, were compared for a non-allergic enterocolitis model induced
by ingestion of dextran sulfate-Na+ (DSS). We used intracellular “sharp” microelectrodes in
the myenteric and submucosal plexuses of guinea-pig small intestine to record synaptic
events evoked by electrical stimulation of mesenteric nerve bundles or the ENS. Ingestion
of 3% DSS for 3-5 days induced enterocolitis marked by mucosal inflammation, diarrhea,
bloody feces and body-weight loss. Electrical stimulation in the mesentery or the ENS
(0.4ms, 20Hz, 5-8mA, 5 pulses) evoked slow excitatory postsynaptic potentials (EPSP) and
associated action potential discharge in 6 myenteric S-type and 14 AH-type neurons in 6
preparations (preps) from 2 each of untreated control, milk-sensitized and DSS-treated
animals. In the submucosal and myenteric plexus, EPSPs were evoked by stimulation of the
ENS, but not by stimulation of mesenteric nerves in 18 controls, 8 milk-sensitized and 7 DSS-
treated preps. Stimulation of mesenteric nerves, with weaker stimulus parameters (0.2ms, 0.5-
2mA), evoked long-lasting EPSPs and repetitive spike discharge in 11 of (5 S-type and 6
AH-type) 16 neurons of 7 preps from 7 different DSS-treated animals. Mesenteric nerve
stimulation with weaker parameters did not evoke EPSPs in preps from 10 control and 10
milk-sensitized animals. Spontaneous spike discharge, which was never found in control or
milk-sensitized preps, was present in 7 (2 S-type and 5 AH-type) out of 16 neurons in DSS-
treated preps. Bath application of capsaicin (0.01-0.05µM), substance P (SP, 0.01-0.5µM),
calcitonin gene-related peptide (CGRP, 0.01-0.05µM) or histamine (0.05-1µM) evoked long-
lasting, concentration-dependent EPSP-like responses in 7 submucosal and 9 myenteric
neurons in preps from DDS-treated animals. These agents, in higher concentrations, also
evoked EPSP-like responses of shorter duration (P<0.05) in preps from controls and milk-
sensitized animals. Bath application of the mast cell stabilizers doxantrazole (30µM) or
cromolyn (5-10µM) suppressed the EPSPs evoked by stimulation of mesenteric nerves or
the ENS. The results support the hypothesis that firing of intraintestinal spinal afferents
releases SP and CGRP, which in turn act to stimulate release of paracrine mediators from
enteric mast cells. An overlay of mast cell mediators on the ENS elevates neuronal excitability
and facilitates slow synaptic excitation. The sensory afferent-mast cell-ENS connection
becomes hyperactive in the inflamed bowel (Supported by NIH RO1 DK37238, RO1
DK57075 and KO8 06468)
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S2170
Functional Expression of Peptide Transporter Pept1 in Mouse Enteric
Neuronal Cells
Anitha Yadav, Mallappa Anitha, Laetitia Charrier, Vanitha Bala, Bindu P. Chandrasekharan,
Shanthi V. Sitaraman, Didier Merlin, Shanthi Srinivasan
Background The peptide transporter PepT1 mediates transmembrane uptake of di- and
tripeptides and peptidomimetic drugs. Bacterial products such as N-formylated peptides
and muramyl-dipeptide (MDP), are important in the development of mucosal inflammation.
Intestinal PepT1 mediates the transport of formyl-Methionyl-Leucyl-Phenylalanine (fMLP)
and MDP into the colonic epithelial cells. Disruption of the mucosal barrier during inflamma-
tion can result in exposure of bacterial products to the enteric neurons. PepT1 expression
in neuronal cells may play an important role in inflammatory enteric neuropathy. PepT1
expression in neuronal cells has so far not been investigated. The aim of our present study
was to examine the functional expression of PepT1 in a mouse enteric neuronal cell line.
Methods Experiments were performed using a mouse enteric neuronal cell line recently
characterized in our laboratory. This cell line isolated from embryonic intestines has the
characteristics of enteric neurons including markers such as peripherin, PGP9.5 and SERT.
PepT1 expression in enteric neurons was assessed by reverse transcription polymerase chain
reaction (RT-PCR) using mouse PepT1 specific primers. Western blot analysis of PepT1
protein expression was performed on the cytoplasmic and membrane fraction of neurons
using polyclonal rabbit anti PepT1 antibody. PepT1-mediated di- and tripeptide transport
activity in mouse enteric neurons were investigated using uptake experiments of 20μM
radiolabeled (14C)-Gly- Sarcosine in the presence or absence of 20 mM unlabeled Gly-Leu
by neuronal cells at different pH. Neurons were treated with fMLP for 24 h and assessed
for PepT1 expression by RT-PCR. Results PepT1 was present in enteric neurons as seen
from immunoblot and RT-PCR analyses. The uptake of 20 μM radiolabeled (14C) Gly-
Sarcosine in the neuronal cells was reduced by about 33%, 60% and 55% at pH 5.2, pH
6.2 and pH 7.4 respectively, in the presence of 20 mM unlabeled Gly-Leu. This indicates
that PEPT1 in enteric neuronal cells partially mediates Gly-Sarcosine uptake. PepT1 activity
was optimal at pH 6.2 for the dipeptide uptake as previously shown for intestinal epithelial
cells. Interestingly, enteric neuronal cells treated with fMLP showed increased expression
of PepT1 as assessed by RT-PCR. Conclusions We report functional expression of PepT1
in mouse enteric neuronal cells which was up-regulated in the presence of fMLP. PepT1
mediated dipeptide transport may play important role in effects of inflammation on the
enteric nervous system. PepT1 may influence neuro-immune interactions and participate in
the pathophysiology of inflammatory enteric neuropathy.
S2171
Role of TRPV1 in the Efferent-Like Effect of Afferent Nerve Stimulation in the
Mouse Jejunum
Sebastien Anguille, Stefan Boeckx, Benedicte Y. De winter, Heiko U. De schepper, Paul A.
Pelckmans, Joris G. De man
Background: Afferent nerves in the gut transmit signals to the central nervous system but
also subserve a local efferent-like effect. This effect is postulated to be mediated by the
transient receptor potential of the vanilloid type 1 (TRPV1) and to play a role in the control
of intestinal motility. Aim: We studied the mechanism of the efferent-like effect of afferent
nerves in mucosa free muscle strips of the mouse jejunum using specific TRPV1 agonists
and antagonists. Results: Mouse jejunal muscle strips contracted to the TRPV1 agonists
capsaicin (0.01-10µM) and RTX (0.001-1µM). The supra-maximal contractions to 1µM
capsaicin and 10nM RTX could be induced only once confirming the irreversible tachyphyl-
axis to TRPV1 activation. The inter-animal variability of the jejunal muscle contraction was
low for the contraction to capsaicin but remarkably high for that to RTX. Capsaicin did not
affect the neurogenic contractions to electrical stimulation (1-8 Hz) of enteric nerves or the
direct smooth muscle contractions to carbachol (0.01-1µM). Tetrodotoxin, atropine or L-
nitroarginine did not affect the contractions to capsaicin. A combination of tachykinergic
NK1, NK2 and NK3 receptor blockers RP68075 (2µM), nepadutant (1µM) plus SR142801
(0.3µM) reduced the contractions to 1 µM capsaicin (from 57±6% to 18±3%, n=6) to a
similar degree as contractions to 0.1µM substance P (from 50±10% to 15±2%, n=5). The
effect of the widely used TRPV1 antagonist capsazepine was compared to that of the more
recently developed TRPV1 antagonists SB366791, iodo-resiniferatoxin (iRTX) and BCTC.
Capsazepine (1-10µM) dose-dependently inhibited contractions to capsaicin and RTX but
also significantly reduced the direct smooth muscle contractions to carbachol. SB366791
(3-10µM) slightly reduced the contractions to capsaicin but also reduced contractions to
carbachol. Independently from its concentration, iRTX (0.1-100nM) inhibited the contrac-
tions to capsaicin by ~50% without affecting contractions to carbachol. BCTC (10-100nM)
dose-dependently inhibited the contractions to capsaicin (from 49±5% to 1±1% by 100nM
BCTC, n=6) and RTX (from 32±3% to 3±3% by 100nM BCTC, n=3) without affecting the
contractions to carbachol. Conclusion:Our results suggest that activation of TRPV1 receptors
in the isolated mouse small intestine induces a contraction that is mediated by substance
P, most likely released from afferent nerve endings located near the smooth muscle. Enteric
cholinergic or nitrergic nerve pathways do not mediate the contraction to TRPV1 activation.
Of all TRPV1 blockers tested, only BCTC showed strong TRPV1 receptor selectivity without
having side effects on non-TRPV1 pathways.
S2172
Central Activation of the Cholinergic Anti-Inflammatory Pathway Reduces
Postoperative Ileus in Mice
Frans O. The, Jan Van der vliet, Wouter J. De jonge, Roelof J. Bennink, Rene M. Van den
wijngaard, Ruud M. Buijs, Guy E. Boeckxstaens
Introduction: Electrical vagal nerve stimulation activates the cholinergic anti-inflammatory
pathway reducing the manipulation induced intestinal muscle inflammation hereby
shortening postoperative ileus in mice. Previous studies in a sepsis model showed that this
pathway can be activated pharmacologically by central administration of semapimod, a p38
MAPKinase inhibitor formally known as CNI-1493. Aim: To evaluate the effect of semapimod
i.c.v. on intestinal inflammation and the subsequent postoperative ileus in mice. Methods:
Mice underwent a laparotomy (L) or intestinal manipulation (IM) 1h after pre-treatment
with 1μg/kg semapimod or saline i.c.v. Drugs were administered through a cannula placed
in the right lateral ventricle one week prior to the experiments. 24h after surgery, gastric
emptying for semi-liquids was measured using scintigraphy. Inflammation was assessed by
MPO-positive cell count in ileal muscle wholemounts. Experiments were repeated 30min
after subdiaphragmal vagotomy to assess vagal nerve dependency of this anti-inflammatory
mechanism. Values are depicted as mean ± s.e.m. P<0.05 was considered statistically signific-
ant. Results: IM significantly delayed gastric emptying 24h after surgery in saline treated
animals (gastric retention at 80min (RT80) L=3±1%, vs. IM 19±4%, p<0.05, n=8) and was
associated with inflammation of the manipulated intestine (MPO-pos. cells/mm2: L= 48±7
vs. IM= 381±27, p<0.05, n=8). I.c.v. semapimod reduced this intestinal inflammation and
improved gastric emptying (MPO-pos. cell/mm2: 227±28, p<0.05; RT80: 5±1%, p<0.05,
n=8). Vagotomy increased IM induced inflammatoin and abolished the effect of semapimod
i.c.v. (MPO-pos.cell/mm2: vagotomy-saline 540±78 vs. saline, n=8, p<0.05 and vs. vagotomy-
semapimod 440±34, n=8, p=0.2). Conclusion: Our findings show that central application
of semapimod reduces manipulation induced intestinal inflammation and shortens POI in
mice by means of the vagus nerve. From these data we conclude that the anti-inflammatory
effect of i.c.v. semapimod is mediated by activation of the cholinergic anti-inflammatory
pathway. Experiments are ongoing identifying the brain nuclei and neurons activated by sem-
apimod.
S2173
Impaired Intestinal Barrier Permeability in Irritable Bowel Syndrome: Role of
Soluble Factors
Thierry Piche, Giovanni Barbara, Philippe Aubert, Vincenzo Stanghellini, Roberto De
giorgio, Jean paul Galmiche, Michel Neunlist
Background: Recent evidence supports a role for soluble mediators released by mast cell or
bacteria origin in the pathophysiology of the irritable bowel syndrome (IBS). However,
whether these mediators can alter intestinal epithelial barrier function is currently unknown.
Therefore, the goals of this study were: to characterize the effect of soluble factors released
by the colonic mucosa of IBS patients: 1) upon intestinal epithelial barrier (IEB) permeability
in confluent Caco-2 cell monolayers and 2) on the expression of key epithelial tight junctions.
Methods: Colonic biopsies were obtained from 39 Rome II IBS patients and 14 healthy
subjects (controls). Biopsies were incubated in Hank's buffer and the released soluble medi-
ators were collected for 20 min in the supernatant (SUP). Confluent Caco-2 cells grown on
Transwell filters were incubated with SUP of IBS or controls for 48h and the following
parameters were evaluated : 1) paracellular permeability, by measurement of Dextran-FITC
flux; 2) transepithelial resistance (TER); 3) mRNA expression of key tight junction proteins
ZO-1 and occludin. In addition, expression of ZO-1 and occludin mRNA level was also
determined in colonic biopsy specimens of IBS patients and controls. Symptoms were
evaluated according to a validated questionnaire. Results: TER was significantly reduced by
48% in Caco-2 incubated with SUP of IBS compared to SUP of controls (p=0.002). The
Dextran-FITC flux across Caco-2 monolayer was significantly increased by 20% by SUP of
IBS patients compared to controls (p=0.009). In addition, the increase in Dextran-FITC flux
induced by the SUP of IBS was significantly correlated with abdominal pain severity (r=
0.46, p=0.003). Compared to controls, in Caco-2 cells, SUP of IBS patients induced a
significant decrease of ZO-1 mRNA (p=0.04). Similarly, the expression of ZO-1 mRNA was
significantly reduced in colonic biopsies of IBS patients as compared to controls (p=0.03).
In contrast, the expression of occludin mRNA was not affected either in Caco-2 cells or in
colonic biopsies. Conclusions: Our study indicates that soluble mediators from colonic
biopsies of IBS patients increase IEB permeability. This effect is at least in part mediated by
a decreased expression of ZO-1 tight junction associated protein. Further studies are now
required to identify the origin and nature of the released soluble mediators involved in
these effects.
S2174
Targeted Deletion of Neuropeptide Y (NPY) Modulates Experimental Colitis
Bindu P. Chandrasekharan, Vanitha Bala, Vasantha L. Kolachala, Matam Vijay-kumar,
Andrew Gewirtz, Shanthi V. Sitaraman, Shanthi Srinivasan
Background and aims: Neural immune regulation has recently been identified to play a
major role in the inflammatory process in IBD. We examined the role of neuropeptide Y (NPY)
in modulating inflammation in colitis. Methods: Colitis was induced by oral administration of
Dextran sodium sulphate (DSS, 3%) and Salmonella typhimurium in wild type (WT) mice
and in NPY knock out mice (NPY-/-). Inflammation was assessed by clinical score, histological
score and myeloperoxidase assay. Colonic NPY expression was assessed by reverse-transcrip-
tion polymerase chain reaction (RT-PCR) and immunofluorescence. The colonic oxidative
stress was assessed by RT-PCR of nitric oxide synthase (NOS) isoforms, nitrite levels, reduced
glutathione (GSH) levels and catalase activity. The ability of NPY to induce TNF-α production
from enteric neurons was assessed by ELISA. The functional significance of inflammation on
colonic motility was assessed by isometric muscle recording. Results: Clinical and histological
scores and MPO were higher in DSS-WT micE. colitis induced significant increase in NPY
mRNA, neuronal and inducible NOS and down regulation of endothelial NOS in WT mice.
Increased nitrite, low GSH levels and increased catalase activity indicated more oxidative
stress in WT mice. NPY- treated rat enteric neurons exhibited enhanced TNF- α production
than untreated controls. Colonic motility was impaired in WT mice but not the NPY-/-
mice. Conclusions: NPY from enteric neurons can modulate nitric oxide production, oxidative
stress and cytokine release, and modulates inflammation and subsequent disturbances in
gastrointestinal motility. Thus the study highlights the role of NPY from enteric neurons as
powerful mediators of inflammatory processes in experimental colitis.
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S2175
Effect of Human Colonic Mucosa Exposure to Lactobacillus Gg On Smooth
Muscle Cells
Michele pier luca Guarino, Simone Carotti, Annamaria Altomare, Massimo Marignani,
Carola Severi, Rossana Alloni, Lorenzo Morelli, Francesco Panzera, Roberto Coppola,
Michele Cicala
Clinical studies support the use of probiotics in the treatment of acute and chronic intestinal
disorders and diarrhea. Recent findings indicate that Lactobacillus strains modulate contractil-
ity of animal isolated tissues. Even if anti-inflammatory and immunomodulatory action of
probiotics at the mucosal level could be involved, a direct effect of probiotics at the intestinal
muscle level cannot be excluded. AIM: To define whether human colonic mucosa exposure
to Lactobacillus GG (LGG) may affect muscle cell contractility. METHODS: Human colon
was obtained from disease-free margins of resected segments for cancer. The mucosa and
submucosa, after dissection, were sealed between two chambers, with the luminal side of
mucosa facing upward and covered with 5mL of Krebs solution, and the submucosal side
facing downward into 20 mL of Krebs solution. Both chambers were oxygenated and kept
at 37°C. LGG obtained from the strain ATCC 53103 (kindly provided by Dicofarm spa
Rome Italy) or normal buffer were added to the luminal side of the mucosa and kept for
30 minutes. Smooth muscle cells (SMC), enzymatically isolated from the circular muscle
layer, were exposed for 30 minutes to buffer from the submucosal chamber of mucosa either
pre-exposed to normal buffer (n-undernatant) or to LGG (360x10<-8> CFU/mL) (LGG-
undernatant). Acetylcholine (ACh) dose-response (10<-12>to 10<-5>M) was obtained for
SMCs. Contraction was expressed as the percentage decrease in mean cell length compared
with unstimulated cells. RESULTS: SMCs exposed to n-undernatant presented a dose-
response to ACh (Maximal contraction: 32±8% with 1μM ACh) similar to unstimulated
SMCs. Exposure to LGG-buffer caused both a 18±3% cell shortening and a 78% inhibition
of Ach-induced contraction. When SMCs were directly exposed to a same dose of LGG, a
significant impairment of contraction (70±5%, compared to control cells) was also observed.
Furthermore, LGG alone significantly shortened SMCs in a dose- and time-dependent man-
ner. CONCLUSIONS: After acute exposure of colonic mucosa to LGG, a significant shortening
of SMCs is observed that might contribute to the reduced contractile response to ACh as
well as to a direct effect of LGG on colonic musculature. Further studies are needed to
establish the mechanisms involved in this effect which could account for the clinical efficacy
of probiotics in intestinal disorders.
S2176
The Effect of Inflammation On Mucosal Serotonergic Signalling in the
Intestine of Patients with Crohn's Disease
Nofel Mahmmod, Jose Ter linde, Itta Minderhoud, Bas Oldenburg, Melvin Samsom
Introduction: The strength and duration of peristaltic and secretory reflexes and transmission
of sensory signals to the CNS initiated by the action of mucosal serotonin (5-HT) is determined
by its availability to 5-HT receptors on peripheral terminals of primary afferent neurones.
5-HT availability is affected by the rate of 5-HT synthesis and uptake. Tryptophan hydroxylase
(TPH)-1 catalyzes the rate-limiting step in the 5-HT biosynthetic pathway. Uptake is mediated
by the 5-HT specific transporter SERT. In animal models of intestinal inflammation SERT
expression is decreased. Reduced expression of TPH-1 and SERT has also been detected in
colonic mucosa from patients with ulcerative colitis. Recently, we found elevated mucosal
TPH-1 levels in the colon of Crohn's disease (CD) patients in remission with Irritable Bowel
Syndrome (IBS)-like symptoms compared to those without IBS-like symptoms. Aim: To
determine the effect of inflammation on mucosal 5-HT signalling in ileum and colon of CD
patients. Methods: Paired mucosal biopsies (macroscopically inflamed and non-inflamed
from the same region) were collected from the ileum or colon of 10 and 12 CD patients
respectively. The mRNA levels of TPH-1 and SERT were quantified by real-time RT-PCR.
For normalization the two reference genes b-actin and PBGD were measured. Results:
Regional comparison revealed that SERT expression was significantly higher in the ileum
than the colon (p<0.001). The relative difference was 680-fold for non-inflamed mucosa.
For inflamed mucosa this regional difference was about 60 times higher. TPH-1 expression
only appeared to be significantly higher (2-fold) in the ileum for non-inflamed mucosa after
normalization against PBGD (p=0.01). Comparison of the paired biopsies for each patient
showed that SERT expression was significantly lower for inflamed mucosa irrespective of
the region (ileum 5-fold, p=0.01; colon 320-fold, p=0.005). Furthermore, TPH-1 expression
was found to be reduced in the inflamed mucosa of the ileum compared to non-inflamed
mucosa. This difference reached statistical significance after normalization against PBGD
(1.9-fold, p=0.01). Inflammation had no significant effect on TPH-1 expression in the colon.
Conclusion: We report significant changes in components of 5-HT signalling for inflamed
mucosa in comparison with non-inflamed mucosa within the same CD patient. These
inflammation induced changes may play a role in the secretomotor and sensory disturbances
in the intestine of patients with CD.
S2177
Inflammation-Induced Synaptic Facilitation in the Guinea Pig Colonic
Myenteric Plexus Does Not Involve Changes in Synaptic Contact Density
Eric Krauter, Keith A. Sharkey, Gary M. Mawe
Gastrointestinal motor function involves precise coordination of motor activity by enteric
neural reflexes. As inflammation is associated with motor dysfunction, we have investigated
the properties of colonic myenteric neurons in colitis, and determined that synaptic events
are augmented due to increased transmitter release from nerve terminals (Linden et al., J
Physiol 547:589-601, 2003; Krauter et al., DDW 2005). Colitis is also associated with a
loss of 20 percent of myenteric neurons (Linden et al., Neurogastroenterol Motil 17:751-
760, 2005). Therefore, we evaluated whether the density of synaptic inputs to the remaining
neurons is increased in colitis due to a rearrangement of the neuropil. Synaptic terminals
directly adjacent to myenteric neuronal cell bodies were evaluated with transmission electron
microscopy in tissue from control guinea pigs and six days after trinitrobenzene sulfonic
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(TNBS) acid administration. Montages of neuronal surfaces were obtained from 31 neurons
(n=15, control; n=16, inflamed) from 8 control and 8 TNBS-treated guinea pig colons.
Neurons were identified by nuclear appearance and size, and synaptic contacts were recog-
nized by membrane bound structures containing vesicles directly apposing neuronal mem-
branes. All micrographs were analyzed using MetaMorph software. No difference was detected
between control and inflamed tissue in the percent of the total membrane of each neuron
covered by presynaptic nerve terminals (control, 16.6 ± 2.3%; inflamed, 13.6 ± 1.5%; p >
0.2, unpaired t-test). Furthermore, no differences were detected in the number of synaptic
contacts per micrometer (control, 0.21 ± 0.03/µm; inflamed, 0.17 ± 0.02/µm; p > 0.2,
unpaired t-test) or in the average area of each discernable nerve terminal (control, 83,780
± 70,970 nm2; inflamed 136,700 ± 88,580 nm2; p > 0.6, unpaired t-test) between groups.
These data suggest that inflammation-induced synaptic facilitation does not involve an
increase in the number of synaptic contacts per neuron but due to changes within preexisting
nerve terminals, which lead to enhanced transmitter release. Supported by NIH grants
DK62267, NS26995 (GMM), and Ruth L. Kirschstein National Research Service Award F31
NS055512-01 from NINDS (EMK)
S2178
Alterations in Rat Mucosal Mast Cell-Nerve Contacts Following Multiple
Infection with Nippostrongylus Brasiliensis
Elaine Fraser, Jennifer Whiteley, Kirk Hillsley, Ronald H. Stead
Background: The relationship between mast cells and nerves in the gastrointestinal tract has
been shown to be a factor in irritable bowel syndrome (IBS). Nippostrongylus brasiliensis (Nb)
infection has been reported to cause mast cell hyperplasia and hyperinnervation of the GI
tract. The aim of this study was to determine if similar effects are observed after a single
and multiple Nb infections in the rat GI mucosa. Methods: Male Lewis rats were infected
with 3000 L3 Nb larvae once or five times at 5 week intervals. Sham infected and naïve weight-
matched animals were used as controls. Jejunal segments were removed from euthanized rats
at 28 - 42 days post infection and fixed in acetic acid / alcohol prior to paraffin embedding.
Sections from single (sham n = 9, infected n = 8) and multiple (sham n = 5, infected n =
4) infected animals were cut, processed and stained with Alcian blue (mast cells) and GAP-
43 (nerves). The number of mast cells and nerves were counted using QWIN software
(Leica); and the number of mast cell-nerve contacts were assessed manually by a blinded
researcher. Data are expressed as mean ± SEM of 20 villi / animal and a two-tailed t-test
was used for statistical analysis. All data are reported as control vs. infected. Results: The
mean number of mast cells / villus was significantly increased following both single (4.9 ±
0.2 vs. 21.4 ± 2.7, p < 0.001) and multiple infection (4.2 ± 0.6 vs. 15.8 ± 2.2, p < 0.01).
There was a significant increase in the number of mast cell-nerve contacts per villus in both
single (2.4 ± 0.2 vs 13.8 ± 2.1, p < 0.001) and multiple infected animals (2.4 ± 0.2 vs 11.3
± 2.1, p < 0.01). The only difference observed between single and multiple infections was
that there was a significant increase in the number of nerves after multiple infection (27.1
± 3.0 vs. 44.8 ± 5.7, p < 0.05) which was not statistically different after a single infection
(29.8 ± 3.8 vs. 38.8 ± 3.8, p = 0.12). Conclusions: These data confirm that there is mast
cell hyperplasia and an increase in the number of nerve-mast cell contacts in the GI mucosa
following Nb infection. These parameters are increased in both single and multiple infected
animals. However, the hyperinnervation is only significantly increased in multiple infected
animals. These data indicate that repeated infections result in greater neural plasticity, but
that mast cell hyperplasia is not any greater than that observed with a single infection.
Modulation of mast cell-nerve contacts is likely to impact on mucosal function and could
be a contributing factor in functional or inflammatory intestinal disorders.
S2179
Altered Proliferation and Cytokine Secretion of Peripheral Blood Mononuclear
Cells in Response to Bacterial and Polyclonal T Cell Stimulation in Patients
with Irritable Bowel Syndrome
Lena Ohman, Ann-charlotte Lindmark, Stefan Isaksson, Iris Posserud, Hans Strid,
Magnus Simren
AIM: Several observations implicate that IBS may, in at least a subpopulation, be an inflammat-
ory disorder. We have therefore investigated blood immune cells responding ability to
bacterial and polyclonal T cell stimulation of IBS patients as compared to controls. METHOD:
Blood samples were taken from 30 healthy subjects (mean age 39±10) and 74 IBS patients
(mean age 34±16), defined by the Rome II criteria. Of the IBS patients 26 had predominantly
diarrhoea (IBS-d), 11 predominantly constipation (IBS-c) and 37 alternating diarrhoea and
constipation (IBS-a). Peripheral blood mononuclear cells (PBMC) were isolated and the cells
were either unstimulated or stimulated with a cocktail of probiotics (L. casei, L. acidophilus,
B. infantis) or with CD3/CD28 antibodies. The cell proliferation and cytokine secretion
were analysed after 72 hours. RESULTS: The proliferation of PBMC from IBS patients
(258±264cpm) stimulated with bacteria was decreased relative to control subjects
(383±305cpm) (p=0.03). Dividing the IBS patients into subgroups revealed that PBMC of
IBS-a (p=0.05) and IBS-c (p=0.02) patients, but not IBS-d patients, proliferated less well in
response to bacterial stimulation. Stimulation with anti-CD3/CD28 resulted in decreased
proliferation of all IBS subgroups (99822±41935cpm) as compared to controls
(137303±24263cpm) (p<0.0001). The cell proliferation of unstimulated PBMC was compar-
able in IBS patients and controls. Cytokine analysis of unstimulated PBMC showed that IBS
patients secreted less amount of the proinflammatory cytokine IFN-γ (26±16 vs 131±80 pg/
ml)(p< 0.0001) and the anti-inflammatory cytokine IL-10 (98±78 vs 210±170 pg/ml)(p=
0.005). The unstimulated PBMC of all IBS subgroups secreted less IFN-γ, whereas the
decreased IL-10 secretion was only found in IBS-a (p=0.003) and IBS-d (p=0.007) patients.
PBMC from IBS patients stimulated with bacteria secreted less IFN-γ (4478±1321pg/ml)
than the controls (6529±4259 pg/ml)(p=0.004), whereas the IL-10 secretion in response to
bacteria stimulation was comparable in IBS patients and controls. Subgroup analysis of the
IFN-γ secretion of bacteria stimulated PBMC showed that IBS-a (p=0.001) and IBS-c (p=
0.01), but not IBS-d patients, had a decreased IFN-γ secretion compared to controls. The
stimulation of PBMC with anti-CD3/CD28 did not lead to any altered IFN-γ or IL-10 secretion
of IBS patients as compared to controls. CONCLUSION: IBS patients have a changed basal
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immune activity of PBMC and an altered immune response to bacterial and polyclonal
stimulation as compared to control subjects. Furthermore, the immune response of PBMC
to bacterial stimulation differs between the IBS subgroups.
S2180
Prior Inflammation Exacerbates the Effects of Subsequent Psychological Stress
On Colonic Damage, Mast Cell Numbers and Bacterial Load
Olga I. Santiago, Marielly Cuevas, Caroline B. Appleyard
Stress has been associated with the exacerbation of symptoms in functional gastrointestinal
disorders such as Irritable Bowel Syndrome (IBS). Previous enteritis infection and changes
in intestinal microflora may also contribute to the low grade mucosal inflammation often
found in IBS patients. AIM: To measure the effects of previous intestinal inflammation on
subsequent stress-induced changes in colonic damage, mast cell numbers and bacterial load.
METHODS: Four groups of female rats were used: normal (untreated); control-WAS (water
avoidance stress), where animals received stress alone; control-colitis, where animals received
trinitrobenzene sulfonic acid (TNBS 30mg in 50% ETOH ic) to induce an acute colitis which
was then allowed to heal for 2 weeks; and colitis-WAS, where the animals received TNBS
as above, then were subjected to WAS 2 weeks later. WAS was induced by placing the
animals on a raised platform in a plastic container filled with water. The stress protocol
consisted of 3 hrs of stress per session, during 3 consecutive days. All animals were evaluated
for weight change, presence of diarrhea, propulsive and myeloperoxidase (MPO) activity,
macroscopic and microscopic damage, and mast cell counts. Colonic tissue samples were
inoculated on Blood agar, MacConkey agar and lactobacillus agar.RESULTS: Stress increased
weight loss in animals that previously had colitis compared to controls (p<0.05). These
animals developed anxiety-like behaviour demonstrated by a decrease in locomotion and
grooming, and also had greater colonic propulsive activity. Stress also increased mast cell
numbers, MPO levels and significantly increased both the macroscopic and microscopic
damage in the colitis tissues compared to non-stressed controls (p<0.05). WAS in animals
which did not have previous inflammation did not cause significant changes in macroscopic
or microscopic damage, MPO levels, or mast cells. These animals did however show increased
colonic propulsive activity (p<0.05) and more weight loss (p<0.05) compared to normal.
There were no significant changes in bacterial load in stressed animals which previously
had inflammation, however all groups had a higher bacterial load than normals. CONCLU-
SION: Prior inflammation increases the susceptibility of the colon to respond to subsequent
psychological stress, resulting in altered motility, increased damage and the infiltration of
immune cells. These animals had a higher bacterial load which was not significantly altered
by the subsequent exposure to stress. Supported in part by NRSA from NIDDK/NIGMS and
2G-12RR03050.
S2181
Gender Determines a Differential Epithelial Response to Stress in the Healthy
Gut
Carmen Alonso, Mar Guilarte, María Vicario, Laura Ramos, Ziad Ramadan, Cristina
Martínez, Esteban Saperas, Sunil Kochhar, Javier Santos, Juan-r. Malagelada
Epithelial dysfunction is a key factor in the generation of gut mucosal inflammation, a
frequent feature of patients with Irritable bowel syndrome (IBS). IBS is highly prevalent
among women, but the mechanisms of increased women susceptibility to IBS, other than
stress-sensitivity and differences in the central processing of visceral stimuli, have not been
elucidated. Aim: to investigate whether epithelial dysfunction is gender-related. Methods: a
closed 20-cm jejunal-segment perfusion was performed in 19 healthy volunteers, with low
but similar levels of chronic psychological stress (Holmes-Rahe scale). After 30 min of
equilibration, intestinal effluents were collected every 15 min, for 30 min under basal
conditions and for 1h after 15 min of intermittent cold pain stress. Throughout the study,
gut epithelial responses including net water flux, macromolecular permeability to albumin
and luminal osmolality were measured along with autonomic (blood pressure and heart
rate), hormonal (plasmatic ACTH) and psychological responses (Subjective Stress Rating
Scale) to cold stress. Results: Ten men (M) and nine women (F) with a mean age of 22±0.8
and 23.7±6.2 years (p=ns) were included. Cold pain stress increased heart rate (Δ M:9.8±11;
F: 9.8±9 beats/min, p<0.05 vs basal), blood pressure (Δ M:18.4±8.1; F: 13±11.8 mmHg,
p<0.05 vs basal) and ACTH (Δ M:11.8±7.2; F:10.2±6.7 pg/mL, p<0.005 vs basal) similarly
in both groups. This autonomic activation was associated with an increase of the levels of
acute stress experienced by participants (Δ M: 1.8±1; F: 0.95±1, p<0.05 vs basal). Basal net
water flux (M: 59.2±51;F: 48.7±64 µL/min/cm, p=ns) and epithelial permeability (M: 1±0.9;
F: 0.7±0.6 mg/15min, p=ns) were similar in men and women. In contrast, a remarkable
enhancement of both secretory response (Δ M: 29.7±50.3; F: 71±97 µL/min/cm; p<0.05 vs
F basal) and epithelial permeability (Δ M: 0.2±0.1; F: 1±0.9 mg/15min; p<0.05 vs F basal)
after cold stress was observed only in the female group without changes in luminal osmolality.
Conclusions: Healthy women display hyperreactive epithelial responses to incoming stimuli
in the jejunum, a mechanism that may contribute to female oversusceptibility to IBS .
S2182
Mast Cell Stabilization As Treatment of Post-Operative Ileus: A Clinical Proof
of Principle Study
Frans O. The, Marrije R. Buist, Aaltje Lei, Roelof J. Bennink, Jan Hofland, Rene M. Van
den wijngaard, Wouter J. De jonge, Guy E. Boeckxstaens
Background: Postoperative ileus in mice is mediated by intestinal inflammation resulting
from handling-induced mast cell activation. Therefore, mast cell stabilization may represent
a new therapeutic approach to shorten postoperative ileus. Aim: To study the effect of
ketotifen, a mast cell stabilizer, on postoperative gastrointestinal transit. Methods: In this
pilot study, 60 patients (age 27-77yrs) undergoing major abdominal surgery for gynecological
malignancy were randomized (double blinded) to treatment with ketotifen (4 or 12mg) or
placebo. Patients were treated for 6 days starting 3 days prior to surgery. Gastric emptying
for liquids and colonic transit were measured at 24, 48 and 72hrs after surgery using
scinitgraphy. Colonic transit was represented as geometrical centre of activity (segment 1=
cecum to 7= stool). Gastric retention (1hr after intake of 40ml radiolabeled H2O) measured
24hr after surgery was selected as primary outcome. Secondary endpoints were colonic
transit and abdominal symptoms. Data are expressed as median (interquartile range) and
p<0.05 was considered statistically significant. Results: Gastric retention 1hr after liquid
intake was significantly reduced by 12mg (median 3% (1-7), p=0.01), but not by 4mg
ketotifen (18% (3-45), p=0.6) compared to placebo (16% (5-75)). The 48-72hr post-surgical
colonic transit in placebo was 0.8 (0.0-1.1) vs. 1.2 (0.2-1.4) colon segments in 12 mg
ketotifen group (p=0.07). Abdominal cramps improved significantly in patients treated
with12mg ketotifen, whereas time to first flatus, bowel movement, solid food intake and
ready for discharge were not affected. Conclusion: Ketotifen significantly improves gastric
emptying and showed a tendency to improvement of colonic transit after abdominal surgery.
These results warrant further exploration of mast cell stabilizers as putative therapy for
postoperative ileus.
S2183
Slowed Small Intestinal Transit Is Associated with Bacterial Overgrowth in the
Cystic Fibrosis Mouse
Robert C. De lisle
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) has been reported to occur in
40-60% of cystic fibrosis (CF) patients and it may play an important role in the gastrointestinal
complications of CF including failure-to-thrive. SIBO occurs in the CF mouse and its
eradication with broad spectrum antibiotics improves body weight gain. A known cause of
SIBO is altered GI motility, and this was explored in the CF mouse. METHODS: CF
(cftrtm1UNC) mice and wild type (WT) littermates congenic on the C57Bl/6 background of
both sexes were used between 6 and 12 weeks of age. Mice were maintained on a liquid diet
(Peptamen) with or without broad spectrum antibiotics (ciprofloxacin and metronidazole), or
on solid chow with Colyte (PEG-based osmotic laxative) in the drinking water. Bacterial
load in the small intestine was measured by quantitative PCR for the bacterial 16S rRNA
gene. Gastric emptying and small intestinal transit were assessed in overnight fasted mice
by measuring the distribution of rhodamine-dextran along the GI tract 20 min after gavage
into the stomach. RESULTS: Gastric emptying under all tested conditions was not signific-
antly different comparing CF to WT mice. In contrast, on the Peptamen diet, small intestinal
transit was significantly less in CF mice compared to WT. When Peptamen-fed mice were
treated with antibiotics small intestinal transit in WT mice was significantly reduced, but
transit was not significantly affected in CF mice. When treated with Colyte, small intestinal
transit in CF mice was normalized and bacterial overgrowth was eliminated. Also, CF mouse
body weight gain was improved with Colyte treatment. CONCLUSIONS: Small intestinal
transit was significantly slower in untreated CF mice and this is likely the major cause of
SIBO in these animals. Although eradication of SIBO with broad spectrum antibiotics
improves body weight gain, it did not correct small intestinal transit in CF mice. In fact,
antibiotics slowed transit in WT mice and this result is consistent with the reported slower
intestinal transit in germ-free rats. Treatment of CF mice with Colyte normalized small
intestinal transit, eliminated SIBO, and significantly improved body weight gain. The current
results emphasize the bidirectional interplay between microflora and the intestine that affects
GI motility. Eradication of SIBO, with or without normalization of intestinal transit, improves
the failure-to-thrive syndrome of CF mice, which demonstrates the importance of the
intestinal microbial ecology in healthy GI function in cystic fibrosis.
S2184
Immune Activation of Intestinal Mucosa in Irritable Bowel Syndrome
Mi young Do, Chang hwan Choi, Su yeon Rhie, Seong hyun Lee, Hyung joon Kim, Jung
uk Kim, Jae kyu Kim, Sae kyung Chang, Sil moo Park, Tae jin Lee
Background/Objectives: The aims of this study were to investigate immune activation of
intestinal mucosa and to evaluate the relationships between the immune activation and the
clinical features in irritable bowel syndrome (IBS). Methods: Forty-four IBS patients satisfying
the Rome II criteria and 25 asymptomatic controls were included. IBS patients were inter-
viewed by using a questionnaire comprising demographic features and IBS symptoms.
Colonosopic biopsy specimens were collected in triplicate from the descending colon and
rectum. H-E stains, immunohistochemical stains for CD3+ lymphocytes, and Toluidine blue
stains for Mast cells were performed. Intraepithelial CD3+ lymphocytes (IE-CD3+) and
lamina proprial CD3+ lymphocytes (LP-CD3+) were enumerated as CD3+ cells per 300
epithelial cells and 300 lamina proprial cells, respectively. Mast cell numbers in lamina
propria were calculated per square millimeter. Results: Mean ages of IBS patients and controls
were 41.4±13.1 and 50.7±13.0 years. The ratio of male to female in IBS patients and controls
were 17:27 and 13:12, respectively. Among the subtypes of IBS, diarrhea predominant was
54.6%, constipation predominant was 15.9%, and mixed was 29.5%. The means of IE-
CD3+ cell, LP-CD3+ cell and Mast cell counts in the descending colon and rectum were
significantly increased in patients with IBS than controls, respectively by ANCOVA test
(Table 1). The LP-CD3+ cell numbers in descending colon and rectum were significantly
increased in female IBS patients than male patients, but the others were not different according
to gender. The numbers of CD3+ cells and Mast cells were not different in terms of the
subtypes of IBS. The Mast cell numbers in descending colon were significantly correlated
with several IBS symptom such as hard stools, straining, incomplete evacuation, bloating,
but the others were not correlated with the symptom severities. Conclusions: The numbers
of CD3+ lymphocytes and Mast cells in the intestinal mucosa were significantly increased
in IBS patients than normal subjects, implicating the immune activation of intestinal mucosa
in pathogenesis of IBS.
Table1. Mucosal CD3+ cells and mast cell counts.
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S2185
Duodenal 25-Hydroxyvitamin-D-1-Alpha-Hydroxylase May Influence Human
Calcium Absorption
Julian R. Walters, Sara Balesaria, Vivienne Taylor, Konstantia-maria Chavele
Background:Absorption of dietary calcium in the intestine is essential for bone mineralization
and the prevention of osteoporotic fractures. Vitamin D is important in the regulation
of calcium absorption and the principal hormonal metabolite 1,25-dihydroxyvitamin D
(1,25(OH)2D3) stimulates expression of transporter molecules including the apical calcium
channel TRPV6. However studies of calcium absorption have also shown significant correla-
tions with 25-hydroxyvitamin D (25OHD), the main storage metabolite. This is converted
to 1,25(OH)2D3 by 25-hydroxyvitamin D 1-alpha-hydroxylase (1aOHase), CYP27B1, expre-
ssed in kidney but also shown to be in other vitamin D target tissues. There have been no
previous studies of 1aOHase in small intestine. We aimed to see whether intestinal 1aOHase
could be a factor affecting calcium absorption. Methods: Duodenal biopsies were obtained
at endoscopy from fasting volunteers aged 24-80. Subjects with significant diseases were
excluded. Blood samples were taken to measure vitamin D metabolites. In some experiments,
biopsies were incubated in groups of 2-4 in tissue culture medium for 6h with 1,25(OH)2D3,
25OHD or vehicle control. RNA was prepared and gene expression determined by quantitative
real time RT-PCR (Taqman) normalized to GAPDH transcript values. Results: Transcripts
of 1aOHase were detected in duodenum where expression levels and those of TRPV6 were
strongly associated (r=0.72, p<0.001). This relationship was found in both men and women
and was as strong, or stronger, respectively than that of plasma 1,25(OH)2D with TRPV6.
Stepwise multivariate analysis indicated that 1aOHase expression and 1,25(OH)2D (both
p<0.001) were the principal associations with TRPV6 expression. Immunohistochemistry
using a well-characterised antibody confirmed 1aOHase expression in duodenal mucosa.
Evidence that this enzyme could be producing 1,25(OH)2D3 came from experiments where
biopsies incubated with 25OHD (10-7M) had similar induction of TRPV6 and other transcripts
as those incubated with 1,25(OH)2D3 (both medians 2.4-fold). The magnitude of the increase
correlated with the expression level of 1aOHase (r=0.82, p=0.02). Conclusions: Expression
of 1aOHase in duodenal mucosa has been demonstrated and is closely associated with
expression of TRPV6. Local production of 1,25(OH)2D3 from 25OHD may have important
effects on human calcium absorption.
S2186
Effect of Long Term Over-Supplementation with Folate On the Vitamin Uptake
By Human Intestinal and Renal Epithelial Cells
Ashokkumar Balasubramaniem, Zainab M. Mohammed, Nosratola D. Vaziri, Hamid M.
Said
Background: Folate plays an essential role in cellular metabolism and its deficiency leads to
a variety of clinical abnormalities including neural tube defects and megaloblastic anemia.
Optimization of folate body homeostasis on the other hand significantly reduces the incidence
of neural tube defects, and may also afford a decrease in the risk of Alzheimer's disease and
protects against certain types of cancer (e.g., colorectal cancer). Because of the many beneficial
effects of folate, all grain products are currently fortified with the vitamin and to be pregnant
women are put on folate supplementation. In addition, consumption of nutritional drinks
and bars that are over-supplemented with folate is on the rise. The effects of long-term
over-supplementation with folate on physiological parameters of the intestinal and renal
folate uptake processes, however, are not known and were examined here. Methods: Both
the human-derived intestinal (Caco-2) and renal (HK-2) epithelial cells were used in this
study and were maintained for 5 generations in a growth medium over-supplemented with
folate (100 μM). Findings were compared to cells maintained under folate-sufficient condition
(0.25 μM) (as well as those maintained under an intermediate folate concentration of 9
µM). Results: Carrier-mediated uptake of 3H-folic acid (2 μM) at buffer pH 5.5 (but not
buffer pH 7.4) by Caco-2 cells maintained under folate over-supplemented condition, was
significantly (P < 0.01) lower than in cells maintained under folate-sufficient condition as
well as those maintained under an intermediate folate concentration of 9 µM (0.97 ± 0.11,
1.28 ± 0.07 and 1.52 ± 0.04 pmol/mg protein/7 min respectively). The same trend was
seen with HK-2 cells (0.36 ± 0.09, 0.58 ± 0.08 and 0.85 ± 0.09 pmol/mg protein/7 min
in over-supplemented and sufficient conditions respectively). The decrease in folic acid
uptake by the folate over-supplemented Caco-2 and HK-2 cells was associated with a
significant decrease in the protein and mRNA levels of the human reduced folate carrier
(hRFC) as well as in the level of activity of the hRFC promoter. We also determined the
effect of folate over-supplementation on the steady state mRNA levels of the folate receptor
(FR) in HK-2 cells and found the level to be significantly lower than that of cells maintained
in folate-sufficient growth medium. Conclusions: Long-term over-supplementation of folate
leads to a specific down-regulation in intestinal and renal folate uptake, which appears to
be (at least in part) mediated via transcriptional mechanism(s) involving the hRFC gene.
[Supported by grants from the NIH and the DVA]
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S2187
Egcg, a Green Tea Catechin, Reduces Pro-Inflammatory Cytokine Production
and Induces Apoptosis in Human Peripheral Blood Monocytes (PBMCS) from
Normal Volunteers As Well As Inflammatory Bowel Disease (IBD) Patients
Hassan H. Qazzaz, Mark W. Linder, Rafael Fernandez-bortan, Craig J. Mcclain, Gerald W.
Dryden
Introduction: Interest in green tea polyphenols (GrTP) has increased, due to anti-inflammat-
ory, pro-apoptotic and multiple other effects on mammalian cells. Of the components
of green tea, (-)-epigallocatechin-3-gallate (EGCG), a potent anti-inflammtory compound,
constitutes 40% of the polyphenolic fraction of green tea. Aim: In order to evaluate the
potential of GrTP for use in treating chronic inflammatory bowel diseases, we examined the
ability of EGCG to inhibit the production of pro-inflammatory cytokines and to induce
apoptosis in human PBMCs In Vitro, in the presence or absence of lipopolysaccharide (LPS).
Methods: PBMCs were pre-incubated for 1hr in the presence of increasing concentrations
of EGCG (0-125 ng/μl) prior to incubation for 16 hrs with 10 ng/mL LPS. The anti-
inflammatory effect of EGCG was measured by the reduction of TNFα production, as a
representative cytokine, in LPS-stimulated cells. The effect of ECGC on apoptosis of LPS-
activated PBMCs was measured by Annexin V-FITC/PI (propidium iodide) staining. UV light
exposure was used as a positive control for apoptosis studies. Results: In the absence of
EGCG, LPS increased TNFα production from a mean of 186 pg/ml to 503 pg/ml. Pre-
treatment of cells with increasing concentrations of EGCG (5-125 ng/μl) proportionally
reduced TNFα production by 20%, 33%, 38%, and 45% at 5, 25, 50, and 125 ng/μl EGCG,
respectively. Reductions in TNFα production were not due to a reduction in cell culture
viability, as assessed by mitochondrial reduction of MTT. EGCG increased apoptosis in a
concentration dependent fashion from 1.5% in untreated cells to 55% at the highest concen-
tration. The reduction of cytokine levels seen was similar between normal volunteers and
IBD patients. Discussion: This study demonstrates the anti-inflammatory effect of EGCG on
TNFα production by human PBMCs, and the ability of EGCG to induce apoptosis in LPS-
stimulated human PBMCs from both normal volunteers and IBD patients. In light of the
fact that PBMCs constitute a main source of pro-inflammatory cytokines in inflammatory
bowel disease, we will proceed to investigate the effects of EGCG In Vitro and In Vivo on
mucosal tissue macrophages from humans with IBD. [Work supported by K23 DK073750-
02 (GWD), K23 AA014235 (MWL)]
Effect of EGCG on TNFα Production +/- LPS
S2188
Maintenance of Serum Vitamin B12 Levels By Daily Intranasal Administration
of Cyanocobalamin in Saline, P0203
Mark S. Dykewicz, Deborah Keaney
BACKGROUND: Pernicious anemia and other gastrointestinal tract disorders can impair
absorption of vitamin B12 (B12) and lead to deficiency that requires replacement, most
commonly administered by intramuscular (IM) injection. OBJECTIVES: Determine if daily
intranasal (IN) administration of cyanocobalamin maintains normal serum B12 levels in
subjects with B12 deficiency who have previously required IM injections of B12. METHODS:
Subjects had a history of documented vitamin B12 deficiency and normal serum B12 levels
during IM B12 replacement. In this open label trial, subjects discontinued IM B12 and self-
administered IN P0203 (cyanocobalamin in physiological saline, Fleming & Co. Pharmaceut-
icals), 1 puff in each nostril once daily (50 mcg) for 8-weeks treatment. Blood monitoring
was obtained at visits every two weeks during treatment. Serum B12 levels were the primary
efficacy endpoint, with exploratory endpoints being serum levels of homocysteine and
methylmalonic acid (elevated levels being associated with physiologic B12 deficiency). Safety
was measured by adverse events (AEs), clinical laboratory tests, and physical examination.
Post study patient assessment of the product was evaluated by a product assessment question-
naire. Data from 25 evaluable subjects were analyzed. RESULTS: P0203 nasal spray was
effective at maintaining serum B12 levels. For primary efficacy analysis, the mean ratio of
B12 levels during IN P0203 treatment to levels during IM B12 treatment was 1.15 (90%
CI 1.06, 1.24), statistically significant (p=0.0096). Methylmalonic acid levels were somewhat
decreased at end P0203 treatment, consistent with the overall mean increases in B12 levels.
Intranasal P0203 had no impact on homocysteine values. One AE was possibly related to
the study drug, a mild nosebleed that resolved with no action taken. Patient satisfaction
with IN P0203 was high, with 68% of subjects “definitely” and 12% “probably” willing to
take IN P0203 in place of IM B12. CONCLUSIONS: Once daily administration of P0203
nasal spray maintained therapeutic vitamin B12 levels in all patients at all treatment visits
with high tolerability and safety. Mean serum B12 levels with IN P0203 treatment were
slightly higher than during IM B12 treatment. Many patients preferred IN P0203 to IM
B12 injections.
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S2189
Vitamin D Levels in Patients Presenting to a Gastroenterology Clinic
Barbara Hoeroldt, P. Basumani, M. Srinivas, A. Ali, R. Ellis, P. Willemse, K. D. Bardhan
Background & Aim Vitamin D deficiency is associated with non-specific symptoms, carries
long-term risk to bone health, and certain groups are at higher risk (alcohol excess, old age,
Asians). The prevalence amongst patients attending gastroenterology clinics is unclear; this
prompted our pilot study. Methods Patients 1. 165 patients randomly chosen: Alcoholic
liver disease - ALD (24), Inflammatory bowel disease - IBD (41), Irritable bowel syndrome
- IBS (52), other liver disease (17), other diagnosis (31). 2. 27 patients with exocrine
pancreatic insufficiency (EPI). Use of OTC supplements was checked and those on vitamin
preparations excluded. Measurements Vitamin D [1,25-(OH) Vitamin D3], calcium profile,
magnesium, ferritin, B12, folate. Demography: 98 females; 11 Asian. Median age 55 (18-
86) years. Results (1) Only 37.5 % had normal levels. (2) Severe deficiency was most frequent
in ALD (54%), EPI (41%), other liver disease (23%) and IBD (24%) (30% overall). Mild-
Moderate deficiency occurred in similar frequency ALD (29 %), EPI (33 %), other liver
disease (32%) and IBD (44 %), but also in IBS (25%). (3) Severe/moderate deficiency
occurred significantly more often Asians (p=0.0193) but was unrelated to age (p=0.6047)
or sex (p= 0.5161) (Fisher's exact test). (4) 12%, 14% & 14% of 121 tested were deficient
in folate, Vit B12 & iron (often associated with normocytosis, excluding patients referred
with Iron Deficiency Anaemia). (5) No patient had toxic Vit D levels. Conclusions (1)
Vitamin D deficiency is common in patients attending gastroenterology clinics, is almost
always subclinical and its long-term significance is unknown. (2) Increasing awareness has
allowed us to recognise the condition more often.
Vitamin levels by patient group
S2190
Nutritional Intervention to Prevent Septic Shock Syndrome in Rat Model
Helieh S. Oz, Willem J. De villiers, Theresa Chen
Sepsis and septic shock syndrome are the major causes of multiple organ failure and death
in GI complication and critically ill patients. LPS released by the colonic baceria translocates
across a compromised lumen leading to upregulated ROS and sepsis. The long chain polyun-
saturated fatty acids, eicosapentaenoic (EPA) and docosahexaenoic (DHA) have been associ-
ated with a reduced production of proinflammatory eicosanoids in the modulation of the
inflammatory response. We hypothesized a nutritional formula rich in EPA-DHA, cysteine
and prebiotic fructooligosaccharides (FOS) would protect against LPS-induced multiorgan
inflammatory syndrome. Methods: Young rats received rat diet (CHOW); whey-peptide-
based liquid diet rich in cysteine, FOS and EPA-DHA (CYSPUFA); or a casein-based liquid
diet, low in cysteine, devoid of FOS and EPA-DHA (CASN). CYSPUFA and CASN diets
provided 25% of calories as protein. Food, water intake and body weight were monitored
daily. After 6 days on respective diets, rats were injected IP with LPS or sham and injected
subQ with ringer to prevent dehydration. Animals were euthanatized at 0, 4h and 18h after,
blood and tissue samples from lung, heart and liver collected. Results: Rats gained weight
on the respective diets and lost weight after LPS administration. Animals tolerated LPS and
survived after 18h. CYSPUFA group gained more weight and lost considerably less weight after
LPS injection (vs CASN<0.01). Inflammatory cytokines (TNF, INF-γ, IL-6) were significantly
upregulated only 4h after LPS administration. Rats developed mild to modrate cardiac and
pulmonary pathology. Rats on CASN showed upregulated liver enzyme ALT, marker of
hepatocyte injury, developed severe hepatic pathology, and became anemic. Rats on CHOW
developed more severe hepatic lesions compared to those on liquid diets. CYSPUFA group
had improved hematocrit levels compared to those allocated to other diets. IL-10 (anti-
inflammatory cytokine) significantly increased after 4h in rats on lipid diets and remained
high 18h after in the CYSPUFA group. Concentration of ALT, and hepatic pathology were
improved in those received CYSPUFA (vs CASN <0.05). The hepatic concentration of
antioxidants, GSH and SAMe increased in rats on liquid diets compared to CHOW measured
by HPLC. However, interhepatic levels of cysteine, adenosine and GSSG were markedly
improved in rats on CYSPUFA compared with CASN (<0.05). Conclusions: These data
indicate that CYSPUFA, the whey-peptide-based liquid diet rich in cysteine, FOS and EPA-
DHA protected rats against LPS-induced systemic inflammatory response and warrants a
clinical trial in critically ill and GI patients.
S2191
Fatty Soup As An Appetizer Reduces Food Intake in Lean and Obese Subjects
Dennis D. Chen, Xiaohong Xu, Juliana H. Chen, Hongbing Zhu, Qian Zhao, Jiande Chen
Absorption of fat in the small intestine induces satiety and slows down gastric emptying.
The aim of this study was to investigate whether a fatty soup consumed before a meal would
reduce food intake in both lean and obese subjects and whether this possible inhibitory
effect would be related to alterations in gastric and sympathovagal functions. Methods:
Twelve lean (7M, 5F, ages 19-45, mean age 32, BMI 22.8±0.7) and 12 obese (8M, 4F, ages
32-59, mean age 45, BMI 35.3±4.6) healthy subjects were recruited. Each subject came to
the lab for two sessions (fatty soup and protein soup with the same calories (160kcal) and
volume). Each session consisted of a 30 min baseline, soup consumption, a 20 min post-
soup period, an “all you can eat” pizza meal, and a 60 min post-meal period. Electrogastrogram
(EGG) and electrocardiogram (ECG) were recorded during each session. Food intake was
assessed by the caloric count of the consumed pizza. Several symptoms (satiety, appetite,
nausea, etc.) were rated at different times of the study. A second study was performed in
12 healthy subjects (7M, 5F, ages 12-45, mean age 21) to observe the effects of the two
soup appetizers in a social setting. Subjects were given the soup appetizer and taken to an
“all-you-can-eat” pizza buffet together. Results: 1) Compared with the protein soup, the
fatty soup significantly reduced the amount of caloric intake with the following meal in
both lean (962.0 vs. 1188.5 kcal, P<0.002) and obese (1331.9 vs. 1544.6 kcal, P<0.0002)
subjects. A similar reduction in caloric intake was also noted in lean subjects eating in the
social setting (1555 vs. 1825 kcal, p=0.006) except that significantly more food was consumed
in both sessions compared with the lab setting. 2) Obese subjects scored a higher appetite
level after the soups than the lean controls (protein: 8.75 vs. 5.92, P<0.006; fat: 8.08 vs.
5.17, P<0.003). 3) The percentage of normal slow waves was similar between the lean and
obese subjects (73.9±5.3 vs. 68.9±5.1, P>0.05) before fatty soup, and was reduced after the
fatty soup in the lean (59.7±5.9% vs. 73.9±5.3%, P<0.02) but not in the obese. 4) Compared
with the lean, the obese showed a higher sympathovagal balance (1.59±0.27 vs. 0.78±0.10,
P<0.009) and sympathetic activity (0.55±0.05 vs. 0.42±0.03, P<0.04) but a lower vagal
activity (0.45±0.05 vs. 0.58±0.03, P<0.04). Conclusions: Fatty soup as an appetizer reduces
food intake by about 20% in both lean and obese subjects and may have a therapeutic
potential for obesity. Sympathetic activity is increased and vagal activity is reduced in obese
subjects. However, gastric slow waves do not seem to be altered in obese.
S2192
Eating Equivalent Cerebral Activation Pattern in the Fasting Status Under
Gastric Stimulation in Morbid Obese Patients - The Pathophysiologic Key?
Claudia Knippig, Oliver Grosser, Stefanie Wolff, Jens Ricke, Marcus Seemann, Peter
Malfertheiner
Introduction: Gastric stimulation is a new operative technique used for weight reduction in
morbid obese patients. Although more than 500 devices already have been implanted
worldwide, the pathophysiologic background for this technique still is not completely under-
stood. The aim of this study is to examine the cerebral activation pattern in patients
with a gastric pacemaker implanted for morbid obesity for a better understanding of the
pathophysiologic mechanisms involved. Method: 7 patients (age: 44,0y+/-5,9 y, BMI: 42+/-
4,7 kg/m2, all female) with a gastric pacemaker implanted for therapy of morbid obesity
were included. Full brain images reflecting the cellular regional cerebral perfusion (rCBF)
were acquired after injection of 99mTc-labeled ECD during different activation paradigm
(fasting state combined with pacemaker on/off) in a cross sectional protocol using Single
Photon computer Tomography (SPECT). SPECT images were reconstructed in axial planes.
Finally, images where realigned and stereotactical normalised to a standard brain SPECT-
Template (MNI-Brain) of SPM2. Statistical analysis on brain images were conducted on a
voxel-by-voxel basis using the SPM2 software package with an extent threshold of 40 voxel.
Results: RCBF was significant increased in fasting patients with activated gastric pacemaker
(p=0.01) versus the non-activated status. In the deactivated modus an increase of cerebral
perfusion was found in the gyrus post-/precentralis (l=left), in the middle and inferior frontal
lobule (l), the putamen (l), nucleus caudatus (l), in the insula (l) and in the thalamus (l).
In the activated modus we identified an increase in cerebral perfusion in the superior
temporal lobule (l/r=right), precuneus(l/r), cingulum-post(l/r), olfactory (l/r), cingulum-
anterior (l/r), superior motor area (l/r) and frontal-orbitofrontalsup (r). Discussion: Our
results suggest a correlation between different fasting states (with/without gastric stimulation)
and rCBF. RCBF in the deactivated group did not match typical “hunger” regions, which
might reflect a disturbance in the fasting pattern of our patients. The activated group however
shows elements of eating equivalent rCBF. This leads to the hypotheses, that the induction
of a “fasting feeling of satiety” induced by gastric stimulation might be the pathophysiologic
key for an understanding of this new technique.
S2193
Impact of Starvation On Plasma Meal Response of Peptide Yy 3-36 Form,
Active and Total Ghrelin in Severely Obese Women
Krystyna Zwirska-korczala, Jerzy Jochem, Mariusz Wylezol, Krystyn Sosada, Krzysztof
Sodowski, Slawomir Grzegorczyn, Pawel Sowa, Monika Adamczyk-sowa, Tomasz
Brzozowski, Stanislaw J. Konturek
Background: Calorie restrictive diet and loss about 5% of body weight in obese subjects
with metabolic syndrome improves proatherogenic traditional risk factors. Circulating ghrelin
levels have been reported to be closely related to insulin resistance and lipoprotein fractions
of cholesterol levels. Aim: This study was designed to determine whether starvation influences
plasma basal and mixed standard meal-breakfast response to acyl-, total ghrelin and PYY3-
36 form concentrations. Methods: Eleven severely obese and non-diabetic women with initial
body mass index 48.6±6.3 kg/m2, 46.2±3.6 % body fat, aged 32±8y, who qualified for
bariatric surgery were tested on two different occasions: at the stable body weight and after
7-days low calorie diet with ad libitum water intake. Blood was taken for analysis of fasting
plasma acyl-ghrelin, total ghrelin, peptide YY3-36 form and lipid profile levels, glucose,
insulin, homeostatic model of insulin resistance (HOMA) and high specific CRP serum
concentrations. Also plasma levels of the hormones at time 30, 60, 120 min after mixed-
standard breakfast were measured. Results: After 7-days, diet body mass index and % of
fat mass fell to 47.4±6.4, 45.6±2.7, respectively. Post-diet subjects had lower total cholesterol
by 18%, triglycerides by 19%, LDL by 31%, glucose by 13%, insulin by 33% and hs-CPR
by 9%, whilst higher HDL-cholesterol by 36% compared to pre-diet values. Basal plasma
PYY3-36 form concentration decreased by 6%, acyl-ghrelin 17%, whereas total ghrelin
increased by 35%. At post-diet time course the profile of total ghrelin demonstrated postpran-
dial fall by 17% beginning at 30min after test meal, whereas there were lack of active ghrelin
and PYY post-meal responses compared to pre-diet measurements. Moreover Changes in
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HOMA index and insulin levels were negatively associated with total ghrelin concentrations
(r= -0.5363, p= 0.1105; r= -0.6969, p= 0.0251, respectively). Our studies demonstrate that
short-lasting lower energy diet evokes the reversal of post meal insulin-induced ghrelin
changes in severely obese women.
S2194
The Postprandial Alterations in Plasma Levels of Peptide YY3-36, Total and
Active Ghrelin, Cholecystokinin and Gastrin in Metabolic Syndrome Obese
Women
Krystyna Zwirska-korczala, Stanislaw J. Konturek, Tomasz Brzozowski, Krzysztof
Sodowski, Mariusz Wylezol, Dorota Kuka, Pawel Sowa, Monika Adamczyk-sowa, Michal
Kukla, Agnieszka Berdowska, Jens F. Rehfeld, Wladyslaw Bielanski
Metabolic syndrome including central obesity, insulin resistance, high blood pressure, dyslipi-
daemia is associated with inflammatory biomarkers. Plasma ghrelin levels alterations have
been reported to be closely related with insulin resistance in obese individuals. The objective
of the study was to analyze postprandial changes in total and active ghrelin, peptide YY(3-
36), cholecystokinin, gastrin and insulin levels. Moreover relationship among these gut-
brain axis peptides levels and metabolic syndrome features and also high specific C reactive
protein (hs-CRP) was investigated. In a 0, 30, 60 and 120 min after meal ingestion and 0
min time hs-CRP and traditional lipid profile were measured. The subjects were divided
into three groups: metabolic syndrome massive (N=38) and moderate obese (N=45) women
and control lean women (N=18). In the first group antropometric parameters such as BMI,
waist circumference, fat mass and plasma levels of LDL-C and hs-CRP were higher compared
to the second group, and both groups revealed significantly higher BMI, waist circumference,
fat mass and plasma levels of TG, LDL-C, fasting glucose, fasting insulin, HOMA IR and
hs-CRP compared to lean subjects. Moreover AUCs for glucose and insulin were higher
compared to control, but similar in both obese groups. Fasting PYY(3-36) level was lower
and fasting active ghrelin was higher in massive obese women then in moderate obese and
AUC for PYY(3-36) was higher compared to lean and moderate obese whilst for moderate
obese it was mach lower than lean women. In moderate obese plasma total and active ghrelin
were significantly lower compared to control group. In both obese groups the AUCs for active
ghrelin, CCK and decremental AUCs for total ghrelin were significantly higher compared to
lean subjects. In the study plasma hs-CRP levels correlated positively with BMI, waist
circumference, fat mass, fasting glucose, HOMA IR and fasting active ghrelin, and negatively
correlated with plasma fasting and AUC for total; ghrelin. Furthermore fasting PYY(3-36)
levels correlated positively and fasting active ghrelin levels correlated negatively with TC
and LDL-C plasma levels. We also observed that plasma fasting active ghrelin correlated
positively with fat mass and plasma total ghrelin correlated positively with BMI, HDL-C,
total ghrelin AUC and negatively with HOMA IR. In summary we may conclude that in
central obese women metabolic syndrome parameters are closely related to PYY(3-36) and
ghrelin basal and post-meal concentrations. Moreover plasma levels of food intake controlling
hormones may be an important marker in prognosis of probable metabolic syndrome
comorbidities appearance.
S2195
Defining a Nutrient-Modulated, CCK-Dependent Cerebral Activation Matrix in
Man
Dan Lassman, Shane Mckie, Lloyd J. Gregory, Massimo D'amato, Graham J. Dockray,
David G. Thompson
Background: Ingested lipid releases cholecystokinin (CCK) from the upper gut which regu-
lates food intake via a CCK-1 receptor dependent pathway but the cerebral activation
response is unknown. The purpose of this study was to define the role of CCK in lipid-
induced cerebral activation in man. Methods: 6 non-obese, healthy volunteers were studied
after a 12 hour overnight fast on four separate occasions, in a Latin-Square design. Each
underwent a continuous 40 minute functional magnetic resonance imaging scan (fMRI).
After a 10 minute baseline period, each received an intra-gastric infusion of either 250ml
lipid solution or saline after pretreatment with the CCK-1 receptor antagonist, dexloxiglumide
(dex) or placebo (plac), in a randomised, double-blind manner. Subjects rated their sensations
of hunger, fullness and nausea every 5 minutes and an anatomical MRI scan was performed
at the start and end of each study to measure change in gallbladder volume. SPM2 was
used to identify voxels showing significant changes in blood oxygen dependent level (BOLD)
in successive 2 minute time-bins compared to the pre-infusion baseline. Results: Mean sum
% post-infusion changes in BOLD signal (90%CI) were estimated in brain areas showing
significant activations (one way ANOVA, family wise error p < 0.05): Brainstem: +29.6%
(23.8-34.2) with lipid/plac and +10.9% (5.7 - 16.0) with lipid/dex; Hypothlamus +31.5%
(26.3 - 36.8) with lipid/plac and 11.5% (6.2 - 16.7) with lipid/dex; Left insula: +25.0 %
(20.2 - 29.9) with lipid/plac and 4.0% (-0.8 - 8.8) with lipid/dex; Mean (SD) % change in
gallbladder volume was -45%(16%) for lipid/plac, +18%(5%) for saline/plac, +45%(18%)
for lipid/dex & 67%(10%) for saline/dex, indicating that CCK signaling was blocked by dex
(repeated measures ANOVA p = 0.001).There was no evidence of a difference in reported
sensations between each condition. Conclusion: We have shown for the first time in man
that ingested lipid modulates a CCK-dependent cerebral activation matrix. Since the lipid/
CCK increases in BOLD signal were not associated with changes in conscious perception,
these activations are compatible with the subliminal responses to food intake, indicating
that conscious responses to ingested nutrients are not CCK dependent in man. We have
therefore established a method which will allow us to fully define the nutrient-modulated,
CCK-dependent cerebral activation matrix in man in both health and in conditions where
there may be aberrant signaling such as obesity.
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S2196
The Effect of Ghrelin Medication On Food Intake After a Total Gastrectomy
Masaru Koizumi, Katsuya Dezaki, Hiroshi Hosoda, Kenji Kangawa, Yoshinori Hosoya,
Naohiro Sata, Yoshikazu Yasuda, Hideo Nagai, Toshihiko Yada
[Aims] Ghrelin is an appetite-stimulating hormone, which is largely (70%) secreted from
the stomach. Generally, a total gastrectomy reduces appetite and body weight. We previously
reported the change in plasma ghrelin following a total gastrectomy in rats. Here we have
produced total gastrectomized rats and asked whether ghrelin medication could increase
food intake. [Methods] Experiment-1) Male Wistar rats aged 8 weeks were divided into two
groups. A group was medicated with subcutaneous ghrelin (10 nM) injection once a day
for seven days. The control group (B group) was injected with an equivalent amount of
saline. Food intake for 24 hours and body weight were measured before and after medication.
Experiment-2) Total gastrectomy was performed in male Wistar rats aged 6 weeks. Recon-
struction was performed by the Billroth II method. They were divided into two groups: at
the 2nd week and 6th week after the operation C group was started to be medicated with
subcutaneous ghrelin (10 nM) injection once a day for seven days , while the control D
group was treated with an equivalent amount of saline. Food intake for 24 hours was
measured before and after medication. Experiment-3) Total gastrectomized rats were divided
into two groups. At 12 weeks after the operation, E group was medicated with subcutaneous
ghrelin (10nM) injection once a day while F group was medicated with saline. Conversely,
E group was medicated with saline and F group was medicated with ghrelin (10 nM) at
the next week. Food intake for 24 hours was measured before and after medication. [Results]
Experiment-1) The total amount of food intake for 7 days was 132.5 ± 1.7 g in A groups
and 125.1 ± 2.9 g in B groups (P=0.04). Food intake increased significantly by ghrelin
medication. Experinent-2) The total amount of food intake for 7 days were 69.2 ± 2.1g in
C groups and 68.2 ± 2.5 g in D groups at six weeks after operation (P=0.75), and 53.7 ±
1.6g in C groups and 52.5 ± 1.3 g in D groups at 12 weeks after operation (P=0.56),
showing no significant difference at each time point. Experinent-3) The total amount of
food intake for 24 hours was 9.0 ± 0.4 g in E groups and 8.0 ± 0.2 g in F groups (P=0.03).
Food intake was significantly increased by ghrelin medication. [Conclusions] In the rats
without total gastrectomy, food intake increased upon ghrelin medication. Although ghrelin
medication did not increase food intake in the early stage post operation, but it increased
food intake when added at three months after total gastrectomy. The results suggest that
ghrelin administration at appropriate periods could help to enhance food intake after
total gastrectomy.
S2197
Urocortins and CCK Act Synergistically to Decrease Food Intake and Delay
Gastric Emptying in Lean But Not Obese Mice
Guillaume Gourcerol, Lixin Wang, Yvette Tache
BACKGROUND: Peripheral urocortins (Ucns) are known to decrease feeding and gastric
emptying through the peripheral corticotropin-releasing factor (CRF) receptor 2 pathway. We
previously reported interaction between intraperitoneally (ip) administered cholecystokinin
(CCK) and other satiety signaling such as leptin. AIM: To assess the interaction between
CCK and Ucns to suppress food intake and gastric motor function in lean and obese mice.
METHODS: Ucn 1 and mouse Ucn (mUcn) 2 (1 μg/kg) were injected ip alone or with
CCK (3 μg/kg) either in fasted lean mice (C57BL/6, 25-30 g) or fasted mice with diet-
induced obesity (DIO; 60% fat diet; 40-55 g). Hourly and cumulative food intake was
quantified for 4 h, as well as gastric emptying using a methylcellulose acaloric meal.
RESULTS: When injected separately, CCK and mUcn 2, but not Ucn 1, decreased feeding in
lean mice at 30 min, but not thereafter (-70.2% and -33.9% compared to saline, respectively;
p<0.05). In fasted DIO mice, CCK, Ucn 1 and mUcn 2 injected alone did not reduce hourly
feeding and only Ucn 1 reduced cumulative food intake at 4 h (compared to saline: 9.5%
for CCK: p>0.05; -37.3% with Ucn 1: p<0.05; and -16.9% for mUcn 2: p>0.05). Co-
administration of CCK with Ucn 1 or with mUcn 2 in lean mice produced a sustained
inhibition of feeding (-68.8% with Ucn 1 and -70.0% with mUcn 2 compared to saline at
1 h; p<0.05), with a decrease of the 4-h cumulative food intake (-31.4% with Ucn 1 and
-26.7% with mUcn 2 compared to saline; p<0.05), yielding a 50% higher inhibition at 4 h
than the calculated additive effect for each peptide. By contrast, the feeding inhibition
induced by combination of CCK and Ucn 1 or 2 in DIO mice was not higher than the
response observed when Ucn 1 and mUcn 2 were injected alone (-31.2% with Ucn 1:
p<0.05 compared to saline and -10.2% with mUcn 2: p>0.05 compared to saline). Switch
of high fat to normal diet in DIO mice did not result in a synergistic effect between Ucn 1
and CCK. Single ip injection of CCK and Ucn 1 at a subthreshold dose did not modify
gastric emptying either in lean or obese mice, whereas co-injection of CCK and Ucn 1
decreased significantly gastric emptying in lean (-50.6% compared to saline; p<0.05), but
not DIO, mice (-22.9% compared to saline; p>0.05). CONCLUSIONS: There is a synergetic
interaction between CCK and Ucns to decrease food intake and gastric emptying in lean
mice that is impaired in DIO mice. This may have implications in satiety signaling in obese
patients. Supported by the French Society of Gastroenterology (SNFGE), and the French
Foreign Office (EGIDE Program).
S2198
Altered Ghrelin and PYY Responses to Meals in Bulimia Nervosa
Shinya Kojima, Toshihiro Nakahara, Akihiro Asakawa, Akio Inui
BACKGROUND: In recent years great advances have been made in our understanding of
the peripheral signals produced within the gastrointestinal tract that regulate appetite, such
as ghrelin and peptide YY (PYY). While ghrelin elicites hunger signals, PYY elicites satiety.
Therefore, alterations in hormone physiology may play a role in the pathogenesis of bulimia
nervosa (BN). In this study, we investigated the postprandial profile of ghrelin and PYY
levels in patients with BN. METHODS: Postprandial plasma ghrelin and PYY levels and
insulin and glucose responses were measured in 10 patients with BN and 12 control patients
in response to a standard 400 kcal meal. RESULTS: Basal ghrelin levels present in BN
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subjects (265.0 ± 25.5 pmol/l) were significantly higher than those in healthy controls (199.3
± 18.4 pmol/l, P < 0.05), while basal PYY levels were equivalent in BN (14.6 ± 1.3 pmol/
l) and control (12.8 ± 1.1 pmol/l, P=0.30) subjects. In comparison to controls, postprandial
ghrelin and PYY responses were significantly blunted in BN patients. Postprandial ghrelin
suppression (decremental ghrelin area under the curve) was inhibited significantly in BN
patients (-96.3 ± 26.8 pmol/l × 3 hours) from the reductions seen in controls (-178.2 ±
25.7 pmol/l × 3 hours, P < 0.05). After a meal, the incremental PYY area under the curve
in BN patients was significantly blunted from that observed in controls (9.2 ± 2.6 pmol/l
× 3 hours vs. 26.8 ± 3.2 pmol/l × 3 hours, P < 0.01). Glucose and insulin responses to
meals were similar between the two groups. CONCLUSIONS: BN patients exhibit elevated
ghrelin levels before meals with reduced ghrelin suppression after eating. In BN subjects,
the rise in PYY levels after meals is also blunted. A gut-hypothalamic pathway involving
peripheral signals, such as ghrelin and PYY, may be involved in the pathophysiology of BN.
S2199
Gastric Pentadecapeptide Bpc 157 (Pl14736 Pliva, Croatia) Counteracts short-
Bowel Syndrome in Rats
Marko Sever, Robert Kliek, Mario Udovicic, Anita Zenko, Vedran Cesarec, Kristijan Sipos,
Luka Brcic, Alenka Boban blagaic, Ivan Zoricic, Tomislav Anic, Sven Seiverth, Predrag
Sikiric
AIM. Gastric pentadecapeptide BPC 157 (BPC 157), safe in clinical trials for inflammatory
bowel disease (IBD) (PLD-116,PL14736 Pliva, Croatia)(Gastroenterology 2005), could be
also useful in IBD complications, as it successfully heals the intestinal anastomosis in rat (Surg
Today, 2006 (in press)). Thereby, we study the therapeutic effect of the pentadecapeptide BPC
157 on the short-bowel syndrome that compromises nutritional status and healing process.
METHODS. To create short bowel syndrome in male Albino Wistar rats, an extensive small
bowel resection (from 4th ileal artery cranially of ileocecal valvule to 5 cm underneath
pylorus) and entero-enteral anastomosis were done as described before (Surg Today, 2006
(in press)). Medication (pentadecapeptide BPC 157 (10 µg, 10 ng, 10 pg) or an equivolume
of saline (5 ml) was given once daily, intraperitoneally (/kg), first application 30 min after
surgery, last 24 h before sacrifice (at the post-operative day 1,3,5,6,7,14,21,28). Assessment
includes gross presentation (body weight, mass of small intestine (3 cm cranially to 3 cm
caudally from anastomosis), diameter measurements (jejunal, ileal and anastomosis diameter),
biomechanical presentation (the volume (ml)infunded through syringe-perfusion pump sys-
tem (1ml/10 sec)) to leak induction), microscopy presentation (Surg Today, 2006 (in press)).
RESULTS. A severe bowel syndrome (severe body weight loss, jejunal diameter increase,
the only minute volume (2-3 ml) before leaking, decreased high of the villi distal to anastom-
osis). These were completely counteracted by the both BPC 157 regimens. Weight gain to
the healthy values goes along with markedly higher volume values (4-6 ml) without leakage.
Healing of the anastomosis is improved (edema markedly attenuated, granulocytes number
decreased, necrosis attenuated, granulation tissue, reticulin and collagen formation substan-
tially increased as well as epithelization). All measured diameters similar to those of healthy
animal, the villi distal to anastomosis higher than in the controls. CONCLUSION. BPC 157
cures short bowel syndrome and improves entero-enteral anastomosis healing.
S2200
Timely Consideration of Intestinal Transplantation Influences Outcomes
Jonathan P. Fryer, Alan L. Buchman
Intestinal transplantation is the treatment of choice for short bowel syndrome (SBS) patients
that are failing TPN therapy. However, intestinal transplant candidates are usually referred
late, and 74.3% of the 1659 patients listed for intestine transplants in the U.S. since 1987
have also needed to be listed for a liver transplant, due to severe parenteral nutrition
associated liver disease (PNALD). Liver-intestine transplant candidates (LIC) have the highest
waiting list mortality of any solid organ candidate population. LI candidates have a higher
relative risk of dying on the waiting list than the candidates that need an intestine only
(IOC) (29.8% vs 8.8%), and a lower relative odds of getting transplanted (51.9% vs 65.5%).
This disparity in waiting list outcomes between LICs and IOCs was similar in both adult
and pediatric candidate populations with 27.6% vs 10.0% of adult candidates dying and
60.1% vs 72.4% getting transplanted, respectively; compared with 30.5% and 7.5% of
pediatric candidates dying and 49.6% vs 62.6% getting transplanted, respectively. Of the
864 patients that were transplanted 69.7% received both a liver and an intestine transplant
(LIT) while 30.3% have received an intestine only transplant (IOT). In the adults LITs were
performed in 49% and IOTs in 51%, while in the pediatric population LITs were more
prevalent (79.6%) compared to IOTs (30.4%). Furthermore, for the patients that were
transplanted, post-transplant survival data was inferior after LI transplant (LIT) compared
with IO transplant (IOT). One year patient survivals after LIT vs IOT was 63.0% vs 81.6%
in adults, and 59.3% vs 81.9% in pediatric recipients, respectively. One year graft survivals
after LIT vs IOT were 56.9% vs 79.1% in adults, and 57.1% vs 76.3% in pediatric recipients.
Overall patient survivals in IOTs are now comparable to those achieved in liver transplants,
while in LITs they are worse than with most other solid organ transplants. These data reveal
that overall outcomes with intestinal transplant candidates have been negatively skewed by
the preponderance of candidates that, due to PNALD, have had to be listed for a liver also,
Because PNALD is insidious and its progression is difficult to recognize, intestine-only
transplants should be considered early for all patients at high-risk for PNALD (< 100 cm
of small bowel) before its progression to irreversibility mandates the inclusion of a liver.
S2201
Teduglutide Is a Potent Stimulus for Intestinal Adaptation in a Neonatal Piglet
Model of short Bowel Syndrome Accompanied By Parenteral Nutrition
Therapy
Brian M. Chung, Kelly A. Tappenden
Teduglutide (Gly2-GLP2) is quickly becoming a promising therapeutic option for adult
patients with intestinal failure who are dependent on parenteral nutrition. Despite this
evidence, teduglutide is poorly studied in pediatric models of intestinal failure. We hypothes-
ized that teduglutide would enhance intestinal adaptation following a massive small bowel
resection. Two-day-old littermate piglets underwent 80% jejunoileal resection and were
randomized into either total parenteral nutrition (TPN) or partial enteral nutrition (PEN=
20% enteral:80% parenteral). Piglets were further randomized to receive either vehicle or
1mg/kg/day teduglutide, resulting in a total of 4 separate groups: TPN, PEN, TPN+teduglutide
and PEN+teduglutide. Tissues were harvested at 3 different times (4-hours, 48-hours and
7-days) following surgery for the analysis of structural and functional adaptations. In the
duodenum, teduglutide stimulated a 19% increase (p<0.05) in villus height compared to
vehicle controls (512.6±28.8 vs 429.3±28.4μm), with no difference in nutrient transport
between groups. No effects of teduglutide or nutrient administration were noted in the
remnant jejunum. Remnant ileal tissues from teduglutide-treated animals demonstrated a
15% increase (p<0.05) in villus height (609.6±22.1 vs 527.2±22.5μm) and 10% increase
(p<0.05) in crypt depth (136.0±3.2 vs 122.9±3.2μm) compared to vehicle control values,
regardless of route of nutrition. Interestingly, teduglutide increased (p<0.05) glucose trans-
port 133% at 4 hours (22.14±4.29 vs 9.49±4.29 ΔIsc μA/cm2), but did not differ at day
7. Colonic tissues from teduglutide-treated animals demonstrated a 15% increase (p<0.05)
in crypt depth (46±17.6 vs. 266.8±16.6μm) regardless of route of nutrition, with no changes
in absorptive function. In summary, teduglutide increased the absorptive surface area in the
small intestine and colon and specifically increased glucose transport within the remnant
ileum 4-hours following resection. Teduglutide appears to evoke intestinal adaptation follow-
ing massive small bowel resection beyond that obtained with partial enteral nutrition and
may be an important therapeutic adjunct in pediatric patients with intestinal failure.
S2202
Complications Are Increased in Chronic Home Parenteral Nutrition Patients
with Crohn's Disease Receiving Monoclonal Antibody Treatment
John K. Siepler, Reid A. Nishikawa, Tom Diamantidis, Rod Okamoto
Background: Monoclonal antibody(MCAB) treatment such as infliximab is beneficial for
certain patients with Crohn's disease. Its use, however, may be associated with an increased
incidence of infections. We studied patients with Crohn's disease and short bowel syn-
drome(SBS) requiring home parenteral nutrition(HPN) to determine if there is any association
of HPN with complications such as infections or catheter changes with MCAB use. Methods:
All patients receiving chronic HPN (defined as on HPN for greater than 5 years) for SBS
resulting from multiple bowel resections associated with Crohn's disease from one home
care provider were eligible for inclusion. The medical records of the patients from Jan-Dec
2005 were reviewed to determine if they had received MCAB(MCAB group). These patients
were compared with those did not receive MCAB(noMCAB group). Incidence of catheter
related blood stream infections(CRBSI), catheter changes(CC), antibiotic use, and hospitaliza-
tions were compared in the two groups. Statistics were done using T test with significance
set at p<0.05. Results: Twenty-nine patients were identified with 5(17.2%) in the MCAB
group. The mean age was 53.8±10.5 with 19(56%) females. This distribution was not different
in the two groups. Incidence of CRBSI/1000cath days(MCAB:5.5±6.8 noMCAB:0.8±1.71
p<0.005) and CC/1000cath days(MCAB:7.78±3 NoMCAB:0.8±2.6 p<0.001) were both signi-
ficantly greater in the MCAB group. Antibiotic use in days and hospital admissions were
greater in the MCAB group, but the difference failed to achieve statistical significance.
Conclusions: HPN patients have a higher infectious complication rate than non HPN patients
due to an indwelling catheter. We evaluated HPN complications in patients with Crohn's
disease and SBS who received MCAB and compared them to those who did not, finding
CRBSI and CC(both n/1,000cath days) but not antibiotic use or hospitalizations were greater
in the MCAB group. Other studies that found higher infection rates in MCAB users investig-
ated patients with rheumatoid arthritis, but this is the first study to evaluate Crohn's disease
patients on HPN. More work is needed in this area.
HPN associated complications
CC:cath change ABX:antibiotic Hosp:hospitalizations *:n/1,000catheter days
S2203
Dietary Glutamine Supplementation Stimulates Jejunal Adaptive Growth in a
Rat Model of Partial Small and Large Bowel Resection
Junqiang Tian, Li H. Gu, Prakash Chandra, Menghua Luo, Ifor R. Williams, Andrew
Gewirtz, Dean P. Jones, Thomas R. Ziegler
BACKGROUND: Gut adaptive growth is the hyperplastic response of the residual intestine
to massive small bowel resection for treatment of a variety of intestinal diseases. It compensates
for the lost absorptive function and is vital for patients' outcome following the operation.
In this study, we investigated the effects of dietary supplementation with glutamine (GLN),
and luminal bacteria on adaptive growth in a rat model of partial small and large bowel
resection. METHODS: In the bowel resection model, we removed 60% of the distal small
intestine, the cecum and 1 cm of proximal colon (RX/CON, n = 11); whereas rats with
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transection of the small intestine at 40 cm proximal to ileoceccal valve were used as surgical
controls (TX/CON, n = 10). In a separate group (RX/GLN, n = 11), GLN (4% of total diet
weight) was supplemented to RX rats post-operatively in a semi-purified diet for 3 wks,
whereas isocaloric and isonitrogenous non-GLN supplemented diet was given to other groups
as the dietary control. In another study group, luminal bacteria were eliminated by an oral
antibiotic (ABX) cocktail (neomycin, metronidazole, and polymyxin) in RX rats from 3 days
before operation until harvest at 3 weeks post-operatively (RX/ABX, n = 9). All groups were
pair-fed. RESULTS: RX tended to increase villus height of the residual jejunum [RX/CON
(523 ± 31 µm) vs TX/CON (600 ± 32 µm), NS]. This increase was significantly enhanced
by dietary GLN supplementation [RX/GLN (703 ± 24 µm) vs RX/CON, P < 0.05]. Similar
changes were observed in crypt depth [TX/CON (140 ± 11 µm), RX/CON (199 ± 14 µm),
RX/GLN (222 ± 9 µm), P < 0.05 for RX/GLN vs TX/CON] and total mucosal height [TX/
CON (694 ± 40 µm), RX/CON (799 ± 43 µm), RX/GLN (925 ± 24 µm), P < 0.05 for RX/
GLN vs RX/CON and TX/CON]. These morphological changes were accompanied by a
moderate increase in epithelial cell proliferation as measured by BrdU incorporation [TX/
CON (308 ± 24), RX/CON (313 ± 26), RX/GLN (344 ± 23), expressed as labeled crypt
epithelial cells/1000 total cells, NS by one way ANOVA]. ABX did not significantly change
any of the growth and proliferative indices in jejunum. CONCLUSION: Our data indicate
that dietary supplementation of GLN potentiates small bowel adaptive growth in rats after
massive combined small and large bowel resection. This effect may have transitional implica-
tions for investigation in patients with short bowel syndrome after combined small bowel-
colonic bowel resection.
S2204
Development of Overweight and Obesity After Intestinal Transplantation
Laura E. Matarese, Lillian Martin, Darlene Koritsky, Guilherme Costa, Geoffrey Bond,
Kareem M. Abu-elmagd
Purpose: Intestinal transplantation (IT) has recently evolved to become the standard of care for
patients with combined intestinal and parenteral nutrition failure. In addition to restoration of
nutritional autonomy, it was observed that some patients became overweight or developed
morbid obesity. Methods: Between May 1990 and December 2005, 188 consecutive patients
underwent IT. Height and actual body weight were measured and collected prospectively
for all patients prior to transplantation and at regular intervals during the postoperative
period. The body mass index (BMI) (kg/m2) was then calculated at each time point. Study
patients were stratified according to the BMI data as underweight (BMI < 18.5), normal
(BMI = 18.5-24.9), overweight (BMI = 25-29.9), and obese (BMI ≥ 30). Related risk factors
were noted. Results: At the time of transplantation, most patients with short bowel syndrome
were underweight or of normal body weight. A few cases were overweight with a single
example of morbid obesity including a strong family history and long-term diabetes. With
a mean follow-up of 35 ± 35 months, 107 recipients are currently alive with fully functioning
grafts and completely off non-volitional feedings. Of these, 12 (11%) that had a normal or
underweight pretransplant BMI are now overweight. Most of these patients are currently
receiving intensive nutrition education with discontinuation, if feasible, of the maintenance
steroid therapy. Interestingly, one patient who was morbidly obese before transplantation
continued to gain weight despite nutrition and exercise intervention. Conclusion: Overweight
and occasionally morbid obesity is a potential complication after IT that could be partially
explained by susceptible genetic backgrounds and co-morbid factors. Accordingly a compre-
hensive educational program including diet and exercise should be part of the multidisciplin-
ary team approach for the postoperative care of this unique population.
S2205
De Novo Ceramide Biosynthesis Is Involved in Resveratrol-Induced Inhibition
of Ornithinedecarboxylase Activity
Sandra Ulrich, Andrea Huwiler, Stefan Loitsch, Helmut Schmidt, Jürgen Stein
Introduction: Previous studies could demonstrate, that the naturally occuring polyphenol
resveratrol inhibits cell growth of colon carcinoma cells at least in part by inhibition of
protooncogene ornithine decarboxylase (ODC). The objective of this study was to provide
several lines of evidence suggesting that the induction of ceramide synthesis is involved in
this regulatory mechanisms. Methods: Cell growth was determined by BrdU incorporation
and crystal violet staining. Ceramide concentrations were detected by HPLC coupled mass
spectrometry. Protein levels of c-myc and ODC were examined by Western blot analysis.
Ornithine decarboxylase activity was assayed radiometrically measuring [14CO2] liberation.
A dominant-negative PPARg mutant was transfected in Caco-2 cells to suppress PPARg-
mediated functions. Results: Antiproliferative effects of resveratrol closely correlate with
a dose-dependent increase of endogenous ceramides (~200% at [100µM], ***p<0.001).
Compared to controls the cell-permeable ceramide analogues C2- and C6-ceramide signific-
antly inhibit ornithine decarboxylase-activity (~50% at [40µM], ***p<0.001) in colorectal
cancer cells after 24h. C6-Ceramide further diminished protein levels of protooncogenes c-
myc (*p<0.05) and ornithine decarboxylase (*p<0.01) after 6h of incubation, which is
strictly related to the ability of ceramides to inhibit cell growth in a time- and dose-dependent
manner. These results were further confirmed using inhibitors of sphingolipid metabolism,
where only co-incubation with serine palmitoyltransferase inhibitor cycloserine but not
sphingomyelinase inhibitor manumycin could significantly counteract resveratrol-mediated
actions. In contrast to the regulation of catabolic spermine/spermidine acetyltransferase by
resveratrol (Cancer Res, 2006), inhibitory effects on ornithinedecarboxylase occur PPARγ-
independently. Conclusion: These data provide evidence for the involvement of ceramide de
novo biosynthesis in resveratrol mediated inhibition of ODC activity in colorectal cancer cells.
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S2206
Antineoplastic Effects On Colorectal Cancer Cells of Plantago Ovata Husk and
Its Interaction with 5-FU According to Different Molecular Features
Anna Giros, Elisenda Pons, Xavier Llor, Jessica Fernandez-morales, Lourdes Fluvia, Rosa
m Xicola, Anna Anguera, Miquel a Gassull
Nutrients play an important role in the development of colorectal cancer. Fiber products
have been extensively studied but results have yielded significant discrepancies between
epidemiological studies, often showing a protective effect, and interventional studies that
failed to confirm this effect. At the experimental level, few studies have attempted to evaluate
the effects of fiber on colorectal malignant cells under conditions that mimic the process
that fiber undergoes inside the human gut. Using this model, we have shown that natural
fiber Plantago ovata husk induces apoptosis in Caco-2 and HT-29 colorectal cancer cells. 5-
FU is a commonly used chemotherapeutic agent in colorectal cancer that inhibits thymidylate
synthase and causes misincorporation of fluoronucleotides into RNA and DNA. Aims: To
evaluate if Plantago ovata husk could enhance the antineoplastic effects of 5-FU and if these
effects depend on different molecular features. Methods: Fresh stool was collected from
healthy human volunteers. Fecal homogenates were incubated with Plantago ovata husk
(20mg/ml) or with no additional fiber, under anaerobic conditions at 37°C for 72h. Five
colorrectal cell lines (HCT116, SW480, LoVo, HT-29 and Caco-2) were supplemented with:
fermentation products of Plantago ovata husk; fermentation products without fiber addition;
5-FU at 50ug/mL. Apoptosis was assessed by flow cytometry after staining cells with annexin
and propidium iodide. Cell cycle analysis was assessed by analyzing DNA content with flow
cytometry. All experiments were repeated at least 3 times. Statistical analysis: Kruskal-Wallis
one-way analysis of variance by rank and Mann-Whitney U-test. Results: Fermentation
products of Plantago ovata husk induced apoptosis in all colorectal cancer cells tested
(P<0.05). 5-FU induced apoptosis in all cells except SW480 (P<0.05). The concomitant
addition of Plantago ovata fermentation products and 5-FU resulted in a potentiating
apoptosis effect in HCT116 and LoVo. Plantago ovata husk caused a significant arrest of
cells at G0/G1 phase while 5-FU's main effect was a decrease of the percentage of cells in
G2/M in all cell lines studied. Conclusions: Products resulting from Plantago ovata husk
fermentation with human gut flora behave as antineoplastic agents through the induction
of apoptosis independently of the mismatch repair and p53 status. Plantago ovata exerts a
potentiating pro-apoptotic effect with 5-FU only in mismatch repair-deficient cells. Plantago
ovata and 5-FU inhibit cell proliferation at different phases of the cell cycle which could
imply a potentiating antineoplastic effect at this level.
S2207
Clinical Significance of Iron Metabolism in Chronic Hepatitis C Or Liver
Cirrhosis
Yasuo Arakawa, Mitsuhiko Moriyama, Hiroshi Matsumura, Akinori Tamura, Kazushige
Nirei, Yasuyuki Arakawa
Aim: We have performed serological and histological studies prospectively on how these
iron metabolism affect clinical profiles and outcome of patients with chronic hepatitis C or
liver cirrhosis. Patients and Methods: To study how liver function test results relate to
histological findings in the liver, we measured the serum ferritin level and iron staining
intensity of liver tissues in 106 patients with chronic hepatitis C (CH) or liver cirrhosis
(LC). We also studied how the serum ferritin level changed during interferon (IFN) therapy.
In addition, we measured the serum ferritin level of patients with CH or LC who underwent
phlebotomy or low iron diets and undertook prospective studies about the relationship
between the serum ferritin levels and changes in ALT, AST levels and platelet counts. Results:
The results of these studies showed that there was a significant correlation between the
serum ferritin level and the ALT value (r = 0.542, p = 0.0021). When we investigated sex
differences in the relationship between the serum ferritin level and iron staining intensity
of liver tissues, we found close correlation (r = 0.612, p = 0.001) in male patients and a
significant correlation (r = 0.415, p = 0.028) in female patients. In a study on the relationship
between histological findings in the liver and serum ferritin level or iron staining intensity
of liver tissues, the serum ferritin level became higher as the necro-inflammatory reaction
(activity) became more sever. With regard to the relationship with the F stage, the serum
ferritin level became higher as the F stage advanced. In patients with high serum ferritin
levels (more than 100μg/dl), the AST and ALT level tended to fluctuate at a high level (80
U/L or higher). On the other hands, in patients with low ferritin levels, the AST and ALT
level maintained low level (less than 80U/L).During IFN therapy, the serum ferritin and
iron level tended to decrease as the ALT value decreased. Conclusion: The serum ferritin
level was closely correlated with the ALT value. It was indicated that the ferritin concentrations
have an effect on the clinical profiles of the liver in each chronic hepatitis C patients.
S2208
Gender-Linked Inverse Correlation Between Colorectal Adenoma Risk and
Serum Folate Concentration Levels: Determination of the Threshold Serum
Folate Concentration Level for Reduced Risk of Colorectal Adenoma in Men
Shunji Fujimori, Katya Gudis, Yoshihisa Sekita, Makoto Kotoyori, Masasi Yoshizawa,
Teruyuki Kishida, Kazuhiro Nagata, Yoshiaki Shibata, Yoshiharu Ohaki, Choitsu Sakamoto
Background & Aims: Studies have reported an inverse correlation between folate serum
concentration levels and risk of colorectal cancer. Nevertheless, the folate therapeutic thresh-
old has yet to be determined. This is the first evidence-based clinical study to analyze serum
folate levels in patients with and without adenoma, to identify the serum folate concentration
level that associates with reduced risk of colorectal adenoma. Methods: Patients with positive
immunologic fecal occult blood tests or suspected colorectal lesions underwent barium
enema examinations. Patients with barium enema data indicative of colorectal lesions then
underwent total colonoscopy. Prior to colonoscopy, history of alcohol consumption was
determined for each patient and blood samples analyzed. Data collected included blood
counts, serum total-protein, albumin, total-cholesterol, triglyceride, iron, ferritin, vitamin
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B12, and folate levels. All polypoid lesions found at colonoscopy were diagnosed by histolog-
ical evaluation. Patients with anemia, history of colonoscopy, daily ethanol intake above
50g, inflammatory bowel disease, malignancies, and those less than 40 or older than 75
years of age were excluded from our study. A total of 458 patients (male, 258; female, 200)
were considered eligible. Variables were analyzed by multivariate analysis adjusting for age.
Results: In men, serum folate concentration was the variable with the most significant
statistical variation between patients without adenoma (9.2 ng/ml) and patients with adenoma
(8.0 ng/ml) (p=0.001). Male patients without adenoma had also significantly higher serum
ferritin levels than male patients with adenoma (143 ng/ml and 122 ng/ml (p=0.03), respect-
ively). We found no other significant variation in factors between groups. In female patients,
only total-cholesterol was significantly higher in patients with adenoma (222 mg/dl) than
in patients without adenoma (215 mg/dl) (p=0.04). Serum folate was 10.9 ng/ml in female
patients without adenoma and 10.7 ng/ml in female patients with adenoma (p=0.34). The
odds ratio of colorectal adenoma for patients with serum folate concentrations above 8.0
ng/ml was 0.49 (95%CI: 0.32-0.66) for men and 0.77 (0.40-1.05) for women, relative to
patients with serum folate below 8.0 ng/ml. Conclusions: We found a significantly lower
risk of colorectal adenoma for male patients with serum folate levels above 8.0 ng/ml than
for patients with serum folate below 8.0 ng/ml. We thus offer the first evidence-based
recommendation of a threshold therapeutic serum folate concentration level of 8.0 ng/ml
for effective reduction in the risk of colorectal adenoma in men.
S2209
Prevalence of Malnutrition in Non-Selected Cancer Patients: A One-Day
Survey
Xavier Hebuterne, Etienne Lemarié, Mauricette Michallet, Claude Beauvillain de
montreuil, Goldwasser Francois
Rationale: In 1980, Dewys et al (Am J Med 1980;69:491-7) have demonstrated a high
prevalence of malnutrition in cancer patients. The aim of the present study was to re-
evaluate, 25 yrs later, the prevalence of malnutrition in a non-selected population of cancer
patients. Methods: A prospective one-day prevalence survey was carried out in 154 wards
of private or public hospitals in 24 cities in France. Height, current and usual body weight
were systematically assessed in outpatients and inpatients who were present that day. Malnu-
trition was defined as a BMI<18.5 or 21 in patients of 75 yrs or more and/or a loss of body
weight >10% since the beginning of the disease. Results: 2,068 patients (1,189 men and
879 women) aged 60±13 yrs were evaluated and nutritional status was available in 1,903
patients. Cancer was local in 25% of patients, loco-regional in 31% and metastatic in 44%.
75.5 % of patients had received chemotherapy, 47.5% had undergone surgery and 42.6%
had received radiation therapy. Performance status (PS) was 0 or 1 in 52.3% of patients, 2
in 25.3%, 3 or 4 in 22.4%. Overall, 38% of women and 40% of men were malnourished.
Prevalence of malnutrition according to the different types of cancer was: head and neck
(n=366): 49%, leukemia/lymphoma (n=377): 34%, lung (n=247): 45%, colon/rectum (n=
191): 39%, stomach (n=41): 59%, oesophagus (n=41): 61%, pancreas (n=42): 67%, breast
(n=229): 21%, ovarie/uterus (n=87): 45%, prostate (n=72): 14%. The prevalence of malnutri-
ton was 22.7% in patients with localized cancer, 44.3% in loco-regional cancer and 45.9%
in metastatic cancer. The prevalence of malnutrition was 14.4%, 31.4%, 52.3%, 53.6%, and
65.3% in patients with a PS ranging from 0 to 4, respectively. Age (OR: 1,00; 95% CI:
0,99-1,02) and previous surgery (OR: 0.85; 95% CI: 0,66-1,09) were not associated with
increasing risk of malnutrition. However loco-regional cancer (OR: 1,96; 95% CI: 1,42-
2,70), metastatic cancer (OR: 2,97; 95% CI: 2,14-4,12 ), previous chemotherapy (OR: 1,41;
95% CI: 1,05-1,89), previous radiotherapy (OR: 1,53; 95% CI: 1,21-1,92) were significantly
associated with malnutrition. Conclusions: Along with an improvement of cancer treatments,
the prevalence of malnutrition is still high in cancer patients. Systematic screening and care
of malnutrition is mandatory in these patients.
S2210
Cholestatic Bile Salt Concentrations Do Not Affect Proliferation Or
Differentiation of Intestinal Epithelial Cells In Vitro
Leonie Los, Henk Wolters, Anna Baghdasaryan, Folkert Kuipers, Henkjan Verkade,
Edmond Rings
Introduction: Bile salts have been implied in the induction of proliferation and apoptosis
in many different cell lines. It is unclear, however, whether bile salts in compositions and
concentrations found in cholestasis affect the proliferation, differentiation or apoptosis of
small intestinal epithelial cells. Compromised differentiation of the intestinal epithelium
could provide an additional pathophysiological mechanism for the frequently encountered
compromised nutritional status during cholestasis. Aim: To determine whether cholestatic
bile salt concentrations affect proliferation, differentiation or apoptosis of intestinal epithelial
cells In Vitro. Methods: Human colon carcinoma cells, Caco-2, which feature a small intestinal
phenotype upon confluency, were exposed to bile salts in cholestatic concentrations and
compositions (molar ratio; GCA:TCA:GCDCA:TCDCA, 2:2:1:1; concentration range 0-450
μM), either in the proliferative or in the differentiated stage. Proliferation was determined
by analyzing cell growth, protein and DNA synthesis, and expression of the cyclin-dependent
kinase inhibitors p21 and p27. Apoptosis was determined by analyzing caspase-3 activity.
To determine the effect on differentiation, mRNA and activity levels of sucrase-isomaltase
and lactase, two enzymes involved in carbohydrate hydrolysis, were quantified. Additionally,
mRNA levels of their upstream intestine-specific transcription factors were measured. A
LDH assay was performed to determine possible cytotoxicity of the bile salts. Results: The
conjugated bile salts did not affect cell growth, protein and DNA synthesis, or p21 and p27
expression. Caspase-3 activity was not affected by cholestatic bile salts in either proliferating
or differentiated cells. No difference was observed in the expression of the genes coding for
the intestinal transcription factors Cdx2, GATA-4 and HNF-1α, or of their downstream
genes coding for sucrase-isomaltase and lactase. Sucrase and isomaltase activities of control
and bile salt-treated cells were virtually identical. The LDH assay confirmed that the bile
salts were not cytotoxic to the Caco-2 cells. Conclusions: Intestinal mucosal cells are resistant
to bile salts in cholestatic concentration and composition. The conservation of small intestinal
function during cholestasis opens up possibilities for optimalization of the nutritional condi-
tion.
S2211
Butyrate Metabolism in Colonic Epithelial Cells Is An Important Factor in
Butyrate Regulation of Gene Expression
Kristian Daly, Soraya P. Shirazi-beechey
Butyrate is a naturally occurring product of the colonic microbial fermentation of dietary
fibre and resistant starch. It plays an important role in the maintenance of human colonic
tissue homeostasis by regulating the expression of genes associated with proliferation, differ-
entiation and apoptosis of colonic epithelial cells. We have previously determined that
transport of butyrate, across the colonic luminal membrane into colonocytes, is an important
factor in the regulation of a number of these butyrate responsive-genes (1,2). Once in the
cell butyrate serves primarily as an energy source for colonocytes, and as such undergoes
mitochondrial beta-oxidation. Here we hypothesise that the mechanism by which butyrate
regulates the expression of certain genes is dependent upon butyrate metabolism. Using the
technique of RNA interference, we impaired butyrate metabolism in several colonic epithelial
cell lines by silencing the expression of short-chain acyl dehydrogenase (SCAD), a key
enzyme in butyrate metabolism. Control cells and cells in which SCAD expression/activity
was inhibited by transfection with specific short inhibitory RNA (siRNA), were exposed to
butyrate for 24 hours. Subsequently, the expression of 10 butyrate-responsive genes, each
associated with proliferation, differentiation and apoptosis of colonic epithelial cells, was
assessed by real time PCR. The butyrate-induced response of two of these genes, DAPK1
and PTEN, was totally abolished in siRNA-treated cells. DAPK1 is a positive moderator of
apoptosis mediated by gamma-interferon, whilst PTEN encodes a dual-specificity phosphat-
ase that negatively regulates PI3K/Akt-dependent cellular survival pathways. The data indicate
that the activity of SCAD in the beta-oxidation of butyrate is required for the butyrate-
responsiveness of these two genes, and provides evidence that butyrate's ability to modulate
gene expression is, for certain genes, dependent upon its metabolism. The financial support
of Tenovus, the cancer charity is gratefully acknowledged. (1) Cuff, M.A. et al. (2005)
Gastroenterology, 128, 676-686. (2) Daly, K. et al. (2005) Biochemical Society Transactions,
33, 733-735.
S2212
Glutamine Supplemented Parenteral Nutrition Prevents Loss of Epithelial
Barrier Function: Potential Mechanisms of Action
Keisuke Nose, Hua Yang, Xiaoyi Sun, Hiroyuki Koga, Daniel H. Teitelbaum
Background: Glutamine (GLU) supplemented parenteral nutrition (PN) has been shown to
prevent loss of epithelial barrier function (EBF). However, the mechanisms responsible
are incompletely understood. We previously reported that intraepithelial lymphocytes(IEL)
undergo marked changes with PN, including a decline in IEL-derived IL-10, increased
interferon gamma (IFN-γ), and decreased expression of tight junction proteins. The purpose
of this study was to determine mechanisms of action of GLU supplemented PN. Methods:
C57BL/6J mice were randomized into 3 groups: 1) Controls (saline infusion with enteral
food); 2) PN group (no enteral nutrition); and 3) PN+GLU group (PN +intravenous 2%
alanyl-GLU). Solutions were isonitrogenous and isocaloric. At 7 days small bowel was
harvested, and IEL-derived cytokine expression detected with real-time PCR and flow cytome-
try (FCM). Tissues were mounted in Ussing chambers for short circuit current (Isc); A
secretory agonist, carbachol, and an absorptive agent, glucose were used. EBF was assessed
with transepithelial resistance (TER,Ω.cm2) and transmural passage of 3H-mannitol (Papp).
Results: IEL derived IL-10 mRNA declined with PN and returned to Control levels with
GLU (29.4±5.4;14.7±4.6*;21.9±9.7 for Control, PN, PN+GLU, respectively). The dominant
population expressing IL-10 by FCM was the CD8αα+ IEL. IFN-γ increased with PN and
declined to Control values with GLU: 8.3±6.1;10.2±2.5;6.8±0.9. IFN-γ was predominately
detected in CD8αβ IEL. As declines in IL-10 and elevations in IFN-γ can diminish EBF,
EBF was assessed. TER in PN group was lower than Controls (48.6±4.8 vs 82.9±6.1); and
this was prevented with GLU (66.6±6.9). Permeability coefficients (Papp) increased with
PN and returned to control levels with GLU (Table). Increases in short circuit current (Isc)
induced by glucose and carbachol were higher with PN; and prevented with GLU. Finally,
to further assess the mechanism of GLU action on EBF, epithelial tight junctional protein
expression (using immunoblots) was performed. Occludin and JAM1 decreased with PN;
and GLU supplemented PN significantly attenuated the decrease of occludin and JAM1
expression. Conclusions: GLU administration in PN mice prevented changes in IEL-derived
cytokines, and this was coincident with improved EBF. The up-regulation of occludin and
JAM1 with GLU suggests that this may be one of the responsible mechanisms.
Resuts expressed as mean±SD. *P<0.05 vs Control, **P<0.05 vs PN
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Disialylganglioside Gd3 Interferes with Nf-κB Signaling and Potently Inhibit
IL-1β Induced IL-8 Production in Intestinal Epithelial Cells
Kalathur S. Ramanujam, John Guan, Stan Cholodofsky, Amy Doherty
Background & Aims: Gangliosides are integral components of most vertebrate tissues. Gang-
liosides are biologically important molecules involved in a variety of cellular processes
including differentiation, proliferation and apotosis. In addition, gangliosides act as receptors
to bind enterotoxins in the gastrointestinal (GI) epithelium. Human milk contains disialylgan-
glioside GD3 and breastfed infants possibly benefit by consuming this critical ingredient
early in life. Recent study (Park et al, 2005) demonstrated that orally fed GD3 is absorbed
in the GI tract and specifically localized in intestinal epithelium. Gangliosides are also present
in lipid rafts and may mediate signaling in cells. Initial screening in our laboratory identified
anti-inflammatory characteristics of gangliosides. We hypothesized that GD3 is an anti-
inflammatory molecule and exert its effects by interference with NF-κB signaling in the GI
tract. Methods: Caco-2 cells were cultured for at least 10 days before pre-incubation with
either pure GD3, monosialyl ganglioside GM3, glucosyl ceramide or bovine milk fractions
enriched in GD3 for 16h. The following day cells were stimulated with IL-1β and the
secreted IL-8/ IL-6 levels were measured by immuno assays in the medium at various time
points. The cells were also collected for analysis of RNA by quantitative real-time PCR. In
some studies the nuclear and whole cell extracts were prepared after incubation with IL-
1β in the presence and absence of ingredients. Results: Pure or enriched fraction of GD3
or GM3 potently inhibited IL-1β induced IL-8/ IL-6 production in intestinal epithelial cells.
This inhibition occurred at the RNA level. Glucosyl ceramide, the precursor molecule for
GD3 or GM3 had no inhibitory effect in intestinal epithelial cells. Analysis of nuclear extracts
revealed impaired translocation of NF-κB upon IL-1β stimulation in presence of GD3.
Analysis of whole cell extracts revealed that there is defective degradation of IκB in cytoplasm
possibly contributing to defective NF-κB translocation. Discussions: Our results demonstrate
that GD3 and GM3 molecules potently inhibit IL-1βmediated IL-8/IL-6 secretion in intestinal
epithelial cells via NF-κB dependent mechanism. GD3 may play a crucial role in protecting
human milk fed infants by controlling inflammatory events during initial exposure to micro-
organisms in the GI tract during early infancy.
S2214
Pediatric Intervention Study with a Polar Lipid Enriched Milk (Inpulse®)
Product On Resistance to Common Infectious Diseases and Well-Being
Gigi W. Veereman, Sofie Staelens, Roeland Rombaut, Koen Dewettinck, Dirk Deboutte,
Robert jan Brummer, Pascale Leruyet, Marc Boone
Polar lipids constitute an important part of cellular membranes. The mucosal surface of the
GI tract is a critical barrier between noxious and immunogenic substances in the lumen
and the mucosal immune system. The purpose of this prospective dbrpc trial was to evaluate
the acceptability, safety & effect on intestinal comfort (constipation) and common infectious
symptoms (fever, diarrhea, cough) of 4 mths daily intake of 200 ml whole milk with or
without enrichment in milk polar lipids (Inpulse®) in healthy 2,5 to 6 yrs old children.
Study was approved by EC, conducted in accordance with GCP, informed consents were
obtained from legal guardians. The Achenbach System of Empirically Based Assessment
(ASEBA), a validated questionnaire to assess behaviour, was submitted to parents after D120.
Data were collected from parental diaries. Primary endpoints for analysis were number of
days with fever, diarrhea, coughing or constipation. Secondary endpoints were number of
doctor's visits, medication intake, number of missed school days, acceptability for study
product and safety. Standard parametric and non-parametric statistical analyses on basis of
per-protocol analysis were applied, with significance at p < 0.05. 253 children were included,
71 dropped out (= subjects with intake <80% or <90 days), no adverse effects led to
discontinuation. Per protocol analysis comprises 97 girls and 85 boys. The group (n=182)
is normally distributed, mean age 4,4 ±0.9 yrs. Amount of product taken in each day and
acceptability is similar in both groups. The number of days with fever > 38.5° as well as
number of short (<3d) febrile periods are significantly (p<0.03) lower in the intervention
group (1.7d ± 2.5) than placebo (2.6d ± 3.1) This significant difference in fever appears
after 6 wks of consecutive intake. Outcome parameters diarrhea, constipation, cough, doctor's
visit and days school missed fail to show significant differences. Analysis of 169 ASEBA
questionnaires with 2 tailed t-test proves significant differences in internal (p<0.003), external
(p<.004) & total problem scores (p<0.002) in favour of the Inpulse® group. Between-
subjects effects are highly correlated (internal p< 0.003, external p<0.005, total p < 0.002
-one way ANOVA). Conclusion: in preschool children the addition of polar lipids to milk
is safe, well tolerated and is associated with a significant drop in the number of short febrile
episodes, thus appearing protective against common infections. The behaviour and well
being of children taking whole milk with Inpulse® is improved. According to their parents
these children score significantly better for emotional and behavioural regulation.
S2215
Prospective Study of the Effect of Perioperative Nutrition with Omega-3 Fatty
Acids On Human Leukocyte Antigen-Dr Expression On Monocytes and T
Lymphocytes in Patients Undergoing Esophago-Gastric Cancer Surgery
Filippo Di franco, Javed Sultan, Irene Anderson, John A. Kirby, Brian K. Shenton, Shaun
R. Preston, Daya Karat, Nick Hayes, Michael Griffin
Introduction. Perioperative nutrition with omega-3 fatty acids (O-3FA) may modulate the
immune response after esophago-gastric cancer surgery. Up regulated expression of the
human leukocyte antigen-DR (HLA-DR) is required for monocytes to trigger T lymphocyte
activation. Activation of these cells in culture with phorbol myristate acetate allows measure-
ment of the potential to increase HLA-DR expression. This study evaluated the effect of
perioperative O-3FA on HLA-DR expression on monocytes and activated T lymphocytes of
patients undergoing esophago-gastric cancer surgery. Methods. This prospective randomized
study compared perioperative feeding with either an O-3 FA (Arm 1) or an isocaloric
isonitrogenous (Arm 2) formula. A control group (Arm 3) was managed with no intention
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to offer supplementary feed. Patients undergoing esophagectomy or total gastrectomy were
fed for seven days preoperatively and for seven days postoperatively. HLA-DR expression
on monocytes and T lymphocytes from venous blood was measured by flow cytometry. T
lymphocytes were activated In Vitro with phorbol myristate acetate for 48 hours. Measure-
ments were performed on days 7 (time 1) and 1 (time 2) before surgery, and 8 days
postoperatively (time 3). The analysis of variance was used for statistical analysis. A multiple
comparison t-test was carried out for statistically significant results. Results. Of the 45
patients recruited, 16 were randomized to arm 1, 14 to arm 2 and 15 to arm 3. In arm 1,
mean HLA-DR expression on monocytes increased from 18109 molecules of equivalent
soluble fluorochrome (MESF) at time 1 to 27995 MESF at time 2 (P=0.04), but it fell to
10555 MESF at time 3 (P=0.00). In arm 2, it decreased marginally from 26853 MESF at
time 1 to 25154 MESF at time 2 (P=0.64), and it fell further to 13605 MESF at time 3 (P=
0.00). In arm 3, there was a moderate fall during the perioperative period (23588, 20756
and 17679 MESF at time 1,2 and 3 respectively) (P=0.16). The percentage of activated T
lymphocytes expressing HLA-DR showed a trend to be up regulated in arm 1. This was
32.3%, 37.7%, and 40.1% at time 1,2 and 3 respectively (P=0.14). In arm 2, there was a
small reduction between time 1 (38.1%) and 2 (36.6%), whereas this was more consistent
at time 3 (29.2%) (P=0.1). There were marginal changes in arm 3 (37.3%, 35.8% and 38.1%
at time 1,2 and 3 respectively)(P=0.8). Conclusions. O-3 FA appears to up regulate HLA-
DR expression on monocytes prior to surgery. Even if a decreased HLA-DR expression on
monocytes was observed postoperatively, the ability of these cells to activate T lymphocytes
In Vitro after surgery showed a trend to be up regulated.
M1007
Risk of Irritable Bowel Syndrome After An Episode of Bacterial Gastroenteritis
Ana Ruigomez, Luis A. García rodríguez, Julián Panés
Background and aim: Bacterial gastroenteritis may be a risk factor for irritable bowel syndrome
(IBS). We aimed to quantify this risk and identify modifying factors in a large population-
based study. Methods: A population-based cohort study was conducted using the General
Practice Research Database. In a previous study, we identified adult patients with a first
episode of bacterial gastroenteritis between 1992 and 2001. Patients with a history of bowel
disease and cancer were excluded, leaving a cohort of 5894 individuals. From the same
source population, we randomly sampled a comparison cohort free of gastroenteritis, fre-
quency-matched by age, sex and calendar year to the gastroenteritis group (n = 46996).
Both groups were followed up to identify incident cases of IBS. We performed a nested
case-control analysis to assess potential risk factors for IBS. Logistic regression analysis was
used to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results: The incidence
of IBS per 1000 person-years was 9.8 (95% CI: 8.7-11.1) in the gastroenteritis cohort and
4.5 (95% CI: 4.2-4.8) in the comparison cohort (mean follow-up: 4.1 years). The adjusted
relative risk of developing IBS was 2.2 (95% CI: 1.5-2.9) in the gastroenteritis cohort
compared with the control cohort. Similar results (OR: 1.8; 95% CI: 1.5-2.1) were obtained
from the nested case-control analysis after adjusting for additional risk factors. In the
gastroenteritis group, younger age and female sex were associated with a greater risk of
developing IBS, but smoking, alcohol use and body mass index were not. The risk of
developing IBS was significantly increased in patients with prior gastrointestinal morbidity,
including gastroesophageal reflux disease (OR: 2.0; 95% CI: 1.6-2.5) and dyspepsia (OR:
2.2; 95% CI: 1.9-2.6). Patients were also at increased risk if they had previously documented
depression, anxiety, stress or sleep disorders. Prolonged antibiotic use after the episode of
gastroenteritis was associated with an increased risk of IBS, most likely because these patients
had more severe gastroenteritis. By contrast, prior asthma, chronic pulmonary disease,
ischaemic heart disease and diabetes did not increase the risk. Conclusion: Suffering bacterial
gastroenteritis doubles the risk of developing IBS, and this risk is independently increased
by pre-existing gastrointestinal or psychological comorbidities.
M1008
A Population-Based Study of Microscopic Colitis Following Renal and Liver
Transplantation
Gilaad G. Kaplan, Sansira Seminowich, Jennifer Williams, Marc P. Dupre, Stefan J.
Urbanski, Sedar Yilmaz, Kelly W. Burak, Paul L. Beck
Background and Aims: Microscopic colitis (MC), consisting of collagenous colitis (CC) and
lymphocytic colitis (LC), is increasingly recognized as an important cause of diarrhea espe-
cially in the elderly. The reported incidence rate and prevalence of MC is 5-6 and 13-
31 per 100,000, respectively. Most patients respond to various therapies including oral
corticosteroids. Although transplantation (Txpl) patients are commonly investigated for
diarrhea, MC has not previously been associated with transplantation. We have observed
patients with MC following Txpl despite patients being on immunosuppressants. Thus, we
set out to determine the prevalence of MC following organ Txpl, to assess clinical features,
and to describe the clinical course. Methods: A population-based cohort study was designed
to identify of all cases of MC diagnosed following renal, pancreas, and/or liver Txpl among
residents of the Calgary Health Region (population 1.2 million). All cases of MC diagnosed
between 2000 and 2005 were ascertained using the centralized Calgary Laboratory Services
pathology database. All incidence cases of MC were confirmed through medical chart review
and then cross-referenced to the kidney, pancreas, and liver Txpl database. Results: In 2005,
649 renal and/or pancreas Txpl patients and 240 liver Txpl patients were followed in the
Calgary Health Region. Among these patients 7 cases (0.8%) of MC (LC:4, CC:3) were
diagnosed in renal (3), renal/pancreas (1), and liver (4) Txpl patients. All Txpl patients
presented with diarrhea (mean latency period was 30.1 months). Four of 7 were female,
the average age at diagnosis was 49.9 +/- 6.1 years and the onset of diarrhea following Txpl
was 50.3 +/- 25.3 months. Six of 7 patients were treated with entocort and all had a complete
response, though 3 required repeated courses. None of the patients were smokers, on NSAIDs,
or had features suggestive of known drug induced GI-injury. None of the immunosuppressant
agents were common to all patients. Conclusion: MC has not been previously recognized
as a sequale of Txpl. With 0.8% of Txpl patients in our study having MC this is 25-60 folds
higher than the prevalence for the general population. Thus, MC should be considered
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strongly in the differential diagnosis in Txpl patients with diarrhea. Further studies in this
area may add to our understanding of the pathogenesis of MC.
M1009
Lymphocytic Colitis: Clinical Presentation, Treatment and Outcomes of 207
Patients
Ahmed Madisch, Stephan Miehlke, Bernd Kusnik, Birgit Bethke, Manfred Stolte
Background: Lymphocytic colitis is a chronic disorder characterized by watery diarrhea.
Clinical features or treatment outcomes in a large group of patients are sparse and only
retrospectively collected. Aim: to evaluate prospectively the clinical features, response to
treatment and outcomes in a large group of patients with lymphocytic colitis. Patients
and Methods: Patients with histologically confirmed lymphocytic colitis were prospectively
enrolled to complete a questionnaire on onset and duration of diarrhea, stool frequency and
consistency, other gastrointestinal symptoms including weight loss, drug history, treatment
success and concomitant diseases. Results: A total of 207 patients (female n=158 (76%);
mean age 61 years, range 22-89 years) were available for analysis. Prior to diagnosis the
mean duration of symptoms was 23 months (range 2 weeks to 45 years). At diagnosis the
daily mean stool frequency was 6 (range 1-20). Abdominal pain were reported by 55 patients
(26,5%), weight loss (mean 6 kg) by 100 patients (48%, and nocturnal stools by 126 patients
(60,8%). Concomitant autoimmune disorders such as thyroid dysfunction, diabetes mellitus,
or rheumatoid diseases were present in 82 patients (29,6%). Sustained clinical remission
was reported by 80 patients (38,6%), 35 patients (16,9%) of them received medication such
as corticosteroids, antibiotics, bismuth or 5-aminosalicyclic. In 125 patients (66,5%) empiric
treatment was not effective. Thirty-eight patients (18,4%) were regularly using Aspirin or
NSAIDs. Histological transition from lymphocytic to collagenous colitis was observed in six
patients (2,9 %), and from collagenous to lymphocytic colitis in one patient. Conclusion:
Lymphocytic colitis is frequently associated with abdominal pain, nocturnal stools, weight
loss and concomitant autoimmune disorders. Overall response rates under empiric treatment
were disappointing. Randomized controlled trials are needed to establish effective therapeutic
approaches to these patients.
M1010
Incidence and Severity of Colonic Diverticulitis in a United States Population
Claude M. Bridges, Hye kung Jung, Santhi Vege, David W. Larson, G. richard Locke,
Stephen Cha, Jeffrey Harrington, Nicholas J. Talley
Background: It is controversial whether recurrent diverticulitis carries a higher risk of
complications than incident diverticulitis. Some reports suggest most complicated diverticu-
litis presents as an index rather than recurrent event, but have often relied on self-report.
Inpatient-based reports have suggested diverticulitis is a more virulent disease in young
males. We aimed to determine the age and sex specific annual incidence of first event
diverticulitis in a well-defined American population, and to characterize disease severity on
presentation in relation to age and sex. Methods: We performed retrospective chart review
of all visits made by Olmsted County, MN residents in the 1998 calendar year that received
HICDA/ICD9 codes of diverticulosis, diverticulitis and its complications. Relevant demo-
graphic, history, exam, lab, radiographic, and surgical findings were abstracted on a standard-
ized data abstraction form. Several incidence cohorts were created to improve robustness
of the incidence estimate. All cohorts required subjects to have demonstrated diverticulosis,
and no prior diverticulitis in their medical record. Cohorts differed by their case definition.
The “clinical” cohort contained subjects diagnosed with diverticulitis by the treating clinicians,
and confirmed by review of all subsequent clinical encounters one year after the index event.
The “lower stringency algorithm” (LSA) and “higher stringency algorithm” (HSA) cohorts
contained subjects whose pattern of findings met pre-defined criteria. The HSA cohort
generally contained subjects who had received CT during diagnostic evaluation. The LSA
cohort contained every HSA subject. Results: 1112 charts were reviewed, with a total of 88
cases qualifying for at least one of the incidence cohorts. Diverticulitis incidence was 126
subjects/100k in the clinical, and 80 subjects/100k in the LSA cohorts. The age range of
incident cases was 30-91. The incidence of diverticulitis varied significantly with age (χ2=
23.2-40.5, p<0.0001) in both cohorts. The incidence was 26-45/100k under age 50, and
rose to 207-452/100k in subjects over age 80. The proportion of females in both incidence
cohorts was 51%. Age-adjusted incidence rates did not vary with sex (χ2=0.62-1.2, p=0.43-
0.27). Most cases were managed as outpatients (55-69%). In the HSA cohort, neither
age nor sex was associated with complicated diverticulitis (χ2=0.006-2.4, p=0.94-0.12)
Conclusions: 1. Diverticulitis incidence sharply increases with age. 2. There does not appear
to be a sex difference in disease incidence. 3. There does not appear to an effect of age or
sex on risk of complicated diverticulitis at index presentation.
M1011
Racial and Socioeconomic Disparities in the Placement of Percutaneous
Endoscopic Gastrostomy (PEG) in Medicare Beneficiaries from 1992 to 2003
Joshua D. Novak, Doug Kou, Gregory S. Cooper, Richard C. Wong
Background: PEG tubes are commonly placed to deliver nutrition and medications in patients
who cannot swallow. Because the procedure is generally performed electively in conditions
such as dementia and stroke, it is unclear whether, as with other discretionary procedures,
race and socioeconomic status are associated with differences in the utilization of PEG.
Objective: To describe patient demographic and clinical characteristics associated with PEG
placement. Methods: All inpatient claims from 1992 to 2003 for a 5% random sample of
cancer-free Medicare beneficiaries age 66 and older were examined. Patients who were
enrolled in Medicare Part A and who were in fee-for-service programs were included. PEG
procedures were evaluated from claims records. U.S. Census 2000 data for median household
income at the census tract level was used as a proxy measure for patient-level socioeconomic
status. Survival was measured from date of initial PEG placement through a 3-year follow-
up period. The Charlson comorbidity index was used to evaluate disease burden. Independent
factors associated with survival time were studied using Cox regression. Results: 7,437
patients had PEG placement. 71.6% were Caucasian, 19.9% were African American, and
8.5% were of other minority descent, compared with 80.4%, 9.0%, and 10.6%, respectively,
in the general Medicare population. African Americans and other minorities were more likely
than Caucasians to have a comorbidity index > 4 at the time of index PEG placement (15.2%
and 16.1% versus 12.1% respectively, p < 0.0001). The median census tract household
income for African Americans with PEG placement was $31,501, compared to $46,128 for
Caucasians and $44,829 in the overall Medicare population. Patients residing in census
tracts with median incomes > $75,000 had better survival with an adjusted risk of death
of 0.90 (95% CI 0.86-0.99) compared to those earning < $50,000. However, the overall
survival was comparable between African American and Caucasian patients (adjusted risk
of death 1.0, 95% CI 0.94-1.08). Conclusions: A disproportionate percentage of African
Americans received PEG tube placement. Although long-term survival following PEG place-
ment was not different in African Americans, individuals residing in more affluent census
tracts had better long-term survival following PEG placement. Although these findings may
be due to differences in patient and/or physician preferences or burden of comorbid illnesses,
further research is needed to explore the underlying causes of these observed disparities.
M1012
Reports of 5-ASA-Associated Pancreatitis from the FDA Adverse Event
Reporting Databases
Alexander P. Ruggieri, Anju Kanumalla, John F. Watson
BACKGROUND: Pancreatitis risk described in the prescribing information for mesalamine,
balsalazide, olsalazine, and sulfasalazine is based on observations from controlled clinical
trials and/or spontaneous postmarketing reports. We sought to examine the reporting of
pancreatitis among the 5-ASA products in the post-approval setting from spontaneous
postmarketing adverse event reports (AERs) in the US Food and Drug Administration Adverse
Event Reporting Database System (FDA AERS). METHODS: Adverse event reports (AERs)
for the 5-ASA class were identified in the U.S. Food and Drug Administration (FDA)
postmarketing surveillance databases, which have captured drug-related adverse events since
1969. For this analysis, we queried reports submitted to the FDA between 1969 and March
31, 2006. Spontaneous reporting of AERs is often limited by incomplete capture of event
related data and difficulties with making causal inference due to confounding factors but
can be used as a means of comparing relative proportions of a specific AER among a group
of products if it is assumed that any inherent limitations and biases within the data apply
to all reports. AERs of pancreatitis were selected using three MedDRA preferred terms:
‘Pancreatitis,' ‘Pancreatitis acute,' and ‘Pancreatitis NOS.' For the 5-ASA class, the proportional
reporting ratio (PRR), defined as the ratio of the proportion of pancreatitis AERs for a drug
of interest with the proportion of pancreatitis AERs in the entire FDA database, was calculated.
In addition, a PRR relative to amoxicillin, a drug generally known not to be associated with
pancreatitis, was calculated to ensure amplification of any pancreatitis report disproportions.
To provide further perspective on any disproportionate reporting for the 5-ASA class, a PRR
relative to azathioprine, a drug known to be associated with pancreatitis and often used in
treatment of inflammatory bowel disease, was also calculated. RESULTS: Out of 6,641 total
reports, there were 159 reports of pancreatitis for the 5-ASA class for a proportion of 2.4%.
The PRRs calculated as described above for the 5-ASA class, amoxicillin, and azathioprine
are shown below. CONCLUSIONS: Pancreatitis has continued to be observed in the postmar-
keting setting for all 5-ASA products and remains a recognized part of the risk profile of
this class.
M1013
Administrative Definition for Inflammatory Bowel Disease Based On ICD
(International Classification of Diseases) Diagnostic Codes
Ali Rezaie, Remo Panaccione, Hude Quan, Li Bing, Robert J. Hilsden
INTRODUCTION: To facilitate the conduction of population-based epidemiologic studies,
this study was performed to develop a valid indigenous criterion for capturing IBD patients
through comprehensive and sophisticated administrative databases available in the province
of Alberta, Canada. METHODS: Reports of endoscopy procedures performed within the
Calgary Health Region (CHR) are housed in a computerized database (EndoPro). Computer-
ized and manual search strategies were conducted on EndoPro database to categorize the
patients undergone a colonoscopy within the period of 05/16/2000 through 04/01/2004
into definite IBD, possible IBD, and definite non-IBD patients (controls). The medical service
history (ICD diagnostic codes) of the IBD patients and controls was tracked by a unique
personal health identification number in physician claims, hospital abstracts and Ambulatory
Care Classification System (ACCS) databases. ACCS is a made-in-Alberta database that
collects information on facility-based ambulatory care (e.g. Day surgeries and procedures).
Between 1996-2004, ICD-9 and ICD-10 codes for Crohn's disease and ulcerative colitis were
extracted. Over 400 administrative definitions were developed for IBD patients depending on
the number and periodicity of IBD codes in each database. In case of disagreement between
administrative criteria and EndoPro complementary chart reviews were done (i.e., 196
individual charts).The most practical definition has been chosen to have a high specificity
and an acceptable sensitivity. RESULTS: 1,399 IBD patients and 15,439 definite non-IBD
individuals were identified through EndoPro database search and chart reviews. The favorable
definition classifies individuals as having IBD only if they have four physician claims OR
two ACCS claims OR a hospitalization with an ICD diagnostic code of IBD. The definition
must be met within a maximum time period of three years.Test characteristics of our criteria
(95% Confidence Interval) are as follows: Specificity=99.75% (99.66%-99.82%), Sensitivity=
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85.70% (83.76%-87.50%), Positive Predictive Value=96.85% (95.72%-97.75%), and Nega-
tive Predicive Value=98.72% (98.53%-98.89%) CONCLUSION: Through a novel methodo-
logy we have developed a reliable ICD coding definition for IBD, which could be used in
future population-based studies.
2×2 table for our administrative IBD criteria
M1014
Prevalence and Predictors of Constipation in the Greek Urban General
Population
George Papatheodoridis, Ioannis Karaitianos, Demetrios G. Karamanolis
Background/Aim: The prevalence of constipation was recently reported to range from 5%
to 9% in Western-Central European countries and to be 18% in USA. However, relevant
data for Greece and other Mediterranean countries are lacking. The aim of this epidemiological
study was to evaluate the prevalence of constipation in the Greek general population as well
as its associations with individual characteristics. Methods: The study sample included 1,000
individuals, 15-64 years, citizens of Athens, Thessaloniki or one of 11 Greek cities with
>10,000 population. The selection was made by a stratified, multi-stage, random sampling
procedure based on the 2001 census and the official households-maps of the Hellenic
Statistic Service. Questionnaires were completed for each individual by personal interviews.
Results: The prevalence of constipation within the last year was 16%. Constipation was
significantly more frequent in females than males (21% vs 11%, Ρ<0.001), in individuals
of older age (15-29 years: 12%, 30-59 years: 16%-18%, 60-64 years: 25%, Ρ=0.007) and
in state employees than free professionals (19% vs 11%, Ρ=0.05), while it was relatively
more frequent in obese (BMI≥30 Κg/m2) (20%) or low BMI (<20 Κg/m2) (18%) individuals
compared to individuals with normal ΒΜΙ=20-25 Κg/m2 (14%) (Ρ=0.14). Constipation was
considered to be due to inappropriate diet (51%), stress (30%) and absence of physical
activity (19%). The mean duration of constipation was 6.3 years (females:6.9, males:5.1).
Constipated patients mostly used dietary modifications (51%) and/or traditional products
(40%) and/or laxatives (43%), while 21% of them did not try to treat constipation. Conclu-
sions: Constipation is present in 16% of the Greek urban general population being signific-
antly more frequent in females and older ages. Current dietary habits, stress and the way
of living seem to represent the most common factors associated with constipation. Although
the duration of constipation is usually long, a substantial proportion of constipated patients
do not try to treat their problem, while the majority of them uses dietary modifications and/
or traditional products without satisfactory results.
M1015
Rates and Predictors of Depression in An Out-Patient Hepatology Practice
Gregory S. Sayuk, Samer El-dirani, Jill E. Elwing, Pat Lustman, Mauricio Lisker-melman,
Jeffrey S. Crippin, Ray E. Clouse
Depression interferes with all aspects of daily living, adherence to medical recommendations,
and treatment outcomes. Depression may be under-recognized in patients with chronic liver
disease (CLD) because many of its symptoms overlap with symptoms attributable to liver
dysfunction. The rate of depression symptoms across types of CLD is not known. We
administered a commonly used depression assessment instrument, the Beck Depression
Inventory (BDI), to out-patients attending a university-based practice to determine the rate
of current depression symptoms and predictors of elevated scale scores. Methods: 345 pts
with CLD [51.1 ±11.9 yr; 193 (55.9%) female; 104 (30.1%) cirrhotic] completed the 21-
item BDI during an office visit (max score 63). Etiologies of liver disease were: hepatitis C
(HCV) 115 (33.3%), NASH/cryptogenic 78 (22.6%), primary sclerosing cholangitis (PSC) 18
(5.2%), primary biliary cirrhosis (PBC) 13 (3.8%), hepatitis B (HBV) 16 (4.6%), autoimmune
hepatitis (AIH) 25 (7.2%), other CLD 52 (15.1%). Prevalence rates of pts having total BDI
≥16, an accepted cut-off for suspecting major depressive disorder, and a score ≥10 on the
cognitive symptom scale (cBDI, excludes overlapping somatic symptoms) were determined
per CLD group. Predictors of total BDI score were determined from a linear regression model
that included demographic (age, sex, BMI), clinical [type 2 diabetes (T2DM), prednisone use,
interferon use, IV drug use (IVDU), current alcohol use], and liver disease variables (MELD
score, encephalopathy, AST). Results: BDI scores ≥16 were found in 37.4% of the total
subject group, ranging from 25.0 - 42.6 % without significant difference across the repres-
ented disorders (HCV 42.6%, NASH 34.6%, PSC 38.9%, PBC 38.5%, HBV 25.0%, AIH
40.0%, other 29.6%; χ2 = 3.96, p=0.78). cBDI scores ≥10 were found in 24.6% of CLD,
ranging from 12.5 - 27.8% across disorders (HCV 27.8%, NASH 26.9%, PSC 27.8%, PBC
23.1%, HBV 12.5%, AIH 16.0%, other 24.1%; χ2=3.65, p=0.81). In regression models of
all CLD subjects, younger age, female sex, T2DM, and IVDU predicted higher total BDI and
higher cBDI scores (p<0.05 for each). Liver disease variables were not independent predictors
of BDI scores in either model. Conclusions: High levels of current depression symptoms
are present in a large proportion of out-patients with CLD. This finding is not related solely
to CLD symptoms that might mimic depression and is not conspicuously affected by type
of CLD. Depression symptoms are best predicted by clinical features associated with depres-
sion in non-CLD populations (female sex, T2DM, IVDU) rather than type of liver disease
or measures of liver disease severity.
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M1016
Mapping of Inflammatory Bowel Disease in Northern France: Spatial
Variations and Association with Affluence
Christophe Declercq, Corinne Gower-rousseau, Gwénola Vernier-massouille, Mamadou
Baldé, Gilles Poirier, Eric Lerebours, Jean-louis Dupas, Véronique Merle, Raymond Marti,
Antoine Cortot, Jean-frédéric Colombel, Jean-louis Salomez
Background: Geographic and socio-demographic variations in incidence of inflammatory
bowel disease may reflect variations in the distribution of environmental etiologic factors.
Aim: To assess small-area spatial variations in the incidence of Crohn's disease (CD) and
ulcerative colitis (UC)in Northern France over the 1990-2003 period and to analyze the
association with a deprivation index. Methods: All incident cases of CD and UC between
January 1st, 1990 and December 31th, 2003 in Northern France (including the Departements
of Nord, Pas-de-Calais, Somme and Seine-Maritime: 5.79 millions inhabitants) were extracted
from the EPIMAD registry. The standardized incidence ratio (SIR) was calculated for each
of the 273 cantons (a French administrative level with a mean population of 21,210 inhabit-
ants)of this region. To take into account instability of small numbers, spatial heterogeneity
and spatial autocorrelation, the SIRs were smoothed using a fully Bayesian hierarchical
model. In order to analyse the association between incidence and deprivation, the Townsend
deprivation index at the last census (1999) was calculated for each canton and entered into
the hierarchical model. Results: Mean annual crude incidence rates of CD and UC were
6.2×10-5 and 3.8×10-5 respectively. The total number of cases was 5038 for CD and 3089
for UC. Mean cumulated numbers of cases by canton were 18.4 (range: 1-183) for CD and
11.3 (0-148) for UC. Mapping of both diseases showed marked significant (p<10-4) spatial
heterogeneity in the SIR for both CD and UC, with a significant spatial autocorrelation for
both diseases. High relative risks for CD were observed in the cantons of south of Nord,
center of Somme and west of Seine-Maritime. All those cantons were mainly rural and peri-
urban. For UC high relative risks were found in the cantons of south and center of Pas-de-
Calais. The relative risks of developing CD and UC were slightly but not significantly lower
in the most deprivated cantons: respectively 0.91 [95% credibility interval = 0.81 - 1.04]
for CD and 0.87 [0.76 - 1.00] for UC in the 5th quintile of the distribution of Townsend's
index. Conclusions: In the largest study so far looking at small-area spatial variations in the
incidence of IBD, we were able to detect spatial heterogeneity in SIR of both CD and UC.
No strong relation was observed with affluence. The influence of socio-demographic and
environmental factors on these patterns of incidence requires more investigation.
M1017
Adherence to Medication in Inflammatory Bowel Disease Patients
Perla Bertomoro, Maria grazia Vettorato, Ketti Mazzocco, Rino Rumiati, Giacomo C.
Sturniolo, Renata D'inca'
Background: Inflammatory bowel diseases (IBD) are chronic conditions requiring medication
throughout life in order to treat the disease and control the risk of relapse and colorectal
cancer. Adherence to prescribed drugs is therefore crucial in their management. Aim: In
order to identify determinants and possible risk factors of non adherence 475 IBD patients
were administered a questionnaire of 24 items at the time of their visit. Patients were
interviewed regarding socio-demographic and disease characteristics, reasons for non adher-
ence and general health behaviour. Results: Adherence was referred by 61,4% of the patients.
No difference was detected between ulcerative colitis and Crohn's disease and socio demo-
graphic characteristics other than age which was significantly associated with non-adherence
in patients younger than 40 yrs (43,3% vs 34,3%, p=0,041). The most common reasons
for non adherence vs adherence were forgetfulness (61% vs 44%, p=0,000), disease remission
(25% vs 10%, p=0,000),, recent diagnosis (24% vs 15%, p=0,000) and full time employment
(55% vs 26%, p=0,045). Oral therapy was significantly more associated with adherence
than rectal therapy(59,7% vs 31,9%, p=0,001). Non adherence to tablets was referred to
difficult swallowing (7,0% vs 1,7%, p=0,003), abdominal pain and nausea (7,0% vs 0,7%,
p=0,000), multiple daily dosing (5,3% vs 2,0%, p=0,045). Enemas were referred difficult
to use (7,0% vs 3,0%, p=0,043), painful or provoking bloating (8,0% vs 3,0%, p=0,013)
and difficult to manage over duties (7,0% vs 1,7%, p=0,003). Patients' behaviour in other
health domains demonstrated a preferential self made aid in non adherent patients having
flu with respect to adherent patients going to the doctor for cure. Communication affects
patient's adherence: a significant interaction was found with adherence and patients <40
yrs communicating with their doctor (46,6% vs 36,1%, p=0,036). Conclusions: Risk factors
for non adherence are young age, busy working activity, recent diagnosis and disease
remission. Communication with the doctor needs to be implemented in order to improve
adherence.
M1018
High Prevalence of Constipation in Adults Presenting with a New Diagnosis of
Coeliac Disease
John Darke, Andrew D. Keegan
Background and Aims: Based on the early literature, diarrhoea is thought to be a common
presenting feature in adult patients with coeliac disease. More recent literature suggests there
has been a shift towards non-diarrhoeal or silent coeliac presentations. The aim of this study
was to evaluate the clinical features of adult patients presenting with a new histological
diagnosis of coeliac disease. Methods: All patients presenting to a community-based metropol-
itan consultant gastroenterologogy practice found to have a new histological diagnosis of
coeliac disease between January 2004 and July 2006 were identified using a computerised
database followed by medical record review. The prevalence of various clinical features that
had been prospectively documented on a standardized proforma were recorded. Results of
laboratory investigations, including haemoglobin, iron studies, folate and vitamin B12 levels,
serum transaminase levels, thyroid function tests and coeliac serology were also evaluated.
Small bowel endoscopic appearance and histology were also recorded. Results: Twenty-two
adult patients with a new histological diagnosis of coeliac disease were identified. Ages
ranged between 14 and 74 years (mean 45 years). There were 15 females (68%) and 7
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(32%) males. The most prevalent symptoms were abdominal pain and bloating, present in
12 (55%) and 11 (50%) patients respectively. Nausea and diarrhoea were each seen in 10
(45%) patients. A history of constipation was recorded in 9 patients (41%); all were female.
Six patients (27%) had a history of weight loss. Anaemia was present in 4 patients (18%)
at diagnosis, with 8 patients (42%) having evidence of iron-deficiency with a low serum
ferritin. Four (18%) patients had a positive family history of coeliac disease. A low serum
folate was present in 3 (18%) patients. The sensitivity of anti-gliadin, anti-tissue transglutami-
nase and anti-endomysial antibodies was 75%, 88% and 100% respectively. Thirteen (59%)
patients had an abnormal appearing duodenal mucosa at endoscopy, while 18 (82%) had
at least mild villous atrophy. Conclusion: The clinical spectrum of adult patients presenting
with a new diagnosis of coeliac disease is variable, with diarrhoea present in less than half
these patients. A history of constipation, particularly in females, should not discourage
physicians from pursuing a diagnosis of coeliac disease.
M1019
Changes in Upper Gastrointestinal Symptoms and Endoscopic Findings in
Japan During the Past 15 Years
Noriaki Manabe, Ken Haruma, Jiro Hata, Hiroaki Kusunoki, Tomoari Kamada
Background and Aims: In Japan, the composition of upper gastrointestinal diseases is chan-
ging with the recent decrease in the rate of H. pylori infection. Among upper abdominal
complaints, discomfort and/or pain, have frequently been encountered in daily practice, but
there have been few reports assessing changes in symptoms over the years. The aim of this
study was to assess changes in endoscopic findings and symptoms over the years in patients
who underwent endoscopy because of chief complaints of upper abdominal symptoms.
Subjects and Methods: Over the past 15 years, we have assessed changes in the complaints
of and endoscopic findings in patients who underwent endoscopy at Kawasaki Medical
School Hospital because of chief complaints of upper abdominal symptoms. The study was
composed of patients treated between 1990 and 1991 (Group A) and between 2004 and
2005 (Group B). There were 914 patients (590 men, 324 women; mean age, 52.2 years)
in Group A and 1724 patients (1014 men, 710 women; mean age, 59.6 years) in Group B.
Results: The most common complaint was discomfort and/or pain in all age. The percentage
of patients with heartburn symptoms has almost doubled (Table 1). Assessment of endoscopic
findings revealed that, among patients who complained of discomfort and/or pain, the
percentage of those with organic diseases decreased (352 patients [58.1%] in Group A vs.
738 patients [42.8%] in Group B) (Table 2). The percentage of patients with GERD including
non-erosive reflux disease among those with heartburn symptoms increased markedly (52.3%
in Group A vs. 92.9% in Group B). Conclusions: Discomfort and/or pain has been the most
common upper gastrointestinal symptom for the past 15 years in Japan, but the composition
of endoscopic diagnoses has changed greatly. The percentage of patients with heartburn
symptoms has increased and many of the cases have been associated with GERD. It is
presumed that in the future there will be fewer patients with MK or GDU and more patients
with GERD or functional dyspepsia among those who complain of upper gastrointestinal
symptoms in Japan.
Table 1. Changes in Upper Gastrointestinal Symptoms
Table 2. Changes in Endoscopic Findings among patients who complained of discomfort
and/or pain
GDU: gastric or duodenal ulcer, MK: advanced gastric cancer, RE: reflux esophagitis
M1020
H. pylori Infection and Allergic Diseases
Akiko Shiotani, Teruo Miyanishi, Tomoari Kamada, Ken Haruma
Background: A negative association between H. pylori infection and allergic diseases has not
been consistent. Aim: To examine the association between allergic diseases and H. pylori
infection in Japan. Methods: Newly enrolled university students completed health survey
questionnaires regarding general health and the presence of allergic diseases. H. pylori
status was determined by the presence of serum H. pylori IgG and the presence of allergic
manifestations was confirmed by interview. Results: One thousand nine hundred fifty-three
students had routine health survey; H. pylori status was determined in 777 including 369 with
allergic diseases and 408 controls. The reported frequencies were: allergic rhinoconjunctivitis
(29%), atopic dermatitis (11.1%), urticaria (2%), bronchial asthma (0.9%), or more than
one manifestation (5%). Age, gender and the prevalence of upper GI symptoms were not
significantly different between the allergic group and the non-allergic group. The prevalence
of H. pylori infection was significantly lower (11.4%) in the allergic group than non-allergic
group (17.6%) (p=0.015). In the total subjects and in men, H. pylori infection was less
frequent in the subjects with the allergic diseases (total subjects, OR 0.60, 95% CI 0.40-
0.90; men OR 0.49, 95% CI 0.27-0.89). However, in women there was no significant
association between the allergic diseases and H. pylori infection. None of the men with more
than one allergic disease was H. pylori positive; The difference of the prevalence of H. pylori
infection was statistically significant (p=0.03).Conclusions: Allergic diseases are frequent in
young Japanese adults and are negatively associated with H. pylori infection especially in men.
M1021
Racial and Ethnic Differences in Pediatric Obesity-Prevention Counseling - A
National Prevalence Analysis of Healthcare Provider Practices
Christopher M. Branner, Tatsuki Koyama, Gordon L. Jensen
Objective.To assess the frequency of pediatric clinician-reported delivery of obesity-prevention
counseling (OPC) at well-child visits, specifically evaluating for racial or ethnic discrepancies.
Methods. Combined, weighted well-child visit data from the National Ambulatory Medical
Care Survey (NAMCS) and the National Hospital Ambulatory Care Survey (NHAMCS) from
2001-2004 were analyzed for patients aged 4-18 years. OPC was defined as the combined
delivery of Diet/Nutrition and Exercise counseling. Patients receiving International Classifica-
tion of Diseases, Ninth Revision diagnosis codes for over- or underweight related diagnoses
were excluded. Counseling frequencies were examined in relation to patient and clinician
characteristics. Multivariate logistic regression models examined the relationship of OPC
with race, ethnicity, region, provider, sex, age, and pay type. Results. Of 55,695,554
(weighted) visits, 24.4% included OPC. Data from NAMCS represented 90.8% of the total
records for analysis (9.2% from NHAMCS). Only 15.4% of Hispanic patients received OPC
compared to 28.8% of non-Hispanics. There were no frequency differences between Whites
and Blacks (25.0 and 27.1%) Clinicians in the West reported less OPC than other regions
of the country (12.6%). Patients with Private insurance received significantly more counseling
(26.9%) than those with Medicaid (19.1%) or who were Self-pay (15.1%). In logistic
regression models, non-Hispanics were more likely to receive OPC (OR: 1.94; CI: 1.13-
3.32), and patients seen in the West were less likely to receive OPC (OR: 0.39; CI 0.18-
0.85). Pay type was not demonstrated to be predictive in regression analysis. When the data
were analyzed based on source (NHAMCS vs. NAMCS), patients seen in hospital-based
practices received less OPC (11.9% vs. 25.7%) with an OR = 0.40; CI 0.22-0.74. Conclusions.
Prevention, like treatment of obesity, is a complex and multi-factorial process. With the
documented racial and ethnic disparities in rates of pediatric obesity, reasons for discrepancies
in the provision of OPC must be further investigated as preventive strategies are formulated.
M1023
Current Prevalence of Helicobacter pylori Infection Among Children and
Adults in High and Low Gastric Cancer Incidence Regions of China
Zhou Li-ya, Zhang Dong-hong, Lin San-ren, Ding Shi-gang, Yan Xiu-e, Meng Ling-mei,
Zhang Jing, Cui Rong-li
Background & Aims: Recent studies indicate that Helicobacter pylori (H. pylori) prevalence
is declining worldwide. H. pylori infection rates were formerly high in China. In the present
study, we determined the current prevalence of H. pylori infection among children and
adults residing in areas with high (Muping, Shandong) and low (Yanqing, Beijing) incidence
rates of gastric cancer in China, and compared the results of 2006 with studies conducted
in early 1990s to assess changes of H. pylori infection in China. Methods: Using Warthin-
Starry silver stain of gastric mucosal biopsy specimens and H. pylori stool antigen test, we
totally detected 2065 asymptomatic children aged 8-15 years and adults aged 40-79 years
in 2006. The volunteers were selected randomly and were similar in regard to age and sex
between the two regions. This study was approved by the Ethics Committee of the Peking
University Health Science Center. Results: In group of children, the prevalence of H. pylori
infection was significantly higher in Muping (37.69%) than in Yanqing (25.58%, p<0.001);
in both regions, the prevalence of H. pylori increased with age but was not related to gender,
and a significant difference was observed between age groups 8-9 and 10-11 years (p<0.05),
but not between the other adjoined age groups (p>0.05); compared results 2006 to results
1991, a decrease of H. pylori prevalence among 8-10 years old children was found both in
Muping (60.00% v 32.07%, p<0.001) and in Yanqing (24.06% v 19.10%, p>0.05). Similarly
in adults group, 50.95% were H. pylori positive rates in Muping, which was significantly
higher than 41.35% in Yanqing (p<0.01); there were no statistically significant differences
in the H. pylori positive rates between the adjoined age groups of 40-49, 50-59, and 60-79
years (p>0.05); The H. pylori prevalence in adults also showed no significant difference
between males and females (p>0.05); significant reductions in H. pylori prevalence were
shown comparing results 2006 with studies done in 1990 (Muping: 73.70% v 50.95%,
p<0.001) and in 1992 (Beijing: 55.35% v 41.35%, p<0.01). Conclusions: The prevalence
of H. pylori infection is significantly higher in high gastric cancer incidence region of China
than in low gastric cancer incidence region both among children and adults. H. pylori
infection rates are decreasing in China during recent years, especially in high gastric cancer
incidence area. H. pylori infection may be a risk factor in gastric carcinogenesis.
M1024
Prevalence of Hepatitis C Among Arab & Chaldean Americans in Southeast
Michigan
Laith H. Jamil, Michael C. Duffy, Monty Fakhouri, Evone Barkho, Radwan Khoury, Haifa
Fakhouri, Hikmet Jamil
Background: The prevalence of Hepatitis C antibodies (anti-HCV) in the U.S. ranges from
1.4% to 1.8%, with a higher prevalence among African Americans and Hispanics. Patients
from Middle Eastern countries may have additional risk factors for Hepatitis C Virus (HCV)
transmission, such as reusing needles for medical therapy, circumcision by informal health
care providers, folk and traditional medical procedures, etc. There are no published studies
on the prevalence of anti-HCV among the Arab/Chaldean American population in the U.S.
Methods: Retrospective review of data collected during an HCV public awareness and
education program conducted by the Arab American and Chaldean Council (ACC), a non
profit organization, in the Arab/Chaldean American population residing in Southeast Michi-
gan (SE MI). Inclusion criteria were anti-HCV positive subjects of Arabic/Chaldean descend,
born in an Arab country but residing in Metropolitan Detroit who underwent HCV antibody
testing (Home Access Hepatitis C Test). Subjects with an “Indeterminate result” were excluded
from further analysis. Results: A total of 436 subjects' data were reviewed. Analysis was
performed on 423 subjects. Excluded subjects were either born in the U.S (8), not of Arab/
Chaldean descend (3), or tested indeterminate (2). Mean age was 43.2 years (range 18-77
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years), males were 50.1%, and 30% did not speak English. The mean number of years of
residence in the U.S was 10.4 (range 0.5-52 years). The overall prevalence of anti-HCV was
4.7% (20 subjects, 9 males, 11 females), with 30% (6 subjects) between ages 40-49. Prevalence
among Chaldeans was 2.3%, and among Arab Americans 5.1%. Highest prevalence was
among Jordanians 20% (2 out of 10), followed by Egyptians 7.6% (8 out of 105). Five
subjects (20%) reported having an episode of “hepatitis”, and 4 subjects (20%) reported
jaundice. Risk factors included needle prick or shared needle (65%), shared personal hygiene
(60%), tattoos and body piercing (40%), blood transfusion before 1992 (25%), medical
therapy by non-sterile instruments (15%), Conclusion: This is the first study looking at the
prevalence of Anti-HCV among the Arab and Chaldean Americans in the U.S. with a
prevalence of 4.7%, which is more than double the national average. There is an estimated
430,000 Arab and Chaldean Americans in SE MI, the largest community outside of the
Middle East. Education regarding HCV (prevention and treatment) is needed for the Arab-
American and Chaldean community.
M1025
The “Altitude Enigma” in Gastric Cancer in Central America
Lindsey Wilfley, Ricardo Dominguez, Christopher Martin, Paris . Heidt, Douglas R.
Morgan
BACKGROUND Gastric cancer is the second-leading cause of cancer mortality worldwide,
with significant geographic variability. Areas of high incidence include Asia and Latin America.
Further variability has been observed between areas of high and low elevation - potentially
between mountainous and coastal regions. This has been observed in Latin America in the
mountainous areas of the Pacific rim, extending from Mexico to Chile. This may relate to
the interplay of host genotypes, H. pylori infection, dietary, and environmental factors. Our
aim was to investigate the variability of gastric cancer incidence based upon municipality
elevation in western Honduras. The mountainous region of western Honduras is identified
as a region of high incidence of gastric cancer. The standardized annual incidence is 30 per
100K (Males,39; Females,21; per 100K, 2001). METHODS The Western Regional Hospital
gastric cancer registry was used to identify incident cases from western Honduras for 1996-
2005. Municipality of residence and origin were determined; The latter was used, as little
mobility was noted in the population. Census data was obtained from the Honduras National
Statistics Institute (INE, 2001 census). Standardized municipality-specific gastric cancer
incidence rates were calculated. Elevations were obtained from Falling Rain Genomics, Inc.
Linear regression was used to evaluate the relation between altitude and gastric cancer
incidence. RESULTS Municipality-specific gastric cancer incidence rates were calculated for
95 municipalities in western Honduras. Thirty-six principal municipalities were identified
with rates ranging between 2.7 and 31.2 cases per annum per 100,000 population, combined
for males and females. The mean elevation of the municipalities ranged 307 to 1210 meters.
Five high incidence municipalities, all at higher elevations, were identified with a combined
annual incidence of at least 20 per 100K. The regression analysis suggests a borderline
positive linear relationship between municipality incidence and altitude (P = 0.065, F =
3.63). The correlation coefficient confirms altitude is not the dominant factor to explain
intra-regional differences in gastric cancer incidence (R = 0.31, R2 = 0.096). CONCLUSIONS
Gastric cancer incidence had a borderline correlation with elevation within the mountainous
region of western Honduras. The observed “Altitude Enigma” in gastric cancer in Latin
America is multifactorial, and more complex than elevation alone. It may be related to
differential risk factors between coastal and mountain populations, including genetic and
dietary factors. Further investigation in Latin America is warranted.
M1026
Prevalence of Fatal Outcome in Acute Pancreatitis-Five Year Experience
Ricardo Borsatto, Mary E. Yokota, Jose A. Perez
Introduction:Acute pancreatitis (AP)resulting in death is fortunately an uncommon event.-
Hospital admissions for this diagnosis have doubled over the past 30 years.In 1992, the
Atlanta consensus defined severe AP as that associated with organ failure and/or local
complications such as necrosis, abscess or pseudocyst.Systemic complications remain a
therapeutic challenge,a main prognostic determinant and account for the mortality in the
disease. Objective:The aim of the study was to determine the fatality rate, complications
and causes of death in patients admitted to Kern Medical Center,with a diagnosis of AP in
5 year period. These results were compared with other epidemiologic studies.Methods:Data
from 667 admissions for AP from July 1,1999 to June 30,2004 were reviewed.Thirty were
excluded: 9 were transferred,6 left against medical advice and 15 were younger than 18
years of age.A total of 637 cases in 589 patients were included. Of these 541 patients were
admitted once,38 twice and 10 admitted three times.Demographic information was obtained
including: etiology, historical data,physical examination findings and radiographic findings
if performed.The mortality rate was calculated and compared.Results:Six hundred thirty
seven admissions resulted in 20 deaths (3.2%).Admissions resulting in death tended to occur
in older individuals (53.5 versus 47.8, p=0.003)and were more associated with ascites on
physical exam (15.1% versus 1.1%, p=0.003).In those patients fulfilling the criteria for
severe AP, abdominal CT was ordered more often (45.5% versus 23.9% P=<0.0001) and
the risk of death was higher (11.1% versus 0.6%, P=<0.0001). A trend toward statistical
significance was seen in the finding of extra-pancreatic fluid on abdominal CT (p=0.09).No
other statistically significant differences were found between the two groups.Discussion: Our
mortality rate of 3.2% in cases of AP is within the range reported in other studies.Ascites
found on initial examination with AP was more commonly associated with death indicating
that this may be an adverse prognostic indicator. Patients who fulfilled the criteria for severe
AP tended to have more imaging at the time of admission and also a fatal outcome.We did
not find differences in outcome based on etiology of AP. Lipase level was not predictive of
fatal outcome
Mortality rate for Acute Pancreatitis in 637 cases admitted at KMC from July
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M1027
The Prevalence of Risk Factors for Gastrointestinal Complications and the
Utilization of Gastroprotective Strategies Among Users of Cardioprotective
Doses of Aspirin: A Population Based Study
Laura E. Targownik, Colleen Metge, Bill Anderson
Background: Aspirin (ASA) is commonly used by patients at increased risk for cardiovascular
(CV) disease, but is also associated with an increased risk of upper gastrointestinal (UGI)
complications. These risks may be particularly pronounced in patients with established risk
factors for ASA-related UGI complications. Gastroprotective strategies (GPS) may decrease
the risk of UGI complications in ASA users. Methods: We used the Manitoba Health Popula-
tion Health Research Data Repository to identify as Manitobans diagnosed with CV disease
in the two years prior to June of 2006, We then distributed an anonymous survey to a
random sample of 3,500 patients with CV disease and no history of peptic ulcer disease
(PUD) or UGI bleeding, and to all 643 subjects with CV disease and prior PUD or UGI
bleeding. The survey asked subjects about their use of non-prescription ASA and NSAIDs,
the presence of other indications for acid-reducing therapy, and also gathered data on their
perception of their own risk for ASA-related UGI complications. Patient-centered survey
data is then to be linked to administrative data maintained by Manitoba Health to determine
the presence of risk factors for UGI complications, including concomitant use of anticoagu-
lants, antiplatelet agents, and NSAIDs; The presence of significant comorbid diseases, and
on the use of GPSs, specifically H2-receptor antagonists and PPIs. Results: To date, 1002/
4143 (24%) have been returned, or whom 979 completed the survey. 91% of CV patients
with no history of PUD were using ASA, compared with 75% of patients with a history of
PUD (p=0.002). 67% of subjects were using low-dose ASA (<=81mg/d), and 19% were
concomitantly using over the counter NSAIDs. 77% of subjects stated they were aware ASA
can cause serious UGI complications, but only 22% of subjects considered themselves to
be at increased risk. Awareness of self-risk was significantly increased in subjects with a
history of PUD (45% vs. 18%, p<0.001). We will shortly be linking the patient-centered
data to our administrative healthcare utilization dataset to determine concurrent medication
use and other risk factors and to determine their relationship to the use of ASA and GPSs,
the results of which will be ready for presentation at DDW 2007. Discussion: ASA use is
significantly lower among patients with a history of PUD, leaving them at risk for serious
complications of CV disease. The majority of aspirin users do not consider themselves to
be at increased risk of ASA-related GI complications. Further linkage to administrative
datasets will provide important insights into the relation of ASA use, GI risk, and the use
of gastroprotective strategies.
M1028
Distribution of Colorectal Adenocarcinoma and High Risk Polyps in African-
Americans from 1996-2005: Is There a Rightward Shift?
Jason M. Collins, Amira Z. Ali ibrahim, Shariff S. Dunlap, Azza M. Ali, Edward L. Lee,
Duane T. Smoot, Hassan Ashktorab
Background: It has been suggested in the literature that there has been a time-trend change
in the anatomical distribution of adenocarcinoma of the colon. However, evidence from
studies addressing this issue has been inconclusive, and there is a lack of data addressing
this phenomenon in minority populations. In this study, we investigated the anatomical
distribution of adenocarcinomas and advanced adenomas over a 10-year period at Howard
University Hospital, an inner city tertiary institution with a large minority population base.
Methods: The records of patients who underwent colonoscopy from 1996 to 2005 were
reviewed. Data collected included age, sex, indication for procedure, outcome of procedure,
including histopathology when adenomas or adenocarcinoma were found, anatomical loca-
tion of the polyps or adenocarcinoma. Adenomas were categorized as advanced adenomas
if they contained villous features, high grade dysplasia or were ≧ 1cm. The right side of
the colon was defined as locations including and proximal to the splenic flexure. The left
side of the colon was defined as locations distal to the splenic flexure. Results: Index cases
of unilateral colorectal adenocarcinoma were identified in 307 patients. 168 (54.7%) were
women and the average age was 66.7 years. From 1996 to 2000, right-sided adenocarcinomas
accounted for 50.3%. From 2001 to 2005, right-sided adenocarcinomas accounted for
49.2%. During this ten year period, advanced adenomas were found in 590 patients. 299
(50.7%) were women; The average age was 64.2. A total of 645 advanced adenomas were
found, 302(46.8%) of which were on the right. Between 1996 and 2000, of the 247 advanced
adenomas found, 101(40.9%) were on the right. Between 2001 and 2005, of the 444
advanced adenomas found, 219(47.3%) were on the right. This increase in right-sided
adenomas was statistically significant (p=<0.0001) using the Chi-square test. Conclusion:
While the anatomical distribution of colorectal adenocarcinoma has been relatively constant
over the last 10 years, there has been a shift of advanced adenomas to the proximal colon.
Colonoscopy remains an invaluable tool in identifying these patients.
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M1029
Healthcare Utilization and Costs Associated with Constipation and Co-
Occurring Irritable Bowel Syndrome and Constipation Compared to Matched
Controls in a Large Managed Care Population
Debanjali Mitra, Keith L. Davis, Robert W. Baran
Health care utilization and costs were evaluated for patients with constipation (C-ONLY)
and for patients with co-occurring irritable bowel syndrome and constipation (IBS+C), and
compared to matched groups of control patients with no such diagnoses. A large US health
plan claims database was retrospectively analyzed from January 2003 through December
2005. Two mutually exclusive cohorts of patients≤65 years of age were identified: C-ONLY
(ICD-9 564.0x, N=84,614); and IBS+C (ICD-9 564.1 and 564.0x co-occurring within the
analysis period, N=10,855). Separate control groups (2:1 ratio) matched for gender, geo-
graphic region, and insurance type were created. Per patient use and costs (charged amount)
of medical services and prescriptions were assessed over a period of 3 months prior to and
9 months after first diagnosis. Total health care costs were $7,079 and $8,983 for patients
with C-ONLY and IBS+C, respectively, compared to $5,439 and $6,950 among patients in
the control samples (difference: $1,640 and $2,033 respectively; both P<0.0001). Inpatient
costs for the C-ONLY cohort were 57% greater compared to controls ($2,645 vs. $1,134;
P<0.0001), while these costs for the IBS+C cohort were 33% greater compared to controls
($2,122 vs. $1,418; P<0.001). Emergency room costs were significantly greater for the C-
ONLY and IBS+C cohorts compared to controls ($142 vs. $96 and $142 vs. $103, respectively;
both P<0.0001). Charges for hospital outpatient services were $1,774 and $2,759 for patients
with C-ONLY and IBS+C, respectively, compared to $1,422 and $1,756 for the control
groups (both P<0.0001), while charges for ancillary services were $1,157 and $1,496 for C-
ONLY and IBS+C, respectively, compared to $815 and $1,148 for controls (both P<0.0001).
Charges for office visits were lower for the C-ONLY cohort compared to their controls ($930
vs. $1,185; P<0.0001), but similar between the IBS-C cohort and their controls ($1,532 vs.
$1,496, P=0.4676). Prescription drug use was lower for the C-ONLY and IBS+C cohorts
compared to controls ($432 vs. $784 [P<0.0001] and $932 vs. $1,029 [P=0.0002], respect-
ively). The percentage of patients with at least one health care encounter in each utilization
category was greater for both case groups compared to controls. This difference was especially
pronounced for inpatient admissions among the C-ONLY cohort compared to their controls
(7.9% vs. 4.8%; P<0.0001). C-ONLY and IBS+C are a significant economic burden to payers.
Institutional services are primary cost drivers for both conditions. Prescription drug use
appears underutilized by both the C-ONLY and IBS+C cohorts.
M1030
General Surgery Indications and Outcomes in Patients with Human
Immunodeficiency Virus (HIV) Infection: A 15-Year Perspective
Marc Fiorillo, Diego Kuperschmidt, William Southern, Paul Feuerstadt, Lawrence J.
Brandt
INTRODUCTION Since the emergence of Acquired Immunodeficiency Syndrome (AIDS)
in 1982, the surgical approach to HIV-infected patients has evolved from one of trepidation
to one of convention. We postulate that the use of highly active antiretroviral therapy
(HAART) has significantly influenced the surgical indications and outcomes in these patients.
OBJECTIVES To compare the indications and outcomes of general surgical procedures in
patients with HIV infection/AIDS during the pre-HAART era (1991-1995) and the HAART
era (1996 to 2006). METHODS Using Clinical Looking Glass software, we identified all HIV-
seropositive patients who underwent emergent or elective surgical procedures at Montefiore
Medical Center between 1991 and 2006. A retrospective chart review identified the preoperat-
ive characteristics of each patient, including age, CD4 count, and whether the patient
was taking HAART. Pathology of resected specimens and the surgical outcomes, including
complications and mortalities, were reviewed and compared. RESULTS Of 190 patients,
28 and 162 patients underwent surgery during the pre-HAART and HAART eras, respectively.
In comparing preoperative characteristics of patients during the pre-HAART era to those
during the HAART era, there was a significant increase in mean patient age (36 vs. 43;
p<0.05) and mean CD4 count (147 vs. 398; p<0.001) at the time of surgery. A CD4 count
≧ 200 was associated with lower postoperative complications (15% vs. 42%; p<0.01) and
mortality (1% vs. 18%; p<0.01) than when the CD4 count was < 200. Postoperatively, all
patients had significantly lower complication rates in the HAART era compared with the
era before HAART (17% vs. 54%; p<0.01). The mortality rate also was decreased in patients
undergoing surgery during the HAART era when compared with those operated on during
the pre-HAART era (3% vs. 29%; p<0.01). From the pre-HAART to HAART era, an increase
in non-AIDS-related pathology of surgical specimens was observed (73% to 95%; p<0.01),
along with a decrease in both AIDS-related infectious (13% to 2.5%) and AIDS-related
neoplastic (13% to 2%) pathologies. CONCLUSIONS The implementation of HAART has
dramatically altered the surgical approach to HIV-infected patients, with great improvements
in postoperative complication and mortality rates. Pathologic findings in surgical specimens
of patients with HIV infection who are on HAART now mirror those of the HIV-negative popu-
lation.
M1031
Methods in the Development of a Multidimensional Measure for Gastro-
Esophageal Reflux Disease (GERD) (Mm-GERD): A Population-Based Study
Hoda M. Malaty, Suhaib Abudayyeh, Mark A. Gilger, Kimberly O’malley, David Y.
Graham
Background: Gastro-esophageal reflux disease (GERD) is very common in children with a
major presenting symptom of abdominal pain, heartburn, regurgitation and vomiting. The
presence of GERD often results in an impaired health-related quality of life for both the
patients and their parents Evaluation of children with GERD continues to challenge physicians
due the lack of a validated measure for GERD. Aims: 1) To develop and test a multidimensional
measure for GERD in children, 2) To evaluate the responses of the measure among children
attending pediatric gastroenterology (GI) clinics. Methods: We conducted a cross sectional
study that enrolled children with GERD from pediatric GI clinic. All children received a
standardized questionnaire concerning socioeconomic parameters, GERD symptoms, dura-
tion, frequency, intensity, and missed activities due to GERD. Each child and parent pair
was interviewed by a physician to completed baseline information for the multidimensional
measure that consisted of 4 scales: symptoms scale (10 items), pain intensity scale (3 items);
disability scale (3 items) and satisfaction scale (3 items). Results: 133 children participated
in the study; 59% girls, ages 4 to 19 years, mean age=10+3, 50%, 10 years and younger.
There was an excellent correlation between the four scales measure among children 10
years and younger (R=0.7, p=0.0001) and children >10 years (R=0.78, p=0.0001). Internal
consistency of the scales using Cronbach's coefficient alpha exceeded 0.80 for all, demonstrat-
ing reliability of the scales for studied children. Pain Intensity was categorized into 3 groups
(high, moderate, and low) based on the pain intensity questions. Children in the highest
pain group had the lowest health satisfaction score compared to those in the middle or
lowest groups (mean score=2.5 vs. 4.3 and 5.0 respectively, p=0.005). There was a significant
inverse correlation between the severity of symptoms child physical activity and number of
missing school days. Conclusions: Children with GERD referred from GI have good responses
to the multi-dimensions measure for GERD in Children, showing that the measure performed
well across populations. The measure was reliable for assessing the symptoms of GERD
in children and is an appropriate outcomes measure for clinical trials involving GERD
in children.
M1032
Adsorptive Granulocytapheresis Reduces Mucosal Concentration of
Neutrophils in Patients with Active Ulcerative Colitis and Is Most Effective in
Steroid Naïve Patients
Tomotaka Tanaka, Hideharu Okanobu, Eisuke Murakami, Aki Kogame, Hiroki Imagawa,
Yoshio Kuga, Takashi Moriya, Abbi Saniabadi, Toshihide Ohya, Goro Kajiyama
Background & Objective: In recent years, several studies from Japan and Europe have
reported that selective depletion of elevated peripheral blood granulocytes and monocytes
by adsorption (GMA) with an Adacolumn was associated with significant clinical efficacy
in patients with active ulcerative colitis (UC). However, as yet, the effect of GMA on the
mucosal level of granulocytes where they can cause uncontrolled tissue damage has not
been reported. This study was undertaken to investigate by colonoscopy and biopsy together
with histology, the impact of GMA on mucosal level of granulocytes in patients with active
UC. Methods: A total of 45 patients with an UC flare, 25 male and 20 female, mean age
44.7 yr, range 14-81 yr were treated at our IBD unit. Twenty-six patients were steroid naïve
and 19 were steroid dependent. Further, 20 patients had total colitis and 25 had left-sided
colitis. Each patient was given up to an 11 GMA sessions with the Adacolumn over 12
weeks. No patient received new or additional medications within 4 weeks (steroid) to 8
weeks (other immunosuppressants) prior to entry or during therapy. Colonoscopy together
with biopsy was done at entry and within 2 weeks after the last GMA session. Results: At
entry, the mean clinical activity index (CAI, by Rachmilewitz) was 12.6; range 10 to 16. A
total of 400 colonic mucosal biopsy specimens were examined which revealed massive
infiltration of granulocytes into the mucosa in patients with active disease and GMA was
associated with a marked reduction of granulocytes in the mucosa. Clinical efficacy assessed
at week 12 showed 33 of 45 patients (73.3%, P<0.01) had responded to the treatment
(CAI = 4 or less). The response rate in steroid naïve subgroup was 21 of 26 patients (80.8%,
P<0.005) and in steroid dependent subgroup was 11 of 19 patients (57.9%, P<0.05 and
P=0.02154 for steroid naïve vs steroid dependent patients). Further, on average the remission
was sustained for 17.2 months in steroid naïve patients and 17.3 months in steroid dependent
patients. Colonoscopy revealed that most non-responders had deep colonic ulcers together
with very extensive loss of the mucosal tissue. Conclusions: This is the first time a decrease
in mucosal level of neutrophils associated with GMA has been reported. Likewise, this is
the first report showing a striking difference in clinical response to GMA between steroid
naïve and steroid dependent patients. Additionally, all patients with an adequate response
(CAI = 4 or less) were spared from further drug therapy.
M1033
Predictors of 5-ASA Prescription Persistence in Patients with Ulcerative Colitis
Sunanda Kane, Simon H. Magowan, Neil Accort, Diana Brixner
Background: Previous work has shown a 40% decline in 5-ASA refill rates at 3 months in
patients with ulcerative colitis. Identification of risk factors associated with non-persistence
may help long-term patient management. Aim: Identify predictive factors for 5-ASA non-
persistence in patients with ulcerative colitis (defined as no 5-ASA refill at 3 months).
Methods: This retrospective cohort study used records of health service utilization from
the Thomson Medstat MarketScan® Research database. Treatment initiation (index date)
was defined as 5-ASA use between October 2002 - September 2004 with no 5-ASA use in
the prior 6 months. Study subjects were patients ≧18 years of age who had a diagnosis of
ulcerative colitis (ICD-9: 556) in the period of interest. 5-ASA prescription refill activity
was captured at 3 months; ‘keepers' were defined as individuals who refilled their 5-ASA
prescription at 3 months (+/-30days) vs. ‘quitters' who did not. Parameters of interest at
index date and 12 months prior were compared between keepers and quitters. Logistic
regression was used to identify independent predictors of refill persistence. Results: A total
of 3,574 UC patients with 5-ASA prescriptions were identified; 1530 patients (42.8% quitters)
did not refill 5-ASA at 3 months. Male gender, psychiatric history, and copay were the most
significant factors predicting non-persistence at 3 months; glucocorticoid use and rectal 5-
ASA use in the 12 months prior to index date were significantly associated with a decreased
risk of not refilling. Age (p=0.15) and endoscopy within 12 months of index date (p=0.07)
were not found to be significant predictors. Conclusions: Persistence with 5-ASA therapy
is multifactorial. Of 15 total parameters that were investigated 7 were independently associ-
ated with non-persistence at the 0.05 level. Clinical knowledge of these factors can help
with patient management.
Significant Factors Associated with Risk of Not Refilling 5-ASA at 3 Months
A-347 AGA Abstracts
a≦12 months prior to index date bParentheses denote the percentage of total study population
with specific characteristic
M1034
The Auscultation of Bowel Sound: The Standard Value and Effect of Palpation
On the Frequency of Bowel Sound
Yutaka J. Kawamura, Yuri Hayashi, Fumio Konishi
AIM The auscultation of bowel sounds is one of the essential procedures in physical examina-
tion and is generally performed for the assessment of the activity of the intestine which
reflects variety of intra- as well as extraabdominal pathologies. However, the definition of
the frequency of ‘normoactive' bowel sound is not clearly defined. The aim of this study is
to define the ‘normoactive' state of the bowel sound in auscultation. MATERIALS AND
METHODS Healthy volunteer and patients without bowel stricture who admitted to the
Department of Surgery for elective surgery were included in this study. Auscultation of the
bowel sound was performed for one minute before and after abdominal palpation. One
bowel sound (gurgle) was defined as a sequence of bowel sound divided by at least one
second of silence. In selected cases, examination was performed before and after meal in
order to determine the effect of the meal on the activity of the intestine. RESULTS Two
hundred times of abdominal auscultation were performed for 59 individuals. The mean age
was 58 years (range: 19-92). The mean frequency of the bowel sound was 19.1±9.4/min.
There was significant difference in the number of bowel sound in male (18.3±8.5/min) and
in female (20.6±10.7/min). Palpation significantly affected the frequency of the bowel sound
(before palpation: 18.7±9.5/min, after palpation: 19.6±9.4/min, P=0.046). Bowel sound
after meal (21.2±10.9/min) was significantly greater than that before meal (16.8±3.5/min).
CONCLUSION Normal range (mean±2SD) of frequency of bowel sound was 0.3-37.9/min.
According to this definition, the frequency of bowel sound was less than one in three minutes
in ‘hypoactive' bowel, therefore, at least three minutes-long auscultation is necessary to
determine that the bowel movement is ‘hypoactive'. There were controversial descriptions
in medical textbooks concerning the effect of abdominal palpation on the frequency of bowel
sound. This study revealed statistically significant but clinically insignificant difference (0.9/
min) in the bowel sound frequency before and after abdominal palpation.
M1035
Clinical Features and Outcomes of Bleeding Peptic Ulcers of Homeless
Akira Mizuki, Tatemichi Masayuki, Hiroshi Nagata, Nobuhiro Tsukada, Toshifumi Hibi
Purpose: The purpose of this study was to clearly establish the clinical features and clinical
outcomes of bleeding peptic ulcers (BPU) in the homeless. Material and Methods: Between
January 1997, and July 2006, 67 homeless males with BPU and 225 non-homeless patients
were diagnosed and treated with endoscopy. The endoscopies were carried out by five
experienced endoscopists and the outcome of each endoscopical treatment was compared.
In cases where bleeding or non-bleeding visible vessels within a peptic ulcer were evident,
endoscopic treatment was done with absolute ethanol and/or hemocrips. All patients were
also treated with histamine (H2) antagonists or PPI after each endoscopical treatment. Results:
The results are summarized in Table 1 and 2. In homeless patients, the Alb level was
significantly reduced in giant gastric ulcers (>3cm) compared to small ulcers (2.9, 3.5mg/
dl, p<0.05). The cases involving surgical treatment in the homeless all involved giant ulcers
(gastric 5, duodenal 2). Conclusion: Homeless patients with BPU demonstrated lower Hb
level, unstable circulation, and larger ulcers than non-homeless. Giant ulcers in the homeless
are partially due to low nutrition and the need for more surgical treatment.
Table 1. Patients Characteristics
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*BP<100mmHg and/or HR>100BPM NS: Not Significant
Table 2. Clinical Outcome in Homeless and Common Patients
NS: Not Significant
M1036
Determination of the Minimal Clinically Important Difference of Health-
Related Quality of Life Improvement in GERD Patients As Assessed By
Gerdyzer™
Oliver Chassany, Kenneth R. Devault, Gerald Holtmann, Martina Bohuschke, Peter
Sander, Holger Schmitt, Juan Malagelada
PURPOSE: Improvement of Health-related quality of life (HRQoL) is now considered an
important treatment outcome. The aim of this study was to determine, which improvement
in HRQoL can be considered clinically relevant,using different methods. METHODS: GER-
Dyzer™ is a 10-dimension validated questionnaire for the assessment of HRQoL in reflux
disease (GERD). Each dimension is illustrated with pictogram-like drawings and HRQoL is
assessed using 100 mm visual analogue scales (VAS). Data from a patient database with
endoscopically confirmed erosive esophagitis (EE) Grades A-D (LA-classification) were
included irrespective of treatment regimen (n=1257). HRQoL was assessed weekly using
GERDyzer™ and GERD symptoms were measured daily with the ReQuest™ questionnaire.
The minimal clinically important difference (MCID) of the GERDyzer™ sum score (min-
max: 0-70) was determined using different methods: the measurement error was determined
using the standard deviation (SD) and Cronbach's alpha and 2 external anchors - the
GERDyzer™ dimension general well-being (determined using VAS) and the ReQuest™-GI
subscale. Using log linear regression the GERDyzer™ sum score was transformed to the
GERDyzer™ dimension general well-being and ReQuest™-GI, respectively. The MCID for
the GERDyzer™ sum score was estimated as the smallest value corresponding to ‘excellent'
general well-being subscale and in addition to the well known GERD symptom threshold
for ReQuest™-GI. The GERDyzer™ sum score corresponding to the GERD symptom thresh-
old for ReQuest™-GI (90% percentile) determined the MCID by ReQuest™-GI subscale.
RESULTS: The MCID of GERDyzer™ sum score using the measurement error was 3.78.
For the external anchor general well-being the MCID value was 4.15. For the external
anchor ReQuest™-GI the MCID value was 3.62. CONCLUSIONS: Based upon our data,
an improvement of the GERDyzer™ score by 3.78 points can be considered clinically
relevant. Using two different external anchors this result could be confirmed within the
expected variance. Thus an improvement of at least 3.78 points can be considered the
benchmark and for example the time until this threshold has been reached compared for
various therapeutic interventions.
M1037
Quality of Colonoscopy Preparation with Polyethylene Glycol At a Va Medical
Center
Thomas F. Imperiale, Charles J. Kahi, Ma'n Abdullah, Peter Castelluccio, Jason Sutherland
BACKGROUND: We developed a computer-based decision support tool (DST) to tailor
preparation (prep) for patients (pts) undergoing outpt colonoscopy (CY). When appropriate,
the DST would allow pts to use sodium phosphate (NaP) instead of polyethylene glycol
(PEG), and would identify pts who might benefit by adding a stimulant laxative. As part of
this project, we obtained and analyzed baseline data about prep quality with PEG at our
VA hospital. OBJECTIVE: To describe and quantify the impact of CY prep with PEG on pt-
and system-specific factors. METHODS: We surveyed endoscopists about prep quality upon
completion of CY for pts at the Indianapolis VAMC from 11/05 through 6/06. The survey
included rating prep quality using a modified Aronchick scale (1 [excellent] to 4 [poor]);
it asked about the effect of prep quality on: 1) whether the CY was aborted because of the
prep; 2) the likelihood of having missed a polyp 5-9 mm; 3) CY time, and; 4) surveillance
or re-screening interval. We correlated responses with the time of day CY was performed
(AM vs. PM) and with CY findings. RESULTS: We received randomly completed surveys
from 14 endoscopists on 609 (41%) of 1484 outpts (mean age 60.7 +/- 9.6 years; 94%
men) and for 28 (80%) inpts, all of whom had PEG prep. Among outpts, CY indication
included screening (44%), symptoms (25%), surveillance (24%), occult bleeding (7%), and
abnormal radiographic findings (1%). Prep quality was excellent in 7%, good in 55%, fair
in 26%, & poor in 11%; resulted in aborted CY in 9.6%, and prolonged CY time in 62%.
Endoscopists were somewhat likely (28%) or very likely (12%) to have missed a 5-9 mm
polyp due to prep quality. For 38% of the pts, re-screening or surveillance was recommended
earlier than in published guidelines because of prep quality. When dichotomized into
satisfactory (excellent or good prep quality) and unsatisfactory (fair or poor quality), PM
CY was more often unsatisfactory than AM CY (45% vs. 34%; RR=1.20; 95% CI, 1.05-
1.39). Prep quality was worse for inpts than for outpts (mean quality score: 2.38 vs. 2.22;
P=0.01), a finding that persisted after adjustment for pt age, gender, time of day, and
neoplastic findings. In multivariable analyses that controlled for age, BMI, endoscopist
experience, and time of day, prep quality was unrelated to polyp detection. CONCLUSION:
Inadequate prep quality is prevalent at our VAMC and impacts negatively on systems factors
because of the need to reschedule aborted CY, by prolonging CY time, and by the scheduling
of early follow-up CY. Improving prep quality is likely to impact positively on systems
variables, and may improve both polyp detection and patient satisfaction.
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Is the Risk of Colon Rectal Cancer Elevated in Chronic Ulcerative Colitis in
the Community?
Douglas J. Sprung, Gregory M. Sprung
Aim: Ulcerative Colitis (UC) has been associated with an increased risk of colon rectal cancer
(CRC) in the literature when present for > 7 years. This has not been our clinical observation,
so we undertook this study to obtain our actual experience over the past 16.5 years. Methods:
A retrospective study of all patients with UC in our private GI practice in Orlando, Fl.
was undertaken between 1/1990-6/2006. Only patients who have had colonoscopic and
pathological verification of UC, and were followed for > 1 year in a surveillance program
were included in our study. Results: 426 patients were identified, 132 with pancolitis (PC),
262 with left-sided colitis (LSC) and 32 with proctitis. The mean age was 45 years. 48%
were male, 52% female. 22/426 patients (5%) had concommitant tubular adenomas. 20/
426 (5%) had low grade dysplasia (LGD) on at least one set of biopsies. No cases of LGD
progressed to cancer and no cases of high grade dysplasia were encountered. 25/426 (6%)
had undergone colectomy for medical or quality of life issues. No cancers were found in
those specimens. One patient with LSC developed rectal cancer one year after a benign
colonoscopy ( UC without dysplasia, polyps or masses).Of 132 patients with PC, 75 (57%)
had a duration of disease > 7 years and a mean duration of 19.6 years, with a range out to
59 years. 36% (48) patients had PC for > 20 years. There were no prevalence cases of CRC.
Conclusions: 1. Over the past 16.5 years, of 426 patients with chronic UC that were in our
surveillance program, only one developed CRC. 2. The one patient with CRC was a 42 year
old male with LSC for 7 years, had a father with CRC and had a colonoscopy 1 year earlier
that showed non-dysplastic LSC, without polyps or masses. 3. No patients with PC developed
CRC despite a mean duration of > 20 years in 48 patients. 4. In our patient population, the
risk of CRC in chronic UC does not exceed the expected risk of CRC in the general population.
M1039
Subspecialty Consultations and GI Testing Following a Diagnosis of Non-
Cardiac Chest Pain
Michael D. Leise, Giles R. Locke, Ross A. Dierkhising, Alan R. Zinsmeister, Nicholas J.
Talley
Background: Non-cardiac chest pain (NCCP) is typically defined by substernal chest pain
in the absence of significant stenoses in the major epicardial coronary arteries. Little is
known about the rate of health care utilization and GI diagnostic testing in this population.
Methods: A previous study identified 2068 Olmsted County, MN residents presenting to 1
of the county's 3 EDs with acute chest pain between 1/1/85 and 1/31/92. From this cohort,
359 patients were dismissed after hospitalization with a diagnosis of NCCP. Of these, 227
patients were labeled as chest pain of unknown origin (NCCP-U) while 93 received a
gastrointestinal diagnosis (NCCP-GI). The Mayo medical record of these 320 patients was
reviewed between 1/1/93 and 1/1/06 and GI diagnostic tests (EGD, esophageal manometry,
and 24 hour pH probe) and health care visits (GI, cardiology, and ED visits) were recorded.
Health care utilization and GI testing was compared between the NCCP-GI and NCCP-U
subset using Poisson Regression. Results: 47% of the total population sought care in the
ED (604 visits), 40% received cardiology consults (562 visits), and 15% percent received
GI consults (164 visits). 46% of the NCCP-U subset were seen in the ED (424 visits), 91%
were seen by a cardiologist (416 visits), and 15% were seen by a gastroenterologist (148
visits), whereas 46% of the NCCP-GI subset was seen in the ED (180 visits), 40% were
seen by a cardiologist (146 times), and 11% were seen by a gastroenterologist (16 visits).
Rate ratios were used to compare utilization between the NCCP-U and NCCP-GI subsets
and were 0.8 for ED visits (p=0.35), 1.0 for cardiology visits (p=0.9), and 3.3 for GI visits
(p=0.004). In regards to GI testing, this population of 320 patients received 247 EGDs, 13
manometry tests, and 6 pH probes. In the NCCP-U subset 35% received an EGD (173),
4% received manometry (9), and 2% received a pH probe (5). In the NCCP-GI subset 43%
received an EGD (74), 3% received manometry (4), and 1% received a pH probe (1). Rate
ratios were used to compare GI test usage for the NCCP-U group versus the NCCP-GI group
and were 0.8 for EGD testing (p=0.46), 0.8 for manometry testing (p=0.56), and 1.8 for
pH probe testing (0.14). Conclusion: The frequency of health care utilization in the NCCP
population is high. There is a paucity of GI consultations. Once NCCP patients receive GI
consultation, EGDs are performed frequently, and further tests including 24 hour pH probes
and manometry are performed infrequently. In this population, patients with NCCP of
unknown origin received 3 times as many GI consults than their counterparts with NCCP
secondary to a known GI disorder.
M1040
The Direct and Indirect Economic Costs of Irritable Bowel Syndrome in a
Large Us Employer Population
Sunny Mahajan, Keith Davis, Michael Minnich, Allison R. Northcutt, Tim Bell
Background: Irritable bowel syndrome (IBS) is a common disorder of the gastrointestinal
tract, reported to occur in 10%-20% of the US population. IBS most often affects persons
in their prime working years (30-50 years of age). This study assessed the economic burden
of IBS in the US using a unique database of retrospective claims from a large population
spanning multiple employers. Objectives: The primary objective of this analysis was to estimate
the direct and indirect costs contributing to the total economic burden of IBS in a large
employer population. Methods: Data were extracted from Medstat's MarketScan® Health
and Productivity Management database, combining medical and pharmaceutical claims linked
to workplace absence and short-term disability from six large US employers over a four
year period (2000-2003). Subjects aged ≥18 years who had at least one primary or non-
primary diagnosis of IBS were eligible for inclusion, and were compared with demographically
matched controls. The primary outcome measures were average annual healthcare utilization,
missed work time due to absence or short-term disability, and associated costs. Results: A
total of 11,306 adults were identified with a diagnosis of IBS. Patients of prime working
age (25-54 years) represented >80% of both the IBS and control samples, and the majority
of both cohorts (≥88%) were employed full time. IBS patients had a much higher rate of
gastrointestinal (GI)-specific co-morbidities (GI-related cancers, inflammatory bowel disease
and diverticulitis) than controls. IBS patients utilized 75% more total annual healthcare
services and had 63% higher annual costs than controls (48.3 vs 27.6 claims; $5,133 vs
$3,156; p<0.0001). Employees with IBS had significantly higher outpatient service use and
costs compared with controls (28.8 vs 15.8 claims; $2,963 vs $1,603; p<0.0001). There
were no significant differences between IBS and controls for inpatient costs. IBS patients
also had a significantly higher number of annual prescription fills and associated costs (17.4
vs 10.4 prescriptions; $1,108 vs $645; p<0.0001). Overall, employers incurred significantly
higher annual indirect costs from missed work time due to illness or short-term disability
for employees with IBS, compared with controls ($1,354 vs $876; 15.6 vs 10.3 days;
p<0.0001). Conclusions: From this study, the incremental burden of IBS to US employers
is significant, including both direct and indirect costs, with an average of $2,455 per employee
per year. The increases in direct and indirect costs associated with IBS impose a substantial
economic burden on both US employers and managed care payers.
M1041
Comparing the Effects of Irritable Bowel Syndrome On Work Productivity and
Healthcare Utilization with Those of Asthma and Migraine: Results from a
Web-Based Patient Survey
Sunny Mahajan, Sheri Fenhel, Michelle Thompson, Michael Minnich, Allison R.
Northcutt, Tim Bell
Background: Irritable Bowel Syndrome (IBS) is a common, episodic condition that often has
a negative impact on patients' quality of life. To better understand the burden IBS places
on society, health economic data were collected from subjects with IBS, as well as subjects
with asthma and migraine, to permit comparison. Objectives: The primary objectives of the
study were to measure and compare the impact of IBS, asthma, and migraine on work
productivity and other daily activities. The secondary objectives were to measure and compare
self-reported health status and healthcare resource utilization among these three patient
populations. Methods: Data were obtained from a web-based survey of US adults diagnosed
with IBS, migraine, or asthma for a minimum of 1 year, reporting symptoms in the past
year, and employed for at least 20 hours per week. Subjects were recruited from an online
panel representative of the US population and completed validated questionnaires, including
the Work Productivity and Activity Impairment Questionnaire (WPAI), the Work Limitations
Questionnaire (WLQ), and the EuroQoL 5 Dimensions (EQ-5D), in addition to standard
health resource items. Statistical analyses were adjusted for demographic characteristics for
all comparisons. Results: The survey sample of 692 participants included 385 subjects with
IBS, 166 subjects with asthma, and 141 subjects with migraine. The majority of the subjects
were female. The prevalence of co-morbid conditions was high in all three groups. WPAI
scores assessing overall work impairment and presenteeism (presence at work, but with
impaired capability) were significantly greater among the IBS group, compared with the
asthma group (p<0.01 for both), and similar to the migraine group; rates of absenteeism
were similar across all three groups. WLQ index and domain scores were significantly higher
in subjects with IBS compared with those with asthma (p<0.01 for all), and comparable to
those with migraine, with the exception that IBS subjects reported less impairment on the
WLQ mental-interpersonal domain (p=0.02). IBS subjects used fewer prescription medica-
tions (p<0.01), but averaged four times the number of over-the-counter medications com-
pared with asthma patients (p<0.01). EQ-5D scores were similar across all three groups.
Conclusions: Asthma and migraine are readily recognized as burdensome illnesses, both to
patients and society. The results of this study suggest that IBS poses a similar financial
impact on both employers and third-party healthcare payers, when compared with these
two conditions.
M1042
Preparation for Colonoscopy in Hospitalized Patients
Nechama Chorev, Bracha Chadad, Negba Segal, Ilana Shemesh, Meli Mor, Shlomit Plaut,
Gerald Fraser, Alex Geller, Eyal Gal, Yaron Niv
Background: Successful colonoscopy depends on good preparation of the colon before
the procedure. Inadequate preparation may lead to cancelled or repeated procedures and
compromise patient safety, quality of care, and cost effectiveness. Aim: The primary aim of
the study was to isolate factors that affect preparation success, especially in older, more
severely ill, and bedridden patients. The secondary aim was to examine the possible differ-
ences in preparation quality between ambulatory and hospitalized patients and the impact
of a staff educational program on the preparation of hospitalized patients for colonoscopy.
Methods: The study group included 303 consecutive ambulatory patients and 104 hospital-
ized patients referred for colonoscopy between January and March 2002, before the depart-
ment introduced an educational program on colonoscopy preparation, and 310 ambulatory
patients and 105 hospitalized patients referred for colonoscopy between January and March
2003. All patients completed an ad hoc questionnaire, and the findings were compared
between ambulatory and hospitalized patients, and between patients treated before and after
the educational program. Results: Polyethylene glycol was used significantly more often for
colonoscopy preparation in hospitalized patients than in ambulatory patients (53.1% vs
8.8%, p=0.0001). The hospitalized group was characterized by more incomplete or repeated
colonoscopies and poorer preparation quality. On multivariate analysis, the variables found
to be independent predictors of good preparation were successful patient completion of the
preparatory procedure according to instructions, colonoscopy performed for follow-up after
polypectomy, and preparation with sodium phosphate. The educational intervention had
no impact on the quality of preparation. Conclusion: Sodium phosphate preparation and
complete adherence to preparation instructions are the most important factors for successful
colonoscopy preparation. Current preparatory methods for hospitalized and severely ill
patients need to be revised.
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Internationalization of High-Impact Gastroenterology Journals, 1970-2005
Phil A. Hart, Jamal A. Ibdah, John B. Marshall
Background and Aims: Recent decades have seen an increase in the number of publications
from the international community in English-language basic science, as well as general and
specialty medical journals. However, to date no one has examined the publishing trends in
gastroenterology and hepatology journals. This study explored the trends relating to the
extent of internationalization as regards high-quality gastroenterology research publications
since 1970. Additionally, we examined the changes in multi-national collaborative research
publications. Methods: We reviewed the three highest ranked gastroenterology journals
based on journal impact factor and total literature citations for 2005, Gastroenterology,
Hepatology, and Gut. All basic and clinical research articles involving original investigation
from 1970 to 2005 (in five year increments) were analyzed. The nation of origin of each
research article was assigned based on the affiliation of the investigators. Additionally, each
article was classified as national or international, with national articles defined as those
published by authors from the country of publication for the journal (Gastroenterology and
Hepatology-United States; Gut-United Kingdom). Results: A total of 5358 articles were
analyzed. International articles in the three journals increased from 31.0% in 1970 to 67.6%
in 2005. The countries most responsible for the increases were Japan and the Western
European countries of Germany, France and Italy. Overall, articles from the U.S. declined
from 42.8% in 1970 to 31.7% in 2005, while articles from the U.K. declined from 35.0%
to 8.9%. In all three journals, a striking increase in the number of multi-national collaborative
publications was seen. For instance, in 1970 these collaborations made up 1.9% of total
research articles in Gastroenterology, compared to 33.5% in 2005. Conclusions: Since 1970,
there has been a dramatic internationalization of the authorship of research articles in the
leading gastroenterology journals. This reflects in part the increased high quality research
being done worldwide. There has also been a marked increase in multi-national research
collaborations. Current explanations for the decline in American and British dominance of
GI research publications are speculative, and demand further investigation to identify and
reverse correctable deficiencies.
M1044
Relationship Between Symptoms of Gastroesophageal Reflux Disease and
Concomitant Disease, Health-Related Quality of Life and Work Productivity: A
Database Study in a Us Cohort
Peter Wahlqvist, Maria Karlsson, David A. Johnson, Susan Bolge, Mari-ann Wallander
Aim: To describe the relationship between symptoms of gastroesophageal reflux disease
(GERD) and self-reported concomitant diseases, health-related quality of life and work
productivity. Methods: A database analysis was performed on results from the 2004 National
Health and Wellness Survey. US respondents with self-reported symptoms of GERD (n =
10028, mean age: 52 years, 58% female) were age- and sex-matched to controls without
GERD symptoms (n = 10028). Information on health-related quality of life was obtained
using the Short-Form (SF)-8 questionnaire. Data on health-related reduced productivity
while at work or when performing daily activities were obtained using the generic version
of the Work Productivity and Activity Impairment questionnaire. Respondents with GERD
were classified by self-reported symptom severity (mild, moderate or severe) and frequency
(low or moderate-to-high: symptoms on < 2 days or ≥ 2 days per week, respectively).
Results: The distribution of respondents with GERD by symptom severity and frequency is
shown in Table 1. Compared with controls, respondents with GERD symptoms had a larger
number of concomitant diseases (mean difference [MD]: 1.6), lower SF-8 mental and physical
health scores (MD: 3.1 units and 4.1 units, respectively), and a higher percentage of health-
related reduced productivity, while at work (MD: 7.5% units) and when performing daily
activities (MD: 12.1% units). The difference between the control group and respondents
with GERD increased with increasing symptom severity and/or frequency for all variables
tested, including health-related reduced productivity while at work (Table 2). Conclusion:
Increasing severity and frequency of GERD symptoms is associated with more concomitant
diseases, lower health-related quality of life, and lower work productivity. Further studies
are needed to help identify patient subpopulations in which re-evaluating the management
of GERD may be warranted.
Table 1. Distribution of respondents with GERD by symptom severity (mild, moderate,
severe) and frequency (low, moderate-to-high).
*Missing severity/frequency data, n = 111
Table 2. Health-related reduced productivity while at work, difference (% units) between
controls and respondents with GERD, by GERD symptom severity and frequency.
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M1045
Patient-Centered Goals in Constipation
Stacy B. Menees, William D. Chey, Anne Mcleod, Raylene Marcum, Dee Fenner
Objective: Patient-centered care recognizes the obligation to understand and meet patient's
expectations. Within gastroenterology, there has been no research in this area, specifically
assessing constipation therapy outcomes. The purpose of this study is to describe patient-
identified goals for constipation and goal related achievement after therapy. Methods: At
the time of initial visit, 31 consecutive subjects listed up to 5 goals for treatment and
completed the following surveys: patient health questionnaire(PHQ), patient assessment of
constipation symptoms (PAC-SYM) and patient assessment of constipation quality of life
(PAC-QOL). At 3 months, patients will report the degree (1-5) to which each goal had
been met(1=strongly disagree,5=strongly agree). Demographic data, medical and surgical
interventions were recorded. Goals were categorized according to symptom relief, physical
activity, general health, social relationships or physical appearance. Preferences and belief
in treatment options were assessed. Rates of self-reported goal achievement will be calculated
at 3 months along with the difference in the proportion of goals achieved by category.
Additionally, these calculations will be correlated to changes in PHQ, PAC-SYM and PAC-
QOL scores. Results: 97% of participants were women, 93% were Caucasian, with a mean
age 54 years. Patients reported a mean of 4.1 goals. 21 of 31(68%) subjects reported 4 or
more goals. Of the 109 goals listed, the majority(61%) dealt with symptom control, 18%
dealt with activity improvement, 16% dealt with general health, and 5% dealt with social
relationships. Patients did not list any goals related to physical image. 29 of 31 subjects(86%)
listed symptom relief goals such as improve stool consistency, increase frequency of bowel
movements and reduce bloating. 14 subjects(48%) listed activity improvement goals(i.e.
exercise, go back to work, ADL's), while 6(21%) listed general health, physical image or
social relationship related goals(i.e. improve energy level, lose weight, better diet). At the
time of initial survey, the average PHQ(normal <4, max of 27) was 9.96 with a PAC-SYM(range
0-4, where 4=greatest severity) and PAC-QOL(range 1-5, where 5=greatest severity) of
2.25, and 2.26, respectively. For treatment of constipation, patients preferred access to
medically trained staff(38%), and dietary intervention(19%) the most with medications the
least(10%). Conclusion: Patients seeking medical help for constipation have goals in line
with symptom based outcomes commonly used in constipation trials. Continued study will
determine if this will be a tool to enhance research and patient care.
M1046
Outcome of Colonoscopy in Elderly African American Patients: An Analysis
Based On Indication
Jason M. Collins, Shariff S. Dunlap, Amira Z. Ali ibrahim, Azza M. Ali, Edward L. Lee,
Duane T. Smoot, Hassan Ashktorab
Background: Colonoscopy is commonly used as a screening test to identify precancerous
and cancerous lesions in the colon and rectum. Colonoscopy is also used as a diagnostic
tool to investigate patients presenting with various complaints. Average risk individuals
should be offered screening beginning at 50 years of age. However, there is no clear consensus
on the age at which patients should no longer be offered a screening colonoscopy. The
purpose of this study was to analyze the outcome of colonoscopy based on pre-procedure
indications. Methods: A retrospective chart review was conducted on all patients who
underwent colonoscopy at Howard University Hospital from January 1, 2001 to Dec 31,
2005. Information collected included age, sex, indication for procedure, and post-op findings.
Patients older than age 75 years were then stratified into an average risk and high risk
categories based on indication. Average risk indications included screening and non-specific
complaints including, but not restricted to abdominal pain and changes in bowel habits. High
risk indications included personal history of cancer or adenomas, evidence of gastrointestinal
bleeding, or anemia. Based on the findings, high risk outcome was assigned if the patient
had an advanced adenoma, such as villous attributes, high grade dysplasia or adenoma
≧1cm, or neoplasm; all others were categorized as low risk outcome. The data were then
analyzed for possible association between pre-procedure risk stratification and post-proced-
ure outcome. Results: During this period, 922 patients underwent colonoscopy. The average
age was 81.3 years and 623 (67.6%) patients were female. Based on pre-procedure indications,
606 (65.7%) patients were considered high risk and 316 (34.3%) were considered low risk.
A low risk outcome was found in 87.7% of pre-procedure high risk patients and in 91.5%
of pre-procedure low risk patients (p=0.09). Screening was the indication for colonoscopy
in 110 patients. One hundred and four (94.5%) patients had a low risk outcome. The
remaining six patients who had screening colonoscopies had advanced adenomas. Malignancy
was not noted in any of these patients (p=0.001). Malignancy was found in 42 (4.5%) of
the total patients, of which 33 (78.6%) were classified as pre-procedure high risk. Conclusion:
The difference in low risk outcome between pre-procedure low risk and high risk patients
was not statistically significant. When patients underwent screening colonoscopy, they were
less likely to have malignancy.
M1047
Work Productivity and Response to Proton Pump Inhibitor Therapy in
Patients with Gastroesophageal Reflux Disease
Peter Wahlqvist, Philippe Ducrotte, Roger Jones, Harley Liker
Background and Purpose: Gastroesophageal reflux disease (GERD) can impair work produc-
tivity to a substantial extent, both because of absence from work and because of reduced
productivity while working. Our study aimed to explore the association between work
productivity and response to treatment with proton pump inhibitors (PPIs) in patients with
GERD. Methods: Interviews were conducted with 1908 patients with symptoms of GERD
in the USA, UK, Germany and France. Patients diagnosed with GERD who were receiving PPIs
were classified as complete responders (no symptoms during PPI therapy), well-controlled
(improvement in symptom severity and/or frequency with compliant PPI use, GERD symp-
toms on ≦ 1 day over the past 7 days), incomplete responders (improvement in symptom
severity and/or frequency with compliant PPI use, GERD symptoms on ≧ 2 days over
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the past 7 days), or non-responders (no symptom improvement or symptoms worsened).
Information was obtained on GERD-related absence from work and reduced productivity
while at work which was caused by GERD-related symptoms over the past 7 days. Results:
The analysis included 237 employed patients with GERD who were on PPI treatment. The
mean number of hours of absence from work because of GERD was 0.1 in complete
responders (n = 57), 0.1 in patients with well-controlled symptoms (n = 32), 0.5 in incomplete
responders (n = 128), and 1.3 in non-responders (n = 20). The mean reduced productivity
while at work was 4.3% in complete responders, 7.8% in patients with well-controlled
symptoms, 14.9% in incomplete responders, and 17.6% in non-responders. When pooling
results for complete responders and patients with well-controlled symptoms vs incomplete
responders and non-responders, mean differences between the two groups were 0.5 hours
for absence from work (0.1 vs 0.6, P < 0.05) and 9.7% for reduced productivity while at
work (5.6% vs 15.3%, P < 0.0001) (Table). The difference in reduced productivity while
at work (9.7%) was equivalent to 3.9 work hours lost (% reduced productivity x hours
worked) per patient, based on a 40-hour working week. Conclusion: There are significant
differences in GERD-related work productivity depending on response to medical treatment,
which suggests that strategies for improving the management of GERD may be warranted.
Work productivity losses by response to PPI treatment
*P < 0.05; **P < 0.001
M1048
How Many Duodenal Biopsies Are Required to Make a Diagnosis of Celiac
Disease?
Wilson Pais, Donald Duerksen, Norman Pettigrew, Charles N. Bernstein
Histopathological diagnosis of celiac disease (CD) is considered the gold standard. Because
the mucosal lesions are patchy in distribution, it has been our routine practice to obtain 4
random biopsies from the second duodenum to clinch or exclude the diagnosis of adult
CD. We do not mount our biopsies prior to pathology submission. We aimed to study how
many duodenal biopsies are needed to clinch the diagnosis of CD. Methods: A chart audit
was carried out at our tertiary care university hospital. All biopsy results in our Pathology
Department database were searched with the keywords ‘consistent with CD', ‘not consistent
with CD', ‘villous atrophy', and ‘intraepithelial lymphocytes'. All the pathology slides were
retrieved, number of biopsy specimens was determined, and each specimen was graded
according to Marsh classification modified by Oberhuber. We considered that Marsh Grade
3A or higher clinched a diagnosis of CD, if found even on 1 biopsy specimen. Results: We
identified 248 patients that met our search criteria from 01/2001 to 05/2006. 1 patient was
excluded due to damaged biopsy specimen. Of 247, 102 were diagnosed with biopsy
confirmed CD. The number of biopsies per case was: 1 in 1 case, 2 in 13 cases, 3 in 22
cases and at least 4 in 66 cases (not all endoscopists accessing our Pathology Department
follow the practice of taking 4 biopsies). All 102 cases had abnormal biopsies with at least
Marsh grade 1 lesions in all biopsies. There were 9 cases where CD could not be clinched
on the basis of histology alone (the highest Marsh lesion identified was grade 1 or 2). Of
the remaining 93 cases, CD could have been clinched if only 2 biopsies were taken in 84
(90%), if only 3 biopsies were taken in an additional 5 (89/93=95%), and if at least 4
biopsies were taken in the remainder. When biopsy specimens were compared in each
patient, we found 76 (75%) had identical Marsh grade, 18 (18%) had 1 grade difference,
and 8 (8%) had 2 or more grade differences. We identified 145 subjects in which CD was
ruled out and all biopsies were uniformly negative. In 3, Marsh grade 1 lesions were identified
but antibody testing was negative. Conclusions: While CD can be patchy, 75% of duodenal
biopsies in CD cases and 100% of biopsies in non-CD cases show uniform findings. When
CD is suspected taking only 2 biopsies will lead to a clinched diagnosis in 90% and a
suspected diagnosis in all. 3 biopsies led to a clinched diagnosis 95% of the time and 4
biopsies led to a clinched diagnosis in 100%. For 100% confidence in clinching the diagnosis,
there is minimal extra time and a small cost. Hence we recommend taking 4 random
duodenal biopsies when CD is suspected.
M1049
Comparison of the Safety and Efficacy of Bisacodyl and Sodium Picosulfate in
the Treatment of Functional Constipation
Chris Schuijt, Michael A. Kamm, Chris C. Jordan, Jean-michel Vix, Ursula Koehler,
Kenneth G. Mandel
BACKGROUND & AIMS: Laxatives are the most common pharmacological intervention for
the treatment of constipation. Bisacodyl (BIS) and sodium picosulfate (SPS), triarylmethane
laxatives, are prodrugs which are metabolized by mucosal and/or colonic flora enzymes to
form the same diphenol active moiety. The laxative action of the metabolite is due to
stimulating propulsive motility and decreasing water absorption in the colon. This open-
label, multi-center, randomized, parallel-treatment study compared the safety and efficacy
of 4 weeks use of BIS and SPS in the treatment of chronic constipation. METHODS: 144
adult outpatients (age ≥ 18 yr; 104 F) with chronic constipation defined as ≥6 months
history of <3 bowel movements (BM) per week and/or frequent painful stools and straining
entered the study and took ≥1 dose of study medication. Following a 1-wk laxative-free
baseline period, subjects were randomized to 4 wks treatment with BIS tablets (n=70) or
SPS drops (n=74), 5-10 mg daily taken at bedtime. Patient diary cards recording daily BMs,
stool consistency, straining, use of concomitant medications and AEs were reviewed after
2 and 4 wks treatment. Primary efficacy measures were change in BM frequency and stool
consistency (5-point scale). Safety was assessed as reported AEs and laboratory parameters.
RESULTS: 136 (94%) patients receiving treatment completed the study. Baseline stool
frequency of 0.46 ± 0.32 and 0.45 ± 0.38 BM/day (mean ± SD), increased significantly to
1.07 ± 0.39 and 1.08 ± 0.42 after 14 days treatment with BIS and SPS, respectively (p <
0.001 each); there was no further increase in BM frequency after 28 days treatment. The
average stool consistency score at baseline was 4.1 (moderately hard), and was decreased
by 1.51 ± 0.82 and 1.57 ± 0.71 points on the 5-point scale by BIS and SPS, respectively
after 14 days treatment (p < 0.0001), with no further increase after 28 days treatment. BIS
and SPS also significantly decreased straining. There were no differences between BIS and
SPS for efficacy, and investigators rated > 97% of patients as being significantly or somewhat
improved after 2 and 4 weeks treatment with either agent. 27 and 24 AEs, none serious,
were reported with BIS and SPS. Most were considered mild, with flatulence, headache and
abdominal discomfort being the most common AEs in either treatment group. Slight changes
in serum bilirubin and sodium were observed at the end of SPS treatment, but these were
not clinically significant. CONCLUSION: Both bisacodyl and sodium picosulfate are effective
for the treatment of constipation over a 4 week period. Both agents are well tolerated.
M1050
Detection of Circulating Tumor Cells in Patients with Pancreatic Carcinoma
Kurihara Toshio, Takao Itoi, Atsushi Sofuni, Fumihide Itokawa, Takayoshi Tsuchiya,
Kentarou Ishii, Shujirou Tsuji, Nobuto Ikeuchi, Fuminori Moriyasu
(Background) It was reported that circulating tumor cells (CTCs) can predict survival in
metastatic breast cancer. To evaluate whether we can predict survival in pancreatic carcinoma,
we tasted the level of CTCs for patients with pancreatic cancer. (Methods) The CellSearch
System was used to detect CTCs in 7.5 ml of blood. We tested 26 patients with pancreatic
cancer for levels of CTCs. Twenty ml of peripheral blood was drawn from patients with
pancreatic cancer within 2 weeks of any anti-cancer treatment likes surgery or chemotherapy.
These patients were treated with surgery or chemotherapy or best supportive care. We
followed their prognosis and response to treatments. (Result) The median age was 69years;
16 patients were male. Initial progression of pancreatic cancer was 1 of stage II, 1 of stage
III, 10 of stage IVa, and 14 of stage IVb. Twelve and two patients with metastatic carcinoma
had liver and lymph node metastases. Three patients were received completely curative
resection. 18 of 23 unresectable patients were received chemotherapy of gemcitabine. The
rest of 5 cases was treated with best supportive care. We defined that more than 1 CTC
count per 7.5 ml of blood is positive CTCs. Positive CTCs were 11 of 26 patients (42 %,
range 1-105, mean 16.9). Two patients of stage II, III were negative CTCs. 3 of 10 patients
of stage IVa were detected 1 CTC. 8 of 14 patients of stage IVb were detected positive
CTCs (mean 22.5). 6 of 11 patients of positive CTCs were treated for chemotherapy of
gemcitabine(mean 3.3 kur). Only two patients could continu chemotherapy more than 3
kur, and CTCs count of these patients were 0 or 1 CTC. Whereas CTCs count of the rest
4 patients were 5,7,16,36. Fifteen patients of negative CTCs were stageII:1, III:1, IVa:6,
IVb:7. Two patients of stage II, III were treated for surgery. These patients were received
adjuvant therapy of gemcitabine and still alive. Twelve of fifteen patients (IVa:6, IVb:6 )
received a median of 6.5 cycles (range 1-11) of chemotherapy, positive CTCs cycle (6.5 vs
3.3 cycles, respesctively, p<0.05).The median follow-up at analysis was 233.3 (5~489) days
for all patients. The median survival time (MST) of positive CTCs and negative CTCs were
each 110.5 days and 375.8 days (p<0.01). In 14 patients of stageIVb, the median survival
time (MST) of positive CTCs and negative CTCs were each 52.5days and 308.3 days (p<0.01).
(Conclusion) Although larger series and longer follow-up are needed to confirm out data,
the present study demonstrated that detection of CTCs in peripheral blood is very useful
to predict prognosis in patients with pancreatic cancer.
M1051
Strain Estimation of Antral Contractions By Ultrasound Strain Rate Imaging.
Influence of Erythromycin
Aymen B. Ahmed, Odd helge Gilja, Trygve Hausken, Hans Gregersen, Knut Matre
Introduction: Evaluation of antral motility by manometry is insufficient because only lumen
occlusive contractions are detected. Strain rate imaging (SRI) is a non-invasive ultrasound
modality that enables the study of mechanical deformation (strain) with high spatial and
temporal resolution. Objectives: To characterise radial strain of individual antral contractions
in the fasting and fed states and to assess the effect of Erythromycin, a Motilin-agonist that
increases gastrointestinal contractility, on antral strain, gastric accommodation and gastric
emptying. Materials and methods: Two-hundred-forty-four antral contractions in 7 healthy
volunteers were studied by SRI on two separate days with and without infusion of intravenous
Erythromycin. Radial strains of fasting and postprandial antral contractions were analysed.
2D ultrasound was used to assess gastric accommodation (proximal gastric area) and gastric
emptying (antral area). Results: There was a gradual increase in anterior radial strain in
antral contractions from early phase II to late phase II and phase III (median anterior radial
antral: 18%, 58% and 82%, respectively, P<0.05). Erythromycin administered in phase I
evoked phase II-like contractions (median antral strain of Erythromycin contractions: 35%)
but it did not increase postprandial strain. The average strain velocity (strain at peak/time
to peak) was lower in the postprandial period (with Erythromycin and placebo) compared
to late phase II and phase III (P=0.01). Atypical strain curves (not sine-formed curved) were
more frequent in Erythromycin-evoked contractions than in naturally occurring contractions
in the fasting state (25% vs. 11%, P<0.05), while no significant difference was found in the
postprandial state (Erythromycin-contractions: 23% vs. placebo: 10%, P<0.079). During
fasting, there were significantly more lumen occlusive contractions with Erythromycin than
in migrating motor complex contractions (69% and 48%, P=0.036), while in the postprandial
period lumen-occlusive contractions with Erythromycin and placebo were 40% and 5%,
(P<0.001). Erythromycin reduced proximal gastric area in the whole postprandial period
compared to placebo (P<0.001). Antral CSA with Erythromycin was smaller only at 10
minutes postprandial (P<0.05). All subjects had rumbling in their abdomens that coincided
with maximal awareness of hunger and detection of intra-gastric air sonographically (92%
of all phase III contractions). Conclusion: SRI enabled detailed strain estimation of individual
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antral contractions. Erythromycin influenced antral contractility and increased the number
of lumen occlusive contractions.
M1052
Usefulness of Tissue Elastography Using Transabdominal Ultrasonography for
the Diagnosis of Pancreatic Diseases
Hiroki Uchida, Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Kazuo Hara, Koji
Nonogaki, Toshifumi Kasugai, Eizaburo Ohno, Naoki Ohmiya, Yasumasa Niwa, Hidemi
Goto
[Introduction] Clinical usefulness of real-time tissue elastography® (EG) that visualize
information of tissue elasticity using transabdominal ultrasonography (EG-US) is reported
mainly in the diagnosis of superficial organ lesions. We investigated the usefulness of EG-
US for the diagnosis of pancreatic diseases. [Subjects and methods] (Preliminary study) The
subjects were 10 normal volunteers, 5 with cancer, 2 with endocrine tumor, 5 with chronic
pancreatitis, and 14 with IPMN. B-mode images of all cases were compared with EG-
mode images, and for obtained fresh specimens, findings on images were compared with
histopathological findings. (Prospective study) The subjects were 53 consecutive patients
with pancreatic lesions (28 with solid focal lesions and 25 with chronic pancreatitis). First,
the visualization rate by EG-US in lesions visualized by B-mode was assessed. Second, the
correct diagnosis rate by B-mode alone or in combination with EG-US was prospectively
evaluated by two reviewers, according to the diagnostic criteria from preliminary study.
Third, interobserver variability of the correct diagnosis rate was estimated. [Results] (Prelimin-
ary study) In the normal pancreas, the pancreas in the ROI was visualized as a homogenous
color. In cancer, EG-US showed a markedly hard area at the site of the hypoechoic tumor
area and distribution of slightly soft spots in its inside. Endocrine tumor was visualized as
a lesion having a uniform hardness comparable to or slightly higher than that of the pancreatic
parenchyma. In chronic pancreatitis, the pancreatic parenchyma was visualized as a mixture
of various colors. In IPMNs, colors indicating hardness were not observed in the cyst cavity.
(Prospective study) Forty-one (77.4%) lesions were visualized by both B-mode and EG-US.
The correct diagnosis rates by B-mode alone were 68.3% (28/41), 70.7% (29/41), and those
by B-mode combined with EG-US were 97.6% (40/41), 95.1% (39/41), respectively. The
visualization rate for each disease was 60.0% (15/25) for cancer, 100% (3/3) for endocrine
tumor, and 92.0% (23/25) for chronic pancreatitis. The correct diagnosis rates by B-mode
alone were 60.0% (9/15), 60.0% (9/15) for cancer, 66.7% (2/3), 66.7% (2/3) for endocrine
tumor, and 73.9% (17/23), 78.3% (18/23) for chronic pancreatitis. The correct diagnosis
rate by B-mode combined with EG-US was 100% (15/15), 93.3% (14/15) for cancer, 100%
(3/3), 100% (3/3) for endocrine tumor, and 95.7% (22/23), 95.7% (22/23) for chronic
pancreatitis. There was statistical concordance between two reviewer's results. [Conclusion]
EG-US is useful for the differential diagnosis of pancreatic diseases.
M1053
Diagnostic Spectrum and Safety of Confocal Laser Endomicroscopy Based On
1000 Procedures
Ralf Kiesslich, Martin Goetz, Arthur Hoffman, Constantin Schneider, Katharina
Lammersdorf, Michael Vieth, S. Biesterfeld, Peter R. Galle, Markus Neurath
Introduction: Confocal laser endomicroscopy (CLE) is a newly developed diagnostic tool
enabling In Vivo histology at subcellular resolution during ongoing endoscopy. Aim of the
current study was the evaluation of diagnostic possibilities and safety of CLE. Methods: CLE
under analgosedation (EC-3870CIFK; Pentax; excitation of 488nm solid state laser; detection
>515 nm; optical slice thickness 7µm; lateral resolution 0.7µm; frame rate 0.8 or 1.6 frames/
sec with 1024x1024 or 1024x512 pixels) was performed in the upper and lower GI tract
of consecutive patients with different GI symptoms evaluating In Vivo histology at different
sites within the gut. Intravenous Fluorescein [10%], topical Acriflavine [0.05%] and cresyl
violet [1%] were used as contrast agents. First, endoscopic, initial diagnosis was made based
on the macroscopic appearance. Subsequently, confocal images were obtained and graded
according to existing confocal pattern classifications or based on known histopathology
changes for the presence of normal, inflammatory, regenerative and (pre)neoplastic changes.
Optical biopsies were subsequently followed by targeted biopsies. Complications were pro-
spectively evaluated. Results:1000 CLE examinations (excluding 18 technical failures) were
performed between 8/03 and 7/06 at Mainz University by four different investigators in 821
patients [340 upper, 660 lower endoscopies; Fluorescein 760, Acriflavine 190, cresyl violet
20; combined 30 cases). Cellular, vascular and connective tissue changes of the mucosal
layer could be readily observed In Vivo at subcellular resolution. Finally, CLE, histopathology
and clinical data revealed 153 cases with reflux disease ; esophageal cancer 22; gastritis 60;
gastric cancer 5; celiac disease 10; lymphoma 4; IBD 390; microscopic colitis 32; adenoma
143; colon cancer 50 and others/normal 131. The overall accuracy rates for CLE were 91%
in the upper and 94% in the lower GI tract. Initial macroscopic diagnosis was changed in
32% (upper) and 19% (lower GI tract) based on microscopic evaluation. Complications
occurred in 14 patients (1.4%) and were related to endoscopic resections (2 perforations,
2 bleedings) and systemic Fluorescein application (nausea 4; decreased blood pressure 6).
Patients reported a transient discoloration (intense yellow) of the skin and urine after
Fluorescein application. No phototoxicity, allergic reactions or procedure related deaths
were noted. Conclusions: Confocal laser endomicroscopy is a safe method and expands
diagnostic possibilities from macroscopic surface visualization to microscopic subsurface
analysis adding clinically relevant diagnostic criteria during ongoing endoscopy.
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M1054
Locally Advanced Rectal Carcinoma: Can Perfusion CT Predict Treatment
Response and Long Term Clinical Outcome?
Dushyant V. Sahani, Saravanan Namasivayam, Sanjeeva P. Kalva, Lawrence S.
Blaszkowsky, Jeffrey C. Clark, Christopher G. Willett
Purpose: To assess whether perfusion CT can predict treatment response and long term
outcome in patients with locally advanced rectal carcinoma undergoing anti-angiogenic and
neoadjuvant chemo-radiotherapy. Materials and Methods: Study group comprised 24 patients
(M:F, 18:6; mean age, 60 years) with locally advanced rectal carcinoma. Baseline contrast-
enhanced dynamic CT was performed with static table position for 45-seconds and data
analyzed using commercial software to calculate blood flow (BF), blood volume (BV), mean
transit time (MTT) and permeability-surface area product (PS). Fifteen patients received
anti-angiogenic bevacizumab (Avastin, Genentech 5-10mg/kg) therapy (BVZT), followed
after 2-weeks by bevacizumab and neo-adjuvant chemo-radiation (BCRT) for 6-weeks. CTp
was repeated 2-weeks after starting BVZT, and 6-weeks after BCRT completion. Tumor
response was defined as downstaging (T) at pathological analysis after surgery. Patients were
followed up (mean, 32.6 months) and favorable long term outcome was defined as no
recurrence or distant metastases. Data was analyzed using student t test. Results: Nine (60%,
9/15) patients responded to treatment, and five (21%, 5/24) patients had favorable long-
term outcome. Tumors with no response to therapy showed significantly higher BF and
lower MTT, than those with response. Likewise, tumors with unfavorable outcome had
significantly higher BF than tumors with favorable outcome. There was significant decrease
in BF and BV, and increase in MTT following BVZT (BF, 48.5±11.9; BV 4.4±1.4; MTT,
11.9±3.6) as well as BCRT (BF, 13.9±6.5; BV, 3.1±1.9; MTT, 20.5±3.7), when compared
to baseline values (BF, 75.3±17; BV, 5.3 ±1; MTT, 7.9±2.7). Concordant with differences
in baseline values, non-responders showed significantly greater, total decrease in BF and
increase in MTT than responders following BCRT (table). Conclusions: Perfusion CT can
predict response to anti-angiogenic and chemo-radiotherapy, and long term outcome for
rectal carcinoma. Higher BF and lower MTT at baseline, and concordantly greater degree
of decrease in BF and increase in MTT following treatment predicted poor response. Patients
with poor long term outcome had greater BF at baseline.
Comparison of CT perfusion parameter change in responders and non-responders
M1055
Optical Diagnosis of Dysplastic Lesions in the Human Stomach Using Near-
Infrared Raman Spectroscopy and Multivariate Techniques
Seng khoon Teh, Khek yu Ho, Ming Teh, Salto-tellez Manuel, Wei Zheng, Khay guan
Yeoh, Zhiwei Huang
Objective: Raman spectroscopy is a molecular vibrational spectroscopic technique that is
capable of optically probing the biomolecular changes associated with diseased tissues. The
purpose of this study was to explore near-infrared (NIR) Raman spectroscopy for distin-
guishing dysplastic gastric mucosal lesions from normal and benign gastric mucosa tissues.
Materials and Methods: A total of 80 gastric tissue samples obtained from 42 patients who
underwent endoscopy investigation or gastrectomy were used in this study, and a rapid-
acquisition dispersive-type NIR Raman system was utilized for tissue Raman spectroscopic
measurements at 785 nm laser excitation. Histopathogical examinations showed that 64
tissue specimens were normal, 11 were benign, and 5 were dysplastic. Multivariate statistical
techniques, including principal component analysis (PCA), linear discriminant analysis (LDA)
were employed to develop effective diagnostic algorithms for classification of NIR Raman
spectra among different types of gastric tissues. Results: High-quality Raman spectra in the
range of 800-1800 cm-1 can be acquired from gastric tissue within 5 seconds. Raman
spectral shapes were significantly different between normal, benign and dysplastic tissues,
particularly in the spectral ranges of 1200-1290 cm-1 and 1500-1800 cm-1 which contain
signals related to amide III, amide I and C=C stretching of lipids. Raman spectra from
normal showed higher intensities at 877cm-1 for hydroxyproline, and lower signals at 1334
cm-1 (CH3CH2 wagging mode of collagen polynucleotide chain) and also at 1451 cm-1
(CH2 proteins/lipids and amide I), compared to benign and dysplastic tissues. PCA-LDA
classifications of Raman spectra from the three groups (normal, benign, and dysplasia) gave
the sensitivity of 73.8% and specificity of 88.9% for differentiation between normal and
benign tissue; The sensitivity 95.2% and specificity of 93.9% for separating dysplasia from
benign tissue, as well as the sensitivity of 87% and specificity of 94.7% for distinguishing
dysplasia from normal gastric tissue. Conclusion: NIR Raman spectroscopy in conjunction
with multivariate technique is capable of differentiating dysplastic gastric mucosal lesions
from normal and benign tissue. Therefore it may potentially be useful for rapid, In Vivo
diagnosis of neoplasia in the human stomach.
M1056
Wide Angle 3d Endoluminal CT Colonography: Impact On Missed Areas and
Polyp Conspicuity
James E. East, Brian P. Saunders, Darren Boone, David Burling, Steve Halligan, Stuart A.
Taylor
INTRODUCTION: Ability to comprehensively visualise the colonic luminal surface at optical
or virtual colonoscopy with a uni- or bi-directional view is dependant on the viewing angle
used (1). Recent data suggests even with a bidirectional 90° view, 5.9% of the surface
remains unseen, with a mean of 16 missed regions 300-1000mm2 and 4 over 1000mm2
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(2). Most CT colonography (CTC) software however does not alert the reader to regions of
unseen mucosa, risking missed neoplasia. We hypothesized that increasing the 3D endolumi-
nal angle of view to 140°, matching that of optical endoscopy, would ensure adequate
mucosal visualisation using a 3D bidirectional flythrough. AIMS & METHODS: CTC software
(Viatronix V3D colon) was customized such that the endoluminal viewing angle could be
altered, and the size and number of missed regions could be recorded. 3D polyp conspicuity
was assessed on a 4 point scale (1, not or barely visible; 4, very well seen) by a blinded
experienced radiologist using snapshots of 12 colonoscopically confirmed polyps, median
size 6mm (range 2-20mm), taken at both viewing angles. Polyps were assessed in isolation
and then in a side by side comparison. RESULTS: 20 datasets were reviewed, mean age 66
yrs (range 41-81), 11 female; prone acquisition unavailable in 2. Supine data presented,
prone result were not significantly different to supine, P>0.2 (Wilcoxon signed-rank test).
When polyps were viewed in isolation there was no statistical difference in conspicuity
between the two viewing angles, P=0.38 (Mcnemar test); however when viewed as image
pairs, 8 of 12 were considered more conspicuous at 90° compared to 140°. CONCLUSION:
Bi-directional 3D endoluminal flythrough with a 140° viewing angle almost eliminates missed
areas and increases confidence for adequate mucosal visualisation, particularly if software
does not provide a “missed regions tool”. Polyp conspicuity however is reduced at 140°, an
observation only apparent after direct side-by-side comparison. The clinical impact of this
requires further study, but suggests optical colonoscopists using very wide angle (170°)
colonoscopes might suffer similar changes in conspicuity. REFERENCES: 1. East JE et al.
Endoscopy 2006;63(Suppl I I ) :A77 2. P ickhard t P J e t a l . Gas t roen te ro logy
2006;130:1582-1587
All comparisons 140 vs 90, P<0.001
M1057
Accuracy of Computed Tomographic Colonography (CTC) for the Detection of
Polyps and Colorectal Tumors: A Systematic Review and Meta-Analysis
Maria Chaparro, Javier P. Gisbert
OBJECTIVE: To perform a systematic review and meta-analysis of diagnostic accuracy of
the CTC for the detection of polyps and colorectal tumors. METHODS: Selection of studies:
assessing the accuracy of CTC for the detection of colorectal polyps and tumors. Search
strategy: electronic bibliographical searches. Study quality: assessing using QUADAS tool.
Data synthesis: meta-analyses combining sensitivities, specificities and likelihood ratios (LRs)
of the individual studies. RESULTS: 41 studies, providing data of 7006 patients, were
included. Studies showed a high degree of heterogeneity. Overall per-polyp sensitivity of
CTC was 64% (95% CI, 62%-66%), for polyps 6 to 9 mm in size it was 58% (56-61%),
and 75% (72-78%) for polyps larger than 9 mm. Per-patient sensitivity was 70% (95% CI,
66-73%), for detection of polyps smaller than 6 mm it was 33% (28-37%), for polyps 6 to
9 mm 60% (56-65%), and 81% (78-84%) for lesions larger than 9 mm. Use of oral contrast,
reconstruction thickness, collimation, mode of imaging and radiation dose explained some
(but not all) of the heterogeneity. Overall CTC specificity was 83% (95% CI, 81-84%).
Positive and negative LRs were 4 (95% CI, 3.1-5) and 0.28 (0.18-0.44) respectively; for
polyps 6 to 9 mm in size, they were 8.3 (5.5-12.5) and 0.22 (0.10-0.47); and 18.1 (13.8
to 23.9) and 0.19 (0.11 to 0.31) for polyps larger than 9 mm. CONCLUSION: CTC is
highly specific for the detection of polyps and colorectal tumors. Some studies reported
high sensitivities, but the results of the studies markedly varied, being highly heterogeneous,
while the extractable variables explained only part of this discrepancy. Accuracy of CTC
was high for the detection of polyps larger than 6 mm, but heterogeneity raised concerns
as to consistency of performance and technical variability.
M1058
A New Scoring System for Evaluating the Chronic Pancreatitic Changes Using
Standardized MRI/MRCP Techniques Correlates Well with the Functional
Changes On the Secretin Stimulated MRCP (SMRCP)
Samer Alkaade, Numan Balci, Frank R. Burton
Background: SMRCP is increasingly accepted as the primary imaging modality for the
diagnosis of chronic pancreatitis due to the functional loss noted after secretin. As to whether
these exocrine changes on SMRCP correlate with the parenchymal and ductal changes on
standardized MRI/MRCP is unknown. Purpose: To determine if the individual or composite
scoring of the pancreatic parenchymal or ductal changes noted on standard MRI/MRCP
correlates with the functional measurements of the SMRCP in patients with suspected chronic
pancreatitis. Methods: Patients with clinical suspicion of chronic pancreatitis, who had
standard pancreatic MRI/MRCP and SMRCP within 72 hours were included in the study.
Data on pre-contrast signal, post-contrast enhancement, atrophy, ductal morphology, and
the volume and timing of maximal duodenal filling after secretin stimulation were obtained
by a radiologist who was blinded to the clinical data. A composite scoring system (SEAM
score) was used that equally weighted the pre-contrast signal on T1-FS images, post-contrast
enhancement ratio in arterial and venous phases, degree of atrophy, and ductal morphologic
abnormalities. For the SMRCP a composite score (VT score) was used that included the
volume and the time to achieve maximal duodenal filling after secretin stimulation. The
volume was graded according to Matos (Radiology 1997). The time delay for maximum
duodenal filling was given an equally weighted score. The correlation of the two scoring
systems (SEAM and VT) was calculated using Spearman's-rho. Results: 34 patients with
suspected chronic pancreatitis were studied. A strong correlation between the VT score and
the SEAM score was observed (Spearman's rho 0.69, P<0.01). There was also a good
correlation between the VT score and the pre-contrast signal score (Spearman's rho 0.77,
P< 0.01) and between the VT score and the atrophy score (Spearman's rho 0.69 , P < 0.01)
when compared separately. The correlation between VT score and the arterial to venous
enhancement ratio, or between the VT score and the morphologic ductal abnormalities alone
were less obvious (Spearman's rho 0.56 and 0.46 respectively, P < 0.01). Conclusion: A
high degree of correlation exists between the parenchymal and ductal changes as measured
by the SEAM score with the functional SMRCP VT score in patients with suspected chronic
pancreatitis. The pre-contrast pancreatic signal and the degree of pancreatic atrophy alone
also correlate well with the volume and timing of duodenal filling. Further studies are needed
to validate this new scoring system in a prospective manner using other methodologies for
the diagnosis of exocrine pancreatic insufficiency.
M1059
Efficacy of Diffusion-Weighted Magnetic Resonance Imaging for Detecting
Lymph Node Metastasis of Rectal Cancer
You Mizukami, Akiyoshi Mizumoto, Hiroki Hashida, Michiyuki Kanai, Takehisa Takagi,
Ryousuke Okumura, Shigene Kohno, Arimichi Takabayashi
Background and Aims: Preoperative diagnosis of lymph node metastasis is important to
determine the therapeutic strategies for advanced rectal cancer patients. It has been shown
that diffusion-weighted magnetic resonance imaging (DWI) is a useful tool for detecting
malignant tumors and nodal metastasis. We, therefore, evaluated the efficacy of DWI for
detecting nodal metastasis in patients with rectal cancer. Methods: 12 patients with advanced
rectal cancer were involved in this study. These patients were assessed as having tumor
invasion more than muscular rectal wall by endoscopical finding and image diagnosis. CT
imaging as well as DWI were diagnosed by independent radiologists whether metastatic
nodes were present or not. These results of two image diagnosis were compared with
microscopical diagnosis of surgically resected lymph nodes. Results: Histological findings
revealed that 9 of 12 patients had metastastic lymph nodes disease. CT detected positive
nodal metastasis 5 of 12 patients, and DWI 8 of 12 patients. The accuracy of CT was 55.6%
of sensitivity, 100% of specificity, 100% of positive predictive value (PPV) and 42.9% of
negative predictive value (NPV). On the other hand, the accuracy of DWI was 88.9% of
sensitivity, 100% of specificity, 100% of PPV, and 75.0% of NPV. Conclusion: This study
showed that preoperative DWI diagnosis is superior to CT imaging for detecting nodal
metastasis in patients with advanced rectal cancer. It is considered that DWI might be useful
for determining the therapeutic strategy for advanced rectal cancer patients.
M1060
Comparison Between Endoscopic Ultrasound and Magnetic Resonance
Cholangiopancreatography in Patients with Suspected Biliary Disease
Rasoul Sotoudehmanesh, Mohammad reza Ghadir, Amir pejman Hashemi taheri, Morteza
Khatibian, Shady Shahraeeni, Shadi Kolahdoozan, Fatemeh Zeinali, Mohammad Bagheri
OBJECTIVES: ERCP is the gold standard for pancreaticobiliary evaluation but is associated
with complications. Less invasive diagnostic alternatives with similar capabilities may be
effective, particularly in situations involving low prevalence of disease. The aim of this study
was to compare the performance of endoscopic ultrasound (EUS) with magnetic resonance
Cholangiopancreatography (MRCP) and ERCP in the same patients with suspected extra
hepatic biliary disease. METHODS: Prospective cohort study of patients referred for ERCP
with suspected biliary disease. MRCP and EUS were performed within 24 h before ERCP.
The investigators were blinded to the results of the alternative imaging studies. RESULTS:
A total of 24 patients were studied. The final diagnoses were CBD stone in 6 patients,
Pancreatic tumor in 4 patients, CBD distal tumor in 5 patients, sphincter of oddi dysfunction
in 2 patients, congenital biliary cyst in one patient, ampullary tumor in 2 patients and
normal biliary tree in 4 cases. No patients had pancreatitis after therapeutic ERCP. EUS was
more sensitive than MRCP in the detection of choledocholithiasis (100.0% vs. 33.3%).
Specificity and positive predictive value for the diagnosis of CBD stones by MRCP were
66.6% and 25.0% compared to EUS (88.8% and 75.0%). MRCP had specificity and positive
predictive value for the diagnosis of periampullary tumors (92.3% and 90.0%) compared
to EUS (100% and 100%), with sensitivity of 100% for EUS and 81.8% for MRCP. The
overall accuracy of MRCP for any abnormality was 75.0% (95% CI, 53.2%-90.2%) compared
to 95.9% (95% CI, 78.9%-99.9%) for EUS. Among those patients with a normal biliary
tree, the proportion correctly identified with each test was 87.5% for EUS (p<0.001, Kappa=
0.87) and 29.1% for MRCP (p=0.6, Kappa= -0.12). EUS related complications were not
seen in any patients. CONCLUSIONS: EUS was superior to MRCP for choledocholithiasis
and peri-ampullary tumors. EUS was most useful for confirming a normal biliary tree
and should be considered a low-risk alternative to ERCP. In patients with low risk for
choledocholithiasis or resectable tumor, initial EUS strategy safe and maybe preferable
procedure for diagnosis.
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M1061
Does Clinicopathologic Factors Influence the Accurate Endosonographic
Assessement of Early Gastric Cancer?
Jie-hyun Kim, Yong chan Lee, Kee sup Song, Young hoon Youn, Jae bock Chung
Background/Aims: The endoscopic ultrasongraphy (EUS) has become a valuable tool for the
patient selection suitable for the endoscopic mucosal resection of early gastric cancer (EGC).
We questioned whether clinicopathologic factors affect the diagnostic accuracy of EUS in
EGC. Methods: 206 patients suspected of EGC endoscopically who underwent EUS examina-
tion and operation for EGC at Severance hospital, Yonsei University College of Medicine,
Seoul, Korea from October 2001 to May 2005 were included. We reviewed the medical
records of 206 patients, compared the preoperative EUS staging with histopathologic staging
of surgical specimen according to the clinicopathologic parameters including the histopathol-
ogic differentiation. Results: The overall accuracy for predicting tumor invasion depth (T
stage) and lymph node metastasis (N stage) was 71.8% (148/206) and 88.3% (182/206),
respectively. The accuracies for T staging according to histologic type were 82.9% (34/41)
in well-differentiated, 77% (47/61) in moderately differentiated, 64.3% (36/56) in poorly
differentiated adenocarcinoma, and 64.6% (31/48) in signet ring cell carcinoma. Accuracy
rate is significantly decreased in undifferentiated type (p=0.021) and larger tumor size group
(p=0.043). The other factors, such as Helicobacter pylori infection and gross morphology of
the lesion etc, did not affect the diagnostic accuracy for tumor invasion depth by EUS. There
was no significant factor associated with the accuracy of lymph node metastasis. Conclusions:
EGC with the undifferentiated histopathology or larger tumor size are more frequently
associated with the incorrect diagnosis for tumor invasion depth by EUS. Histologic differenti-
ation and size should be taken into account when tumor invasion depth is predicted by
EUS in EGC.
M1062
Comparison of 4 Different Enhancement Techniques in Barrett's Esophagus By
Non-Expert Endoscopists
Wouter L. Curvers, Bert Baak, Clarisse Bohmer, Rosalie Mallant-hent, Ton Naber, Arnout
Van oijen, Cyril Ponsioen, Kausilia K. Krishnadath, Fiebo J. Ten kate, Paul Fockens,
Jacques J. Bergman
Introduction Indigo carmine chromoendoscopy (ICC), acetic acid chromoendoscopy (AAC)
and narrow band imaging (NBI) combined with magnification endoscopy have been reported
to recognize typical arrangements of mucosal and or vascular patterns in Barrett's esophagus
(BE) that may correlate with histology. The aim of this study was to compare images obtained
with magnifying high-resolution white light endoscopy (WL), NBI, ICC and AAC in order
to determine the best technique for use in BE. Methods 14 BE patients underwent endoscopy
by one expert endoscopist in BE. Areas selected by the discretion of the endoscopist were
first imaged with WL followed by NBI, ICC and ACC (after gently washing off the indigo
carmine). From 22 areas (8 areas with high-grade dysplasia (HGD) or early cancer (EC))
good quality images with all 4 techniques were obtained. Six endoscopists from non-
university hospitals and no specific expertise in BE or advanced imaging techniques evaluated
these images. After a short training on mucosal morphology in BE, they first evaluated the
WL images of the areas. Subsequently they assessed (in random order) NBI, ICC and AAC
images with their corresponding WL images. Finally all 4 techniques were shown together.
All images were assessed for their appreciated overall image quality, mucosal image quality
and vascular image quality. Subsequently, mucosal morphology (i.e. presence of irregular
mucosal or vascular patterns and the presence of abnormal blood vessels) was scored. Results
When all 4 techniques were assessed together, AAC was ranked best for overall imaging
quality and mucosal imaging quality. NBI was ranked best for vascular imaging quality.
Inter-observer agreement for mucosal morphology and the sensitivity of these techniques for
detecting the areas with HGD/EC are shown in Table 1. Conclusion Non-expert endoscopist
appreciate AAC best for overall image quality and mucosal image quality whereas NBI is
best appreciated for vascular image quality. The addition of ACC, ICC or NBI did however
not improve the inter-observer agreement for mucosal morphology (i.e. presence of irregular
mucosal or vascular patterns and the presence of abnormal blood vessels) or the sensitivity
for detecting HGD/EC. The additive value of these enhancement techniques in daily clinical
practise is, therefore, questionable.
Table 1
M1063
Oral Contrast Enhanced Microct Virtual Colonoscopy of APC Knockout Mouse
Colon Polyp Model
Jianwu Xie, Paul Jabour, Daniel Schimel, Robert L. Van uitert, Jianhua Yao, Julien Lamy,
Ronald M. Summers
The purpose of this study was to perform virtual endoscopies of APC knockout mice with
colonic polyps and analyze the mechanism behind adherent contrast in colonic polyps. In
an ACUC approved protocol, 10 normal healthy C57BL/6J mice were used to optimize
dosage concentration of Dulcolax and Phosphosoda for mouse bowel prep and barium and
Gastroview for oral contrast agents. Nine C57BL/6J-ApcMin/J mice bred to develop polyps
in the bowels were imaged with MicroCT. The administration of 0.1ug/g mouse weight of
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Dulcolax and 1uL/g mouse weight of Phosphosoda began colon cleansing. Twelve hours
later, a 100uL 1:3 dilution of barium sulfate and Gastroview was given separately for
opacification of luminal fluid. Mice were then administered an additional 100 uL 1:3 dilution
of Gastroview three hours prior to MicroCT imaging. Under isoflurane gas anesthesia, the
mouse colon was distended with 3 cc room air and imaged with MicroCAT II (Imtek,
Inc.) using respiratory gating. MicroCT images were processed with an established CT
colonography computer-aided detection (CAD) program to segment the colon and generate
colonic surface files. A 3D endoluminal viewer used these surface files in combination with
DICOM images from the MicroCT scanner to visualize anatomical landmarks and polyps
in the colon. A virtual colonoscopy of the mouse model was produced (Figure 1). A virtual
colonoscopy of a mouse colon scanned with MicroCT was successful. This is a necessary
first step in order for CAD systems to analyze mice colonic polyps. We expect further
improvements in both image quality and mice polyp quantity to yield visualization of
colonic polyps.
Figure 1: Virtual Colonoscopy View of the Mouse Colon
M1064
Dark Lumen Versus Bright Lumen MR-Colonography: What's Better for
Detection of Colonic Lesions?
Juergen M. Gschossmann, Peter Netzer, Barbara Seifried, Christian Jost, Christos
Loupatatzis, Ulrich Scheurer, Peter Vock, Bettina Saar
Background: MR technology for colon delineation has evolved as promising alternative to
colonoscopy in the detection of colorectal lesions. Dark lumen MR colonography (MRC)
has shown high accuracy in lesion detection. However, this technique requires the injection
of contrast media. In contrast, the bright lumen approach only necessitates a rectal enema
of tap water. A comparison of both techniques using a 3 Tesla device for the diagnosis of
both benign and malignant polyps in the lower GI tract has not been performed yet. Aim:
Comparison of dark lumen versus bright lumen MR colonography using 3 Tesla magnetic
field strength for the detection of colonic lesions. Methods and materials: Twenty-seven
patients (15 male, 12 female, age 22-87 years) who had been referred to the endoscopy
unit of our institution for further diagnosis of suspected colorectal pathologies, were included
into the study. Prior to conventional colonoscopy (CC), all patients underwent MRC. MRC
was performed using a 3 Tesla device (TRIO, Siemens, Germany). For colon distension an
enema with tap water was used. A) bright lumen MRC: A standard T2-weighted HASTE-
sequence (Half-Fourrier Acquisition Single-Shot Spin Echo, multi-breathhold, slice thickness
5 mm, overlapping packages) was performed followed by a second T2-weighted 3D-GRE
(3D-True FISP, slice thickness 2.5 mm, parallel imaging (iPAT, factor 2), breathhold tech-
nique), both in prone position. In a second step, the patient was turned to supine position
and both sequences were repeated to image also regions of trapped air. B) Dark lumen
MRC: A T1-weighted 3D-GRE (VIBE (volume interpolated breathhold sequence), iPAT 2-
3, slice thickness 1.5-1.8 mm) was performed after injection of GD-BOPTA 0.2 mmol/kg
(Multihance, Bracco) in supine position only. The results of CC served as standard of
reference. Results: Twenty-seven polyps and 3 carcinomas were found by CC. MRC was
successfully performed in all patients. Except 4 polyps smaller than 5mm in size, dark
lumen MRC correctly identified all lesions. In bright lumen MRC, the HASTE sequence was
of good imaging quality, but lesions smaller than 2 cm in size were missed. The Tru FISP
with a higher spatial resolution and the possibility of creating multiplanar reconstructions
showed all lesions of more than 1.5 cm. Conclusion: In this pilot study with symptomatic
patients, dark lumen MRC was superior to bright lumen MRC. Based upon our findings,
high spatial resolution as well as high contrast of the colorectal lesion versus the bowel wall
contribute to an increase in accuracy of MR technology in colonic diagnostics.
M1065
Validation of Ultrasound As a Reliable Method to Diagnose Moderate-Severe
Nonalcoholic Fatty Liver Disease in Overweight Adolescents
Sheela Deivanayagam, Samuel Klein, Marilyn J. Siegel
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common liver abnormality
in overweight adolescents, with prevalence as high as 23%. NAFLD is associated with insulin
resistance, metabolic syndrome and cardiovascular risk factors. The diagnosis of NAFLD
requires evaluating intrahepatic lipid (IHL) content. Proton magnetic resonance spectroscopy
is considered the best non-invasive method for measurement of IHL content, but this
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technique is expensive and requires specialized equipment and expertise. In contrast, ultra-
sound is inexpensive and widely-available, but its reliability in evaluating moderate-severe
steatosis in adolescents has not been validated. Therefore, the purpose of this study was to
evaluate the use of ultrasound as a potential tool to diagnose moderate-severe NAFLD in
overweight adolescents. Methods: After subjects fasted overnight (~12 h), IHL content was
measured quantitatively by using magnetic resonance spectroscopy and qualitatively by using
ultrasound in 28 overweight adolescents, who had normal livers or moderate-severe hepatic
steatosis, defined a priori as <5.6% and >10% IHL content, respectively. All magnetic
resonance spectroscopy and ultrasound analysis were performed in a blinded fashion by
one radiologist (MS). Results: 10 boys and 9 girls had normal IHL content (IHL content:
3±2%, range 0.5-5.6%; age: 15±1 years, body mass index (BMI): 35±5 kg/m2, BMI percentile:
98±2) and 8 boys and 1 girl had moderate-severe steatosis (IHL content: 32±8%, range
17.7-43.7%; age: 17±1 years, body mass index (BMI): 36±4 kg/m2, BMI percentile: 98±0).
Normal livers were identified in 19/28 subjects and moderate-severe steatosis in 9/28 subjects
by using either magnetic resonance spectroscopy or ultrasound. No subjects who had
moderate-severe steatosis were missed by ultrasound and ultrasound did not identify any
subjects with normal livers as having moderate-severe steatosis. Conclusions: Ultrasound is
a reliable tool to screen for moderate-severe steatosis in overweight adolescents. Additional
studies to evaluate the ability of ultrasound to detect mild steatosis (5.7%-17.6% IHL content)
are needed.
M1066
Diagnosis of Gallbladder Diseases By Contrast-Enhanced Phase-Inversion
Harmonic Ultrasonography
Tatsuo Inoue, Masayuki Kitano, Masatoshi Kudo, Hiroki Sakamoto
Abstract- We evaluated the usefulness of contrast-enhanced ultrasonography(US) for
detecting and differentiating gallbladder lesions. Contrast-enhanced coded phase-inversion
harmonic US was performed on 90 patients with gallbladder abnormalities. After adminis-
tering Levovist®, we observed the gallbladders in real time. Contrast-enhanced coded phase-
inversion harmonic ultrasonography was compared to B-mode US and contrast-enhanced
computer tomography (CT) with regard to the sensitivity and specificity in depicting the
elevated gallbladder lesions. Furthermore, we assessed how the vascular patterns of the
elevated gallbladder lesions depicted by contrast-enhanced US correlated with the diagnosis.
Contrast-enhanced US efficiently discriminated true lesions from biliary sludge, unlike B-
mode US. Consequently, contrast-enhanced US was more specific (100%) than B-mode US
(81%), although their sensitivities were similar (98% and 96%, respectively). Contrast-
enhanced US was also more sensitive that contrast-enhanced CT (98% vs 79%), although
the two methods were equally sensitive (100% vs 95%). We classified the vascular patterns
of the abnormalities depicted by contrast-enhanced US in the 90 cases into Types 1-4, which
represent branch-like, heterogeneous, homogeneous, and avascular patterns, respectively.
All Type 1 and 2 lesions were over 10mm in size while most (88%) Type 3 lesions were
10mm or less in size. While the majority of carcinomas (86%) were Type 1 or 2, three
benign lesions also showed these patterns. Thus, the vascular pattern may simply reflect
the size of the lesion and therefore its usefuleness in diagnosing gallbladder lesions may be
limited. Nevertheless, contrast-enhanced US is clearly superior to the other techniques in
discriminating biliary sludge from other lesions.
M1067
EUS-FNA for Solid Pancreatic Lesions- A Large Single Referral Center Series
Darren A. Pavey, Paul S. Jowell, Jorge Obando, Frank G. Gress
BACKGROUND: Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) has been
shown to be an accurate technique for the diagnosis of pancreatic cancer. However, several
of the previous studies have been highly selected series, including only subjects with suspected
pancreatic cancer or with a pancreatic mass seen on imaging. In addition, some of these
studies have excluded subjects with chronic pancreatitis. The accuracy of EUS-FNA in less
selective cohorts, such as all subjects referred for EUS and found to have a solid pancreatic
lesion, has not been widely studied. AIMS: To evaluate the diagnostic accuracy of EUS-FNA
in patients with solid pancreatic lesions from a large referral center. In this less selective
series, this includes subjects with underlying chronic pancreatitis. METHODS: All patients
who underwent EUS between 8/29/2001 and 12/27/2005 were identified from a search of
a prospectively collected endoscopy database. Inclusion criteria consisted of all patients who
underwent EUS and were found to have a solid pancreatic lesion. Results of EUS-FNA
cytology findings were compared to the gold standard of surgical histopathology or long
term clinical follow-up. EUS-FNA cytology reported by a cytopathologist as malignant was
considered diagnostic; whilst suspicious, atypical and negative results were considered non-
diagnostic. RESULTS: A total of 540 solid pancreatic lesions were evaluated by EUS during
the study period. The group was comprised of 300 males and 240 females, mean age 65
years (range 18-91). The distribution of lesions identified in the pancreatic head, body and
tail was 410, 100 and 23 respectively. There were 7 additional lesions where the location
was not specified. A discreet mass was visualized on EUS in 422 (78%) cases, whilst a
hypoechoic area without a discreet mass was reported in 118 (22%) cases. The mean number
of passes for FNA was 4 (range 1-8 passes). A cytopathologist was available in the room
for an immediate evaluation of the specimen in 485 (90%) cases. Surgical histopathology
was available for correlation in 159 (29%) cases; The remaining cases were correlated with
long term clinical follow-up. The mean clinical follow-up period following EUS was 6.5
months. The sensitivity, specificity, PPV, NPV, and accuracy of EUS-FNA in solid pancreatic
masses were 74%, 100%, 100%, 49%, and 79%, respectively. CONCLUSIONS: EUS-FNA
is an accurate technique for diagnosing pancreatic malignancy in a less selective series,
including patients with underlying chronic pancreatitis. FNA should be performed when a
solid pancreatic lesion is identified by EUS.
M1068
Accuracy of Endoscopic Ultrasound in Diagnosing Celiac Axis Lymph Node
Metastasis of Esophageal Cancers: A Meta-Analysis and Systematic Review
Srinivas R. Puli, Jyotsna Bk reddy, Jamal A. Ibdah, Mainor R. Antillon
Background: Celiac axis lymph nodes (CLN) metastasis in patient with esophageal cancers
has therapeutic implications and infers a poor prognosis. The published data on accuracy
of endoscopic ultrasound (EUS) to diagnose CLN metastasis in patients with esophageal
cancer has been varied. Aim: To evaluate the accuracy of EUS in diagnosing CLN metastasis
in patients with esophageal cancers. Method: Study Selection Criteria: Only EUS studies
confirmed by surgery were selected. EUS criteria used for nodal invasion were: larger than
one centimeter, hypoechoic, and round instead of elliptical. Only studies from which a 2
X 2 table could be constructed were included. Data collection & extraction: Articles were
searched in MEDLINE, Pubmed, Ovid journals, CINAHL, International pharmaceutical
abstracts, old Medline, Medline non-indexed citations, and Cochrane control trial registry.
Two reviewers independently searched and extracted data. The differences were resolved
by mutual agreement. 2 X 2 tables were constructed with the data extracted from each
study. Statistical Method: Meta-analysis for the accuracy of EUS was analyzed by calculating
pooled estimates of sensitivity, specificity, likelihood ratios, and diagnostic odds ratios.
Pooling was conducted by both Mantel-Haenszel method (fixed effects model) and DerSimon-
ian Laird method (random effects model). The homogeneity of studies was tested using
Cochran's Q test based upon inverse variance weights. Results: Initial search identified 2410
reference articles, in which 306 relevant articles were selected and reviewed. Data was
extracted from 23 studies (N= 1966) that met the inclusion criteria. Pooled sensitivity of
EUS in diagnosing CLN involvement by esophageal cancers was 66.6% (95% CI: 61.9 -
71.1). EUS had a pooled specificity of 98.1% (95% CI: 97.3 - 98.7). The positive likelihood
ratio of EUS was 20.4 (95% CI: 10.6 - 39.1) and negative likelihood ratio was 0.3 (95%
CI: 0.2 - 0.5). The diagnostic odds ratio, the odds of having nodal metastasis in positive as
compared to negative EUS studies, was 74.6 (95% CI: 36.6 - 151.9). All the pooled estimates,
calculated by fixed and random effect models, were similar. SROC curves showed an area
under the curve of 0.91. The p for chi-squared heterogeneity for all the pooled accuracy
estimates was > 0.05. Conclusion: EUS is a good diagnostic tool to evaluate celiac axis nodal
metastasis of esophageal cancers. This meta-analysis shows that EUS has a low sensitivity
but high specificity to diagnose CLN metastasis. Improvements in EUS technologies and
criteria are required to improve the sensitivity of diagnosing CLN metastasis.
M1069
Comparison of Chromoscopic Magnifying Colonoscopy and Convetional
Colonoscopy for Colorectal Cancer Screening: Preliminary Results
Hulya Cetinkaya, Mehmet Bektas, Evrim Kahramanoglu, Ali Tuzun, Berna Savas, Murat
Toruner, Irfan Soykan, Arzu Ensari, Ali Ozden
Background: Conventional colonoscopic examination has been reported to be one of the
most commonly used techniques in colorectal cancer screening. In recent years, it has been
shown that chromoscopic magnifying colonoscopy combined with chromoscopic agents
permits early detection of neoplastic colorectal lesions, especially flat and depressed types
which are known to be somehow difficult to detect with conventional colonoscopy. We
therefore conducted a study to examine the role of chromoscopic magnifying colonoscopy
in colorectal cancer screening. Patients and Methods: 145 asymptomatic subjects over 50 years
old who were admitted to Ankara University Medical School, Gastroenterology department for
colorectal cancer screening were recruited into this study. Following an appropriate sedation
with either propofol or midozolam, “back to back colonoscopy” was performed to each
patient. Conventional pan-colonoscopy with targetted biopsy was performed initially, fol-
lowed by magnifying colonoscopy for chromoscopic evaluation of recto-sigmoid area. Addi-
tional biopsies were obtained as well during magnifying colonoscopy from additional suspi-
cious lesions. Results: The median age of the study group (65 men) was 58 years (range:
50-80). Median colonoscopy time (both first phase “conventional” and second phase “back
to back” was 35 (10 - 94) minutes. Mean volume of 0.4% Indigo Carmine was 9.1±5.3
mililiters. Overall, one hundred and one suspicious lesions were detected in 60 subjects
(41.4%), following indigo carmine dye spraying 96 additional abnormalities were detected
in 96 subjects (66.2%). Thirteen of the additional abnormalities were serrated adenomas,
while thirty-seven of them were flat elevated lesions, thirty-nine of them were polipoid lesions
and twenty of them were flat-depressed lesions. Conclusion: Chromoscopic magnifying
colonoscopy might be a better technique than conventional colonoscopy in detecting colorec-
tal malignant and/or pre-malignant lesions. However, studies to evaluate cost effectiveness
of this technique in colorectal cancer screening should be performed before using it in
population screening.
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What Does MR Proctography Add in Comparison to Fluoroscopic
Proctography in Patients with Evacuation Difficulty?
Dave R. Chatoor, Anton V. Emmanuel, Suzie Elneil, Richard Cohen, Alastair Windsor,
John Osborne, Steve Halligan, Stuart A. Taylor
Introduction Fluoroscopic Barium Proctography (FP)is our current gold standard in assessing
functional abnormalities in patients with evacuation disorders,with its inherent drawbacks
of ionising radiation. Impaired evacuation is often a symptom of more global pelvic floor
dysfunction,accurate assessment of anterior, middle and posterior pelvic floor compartments
is required to optimise therapeutic strategy. Supine MR Proctography (MRP) allows for
global pelvic floor assessment, though its putative clinical value over FP has not been
evaluated. Methods 30 women with evacuation difficulty had both FP and MRP following
standard protocols. MRP was reported by a GI radiologist, blinded to the result of FP. A
consensus committee (Gastroenterologist, 2 Colorectal surgeons, 2 Urogynaecologists, 2 GI
radiologists) joined together for live reporting of FP, knowledgeable of the clinical findings.
Each patient's MRP was then reviewed by the committee, and additional findings over and
above those on FP noted to create a consensus reference standard. Note was then made as
to whether FP and MRP agreed, underestimated or overestimated abnormalities compared
to this standard. The impact of each imaging modality on (1) diagnostic confidence and (2)
management was assessed by the clinician in charge (by visual analogue scale,VAS). Results
Both tests agreed exactly with the consensus diagnosis in 11/30 (37%), MRP alone in 9/
30 (30%) and FP alone in 10/30 (33%). MRP failed to identify: anismus (5/13=38%),
intussusception (8/18= 44%), trapping within a rectocoele 1/11=9% and pelvic floor descent
on straining (8/29=28%), compared to 1/13=8%, 5/18=28%, 3/11-28% and 3/29=10% for
FP respectively. MRP overestimated rectocoele size in 9/30 (30%). However, MRP revealed
peritoneoceles in 8 patients, cystoceles in 26 and gynaecological prolapse in 25, none of
which were identified by FP. Referring clinicians found the combination of both tests helpful
in influencing management over either test individually in 12/30 (40%), particularly when
abnormalities of anterior or middle compartments were identified. MRP was deemed unhelp-
ful in influencing management in 10/30 (30%), [of whom 6 (60%) had underlying anismus],
and FP in 6/30 (20%). Conclusion MRP particularly helps in identifying abnormalities in
anterior and middle pelvic compartments. However,MRP underestimates the prevalence of
functional rectal evacuation difficulties and intussusception(possibly due patient positioning
during the study and reduced viscosity of contrast gel compared to barium).Fluoroscopic
and MR proctography are complimentary,particularly in patients with combined functional
and anatomical abnormalities.
M1071
Prospective Evaluation of Magnetic Resonance Imaging in Diagnosis and
Outcomes of Small Bowel Crohn's Disease
Andrius Kalade, Andrew Taylor, Wai kit Lee, Peter Smith, Paul V. Desmond
Introduction: Patients with Crohn's frequently require repeat imaging of the small bowel.
MRI avoids cumulative radiation exposure of conventional imaging and can be used for the
small bowel (SB) but prospective diagnostic and outcomes data in patients with Crohn's
disease are lacking. This study aimed to assess these in patients with known or suspected
SB Crohn's. Methods: Patients 18-80 yo from a single tertiary hospital with known history
or high clinical suspicion of SB Crohn's and clinical need for radiological investigation of
the SB were eligible. MRI SB protocol was performed in addition to conventional imaging
(CT, small bowel follow-through, colonoscopy with ileoscopy). CT and MRI were reported
by radiologists blinded to other imaging results. Involved segments were compared to obtain:
correlation (positive or no findings) or no correlation (major differences). Data collected:
demographic; Crohn's, treatment history; pathology; enrolment IBDQ. Post MRI question-
naires assessed: patients on perceptions of MRI; referring doctors on outcomes (change in
diagnosis, management, and usefulness of MRI). Results: May 2005 - Sept 2006 included
50: females 72% (n=36), mean age 34 (19-63), mean IBDQ 132; 68% outpatients; 78%
with known SB Crohn's disease. Correlation MRI with CT for reported SB segments: overall
82% (correlation with abnormal bowel 64%, normal bowel 18%). No correlation with
major differences 18%. MRI compared to endoscopy and/or surgery (n=14) sensitivity 89%
specificity 100% PPV 100% NPV 83% accuracy 93%; CT sensitivity 88% specificity 100%
PPV 100% NPV 86% accuracy 93%. Patients preferred MRI 61% to CT 33%; 81% said they
would easily agree having MRI again; least comfortable MRI aspect was drinking water
contrast, 38%. Referring doctors found MRI increased diagnostic certainty in 73%, changed
management 58%, avoided additional investigations 65%. 85% would use this modality
again in similar circumstances. Summary/Conclusions: In imaging for SB Crohn's disease
MRI correlated well with CT in most patients. Patients tolerated MRI with no complications,
and mostly preferred MRI to other investigations. MRI influenced outcomes with changes
in diagnostic certainty, management, and in avoiding additional investigations. This suggests
a potential role for MRI in management of SB Crohn's disease.
M1072
Visualization and Its Clinical Application of Microvasculature in Biliary and
Pancreatic Lesion Using a New Ultrasonography Technique with a Second
Generation Contrast Agent
Atsushi Sofuni, Takao Itoi, Fumihide Itokawa, Takayoshi Tsuchiya, Toshio Kurihara,
Syujirou Tsuji, Kentarou Ishii, Nobuto Ikeuchi, Fuminori Moriyasu
Objective: The second generation contrast agent of low MI (mechanical index), SonoVue,
has the advantages of low destruction of granules caused by ultrasonography and higher
resolution real-time images compared to high MI contrast agent, Levovist. In this study,
dynamic imaging and micro flow imaging (MFI) with SonoVue were used to diagnose biliary
and pancreatic lesions and the results compared with CE-US using Levovist. Methods:
Informed consent was obtained from 20 patients with biliary and pancreatic lesions confirmed
histologically by surgical sectioning or biopsy. 12 pancreatic carcinomas, 2 tumor forming
pancreatitis, 1 solid pseudo-papillary tumor (SPT), 1 metastatic pancreatic tumor (renal
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carcinoma), 2 endocrine tumors, 1 bile duct carcinoma, and 1 gallbladder carcinoma. The
ultrasound used was Aplio (Toshiba) and the contrast agents were SonoVue and Levovist.
Dynamic imaging and MFI with SonoVue and standard methods with Levovist were used
to observe the hemodynamics and microvasculature in the lesions and their peripheries.
Results: While almost all the lesions were classified into the same enhancement pattern with
both contrast agents, in the MFI with SonoVue, the microvasculature in the tumor could
be observed in real time. The imaging with Levovist has been based mainly on assessing
the extent of the enhancement pattern of tumors and therefore it has been difficult to clearly
visualize the microvasculature in the tumors. However, in MFI imaging with SonoVue, the
microvasculature of the tumor can be visualized making it possible to observe the hemodyn-
amics of the tumor blood vessels in detail. The method has several other advantages that
include: the observations can be performed at low MI; The lesions can be observed by
capturing images adequately in a less degraded state than achieved previously; The observa-
tions can be repeated several times; The microvasculature and hemodynamics inside the
tumors can be observed in detail resulting in better differentiation between malignant and
benign tumors; and the degree of advancement of the lesion can be assessed. The method
has no obvious disadvantages until now. Conclusion: CE-US is a low invasive diagnostic
technique. The use of MFI with SonoVue, results in better visualization of the microvasculat-
ure inside tumors. This should lead to improvements in diagnostic performance of biliary
and pancreatic lesions compared to conventional CE-US with Levovist.
M1073
Gastrointestinal Blood Flow Reducted Less By COX-2 Inhibitor Than By
Indomethacin. (Quantitation of Canine Small Intestinal Blood Flow By
Contrast-Enhanced Ultrasonography)
Motonori Sato, Jiro Hata, Hiroaki Kusunoki, Noriaki Manabe, Manabu Ishii, Toshiaki
Tanaka, Ken Haruma
Aim: To investigate the protective effect of etodolac, a selective cyclooxygenase (COX)-2
inhibitor against gastroenteropathy, we compared canine gastrointestinal blood flow reduc-
tion induced by etodolac with that induced by indomethacin, using Laser Doppler Flowmetry
(LD) and contrast-enhanced ultrasonography (US). Methods: Under general anesthesia,
gastric and small intestinal mucosal blood flow was measured by LD and US in 1 5 healthy
male beagles. US was performed with real-time harmonic imaging under low acoustic power
( mechanical index : 0.2 ) after intravenous contrast injection of Definity (60 mg/kg). sixty
min after administration of indomethacin ( 1.0 mg/kg) or etodolac (12.5mg/kg), LDF and
US were repeated. The examination was done in a crossover, singleblinded fashion. Results:
The blood flow decreased by -42.1±36.6 % in the gastric body and by -36.3±23.1 % in the
small intestine in the indomethacin group, while the decreases in the etodolac group were
significantly smaller: 0.14±0.79% in the gastric body and -4.0±45.5% in the small intestine
(P = 0.0025 for the gastric body, P = 0.033 for the small intestine). Conclusion: Gastrointesti-
nal blood flow could be evaluated in real-time by low-mechanical index imaging with
Definity Gastrointestinal blood flow reduction with etodolac was less than with indomethacin.
This may be one reason why COX-2 inhibitor is a safer anti-inflammatory drug for the
prevention of gastroenteropathy than classic NSAIDs.
M1074
Targeted Delivery to the Proximal Colon: In Vivo Validation of Enteric Coated
Capsules in Humans
Steven Vanhoutvin, Freddy Troost, Henrike Hamer, Serve Halders, Nathalie Huyghebaert,
Robert-jan Brummer
Introduction/aims: In Vivo research on the human colon gives rise to challenges caused by
the limited accessibility of the human colon for delivering drugs or for sampling. A variety
of tools are nowadays available for colon delivery in scientific intervention studies such as
catheters and remote controlled capsules. However, these are expensive and/or not user-
friendly. Alternatively, capsules can be used after applying a pressure, pH or time sensitive
or microbially degradable coating. However, the appropriate equipment and training for
coating is often lacking. Moreover, as only small batches are required, they cannot be
produced on industrial scale. Huyghebaert et al. described a new protocol for the production
of ready-to-use enteric coated capsule, which can be easily filled prior to oral consump-
tion(Huyghebaert et al., Eur. J. Pharm. Biopharm. 21 (2004) 617-623). The aim of this
study was to evaluate and validate In Vivo these capsules, coated with the pH sensitive
polymer Eudragit® FS30D, which dissolves from pH 7.4 for delivering a substance in
the terminal ileum or proximal colon. Materials and methods: HPMC capsules size 00
(Capsugel,VCaps) were coated with Eudragit® FS30D (Röhm) and filled with radio labelled
Indium (111In, 3.7 MBq). Next, they were administered to seven healthy volunteers (age 30
± 15y) (16 capsules in total). Gamma camera recordings were performed with two-hour
intervals starting from the moment of administration (8:00 AM) until 5:00 PM. Subjects
were in a fasted state up to five hours after administration of the capsules. From that moment
subjects were allowed to eat and drink ad libitum. The final recording for the evaluation
of the capsule opening was performed 24 hours after administration. For comparison of the
consecutive recordings a technetium marker was placed on the volunteers umbilicus. Results
and discussion: From the 16 capsules that were tested, three capsules opened distal to the
target area (transverse and/or descending colon). The remaining 13 capsules opened in the
target area (11 in terminal ileum and 2 in the proximal ascending colon). None of the
capsules opened proximal to the target area. The three capsules with the deviating opening
locations were all in the same volunteer. In conclusion this study has shown that the ready-
to-use enteric-coated capsules provide a reliable, cheap and easy tool for terminal ileum/
proximal colon delivery of a broad range of substances (substrates and/or drugs) for
research purposes.
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Benefit of Wireless Real Time Volumetric Data Fusion By Osirix with Carbon
Dioxide Mdct Cholangio-Pancreatography for Virtual Navigation in Biliary and
Pancreatic Cancer Surgery
Maki Sugimoto, Hideki Yasuda, Keiji Koda, Masato Yamazaki, Tohru Tezuka, Chihiro
Kosugi, Yoshihisa Watayo, Shuji Naka
PUOPOSE: The final decision of surgical procedure procedures for biliary and pancreatic
cancers depends on site and degree of progress, requiring accurate diagnosis of progress by
dependable pre-operative diagnostic imaging plus procedural simulations. To improve sur-
gical prognosis for biliary and pancreatic cancers by dependable pre-operative diagnostic
imaging plus procedural simulations, we generated carbon dioxide MDCT cholangio-pancrea-
tography (CMCP) which involves three-dimensional reconstruction using carbon dioxide as
negative contrast medium. We describe the benefit of real time volumetric data fusion by
OsiriX with CMCP for virtual navigation in biliary and pancreatic surgery. METHODS: Total
of 50 biliary and pancreatic cancers were included in this study. MDCT was performed
under trans-papillary infusion of CO2. Synchronously intravenous contrast medium was
applied for fusion CMCP-Angiography. Also real time 3-D reconstructions (rendering) were
incorporated during surgery on the patients' body surface from above projector plugged in
PC workstation. Capability of the intra-operative virtual navigation by data fusion was
evaluated. RESULTS AND DISCUSSIONS : Data fusion by OsiriX and CMCPA provided
accurate information for localizing the target lesions of pancreato-biliary malignancies with
its relationship to the surrounding vessels compared with open laparotomy. The simulated
operative procedures were exactly navigated. The wireless navigation of the data projection
could help reducing the differences between virtual and real images. This procedure could
avoid the needless extended dissections and help decreasing intraoperative complications.
CONCLUSION: Our data fusion techniques are dependable intra-operative diagnostic
imaging and procedural simulations and navigations for biliary and pancreatic cancer surgery.
M1076
Wide Angle (140°) Uni-Directional Flythrough At CT Colonography Reduces
Scan Review Times
James E. East, Darren Boone, Brian P. Saunders, David Burling, Steve Halligan, Stuart A.
Taylor
INTRODUCTION: CT colonography (CTC) utilising a 90° 3D bidirectional flythrough
(rectum to caecum and back) is time consuming and leaves some colonic mucosa unseen.
Some CTC software can show the number and size of missed regions after bidirectional
flythrough. Experts recommend review of all areas >300mm2 to ensure clinically adequate
mucosal visualisation (1). Review of missed regions is quick, taking ~20 seconds, compared
with the several minutes required for bidirectional 3D fly-through. A unidirectional (rectum
to caecum only) flythrough using a wider (140°) field of view achieves surface visualisation
at levels approaching that of a bidirectional flythrough at 90° [88% vs 94%](1,2) and may
be an effective and more time efficient method of colonic evaluation when combined with
the missed areas software tool. AIMS & METHODS: Using customised CTC software allowing
changes in 3D viewing angle (V3D colon; Viatronix), mucosal visualisation and reading time
using a unidirectional 140° field of view flythrough combined with review of missed regions,
were compared with those obtained using a bidirectional flythrough at the standard 90°
field of view. Prone and supine CTC scans for 20 patients were reviewed by an experienced
radiologist using both reading paradigms. RESULTS: Data presented as mean±SD, table.
Total reading time was significantly less, by 230 seconds (41% reduction), with a 140°
unidirectional flythrough compared to 90° bidirectional flythrough, each combined with
missed area review, for an almost identical level of surface visualisation. 140° unidirectional
flythrough without missed area review lead to a modest increase in missed regions in all
size categories. CONCLUSION: A unidirectional wide angle (140°) 3D flythrough combined
with missed region review was substantially more time efficient than a standard bi-directional
flythrough, almost halving the total review time with the same level mucosal visualisation.
However without the ability to review missed regions, the area of unseen colonic mucosa
would have been greater using a 140° unidirectional flythrough. REFERENCES: 1. Gastroen-
terology 2006;130:1582-1587. 2. Endoscopy 2006;38 (Suppl II):A77
Results for uni- and bidirectional flythrough in supine and prone positions combined
*paired t-test
M1077
The Performance of CT Colonography in a Clinical Setting, with the Use of
Referral Colonoscopy for Polyps 6mm Or Larger Detected On Screening CT
Colonography
Young sun Kim, Nayoung Kim, Soo young Kim, Min jung Park, Jung yoon Yim, Seon
hee Lim, Kyoung soo Cho, Kyung ran Cho, Dong hee Kim, Chung hyeon Kim, In sung
Song, Chan soo Shin, Sang-heon Cho, Byung-hee Oh
PURPOSE: Substantial controversy and obstacles remain with regard to the current role of
CT colonography (CTC) as a screening method, including the problem of referral colonoscopy
for polyp detected on CTC in clinical practice. Therefore, the aim this of study was to
evaluate the performance of CTC in a clinical setting, using referral colonoscopy for polyps
6mm or larger detected on screening CTC. MATERIALS AND METHODS: A total of 1021
asymptomatic adults (385 women, 636 men; mean age, 56.1 years), who underwent CTC
screening between Mar. 2004 and Mar 2005, were enrolled. The CTC examination was
performed using 16-raw multi-detector CT, and the interpretation was performed prospect-
ively, using primary two-dimensional polyp detection, by experienced radiologists. Patients
with polyps 6mm or larger were referred for optical colonoscopy. An advanced adenoma
was defined as any adenoma ≥ 10 mm, or the demonstration of any villous histology or
high-grade dysplasia. The CTC findings were compared with those found on colonoscopy.
Results: Polyps ≥6 mm were identified on CTC in 174 (17.0%) of the 1021 subjects; 35
(3.4%) with polyps ≥10mm and 139 (13.6%) with polyps sized between 6 and 9 mm. Of
these, 168 (96.6%) underwent a colonoscopy (mean time interval of follow - up colonoscopy,
65 days; range, 0-120 days). Concordant lesions were identified in 117 of the 168 patients
(69.6%) who underwent a colonoscopy; 28 with polyps≥10mm and 89 with polyps between
6 and 9 mm, resulting in per-patient positive predictive values of 80.0% (28/35) and 66.9%
(89/133) for polyps ≥10mm and between 6 and 9 mm, respectively. The diagnostic yields
of CTC for patient with an advanced adenoma or cancer were 4.7% (48/1021) and 0.3%
(3/1021), respectively. Sixteen additional advanced adenomas, in 10 patients, were detected
on colonoscopy, giving per-patient sensitivity for CTC of 82.8% (48/58), but no additional
cancers were detected on colonoscopy. CONCLUSION: CTC demonstrated modest concord-
ance with the positive findings in a clinical setting using referral colonoscopy for polyps
6mm or larger detected on screening CTC. However, it showed good performance for
detecting patient with advanced adenomas and cancer. Therefore, further investigations are
warranted to gain universally accepted guidelines and surveillance strategies for polyps
detected on CTC.
M1078
MRI Assessment of Gastric Function After Laparoscopic Adjustable Gastric
Banding - A Pilot Study
John Bennett, Paul Malcolm, Benedict Simpson, Martin Wickham, Stuart Williams, Ian T.
Johnson, Michael Rhodes
Background: LAGB is a restrictive bariatric surgical procedure. Patients remain full for several
hours post prandially after LAGB surgery. We utilised MRI to investigate post LAGB gastric
function. Method: TruFISP, HASTE and EPI MRI scanning after an eight-hour fast with two
test meals (water and 3% Locust Bean Gum (LBG)) of post-LAGB patients and age/sex
matched controls. Scans are repeated every 15 minutes out to 90 minutes post test meal.
Axial MRI slices are examined to calculate gastric volumes. Visual analogue scores for hunger
were recorded prior to each scan. Results: 5 post-LAGB patients (47yrs, 32-53) with good
weight loss (%EWL mean 84.8±12.0) and good subjective assessment of post meal satiety
and 5 non-obese controls (38 yrs 29-50) have been recruited. To date LBG scans have been
completed on all controls and patients, and water on all patients and 3 controls. Patients
consistently score lower for hunger at all stages despite the same length of fast (pre-scan:
LAGB 23.5, control 52.3), and controls become hungry sooner (90 minutes: LAGB 6.8,
controls 43.4). Meal volume consumed is lower for LAGB patients (68.74 vs 185.19 LBG,
477.4ml vs 916.0 ml water). Individual gastric emptying curves vary considerably, possibly
due to the retention of food noted in 3 post LAGB patients after LBG. The rate of gastric
emptying after LBG is faster for controls (mean 2.28 mlmin-1 vs 1.49 mlmin-1) but taking
into account the difference in gastric volume at the start and each subsequent time point
the results demonstrate little difference - 0.00921 mlmin-1 per ml of gastric volume for
patients vs 0.0107 mlmin-1 per ml gastric volume for controls. Discussion: The study
demonstrates that post LAGB patients have lower appetite scores despite consumption of
smaller test meal volumes. Overall gastric emptying rates, taking into account differences
in meal volume, do not appear to differ. Gastric emptying curves vary considerably post
LAGB, possible due to the occurrence of significant oesophageal dilatation/ retention, which
is undergoing further investigation with repeat scanning.
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Anal Sphincter Complex Assessment By Magnetic Resonance (MRI) and three-
dimensional Ultrasound (3dus) Imaging Techniques
Milena M. Weinstein, Sung-ae Jung, Dolores H. Pretorius, Charles W. Nager, Debbie Den
boer, Robert F. Mattrey, Ravinder K. Mittal
Background and aims: The internal anal sphincter (IAS), external anal sphincter (EAS) and
puborectalis muscle (PRM) maintain anal continence. Magnetic Resonance Imaging (MRI)
and 3 dimensional ultrasound imaging (3DUS) can assess anatomical integrity and dynamic
motion (function) of the anal sphincter complex. Advantages of the 3DUS are that the exam
is quick and can be performed transcutaneously. Materials and Methods: Studies were
performed in 5 nulliparous, asymptomatic female volunteers (mean age 31 yrs) to assess
the anal sphincter complex using MRI and 3DUS. MRI was performed using T-2 weighted
images in the axial plane to assess anatomical integrity. Dynamic MRI images were recorded
in the coronal and sagittal planes during pelvic floor contraction. For the 3DUS imaging,
the transducer was placed just outside the vaginal introitus and recordings were performed
in the posterior and cranial directions at rest and during sustained pelvic floor contraction
using HD11, Philips Medical Systems. Results: Two portions of the EAS, i.e., subcutaneous
(located caudal to the IAS) and superficial (surrounding the IAS) are seen by both techniques,
but visualization is better seen in the MR images. On the other hand, the IAS is better seen
in the 3DUS images (Fig1). During pelvic floor contraction, both MRI and 3DUS allow
dynamic evaluation in the sagittal plane (anterior-posterior movement) but movements in
the coronal plane (cranio-caudal direction) are better assessed by the MRI. Conclusions:
MRI and 3DUS are complementary imaging techniques in the assessment of the anal sphinc-
ter complex.
AP length = distance between lower end of pubic symphysis and anorectal angle; * p<0.05
shortening with squeeze
M1080
Evaluation of Age-Related Change of Pancreatic Parenchyma Using Real-Time
Tissue Elastography™
Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Kazuo Hara, Hiroki Uchida, Kouji
Nonogaki, Toshifumi Kasugai, Eizaburo Ohno, Naoki Ohmiya, Yasumasa Niwa, Hidemi
Goto
Pancreatic parenchyma results in atrophy with aging. For B-mode US (transabdominal
ultrasonography) findings in the elderly, the main pancreatic duct dilatation or small cysts
in the peripheral parenchyma are observed, and atrophy is found for a change of the
parenchyma. Real-time tissue elastography™(EG: Hitachi, Japan) is the technology that
images the difference of distortion between hard tissue and soft tissue in real time. We
aimed at investigating the pancreatic parenchymal changes of the elderly using US-EG.
(Subject and Methods) Subjects consist of 71 consecutive patients, including 16 pancreatic
ductal carcinoma (PC) (average age: 65.4, range: 45-78), 25 chronic pancreatitis (CP) (average
age: 61.7, range: 41-81), 13 intraductal papillary mucinous neoplasm (IPMN) (average age:
67.6, range: 46-85) and 17 normal pancreas (average age: 55.5, range: 18-83). US-EG was
performed in all cases at the pancreatic body followed by classifying three categories: A—-
random pattern, B—-A<<C, C—-uniform pattern. As to PC and IPMN cases, all lesions
were present at pancreatic head accompanied by the dilated main pancreatic duct of the
pancreatic body-tail. Spearman's rank correlation coefficient was used to evaluate the correla-
tion of between US-EG images and age and p<0.05 was considered significant. The ultrasound
machine used was EUB-8500 (Hitachi, Japan). (Results) According to our grading system,
US-EG images were classified (A, B, C in this order) as follows; (22, 3, 0) for PC, (5, 6, 2)
for CP, (9, 6, 1) for IPMN and (4, 4, 9) for normal pancreas. There were no correlation
between US-EG grade and age in PC, CP and IPMN (p=0.410, 0.335, 0.713, respectively).
On the other hand, for the normal pancreas, there was a significant correlation between
US-EG grade and age (p=0.02). It became clear that up-stream side of pancreatic parenchyma
developed a similar change of chronic pancreatitis regardless of age. In addition, a similar
change occurred in a normal pancreas, but this change depended upon aging. (Conclusion)
This study proved to image the pancreatic parenchymal change with aging using US-EG,
but it may be necessary to investigate correlation between this change and pancreatic function
in future.
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M1081
How Good Is Capsule Endoscopy for Detection of Periampullary Lesions?
Results of a Tertiary Referral Center
John O. Clarke, Samuel A. Giday, Priscilla Magno, Jonathan M. Buscaglia, Eun J. Shin,
Sanjay B. Jagannath, Gerard E. Mullin
Introduction: Ampullary adenomas are increasingly recognized, particularly in patients with
Familial Adenomatous Polyposis. Capsule endoscopy (CE) is now routinely recommended
for surveillance of small intestinal polyposis syndromes as well as for more conventional
indications including obscure GI bleeding, suspected Crohn's disease, suspected small intest-
inal tumors, and malabsorption. Despite its widespread use, the performance characteristics
of CE for the detection of periampullary lesions is still unclear. Aim: To evaluate the ability
of CE to detect the major duodenal papilla as a surrogate marker for periampullary adenomas.
Methods: 146 consecutive CE studies were reviewed by 2 experienced gastroenterologists
at 5 frames per second using single-image viewing. The primary outcome was visualization
of the major duodenal papilla. All discrepancies were reviewed by a panel of 5 experienced CE
gastroenterologists. Patients with gastric retention, surgery affecting papillary visualization,
repeated studies for a single patient and age < 18 were excluded. Results: Among 146
consecutive CE studies, 21 were excluded as follows: gastric retention (2), esophageal
retention (1), age < 18 years (6), duplicate study (8) and surgery possibly affecting the
papilla (4). Of the remaining 125 studies, indications for CE were as follows: obscure GI
bleeding (45.6%), iron deficiency anemia (19.2%), abdominal pain (17.6%), diarrhea
(10.4%), Crohn's disease (4.8%) and other indications (2.4%). The average age was 54.3 ±
15.3 years; 50.4% were female; 76.0% were outpatients. In total, 13 major duodenal papillae
were visualized. The median time of papillary detection was 31 seconds after the first
duodenal image. These findings translate to a CE sensitivity of only 10.4% for the detection
of periampullary small bowel lesions. Conclusion: CE has a limited sensitivity to visualize
the major papilla and, by extrapolation, polypoid lesions in the periampullary small intestine.
Given these results, a nondiagnostic CE study must not be relied upon as proof that a small
bowel lesion does not exist. Strong consideration should be given for push or double-balloon
enteroscopy in cases where significant clinical concern exists for an unrecognized lesion.
Furthermore, guidelines regarding surveillance for small bowel polyposis syndromes may
need to be reconsidered given the poor ability of CE to visualize the ampulla. To our
knowledge, this is the largest study to date that examines this issue.
M1082
Role of Magnifying Chromoendoscopy in Differentiating Adenomatous and
Non-Adenomatous Colonic Lesions
Murat Toruner, Hulya Cetinkaya, Ali E. Tuzun, Mehmet Bektas, Evrim Kahramanoglu,
Berna Savas, Arzu Ensari, Irfan Soykan, Ali Ozden
Introduction: Flat lesions in colon are difficult to obtain with conventional colonoscopy. In
recent years, it has been shown that magnifying chromoendoscopy might be helpful to identify
such lesions. Furthermore, this colonoscopy technique is believed to help differentiating
adenomatous and non-adenomatous colonic lesions. Materials and Methods: Two hundred
and eighty one patients (174 women, median age: 53 [16-84] years) with several gastrointesti-
nal symptoms were enrolled in to this study. Magnifying chromoendoscopy was performed
to each patient after appropriate sedation. Pit patterns of flat lesions (flat, flat depressed and
flat elevated) were evaluated using kudo classification. Afterwards, endocopic findings were
compared to the histo-pathological examination. Results: Flat and polypoid lesions were
found in 47% of the patients with conventional colonoscopy. Using magnifying chromoendo-
scopy, additional lesions were identified in 65 (23%) patients. A total number of 431 lesions
were identified by magnifying chromoendoscopy. Most of the lesions were localized in left
colon (78%). 24% of lesions with type I-II patterns were found as adenomatous whereas
78% of lesions with type III-IV patterns were identified as adenomatous mucosa histopathol-
ogically. Overall sensitivity, specifity, positive predictive value and negative predictive value
for magnifying chromoendoscopy were calculated as 70.3%, 90.1%, 75% and 87.8%, respect-
ively. Conclusion: Magnifying chromoendoscopy is a superior technique than conventional
colonoscopy to identify flat lesions. In addition, when used appropriately in experienced
hands, this technique might offer a valuable adjunct to standard colonoscopy in predicting
the histologic characteristics of flat lesions polyps.
M1083
6-Thioguanine Nucleotide (6-Tgn) Concentrations and Efficacy of Azathioprine
(AZA) and Mercaptopurine (Mp) in Inflammatory Bowel Disease: The Metaza
Study
Javier P. Gisbert, Y. Gonzalez-lama, F. Bermejo, M. Esteve, A. Lopez-sanroman, D. Ginard,
J. L. Cabriada, R. Pajares, M. Calvo, M. Muñoz, M. Velasco, J. A. Carneros, J. M. Milicua,
C. Froilan, C. Cara
OBJECTIVE: Some authors have suggested that inflammatory bowel disease patients achieving
remission with AZA/MP treatment have higher mean 6-TGN concentrations than those not
responding to these drugs. Our aim was to evaluate the accuracy of the determination of 6-
TGN concentrations as marker of AZA/MP treatment efficacy. METHODS: In this multicenter
national study, patients with inflammatory bowel disease starting treatment with AZA (2.5
mg/kg/day) or MP (1.5 mg/kg/day) for steroid-resistant or steroid-dependent disease were
consecutively included. TPMT activity was assessed before starting AZA/MP treatment, and
patients with values < 5 U/mL were excluded. 6-TGN concentrations were determined 2
weeks after starting AZA/MP treatment, at 1 and 2 months, and then every 2 months up
to 1 year. Truelove modified index and CDAI were used to assess clinical response. RESULTS:
To date, 40 patients (mean age 38 ± 13 years, 51% males) have received AZA/MP treatment
for 2 weeks, and 22 have completed the 4 month follow-up. Mean 6-TGN concentrations
at 2 weeks, 1 month, 2 months, and 4 months were: 220 ± 114, 263 ± 179, 263 ± 134, and
270 ± 191 pmol/8 x 108 red blood cells. The detection at 2 weeks of 6-TGN concentrations >
230 had a sensitivity and a specificity of only 28% and 67% for the diagnosis of clinical
remission. Increasing the cut-off point up to 250 did not change the sensitivity, and only
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slightly increased specificity (73%). The area under the ROC curve (AUC) which assesses
the global accuracy of the 6-TGN determination to estimate the response to AZA/MP was
of only 0.49. 6-TGN determination at 1 and 2 months did not improve previous results
(AUC of 0.57 in both cases). Finally, 6-TGN determination at 4 months was associated with
a higher diagnostic accuracy, although it was still deficient (AUC of 0.62; sensitivity and
specificity of the cut-off point set at 188 pmol/8 x 108 red blood cells, was 81% and 67%
respectively). CONCLUSION: Early determination (during the first 2 months after starting
AZA/MP) of 6-TGN concentrations is not useful in estimating the response to these drugs.
It is possible that a delayed quantification (e.g. at 4 months) of these metabolites is associated
with a higher diagnostic accuracy in patients receiving AZA/MP, but the practical use of
this strategy needs to be confirmed. Meanwhile, and until the follow-up of the patients of
the present study has been completed, and the choice of the appropriate cut-off point for
the definition of normal/abnormal 6-TGN has been clarified, systematic quantification of 6-
TGN concentrations in patients receiving AZA/MP cannot be recommended.
M1084
Use of Faecal S100a12 in the Investigation of Children with Symptoms
Suggestive of Inflammatory Bowel Disease
Andrew S. Day, Marc Sidler, Steven Leach
Introduction: We have recently established and validated faecal S100A12 measurement as
a non-invasive and simple assessment of gut inflammation. The aim of this study was to define
the utility of S100A12 testing in children presenting with gut symptoms, with comparison to
other serum and faecal markers. Methods: Stool samples were obtained from 61 children (aged
2.2 to 16 yrs) presenting with gastrointestinal symptoms who required upper gastrointestinal
endoscopy and colonoscopy. Children diagnosed with inflammatory bowel disease (IBD)
based on standard criteria were compared to children without IBD (control group). Faecal
and serum S100A12 and faecal calprotectin were measured by immunoassay and compared
with standard inflammatory markers (CRP, ESR, platelet count, albumin). Results: In children
diagnosed with IBD (n = 31) median faecal S100A12 concentrations (55.2 mg/kg) and
calprotectin (1265 mg/kg) were elevated compared to controls (n=30) (S100A12 1.1 mg/
kg; calprotectin 30.5 mg/kg) (p < 0.0001). Faecal S100A12 provided sensitivity and specificity
of 97% for the detection of IBD. In contrast, faecal calprotectin had a sensitivity of 100%
and specificity of 67%. Both faecal markers were superior compared to the sensitivities and
specificities of any standard blood test and serum S100A12. Conclusion: Faecal S100A12
measurement is highly sensitive and specific in distinguishing children with IBD from other
children presenting with gut symptoms. Faecal S100A12 is a simple, non-invasive test that
can be used to screen and select children warranting further invasive and expensive proced-
ures (such as colonoscopy) in the investigation of their symptoms. Further studies are now
required to fully define the potential roles of this marker in children with IBD, including
indications such as monitoring of response to therapies.
M1085
Gene Expression Profiles in Ulcerative Colitis and Crohn Disease Studied By
Means of DNA Microarray and Real-Time Qpcr
Mark Varsanyi, Linda Gillberg, Mikael Lördal, Jorge M. Castro, Per M. Hellstrom
The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn disease (CD)
comprise complex genetic disorders with multiple contributing genes. To study genes
involved in the regulation of the inflammation may help to clarify the pathogenesis of the
disease. Patient samples: Biopsies were obtained during colonoscopy from patients with
ulcerative colitis (n=20) or Crohn disease (n=20) and controls (n=11) as approved. Methods.
RNA extraction: The isolated biopsies were stored in the “RNAlater” RNA stabilization reagent
(Qiagen, Hilden, Germany) at -20o C. Total RNA was isolated using the RNeasy kit according
to the manufacturer instruction (Qiagen). RNA was digested with DNase I. to remove traces
of chromosomal DNA. Visualizing ethidium bromide stained agarose gels assessed RNA
integrity. Microarray analysis: For the analysis of the differential expression of multiple genes
involved in IBD, we used the GEArray Q series human nitric oxide gene array (HS-034,
SuperArray Inc., Frederick, MD, USA) containing cDNA of 96 genes whose expression is
controlled by or involved in signalling by the second messenger nitric oxide (NO), as well
as of control housekeeping genes, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH). Of the individually analyzed 20 UC and 20 CD samples gene expression profiles
were compared to a pool of control samples, as obtained both by microarray as well as real-
time qPCR. A 100% change was taken as significant. Real-Time qPCR detection: In order
to substantiate our results obtained by the microarray technology, real-time quantitative
PCR assay was performed with SYBR-green as ds-DNA binding dye using the BioRad iCycler
iQ Real Time detection system and SYBR-green SuperMix reaction mix (BioRad Laboratories,
Hercules, CA, USA). Results: In the microarray analysis metalloproyteinase-1 (MMP-1),
interleukin-1beta (IL-1b), inducible nitric oxide synthase (iNOS) and tyrosinase to be highly
expressed. Real-time qPCR showed iNOS to be increased 5-11 times over control, metallopro-
teinase-1 7-13 times, interleukin-1beta 5-9 times and tyrosinkinase 2-5 times. The overexpr-
ession of these genes tended to follow the degree of inflammation as verified by endoscopic
index. We also noticed that at least one gene, tyrosinase, was overexpressed in a higher
proportion of CD patients (8/20) compared to UC patients (2/20). Conclusion: Our data
suggest that certain genes that are indicative of inflammation (MMP-1 and IL-1b) are up-
regulated in IBD. In agreement with this also iNOS is up-regulated which is of interest as
rectal gas samples analyzed for NO can be feasibly used for diagnostic and monitoring
purposes in IBD.
M1086
Long Pentraxin Ptx3 Is An Useful Inflammation Marker in the Patients with
Inflammatory Bowel Diseases
Shingo Kato, Masataka Ito, Kyoko Takeuchi, Junko Imaki, Kazuro Itoh, Koji Yakabi
Backgrounds & Aims: Inflammation has a pathogenic role in inflammatory bowel diseases
(IBDs). CRP, short pentraxin C-reactive protein, is often used in the evaluation of inflammat-
ory status in IBDs. However, usually serum CRP level does not increase in active ulcerative
colitis because the short pentraxin CRP is produced mainly by the liver in response to
interleukin (IL)-6, as well as IL-6 level is not so high in patients with ulcerative colitis.
Useful inflammation marker is needed in the treatment of patients with IBDs. Pentraxin-3
(PTX3) is a prototypic long pentraxin mainly by dendritic cells, macrophages and endothelial
cells in response to primary inflammatory stimuli. The aims of this study were to investigate
the expression of PTX3 and evaluation of usefulness of PTX3 as an inflammation marker
in IBDs. Materials & Methods: Immunohistochemistry; PTX3-immunoreactivity was exam-
ined in operated specimens from three UC patients, four CD patients and three colon cancer
patients as normal controls. Primary antibody against PTX-3, CD45RO (UCHL-1), CD20
(L26) and myeloperoxidase were used. Plasma PTX3 levels were examined in 17 UC patients,
25 CD patients and 6 normal controls by ELISA. Mayo Scoring system was used to evaluate
disease activity in UC patients, as well as IOIBD score was also used in CD patients.
Results: PTX3-immunoreactivity was recognized in the infiltrating cells containing T- and
B-lymphocytes, neutrophils and vessels in the inflamed gut. Total Mayo score was successfully
examined in 15 UC patients, as well as partial Mayo score was examined in 17 UC patients.
There was more significant correlation between partial Mayor score and plasma PTX3
concentration (r=0.63, p<0.01) than between partial Mayor score and serum CRP concentra-
tion (r=0.51, p<0.05) in UC patients. Sensitivity and specificity of plasma PTX3 concentration
to evaluate disease activity were 91% and 75% in UC patients. However, sensitivity and
specificity of serum CRP concentration were 45% and 100%. In Crohn's disease there was
a significant correlation between IOIBD score and plasma PTX3 concentration (r=0.49,
p<0.01), as well as there was a significant correlation between IOIBD score and serum CRP
concentration (r=0.61, p<0.01). Sensitivity and specificity of plasma PTX3 concentration to
evaluate diseases activity were 71% and 62% in CD patients, as well as sensitivity and
specificity of serum CRP concentration were 71% and 56%. Conclusions: PTX3 is directly
produced from inflamed gut in IBDs. Plasma PTX3 concentration is an useful inflammation
marker in IBD patients, especially in UC.
M1087
Prevalence and Clinical Characteristics of 6-Mercaptopurine Rapid
Metabolizers Among Adult and Pediatric Inflammatory Bowel Disease Patients
Mark Gerich, J. antonio Quiros, James P. Marcin, Thomas Prindiville
6-mercaptopurine (6-MP) is often utilized as a therapeutic agent in the treatment of inflam-
matory bowel disease (IBD). A significant but unclear proportion of poor response to 6-MP
has been attributed to rapid metabolism of 6-MP by the enzyme thiopurine methyltransferase
(TPMT) towards the toxic metabolite, 6-methyl-mercaptopurine (6-MMP), rather than 6-
thioguanine (6-TGN), levels of which correlate with clinical efficacy. Deficiency of the
enzyme, inosine triphosphatase pyrophosphatase (ITPase), can also limit 6-MP efficacy,
resulting in the accumulation of toxic intermediate metabolites causing adverse clinical
reactions. This study was conducted to evaluate the prevalence and characteristics of 6-MP
rapid metabolizers (RM) and ITPase deficiency among both adult and pediatric IBD patients.
METHODS The clinical records of 350 adult (n=289) and pediatric (n=61) patients on 6-
MP therapy for IBD were reviewed. Demographic, clinical, and pharmacodynamic data were
abstracted. RM were defined as patients with concomitant [6-TGN] < 250 pmol/8x108 RBC
and [6-MMP] > 5700 pmol/8x108 RBC. ITPase deficiency was clinically defined as the
presence of flu-like symptoms, rash, and/or pancreatitis that necessitated discontinuation of
6-MP therapy. Data was analyzed using chi squared analyses and Student's t-test. RESULTS
285 patients had sufficient data to characterize 6-MP metabolism. Mean age was 38 years
old (range 5 - 87). 57% of patients were female, 87% were Caucasian, 72% had Crohn's
disease (CD) and 28% had ulcerative colitis (UC). TPMT enzyme genotype and phenotype
was evaluated in 174 and 25 patients, respectively, prior to starting therapy. 87% had a
normal TMPT genotype. Mean TPMT enzyme activity was 31.9 EU (range 16.4 - 49.8). In
total, 88/285 (30.9%) of patients were RM. There was no significant difference between the
mean age of RM and normal metabolizers (36.4 vs. 38.0; p=0.50). 27.8% of males and
33.1% of females were RM (p=0.34). 31.5% of CD and 28.8% of UC patients were RM (p=
0.65). 28.4% of Caucasian and 40% of non-Caucasian patients were RM (p=0.2). 19/289
(6.6%) of adults were clinically ITPase deficient. CONCLUSIONS Rapid metabolism of 6-
MP resulted in elevation of 6-MMP above its toxicity threshold and limited optimization of
6-MP therapy in 31% of adult and pediatric IBD patients. Age, gender, ethnicity, and IBD
subtype did not differ between RM and normal 6-MP metabolizers. As alternative treatments
for IBD are not without risk, therapeutic strategies for optimizing 6-MP therapy by monitoring
and shifting metabolism preferentially towards 6-TGN merit further evaluation in this large
subset of IBD patients.
M1088
5-Aminosalicylates (5-Asas) and Renal Function in Inflammatory Bowel
Disease (IBD): A Systematic Review
Javier P. Gisbert, Yago Gonzalez-lama, Jose Mate
AIM: Nephrotoxicity, which may be potentially irreversible, has been described in some
patients with IBD treated with 5-ASA. Our aim was to conduct a systematic review of studies
evaluating incidence of nephrotoxicity in IBD patients treated with 5-ASA. METHODS:
Bibliographical searches were performed in MEDLINE electronic database up to 2006 looking
for several terms dealing with IBD, 5-ASAs, and renal disease. Case reports of patients with
IBD and renal disease associated with 5-ASA treatment were specifically reviewed. Moreover,
studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured
regularly were also reviewed. The mean percentage of patients with renal impairment was
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calculated and expressed as weighted mean. As the follow-up time markedly varies among
studies, the risk of renal impairment is better expressed as the incidence of nephrotoxicity
per patient-years of follow-up, and therefore the annual nephrotoxicity rate (per patient-
year), was also calculated. RESULTS: 33 case reports of renal disease associated with 5-ASA
treatment in patients with IBD were found. The actual development of 5-ASA-related renal
disease seems rare, as only 46 patients with this complication have been reported. From
these 46 patients, 15 had Crohn's disease, and 30 ulcerative colitis (the IBD type was unknown
in one patient). Nevertheless, the apparent higher frequency of 5-ASA nephrotoxicity in
ulcerative colitis may merely indicate that 5-ASA has proven efficacy in inducing and
maintaining clinical remission and that lifetime maintenance treatment is usually recom-
mended for ulcerative colitis, in contrast with Crohn's disease, where the role of 5-ASA is
more debatable. 32 studies with 5-ASA treatment in which serum creatinine or creatinine
clearance was measured regularly were identified: 2,671 patients received 5-ASA treatment
during a total of 3,070 years of follow up. The mean overall risk of nephrotoxicity was
0.3% (95%CI=0.15-0.6%), and mean annual nephrotoxicity rate (per patient-year) was only
0.26% (95%CI=0.13-0.5%). CONCLUSION: Studies with 5-ASA treatment in which serum
creatinine or creatinine clearance was measured regularly show that nephrotoxicity is excep-
tional, as the incidence of renal impairment in IBD patients receiving 5-ASA therapy is less
than 1% (mean annual nephrotoxicity rate of only 0.26% per patient-year). There have been
several case reports, including 46 patients, of renal disease associated with 5-ASA treatment
in patients with IBD. Nevertheless, the progressive increasing number of reports suggests
that this adverse drug reaction may be underrecognised and underreported.
M1089
Fecal S100a12 As Non-Invasive Marker Distinguishing Inflammatory Bowel
Disease from Irritable Bowel Syndrome
Dirk Foell, Jost Langhorst, Thomas Kaiser, Helmut Wittkowski, Andreas Rueffer, Gustav
Dobos, Johannes Roth
Objective: S100A12 is a pro-inflammatory protein which is secreted by granulocytes.
S100A12 serum levels increase during inflammatory bowel disease (IBD). We performed
the first study analyzing fecal S100A12 in adults with signs of intestinal inflammation,
correlating our results with findings in endoscopy and histology. Methods: Fecal S100A12
was determined in fecal specimens of 83 consecutive patients and 24 healthy controls. All
patients underwent endoscopic and histological investigation to evaluate inflammation in
the gut. Thirty-two patients had Crohn`s disease, 27 patients had ulcerative colitis, and 24
individuals had irritable bowel syndrome (IBS). Intestinal S100A12 expression was analyzed
in biopsies obtained from all patients. Fecal calprotectin and lactoferrin were used as addi-
tional noninvasive surrogate markers of inflammation. Results: Fecal S100A12 was signific-
antly higher in patients with active IBD (2.45 ±1.15 mg/kg) compared to healthy controls
(0.006 ±0.03 mg/kg; p <0.001) or patients with IBS (0.05 ±0.11 mg/kg; p <0.001). Fecal
S100A12 distinguished active IBD from healthy controls with a sensitivity of 86% and a
specificity of 100%. We also found excellent sensitivity of 86% and specificity of 96% for
distinguishing IBD from IBS compared to fecal calprotectin with 63% and 86%, respectively.
Fecal S100A12 correlated better to intestinal inflammation than fecal calprotectin or other
biomarkers. Conclusions: Fecal S100A12 is a novel noninvasive marker distinguishing IBD
from IBS or healthy individuals with a high sensitivity and specificity. Furthermore, S100A12
reflects inflammatory activity of chronic IBD. As a marker for neutrophil activation, fecal
S100A12 may significantly improve our arsenal of noninvasive biomarkers of intestinal
inflammation.
M1090
Profiling of Amino Acids Metabolism (“Amino Index”) Is Useful for Diagnosis,
Judgment of Clinical Activity, and Understanding of Pathophysiology in
Inflammatory Bowel Disease
Tadakazu Hisamatsu, Susumu Okamoto, Ayatoshi Andou, Takahiko Muramatsu,
Nobuhiko Kamada, Tetsuro Takayama, Yasuhiro Takada, Hitoshi Ichikawa, Motoko
Izumiya, Atsushi Sakuraba, Makoto Naganuma, Atsushi Nakazawa, Haruhiko Ogata,
Yasushi Iwao, Nobukazu Ono, Ryosei Sakai, Manabu Suzuki, Toshifumi Hibi
Backgrounds & Aims: Metabolomics, the examination of dynamic changes in the metabol-
ome, has emerged as a powerful technique in diverse fields such as drug discovery and
clinical diagnosis. Amino acids (AAs) play important roles both as basic substrates and as
regulators in many metabolic pathways, however information from aminogram data has not
been sufficiently utilized for monitoring physiologic states, nutritional control, or clinical
diagnosis. In this study, we aimed to develop “Amino Index” as a novel powerful diagnostic
tool for inflammatory bowel disease. Materials & Methods: 1) All patients of Crohn's disese
(CD, n=95) and ulcerative colitis (UC, n=95) were recruited from the Keio University Hospital
(Tokyo, Japan). Age and sex matched healthy controls (HC, n=95) were recruited from
Center for Multiphasic Health Testing and Services, Mitsui Memorial Hospital (Tokyo, Japan).
2) Fasting plasma AAs concentrations were measured by an automatic analyzer (ion-exchange
chromatography). 3) The basic algorithm to generate diagnostic “Amino Index” was per-
formed as previously reported (Noguchi Y, et al. Am J Clin Nutr 2006; 83 (suppl):513S-9S).
As “Amino Index” is based on a ratio model, which is nonlinear, the search for an optimal
function used a systematic search method. Results: 1) Total plasma essential AAs were
significantly decreased in IBD patients (HC vs. CD, HC vs. UC; p<0.01). 2) Imbalance of
branched AAs (Leu↓, Val↓, Ile→) were observed in IBD patients. 3) Glucogenic AAs were
decreased in UC, while basic AAs were decreased in CD. 4) The index {(Tau+Cystine+Orn)/
(Asn+His+Val)} was derived as the optimal index for separating CD from HC (Area Under
Curve (AUC) of receiver-operating characteristic (ROC) curve=0.965). Other indexes also
can distinguish UC from HC (AUC=0.945), active CD (CDa) from active UC (UCa) (AUC=
0.905), CDa from remission CD (CDr) (AUC=0.935 , cf. C-reactive Protein (CRP) AUC=
0.762) and UCa from remission UC (UCr) (AUC=0.786 , cf. CRP AUC=0.723). 5) The index
value for discriminating CDa from CDr is correlated with disease activity (CDAI) (spearman
rank correlation r=0.607, p<0.001) and CRP (r=0.354, p<0.01), and the one for discriminating
UCa from UCr is correlated with disease activity (DAI) (r=0.442, p<0.001). From the
preliminary observations, these indexes may reflect clinical activity in serial time-course
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observation of patients. Conclusions: Profiling of plasma AAs was a novel, non-invasive,
and effective method for diagnosis and assessment of disease activity in IBD. Analysis of
amino acids metabolism provides new insights into pathophysiology of IBD.
M1091
Serum Protein Profiling in Inflammatory Bowel Disease By Matrix Assisted
Laser Desorption/Ionization - Time of Flight Mass Spectrometry (Maldi-Tof
MS)
Andrea Belluzzi, Giulia Roda, Paolo Nanni, Daniela Parisi, Monica Casale, Francesca
Tonon, Enrico Roda, Lloyd F. Mayer, Aldo Roda
BACKGROUND AND AIM: The pathogenesis of inflammatory bowel disease (IBDs) is still
unclear since multiple factors contribute. Recently, new biomarkers have been reported, but
none of them alone has reached optimal diagnostic specificity and sensitivity. Thus, the
identification of new biomarkers or a disease related protein fingerprint for IBDs represents
a major task in the diagnosis, prognosis and pharmacological therapy.To address these
issues, a simple method for analyzing serum protein profiles based on soft impact mass
spectrometry (MS) and class selective protein extraction was developed. PATIENTS AND
METHODS: 122 serum samples from 51 healthy subjects, 31 Crohn's disease (CD) and 40
ulcerative colitis (UC) patients were studied. Samples were extracted with different surface
derivatized beads (IMAC-Cu2+, SAX, silica C18) in order to perform a selective capture and
enrichment of proteins/peptides (~2-10 kDa) without desalting steps and protein depletion
prior to matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) MS analysis.
The “protein-derivatized surface-suspension” was directly applied onto the MALDI-target,
mixed with an appropriate matrix and analyzed by MALDI-TOF MS. The resulting mass
spectra data, comprising more than 103 m/z signal, were reduced using a chemometric
approach, and a multivariate analysis method, Linear Discriminant Analysis (LDA), was
applied for the classification of samples by minimizing intragroup variance and maximizing
intergroup variance. RESULTS: as a preliminary step a selected number of serum samples
(20 for each group) were extracted with IMAC-Cu2+, SAX and silica C18 and MALDI spectra
obtained were analyzed by LDA. Silica C18 extraction was selected, since a best discrimination
ability between the different IBDs groups was obtained (SAX: 91%, IMAC-Cu2+: 96%, C18:
98%). When all the samples were analyzed, a 93% correct classification among the three
groups was achieved; The prediction ability was 84% for healthy subjects, 93% for CD and
80% for UC . In a follow up study using new blind samples as test set a 85% specificity
and a 60% sensitivity for both diseases was obtained. CONCLUSION: a simple analytical
method allowing for the discrimination between different IBDs only on the basis of serum
protein expression profiles was developed. The selected m/z variables associated with the
proteins responsible for this discrimination will be identified using electrospray ionization/
quadrupole-time of flight (ESI/Q-TOF) MS. These preliminary data may improve the dia-
gnostic screening in classifying IBD patients and provide the basis for the discovery of new
specific biomarkers of disease activity.
M1092
The Usefulness of Quantitative Real-Time PCR Assay for Early Detection of
Cytomegalovirus in Patients with UC Refractory to Immunosuppressive
Therapies
Takuya Yoshino, Hiroshi Nakase, Satoko Inoue, Hiroshi Kitamura, Satoru Ueno,
Norimitsu Uza, Sakae Mikami, Minoru Matsuura, Tsutomu Chiba
Background: Recently, several cases of inflammatory bowel disease (IBD) associated with
cytomegalovirus (CMV) infection have been reported. Particularly, there is a high possibility
that CMV infection contributes to exacerbation of disease activity in patients with ulcerative
colitis (UC) refractory to immunosuppressive therapies. Therefore, it is important to make
a rapid diagnosis of CMV infection. Aim: The aim of this study is to investigate the usefulness
of quantitative real-time PCR assay for early detection of CMV in patients with UC refractory
to immunosuppressive therapy. Method: From 2003 to 2006, thirty patients (mean age:
41±18 year, 14 men, 16 women) with UC refractory to immunosuppressive therapies were
enrolled. The severity of UC was assessed using with DAI score. The presence of CMV
inclusion bodies in colonic biopsies was examined by H&E staining and immunohistochem-
istry staining using anti-CMV monoclonal antibodies. CMV-atnigenemia assay was also
performed. Quantitative real-time PCR assay of CMV-DNA was done as follows: DNA for
real-time PCR assay was extracted from colonic tissues using QIAmp DNA Blood Mini Kit
according to the manufacturer's protocol. The oligonucleotide primers used for CMV-DNA
amplification was made for detection of the immediately early gene. Results: (1) CMV-DNA
was detected in colonic mucosa in seventeen (56.7%) of 30 patients with UC. Moreover,
CMV-DNA was detected in inflamed but not in noninflamed mucosa. Only four of these
17 patients were positive for CMV-antigenemia or inclusion bodies identified in histological
examination. (2) Twelve (70.6%) of these 17 patients were treated with ganciclovir for two
weeks. After antiviral therapy, only five patients improved and went into remission, another
five were treated with additional granulocytapheresis, one treated with tacrolimus and two
finally undertook colectomy. Three of the remaining five positive for CMV-DNA, without
antiviral therapy needed colectomy, and two went into remission only by withdrawal immu-
nosuppressive drugs. (3) Twelve of 13 patients negative for CMV-DNA went into remission
after treatment with additional immunosuppressive therapies. Only one patient finally needed
colectomy. (4) There was no significant difference of endoscopic grade, extent of disease,
and DAI score between CMV-positive and negative patients with UC. Conclusion: Our study
strongly demonstrated that quantitative real-time PCR assay of CMV-DNA may be the most
sensitive and useful modality for early diagnosis of CMV infection. This diagnostic modality
is also helpful for making decision of treatment for patients with UC refractory to immunosup-
pressive therapies.
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M1093
Recurrent Prolonged Antigen Encounters Are Necessary for 6-MP Induced
Clonal Deletion of Antigen-Specific Memory T-Cells In Vivo
Shomron Ben-horin, Itamar Goldstein, Zohar Yerushalmi, Orit Picard, Ella Fudim, Iris
Barshack, Alon Lang, Yifat Goldschmid, Simon Bar meir, Yehuda Chowers
Introduction: We previously demonstrated that the delayed onset of effect of Azathioprine/
6-MP may be due to their inability to suppress effector functions of activated T-cells.
However, the mechanism of their eventual effect remained obscure. Aim: To test the effect
of 6-MP on T-cell Ag-specific responses. Methods: Balb/C mice were immunized simultan-
eously with HEL/IFA and Ovalbumin/ IFA. After a 4 week interval, one group was treated
daily with i.p. 6-MP and the other with vehicle only. Both groups continued to receive bi-
weekly i.p immunizations with HEL antigen only. Mice were sacrificed after 4 or 20 weeks
of treatment. Proliferation of CD4+ splenocytes to HEL, Ovalbumin, or medium was deter-
mined by CFSE dilution. Results: CD4+ memory response to HEL and Ovalbumin was
similar among mice sacrificed after 4 weeks, regardless of 6-MP treatment. However, after
20 weeks, the CD4+ memory response to HEL was markedly decreased in 6-MP treated
mice compared to mice treated with vehicle only (% proliferation 7.6±3 vs. 23±7.5, P=
0.01). Importantly, the memory response to Ovalbumin was not different between 6-MP
treated or un-treated mice (% proliferation 22±3.9 vs. 29±6.8, P=NS). Intriguingly, the
spleen weight of the 20 weeks 6-MP treated mice was lower than the spleen weight of
untreated mice (115±9gr Vs. 150±12gr, p=0.05), and the total number of splenocytes was
reduced (35±2X106 Vs. 58±4X106 cells, P<0.01). Conclusions: These data suggest that the
onset of suppression of inflammation by 6-MP, is associated with deletion of T-cell memory
towards repeatedly encountered cognate antigens and may thus allow to manipulate these
responses.
M1094
Assessment of Perianal Disease Activity in Patients with Crohn's Disease
Alessandra Losco, Chiara Viganò, Dario Conte, Bruno M. Cesana, Guido Basilisco
Background and aim: Assessing perianal activity is clinically important in patients with
Crohn's disease, but the currently used Fistula Drainage Assessment (FDA) and Perianal
Disease Activity Index (PDAI) must still be fully validated. As it has been recently reported
that anal ultrasound (AUS) with computer-assisted image analysis can quantitatively assess
fistula track activity (Am J Gastroenterol 2006; 101: 1551-8), the aim of this study was to
verify the diagnostic accuracy and agreement of FDA, PDAI and AUS in assessing perianal
Crohn's disease activity, and evaluate whether their combination increases the diagnostic
accuracy. Material and methods: Fifty-one consecutive patients with Crohn's disease-related
perianal fistulas (34 males; mean age 41 years, range 22-73) underwent clinical examination,
FDA, PDAI scoring and AUS. Perianal disease was considered active in the presence of
visible fistula drainage and/or signs of local inflammation (i.e. induration and pain at digital
compression) at clinical examination. Fistula drainage was the criterion of activity at FDA.
The AUS images were analysed using dedicated image analysis software that calculated the
mean grey-scale tone in the area corresponding to the lesion. The AUS and PDAI values
discriminating active and inactive perianal disease were defined by ROC statistics. Diagnostic
accuracy was assessed with 95% confidence intervals, and the K test was applied to evaluate
agreements. Results: Perianal disease was clinically active in 39 patients. FDA had an
accuracy of 86% (CI: 74-94%). A PDAI of >4 maximised sensitivity and specificity, and had
an accuracy of 84% (CI: 71-93%). At AUS, a mean grey-scale tone cut-off value of 118
maximised sensitivity and specificity, and had a diagnostic accuracy of 84% (CI: 71-93%).
The agreement between FDA, PDAI and AUS was fair to moderate (0.518 for FDA vs PDAI;
0.318 for PDAI vs AUS; 0.461 for AUS vs FDA). The addition of FDA or PDAI to AUS
increased diagnostic accuracy to respectively 98% and 100%. Conclusion: In patients with
active perianal Crohn's disease, FDA, PDAI and AUS showed good diagnostic accuracy and
fair-moderate agreement in assessing perianal Crohn's disease activity. Overall accuracy can
be maximised by combining FDA or PDAI with AUS.
M1095
Transcript Levels of Different Cytokines and Chemokines Correlate with
Clinical and Endoscopic Activity in Ulcerative Colitis
Alexandra Zahn, Thomas Giese, Max Karner, Wolfgang Stremmel, Robert Ehehalt
Background & aims: A definition of disease activity in ulcerative colitis (UC) is difficult.
The clinical activity index (CAI) is only an indirect assessment tool of bowel inflammation
and the endoscopic activity index (EAI) sometimes cannot reflect the severity of disease to
the full extent. Therefore, there is a need for a reliable and objective means to quantitate
inflammatory activity in mucosal biopsies. In our study, we wanted to examine the correlation
between transcript levels of interleukin 8 (IL-8), interferon γ inducible protein 10 (IP10),
myeloid-related protein 14 (MRP14), macrophage inflammatory protein 2 α (MIP2α) with
CAI and EAI in UC. Patients & methods: Cytokine and chemokine transcripts were quantified
using real-time PCR in mucosal biopsies from non-inflamed areas from 25 patients with
UC. All patients participated in a randomized, double-blind and placebo controlled clinical
study concerning the anti-inflammatory effect of retarded release phosphatidylcholine (PC).
Cytokine transcript levels in the biopsies at the beginning and at the end of the study (3
months later) were correlated with CAI and EAI. Furthermore, the intraindividual course
of cytokine transcript levels was studied. Thus, 36 biopsies from PC group patients and 14
biopsies from placebo group patients were examined. Results: There was a statistically
significant positive correlation between IL-8 (p=0.01), IP10 (p=0.04), MRP14 (p=0.01), and
MIP2α (p=0.02) and CAI. Concerning EAI significant positive correlations could also be
found for IL-8 (p=0.04), MRP14 (p=0.02), IP10 (p=0.03) and MIP2α.(p=0.03). Clinical and
endoscopic improvement led to a decrease in cytokine levels whereas a deterioration of
clinical and endoscopic activities were accompanied by increased cytokine levels. PC led to
a lowering of cytokine levels in most of the patients whereas in the placebo group cytokine
levels were not predictable. Conclusion: From our data, we conclude that real-time PCR
quantification of IL-8, IP10, MRP14 and MIP2α in colonic biopsies is a simple and valid
method for grading inflammation of intestinal mucosa in UC. It correlates significantly with
the standard CAI and EAI indices. Measurement of these cytokines might therefore be used
as an objective tool in clinical trials to evaluate anti-inflammtory and immunomodulatory regi-
mens.
M1096
Altered Intestinal Permeability Is Predictive of Early Relapse in Children with
Steroid Responsive Ulcerative Colitis
Erasmo Miele, Filomena Pascarella, Lucia Quaglietta, Eleonora Giannetti, Luigi Greco,
Riccardo Troncone, Annamaria Staiano
Background & Aims: The predictive values of many clinical disease activity indices and
histologic and laboratory parameters in identifying patients at risk of relapse of inflammatory
bowel disease have generally been disappointing. The purpose of this study was to determine
if upper gastrointestinal involvement at diagnosis could predict early relapse in children
with ulcerative colitis (UC). Methods: The study was a prospective, one-year evaluation of
children with newly diagnosed UC. Participants were evaluated a three time points: within
1 month , 6 months after diagnosis, and 1 year after diagnosis. Lichtiger colitis activity
index (LCAI), and a physician's global assessment (PGA) were used to measure disease
activity. Laboratory studies were performed at each visit and/or at the time of relapse. At
diagnosis, all patients underwent colonoscopy and a cellobiose/mannitol small intestinal
permeability study (CMPS). Some children were further investigated with an UGI endoscopy.
Results: Thirty-three patients completed one-year study. Overall, 9 patients (27.3%) relapsed
within 6 month of diagnosis, one patient (3%) within one year, whereas 23 patients (69.7%)
did not relapse during the follow-up. The mean LCAI and the PGA did not show differences
among patients with and without early relapse and those that did not (p=0.724). Laboratory
parameters, extent of colonic involvement , upper and lower GI histologic features were not
predictive of early relapse. In contrast, results of the CMPS were significantly lower in
children who relapsed within 6 months (Mean: 0.036, range: 0.008-0.1; p<0.013) compared
to children who did not relapse (Mean: 0.017, range: 0.003-0.17). The CMPS was abnormal
in 77.8% of early relapsers compared with only 8.3% of non-relapsers. Conclusions: An
abnormal small intestinal permeability in children with UC could predict a more relapsing
disease. If these data are confirmed in a more larger scale, the CMPS may represent a non-
invasive test useful in identifying the patients requiring more targeted treatment.
M1097
Peripheral Blood Granulocyte STAT3 Activation Correlates with Mucosal
Inflammation in Inflammatory Bowel Disease
Ingrid Jurickova, Rebecca Carey, Erin Bonkowski, Edgar Ballard, Lee Denson
Clinical trials in Inflammatory Bowel Disease (IBD) are limited by a lack of biomarkers for
mucosal inflammation. Local activation of the IL-6 dependent Signal Transducer and Activator
of Transcription 3 (STAT3) transcription factor correlates very well with the degree of
intestinal inflammation. We hypothesized that peripheral blood leukocyte (PBL) STAT3
activation would also correlate with the degree of mucosal inflammation in IBD. Methods:
Serum IL-6, CRP, and fecal calprotectin were determined in a cohort of thirty pediatric
Crohn's Disease (CD) patients and healthy controls (NL) undergoing diagnostic colonoscopy.
Peripheral blood cells were fixed with paraformaldehyde, permeabilized with ice-cold meth-
anol, and stained with anti-CD3, CD4, CD25 and pSTAT3 (recognizes tyrosine phosphoryl-
ated residue of activated STAT3). Stained cells were acquired on FACscan flow cytometer
(BD) and analyzed by Cell Quest software (BD). Mucosal inflammation was scored using
the CD Histological Index of Severity (CDHIS) and the CD Endoscopic Index of Severity
(CDEIS). Results: Serum IL-6 was increased in active CD compared to NL. However, only
63% of CD patients with active intestinal inflammation by endoscopy had an elevated CRP.
Moreover, CRP did not correlate with either the CDHIS (r2=0.14) or CDEIS (r2=0.15). When
using a cut-off of 150 mcg/gm stool, fecal calprotectin exhibited a sensitivity of 84% and
specificity of 100% for detecting the presence of intestinal inflammation in CD patients.
However, fecal calprotectin did not correlate well with either the CDHIS (r2=0.01) or the
CDEIS (r2=0.02). The number of pSTAT3+ cells per high powered field in colon biopsy
samples correlated well with the CDHIS by linear regression analysis, with r2=0.48, p<0.0001.
The frequency of pSTAT3+ peripheral blood lymphocytes or monocytes was not increased
in CD. However, the frequency of pSTAT3+ granulocytes was increased, to 31 ± 18, reactive
to 6.3 ± 5 in controls. Using a cut-off of 15, the pSTAT3+ FACS assay had a sensitivity of
87% and a specificity of 100% for detecting intestinal inflammation. Receiver Operator
Characteristic (ROC) analysis was performed using PRISM™ software. The PBL STAT3 assay
demonstrated an area under the curve (AUC) of 0.92 (95% CI: 0.8 to 1.1), p<.001. The
PBL STAT3 activation assay exhibited a correlation with the CDHIS, r2 = 0.5, p = 0.01,
which was comparable to that observed in stained colon biopsy samples. Conclusions: We
have developed a PBL STAT3 activation assay which correlates well with the degree of
intestinal inflammation in CD patients, and may ultimately provide a useful biomarker for
clinical trials.
M1098
6MMP/6TGN Metabolite Ratios Predict Therapeutic Outcomes and Reflect
Thiopurine Methyltransferase Genotype in IBD
Ernest G. Seidman, Marc Girardin, Devendra Amre, Yves Theoret
Background: We have shown that the efficient conversion of the thiopurine drugs 6-mercapto-
purine (6-MP) and azathioprine (AZA) to 6-thioguanine nucleotides (6TGN) is the principal
determinant to clinical efficacy in IBD. The principal catabolic metabolite, 6-methylmercapto-
purine (6MMP), is formed via the competing enzymatic pathway via thiopurine methyltrans-
ferase (TPMT). Polymorphisms of TPMT can lead to excessive 6TGN levels and cause
myelotoxicity. Aim: To assess the clinical utility of the calculated metabolite ratio [6-MMP/
6-TGN] in predicting clinical outcomes and myelotoxicity risk due to TPMT mutations.
Patients & Methods: 6-MP metabolite levels were measured prospectively at 4-6 monthly
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intervals, as well as at each clinical relapse point or any episode of drug toxicity in IBD
patients (adult & pediatric) on 6-MP or AZA for > 3 mo. Therapeutic response was determined
by standard disease activity indices and by physical exam ascertained at each clinical evalu-
ation point and correlated to 6-MP metabolite measurements. Erythrocyte 6-TGN and 6-
MMP concentrations (pmol/8x108 RBC) were measured by HPLC assay at Ste Justine Hos-
pital. Patients were genotyped for common polymorphisms in TPMT transitions using a
PCR-allele specific oligonucleotide hybridization assay. Logistic regression analyses were
carried out after controlling for correlation between repeated measures. Results: Data was
analyzed for 1262 clinical evaluation points with metabolite values and ratios in 315 patients.
Clinical remission correlated with higher erythrocyte 6-TGN levels (< 0.001). Higher 6-MMP
values (> 5380) were associated with reduced likelihood of therapeutic success (p<0.001). A
significantly increased risk for relapse (p=0.002) was associated with high (>30.5) ratios of
6MMP/6TGN. With each 15 unit increase in the ratio above 30, the probability of a successful
outcome on thiopurine drug therapy decreased by 29% (p<0.001). Ratios above 65 indicate
very low likelihood (<10%) of therapeutic success. Heterozygous mutations in TPMT (n=
34) were associated with very low ratios (mean 2.03), and a high likelihood (83.5%) of
excessive 6-TGN levels in the myelotoxicity range (450-1243). Conclusions: Calculated 6-
MMP/6-TGN ratios portend outcomes to thiopurine drug therapy: High ratios (> 30) due
to excessive TPMT activity are associated with a higher likelihood of drug failure, while low
ratios (< 3) are associated with TPMT mutations and higher risk of myelotoxicity.
M1099
Quantitative Expression of Cd64 On Polymorphonuclear Neutrophils in
Patients with Inflammatory Bowel Disease: A New Laboratory Marker with
Unique Properties
Wolfgang Tillinger, Ruth Jilch, Ursula Köller, Nother Zwerina, Harald Brunner
Background Intestinal bacterial infections and non-inflammatory intestinal disorders, such
as lactose or fructose intolerance (LFI), may present with symptoms similar to those of
inflammatory bowel disease (IBD). However, a discriminative laboratory marker is not
available. Here, we investigated the utility of CD64 to differentiate between active and
inactive IBD, intestinal bacterial infections, and LFI. Patients and Methods Quantitative
expression of CD64 on PMN was determined by FACS analysis using a fluorescence quantita-
tion kit (QuantibriteTM PE, BD Biosciences). We investigated patients with active (n=27)
or inactive (n=49) IBD, infectious enterocolitis (n=24, i.e. Campylobacter [n = 13], Salmonella
[n =7], Shigella [n = 1], and Clostridium difficile [n = 3]), LFI (n=32), and healthy subjects
(n=28). Clinical measures of disease activity included the Crohn's disease activity index
(CDAI) for patients with Crohn's disease (n=52), and the colitis activity index (CAI) for
patients with ulcerative colitis (n=24). Active IBD was defined as CDAI > 150 and CAI >
6, respectively. Statistical comparisons of means were done by t-test. Correlations were
assessed by means of Spearman's correlation coefficient. Receiver operating characteristic
curves were generated in order to define discriminative cut off values of CD64 expression.
Data are given as median and range from the 25th to the 75th quartile (IQR). Results The
quantitative expression of CD64 was significantly higher in patients with IBD (1125, 621-
2083), than in healthy subjects (569, 387-756, p<0.01), or in patients with LFI (531, 435-
605, p<0.001). In patients with active IBD the CD64 expression was significantly higher
(2158, 1230-7709) than in patients in remission (755, 438-2109, p<0.0001). CD64 correl-
ated with the CDAI (110, 44-197; 0.55, p<0.0001), the CAI (2, 0-5; 0.63, p<0.0001), and
with serum of levels of CRP (0.93, 0.4-2.67; 0.65, p<0.0001). With a cut off point of 800
CD64 had a 96% sensitivity and a 97% specificity in discriminating between LFI and
active IBD. In patients with infectious enterocolitis (15209, 11410-22965) the quantitative
expression of CD64 was significantly higher than in patients with active IBD (4058±3590,
p<0.001). With a cut off point of 10000 CD64 had a 88% sensitivity and a 93% specificity
in discriminating between infectious enterocolitis and active IBD. Conclusion CD64 is a
discriminative marker for active and inactive IBD, infectious enterocolitis, and LFI. Thus,
it may serve as a valuable diagnostic tool for the differential diagnosis and for monitoring
of IBD.
M1100
Metabonomic Signature of Faecal Microbiota As a Contributory Factor to the
Phenotype of IBD
Julian Marchesi, Fergus Shanahan, Elaine Holmes, Yulan Wang
Background: Comprehensive phenotyping of patients with Crohn's disease (CD) and ulcerat-
ive colitis (UC) should include not only an assessment of mammalian pathophysiology but
also the indigenous enteric microbiota. Individual differences in composition of microbiota
suggest that the enteric bacteria may not only contribute to the pathogenesis of disease but
might also provide a basis for a diagnostic biomarker. Aim: To develop a non-invasive
molecular profile of the faecal microbial metabonome in patients with inflammatory bowel
disease (IBD). Method: We present here the first characterization of faecal extracts obtained
from patients with CD (n=10) and UC (n=10) vs controls (n=10) by employing a metabonom-
ics approach, which combines high resolution 1H NMR spectroscopy and multivariate pattern
recognition techniques. Results: The faecal extracts of both CD and UC patients were
characterized by reduced levels of butyrate, acetate, methylamine and trimethylamine in
comparison with a control population, suggesting changes in the gut microbial community.
Also, elevated quantities of amino acids were present in the faeces from both disease groups,
implying malabsorption caused by the inflammatory disease or an element of protein losing
enteropathy. Metabolic differences in faecal profiles were more marked in the CD group in
comparison with the control group indicating that the inflammation caused by CD is more
extensive in comparison with UC and involves the whole intestine. Furthermore, glycerol
resonances were a dominant feature of faecal spectra from patients with CD, but were present
in much lower concentration in the control and UC groups. Conclusions: This work
illustrates the potential of metabonomic technology to generate novel non-invasive diagnostics
for gastrointestinal diseases, and may further our understanding of disease mechanisms.
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M1101
Association Between C-Reactive Protein (Crp), Orosomucoid, Interleukin-6
(IL-6), Fecal Lactoferrin and Fecal Calprotectin and Clinical and Endoscopic
Indices of Disease Activity in Patients with Crohn's Disease
Jennifer Jones, Edward V. Loftus, Scott Harmsen, Emelie Helou, Steve Ingle, William A.
Faubion, Connor Loftus, Jonathon Clain, William J. Tremaine, Darrell S. Pardi, Kenneth
W. Schroeder, Allan Zinsmeister, Joseph Mcconnell, Remo Panaccione, Linnha Beaudhuin,
Sandra Petersen, Brian G. Feagan, Karen Hansen, William J. Sandborn
Background: Serological and fecal biomarkers hold great promise as tools to estimate disease
activity in Crohn's disease (CD). Genetic polymorphisms (PM) within the CRP gene as well
as upstream regulators of CRP have been shown to influence both baseline and stimulated
CRP response in select patient populations. Concentrations of fecal biomarkers calprotectin
(Cp) and lactoferrin (Lf) are elevated in association with active luminal inflammation and
have been demonstrated to reliably distinguish between inflammatory and non-inflammatory
luminal disease states. Objective: To evaluate the relationship between CRP, IL-6, orosomu-
coid (APG), fecal Cp, fecal Lf and clinical and endoscopic measures of disease activity; and
to determine if select genetic PMs influence CRP concentrations. Methods: One hundred
fifty-four patients with Crohn's disease undergoing colonoscopy at Mayo Clinic (Rochester
Minnesota, USA) and University of Calgary (Calgary Alberta, Canada) between November
2004 and November 2006 were enrolled in the study. Clinical, demographic and disease-
specific characteristics were recorded. All patients completed a Crohn's disease activity index
(CDAI). Colonoscopies were scored using the Simplified Crohn's Disease Activity Index
(SES-CD). Sera and stool samples were assayed for CRP, IL-6, APG, Lf and Cp concentrations.
Samples were then analyzed by multiplex assay for select genetic PMs of the CRP, TNF and
IL-6 genes. Statistical analyses were performed to explore associations. Results: None of the
serological or fecal biomarkers correlated with clinical disease activity. CRP, IL-6, Cp and
Lf concentrations were significantly higher in patients with more severe endoscopic disease
activity (SES-CD > 7) (p<0.001). Interestingly, there was no association between the CDAI
and SES-CD. Fecal biomarker concentration did not correlate with the site of active inflamma-
tion (ileal, colonic or ileocolonic) at the time of colonoscopy. CRP 717 mutant homozygote
and heterozygote status was associated with significantly lower concentrations of CRP (p=
0.02). There was a trend toward higher CRP concentrations in the 286 heterozygous AMT
mutant genotype, but this did not reach statistical significance. Conclusion: Serological and
fecal biomarker concentrations are associated with endoscopic but not clinical activity.
Stimulated CRP concentration is significantly affected by select genetic PMs. Further explorat-
ory anaylsis will be performed to evaluate the relationships between genotype-adjusted CRP
concentrations and measures of disease activity as well as biomarker cut-points and measures
of endoscopic disease activity.
M1102
Adverse Skin Reactions to Anti-TNF Agents: A Systematic Review of a Single
Center Cohort
Pieter Vandecandelaere, Herma Fidder, Marc Ferrante, Paul J. Rutgeerts, Gert A. Van
assche, Siegfried Segaert, Severine Vermeire
Introduction: Anti-TNF agents are very efficacious for the treatment of ulcerative colitis (UC)
and Crohn's disease (CD). The safety profile has been overall positive. Skin reactions have
been described in case reports but no large series are available on the size of the problem
and the outcome. Aim & Methods: We reviewed all IBD patients treated with anti-TNF
who reported skin abnormalities under treatment that were judged serious enough by the
clinician. All patients were referred to one dermatologist and a detailed questionnaire asking
for history of allergic conditions was performed. Results: At present, 21 patients with serious
skin lesions under anti-TNF (17 female, 5 UC, 16 CD) were identified, 18 received IFX
and 3 patients received adalimumab (2 previous IFX and 1 IFX naieve). Lesions were
psoriatiform in 12 and wet with crustae in 10 and were located primarily on the scalp (n=
10), facies (n=11), hand palms and feet (n=8) and the pubic region (n=11). The median
time to onset was 19 weeks after first IFX (range 0-52). In most patients, lesions were
transient but worsened after each infusion in 9/21. All patients responded well to topical
steroids and 2 patients did not receive any therapy. Stress factors were clearly reported as
triggers by 7 patients. These skin abnormalities moderately or severely affected quality of
life in 19/21 patients. Remarkably, 53% of patients were ANA positive. A previous history
of allergic conditions (eczema, hay fever or asthma) was observed in only 8/21 patients. 4
patient had psoriasis before starting anti-TNF. Two patients eventually needed to stop anti-
TNF (both IFX) due to this side effect. Conclusion: Psoriatiform-like lesions but also other
skin lesions are a reported side effect of anti-TNF agents. This side effect is most likely
class-mediated. Most lesions can be easily managed by topical therapy and rarely lead to
definite stop of therapy. Remarkably, 53% of patients were ANA positive. Further mechanistic
studies are required to explain why psoriatiform-like lesions develop as a side effect of anti-
TNF, while the same drug has a proven efficacy in the treatment of psoriasis.
M1103
Increasing Prevalence of Serological Markers Predicts Aggressive CD Behavior
Abdul A. Elkadri, Simon Lal, Joanne M. Stempak, Thomas Walters, Anne M. Griffiths,
Gordon R. Greenberg, A. hillary Steinhart, Mark S. Silverberg
Background: Crohn's Disease (CD) likely results from an aberrant immune response to
commensal intestinal bacteria in genetically susceptible individuals. Antibodies to microbial
antigens have been associated with diagnosis and phenotypic expression of CD. We aimed
to further evaluate the clinical relevance of serological antibodies (IgA/IgG ASCA, anti-OmpC
and Flagellin) in a cohort of CD patients. Methods: Serum samples were collected from 391
CD and 62 healthy controls (HC) in a tertiary care Inflammatory Bowel Disease center. The
diagnosis for each patient was based upon endoscopic, histologic and radiographic features
and phenotypes were assigned using the Montreal Classification. Blinded serological analysis
was performed at Prometheus Laboratories Inc. (San Diego, CA). A series of tests were
performed to assess univariate relationships between phenotypic characteristics and the total
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number of positive antibody responses. Results: CD subjects were more likely to have positive
ASCA (IgA+/IgG+), anti-OmpC and Flagellin than HC (p<0.0001 for all). Multivariate analysis
revealed the following positive associations (p<0.05 for all): perianal disease with Flagellin
and IgA ASCA, penetrating behavior with ASCA, younger age of diagnosis with ASCA and
Flagellin, number of surgeries with anti-Omp C. Phenotypic associations with increasing
positive antibody responses are shown in Table 1. Conclusion: Increased numbers of positive
serological markers are associated with a younger age of diagnosis, and a more aggressive
disease phenotype including stricturing and penetrating behavior, perianal disease and an
increased number of surgeries. These findings raise the possibility that serological assessment
in individual patients will allow clinicians to predict those at risk for more severe disease
behavior. This cohort could potentially be considered for early biological therapy aimed at
changing natural history prior to the development of these complications.
Table 1. Number of positive antibody responses based on prevalence of antibodies for ASCA,
Omp-C and Flagellin
M1104
Metabolomic Analysis of Inflammatory Bowel Disease in Interleukin-10 Gene-
Deficient Mice
Travis B. Murdoch, Hao Fu, Sarah Martin, Carolyn Slupsky, Richard N. Fedorak
Background: Metabolomics, the study of small-molecule metabolite profiles, is a novel
method of investigating disease. Nuclear magnetic resonance spectroscopy (NMR) has been
shown to be effective for simultaneously identifying and quantifying hundreds of small
molecules in complex mixtures of bio-fluids and tissues. Recent metabolomic studies have
demonstrated that urinary metabolic profiles can be altered by enteric bacteria. Inflammatory
bowel disease (IBD) is known to be associated with marked changes in enteric bacterial
profiles. Objective: To investigate whether IBD confers a distinct metabolic “fingerprint” that
could be used as a diagnostic tool for this disease, and to examine the contribution of enteric
bacteria to this “fingerprint” and thus to the pathogenesis of IBD. Methods: IL-10 gene-
deficient mice (IL10KO) (N=4), which develop IBD similar to human Crohn's disease, were
compared to age and sex-matched wild-type controls (N=3). At 4, 8 and 16 wk of age, 22
h urine samples were obtained. At 20 wk of age, the mice were sacrificed, their colons
removed, homogenized and subjected to methanol/chloroform extraction followed by lyophi-
lization. Urine and colonic tissue extract samples were run on a Varian 600 MHz NMR
spectrometer and metabolite concentrations were determined using Chenomx NMRSuite
4.0 (Chenomx Inc. Edmonton, Canada). Statistical analysis was conducted via Principal
Components Analysis (PCA) using standard procedures as implemented in SIMCA P11.0
(Umetrics, Umeå, Sweden). The student's t-test was used to determine significance. Results:
PCA of urine and colonic extracts revealed that IL10KO mice with IBD had markedly different
metabolic profiles relative to their matched wild-type controls. Loading plots revealed the
following separating metabolites: methylamines, purine metabolites, and citric acid cycle
intermediates. Most dramatically, trimethylamine (TMA) was significantly increased in
IL10KO mouse urine at 8 (p=0.03) and 16 (p=0.02) wks of age as compared to wildtype
mice, paralleling the histologic development of IBD and change in luminal microflora.
Conclusion: This study demonstrates the potential of urine NMR metabolomic “finger-
printing” as a diagnostic technique for IBD. Moreover, our ongoing metabolomic studies
may provide insight into the etiology of IBD. TMA production in the mouse has been shown
to be dependent on the presence and composition of enteric microflora. Identification of
the bacteria responsible for TMA production may assist in identifying the microbial factors
responsible for initiation and perpetuation of IBD.
M1105
Receipt of Preventive Health Services in IBD Patients Is Significantly Lower
Than in Primary Care Patients
Lisbeth A. Selby, Sunanda Kane, Purnima Balla, Brian Riff, Christopher Bingcang, Smita
Pande, Andrew Hoellein, John Wilson, Willem De villiers
Background: Persons with chronic diseases, like rheumatoid arthritis, often do not receive
preventive health services at the same rate as the general population. Reasons for this are
not clear but may include such issues as consumption of provider time by the chief disease,
unclear primary care roles, and underinsurance of the chronically ill. We conducted a cross
sectional survey of inflammatory bowel disease (IBD) patients and controls to assess the rates
of receipt of 10 widely recommended preventive health services. Source of recommendations :
US Preventive Services Task Force; Advisory Committee for Immunization Practices. Methods:
Consecutive outpatients from two IBD centers were surveyed from 3/06-8/06. One group
was surveyed by trained clinicians with standardized data collection forms and the other
by self-administered surveys. Subject report was augmented by chart data. Other data
collected included: demographics, measures of disease control, insurance, and measures of
health care usage. A group of primary care outpatients were surveyed as controls in the
same time period. Results: 117 subjects were enrolled at one center (response rate 100%)
and 125 at the second (response rate 98%). Patients from each center were similar in
demographic variables. Mean age was 40. 47% were males. 73% had Crohn's disease; 4
subjects had indeterminate colitis. Mean disease duration was 9 yrs. Mean disease control
rating was 2.8 (0 = poor; 5= well). Median number of physician visits/yr was 8. Median
primary care visits/yr was 2. 100 control subjects were recruited (response rate 89%). The
mean age was 47. 37% were males. Median number of clinic visits was 4. Median number
of primary care visits/yr was 2. Age/sex adjusted screening rates are significantly lower in
IBD subjects than in controls (75%, 67% v 83%, p = 0.0002). After adjustment for insurance
status, the difference in screen rates is still lower for IBD than controls (71% v 78%; P=
0.022). Neither disease type nor disease control rating predicted screen rates. Conclusions:
Our data suggest IBD patients do not get preventive services at the same rate as a general
medical patients; insurance status is a predictor of lack of receipt of such services. Pervasive
flaws in the healthcare system may be a fundamental issue.
M1106
A Unique Inflammatory Mechanism for Intestinal Injury During IBD:
Modulation of a Distinct Phospholipase C-γ1 (PLC-γ1) Dependent Pathway
Could Underlie EGF-Receptor Initiated Pathways That Lead to Mucosal
Oxidative Stress and Nf-κB Activation in Man
Ali C. Banan, Maliha Shaikh, Lijuan Zhang, Christopher B. Forsyth, Ashkan Farhadi, Ece
Mutlu, Yueming Tang, Ali Keshavarzian
Upregulation of NFκB & oxidative stress are key events in human IBD. Our own In Vitro
studies suggest that modulation of a distinct pathway dependent on PLC-γ1 isotype and an
EGF-Receptor initiated processes attenuate upregulation of the oxidative stress & inflammat-
ory response in cells. However, these novel processes are not well-characterized in human
IBD. We thus aimed to determine whether: [1] activation of PLC-γ1 isotype & its tyrosine
kinase activity and activation of an EGF-R pathway occur in inflamed IBD mucosa; [2] PLC-
γ1 and EGF-R pathway activity compare with markers of gut inflammation & injury. Methods:
We used pinch biopsies from IBD patients (UC, CD, specific colitis) & normal controls,
and measured: PLC-γ1 & its tyrosine kinase activity (tissue distribution/expression); EGF-
R (levels/activity/distribution); markers of gut inflammation & oxidative injury (IkK, NFkB,
IκB, iNOS, NO, barrier protein/cytoskeletal oxidation/instability). Results: Compared to
normal mucosa, inflamed IBD mucosa showed marked increases in PLC-γ1 (145 kDa)
distribution, expression & tyrosine kinase activity, indicating its upregulation. We also found
up-regulation & activation of EGF-R (180 kDa) (increased in mucosal membrane fractions).
In parallel, large increases in IkK activation, NFkB activation (p50/p65 subunits), IκBα
phosphorylation, iNOS upregulation, oxidant generation (NO, O2), & protein carbonylation/
nitration were seen. In normal appearing (non-inflamed) mucosa, smaller changes in all of
the oxidative markers & EGF-R—PLC-γ1 isotype were found. Both tissue structural &
barrier proteins were largely oxidized in inflamed mucosa, less so in normal mucosa. Mucosal
EGF-R—PLC-γ1 activation correlated positively with tissue inflammation, oxidative injury
& with IBD severity. Changes in EGF-R, PLC-γ1, NFkB/iNOS, & oxidation were mostly
seen within the epithelial layer. Conclusions: 1) EGF-Receptor—PLC-γ1 are up-regulated
and activated in IBD mucosa while NFkB—NO oxidative pathways are also up-regulated
and hyperactivated. Tissue structural & barrier proteins also exhibited oxidative stress and
instability when PLC-γ1 was hyperactivated. 2) Measures of tissue inflammation & oxidative
injury directly compared to mucosal EGF-R/ PLC-γ1 and IBD disease severity. 3) Marked
activation of EGF-R—PLC-γ1 and activation of NF-κB—iNOS signaling (& structural protein
oxidation) were only seen in inflamed mucosa. These findings suggest for the first time that
a novel EGF-R and PLC-γ1 isotype dependent mechanism underlies NF-κB—NO upregul-
ation and that these key processes are required for mucosal inflammation and IBD flare in
man {Support DK60511 & AM01581; AA13745}.
M1107
Anti-Cbir1 Is Helpful in Characterizing Children with Indeterminate Colitis
James Markowitz, Wallace V. Crandall, Jonathan S. Evans, Subra Kugathasan, Neal S.
Leleiko, David R. Mack, M. susan Moyer, Maria M. Oliva-hemker, Anthony Otley, Marian
D. Pfefferkorn, Joel R. Rosh, Christine Langton, Jeffrey Hyams
BACKGROUND: A serologic marker to a novel flagellin antigen, anti-cBir1, has been reported
to identify IBD patients with Crohn disease (CD), and to identify those ANCA+ patients
who have “UC-like” CD. AIM: To examine how addition of the anti-cBir1 assay to a standard
serologic panel helps predict whether children with indeterminate colitis (IC) have CD or
UC. METHODS: Data were drawn from the Pediatric IBD Collaborative Research Group
Registry, a prospective observational inception cohort begun in 2002. At or shortly after
diagnosis of IBD, subjects were tested for neutrophil specific ANCA, ASCA IgA, ASCA IgG
and anti-ompC (Prometheus Labs). Using these data, CD was predicted if ASCA &/or ompC
was positive, irrespective of ANCA status. ANCA+ subjects without other markers were
predicted to have UC. Banked sera were subsequently tested for anti-cBir1 (Prometheus).
Subjects with anti-cBir1 >21.0 EU/ml were predicted to have CD. The Prometheus “Smart
Diagnostic Algorithm” was not used for these predictions. In all subjects, the initial diagnosis
of IC and any subsequent change in clinical diagnosis were made by the treating physician
without knowledge of the serologic results. RESULTS: Among 22 IC subjects (mean age
11.4±3.8 yrs, 77% male), initial serologic assay revealed 14 with detectable markers (11
ANCA+, 2 ompC+, 1 ASCA IgA+). anti-cBir1 assay was subsequently found to be positive
in 6/22 subjects (3 had no other detectable markers, 3 were ANCA+). Over 29±15 months
of follow-up, 15 children had their diagnoses changed based on clinical criteria to either
CD (n=6) or UC (n=9). Among the 6 with a final diagnosis of CD, serology without cBir1
only predicted CD in 1 (ASCA+), while UC was predicted in 2. Adding cBir1 to the diagnostic
panel resulted in a prediction of CD in 5/6, including 3/3 who were negative for all other
markers and 1/2 initially predicted to have UC. Among 9 subjects with a final clinical
diagnosis of UC, initial serologic testing predicted UC in 5 and CD in 1 (ompC+). Anti-
cBir1 was positive in 2/9 (both ANCA+). Final serologic predictions were 3/9 UC, 3/9 CD,
3/9 negative for all 5 markers. The 1 UC subject whose clinical diagnosis was confirmed
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by colectomy was negative for all markers. 7 IC subjects did not have a change in clinical
diagnosis. All lacked anti-cBir1. CONCLUSIONS: Adding anti-cBir1 to the standard serologic
panel improves the diagnostic accuracy for identifying IC children who over time demonstrate
clinical characteristics of CD. Whether anti-cBir1 positivity in those ultimately felt to have
UC is due to serologic overlap between CD and UC, or due to incorrect clinical diagnosis
will require further follow-up.
M1108
Identification of Candidate Biomarkers for Inflammatory Bowel Disease Using
a Seldi Proteinchip System
Shuji Kanmura, Hirofumi Uto, Masatsugu Numata, Keiko Toyama, Hiroo Abe, Tadashi
Miike, Yoshihiro Tahara, Mayumi Kodama, Kazuya Shimoda, Hirohito Tsubouchi
Aims: New serologic biomarkers for inflammatory bowel disease (IBD) may be useful for
identifying novel diagnostic markers, for the assessment of disease activity, and as therapeutic
targets. The aim of this study is to identify serum protein biomarkers specific for IBD using
a proteomics approach that is based on surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF/MS) and ProteinChip technology. Methods: A total
of 60 serum and plasma samples from patients and healthy controls were analyzed. Twenty-
three and 18 of the patients were diagnosed with ulcerative colitis (UC) and Crohn's disease
(CD), respectively. The control group comprised six patients with colon carcinomas and 13
healthy subjects. To identify proteins associated with IBD, the samples were analyzed using
the SELDI ProteinChip system. All samples were applied to CM10 ProteinChip arrays (weak
cationic exchange capacity), and differences in the proteomes were analyzed using Ciphergen
ProteinChip Software 3.0.2. The target protein was detected and characterized using an
immunoassay. Statistical differences were determined using the Mann-Whitney's U test. p-
values less than 0.05 were considered to be statistically significant. Results: In a preliminary
analysis using the SELDI ProteinChip system, significant peak-intensity differences between
11 of the UC patients and seven healthy controls were found for 27 serum proteins. The
particularly dramatic differences were detected for proteins between 3300 and 3500 mass/
charge ratio (m/z). These proteins were identified as alpha-defensins (HNP1-3) and its
presence in the sera of the patients were confirmed with an immunodepletion assay. ELISA
assays demonstrated that the concentration of alpha-defensins in plasma were significantly
higher in UC patients compared with CD patients and the control group. Conclusions:
Serum and plasma profiling with the SELDI ProteinChip system is useful for the identification
of new biomarkers and therapeutic targets. In addition, alpha-defensins are potential dia-
gnostic markers for UC.
M1109
Severity of Crohn's Disease Recurrence After Ileo-Colon Resection: Correlation
Between Endoscopic Score and Sonographic Findings
Emma Calabrese, Carmelina Petruzziello, Sara Onali, Marta Cossignani, Giuseppe Sica,
Francesco Pallone, Livia Biancone
Background. Ileocolonoscopy (IC) is the gold standard for assessing post-operative recurrence
of Crohn's Disease (CD). Small intestine contrast ultrasonography (SICUS) is a non-invasive
technique able to visualize lesions of the small bowel wall in CD. SICUS is also able to
visualize extraluminal lesions, while colonoscopy the inner bowel surface. Whether informa-
tion provided by SICUS and IC are comparable in terms of assessment of CD post-operative
recurrence is unknown. Aims. To investigate the usefulness of SICUS for assessing CD
postoperative recurrence after ileo-colonic resection, when using IC as a gold standard.
Specific aim was to assess possible correlation between the severity of CD recurrence assessed
by the bowel wall thickness (mm) detected by SICUS and the endoscopic Rutgeert's score.
Methods. 48 pts.(26 M, median age 42, range 15-74 yrs) with ileo-colonic resection (time
from surgery: median 12 mths, range 6-156), requiring endoscopic assessment were enrolled.
All 48 pts. underwent both IC and SICUS within 6 mths: 6 pts. repeated the 2 procedure.
Therefore, results from 54 procedures were compared. IC was performed by the same
endoscopist, with the degree of recurrence assessed by the Rutgeerts' score (0-4). SICUS
was performed after PEG ingestion (375 ml) by the same sonologist, considering findings
compatible with recurrence: increased bowel wall thickness (>3 mm), small bowel dilation
(lumen diameter>2.5 cm), bowel stricture (lumen diameter<1 cm). The correlation between
the severity of recurrence assessed by the 2 techniques was searched by using the peri-
anastomotic bowel wall thickness (mm) detected by SICUS and the endoscopic Rutgeert's
score (0-4). The sonologist was unaware of the endoscopic findings. The correlation was
assessed by the coefficient of correlation, while the c2 test was used for assessing concordance
in terms of detection of recurrence by using the two techniques. Results. Endoscopic recur-
rence was detected in 49 out of 54 (91%) procedures. Sonographic findings compatible
with recurrence were detected in 50 out of 54 (92.5%). When assessing the correlation
between the severity of recurrence by using the two techniques, the peri-anastomotic bowel
wall thickness (mm) as assessed by SICUS was significantly correlated with the endoscopic
Rutgeerts' score of recurrence (p=0.002; r=0.417). Conclusions. Although SICUS and IC
detect different views of the bowel, a significant correlation is observed between these 2
techniques in terms of assessment of presence and severity of recurrence. SICUS may be
used as an alternative non-invasive technique for assessing CD recurrence in pts. with ileo-
colonic resection.
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M1110
Expression of Grail, An E3 Ubiquitin Ligase for Induction of T Cell Anergy, in
Cd4+ T Cells of Patients with Ulcerative Colitis
Satoshi Egawa, Hideki Iijima, Shinichiro Shinzaki, Sachiko Nakajima, Jumpei Kondou,
Shuji Ishii, Toshiyuki Yoshio, Takanobu Irie, Yoshimi Kakiuchi, Tsutomu Nishida,
Masakazu Yasumaru, Masahiko Tsujii, Shingo Tsuji, Norio Hayashi
Background and Aims Insufficient tolerance against luminal antigens may be an important
factor that causes inflammatory bowel diseases including ulcerative colitis (UC). T cell anergy
is one of the mechanisms regulating immune tolerance. On the other hand, gene related to
anergy induced in lymphocyte (GRAIL) is an E3 ubiquitin ligase that downregulates down-
stream signals of T cell receptor and is required when T cells become anergic. The aim of
this study was to investigate the level of GRAIL expression in T cells of healthy subjects
and UC patients. Patients and Methods Peripheral mononuclear cells were obtained from
17 UC patients (active UC: 12, UC in remission: 5) and 10 healthy volunteers (HV) by
centrifugal leukocytapheresis or sampling of peripheral blood. CD4+ T cells were isolated
by magnetic cell sorter and expression of GRAIL mRNA in these cells was measured by
real-time quantitative RT-PCR. The level of GRAIL mRNA expression was compared between
in active UC patients, UC patients in remission and HV. The expression of GRAIL was
also followed in 5 active UC patients who were treated by corticosteroid and centrifugal
leukocytapheresis. Results Anergic CD4+ T cells obtained by anti-CD3 mAb stimulation
alone In Vitro revealed higher GRAIL expression when compared with activated T cells
stimulated with anti-CD3 and anti-CD28 mAbs. The GRAIL expression in CD4+ T cells of
UC patients in remission (average 1.0 AU (arbitrary unit, GRAIL/beta-actin)) was significantly
higher than that of active UC patients (average 0.28 AU, p<0.05) or that of HV (average
0.23, p<0.05). GRAIL expression was higher in CD4+ T cells than CD4 negative cells in
peripheral blood and there was no significant difference in GRAIL expression between the
regulatory CD4+CD25+ T cell subset and CD4+CD25- T cells. In active UC patients, the
GRAIL expression was not correlated with the clinical activity index. However, the GRAIL
expression increased after the leukocytapheresis in active UC patients. Conclusion Upregul-
ation of GRAIL expression which induces anergy in CD4+ T cells seems to be important
for induction of remission in UC patients. These results indicate that GRAIL is a potential
therapeutic target of inflammatory bowel disease.
M1111
Novel Endoscopic Activity Index Is Useful to Decide Treatment Options of
Active Ulcerative Colitis
Makoto Naganuma, Hitoshi Ichikawa, Tadakazu Hisamatsu, Susumu Okamoto, Atsushi
Sakuraba, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi
Aims: Intravenous corticosteroid therapy is fundamental treatment for moderate to severe
ulcerative colitis (UC). In the past decade invravenous cyclosporine-A (CsA) has been
reported to be effective for severe steroid-refractory UC. Clinical symptom was most important
to evaluate the severity of colitis while colonoscopy was also useful tool to assess the extend
and the severity of disease to decide treatment for UC. Recently we draw up Endoscopic
Activity Index (EAI) to assess the severity of UC and to decide treatment options, such as
intravenous corticosteroid or CsA. Correlation among EAI, other endoscopic index and
clinical score was assessed in present study. Methods: Clinical symptoms and endoscopic
finding were evaluated in 149 moderate to severe UC patients who were treated with
corticosteroids (n=42), apheresis therapy (n=45) and CsA (n=62). EAI was scored as following
six items; size of ulcers (0 none, 1 erosion/small ulcers, 2 intermediate, 3 wide-ranged
mucosal defect), depth of ulcers (0 none, 1 shallow, 2 intermediate, 3 deep), redness (0
none, 1 mild, 2 severe), bleeding (0 none, 1 contact bleeding, 2 spontaneous, 3 massive),
edema (0 none, 1 mild, 2 moderate, 3 severe) mucus exudates (0 none, 1 mild, 2 marked).
Matts' grade (1-4) and endoscopic index by Rachmilewitz (0-12) was also scored. We
compared EAI with other endoscopic indexes and clinical activity index (CAI)(0-21). Results:
1) EAI was closely correlated with CAI (r=0.83, p<0.001), Matts' grade (r=0.82, p<0.001)
and Rachmilewitz's endoscopic index (r=0.87, p<0.001). 2) EAI was significantly decreased
in responders although Matts' grade was not changed in some of responders who are treated
with intravenous cyclosporine-A (12/42, 28.6%) and steroid (9/23, 39.1%). 3) EAI scores
in patients whose Rachmilewitz endoscpoic index was full (12) ranged from 11pt to 16 pt.
Patients with higher EAI (14-16) tended to be refractory to corticosteroid therapy (responder:
12%) and apheresis therapy (responder: 25%), compared to cyclosporine-A (47%). On the
other hand, steroid therapies were effective for 58 % of patients with 11-13 pt of EAI.
Apheresis therapy was also responded to 6 (50%) of 12 patients whose EAI was 11-13. 4)
Wide-ranged mucosal defect was refractory factors in patients with corticosteroid/apheresis
therapy while endoscopic findings to predict for responders were not observed in patients
who were treated with cyclosporine-A. Conclusions: EAI is equivalent to others endoscopic
indexes and more useful for severe UC patients to make decision of treatments.
M1112
Infliximab Treatment Decreases Serum Osteoprotegerin Concentration in
Patients with Crohn's Disease
Pál Miheller, Györgyi Muzes, Károly Rácz, Anna Blázovits, Péter Lakatos, László
Herszényi, Zsolt Tulassay
Background. Crohn's disease (CD) is frequently complicated with low bone mineral density
(BMD) and altered bone metabolism. Recent studies indicate increased serum osteoprotegerin
(OPG) level in the affected patients. In Vitro, OPG was secreted from the inflamed macro-
phages and dendrtitc cells. Infliximab (IFX), the chimeric monoclonal antibody against
TNFalpha influences BMD favourably in CD but its effect has not yet been clarified. Aim.
To assess the possible molecular pathways of IFX on bone metabolism in patients with CD.
Methods. Twenty nine patients with CD treated with three infusions of 5 mg/kg IFX at
baseline (day 1), week 2 (day 14) and week 6 (day 42) were included in the study. Serum
samples were collected at the same time for measurements of biochemical markers of bone
turnover (osteocalcin, OC, and beta-crosslaps, bCL), and of their orchestrating cytokine
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elements osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappa-B
ligand (sRANKL). OC, bCL, OPG and sRANKL were determined by enzyme-linked immuno-
assays. Results. Serum levels of OC and sRANKL increased, ie. OC concentration was
27.66±14.98 ng/ml vs. 34.77±20.05 ng/ml (p<0.005) at baseline and day 42, respectively
and sRANKL elevated from 0.0105±0.026 ng/ml up to 3.63±1.49 ng/ml (NS) at the end of
the study. Serum concentrations of bCL and OPG decreased, ie. bCL level was 0.633±0.563
ng/ml vs. 0.539±0.24 ng/ml (NS) at baseline and day 42, respectively while OPG decreased
from 3.633±1.499 ng/ml to 3.342±1.61 ng/ml (p<0.05) on the same days. At the end of
the study a positive correlation (0.572, p<0.05) was detected between bCL and OPG.
Conclusions. In CD the elevated OPG could reflect a counterregulatory response to inflammat-
ory cytokines. Furthermore, it may indicate T-cell activation. IFX therapy decreased both
serum OPG and bCL concentrations of patiens, however, levels of OC and sRANKL were
detected to be increased. Since IFX can inhibit the production of T-cell dependent cytokines,
eg. IFNgamma, wich is a known potent inhibitor of osteoblast activity and osteoclastogenesis,
our findings indicate its indirect effect on bone metabolism.
M1113
Comparison of Breath Testing with Fructose and High Fructose Corn Syrups
in Health and IBS
Suzanne M. Skoog, Adil E. Bharucha, Alan R. Zinsmeister
Background - Incomplete absorption of fructose (F) may contribute to symptoms in IBS.
However, most foods are sweetened by high fructose corn syrups (HFCS), which contain
glucose (G) and F. Because G increases F absorption, we hypothesized that fructose intoler-
ance (FI) will occur less frequently after HFCS compared to F alone. Aims - To compare
absorption and symptoms after F alone or HFCS in health and IBS. Methods - Breath H2
levels and gastrointestinal symptoms were recorded every 30 minutes for 3 hours after 40
gm of F in 330 cc of tap water [12%] or 40 gm of F as 95 gm HFCS-55 (77% dry weight)
in 600 cc water [12%], administered in randomized order, on 2 days in 20 healthy subjects
[(age 28 ± 3 years (Mean ± SEM)] and 30 patients with functional bloating or IBS (age 41
± 2 years). F and HFCS were administered in a double-blind manner. Symptoms (i.e.,
bloating, flatulence, nausea, and pain) were recorded on separate 100 mm Visual Analogue
Scales and summarized by adding values for each symptom over 3 hours. We compared
the prevalence of an abnormal breath H2 response (i.e., 20 ppm increase over baseline) after
F to HFCS in each controls and in IBS by McNemar's test. The relationship between symptoms
and breath testing was analyzed by Spearman's coefficient; Breslow-Day test assessed for
differences between health and IBS. Results - An abnormal breath H2 response occurred
more frequently after F compared to HFCS in health and IBS. Scores for several symptoms
[e.g., bloating (r = 0.35) and pain (r = 0.36)] were correlated (p ≤ 0.01) to an abnormal
breath H2 response after F but not HFCS; in the F group, this association did not differ
between health and IBS. Symptoms were not significantly different after F compared to
HFCS. Conclusions - These data suggest that FI is less prevalent with HFCS, the common
sweetener, than with F. The current practice of using F to test for FI will overestimate the
frequency of FI. Therefore, if breath testing is considered, HFCS-55 may be preferable to
F. Incomplete absorption contributes to symptoms after F. After HFCS, the relationship
between symptoms and the breath H2 response was not significant, suggesting that other
mechanisms (e.g., volume, osmolarity) contribute to symptoms. Supported by NIH DK-
68055
† p = 0.004, *p < 0.001 for fructose vs HFCS (McNemar's test)
M1114
Preoperative Plasma Citrulline Level Is a Marker of Small Bowel Potential
Function After Reestablishment of Bowel Continuity
Isabelle Nion-larmurier, Philippe Seksik, Virginie Sebbagh, Diana Cardenas, Pascal Pernet,
Jacques Cosnes
Citrulline is an amino acid exclusively produced by the enterocyte. Plasma citrulline level
reflects the functional enterocyte mass and is correlated with the remnant small bowel (SB)
length after intestinal resection. A value > 19 µmol is a marker of nutritional autonomy.
However plasma citrulline variations after intestinal disruption or resection had not been
described. The aim of this study was to assess the evolution of plasma citrulline according
to the exclusion status of a digestive segment. Methods: 23 patients with a SB resection and
transient jejuno- or ileo-stomy (median SB length in circuit 170 cm, range 15-320) were
studied. The excluded segment comprised a SB segment (median SB length 60 cm, range
5-160) and the colon in 11 patients and only one part of the colon in 12 others. Controls
were 17 patients with a definitive short bowel (median SB length 95 cm, range 26 - 200;
5 with stoma). Basal plasma citrulline was measured both before and after reestablishment
of bowel continuity (RBC) in 16 patients and only before in 7. Intestinal autonomy was
defined as achievement of nutritional and fluid and electrolyte balance without any need
for parenteral nutrition and/or electrolyte replacement during at least 6 consecutive weeks.
Results: Plasma citrulline (mean +/- SD) before RBC was 20.9 +/- 8.6 µmol (n = 23). Its
value was correlated with the SB length in circuit (r= 0.76 ; p = 0.005) as well as the total
SB length (r =0.83 ; p=0.002). Plasma citrulline was a poor indicator of intestinal autonomy
before RBC: 5 patients out of 12 with a value > 19 µmol achieved intestinal autonomy
before RBC vs. 2 out of 11 with a value < 20 µmol (NS). However plasma citrulline before
RBC was predictive of intestinal autonomy 3 months after RBC : 12 patients out of 12 with
a value > 19 µmol achieved intestinal autonomy after RBC vs. 5 out of 11 with a value <
20 µmol (p = 0.01). Among the 16 patients having had 2 dosages, mean plasma citrulline
did not change significantly : from 20.4 +/- 9.4 before to 21.8 +/- 11.6 µmol after RBC.
Plasma citrulline values before and after RBC were correlated (r= 0.60; p=0.01). As expected,
plasma citrulline after RBC was an indicator of intestinal autonomy at 3 months: 8 out of
8 patients with a value > 19 µmol were autonomous vs. 2 out of 8 with a value < 20 µmol
(p = 0.001). The same result was observed in controls: 6 patients out of 6 with a value >
19 µmol were autonomous, vs. 4 out of 11 with a value < 20 µmol (p=0.03). Conclusion:
Reestablishment of a segment of small bowel and/ or colon does not significantly influence
plasma citrulline. A value >19 µmol before RBC is predictive of the intestinal autonomy
after RBC.
M1115
Plasma Citrulline: A Biomarker of Intestinal Function During Adaptation in a
Model of short Bowel Syndrome
Nathan S. Teuscher, Rebecca C. Macchione, Kerri L. Trendler, Lidia L. Demchyshyn,
David S. Wells
BACKGROUND: Following small bowel resection, the remnant intestine undergoes adapta-
tion, a process resulting in increased mucosal mass and absorptive capacity. The adaptive
response is characterized by increased enterocyte proliferation and decreased apoptosis,
increased villus height and crypt depth, enhanced nutrient absorption and decreased motility.
Recent findings have suggested that plasma citrulline, an endogenous, non-peptide amino
acid produced exclusively by the small intestine, can serve as a non-invasive biomarker for
intestinal function. OBJECTIVE: The following study assessed plasma citrulline levels follow-
ing small bowel resection in rats using a population pharmacodynamic model. METHODS
& RESULTS: Sprague Dawley rats were randomized into resected or sham-resected control
groups. Resected animals underwent either a 50% or 80% proximal or distal resection.
Following ligation of the mesenteric vessels, the resected tissue was removed and bowel
continuity restored using an end-to-end jejunoileal anastamosis. At least 10 cm of ileum
was retained to ensure survival without supplemental intravenous nutrition. The sham
resections were performed in identical fashion except a single partial transection was made
in the ileum. Following surgery, animals received water and food ad libitum throughout
the remainder of the study. Blood samples for plasma citrulline analysis were obtained 24-
48 hours prior to surgery (Day 1), on Days 2 through 29 and just prior to euthanasia on
Day 30. All small bowel resection groups demonstrated a significant decrease in plasma
citrulline levels (range: 25 - 34 umol/L) immediately following surgery. Thereafter, an
exponential increase in plasma citrulline concentrations to a new steady-state level was
observed. The new steady-state level (range: 57 - 65 umol/L) was below pre-surgery levels
(range: 89 - 91 umol/L) for all resection groups. All resection groups had similar minimum
and maximum citrulline concentrations, however the change in citrulline level rate constant
was two-fold greater in the 50% resection groups (0.24 day-1) than the 80% resection
groups (0.12 day 1). The growth rate appeared to be proportional to the tissue remaining
following the resection. In addition, plasma citrulline reached maximal levels within 15-25
days following resection, consistent with the adaptive response of the remnant rat intestine.
CONCLUSIONS: The results of this study suggest that the adaptive process of the intestine
in rat can be predicted using plasma citrulline and therefore, that this amino acid might be
of clinical utility as a biomarker for intestinal function.
M1116
Endoscopic Appearance of Ileal Galt in HIV Infection Is Independent of
Mucosal Cd4 Cell Levels and Measures of Viral Burden
Michael D. Yao, Emily Ciccone, Sarah Read, Cheryl Chairez, Irini Sereti, Joseph Kovacs,
Peter J. Mannon
BACKGROUND: Gut-associated lymphoid tissue (GALT) has been shown to be a significant
reservoir of HIV infection. GALT CD4+ T-cells are preferentially depleted compared to
peripheral blood (PB) in both acute and chronic infection. A recent report (J Exp Med 2004
6:749) suggests HIV+ patients lack any endoscopic appearance of terminal ileal (TI) GALT
but other data suggest GALT CD4 cells may be reconstituted with prolonged antiretroviral
therapy (ART). AIM: Document the endoscopic appearance of TI GALT in HIV+ patients
and correlate with the status of HIV infection and the severity of CD4 cell depletion.
METHODS: Three groups of patients were studied: 8 HIV-, 6 HIV+/ART-, 14 HIV+/ART+.
Ileal photographs and biopsies were obtained during colonoscopy. Images were scored for
visible TI GALT (1=no nodules, 2=1-5 nodules, 3=>5 nodules). Biopsies were processed for
mononuclear cell flow cytometry. Tests of significance were assessed by the Student t, Mann-
Whitney, or Spearman's rank correlation where appropriate. RESULTS: Mean age was
similar for all groups, 43-46 years. Mean PB CD4 and viral load (VL) for HIV+/ART- vs
HIV+/ART+ were 330 vs 672 cells/µL and 76,635 vs <50 copies/mL, respectively. Mean
percentage of TI CD4 cells was significantly lower in HIV+/ART- (9.5%) than HIV+/ART+
(21.8%, p<0.05) and HIV- (39.6%, p<0.003) groups though the absolute numbers of TI
CD4 cells/gm tissue were not significantly different. The rates of endoscopically visible GALT
were the same among the groups. There were no differences among mean TI GALT scores:
HIV+/ART- (1.7), HIV+/ART+ (1.6), HIV- (1.5). Furthermore no significant correlation was
seen between individual TI scores and VL, PB CD4 count, ileal CD4% or ileal CD4/CD8
ratio in the combined HIV+ groups. When HIV+ patients were stratified by the presence
or absence of visible TI GALT, there were no differences in ileal CD4%, absolute CD3 or
CD4 cell number/gm tissue, ileal CD4/CD8 ratio or VL between groups. CONCLUSIONS:
These data document the presence of endoscopically detectable GALT in HIV+ patients.
The endoscopic appearance of GALT in HIV+ patients is independent of peripheral blood
viral load, PB and ileal CD4 cell counts, total ileal CD3 counts and use of ART. Since
endoscopically visible GALT reflects follicular (inductive) and not lamina propria (effector)
T cell areas, the follicular T areas may be less affected by HIV infection consistent with
reported lower concentrations of CCR5+ CD4 cells normally found in these areas.
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M1117
Small Bowel Biopsies in Patients with Collagenous Colitis
Jianlin Xie, Sita S. Chokhavatia, Gabriel Levi, Noam Harpaz
Background: The characteristic clinical feature of collagenous colitis is chronic watery
diarrhea. Early case reports have linked celiac disease with collagenous colitis. Collagenous
colitis has no known malignant potential. Celiac disease is associated with an increased risk
of malignancy if not treated and treatment requires a life-long adherence to a gluten-free
diet. Prior retrospective pathologic survey studies of small intestinal biopsies in collagenous
colitis showed conflicting results. The prevalence of non-celiac disease pathologic findings
of the upper gastrointestinal (GI) tract is unknown. Aims: Determine the prevalence of upper
GI findings in patients with collagenous colitis undergoing upper endoscopy. Methods:
Patients were identified from a pathology registry of collagenous colitis from 2003 to 2006.
Pathology reports were reviewed for previous small bowel biopsies. A pathologic finding of
collagenous colitis prompted search for other pathology slides on that patient to determine
if other upper GI histopathologies were present. Results: 153 patients with collagenous
colitis were identified. The mean age was 67 yr (range 19-101). Of 153 patients, 118 (77%)
were female and 35 (23%) were male, giving a gender ratio of 3.37:1. A total of 29 patients
(19%) underwent upper endoscopy. Of these 29 patients, esophageal, gastric and small
bowel (duodenal or jejunal) biopsies were performed in 3, 12 and 25 patients, respectively.
Mild esophagitis was diagnosed in 2 patients, mild chronic gastritis in 8 patients and
Helicobacter pylori was negative in all 7 patients who had the test. Collagenous gastritis was
diagnosed in 2 patients (17%). Mild duodenitis was found in 5 patients and celiac disease
in 3 patients (12%). Conclusions: 19% of patients with collagenous colitis underwent upper
endoscopy. Collagenous gastritis and celiac disease were found to be 17% and 12%, compared
to a rare disorder and 0.4% in previous studies, respectively. These findings support a role
for upper GI endoscopy in patients with collagenous colitis.
M1118
Irritable Bowel Patients with Diarrheal Predominance Have a High Frequency
of Bacterial Overgrowth and Disaccharidase Deficiencies
Charles W. Randall, Anson Liu, Carlo M. Taboada, Rosario Najera, Gary Gossen, Russell
Havranek, Franz Zurita, David Stump, Janet Ford
INTRODUCTION Recent studies have implicated bacterial overgrowth (BOG) and disacchari-
dase deficiencies (DD) as causes for functional diarrhea and gas/bloat syndromes. In this
study we analyzed the prevalence of BOG and DD in patients with diarrheal predominant
IBS (IBS-d). METHODS 100 patients with documented IBS-d were prospectively followed
to determine frequency of a positive breath test. 77 patients completed testing for BOG and
DD. Patients were divided into those with gas/bloating (IBS-d [+]) and those without gas/
bloating (IBS-d [-]). All patients received standard hydrogen breath testing. The number of
positive tests was also recorded for each patient. RESULTS 65 patients had IBS-d [+]. In
this group, 40 patients had 1 positive test (61.5%), 20 had 2 positive tests (30.8%); 1 was
positive for all 3 (1.5%); and 4 tested negative for all 3 tests (6.2%). 12 patients had IBS-
d [-]. 2 were positive for 1 test (16.7%); 1 tested positive for 2 tests (8.3%); and 9 tested
negative for all 3 tests (75%). CONCLUSIONS 1.Patients with IBS-d whom have gas/bloating
among their symptoms, have a high prevalence of BOG and/or DD (93.8%). 2.This data
suggests breath testing for BOG and DD is relevant in the evaluation of IBS-d patients with
gas/bloating (IBS-d [+]). 3.Though the numbers are small, the trend is for IBS-d patients
without gas/bloating to have a negative test for BOG and DD (75%).
M1119
Contamination of Vegetables with Enteric Pathogens in Restaurants in
Guadalajara, Mexico and Houston, Texas
Hoonmo Koo, Zhi-dong Jiang, Eric Brown, Coralith Garcia, Herbert L. Dupont
Background: Food is an important cause of traveler's diarrhea and food-borne gastroenteritis.
Objective: Compare fecal contamination of vegetables with coliform pathogens in restaurants
from Guadalajara, Mexico and Houston, Texas and to determine the microbiologic effects
of cooking and serving vegetables in buffet vs. non-buffet fashion. Methods: Vegetable
samples were collected from different restaurants in Guadalajara, Mexico and in Houston,
Texas. The food samples were cultured for enteropathogens. 5 E.coli-like colonies from
MacConkey agar plates of the vegetable samples were tested for heat stable (ST) and labile
(LT) toxin by PCR for enterotoxigenic coliforms and by the HEp-2 cell adherence assay for
enteroaggregative coliforms. Identification of coliforms by biochemical testing is in progress.
Results: (Insert table here). 64 vegetables from Guadalajara and 67 vegetables from Houston
restaurants were tested. Vegetables were analyzed for contamination with coliforms by
location, cooked vs uncooked status, buffet vs nonbuffet, temperature food was served -
room T uncooked, room T cooked, heated cooked (33.9 to 100 deg C), and contamination
with enterotoxigenic and enteroaggregative coliforms based on location. 52/64 (81%)Guada-
lajara vegetables were contaminated with coliforms vs 21/67 (31%)Houston vegetables
(P<0.001). Enterotoxigenic coliforms were in 24/64 (38%) Guadalajara vegetables vs. 7/67
(10%) Houston vegetables (P<0.001). Enteroaggregative coliforms were in 45/64 (70%)
Guadalajara vegetables vs. 16/67 (23%) Houston vegetables (P<0.001). Conclusions: Contam-
ination of both cooked and uncooked vegetables with coliforms was common in restaurants
in Guadalajara, more so than in Houston restaurants. The temperature at which the vegetables
were served was more important than whether the vegetables were cooked or uncooked.
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(1) P values for percentages calculated by Chi square and Fisher exact tests (2) P values for
means calculated by ANOVA (3) P values for medians calculated by Mann-Whitney test
M1120
Decreasing Mortality from Shigella Colitis in Asia Without Shigella-Specific
Interventions
Pradip K. Bardhan, Abu S. Faruque, Aliya Naheed, David A. Sack
Background: Shigellosis remains an important cause of infectious colitis, often with fatal
outcome, particularly in young children. A recent review based on data collected between
1974 and 1989 estimated about 1.1 million deaths annually from shigellosis resulting from
about 163.2 million episodes in the developing countries1, about 90% of them occurring
in Asia. In the recent years, this disease burden might have changed due to several factors,
including emergence of multi-drug resistant Shigella strains, increasing rates of HIV-AIDS
in some countries, and improved nutrition and health care delivery in many countries.
Widespread use of measles vaccine and vitamin A supplementation might also reduce the
severity of intestinal infections. Aim: To update the estimate of burden of Shigella infections
in Asia. Methods: Epidemiological and clinical studies from Asia since 1990 and ongoing
diarrhea surveillance programs were reviewed to provide estimates of infections and fatalities
from shigellosis. The number of cases of Shigella infection and the associated mortality
occurring annually by age and clinical category (as a proxy of disease severity) were calcu-
lated1. A sensitivity analysis was performed to estimate the high and low range of morbid
and fatal cases in each category. Results: Data since 1990 suggests that the annual number
of Shigella infections in Asia is approximately 102 million episodes. Of these about 85,400
are fatal. This represents a modest reduction in infection rate, but about a 90% reduction
in fatalities. This large reduction in fatalities seems primarily due to reduced case fatality
rates (Table). Within the last two decades, prevalence of childhood malnutrition decreased
by >30%, and measles vaccination and vitamin A coverage rose from <5% to 78% and <3%
to 41% respectively. Conclusion: Shigella infections are still very common in Asia. However,
there has been a large reduction in Shigella deaths during a period when there were no
Shigella specific interventions. This seems most likely due to children being healthier at the
time of infection. We speculate that other non-specific interventions e.g. measles vaccination,
vitamin A distribution, and improved nutrition may have lead to this reduced burden from
shigellosis. 1Kotloff et al. Bull WHO 1999; 77(8):651-666.
Estimated Annual Mortality from Shigella colitis in Asia
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M1121
Diosmectite in the Treatment of Acute Diarrhea in Adults: Results of a
Placebo Controlled Double Blind Study
Faouzi Khediri, Hélène Mathiex-fortunet, Philippe Garnier, Antoine Cortot
INTRODUCTION: Diosmectite (DSM) is purified clay made of double layers of aluminum
and magnesium silicate, largely prescribed for the symptomatic treatment of diarrhea in
children and adults. PATIENTS AND METHODS: The aim of this study was to asses the
efficacy of DSM on the time to stop an acute diarrhoea episode (i.e. 3 watery stools/d since
48h or less) in adults from 18 to 65 years. It was a multicenter, randomized, double blind,
placebo controlled, parallel groups study. The criteria of non inclusion were: seriousness
signs (fever >39° C, blood or pus in the stools, severe dehydration), “traveler's diarrhoea”,
drug induced diarrhoea, antidiarrheal agent intake. The patients received 6g x 3/d of DSM
during 4 days at a minimum, then longer if necessary until complete recovery. The primary
endpoint was the time (in hours=h) between the 1st intake of DSM and the first formed
stool followed by a non watery stool. Secondary endpoints were: time from the 1st intake
of DSM and the last liquid stool, and per period of 12h: % of patients achieving the primary
endpoint, stool frequency & consistency, associated symptoms such as nausea, vomiting
and anal irritation. The main statistical analysis was carried out in ITT, the analysis in PP
being supportive. RESULTS: 166 patients (140 in PP) received the DSM and 163 (142 in
PP) a placebo. The 2 groups were comparable in particular for the length of the diarrhoea
episode and the demographics. The time to stop diarrhea episode was reduced by 15.2h
(median) in DSM group: 53.8 (3.7-167.3) h, versus 69.0 (2.2-165.2) h in the placebo group,
(p= 0.029). In PP the reduction of the time to stop diarrhea episode was 13.7h not reaching
the statistical significance: DSM group: 54.5 h (3.7-167.3), placebo: 68.2 h (2.2-165.0) (p =
0.067). The cumulated % of patients achieving the primary endpoint was higher in DSM
group than in placebo group in the period 24 to 36 h : 28.5 % vs 19.2 % (p = 0.055), 36-
48h period: 43.7 % vs 29.5 % (p=0.009) and 48-60 h period: 52.5 % vs 41.0 % (p=0.041).
Other secondary criteria were all improved without significant difference with the placebo.
DSM was very well tolerated. CONCLUSION: In a randomized double blind placebo
controlled trial in adults, 6g X 3/d of diosmectite reduced the time to recovery of a diarrhoea
episode in a clinically relevant manner and was well tolerated.
M1122
Alterations of PLC-γ1-Pkc Isoform Pathway and the I-Kappa B Kinase (I-kK)—
NFkB Pathway Predict the Extent of Mucosal Barrier Protein Isotype
Instability in Man: A Novel Barrier Dependent Mechanism for Oxidation and
IBD Pathophysiology
Ali C. Banan, Maliha Shaikh, Lijuan Zhang, Jeremy Z. Fields, Ece Mutlu, Ashkan Farhadi,
Christopher B. Forsyth, Ali Keshavarzian
NFkB activation & barrier instability appear to be early hall-marks of IBD. Despite many
cell studies, the mechanism underlying gut barrier instability in man and its contribution
to tissue oxidation & injury remain unclear. In Vitro studies suggest that the mechanism
may depend on PLC, PKC, NF-kB signaling, oxidative stress, & instability of barrier proteins.
But, these key events are only poorly characterized in human IBD. Aims: We sought to
determined whether in the inflamed IBD mucosa there are any: (A) changes in activity of
PLC-γ1 & PKC isoforms (-ζ, -β1); (B) oxidation & degradation of key barrier or tight-
junctional proteins (65 kD Occludin, 22-25 kD Claudins 1-5); (C) dysregulation of I-kK /
NF-kB pathway signaling (I-kK isotypes α/β, IkB, NF-kB subunits, iNOS) & tissue oxidative
stress. (D) These variables are comparable with markers of gut inflammation & injury.
Methods: Mucosal biopsies from IBD patients (ulcerative colitis, Crohn's Disease, specific
colitis) and healthy/normal controls were used to measure: PKC-ζ/ PKC-β1 (tissue levels/
activity/ distribution), PLC-γ1 (expression/ distribution/ tyrosine kinase activity); occludin
& claudins oxidation & instability; I-kK pathway levels/ phosphorylation/ activation; markers
of mucosal oxidation & injury (protein carbonylation / nitration, NO levels). Results: Occlu-
din & Claudins were largely carbonylated, nitrated & destabilized in inflamed IBD mucosa,
but not so in normal-appearing mucosa. Also, PLC-γ1 distribution/ expression & tyrosine
kinase activity was markedly increased while PKC-β1 (78 kDa) and PKC-ζ (72 kDa) were
down-regulated & deactivated (both reduced in mucosal membrane/cytoskeletal fractions).
Inflamed mucosa also showed marked increases in phosphorylation of I-kK-α/β isotypes &
of IkBα; degradation of IkBα; hyperactivation of I-kK-β & of NF-kB (p50/65 subunits).
Other mucosal oxidation markers (e.g., iNOS, NO metabolites, protein nitration) were also
increased. These changes were not seen in normal-appearing, non-inflamed, IBD mucosa.
Furthermore, changes in PLC-γ1—PKC isoforms and I-kK—NFkB pathways & barrier
proteins were primarily seen within the epithelial layer; these variables linked positively
with IBD disease severity. Conclusions: Our findings clearly suggest for the first time that
pivotal barrier and PLC-γ1—PKC isoforms & I-kK dependent mechanisms underlie human
IBD pathophysiology. This novel mechanism is one in which dysregulation of a PLC-γ1—
PKC/ I-kK driven pathway is required for mucosal barrier protein oxidation and instability.
These crucial signaling & barrier altering events consequently could lead to initiation and/
or perpetuation of IBD flare in man.
M1123
The Fungal Defensin Plectasin Protects the Intestinal Epithelial Barrier
Jan-michel Otte, Anna-elisabeth Zdebik, Hans-henrik Kristensen, Stephan Brand, Frank
Schmitz, Per H. Mygind, Wolfgang E. Schmidt, Lars Steinstraesser
Background & Aims: Plectasin is a novel antimicrobial peptide derived from the saprophytic
ascomycete Pseudoplectania nigrella. It has been shown to be highly efficient and well
tolerated in experimental infections including experimental peritonitis. Its effects on intestinal
epithelial cells, luminal barrier function and additional putative protective properties have
not been studied yet. Therefore, the current study was designed to characterize effects of
plectasin on intestinal epithelial cell (IEC) viability, apoptosis, proliferation, migration and
induction of mucin expression. Methods: Caco-2 and HT-29 cells were stimulated for up
to 72 h with 0.1 - 10 µg/ml plectasin. Viability was monitored by MTT assays, apoptosis
by detection of fragmented DNA, proliferation quantified by BrdU incorporation, migration
characterized in standard wounding assays and expression of mucins 1, 2, 3 and 5AC
detected by real-time PCR. Receptors and pathways involved in plectasin induced signaling
were characterized by use of specific inhibitors. Results: In the concentrations used, plectasin
was well tolerated by intestinal epithelial cells and did not induce apoptosis. Whereas
proliferation was not significantly altered, plectasin indirectly, by release of mitogens from
subepithelial myofibroblasts, significantly stimulated migration of IEC, with TGF-β identified
as a key mediator. Furthermore, plectasin significantly increased expression of mucins 2
and 3 by IEC. Pre-incubation with plectasin significantly decreased TRAIL induced apoptosis
in IEC. Receptors and pathways involved in plectasin induced signaling include G-protein
coupled receptors as well as activation of the MAP kinase p38. Conclusion: Plectasin is well
tolerated by intestinal epithelial cells. In addition to its antimicrobial properties it exerts
further protective effects on the intestinal barrier function by promoting anti-apoptotic
mechanisms and stimulation of wound healing. These features make this fungus derived
host defense peptide a promising therapeutic candidate for gastrointestinal diseases.
M1124
Pelvic Radiotherapy Causes Instability in Intestinal Microbiota
Chaysavanh Manichanh, Encarna Varela, Cristina Martinez, Maria Antolin, Marta Llopis,
Joel Dore, Francisco Guarner, Juan-r. Malagelada
Background: Pelvic radiotherapy is an established treatment for intra-abdominal malignanc-
ies but commonly associated with gastrointestinal toxicity, especially severe diarrhea that
may force interruption of treatment. The pathophysiological mechanisms causing diarrhea
are not completely known, and are likely to be related with an imbalance in the intestinal
microbial ecosystem. Aim: To investigate the implication of the microbiota disturbance on
the gastrointestinal toxicity in patients submitted to radiotheraphy. Material and methods:
Ten patients ongoing 5 weeks of radiotherapy for different abdominal tumors were studied.
Four fecal samples were collected on each patient: before starting the treatment (w0), between
the second and third week of radiotherapy (w3) at the end of the treatment (w5) and two
weeks later (w7). Five healthy volunteers served as controls and collected samples at the
same time points. Total DNA was isolated from the fecal samples and used as a template
to amplify by PCR the V6 to V8 variable regions of fecal bacterial 16S rRNA gene. The
PCR amplicons were then separated by DGGE. The gel profiles were compared using the
BioNumerics software package and similarity indices were calculated from densitometric
curves using the Pearson product moment correlation coefficient. Results: The composition
of the microbiota in the patients undergoing radiotherapy varied notably over time. Thus,
the percentage of similarity versus w0 were already decreased at w3: 52±14% (mean±SD,
p<0.05), remained reduced at the rest of the treatment and were not recovered 2 weeks
after the end of the radiotherapy. In contrast, the healthy subjects group showed a more
preserved profile at w3 (similarity 70±15%). Furthermore, the subgroup of patients that
developed diarrhea (6/10) showed a more severe disturbance of the initial profile during
the entire period of study (Table, results expressed as mean±SD, * p<0.05 vs no diarrhea).
Conclusions: Pelvic radiotherapy has a deep impact on the microbial gut ecosystem that
may be involved in the pathogenesis of the diarrhea and associated symptoms.
M1125
Novel Therapies Against Inflammation Using Botanical Dietary Supplements -
Scuttelaria Baicalensis Is a Potent Suppressor of NF-kB Pathway: Anti-
Inflammatory Potential Via Prevention of I-kb Degradation in Intestinal
Epithelium
Ali C. Banan, Philip Engen, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth,
Yueming Tang, Ali Keshavarzian
NF-kB activation is a critical factor in the pathogenesis & development of the inflammation
in a wide variety of GI disorders, including inflammatory bowel disease (IBD). To date
in spite of intensive investigation an effective & safe means of suppressing the NF-kB
proinflammatory pathways in the GI tract diseases remains poorly explored. Traditional
Complementary Alternative Medicine (CAM) systems recommend putative anti-inflammatory
herbs such as Scuttelaria Baicalensis (SB). Despite claims, whether this herb has anti-
inflammatory effects & is beneficial against intestinal inflammation, and its mechanism of
action is not established. Aims: We sought to determine if NF-kB pathway inactivation &
cellular protection can be induced by SB under oxidative stress injury. Methods: Intestinal
cells were pretreated with SB &/or NF-kB modulators (activators, inhibitors) prior to oxidant
(H2O2). In separate studies, cells were transfected with an IkB mutant to inhibit NF-kB.
We measured monolayer integrity (LIVE/DEAD assay, fluorometry), NF-kB p50/p65 subunit
activities (EMSA, ELISA), NF-kB modulator, IkB-α levels/phosphorylation (PAGE), and
structural protein integrity (laser confocal microscopy, SDS-PAGE), n=6/grp. Results: {A}
Pretreatment with SB dose-dependently reduced IkB instability, decreased NF-kB nuclear
translocation, and reduced NF-kB subunit activities while protecting barrier protein cyto-
architecture & monolayer integrity. {B} NF-kB inhibitors or IkB stabilizers (MG-132, Lactacys-
tin, etc) prevented effects induced by oxidant challenge and also led to synergy induced
protection in the presence of SB. Moreover, selective potentiation of NF-kB activity by
phosphoseryl/threonyl protein phosphatases [PAO, PV] prevented protection under oxidant
stress. {C} IkB stabilization by a dominant mutant transfection (preventing NF-kB activation)
led to protection as well. Indeed, similar to blunting effects of pharmacological agents,
mutant stabilization of IkB led to synergy induced protection & abolished alterations in NF-
kB activity. Conclusions: Our data indicate a novel anti-inflammatory affect for a traditional
botanical dietary supplement, Scuttelaria Baicalensis. (1) Scuttelaria Baicalensis appears to
protect against oxidant stress through the inactivation of a key pro-inflammatory factor
NF-kB. (2) The molecular mechanism underlying this potent anti-inflammatory affect of
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Scuttelaria Baicalensis appears to depend on the stabilization of the endogenous inhibitor
of NF-kB, namely IkB-α. Thus, this botanical dietary supplement can be useful for develop-
ment of innovative therapies for a wide variety of inflammatory GI disorders where NF-kB
is activated.
M1126
Curcumin Sensitizes Human Intestinal Microvascular Endothelial Cells
(HIMEC) to Ionizing Radiation By Targeting Mtor and Akt
Parvaneh Rafiee, Vicky M. Nelson, Yasmin Kanaa, Mary F. Otterson, David G. Binion
INTRODUCTION: The mechanisms of radiation therapy are now appreciated to include an
anti-angiogenic effect on tumors, inhibiting endothelial proliferation and survival in the
tumor microvasculature. However, low level damage from radiation can induce a paradoxical
effect, stimulating survival mechanisms in endothelial cells. Exposure of human intestinal
microvascular endothelial cells to low doses of ionizing radiation (1-5 Gy) activates the
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which is involved in cell cycle
re-entry and cell survival. A critical downstream effector of (PI3K)/Akt is mammalian target
of rapamycin (mTOR) which contributes to angiogenesis in tumors through promotion of
endothelial proliferation. The aim of this study was to investigate the radio-sensitizing effects
of curcumin, a promising natural compound with anti-inflammatory activity, on primary
cultures of HIMECs subjected to irradiation. METHODS: Serum-deprived HIMEC cultures
(passage 8 ? 12) with and without curcumin were exposed to 0?5 Gy ionizing radiation and
incubated for 1-10 days. The effect of a combination of curcumin and radiation on cell
survival was assessed by, PI3K/Akt/mTOR expression and phosphorylation, NFkB activity,
and induction of caspase-3 cleavage. Analyses were performed using RT-PCR, Western
blotting, In Vitro Kinase activity, and Tunnel assay. The immunosuppressant rapamycin,
which specifically binds and inhibits mTOR was used as a positive control to inhibit mTOR
mediated signaling in endothelial cells. RESULTS: Irradiation induced Akt and mTOR phos-
phorylation which were attenuated by both curcumin and rapamycin pretreatment. Irradi-
ation-induced mTOR phosphorylation was mediated via PI3 kinase, as LY294002 (specific
inhibitor of PI3K) pre-treatment of HIMEC resulted in inhibition of mTOR phosphorylation.
In addition, curcumin induced caspase-dependent apoptosis, an important mechanism of
cell death in irradiated HIMEC, by induction of caspase-3 cleavage, suggesting that curcumin
increased radiosensitization of HIMEC. Curcumin in combination with radiation significantly
abolished NFkB and PI3k/Akt activity and enhanced HIMEC apoptosis. CONCLUSION:
Inhibition of mTOR in HIMEC resulted in increased radiosensitivity. Curcumin treatment
of HIMECs prior to radiation inhibits NFkB and attenuated activation of the radiation-
induced pro-survival signaling through the PI3/Akt pathways and enhanced the effects
of radiation in these gut specific endothelial cells. Thus, curcumin may be a potential
radiosensitizing agent for enhanced antiangiogenic effect during radiation therapy of colorec-
tal cancers.
M1127
Volatile Organic Compounds from Feces and Their Potential for
Gastrointestinal Disease Diagnoses
Christopher Probert, C. E. Garner, Steve Smith, Ben De lacy costello, Paul White, Robert
Spencer, Norman Ratcliffe
Little is known about the volatile organic compounds (VOCs) in feces and their potential
health consequences. Patients and healthcare professionals have observed that feces often
smells abnormal during gastrointestinal disease. The aim of this work was to define the
volatiles emitted from the feces of healthy donors and of patients with gastrointestinal disease.
Our hypotheses were that i) VOCs would be shared in health, ii) VOCs would be constant
in individuals, and iii) specific changes in VOCs would occur in disease. Volatile emissions
in health were defined in a cohort and a longitudinal study. Subsequently, the pattern of
volatiles found in the cohort study were compared to that found from patients with ulcerative
colitis, , Campylobacter jejuni and Clostridium difficile. Volatiles from feces were collected by
solid phase micro-extraction and analyzed by gas chromatography / mass spectrometry. In
the cohort study (30 subjects), 297 volatiles were identified, in all samples ethanoic, butanoic,
pentanoic acids, benzaldehyde, ethanal, carbon disulfide, dimethyldisulfide, acetone, 2-
butanone, 2,3-butanedione, 6-methyl-5-hepten-2-one, indole and 4-methylphenol were
found. Forty four compounds were shared by 80% of subjects. In the longitudinal study
(10 subjects, 5 samples each), 292 volatiles were identified; there was some inter and intra
subject variations in VOC concentrations with time. When compared to healthy donors,
volatile patterns from feces of patients with ulcerative colitis (18), Clostridium difficile (22)
and Campylobacter jejuni (31), were significantly different. Application of discriminant func-
tions on the sample data gives 100% predictive accuracy and 96% predictive accuracy when
cross-classifying using the leave-one-out procedure. Repeating the analysis but omitting each
compound in turn gives an average within sample predictive accuracy of 99.9% (with a
minimum of 99.0%) and an average of 94.9% predictive accuracy (with a minimum of
90.1%) using the leave-one-out procedure. We have comprehensively described, for the
first time, the VOC profile of normal stool and show robust differences in disease. These
findings could lead the way to the development of a rapid diagnostic device based on
VOC detection.
M1128
The Colonic Contribution to Halitosis
Terry Bolin
Halitosis is common and the precise pathophysiological mechanisms remain unclear. The
usual factors invoked are oropharyngeal. Most studies conclude that volatile sulphide com-
pounds are the main culprits, these being hydrogen sulphide, methyl mercaptan and dimethyl
sulphide. All of these compounds are primarily formed in the colon by bacterial fermentation
of normal substrates in subjects whose colons contain sulphite-reducing bacteria and these
gases may be re-absorbed from the colon and expired in the breath. AIM To evaluate subjects
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presenting with halitosis and to confirm whether or not they expire volatile sulphides and
then to determine whether oral bismuth, a compound that binds to hydrogen sulphide, has
the potential to reduce volatile sulphide excretion on the breath and resolve the problem
of halitosis. METHOD Thirty subjects recruited because of halitosis had their breath sulphides
evaluated by use of the Halimeter and a Lactulose breath test with measurement of methane
and hydrogen following ingestion of 25 gm of Lactulose. As methanogenic and sulphite
reducing bacterial populations are generally mutually exclusive the production of methane
indicates that the subject does not have the sulphite reducing bacteria as the predominant
organism. Concurrent C13 urea breath tests were carried out for evidence of Helicobacter
pylori. Bismuth subcitrate 120 mg was swallowed bd. There were 14 females/16 males
ranging in age from 21 - 71 years. RESULTS Six of the thirty subjects did not have volatile
sulphides measured on the breath. The remaining twenty four had the presence of large
amounts of volatile sulphides confirmed. All failed to produce methane which by implication
suggests that these subjects have a dominant sulphide reducing bacterial population capable
of producing hydrogen sulphide gas. Twenty-one of the twenty four subjects had symptomatic
improvement with disappearance of their halitosis following the ingestion of oral Bismuth
subcitrate within two weeks. Bismuth subcitrate subsequently needed to be taken periodically.
Only two patients had Helicobacter pyloric infection. CONCLUSION It seems likely that the
colon is a common cause of halitosis via the production of volatile sulphides and this has
the potential for treatment with compounds such as Bismuth that will bind hydrogen sulphide
gas in the colon and therefore be an effective therapy for halitosis.
M1129
Can EUS with Doppler Be Used to Screen for Chronic Mesenteric Ischemia
(CMI)?
Kyung W. Noh, Surakit Pungpapong, Michael B. Wallace, Timothy A. Woodward,
Mohammad A. Al-haddad, Seth A. Gross, Telemaco Federici, Massimo Raimondo
Background: EUS has been proposed as a single test to evaluate persistent upper abdominal
pain as it can diagnose or exclude virtually all common causes. CMI has not been evaluated
by EUS. As Doppler flow in the celiac artery (CA) and superior mesenteric artery (SMA)
can be measured, we propose that EUS can be used to screen for CMI. Doppler transabdominal
ultrasound (TUS) has been validated as a non-invasive tool to screen for CMI. A peak systolic
velocity > 275 cm/s in the SMA and 200 cm/s in the CA predict >70% stenosis. Methods:
Patients undergoing evaluation for chronic abdominal pain with risk factors for CMI were
prospectively enrolled. Doppler measurements of the peak systolic velocity of the CA and
SMA were recorded. In addition, any other diagnoses discovered during the EUS exams
(Olympus GF UC 140 P, Aloka Pro α-5) were recorded. MRA served as the gold standard
when available. A stenosis of >70% was considered a positive test. Alternatively, if MRA
was not available, negative EUS and TUS exams served as negative gold standard test. Results:
A total of 109 patients were enrolled. 102 underwent EUS, 77 underwent TUS, 44 underwent
MRA and a gold standard was available in 73 patients. EUS Doppler measurements of the
CA and SMA could be performed in all 102 patients (100%) and 89 patients (87%),
respectively. TUS measurements of the CA and SMA could be performed in 63 patients
(82%) and 67 patients (87%), respectively. Both EUS and TUS had high accuracies in
evaluating abnormal flow in the CA (86% vs. 92%) and SMA (96% vs. 89%). When compared
to MRA, EUS had a sensitivity and specificity of 43% and 81% in predicting the presence
of >70% stenosis. When both EUS and TUS are negative, MRA was negative for stenosis of
the CA and SMA in 100% and 90% of cases. During EUS examination, a potential cause
of abdominal pain was found in 47 out of 102 examinations (46%). Conclusion: CA and
SMA Doppler flow measurements can be obtained during EUS examination. EUS flow
measurements of the CA and SMA can diagnose and more importantly exclude CMI as a
cause of upper abdominal pain. EUS has an advantage over TUS as it can yield alternative
disorders that may be contributing to chronic upper abdominal pain. EUS with Doppler
has the potential to be used as a single comprehensive test in the evaluation of persistent
upper abdominal pain.
M1130
E. coli Nissle 1917 Is a Potent Modulator of Mucosal Inflammation and
Visceral Sensory Function
Birgit Adam, Stefanie Bertram, Tobias Liebregts, Andrew Ruszkiewicz, Nektaria Pezos,
Armin Schreiner, Lothar Schulze, Ulrich Sonnenborn, Gerald Holtmann
Background: Visceral hyperalgesia plays a central role in the pathophysiology of irritable
bowel syndrome (IBS) and a transient mucosal inflammation has been identified as important
risk factor in the manifestation of IBS (Adam et al., Pain 2006;123(1-2):179-86). The
probiotic Escherichia coli Nissle 1917 (EcN) has been shown to have anti-inflammatory effects
in patients with ulcerative colitis. We aimed to characterize effects of EcN on 1) visceral
sensory function, 2) mucosal inflammation and 3) systemic cytokine levels after preventive
(treatment only before the induction of an acute inflammation) and/or therapeutic (EcN
started immediately after induction of inflammation) treatment in male Lewis rats. Methods:
A transient colitis was induced by colorectal instillation of TNBS (5 mg/kg)/ethanol or saline
(control). Animals randomized to the preventive treatment groups received oral administration
of EcN (2.5-25x109 bacteria) or placebo for a 14 days period prior to colitis induction.
Animals receiving therapeutic administration started at the day of colitis induction for 14
consecutive days. In a third treatment arm preventive and therapeutic administration was
combined. The visceromotor response (VMR) was characterized by measuring the abdominal
EMG activity in response to standardized colorectal distensions which were conducted at
day 0 (TNBS or saline instillation), 3, 5, 14 and 35. Colonic tissue samples were obtained
for histological assessment and blood samples collected to assess systemic cytokine release
of pro-inflammatory cytokines (IL- 2, IL-6) via ELISA. Results: TNBS, but not saline caused
a transient inflammation (peak at day 5) with complete histological healing (day 14) and a
chronic visceral hyperalgesia (peak at day 35). EcN did not alter VMR in saline treated
animals. The VMR to CRD was significantly (p<0.05) attenuated in TNBS treated rats by
preventive (-28.4±3.3%) and therapeutic EcN treatment (-32.4±4.1%) compared to placebo.
Combined treatment with EcN significantly reduced the VMR (-47.6±5.1%, p<0.05) in TNBS
treated rats compared to placebo and compared to other EcN treatment arms. Histological
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assessment revealed an EcN induced attenuation of mucosal lesions at day 5 in the preventive
and combined but not therapeutic EcN treatment group compared to placebo. Plasma cytokine
levels were significantly higher in TNBS treated animals compared to saline control, while
EcN treatment did not yield a significance difference. In conclusion, EcN attenuates mucosal
inflammation and visceral hyperalgesia in TNBS treated rats compared to placebo with
superior results for combined (preventive plus therapeutic) administration.
M1131
Lemon Grass (Cymbopogon Citratus) Decreases T Lymphocytes Migration to
Inflamed Intestinal Microvessels
Chikako Watanabe, Ryota Hokari, Shunsuke Komoto, Hisayuki Matsunaga, Koichi
Takebayashi, Yoshikiyo Okada, Chiezo Kurihara, Toshihide Ueda, Ryuichi Yamamoto,
Masaaki Higashiyama, Yoshikazu Tsuzuki, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro
Itoh, Soichiro Miura
<Background&Aim>Aberrant leukocyte migration has been implicated in the pathogenesis
of inflammatory bowel disease. Recently vitamin A (retinol) metabolite, retinoic acid (RA),
is reported to play a key role on T cell migration to the gut by enhancing the expression
of β7 integrin on T cells. Lemon grass (Cymbopogon citratus)is widely used in Thai and
Vietnamese cooking. This grass is rich in a substance called citral, which decreases RA by
inhibiting metabolism of retinol to RA. Thus we hypothesized that this natural herb could
attenuate aberrant leukocytes migration to intestinal mucosa by decreasing β7 integrin
expression. The aims of this study are to monitor the effect of lemon grass drinking on
expression of integrin molecules and migration of T lymphocytes to inflamed intestinal
mucosa and to determine whether this herb improves the murine colonic inflammation.
<Method>T cells were isolated from the spleen of C57B6. Lemon grass was boiled and
added to the drinking water. Some mice received herb tea for 2 weeks before isolation of
T cells. CFSE labeled T cells were administered via the jugular vein of recipient mouse.
Adhesion of lymphocytes to microvessels in the intestinal mucosa was monitored using
intravital microscopy. In some recipient, E. coli lipopolysaccharide (LPS 15mg/kg) was
injected intraperitoneally 2.5 hours before experiment. Expression of α4-integrin, β7-inte-
grin, and L-selection on T lymphocytes was analyzed by FACS. In another set of experiments
mice received dextran sodium sulfate in drinking water to induce colitis and the attenuating
effect of lemon grass drinking from 2 weeks before colitis induction were investigated.
<Result>Intravital observation demonstrated that LPS induced a significant increase in T
cell accumulation in microvessels of small intestine and colon. T cells isolated from mice
drinking lemon grass significantly decreased the number of adherence in both control and
inflamed intestinal mucosa. FACS analysis showed the decreased expression of β7 integrin
in splenic and mesenteric lymph node cells by lemon grass treatment, but the expression
of L-selectin was not changed. Activity of DSS colitis as assessed by shortening of colonic
length was also ameliorated in herb drinking group. <Conclusion>Lemon grass, widely
used natural herb, significantly suppressed the increased T lymphocyte migration in the
inflamed mucosa induced by LPS. Lemon grass also ameliorated colitis possibly through
decreasing T cell migration by inhibiting β7 expression, suggesting its therapeutic usefulness
for IBD.
M1132
Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 (Ctla4) Antibody Induced
Colitis and Its Management
Richard L. Johnston, Jose Lutzky, Jamie S. Barkin
Introduction: Anti-CTLA4 antibodies (ipilimumab and ticilimumab) are human monoclonal
antibodies being studied in the treatment of metastatic melanoma (MM). CTLA4 is an
inhibitory receptor on cytotoxic T cells that suppresses the host immune response, thereby
hindering the innate defense to cancer; blockade of this receptor will therefore activate T
cells and allow them to attack malignant cells. Normal host cells may also be affected, and
several immune-mediated toxicities related to these medications occur, the most common
of which is enterocolitis. Purpose: This is a prospective observational study on the use of
corticosteroids and infliximab in the treatment of patients with immune-mediated colitis
secondary to anti-CTLA4 antibody treatment of MM. Patient population: Five patients (3
females, 2 males) with MM, mean age of 68.6 (range 60-78 years) had drug-induced colitis.
Four received ticilimumab in the adjuvant setting and 1 received ipilimumab for metastatic
disease. All presented with acute diarrhea after medication administration. Infectious colitis
was excluded and subsequent flexible sigmoidoscopy showed contiguous colitis in 4 patients
and distal proctitis with normal mucosa proximally in 1. Pathology of all 5 showed acute
and chronic inflammation, with crypt abscesses seen in 4. Treatment results: High-dose
corticosteroids (40-60 mg daily) were administered to all patients. This ameliorated the
diarrhea in 1. A 2nd patient was recently begun on steroids, with response to be followed.
Steroids given for 1-6 weeks failed to improve symptoms in 3 patients; they were subsequently
treated with infliximab 5 mg/kg and experienced resolution of diarrhea within 1-2 days.
Discussion: A common side effect of anti-CTLA4 antibodies is immune-mediated colitis with
symptomatic diarrhea. The presence of crypt abscesses and the mechanism of action of anti-
CTLA4 antibodies suggest that the pathogenesis of immune-mediated colitis may be similar
to that of ulcerative colitis. The initial treatment of these patients should be high-dose
corticosteroids, with a response rate of 25% in our series. Patients who are steroid unrespons-
ive after 7 days can be treated with infliximab 5 mg/kg; all 3 who received this treatment
in our series had resolution of symptoms. Our results are similar to those of Beck et al
(J Clin Oncol. 2006;24:2283-2289), who reported 5 patients treated with infliximab for
ipilimumab induced immune-mediated colitis. Four were refractory to corticosteroids but
all were responsive to infliximab.
M1133
Lactobacillus Acidophilus Ncfm Modulates Intestinal Pain and Induces Opioid
and Cannabinoid Receptors in the Gut
Christel Rousseaux, Xavier Thuru, Agathe Gelot, Nicolas Barnich, Christel Neut, Laurent
Dubuquoy, Caroline Dubuquoy, Emilie Merour, Karen Geboes, Mathias Chamaillard,
Arthur C. Ouwehand, Greg Leyer, Didier Carcano, Jean-frédéric Colombel, Denis Ardid,
Pierre Desreumaux
Experimental and clinical data suggest that specific probiotic may prevent abdominal symp-
toms observed in irritable bowel syndrome (IBS).We previously demonstrated that certain
strains of probiotics are able to induce expression of mu opioid (MOR) and cannabinoid-
2 (CB2)receptors in intestinal epithelial cells.Aim:To evaluate the functional role of MOR and
CB2 induced by Lactobacillus acidophilus NCFM on intestinal pain in rats.Methods:Visceral
perception in healthy rats and in rats having a butyrate-induced visceral hypersensitivity
was evaluated by colorectal distension after oral NCFM administration at a clinically relevant
concentration (109 CFU/d) for 15 consecutive days.Optimal dosage (107,108 and 109 CFU/
d) and time-course response (7,10,14 and 21d) of NCFM administration were determined.In-
fluence of NCFM administration on morphine efficacy was assessed together with the
involvement of MOR and CB2 in the regulation of visceral pain after ip injection of specific
antagonists for CB2 (AM-630,3mg/kg) and opioid receptors (naloxone methiodide,2mg/
kg).Results:Oral administration of the NCFM strain (109 CFU/d) during 15d decreased
normal visceral perception, allowing a 20% increase in the pain threshold (P<0.01).This
analgesic effect was enhanced as the NCFM dosage was increased from 107 CFU/d to 109
CFU/d(P=0.002).At a concentration of 109 CFU/d, the analgesic effect was induced rapidly
within 10d, maintained for the duration of the treatment (10,14 or 21d) and disappeared
3d after the last NCFM administration.In chronic colonic hypersensitivity model, elicited
by butyrate enemas and mimicking IBS, the hypersensitivity of rats was improved by the
NCFM strain:treatment with NCFM increased the colorectal distension threshold by 44%
compared to that in untreated rats (P<0.001).In this model, NCFM resulted in an antinocicep-
tive effect of the same magnitude as that caused by subcutaneous administration of 1 mg/
kg morphine. Moreover, it enhanced by 65% the suboptimal analgesic effects of 0.1 mg/
kg morphine (P<0.001).NCFM-induced analgesia was significantly inhibited by peritoneal
administration of AM-630 but not by naloxone methiodide, providing indirect evidence for
a CB2 physiological role in the control of intestinal pain.Conclusion:Lactobacillus acidophilus
NCFM modulate and restore the normal perception of visceral pain.The similar efficacy, in
treating pain, of orally administered NCFM and a standard dosage of morphine suggests
that specific modulation of intestinal flora may be a promising, safe and relatively inexpensive
new treatment for abdominal pain, a prominent symptom of irritable bowel syndrome,
which affects 20% of the general population.
M1134
The Value of Jejunal Exercise Tonometry for the Diagnosis of Chronic
Gastrointestinal Ischemia. Comparison of Jejunal with Gastric Exercise
Tonometry in 100 Patients Suspected of GI Ischemia
Renzo Veenstra, Peter Mensink, Ad Huisman, Bob Geelkerken, Jeroen Kolkman
Gastric exercise tonometry has been shown to be a validated and useful diagnostic test for
suspected gastrointestinal ischemia (Mensink et al. J Vasc Surg 2006). Although in most
patients with symptomatic ischemia the celiac artery is stenotic, doubt remains whether
exercise tonometry testing in the stomach alone is sufficient. We investigated the additional
value of jejunal exercise tonometry in the evaluation of 100 patients (pts) suspected of
chronic gastrointestinal ischemia. Methods Pts referred for suspected gastrointestinal ischemia
had a standard diagnostic work up including duplex ultrasound of the splanchnic arteries
and/or abdominal angiography and gastric exercise tonometry. The latter was combined
with jejunal exercise tonometry. Using automated air tonometry jejunal pCO2 was measured
before, during and after 10 min of exercise. Jejunal exercise tonometry was regarded abnormal
when luminal-arterial gradient was >1.3 kPa with a rise of luminal pCO2 on exercise (Otte
et al. submitted). Final diagnosis of chronic gastrointestinal ischemia was made by our
institutional multidisciplinary working group on GI ischemia. Results In 100 pts (68 F 32
M) combined jejunal and gastric exercise tonometry was evaluated. One or more splanchnic
stenosis were found in 54 pts. In 35 pts a final diagnosis of chronic splanchnic syndrome
was made and in 9 pts non-occlusive mesenteric ischemia was diagnosed. Jejunal exercise
tonometry predicted correctly GI ischemia in 20/44 pts and correctly no ischemia in 51/56
pts representing a sensitivity of 45% and specificity 91%. The sensitivity and specificity of
gastric exercise tonometry were 73% (32/44 pts) and 79% (44/56 pts) respectively. When
combining the results of jejunal and gastric exercise tonometry sensitivity increased to 86%
(38/44 pts) with a corresponding specificity of 75% (42/56 pts). Conclusions This study
shows that jejunal exercise tonometry has a low sensitivity but a high specificity for the
diagnosis of chronic GI ischemia. Combining jejunal and gastric exercise tonometry in pts
suspected of chronic GI ischemia increased sensitivity for the diagnosis of chronic GI ischemia
to 86%.
M1135
Intestinal Permeability in Autistic Disorder
Valeria Familiari, Laura De magistris, M. Carteni, Carolina Bravaccio, Alex Frolli, R.
Riegler, Roberto Militerni, Vincenzo Pascotto, Alessio Fasano
BACKGROUND: There have been indications that autistic children have an impaired barrier
function of the gastrointestinal tract leading to elevated intestinal permeability. According
to the leaky gut hypothesis, the intestinal mucosa is abnormally permeable in autistic children.
Digestion products of natural food could gain access to the bloodstream through the leaky
mucosa and induce antigenic responses as well as interfere directly with the central nervous
system. AIM: to evaluate barrier function and intestinal inflammation in children with autistic
disorder and their first degree relatives. MATERIALS AND METHODS: 25 (mean age± SD =
5.8 ± 3.7; F=3, M=22) consecutive outpatient children with autistic disorder, diagnosed
according to the DSM-VI criteria, and 50 (mean age± SD=38.5± 8.3; F=28, M=22) first
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degree relatives were recruited. The intestinal permeability was evaluated by means of
lactulose and mannitol test (LA/MA). Faecal calprotectin was performed to evaluate an
eventual intestinal inflammation. In all patients serum tissue transglutaminase and HLA
DQ2 DQ8 were determined to rule out celiac disease. RESULTS: In 48 % of patients with
autistic disorder the LA/MA values were higher than the cut off range (0.030). In the group
of first degree relatives 34% resulted higher than normal. Calprotectin values indicated
inflammation in 7/25 patients (28%) and only 3/50 (6%) relatives. The tissue transglutaminase
was normal in all patients. HLA haplotype resulted DQ2 positive in only one of the seven
patients investigated so far. CONCLUTIONS: Our results showed that a subgroup of autistic
patients and their family members showed altered intestinal permeability, sometimes associ-
ated to biochemical signs of intestinal inflammation. These results suggest a genetically-
determined defect of intestinal barrier function in a subgroup of large spectrum autistic
disorder patients and their family members.
M1136
Doppler Sonography Evaluation of Aorta and Superior Mesenteric Artery Flow
to Assess Crohn's Disease Activity in Correlation with CDAI: A Prospective
Study
Homero S. Fogaça, Thais Guaraná, Melissa T. Pitrowsky, Joana M. Amaral, Leonardo
Alves, Alice Moll, Cyrla Zaltman, Antonio josé Carneiro, Celeste Elia
Crohn's disease is a chronic inflammatory disease that affects the entire digestive tract, but
mainly the bowel. In Crohn's disease, assessment of disease activity is of major clinical
importance. There is no absolute method to assess disease activity. Crohn's disease activity
index (CDAI) is a well established parameter for estimating clinical status. Pathologic and
angiographic studies have shown changes in the splanchnic circulation of patients with
Crohn's disease. Doppler ultrasound has been found to be increasingly useful for the investi-
gation of splanchnic haemodynamics, mainly due to the fact that it is not invasive, is accurate
and reproducible, avoids exposure to radiation and can be easily repeated. The aim of this
study was to evaluate the changes of splanchnic blood flow in patients with active and
inactive Crohn's disease, compared with a control group with no intestinal disease, using
Doppler ultrasound, and to correlate then with CDAI. The study was performed on 36
patients (mean age 39,4 years) with Crohn's disease and on 12 healthy individuals without any
manifestation of disease (mean age 28,2 years). Patients with comorbidities were excluded.
Diagnosis of Crohn's disease was made by clinical, endoscopic, radiologic and/or histopathol-
ogic ways.The degree of activity of Crohn's disease was judged by evaluating the CDAI. The
extent of the disease was evaluated by barium enema of small bowel and by colonoscopy.
The exam was performed in the supine position, with the “HDI 3000 Ultrasound System,
ATL/Philips Company”, using a 3.5 MHz convex transducer. All patients obtained informed
consents approved by ethic committee of our institution. Statistical evaluation of results was
made using SPSS for Windows 11.0. It was observed that patients with Crohn's disease had
a lower mean velocity in aorta than that found in control group (p= 0,004), and also a
lower systolic velocity in this artery (p=0,002). The resistance index of the mesenteric
superior artery was lower in patients (p=0,03), as the pulsatility index (p=0,02) when
comparing with control group. In this artery the diastolic velocity was higher (p=0,02).
Patients with CDAI&;150 presented a lower resistance index in the superior mesenteric
artery (p=0,01) and also a lower pulsatility index in this artery (p=0,009), comparing with
those patients with CDAI lower than 150. As a preliminary result, we can resume that
patients with Crohn's disease presents, at Color Doppler ultrasound, changes in splanchnic
haemodynamics which correlate well with CDAI. Therefore, Color Doppler ultrasound could
be another non-invasive method used, as routine, to evaluate Crohn's disease activity.
M1137
Inhibition of Dipeptidyl Peptidase Activity Increases Circulating Glucagon-
Like Peptide-2 and Decreases Neutrophil Infiltration During Experimental
Colitis in Mice
Roger Yazbeck, Gordon S. Howarth, Hans ulrich Demuth, Jens J. Holst, Catherine A.
Abbott
Introduction: Glucagon-like peptide (GLP)-21-33 is a potent, intestinotrophic factor. Previous
studies in our laboratory have shown inhibition of dipeptidyl peptidase (DP) activity, includ-
ing DPIV, DP8 and DP9 to partially attenuate the effects of dextran sulfate sodium (DSS)
colitis in mice. To determine the mechanisms behind this, we investigated whether DPIV
knockout mice (DPIV-/-) and wild-type (WT) mice treated with DP inhibitor, have an
increased GLP-21-33 bioavailability. Methods: WT and DPIV-/- mice (n=12) consumed 2%
DSS in drinking water for 6 days to induce colitis. Mice were treated with saline or a DP
inhibitor, either isoleucyl-cyano-pyrrolidine (ile-cyano-pyrr) or isoleucine-thiazolidine (ile-
thia). Disease severity was assessed daily using a disease activity index (DAI). Measurements
of GLP-17-36, GLP-19-36 and GLP-21-33 were made using a radioimmunoassay. Neutrophil
infiltration was assessed by a myeloperoxidase (MPO) assay. All results were expressed as
mean±SEM. Results: DAI was lower in WT+ile-cyano-pyrr (2.8±0.8) and WT+ile-thia mice
(2.5±0.8) compared to WT+saline mice (4.4±0.7, p<0.05). At day 5, percentage body weight
was higher in WT+ile-cyano-pyrr mice (100±1%) compared to WT+saline (96±2%, p=0.05).
Basal concentrations of GLP-21-33 were greater in DPIV-/- mice at day 0 (45.7±10.3pM) in
comparison to WT mice (14.2±4.0pM, p<0.05). After 6 days DSS, circulating concentrations
of GLP-21-33 were significantly increased in DPIV-/-+saline mice (46.5±14.2pM) and WT+ile-
cyano-pyrr mice (62.1±13.7pM) compared to WT+saline mice (28.8±3.8pM, p<0.05). At
day 0 circulating GLP-17-36 and GLP-19-36 were higher in DPIV-/- mice (45.6±10.3pM)
compared to WT mice (14.2±4.0pM, p<0.05). At day 6 of DSS, circulating GLP-17-36 and
GLP-19-36 were significantly higher in WT+saline mice (30.5±12.8pM) compared to DPIV-/-
+saline mice (12.0±0.0pM, p<0.01). MPO activity was significantly increased after 6 days
DSS in WT+saline mice (6.9±1.7U/mg protein) from day 0 (1.1±0.2U/mg protein, p<0.01).
MPO activity was not significantly increased in DPIV-/-+saline mice (2.3±0.6U/mg protein)
compared to day 0 DPIV-/- mice (1.2±0.3U/mg protein). Furthermore, MPO activity was
significantly lower by 67% in DPIV-/-+saline mice compared to WT+saline mice after 6 days
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DSS (p<0.01). Conclusions: Inhibition of DP activity resulted in increased circulating GLP-
21-33 as well as decreased circulating GLP-17-36 and GLP-19-36 after 6 days of DSS. Further-
more, during DSS colitis, neutrophil infiltration is partially attenuated in DPIV-/- mice
compared to WT mice. This study provides further evidence for the role of DP inhibition
as a potential treatment strategy for IBD.
M1138
Dextran Sulfate Sodium-Induced Crypt Hyperplasia in the Jejunum and Ileum
Is Prevented By Oral Administration of Lactobacillus Fermentum Br11 and
Bifidobacterium Lactis Bb12 to Rats
Cassie L. Smith, Mark S. Geier, Ross N. Butler, Gordon S. Howarth
Background: The dextran sulphate sodium (DSS) model of colitis is frequently employed
to assess novel treatments for ulcerative colitis. Recent studies suggest that DSS-induced
damage extends to the small intestine; however, this remains untested. We investigated the
effects of DSS on small intestinal injury in rats, and the concomitant effects of four candidate
probiotics. Methods: Rats (n=8 per group) were gavaged 1ml probiotic [Lactobacillus
rhamnosus GG (LGG), Streptococcus thermophilus TH-4 (TH-4), Bifidobacterium lactis Bb12
(Bb12) or Lactobacillus fermentum BR11 (BR11)] at 1x109 cfu ml-1 or vehicle (skim milk)
twice daily for 14 days. Rats consumed 2% DSS in drinking water between days 7 and 14.
Crypt depth (CD) and villus height (VH) in the jejunum and ileum was assessed. Ileal crypt
cell proliferation (labeling index-LI) was assessed in normal controls, Vehicle+DSS and
BR11+DSS-treated rats by PCNA immunohistochemistry. An In Vitro caspase 3/7 assay
determined the level of apoptosis in untreated, DSS-treated and DSS+BR11 treated Caco-2
cells. Data was compared by one-way ANOVA with Tukey's post hoc test with p<0.05
considered significant. Results: Jejunal CD increased in vehicle+DSS (10%) and TH-4+DSS
(15%) treated rats, however, BR11, Bb12 and LGG administration did not affect CD compared
to normal controls. Jejunal VH in normal controls was not significantly different to
vehicle+DSS-treated rats (p>0.05). However, TH-4+DSS treatment increased jejunal VH by
19% compared to vehicle+DSS-treated rats. Ileal CD increased in vehicle+DSS (19%),
LGG+DSS (15%) and TH-4+DSS (26%) treated rats. BR11 and Bb12 administration did not
affect ileal CD compared to normal controls. Ileal VH in normal controls was not significantly
different to DSS-treated rats (p>0.01). Ileal VH increased in LGG+DSS (17%) and TH-4+DSS
(19%) treated rats, whereas BB12 and BR11 administration did not affect VH compared to
normal controls. DSS treatment increased ileal LI by 59%, compared to normal controls,
however, BR11+DSS reduced ileal LI by 59% to that of SM+water. Caco-2 cells treated with
DSS displayed an 85% increase in apoptosis. DSS+BR11-treated cells had a 62% significant
decrease compared to DSS treatment alone. Conclusion: The DSS-colitis model produced
low-grade crypt hyperplasia, which was not prevented by LGG or TH-4, although Bb12
and BR11 partially attenuated these effects. DSS induced increases in ileal crypt cell prolifera-
tion and Caco-2 cell apoptosis, however, following BR11 treatment these effects were partially
attenuated. Further studies of DSS effects and probiotic interventions in the small intestine
are indicated.
M1139
A Unique Botanical Dietary Supplement - Scuttelaria Baicalensis - Protects
Gut Epithelial Barrier Function By Inactivating Crucial Transcription Factors
and Stabilizing Tight-Junctional Proteins
Ali C. Banan, Philip Engen, Maliha Shaikh, Christopher B. Forsyth, Lijuan Zhang, Ali
Keshavarzian
NF-kB activation & barrier disruption are key factors in pathogenesis of inflammatory
GI diseases (eg, inflammatory Bowel Disease, IBD). Not surprisingly, several traditional
Complementary Alternative Medicine (CAM) systems recommend putative anti-inflammatory
herbs such as Scuttelaria Baicalensis (SB) for IBD. Despite claims, whether this herb has
anti-inflammatory effects & is beneficial in IBD and can prevent barrier disruption is not
known. Also, its mechanism of action has not been directly evaluated in a model appropriate
for IBD. Aims: To determine if NF-kB signal inactivation is key in SB-mediated protection
of tight junction proteins & barrier function under oxidant injury. Methods: Human intestinal
monolayers (Caco-2) were incubated in injurious doses (100 & 500 uM) of H2O2 ± SB (1-
100 ug/mL) or NF-kB modulators. Other studies were done in IkB mutant cells where NF-
kB was inactivated. We assessed: barrier function (fluorometry, TER), occludin/ZO/actin
integrity (confocal microscopy, SDS-PAGE), NF-kB activity (EMSA), NF-kB modulator, IKB
(PAGE), n=6/grp. Results: Pretreatment with SB (10 ug/mL) prior to oxidant insult resulted
in: 1) decreased IkB degradation, 2) reduced NF-kB nuclear translocation, 3) concomitant
decrease in intranuclear NF-kB activation, 4) maintenance of normal barrier proteins architec-
ture, & 5) enhancement of barrier function comparable to controls. These protective effects
were synergized by different IkB stabilizers. To further confirm the role of NF-kB in SB
protection: [A] preincubation with any of several NF-kB inhibitors (MG-132, Lactacystin)
or stabilization of IkB by a dominant mutant transfection synergized the protective effects
by SB. [B] While, pretreatment with potentiators of NF-kB activation [PAO, PV] prevented
SB maintenance of barrier function & stabilization of tight junction structure under oxidant
insult. [C] IkB stabilization by mutant transfection, similar to SB, also led to stability of
tight junctions & protection of barrier function. Indeed, oxidants disruptive effects on barrier
were largely prevented by mutant IkB stabilization while they were exaggerated by inhibitors
of phosphoseryl/threonyl protein phosphatase (ie, NF-kB potentiators). Finally, an endogen-
ous defensive factor EGF led to similar beneficial effects as that of SB. Conclusions: Our
data indicate for the first time that Scuttelaria Baicalensis protects against oxidant-induced
intestinal epithelial hyperpermeability by stabilizing the tight junctions through the inactiva-
tion of NF-kB via stabilization of IkB. Thus, this traditional herb could be a potentially
useful, innovative strategy to maintain gut barrier health during IBD.
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Prospective Comparative Evaluation of a Quick Fecal Calprotectin Test with
An Established ELISA for Assessing Intestinal Inflammation
Yogesh Shastri, Nada Povse, Jürgen Stein
Background: Calprotectin is a calcium-binding neutrophil protein which is richly found in
stool and body fluids (plasma, urine and saliva). Its level is significantly elevated in any
infectious or inflammatory conditions of the bowel and is rightly termed as ‘ESR of gut'. It
has been considered as a reliable marker for diagnosis, management and follow up of
gastrointestinal inflammatory pathologies. Enzyme Linked Immunosorbent Assay (ELISA)
is used to determine calprotectin. But it needs a well equipped laboratory i.e. an ELISA
reader, limiting their widespread use because of costs and logistics issues. Aim: New, rapid
Sandwich ELISA test was compared with an established ELISA in varied group of patients.
Methods: 823 patients (426 females) underwent a commercial quantitative ELISA (Immunod-
iagnostik, Bensheim, Germany) and the rapid bedside test (PreventID® CalDetect, Preventis,
Bensheim, Germany), which is a semiquantitative immunochromatographic rapid test using
monoclonal antibodies, from Jan 2005 till Nov 2006. Both these tests were performed by
an experienced technician who was blinded to the patient's clinical profile. 15 ng/mL was
the cut off used for these tests. Results: 471 patients had Inflammatory bowel disease (339-
Crohn's Disease and 132-Ulcerative colitis), 162 had diarrhea, 120 with miscellaneous
diagnoses while 70 were healthy controls. Performance characteristics in various group of
patients were as shown in Table. Conclusion:New bedside IFOBT was found to be as accurate
as an established ELISA test. Also it was simple, rapid (needs 5 min), convenient, doesn't
need ELISA reader & can be performed at patient's bedside or in physician's office by any
health care personnel. It can potentially replace the cumbersome ELISA technique.
Table. Performance characteristics
Values in bracket indicate 95% CI
M1141
Is Double-Balloon Endoscopy Consummate in Diagnosis and Treatment of
Small-Intestinal Disorders?
Wen Li, Zhongsheng Lu, Gang Sun, Qiyang Huang, Lihua Peng, Xiangdong Wang,
Jiangyun Meng, Hong Du, Yunsheng Yang
Introduction: Double-balloon endoscopy is a novel technique that can potentially examine
the whole small intestine. However, the advantages and disadvantages of the technique in
diagnosis and treatment of small intestinal disorders remain to be clarified. Aims: To evaluate
the role of double-balloon endoscopy in diagnosis and treatment of small intestinal disorders.
Methods: One hundred and ninety-six consecutive patients, 132 males and 64 females, age
ranged 12-79 years old (mean 46.8 years old), received double-balloon endoscopy (Fujinon,
Japan) from August 2003 to September 2006. Eighty-two cases of enteroscopy were per-
formed via oral routes, 52 cases per anal routes and 62 cases via combined oral and anal
routes. Premedication was utilized in 3 periods: no medicine in the early phase (n=44); The
conscious sedation in the middle stage (n=99); and the general anesthesia lastly (n=53). The
entire small intestinal view was defined as one of the following situations: 1. observation
of the ileum-colon valve by the oral route; 2. observation of the duodenal papilla with the
anal route, or 3. observation of the marker with the combined routes, which was made by
one single route. Results: In three of the cases (2.1%) patients failed to cooperate with
doctors because of abdominal pain and poor toleration of unsedated endoscopy or conscious
sedation. The success rate for viewing the entire small intestine was 0% for both the oral
and anal routes, and only 11.1% with combined routes. Procedure time was 72 +/- 30.0
min (20-137 min) with oral routes, 101 +/- 49.4 min (30-270 min) with anus routes and
156 +/- 57.8 min (80-320 min) with combined routes. The clarification rate of small intestinal
disorders was 69.7% with hemorrhaging, 53.5% with abdominal pain, 85.7% with vomiting
and 55.6% with diarrhea. Therapeutic enteroscopy was conducted for 6 patients: polypec-
tomy for the Peutz-Jeghers' Syndrome, dilatation with hydrostatic balloon for jejunum
stricture, hemostasis with an epinephrine injection for acute hemorrhaging from ileum
angiodysplasia, and extraction of a trapped capsule endoscope with double-balloon tech-
nique. Submucosal hematoma of the colon occurred during the procedures in 1 patient
with anal route examination and transient hoarseness happened in 3 patients with oral route.
The morbidity and mortality was 2.0% (4/196) and 0% respectively. Conclusions: Double-
balloon endoscopy is expanding the view of the small intestine and contributes to a better
understanding of intestinal disorders. However, the procedure is very time-intensive and
there are still some blind spots remaining in the small intestine.
M1142
Treatment of Irritable Bowel Syndrome with Curcumin: A Case Series
Abraham M. Panossian, Christopher D. Romberg, Amy C. Mcclune, Hardeep M. Singh,
Anshu Kumar, Chris N. Conteas
Introduction and Aims: Curcumin is the organic extract of turmeric, a ground powder from
the root of the Curcuma plant which has long been used in Chinese and Ayuverdic medicines
to treat various digestive ailments. Curcumin has recently been recognized for its anti-
oxidant and anti-inflammatory properties. Our aim is to investigate the utility of curcumin
in the treatment of Irritable Bowel Syndrome (IBS), specifically the gas, bloating and abdom-
inal pain variant for which no standard singular therapy presently exists. Methods: We
enrolled in our study 50 consecutive patients with gas, bloating and abdominal pain who
were diagnosed with IBS after a thorough evaluation to exclude other etiologies. Patients
were recommended a curcumin dose within the range of 1000-3000 mg per day. Mean
duration of follow-up was 5 months. Via a telephone survey, patients were asked to rate
global improvement in their symptoms as none, mild, moderate or excellent based on
a standardized questionnaire. Patients were sub-categorized based on bowel movement
symptomatology of diarrhea (IBS-D), constipation (IBS-C) or alternating diarrhea and con-
stipation (IBS-A). Actual curcumin doses used and changes in the frequency of bowel
movements and in stool consistency were noted. Results: Seventy-two percent (n=36) of all
patients reported global improvement in symptoms of gas, bloating and abdominal pain
with 22% mild (n=11), 28% moderate (n=14) and 22% excellent (n=11) ratings. The
cumulative response of IBS-D patients (83% response, n=11) and IBS-A patients (100%
response, n=6) was 88%, which was significantly better compared to 42% (n=12) of IBS-
C patients (OR = 10.5, 95% CI = 1.6 - 68.1). Patients with diarrhea reported an average
of 4.4 bowel movements per day before treatment compared to 2.2 bowel movements per
day after treatment ( -2.2, SD ±1.1), with an overall improvement in stool consistency. The
mean reported dose was 1841 mg (SD ±1505). No clear dose-response relationship was
noted. No adverse reactions to curcumin were reported by any patients. Conclusion: Our
study suggests that curcumin is effective in relieving the symptoms of gas, bloating and
abdominal pain associated with IBS. Global response was higher in patients with IBS-D and
IBS-A compared to those with IBS-C. Moreover, an improvement in stool frequency and
consistency was noted in patients with diarrhea. Based on our data, we feel that a larger
prospective, controlled trial is in order to further evaluate the above findings.
M1143
Prospective Multicentre Double Blind Randomized Controlled Trial for
Predicting Microbiological Stool Culture Positivity for Acute Diarrhea
Yogesh Shastri, Dominik Bergis, Nada Povse, Oliver Schröder, Volker Schäfer, Wolfgang
Caspary, Jürgen Stein
Background: Every year more than 4 billion cases of diarrhea occur worldwide culminating
in about 2.5 million deaths, almost all in the developing nations. Reliable diagnosis of acute
infectious diarrhea which could be appropriately managed with antibiotics at presentation
still remains a formidable challenge to the clinicians. To address this issue of correctly
diagnosing acute infectious diarrhea, a prospective study involving 381 patients (198 males)
with acute diarrhea was undertaken. Stool samples were collected for performing culture,
Guaiac based fecal occult blood test (FOBT), Calprotectin and lactoferrin assays simultan-
eously in these patients. This is the first reported study using fecal calprotectin as a diagnostic
marker in acute diarrhea. Patients & Methods: The patient's age ranged from 1-95 yrs and
the study duration was from Dec 03-Oct 06. Patients having various systemic or chronic
diseases (GI malignancy, IBD, Transplants etc.) were excluded as these could have caused
false positive results. Estimation of fecal calprotectin was performed using a commercial
quantitative ELISA (Immunodiagnostik, Germany), lactoferrin (Techlab Blacksburg, USA)
while FOBT using Hemoccult (Beckman Coulter Inc USA). Tests were performed by a
technician who was blinded to the patient's clinical profile. It requires 6 hrs to perform
fecal calprotectin as against minimum 48 hrs for the results of stool culture to be ready. Result:
The patient's characteristics as shown in Table 1. Conclusion: A positive fecal calprotectin test
showed high correlation with culture positive infectious diarrhea as opposed to lactoferrin
and Hemoccult test. It may potentially revolutionise management algorithm for patients
with acute diarrhea. As a screening test fecal calprotectin can generate results within hours
which can support the presumptive diagnosis of infectious diarrhea and thus will determine
the suitability of stool samples for culture, and of patients for empirical antibiotics (pending
stool C&S). Thus morbidity, mortality and costs associated with acute infectious diarrhea
can be significantly reduced.
Patient characteristics for 3 tests
Values in bracket indicate 95% CI
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M1144
Treatment of AIDS Enteropathy with Curcumin
Hardeep M. Singh, Timothy T. Tran, Chris N. Conteas
Background and Aims: Curcumin is the organic extract of turmeric, a ground powder from
the root of the Curcuma plant. Historically, it has been used in Chinese and Ayurvedic
medicine for digestive disorders and wound healing. Currently, it is being investigated as
a treatment for conditions including osteoarthritis, Alzheimer's disease, and inflammatory
bowel disease. Our aim was to explore the utility of Curcumin in patients with AIDS
enteropathy. Methods: Eight consecutive patients with AIDS enteropathy were identified
and agreed to participate in the study. All of the patients were male with a mean age of
47.3 years. The mean CD4 count of the study patients was 566 (range 1-1282). Infectious,
dietary, and pharmacologic causes of diarrhea were previously excluded. Patients were given
a mean dose of 1862 mg/day of Curcumin in capsular form. Patients were followed for a
mean period of 41 weeks. Number of bowel movements, stool quality, change in weight,
and side-effects were recorded pre- and post-therapy. Results: All 8 of the patients treated
with Curcumin had resolution of their diarrhea and normalization of their stool quality.
The mean time to resolution of diarrhea was 13 ± 9.3 days. Prior to starting Curcumin, the
patients had a mean of 7 ± 3.6 bowel movements per day. Post-therapy, the patients had
a mean of 1.7 ± 0.5 bowel movements per day. Seven of 8 patients had considerable weight
gain while on Curcumin (10.8 ± 8.9 lbs). The only notable side effects were belching and
foul-smelling stool, reported in 3 of the 8 patients. Five of 6 patients that had bloating and
abdominal pain prior to the study noted resolution of these symptoms while on Curcumin.
Seven patients were on anti-retroviral therapy during the study and experienced no drug
interactions, no changes in CD4 count, and no changes in HIV viral load while taking
Curcumin. Patients noted a substantial impact on quality of life, owing to resolution of
their diarrhea. Conclusion: This study assesses the use of Curcumin in patients with AIDS
enteropathy. Curcumin therapy was associated with rapid and complete resolution of
diarrhea, substantial weight gain, improvement in bloating and abdominal pain, without
any notable side-effects or drug interactions. Given our findings, a larger study of Curcumin
in AIDS enteropathy is warranted.
Curcumin Therapy for AIDS Enteropathy
M1145
Hydrogen Breath Testing Is a Great, Cost-Saving Pre-Colonoscopy Tool to
Predict Successful Colonic Preparation
Michele Vacca, Rosa cinzia Sasso, Roberta Montelli, Salvatore Rizzi, Giovanni
Maurogiovanni, Antonio Mongelli, Raffaele Moschetta, Giuseppe Palasciano, Piero
Portincasa
Successful colonic preparation is essential for complete visualization of the colon in patients
undergoing colonoscopy. Polyethylene glycol (PEG) or mannitol solutions are often used to
cause diarrhea and, in turn, depletion of fermentable substrates by hydrogen (H2)-producing
colonic microflora. Aim: to assess time-dependent changes of H2 levels in breath to predict
colonic preparation in patients scheduled for colonoscopy (n=112). Methods: Preparation
was obtained with a standard diet followed by drinking 4L solution with PEG 280 mg (n=
91). Because the oligosaccharide inulin has prebiotic properties with negligible osmotical
activity, a subgroup of 21 patients ingested inulin (10g in 200 mL water at breakfast) as
additional substrate to increase colonic H2 production. H2 levels (ppm) in expired air
samples were measured immediately before and after colonic preparation by a portable
Lactofan® analyzer (Lans Medical, The Netherlands and Italchimici, Italy). The quality of
colonic preparation was scored as excellent-fair (i.e. successful pancolonoscopy extended
to the last ileal tract) and poor (incomplete colonoscopy due to multiple faecal debris).
Results: H2 breath levels decreased from 8.95±2.47 ppm before PEG to 1.50±0.3 ppm after
PEG (n=91, P<0.01), when H2 levels were significantly (P<0.01) lower in 73 patients with
excellent-fair preparation (1.36±0.14) than in 18 patients with poor preparation (3.22±0.28
ppm). Inulin caused an overall increase of H2 levels but improved the discrimination
between patients with excellent-fair and poor colonic preparation. Conclusions: poor colonic
preparation - meaning unsatisfactory colonoscopy- can be as high as 20%. Decreasing this rate
leads to cost savings, and low discomfort/stress for the patient due to repeated colonoscopy.
Measuring hydrogen in breath under standardized conditions is a simple, reliable and non-
invasive method to predict successful colonic preparation.
M1146
A Randomized Controlled Trial of the Probiotic Combination Lactibiane® in
Irritable Bowel Syndrome, the Lactibiane® Study Group
Sophie Holowacz, Séverine Bieuvelet, André Burckel, Murielle Cazaubiel, Xavier Dray,
Philippe Marteau
Introduction : Probiotics may have a role in regulating the motility of the digestive tract or
improving abdominal pain. Some preliminary studies have suggested that some of them
may help to alleviate the common symptoms of irritable bowel syndrome (IBS). This work
addresses the efficiency of Lactibiane®, a probiotic dietary supplement (containing 4 strains
of Bifidobacterium longum LA101, Lactobacillus acidophilus LA102, Lactococcus lactis
LA103 and Streptococcus thermophilus LA104), on symptoms of IBS. Methods : 116 patients
with IBS fulfilling the Rome II criteria were randomized in a parallel group, double-blind
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design to receive placebo or Lactibiane® 2.5 g (1.1010 ufc once daily) for 4 weeks. IBS
symptoms were monitored weekly: discomfort pain (0 to 3) and abdominal pain (0 to 10)
applying a scoring system, and stools frequency and quality. The primary end point was a
overall IBS score. Measures of quality of life (SF36 and FDD-QOL questionnaires) were also
recorded pre and post-treatment. Results : 100 subjects completed the study (48 Lactibiane®,
52 placebo). Lactibiane® was not superior to placebo in relieving the overall IBS score
(42.6% vs 42.3% improvement with Lactibiane® and placebo respectively). However, the
probiotic decreased abdominal pain score (2.71 ± 2.16 vs 3.34 ± 2.24 , p=0.054), particularly
in the alternance diarrhea/constipation sub-group (2.47 ± 1.66 vs 3.60 ± 2.06 , p=0.023).
Colonic transit was accelerated in the constipated sub-group from the first week of treatment
with Lactibiane® (1.41 ± 0.86 bowel movement /day vs 0.93 ± 0.39, p=0.043). Conclusion
: The probiotic combination Lactibiane® reduced abdominal pain in IBS and accelerated
the colonic transit in constipated patients.
M1147
Performance Characteristics of the Gastroparesis Cardinal Symptom Index in
Patients Referred for Suspected Delayed Gastric Emptying
Daniel W. Cassilly, Frank K. Friedenberg, Alan Maurer, Richard Wang, Henry P. Parkman
Introduction: Gastroparesis is characterized by a constellation of upper GI symptoms. It has
been difficult to associate specific dyspeptic symptoms with delayed gastric emptying. The
Gastroparesis Cardinal Symptom Index (GCSI) was developed to identify patients in whom
delayed gastric emptying should be suspected as a cause for dyspepsia. The GCSI has
subscores for nausea/vomiting, postprandial fullness, and bloating. Validation of the GCSI
and its subscores in patients suspected of having delayed gastric emptying is necessary to
better understand its utility in evaluating dyspeptic patients. Methods: Patients with suspected
delayed gastric emptying referred for gastric emptying scintigraphy (GES) filled out the 9
question GCSI just prior to their test. The questionnaire grades each symptom on a 6 point
Likert scale from 0 (none) to 5 (very severe) over the past 2 weeks. Fasting GES was then
performed using a technetium-99m labeled egg sandwich with water. Imaging was performed
at 0, 2,and 4 hours after meal ingestion. Normal values are < 50% retention at 2 hours and
< 10% retention at 4 hours. Results: 269 patients underwent GES during the 8 month study
period. Results of both the GES and GCSI were available for 229 patients. In 122 (54.5%)
GES was normal, in 44 (19.6%) 2 or 4-hr GES was delayed, and in 63 (28.1%), both 2
and 4-hr GES were delayed. Mean GCSI total scores did not differ for these 3 groups (range
20.3-22.6;P=0.29,1-way ANOVA). Area under the ROC demonstrated marginal performance
of the total GCSI for detecting patients with delayed gastric emptying at either 2-hr (0.55;
95%CI 0.47-0.63) or 4-hr (0.57; 0.49-0.65). Post-prandial fullness subscore of the GCSI
correlated weakly with 2-hr GES result (r-sq=2.7;P=0.01). The N/V and bloating subscores
did not correlate with 2 or 4-hr GES. Using stepwise linear regression, only age marginally
correlated (inversely) with the total GCSI score (slope=-0.15;model r-sq=0.02,P=0.03). Inde-
pendent variables excluded by the stepwise process were 2 and 4-hr GES, gender, diabetes,
and BMI. Conclusions: In this,the largest validation study to date, the GCSI performed
poorly in identifying patients suspected of having delayed gastric emptying. The GCSI post-
prandial fullness subscore was higher in patients with delayed 2-hr GES. There was a
significant, albeit weak, statistical correlation between increasing age and lower GCSI score.
Better instruments are needed to identify patients with suspected delayed gastric emptying.
M1148
Presentation, Diagnosis, Mechanism and Treatment of Post-Fundoplication
Dumping Syndrome in Adults
Joris Arts, Elke Roofthooft, Philip Caenepeel, Raf Bisschops, Dominiek De wulf, Jan Tack
Dumping after Nissen fundoplication has been reported in children (Ng 2001), but not in
adults. The pathophysiology of dumping syndrome depends on rapid passage of nutrients
from the stomach to the small bowel, which may occur after (partial) gastric resection or
vagotomy. The aim of the present study was to evaluate the presence of post-Nissen dumping
syndrome in adults, the underlying pathophysiology and the yield of a stepwise diagnostic
and therapeutic approach. Methods: Consecutive patients with symptoms suggestive of
dumping syndrome (early: postprandial weakness, tremor, cramps, palpitations; late: sweat-
ing, pallor, reduced or loss of consciousness) after a Nissen fundoplication were evaluated
prospectively. Symptoms, oral glucose tolerance testing, glycemia during symptoms, gastric
emptying rate, accommodation of the proximal stomach and, in a subset, vagal integrity
were evaluated. Initial treatment consisted of diet, followed by the glucose sequestrator
acarbosis, followed by the somatostatin analog octreotide in case of persisting symptoms.
Results: 21 patients (8 women, mean age 42±4 years, 5.3±1.5 years after the fundoplication)
with symptoms suggestive of early (all) or late (18) dumping post-Nissen fundoplication
were evaluated. Hypoglycemia at the moment of symptoms (present in 6) and late hypoglyce-
mia during oral glucose load (present in 13 patients) had the best diagnostic yield. The
prevalence of fast liquid emptying (3) or of fast solid emptying (3) was unexpectedly low.
Gastric accommodation was significantly impaired (meal-induced accommodation -7±29
ml [normal >64 ml]; with “negative” accommodation in 43% of patients). Vagal integrity
determined by evaluation of insulin-induced hypoglycemic stimulation of gastric acid secre-
tion, was abnormal in only 1/6 patients. Diet and acarbosis were sufficient in 6 patients,
and 11 responded to the long-acting somatostatin analogue octreotide L.A.R. Two refractory
patients underwent a surgical reintervention. Conclusion: Nissen fundoplication may be
complicated by the occurrence of dumping syndrome in adults too. In the majority there
is no evidence of vagal dysfunction based on gastric emptying rate and vagal integrity
testing. Severely impaired gastric accommodation, possibly through impaired gastric reservoir
capacity, could contribute to the pathogenesis of dumping syndrome. A stepwise therapeutic
approach is successful in the majority of cases.
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Implication in Pattern of Continuous 13C Breath Testing for Gastric Emptying
By Simultaneous Comparison with Gastric Fundic Accommodation Curve By a
Barostat Device
Toshihiro Konagaya, Akihito Iida, Yasushi Funaki, Hiroshi Imamura, Kentarou Tokudome,
Hiroshi Kaneko, Shinichi Kakumu
Although gastric accommodation and emptying play an important role in postprandial gastric
motility, few studies have been conducted to investigate both simultaneously. Breath testing
using 13C compounds has been widely utilized to evaluate gastric emptying. However, the
implication in pattern of 13CO2 %dose/h curve has not been discussed enough. Aim: We
simultaneously evaluated gastric emptying rate with 13C compounds by continuous real
time breath testing system (Oridion Breath ID) and gastric accommodation by a barostat
device, with a special attention to the relationship among parameters in both examinations,
as well as pattern of 13CO2 %dose/h curve and gastric volume curve. Methods: Twelve male
volunteers with a barostat bag (maximal capacity=750 mL) in the stomach at the pressure
of MDP + 2 mm Hg controlled by a barostat system, were ordered to drink liquid nutrient
(200 mL, 300 kcal) with 100 mg of 13C-sodium acetate. Gastric fundic volume detected by
a barostat device and 13CO2 rate in exhalation were recorded continuously for 90 min. In
the present study, Breath ID was utilized for measurement of 13CO2 rate, as it enables to
collect exhalation without changing abdominal pressure which should affect gastric volume.
Results: Simultaneous measurement of gastric emptying and accommodation were successful
in eleven subjects. A significant positive correlation was observed between gastric accom-
modation volume and T max (r=0.59) or T half (r=0.67) in gastric emptying. Time points
at which a change in slope was observed in 13CO2 curve were similar to those in gastric
volume curve. Subjects were divided into two groups, depending on whether or not they
have an initial rush in 13CO2 curve immediately after drinking. In positive initial rush group
(n=6), the first time point at which a change in slope was observed in 13CO2 curve accorded
with the time when peak accommodation was accomplished. Conclusions: There is a
significant correlation between gastric accommodation and emptying rate. Taking the report
that a plastic bag to detect accommodation volume did not affect the rate of gastric emptying
(Am J Physiol 2006) into consideration, this is the first report that gastric emptying is
regulated by accommodation with harmonization in healthy men.
M1150
Randomized, Placebo-Controlled Trial of Botulinum Toxin a for the Treatment
of Delayed Gastric Emptying
Frank K. Friedenberg, Amiya Palit, Henry P. Parkman, Deborah Nelson
Delayed gastric emptying (DGE) may occur secondary to diabetes or vagal nerve injury.
Many cases are idiopathic. Treatment with prokinetics is often unsatisfactory. Our aim was
to determine whether injection of botulinum toxin A (Btx) directly into the pylorus would
improve gastric emptying and symptoms related to DGE. Methods: Patients with DGE
unresponsive to medical therapy were recruited. Patients had to have a Gastroparesis Cardinal
Symptom Index (GCSI) score ≥ 27 and DGE of a standardized Tc-99 labeled egg meal 2
and/or 4 hrs after ingestion. Patients also completed a Gastroparesis Visual Analog Scale
(GVAS), and QOL scale. Patients were computer randomized, double-blind to either 200U
of Btx or saline injected circumferentially into the pylorus during EGD. Patients completed
a follow-up GCSI and GVAS at 1,3,6,9,and 12 months after injection. Repeat gastric emptying
was assessed at 4 weeks. Open-label Btx was allowed after 4 weeks if the patient did not
experience a clinical response (i.e. symptom reduction) defined as a drop in GCSI by ≥ 9
points. The primary endpoint was clinical response at 1 month. Secondary endpoints were
clinical response from month 3 to 12 and gastric emptying 1 month after injection. Results:
16 patients were randomized into each arm. The groups were well matched for age (approx
41 years),gender (M:F= 3:13 in both), baseline 2h,4h gastric emptying, baseline QOL,and
GVAS scores (all P >0.05). At month 1, 37.5% of Btx patients experienced a clinical response,
however 56.3% who received placebo responded. Mean GCSI improvement was greater for
placebo (-10.1 ± 12.7 vs. -6.8 ± 9.2 points;P=0.21). One month 2h (-16.3 ± 22.9 vs.-10.8
± 20.6%; P=0.02) and 4h (-13.3 ± 18.0 vs. -3.6 ± 25.5%; P=0.01) gastric emptying changes
were superior for the Btx group. We could not identify predictors of response for the patients
(n=6) who responded at 1 month to Btx. A similar number of patients in the Btx (n=9) and
Placebo (n=7) groups requested open-label Btx sometime after 4 weeks. Percent improved
at 3 months (P=0.69) and 12 months (P=0.53) were similar for both groups. QOL improved
significantly in only the Btx group and only at month 12 (P=0.05). Conclusions: Btx is not
superior to placebo in the treatment of DGE. Moreover, we could not identify clinical
characteristics of patients likely to respond to this treatment. Btx, but not placebo, accelerated
gastric emptying at 2h and 4h, 1 month after injection. These results suggest that symptoms
of gastroparesis may not be due to DGE and/or the GCSI may not be a suitable measure
for quantitating gastroparesis symptoms. Overall,Btx cannot be recommended for the treat-
ment of DGE.
M1151
Is Pyloroplasty a Surgical Option in the Treatment of Refractory
Gastroparesis?
Linda anh B. Nguyen, Shelly Parker, William J. Snape
Background: Gastroparesis is a disorder of gastric motility that results in delayed gastric
emptying in the absence of mechanical obstruction. Pylorospasm (tonic pyloric contractions
>10mmHg) has been implicated in gastroparesis (Mearin et al.Gastro1986). A number of
studies showed botulinum toxin A(BT) injection into the pylorus improved symptoms and
gastric emptying. Treatment with BT has a median duration of 4 months (Bromer et al.
Gastrointestinal Endo 2005). Due to the limited durability of intrapyloric BT injection, we
hypothesized that surgical pyloroplasty may be a more durable option in patients who have
documented pylorospasm and favorable response to BT injection. Aims: 1) Evaluate the
efficacy of surgical pyloroplasty in patients with gastroparesis. 2) Identify antroduodenal
manometry(ADM) patterns that affect response to pyloroplasty. Patients and Methods: 11
patients (M=4, F=7, mean age 41.6+3.6 years) with symptomatic gastroparesis [diabetes
mellitus (DM)=2, idiopathic(ID)=5, postsurgical=4; mean 4hr gastric retention= 49.6+9.3%)
underwent surgical pyloroplasty. Prior to surgery, 9/11 patients had pyloric manometry and
ADM followed by intrapyloric BT injection for pylorospasm (mean basal pyloric pressure=
25.9+5.4 mmHg). 8/11 patients had a follow up gastric emptying test post-pyloroplasty.
Results: 7/9(77.8%) patients had symptomatic improvement after intrapyloric BT injection.
57.1% of these patients had normalization of their gastric emptying post-injection. 3/9
patients (DM=1, ID=2) who underwent intrapyloric BT injection improved post-pyloroplasty.
There was no significant difference in the 4hr gastric retention post-pyloroplasty in patients
who improved vs. those who did not (54.0±19.5% vs. 32.4±15.7%, p=0.43). All 3 patients
who improved had antral hypomotility on ADM. Antral hypomotility (N=2), bradygastria(N=
1), and normal antral contractions(N=2) were seen in patients who did not respond to
pyloroplasty. Antral contractions at a frequency of 3 cpm were able to be stimulated with
IV erythromycin during ADM in all patients. Conclusions: 1) Pyloroplasty may be helpful
in a subset of patients with gastroparesis; however, clinical parameters should be defined
to select patients who will benefit from surgery. 2) ADM patterns do not aid in the selection
of patients for pyloroplasty. 3) The clinical response to intrapyloric BT injection in patients
with known pylorospasm does not help to predict which patients will respond to pyloroplasty.
This suggests that BT injection may have other beneficial affects in the treatment of gastropar-
esis other than purely paralysis of the pylorus.
M1152
Measurement of Intragastric Pressure During Air Insufflation in Patients with
Functional Dyspepsia - Evaluation of Gastric Function in Patients Receiving
Itopride Hydrochloride -
Tsuyoshi Suzuki, Masanori Hirano
[Aim] We have reported that gastric hypersensitivity and degree of gastric relaxation can
be readily assessed through measurement of changes in intragastric pressure (IP) during air
insufflation as part of endoscopy (Gastroenterology 130(4), A437-8, 2006). In the present
study, we evaluated gastric compliance using this method with the additional parameter of
total gastric compliance in order to determine whether treatment with prokinetics improves
gastric condition in patients with functional dyspepsia (FD). [Subjects] The participants
were 18 healthy volunteers and 38 FD patients. Four FD patients underwent IP monitoring
during air insufflation prior to and at the end of 2-week treatment with itopride hydrochloride
150 mg/day using the same methodology. [Methods] During endoscopy, we induced gastric
distension by air insufflation until epigastric symptoms developed, and monitored IP using
a pressure transducer. The parameters determined were baseline IP (mmHg), IP at onset of
symptoms (threshold pressure, mmHg), time to reach threshold pressure (sec), segmental
pressure gradients during increments from 0 to 5 mmHg (mmHg/sec), and total pressure
gradient to the threshold pressure (mmHg/sec). [Results] (1) IP before air insufflation was
12.7±2.9 (mean±SD) in the control group and 14.4±3.0 mmHg in the FD group, with no
significant difference between the groups. (2) Time to reach threshold pressure was signific-
antly shorter in the FD group (45.6±20.2 sec) than in the control group (66.5±19.3 sec)
(p<0.05). (3) Threshold pressure did not differ significantly between the control and FD
groups. (4) Segmental pressure gradient (0-5 mmHg): The initial gradients, which reflect
relaxation of the gastr ic fundus, were signif icantly larger in the FD patients
(Control;0.34±0.18, FD;0.56±0.42 mmHg/sec)(p<0.05). (5) Gradient to threshold pressure
was 0.22±0.06 and 0.26±0.12 mmHg/sec in the control and FD groups, respectively, indicat-
ing that the stomach was significantly more flexible in the control group (p<0.05). (6) In
the FD patients receiving itopride hydrochloride, the following changes in parameters were
observed (before→after treatment, mean values): Baseline IP, 19.0→14.5 mmHg; time to
reach threshold pressure, 43.3→ 91.5 sec (p<0.05); threshold pressure, 28.8→23.8 mmHg;
segmental pressure gradient, 0.65→0.44; and pressure gradient to the threshold pressure,
0.24→0.12 mmHg/sec (p<0.05). [Summary] The shorter threshold time and higher seg-
mental and total pressure gradients in the FD group indicate that the stomach is difficult
to enlarge in FD patients. Our findings show that this method is simple and useful for
evaluating the efficacy of prokinetics.
M1153
13C-Octanoic Acid Gastric Emptying Breath Test in 1290 Patients: Application
of Different Mathematical Models Reveals Major Differences in T ½
Estimation
Jutta Keller, Viola Andresen, Peter H. Layer, Julia Wolter, Alan R. Zinsmeister, Michael
Camilleri
Background: Different mathematical models such as the original nonlinear (NL) regression
model (Ghoos 1993) and the reduced generalized linear regression model (GL) based on 3
breath samples (Lee 2000) have been developed for analysis of gastric emptying (GE)
curves derived from 13C-octanoic acid breath tests (OBT). While both models correlate with
scintigraphic GE half time (t ½) in healthy subjects, calculated t ½ values were markedly
different in a small study in health (Choi 1997), and this was attributed in part to the lack
of steady state 13CO2 excretion at time = infinite (parameter m in the NL model). Aims and
Methods: We compared t ½ calculated by the NL and GL models in symptomatic patients
who underwent an OBT and in healthy controls at the Israelitic Hospital, Hamburg, Germany
between 05/1998 and 08/2005. Multiple linear regression analysis was applied to investigate
the influence of age, gender, BMI, presence of diabetes, specific GI diseases and psychiatric
disorders on cumulative 4 hour 13C-exhalation, and t ½ by NL and GL. Results: Data were
available for 1290 subjects (864 females, age: 54±0.5 yrs, BMI:24.1±0.1 kg/m2, mean±SE).
T ½ NL exceeded 400 min in 182 subjects, t ½ GL in 41 subjects. After these unrealistic
values were excluded, there was a weak correlation between t ½ GL and NL (R=0.25,
p<0.001, n=1067). Further exclusion of all subjects with m<15% or m>60% of the dose
administered resulted in a better correlation (R=0.46, p<0.001, n=891). However, the regres-
sion shows very dissimilar results with an intercept of 110 min (95% CI interval: 102-118
min) and a slope of 0.47 (95% CI interval: 0.41-0.53). In the multivariate regression models,
13CO2-exhalation was significantly predicted by diabetes, after adjusting for age, gender,
BMI, and constipation. Similarly, t ½ GL was significantly predicted by diabetes after adjusting
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for age and gender. However, the variance in these GE parameters that was predictable by
diabetes was low (R2=0.032 and R2=0.023, respectively). Fundoplication and ulcerative
colitis were univariate predictors of t ½ NL (p<0.05) but no multivariate model could be
established. Conclusions: The NL and GL models do not provide compatible estimates of
t ½ in a large patient series. Thus, further validation is required to identify which model
best reflects gastric emptying before standard use of the OBT in clinical practice or research.
IQR=interquartile range, *total data set,** outliers excluded as indicated in text
M1154
A Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Effects
of Asimadoline Versus Placebo On Global Gastric Function and Dyspepsia
Score in Patients with Functional Dyspepsia
Rok seon Choung, Denesh K. Chitkara, Jonathan Gonenne, Filippo Cremonini, Michael
Camilleri, Ross A. Dierkhising, Alan R. Zinsmeister, Nicholas J. Talley
Background:Asimadoline, a kappa opioid agonist, reduces visceral sensitivity in experimental
animal models and may decrease satiation and postprandial fullness in healthy individuals.
However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit
has not been explored. Aims:To compare the effects of asimadoline (0.5 mg p.o. b.i.d, 1.0
mg p.o. b.i.d) and placebo on satiation volume, postprandial symptoms and dyspepsia in
functional dyspepsia. Methods:Randomized, double-blind, placebo-controlled study evalu-
ated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n=
13) or 1.0 mg (n=13) or placebo (n=14) b.i.d. in patients with functional dyspepsia by
Rome II criteria. Validated methods were used to study satiation post-nutrient challenge.
The study was powered (80%) based on the primary efficacy end point, change from baseline
in satiation post-nutrient challenge. Secondary end points were change from baseline in the
severity of daily symptoms of functional dyspepsia (as assessed by daily diary). Results:The
3 arms were comparable with regard to age, gender, body mass index, HAD (hospital anxiety
and depression) score, GSRS (Gastrointestinal Symptom Rating Scale) and Nepean Dyspepsia
Index. During 8 weeks treatment, asimadoline had no significant effect on the mean severity
daily symptom score (range 0 to 4) compared to placebo. There were no significant effects
of asimadoline on maximum tolerated volume, gastrointestinal symptom score or aggregate
symptom score with nutrient drink challenge (table). Conclusions:Asimadoline does not
appear to have significant effects on satiation post-nutrient challenge or reduce the daily
dyspepsia symptom score over 8 weeks. However, given the high placebo response typically
seen in functional dyspepsia, a large trial is needed before dismissing the potential of
asimadoline. Supported by Tioga Pharmaceuticals
Mean (± SEM) daily severity symptom score, and Post treatment nutrient drink test maximum
tolerated volumes and symptom scores (30 minutes post) on asimadoline 0.5 mg or 1.0 mg
or placebo
† mean (± SE), Symptoms Scores on 100 mm VAS, adjusted for age, gender, and baseline
satiation test
M1155
Association of the Gnb3 825t-CC with Meal Related Symptoms During a
Standardized Nutrient Challenge
Montri Gururatsakul, Tobias Liebregts, Birgit Adam, Christoph Bredack, Sarah Downie-
doyle, Susan Lester, Richard H. Holloway, Nicholas J. Talley, Winfried Siffert, Gerald
Holtmann
Background: GNB3 825T-CC has been found to be associated with functional dyspepsia
(FD) (GE 2004;126:1193-5, Am J Gastroenterol. 2006;101:581-92) although the role in
irritable bowel syndrome is less clear. A large subset with FD has meal related symptoms
but whether there is an association between GNB3 825T-CC and symptoms induced by a
standardized nutrient challenge has not been studied. We hypothesised that subjects with the
GNB3 825T-CC would report more severe symptoms during a nutrient challenge compared
subjects with TT or CT. Method: We recruited 38 subjects. After an 8 hr fast, they received
200 ml of a standardized enteral feeding solution (Ensure®) every 5 min up to a cumulative
volume of 800 ml. After each 200 ml drink, symptoms were assessed with the validated
Adelaide-Dyspepsia-Tool (ADT). This tool assesses 6 key symptoms (fullness, abdominal
pain, retrosternal/abdominal burning, nausea, regurgitation, other) and determines peak and
cumulated symptom response. Data analysis: The maximum symptom scores reported for
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upper abdominal pain, fullness and nausea were analysed. Symptom scores among genotypes
were analysed, adjusting for age, gender and BMI, using analysis of variance. Results: 16
subjects had GNB3 825T-CC genotype, 15 CT and 7 TT. During the standardized nutrient
challenge, the highest scores were reported for fullness, followed by nausea and pain. Subjects
with the CC genotype had significantly higher fullness scores (52±27mm) compared to
subjects with CT (26±28mm, p<0.05). But no significant differences were found for nausea
(CC: 10.9±23, CT: 7.0±19, TT: 14.9±32mm) and pain (CC: 6.7±13, CT: 7.7±19, TT:
5.1±8.7mm). In addition the highest symptom score occurred significantly later in patients
with the GNB3 825T-CC compared with CT and TT (18±5min vs. 13±9min, p<0.05).
Conclusions: Subjects with GNB3 825T-CC have significantly higher fullness scores during
a standardized nutrient challenge compared to CT. While the data require confirmation in
a larger sample, they are consistent with the concept that GNB3 825T-CC plays a role in
the processing of visceral sensory information or the motor responses to a nutrient challenge.
M1156
In Healthy Subjects TD-5108, a Selective High Intrinsic Activity 5-HT4
Receptor Agonist, Shows Dose-Proportional Pharmacokinetics and Exhibits a
Profile Consistent with Once-Daily Dosing
Shekman L. Wong, Michael R. Goldberg, Jeng-pyng Shaw, Carmine Lanni, Jitenda Ganju,
Charles H. Ballow, Michael M. Kitt
TD-5108, a potent agonist at 5-HT4 receptors with significant selectivity over other 5-HT
receptor sub-types, is being evaluated for the treatment of disorders of reduced GI motility.
The pharmacokinetics (PK) of TD-5108 were evaluated following ethical committee review
in two studies, a single-ascending dose study (SD) and a multiple-dose (MD) study in 48
healthy subjects. In the SD study, subjects were dosed once weekly with rising doses of
TD-5108 (0.1 to 90 mg) or placebo in 2 alternating panels of 10 subjects and a third panel
of 10 subjects. In the MD study, 9 subjects each received 50 mg/day of TD-5108 or placebo
once daily for 14 days. Subjects were dosed after an overnight fast and serial plasma samples
were collected. Plasma samples were analyzed using a sensitive liquid chromatography/
tandem mass spectrometry method. In the SD study, PK parameters could not be obtained
from the lowest and highest doses due to lack of detectable TD-5108 concentrations at the
0.1 mg dose and enrollment of only one subject at the 90 mg dose. Mean Cmax and AUC0-
∞ values were proportional to the TD-5108 dose administered in the SD study (Table 1).
The mean Tmax and terminal t1/2 were approximately 1.6 to 6.0 hr and 12.0 to 17.6 hr,
respectively, for the 0.5 to 70 mg doses studied in the SD study. In the MD study, mean
Tmax and terminal t1/2 were 3.0 hr and 17 hr, respectively, on Day 14. Mean accumulation
observed for TD-5108 Cmax and AUC0-∞ was 84% and 78%, respectively, from Day 1 to
Day 14. In conclusion, the PK exposure for TD-5108 shows dose-proportionality over a
wide range of studied doses in healthy subjects. The 17 hr terminal t1/2 observed for TD-
5108 suggests that this drug is suitable for once daily dosing.
Table 1. Mean (±SD) Cmax (ng/mL) and AUC0-∞ (ng●hr/mL) values for TD-5108 after
single dose administration
M1157
Inhibitory Effects of Audio Stimulation On Gastric Slow Waves Mediated By
the Extrinsic Sympathovagal Pathway in Adolescence
Dennis D. Chen, Xiaohong Xu, Qian Zhao, Jieyun Yin, Hanaa Sallam, Jiande Chen
The aim of this study was to investigate the effects of different audio stimulations on gastric
myoelectrical activity and sympthovagal balance and the difference in the effects between
adolescents and adults. Materials and methods: The study was performed in 11 healthy
adults (6F, 5M, mean age: 37yrs) and 12 healthy adolescents (8F, 4M, mean age: 15yrs).
Each subject underwent two sessions, one for classical music and the other for domestic
noise. Each session consisted of the following sequence: 30 min baseline, 30 min with audio
stimulation (music or noise), a test meal, 30 min with audio stimulation, and 30 min recovery.
Electrocardiogram (ECG) and electrogastrogram (EGG) were recorded simultaneously. The
heart rate variability (HRV) was derived from the ECG and power spectral analysis of HRV
was performed to derive the following parameters: sympathovagal balance LF/HF ratio,
sympathetic activity LF and vagal activity HF. EGG parameters included dominant frequency
(DF), dominant power (DP), and percentage of normal gastric slow waves. Results: 1) In
adolescence, noise reduced the percentage of normal gastric slow waves in the fasting state
(71.3+4.6% to 65.9+4.3%, P<0.05) and music increased the percentage of tachygastria (15.2
+ 4.7% vs. 21.8 + 4.4% p < 0.05). In contrast, in adults, noise had no effects on gastric
slow waves and music marginally increased the percentage of normal gastric slow waves
(76.3+5.0% vs. 81.9+5.4%, P=0.07). These effects were however, suppressed by the test
meal. 2) In adolescence, the sympathovagal balance in the fasting state was increased with
both noise (0.96+0.15 vs. 1.17 + 0.12, p = 0.05) and music (0.99 + 0.23 vs. 1.34 + 0.32,
p = 0.01). In adults, the same effect was noted only with noise (0.93 + 0.13 vs. 1.19 +
0.13, p < 0.002). The test meal increased the sympathovagal balance in both groups and
abolished the effects of audio stimulation. Conclusions: Adolescence is more vulnerable to
audio stimulation compared with adults. Gastric slow waves may be impaired with audio
stimulation in adolescence and the impairment may be mediated via the extrinsic sympathova-
gal pathway.
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M1158
The Relationship Between Psychosocial Factors, Somatization & Gastric
Emptying in Functional Dyspepsia
Lukas Van oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Benjamin Fischler,
Koen Demyttenaere, Jan Tack
Background A significant subgroup of functional dyspepsia (FD) patients has a delayed
gastric emptying rate. Although severely delayed emptying is often considered a marker of
gastrointestinal neuromuscular dysfunction, it is unknown whether psychosocial factors and
somatization, important co-morbid factors in FD, also influence gastric emptying rate. Aim
To determine the relationship between psychosocial factors and somatization on one hand
and gastric emptying rates for solids and liquids on the other hand. Methods In 118
consecutive tertiary care FD patients (mean age 40±13), gastric half emptying time (t1/2) for
solids and liquids was studied using the 14C octanoic acid breath test and 13C glycin
breath test, respectively. Psychosocial factors (depression, anxiety, positive & negative affect,
alexithymia, perceived stress & abuse history), somatization and co-morbid functional
somatic symptoms (IBS & chronic fatigue symptoms) were assessed using self-report ques-
tionnaires. Psychosocial factors & somatization measures were correlated with gastric empty-
ing rates. Their univariate correlates were entered into a multiple linear regression model.
Results Univariate associations Half emptying time for solids Depression, dyspepsia symptom
score (DSS), momentary fatigue score and somatization were positively associated with t1/2
for solids, whereas lifetime history of physical abuse was negatively associated with t1/2 for
solids. Half emptying time for liquids Depression, adult history of sexual abuse, DSS,
momentary fatigue score, presence of chronic fatigue symptoms and somatization were
positively associated with t1/2 for liquids. Multiple linear regression Lifetime history of physical
abuse (β=-0.35, p=0.0009), momentary fatigue score (β=0.28, p=0.02) and somatization
(β=0.21, p=0.08) were found to be independently related to half emptying time for solids
(model R2=0.25, p<.0001). Adult history of sexual abuse (β=-275.3, p<0.0001), somatization
(β=-13.2, p=0.0009) and their interaction (β=15.3, p=0.0002) were found to be independ-
ently related to half emptying time for liquids (model controlling for educational status (p=
0.005) and occupational status (p=0.03), R2=0.59, p<0.0001). Conclusion These results
confirm the complex relationship between psychosocial factors (especially history of abuse),
somatization and gastric emptying rate in FD. Although the biopsychosocial processes
underlying this relationship remain to be determined, the autonomic nervous system as well
as the stress hormone system (Hypothalamo-Pituitary-Adrenal-axis) are likely to be involved.
M1159
A Slow Caloric Satiety Drinking Test in Patients with Temporary and Chronic
Gastric Electrical Stimulation (GES)
Stina Andersson, Anders Elfvin, Gisela Ringstrom, Magnus Simren, Hans Lonroth, Hasse
Abrahamsson
The mechanism for the effect of GES on nausea and vomiting is unkown. An increased
gastric accommodation to meals has been proposed, but has been studied in only few patient
groups. A slow caloric satiety drinking test has been proposed as a measure of gastric
accommodation capacity (Tack et al, Gut 2003). We have performed this drinking test in
patients undergoing GES, both under double blind and open permanent GES conditions.
METHODS: 7 patients with therapy refractory nausea and vomiting and a non-established
diagnosis for GES underwent temporary percutanaeous GES (TPGES)(Gastroenterology
2006;130, Suppl 2:A-430) for 10-14 day periods, randomized to stimulation (stim) ON or
OFF, respectively. At the end of each period the patients did a caloric satiety drinking test.
Nutridrink® 1.5 kcal/ml was ingested at a constant rate, 15 ml/min, until maximal satiety
was reached. Thirty min after stopping, 4 symptoms (fullness, bloating, nausea and abdominal
pain) were assessed using a visual analogue scale, and a composite score was created. The
diagnoses were functional dyspepsia (FD, 3 pts), postsurgical gastroparesis (PSGP, 3 pts),
chronic intestinal pseudo-obstruction (CIP, 1 pt). Sixteen patients (idiopathic gastroparesis
3, diabetic gastroparesis 5, FD 4, CIP 1, PSGP 3), three of them having undergone TPGES,
were implanted for permanent GES (Enterra, Medtronic) and had a satiety test at the six
months follow up. During the TPGES periods all patients had the standard setting (5mA,
12 stim/min) during the ON period. After permanent implant two patients had increased
stim (7.5 mA) at the six months control. RESULTS: For patients having TPGES, there was
no significant change in drinking capacity during stim ON(690±370 kcal; mean±SD) com-
pared to the control period (stim OFF)(710±450 kcal), and the composite score was
unchanged. There was a non-significant tendency to decreased drinking capacity during the
second period (686 kcal, mean) compared with the first period (724 kcal, mean), irrespective
of the stim being ON or OFF. For patients having a permanent implant there was no
significant difference in drinking capacity at the six months control (870±290 kcal) compared
to baseline (892±450 kcal). Furthermore, when patients were categorized as responders and
non-responders there was no difference in change in drinking capacity during stimulation
compared to baseline (P>0.1). CONCLUSIONS: GES seems to have no or minimal effect
on proximal gastric function as evaluated by the slow caloric satiety drinking test. This
seems to be the case for pts with established and as well as non-established indications for
GES, and irrespective of the symptomatic response.
M1160
Can Nutrient Drink Test Evaluate Gastric Accommodation? from Comparison
with Barostat Study and Preliminary Effect of Itopride
Akihito Iida, Toshihiro Konagaya, Yasushi Funaki, Hiroshi Imamura, Kentarou Tokudome,
Hiroshi Kaneko, Shinichi Kakumu
Gastric dysaccommodation is thought to be one of the important pathogeneses in functional
dydpepsia. However, it is difficult to evaluate it precisely, easily, and noninvasively. Nutrient
drink tests have been proposed as a surrogate for measurement of gastric accommodation
by some Western investigators. The AIM of this study is to evaluate the significance of
nutrient drink tests by comparing with gastric barostat study. To verify the usefulness of
drink test, the effect of itopride, a gastroprokinetics which enhances gastric accommodation,
on satiation volume was also investigated. METHODS: Eighteen healthy male volunteers
(average 31 y.o.) with a plastic bag (maximal capacity=750 mL) into the stomach were
investigated. Gastric perception was examined with stepwise bag distension. Both pressure
and volume were recorded when subjects claimed first perception and maximal pain. Maximal
gastric volume with a bag controlled at MDP+2 mmHg, was measured as an accommodation
volume after drinking a liquid meal (Ensure-H®, 200 mL, 300 kcal). On another day,
subjects took a drink test to continue drinking Ensure-H® at the rate of 15 mL/min and to
score their satiation at 5 min interval. Perception, maximum satiation and accompanied
symptom were recorded. To evaluate the reproducibility, the second drink test was conducted
4 weeks after the first one. In addition, the tests were performed in subjects taking itopride
(50 mg, t.i.d) for 2 weeks.RESULTS: 1) The volume of perception, pain, and accommodation
were 278±39 mL, 628±21 mL, and 458±28 mL, respectively, in barostat study. 2) In drink
test, perception and satiation volume were 133±14 mL and 731±71 mL, respectively. 3)
Analyzing correlation among each parameter, a positive correlation (r=0.37) was observed
between an accommodation volume and a volume at maximal satiation. 4) Good reproducibil-
ity was observed in drink test. 5) Administration with itopride brought a significant increase
(from 492±86 mL to 598±112 mL : p<0.01) in a volume at maximal satiation. CONCLU-
SIONS: These results suggest that satiation during drink test may reflect fundic accoomod-
ation and itopride may be effective to postprandial dyspepsia by improving fundic dysaccom-
modation in functional dyspepsia.
M1161
Gastroparetic Symptom Severity Correlates with Food Sensitivity in Diabetic
Patients
Stephen J. Inns, Stuart Bloom, Stephen Hurel, Anton V. Emmanuel
BACKGROUND: An association between diabetes mellitus (DM) and upper gastrointestinal
symptoms is described and has been termed diabetic gastropathy. However, the correlation
between these symptoms and objective gastroparesis is poor. While there is no specific tool
for the assessment of the whole spectrum of diabetic gastropathy, a validated tool for the
measurement of symptom severity in diabetic gastroparesis, labelled the gastroparesis cardinal
symptom index (GCSI) has been developed (Aliment Pharm Ther 2003, 18:141). While the
role of food intolerances and sensitivities in the production of symptoms in functional lower
GI disorders has been extensively investigated, and the importance of nutritional management
in diabetic gastropathy is well recognised, there is no published data regarding food intoler-
ance and sensitivity in diabetic gastropathy. AIMS: The primary aim of this pilot study was
to describe the pattern and prevalence of food sensitivity in DM patients and to correlate
this with symptom severity using the GCSI. The secondary aim was to correlate patient
reported food sensitivity with allergy testing in the form of IgG food specific antibodies.
METHODS: Consecutive patients with type II DM attending the diabetes clinic at UCLH
were recruited to the study. Each patient completed the GCSI and a questionnaire regarding
the presence of gastrointestinal (GI) and extra-GI food sensitivities to a panel of 92 different
foods. All participants had blood collected for food specific IgG antibody analysis using the
Yorktest FoodscanÒ test. RESULTS: 26 patients were enrolled between June and August
2006. 10 (38%) patients reported sensitivity to one or more foods. The most common foods
which patients reported sensitivity to were chilli, tomato, wheat lemon and cashew nuts.
Patients reporting sensitivity to two or more foods scored significantly higher on the GCSI
than patients with one or no foods to which they reported sensitivity. There was no correlation
between food specific IgG titres and reported food sensitivity. DISCUSSION: Over one-third
of type II DM patients report multiple food sensitivities. This pilot study represents the first
report of a correlation between the presence of food sensitivity and severity of diabetic
gastropathy symptoms. If further investigation confirms this association, it suggests a role
for trials of dietary exclusion and double blind placebo controlled food. Additionally, our
findings may challenge the assumption that gastroparetic symptoms relate to gastric dysmotil-
ity, an alternative possibility being food sensitivity.
M1162
Is Only PPI Administration Actually Effective? ; Possible Synergistic Effect of
Enterokinetic Agent
Hideyuki Miyachi, Nobuo Aoyama, Daisuke Shirasaka, Ikuya Miki, Masanori Toyoda,
Mitani Toshifumi, Yuko Matsumoto, Yoshinori Morita, Takao Tamura, Hiromu Kutsumi,
Hideto Inokuchi, Takeshi Azuma, Masato Kasuga
[Background] Proton pump inhibitors (PPIs) are routinely administered in the gastroenterol-
ogical field to treat gastroesophageal reflux disease (GERD) and peptic ulcers. PPIs are
unstable in the presence of gastric acid, and have been developed as enteric-coated tablets.
To obtain stable effects, these tablets must be rapidly excreted out of the stomach after oral
administration. Some studies have reported that atrophy of the gastric mucosa and diabetes
delay gastric emptying. However, few studies have investigated the influence of orally
administered PPIs and synergistic effect of enterokinetic agents on gastric emptying. [Aim]
Using 13C-acetate, not absorbed in the stomach and initially absorbed in the small intestine,
we investigated the influence of rabeprazole and domperidone on gastric emptying. [Methods]
The subjects were 12 healthy adults (8 males, 4 females, H. pylori+: 9 patients, -: 3 patients)
with a mean age of 30.5±4.3 years. Gastric emptying was measured by an expired breath
test with 13C-acetate before administration (Day 0), 7 days after the start of oral administration
of rabeprazole at 10 mg (once a day) (Day 7), and after 7 days of subsequent therapy with
rabeprazole at 10 mg (once a day) and domperidone at 30 mg (3 times a day) (Day 14).
Atrophy of the gastric mucosa was evaluated according to the PG I/II. [Results] Tmax
(min), T1/2 (min), and GEC values before administration were 58.1±6.5, 100.1±11.8, and
3.63±0.19, respectively. On Day 7, the values were 69.9±10.7, 108.1±15.3, and 3.32±0.41,
respectively; gastric emptying was significantly delayed (P <0.05). However, on Day 14, the
values were 61.0±11.3, 98.7±13.9, and 3.19±0.35, respectively; delayed gastric emptying
was significantly recovered (P <0.05). No subjects had advanced atrophy of the gastric
mucosa. [Conclusion] PPI therapy delayed gastric emptying. However, it was improved by
combination therapy with domperidone. Delayed gastric emptying may have been associated
with PPI-related hypoxia and hypergastrinemia. Considering that delayed gastric emptying
may be involved in the development and deterioration of GERD, combination therapy with
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PPI and enterokinetic agent should be recommended for those with severe GERD and/
or diabetes.
M1163
Does Hemodialysis Improve Gastric Motility and Gastrointestinal Symptoms
in Patients with Chronic Renal Failure?
Takeshi Kamiya, Hiroshi Adachi, Makoto Hirako, Michiko Shikano, Eriko Matsuhisa,
Makoto Sasaki, Hiromi Kataoka, Takashi Joh
Background: There have been several reports concerning impaired gastric motility in patients
with chronic renal failure (CRF), and most of these studies did not distinguish the patients
on dialysis from those treated conservatively. We have previously demonstrated that the
patients with predialysis end-stage renal disease showed a high prevalence of gastrointestinal
(GI) symptoms and gastric hypomotility, including impaired gastric myoelectrical activity
and delayed gastric emptying, and that gastric hypomotility appears to be an important
factor in the generation of GI symptoms (J Gastroenterol. 2005). However, it is not clear
whether impaired gastric motor function would improve after the hemodialytic treatment.
Aims: Measure gastric myoelectrical activity and gastric emptying in patients with CRF on
hemodialysis to elucidate the effect of treatment on gastric motility and GI symptoms.
Methods: The study was performed in 21 patients with CRF treated with hemodyalysis for
more than 6 months. The control group comprised 12 asymptomatic matched healthy
volunteers. All patients completed a self-administrated questionnaire to assess subjective GI
symptoms. The symptom scores were summed in each patient, giving a total score ranging
from 0 to 15. Gastric motility was evaluated with gastric myoelectrical activity by cutaneous
recorded electrogastrographs (EGGs) and gastric emptying using the 13C-octanoic acid
breath test. EGG was recorded for 60 min during fasting and after the test meal respectively,
and the percentage of normal 2-4 cpm slow wave (normogastria) and power ratio were
evaluated for each subject. Breath samples were collected at 15 min intervals during the 3
hours after the meal, and half emptying time (T1/2) was used to assess the degree of gastric
emptying. Results: Eight patients (38.1%) had no symptoms, and 11 (52.4%) had slight GI
symptoms with a total symptom score of less than 5. Only 2 demonstrated a score of more
than 5. The CRF patients had a significantly lower percentage of normogastria in a fasting
state. No significant difference was observed in EGG power ratio and in T1/2 between
healthy control and CRF patients. Twelve patients had normal gastric motor function (Group
A), and 9 showed abnormalities of either gastric myoelectrical activity or gastric emptying
(Group B). There was no difference in symptom score between Group A and Group B.
Conclusions: More than half of the patients with CRF on hemodialysis demonstrated normal
gastric motility, and most of CRF patients had either no GI symptoms or only slight ones.
Hemodialytic treatment might improve impaired gastric motility and reduce GI symptoms
in patients with CRF.
M1164
Effect of Sildenafil On Gastric Function Assessed with Magnetic Resonance
Imaging
Jeoffrey J. Haans, Noortje P. Paridaans, Paul H. Eilers, Joost Doornbos, Albert De roos, Ad
A. Masclee
Previous gastric barostat studies have shown that gastric accommodation consists of an
adaptive relaxation of the stomach that is larger than the volume of the meal provided.
However, when measured with Magnetic Resonance Imaging (MRI) adaptive relaxation
consists solely of an adaptation equal to the volume of the meal provided. Sildenafil, a PDE
type 5-inhibitor, is known for its smooth muscle relaxing effect and has been shown to
enhance adaptive relaxation when measured with the barostat. Aim of our study was to
evaluate the effect of sildenafil on gastric emptying, gastric accommodation and intragastric
meal distribution measured with MRI in a randomized single blind placebo controlled study.
Twelve healthy subjects (two men; mean age 21.3 years; BMI 23 ± 3 kg m-2) participated
in two experiments performed on separate days. MRI was used to measure momentary
volumes prior to administration of sildenafil 50 mg or placebo orally. Volumes were obtained
every 5 min, starting 30 min prior to ingestion of a meal, up until 90 min and thereafter
at 120, 180 and 240 min. The meal (205 kcal) consisted of a scrambled egg, two slices of
bread and margarine. At the start of the experiment fasting stomach volumes did not differ
significantly between the sildenafil and placebo experiment; 51 ± 27 vs 52 ± 24 ml resp.
Immediately after meal ingestion both stomach volume and contents volume did not differ
significantly between the sildenafil and placebo experiment; 251 ± 48 vs 266 ± 30 ml resp.
for the stomach volume and 182 ± 29 vs 195 ± 20 ml resp. for the contents volume.
Throughout the experiment both stomach volume and contents volume were significantly
(p<0.01) higher for the sildenafil experiment compared with placebo; mean difference of
16 ml [9-24] for the stomach volume and 13 ml [7-18] for the contents volume. This
difference was not due to a difference in gastric emptying rate between the sildenafil and
placebo experiment; 0.64 ± 0.25 vs 0.77 ± 0.11 ml min-1 resp. Immediately after meal
ingestion air volume increased significantly in both the sildenafil and placebo experiment;
69 ± 34 vs 71 ± 23 ml resp. Throughout the experiment air volume did not differ significantly
between the experiments. Proximal gastric contents volumes were significantly larger
throughout the sildenafil experiment compared with placebo, whereas distal gastric contents
did not differ between the experiments. We conclude that measured with MRI, and under
physiological conditions, sildenafil does not induce an increased gastric accommodation
response. Moreover, sildenafil does not influence the rate of gastric emptying, but does
influence intragastric meal distribution.
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M1165
Experience with Change of Stimulation Settings in Patients with Gastric
Electrical Stimulation (GES)
Hasse Abrahamsson, Stina Andersson, Gisela Ringstrom, Magnus Simren, Hans Lonroth
GES has a significant effect on nausea and vomiting in some disorders, e.g. diabetic and
idiopathic gastroparesis (DGP, IGP). However, despite significant symptom decrease consid-
erable symptoms may remain. Increase of stimulation (stim) current and impulse (imp)
frequency may have additional effect (Abell et al). One concern is that battery life shortens
exponentially at stim above 3.5 V. We studied the effect of altered stim settings in five
patient (pt) groups treated with GES for drug refractory nausea and vomiting. METHODS:
21 pts with chronic GES treatment (Enterra, Medtronic) having the standard bipolar stim
(5 mA, 14 Hz, stim on 0.1 sec, stim off 5.0 sec) were included. The diagnoses were: DGP
7 pts, IGP 3 pts, chronic intestinal pseudo-obstruction (CIP) 3 pts, postsurgical gastroparesis
(PSGP) 4 pts, and functional dyspepsia (FD) 4 pts. Indications for stim changes were either
residual symptoms at standard stim, relapse of symptoms for ≥2 months, or new upper
abdominal symptoms linked to the stim preventing voltage increase of stim. The main
symptoms evaluated were nausea, vomiting and regurgitation at night. Improvement within
3 weeks and maintained after three months was considered a positive response. The order
of stim change was: increase of current to 7.5 mA, increase to 10 mA, 2 to 5-fold increase
of imp/min by decrease in OFF time/increase in ON time. In addition, change of the polarity
for stim using the subcutaneous imp generator case as anode and one or both gastric
electrodes as cathode (monopolar stim) was tried in 5 pts. RESULTS: The proportion of
responders to stim at 7.5 mA was significantly larger in pts with established 'organic' etiology
(7/7 DGP pts, 3/3 CIP pts, 4/4 PSGP pts) compared with 'functional' disorders (IGP 0/3
pts, FD 1/4 pts)(P=0.0001). Only one pt (PSGP) out of five had additional effect of increased
stim frequency. With changed polarity (case positive) the impedance was decreased compared
with standard bipolar setting by 28% (range 25-30) for individual electrodes and by 49%
(range 44-53) when both electrodes were cathode. Two pts (FD 1, IGP 1) who did not
tolerate bipolar stim at 5 and 7.5 mA, respectively, improved with monopolar stim at a
voltage reduced according to the lower impedance. Three pts (FD 2, IPG 1, non-responders
to increased voltage and imp/min with bipolar stim) did not improve with monopolar stim.
CONCLUSION: Increase of GES current by 50% yielded a high response rate in patients
with DGP, CIP and PSGP. The response in two patients to monopolar stim with the stim
case as anode and effects at a low stim voltage is interesting and warrants further studies,
e.g. with respect to battery life.
M1166
The Relationship Between Psychosocial Factors, Somatization & Gastric
Sensitivity in Functional Dyspepsia
Lukas Van oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Benjamin Fischler,
Koen Demyttenaere, Jan Tack
Background Several studies have shown that a subgroup of functional dyspepsia (FD)
patients are hypersensitive to gastric distension. However, gastric sensitivity testing relies
on subjective reporting and the impact of psychosocial factors and somatization on symptom
intensity reporting remains unclear. Aim To determine the relationship between psychosocial
factors and somatization on one hand and gastric discomfort and pain thresholds on the
other hand. Methods In 175 consecutive tertiary care FD patients (mean age 40±13), gastric
sensory function was studied with a barostat. Psychosocial factors (depression, anxiety,
positive & negative affect, alexithymia, perceived stress & abuse history), somatization
(exclusive of GI symptoms) and functional somatic symptoms (dyspepsia, IBS & chronic
fatigue symptoms) were assessed using self-report questionnaires. Psychosocial factors &
somatization measures were correlated with gastric discomfort and pain thresholds. Their
univariate correlates were entered into a multiple linear regression model. Results Univariate
associations: Discomfort threshold: Age, positive affect & lifetime history of physical &
psychological abuse were positively associated with discomfort threshold, whereas childhood
history of sexual abuse, somatization, dyspepsia symptom score, momentary fatigue &
presence of comorbid IBS were negatively associated with discomfort threshold. Pain thresh-
old: Female gender, lifetime history of sexual abuse & comorbid chronic fatigue symptoms
were associated with lower pain threshold. Multiple linear regression: Discomfort threshold:
Lifetime history of physical abuse (β=-3.3, p=.0008), childhood history of sexual abuse (β=
2.5, p=.04) and somatization (β=-0.3, p=.01) were found to be independently related to
discomfort threshold (model controlling for age (β=0.08, p=.01) and work status (NS), R2=
0.31, p=0.0004). Pain threshold: Lifetime history of sexual abuse (β=2.6, p=.005) and
comorbid chronic fatigue symptoms (β=1.5, p=.05) were found to be independently related
to pain threshold (model controlling for gender (NS), R2=0.19, p=0.001). Conclusion These
results confirm the complex relationship between psychosocial factors (especially history of
abuse), somatization and gastric sensory thresholds as measured by barostat. Whether the
influence of abuse history on gastric sensory function is mainly determined by “hard-wired”
neurobiological processes influencing pain-processing systems or rather by psychological
processes including hypervigilance or hyperarousal remains to be elucidated.
M1167
Influence of Duodenal Acidification On Meal-Related Symptoms and Satiety
Induced By the Slow Nutrient Drink Test in Man
Kostas Mimidis, Filiz Akyuz, Heleen Nicolai, Rita Vos, Tim Vanuytsel, Jan Tack
A subset of functional dyspepsia (FD) patients have increased duodenal acid exposure (Lee
2004). We recently showed that duodenal acidification induces proximal gastric relaxation,
increases sensitivity to gastric distention, and inhibits meal-induced accommodation (Lee
2004). The impact of duodenal acidification on meal-related dyspeptic symptoms is
unknown. Aim: To study the effect of duodenal acidification on maximum tolerated nutrient
volume and postprandial symptoms. Materials and methods: 14 healthy volunteers (mean
age 24.9±1.4 years) underwent a satiety drinking test twice, with administration of saline
or 0.1 N HCL in a double-blind randomized cross-over design, via a thin nasoduodenal
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tube, positioned in the second part of the duodenum. Infusion of acid or saline at 5ml/min
was started 15 min before the drinking test and continued 30 min thereafter. A peristaltic
pump filled one of two beakers at a rate of 15 ml/min with a liquid meal (Nutridrink®).
Subjects were requested to maintain intake at the filling rate, alternating the beakers. At 5-
minute intervals, they filled out a visual analogue scale for 10 epigastric symptoms and to
score their satiety using a graphic rating scale that combined verbal descriptors on a scale
graded 0-5 (1=threshold, 5=maximum satiety). Meal intake was stopped when a score of 5
was reached. Participants were monitored three hours after reaching maximal satiety. Using
a visual analogue scale (VAS), the postprandial evolution of satiety and other meal related
symptoms were evaluated every 15 minutes. Nutrient tolerance, area under the curve (AUC)
for symptom intensities and symptom satiety scores were recorded and compared by paired
t-test and ANOVA. Results: Duodenal acid perfusion significantly decreased nutrient tolerance
(max intake 630±221 vs. 472±162 ml, p=0.0009). During acid perfusion significantly higher
symptom scores were obtained for fullness (AUC 1151.8±92.6 vs. 1607.1±146 mm*min,
p=0.0013), satiety (AUC 1180.4±81.9 vs. 1532.1±146.1 mm*min, p=0.0096) and epigastric
burning (AUC 39.3±29.1 vs. 285.7±125.8 mm*min, p=0.0390). The other symptoms -
bloating, discomfort, nausea, heartburn, belching, epigastric pain and abdominal cramps,
were not altered. First sensation of satiety also occurred significantly earlier during acid
perfusion (5.7 vs. 10 ml, p=0.003). No differences in the evolution of symptom intensity
scores occurred during postprandial follow-up. Conclusion: Duodenal acid perfusion reduces
maximum tolerated nutrient volume and increases meal-related symptoms such as fullness
and satiety. These observations support the pathophysiological relevance of increased duo-
denal acid exposure in FD.
M1168
Migrating Activity Fronts Are Associated with Duodenal Axial Shortening
Johanna Wennerblom, Eva Een, Claes Jonson, Soren Lundberg, Lars Fandriks
Background/Aim: It is well known that circumferential intestinal contractions create pressure
gradients that mix and propel the luminal contents. The function of the longitudinal muscular
layer, on the other hand, is less obvious and has because of lack of appropriate methodology
been only sparsely explored. The present study investigates in man longitudinal movements
of the duodenum simultaneously with conventional side-hole manometry. Methods: Five
healthy volunteers were subjected to gastroduodenoscopy. Radio-opaque clips were attached
to the mucosa of the descendo-horisontal parts of the duodenum. On a separate study day
the presence of the mucosal clips was confirmed by use of fluoroscopy.The volunteer was
then intubated with a naso-gastroduodenal manometric catheter with 8 sideholes positioned
in the descendo-horisontal part of the duodenum. During various motility patterns position
of the clips were captured by fluoroscopy. Interclip distances were determined by relating
the clips to radioopaque indicators of known size situated within the intraluminal manometric
catheter. ”Activity fronts” were defined as either endogenous migrating motility complex
(MMC) phase III, or a similar cluster of coordinated contractions propagating distally upon
administration of erythromycin (50 mg i.v.) during MMC phase I. Results: Seven MMC
phase III were recorded and were all associated with a duodenal shortening (mean: -27%;
range: -8 to -40%) as compared to duodenal segmental length during the preceding phase
II motor activity (p<0,005). The duodenal length returned to control values upon transition
to MMC phase I. Eight erythromycin-induced activity fronts were analysed and also these
exhibited segmental duodenal shortenings (mean: -22%; range: -6 to -56%) when compared
to the length of each segment during preceding MMC phase I. Motor activity of two or
three consecutive duodenal segments were analysed in three subjects and demonstrated that
the duodenal shortening was confined to the duodenal segment harbouring the activity
front. Conclusion: A longstanding duodenal shortening migrates together with a circular
motor activity fronts. Such duodenal axial motor activity is a previously almost unrecognised
phenomenon in man. Biomechanical consequences during physiological and pathological
conditions remain to be explored.
M1169
Outcome of Gastric Electrical Stimulation (GES) for Non-Established
Indications. Role of Temporary Percutaneous GES for Patient Selection
Hasse Abrahamsson, Magnus Simren, Gisela Ringstrom, Hans Lonroth, Anders Elfvin,
Stina Andersson
GES is often effective in diabetic gastroparesis with drug refractory nausea/vomiting while
a non-responder frequency of 35-50% has been reported for idiopathic gastroparesis. We
studied the outcome of chronic GES for other indications after initial patient (pt) selection
with temporary percutaneous GES (TPGES). METHODS: TPGES (Gastroenterology
2006;130, Suppl 2:A-430) was tested for 1-6 weeks (w) in 14 pts with drug refractory nausea
and/or vomiting. Ten responders (7 functional dyspepsia, FD, 2 postsurgical gastroparesis, 1
chronic intestinal pseudoobstruction, CIP) were selected for permanent implant. Three pts
were selected from double-blind crossover TPGES while 7 pts had responded during open
stimulation (stim) for 1-6 weeks. Implantation for permanent GES (Enterra, Medtronic) was
done laparoscopicly. Pts are followed up with symptom diaries and visits 3, 6, 12 and 24
months after surgery. RESULTS: During TPGES the seven pts responding to open stimulation
had less nausea (11 vs. 19.3 hrs/w, mean) and lower weekly vomiting frequency (1.6 vs.
5.1 vomits/w) compared with baseline. The three pts selected from double blind TPGES
had a reduction of main symptom (nausea or vomiting) > 80% (82, 85, 87%) during stim
ON compared with the stim OFF period. At the 6 months follow up 8 of the 10 pts were
improved compared to baseline (including the double blind responders). One pt requiring
increased stim at 8 mA for response during TPGES also required this stim efter permanent
implant. Two FD pts (responders only to open TPGES) were not improved at 6 months
compared to baseline, neither with standard settings (5 mA, 12 stim/min), nor with increased
stim strength and frequency. For seven patients who have passed the 12-month control the
responder/nonresponder outcome was unchanged compared to 6 month. CONCLUSION:
The present results together with other recent publications, indicate that chronic GES is a
treatment option for some new patient categories with severe nausea and vomiting. TPGES
is a promising tool to select patients for permanent implantation and should preferably be
performed under double-blind crossover conditions.
M1170
The Effect of short-Term, Low-Dose Tricyclic and Tetracyclic Antidepressant
Treatment On Satiation, Post-Nutrient Load Gastrointestinal Symptoms and
Gastric Emptying: A Double-Blind, Randomized, Placebo-Controlled Trial
Rok seon Choung, Filippo Cremonini, G. richard Locke, Alan R. Zinsmeister, Prabin
Thapa, Nicholas J. Talley
Background Antidepressants are commonly prescribed for patients with functional dyspepsia.
The rationale for the use of antidepressants in this condition includes (1) reduced central
processing of visceral pain stimuli and (2) modulation of gut sensorimotor functions. How-
ever, the effect of tricyclic antidepressants on satiation and gastric emptying remains unclear,
and there are no data for tetracyclic compounds. Aims To compare the effects of nortriptyline
(50 mg od. hs.), mirtazapine (30 mg od. hs.) and placebo on gastric satiation, gastric
emptying, and postprandial symptoms after a nutrient load in healthy volunteers. Methods
Randomized, double-blind, placebo-controlled study evaluated gastric function before and
after 14 days of nortriptyline (n= 13), mirtazapine (n=12), or placebo (n=14) in healthy
volunteers. Validated methods were used to study gastric emptying and satiation post-
nutrient challenge. Results The 3 arms were comparable with regard to age, gender, body
mass index, and HAD (hospital anxiety and depression) score. There were no statistically
significant effects of mirtazapine or nortriptyline on gastric emptying compared to placebo.
Maximum tolerated volume was similar on drug and placebo (table, p=0.55). Aggregate
symptom score 30 minutes post maximum tolerated volume after nutrient drink challenge
on placebo was 128 (± 20.7), versus 170 (± 22.2) on mirtazapine, and 124 (± 20.9) on
nortriptyline 50 mg, respectively (p=0.28). Conclusion Tricyclic and tetracyclic antidepress-
ant agents do not appear to have significant effects on gastric motor and sensory function
in healthy individuals. The tetracyclic mirtazapine appeared to potentially worsen symptom
score with nutrient drink challenge although this was not significant.
Table. Post treatment nutrient drink test maximum tolerated volumes and symptom scores
(30 minutes post) on mirtazapine, nortriptyline and placebo.
† mean (±SE), Symptoms Scores on 100 mm VAS
M1171
The Role of Synaptic Plasticity On the Rats with Visceral Hypersensitivity
Induced By Acute Restraint Stress
Xiaojun Yang, Yang Guan, Wei Qian, Lei Shen, Xiaohua Hou
Aims: Visceral hypersensitivity is found in rats after acute partial restraint stress (APRS), but
its mechanism is unclear. The aim of our study is to find if the changes of synaptic plasticity
in ENS play any role on visceral hypersensitivity in ARS rats. Methods: In this study, adult
male Sprague-Dawley rats (n=20) weighing about 200-250g were randomly divided into
control group and APRS group. We detected abdominal electromyography (EMG) while
graded CRD (20, 40, 60, 80mmHg, 10s) was applied in both groups. The CRD was repeated
three times and mean number was used to evaluate the visceral sensitivity. The ultrastructure
of synapse was observed with transmission electron microscope. RT-PCR was employed to
detect synaptophysin mRNA in the ileocecum, proximal and distant colon. We also detected
synaptophysin, PSD95 and calbindin protein using Western-blot. Results: (1)The numbers
of EMG discharge showed significantly positive correlation with CRD pressure in control
group (r=0.992, P=0.008) and APRS group (r=0.978,P=0.022). While, under the pressure
of 40mmHg,60mmHg,80mmHg, the numbers of EMG discharge in APRS group were signific-
antly increased comparing with control group (193.76±104.90vs.923.60±842.95,
506.791±202.65 vs.1545.93±1022.11, 742.47±490.60 vs. 1714.20±916.23; P=0.043,
0.024, 0.038 respectively). (2) With qualitative synapse ultrastructure assay, more synaptic
vesicles accumulated in the presynaptical terminal and increased PSD was also shown in
APRS rats than controls. (3) In proximal and distant colon, synaptophysin mRNA expression
was statistically higher in APRS rats than controls (0.28±0.08 vs. 0.69±0.14, 0.92±0.20
vs.0.54±0.16; P=0.015, 0.010 respectively). (4) In ARS rats, the protein expression of
synaptophysin, PSD95 and calbindin were all upregulated in proximal (P=0.033, 0.042,
0.027 respectively) and distant colon (P= 0.045, 0.031, 0.047 respectively). In comparison
of control rats, the expression of three proteins was elevated in the ileocecum, but there
was no statistical difference. Conclusion: Synapse in enteric nervous system shows plasticity
induced by acute restraint stress. Synaptic plasticity plays an important role in the formation
of high visceral hypersensitivity.
M1172
Ingestion of Capsaicin Capsules Induces Symptoms in Patients with Non
Ulcer Dyspepsia: Chemical Hypersensitivity Or Hypervigilance?
Martina Führer, Harald Vogelsang, Johann Hammer
Introduction: The ingestion of capsules containing capsaicin, the pungent ingredient of
chili pepper, induces more intense upper GI sensations in patients with non ulcer dyspepsia
(NUD) than in health, in patients with inflammatory bowel disease (IBD), peptic ulcer
disease (PUD), and other GI disorders. Whether this is due to chemical hypersensitivity or
hypervigilance is yet not clear. Aims: 1) to further evaluate whether oral ingestion of capsaicin
containing capsules ('capsaicin test') induces more symptoms in patients with NUD than in
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health and in patients with upper GI symptoms of other origin. 2) to determine whether
in NUD patients the symptoms induced by the ingestion of capsaicin capsules are due to
chemical hypersensitivity or hypervigilance. Methods: N=200 outpatients (73 NUD, 26 IBD,
23 PUD, 36 irritable bowel syndrome (IBS) and 42 other diseases) and N=86 healthy controls
swallowed a capsule containing 0,75mg capsaicin after an overnight fast. Subjects completed
a graded questionnaire evaluating intensity of 9 different upper GI symptoms (5 grades per
symptom) before and 30 minutes after capsule ingestion. Symptom scores were summarized
and a score difference (score after minus score before capsule ingestion) was calculated;
according to previous findings, a score difference >9 was considered as positive test. Addi-
tional N=20 healthy subjects and N=13 NUD patients who had a positive test received a
second capsule containing placebo. NS=not significant. Results: Score difference in NUD
was 9.5±6.2, i.e. significantly higher than in PUD (1.9±5.0, p<0.001), IBD (4.5±4.7; p<0.01),
IBS (5.2±4.9; p<0.05) and ‘other GI disorders' (2.9±3.4; p<0.001), as well as healthy controls
(6.5±4.3; p<0.001). 51% of patients with NUD had a positive test, 49% a negative test. The
result of the capsaicin test was independent of the subgroup of NUD (pain or discomfort
predominant). Healthy subjects (n=20) had a symptom score of 1.0±1.9 when receiving
placebo and 2.5±2.1 after capsaicin. NUD patients (n=13) had a score difference of 2.0±1.7
after placebo (NS vs. health) and 15.8±2.6 after capsaicin. No patient had a positive test
after placebo. Conclusion: Capsaicin induces symptoms in patients with NUD due to
chemical hypersensitivity rather than hypervigilance (no reaction to placebo). Chemical
hypersensitivity discriminates functional disorders from healthy controls and patients with
other upper GI disorders. The capsaicin test is a simple and non invasive method to detect
a subgroup of functional dyspepsia with chemical hypersensitivity. Targeting the VR1 receptor
might be a therapeutic option in a large subgroup of patients with functional dyspepsia.
M1173
Regional Brain Activation During Gastric Distension in Functional Dyspepsia
(FD): A H2O15-PET Study in Normo- and Hypersensitive Patients
Lukas Van oudenhove, Patrick Dupont, Joris Vandenberghe, Brecht Geeraerts, Dominique
Vanderghinste, Guy Bormans, Koen Van laere, Stijn Dirix, Rita Vos, Benjamin Fischler,
Koen Demyttenaere, Jan Tack
Background & Aim In FD patients with visceral hypersensitivity, gastric balloon distension
activates somatosensory cortices (SI/SII) & lateral orbitofrontal cortex (LOFC), but not
anterior cingulate or insula (Vandenberghe 2007). It is unclear whether these findings would
apply to mixed normo- & hypersensitive FD. Methods Brain H2O15-positron emission
tomography (PET) was performed in 22 FD patients (17 women, mean age 32, 11 hypersensit-
ive) during 3 conditions (randomized order): no distension (baseline), sham distension
(anticipated, not delivered) & distension at individual pain threshold. Psychosocial factors
were measured using self-report questionnaires. PET data were co-registered with MRI
scans & analysed using statistical parametrical mapping (SPM2). Subtraction analyses were
performed to determine activations and deactivations during pain & sham compared to
baseline. Statistical threshold was set at pcorrected<0.05(cluster level). Results Pain-Baseline
showed activation in the following areas: 1. large anterior clusters bilaterally (both
pcor<0.0001) with local maxima in the anterior lateral temporal cortex [gyrus temporalis
superior, medius & inferior (Brodmann Areas (BA) 20,21,22,38)]; LOFC [gyrus frontalis
medius & inferior (BA 47,10)] & frontoparietal operculum (including SII) [gyrus pre- &
postcentralis, gyrus frontalis inferior (BA 6,43,44)]. 2. bilateral cerebellum (both
pcor<0.0001). 3. right insula (pcor=0.01). Baseline-Pain showed activation in the following
areas (deactivation during pain): 1. large posterior bilateral cluster (pcor<0.0001) with local
maxima in parietal & occipital sensory (association) cortices (BA 7,37,39,40,18,19); posterior
lateral temporal cortex (BA 20,21,22); dorsal precentral gyrus (BA 6,8) & dorsal SI (BA 2,3).
2. left medial prefrontal cortex (BA 10) (pcor=0.0001). 3. medial orbitofrontal cortex (BA 11)
(pcor=0.0002). Sham-Baseline & Baseline-Sham showed no significant activations. Conclusion
Brain activation during gastric distension was comparable to findings reported in the hyper-
sensitive FD subgroup. However, extensive deactivations during pain were found in this
mixed group, mainly in posterior brain areas involved in exteroceptive sensory processing.
This may reflect a shift from exteroceptive to interoceptive processing during gastric distension
in FD patients. Ventromedial prefrontal deactivation during pain is consistent with its role
in processing appetitive stimuli or may be implicated in dysregulation of visceromotor
responses. Subsequent analyses will include direct comparisons between both subgroups
and covariate analyses to assess the influence of psychosocial factors on brain activation.
M1174
Determinants of Health-Care Utilization in Patients with Functional Dyspepsia
(FD) Treated in a Tertiary Referral Setting: Symptom Intensity, Psychiatric Co-
Morbidity Or Impaired Quality of Life?
Sebastian Haag, Sefik Tagay, Wolfgang Senf, Ute Braun-lang, Angelika Pietsch, Gereon
Heuft, Nicholas J. Talley, Gerald Holtmann
Background: Even though patients with functional dyspepsia (FD) have a high health-care
utilization, data about predictors of consultations are remarkably sparse. Therefore we aimed
to characterize the links between health-related quality of life (HRQOL), psychological co-
morbidities and health care utilization in FD patients. Methods: 147 consecutive FD patients
with chronic refractory symptoms (>5 years) were investigated. 278 healthy consecutive
blood donors (BD) served as controls. Utilizing validated instruments, generic and disease-
specific HRQOL (SF-36 Mental (MCS) and Physical Composite Scores (PCS), Nepean Dyspep-
sia Index-NDI), psychological morbidity (SCL-90-R), sense of coherence (SOC), and anxiety
and depression (HADS) were assessed. In FD patients the number of consultations due to
FD symptoms during the 12 months prior to referral was assessed as the dependent variable.
Results: During 12 months before presentation at the tertiary center and compared to BD,
FD patients had on average 25.7 (95% CI 21.0-30.4) vs. 2.7 (1.3-5.4, p<0.001) consultations,
while 12 months after referral the consultation rate dropped to 9.4 (7.5-16.7). In FD patients
but not BD, health care utilization was significantly linked to psychological co-morbidity
(adjusted r2=0.22) but not symptom severity or sociodemographic status. In FD, HRQOL
was significantly impaired compared to controls (PCS = 40.4±8.6 vs. 55.5±5.5; MCS =
38.8±11.7 vs. 51.6±8.5, p both <0.0001). In FD, stepwise multiple regression yielded
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symptom severity (p<0.001) and age (p<0.002) as independent predictors (adjusted r2=
0.36) of PCS. MCS was independently predicted by depression (p<0.001), symptom severity
(p<0.005), and stress (p=0.022) (adjusted r2=0.60). Dyspepsia-specific HRQOL was inde-
pendently explained by symptom severity (p<0.001), depression (p<0.005), and autonomic
sensations (p=0.021) (adjusted r2=0.47). Conclusion: In FD patients seen at a tertiary referral
center, resource utilization is very high prior to referral. While in FD, HRQOL is severely
impaired compared to controls, health care utilization is closely linked to psychiatric co-
morbidity rather than symptom severity. The data suggest that addressing psychiatric co-
morbidity might be a key issue to reduce health care expenditures in FD patients.
M1175
Relationship Between the Frequency of Gastric Contractions and Gastric
Emptying of a Non-Digestible Solid in Controls and Gastroparetics Using
Smartpill Pressure Recording Capsule: Its Future Clinical Potential
Irene Sarosiek, Savio Reddymasu, Kenneth Koch, William Hasler, Jeff Lackner, Leonard
Katz, Michael Sitrin, Henry Parkman, John Wo, Jerzy Sarosiek, William Chey, Jack
Semler, Braden Kuo, Richard Mccallum
Introduction: The SmartPill (SP) wireless pH and pressure recording capsule has been
recently approved by the FDA for assessment of gastric emptying. The rate of gastric
contractions sets the stage for the transit times within the stomach and beyond. Non-
digestible solids are thought to empty with the return of the phase III migrating complex
in the inter-digestive stage. Aims: To utilize SP wireless technology to explore the correlation
between frequency of gastric contractions (FGC) and GRT of non-digestible solids in asympto-
matic volunteers and patients with gastroparesis (GP). Methods: In a multicenter study, 55
asymptomatic volunteers (21F, 34 M, mean age of 35y) and 23 patients with GP of diabetic
and idiopathic etiology (16F, 7 M, mean age of 45y) swallowed the SP after an overnight
fast together with a isotope-labeled standardized meal of 120 g Eggbeaters, 2 pieces of bread
with jam; 255 kcal, (2% fat) and 120 cc water. The TTT was measured from the time of
ingestion of the wireless capsule until a drop in temperature or abrupt loss of signal associated
with a bowel movement confirmed by patients' diary. The time between ingestion of SP
and the rapid, sustained rise of and at least 3 pH units from baseline and exceeding pH
4.0 was defined as GRT. A sudden drop of more than 1 pH unit for >5 min. was regarded
as an ileo-caecal (I-C) arrival. By subtracting GRT from I-C junction time, SBTT was calculated,
and in turn LBTT was determined. FGC/minute (CPM) were assessed within the last hour
of the gastric SP residency time and divided into three 20 min intervals (time 60-40min;
time 40-20min and time 20-0min, where 0 is SP exit from the stomach). Results: In GP
patients a significant negative correlation was found between GRT (r=-0.609; P<0.01) and
FGC for the 20 min period before the capsule emptied from the stomach but not in controls.
GPs also had significantly fewer contractions as a group than controls over the 60-0 min
period 61.6 vs. 107.1 CPM (p=0.0013). On the other hand, a significant correlation was
found between TTT and FGC at 60-20 min period (r=0.282; P<0.05) as well as 20-0min
period (r=0.294; P<0.05) in controls but not in patients with GP. Of interest, was a significant
correlation between LBTT and FGC at 60-20 min (r=0.332; P<0.02) as well as 20-0min
periods (r=0.412; P<0.005) in controls but not in GPs. Conclusions: 1) GPs have impaired
gastric interdigestive motility associated with a prolong GRT, consistent with an underlying
neuropathy in these patients. 2) SmartPill technology can non-invasively explore correlations
of interdigestive motility associated with a non-digestible solid in different regions of the gut.
M1176
Role of Mucosal Nerve Endings in Acid-Induced Duodenogastric Sensorimotor
Reflexes in Man
Tim Vanuytsel, Kostas Mimidis, Filiz Akyuz, Rita Vos, Jan Tack
Background Recently, we reported increased duodenal acid exposure in a subgroup of
functional dyspepsia patients with higher symptom scores. In healthy controls, duodenal
acid induces gastric relaxation and sensitizes to gastric distension (Lee 2004). The pathway
underlying this duodenogastric inhibitory motor and sensitizing reflex remains unknown.
The aim of our study was to investigate the role of local mucosal nerve endings in duodenal
acid-induced gastric changes. Materials and methods Thirteen healthy volunteers (5 men,
mean age 24.9±1.9 years) were studied on two occasions, at least one week apart. Two infusion
tubes with attached pH electrode were positioned in the second part of the duodenum, and
a barostat bag was located in the gastric fundus. Proximal stomach tone and sensitivity to
isobaric distensions were assessed before and during duodenal acid infusion of 0.1 N HCl,
after 15 minutes pre-treatment with duodenal saline or a 0.75% benzocaine preparation in
a randomized, double-blind, cross-over fashion. Duodenal pH-measurement and assessment
of 9 dyspeptic symptoms by means of 100 mm visual analogue scales (VAS) were obtained.
Results are given as mean±SEM and compared by Student's t-test and single factor ANOVA.
Results Prior to acidification, duodenal benzocaine perfusion induced a relaxation of the
proximal stomach, which did not occur with saline (volume increase of 111±32ml vs. 3±20
ml; p<0.01). This was accompanied by a rise in duodenal pH (5.43±0.15 to 6.25±0.08;
p<0,001) during benzocaine and not during saline perfusion, although both solutions had
a similar pH of 7. After benzocaine, acid-induced gastric relaxation was significantly reduced
compared to saline pre-treatment (volume increase of 79±25 ml vs 147±25 ml; p<0.05).
The final volume during acid perfusion, which reflects the accumulation of the solution-
and acid-induced relaxations, was similar after both placebo or benzocaine (355±38 ml vs.
383±44 ml, NS). During isobaric distensions, gastric compliance was increased during
benzocaine perfusion (p<0.01) and not during saline (NS). We did not observe a significant
effect of benzocaine on phasic motility indices of the proximal stomach (32.6±4.33 after
placebo vs. 28.4±6.82 after benzocaine, NS). There was no influence of the local anaesthetic
on the reported symptoms during balloon distension and acid perfusion. Conclusions 1)
Duodenal benzocaine instillation induces gastric relaxation, which indicates the existence
of a duodenogastric excitatory tone. 2) Duodenal mucosal receptors are involved in the
acid-induced duodenogastric inhibitory motor reflex, but not in the acid-induced sensitisation
and symptom generation.
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M1177
Association of Adrenergic, Serotonergic and Cannabinoid Genotype and
Gastrointestinal Motor Function in Patients with Functional Gastrointestinal
Disorders and Healthy Controls
April B. Grudell, Michael D. Ryks, Hugh Gorman, Paula Carlson, Duane Burton, Kari
Baxter, Alan R. Zinsmeister, Michael Camilleri
Background: There is evidence that adrenergic, serotonergic, and cannabinoid mechanisms
alter gut motor functions in humans. Fatty acid amide hydrolase (FAAH) metabolizes the
endocannabinoid, anandamide, which modulates cholinergic function. Patients' genotype
may influence symptom phenotype in patients with functional gastrointestinal disorders
(FGID). Our aim was to examine the association between genotype and gastrointestinal (GI)
motor physiology phenotype in humans. Methods: Using data collected from 2000 to 2006,
a database of 211 people was created combining subjects' genotype data with their GI motor
function acquired using validated scintigraphy including 99mTc-SPECT to measure gastric
volumes. We studied the association between different single nucleotide polymorphisms
(SNPs) or insertions of candidate genes and GI motility endpoints (gastric emptying [GE]
at 2 and 4 h, colonic filling at 6 h, colonic geometric center [GC] at 24 h, fasting gastric
volume [FGV], postprandial change in gastric volume [ΔGV]). The polymorphisms evaluated
were: α2A adrenergic (C-1291G), α2C (Del 332-325), 5-HT transporter (SLC6A4), GNβ3
(C825T), and FAAH gene (385C to A). We sought associations between motor function
and either gene effects (wild type vs grouped non-wild type) or gene by disease group
interactions, adjusting for age, gender and BMI. Results: There were 18 patients with IBS
and alternating bowel habit (IBS-Alt), 39 with IBS-C, 36 with IBS-D, 34 with functional
dyspepsia (FD) and 83 healthy controls. All genotypes were assayed among these 210
participants, except for the FAAH genotype, which was available in 62. Genetic variation
in SLC6A4, α2C adrenoreceptor, and FAAH significantly influenced gastric emptying and
gastric volumes (see table). There were associations with disease groups (see table). There
were no significant associations for colonic transit or for patient groups FD or C-IBS.
Conclusions: Genetic variation in the control of adrenergic, serotonergic and cannabinoid
function may be associated with alterations in gastric emptying and volumes. Further studies
of the potential role of genetic variation in the manifestations of FGID and response to
treatment are warranted.
* IBS-Alt, IBS-D # health, D-IBS, Alt-IBS showed numerically different motor responses in
association with the respective genes
M1178
Gastric Histology in Gastroparesis: Correlation with Gastric Emptying
Justin Harberson, Rebecca Thomas, Sean Harbison, Henry P. Parkman
Pathologic assessment of gastric tissue in patients with gastroparesis is limited. Some patients
with gastroparesis may have reduced number of interstitial cells of Cajal (ICCs) - the
electrical pacemaker cells. It is unclear whether abnormalities in gastric ICCs influence
gastric emptying. AIM: To evaluate the pathology of the gastric ICCs and myenteric plexus
in patients with gastroparesis and correlate the pathologic findings with severity of delayed
gastric emptying. METHODS: Full thickness antral biopsies were obtained in 14 patients
with gastroparesis undergoing placement of a gastric electric stimulator (10 patients with
diabetic gastroparesis and 4 with idiopathic gastroparesis). Control data were obtained from
normal appearing tissue of patients undergoing gastric resection for gastric tumors. Biopsies
were placed in formalin, followed by sectioning and staining for the presence of inflammatory
infiltrate (H&E), presence of nerves (anti-S-100 antibody), and presence of ICCs (c-kit).
Decreased number of ICCs was defined as less than 10 ICCs per high-powered field. Each
patient had previously undergone a gastric emptying scintigraphy (GES) test. The result of
the GES was graded as mild delay (10-20% gastric retention at 4 hours), moderate (20-
40%), severe (>40%). RESULTS: H&E staining showed a mild lymphocytic infiltrate in the
myenteric plexus of nerves and ganglion cells in 7 out of 14 patients (2 of 4 idiopathic
gastroparesis, 5 out of 10 diabetic gastroparesis). S-100 staining showed normal ganglion
cells and nerve fibers in the myenteric plexus in all 14 patients. C-kit staining showed a
reduction of c-kit positive cells in 3 patients - a paucity in both layers of the muscularis
propria. Two other patients had abnormal ICC morphology on c-kit staining with a more
rounded (“stubby”) morphology with less dendritic processes. Both of these patients had
idiopathic gastroparesis. Twelve of the 14 patients successfully completed a GES test (the
other two patients vomited). Of these 12 patients, 9 had severe delay, 1 had moderate delay,
and 2 had mild delay. Out of nine patients with a severe delay of gastric emptying, 4 had
a lymphocytic infiltrate, 3 had decreased numbers of ICCs, one had both lymphocytic
infiltrate and ICC morphologic abnormalities, while one had normal histology. The one
patient with a moderate delay of gastric emptying had ICC morphologic abnormalities. The
two patients with mild delay of gastric emptying had normal histology. CONCLUSIONS:
In this study, most patients with moderate to severe gastroparesis had histologic abnormalities
- either an inflammatory process of the myenteric plexus and/or ICC abnormalities.
M1179
Is Electrogastrogram a Clinical Marker for Depleted Interstitial Cells of Cajal?
Jesse Liu, Linda B. Nguyen, Shelly Parker, Richard Garcia-kennedy, William J. Snape
Background The clinical utility of EGG remains poorly defined. Tachygastria associated with
depletion of interstitial cells of Cajal(ICC) has been described in up to one third of patients
with gastroparesis requiring gastric electrical stimulator(GES) implantation. Identifying typ-
ical EGG findings in patients with loss of ICC may improve GES application. Methods EGG
results and full-thickness antral wall biopsies, performed at the time of GES placement were
reviewed for 11 patients(9 DM,1 postsurgical,1 other). EGG data included fasting and
postprandial dominant frequency(DF)(cpm), normal slow waves rhythm(NSW)(%), tachyga-
stria(T)(%), bradygastria(B)(%), slow wave coupling(SWC)(%) and postprandial power
ratio(PR)(dB). Biopsies were stained with c-kit and graded by a pathologist against a reference
control(1=near complete loss, 2=few, 3=many, 4=equal to control). Intramuscular(ICC-IM)
and myenteric(ICC-M) cells were graded separately. EGG data was compared using Student's
t-test. Results ICC depletion (grade 1-2) was observed in 4/11 patients (2 ICC-IM and ICC-
M,1 ICC-IM,1 ICC-M) but did not correlate with specific EGG findings. Data for ICC-IM+
vs. IM- patients is as follows:(Mean IM+/IM-) NSW-pre: 70/62.2, p=0.61; NSW-post 65/
75.4, p=0.54; DF-pre: 3.1/3.3, p=0.19; DF-post: 2.7/2.9, p=0.46; T-pre: 7.7/17.2, p=0.33;
T-post: 17.7/6.0, p=0.37; SWC-pre: 37.6/50.0(n=2); SWC-post 36.1/44.9(n=2). Data for
ICC-M+ vs. M- patients is as follows:(Mean M+/M-) NSW-pre: 63.1/80.5, p=0.24; NSW-
post 63.3/80.1, p=0.32; DF-pre: 2.9/3.3, p=0.19; DF-post: 2.7/3.0, p=0.21; T-pre: 12.5/4.6,
p=0.42; T-post: 17.3/7.0, p=0.43; SWC-pre: 39.1/42.3, p=0.87; SWC-post 37.3/39.2, p=
0.87. Normal slow waves (>70% recording) were seen in 6/7 patients with normal ICC and
4/4 with loss of ICC. Normal slow wave coupling (>50%) was observed in 2/8 patients with
normal ICC-IM and 1/2 patients with loss of ICC-IM (No data for 1 pt with loss of ICC-
IM). Tachygastria (>15% recording) was absent in 3/3 patients with ICC-M loss. Summary
1) The prevalence of ICC loss (36%) in patients with gastroparesis is consistent with prior
reports. 2) No EGG findings suggestive of ICC depletion were identified. 3) Normal slow
wave activity was observed in all patients with ICC loss. 4) Abnormal slow wave coupling
was observed in 73% of all patients and was not altered by the presence or absence of ICC.
5) Tachygastria was not observed in patients with ICC-M loss. In conclusion, patients with
refractory gastroparesis, irrespective of ICC loss, continue to generate normal slow waves,
but have abnormal slow wave coupling. As such, EGG appears to be a poor clinical marker
for ICC depletion.
M1180
Of Gastric Motor Function By Means of a Satiety Drinking Test and a Gastric
Emptying Breath Test in Childhood Functional Dyspepsia and Obesity
Ilse Hoffman, Jan F. Tack, Rita Vos
Food intake is associated with important changes in gastric motor control, aimed at initial
storage of the meal, subsequent grinding and followed by emptying. In adults, impaired gastric
accommodation and delayed gastric emptying have been implicated in the pathogenesis of
functional dyspepsia (FD) symptoms. Abnormalities of gastric motility have also been
reported in obese adults, although the contribution of motility changes to the pathogenesis
of obesity remains unclear. The aim of the study was 1) to compare gastric emptying rate
and nutrient tolerance during a satiety drinking test in children with FD and obesity to
previously established normal ranges, and 2) to study the relationship between daily mean
caloric intake and the result of a satiety drinking test in dyspeptic and obese children.
Methods: A total of 16 dyspeptic children (12 girls, mean age 12.4±3.3years) and 13 obese
children (6 girls, 13.8±2.0years) were studied. On two separate days, maximum one day
apart, the patients underwent an octanoic acid gastric emptying breath test and a satiety
drinking test. Prior to both tests, a dyspepsia questionnaire was filled out and a three day
nutrient history was assessed to calculate the mean calorie intake. Results: The most prevalent
dyspeptic symptoms were early satiety (93.8%), postprandial fullness (75%) and epigastric
pain (75%), followed by nausea (62.5%). None of the obese children reported FD symptoms.
(All dyspeptic and obese children (n=29) started the satiety drinking test and 25 children
completed the test until a score of 5 was reached.) The maximum ingested volume in FD
was significantly lower than in obesity or in age-matched healthy controls (235±24 vs.
respectively 433±65 and 359±29 ml, both p<0.05). As a group, dyspeptic children had
significantly slower gastric emptying than obese children (112.7±65.8 vs. 73.0±29.6 min,
p =0.01), and the emptying was slower than the age-matched normal range in 3 FD patients.
Daily calorie intake was significantly higher in obese children than dyspeptic children
(2325±469 vs. 1503±272 cal, p<0.0001), although the distribution of calories did not differ
significantly. The endpoint of the satiety drinking test was significantly correlated with body
weight or BMI (both R=0.41, p=0.04), but not with daily calorie intake, gastric emptying
rate or age. Conclusion: The satiety drinking test is a potentially useful non-invasive tool
in the investigation of children with FD. Childhood obesity is a multifactorial problem, and
the nutrient challenge and gastric emptying test did not give a uniformly abnormal result
in this group of patients.
M1181
Psychological Comorbidity, Esophageal Hypersensitivity and Abnormal
Autonomic Nerve System Function in Patients with Functional Heartburn
Yanli Zhang, Meiyun Ke, Xiucai Fang, Xiaohong Sun, Zhifeng Wang
Background: The clinical features and pathogenesis of functional heartburn (FH) were
unclear. Previous studies have suggested that psychological factors may participate in patients
reporting. Esophageal visceral hypersensitivity and abnormal autonomic nerve system (ANS)
function might implicate in the pathogenesis of FH. Aims: To investigate the psychological
profiles, esophageal visceral sensitivity to acid and ANS function in patients with FH.
Methods: Defined by the Rome III criteria, heartburn patients with negative findings in
endoscopy, normal acid exposure time of esophageal pH monitoring, no abnormality in
esophageal manometry, and unsatisfactory response to PPI trial were diagnosed FH. 10
patients with FH (3M, 7F, mean age 44yrs) and 12 healthy subjects (HS) (5M, 7F, mean
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age 40yrs) were enrolled. Psychological profiles including depression and anxiety were
documented by Zung's self-rating anxiety and depression scale (SAS, SDS). All subjects
underwent acid perfusion test (APT) to evaluate esophageal sensitivity, and simultaneously
assessed ANS function included electrocardiogram with spectral analysis of heart-rate variabil-
ity (HRV). In APT, subject reporting heartburn or chest pain was considered positive. The
assessment of ANS was performed on three stages: baseline, pre-perfusion (after insertion
of the perfusion catheter, prior to acid perfusion) and during perfusion. ANS parameters
included mean heart rate (M-HR), sympathetic activity (SA), vagal activity (VA) and sympa-
tho-vagal ratio (SVR). Results: 1).There was no significant difference in demographics between
the two groups. 2).Patients with FH had apparently depressive mood, whose mean score
of SDS was significantly higher than HS (mean 55 vs 37, p<0.01). SAS score of patients
with FH was also higher than HS (mean 45 vs 37, p<0.01). 3).There was 7 patients (70%)
with positive APT, while all of HS were negative (p<0.01). 4).In patients with FH, SVR
during-perfusion was significantly decreased compared with that of pre-perfusion stage
(P<0.05, Table 1). But in HS group, there were no differences exited in all parameters
of ANS either in three stages (P>0.05). Conclusions: These observations suggested that
psychosocial factors, esophageal hypersensitivity, and abnormal ANS function might play
important roles in the pathophysiological mechanisms of FH.
Comparing parameters of ANS funtion in patients with FH
*P<0.05 compared to pre-perfusion
M1182
Elevated Plasma Cholecystokinin Concentration Is Associated with Delayed
Gastric Emptying in Critical Illness
Nam Q. Nguyen, Marianne Chapman, Robert Fraser, Laura K. Bryant, Carly Burgstad,
Judith Wishart, Richard H. Holloway, Michael Horowitz
Cholecystokinin (CCK) is released in response to intestinal nutrients, especially lipid, and
plays an important physiological role in the regulation of gastric emptying. Both basal and
nutrient-stimulated CCK concentrations are elevated in critically ill patients, particularly in
those with a history of feed intolerance. Thus, CCK may be of pathogenic significance in
the slowing of gastric emptying, which occurs frequently in this patient group. Aim: To
evaluate the relationship between plasma CCK and gastric emptying in critical illness.
Methods: Gastric emptying was assessed in 40 mechanically ventilated critically ill patients
(25M; 55.7 ± 2.5 years) using a 100ml intra-gastric bolus of Ensure® (106kcal, 21% fat)
mixed with 0.1g of 13C-octanoic acid. Breath samples were collected at time intervals over
240 minutes and analyzed for 13C02 concentration using isotope ratio mass spectrometry
and the gastric emptying coefficient (GEC, normal = 3.2-3.8) was determined. Blood samples
were collected for the measurement of plasma CCK concentrations at 0, 60 and 120 min
following test meal administration. Results: Gastric emptying was delayed in 65% (26/40)
of the patients. There were no differences in age, BMI, APACHE II score, use of morphine
or inotropes in those patients with delayed gastric emptying compared to those with normal
gastric emptying. In patients with delayed gastric emptying, baseline plasma CCK was higher
(9.1 ± 1.2 vs. 6.2 ± 0.6 pmol/L; P =0.045) and there was an inverse relationship between
GEC and baseline plasma CCK concentrations (r = -0.31, P =0.04). In both groups, plasma
CCK concentrations increased after nutrient delivery (P<0.01) with no difference in the
magnitude of the response (AUCt0-t120: 123 ± 24 vs. 161 ± 24 pmol/l.min, NS). Nutrient-
stimulated plasma CCK concentrations were higher in patients with delayed enteral nutrition
(P =0.02). Conclusion: In critical illness, delayed gastric emptying is associated with higher
plasma CCK concentrations. These observations are consistent with the concept that CCK
contributes to the slowing of gastric emptying in critical illness and suggest a potential
therapeutic role for CCK antagonists.
M1183
High Resolution Manometry in a Tertiary Referral Centre: 100 Consecutive
Patients with Dysphagia
Mark R. Fox, Roy Anggiansah, Terry Wong, Angela Anggiansah
Introduction: The cause of swallowing problems and other oesophageal symptoms remains
uncertain in some patients despite conventional investigation. High-resolution manometry
(HRM) detects focal oesophageal dysmotility and measures the oesophago-gastric pressure
gradient that drives bolus transport. This report summarizes the clinical experience of a
tertiary referral centre with HRM (ManoScan 360, Sierra Systems). Method: Retrospective
assessment of 100 consecutive patients referred for investigation of swallowing problems.
After nasal intubation the catheter position was checked by deep breaths to highlight the
pressure inversion point. Baseline LOS recordings, 10 water swallows and at least 5 solid
(bread) bolus swallows were performed in the upright position. Then 250ml water was
given to highlight raised intra-bolus pressure (resistance to flow). A test meal was provided
if post-prandial symptoms were prominent. The impact of HRM on clinical diagnosis was
assessed. Results: 100 patients (43M:57F, age range 13-89 (median 52)) with predominant
symptoms of oesophageal dysphagia (63 (post-oesophageal surgery 5)), oropharyngeal dys-
phagia (5), reflux (17), chest pain (10), recurrent ‘belching or vomiting' (5). Note: reflux
without dysphagia was investigated by conventional techniques. All had upper gastrointestinal
endoscopy, many barium swallow (12 suggestive of achalasia). Normal or non-specific
findings on conventional manometry were available in 15. HRM was unsuccessful in 5 (1
pain, 4 looping in dilated oesophagus). Diagnoses included: achalasia (19), oesophageal
spasm (26), hypertensive contractions (4), hypotensive contractions / peristaltic failure (17),
abnormal resistance to flow in the pharynx or oesophagus / LOS (9), normal (23). Of the
latter 5 showed rumination or supragastric belching after a test meal. Certain diagnoses
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would have been difficult to establish (or fully appreciate) by conventional manometry.
HRM detected symptomatic, focal abnormalities of peristalsis (aperistalsis or spasm) in 15
patients, including longitudinal muscle spasm (i.e. oesophageal shortening). HRM detected
abnormal resistance to flow (abnormal intra-bolus pressure gradient) due to structural or
functional abnormalities in the pharynx (4), oesophageal body (2) and LOS (3) that had not
been detected by endoscopy, imaging or conventional manometry, including abnormalities of
the upper oesophageal sphincter and a submucosal oesophageal tumor. HRM was also useful
in defining the cause of symptoms after anti-reflux surgery. Conclusion: HRM is a useful
addition to existing investigations for patients with swallowing difficulties and other oesopha-
geal symptoms.
M1184
Impact of Delayed Enteral Feeding On Gastric Emptying and Plasma
Cholecystokinin in Critically Ill Patients
Nam Q. Nguyen, Marianne Chapman, Robert Fraser, Laura K. Bryant, Carly Burgstad,
Max Bellon, Judith Wishart, Richard H. Holloway, Michael Horowitz
In health, gastric emptying (GE) and cholecystokinin (CCK) release are influenced by
starvation. In critical illness, early enteral feeding reduces mortality and sepsis. However,
nutrient delivery is frequently inadequate and may be associated with gastro-oesophageal
reflux and aspiration. CCK slows gastric emptying and plasma CCK concentrations are
elevated in critically ill patients, particularly in those with feed intolerance. Although nutrient
deprivation and malnutrition are common in these patients, the effects of delayed feeding
on GE and CCK are unclear. Aim: To evaluate the impact of delayed initiation of enteral
feeding on GE and plasma CCK concentrations in critically ill patients. Methods: 28 critically
ill patients were randomised to receive enteral nutrition (EN) either (i) within 24 hours
(“early EN”: n=14; 54.9±3.3 yrs; APACHE II=23.0±1.8) or (ii) after 4 days (“late EN”: n=
14; 56.1±4.2 yrs; APACHE II=21.7±1.8) of intensive care admission. On day 4, GE was
assessed in all patients by scintigraphy (100ml Tc99m labelled Ensure®: 106kcal, 21% fat)
and the half-emptying time (t1/2), meal retention (at 60, 120, 180 and 240min) and intra-
gastric meal distribution were measured. Delayed GE was defined as ≥10% retention at
240 min. Plasma CCK concentrations were measured at baseline, 60 and 120 min. All
patients received an insulin infusion as per protocol and blood glucose concentrations were
monitored and maintained between 5-7.9 mmol/L. Results: Age, APACHE II score, use of
inotropes and type of sedative drugs were similar between the 2 groups. The proportion of
patients with slow GE was similar between the groups (late: 11/14 vs. early: 10/14, P=0.99).
There was no significant difference in GE (t1/2: 313±113 vs. 355±156 min, late vs. early
respectively) between the 2 groups, but in those with “early EN” The retention in the
proximal stomach was greater in the first 120 min (P<0.001). There were no significant
differences in either baseline (late: 7.7±1.2 vs. early: 9.3±1.7 pmol/l; P=0.35) or nutrient-
stimulated (P=0.78) plasma CCK concentrations between the 2 groups. Blood glucose concen-
trations were similar between the groups at baseline and throughout the study. Conclusions:
Delayed EN has little impact on either gastric emptying or plasma CCK concentrations,
suggesting factors other than timing of initiation of feeds are important determinants of GE.
The proximal distribution of the meal in the early feeding group, however, may contribute
to the increased risk of gastro-oesophageal reflux and aspiration in these patients.
M1185
Impaired Gastric Accommodation in Functional Dyspepsia (FD) Is Solely
Caused By Impaired Relaxation of the Proximal Stomach and Not
Accompanied By Altered Accommodation of the Distal Stomach: A Magnetic
Resonance Imaging (MRI) Study
Ivo R. Van der voort, Marco Schmidtmann, Peter Kobelt, Hassan Abou-rebyeh, Bertram
H. Wiedenmann, Hubert Mönnikes
Impaired relaxation of the proximal stomach has been reported in 40 % of patients with
FD using the invasive barostat technique. Impaired relaxation of the proximal stomach will
lead to an abnormal meal distribution, as observed in earlier scintigraphic and ultrasound
studies, with increased filling of the distal stomach. The aim of this study was to compare
postprandial (pp) relaxation and emptying of the whole stomach, and the proximal and
distal parts of the stomach in healthy volunteers and patients diagnosed with FD using the
non-invasive technique of MRI. Material & Methods: 15 healthy controls (HC; 7 female,
mean age (MA) 38 years), 22 patients diagnosed with FD (11 female, MA 42 years) underwent
MRI studies. MRI sequences covering the complete gastric region were performed up to 90
minutes after a liquid meal. Total, proximal, and distal stomach volumes and meal volumes
were determined. Changes in gastric and meal volumes were calculated. Results: The
cumulative increase of total gastric volume in the early pp phase (0-15 min) was significantly
lower in FD compared to HC (table 1). This difference between both groups was due to a
difference between significant lower increases in the proximal gastric volume in FD (table
1). In contrast, the cumulative change in the distal gastric volume was not significantly
different between both groups (table 1). In 41 % of patients with FD the regular increases
in pp total and proximal gastric volumes were lacking. Accordingly, the increase in the total
intragastric liquid volume in the early pp phase (0-15 minutes) was significantly diminished
in FD compared to HC (table 1). The cumulative changes in the distal intragastric liquid
volumes were not different between FD and HC (table 1). Gastric emptying over 90 minutes
was delayed in 18 % of patients with FD. Only one patient with FD had an impaired
gastric relaxation plus a delayed emptying. Conclusion: Impairment of postprandial gastric
relaxation of the proximal stomach to a liquid test meal is not accompanied with changes
in gastric volumes of the distal stomach in patients with FD or changes in the intragastric
distribution of the meal.
Cumulative change in volume during the early postprandial phase in FD patients and
healthy controls.
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* p < 0.01 versus HC
M1186
Influence of Naloxone On Meal-Related Symptoms and Gastric Emptying Rate
in Man
Kostas Mimidis, Filiz Akyuz, Brecht Geeraerts, Heleen Nicolai, Rita Vos, Jan F. Tack
Impaired gastric accommodation is present in almost 40% of functional dyspepsia (FD)
patients, but the relevance of this abnormality to FD symptom generation has remained
controversial. We recently demonstrated that administration of naloxone, a non-selective
opioid antagonist, inhibits the gastric accommodation reflex in man (Geeraerts, DDW 2006).
Our aim was to study the influence of naloxone on meal-induced symptoms. Methods: 15
healthy subjects (25.7±5.3 years) participated in a placebo-controlled, double-blind cross-
over study. All subjects underwent a satiety drink test and a gastric emptying breath test
on two occasions. Continuous infusion of saline or naloxone (20μg/kg/h after 0.4mg bolus)
was started 15 min prior to the start of the meal. The 13C-octanoic acid and 14C-glycine
breath test was used to quantify solid and liquid emptying rates. For the satiety test, a
peristaltic pump filled one of two beakers at a rate of 15 ml/min with a liquid meal
(Nutridrink®, Nutricia). Subjects were requested to maintain intake at the filling rate, thereby
alternating the beakers as they are filled and emptied. At 5-minute intervals, they were asked
to fill out a visual analogue scale (VAS) for 10 epigastric symptoms and to score their satiety
using a scale that combined verbal descriptors on a numerical scale 0-5 scale (1=threshold,
5=maximum satiety). Meal intake was stopped when a score of 5 was reached. During a 3-
hour post-meal observation period, participants scored the postprandial evolution of satiety
and other meal related symptoms every 15 minutes. Nutrient tolerance, area under the curve
(AUC) for symptom intensities and symptom satiety scores were recorded and compared
by paired t-test and ANOVA. Results: Both solid and liquid emptying rates were not altered
by naloxone. During the satiety test, naloxone significantly inhibited nutrient tolerance (max
intake 617±221 vs 715±279 ml, p=0.03). This was associated with significantly higher scores
for fullness (AUC 1180.77±168.4 vs 1530.77±247.24mm*min, p=0.03) and satiety (AUC
1226.92±163.8 vs 1498.08±178.74mm*min, p=0.01). Scores for the other epigastric symp-
toms did not differ between both conditions. No differences in symptom intensity scores
occurred during the postprandial follow-up period. Conclusion: The opioid antagonist
naloxone, which was previously shown to inhibit gastric accommodation, decreases nutrient
volume tolerance and enhances symptoms of meal-induced satiety and fullness. These effects
occur in the absence of a change in gastric emptying rate, thereby supporting the role of
impaired accommodation to symptom generation in FD.
M1598
Regulation of P27KIP1 Degradation and Proliferation By the Cysteine Protease
Cathepsin B in Colon Cancer Cells
Jim Boulanger, Nathalie Rivard
Decreased expression of p27 (cyclin-dependent kinase inhibitor-1B, CDKN1B or KIP1) in
human colorectal cancer has been associated with poor prognosis. It is thought that decreased
p27 expression in tumors is caused by increased proteasomal turnover. Suspecting that p27
protein expression may be regulated by other molecular mechanisms in colorectal cancer,
we conducted a yeast two-hybrid screen of a colon cancer cell cDNA library using the full-
length p27 as bait. Methods. An expression vector was constructed by fusing the GAL4
DNA-binding domain to p27 protein. This bait plasmid was co-transformed in yeast with
a prey plasmid containing Caco-2/15 cDNA expression library fused to the GAL4 activation
domain. RT-PCR, Western blot, pull down-GST and immunofluorescence experiments were
performed in the normal intestinal epithelial cells HIEC and in colon cancer cells Caco-2/
15, Lovo and HCT116. Results. 1-Characterization of many positive clones revealed a 0.9
kb insert whose sequence was identical to a part of cathepsin B cDNA sequence. 2-The
interaction between cathepsin B and p27 observed in yeast was confirmed by pull-down
GST and co-immunoprecipitation in Caco-2/15 cell extracts. 3- p27 and cathepsin B co-
localized in the nucleolus of HIEC, Caco-2/15, Lovo and HCT116 cells. 4- Cathepsin protease
activity was well detected in colon cancer cell nuclear extracts. 5- Treatment of colon cancer
cells with CaO74 (5 uM), a potent inhibitor of cathepsin B activity, led to an increase in
expression levels of p27 protein and to the inhibition of Cdk2-associated complexes activity
comparatively to non-treated cells. 6- RT-PCR analysis revealed the presence of a novel
transcript variant of cathepsin B in colon cancer cells. This new transcript variant results
from alternative splicing of the primary cathepsin B transcript using a cryptic splicing
acceptor site within exon 1. As a consequence, this variant is missing exons 2, 3 and 4. 7-
In Vitro, p27 protein was efficiently cleaved by recombinant cathepsin B resulting in two
proteolytic fragments. In contrast to full-length p27, these fragments could not bind and
block cyclin E/Cdk2 kinase activity. 8- The lentiviral infection of a shRNA which specifically
knocked-down cathepsin B expression enhanced p27 protein levels and significantly slowed
down proliferation rate of HCT116 and Lovo cells but not proliferation rate of normal
epithelial intestinal crypt cells HIEC. Conclusion. Our data suggest that the degradation of
p27 protein expression in colon cancer cells is mediated by the nucleolar-associated cathepsin
B protease.
M1599
Smad3 Deficiency Disrupts Organization of Proliferative Zones in the Colonic
Crypts By Suppressing EPHB Receptor Expression
Kiyoshi Furukawa, Toru Sato, Tatsuro Katsuno, Kazuki Hatakeyama, Atsushi Isono,
Tomoo Nakagawa, Atsuko Tokumasa, Kotaro Yokote, Yasushi Saito
Background: We reported previously that deficiency of Smad3, an intracellular mediator
of TGF-β signaling, significantly accelerates re-epithelialization of the colonic mucosa (Toku-
masa A., et al. BBRC 2004). Aim: The present study investigated the molecular mechanisms
by which Smad3 controls colonic epithelial cell proliferation and colonic crypt formation.
Methods: Smad3ex8/ex8 C57BL/6 mice (provided by Dr. Anita B. Roberts, NCI) were used
in this study and the wild-type littermates were served as controls. Colons were removed
from the mice and immunohistochemistry was performed for Ki-67, β-catenin, EphB2, and
EphB3. Viable colonic epithelial cells were isolated using an EDTA-perfusion method. Cell
proliferation was assessed by monitoring BrdU uptake. Protein levels were evaluated by
Western blotting. Results: Immunohistochemistry revealed that number of Ki-67-positive
proliferating cells in the crypts of Smad3-/- mice was twice as much as that of the wild-type
littermates. Notably, Ki-67-positive cells were scattered throughout the midcrypt accompan-
ied by increased number of nuclear β-catenin-positive cells in Smad3-/- mice, whereas Ki-
67-positive and nuclear β-catenin-positive cells were restricted to the bottom of the crypts
in the wild-type littermates. Analysis of BrdU uptake in isolated colonic epithelial cells also
demonstrated that a significant increase (205 ± 27%) in number of cells in cell cycle in the
colonic epithelium of Smad3-/- mice. Protein levels of the cell-cycle inhibitors p21 and p27
were significantly decreased, while c-Myc was increased in the isolated colonic epithelium
of Smad3-/- mice. Intriguingly, protein expressions of EphB2 and EphB3, which have been
shown to prevent intermingling of proliferating and differentiated cells in the intestinal
epithelium, were markedly suppressed in the isolated colonic epithelium of Smad3-/- mice
in compared with those of the wild-type littermates. Immunohistochemistry showed no
staining of EphB2 and EphB3 proteins was found throughout the colonic crypts in Smad3-/-
mice, whereas strong staining of these proteins was observed at the bottom of the crypts
in the wild-type littermates. Conclusions: Smad3 deficiency not only accelerates cell cycle
of the colonic epithelial cells by altering cell-cycle protein expressions accompanied by
enhanced nuclear translocation of β-catenin, but also leads to mispositioning of the prolifer-
ating cells in the crypts by down-regulating EphB receptor proteins whose expressions are
reported to be controlled by Wnt/β-catenin signaling. The present study illustrates a crosstalk
between TGF-β/Smad and Wnt/β-catenin signaling in the colonic mucosa.
M1600
Sox9 Is Required for the Differentiation of Paneth Cells and Regulates
Intestinal Epithelial Cell Proliferation
Yuko Mori-akiyama, Maaike Van den born, Johan Van es, Stanley R. Hamilton, Hans
Clevers, Benoit De crombrugghe
The transcription factor Sox9 has been shown to be required for the differentiation of a
small number of cell lineages, during which Sox9 has an essential role in decisions of cell
fate. In the intestine Sox9 is expressed in all epithelial cells in the lower two thirds of the
crypts, namely in the domain of transiently proliferating cells and in Paneth cells. Sox9 is
also a target of the Wnt/b-catenin signaling pathway. To examine the function of Sox9 in
the intestine, we have inactivated the Sox9 gene in intestinal epithelial cells by generating
mice harboring a conditional Sox9 gene and a Villin-Cre transgene. In the absence of Sox9,
Paneth cells were not formed. Indeed, the characteristic cytosolic granules typical of Paneth
cells were completely absent in the cells of the crypts in the mutant mice. The absence of
lysozyme, MMP7, Cryptdin-1, and Cryptdin-6 expression further supported the view that
Paneth cells were missing. In contrast, the differentiation of other intestinal epithelial cell
types was unaffected. The average number of Goblet cells as well as enteroendocrine cells
per villus did not show any significant difference between mutant and control mice. Moreover,
transmission EM of the villi of mutant mice showed the presence of abundant enterocytes with
typical microvilli, which were undistinguishable from those in control mice. We conclude that
Sox9 is required for the differentiation of Paneth cells. Our results thus elucidate an essential
step in the differentiation of gut epithelium. The lack of Sox9 further lead to crypt enlargement
documented by an increase of both the width and the depth of the crypts in the mutant
mice. There was also a marked increase in cell proliferation throughout the crypts as shown
by the number of the Ki67 positive cells as well as BrdU positive cells. Our results also
suggest that Sox9 has an inhibitory role in the regulation of proliferation of intestinal epithelial
cells. Based on previous experiments showing that Sox9 can inhibit b-catenin transcriptional
activity, we speculate that in the intestinal epithelium Sox9 may exert a feedback control
on Wnt signaling.
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Protein Kinase D Prevents H2O2-Induced Apoptosis Via Upregulation of Nf-κB
and Downregulation of P38 in Intestinal Epithelial Cells
Jun Song, Jing Li, Jingbo Qiao, B. mark Evers, Dai H. Chung
We have recently found that protein kinase D (PKD) plays an important role in the protection
of oxidative stress-induced cell death in intestinal cells; however, the downstream targets
remain unknown. Nuclear factor-κB (NF-κB) and mitogen-activated protein kinases
(MAPKs)have been implicated in the regulation of oxidative stress-induced apoptosis in
certain cell types. The exact role of PKD in the regulation of NF-κB and MAPKs and the
protection of oxidative stress-induced intestinal epithelial cell apoptosis is unknown. The
purpose of our present study was two-fold: (i) to define the role of NF-κB and MAPKs
during H2O2-induced PKD activation in intestinal epithelial cells, and (ii) to determine
which MAPKs are involved in PKD-mediated cell survival. METHODS. (i) To determine the
activation of NF-κB in H2O2-induced intestinal apoptosis, electrophoretic mobility shift and
reporter luciferase assays were performed; (ii) immunofluorescent staining and fluorescent
microscopy were utilized to demonstrate the translocation of p65/NF-κB induced by H2O2;
(iii) to detect IκB-α, ERK1/2, JNK and p38 signaling, RIE-1 cells were transfected with wild-
type or kinase-dead PKD1 plasmids as well as PKD1 siRNA. Western blot analysis was
performed. RESULTS. H2O2 treatment induced NF-κB binding activity in both a dose- and
time-dependent fashion and IκB-α phosphorylation, which is required for NF-κB activation.
H2O2 treatment also induced nuclear translocation of p65/NF-κB. More importantly, PKD1
siRNA inhibited H2O2-induced NF-κB activation and translocation as well as IκB-α phos-
phorylation. Overexpression of wild-type PKD1 attenuated H2O2-induced p38 phosphoryl-
ation, whereas phosphorylation was increased by PKD1siRNA or kinase-dead PKD1. In
contrast, the p38 inhibitor, SB203580, did not affect PKD1 phosphorylation. Phosphorylation
of both ERK and JNK was not altered by transfection of PKD1 siRNA and plasmids. CONCLU-
SIONS. Our findings suggest that PKD1 protects intestinal cells from oxidative stress-induced
cell death through the upregulation of NF-κB and downregulation of p38; ERK and JNK
pathways are not involved in this process. These findings further suggest the important roles
of intracellular transduction pathways in the protection of intestinal epithelial cells during
oxidative stress-mediated injury, therefore, providing potentially novel targets in the manage-
ment of GI diseases, such as necrotizing enterocolitis in infants.
M1602
Colonic Hyperplasia in Keratin 8-Null Mice Is Mediated By Resistance to
Apoptosis and Presence of Luminal Microflora
Aida Habtezion, Diana Toivola, Jackie Brooks, Gregory S. Kronmal, Eugene Butcher, Bishr
Omary
Background: Keratin 8 (K8) is the major type II intermediate filament protein present in
colonic epithelial cells. It serves an important cytoprotective function in the liver via protecting
hepatocytes from Fas-mediated apoptosis. K8-null mice develop colonic hyperplasia,
diarrhea, and chronic spontaneous Th2-type colitis amenable to broad-spectrum antibiotic
treatment. The etiology of the colitis and hyperplasia are poorly understood. Aim: We sought
to identify colonic genes that are differentially expressed in response to K8 absence and
suppression of colonic microflora. Methods: Microarray analysis was used to examine differ-
ences in gene expression between colonocytes freshly isolated from K8 wild-type (WT) and
K8-null mice or from the similar mice treated with vancomycin and imipenem. Several
highly upregulated and downregulated genes were confirmed by RT-PCR. Colon organ
culture was carried out in media +/- staurosporine, +/- Fas antibody in order to test the
role of the differentially regulated genes in the apoptotic pathway. Protein expression was
analyzed by immunoblotting. Results: The majority of the highly altered genes in antibiotic-
untreated K8-null versus WT colonocytes were related to apoptosis, growth and differenti-
ation. Alteration of the apoptosis related genes was verified by RT-PCR and included TNF
receptor associated factor 1 (TRAF1; 3-fold) and caspase 14 (3-fold) as down-regulated
genes, whereas survivin (5-fold) was up-regulated in the K8-null versus WT colonocytes.
Caspases 3 and 9 were not altered significantly by array and RT-PCR analysis. Colon organ
cultures showed that upon baseline isolation (time 0) cleaved-caspase 7 was easily detected
by blotting in WT but not K8-null colons. After 1 h culture with staurosporine or Fas
antibody, cleaved-caspase 7 was significantly increased in the WT compared to the K8-
null colons. Notably, nearly all of the differentially regulated genes in K8-null versus WT
colonocytes were normalized after antibiotic treatment. Conclusion: The colonic hyperplasia
of K8-null mice can be accounted for, at least in part, by resistance to apoptosis. Restoration
of “normal” gene expression in K8-null colons after antibiotic treatment highlights the
importance of colonocyte interaction with the luminal bacterial milieu in manifesting the
intestinal phenotype of K8-null mice. Unlike the situation in hepatocytes, K8-null colonocyte
interaction with its luminal environment confers a paradoxical protection from apoptosis.
M1603
Raf-1 Promotes Cell Survival Following Injury and Inflammation in the
Intestinal Epithelium
Karen L. Edelblum, Mary K. Washington, Tatsuki Koyama, D. brent Polk
Anti-tumor necrosis factor (TNF) antibodies are commonly used in the treatment of IBD;
however, studies have demonstrated that TNF or TNF receptor (R)-1 knockout mice develop
more severe injury in experimental colitis models. A possible explanation for the apparent
conflict is the fact that TNF promotes both pro- and anti-apoptotic signaling pathways in
the intestinal epithelium in response to inflammation. One of the downstream effectors of
TNFR-1 is Raf, a serine/threonine kinase involved in cellular functions including proliferation,
differentiation, and cell survival. This study addresses the role of Raf in anti-apoptotic
responses following dextran sodium sulfate (DSS)-induced injury and inflammation.
Methods: Conditional intestine-specific Raf knockout mice were generated by injecting 6
week-old Raf flx;villin-Cre ERT2 mice with tamoxifen to induce Cre recombination of a
loxP-flanked Raf-1 allele. Active recombination of the floxed Raf allele occurred within 2
weeks prior to administration of DSS. At 8 weeks of age, mild colitis was induced by
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administration of 3% DSS and mice were sacrificed after 4 days to assess acute injury. A
well-described histological scoring system was used to grade crypt damage and extent of
intestinal inflammation. Ablation of Raf expression was confirmed by Western blot analysis
of colonic mucosal scrapings from oil- and tamoxifen-injected Raf flx;villin-Cre ERT2 mice.
Apoptosis was detected by immunohistochemistry in colon sections from control and Raf
intestine-KO mice. Whole colon lysates from control and Raf intestine-KO mice were assessed
by cytokine array (RayBiotech) to determine if Raf expression altered cytokine production
in response to DSS treatment. Results: While untreated Raf intestine-KO mice do not display
any gross histological defects, these mice exhibit significantly more severe histological scores
in response to DSS compared to controls (p=0.011). Furthermore, the Raf-null intestinal
epithelium shows increased sensitivity to apoptosis following DSS-induced injury as shown
by in situ oligo ligation and active-caspase 3 immunostaining. In control mice, TNF expression
in the colon is increased 20-fold in response to DSS, compared to a 6-fold increase in DSS-
treated Raf intestine-KO mice. Although TNF production is reduced, MIP-2 expression is
elevated 40-fold in Raf intestine-KO mice during DSS-induced injury compared to an only
2-fold increase in control mice. Conclusions: These data show that Raf plays a protective
role in response to injury and inflammation in the colonic epithelium, perhaps through
regulation of mucosal cytokines.
M1604
Hypoxia Inducing Factor-1α Mediates TGF-β-Induced Apoptosis in Intestinal
Epithelial Cells
Yanna Cao, Weili Zhang, Guo-hua Zhang, Courtney M. Townsend, Tien C. Ko
TGF-β inhibits enterocyte proliferation and induces enterocyte differentiation and apoptosis
thereby plays an important role in gut homeostasis. TGF-β signaling is mediated by Smad
proteins, which regulate gene transcription through the functional cooperation and associ-
ation with other transcription factors. Previously, we have shown that TGF-β induces
apoptosis through the activation of Smad3 and the subsequent repression of inhibitor of
differentiation 2 (Id2). Since Id2 is a helix-loop-helix (HLH) protein which lacks a basic
domain and sequesters basic HLH transcription factors and blocks their binding to DNA,
we undertook a proteomic approach using the TranSignalTM Protein/DNA Array I-III to
identify transcription factors which act down-stream of Smad3 and Id2 to mediate TGF-β-
induced apoptosis. One such candidate target is hypoxia inducing factor-1 (HIF-1), a well-
characterized transcription factor complex which is activated by hypoxia and regulates
hypoxia-driven gene expression. HIF-1 is composed of a heterodimer of two basic HLH
proteins, the rate-limiting factor HIF-1α and the constitutively expressed HIF-1β. The
purpose of this study was to determine whether HIF-1α mediates TGF-β induced apoptosis
in gut epithelial cells and liver cells. In order to examine TGF-β-induced apoptosis in gut
epithelial cells, we used RIE-1 cells overexpressing Smad3 (RIE-1/Smad3) which have greater
apoptotic response to TGF-β compared to parental cells and is a useful model for examining
down-stream targets of Smad3. RIE-1/Smad3 cells were transfected with short interfering
RNAs (siRNAs) targeting rat HIF-1α (Dharmacon) and analyzed for HIF-1αmRNA expression
by quantitative RT-PCR and apoptosis by DNA fragmentation ELISA assay. HIF-1α siRNAs
inhibited HIF-1α mRNA expression by 72% and blocked TGF-β-induced apoptosis in RIE-
1/Smad3 cells. We also examined the role of HIF-1α in human liver cells (Hep3B) which
are sensitive to TGF-β-induced apoptosis. Hep3B cell were transfected with siRNAs targeting
human HIF-1α (Dharmacon). Although HIF-1α siRNAs inhibited HIF-1αmRNA expression
by 92%, it had no effect on TGF-β-induced apoptosis in Hep3B cells. From these data, we
conclude that HIF-1α acts downstream of Smad3 and Id2 to mediate TGF-β-induced
apoptosis in gut epithelial cells. Furthermore, the role of HIF-1α appears to be tissue-specific
as it has no effect on human liver cells. These findings suggest a novel cross-talk between
TGF-β and hypoxia in the regulation of apoptosis.
M1605
Intestinal Epithelial Cell Survival Is Mediated, in Part, By the Mtor Pathway
in Glutamine-Deprived Cells
Shawn D. Larson, Dai H. Chung, B. mark Evers
Glutamine (Gln), the most abundant amino acid in the bloodstream, is essential for intestinal
cell homeostasis. Deprivation of Gln leads to intestinal mucosal atrophy; however, the
molecular mechanisms regulating the effects of Gln in the gut remain poorly understood.
Mammalian Target Of Rapamycin (mTOR), a downstream effector protein of the phosphatidy-
linositol 3-kinase (PI3K) pathway, plays a vital role as a cellular nutrient sensor in regulating
protein translation. Recent evidence suggests that amino acids, particularly Gln, play a crucial
role as cell signaling regulators to promote growth and prevent apoptosis. The purpose of
our study was to determine whether Gln deprivation alters mTOR expression and whether
this expression contributes to intestinal cell survival. Methods. (i) Rat intestinal epithelial
(RIE-1) cells were serum- and Gln-deprived for 24 h. Cells were then treated with Gln (1
mmol/L) or vehicle (control), lysed and protein extracted over a time course (0, 1, 2, 4,
and 24 h). Expression of phosphorylated and total mTOR protein levels was assessed by
Western blot. (ii) RIE-1 cells were treated with Gln (1 mmol/L) or vehicle and the PI3K
inhibitor wortmannin (100 nM) or vehicle after 24 h serum- and Gln-deprivation. Protein
was extracted and assessed by Western blot. (iii) Cells were cultured in the presence or
absence of Gln for 24 h and treated with wortmannin (100 nM) or vehicle; apoptosis was
quantitated using DNA fragmentation ELISA. Results. (i) Phosphorylated (ie, activated) mTOR
(p-mTOR) was increased in Gln-deprived cells at 1 and 2 h; conversely, Gln treatment
decreased p-mTOR. Total mTOR protein levels were unchanged. (ii) Wortmannin decreased
p-mTOR; total levels were unaltered. (iii) Treatment with wortmannin significantly increased
RIE-1 cell apoptosis in Gln-deprived cells; Gln supplementation reduced apoptosis in the
presence of wortmannin. Conclusions. Gln is an essential amino acid for intestinal growth
and survival; deprivation of Gln induces apoptosis and increases expression of p-mTOR.
Furthermore, p-mTOR expression is reduced following chemical inhibition of PI3K. These
results suggest an important role for mTOR, acting downstream of PI3K, as a cell survival
protein which is activated in intestinal cells deprived of Gln; addition of Gln decreases p-
mTOR and promotes cell growth.
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M1606
Differential Expression Pattern of PI3K Pathway Components and β-Catenin
in the Colon and Rectum
Takeyoshi Yamauchi, Hiroshi Saito, B. mark Evers
Epidemiologic studies have suggested a predilection for cancers in the distal colon and
rectum. Although this distribution pattern is controversial, it is becoming increasingly clear
that proximal and distal colon cancers arise through different tumorigenic pathways. Our
laboratory has demonstrated an important role for phosphatidylinositol 3-kinase (PI3K),
acting through its downstream effector proteins, Akt, GSK3-β and mammalian target of
rapamycin (mTOR), in colorectal cancer cell growth and migration. The purpose of our
present study was to investigate potential mechanisms for carcinogenesis in the proximal
and distal colon focusing on differential expression of PI3K pathway proteins. METHODS.
For these studies, 4-mo-old male C57BL/6 mice were used. (1) The colons were excised
and divided into 8 equal segments from proximal (excluding cecum) to distal rectum. Protein
was extracted for Western blot using antibodies directed to p-Akt/Akt, p-GSK3-β/GSK3-β
and p-mTOR/mTOR. In addition, expression of p-β-catenin and total β-catenin was analyzed.
(2) To confirm PI3K activation, mice were randomized to either fasting (for 48 h) or fasting
with refeeding (for 2 h) and further subdivided to receive wortmannin (a PI3K inhibitor;
1.5mg/kg, i.p.). Colons were removed, divided into 4 equal segments and expression of
PI3K/Akt components and β-catenin determined by Western blot. RESULTS. (1) p-Akt, p-
GSK3-β and p-mTOR expression was significantly higher in the distal colon compared
with the proximal segments (p<0.001, p<0.001 and p=0.015 respectively); there were no
differences in total Akt, GSK3-β or mTOR expression. The level of p-β-catenin (the inactive
form of β-catenin) expression was lower in the distal colon, whereas total β-catenin expression
was higher in the distal colon (p<0.001, p=0.003, respectively). (2) Fasting decreased p-
Akt, p-GSK3-β and p-mTOR expression, whereas refeeding dramatically increased expression
of these proteins. Neither fasting nor refeeding affected β-catenin expression. Wortmannin
decreased p-Akt, p-GSK3-β and p-mTOR expression levels in both the proximal and distal
colon but had only a minimal effect on β-catenin expression. CONCLUSIONS. Our study
is the first to show differential expression patterns of p-Akt, p-GSK3-β, p-mTOR and β-
catenin in the colon with increased expression noted in the distal colon, suggesting different
mechanisms for colorectal cancer depending on the location. Both p-GSK3-β and p-mTOR
expression was affected by the changes in p-Akt, whereas β-catenin expression was independ-
ent of the PI3K pathway.
M1607
Proliferative Response to Guanylate Cyclase C Activation Via Pkc/ERK in a
Colorectal Cancer Cell Line
Kris A. Steinbrecher, Eleana M. Harmel-laws, Juxian Mao, Katie Meier, Mitchell B. Cohen
Background: The role of cGMP in proliferation and apoptosis in colorectal cancer cells is not
completely understood. A central regulator of enterocyte cGMP levels is the transmembrane
receptor guanylate cyclase C (GC-C) and its luminally secreted ligands guanylin and uroguan-
ylin. Expression of GC-C is maintained in colorectal cancer but guanylin and uroguanylin
are not. Use of GC-C activating peptides is a suggested therapeutic approach for treatment
of a wide range of gastrointestinal pathology including intestinal neosplasia. While numerous
and often conflicting reports implicate GC-C in proliferation and apoptosis of normal and
transformed enterocytes, the mechanistic rationale for use of GC-C agonists as therapeutic
agents and how this relates to cell cycle progression is not well understood. Therefore, we
investigated the effects of GC-C activation in a human colorectal cancer cell line with an
initial emphasis on signaling pathways that mediate enterocyte division. Methods: The
effects of GC-C activation on proliferation were determined in Caco-2 BBE cells using a
tetrazolium salt-based assay as well as BrdU ELISA. GC-C agonists included guanylin and
heat stable enterotoxin (STa). Protein kinase Cα (PKCα) and PKCβ II activity were determined
by western blotting of membrane/cytoplasmic fractions and l-diltiazem was used to determine
the requirement of calcium channel function in GC-C-mediated PKC activation. Extracellular
signal-regulated kinase (ERK) activity was also determined through phospho-antibody west-
ern blotting and PD98059 was used to block ERK activity. Results: GC-C activation by
guanylin or STa was able to increase proliferation in serum starved cells to a degree similar
to that seen with serum stimulation. Treatment of cells with guanylin or STa resulted in
calcium channel-dependent membrane association of PKCα and PKCβ II. In addition, ERK
phosphorylation was elevated upon GC-C activation and was dependent on PKC activity,
as were increases in cyclin D1 protein levels and retinoblastoma protein phosphorylation.
Blockade of GC-C-induced ERK activity also blunted cyclin D1 accumulation. Conclusions:
We have shown that stimulation of GC-C activates a PKC/ERK signaling cascade that results
in a significant proliferative response. We suggest that changes in cGMP-activated protein
kinase function during colon tumor progression may dictate the cellular response of colorectal
cancer cells to GC-C agonists. Elevated expression of pro-cell division PKC isoforms such
as PKCβ II during tumor progression suggests that caution may be warranted in use of GC-
C agonists for treatment of intestinal cancers.
M1608
Relationship of B-Raf Mutation, Morphology and Apoptosis in Early Colorectal
Cancer
Shiei Yoshida, Nobunao Ikehara, Nobuo Aoyama, Daisuke Shirasaka, Masanori Sakashita,
Shuho Semba, Tadateru Hasuo, Ikuya Miki, Yoshinori Morita, Takao Tamura, Hiroshi
Yokozaki, Takeshi Azuma
Background and aims: Many investigators have reported flat and depressed lesions as a new
type of precursor of colorectal cancer. In our previous study, we determined that mutations
in the BRAF gene may contribute to colorectal carcinogenesis by inhibiting apoptosis. How-
ever, the relationship among BRAF mutations, morphology and apoptosis in early colorectal
cancer has not been clear. Therefore, gene alternation, morphology and apoptosis in early
colorectal cancer were investigated. Patient/ methods: Forty-five flat and depressed early
colorectal cancer samples and 43 polypoid early colorectal cancer samples were analyzed.
Mutations in the BRAF gene and the K-ras gene were examined by direct sequence analysis,
and proliferative activity and induction of apoptosis were evaluated using immunohistochem-
ical status. Results/ findings: BRAF mutations were found in 5 (11.1%) of 45 flat and
depressed early colorectal cancer samples. No BRAF alteration was found in polypoid early
colorectal cancer samples. Mutations in the K-ras gene were detected in 13 (30.2%) of 43
polypoid early colorectal cancer samples. The rate of submucosal invasion and moderate
differentiation of the samples with BRAF mutations was significantly higher than that of the
samples with K-ras mutations (p<0.05). The number of apoptotic bodies was significantly
lower in the samples with BRAF mutations (p<0.05). Interpretation/ conclusions: In this
study, BRAF mutations were found in 11.1% of flat and depressed early colorectal cancer,
but were not found in polypoid early colorectal cancer. In addition, in early colorectal cancer
with BRAF mutations, apoptosis was significantly inhibited. To our knowledge, this is the
first report to examine a large number of early colorectal cancer samples by a direct sequencing
procedure, and to investigate the relationship among BRAF mutations, morphology and
apoptosis. In other words, BRAF and K-ras mutations were independent factors that influ-
enced morphology in early colorectal cancer. Flat and depressed early colorectal cancer with
BRAF mutations has a higher malignancy and plays an important role in the developmental
process of colorectal cancer by inhibiting apoptosis.
M1609
Cyclic-AMP Inhibition of Apoptosis in the Murine Jejunal Crypt
Jeffrey A. Rudolph, Julia Pratt, Mitchell B. Cohen
Introduction: Intestinal crypt cell apoptosis plays a central role in multiple disease processes
such as intestinal transplant rejection, chemotherapeutic induced mucositis, and graft versus
host disease. The ability to inhibit apoptosis would greatly enhance the prevention or
treatment of these illnesses. We have previously demonstrated in a non-transformed intestinal
epithelial cell line, cAMP inhibits both staurosporine and Fas-Ab mediated apoptosis. We
hypothesized that this survival effect could be translated in the intact jejunum of mice using
an irradiation model of intestinal injury. Methods: Female C57/Bl 6 mice were administered
20 µg cholera toxin by orogastric gavage or vehicle (H2O) prior to inducing intestinal crypt
cell apoptosis with 5 Gy of total body γ-irradiation (TBI). Three hours after the induction
of injury, mice were sacrificed and proximal jejunum was harvested for histology. For
measurement of cAMP levels in the intestinal epithelium, mucosal scrapings were obtained
in intestinal segments just proximal to the histological sections. Cyclic-AMP levels were
measured using an enzyme linked immunoassay and normalized to mg soluble protein.
Twenty complete crypts were captured from each specimen and apoptosis was quantified
in blinded fashion by morphological analysis and by cleaved caspase-3 staining. Results
were expressed as the mean number of apoptotic events/crypt and by cell position. Results:
In mice treated with vehicle alone or with TBI (n=12), cAMP levels were 20 pmol/mg soluble
protein. Treatment with CT alone or CT and TBI (n=12) increased cAMP 2-fold (34 pmol/
mg soluble protein, p = 0.00001). TBI did not change cAMP levels independent of CT.
Mice that received vehicle and TBI (n=8) showed 4.0 apoptotic events/crypt while CT
treatment prior to TBI (n=9) decreased apoptosis by 35% (2.6 events/crypt, p=0.01) with
a blunting of the apoptotic response in the cells residing in the cell positions just above the
Paneth cells. Cleaved caspase-3 staining mirrored the morphological analysis, though less
apoptotic cells were identified by caspase-3 staining alone (1.95 vs. 0.97 apoptotic events/
crypt). Importantly, CT alone did not increase apoptosis above baseline. Conclusions: These
studies demonstrate that similar to our cell culture model, cAMP has the capability to inhibit
irradiation induced crypt cell apoptosis and suggest that this effect is relevant to the progenitor
cells responsible for the re-population of epithelium at times of injury. We speculate that
modulation of cAMP activity is a potential therapeutic target for the inhibition of apoptosis
in intestinal diseases where apoptosis plays a crucial role.
M1610
Src Kinase Is a Key Molecule in Cell Contact-Mediated Survival Signaling in
Primary Human Colonic Epithelial Cells
Claudia Hofmann, Werner Falk, Juergen Schoelmerich, Gerhard Rogler, Florian
Obermeier
Background: Cell-matrix anchorage and cell-cell anchorage are of critical importance for
survival of primary human colonic epithelial cells (CEC). Loss of both results in the rapid
induction of apoptosis (anoikis), while maintenance of either cell-matrix or cell-cell contact
completely blocks the apoptotic cascade. However, little is known about the molecular
mechanisms by which signals originating from cell-matrix and cell-cell interactions are
coordinated. Src kinase has been shown to associate with structures constituting both cell-
matrix and cell-cell adhesion and is therefore likely to be implicated in signal transduction
mediated by cell contacts. We therefore investigated the role of Src kinase in cell adhesion-
dependent survival signaling in primary human CEC. Methods: CEC were isolated as intact
crypts from the mucosa of surgical specimens. Induction of anoikis was achieved by incuba-
tion of crypts in suspension. Reconstitution of cell-cell contacts was obtained by “pelleting”
of CEC. Induction of anoikis was demonstrated by caspase-3 activation (Western Blot,
DEVD-pNA). Cell lysates were analyzed for phosphorylation of Src and FAK by Western
Blot. Src-dependent signaling was blocked by using the inhibitor PP1. Results: In the absence
of cell-matrix anchorage anoikis could effectively be blocked by the maintenance of cell-
cell contacts. In these cells a rapid deactivation of FAK, however, only a delayed and
incomplete dephosphorylation, of Src was observed. Inhibition of Src-dependent signals in
CEC with preserved cell-cell contacts resulted in a strong and dose-dependent increase of
apoptosis (p=0.004). The complete loss of cell anchorage induced a rapid and strong
increase of Src activation before active caspase-3 could be detected. This Src hyperactivation
contributed to transient protection from anoikis in CEC as cells could be “rescued” by
reconstitution of their cell-cell contacts by which caspase-3 activity was reduced by up to
50% (p=0.007). Inhibition of Src in this model reversed the anoikis-blocking effect of
reconstituted cell contacts and accelerated apoptosis. Conclusions: Src signaling is of pivotal
importance for cell-cell contact-mediated survival in CEC. Hyperactivation of Src significantly
contributes to the transient protection from anoikis immediately after loss of cell anchorage
in CEC. Our findings indicate that Src kinase is a key regulatory molecule coordinating
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survival signals mediated by cell-matrix and cell-cell adhesion. Moreover Src senses loss of
cell anchorage and simultaneously provides a transient protection mechanism from anoikis.
M1611
Therapeutic Effect of Exogenous Ghrelin in Chronic Gastric Ulcers in Rats.
Involvement of Growth Hormone and IGF-1
Artur Dembinski, Zygmunt Warzecha, Piotr Ceranowicz, Jakub Cieszkowski, Marcin
Dembinski, Ryszard Sendur, Wieslaw W. Pawlik, Atsukazu Kuwahara, Ikuo Kato, Peter C.
Konturek
Background: Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor,
is a 28-residue peptide primary isolated from the human and rat stomach. It stimulates the
release of growth hormone, food intake, gastric motility, and protects gastric mucosa against
ethanol- and stress-induced damage. This protective effect requires administration of ghrelin
before exposure to damaging factors and therefore has minimal clinical value. Aim of the
study was to determine whether ghrelin administration affects the healing rate of chronic
gastric ulcers, if so, what is the role of growth hormone (GH) and insulin-like growth factor-
1 (IGF-1) in this effect. Methods: Two weeks after sham-operation or hypohysectomy,
chronic gastric ulcers were induced by 100% acetic acid applied to the serosal surface of
gastric wall. Animals were treated intraperitoneally twice a day with saline, ghrelin (4, 8 or
16 nmol/kg/dose) or IGF-1 (20 nmol/kg/dose). Six or ten days after induction of ulcers, the
stomach was exposed for measurement of gastric blood flow and ulcer area. Serum level of
ghrelin, growth hormone and IGF-1 was determined. Biopsy samples from the gastric mucosa
were taken for determination of mucosal DNA synthesis, as an index of mucosal cell
proliferation. Results: In animals with intact pituitary, treatment with ghrelin increased
serum level of ghrelin, GH and IGF-1. These effects were accompanied by the increase in
mucosal cell proliferation, gastric blood flow and healing rate of gastric ulcers. Ghrelin at
the dose 8 nmol/kg exhibited maximal beneficial effect. After hypophysectomy, the healing
of gastric ulcers was delayed. This was accompanied by a significant increase in serum level
of endogenous ghrelin but serum concentration of GH and IGF-1 was reduced. Also,
gastric blood flow and mucosal DNA synthesis were decreased. In hypophysectomized rats,
administration of exogenous ghrelin increased serum level of this peptide, but it was without
effect on serum level of GH and IGF-1. In these rats, ghrelin was without effect on healing
rate of gastric ulcers, gastric blood flow or mucosal cell proliferation. In contrast to that,
administration of IGF-1 accelerated healing of gastric ulcer in hypophysectomized rats.
Healing rate reached a similar value as in pituitary-intact rats treated with ghrelin. This
therapeutic effect was associated with an increase in gastric mucosal blood flow and cell
proliferation. Conclusions: Treatment with ghrelin increases gastric mucosal blood flow and
cell proliferation leading to acceleration of healing of gastric ulcers. Endogenous growth
hormone and IGF-1 are indispensable in this therapeutic effect of ghrelin.
M1612
Alternatively Activate Macrophages (AamΦ) Play a Key Role in Nematode
Infection-Induced Changes in Epithelial Cell Function
Rex Sun, Aiping Zhao, Jennifer Stiltz, Kathleen B. Madden, Joseph Urban, Terez Shea-
donohue
Nematode infection upregluation of Th2 cytokines increases the influx aaMΦ. Infection is
associated with increased intraluminal fluid accumulation due, in part, to reduced glucose
absorption and increased epithelial permeability. The mechanism of these effects, however,
remains unclear. Aim: To determine the contribution aaMΦ to infection-induced alterations
in epithelial cell function. Methods: Balb/C mice were infected with N. brasiliensis (Nb) and
studied after 9 days. Groups of infected mice were injected with 0.2 ml of PBS- or clodronate
(Cl2MDP)-liposomes to deplete macrophages. Muscle-free sections of jejunum were placed
in Ussing chambers to determine resistance (R) and changes in Isc in response to glucose.
Real-time PCR was performed to assess mRNA expression of cytokines, macrophage markers,
and glucose transporters expressed by epithelial cells (SGLT1) and by other cells including
MΦ (GLUT1&3). Separate groups of mice were injected with IL-13 (10μg/mouse iv) for 7
days and treated with PBS- (IL-13 PBS) or Cl2MDP- (IL-13 Cl2MDP) liposomes. Muscle-
free jejunum was mounted in microsnapwells for measurement of transepithelial resistance
(TER). Results: Nb infection induces an accumulation of aaMΦ. Cl2MDP treatment abrogated
the Nb-induced upregulation of CD206 (3.6±0.5 vs 0.5±0.1 fold) and Arginase-1 (10.1±0.9
vs 1.4±0.5 fold). Macrophage depletion alone reduced R, but did not prevent the Nb-induced
drop in R. When compared to PBS, IL-13 PBS dramatically lowered TER (66.8±5.6 vs
9.8±0.7 Ω*cm2 p<0.001). This effect was attenuated modestly in IL-13 Cl2MDP mice (15.8
±0.2 Ω*cm2, p<0.05 vs IL-13 PBS). Infection inhibited glucose absorption but did not alter
SGLT1. Of interest was that Nb increased expression of GLUT1 (12.5±1.7 fold), but not
GLUT3 (1.2±0.1 fold). Cl2MDP prevented Nb-induced inhibition of glucose absorption and
attenuated the Nb-induced upregulation of GLUT1 expression (4.4±1 fold). Conclusions:
These data indicate that 1)aaMΦ do not mediate Nb-induced changes in barrier function;
2)aaMΦ compete with epithelial cells for glucose through upregulation of GLUT1 expression;
and 3)aaMΦ play a key role in Nb-induced reduction in glucose absorption that does not
involve altered expression of SGLT1. The effect of aaMΦ on glucose is similar to the inhibitory
actions of MΦ on glucose uptake in adipocytes suggesting novel interaction between aaMΦ
and epithelial cells on nutrient absorption.
Values= Mean±SE *p<0.05 vs PBS; n=3-5/group; γ p<0.05 vs Cl2MDP.
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M1613
Modulation of Cytokine mRNA Expression After Exposure to Fatty Acids in
Macrophages from Mesenteric Lymph Nodes
Chie Kurihara, Ryota Hokari, Hisayuki Matsunaga, Koichi Takebayashi, Keisuke
Okudaira, Toshihide Ueda, Ryuichi Yamamoto, Yoshikiyo Okada, Chikako Watanabe,
Shunsuke Komoto, Yoshikazu Tsuzuki, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Itoh,
Soichiro Miura
Aims: Dietary fat is an important factor for triggering exacerbation of mucosal inflammation
in inflammatory bowel diseases. However, the direct effect of fatty acid exposure on function
of intestinal macrophages (Mφs) has not been reported. Intestinal Mφs are known to be
divided into two distinct subsets; granulocyte M-colony-stimulating factor (CSF) induces
GM-Mφs and Mφ-CSF induces M-Mφs. We investigated how exposure to fatty acids affects
the cytokine expression in Mφs from mesenteric lymph nodes (MLN-Mφs) and compared the
profile with that of bone marrow (BM)-derived GM-Mφs and M-Mφs. The signal transduction
molecules related to toll-like receptors (TLR) were also compared. Methods: MLN-Mφs were
isolated as CD11b+ cells by magnetic cell sorting from MLN of C57BL/6 mice. For induction
of differentiation, BM-derived CD11b+ cells were cultured with recombinant M-CSF or GM-
CSF. Mφs were treated with saturated (lauric acid, LA), or polyunsaturated fatty acids
(arachidonic acid, AA; n-6 or docosahexaenoic acid, DHA; n-3) for 8 hrs in the absence or
presence of lipopolysaccharide (LPS). mRNA expression of inflammatory cytokines and TLR
signaling pathway molecules in cell lysates was determined by quantitative RT-PCR. Results:
M-Mφs showed the lower expression of inflammatory cytokines such as IL-6 mRNA, while
the higher expression of IL-10 mRNA than GM-Mφs in control condition. MLN-Mφs showed
the relatively high expression of IL-10 mRNA, that is similar to M-Mφ. In MLN-Mφs AA
decreased the expression of IL-10 mRNA. The decreased IL-10 mRNA was also observed
in case of M-Mφs after exposure to LA or AA, but not observed in case of GM-Mφs, in
which LA and AA significantly stimulated TNF-α and IL-6 mRNA. DHA did not show a
significant effect on cytokine expression in MLN-Mφs, suggesting the beneficial role of n-3
fatty acids in inflammation. LPS stimulation strongly increased TNF-α in all Mφs. However,
these increases were dose-dependently attenuated by simultaneous exposure to fatty acids,
suggesting that they compete for the same receptor. Quantitative RT-PCR of mRNA related
to TLR revealed that MLN-Mφs showed the higher expression of inhibitory molecules, such
as Bcl-3, SOCS1 and SOCS3 than BM-derived Mφs. Conclusion: Cytokine mRNA expression
in MNL-Mφs showed a similar profile to that of In Vitro differentiated M-Mφs. MLN-Mφs
were relatively unresponsiveness to fatty acid exposure compared with GM-Mφs, in the latter
fatty acids significantly enhanced expression of inflammatory cytokines. Higher expression
of suppressor factor of TLR-mediated-signal transduction in MLN-Mφs may be related to
their peculiar response to fatty acids.
M1614
CXCR4 Expression Is Upregulated By Pro-Inflammatory Cytokines in Human
Gastric Cancer Cells
Alexander Dubeykovskiy, Timothy C. Wang
Background and Aims: Inappropriate activation of chemokine signaling occurs in many
cancers, and has been shown to play a pivotal role in the tumor progression and metastasis.
The chemokine, Stromal Derived Factor 1 (SDF-1) and its cognate receptor CXCR4 appear
to contribute to the dissemination of primary tumors of different origins. Recently, expression
of the CXCR4 receptor has been detected in primary gastric tumor specimens. We aimed
to investigate the regulation and signaling properties of the CXCR4 receptor in transformed
gastric cells. Methods: Real-time RT-PCR, FACS and Western Blot analysis were performed
on human gastric cell lines and mouse primary gastric epithelial cells to assess CXCR4
mRNA, receptor and MAPK/Akt kinase status, respectively. CXCR4 promoter mutagenesis
and reporter assays in Kato III cells were employed to assess responses to pro-inflammatory
cytokines. Results: Real-time RT-PCR and FACS analysis revealed that the majority of human
gastric cancer cell lines abundantly express CXCR4 mRNA and receptor in the cytosol, while
variable expression of the CXCR4 receptor was observed on the cell surface. No SDF-1
mRNA expression was detected in the same cells. Nevertheless, exogenous SDF-1 stimulated
CXCR4 receptor signaling, including increases in Ca2+ flux, MAPK- and Akt- phosphorylation
in these cells. In Vitro studies demonstrated the importance CXCR4 activation for survival
under conditions of serum deprivation, and or production of the pro-angiogenic chemokine,
IL-8. Since gastric tumors arise in the set of chronic inflammation, we tested the effect of
pro-inflammatory cytokine on CXCR4 expression. These studies showed that CXCR4 mRNA
abundance can be further increased (4-6 fold) by the pro-inflammatory cytokines, TNFα
or IL-1β, as well as by hypoxia, but not by INFγ in gastric cancer cells. Mutational analysis
of the CXCR4 promoter revealed a specific region (-540-140 to ATG) containing an NF-
kappaB binding site which is responsible for both basal activity and cytokine-mediated
activation of transcription in Kato-III gastric cancer cells. To extend this observation, we
isolated primary mouse gastric epithelial cells and demonstrated a similar regulation of
CXCR4 by pro-inflammatory cytokines in these cells. Conclusions: Overall our data indicate
that the CXCR4 gene is a novel target of pro-inflammatory cytokines in gastric cancer cells.
Since SDF-1 is known to be abundantly expressed by tumor stromal fibroblasts In Vivo, it
strongly suggests that the inflammation-activated CXCR4 axis likely contributes to growth
and angiogenesis of gastric tumors, and may represent an attractive therapeutic target.
M1615
Effects of Neurotensin On Small Intestinal Afferent Fibre Activity in the Rat
David C. Bulmer, Holly Rossiter, Kevin Lee, Wendy J. Winchester
Neurotensin (NT) is one of the many peptides contained within enteroendocrine cells within
the gastrointestinal mucosa. A number of such peptides have been shown to modulate
visceral afferent sensitivity. Thus, the aim of this study was to evaluate whether NT modulates
afferent function and to characterise the response seen. Mesenteric nerve activity was recorded
from a cannulated segment of ileum in male Sprague Dawley rats (300-450g) anaesthetised
with sodium pentobarbitone (bolus 60 mg/kg i.p.; followed by 10-50 mg/kg/hr i.v.) in
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accordance with the UK Animal Scientific Procedures Act (1986). Changes from baseline
in nerve activity, luminal pressure and mean blood pressure are expressed as mean ± sem.
Statistical comparisons were performed using Student's paired t-test with significance being
determined with p<0.05. NT (0.1, 0.3, 1.0, 3.0 and 10 nmoles/kg i.v. n=5) caused a dose
dependent increase in afferent activity (18.5 ± 3.0 spikes/s at 0.1 nmoles/kg; 57.7 ± 4.6
spikes/s at 1.0 nmoles/kg and 45.6 ± 4.2 spikes/s at 10 nmoles/kg), with the response
saturating at 3 nmoles/kg and above. Pre-treatment with the selective NT1 receptor antagonist
SR48692 (10 mg/kg i.v. n=4) abolished the increase in nerve activity elicited in response
to 0.3 nmoles/kg NT (eg 71.6 ± 2.1 vs 1.4 ± 1.7). In addition to the afferent fibre response,
NT also elicited an increase in ileal pressure and a decrease in blood pressure which were
also abolished by pre-treatment with SR48692 (eg luminal pressure 2.9 ± 0.4 mmHg vs 0.3
± 0.2 mmHg, blood pressure -19.2 ± 12.9 mmHg vs -7.1 ± 4.8mmHg). To determine
whether the effect of NT on afferent activity was secondary to changes in luminal pressure,
the response to NT (0.3 nmoles/kg) was compared before and after injection of nifedipine
(1 mg/kg i.v. n=5). No change in luminal pressure was observed in response to NT following
nifedipine, however a robust increase in afferent activity was still observed (34.0 ± 6.6
spikes/s). To exclude involvement of the depressor effect of NT on the afferent response,
sodium nitroprusside (0.3 mg/kg i.v. n=3) did not alter afferent nerve activity indicating
the depressor effect of NT does not contribute to its excitatory effect on nerve activity. In
conclusion, NT activates intestinal afferents directly and indirectly via increased motility.
Both actions are mediated via the NT1 receptor. These data indicate a possible role for NT
in the signalling of sensory information from the gastrointestinal tract.
M1616
PYY-Induced Stimulation of Intestinal Feedback Involves Apolipoprotein (apo)
a-IV and Cholecystokinin Type 1 Receptors (CCK1Rs)
Kellie Whited, Patrick Tso, Helen Raybould
PYY, released from the distal gut by intestinal lipid, elicits functional effects that comprise
the ileal brake, including inhibition of food intake and delayed gastric emptying. Lipid
initiates intestinal feedback via a vagal afferent pathway involving apo A-IV and CCK1Rs;
The aim of the present study was to determine the role of this pathway in mediating responses
to PYY3-36, selective for the Y2 receptor. Methods: Activation of the vagal afferent pathway
was determined by immunohistochemical localization of Fos protein in neurons in mid-
region of nucleus of solitary tract (NTS; bregma -7.32 to -7.76 mm) following exogenous
administration of PYY3-36 (5μg/100g IP) in C57/B6 mice following either systemic treatment
with the sensory neurotoxin capsaicin to ablate vagal afferents, administration of the CCK1R
antagonist devazepide (1mg/kg), the peripherally-acting Y2R antagonist, BIIE0246 (2 and 6
mg/kg) or corresponding vehicle controls (n=4-6/group). Experiments were also performed
in CCK1R-/- and apo A-IV-/- mice and wildtype (WT) counterparts. Inhibition of food intake
and gastric emptying of chow in response to PYY3-36 (5μg/100g IP) was measured during
the dark cycle in mice fed ad libitum following CCK1R blockade and in apo A-IV-/- mice.
Results: PYY3-36 induced Fos expression in the NTS (52 ± 3 vs 240 ± 10 neurons; vehicle
vs PYY3-36, p<0.01, n=4,5) was significantly reduced by 65% by capsaicin treatment, 78%
by CCK1R blockade, and 39% by peripheral Y2R blockade. PYY3-36-induced Fos expression
was reduced by 89% in CCK1R-/- mice and by 67% in apo A-IV-/- mice compared to WT
controls. PYY3-36 significantly inhibited gastric emptying of a chow meal in WT mice (gms
remaining in stomach; 0.33 ± 0.01 vs 0.53 ± 0.03, saline vs PYY3-36, p<0.05, n=5). PYY3-
36-induced inhibition of gastric empting was reduced by 75% in A-IV-/- mice and abolished
by CCK1R blockade. PYY3-36 significantly inhibited 4 hr food intake in WT mice (111 ± 5
vs 86 ± 2 mgs/gm BW; saline vs PYY, p<0.01; n=10); CCK1R blockade or lack of apo A-
IV (null mice) had no effect on PYY3-36-induced inhibition of food intake. Conclusions:
The data suggest a role for apo A-IV and the CCK1R in PYY-induced activation of the vagal
afferent pathway and inhibition of gastric emptying, but this is likely not the pathway
mediating the effects of PYY3-36 on food intake.
M1617
Cholecystokinin (CCK) Enhanced Human Urocortin 2 (Hucn 2)-Evoked
Gastric Vagal Afferent (Gva) Fiber Responses Via CCK-a Receptor in Rat
Gastric Vagus In Vitro Preparation
Yuhua Wang, Lixin Wang, Jen yu Wei, Guillaume Gourcerol, Mulugeta Million, Yvette
Tache
BACKGROUND: hUcn 2-induced rat GVA fiber discharge via activation of CRF2 receptor,
and most of hUcn 2-responsive GVA fibers are also responsive to CCK and local mechanical
stimuli (Gastroenterology, 2005;128:W1729). CCK exerts potent effects on the activity of
GVAs and interacts with other peptides to inhibit gastric emptying and suppress food intake
(AJP, 1997;273:R833). Recently, our group established that there is a potentiating interaction
between hUcn 2 and CCK to suppress food intake in rodents. AIM: To determine CCK
and CCK-A receptor actions on hUcn 2-induced GVA discharge. METHODS: Fasted, and
isoflurane-anesthetized male rats (250 to 300 g) were used. Experiments were performed
in a rat In Vitro isolated gastric-vagus nerve preparation as previously described (AJP,
2000;279:E695). The GVA fibers response to intra-arterial injection of vehicle (saline, 0.1
ml), hUcn 2 (75 ng) or CCK (1 ng) and a CCK-A receptor antagonist, devazepide (10 μg),
at 10 to 30-min intervals were recorded from the ventral gastric vagal nerve filaments. The
gastric distension (GD, 1 ml) and local mechanical receptor field searching (RF) were also
examined at the end of experiments. A response quotient (Q) calculated as the 5-min total
spike count after/before treatment or the 20 s pulse count pre/during GD were compared.
A total of 63 single units were analyzed from 19 preparations from 3 groups, with 55 units
having basal activity with 0.90 ± 0.13 of average spikes/s, and 8 others were silent units.
21 units were from 7 rats injected with hUcn 2 (group 1, as a control), 23 units from 7
rats with CCK (pretreated) plus hUcn 2 (group 2) and another 11 units from 5 rats with
devazepide plus CCK (group 3). RESULTS: CCK significantly enhanced hUcn 2-induced
GVA fiber discharge of units with basal activity. Devazepide abolished CCK's enhancing
effect, but did not influence GD response. 5 out of 8 silent units responded to GD, and 3
and 4 units responded to CCK and hUcn 2, respectively. All of 63 units responded to RF.
CONCLUSIONS: The data provide evidence that peripheral CCK at a low dose enhanced
hUcn 2-evoked GVA terminals' sensitivity via CCK-A receptor, suggesting possible a interac-
tion between CRF2 signaling and CCK in food intake and gastric motility regulation under
stress. Supported by NIH grant DK33061 (YT).
Values are mean ± SEM. *P < .05, **P < .01 vs. corresponding vehicle, or vs. pre-GD.
Paired or unpaired t test.
M1618
Endocannabinoids Attenuate Ethanol and Ischemia-Reperfusion Injury By the
Mechanism Involving Nitric Oxide Pathway and Sensory Afferent Nerves
Zbigniew Sliwowski, Tomasz Brzozowski, Peter C. Konturek, Robert Pajdo, Jolanta Majka,
Michal Pawlik, Urszula Szczyrk, Stanislaw J. Konturek, Wieslaw W. Pawlik
Endocannabinoids such as eicosanoid anandamide and arvanil, both agonists of CB1 and
type 1 vanilloid (VR-1) receptors, exert neuroprotection in several models of neuronal injury
and anti-inflammatory action in the gut but their potential role in the maintenance of
gastrointestinal integrity and gastroprotection remains unknown. We compared the effect
of intraperitoneal (i.p.) administration of anandamide and arvanil with that of WIN 55212,-
2, the mixed CB1/CB2 agonist on basal and histamine- or pentagastrin-stimulated gastric
acid secretion in rats equipped with gastric fistula (GF) (series A) and on gastric lesions
induced by i.g. application of 75% ethanol and ischemia-reperfusion (I/R) induced by
clamping of celiac artery for 30 min and subsequent clamp release to allow for 3 h of
reperfusion (series B) in rats with or without AM-251 (1 mg/kg i.p.), the selective antagonist
of CB1 receptors, capsazepine (10 mg/kg i.g.), an antagonist of VR-1 receptors and in those
pretreated with L-NNA (20 mg/kg i.p.), to suppress NO synthase activity and capsaicin
(125 mg/kg s.c.) to induce the functional ablation of sensory nerves. The area of gastric
lesions was determined by planimetry, the gastric blood flow (GBF) was assessed by H2-
gas clearance method and the plasma gastrin level was determined by specific RIA. Ethanol
and I/R produced typical hemorrhagic gastric lesions while producing a significant fall in
the GBF and these effects were further agumented in L-NNA-treated and capsaicin-denervated
animals. Anandamide (50 - 300 mg/kg i.p.) and arvanil (10 - 200 mg/kg i.p.) significantly
decreased pentagastrin- and histamine-stimulated gastric acid secretion while WIN 55212,-
2 (20-150 mg/kg i.p.) inhibited only pentagastrin-stimulated gastric acid secretion. Anandam-
ide, arvanil and WIN 55212,-2 dose-dependently reduced ethanol and I/R-induced gastric
lesions while elevating significantly the GBF and plasma gastrin levels. These protective and
hyperemic effects of were significantly attenuated by AM 251, and capsazepine and completely
abolished by capsaicin-denervation and further restored by the addition of exogenous CGRP
(10 mg/kg s.c.) to arvanil and anandamide in rats with capsaicin-deactivation. We conclude
that cannabinoids afford gastroprotection against lesions induced by acid-independent (eth-
anol) and acid-dependent (I/R) model of gastric damage and this could be due to an activation
of cannabinoid CB1 and VR-1 receptors, antisecretory activity of these compounds and an
increase in the gastric microcirculation mediated by NO, gastrin and vasodilatory neuropep-
tides such as CGRP released from sensory nerves.
M1619
Identification and Characterization of Novel Human CRF Receptor Isoforms
Expressed in the GI Tract
Shuping V. Wu, Pu-qing Yuan, Meisheng Jiang, Yvette Tache
Background: Human corticotropin-releasing factor (CRF) system consists of four peptide
hormones: CRF, urocortin (Ucn) 1, Ucn 2 and Ucn 3, one CRF/Ucn binding protein, and
two G-protein coupled receptors: CRF1 and CRF2. Multiple human CRF1 (1a-1h) and CRF2
(2a-2c) isoforms have been identified in tissue and cell-specific manner. Stress-related GI
functional disorders and diseases have been linked to a dysregulated CRF system that implies
altered CRF receptors and functions. We have previously demonstrated that human pancreatic
carcinoid BON cells express multiple CRF-related peptides and CRF receptors that regulate
serotonin release (Gastroenterology 128:A-358 2005). Objective: To characterize the identit-
ies and functions of novel CRF receptor isoforms that are expressed both in normal GI
tissues and neuroendocrine tumor cell lines. Methods: Expression of native CRF receptors
and hormone ligands in human cell lines and GI tissues was determined by RT-PCR and
verified by DNA sequencing and immunoblot analysis. Functional characterization of native
and cloned CRF receptors were performed in BON cells and transfected HEK-293 cells,
respectively. Intracellular cAMP accumulation and medium serotonin release were measured
by ELISA following stimulation with selective CRF agonists and/or antagonists. Results: Both
CRF1 and CRF2 receptor wild-type and splice variants including a novel exon 4-skipping
CRF1, referred to as 1i, and three intron or cryptic exon-containing CRF2 transcripts (2d-
1 to 2d-3) were identified and confirmed in human BON cells and various GI tissues
including esophagus, stomach, small intestine and colon. While expression of CRF was
more restricted and less abundant in the peripheral tissues and cell lines, CRF2 cognate
ligands Ucn 2 and Ucn 3 were widely distributed and highly abundant in the BON cells.
Three novel human CRF2d receptor variants encoding membrane-bound isoforms with
distinct carboxyl-terminal domains were expressed in HEK-293 cells and exhibited differen-
tial cAMP responses to selective CRF agonists compared to the wild type CRF2a receptors.
The ligand and dose-dependent cAMP responses mediated by CRF2d were inhibited by
CRF2-selective antagonist astressin2-B. Conclusions: We identified novel CRF1i and CRF2d
receptor isoforms generated from alternate deletion of known exon or inclusion of previously
unrecognized cryptic exons. Their unique gene expression profile and functional responses
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to CRF ligands suggest that CRF and urocotins may exert normal or altered peripheral effects
on GI motility and secretion through the combination of various receptor isoforms.
M1620
Effects of Peptide Yy (PYY) On Small Intestinal Afferent Fibre Activity in the
Rat
Holly Rossiter, David C. Bulmer, Kevin Lee, Wendy J. Winchester
Peptide YY (PYY) is synthesised and secreted post-prandially from specialised L cells within
the ileum and colon in proportion to the calorific value of ingested food. Peripheral adminis-
tration of PYY reduces food intake and is thought to play an important role in the ileal
brake mechanism, delaying gastric emptying. The effects of PYY on afferent fibres innervating
the ileum have not previously been documented and so the aim of the present study was
to examine this further. Mesenteric nerve activity was recorded from a cannulated segment
of ileum in male Sprague Dawley rats (300-450g) anaesthetised with sodium pentobarbitone
(bolus 60 mg/kg i.p.; followed by 10-50 mg/kg/hr i.v.) in accordance with the UK Animal
Scientific Procedures Act (1986). Changes from baseline in mesenteric nerve activity, luminal
pressure and mean blood pressure were determined and expressed as mean ± sem. Statistical
comparisons were performed using Student's paired t-test p<0.05. Injection of increasing
doses of PYY (0.1, 0.3, 1.0, 3.0 and 10 nmoles/kg i.v. n=5) elicited a significant dose related
increase in afferent nerve activity, intestinal pressure and blood pressure (Table 1). To
determine whether the increase in afferent nerve activity was secondary to the increase in
luminal pressure the effects of PYY (3 nmoles/kg) were compared before and after treatment
with nifedipine (1 mg/kg n=3). No change in luminal pressure was observed to PYY following
nifedipine however a significant increase in nerve activity was still observed (53.5 ± 12.8
spikes/s). Furthermore, to exclude the possibility that increasing blood pressure may have
contributed to the afferent fibre response elicited by PYY, injections of phenylephrine (10
ug/kg i.v. n=3) were made to raise blood pressure to comparable levels. No change in
afferent nerve activity was observed following injection of phenylephrine. The results of this
study demonstrate that exogenous application of PYY increases ileal afferent fibre activity
both directly and indirectly by increasing luminal pressure. These data suggest that the
effects of peripheral administration of PYY on food intake may be mediated through the
activation of afferent nerves innervating the ileum.
Table 1: change in nerve activity, luminal pressure and blood pressure following PYY
M1621
Effects of Neuropeptide Ff (Npff) On Jejunal Afferent Fibre Activity in the Rat
David C. Bulmer, Holly Rossiter, Gary Moore, Kevin Lee, Wendy J. Winchester
The role of the opioid modulating, FMRFamide family peptide, neuropeptide FF (NPFF) in
the central and spinal processing of somatic pain has been well documented (Mollereau et
al 2005). However, the effect of NPFF on primary afferent fibre activity has not previously
been reported. The aim of the present study was to determine the effects of NPFF on visceral
afferent fibres innervating the jejunum. Mesenteric nerve activity was recorded from a
cannulated segment of jejunum, in male Sprague Dawley rats (300-450g) anaesthetised with
sodium pentobarbitone (60 mg/kg i.p.; 10-50 mg/kg/hr i.v.), in accordance with the UK
Animal Scientific Procedures Act (1986). Changes in nerve activity and mean arterial blood
pressure were determined from baseline ongoing activity in response to intra venous injection
of NPFF or related peptide RFRP-1 and are expressed as mean ± sem. Statistical comparisons
were performed using Student's paired t-test with significance being determined with p<0.05.
Injection of NPFF (300 nmoles/kg i.v. n=4) elicited a robust significant increase in afferent
nerve activity (59 ± 9.5 spikes/s). Pre-treatment with naloxone (1mg/kg i.v. n=4) did not
change the increase in afferent activity (58 ± 9.2 spikes/s) following injection of NPFF (300
nmoles/kg i.v. n=4), indicating that the effects of NPFF were not mediated through the
release of endogenous opioids. To determine the NPFF receptor subtype mediating the
effects of NPFF, dose response curves were constructed comparing the effects of NPFF and
related peptide RFRP-1 on afferent fibre activity. NPFF and RFRP-1 have similar potencies
at the NPFFR1 receptor, however NPFF is more potent (>150 fold) than RFRP-1 at the
NPFFR2 receptor (Liu et al 2001). RFRP-1 increased afferent nerve activity with similar
ED50 values to NPFF, strongly suggesting that these effects were mediated through the
NPFFR1 receptor (ED50; RFRP-1 373 nmoles/kg vs NPFF 246 nmoles/kg n=5). Injection
of NPFF or RFRP-1 also increased blood pressure (36.9 ± 3.8 mmHg NPFF 300 nmoles/
kg n=4). The ED50 values for this pressor effect were similar (RFRP-1, 123 nmoles/kg vs
NPFF, 323 nmoles/kg n=5) suggesting that this was also mediated through NPFFR1 receptors.
The results of this study demonstrate that exogenous injection of NPFF stimulates jejunal
afferent fibre activity and suggests that this activation is mediated through the NPFFR1
receptor. The data generated supports a potential role for NPFF in the signalling of sensory
information from the intestines. Mollereau C et al. Current Topics in Medicinal Chemistry
5 341-355 (2005). Liu Q. et al. The Journal of Biological Chemistry 276 (40) 36961-
36969 (2001).
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M1622
Down-Regulation of CRF Receptor Type 1 (CRF1) and Up-Regulation of
Interleukin -1β in the Colon By Abdominal Surgery in Mice: Implications in
Postoperative Ileus
Pu-qing Yuan, Gourcerol Guillaume, Million Mulugeta, Lixin Wang, Yvette Tache
Background: Postoperative ileus is characterized by motility disorder in gut that occurs after
abdominal surgery (Gastroenterology 1999; 117: 489-492). The colon is a crucial component
for recovery of GI motor function after surgery (Ann Surg. 2002; 236: 56-66). Peripheral CRF
induced a CRF1-dependent stimulation of colonic motility. The proinflammatory cytokines
decrease the expressions of CRF1 in pituitary and CRF2 in aorta- derived A7R5 cell line
(Endocrinology 1996; 137:1758-1763; 2000; 141: 2285-2293). Aims: To investigate the
colonic expressions of CRF receptors and proinflammatory cytokines in mice after abdominal
surgery. Methods: Fasted female C57BL/6 mice (21-28g) were anesthetized with isoflurane
and underwent either surgery (midline celiotomy and cecal palpation for 60 sec) or sham
(no surgery). Colonic motility was monitored in conscious mice using intraluminal pressure
microtransducer (SPR-524, Millar system, Houston, TX) inserted 2 cm in the colon. After
a 15 min onset, the area under the curve (AUC) was measured 1 h before and after surgery
or sham. Proximal and distal colonic tissue samples were harvested 110 min after surgery
or sham. The gene expressions of CRF1,CRF2,IL-1β,TNF-α,TGF-β were measured by RT-
PCR and quantitative analysis was carried out using Scion imaging software. Immunohistoch-
emical locolization of CRF1 was performed in proximal and distal colon of naive mice.
Results: Abdominal surgery resulted in a significant decrease in colonic motility (intra-
colonic pressure: 2601±432 mmHg/h, n=5, vs 7525±1110 mmHg/h in sham, n=5; p<0.05).
CRF1 mRNA level was significantly decreased by surgery in proximal colon, but not in
distal colon while CRF2 was not altered in both proximal and distal colon. Surgery increased
significantly mRNA levels of IL-1β in proximal colon and TGF-β in distal colon (Table 1).
CRF1 immunoreactivity was mainly located in colonic submucosal and myenteric plexus.
Conclusions: These findings showed the inhibition of colonic motility initiated by surgery
in mice; this is associated with a decreased CRF1 mRNA expression and increased proinflam-
matory cytokine expression that may contribute to postoperative ileus.
Table Effect of abdominal surgery on mRNA expression (% proximal colon in sham; *p<0.05
vs sham)
M1623
Increased Apelin Expression in Response to LPS Is Mediated By IL-6
Song Han, Xiang Qi, Guiyun Wang, George H. Greeley
Apelin is the endogenous ligand for the APJ receptor and apelin and APJ are expressed
throughout the GI tract. Apelin has been shown to influence intestinal and pancreatic
hormone and gastric acid secretion. Intestinal inflammation increases enteric apelin expres-
sion. Purpose. The aim of this study was to examine involvement of IL-6 in the upregulation
of apelin expression during inflammation. Methods. Experiment 1 (Exp 1): six-day-old
Sprague-Dawley rat pups, C57BL/6 mice or nude mice were given LPS (1 mg/kg, IP). Ileums
were harvested at different times after LPS, total cellular RNA extracts were prepared and
apelin mRNA levels measured by Northern analysis or real time RT-PCR. Exp 2: colon cell
lines (HT116, HT29) and primary rat ileal cells were treated with LPS (2 μg/ml). Cell apelin
mRNA levels were measured. Exp 3: HT116 cells were treated with either IL-6 (20 ng/ml)
or media harvested from LPS-or IL-6-treated thymocytes. Exp 4: rat pups were treated with
IL-6 (100 ng, IP) and ileal apelin mRNA levels measured. Results. Exp 1: In Vivo LPS
treatment increased apelin mRNA levels in the rat (2.5-fold) and mouse (2.4-fold) ileum
(Table). In nude mice, LPS-induced apelin expression was impaired signficantly (1.5-fold).
Exp 2: LPS treatment of cultured cells did not increase apelin expression. Exp 3: Treatment
of H116 cells with IL-6 (control: 11.9±1.8 vs IL-6: 18.5±1), media harvested from LPS-
(control: 0.9±0.1 vs LPS-treated: 2±0.3) or IL-6 (control: 11.9±1.8 vs IL-6 treated: 20.4±0.8)
treated thymocytes increased apelin expression significantly. Exp 4: IL-6 treatment of rat
pups increased ileal apelin expression seven-fold (control: 0.06±0.03 vs IL-6: 0.46±0.05).
Conclusions and Discussion. The finding that LPS increases apelin expression In Vivo, but
not In Vitro indicates that LPS acts indirectly to increase intestinal apelin expression. The
inflammation-induced elevation in intestinal apelin expression may be triggered partly by
T cell mediators since LPS-induced apelin expression is reduced in nude mice. Evidence
that IL-6 mediates LPS effects on apelin expression is given by the increased apelin expression
in cells exposed to media harvested from LPS or IL-6 treated thymocytes. In addition, a
role for IL-6 in activating apelin expression is demonstrated by the increased ileal apelin
expression with IL-6 treatment In Vivo. * = p<0.05.
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M1624
The Specific Nicotinic α7 Receptor Agonist Ar-R17779 Reduces Inflammation
in a Mouse Model of DSS Colitis
Susanne A. Snoek, Marleen I. Verstege, Esmerij P. Van der zanden, Greg Larosa, Guy E.
Boeckxstaens, Anje Te velde, Wouter J. De jonge
INTRODUCTION: The parasympathetic nervous system represses inflammation through the
nicotinic α7 acetylcholine receptor (α7 nAChR) which is expressed on macrophages. As
macrophage activation by luminal antigens is an important feature in de induction and
perpetuation of inflammatory bowel disease, theα7 nAChR might be an important therapeutic
target to reduce gastrointestinal inflammation. Therefore we assessed the potency of a selective
α7 nAChR agonist AR-R17779 to ameliorate gastrointestinal inflammation in a DSS colitis
mouse model. METHODS: Mice received 1.5% DSS in drinking water for up to 7 days.
Vehicle (0.9% NaCl), 1 mg/kg or 5 mg/kg AR-R17779 was administered daily by intraperi-
toneal injection. The mice were killed after 7 days and colonic inflammation was assessed
according to clinical parameters. To determine bacterial translocation, caudal lymph nodes
were homogenized and plated onto blood agar plates. After 24h incubation at 37oC, the
amount of colony forming units per lymph node was assessed. The data represent the mean
± SE. Differences between groups were analysed using the nonparametric Mann-Whitney
U test. RESULTS: Treatment with AR-R17779 significantly reduced DSS-induced weight
loss, colonic shortening, histopathology score and disease activity index (table 1). Also,
bacterial translocation (number of colony forming units cultured from caudal lymph node
after 7 days of DSS) was significantly decreased after treatment with AR-R17779 [vehicle:
409.0±168.0, AR-R17779 1 mg/kg:106.0±60.0, AR-R17779 5 mg/kg: 4.0±2.0 (p<0.05)].
CONCLUSION: Administration of AR-R17779 significantly ameliorates disease parameters
in DSS colitis. In addition, treatment with AR-R17779 reduced bacterial translocation indicat-
ing that intestinal barrier function is improved. These data suggest that α7 nAChR-agonists
might be a potential new treatment for inflammatory bowel disease.
Table 1: Clinical parameters after 7 days of DSS. * The disease activity index is the combined
score of weight loss, stool consistency and bleeding divided by three. Weight loss: 1-5% =
1, 5-10%=2, 10-20%=3, <20%=4; stool consistency: normal=0, loose stools=2, diarrhoea=
4; bleeding: negative=0, positive=2, gross bleeding=4 $ Score grading from 0 to 26 points
consisting of: the extent of the involved area, the number of follicle aggregates, oedema,
ulceration, crypt loss, infiltration of mononuclear and polymorphonuclear cells.
M1625
Involvement of Brain Alpha-2a Adrenoceptors in the Regulation of Gastric
Acid Secretion in Pylorus Ligated Rats
Katalin Müllner, Katalin Fülöp, Klára Gyires, Zsolt Tulassay
Background: Previously it was shown that α2-adrenoceptor agonists given peripherally
exerted antisecretory effect on the gastric mucosa in rats. Aims & methods: The aim of our
study was to analyse the possible involvement of different central α2-adrenoceptor subtypes
in the regulation of gastric acid secretion. Pylorus ligation was carried out in rats according
to Shay et al. The different test compounds were injected intacerebroventricularly (icv.).
The gastric volume was measured and the samples were analyzed for gastric acidity by
titration with 0.1 N NaOH. Results: Clonidine given icv. exerted a dose dependent inhibitory
effect on the gastric acid secretion (ED50=20 nmol/rat). The antisecretory effect of clonidine
was blocked by yohimbine, a non-selective α2-receptor antagonist (51.2 nmol/rat icv.)
indicating that the action was mediated by presynaptic α2-adrenoceptors. Prazosin (4.7
nmol/rat icv.) and ARC-239 (10.4 nmol/rat icv.) - antagonists of α2B-adrenoceptor subtype
- failed to inhibit the antisecretory effect of clonidine suggesting that α2B-adrenoceptors are
not likely to be involved in this centrally induced action of clonidine. Furthermore, the
α2A-adrenoceptor agonist oxymetazoline decreased the gastric acid secretion in a dose
dependent manner (ED50=7.5 nmol/rat icv.). BRL-44408 (120 nmol/rat icv.), an α2A-
adrenoceptor selective antagonist, inhibited the centrally induced antisecretory action of
oxymetazoline. Conclusions: These findings indicate that activation of central α2A-, but
not α2B-adrenoceptor subtype result in an inhibition of gastric acid secretion in pylorus
ligated rats.
M1626
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Stimulates Both
Acid and Pepsinogen Secretions in Rat Stomachs Via Histamine Release
Eitaro Aihara, Fumitaka Ise, Shinichi Kato, Koji Takeuchi
Background/Aims: Pituitary adenylate cyclase-activating polypeptide (PACAP), a biologically
active neuropeptide, has two amidated forms, PACAP-27 and -38, which are structurally
similar to that of vasoactive intestinal polypeptide (VIP). Several studies reported that PACAPs
increase gastric acid secretion but the results are not without controversy. In addition, their
effects on pepsin secretion have not been much studied. In the present study, we investigated
the effect of PACAPs on gastric acid and pepsin secretions in rats. Methods: Male SD rats
were used after 18 h fasting. Under urethane anesthesia, the stomach was mounted on an
ex-vivo chamber and superfused with saline. The secretion of acid was measured at pH 7.0
using a pH-stat method and by adding 50 mM NaOH, while that of pepsinogen was measured
by the modified Anson method. Luminal content of histamine was determined by enzyme
immunoassay. PACAP-27 (4~32 nmol/kg), PACAP-38 (0.5~8 nmol/kg), VIP (4 nmol/kg) or
histamine (1 mg/kg) was given IV as a single injection. In some cases, PACAP6-38 (PAC1
antagonist; 40 nmol/kg), verapamil (0.2 mg/kg) or atropine (1 mg/kg) was given IV 10 min
before the administration of PACAP-38, while cimetidine (200 mg/kg) was given IP 30 min
before. In addition, cysteamine (400 mg/kg, a depletor of somatostatin from D cells) was
gvien PO 4 h before the administration of PACAP-38. Results: Both PACAP-27 and PACAP-
38 significantly stimulated gastric acid secretion in a dose-dependent manner, while VIP
had a significant but minimal effect on the secretion, the order of potency being PACAP-
38>PACAP27>>VIP. The acid stimulatory effect of PACAP-38 was significantly attenuated
by cimetidine and PACAP6-38, a PAC1 antagonist, but not verapamil or atropine. PACAP-
38 increased the luminal content of histamine. It was also found that the acid stimulatory
action of PACAP-38 was prolonged when the animals were pretreated with cysteamine. In
addition, PACAP-38 also stimulated the secretion of pepsin at the same dose levels that
increased acid secretion. The pepsin stimulatory effect of PACAP-38 was also inhibited by
PACAP6-38 and cimetidine but not by atropine. VIP also stimulated the secretion of pepsin,
though the effect was minimal. Conclusions: These results suggest that PACAP stimulates
gastric acid as well as pepsin secretions, through the release of histamine from enterochromaf-
fin-like cells, and these effects may be mediated by the activation of both PAC1 and VPAC1
receptors. In addition, the acid response to PACAP may also be negatively affected by
endogenous somatostatin released from D cells.
M1627
Somatostatin Inhibits Gastric Acid Secretion and Reduces the Activity of
Carbonic Anhydrase IV in Gastric Parietal Cell.a New Mechanism of Action
Ioan Puscas, Andrei Todea, Adrian Maghiar, Marcela Coltau, Gabriela Domuta, Paula
Mare, George Ionescu
Somatostatin inhibits gastric acid secretion (GAS) by a paracrine mechanism. Previous work
performed by us showed that somatostatin inhibits erythrocyte and gastric mucosa carbonic
anhydrase (CA) I and CA II, and antagonizes the activating effect of pentagastrin on CA,
while cimetidine does not modify this activating effect. AIM: we have studied the effect of
somatostatin on CA IV - a membrane-bound enzyme located both in gastric parietal cells
and in the kidney. We also studied In Vivo the relationship among somatostatin, CA IV and
gastric acid secretion. MATERIAL AND METHOD: In Vitro, we have investigated the effect
of somatostatin according to dose-response relationship, at concentrations between 10(-8)M
and 10(-4)M on gastric and renal CA IV. In Vivo, a group of 34 healthy volunteers received
a single s.c.dose of 100 I.U. somatostatin. Gastric mucosa was removed by endoscopic biopsy
both before and after somatostatin administration. Parietal cells isolation was performed by
the Lewin method, and CA IV separation according to a technique described by Maren. CA
activity was achieved by the stopped-flow method. At the same time the gastric acid secretion
was measured before and after 1 hour somatostatin administration in order to establish the
basal acid output (BAO). DISCUSSION AND CONCLUSIONS: Somatostatin inhibits gastric
CA IV by a direct mechanism of action both In Vitro and In Vivo and do not modify the
activity of renal CA IV. In Vivo, somatostatin reduces gastric acid secretion in parallel with
parietal cell membrane CA IV inhibition. The reduction of gastric acid secretion induced
by somatostatin in parallel with CA IV inhibition suggests the presence of a dual mechanism
of action for this hormone which reacts both with its specific receptor and also with the
membrane enzyme CA IV, respectively. The pH changes initiated by CA IV inhibition might
be propitious to the somatostatin-cell receptor binding, to the information transmission
within the cell and to gastric acid secretion inhibitory response.
RESULTS
M1628
The Presence of AMP-Activated Protein Kinase and Its Regulatory Role in
Gastric Acid Secretion
Shafik Sidani, Thenral Socrates, Michael Föller, John P. Geibel
Backround: AMP-activated protein kinase (AMPK) has been shown to be a metabolic sensor
and regulator of energy balance in various cells of the body. Activation is a direct result of
rising AMP coupled with falling ATP. As a result, AMPK activation to its phosphorylated
form during metabolic stress reduces ATP consumption. Thus far, the presence of AMPK
has been demonstrated in the liver, skeletal muscle, pancreas, brain, heart, and adipose
tissue. The gastric parietal cell is known to have a particular abundance of mitochondria
due to the numerous energy dependent transporters and channels responsible for acid
secretion. In that light, we elected to localize AMPK in the parietal cell as a metabolic fuel
sensor and regulator that could switch acid secretion off as cellular ATP levels fall. We also
measured secretagogue-induced acid secretion in murine isolated gastric glands following
activation and deactivation of AMPK. Methods: AMPK presence was evaluated by immuno-
histochemistry as well as Western blot analysis of lysate protein obtained from gastric glands
of murine corpus. We used a digital-imaging system to observe proton efflux from parietal
cells in hand dissected gastric glands loaded with the pH sensitive dye BCECF. Individual
murine gastric glands were exposed to either: histamine (100μmol), pentagastrin (100 μmol),
or carbachol (100μmol) and a HCO3-/Na+ free perfusate to induce an acid load. To activate
AMPK in wild type mice we used 10mM AICAR. Subsequently, AMPK was deactivated using
20µM Compound C. Intracellular pH recovery rates were evaluated in the above protocols
and compared to each other as well as to control with only secretagogue. Results: Immuno-
histochemistry and Western blot analysis demonstrated the presence of AMPK in the parietal
cell. AICAR significantly reduced secretagogue-induced acid secretion whereas Compound
C restored it. Conclusion: AMPK was found to be present in the parietal cell. Acid secretion
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induced by histamine, pentagastrin, and carbachol could be significantly reduced with its
activation and restored with its deactivation. These results demonstrate a substantial regu-
latory presence of AMPK as the energy sensor in the acid secreting gastric parietal cell.
M1629
Helicobacter pylori Status Is Associated with Ghrelin Levels in Gastric Juice
Peter L. Shue, Jatin Roper, Fritz Francois, Zhiheng Pei, Asalia Z. Olivares, Guillermo I.
Perez-perez, Martin J. Blaser
Background: Ghrelin, a gastric hormone involved in mammalian energy homeostasis also
exerts anti-proliferative effects in tumor cell lines and anti-ulcerative effects in the rat stomach.
The ghrelin type 1b receptor has been identified in the human stomach and esophagus. We
hypothesized that ghrelin may act locally in the gastric lumen via gastric secretions, and
that Helicobacter pylori colonization may affect levels of ghrelin in gastric juice. Methods:
We prospectively enrolled 256 male patients referred for upper endoscopy at the Manhattan
VA Medical Center. Gastric juice was collected from each subject during the endoscopic
procedure. Based on histological, chemical and serological tests, patients were categorized as
H. pylori-positive or H. pylori-negative. We validated an enzyme immunoassay for quantifying
ghrelin in gastric juice and applied it to our specimens. Results: Of the 256 subjects, 120
were H. pylori-positive and 96 were H. pylori-negative (40 patients of indeterminant status
were excluded from further analysis). The H. pylori-positive group had significantly higher
gastric pH than the H. pylori-negative group (median 5, IQR (2-7) vs. median 3, IQR (2-
6), p=0.005), which was independent of proton pump inhibitor (PPI) use. Addition of
ghrelin to representative gastric juice samples (pH 2 to 7) could be fully detected. In the
216 patients, ghrelin levels in juice varied over 4 orders of magnitude (<80 pg/ml to 776,000
pg/ml). Ghrelin levels in gastric juice correlated with gastric pH in the H. pylori-positive
group (R=0.68, p<0.0001) in both PPI users and non-users. In the H. pylori-negative group
there was a significant correlation between ghrelin and gastric juice pH in PPI users (R=
0.50, p=0.001), but not in PPI non-users. Ghrelin levels (pg/ml) in gastric juice were
significantly higher in H. pylori-positive than in H. pylori-negative subjects (median 1101, IQR
(390-23413) vs. 711 (323-1851); p= 0.019). Conclusions: These results indicate substantial
variation in gastric juice ghrelin levels, which are stable over the physiologic range of acidity.
Ghrelin levels in gastric juice are positively associated with both gastric pH and H. pylori
status. By raising gastric pH, H. pylori may stimulate intraluminal ghrelin secretion.
M1630
Absence of Functional Proteinase-Activated Receptor-2 (PAR2) Attenuates the
Inflammatory Responses in Mouse Intestine in a Th2 Mouse Model of Colitis
Eric Hyun, Nathalie Vergnolle, Patricia Andrade-gordon
Background and aims: Previously, we have shown that PAR2 deficiency confers a protection
to mice against the development of experimental colitis, in models of dextran sodium sulfate
(DSS) and trinitrobenzene sulphonic acid (TNBS) that are mainly associated with Th1
cytokine profile. Because another member of the PAR family, PAR1, seems to be involved
in Th1 but not Th2-induced colitis, we wanted to investigate similar possible involvement
for PAR2. Thus, the aim of this study was to investigate the effects of PAR2 deficiency on
colitis with a Th2 cytokine profile. Methods: Colonic inflammation in C57BL6 wildtype and
PAR2-deficient (PAR2 -/-) mice was induced by pre-sensitizing mice with 3% oxazolone
(dissolved in olive oil), applied to the abdomen, and challenging mice, seven days later,
with a single intracolonic injection of 1% oxazolone (dissolved in 50% ethanol). Change in
the weight of the animals was assessed daily after the oxazolone challenge. Four days after
challenge, intravital microscopy was performed on selected venules of the colon to assess
the role of PAR2 activity on leukocyte rolling, adhesion and vasodilation. Immediately
following intravital microscopy, colon samples were harvested to assess various inflammatory
parameters including myeloperoxydase (MPO) activity (index of granulocyte infiltration),
bowel thickness, and microscopic/macroscopic damage scores. Results: Treatment with
oxazolone induced strong signs of colitis including granulocyte infiltration, macroscopic and
microscopic damage, and edema formation. Significantly lowered MPO activity, macroscopic
damage scores, and bowel thickness were observed in PAR2 -/- compared to wildtype
mice. Microscopic damage scores, particularly parameters of cellular infiltration, submucosal
edema, and damage/necrosis were significantly reduced in PAR2 -/- mice. The degree of
weight loss was significantly higher in the wildtype mice than PAR2 -/- throughout the
development of oxazolone-induced colitis. Lastly, PAR2 -/- displayed significant lower num-
bers of adherent leukocytes to the vessel wall compared to wildtype animals. Conclusions:
Our results indicate that PAR2 activation attenuates the inflammatory responses in the
experimental model of colitis associated with a Th2 cytokine profile, in the mouse colon.
Together with our previous studies demonstrating an active pro-inflammatory role for PAR2
activation in Th1 models of colitis, we can now conclude that PAR2 activation in the gut
is pro-inflammatory, and this effect does not depend on a Th1 or Th2 cytokine profile. This
study further highlights PAR2 as a potential target for inflammatory bowel diseases.
M1631
Deficiency in Proteinase-Activated Receptor-2 (PAR2) Attenuates the
Inflammatory Responses in Mouse Intestine: Role of PAR2 in Leukocyte
Recruitment
Eric Hyun, Nathalie Vergnolle, Patricia Adrade-gordon
Background and aims: In a previous study, we have examined the effects of PAR2 deficiency
in models of mouse colitis (the trinitrobenzene sulfonic acid model and the dextran sodium
sulfate model). Different parameters of inflammation were reduced in PAR2-deficient mice
(PAR2-/-) for both models, demonstrating a pro-inflammatory effect of PAR2 activation in
the course of experimental colitis. Among the inflammatory parameters observed, infiltration
of granulocytes to the colon was consistently reduced by PAR2 deficiency. Therefore, we
hypothesized that PAR2 activation could play a major role in leukocyte recruitment to
inflammatory tissues. The aim of this study was to examine the effects of PAR2 deficiency
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(via the use of PAR2-deficient mice: PAR2 -/-) on the recruitment of leukocytes in colonic
venules. Methods: Using intravital microscopy, we evaluated the ability of various leukocyte
stimuli (fMLP, TNF-α and platelet activating factor - PAF) to induce leukocyte trafficking
and vasodilation in colonic venules of PAR2 -/- versus PAR2+/+ mice. In anaesthetized
animals, leukocyte rolling/adherence and vasodilation were induced on selected venules, by
topical administration of fMLP (100 μM) or PAF (100 nM) or by intraperitoneal injection
of TNF-α (0.5 μg - given 3 hours before the intravital microscopy). The number of rolling
and adhering leukocytes and vessel diameter were evaluated on video playback of venule
recordings. Results: fMLP and PAF (within minutes) as well as TNF-alpha (three hours after
injection) induced vasodilation and a significant increase in rolling and adhesion of leukocytes
in mouse colonic venules. PAR2 -/- mice showed significantly lower leukocyte rolling com-
pared to the wildtype mice in response to fMLP topical administration. The leukocyte
adherence induced by fMLP and TNF- α was significantly lower in PAR2 -/- mice compared
to wild types as well. No difference was observed between PAR2 -/- and wildtype for
leukocyte rolling and adherence. Changes in vessel diameter were not significantly different
between PAR2 -/- and wildtype mice in all three leukocyte stimuli. Conclusions: The lack
of PAR2 expression attenuated leukocyte trafficking in response to fMLP and TNF- α but
not to PAF. The involvement of PAR2 activation in mouse colon leukocyte trafficking
demonstrated by the present study, provides a possible explanation to the anti-inflammatory
effects of PAR2 deficiency previously described in the development of experimental colitis.
Moreover, it highlights PAR2 as an important mediator or inflammatory cell recruitment
and thereby a potential target for the treatment of inflammatory bowel diseases.
M1632
Protease-Activated Receptor 2, Dipeptidyl Peptidase I and Tryptic Proteases
Mediate Clostridium difficile Toxin a-Induced Ileitis in Mice
Graeme S. Cottrell, Silvia Amadesi, Stella Pikios, Eric Camerer, Adam Willardsen, Brett
Murphy, George Caughey, Paul Wolters, Shaun R. Coughlin, Anders Peterson, Wolfgang
Knecht, Charalabos Pothoulakis, Nigel W. Bunnett, Eileen F. Grady
Multiple serine proteases are generated during tissue injury and inflammation. Certain
proteases, such as trypsins, mast cell tryptase, coagulation factors VIIa and Xa, and kallikreins,
cleave protease-activated receptor 2 (PAR2) and thereby induce inflammation in the skin
and intestine. The aim of this study was to define the contributions of PAR2 and the enzymes
that activate PAR2 in Clostridium difficile-induced enteritis. We induced inflammation by
injecting toxin A (TxA) from C. difficile into the ileal lumen of mice in which PAR2 or the
mast-cell processing protease, dipeptidyl peptidase I (DPPI), was deleted, and in wild-type
mice pretreated with either the tryptase inhibitors nafamostat mesilate (FUT-175) or MPI-
0442352, or soybean trypsin inhibitor (SBTI). In wild-type mice, TxA (0.5-1 µg) caused a
robust inflammation within 3 h, that was characterized by fluid secretion into the intestinal
lumen, elevated levels of granulocyte myeloperoxidase (MPO) activity in luminal fluid and
tissues, and histological findings of epithelial damage, edema and neutrophil infiltration.
Deletion of PAR2 decreased TxA-induced inflammation, indicated by 30% reduced luminal
fluid secretion, 50% decreased tissue and fluid myeloperoxidase, and diminished histological
damage. Deletion of DPPI reduced secretion by 40% and fluid myeloperoxidase by 55%.
In wild type mice, FUT-175 or MPI-0442352 inhibited TxA-induced secretion by 24-28%
and tissue and fluid myeloperoxidase by 31-70%. SBTI decreased secretion to basal levels,
and reduced tissue myeloperoxidase by 50%. Administration of pancreatic trypsin I/II,
extrapancreatic trypsin IV, p23, tryptase, and PAR2-activating peptide SLIGRL-NH2 into the
lumen also caused inflammation. The neurokinin 1 receptor antagonist SR140333 inhibited
PAR2-induced inflammation, indicative of a substance P-mediated neurogenic mechanism.
TxA treatment markedly upregulated expression of immunoreactive PAR2 in the intestinal
mucosa, and exposure of human NCM460 colonocytes to TxA caused a 2-fold increase in
Ca2+ responses to PAR2 agonists, and a 2-fold increase in PAR2 and trypsin IV mRNA after
4-6 h. Thus, PAR2 and the enzymes that activate PAR2 play a major pro-inflammatory role
in TxA-induced enteritis. The mechanisms involve both stimulation of existing PAR2 and
upregulation of PAR2 and activating proteases, to cause inflammation by neurogenic mechan-
isms. PAR2 and proteases thereby play a major role in C. difficile-induced ileitis, an important
human disease. Supported by NIH DK43207, DK57480, DK52388 and Astra-Zeneca.
M1633
Gut Homing Properties of Circulating T Cells in Patients with Irritable Bowel
Syndrome (IBS)
Birgit Adam, Tobias Liebregts, Christoph Bredack, Stuart M. Brierley, Kate R. Pilkington,
Julia G. Junne, Alexander Roeth, L.ashley Blackshaw, Nicholas J. Talley, Gerald Holtmann
Background: Inflammation and immune activation may contribute to the manifestation of
symptoms in at least a subgroup of patients with IBS. Preliminary studies suggest increased
mucosal T cells occuring in a subset of patients with IBS. We have previously demonstrated
that peripheral blood lymphocytes from patients with diarrhea- predominant IBS have an
augmented cytokine release (Gastroenterology 2006; 130 (4):A51). Detection of alpha-4
integrin (α4) and beta-7 integrin (β7) on circulating T cells identifies specific lymphocyte
subsets trafficking between the circulation and the gut. We therefore hypothesized that
patients with IBS have increased circulating ‘gut homing' T cells compared to healthy controls.
Thus, we aimed to quantitate a) circulating T cell numbers, b) and α4+β7+ positive T cell
subsets in patients with IBS compared to healthy controls. Methods: Peripheral blood
mononuclear cells (PBMC) from 47 patients with IBS (n=17 D(diarrhea)-IBS, 14 C(constip-
ation)-IBS, 16 M(mixed)-IBS) and 32 matched healthy controls were isolated by density
gradient centrifugation. Cell surface expression of CD4, alpha-4 integrin and beta-7 integrin
was analyzed by flow cytometry, while quantitative α4 and β7 mRNA expression was
characterized by RT-PCR in comparison to 4 different plasmid standards. Results: Overall
no significant differences were observed for numbers of CD4+ T cells between patients and
healthy controls. In contrast patients with D-IBS showed a significantly (p<0.05) higher
percentage of α4+β7+ CD4+ T cells (35.4±5.9%) compared to HC (20.5±2.6%), C-IBS
(23.5±4.9%) or M-IBS (21.6±4.5%). RT-PCR showed significantly enhanced mRNA expres-
sion for alpha-4 integrin (p<0.01) and beta-7 integrin (p<0.05) in D-IBS, while no significant
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changes were observed for any other IBS subgroup compared to HC. Summary and Conclu-
sion: Patients with D-IBS are characterized by altered homing properties of circulating T
lymphocytes with increased numbers of CD4+ α4+β7+ T cells. These findings are consistent
with increased activated T-cells homing into the gut in D-IBS. An underlying disturbance
of immune function may play a central role in the manifestations of D-IBS associated with
persisting low-grade gut inflammation.
M1634
Continuous Recirculation of Colitogenic Cd4+ T Cells May Be Required for
Perpetuation of Chronic Colitis
Takayuki Tomita, Takanori Kanai, Toshimitsu Fujii, Yasuhiro Nemoto, Shin Makita, Teruji
Totsuka, Mamoru Watanabe
Background: Crohn's disease (CD) is characterized by chronic intestinal inflammation. Surgery
does not cure CD, suggesting that CD is not a circumscribed disease, but rather a systemic
disease that colitogenic CD4+ T cells distribute throughout the body via bloodstream.
Consistent with this hypothesis, usefulness of leukocytoapheresis for patients with inflammat-
ory bowel diseases (IBD), which has been recently appreciated in Japan as an selective
removal therapy targeting pathogenic immune cells in the blood, suggests that recirculation
of colitogenic lymphocytes plays a role in the perpetuation of colitis. We here assess whether
continuous recirculation of colitogenic CD4+ T cells is required for perpetuation of chronic
colitis using a murine model of colitis induced by adoptive transfer of CD4+ CD45RBhi T
cells into SCID mice. Methods: We first checked if CD4+ T cells circulate in thoracic duct
(TD) and peripheral blood (PB), mensentic lymph nodes (MLN), spleen (SP) and bone
marrow (BM) in established colitic SCID mice at 8 wk after transfer. We next assessed
whether new SCID mice transferred with colitic PB CD4+ cells develop colitis. We further
assessed whether colitis is transferable in parabiosis system between colitic donor and new
host SCID mice. We lastly evaluated whether FTY720, which has an activity to turn off the
circulation of CD4+ T cells by suppressing their egress from lymph nodes to efferent lympatics,
suppresses the development of colitis induced by the adoptive transfer of colitogenic CD4+
T cells. Results: In colitic mice, almost all CD4+ CD45RBhi naïve T cells after the transfer
were converted to CD4+ CD45RBlow CD44hi CD62L- IL-7Rhi effector-memory T cells and
were found throughout the whole body, such as LP, TD, PB, MLNs, SP, and BM, rather
than only in the LP. New SCID mice re-transferred with colitic PB CD4+ T cells developed
chronic colitis. In parabionts between the colitic donor SCID and new host SCID mice, host
SCID mice also developed colitis 3-4 wk after surgery. Furthermore, we found that new
SCID mice re-transferred with colitogenic LP CD4+ T cells and treated with FTY720 did
not develop colitis. Conclusions: Collectively, these findings suggest that the continuous
recirculation of colitogenic CD4+ T cells throughout the whole body may contribute to the
perpetuation of colitis, and its blockade strategies, such as leukocytoapheresis and FTY720
treatment, may be rationale for the therapy of human IBD.
M1635
Aberrant Mucin Assembly Links Endoplasmic Reticulum Stress with
Ulcerative Colitis
Michael A. Mcguckin, Rajaraman Eri, Chad K. Heazlewood, Matthew C. Cook, Doug R.
Taupin, David J. Thornton, Chin wen Png, Tanya L. Crockford, Richard J. Cornall,
Masato Kato, Keats A. Nelms, Nancy A. Hong, Christopher C. Goodnow, Timothy H.
Florin
The major macromolecular constituent of the intestinal mucus barrier is MUC2 mucin
secreted by goblet cells as an oligomerized complex. Contrasting goblet cell and secreted
mucus phenotypes are seen in ulcerative colitis (UC) and Crohn's disease: in Crohn's disease,
there is typically an increase in goblet cells and a thicker mucus layer, whereas in UC there
is a reduction in goblet cells, decreases in production and sulfation of MUC2, accumulation
of MUC2 precursor and a reduction in secreted mucus. Using ENU mutagenesis we developed
two strains of mice with chronic diarrhea and mild intestinal inflammation. Positional cloning
revealed that these strains, Winnie and Eeyore, have single missense mutations in the N-
and C-terminal oligomerization domains of Muc2, respectively. Like UC, both strains have
increased epithelial apoptosis (5.2 ± 1.6 (mean±SEM) and 5.6 ± 1.3 fold, respectively) and
mitosis (4.4 ± 0.4 and 6.3 ± 0.6 fold, respectively), and mild inflammation (neutrophilic
infiltrate, crypt abscesses, focal erosions), particularly in the distal colon and rectum. The
intestinal goblet cells of both strains appear less frequent, have small thecae and the mucus
barrier is reduced. Muc2 intesinal mRNA is decreased 2.3 fold in both strains and Muc2
protein accumulates in the basal region of goblet cells. Electron microscopy revealed large
cytoplasmic vacuoles surrounded by rough endoplasmic reticulum (ER), a hallmark of
protein misfolding and ER stress. The N-terminal D3 oligomerization domain of Muc2
carrying the Winnie mutation hyper-oligomerized when expressed in MKN45 cells, and
secretion was blocked, consistent with aberrant assembly of Muc2 In Vivo. Western blotting
of Winnie and Eeyore intestinal tissue demonstrated increased expression (4.4 ± 0.4 and
3.4 ± 0.4 fold, respectively) of the chaperone, GRP78, which accumulates with misfolded
proteins in the ER, and cleavage of ATF6 (17.2 ± 6.8, and 25.5 ± 8.2 fold increase,
respectively) consistent with activation of the unfolded protein response. We demonstrate
similar ultrastructural evidence of ER stress in goblet cells in human UC (dilated ER,
vacuoles), even in unaffected proximal intestinal tissue, together with accumulation of the
MUC2 precursor and increased expression of GRP78. ER stress in UC could occur due to
polymorphisms in MUC2 oligomerization domains and/or due to luminal ER stressors such
as microbial or dietary toxins. Goblet cell ER stress may directly activate local inflammation
in addition to diminishing the mucus barrier. These findings directly link aberrant MUC2
assembly and consequent ER stress with intestinal inflammation, and demonstrate a novel
candidate pathway to UC.
M1636
Ameliorating Effect of Anti-Nkg2d in Cd4+ Cell-Mediated Murine Model of
Chronic Colitis
Yumi Ito, Takanori Kanai, Yasuhiro Nemoto, Shin Makita, Teruji Totsuka, Kiichiro
Tsuchiya, Hideo Yagita, Mamoru Watanabe
Background & Aims: Crohn,s disease (CD) is a chronic inflammatory bowel disease character-
ized by massive infiltration of CD4+ T cells and macrophages in the colon. It is well known
that the activation of T cells requires the costimulatory signal, derived from the interaction
between the costimulatory molecules on T cells and their ligands on antigen-presenting cells
(APC) with TCR signaling. NKG2D is a newly identified costimulatory molecule on NK
cells, activated CD8+ T cells and gamma delta T cells. To investigate the role of NKG2D
pathway in the regulation of T cell activation and chronic intestinal inflammation, we assessed
its expression and functional role in a murine CD model of chronic colitis. Methods: In this
study, we used a Th1-CD4+ T-cell-mediated chronic colitis model, which was induced by
adoptive transfer of CD4+CD45RBhigh T cells to immunodeficient SCID mice to characterize
a role on colitogenic CD4+ T cells for the development of colitis. We first examined expression
profiles of NKG2D on CD4+ T cells in these colitic mice and age-matched control BALB/c
mice. Second, we assessed the therapeutic potential of anti-NKG2D mAb (HMG2D). Results:
Intestinal inflammation is characterized by a significant increase in the number of
CD4+NKG2D+ T cells and constitutive expression of its ligand, Rae-1, in colitic mice induced
by the adoptive transfer of CD4+CD45RBhigh T cells into SCID mice. Treatment with a
nondepleting anti-NKG2D mAb three times per week, starting at the day of T cell transfer,
over a period of 8 weeks significantly suppressed wasting disease with colitis, abrogated
leukocyte infiltration, and reduced production of IFN-gamma by lamina propria CD4+ T
cells. Conclusions: These findings demonstrate that NKG2D/Rae-1 pathway is critically
involved in CD4+ T cell-mediated disease progression and suggest a new therapeutic target
for inflammatory bowel diseases.
M1637
Liver Injury Limits Colonic Inflammation Through Activation of
Cd4+Cd25+Foxp3+ and Natural Killer T Cells
Dania Chakass, Edmone Erdual, Francois Trottein, Laurent Dubuquoy, Paul Arnaboldi,
Jon Bromberg, Emilie Gantier, Jean-pierre Decavel, Emmanuel Letavernier, Laurent Baud,
Philippe Mathurin, Matthieu Allez, Jean-frédéric Colombel, Dominique Kaiserlian, Lloyd
Mayer, Pierre Desreumaux, Mathias Chamaillard
BACKGROUND CD4+CD25+Foxp3+ and Natural Killer T-cells display pivotal role in inflam-
matory diseases and autoimmunity. AIM Given the extensive milder colonic phenotype of
ulcerative colitis (UC) patients with primary sclerosing cholangitis (PSC) compared to other
UC patients, we hypothesized that upon liver injury regulatory cells might circulate and/or
expand to mitigate colonic inflammation. METHODS Colitis was induced by intra-rectal
administration of TNBS (150mg/kg, 2 days) or by administrating 5% of Dextran sulphate
sodium (DSS) in wild-type mice. For hepatitis induction, wild-type mice received either an
intra-peritoneal injection of CCL4 (30 mg/animal) or a retro-orbital injection of ConA (30
mg/kg). Bile duct ligation (BDL) was performed by dissecting the common bile duct below
the entrance of the cystic duct. The intensity of colitis was assessed by histologic inflammatory
scores and quantification of inflammatory mediators and lymphocyte markers by quantitative
real-time PCR. Plasma levels of alanine transaminase (ALT) and aspartate aminotransferase
(AST) were also determined. Scid, CD1d- and invariant Va14-deficient mice were used to
determine the essential regulatory role of particular lymphocytes and NK-T cells, as well as
the FoxP3GFP mice to monitor the recruitment and/or expansion of FoxP3-expressing cells.
RESULTS By using four distinct experimental models combining colitis and liver injury, we
found that hepatitis is sufficient to improve the severity of colonic inflammation. Notably
whereas the injured liver showed a marked reduction in IL-10 and Th2 cytokines, as well
as of markers of NK-T cells (CD49b) and Treg cells (CD25, Foxp3 and Ctla4), we noticed
a marked increased expression of such markers in peripheral blood monocytes. Consistently,
we found increased number of CD4+CD25+Foxp3+ Tregs in the spleen and the mesenteric
lymph nodes following liver injury. Conversely, we failed to notice improvement of colonic
inflammation by treating mice with anti-NK1.1 Ab three days before induction of hepatitis and
colitis. Similar results were obtained in mice bearing the severe combined immunodeficiency
mutation and in mice deficient for CD1d and Va14. CONCLUSIONS Taken as a whole, we
have evidences that liver injury activate CD4+CD25+Foxp3+ and NKT cells, providing a
mechanism by which liver injury improve intestinal inflammation in mice and a possible
explanation for milder colonic phenotype in UC patients with PSC. Finally, our results
suggest that CD4+CD25+Foxp3+ Treg and NKT cells hold promising therapeutical potential
and should be monitored in both inflammatory bowel and liver diseases.
M1638
Critical Role of the Vitamin D Receptor in Intestinal Barrier Integrity
Juan Kong, Zhongyi Zhang, Mark W. Musch, Jun Sun, Marc Bissonnette, Yan chun Li
The intestinal mucosal barrier is composed of epithelial cells and junction complexes that
seal the paracellular space. The barrier regulates macromolecule trafficking and prevents
hazardous luminal materials from entering the body. Compromised intestinal barrier caused
by impaired mucosal wound healing or disrupted junction complexes results in aberrant
exposure of the host to luminal antigens and bacteria, leading to inflammation and GI
disorders including IBD. The vitamin D receptor (VDR) is a nuclear receptor that mediates
the actions of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. There is increasing evidence
supporting a pathological link between vitamin D deficiency and IBD risk. It has been
reported that VDR plays an important role in suppressing T cell-mediated colonic inflamma-
tion; however, whether VDR plays a role in the intestinal barrier homeostasis has not been
studied. We therefore used the DSS-induced colitis model to investigate the role of VDR in
maintaining the mucosal barrier integrity. We found that 2.5% DSS treatment induced much
more severe colitis in VDR(-/-) mice than in WT mice. While WT mice were relatively
resistant to this dose, VDR(-/-) mice developed severe diarrhea, rectal bleeding and marked
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body weight loss; by 12 day, most VDR(-/-) mice had died whereas no deaths occurred in
WT mice. Histological examination revealed extensive ulceration and delayed wound healing
in the colonic epithelium of DSS-treated VDR(-/-) mice, suggesting that mice are highly
susceptible to mucosal damage in the absence of VDR. Severe ulcerations in VDR(-/-) mice
were preceded by a greater loss of intestinal transepithelial electric resistance (TER) compared
to WT mice. Consistently, confocal microscopy revealed that the tight junction was more
damaged in VDR(-/-) mice than in WT mice after 3-day DSS treatment. To explore the
mechanism of mucosal protection by VDR, we found that 1,25(OH)2D3 markedly
strengthened the tight junction formed in Caco-2 monolayers by increasing junction proteins
and the TER, and by preserving the structural integrity of the tight junction in the presence
of DSS. Knockdown of VDR with siRNA reduced the junction proteins and TER in the
Caco-2 monolayer. Based on these observations, we speculate that VDR plays a critical role
in mucosal barrier homeostasis by preserving the integrity of junction complexes and the
healing capacity of the epithelium. In the absence of VDR or in vitamin D-deficiency, the
mucosal barrier is compromised, leading to increased susceptibility to mucosal damage and
inflammation. This conclusion may explain in part the link between vitamin D-deficiency
and increased IBD risk.
M1639
A Role for Toll-Like Receptor Inhibitory Protein (TOLLIP) in Experimental
Colitis
Christopher Waterhouse, Donna-marie Mccafferty, Paul Kubes
Introduction: Recognition of intestinal flora plays an important role in the development of
inflammatory bowel disease in susceptible individuals and in animal models. Evidence also
indicates deleterious effects on mucosal healing in the absence of protective bacterial signalling
to the host - a dichotomy highlighting the need for better understanding of the role bacterial
recognition plays in the normal and diseased intestine. Tollip is an intracellular protein that
associates with the members of the Toll-like receptor (TLR) signalling family. It has been
implicated as a negative regulator of signalling by TLR ligands and interleukin 1. We
hypothesized that absence of this protein may result in increased severity of experimental
colitis in mice. Experimental design: Three to five month old wild type (WT) or Tollip-/-
mice received 4mg of trinitrobenzene sulfonic acid (TNBS) in 30% ethanol per rectum and
were harvested at 3 and 7 days post treatment. Clinical and gross scores were calculated
and tissues were taken for histology, myeloperoxidase assay, Tollip mRNA measurement by
real-time RT-PCR and protein expression by Western blotting. Results: Both WT and
Tollip-/- mice developed marked colitis by 3 days post TNBS treatment. There was a trend
to more severe, sustained weight loss in the Tollip-/- mice that was not statistically significant.
Each group had severe gross scores at d3; those in the Tollip-/- group remained elevated
at d7 whereas WT animals had scores not significantly different than animals treated with
vehicle alone. A similar trend was seen with myeloperoxidase assay in each group that did
not reach significance. No differences in colonic Tollip mRNA expression were seen in TNBS-
treated WT animals compared to vehicle or untreated animals. Tollip protein expression was
below the level of detection in samples from throughout the small bowel and colon in
untreated animals; animals treated with TNBS did not exhibit a detectable increase in
Tollip protein expression. Conclusion: In the TNBS model, absence of Tollip expression is
associated with prolonged colitis, highlighting an important role for this protein in mucosal
healing. A better understanding of the role this protein plays in the evolution of colitis will
improve our understanding of disease pathophysiology and perhaps give insight into new
therapies for inflammatory bowel disease.
M1640
ω-3 Fatty Acids Exacerbate Inflammation in DSS-Induced Murine Colitis
Through Decrease in Colonic Adiponectin
Hisayuki Matsunaga, Ryota Hokari, Chie Kurihara, Yoshikiyo Okada, Koichi Takebayashi,
Keisuke Okudaira, Chikako Watanabe, Syunsuke Komoto, Yoshikazu Tsuzuki, Atsushi
Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Soichiro Miura
BACKGROUND&AIMS: Dietary fat is known as an important regulator of intestinal inflam-
mation. Although an ameliorating effect of ω-3 fatty acid on inflammation has been reported,
the effect of dietary intake of ω-3 fat on inflammatory bowel diseases (IBD) is controversial,
suggesting that it may not be effective for the inflamed colon. Recently, adiponectin is
recognized as immunoregulatory pathway by suppressing excessive inflammation. But the
role of adiponectin in the inflamed colonic mucosa has not been reported yet. Here, we
hypothesized that adiponectin may be related in disease activity of IBD, and that it may
also be involved in modulatory effect of dietary fat. In this study we investigated whether
adiponectin and its receptors are present in the colon, and whether this system plays a role
in exacerbation of colonic inflammation after different kinds of fat intake. MATERIALS&ME-
THODS: Eight weeks aged C57BL/6 mice received dextran sulfate sodium (DSS) for induction
of colitis. Mice were fed with four different kinds of diets, a diet containing 8% fish oil as
ω-3 fat, 8% safflower seed oil as ω-6 fat, 8% sevum bovinum as saturated fat, and control
fat-free diet. Colon was removed and messenger RNA expressions of adiponectin, its receptor
1 and 2, TNF-α and IFN-γ were analyzed by quantitative RT-PCR. Some mice were adminis-
trated PPAR γ agonist, pioglitazon, orally to increase adiponectin. In additional study m-
RNA expression of adiponectin in colonic mucosa from ulcerative colitis (UC) patients was
analyzed by quantitative RT-PCR. RESULTS: In the control condition, adiponectin and its
receptors were expressed in the colonic mucosa of mice. Induction of colitis significantly
decreased the expression of adiponectin accompanied with increased expressions of TNF-
α and IFN-γ. ω-3 fat diet exacerbated the DSS-induced colitis and it was accompanied with
further decrease of adiponectin mRNA expression and increase in TNF-α mRNA expression
in the colonic mucosa. The other fat diet groups did not change the degree of colonic
inflammation compared with control diet group. Pioglitazon treatment on ω-3 fat diet
groups ameliorated the decreased expression of adiponectin and it also improved colonic
inflammation. In patients with UC, expression of adiponectin in colonic mucosa was also
decreased compared with normal colon. CONCLUSIONS: We demonstrated for the first
time that adiponectin is actually expressed in colonic mucosa of mouse and human. The
levels of adiponectin were significantly suppressed by induction of colonic inflammation.
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Aggravation of DSS colitis after exposure to ω-3 fat may be attributed to the decreased level
of adiponectin in colonic mucosa.
M1641
The Role of Dendritic Cells in the Development of Acute Dextran Sulfate
Sodium Colitis
Bradford E. Berndt, Min Zhang, Gwo-hsiao Chen, Gary Huffnagle, Kevin Lai, John
Zhang, John Y. Kao
Background: Dendritic cells (DCs) are essential mediators of host immune response to the
surrounding microbes. Clinical studies have found an increased number of activated dendritic
cells in colitis tissues of patients with active inflammatory bowel disease. Aim: We investigated
the role of DCs in acute dextran sulfate sodium (DSS) colitis. Methods: Day-6 C57BL/6
mouse bone marrow (BM)-derived DCs using GM-CSF/IL-4 or BM-derived macrophages
using M-CSF containing L-cell media were stimulated for 18 h with 0.05-1% DSS In Vitro.
The release of IL-12p70, TNF-α, KC, MIP-1α, MIP-2, and MCP-1 were measured by ELISA
(pg/mL). We compared the effect of adoptively transferring 10^6 BM-derived DCs, ablating
CD11c+DCs with diphtheria toxin using transgenic CD11c-DTR/GFP mice, or PBS injection
prior to 7-day treatment with 5% DSS in drinking water (n=10 per group). Colitis scores
were determined based on the degree of inflammation, crypt distortion, submucosal edema,
hemorrhage, and transmural involvement (Law et al, Nucleic Acids Res., 2006, 34:1342-
1350). Results: BM- DCs released higher levels than BM-derived macrophages of proinflam-
matory cytokines (IL-12=360.7±94.2 vs. 2.3±1.6, and TNF-α=713.2±96.1 vs. 71.0±37.8,
respectively) and chemokines (KC=266.2±184.8 vs. 47.9±14.4, MIP-1α=3085.1±323.3 vs.
1199.6±278.5, MIP-2=414.1±96.6 vs. 84.1±23.0, and MCP-1=1977.2±880.5 vs.
220.5±85.3, respectively). Adoptive transfer of BM-derived DCs exacerbated DSS colitis
compared to PBS controls while DC ablation attenuated colitis (Fig. 1). Conclusions: We
conclude that DCs are crucial for the development of experimental colitis by contributing
to the release of proinflammatory cytokine and chemokines required for initiating colitis.
Activation of DCs may be a prerequisite for induction of colitis.
Figure 1. Adoptive transfer of BM-derived DCs exacerbates colitis and DC ablation attenu-
ates colitis.
M1642
Abnormally Differentiated Intestinal Macrophage Causes Both Th1 and Th17
Induction in IL-10 Deficient Mice
Taku Kobayashi, Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, Hiroshi
Chinen, Riko Saito, Hidemi Goto, Toshifumi Hibi
<Background> Recently, increasing numbers of papers concerning IL-23/17 axis in some
inflammatory conditions have been reported. IL-12p70/IL-23 are considered to regulate
Th1/Th17 reciprocally In Vitro, however, In Vivo, both IFN-γ and IL-17 were reported to
be upregulated in murine and human inflammatory bowel diseases. We previously reported
the excess production of IL-12 and IL-23 in response to bacteria by macrophages differenti-
ated by M-CSF (M-Mφ) in IL-10 deficient mice and these macrophages played a key role
in the initiation of Th1-dominant colitis (Kamada et al. J Immunol 2005; 175(10)). In the
present study, we have examined the induction of IFN-γ and IL-17 production from T cells
by these abnormally differentiated macrophages. <Materials & Methods> Colonic lamina
propria CD4+ T cells were isolated from WT C57BL/6J and IL-10-/- mice and then examined
for IFN-γ and IL-17 production by intracellular cytokine staining and ELISA. Next, bone
marrow CD11b+ cells were isolated and cultured for 7 days with M-CSF to generate M-
Mφ. Cells were allowed to adhere and then stimulated with heat-killed E.coli. Supernatants
of stimulated M-Mφ were collected and IL-12 and IL-23 were measured by ELISA. Finally,
CD4+ splenocytes were isolated and stimulated for 48h in the presence of anti-CD3/CD28
antibodies and cytokines (IL-12, IL-23, IL-6, or TGF-β) or supernatant of Mφ (10% of final
volume). IFN-g and IL-17 in the supernatant were measured. <Results> Both IFN-γ and IL-
17 were higher in the lamina propria of IL-10-/- mice than WT. M-Mφ derived from IL-
10-/- mice produced both IL-12 (715.1±97.8pg/ml) and IL-23 (964.0±195.8) in response
to E.coli, while those from WT mice did not at all. Recombinant IL-23 induced IL-17
production from CD4+ T cells (528.9±65.0pg/ml) but IL-12 inhibited (140.1±36.5) com-
pared to anti-CD3/28 alone (181.1±27.6). On the other hand, IL-12 induced IFN-γ produc-
tion (10654.8±4934.0) but IL-23 inhibited (949.5±404.5) compared to anti-CD3/28
(1787.0±982.0). Interestingly, supernatant of IL-10-/-M-Mφ increased both IL-17
(1104.9±174.0) and IFN-g (2669.3±418.6) from T cells and IL-17 was about twice as high
as that induced by recombinant IL-23, although the final IL-23 concentration in the media
was less than 1% of recombinant IL-23. Anti-IL-12p40 antibody could not completely
neutralize this effect on IL-17 production. IL-6 and TGF-β could not induce similar level
of IL-17 to Mφ supernatant. <Conclusions> Abnormally differentiated intestinal macrophage
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in IL-10-/- mice can induce both Th1 and Th17 cytokines through the production of some
other cytokines in addition to IL-12/23.
M1643
Dendritic Cell Recruitment in the Initiation and Recovery from Colitis
Seiji Arihiro, Jan H. Niess, Bayasi Guleng, Sonal Gupta, Atsuko Fukazawa, Hans-christian
Reinecker
AIM: DCs form organ specific immune surveillance systems responsible for the initiation of
innate and adaptive immune responses. We aimed to define the organization of DCs subsets
in the colon and their regulatory function in the acute and healing phases of intestinal
inflammation induced by DSS. METHODS: C57BL/6 mice were treated with 2.5-4% DSS
for 5 days and DC subset recruitment into the colonic mucosa was assessed before, at day
5 during the acute inflammatory phase and at day 12 when the colitis had resolved. DCs
subsets were isolated and characterized by FACS for the expression of CD11c, CD11b,
Ly6C, B220, CD8, and CX3CR1. 3D and 4D reconstructive confocal microscopy was used
to assess the distribution and migration of DC subsets in mice in which one or both copies
of the gene encoding the chemokine receptors CX3CR1 were replaced with a GFP reporter
or in transgenic mice in which the CD11c promoter drives GFP expression. RESULTS: The
colonic mucosa is populated by three major CD11c+ cell subsets which distribute to the
lamina propria, mucosal lymph follicles and the muscle layers. Myeloid derived
CD11c+CD11b+Ly6C- DCs comprised the majority with 70% of all CD11c+ cells. These
DC also express CX3CR1 and form a connected network underlying the surface epithelium
to which they establish close contacts. In normal colon mucosa the remaining major DC
subsets were CD11c+CD11b-Ly6C-CX3CR1- with 12 % and 4% plasmacytoid DCs which are
CD11c+CD11b-Ly6C+ and express intermediate levels of CX3CR1. During the inflammatory
episode we observed the local redistribution of myeloid DCs into areas with epithelial
ulcerations. Despite the high turnover observed for this population, the initial loss of this
subset could not be compensated within 12 days. During acute inflammation the major
subset newly recruited into the lamina propria were the CD11c+CD11b-Ly6C- cells repres-
enting 40% of DCs at day 5. In contrast, plasmacytoid DCs were recruited in a CX3CR1
dependent manner during the healing phase of the colitis. In wildtype mice, 25% of DCs
at day 12 were CD11c+CD11b-Ly6C+ cells in the lamina propria. Loss of CX3CR1 expression
resulted in the reduced recruitment of this DC subset and subsequently in delayed mucosal
healing. CONCLUSION: Mucosal defense activation involves the recruitment of specific DC
subsets to support the resident population normally concerned with antigen acquisition and
immune surveillance. The migratory responses of DCs to mucosal insults in the colon reveal
a surprising system of cell subspecification adapted to cope with acute injury and the
promotion of healing.
M1644
Colitis in Wiskott-Aldrich Syndrome Protein Knockout Mice Is IL-4
Dependent
Deanna D. Nguyen, Michel H. Maillard, Vinicius Cotta-de-almeida, Ivan J. Fuss, Cathryn
Nagler, Atul K. Bhan, Scott B. Snapper
Background/Aim: Mice deficient in Wiskott-Aldrich Syndrome Protein (WASP), an intracellu-
lar signaling molecule expressed exclusively in hematopoietic cells that regulates the actin
cytoskeleton, develop spontaneous colitis by four months of age. We have previously shown
that CD4+ T cells from mesenteric lymph nodes of colitic WASP KO mice are sufficient to
transfer disease, and lymphocytes from colonic lamina propria express high levels of IL-4
and IL-13, making this a rare Th2-associated model of spontaneous colitis. Our aim was to
define the role of IL-4 in the pathogenesis of colitis in WASP KO mice. Methods: WASP
KO mice at 2.5 months of age were treated with weekly injections of 1mg/mouse anti-IL-
4 antibody, total rat IgG antibodies, or nothing for 8 weeks. Weight was followed during
treatment. Mice were sacrificed on the 9th week and microscopic colitis was analyzed (score
of 0-8 reflects level of mucosal thickening, LP infiltrate, and crypt abscesses). We also
generated WASP/IL-4 double KO mice on a mixed background and backcrossed them for
five generations back to 129 SvEv and compared microscopic colitis scores of 6-8 month-
old mice with age-matched WASP KO mice on 129 background. Results: IL-4 neutralization
attenuated colitis (average colitis score of 0.1 out of 8, n = 8) compared to mice treated
with control rat IgG (average colitis score of 2.2 out of 8, n = 7, p < 0.05). Mice treated
with IL-4 neutralizing antibody also gained weight whereas those treated with IgG did not.
In addition, IL-4 and IL-13 levels remained elevated in mice treated with IgG that developed
colitis but not in mice treated with anti-IL-4 antibody. Interestingly, control rat IgG appeared
to have a therapeutic effect, since mice without any treatment had more severe colitis (average
colitis score of 3.25 out of 8). In addition, we also demonstrated that 6-8 month old mice
deficient in both WASP and IL-4 had lower microscopic colitis scores (average score 1.5
out of 8, n = 7) compared to age-matched WASP KO mice with intact IL-4 (average score
3.6, n = 6, p = 0.02). Conclusions: IL-4 is crucial for the development of colitis in WASP
KO mice. The Th2 cytokine dependence, along with the spontaneity of inflammation, the
presence of regulatory T cell dysfunction, and the presence of an IBD-like disease in some
patients with the same genetic defect, render WASP KO mice a unique model of human
inflammatory bowel disease.
M1645
Chemokine Receptor Cxcr6 Deficiency On Donor Leukocytes Accelerates
Accumulation of Cellular Infiltrate in GVHD Colitis
Tohru Sato, Wah-ping Luk, Christopher H. Contag, Eugene Butcher, Thomas D. Wang
Graft versus host disease (GVHD) induced colitis is a major complication of bone marrow
transplantation in which the pathological mechanism is a direct cytotoxic attack on mature
villous enterocytes. This accumulation of leukocytes into target tissues of GVHD is mediated
by homing molecules with chemokine receptors and their ligands playing a central role.
The chemokine receptor CXCR6 is expressed on activated T cells and NKT cells, and is
upregulated on naive T cells upon stimulation by allogeneic dendritic cells under Th1
polarizing conditions, suggesting their importance in targeting leukocytes to target tissues.
CXCR6 is important in targeting lymphocytes to the liver, and this present study examines
the role of the receptor in accumulating immune cells to the colon. Using a parent into F1
model for acute GVHD, fluorescent CXCR6 deficient donor cells accumulated in the colon,
unexpectedly, with accelerated kinetics compared to wild type. Diseased mice were examined
in a non-invasive manner using a novel flexible fiber optic fluorescent microendoscope (Cell
Vizio, Maunea Kea Technologies). The small diameter (300 micron) recording microendo-
scope was inserted into the rectum and descending colon, flush on the mucosal surface to
record green fluorescent protein (GFP) positive donor leukocyte accumulation. This proced-
ure was repeated on sequential days in order to obtain a high resolution kinetic profile of
disease progression. Bulk CXCR6-deficient (Cxcr6gfp/gfp) cells were first seen in the colon
at day 3 versus day 6 for wild type (Cxcr6gfp/+); moreover the accumulation of cells filled
the 300 micron by 300 micron recording field in CXCR6 deficient animals with over 100
cells per field versus the wild type, which on average accumulated 25 cells per field. With
the use of the new non-invasive tool for studying leukocyte accumulation to the colon, we
found CXCR6 deficiency to have an unexpected role in accelerating disease kinetics, sug-
gesting the importance of the chemokine receptor in modulating disease progression.
M1646
Stimulation of Vagus Nerve Attenuates Inflammation By Activating α7
Nicotinic Acetylcholine Receptors On Cd4+ T Cells in the Colon of
Oxazolone-Induced Ulcerative Colitis Mouse
Minako Yoshida, Takeshi Yamamoto, Kanae Fujiwara, Makoto Kadowaki
It has been reported that the cholinergic anti-inflammatory pathway that is controlled by
the vagus nerve inhibits local cytokine release. Epidemiologic reports suggest that smoking
and nicotine may improve the symptoms of ulcerative colitis (UC). T helper cell type 2
(Th2) immune responses may play an important role in UC, whereas its pathogenesis remains
unclear because of the lack of suitable Th2-mediated experimental colitis models. We have
already reported that the central stimulation of vagus nerves with 2-deoxy-d-glucose and
nicotine improved mouse Th2-mediated oxazolone (OXZ) colitis. The purpose of the present
study was to investigate pathophysiological role of nicotinic receptors subtype in the OXZ
colitis. METHODS: OXZ was injected into the colon of BALB/c mice (Th2 dominant strain).
Nicotine and hexamethonium (C6) and α7 nicotinic receptors (nAChR) antagonist methylly-
caconitine (MLA) was administerd once a day for three consecutive days. OXZ colitis was
assessed with the disease activity score (DAS) on weight loss, diarrhea and hemorrhage and
with colonic damage score (CDS) by macroscopic evaluation. Transcript levels of cytokines
and α7-nAChR were analyzed with real-time PCR. RESULT: Nicotine (0.32 - 3.2mg/kg s.c.)
significantly alleviate DAS, CDS and myeloperoxidase (MPO) activity in a dose-dependent
fashion. Noteably, C6 and MLA significantly prevented the therapeutic effects of nicotine
on the increases of DAS, CDS and MPO activity in OXZ colitis. Transcript levels of Th2
cytokines [interleukin (IL)-4, IL-5, and IL-10] significantly increased in the spleen and the
colon of OXZ colitis mice. On the other hand, Th1 cytokine, interferon (IFN)-γ mRNA
significantly decreased in the spleen and significantly increased in the middle colon. In both
the spleen and the colon of nicotine-treated mice, both Th1 and Th2 cytokines mRNAs
were significantly down-regulated. Transcript levels of α7-nAChR significantly increased in
the colon of OXZ colitis mice. Therefore, to identify α7-nAChR in the colon, unfixed
cryosections of colon from OXZ colitis mice were stained with FITC-labelled α-bungarotoxin
(α-BTx). α-BTx-binding cells were upregulated in the OXZ colitis colon, and nicotine
pretreatment markedly reduced the intensity of the fluorescence.of α-BTx. Furthermore,
CD4+ T cells were upregulated in the OXZ colitis colon. Double staining with α-BTx and
anti-CD4 mAb showed that α7-nAChR localized on a considerable part of CD4+ T cells in
the mucosa of the OXZ colitis colon. CONCLUSION: We conclude that the vagal anti-
inflammatory and immune pathway acts by α7-nAChR on CD4+ T cells in the mucosa of
the colon to alleviate Th2-mediated OXZ colitis.
M1647
Relevance of the Homeobox Gene Cdx2 in Intestinal Inflammatory Disease
and Related Cancers
Alexandre Calon, Isabelle Gross, Benoît Lhermitte, Elisabeth Martin, Felix Beck, Bernard
Duclos, Michèle Kedinger, Isabelle Duluc, Claire Domon-dell, Jean-noël Freund
Background and aims Disruption and repair of the gut epithelium occurs in inflammatory
bowel diseases. The CDX2 homeoprotein is a gut epithelium-specific transcription factor
involved in homeostasis. Here we investigated its relevance during acute and chronic inflam-
mation in mice. Methods Intestinal inflammation was induced by dextran sodium sulfate
(DSS, 3 % in drinking water) in wild type and Cdx2+/- mice. Migration assays were performed
using Transwell inserts on cells transfected with control or specific siRNAs to knock-down
Cdx2. Protein-protein interactions were investigated by co-immunoprecipitation and GST-
pulldown. Results Acute treatment during 5 days revealed that Cdx2+/- mice were hypersens-
itive to DSS-induced inflammation, as assessed by accelerated body weight loss and blood
in the stools. Of note, histological examination indicated that the colonic epithelium was
better repaired in Cdx2+/- compared to wild type animals at the end of the inflammatory
challenge. Moreover, tissue areas with disorganized structures occurred in wild type unlike
Cdx2+/- mice after 5 repeated cycles of DSS treatment (each cycle is 5 days of 3 % DSS
followed by 16 days recovery) to mimic chronic inflammation. Ultimately, 50 weeks after
repeated DSS treatment, wild type animals developed colonic tumors in contrast to Cdx2+/-
mice (2.7 vs 0 tumors / animal). Tissue repair, which is enhanced in Cdx2+/- mice, is
dependent in cell migration. Thus, we addressed the effect of Cdx2 expression on cell
migration In Vitro. We demonstrated using Transwell assays, that migration of SW480 colon
cancer cells was 2.2-fold stimulated by siRNA-mediated knockdown of Cdx2. Improved
repair of the damaged intestinal epithelium characterizes Smad3-/- mice, like Cdx2+/-
animals. We demonstrated a functional link between the CDX2 and SMAD3 proteins.
Indeed, transfection assays and luciferase measurements revealed that CDX2 activated the
transcriptional activity of SMAD3 in a SMAD4-independent manner. Moreover, GST-pull-
down and HA co-immunoprecipitation revealed physical interactions between CDX2 and
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SMAD3. Conclusion The level of Cdx2 expression is critical for inflammation-induced
disruption and repair of the colonic epithelium. A reduced expression of CDX2 in Cdx2+/-
mice enhances epithelial repair after inflammatory injury, which ultimately protects them
against chronic inflammation-induced colorectal cancers. In line with this observation, CDX2
is an inhibitor of cell migration. Finally, CDX2 physically interacts with and modulates the
transcriptional activity of SMAD3, an element of the TGFβ signaling pathway crucial for
tissue restoration after injury.
M1648
Dietary Calcium Prevents Deterioration of Intestinal Permeability and
Diarrhea During Colitis Development in HLA-B27 Transgenic Rats
Marloes Schepens, Arjan Schonewille, Carolien Vink, Roelof Van der meer, Ingeborg
Bovee-oudenhoven
Introduction: Various factors are involved in the pathogenesis of inflammatory bowel disease,
including impairment of the intestinal barrier. We have shown in several controlled rat and
human infection studies that dietary calcium improves intestinal resistance and strengthens
the mucosal barrier. In addition, calcium binds intestinal surfactants resulting in reduced
luminal cytotoxicity. Based on these generic mechanisms, we hypothesized that supplemental
calcium may have a protective effect on intestinal inflammation as well. Aim: To investigate
the effect of dietary calcium on spontaneous colitis in HLA-B27 transgenic rats. Methods:
HLA-B27 transgenic rats and their wild-type counterparts were fed a purified Western high-
fat diet containing different calcium concentrations (30 and 120 mmol CaHPO4/kg diet).
Inert chromium ethylenediamine-tetraacetic acid (CrEDTA) was added to the diets to quantify
intestinal permeability by measuring urinary CrEDTA excretion. Relative fecal dry-weight
was determined to assess diarrhea. After 7 weeks of dietary intervention, rats were killed
and colitis was evaluated macroscopically. Colonic mucosal inflammation was determined
by measuring myeloperoxidase. Further analyses of inflammation markers are ongoing.
Results: The high-calcium diet significantly prevented the increase in intestinal permeability
and diarrhea with time in HLA-B27 rats developing colitis as compared to the low-calcium
fed group. Colon weight was not affected by the dietary intervention but calcium prevented
shortening of the colon resulting from intestinal inflammation. The macroscopic colitis score
and mucosal myeloperoxidase concentration were lower in the high-calcium group, but this
did not reach statistical significance. Conclusion: Dietary calcium beneficially influences
colitis development by preventing the increase in intestinal permeability and diminishing
diarrhea.
M1649
Critical Role of the CD40-CD40 Ligand Pathway in Governing Mucosal
Inflammation-Driven Angiogenesis in Inflammatory Bowel Disease
Silvio Danese, Franco Scaldaferri, Stefania Vetrano, Tommaso Stefanelli, Salvatore
Comunale, Alessandro Repici, Riccardo Ricci, Giuseppe Straface, Alberto Malesci, Claudio
Fiocchi, Sergio Rutella
Angiogenesis is a novel component in inflammatory bowel disease (IBD). We have previously
shown that the CD40-CD40 ligand (CD40L) pathway contributes to intestinal inflammation,
but its effect in governing inflammation-driven angiogenesis is unknown. This study evaluated
the CD40-CD40L interactions in the promotion of immune-mediated angiogenesis in IBD.
Human intestinal fibroblasts (HIF) and human intestinal microvascular endothelial cells
(HIMEC) were activated with soluble CD40 ligand (sCD40L), or CD40L-lamina propria T
cells (LPT), and the production of angiogenic cytokines was measured in the culture.
Antibodies against CD40 or CD40L were used to disrupt the CD40-CD40L interaction.
HIMEC migration and tubule formation were used as angiogenesis assays. The dextran
sodium sulphate (DSS) model of experimental IBD in CD40- and CD40L-KO mice was used
to assess whether the CD40-CD40L pathway was implicated in inflammation-driven In Vivo
angiogenesis, assessed by CD31 staining. Engagement of CD40 on HIF promoted IL-8 (50
fold increase, p<0.001), VEGF (6 fold increase, p<0.01) and HGF production (5 fold increase,
p<0.01). LPT were inducers of angiogenic cytokine secretion by HIF in a CD40-dependent
manner, as assessed by CD40 and CD40L blockade (both p<0.001). Supernatants from
sCD40L-activated HIF induced HIMEC migration (from 8±2 to 46±8 cells/field, p<0.01)
and tubule formation, that were inhibited by antibody blockade of IL-8, VEGF or HGF (all
at p<0.05). Compared to wild-type, CD40- and CD40L-KO mice were significantly protected
from DSS-induced colitis, as assessed by colitis activity index (p<0.05), weight loss (p<0.05)
and histological score (p<0.01). Compared to wild-type (70±6 vessels/field), both CD40-
(48±6 vessels/field) and CD40L- (42±8 vessels/field) deficient mice displayed a significant
amelioration of gut inflammation-driven angiogenesis, as measured by a reduced number
of CD31-positive vessels in the mucosa (both p<0.05). Our results show that CD40-CD40L
pathway is involved in regulating immune-driven angiogenesis in intestinal inflammation.
Strategies aimed at inhibition of pathological angiogenesis through blockade of CD40-
CD40L-mediated interactions may represent a novel and beneficial approach to the treatment
of human IBD.
M1650
Genetic Evidence for a Protective Role of Heat Shock Factor 1 (HSF1) and
Heat Shoch Protein 70 (Hsp70) Against Dextran Sulfate Sodium (DSS)-
Induced Colitis
Ken-ichiro Tanaka, Tohru Mizushima
Background & Aims: Inflammatory bowel disease (IBD) is a common and chronic gastrointes-
tinal disorder characterized by mucosal tissue damage induced by reactive oxygen species
(ROS) and intestinal inflammation induced by up-regulation of pro-inflammatory cytokines
(such as tumor necrosis factor (TNF)-a) and cell adhesion molecules (such as VCAM-1 and
ICAM-1). HSPs are induced by various stressors and make cells resistant to various stressors.
HSF1 is a transcription factor for hsp genes and also was shown to negatively regulate the
expression of TNF-a. Therefore, HSF1 and HSPs seem to play a protective role against IBD.
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However, no direct evidence has been reported to support this idea and other reports showed
data against this idea. In this study, we examined the role of HSF1 and HSPs in animal
model of IBD, DSS-induced colitis, using HSF1-null mice and transgenic mice expressing
HSP70. Methods: The severity of colitis was assessed by body weight, disease activity index,
MPO activity and TBARS index. Expression of proteins was monitored by immuno-blotting,
immunohistochemical analysis and real-time RT-PCR. Results: The DSS-induced colitis was
stimulated or suppressed in HSF1-null mice or HSP70-expressing transgenic mice, respect-
ively, when compared to wild-type mice. DSS-administration up-regulated HSP70 at the
intestinal mucosa in an HSF1-dependent manner. More apoptotic cells were observed in
the intestinal mucosa in HSF1-null mice than in wild-type mice. Suppression of HSP70-
expression stimulated ROS-induced apoptosis in cultured intestinal cells. Levels of various
pro-inflammatory cytokines (such as TNF-a) at intestinal mucosa were increased or decreased
in HSF1-null mice or HSP70-expressing transgenic mice, respectively. Macrophages prepared
from HSF1-null mice showed higher activity for lipopolysaccharide (LPS)-dependent stimula-
tion of TNF-a-generation than those from wild-type mice. DSS-administration caused up-
regulation of various cell adhesion molecules (such as VCAM-1 and ICAM-1) and this up-
regulation is stimulated or suppressed in HSF1-null mice or HSP70-expressing transgenic
mice, respectively. Suppression of hsf1 gene expression stimulated LPS-induced up-regulation
of these cell adhesion molecules. Conclusions: This study provided genetic and direct
evidence showing that HSF1 and HSP70 play a protective role against DSS-induced colitis.
Furthermore, results suggested that this protective role involves various mechanisms, such
as HSP70-dependent protection of intestinal mucosal cells against ROS-induced apoptosis
and HSF1-dependent suppression of expression of TNF-a and cell adhesion molecules.
M1651
Interleukin (IL-) 9 Plays a Critical Role in Oral Antigen-Induced Intestinal
Anaphylaxis
Elizabeth E. Forbes, Richard E. Ahrens, J.pablo Abonia, H.faith Rainey, Eric B. Brandt,
Andrew N. Mckenzie, Klaus I. Matthaei, Marc E. Rothenberg, Paul S. Foster, Simon P.
Hogan
Oral antigen-induced intestinal anaphylaxis has been demonstrated to be associated with
increased levels of T-helper 2 (Th2) cytokines. The Th2 cytokine IL-9 has been proposed to
be involved in allergic inflammatory processes; specifically, mast cell mediated inflammatory
cascades. To elucidate the importance of IL-9 in mast cell mediated oral antigen-induced
intestinal anaphylaxis we employed IL-9 deficient (IL-9-/-) and BALB/c wild type (WT) mice
and examined their susceptibility to disease parameters including diarrhea, intestinal mast
cell levels and serum mouse mast cell protease-1 (mMCP-1) as compared to unsensitized,
OVA-challenged WT controls. In OVA-sensitized, OVA-challenged WT mice 100% developed
diarrhea in contrast to 0% in unsensitized, OVA-challenged WT mice and displayed intestinal
mastocytosis (31.29±0.57 mast cells/high power field (HPF) compared to 1.27±0.34 mast
cells/HPF, p<0.01) and elevated serum mMCP-1 (16260.57±4817.16 ng/ml mMCP-1 as
opposed to 23.91±3.64 ng/mlp<0.01). In contrast, in the absence of IL-9, in OVA-sensitized,
OVA-challenged IL-9-/- mice we show a significant attenuation in disease parameters as
compared to OVA-sensitized, OVA-challenged WT mice. Diarrhea occurrence presented at
16%, an ablation of the mastocytosis in the jejunum (4.11±0.22 mast cells/HPF, p<0.01)
and a significant decrease in serum mMCP-1 levels (1883.42±149.68 ng/ml mMCP-1, p<0.05)
was observed. The ablation of intestinal mastocytosis in OVA-sensitized, oral antigen chal-
lenged IL-9-/- mice lead us to examine mast cell progenitor (MCp) levels in the intestine of
IL-9-/- and WT mice, to assess whether the reduction in mast cell numbers and subsequent
attenuation of mast cell mediated oral antigen-induced intestinal anaphylaxis was not due
to a defect in MCp recruitment. We show the level of progenitors in the intestine of IL-9-/-
mice under basal conditions was equivalent to that of WT mice (1524±198 MCp/1x106
cells in IL-9-/- mice versus 2089±235 MCp/1x106 cells in WT mice) suggesting the reduction
in mast cell numbers was not due to a defect in mast cell progenitor recruitment but in
maturation. These studies demonstrate that oral antigen-induced intestinal anaphylaxis is
attenuated in IL-9-/- mice suggesting a critical role for IL-9 during oral antigen challenge.
Furthermore, we identify an important role for IL-9 in the homeostatic maintenance of mast
cell progenitor maturation in the intestine.
M1652
The Role of Helminth-Induced Alternatively Activated Macrophages in
Concurrent Bacterial Enteritis
Meiqian Weng, Deke Huntley, Lijian Wang, Ondulla Foye-jackson, W. allan Walker,
Bobby Cherayil, Hai ning Shi
Inflammatory bowel diseases (IBD) are chronic immune mediated diseases of the intestinal
tract of unclear etiology. In recent years, growing evidence has supported the crucial role
of luminal bacteria in the pathogenesis of the intestinal inflammation in IBD. Based on the
inverse correlation between exposure to helminth parasites and the incidence of certain
immune-mediated diseases, helminths or helminth extracts have been proposed as a novel
form of therapy for IBD. However, our understanding of the exact mechanism by which
helminths modulate the mucosal response to enteric bacteria is incomplete. In order to
dissect the mechanisms by which helminths modulate the host's response to enteric bacteria
and bacteria-mediated intestinal inflammation, we have established a co-infection model,
which involves two murine enteric infectious agents that induce distinct Th responses. Using
this model, we have shown recently that co-infection with the helminth Heligmosomoides
polygyrus exacerbates colitis induced by infection with the Gram negative bacterial pathogen
Citrobacter rodentium via a STAT6 dependent pathway. We also observed that the exacerbated
colitis found in the co-infected mice was correlated with high Citrobacter loads in the gut,
translocation of the bacteria into mucosal and systemic immune compartments, delayed
bacterial clearance and a significantly enhanced colonic TNFα response. A series of recent
studies have suggested that the Th2 cytokine response induced by nematode parasites
promotes the development of alternatively activated macrophages. In this study, using our
In Vivo co-infection model system as well as In Vitro approaches, we test the hypothesis that
the phenotypic and functional alterations in macrophages induced by the helminth-driven
T cell response may contribute to the observed alterations in the response to C. rodentium.
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Our results show that H. polygyrus co-infection results in a marked infiltration into colonic
laminar propria of F4/80+ cells that have the phenotype of alternatively activated macro-
phages, i.e. high level expression of the Fizz1, Ym1 and arginase 1 genes. Functional analysis
of these macrophages further shows that they are impaired in their killing of internalized
bacteria. Yet these cells produce an enhanced amount of TNFα in response to C. rodentium
infection In Vitro. These results demonstrate that helminth infection can impair host protec-
tion against concurrent enteric bacterial infection and promote bacteria-induced intestinal
injury through a mechanism that involves the induction of alternatively activated macro-
phages.
M1653
Rolf of Leptin-Mediated STAT3 Signaling in DSS-Induced Colonic
Inflammation
Melissa E. Gove, Davina Rhodes, Maria Pini, Martin G. Myers, Giamila Fantuzzi
Leptin is an adipokine involved in the regulation of metabolic, endocrine, and immune
functions. Activation of the long form of leptin receptor (LEPR) results in the autophosphoryl-
ation of JAK2, which leads to the phosphorylation of residues Y985, Y1077, and Y1138 in
LEPR. P-Y1138 recruits STAT3, a cytokine-regulated transcription factor involved in immune
function, resulting in its phosphorylation and nuclear translocation. Leptin- and LEPR-
deficient mice display decreased immune function and are resistant to colitis induced by
DSS or TNBS, but the signal transduction pathways involved have not been identified to
date. To investigate the involvement of leptin-mediated STAT3 signaling in regulating colonic
inflammation, we used mice in which the Y1138 residue of LEPR was substituted with a
serine residue, thus impeding STAT3 phosphorylation. Colonic inflammation was induced
by giving S1138 mice, their control littermates and leptin receptor-deficient db/db mice 3%
DSS in drinking water for 5 days followed by 5 days of normal drinking water. Throughout
the 10-day experiment a clinical score was calculated to quantify disease severity by weight
loss, diarrhea, and blood in stools. Colon length was measured and cytokine production
by colon cultures cytokine was evaluated. As expected, db/db mice had a significantly lower
clinical score than WT mice beginning on day 5 and throughout the remaining of the
experiment (p<0.001). The clinical score of S1138 mice was intermediate between WT and
db/db mice, being significantly lower than the score of WT mice (p<0.02) and significantly
higher than that of db/db mice (p<0.01). After treatment with 3% DSS, colon length of WT
mice was significantly shorter than that of db/db mice (p<0.001), as previously shown.
Colon length of S1138 mice was significantly longer than that of WT mice (p<0.001) but
significantly shorter than that of db/db mice (p<0.001). Production of IL-6, INF-gamma
and MIP-2 by colon cultures was significantly higher in WT mice compared to db/db mice
(p<0.003). Cytokine production in S1138 mice was intermediate between the db/db and
WT groups. These data suggest that leptin-induced STAT3 signaling is involved in leptin-
mediated regulation of colonic inflammation; however, other signal transduction pathways
are likely involved in the immunomodulatory effects of leptin.
M1654
Pathological Role of Mucosal Mast Cells and Cd4+ T Cells for the Induction
of Food Allergy in Mice
Toshihisa Kodama, Takeshi Yamamoto, Kanae Fujiwara, Minako Yoshida, Shigeo Koyasu,
Makoto Kadowaki
Although gastrointestinal allergic disorders have increased in prevalence over the last several
decades, the underlying mechanisms of food anaphylaxis have yet to be fully defined. An
essential question is to determine the specific cells and mediators responsible for these
disorders. METHODS: For the induction of food allergy (FA), a group of BALB/c mice was
primed with ovalbumin (OVA) and aluminum hydroxide gel as adjuvant by intraperitoneal
injection, and the occurrence of diarrhea following repeated oral challenges with OVA in
the primed mice was recorded. Furthermore, with immunohistochemical technique we
examined the expression of mucosal mast cells in the colon with an antibody against mouse
mast cell protease-1 (mMCP-1; A marker of mouse mucosal mast cell) and the expression
of CD4+ T cell in the colon. Moreover, we used phosphatidylinositol-3 kinase (PI3K) deficient
mice (BALB/c background) selectively lacking gastrointestinal mast cells and nu/nu mice
(BALB/c background) to compare severity of allergic symptoms and expression of mucosal
mast cells and CD4+ T cell. RESULTS: Exposure of the primed mice to repeated oral OVA
challenges developed allergic diarrhea [85.4 ± 8.5% (mean ± S.E.) after six OVA challenges]
with dramatically increased OVA-specific IgE levels in plasma (from 0.1ng/ml to 3.8ng/ml).
In the spleen, the transcript levels of IL-4, IL-5 and IL-10 (Th2 cytokines) significantly
increased but IFN-γ (Th1 cytokine) significantly decreased in the FA mice, indicating Th2
dominant situation. On the other hand, transcriptions of both Th1 and Th2 cytokines
significantly up-regulated in the colon of the FA mice, indicating that in the local immune
system both of Th1 and Th2 became hyperresponsive to allergens, which may contribute
to the pathogenesis of FA. The nu/nu mice that had scarcely CD4+ T cell in the colon were
resistant to oral OVA challenges. Although the primed PI3K (-/-) mice did not develop
allergic diarrhea, CD4+ T cells in the colon and OVA-specific IgE levels in plasma were
significantly upregulated compared with food allergy BALB/c mice (74.8ng/ml vs 3.8ng/ml).
OVA challenge induced a large number of mMCP-1 positive mast cells in the colon of BALB/
c mice. In contrast, there were only few mMCP-1 positive mast cells in the colon of OVA-
challenged nu/nu mice and PI3K (-/-) mice, and mMCP-1 levels in plasma of OVA-challenged
nu/nu mice (0.3 ± 0.1 mg/ml) and PI3K (-/-) mice (0.9 ± 0.3 mg/ml) were much lower
than those in BALB/c mice (41.0 ± 27.2 mg/ml). CONCLUSIONS: CD4+ T cell-dependent
development of mMCP-1 positive mucosal mast cells in the colon play a critical role in the
induction of Th2-mediated food anaphylaxis.
M1655
Genetic Evidence for Cd8+ T Cell Immunoregulation in Murine Cd4+ T Cell
Colitis
Bo Wei, Michael Macpherson, Peter Velazquez, Daisuke Fujiwara, Jonathan Braun
Background: Abnormal CD4+ T cell activity and consequent tissue damage are major patho-
genic features of inflammatory bowel disease (IBD), as well as many systemic and tissue
restricted autoimmune diseases. Disease susceptibility may involve deficiency of normal
mucosal immunoregulation that normally attenuates CD4+ T cell activity targeting the
mucosa. CD8+ T cells have emerged as one such regulatory population, but their modes of
induction and targeting are poorly understood. In mice, B cells attenuate several modes of
immune colitis, and transfer data indicates that this regulation requires interaction with
CD8+ T cells (B Wei, 2005, PNAS 102:2010). Here, the genetics of B cell traits involved in
immunoregulation were evaluated. Methods. Gαi2-/- mice develop immune (Th1-like) colitis
due to deficiencies in B lymphocyte homing and differentiation (H Dalwadi, 2003, J Immunol
170:1707). Colitis was induced by intravenous transfer of 106 sorted splenic Gαi2-/- T cells
into C57BL/6 RAG2-/- mice; mesenteric B cells were sorted from C57BL/6 mice bearing
null mutation of several immune interaction genes, and 106 were co-transferred to test for
immunoregulation of Gαi2-/- T cell colitis (B Wei, 2005, PNAS 102:2010). Mice were
monitored for colitis activity by quantitative colonic histology, and by flow cytometric
analysis of intestinal, mesenteric, and splenic lymphocytes, and blood cytokine levels. Results.
Transfer of Gαi2-/- T cells from 4-5 weeks mice (prior to colitis onset) induced progressive
colitis, with additional features of systemic immune inflammation (notably, granulomatous
skin and lung disease). Mesenteric node B cells from wild type mice inhibited colitis and
systemic inflammation, and blocked the attendant CD4+ T cell expansion expressing TNF-
α, IFN-γ and IL-17. Surprisingly, the protective function of B cells did not require genetic
sufficiency for MHC class II, indicating that they did not directly interact with colitigenic
or regulatory CD4+ T cells. However, protection required both MHC class I and TAP1
sufficiency, indicating that they augmented immunoregulation through direct interaction
with classical peptide-restricted CD8+ T cells. Conclusion. These findings provide new
evidence for CD8+ T cell immunoregulation in colitis, and suggest that functional or numerical
deficiencies of cooperative B or CD8+ T cell subpopulations may be susceptibility traits, and
targets for compensatory therapy, in inflammatory bowel disease. Supported by NIH DK4673
and DK69434.
M1656
Interaction of Vegf and Transcription Factor Egr-1 in the Pathogenesis of
Experimental Ulcerative Colitis: Marked Improvement of Colitis with
Neutralizing Antibody Against Vegf
Ganna Tolstanova, Tetyana Khomenko, Xiaoming Deng, Longchuan Chen, Zsuzsanna
Sandor, Sandor Szabo
Recent clinical and animal model investigations revealed increased vessel density and levels
of angiogenic factors during active inflammatory bowel disease (IBD), suggesting that angiog-
enesis plays a role in this multifactorial disease. Levels of VEGF correlate with disease activity
in human and experimental IBD. In this study we tested hypothesis that VEGF may have
a mechanistic role in the pathogenesis of experimental ulcerative colitis (UC). Methods: UC
was induced in unfasted Sprague-Dawley rats by 6% iodoacetamide (IA) in 1% methylcellu-
lose (0.1ml/rat, intracolonically). Neutralizing antibody against VEGF (anti-VEGF Ab) (50ug/
rat) or vehicles-mouse IgG (50ug/rat), saline (0.1ml/rat) were injected i.m. on 3rd and 5th
days after IA enema (autopsy-7 days). Body weight and diarrhea were recorded daily. Macro-
and microscopic damage scores of colonic lesions were assessed 0.5, 1, 2, 6hr and 3, 7 days
after IA enema. Levels of proteins and transcription factor (TF) Egr-1 transcription interactions
were assessed in colonic mucosa by Western blot, ELISA and TF-TF array, respectively.
Results: Levels of VEGF increased as early as 0.5hr after IA enema and were further elevated
at 1, 2, 6hr and 3, 7 days. Administration of anti-VEGF Ab markedly improved the clinical
and morphologic signs of UC: colonic lesion areas (mm2) were decreased from 370.5±140.6
(saline) and 311.2±170.1 (mouse IgG) to 122.2±57.7 (p<0.05) in the anti-VEGF group.
Levels of VEGF as well as of PDGF and FGF-2 were reduced in the anti-VEGF group. Since
exogenous VEGF activates gene expression for Egr-1 through phosphorylation of Erk1/2
and Egr-1 is a critical TF in angiogenesis, we assessed that Egr-1 may mediate interaction
of VEGF with FGF-2 and PDGF in UC. Indeed, we found that levels of pErk1/2 and Egr-
1 rapidly increased in the colonic mucosa (0.5, 1, 2, 6hr, 3, 7 days) after IA. Furthermore,
we detected increased binding of Egr-1 to DNA and enhanced interaction of Egr-1 with
other TFs such as AP-2, PPAR, SRE, OCT-1, NF-EI, GAS/ISRE in nuclear extracts of colonic
mucosa from rats with UC. Suppression of VEGF activity by anti-VEGF Ab didn't change the
Erk1/2 levels but significantly inhibited pErk1/2 and Egr-1. Conclusions: 1) Administration of
anti-VEGF Ab markedly ameliorated chemically induced UC in rats; 2) Anti-VEGF Ab
reduced the colonic levels of VEGF, PDGF and FGF-2; 3) Egr-1 levels, its binding to DNA
and transcription interaction were strongly enhanced in colonic mucosa of rats with UC;
4) Anti-VEGF Ab reduced the synthesis of Egr-1 through inhibition phosphorylation of
Erk1/2; 5) TF Egr-1 may play a pivotal role in the VEGF actions in the pathogenesis of
experimental UC.
M1657
Helicobacter hepaticus Hhgi1 Is a Potential Pathogenicity Island Associated
with Typhlocolits in Il10-/- C57bl/129 Mice
Zhongming Ge, Torsten Sterzenbach, Mark T. Whary, Barry Rickman, Arlin B. Rogers,
Zeli Shen, Nancy S. Taylor, Sebastian Suerbaum, Christine Josenhans, James G. Fox
Helicobacter hepaticus infection has been associated with chronic active hepatitis, hepatocel-
lular carcinoma, colon tumors, inflammatory bowel disease, cholesterol gallstones, and
mammary tumors in susceptible mouse strains. HHGI1, a genomic island of ~71 kb with
some of common features shared among known bacterial pathogenicity islands, is present
within the H. hepaticus genome. In this study, we characterized the pathogenic potential
of HHGI1 by infecting C57BL/129 IL10-/- mice with an HHGI1-deficient isogenic mutant,
A-393 AGA Abstracts
which lacks a 20-kb region containing 19 predicted genes within HHGI1. This mutant lost
the ability to induce pathological manifestations such as typhlocolitis and hyperplasia that
developed in WT H. hepaticus-infected IL10-/- mice (P < 0.001); however, its colonization
levels were significantly higher in the cecum (P <0.007) and similar in the colon (P=0.27)
when compared to WT H. hepaticus by 13 or 16 weeks post inoculation (WPI). In addition,
the Th1-associated IgG2c response to infection with the island mutant was lower than that
to WT H. hepaticus infection (P < 0.004), whereas there was no significant difference in
Th2-associated IgG1 response between these two infections. Furthermore, cecal and colonic
mRNA levels of proinflammatory mediators IFN-γ and TNF-α in the mutant-infected mice
were significantly lower than those in the WT H. hepaticus-infected mice (P <0.001 for the
cecum and 0.05 for the colon) at 13 WPI. These results demonstrate that HHGI1 contributes
to the pathogenicity of H. hepaticus at least in part via up-regulation of proinflammatory
mediators IFN-γ and TNF-α, supporting the proposal that HHGI1 is a H. hepaticus patho-
genicity island.
M1658
GM-CSF Treatment Ameliorates Disease Activity in Models of IBD
Satheesh K. Sainathan, Eyad Hanna, Kumar S. Bishnupuri, Rodney D. Newberry,
Qingqing Gong, Courtney W. Houchen, Shrikant Anant, Brian K. Dieckgraefe
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Although
the origin of the diseases has not been elucidated, recent evidence suggests that the defects
in mucosal innate immune function may have a critical role in development of CD. Current
treatments utilize immunosuppressive medications but are often complicated by serious
infections. A recent clinical trial showed efficacy of an agent that stimulates innate immunity
i.e. recombinant GM-CSF in humans with CD. Our previous studies demonstrated that GM-
CSF is effective in DSS colitis model based on histology and clinical disease activity. To
further investigate the gene expression changes associated with disease activity, microarray
analysis was performed. PolyA+ RNA isolated from colons of mice treated with DSS was
used. A primary statistical analysis of the array data was performed using the Significance
Analysis of Microarrays (SAM) procedure. 369 gene were identified that were significantly
upregulated in acute DSS colitis model. We next examined the effect of GM-CSF on these
gene markers; most were found to be downregulated by GM-CSF treatment. To validate
the microarray data, we investigated the expression of TNFα and IL1β by real time RT-PCR
and protein levels by Bioplex. These two cytokines are associated with disease activity in
human CD. Our results demonstrated that GM-CSF treatment significantly reduced the
expression of TNFα and IL1β at mRNA and protein levels. To further understand the efficacy
of GM-CSF treatment, we performed similar set of experiment in RAG1-/- mice, which lacks
mature T and B cells. We induced colitis with 4% DSS in these mice and observed that
GM-CSF treatment significantly improved histopathology and reduced DSS-induced increases
in proinflammatory cytokines including TNFα and IL1β. We next performed flow cytometry
analysis to identify changes in cell populations following GM-CSF treatment. We observed
a significant expansion of dendritic cells (CD11c+) and macrophages (F4/80) and neutrophils
(Gr-1). To determine the functional significance of increased DC populations, CD11c+ cells
were isolated and stimulated with bacterial products and changes in IL10 were assessed by
ELISPOT. GM-CSF treatment resulted in significant increases in the percentage of cells
secreting IL10. Conclusion: GM-CSF ameliorates experimental colitis in mice in a mechanism
independent of T and B cells. Furthermore GM-CSF treatment resulted in functional differ-
ences in the total DC response to bacteria and bacterial products.
M1659
Amelioration of TNBS-Induced Colonic Muscle Inflammation and
Upregulation of IGF-I, Mgf and Igfbp-5 in Integrin β3 Knockout Mice
Krystina M. Berg, Jennifer Bowers, Liya Qiao, John F. Kuemmerle
We have shown that expression of the endogenous ligands of αVβ3 integrin, vitronectin
and fibronectin, are increased in intestinal muscle cells in active Crohn's Disease and TNBS
colitis. Occupancy of αVβ3 integrin regulates the intensity and duration of Insulin-like
Growth Factor-I (IGF-I) stimulated IGF-I proliferation, and inhibition of apoptosis in smooth
muscle. Crohn's Disease and TNBS-induced colitis increases expression of IGF binding
protein-5 (IGFBP-5) and Mechano-Growth Factor (MGF) which regulate muscle cell hyper-
plasia and hypertrophy, respectively. Aims: To determine the role of the αVβ3 integrin in
mediating the increase in IGF-I, IGFBP-5 and MGF in development of chronic muscle
inflammation in TNBS colitis. Methods: Transgenic mice with deletion of the integrin β3
gene, β3(-/-), (B6;129S2-Itgb3tm1Hyn/J) and their controls, C57/B6 were administered 2.5 mg of
TNBS in 50% ethanol or vehicle alone intrarectally. After 7 days, when chronic inflammation is
present, colons were harvested and used to prepare tissue sections for histology. RNA and
protein lysates were prepared from isolated smooth muscle. Histologic scoring of extent of
muscle thickening (0-3) and cellular infiltration (0-3) was used to grade muscle inflammation.
Levels of IGF-I, MGF, and IGFBP-5 RNA were quantitated using real-time PCR using the
ΔCt method with β-actin as control. Levels of MGF and IGFBP-5 protein were measured
by immunoblot analysis. Results: Both control mice and β3(-/-) mice treated with vehicle
alone had mean histologic scores of 0. TNBS-induced muscle inflammation was ameliorated
in β3(-/-) mice compared to control mice with mean histologic scores of 3 and 6, respectively.
In untreated mice, levels of IGF-I, IGFBP-5, and MGF RNA were similar in control and
β3(-/-) mice. TNBS treatment in control mice elicited a 1.7 fold increase in IGF-I RNA whereas
the increase induced by TNBS was abolished in β3(-/-) mice. IGFBP-5 (1.7 fold) and MGF
RNA (1.2 fold) were increased TNBS treated control mice but no increase was observed in
β3(-/-) mice (0.2 and 0.1 fold, respectively). TNBS treatment of control mice elicited a 60
± 5% increase in IGFBP-5 protein level and a 69 ± 8% increase in MGF protein level. In
β3(-/-) mice the increase in IGFBP-5 protein induced by TNBS was inhibited 60% and the
increase in MGF protein was inhibited 85%. Conclusions: Activation of β3 integrin is
involved in the development of chronic muscle inflammation in TNBS-induced colitis.
Deletion of the β3 integrin gene also decreases the upregulation of IGF-I, IGFBP-5 and
MGF that contributes to muscle cell hyperplasia and hypertrophy that occurs in chronic
muscle inflammation.
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M1660
Ghrelin - A New Mediator of Colonic Inflammation?
Peter C. Konturek, Thomas M. Brzozowski, Artur Dembinski, Piotr Gaca, Eckhart G.
Hahn, Stanislaw J. Konturek
Background and Aims: Ghrelin is a novel growth hormone (GH)-releasing and orexigenic
peptide which has been isolated from the fundic portion of the stomach. Recently anti-
inflammatory and gastroprotective effect of this hormone have been demonstrated, but the
role of ghrelin in the colonic inflammation is still controversial. The aim of the present
study was: 1) to examine the expression of ghrelin mRNA in the inflamed colonic mucosa
of patients with ulcerative colitis, 2) to analyze the effect of exogenous ghrelin on the healing
of TNBS-induced colitis in rats, and 3) to assess the effect of ghrelin treatment on expression
of mRNA for PPARγ, COX-2 and iNOS. Material and Methods: 20 patients with ulcerative
colitis (UC) and 20 controls were enrolled in this study. Expression of TNFα and ghrelin
was assessed by quantitative RT-PCR in the biopsies obtained during colonoscopy from
colon ascendens and rectum from UC patients and controls. In addition, the effect of
exogenous ghrelin on TNBS colitis was tested in Wistar rats without or with capsaicin (125
mg/gk s.c.) to induce the functional ablation of sensory nerves. The mucosal PGE2 generation
and NO release into colonic lumen was determined by RIA and ELISA, respectively. Results:
Patients with CU showed a significant upregulation of ghrelin and TNFα in colonic mucosa
as compared to that observed in controls. The expression of ghrelin correlated with the
grade of inflammation and expression of TNFα. The exogenous ghrelin at dose 20µg/kg i.p.
daily significantly accelerated the healing of TNBS colitis (mean lesion area at day 14 after
induction of colitis: 17.3± 2.1 mm2 vs. 4.7± 0.4 mm2). This effect was accompanied by
increase in COX-2 and iNOS mRNA expression and a significant rise in the mucosal
generation of PGE2. The PPARγ mRNA which was down-regulated in rat colonic mucosa
after exposure to TNBS as compared to intact colonic mucosa was not significantly influenced
by ghrelin treatment. Conclusion: 1) Patients with ulcerative colitis show an increased
mucosal expression of mRNA for ghrelin in the colon; 2) Ghrelin accelerates healing of
colonic lesions in animal model of colitis via increased release of NO and PGE2 due to an
increase in iNOS and COX-2 expression and activity and sensory neuropeptides such as
CGRP released from sensory afferent endings.
M1661
Differential Effects of Anti-TNF Antibodies On Activated Macrophages and
Dendritic Cells In Vivo and In Vitro
Stefan Koch, Pia Lebiedz, Wolfram W. Domschke, Andreas Lügering, Torsten F. Kucharzik
Background and Aims: Anti-TNF antibodies are a potent tool in the treatment of inflammat-
ory bowel disease (IBD). Despite an increased investigatory focus on these drugs over the
last years, their mode of action In Vivo is not fully understood. However, previous reports
hint at an alteration of inflammatory cells, e.g. by inducing apoptosis in monocytes from
IBD patients. In this study, we further investigated mechanisms of action of anti-TNF
antibodies using a mouse peritonitis model, which provides a huge number of inflammatory
monocytes/macrophages and dendritic cells (DC). In addition, murine cell lines and In Vitro
differentiated human macrophages and dendritic cells were employed to validate In Vivo
observations. Methods: Peritonitis was induced in mice by i.p. injection of thioglycollate
medium. 72 hours after induction, mice were treated with either infliximab, anti-murine-
TNF antibody or IgG control. Inflammatory cells were retrieved by peritoneal lavage the
next day. Cells were identified by flow cytometric analysis of a variety of surface markers.
Apoptosis induction in these cells and in In Vitro differentiated human macrophages and
DC was determined by annexin V/PI staining. MAP kinase activation in murine RAW 264.7
and JAWS II cell lines was analyzed by western blotting. Results: Using different monocyte/
macrophage markers, we could determine that anti-TNF treatment in mice leads to a
significant reduction of monocytes and macrophages In Vivo, which appears to be at least
in part related to apoptosis. Conversely, an increased number of activated DC showing no
signs of apoptosis could be observed. In accordance with our In Vivo findings, In Vitro
experiments showed that infliximab dose-dependently induces apoptosis in human macro-
phages, but not in dendritic cells. Agreeing observations could be made in the murine
macrophage cell line RAW 264.7, in which anti-TNF treatment reduces the activation of
p38 and p42/44, but not in the dendritic cell line JAWS II. Conclusions: Our data confirm
previous results showing that induction of monocyte apoptosis is a major mechanism of
anti-TNF treatment. However, while there is a significant reduction of cells in the monocyte/
macrophage population, dendritic cells are activated through anti-TNF treatment and do
not show any signs of apoptosis either In Vivo or In Vitro. TNF antibodies therefore appear
to exert their anti-inflammatory effects through different mechanisms on various cell popula-
tions.
M1662
Comparative Genomic Analysis of Rat IBD Models Identifies New Genes and
Biological Processes As Potential Therapeutic Targets
Trinidad Montero, Jose maria Vieites, Xavier Llor, Olga Martinez-augustin, Fermin
Sanchez de medina, Angel Gil, Miguel A. Gassull, Antonio Suarez
There have been significant gains over the past few years in the knowledge of the pathogenesis
of inflammatory bowel disease (IBD). In spite of that, a curative therapy for the treatment
of this disorder is still lacking. Existing treatments are based on the use of antibiotics,
antiinflammatory drugs, including aminosalicylates or steroids, and inmunomodulators such
as anti-TNF drugs. New drugs targeting the biological processes leading to inflammation in
IBD are needed since many patients do not respond to these therapies or suffer undesirable
side-effects which causes morbidity and an increase in the cost of health care. Animal models
of colitis are useful to screen the effects of new drugs. Two of the most widely used IBD
models are the dextran sodium sulfate (DSS) and trinitrobenzenesulfonic acid (TNBS)-
induced colitis. These models are cheap, colitis is easy to induce, very reproducible and
resembles, in many aspects, ulcerative colitis and Crohn's disease, respectively. In this study,
we have used the DSS and TNBS models to characterize the genomic profile associated to
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colitis induction using the Affymetrix GeneChip® (Rat Genome 230 2.0, n=3 in each time
point) and, more specifically, to identify new potential therapeutic targets by comparing their
expression profiles with PharmGKB (www.pharmgkb.org) and other databases (PubMed,
GeneOntology, Panther, ...). In the DSS colitis model (7 days with 5% DSS; 8 days with
2% DSS; 7 days with no DSS), we found 10,125 differentially expressed annotated sequences
(ANOVA p<0.05), of which 545 were drug targets according to databases. In the TNBS
colitis model (10 mg TNBS in 50% ethanol), 3,140 annotated sequences were differentially
expressed (p<0.05), 203 of which were included in the aforementioned databases. Genes with
known targeting drugs are involved in several biological processes according to GeneOntology
classification: transport (Kcnh2); metabolism of xenobiotics (Gstp1), glutathione (Gstt1),
nucleic acids or phospholipids; activation of MAPK activity (Adra2a); cyclin dependent
protein kinase activity; biosynthesis of glutamate, glycine, leukotriene (Ltc4s) or prosta-
glandins (Ptgs2); signal transduction; defense and immune response; proliferation and
apoptosis; angiogenesis; transcription regulation (Ppara). The comparison between the two
models yielded 66 genes present in both lists (Il1a, Il10, Il2r, Gstm1, Scn5a …). Post-
genomic real-time RT-PCR experiments have confirmed the gene expression changes that
may provide a basis to explore the efficacy of new IBD treatments in these models.
M1663
IL-18 Regulates Both Constitutive and Stress-Induced Expression of Muc2
Gene in the Mouse Colon
Kensei Nishida, Mai Kamizato, Masuda Kiyoshi, Tomoko Kawai, Shigetada Teshima-
kondo, Haruki Okamura, Atsuo Sekiyama, Kazuhito Rokutan
Backgrounds & Aims: IL-18, known as interferon-γ-inducing factor, exerts pleotropic roles
as a potent pro-inflammatory cytokine. We already reported that this cytokine had a crucial
role in the initiation of cytokine responses in mice exposed to psychological stress (Immunity
2005). The present study was designed to elucidate a potential role of this cytokine in
psychological stress-initiated dysfunction of the mouse colon. Using IL-18-/- mice, we report
here that IL-18 regulates both constitutive and stress-induced expression of the MUC2 gene
that encodes the structural component of the colon mucus layer. Methods: This study was
approved by the Animal Care Committee of the University of Tokushima. C57BL/6 mice
or IL-18-/- mice housed 3-5 per cage were exposed to isolation stress or immobilization
(IMO) stress using a restrainer (plastic tube, 27 mm diameter). The expression of mRNAs
for MUC2, IL-18, and TFF3 was measured by real-time RCR. Changes in goblet cell number
and amount of MUC2 were assessed by immunohistochemistry using an anti-MUC2 antibody.
Results: Isolation stress increased the MUC2 mRNA level 2-fold in the proximal portion of
the colon, while the stress rather decreased the MUC2 transcript level in association with
declines of goblet cell numbers and mucin contents in the rectum. Isolation stress similarly
increased the TFF3 mRNA in the proximal colon, while it did not significantly change this
mRNA level in the rectum. These changes were reproducible in the IMO model. In wild
mice, IMO significantly up-regulated the expression of IL-18 mRNA in the rectum, but not
in the proximal colon. IL-18-/- mice constitutively expressed higher levels of both MUC2
and TFF3 mRNAs in the colon and rectum more than 2-fold, compared with wild mice.
We found that IL-18-/- mice were insensitive to isolation and IMO stresses; both stresses
did not change goblet cell number, mucin content, and MUC2 mRNA in the rectum of IL-
18-/- mice. Conclusion: Our results suggest that the colon and the rectum may exhibit
completely different response to psychological stressors. The responses of the MUC2 gene
in our stress models may explain the sensitivity and vulnerability of the rectum to psycholo-
gical stress. IL-18 abundantly expressed in the rectum may not only regulate local mucosal
defense but also participate in the high sensitivity of the rectum to psychological stress.
M1664
Therapeutic Effects of Saireito, a Traditional Herbal Medicine, in Oxazolone-
Induced Mouse Ulcerative Colitis Via the Suppression of Enhanced Expression
of the Suppressor of Cytokine Signaling (SOCS)-3
Tetsuo Watanabe, Takeshi Yamamoto, Minako Yoshida, Kanae Fujiwara, Hiroyuki
Aburatani, Yutaka Shimada, Makoto Kadowaki
Ulcerative colitis (UC) is intractable inflammatory disorders of the colon, and its etiology
remains unclear. We have reported pathophysiological role of the cholinergic anti-inflammat-
ory pathway in oxazolone (OXZ)-induced mouse ulcerative colitis model. In the present
study, we analyzed the immunological features of OXZ colitis and then examined the effects
of Saireito (TJ-114), a traditional herbal medicine, in OXZ colitis that has been reported to
exert therapeutic effects on human UC. METHODS: OXZ was injected into the colon of
BALB/c mice (Th2 dominant strain). TJ-114 was orally administered once a day for three
consecutive days. OXZ colitis was assessed with the disease activity score (DAS) on weight
loss, diarrhea and hemorrhage and with colonic damage score (CDS) by macroscopic evalu-
ation. The middle colon (adjacent to lesional site in the distal colon) and spleen were
analyzed with real-time PCR and global transcriptome analysis utilizing Affymetrix GeneChip
was also performed. RESULTS: The OXZ-treated mice developed colitis marked by sustained
weight loss, diarrhea and bloody stool associated with increased MPO activities in the middle
colon. Transcript levels of Th2 cytokines [interleukin (IL)-4, IL-5, and IL-10] significantly
increased in the spleen and middle colon of OXZ colitis mice. On the other hand, Th1
cytokine, interferon (IFN)-γ mRNA significantly decreased in the spleen and significantly
increased in the middle colon. Oral administration of TJ-114 significantly (P<0.01) alleviated
OXZ colitis [DAS: 9.6±0.9 vs 4.8±1.0; CDS: 7.5±0.6 vs 3.4±0.7; (OXZ colitis, n=42 vs TJ-
114-treated mice, n=32)]. In the middle colon of TJ-114-treated mice, the enhanced Th2
cytokines mRNAs were significantly down-regulated, while the enhanced IFN-γ mRNAs
were further up-regulated. In contrast, TJ-114 had no effect on mRNAs of every cytokines
in the spleen of OXZ colitis. In the global transcriptome analysis, we found 12 genes with
greater than 3-fold increase over normal levels by OXZ and less than OXZ colitis levels by
TJ-114. Among these genes, we focused on the suppressor of cytokine signaling (SOCS)-3
that is a negative feedback regulator of IL-12 signaling. With real-time PCR, the enhanced
SOCS3 mRNAs in OXZ colitis were significantly downregulated by TJ-114. DISCUSSION:
In OXZ colitis, systemic immune system (spleen) was shifted to Th2 dominant situation,
whereas in the mucosal immune system of the colon, both Th1 and Th2 immune responses
were enhanced. TJ-114 may have therapeutic potential for the control of ulcerative colitis
via an innovative mechanism, the suppression of upregulated SOCS-3 in the colon to drive
Th1 polarization.
M1665
Diet-Induced Obesity Confers Protection Against TNBS-Induced Colitis in
Rats
Niall P. Hyland, Adam P. Chambers, Quentin J. Pittman, Keith A. Sharkey
Diet-induced obesity (DIO) shares similarities with human obesity, having both genetic and
environmental components. Previously it was shown that colitis does not develop in leptin-
deficient mice in response to trinitrobenzene sulphonic acid (TNBS). Our aim was to
characterize the response to TNBS in DIO and diet-resistant (DR) rats, in addition to
accompanying changes in colonic function. 5-6 week old inbred male DR and DIO rats
were fed a medium high fat diet (32 Kcal %fat) ad libitum. 9 weeks later, DIO animals
weighed 27% more than DR rats. Both groups received 0.5ml intracolonic saline or TNBS
(50mg/ml in 50% ethanol). Animals recovered for 7 days and body weight and food intake
were monitored daily. Macroscopic damage scores and myeloperoxidase (MPO) activity were
assessed. Colonic segments adjacent to damaged sites were mounted in Ussing chambers,
and responses to veratridine (30µM) and forskolin (10µM) were assessed. To discriminate
between the effect of the DIO phenotype and body weight per se on the severity of colitis,
weight matched DR and DIO animals were also studied. Macroscopic damage scores were
significantly increased in TNBS treated groups compared to vehicle-treated controls (data
not shown). DR colon displayed significantly increased macroscopic damage compared to
DIO tissues (DR, 13.1 ± 0.7, n=6 vs DIO, 11.8 ± 0.4, n=6, P<0.001). TNBS treated DR
animals lost significantly more weight than DIO rats as early as two days after TNBS treatment
(14.2g difference on day 2, P<0.001), and continued to lose weight up to six days after
TNBS. This was accompanied by a significant decrease in food intake in DR compared to
DIO rats. TNBS treatment significantly increased MPO activity, but no differences were
observed between DR and DIO tissues (DR, 62 ± 13U/g, n=6 vs DIO, 51 ± 10U/g, n=5).
Weight matched DR animals also had significantly increased macroscopic damage score, a
significantly greater decrease in body weight and food intake after TNBS treatment compared
to DIO animals. Basal electrical properties were comparable in all groups. TNBS treatment
significantly decreased veratridine-stimulated responses compared to saline controls. This
was blunted to a lesser extent in DR colon (DR, 52 ± 21µA.cm-2, n=6 vs DIO, 2 ± 2µA.cm-
2, n=5), and may be related to decreased epithelial responses to forskolin in DIO tissues
compared to DR animals (DR, 76 ± 23µA.cm-2, n=6 vs DIO, 17 ± 5µA.cm-2, n=5, P<0.01).
Our data suggests that the severity of colitis is reduced in DIO rats and associated with
alterations in secretomotor function in the colon. We conclude that genetic and environmental
influences alter gut function and the expression of colitis.
M1666
Does the Vagus Nerve Exert An Effect In Vivo On NfκB Activation?
Caitlin O'mahony, Hanneke Van der kleij, Erin L. Symonds, Sharon Murphy, John
Bienenstock, Fergus Shanahan, Liam O'mahony
Introduction & Aim: The vagus nerve is a conduit for bi-directional signalling between
the brain and the gut, and exerts a neuro-immune down-regulatory influence on mucosal
immune activation. The aim of this study was to assess the impact of vagal signalling on
the activation status of the transcription factor Nuclear Factor -kappaB's (NFκB) In Vivo in
the murine gut. Methods: Subdiaphragmatic vagotomy was performed to examine the role
of the vagus nervE. colitis was induced in NFκBlux transgenic mice by administering 4%
dextran sulfate sodium (DSS) solution in drinking water for 5 consecutive days followed
by water for 1 additional day. In Vivo imaging measurements were obtained from mice
placed in a ventral recumbent position in a light-sealed chamber in the IVIS imaging system
chamber. Activation of NFκB resulted in the expression of luciferase which was quantified
as photons emitted/second/cm2. Results: Vagotomised mice exposed to DSS lost more body
weight accompanied by a more severe disease score compared to sham operated mice
exposed to DSS (p<0.05). In addition, increased levels of the inflammatory cytokines MCP-
1 (p=0.0018), IL-6 (p=0.0525) and TNF-α (p=0.0066) were observed in vagotomised mice
compared to the sham operated group exposed to DSS. NFκB activation in the vagotomised
animals was significantly greater in the small intestine, liver, colon and spleen (p<0.05).
Conclusion: Vagal efferents have a protective role in DSS-induced colitis which is associated
with attenuation of NFκB transcription factor activity.
M1667
Genomic Expression Analysis Reveals New Molecular and Cellular Events
Involved in the Pathogenesis of Dextran Sulfate-Induced Colitis
Trinidad Montero, Jose maria Vieites, Fermin Sanchez de medina, Xavier Llor, Olga
Martinez-augustin, Angel Gil, Miguel A. Gassull, Antonio Suarez
The dextran sulphate (DSS)-induced colitis is one of the most widely used mice models as
a means to probe the pathogenesis of inflammatory bowel disease. The present hypothesis
states that DSS produces a direct toxic effect on epithelial layer leading to alterations in
mucosal permeability, disruption of mucosal barrier and activation of T cell-mediated immune
response. Genome expression wide analysis offers the opportunity to confirm this hypothesis
and to examine the molecular and cellular events involved in the generation and recovery from
induced colitis: epithelial cell functionality, damage and renewal; immune cell recruitment;
mucosal fibrosis and inflammation; bacterial sensing mechanisms; host defense activation;
tissue remodelling, … We analysed the induction and recovery from DSS-induced colitis
in a longitudinal experiment: rats drunk a 5% DSS solution - days 1, 3, 5 and 7-, followed
by 2 % DSS - days 9, 11, 13 and 15- and, finally, no DSS - days 17, 21 and 23. Rats (n=
5 in each time point) were sacrificed and colon total RNA was extracted and used for gene
expression analyses with Affymetrix GeneChip Rat Genome 230 2.0 (n=3 in each time
point). After quality control, normalization and statistical analyses, we obtained 10,125
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differentially expressed annotated sequences (ANOVA p<0.05). As expected, many described
inflammation-related genes were overexpressed (Ptgs2, Il1b, Il6, Nos2 Csf1, Cxcl1, Cxcl2,
S100a and S100a9) which indicated the onset of neutrophil- and macrophage-mediated
innate immunity response. Expression of cell junction, cell structure and extracellular matrix
genes was altered which suggested a disruption of the epithelial barrier. Our genomic study
not only characterized the time course evolution of previously described changes but showed
alterations in other biological processes and functions: alterations in the metabolism of
carbohydrate, lipid, amino acid, vitamin, purines or pirimidines metabolisms; transporters
(amino acid, nucleoside, oligopeptide, electrolytes and water); serine protease inhibitors;
glutamate and GABAergic neurotransmission; biologically active peptides... Post-genomic
real time RT-PCR analyses confirmed the disease-course expression changes of key genes
in the aforementioned biological processes. Our data may provide a rationale to dissect the
molecular and cellular events involved in the onset, evolution and recovery from DSS-
induced colitis. We believe that the comparison the genomic fingerprint of human IBD with
that of chemically-induced and knockout animal models of colitis may increase our know-
ledge on the underlying mechanisms that trigger and develop chronic colitis in Humans.
M1668
Influence of Adenosine Receptor Ligands On Tnba-Induced Inflammation in
Rat Isolated Small Intestine Preparations
Karen Nieber, Sebastian Michael, Olaf Kelber, Claudia Warstat
Inflammatory diseases of the intestine are accompanied with changes in gastrointestinal
motility and morphology. Functional studies have revealed that adenosine exerts a variety
of effects in different regions of the intestine including modulation of inflammatory processes.
Adenosine can influence gastrointestinal motility directly, by activating receptors located on
smooth muscle or indirectly, by regulation neurotransmitter release from enteric neurons.
The adenosine receptors are subdivided in A1, A2A, A2B and A3 receptors by the relative
order of potency of agonists and antagonists and by the coupled transduction mechanisms.
Their localization and function vary depending on the intestinal region. The aim of our
study was to establish an inflammatory model In Vitro by characterization of disordered
contractility, morphology and production of the inflammatory mediator TNF-α and to
investigate the influence of adenosine receptor ligands on these parameters. The experiments
were performed on the rat terminal ileum. All animal procedures complied with regulations
of the German Guidelines for Animal Care. Experimental inflammation was induced by
intraluminal application of 2,4,6-trinitrobenzolsulfonic acid (TNBA), a compound which
causes morphological and functional changes associated with chronic bowel inflammation
In Vivo. TNBA induced a concentration- and time-dependent decrease of the acetylcholine
(ACh)-mediated contraction of the ileum. Histological studies (van Gieson staining) indicate
changes in morphology after exposure to TNBA. Using RT-PCR technique an increased of
TNF-α mRNA in the TNBA-treated ileum was evident. The adenosine A1-receptor (A1R)
agonist cyclopentyladenosine induced a pronounced decrease of the ACh-induced contraction
when it was co-incubated with TNBA for 30 min. The effect was reversed by the A1R
antagonist 8-cyclopentyl-1,3-dipropylxanthine. The adenosine A2A-receptor (A2AR) agonist
CGS21680 diminished the TNBA-induced reduction of the ACh-induced contraction. The
A2AR antagonist 8-(3-chlorostyryl)-caffeine reversed the effect of CGS21680. Histological
studies indicate a protective effect of CGS21680 on TNBA-induced morphological changes
of the smooth muscle and mucosa. TNBA-induced increase of TNF-α mRNA was decreased
after pre-incubation of the ileum with the A2AR agonist CGS21680. Our results provide
evidence that the selective activation of A2AR acts protective against inflammatory damages,
whereas the activation of A1R increased the inflammatory process. The activation of the
A2AR by selective agonists could be a new approach for the treatment of inflammatory
bowel diseases.
M1669
Does Defective Mitochondrial Electron Transport Chain Activity Play a Role in
Development of Ulcerative Colitis?
Subapriya Rajamanickam, Balakrishnan S. Ramakrishna, Aparna Venkatraman
Introduction: Reactive oxygen/nitrogen species (ROS/RNS) seem to play a pivotal role in
the pathogenesis of ulcerative colitis (UC), where upregulation of inducible nitric oxide
synthase has also been documented. Mitochondria are an important cellular target for nitric
oxide (NO). Since the mitochondrial electron transport chain (ETC) is the main source of
ROS/RNS in living cells, it was hypothesized that NO-induced increase in ROS production
due to compromised ETC function may have a role in the early stages of disease development.
Aim: To evaluate the sequential changes in the mitochondrial respiratory chain complexes
I, II, III, IV and V activities along with ROS & RNS levels in experimental colitis induced
in mice by oral administration of dextran sodium sulfate (DSS). Methods: Animals were
divided into 4 groups. Group 1 were administered 4% DSS in feed, group 2 were administered
feed without DSS and served as controls. Group 3 had feed with DSS + aminoguanidine
(specific inhibitor of inducible nitric oxide synthase) and group 4 were given aminoguanidine
alone. Animals from each group were sacrificed at 2, 4 and 8 days. Colonic length and
histological damage score were measured. Mitochondrial ETC I, II, III, IV and V activities
were analyzed in the distal colon. Results: Shortening of colon, loss of body weight and
presence of occult blood in stool was evident from 4th day onwards in animals administered
DSS compared to control. Histologically, this was accompanied by crypt loss and infiltration
of inflammatory cells. Increase in NO was observed from day 2 onwards. Interestingly,
animals receiving DSS for only 2 days showed significant decrease in activities of complex
IV, which was reversed in animals supplemented with aminoguanidine. Complex III and I
were decreased only on day 4 onwards. Conclusion: These results suggest that the increase
in NO by iNOS and reduced mitochondrial complex IV activity are very early changes in
colitis, resulting in compromised ETC function and followed by reduction in complex III
& I activity. NO-induced inhibition of complex IV activity could play a critical role in
development of disease.
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M1670
Protective Effects of Thrombomodulin in DSS-Induced Murine Colitis
Mark Lust, Gregory T. Moore, Steven J. Brown, Sally Bell, William Connell, P. R. Elliott,
John Slavin, Harshal Nandurkar, Peter Cowan, Paul V. Desmond, Tony D'apice
Background: Thrombomodulin (TM) is highly expressed on the microvascular endothelium,
where it activates protein C, a potent anticoagulant and anti-inflammatory molecule. TM
also reduces leukocyte adhesion to the endothelium, an effect independent of its anticoagulant
function. The reduced expression of TM in the mucosal vasculature of patients with Inflam-
matory Bowel Disease (IBD) results in impaired protein C activation and contributes to the
hypercoagulable state that characterizes IBD. Inflammation and coagulation are closely linked
and failure to downregulate the coagulation cascade may result in maintenance or amplifica-
tion of the inflammatory response in IBD. We studied the effects of overexpression of TM
in mice using the dextran sodium sulfate (DSS) model of colitis. Methods: Human TM
(hTM) transgenic mice and C57Bl6 wild type (WT) littermates received either 3% dextran
sulfate sodium (DSS) in their drinking water or normal water alone for 7 days. Disease
activity was assessed daily based on change in weight, stool consistency and presence of
blood in the stools. Mice were sacrificed on day 7 and colons were harvested for histological
assessment. Coagulation was measured in whole blood using a Chrono-Log Aggregometer
following stimulation with 4 mcg/ml of collagen. Results: Mice receiving DSS developed an
acute colitis characterized by weight loss and bloody diarrhoea that was not seen in mice
receiving water alone. There was a moderate reduction in the clinical severity of colitis in
hTM transgenic mice compared to WT mice as evidenced by less weight loss (11% vs 17%
of baseline weight; p<0.05) and lower disease activity scores (mean 7 vs 8.6; p=0.03). There
was no significant difference in colon length (69.7mm vs 68.2mm), however mean histology
scores were markedly reduced in hTM transgenic mice compared to WT mice (11.6 vs 22.2;
p<0.005). Whole blood aggregometry demonstrated a mild increase in coagulation in colitic
WT mice compared to WT controls as measured by the amplitude of impedance (17.8 vs
15.7 Ohm; p=0.001). Coagulation in colitic hTM transgenic mice was similar to that in WT
mice with colitis (amplitude 19.3 Ohm). Conclusions: Enhanced expression of hTM reduces
disease severity in the DSS model of colitis, potentially highlighting a new therapeutic target
in the management of IBD. Based on our aggregometry results, the protection afforded by
TM does not appear to be a result of its anticoagulant function. Further work is required
to determine the direct effect of TM on intestinal inflammation.
M1671
Amelioration of Dextran Sulfate Sodium Induced Colitis in Angiotensin II
Type 1 Receptor Knockout Mice
Makoto Sasaki, Tsuneya Wada, Takashi Mizushima, Naotaka Ogasawara, Eiji Kubota,
Yoshinori Mori, Takaya Shimura, Tsutomu Mizoshita, Yasuyuki Okamoto, Hiromi
Kataoka, Takeshi Kamiya, Takashi Joh
Background: A number of recent studies have demonstrated a protective effect of renin-
angiotensin system (RAS) antagonism against immune mediated disease as well as colitis (Y
Inokuchi et al. Gut 2005). Among the RAS, we have suggested that the type 1 receptor of
angiotensin II may plays an important role in the pathogenesis in the colitis (T, Wada et
al. AGA 2006). Aims: We evaluated the direct effect of angiotensin II type 1 receptor (AT1R)
on the pathogenesis of immune mediated colitis using AT1R deficient homozygous (AT1R-/-
) mice. Method: Dextran sulfate sodium (DSS) colitis was induced in AT1R-/- and wild type
(AT1R+/+) mice. During the oral administration of 5% DSS ad libitum for 5 days, colonic
inflammatory scales (body weight (BW), disease activity index (DAI) including BW, stool
characteristic, and fecal blood on a scale of 0 to 4) were examined. Level of proinflammatory
cytokines in the colon were determined by RT-PCR. Histological analysis and myeloperoxid-
ase (MPO) activity were also examined. Result: Although AT1R-/- mice developed colitis,
the degree was much milder than in AT1R+/+ mice. Colonic histological examination showed
that inflammation score and crypt damage score were significantly lower in AT1R-/- compared
with AT1R+/+ mouse (2.0 vs. .7.5; p<0.05, 4.3 vs. 12; p<0.05). MPO activity was improved
in AT1R-/- mice (0.045 vs. 0.086; p<0.05). BW loss and DAI in AT1R-/- mice (12.8%, 2.6)
was significantly less than that of AT1R+/+ mice (22.6%, 4.0). The colonic expression of
proinflammatory cytokine (IL-1beta, IFN-gamma) was suppressed in AT1R-/- compared
with AT1R+/+ mice. Furthermore administration of AT1R blocker candesartan ameliorated
DSS induced colitis. Conclusion: Angiotensin II type 1 receptor plays crucial role in the
pathogenesis in the murine colitis and AT1R blockage is a potential prophylactic strategy
for the treatment of human inflammatory bowel disease.
M1672
Very High and Very Low Dietary Folate Induce Intestinal Pro-Inflammatory
Cytokine Secretion Leading to Severe DSS Induced Colitis in Mice
Alon Lang, Ifat Goldshmith, Orit Picard, Iris Barshak, Simon Bar meir, Yehuda Chowers
Background: The level of inflammation has recently shown to affect the risk of colorectal
cancer in chronic colitis. Folate supplementation has been suggested as chemoprevention
in colitis. However, the effect of folate on intestinal inflammation is not clear. Aim: to study
the effect of folate on intestinal cytokine secretion and inflammation. Methods: BALB-C mice
were fed with weaning diets containing 0, 2 (basal requirement), 8, or 20 mg folate/kg diet.
After 3 months of dietary intervention, Intestinal mRNA of TNF-α and IL-1 β were assessed
by real time PCR. Mice were then treated with 5% DSS to induce colitis. Histological score
of colitis (0-4) was determined. Tissue reinstitution was assessed by skin wound healing
and In Vitro by tissue culture wound healing model. Results: Serum folate levels correlated
with the different diets. No death occurred in the control groups (not treated with DSS).
Increased levels of TNF-α were noted in the zero folate group and increased levels of IL-1
β was noted in the very high folate group compare to the other two groups. Following DSS
treatment, an increased mortality rate was noted for the zero folate group and the very high
folate group (62 % and 50 %, respectively) compared to the basal folate and the moderate
folate supplementation (16% and 30%, respectively). Mortality rates correlated with the
inflammatory score. Scores of 2.8±0.3 and 2±0.2 were noted in the zero folate group and
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the very high folate group, respectively, compared to scores of 1.6± 0.2 and 1±0.1 in the
basal and mild supplementation group, respectively. No difference in skin or tissue culture
wound healing was noted between the 4 groups. Conclusion: Dietary folate affects mortality
and inflammation in a colitis mouse model. Too much folate may be as harmful as lack of
folate. The effect seems to be related to the effect of folate levels on TNF-α and IL-1 β.
M1673
Chronic Psychological Stress Reactivates Dextran Sulfate Sodium(DSS)-
Induced Chronic Colitis in Mice
Silvia Melgar, Kerstin Engström, Vicente Martinez
Inflammatory bowel disease (IBD) is a chronic inflammatory condition characterized by the
alternance of active and quiescent phases of inflammation. Stress has been suggested as a
factor triggering the relapse of IBD. AIM: To determine the role of stress in the reactivation
of colonic inflammation in a model of DSS-induced mild chronic colitis in mice. METHODS:
Colitis was induced in C57BL/6 female mice by exposure to DSS (3%, 5 days) added to the
drinking water. 28 days after, during the chronic phase of inflammation, animals were
subjected to either psychological stress [water avoidance stress (WAS): 1 h/day for 7 days]
or maintained in non-stressful conditions; and simultaneously exposed to a sub-threshold
concentration of DSS (1%, 5 days) or normal water (n=6 per group). Clinical signs of
inflammation (body weight, fecal consistency and general health condition) were assessed
daily. At the end of the stress period animals were euthanized and colonic inflammatory
scores and inflammatory markers assessed [colonic levels of interleukin 1β (IL-1β) and
plasma levels of acute phase protein haptoglobin]. RESULTS: Animals exposed to 3% DSS
lost weight (peak lost of 10%, 8-10 days after DSS exposure) and showed signs of colonic
inflammation, compared to controls receiving normal water. WAS resulted in a significant
and stable increase in pellet output during the 7 days of stress (mean pellet output: WAS:
8.3±0.4 pellets/h; sham stress: 1.3±0.2 pellets/h). At necropsy, animals subjected to 3%
DSS, with or without WAS, had increased levels of corticosterone (Table) compared to
healthy non-stressed controls (67.3±36.1 ng/ml). Animals exposed to 3% DSS and WAS
had higher colonic weight, colonic inflammatory score, colonic levels of IL-1b and plasma
haptoglobin than non-stressed mice (Table). In animals receiving normal water, neither
WAS nor expossure to 1% DSS, alone or in combination, elicited any inflammatory response.
CONCLUSIONS: Psychological stress worsened inflammation in animals with mild chronic
colitis and this effect was independent of the presence of a sub-threshold concentration of
DSS (1%). These data suggest that stress, per se, reactivates an on-going inflammatory state
leading to a phase of acute-like inflammation. Stress can be a factor triggering the relapse
of IBD.
Colonic and systemic inflammatory parameters
Data are mean±SEM, n=6 per group.
M1674
Hypersensitivity to DSS-Induced Mucosal Injury in NHE3 Knockout Mice
Pawel R. Kiela, Claire B. Larmonier, Monica M. Kiela, Robert D. Thurston, Fayez Ghishan
Background: NHE3 is a Na+/H+ exchanger responsible for the majority of electrolyte transport
across the gastrointestinal tract, and is the target for inhibition by inflammatory cytokines
likely contributing to inflammation-associated diarrhea. NHE3-/- mice exhibit mild diarrhea,
decreased body fat, metabolic acidosis, lower blood pressure, distal colonic mucosal hyper-
trophy, and increased small intestinal expression of IFNγ. All phenotypic changes have been
attributed to impaired intestinal and renal transport. Aim: To investigate an alternative role
for NHE3 in maintenance of mucosal integrity. Methods: 6-8 week old wild-type (WT),
NHE3+/-, or NHE3-/- mice were given water with or without 0.5, 1, or 4% dextran sulfate
(DSS) for 7 days. Mortality and body weight were recorded daily. Blood and tissue samples
were taken 2 days into the treatment. Results: NHE3-/- mice treated with all concentrations
of DSS showed dramatic increase in mortality compared to WT littermates. No NHE3-/-
mice survived day 5 on 1-4% DSS. Mortality in NHE3+/- mice treated with 4% DSS was
higher than of WT mice (50% vs. 5%). NHE3-/- mice treated with 4% DSS for 2 days
exhibited panleukocytosis, intestinal haemorrhage extending into the proximal jejunum, a
sharp drop in red blood cells (RBC) and hematocrit (Ht). No exacerbated diarrhea was seen
based on the weight of cecal content. Basal expression of IFNγ mRNA was elevated 27-fold
in the jejunum, but not colon of the NHE3-/- mice. This was accompanied by increased
expression and phosphorylation of Stat1 (pY701). In NHE3-/- mice iNOS mRNA was induced
80-fold in the jejunum and 30-fold in the colon, while expression of endothelin (ET-1) was
reduced by 90% and 40%, respectively. Inhibition of iNOS with aminoguanidine in DSS
treated NHE3-/- mice reduced intestinal bleeding and reversed the drop in RBC and Ht, but
did not improve survival or neutrophilia. Compared to WT mice, DSS significantly increased
bacterial association with the colon of NHE3-/- mice. Microarray analysis demonstrated
dramatic differences in gene expression profiles in both small intestine and colon of control
WT and knockout mice. We observed a surprising dysregulation of small intestinal gene
expression in DSS-treated NHE3-/- mice, never seen in WT mice (363-/- vs. 38+/+ genes, >2-
fold, p<0.05). NHE3 status greatly influenced not the quantity (309+/+ vs. 321-/- genes) but
the composition of the pool of genes regulated by DSS (only 13 common genes between
genotypes). Conclusion: NHE3 participates in maintenance of intestinal epithelial integrity,
and serves as a modifier gene determining the extent and quality of response to mucosal
injury. Support: R01DK041274
M1675
Regulation of Human T Cell Function By Adenosine: Evidence of a2a
Adenosine Receptor Inhibition of Cytokine Production By Cd4+ T Cells and
Gastric T Cells
Mohammad S. Alam, Elizabeth Wiznerowicz, Jeffrey Wilson, Brent Burnette, Joel Linden,
Robert Figler, Sheila Crowe, Peter B. Ernst
Background & Aims: Adenosine is a naturally occurring autocoid that limits tissue damage
associated with inflammation. A2A adenosine receptors (A2AAR) are found on neutrophils,
antigen presenting cells and lymphocytes. Activation of A2AAR on these cells produces
responses that in general, are anti-inflammatory. To understand the role of adenosine in the
regulation of gastric immune response, we investigated the expression of surface apyrases
(e.g. CD39) and ecto-5'-nucleotidase (CD73); The expression of adenosine receptors (ARs)
in helper T cells (Th); and evaluated the effect of A2AAR agonists on Th cell function.
Methods: Magnetic bead-purified human CD4+ Th cells, Jurkat T cells or gastric T cells
isolated from biopsy specimens, were stimulated with anti-CD3/CD28 mAb and assayed for
the expression CD39/CD73, all 4 adenosine receptor subtypes and cytokine expression by
flow cytometry, ELISA or RT-PCR. The selective A2AAR agonist, ATL313 or antagonist,
ZM241385 were evaluated for their ability to modulate T cell function. T cells were also
assayed for intracellular cyclic AMP (cAMP) levels using a chemiluminescent immunoassay.
Results: We report that in Th cells, the expression of both CD39 and CD73 is up-regulated
after activation; CD39 expression was increased from 5% to 9% and CD73 expression was
increased from 17% to 42%. Expression of these molecules was biased to certain Th cell
subsets, particularly the CD25+Foxp3+ regulatory T cell which expressed higher levels of
these enzymes (>35% for CD39 and >62% for CD73). As CD39 and CD93 catalyze the
formation of adenosine from ATP and 5'-AMP released in inflamed tissues, these data suggest
that Th cells contribute to the local accumulation of adenosine. We also demonstrated that
activation of Th cells caused a rapid 8-fold increase in A2AAR mRNA, which also significantly
increased the efficacy of A2AAR-mediated cAMP accumulation in these cells. A2AAR mRNA
was the predominant subtype expressed in resting and stimulated Th cells or gastric T cells.
A2AAR activation reduced anti-CD3/CD28 mAb-mediated production of IL-2 by 20 to 50%
with 100 nM to 500 nM of ATL313 treatment in Th cells and gastric T cells. Similar
suppressive effect by ATL313 was also observed for TNF-α and IFN-γ. The selective A2AAR
antagonist reversed the inhibitory effect of ATL313. Conclusion: The expression of CD39
and CD73 by T cells along with the rapid induction of A2AAR in response to activation
suggest that T cells contribute and respond to local adenosine accumulation. The A2AAR
can provide a mechanism for limiting the pro-inflammatory effects of T cells thereby reducing
inflammation in the gastric mucosa.
M1676
A Novel Pathway of Intestinal Inflammation-Associated Iga+ Plasma Cell
Development
Yasuyo Shimomura, Atsuhiro Ogawa, Ken Sugimoto, Mayumi Kawada, Emiko Mizoguchi,
Atul K. Bhan, Atsushi Mizoguchi
BACKGROUND & AIMS: IgA+ plasma cells in small intestine have been demonstrated to
originate from B1 cells or migrate from organized lymphoid tissues such as Peyer's patches.
However, the pathway of IgA+ plasma cell development associated with large intestine (LI)
has not yet been identified. METHODS: Development pathway of IgA+ plasma cells in the
LI was examined by enhancing B cell lymphopoiesis through an acute LI inflammation that
is induced in mice by administration of 4% Dextran sodium sulfate (DSS) in drinking water
for 4 days. After termination of the DSS treatment, the mice were followed till day 30.
RESULT: Intestinal inflammation activated the mobilization of AA4.1+ immature B cells from
the bone marrow (BM) into the LI during the recovery phase (day 8) but not in the acute
phase (day 4) of DSS colitis. BrdU-pulsing experiment demonstrated that the BM-derived
immature B cells mature within the LI mucosa into a unique AA4.1-CD24high IgM+ B cells
that exhibit characteristic of both type 1 and type 2 transitional stages of B2 lineage cell
maturation. The development of this unique B cell population was induced through BAFF
(B cell activation factor from the TNF family)-dependent innate immune responses as
indicated by absence of inflammation-induced LI B cell expansion in the BAFF mutant mice
and by significant expansion of LI B cells in two distinct mouse strains that lacks B cell
receptor (BCR) signaling or that contains only a monoclonal B cell population that expresses
a restricted B cell receptor specific for hen egg lysozyme. In addition, study utilizing splenotec-
tomized LTα knockout (KO) mice revealed that secondary lymphoid tissues including the
spleen and organized lymphoid tissues are not required for the development of the unique
AA4.1-CD24high LI B cells. Furthermore, two distinct approaches of B1 cell reconstitution
in recipient RAG KO and utilizing IL-7R KO mice that lack B2 but not B1 cells confirmed
the B2, but not B1, -lineage origin of the unique LI B cells. Of note, these unique AA4.1-
CD24high LI B cells completed their differentiation into IgA-producing plasma cells within
the MLN but not within the LI as indicated by a data that, after local injection of IgA- LI
B cells from donor green fluorescence protein (GFP)-transgenic mice into the colon of
recipient WT mice, IgA+ cells among GFP+ cell population were detectable in the recipient
MLN but not LI. The actual secretion of IgA was further confirmed using enzyme-linked
immunospot (ELISPOT) assay. CONCLUSION: This study identifies a navel pathway for LI
IgA+ plasma cell development by facilitating B cell lymphopoiesis through acute LI inflamma-
tion.
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M1677
Commensal Microbiota and Cd8+T Cells Link to Control Systemic Levels of
Plasmacytoid Dendritic Cells
Daisuke Fujiwara, Bo Wei, Michael Mcpherson, Jonathan Braun
Background The intestinal microbiota is an abundant and highly diverse community. Recent
work indicates that its composition is a stable trait for an individual during life, but that
the composition is divergent between individuals. Dendritic cells (DCs) are important in
regulating the quality of the host response to microbiota, and respond to microbial products
in their differentiation and functional state. We therefore wondered whether individuals
bearing divergent intestinal microbiota are distinct in their dendritic cell populations.
Methods. Cells were isolated from spleen, mesenteric node, and intestinal superficial lamina
propria, and analyzed by flow cytometry for conventional DCs (CD11chighCD11b+B220-)
or plasmacytoid DCs (pDC: CD11clowCD11b-mPDCA-1+), and for their expression of CD8α
and intracellular cytokines. C57BL/6 mice were compared from specific pathogen-free (SPF),
germ-free (NIH Gnotobiotic facility), or restricted flora (AJ Scupham. 2006. Appl. Environ.
Microbiol. 72:793); and, from C57BL/6 mice bearing MyD88, CD8, and CD4 null mutations.
Results A large (80-90%) and systemic reduction in absolute numbers of plasmacytoid
dendritic cells (pDCs) was observed in RF (restricted flora, predominant for Clostridium and
Firmicutes taxa) vs. SPF (specific pathogen-free, predominant for Lactobacillus, Bacteroidetes,
and Acinetobacter taxa) mice. This reduction was selective, in that numbers of conventional
DCs and CD8+ DC were unaffected in these mice. The reduction was not observed in germ-
free (GF) mice, or SPF MyD88-/- mice, suggesting that the pDC deficiency was not due
simply to a lack of products from intestinal microorganisms, or their sensing by the MyD88-
dependent TLR signaling pathway. However, when the role of adaptive T cell immunity
was assessed, CD8-/- RF mice were preserved in pDC numbers. In contrast, CD4-/- RF mice
retained the low pDC phenotype. Furthermore, injection of anti-CD8 antibody to RF mice
restored pDC, and injection of RF CD8+T cells with RF lumen contents reduced pDC. In
RF mice, conventional DCs were increased for expression IL-12 and co-stimulatory molecules,
several changes in systemic T cells (T Huang 2005. Clin Immunol. 117: 221), and resistance
to immune colitis. These data indicate that intestinal microbiota program CD8+T cells to
control levels of pDCs, a DC population which may interfere with host microbial clearance
that protect against colitis susceptibility. Supported by NIH DK4673 and DK69434.
M1678
Human Colonic Myofibroblasts Promote the Expansion of Cd4+ Cd25high
Foxp3+ Regulatory T Cells
Iryna V. Pinchuk, Ellen J. Beswick, Jamal I. Saada, Victor E. Reyes, Don W. Powell
Background & Aims: Intestinal immune responses are normally regulated to maintain a state
of immune balance (mucosal tolerance). While the exact mechanism(s) underlying peripheral
tolerance remain(s) unknown, antigen presenting cells (APCs) are likely involved since they
are key regulators of T cell responses. We recently reported that human colonic myofibroblasts
(CMFs) are novel non professional APCs and are the most abundant MHC class II expressing
cell phenotype in the normal human colonic mucosa. We showed that CMFs directly
suppress proliferation of activated CD4+ effector T cells via mechanisms involving B7-
negative costimulator signals. This finding led us to hypothesize that CMFs are local negative
regulators of activated T effector cell responses. In the present work we extend our study
of suppressive capacity of CMFs and evaluate whether these cells may stimulate expansion
of suppressive T regulatory cells (Treg) with a CD4+ CD25high FoxP3+ phenotype. Cells
with this phenotype have been recently found in the human colonic mucosa and are important
in maintaining tolerance. Methods: T cell phenotype was determined by immunostaining
followed by FACS analysis. Lymphoproliferation assays and cytokine ELISAs were used to
evaluate proliferation and activation of Treg cells co-cultured with CMFs. Results: Our data
demonstrate that CMFs induce the proliferation of CD4+CD25highFoxP3+ Treg cells which
express high levels of CTLA-4. Moreover, CMFs induced de novo generation of the
CD4+CD25highFoxP3+ Treg cells from naïve CD4+ CD45RA+CD45RO-CD25-FoxP3- T
helper cells. These processes were MHC class II- and PGE2-dependent since the frequency
of the Treg cells was markedly decreased (50-60%) in the presence of anti-MHC class II
blocking antibodies or the PGE2 synthesis inhibitor indomethacin (10 μM). The de novo
generated Treg cells were shown to be functionally active, since they inhibited the proliferation
of activated autologous CD4+ effector T cells. Conclusions: These findings support our
hypothesis that CMFs may be key contributors in the induction and maintenance of mucosal
tolerance in the colon via at least two independent mechanisms: (1) expression of B7 negative
co-stimulators and (2) induction of the distinct population of the regulatory T cells. Supported
by NIDDK, GRIP and the Gulf Coast DDC, McLaughlin Endowment.
M1679
Visilizumab Can Induce Regulatory Cd8 T Cells In Vitro
Lloyd Mayer, Okebugwu Kamalu, Jacky Woo, Linda Zeng, Tanny Tsao, Ed Tom, Keith
Wilson, Vladimir Vexler
INTRODUCTION: Open-label Phase I studies of visilizumab, a humanized non-FcR-binding
anti-CD3 monoclonal antibody, in intravenous steroid-refractory ulcerative colitis (IVSR-
UC) patients (pts) showed tolerability and activity. The responses in the majority of pts
persisted long after visilizumab was cleared from the circulation suggesting that the mechan-
ism of action may reflect more than just the previously reported rapid apoptosis of activated
T cells and changes in trafficking of CXCR3+ T cells. Preliminary data from two-thirds of
the dosed patient population suggested that the clinical response on day 30 was associated
with an increased peripheral blood (PB) CD8+ T cell count. We therefore hypothesized that
visilizumab could preferentially affect the CD8 T cell population, inducing regulatory CD8+
T cells. AIM: To examine the phenotypic and functional activity of PB T cells from normal
controls (NC) and inflammatory bowel disease (IBD) patients following In Vitro exposure
to visilizumab. METHODS: Peripheral blood mononuclear cells (PBMC) were exposed either
to visilizumab (100 ng/mL) or isotype control for up to 11 days. CD8+ and CD4+ T
cells were analyzed phenotypically, negatively selected and their effect on proliferation and
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cytokine production by autologous PBMC was evaluated using various regulatory assays.
RESULTS. Treatment of PBMC with visilizumab led to an expansion (proliferation) of CD8+
but not CD4+ T cells from all NC. There were no differences in apoptosis. Visilizumab-
exposed CD8+ cells, at various CD8+:PBMC ratios (from 1:1 to 1:8), contact-dependently
inhibited anti-CD3/CD28-induced proliferation by 80% and cytokine (IFN-γ, TNF-α, IL-2,
IL-5, IL-13) secretion by 50-80%, suggesting the presence of regulatory activity. DNA-
microarray revealed an increase in expression of CTLA-4 and CD103, and a down regulation
of CD127 in visilizumab-treated CD8+ cells. In contrast to NC, PBMC from 3/13 Crohn's
disease (CD) and 2/6 UC pts failed to expand CD8+ T cells. This expansion was further
measured in PBMC from 3 IBD patients prior to visilizumab infusion and correlated with
clinical response (30 days). Of the 3, 1 clinical responder decreased the CD4/CD8 ratio In
Vitro from 4.6 to 2.9. However, 2 non-responders (one CD and one IVSR-UC) failed to
alter their CD4/CD8 ratio In Vitro. CONCLUSION: Our results demonstrate that In Vitro
visilizumab can induce the expansion of regulatory CD8+ T cells. This mechanism, if
confirmed In Vivo, could contribute to the observed long-term response to visilizumab in
some IVSR-UC pts. Furthermore, a decrease in CD4/CD8 ratios In Vitro might predict a
clinical response in visilizumab-treated subjects
M1680
NF-kB Controls the Expression of Flip, An Inhibitor of Fas-Mediated
Apoptosis, in Crohn's Disease Lymphocytes
Flavio Caprioli, Daniele Fina, Roberta Caruso, Ilaria Peluso, Massimo C. Fantini, Carmine
Stolfi, Giuseppe Sica, Angelamaria Rizzo, Saskia Janssen, Livia Biancone, Francesco
Pallone, Giovanni Monteleone
Background and aims. The marked accumulation of T cells in the gut of Crohn's disease
(CD) patients is supposed to rely partly on the resistance of such cells to Fas-mediated
apoptosis. We previously showed that CD lamina propria lymphocytes (LPL) contain elevated
levels of Flip, an inhibitor of Fas-mediated apoptosis, and that inhibition of Flip by antisense
oligonucleotides reverted the resistance of CD LPL to Fas-induced apoptosis. How Flip is
regulated in CD remains unclear. We here examined the molecular mechanisms that control
Flip in CD. Methods. Paired colonic biopsy samples of patients with CD, patients with
ulcerative colitis (UC) and healthy controls (HC) were analysed for Flip RNA and protein
by real-time PCR and Western blotting (WB) respectively. Samples were also evaluated for
Stat3, Akt and NF-kB/p65 activation by WB. Additionally, Flip was evaluated in biopsies
of CD and HC cultured with TPCK (NF-kB inhibitor), or AG490 (JAK2/Stat3 inhibitor), or
wortmannin (pAkt inhibitor). Finally, CD and HC CD4+ LPL were treated with TPCK per
24 hours and then with Fas-ligand for further 24 hours. Apoptotic cells were eventually
evaluated by FACS. Results. A more pronounced expression of Flip protein was seen in CD
as compared to UC and HC. Additionally, Flip RNA levels were significantly increased in
CD in comparison to UC and HC, indicating that Flip is controlled at the transcriptional
level in CD. Notably, the same CD samples contained high levels of active Stat3, Akt and
NF-kB, all of which have been reported to enhance Flip in other systems. However, inhibition
of NF-kB but neither AkT nor Stat3 reduced Flip in CD biopsies and LPL. Consistently,
TPCK restored the susceptibility of CD LPL to FAS-mediated apoptosis. Conclusions. Data
show that, in CD, Flip is transcriptionally controlled by NF-kB, thus elucidating an additional
mechanism by which NF-kB helps sustain the ongoing inflammation in CD.
M1681
IL-21 Selectively Prevents TGF-Beta Induced Regulatory T Cells
Massimo C. Fantini, Daniele Fina, Angelamaria Rizzo, Ilaria Peluso, Carmine Stolfi,
Roberta Caruso, Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Introduction: IBD-related tissue damage is supposed to be due to an exaggerated T cell
immune response in the gut wall that is inadequately controlled by counter-regulatory
mechanisms. Peripherally induced regulatory T cells are supposed to play a central role in
the maintenance of the gut immune homeostasis. This is substantiated by the observation
that TGF-beta-induced regulatory cells prevent experimentally induced colitis in mice. How-
erver how the generation and function of these cells is influenced by cytokines released by
inflammatory cells is poorly understood. IL-21, a T lymphocyte-derived cytokine which is
upregulated in IBD, is able to expand autoreactive T cells in autoimmune mediated diseases.
Whether this is due to the ability of this cytokine to interfere with Tregs induction and/or
activity remains unclear. In this study we have investigated whether IL-21 contrasts the
differentiation of TGF-beta induced regulatory cells (Ti-Tregs). Methods: Murine naïve
CD4+CD25- cells were activated in presence of TGF-beta with or without IL-21 for five
days and the transcription factor FoxP3, markers of T cell activation, and T cell-derived
cytokines were evaluated. The suppressive capacity of Ti-Tregs generated in presence of IL-
21 was evaluated in a conventional coculture assay, while proliferation and apoptosis were
analyzed by cytofluorimetry. Results: IL-21 significantly reduced the number of Ti-Treg cells
as shown by the reduced expression of FoxP3 at RNA and protein level and by diminished
capacity of these cells to suppress the growth of freshly isolated CD4+ naïve cells. Annexin-
V/PI staining revealed that IL-21 did not affect the survival of Ti-Tregs. By contrast, CFSE
dilution assay showed that IL-21 selectively reduced the growth of Ti-Tregs. Notably induc-
tion of activation markers CD25, CD69, CD45RB, CD44 and CD62L in presence of TGF-
beta was not modified by IL-21 suggesting that IL-21 suppress the induction of FoxP3 rather
then inhibiting TGF-beta signaling. Additionally we demonstrate that IL-21 but not IL-6
suppressed Ti-Treg cells when added later to the TGF-beta stimulated cell cultures. Conclu-
sions: These data suggest a novel function of IL-21 as a negative regulator of induction and
expansion of peripherally induced regulatory cells.
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M1682
Helminths Induce Cd8+/Foxp3+ Treg in the Intestine That Control Colitis
Joel V. Weinstock, Long Hang, Tommy Setiawan, Arthur Blum, Joseph Urban, Korynn
Stoyanoff, Andrew Leiter
Helminths are worm like organisms that may prevent IBD in people and can prevent or
treat IBD in murine models of colitis. The aim of this study was to further define the
mechanisms through which helminths modulate IBD. FoxP3 is a transcription factor that
identifies a subset of regulatory T cells (Treg). We used a mouse with enhanced green
fluorescent protein knocked into the FoxP3 locus to generate a FoxP3-EGFP fusion protein
to identify FoxP3 expressing regulatory cells in the host in response to infection with the
helminth, H polygyrus (Hp). Hp is an intestinal worm that resides in the proximal intestine.
Mice were colonized with Hp for 2wks. Then, dispersed LPMC (terminal ileum), MLN and
splenocytes (spl) were examined for EGFP+/FoxP3+ cells using multicolor flow cytometry.
EGFP fluorescence and immunohistochemistry for EGFP showed their location in the intest-
ines. Results: In uninfected mice, FoxP3 was expressed mostly in a small subset of intestinal
CD4+ T cells. Worm infection induced lamina propria (LP) CD8+, but not CD4+ T cells
to express FoxP3. (FoxP3+ CD8+ T cells: no worms 0.8± 0.2% vs. worms: 13.6±1.7%, N=
6)(also see figure). However, there was no increase in the relative number of LP T cells
expressing CD8. FoxP3 expression in CD8+ T cells in the MLN and spl were minimally
affected. Immunohistochemistry showed that the worm-induced, mucosal FoxP3 CD8+ T
cells were distributed diffusely in both colon and ileal LP. Isolated mucosal CD8+Tregs
induced by Hp strongly inhibited lymphocyte proliferation in an In Vitro assay. CD8+ T
cells also were effective at limiting colitis in a Rag transfer animal model of IBD. Thus,
intestinal helminths can induce a unique CD8+Treg that is important for limiting murine
colitis. (support: K38327, DK58755, DK034928)
M1683
Increased Telomerase Expression Correlates with Proliferation of Mucosal T
Cells in Crohn's Disease
Heitor Souza, Manijeh Phillips, Gail West, Melanie Rhee, Claudio Fiocchi
A fully effective immune response depends on optimal T cell proliferation, a fundamental
process which relies on maintenance of telomere length by the activity of the enzyme
telomerase. The telomerase complex contains a catalytic component called human telomerase
reverse transcriptase (hTERT), which closely correlates with enzymatic activity. We investig-
ated whether changes in hTERT expression were associated with differences in proliferative
capacity between T cells from inflammatory bowel disease (IBD) and normal mucosa. hTERT
expression was assessed in whole mucosal tissue, isolated lamina propria mononuclear cells
(LPMC) and T cells (LPT), as well as cytosolic and nuclear fractions using immunohistochem-
istry, mRNA, and Western blotting. LPMC and LPT were cultured under unstimulated and
stimulated conditions, including IL-2 and anti-CD3±CD28 activation. Immunohistochem-
istry showed a markedly increased number of hTERT-positive cells in Crohn's disease
(CD), but not in ulcerative colitis (UC), compared to control mucosa, and confocal double
immunofluorescence demonstrated that hTERT-positive cells in the lamina propria were T
cells. Both hTERT mRNA and protein levels were significantly (p=0.015) higher in freshly
isolated CD compared to UC and control LPMC. When LPMC were cultured in the presence
of IL-2, the number of cells increased progressively over a 14 day period, but significantly
(p=0.003) more in CD than UC and control cultures, and this occurred in parallel with an
increase of hTERT mRNA and protein. In contrast to freshly isolated LPMC, where hTERT
had a predominantly cytoplasmic distribution, hTERT nuclear fraction considerably increased
in long term IL-2-stimulated cultures. When LPMC were treated with anti-CD3±CD28, both
hTERT mRNA and protein levels increased proportionally in all cultures. The above results
show that hTERT is present at low levels in normal mucosal T cells, but its expression
vigorously increases under inflammatory conditions, particularly CD. Receptor- or growth
factor-mediated activation leads to an increase in hTERT in IBD and control cultures, though
clearly more in CD, and this response is accompanied by the translocation of hTERT from
the cytoplasm to the nucleus. Overall, this indicates that telomerase activity is necessary for
mucosal T cell proliferation and may represent a mechanism to compensate for telomere
shortening that commonly occurs in chronic inflammatory conditions, where cellular turn-
over is high, such as IBD.
M1684
First Live Observation of In Vivo Leucocyte Trafficking in Patients with Celiac
Sprue
Heiko Pohl, Barbara T. Tanczos, Bertram H. Wiedenmann, Thomas Rösch, Daniel C.
Baumgart
Background: Enhanced endoscopic techniques provide an unprecedented spectrum of novel
imaging details. Leucocyte migration is a key aspect of various intestinal inflammatory
disorders and promising therapeutic target. Here we report the first real time visualization
of migrating leucocytes in the duodenum of patients with celiac sprue. Methods: We studied
the usefulness of endocytoscopy (EC) for the detection of pathological hallmark features in
nineteen celiac sprue patients aged 40.8 ± 17.3 years with either well controlled disease or
ongoing inflammation. To assess leucocyte trafficking we acquired video sequences at 450x
and 1125x magnification of the duodenal mucosa. The most revealing still images were
selected and cut from video sequences recorded at 25 frames per second. Results: In 4 out
of 32 video sequences recorded at 1125x magnification we were able to track small mononu-
clear cells migrating between villi and intermittently adhering to the epithelial surface. These
cells also closely interacted with epithelial cells. To fit through the tight interepithelial spaces,
these cells impressively adapted their morphology. Conclusion: To our knowledge these
recordings represent the first live In Vivo endoscopic observation of migrating leucocytes.
This technique may provide valuable new insight into leucocyte trafficking and could be
potentially be used to assess therapeutic efficacy of selective adhesion molecule blockers in
chronic inflammatory conditions of the gut.
M1685
Intestinal Epithelial Cell-Derived IL-7 in the Development of Intraepithelial
Lymphocyte: Role of Integrin αEβ7
Hua Yang, Keisuke Nose, Xiaoyi Sun, Hiroyuki Koga, Deborah L. Gumucio, Blair
Madison, Daniel H. Teitelbaum
Background: Our previous work has shown that intestinal epithelial cell (EC) specific over-
expression of IL-7 leads to changes in intestinal intraepithelial lymphocyte (IEL) phenotype
and function, and increased IEL numbers. Because integrin αEβ7 (CD103) is important for
homing and maintenance of IEL to the intestine, we hypothesized that integrin αEβ7 is
involved in IEL changes induced by IL-7. Method: Transgenic mice with specific intestinal
EC-derived IL-7 over-expression were developed using an EC-specific villin promoter
(P12.4KVill). IL-7vill mice were sacrificed at 8 weeks of age. Wildtype C57BL/6J mice (WT,
n=5) were used as controls. Isolated TCRaβ+ and TCRγδ+ IEL were separated by using
magetic beads. Integrin αEβ7, TGF-β mRNA expression were detected by real time PCR.
Changes in IEL phenotype were detected by flow cytometry. Results: Numbers of IEL in
IL-7vill mice were significantly (P<0.05) higher than WT mice (Table). CD8αβ+ increased
5.6-fold in IEL, CD4+CD8- IEL increased 6.5-fold, TCR-αβ+ IEL increased 2.5-fold, mature
CD4+ IEL (denoted by CD44+) increased 1.5-fold; and activated CD4+IEL (CD4+,CD69+)
increased 7.6-fold compared to WT mice. Integrin αEβ7 expression in IL-7vill mice signific-
antly increased in both TCR-αβ+ and TCRγδ+ IEL compared to WT mice. TCRαβ+ IEL
integrin αEβ7 expression was higher than TCR-γδ+ IEL in both WT mice and IL-7vill mice.
The expression of TGF-β was examined as it has been shown to induce IEL integrin αEβ7
expression; and was also significantly increased in IL-7vill mice. As E-cadherin is the ligand
of integrin αEβ7, EC-derived E-cadherin expression was studied, and was significantly
increased in IL-7vill mice (Table). Finally, to further assess the relation of IL-7 and integrin
αEβ7 expression, IL-7 receptor (IL-7R) was blocked with anti-IL-7R antibody in normal WT
mice. This resulted in decreased integrin αEβ7 expression in both TCR-αβ+ and TCR-γδ+
IEL, and significantly decreased total IEL numbers (4.2±0.4×106 v.s. 8.1±1.7×106in WT
group), as well as changes in IEL phenotype (decline in CD4+(2.9±0.3% vs 5.9±1.4 for
Controls) and CD8αβ+(3.8±0.6% vs 8.5±1.0) IEL). Conclusions: IL-7 over-expression by
intestinal EC significantly affected IEL populations, resulting in over-expansion of the CD4+
and CD8αβ+ IEL subtypes, as well as an increase in a mature and activated CD4+ IEL
population. IL-7 may mediate some of these changes via an up-regulation in integrin αEβ7-
E-cadherin signaling.
Results are mean±SD. *P<0.05, using t test compared to WT group.
M1686
IL-21 Inhibits IL-15-Induced STAT3 and Stat5 Phosphorylation By Human
Intestinal Intraepithelial Lymphocytes (IELs)
Ellen C. Ebert
Introduction: IL-21, produced by CD4+ T cells, is a member of the cytokine family utilizing
the common γ-chain receptor subunit, as do IL-2 and IL-15. IL-21 is a potent up-regulator
of cytotoxic T lymphocyte activity by CD8+ T cells and is effective in tumor rejection.
It has been shown to synergistically enhance IL-15-induced activities. Human IELs are
CD8+TCRαβ+ T cells, located between epithelial cells, which develop cytotoxicity, prolifera-
tion, and IFNγ production in response to IL-15 without CD3/TCR crosslinking. The hypo-
thesis of this study is that IL-21 is a potent up-regulator of T cell functions by IELs. Methods:
Human IELs were isolated from jejunal specimens from patients undergoing gastric bypass
operations for morbid obesity. Cytotoxicity was determined by the 51chromium-release assay;
proliferation, by 3H-thymidine incorporation; fas ligand (FL) release, by ELISA; and STAT
3 and 5 phosphorylation, by immunofluorescence (since signals were too low to be detected
by Western blot assay). Results: A three-day culture of IELs with IL-15 resulted in 1. cytotoxic
activity against HT-29 cells (25 to 40% lysis), 2. proliferation (2.2-fold greater than medium-
cultured IELs), and 3. FL release (5.3-fold greater than medium-cultured IELs). A three-
day culture with IL-21, in contrast, induced none of these actions. Surprisingly, IL-21
inhibited IL-15-induced cytotoxicity, proliferation, and FL expression so that the results
were similar to those obtained from cultures in medium alone. IL-15 induced phosphorylation
of STAT5 and to a lesser extent, STAT3. This action, too, was inhibited by IL-21. The effects
of IL-21 were not due to cell death since the numbers of apoptotic and necrotic IELs were
the same regardless of the cytokine stimulus. Conclusion: These novel data demonstrate
inhibitory activities of IL-21, which down-regulates IL-15-induced proliferation, cytotoxicity,
FL release, and phosphorylation of STAT3 and STAT5 by human IELs.
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Toll-Like Receptor 9-Signaling Mediates Innate Immune Response in Murine
Intestinal Cd5+ B Cells
Yoshiyuki Mishima, Shunji Ishihara, Mohammad Rumi, M. D. Aziz, Ichiro Moriyama,
Chikara Kadota, Naoki Oshima, Norihisa Ishimura, Hideaki Kazumori, Yasunori
Kadowaki, Yuji Amano, Yoshikazu Kinoshita
(Background & Aim) B lymphocytes are divided into subpopulations based on their various
phenotypic and functional characteristics, of which CD5+ B cells are a unique subset that
localize in peritoneal and pleural cavities, as well as mucosal compartments. CD5+ B cells
are able to sense pathogen-associated molecules and initiate host innate immune responses,
however, little is known regarding their role in the regulation of intestinal inflammation.
Since signaling through toll like receptors (TLRs) plays a major immunoregulatory role in
gut mucosa, we investigated innate immune responses by murine intestinal CD5+ B cells in
relation to TLR signaling. (Materials & Methods) Seven-week-old male BALB/c mice with
or without acute colitis, induced by administering a 2.5% dextran sulfate sodium (DSS)
solution in drinking water for 7 days, were studied. Mononuclear cells were isolated from
lamina propria in the colon as well as from the peritoneal cavity, spleen, and mesenteric
lymph nodes (MLNs). The expressions of B220, CD5, IgM, TLR4, and TLR9 in isolated
cells were analyzed by flow cytometry, while immunostaining was used for detection of
CD5+ B cells in histological sections. For In Vitro experiments, CD5+ and CD5- B cells were
separated from isolated mononuclear cells using immunomagnetic beads. Purified CD5+ and
CD5- B cells were then cultured and stimulated with LPS or CpG DNA, and interleukin
(IL)-10 contents in culture media were measured using enzyme immunoassays. (Results)
The ratios of CD5+ B cells among B220+ B cells in the colon, peritoneal cavity, spleen, and
MLNs were 15%, 60%, 14.5%, and 13%, respectively. As compared to CD5- cells, CD5+ B
cells from the colon had higher levels of IgM and TLR9, and a lower level of TLR4 expression,
with a similar expression pattern observed in CD5+ B cells isolated from the peritoneal cavity,
spleen, and MLNs. CD5+ B cells in the lamina propria of the colon were immunoreactive for
both B220 and CD5, and their number increased significantly during DSS-induced colonic
inflammation. When purified CD5+ or CD5- B cells were stimulated with TLR ligands In
Vitro, CpG-DNA induced a significant amount of IL-10 production in colonic CD5+ B cells,
but not in CD5- B cells. (Conclusion) CD5+ B cells were detected in murine colon tissues
and their numbers increased during inflammation, suggesting a possible regulatory role for
these cells. CD5+ B cells also showed a higher level of TLR9 expression and CpG-DNA
stimulated abundant IL-10 production from them. We speculated that innate immune
responses by CD5+ B cells play an antiinflammatory role during acute colitis.
M1688
Regulation of Intestinal Inflammation By Interleukin 27 Through T-Cell
Apoptosis
Jan C. Preiss, Rainer Duchmann, Martin Zeitz, Warren Strober
Inflammatory bowel disease is characterized by a pathological response of T cells to apoptotic
stimuli. In Crohn's disease lamina propria T cells are less likely to undergo apoptosis. Also
most drugs used for treatment of inflammatory bowel disease induced T-cell apoptosis.
Interleukin 27 (IL-27) is a novel heterodimeric cytokine composed of EBI3 and the IL-
27p28 subunit. Production of IL-27 can be observed during different types of intestinal
inflammation, e.g. infections with T. muris as well as autoimmune diseases. It is generally
believed that IL-27 plays a role in TH1-type T-cell differentiation. On the other hand it
seems to have an anti-inflammatory role, partially mediated through inhibition of IL-2 and
IL-17. We wanted to investigate whether IL-27 can also exert its anti-inflammatory role
through increased apoptosis of CD4+ T cells. Naïve CD4+ T cells were isolated from murine
spleens. They were stimulated in the absence or presence of recombinant IL-27. Stimulated
cells were subjected to different kinds of apoptotic stimuli. After activation in the presence
of IL-27 CD4+ T cells show a marked increase in Fas-mediated apoptosis (25 % vs. 50 %
on day 3). This effect becomes apparent on the second day of stimulation. Accordingly
activation-induced cell death (AICD) is higher in IL-27-stimulated cells. IL-2 deprivation
also leads to higher rates of apoptosis in IL-27 stimulated cells (20 % vs. 40 % on day 3).
Interestingly apoptosis through TRAIL or TNF, which was almost undetectable in cells
stimulated without IL-27, was largely unaffected. Quantitative PCR revealed uniformly pro-
apoptotic changes in mRNA expression of components of the Fas pathway. Also cholesterol
depletion showed changes in raft localization of the Fas signaling complex. Furthermore
expression of GADD45β and GADD45γ mRNA was measured and the influence of MAPK
inhibitors on the IL-27 effect was investigated. Here no significant changes were found.
Apoptosis is an important mechanism for regulation of a T-cell reaction. During overshooting
immune response T cells are undergoing Fas-mediated activation-induced cell death (AICD)
and after clearance of the infectious agent lack of growth factors, namely IL-2, leads to
apoptosis through the mitochondrial pathway. In inflammatory bowel disease these mechan-
isms are defective. IL-27 increases the susceptibility of T helper cells to each of these forms
of apoptosis. This provides an attractive mechanism for the regulatory role of IL-27 in
intestinal inflammation. The role of IL-27 during pathological immune reaction as in Crohn's
disease and ulcerative colitis needs to be further investigated.
M1689
Characterization of Lamina Propria Dendritic Cell Subsets in the Normal
Mouse Small Intestine
Xiao Wang, Heng-fu Bu, Xiu-li Zuo, Roxanne Y. Williams, Maurice R. O'gorman, Xiao-di
Tan
BACKGROUND AND AIMS: Dendritic cells (DCs) play a central role in the orchestration
of immunity and tolerance. There are several DC subtypes exhibiting a variety of functions
identified primarily by specific surface antigen expression patterns. In the gut, DCs are
located in mesenteric lymph node (MLN), Peyer's patch (PP), and lamina propria (LP).
Although MLN and PP DCs have been well studied, the functions and specific subsets of
DCs in LP have not been well characterized. We examined the various subsets of DCs in
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the LP of normal mice. METHODS: Wild type inbred mouse strains were used. Mononuclear
cells were isolated from MLN, PP, and LP followed by staining with appropriate fluorescently
labeled antibodies and analysis by flow cytometry. Lineage negative (CD3-, CD19- and F4/
80-; Lin-) cells were analyzed for the expression of surface markers associated with specific DC
phenotypes. RESULTS: The Lin- LP mononuclear cells contained two main DC populations:
B220highCD11cintIA/AElowLin- (i.e. plasmacytoid DCs; pDCs) and B220-CD11chighIA/IE+Lin-
(i.e. myeloid DC; mDC). The pDCs were the dominant form in the LP. LP pDCs contained
predominantly CD11cintB220+Ly6C+CD8α- cells whereas pDCs from the MLN and PP con-
tained both CD11cintB220+Ly6C+CD8α+ and CD11cintB220+Ly6C+CD8α- cells. The small
proportion of mDCs in the LP was further characterized for their expression of CD4, C8α
and CD11b makers. The mDCs in LP contained only CD11c+CD11b+CD4-CD8α- whereas
the mDC in MLN and PP contained both CD11c+CD11b+CD4-CD8α- and CD11c+CD11b-
CD4-CD8α-. Further characterization of the maturity of the DCs in the LP using CD80
indicated that the pDCs were more immature than mDCs. CX3CR1 expression on DCs is
known to be associated with the uptake of antigens from the lumen. The pDCs in MLN
and in the LP contained both CX3CR1+ and CX3CR1- subpopulations, whereas pDCs in
PP contained only CX3CR1- cells. However, the mDCs in MLN, PP, and LP did not express
CX3CR1 on the cell surface. CONCLUSIONS: We have observed that both plasmacytoid
and myeloid DCs reside in the intestinal lamina propria and that both DC subsets contain
distinct subpopulations of DCs based on their expression of well characterized surface
markers. In the lamina propria, the pDC subset predominates and expresses variable levels
of CX3CR1. Studies are underway to further characterize the functions of the specific subsets
of pDCs that we identified in the lamina propria. Characterization of heterogeneity of DC
subsets in lamina propria will allow for a better understanding their role in mucosal immunity
and the pathogenesis of intestinal injury.
M1690
Transforming Growth Factor-β Blockade Up-Regulates T-Bet Expression and
Increases Proinflammatory Cytokines and Stromelysin-1 (MMP-3) in Normal
Colonic Mucosa
Antonio Di sabatino, Laura Rovedatti, Giovanni Monteleone, Thomas T. Macdonald
Background & Aims: The role of transforming growth factor (TGF)-β in inhibiting T cell
function has been studied with dominant-negative TGF-β receptor transgenic models. How-
ever, the full impact of TGF-β signalling on gut T cells remains poorly understood. Therefore,
we tested the effect of TGF-β blockade on T-bet expression, Th1 cytokine production and
stromelysin-1 (MMP-3) expression in normal colonic biopsies grown ex vivo. Methods:
Perendoscopic biopsy specimens were collected from the colon of 11 subjects who turned
out to have functional diarrhoea at the end of their diagnostic work-up. Biopsies were placed
on iron grids in the central well of an organ culture dish located in a tight container with
95% O2/5% CO2 at 37°C, and cultured for 24 h in the presence of 10 mg/ml pan-neutralizing
anti-TGF-β antibody or its isotype matched control (10 mg/ml rabbit IgG). After culture,
T-bet and MMP-3 expression were determined by Western Blotting in homogenized tissue
samples, and levels of interleukin (IL)-2, IL-8, IL-17 and interferon (IFN)-γ were measured
by ELISA in organ culture supernatants. Results: T-bet expression, normalised for β-actin,
was significantly up-regulated in biopsies treated with anti-TGF-β blocking antibody. More-
over, TGF-β blockade induced a significant increase of IL-2, IL-8, IL-17 and IFN-γ levels
in organ culture supernatants. Significantly higher expression of the active form of MMP-3
(44-49 kDa) was observed both in the tissue and supernatants of biopsies treated with anti-
TGF-β blocking antibody. Conclusions: Our findings support a crucial role for TGF-β in
dampening T-cell mediated tissue-damaging responses in the gut, and provide a pathophysi-
ologic explanation for the development of chronic inflammatory conditions such us Crohn's
disease in which TGF-β signalling is impaired.
M1691
Probiotics and Synbiotics Protect Mdr1a -/- Colitic Mice from Developing
Altered Bone Mineral Density
Silvia C. Resta-lenert, Susan J. Lee
Background: Osteoporosis and reduced bone mass are frequent co-morbidities of inflammat-
ory bowel disease (IBD). Constant remodeling through bone formation and resorption are
characteristic of bone homeostasis. We have shown that dysregulated bone homeostasis in
mouse models of colitis is due to an imbalance of both processes. Moreover, we have shown
that probiotics and synbiotics promote calcium uptake in the gut. We hypothesized that
probiotic and synbiotic treatment may reverse the effects of chronic inflammation on dysregul-
ated bone homeostasis. Methods: 12 wk old colitic mdr1a knock out (KO) mice, and wild
type (WT) counterparts matched for age and gender (6-10 mice/group) were treated for 4
weeks with the probiotic combination S. thermophilus-L. acidophilus (ST/LA), with the
synbiotic ST/LA plus inulin (ST/LA/IN) or placebo. At the end of treatment, KO and WT
mice were tested for femoral length, bone mineral density (BMD), serum OPG, RANKL and
tartrate-resistant acid phosphatase (TRAP) levels, and colonic OPG mRNA and protein levels.
Results: At the end of treatment, probiotic- and synbiotic-treated KO mice femurs were
comparable in length to WT controls, whereas placebo-treated KO mice had significantly
shorter femurs (in mm: 11±1.2 vs 16±1.5; p<0.05) than their WT counterparts. Moreover,
the incidence of low BMD among the KO mice was significantly reduced by probiotics or
synbiotics compared to placebo treatment (20% vs 90%, respectively; p<0.01, n=10). In
probiotic- or synbiotic-treated KO mice, serum OPG, RANKL and TRAP returned to levels
not different from WT mice, whereas the OPG/RANKL ratio and TRAP levels were still
significantly elevated (4.1 vs 1.1; p<0.01, and, in U/L: 9.2±0.8 vs 4.4±0.5, respectively) in
placebo-treated KO mice vs their WT counterparts. Colonic OPG mRNA was significantly
reduced in probiotic- and synbiotic-treated mdr1a KO mice compared to the placebo-treated
KO group (3.3 fold decrease). Conclusions: Our data suggest that bone loss in chronic
colitis may be corrected by manipulating the intestinal microbiota, and support a role for
probiotics and synbiotics for treatment and prevention of osteoporosis associated with IBD
and other chronic diseases. Supported by grants NIH-DK062096 and UCSD Academic Senate
(SRL), and UCSD D. Howell Scholarship (SJL).
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In Vitro Effects of the Probiotic Escherichia coli Strain M-17: Inhibition of
Nuclear Factor-Kappa B and Pro-Inflammatory Cytokines
Leo R. Fitzpatrick, Jeffrey S. Small, Eileen F. Bostwick, Robert A. Hoerr, Lynn W. Maines,
Walter Koltun
Previously, we found that E. coli strain M-17 (EC-M17) improved DSS-induced colitis in
mice (2006 DDW meeting). The mechanisms of anti-colitis action for some probiotics include
decreasing the production of relevant pro-inflammatory cytokines, by inhibiting signal trans-
duction pathways. Purpose: Our first goal was to determine whether EC-M17 could inhibit
the nuclear factor-kappa B (NF-κB) signaling pathway. A second goal was to evaluate the
effects of EC-M17 on NF-κB and relevant pro-inflammatory cytokines in a macrophage cell
line. In this regard, the pharmacological profile of EC-M17 was compared to that of VSL#3.
Methods: Initially, NF-κB signaling was examined with a HEK 293T cell line. Specifically,
we used this NF-κB luciferase reporter stable cell line, when cells were stimulated with
TNF-α (100 ng/ml). EC-M17 was tested at concentrations from 5 x 107 to 5 109 CFU/ml.
Next, the effects of EC-M17 were evaluated with a RAW 264.7 macrophage cell line. Cells
were exposed to LPS (5 μg/ml), and then relevant parameters were measured during the
ensuing four-hour period. The nuclear binding of the p65 subunit to the NF-κB consensus
binding site was determined with a relevant kit. TNF-α, IL-1β and IL-6 were measured by
ELISA. The effects of EC-M17 were compared to VSL#3 (1 x 108 CFU/ml), for inhibiting
cytokine secretion by macrophages. Cell viability was determined by the trypan blue exclusion
method, or colorimetric MTS assay. Results: EC-M17 dose dependently inhibited TNF-α
induced NF-κB signaling with the luciferase reporter gene assay system. At 1 x 108 CFU/
ml, EC-M17 inhibited signaling by 68%. Three hours after LPS stimulation, the nuclear
binding of NF-κB was increased in the macrophage cell line. Nuclear p65 binding was
significantly inhibited (78%, p < 0.05) with 1 x 108 CFU/ml of EC-M17. ECM-17 alone
(without LPS) only mildly stimulated NF-κB signaling and cytokine secretion in the macroph-
age cell line. In contrast, VSL#3 clearly induced cytokine production by macrophages. EC-
M17 also inhibited (by > 90%) the LPS-induced secretion of TNF-α, IL-1β and IL-6. VSL#3
was less effective than EC-M17 for inhibiting LPS-stimulated cytokine secretion. For VSL#3
treatment, the mean percent inhibitions were: 0% (TNF-α), 29% (IL-6), and 75% (IL-1β).
Heat-killed EC-M17, as well as EC-M17 conditioned media, was not effective for reducing
cytokine secretion by macrophages. Therefore, the inhibitory effects of EC-M17 required
live bacteria, but not a secreted metabolite. EC-M17 did not affect cell viability. Conclusion:
EC-M17 is a novel probiotic agent with pharmacological properties that may be useful for
the treatment of intestinal inflammation.
M1693
The Probiotic Escherichia coli Strain Nissle 1917 (EcN) Induces Apoptosis of
γδ T Cells Via Caspase and Fas-L Dependent Pathways
Claudia Guzy, Daniela Paclik, Uta Berndt, Ulrich Sonnenborn, Axel U. Dignass, Bertram
H. Wiedenmann, Andreas Sturm
BACKGROUND: Since γδ T cells specifically recognize microbial antigens such as pathogen-
associated molecular patterns (PAMPs) without the need of antigen presenting cells or MHC
molecules, they play a central role in the regulation of inflammatory processes. We previously
demonstrated that the probiotic E. coli strain Nissle 1917 (EcN) ameliorates intestinal inflam-
mation by inhibiting peripheral T cell expansion, prompting us to investigate the effect of
EcN on γδ T cells. METHODS: Peripheral blood mononuclear cells from healthy volunteers
were stimulated with Isopentylpyrophosphat and IL-2 and cultured in the presence or
absence of 25% (vol/vol) steril filtered EcN supernatants (EcN-SN) for 72h. T cell populations
were identified by flow cytometric analysis or for some experiments γδ T cells were negatively
sorted using magnetically labeled anti-αβ TCR antibodies. Flow cytometry was used to
assess apoptosis (Annexin V) and necrosis (PI) of γδ T cells (anti-γδ TCR) as well as
their Fas, Fas-L and TNF-α receptor expression profiles. To determine apoptotic pathways,
stimulated cells were cultured with caspase inhibitors and blocking anti-Fas antibody followed
by flow cytometry analysis. The mitochondrial membrane potential was determined by
rhodamin123 staining. RESULTS: Compared to controls, EcN significantly increased γδ T
cell apoptosis by 36.9±5% (p<0.05) and necrosis by 25.3±3% (p<0.05). In contrast, EcN
did not induce αβ T cell death. EcN increased Fas-L expression of γδ T cells by 34.3±6%,
while TNF-α receptor expression dropped by 42.1±4% and Fas expression remained
unchanged. EcN-induced γδ T cell death was significantly inhibited by the ubiquitous caspase
inhibitor zVAD, the caspase inhibitors-3, -8 and -9, and blocking Fas-L antibodies. Examining
the intrinsic apoptotic pathway, EcN decreased the mitochondrial membrane potential of
γδ T cells. CONCLUSION: Our data demonstrate that EcN potently induces γδ T cell death
via caspase and Fas-L dependent pathways. Inflammatory bowel diseases are characterized
by an uncontrolled immune response against the indigenous gut flora. γδ T cells are strongly
involved in the recognition of microbial antigens and the perpetuation of inflammatory
processes. Thus, the blockage of this pathway by EcN might further explain its beneficial
effects in inflammatory bowel diseases and help to better understand the role of γδ T cells
in mucosal inflammatory processes.
M1694
Involvement of B Cells in the Hygiene Hypothesis
Yasuyo Shimomura, Emiko Mizoguchi, Ken Sugimoto, Atsushi Mizoguchi, Atul K. Bhan
BACKGROUND & AIMS: According to the “hygiene hypothesis”, enhanced microbial expo-
sure due to early childhood infections leads to reduction of Th2-mediated allergic diseases
and inflammatory bowel disease. However, the mechanisms involved have not been fully
defined yet. METHODS: TCRα deficient (TCRα KO) mice and B cell-deficient TCRα double
knockout (αμ DKO) mice, which spontaneously develop Th-2 mediated colitis, were main-
tained under specific pathogen-free (SPF) and conventional (CV) facilities for more than
five generations. RESULT: Unexpectedly, TCRα KO mice that spontaneously develop colitis
in SPF conditions did not develop colitis under non-sanitary conditions present in CV
facility. In contrast, αμ DKO mice developed colitis in both SPF and CV facilities, indicating
a role of B cells in non-sanitary condition-associated inhibition of colitis. QPCR analysis
revealed that the expressions of majority of toll-like receptors (TLRs) were significantly
upregulated in the purified B cells from CV TCRα KO as compared to SPF TCRα KO mice.
In addition, ELISPOT assay showed a significant increase (over 20 times) in the number of
IgM producing B cells in the spleen, but not gut-associated lymphoid tissues, of CV TCRα
KO mice as compare to SPF TCRα KO mice. B1 cells are well known to the produce
“natural” IgM antibodies that recognize phosphoryl choline (PC) and activation of peritoneal
B1 cells through TLRs induces their migration from the peritoneal cavity to spleen. Indeed,
the absolute numbers of peritoneal B1a cells were significantly decreased in CV TCRα KO
mice as compared to SPF TCRα KO mice and IgM-specific anti-PC antibody in the serum
and faeces was significantly increased in CV TCRα KO mice as compare to SPF TCRα KO
mice. The activation of B1 cells may play a role in suppression of colitis observed in CV
TCRα KO. CONCLUSION: The findings suggest that B cells mediate inhibition of Th2-
mediated colitis development in the non-sanitary environment. Furthermore, the suppression
of colitis is associated with activation of B1 cells.
M1695
Commensal Microbiota, Including Probiotics, Promote T Regulatory Cells and
Attenuation of Inflammatory Responses to Murine Salmonella Infection
Caitlin O'mahony, Paul Scully, David O'mahony, Anne Lyons, David O'sullivan, John
Macsharry, Barry Kiely, Fergus Shanahan, Liam O'mahony
Background. Host defence against infection requires a range of innate and adaptive immune
responses which if unchecked result in tissue damage. Immune-mediated pathology can be
controlled with appropriate T regulatory (Treg) activity. The commensal flora may be a
contributory factor in the induction of immune regulatory pathways. Aim. Determine the
impact of gut flora signalling on Treg cellular activity and inflammation associated with
infection. Methods. Balb/c mice consumed the commensal micro-organism Bifidobacterium
infantis 35624 followed by infection with Salmonella typhimurium UK1. CD4/CD25/Foxp3
T cell phenotypes were assessed in Peyer's patch and spleen using flow cytometry. S.
typhimurium numbers were quantified using q-PCR and murine sickness behaviour assessed
visually. In Vitro Peyer's patch and splenocyte culture supernatant cytokine levels were
assessed by cytometric bead array. NF-κB activity was assessed In Vivo using the NF-κ Blux
mouse and visualised using biophotonic imaging.Results.CD4/CD25 positive T cell numbers
and activity were significantly increased in infected and non-infected mice when previously
fed with B. infantis. Increased Treg numbers were noted in both Peyer's patch and spleen
which was associated with elevated In Vitro secretion of IL-10. Pro-inflammatory cytokine
(TNF-α, IL-6, MCP-1) production was significantly reduced in infected mice consuming B.
infantis. S. typhimurium numbers and murine sickness behaviour scores were significantly
improved in B. infantis fed mice while imaging of luciferase induction revealed profound
inhibition of infection induced NF-κB transcription factor activity. Conclusion. Consump-
tion of a single commensal micro-organism, i.e. B. infantis 35624, increases Treg numbers
and anti-inflammatory activity in the mucosa and spleen. The anti-inflammatory effect is
mediated in part due to inhibition of NF-κB signalling suggesting that B. infantis-induced
immune regulation could have therapeutic application to a wide range of inflammatory dis-
orders.
M1696
Heligmosomoides polygyrus Alters the Bacterial Microbiota of the Murine GI
Tract
Vincent B. Young, Dionysios Antonopoulos, Thomas M. Schmidt, Jason Pratt, Arthur
Blum, Joel V. Weinstock
Introduction Experimental treatment of IL-10-/- mice with H. polygyrus inhibits inflammatory
cytokine production and colitis triggered by piroxicam. It is unknown if addition of H.
polygyrus to the GI milieu alters composition of the indigenous bacterial microbiota. Such
alterations could play a role in reversal of colitis in H. polygyrus-treated mice. Methods
Wild-type (WT) and IL-10-/- C57BL/6 mice were experimentally infected with H. polygyrus.
DNA was extracted from the distal GI tract of animals 2 weeks after challenge. The GI
microbiota was examined by 16S clone library analysis and 16S terminal restriction fragment
length polymorphism (T-RFLP) analysis. Community structure was compared by calculation
of ecologic distance metrics.Results T-RFLP analysis demonstrated that H. polygyrus infection
was associated with reproducible alterations in the GI tract microbiota. For example, in
terminal ileum, the average Bray-Curtis distance (an ecologic metric that weighs the relative
abundance of individual species in two communities) between communities from control
animals was 0.426 ± 0.14 and between communities from helminth-treated animals it was
0.446 ± 0.075. For the comparisons between treated and untreated groups, the mean distance
was greater (p<0.05) with an average Bray-Curtis distance of 0.828 ± 0.054. Cluster analysis
(figure) reaffirmed grouping based on helminth treatment. 16S clone library analysis revealed
alterations within specific groups of bacteria. In the terminal ileum of helminth-treated mice,
there was a seven-fold increase in relative abundance of Bacteroidetes and a corresponding
decrease in members of the Firmicutes. Comparison between WT and IL-10-/- animals
revealed baseline differences in GI microbiota. Discussion Murine infection with H. polygyrus
shifts the microbial community of the distal GI tract. This may be due to altered mucosal
cytokine profiles following helminth colonization, a conclusion supported by baseline differ-
ences in the microbial communities in WT and IL-10-/- mice. Alternately, H. polygyrus may
elaborate factors into the GI tract lumen that influence downstream microbes. It is unknown
if specific changes in the GI microbiota play a direct role in amelioration of IBD byH. polygyrus,
possibly by altering the microbial antigens that drive proinflammatory cytokine production.
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The VSL#3 Probiotic Formulation Stimulates Cytokine Production and
Induces Nuclear Translocation of Nf-κB in Intestinal Organ Cultures from
Samp1/Yitfc Mice with Crohn'S-Like Ileitis: A Novel Mechanism of Action
Rubina W. Saeed, Cristiano Pagnini, Sarah A. De la rue, Claudio De simone, Theresa T.
Pizarro, Fabio Cominelli
BACKGROUND: Treatment with probiotics has been shown to be effective in patients with
IBD and animal models of colitis. We have recently reported that pre-treatment of SAMP1/
YitFc (SAMP) mice with Crohn's-like ileitis using the VSL#3 probiotic formulation prevents
the development of ileitis in these mice. These effects were associated with complete restitu-
tion of intestinal barrier function in the ileum and increased expression of TNF in the
intestinal epithelium. Interestingly, no effects were observed with VSL#3 treatment in SAMP
mice with established ileitis. Overall, these data suggest that stimulation of intestinal innate
immune responses, rather than suppression may underlie the mechanism of action of probi-
otics in Crohn's disease. The aim of this study was to investigate the effects of VSL#3 on
NF-κB activation, and production of pro-inflammatory and regulatory cytokines in SAMP
mice. METHODS: We prepared VSL#3-conditioned media (CM) as previously described.
In addition, fecal antigens (FAg) from SAMP mice were prepared. We then used ileal organ
cultures to examine the effects of CM and FAg on cytokine production and induction of
NF-κB in SAMP mice. Cytokine levels were directly assessed using commercially available
ELISAs. The effects of CM and FAg on nuclear translocation of the NF-κB transcription
factor were investigated by isolating cytoplasmic and nuclear protein fractions from organ
cultures and performing Western blots analysis. RESULTS: The levels of the IL-12, TNFα,
IFNγ, MCP-1 and IL-10 cytokines were significantly increased in response to CM alone.
When FAg was added to the culture along with CM, cytokine levels were significantly
suppressed. In addition, CM alone significantly induced nuclear entry of NF-κB compared
with control or FAg alone. This increase in nuclear entry in response to CM was significantly
reduced by simultaneous addition of FAg. A concomitant reduction and elevation in the
cytoplasmic levels of IκBα was also observed in response to CM and FAg, respectively.
CONCLUSIONS: Collectively, these data demonstrate a stimulatory effect of VSL#3 on
cytokine production in ileal organ cultures from SAMP mice. These effects appear to be
mediated by increased activation of NF-κB in the intestinal epithelium. We propose a novel
and provocative anti-inflammatory mechanism-of-action of VSL#3 mediated by stimulation
of innate cytokine production in the intestinal epithelium. Therefore, treatment with VSL#3
may be a novel therapeutic option for prevention or maintenance of permanent remission
in patient's with Crohn's disease.
M1699
Effect of Lactobacillus SP. (Lb) Probiotic Ingestion On Membrane Properties of
Intrinsic Sensory Neurons in Rat Colon
Wolfgang Kunze, Yu kang Mao, Paul Forsythe, John Bienenstock
Animal models and clinical studies suggest a role for probiotic bacteria in the management
of inflammatory intestinal disorders such as pouchitis, Crohn's disease and colitis as well
as in irritable bowel syndrome. Gut mucosal villi are richly innervated by intrinsic sensory
neurons (ISNs) each of which also supplies many villi. Enteric nervous system (ENS) output
has been reported as having constitutive effects that are anti-inflammatory on the mucosa
(von Boyen M et al., Scand J Gastroenterol 37, 621, 2002) and relaxing for the circular
smooth muscle. Thus, the ENS, and especially ISNs are potential routes for the anti-
inflammatory and contractility-normalizing actions of probiotics. Therefore, we tested
whether ingestion of a LB could alter ISN function. Methods: Male SD rats were fed for 9
days with 10^9 LB in medium or with unconditioned medium. In situ whole cell patch
clamp recordings were made from distal colon myenteric plexus AH cells (ISNs) and mem-
brane properties measured in current clamp mode. Neurobiotin marker was injected into
6 AH cells. Results: All AH cells had a single spike slow afterhyperpolarization (sAHP) and
6/6 AH cells were had Dogiel type II shape. Membrane parameters (mean ± s.e.m., n) for
control vs LB rats were: membrane capacitance (pF), 37 ± 5, 11 vs 34 ± 3, 13 (P = 0.6);
membrane polarization (mV), -56 ± 3, 10 vs -55 ± 3, 13 (P = 0.7); leak conductance (pS/
pF), 0.11 ± 0.02, 11 vs 0.11 ± 0.03, 13 (P = 0.8); AP amplitude (mV), 88 ± 6, 6 vs 88 ±
6, 12 (P = 0.9); AP ½ width (ms), 3.0 ± 0.7, 7 vs 3.5 ± 0.7, 12 (P = 0.6); Firing threshold
(pA/pF), 3.4 ± 1.5, 8 vs 1.9 ± 0.7, 12 (P = 0.4); sAHP amplitude, -3.1 ± 0.7, 6 vs -2.5 ±
0.8, 11 (P = 0.7); sAHP duration (s), 9.9 ± 1.8, 7 vs 4.4 ± 1.4, 11 (P = 0.04). The no. of
APs fired during a 500 ms depolarizing current pulse at two times threshold intensity was
1.4 ± 0.2 , 9 vs 2.5 ± 0.4, 10 (P = 0.06). Conclusion: LB treatment shortened the post-AP
relative refractory period (sAHP) for ISNs and hence may increase firing in response to
depolarizing stimuli such as sensory or synaptic input. This action may represent a mechanism
to compensate for the loss in enteric neuron number and function that occurs in chronic
inflammatory disease. The data indicates that the therapeutic effect of probiotics could
involve modulation of the ENS and thus its control of motility and the immune system.
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M1700
Anti-Inflammatory Effects of Bifidobacteria On Macrophages By Modification
of Phospho-IκB and Proinflammatory Cytokines
Yoshikiyo Okada, Ryota Hokari, Yoshikazu Tsuzuki, Keisuke Okudaira, Koichi
Takebayashi, Hisayuki Matsunaga, Shunsuke Komoto, Chikako Watanabe, Chie Kurihara,
Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Soichiro Miura
BACKGROUND: The intestinal microflora seems to be involved in triggering of IBD, as
observed in several animal models, whereas some genus bacteria in intestinal microflora are
known to be effective for improvement of intestinal inflammation. We previously reported
that a prebiotic which increases bifidobacteria attenuated colonic inflammation in NSAID-
treated IL-10 K/O mice (AGA 2006). Bifidobacteria may be effective for reduction of inflam-
mation in rodent models, however, the direct action of Bifidobacteria on immune cell
functions has not been elucidated. In this study, we investigated whether different strains
of bifidobacteria can modulate the function of LPS-stimulated macrophages In Vitro using
macrophage cell line, RAW264.7. MATERIALS & METHODS: Three kinds of bifidobacteria,
B.breve, B.longum and B.adorescentis were used in this study. All bifidobacteria were cultured
for 48 h. RAW264.7 cells were cultured for 24 h, and then cells were incubated with living
bifidobacteria of each species for 8 hours. In some tests, the effect of LPS was also investigated.
After incubation cells were harvested, and mRNA levels of several cytokines and IκBNS
were determined by quantitative real-time PCR. Expression of phospho-IκB (p-IκB) was
analyzed by Western blotting. RESULTS: mRNA levels of all cytokines and expression of
p-IκB were increased by LPS exposure compared with negative controls. In bifidobacteria
exposure alone (without LPS), mRNA levels of these cytokines and expression of p-IκB were
lower than those in LPS alone group except for B.longum in which mRNA level of TNF-α
was equal to LPS alone. In groups of exposure to LPS concomitant with the bifidobacteria
(dual exposure), mRNA level of IL12p40 was significantly decreased by B. breve and B.longum
than LPS alone. mRNA level of IL-1β was also inhibited by B. breve, but not by other two
species. In addition, there was a decreased mRNA level of TNF-α by co-culture with B.
adorescentis than LPS alone. The expression of p-IκB was suppressed by adding all three
bifidobacteria compared with LPS alone. mRNA level of IκBNS in LPS or bifidobacteria
alone was lower than control group, however, the degree of inhibition was smaller in
bifidobacteria alone than LPS alone group. CONCLUSIONS: Although three bifidobacteria
species differently modified mRNA levels of cytokine production from macrophages, their
stimulatory effect was less significant compared with LPS. Suppression of expression of
IL12p40 and p-IκB by co-culture with bifidobacteria under LPS stimulation suggests their
ability to suppress proinflammatory process via regulation of NF-κB activation in macro-
phages.
M1701
Inhibition of Jnk Activity Attenuates Osmotic Stress-Induced Disruption of
Tight Junctions (TJ), and Reduced Expression of JNK1/2 Accelerates the
Assembly of TJ
Geetha Samak, Takuya Suzuki, Ankur Seth, Parimal Sheth, Julia J. Hoy, Aditi Bhargava,
Radhakrishna (rk) Rao
Intracellular signaling molecules, such as ERK, are involved in the regulation of TJ. JNK1/
2, the members of MAP Kinase family, are activated by stress. The present study was aimed
to investigate the role of JNK in the regulation of intestinal epithelial TJ. Methods: Osmotic
stress was induced in Caco-2 cell monolayers by apical mannitol load (0.4M). Cells were
transfected with missense (MS-oligo) or antisense oligos for JNK1 (AS-JNK1) or JNK2 (AS-
JNK2), and JNK activity was inhibited by SP600125. TJ assembly was induced by calcium-
switch method. In Vivo changes in TJ proteins were examined in ileum and colon of rats
subjected to cold-restraint stress (for 3h at 4°C). Unstressed rats served as controls. TJ
permeability was evaluated by measuring transepithelial resistance (TER) and FITC-inulin
flux. The levels of TJ-proteins and JNK were evaluated by immunoblot analysis. Distribution
of TJ-proteins, p-JNK and actin was assessed by confocal microscopy. Results: Osmotic stress
rapidly decreased the TER and increased inulin flux; this was associated with redistribution of
occludin and ZO-1, and reduction in the level of ZO-1. Osmotic stress rapidly increased
p-JNK, and the disruption of TJ was prevented by SP600125. Metalloproteinase inhibitor,
1,10-phenanthroline, prevented the reduction of ZO-1 level, but it failed to prevent the
mannitol-induced TJ disruption, suggesting that proteolytic degradation of ZO-1 is a second-
ary response. Transfection of cells with AS-JNK1 and AS-JNK2 reduced the levels of JNK1
and JNK2, respectively. Reduced expression of JNK1 or JNK2 resulted in a remarkable
increase in TER and decrease in inulin flux. Significantly high levels of ZO-1, occludin and
claudin-4 were localized at the intercellular junctions of AS-JNK1 or AS-JNK2-transfected
cells, compared to MS-oligo-transfected cells. Immunoblot analysis showed that ZO-1 and
claudin-4 levels were much greater in AS-JNK1 and AS-JNK2-transfected cells. The levels
of occludin, ZO-3 and claudin-5 were unaffected, while E-cadherin and β-catenin were
significantly reduced. The rate of calcium-induced TJ assembly was significantly greater in
AS-JNK1 and AS-JNK2-transfected cells compared to MS-oligo-transfected cells. All the
effects of AS-JNK1 and AS-JNK2 on TJ integrity and barrier function were reproduced by
inhibition of JNK activity by SP600125. Cold-restraint stress in rats increased the levels of
p-JNK in ileum and colon compared with unstressed controls. Elevated p-JNK was associated
with the disruption of actin cytoskeleton and TJ. Conclusion: JNK1/2 negatively regulates
the integrity of TJ in Caco-2 cells. Support: DK55532; AA12307; DBT, India.
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M1702
Elevated Fecal Serine-Protease Activity: Protease-Activated Receptor 2 (PAR2)
Mediated Alteration of Colonic Permeability in Diarrhea-Predominant Irritable
Bowel Syndrome
Krisztina Gecse, Richárd Róka, Laurent Ferrier, András Rosztóczy, Tibor Wittmann, Jean
Fioramonti, Lionel Bueno
Background and aims: Impaired intestinal permeability is considered to be a common
feature in the majority of patients with irritable bowel syndrome, characteristically in its
diarrhea-predominant subtype (IBS-D). We have recently reported on elevated colonic
luminal serine-protease activity in IBS-D patients. Therefore, the aims of our present study
were i) to establish a possible link between elevated fecal serine-protease activity and altered
colonic permeability in IBS-D and ii) to examine the potential involvement of PAR2 activation
in this process using PAR2 deficient mice. Methods: Fecal samples from IBS patients and
healthy subjects were dissolved in NaCl 0.9%, centrifuged and filtered. Permeability changes
were studied In Vitro on colonic strips of C57BL/6J wild type and PAR-2 deficient mice in
Ussing chambers. The mucosal to serosal flux of fluorescein-isothiocyanate (FITC)-dextran
was measured 60 min after the administration of fecal supernatants from diarrhea- or
constipation-predominant IBS patients, control subjects, saline or supernatants from IBS-D
patients previously incubated with a mixture of serine-protease inhibitors (soybean tryptase
inhibitor + aprotinin) in wild type mice and after the administration of supernatants from
IBS-D patients and saline in PAR2 deficient mice. Colonic paracellular permeability (CPP)
evoked by supernatants was expressed in percentage of CPP induced by their saline controls.
Results: Administration of fecal supernatants from healthy subjects or IBS-C patients bearing
with low serine-protease activity did not significantly alter CPP compared to saline (128±16.5,
137.6±19.3 vs. 100±6.4%, respectively). On the contrary, addition of fecal supernatants
from IBS-D patients significantly increased colonic permeability compared to supernatants
from healthy controls (192.5±13.9%, p< 0.05). Incubation of the supernatants from IBS-D
patients with protease-inhibitors prior to administration significantly decreased CPP evoked
by supernatants from IBS-D patients (111.1±17.3 vs. 202.5±16.9%, p<0.01). In contrast to
observations on colonic strips of C57BL/6J wild type mice, no increase in CPP was detected
in response to fecal supernatants from IBS-D patients on colonic strips of PAR2 deficient
mice (127.6±28.7 vs. 248.3±42.4%, p< 0.05). Conclusions: Supernatant of IBS-D patients
containing high level of serine-protease is responsible for its effect on colonic permeability
through PAR2 receptors. If such increase in CPP participates in triggering symptoms such
as abdominal pain in IBS-D, these data offer novel therapeutical approaches in the treatment
of the disease
M1703
Insight Into Molecular Mechanism of Tumor Necrosis Factor-α (TNF-α)
Regulation of Myosin Light Chain Kinase (MLCK) Gene Expression
Dongmei Ye, Thomas Y. Ma
TNF-α induced increase in MLCK gene activation has been shown to play a central role in
mediating TNF-α induced increase in Caco-2 intestinal epithelial TJ permeability.(AJP 2006;
290:G496-504) It is well-established that increase in MLCK protein expression and activity
plays a critical role in the regulation of intestinal TJ permeability. However, the molecular
mechanisms that mediate the MLCK gene activity and expression remain unclear. The
purpose of this study was to delineate the molecular processes that regulate both the basal
and TNF-α induced stimulation of MLCK gene activity in the filter-grown Caco-2 intestinal
epithelial monolayers. Methods: A MLCK promoter was cloned (Gene ID DQ 090939) and
various molecular and biochemical methods were used to study the regulatory mechanisms.
Results: 1) Similar to the native intestinal epithelial cells, MLCK was expressed as two
isoforms, MLCK1 and MLCK2, in Caco-2 cells. 2) TNF-α produced an increase in MLCK
mRNA and protein expression. 3) TNF-α produced an increase in MLCK promoter activity.
4) MLCK minimal promoter region was identified (MLCK-448) by progressive 5' deletion
of cloned MLCK promoter. 5) Two functionally active NF-κB binding sites were present on
the promoter region: a cis-κB motif (-84/-75) located within the minimal promoter region
and a trans-κB motif (-456/-447) located outside the minimal promoter region. 6) [Our
previous studies (AJP 2004; 286:G367-76) showed that NF-κB activation was required for
the TNF-α induced increase in Caco-2 TJ permeability.] The TNF-α induced increase in
MLCK promoter activity was prevented by NF-κB inhibitors PDTC and curcumin. 7) More-
over, targeted NF-κB silencing with NF-κB p65 siRNA also inhibited the increase in promoter
activity. 8) By specific site-directed mutagenesis of trans or cis-κB binding sites and DNA
binding studies, we found that TNF-α induced increase in NF-κB p50/p65 binding to the
cis-κB site mediated the increase in MLCK promoter activity. 9) Interestingly, we found that
NF-κB p50/p50 homodimer binds to the trans-κB site and causes a decrease in basal MLCK
promoter activity. Conclusions: Our results indicate that TNF-α induced activation of MLCK
promoter is regulated by binding of activated NF-κB p50/p65 to the cis-κB site on the
promoter. Interestingly, NF-κB p50/p50 binding to the trans-κB site suppresses the promoter
activity. Thus, our findings indicate that MLCK promoter activity may be differentially
regulated by selective activation of NF-κB p50/p65 or p50/p50 dimer. These studies provide
important novel insight into the molecular mechanisms that regulate basal and TNF-α
modulation of MLCK gene activity.
M1704
Molecular Mechanisms of Physiologically Relevant Heat Exposure-Induced Up-
Regulation of Occludin Protein Expression: Regulatory Role of Heat Shock
Factor-1
Karol Dokladny, Dongmei Ye, John C. Kennedy, Thomas Y. Ma
The heat stress (HS)-induced increase in occludin protein expression has been postulated
to play an important protective role in HS-induced disruption of intestinal tight junction
(TJ) barrier function (Am. J. Physiol. 290(2): G204-212, 2006). The intracellular mechanisms
that mediate the HS-induced increase in occludin protein expression remain unclear. The
aim of this study was to elucidate the intracellular and molecular processes that mediate
the HS-induced up-regulation of occludin protein expression. Methods: Filter-grown Caco-
2 intestinal epithelial monolayers were used as an in-vitro intestinal epithelial model system
and various biochemical and molecular methods were used. Results: 1) As in previous
studies, modest heat exposure (39-41°C) resulted in a marked increase in occludin protein
expression (~300% increase). 2) HS (39-41°C)-induced increase on occludin expression was
preceded by an activation of heat shock factor-1 (HSF-1). 3) Inhibition of HSF-1 activation
by known HSF-1 inhibitor quercetin prevented the HS-induced increase in occludin protein
expression. 4) The HS-induced increase in occludin expression was preceded by an increase
in occludin mRNA expression and increase in occludin promoter activity. 5) HSF-1 inhibitor
quercetin also prevented the HS-induced increase in occludin mRNA expression and pro-
moter activity, suggesting that HSF-1 mediated the increase in occludin gene activity. 6) Using
Genomatix software, a HSF-1 binding motif on occludin promoter region was identified. HS
resulted in a rapid increase in binding of activated HSF-1 to the DNA binding site on the
promoter region. The mutation of the HSF-1 binding site on the occludin promoter region
prevented the HS-induced increase in HSF-1 binding to the DNA binding region. 7) Similarly,
site-directed mutagenesis of HSF-1 binding site on the full-length 2023bp occludin promoter
region resulted in inhibition of HS-induced increase in promoter activity. 8) To further
validate the role of HSF-1 in the occludin promoter regulation, HSF-1 expression was
silenced in Caco-2 cells by siRNA transfection. HSF-1 knock-down by siRNA transfection
inhibited the HS-induced increase in occludin promoter activity, mRNA expression and HS-
induced increase in occludin protein expression. Conclusion: Heat stress-induced increase
in occludin protein expression was due to an increase in occludin gene activity and transcript
expression. Our findings suggest that HS-activated HSF-1 binds to the occludin promoter
and sequentially activates occludin promoter activity, mRNA transcription, and protein trans-
lation.
M1705
Intestinal Epithelial TNF Receptor Signalling Is Not Required for Rejection
Mediated Changes in Tight Junction Permeability in Small Bowel Allografts
Zheng J. Zhang, Yu Lu, Kang Chen, Daniel R. Clayburgh, Jerrold R. Turner, Terry Barrett,
Jonathan P. Fryer
Background:We have previously shown that changes in graft epithelial tight junction proteins
and epithelial permeability seen in early small bowel (SB) allograft rejection are NFκB
dependent. However, the factors driving epithelial NFkB activation during SB rejection have
not been defined. TNF, which is known to mediate NFkB activation via TNF receptor
ligation, is upregulated in SB allograft tissues during early rejection. We sought to determine
if TNF is required for rejection-mediated, NFκB-dependent tight junction permeability
changes during SB allograft rejection. Methods:SBs from B6 wt, (wt allografts) or B6 TNF
receptor 1/2 double knock out(DKO)mice were transplanted in BALB/c Recipients. B6
isografts were used as controls. SB graft epithelial permeability was assessed on the 3rd or
5th post-operative day (POD) by examining one hour luminal accumulation of i.v. injected
Alexa Fluor labeled Dextran probes. To assess tight junction integrity, membrane and
cytosolic proteins were extracted from epithelial cells isolated from SB grafts and occludin
expression was determinded by western blot. Epithelial NFκB activation was determined
by ELISA based assay of nuclear p65-DNA binding activity. Results:On POD3 and POD5,res-
pectively, SB allografts were found to have 2 and 3 fold increases in epithelial permeability
to dextran probes, compared to SB isografts (p<0.05). Furthermore, epithelial cells from SB
allografts demonstrated signficant cytoplasmic relocation of Occludin while this was not
seen in the epithelial cells from SB isografts or normal SBs. These findings suggest that SB
allograft rejection was likely responsible for these changes in graft epithelial tight junction
formation. To evaluate the role of TNF receptor ligation in the graft epithelial cells we
performed additional SB allograft transplants transplanting grafts from TNF receptor 1/2
double knockouts (DKOs) into BALB/c recipients. No effect on epithelial permeability or
tight junction protein relocations was seen as the TNFR 1/2 DKO allografts demonstrated
comparable luminal probe concentrations and cytosolic occludin expression to wt allografts.
Furthermore, we found that blocking epithelial TNFR signaling pathway did not influence
rejection mediated activation of NFκB in SB epithelial cells, and did not prevent SB allograft
rejection as the DKO SB allografts developed acute rejection in a fashion similar to wt SB
allografts. Conclusions:These data suggest that signaling through graft-derived TNFR path-
way is not required for rejection mediated, NFκB-dependent tight junction dysfunction and
other factors known to activate NFkB, such as TLRs, need to be evaluated
M1706
Matrilysin Is Induced By Tumor Necrosis Factor-α and Influences Barrier
Permeability in Colonic Epithelial Cells
Feng Wu, Nicholas Zachos, Miguel Sabogal, Mark Donowitz, John H. Kwon
BACKGROUND: The epithelial lining of the intestine forms a protective barrier which
separates the luminal contents from the rest of the intestine. This barrier is compromised
in intestinal infections as well as in chronic inflammatory states, such as inflammatory
bowel disease (IBD). Other laboratories have demonstrated that matrix metalloproteinase-
7 (matrilysin) is expressed in intestinal epithelial cells and its expression is increased in the
inflamed intestine of patients with IBD. Matrilysin directly influences epithelial barrier
permeability in other organ systems. AIM: To determine whether matrilysin influences
colonic epithelial barrier function. METHODS: T84 colonic epithelial cells were cultured
on Transwell inserts to 10 days post-confluency then switched to serum-free medium. Cells
were exposed to TNFα (10ng/ml) or activated matrilysin (25 to 250nM) for 0, 1, 4, 24 and
48 hours. Matrilysin mRNA expression was determined by quantitative RT-PCR. Epithelial
barrier permeability was determined by measuring transepithelial resistance (TER) and FITC-
dextran flux. Apoptosis was assessed using a homogeneous Caspase 3/7 assay and viability
was assessed using the CellTiterBlue assay (Promega). RESULTS: TNFα induced a 2.4-fold
increase in matrilysin mRNA expression in T84 cells within 4 hours (P<0.05) and an increased
apical and basolateral secretion of pro-matrilysin by 24 hours. TNFα-induced a 4.2-fold
and 4.9-fold increase in DQ-collagen IV cleavage in apical and basolateral supernatants after
24 hours, respectively (P<0.05). The cleavage activity was inhibited by the addition of a
neutralizing antibody to matrilysin. The direct exposure of polarized T84 cells to activated
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matrilysin (50nM) resulted in a 44% reduction in TER and a 8.5-fold increase in FITC-
dextran flux, respectively. This increased barrier permeability in response to activated matrily-
sin occurred in the absence of increased apoptosis or decreased cell viability. CONCLUSIONS:
1) Matrilysin mRNA expression, protein secretion and activation in colonic epithelial cells
are increased in response to TNFα. 2) Activated matrilysin induces increased colonic epithelial
barrier permeability. 3) Matrilysin may play a role in the pathogenesis of increased barrier
permeability in inflammatory conditions in the gastrointestinal tract.
M1707
Induced Jund Represses ZO-1 Transcription Through Proximal Promoter
Region Leading to Dysfunction of Intestinal Epithelial Barrier
Jie Chen, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Bernard S. Marasa, Ai-hong Zhang,
Lan Xiao, Douglas J. Turner, Jian-ying Wang
The tight junction (TJ) of intestinal epithelial cells is the principal barrier to a wide array
of noxious substances in the lumen. Zonula occludens-1 (ZO-1) is a major TJ-plaque protein
and links intracellular domain of TJ-transmembrane proteins such as occludin to actin
cytoskeleton. The interaction between ZO-1 and TJ-transmembrane proteins plays a crucial
role in maintaining the structure of TJs and epithelial barrier function, but the exact mechan-
isms by which ZO-1 expression is regulated at the molecular level remain elusive. JunD is
a member of the AP-1 family transcription factors and binds to DNA at AP-1 sequence and
regulates transcription of AP-1 target genes. The current study tests the hypothesis that
JunD regulates ZO-1 transcription and is implicated in modulation of epithelial barrier
function. Methods: Studies were conducted in Caco-2 cells. Full-length ZO-1 promoter was
cloned from human genomic DNA, and various constructs of wild-type and mutated ZO-
1 promoter luciferase reporters were generated. Ectopic expression of JunD was induced
by transient transfection with the vector containing JunD cDNA under the control of PCMV
promoter. ZO-1 mRNA and protein were examined by real-time RT-PCR and Western blot
analysis. Barrier function was detected by paracellular tracer flux assay. Results: When cells
were transfected with the JunD expressing vector, levels of JunD protein were increased by
~15-folds at 48 and 72 h thereafter. Induced JunD repressed ZO-1 promoter activity (by
~60%) and decreased levels of ZO-1 mRNA (by ~50%) and protein (by ~90%), but failed
to affect expression of ZO-2, occludin and E-cadherin. Experiments using different ZO-1
promoter mutants showed that transcriptional repression of ZO-1 by JunD was mediated
through its proximal promoter region, because deletion of nucleotides from positions -2787
bp to -501 relative to the transcriptional start site did not prevent the repression of ZO-1
promoter activity by JunD. However, deletion of the sequence containing CREB-binding
site within its proximal promoter region (-1007 to -501) or point-mutation of CREB site in
this promoter region completely prevented ZO-1 repression by JunD. Induced JunD also
impaired function of epithelial barrier as indicated by an increase in paracellular permeability
(by ~30%). Consistently, increased levels of endogenous JunD by depletion of cellular
polyamines also inhibited ZO-1 expression and increased paracellular permeability. Conclu-
sions: These findings indicate that induced JunD represses ZO-1 transcription through the
CREB-binding site within a proximal region of ZO-1 promoter, leading to dysfunction of
epithelial barrier.
M1708
Inactivation of the Atypical Pkc-Lambda (Pkc-λ) Isoform Enhances Cellular
Migration and Cytoskeletal Remodeling in Enterocyte Monolayers: A Novel
Wound Healing Mechanism in Epithelium
Ali C. Banan, Lijuan Zhang, Maliha Shaikh, Yueming Tang, Christopher B. Forsyth, Ali
Keshavarzian
Despite many studies over the past decade on cell migration, major gaps in our knowledge
exist regarding the intracellular processes that orchestrate wound healing during inflammat-
ory GI disorders. To date, these molecular events remain unclear. Since -λ isoform of PKC
is translocated to cellular membrane fractions under pro-inflammatory & oxidative stress
conditions in native gut cells, we hypothesized that PKC-λ inactivation is required for
enhanced cell migration & cytoskeletal remodeling in intestinal cells under oxidative stress.
Methods: Intestinal cells were transfected to either stably overexpress or underexpress PKC-
λ isoform. Transgenic clones were preincubated with growth factor EGF (1-100 ng/mL) or
PKC activator (DAG analog OAG, 0.01-1 uM) before oxidant (H2O2, 10-100 uM). Wild
type (WT) cells were treated similarly. We monitored cell migration/ monolayer repair {3D
imaging of migrating cells, fluorometry}, cytoskeletal integrity/ oxidation {laser confocal
microscopy, SDS-PAGE fractionation}, PKC-λ subcellular activity/ distribution {In Vitro
kinase, immunofluorescence}, oxidative stress (quenchable fluorescence), polymerized/
monomeric actin and tubulin (subunits of cytoskeleton, SDS-PAGE), n=6/grp. Results: {A}
Pretreatment of WT cells with EGF or transfection of cells to under-express 74 kDa PKC-
λ under oxidant stress enhanced repair as indicated by: native PKCλ inactivation, oxidative
stress reduction, cell migration enhancement, stable actin & tubulin increases (F/G-actin or
S1/S2 ratios) at the leading migration edge, architectural remodeling of actin & microtubule
elements at leading edge, & monolayer integrity. Transfected clones exhibited increased cell
migration & actin/ tubulin remodeling by low, previously non-repair inducing doses of
EGF. {B} Stable overexpression of native PKC-λ substantially decreased all measures of
monolayer repair, mimicking oxidant-like effects. Also, overexpression induced reduction
of migration was potentiated by oxidants. These effects were prevented by PKC inhibitors
(e.g., bisindolylmalemide). {C} Most of expressed PKC-λ resided at the leading edge mem-
branes. In both transfected clones & oxidant treated WT cells, PKC-λ (74 kDa) was active
& endogenously complexed with actin (43 kDa) &/or tubulin (50 kDa). Conclusions: We
have discovered that 1) Enhanced cellular migration requires the inactivation of PKC-λ
isoform in intestinal cells under oxidant insult; 2) PKC-λ is a novel intracellular signal
modulated for wound healing in epithelium; 3) The ability of PKC-λ to suppress dynamics
of re-epithelialization & wound remodeling is a new repair mechanism not previously
reported in cells.
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M1709
Effect of Lactadherin/Milk Fat Globule-EGF Factor 8 On Intestinal Mucosal
Integrity and Repair
Xiu-li Zuo, Heng-fu Bu, Xiao Wang, Vjola Koti, Xiao-di Tan
BACKGROUND AND AIMS: Lactadherin/milk fat globule-EGF factor 8 is a phosphatidylser-
ine and integrin-binding glycoprotein secreted by macrophages and dendritic cells. It pro-
motes VEGF-dependent neovascularization. However, the impact of lactadherin on intestinal
mucosal integrity and repair is unclear. METHODS: The intestinal mucosal injury was
induced in mice by cecal ligation and puncture (CLP), a classic septic peritonitis model.
The restitution or migration of enterocytes along the crypt-villus axis was determined by
assessing bromodeoxyuridine labeled cells. Gene expressions in the small intestine were
determined with western blot and immunofluorescence. In Vitro, IEC-18 cells were examined
for wound closure, lactadherin binding, and actin cytoskeleton. RESULTS: Immunofluoresc-
ent staining revealed lactadherin protein in cytoplasm of macrophages in lamina propria of
the small intestine. The intestinal mucosal injury occurred in mice as a result of CLP-
challenge. The injury was associated with a delayed intestinal epithelial migration along the
crypt-villus axis and decrease in lactadherin gene expression in intestines. In contrast, the
expression of intestinal trefoil factor, a restitution factor synthesized by goblet cells, was
up-regulated in the small intestine after CLP. With an In Vitro wound-healing model and
immunofluorescence, we revealed that lactadherin selectively bound to phosphatidylserine
on the posterior of intestinal epithelial cells at the wound-edge. The cells at the wound-
edge reoriented their actin cytoskeleton and exhibited an altered morphology typical of
locomoting cells after treatment with lactadherin. In addition, we demonstrated that lacta-
dherin promoted migration of intestinal epithelial cells in a dose dependent manner. Pretreat-
ment with selective protein kinase C inhibitors blocked lactadherin-induced cell migration,
suggesting that the kinase was involved in lactadherin action. Furthermore, In Vivo adminis-
tration of a neutralizing monoclonal antibody to lactadherin markedly inhibited intestinal
epithelial migration along the crypt-villus axis. CONCLUSIONS: Lactadherin is a novel
restitution factor secreted by macrophages in intestinal lamina propria. It plays an important
role in the maintenance of intestinal epithelial homeostasis. A decrease in lactadherin gene
expression occurs in intestines and may delay the healing of damaged intestinal mucosa
during severe systemic inflammation.
M1710
SP and CGRP Differentially Modulate Epithelial Cell Restitution Via
Expression of TGF-Beta, TGF-Alpha and EGF-Receptor RNA in Fibroblasts
and Mast-Cells in An In Vitro Wound Assay
Kerem Bulut, Peter Felderbauer, Karoline Hoeck, Susanne Deters, Wolfgang E. Schmidt,
Peter Hoffmann
Background: Substance P (SP) and calcitonin gene related peptide (CGRP) are neurotransmit-
ters of the extrinsic afferent sensory nervous system. In experimental animal models of
colitis, a protective role of SP and CGRP on intestinal mucosa was presumed. The mucosal
protection in part depends on a SP and CGRP mediated modulation of mucosal blood flow
after injury, but other mechanism seem to add to that protective effect. We demonstrate a
mast cell and fibroblast mediated effect of SP and CGRP on epithelial cell restitution In Vitro
and identified potential contributing cytokines. Methods: Mast cell and rat kidney fibroblast
(NRK-49F) cell-lines were exposed to CGRP or SP in various concentrations. After incubation,
the cell culture supernatants were taken from the mast cell or fibroblast cultures and were
directly applied to IEC-18 monolayers. While migration and proliferation had been shown
in initial experiments, rt-PCR was performed of TGF-beta, TGF-alpha and EGF-Receptor-
expression at 2h, 4h, 6h, 12h and 24h. Results: Mast cell stimulation by CGRP but not SP
significantly induced epithelial cell migration and proliferation. These effects are accompanied
by a time dependent increased expression of TGF-alpha, TGF-beta and EGF-R. In opposite,
SP but not CGRP significantly induced epithelial cell migration but inhibited epithelial cell
proliferation via the stimulation of fibroblasts. While the results of TGF-beta release over
the time course underlined this effect and could be abolished by anti-TGF-beta antibody,
SP and CGRP had no effects on epithelial cell proliferation or migration when applied
directly to epithelial cells. Conclusion: CGRP and SP differentially modulate epithelial cell
restitution In Vitro mediated either by mast cells or fibroblasts. While the epithelial cell
migration depends on a TGF-beta release from CGRP stimulated mast cells and SP stimulated
fibroblasts, the proliferative effects are mediated by TGF-alpha. This observation underlines
an important role for the extrinsic afferent sensory nervous system in mucosal defence and
repair and in keeping the mucosal homeostasis.
M1711
Systemic Inflammation Increased Intestinal Permeability During Experimental
Human Endotoxemia
Willem Renooij, Falco Hietbrink, Marc G. Besselink, Martin B. De smet, Annelies
Draisma, Hans Van der hoeven, Peter Pickkers
In experimental septic models gastrointestinal mucosal perfusion deficits have been associated
with a decrease in gut barrier function, which could cause augmentation of systemic inflam-
mation by bacterial translocation. Polyethylene glycols (PEGs) of various molecular mass
have been used as markers for intestinal permeability in non critically ill patients. PEG 400
supposedly freely passes the intestinal mucosal barrier, larger PEGs can only pass when
intestinal permeability is compromised. We investigated whether intestinal permeability
measured as urinary recovery of orally administered PEGs is altered during systemic inflam-
mation induced by experimental endotoxemia in humans. Twelve healthy subjects received
2ng/kg E. coli endotoxin (lipopolysaccharide, LPS) intravenously. Cytokines (IL-6, IL-10,
IFNγ, TNFα) were measured at regular time intervals for 6 hours as indicators of inflamma-
tion. The PEG-based intestinal permeability test was performed the day before the LPS
challenge and was repeated on the day of the LPS challenge. One hour before LPS infusion,
subjects ingested a solution of 5 g PEG 400, 1.5 g PEG 1500, 5 g PEG 4000 and 10 g PEG
10 000 dissolved in 100 ml water. Urine was collected in the following 2, 4, 8, and 24
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hours and was analyzed for PEG by HPLC. Results are expressed as means ± s.e. Statistical
analysis was performed using a two-tailed paired samples T-test. Administration of LPS
resulted in an increase of pro-inflammatory cytokines, body temperature, influenza-like
symptoms and cardiovascular changes. Peak concentrations of IL-6 (1785 ±230 pg/mL), IL-
10 (155 ±28 pg/mL), IFNγ (361 ±44 pg/mL) were reached 2 hours after LPS administration,
TNFα peaked (927 ±182 pg/mL) at 1.5 hours after LPS. The 24-hour recovery of PEG 400
did not change after LPS infusion (130 ±12 mg/mmol creatinine before and 122 ±16 mg/
mmol creatinine after LPS, p = NS). PEG 1500 recovery increased from 2.51 ±0.38 mg/mol
creatinine before to 4.02 ±0.85 mg/mmol creatinine after LPS infusion (p<0.031). PEG 4000
recovery increased from 0.034 ±0.016 mg/mmol creatine before to 0.188 ±0.058 mg/mmol
creatinine after administration of LPS (p=0.011). PEG 10 000 was not recovered in any
sample. In conclusion, intestinal permeability measured as urinary recovery of orally adminis-
tered PEGs is significantly increased during systemic inflammation in humans induced by
endotoxemia. Increased intestinal permeability during systemic inflammation may explain
sustained endotoxin stress and possible bacterial translocation seen in some critically ill
patients.
M1712
Cholinergic Activation Alter Epithelial Resistance and the Response Is
Increased in Sigmoid Colon of Patients with Ulcerative Colitis in Remission
Jenny Gustafsson, Lisbeth Eklund, Lars Stage, Henrik Sjövall
Background: Ulcerative colitis (UC) is a chronic inflammatory disease, characterized by
periods of active and inactive disease. The normal colonic mucosa functions as a protective
barrier against pathogens but in UC this barrier may be disturbed. Mechanisms behind the
disturbed barrier function are not fully understood. There is some evidence for a neural
control of colonic barrier function [1]. We here aimed to study the electrical properties (e.g.
Tight junction electrical resistance (TJER) and epithelial capacitance) of biopsies from patients
with UC in remission, as compared to healthy controls. Methods: We included 14 patients
with UC in remission (females; mean age 57 years, males; mean age 50 years) and 11 control
patients without inflammatory disease (females; mean age 63 years and males; mean age 65
years). Biopsies from ascending and sigmoid colon were mounted in an Ussing chamber
with an exposure area of 0.03 cm2. Cholinergic stimulation was mimicked by 1mM Carbachol
(CCh) on the serosal side. TJER and epithelial capacitance (mainly reflecting exposed mem-
brane area) were measured by square wave current analysis [2]. Results: Increased basal
sigmoid TJER was seen in the UC in remission group (5.83 ±0.69 Ω*cm2 vs. 3.16±0.37
Ω*cm2, P=0.01) together with an increased resistance response to CCh (-1.18 ±0.35Ω*cm2
vs. -0.26±0.11 Ω*cm2, P< 0.05). No differences between the groups were seen in the
ascending colon. Decreased basal sigmoid capacitance was seen in the UC in remission
group (83.46 ±7.98 µF/cm2 vs. 112.87±12.14 µF/cm2, P< 0.05). CCh induced a significant
increase in capacitance and the magnitude of the response was similar in the two groups.
No significant differences between the groups were seen in the ascending colon. Conclusion:
During UC in remission, the epithelium of the sigmoid colon, but not that of the ascending
colon, decreases its electrical resistance relatively more in response to CCh stimulation. The
tight junctions of UC patients in remission may be hyperresponsive to cholinergic stimulation.
1. Sun, Y., Fihn, B. M., Sjovall, H and Jodal, M. Enteric neurons modulate the colonic
permeability response to luminal bile acids in rat colon In Vivo Gut (2004) 53(3) 362-7 2.
Hemlin, M., Jodal, M., Lundgren, O., Sjovall, H and Stage, L. The importance of the
subepithelial resistance for the electrical properties of the rat jejunum In Vitro Acta physiolog-
ica Scandinavica (1988) 134(1) 79-88
M1713
Human Beta Defensin 2 Promotes Intestinal Wound Healing<B/B&;
Jan-michel Otte, Ilka Werner-martini, Stephan Brand, Ansgar M. Chromik, Frank
Schmitz, Michael Kleine, Wolfgang E. Schmidt
Background & Aim: Limiting microbial threats by killing invading organisms as well as
maintenance and re-establishment of the mucosal architecture are vital for the formation of
a protective barrier function. Antimicrobial peptides have been recognized as essential defense
molecules and decreased expression of defensins has been attributed to chronic inflammation
of the intestinal mucosa as it can be observed in Crohn`s disease. However, currently it is
unknown, whether the human β-defensin 2 (hBD-2) in addition to its known antimicrobial
properties has potential further effects on healing and protection of the intestinal epithelial
barrier. Methods: Caco-2 and HT-29 cells were stimulated with 0.1 - 10 µg/ml hBD-2 for
6 - 72 h. Effects on cell viability and apoptosis were monitored by MTT or detection of
DNA fragmentation, respectively. Proliferation was quantified by BrdU incorporation and
expression of mucins was determined by quantitative PCR. Furthermore, anti-apoptotic
capacities of hBD-2 were studied. Results: Over a broad range of concentrations and stimula-
tion periods, hBD-2 was well tolerated by IECs and did not induce apoptosis. hBD-2
significantly increased migration but not proliferation of intestinal epithelial cells. Further-
more, hBD-2 induced expression of mucins 2 and 3 in the cell lines analyzed. The extent
of TRAIL induced apoptosis was significantly decreased in cultures pre-incubated with hBD-
2. Conclusion: In addition to its known antimicrobial properties, hBD-2 displays important
protective effects on the intestinal epithelium. Lack of hBD-2 expression might therefore
play a dual role in impaired intestinal barrier function observed in patients with inflammatory
bowel disease, i.e. Crohn`s disease.
M1714
Effects of Methotrexate and Fasting On the Psychologic Stress Induced
Bacterial Translocation in Rat
Jeong wook Kim, Woo kyu Jeon, Eun jeong Kim, Sun ok Lee
Background and Aims : Chemotherapeutic agents such as methotrexate (MTX) has been
used in the treatment of malignancies and rheumatoid disease. Chemotherapy treatment
can induce high levels of psychological stress, which are particularly pronounced prior to
the first infusion of cytotoxic agents. Psychologic stress cause gut barrier damage and bacterial
translocation (BT) without enteric bacterial overgrowth. Chemotherapeutic agents induce
various side effects, such as gut barrier damage and poor oral intake, and shows antimicrobial
activities. Fasting fewer than 72 hours induce enteric bacterial overgrowth without gut
barrier damage. The aim of this study is to investigate the effect of MTX and fasting on the
psychologic stress induced bacterial translocation in rat. Methods : Rats were divided into
five group (non-stressed control; stressed ; stressed with MTX; stressed with MTX and 24
hour fasting; stressed with MTX and 72 hour fasting). Psychological stress induced by long-
term acclimation after transportation. Rats with MTX recieved MTX 25 mg/kg orally. Rats
with MTX and fasting not received chows during 24 or 72 hours prior to operation that
executed MTX administration 72 hours later. Gut barrier dysfunction was assessed by
measuring 24 hour urine excretion of phenolsulfonphthalein) and stool pellet number was
measured for same period. The numbers of total aerobes and gram negatives in distal ileal
and cecal contents were measured for an assessment of the enteric bacterial number. The
numbers of gram negatives in mesenteric lymph node, liver, spleen, kidney and heart were
counted for an assessment of BT. Also, amounts of food intake and body weight changes
were measured. Results : Psychologic stress induced gut barrier damage and the increase
in BT without the changes of enteric bacterial number. MTX administration increase stress
induced gut barrier damage, but not increased BT with the decrease in cecal gram-negative
bacterial number. Fasting increased cecal total aerobic and gram-negative bacterial numbers,
but not induced gut barrier damage and BT than stress with methotrexate. The changes of
amounts of food intakes and body weight changes not influenced these changes. Conclusion
: MTX administration not increased psychologic stress-induced BT despite increasing gut
barrier damage, and fasting not influenced these changes despite enteric bacterial overgrowth.
These findings suggest that antibacterial activity of MTX may suppress psychologic stress
and fasting induced BT.
M1715
Muscarinic Type 3 Receptors (M3R) Contribute to Ileal Mucosal Barrier
Function
Leon P. Mclean, Rex Sun, Jennifer Stiltz, Aiping Zhao, Jean-pierre Raufman, Terez Shea-
donohue
Bile acids (BA)reportedly have both beneficial and deleterious effects on barrier function.
Unconjugated BA (UBA) increase epithelial permeability; however, conjugated BA (CBA)
were shown to reduce bacterial translocation and increase survival in cirrhotic ascitic rats.
Deoxycholyglycine (DCG) or lithocholytaurine (LCT) can act as agonists at M3R, which
mediate the direct effects of acetylcholine on epithelial cells. Aim: To determine the role of
M3R in CBA-induced changes in mucosal barrier function. Methods: Sections of ileum from
WT or M3R-deficient (M3R-/-) 129SvEv mice were prepared for histological analysis. RNA
expression of tight junction proteins (TJP) and cytokines was assessed by real-time PCR
(RT-PCR). Muscle-free sections of ileum were placed in microsnapwells to determine transepi-
thelial resistance (TER) over 120 min. After 30 min, tissue was exposed to vehicle, DCG
or LCT. Results: The microscopic appearance of the mucosa was similar in the two strains.
When compared to WT, vehicle-treated tissue from M3R-/- mice had significantly lower TER
at all time points (31.2±1.0 vs 11.9±1.8 Ω×cm2 at 60 min; p<0.001), which was associated
with significant (p<0.05) upregulation in the fold-expression of the proinflammatory cyto-
kines IFN-γ (3.1±0.4) and IL-17a (66±20) as well as the pore-forming TJP claudin-2 (5.2±1.6).
In contrast, expression of the TJP, occludin, (40±7% of WT) and the Th2 cytokine, IL-13
(18±3% of WT), was decreased(p<0.05). NOS-2, TNF-α and TLR4 expression were
unchanged. M3R deficiency did not induce compensatory changes in expression of M2R.
WT and M3R-/- ilea exhibited a gradual decrease in TER over 120 min that was greater in
M3R-/- mice (Table 1). This decrease was attenuated by LCT in WT and both DCG and LCT
in M3R-/- mice. Conclusions: Intestinal M3R deficiency is associated with a proinflammatory
state, impaired barrier function, and alterations in TJP. These findings support a physiological
role for M3R in the maintenance of ileal mucosal barrier function. CBA improve mucosal
resistance, particularly in mice with impaired barrier function, but the mechanism appears
to be independent of M3R. Beneficial effects of CBA on epithelial resistance may play an
important role in preventing or reversing bacterial translocation in patients who might
otherwise become critically ill.
Table 1: Effect of CBA on TER in WT and M3R-/- murine ileum.
TER at 120 min = % of the initial TER; *p<0.05;**p<0.01vs WT control;Φp<0.05ΦΦp<0.01
vs M3R-/- control
M1716
The Flavonoid Quercetin Has Protective Barrier Effects in Caco-2 Cell
Monolayers
Maren Amasheh, Susanne Schlichter, Salah Amasheh, Martin Zeitz, Michael Fromm, Joerg
D. Schulzke
Background: High dietary intake of fruits and vegetables is associated with a reduced disease
risk. It is supposed that flavonoids, a group of secondary plant components, are involved
in this protective effect. Although numerous findings have shown interactions of flavonoids
with molecular cell structure and functions, there is only limited information about their
effects on the intestinal barrier. Therefore, we aimed to investigate the influence of quercetin
on the barrier function of Caco-2 cell monolayers. Methods: Quercetin was added to highly
differentiated caco-2-cell-monolayers in a concentration of 50 to 200 µM to the apical and
basolateral culture medium. By means of the Ussing-technique, short-circuit current and
electrical resistance (Rt) as well as bidirectional sodium, chloride and mannitol fluxes were
measured. Expression and distribution of tight junction proteins were analyzed by rt-PCR
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technique, Western blotting, and by confocal laser scanning microscopy. Results: Addition
of quercetin increased Rt of Caco-2 monolayers in a concentration-dependent manner. After
incubation with 200 µM quercetin, Rt increased from 130 ± 5 (control) to 258 ± 5 Ωcm2,
while mannitol fluxes (ctrl 104 ± 5 versus quercetin 107 ± 3 nmolh-1cm-2) and apoptotic
ratio retained unchanged (ctrl 1.30 ± 0.42 versus quercetin 1.02 ± 0.37 %). Sodium and
chloride m-s flux (ctrl JNams 3.3 ± 0.1 versus quercetin 2.5 ± 0.1 nmolh-1cm-2; ctrl JClms
1.6 ± 0.1 versus quercetin 1.1 ± 0.1 nmolh-1cm-2; p<0.001) and s-m flux (ctrl JNasm 3.1 ±
0.1 versus quercetin 1.9 ± 0.1 nmolh-1cm2; ctrl JClsm 1.6 ± 0.0 versus quercetin 1.0 ± 0.0
nmolh-1cm2; p<0.001) were decreased, but net ion flux was not affected by quercetin. Tight
junction protein immunoblotting showed an increase of claudin-4 expression after quercetin
incubation (340 ± 28% of control). In quantitative PCR technique mRNA level of claudin-
4 in the quercetin group was 3-fold increased compared to control (283 ± 50 % of control).
Immunofluorescent stainings primarily revealed a strong increase of claudin-4, which was
localized within the tight junction as well as in subjunctional regions. Conclusion: The
flavonoid quercetin improves epithelial barrier function in Caco-2 cell monolayers. This is
caused by a change in tight junction protein composition with a 3.5fold increase of claudin-
4 and a marked increase of claudin-4 staining within the tight junctional complex. Thus
the barrier upregulation by quercetin mainly comprises an increased expression and proper
insertion of the “tightening” tight junction protein claudin-4.
M1717
Administration of Dimethyloxalylglycine (Dmog) As a Novel Gastrointestinal
Repair Strategy
Asif Mahmood, Tania Marchbank, Sarah Harten, Patrick H. Maxwell, Subrata Ghosh,
Raymond J. Playford
Background:Hypoxia inducible factor-1 (HIF) is upregulated by low oxygen tension, increas-
ing production of angiogenic peptides and growth factors. Its role in injury and repair is,
however, unclear. Modulation of HIF levels may provide a novel approach to the prevention
and/or treatment of gastrointestinal disease. We therefore examined the effect of dimethylox-
alylglycine (DMOG), which increases intracellular HIF levels, in a variety of In Vitro and In
Vivo models of gut injury and repair. Methods: In Vitro studies utilised pro-migratory
(wounded monolayer) and proliferation ([3H] thymidine incorporation) assays of human
colonic HT29 epithelial cells. In Vivo studies utilised a rat gastric (indomethacin, 20 mg/kg
& 3 hour restraint) damage model.Results:DMOG stimulated migration in a dose-dependent
manner, causing an approximate two-fold increase in migration when added at 25 μMol (p
< 0.01). Additive/synergistic effects were seen when DMOG was added to cells in hypoxic
conditions. DMOG also stimulated thymidine uptake by about 2-fold when added at 50
μMol. In the rat gastric (indomethacin, 20 mg/kg & 3 hour restraint) damage model, both
oral and subcutaneous administration of DMOG decreased gastric injury without influencing
intragastric pH (50% reduction when 1 ml gavaged at 0.57 mM, p< 0.01). Conclusion:
These initial studies suggest that non-peptide factors such as DMOG, that modulate HIF
levels, may be useful to stabilise or repair gut mucosa. Further studies appear warranted.
M1718
Polyamines Are Essential for Expression of GTP-Binding Protein Rac1
Through Ca2+ Influx Promoting Intestinal Epithelial Restitution After
Wounding
Rao N. Jaladanki, Stephen Liu, Tongtong Zou, Lan Liu, Bernard S. Marasa, Ai-hong
Zhang, Lan Xiao, Jie Chen, Douglas J. Turner, Jian-ying Wang
Early epithelial restitution after superficial wounds is an important repair modality in the
gastrointestinal mucosa and occurs as a consequence of cell migration rather than prolifera-
tion. Although the exact mechanisms underlying this rapid mucosal repair remain unclear,
increasing evidence indicates that cellular polyamines are necessary for the stimulation of
cell migration after wounding. Our previous studies have shown that polyamines enhance
epithelial restitution by regulating cytosolic free Ca2+ ([Ca2+]cyt) concentration through
modulation of Kv and TRPC1 channel activities. However, how induced [Ca2+]cyt stimulates
epithelial cell migration following up-regulation of cellular polyamines are still elusive. Rac1
is a small GTP-binding protein, shown to increase cell motility in a variety of cell types
including epithelial cells. The current study tested the hypothesis that polyamines regulate
Rac1 by altering [Ca2+]cyt and that induced Rac1 mediates cell migration during restitution.
Methods: Studies were conducted in stable Cdx2-transfected intestinal epithelial cells (IEC-
Cdx2L1 line). [Ca2+]cyt was measured by digital imaging analysis, and cell migration was
measured in an In Vitro model that mimics early cell division-independent restitution.
Functions of Rac1 were investigated by using a chemical inhibitor NSC23766 and siRNA
targeting Rac1 mRNA (siRac1). Results: Differentiated IEC-Cdx2L1 cells exhibited increased
levels of cellular polyamines, [Ca2+]cyt, and Rac1 expression, which was associated with a
significant increase in cell migration after wounding. In contrast, decreasing cellular polyam-
ines by treatment with DFMO (specific inhibitor for polyamine biosynthesis) reduced
[Ca2+]cyt, inhibited Rac1 expression as indicated by decreases in its mRNA and protein, and
represses cell migration after wounding. Level of Rac1 mRNA and protein was decreased
by ~50% in cells-exposed to DFMO for 6 days, while cell migration was inhibited by ~70%.
Increasing [Ca2+]cyt in polyamine-deficient cells by exogenous polyamine putrescine or
exposure to Ca2+ ionophore ionomycin not only overcame the inhibited Rac1 expression
but also prevented the inhibition of cell migration. Furthermore, suppression of Rac1 activity
by NSC23766 or specific inhibition of Racl expression by siRac1 reduced myosin stress
fibers and repressed cell migration after wounding. Cell migration was decreased by ~40%
when Racl was knockdown by siRac1. Conclusions: These results indicate that 1) polyamines
are necessary for Rac1 expression through Ca2+ influx and 2) induced Rac1 plays an important
role in the polyamine-dependent epithelial cell migration after wounding.
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M1719
Estrous Cycle-Dependent Variation of Colonic Epithelial Permeability in the
Female Rat: Role of Estrogen
Viorica Braniste, Lionel Bueno, Jean Fioramonti, Eric Houdeau
Background. Estrogen exerts multiple effects in the colon, involving anti-inflammatory
activity mediated by estrogen receptor (ER), as well as non-genomic effects on transepithelial
ion transport. Also, estrogen contributes to architectural maintenance of the colonic epithe-
lium, in regulating proliferation and differentiation of epithelial cells. On this basis, we
investigated whether estrous cycle-dependent variations in sex hormones, and estrogen itself,
affect colonic barrier function in the rat. Methods. In adult female Wistar rats, estrous cycle
stages were assessed through daily vaginal smears, while other rats were ovariectomized
(OVX). In estrus (high plasma estrogen levels) and diestrus (low plasma estrogen) stages,
colonic paracellular permeability was assessed by measuring i/ In Vivo lumen-to-blood 51Cr-
EDTA clearance for 24h (% administered dose into the colon), and ii/ In Vitro mucosa-to-
serosa dextran flux and tissue resistance of colonic strips mounted in Ussing chambers.
Strips from OVX rats treated with subcutaneous capsules containing estradiol benzoate (EB)
for 4 days, in the presence and the absence of the ER antagonist ICI 182,780 (2mg/kg/day
s.c.), were also assessed for dextran flux and tissue resistance. Results. Estrus rats showed
a lower colonic permeability to 51Cr-EDTA compared with diestrus rats (1.0±0.1 vs 1.8±0.2
% of total 51Cr-EDTA recovered in urine, respectively; P<.01). In Ussing chambers, similar
inhibition of dextran flux was observed in colonic strips from estrus rats (1.0±0.1 vs 1.6±0.1
nmol.cm-2.h-1 in diestrus; P<.001), while baseline tissue resistance tended to increase
(93.9±7.7 vs 74.4±5.5 ohm.cm-2 in diestrus). In OVX rats exposed to EB implants, colonic
dextran flux was decreased compared to control OVX animals (0.39±0.04 vs 0.69±0.04
nmol.cm-2.h-1, respectively; P<.001), and co-treatment with ICI 182,780 reversed this
effect (0.64±0.08 nmol.cm-2.h-1; ns vs OVX controls). In the same animals, EB treatment
significantly enhanced baseline tissue resistance compared to OVX controls (89.8±3.7 vs
76.7±3.8 ohm.cm-2, respectively; P<.05), which was inhibited by ICI 182,780 (75.6±3.1
ohm.cm-2). Conclusion. This study reports estrous cycle-dependent fluctuations of colonic
paracellular permeability in the female rat, improving epithelial barrier function under
plasma estrogen dominance. These changes involve ER-mediated activities, since the pure
ER antagonist ICI 182,780 blocked estrogen effects. It is suggested that estrogen may limit
the transepithelial passage of adverse luminal compounds, to protect against antigen load
and inflammation in the colonic mucosa.
M1720
Analysis of Binding Affinity of the Zot Agonist (AT1002) and Antagonist
(AT1002) to the Zot Intestinal Receptor
Swati Kolpuru, Maria grazia Clemente, Amit Tripathi, Alessio Fasano
Background: Vibrio cholerae derived zonula occludens toxin (Zot) and its eukaryotic analogue
Zonulin, both modulate intestinal tight junction (tj) permeability. We have found that
Zonulin pathway is involved in a series of autoimmune diseases, including type 1 diabetes
and celiac disease (CD). We have also demonstrated that the effect of Zot on the cell
cytoskeleton and tj permeability can be mimicked by its synthetic peptide agonist AT1002
and can be inhibited by the synthetic peptide AT1001. Both peptides seem to bind to the
same Zot receptor through a specific binding motif. Aim: To analyze the binding affinity of
Zot agonist and antagonist to Caco2 intestinal epithelial cells by fluorescence microscopy.
Materials and methods: CaCo2 cells were used to analyze the affinity of AT1001 and AT1002.
AT1001 untagged and tagged with FITC, AT1002 untagged and tagged with FITC and
scrambled peptide tagged with FITC was obtained. Cells were cultured and fixed on 8
chamber mounted on glass slide and incubated with FITC labeled peptide (AT1001 or
AT1002) either in the presence or absences of unlabelled peptide. Slides were then analyzed
in blind fashion with a fluorescence microscope. Scrambled peptide was used as a negative
contol. Results: Both AT1001 and AT1002 bind to CaCo2 cells, while no detectable binding
was observed with the scrambled peptide. FITC-AT1001 was displaced when untagged
AT1001 was used at a concentration >100 times that of the tagged peptide. FITC-AT001
was also displaced by untagged AT1002 but at lower concentrations (75 times). Similarly,
FITC-AT002 was displaced by untagged AT1002 and AT1001 but at higher concentrations
(>150 times for untagged AT1002 and >200 for untagged AT1001). Conclusions: Our results
demonstrated that both AT1001 and AT1002 bind to the same receptor with AT1002
showing higher affinity than AT1001. These findings will assist us to develop strategies
to properly antagonize the zonulin pathway for the treatment of autoimmune diseases,
including CD.
M1721
Inhibition and Reduced Expression of Pkcζ Attenuates Phosphorylation of
Occludin On Serine and Threonine, Resulting in the Disruption of Tight
Junctions (TJ) and Delay in Its Assembly
Suneet Jain, Ankur Seth, Takuya Suzuki, Radhakrishna (rk) Rao
Occludin, a transmembrane protein of TJ, is phosphorylated on Ser/Thr residues. Disruption
of TJ by various factors is accompanied by dephosphorylation of occludin on Ser and Thr,
suggesting that Ser/Thr phosphorylation of occludin may play a crucial role in regulation
of TJ integrity. Although the identity of protein kinases and phosphatases involved in occludin
phosphorylation is not known, PKCζ was localized at the TJ. In the present study, we aimed
to elucidate the role of PKCζ in the phosphorylation of occludin and TJ dynamics. Methods:
Caco-2 and MDCK cells were transfected with antisense oligos to PKCζ (AS-PKCζ) or PKCζ
shRNA; missense oligos (MS-oligo) or vector were used as controls. PKCζ level was assessed
by immunoblot analysis. Assembly of TJ was evaluated by calcium switch method. Cells on
Transwell inserts were treated with 10-50 μM PKCζ-PS (pseudo substrate, a specific PKCζ
inhibitor). TJ integrity was evaluated by measuring TER, FITC-inulin flux and confocal
microscopy of occludin and ZO-1. Triton-soluble and insoluble fractions were immunoblot-
ted for occludin and ZO-1. Ser/Thr-phosphorylation of occludin was evaluated by immunop-
recipitation of p-Thr or p-Ser and immunoblot analysis; cell viability tested by measuring
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LDH release and MTT assay. Phosphorylation of occludin was determined by incubation of
GST-Occludin-C (C-terminal 150 A.a.) with recombinant PKCζ.Results: PKCζ-PS decreased
TER, increased inulin flux and induced redistribution of occludin and ZO-1, suggesting a
role of PKCζ in the maintenance of basal TJ integrity. PKCζ-PS rapidly dephosphorylated
occludin on both Ser and Thr. The levels of occludin and ZO-1 in Triton-soluble fraction
were gradually reduced by PKCζ-PS, suggesting that these proteins undergo proteolytic
degradation after release from the junctions. The lack of changes in LDH release and MTT
rule out any loss of cell viability. PKCζ-PS also attenuated calcium-induced TJ-assembly as
indicated by higher inulin flux and lack of junctional distribution and Ser/Thr-phosphoryl-
ation of occludin and ZO-1 in PKCζ-PS-treated cells compared to untreated cells; indicating
that PKCζ activity is required for the assembly of TJ. This was further confirmed by
transfection of cells with AS-PKCζ or shRNA, which reduced the level of cellular PKCζ.
The rate of calcium-induced assembly of TJ was significantly low in PKCζ-depleted cells
compared to MS-oligo or vector-transfected cells. PKCζ phosphorylated GST-Occludin-C
on both Ser and Thr. Conclusion: These results indicate that PKCζ plays crucial role in
Ser/Thr phosphorylation of occludin and in the assembly and maintenance of TJ. Support:
DK55532 and AA12307.
M1884
T Cells in the Myentheric Plexus of Achalasia Patients Show a Skewed TCR
Repertoire and React to Hsv-1 Antigens
Ignazio Castagliuolo, Paola Brun, Monica Facco, Ilaria Baesso, Mario Costantini, Christian
Rizzetto, Alessandro Berto, Nicola Baldan, Giorgio Palù, Gianpietro Semenzato, Giovanni
Zaninotto
Background and aims: Achalasia is an motor disorder of the Lower Esophageal Sfincter
(LES) secondary to an inflammatory-mediated neuronal degeneration. Neurotropic viruses,
such as herpes viruses, have been suggested as possible factors able to trigger inflammatory
mediated tissue damage in patients with chronic idiopathic neuronal degenerative disorders.
Since the presence of a lymphocytic infiltrate within the myenteric ganglia of achalasia
patients (AP) suggests an immuno-mediated mechanism we investigated the phenotype, the
T Cell Receptor (TCR) repertoire and the ability to recognize HSV-1 antigens of LES-
infiltrating lymphocytes in AP. Methods. Mononuclear cells were purified from peripheral
blood (PMN) and strips of esophageal muscle (EMC) harvested during laparoscopic myotomy
from AP (n=49) or from multiorgan transplant donors (control, n=30). PMN and ECM from
16 AP and 13 controls were employed for flow cytometry evaluation (mAbs to CD3, CD4,
CD8, CD16, CD19) or molecular studies by CDR3 length spectratyping analysis, whereas
33 AP and 17 controls were utilized in functional assays to quantify HSV-1-induced prolifera-
tion and cytokine release. Results. AP were characterized by a significantly higher lymphocytic
infiltrate in the esophagus than controls (24.71±3.11% and 9.54±1.34%, respectively; p<.05),
mainly represented by CD3+CD8+ T cells. Compared to peripheral blood the esophageal
CD4/CD8 ratio was significantly lower in AP than in controls (p<.05). Furthermore, the
frequency of B and NK lymphocytes in the esophagus of AP was superimposable to that of
controls, however NK cells infiltrating the LES of AP, but not controls, were significantly
lower than circulating NK lymphocytes (9.25±3.58% and 17.93±5.28%, respectively; p<.05).
Characterization of TCRBV repertoire of CD3+ cells showed the expression of a limited
number of TCRBV gene families (from two to five out of 26), with highly restricted patterns
that suggests a disease-associated oligoclonal selection of T-cells. Indeed, lymphocytes from
AP LES, but not from controls, responded to HSV-1 antigens as demonstrated by significantly
increased H3-thymidine incorporation and IFN-γ release (p<.01). Summary and conclusions.
The LES of AP, as compared to controls, presents an increased CD3+ CD8+ T lymphocytic
infiltrate with a skewed TCRBV repertoire. In addition these EMC show a strong reactivity
toward HSV-1 antigens. These data are strongly suggestive of an immune-inflammatory
reaction triggered by HSV-1 antigens that may be involved in the tissue damage (neuronal
ganglia) responsible for the clinical manifestations of idiopathic achalasia.
M1885
Novel Vegf Polymorphism for Gastroduodenal Ulcer Prediction and Vegf Gene
Restoration for the Quality of Ulcer Healing
Ki-baik Hahm, Yong seok Kim, Min ho Kim, Jeong a Lee, Hyeon wook Paik, Byeom seok
Oh
Questions about why some individuals develop gastroduodenal ulcer, while others do not
under the same exposure to etiologic risks and another curiosity why chronic ulcer develops
mostly on the lesser curvature side of stomach including incisura and anterior wall of
duodenal bulb have been remained unanswered. In addition, the reason why gastroduodenal
ulcers tend to recur at the same location has not been clear until now. Here, we report that
newly discovered VEGF gene polymorphism, VEGF -1780 T/C, is associated with an increased
risk of gastroduodenal ulcer disease based on the finding that TT carrying individuals were
very protective (odd ratio 8.62; CI=2.95-25.21) from gastroduodenal ulcer, whereas CC
carrying individuals are quite susceptible to peptic ulceration (OD 3.21; CI=2.08-4.96). The
functional genomic analysis that homozygote mutant of -1780 C/C showed lesser angiogenic
actvities than wild type -1780 T/T through the repressed promoter activity, supporting the
preference of ulcerogenesis in these high risk populations carrying novel SNP polymorphism
on incisura of stomach and anterior wall of duodenum, where vascular supply, so called
“end artery of extramural origin”, has been known to be prevailing on these high vulnerable
site. Similar to the previous report in Gastroenterology, we can confirm the fact that the
VEGF gene transfer significantly accelerated gastric ulcer healing, but we can add the more
novel finding satisfying the achievement of quality of ulcer healing with VEGF gene transfer,
based on that VEGF restoration could achieve the resistance to ulcer recurrence, as for which
ideally remodeled regenerating gastric glands was responsible. Conclusively, VEGF gene
polymorphism with its transcriptional impairment selectively in the stomach is closely
associated with the predisposition to PUD after the exposure to same etiologic risk. VEGF
restoration through gene transfer could be ideal option for overcoming these pathogenic
inferiorities to peptic ulcer disease.
M1886
Fundic Gland Polyps Induced By Proton Pump Inhibition Are Not Related to
the Level of Hypergastrinemia and Serum Chromogranin a Is Affected By
Meals
Reidar Fossmark, Constantin S. Jianu, Tom C. Martinsen, Gunnar Qvigstad, Unni
Syversen, Helge L. Waldum
AIM: Patients using proton pump inhibitors (PPI) have an increased risk of developing
fundic gland polyps but the exact mechanism behind polyp development is not known.
The use of PPI causes hypergastrinemia and gastrin has a well known trophic effect on the
oxyntic mucosa and on the enterochromaffin-like (ECL) cell in particular. In the present
study we have examined whether patients developing fundic gland polyps have a more
pronounced gastric hypoacidity, hypergastrinemia or increased serum chromogranin A (CgA),
which is an ECL cell marker. METHODS: Patients with gastroesophageal reflux disease and /
or Barrett's esophagus having developed multiple fundic gland polyps during PPI-use were
included. All patients had a normal stomach evaluated by endoscopy before starting treatment.
PPI-users without fundic gland polyps (n=6), as well as healthy individuals (n=6) were used
as controls. The duration of PPI use was 6.1 years in patients having developed polyps
versus 5.0 years in PPI-users in patients without polyps. All PPI-users underwent 24-hour
gastric pH registration, and repeated measurements of serum gastrin and CgA concentrations
during one day with standardized meals (at 0830 h, 1200 h and 1530 h), whereas only
gastrin and CgA were measured in the healthy individuals. H pylori status was determined
in all participants. RESULTS: There was no significant difference in the number of hours
with gastric pH > 4 between PPI users with and without polyps (13.2 ± 1.2 vs. 15.6 ± 1.4
hours, p = 0.29). Gastrin concentrations did not differ significantly between PPI-users with
and without fundic gland polyps, but was eight and nine times higher, respectively, at 1200
h compared to healthy individuals not using PPI. Fasting CgA was elevated in all PPI-users,
and CgA more than doubled during the day in all groups. All patients with fundic gland
polyps were H pylori negative, whereas four of six PPI-users without fundic gland polyps
were H pylori positive. CONCLUSIONS: The level of hypergastrinemia does not play a
determinant role in fundic gland polyp development during PPI therapy and other growth
promoting factors must be more important. Patients using PPI as well as healthy individuals
had a more than two-fold increase in CgA during the day, indicating that serum CgA, being
the most important marker for neuroendocrine tumors, should be measured in blood samples
from fasting patients.
M1887
Measurement of Gastric Compliance Using a New Technique
Anil K. Vegesna, Ramashesai Besetty, Umar Farooq, Amit Kalra, Javier Gomez, Joseph P.
Kim, Muhammad Y. Haroon, Shahzeb Khan, Robert S. Fisher, Henry P. Parkman, Wasif
Riaz, Barry Levitt, Annapurna Korrimili, Larry . Miller
Background: Compliance is a measure of the change in volume over the change in pressure
ΔV/ΔP. Gastric compliance has been measured in the past using a barostat which can be
cumbersome and difficult to use. Purpose: The purpose of this study was to develop a
simple method of measuring gastric compliance, and to determine normative data for gastric
compliance using this method. Methods: 10 normal volunteers (Mean age 34 yrs, 7 Male
and 3 Female)underwent endoscopy. During endoscopy a water perfused pressure transducer
was placed through the biopsy channel. Air was removed from the stomach and a gastric
baseline pressure was measured in a retroflexed position. Air was then infused in the stomach
during endoscopy at a constant flow (previously determined In Vitro). Air was infused until
the GEJ opened or until the subject complained of discomfort. Compliance curves were
plotted based on the infused volume of air (continuous, constant flow) and the intragastric
pressure at each volume (250 pressure measurements/sec). Results: Linear compliance curves
were obtained demonstrating ΔV/ΔP. The mean change in volume per unit pressure (slope
of the compliance curves) was 89.15 ± 24.31 ml/mmHg. Conclusions: A new method of
measuring gastric compliance was developed using a simple endoscopic technique. These
compliance curves correlate with previous compliance curves obtained using barostat techno-
logy. In the future we plan to evaluate various gastric motility disorders, for example
gastroparesis, using this technique.
M1888
A Novel Endoscopic Treatment for Gastrocutaneous Fistulae
Charles W. Randall, Carlo M. Taboada, Jesse Ramos, Anson Liu, Rosario Najera
INTRODUCTION A complication of percutaneous endoscopic gastrostomy (PEG) is a gastro-
cutaneous (GC) fistula at the stoma. These fistulae develop secondary to trauma and/or
severe malnutrition. Removal of the PEG generally allows closure. When fistulae persist,
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traditional management has been surgical treatment. This paper describes an endoscopic
method for GC fistula closure. METHODS 6 patients were evaluated with persistent GC
fistulae that had failed to close with standard management that included nasogastric suction,
antisecretory agents, local wound care and fasting. All patients had patent fistulae after 1
week of conservative treatment. For each patient the albumin level and width of the fistula
was recorded. Endoscopic closure was performed using Endoclip® (Microvasive; Boston
Scientific). The numbers of clips and time to complete closure were noted for each patient.
RESULTS The patients ranged in age from 58-83 years. Albumin levels ranged from 1.8-
2.6 gm/dl with a mean of 2.3 gm/dl. 5 patients had fistula dimensions of ≤ 1.0 cm. One
patient had a width of 1.6 cm. The 5 patients with dimensions ≤ 1.0 cm all had albumin
levels > 2.0 gm/dl and all had complete closure of their fistulae by day 3. The 6th patient
initially closed but reopened at day 4. This patient had an albumin of 1.8 gm/dl and a GC
fistula width of 1.6 cm. The mean number of clips placed per case was 3 with a range from
2-5. CONCLUSIONS 1.Endoscopic therapy for GC fistulae is safe and successful. 2.With
an overall success rate of 83.3% an endoscopic approach should be the initial treatment
option. 3.Nutritional status and size of fistula may predict success rate.
M1889
Sporadic Duodenal Adenoma Is Associated with Colorectal Neoplasia
D. Ramsoekh, M. E. Leerdam van, E. Dekker, R. J. Ouwendijk, E. J. Kuipers
Background: Sporadic duodenal adenoma is an uncommon finding and data are sparse. A few
studies have suggested an association between sporadic duodenal adenomas and colorectal
neoplasia, but the extent of this association is unknown. The aim of the present study was
to determine the presence of colorectal neoplasia in patients with sporadic duodenal adenoma
in comparison with a control population. Methods: Patients with a diagnosis of histological
proven sporadic duodenal adenoma in the period between 1991 and August 2006 were
identified using the digital endoscopic report system of two academic and one regional
hospital. Patients with duodenal carcinoma, patients with, or belonging to, familial aden-
omatous polyposis and hereditary non-polyposis colorectal cancer kindreds were excluded.
Medical records for identified patients were examined for diagnosis of colorectal neoplasia.
Location, size and histology were recorded for both duodenal adenoma and colorectal
neoplasia. Patients with multiple lesions were classified according to the most advanced
lesion found. Advanced adenomas (duodenal and colorectal) were defined as having a size
≧ 10 mm, > 25% villous component or high-grade dysplasia. Colonoscopic findings in all
patients with sporadic duodenal adenomas (cases) were on a 1:3 basis compared with
randomly selected age and sex matched symptomatic patients (controls) who underwent
both upper GI endoscopy and colonoscopy for various reasons. Results: A total of 102
patients with sporadic duodenal adenomas were identified. The mean age of patients was
65 years, 57% was male. Most of adenomas were located in the ampullary region (47%).
Large duodenal adenomas (≧ 10 mm) were found in 46 patients (45%). In 78 patients
(77%) the duodenal adenomas were classified as advanced. Colonoscopy was performed in
only 46 patients (45%), colorectal neoplasia was found in 21 (46%) of them. Colorectal
cancer was detected in 4 patients (9%), advanced colorectal adenoma in 9 patients (20%)
and non-advanced colorectal adenoma in 8 patients (17%). When comparing the colonos-
copic findings between the cases with sporadic duodenal adenoma and the control group
(n=138), both colorectal neoplasia (46% vs. 21%, OR 4.2 (95% CI 2.0-9.0)) and advanced
colorectal adenoma (20% vs. 4% OR 7.0 (95% CI 2.2-22.8)) were significantly more common
in the patients with sporadic duodenal adenoma. Conclusions: The majority of sporadic
duodenal adenomas are diagnosed as advanced lesions. Sporadic duodenal adenomas are
associated with the presence of colorectal neoplasia. These data strongly advocate to perform
colonoscopy in patients with sporadic duodenal adenomas.
M1890
GERD Overlaps Other Gastrointestinal Symptoms; Results of a Population
Based Study
Seyed mehdi Nouraie, Haniyeh Zaer-rezaii, Amir reza Radmard, Majid Sorouri,
Mansoureh Mamarabadi, Hadi Razjouyan, Siavosh Nasseri-moghaddam, Reza Malekzadeh
Background and Aims: Gastroesophageal reflux disease (GERD) has profound effects on
health economics, disturbs the patient's health-related quality of life. Population-based data
on GERD prevalence and its overlap with other GI disorders in Iran are lacking. We aimed
to assess this overlap and association in Iran. Methods: We conducted a cross sectional
study in a cluster random sample of adult population (18-65 years) of Tehran, Iran. Subjects
were grouped to GERD and normal subjects, using a validated questionnaire. GERD was
defined as at least weekly heartburn or acid regurgitation during the last six months. Subjects
were offered to fill out the validated Gastrointestinal Rating Symptom Score questionnaire
(GSRS). Five GI symptoms were assessed by GSRS, including abdominal pain, diarrhea
syndrome, indigestion syndrome, constipation syndrome, reflux syndrome. Age, sex, resid-
ency location, and education, ethnicity and tobacco use were assessed in all subjects. Results:
From 3019 eligible subjects, 2561 (85%) completed the GSRS questionnaire. Mean age (SD)
was 35.5 (13.6) years, 1083 (42.3%) were men, 151 (5.9%) were rural, and 542 (21.2 %)
had GERD. GERD increases scores in all five gastrointestinal symptom categories. The mean
symptom score was increased from 1.38 to 2.34 (70%) in indigestion and abdominal pain,
1.36 to 2.21 (63%) in constipation, 1.19 to 1.48 (24%) in diarrhea. A 120% increase in
reflux syndrome was shown in GERD patient as was expected. After controlling the effect
of all other variables in multivariate models, GERD had significant relationship in increment
of all symptom scores. The multivariate analysis indicated that gender had a significant
relationship with constipation, indigestion and abdominal pain syndromes. Education had
a significant relation with reflux, indigestion, diarrhea and constipation scores. Ethnicity
and tobacco use had no significant effect. Indigestion and reflux symptoms scores were
higher among urban and rural population, respectively. Age was significantly associated
with abdominal pain, indigestion and constipation symptom scores. Mean Constipation
score was higher and abdominal pain was lower in older people while indigestion score
was increased up to 55 years old and then decreased. Conclusions: Our study indicated
that GERD in adult Iranian population is as prevalent as west. GERD dramatically increased
all GI symptoms scores. It is concordant with other studies showing an overlap between
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GERD and other GI symptoms and may support the hypothesis of common etiopathologic
pathway. Sex, age, education and residency location had different effects on the GI symptoms.
M1891
The Prevalence of Non Helicobacter Non NSAID Peptic Ulcer Disease in
Children
Arie Levine, Rania Egbaria, Ron Shaoul
Background: Peptic ulcer disease is relatively uncommon in children. Until recently, Helicob-
acter pylori accounted for most of peptic ulcer disease in both adults and children. Recently
several publications in adults have shown an increase in the incidence of non helicobacter
non NSAID peptic ulcer disease which may be related to the decrease of the incidence of
Helicobacter pylori in developed countries. There is only one publication in the pediatric
literature that studied the incidence of non helicobacter non NSAID peptic ulcer disease
which showed that only 3/11 children with peptic ulcer disease were helicobacter positive.
Our aim was to describe the incidence and characteristics of peptic ulcer disease in our
population. Methods: We conducted a retrospective study over the years 2003- May 2006.
Over these years we had information on 751 diagnostic upper endoscopies performed at
the Bnai Zion and Wolfson Medical centers. Peptic ulcer was regarded as erosions or ulcer
in either the stomach or duodenum. Helicobacter status was assessed using rapid urease
test and gastric biopsy. Information on NSAID use was available for almost all patients with
peptic ulcer disease and completed as necessary. The main results of the study are presented
in the table. Results: Erosive disease or ulcers were detected in 169 patients. Eight patients
had IBD (Seven Crohn's disease, one ulcerative colitis). A history of NSAID use was available
for 10 patients with HP negative peptic ulcer. All of the patients with HP negative peptic
ulcer were treated with proton pump inhibitors (PPI) and most of them resolved their
symptoms. Those who did not respond to PPI treatment, or had some abnormality in their
laboratory tests were further evaluated. Twenty one had normal gastrin levels and 9 had
normal small bowel follow through. Conclusions: Peptic ulcer disease is much more common
in our population than previously reported. Non helicobacter peptic ulcer disease in children
accounts for third of the cases. Most of the cases are idiopathic and usually resolve with
PPI treatment. More studies should be encouraged to further define this group.
Table 1
M1892
Intense MID-Zone Gastritis: An Impressive Disease in Search of a Syndrome
Scott R. Owens, Henry D. Appelman
Background: We have seen a number of gastric biopsies in which there was a pattern
of inflammation that differed from any named gastritis. All biopsies had intense chronic
inflammation in the middle of the mucosa, including the neck and superficial glandular
compartments. This differed markedly from H. pylori (Hp) gastritis, which is most intense
superficially, and from atrophic gastritis, since there was no atrophy and no metaplasia. As
far as we can tell, there is no published information covering this impressive gastritis.
Therefore, we decided to study these cases to see if there were any recurring clinical,
epidemiologic or etiologic associations. Methods: Thirty-four cases of mid-zone dominant
gastritis were reviewed for distribution and composition of inflammation, and for presence
of Hp. Clinical records were reviewed to evaluate age, sex, symptoms, endoscopic findings
and medications. Results: In addition to mid-zone gastritis, 2 had a component of superficial
inflammation and 13 had deep inflammation extending to the base of the mucosa. None
had Hp. Twenty had neutrophilic activity, 14 had numerous eosinophils, and 9 had lymphoid
follicles. There were 21 females and 11 males, with ages ranging from 14-90 years (mean
49.5). Four patients were under age 18. Clinical history was available for 31 cases. On
endoscopy, 12 cases had antral erosions/ulcers; other endoscopic findings included erythema,
nodularity or normal mucosa. Four cases had a history of Hp gastritis or had been treated
based on clinical suspicion or serology. Three were later diagnosed with Hp (or Hp-type)
gastritis. Four patients had a clinical suspicion of Crohn's disease, 11 were taking proton
pump inhibitors and 5 were taking H2-blocker therapy at the time of the biopsy. There
was no consistent pattern of associated diseases or medication history, and the findings were
randomly distributed among the three groups, throughout all ages and sexes. Conclusion:
We report a group of unusual gastritides characterized by intense mid-zone inflammation.
No distinct clinical, endoscopic or historical features unite them, suggesting that this pattern
is the result of multiple causes. Further study is needed to identify any unifying feature(s)
in an effort to elucidate the cause(s). We propose the term mid-zone gastritis of unknown
etiology to distinguish them from the more typical types of gastritis, such as Hp, lymphocytic,
atrophic and inflammatory bowel disease-associated focal gastritis.
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Peptic Ulcer Disease: Does Diabetes Make a Difference?
Svetlana Korenfeld, Christina Tseng, Lawrence J. Brandt
Purpose: It is traditionally believed that peptic ulcer disease (PUD) is less common in
diabetics than in nondiabetic (ND) controls, which is surprising in view of the increased
prevalence of H. pylori in diabetics. PUD in diabetics also is thought to be associated
with more adverse outcomes due to autonomic neuropathy (gastric outlet obstruction) and
atherosclerosis (bleeding and delayed ulcer healing). Methods: We performed a retrospective
chart review of all cases of PUD with age-matched controls who had esophagogastroduodeno-
scopy (EGD) at Montefiore Medical Center between June 2005 and July 2006. Severity of
diabetes, nonsteroidal anti-inflammatory drug (NSAID) use, incidence of H. pylori, indications
for EGD, number and location of ulcers, endoscopic interventions, short-term outcomes
and mortality were studied. Results: 406 patients with PUD and 406 controls were identified.
The incidence of diabetes (27% and 30%) and insulin dependence (11% and 13.5%) was
respectively similar in PUD patients and controls. NSAID use in diabetics (47%) was twice
that in ND (24%) but was equal in diabetic ulcer patients (48%) and diabetic controls
(47%). The incidence of H. pylori was increased in ulcer patients (38%), but similar in
diabetics (34%) and ND (36%). Multiple ulcers were seen equally frequently in diabetics
(25%) and ND (20%). Ulcer location was no different in diabetics and ND (diabetics: 62%
antrum, 29% duodenal; ND: 56% antrum, 34% duodenal). Indications for EGDs showed
similar rates of gastrointestinal bleeding (diabetics: 36%; ND: 29%) but lower rates of
abdominal pain or dyspepsia in diabetics (33.5%) compared with ND (41%). 7% of diabetic
ulcer patients either underwent surgery or died compared with 2% of ND. Death was
attributable to bleeding or associated complications in all cases. Diabetics showed decreased
ulcer healing rates (50%) compared with ND (76%) over a 6-month evaluation of patients
having repeat EGDs (p<0.05). Conclusions: 1) Incidences of PUD, H. pylori and location
and numbers of ulcers were similar in diabetics and ND. 2) Diabetics had less abdominal
pain or dyspepsia as indications for EGD perhaps reflecting autonomic neuropathy. 3)
Adverse short-term outcomes, including surgical intervention and death, were more common
in diabetics than ND, and in all cases death was attributable to bleeding or associated
complications in all cases. 4) Ulcers in diabetics demonstrated significantly decreased healing
rates compared with ND.
M1894
Prediction of Gastric Erosiv Complications in Uremic Diabetic Patients Using
Multigene DNA Sequencing Arrays
Dominika Szoke, Yvett Mandy, Andras Szabo, Klara Berta, Norbert Solymosi, Bela Molnar,
Zsolt Tulassay
Background and Aims: Genetic polymorphisms of angiogenezis, steroid hormon receptor,
inflammatory cascade, apoptosis controlling genes can influence the gastric erosiv complica-
tions of diabetic uraemic patients. Parallel evaluation multiple genetic polymorphism became
available with the development of DNA sequencing arrays. We aimed to develop a 17 gene,
17561 nucleotid sequencing array for genetic prediction of these complications. Patients
and Methods: DNA was isolated from 10 ml peripheral blood of 40 non-ureamic diabetic
and 40 uremic diabetic patients 37 from them with gastric erosiv complications. An Affymetrix
DNA sequencing array was developed containing altogether 45 PCR products for 17560
base pairs from the following genes: CYP17, glucocorticoid receptor gene, hydroxy-delta-
5-steroid dehydrogenase 3 beta and steroid delta-isomerase 1, hydroxysteroid(11-beta) dehy-
drogenase 1 (HSD11B2), TNF-α, IL-1β, IL-4Rα, IL-6, IL-8, HSP70, Apoliporotein B-100,
Apoliprotein E (ApoE), Cholesteryl Ester Transfer Protein, P53, D-vitamin receptor, vascular
endothelial growth factor (VEGF), Galectin 1. Confirmatory analysis was performed for 3
known polymorphisms by SSCP, for 3 other ones by RFLP and for 4 polymorphisms by
capillary sequencing. Prediction analysis was performed using the Bayes statistical methods
for correlation prediction in the R program package. Results: The correlation between the
DNA sequencing array results and the confirmatory methods were 98,7 % in relation to
SSCP , 97,1 % to RFLP and 99,1 % to capillary sequencing. Taking the odds ratio of 1 and
95% confidence interval and 2 ordds ratio genetic polymorphisms of the followig genes
were found to be predictive between the uremiac and non-uremic group. ApoE, P53, HSP70,
IL1, TNF, VEGF. In relation to the gastric erosiv complaints the p53 exon 10, pos. 150
polymorphism of the gene was found to be highly predictive, as confirmed by the capillary
sequencing method. Conclusions: DNA sequencing arrays can contribute to multiparameter,
multilocus genetic analysis yielding highly correlating results with the single parameter
methods. P53 gene polymorphism is highly correlated to the development of gastric erosions
in diabetic, uremic patients.
M1895
Postprandial Intragastric Acid Buffering in Response to Different Meal
Compositions
Sajneet Khangura, Siva Doma, Robert S. Fisher, Henry P. Parkman
Meals are known to buffer intragastric acid. Differences exist in intragastric acid buffering
depending on contents of a meal. The time frame for buffering of different meals is not
well described. AIM: To determine the onset, magnitude and duration of the postprandial
intragastric buffering effect for bland, spicy and fatty meals in different regions of the stomach.
METHODS: Ten normal subjects underwent esophagogastric pH monitoring using a 4-
probe pH catheter. After fasting overnight, the pH catheter was placed with the proximal
probe 2 cm above the proximal border of the manometric LES; The other probes were in
the stomach 7, 10 and 17 cms below the proximal probe. Subjects were given a bland
breakfast consisting of an egg sandwich with orange juice (341 cal; 31% fat), a spicy lunch
consisting of Turkey sandwich with mustard, hot cherry peppers and apple juice (570 cal;
28% fat), and a high fat dinner composed of two hamburgers, green salad with Thousand
Island dressing and milk (955 cal; 51% fat). Results are expressed as Mean±SEM. RESULTS:
The pre-prandial pH was higher for the breakfast (3.0±0.1 in proximal stomach and 2.7±0.1
in distal stomach) than for lunch (1.6±0.1 and 1.4±0.1, respectively) and dinner (1.7±0.1
and 1.1±0.1, respectively). A rise in pH was seen as soon as the subjects started eating the
meal. The duration of buffering and maximal pH reached in the proximal stomach were
significantly longer and higher than in mid/distal stomach. The elevation of intragastric
buffering after the fatty meal was significantly longer than for the spicy or bland meals. The
highest pHs reached in the proximal stomach were 5.3±0.1, 4.2±0.1, and 3.9±0.1 for fatty
dinner, spicy lunch and bland breakfast, respectively (p<0.05). Total duration of gastric
acid buffering above pH 3 in the proximal stomach was 180±26 minutes with fatty dinner,
100+14 minutes with spicy lunch, and 35±12 minutes with bland breakfast. Corresponding
values for buffering above pH 4 in the proximal stomach were 129±31 minutes with fatty
dinner, 35±16 minutes with spicy lunch, and 19±10 minutes with the bland breakfast.
SUMMARY: Buffering of intragastric acid starts shortly after meal ingestion and lasts for
variable periods of time depending on the composition of a meal. Peak buffering and duration
of buffering also vary with the composition of the meal; maximum buffering being with a
fatty meal. The buffering of intragastric acid was highest and lasted longest in the proximal
stomach compared to the mid/distal stomach. In conclusion, a fatty meal was significantly
more potent than a bland or spicy meal in the magnitude and duration of buffering intra-
gastric acid.
M1896
Functional GI Disorders (FGID) in Adolescent, Epidemiology and Reliability
of the Rome II Questionnaire in Iran
Seyed mehdi Nouraie, Sahand Sohrabi, Somayyeh Baghizadeh, Hooman Khademi,
Siavosh Nasseri-moghaddam
Introduction: Rome II questionnaire is widely used for screening and diagnosis of functional
GI disorders. A few studies assessed the reliability of this questionnaire. We aimed to estimate
the prevalence of functional GI symptoms in Iranian young population using Rome II criteria
and find the reliability of the questionnaire. Material and methods: A multistage random
sample of Tehran students, aged 12-18 was selected. All subjects completed a Rome II
integrative questionnaire by themselves. Among them a random sample were selected to
retest the questionnaire with 7-14 days interval. Demographic and socioeconomic variables,
history of any organic disease and medication were included in the questionnaire, too.
Subjects and school mangers filled informed consent before completing the questionnaire.
Results: A total number of 1436 students were enrolled, 736 (51.3%) were men. Mean age
(SD) was 16.9 (1.7). The five most prevalent FGIDs were Bloating (16.9%), Heartburn
(4.9%), Incontinence (4.3%), and IBS (4.1%). The prevalence of Globbus, Rumination, and
abdominal pain was less than 2%. There was no significant relationship between age, sex,
and socioeconomic factors and FGID in this population. Total number of 536 students
completed the questionnaire for the second time. Kappa value was different by diseases,
functional diarrhea (0.66), IBS (0.64), dysphagia (0.55), bloating (0.54), functional abdom-
inal pain syndrome (0.50), globus (0.50), aerophagia(0.49), heart burn (0.47), chest pain
(0.44) and proctalgia fugax(0.41). Other diseases had Kappa less than 0.40. There were no
significant difference in Kappa scores by age, and sex. Conclusion: Early young ages are
prone to FGID. The Rome II questionnaire has good reliability in diagnosing most of FGID
in this age group. The relative high prevalence of FGID in young Iranians should be
considered more.
M1897
The Effect of Cholestyramine in Patients with Duodeno-Gastro-Esophageal
Reflux. A Prospective Study
Daniel Kotlar, Uli Mueller, Herbert Lochs, Jana Hoeppner, Vera Loening-baucke, Winfried
Voderholzer
BACKROUND: Current data indicate a causative link between duodeno-gastro-esophageal
reflux (DGER) and the development of Barretts metaplasia, suggesting that pharmacological
inhibition of DGER could be beneficial in the prevention of metaplasia (Vaezi et al. Baillières
Clinical Gastroenterology 2000; 14: 719-29). We therefore reasoned whether bile acid
binding resins like cholestyramine might reduce DGER and associated symptoms. OBJECT-
IVE: To prospectively evaluate the efficacy of cholestyramine, esomeprazole (=Eso), or
antacids in decreasing DGER and improving symptoms associated with DGER. METHODS:
15 Patients with reflux disease and additional pathological DGER were randomized to 3
groups (N=5) to take either Eso 40 mg/d alone (= group I) or Eso 40 mg/d and cholestyramine
12 g/d (=group II) or Eso 40 mg/d and antacids 3 g/d (= group III). Ambulatory 24 h
measurements of acid reflux and DGER (Bilitec 2000) were performed at baseline and after
a 4-week treatment period. A Bilirubin absorption > 10.7% of total time and acid exposure
> 8.0% of total time were considered pathological. All patients were asked to record symptoms
using an established scoring system (rating 1 - 5). RESULTS: Table 1 shows DGER evaluation
for each treatment group and the results of the acid measuring. DGER was significantly
decreased by cholestyramine treatment, whereas it was not affected by Eso alone or in
combination with antacids. Typical reflux symptoms such as heartburn and acid regurgitation
did not change significantly in either group. However, bloating, nausea and belching signific-
antly decreased during cholestyramine treatment bloating score (3.2±0.8 vs. 0.6±0.5, p<0.05),
nausea score (4.2±0.8 vs. 0.8±0.4, p< 0.05), belching score (3.4±0.9 vs. 0.4±0.5, p<0.05).
As expected, Eso or antacids did not affect DGER. CONCLUSIONS: These preliminary data
suggest that cholestyramine could be beneficial by decreasing associated symptoms which
are not controlled by Eso and in preventing Barretts metaplasia.
Table 1. Mean (±SEM) Baseline and Posttherapy DGER Parameters (Bilitec) and total pH-
Metry scores
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M1898
Risk Factors of Thyroid Disease(Td) in Patients with Atrophic Body
Gastritis(ABG) Assessed with Artificial Neural Networks(ANNs)
Bruno Annibale, Edith Lanher, Giacoma Agnello, Gianfranco Delle fave, Marco Intraligi,
Massimo Buscema, Enzo Grossi
Introduction Many patients with ABG are unaware to be affected by a subclinical TD. The
prevalence of TD in patients with ABG and risk factors are poorly investigated. Aim The
aim of the study is to assess the prevalence of association between TD and ABG in a large
cohort of patients and the possibility to predict TD through clinical, biochemical and gastric
histological features analyzed with Logistic Regression(LR) and ANNs Materials and methods:
319 consecutive outpatient with ABG diagnosis were systematically evaluated for TD. Vari-
ables concerning anagraphical, life style, family history, biochemical and histological data,
collected at the time of diagnosis of ABG, were compared between ABG patients with(N.169)
and without (N.150) TD. The presence of risk factors for the occurrence of TD in ABG
patients was assessed by performing LR analysis. Furthermore, the prediction of TD in ABG
patients was assessed through the ANNs models applied to a dataset containing 29 clinical
and biochemical variables (biochemical and ultrasonographic data of thyroid evaluation were
not included). In order to select the most informative variables in the prediction task of
ANN models, ANNs-based data pre-processing tools were used. Results: The prevalence of
TD was 53%. The prediction of the presence of TD and ATD associated with ABG, trought
the logistic regression model show that female gender, presence of metaplastic atrophy, and
positivity to parietal cell antibodies resulted to be significantly predictive. In the same
prediction task carried out with ANN models also the presence of anemia, of other autoim-
mune diseases, and the Pepsinogen I level were recognized as determinant. LR reached a
mean predictive accuracy of 65.2% (sensitivity 82.2% and specificity 45.8%). The best
ANNs performance reached a mean accuracy of 75.8% (81.8% sensitivity and specificity
69.9%).ANNs outperformed LR in recognizing ABG patients with a healthy thyroid gland
(p=0.0003). Conclusions: Our study shows the high prevalence of TD in ABG patients. The
ABG patients with concomitant presence of TD, may be predicted by the traditional multivari-
ate statistic models with a high accuracy on the basis of a few independent predictive
parameters. However, the ANNs performance are significantly higher than the statistical
models. Thus, ANNs would appear to be promising tools for clinical decision-making able
to identify accurately those ABG patients with an undiagnosed subclinical TD.
M1899
Analysis of Gastric Ulcer After One Week Treatment with rabeprazole and
OMEPRAZOLE in Japan
Takashi Ando, Takeshi Ishikawa, Yuji Naito, Norimasa Yoshida, Toshikazu Yoshikawa
Background: Parietal cells migrate from their generating region to the base of gastric gland
and gradually lose acid secretory activity during their life span. Accumulation of rabeprazole
(PPI, its pKa is about 5.0) in weakly acidic region is greater than those of other PPIs (pKa
are around 4.0). Thus, rabeprazole may inhibit gastric acid pump in both the luminal and
basal parietal cells. Rabeprazole transforms into its acid-activated form more rapidly and
inhibits In Vitro acid pump faster than other PPIs (Besancon et al. J Biol Chem 1997). In
Japanese patients, 10 mg rabeprazole showed faster onset of action and more profound
suppression of acid secretion than 20 mg omeprazole on the first 3 days of administration
(Saitoh et al. Aliment Pharmacol Ther 2002). Here, we studied ulcer improvement after one
week treatment with rabeprazole and omeprazole in Japanese patients. Methods: 74 patients
with active stage gastric ulcer (45 male and 29 female) who had not taken anti-ulcer treatment
prior to this study were enrolled. Patients received 10 mg rabeprazole (n = 39) or 20 mg
omeprazole (n = 35) daily and took endoscopic examinations before and after 1 and 8 week
of PPI administration. A rubber disc (6mm in diameter) was placed on the side of the ulcer
for measurement of the ulcer area. The improving ratio was given as [(baseline index -
treatment index) / baseline index] x 100. CYP2C19 genotype was determined by PCR-RFLP.
Results: The distributions of CYP2C19 genotypes for rabeprazole and omeprazole groups
were 20 and 15 in homoEM, 14 and 14 in heteroEM, and 5 and 6 in PM subjects, respectively.
Before the treatment, the gastric ulcer area showed no deviation among 3 genotypes and
the both groups. After 1 week treatment, the improving ratio of ulcer area for rabeprazole
group (61%) was significantly greater than that of omeprazole groups (46%) in homoEM
subjects (p = 0.039). These values were 65% and 62% in heteroEM, and 55% and 63% in
PM subjects, respectively. Discussion: The power of gastric acid secretion in Japanese is
generally weaker than that in Caucasians. 10 mg rabeprazole is an indicated dosage and
esomeprazole is not available in Japan. The present faster improvement with rabeprazole
compared with omeprazole in homoEM subjects may owe to the differences in pKa and the
pump inhibition speed. Conclusion: After 1 week treatment, the gastric ulcer improving
ratio with 10 mg rabeprazole was greater than that of 20 mg omeprazole in homoEMs.
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M1900
Clinical, Demographic, and Habit Characteristics of GERD Patients with and
Without Erosive Esophagitis
Siavosh Nasseri-moghaddam, Hadi Razjouyan, Mansoureh Mamarabadi, Seyed mehdi
Nouraie, Azadeh Mofid, Maysam Alimohammadi, Mohamad-hamed Ghotbi, Shahnaz
Tofangchiha, Reza Malekzadeh
Introduction: Gastro-esophageal Reflux Disease (GERD) is a common, chronic, and relapsing
disorder with increasing prevalence. GERD is classified as erosive (EE) or non-erosive (NERD)
according to endoscopic findings. We aimed to assess clinical, demographic, and habitual
differences between these two groups and assess risk factors for erosive esophagitis. Materials
and methods: Patients with clinical GERD underwent upper GI endoscopy. All had at least
one of the following symptoms for at least 4 weeks over the past 3 months: acid regurgitation
(AR), heartburn (HB), dysphagia (D), or non cardiac chest pain (NCCP). Minor symptoms
were also sought. A composite symptom score (SS) was calculated for each, considering
frequency and severity of the major and minor symptoms. Educational level (illiterate,
elementary school, highschool, and university), Age, smoking, tea drinking, and symptom
duration were asked. H Pylori infection was confirmed by rapid urease test (RUT). Multivari-
able analysis was done. Results: Of the 460 cases (39% male, mean age: 38.6 yr), 250
(54.3%) had NERD. Frequency of HB, AR, NCCP, and D were not different betwene the 2
groups, although NCCP tended to be more common among patients with NERD (37.1%
vs. 29.4%, p:0.08) Frequency of chronic interscapular pain was significantly higher among
the NERD group (48.0% vs. 36.7%, P: 0.01). Female gender, illiteracy, not smoking, absence
of sliding hiatal hernia (SHH), size of SHH, Helicobacter pylori (HP) positivity, lower weight,
and lower BMI were more frequent among NERD than EE patients (All P values<0.05).
Drinking tea was not different between the 2 groups. No difference was seen between these
groups considering age. Although mean symptom score, and duration of symptoms was
more among patients with erosion but they were not statistically significant.The independent
risk factors for erosive esophagitis were male sex (OR: 1.83, 95% CI: 1.19-3.18; P: 0.005),
presence of sliding hiatal hernia (OR: 4.01, 95% CI: 2.61-6.16; P: <0.001) and symptom
duration more than 36 months (OR: 2.17, 95% CI: 1.30-3.62;P: 0.003). Presence of H
Pylori was a protective factor for erosive esophagitis (OR: 0.52, 95% CI: 0.33-0.81; P: 0.004).
Conclusions: In comparison to EE patients, NERD subjects are more expected to be female,
non-smoker, have lower BMI, and less educated. Absence of sliding hiatal hernia and being
infected with HP is more commonly seen with NERD patients. Male sex, presence of SHH,
and symptoms more than 36 months are the major independent risk factors and presence
of H Pylori is a protective factor.
M1901
Luminal CO2 Induces Esophageal Hyperemia Via Epithelial Carbonic
Anhydrases and Acid Sensors in Rats
Yasutada Akiba, Misa Mizumori, Paul H. Guth, Eli Engel, Jonathan D. Kaunitz
Heartburn is common symptom that is usually triggered by acid in the esophageal lumen.
The mechanism by which the luminal chemical signal is transduced into a neural afferent
signal is controversial. Since the esophageal mucosa is permeable to CO2, we hypothesized
that luminal CO2, rather than H+, permeates through the stratum epithelium, where it is
reconverted to H+ by carbonic anhydrase (CA) activity, and then interacts with epithelial
and subepithelial acid chemosensors, producing an afferent neural signal. We thus examined
the effect of luminal CO2 on esophageal mucosal interstitial pH (pHint) and blood flow and
their dependence on CA activity and the function of acid sensors (TRPV1 and ASIC) in rats.
Methods: Under isoflurane anesthesia, the rat lower esophageal mucosa was exposed and
topically superfused with pH 7.0 buffer, and pH 1.0 or pH 6.4 high CO2 (PCO2 = 260
mmHg) solutions with or without perfusion of cell-permeant CA inhibitor methazolamide
(MTZ, 1 mM), the cell-impermeant CA inhibitor benzolamide (BNZ, 0.1 mM), the TRPV1
antagonist capsazepine (CPZ, 0.5 mM), or the ASIC inhibitor amiloride (0.1 mM). We
measured pHint with 5,6-carboxyfluorescein (5 mg/kg iv) loaded into the interstitial space
of the esophageal mucosa and blood flow with laser-Doppler flowmetry. Expression of
membrane-bound CAs, TRPV1 and ASIC1-3 were assessed with immunofluorescence, RT-
PCR and western blot. Results: Perfusion of a high CO2 solution induced hyperemia without
pHint change, mimicking the effect of pH 1.0 perfusion. Perfusion of MTZ, BNZ, CPZ and
amiloride all inhibited CO2-induced hyperemia. Immunofluorescence revealed expression
of extracellular CA isoforms CA XIV in the prickle cells and CA XII in the basal cells, but
failed to identify CA IV and IX. TRPV1 was expressed in the stratum granulosum and in
the muscularis mucosa, whereas all ASICs were expressed in the prickle cells and ASIC3
was also in the muscularis mucosa and muscle layer, confirmed by RT-PCR and western
blot. Conclusions: Luminal CO2 perfusion reproduced the physiological response to acid
in esophagus, suggesting that CO2 diffuses through the stratum epithelium, interacting with
the putative acid sensors TRPV1 and ASICs in the epithelium or submucosa. Inhibition of
the hyperemic response to luminal CO2 by CA, TRPV1 and ASIC inhibitors implicates CA
and these chemosensors in transduction of the luminal acid signal. Transepithelial CO2
permeation may explain how H+ equivalents can rapidly be sensed, producing physiological
responses such as hyperemia, presumably accompanied by the sensation of heartburn.
M1902
Inhibition of Proteinase-Activated Receptor 1 Accelerates Duodenal Ulcer
Healing in Rats: Novel Implication for the Critical Role of Angiogenesis
Xiaoming Deng, Tetyana Khomenko, Ximing Xiong, Ganna Tolstanova, Longchuan Chen,
Sandor Szabo
Proteinase-activated receptor 1 (PAR1), a G protein-coupled seven transmembrane domain
receptor activated by thrombin, is highly expressed in a variety of cells including enterocytes,
endothelial cells, enteric neurons and smooth muscle cells of the gastrointestinal tract. It
has been demonstrated that PAR1 activation mediates the release of VEGF and endostatin
from platelets, changes vascular tone, and increases vascular permeability and granulocyte
chemotaxis. In this study, we tested the role of PAR1 in duodenal ulcer healing in rats.
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Methods: Duodenal ulcers were induced in unfasted Sprague-Dawley rats (180-200g) by
cysteamine-HCl (25mg/100g, x3) given intragastrically on the first day. The rats were
randomly divided into two groups on the second day and given intragastrically either selective
PAR1 antagonist (SCH79797, Tocris, Ellisville, MO), 50μg/rat, x2 daily for 5 days or saline
0.5 ml/rat, x2 daily for 5 days. All rats were killed 7 days after cysteamine administration
and duodenal ulcer size was measured; and scrapings of proximal 2.5 cm duodenal mucosa
were harvested and frozen in liquid nitrogen. VEGF, endostatin and angiostatin levels in
duodenal mucosa were determined by Western blotting and ELISA. The experiment was
repeated twice and results were pooled. Results: Duodenal ulcer size was markedly decreased
in PAR1 antagonist-treated group (5.2±2.8 mm2) vs. the control group (13.6±7.8mm2).
Western blotting showed that expression of 20 kDa endostatin and 50 kDa angiostatin in
the PAR1 antagonist-treated group was reduced by more 2-fold than in the control group,
while the expression of 23 kDa VEGF was not different between the two groups. These results
were confirmed by ELISA that showed a 50-60% reduction of endostatin and angiostatin
concentration in the PAR1 antagonist-treated group when compared with the control group.
Conclusions: Our studies demonstrated for the first time: 1) Inhibition of PAR1 accelerated
duodenal ulcer healing in rats; 2) The accelerated ulcer healing by PAR1 inhibition was
likely modulated through the downregulation of angiogenesis inhibitors endostatin and
angiostatin; and 3) Thus, PAR1 seems to be involved in duodenal ulcer healing through
regulating the balance of angiogenic and anti-angiogenic factors.
M1903
Adaptive Gastric Cytoprotection Is Mediated By Prostaglandin E Receptor Ep1
But Not Ep4 Subtype
Mayu Tanigami, Ryo Hatazawa, Michitaka Ogura, Yasuyuki Ito, Akiko Tanaka, Koji
Takeuchi
Background/Aim: Endogenous prostaglandins (PG) play a central role in adaptive cytoprotec-
tion induced in the stomach by mild irritants. We have previously reported that this action
of PGs is mediated mainly by EP1 receptors but not other subtypes. However, the involvement
of EP4 receptors in this action remained pending, because of the lack of specific prostanoids
binding to EP4 receptors. Recently, highly selective EP4 agonist and antagonist become
available. In the present study, we thus examined using the specific EP4 agonist and antagonist
the involvement of EP4 receptors in adaptive cytoprotection induced in rat stomachs by
taurocholate Na (TC). Methods: Male SD rats were used after 18 h fasting. Gastric lesions
were induced by PO administration of HCl/ethanol (60% ethanol in 150 mM HCl), and
the animals were killed 1 h later. PGE2 (0.01-0.1 mg/kg) or TC (5-20 mM) was administered
IV 10 min or PO 30 min, respectively, before challenge of HCl/ethanol. Indomethacin (5
mg/kg), NS-398 (COX-2 inhibitor: 10 mg/kg), ONO-8711 (EP1 antagonist: 30 mg/kg) or
AE-3-208 (EP4 antagonist: 1 and 3 mg/kg) was given SC 1 h or IV 10 min, respectively,
before the administration of PGE2 or TC. In some cases, AE1-329 (EP4 agonist: 0.3-10 μg/
kg) was administered PO 1 h before HCl/ethanol, in the absence or presence of AE-3-208.
Results: HCl/ethanol-induced gastric lesions were dose-dependently prevented by TC, and
the effect at 20 mM was equivalent to that induced by PGE2 at 0.03 mg/kg. The protective
effect of TC was significantly attenuated by indomethacin as well as ONO-8711, the EP1
antagonist, but not affected by AE3-208, the EP4 antagonist, as well as NS-398. Likewise,
the protective action of PGE2 against HCl/ethanol-induced damage was also antagonized
by ONO-8711 but not AE3-208. TC significantly increased the mucosal PGE2 contents in
the stomach, and this effect was blocked by prior administration of indomethacin but not
NS-398, ONO-8711 or AE3-208. Of interest, the EP4 agonist AE1-329 dose-dependently
reduced the severity of HCl/ethanol-induced gastric lesions, but this effect was significantly
but only partially mitigated by AE3-208 the EP4 antagonist. Conclusion: The present findings
confirmed a critical role for endogenous PGE2 produced by COX-1 in adaptive cytoprotection
and further suggested that this action is mediated by activation of EP1- but not EP4-receptors.
Although the EP4 agonist exhibits gastroprotection against HCl/ethanol, this effect may be
largely due to the actions unrelated to the activation of EP4 receptors.
M1904
Lafutidine Promotes Healing of Gastric Ulcer in Streptozotocin-Induced
Diabetic Rats Via Upregulation of Vascular Endothelial Growth Factor
Tetsuya Tanigawa, Toshio Watanabe, Masahiro Ochi, Fumio Tanaka, Takashi Sugawa,
Masatsugu Shiba, Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide
Higuchi, Tetsuo Arakawa
Background and Aim: Diabetes mellitus (DM) has a deleterious influence on various func-
tions of the gastrointestinal tract. However, the influence of DM on the healing of gastric
ulcer remains unknown. Lafutidine, a histamine H2 receptor antagonist, exhibits gastric
mucosal protective action mediated by capsaicin-sensitive afferent neurons. In this study,
we examined the influence of DM on the healing of acetic acid-induced gastric ulcer in rats
and the healing promoting effect of lafutidine on this lesion. Methods: DM was induced in
male SD rats by a single intravenous injection of streptozotocin (STZ, 70 mg/kg) and the
rats with a blood glucose level of more than 300 mg/dl one week after injection of STZ
were used as a DM animal model. Gastric ulcers were developed by focal serosal application
of 100% acetic acid for 60 sec. Lafutidine (30 mg/kg BW), cimetidine (100 mg/kg BW) or
vehicle was given orally once daily from 3 days after ulceration (Day 0) for up to 8 days
(Day 8). The stomach was removed and ulcer size was measured at Day 4 and 8 of treatment.
Expression of mRNA for vascular endothelial growth factor (VEGF) in ulcerous tissue and
normal mucosa were assessed by real-time RT-PCR. To clarify the role of capsaicin-sensitive
afferent neurons in lafutidine-mediated gastric ulcer healing, we examined the effect of
sensory denervation induced by repeated subcutaneous injections of capsaicin (total dose:
100 mg/kg) on healing of gastric ulcer and expression of mRNA for VEGF in ulcerous tissue
in normal rats treated with lafutidine. Results: Induction of DM by STZ resulted in delay
of ulcer healing (ulcer index: 6.83 ± 5.83 mm2 in normal rats vs 26.29 ± 11.43 mm2 in
DM rats at Day 4 and 2.06 ± 0.49 mm2 in normal rats vs 12.67 ± 12.02 mm2 in DM rats
at Day 8). In diabetic rats, lafutidine accelerated ulcer healing compared with vehicle or
cimetidine-treated rats. Lafutidine increased the expression of mRNA for VEGF in ulcerous
tissue of diabetic rats compared to vehicle-treated diabetic rats by 2.7-fold, while cimetidine
did not affect it. In normal rats, the effects of lafutidine on healing of gastric ulcer and
expression of mRNA for VEGF were completely abolished by chemical ablation of capsaicin-
sensitive sensory neurons. Conclusion: These results suggest that (1) DM impairs the healing
of gastric ulcer, (2) lafutidine accelerates the healing of gastric ulcer impaired by DM via
upregulation of VEGF and (3) this healing promoting effect of lafutidine on gastric ulcer
healing impaired by DM is not related to acid suppression, but is associated with the gastric
mucosal protective action of capsaicin-sensitive afferent neurons.
M1905
Protective Effect of Probiotic Escherichia coli Nissle 1917 (EcN) Bacterial
Strain Against Stress-Induced Acute Gastric Mucosal Lesions
Peter C. Konturek, Thomas M. Brzozowski, Gregor Burnat, Robert Pajdo, Eckhart G.
Hahn, Stanislaw J. Konturek
Background and Aims: Previous studies demonstrated preventive and healing effects of EcN
on acute and chronic intestinal inflammation in various models of murine colitis. However,
the gastroprotective effects of EcN against mucosal injury has been little studied and therefore
we tested the effect of pretreatment of rats with EcN on the development of acute stress-
induced gastric lesions in rat. Methods: Rats were divided in following treatment groups:
1) vehicle (control); 2) EcN 10(1) CFU/ml; 3) EcN 10(4) CFU/ml and 4) EcN 10(8) CFU/
ml. One hour after pre-treatment, the rats were exposed to 3.5 h of water immersion and
restraint stress (WRS) and then sacrificed. Involvement of prostaglandins was tested using
non-selective COX-inhibitor, indomethacin 5 mg/kg applied i.p. 1 h before WRS, whereas
that of sensory nerves was assessed by capsaicin (125 mg s.c.) used 10 days before WRS
in rats pretreated with EcN 108 CFU/ml or vehicle. The expression of pro-inflammatory
cytokine (IL-1β), peroxisome proliferator receptor gamma (PPARγ) and heat-shock protein
(Hsp70) was assessed by quantitative RT-PCR (Taqman) and immunblot. In addition, the
activation of NFκB in nuclear cell extracts was measured. Results: Exposure to WRS in vehicle-
pretreated rats caused acute gastric stress erosions. Pretreatment with EcN significantly and
dose-dependently reduced stress lesion number and increased gastric mucosal blood flow
(GBF) assessed by H2-gas clearance. These protective effects were completely abolished by
indomethacin and siginifcantly attenuated by capsaicin-denervation. The exposure to WRS
was associated by an increase in gastric mucosal mRNA and protein expression for IL-1β,
PPARγ, Hsp70 and COX-2. In rats pretreated with EcN, a significant down-regulation of
mRNA and protein expression for IL-1β, COX-2 and PPARγ, reduction in the activation of
NFkB and increased expression of Hsp70 were observed. Conclusions: 1) EcN-induced
protection against stress-induced gastric mucosal injury could be due to its anti-inflammatory
and vasodilatatory actions and stimulation of Hsp70 expression; 2) prostaglandins and
sensory afferent neurons are involved in gastroprotection induced by this probiotic, and 3)
EcN deserves a clinical application in the prevention of acute gastric mucosal damage
in humans.
M1906
Melatonin Enhances Gastric Ulcer Healing Through Activation of NO/NOS,
Ghrelin Release and Anti-Inflammatory Actions
Peter C. Konturek, Tomasz Brzozowski, Gregor Burnat, Wieslaw W. Pawlik, Eckhart G.
Hahn, Stanislaw J. Konturek
Aims and Background: The gastrointestinal tract is a major source of extrapineal melatonin
(MT). Previous studies, including our own, showed the protective effect of MT against acute
gastric mucosal damage, but the role of MT in ulcer healing is still poorly understood. The
aim of the present study was 1) to investigate the effects of MT and its precursor, L-
tryptophan (Trp) on the course of gastric ulcer healing, gastric blood flow (GBF) and the
gene expression of N-acetyltransferase (NAT), melatonin receptor (MT2), COX-2, iNOS,
ghrelin and proinflammatory cytokines (TNFα and IL-1β), and CGRP in gastric mucosa
and 2) to analyze the effect of MT and TRP on ulcer healing after capsaicin-induced ablation
of sensory nerves.Methods: MT (2.5-20 mg/kg-d i.g.) and Trp (25-100 mg/kg-d i.g.) was
given for 8 days after induction of gastric ulcers by acetic acid method in rats with intact
(group A) or capsaicin deactivation of sensory nerves (group B). At day 3 and 8 the ulcer
area was measured by planimetry and GBF by H2-gas clearance method. The expression of
COX-2, NAT, ghrelin, TNFα, IL-1β, MT receptors and CGRP in the mucosa was analyzed
by quantitative RT-PCR (Taqman). The luminal concentration of NO was measured using
nitrate/nitrite kit. In separate experiments, MT and Trp treatment was combined with addition
of NO-synthase blocker (L-NAME 20 mg/kg i.p.) Results: MT and tryptophan accelerated
dose-dependently the ulcer healing, while increasing GBF. At the mRNA level the expression
of NAT and MT-2 receptor was significantly upregulated in ulcerated mucosa as compared
with non-ulcerated mucosa. The expression of ghrelin and iNOS was strongly upregulated
in ulcerated than in intact mucosa and this effect was further enhanced by MT as compared
to that in Trp group. The expression of IL-1β and TNFα was significantly increased at day
0 and decreased at day 8 after ulcer induction. The decrease in the IL-1β and TNFα
expression was more pronounced in MT and Trp-treated rats than in vehicle-treated controls.
Denervation of sensory nerves or use of L-NAME significantly attenuated the stimulatory
effect of MT on ulcer healing. COX-2 was upregulated in ulcerated mucosa as compared
with intact mucosa but MT and Trp failed to influence significantly the expression of this
enzyme. Conclusion: Exogenous MT and that derived from its precursor Trp accelerate ulcer
healing in rat through local activation of MT receptors in the ulcer area and an increase in
GBF and release of protective factors such as ghrelin, NO and CGRP from sensory nerves
and decrease of anti-inflammatory cytokines.
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M1907
Interaction Between Nitric Oxide (NO) and Prostaglandins (Pgs) in the
Regulatory Mechanism of Gastric HCO3- Secretion in Mouse Stomachs In Vitro
Kazutomo Kita, Eitaro Aihara, Koji Takeuchi
Background & Aims: Gastric HCO3- secretion is stimulated by PGE2 and NO, mediated
intracellularly by Ca2+ (via the activation of EP1 receptors) and cGMP, respectively. We
recently reported that gastric HCO3- response to NOR-3, a NO donor, was regulated by
the phosphodiestrase (PDE) isozymes of 1 and 5, while the response to PGE2 was not,
suggesting the independent pathway for NO and PGs in stimulation of HCO3- secretion.
However, it is known that NO released locally in response to acid increased HCO3- secretion
in the duodenum by stimulating PGE2 generation. It is thus assumed that NO stimulates
HCO3- secretion also in the stomach through interaction with PGs. To investigate the
interaction of NO/cGMP pathway and PGE2/Ca2+ pathway, we examined in the present
study the effects of indomethacin and EP1 antagonist on gastric HCO3- response induced
by NOR-3 or 8-Br-cGMP in mouse stomach In Vitro. Methods: The gastric mucosa of male
DDY mice, stripped of the muscule layers, was mounted on an Ussing chamber and bathed
in saline gassed with 100% O2 on the mucosal side and HCO3—Ringer's solution gassed
95% O2/5% CO2 on the serosal side. HCO3- secretion was measured at pH 7.0 using a
pH-stat method and by adding 2 mM HCl. NOR-3 (3x10-4~10-3 M) and 8-Br-cGMP (10-
5~10-3 M) were added to the serosal side. Methylene blue (guanylate cyclase inhibitor: 10-
4 M), vinpocetine (PDE1 inhibitor: 10-6 M), zaprinast (PDE5 inhibitor: 10-6 M), ONO-8711
(EP1 antagonist: 10-6 M) or indomethacin (10-5 M) was added serosally 30 min before the
addition of NOR-3 or 8-Br-cGMP. Results: Both NOR-3 and 8-Br-cGMP stimulated HCO3-
secretion in a dose-dependent manner. The HCO3- stimulatory effect of NOR-3 was accom-
panied by an increase of mucosal cGMP levels, and these responses were both significantly
inhibited by pretreatment of methylene blue. In addition, the HCO3- responses induced by
NOR-3 and 8-Br-cGMP were significantly attenuated by ONO-8711 as well as indomethacin
and markedly potentiated by both vinpocetine and zaprinast at the doses that had no effect
by themselves on basal secretion. NOR-3 increased the mucosal PGE2 content in a methylene
blue-inhibitable manner. On the other hand, gastric HCO3- response to PGE2 was completely
abrogated by ONO-8711, the EP1 antagonist, but not affected by either indomethacin or PDE
inhibitors. Conclusions: These results suggest that NO stimulates gastric HCO3- secretion
essentially mediated intracellularly by cGMP and modified by both PDE1 and PDE5, and
this response is finally mediated by endogenous PGE2 via the activation of EP1 receptors.
M1908
Aggravation of Stress- and Indomethacin-Induced Erosions After
Administration of Pharmacological Doses of Glucocorticoids Could Be Due to
Inhibition of the Acute Endogenous Corticosterone Release in Response to the
Ulcerogenic Stimuli
Ludmila Filaretova, Tatiana Podvigina, Tatiana Bagaeva, Ol'ga Morozova, Akiko Tanaka,
Koji Takeuchi
Background/Aim: Our previous findings suggest that glucocorticoids produced in response
to acute stress play as the gastroprotective but not ulcerogenic hormones, challenging the
generally accepted idea that these hormones cause deleterious influences in the stomach.
The present study was designed to verify a hypothesis that the deleterious effect of glucocort-
icoids at pharmacological doses on the gastric ulcerogenic response could be due to inhibition
of acute release of endogenous glucocorticoids in response to ulcerogenic stimuli. Methods:
Gastric erosions were induced by stress (3 h cold-restraint or water immersion plus restraint)
or indomethacin (35 mg/kg, SC) in male Sprague Dawley rats after 24 h fasting. The effects
of cortisol at pharmacological dose (300 mg/kg, IP) on stress- or indomethacin-induced
gastric erosions and corticosterone production were investigated 1 or 4 weeks after the
hormone administration. We started the experiments 1 week after cortisol administration
because in this time exogenous cortisol has already been eliminated. CRF-41 content in
median eminence, blood plasma ACTH level and gastric prostaglandin (PG) content were also
estimated 1 week after cortisol administration. Plasma corticosterone levels were measured by
fluorometry. CRF-41 contents and ACTH levels were evaluated using RIA kits. The concentra-
tion of PGE2 was measured using a PGE2 enzyme immunoassay kit. Results: Both stress
and indomethacin caused plasma corticosterone rise, but these responses were almost totally
prevented in cortisol pre-treated rats 1 week after the treatment. The results of CRF-41 and
ACTH measurements suggest that the deficient corticosterone response observed in this time
could be due to inhibition of hypothalamic-pituitary adrenocortical (HPA) axis on the
hypothalamic and pituitary levels. One week after cortisol pre-treatment the severity of
stress- or indomethacin-induced gastric erosions was significantly aggravated, and this
aggravation was prevented by an acute corticosterone replacement (4 mg/kg, SC), mimicking
the stress-induced corticosterone rise. Four weeks after cortisol pre-treatment when the
recovery of HPA axis activity with consequent normal corticosterone increase in response to
ulcerogenic stimuli was observed, aggravation of the severity of gastric erosions disappeared.
Gastric PGE2 content remained unchanged 1 week after cortisol administration. Conclusions:
These results suggest that inhibition of HPA axis with consequent deficient corticosterone
production may be one of the reasons for the aggravation of stress- and indomethacin-
induced erosions after administration of pharmacological doses of glucocorticoids.
M1909
Role of Prostaglandins (PG), Nitric Oxide (NO) and Lipid Peroxidation in the
Gastroprotective and Ulcer Healing Activities of 1-Methylnicotinamide (Mna)
Slawomir Kwiecien, Tomasz Brzozowski, Peter C. Konturek, Zbigniew Sliwowski, Stefan
Chlopicki, Ewa Slonimska, Jerzy Gebicki, Stanislaw J. Konturek, Wieslaw W. Pawlik
1-methylnicotinamide (MNA), the liver metabolite of nicotinamide (vitamin B3) that was
hitherto considered as biologically inactive has been recently shown to exhibit antiinflammat-
ory and antithrombotic properties. Here we analyzed the ability of MNA to influence gastric
mucosal defense and ulcer healing in rats. For the purpose rats were pretreated 30 min
prior to exposure to 75% ethanol with 1) vehicle (saline), 2) MNA (2.5 - 200 mg/kg i.g.)
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and 3) nicotinamide (NA, 2.5 - 200 mg/kg i.g.) with or without the combined treatment
with a non-selective COX or NOS inhibitor; indomethacin (5 mg/kg i.p.) or L-NNA (20 mg/
kg i.p.). In chronic study, rats with preexisting gastric ulcers induced by serosal application of
acetic acid (ulcer area=28 mm2) were treated daily with MNA (50 mg/kg i.g.) without or
with concurrent treatment with indomethacin or L-NNA. The area of gastric lesions was
measured by planimetry, the gastric blood flow (GBF) determined by H2-gas clearance
technique. Myeloperoxidase (MPO), superoxide dismutase (SOD) activities in gastric tissue,
the concentration in plasma of malonyldialdehyde (MDA) as an index of lipid peroxidation,
and MNA and its metabolites (met-2PY and met-4PY) as well as proinflammatory cytokines
(IL-1β, TNF-α) and expression of COX-1-, COX-2-, IL-1β-, and TNF-α mRNAs were also
determined. Ethanol caused multiple gastric lesions and reduced significantly GBF and SOD
activity, while increasing MPO activity and MDA content by 2-3 folds over basal and these
effects were significantly reduced by MNA, but not by nicotinamide (NA). The protective
activity of MNA was accompanied by a significant elevation of plasma levels of MNA and
its metabolites (met-2PY and met-4PY). MNA markedly attenuated the expression and
concentration in plasma of IL-1β and TNF-α and these effects were counteracted by indo-
methacin and L-NNA. The 8-day treatment with MNA accelerated ulcer healing and signific-
antly raised GBF at ulcer margin and these effects were accompanied by the attenuation of
MDA content and downregulation of mRNA expression for TNF-α and IL-1β and a fall in
their plasma levels. Concomitant treatment with indomethacin or L-NNA reversed the MNA-
induced reduction in the area of gastric ulcer and significantly raised the mucosal MPO and
MDA contents. We conclude that MNA affords protection against acute gastric lesions
induced by ethanol and accelerates healing of preexisting gastric ulcers possibly due to the
enhancement in the gastric microcirculation that is mediated by COX/PG and NOS/NO
systems, and subsequent attenuation of oxidative stress and inflammation in gastric tissue.
M1910
Stimulation By Coca-Cola of Gastroduodenal HCO3- Secretion in Rats
Yoko Sasaki, Eitaro Aihara, Koji Takeuchi
Background/Aims: The proximal duodenum is exposed to extreme elevation of PCO2 because
of the continuous mixture of secreted HCO3- with gastric acid. It is known that luminal
CO2 diffused into the duodenal epithelial cells, where it was converted into carbonic acid,
then dissociated into H+ and HCO3- by catalysis of carbonic anhydrase (CA). Coca-Cola,
one of the most famous carbonated beverages, is consumed up to a billion cups daily in
around 200 countries. It is interesting to test whether Coca-Cola and other carbonated
beverages increase HCO3- secretion in the gastroduodenal mucosa, just as the high CO2
solution does. In the present study, we examined the effect of various carbonated beverages,
especially Coca-Cola, on HCO3- secretion in the rat stomach and duodenum and investigated
the involvement of CA and prostaglandins (PGs) in the mechanism of these responses.
Methods: Male SD rats were used after 18 h fasting. Under urethane anesthesia, a chambered
stomach (in the presence of omeprazole) or a proximal duodenal loop was perfused with
saline, and HCO3- secretion was measured at pH 7.0 using a pH-stat method. Coca-Cola
was applied topically to a chambered stomach or a duodenal loop for 10 min. Acetazolamide
(an inhibitor of CA; 100 mg/kg), indomethacin (5 mg/kg) or L-NAME (a NOS inhibitor;
20 mg/kg) was given SC 1 h or 3 h before the treatment. The mucosal PGE2 contents were
determined by EIA. Results: The amount of CO2 contained in Coca-Cola was 7.1 g/L CO2
and pH 2.2 while that of other beverages (sparkling water, Fanta Grape or cider) was about
4~7 g/mL. Coca-Cola topically applied to the mucosa significantly increased HCO3- secretion
in both the stomach and the duodenum. The HCO3- response in the duodenum was totally
abolished by indomethacin and partially inhibited by acetazolamide. Likewise, the response
in the stomach was also markedly inhibited by either acetazolamide or indomethacin. The
HCO3- stimulatory effect of Coca-Cola was also partially mitigated by sensory deafferentation.
On the other hand, the acid-induced gastroduodenal HCO3- secretion was significantly
inhibited by indomethacin but not by acetazolamide. Mucosal application of Coca-Cola
increased PGE2 contents in both the stomach and duodenum. Other carbonated beverages
also increased the HCO3- secretion in these tissues. Conclusions: These results suggest that
Coca-Cola, like other carbonated beverages, stimulates HCO3- secretion in both the stomach
and duodenum, and these responses may be attributable to both the intracellular supply of
HCO3-, by the aid of CA, and endogenous PGs, probably related to the acidic pH of
the solution.
M1911
Stimulation By Mustard and Horseradish of Gastric HCO3- Secretion in Rats
Yoko Sasaki, Nahoko Izumi, Eitaro Aihara, Shusaku Hayashi, Koji Takeuchi
Background & Aims: Mustard (Karashi) and horseradish (Wasabi), sharing the common
taste of pungency, are structurally related to the isothiocyanate moiety. A recent study
showed that allyl isothiocyanate activates the transient receptor potential subtype A1 (TRPA1),
a member of the TRP ion channel family, and is known to be one of 6 thermo-receptors
activated at around 17°C, the temperature reported as being painfully cold for humans. It
is also known that TRPA1 is invariably co-expressed with TRPV1, the receptor for capsaicin.
We previously reported that capsaicin stimulated both HCO3- secretion and gastric mucosal
blood flow (GMBF) mediated by TRPV1 in the rat stomach. In the present study, we
examined the effect of Karashi and Wasabi on gastric HCO3- secretion and MBF in rats
and investigated the mechanisms involved in these responses. Methods: Male SD rats were
used after 18 h fasting. Under urethane anesthesia, the stomach was mounted on an ex-
vivo chamber and perfused with saline. Acid secretion had been inhibited by omeprazole
(60 mg/kg) given IP. Under these conditions, gastric HCO3- secretion was measured using
a pH-stat method, while GMBF was determined by a laser Doppler flowmeter. Karashi (10-
100 mg/kg), Wasabi (10-100 mg/kg) or allyl isothiocyanate (TRPA1 agonist; 0.3-3 mg/kg)
was applied topically to the chamber for 10 min. Indomethacin (5 mg/kg, SC), an inhibitor
of prostaglandin (PG) biosynthesis or NG-nitro-L-arginine methyl ester (L-NAME: 20 mg/
kg, SC), an inhibitor of nitric oxide (NO) synthesis, was given 30 min or 3 h before
the treatment of the above agents, respectively. Results: Either Karashi, Wasabi or allyl
isothiocyanate increased both the secretion of HCO3- and GMBF in the stomach in a dose-
dependent manner, and among them the effect of Karashi was most potent. The increase
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in the HCO3- secretion and GMBF induced by Karashi was significantly attenuated by prior
administration of indomethacin and L-NAME and partially mitigated by chemical ablation of
capsaicin- sensitive afferent neurons. Mucosal PGE2 content in the stomach was significantly
increased by topical application of Karashi. Neither HCO3- secretion nor GMBF was affected
by the application of saline adjusted at 17°C. The expression of TRPA1 mRNA and protein
was confirmed in the rat stomach. Conclusions: These results suggest for the first time that
the TRPA1 agonists, such as Karashi and Wasabi, stimulated both the secretion of HCO3-
and GMBF in the rat stomach. It is assumed that these responses essentially occur through
the interaction with TRPA1 on capsaicin-sensitive afferent neurons and also are mediated
by endogenous PGs and NO.
M1912
Dual Action of Nitric Oxide in the Pathogenesis of Ischemia/Reperfusion-
Induced Mucosal Injury in Mouse Stomachs
Atsushi Kobata, Tohru Kotani, Kikuko Amagase, Shinichi Kato, Koji Takeuchi
Background/Aims: The nitric oxide (NO) synthase (NOS), the enzyme responsible for generat-
ing NO, exists in two isoforms; cNOS is expressed constitutively in various tissues, including
the stomach, while iNOS is expressed in few tissues but rapidly induced in response to
cytokines. Recent studies showed the involvement of NO in the pathogenesis of gastric
lesions induced by ischemia-reperfusion (I/R), yet the results are not without controversy;
some studies suggested the beneficial effect while others showed the deleterious effect. In
the present study, we investigated the roles of NO/NOS isoforms in the pathogenesis of I/
R-induced gastric injury in mouse stomachs. Methods: Male C57BL/6 (WT) mice were used
after 18 h fasting. Under urethane anesthesia, the celiac artery was clamped (ischemia), and
then reperfusion was established 30 min later by removal of the clamp. After a 60 min-
reperfusion, the stomach was excised, and the area of macroscopic lesions was assessed. L-
NAME (a non-selective NOS inhibitor) was given SC 30min before ischemia or IP 5 min
before reperfusion, while 1400W (a selective iNOS inhibitor) was given SC 30 min before
ischemia. In some cases, L-arginine was given IP 60 min before ischemia. Expression of
NOS mRNAs was determined by RT-PCR. Levels of NO in the mucosa were measured by
Greiss method. Results: Following I/R, multiple hemorrhagic lesions were induced in the
gastric mucosa of WT mice, although ischemia alone caused no visible damage. Prior
administration of L-NAME significantly increased the severity of these lesions, in a L-arginine-
inhibitable manner. By contrast, pretreatment with the selective iNOS inhibitor 1400W
significantly and dose-dependently prevented the occurrence of I/R-induced gastric lesions.
Of interest, later treatment with L-NAME, given 10 min before reperfusion, significantly
reduced the severity of I/R-induced gastric lesions, and this effecrt was again reversed by
co-administration of L-arginine. The expression of iNOS mRNA was markedly up-regulated
in the gastric mucosa following I/R, with an increase in the mucosal NO content, and the
increased NO production was totally attenuated by L-NAME and partially mitigated by
1400W. Myeloperoxidase (MPO) activity was increased in the gastric mucosa after I/R, and
this response was significantly enhanced or attenuated by prior administration of L-NAME
or 1400W, respectively. Acid secretion showed no difference among the groups. Conclusions:
These results suggest that endogenous NO play a dual effect in the pathogenesis of IR-
induced gastric lesions; NO derives from nNOS is protective while NO derived from iNOS
is proulcerogenic in the stomach during I/R.
M1913
Importance of Prostacyclin/IP Receptors in Maintenance of Mucosal Integrity
of Mouse Stomachs Under Cold-Restraint Stress Conditions
Yuka Takahira, Nahoko Izumi, Akiko Tanaka, Koji Takeuchi
Background/Aims: Endogenous prostaglandins (PGs) play an important role in maintaining
the gastric mucosal integrity under stress conditions, yet the roles cyclooxygenase (COX)
isozymes/PGs and prostanoid receptors play in the mucosal protection under stress conditions
remain still unexplored. Recently, we devised a simple method to produce gastric lesions
in mice under cold-restraint conditions and demonstrated that multiple hemorrhagic lesions
developed in a short time at an incidence of 100%. In the present study, we investigated
using this model the roles of COX isozymes/PGs and their receptors (subtype) in the mucosal
defense against stress-induced gastric lesions. Methods: Male C57BL/6 wild-type mice, those
lacking EP1-, EP3- or IP-receptors as well as those lacking COX-1 or COX-2 were used
after 18 h fasting. The animals were restraint in ballman cages and kept in cold room at
10°C for 90 min. Indomethacin (a non-selective COX inhibitor), SC-560 (a selective COX-
1 inhibitor) or rofecoxib (a selective COX-2 inhibitor) was given PO 60 min before the
onset of stress while PGE2 or iloprost, the analogue of prostacyclin (PGI2), was given IV
10 min before indomethacin. Expression of mRNAs was examined by RT-PCR. Results: Cold
restraint stress (10°C, 90 min) induced multiple hemorrhagic lesions in wild-type mice
stomachs. The severity of these lesions was significantly aggravated by pretreatment of
indomethacin or SC-560 but not rofecoxib, resulting in an increase in the lesion score with
enhanced bleeding. Likewise, the development of these lesions was significantly increased
in the animals lacking COX-1 but not COX-2. The expression of COX-2 mRNA was not
detected in the stomach following stress while the COX-1 expression was observed under
normal and stressed conditions. On the other hand, the gastric ulcerogenic response to cold-
restraint stress was similarly observed in EP1- or EP3-knockout animals, as compared to
wild-type mice, but significantly worsened in the animals lacking IP-receptors. Pretreatment
of wild-type animals with iloprost significantly prevented the stress-induced gastric lesions
in the absence and presence of indomethacin. PGE2 also reduced the severity of these
lesions, yet the effect was much less pronounced than that of iloprost. Conclusions: These
results suggest that endogenous PGs derived from COX-1 play a crucial role in gastric
mucosal defense during cold-restraint stress, and this action is mainly mediated by PGI2
through the activation of IP receptors.
M1914
Diffusion Barriers in the Mounted, Stripped Mouse Duodenum
Maggie Ham, Tetsu Takeuchi, Misa Mizumori, Paul H. Guth, Eli Engel, Jonathan D.
Kaunitz, Yasutada Akiba
Chambered muscle-stripped intestine has long been used to measure transmucosal solute
flux and current. Intestinal villous rather than planar architecture, combined with leaky
intercellular junctions may confound the polarity of the effects of apically or serosally
perfused compounds. We hypothesized that diffusion barriers exist between the serosal
solution and villous epithelium, impeding access of solutes to the villous cell. We thus
examined the effects of apically or serosally perfused ion transport inhibitors and acid stress
on villous cell intracellular pH (pHi), and the diffusion of compounds into the villous core
in mounted, stripped mouse duodenum. Stripped mouse duodena were mounted in two-
sided perfusion chamber designed for fluorescence microscopy. Villous tip cell pHi was
measured with BCECF. The selective Na+/H+ exchanger-1 (NHE1) inhibitor zoniporide (10
µM), the nonspecific NHE1 inhibitor dimethylamiloride (DMA, 0.1 mM), or the anion
exchanger inhibitor DIDS (1 mM), and pH 6.4 high CO2 solution were alternately perfused
in the apical and serosal hemichambers. Diffusion of compounds from serosal perfusate to
the villi was assessed with a cell-impermeant dye, 5,6-carboxyfluorescein (CF). Villous cell
pHi was constant during serosal perfusion of a gassed pH 7.4 CO2/HCO3- buffer for ~15
min followed by gradual pHi decrease, concurrent with visible villous cell damage. Histology
confirmed intact villous structure after a 10 min perfusion and severely damaged, sloughed
villi after 60 min. Apical high CO2 solution rapidly acidified the villous cells with pHi
recovery after its removal. Apical zoniporide enhanced the CO2-induced acidification. Serosal
zoniporide, DMA or DIDS failed to alter CO2-induced acidification; serosal high CO2 buffer
acidified the villous cells. Serosal 5-HT (0.1 mM) rapidly acidified the cells via a tetrodotoxin-
sensitive mechanism. Serosal CF (10-100 µM) stained the crypt area, but not the villi or
villous cells, as confirmed by corresponding frozen sections, even though fluorescence leakage
from serosal to apical solution was time- and dose-dependent. In contrast, iv CF quickly
stained the villous core in mouse duodenum In Vivo, with interstitial staining of the entire
mucosa. Serosal solutes in stripped duodenal preparations are likely to only diffuse as far
as crypt cells and thus will have little direct effect on villous cells due to little diffusional
access to the villous cell basolateral membrane. In contrast, rapid villous cell responses to
serosal solutes are best explained by neural reflexes. Limited viability of the villous cells
further limits long-term, villous cell functional studies in this preparation.
M1915
Novel Function of Stress-Inducible Tra2 Beta mRNA Isoform Including Exon 2
Tomoko Kawai, Keiko Takeo, Kiyoshi Masuda, Kumiko Tominaga, Kensei Nishida, Atsuo
Sekiyama, Shigetada Teshima-kondo, Keiya Nakamura, Kazuhito Rokutan
Transformer beta 2 (Tra2 beta) is known an alternative splicing regulator. We found that
acute stress specifically induced a splicing variant mRNA isoform containing exon 2 in rat
gastric mucosa. The exon 2 has multiple stop codons; therefore, wild functional Tra2 beta
protein is not translated from this mRNA isoform. The tra2 beta mRNA has a substitute
initiation codon that is encoded in exon 4, and a truncated N-terminal-deficient Tra2 beta
protein is considered to be translated from the stress-inducible, exon 2-containing mRNA
variant. However, the presence of exon 2 leads to preferentially inhibit the use of the
substitute initiation codon encoded in exon 4 and does not increase the truncated Tra2 beta
protein. These results strongly suggest the novel function of the stress-inducible tra2-beta
mRNA isoform containing exon 2. First, we examined whether the phenomenon observed
in rats exposed to acute stress was reproducible In Vitro using a human gastric cancer cell
line (AGS cells). AGS cells constitutively expressed low levels of the splicing variant tra2
beta mRNA isoform including exon 2. When AGS cells were exposed to arsenite or hydrogen
peroxide, the cells specifically induced the splicing variant isoform more than 5-fold with
a peak at 2 h after the treatment, while the level of wild Tra2 beta protein was not changed
during the oxidative stress. Next we knocked down the tra2 beta mRNA using several siRNA
sequences targeting exon 2 or exon 3. When one of exon 2-targeted siRNAs was introduced
into AGS cells, the cells dramatically increased their size without changing cell number. We
found that the mRNA level of alpha-tubulin, but not beta-tubulin, was increased more than
3-fold in association with enormous increase in alpha-tubulin protein. These cells became
sensitive to the oxidant-induced apoptosis. In contrast, when wild type tra2 beta mRNA
was mainly disrupted using siRNA targeting exon 3, changes in the alpha-tubulin mRNA
level and cell morphology were not observed. Our results suggest that the exon 2 of the
tra2 beta gene that is specifically transcribed under oxidative stress might act as a functional
RNA regulating transcription of distinct genes including alpha-tubulin gene for cell survival
under stressful conditions. Thus, alternative splicing of distinct genes is an important mechan-
ism for adaptation to stressful conditions.
M1916
Mechanisms of Gastroprotective Action of Glucocorticoid Hormones: The
Maintenance of Gastric Mucosal Homeostasis Through the Maintenance of
General Body Homeostasis
Ludmila Filaretova, Tatiana Podvigina, Peter Bobryshev, Tatiana Bagaeva, Akiko Tanaka,
Yoko Omoto, Koji Takeuchi
Background/Aim: Our previous results suggest that glucocorticoids released during acute
activation of hypothalamic-pituitary-adrenocortical (HPA) axis are important gastroprotective
factors, allowing us to re-evaluate the traditional view about their ulcerogenic effect. We also
showed that the gastroprotective action of glucocorticoids may be provided by maintenance of
gastric mucosal blood flow and mucus secretion as well as the attenuation of gastric hypermot-
ility. In the present study we tested the hypothesis that the maintenance of general body
homeostasis by glucocorticoids accounts for their action on the gastric mucosal homeostasis.
Methods: Gastric erosions were induced by stress (cold-restraint or water immersion plus
restraint) or indomethacin (35 mg/kg, SC) in male SD rats after 24 h fasting. The effects
of glucocorticoid deficiency alone or with corticosterone replacement on gastric erosions,
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microcirculation and motility as well as blood glucose levels, arterial blood pressure (BP)
and body temperature (BT) were investigated. Glucocorticoid deficiency was caused by
adrenalectomy (ADX) or pharmacological inhibition of HPA axis 1 week before the onset
of the ulcerogenic stimuli. An In Vivo microscopy technique for the direct visualization of
gastric microcirculation and the analysis of red blood cell (RBC) velocity was employed.
Results: Stress caused gastric erosions with a decrease of RBC velocity, BP and BT. Indometh-
acin produced gastric erosions with an increase in gastric motility, a decrease in RBC velocity
and glucose level. All ulcerogenic stimuli induced plasma corticosterone rise, the event being
prevented by pharmacological inhibition of HPA axis or ADX. Deficiency of corticosterone
aggravated stress- and indomethacin-induced gastric erosions and potentiated the influences
of the ulcerogenic stimulus on both gastric local (microcirculation and motility) and general
parameters (glucose level, BP, BT). All these effects were prevented by acute corticosterone
replacement (4 mg/kg, SC), mimicking the stress-induced corticosterone rise. Conclusions:
The results suggest that 1) the beneficial action of glucocorticoids on gastric mucosal blood
flow may be provided through its beneficial influence on systemic BP, 2) the attenuated
effect of glucocorticoids on gastric hypermotility may be related to their maintenance of
glucose homeostasis, and 3) gastroprotective action of glucocorticoids is functionally associ-
ated with their beneficial influences on maintenance of body temperature. Thus, glucocortico-
ids released during activation of HPA axis may contribute to gastroprotection through their
contribution to general body homeostasis.
M1917
NSAIDs Intake Is a Risk Factor for Gastroesophageal Reflux (GER)
Philippe Ruszniewski, Christine Soufflet, Philippe Barthélemy, Raymond Colin
Background and aim- The implication of NSAIDs in peptic ulcer disease is well established,
but data about the relationship between NSAIDs intake and GER are very limited. The aim
of this study was to determine whether NSAIDs intake was associated with an increased
prevalence of GER symptoms. Methods - A survey was performed in October/November
2005 by TNS Healthcare in a representative sample of 10,000 subjects in the French adult
(> 18 years) population using a self-administered questionnaire. Subjects were asked about
NSAIDs and aspirin (ASA) intake, and the presence of GER symptoms defined as heartburn
and/or acid regurgitation. In order to avoid potential bias, the analysis was also performed
excluding patients currently receiving PPIs. Logistic regression was performed to search for
potential risk factors associated with GER symptoms in patients not receiving PPIs or ASA
daily. Results- The questionnaire was returned by 72.6% of the population. 6,823 subjects
(females 52% , mean age 48±18 years) were evaluable for NSAID intake and assessment of
reflux symptoms. 2,501 subjects (37%) had experienced reflux symptoms at least once,
1,463 of whom (21%) during the last 3 months. 2,262 (33%),166 (4%),and 781 (11%)
subjects had received NSAIDs, daily ASA (for cardiovascular purpose, 83%) and PPIs within
the last 3 months, respectively. Among subjects with NSAIDs intake, 50% of them received
NSAIDs for 6 days or less during the last 3 months, and 21 % for one to two weeks. The
most frequent NSAIDs were arylcarboxylic (81%), fenamates (15%), oxicam (13%) and cox-
2inhibitors (4%). The prevalence of GER symptoms was significantly higher among subjects
older than 65 years (27%), as compared with those between 45-64 years (22%) and 18-44
years (19%, p<0.01), and in females (23 vs 20%, p<0.01). Prevalence of GER symptoms
during the last 3 months in subjects taking/not taking NSAIDs was 27 and 19% respectively
(OR = 1.6, p<0.01). Corresponding figures excluding patients receiving PPIs were 23 and
15% respectively (OR = 1.65, p<0.01).Similar findings were observed in subjects receiving
ASA daily (28 vs 21%, OR = 1.45, p<0.05). Logistic regression identified 3 independent
factors associated with the presence of GER symptoms : NSAID intake (OR = 1.6), age >
65 years (OR = 1.3) and female gender (OR = 1.2). Conclusion- NSAID intake during the
last 3 months is associated with an increased prevalence of reflux symptoms. A similar
pattern is observed with daily ASA intake.
M1918
Risk of Upper Gastrointestinal Complications Among Users of Antithrombotic
and Anticoagulant Agents
Luis A. García rodríguez, Angel Lanas
Bakground and Objective: The use of antithrombotic or anticoagulant agents, alone or in
combination with other drugs, is being increasingly used in clinical practice. Here we report
on the relative risk of non-variceal upper gastrointestinal complications (UGIC) among
patients taking these drugs alone or combined with others that have been associated with
an increased risk of ulcer bleeding. Design: We conducted a nested case-control study using
The Health Improvement Network (THIN) database in the United Kingdom identifying
1,561 cases of UGIC between Jan 2000 and 2005. A random sample of 10,000 controls
was frequency matched to the cases by age, sex, and calendar year. We analysed these
data using multivariate methods controlling for all known potential confounders. Results:
Estimates of adjusted relative risks of UGIC were 1.9 (95% CI: 1.6 to 2.1) for low dose
aspirin, 1.3 (0.8-2.0) for clopidogrel, 0.9 (0.5-1.5) for dipyridamole, 1.9 (1.5 to 2.5) for
warfarin, and 1.4 (1.1-1.9) for oral steroids. Use of low-dose ASA plus clopidogrel was
associated with a RR of 2.0 (95% CI: 1.0-4.3) whereas the RR for the combination of ASA
plus dypridamol was 0.9 (95% CI: 0.4-2.0) and low-dose aspirin plus steroids was 3.0 (95%
CI: 1.8-5.1). The RR of UGIC associated with current use of warfarin plus low-dose aspirin
was 4.8 (95% CI: 2.7-8.6) and 2.0 ( 95% CI: 0.2-20.8) for the combined use of warfarin
and COX-2 selective inhibitors, whereas concomitant use of warfarin plus traditional NSAIDs
was associated with the highest RR of UGIB 13.5 (95% CI: 5.1-35.8). Conclusions: The use
of antithrombotic and anticoagulant agents alone increased slightly the risk of UGIC and
yielded similar RRs of UGIC between them. Combination of these drugs, including coxibs
plus warfarin, do not result into a substantial increase of the risk of UGIB (this latter based
on relatively limited information). However, the combination of traditional NSAIDS plus
warfarin was associated with a marked increased risk of UGI
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M1919
The Clinical and Economic Effects of Proton-Pump Inhibitor Co-Therapy in
Patients On Long-Term, Low-Dose Aspirin
Sameer D. Saini, Mark Fendrick, James Scheiman
Background: The cardiovascular (CV) benefit of long-term, low-dose aspirin (ASA) in patients
with known CV disease is well-established. Despite this proven benefit, ASA utilization rates
remain suboptimal. Of patients who are prescribed ASA after an acute CV event, approxim-
ately 25% will discontinue the drug within one year. The reasons for this non-adherence
include ASA-related adverse effects, such as upper gastrointestinal bleeding (UGIB) and
dyspepsia. Co-therapy with a proton-pump inhibitor (PPI) can mitigate these adverse effects,
improving GI outcomes by reducing UGIB-related complications and improving CV outcomes
by reducing dyspepsia-related ASA non-adherence. However, no study has investigated the
GI and CV benefits of PPI co-therapy in long-term, low-dose ASA users. Methods: A Markov
model was developed to compare the clinical and economic effects of low-dose ASA alone
versus low-dose ASA plus PPI. The published literature was used to estimate risks, benefits,
and costs. The target population was men and women over the age of 50 requiring ASA
indefinitely for secondary prevention of CV disease. The base-case assumptions (and ranges
for sensitivity analysis) were: (1) annual per patient cost of PPI: $250 (range $250-$1000);
(2) dyspepsia-related ASA non-adherence: 5% per year (1%-10%); and, (3) effectiveness of
PPI in controlling dyspepsia (relative risk reduction): 75% (25%-75%). Outcomes measured
included UGIB events, CV events, and ASA adherence rates. Results: In the base-case analysis,
ASA plus PPI compared to ASA alone resulted in fewer lifetime UGIBs (4.8% vs 7.1%),
fewer CV deaths (68.9% vs 69.0%), and an absolute increase in ASA adherence of 7%. ASA
plus PPI was more costly than ASA alone, with an incremental cost-effectiveness ratio (ICER)
of $23,000 per life-year saved (LYS). These results were highly sensitive to: (1) the cost of
PPI; and, (2) the rate of dyspepsia-related ASA non-adherence. Specifically, increasing the
annual per-patient cost of PPI from $250 (base) to $1,000 resulted in an ICER of $116,000
per LYS. Varying the annual rate of dyspepsia-related ASA non-adherence from 1% to 10%
resulted in ICERs between $53,000 and $12,000 per LYS. Reducing the effectiveness of PPI
in controlling dyspepsia from 75% to 25% resulted in an ICER of $45,000 per LYS.
Conclusions: PPI co-therapy in patients taking long-term, low-dose ASA has the potential
to be effective in reducing both GI and CV events and is highly cost-effective provided that
PPIs are available at current OTC prices. Future studies to better define the impact of PPIs
on ASA-related adverse events and long-term ASA adherence are needed.
M1920
Significant Early Reduction of Ulcer Complications with Lumiracoxib
Compared with Naproxen At Day 8 of Treatment in Target
Christopher J. Hawkey, Wilfred M. Weinstein, Walter E. Smalley, Dominik Richard,
Gerhard Krammer, Peter Sallstig, Bernhard Mellein, Patrice Matchaba
Introduction The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET)
demonstrated a 79% reduction in upper gastrointestinal (GI) ulcer complications with
lumiracoxib vs nonsteroidal anti-inflammatory drugs (NSAIDs) (naproxen or ibuprofen) in
patients with osteoarthritis (OA) who were not taking aspirin, over 52 weeks. Whether a
selective cyclooxygenase-2 (COX-2) inhibitor, such as lumiracoxib, has advantages over a
nonselective NSAID with short-term use is not known. We therefore investigated how early
after the start of treatment a significant benefit of lumiracoxib vs naproxen could be detected.
Methods Patients aged ≥50 years with OA were randomized to receive lumiracoxib 400
mg once daily (od, four times the dose recommended for OA, n=4741) and naproxen 500
mg twice daily (bid, n=4730) for 52 weeks in one of the two sub-studies in TARGET.
Randomization was stratified by age and low-dose aspirin use. The primary endpoint was
the cumulative incidence of independently adjudicated definite or probable upper GI tract
(UGIT) ulcer complications. In this analysis of UGIT ulcer complications we generated
pointwise 95% confidence intervals (CI) for the between treatment differences in Kaplan-
Meier estimates (KMEs). Results Based on the upper 95% CI for the difference in KMEs
(Fig) the advantage of lumiracoxib vs naproxen occurred as early as Day 8 of treatment and
was maintained until end of study. Conclusions Lumiracoxib appears to have GI safety
advantages over naproxen even when given in the short term. The significant long-term GI
safety advantage has been demonstrated previously.
A-414AGA Abstracts
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Rapid Protection (<24 Hours) By rabeprazole Againist Aspirin-Induced
Gastroduodenal Mucosal Injury
Robert S. Fisher, Benjamin Krevsky, Shayan Irani, Jane Kim-jaffe
Introduction: Therapeutic doses of aspirin (ASA) can cause gastroduodenal lesions and
bleeding soon after initiation of therapy. Although regular dose proton pump inhibitors can
prevent or heal ASA and other NSAID-induced lesions, there are no data about the speed
of onset of these protective effects. Aim: To determine whether oral rabeprazole, administered
5 hours before the initiation of therapeutic dosing of ASA (650 mg, q4 hours), protects the
gastroduodenal mucosa from damage within 24 hours. Protocol: Normal subjects were
randomized into two groups—one received rabeprazole, 20 mg at 0700 hours, before
initiation of ASA at 1200 hr, and once daily for 3 days(n=15; 4 females, 11 males; 34.5±2.2
yr; BMI 26.8±1.1) and the other group received placebo at 0700 hr, before initiation of
ASA at 1200 hr, and once daily for 3 days (n=15; 5 females, 10 males; 31.9±2.0 yr; BMI
24.8±1.0). Serum salicylate levels were measured at baseline, 24, 48 and 72 hours after
initiating ASA. Upper endoscopic examinations were performed at baseline, 24 and 72 hours
after initiation of ASA. Gastroduodenal mucosal damage was scored as the number of
submucosal hemorrhages and erosions in endoscopic fields on the anterior and posterior
walls of the gastric antrum. These data were used to calculate global Lanza scores. Results:
All 30 subjects were compliant with study medications and underwent all three endoscopic
examinations. There were no differences in age, sex or BMI between study groups. Throughout
the study, serum salicylate concentrations were similar for both placebo and rabeprazole
groups at all times (baseline: <4 vs <4; 24 hr: 9.0±1.5 vs 10.1±1.4; 72 hr: 13.8±2.4± vs
14.0±2.2 mg%; all p>.05. Rabeprazole had a protective effect against submucosal hemor-
rhages and erosions in the antrum. Lanza scores were significantly lower with rabeprazole
compared to placebo at 24 hr: (1.33±0.26 vs 2.13±0.2, p<.05) and at 72 hr: 1.33±0.29 vs
2.27±0.28, p<.05). Gastric antral erosion counts were less with rabeprazole than placebo
at 24 hr (4.1±1.3 vs 7.6±2.0 (p>.05)and 72 hr: 5.3±1.8 vs 8.0±1.5; p>.05). Conclusion:
Rabeprazole prophylaxis, initiated only 5 hr before the start of therapeutic dosing with ASA
decreased the global Lanza scores and antral erosion counts even at 24 hours. These findings
demonstrate that rabeprazole's protective effects occur within the first 24 hours of initiating
therapy and suggest that prophylaxis with rabeprazole could start concurrently with ASA
administration.
M1922
The Effect of Low Dose, Enteric-Coated Aspirin On the Gastrointestinal
Bleeding in the Patients' Pool of Coronary Artery Disease
Chang kyu Choi, Nayoung Kim, Young soo Park, Jin-hyeok Hwang, Jin-wook Kim, Sook-
hyang Jeong, Dong ho Lee, Hyuk-jae Chang, Young-seok Cho, Woo-young Chung, In-ho
Chae, Dong-ju Choi, Cheol-ho Kim
Background & Aims : Low dose aspirin has been used widely to prevent and treat cardiovascu-
lar disease, but it is controversial whether low dose aspirin is a cause of gastroduodenal
mucosal injury and gastrointestinal bleeding or not. This study was conducted to evaluate
the rate of gastroduodenal mucosal damage and gastrointestinal bleeding in the patients
who had taken low dose enteric coated aspirin and/or clopidogrel after coronary angiography
Patients and methods : The medical records of 387 patients who had had esophagogastroduo-
denoscope after coronary angiography in Seoul National University Bundang Hospital from
May 2003 to Dec. 2005 were reviewed. They were divided into three groups, the patients
who had not taken aspirin or clopidogrel were classified as control group, the patients who
had taken 100 mg low dose enteric coated aspirin every day at least 30 days were classified
as ASA group, and the patients who had taken 100 mg low dose enteric coated aspirin and
75 mg clopidogrel every day at least 30 days were classified as ASA + CLO group. The rates
of the gastroduodenal mucosal injury and gastrointestinal bleeding were analyzed among
these 3 groups. Results : The rates of gastroduodenal mucosal injury such as acute erosive
gastritis, hemorrhagic gastritis, and gasroduodenal ulcer were was significantly higher in the
ASA + CLO group, 57.7% than that in the control group, 29.3% (p=0.001) or that in the
ASA group 42.9% (p=0.012). In addition, that in the ASA group was significantly higher
than that in the control group (p=0.049). The rates of gastrointestinal bleeding were 2.4%
in the control group, 3.8% in the ASA group, and 9.4% in the ASA + CLO group. The rate
of gastrointestinal bleeding in the ASA + CLO group was significantly higher than that in
the control group (p=0.048). The risk factors of the gastrointestinal bleeding were turned
out to be two, old age (p=0.042) and comorbidities of ≥ 2 (p=0.054). Conclusion : Low
dose enteric coated aspirin was safe in the aspect of gastrointestinal bleeding. However,
the addition of clopidogrel on the low dose enteric coated aspirin increased the rate of
gastrointestinal bleeding, suggesting that combined use of clopidogrel with aspirin should
be cautious when old age person with 2 or more comorbidities.
M1923
Insight Into the Mechanism of Indomethacin-Induced GI Injury and Its
Reversal with a Phosphatidylcholine Conjugate
Lenard M. Lichtenberger, Jim Romero, Elizabeth J. Dial
Background: Indomethacin (Indo) is an NSAID that induces gastroduodenal ulceration in
humans and induces intestinal perforation and bleeding in rodent model systems upon
either enteral or parenteral administration. In this study we evaluated the role of biliary
excretion of indomethacin in its mechanism of pathogenesis, and the utility of phosphatidyl-
choline (PC)-associated Indo as a therapeutically effective parenteral NSAID with reduced
GI toxicity. Methods: We employed a number of rodent models in this study including: 1)
bile duct cannulated rats that were administered 14C-labelled Indo either intragastrically or
intravenously; 2) an acute model of NSAID-induced GI bleeding, in which L-NAME (20 mg/
kg, i.p) pre-treated rats were i.v. administered saline, Indo (10 mg/kg) ± PC and euthanized 18
hrs later at which time the intestine was flushed with cold saline and perfusate collected
for hemoglobin (Hb) analysis; and 3) a model of adjuvant- induced joint inflammation, in
which rats were injected (0.1 ml, s.c.) with Complete Freund's Adjuvant (CFA) into the
dorsal surface of their left hindpaw, 4 days later were i.v. injected with saline, Indo (5 mg/
kg) ± PC, and 30 minutes later the pressure pain sensitivity of the affected hindpaw was
assessed. Upon euthanasia, the synovial fluid was collected for PGE2 radioimmunoassay
and plasma was collected for Indo analysis by HPLC. Results: > 85% of the labelled Indo
enters the bile within 2 hrs regardless of the route of administration. Indo acutely induces
severe GI bleeding after i.v. administration (4.2±0.82 mg/ml Hb) in comparison to control
rats (0.1±0.1 mg/ml Hb) (p<0.001) which was markedly reduced in rats that were i.v
administered an equivalent dose of Indo/PC (0.48±0.1 mg/ml Hb, p< 0.001). Indo/PC had
comparable bioavailability and therapeutic efficacy to Indo, based upon HPLC analysis of
plasma and its ability to significantly (vs values of saline-treated controls): increase the pain
pressure threshold; and inhibit the PGE2 conc of the CFA-injected inflamed joint. Conclusion:
Indo rapidly enters the bile after either i.v. or intragastric administration reinforcing the
importance of this enterohepatic pathway in Indo-mediated GI ulceration and bleeding. PC-
associated Indo appears to be a GI safe and therapeutically effective parenterally adminis-
tered NSAID.
M1924
Role of Disruption of the Surface Hydrophobic Barrier in the Mechanism of
Gastric Injury Upon the Combined Use of Aspirin (ASA) with a Selective
COX-2 Inhibitor (Coxib): Reversal with Phosphatidylcholine (PC) - Associated
ASA
Lenard M. Lichtenberger, Jim J. Romero, Elizabeth J. Dial
Background: Clinical studies demonstrate that aspirin consumption reverses the GI benefits
of coxibs, by an undefined mechanism. Methods: Rodent models were employed to investigate
the effects of combinations of celecoxib (Cel, 15 mg/kg) and ASA (40 mg/kg) on gastric
lesion formation, surface hydrophobicity - by contact angle (CA) analysis and ulcer healing.
We also evaluated the effects of PC-ASA in these rodent models and confirmed its cyclooxy-
genase (COX)-inhibitory activity by measuring mucosal PGE2 concentration. Results: ASA's
ability to induce gastric lesions in rats (1.9±1.2 lesions/stomach), is exacerbated in the
presence of Cel (23.9±4.8 lesions/stomach) and is dependent on its ability to reduce gastric
surface hydrophobicity (CA,degrees: controls = 62.6±2.6; ASA = 44.6±4.3; ASA + Cel =
50.1±3.3). In contrast, co-administration of ASA/PC + Cel induced little or no gastric injury
(6.4±2.3 lesions/stomach) and maintained the stomach's hydrophobic properties (67.5±4.4
degrees). Interestingly, ASA and ASA/PC had equivalent efficacy to inhibit gastric mucosal
PGE2 conc to <20% of control levels, which was not affected by the use of Cel. The healing
of acetic acid-induced gastric ulcers was delayed when ASA was used in combination with
Cel vs saline-treated control values (lesion surface area = 45.1±5.4 mm2 vs 28.4±2.3 mm2),
whereas healing rates of rats treated with Cel + ASA/PC (19.9±2.1 mm2) were comparable
to control values. Conclusions: ASA's gastric toxicity in combination with a coxib can be
dissociated from its ability to inhibit COX and appears to be dependent, in part, on its
ability to attenuate the stomach's surface hydrophobic barrier. This adverse drug interaction
between aspirin and coxibs, which impacts the treatment of osteoarthritic and cardiac patients
requiring cardiovascular prophylaxis, can be circumvented by the administration of ASA/PC
to maintain the stomach's hydrophobic properties. (Supported by NIH grant R42DK063882).
M1925
Evidence That NSAIDs Reduce the Critical Micellar Concentration (CMC) of
Bile Acids: A Simple Physico-Chemical Mechanism to Explain the GI Toxicity
of NSAIDs Excreted Into the Bile
Rand Doyen, Elizabeth J. Dial, Lenard M. Lichtenberger
Background: Indomethacin (Indo) and a number of other NSAIDs that possess high toxicity
to the GI and hepato/biliary tract systems are known to be excreted into the bile in high
concentration. Rodent studies have indicated that intestinal injury and perforation can be
prevented if the bile duct is ligated. It is also been demonstrated that Indo can increase the
cytotoxicity of bile acids under In Vitro conditions. In this study we investigated one
mechanism by which the presence of NSAIDs in bile can alter the physico-chemical properties
of bile acids to increase their membrane-disrupting detergent properties, based upon the
amphipathic properties of these two classes of molecules. Methods: In these studies we
investigated the ability of Indo to alter the CMC of a number of unconjugated and conjugated
bile acids. In order to accomplish this aim we used an established fluorometric In Vitro
assay system using the shift in the wavelength of maximal absorption (λmax) of the dye
Rhodamine 6G to determine the CMC of a number of unconjugated and conjugated bile
acids in the presence and absence of 2 mM Indo. Results: The table below, indicates that
in every case tested the presence of Indo induced a significant reduction in the CMC of the
bile acids ranging from 35-80%. It should be noted that Indo in the absence of bile acid,
failed to aggregate into micelles as assessed by this method. Conclusion: Based upon their
amphipathic properties, NSAIDs can form mixed micelles with bile acids, and in doing so
initiate the formation of these potentially toxic membrane- disrupting macromolecules at
concentrations below the normal CMC for the respective bile acids. This simple physico-
chemical change may contribute to the pathogenic mechanism by which NSAIDs excreted
into the bile induce injury to GI and hepato/biliary tract systems.
Bile Acid CMC reduction in the presence of Indomethacin
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M1926
NSAIDs Induce Apoptosis During Gastric Epithelial Cell Injury By Activation
of Pro-Apoptotic Genes in the Bcl-2 Family and TNF(R) Superfamily
Shiun-kwei Chiou
Background: Nonselective NSAIDs such as indomethacin cause gastrointestinal damage.
Apoptosis induction is one of the mechanisms. The molecular pathways of NSAID-induced
apoptosis in a variety of cancers have been examined, but the mechanisms of NSAID-induced
apoptosis in non-neoplastic gastrointestinal injury remain unclear. In this study, we examined
the apoptosis genes that are up- or down- regulated by indomethacin and the sulindac
metabolites, sulindac sulfide (pharmacologically active form) and sulindac sulfone (pharma-
cologically inactive form), and their relationship to cell death and apoptosis. Metabolites
were used since the prodrug sulindac is insoluble in culture medium. Methods: Normal rat
gastric epithelial, RGM-1 cells were cultured in DMEM:F12 medium with 10%FBS, then
serum starved and treated with vehicle only, 0.5mM Indomethacin, 0.5mM sulindac sulfide,
or 0.5mM sulindac sulfone for 4 hours. At this time, cells were collected and total RNA
was extracted for: 1) gene array analysis using a quantitative realtime PCR- based focused
array containing 81 apoptosis related genes, where each treatment was performed in triplicate
arrays for statistical analysis; and 2) validation of genes that are up- or down-regulated by
each treatment, utilizing two different pairs of gene specific primers for each affected gene
in quantitative realtime PCR analyses. After 8 hours of treatment, extent of cell death and
apoptosis were determined by LDH release and FITC labeled annexin V binding assays.
Results: 1) Indomethacin and sulindac sulfide treatments up-regulated death-inducing genes,
including BCL10 (3.03 + 1.01), BAK1(2.76 + 1.3), BID (20.14 + 10.75), death-inducing
DFFA-like effectors CIDEA (11.34 + 6.20) and CIDEB (5.66 + 0.38), TNFRSF10A (5.01 +
1.04), TNFRSF9 (4.31 + 0.93), and TNFSF10 (4.15 + 0.72). Both NSAIDs also down-
regulated TNFRSF25 (7.15 + 2.09). P<0.05 for all data. 2) The changes in gene expression
were confirmed by quantitative realtime PCR analysis. 3) Indomethacin induced 73 + 4.96
% cell death and apoptosis (p<0.05), and sulindac sulfide induced 86 + 2.51 % cell death
and apoptosis (p<0.05). 4) Sulindac sulfone neither altered expression of apoptosis related
genes nor induced cell death and apoptosis. Conclusion: This study shows for the first time
that activation of specific pro-apoptotic genes is associated with NSAID-induced apoptosis.
Thus NSAIDs likely induce gastrointestinal cell injury through up-regulation of pro-apoptotic
genes, many of them in the BCL-2 family and the TNF and TNF Receptor superfamilies.
M1927
Soluble Dietary Fibers Prevent the Formation of Intestinal Lesions Induced By
NSAIDs in Cats
Hiroshi Satoh, Toshiko Hara, Noriko Otsuka
BACKGROUND: It is widely accepted that NSAIDs often cause ulcers not only in the stomach
and duodenum, but also in the small intestine. However, there are few anti-ulcer agents
which can prevent the ulcer formation in the small intestine. We have reported that insoluble
dietary fibers (DF) such as cellulose play an important role in the formation of intestinal
lesions by indomethacin (IM), and that diets with no- or less DF could prevent the lesions
in all of rats, cats and dogs. In the present study, we studied the role of soluble DF in IM-
induced intestinal lesions in cats, and found that soluble DF could prevent the lesions.
METHODS: Both male and female cats (2.5-3.5kg) were used (4 cats in each group). Several
types of diets containing various percentages of soluble and insoluble DF were given to
animals twice a day during the experiment. IM was administered orally once a day after a
morning meal for 3 days. The animals were sacrificed 24 hrs after the final dose of IM, and
mucosal lesions in the small intestine were examined. RESULTS: In cats given dry food
containing 4 % DF, IM (3 mg/kg) produced many lesions in the middle and lower intestine;
The mean lesion areas (MLA) were 7.5±2.6 cm2. The lesions were markedly decreased in
cats given canned diets containing less than 0.4% DF (MLA: 0.1±0.1 cm2, p<0.05). Whereas
the lesions were increased significantly in animals given the canned diet supplemented with
3 or 6% cellulose (insoluble fiber), but not by addition of 3% pectin (soluble fiber). The
MLA were 4.5±2.3 cm2, 12.1±3.6 cm2, 0.1±0.1 cm2, resp. The increase of the MLA with
3% cellulose was completely inhibited by addition of 3% pectin. The addition of pectin (1,
3 and 10%) to the dry food also prevented the intestinal lesion formation by IM in a dose-
dependent manner. The MLA were 1.9±0.9 cm2, 0.6±0.3 cm2, 0.0±0.0 cm2, resp. The
inhibitions by 3 and 10% pectin were significant (p<0.05 vs dry food alone). CONCLUSIONS:
It could be concluded that soluble DF such as pectin can prevent the formation of intestinal
lesions by NSAIDs, probably by protecting the mucosa from aggressive factors such as IM-
induced strong contractions of the intestine, bile acids or intestinal bacteria. As small amount
of pectin (1%) decreased the lesion formation by 75%, pectin could be used as a novel,
safe and useful protective agent on the GI mucosa against adverse effects of NSAIDs.
M1928
The Cyclooxygenase and 5-Lipoxygenase System Can Replace Each Other in
Protecting the Mucosa During Ischemia-Reperfusion of the Rat Stomach
Nadia Sawka, Karlheinz Ehrlich, Bernhard A. Peskar, Brigitta M. Peskar
BACKGROUND: Aggravation of rat gastric damage during ischemia-reperfusion (I/R) induced
by suppression of cyclooxygenase (COX) is prevented by cotreatment with 16,16-dimethyl-
prostaglandin (PG) E2 (Maricic et al., Br J Pharmacol 128, 1659, 1999). Similarly, injury
following inhibition of 5-, 12- or 15-lipoxygenase (LO) is counteracted by administration
of lipoxin (LX) A4 (Sawka et al., Gastroenterology 128, A346, 2005). This indicates that
damage due to reduced formation of protective metabolites can be counteracted by replace-
ment with derivatives of the same system. This study examines whether injury due to
inhibition of COX or LO is antagonized by treatment with a derivative of the other protective
system. METHODS: Male Wistar rats (4-8/group) were fasted overnight and anaesthetized.
The celiac artery was clamped for 30 min followed by reperfusion for 60 min. Then gastric
damage was assessed by calculation of a lesion index (LI). Rats were treated sc 30 min
before I/R with the non-selective COX inhibitor indomethacin (3 mg/kg), the selective COX-
1 inhibitor SC-560 (7.5 mg/kg), the selective COX-2 inhibitor rofecoxib (3 mg/kg) or
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dexamethasone (2 mg/kg) which inhibits COX-2 upregulation during I/R. Other rats were
pretreated ip with LXA4 (2.5 µg/kg) 30 min before dosing COX inhibitors. Further rats
received sc the 5-LO inhibitor MK-886 (5 mg/kg), the 12-LO inhibitor baicalein (10 mg/
kg), the 15-LO inhibitor PD 146176 (10 mg/kg) or the LXA4 receptor antagonist Boc-1 (1
µg/kg) 60 min before I/R. Finally, rats were cotreated with 16,16-dimethyl-PGE2 (2 injections
of 8 ng/kg, sc) 5 min before LO inhibitors or Boc-1 and immediately before I/R. RESULTS:
I/R alone induced negligible damage (LI 4+-0.3). Indomethacin, SC-560, rofecoxib or
dexamethasone significantly (p<0.001 each) increased I/R damage (LI 33+-2, 40+-2, 38+-3
and 39+-2, respectively). LXA4 reversed the effect (LI 4+-1, 4+-1, 4+-3 and 10+-2, respect-
ively, p<0.001 each). MK-886, baicalein, PD 146176 and Boc-1 markedly increased I/R
damage (LI 42+-1, 42+-1, 41+-2 and 42+-2, respectively, p<0.001 each). Cotreatment with
16,16-dimethyl-PGE2 antagonized the ulcerogenic activity of MK-886, baicalein, PD 146176
and Boc-1 (LI 6+-1, 5+-1, 4+-1 and 4+-1, respectively, p<0.001 each). DISCUSSION: 1) I/
R damage induced by inhibition of COX is prevented by co-administration of LXA4. Likewise,
damage evoked by LO inhibitors or Boc-1 is counteracted by cotreatment with 16,16-
dimethyl-PGE2. 2) The findings suggest that the COX and LO systems act in concert to
strengthen the resistance of the gastric mucosa against I/R damage and that suppression of
one protective system can be compensated by the other system.
M1929
Aspirin Induces Gastric Epithelial Barrier Dysfunction By Activating P38 MAP
Kinase Via Claudin-7
Tadayuki Oshima, Takashi Joh, Hiromi Kataoka, Makoto Sasaki, Takayuki Matsumoto,
Hiroto Miwa
Background and Aims: Tight junctions create a paracellular permeability barrier. Non-
steroidal anti-inflammatory drugs cause gastrointestinal injury, including increased gastroin-
testinal permeability. The role of aspirin on the function of gastric epithelial tight junctions,
however, remains unknown. In this study, we examined the effect of aspirin on gastric
mucosal barrier properties and tight junction organization. Methods: Human gastric epithelial
cells, MKN28, were used in this study. Epithelial barrier integrity was measured by trans-
epithelial electrical resistance (TEER) using a volt-ohm meter with ‘chopstick' electrodes
and also by measuring paracellular flux of labeled dextrans. To examine the effects of aspirin
on junctional proteins, were performed immunoblotting and immunofluorescent staining
for tight junction proteins (claudins-2, -3, -4, -5, -7, ZO-1 and occludin). In some experi-
ments, cells were dual-immunostained and analyzed by confocal laser microscopy. Protein
message was analyzed by real-time PCR. The activation of p38 MAP kinase was measured
by phosphospecific western blotting. Kinase activity was investigated using SB203580, (p38
MAP kinase inhibitor), U0126 (MAP kinase kinase (MEK) 1 inhibitor), and SP600125 (c-
Jun N-terminal kinase (JNK) inhibitor). Results: MKN28 cells express claudins-3, -4, -7,
ZO-1, and occludin, but not claudin-2 or -5. Aspirin (5 mM) treatment of gastric epithelial
monolayers significantly decreased TEER, and increased dextran permeability. Both Aspirin-
mediated permeability and phosphorylation of p38 MAP kinase were significantly attenuated
by SB203580 (1 μM), but not by U0126 (1 μM) or SP600125 (1 μM). Aspirin significantly
decreased claudin-7 expression (immunostaining, western blotting and real time PCR).
Interestingly although aspirin did not alter occludin or claudin-3 proteins, it increased their
mRNA. Claudin-4, and ZO-1 expression were not affected by aspirin. Aspirin-induced
claudin-7 degradation and disorganization were completely abolished by SB203580 pretreat-
ment. Conclusions: These results demonstrate for the first time that changes in claudin-7
expression are important in the aspirin-induced gastric barrier loss, and that p38 MAP kinase
activity mediates this epithelial barrier dysfunction.
M1930
Inhibition of Lipoxygenases Or Antagonism of the Lipoxin A4 (Annexin-1)
Receptor Increase the Ulcerogenicity of Anti-Inflammatory Drugs in the Rat
Stomach
Nadia Sawka, Karlheinz Ehrlich, Bernhard A. Peskar, Brigitta M. Peskar
BACKGROUND: Aspirin-triggered formation of 15(R)-epi-lipoxin (LX) A4 via acetylated
cyclooxygenase (COX)-2 or exogenous LXA4 reduce aspirin-induced damage in the rat
gastric mucosa whereas inhibition of COX-2 or blockade of the LXA4 receptor aggravate
aspirin injury (Fiorucci et al., Gastroenterology 123, 1598, 2002). We have shown that
inhibition of 5-, 12- or 15-lipoxygenase (LO) or antagonism of the LXA4 receptor markedly
increase gastric damage during ischemia-reperfusion (I/R) in the absence of aspirin (Sawka
et al., Gastroenterology 128, A346, 2005). In addition, inhibitors of COX-1, COX-2 or
dexamethasone augment I/R damage (Maricic et al., Br J Pharmacol 128, 1659, 1999). This
study examines whether low doses of inhibitors of the LO and COX system that are not
ulcerogenic when given alone, become injurious after simultaneous administration.
METHODS: Male Wistar rats (4-8/group) were fasted overnight and anaesthetized. The celiac
artery was clamped for 30 min. After 60 min reperfusion, gastric damage was assessed by
calculation of a lesion index (LI). The 5-LO inhibitors MK-886 (2.5 mg/kg) or A63162 (2.5
mg/kg), the 12-LO inhibitor baicalein (2.5 mg/kg), the 15-LO inhibitor PD146176 (5 mg/
kg) and the LXA4 receptor antagonist Boc-1 (0.3 µg/kg) were injected sc 30 min after sc
administration of the COX inhibitors indomethacin (1 mg/kg), celecoxib (1 mg/kg), S-
flurbiprofen (1 mg/kg), R-flurbiprofen (1 mg/kg) or dexamethasone (0.5 mg/kg). Thirty min
later, I/R was performed. RESULTS: I/R alone caused negligible damage (LI 4+-0.2). MK-
886, A63162, baicalein, PD146176 and Boc-1 at the doses used did not significantly increase
I/R damage when given alone. Likewise, the nonsteroidal-antiflammatory drugs and dexame-
thasone given alone were not ulcerogenic. However, cotreatment with one of the LO inhibitors
or Boc-1 and indomethacin, celecoxib, S- or R-flurbiprofen or dexamethasone, respectively,
induced significant gastric damage (LI ranging from 30-42, p<0.001 each). CONCLUSIONS:
1) Non-ulcerogenic doses of the 5-LO inhibitors MK-886 and A63162, the 12-LO inhibitor
baicalein, the 15-LO inhibitor PD146176 and the LXA4 receptor antagonist Boc 1 render
indomethacin, celecoxib, S- and R-flurbiprofen and dexamethasone ulcerogenic even at
doses which do not damage the gastric mucosa when given alone. 2) The findings suggest
that both the LO and COX system are involved in the resistance of the gastric mucosa
against I/R damage. 3) While low doses of compounds interfering with one system are not
A-416AGA Abstracts
injurious, simultaneous interference with both systems invalidates the capacity of the gastric
mucosa to maintain integrity during I/R.
M1931
Leukotriens May Play An Important Role in the Formation of Intestinal
Lesions Induced By NSAIDs in Cats
Hiroshi Satoh, Kana Hatao, Toshiko Hara
BACKGROUND: Many reports indicate that selective inhibitors of both cycloxygenase (COX)
isoforms, COX-1 and COX-2, and dual inhibitors on COX/LOX (lipoxygenase) infrequently
cause lesions in the gastrointestinal (GI) mucosa. However, non-selective COX inhibitors
often cause such lesions. It is still unclear why the selective or dual inhibitors do not show
any significant adverse effects on GI mucosa. In the present study, we compared ulcerogenic
actions of various NSAIDs on the small intestine in cats, and also studied the effect of LOX
inhibitor (AA-861) on the lesion formation by NSAIDs. METHODS: Both male and female
cats (2.5-3.5kg) were used (4 animals in each group). NSAIDs were administered p.o. or
s.c. once a day after a morning meal for 3 days. The animals were sacrificed 24 hrs after
the final dose of NSAIDs, and mucosal lesions in the GI tract were examined. In the study
of LOX inhibitor, AA-861 was given orally twice a day, i.e., 1 hr before and 8 hrs after IM
administration. RESULTS: 1. Ulcerogenic actions of various NSAIDs: 1) non-selective COX
inhibitors: All of indomethacin (IM, 3 mg/kg,p.o.), ketoprofen (2 mg/kg, s.c) and fulnixin
meglumine (1 mg/kg, s.c.) produced many lesions in the middle and lower small intestine;
The mean lesion areas (MLA) were 7.5±2.6 cm2 , 1.8±0.2 cm2 and 5.4±1.7 cm2 , resp. 2)
COX-2 selective inhibitors: Neither meloxicam (0.6 mg/kg, s.c) nor carprofen (13.2 mg/kg,
p.o.) at 3 times the dose clinically used in dogs produced visible lesions in the small intestine.
3) COX/LOX dual inhibitor: Tepoxalin did not cause visible lesions in the small intestine
even at very high dose of 30 mg/kg, p.o. 2. Effect of LOX inhibitor on the lesion formation
by IM: The lesion formation by IM (3 mg/kg, p.o.) was markedly inhibited by treatment
with AA-861 (30 mg/kg, p.o.), and the MLA was 1.3±0.5 cm2. CONCLUSIONS: Present
results support the notion that stimulation of LOX pathway (and an increase of leukotriens)
as a result of inhibition of COX pathway plays an important role in the formation of GI
lesions caused by NSAIDs with non-selective COX inhibition, and may explain, at least in
part, the mechanism why both COX-1 and COX-2 selective inhibitors and COX/LOX dual
inhibitors do not cause lesions in the GI mucosa.
M1932
Apple Polyphenol Extracts Prevent Aspirin-Induced Damage to the Rat Gastric
Mucosa
Concetta Tuccillo, Giovanna Mazzone, Ilenia Grandone, Antonietta g Gravina, Giulia
Graziani, Vincenzo Fogliano, Marco Romano, Giuseppe D’argenio
BACKGROUND: Aspirin (ASA), even in low daily dose, and other nonsteroidal anti-inflam-
matory drugs (NSAIDs), are a well-recognized cause of iatrogenic disease, principally because
of their ability to cause gastro-duodenal ulcers and complications. Nutraceuticals have been
proven to exert beneficial effects in the gastrointestinal tract. Whether natural products are
able to prevent ASA injury to the stomach is not known. AIM: to evaluate whether polyphenol
extracts obtained from “Annurca” apple (APE) prevent ASA-induced injury to the rat gastric
mucosa and to assess the mechanism of any such protection. METHODS: 1) 20 rats (5/
group) were given regular drinking water or drinking water plus APE 10-4 M for ten days
prior to oral administration of ASA 200 mg/kg. Four hours later, animals were sacrificed
and the extent of gross and microscopic gastric injury assessed; 2) cyclooxygenase-2 (COX-
2), transforming growth factor α.(TGFα) and heparin binding epidermal-like growth factor
(HB-EGF) mRNA and protein expression in the gastric mucosa were assessed by RT-PCR
and western blot analysis, respectively, in animals treated with: a) vehicle for APE (control);
b) APE; c) vehicle followed by ASA; d) APE followed by ASA; 3) gastric malondialdehyde
(MDA), a marker of oxidative damage, was determined by HPLC with UV detection in rats
treated with ASA with or without pre-treatment with APE; 4) The effect of APE on pylorus
ligation stimulated gastric acid secretion was also determined. RESULTS: 1) APE significantly
prevented ASA-induced injury to the rat gastric mucosa both macroscopically (lesion score:
15.2 + 4.8 vs 27.1 + 5.2, p<0.05) and microscopically (39.1 + 3.2 vs 68.2 + 2.9, p<0.05)
; 2) ASA-induced gastric injury was associated with increased mRNA and protein expression
of COX-2 and HB-EGF, but not of TGFα; 3) APE by itself did not affect COX-2, TGFα or
HB-EGF mRNA and protein levels, but prevented ASA-induced mRNA and protein over-
expression of COX-2 and HB-EGF; 4) ASA -induced gastric injury was associated with a
significant increase in gastric MDA and this increase was significantly counteracted by APE
pre-treatment; 5) APE did not affect significantly gastric acid secretion. CONCLUSIONS:
1) APE significantly prevent gross and histological gastric damage brought about by ASA
to the rat stomach; b) this effect is at least in part mediated by the anti-oxidant properties
of APE and is independent of inhibition of gastric acid secretion; 3) APE protection decreases
COX-2 and HB-EGF over-expression following ASA-induced injury; 4) We speculate that
APE might be regarded to as potential therapeutic agent in the prophylaxis of ASA-
related gastropathy.
M1933
Effect of Deracoxib, a Selective Cyclooxygenase (COX) 2 Inhibitor, On COX
Protein and Prostanoid Levels in Canine PYLORIC and Duodenal Mucosa
Jenna G. Wooten, Anthony T. Blikslager, Kathleen A. Ryan, Steven L. Marks, B. duncan
X. Lascelles
Recent studies suggest canines have the same predilection for pyloric and duodenal non-
steroidal antiiflammatory (NSAID) related ulcers as humans, making them a viable NSAID
injury model. The role of COX-2 in pyloric and duodenal mucosa is unknown in humans
and canines, as is the effect of selective COX-2 inhibitors on its function. In the canine,
carprofen is approximately 3-5 fold selective for COX-2 and deracoxib is in excess of
36-fold selective for COX-2 in canine whole blood. We hypothesized COX-2 protein is
constitutively expressed in pyloric and duodenal mucosa but its inhibition by a selective
COX-2 inhibitor has less effect on prostaniod production compared to non-selective NSAIDs.
The study was a randomized, placebo controlled, blinded, cross-over design. Eight purpose
bred mongrel dogs (8-13 kg) were used. Each received carprofen (4.4mg/kg q24h), deracoxib
(2mg/kg q24h), aspirin (10mg/kg q12h), or placebo for 3 days with a 4-week washout
period between drugs. Prior to, and on day 3 of drug administration, pyloric and duodenal
mucosal biopsies were obtained endoscopically. COX-1 and COX-2 protein levels were
measured by Western blotting and prostanoids using an ELISA. Data was analyzed using
ANOVA. Drug administration had no effect on COX-1 protein expression in the pylorus or
duodenum and no effect on COX-2 protein expression in the pylorus; aspirin significantly
increased COX-2 expression in duodenal mucosa compared to deracoxib and carprofen
(p<0.05). Prostaglandin (PG) E2 levels were significantly greater in pyloric versus duodenal
mucosa (p<0.05). Aspirin significantly reduced PGE2 in pyloric and duodenal mucosa
compared to all other groups (p<0.05). In pyloric mucosa, carprofen significantly reduced
PGE2 compared to deracoxib and baseline. Thromboxane (TX) B2 levels were significantly
greater in pyloric versus duodenal mucosal tissue. Aspirin significantly reduced TXB2 in
pyloric mucosa compared to all other treatments; carprofen administration significantly
reduced TXB2 compared to deracoxib administration (p<0.05). In duodenal mucosa, aspirin
significantly reduced TXB2 compared to all groups (p<0.05). Prostaniod production is greater
in pyloric mucosa compared to duodenal, which may explain the onset of duodenal injury
in select clinical patients. Non-selective NSAIDs significantly reduced prostanoid levels in
pylorus and duodenum compared to a selective COX-2 inhibitor, deracoxib, suggesting an
increased safety profile of Coxibs. However, constitutive production of COX-2 suggests
caution with all NSAIDs, including COX-2 inhibitors.
M1934
Phase 2a Dose Escalation Trial of OncoGel® (Regel®/Paclitaxel) As
Adjunctive Local Therapy to External Beam Radiation in Patients with
Inoperable Esophageal Cancer
Aaron Duvall, Dino Tarabar, Richard H. Seidel, Radoje Doder, Nancy L. Elstad, Kirk D.
Fowers
Background: OncoGel® is paclitaxel formulated in a biocompatible biodegradable copolymer
ReGel®. OncoGel is a low viscosity thermosensitive polymer that forms a gel at body
temperature with controlled release of paclitaxel over 6 weeks at the injection site. Local
administration of paclitaxel from OncoGel is designed to provide direct cytotoxicity and
continuous radiosensitization without attendant systemic toxicity. Methods: Patients with
adeno- or squamous cell esophageal carcinoma who were not candidates for surgery but
were eligible to receive external beam radiation therapy (EBRT) were enrolled in this multi-
center dose escalation study. Three cohorts were to be dosed at increasing concentrations
of OncoGel (0.48, 1.0 and 2.0 mg paclitaxel/cm3 tumor volume). Tumor volume was
measured using endoscopic ultrasound (EUS) at baseline to determine OncoGel injection
volume and at Week 11 for tumor response. OncoGel was injected into the primary tumor
and selected adjacent involved lymph nodes using conventional endoscopic injection tech-
niques. After injection, EBRT was administered (50.4Gy in 1.8Gy fractions over 5.5 weeks).
Pharmacokinetic (PK) sampling was performed immediately before dosing, at 3, 6, 24 and
72 hours and at 3 weeks after dosing. Results: To date, 7 patients in 2 cohorts have completed
dosing and 11 week follow-up including the entire prescribed course of EBRT. Absolute
paclitaxel doses ranged from 16-67mg. No DLTs or medical concerns, including hematologic
or systemic toxicities, have been identified. At Week 11 dysphagia improved 2-points for
5 patients and 1- or 0 points for 2 patients. Week 11 tumor volumes were reduced for
all patients despite radiation-induced inflammation/erythema being indistinguishable from
residual tumor by EUS. Week 11 biopsies were negative for carcinoma in 5/7 patients (all
5 were considered surgical candidates). One patient underwent a successful esophagectomy
with negative margins. Plasma paclitaxel was detectable for 24 hours in 7/7 patients, 72
hours in 6/7 patients and 3 weeks in 3/7 patients. Cmax occurred at 24 hrs in 6/7 patients
(0.529-1.46ng/ml) and 6 hrs in 1 patient (1.01ng/ml). Data for the final cohort is being
collected. Conclusions: OncoGel, a depot formulation of paclitaxel when combined with
EBRT was technically achievable and well tolerated. Dysphagia scores, tumor assessments and
follow-up biopsies indicate that this combination was effective. PK data indicate prolonged
paclitaxel release with minimal systemic exposure and no systemic toxicity at the doses
studied. OncoGel may be a candidate for incorporation into controlled studies of combined
modality therapy in esophageal cancer.
M1935
Proton Pump Inhibitors Are Associated with Reduced Incidence of Esophageal
Malignant Tumors in Patients with Gastro-Esophageal Reflux Disease
Vikas Khurana, Madhusudanan S. Ramaswamy, Gloria Caldito, Jamie S. Barkin
AIM: To investigate the effect of proton pump Inhibitors (PPI) use in patients with gastro
esophageal reflux disease (GERD) on the development of esophageal cancer in the US
veteran population. BACKGROUND: PPIs are commonly used medications for treating
GERD, however clinical data for protection against esophageal malignant tumors in patients
with GERD is lacking. DESIGN: The VISN 16 database contains clinical and demographic
information on all veterans (> 1.4 million patients) who were treated in the South Central
VA Health Care Network. The data was queried from Oct 1998 to June 2004, using a
retrospective case control design. Statistical analysis was performed using SAS software
version 9.0 (Chicago, IL). Multiple logistic regression analysis were used with calculation
of odds ratios and 95% confidence intervals. The data was adjusted for age, smoking, alcohol
use and diabetes. RESULTS: A total of 483,733 patients were evaluated. The mean age was
61.2 (SD+/-15.1) years and 91.7% were men. Of these 80,784 patients with GERD (ICD-
9: 530.11, 530.81) were included in the study. 55,875 (69.2%) patients were using PPI.
Esophageal cancer (ICD code of 150) occurred in 223 ( 0.3%) patients. Using multivariate
analysis PPI users were less likely to develop esophageal cancer (Odds ratio 0.52; 95% CI
0.40-0.70, p <0.0001). Covariates studied included age, race, gender, smoking, alcohol use,
BMI, NSAID use, statin use, and diabetes. DISCUSSION: Patients were placed in the PPI
users group if they were using PPI prior to the diagnosis of esophageal cancer but the dose,
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duration and type of PPI used were not factored into the analysis. The pathological type of
cancer is not available .In addition, some factors known to increase the risk of esophageal
cancer like Barrett's esophagus was not incorporated into the study. Therefore our data
should be evaluated with caution, given the limitations of the population, the database and
the fact that this is a case controlled study. CONCLUSION: Proton Pump Inhibitors are
associated with a 48% reduced incidence of esophageal malignant tumors after controlling
for age, race, gender, smoking, alcohol use, BMI, NSAID use, statin use, and diabetes.
M1936
Differential Regulation of COX-2 and Cyclin D1 By Bile Acids At Neutral and
Acid pH in Esophageal Adenocarcinoma Cells
Shumei Song, James C. Byrd, Robert S. Bresalier
BACKGROUND: Reflux of acid and bile contributes to esophageal injury and neoplasia. COX-
2 and cyclin D1 are involved in inflammation and proliferation, and increased expression of
both COX-2 and cyclin D1 has been noted in the progression of Barrett's adenocarcinoma.
Previous In Vitro results indicated that, at neutral pH, unconjugated bile acids, but not
conjugated bile acids, can induce expression of COX-2, but effects on cyclin D1 and pH
dependence were not studied. AIM: Determine the effects of bile acids on COX-2 and cyclin
D1 expression in esophageal adenocarcinoma cells at neutral and acid pH. METHODS: SEG-
1 and SKGT-4 cells were incubated for 16 h at pH 7.4 or pH 5.0 in media with 0-100 uM
conjugated bile acids taurocholic acid (TCA), taurodeoxycholate (TDC), or glychocholic acid
(GC), or with 0-400 uM unconjugated bile acids deoxycholate (DC) or chenodeoxycholate
(CD), with no effect on viability. COX-2 and cyclin D1 proteins and the status of ERK and
AKT phosphorylation/activation were determined by western blots. RESULTS: In neutral
media, COX-2 protein expression was increased by DC and CD (in a dose- and time-
dependent manner), but not by conjugated bile acids. Expression of cyclin D1, in contrast,
was decreased by exposure to DC and CD in neutral media, and unaffected by TCA, TDC,
and GC. Exposure of the cells to pH 5.0 also increased COX-2 and decreased cyclin D1.
Furthermore, exposure to low pH modifies the response to bile acids. In acidic media,
conjugated bile acids further increased COX-2 and further decreased cyclin D1. However,
exposure to DC and CD at acid pH decreased the expression of COX-2 and increased cyclin
D1. Induction of COX-2 by acid or by DC and CD at pH 7.4 was due to activation of both
ERK MAPKinase and AKT. In contrast, cyclin D1 down-regulation was completely blocked
by the specific proteosome inhibitor MG132. CONCLUSIONS: These results indicate that
exposure to acid, to conjugated bile acids, and to unconjugated bile acids have different
effects on the expression of COX-2 and cyclin D1. Conditions that increase the expression
of COX-2 decrease the expression of cyclin D1 In Vitro, and vice versa. This suggests that
different mechanisms are responsible for the inflammatory and proliferative effects of acid
and bile acids.
M1937
A Detailed Analysis of the Epithelial Types in the Columnar Lined Esophagus
and Their Association with Dysplasia
Sharad Mathur, Srinivas R. Puli, Sachin B. Wani, Ajay Bansal, Amit Rastogi, Prateek
Sharma
Background The metaplastic epithelium of columnar lined esophagus (CLE) consists of 3
epithelial types: fundic, cardiac and intestinal metaplasia (IM). IM is presumed to be the
premalignant lesion but recent European guidelines have not mandated IM for diagnosing
Barrett's esophagus (BE). A systematic evaluation of distribution of these epithelial types in
CLE has not been performed. Aims (1) To determine relative distribution of IM, cardiac
and fundic epithelial types in CLE at different levels (2) To evaluate which epithelial type
is associated with presence of dysplasia in CLE. Methods Pts with CLE who underwent
quadrantic biopsies every 2 cm were included. Biopsies were classified based on the level
-biopsies obtained above the GEJ (distal), closest to the new SCJ (proximal) and between
these two levels (mid). All specimens were reviewed by a single pathologist. The distribution
of IM, cardiac and fundic mucosa alone or in combination was evaluated. Each biopsy
specimen was evaluated for dysplasia and concomitant epithelial type in the same biopsy
specimen was recorded. Results 96 pts with CLE were evaluated; mean age 60 yrs (range:
29-81);99% males and 95% Caucasians. Mean CLE length was 3.1 cm (range: 0.5-17). Pt-
based analysis depicting distribution of epithelial types is shown in Table. In non-dysplastic
(ND) CLE pts, IM was seen in the proximal, mid and distal biopsies in 56%, 57%, and
14% respectively. The distribution of IM in CLE pts with low-grade dysplasia (LGD) was
100% (proximal), 100% (mid) and 64% (distal). In pts with high-grade dysplasia in CLE,
100% had IM at each level. In biopsy based analysis, 84 biopsies with LGD and 20 biopsies
with HGD were evaluated. 100% of biopsies with LGD and HGD had IM, none had cardiac
or fundic type alone. Conclusions These data suggest that IM is distributed more proximally,
fundic distally and cardiac evenly in the BE segment. Dysplasia is always associated with
IM within the same biopsy specimen and no specimen of dysplasia with cardiac type or
fundic type mucosa alone was identified. Definition of BE should include IM as it is the
premalignant lesion.
Distribution of Epithelial Types in BE patients
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The Role of Obesity, Gastroesophageal Reflux and Smoking in
Adenocarcinomas of the Esophagus and Esophago-Gastric Junction
David Whiteman, Shahram Sadeghi, Nirmala Pandeya, Mark Smithers, David Gotley,
Christopher Bain, Adele Green
Background: Obesity, gastro-esophageal reflux and smoking have each been implicated as
causal factors for adenocarcinomas of the esophagus (EAC) and esophago-gastric junction
(EGJAC). However, it is not clear whether the risk of adenocarcinoma associated with these
factors differs according to the anatomical site of the tumor, nor whether the factors act
independently or synergistically to increase risk. Methods: In a nationwide case-control
study, patients with EAC (n=376) and EGJAC (n=417) were identified through hospitals
and cancer registries. Control participants, frequency matched by age, sex and state to the
cases, were sampled from a population register (n=1580). Participants self-reported their
height, pre-morbid weight and histories of reflux symptoms and smoking. We calculated odds
ratios [OR] (and 95% confidence intervals [95% CI]) for these exposures using multivariable
polytomous logistic regression models. Combined effects of these exposures were also
assessed. Results: We observed stepwise increases in risk of EAC and EGJAC with increasing
BMI. Highest adjusted risks were observed for those with BMI >40 kg/m2 (EAC OR 5.9,
95% CI 2.7-13.1; EGJAC OR 2.3, 95% CI 1.0-5.5) compared with healthy BMI. Significantly
increased risks were observed for frequent reflux symptoms (EAC OR 8.4, 95% CI 5.3-
13.2; EGJAC OR 4.6, 95% CI 2.9-7.3) compared with no reflux, and current smokers (EAC
OR 2.4, 95% CI 1.6-3.5; EGJAC OR 4.0, 95% CI 2.9-5.6) compared with never smokers.
For EAC but not EJGAC, obesity in the presence of reflux led to substantially higher risks
(OR 14.9, 95% CI 8.2-27.0) than obesity alone (OR 2.1, 95% CI 1.1-4.1) or reflux alone
(5.4, 95% CI 2.8-10.6). Conclusions: Obesity, reflux and smoking are independent risk
factors for EAC and EGJAC, although magnitude of risk differs between the sites. For EAC,
the combined effects of obesity and reflux appears consistent with synergistic mechanisms
for these factors.
M1939
Patients with Prostate Cancer Are Less Likely to Develop Oesophageal
Adenocarcinoma - Could Anti-Androgen Therapy Have a Protective Role?
Sheldon C. Cooper, Stacey Croft, Rosie Day, Catherine S. Thomson, Nigel J. Trudgill
Introduction The incidence of oesophageal adenocarcinoma (OA) is much higher in men,
unlike oesophageal squamous cell carcinoma (OSCC) that is equally common in both
genders. It has been suggested that androgens may contribute to the pathogenesis of OA.
Prostate cancer, an androgen sensitive tumour with a long natural history, may allow insights
into this putative association. Aims and Methods The West Midlands Cancer Intelligence
Unit (WMCIU) records cancer diagnoses from an area covering 10% of the English popula-
tion. WMCIU data from 1977-2004 was examined to identify patients with a first malignant
primary (excluding non-melanoma skin cancer) of prostate cancer. These patients were
followed until diagnosis of a second primary cancer, death or end of the time period
examined. Those with less than three months follow-up were excluded. Age- and period-
adjusted standardised incidence ratios (SIR) were calculated as an estimate of relative risk
(RR) for a second malignant primary of the oesophagus. Results Between 1977 and 2004,
44,819 men within the West Midlands developed prostate cancer as a first primary malig-
nancy. After exclusion for lack of follow-up, 38,627 men were eligible for the study, providing
152,994.7 person years at risk for further analysis. Overall, 86 second primary oesophageal
cancers were observed in the study population, compared with 117 expected, resulting in
an SIR of 0.73 (95%CI 0.59-0.91). There was a significantly reduced risk of OA (SIR 0.66,
95%CI 0.47-0.90), but not with OSCC (SIR 0.96, 95% CI 0.65-1.37). Discussion The risk
of developing OA, but not OSCC, is significantly lower than expected in patients with
prostate cancer. We hypothesise that this maybe mediated through anti-androgen therapy
employed in the treatment of prostate cancer, suggesting that gender differences in the
incidence of OA may relate to sex hormone differences.
M1940
Oesophageal Carcinoma in the West Midlands, United Kingdom: Changing
Incidence and the Influence of Socio-Economic Status and Ethnicity
Sheldon C. Cooper, Rosie Day, Colin Brooks, Cheryl Livings, Nigel J. Trudgill
Background The incidence of oesophageal cancer, especially oesophageal adenocarcinoma
(OA), has risen in the developed world in the last 30 years. In the USA, oesophageal
squamous cell carcinoma (OSCC) is associated with deprivation and black ethnicity and
oesophageal adenocarcinoma (OA) with affluence and white ethnicity. The influence of
social deprivation and ethnicity on oesophageal cancer has not been studied in the UK.
Aims and Methods West Midlands Cancer Intelligence Unit (WMCIU) data was used to
study the incidence of OSCC and OA and to examine the influence of age, gender, socio-
economic status (Townsend Quintiles by postcode) and ethnicity (Hospital Episode Statistics).
The WMCIU covers 10% of the population of England. Validation of coding of cancer
morphology and site was performed in 28% (n=4252) of cancers by examination of patient
records. Results From 1977-2004, 15 138 oesophageal cancers were identified within the
unchanging borders of the registry. Oesophageal cancer incidence increased - five year rolling
directly age standardised incidence rates per 100,000 (95% CI): 1977-81 men 8.57 (8.03-
9.1), women 5.04 (4.69-5.39); 2000-2004 men 13.73 (13.13-14.32), women 6.28 (5.92-
6.64). OSCC incidence has not significantly altered, but OA incidence is rapidly rising,
particularly in men: 1977-81 men 2.14 (1.87-2.4), women 0.52 (0.41-0.64); 2000-2004
men 8.53 (8.06-9.0), women 1.72 (1.53-1.9). The median age of diagnosis of OA (IQR)
has risen: 1977-81: men 65 (58-71.8), women 72.5 (63.3-78); 2000-4 men 70 (61-77),
women 78 (69-83). OSCC was strongly associated with the most socially deprived quintile
(5) (1977-81: men quintile 5 - 6.19 (5.05-7.33) vs. quintile 1 - 1.85 (1.31-2.4); women
quintile 5 - 3.67 (2.88-4.45) vs. quintile 1 - 2.03 (1.52-2.54)). This association persisted
until 1999-2003 when the rising incidence in the most affluent quintile converges with the
most deprived quintile. OA was not associated with differences in social deprivation or
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affluence. OA was significantly more common in white men 7.30 (6.92-7.68) and women
1.49 (1.34-1.64) compared with black and asian populations. OSCC was not associated
with any particular ethnic group. Conclusions Within the West Midlands, the incidence of
OA is rapidly rising, particularly in men. The incidence of OSCC has not significantly altered
in the last three decades. OSCC has been strongly associated with deprivation, but this
association has recently been lost. OA is not associated with differing socio-economic status.
OA is associated with white ethnicity.
M1941
Hypochlorhydria in Esophageal Squamous-Cell Carcinoma
Katsunori Iijima, Tomoyuki Koike, Yasuhiko Abe, Hatsushi Yamagishi, Akira Imatani,
Shuichi Ohara, Tooru Shimosegawa
Background Recent studies in Swedish population demonstrated that gastric atrophy induced
by H. pylori infection may increase the risk of esophageal squamous-cell carcinoma (ESCC).
We have demonstrated that the association is also true in Japanese population. There is a
possibility that gastric atrophy may increase the risk of ESCC through abolishment of normal
gastric secretion, although, so far, there have been no reports on the gastric acid secretory
level in patients with ESCC. The aim of this study is to investigate the acid secretory level
in patients with ESCC in case-control study. Methods From April 2004 to March 2006, 73
consecutive subjects (66 men, mean age: 69 years) who had received endoscopic mucosal
resection for early ESCC before the entry were prospectively enrolled. For each case, age-
and sex- matched asymptomatic control subjects were randomly selected from patients who
visited our hospital during the same period. Biopsy specimens from the gastric body were
evaluated histologically regarding the prevalence of mucosal atrophy. Gastric fundic atrophy
was also evaluated serologically (serum PG I < 25 mg/ml). Gastrin-stimulated acid output
was assessed by endoscopic gastrin test (EGT) as reported previously (AJG 1999) and
hypochlorhydria was defined as the mean - 2 S.D. (0.6 mEq/10min) or below (ATP 2004).
Results Histologic and serological fundic atrophy were more prevalent in ESCC patients
compared with controls (histologic atrophy: 59% vs. 29%, p < 0.01; serologic atrophy: 45%
vs. 16%, p < 0.01). Hhypochlorhydria was also prevalent in ESCC patients than controls
(60% vs. 30%, p<0.01). After controlling for smoking status, alcohol consumption, and H.
pylori status, hypochlorhydria was independently associated with an increased risk for ECSS
(OR 4.7, 95 % CI 1.9 - 11.3) Conclusion Hypochlorhydria concomitant with fundic
atrophy was an independent risk factor for ESCC patients after controlling for well-known
conventional risk factors such as smoking and heavy drinking. Hypochlorhydria forms a
milieu that favors bacterial overgrowth in the stomach, probably leading to endogenous
nitrosamine formation. Nitrosamine generated in the stomach can conceivably reach the
esophagus through reflux or venous plexus between the two adjacent organs and may be
relevant to the development of ESCC.
M1942
Overexpression of Aurora Kinase a in Barrett's Adenocarcinoma Is Associated
with Potent Anti-Apoptotic Properties
Altaf Dar, Alexander I. Zaika, Maria Piazuelo, Abbes Belkhiri, Kay Washington, Wael M.
El-rifai
Using comparative genomic hybridization, we (and others) have shown frequent high-level
amplifications of chromosome arm 20q13 in many cancers including Barrett's adenocarcin-
oma (BA). This region harbors the gene, Aurora kinase A (AURKA). In this study, we
investigated AURKA's molecular and biological bases in adenocarcinomas of the stomach
and esophagus, which include BAs. To carry out our study, we used quantitative real-time
PCR analysis to evaluate DNA amplification and mRNA over-expression of AURKA in primary
tumor samples as compared to normal mucosae. In addition, we used immunohistochemistry
on tumor tissue microarrays and performed several In Vitro experiments to dissect the
biological functions of AURKA in BA. Using quantitative real-time PCR analysis of 67 tumors,
we detected increased DNA amplification in BAs (33%) than in gastric cancers (18%), and
over-expression of AURKA mRNA was more frequent in BAs (19/26, 73%) than in gastric
cancers (5/13, 39%) (p=0.036). Immunohistochemistry analysis on tissue microarrays
revealed moderate-to-strong immunostaining for AURKA in 20/36 (55.5%) gastric cancers
and 53/85 (62.3%) BAs. Over-expression of AURKA in NIH3T3 cells led to increased survival
of cells. Treatment of AURKA over-expressing cells with camptothecin and ceramide provided
resistance against drug-induced toxicity. Using luciferase assays and Western blot analysis,
we demonstrated that AURKA over-expression leads to suppression of the transcription
activity and protein levels of p53 and p21. This was associated with a reduction in the
mRNA and protein levels of p53 pro-apoptotic transcriptional targets, Puma and Noxa. We
also found significant reductions in cleavage and activation of caspase-9 and -3. The subG1
phase of cell cycle was reduced by up to 50% in NIH3T3 and RIE-1 AURKA-transduced
cells on treatment with camptothecin. We validated all results using AURKA-specific siRNA
and AURKA D274 mutant. In addition, we found that AURKA over-expression in esophageal
(SEG-1) and gastric cancer (AGS) cells led to up-regulation of phosphorylated Akt. This
was associated with up-regulation of the Akt downstream target, Mdm2, which is a crucial
protein that mediates degradation of p53. Down-regulation of p53, as observed by AURKA,
may be attributed to up-regulated MDM2 since MDM2 is a major p53 regulator. Using PI3
kinase inhibitors, LY2940002 & Wortmannin, we confirmed that AURKA-mediated Akt
activation and up-regulation of MDM2 is PI3 kinase-dependent. In combination, our results
indicate that AURKA is frequently over-expressed in BAs and provides notable anti-apoptotic
and pro-survival properties to tumor cells.
M1943
Nurse-Led Follow-Up of Patients After Esophageal Cancer Surgery: A
Randomized Trial
E. M. Verschuur, M. L. Essink-bot, E. J. Kuipers, S. Polinder, T. C. Tran, A. Van der
gaast, L. P. Stassen, H. W. Tilanus, E. W. Steyerberg, P. D. Siersema
Background: A surgical resection for esophageal cancer is accompanied by significant morbid-
ity and impact on quality of life of patients. It is important that in this group of patients
disease-related symptoms and patient's questions regarding prognosis should be adequately
addressed during follow-up visits. Aim: To compare home visits by a specialist nurse with
routine control visits to the outpatient clinic with regard to quality of life, patient satisfaction
and cost-effectiveness of follow-up after intentionally curative surgery for esophageal cancer.
Methods: Between January 2004 and February 2006, 109 patients were randomized to
standard follow-up by group of 5 surgeons at the outpatient clinic (usual care; n=55) or by
regular home visits by a specialist nurse (nurse-led follow-up; n=54) at 6 weeks and 3, 6,
9 and 12 months after surgery. Longitudinal data on generic (EORTC QLQ C30, EQ-5D,
HADS) and disease specific quality of life (EORTC OES18), patient satisfaction and cost
were collected at baseline at 6 weeks postoperatively and at 4, 7 and 13 months afterwards.
Differences in outcome over time at 4 and 7 months were assessed by analysis of variance,
chi-square tests and Mann-Whitney tests. Results: A significant and clinically relevant
improvement during follow-up in the eating scale (EORTC OES18), and in the fatigue,
physical, role and social functioning scales and global health (EORTC C30) were found
during follow-up, whereas other scales, for example pain and dysphagia (EORTC OES18)
remained almost stable during follow-up. We found no significant differences in health-
related quality of life scores between the two follow-up groups over time. In addition, no
differences were found for patient satisfaction between the two groups, except for time spent
during follow-up visits (p=0.02 in advantage of nurse-led follow-up). Initial costs of nurse-
led follow-up were lower than costs of usual care ( €190 vs. €370; p<0.001). In total, 11
(20%) patients in the nurse-led follow-up group and 16 (29%) patients undergoing usual
care developed metastases at a median of 8 months after randomization (p=0.29). Mean
hospital stay was 3.6 days for nurse-led follow-up versus 7.0 days for usual care. Total medical
costs, including hospital stay, diagnostic procedures and retreatments, and extramural health
care, were significantly lower for nurse-led follow-up (€1840 vs. €2750; p=0.045). Conclu-
sions: Patients after curative esophageal cancer surgery can safely be followed up by a
specialist nurse. This alternative follow-up is less costly compared to usual care and does
not adversely affect quality of life and patient satisfaction.
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The Optimal Strategy to Detect Distant Metastases in Patients with
Esophageal Or Gastric Cardia Cancer
E. P. Van vliet, E. W. Steyerberg, M. J. Eijkemans, E. J. Kuipers, P. D. Siersema
Introduction: Although positron emission tomography (PET) is increasingly being used to
detect distant metastases in patients with esophageal or gastric cardia cancer, computed
tomography (CT) is still the standard procedure in many centers. The role of ultrasound
(US) abdomen, US neck, chest X-ray and endoscopic ultrasonography (EUS) is uncertain.
Aim: To determine the diagnostic value of staging investigations (US abdomen, US neck,
chest X-ray and EUS) in addition to CT for metastases detection in patients with esophageal
or gastric cardia cancer. Methods: We included 569 patients who had undergone CT, and
US abdomen, US neck, chest X-ray and/or EUS in the period 1994-2003. Three strategies
were compared for each organ: CT alone, CT plus an investigation if CT was negative for
metastases (1 positive scenario), and CT plus an investigation if CT was positive, requiring
that both were positive for a positive result (2 positive scenario). Sensitivity and specificity
were first determined at an organ level (results of investigations per organ), and then at a
patient level (results for combinations of investigations), with the assumption that detection
of distant metastases is a contraindication to surgery. Costs, life expectancy and quality
adjusted life years (QALYs) were compared between strategies. Results: CT showed sensitivit-
ies for detecting metastases in celiac lymph nodes, liver and lung of 69%, 73%, and 90%,
respectively, which was higher than the sensitivities of US abdomen (celiac lymph nodes:
44%; liver metastases: 65%), EUS (celiac lymph nodes: 38%) and chest X-ray (lung metastases:
68%). US neck showed a higher sensitivity for supraclavicular lymph nodes than CT (85%
versus 28%). At a patient level, sensitivity and specificity for detecting distant metastases
with CT alone was 66% and 95%, respectively. A higher sensitivity (86%) was achieved
when US neck was added to CT (1 positive scenario) at the same specificity. This strategy
resulted in lower costs compared to CT alone, at an almost similar QALY. Slightly higher
specificities (97-99%) were achieved by requiring confirmation of liver and/or lung metastases
found on CT by US abdomen or chest X-ray, respectively. These strategies had slightly
higher QALYs, but substantially higher costs. Conclusion: The combination of CT and US
neck was most cost-effective for detecting metastases in patients with esophageal or gastric
cardia cancer. US abdomen, chest X-ray and EUS had only limited additional value for
metastases detection. It remains to be established whether adding higher quality EUS than
used in the present study and PET will improve this algorithm.
M1945
Baseline Nutritional Status Is Predictive of Response to Treatment and
Survival in Patients Treated By Definitive Chemoradiotherapy for Esophageal
Cancer
Frédéric Di fiore, Stéphane Lecleire, Daniela Pop, Bernard Paillot, Eric Lerebours, Pierre
Michel
Introduction. Influence of nutritional parameters on outcome has not been demonstrated
in patients with locally advanced esophageal cancer treated by definitive chemoradiotherapy
(CRT) in a curative intent. Aim. The aim of the study was to assess the impact of baseline
nutritional status on treatment response and survival in non-metastatic patients with an
esophageal cancer treated with definitive CRT. Patients and Methods. One hundred and five
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patients with locally advanced esophageal cancer treated by definitive CRT were retrospect-
ively included. The CRT regimen was based on an external radiation (50 to 60 Grays)
delivered concomitantly to a cisplatin-based chemotherapy. Patients were considered to have
a complete response to CRT if no residual esophageal tumor and no distant metastases were
detected at endoscopy and CT scan performed two months after the end of CRT. Based on
the univariate analysis results, we performed a multivariate analysis and calculation of Odds
Ratio (OR) of the complete response to CRT and survival using respectively a logistic
regression and a Cox model. Results. Among the 105 included patients, 61 (58.1%) were
responders to the CRT. In univariate analysis, the complete response to CRT was correlated to
baseline serum albumin level (p<0.0001), BMI (p=0.003), nutritional endoscopic intervention
during CRT (nasogastric tube, dilation or esophageal stent; p=0.013), initial weight loss (p=
0.016), WHO performance status (p=0.025), tumor length (p=0.02), tumor stage (p=0.038),
achievement of chemotherapy regimen (p=0.035). In multivariate analysis, serum albumin
level was the only independent predictive factor of complete response to CRT (p=0.003;
OR 5.8; IC95:1.8-18.5). Overall survival was correlated in univariate analysis to serum
albumin level (p=0.007), BMI (p=0.0006), WHO performance status (p=0.004), tumor stage
(p=0.02), achievement of chemotherapy and radiotherapy regimens (p=0.007 and p=0.0008,
respectively) and to complete response to CRT (p<0.0001). In multivariate analysis, the
independent prognostic factors were BMI (p=0.0007; OR 8.6; IC95: 2.4-29.9), the dose of
radiotherapy (p=0.0001; OR 4.7; IC95:2.1-10.5) and complete response to CRT (p<0.0001;
OR 6.5; IC95: 3.3-13.1). Conclusion. This study highlights that baseline nutritional status
is an independent predictive and prognostic factor in patients treated in a curative intent
with a definitive CRT for an esophageal cancer. Our results suggest that specific nutritional
support before or during treatment may be of high interest in undernourished cancer patients
in order to improve the treatment success.
M1946
Transformation of Benign Barrett's Epithelial Cells By Repeated Acid and Bile
Exposure Over 22-34 Weeks: An in-Vitro Model of Metaplasia to Neoplasia By
Environmental Factors
Yingxin Kong, Kim M. Hirshfield, Manisha Bajpai, Kiron M. Das
Barrett's epithelium (BE) is a metaplastic process at the distal esophagus which commonly
occurs in patients with gastroesophageal reflux disorder. BE can lead to dysplasia and
adenocarcinoma, a cancer with the highest rate of increase in Western countries. The reason
for this increase and mechanism of progression from metaplasia to adenocarcinoma are
unknown. Materials andMethods: We have examined the process of metaplasia to dysplasia
in-vitro by utilizing a telomerase (hTERT)-immortalized benign Barrett's cell line (BAR).
Cells were exposed to acid (pH 4) and bile salt (100μM chenodeoxycholic acid) daily for
5 mins. for 34 wks or grown in parallel without acid/bile exposure. Molecular changes at
the gene expression level for TC22, p53, p21, mdm2 and COX-2 were analyzed systematically
by real time RT-PCR at 4-6 wk intervals. Protein expression was measured by fluorescence
activated cell sorting. TC22, a novel tropomyosin (TM) isoform reported by our laboratory
(Gastroenterology 123:152,2002), is expressed by transformed cells but not by normal
epithelial cells that express human TM isoform 5 (hTM5). TC22 is an alternatively spliced
product of hTM5 with a distinct C-terminal peptide (222-247) coding the exon 9 and is
expressed in 100% of adenocarcinomas of the colon. Results: Combined, repeated exposure
to acid and bile salt did not change TC22 gene expression until 18 wks., but then reached
a 2-fold increase at 22 weeks and a 3-fold increase at 34 weeks when compared to the
initial value and untreated control cells of the same duration. TC22 protein expression also
doubled at 34 wks., but remained unchanged in unstimulated control cells at the same time
points. hTM5 expression did not change in both treated and control cells over 34 weeks.
In addition, p53 gene expression also increased at 22 weeks, with a 2.2-fold induction at
34 weeks. P21 and mdm2 are also induced at 2.6- and 6.4-fold respectively at 34 weeks.
Untreated cells and cells stimulated with acid alone did not show such changes. COX-2
gene expression increased (2-10-fold) with acid and bile exposure within a few weeks, but
varied randomly at different points. There was also change in the cell morphology. Conclu-
sion: Benign Barrett's cells can be induced from metaplasia to neoplasia in-vitro by the
environmental factors of acid and bile salt together and not by acid alone. These studies
provide a novel in-vitro model to investigate the molecular mechanism of progression from
metaplasia to carcinoma and possible therapeutic strategies.
M1947
Previous Radiotherapy for Breast Cancer Does Not Increase the Risk of
Developing Oesophageal Cancer: Analysis of Over Half a Million-Person Years
of Risk
Sheldon C. Cooper, Stacey Croft, Rosie Day, Catherine S. Thomson, Nigel J. Trudgill
Introduction The incidence of oesophageal adenocarcinoma (OA) in women has risen three-
to-four fold since 1977 in the West Midlands. The incidence of female breast cancer has
also risen, and previous studies have postulated that radiotherapy for breast cancer may
predispose to a future oesophageal primary malignancy. Aims and Methods West Midlands
Cancer Intelligence Unit (WMCIU) data, recording cancer diagnosis and treatment informa-
tion from an area covering 10% of the English population, was examined to identify patients
with a first malignant primary (excluding non-melanoma skin cancer) of breast cancer
between 1977 and 2004. These patients were followed until diagnosis of a second primary
cancer, death or end of the time period examined. Those with less than three months follow-
up were excluded. Use of radiotherapy was recorded. Age and period adjusted standardised
incidence ratios (SIR) were calculated as an estimate of relative risk (RR) for a second
malignant primary of the oesophagus. Results Between 1977 and 2004, 80,025 women
within the West Midlands developed breast cancer as a first primary malignancy. After
exclusion for lack of follow-up, 73,185 women were eligible for the study, providing
501,298.5 person years at risk for analysis. Overall, 131 second primary oesophageal cancers
were observed in the study population, compared to 125 expected, yielding an SIR close
to unity (SIR=1.05; 95%CI 0.87-1.26). Radiotherapy treatment in 37,855 women did not
affect the risk of developing an oesophageal second primary malignancy (SIR=1.03; 95%CI
0.76-1.36). No increased risk was seen overall for OA (SIR=1.02; 95%CI 0.69-1.45), or OSCC
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(SIR=1.09; 95%CI 0.85-1.37), with similar results in patients treated with radiotherapy.
Discussion There is no association between breast cancer and a second primary oesophageal
cancer. The use of radiotherapy treatment of primary breast cancer, local nodes or recurrence
is not associated with an increased relative risk of developing a second primary oesophageal
cancer. The lack of association remains on examining oesophageal cancer subtypes by mor-
phology.
M1948
Barrett's with Low Grade Dysplasia: How Often Does It Progress and What
Factors Predict Progression?
Amir R. Ahmed, Sharmila Anandasabapathy
Introduction: Endoscopic surveillance is recommended for patients with all pathologic grades
of Barrett's esophagus; however, the vast majority never progress to esophageal adenocarcin-
oma (EAC). Indeed, for subjects with low-grade dysplasia (LGD), surveillance every 6-12
months is recommended in the absence of evidence supporting a specific interval and studies
examining the natural history of LGD. Identification of clinical or endoscopic factors that
predict progression will allow better patient selection for more intensive surveillance, poten-
tially easing the burden on our health care system. Our goal was to study the natural history
of LGD and to identify any clinical and/or histological factors that predict progression to
HGD or EAC. Methods: Between 1991-2006, 61 patients seen at the M.D. Anderson Cancer
Center were diagnosed with Barrett's LGD as determined by 2 consecutive specimens with
LGD, read by an expert GI pathologist, within a 6-month period. Mean follow-up was 4
years (range 1-15). Clinical, endoscopic and pathologic information was obtained from a
detailed institutional registry. Fisher's exact test was used to compare the three groups with
regards to multiple variables including: age, PPI use, H. pylori status, alcohol intake, smoking,
gender, ethnicity, hernia presence and size, and segment length. Results: In our patient
cohort, 25% of the study subjects were female and the mean age was 61.4 yrs (range: 29-
85). Four patients (6.6%) progressed: 1 to HGD and 3 to EAC, 37 patients (61%) remained
stable at LGD, and 16 patients (26%) ‘regressed': 8 to indefinite-for-dysplasia and 8 to
metaplasia. Four patients were lost to follow up. A segment length > 6 cm was strongly
predictive of progression (OR: 13.79, P value = 0.004). Increasing age approached significance
(OR: 1.05, P value= 0.08). The mean interval to progression to HGD or EAC was 39 months.
The cumulative incidence of progression to EAC was 2.3% per year. Conclusion: In our
cohort of subjects with LGD, the cumulative incidence of esophageal adenocarcinoma was
2.3 % per year. The majority (61%) of subjects remained stable with LGD and 6.6% of
subjects progressed to either HGD or EAC over a mean interval of 39 months. Barrett's
segment length > 6 cm was strongly predictive of progression. Given these findings, current
endoscopic guidelines may need to be reconsidered. Further prospective studies are needed
to determine whether surveillance intervals can be extended in individuals with LGD and
shorter Barrett's segments, thus easing the current burden of surveillance.
M1949
Variation in 18f-Fluorodeoxyglucose Uptake By Positron Emission
Tomography in Esophageal Tumors: Correlation with Glucose Transporter-1
Protein and Response to Neoadjuvant Chemoradiotherapy
Ali Raouf, Vinod Malik, Mairead Griffin, John Reynolds
Aims: to investigate whether 18F-fluorodeoxyglucose (FDG) uptake, quantified by positron
emission tomography (PET), correlates with tumor stage, response to preoperative chemorad-
iation therapy, cell proliferation, and glucose metabolism in patients with esophageal carcin-
oma. Methods: Sixty-eight patients (56 male, 12 female) were studied. Thirty-six patients
received chemoradiation therapy before surgery, 14 patients received palliative chemotherapy
or radiotherapy without surgery and 18 patients received surgery alone. PET images were
acquired with a PET scanner for all patients after administration of FDG (5 MBq/kg) at
baseline and after the first course of chemo-radiation therapy. Mean and maximum standard-
ized uptake values (SUVmean, SUVmax) and tumor metabolic volume (TMV) were both
recorded. Tumor stage based on TNM classification. MIB-1 and Glut-1 expression was
detected using immunohistochemistry. Results: Baseline FDG-PET maximum and mean
SUVs were positively correlated with TMV (p<0.0001). The Mean SUV, Maximum SUV,
and TMV were significantly higher in patients with squamous cell carcinoma (n=22) than
in those having adenocarcinoma (n=46) (p=0.0002, p=0.002 and p=0.01) respectively. The
mean and maximal SUVs were significantly higher in Glut-1 positive tumors compared to
Glut-1 negative tumors (p=0.001 and p=0.007) respectively. Glut-1 expression was signific-
antly (p<0.0001) higher in squamous cell carcinomas than in adenocarcinomas, whereas,
MIB-1 expression was higher in adenocarcinomas (p=0.002). In patients with squamous
cell carcinoma, the mean SUV, maximum SUV, and TMV were significantly correlated with
tumor growth index (MIB-1 score) (p=0.001, p=0.002 and p=0.03) respectively. Over all,
the mean and maximum SUVs and TMV were significantly reduced after the fist course of
chemoradiation therapy. Baseline and chemoradiotherapy induced changes in FDG-PET
uptake did not correlate with tumors' pathological response at surgery. Conclusion: Baseline
18F-FDG PET uptake in esophageal tumors correlates with Glut-1 expression. Low expression
of Glut-1 was detected in adenocarcinoma whereas in contrast, high expression was found
in squamous cell carcinoma. Higher FDG PET values were correlated with higher growth
activity. Pathologic response to neoadjuvant chemoradiation therapy in esophageal cancer
could not be predicted by FDG PET.
M1950
Luminal Response As a Predictor of Pathological Response to Neoadjuvant
Therapy in Oesophageal Carcinoma
Abdulla Fakhro, Jurgen Mulsow, Eamon Leen, Thomas N. Walsh
Background: Twenty-five percent of patients with oesophageal adenocarcinoma and approx-
imately 40% with squamous cell carcinoma have a complete pathological response to neoad-
juvant chemoradiotherapy. These patients can derive no benefit from oesophageal resection
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and surgery exposes them to considerable risk of morbidity and mortality. Identification of
this cohort of patients following therapy would be advantageous. The aim of this study was
to assess the accuracy of the luminal response in predicting complete pathological response
to neoadjuvant therapy. Methods: Forty-nine patients who had received neoadjuvant chemor-
adiotherapy for oesophageal cancer and in whom we had performed pre- and post resection
endoscopy, photography and biopsy were identified. The luminal response was compared
to pathological findings in the oesophagectomy specimen. Results: Twenty patients (40%)
had a complete pathological response. All demonstrated a complete luminal response.
Twenty-nine (60%) patients had an incomplete response. Preoperative oesophagoscopy and
biopsy identified residual tumor in 22 patients and was falsely negative in seven. Conclusion:
A complete luminal response in patients with oesophageal cancer is 74% predictive of a
complete pathological response following neo-adjuvant therapy. Further refinement of
response indicators will facilitate decision making following neo-adjuvant therapy and may
allow unnecessary surgery in a significant cohort of patients to be avoided.
M1951
Risk Factors for the Development of Oesophageal Cancer in Barrett's
Oesophagus: A Primary Care Cohort Study
Sheldon C. Cooper, Phil Graham, Nigel J. Trudgill
Introduction The annual risk of Barrett's oesophagus (BO) progressing to oesophageal cancer
is estimated between 0.5-2%. Previous studies examining risk factors for oesophageal cancer
in BO have been limited to surveillance program patients, with inherent selection biases.
Methods The Health Improvement Network (THIN) database collects information from
primary care consultations from 4.5 million patients in the UK. Patients with BO with at
least two years of follow-up were identified. The influence of age, gender and drugs potentially
associated with the development of oesophageal cancer (aspirin, NSAIDs, statins, COX-2
inhibitors, ACE inhibitors and lower oesophageal sphincter (LOS) relaxing drugs nitrates,
calcium-channel blockers, anti-cholinergics, benzodiazepines, theophyllines and β-agonists)
were examined. Cox regression analysis generated hazard ratios for association of these risk
factors with the development of oesophageal cancer. Results Of 5110 patients with BO,
3375 were eligible for the study and 50 of these developed oesophageal cancer. Median age
(IQR) in BO patients was 63 (52-72) and cancer group 67 (59-73), hazard ratio (95% CI)
1.03 (1.01-1.06, p=0.004) for each increasing year. Male gender was associated with develop-
ing cancer (82% male), BO (62% male); 2.8 (1.36-5.76, p=0.005). No drug therapy was
negatively associated with progression to cancer. Two drugs groups were associated with
progression to cancer: nitrates (cancer 36% vs. remaining BO 21%, 1.89 (1.04-3.32, p=
0.036)); β-agonists (cancer 46% vs. remaining BO 29%, 1.91 (1.09-3.33, p=0.023). All
other drugs examined were not individually associated with cancer. However, cumulative
addition of LOS relaxing drugs led to an increasing association with cancer: 1 drug 0.97
(0.37-2.5), 2 drugs 1.94 (0.8-4.68), 3 or more drugs 2.61 (1.15-5.94, p=0.02). Discussion
Male gender and increasing age in BO were associated with progression to oesophageal
cancer. Ingestion of aspirin or NSAIDs were not negatively associated with developing cancer.
β-agonist and nitrate use were associated with the development of oesophageal cancer.
Increasing ingestion of different LOS relaxing drugs was also associated with progression
to cancer in this BO cohort.
M1952
Constitutive Activation of Ikk/Nf-κB in Gastric Cancer Cells Plays a Pivotal
Role in Cancer Expansion
Ayako Yanai, Shin Maeda, Youko Hikiba, Wataru Shibata, Tomoya Ohmae, Kei Sakamoto,
Hayato Nakagawa, Keiji Ogura, Masao Omata
NF-κB is an important transcriptional factor that controls various biological processes, such
as inflammation, cell cycle, and cell survival or death. Constitutive NF-κB activity plays a
crucial role in the development and progression of lymphoma, leukemia, and some cancers.
The aim of our study is to clarify the importance of constitutive IKK/ NF-κB activation in
gastric cancer. To investigate whether NF-κB is constitutively activated in gastric cancer
cells, EMSA was performed in eight human gastric cancer cell-lines. NF-κB DNA binding
activity was increased constitutively in three cell lines (MKN-1, MKN-45, SH101-P4). Next,
we investigated the production levels of IL-8, which is strongly regulated by NF-κB and linked
to tumor expansion due to recruiting inflammatory cells. We found that IL-8 production levels
were significantly increased in these three cell-lines. Cell proliferation and IL-8 production
were analyzed in these cells by use of NF-κB inhibitor, and cell proliferation was suppressed
by the treatment of NF-κB inhibitor. In addition, production levels of IL-8 were also
significantly suppressed by the treatment of NF-κB inhibitor. To analyze the effect of NF-
κB for tumor progression In Vivo, we established SH101-P4 gastric cancer cells with stable
knockdown of IKK-γ which is critical regulator of NF-κB activation using RNA interference
(RNAi). In IKK-γ knockdown cells, cell proliferation was weaker than wild type cells. IL-8
production was significantly suppressed in IKK-γ knockdown cells. Finally, we transplanted
wild or IKK-γ knockdown cells to male BALB/c nude mice. After 28 days, tumor expansion
was suppressed for 76% in IKK-γ knockdown cells. Our results suggest that IKK/NF-κB
plays a crucial role in the expression of gastric cancer. This molecule may become one of
the important molecular targets of a new therapy against gastric cancer.
M1953
Helicobacter pylori-Induced FAK Activation and Cytoskeletal RE-Organization
Require Oipa Dependent Signaling with a Possible Involvement of EGFR
Fazal Tabassam, David Y. Graham, Yoshio Yamaoka
Background: Helicobacter pylori infection of gastric epithelial cells results in cytoskeletal
reorganization, motility and elongation. However, the sequence of signaling events leading
to these phenotypic changes remains unclear. Focal adhesion kinase (FAK) a non receptor
tyrosine kinase plays an important role to regulate actin cytoskeletal organization, focal
adhesion formation, and cell motility. Aim: To investigate H. pylori-induced activation of
FAK in mediating downstream signaling responsible for actin stress fiber formation in gastric
epithelial cells. Methods: AGS cells were co-cultured with live H. pylori or its isogenic cag
pathogenicity island (PAI) or oipA mutants and their effect on FAK site specific phosphoryl-
ation were evaluated by immunoblot and fluorescence microscopy using phosphospecific
antibodies. Results: Exposure of live H. pylori to AGS cells induced rapid and transient
tyrosine phosphorylation of FAK Y397 followed by phosphorylation of Src Y418 resulting
in activation of FAK Y407, Y576, Y577, Y861, and Y925 in a dose-and time-dependent
manner. Complete activation of FAK following formation of a FAK-Src signaling complex
resulted in activation of downstream effectors subsequently leading to actin stress fiber
formation. Moreover, inhibiting FAK expression using FAK-specific siRNA resulted in inhibi-
tion of H. pylori-mediated paxillin phosphorylation and stress fiber formation. oipA mutants
significantly reduced activation of FAK Y397, Y576, Y577 and Y925 and resulted in inhibition
of stress fiber formation and altered cell morphology. In contrast, cag PAI mutants markedly
reduced activation of FAK Y407, and Y861 without significant affect on stress fiber reorganiza-
tion than oipA mutants consistent with OipA being involved in tyrosine phosphorylation of
FAK and their downstream effectors. CagA formed a signaling complex with phosphorylated
FAK Y861 in a time and concentration dependent manner suggesting that the FAK-CagA
signaling complex may modulate downstream signaling and cellular responses. Chemical
inhibitors of EGFR resulted in inhibition ofH. pylori FAK phosphorylation and stress fiber
formation indicating an important role of EGFR in regulating intracellular signaling. Conclu-
sion: OipA, possibly through involvement of EGFR, is required in initiating FAK activation
which contributes to downstream signaling regulating H. pylori-associated cellular phenotypic
changes. FAK is an intracellular target of H. pylori-mediated signaling. Inhibition of site
specific activation of cytoskeletal proteins may provide a novel strategy for inhibition of H.
pylori-mediated downstream effectors.
M1954
Proteinase-Activated Receptors Increase Interleukin-8 Expression in Colonic
Epithelial Cells
Hongying Wang, France Moreau, Wallace K. Macnaughton
Proteinase-activated receptors (PARs) are G protein-coupled receptors that are activated by
serine proteinases such as thrombin, trypsin and tryptase, and which play important roles
in the processes of inflammation and tumorigenesis. It has previously been shown that
activation of PARs stimulates interleukin-8 (IL-8) expression in airway epithelial cells. IL-8
is a potent chemoattractant for neutrophils and is also involved in angiogenesis. We tested
whether PARs stimulate IL-8 expression in colonic epithelial cells and sought to determine
the mechanism whereby this occurred. HT29 colonic epithelial cells were exposed to the
PAR1-activating peptide (AP), TFLLR-NH2 (50 micro-Mol), or the PAR2-AP, SLIGRL-NH2
(50 micro-Mol). The expression of IL-8 mRNA was determined by semi-quantitative RT-
PCR, and IL-8 protein in the cell culture medium was measured by ELISA. Both the PAR1-
AP and PAR2-AP increased the mRNA level of IL-8 by 2 hours and the release of IL-8
protein by 18 hours. An IL-8 promoter luciferase reporter (bp -135 to +46) assay revealed
that PAR1- and PAR2-activating peptides caused a 3-fold increase in wild type reporter
activity. Further experiments were conducted in which HT29 cells were transfected with
IL-8 promoter constructs containing mutations of either nuclear factor-kappa B (NF-kappa
B) or activator protein-1 (AP-1) activation sites. Both mutations completely blocked PAR1-
and PAR2-induced IL-8 promoter activation in the luciferase assay. Further experiments, in
which HT29 cells were transfected with a loss of function mutation of the CCAAT/Enhancer-
binding Protein (C/EBP) site, showed a 50% reduction in PAR-induced IL-8 promoter
luciferase activity. These data indicated that the binding of NF-kappa B and AP-1 elements
are required for PAR1- and PAR2-induced transcriptional activation of IL-8. Activation of
the C/EBP site on the IL-8 promoter plays a partial role. In conclusion, activation of both
PAR1 and PAR2 stimulates the transcriptional expression and release of IL-8 through NF-
kappa B- and AP-1 transcription pathways in HT-29 cells. Therefore, this study provides
evidence suggestive of a new role for serine proteinases, acting through PAR1 and PAR2,
in colonic inflammation and tumorigenesis. (H. Wang is supported by a CAG-CCFC Fellow-
ship.)
M1955
CCK2 Receptor Splice Variants Stimulate Ncm356 Colonic Epithelial Cell
Growth and Tumorigenicity Via Autocrine Receptor Activation
Celia Chao, Xueliang Han, Kirk L. Ives, Courtney M. Townsend, Mary P. Moyer, Mark R.
Hellmich
Introduction: The expression of gastrin and CCK2 receptor splice variants (CCK2R and
CCK2i4svR) are upregulated in colonic adenomas where they are thought to regulate tumor
growth and progression. The aim of this study was to determine the effects of ectopic CCK2
receptor variant expression on colonic cell growth both In Vitro and In Vivo using the non-
transformed colonic epithelial cell line, NCM356. Methods: NCM356 cells were derived
from the normal colon mucosa of a patient with rectal cancer. Like normal colonic cells,
NCM356 cells do not express CCK2 receptor variants, do not grow in soft agar, and are
non-tumorigenic nude mice. Receptor expression was induced using a retroviral expression
vector containing CCK2i4svR or CCK2R, and quantified by I125G17 binding. In Vitro cell
growth was assessed with a Coulter counter. For In Vivo growth studies, nude mice (6/
group) were injected SQ with 5x106 cells. Gastrin mRNA expression and secretion by
NCM356 cells were assessed by RT-PCR and intracellular Ca2+ imaging using fura-2 loaded
RIE/CCK2 cells treated with NCM356 conditioned media (CM), respectively. MEK/ERK
pathway activity was assessed by immunoblotting for phospho-ERK (pERK). MEK and PKC
were inhibited with PD98059 (5 μM) and GF109302X (5 μM), respectively. Receptor-
mediated signaling was antagonized with YM022 (1 μM). Results: NCM356 cells expressing
CCK2R (7 fmol/mg) or CCK2i4svR (12 fmol/mg) grew faster (~3-fold) and exhibited a 6-fold
increase in basal levels of pERK, compared to vector infected cells. RT-PCR and intracellular
Ca2+ imaging of RIE/CCK2 cells treated with NCM356 CM revealed that NCM356 cells
express gastrin mRNA and secret biologically active peptide. YM022 inhibited the growth
of CCK2R- and CCK2i4svR-expressing NCM356 cells, but not the control cells. PD98059
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and GF109203X inhibited basal pERK and growth of receptor-expressing cells. Glycine-
extended gastrin (1 μM) did not increase [Ca2+]i or growth of CCK2R or CCK2i4svR-expressing
NCM356 cells, supporting previous reports that CCK2 receptor variants do not mediate the
trophic actions of non-amidated gastrins. Finally, NCM356 cells infected with the control
vector did not form tumors in nude mice, whereas, both CCK2R- and CCK2i4svR-expressing
cells formed large tumors (~600mm3) by 35 days. Conclusion: Autocrine activation CCK2
receptor splice variants is sufficient to increase both the In Vitro growth and tumorigenicity
of non-transformed NCM356 colon epithelial cells via a pathway involving PKC and MEK/
ERK, supporting the hypothesis that ectopic expression of gastrin and its receptors in human
colonic adenomas contributes to tumor cell growth.
M1956
New Crosstalk Between Insulin Receptor and G-Protein Coupled Receptor
Signaling Pathways in Human Pancreatic Cancer Cells
Krisztina Kisfalvi, Osvaldo Rey, Steven H. Young, Enrique Rozengurt
Background: Multiple lines of evidence support the existence of a fundamental crosstalk
between insulin receptor and G protein-coupled receptor (GPCR) signaling systems in both
the regulation of normal physiological functions as well as in the pathogenesis of a variety
of abnormal processes. For example, epidemiological studies have linked hyperinsulinemia
and Type II diabetes with increased risk for developing a variety of clinically aggressive
cancers of several tissues, including pancreatic ductal adenocarcinoma. Our previous results
demonstrated that pancreatic cancer cells express multiple G protein-coupled receptors.
Here we explored molecular mechanism(s) that mediate interaction between the insulin and
GPCR signaling pathways.Methods and Results: Exposure of ductal pancreatic adenocarcin-
oma BxPc-3, HPAF-II and PANC-1 cells to insulin for 1-5 min rapidly enhanced the
magnitude and the rate of increase in the intracellular Ca2+ concentration ([Ca2+]i) produced
by the G protein-coupled receptor (GPCR) agonists bradykinin, angiotensin II, vasopressin,
neurotensin and bombesin. The potentiating effect of insulin was dose-dependent, produced
in response to Gq-coupled, but not Gi-coupled receptor agonists and a consequence of Ca2+
mobilization from internal stores. Real-time imaging of single cells using a fusion protein
between GFP and the PH domain of PLC-δ1, (a sensor of PLC-mediated Ins(1,4,5)P3
synthesis) indicated that insulin enhanced phospholipase C (PLC)-mediated PtdIns(4,5)P2
hydrolysis and production of Ins(1,4,5)P3 elicited by Gq-coupled receptors. Short-term
treatment with either rapamycin or the PI 3-kinase and mTOR inhibitors LY-294002 and
wortmannin completely abrogated the ability of insulin to increase the rate and magnitude
of Ca2+ signaling and production of Ins(1,4,5)P3 in response to GPCR activation in pancreatic
cancer cells. Conclusion: Our results revealed that in pancreatic cancer cells treatment with
insulin enhanced the rate and magnitude of PLC-mediated PtdIns(4,5)P2 hydrolysis and
generation of Ins(1,4,5)P3, leading to Ca2+ mobilization from internal stores in response to
GPCR stimulation through an mTOR-dependent pathway. The potentiation of GPCR sig-
naling by insulin via mTOR provides a mechanism by which insulin enhances cellular
responsiveness to Gq-coupled receptor agonists, including GPCR-mediated autocrine and
paracrine loops in pancreatic cancer cells.
M1957
Role of Hypoxia-Inducible Factor (Hif)-1α Versus Hif-2α in the Colon Cancer
Takaaki Imamura, Eva-maria Duerr, Kotoyo Fujiki, Maria teresa Herraiz, Bo R. Rueda,
Daniel C. Chung
Introduction: Hypoxia-inducible factor (HIF) is a key regulator of the hypoxic response.
However, the specific roles of the two different isoforms, HIF-1α and HIF-2α, are not well
defined. Although both HIF-1α and HIF-2α appear to be regulated in a similar fashion by
hypoxia, recent evidence suggests that there is little redundancy between their functions.
Our goal was to better define the individual roles of HIF-1α and HIF-2α in colon cancer.
Methods: 1) Retroviral RNAi vectors targeting HIF-1α or HIF-2α were stably introduced
into the colon cancer cell line SW480, and designated W1/W2 (HIF-1α WT/ HIF-2α WT),
K1/W2 (HIF-1α knockdown/ HIF-2αWT), and W1/K2 (HIF-1αWT/ HIF-2α knockdown).
2) The polyclonal cells were evaluated in growth, migration, and soft agar assays. 3) Mutant
cells were injected into flanks of nude mice and the subsequent tumors were analyzed for
mass and CD31, PCNA, and Ki67 by immunostaining. 4) Differential gene expression was
assessed by cDNA microarray. Results: Although the In Vitro growth patterns were relatively
equivalent, the numbers of colonies on soft agar were significantly increased in HIF-2
knockdown cells compared with HIF-2 WT cells (W1/W2 26.3±3.5, K1/W2 24.8±6.2, W1/
K2 53.3+/-4.6 colonies/ x100). In contrast, a migration assay revealed that significantly fewer
HIF-1-deficient cells migrated through an 8um pore when compared to HIF-1 WT cells
(W1/W2 203.3±18.2, K1/W2 27.7±3.5, W1/K2 288.7±14.0 cells/ x100). The weights of
HIF2-deficient xenograft tumors were significantly higher (W1/W2 0.19±0.07g, K1/W2
0.07+/-0.02g, W1/K2 0.50±0.22g). CD31 IHC revealed that the mean microvessel density
(MVD) per tumor was similar in all groups (W1/W2 35.1±9.7, K1/W2 24.1±8.1, W1/K2
23.0±10.6). The percentage of PCNA positive cells was higher in the HIF2-deficient tumors
(W1/W2 58.8±10.8%, K1/W2 49.6±6.7%, W1/K2 86.3±6.7%). cDNA microarray analysis
revealed 894 hypoxia-responsive genes, of which 300 were both HIF-1 and HIF-2 dependent,
189 were only HIF-1 dependent, 113 were only HIF-2 dependent, and 294 were HIF
independent. Conclusions: Both In Vitro and In Vivo data demonstrated that HIF-1α and
HIF-2α have distinct roles in colonic tumorigenesis. Cells deficient in HIF-2 displayed a
greater ability to form tumors in soft agar but no change in migratory capabilities. Consistent
with this observation, HIF-2α deficient xenografts were larger and had higher proliferative
rates. No significant differences in MVD were seen in the 2 groups. These data suggest that
HIF-1α and HIF-2α can function in opposing manners to regulate tumor growth. This has
important implications for strategies that target HIF for the treatment of colon cancer.
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M1958
Regulation of the Hedgehog Signaling Pathway By Epidermal Growth Factor in
Gastric Cancer
Motoko Seto, Miki Ohta, Yoshinari Asaoka, Keisuke Tateishi, Lian-jie Lin, Motohisa Tada,
Yasuo Tanaka, Fumihiko Kanai, Takao Kawabe, Masao Omata
[Background and Aim]While recent studies have shown that activation of hedgehog (HH)
signaling has been implicated in the growth and maintenance of variety of tumors including
gastrointestinal cancers, the precise mechanism of activation remains poorly understood.
The aim of this experiment is to investigate the regulation of HH signaling by growth factor
stimulation in gastric cancer cells. [Materials and Methods]Human gastric cancer cell lines
AGS, MKN1, MKN45, MKN74, SH101-P4 and tissue specimens from 17 patients with
gastric carcinoma who underwent gastrectomy were used. Transfection assays were performed
with GLI reporter plasmid and the expression plasmid of human GLI1, SUFU, p110α,
KRAS, BRAF and MEK1. The expression of mRNA was quantified using quantitative reverse
transcription-PCR. The expression of protein was detected by immunoblot assay or immuno-
histochemistry. [Results]The luciferase activity of GLI was increased by EGF stimulation in
AGS cells. EGF stimulation upregulated also the gene expression of GLI1, PTCH and BCL2,
which are known as target genes of HH signaling. KRAS, BRAF and MEK1 transfection also
induced an increase in the GLI-luciferase activity, which was blocked by MEK1/2 inhibitor,
while transfection of constitutively active mutant of p110α did not affect the GLI-luciferase
activity. The increased activity of HH signaling by KRAS stimulation was also observed in
all of the five gastric cancer cells examined. The regulation of activity of GLI by MEK1 was
also observed when GLI1 was overexpressed in AGS cells, which suggested that GLI1 was
implicated in the regulation of HH signaling by MEK1. Moreover, the activation of HH
signaling by MAPK signal stimulation was blocked by SUFU, which is know as one of the
negative regulator of HH signaling. In immunohistochemical assay using 17 cancer tissue
specimens, PTCH was detected in 10 samples and ERK1/2 was phosphorylated in four
samples in which strong expression of PTCH was detected. [Conclusions]HH signal activity
is increased by EGF stimulation in RAS-RAF-MEK dependent and PI3K independent manner
in gastric cancer cells. MEK1 upregulates the GLI activity by a different mechanism with
one of SUFU regulation of HH signaling.
M1959
Augmented Gp130-Mediated Cytokine Signaling Accompanies Human Gastric
Cancer Progression
Cameron B. Jackson, Louise M. Judd, Ian Kronborg, Christopher Dow, Neville D.
Yeomans, Alex Boussioutas, Andrew S. Giraud
H. pylori infection accounts for most cases of gastric cancer, but the initiating events are
unclear. Recently it has been shown that the H. pylori cytotoxin CagA is injected into gastric
epithelial cells where it disrupts signaling pathways including those used by IL-6 family
cytokines. Our mouse model of stomach tumourigenesis has shown that imbalancing IL-6
signaling produces homeostatic dysregulation leading to antral tumours that progress from
gastritis to dysplasia. Early formative events are loss of tumour suppressor gene tff1 expression
and constitutive activation of oncogenic STAT3. We hypothesise that H. pylori infection
might also imbalance IL-6 family cytokine signaling pathways in human stomach in a
homologous fashion to the mouse. Here we have investigated whether: (i) STAT3 and ERK1/
2 activation is augmented in gastritic human stomach; (ii) these profiles are more pronounced
in CagA+ H. pylori infection; (iii) the expression profiles of pro-inflammatory cytokines that
activate STAT3 and ERK 1/2 pathways correlates with the progression to gastric cancer. IL-
6 family cytokines IL-6, IL-11 and for comparison the known H. pylori inducible cytokine
IL-8 mRNA were analysed by RT and Q-PCR, and activated (p)STAT3 and (p)ERK1/2 by
Western blotting. The STAT3 target gene socs3 was quantified by Q-PCR. Antral stomach
biopsy extracts from gastritic, non dysplastic patients, with or without CagA+ or CagA- H.
pylori infection, and from resected antral stomach with intestinal metaplasia or intestinal-
type adenocarcinoma were analysed. H. pylori infection stimulates both STAT3 and ERK 1/
2 activation (3-4 fold;both p<0.001), an effect enhanced by CagA. IL-6 and IL-8 expression
were increased after H. pylori infection, and these cytokines as well as IL-11 were further up-
regulated in gastric cancer (all p<0.05). Increased STAT3 and ERK1/2 activation accompanies
infection by CagA+ H. pylori, and is driven in part in an IL-6 family cytokine-dependent
fashion. These altered signaling eventsmay contribute to early neoplastic progression in
susceptible individuals.
M1960
Attenuated Number of Azoxymethane (Aom)-Induced Colon Tumors in M3
Muscarinic Receptor (M3R)-Deficient Mice Compared to Wild-Type (wt)
Controls
Kunrong Cheng, Roxana Samimi, Jean-pierre Raufman
Colon epithelial cells express M3R and the majority of colon cancers over-express M3R (Clin
Can Res 5:2532, 1999; Carcinogenesis 21:1789, 2000). In Vitro studies in human colon
cancer cell lines indicate that post-M3R signaling stimulates EGF receptor transactivation
and cell proliferation (Cancer Res 63:6744, 2003). To explore the importance of M3R in
colon cancer, we applied the murine AOM colon tumor induction model to M3R-deficient
and control 129SvEv mice. Animals were treated with weekly x 6wks intraperitoneal injection
of vehicle (PBS, N=10 WT mice) or AOM (N=22 WT and 16 M3R-/- mice). Mice were weighed
weekly, observed for evidence of tumor formation (e.g. anal bleeding), and euthanized at
wk 22. Excised colon length was measured and tumors identified using a dissecting micro-
scope (Nikon SMZ1500)-segments were opened longitudinally, photographed and tumor
number and diameter measured (Image-Pro). Tumor volume (vol) was calculated: vol=1/2
width x length2. As reported previously (Nature 2001,410:207), at wk 0 M3R-deficient mice
weighed less than WT mice (19.3±0.7 vs. 25.6±0.6 g; mean±SE; p=3x10-9) and although
both groups gained weight over the 22-wk study, WT persistently weighed ~17% more
than M3R-deficient mice. Starting at wk 4 and persisting to wk 22, AOM-treated WT mice
weighed less than PBS-treated WT mice (34.1±0.6 vs. 38.8±0.5 g at wk 22; p=0.003).
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Despite weight differences, at 22 wks colon length was the same (11.6±0.4 vs. 11.6±0.2 vs.
10.7±0.2 cm; WT-PBS vs. WT-AOM vs. M3R-/--AOM; all p > 0.05). No mice had rectal
bleeding. At 22 wks, 50% of WT-PBS, 100% of WT-AOM and 94% of M3R-/--AOM mouse
colons had tumors (p= 0.001 for WT-PBS vs WT-AOM). Clearly, AOM treatment induced
tumor formation; WT-PBS animals had 4.3±1.6 and WT-AOM had 21.1±2.4 tumors/mouse
(p<0.005). Strikingly, M3R-/--AOM had only 7.9±1.0 tumors/mouse, a 79% reduction com-
pared to tumor number in WT-AOM mice (p=0.00006) and not significantly different from
WT-PBS mice (p>0.05). Tumor number ranged from 5-51/mouse in WT-AOM compared
to 0-14/mouse in M3R-/--AOM mice. PBS-treated mice had smaller tumors than AOM-treated
mice; mean vol per tumor was 1.5±0.3 in WT-PBS mice vs. 5.6±0.6 and 4.5±0.6 mm3 in
WT-AOM and M3R-/--AOM mice (WT-PBS p<0.05 and <0.005 compared to WT-AOM and
M3R-/--AOM, respectively). Maximal tumor vol in WT-AOM mice was 167 mm3 vs. 40 mm3
in M3R-/--AOM mice but mean tumor vol was the same in M3R-/--AOM compared to WT-
AOM animals (p=0.4). In conclusion, compared to WT, M3R-deficient mice had a 79%
reduction in the number of AOM-induced colon tumors. In Vivo findings in this murine
model confirm that expression of M3R is important for colon carcinogenesis.
M1961
Bombesin (Bn)-Stimulated Human Carcinoma-Associated Fibroblasts (Cafs)
Induce Cyclooxygenase-2 (Cox2) Expression and Prostaglandin E2
(PGE2)Synthesis
Celia Chao, Kirk L. Ives, Courtney M. Townsend, Mark R. Hellmich
Introduction: Reciprocal interplay between epithelial and stromal cells contribute to colorec-
tal carcinoma development, with CAFs as the major cell type in cancer stroma. Induction
of the pro-oncogenic COX2 occurs early in the CAFs in premalignant polyps, and then later
in the invasive cancer cells. Studies have shown that subjects who use COX2 inhibitors
have much lower incidence of adenomatous polyps, indicating that early blockade of COX2
may prevent cancer. COX2 expression is stimulated by GI peptide hormones, including
gastrin-releasing peptide (GRP)or its homologue, BN,and its cognate receptor, GRPR. We
have reported GRPR is expressed on CAFs in 19/20 primary colorectal cancer specimens
examined. The aim of this study was to determine if BN-activation of GRPR-positive CAFs
is mechanistically linked to the regulation of COX2 expression and activity. Methods:
Primary human colorectal carcinomas were collected under an IRB-approved protocol. We
identified CAFs as vimentin-positive, cytokeratin-negative cells and assessed presence of
functional GRPR by BN-stimulated Ca2+ imaging. COX2 induction was assessed by immuno-
cytochemistry using anti-COX2 antibody; The MEK/MAPK pathway was inhibited with
PD98059. Conditioned media (CM) from CAFs treated ±BN were collected and PGE2 release
was analyzed by enzyme-linked immunosorbent assay. Statistical analysis comparing groups
was performed using the student's t-test. Results: CAFs were plated on collagen-coated
coverslips. GRPR-expressing cells were identified using Ca2+ imaging. Cells were then fixed
and immunostained for COX2 protein. At the single cell level, the BN-stimulated, Ca2+-
responsive CAFs were also the same cells that exhibited increased levels of COX2 protein
expression 8 h after agonist treatment compared to control by immunostaining. This effect
was attenuated by PD98059, a MEK1,2 inhibitor. Since COX2 causes overproduction of
PGE2, CM from CAFs treated ±BN were measured. BN-stimulated CAFs increased the release
of PGE2, compared to control (1320±46 v 327±13 pg/ml; p<0.001). To evaluate the mitogenic
actions of BN, CAFs were treated overnight with vehicle or BN (10-7M) and cell proliferation
was determined using a colorimetric immunoassay measuring cellular 5-bromo-2'deoxyurid-
ine incorporation. BN stimulated CAF DNA synthesis compared to vehicle (p=0.002). Con-
clusions: We have demonstrated a direct mechanistic link between BN activation of CAFs
with induction of COX2 protein expression and PGE2 synthesis. These data contribute to
the hypothesis that BN stimulates colorectal carcinogenesis, not by directly regulating colonic
epithelial cells, but rather, indirectly, by activating the CAFs.
M1962
Cooperative Induction of COX-2 By Gastrin and TGF-β Requires
Transactivation of EGF Receptor
Yan-shi Guo, Mark R. Hellmich, Courtney M. Townsend
Background: Multiple lines of evidence suggest that cyclooxygenases (COX-2) has an import-
ant role in colorectal carcinogenesis. The molecular mechanisms that lead to increased levels
of COX-2 in the gut are not well defined. Gastrin is trophic for the normal gastric oxyntic
mucosa and exerts a growth-promoting action on gastrointestinal malignancy. Gastrin and
its receptor, CCK-B receptor, are increased in most colorectal cancers. We have reported
that gastrin stimulates expression of COX-2 mRNA, protein and its promoter activity in
intestinal epithelial cells (J Biol Chem 2002; 277:48775). TGF-β was shown to increase
COX-2 expression in intestinal cells. The purpose of this study was to determine whether
gastrin and TGF-β synergistically upregulate COX-2 gene expression in gut cells, and if so,
what mechanisms are involved. Methods. A non-tumorigenic rat intestinal cell line (RIE/
CCKBR) that stably transfected CCK-B receptor was grown in DMEM medium containing
5% fetal calf serum and 400 μg/ml of G418. Cells were treated with either gastrin or TGF-
β in serum-free conditions. The levels of COX-2 mRNA and protein were examined by
Northern blot and Western blotting, respectively. Results. Gastrin (1, 10 and 100 nM) and
TGF-β1 (0.3, 1, and 3 ng/ml) treatment alone increased COX-2 mRNA and protein in dose-
and time-dependent fashions, but the stimulation of COX-2 expression by TGF-β1 was
maintained for a longer time than that observed with gastrin (Fig. 1). The combination of
both peptides synergistically stimulated the COX-2 protein (Fig. 1) and mRNA expression.
To determine the mechanisms of cooperative induction of COX-2, we found that treatment
with both peptides enhanced the COX-2 mRNA stability. Moreover, a selective inhibitor of
the EGF receptor AG1478 (0.1-1 μM) significantly suppressed the synergistic induction of
COX-2 protein. Conclusions. Gastrin acts synergistically with TGF-β1 to upregulate COX-
2 expression in intestinal epithelial cells. This effect is due to increased COX-2 mRNA stability
and requires the activation of EGF receptor in the cells. These results have implications for
providing a potential mechanism for upregulation of COX-2 during colorectal carcinogenesis.
M1963
TGFβ Induces Pkcα Activation Through IP3 Receptor Activation and Calcium
Release in Pancreatic Cancer Cells
Jimmy Y. Chow, Hui Dong, Daniel Poon, Khai Quack, Kevin Chen, Eric J. Smoll, John
M. Carethers
Background: Transforming growth factor-beta (TGFβ) is a key tumor suppressor for normal
pancreatic cell homeostasis. In pancreatic cancer, the suppressor function is lost in part by
events that affect the TGFβ-SMAD signaling pathway, such as allelic loss of SMAD4 and
oncogenic K-RAS activation which slows nuclear translocation of SMADs. With loss of
suppressive SMAD signaling, TGFβ can promote cellular proliferation, but the mechanisms
leading to proliferation are not understood. We examined if TGFβ could activate PKCα as
a possible proliferative pathway. We hypothesized that TGFβ induces PKCα activity by
increasing intracellular calcium levels through activation of the IP3 receptor (IP3R) on the
endoplasmic reticulum membrane. Methods: BxPc-3 human pancreatic cancer cells were
treated with TGFβ, BAPTA-AM (a calcium chelator), and 2APB (an IP3R inhibitor) at different
time points. Proteins were extracted from the membrane and cytosol fractions of the cells
and probed for the presence of PKCα by Western blotting. Intracellular calcium levels were
measured using a fluorescent calcium-sensitive dye, FURA-2AM. Results: TGFβ activates
PKCα by translocating it from cytosol to membrane. TGFβ increases the intracellular calcium
levels while pre-treatment with 2APB inhibits this effect. Pre-treatment of the cells with
BAPTA-AM or 2APB reverses TGFβ-induced PKCα activity. Conclusion: TGFβ activates
PKCα in part by activting the IP3R, which releases calcium from the endoplasmic reticulum.
These intracellular stores of calcium are important for PKCα activity and tumor cell prolifera-
tion. Because calcium may potentially enter the cytosol through different receptors in addition
to IP3R,, further investigation is required. This is the first demonstration to show TGFβ can
mobilize calcium stores to activate proliferative PKCα signaling in pancreatic cells. Future
treatments of pancreatic cancer and other cancers may involve manipulation of intracellular
calcium levels and PKCα activity.
M1964
Astragalus Saponins Induce Transcriptional Activation of NSAID-Activated
Gene (Nag-1) in Colon Cancer Cells Via a PI3K-Akt/Egr-1 Signaling Pathway
Joshua K. Ko, Kathy K. Auyeung, Mandy M. Tin, Chi-hin Cho
Background & Aims: We had previously reported that total astragalus saponins (AST) possess
strong anti-proliferative and pro-apoptotic effects in colon cancer cells, which involve over-
expression of a novel pro-apoptotic factor NSAID-activated gene (NAG-1). In the present
study, we further examined the upstream signaling pathway that regulates the above effects.
Methods: AST was incubated in HCT116 colon adenocarcinoma cell culture for different
treatment times. Protein expression of various transcriptional factors in the colon cancer
cells was evaluated by Western blotting. The promoter activity of NAG-1 and DNA binding
activity of Egr-1 (the upstream activator of NAG-1) were determined by luciferase reporter
assay and electrophoretic mobility shift assay, respectively. Regulation of AST-induced NAG-
1 transcriptional activation was tested by using specific Akt and phosphatidylinositol 3-
kinase (PI3K) inhibitors. Results: AST (60 and 80 µg/ml) caused an utmost NAG-1 protein
over-expression after 24 h of treatment in HT116 cells, of which the induction of NAG-1
promoter activity was peaked at 6 h (with 1.5- to 2-fold increase). Corresponding peak
over-expression of Egr-1 protein was observed at 12 h after AST treatment, whereas its DNA
binding activity remained prominent between 3-12 h. Specific Akt inhibitor (10 µM) increased
NAG-1 protein expression (by 3.3 folds), although to a lesser extent than that induced by
AST (by 6 folds). When Akt inhibitor was treated along with AST, NAG-1 expression was
drastically increased by 13.4 folds. Although PI3K is a known upstream activator of Akt,
treatment of its specific inhibitor LY294002 (50 µM) could not produce a significant up-
regulatory effect on AST-induced NAG-1 expression. Nevertheless, LY294002 caused a
reduction in Egr-1 protein expression, which was not achieved by using Akt inhibitor. In
addition, it is interesting to note that AST treatment for 24 h could in turn lead to increased
expression (by 1.5 fold) of p-Akt (ser 473), the active form of Akt. Conclusion: These
findings exemplify a complicated signaling pathway of AST-induced NAG-1 induction in
colon cancer cells. NAG-1 transcriptional activity has been induced by AST via increased
Egr-1 DNA binding activity, which could be facilitated by PI3K. Akt is shown to be a negative
regulator of AST-provoked NAG-1 induction, which appears to be PI3K-independent. The
activation of Akt by AST could designate a special self-regulatory mechanism, which needs
to be further clarified.
M1965
Up-Regulation of Gastrin Gene Expression Under Hypoxic Conditions Occurs
Via Hypoxia Inducible Factor-1α Within Gastrointestinal Carcinomas
Eve Royal, Anna M. Grabowska, Susan A. Watson
Introduction: Tumour hypoxia has been linked to increased resistance to radio/chemotherapy.
Under hypoxic conditions, genes that promote tumour growth and survival are up-regulated,
mediated by the transcription factor subunit, hypoxia-inducible factor-1α (HIF-1α), which
is often over-expressed in tumours. The digestive hormone gastrin, which is over-expressed
in cancers, plays a pro-angiogenic and anti-apoptotic role in carcinoma progression, leading
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to increased cell proliferation, differentiation and migration. The relationship between HIF-
1α and gastrin expression was investigated in gastrointestinal (GI) carcinoma cell lines.
Methods: GI carcinoma cell lines (PAN1, pancreatic; HCT116, colonic; MGLVA1, gastric)
were exposed to normoxia or hypoxia (1% oxygen) or treated with 1nM gastrin. A specific
HIF-1α siRNA and a dominant-negative HIF-1α plasmid were used to down-regulate HIF
expression. RNA was extracted from the cells, obtained from the different treatments and
investigated for HIF-1α, VEGF and gastrin expression using real-time PCR. Nuclear HIF-
1α protein expression was investigated using Western blotting. The promoter region of the
gastrin gene was examined using the Ensembl genome browser and SDSC Biology WorkBench
software. Results: HIF-1α nuclear protein expression increased under hypoxic conditions,
with maximal expression occurring between 4-8hr. This led to a subsequent increase in
VEGF gene expression (p<0.0001), which correlated with the maximal increase in HIF-1α
protein. After 16hr hypoxic incubation, gastrin gene expression was shown to increase by
6-20 fold (p<0.0001), depending on the cell line tested. Inhibition of HIF-1α using target-
specific siRNA resulted in a 60% down-regulation of gastrin gene expression under hypoxia
(p<0.0001). The presence of a potential hypoxia-response element (HRE) was discovered
in the gastrin promoter, which showed high levels of homology with the VEGF HRE sequence.
Conclusion: Gastrin gene expression is up-regulated in hypoxia and this is mediated, at
least in part through HIF-1α since knock-down of HIF-1α reduced hypoxic up-regulation
of gastrin. HIF-1αmay act through a putative HRE located upstream of the gastrin transcrip-
tion start-site, which has homology with the VEGF HRE. Up-regulation of gastrin during
hypoxia may promote GI tumour cell survival and resistance to radio/chemotherapy.
M1966
Helicobacter pylori-Mediated Hypergastrinaemia Stimulates Hb-EGF Shedding
Via Up-Regulation of Matrix Metalloproteinase-7
Yinfei Yin, Anna M. Grabowska, Susan A. Watson
Background and Aims: Helicobacter pylori (H. pylori) infection is the strongest risk factor
in the development of distal gastric adenocarcinoma and leads to up-regulation of heparin-
binding epidermal growth factor (HB-EGF) gene expression and protein shedding through
the induction of serum gastrin. We investigated the possibility that matrix metalloproteinase
(MMP)-7 is also up-regulated in H. pylori infection as a result of hypergastrinaemia since
this enzyme may play a role in increased shedding of HB-EGF. Methods: The gastric cell
line MGLVA1 was co-cultured with H. pylori strain 60190 in an In Vitro H. pylori infection
model. Small interfering RNAs (siRNAs) were used to knock down gastrin and MMP-7
expression. A MMP-7 neutralizing antibody was used to inhibit MMP-7 activity. Gene
expression was quantified by real time-PCR and HB-EGF shedding was measured using an
ELISA. The transgenic InsGas mouse model of gastric cancer was used for the In Vivo study,
which over-expresses gastrin in the pancreas, resulting in raised serum gastrin levels and
the development of gastric carcinogenesis. InsGas mice were immunised with the gastrin
immunogen, G17DT. Mouse stomachs were collected at 40 weeks and paraffin-embedded.
MMP-7 and HB-EGF expression in the samples was investigated using immunohistochem-
istry. Results: Gastrin, MMP-7 and HB-EGF gene expression was up-regulated significantly
in MGLVA1 exposed to H. pylori (p<0.001). Down-regulation of gastrin by siRNA decreased
the gastrin induced up-regulation of MMP-7 and HB-EGF during H. pylori and epithelial
co-culture (p<0.01). MMP-7 neutralizing antibody inhibited H. pylori-mediated up-regulation
of HB-EGF shedding (p<0.006). In stomachs obtained from InsGas mice, MMP-7 was
detected at the base of the glands and G17DT treatment down-regulated MMP-7 expression
(p<0.002). HB-EGF expression was more distributed over the whole section and also down-
regulated in the G17DT treated group compared with the control (p<0.008). Conclusion:
MMP-7 is up-regulated in H. pylori infection at least partially as a result of hypergastrinaemia.
The up-regulation of MMP-7 may play a role in increasing HB-EGF gene expression and
shedding. This might be a potential pathway which contributes to the development of gastric
cancer caused by H. pylori infection.
M1967
The Focal Adhesion Kinase FAK, But Not Pyk2, Plays a Central Role for
Growth Factor and CCK Stimulated Signaling in PANC-1-Cells
Andrea Pace, Meike A. Müller, Michael Bläker, Ansgar W. Lohse, Andreas De weerth
INTRODUCTION: The structurally related focal adhesion kinases FAK and PYK2 are involved
in key signal transduction pathways in normal and malignant tissues. In spite of their
structural homology, they have distinct roles in key cellular events such as cell adhesion,
regulation of the cell cycle and apoptosis. In contrast to PYK2, FAK promotes cell-survival
and proliferation. Pancreatic carcinoma is one of the most frequent GI-cancers with a very
poor prognosis. There is rising evidence for FAK to be implicated in pancreatic cancer. The
aim was to study the expression of focal adhesion kinases, their activation by HGF and
CCK and their involvement in intracellular pathways in pancreatic cancer. METHODS: FAK
and PYK2 were detected in PANC-1 by immunoprecipitation (IP), their activation assessed
by western blotting with phosphotyrosine antibodies. The involvement with other proteins
was assessed by coimmunoprecipitation. Their expression in human pancreatic cancer tisuues
was assessed by PCR and immunohistochemistry. RESULTS: In spite of their simultaneous
expression in non malignant pancreatic cells, FAK, but not PYK2 is expressed in PANC-1
cells as shown by WB, PCR and immunostaining. The stimulation with HGF and CCK
stimulated the tyrosine phosphorylation (TyrP) of FAK and its autophosphorylation site
pY397. HGF and CCK induced an association between FAK and the pp60Src. Furthermore
the GF and CCK stimulation leads to the activation of one of FAKs downstream targets,
ERK 1/2. The addition of the specific Src-inhibitor PP2 inhibited FAKs TyrP and ERK 1/2
activation. CONCLUSION: Similar to the expression in other malignant tissues and cell
lines, we found FAK but not PYK2 expression in the pancreatic carcinoma cell line PANC-
1. FAK gets activated upon growth factor and CCK stimulation. This TyrP is dependent on
Src. Moreover, the HGF and CCK induced ERK activation is Src dependent. These data
suggest that FAK mediates mitogenic signaling in pancreatic carcinoma, implying a central
role in pancreatic carcinogenesis for FAK.
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M1968
Proteolytic TGF-β1 Activation in Gastric Cancer
Lukas Hawinkels, Hein W. Verspaget, Wim Van duijn, Johanna Van der zon, Frank
Kubben, Gerrit Griffioen, Daan Hommes, Cornelis B. Lamers, Cornelis Sier
Transforming Growth Factor Beta 1 (TGF-β1) is a cytokine exerting a tumor-suppressive
and a tumor-promoting role, depending on tumor type and stage. TGF-β1 is synthesized
as a latent complex, which is bound to the extracellular matrix (ECM) after release. Activation
occurs presumably by proteolytic cleavage or conformational change. Active TGF-β1 binds
to TGF-β receptor II, leading to signal transduction and subsequent ECM deposition, promo-
tion of angiogenesis, and immune suppression. We examined TGF-β1 activation in human
gastric cancer. Immunohistochemistry in normal gastric mucosa showed some epithelial and
stromal staining for total TGF-β1, and little or no immunoreactivity for active TGF-β1. In
the tumors an increase in stromal and epithelial total TGF-β1 staining was observed. Active
TGF-β1 was present in malignant epithelial cells, but also strongly in smooth muscle actin
expressing fibroblasts, suggesting that increased levels of activated TGF-β1, more than overall
TGF-β1 levels, are associated with accumulation of myofibroblasts in gastric cancer. ELISA
measurements on homogenates of the same tissue samples confirmed a strong increase of
active TGF-β1 in tumors compared to normal mucosa. Moreover, high tumor TGF-β1
activity levels were significantly associated with clinical parameters, including survival of
the patient, suggesting a clinical relevance for unraveling the activation mechanism. Total
and active TGF-β1 levels were not correlated, suggesting a specific activation process. Active
TGF-β1 levels were not related with total levels of urokinase and matrix metalloproteinases-
2 and -9, proteinases possibly involved in the release of active TGF-β1. Because total
proteinase levels do not reflect activity, we also used bioactivity assays. Only urokinase
activity correlated significantly with TGF-β1 activity. In conclusion, we have shown the
clinical relevance of active TGF-β1 levels in gastric cancer tissue, localization of the active
compound in myofibroblasts and an association of active TGF-β1 levels with urokinase
activity, suggesting a role for plasmin in TGF-β1 activation. We propose that tumor-associated
proteinases can activate ECM bound latent TGF-β1, resulting in transdifferentiation of
resident fibroblasts into the myofibroblast phenotype.
M1969
Growth of Human Pancreatic Cancer Is Inhibited By Rnai- and Antisense-
Targeted Down-Regulation of Gastrin
John F. Harms, Gail L. Matters, Christopher O. Mcgovern, Jill P. Smith
Background: The gastrointestinal peptide gastrin stimulates pancreatic cancer growth by
an autocrine mechanism. Unlike normal pancreas, pancreatic cancer cells produce gastrin,
and gastrin expression has been correlated with clinical aggressiveness. Gastrin signaling
stimulates Src and JAK2/STAT3 activation and transcriptional induction of the COX-2 gene,
indicating that gastrin has an important role in tumor progression. Our hypothesis is that
decreasing gastrin synthesis through antisense or RNAi technologies will significantly
reduce In Vivo pancreatic tumor growth. Methods: A panel of six human pancreatic cancer
cell lines was screened for gastrin expression by Real-Time RT-PCR and In Vivo tumorigenicity
in nude mice. To further examine the contribution of gastrin to tumor growth and metastasis,
gastrin was down-regulated in BxPC-3 pancreatic cancer cells using two parallel techniques:
1) stable transfection of an antisense gastrin cDNA with Lipofectamine® and 2) RNAi
downregulation by transfection of 3 different shRNA (short hairpin RNA) constructs targeting
independent regions of the gastrin mRNA. Control cells were transfected with either empty
vector or a nonspecific shRNA. The quantity of gastrin expression was determined in
antisense, shRNA, and control clones, and wild type (WT) cells by Real-Time RT-PCR. In
Vivo growth was evaluated in each antigastrin clone or control by injection of 106 cells in
100μl HBSS either subcutaneously (SC) or orthotopically (OT) in the pancreas. After 5 to
6-weeks tumors were measured and animals necropsied. Results: Gastrin Real-Time RT-
PCR revealed that WT cancer cells which endogenously express lower levels of gastrin mRNA
(e.g. MIA PaCa-2, PANC-1) formed slower growing tumors than those with higher gastrin
levels (e.g. BxPC-3, AsPC-1). Stable transfection of an antisense gastrin gene or shRNA into
BxPC-3 cells resulted in clones with up to 90% reduction in gastrin mRNA (p<0.002)
compared to clones from a non-specific shRNA sequence or WT cells. In Vivo, antisense
clones with significant gastrin reduction formed both smaller SC tumors and OT tumors
compared to control clones or WT cells. Tumors from stable shRNA clones had an average
of 60% smaller SC and OT tumors (by weight) and fewer metastases than non-specific
control clones or WT tumors (p<0.005).Conclusions:Down-regulation of gastrin expression
by either antisense or RNAi techniques significantly inhibits growth of pancreatic cancer.
The efficacy of the shRNAs in decreasing gastrin expression and In Vivo pancreatic tumor
growth suggests RNAi targeting of gastrin could serve as a new and effective approach for
the treatment of pancreatic cancer.
M1970
Toll-Like Receptor-4 (TLR4) Signaling Induces a Disintegrin and
Metalloproteinase (Adam)-17 and Amphiregulin in Colitis-Associated
Neoplasia
Masayuki Fukata, Zahra Ghiassi-nejad, Anli Chen, Keith Breglio, Tyralee Goo, Daisy
Conduah, Kotha Subbaramaiah, Andrew J. Dannenberg, Maria T. Abreu
Background: Increased mucosal activation of ADAM-17, the tumor necrosis factor (TNF)-
α converting enzyme, has been reported in IBD. ADAM-17 may play a role in colorectal
carcinogenesis because of its ability to cleave and release epidermal growth factor receptor
(EGFR) ligands. Previously, we found that TLR4 signaling is linked to activation of EGFR
and enhanced epithelial cell proliferation in colitis. In this study, we investigated the hypo-
thesis that TLR4 regulates colorectal carcinogenesis and the potential involvement of the
ADAM-17-amphiregulin (AR)-EGFR signaling pathway. Methods: A TLR4-expressing human
colorectal cancer cell line, SW480, was stimulated with LPS. Expression and release of AR,
an EGFR ligand, were examined by real-time PCR and ELISA, respectively. Active ADAM-
17 was analyzed by Western blot. Colitis-associated tumors were induced by a single IP
A-424AGA Abstracts
injection of azoxymethane (AOM) (7.4 mg/kg), followed by 2 cycles of 3% dextran sodium
sulfate (DSS) in drinking water for 7 days, and changing to normal water for 14 days
thereafter. Inflammation and dysplasia were assessed histologically. ADAM-17, AR, and
phosphorylated EGFR expression were examined by methods including immunohistochem-
istry. Results: LPS activated ADAM-17 and there lease of AR within 30 min of treatment of
SW480 cells. This stimulatory effect of LPS was blocked by TAPI-2, an ADAM-17 inhibitor.
Next we attempted to translate these In Vitro findings. Because LPS is a ligand for TLR4,
we evaluated the ADAM-17-AR-EGFR axis in a model of colitis-associated neoplasia. TLR4
deficiency led to a profound reduction in colorectal tumorigenesis and lower levels of AR
and phosphorylated EGFR in colonic tissues. Conclusion: Activation of TLR4 stimulates the
release of AR and thereby enhances EGFR phosphorylation by an ADAM-17-dependent
mechanism. These findings are likely to be important for explaining the link between TLR4
signaling and inflammation associated colorectal carcinogenesis.
M1971
Nuclear Expression of E2f4 Induces P53-Dependent Apoptosis in Normal
Human Intestinal Epithelial Crypt Cells But Not in Intestinal Tumors of
Apcmin Mice and Human Colon Cancer Cells
Hugo Garneau, Marie-christine Paquin, Laetitia Alvarez, Carine Lussier, Nathalie Rivard
The E2F transcription factors controls cell cycle progression. The localization of E2F4 in
intestinal epithelial cells is cell cycle-dependent, being cytoplasmic in quiescent differentiated
cells but nuclear in proliferative cells stimulated by growth factors. Aims of the study. To
investigate the endogenous expression of E2F4 in colon cancer cells, in intestinal tumors
of ApcMin/+ mice and to verify the impact of constitutive nuclear expression of E2F4 in
normal intestinal epithelial cells. Methods. Expression and localization of E2F4 and of
survival/apoptosis regulatory proteins were analyzed by Western blot and immunofluoresc-
ence. Adenoviruses expressing fusion proteins between GFP and either wild-type E2F4
(wtE2F) or E2F4-NLS containing a strong NLS from SV40LgT were used to infect non
immortalized human intestinal crypt epithelial cells (HIEC). Cell death was analyzed by
trypan blue exclusion and annexin V assays and electron microscopy. Results. 1- Forced
nuclear E2F4 expression induced morphological and cellular changes associated with
apoptosis including annexin V staining, membrane blebbing and chromatin margination;
by contrast, forced expression of wtE2F4 had no effect in HIEC. 2- Three days after infection,
HIEC-expressing E2F4-NLS demonstrated cytoplasmic shrinkage and died. 3- An induction
of p53 (5.5-fold), phosphoSerine-15-p53 (4-fold), PUMA (3.5-fold), FAS (2-fold), BAX (2-
fold) and RIP (4-fold) was also observed in HIEC-expressing E2F4-NLS comparatively to
cells-expressing GFP or wtE2F4. 4-The lentiviral infection of a shRNA which specifically
knocked-down p53 expression inhibited cell death induced by E2F4-NLS expression in
HIEC. 5- In contrast to normal crypt cells, endogenous E2F4 in colonic cancer cells (Caco-
2, HCT116, DLD-1 and LOVO) was overexpressed and constitutively nuclear even in absence
of exogenous growth factors and independently of p53, Bax and PUMA gene status, suggesting
that the growth factor-dependency of E2F4 nuclear localization is lost during intestinal cell
tumorigenesis. In addition, the level of apoptosis in these cells was negligible. 6- Finally, E2F4
protein was up-regulated and nuclear in intestinal tumors of ApcMin/+ mice. Conclusions.
Persistent localization of E2F4 into the nucleus of normal human crypt cells induce apoptosis
in a p53-dependent manner. Hence, mutations that deregulate E2F4 localization may provide
an initial proliferative advantage but also may accelerate cell death. However, intestinal
tumor cells acquiring mutations in p53 locus or in other genes regulating cell survival
(INK4A/ARF, ATM/ATR, APC, etc.) may escape apoptosis, thereby revealing the full mitogenic
potential of E2F4.
M1972
Trpv6 Mediates Capsaicin-Induced Apoptosis in Gastric Cancer Cells -
Mechanisms Behind a Possible New “Hot” Cancer Treatment
Justine Chow, Manith Norng, Jasmine Chai, Jianyuan Chai
Background & Aims: Capsaicin is an organic compound found in chili peppers which are
commonly consumed by more than one-quarter of the world's population daily. Studies
have shown that capsaicin can induce apoptosis in some cancer cells by a mechanism that
has not been fully understood. Based on numerous studies conducted in neuronal systems,
capsaicin is traditionally thought to signal through a non-selective cation channel protein
TRPV1. The aims of this study were to determine whether and how capsaicin induces
apoptosis in gastric cancer cells as compared to normal cells. Methods: Both gastric cancer
cells (AGS) and normal epithelial cells (GES-1) were treated with capsaicin at 50 μM for 1,
6 and 24 hours. Apoptosis was examined by Annexin V binding assay. Results: Capsaicin
induced apoptosis in both gastric cancer and normal cells, although cancer cells were more
susceptible. Instead of TRPV1, another member of the TRPV subfamily - TRPV6 (a calcium-
selective channel protein predominantly expressed in gastrointestinal epithelial cells) was
increased in a time-dependent manner in response to capsaicin treatment. Moreover, the
basal expression level of TRPV6 was 5 fold higher in AGS cells than it in GES-1 cells.
Furthermore, the susceptibility of both AGS and GES-1 cells to the apoptotic effect of
capsaicin depended on the availability of TRPV6, as overexpression of TRPV6 in GES-1 cells
increased capsaicin-induced apoptosis by 4 fold (P < 0.001) and knockdown of TRPV6 in
AGS cells reduced it by 72±5 % (P < 0.01). We further demonstrated that capsaicin disrupted
mitochondrial integrity and induced cytochrome c release through up-regulation of the pro-
apoptotic protein Bax. Capsaicin also activated and stabilized p53 in a JNK-dependent
manner, as inactivation of JNK using a specific inhibitor SP600125 significantly shortened
the half-life of p53 by ~15 fold (P < 0.01) and completely abolished capsaicin-induced
apoptosis in AGS cells. Conclusions: 1) TRPV6, rather than TRPV1 (the well known capsaicin
receptor), mediates capsaicin-induced apoptosis in gastric cells; 2) Abundance of TRPV6 in
gastric cells determines their live or death under capsaicin treatment; and 3) Capsaicin
induces apoptosis by stabilization of p53 protein through activation of JNK. Taken together,
our data suggest that capsaicin may be a promising dietary candidate for cancer chemopreven-
tion.
M1973
Activation of Pparγ and Inhibition of Xiap in Human Cancer Cells: Synergistic
Effects On Cell Proliferation, Apoptosis, and Tumorigenesis
Yun Dai, Liang Qiao, Qing Gu, Harry hx Xia, Ting kin Cheung, Juan Ma, Bing Zou,
Benjamin c.y. Wong
Background and objectives: In colon cancer, the anti-tumor effect of Peroxisome proliferator-
activated receptor gamma (PPARγ) on tumorigenesis is controversial. Over-expression of X-
linked inhibitor of apoptosis (XIAP) in colon cancer has been linked to treatment resistance
and poor prognosis. The aims of our present study are to explore the synergistic effects of
PPARγ activation and XIAP inhibition on the cell proliferation, apoptosis, and tumorigenesis
in colon cancer In Vitro and In Vivo. Materials and methods: Colon cancer cell line HCT116
XIAP+/+ and HCT116XIAP-/- were cultured, and troglitazone (TGZ) was used as PPARγ agonist.
Cell proliferation was measured by WST-1 assay. Apoptosis was determined by ELISA kit.
Protein expression was detected by Western blot. In In Vivo tumorigenesis studies, Balb/c
nude mice were subcutaneously inoculated with 1×107 cells to generate colon cancer xenog-
raft. TGZ (200 ppm) was given on the day of tumor cell inoculation. The volume of tumor
was measured every other day. Expressions of Ki67 and VEGF in tumor tissues were
detected by Western blot. Results: TGZ induced apoptosis and inhibited the proliferation
of HCT116XIAP+/+ and HCT116XIAP-/- cells in a time- and dose-dependent manner, and
these effects were more significant in HCT116XIAP-/- cells. The IC50 values of TGZ against
HCT116XIAP+/+ and HCT116XIAP-/- cells after 48h treatment were 88.80μM and 68.04μM,
respectively. Caspase 3, 7, 8, and 9, as well as poly(ADP-ribose) polymerase were activated
more obviously in HCT116XIAP-/- cells compared to HCT116XIAP+/+ cells. In addition, com-
bined with XIAP inhibitor 1396-12 increased apoptosis and cell growth inhibition in
HCT116XIAP+/+ cells when compared to TGZ alone. The study In Vivo showed there was no
difference in the tumor development in HCT116XIAP+/+ and HCT116XIAP-/- cells xenograft
model. TGZ retarded the growth of xenograft colon cancer, and such a growth inhibition
was more significant in HCT116XIAP-/- cells-derived tumors than in HCT116XIAP+/+ cells-
derived tumors, with a tumor volume reduction rate of 83.3% and 32.5% on day 33,
respectively. This increased therapeutic benefit correlated with significant decreased expres-
sion of Ki67 and VEGF in tumors. Conclusion: Simultaneous activation of PPARγ and
inhibition of XIAP may have synergistic anti-tumor effect against colon cancer.
M1974
Regulation of Fas Ligand Expression in Colon Cancer By the Cyclooxygenase
Signaling Pathway
Aileen Houston, Fergus Shanahan
During carcinogenesis, tumors develop multiple mechanisms to evade the immune system
and suppress the anti-tumor immune response. Upregulation of Fas ligand (FasL/CD95L)
expression may represent one such mechanism. FasL is a member of the tumor necrosis
factor (TNF) superfamily that triggers apoptotic cell death following ligation to its receptor,
Fas (CD95/APO-1), on sensitive cells. Numerous studies have shown that human cancers
express FasL, and have strongly implicated tumor-expressed FasL as a major inhibitor of
the anti-tumor immune response. We have previously shown that specific inhibition of FasL
expression in colon tumor cells significantly reduced tumor formation and growth In Vivo.
Thus, inhibiting FasL expression in tumors may have therapeutic potential, due to an
improved anti-tumor immune response. However, no attempt has been made to date to
target this mechanism of immune evasion therapeutically and little is known about the
factors that underlie FasL upregulation in tumors. Here we show that the cyclooxygenase
(COX) signaling pathway, and in particular prostaglandin E2 (PGE2), plays a role in the
upregulation of FasL expression in colon cancer. Suppression of either COX-2 or COX-1
by RNA interference (RNAi) in HT29 and HCA-7 colon tumor cells reduced FasL expression
at both the mRNA and protein level, as assessed by Quantikine FasL mRNA, Western blotting
and immunofluorescence, respectively. Conversely, exogenous PGE2 induced FasL mRNA
and protein production, demonstrating a direct effect of COX-derived PGE2 on FasL expres-
sion. Expression of FasL was increased 4.1-fold in HCA-7 cells and 3.4-fold in HT29 cells,
with maximum induction occurring at 0.5 - 1.0μM. This effect was specific for FasL and
did not affect other members of the TNF superfamily. Immunohistochemical staining of
human colon adenocarcinoma tissue sections revealed a positive correlation between FasL
and COX-2 expression in tumor tissue (n=56; p<0.01), demonstrating that these observations
may have clinical significance. Thus, these findings provide evidence that the COX signalling
pathway, and in particular PGE2, plays a role in upregulating FasL expression in colon
tumor cells. Targeting the PGE2, - FasL signalling pathway may aid in the development of
new therapeutic strategies to both prevent and treat this malignant disease.
M1975
Inhibition of Hif-1alpha Induces Anoikis in Gastric Cancer Cells Via
Upregulation of Integrin Alphav
Nadine Rohwer, Martina Welzel, Katharina Detjen, Bertram H. Wiedenmann, Michael
Höcker, Thorsten Cramer
Background: Hypoxia is a hallmark of solid tumor formation and constitutes an independent
prognostic factor. Intratumoral hypoxia is associated with local invasion and metastasis,
thereby limiting patient survival by systemic tumor spread. Adaptation to hypoxia is in large
part achieved by the transcription factor HIF-1alpha, which is activated in a vast number
of solid gastrointestinal cancers, e.g. gastric, pancreatic and colon cancer. Inhibition of HIF-
1alpha has been shown to reduce tumor growth in diverse subcutaneous human tumor
xenografts. However, HIF-1alpha's tumor supporting action seems to be depending on cell
type and microenvironment and the precise molecular mechanisms of the role of HIF-1alpha
in the pathogenesis of cancer are only beginning to emerge. Methods: Functional Inactivation
of HIF-1alpha was achieved by lentiviral-mediated siRNA transfer. Substrate-independent
growth was analyzed by the soft agar assay. Anoikis was determined by FACS after culturing
the cells on Poly-HEMA. Integrin alphaV expression was determined by FACS and Western
Blot. Results: Loss of HIF-1a in human gastric cancer cell lines AGS and MKN-45 did not
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interfere with proliferation of these cells under substrate-dependent conditions. However,
HIF-1alpha knock-down cells displayed a 65% reduction of colonies when grown substrate-
independently in soft agar. Inactivation of HIF-1alpha resulted in a 3-fold elevation of anoikis
after culturing on poly-HEMA. Integrin alphaV expression was markedly upregulated in the
HIF-1alpha deficient cells as determined by FACS analysis and Western Blot, whereas none
of the other known integrin subunits displayed a changed expression profile. Discussion:
Substrate-independent growth is a hallmark of malignant cells and an essential prerequisite
for metastatic spread. Our results indicate that HIF-1alpha is centrally regulating the ability
of tumor cells to proliferate under substrate-independent conditions. Furthermore, we could
show that the expression of integrin alphaV, a pivotal inducer of anoikis, is elevated in HIF-
1alpha deficient human gastric cancer cells. These results therefore argue for a new role of
HIF-1alpha during tumor progression via suppression integrin alphaV.
M1976
Functional Interaction of Xom and Lef1/Tcf Factors in Cell Fate Determination
Hong Gao, Bin Wu, Jin-taek Hwang, Roger Giese, Zhenglun (jerry) Zhu
LEF1/TCFs are HMG box-containing transcriptional factors mediating Wnt/b-catenin sig-
naling during early embryogenesis. Excessive transcriptional activation of LEF1/TCF-medi-
ated transcription by b-catenin of the Wnt signaling pathway has been implicated in the
pathogenesis of a variety of GI malignancies, such as colorectal cancer and hepatocellular
carcinoma. The b-catenin-LEF1/TCF signaling leads to dorsalization and is counteracted by
the BMP4/Xom signaling during early embryogenesis. To explore the molecular mechanism
of BMP4/Xom inhibition of b-catenin-LEF1/TCF signaling, we utilized the Xenopus laevis
model system and examined the effect of Xom expression on LEF1/TCF-mediated transcrip-
tion, using the TOPflash assay, a prior established reporter of b-catenin-LEF1/TCF signaling.
We found that Xom expression activates LEF1/TCF-mediated transcription by forming a
complex with LEF1/TCF factors. Our data show that dominant-negative Xom that lacks the
LEF1/TCF transactivation domain fails to transactivate critical ventralization genes, such as
BMP4 and Xom itself, and leads to embryonic arrest at the gastrulation stage, suggesting a
essential role of Xom-LEF1/TCF signaling in cell fate determination. In contrast to the
implicated oncogenic effects of b-catenin-LEF1/TCF signaling, co-expression of Xom and
LEF1 leads to growth arrest of colorectal cancer cells. Our data suggest that the functional
interaction of Xom and LEF1/TCF-factors is essential for cell fate determination and that
LEF1/TCF factors may function as a point of competition of the Wnt/b-catenin and BMP4/
Xom pathways in cell fate determination.
M1977
Involvement of Up-Regulation of Puma in Non-Steroidal Anti-Inflammatory
Drug-Induced Apoptosis
Tomoaki Ishihara, Tohru Mizushima
Background & Aims: Non-steroidal anti-inflammatory drugs (NSAIDs) are very useful medi-
cine for treatment of pain, fever and inflammation. The anti-inflammatory action of NSAIDs
is mainly mediated through their inhibitory effect on cyclooxygenase (COX) activity. Epidemi-
ologic studies show that NSAIDs use is associated with a reduced risk of cancer, and
preclinical and clinical studies have shown that some NSAIDs are effective for the treatment
and prevention of cancer. NSAIDs, such as celecoxib, induce apoptosis in cancer cells and
this effect is involved in their anti-tumor activity. We recently demonstrated that increase
in intracellular Ca2+ levels and resulting calpain activation and up-regulation of CHOP
(apoptosis-inducing transcription factor up-regulated by endoplasmic reticulum (ER) stress)
play an important role in celecoxib-induced apoptosis. Puma (p53 up-regulated modulator
of apoptosis) is a newly-identified Bcl-2 family protein with potent apoptosis-inducing
activity. It was recently reported that Puma is induced by various ER stressors. We here
examine the role of Puma in celecoxib-induced apoptosis. Methods: Up-regulation of Puma
by NSAIDs was monitored by immuno-blotting and real-time RT-PCR. Induction of apoptosis
was assessed by FACS analysis. Small interfering RNA (siRNA) technique was used to
suppress the expression of distinct protein. Results: Various NSAIDs (celecoxib, indometh-
acin, diclofenac and meloxicam) up-regulated PUMA in both mRNA and protein levels in
various types of gastrointestinal cancer cells, accompanying with induction of apoptosis.
This activity of NSAIDs was not related to their ability to inhibit COX. Suppression of this
up-regulation of Puma inhibited the celecoxib-induced apoptosis. Both the intracellular Ca2+
chelator (BAPTA-AM) and siRNA for CHOP inhibited the celecoxib-induced up-regulation
of Puma. Furthermore, siRNA for activating transcription factor (ATF) 4 or ATF6, both of
which are involved in ER stress response, also inhibited the celecoxib-induced up-regulation
of Puma. On the other hand, a calpain inhibitor (Z-Leu-Leu-H) did not affect the celecoxib-
induced up-regulation of Puma. Conclusions: Results suggest that up-regulation of PUMA
is involved in NSAID-induced apoptosis and their anti-tumor activities. This up-regulation
of PUMA is COX-independent and seems to be mediated by Ca2+-induced activation of
ATF4 and ATF6.
M1978
Antagonism of Reg IV Increases Cell Susceptibility to Radiation-Induced
Apoptotic Death in a Tumor Xenograft Model
Kumar S. Bishnupuri, Kento Kikuchi, Qizhi Luo, David Venker, Satheesh K. Sainathan,
Courtney W. Houchen, Shrikant Anant, Brian K. Dieckgraefe
Background: The Reg IV, a dominant member of human regenerating (Reg) gene family is
expressed at highest levels in the colonic mucosa and is further upregulated in malignancies
of the gastrointestinal (GI) tract including colorectal carcinomas (CRC). Overexpression of
Reg IV is also associated with increased proliferation and resistance of CRC cells to apoptotic
death. The present study tests the hypothesis that endogenous Reg IV regulates cell susceptib-
ility to ionizing radiation (IR) and antagonism of Reg IV signaling will increase IR-induced
apoptotic death. Methods: A total of 3.0 x 106 human colon adenocarcinoma cells (HCT116)
were subcutaneously injected into the lower flanks of 6-week old male athymic nude mice.
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After 2 weeks, when tumors were palpable, mice were exposed to various doses of IR.
Experimental groups also included mice treated with specific monoclonal antibody (mAb)
3E5 (dose: 0.5 mg/day) directed against Reg IV protein. Mice were administered 3E5
intraperitoneally 24 h prior to IR (8 Gy) and continued for 5 alternate days. Tumor growth
was assessed by measuring tumor volume at a regular basis. To assess apoptotic cell death,
tissues from tumor xenograft were stained with Hematoxilin/Eosin or antibody against
activated Caspase-3. Results: Mice treated with 3E5 in combination to IR exhibited a signific-
ant reduction in tumor size in comparison to IR alone. Histological observation of the tissues
from tumor xenograft exhibited increased number of apoptotic cells in 3E5-treated group.
Apoptotic cells were distributed throughout the section including prominently increased
number towards the periphery of the tumor. Real time RT-PCR analysis of RNA isolated
from tissues of tumor xenograft exhibited a IR-dose-dependent increase in the expression
of Reg IV and anti-apoptotic genes, including Bcl-2, Bcl-XL and Survivin. Treatment with
3E5 led to significant decrease in IR-induced expression of these anti-apoptotic genes. These
data suggest that increases in Reg IV expression lead to increased expression of anti-apoptotic
genes and constitute a cellular response to IR-induced apoptotic death. Blocking of Reg IV
signaling with specific mAb increases CRC cell susceptibility to IR resulting in an increased
apoptotic death. Conclusion: Reg IV serves as an anti-apoptotic mediator of CRC. Antagonism
of endogenous Reg IV signaling increases CRC cell susceptibility to IR-induced apoptotic
death. Therefore, therapeutic strategies may be designed to potentate the effect of radiation
by interfering with endogenous Reg IV activity.
M1979
Specific Monoclonal Antibodies Directed Against Reg IV Protein Inhibits Cell
Proliferation and Induces Apoptotic Death of Human Colon Adenocarcinomas
Qizhi Luo, Kumar S. Bishnupuri, Courtney W. Houchen, Shrikant Anant, Brian K.
Dieckgraefe
Colorectal cancer (CRC) is the third most common cause of cancer and second leading
cause of cancer death in Europe and the United States. Reg IV, a recently identified member
of regenerating (Reg) gene family is of special interest as it is highly expressed in colonic
mucosa and is further up-regulated in CRC. Recently, we observed that Reg IV is mitogenic
for CRC cells. The present study tests the hypothesis that specific monoclonal antibodies
(mAbs) directed against Reg IV protein will inhibit cell proliferation and induce apoptotic
death of human colon adenocarcinoma cells. We developed two mAbs directed against Reg
IV protein; 3E5 and 2H6. Cell proliferation was assayed by standard enzymatic assay at
days 0, 2, 4 and 6 to determine the effect of mAbs. Addition of mAbs (400 ug/ml) to the
cultures of HT29 and HCT116 human colon adenocarcinoma cells led to significant inhibition
(~50%) of cell proliferation at days 4 and 6 when compared to controls. Next we determined
the effect of Reg IV-specific mAbs on radiation-induced cell death. Ionizing radiation (IR)
treatment demonstrated a dose-dependent increase in fractional cell death. Addition of Reg
IV function-blocking antibodies (but not control antibodies) to the cultures of HT29 and
HCT116 cells further increased susceptibility to radiation-induced cell death following IR
(0 - 6 Gy) as assessed by an In Vitro radiation-survival colony assay. Addition of 3E5 and
2H6 antibodies to the culture media resulted in 28.5 and 35.6 percent reductions in colony
counts, and a 46.0 and 58.1 percent reduction of total colony area following 2 Gy IR. We
next examined the effects of these mAbs on expression of anti-apoptotic genes, Bcl-2 and
Bcl-xL, in HT29 and HCT116 cells by real-time RT-PCR. Addition of 3E5 to the culture
media for 5 days led to a 2 - 4 fold reduction in expression of Bcl-2 and Bcl-xL genes.
Conclusion: mAbs directed against Reg IV protein reduce cell proliferation and lead to
enhanced apoptotic death in human colon adenocarcinomas. These results support the
concept that therapies targeting Reg genes may be useful adjunctive treatments for human
CRC and other gastrointestinal malignancies.
M1980
Krüppel-Like Factor 5 Interacts with and Enhances the Activity of β-Catenin
In Vitro
Agnieszka Bialkowska, Beth B. Mcconnell, Cassandra R. Williams, Mandayam O. Nandan,
Vincent W. Yang
BACKGROUND and AIM:Krüppel-like factor 5 (KLF5) is a zinc finger-containing transcrip-
tion factor previously shown to stimulate proliferation of intestinal epithelial cells. In the
intestinal epithelium, KLF5 exhibits a gradient of expression, with the highest concentration
found in the proliferating crypt epithelial cells. β-catenin is a multifunctional protein that
is an important part of the Wnt signaling pathway, a critical pathway for proliferation of
intestinal epithelial cells. As both KLF5 and β-catenin are known to be pro-proliferative and
are localized to a similar zone of proliferation in the gut epithelium, we sought to investigate
the possibility that these two proteins might interact with each other. METHODS: Expression
plasmids containing a constitutively active β-catenin (S33Y) or KLF5 under the control of
the CMV promoter were transiently transfected into COS-7 cells either individually or in
combination. To measure β-catenin regulated activity, the TOPFLASH reporter plasmid was
co-transfected with these plasmids. The TOPFLASH plasmid expresses luciferase under the
control of a β-catenin responsive element. Northern and Western blot analyses were per-
formed to assess the mRNA and protein levels of β-catenin and KLF5, respectively. Antibodies
directed against KLF5 and β-catenin were used in immunoprecipitation experiments.
RESULTS: Ectopic expression of β-catenin in COS-7 cells resulted in a 3-fold induction in
TOPFLASH luciferase activity when compared to cells transfected with an empty vector
alone. In contrast, ectopic expression of KLF5 had no effect on TOPFLASH activity, whereas
co-expression of KLF5 and β-catenin resulted in a 6-fold induction over that of control.
Western blot analysis showed that the protein levels for both KLF5 and β-catenin were
higher in co-transfected cells when compared to those in singly transfected cells. However,
Northern blot analysis showed that the mRNA levels for KLF5 and β-catenin in co-transfected
cells were similar to those in singly transfected cells, suggesting that the elevation in protein
levels occurs post-translationally. Immunoprecipitation of lysates from co-transfected cells
demonstrated that KLF5 co-immunoprecipitated with β-catenin, suggesting that the two
proteins physically interact with each other. CONCLUSIONS: Results of our study indicate
that KLF5 and β-catenin directly interact with each other. This interaction leads to the
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stabilization of the two proteins, resulting in elevated protein levels and enhanced transcrip-
tional activity for β-catenin. We conclude that KLF5 is a positive regulator of β-catenin
activity.
M1981
Induction of Krüppel-Like Factor 5 Expression By Lysophosphatidic Acids
Huanchun Zhang, Raluca Rusovici, Agnieszka Bialkowska, Sengthong Chanchevalap,
Jonathan P. Katz, Hyunsuk Shim, Vincent W. Yang, C. chris Yun
Lysophosphatidic acids (LPA) stimulate proliferation in many cell types, but the mechanisms
underlying the proliferative effect by LPA are diverse and are only partially elucidated. In
mammals, there are at least 16 Krüppel-like factors (KLFs) that exhibit homology to Krüppel
from Drosophila. In the intestine, KLF5 is found mainly in the proliferating crypt epithelial
cell population where it positively regulates cell proliferation. The goal of this study is to
examine whether KLF5 is a target of LPA-mediated signaling and to determine the mechanism
of KLF5 induction by LPA. We found that LPA stimulated the expression levels of KLF5
mRNA and protein in Caco-2, SW480 and IEC6 cells. This effect was specific to LPA as
sphingosine 1-phosphate or epidermal growth factor did not change KLF5 expression levels.
To determine the role of KLF5, the expression of KLF5 in SW480 cells was knocked down
by siRNA. Silencing of KLF5 significantly attenuated the rate of cell proliferation, suggesting
the importance of KLF5 in LPA-mediated proliferation. To determine the mechanism of
KLF5 induction by LPA, we used pharmaceutical inhibitors. We found that the PI3K inhibitor
LY290042, the p38 MAPK inhibitor SB203580, and the PLCβ inhibitor U37122 had no
effect, whereas the MEK1 inhibitor U0126 showed a small effect. Similarly, a broad PKC
inhibitor GF109203X exhibited a small effect on the expression level of KLF5. The PKCδ-
specific inhibitor rottlerin drastically abrogated the effect of LPA, but siRNA against PKCδ
failed to block the induction of KLF5 by LPA. Rottlerin binds to eukaryotic elongation factor
2 kinase (eEF2k), aka calmodulin/Ca2+-dependent kinase III, with a similar affinity to PKCδ.
Inhibition of calmodulin with trifluoperazine abrogated LPA-mediated induction of KLF5.
In summary, we identify KLF5 as an intermediate inducing cell proliferation by LPA. This
induction was inhibited by rottlerlin but was independent of PKCδ. The sensitivity to
calmodulin inhibitors suggests that eEF2k is a potential regulator of KLF5 expression by LPA.
M1982
Inhibition of COX-2 with NS-398 Decreases Colon Cancer Cell Motility
Through Blocking Epidermal Growth Factor Receptor Transactivation:
Possibilities for Combination Therapy
Nahida Banu, Andrea Buda, Simon Chell, Elder Douglas, Moganaden Moorghen, Christos
Paraskeva, David Qualtrough, Massimo Pignatelli
The use of NSAIDs has proved of great interest in the prevention and treatment of colorectal
cancer. Overexpression of COX-2 and prostaglandin production promote metastasis and
have been shown to increase cell motility In Vitro. We investigated whether specific inhibition
of COX-2 with NS-398 inhibited the motility of colorectal cancer cells and whether this
was modulated through EGFR transactivation. A trans-well filter assay was used to study
cell motility. Expression of COX-2, EGFR phosphorylation and PGE2 receptors was assessed
by Western blot and RT-PCR. NS-398 significantly reduced PGE2 levels and reduced cell
migration in HT29 and HCA7 colorectal cancer cells and this effect was rescued by addition
of PGE2. Specific inhibition of COX-2 with NS-398 reduces EGFR phosphorylation. Inhibition
of EGFR activity with AG1478 reduced PGE2-stimulated motility, demonstrating that PGE2
acts via the EGFR signalling pathway. The novel combination of NS-398 and AG1478
dramatically reduced migration of colorectal cancer cells. The data presented here indicate
that use of NS-398 in chemoprevention and adjuvant therapy for colorectal cancer may
work in part, through the inhibition of cell motility. Our data suggests that the combined
use of NSAIDs with EGFR antagonists could be explored further for future use in the clinic.
M1983
Cyclooxygenase 2 Modulates Killing of Cytotoxic T Lymphocytes By Colon
Cancer Cells
Quanxin Wang, Yoshiyuki Takei, Kenichi Ikejima, Satoko Suzuki, Osamu Kobayashi,
Nobuhiro Sato, Sumio Watanabe
(Background) Although anti-cancer effects of cyclooxygenase 2 (COX2) inhibitors have been
reported, most of those studies focused on the direct anti-tumor effects of COX2 inhibiters
on colon cancer cells. On the other hand, several types of human cancers express Fas ligand
(FasL) and/or TRAIL and mediate apoptosis of T cells In Vitro. The “counter-attack” machinery
may account for at least in part the mechanisms by which tumors evade host immune
surveillance. In this study we determined if a selective COX2 inhibitor could modulate
expression of effector molecules of cell death on colon cancer cells thereby changing their
cytotoxic effects on cytotoxic T lymphocytes. (Methods) Two lines of human colon adenocar-
cinoma cells, HCA7 and HCT116, the former being COX2-positive and the latter COX2-
negative, were pre-incubated with/without a COX2 selective inhibitor, NS398 (0-10 μM).
Subsequently, the cells were co-cultured with Jurkat human T cell leukemia cells labeled
with 3H-methyl-thymidine (the effector to target ratio =10), and damage to Jurkat cells was
determined. (Results) Western analysis and immuno-fluorescence staining revealed that FasL
and TRAIL were expressed in both HCA7 and HCT116 cells. Treatment with NS398 resulted
in a marked reduction of expression of FasL and TRAIL in HCA7 cells, whereas NS398 did
not affect the expression of FasL and TRAIL in HCT116 cells. Jurkat cells expressed both
Fas and DR4. NS398 did not alter the expression of these proteins in Jurkat cells. The
number of viable Jurkat cells was diminished by about 25-40% when cells were co-cultured
with naive, non-pretreated HCA7 or HCT116 cells. The colon cancer cell-induced Jurkat
cell toxicity was prevented by pretreatment of HCA7 and HCT116 cells with an anti-FasL
or anti-TRAIL neutralizing antibody. Further, preincubation of HCA7 cells with NS398
before co-culture blunted the HCA7 cell-induced cell toxicity on Jurkat cells in a dose-
dependent manner reaching almost complete loss of cytotoxicity at 10 μM. In marked
contrast, pretreatment with NS398 failed to inhibit the HCT116-induced Jurkat cell killing.
(Conclusion) Our results collectively suggest that COX2 regulates the expression of FasL
and TRAIL on COX2-positive colon cancer cells thereby evoking a counter-attack against
cytotoxic T cells, which may lead to compromised host immune responses.
M1984
Suppression of Cyclooxygenase (COX)-2 and Cellular Proliferation in
Colonocytes By Indomethacin: Role of Leukotriene (LT)B4, a (Ppar)α Ligand
Anthony Shonde, Andrew Bennett, Christopher J. Hawkey
Introduction Mechanisms underlining the chemo suppressive effects of NSAIDs against colon
cancer are uncertain. We hypothesized that they might act by enhanced synthesis of LTB-
4 the natural ligand for Peroxisome Proliferator Activated Receptorα (PPARα) which has been
shown to mediate reduced polyp development in APC min/+ mice1. Methods Spontaneous
synthesis of LTB-4 by normal and malignant human colonic tissue and the In Vitro effects
indomethacin were investigated by organ culture of human colonic mucosa explants. The
ability of leukotriene B-4 10µM to activate PPARα was investigated in the human colonocyte
line HCA7 clone 29 transfected with PPARα (or control PPARδ and γ) and the PPAR receptor
PPRE for control activators. The effect of LTB-4, as well as the pharmacological PPARα
ligand fenofibrate on COX-2 expression was investigated in HCA7 by Western blotting,
using Alpha actin as housekeeping control. The effect of LTB-4 10µM on thymidine incorpora-
tion was also measured on HCA7 cells and on apoptosis by measuring Annexin V expression
and propidium iodide uptake by flow cytometry. Results Uninvolved human colonic mucosa
synthesized 14.6±3.5 pg/mg LTB-4 over 24 hours was increased to 295.6±110.5pg/mg in
matched malignant tissue. Indomethacin 10-6m and 10-5M cause dose dependant increases,
to 50.6±7.6 and 97.5±7.5pg/mg in normal and to 323.3± 123.8 and 526.3±162.3pg/mg in
malignant tissue. LTB-4 at levels achieved in these incubations had profound biological
effect on human colonocytes enhancing luciferase activity in the PPARα construct by three
fold. LTB-4 in the dose range 10-11, 10-9M dose dependently suppressed COX-2 expression.
Fenofibrate 10-6 - 10-4 M had similar effects. LTB-4 suppressed cellular proliferation as
measured by thymidine incorporation by 20% ( P < 0.0009) compared to control, whilst
having no effect on apoptosis as judged by Annexin V/PI staining. Conclusions Human
colonic mucosa produces substantial amounts of LTB-4 that is increased by indomethacin
and capable of causing a range of changes of malignant colonocytes that would be expected
to have a profoundly chemo-suppressive effect in colon cancer. The data support a key role
for PPARα in this process. 1. Potential role for peroxisome proliferator activated receptor
(PPAR) in preventing colon cancer. Jackson L, Wahli W, Michalik L, Watson SA, Morris T,
Anderton K, Bell DR, Smith JA, Hawkey CJ, Bennett AJ. Gut. 2003 Sep;52(9):1317-22.
M1985
Transcriptional Upregulation of Gastrin in Response to a Peroxisome
Proliferator-Activated Receptor γ Agonist Triggers Cell Survival Pathways
Agata Ptak-belowska, Agata Krawiec, Wieslaw W. Pawlik
Introduction: Proliferator-activated receptors (PPARs) are members of the largest nuclear
hormone receptor family of transcription factors. The effects of thiazolidinedione PPARγ
agonists on GI carcinogenesis remain controversial. There are data showing that PPARγ acts
as a tumour suppressor, promoting cell differentiation, exerting antiproliferative effects and
inhibiting angiogenesisresulting in reduced formation of polyps in the colon in response to
carcinogens. In Vitro, they stimulate apoptosis of both colorectal and pancreatic cancer cells.
However, in the APCmin mouse, inhibition of tumour growth by PPARγ agonists has only
been seen in one study; instead tumour formation is unaffected or increased. The link
between PPARγ and gastrin gene expression has not been evaluated. Aim of the study: Our
study aimed to assess the iteractions between PPARγ and gastrin on carcinogenesis and a
possible role for gastrin in circumvention of apoptosis using human pancreatic and colon
cancer cell lines as In Vivo models. Materials & methods: The human pancreatic (PAN1,
PANC1) and colon (HT29) cancer cell lines. Cell lines were treated with the PPARγ agonist
ciglitazone to investigate apoptotic potential in relation to PPARγ and gastrin gene expression
by means of Real-Time PCR and confirmatory Western Blot methods. Results: Ciglitazone
increased gastrin gene expression and Bcl-2 and PKB/Akt protein levels in all three cancer
cell lines. Furthermore transfection of the PAN1 and HT29 cells with a gastrin siRNA reversed
ciglitazone-induced PKB/Akt phosphorylation and Bcl-2 protein up-regulation. In the pancre-
atic cell-lines, upregulation of the gastrin gene was negated by knockdown of PPARγ but
in the colorectal cell-line, the effect was independent of PPARγ expression In conclusion,
the PPARγ agonist, ciglitazone, increases anti-apoptotic potential indirectly through up
regulation of the gastrin gene in GI cancer cell lines. This may contribute to the tumour-
promoting effects of PPARγ agonists in some settings such as cells with aberrant Wnt signal-
ling.
M1986
Bile Acid-Induced NADPH Oxidase Nox5s Expression in Barrett's Esophageal
Adenocarcinoma Cells
Jin Si, Jose Behar, Jack R. Wands, David Beer, David Lambeth, Weibiao Cao
Bile acids have been suggested to contribute to the development of esophageal adenocarcin-
oma in animal models, and it has been reported that pulsed treatment with bile salts increases
cell proliferation in Barrett cells. We have shown that NADPH oxidase NOX5S (S stands
for short, that lacks EF-hand motifs at its N-terminal) is overexpressed in SEG1 esophageal
adenocarcinoma cells associated with Barrett's esophagus (BE) and in BE with high-grade
dysplasia. NOX5S also contributes to increased cell proliferation and decreased apoptosis
in SEG1 cells. In the present study we examined whether continuous exposure to bile acid
increases cell proliferation and upregulates NOX5S in SEG1-esophageal adenocarcinoma
cells. In SEG1 cells, low dose of taurodeoxycholic acid (TDCA 10-11M, 24h), but not high
dose of TDCA (10-7M, 24h), significantly increased 3H-thymidine incorporation, suggesting
that low dose of TDCA increases cell proliferation. TDCA-induced increase in thymidine
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incorporation was significantly reduced by phosphatidylcholine (PC)-specific phospholipase
C (PLC) inhibitor D609, the phosphatidylinositol (PI)-specific PLC inhibitor U73122, and
the MAP kinase kinase inhibitor PD98059, but not by the p38 MAP kinase inhibitor
SB203580. TDCA also significantly increased ERK2 phosporylation. The data suggest that
TDCA-induced increase in cell proliferation may depend on activation of PC-PLC, PI-PLC
and ERK MAP kinases. In addition, low dose of TDCA significantly increased NOX5S
expression and hydrogen peroxide (H2O2) production. TDCA-induced increase in NOX5S
expression and H2O2 production was also significantly reduced by D609, U73122, and
PD98059, but not by SB203580. Knockdown of NOX5S by NOX5 small interfering RNA
blocked TDCA-induced cell proliferation. We conclude that in SEG1 cells low dose of TDCA
increases cell proliferation. This increase in cell proliferation seems to depend on activation
of PC-PLC, PI-PLC, ERK MAP kinases and NADPH oxidase NOX5S. Supported by NIDDK
R21 DK073327-01 and NIH NCRR 1 P20 RR17695-01.
M1987
Overexpression of the Transcriptional Repressor Snail Fosters Colorectal
Cancer (CRC) Hyperproliferation
Jennifer Koetsier, Harrison Brand, Ramesh K. Wali, Dhananjay Kunte, Mary Nyhuis,
Hemant K. Roy
Background: Recent studies have shown the central importance of SNAIL in a variety of
cancers (breast, melanoma etc.). We and others have noted that SNAIL is overexpressed in
most CRCs and is associated with more aggressive disease (DDAS 2005). Importantly, we
have also shown that SNAIL upregulation is an important event in initiation of CRC (Mol
Cancer Ther 2004). However, the molecular consequences of SNAIL remains largely unex-
plored. Given the importance of Wnt dysregulation in CRC initiation, we investigated whether
SNAIL regulated β-catenin signaling. Methods: Our approach was to knock down SNAIL
using siRNA in the human CRC cell line HCT-116. A scramble sequence was used as a
control. We evaluated both message and protein of potential downstream events with RT-
PCR and immunoblotting. We also performed whole genome microarray analysis. Results:
The modest SNAIL knockdown by siRNA was accompanied by a robust induction of E-
cadherin protein (143% of the control). Since E-cadherin is known to bind β-catenin,
sequestering it to the plasma membrane, we measured β-catenin transcriptional activity by
TOPFLASH reporter plasmid and noted a marked decrease (72.1% of control, p<0.001).
β-catenin protein levels were unchanged suggesting altered translocation rather than degrada-
tion. The consequences of this included a marked decrease in proliferation as measured by
PCNA (64.8% of the control, p<0.05). Whole genome microarray approach in HCT-116
supported these findings. For instance, cyclin D1, a well established pro-proliferative tran-
scriptional target was decreased by 80% (p<0.0001). Conclusion: Our results indicate that
SNAIL induction represents a potentially important mechanism for the early induction of
proliferation during colon carcinogenesis. We present a paradigm for SNAIL to downregulate
E-cadherin, thereby allowing nuclear localization and hence transcriptional activation of
β-catenin.
M1988
Bax and Bim Are Required for Rack1-Induced Apoptosis of Human Colon
Cells
Vidya Mamidipudi, Chris Cartwright
Previously we showed that Src tyrosine kinases are activated early in the development of
human colon cancer, and are suppressed during intestinal cell differentiation. We identified
RACK1 as an endogenous substrate, binding partner and inhibitor of Src. We demonstrated
that RACK1 regulates colonic cell growth by suppressing Src activity: 1) at G1 and mitotic
checkpoints, 2) in the intrinsic apoptotic pathway, and 3) in the Akt cell survival pathway.
Here we show that Bax and Bim are required for RACK1-mediated colonic cell death via
the intrinsic pathway. RACK1 induces the translocation of both proteins to mitochondria,
and the oligomerization of Bax. The latter requires Bim and RACK1 inhibition of Src activity.
RACK1 depletion protects colon cells from staurosporine-induced cell death by inhibiting
Bax oligomerization at mitochondria. Thus, RACK1 works through Bax and Bim and by
inhibiting Src activity in the intrinsic pathway to induce apoptosis of colon cells. Collectively
our results suggest that RACK1 is a tumor suppressor because it inhibits growth and induces
death of colon cells. Exploitation of these dual functions could be used to develop new and
more powerful and selective strategies for treatment of human colon cancer.
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M1989
Alterations in Cell Turnover and Histologic Grade Are Related to the Cellular
Localization of EGFR in Human Colon Carcinomas
Rafaela L. Rego, Thomas C. Smyrk, Nathan R. Foster, Daniel J. Sargent, Frank A.
Sinicrope
BACKGROUND. The Epidermal Growth Factor Receptor [EGFR (ErbB-1)] is a cellular
transmembrane receptor tyrosine kinase that is important for colon cancer cell growth and
represents a therapeutic target. We tested the hypothesis that subcellular localization of
EGFR may have different functional consequences. METHODS. We analyzed EGFR expres-
sion (EGFR pharmDx™, DAKO), localization, and relationship to rates of cell turnover,
histologic grade and clinical outcome in TNM stage II and III colon carcinomas (n= 361)
from patients treated in a 5-fluorouracil-based adjuvant trial. RESULTS. EGFR membrane
staining was detected in 214 (59.3 %) tumors. Increased EGFR intensity (2+, 3+) was
associated with a higher number of caspase-3- (p= 0.02) and Ki-67-(p< 0.001)-positive
tumor cells. Increased EGFR intensity (p= 0.02) and extent (p= 0.03) were associated with
poor differentiation, but did not depend upon DNA mismatch repair status. In contrast,
exclusive cytoplasmic staining [58 (16.1%) tumors] was associated with reduced Ki-67
(p=0.04) and better differentiation (p=0.06). Neither membranous nor cytoplasmic EGFR
expression were significantly associated with patient survival rates. CONCLUSIONS. Mem-
branous EGFR is associated with increased cell turnover and poor differentiation whereas
opposite relationships were found for cytoplasmic localization. Therefore, colon cancers
overexpressing EGFR show alterations in cell turnover and histologic grade that are related
to the cellular localization of EGFR.
M1990
Gastric Cancer and An Asian Pattern of Risk Cytokine Genotypes in Central
America: IL-8, IL-1β, IL-10, TNFα
Ricardo Dominguez, Douglas R. Morgan, Katherine S. Garman, Temitope O. Keku, Paris .
Heidt, Joseph Galanko, Robert S. Sandler
BACKGROUND Gastric cancer(GC) is the second leading cause of cancer mortality, with
geographic variability. Cytokine polymorphisms (IL-1β, IL-10, TNFα) are important host
factors in gastric adenocarcinoma in H. pylori infected patients. The IL-8-251A promoter
polymorphism is associated with GC in Asia. IL-8 is a pro-inflammatory cytokine, angiogenic
factor, chemoattractant. IL-8 levels correlate with depth of tumor, venous/lymphatic invasion,
and lower survival. In western Honduras, a high incidence region, we recently demonstrated
a high prevalence of cytokine risk alleles in population-based controls: IL1β-511T+, 81%,
and IL-10-1082A+, 93% [MorganDR, CGH 2006]. In spite of this high background preval-
ence, the high risk haplotype was associated with gastric cancer(IL-1β-511TT/IL-10-
1082AA): OR 2.6, 95%CI 1.0-6.8. Our aim was to investigate IL-8 cytokine genotypes in
GC, previously uninvestigated in Latino populations. METHODS We conducted a popula-
tion-based case-control study in western Honduras (95% Mestizo) with IL-8 analysis for
153 incident GC cases and 140 healthy village controls. Genomic DNA was extracted from
lymphocytes, with TaqMan assay genotyping. (IL-1β-511C>T, IL-10-1082G>A, TNF-α-
308G>A, IL-8-251T>A). RESULTS In population-based controls, IL-8-251A+ risk allele
prevalence was 56% (TT 44%,AT 43%,AA 13%), similar to Asian populations(Table).
Endemic H. pylori infection was confirmed, 85%. Among GC subjects, IL-8-251A+ prevalence
was 62% (TT 38%,TA 48%,AA 14%). Although a trend was noted, the IL-8-251 TA & AA
genotypes were not significantly associated with GC: ORa 1.38 (95%CI 0.82-2.30), adjusted
for gender, age, H. pylori, and IL-1β / IL-10 status. When compared to the wild type, the
accumulation of >3 risk alleles (IL-8-251A, IL-1B-511T, IL-10-1082A) did not have a
significantly increased association with GC: OR 1.53 (95%CI 0.57-4.08). CONCLUSIONS
An Asian pro-inflammatory cytokine risk allele pattern, with endemic H. pylori infection, is
observed in Honduras, which may help explain the high rates of gastric cancer. In this first
study in the Latino population, the IL-8-251A risk genotype was not significantly associated
with GC. This may be due to high IL-1β/IL-10 prevalence and sample size. Also, IL-8
genotypes may better correlate with diffuse histology, and prognosis/metastatic disease.
Asian pattern of Gastric Cancer Cytokine Risk Alleles in Controls (%)
M1991
Using Somatic APC Mutations As Clonal Markers to Demonstrate
Polyclonality in Colonic Polyps
Simon Leedham, Christina Thirlwell, Marco Novelli, Ian Tomlinson, Nick Wright
INTRODUCTION. Conventional wisdom suggests that human tumours are clonal in origin
as cancer is a disease of stem cells. However earlier work in both humans (Novelli MR,
Science, 1996; 272: 1187) and mice (Merritt S, PNAS, 1997; 94, 1392) suggests that up to
79% of adenomas are polyclonal. We sought to investigate this definitively using somatic
APC markers as clonal markers. METHODS. Paraffin embedded polyp tissue was obtained
from patients with classical familial adenomatous polyposis, attenuated FAP and sporadic
lesions. Individual crypts were dissected from across the polyps using laser capture microdis-
section. Somatic mutations in whole polyp lysate were identified using SSCP analysis of the
mutation cluster region of the APC gene. Individual crypt lysate DNA were then amplified
by nested PCR and sequenced using an ABI 3100 sequencer. RESULTS. All 5 classical FAP
polyps analysed, including a microadenoma just 5 crypts in size were polyclonal with some
dysplastic crypts possessing identified somatic mutations but with other crypts in the same
polyp wild-type. 5 attenuated FAP polyps, however were clonal with the same mutation
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identified in all dissected crypts, including one polyp demonstrating clonal second and third
hits. 3 sporadic polyps were also clonal for their identified mutations, however one sporadic
polyp was heterogeneic for a somatic mutation suggesting polyclonality. Top down growth
was also demonstrated in this lesion with mixed crypts demonstrating a somatic mutation
at the top of the crypt but not at the bottom. CONCLUSION. These results raise several
questions. (1) Are the earliest lesions, the microadenomas, in FAP polyclonal from the
outset? (2) As lesions grow, do they revert to monoclonality as one clone outgrows the rest,
possibly via a top down mechanism in larger polyps? (3) Can these results be explained on
the basis of very early collision of crypts with a second APC mutation? If the latter then
the proportion involved would indicate non-random collision, possibly through epithelio-
mesenchymal interactions, and this early co-operativity between early neoplastic crypts
warrants closer study.
M1992
Heterocygosity At the Card8 (Tucan) Locus Protects Against Early Onset
Colorectal Cancer
Stephan Buch, Clemens Schafmayer, Philip Rosenstiel, Oliver Von kampen, Andre Franke,
Christian Roeder, Mario Brosch, Alexander Katalinicz, Ulrich R. Fölsch, Fred Faendrich,
Holger Kalthoff, Stefan Schreiber, Juergen Tepel, Jochen Hampe
Background: Familial clustering of “sporadic” colorectal carcinoma (CRC) has been consist-
ently shown, but molecularly to date only incompletely explained. Chronic inflammation
is a possible carcinogenic pathway and association of the Crohn disease gene CARD15 with
CRC has been shown previously. A truncating variant at amino acid position 10 in CARD8
(TUCAN) has been reported as a risk factor for Crohn disease. Aims:. To investigate the
impact of truncating variation rs2043211 and of a set of haplotype tagging SNPs in CARD8
on the inherited risk for sporadic CRC. Patients and Methods:. Onethousand and forty four
patients, who were operated with sporadic colorectal carcinoma (median age of onset 59
years) were recruited for the study and compared to 724 sex-matched population based
controls (median age 68 years). Analyses were performed for the total patent sample and
the subgroup of patients with an age of onset below 50. Results: Twentynine percent of
young patients (age of onset <50) with colorectal cancer are heterozygous for rs2043211
as compared to 43% of control individuals (p=0.002). Both homozygote genotypes are over-
represented in CRC cases. The SNP rs2043211 leads to a premature STOP only in the
TUCAN48 isoform, but has non-truncating effects on other isoforms like TUCAN54. Conclu-
sions: Heterozygote advantage at immune loci has been shown to be important in the defence
against various infections and results in a reproductive advantage in primates. Here, we first
demonstrate heterozygote advantage in the protection against a tumor. As CARD8 is an
essential part of the NALP2/3 inflammasome, the increased diversity in the FIIND-domain
of CARD8 might contribute to a more efficient regulation in the context of inflammatory
tumorigenic stimuli.
M1993
Polymorphisms in COX-2 and iNOS Genes in the Molecular Pathogenesis of
Esophageal Adenocarcinoma
Heather R. Ferguson, Liam J. Murray, Brian T. Johnston, Lesley A. Anderson, Seamus J.
Murphy, Peter Watson, Jim Mcguigan, John V. Reynolds, Harry Comber, Chris P. Wild,
Laura J. Hardie
Introduction Chronic inflammation is implicated in carcinogenesis, as it can result in tissue
damage due to production of free radicals. These cause activation of 'pro-survival' genes
including cyclo-oxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS), which
can lead to carcinogenesis through DNA damage, angiogenesis and immunosupression. There
is extensive evidence that expression of both COX-2 and iNOS is increased in esophageal
adenocarcinoma (EAC), its precursor Barrett's esophagus (BE) and in reflux esophagitis (RE).
The aim of this study was to investigate possible associations between variations in the COX-
2 and iNOS genes and these increasingly common oesophageal conditions. Methods In a
case-control study, patients with EAC (n= 210), BE (n=212), RE (n=230) and population
controls (n=248) were recruited from throughout Ireland. Using genomic DNA extracted
from blood samples, single nucleotide polymorphisms in the COX-2 3' untranslated region
(8473 T>C) and iNOS codon 608 (Ser>Leu) were genotyped using a TaqMan 5' nuclease
assay. Allele and genotype frequencies were compared between cases and controls using the
Chi-square test. Logistic regression analysis was used to test for association between genotype
and disease whilst adjusting for potential confounding factors including age, sex, body mass
index, smoking and alcohol intake. Results A significantly higher COX-2 8473 C allele
frequency was observed in EAC cases than controls (p=0.02). The COX-2 8473 TC genotype
was associated with an increased risk of EAC (OR=1.54, 95% CI 0.99-2.39), and this risk
was higher in association with the COX-2 8473 CC genotype (OR=1.75, 95% CI 0.89-
3.43). No significant differences were observed in the distribution of iNOS Ser608Leu alleles
or genotype between the different disease groups and controls. Conclusion The variant COX-
2 8473 C allele was associated with an increased risk of EAC compared to the wild type
allele. To our knowledge this is the first study to date investigating these genetic variations
in association with esophageal disease. Further larger studies are required to assess whether
the variant COX-2 8473 C allele may be a useful potential genetic marker for susceptibility
to EAC.
M1994
The Interleukin-8 -251a Allele Is Associated with Increased Risk of Intestinal
Type Gastric Adenocarcinoma in Helicobacter pylori-Infected Korean
Population
Byong duk Ye, Sang gyun Kim, Ji hyun Park, Joo sung Kim, Hyun chae Jung, In sung
Song
Background: Chronic inflammation associated with long-term Helicobacter pylori(H. pylori)
infection is known to be the risk factor of gastric cancer. Interleukin-8 (IL-8) secreted by
gastric epithelial cells plays an important role in gastric mucosal inflammation induced by
H. pylori infection. Recently, genetic polymorphisms of various proinflammatory cytokines
such as interleukin-1β and tumor necrosis factor-α have been known to be associated with
gastric carcinogenesis. However, the studies on the association of genetic polymorphisms
of various cytokines with gastric cancer have shown different results depending on ethnic
groups. Objectives: This study was performed to investigate whether the IL-8 -251A/T
polymorphism is associated with the risk of gastric cancer in H. pylori-infected Korean
population. Materials and Methods: The IL-8 -251A/T polymorphism was identified by
polymerase chain reaction-restriction fragment length polymorphism method using DNA
from 585 H. pylori-infected subjects (206 controls, 149 chronic atrophic gastritis and/or
intestinal metaplasia's, 97 gastric adenoma's, and 133 intestinal type gastric adenocarcin-
oma's). The degrees of inflammation at gastric body and antrum were assessed by the
updated Sydney system. Gastric mucosal secretion of IL-8 was assessed by enzyme-linked
immunosorbent assay. Results: The IL-8 -251A/T carriers showed a higher risk of intestinal
type gastric adenocarcinoma (adjusted odds ratio 2.34, 95% confidence interval 1.27-4.32,
p=0.006) than IL-8 -251T/T genotypes. The IL-8 -251A was also associated with the risk of
gastric adenoma with marginal statistical significance (adjusted odds ratio 1.73, 95% confid-
ence interval 0.94-3.18, p=0.079). The IL-8 -251A allele was significantly associated with
the level of neutrophil infiltration, atrophy and intestinal metaplasia compared with IL-8
-251T/T genotype in H. pylori-infected young age group. Among chronic atrophic gastritis
and/or intestinal metaplasia group, mucosal IL-8 level was significantly higher in subjects
with IL-8 -251A allele than those having IL-8 -251T/T genotypes (p=0.011). Conclusions:
The IL-8 -251A allele is associated with higher IL-8 production, more severe inflammation,
mucosal atrophy and intestinal metaplasia than IL-8 -251T/T genotype in H. pylori-infected
hosts. The IL-8 -251A allele may also increase the risk of intestinal type gastric adenocarcin-
oma through enhanced inflammatory process in H. pylori-infected Koreans via atrophy/
intestinal metaplasia - adenoma - carcinoma sequence.
M1995
DNA Repair Gene Polymorphisms in the Reflux Esophagitis-Barrett's
Esophagus-Esophageal Adenocarcinoma Sequence
Heather R. Ferguson, Liam J. Murray, Brian T. Johnston, Lesley A. Anderson, Seamus J.
Murphy, Peter Watson, Jim Mcguigan, John V. Reynolds, Harry Comber, Chris P. Wild,
Laura J. Hardie
Introduction Oxidative stress is a major cause of DNA damage in cells and the base excision
repair (BER) pathway repairs such damage. The BER pathway involves various enzymes,
but two of the most important are hOGG1 and XRCC1. The hOGG1 enzyme repairs the
lesion 8-oxoGuanine, levels of which have been shown to be increased in Barrett's esophagus
(BE) and esophageal adenocarcinoma (EAC). XRCC1 acts as an important scaffold protein
in DNA repair. Cigarette smoking has been implicated in the pathogenesis of EAC, BE and
reflux esophagitis (RE). XPD enzyme, as part of the nucleotide excision repair pathway,
helps to repair smoking related DNA damage. The aim of this study was to investigate
possible associations between polymorphisms in the hOGG1, XRCC1 and XPD genes and
RE, BE and EAC. Methods Patients with RE (n=230), BE (n=212), EAC (n=210) and
population controls (n=248) were recruited in an all Ireland case-control study. Using
extracted genomic DNA , single nucleotide polymorphisms in hOGG1 codon 326 (Ser>Cys),
XRCC1 codon 399 (Arg>Gln) and XPD codon 751 (Lys>Gln) were genotyped. Allele and
genotype frequencies were compared between cases and controls using the Chi-square test.
Logistic regression analysis was used to test for association between genotype and disease
whilst adjusting for potential confounding factors including age, sex, body mass index,
smoking and alcohol intake. Results A significantly lower hOGG1 326Cys allele frequency
was observed in EAC cases than controls (p=0.03). The hOGG1 Ser326Cys and Cys326Cys
genotypes were associated with a reduced risk of EAC (OR=0.73, 95% CI 0.47-1.12; OR
0.33, 95% CI 0.10-1.14). No significant differences were observed in the distribution of
XRCC1 Arg399Gln and XPD Lys751Gln alleles or genotype, between the different disease
groups and controls. Conclusion The variant hOGG1 326Cys allele was associated with a
reduced risk of EAC compared to the wild type allele. There is a need for future studies to
establish the functional impact of this polymorphism, as well as larger epidemiological
studies assessing its association with these increasingly common esophageal pathologies.
M1996
The Association of the Grb2-Associated Binder 1 Polymorphism with Gastric
Cancer and Gastric Atrophy
Takafumi Ando, Yasuyuki Goto, Kazuhiro Ishiguro, Osamu Maeda, Osamu Watanabe,
Daisuke Ishikawa, Naoki Ohmiya, Yasumasa Niwa, Nobuyuki Hamajima, Hidemi Goto
Background & Aims: Gab1 functions upstream of at least Ras, most likely to regulate the
activity of the GDP / GTP exchanger, in a variety of growth receptor signaling to activate
extracellular-regulated protein kinase (ERK). The interaction between Gab1 and SHP2 is an
essential component for ERK activation. We have reported previously that the G/G of the
PTPN11 gene encoding SHP-2 increased the risk of gastric atrophy. We investigated the
association of Gab1 polymorphism and the combination of SHP-2 and Gab1 genotypes with
gastric cancer and gastric atrophy as the precursor lesion of gastric cancer. Methods: A single
nucleotide polymorphism at exon 3 of Gab1 (JST164345) was examined for 454 Japanese
health checkup examinees and 202 gastric cancer patients. Results: Gab1 polymorphism
was associated with the low risk of H. pylori infection and the high risk of gastric atrophy.
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The decreased OR of the T/T for HP seropositivity was 0.24 (95% CI, 0.08-0.72). Among
seropositive healthy controls, the OR of T/C+T/T for gastric atrophy was significant (OR =
1.95, 95% CI = 1.12 -3.40). Individuals with SHP-2 G/G and Gab1 C/T+T/T demonstrated
the highest risk of gastric atrophy with significance relative to SHP-2 G/A+A/A and Gab1
C/C, the lowest risk combination, as a reference. However, the multiplicative effect of SHP-
2 and Gab1 was not observed (the OR of the gene-gene interaction=1.39, 95% CI, 0.41-
4.66). Compared to gastric cancer case, the Gab1 did not influence the atrophy/metaplasia-
gastric cancer sequence. Conclusions: Gab1 polymorphism was associated with the low risk
of H. pylori infection and the high risk of gastric atrophy but not gastric cancer. Individuals
with SHP-2 G/G and Gab1 C/T+T/T demonstrated the greatest risk of gastric atrophy.
M1997
Relationship of Helicobacter pylori and Cytokine Gene Polymorphisms in
Esophageal Squamous Cell Carcinoma Development
Huang-ming Hu, Chao-hung Kuo, Fu-chen Kuo, Chien-hung Lee, Ming-tsang Wu, Deng-
chyang Wu
Background: According to the recent studies, Helicobacter pylori (H. pylori) seem to have
protective role in development of esophageal squamous cell carcinoma (ESCC). The reason
was not clear. High mucosal level of interleukin-1β (IL-1β) and tumor necrosis factor-α
(TNF-α) have been described in H. pylori infected patients, in association with hypoch-
lorhydric response, but their roles in ESCC were not yet to be been well studied. Aim:
We aimed to evaluate the correlation between H. pylori infection, IL-1β, TNF-α genetic
polymorphisms and the occurrence of ESCC. Methods: We assessed polymorphisms of the
IL-1β-511 and TNF-α-857 and H. pylori infection in a population-based case-control study,
including 228 ESCC cases 291 controls. Each one received the endoscope exam and blood
sample collection. They also answered the questionnaire for evaluating the environmental
risks exposure. PCR-restriction fragment length polymorphism (RFLP) was used to analyze
the genotype of polymorphism. Besides, we used enzyme-linked immunosorbant assay to
measure the serum IgG of H. pylori. We modeled the data by use of logistic regression to
estimate relative risks in the form of odds ratios (ORs) with 95% confidence intervals (CIs).
Results: We found that the one without H. pylori infection had increased risk of ESCC (OR
2.48, 95% CI 1.30-4.70). The risk of ESCC was also elevated in subjects with IL-1β-511
non-T/T genotype (OR 2.14, 95% CI 1.03-4.44). Individuals who carried IL-1β-511 non-
T/T genotype but without H. pylori infection had higher risk in developing ESCC than the
one of IL-1β-511 T/T genotype with H. pylori infection (OR: 6.79, 95% CI, 1.99-23.13).
TNF-α-857 polymorphism was not associated with ESCC development, no matter what the
H. pylori infection status. Conclusions: H. pylori and IL-1β-511 T/T genotype seem to play
protective roles in ESCC development, especially when both are present simultaneously,
possibly by inducing a hypochlorhydric response. However, there is not such a relationship
between H. pylori, TNF-α polymorphism and ESCC.
M1998
Relevance of Ptgs1 and Ptgs2 Gene Polymorphisms On Gastric Cancer
Susceptibility
Maria asuncion Garcia-gonzalez, Enrique Quintero, Rafael Benito, Mark Strunk, David
Nicolas, Adolfo Parra-blanco, Santos Santolaria, Federico Sopeña, Cristina Pascual, Eva
Mas, Pilar Irun, Jesus Espinel, Rafael Campo, Marisa Manzano, Fernando Geijo, Miguel
Simon, Maria Pellise, Ferran Gonzalez-huix, Miguel Nieto, Maria angeles Perez-aisa, Jorge
Espinos, Llusia Tito, Luis Bujanda, Manuel Zaballa, Angel Lanas
Background & aim: Cyclooxigenases 1 (COX-1) and 2 (COX-2) are key enzymes in mediat-
ing the conversion of arachidonic acid into prostaglandins which are important regulators
of the immune inflammatory response in the gastrointestinal mucosa. COX-1 is constitutively
expressed in most cell types and involved in maintaining gastric mucosal homeostasis,
whereas COX-2 is induced by proinflammatory and mitogenic stimuli and involved in many
mechanisms of gastric cancer (GC) development. Since variants in the PTGS1 and PTGS2
genes may modify the expression or function of their encoded enzymes COX-1 and COX-
2, the aim of our study was to assess the relevance of several functional PTGS1 and PTGS2
gene polymorphisms on GC susceptibility. Methods: DNA from 415 unrelated Spanish
Caucasian patients with GC and 415 sex- and aged- (± 5 years) matched cancer-free healthy
controls was typed for 10 single nucleotide polymorphisms (SNPs) in the PTGS1 (+50C/T,
and +644C/A) and PTGS2 (-1195A/G, -765G/C, -297C/G, +3050G/C, +8473T/C, +9850A/
G, +10335G/A, and Val511Ala) genes by PCR, RFLP and TaqMan assays. H. pylori infection
and CagA/VacA antibody status were also determined by western blot in patients and controls.
Results: H. pylori infection with CagA strains (OR: 2.54; 95% CI: 1.77-3.66), smoking habit
(OR: 1.91; 95% CI: 1.25-2.93) and positive family history of GC (OR: 3.67; 95% CI: 2.01-
6.71) were identified as independent risk factors for GC. Concerning gene polymorphisms,
no differences in carriage, genotype, and allele frequencies of the PTGS1 and PTGS2 gene
polymorphisms were found between GC patients and controls. However, when GC patients
were stratified according to the localization of the tumor, we found that carriers of the
PTGS2 -1195G allele were significantly more frequent in the group of cardia-GC patients
than in controls (46.8% vs. 32.8%; OR: 1.77; 95% CI: 1.06-2.95; p=0.03). Moreover, carriers
of the PTGS2 GGGTAG haplotype that contains the PTGS2-1195G allele, were also more
frequent in the group of cardia-CG patients than in controls (41.3% vs. 32.1%; OR: 1.73;
95% CI: 0.86-3.49). Finally, no differences in carriage, genotype, and allele frequencies of
the PTGS1 and PTGS2 gene polymorphisms were found when GC patients were categorized
according to the gender, age, smoking habit, H. pylori infection, CagA/VacA antibody status,
previous history of peptic ulcer disease, family history of gastric cancer, and histological
subtype of the tumor.Conclusion: Our data show that the PTGS2-1195A/G gene polymorph-
ism is involved in defining the genetic basis of the susceptibility to cardia-gastric cancer.
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M1999
Examination of Polymorphisms of Tlr2, TLR4 and Cd14 in Japanese Gastric
Cancer Patients
Tomomitsu Tahara, Tomiyasu Arisawa, Tomoyuki Shibata, Masakatsu Nakamura, Naoko
Maruyama, Yoshio Kamiya, Shin Hasegawa, Masahiko Nakamura, Hiroshi Fujita, Tamaki
Takagi, Mitsuo Nagasaka, Masami Iwata, Kazuya Takamama, Makoto Watanabe, Makoto
Kuroda, Ichiro Hirata, Hiroshi Nakano
Background: Host genetic susceptibility may influence gastric carcinogenesis caused by
Helicobacter pylori (H. pylori) infection. Toll like receptors (TLRs) and CD14 play important
roles in the signaling of many pathogen-related molecules and endogenous proteins associated
with immune activation. Therefore, one of our recent projects has been designed mainly
on the identification of genetic alterations in Japanese patients with gastric cancer, with an
attempt to clarify the association between molecular variations that alter the innate immune
response to H. pylori infection and carcinogenesis in stomach. Aims: The aim of the present
study was to investigate the association between polymorphisms of TLR2, TLR4, CD14, and
risk of gastric cancer including its subtypes and clinicopathologic features in a Japanese
population. We also investigated the effects of these polymorphisms on histologic degree
of H. pylori induced gastritis. Subjects: The study was performed in 289 gastric cancer (GC)
cases [mean age 64.0±12.4,M:F=0.63] and 309 patients without evidence of GC [mean age
64.1±12.3,M:F=0.71] as the control group. Methods: TLR4 Asp299Gly, Thr399Ile and CD14
promoter -C260T were determined by polymerase chain reaction-restriction fragment length
polymorphism. TLR2 -196to174 ins/del was determined by PCR. Gastritis scores of non-
cancerous gastric mucosa were assessed according to the updated Sydney system. Results:
The frequency of TLR2 -196 to 174 del/del was significantly higher in gastric cancer patients
than in controls (OR=2.02; 95%CI=1.22-3.33).The same genotype significantly increased
the risk of both intestinal and diffuse type gastric cancer (OR=2.00; 95%CI=1.12-3.59, OR=
2.05; 95%CI=1.11-3.80, respectively). The frequencies of CD14-260 TT and T carrier were
significantly lower in patents with intestinal type gastric cancer than in controls (OR=0.31;
95%CI=0.12-0.78, OR=0.38;95%CI=0.18-0.81, respectively). Compared with patients older
than 61 years, atrophy score in antrum was significantly lower in TT and CT patients. TLR4
Asp299Gly, Thr399Ile were not detected in all the patients. Conclusion: We showed that
TLR2 -196 to 174 del/del was associated with increased risk of both histologic subtypes of
gastric cancer, CD14 promoter-260TT and CT were associated with lower risk of developing
gastric mucosal atrophy in H. pylori infected patients more than 61 years of age, and these
genotypes may reduce the risk of gastric cancer featuring intestinal type histopathology and
TLR4 Asp299Gly, Thr399Ile are very rare in the Japanese population.
M2000
SNPs and Esophageal Cancer: Replication of a Genome-Wide Mapping Case-
Control Study
David Ng, Nan Hu, Ying Hu, Carol Giffen, Ze-zhong Tang, Xiao-you Han, Howard H.
Yang, Maxwell P. Lee, Alisa M. Goldstein, Philip R. Taylor
Background: Previously, we applied the Affymetrix mapping 10K SNP array in a pilot case-
control study to determine differences in genotypes between esophageal squamous cell
carcinoma (ESCC) cases and controls from a high-risk area in China and identified 38 SNPs
in or near one of 33 genes. The present study attempted to replicate the results of these 38
gene-related SNPs in a new sample of cases and controls. Methods: A subset of 300 ESCC
cases and 300 matched controls from a larger case-control study conducted in Shanxi
Province, China was selected for the present study. A series of multiplex oligonucleotide
ligation assays to genotype these 38 target SNPs were developed and applied to germline
DNA from study subjects. Assays were validated by direct sequencing of eight SNPs in 12
pairs of cases and controls, and Hardy-Weinberg equilibrium was examined in control
samples. General linear models were used to derive odds ratios (ORs) for dominant, recessive,
and additive modes of transmission adjusted for baseline risk factors and one or more SNPs.
Factor analysis was used to predict individual risk of ESCC. Results: Among 36 evaluable
SNPs, four were significant in one or more analyses, including SNPs in EPHB1, PIK3C3,
SLC9A9, and PGLYRP2. Risks were significantly increased for subjects with the T/T genotype
in SNPs in EPHB1, PIK3C3, and SLC9A9, and for subjects with the A/A genotype in the
PGLYRP2 SNP. The best factor analysis models accurately classified case/control status in
approximately half of the subjects. Conclusions: Four of 38 previously identified gene-
related SNPs remained significant in this replication study. While EPHB1, a receptor protein
tyrosine kinase previously associated with colorectal cancer, merits particular consideration
as a candidate tumor suppressor gene for ESCC, further exploration of all four genes in
ESCC is recommended.
M2001
Gene Polymorphisms of Folate Metabolizing Enzymes and the Risk of Gastric
Cancer
Tobias Götze, Christoph Röcken, Jutta Dierkes, Matthias Ebert
Multiple studies have reported an association between disturbances of folate metabolism
and increased risk of gastric cancer, including low intake of folate, low levels of folate in
blood or genetic factors affecting folate metabolism. Among the genetic factors, in particular
a common polymorphism in gene encoding for 5,10-methylenetetrahydrofolate reductase
(MTHFR C677T) has been linked to gastric cancer. Other polymorphisms in folate-metabolis-
ing genes have been less frequently investigated. Therefore, we analyzed this polymorphism,
the glutamate carboxypeptidase (GCP) II C1561T and the reduced folate carrier (RFC) G80A
in a case-control study involving 106 patients with histologically confirmed and characterized
gastric cancer with adjustment for other established risk factors for gastric cancer in compar-
ison to 106 age- and sex-matched controls. Neither the MTHFR nor the GCP gene polymorph-
isms showed an association to cancer diagnosis, to tumor stage, grade of differentiation or
Lauren type. However, non-cardia cancers were more likely to exhibit the 80GA and 80AA
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RFC genotypes, compared to cancers of the gastric cardia (adjusted OR 0.28; 95% CI=0.11-
0.71). Thus, gene polymorphisms of the RFC gene might contribute to an increased risk of
developing distal gastric cancer.
M2002
Genetic and Epigenetic Alterations in Colorectal Caners with Loss of
Imprinting of the Insulin-Like Growth Factor-II
Miki Ohta, Fumihiko Kanai, Takafumi Sugimoto, Motoko Seto, Lian-jie Lin, Yoshinari
Asaoka, Motohisa Tada, Yasuo Tanaka, Takao Kawabe, Masao Omata
BACKGROUND: Loss of genomic imprinting (LOI) is an epigenetic alteration of some cancers
involving loss of parental origin-specific expression of imprinted genes. The LOI of Insulin-
like Growth Factor-II (IGF2) is often detected in colorectal carcinoma (CRC), adenoma and
also in normal mucosal tissue adjacent of colorectal neoplasia. But the genetic alterations
in CRC with LOI yet to be fully determined. We investigated the correlation between LOI
of IGF2 and genetic/epigenetic alterations to clarify the carcinogenesis of CRC with LOI.
MATERIALS and METHODS: The genome DNA samples had been collected from 52 CRC
tissues using laser microdissection system. The methylation status of the defferentiated
methylated region of IGF2 gene were determined by sodium bisulfite treatment of DNA
followed nested PCR and sequence analysis. The DNA methylation of three CpG island
methylator phenotype (CIMP) related genes (MINT1, MINT2 and MINT31) were also exam-
ined using sodium bisulfite treatment of DNA followed by methylation specific PCR. The
fluorescent multiplex PCR assay with the use of five mononucleotide repeat markers were
performed to determine the microsatellite instability (MSI). Direct sequencing of KRAS exon
1, BRAF exon 15 and PIK3CA exon 9 and 20 was performed to determine the genetic
mutations. Immunohistochemistry was examined to determine the aberrant expression of
TP53 in CRC tissue. RESULTS: The age at present of CRC with normal imprinting status
and with LOI was 62.8 ± 11.1 and 66.7 ± 9.7 year old (mean ± SD), respectively (P = 0.19).
Most of normal imprinting cancer was located at distal colon and rectum (77.2 %), contrary
that the cancer with LOI tended to locate in proximal site of colon (56.6 %, P = 0.023).
Active genetic mutation was detected in 36.3 % of KRAS and 9.1 % of BRAF in CRC with
normal imprinting, and in 40.0 % of KRAS and 13.3 % of BRAF in CRC with LOI (KRAS,
P > 0.99; BRAF, P > 0.99), while PIK3CA mutation was highly detected in normal imprinting
CRC (27.3 %) compared to CRC with LOI (6.7 %, P = 0.058). TP53 expression, MSI or
CIMP status were not associated in imprinting status (TP53, P > 0.99; MSI, P = 0.23; CIMP,
P = 0.36). In logistic regression analysis adjusting for age and sex, there were statistically
significant relations between the location of tumor and PIK3CA genetic mutation, and
imprinting status of IGF2 (location, P = 0.037; PIK3CA mutation, P = 0.024). CONCLUSION:
This study demonstrates that CRC with LOI of IGF2 have a tendency to outbreak in proximal
site of colon with lower frequency of PIK3CA genetic mutation.
M2003
Interaction Between Cyclooxygenase-2 Gene Polymorphisms and Risk of
Gastric Cancer in Japanese Population
Tomoyuki Shibata, Tomomitsu Tahara, Tomiyasu Arisawa, Ichiro Hirata, Hiroshi Nakano
Backgrounds & Aims: The cyclooxygenase-2 (COX-2) gene is a member of the prostaglandin
synthase genes. Recently, the progress of investigation about this gene has shown the COX-
2 gene is a key regulator of inflammatory changes and the COX-2 gene is associated with
gastrointestinal cancer development. The COX-2 -765G>C promoter variant is located in a
putative SP1 binding site and affects COX-2 expression. This variant was studied only in
colorectal cancer patients in Japanese. There is another polymorphism within the 3'-untrans-
lated region (3'-UTR 8473T>C) of COX-2. This variant and gastric cancer risk has not been
studied previously. Here we showed the interaction between the COX-2 gene -765G>C
promoter polymorphism or 3'-UTR T>C polymorphism and gastric cancer development.
Methods: At endoscopic procedure, we performed biopsy from a stomach, and extracted
DNA from the biopsy specimens. All subjects were given written informed consent about
this study. DNA from 129 Japanese patients with gastric cancer (96 males and 33 females)
aged 30 to 94, and 126 age matched control patients (90 males and 36 females) aged 25
to 88 was examined for the COX-2 polymorphism at position -765G>C and 3'-UTR 8473T>C
by PCR-RFLP methods. Odds ratios and 95% confidence intervals were calculated. Genotyp-
ing was confirmed by direct sequencing. Results: The promoter polymorphism was not
associated with an increased risk of gastric cancer (OR=0.98, 95% CI 0.29-3.29). And CC
genotype was not detected in both groups. Homozygous carriage of the COX-2,8473C allele
was associated with an increased risk of gastric cancer, compared to subjects homozygotes
for the T allele (OR=3.72, 95% CI 0.99-13.94). Conclusions: These findings suggest that
the COX-2, 3'-UTR 8473T>C polymorphism could be used as a marker for the genetic
susceptibility to gastric cancer in Japanese population. And our results demonstrate that
COX-2 promoter -765G>C polymorphism is very rare in Japanese population.
M2004
The Relationship Between Promoter Polymorphism of Nrf2 Gene and
Helicobacter pylori Infection in Gastric Carcinogenesis
Tomiyasu Arisawa, Tomomitsu Tahara, Tomoyuki Shibata, Masakatsu Nakamura, Tamaki
Takagi, Yoshio Kamiya, Hiroshi Fujita, Shin Hasewaga, Mistuo Nagasaka, Ichiro Hirata,
Hiroshi Nakano
[Background and Aims] Transcription factor Nrf2 regulates the expression of detoxifying
and antioxidant genes. In addition, three polymorphisms of Nrf2 gene (at positions -686,
-684, and -650) have been clarified. We attempted to clarify the relationship of Nrf2 gene
polymorphisms with the carcinogenesis of stomach in a Japanese population. [Methods]
The study was performed in 209 patients with gastric cancer (mean age 65.2, M:F=152:57,
Helicobacter pylori (H. pylori) positive ratio=88.8%) and 198 patients with no evidence of
malignant gastric malignancies (mean age 63.3, M:F=121:110, peptic ulcer diseases; 83/
198, H. pylori positive ratio=71.6%) on upper gastrointestinal endoscopy. We employed
PCR-SSCP method to detect gene polymorphisms using DNA extracted from peripheral
blood or from antral biopsy specimens obtained by endoscopy. The severity of histological
chronic gastritis on antral biopsy specimens was classified according to the updated Sydney
system. [Results] Overall, minor allele frequencies were 43.3, 3.8, and 25.4% at positions
-686(G/A), -684(G/A), and -650(C/A), respectively. Strong allelic associations were recog-
nized among 3 polymorphisms. Both SNP(-686) and SNP(-650) were not significant risk
factors of carcinogenesis in the stomach by logistic regression analysis after adjustment for
gender and H. pylori status. These findings were not dependent on clinicopathological
features, such as tumor staging, histologic classification, metastasis, and cancer cell dissemina-
tion. However, the number of -686 G alleles was significantly interacted with H. pylori
infection to carcinogenesis, especially of diffuse-type, in the stomach (p=0.039 by ANCOVA).
In addition, the number of -686 G alleles correlated with infiltration of mono nuclear cells
(p=0.02), although not so closely correlated with neutrophil activities and mucosal atrophy
(p=0.07 and p=0.06, respectively). [Conclusions] The number of Nrf2 -686 G alleles may
associate with the development of gastric inflammation, consequently promote the carcino-
genesis in the stomach under the influence of H. pylori infection.
M2005
Does Colorectal Carcinogenesis Follow a Different Pathway in North Indians
Patients?
Rakesh Kochhar, Pooja Anand, S. Mahmood, K. Vaiphei, J. Wig, B. Radotra
Background: We have earlier documented that patients with colorectal cancer in India have
synchronous adenomas and carcinomas rarely, suggesting that CRC may have a different
pathogenetic pathway tahn the classical adenoma-carcinoma sequence. Objective: Progressive
genetic changes such as the inactivation of tumor suppressor genes e.g. APC, p53 and p16
& mismatch repair genes e.g. hMLH1 & hMSH2 and the activation of proto-oncogene e.g.
K-ras are thought to play an important role in the initiation and progression of colorectal
cancer (CRC). The frequency of mutation of these genes in CRC in India has not yet been
determined. So the present study was planned to explore the genetic alterations in the APC,
K-ras, p53 , p16, hMLH1 & hMSH2 genes during colorectal carcinogenesis. Materials and
Methods: Specimens of tumor, adjoining (2-5 cm from tumor) and of normal tissues from
30 cases of CRC were screened for alterations in these genes. Mutation analysis of K-ras
was determined by PCR-Restriction digestion and p53 and APC gene were checked by PCR-
SSCP and inactivation of p16, hMLH1 and hMSH2 genes was determined by Methylation
specific PCR. Results: Age range in the 30 cases was from 24-84years, 20 males: 10 females.
The site of primary tumor was: right colon 9: left colon 21. No synchronous lesion was
seen. None of the cases had family history of colon carcinoma. 7 cases had regional lymph
node metastases. Point mutations of K-ras gene, were found in 8/30(26.6%) of the cases.
No K-ras mutation was observed in normal and adjoining mucosa. APC and p53 mutations
were found in 20/30(66.6%) and 14/30(46.6%) of the cases respectively. In the adjoining
mucosa, APC mutation was seen in 15/30(50%) and p53 mutation in 4/30(13.3%) cases.
Combination of APC, K-ras & p53 Mutation was K-ras + p53 : 3(10%), APC + K-ras :
6(20%), P53 + APC : 10 (33.3%). 2 cases (6.6%) had all the three mutations i.e. APC, K-
ras and p53. The commonest combination seen was APC and p53 . Hypermethylation of
hMLH1 promoter region was found in 22/30(73.3%), of hMSH2 promoter region in 13/
30(43%) and of p16 promoter region in 12/30(40%) cases. No promoter methylation of
hMLH1, hMSH2 & p16 genes was observed in normal and adjoining mucosa. Conclusions:
The frequency of mutations in APC, K-ras and p53 genes was 66.6%, 26.6% and 46.6%
respectively and frequency of methylation in hMLH1, hMSH2 and p16 genes was 73.3%,
43% & 40% respectively and these figures are different from those in the west. So our findings
suggest that these mutations may lie on alternate pathways of colorectal tumor development.
M2006
Interleukin-10 Gene Transfer to Peritoneal Mesothelial Cells Suppresses
Dissemination of Gastric Cancer Cells Mediated By Its Continuous and High
Concentration in Peritoneal Cavity
Fumio Tanaka, Kazunari Tominaga, Masahiro Ochi, Hikaru Kuwamura, Masayuki Shiota,
Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide
Higuchi, Hiroshi Iwao, Tetsuo Arakawa
Background: Peritoneal metastasis is a common feature of advanced gastric cancer but must
be overcome because it is responsible for prognosis. Interleukin (IL)-10, an immunosuppress-
ive and anti-inflammatory cytokine, has an inhibitory property of tumor growth and meta-
stasis of melanoma and mammary tumor. We focused on IL-10 gene transfer to peritoneal
mesothelial cells (PMCs), because PMCs abundantly exist in peritoneal cavity and can be
suitable sources for continuous synthesis of IL-10 after the gene transfer. We examined
therapeutic effects of intraperitoneal IL-10 gene transfer on peritoneal disseminated tumor
growth. Materials & Methods: PMCs were isolated from rat peritoneum as previously
described method. Transfection efficiency was assessed by X-gal staining technique using
the adenovirus vector expressing β-galactosidase (Ad-LacZ). Cell viability of gastric cancer
cells (MKN45) treated with recombinant human IL-10 (rhIL-10) was measured by MTS
assay. Peritoneal dissemination was generated by intraperitoneal injection of MKN45 in
BALB/c nude mouse. Three days later, mice were divided into three groups and received
intraperitoneal injection with adenovirus vector expressing mouse IL-10 (Ad-mIL-10), Ad-
LacZ, or PBS, respectively. On day 24, mice were sacrificed and total intestinal tract,
peritoneum, and peritoneal tumors were excised en bloc, and number of peritoneal nodules
larger than 1 mm in diameter was counted. IL-10 levels in peritoneal lavage and plasma
samples were quantified by ELISA method. Intratumoral IL-10 mRNA expression was meas-
ured by real time RT-PCR. Results: PMCs characters were confirmed by immunostaining
with vimentin and cytokeratin. Transfection efficiency of adenovirus showed markedly higher
to PMCs than MKN45. In Vitro cell viability of MKN45 was not suppressed by rhIL-10.
But, Ad-mIL-10 treatment both decreased total number of peritoneal metastatic nodules
(8.7 ± 4.1) compared with PBS or Ad-LacZ treatment groups (58.9 ± 15.3 or 37.4 ± 12.9)
and improved their cachexia. Peritoneal IL-10 levels were remarkably increased in Ad-mIL-
10 group (3163 ± 835 pg/ml) but not in other groups. Plasma IL-10 was not detected in
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all groups. Intratumoral IL-10 mRNA expression levels in Ad-mIL-10 group were about 23-
folds higher than those in other groups. Conclusion: Continuous high peritoneal IL-10
concentration induced by its gene transfer to PMCs may suppress the peritoneal dissemination
of gastric cancer.
M2007
Silencing of Epha2 Receptor in Combination with Gemcitabine Reduces
Pancreatic Tumor Growth and Invasion In Vivo
Pavel A. Levin, Thiru Arumugam, Anil Sood, Gabriel Lopez-berestein, Craig D. Logsdon
Background: We have observed that EphA2 is over-expressed in pancreatic cancer. EphA2
was reported to increase metastatic potential in pancreatic ductal adenocarcinoma (PDAC).
In this study, we determine the significance of the EphA2 receptor in PDAC and examine
the effectiveness of liposomal delivery of siRNA In Vivo. Methods: MPanc96 cells were stably
transfected with the luciferase (Luc) gene. Effectiveness of EphA2 siRNA (siEphA2) silencing
was confirmed by western blot In Vitro. MPanc96-Luc cells were injected orthotopically into
the pancreas of nude mice for In Vivo silencing. After one week, tumor burden of each
mouse was measured by bioluminescence. Mice were divided into 4 groups having similar
tumor load to test liposomal siRNA delivery system. Groups were treated by IP injections
with vehicle, siEphA2 (5μg/per animal/biweekly), gemcitabine (100mg/kg.b.wt/biweekly) or
combination of siEphA2 and gemcitabine. Neutral liposomes were coupled with siRNA and
delivered one day prior to gemcitabine treatment. Tumor growth was monitored for 4 weeks.
After 6 weeks of treatment, animals were sacrificed and tumors were excised and weighed.
Metastasis to liver and lung were counted and analyzed. Tumor tissue was stained for EphA2
and PCNA. Results: siEphA2 significantly silenced EphA2 expression in MPanc96 cells by
~80% In Vitro. Liposomal siRNA delivery In Vivo did not have any visible adverse effects
on mouse well-being or body weight. siRNA treated mice were the only group which did
not exhibit any decrease in body weight. Treatments with either siEphA2 or gemcitabine
alone showed no significant reduction in tumor mass from control, however, the combination
treatment reduced tumor growth significantly (p<0.01). These findings were confirmed by
both bioluminescence and tumor weight. Treatments with the siEphA2 alone reduced PCNA
positive tumor cells (p<0.05), animals with lung metastasis (20% reduction), and metastatic
foci (liver 53%, lung 32% reduction). Gemcitabine alone did not significantly reduce PCNA
positive tumor cells, but reduced animals with lung metastasis (25% reduction), and meta-
static foci (liver 71%, lung 62% reduction). The combination treatment reduced PCNA
positive tumor cells (p<0.01), animals with metastasis (liver 25%, lung 50% reduction) and
metastatic foci (liver 80%, lung 85% reduction). Conclusion: Liposomal delivery of siRNA
is an effective delivery system In Vivo and can be considered a novel approach to treatment
of PDAC. For all factors, EphA2 silencing combined with gemcitabine demonstrated a greater
effect than either treatment alone and significantly inhibited pancreatic tumor progression
and invasion in this model.
M2008
Gemcitabine Increases the Efficiency of Specific Tumor Endothelial Cell
Targeting in a Nude Mouse Model of Human Pancreatic Cancer
Hubert G. Hotz, Birgit Hotz, Heinz J. Buhr
Targeting of tumor endothelial cells by a fusion protein where the Vascular Endothelial
Growth Factor isoform VEGF-121 is linked to the A-subunit of Shiga-like Toxin 1 (SLT-
VEGF) has been shown to be effective in pancreatic cancer. SLT-VEGF binds to tumor
endothelial cells via VEGF-receptors and inhibits protein synthesis. This study investigated
whether a combination of SLT-VEGF with the cytotoxic drug Gemcitabine increases the
therapeutic potential in an nude mouse model of pancreatic cancer. Methods: In Vitro:
Human pancreatic cancer cells (AsPC-1) were incubated with SLT-VEGF (0.1 - 10 nM) or
Gemcitabine (0.1 - 100 µM). Cell proliferation was assessed after 72 hours by cell count.
In Vivo: 5 million AsPC-1 cells were injected subcutaneously into nude mice. 1 cmm fragments
of the resulting sc. tumors were implanted into the pancreas of 84 other mice. Animals
were randomized into control and 6 treatment groups: application of the SLT-VEGF fusion
protein (200 µg/kg, every other day ip.), Gemcitabine (125 mg/kg, weekly ip.), or the
combination of both drugs began either 3 days (prophylaxis) or 6 weeks (therapy) after
tumor induction. Treatment was continued for 14 weeks or until death. Volume of the
primary tumor (TU-Vol), local infiltration and metastatic spread (dissemination score: D-
Score) were determined at autopsy. Microvessel density (MVD) was analyzed in CD31-
stained tumor sections. Results: In Vitro: SLT-VEGF did not influence proliferation of pancre-
atic cancer cells, whereas Gemcitabine treatment resulted in a dose-dependent reduction by
up to 83 %. In Vivo: all control animals developed extensive primary tumor growth, local
infiltration, and distant metastasis. The effects of SLT-VEGF monotherapy and the combina-
tion therapy after delayed onset (therapy) and early begin (prophylaxis) are summarized in
the table. The results of Gemcitabine alone were comparable with SLT-VEGF monotherapy.
Conclusions: Combination therapy with SLT-VEGF fusion protein and Gemcitabine increases
the therapeutic potential in a pancreatic cancer model in comparison to the respective
monotherapies. In Vitro data and microvascular density indicate that SLT-VEGF acts by an
antiangiogenic mechanism, whereas Gemcitabine directly inhibits cancer cell growth.
In Vivo results
p<0.05: * vs. control, # vs. respective therapy group, ° vs. respective SLT-VEGF group
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
M2009
Saccharomyces Boulardii Inhibits EGFR Signaling and Reduces Intestinal
Tumor Growth in APC(Min/+) Mice
Xinhua Chen, Johannes Fruehauf, Kianoosh K. Katchar, Nasima Mustafa, Hoon wai
Koon, Dezheng Zhao, Efi G. Kokkotou, Jeffrey D. Goldsmith, Charalabos Pothoulakis,
Ciaran P. Kelly
Background and Aims: The probiotic yeast Saccharomyces boulardii (Sb) ameliorates intest-
inal injury and inflammation from diverse etiologies. We have reported that Sb can modulate
host signaling pathways including Erk1/2 MAP kinase both In Vitro and In Vivo. We hypothes-
ized that Sb inhibited Erk activation via an upstream effect on Epidermal Growth Factor
Receptor (EGFR) signaling. We also examined whether the effects of Sb on EGFR signaling
can influence proliferation and apoptosis of colon cancer cells In Vitro, as well as intestinal
tumor growth in Apc(min/+) mice In Vivo. Methods: Human adenocarcinoma HT-29
colonocytes were incubated with Sb conditioned media (SbS) at different time points. The
effect of SbS on Erk1/2, MEK1/2, EGFR and Akt activation was studied by western blotting.
Cell proliferation was measured by MTT and cell colony formation assays. Apoptosis was
examined by Flow Cytometry and Homogenous Caspase Assay. Sb was administrated to
C57BL6/min/+ mice daily in their drinking water and 3 times each week by oral gavage
from 7 until 16 weeks of age. Mice were then sacrificed and intestinal tumor number, size
and grade of dysplasia were measured. Immunostaining was performed for p-EGFR, p-AKT
and PCNA. Results: SbS prevented activation of the EGFR-MEK-Erk pathway in HT-29.
EGFR-mediated Akt activation was also reduced. SbS inhibited both HT29 cell proliferation
in response to stimulation by EGF and reduced cell colony formation in response to serum.
Furthermore, SbS induced HT29 cell apoptosis demonstrated by both flow cytometry and
caspase assay. Orally administered Sb caused a significant reduction in both number (p=
0.03) and size (p=0.03) of intestinal tumors in Apc(min/+) mice with control (average no.
29.7, average diameter 3.3mm, n=8) compared to Sb-treated mice (16.4, 2.6mm, n=6). Sb-
treated mice also have a lower fraction of tumors with low-grade and high-grade dysplasia
compared to control mice (p=0.01 & p=0.12 respectively). Immunochemistry showed that
Sb treated Apc mice had less proliferation in their tumors (PCNA staining), as well as less
p-EGFR(Y1173) and p-Akt staining. Conclusions: S. boulardii inhibits EGFR-MEK-Erk as
well as EGFR-Akt activation and signaling, reduces EGF-mediated cancer cell proliferation
and increases apoptosis. Sb also inhibits intestinal tumor growth in APC/min mice In Vivo.
Thus, in addition to its beneficial role in intestinal inflammation, S. boulardii may also serve
a novel therapeutic or preventive role in intestinal neoplasia.
M2010
Curcumin Synergises with Colon Cancer Chemotherapeutics Through EGF-
Receptor (EGFR) and Insulin-Like Growth Factor Receptor-1 (IGF-1r)
Signaling
Bhaumik Patel, Radha Sengupta, Sadia Qazi, Arun K. Rishi, Adhip N. Majumdar
Despite recent advances in medicine, mortality from colorectal cancer remains unacceptably
high. Currently, surgery and chemotherapy remain the best choice of treatment, but with
limited success. Therefore, interests to develop alternative therapeutic strategies have greatly
intensified over the past decade. Recent advances in the understanding of the molecular
pathogenesis of cancer have been instrumental in the development of “targeted” therapies.
It is becoming increasingly clear that many solid tumors, including those in the colon, show
constitutive activation of multiple signaling pathways, specifically those induced through
activation of EGFR/ErbB-1, ErbB2/HER-2, ErbB-3/HER-3 and/or ErbB-4/HER-4 [collectively
referred to as EGFRs] and also IGF-1R. Therefore, inhibition of these pathways with tolerable
doses of noncytotoxic agents represents a logical therapeutic approach. Curcumin [diferuloyl-
methane], the major yellow pigment extracted from turmeric, commonly used as a coloring
and flavoring additive in many South Asian cuisines, has known to possess anti-inflammatory
and anti-oxidant properties. We have recently demonstrated that curcumin attenuates EGFR
and IGF-1R activation (Nutr. Cancer 55: 185-194, 2006). The present investigation was
undertaken to examine whether curcumin in combination with conventional chemothera-
peutic agent(s)/regimen will be a superior therapeutic strategy for colon cancer. Indeed, results
of our In Vitro studies demonstrate that curcumin together with FOLFOX (5FU+oxaliplatin]
produces a significantly greater inhibition (p<0.01) of growth of colon cancer HCT-116 and
HT-29 cells than that caused by curcumin, 5-FU, curcumin + oxaliplatin or FOLFOX alone,
compared with the controls. These changes were associated with decreased expression and
activation (tyrosine phosphorylated form) of EGFR, HER-2 and HER-3 (72-100%) and also
IGF-1R (67%) as well as their downstream mediators such as Akt and COX-2 (51-97%).
We have also observed that while these agents produced a 2-3-fold increase in the expression
of IGF binding protein-3 (IGFBP-3), curcumin together with FOLFOX produced a 5-fold
increase in IGF binding protein-3 (IGFBP-3), when compared with the controls. This in
turn led to increased sequestration of IGFs by IGFBP-3 rendering IGF-1 unavailable for
binding to and activation of IGF-1R. We conclude that the superior effects of the combination
therapy of curcumin and FOLFOX are due to attenuation of EGFRs and IGF-1R signaling
pathways. We also suggest that inclusion of curcumin to the conventional chemotherapeutic
agent(s)/regimen could potentially be an effective therapeutic strategy for colon cancer.
M2011
Inhibition of COX-2 Expression By the mRNA Decay Factor Tristetraprolin
(TTP)
Vimala Kasa, Kristi Bemis-standoli, Dan A. Dixon
COX-2 is the enzyme responsible for increased prostaglandin formation during inflammation
and is a primary target of NSAIDs. Normally COX-2 expression is tightly regulated, however
overexpression plays a critical role in colorectal cancer and associated inflammatory diseases.
A central point of COX-2 gene regulation occurs at the post-transcriptional level through
AU-rich mRNA elements (AREs) present in the mRNA 3'-untranslated region (3'UTR). The
ARE is a common feature among immediate-early response genes and identifies them for
post-transcriptional regulation through interaction with RNA-binding proteins. With regard
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to this, we have identified the mRNA decay factor tristetraprolin (TTP) as a potent inhibitor
of COX-2 gene expression. Using an inducible TTP expression system, inhibition of COX-
2 mRNA and protein expression correlated with induction of TTP expression. Similarly, in
HeLa cells treated with agonists to induce endogenous COX-2 expression, inhibition was
detected in the presence of TTP. The impact of TTP was observed through inhibition of
COX-2-dependent prostaglandin synthesis to levels similar as the COX-2 specific inhibitor
NS-398. To understand the mechanism of TTP-mediated attenuation of COX-2 expression,
reporter gene constructs containing either the COX-2 promoter region or ARE-containing
3'UTR were transfected in TTP-expressing cells. The presence of TTP did not alter COX-2
promoter activity, whereas TTP inhibited expression of constructs bearing the ARE and
functional binding of TTP to the COX-2 ARE was detected by UV-light RNA/protein crosslink-
ing. We previously have demonstrated that COX-2 overexpression in colon cancer is, in
part, due to elevated levels of the mRNA stability factor HuR. In contrast to HuR overexpres-
sion observed in cancer cells, TTP expression levels are decreased in colon cancer cells and
tumors whereas in normal GI tissues TTP expression is detected. Since HuR and TTP display
overlapping ARE-binding specificities, the ability of TTP to displace HuR and target COX-
2 for rapid decay was examined. In cells overexpressing HuR, low-levels of TTP dramatically
attenuated the ability of HuR to promote COX-2 expression, demonstrating its ability to
counteract HuR stabilization effects. In response to a clinical need for potential alternative
strategies directed at limiting COX-2-dependent prostaglandin levels in cancer, we have
identified TTP as a viable means to target and control COX-2 levels. Furthermore, we
propose expression of TTP will suppress an array of HuR-stabilized transcripts associated with
promoting cancer cell growth and proliferation, angiogenesis, cell survival, and metastasis.
M2012
Interferon-Gamma-Dependent Tumor-Suppressive Mechanisms of a COX-2
Inhibitor in Combination with 5-Fluorouracil
Takanobu Irie, Masahiko Tsujii, Shingo Tsuji, Toshiyuki Yoshio, Shuji Ishii, Shinichiro
Shinzaki, Satoshi Egawa, Yoshimi Kakiuchi, Tsutomu Nishida, Masakazu Yasumaru,
Hideki Iijima, Hiroaki Murata, Tetsuo Takehara, Sunao Kawano, Norio Hayashi
Background & Aims: Cyclooxygenase-2 (COX-2) inhibitors are effective chemopreventive
agents against colorectal cancers. For treatment of advanced cancers, combination of COX-
2 inhibitors and chemotherapy has been attempted, but the results are still controversial.
In the present study, the effects of the COX-2 inhibitor celecoxib on the anticancer potential
of chemotherapy, and its mechanisms of action were investigated in point of the angiogenesis
and the immune response using an advanced cancer model in mice. Methods: BALB/c mice
or BALB/c IFN-γ null mice were inoculated with colon 26 cells. After the allograft grew up
to 5mm in diameter, the animals received celecoxib (3mg/kg), 5FU (20mg/kg), or a combina-
tion of 5FU and celecoxib (5FU/celecoxib). After 21-days of the treatment, tumors were
harvested and used for analyzing angiogenesis (expression of CD31) or leukocyte infiltration
(CD45 expression) by immunohistochemistry and for measuring VEGF, IFN-γ concentration
by ELISA. The frequency of infiltrating immune cells in the tumors was also analyzed by
flow cytometric analyses. Results: 5FU/celecoxib significantly inhibited the tumor growth
and the tumor vessel density compared with the other groups. Celecoxib, 5FU or 5FU/
celecoxib significantly suppressed the VEGF content in tumor tissues. 5FU/celecoxib also
enhanced IFN-γ levels in tumor tissue, which could be involved in the potent antitumor
effects of 5FU/celecoxib. This hypothesis was proven, because in IFN-γ null mice, the
inhibitory effects of 5FU/celecoxib on angiogenesis and tumor growth were significantly
impaired compared with that in wild type mice. 5FU decreased leukocyte infiltration and
increased CD4+CD25high T cell frequency, but the addition of celecoxib reversed these 5FU
treatment related effects. 5FU and 5FU/celecoxib increased frequency of matured dendritic
cells in the tumors compared with control. Conclusion: These results suggest that celecoxib
enhances the antitumor effect of 5FU against an advanced colon cancer model by suppressing
angiogenesis and enhancing the immune response against the tumor. In addition to VEGF,
IFN-γ has pivotal roles in tumor suppression induced by a COX-2 inhibitor.
M2013
Cd24, a Novel Oncogene in Colorectal (CRC) and Pancreatic (PC) Cancers, Is
a Promising Target for Treatment By Monoclonal Antibodies Or Introduction
of Sirna, in- Vitro and in-Vivo
Eyal Sagiv, Diana Kazanov, Adi Porat, Irene Pankova-kholmyansky, Nadir Arber
Background: We had found, through gene expression arrays that CD24 is an important
oncogene in the gut. We had shown that it is highly expressed in about 90% of malignant
and pre-malignant tissues from the entire GI tract, and only in 17% of normal epithelium
(N=389). Aim: The impact of down regulation of CD24 In Vitro and In Vivo, using MAB
and siRNA. Methods: 1. We tested the response of six cancer cell lines to three anti-
CD24 monoclonal antibodies (MAB) ± combination with standard chemotherapeutic agents
(doxorubicin, paclitaxel and 5-fluorouracil). Cell viability was measured using methylene-
blue assay. HT29 (107 cells) which express high level of CD24 were injected subcutaneously
into nude mice (n=20); anti-CD24 MAB were injected to the tail-vein twice weekly when
tumor volume was 0.1 ml. 2. HT29 cells were stably transfected with two siRNA expression
vectors, pSUPER, encoding for molecules align to two regions of the CD24 mRNA or to
non-coding RNA (vector control). Cell growth was examined by in-vitro growth curves and
in-vivo by subcutaneous injection to nude mice. Changes in cell motility were examined
by seeding (60,000 cells) into transwell (0.8mm pore size) chambers. Cells that migrated to
the lower chamber were counted 48 hours after seeding. Results: All cancer cells demonstrated
significant growth inhibition (up to 90%) in response to MAB therapy, according to their
CD24 expression levels, in a dose and time dependent manners. These results were repetitive
for three different antibodies. Cancer cells not bearing CD24 were not inhibited, nor did
the control antibody (IgG) induce growth inhibition. Growth inhibition was augmented by
the addition of the 3 classic chemotherapies. In Vivo, tumor burden was significantly smaller
in MAB treated mice (figure is very impressive). CD24 was markedly down regulated in the
siRNA-expressing HT29 derivatives. The growth of the siRNA clones was slower. Introduction
of siRNA and exposure to MAB lead to a reduced migration of the cells. Conclusions: CD24
is a putative new oncogene that is overexpressed in GI malignancies, already at an early
stage of carcinogenesis. It is a potential useful target for early intervention in the prevention
and treatment of cancer.
M2014
Curcumin Potentiates Anti-Tumor Activity of Gemcitabine in An Orthotopic
Model of Pancreatic Cancer: Role in Inhibition of Proliferation, Angiogenesis,
and Nf-κB Regulated Gene Products
Ajaikumar Kunnumakkara, Sunil Krishnan, Parmeswaran Diagaradjane, Juri Gelovani,
Bharat Aggarwal, Sushovan Guha
Background: Pancreatic cancer (PaCa) is the 4th leading cause of cancer mortality in both
men and women in the United States. Its intransigence to chemotherapy renders PaCa as
one of the most fatal cancers with 5-year survival rate of less than 5%. Transcription factor
NF-κB is constitutively expressed in most of PaCa and plays a significant role in survival,
cell proliferation, and invasion. PaCa cells eventually get resistant to gemcitabine, which is
a known activator of NF-κB. Curcumin, a component of Indian spice turmeric, is a potent
inhibitor of NF-κB. We hypothesized that curcumin will potentiate the effects of gemcitabine
for the treatment of PaCa. Aim: To determine whether curcumin alone or in combination
with gemcitabine inhibits tumor growth in an orthotopic nude mice model of PaCa. Methods
and Results: Using EMSA and live and dead assay, we showed that curcumin significantly
potentiates the effects of gemcitabine in blocking NF-κB expression and inducing apoptosis
of PaCa cells. Next we analyzed the effects of vehicle, curcumin (1 g/kg/d oral), gemcitabine
(25 mg/kg/twice weekly I.P.), and curcumin + gemcitabine in an orthotopic nude mice
model system using MIA PaCa-2 cells stably transfected with luciferase. The mice were
randomized into 4 groups (n = 8/group) after 1 week based on luciferase bioluminescence
using Xenogen IVIS 200. Treatments were continued for 4 weeks and tumor volumes were
measured weekly using bioluminescence imaging. Animals were sacrificed at 6th week
after tumor implantation and tumor volumes were measured. The tumor tissues were then
processed for EMSA (NF-κB), western blots (VEGF, COX-2, Cyclin D1, c-Myc, survivin,
caspase-3, caspase-9, Bcl-2, IAP1, and Bcl-xL), and immunohistochemistry (Ki-67, CD31,
p65, VEGF, COX-2, and phospho-STAT3). We showed that curcumin + gemcitabine signific-
antly (p = 0.008 vs control; p = 0.036 vs gemcitabine) reduced PaCa tumor volume and
Ki-67 proliferation index (p = 0.030 vs control). Further, combination of curcumin and
gemcitabine completely abrogated NF-κB activation and potently reduced expression of
several pro-survival genes. Interestingly, curcumin + gemcitabine strongly reduced microves-
sel density (CD31+ cells, p = 0.018 vs control) and completely blocked expression of VEGF
and COX-2 in PaCa tumors. Conclusion: Our results suggest that curcumin potentiates
anti-tumor effects of gemcitabine through inhibition of NF-κB and of angiogenesis in PaCa.
Thus curcumin, a bioactive non-toxic dietary molecule, can be considered as a novel chemo-
therapy-sensitizing agent in PaCa.
M2015
Sparc-Mediated Chemosensitizing Effect On Colorectal Cancer Cells Can Be
Enhanced By Vitamin D
Farnaz Taghizadeh, Michelle J. Tang, Isabella T. Tai
Therapy-refractory colorectal cancers (CRC), commonly seen in advanced disease, contributes
to the high mortality rates in these patients. We previously identified SPARC as a potential
chemotherapy sensitizer from a common signature profile of differentially expressed genes
in chemotherapy resistance, and later demonstrated significantly greater tumor regression
of xenografts of 5-fluorouracil (5-FU) resistant CRCs in mice treated with SPARC + 5-FU.
This same set of gene expression profile also revealed lower levels of expression of the
vitamin D receptor (VDR) in resistant CRC. Interestingly, vitamin D, which upregulates
VDR, is well known for its growth inhibitory properties in CRC. This led us to wonder
whether there was a correlation between therapy sensitivity and VDR levels, and how this
may be contributing to the resistant phenotype. Therefore, the OBJECTIVE of this study
was to examine if vitamin D has any effect in enhancing chemotherapy response in CRC,
and whether SPARC modulates this effect. METHODS: MIP101 & HCT116 CRC cells, their
resistant counterparts (MIP/R, HCT/R) and SPARC-overexpressing MIP101 (MIP/SP) cells
were used to assess the effect of treatment with incremental doses of 1α,25-dihydroxyvitamin
D3 (1,25-D3) (1.25-62 nM) + 5-FU or CPT-11 on: (1) cell viability, (2) apoptosis, and (3)
cell cycle progression. We also examined VDR expression in tumor xenografts harvested
from mice treated with SPARC, or 5-FU, or SPARC+5-FU. Our RESULTS confirmed lower
VDR mRNA in MIP/R and HCT/R cells, and also noted upregulation of both VDR and SPARC
expression in response to 1,25-D3 treatment. In addition, treatment of sensitive and resistant
cells with 1,25-D3 significantly reduced cell viability, enhanced chemotherapy-induced
apoptosis and inhibited the growth of CRC cells, especially in the presence of SPARC. In
MIP/SP cells, cell viability decreased significantly from 100.00 +/-0.01% to 73.3+/-8.7%
with only 500 µM of 5FU, but even further to 57.5+/-8.8% following exposure to 500 µM
5FU in combination with only 2.4 nM 1,25-D3. These same experimental conditions had
negligible effect on control MIP 101 cells. This was accompanied by greater inhibition of
p-Akt and Bad. Moreover, in tumor xenograft mouse models, upregulation of VDR was seen
in tumors that had the greatest regression following treatment that combined SPARC with
chemotherapy. In CONCLUSION, we were able to observe a synergistic effect between
SPARC and low doses of 1,25-D3 that further augmented the sensitivity of tumors to
chemotherapy. This combination may prove to be useful in the treatment of CRC, especially
in those patients with therapy-refractory disease.
A-433 AGA Abstracts
M2016
Anti-Tumor Effect of An Anti-Cd9 Monoclonal Antibody On Gastric Cancer In
Vivo
Taisei Nakamoto, Yoko Murayama, Takashi Fujimoto, Takahiro Yamamoto, Akira Wada,
Shusaku Tsutsui, Tatsuya Kiyohara, Shinji Tamura, Norio Hayashi
Background & Aim: CD9 is a member of the tetraspanins, and has been shown to be
involved in a variety of cellular activities such as migration, proliferation and adhesion. In
addition, it has been known that CD9 can associate with other proteins. We previously
reported that anti-CD9 monoclonal antibody (ALB6) leaded to apoptosis through the activa-
tion of JNK/SAPK, p38 MAPK, caspase 3 and the p46 Shc isoform In Vitro. In this study,
we investigated that whether ALB6 has anti-tumor effects In Vivo. Methods: Human gastric
cancer cell lines (MKN-28)(5×106) were inoculated subcutaneously (s.c.) into the dorsal
region of the mice (9 mice in each group). After a tumor was visualized, the animals assigned
into the ALB6 treatment group [ALB6, 100μg/body/time, intravenous, 3 times per week
(day1,4,7) for 1wk] control group [control IgG, 100 μ g/body/ time, intravenous, 3 times
per week (day1,4,7) for 1wk]. Tumor volumes from each group was assessed as
width2×length×0.52(mm3). Proliferation of tumor was investigated by assessing with 5-
bromo-2'-deoxyuridine (BrdU) immunostain, and the rate of apoptosis was determined by
TUNEL methods. Results: The tumor volume was suppressed after the ALB6 treatment
compared with control on the 29th day [2130±637mm3 (n=8) versus 5220±824mm3 (n=
8), P=0.009]. The BrdU uptake index in tumor specimens from an ALB6 treated group was
lower than those from control group [10.6±1.39% (n=8) versus 15.8±1.27% (n=8), P=0.031].
The apoptotic cells in tumor of ALB6 treated group were higher than those from control
group. [51.0±2.65% (n=8) versus 20.2±2.75% (n=8), P<0.001]. In addition, macroscopical
liver or lung metastasis was observed in only 2 out of 8 (25%) mice in ALB6 treated group,
while 4 out of 8 (50%) in control group. Conclusions: These results suggest that the treatment
with anti-CD9 antibody, inducing anti-proliferative, apoptotic, and anti-migratory effects,
might be a new strategy for the patients with gastric cancers.
M2017
Clinical Relevance of Kras Mutation Detection in Metastatic Colorectal Cancer
Treated By Cetuximab Plus Chemotherapy
Frédéric Di fiore, Florence Le pessot, France Blanchard, Francoise Charbonnier, Aude
Lamy, Thierry Frebourg, Pierre Michel
In patients with a metastatic colorectal cancer (MCRC) treated with cetuximab, the predictive
value for treatment response of genetic alterations in the effectors of the Epidermal Growth
Factor (EGF) signalling pathway is still debated with contradictory results in literature. Aim.
The aim of the study was to evaluate whether KRAS gene mutations, EGFR immunochemistery
(IHC) and EGFR gene copy number correlated with response to cetuximab in patients with
a MCRC. Patients and Methods. Patients with a MCRC histologically proven and treated
with cetuximab between 01/04/2004 and 01/12/2005 were included. Tumour response was
evaluated according to the RECIST criteria. EGFR expression was performed by IHC on
primary tumor using the Dako kit. EGFR gene copy number was determined by the standard
FISH method (Fluorescence in Situ Hybridization) (Dako kit). Detection of KRAS gene
mutations on exon 2 was performed by direct sequencing of extracted and amplified paraffin-
embedded DNA and then by two sensitive methods, SNaPshot and PCR-LCR, that we
specifically developed for the study to detect small fractions of mutated tumor cells. The
response to cetuximab was evaluate according to the results of EGFR IHC, EGFR gene copy
number and KRAS gene mutations using the Fischer exact test. Times to progression (TTP)
were calculated using the Kaplan-Meier method and compared with log-rank test. Results.
A total of 59 patients were included. Twelve patients (20%) responded to cetuximab (2
patients with compete response and 10 patients with partial response), 19 (32.6%) had
stable disease and 28 (48%) were non-responders. A KRAS mutation was detected in 22/
59 tumours and, in 6 cases, was missed by sequencing analysis but detected using the
SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients
with clinical response. KRAS mutation was associated with disease progression (p = 0.0005)
and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, p = 0.015).
There was no correlation between IHC results and cetuximab response. More, no EGFR
gene copy number increase was detected by FISH in responders patients to cetuximab .
Conclusions. Our study shows that KRAS mutation is highly predictive of a non-response
to cetuximab in MCRC and highlights the need to use sensitive molecular methods, such
as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
M2018
Inhibitory Effect of Z-360, a Novel, Orally Active CCK-2/Gastrin Receptor
Antagonist, On Gastrin-17-Induced Proliferation, Pkb/Akt Phosphorylation and
In Vivo Growth of Human Pancreatic Adenocarcinoma Cell Lines
Yutaka Emori, Daisuke Kawasaki, Runa Eta, Yuka Iino, Hiroki Hamano, Koji Yoshinaga,
Takao Tanaka, Mineo Takei, Susan A. Watson
Aim: It is now widely accepted that gastrin promotes the growth of several gastrointestinal
tumour types, including pancreatic, colorectal and gastric tumours expressing the CCK-2/
gastrin receptor. We investigated the inhibitory effect of Z-360, a potent and selective
human CCK-2/gastrin receptor antagonist, in murine xenograft models of human pancreatic
carcinoma. Methods: MiaPaCa2 or PANC-1 human pancreatic carcinoma cells were injected
subcutaneously (3×10^6) into the right flanks of nude or SCID mice, respectively. In addition,
PANC-1 tissue grafts were implanted orthotopically into the pancreas of SCID mice. Z-360
was administered orally at doses of 10 to 100 mg/kg once daily. Gemcitabine hydrochloride
(GEM) at a dose of 100 mg/kg was administered intravenously on days 5, 8 and 12 after
tumour cell injection either alone or together with Z-360. For the In Vitro studies, human
CCK-2 receptor-expressing CHO-K1 or HT-29 cell lines were pre-treated with Z-360 (10-
1000 nM) before addition of gastrin-17 (10-100 nM). The cells were lysed and either BrdU
uptake or Akt phosphorylation in cell lysates were measured by ELISA. Results: Z-360 at
doses above 30 mg/kg significantly inhibited the growth of MiaPaCa2 in nude mice (39.6%
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inhibition, p<0.05). The combination of Z-360 and GEM significantly inhibited the growth
of PANC-1 in SCID mice (36.5% inhibition, p<0.001). Notably, the combination of Z-360
and GEM (50% median survival: 57 days, p<0.05) significantly prolonged the survival time
of SCID mice implanted orthotopically with PANC-1 compared with the vehicle control
(50% median survival: 49 days). Pre-treatment of human CCK-2 receptor-expressing cell
lines with Z-360 In Vitro resulted in blockade of gastrin-17-induced BrdU uptake and Akt
phosphorylation. Conclusion: We showed that Z-360 combined with GEM can dramatically
inhibit pancreatic tumour growth and prolong survival in a pancreatic carcinoma xenograft
model, and Z-360 inhibits gastrin-17-induced cell proliferation and Akt phosphorylation In
Vitro. These results suggest that Z-360 might be a useful adjunct to GEM for the treatment
of pancreatic carcinoma and might also be a therapeutic option for patients with advanced
pancreatic cancer.
M2019
Chemopreventive Properties of Pinoresinol-Enriched Olives Involve a Selective
Activation of the P53 Cascade in Colon Cancer Cells
Lucia Fini, Erin Hotchkiss, Vincenzo Fogliano, Marco Romano, Edward B. Devol,
Huanying B. Qin, C. richard Boland, Luigi Ricciardiello
The Mediterranean diet, rich in extra virgin olive oil (EVOO), is associated with lower
incidences of colorectal cancer (CRC). The chemopreventive effects of olive oil have been
attributed to the presence of monounsaturated fats, although recently, greater importance
has been assigned to minor components such as phenolic compounds. The precise effects
of these compounds are not well understood. Aim: To assess the anticancer properties of
olive oil phenolic extracts using In Vitro colon cancer models. Methods: Phenol compounds
were extracted from two different EVOO and the extract composition was assessed by LC-
MS. Cell viability was determined by MTT assay. The human CRC cell lines, RKO and
HCT116 (p53 proficient), and HT29 (p53 mutant) and HCT116-p53KO (p53 knocked
out), were treated with EVOO extracts for 4 days. Apoptosis was determined by Tunel assay
and real-time PCR for BAX expression. Cell cycle analysis was determined by flow cytometry.
Expression of proteins involved in the cell cycle and apoptosis was evaluated by western
blot. Results: Chemical characterization of the EVOO extracts showed that the main difference
between the two extracts was in the pinoresinol concentration (62% vs 18%). Only the
pinoresinol-rich EVOO extract inhibited cellular proliferation in all cell lines in a time- and
concentration-dependent manner compared to untreated controls. Thus, the pinoresinol-rich
extract was selected for these studies. The growth inhibitory effects were more pronounced in
p53-proficient cells starting at 200 nM (p<0.0001). An increase in apoptosis was demon-
strated in p53-proficient cells by Tunel assay and by increased BAX transcripts (p=0.0004).
No changes in the cell cycle profile were detected in the p53-deficient cell lines, but a
significant arrest in G2/M was seen in the p53 wild type cell lines. Three p53 downstream
pathways can inhibit the cyclin B complex activation: p21cip/waf, 14-3-3σ and GADD45.
Increases of p53 and phospho-p53 (Ser 15) were observed in the p53-proficient cell lines
(p<0.05) followed by increases in the downstream targets p21cip/waf, 14-3-3σ and GADD45
(p<0.006). Decreases in Cdc2 levels, which promote entry into mitosis, with increases in
phospo-Cdc2 (Tyr 15) were detected in p53-proficient cells after treatment (p<0.04). Slight
decrease in Cyclin B and E, controlled by Cdc2, was also detected. Conclusion: Our results
demonstrate that pinoresinol-rich EVOO extracts have chemopreventive properties in colon
cancer cell lines at very low concentrations, by specifically upregulating p53 and its down-
stream pathways. These findings suggest that these extracts could be useful as chemopreven-
tive agents in colon cancer.
M2020
Targeting of the EGFR Pathway with Gefitinib (Iressa™) in Preclinical Models
of Intestinal Neoplasia
Denis G. Alferez, Robert A. Goodlad, Andy J. Ryan, Judith E. Anderton, Steve R. Wedge,
Richard Poulsom, Mark D. Hickinson, Nikki Mandir, Nicholas Wright, Robert Wilkinson
Introduction Small molecule tyrosine kinase inhibitors (TKIs) have shown considerable
promise as therapeutic agents in oncology. Overexpression of epidermal growth factor
receptor (EGRF) and increased tyrosine kinase activity are implicated in colorectal (CRC)
tumorigenesis. We have examined the activity of gefitinib, a highly selective TKI for EGFR,
in several preclinical models of intestinal cancer. Methods Gefitinib was tested In Vitro
against a panel of human tumor colorectal cell lines and screened for effects on kinase
activity (pEGFR levels), proliferation (BrdU incorporation) and viable cell count (MTS).
Gefitinib was tested for anti-tumor efficacy in two In Vivo models: (i) human CRC tumor
(LoVo) xenograft subcutaneous implant in an athymic mouse model; at 75 or 150 mg/kg/
day p.o. and (ii) a murine spontaneous model of multiple intestinal neoplasia (ApcMin/+) at
50 mg/kg/day p.o. In both studies mice received gefitinib or vehicle (n=10 per group) by
oral gavage for four weeks. In the ApcMin/+ studies the animals were humanely killed after
the treatment course, intestines were extracted, rinsed, opened, spread out on card and
fixed in Carnoy's fluid. Polyp number and diameter were scored under a stereomicroscope.
The total polyp burden was calculated assuming that small intestinal polyps were spherical
and colonic polyps were hemispherical. Results In Vitro studies with gefitinib revealed
phenotypes consistent with EGFR TK inhibition. Phosphorylation of the EGFR at tyrosine
1068 was suppressed, followed by reduced tumor proliferation and cell viability. Gefitinib
dosed (75 or 150 mg/kg/day) groups showed a dose dependent tumor growth inhibition
in LoVo bearing athymic mice (37% and 58%; maximum inhibition of tumor growth,
respectively, P>0.05). Gefitinib treatment of the ApcMin/+ mouse, reduced polyp number in
the small bowel by 37%, while in the colon, polyp number was reduced by 20% (P<0.001
and P=0.024 respectively). Gefitinib treatment also reduced the diameter of small bowel
lesions, therefore overall small bowel tumor burden was reduced by 66% (P<0.001). Pharmac-
odynamic analysis of ex-vivo intestinal tissue demonstrated a reduction in pEGFR in gefitinib-
treated animals. β-catenin immunohistochemical staining indicated that gefinitib treatment
reduced the intensity of nuclear localisation of β-catenin. Discussion Gefitinib leads to anti-
tumor activity in two separate CRC In Vivo models. These data demonstrate that EGFR
signalling may play a significant role in the development and growth of CRC and provide
supportive evidence for the usage of EGFR-targeted approaches in this disease setting.
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Comparable Effects of Annurca Apple Polyphenols and 5-AZA-2'-
Deoxycytidine (5-AZA-2dc) On the Demethylation of Tumor Suppressor Gene
Promoters in Colon Cancer Cells
Lucia Fini, Erin Hotchkiss, Vincenzo Fogliano, Marco Romano, C. richard Boland, Luigi
Ricciardiello
Background: The CpG island methylator phenotype (CIMP) is characterized by DNA hyper-
methylation in the promoters of tumor suppressor genes with subsequent silencing of
transcription, and is a feature of 40-50% colorectal cancers (CRCs). Treatment with 5-aza-
2dC reverses this process, but the toxicity strongly limits its use in clinical settings. Polyphen-
ols extracted from green tea and soy have been demonstrated to reverse hypermethylation
in esophageal cancer models. The Mediterranean diet, rich in polyphenols, is associated
with lower incidence of CRC. Annurca apples, a variety typical of southern Italy, is extremely
rich in catechin, epicatechin and chlorogenic acid, and other polyphenols. Aims: To evaluate
mechanisms of putative anticancer effects of Annurca polyphenol extracts (APEs) using in-
vitro models of CRC. Methods: Polyphenols were extracted from dried Annurca apple flesh.
The IC50 was determined by an MTT assay. RKO (a CRC model of CIMP) and HT29 cells
(CRC cells, not CIMP) were treated with the appropriate amount of APEs for 1-4 days.
Apoptosis was assessed by Annexin-V and Tunel assays. Cell cycle dynamics were studied
by flow cytometry and western blot of regulatory proteins. DNA methylation of hMLH1
and selected tumor suppressor genes was evaluated by MSP and COBRA, and the expression
of RNA and proteins was evaluated after treatment with APE and 5-aza-2dC. DNA methyl-
transferases 1 and 3b (DNMTs) were studied at both RNA and protein levels. Results: 2 µM
APE inhibited cell proliferation in both cell lines by 50% (p=0.04). A significant (p<0.001)
increase in apoptosis was demonstrated in both cell lines after either 1 day (annexin V) or
4 days (Tunel) of treatment. Cell cycle analysis showed a slight arrest in S-phase without
significant changes in the expression of cyclins D, E, or B. Significant (p<0.05) increases
were detected in p21 (RKO and HT29) and p53 (RKO) after treatment. DNA methylation
was strongly reduced in the promoters of hMLH1, p14ARF and p16INK4a with consequent
expression of the cognate RNAs and proteins in RKO cells. These results were comparable
with those obtained after treatment with 5-aza-2dC. These results were also obtained by
treating the CIMP-positive cells SW48. No changes where detected in the RNA levels of
DNMTs, but a significant (p<0.001) reductions in protein expression were obtained after
treatment, suggesting a post-translational mechanism. Conclusion: Annurca extracts display
a high degree of demethylating activity through the inhibition of DNMTs and consequent
re-expression of silenced genes. The lack of toxicity in Annurca extracts could make them
suitable for the chemoprevention of CRC.
M2022
Fty720 Prevents Tumour Growth in Human Colon Cancer Cell Lines Both Via:
Cell Cycle Arrest and Induction of Apoptosis
Carolin Daniel, Sophia Okouoyo, Gerd Geisslinger, Juergen M. Stein
Background and purpose: FTY720 is a unique immunomodulator, which has recently also
been documented to possess a substantial anticancer potential. However, the molecular
signalling mechanisms mediating the anticancer effects of FTY720 are far from being com-
pletely understood and have not been related to colon cancer so far. The object of the
present study was to elucidate the In Vitro effects of FTY720 on cell cycle regulation, cell
survival and apoptosis pathways in three colorectal cancer cell lines. Materials & Methods:
The impact of FTY720 on cell growth was assessed by analysis of BrdU-incorporation, crystal
violet staining and MTT-assay. Cell cycle regulatory proteins p27, Cdk4 and Cyclin D1, as
well as p42/p44 MAPK and PTEN were evaluated by Western blot. Apoptosis induction
was analysed by determination of DNA-fragmentation, Bax/Bcl-2 ratio as well as TRAIL,
cleaved caspase 3 expressions and caspase 3-activity. Results: FTY720 significantly inhibited
cell growth in colon cancer cell lines. p27Kip1 expression was upregulated by FTY720 (up
to 215% of control at 15 µmol/L FTY720;p<0.05), while Cdk4 (40% of control; p<0.001)
and Cyclin D1 (49% of control; p<0.01)were reduced indicating a cell cycle arrest in the
G1-phase. FTY720 led to a dephosphorylation of p42/44 MAPK and together with the PI3-
K/Akt pathway it increased PTEN expression significantly. FTY720 substantially affected
apoptosis induction, as we observed a significant induction of DNA-fragmentation accompan-
ied by an increase of the Bax/Bcl-2 ratio (291% of control value; p<0.001) and an induction
of TRAIL protein expression, finally leading to the upregulation of caspase 3-activity. Conclu-
sions: Thus, FTY720 may function as an auspicious novel therapeutic instrument for colorec-
tal cancer that inhibits cell growth via a G1-arrest, while extrinsic and intrinsic apoptosis
pathways are induced.
M2023
Gstp1 Promotes Chemotherapy Resistance By Maintaining ERK and Akt
Phosphorylation
Fang Chen, Sang Chun, Duyen Dang, Long H. Dang
BACKGROUND: GSTP1 is a member of the glutathione S-transferase enzyme superfamily.
GSTP1 is important for detoxification, as it catalyzes the conjugation of electrophiles such
as reactive oxidative species and xenobiotics with glutathione. GSTP1 is widely overexpressed
in colorectal cancer, from aberrant crypt foci to advanced carcinomas (Gastro 2001:865).
While GSTP1 is thought to be important for drug detoxification, its role in tumor response
to chemotherapy remains unclear. As such, while an inhibitor to GSTP1 is available, its
clinical utility remains to be determined. AIM: To determine the mechanisms by which
GSTP1 promotes human colorectal cancer cell resistance to chemotherapy. METHODS: The
GSTP1 gene in HCT116, RKO, and LOVO human colorectal cancer cells was disrupted
using targeted homologous recombination, as previously described (Cancer Research 2005:
9485). The resulting cells are isogenic with their parental cells, with the exception of GSTP1
ablation. The effects of GSTP1 disruption on human colorectal cancer cell response to
standard doses of 7-Ethyl-10-Hydroxycamptothecin (SN-38), sulindac, and 2-deoxyglucose
(2-DG) were examined. These three agents were chosen because they are novel agents in
the treatment of colorectal cancer, with different mechanisms of action. RESULTS: Disruption
of GSTP1 led to increased susceptibility to apoptosis and cell cycle arrest in response to
SN-38 and sulindac in HCT116 and LOVO, but not RKO cells; as measured by flow
cytometry. Disruption of GSTP1 led to increased susceptibility to apoptosis and cell cycle
arrest in response to 2-DG in all three cell lines, as measured by flow cytometry. In all cell
lines, the increased susceptibility to drug treatments in GSTP1 knockouts were all associated
with decreased phosphorylation of ERK and AKT survival signaling; as measured by western
blot analyses. Surprisingly, the increased susceptibility to drug treatments in GSTP1
knockouts were not associated with increased oxidative stress, as measured by 2',7'-Dichloro-
fluorescein diacetate for reactive oxygen species, and rhodomine-123 for mitochondrial
membrane potentials. CONCLUSIONS: These data show that in a subset of cancer cells,
GSTP1 promotes resistance to chemotherapeutic agents by maintaining ERK and AKT phos-
phorylation. Notably, GSTP1 protection against oxidative stress does not appear to contribute
to the mechanisms by which GSTP1 promotes resistance to chemotherapy. These data
suggest a novel strategy in cancer therapy in a subset of colorectal cancers: combining GSTP1
inhibitors with anti-ERK/anti-AKT agents and SN-38, sulindac, or 2-DG.
M2024
Msx2 Promotes Epithelial Mesenchymal Transition and Associates with Twist
1 Expression in Human Pancreatic Cancer Cells
Kennichi Satoh, Shin Hamada, Kenji Kimura, Atsushi Kanno, Morihisa Hirota, Tooru
Shimosegawa
Background & Aims: MSX2 is considered to be a regulator of development of a variety of
organs and is suggested to be an important downstream target molecule of the ras gene
signaling pathway. However, little is known about the role of MSX2 in pancreatic cancer,
most of which harbor a K-ras gene mutation. Methods: Expression of MSX2 in 4 pancreatic
cancer cell lines and 32 human pancreatic carcinoma tissues was analysed by reverse transcrip-
tion (RT) - PCR and immunohistochemistry, respectively. MSX2 function was investigated
by generating stably MSX2 expressing and down-regulated pancreatic cancer cell clones by
transfecting MSX2 or small interfering RNA (siRNA) expressing vector. Cell proliferation rate,
cell migration and anchorage independent cell growth were assessed by BrdU incorporation,
wound healing scratch assay and soft agar assay, respectively. Tumor growth rate and
formation of metastasis or dissemination In Vivo were evaluated by injection of tumor cells
into subcutaneous and the pancreatic tail of nude mice, respectively. Downstream targets
of MSX2 were identified using cDNA microarrays. Results: MSX2 was expressed in all four
human pancreatic cancer cell lines and 23 of 32 (71.8%) human pancreatic carcinoma
tissues. Increased expression of MSX2 was significantly correlated with higher tumor grade
and vascular involvement (P = 0.004 and P = 0.00003, respectively). MSX2 expressing
pancreatic cancer clones showed a flattened and scattered morphology accompanied with
the change of localization of E-cadherin and β-catenin from membrane to cytoplasm. This
localization was restored in MSX2 inactivated pancreatic cancer cells by stably transfected
with MSX2si construct. Cell proliferation rate, cell migration and anchorage independent
cell growth were promoted in MSX2 expressing cells. MSX2 expressing cells formed larger,
faster growing tumors in nude mice than did control cells. MSX2 expressing cells also show
significantly more frequent liver metastases and disseminations in nude mice than did control
cells when cells were injected into pancreas and this effect was reversed when MSX2 was
down-regulated. Microarray analysis revealed a significant induction of Twist 1 by MSX2.
Twist 1 expression was significantly associated with MSX2 expression in human pancreatic
carcinoma tissues (P = 0.0009) and was down-regulated in MSX2 inactivated pancreatic
cancer cells. Conclusions: Taken together these data indicate that MSX2 plays a pivotal role
in pancreatic cancer cell development by leading pancreatic cancer cells to the state consistent
with epithelial to mesenchymal transition (EMT) through enhanced expression of Twist 1.
M2025
Regression of Pancreatic Carcinoma in Mice After Intratumoral Injection of
Attenuated S. Pyogenes and a Streptococcal Lysate
Claudia Maletzki, Franziska Charrier, Bernd Kreikemeyer, Michael Linnebacher, Stefan
Liebe, Joerg Emmrich
BACKGROUND & AIMS: Recently, we could show, that a single intratumoral (i.t.) injection
of wildtype S. pyogenes M49 results in complete regression of pancreatic carcinoma in mice
mediated as well as by an unspecific toxicity and by specific immune reactions against tumor
cells (Pancreas 2006; 33: 480). Hence, in the present study we investigated the potential
of both, an attenuated strain of S. pyogenes, devoided of its lytic toxin streptolysin S (SLS-
) and a streptococcal lysate to induce tumor regression without the risk of bacterial sepsis.
MATERIAL & METHODS: In a syngeneic mouse model, s.c. Panc02 tumors were either
infected with SLS- or were treated with the streptoccal lysate. Control animals received
equivalent volumes of solvent only. In addition to assessment of tumor histology and
immunohistochemistry, we performed flow cytometry to detect lymphocyte subpopulations
in peripheral blood. Subsequently, we used LDH assays to determine the cytotoxic effect
of lymphocytes against tumor targets. RESULTS: A single i.t. injection of SLS- affected
pancreatic carcinoma only in some extend (771±128mm3 vs. control 1350±195mm3), while
the bacterial lysate caused nearly complete regression within 28 days (365±73mm3 vs. control
1350±195mm3). Histological analyses showed massive increased numbers of granulocytes,
CD8+- and CD4+- T-cells in both groups compared with the controls. By means of flow
cytometry, monocytes, macrophages and granulocytes were elevated during the whole obser-
vation period, while levels of NK-cells continuously arised with up to 38% (SLS-) and 45%
(lysate) compared to 16% in the control groups. Concomitantly, lytic activity of lymph
node-derived lymphocytes against tumor cells gradually increased postinfection (SLS- 42%
and lysate 50% vs. controls 8%), thereby indicating activation of immune response mechan-
isms. CONCLUSIONS: The present study shows that both, viable and non-viable bacteria
are able to reduce pancreatic tumor growth in mice. There is evidence, that the bacteria
destroy tumor cells accompanied by the induction of immune reactions against tumor cell
structures. In terms of the stronger antitumoral effect of the bacterial lysate when compared
to the attenuated SLS-, these data point out for the therapeutic potential of this strategy.
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M2026
Gemcitabine Significantly Potentiates the Anti-Tumor Effect of Conditionally
Replicative Adenovirus in Pancreatic Cancer Model
Amy Nelson, Julia Davydova, Tatyana Gavrikova, Masato Yamamoto
Conditionally replicative adenovirus (CRAd) is one of the promising approaches for the
development of novel therapeutics for pancreatic cancer. We have been developing CRAds
for pancreatic cancer, and one of the resultant vectors (RGD-modified COX-2 promoter-
controlled CRAd, RGDCOX2CRAdF) is in preclinical toxicological study towards clinical
trials. In the currently treatment regimen, majority of unresectable pancreatic cancer cases
are treated with gemcitabine. Thus, combination of CRAd and gemcitabine has practical
meaning in clinics. However, there is a possibility that nucleotide analogues impede DNA
viral replication. In this sense, the effect and mechanism of such combination need to be
studied in detail. In this study, we assessed the effect of combination of RGD-modified
COX-2 promoter-controlled CRAd and two typical pancreatic cancer chemotherapeutics
(gemcitabine and 5-FU). In Vitro study was performed with four different human pancreatic
cancer cell lines (MiaPaca-2, Hs766T, Capan-1, Panc-1). In the context of cell viability
measured by MTS assay, each pancreatic cancer cell line showed different response to
combination therapy. Hs766T showed synergic effect when it was treated with CRAd before
chemotherapeutics while reverse administration order showed inhibitory effect. MiaPaca-2
showed synergy when treated with chemotherapeutics first and inhibitory effect in opposite
administration order. The assessment of virus infectivity and COX-2 promoter activity with
chemotherapeutics suggested that the observed synergy in MiaPaca-2 after chemotherapeutic
treatment was mainly due to viral infectivity enhancement. In fact, FACS analyses revealed
that MiaPaca-2 cells showed significantly increased level of both adenoviral primary receptor
(CAR) and secondary receptor (RGD-binding integrins) after treated with chemotherapeutics.
In Vivo experiment with Hs766T subcutaneous xenografts showed beneficial outcome of
combination with both Gemcitabine and 5-FU. In this model, chemotherapeutic treatment
after CRAd administration showed more significant antitumor effect than reverse administra-
tion order. Gemcitabine treatment after vector administration most strongly potentiated the
effect of RGDCRAd and resulted in shrinkage of the tumor. The tumor volume in this group
was significantly smaller than gemcitabine alone (p=0.001) and RGDCOXCRAdF alone (p=
0.012) groups (day 12). In summary, In Vitro and In Vivo results indicated that combination
of CRAd and chemotherapeutics (especially gemcitabine) potentiated the CRAd therapeutic
ability, suggesting that future CRAd clinical trial design needs to take it into consideration.
M2027
A Glyco-Proteomic Approach to Differentiate Mucin-Producing and Serous
Cystic Neoplasms of the Pancreas Using Antibody Microarrays
Brian Haab, D. Bergsma, M. Shafer, David Heidt, Cheong Lee, Michelle A. Anderson,
Diane Simeone
Differentiation of pre-malignant or malignant mucin-producing cystic tumors of the pancreas
(MCN or IPMN) from their benign counterparts (serous cystadenomas) can be difficult and
no tests currently exist that reliably differentiate these lesions. Molecular biomarkers in the
cyst fluid may yield improved diagnostic accuracy. We used a novel antibody array method
to investigate the variation in specific protein and glycan levels in cyst fluid collected from
patients with mucinous (n = 12; 4 IPMN and 8 MCN) or serous (n = 6) cystic neoplasms
of the pancreas. Samples were obtained using EUS-FNA and histologic diagnoses were
confirmed following operative resection. Small volumes (<4 ul) of cyst fluid samples were
incubated on arrays of antibodies targeting 58 different proteins that previously had been
associated with gastrointestinal and pancreatic cancers, and the proteins captured on the
arrays were probed with antibodies and lectins to measure the protein and glycan levels
present in cyst fluid. Comparisons between mucinous fluid and serous fluid showed that
several protein and glycan levels were significantly different between the two groups. CA
19-9 was highly elevated in 9/12 patients with mucinous cysts but only in none of the
patients with serous cysts (p=0.004). Alpha-1-antitrypsin was highly elevated in 6/6 patients
with serous cysts but just 2/12 of patients with mucinous cysts (p<0.001). Immunoprecipit-
ation and western blot experiments were used to confirm the elevation of alpha-1-antitrypsin
and also detect an isoform of the protein that is present in only the serous samples. Initial
results show promise in differentiating mucin-producing and serous cystic neoplasms using
a technique that has a high potential for clinical application. Ongoing experiments aim to
further characterize the protein and glycan differences between the serous and mucinous
cyst fluid in larger numbers of fluid samples, and ultimately to evaluate the diagnostic
potential of these measurements.
M2028
Mini Scale Array for Early Detection of Pancreatic Cancer
Koji Yoshida
Pancreatic ductal carcinoma (PDC) remains one of the most intractable human malignancies
because of the lack of sensitive detection in early stage. A cure for this disorder will thus
depend on development of an approach that is able to detect tumors at an early stage of
carcinogenesis. DNA microarray analysis allows the simultaneous monitoring of the expres-
sion of genes and is therefore a potentially suitable approach to identify PDC-specific genes.
In order to develop the detection system of early pancreatic cancer, we constructed the
largest gene expression database available to date for purified pancreatic ductal cells from
pancreatic juice. Our statistical approach to identify genes associated with a diagnosis of
pancreatic ductal carcinoma resulted in the extraction of 21 probe sets. We developed the
diagnostic mini scale array consists of 98 probe sets including this 21 probe sets. We evaluate
the diagnostic mini scale array for early detection of pancreatic cancer. This new mini scale
array makes it possible to diagnose non invasive cancer (PanIN 3 lesion). Our microarray-
based prediction scheme should be of clinical importance even for patients with pancreatic
juice containing small amounts of cancer cells. Our new mini scale diagnostic array facilitates
the development of early detection systems for PDC that relies on pancreatic juice, which
is routinely obtained in the clinical setting.
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M2029
Microrna Expression Profile in Pancreatic Adenocarcinoma: Role of Let-7
Antioncogenic Microrna
Laurie Parmentier, Anny Souque, Michèle Bouisson, Barbara Bournet, Jean R. Escourrou,
Pierre Senesse, Marc Barthet, Nathalie Lesavre, Philippe Ruszniewski, Dermot O'toole,
Alain Aubert, Pascal Hammel, Philippe Levy, Lucien Pradayrol, Louis Buscail, Pierre
Cordelier
Background : pancreatic ductal carcinoma (PC) is the fifth leading cause of cancer related
deaths in Western countries, with an increasing incidence over the last 40 years. Because
of a late diagnosis due to a long, silent clinical phase during tumor development and the
absence of early, disease-specific markers, PC prognosis is very poor. So far, no effective
therapies have been established to alleviate this devasting and often fatal end-stage condition.
Thus, there is an urgent need for the development of new modalities to improve diagnosis
and treatment of PC. MicroRNAs (miR) are small non-coding transcripts that regulate gene
expression by inhibiting translation. Emerging studies suggest that many miRNAs may
participate in human disease, including oncogenesis. The aim of present work was to establish
the pattern of expression of miR known to potentiate (miR-211, mir-301), or to inhibit
oncogenesis (miR-21, miR-221, miR-222, miR-16, miR-15a, miR 17-5-p, Let-7a) in PC-
derived cell lines, tumors and fine needle aspiration (FNA). Methods: RNA was purified
from PC-derived cell lines, tumors and FNA. RNA collected by aspiration was amplified
using the Full Spectrum ® procedure (SBI). As controls, we used RNA purified from normal,
adjacent pancreas to PC. miR levels were ascertained by Taqman RT-PCR. Results: using
Taqman-based RT-PCR, we identified a global down regulation of anti-oncogenic miR in
PC samples, when oncogenic miR were elevated. Eventually, we identified a global down
expression of let-7 miR family members in 30 FNA of PC tumors. Lack of expresion of let-
7 in PC tumors was confirmed by in situ RT-PCR. Bercause ki-RAS oncogene is a validated
target of Let-7 miR, we transfected Capan-1 cells derived from PC with Let-7. We observed
a dramatic decrease in PC-derived cells proliferation, with a concomittant inhibition of ki-
RAS protein expression. Conclusion: a better understanding of the molecular mechanisms
involved in PC oncogenesis could lead to the development of new molecular markers for
either early diagnosis or targeted therapy. Here we show that anti-oncogenic miR expression,
such as let-7, is strongly down regulated in PC smaples. Taken together, this study describes
the potential clinical and therapeutic interest of studying miR equipment in PC.
M2030
Proteasome Inhibition By Bortezomib Targets Lysosomes to Enhance
Apoptotic Signaling in Human Pancreatic Cancer Cells
Ming H. Sy, Frank A. Sinicrope
BACKGROUND. Tumor invasion and metastasis involve expression of lysosomal proteases
termed cathepsins. Emerging data suggest that lysosomal disruption may also sensitize cancer
cells to death pathways. We studied the mechanism of bortezomib-induced lysosomal
permeabilization (LMP) and its role in sensitizing cancer cells to TNF-related apoptosis
inducing ligand (TRAIL; Apo2L, ). METHODS. The effect of bortezomib upon LMP, reactive
oxygen species (ROS) generation, and endoplasmic reticulum (ER) stress in BxPC-3 and Panc-
1 cells were determined using immunofluorescence, FACS analysis, and immunoblotting.
Apoptosis was determined using the annexin V assay. RESULTS. Bortezomib treatment
produced a release of lysosomal cathepsin B and an increase in LMP in BxPC-3 cells. These
changes were accompanied by induction of BiP (a marker of ER stress), and an unfolded
protein response in BxPC-3 and Panc-1 cells. Accumulation of ubiquitin-conjugated proteins
and their aggregates, i.e, aggresomes were also observed. Pretreatment of cells with nocoda-
zole, an inducer of ER stress, enhanced LMP compared to cells treated with bortezomib
alone. In contrast, pretreatment with a neutral sphingomyelinase inhibitor (3OMe) attenuated
bortezomib-induced ROS, LMP, and inhibited cytosolic cathepsin B release. Next, we deter-
mined whether bortezomib-induced LMP can augment TRAIL-mediated apoptosis. While
ROS was not induced, the percentage of cells undergoing LMP increased in association with
apoptosis induction by TRAIL. Bortezomib augmented TRAIL-mediated apoptosis (~20%)
compared to cells treated with either drug alone. CONCLUSION. Bortezomib-induced LMP
and cathepsin B release are mediated by ER stress. Furthermore, bortezomib alters LMP
upstream of ROS generation during its augmentation of TRAIL-mediated apoptosis. These
findings demonstrate that targeting tumor cell lysosomes contributes to apoptotic cell death
and may be a novel therapeutic strategy for human pancreatic cancers.
M2031
Curcumin Inhibits In Vitro and In Vivo Pancreatic Cancer Cell Growth and
Tumor Xenografts
Juan diego Alonso, Dharmalingam Subramaniam, Randal May, David Linehan, Rama P.
Ramanujam, Courtney W. Houchen, Shrikant Anant
Adenocarcinoma of the Pancreas is a fourth leading cause of cancer-related mortality in the
USA, with no effective treatment paradigm. Curcumin has been shown to inhibit proliferation
and expression of tumor promoting genes. Curcumin inhibits targets of nuclear β-catenin
transcription such as cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF)
and cyclin D1. Here, we have demonstrated that curcumin inhibits pancreatic cancer growth
both In Vitro and In Vivo. Methods: Increasing doses (0-50 μM) of curcumin on the prolifera-
tion of AsPc-1, MiaPaCa-1, Panc-1, Capan-1 (all human) and Pan02 (mouse) pancreatic
cancer cells was determined by the enzymatic hexosaminidase assay. Real Time PCR analyses
of total RNA from MiaPaCa-1 cells treated with 30 μM curcumin for 24 h was performed
to determine the levels of COX-2 expression. Syngeneic tumor xenografts were established
by injecting a single-cell suspension of >95% viable murine Pan02 cells implanted subcutane-
ously into the backs of Balb/c athymic nude mice. Curcumin (5 μg) was injected intraperitone-
ally every day from day 7 until day 30 to determine its effects on tumor growth. Tumor
sections were stained for CD31, an endothelial surface marker to determine microvessel
density. Real Time RT-PCR was performed to determine the level of COX-2 and VEGF
expression in the tumors. Western blot analyses were performed to determine the levels of
A-436AGA Abstracts
COX-2, VEGF and cyclin D1 protein expression. Results: Curcumin treatment resulted in
a dose-dependent inhibition of proliferation in all the pancreatic cancer cells. The most
effective dose at which curcumin activity was observed was at a concentration of 30 μM.
Furthermore, treatment of Pan02 tumor xenografts with curcumin resulted in a significant
decrease (p < 0.01) in the growth of the tumors, with notably lower tumor volume and
weight. Tumor angiogenesis, based on microvessel density was also significantly lower (p
< 0.01) in the tumors following curcumin treatment compared to control tumors. Real Time
PCR analyses demonstrated lower levels of COX-2 and VEGF mRNA. Furthermore, western
blot analyses demonstrated inhibition of COX-2, VEGF and cyclin D1 protein expression
levels in the xenograft tissues. Conclusion: Curcumin is a potent inhibitor of pancreatic tumor
growth and angiogenesis through modulation of β-catenin activity resulting in decreased
expression of COX-2, VEGF and cyclin D1. Our findings suggest a potential use of curcumin
as a therapeutic or chemopreventive agent for pancreatic cancers.
M2032
Enhanced Anti-Tumor Effect of Combination Therapy with Gemcitabine and
Apigenin in Pancreatic Cancer Cells
Sang hyub Lee, Ji kon Ryu, Sang myung Woo, Ji won Yoo, Joo kyung Park, Yoon jun
Kim, Yong-tae Kim, Yong bum Yoon
Objective: Gemcitabine is the standard chemotherapeutic agent against pancreatic cancer.
However, gemcitabine induce Akt activation in pancreatic cancer, and it can inhibit gemcitab-
ine-induced apoptosis and confer chemo-resistance. Apigenin, a common dietary flavonoid
is believed to possess preventive and therapeutic potential against other cancers through
the down regulation of Akt pathway. The present study was designed to investigate whether
combination therapy with gemcitabine and apigenin is more effective than gemcitabine alone
in inhibiting pancreatic cancer growth In Vitro and In Vivo model. Methods: For In Vitro
study, the effect of gemcitabine or apigenin on apoptosis and cell growth in pancreatic
cancer cell lines (MiaPaca-2, AsPC-1)—either alone or combined—was determined by FACS
analysis and MTS assay, respectively. Also, apoptotic signaling proteins were explored by
immunoblot assay. For In Vivo study, a mouse xenograft model of MiaPaca-2 was used.
Tumor bearing animals were divided into the following 4 treatment groups: vehicle alone,
gemcitabine alone, apigenin alone, and gemcitabine with apigenin. Gemcitabine or apigenin
was injected intraperitoneally for 3 weeks. The In Vivo anti-tumor efficacy was evaluated
by measuring tumor volume, tumor weight. The tumor cell proliferation and apoptotsis
were measured by BrdU incorporation and TUNEL stain in histopathology, respectively.
Apoptotic signaling proteins in tumor tissue were explored by immunoblot assay, also.
Result: In Vitro study, apigenin inhibited the growths and induced the apoptosis of both
cell lines in a dose-dependent manner. Furthermore, the combination of gemcitabine and
apigenin resulted in significantly greater growth inhibition and more apoptosis, also. The
combination treatment induced the enhanced activation of Bax and down-regulation of Akt
and Bcl-2. When apigenin was combined with gemcitabine, it showed significant tumor
growth inhibition in xenograft model. The combination therapy showed stronger inhibition of
tumor cell proliferation and induction of apoptosis in histopathology, also. The combination
treatment induced the enhanced activation of Bax and down-regulation of Akt in immunoblot
assay of tumor tissue. Conclusion: The combination of gemcitabine and apigenin enhanced
anti-tumor efficacy In Vitro and In Vivo model of pancreatic cancer through Akt suppression
and apoptosis induction. These results demonstrate promising anti-tumor activity of the
combination chemotherapy with gemcitabine and apigenin against pancreatic cancer.
M2033
Overexpression of Inhibin βa and Sparc in Patients with Pancreatic Cancer
Was Correlated with Shorter Disease Free Interval and Survival
Myoung hwan Kim, Seungmin Bang, Kyung hwa Park, Seung woo Park, Jae bock Chung,
Si young Song
Background/Aims: Inhibins βA belong to the transforming growth factor-β(TGF-β) superfam-
ily of multifunctional cytokines that bind to transmembrane receptors with serine/threonine
kinase activity. SPARC(Secreted protein acidic and rich in cysteine) is a phosphorylated,
acidic, glycine-rich glycoprotein of 43 kDa that is secreted by endothelial cells. We character-
ized up-regulation of inhibin βA and SPARC using cDNA microarray originating from
human pancreatic tissues. We aimed to validate expression of inhibin βA and SPRAC using
immunohistochemistry with tissue microarray and evaluate that inhibin βA and SPARC can
predict for survival and disease free interval (DFI) of patients with pancreatic cancer. Methods:
Thirty nine patients who have underwent pancreatic cancer surgery included and clinical
characteristics, recurrence and duration of survival were analyzed. We created tissue microar-
rays out of pancreatic cancer tissues resected from patients. Immunohistochemical stain
with anti-inhibin βA-antibody and anti-SPARC-antibody would be used for validate the
expression of inhibin βA and SPARC. The stains were reviewed by two pathologists blind
to the original diagnosis and stained cells were scored semiquantitatively as negative, focal
positive, diffuse positive, (0-2) using a previously published method (Human pathol
2004;35:357-366). DFI and survival were calculated with the Kaplan-Meier method and
their differences were evaluated by the log rank test. Results: Of the 39 patients (28 men,
11 women; mean age 60.8 [8.4] years), stage(TNM staging) I was 3, stage II was 17, stage
III was 11, and stage IV was 8, respectively. Immunohistochemical stain for inhibin βA was
diffuse positive in 21 patients, focal positive in 12 patients and negative in 6 patients.
Immunohistochemical stain for SPARC was diffuse positive in 9 patients, focal positive in
14 patients and negative in 16 patients. Patients with inhibin βA overexpression (diffuse
positive) tended to be shorter duration of DFI than without inhibin βA overexpression
(median 6 months vs 10 months, p=NS) and trended toward shorter survival (median
14 months vs 23 months) although this did not reach significance. Patients with SPARC
overexpression tended to be shorter duration of DFI than without SPARC overexpression
(median 7 months vs 9 months, p=NS) and trended toward shorter survival (median 10
months vs 19 months) although this did not reach significance. Conclusions: These data
show inhibin βA and SPARC was overexpressed in patients with pancreatic ductal adenocarci-
noma and suggest inhibin βA and SPARC overexpression tend to be correlated with DFI
and survival.
M2034
Radiation Enhances Adenoviral Gene Therapy in Pancreatic Cancer Via
Activation of CMV Promoter and Increase of Adenovirus Uptake
Takuya Egami, Kenoki Ohuchida, Kazuhiro Mizumoto, Eishi Nagai, Shoko Nishio,
Manabu Onimaru, Masao Tanaka
A vast majority of patients with pancreatic cancer have poor outcomes because of difficulties
in early diagnosis and limited efficiency of conventional therapies. Recently, molecular
therapy combined with conventional therapies can be a new strategy for the treatment of
pancreatic cancer. In this study, we investigated the effect of radiation on the transduction
efficiency of a target gene of gene therapy using adenovirus expressing NK4 (Ad-NK4), an
antagonist of HGF, as a representative model of gene therapy. First, we measured the intra-
cellular or extra-cellular protein levels of NK4 in pancreatic cancer cells infected with Ad-
NK4 with or without radiation. Radiation significantly increased NK4 expression both inra-
cellulary or extra-cellulary in all four cell lines of human pancreatic cancer in a dose-
dependent manner (SUIT-2: P<0.01, KP-N1, PANC-1, AsPC-1: P<0.05). Radiation-enhanced
expression of NK4 significantly inhibited HGF-induced invasiveness of pancreatic cancer In
Vitro. Ad-NK4 uses a cytomegalovirus (CMV) promoter to express the target gene. Thus,
we next examined the effect of radiation on CMV promoter in Ad-NK4. SUIT-2 cells,
transfected with NK4-expressing plasmid, were irradiated with 10 Gy. Irradiated cells expre-
ssed significantly higher levels of NK4 than did non-irradiated cells. Expression of transgenes
driven by CMV promoter could be up-regulated via activation of p38 MAPK, or NF kappaB.
We found that radiation increased expression of phosphorylated p38 MAPK but showed
no effect on NF kaapaB activation. Furthermore, p38 inhibitor (SB203580) significantly
reduced NK4 expression in irradiated cells. Next, we investigated the effect of radiaton to
adenoviral gene uptake in pancreatic cancer cells. Viral DNA content, quantitatively deter-
mined by real-time PCR, in irradiated cells was significantly higher than that in non-irradiated
cells. Endocytosis of adenovirus requires the action of large GPTase dynamin. Therefore,
we examined the expression of Dynamine 2 after irradiation. Dynamine2 mRNA expression
was significantly increased by 10 Gy irradiation, and Dynamin2-targeting siRNA clearly
inhibited the increased uptake of viral DNA after irradiation. In conclusion, radiation increases
transduction efficiency of a target gene with adenovirus vector via enhanced activation of
CMV promoter in relation to the phosphorylation of p38 MAPK. Furtheremore, irradiation
increase adnoviral uptake through up-regulation of Dynamin2. Combination of radiotherapy
and adenovirus-mediated gene therapy may become a potent modality for cancer treatment.
M2035
Hsp70 Inhibits Apoptosis in Pancreatic Cancer Cells By Stabilization of
Lysosomes and Attenuation of Calcium Signaling
Vikas Dudeja, Phoebe Phillips, Rajinder Dawara, Selwyn M. Vickers, Ashok K. Saluja
Pancreatic cancer cells are resistant to apoptosis leading to a poor response to therapy. We
have shown that HSP70 is overexpressed in pancreatic cancer cells and its downregulation
by HSP70 siRNA, triptolide or quercetin induces apoptosis by release of cytochrome c (cyt
c). This suggests that HSP70 inhibits apoptosis in pancreatic cancer cells upstream of
mitochondrial cyt c release. Our group's interest has been to evaluate the role of Ca2+ and
lysosomal enzymes which are the two main regulators of mitochondrial cyt c release, in
apoptosis induced by downregulation of HSP70. Our initial studies have shown that downreg-
ulation of HSP70 leads to increased cytosolic Ca2+ and release of lysosmal enzymes. We
hypothesize that HSP70 overexpression in pancreatic cancer cells prevents apoptosis by two
separate and independent mechanisms i.e. stabilization of the lysosomes and attenuation of
cytosolic Ca2+. The Aim of this study is to investigate the role of lysosomes and Ca2+in
apoptosis induced by HSP70 inhibition in pancreatic cancer cells. Methods - MiaPaCa-2 or
PANC-1 (pancreatic cancer cells) were pretreated with either BAPTA-AM 10µM or CA074me
10μM (Cathepsin B inhibitor) or with both in combination followed by HSP70 inhibition
by triptolide (0.2µM) or quercetin (100µM) for 24h. Cell viability, Annexin V and Caspase
3 were measured. Results ¬- Downregulation of HSP70 significantly decreased MiaPaCa-2
viability and induced apoptosis reflected by increased Annexin V and Caspase 3 levels (Table).
Pre-treatment with BAPTA-AM or CA074me prior to HSP70 downregulation significantly
improved MiaPaCa-2 viability (Table) and reduced apoptosis, suggested by decrease Annexin
V staining and caspase 3 activation (Table). Pre-treatment with both BAPTA-AM or CA074me
prior to HSP70 downregulation increased viability and decreased apoptosis significantly,
over and above that induced by BAPTA-AM or CA074me alone (Table). Similar results were
observed in the other pancreatic cancer cell line PANC-1 (Data not shown). Conclusion -
Lysosomal enzymes and Ca2+ both independently play a role in the apoptosis induced by
inhibition of HSP70 expression.
Table: Viability and Caspase 3 in MiaPaCa-2 (% of control, Mean±SE, n=3, *p≤0.05)
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M2036
Efficacy of Thermochemotherapy for Inoperable Advanced Pancreatic Cancer
Mitsunori Yasuda, Mooharu Kondo, Satoshi Kokura, Yuji Naito, Norimasa Yoshida,
Toshikazu Yoshikawa
Objectives: Systemic chemotherapy is often, and radiotherapy sometimes, selected for inoper-
able advanced pancreatic cancer. Hyperthermia, though seldom used in such cases, provides
safe treatment, and combination of it with systemic chemotherapy is expected to improve
the outcome of systemic chemotherapy. The present study was therefore performed to
evaluate the clinical efficacy of hyperthermia combined with chemotherapy (hyperthermic
chemotherapy) for inoperable advanced pancreatic cancer. Subjects and Methods: Since
2002, 39 patients with inoperable advanced pancreatic cancer (25 males and 14 females)
have undergone hyperthermia at our hospital. Response rate, survival period, adverse reac-
tions, etc., were compared between the uncombined hyperthermia group (n = 23) and the
hyperthermic chemotherapy group (n = 16). Each session of hyperthermia involved 50-
minute heating of the tumor and the surrounding area deep in the abdomen using a
radiofrequency local heater (Thermotron-8, Yamamoto Vinita Co., Ltd., Osaka). Hyper-
thermic chemotherapy involved administration of gemcitabine (1000 mg/m2 as a rule)
immediately before hyperthermia (i.e., hyperthermia in the presence of peak blood drug
level) to obtain heat-induced enhancement of local anti-cancer agent's effects, given the
previous finding that local heating elevated blood flow through the tumor-affected area and
increased local anti-cancer drug concentration. A drug cessation period was incorporated
once every several weeks. Results were also compared with those in the chemotherapy-alone
group. Patients in each group received treatment once a week as outpatients. Each treatment
was continued as long as possible. Results: The mean survival period and one-year survival
rate for the entire patient population receiving hyperthermia were 8.1 months and 42%,
respectively. Both mean survival period and one-year survival rate were significantly greater
in the hyperthermic chemotherapy group (12.2 months, 48%) than in the uncombined
hyperthermia group (4.1 months, 29%). Results in the hyperthermic chemotherapy group
were also better than those in the chemotherapy-alone group. No serious adverse reaction
was noted in the uncombined hyperthermia group. In the hyperthermic chemotherapy
group, some patients developed cytopenia, but no serious adverse reaction requiring hospital-
ization was noted. Conclusion: Hyperthermic chemotherapy is a promising means of treating
inoperable advanced pancreatic cancer, since it can be administered safely on an outpatient
basis and can extend survival compared to treatment with hyperthermia or chemotherapy
alone.
M2037
Bcl-2/Bcl-Xl Mediate the Proapoptotic Effects of ROS in Pancreatic Cancer
Cells
Izumi Ohno, Anna S. Gukovskaya, Irina Odinokova, Stephen J. Pandol
Background and Aims: Pancreatic cancer (PaCa) cells are notoriously resistant to apoptotic
stimuli. It was reported that important antiapoptotic regulators Bcl-2/Bcl-xL proteins were
overexpressed in various cancer tissue including pancreatic cancer. So the inhibition of
antiapoptotic Bcl-2 and Bcl-xL proteins is a novel strategy for cancer treatment. Two inhibitors
of Bcl-2/Bcl-xL, BH3I-2'and HA-14, have recently become available and were shown to
induce death in several different cancer cells. The aim of this study was to determine the
effects of the Bcl-2/Bcl-xL on apoptosis in PaCa cells and elucidate the mechanisms underlying
these effects. Methods: Bcl-2 and Bcl-xL were inhibited pharmacologically by BH3I-2'and
HA-14, or by siRNA silencing in MIA PaCa-2 and PANC-1 cells. Apoptosis was measured
with Cell Death ELISA kit and Annexin V/PI staining using flow cytometry. Cytochrome c
release was measured by Western blot. Reactive oxygen species (ROS) were measured with
the fluorescent dye DCF using flow cytometry. Mitochondria were isolated from PaCa cells
by differential centrifugation. In isolated mitochondria, we measured the effects of BH3I-2'
and HA-14 on ΔΨm change, respiration and ROS using, TPP+ and Clark electrodes and
the fluorescent dye Amplex-Red, respectively. Results: Bcl-2/Bcl-xL inhibitors and the siRNA
silencing of Bcl-2/Bcl-xL both induced apoptosis in PaCa cells effectively. The inhibitors
induced apoptosis dose-dependently in the range of concentrations (25-100 μM) at which
they inhibited Bcl-2/Bcl-xL activities, as measured by fluorescence polarization assay. At the
molecular level, the inhibition of Bcl-2/Bcl-xL stimulated cytochrome c release and inhibited
mitochondrial ROS production, resulting in a decrease in intracellular ROS. The observed
stimulation of cytochrome c release, a key mediator of apoptosis, represents one mechanism
through which the inhibition of Bcl-2/Bcl-xL induces apoptosis in PaCa cells. Another
mechanism whereby Bcl-2/Bcl-xL inhibition induces death responses could be through
inhibition of ROS. Indeed, we recently showed that ROS play a pro-survival role in PaCa
cells by activating antiapoptotic pathways such as PI3K/Akt. ROS are also known to mediate
proliferation of cancer cells. Conclusions: Bcl-2/Bcl-xL promote survival of pancreatic cancer
cells partially by their ability to increase ROS production. The ROS, in turn, promote
proliferation and inhibit apoptosis in PaCa cells.
M2038
Activation of the Phosphatidylinositol-3 Kinase/Akt Signaling Pathway in a
Subset of Pancreatic Adenocarcinomas
Zekuan Xu, Wenyu Zhao, Yi Zhu, Xiao Han, Yi Miao
The phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway has been implicated in the
development of several types of cancer. Activation of Akt through a wortmannin-sensitive
PI3K mechanism results in phosphorylation of Akt (p-Akt) at Ser473. p-Akt plays a key
role in cell proliferation and survival, but the role of the PI3K/Akt pathway in pancreatic
carcinogenesis remains unclear. Aims: The aims of this study were to investigate the expression
of p-Akt in human pancreatic adenocarcinomas, and to evaluate the role of the PI3K/Akt
signaling pathway in the proliferation of two pancreatic cancer cell lines. Methods: As a
measure of Akt activation, we performed immunohistochemical staining of p-Akt (Ser473)
in 40 surgical cases of pancreatic adenocarcinoma (age range: 25-78 y; median: 59 y).
Positive intracytoplasmic staining of endothelial cells in the non-cancerous areas in each
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specimen was used as an internal positive control. Stained sections were evaluated in a
blinded fashion, and the staining intensity in the cytoplasm of the tumor cells was categorized
as follows: weaker (negative) or equal to (positive) or stronger (positive, elevated) than that
of the endothelial cells. We also tested the effects of blocking the PI3K/Akt signaling pathway
using wortmannin (0 to 1000 nM for 24, 48 or 72 h) in two pancreatic cancer cell lines,
CFPAC-1 and PANC-1 (parameters: cell proliferation, p-Akt expression by Western blot,
colony formation). Results: Staining for p-Akt was positive in 13 (32.5%) of 40 pancreatic
adenocarcinomas, and 8 of these positive cases had elevated staining. Wortmannin decreased
cell proliferation in CFPAC-1 cells in a dose-dependent manner, with a maximum inhibitory
effect of 30%. Similarly, the expression of p-Akt of CFPAC-1 cells was inhibited by treatment
with wortmannin. In PANC-1 cells, wortmannin did not significantly affect cell proliferation
or p-Akt expression. However, wortmannin had a dose-dependent inhibitory effect on colony
formation, with a greater effect on CFPAC-1 cells than PANC-1 cells (-66% vs -38% at 1000
nM). Conclusions: In approximately 33% of pancreatic adenocarcinomas, the expression of
p-Akt was evident, suggesting that the PI3K/Akt signaling pathway may play a contributory
role in the development of these tumors. In CFPAC-1 cells, wortmannin decreased both p-
Akt expression and cell proliferation, but these effects were not observed in PANC-1 cells.
These findings suggest that PI3K/Akt signaling may be activated in a subset of pancreatic
adenocarcinomas, and that inhibition of this pathway may have antiproliferative effects only
in this subset of pancreatic tumors.
M2040
The Pro-Apoptosis Survivin-2b Isoform Is Involved in Differentiation-Induced
Susceptibility of HT-29 Colon Cancer Cells to NSAID-Induced Apoptosis
Shiun-kwei Chiou, Sarathy Mandayam
Background: Usage of NSAIDs is associated with reduced risk of gastrointestinal (GI) cancers
including colon cancer, a major cause of cancer deaths worldwide. One mechanism of this
NSAID protection is induction of cancer cell apoptosis. NSAID treatment reduces levels of
survivin, an anti-apoptosis and cell cycle facilitator protein, in GI epithelial and cancer cells
both In Vivo and In Vitro, and siRNA suppression of survivin expression induces gastric
epithelial cell death, suggesting that downregulation of survivin is a mechanism of NSAID-
induced apoptosis. Survivin has spliced variants: wildtype (WT) survivin, survivin 2B and
survivin deltaEX3. WT survivin and survivin deltaEx3 are anti-apoptotic, and survivin 2B
is pro-apoptotic. The roles of these survivin isoforms in NSAID-induced apopotosis have
not been explored. In this study, we examined the effect of NSAIDs on expression levels
of survivin isoforms, and the roles of these isoforms in NSAID-induced colon cancer cell
death. Methods: Undifferentiated HT-29 cells are more susceptible than differentiated HT-
29 cells to NSAID induced apoptosis, allowing the same cell line to be used to examine
different apoptosis susceptibilities. HT-29 cells were maintained in an undifferentiated state
in McCoy's 5A medium supplemented with 10% FBS, and stimulated to differentiate in
medium containing 5mM NaBt for 48 hours. Both undifferentiated and differentiated HT-
29 cells were treated with 0.5mM indomethacin or vehicle only, and monitored for 1)
survivin isoform levels at 0, 1, 3 and 6 hours using isoform-specific PCR primers in a
Realtime quantitative PCR analysis, 2) cytotoxicity and apoptosis by LDH release and fluor-
escein labeled annexin V binding assays, respectively, at 0, 24 and 48 hours, and 3) resistance
to indomethacin-induced cell death after morpholino anti-sense oligo suppression of survivin
2B splice variant. Results: 1) Indomethacin treatment significantly increased levels of survivin
2B (9.3 + 2.1 fold at 6 hours, p<0.05) relative to that of WT survivin and survivin delta
EX3 in undifferentiated, but not differentiated HT-29 cells. 2) Undifferentiated HT-29 cells
were more susceptible to indomethacin induced cytotoxicity and apoptosis than differentiated
HT-29 cells (20 + 5 fold vs 7 + 2 fold at 48 hours, p<0.05). 3) Suppression of survivin 2B
rendered both undifferentiated and differentiated HT-29 cells resistant to indomethacin-
induced cell death. Conclusion: This study shows that the relative abundance of pro-apoptosis
survivin 2B vs anti-apoptosis survivin variants may determine the susceptibility of colon
cancer cells to NSAID-induced cell death.
M2040a
ACE-Inhibitors and Risk of Esophageal and Gastric Cancer
Tomas Sjöberg, Luis A. García rodríguez, Mats Lindblad
Experimental evidence suggests a antineoplastic effect of ACE-inhibitors. Results from obser-
vational studies regarding an association with esophageal and gastric cancer are few, but a
recent case-control study showed a 55% reduced risk of esophageal cancer. Our aim was
to ascertain whether use of ACE-inhibitors decrease the risk of esophageal or gastric cancer.
We conducted a population-based case-control study nested within the comprehensive and
validated General Practitioners' Research Database (GPRD). GPRD prospectively records
diagnoses, drug prescriptions, laboratory results and hospital letters. Our cohort consisted
of individuals aged 40-84 years who were collected between 1994 and 2001. Subjects were
followed until one of the following events occurred: detection of an esophageal or gastric
cancer (selected as cases), detection of any other cancer (except skin cancer), age of 85
years, death, or end of study period. From the cohort, 10,000 randomly selected controls
were matched for age, sex and calendar year at index date. Drug exposure was classified
into current, past or non-use. Dosage was grouped into low/medium or high. Use of ACE-
inhibitors was compared with that of other antihypertensive agents, with respect to risk of
esophageal and gastric cancer. Adjustments were made for age, sex, calendar year, smoking,
alcohol, body mass index, upper gastrointestinal disorders, and concurrent use of other
antihypertensive agents, aspirin, and non-steroidal anti-inflammatory drugs. In all, 2,128
cases of esophageal and gastric cancer were found during 4.34 million person-years at risk.
Exclusion of 196 cases was made after a review of medical and computer records. Thereafter
909 cases of esophageal cancer and 1,023 cases of gastric cancer remained for analysis. Use
of ACE-inhibitors decreased the risk of esophageal cancer (odds ratio (OR) 0.75, 95%
confidence interval (CI) 0.56-1.00) compared to non-users. Current use of low/medium
doses and high dose of ACE-inhibitors showed a statistically non-significant (OR 0.85, 95%
CI 0.61-1.18) and a significant (OR 0.50, 0.3-0.83) risk reduction of esophageal cancer,
respectively, compared to non-users. No clear association was found between use of other
antihypertensive drugs and risk of esophageal cancer. Our data showed no clear association
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between current use of ACE-inhibitors and risk of gastric cancer (OR 1.07, 95% CI 0.84-
1.36), or between other anti-hypertensive drugs and this cancer. Our population-based
study supports the hypothesis that ACE-inhibitors is associated with a reduced risk of
developing esophageal cancer. No apparent effect was observed with regard to the risk of
gastric cancer.
M2041
Potentiation of Colorectal Cancer (CRC) Chemoprevention Through Novel
Cyclooxygenase (COX)-Lipooxygenase (LOX) Inhibitors
Dhananjay Kunte, Subhash Padhye, Ajit Zambre, Abeda Jamadar, Ramesh K. Wali,
Jennifer Koetsier, Mary Nyhuis, Hemant K. Roy
Background: COX and LOX are important enzymes in the arachidonic acid metabolism
and are up-regulated in CRC. Numerous studies have shown that inhibitors of both COX
and LOX are chemopreventive against CRC. However, COX inhibitors have toxicity (GI
ulcers of COX-1 inhibitors and cardiotoxicity of COX-2 inhibitors). LOX inhibitors, on the
other hand, appear to be safer but the efficacy is modest at best. One strategy would be to
combine COX/LOX inhibition. However, there are few natural compounds that possess
these attributes. Our multi-disciplinary group, consisting of cancer biologists, chemists and
gastroenterologists, tested the chemopreventive efficacy of the specifically designed COX-
LOX inhibitors on human CRC cell line HT-29. Methods: The dual COX-LOX inhibitors
A2S and CA2S were synthesized from modification of di-tert-butyl phenols. HT-29 cells
were treated with different doses (6.25-100 µM) of A2S and CA2S and the effect of these
dual inhibitors on cell proliferation was studied using the WST-1 assay. In order to determine
the anti-proliferative and pro-apoptotic effects of the COX-LOX inhibitors, proteins from
HT-29 cells treated with either vehicle or the dual inhibitors (50 µM) were subjected for
western blot analysis and probed for the proliferation specific marker PCNA. Apoptosis was
assessed by flow cytometry (sub-diploid fraction and M30 staining). Results: Treatment of
HT-29 cells with the dual COX-LOX inhibitors A2S and CA2S resulted in a concentration-
dependent decrease in cell proliferation as assessed by the WST-1 assay. At the maximum
concentration (100µM) A2S and CA2S caused a 52% and 58% (p<0.05) inhibition in cell
proliferation respectively. This was further confirmed by a corresponding 22% and 24%
decrease in PCNA. Sulindac sulfide (100µM), A2S and CA2S (50µM each) caused significant
increase in the number of sub-diploid (apoptotic) cells with the CA2S showing significantly
more apoptosis than sulindac (p<0.01). This was confirmed by induction of apoptosis marker
M30 in which both A2S and CA2S manifested dramatically greater apoptosis than sulindac
sulfide. Conclusion: The anti-proliferative and pro-apoptotic effects of the dual COX-LOX
inhibitors against human CRC cell line HT-29 were more pronounced than the most-well-
studied NSAID-sulindac sulfide. Thus, the dual COX/LOX inhibitors could potentially be
used as an alternative to conventional NSAIDs for better efficacy and lesser side effects.
M2042
Mesalazine Causes Inhibition of the Anti-Apoptotic Proteins Survivin and Xiap
Via a Pparγ Dependent-Pathway
Markus Schwab, Jürgen Stein, Oliver Schröder
Introduction: Mesalazine has been identified as a candidate chemopreventive agent in colon
cancer prophylaxis for its anti-proliferative and pro-apoptotic effects. However, the precise
mechanisms of action are not fully understood. Since the peroxisome proliferator-activated
receptor γ (PPARγ) was suggested to be involved in growth response of colon cancer cells,
our study intended to investigate the role of this receptor in mesalazine's anti-carcinogenic
actions in Caco-2 cells. Methods: Caco-2 cells were treated with increasing concentrations
of mesalazine (10-50 mM) for 24, 48 and 72 h, respectively. Cell growth was determined
by BrdU incorporation, cell count by crystal-violett staining. Expression of activated caspase-
3, PARP, caspase-8 and 9, as well as the expression of Xiap and Survivin was determined
in response to mesalazine (30 mM) by ELISA or western blot analysis, respectively. To
scrutinize any involvement of PPARγ on the growth inhibitory effects of mesalazine, experi-
ments were also performed in Caco-2 cells transfected with a dominant-negative PPARγ
mutant to inhibit wild-type PPARγ action. Moreover, Caco-2 wild-type cells were also
subjected to combined treatment with mesalazine and butyrate (3 mM), the latter known
to activate PPARγ in colonic epithelial cells. Results Mesalazine provoked a time- and dose-
dependent decrease in both cell growth and proliferation at concentrations ≥ 30 mM.
Growth inhibition was accompanied by a significant increase in activated caspase-3 (44 ±
12%), PARP (+223 ± 21%) and caspase-8 (+49 ± 11%) after 48 h of incubation with
mesalazine, while the expression of XIAP (-28 ± 4%) and Survivin (-13 ± 4%) was decreased
simultaneously. In contrast, no influence on caspase-9 activity could be observed. Mesalazine-
mediated anti-proliferative actions and its effects on the apoptosis-regulatory proteins except
for expression of XIAP were intensified by co-incubation with butyrate. The growth-inhibitory
effect of mesalazine was reduced in dominant-negative PPARγ mutant Caco-2 cells. In
addition, mesalazine-mediated increased expression of activated caspase-3, PARP, caspase-
8 as well as Survivin and XIAP were completely abolished in this transfected cell line.
Conclusions: Our data clearly demonstrate that mesalazine acts via PPARγ to induce its anti-
proliferative and pro-apoptotic actions via the caspase signalling pathway in the colon cancer
cell line Caco-2. Activation of caspase-8 and down-regulation of Xiap and survivin are
responsible for increased caspase-3 activity. Moreover, our data demonstrate that combined
treatment with butyrate enhanced the chemopreventive capacity caused by mesalazine.
M2043
Sorafenib (Bay 43-9006) Inhibits Acid and Bile Acid Stimulated Proliferation
in Barrett's Adenocarcinoma Seg-1 Cells: Potential Role of the Mapk Pathways
Rajesh N. Keswani, Anusara Chumsangsri, Reba Mustafi, Jorge Delgado, Marc Bissonnette
Background: The incidence of Barrett's esophagus and the development of adenocarcinoma
continue to rise in the United States, but an effective chemopreventive agent has not yet
been identified. The mitogen activated protein kinase (MAPK) pathways, including ERK and
p38, are believed to play important roles in the pathogenesis of esophageal adenocarcinoma
and are potential targets for chemoprevention. Seg-1 cells were derived from a Barrett's
esophageal adenocarcinoma and have been used to study the cancer cell biology of Barrett's
esophagus. Sorafenib is an orally active inhibitor of Raf, a component of the MAPK pathways.
The aim of this study was to investigate the effects of sorafenib on Seg-1 cell proliferation
and MAPK activation by acid or bile acid treatment. Methods: Seg-1 cells were exposed to
acid conditions (pH 3.5) or bile acid (taurocholate 100 μM) for 5 minutes. Where indicated,
cells were pre-treated with 10 μM sorafenib for 2 hours. Activation levels of ERK and p38
were assessed by quantitative Western blotting using phospho-active antibodies. Proliferation
was determined by WST-1 assay at 36 and 48 hours. Statistical comparisons were calculated
by Student's t-test. Results: As shown in Table 1, compared with control, acid significantly
activated ERK and p38 and increased Seg-1 cell proliferation. Sorafenib significantly inhibited
these acid-induced changes. Similarly, taurocholate (TC) significantly activated ERK and
increased proliferation, and sorafenib inhibited these changes. Similar, but non-significant
changes were observed with TC activation and sorafenib inhibition of p38. Conclusion:
Sorafenib inhibited ERK and p38 activations and Seg-1 proliferation stimulated by acid pH.
Sorafenib also inhibited ERK activation and Seg-1 proliferation stimulated by TC. Thus,
sorafenib is a promising, novel chemopreventive agent to block Barrett's neoplastic progres-
sion, perhaps by inhibiting ERK and p38 signals. Studies In Vivo are ongoing.
Table 1 All values are expressed as fold of control (vehicle-treated) cells * p < 0.05 compared
to control ** p < 0.05 compared to agonist-stimulated cells
M2045
Accuracy of Chromocolonoscopy, Narrow-Band-Imaging-Colonoscopy and
Standard Colonoscopy in the Surveillance of HNPCC Gene Carriers
Robert Hüneburg, Christof Lamberti, Frank Lammert, Christian Rabe, Constanze
Pagenstecher, Reinhard Büttner, Tilman Sauerbruch
Introduction: The risk for colorectal cancer in carriers of hereditary nonpolyposis colorectal
cancer (HNPCC) is 70% by the age of 70 years. Progression from adenoma to carcinoma
is believed to be faster than in sporadic colorectal cancer and early detection of new small
adenomas is an important goal of surveillance. According to tandem colonoscopies up to
25% of small adenoma are missed by standard colonoscopy (SC). This missing rate can be
lowered by chromocolonoscopy (CC). Since narrow-band-imaging colonoscopy (NBI) was
similarly effective as CC for Barrett's esophagus we first compared SC with CC and than
CC with NBI with respect to detection of polypoid lesions in patients with HNPCC. Methods:
52 HNPCC gene carriers were included. SC was compared with CC for the first 29 patients
and NBI with CC in the following 23 patients. Size and localization of all lesions was
documented. Relevant lesions were biopsied or excised. Results: The detection rate in the
first 29 patients was as follows: Hyperplastic polyps 9 SC/30 CC (p<0.001), adenomas with
low-grade dysplasia 2 SC/4 CC and adenomas with middle-grade dysplasia 0 SC/1 CC. In
the following 23 patients the detection rate was as follows: Hyperplastic polyps 11 NBI/19
CC (p<0.017), adenomas with low-grade dysplasia 3 NBI/14 CC. One cancer in this series
was detected (NBI and CC positive). Conclusion: Chromocolonoscopy is superior to standard
and narrow-band-imaging colonoscopy in detection of polypoid lesions in patients with
HNPCC. The relevance of this finding remains questionable since proportion of adenomas
with higher dysplasia or carcinomas were not increased.
M2046
Gene Expression Analysis Proposes Alternative Pathways for the Mechanism
By Which Celecoxib Selectively Inhibits the Growth of Transformed But Not
Normal Enterocytes
Eyal Sagiv, Uri Rozovsky, Diana Kazanov, Nadir Arber
Aims: Cox-2 inhibitor (celecoxib) is a promising chemopreventive agent (NEJM). Its long-
term use may be limited due to increase CVS toxicity (Circulation). To identify genes and
pathways that are differentially expressed in normal and transformed enterocytes following
short and long exposures to celecoxib. Methods: Normal rat enterocytes (IEC18 cells) and
their Ras transformed derivatives (R1 cells), were exposed for 72 hours and for over 6
months (drug- resistant cells) to celecoxib (5µM). Gene expression analysis, using Genech-
ip®(RG-U34), was performed and compared the normal and transformed cells following
short and long incubation periods. Statistical and cluster analyses were performed using
GeneSpring® software; functional analysis was carried out based on Gene Ontology (GO)
groups. Results: Non-supervised analysis differentiated between transformed and non-trans-
formed cells. In supervise analysis, 538 genes were differentially expressed following trans-
formation, 52 passed FDR and 4 passed Bonferonni corrections. For 121 genes the interaction
of treatment and transformation status was significant and one gene, cyclin-D1, passed FDR
correction. The expression levels of 70 and 126 genes respectively were affected by short
and long treatments of the transformed cells. Clustering according to expression patterns
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demonstrated that 3 out of 4 clusters showed different expression in the transformed cells
that reverted to normal level following exposure to the drug. The fourth was the group of
unchanged expression. The hyper-active transformed pathways that were suppressed by
celecoxib were Ras, nucleic acids metabolism and carbohydrates metabolism; specific genes
among these clusters included pro-cancerous genes such as Erk1, Jagged 2, interleukin-2
and lysyl-oxidase. Conclusions: Celecoxib selectively affects transformed and not normal
enterocytes. It targets genes and pathways that are involved in the malignant transformation
of colorectal cells, and are reversible. These pathways, while suppressed, offer alternative
mechanisms for the cancer preventive role of celecoxib, other than the classical mechanism
of inhibiting prostaglandin synthesis. Unraveled, these pathways may help in the development
of new safer and more effective drugs, as well as better selection of patients.
M2047
The Chronic Celecoxib Users Have a More Evident Regression of Gastric
Intestinal Metaplasia After H. pylori Eradication
Bor-shyang Sheu, Hsiao-bai Yang, Jiunn-jong Wu
Background and aims: The gastric intestinal metaplasia, a precancerous lesion of gastric
cancer, expressed with high cycloxygenase-2 (COX-2) during H. pylori infection. This study
tested whether the chronic users of celecoxib, a selective COX-2 inhibitor, had less H. pylori-
related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear
after H. pylori eradication. Method: There were 366 consecutive patients (150 chronic
celecoxib users and 216 non-users) received panendoscopy to detect H. pylori infection and
its-related intestinal metaplasia. One hundred and three H. pylori-infected patients with
intestinal metaplasia (43 chronic celecoxib users, and 60 non-user controls) have received
anti-H. pylori therapy, and completed the 12th-month follow-up to survey the regression
of intestinal metaplasia by mean intestinal metaplasia score. Results: There were no difference
of the prevalence of H. pylori-related intestinal metaplasia and mean intestinal metaplasia
score between the chronic celecoxib users and controls (P > 0.05). On the 12th month after
H. pylori eradication, the chronic celecoxib users had a lower mean intestinal metaplasia
score than the non-user controls (1.23 vs. 1.81, P < 0.005). The celecoxib users achieved
a higher regression rate of intestinal metaplasia after H. pylori eradication than controls
(41.7% vs. 20%, P = 0.027, relative risk: 2.88, 95% CI: 1.88~6.91). Conclusions: Under
the presence of H. pylori infection, the chronic celecoxib users still showed limited effect to
decrease the intestinal metaplasia. Nevertheless, celecoxib should be promising to assist H.
pylori eradication for the control of gastric intestinal metaplasia and cancer risk.
M2048
Chemopreventive Effect of High Selenium Enriched Milk Protein On
Azoxymethane-Induced Colonic Tumorigenesis
Ying Hu, Richard Leleu, Graeme Mcintosh, Graeme Young
The chemical form of selenium (Se) affects its bioavailability and this may be relevant for
protection against colorectal cancer (CRC). Se is readily incorporated into milk and milk
protein c (Tatura BioTM Se 5ppm) (Tatura Milk Industries, Victoria Australia) by feeding
cows with organic Se Yeast (Sel-Plex) (Alltech). Selenium might act to enhance the homeostatic
response to DNA damage. Aim: 1. To determine whether Tatura-Bio Se is more effective
than Se Yeast in suppressing colorectal neoplasia induced by azoxymethane (AOM). 2. To
determine if Tatura-Bio Se regulates colonic epithelial response to DNA damage induced by
AOM. Methods: 1. five dietary treatments were used for the study. At 4 weeks of age, 2
groups (n=12) of C57BL/6J mice were fed diets containing either Tatura-Bio Se (Se in diet
1ppm) or milk protein control as protein source. The other 3 groups (n=12) of mice were
fed diets using casein as protein source, either with no added Se (control) or with added
Se Yeast at 1ppm and 4ppm. Two weeks later, all mice were given 4 weekly AOM (15mg/
kg) injections to induce aberrant crypt foci (ACF). Mice were killed 6 weeks later. The
number of ACF and the number of crypts in each focus were determined using a dissecting
microscope. 2. At 8 weeks of age, 5 groups of mice (n=12) were fed with same diets used
for ACF study. After four weeks on diets, mice were given a single AOM (10mg/kg) injection
to induce DNA damage and were killed 6 hours later. Apoptotic response to DNA damage
was measured in distal colon by counting apoptotic rates in crypt columns and cell prolifera-
tion was measured by Ki-67 immunostaining. Plasma Se concentration was analyzed using
spectrofluorimeter; colon and liver glutathione peroxidase (GPx) activities were measured
using GPx cellular activity assay kit (Sigma). Results: Tatura-Bio Se at dose of 1ppm signific-
antly suppressed total colonic AOM-induced ACF as well as large ACF (>3 crypts/focus).
Se yeast at equivalent does of 1ppm had no effect on ACF formation although it showed
some protection at dose of 4ppm (large ACF). Tatura-Bio Se significantly increased the acute
apoptotic response to AOM in colonic epithelial cells but had no effect on cell proliferation.
Tatura-Bio Se significantly increased plasma Se levels relative to Se Yeast containing the
same Se level. Conclusions: Tatura-Bio Se is superior to Se Yeast in term of suppression of
AOM-induced ACF. It may achieve this by enhancing the acute apoptotic response to DNA
damage. Se is more bioavailable from milk protein than from Se Yeast. Supplementation of
Se via dairy products might be a practical and effective approach to increase human Se
intake and prevent CRC.
M2049
Ursodeoxycholic Acid Suppresses COX-2 Expression in Colon Cancer: Roles
of RAS, P38 and Ccaat/Enhancer-Binding Protein
Sharad Khare, Reba Mustafi, Sonia Cerda, Weihua Yuan, Urszula Dougherty, Cory
Holgren, Yan Li, Allen Samarel, Marc Bissonnette
Western style high fat diets are implicated in colonic carcinogenesis. Fecal bile acids are
increased by such high fat diets and believed to contribute to this increased risk. In the
azoxymethane (AOM) model of experimental rodent colon cancer, cholic acid and its colonic
metabolite deoxycholic acid strongly promote tumorigenesis. In contrast, we showed that
ursodeoxycholic acid (UDCA), a low abundance bile acid, inhibited AOM tumorigenesis.
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
Dietary UDCA also blocked the development of tumors with activated Ras and suppressed
cyclooxygenase-2 (Cox-2) up-regulation in AOM tumors. In this study we compared the
effect of dietary supplementation with tumor-promoting cholic acid to chemopreventive
UDCA on Cox-2 expression in AOM tumors. Cholic acid enhanced Cox-2 up-regulation in
AOM tumors, whereas UDCA inhibited this increase and concomitantly decreased CCAAT/
enhancer binding protein β (C/EBPβ), a transcriptional regulator of Cox-2. To elucidate the
signaling pathways regulating Cox-2 that are modulated by bile acids, we examined the
effects of UDCA and deoxycholic acid (DCA) on HCA-7 colon cancer cells. These cells
possess wild type Ras and express Cox-2. In these cells, DCA activated Ras and increased
C/EBPβ and Cox-2 by a mechanism requiring the mitogen-activated protein kinase p38.
UDCA inhibited DCA-induced p38 activation and decreased C/EBPβ and Cox-2 up-regula-
tion. Using transient transfections, UDCA inhibited Cox-2 promoter and C/EBP reporter
activation by DCA. Adenovirus mediated infection with dominant-negative 17N-Ras abol-
ished DCA-induced p38 activation and C/EBPβ and Cox-2 up-regulation. Taken together,
these studies have identified a transcriptional pathway regulating Cox-2 expression, involving
Ras, p38 and C/EBPβ that is inhibited by UDCA. These signal transducers are novel targets
of UDCA's chemopreventive actions.
M2050
COX-2 Protein Expression in Stromal Cells Predict Recurrence of Colorectal
Adenomas
Robert Benamouzig, Jacques Deyra, Antoine Martin, Elisabeth Longchampt, Bernard
Girard, Baktiar Bejou, Jean-jacques Raynaud, Stanislas Chaussade
Background & aims : The cyclo-oxygenase-2 (Cox-2) is overexpressed in epithelial and
stromal cells in colorectal adenomas. The present study was designed to evaluate the preval-
ence of Cox-2 overexpression on a large series of colorectal adenomas and to analyse if
the Cox-2 expression is as a prognostic of a colorectal adenoma recurrence. Methods :
Overexpression of Cox-2 was found in a large series of 219 adenomas which were obtained
from the first 136 patients (93 males and 43 females) included in a prospective multicentre
study evaluating the chemopreventive effect of low dose aspirin on the relapse of polyps.
Cox-2 expression were evaluated specifically in epithelial, interstitial and interstitial deep
cells by immunohistochemistry and quantified blindly using a duplicate analysis according
to a 4 levels score. The predictive character of the overexpression of Cox-2 was appreciated
by the presence of adenomas and by the “adenomatous polyp burden” after 1 and 4 years
at controls colonoscopies. Results : 96% of the cases displayed Cox-2 expression with a
moderate to strong labeling for 38% of the cases. This expression was related to the degree
of dysplasia (High-grade vs. Low-grade; p=0.01; RR=1.37 95% CI [1.08; 1.75]), the size of
adenomas (at least one >10 cm; p=0.02; RR=1.33 95% CI [1.04; 1.94]), the type of adenomas
(Sessile, pediculate, half-sessile; p=0.01) and the archetype (villous or tubulovillous; p=0.03;
RR=1.28 95% CI [1.03; 1.6]). In patients with an overexpression of Cox-2 in the stromal
cells at the enrolment, a higher rate of adenoma recurrence was observed after 1 and 4
years of follow-up (p=0.04; RR=1.29 95% CI [1.01; 1.64]). No relation between the initial
expression of Cox-2 in the epithelial cells and recurrence of adenomas was observed (p=
0.98). No relation was observed between an high initial expression of Cox-2 in the epithelial
cells and the “adenomatous polyp burden” calculated at 1-4 years of control colonoscopy.
This effect was the same in the treated and placebo groups. Conclusions : These data show
that Cox-2 expression in epithelial and stromal cells is frequent in colorectal adenomas.
This expression correlated with the degree of dysplasia, the size, the type and the archetype
of adenomas suggesting its involvement at a very early stage of carcinogenesis. Only the
Cox-2 expression in the stromal cells was associated with an increase risk of adenoma
recurrence. Thus, one of the therapeutic target for the prevention of the colon cancer could
be the development of specific inhibiting agents targeting the stromal cells.
M2051
Cyclooxygenase-2 (COX-2) Inhibition Attenuates the Growth of Colorectal
Cancer Associated with the Use of Immunosuppression Following
Transplantation
Wanda P. Blanton, Daniel Prabakaran, Bagoui Wang, Min Yao, M. michael Wolfe
Background: The incidence of post-transplant malignancy has been estimated at 20% after
ten years of chronic immunosuppression. Post-transplant recipients are not only at greater
risk for developing colorectal cancer (CRC), but at each cancer stage, these individuals have
markedly lower survival rates compared with the general population. Studies in patients
with CRC taking nonsteroidal anti-inflammatory drugs (NSAIDs) have shown a reduction
in mortality. We hypothesized that NSAIDs may attenuate CRC tumor growth in the immuno-
suppressed transplant recipient. Purpose: To determine the effects of selective COX-2
inhibition and immunosuppression on CRC tumor progression and on skin graft survival
in animals receiving these agents. Methods: 2 x 104 MC-26 cells (mouse colorectal adenocar-
cinoma cell line), were injected subcutaneously into the flanks of 6-8 week old BALB/c
mice. Tumor volume was measured at regular intervals during a period of 22 days. Experi-
mental groups included: (1) standard chow, no cyclosporine, (2) standard chow, + cyclospor-
ine (20 mg/kg), (3) rofecoxib chow (0.01%), no cyclosporine, (4) rofecoxib chow + cyclospor-
ine. Skin xenografts from donor black B6 mice were simultaneously transplanted to the
backs of the mice. Results: Tumor volume in BALB/c mice was markedly reduced in the
group receiving rofecoxib compared with control chow (394.75 ± 273.37 vs. 920.81 ±
511.10 mm3). In contrast, cyclosporine enhanced tumor growth compared with control
(1217.42 ± 725.25 mm3). When rofecoxib chow was given to animals treated with cyclospor-
ine, tumor volume was decreased by 75% compared to the group receiving cyclosporine
alone (317.13 ± 149.97 mm3). As expected, the skin graft had failed by day 11 in control
mice and in those receiving rofecoxib alone. Cyclosporine, as anticipated, did prolong graft
survival, and COX-2 inhibition had no effect on graft survival. At day 15, skin graft survival
was 100% in the groups receiving cyclosporine alone and the combination of cyclosporine
and rofecoxib compared with 0% in control group and the group receiving rofecoxib alone.
Summary and Conclusion: Cyclosporine alone enhanced tumor progression, whereas the
addition of a COX-2 inhibitor attenuated tumor growth by 75%, while having no significant
impact on skin graft survival. These results suggest that a combination of NSAIDs and
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immunosuppressive agents appears to represent a potential treatment for CRC and other
malignancies. Furthermore, NSAIDs may attenuate tumor growth in transplant patients on
immunosuppressive therapy, who have a higher incidence and mortality from CRC and
other malignancies.
M2052
Effect of Folate Supplementation On Gene Expression in Human Recto-
Sigmoid Mucosa
Petr Protiva, Michael E. Hopkins, Joel B. Mason, Zhenhua Liu, Celeste Nelson, James R.
Marshall, Martin Lipkin, Peter R. Holt
Background: Folate is important in single carbon metabolism regulating DNA synthesis and
methylation. Low folate intake correlates with enhanced risk of colon neoplasia. Recent
studies reported increased risk with folate supplementation. The mechanism of folate action
in the colon is unknown. Aims: To determine the effect of folate supplementation (1mg/
day) on gene expression in human rectosigmoid mucosa. Methods: 10 subjects at increased
risk for colorectal neoplasia were administered 1 mg folic acid po daily for 2 month in an
outpatient GCRC setting under tight nutritional control following a 2 month average folate
diet run-in period. Serum samples and rectosigmoid mucosal biopsies were taken before,
during and after intervention. Serum folate and homocysteine were measured and RNA
extracted from biopsies for gene expression profiling. Gene arrays were performed with
Illumina 24K bead array using biological and technical duplicates. Results were analyzed
by Genespring software, gene ontology (GO) and Ingenuity Pathways Analysis (IPA) using
hypergeometric probability and/or right-tailed Fisher's Exact Test. Results: Serum folate level
increased significantly with supplementation. 926 genes changed expression significantly
after folate intervention. (368 genes upregulated; 558 genes downregulated.) GO and IPA
analysis showed that upregulated genes are involved in chemotaxis, immune response and
cell to cell signaling. Significantly enriched canonical pathways included methionine metabol-
ism and PDGF/TGF beta/IL2/NF kappa B signaling. The 3 most upregulated genes were
cytokines CCL20, CXCL13 and CCL19 that promote chemotaxis and migration of B and T
lymphocytes and some cancer cell lines. Downregulated genes were involved in DNA replica-
tion, recombination and repair, cell cycle, control and assembly and organization. Conclusion:
Folate administration resulted in significant changes in genes involved primarily in chemot-
axis, cell migration and immune signaling and in genes governing cell division and DNA
repair. These results suggest, for the first time, what genes may underlie the effect of folate
on the human colon.
M2053
Differential Effects of Fluorinated Vitamin D3 Analogues On iNOS and COX-2
Induction By Lipopolysaccharide (LPS) in Raw 264.7 Macrophages Cells
Reba Mustafi, Sonia R. Cerda, Anusara Chumsangsri, Jorge Delgado, Marc Bissonnette
Background: Vitamin D3 metabolites and analogues cause potent effects on colon cancer
cell growth, differentiation and immune responses. We previously showed that a noncalcemic
fluorinated analogue of vitamin D3 (F6-D3) was chemopreventive in the azoxymethane
(AOM) model of colon cancer. Increased expression of pro-inflammatory cyclooxygenase-
2 (Cox-2) and inducible nitric oxide synthase (iNOS) play important roles in AOM tumorigen-
esis. Concomitant with tumor inhibition, F6-D3 suppressed Cox-2 and iNOS up-regulation
in AOM tumors. Since stromal cells are important sources of Cox-2 and iNOS in colonic
tumorigenesis and p38 MAP kinase pathways regulate these enzymes, we examined the
effects of several fluorinated vitamin D3 analogues on p38 activation and Cox-2 and iNOS
induction by LPS in murine macrophages cells. Methods: RAW 264.7 cells were seeded in
six-well plates in DMEM supplemented with 10% FBS. When 50-60% confluent, cells were
pre-treated overnight with 100 nM hexafluorinated vitamin D3 analogues (RO I-VI) or
ethanol (vehicle) in 2% serum medium. Cells were then treated with LPS (25 ng/ml) or
water (vehicle). After 6 hrs, cell lysates were prepared and phospho-p38, iNOS, and Cox-
2 were assessed by Western blotting. Results: LPS significantly induced expression levels
of phospho-p38, iNOS and Cox-2 >5 fold in RAW 264.7 cells (p<0.05). As shown in the
Table, RO I and III enhanced LPS stimulated Cox-2 and iNOS (p<0.05). In contrast, RO
II, IV, and VI reduced LPS stimulated Cox-2 and iNOS levels (p<0.05). Surprisingly, RO
V selectively inhibited LPS induced Cox-2 but not iNOS (p<0.05). Parallel to these changes,
the same fluorinated vitamin D3 analogues enhanced (RO I and III) or inhibited (RO II,
IV, and VI) LPS activation of p38 kinase (p<0.05). Results were confirmed in two independent
experiments plated in triplicate. Conclusion: This In Vitro study indicates that fluorinated
analogues of vitamin D3 cause differential effects on LPS induced Cox-2 and iNOS, ranging
from inhibition to stimulation. Furthermore, our data suggests that regulation of these
pro-inflammatory enzymes by fluorinated vitamin D3 analogues involves p38 MAP kinase
pathways. We have demonstrated specific functional consequences of vitamin D3 analogues
that may have important therapeutic implications. Animal studies will be needed to ultimately
define the safety and chemopreventive efficacy of these compounds in colonic carcinogenesis.
M2054
Mesalazine Counteracts the Mutagenic Effect of the Intercalating Agent 9-
Aminoacridine
Christoph Campregher, Maria gloria Luciani, Christoph Gasche
BACKGROUND: Mesalazine (5-ASA) improves replication fidelity at poly(CA) tracts (Gasche,
Cancer Res 2005) and activates a replication checkpoint (Luciani, Gastroenterology 2007).
The exact mechanism, however, is unknown. It has been proposed that 5-ASA's anti-
mutagenic activity is explained by its excellent oxygen scavenging properties. 9-Aminoacrid-
ine (9-AA) is an intercalating mutagen. In this study we tested the ability of 9-AA to increase
mutations in colon epithelial cells and to prevent such mutations with 5-ASA. METHODS:
Clone A3.7 of HCT116+ch3, an hMLH1-corrected colorectal cell line, that had been previ-
ously transfected with pIREShyg2-EGFP/CA13, a EGFP-based plasmid [in which the (CA)13
shifts the EGFP reading frame into a +2 position (Gasche, PNAS 2003)] and harbors 2
integrated copies of the plasmid was seeded in 10cm plates. 9-AA (0-10µM) was added on
day 2. After 24 hours, 9-AA was removed and 5-ASA (2.5µM) was added for another 7
days. The total cell number (c) and the EGFP-positive fraction [mutant fraction (MF)] were
analyzed by flow cytometry. The mutation rate [m/(CA)13/generation (gen)] was estimated
by m = MF/(gen+1) and gen =log2(c/1000 x cloning efficiency). RESULTS: 9-AA caused a
dose dependent decrease of total cell number and increase of MF and mutation rate in
hMLH1-/+ cells. The best increase in MF and mutation rate was observed at 5µM (about
10-fold). 5-ASA had little effect on total cell number but reduced spontaneous MF and
mutation rate (by about 45%; table). A similar effect (for the total cell number, MF, and
mutation rate) was observed when 5-ASA was added to 9-AA treated cells (table). Simultan-
eous treatment with 5-ASA and 9-AA (for 24h) did not show such an effect. CONCLUSIONS:
In our model, 5-ASA reduces both the spontaneous and 9-AA-induced mutation rate.
These data support the concept that 5-ASA improves replication fidelity at a poly(CA) tract
independent of its anti-inflammatory or oxygen scavenging properties.
M2055
Role of Epidermal Growth Factor Receptor (EGFR)-Snail Axis in Polyethylene
Glycol (PEG)-Mediated Colorectal Cancer (CRC) Chemoprevention
Ramesh K. Wali, Dhananjay Kunte, Jennifer Koetsier, Mary Nyhuis, Hemant K. Roy
Background: Both pre-clinical and population based studies validate exceptional efficacy
and safety of a novel chemopreventive agent, PEG in CRC prevention. We have previously
shown that PEG suppressed mucosal proliferation via inhibition of Snail/β-catenin signaling
[Mol Cancer Ther 2006]. Since the large molecular size of PEG makes its interaction with
intracellular factors less likely, we took a candidate approach of focusing on EGFR for its
importance in cancer and regulation of the transcriptional repressor Snail. Furthermore,
inhibition of EGFR and Snail has been shown to reduce colonic hyperproliferation and
tumorigenesis. Here we studied if PEG-mediated CRC chemoprevention is modulated by
the EGFR/Snail axis. Methods: 24 Fisher 344 rats were given AOM (15 mg/kg i.p.) weekly
for 2 wks. Seven wks post AOM (premalignant gp), 12 rats were randomized to either
vehicle or 10 % PEG-3350 for 1 wk before euthanisia. Remaining rats (tumor gp) were
randomized to either vehicle or PEG for 35 weeks before euthanasia. Colons were isolated,
tumors harvested and subjected to immunostaining of EGFR and Snail and the mucosa
subjected to western blotting. To study the molecular effects of PEG on EGFR/Snail axis,
we developed the EGFR shRNA stable construct in HT-29 cells and analyzed EGFR and
Snail by flow cytometry. Results: In the premalignant colon, PEG decreased proliferation
(by 45%), reduced expressions of EGFR (by 60%) and Snail(by 40%)demonstrating a clear
relevance of EGFR-snail axis. Tumors that escaped PEG chemoprevention were mostly EGFR
negative (75%) but snail positive, indicating uncoupling of EGFR-snail axis in these tumors.
In HT-29 cells, PEG caused a 52 % decrease in cell proliferation with a 50% reduction in
EGFR. This effect was blunted by inhibitors of lysosomal degradation pathway. Further, the
PEG-mediated EGFR down-regulation was blocked by Iressa, a specific EGFR inhibitor.
Also, while PEG significantly decreased both EGFR and snail in wildtype cells, its effect was
blunted in EGFR knockdown cells (Table 1). Conclusions: These studies provide compelling
evidence that modulation of EGFR-Snail axis plays an important role in the anti-proliferative
activity of PEG during early carcinogenesis.
Table 1: Modulation of EGFR/Snail axis by PEG
Membrane EGFR and cytoplasmic Snail were analyzed by flow cytometry (FACS) using
mouse mAb anti-EGFR (528) and goat polyclonal anti-Snail primary antibodies and Alexa
Fluor 488 (green) secondary antibody.
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M2056
5-ASA Differentially Regulates Genes Involved in Cell Cycle Progression, DNA
Methylation, and Wnt Signaling in Colon Cells
Maria gloria Luciani, Boris Tichy, James Hutchins, Sarka Pospisilova, Christoph Gasche
BACKGROUND: Individuals with ulcerative colitis (UC) are particularly at risk of developing
colorectal cancer (CRC). Epidemiological and animal studies suggest that 5-aminosalicylic
acid (5-ASA) protects from the development of CRC. Recent laboratory analysis revealed that
5-ASA has a role in regulating multiple cellular pathways including PPAR-g (C. Rousseaux, J
Exp Med 2005), promoter methylation (A. Goel, UEGW 2006), phosphatase PP2A inactiva-
tion and beta-catenin degradation (C. L. Bos, Carcinogenesis 2006). Previous results from
our laboratory indicate that 5-ASA reduces mutations (C. Gasche, Cancer Res 2005) and
restrains cell cycle progression by activating a reversible replication checkpoint (M. G.
Luciani, Gastroenterology 2007). However, the complexity of 5-ASA-targets within the
cellular machinery is poorly understood. We aimed to identify further molecular targets by
investigating differential gene expression by DNA microarray analysis. METHODS: Colon
cells HT29 and HCT116 were treated with 0 or 20mM 5-ASA for 8 or 24hr. Total RNA
was extracted and 500ng were reverse-transcribed into cDNA using fluorescent-labelled
oligo-dT primers (Genisphere 3DNA Array 900HS Cy3/Cy5 Kit). cDNAs were hybridized
onto Whole-genome Oligo Arrays (Agilent); The arrays were scanned using ScanArray
Express (PerkinElmer) and analyzed by QuantArray (Packard BioChip) and GeneTools
(www.genetools.no) software. RESULTS: From 40,000 genes analyzed, 269 were differentially
regulated above 1.5-fold (100 up-regulated, 169 down-regulated), of which only 28 genes
were above 2.5-fold (13 up-regulated, 15 down-regulated). 5-ASA induced differential
expression of genes involved in cell growth, DNA methylation and Wnt pathway regulation.
Genes involved in cell cycle progression such as the replication factor CDC6, the kinase
CDK4 and the GTPase RAN were down-regulated, as well as the DNA methylase DNMT2
and the regulatory subunits of phosphatases PP2A (PP2CA) and PP1 (PP1R8). In contrast,
the expression of the CDK inhibitors p15 and p57 was up-regulated, as well as that of the
negative regulator of the Wnt signaling pathway DKK1. CONCLUSIONS: By using a system-
atic and unbiased approach, we identified a relatively small number of differentially regulated
genes, many of them being involved in cell cycle progression, DNA methylation and Wnt
signaling, molecular pathways that had been previously associated with 5-ASA's chemoprev-
entive activity. Our study also revealed novel targets of 5-ASA, which adds to our understand-
ing of the diverse actions of this compound in colon carcinogenesis.
M2057
Regular Statin Use and Colorectal Adenoma Risk
William H. Fiske, Walter E. Smalley, Martha Shrubsole, Harvey Murff, Yu Shyr, Reid M.
Ness, Wei Zheng
Background: Statins are a class of medication that inhibit HMG-CoA reductase, and are widely
used in the treatment of hyperlipidemia. HMG-CoA reductase is found to be overexpressed in
colorectal cancers, and statins have been shown to inhibit polyp formation in mice. Clinical
trials of statins with cancer as secondary outcomes have had inconclusive results. A large
case-control study showed prolonged statin use to be associated with a reduced risk of
colorectal cancer. However, a pooled analysis of adenoma chemoprevention trials failed to
detect a reduction in the risk of recurrent adenomas among patients reporting statin use.
Methods: The Tennessee Colorectal Polyp Study is an ongoing colonoscopy-based case-
control study which began in 2003, and is designed to evaluate lifestyle and genetic factors
that influence adenomatous polyp incidence through the use of questionnaire data as well
as tissue sampling. Subjects are recruited from patients with no known history of colorectal
cancer or colon polyps who are undergoing elective colonoscopy at either Vanderbilt Univer-
sity or the VA-Tennessee Valley Health Care System. We evaluated whether self-reported
use of statin medications is associated with a reduced incidence of colorectal adenomas.
Cases were defined as patients with at least one adenoma and controls were defined as all
other patients who had no adenomas or cancer identified on a complete colonoscopy. Statin
use, including type, frequency and duration, in the 5 years prior to colonoscopy was assessed
with an interviewer-administered telephone questionnaire. Logistic regression models were
used to derive odds ratios in relation to statin use after adjusting for age, site, year, smoking
status, BMI, family history, income, education level, race, regular exercise, and use of aspirin
or NSAIDs. Results: Data was available for 1570 subjects (554 cases and 1016 controls), of
whom 35.1% reported regular use of statin medications over the previous 5 years. The
unadjusted OR for statin exposure in patients with adenomas compared to patients without
adenomas was 1.28 (95% CI 1.03 - 1.6). After adjustment the OR was 0.96 (95% CI 0.77
- 1.21). Among patients with at least 5 years of statin exposure the adjusted OR was 0.92
(95% CI 0.56 - 1.52), and among current statin users the adjusted OR was 1.02 (95% CI
0.80 - 1.29). There were no significant associations detected among patients with advanced
adenomas, multiple adenomas, villous adenomas, or large (> 1 cm) adenomas. Conclusions:
This case-control study did not find any significant association between statin use and the
occurrence of colorectal adenomas, regardless of duration of use.
M2058
Patient Preferences for Colorectal Cancer Chemoprevention
Chin Hur, Darcy E. Broughton, Chung Y. Kong, Elissa Ozanne, Thanh Truong, G scott
Gazelle
BACKGROUND: Although evidence suggests that aspirin and celecoxib may decrease the
risk of colorectal cancer (CRC), this potential benefit comes at the cost of potential harms,
most notably the increased risk of cardiovascular events associated with celecoxib. The
purpose of this study was to determine and characterize patient preferences for the use of
these two drugs for CRC chemoprevention. METHODS: Data on individual preferences were
collected using a computer-based, interactive questionnaire, which incorporated standard
risk communication techniques to create a preference-threshold elicitation interface. Subjects
were recruited from two locations: 1) waiting area of an endoscopy center in a large urban
hospital [HOSP]; and 2) using a survey company's stratified panel of internet users [WEB].
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Participants were provided summary profiles outlining the lifetime benefits and harms of
celecoxib and aspirin (presented anonymously as Drug A and B). Both celecoxib and aspirin
were portrayed as reducing the risk of CRC and increasing the risk of GI events. However,
celecoxib would increase the risk of heart attack (HA) and stroke, while aspirin would
reduce the risk of HA in men and stroke in women. Participants were then asked if they
would be willing to take each drug. Depending upon the original choice, subjects responded
to a series of binary, follow-up questions where the harm-benefit ratios were altered in a
‘ping-pong' fashion to determine conditions under which a patient might be willing to take
the two drugs. RESULTS: 1216 participants completed the survey [202-HOSP; 1014-WEB],
with a large majority 35-64 in age and 51% female. Base conditions: 8.4% would take
celecoxib and 38.2% would take aspirin. Acceptability threshold exploration: on average,
participants would be willing to take celecoxib if it reduced the future risk of CRC by >81%
or if it did not increase the risk of HA by >9%. On average, patients would take aspirin if
it reduced the future risk of CRC by >55% or if it did not increase the risk of GI events
more than 108% (or 2.08x). The most important factor determining celecoxib use was the
increased risk of HA, and for aspirin, the increased risk of GI events. CONCLUSIONS: A
majority of those surveyed stated that they would not take either drug, although participants
were 4.5x more willing to take aspirin than celecoxib. The increased risk of HA and GI
events were the most important factors determining celecoxib and aspirin use, respectively.
These data can serve to inform physicians regarding the variability of patient preferences
contemplating these drugs for CRC chemoprevention.
M2059
Efficacy of Conservative Therapy As Taught in the Primary Care Setting for
Infant Reflux Symptoms: Prospective Validated Assessment By the I-Gerq-R
During the Run-in for a Placebo-Controlled Clinical Trial of Nizatidine Oral
Solution
Susan R. Orenstein, John D. Mcgowan, Anton L. Duke, Maryam Taghadosi, Laurie A.
Harris-ford, Brian M. Harvey, John D. Lauzon
Conservative therapy (“lifestyle measures,” non-pharmacologic treatment), taught over the
phone by a nurse experienced in gastroesophageal reflux disease (GERD) management,
effects, in 2wk, satisfactory improvement in GERD symptoms for 26% of infants referred
by pediatricians to pediatric gastroenterologists.1 However, untested are the efficacy of these
measures for un-referred infants, the ability of non-specialists in primary care offices to impart
the information, and the specifics of the symptomatic improvement as tested prospectively by
a questionnaire validated for responsiveness as an evaluative instrument2. We therefore
explored these issues during the run-in period for a double-blind randomized placebo-
controlled trial of nizatidine oral solution. METHODS: Consenting parents of the first 50
infants meeting inclusion/exclusion criteria for the IRB-approved study, and having abnormal
(>16/42) screening scores on the I-GERQ-R2 (n= 40), at 5 sites 8/31-10/2/06, were taught
conservative therapy measures by each site's study nurse under supervision by the site's
pediatrician investigator. Measures taught were feeding modifications (including hypoallerg-
enic formula), positioning, and tobacco smoke avoidance.1 We compared I-GERQ-R scores
before and 2wk after institution of these measures by 2-tail Wilcoxon signed ranks test in
the 37 infants (ages 4-43 wk, median 13wk; 59% male; 68% white, 16% Hispanic, 16%black)
who completed the run-in. We analyzed the proportions of infants whose scores improved
or normalized, and explored details of symptom responses descriptively. RESULTS: Median
initial and final scores were 23 (16-36) and 18 (7-34), p<0.0001. Median score change was
-5 (+6 to -16). Scores of 78% (29/37) improved. Scores of 24% of infants became normal.
Final global assessments of 30% were <“mild.” Older infants (>20wk and >26wk) were not
more likely to improve than younger ones (chi square NS). Most individual symptoms
improved significantly. CONCLUSIONS: Conservative therapy measures improved GERD
symptoms in 78% of infants treated by non-specialists in the primary care setting in 2wk,
normalizing scores for 24% of them. These results, documented by a responsiveness-validated
questionnaire, are similar to those in sub-specialist-treated, referred infants. The power of
2wk conservative therapy for infant GERD symptoms highlights its importance as a run-in
for clinical trials of drug therapy for infant GERD symptoms, as well as for clinical care. It
also re-emphasizes the need for placebo controls in drug trials. 1. Shalaby TM, Orenstein SR. J Pediatr
142:57-61, 2003. 2. Kleinman L, et al. Clin Gastro Hep 4:588-96, 2006.
M2060
Obesity Is Associated with An Increased Prevalence of Gastroesophageal
Reflux Symptoms in Children
Dinesh Pashankar, Zachary Corbin, Syed K. Shah, Sonia Caprio
Background :Many studies in adults report an association of obesity with gastroesophageal
reflux (GER) symptoms such as weekly heartburn and regurgitation. One recent study from
Norway reported a higher prevalence of a reflux symptom score in obese children (1). We
aimed to test the hypothesis that obese children are at higher risk of having GER symptoms
compared to the control group of normal-weight children. Methods: In a prospective study,
283 obese children and 153 normal-weight children (3-18 years) were interviewed using a
standard questionnaire, consisting of weekly symptoms of vomiting, heartburn, regurgitation,
nausea, dysphagia, epigastric pain, abdominal pain and use of antireflux medications (2).
Obesity was defined as body mass index (BMI) more than 95th percentile for age and gender.
Obese children were recruited from obesity clinic and the control children from general
pediatric clinics. Demographic data were collected in all children. A previously validated
(1) symptom score was calculated from 5 symptoms of vomiting, heartburn, regurgitation,
nausea and dysphagia. We compared rates of a positive symptom score (3 or more), heartburn
,and regurgitation between two groups.Chi-square and t tests were used for analysis. Results:
Obese children had significantly higher prevalence of reflux symptoms (a positive score,
heartburn, and regurgitation) compared to the control group (Table). When stratified by
age (3-10 years and 10-18 years), gender (boys and girls), and race (African American and
Hispanics), prevalence of reflux symptoms remained significantly higher in obese children
compared to the control group, except for White children (due to a small sample size). A
positive symptom score increased significantly (P<0.001) from 1.9 % in the control group
to 11.6% in 232 obese children to 23.5% in 51 severely obese children (BMI > 15 points
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above 95th percentile). Only 10 (4%) obese children were on antireflux medications. Conclu-
sions: Obese children are at higher risk of having GER symptoms compared to the normal-
weight children. This risk is independent of age or gender and increases with increasing
BMI. 1.Stordal et al. Acta Pediatrica 2006;95:1197-1201 2.Nelson et al. Arch Pediatr Adolesc
Med 2000;154:1504.
NS- Not Significant. Supported by TAP Pharmaceutical Products Inc. and GCRC Grant.
M2061
Partial Iga Deficiency and the Accuracy of Iga Tissue Transglutaminase
Antibodies in Childhood Celiac Disease
Dascha C. Weir, Tracey Roiff, Jonathan Glickman, Clarissa Valim, Alan M. Leichtner
IgA deficiency has been reported to be 10-15 times more prevalent in patients with celiac
disease (CD) than the general population. Knowledge of total serum IgA levels is essential
when interpreting standard CD serologic tests since IgA-based serologic tests are clearly less
accurate in IgA-deficient patients. However, there is limited data about the usefulness of
these tests in patients with partial IgA deficiency. We undertook a study to determine the
relationship of total serum IgA levels to clinicopathologic features and the results of IgA
tissue transglutaminase antibodies (TTG) in children with confirmed CD. We examined 201
consecutive CD cases diagnosed by intestinal biopsy at Children's Hospital - Boston over a
5-year period (2001-5). All biopsies were reviewed by a single pathologist (J.G.), blinded
to the clinical data, and were scored by Marsh criteria. Patchiness of histopathologic mucosal
abnormalities was defined as presence variation of at least one Marsh grade among separate
fragments in a biopsy set. Absolute IgA deficiency was defined as a total serum IgA level
<15 mg/dL. Partial IgA deficiency was defined as a level greater than 15 mg/dL, but less
than the normal value for age. Results: In 113/201 patients (56.2%), levels of both total
serum IgA level and IgA TTG were determined. Patients with a documented total serum
IgA were more likely to have diabetes mellitus (28.3% vs 9.8%, p<0.0009) and more likely
to have a history of weight loss or poor weight gain (38.8% vs 21.6%, p<0.03). No other
significant differences with respect to age, gender, symptoms, associated diseases and histopa-
thologic patchiness, were noted between patients with and without a documented IgA level.
4/113 patients (3.5%) had absolute IgA deficiency. 12/113 patients (10.6%) had partial IgA
deficiency. 97/113 patients (85.8%) had normal or elevated levels of IgA for age. No significant
differences were found between these 3 subgroups with respect to age, gender, symptoms,
associated diseases and histopathologic patchiness. False negative IgA TTG rates were 75%
for children with absolute deficiency, 0% for children with partial deficiency and 4.12%
for children with normal/elevated IgA levels (p value<0.001). Of note, 3 of the children
with normal/elevated IgA levels and false negative IgA TTG results and none of the patients
with absolute deficiency were under the age of 2 years. Conclusion: As previously demon-
strated, the TTG IgA assay has high false negative rates in patients with absolute IgA
deficiency. However, partial IgA deficiency does not affect the accuracy of TTG IgA levels
in the diagnosis of celiac disease.
M2062
Pediatric Onset Crohn's Disease Is Characterized By Age and Genotype-
Related Colonic Susceptibility
Arie Levine, Subra Kugathasan, Vito Annese, Vincent Biank, Esther Leshinsky-silver, Ofir
Davidovich, Gad Kimmel, Ron Shamir, Orazio Palmieri, Amir Karban, Ulrich Broeckel,
Salvatore Cucchiara
Objectives: Pediatric onset Crohn's (CD) disease has been associated with more colitis, and
less ileitis, in comparison to adult onset CD. Differences in disease location by age may
suggest a different genotype, or a different age-related host response such as decreased
susceptibility of the ileum or increased susceptibility of the colon. Design: We evaluated
721 pediatric onset CD patients from 3 cohorts with a high allele frequency of NOD2/
CARD15 mutations. Children with isolated upper intestinal disease were excluded. The
remaining 678 patients were evaluated for interactions between age of onset, NOD2/CARD15
and disease location. Results: We found an age related tendency for colitis. Among pediatric
onset patients without NOD2/CARD15 mutations, colitis without ileal involvement was
significantly more common in first decade onset patients ( p=0.000047, OR 2.76 ,95% CI
1.72-4.43 ). This was not true for colonic involvement or in patients with NOD2/CARD15
mutations (p=0.61). A focused analysis of 229 patients with ileal and/or ileocolonic disease
and a NOD2/CARD15 mutation disclosed that ileocolonic disease was more prevalent through
age 10, while isolated ileitis was more prevalent above age 10 (p=0.016). NOD2/CARD15
mutations were not associated with age of onset. Conclusions: Crohn's disease manifesting
during childhood is characterized by increased colonic susceptibility and modified by a
NOD2/CARD15 independent mechanism. The higher risk for isolated colitis in early onset
NOD2/CARD15 wild type patients suggests that genes other than NOD2/CARD15 are associ-
ated with early onset CD and responsible for this phenotype. Early onset disease in patients
with NOD2/CARD15 mutations, predisposes to an ileo-colonic location phenotype.
M2063
Immunomodulators Are Not Required to Maintain Efficacy with Infliximab in
Pediatric Inflammatory Bowel Disease (IBD)
Subra Kugathasan, Rebecca Ehlert, Michael C. Stephens, Vincent Biank, Manu R. Sood,
Karen Sherry, Steven L. Werlin
Infliximab (IFX) has been shown to be efficacious in induction and maintenance of remission
in children with moderate to severe IBD. IFX is often used in children with IBD in conjunction
with immunomodulatory (IM) therapy to improve efficacy and to reduce immunogenecity
(anti-infliximab antibody (HACA) formation). However, recent reports of hepatosplenic T
cell lymphoma in children with CD treated with IFX and IM has changed our approach to
combination therapy. Since April 2006, in our pediatric tertiary IBD center, discontinuation
of IM occurred in many children with IBD to IFX monotherapy. Aim: To analyze the efficacy
or loss of response of IFX monotherapy to combination therapy in a pediatric IBD cohort
following discontinuation of IM therapy. Reduced efficacy / or loss of response to IFX was
defined as the need for increase IFX dose or reduced infusion intervals. Those with evidence
of immunogenecity (detectable HACA) while taking combination therapy were excluded (n=
3). 94 IBD children (83CD, 11UC) who received combination (mean duration of combination
therapy 2.2 years) for more than one year with IFX and IM (87 with azathioprine /6-MP
and 7 with methotrexate) were eligible for inclusion. Combination therapy was continued
in 52 (54%), and IM was discontinued in 45 (46%) since April 2006. At 6 months of mean
follow up, no differences (Mann Whitney U test) in efficacy was observed before and after
IM discontinuation in those 45 patients receiving IFX alone (IFX interval 8.4±1 and 8.5±1.1
weeks before and after IM discontinuation respectively). In addition, no difference in efficacy
was seen between the IFX alone group (n=45) and the combination therapy group (n=53)
at the latest follow up as all the patients remained in remission with the same IFX infusion
interval and dosage. Trough IFX level was available in 70% (n=68) of patients. IFX level
was undetectable in 10 patients (5 in each group), 5.5 ±3.3mcg/l in patients with IFX
alone group (within 2 months of IM discontinuation) while 5.1± 3in those patients with
combination therapy group. Conclusions: In patients with sustained remission on combina-
tion therapy discontinuation of IM does not appear to reduce short term IFX efficacy. This
suggests IM is not necessary for maintenance of remission in IBD children receiving IFX.
Longer follow up including further measurement of IFX levels and HACA at later time points
may determine if discontinuation of IM results in reduced efficacy or loss of response in
long term.
M2064
Rate and Predictors of Bone Mineral Acquisition in Young Patients with
Inflammatory Bowel Disease
Helen Pappa, Wanda Admiraal, Tracee Saslowsky, Catherine Gordon, Richard J. Grand
Introduction: There is a high prevalence of low bone mineral density (BMD) in children
and adolescents with inflammatory bowel disease (IBD). Since peak bone mass is attained
by early adulthood, children with IBD and low BMD may enter adulthood with a suboptimal
peak bone mass, which is strongly correlated with fractures in later life. This hypothesis
has not been tested with prospective studies to date to our knowledge. We examined
prospectively: a) the rate of bone mineral acquisition (BMA), and b) the influence of several
risk factors on the rate of BMA in a cohort of young patients with IBD, over an 18 month
period. Participants were given 400 IU of oral vitamin D supplement, and 1,200 mg (if ≥
11 years old) or 800 mg (if < 11 years old) of elemental calcium per day orally. Methods:
This was a prospective cohort study of the rate of BMA in 27 subjects (17 male) at Children's
Hospital Boston, ages 8 to 22, with a diagnosis of IBD and Z-score of lumbar spine BMD
(ZLSBMD) ≤ -1 SD, over a period of 18 months. The diagnosis of IBD was established by
standard clinical, endoscopic, and radiographic criteria. Lumbar spine BMD was measured
at baseline and 18 months using a Hologic QDR 4500 dual energy x-ray absorptiometry
scanner (Hologic Inc., Bedford MA). Participants underwent clinical, nutritional, and laborat-
ory evaluations every 3 months. Data collected included: age, pubertal stage, anthropometric
measurements, physical activity, nutrient intake, disease activity, corticosteroid exposure,
disease complications, immunosuppressant use, serum albumin concentration, and ESR.
Results: The average ZLSBMD of the cohort improved significantly (from - 2.1 ± 0.8 to -1.1
± 1.1, p < 0.001). Younger age and greater improvement in height Z-score (ΔZHt), were
significantly correlated with greater improvement in ZLSBMD (r = -0.54, p = 0.004 for age,
r = 0.41, p = 0.04 for ΔZHt). Higher daily vitamin K intake was also correlated with greater
improvement in ZLSBMD (r = 0.37, p = 0.08). Pubertal participants demonstrated greater
improvement in ZLSBMD than post pubertal (1.1 ± 0.8 vs. 0.5 ± 0.5, p = 0.08). Conclusions:
The bone health of children with IBD improved over a period of 18 months. Younger age,
linear growth, higher vitamin K intake, and puberty may be important predictors of BMA
in young patients with IBD. Consideration should be given in targeting younger/pubertal
patients, and improving vitamin K intake and linear growth to achieve optimal peak bone
mass. Larger numbers of patients may be needed to evaluate the effects of systemic inflamma-
tion, corticosteroid exposure, immunosuppressant use, and other factors on BMA in this
population.
M2065
Capsule Endoscopy (CE) Impacts Diagnosis and Alters Management of
Pediatric Inflammatory Bowel Disease (IBD): A Prospective Study
Stanley A. Cohen, Ian M. Gralnek, Hagit Ephrath, Angela Napier, Tamara Gobin, Olga
Sherrod, Jeffrey Lewis
Background / Aims: We recently reported retrospective CE data on 28 pediatric patients
with IBD who underwent CE for disease exacerbation: 5 of 7 pts with previously diagnosed
Ulcerative or Indeterminate Colitis (UC/IC) were found to have small bowel (sb) Crohn's
Disease (CD). Of the 21 with prior CD, 61.9% had evidence of more extensive sb disease
and 61.5% of the entire population had change in medical therapy. Since prospective data
are limited, the present study attempts to determine if CE improves diagnosis and alters
therapeutic decisions. Methods: Pts with suspected or known IBD, 10-21 yrs of age, who
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were to be evaluated with CE for diagnosis or exacerbation of IBD were enrolled prospectively
and preceded CE with patency capsule evaluation. Disease activity (baseline and follow-
up)was measured with Harvey-Bradshaw (HB) and the Pediatric Crohn's Disease Activity
Index (PCDAI). Physicians completed a questionnaire before and after CE assessing their
clinical suspicions, intended pt management, and impact of CE findings. Results: Thirty
subjects ingested patency capsules; 18 (10 suspected/8 known CD) passed this capsule
within 40 hrs and subsequently underwent CE. This cohort included 11F/7M with a mean
age(SD)=13.8 yrs(± 2.5); mean Hgb=11.9 g/dl; ESR=24.5; albumin=3.7. Two of the suspected
IBD patients had normal CE, UGI/SB and colonoscopy. Three others had UGI/SB x-rays; 2
of these had abnormal CE. 13 others underwent colonoscopy within 1 wk of CE (3 had
colonoscopies 2 wks-3 mos prior to CE). One was entirely normal, with abnormal CE. Based
primarily on CE, 4/5(80%) UC/IC pts with known IBD were reclassified as CD and 6/10(60%)
CD pts had more extensive sb involvement diagnosed. Importantly, disease reclassification or
newly recognized more extensive sb disease impacted pt management. Despite the results
on other studies and 2 pts with non IBD, physicians reported CE helped diagnosis in 15/
18 (83.3%) and therapeutic decision making in 13/18 (72.2%) with a change in management
occurring in 15/18 (83.3%). Improvement in HB (mean 4.5 to 4.1) and PCDAI (mean 25.8
to 18.6) scores during mean f/u of 70 days was not significant. No CE capsule retentions
occurred, yet 2 patency capsules were initially retained, leading to surgery for obstruction
in one. Conclusions: These prospective data provide additional support for our retrospective
findings that CE provides a more accurate and complete assessment of sb disease in children
with IBD, assists in diagnosis and impacts therapeutic decisions. CE may also result in a
high rate of UC/IC disease reclassification to CD in pediatrics. Additional studies to evaluate
improved patient outcome are needed.
M2066
The Use of Endoscopic Ultrasound in Pediatric Patients with Perianal Crohn's
Disease
Michael J. Rosen, Dedrick Moulton, Cheryl A. Little, Walter M. Morgan, Edmund Yang,
Alan Herline, Roberta Muldoon, Paul E. Wise, D. brent Polk, David Schwartz
Background and Aims: Perianal fistulae are a frequent complication of Crohn's disease in
the pediatric population. Treatment is comprised of a combination of immunomodulatory
drugs, antibiotics, infliximab and surgical intervention. Unfortunately, there is a high rate
of recurrence once therapy is discontinued. In adults, endoscopic ultrasound (EUS) has
been demonstrated to accurately assess fistula closure and to be useful in guiding the
combined medical and surgical therapy of patients with perianal disease. Our aim was to
report our experience using EUS to guide the management of pediatric patients with perianal
Crohn's disease. Methods: Charts of all pediatric patients who underwent EUS for perianal
Crohn's disease at our institution were reviewed retrospectively. At a minimum, all patients
were treated with antibiotics (ciprofloxacin and/or metronidazole) and an immunomodula-
tory agent. Results: Between 2003 and 2006, 11 patients between the ages of 8 and 17
years (mean age 13.7 years) underwent 17 EUS examinations. Twelve perianal fistulae (6
trans-sphincteric, 2 horseshoe, 1 rectovaginal, 2 superficial, 1 healed fistula) were identified
in 9 patients with two patients having no lesion identified. Two fistulae had associated
abscesses. Seven EUS examinations were followed by an exam under anesthesia (EUA) within
1 month. All lesions identified by EUA were also identified by EUS. Five patients had at
least one EUS performed after placement of a seton to help guide further medical and surgical
management. Of these, 2 demonstrated fistula inactivity after treatment with infliximab, the
setons were removed and there were no recurrences on continued infliximab therapy for a
mean follow-up of 211 days; 1 demonstrated fistula inactivity without infliximab therapy,
a fistulectomy was performed with removal of the seton, and the patient has ongoing drainage
after a follow-up of 298 days. Two patients managed without infliximab had either persistence
or extension of an active fistula after a mean follow-up of 139 days prompting either leaving
the seton in place or revision of the seton and initiation of infliximab therapy. Conclusions:
This is the first report of the use of EUS in the management of Crohn's perianal fistulae in
a pediatric population. EUS may be useful for defining the extent of disease and has the
potential to guide the combined medical and surgical management of perianal Crohn's
disease in pediatric patients. The results serve as rationale for future prospective studies of
the use of EUS in pediatric populations.
M2067
Increased Dosing Requirements of 6-Mercaptopurine and Azathioprine for
Inflammatory Bowel Disease Patients Six Years Old and Younger
Andrew B. Grossman, Angela Noble, Robert N. Baldassano
Introduction: 6-mercaptopurine (6-MP) and its pro-drug azathioprine (AZA) are potent
immunomodulators that are effective for maintenance of remission and reduction in corticos-
teroid exposure in pediatric inflammatory bowel disease (IBD). The accepted standard dose
of AZA is 2.0-2.5 mg/kg/d. The concentration of 6-thioguanines (6-TG), an active metabolite
of 6-MP, has been shown to correlate with therapeutic efficacy, with an established target
range of 230-400. We have observed that IBD patients 6 years old and younger often require
higher doses of 6-MP/AZA to achieve therapeutic 6-TG levels and clinical remission. Methods:
A retrospective chart review of all IBD patients six years old and younger treated with 6-
MP/AZA at The Children's Hospital of Philadelphia since 2001 was conducted. Data was
recorded for visits corresponding to 6-TG measurements and 0, 3, 6, and 12 months post
initiation of 6-MP/AZA therapy. The mg/kg dose of 6-MP was multiplied by 2.08 to establish
an equivalent AZA dose. An abbreviated Pediatric Crohn Disease Index (aPCDAI) was
approximated for each visit. Data are presented with descriptive statistics; comparisons with
Fisher's exact test (STATA 9.0). Results: 28 patients were identified who met the inclusion
criteria; 54% with Crohn Disease, 36% with indeterminate colitis, and 10% with ulcerative
colitis. The median age at diagnosis was 3.3 yrs [2.3-4.7 yrs*]. The median final AZA-
equivalent dose was 2.8 mg/kg/d [2.4-3.5*; max. dose 5.2]. 43% of our patients required
a final AZA-equivalent dose of >3.0 mg/kg/d; all therapeutic 6-TG levels were in this group
(TABLE 1). More patients in the AZA >3.0 mg/kg group achieved an aPCDAI<10, but this
was not statistically significant (p=0.14). 77% were successfully weaned from steroids while
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20% were started on infliximab, independent of AZA-equivalent dose. Two cases of leukop-
enia and one case of hepatitis occurred in the AZA > 3.0 mg group and one case of hepatitis
occurred in the AZA 2.0-3.0 mg group. Conclusions: 1. The 57% of our IBD patients six
years old and younger who were treated with a standard AZA-equivalent dose of <3.0 mg/
kg/d did not achieve therapeutic 6-TG levels and trended towards less clinical remission.
This suggests that many patients in this age group require a higher than standard dose of
6-MP/AZA. 2. AZA-equivalent doses of >3.0 mg/kg/d were well tolerated. *[25th-75th %ile]
Table 1
* Includes 2 patients with AZA dose < 2.0 mg/kg/d
M2068
Family-Based Intervention for Children with Inflammatory Bowel Disease: A
Pilot Study
Rona L. Levy, Shelby Langer, Dennis Christie, William E. Whitehead, Lynn Walker, Joan
Romano, Nader Youssef, Lila Garner, Melissa Young, Melissa Dupen, Andrew D. Feld
Introduction: Previous research has shown solicitous parental responses to the illness behavior
of children with Recurrent Abdominal Pain is associated with greater functional disability.
However, no studies have examined the feasibility or outcomes of an intervention aimed at
changing parental and child responses to symptoms in children with inflammatory bowel
disease (IBD). Aims: To pilot test whether a cognitive behavioral intervention based on
principles of social learning theory would be feasible and result in an increase in quality of
life and a decrease in functional disability in children with IBD. Methods: 15 IBD patients
and their parents selected from a large tertiary children's hospital (parents: 87% females;
mean age = 43 years; children: 53% females; mean age = 12 years) participated in three
treatment sessions. Assessments were completed one week pre-treatment, and one week
post-treatment. Children provided responses via phone to the Pediatric Quality of Life Scale
(Peds QOL), the Functional Disability Inventory (FDI), and the GI Symptom Index (GSI),
a subscale of the Child Somatization Inventory. Peds QOL total scores range from 0 -100,
with higher numbers indicative of better functioning. FDI summary scores can range from
0 - 60, with higher numbers indicative of greater disability. GI Symptom Index summary
scores can range from 0 -28, with higher numbers indicative of greater severity. Results:
Children reported a significant improvement in quality of life pre to post treatment (73.19
+ 11.03 vs. 83.51 + 10.55 (mean and standard deviation, p = .002). Changes in FDI scores
approached trend, but did not reach significance (7.95 + 6.75 vs. 5.50 + 7.15; NS). Changes
in symptoms were also in the desired direction, but not significant (5.58 + 3.87 vs. 4.58 +
4.98, NS). Conclusions: This is the first study demonstrating feasibility of a family based
cognitive behavioral intervention in pediatric patients with IBD. Significant changes in quality
of life, with all other measures in the desired direction, is most encouraging. Further
research into the effectiveness of these techniques with this population through a large scale,
randomized controlled trial is recommended. [Supported by NIH grant R0I HD36069]
M2069
Infliximab As An Induction Agent Versus Ongoing Maintenance Therapy in
Mild-Moderate Pediatric Crohn's Disease
Tamara L. Feldman, Nader N. Youssef, Irizarry Ruth, Joel R. Rosh
Background: Infliximab (INFLX) is currently indicated for induction and maintenance of
remission in children and adults with moderate-severe Crohn's disease (CD). Whether INFLX
requires ongoing scheduled maintenance or if short-term administration can be efficacious
is not known. Aim: To compare the efficacy of induction only versus ongoing treatment
with INFLX in pediatric patients with mild-moderate CD. Methods: A retrospective review
was performed of all patients followed at the Goryeb Children's Hospital IBD program
from1/2001—9/2006. All responders to an induction course of INFLX who had > one year
of follow up were included. PCDAI at 0, 6 and 12 months; demographics; number of INFLX
doses; disease location; hospitalizations and surgeries were recorded. Results: 39 patients
met inclusion criteria. 64 % male (4-17;12+3.3yrs) and 36% female (10-17;13+2.6yrs). All
but one patient received concomitant immunomodulator therapy. All INFLX doses were
5mg/kg. Induction INFLX was infused at 0, 2 and 6 wks. Additional INFLX was given
episodically for a clinical rise in disease activity. Patients who received two additional doses
by 20 weeks were subsequently placed on every 8 week scheduled maintenance. 33% (13/
39) received induction therapy only (IND); 44% (17/39) continued with episodic dosing
(EPI) and 23% (9/39) received scheduled maintenance (MAN). There was no difference in
disease location between groups. Mean PCDAI between groups was similar at time initial
(IND 22.7+12.5; MAN 25.8+10.6; EPI 23.8+8.1; p = NS) and 6 months (IND 7.5+8.4;
MAN 5+5.4; EPI 4.9+9.3; p = NS). PCDAI at 12 months was only different between IND
(2.5+2.5) and EPI (12.1+9.6; p=0.005). The mean number of infusions for EPI and MAN
were 4.9 and 5.4, respectively (p = NS). No infusion reactions or INFLX-related adverse
events were noted. 8% (3/39) of the patients were hospitalized: one at the time of initial
infusion with concomitant Rotavirus infection; one for ileocolonic resection 5 months after
IND; and one at the time of initial INFLX infusion for peri-anal skin graft due to complications
of prior pyoderma gangrenosum. Conclusions: 1. INFLX can be used as a short-term agent
to successfully induce durable remission in some pediatric patients with mild-moderate
Crohn's disease. 2. After INFLX induction, patients who relapse despite concomitant immun-
omodulator therapy are likely to need ongoing INFLX maintenance through the first year.
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3. Further study is needed to help predict which mild-moderate pediatric Crohn's patients
would benefit from using INFLX for induction only and whether this offers a safer, more
effective strategy than conventional induction agents.
M2070
Association Between Il17a and Il17ra Genes and Inflammatory Bowel Diseases
(IBD)
Ling Mei, Xiaowen Su, Andrew F. Ippoliti, Kent D. Taylor, Stephan R. Targan, Jerome I.
Rotter
IL17A is produced by TH17 CD4+ T cells, and in some mouse models of colitis, IL17A is
responsible for mucosal inflammation. Its role in human IBD is not yet known. IL17RA is
a ubiquitously expressed receptor that is essential for IL17A biologic activity. The aim of
this study was to determine whether IL17A and/or IL17RA genes are associated with IBD.
Methods: SNPs were selected to tag common Caucasian haplotypes in IL17A (#3605) and
IL17RA (#23765) and genotyped in 763 Crohn's disease (CD), 351 ulcerative colitis (UC)
and 254 controls using Illumina technology. Analysis was first done in the total sample, and
then separated into Jewish and non-Jewish sub-groups. Haplotype blocks were constructed by
Haploview 3.3. Individual haplotypes were obtained by PHASE v2 and ordered by frequency
(table). Results: IL17A. Two major haplotypes (H2 and H4) of IL17A were associated with
CD. In non-Jews, CD patients had a higher frequency of H2 (23.7% vs. 18.2%, p=0.03)
and a lower frequency of H4 (8.5% vs. 12.3%, P=0.03) when compared with controls;
however, an opposite trend was found in the Jewish population for H2 (22.1% vs. 31.4%,
P=0.04). Diplotype (ie haplogenotype) analysis for IL17A in non-Jews showed a significant
trend for odds ratio (OR): H4/no H2 (OR 0.8), other combinations (OR 1), H2/no H4 (OR
1.7, P Mantel-Hanzel =0.004). IL17RA. Two haplotype blocks were identified for IL-17RA.
In the total sample, haplotype 3 (H3) in block 1 was negatively associated with both CD
and UC when compared with controls (4.0% vs. 8.1%, P<0.0001). In block 2, H4 was
positively associated with IBD (14.8% vs. 10.4%, P=0.01). The results were similar in Jews
and non-Jews. The combined analysis for the two blocks of IL17RA also displayed a significant
trend for increased OR: H3 block 1/ no H4 block 2 (OR 0.55), other, (OR 1), H4 no H3
(OR: 1.84, P Mantel-Hanzel <0.0001). Conclusions: (1) IL17A appears to be an ethnic
specific gene for CD; (2) IL17RA is a gene associated with both CD and UC. As is the case
in mouse colitis, this cytokine/receptor pair could be important in the pathogenesis of a
subtype of CD.
Haplotype of IL17A (1: rare allele)
Haplotype of IL17RA (1: rare allele)
M2071
Replication of Genetic Association of Myo9b Gene with IBD
Anna Latiano, Orazio Palmieri, Fabrizio Bossa, Renata D'inca', Salvatore Cucchiara, Danila
Guagnozzi, Maria R. Valvano, Tiziana Latiano, Giuseppe Corritore, Angelo Andriulli, Vito
Annese
Background and Aims: The association between myosin IXB (MYO9B) gene variants and
inflammatory bowel disease (IBD) has been recently reported. The gene lies on chromosome
19p13.1 in a linkage region for the IBD, and encodes for a single motor protein implicated
in epithelial paracellular permeability. We tested the three maximally associated single
nucleotide polymorphisms (SNPs) of the gene and searched for likely correlation with clinical
phenotypes in Cronh's disease (CD) and ulcerative colitis (UC) patients. A possible interaction
between MYO9B and the CARD15 genes was also investigated. Methods: 549 CD patients,
658 UC patients, and 674 healthy controls were genotyped for MYO9B SNPs rs962917,
rs1545620 and rs2305764, by using the TaqMan allelic discrimination method. The three
major variants of CARD15 were detected using DHPLC (R702W, L1007fsinsC), and RFLP
(G908R) techniques, respectively. Results: Highly significant genotype association with both
CD and UC was shown for all three SNPs, with odds ratios ranging from 1.45 to 1.73
(p<0.01 - <0.002). A significant difference in allele frequencies was also observed in IBD,
CD and UC patients for all SNPs; The single most significant association was found for the
rs1545620 SNP [Ala1011Ser], which was present in 47% of IBD, 47% of CD, 47% of UC
patients, and 42% of controls (p<0.005). After stratifying the patients according to the
presence of at least one CARD15 variant, an increased frequency of the rs1545620 risk
allele was found in UC patients lacking CARD15 variants (P = 0.021, OR = 1.7). No significant
association with any specific sub-phenotypes was found, at the exception of an increased
frequency of upper gastrointestinal involvement in CD patients carrying the rs1545620 risk
allele (P = 0.06). Conclusions: Our findings confirm the association between the MYO9B
polymorphisms and susceptibility to both UC and CD, adding further evidence for the role
of this gene in disease susceptibility and genotype/phenotype correlation.
M2072
Il23 Receptor (Il23r) Gene Protects Against Pediatric Crohn's Disease
Marla C. Dubinsky, Dai Wang, Yoana Picornell, Iwona T. Wrobel, Lirona Katzir, J. antonio
Quiros, Ghassan Wahbeh, Gary Silber, Ron J. Bahar, Emebet Mengesha, Kent D. Taylor,
Jerome I. Rotter
Background: IL23R has recently been found to be associated with small bowel Crohn's
disease (CD) in a large whole genome association study and the rare allele of the R381Q
SNP conferred protection against CD. In the IL10-knockout mouse model of colitis, IL23R
has been demonstrated to play a role in intestinal inflammation. It is unknown whether
IL23R is associated with IBD in children. Aim: To examine the association of IL23R with
susceptibility to ulcerative colitis (UC) and CD in pediatric patients. Methods: DNA was
collected from 610 subjects (152 CD trios, 52 UC trios). Both parents and the affected child
were genotyped for the protective R381Q SNP (rs11209026) of the IL23R gene and 4
variants of the CARD15 gene (SNP5, SNP8, SNP12, SNP13) using Taqman technology.
The transmission disequilibrium test (TDT) was used to test association to disease using
GENEHUNTER 2.0. Results: The rare allele of R381Q SNP was present in 5.3% of CD and
5.9% UC probands. CARD15 frequency (any variant) was 35% (CD) and 11% (UC). Similar
frequencies were observed for parents for both genes. The IL23R allele was negatively
associated with IBD: the R381Q SNP was undertransmitted in children with IBD (8 transmit-
ted (T) vs. 27 untransmitted (UT); p= 0.001) (Table). This association was significant for
all CD patients (6 T vs. 19 UT; p= 0.009), especially for non-Jewish CD patients (2 T vs.17
UT; p=0.0006). TDT showed a borderline association for UC (T 2 vs. 8 UT; p=0.06). As
expected, CARD15 was associated with CD in children by the TDT: (63 T vs. 30 UT p=
0.0006), but not with UC. Conclusions: The CARD15 association acted as a control in this
study: the observed association with CARD15 demonstrated that applying the TDT to this
pediatric cohort will be useful in further gene finding for IBD. The protective IL23R R381Q
variant was particularly associated with CD in non-Jewish children. Thus, the initial whole
genome association study based on ileal CD in adults has been extended to the pediatric
population and beyond small bowel CD. The functional and therapeutic implications of
IL23R in pediatric IBD merit further exploration.
T=Transmitted UT=Undertransmitted
M2073
High Frequency Il23r Haplotypes Explain a High Percentage of CD Risk
Kent D. Taylor, Stephan R. Targan, Ling Mei, Mark S. Silverberg, Dai Wang, Carol
Landers, Emebet Mengesha, Andrew F. Ippoliti, Jerome I. Rotter
Background: The IL23R gene was associated with Crohn's disease (CD) by a recent whole
genome association study. In particular, a low frequency R381Q SNP confers protection
against CD. Serum expression of antibodies to microbial antigens have also been associated
with CD. Aim: To study the association of IL23R haplotypes with CD and associated serotypes.
Methods: CD subjects (n=763) and ethnically-matched controls (254) were genotyped for
20 single-nucleotide polymorphisms (SNPs) using Illumina and TaqMan MGB technologies.
SNPs were selected to tag Caucasian haplotypes using HapMap data. Serum expression of
antibodies was determined by ELISA. Presence of disease, IL23R genotype, and serum
antibodies were each determined blinded. Haplotypes were determined with PHASE v2;
associations with disease were tested by chi-square and to antibody expression by Wilcoxon
test. Results: Three haplotype blocks were observed in the IL23R gene. Block 3 spans the
protective SNP R381Q. Associations with both a “risk” haplotype and a “protective” haplotype
were observed in Blocks 2 and 3 (Block 2: Risk, 64% in CD, 55% in controls, p=0.015;
Protective, 54% in CD, 65% in controls, p=0.005; Block 3: Risk, 64% CD, 56% controls,
p=0.015; Protective, 37% CD, 47% controls, p=0.003). Block 2 risk and Block 3 risk are
additive for increased risk (ptrend=0.0072) and Block 2 protective and Block 3 protective
are additive for decreased risk (ptrend<0.0001). Population attributable risk (PAR) for Block
2 and Block 3 risk is ~10-20% and is much greater than the PAR for the low frequency
R381Q (~2%). The Block 3 risk haplotype was associated with increased serum expression
of anti-I2 antibody (median I2 level for presence of risk haplotype 27.5 compared with 19.6
for absence of risk haplotype, p=0.01). Conclusions: IL23R risk haplotypes confer marked,
additional CD risks compared with the functional, protective SNP IL21R R381Q. IL23R
therefore accounts for a substantial increase in CD risk. Furthermore, IL23R haplotypes are
associated with serum expression of antibody to I2, a Pseudomonas related antigen. Subjects
with these haplotypes will be important for studying IL23R function. These observations
increase the relative importance of this gene in the etiology of CD, and raise the possibility
that there is more variation to be discovered in IL23R.
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M2074
A Large, Nationwide, Case-Control Study for the Association of DLG5, Octn1/
2 and CARD15 with Inflammatory Bowel Diseases in the Netherlands
Rinse K. Weersma, Pieter C. Stokkers, Adriaan A. Van bodegraven, Ruud A. Van
hogezand, Hein W. Verspaget, Dirk J. De jong, C. J. Van der woude, Bas Oldenburg,
Ronald K. Linskens, Gerrit Van der steege, Daniel W. Hommes, Cisca Wijmenga, J. B.
Crusius, Ilja M. Nolte, Gerard Dijkstra
Introduction: Chronic inflammatory bowel diseases (IBD) comprising Crohn's disease (CD)
and ulcerative colitis (UC) have a complex genetic background. Conflicting results have
been reported in association studies for genetic variants in Drosophila Discs Large Homologue
5 (DLG5) and in organic cation transporters 1 and 2 (OCTN1/2) and IBD. Therefore, a large,
collaborative, nationwide study was conducted. DNA samples and clinical characteristics of
IBD patients from seven University Medical Centers in the Netherlands were studied.
Methods: 3061 IBD mainly Dutch Caucasian patients (1818 CD and 1243 UC) and 1518
healthy controls were included. Phenotypic details were available for 2317 patients (1497
CD / 820 UC). For DLG5 the risk associated SNP 113G→A and rs2165047 and for OCTN1/
2 SNPs 1672 C→T and -207G→C were analyzed. Additional SNPs (rs272893, rs273900,
rs274551) in OCTN1/2 were analyzed in a subset of 1263 (695 CD / 568 UC) patients.
Results were stratified the three common CD risk associated alleles for CARD15. Results:
For DLG5, 113G→A was associated with IBD (p=0.022), UC (p=0.033) and proctitis in UC
(p=0.017) but not with CD. rs2165046 was associated with IBD (p=0.0042) CD (0.0043),
familial occurrence in CD (p=0.0050) and proctitis in UC patients (p=0.033). OCTN1/2
SNPs 1672C→T and -207G→C were not associated with IBD, CD or UC except for subsets
of stricturing CD (1672C→T, p=0.046) and leftsided UC or colectomy in UC (-207G→C, p=
0.02 and p=0.035). rs272893, rs273900, rs274551 in OCTN1/2 were significantly associated
(p<0.05) with an increased risk for IBD and CD. rs274551 was associated with UC (p=
0.026), particularly with an early age of onset (p=0.008). No interaction with CARD15 was
found for either DLG5 or OCTN1/2. Conclusion: In this large, well phenotyped, nationwide
study in the Netherlands, we found an association of DLG5 113G→A with IBD, though
not with CD but with UC. Furthermore rs2165046 (haplotype B) in DLG5 was associated
with IBD and CD. We did not find an association for OCTN1/2 with IBD, CD or UC and
SNPs 1672C→T and -207G→C, except for stricturing CD and leftsided UC or need for
colectomy in UC. However, significant association was found with IBD, CD and (early onset)
UC, for three additional SNPs in OCTN1/2. This supports the view that OCTN1/2 might
be the associated gene in the IBD5 locus, but further analysis concerning the haplotype
structure of IBD5 is needed. No epistasis between DLG5, OCTN1/2 and CARD15 was
observed. Large, nationwide, case-control studies in rigorously phenotyped cohorts of IBD
patients are needed to confirm previously described genetic associations.
M2075
Prostaglandin E Receptor Subtype Ep1 (Ptger1): A New Candidate Gene for
IBD
Alessandra Geremia, John B. Beckly, Laura Hancock, Fraser Cummings, Rachel Cooney,
Saad Pathan, Derek Jewell
INTRODUCTION: Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD)
and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder of the gastrointesti-
nal tract. Available evidence suggests that IBD involves an aberrant inflammatory response
to intestinal bacteria in genetically susceptible individuals. Linkage genome-wide studies
have led to the identification of a number of susceptibility loci for IBD. The area of linkage
on chromosome 19p13 (IBD6) has been identified by a genome-wide scan conducted by
Rioux et al. (LOD score: 4.6). This locus appeared to confer susceptibility to both CD and
UC. To date, the susceptibility allele underlying the area of linkage on chromosome 19p13
has not been identified. PTGER1 lies within the IBD6 locus and encodes for the EP1 receptor
of Prostaglandin E2 (PGE2). A role for prostaglandins in the pathogenesis of IBD has been
suggested and greater expression of PGE2 has been described in intestinal tissue of IBD
patients. For functional and topographic reasons PTGER1 represents a good candidate gene
for IBD. AIMS & METHODS: The aim of this association study was to evaluate the contribu-
tion of polymorphisms within PTGER1 to IBD susceptibility. Single nucleotide polymorph-
isms (SNPs) within the PTGER1 gene were selected using the publicly available databases
and genotyped in 1278 cases (608 CD and 670 UC patients) and 1131 controls. All study
subjects were unrelated UK non-Jewish white Caucasians. The SNPs were genotyped using
the MALDI-TOF homogenous mass extendTM platform. RESULTS: A significant association
was found between the minor allele of the SNP rs2241360 and both the combined IBD (P=
0.018) and CD phenotypes (P=0.02). Stratification of the CD cohort by known variants
showed that the rs2241360 minor allele is rarely observed in patients carrying any of the
three susceptibility NOD2 variants (P=0.046). On sub-phenotype analysis there was also an
association with non-stricturing behaviour of the disease (P=0.045). CONCLUSION: An
association was found between CD and a SNP within the PTGER1 gene. This polymorphism,
due to its location in an intron-exon boundary, might be implicated in splicing regulation.
However, further studies are needed to elucidate if this is the causal variant or if it is in linkage
disequilibrium with the functional SNP elsewhere in the gene or in a neighbouring region.
M2076
Two Haplotypes in the Familial Mediterranean Fever Gene (MEFV) Confer
Susceptibility to Inflammatory Bowel Disease: A Follow-Up Study
Alexandra-chloe Villani, Mathieu Lemire, Edouard Louis, Mark Silverberg, Catherine
Collette, Elaine r Nimmo, Genevieve Fortin, Cécile Libioulle, Jacques Belaiche, Alain
Bitton, Daniel Gaudet, Albert Cohen, John D. Rioux, Gary E. Wild, Ian dr Arnott, Paul J.
Rutgeerts, Jack Satsangi, Severine Vermeire, Thomas J. Hudson, Denis Franchimont
We previously reported MEFV as a susceptibility gene for IBD. The haplotype referred as
‘A' confers UC susceptibility in both Belgian (Leuven and Liege) and Canadian (Quebec and
Toronto) cohorts, and a second haplotype referred as ‘B' confers CD susceptibility in both
Canadian and Jewish Canadian cohorts. Both haplotypes A and B cover MEFV intron 2 to
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its direct 5' flanking region, and no coding variants were found to explain these significant
associations. We sought to replicate haplotype A association in a fifth UC case-control cohort
and to perform in depth association analysis in all cohorts. Methods: DNA samples were
obtained from 5 centers: Liege (190 IBD trios, 96 IBD cases, 107 controls), Leuven (435
IBD trios), Quebec (125 IBD trios), Toronto (190 IBD trios), and Edinburgh (521 IBD cases,
300 controls). From the exploratory genetic screening (65 SNPs), 12 tagging SNPs were
selected and genotyped in all cohorts. Association analysis was performed using FBAT
and standard Chi-square test. For genotype-phenotype association, we considered disease
localization, behavior, age of onset and EIM for CD, and disease extent, surgery, age of
onset and EIM for UC. Phenotypic information was available for the Belgian and Edinburgh
centers. Results: No difference in haplotype A frequency is observed in the Edinburgh cohort
(case frequency: 21.4%; control frequency: 22.4%; p=0.610). Only a weak association (p=
0.0407) with a tagging SNP located in MEFV intron 2 is observed. Further analysis in the
Belgian and Canadian cohorts revealed a modifier gene effect as inverse significant associations
of the two common haplotypes (A and B) are detected with both CD and UC. Haplotype
A is significantly overtransmitted in the Belgian UC (p=0.00413) and is significantly under-
transmitted in the Belgian CD patients (p=0.0288). Similarly, haplotype B is overtransmitted
in the Canadian (p=0.0363) and Jewish Canadian CD (p=0.0213) and is undertransmitted
in the Belgian UC (p=0.0100). The strength of associations is significantly more important
in the UC no-surgery subgroup. Haplotype A is significantly more overtransmitted (no-
surgery p=0.00427; surgery p=0.414) and haplotype B significantly more undertransmitted
(no-surgery p=0.000352; surgery p=1.000) in both UC Belgian no-surgery subgroups, and
this is replicated in the no-surgery Edinburgh subgroup (haplotype A surgery frequency=
14% and no-surgery frequency=23%, p=0.0115; haplotype B surgery frequency=41% and
no-surgery frequency=29%, p=0.0036). This study has shown that MEFV contributes to
IBD susceptibility. Furthermore, it also suggests that MEFV is a modifier gene which influ-
ences severity of intestinal inflammation.
M2077
The -A2518g Polimorphism of Monocyte Chemoattractant Protein 1 (Mcp-1) Is
Associated with Crohn Disease
Orazio Palmieri, Enrica Salvatori, Anna Latiano, Maria R. Valvano, Fabrizio Bossa, Tiziana
Latiano, Giuseppe Corritore, Angelo Andriulli, Vito Annese
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine able to promote monocytes
migration in sites of chronic inflammation. The -A2518G variation in the MCP-1 gene
promoter has recently been implicated in the pathophysiology of many autoimmune diseases.
Aim: To investigate MCP-1 polymorphisms and protein plasma levels in patients with
inflammatory bowel disease (IBD). Material and methods: The -A2518G SNP was genotyped
by RFLP in 671 IBD patients (435 with Crohn's disease [CD], 236 with ulcerative colitis
[UC]), 302 parents of CD patients (trios), and in 310 healthy controls (HC).Family-based
(TDT) and case-control association analyses were performed. Plasma levels of MCP1 protein
in 105 CD patients (48 with active and 57 with inactive disease), 39 UC (19 with active
and 20 with inactive disease), and 37 HC were assessed in duplicate by an immuno-absorbent
assay (ELISA) (R&D Systems, Abingdon, United Kingdom). The R702W, G908R, and
L1007finsC variants of the CARD15 gene were also genotyped by multiplex pyrosequencing.
Results: The -A2518G variation was in Hardy-Weinberg equilibrium. Compared to the
frequency in HC (29.5%), either in case-control and TDT analysis, the frequency of the risk
allele (G) was significantly decreased in the overall population of IBD pts (24.6%; p=0.02),
and, more specifically, in the subset with CD patients (23.2%; p=0.006)(TDT: p=0.004).
Homo- and heterozygous carriers of risk allele were significantly less frequent in IBD (44.1%;
p=0.01), and in CD patients (41.6; p=0.003), than in HC controls (52.6%). No significant
difference for the allele (27.3%) and risk genotype (48.7%) frequencies was found in UC.
Mean (and median) plasma levels of MCP-1 were not significantly different in IBD patients
and controls, irrespective of different genotypes and disease activity. All UC patients (either
with active or inactive disease) had their MCP-1 levels within normal ranges. Conversely,
19 CD patients (18%) had a higher (> 2 SD) MCP-1 plasma levels, irrespective of disease
activity, localization, or MCP-1 genotypes. By evaluating MCP-1 plasma levels in quartiles,
the values of IV quartile were significantly higher in CD patients (p=0.005) compared
to controls, especially in carriers of the G allele (p=0.04). Conclusion: The investigated
polymorphism of MCP-1 gene is a protecting factor for CD. No interaction with CARD15
variants, nor a correlation with any clinical sub-phenotypes was found. CD patients carriers
of the G allele have a significantly higher MCP-1 plasma levels, which may deserve thera-
peutic implication.
M2078
The Hermansky-Pudlak 1 (Hps1) Gene Is Associated with IBD in Puerto Rico,
Independent of the Known Hps1 Insertion Mutation
Esther A. Torres, Huiying Yang, Federico Gregory, Roberto Mera, Debra Dutridge, Ling
Mei, Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor
A project of the NIDDK IBD Genetics Consortium Background: Hermansky-Pudlak Syndrome
(HPS) is a somewhat rare autosomal recessive disorder with oculocutaneous albinism, bleed-
ing, and abnormal lysosomal storage. A form of IBD has been associated with HPS; most
patients with HPS-related bowel disease have been from Puerto Rico. A 14bp insertion
creates a frameshift mutation and is specific to the Puerto Rican population. Expression
studies suggest that HPS1 is involved in immune and myeloid development. Aim: To test
the association between the HPS1 gene and IBD in a sample from the Puerto Rican population;
that is, to test the possibility as to whether general, non-HPS associated IBD in the Puerto
Rican population is due in part to heterozygosity for the known HPS1 mutation. Methods:
DNA was available for this study from 158 CD, 96 UC, and 209 ethnically matched controls.
Disease was ascertained using standard criteria. SNPs in the HPS1 gene were selected from
HapMap data to tag major Caucasian- and African-American haplotypes and were genotyped
using Illumina Bead technology. The 14bp insertion was genotyped using ABI microsatellite
technology. The association between SNP allele and disease was tested using chi-square.
Haplotypes were examined using Haploview. Results: There was no association between
non-HPS-IBD and the HPS1 insertion mutation specific to the Puerto Rican population. The
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haplotype structure revealed by Haploview analysis was complicated: there were 3 haplotype
blocks, with Block 2 spanning the HPS1 insertion mutation, along with 4 SNPs not in
blocks. A major haplotype in Block 3 is tagged by SNP rs7071947. Unexpectedly, this SNP,
not in linkage disequilibrium with the HPS1 mutation, is in fact associated with IBD,
particularly in heterozygotes (genotype AA 13% in IBD patients, 20% in controls, genotype
AG was 50% in IBD patients, 33% in controls and genotype GG was 37% in IBD patients,
47% in controls, p=0.0019). Conclusions: A SNP in HPS1, but not the Puerto Rican-specific
insertion mutation, was associated with non-HPS-IBD in a sample from Puerto Rico. This
means that two different independent variations in the same gene, one of which predisposes
to a Mendelian disorder (HPS) with IBD, and one which predisposes to non-HPS-IBD, are
both increased in the Puerto Rican population. This finding raises the intriguing possibility
that selection is acting on the HPS1 gene in Puerto Rico.
M2079
Confirmation of Association Between Tnfsf15 and Crohn's Disease
Mark Tremelling, Carlo Berzuini, Francesca Bredin, Catherine Price, Stephen Middleton,
Jeremy M. Woodward, Miles Parkes
Introduction: The tumour necrosis factor super family member 15 gene (TNFSF15) is a
strong candidate IBD susceptibility gene encoding a novel TNF-like factor expressed by
macrophages and lymphocytes.[1] Association between variants in TNFSF15 on chromosome
9q32 and Crohn's disease (CD) was recently demonstrated in a Japanese panel.[2] In this
study a common risk haplotype was identified (frequency 0.69 in cases 0.53 in controls P=
7.8 x10-11). Replication in a UK population using TDT and case control panels confirmed
association although the effect was weaker (P=0.0005 and P=0.02 respectively).[2] The
discrepancy in effect size is consistent with other studies demonstrating heterogeneity at
confirmed CD susceptibility loci between european and Japanese populations.[3] Aims and
Methods: Our aim was to replicate association between variants in TNFSF15 and CD in the
UK population using a large independent East Anglia case control panel. 756 CD patients
and 636 geographically matched controls were genotyped for 3 SNPs in TNFSF15 which
define the risk haplotype using Taqman. Results were analysed using logistic regression
methods within STATA. Haplotypes were reconstructed using SNPHAP v1.3. Results: Two
SNPs (rs3810936 and rs7848647) showed significant association between CD and TNFSF15
overall (see table 1.) There was significant LD between these loci (D' 0.80 r2 0.61). No
significant haplotype association was found. Case only analysis by CD site, behaviour or
need for surgery showed no significant SNP association with any disease subphenotype.
Conclusion Our results are very similar to the UK panel in the index study and provide
independent replication of the association between variants in TNFSF15 and CD. We also
confirm that TNFSF15 has a smaller effect on susceptibility to CD in UK than in Japanese
populations. Attempts should now be made to fine map the locus and identify the disease
causing variants. References 1. Bamias J Immunol 2003;171(9):4868-74. 2. Yamazaki Hum
Mol Genet 2005;14(22):3499-506. 3. Yamazaki J Hum Genet 2002;47(9):469-72.
Table 1.
M2080
Natural Resistance-Associated Macrophage Protein 1 Gene Polymorphisms in
Crohn's Disease
Maria Gazouli, Vassilios Atzaves, Gerassimos J. Mantzaris, Athanassios Archimandritis,
Nickolaos Anagnou
Introduction: Crohn's disease (CD) is characterized by chronic activation of macrophages.
Natural Resistance-Associated Macrophage Protein 1 (NRAMP1) gene regulates antimicrobial
activity of macrophages, and has many pleiotropic effects on macrophage functions. Hence,
NRAMP1 may be involved in the resistance to intracellular pathogens, and this effector of
the innate immunity may be implicated in the pathogenesis of CD. Polymorphic alleles at
NRAMP1 have been previously associated with susceptibility to putative infectious agents
and to autoimmune disorders. Material and Methods: Based on this background we have
investigated the hypothesis that NRAMP1 is a candidate genetic determinant of CD in an
association-based study comparing 200 patients with Crohn's disease with 200 healthy
subjects. The 5'(GT)n promoter polymorphism and 9 single nucleotide or insertion/deletion
polymorphisms were genotyped across NRAMP1 gene. Semi-quantitative RT-PCR was per-
formed to assess NRAMP1 mRNA levels in RNA isolated from blood of patients with CD.
Results: Three NRAMP1 polymorphisms [5'(GT)n, D543N, INT4G/C] were significantly
associated with CD. Consistent with studies in autoimmune diseases, allele 3 at the functional
(GT)n promoter region repeat polymorphism was significantly associated with CD compared
with healthy controls (OR 1.59; 95%CI: 1.20-2.10; p=0.0011). Interestingly, patients with
CD who were homozygous for the allele 3 expressed 4 times more NRAMP1 mRNA compared
with carriers of allele 2. Discussion: Based on this, we can speculate that over-representation
of allele 3 in CD patients may lead to hyperactivation of intestinal macrophages that are
chronically exposed to LPS; this, in turn, could cause the autoimmune-like phenotype which
characterizes CD. Collectively, our data indicate that genetic polymorphisms of NRAMP1
may be associated with susceptibility to CD.
M2081
Distinct Intestinal Gene Expression Profiles in the Terminal Ileum of Patients
with Crohn's Disease
Colin L. Noble, Alex Abbas, Jennine Cornelius, Ian Penman, Ian D. Arnott, Zora
Modrusan, Karen Toy, Lauri Diehl, Jack Satsangi
Introduction: Gene expression technology using microarray allows a comprehensive picture
of gene expression. The aim of this study was to investigate differential gene expression in
endoscopic terminal ileal (TI) biopsies of a well phenotyped cohort of Crohn's disease (CD)
patients and controls. Patients and methods: Paired TI biopsies from 16 patients with CD
and 6 healthy control TI biopsies were collected for RNA extraction and histology. Patients
symptoms were scored at the time of endoscopy and phenotypic data were collected by
patient questionnaire and case note review. Microarray studies were carried out using the
Agilent whole human genome oligonucleotide chip. Results were confirmed by RTPCR.
Results: Using unsupervised hierarchical clustering, discrete separation between the female
CD TI biopsies and female control TI biopsies was observed. When all the CD TI biopsies
(16 biopsies) were compared to controls (6), 296 sequences were upregulated and 312
sequences were downregulated (Fold change [FC] greater or less than 2, 0.01> p > 1x10-
45). By removing the acute inflammatory signal to compare quiescent CD TI biopsies (6)
to controls (6), 87 sequences were upregulated and 83 sequences were downregulated (FC
greater or less than 2, 0.01 > p > 1.68x10-44). To further investigate the acute inflammatory
signal 10 inflamed CD TI biopsies were compared to 6 non-inflamed CD biopsies. 149
sequences were up regulated and 156 sequences were downregulated, (FC greater or less
than 2, 0.0095 > p > 1x10-45). Gene ontology revealed a preponderance of these differentially
regulated sequences were associated with endoplasmic reticulum stress when gene pathways
were considered and lipid metabolism when biological function was considered. Interestingly,
and contrary to previous data,1 no change in alpha defensin 5 and 6 expression was observed
between the CD TI biopsies and controls. This was confirmed by real time PCR. Conclusions:
Genome wide microarray analysis of CD TI biopsies has allowed us to characterise distinct
expression signatures and to identify candidate genes involved in disease pathogenesis that
could be considered novel therapeutic targets. 1.Wehkamp, J. et al. Reduced Paneth cell alpha-
defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. U. S. A 102, 18129-18134 (2005).
M2082
Analysis of Genetic Interaction Between Tnfsf15 and Dqb1*04 in Japanese
Patients with Crohn's Disease
Yoichi Kakuta, Yoshitaka Kinouchi, Kenichi Negoro, Eiki Nomura, Sho Takagi, Seiichi
Takahashi, Tooru Shimosegawa
Background and Aims: Genetic studies on inflammatory bowel disease have identified
multiple susceptibility loci, and these genetic variants may influence the disease susceptibility
independently (heterogenity) or interact with each other (epistasis). In European cohorts,
although an epistatic relationship between IBD5 and CARD15 in the susceptibility to ulcerative
colitis was reported, that in Crohn's disease (CD) was not found. In the Japanese, HLA-
DQB1 and -360C/T polymorphisms in TNFSF15 have been reported to be associated with
CD, but the genetic relationship between the two loci is unknown. To demonstrate the
complex genetic basis to Japanese CD, we performed genetic analyses between HLA-DQB1
(chromosome 6) and TNFSF15 (chromosome 9). Subjects: A total of 522 Japanese indi-
viduals, 248 patients with CD and 274 healthy controls (HCs), were analyzed in this study.
Methods: We genotyped for the CD risk allele, DQB1*04 and -360C in TNFSF15, by a
multiplexed sequence specific PCR amplification or PCR-RFLP analysis. To estimate the
significance of the apparent effects due to genetic heterogeneity or epistasis, chi-square test
for independence based on the haplotype frequencies was performed. A significant p value
indicates an epistatic interaction between two loci. The haplotype frequencies were calculated
by EM algorithm on the assumption that DQB1 and TNFSF15 exist in the same chromosome,
because the theory of gene-gene interaction between two loci was similar to that of linkage
disequilibrium. We additionally classified CD and HCs into two subgroups according to
the TNFSF15 genotype, which had -360C (risk) homozygotes (risk-homo, RH group) or not
(non-risk-homo, nonRH group), and performed a case-control association study of DQB1*04
in each group. Results: A nonepistatic relationship was found between DQB1*04 and -360C
by chi-square test for independence (p=0.38). The allele frequencies of DQB1*04 in CD and
HCs were 28.4% and 18.3% in the overall group (OR=1.77, p=0.00012), 29.2% and 18.4%
in the RH group (OR=1.83, p=0. 0063), and 27.4% and 18.3% in the nonRH group
(OR=1.70, p=0.010), respectively. Significant associations between DQB1*04 and CD were
confirmed in both the RH and nonRH groups, suggesting the possibility that the DQB1*04
association was independent of -360C. Conclusions: No evidence of genetic interaction
between HLA-DQB1 and TNFSF15 was found in the susceptibility to Japanese CD, suggesting
heterogeneity between the two loci.
M2083
A Functional Promoter Polymorphism in CARD15 Associated with Crohn's
Disease
Debby Laukens, Michaela Loos, Sara Bogaert, Harald Peeters, Jurgen Del-favero, Martine
De vos
Background & aims: Three single nucleotide polymorphisms (SNP) within the CARD15
gene have been independently associated with Crohn's disease (CD). Although this association
is strong, 60 to 70% of CD patients do not carry any of these SNPs. Furthermore, they do
not account for all of the linkage observed between CD and the IBD1 locus. Since CARD15
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is highly up-regulated during inflammation, we looked for additional CD-associated poly-
morphisms in the CARD15 promoter region. Methods: A promoter region (-286 to +145)
of CARD15 was sequenced in 28 Flemish CD patients. A frequent c.-59G>A polymorphism
was genotyped in 104 CD patients and 60 controls, and allele frequencies were compared.
An In Vitro luciferase gene reporter assay in HEK293T cells was used to assess the functionality
of the promoter polymorphism in response to tumor necrosis factor alpha (TNF). Results:
Sequencing of the promoter region revealed a c.-59G>A polymorphism in the 5' untranslated
region (5'UTR), contained within a conserved potential binding site for the E2F transcription
factor. This polymorphism was significantly associated with CD (Chi-square=13.3, df=1, P=
0.003). However, in 99% of the cases, the CD-associated CARD15 mutations occur in the
c.-59G>A background, suggesting that they are in linkage disequilibrium (LD). If stratified
for CARD15 common SNPs, the association of c.-59G>A was not significant (Chi-square=
2.3, df=1, P=0.119, 52 controls versus 47 CD patients). Based on an In Vitro reporter assay,
the minor c.-59A allele was less responsive to TNF stimulation as compared to the c.-59G
allele (P<0.005). Using public HapMap data from CEPH trios, the complete CARD15 gene
is located within a single haplotype block, and we are currently determining the haplotype
structure in our patient population to evaluate the position and relative contribution of the
c.-59G>A CARD15 promoter polymorphism in specific haplotypes. Conclusions: A promoter
polymorphism, which is in LD with the common CD-associated SNPs, was identified in the
CARD15 5'UTR. A difference in responsiveness between both alleles to inflammatory stimuli
indicates a novel functional defect of CARD15 in CD patients.
M2084
Changes in the Prevalence of Inflammatory Bowel Disease (IBD) Over Time
Among Family Members of Patients with Pediatric-Onset IBD
Barbara S. Kirschner, Megan C. Toth, Harry Rosenberg, Ranjana Gokhale, Dezheng Huo
Background: The etiology of IBD is unknown; however, there is evidence that multiple
genetic factors may play an important role. The importance of defining models for disease
susceptibility increases as additional genetic associations are established for IBD. The aim
of this study was to determine changes in the prevalence of a positive family history (FH)
for IBD in pediatric patients at diagnosis and during longitudinal follow-up. Methods: Patients
with pediatric-onset IBD seen between 1970 and 2006 in the Pediatric Gastroenterology
Clinic at the University of Chicago were queried during visits or by phone to determine
current FH information with a standard questionnaire. A dedicated IBD database and medical
records were used to determine baseline FH at diagnosis of proband's IBD. Kaplan-Meier
method was used to estimate the proportion of positive FH over time. Results: 402 patients
were enrolled (221 during visits, 181 by phone). Of the 402 probands, mean age at diagnosis
11.1 (SD=3.8) years, 215 (53.5%) male, 351 (87.3%) Caucasian, 40 (10.0%) African Amer-
ican, 283 (70.4%) Crohn's disease, 96 (23.9%) ulcerative colitis, and 23 (5.7%) indeterminate
colitis. The point prevalence of IBD FH of any degree was 37.6% at diagnosis of the proband
and increased to 44.0% and 54.1% after 5 and 15 years, respectively. Caucasians were 2.53
(95% CI: 1.29-4.94) times more likely to have a FH of IBD than African Americans. Jewish
Caucasians were 1.37 (95% CI: 0.99-1.89) times more likely to have a FH of IBD than non-
Jewish Caucasians. Prevalence of IBD FH was not impacted by gender, age at diagnosis,
and type of disease. The point prevalence of IBD FH of 1st and 2nd degree relatives was
24.1% at diagnosis and increased to 30.1% and 38.6% after 5 and 15 years, respectively.
Conclusion: Prevalence of FH of IBD increases over time and varies by race and ethnicity.
Support: Barnett Family and Procter & Gamble Pharm.
M2085
The Role of the Selenoprotein S (Seps1) -105g-&;a Promoter Polymorphism in
Inflammatory Bowel Disease
Julia Dambacher, Julia Seiderer, Benjamin Kuehnlein, Simone Pfennig, Astrid Konrad,
Burkhard Goeke, Thomas Ochsenkuehn, Peter Lohse, Stephan Brand
Background/Aim: Recently, a promoter polymorphism (-105G-&;A) in selenoprotein S
(SEPS1), a membrane protein of the endoplasmatic reticulum (ER) regulating the redox
balance, has been identified and shown to be functionally involved in inflammatory responses
as reflected by an increased production of the proinflammatory cytokines IL-1β, TNF-α and
IL-6 (Nature Genetics 2005; 37:1234-41). We therefore initiated a large genotype-phenotype
study to investigate the potential phenotypic consequences of this polymorphism in patients
with inflammatory bowel disease (IBD). Methods: Genomic DNA from 563 individuals
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(Crohn's disease (CD): n=205; ulcerative colitis (UC): n=154; healthy controls: n=204) was
analyzed for the presence of the -105G-&;A polymorphism located on chromosome 15q26.3.
In addition, we performed CARD15 genotyping of the three common CARD15/NOD2
variants p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008. SEPS1 mRNA expression in
intestinal epithelial cells (IEC) stimulated with LPS, IL-1β, IFN-γ and TNF-α was measured
by quantitative PCR. Moreover, SEPS1 mRNA expression was analyzed by quantitative PCR
in colonic biopsies of IBD patients. Results: SEPS1 mRNA is expressed in IEC and its
expression increased after stimulation with LPS (2.3-fold), IL-1β, (2.4-fold), IFN-γ (2.2-
fold) and TNF-α (2.6-fold). Interestingly, in colonic biopsies of CD patients, SEPS1 expression
was lower in inflamed tissue than in uninflamed biopsies, which was inverse to IL-8 and
CCL20 mRNA expression which were used as control markers of tissue inflammation. The
-105G-&;A polymorphism was observed with similar frequencies in IBD patients and healthy
controls and was not found to be associated with certain phenotypic consequences in CD
or UC patients. In addition, there was no significant association between the 105G-&;A
polymorphism and serum levels of TNF-α or CRP in IBD patients. Medium serum TNF-α
was 1.29 pg/ml in IBD patients, while none of the healthy controls had TNF-α levels above
the detection threshold (p<0.0001). Conclusion: SEPS1 expression in IEC is up-regulated
by proinflammatory stimuli In Vitro but decreased in inflamed colonic lesions of CD patients
In Vivo. Although the SEPS1 -105G-&;A polymorphism has been shown to influence proin-
flammatory cytokine production in control populations, it is not associated with disease
susceptibility of IBD and does not contribute to a certain disease phenotype or increased
TNF-α levels in these patients. Further functional studies are required to investigate the
effect of different selenoprotein gene variants on chronic inflammatory disorders.
M2086
Functional Irf5 Variant Associated in Individuals with Crohn's Disease
Grace Gathungu, Morassa Mohensi, Jing Li, Sania Raza, Samuel Bracamonte, Richard H.
Duerr, Steven R. Brant, Judy H. Cho
BACKGROUND - Interferon Regulatory Factor (IRF) 5 is a member of a family of transcription
factors that is constitutively expressed in the cytosol and participates in the Toll-like receptor
(TLR) signaling pathway. The T allele of the single nucleotide polymorphism (SNP)
rs2004640 affects mRNA splicing, allowing expression of several unique IRF5 isoforms, and
has been positively associated with Systemic Lupus Erythematosus (SLE) 1. Up-regulation
of IRF5 leads to the production of the proinflammatory cytokines IL-12, IL-6, and TNF-a,
and transactivation of type I IFN and IFN responsive genes2. METHODS - A collection of
384 independent Jewish and Non-Jewish cases and 549 independent Jewish and Non-Jewish
controls was analyzed by case-control analysis. 124 Jewish CD nuclear families were analyzed
by the transmission disequilibrium test (TDT) using Haploview. The rs2004640 SNP was
typed by TaqMan. RESULT - We found significant enrichment of the T allele frequency in
Jewish cases compared with Jewish controls (65.7% in cases versus 54.9% in controls; P =
0.0003); Table 1, but no association in non-Jewish CD (55% in cases versus 56% in controls).
TDT analysis revealed that the T allele is over-transmitted in Jewish CD (transmitted: not
transmitted 75:49, p = 0.01955). The T allele frequency in Jewish CD is significantly higher
than that observed in other previously reported populations, including that observed in
SLE. CONCLUSION - These data reveal an enrichment of the T allele in Jewish CD cases
when compared to controls. This suggests that pathogenesis of CD in Jewish cases may
involve increased IRF5 activity, possibly through genotype-dependent over-expression of
IRF5. Understanding the role of IRFs in proinflammation may outline new targets to augment
dysregulated immune responses common to autoimmune and inflammatory disorders. REF-
ERENCES 1. Graham, R. et al. A common haplotype of interferon regulatory factor 5 (IRF5)
regulates splicing and expression and is associated with increased risk of systemic lupus
erythematosus Nat Gen 38(5):550-5 2006 2. Barnes B J, et al. Virus-specific activation of
a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon a
genes. J Biol Chem 276:23382, 2001
Table 1
M2087
Matrix Metalloproteinase-9 Gene Polymorphism Is Associated with
Collagenous Colitis
Ahmed Madisch, Stephan Miehlke, Stephan Schreiber, Birgit Bethke, Manfred Stolte,
Stephan Hellmig
Background: Collagenous colitis is a chronic inflammatory bowel disease of unknown origin
with a histological typical thickened subepithelial collagen layer. Reduced matrix degradation
has been shown to be responsible for subepithelial collagen accumulation. Additionally,
expression of the matrix-metalloproteinase-1 (MMP-1) is restricted, while expression of
TIMP-1, a tissue inhibitor of metalloproteinases, is increased. Aims: to assess the influence
of genetic variants of MMP-1, -7, and-9 genes on the susceptibility to collagenous colitis.
Patients and Methods: Seventy-five patients with symptomatic collagenous colitis participat-
ing in clinical trials of our group and 534 healthy blood donors from Germany were
genotyped for the functional promotor polymorphisms MMP-1-1607, MMP-7-153, MMP-
7-181 and one SNP in exon 6 of MMP-9 using TaqMan technology. Susceptibility to
collagenous colitis was tested in a case-control setting using Chi2-Test. Results: 24.0% of
Patients with collagenous colitis were homozygous for the rare allele G of MMP-9 exon 6
compared to 14.3% of the controls (p=0.039). Assuming a dominant model of inheritance
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homozygosity for allele G depicts a 1.9 fold increased risk to develop collagenous colitis
(95%CI: 1.0-3.5). None of the other SNPs of MMP-1 and -7 was associated with collagenous
colitis. Conclusion: Genetic variations of the MMP-9 gene may be part of a complex genetic
risk profile to develop collagenous colitis. Further studies have to elucidate the role of MMP9
in the pathophysiology of collagenous colitis.
M2088
Reduced Nuclear Factor(Nf)-κB Expression in Cell Lines from Anti-Cbir1-
Associated Nfkb1 Haplotypes
Hidetoshi Takedatsu, Kent D. Taylor, Charles O. Elson, Rivkah Gonsky, Carol Landers,
Ling Mei, Jerome I. Rotter, Stephan R. Targan
Background: The mouse Cytokine deficiency-induced colitis susceptibility (Cdcs) 1 locus
has been demonstrated to reduce NFKB1-driven cytokine release from bone-marrow derived
dendritic cells. We linked immune response to flagellin to this mouse locus and subsequently
we linked anti-CBir1 expression in humans to a human Chromosomal 4 region spanning
the NFKB1 gene and syntenic to mouse Cdcs1. Aim: To determine whether the human
NFKB1 gene is associated with anti-CBir1 expression and to test the relationship between
NFKB1 genetic variants and NF-κB expression. Methods: NFKB1 gene single-nucleotide
polymorphisms (SNPs) were selected to tag common Caucasian haplotypes and genotyped
in 763 Crohn's disease (CD) and 254 controls using Illumina technology. Anti-CBir1 antibody
and Saccharomyces cerevisiae antibody (ASCA) were measured by ELISA. Nuclear proteins
from Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines from subjects with
specific haplotypes were extracted and electro mobility shift assay (EMSA) was performed
for nuclear protein-DNA binding to consensus NF-κB motif. Quantitation of EMSA was
performed by densitometric analysis. Result: We found six major haplotypes of NFKB1 gene
from H1 to H6. One NFKB1 haplotype, H3, was associated with ASCA expression (62% of
ASCA positive patients had H3 compared with 51% of ASCA negative patients, p=0.023)
and another, H1, was associated with anti-CBir1 expression (64% of anti-CBir1 positive
subjects had H1 compared with 53% of anti-CBir1 negative subjects, p=0.003). Using EBV-
transformed cell lines from H3 positive H1 negative (n=11) and H1 positive H3 negative
(n=14) subjects, the median NF-κB expression was lower for patients with H1 compared
with patients with H3 (median NF-κB expression for H3 was 1.79 densitometric relative
ratio compared with H1, 1.28, p=0.02, Wilcoxon test). Conclusion: Human NFKB1 haplo-
types were differentially associated with both ASCA and anti-CBir1 expression. The anti-
CBir1-associated haplotype (H1) showed less NF-κB induction, even following EBV-signaling,
normally a strong inducer. We hypothesize that differences due to H1 may be greater under
less strong induction, eg. signals due to TLR in monocytes. These observations in humans
are consistent with the reduced induction of NFKB1 driven inflammatory genes that is
associated with the colitigenic Cdcs1 locus in the mouse.
M2089
Genomic DNA Hypermethylation in Colorectal Mucosa of Patients with
Ulcerative Colitis (the Boricc Study)
Ramesh P. Arasaradnam, Kevin Khoo, Daniel Commane, Seamus Kelly, Mike Bradburn,
Ian T. Johnson, John Mathers
Background: Alterations in DNA methylation patterns are seen commonly in tumours and
may be affected by folate status. Folate deficiency can result in both genomic DNA hypome-
thylation as well as aberrant methylation of specific genes. Global DNA hypomethylation
has previously been reported in rectal mucosa of patients with active and quiescent Ulcerative
Colitis (UC) but folate status was unknown[1]. In UC, folate status may be adversely affected
by chronic inflammation, malabsorption and certain drugs. Aims & Method: To assess the
genomic DNA methylation status in the macroscopically normal mucosa and folate status
in a cohort of UC patients. 244 subjects were recruited (24 UC patients and 220 normal
controls). Colorectal mucosal biopsies were obtained and DNA extracted. Genomic DNA
methylation was measured using the tritium-labeled cytosine extension assay (3[H] dCTP)
as described by Pogribny et al[2]. In this assay, the extent of 3[H] dCTP incorporation into
DNA is inversely proportional to the global DNA methylation status. Results: Mean duration
of UC was 9 years with on average 1 flare-up/year and mean SCCAI score was 2. Genomic
DNA methylation (as measured by 3[H] dCTP incorporation) was higher in UC patients
than in control subjects even when controlling for age as a covariate (p < 0.001). Folate
status was lower in UC patients (p < 0.001) compared with controls. Conclusion: Low folate
status and genomic hypomethylation have both been shown to be associated with colorectal
cancer[3] although recent data have challenged this concept, suggesting a protective effect
of low folate status on risk of colon cancer[4]. We have shown a higher methylation status
in UC patients, with a corresponding lower folate status compared to control subjects. Our
findings are in contrast with a previous report, but our study size was significantly larger,
involved quiescent UC and used a more reproducible assay. Further investigation is required
to determine the precise effects of folate status on genomic methylation and its association
with colorectal cancer. This study is funded by the Food Standards Agency, UK (N12015)
References: 1. Gloria L et al. Cancer. 1996 Dec 1;78(11):2300-6 2. Pogribny I et al. Biochem
Biophys Res Commun. 1999 Sep 7;262(3):624-8 3. Pufulete M et al. Gastroenterology
2003;124:1240-1248 4. Van Guelpen B et al.Gut 2006;55:1461-1466
SD = Standard Deviation Figures in brackets indicate 95% confidence intervals † indicate
Statistical significance
M2090
Typicality of the Amino Acid Sequences of Certolizumab Pegol, Adalimumab,
and Infliximab with Respect to Naturally Occurring Human Immunoglobulin
Sequences
Andrew C. Martin, Kerry Tyson, Matt J. Page, James R. Snowden, Gianluca Fossati,
Abhinandan K. Raghavan, Alastair D. Lawson, Andrew M. Nesbitt, Andrew G. Popplewell
Background: A common view is that a ‘fully human' antibody from a phage library, such
as adalimumab (ADA), is probably less immunogenic than a humanized reagent, such as
certolizumab pegol (CERTO), or a chimeric human-mouse antibody, such as infliximab
(IFX). However, these antibody sequences have not been compared before with normal
human affinity matured IgG antibodies. We compared the V-region sequences of CERTO,
ADA, and IFX with a database of normal human IgG V-region sequences to assess how
typical they are of naturally occurring human IgG. Methods: B cells expressing surface IgG
were isolated from healthy donors to prepare RNA — The template for RT-PCR to amplify
VH (variable heavy) and VK (variable kappa light) DNA sequences. The DNA sequences of
243 unique VH and 312 unique VK were obtained and translated to give databases of
rearranged human VH and VK sequences. Each sequence was compared to the closest human
‘germline' sequence to assess the nongermline residue content and was also scored against
every other sequence of the same chain type using percentage identity as a metric of sequence
similarity. A frequency distribution of average percentage identities was plotted and Z-scores
calculated. A positive Z-score indicates a sequence that is more typical than average of a
human sequence. The converse is true for negative Z-scores. The V-region sequences of
CERTO, IFX, and ADA were analyzed.Results: The mean number of nongermline framework
residues in rearranged antibodies in the database was 4.3% for VK and 8.8% for VH. The
CERTO V-region has 3.8% nongermline residues for VK and 8.5% for VH, making its
frameworks typical compared to rearranged human sequences. ADA has 1.3% and 1.2%
and IFX 31.3% and 22.2%, respectively (i.e. less typical than CERTO). On analysis of the
‘typicality with respect to human' scores for the V-regions as a whole, both the VK and VH
sequences of CERTO give positive Z-scores (0.15 and 1.46, respectively) (i.e. both are more
similar to the sequences in our human database than is typical for the average human
antibody). Comparatively, ADA VH sequences score marginally less well (1.34), while the
VK scores a little better (0.67). IFX V-region sequences give negative Z-scores (-2.37 VK,
-0.58 VH) (i.e. are less typical of human sequences). Conclusions: The CERTO V-region
framework sequence contains close to the mean number of nongermline residues seen in
human IgG V-region frameworks. The complete VH and VK sequences score as more human-
like than average against a database of human IgG sequences. Thus, the CERTO Fab' sequence
can be considered as typical of naturally occurring human IgG.
M2091
Genotoxic Assessment of Ulcerative Colitis By Comet Assay
Abdulkerim Bedir, Ahmet Bektas, Duygu E. Suvaci, Ali Okuyucu, Levent Altintop, Muge
Ustaoglu, Ayhan G. Kalayci
Introduction: Ulcerative colitis (UC) is an inflammatory disease, characterized by cycles of
inflammation and ulceration of colonic mucosa. Inflammatory diseases create significant
oxidative stress to cells and tissues. Chronic inflammation in the gastrointestinal tract increases
the risk for development of cancer. UC-associated colorectal carcinogenesis is probably
driven by chronic inflammation but the mechanism is unclear. Patients with more than 10-
year history of disease have a 20- to 30-fold greater risk of developing colorectal cancer.
Aims: The aim of this study was to determine whether active UC patients have more
genotoxicity than non-active UC patients and investigate the differences in DNA repair
capacity in these groups of patients by single cell gel electrophoresis (SCGE)/Comet assay.
Method: We studied 41 patients with active UC (n=26) and non-active UC (n=15). UC was
biopsy-proven and active UC patients were sex- and age-matched with non-active ones. For
the assessment of genotoxicity, we performed SCGE in epithelial cells from colonic biopsies
and peripheral blood lymphocytes. Using comet assay, DNA repair capacity was assessed
after challenging lymphocytes with 75 µM H2O2. After electrophoresis, captured images
are subjected to digital image analysis to find the values for % of DNA in tail (% TailDNA)
from comet assay parameters consistent with genotoxicity. Fifty cells from each of the slides
were scored for DNA damage. Results: We found significantly higher DNA damage (p<0.001)
in biopsy specimens from the patients with active UC compared with non-active UC patients
(22.24±0.85 vs 15.93±1.13, respectively) as assessed by % tail DNA. Patients with active
UC had increased DNA damage (p<0.001) in blood lymphocytes when compared with the
patients with non-active UC (4.10±0.27 vs 2.43±0.19, respectively), representing systemic
effects of UC. Moreover, there has been no clear difference between two groups in relation
to DNA Repair Capacity % (75.16±6.73 vs 69.16±6.98, p=0.52). Conclusion: Genotoxicity,
as assessed by comet assay, is increased in active UC patients compared to non-active ones.
We also suggested that oxidative DNA damage did not derive from defective base excision
repair, as assessed by DNA Repair Capacity %.
M2092
Role of the Pxr Gene Locus in Inflammatory Bowel Diseases
Juan L. Mendoza, Alfonso Martinez, Ana Marquez, Raquel Lana, Carlos Taxonera, Emilio
G. De la concha, Urcelay Elena, Manuel Diaz-rubio
Background and aims: The chromosome 3q locus, where the pregnane X receptor gene
(PXR / NR1I2) maps, has been recently associated with an increased risk to inflammatory
bowel disease. This nuclear receptor regulates an entire set of genes involved in the detoxifica-
tion process in the liver and the intestine. PXR expression was significantly reduced in the
colon of patients with ulcerative colitis (UC), but remained unaffected in patients with Crohn's
disease (CD). Subsequent case-control studies failed to replicate the original association in
two independent populations. Considering this apparent discrepancy, we aimed at investiga-
ting the impact of this locus on IBD predisposition in the Spanish population. Methods:
Three PXR polymorphisms, including the one more strongly correlated with IBD risk in the
initial study (rs3814055), and the six haplotypes conformed by them were analyzed by
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TaqMan technology in 367 UC and 322 CD patients and compared with 500 ethnically
matched controls. Results: The overall haplotypic distribution showed a significant difference
between controls and UC patients, but not between controls and CD patients (p=0.036 and
p=0.4, respectively). Among UC patients, a difference was evidenced between those with
extensive colitis and controls (p=0.003; X2=17.85), mainly due to the presence of a risk
haplotype [rs3814055*T// rs6784598*C// rs2276707*C: p= 0.0007; OR (95% CI)= 1.76
(1.25- 2.448)]. Conclusion: Our data support the association of the PXR locus with UC
initially observed in other European population. The specific risk conferred to the extensive
form of colitis might suggest a phenotypic effect which would explain the apparently divergent
results found to date.
M2093
DNA Variants in the Leukotriene B4 Omega-Hydroxylase Gene (Cyp4f3) and
Associations with Pediatric Crohn's Disease
Irina Costea, Ernest G. Seidman, Kenneth Morgan, Philippe Lambrette, Liliane Law,
Alfreda Krupoves, Guy Grimard, David M. Israel, David R. Mack, Anne M. Griffiths,
Parviz Ghadirian, Colette Deslandres, Emile Levy, Devendra K. Amre
Background & Aims - Leukotriene B4 (LTB4), a key regulator of inflammation is deactivated
by the Cytochrome P-450 4F3 (CYP4F3) enzyme. The CYP4F3 gene is located on chromo-
some 19p13.2 a region previously reported to be linked with Crohn's disease (CD). We
postulated that DNA variants in the CYP4F3 gene could determine susceptibility for CD in
children. Methods - A case-parent trio design was implemented at 4 pediatric centers across
Canada. Newly diagnosed cases of CD less than 20 years of age with a confirmed diagnosis
were recruited along with their parents. DNA samples were collected and genotyped for tag-
single nucleotide polymorphisms (tag-SNPs) in the gene. Maximum likelihood transmission
disequilibrium test (ML-TDT) was utilized to study association between the SNPs and CD.
Mixed regression models were applied to the case-parent data to study associations between
tag-SNP haplotypes and CD. Results - A total of 172 cases were recruited. The mean age
(± SD) at diagnosis was 11.3 (3.5). There was a slight predominance of males (56%) and
90% of the cases were Caucasian. Six tag-SNPs in the CYP4F3 gene were studied. ML-TDT
showed that SNP rs2283612 was significantly under-transmitted to CD cases (p=0.008),
whereas there were suggestions of over-transmission of SNP rs3794987 to CD cases (p=
0.058). Haplotype analysis showed that specific haplotypes formed by the tag-SNPs were
significantly associated with CD. Conclusions - Findings from our study indicate that inter-
individual differences in LTB4 metabolism resulting from inherited DNA variants in the
CYP4F3 gene may underlie susceptibility for CD among children.
M2094
Association of a Functional Microsatellite Polymorphism in Tlr2 with Crohn's
Disease; Evidences for Interactions with CARD15 Mutations
Molla Y. Teshome, Laurian Tonenchi, Juergen Glas, Vanessa E. Beynon, Stephan Brand,
Christian Folwaczny, Matthias Folwaczny, Helga P. Torok
BACKGROUND: An impaired interaction between CARD15 and other receptors of the innate
immune system, resulting in a loss of synergistic host responses to pathogens, has been
reported in the presence of Crohn's disease (CD) associated CARD15 mutations. This func-
tional interaction has not been mirrored by genetic data yet. In intron II of the human Toll-
like receptor (TLR) 2 gene, a (GT)n repeat microsatellite polymorphism has been described
recently (12≤n≤28). Shorter (n≤16) GT repeats result in weaker promotor activities and
lower TLR2 expression and are associated with mycobacterial infection. Herein the distribu-
tion of this TLR2 polymorphism in patients with CD and ulcerative colitis (UC) has been
studied. Furthermore, potential genotype-phenotype correlations and genetic interactions
with CD associated mutations in CARD15 were tested. . SUBJECTS AND METHODS: The
(GT)n repeat microsatellite polymorphism in intron II of the TLR2 gene has been assessed
in a total of 437 patients with CD, 247 patients with UC and 514 controls. Genotyping
was performed by polymerase chain reaction and subsequently sizing of PCR products using
an automatic sequencer. Association with disease susceptibility, clinical phenotypes defined
by the Vienna classification, and possible genetic interactions with CARD15 variants in CD
were tested by case-control analysis. RESULTS: In CD, the frequency of individuals carrying
at least one short (GT)n allele (defined as n≤16) was significantly higher compared to
healthy controls (18.3 % vs. 13.2 %, p<0.040). A significant increase in the frequency of
carriers of shorter GT repeats was only observed in patients with CD bearing at least one
disease associated variant in CARD15 (25.3 % vs. 13.9 %, p=0,0004 vs. controls, OR 2.22,
95 % CI (1.40-3.50)). Notably, a dose-effect was noted: the frequency of carriers of shorter
GT repeats increased in patients with double-dose mutations in CARD15 (31.3 % vs. 22.9
% in single-dose carriers and 13.9 % in wildtype CARD15 patients, respectively). In CD
patients with exclusively wildtype CARD15 and in UC no significant differences were
observed. No significant associations with CD phenotypes were noted. CONCLUSION: The
results provide novel evidence for dose-dependent genetic interactions between CARD15
and a functional polymorphism in TLR2, increasing susceptibility to CD. This observation
sustains the hypothesis of an impaired cross-talk between different receptors of the innate
immune system as a major first step in the pathogenesis of CD.
M2095
The P631h Variant of the Tlr2 Gene Is Associated with Sero-Reactivity to
Microbial Antigens in Jewish Patients with Crohn's Disease
Shane M. Devlin, Ling Mei, Kent D. Taylor, Xiaowen Su, Konstantinos A. Papadakis,
Andrew F. Ippoliti, Jerome I. Rotter, Stephan R. Targan
Background & Aims: Variants of NOD2 have recently been shown to be associated with
sero-reactivity to microbial antigens in an ethnically diverse Crohn's disease (CD) cohort
while no relationship was found between sero-reactivity and a variety of toll-like receptor
(TLR) variants (Devlin et al Gastro in press). A relationship between TLR5 variants and
reactivity to OmpC and CBir1 was, however, demonstrated specifically in Jewish patients
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with CD (Taylor et al DDW 2006). Since there seems to be a differential interaction between
innate immune alterations and sero-reactivity in Jewish versus non-Jewish patients, the aim
of our study was determine if the relationship between variants in innate immune receptors
and sero-reactivity to microbial antigens differed in Jewish (J) versus non-Jewish (NJ) patients
with CD. Methods: Sera from 731 CD patients (282 J, 449 NJ) were tested for ASCA, anti-
I2, anti-OmpC, and anti-CBir1 by ELISA while DNA was tested for five TLR2, two TLR4,
and two TLR9 variants. The magnitude of responses to microbial antigens was examined
according to variant status. Overall quartile sums (QS) (ranging from 4-16) of levels for all
four antibodies were calculated as previously described (Mow et al Gastro 2004;126:414).
Results: 1] There was no association between any TLR4 or 9 variant and sero-reactivity to
microbial antigens in Jewish or non-Jewish patients with CD. 2] There was an association
between the non-synonymous, non-conservative P631H variant of TLR2 and ASCA positivity
in Jewish patients (OR 2.75, p for interaction = 0.01). 3] There was an association between
the P631H variant of TLR2 and cumulative quantitative response to microbial antigens in
Jewish patients with CD. QS were clustered into four groups by increasing cumulative
quantitative immune response (group 1=4-6, group 2=7-9, group 3=10-13, and group 4=
14-16). The frequency of carriage of the P631H variant of TLR2 increased in parallel with
QS cluster in Jewish patients; 2.86%, 3.70%, 7.02%, and 13.46% in groups 1, 2, 3, and
4, respectively (p for trend=0.03). No similar association was found in non-Jewish patients;
7.14%, 10.42%, 6.67%, and 5.45% in groups 1,2,3, and 4, respectively (p for trend=0.40)
Conclusions: Jewish, but not non-Jewish, patients with CD who carry the P631H variant
of TLR2 have increased sero-reactivity to microbial antigens. These data add evidence to
the paradigm that, in CD, innate immune defects lead to enhanced adaptive immune response
to microbial antigens. This differential response to the same genetic variant in two different
populations implies a possible gene-gene interaction consistent with the multigenic nature
of CD.
M2096
Mixed IBD Families: A Distinct Entity Within IBD
Marie Pierik, Kristel Van steen, Marie Joossens, Paul J. Rutgeerts, Severine Vermeire
BACKGROUN & AIM: Twenty percent of inflammatory bowel disease (IBD) patients report
a positive familial history and there is a high concordance of disease type, location and
behavior within families. In mixed IBD families however both ulcerative colitis (UC) and
Crohn's disease (CD) are present. We were interested in differences in genetic background,
serologic response and phenotypes between patients belonging to mixed families and other
IBD patients. We also studied the environmental and genetic factors that modulated the
development of CD and UC in these families. MATERIALS & METHODS We confirmed
the diagnosis of CD and UC in 33 mixed families. 929 independent IBD patients and 209
volunteers served as controls. All subjects were genotyped for TLR4 D299G and the 3 CD
associated CARD15 variants. ASCA and OmpC were assessed with ELISA. To account for
multiple CD or UC patients in one mixed family the effects of these patients were averaged
before inclusion in the statistical model. RESULTS: CD patients belonging to mixed families
more often had colonic disease and TLR4 variants compared to other CD patients (p=
0.035 OR 2.483 95%CI{0.983-6.273} and p 0.054 OR 2.610 95%CI{1.069-6.374}) (disease
location, ASCA, age at diagnosis (AAD), smoking behavior at diagnosis (SAD), gender,
CARD15 and TLR4 included in the model). UC patients of mixed families more often had
mutations in CARD15 compared to UC patients (p<0.01 OR 4.217 95%CI{1.758-10.114})
(disease extension, SAD, AAD, gender, CARD14 and TLR4 included in the model). CARD15
variants were more frequent in UC patients belonging to mixed families compared to controls
(p<0.01). When comparing CARD15 and TLR4 prevalence, gender, AAD, SAD, ASCA and
OmpC between UC and CD patients belonging to mixed families we found that ASCA was
more often found in CD patients (p=0.032, OR -2.067 95%CI{-3.948,-0.186}. Although in
8 out of 10 CD-UC pairs discordant for disease and smoking the smoker had CD no
significant difference in smoking behavior was found. CONCLUSION: CD patients of mixed
IBD families have certain UC characteristics (colonic disease) and UC patients have some
characteristics typical for CD (CARD15 variants). We therefore show that mixed IBD families
behave differently and that they represent a distinct entity within IBD. Furthermore TLR4
variants are more frequent in these families. Why some patients in these families develop
CD and others UC is not clear but ASCA remains a CD specific finding, suggesting a
microbiological challenge underlying disease differentiation.
M2097
Gender Related Association of DLG5 Variant R30q with Inflammatory Bowel
Disease (IBD) in a Familial IBD Registry
Zhenwu Lin, Lisa S. Poritz, Tong-yi Li, Kathryn A. Byrnes, Yunhua Wang, Anthony W.
Gebhard, Colin Macneill, Neal J. Thomas, Walter A. Koltun
INTRODUCTION: Inflammatory bowel disease (IBD) is a heterogeneous disease determined
by genetic and environmental factors. The contribution of inherited factors to IBD has been
studied in several genes including NOD2, DLG5, OCTN1,OCTN2, and IL23R. DLG5 is a
member of the membrane associated guanylate kinase family that plays a role in the formation
of cell junction, maintenance of cell shape and clustering of channel proteins at cell surface.
Genetic association of DLG5 R30Q with IBD has been identified and supported by several
studies. Recently, gender difference was observed by Friedrichs et al in 2006. The R30Q
variant leads to an amino acid change from Arg to Gln in the DLG5 protein and may have
impact on protein function(s). Here, we studied the association of R30Q in a familial IBD
registry. METHODS: The three populations studied here include a central Pennsylvania
familial IBD registry (244 individuals from 58 families with at least 2 IBD affected individuals
in each family), 170 sporadic IBD patients, and 170 healthy controls. Genomic DNA isolated
from B cell lines, tissues, and blood was used for genotyping. The genotype analysis was
carried out with PCR-based Msp I RFLP and converted Bse YI RFLP methods. RESULTS:
The results show that the A allele of R30Q is significantly associated with IBD in sporadic
IBD (OR=2.131, p value=0.0061), and in the familial IBD registry (OR=1.778, p value=
0.0368). A difference in expression/phenotype was observed among families in the familial
registry. The gender related association of the A allele with IBD in men and women is shown
in Table 1. This suggests that the A allele of R30Q confers a much higher risk of IBD in
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men than women. CONGLUSION: These data indicate that the A allele of R30Q is increased
in both sporadic IBD patients and in the familial IBD registry. The elevated presence of the
allele in the unaffected family members is still consistent with its potential role as a genetic
factor that contributes to disease expression. This suggests that the A allele of DLG5 is a
risk factor for developing IBD. The clinical outcome of the A allele of R30Q is affected by
familial/genetic factors including gender.
Table 1. Gender related association of A allele of DLG5 R30Q with IBD in men
M2098
The ATP-Binding Cassette Transporter Abcg2 (BCRP) and Abcb1 (Mdr1)
Variants Are Not Associated with Disease Susceptibility, Disease Phenotype,
Response to Medical Therapy Or Need for Surgery in Hungarian Patients with
Inflammatory Bowel Diseases
Simon Fischer, Peter L. Lakatos, H. Hungarian ibd study group, Laszlo Lakatos, Agota
Kovacs, Tamas Molnar, Istvan Altorjay, Maria Papp, Aniko Szilvasi, Zsolt Tulassay, Janos
Osztovits, Janos Papp, Pal Demeter, Richard Schwab, Attila Tordai, Hajnalka Andrikovics
Background: MDR1 (ABCB1), a member of the ATP-binding cassette (ABC) transporters, is
an attractive candidate gene for the pathogenesis of inflammatory bowel diseases (IBD)
and perhaps response to therapy. Since limited data are available on MDR1 and ABCG2
polymorphisms in East European IBD patients, our aim was to study the ABCG2 and MDR1
variants and patients' response to medical therapy and/or disease phenotype in Hungarian
patients. Patients and Methods: 414 unrelated IBD patients (CD:265, age:35.2±12.1years,
duration:8.7±7.6years and UC:149, age:44.4±15.4years, duration:10.7±8.9years) and 149
healthy subjects were investigated. ABCG2 G34A, C421A and MDR1 C3435T, G2677T/A
SNPs were detected using real-time PCR. Detailed clinical phenotypes were determined by
reviewing the medical charts. Results: The frequency of the ABCG2 and MDR1 SNPs was
not significantly different among IBD, CD, UC patients and controls. The risk for steroid
resistance was not different in CD patients carrying variant ABCG2 (19.6% vs. non-carriers
18.4%, p=NS) or MDR1 3435T (CC:22.2% vs. CT/TT:17.6%) alleles. Additionally, carriage
of the variant allele was not associated to disease phenotype, presence of extraintestinal
manifestations, smoking, response to infliximab therapy or need for surgery. In UC, the
carriage of variant ABCG2 alleles seemed to be preventive for arthritis (15.5% vs. 31.7%,
OR:0.39, 95%CI:0.16-0.98). Conclusions: MDR1 and ABCG2 SNPs were not associated to
disease susceptibility or disease phenotype in Hungarian patients, as well as variant alleles
did not predict the response to medical therapy or need for surgery. Further studies are
needed to clarify the association between the presence of ABCG2 variants and arthritis in UC.
M2099
Tnfsf15 Genotype Is Associated with Anal Lesions and Frequent Relapse in
Crohn's Disease
Eiki Nomura, Masaki Matsuura, Yoichi Kakuta, Kenichi Negoro, Sho Takagi, Seiichi
Takahashi, Yoshitaka Kinouchi, Tooru Shimosegawa
Background and aims: Crohn's Disease (CD) is a multifactorial disorder with both genetic
and environmental factors. We previously reported that the -360C/T SNP in TNFSF15
conferred susceptibility to CD in Japanese patients (OR=1.89, P=1.8 x 10-6). However, so
far there has been no convincing report about a TNFSF15 genotype - phenotype / clinical
course association. The purpose of this study was to clarify the correlation between TNFSF15
polymorphism and clinical data including disease phenotype and the cumulative rates of
non-relapse and non-surgery. Methods: A total of 252 patients with CD were enrolled in
this study. All patients gave written and informed consent to participate in this study. The
-360C/T in TNFSF15 was genotyped by polymerase chain reaction-restriction fragment length
polymorphism. CD patients were subsequently classified into two subgroups according to
the genotype of -360C/T: the risk homo (RH) group which had the -360C risk allele (n=
144), and the non risk homo (NRH) group (n=108). Clinical records of all patients were
systematically reviewed, and detailed phenotypic information was obtained. Clinical and
demographical parameters were compared between the RH group and NRH group by chi-
squared test for disease phenotype (sex, past history of surgery, location of disease, existence
of fistula, stenosis, and anal lesion), t-test for age at diagnosis, and the log rank test in
Kaplan-Meier method for the cumulative rates of non-relapse and non-surgery. The strength
of association in the chi-squared test was estimated by odds ratio (OR). P values of less
than 0.05 were regarded as statistically significant. Results: The patients of the RH group
had a significantly higher risk of having anal lesions compared with the patients of the NRH
group (OR=2.0, P=0.0059). Moreover, relapse was significantly more frequent in the RH
group than in the NRH group (P=0.036). There were no significant differences between the
subgroups in other parameters. Conclusions: Our results demonstrated that the TNFSF15
genotype (-360C risk allele homo or not) was associated with not only CD susceptibility
but a phenotype of CD with anal lesions and frequent relapse. A functional study is now
needed to clarify the mechanism based on experimental evidence.
M2100
HLA-Drb1 May Influence Disease Phenotype in Japanese Patients with
Ulcerative Colitis
Yoichi Kakuta, Yoshifumi Matsumura, Eiki Nomura, Kenichi Negoro, Sho Takagi, Seiichi
Takahashi, Yoshitaka Kinouchi, Tooru Shimosegawa
Background and Aims: The HLA region has been implicated in the disease susceptibility
of inflammatory bowel disease by several linkage and association studies. We previously
reported that HLA-DRB1 were strongly associated with ulcerative colitis (UC) in the Japanese
population. The strongest association was found in DRB1*1502 (OR=3.7, p<10-14). In Caucas-
ians, DRB1 was reported to determine the clinical phenotypes of UC. However, the contribu-
tion to the clinical phenotype in Japanese has not been known. To investigate whether HLA-
DRB1 influences the UC phenotypes in Japanese, we analyzedHLA-DRB1 in clinical subgroups
of UC. Subjects: A total of 292 Japanese patients with UC were recruited for this study.
Patients with UC were classified into subgroups by sex, age at diagnosis (below 40, above
40), disease extent, past history of colectomy or intensive intravenous steroid therapy. Disease
extent was defined by the proximal point of inflammation and classified into three groups
(proctitis, left-sided colitis, and extensive colitis). Methods: Genotyping for HLA-DRB1 was
determined by a multiplexed sequence specific PCR amplification analysis. PCR-RFLP analysis
was subsequently performed to determine DRB1*1501/*1502 heterozygote or DRB1*1501
homozygote. Each allele frequency in DRB1 was compared between the subgroups. The
allelic distribution in DRB1 was also compared by a genotypic differentiation test using
GENEPOP software. Results: The allele frequency of DRB1*1502 was significantly higher
(OR=2.48, p=0.011) and DRB1*09 was significantly lower (OR=0.41, p=0.011) in patients
with UC diagnosed at below 40 years than in those diagnosed at above 40 years. The allele
frequency of DRB1*08 was significantly higher in patients with left sided colitis (OR=3.11,
p=0.0035) or both left sided colitis and extensive colitis (OR=2.72, p=0.0060) than in those
with proctitis. No significant differences were found in the other allele frequencies between
the subgroups. No significant differences were found by the genotypic differentiation test
for the allelic distribution between the subgroups. Conclusions: We demonstrated that
DRB1*1502 was associated with not only UC susceptibility but the age at diagnosis in
Japanese. We also demonstrated that DRB1*08 was associated with the disease extent. These
results suggested that HLA-DRB1 was associated with not only UC susceptibility but the age
at diagnosis and the disease extent.
M2101
Determination of Alpha-Defensin Gene Copy Number By Taqman Real-Time
PCR and Typing By Pyrosequencing in Danish Crohn Disease Patients
Johan Burisch, Marianne Dybdahl, Cathrine Jespersgaard, Severin Olesen-larsen, Ida
Vind, Claudio Csillag, Pia Munkholm, Ole Haagen nielsen, Paal Skytt andersen
Background: Defensin genes encode a family of small cationic, antimicrobial peptides that
play a sig-nificant role in the innate immune system. The genes have been mapped to
chromosome 8p22-p23. Apart from its antimicrobial effect, alfa-defensins also serve as
chemo-attractants for T cells and dendritic cells, suggesting that the defensins may act as
mediators of the innate and the adaptive immune system. Recent studies have shown that
defensin genes display copy number variation in the human genome in a complex manner.
A large defensin gene cluster has been identified in the 8p23 region. The alfa-defensin gene
DEFA1A3 gene copy number varies independently of the well-characterized DEFB4 where
copy-number seems to be associated to Crohn's Disease (CD). It was also shown recently
that DEFA1A3 is expressed in the intestinal tissue. It was therefore of great interest to
determine whether DEFA1A3 copy-number also is associated with CD Results: We have
determined the copy number variability for DEFA1A3 in a cohort of 87 Crohn's Disease
patients with a severe disease course and compared to healthy donors using Taqman real-
time PCR. DEFA1A3 copy numbers varied from 2-10 assuming two copies as the lowest
number, and the most frequent numbers were 4-5. The copy number variability for DEFA1A3
found in our study is in accordance with previously reported results. A single nucleotide
polymorphism in DEFA1A3 leading to an amino acid change gives rise to the two alleles
DEFA1 and DEFA3. The product of DEFA1 is a more potent antibiotic than the DEFA3
peptide, making the discrimination between these two alleles highly relevant. Therefore, we
have initiated studies of allele quantification of DEFA1 and DEFA3 based on pyrosequencing.
Conclusion: The defensin assays using real-time PCR proved to be a reliable and fast method
to screen gene copy number polymorphisms and the pyrosequencing assay allowed for
determination of indi-vidual alleles in a highly reproducible way. There was no significant
difference in copy number or al-lelic distribution between the CD patients and the control
group or in the subgroups of ileal and colo-nic disease vs. controls.
M2102
A Gene-Wide Evaluation of Associations Between the Abcb1/Mdr1 Gene and
Pediatric Onset Crohn's Disease
Alfreda Krupoves, Ernest G. Seidman, Philippe Lambrette, Irina Costea, Colette
Deslandres, Guy Grimard, David R. Mack, David M. Israel, Liliane Law, Emile Levy,
Kenneth Morgan, Devendra Amre
Background and Objectives Although, some functional studies support a biological role
for the involvement of the ABCB1/MDR1 gene (that codes for the P-glycoprotein 170 efflux
protein) in the pathways leading to inflammatory bowel disease (IBD), epidemiological
evidence in particular for Crohn's disease (CD) is conflicting. In this study we explored
associations between DNA variants in the gene and CD in a pediatric cohort of patients
using a gene-wide approach. Methods A case-control study using family-based and unrelated
controls was carried out. Patients were children less than 18 years of age diagnosed with
CD at 3 tertiary gastroenterology centers across Canada (Montreal, Vancouver and Ottawa).
Diagnosis of CD was confirmed using standard clinical, radiological, endoscopic and histolog-
ical criteria. To identify potential disease susceptibility variants, single nucleotide polymorph-
isms (SNPs) that were in linkage disequilibrium (LD) with other SNPs (tag-SNPs) in the
gene and that were constructive representatives of the haplotype variation in the gene, were
determined and genotyped. CD phenotype (disease location and behaviour) was classified
according to the Montreal Classification. Associations between the SNPs and disease suscept-
ibility and/or disease-phenotype were evaluated using the Transmission Disequilibrium Test
(TDT) and chi-square tests. Results A total of 222 case-parent families and 128 controls
were recruited. Mean age (±SD) at diagnosis of CD was 11.2 (±3.5). The majority of the
cases were male (56%) and Caucasian (~90%). Most patients had isolated colonic disease
(38%), and the inflammatory disease phenotype (80%), at diagnosis. 14 tag-SNPs across
the ABCB1/MDR1 gene were evaluated. No associations with disease susceptibility were
detected for any SNP using either family-based or unrelated controls. However, stratification
on disease location revealed significant associations with 3 SNPs: rs6950978 with isolated
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ileal (p=0.04) and ileo-colonic (p=0.04) disease; rs10248420 with ileo-colonic disease (p=
0.03) and rs10264990 with both ileal (p=0.05) and ileo-colonic disease (p=0.05). No
associations with disease behaviour were evident. Conclusions Our findings reveal that
variants in the ABCB1/MDR1 gene are not associated with susceptibility for CD in children.
However, the gene could modify disease presentation and determine ileal or ileo-colonic dis-
ease.
M2103
The Phenotype of Familial IBD Influences the Clustering of Time At Diagnosis
in Parents-Child Pairs
May-bente Bengtson, Camilla Solberg, Geir Aamodt, Morten H. Vatn
Aims: To compare clustering of time at diagnosis and phenotype of inflammatory bowel
disease (IBD) between affected parents and children. The within pair differences in age at
diagnosis in affected sib-sib and parent-child pairs were explored, as well as concordance
of clinical characteristics and the influence of smoking habits at diagnosis. Methods: 84
affected pairs from 45 families were selected for the study from five counties in south eastern
Norway. Clinical data were obtained by phone interviews and by hospital records. Results:
Of the 84 affected pairs, 43 were sib-sib pairs, 2 grandparents-grand child and 39 parents-
child pairs. Twenty six pairs had mixed disease, equally distributed by sib-sib and parents-
child pairs. Of the 39 parents-child pairs 14 and 25 pairs had a parent with IBD and
offspring with ulcerative colitis (UC) and Crohn's disease (CD), respectively. When the time
interval between diagnosis in parent and child was split in two groups, below and above 5
years, 64% of pairs with UC-offspring where diagnosed within 5 years, compared to 24 %
of pairs with CD-offspring (OR = 5.7, CI: 1.4, 23.8). In the same pairs, the difference in
mean age at diagnosis was 20 in UC and 14 years in CD pairs (p < 0.001), which was only
partly explained by date of birth (R2 = 0.48, SE = 10.2). Time interval between diagnosis
and age difference at diagnosis and in sib-sib pairs were 3.5 and 2 years(mean difference),
respectively, regardless of phenotype. Concordance for smoking habits was low in 26 pairs
with mixed disease (κ = 0.15), whereas patients with CD tended to be current smokers.
The concordance for perianal fistula (κ = 0.79) was high in CD-pairs, as well as for stricturing
disease in sib-sib pairs (κ = 0.77). Conclusions: This study confirmed the effect of smoking
habits on IBD phenotype. The time interval between diagnosis of the parents and offspring
tended to be lower when the offspring developed UC compared to CD, and might suggest
the importance of shared environmental factor for developing UC. The variance for within
pair difference in age at diagnosis in affected pairs of parents-offspring was only partly
explained by date of birth.
M2104
N-Acetyltransferase 2 Slow Acetylator Genotype Was Associated with Adverse
Effects of Sulphasalazine in the Treatment of Inflammatory Bowel Disease
Bing Xia, Min Chen, Bixiao Chen, Qiusha Guo, Jin Li, Mei Ye
Aim: N-acetyltransferase 2 (NAT2) is an important enzyme catalyzing N-acetylation of
sulfasalazine (SASP). Interindividual variability of therapeutic effectiveness and/or adverse
reactions of drugs are often influenced by polymorphisms of metabolic enzymes. Inheritance
of a slow acetylator genotype for NAT1 could potentially lead to an increased efficacy.
Similarly, adverse effects may occur more frequently in patients with slow acetylator NAT2
genotype who is treated with SASP. The patients with rheumatoid arthritis with the slow
NAT2 acetylator genotypes have been shown to have more adverse effects than fast acetylator
genotypes when taking SASP. The aim of our study is to investigate associations of the
genotypes of NAT2 with inflammatory bowel disease (IBD) and with adverse effects of SASP
used as the first line for the treatment of IBD. Methods: The wild-type allele (NAT2*4) and
three variant alleles (NAT2*5B, *6A and *7B ) of NAT2 gene were determined in 101
patients with IBD (84 patients with ulcerative colitis and 17 patients with Crohn's disease)
and 109 healthy controls by PCR-RFLP. Sixty-eight patients of IBD treated with SASP were
followed and recorded adverse reactions. Results: Distribution of NAT2 alleles and acetylator
genotypes in IBD patients was not significantly different from that in healthy controls. Eleven
patients (16%) had experienced adverse effects from SASP, including 9 cases of sulfapyridine-
dose related adverse effects and 2 cases of hypersensitive reaction (skin rash). The slow
acetylator genotypes without NAT2*4 allele had experienced more adverse effects than the
fast acetylator genotypes with at least one NAT2*4 allele (36% vs. 11%, P=0.051, OR=
0.26, 95%CI=0.065-1.004). However, the slow acetylator genotypes had experienced more
sulfapyridine-dose related adverse effects than the fast acetylator genotypes (36% vs 8%, P=
0.019, OR=0.17, 95%CI=0.039~0.749). Conclusions: The NAT2 gene polymorphism was
not associated with susceptibility to IBD in Chinese patients, but the NAT2 slow acetylator
genotypes were significantly associated with sulfapyridine-dose related adverse effects of
SASP in treatment of IBD.
M2105
Genetic Variants of DLG5 Gene, E514q, P979l, G1066g, and P1371q in a
Familial Inflammatory Bowel Disease (IBD) Registry
Zhenwu Lin, Lisa S. Poritz, Tong-yi Li, Kathyrn A. Byrnes, Yunhua Wang, Anthony W.
Gebhard, Colin Macneill, Neal J. Thomas, Walter A. Koltun
INTRODUCTION: The DLG5 is a member of the membrane associated guanylate kinase
family. Using a central Pennsylvania familial IBD registry, we studied the genetic variants
of DLG5 in IBD. In addition to DLG5 R30Q (reported elsewhere), with this report we
studied another four single nucleotide polymorphisms (SNPs): E514Q, P979L, G1066g, and
P1371Q. Of these SNPs, E514Q, P979L, and P1371Q are missense mutations that lead to
protein amino acid sequence changes, while G1066G does not change the coding amino
acid, may have impact on DLG5 RNA splicing. METHODS: The populations studied here
are from a central Pennsylvania familial IBD registry (244 individuals from 58 families with
at least 2 IBD affected individuals in each family), and sporadic IBD patients (170), and
healthy controls (170). Genomic DNA isolated from transformed B cell lines, tissues, and
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blood was used for genotyping. The genotype analysis was carried out with PCR-based nature
restriction fragment length polymorphism (RFLP) and converted RFLP (cRFLP) methods.
RESULTS: The results show that: 1) Both E514Q and P979L are rare mutations, and they
exist in both IBD patients and controls. 2) For SNP G1066G, the frequency of TT+CT is
47% and CC is 53% in controls, and of TT+CT is 48.3% and CC is 51.7% in the familial
registry. 3) For SNP P1371Q, the A allele of P1371Q is associated with IBD in sporadic
IBD, OR=2.335, p=0.0246. However, in the familial IBD registry, the association was very
weak. Further analysis of gender specific association indicated that the A allele of P1371Q
is associated with IBD in females (OR=3.765, p=0.0095), but not in males (OR=1.141, p=
0.8135). The combination of A allele of P1371Q and A allele of R30Q are more significantly
associated with IBD in sporadic IBD (OR= 2.265, p=0.0007) and in the familial IBD registry
(OR=1.805, p=0.0138). CONCLUSION: The results indicate that the DLG5 variant G1066G
is most likely not associated with IBD. The association of DLG variants, E514Q and P979L
with IBD needs to be further studied in a large number of populations. The P1371Q is
found at an increased incidence in both the sporadic IBD and members of the familial
registry. The association of the combination of P1371Q and R30Q is highly significant in
sporadic IBD and also in the familial IBD registry. The A allele of P1371Q is significantly
associated with IBD in women. Considering the A allele of P1371Q as an IBD mutation for
women, and the A allele of R30Q as an IBD mutation for men, these two are more highly
associated with IBD in sporadic IBD patients (p<0.001) and in the familial IBD registry
(p=0.0034).
M2106
Analysis of Ibd5-Related Polymorphisms: Irf1, But Not Slc22a4 Or Slc22a5, Is
Associated with IBD in the Puerto Rican Population
Kent D. Taylor, Esther A. Torres, Federico Gregory, Roberto Mera, Huiying Yang, Debra
Dutridge, Ling Mei, Stephan R. Targan, Jerome I. Rotter
A project of the NIDDK IBD Genetics Consortium Background: A linkage disequilibrium
study of the IBD5 locus on human Chromosome 5 has previously identified a 250kb common
haplotype that increased Crohn's disease (CD) risk; extreme linkage disequilibrium across
the region made identification of the actual predisposing gene difficult. This region spans
the IRF1—SLC22A4—SLC22A5—PDLIM3 gene cluster. Subsequent mutation analysis iden-
tified two single nucleotide polymorphisms (SNPs) in SLC22A4 (L503F, rs1050152) and
SLC22A5 (-207, rs2631367) that were associated with CD, though this did not resolve the
issue of gene identification. A large association study performed by the NIDDK IBD Genetics
Consortium has established that other genes in the region may be just as important for CD
pathogenesis (Silverberg et al 2006. Eur J Hum Genet, in press). IRF1 codes for an interferon
regulatory factor, a transcriptional activator for genes induced by interferon gamma; SLC22A4
and SLC22A5 code for organic cation transporters. Aim: To examine the association of SNPs
related to the IBD5 locus in the Puerto Rican population, in order to determine if this
population, with its own linkage disequilibrium pattern, will aid in distinguishing the
responsible gene(s) in this locus. Methods: DNA was available for this study from 158 CD,
96 UC, and 209 ethnically matched controls. Disease was ascertained using standard criteria.
SNPs in the IRF1 gene were selected from HapMap data to tag major Caucasian- and African-
American haplotypes and were genotyped using Illumina Bead technology. The association
between SNP allele and disease was tested using chi-square. Haplotypes were examined
using Haploview. Results: There was no association between IBD and the two previously
associated variants in the SLC22A4 and SLC22A5 genes in the Puerto Rican population. In
contrast, haplotype 3 (H3) of a haplotype block spanning the IRF1 gene was protective
for IBD (H3 present in 10% of IBD cases, 19% of controls, p=0.018, pempirical=0.045).
Conclusions: In contrast to studies of other populations, IRF1, rather than SLC22A4 or
SLC22A5, appears to be important for IBD susceptibility in the Puerto Rican population.
This finding further suggests that study of the IBD5 locus in this population may aid sorting
out the role of this very complex genetic locus, and further emphasizes the importance of
trans-ethnic mapping of disease susceptibility loci and genes.
M2107
Inflammatory Bowel Disease in a German Twin Cohort: Results of a
Nationwide Study
Martina E. Spehlmann, Ekaterini Saroglou, Jens Burghard, Alexander Begun, Patricia
Lepage, Mufid Al-yousef, Andreas Raedler, Stefan Schreiber
Background: A genetic predisposition as the cause of inflammatory bowel disease (IBD) has
been proven by both the study of first degree relatives and twins and the identification of
genetic variants associated with the disease. The aim of our study was to determine the
concordance levels for IBD in German twin pairs. Methods: Volunteers were asked to
participate and complete a questionnaire if they had IBD and were born as one of a twin
pair. Recruitment was performed via a publication in a newsletter distributed by the German
Crohn's and Colitis Association (DCCV e.V.) and the Kompetenznetz Darmerkrankungen
e.V. The questionnaire contained questions about zygosity, demographic data and medical
history. Results: One hundred eighty six twin pairs for which at least one member had IBD
were identified (68 monozygotic and 121 dizygotic pairs). Eleven out of 31 (35%) monozyg-
otic pairs were concordant for Crohn's disease (CD) and 6 out of 37 (16%) monozygotic
pairs were concordant for ulcerative colitis (UC). Two of the 58 (3%) dizygotic twins with
CD and 1 out of 63 (1%) dizygotic pairs with UC were concordant for the disease. In 23
out of 31 (74%) monozygotic CD pairs and 30 out of 37 (81%) monozygotic pairs with
UC the first-born was affected by IBD. For dizygotic twins, in 41 out of 58 (70%) pairs
with CD and in 44 out of 63 (69%) pairs with UC the first in birth ranking had IBD.
Conclusions: This study confirms that the genetic influence is stronger in Crohn's disease
than in ulcerative colitis. Since concordance was only 35%/16% in monozygotic twins, one
can assume that environmental factors have a strong impact in the development of IBD in
the German population. Being the first-born is a risk-factor for the development of IBD,
independently of the genetic background.
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M2108
Prevalence of Abcb 11 Mutations Among Children with Cholelithiasis
A O. Scheimann, Vivekanandan Perumal, Mike Torbenson
Introduction: Pediatric cholelithiasis is commonly attributed to hemolysis, parenteral nutri-
tion, malabsorption and obesity but the diagnosis is unclear for some patients (pts). Other
influences on bile composition such as alterations in canalicular transport may enhance
lithogenic tendencies. Mutations in the ABCB11 gene have been previously reported among
patients with history of benign recurrent intrahepatic cholestasis and cholelithiasis, but not
isolated cholelithiasis. Materials and Methods: After appropriate approval was obtained, a
retrospective review was undertaken of individuals under 12 years of age who underwent
cholecystectomy between 1986-2006. Cases were subdivided into those with known causes
of gallstones (e.g., hemolytic disease) and without known causes of gallstones. Data was
collected from the medical charts including demographic information, past medical history,
family history, anthropometry, and lab work. Based upon recent studies linking cholelithiasis
to mutations in ABCB11, selected exons were amplified and sequenced from genomic DNA
obtained from archival paraffin embedded surgical pathology specimens. Results: Forty-four
children underwent cholecystectomy between 1986-2006. In 34 cases (77%) (Group A) a
known cause for stone formation was identified, including sickle cell disease, hereditary
spherocytosis, malabsorption or parenteral nutrition. However, 10 cases (23%) (Group B)
had no identifiable risk factors. Among those in group B, the mean age was 9.4 + 2.5 yrs;
50% were female. Four individuals in Group B had a family history of gallstones. The mean
BMI z-score was 1.1 + 1 kg/m2. Only1 pt in group B had a history of cholestasis and
pruritus with prior diagnosis of alpha-1- antitrypsin (SZ PI type). A mutation was found in
exon 7 (V164I) in one of 10 individuals in group B, a 12 year old female with a family
history of gallstones. No mutations were seen in exons 17 or 20. Conclusion: A significant
number of children with gallstones have no identifiable risk factors (23%). A mutation in
ABCB11 has been found in one case without prior history of cholestasis.
M2109
Is the Insulin-Like Growth Factor-1 a Link in the Association of Gallstones
and Cardiovascular Disease?
Daniel Zamora-valdes, Genaro Vazquez-elizondo, Jezer I. Lezama-mora, Julio A. Perez-
sosa, Martha H. Ramos, Misael Uribe, Nahum Mendez-sanchez
Background and aim: Gallstone disease and Cardiovascular disease (CVD) are highly prevalent
diseases worldwide accounting for a great economical impact. In a previous report, we
demonstrated that both diseases are strongly associated. Recent reports show that patients
with low insulin-like growth factor-1 (IGF-1) serum levels exhibit an increased risk for
CVD. Also it has been suggested that IGF-1 serum levels are positively associated with
postprandial gallbladder emptying and cholecystokinin release, relevant factors in gallstones
pathogenesis. The aim of this study was to assess the association of gallstones and CVD and
to evaluate IGF-1 as a potential link between these diseases. Material and methods: A cross-
sectional study was conducted. Cases were defined as patients with gallstones on ultrasound
examination and controls defined as patients without evidence of gallstones. Clinical and
biochemical variables were collected. Body mass index (BMI), hip-to-waist ratio and insulin
resistance index (HOMA-IR) were calculated.Metabolic syndrome was evaluated using ATP
III criteria. Carotid artery intima-media thickness (CIMT) was determined by a standard
ultrasound protocol. The CIMT was considered as a risk for CVD. IGF-1 serum levels were
measured by RIA. Results: We studied 191 patients, 62 cases and 129 controls, 53.2% of
the cases were male vs 65.9% controls. Cases were older (49.3 ±12.3 vs 46.1 ±10.2 p <0.05),
exhibited higher BMI (28.1 ±4.6 vs 26.4 ±3.5 p <0.01), body fat percentage (31.3 ±7.4%
vs. 28.5 ±6.2% p <0.01), HOMA index (2.4 ±2.4 vs 1.74 ±1.2 p <0.05), metabolic syndrome
(33.2% vs 22.8% p <0.05) and CIMT (0.61 ±0.14 vs 0.65 ±0.18 p <0.05). Patients with
gallstones had a significantly higher risk of stroke (CIMT > 0.75 mm; 38.7% vs 20.1% p
< 0.01). IGF-1 range was 26.9-633.4 µg/L (186.6 ±103.9) Patients with the metabolic
syndrome showed significantly lower levels of IGF-1 (147.4 ±104.7 vs 198.3 ±101.1 p
<0.0001). IGF-1 levels were negatively correlated with CIMT (r = -0.32, p < 0.01). Patients
with CIMT > 0.75 mm exhibited significantly lower IGF-1 levels (159.3 ±77 vs 196.3 ±110.5
p <0.05). IGF-1 levels were nonsignificantly lower among cases (179.6 ±93.8 vs 190 ±108.6
p= NS). Conclusions: In this study significantly higher CIMT and risk for stroke were found
in patients with gallstones, supporting the association between gallstones and CVD. IGF-1
was found to be a reasonably good marker for cardiovascular risk; however, its serum levels
were not significantly different among patients with gallstones. Therefore, the results of this
study do not support a role for IGF-1 in the association between gallstones and CVD.
M2110
Deletion of the Gallbladder Mucin Gene 4 (Muc4) Decelerates Cholesterol
Gallstone Formation and Reduces Stone Size in Mice
Helen H. Wang, Wanda O'neal, David quan-hai Wang
Mucin secretion and accumulation in the gallbladder are determined by multiple mucin
genes and Muc4 determines presence of membrane-associated epithelial mucin. Increased
gallbladder mucin has a crucial effect on accelerating biliary cholesterol crystallization and
stone growth because of its ability to bind biliary lipids. Our aim was to study whether
Muc4 influences susceptibility to cholesterol gallstone formation. Methods: We investigated
male Muc4 (-/-) and (+/+) mice in a C56BL/6 background before and during feeding a
lithogenic diet containing 1% cholesterol and 0.5% cholic acid for 56 days. Gallstones in
gallbladder biles were quantified by microscopy. Mucin accumulation was examined by
physical-chemical methods. Gene expression of the gallbladder Muc1, Muc2, Muc3, Muc4,
Muc5ac, and Muc5b was determined by real-time PCR. The common bile duct was cannulated
for measurement of biliary lipid secretion rates. Biliary lipid compositions were analyzed by
HPLC. Results: At day 1, expression levels of the gallbladder Muc1, Muc3, and Muc5ac were
up-regulated by 3 to 8-fold in (+/+) and (-/-) mice because of stimulation of cholesterol
supersaturated bile. The Muc4 mRNA expression was increased by 5 folds in (+/+) mice.
There was a lack of Muc4 expression in (-/-) mice, coupled with reduced expression levels
of the gel-forming mucin Muc5b. Little or no Muc2 mRNAs were detected in both groups
of mice. Mucin accumulated at day 3 in (+/+) mice and at day 7 in (-/-) mice. At day 14,
gallbladder completely filled with mucin gel in 25% of (+/+) mice and in 15% of (-/-) mice.
Lots of agglomerated cholesterol monohydrate crystals in (+/+) mice and scattered small
crystals in (-/-) mice were detected. At day 28 and 56, gallstone prevalence was 25% and
70% in (+/+) mice and 15% and 65% in (-/-) mice, respectively. At 56 days, gallstone sizes
were 0.32±0.10 mm in (+/+) and 0.13±0.07 mm in (-/-) mice (P<0.05). Hepatic outputs of
biliary cholesterol (28-33 μmol/h/kg), phospholipid (51-57 μmol/h/kg) and bile salts (215-
230 μmol/h/kg) were essentially similar in (+/+) and (-/-) mice. Cholesterol saturation index
(1.3-1.5) and total bile salt pool size (5.4-6.2 μmol) were identical in these two groups of
mice. Biliary bile salt compositions were similar in (+/+) and (-/-) mice with 62% taurocholate,
23% taurochenodeoxycholate and 10% tauro-β-muricholate. Conclusions: Deletion of Muc4
reduces mucin accumulation in the gallbladder and retards cholesterol crystallization and
gallstone formation, but does not influence hepatic secretion of biliary lipids and bile salt
compositions. Our results suggest that other mucin genes also contribute to cholelithogenesis
in (-/-) mice.
M2111
Microbiological and Immunohistochemical Detection of Helicobacter pylori in
Cholecystic Bile of Patients with Symptomatic Gall Stones
Asem Elfert, Hanan Soliman, Ahmed Amin, Maha Shamlolah, Walaa Alkhalwany, Elshazly
Sheta
Few studies has been investigated the presence of Helicobacter DNA in bile of patients with
biliary diseases. A debate is growing between pros and cons. The aim of this study was to
detect Helicobacter pylori in the bile and gall bladder mucosa of patients with symptomatic
gall bladder stones. Twenty patients with symptomatic gall bladder stones treated with
cholecystectomy were subjected to preoperative esophagogastroduodenoscopy, and rapid
urease test for gastric antral biopsy. Polymerase chain reaction was done for H. pylori in
Cholecystic bile. Gall bladder tissue was subjected to histopathology and immunohistochem-
istry. Twenty other patients with asymptomatic gall bladder stones were used as a control.
DNA sequences of H. pylori were detected in cholecystic bile in 45% of patients with
symptomatic gallbladder stones. A significant correlation was found between biliary and
gastric infections with H. pylori. Also, a significant correlation was found between biliary
infection with H. pylori and the degree of histological cholecystitis. Immunohistochemical
staining using H. pylori-specific antibodies have confirmed the presence of immunoreactive
curved rods on the gall bladder mucosa. This had been correlating with the detection of H.
pylori DNA by PCR. Urease test had a 100% sensitivity, 40% specificity, and 66% accuracy
compared to PCR. So, Urease test could be used to predict H. pylori biliary infection with
a relatively good accuracy. We can conclude that H. pylori infection of the stomach and bile
had an association with symptomatic calcular gall bladder disease and that gastric infection
have benn correlating with biliary infection in most of our patients. Future studies are
needed to settle a causal relationship and assess the effect of treatment.
M2113
Calcium Carbonate in Gallstones. Use of Scanning Electron Microscopy to
Generate Hypothesis Concerning the Form of Caco3 Precipitation
Roger D. Soloway, D. R. Taylor, J. W. Wen, Mark D. Stringer, Jinguang Wu
Recently, our group determined that CaCO3 accounted for more than 90% of the content
of some stones from Leeds UK while occurring only as rings in cholesterol stones in Galveston
TX. This suggested that pathogenesis differed for CaCO3 precipitation in these separate
geographic locations. In developing standards to quantitate these differences spectroscop-
ically, formation of various isomorphs was monitored using scanning electron microscopy
(SEM) and Fourier transform infrared (FT-IR) microspectroscopy. Serial observations demon-
strated that In Vitro, amorphous calcium carbonate (ACC) (3-5μ) was present transiently
(5-15 min) before cuboidal calcite (70-80μ) formed as the stable end product. Aim: to
compare the structures of CaCO3 isomorphs in gallstones from Leeds, UK and Galveston
TX using SEM. Methods: particles of gallstones from Leeds or rings from cholesterol gallstones
from Galveston were mounted, gold-coated and examined by SEM. Composition was deter-
mined on similar particles by FT-IR microspectroscopy. Results: By FT-IR, the predominant
isomorph in Leeds stones was calcite with small amounts of ACC. In Galveston stones,
calcite was still the largest isomorph but free and bound ACC was increased. We hypothesized
that protein was coating ACC to prevent it from converting to calcite. Deposits identified
as ACC were found attached to and covered by a thick coat of protein with a spectrum
similar to that of mucin. These deposits were not identified in Leeds stones that were
predominantly calcite. Instead, stacks of 1-2μ thick plates of calcite were identified, many
larger than the limits formed by pure calcite crystals. The edges of each layer did not follow
a straight line characteristic of the calcite standard. Since protein did not make up a significant
proportion of these stones by FT-IR analysis, we hypothesized that the hardness of Leeds
stones was caused by very thin layers (less than 1μ thick) of mucin glycoproteins intercalated
between the calcite plates, strengthening the overall structure. Conclusions: Glycoprotein
in Leeds stones serves as a thin layer of “cement” between plates of calcite while a thicker
layer of glycoprotein in Galveston stones coats ACC and prevents a variable amount of ACC
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from converting to calcite after precipitation. Hypothesis: less mucin or a mucin of different
composition may be secreted by patients with gallstones in Leeds UK than in Galveston TX.
M2114
Endogenous Sphingosine-1-Phosphate and Ceramide in Serum and Bile As
Potential Mediators for Cholesterol Gallstone Formation in C57bl/6 Mice
Ji hyun Kim, Jae seon Kim, Hwan-soo Yoo, Seikwan Oh, Jong eun Yeon, Jong-jae Park,
Kwan soo Byun, Young-tae Bak
Background/Aim: Sphingosine-1-phosphate (S1P) and ceramide, bioactive sphingolipid met-
abolites, are implicated in diverse biological functions including cell growth, death, differenti-
ation and calcium homeostasis as well as the regulation of signaling pathway for smooth
muscle cell contraction and lymphocyte sequestration. The purpose of this study was to
evaluate whether the levels of S1P and ceramide in both serum and bile are related to the
gallstone formation in C57BL/6 mice. Methods: Eight week-old mice were divided into 3
groups (n=17 per group) according to the intakes of control and lithogenic diets for 4 weeks
(group A) and 8 weeks (group B). Lithogenic diets contained 1.2% cholesterol and 0.5% cholic
acid. Mice of control group and lithogenic diet group were sacrificed, and concentrations of
ceramide and S1P in bile and serum were measured by HPLC analysis. Expressions of β-
actin, ERK, pERK, JNK, p38, p-p38, STAT3 and pSTAT3 in the extracted gall bladder (GB)
were determined by Western blot analysis. Results: Serum levels of S1P and ceramide in
group A and B were significantly lower than those in control group. There was an increasing
tendency in S1P and ceramide level from bile in group A and B compared with control
group, but the differences were not statistically significant (Table 1). Expression levels of
pSTAT3 and pERK from GB were higher in group B than those in controls and group A
(Fig 1). Conclusion: The level of sphingolipid metabolites in serum and bile may be related
with the gallstone formation induced by high cholesterol diet, and pERK and pSTAT signaling
pathways also may be involved in the sphingolipid-mediated process. Further studies are
needed to confirm the relationship between cholesterol gallstone formation and the level of
sphingolipid metabolites in serum and bile.
Table . Ceramide and S1P Level from Serum and Bile in Each Group
M2115
Cholesterol Nucleation in Native Bile Occurs More Rapidly in Female Than
Male Prairie Dogs: Estrogen Is a Potential Contributory Factor
Angela C. Brown, Ronald A. Figueredo, Rena Nasser, Steven P. Wrenn, Mohammad Z.
Abedin
Background and Aims: Gallstone disease is one of the most common and costly digestive
diseases, especially among women, who have a two to three times higher incidence rate
than men. Female sex hormones, particularly estrogens, have been suggested as a contributory
factor to the promotion of gallstones. Cholesterol nucleation from cholesterol-rich phospholi-
pid vesicles is the initial event in gallstone formation, and estrogen, which has been shown
to alter membrane fluidity, may influence the likelihood of cholesterol nucleation from
cholesterol-rich domains within the vesicles. The aim of the present study was to determine
if there is a difference in cholesterol nucleation rates in male and female bile, and to investigate
whether estrogen is the contributory factor causing such differences. Methods: Gallbladder
bile was harvested via cholecystectomy from both male and female prairie dogs fed normal
chow, and domain size was examined by a Förster Resonance Energy Transfer (FRET)
assay at intervals of 0, 14, 28 and 56 days. Model bile was created from cholesterol
and dimyristoylphosphatidylcholine (DMPC), and the dose-dependent effect of estrogen on
domain size was examined by FRET. Estrogen was added to the model bile in one of three
ways: i) estrogen was incorporated into phospholipid vesicles which were added to the bile,
ii) estrogen was conjugated to bovine serum albumin (BSA) and added to the bile, or iii)
estrogen was directly incorporated into the model bile. Results: Female bile samples showed
more pronounced energy transfer than did male bile suggesting that cholesterol nucleation
occurred more readily in female bile than in male bile. Model bile experiments demonstrated
that energy transfer and cholesterol nucleation tend to increase upon addition of estrogen,
regardless of the method of estrogen addition. Conclusion: Cholesterol nucleation appears
to occur more rapidly in female than male bile and estrogen is a potential factor promoting
nucleation and contributing to gender differences in gallstone pathogenesis.
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M2116
Cholecystectomy Has NO Significant Influence On the Plasma Lipid Profile
Although the BMI Was Significantly Increased After One Year
Uwe Reinhold, Antal Bajor, Kjell-arne Ung
Background: The hepatic synthesis of bile acids is the most important catabolic pathway
for cholesterol. An increased fecal bile acid wasting results in decreased plasma cholesterol
levels. There is a direct relationship between the hepatic triglyceride synthesis and bile acid
synthesis mediated by the farnesoid X receptor. Post-cholecystectomy diarrhea has been
attributed to bile acid malabsorption. The bile acid synthesis increases after cholecystectomy.
Aims: To study whether cholecystectomy has an impact on the plasma lipid profile and
body mass index (BMI). Methods: Plasma total cholesterol, High-density lipoprotein (HDL),
Low-density lipoprotein (LDL) and triglycerides were analysed prior to and 3 and 12 months
after elective cholecystectomy. All samples were drawn and analyzed under standardized
conditions. BMI was also calculated. Results: Sixty-seven patients (45 female, 22 male) with
mean age 53.8 (SD: 14.3) years were included in the study. Forty-seven were operated on
because of pain and 20 because of previous cholecystitis. No significant differences were
seen after three months. The BMI had increased significantly after one year (26.9, SD:4.3
vs. 27.4, SD:4.0, p=0.0014). No significant changes in the plasma lipids were observed after
one year although there were trends for increased cholesterol (5.43mmol/l, SD:1.19 vs.
5.60mmol/l, SD:1.35, p=0.075) and LDL (3.25mmol/l, SD:0.99 vs. 3.37mmol/l, SD:1.08,
p0.069). The triglyceride levels were: (mean:1.33mmol/l, SD:0.73, p=0.092) 3 months after
the operation and (mean:1.43mmol/l, SD:0.82, p=0.097) after one year vs (1.33mmol/l,
SD:0.73) before. Conclusions: The expected decrease of cholesterol due to increased bile
acid synthesis after cholecystectomy was not seen. On the contrary, there was even a trend
to increased cholesterol and LDL which may be linked to the increased BMI. Furthermore,
the removal of the gallbladder did not result in the expected increase of the plasma triglycer-
ides although the higher BMI should further contribute to such a change.
M2117
Phosphatidylcholine Transfer Protein (PC-TP) Controls Hepatic Insulin
Sensitivity By Regulating Body Fat Mass
Erez F. Scapa, Alessandro Pocai, Keishi Kanno, Luciano Rossetti, David E. Cohen
Background: PC-TP is a highly specific intracellular lipid binding protein with a broad
tissue distribution. The absence of PC-TP expression in Pctp-/- (KO) mice is associated with
altered fatty acid fluxes, as well as increased insulin sensitivity when determined by glucose
and insulin tolerance tests. Moreover, plasma concentrations of leptin and adiponectin are
increased in KO mice. Aim: To test the hypothesis that PC-TP controls hepatic insulin
sensitivity by regulating body fat mass. Methods: Eighteen to 20wk old male KO and wild
type (WT) mice were fed a chow diet (n≥5/group). Whole body adiposity was quantified
by MRI. Visceral fat was compared by weighing epididymal fat pads. Euglycemic, hyperinsuli-
nemic clamp studies were performed: 10% glucose was infused i.v. at the rate required to
maintain euglycemia (8mM), and mice received a constant infusion of [3H]-glucose (0.1μCi/
min) and insulin (3.6mU/min/kg). Plasma was collected at 10min intervals for 90min to
determine glucose concentration and specific activity. Additionally, 10min before the end
of clamp studies [14C]-lactate was administered intravenously for determination of hepatic
14C-phosphoenolpyruvate and 3H/14C-UDPglucose by HPLC. Results: There was no differ-
ence (mean±SEM) in body weight (g) attributable to PC-TP expression (KO 31.1±0.5;WT
31.0±0.4). Whereas in KO mice whole body adiposity (%BW) was increased by 46% (KO
23.3±1.1;WT 15.9±1.2,P<0.001), epididymal fat pad weight (mg/g BW) was reduced by
25% (KO 6.4±0.4;WT 8.5±0.5,P<0.003). In order to maintain euglycemia, KO mice required
an 89% increase in glucose infusion rates (GIR,mg/kg/min) (KO 56.4±3.5;WT
29.9±5.8,P<0.003). However, there was no difference in the rate of peripheral glucose uptake
from plasma (mg/kg/min) (KO 58.6±2.9;WT 56.0±5.1). Rather, the increase in GIR in KO
mice was explained by a profound 92% reduction in hepatic glucose production (mg/kg/min)
(KO 2.1±1.8;WT 26.0±4,P<0.0003) that was attributable to decreases in gluconeogenesis
and glycogenolysis of 85% (KO 1.5±1.1;WT 10.0±2.8,P<0.03) and 96% (KO 0.7±0.8;WT
16.1±3.5,P<0.003), respectively. Conclusions: Decreased visceral adiposity in the setting
of increased total body fat presumably explains increased plasma leptin and adiponectin
concentrations in KO mice. Consistent with the biological activities of these adipokines as
sensitizers of liver to insulin action, there was a marked decrease in HGP (gluconeogenesis
and glycogenolysis) in KO mice during the clamp study. We speculate that PC-TP is a
critical regulator of fatty acid homeostasis as well as triglyceride distribution, which in turn
controls hepatic insulin signaling and glucose metabolism.
M2118
Effect of the Angiotensin Receptor Blocker, Telmisartan, On Human
Gallbladder Motility
Yvonne F. Finn, Mary A. Neylon, Luke J. O'donnell
Background-Gallbladder motility has been shown to be controlled and modulated by various
hormones and neurotransmitters. Angiotensin receptor blockers are a newer class of antihy-
pertensives which act by blocking the angiotensin II type 1 receptors. This effect is achieved
by their action on vascular tissue smooth muscle receptors. The effects of angiotensin receptor
blockers on gallbladder smooth muscle and motility is unknown. Aims-To determine the
effect of telmisartan, an angiotensin receptor blocker, on gallbladder motility in healthy
subjects in a randomised single blind paired study. Methods- Ethics approval was obtained
at both national and local levels. Twelve healthy male volunteers were randomly assigned
to take telmisartan (t1/2, 24 hours) 40mg (Micardis, Boehringer Ingelheim) at 10pm on one
evening and no medication on the other evening prior to measurement of gallbladder volumes
by ultrasonography. Fasting gallbladder volume was measured at 8 AM, subjects were then
given a proprietary liquid feed (Ensure Plus 200 mls) and gallbladder volumes were measured
every five minutes for fifty minutes. Nonparametric-paired data were analyzed using the
Wilcoxon matched-pairs signed rank test. Values <0.05 were considered significant. Results-
In ten out of the twelve subjects there was an increase in fasting gallbladder volume
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after telmisartan compared with no medication. Telmisartan significantly increased fasting
gallbladder volume to a mean of 109.9% of pre-treatment volume (p<0.001). In eight out
of the twelve subjects there was an increase in postprandial residual volume after telmisartan
compared with no medication. Telmisartan significantly increased residual gallbladder vol-
ume to a mean of 112.8% of pre-treatment volume (p<0.05). None of the twelve subjects
reported any side-effects from the ingestion of a single dose of telmisartan 40mg. Conclusions-
This study shows that a single dose of telmisartan 40mg significantly increases fasting and
postprandial residual gallbladder volumes in healthy subjects. These findings may have
significance for gallstone formation in patients on longterm angiotensin receptor blocker
hypertensive treatment.
M2119
Ursodeoxycholic Acid (UDCA) Stimulates Intestinal Fibroblast Growth Factor
15 (Fgf-15) Expression Independent of the Farnesoid X Receptor (FXR)
Martin Wagner, Tarek Moustafa, Peter Fickert, Gernot Zollner, Judith Gumhold, Dagmar
Silbert, Andrea Fuchsbichler, Helmut Denk, Michael Trauner
Background & Aim: Fgf-15 signals from the ileum to the liver resulting in repression of
hepatic bile acid biosynthesis via reduction of Cyp7a1, stimulation of hepatic β-oxidation
of fatty acids via reduction of acetyl CoA carboxylase 2 (Acc2) and modulation of gallbladder
filling (Inagaki et al., Cell Metabolism 2005; Fu et al., Endocrinology 2004; Choi et al.,
Nature Medicine 2006). Fgf-15 is secreted in the terminal ileum upon induction of its
expression by natural or synthetic FXR ligands. Since FXR agonists may be promising future
therapeutics in treatment of cholestatic and metabolic liver disease, we aimed to investigate,
whether UDCA, the current gold standard in the treatment of cholestasis and a weak FXR
agonist, is capable of inducing Fgf-15 and whether this depends on FXR. Methods: FXR+/
+ and FXR-/- mice were fed a diet supplemented with UDCA (1% w/w) or - for comparison
- cholic acid (CA) (1% w/w). In addition, FXR+/+ and FXR-/- mice were subjected to
common bile duct ligation (CBDL), resulting in disruption of the enterohepatic bile acid
circulation. Expression of ileal Fgf-15 and its hepatic target genes, Cyp7a1 and Acc2 were
determined by Taqman RT-PCR. Results: Ileal Fgf-15 baseline levels were significantly
reduced in FXR-/- (12% of FXR+/+, p<0.05), while Cyp 7a1 baseline levels were significantly
induced in FXR-/- (160% of FXR+/+, p<0.05). Acc2 levels did not significantly differ between
both genotypes under baseline conditions. CA significantly induced Fgf-15 in FXR+/+ (82-
fold) and FXR-/- (9-fold, p<0.05). UDCA also significantly stimulated Fgf-15 in both FXR+/
+ (22-fold) and FXR-/- (9-fold of baseline control; p<0.05). In line with ileal Fgf-15 induction,
both CA and UDCA repressed hepatic Cyp7a1 levels in FXR+/+ (7% and 7% of untreated
FXR+/+, respectively, p<0.05) and to smaller extent in FXR-/- (26% and 41% of untreated
FXR-/-, p<0.05). In CBDL FXR+/+ and FXR-/- ileal Fgf-15 was completely lost, while hepatic
Cyp7a1 levels were slightly induced in FXR+/+ and to greater extent in FXR-/-. Neither bile
acid feeding nor CBDL significantly altered hepatic Acc2 expression levels. Summary and
Conclusions: Fgf-15 baseline expression depends on FXR. UDCA and CA induce ileal FGF-
15 in FXR+/+ and FXR-/- suggesting additional FXR-independent mechanisms for Fgf-15
regulation. Therapeutic properties of UDCA in man may at least in part, be related to ileal
Fgf-19 induction, the human orthologue of Fgf-15 Further studies in humans are warranted
to explore the potential role of FGF-19, in cholestasis and its modulation by anti-choles-
tatic therapies.
M2120
Effects of ATP On Membrane Potential and Action Potential Frequency in
Guinea Pig Gallbladder Smooth Muscle
Aaron C. Bartoo, Mark T. Nelson, Gary M. Mawe
Adenosine 5-triphosphate (ATP) is a ubiquitous signaling molecule found throughout the
nervous system and gastrointestinal tract where it contributes to neurotransmission and
intestinal motility. In the urinary bladder it is released from urothelial cells leading to
modulation of smooth muscle function. Previous studies in the guinea pig gallbladder have
provided evidence that ATP is a signaling molecule that contributes to gallbladder motility.
However, the mechanisms of ATP actions in the gallbladder are unknown. Intracellular
microelectrode recordings were performed on guinea pig gallbladder muscularus preparations
devoid of mucosa to determine the effects of ATP on gallbladder smooth muscle (GBSM).
Application of ATP (100μM) caused a modest depolarization of the GBSM (4.6±1.3mV) and
an excitatory period characterized by a significant increase in action potential frequency
(0.38±0.08Hz control vs. 0.63±0.05Hz ATP; p=0.007 paired t-test, n=6). In 3 of 5 cells in
which prolonged recordings were maintained, ATP induced a biphasic response in which
a hyperpolarization associated with a decrease in action potentials was observed (4-6 minutes
after the application of ATP). The ATP induced excitatory response was not altered by
tetrodotoxin (TTX; 0.5μM, n=2) and persisted in the presence of the non-selective P2X
antagonist, PPADS (30μM, n=3). However, suramin (100μM; n=3) antagonized the excitatory
response and led to an augmentation in the inhibitory component of the ATP response.
These results suggest that ATP acts directly on GBSM, possibly via a P2 receptor, to induce
gallbladder contraction. ATP may also contribute to gallbladder relaxation through a suramin-
insensitive mechanism. These findings support the concept that ATP, released from nerves
and/or gallbladder epithelial cells, could influence gallbladder motility. Supported by NIH
grant NS26995.
M2121
Hepatic Bile Acid Transporters Are Down Regulated in Experimental
Necrotizing Enterocolitis
Ludmila Khailova, Nathan Cherrington, Dania Molla hosseini, Bohuslav Dvorak, Melissa
Halpern
Background: Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease
of premature infants. We have recently shown that accumulation of ileal bile acids (BAs)
contributes to intestinal damage in experimental NEC via dysregulation of ileal BA trans-
porters. Enterohepatic circulation of BAs also requires secretion of BAs from the liver into
bile via the bile salt excretory pump (Bsep) and multi-drug-resistance-associated protein 2
(Mrp2) as well as uptake of BAs from portal blood back to the liver via the sodium-dependent
taurocholate transporting polypeptide (Ntcp) and members of the organic anion-transporting
polypeptide (Oatp) family. We have previously shown that hepatic TNF-α plays an important
role in NEC pathogenesis and neutralization of TNF-α markedly reduces the severity and
incidence of NEC. Importantly,TNF-α has been shown to down-regulate hepatic BA trans-
porters. Objective: To determine if hepatic BA transporters are altered during experimental
NEC. Methods: Prematurely born rats were divided into the following experimental groups:
DF (n = 8) - pups allowed to feed from the mother and exposed to asphyxia and cold stress
twice per day (A/C); NEC (n = 8) - pups hand-fed with formula and exposed to A/C; and
NEC + anti-TNF-α (n = 8) - pups hand-fed with formula, exposed to A/C and injected with
5 mg/kg anti-TNF-α. After 4 days, the liver from each rat was removed and mRNA expression
of Bsep, Mrp2, Ntcp, Oatp2 and Oatp4 was assessed using the Quantigene signal amplification
assay. Percent incidence of NEC was determined via histological evaluation by a blinded
observer of distal ileum from each animal using a scale of 0 (normal) - 4 (full necrosis).
Animals with a histological damage score of 2 or greater were considered NEC positive.
Results: Ntcp, Oatp4 and Mrp2 mRNA were significantly decreased in rats with NEC
compared to DF animals; Bsep, and Oatp2 were unchanged. While Ntcp mRNA levels were
up-regulated in animals with NEC given anti-TNF-α, Oatp4 and Mrp2 levels remained low
after neutralization of TNF-α. Conclusion: Hepatic BA transporters are down-regulated
during the development of experimental NEC. While down-regulation of Ntcp may be a
consequence of elevated TNF-α, the data suggests that another factor may down-regulate
Oatp4 and Mrp2 in NEC. Supported by NIH grant HD047237.
Data are expressed as mean RLU/5mg total RNA (SD). *p ≦ 0.05 vs DF; #p ≦ 0.05 vs NEC.
M2122
Effect of VIP-Induced Relaxation and Phosphorylation of Hsp20 On
Acetylcholine-Induced, Pkc-Mediated Phosphorylation of Caldesmon in
Colonic Smooth Muscle
Sita Somara, Robert R. Gilmont, Khalil N. Bitar
Background: Acetylcholine (Ach)-induced contraction is associated with phosphorylation
of HSP27 which is crucial for phosphorylation of PKCα, caldesmon (CD) and association
of caldesmon with HSP27. Vasoactive Intestinal Peptide (VIP)-induced relaxation is associated
with phosphorylation of HSP20. Objective: To understand the effect of VIP-induced HSP20
phosphorylation in altering the role of CD to facilitate relaxation. Methods: Smooth muscle
cells (CSMC) were freshly isolated from rabbit colon and transfected with phospho-HSP20
cDNA (16S/D) and non-phospho-HSP20 cDNA (16S/A). Results:1) In freshly isolated CSMC,
a) Ach-induced: an increase in the phosphorylation of: PKCα (ser657), Caldesmon (ser789),
HSP27 (ser82) and an increase in MLC20 (ser19) phosphorylation which were inhibited by
preincubation of the cells with relaxant neurotransmitter, VIP; 2) In CSMC transfected with
non-phospho-HSP20 cDNA(16S/A), Ach induced: a) increase in the association of HSP20 with
phosphorylated caldesmon (ser789); b) no difference in the association of HSP20 with
PKCα; while VIP induced: a) decrease in the association of HSP20 with phosphorylated
caldesmon (ser789); b) increase in the association of HSP20 with PKCα; 3) In CSMC
transfected with phospho-HSP20 cDNA (16S/D), Ach induced a) no difference in the association
of HSP20 with phosphorylated caldesmon (ser789); b) increase in the association of HSP20
with PKCα; while VIP induced a) increase in the association of HSP20 with phosphorylated
caldesmon (ser789); b) no change in the association of HSP20 with PKCα. Summary: a)
Ach-induced a rapid and sustained increase in phosphorylation of MLC20 (ser19), HSP27
(ser82), CD (ser789), and PKCα (ser657) which were inhibited by preincubation of the
cells with VIP. Transfection of smooth muscle cells with either phospho-HSP20 cDNA or
non-phospho-HSP20 cDNA induced a different pattern of association of HSP20 with both
phospho-caldesmon and PKCα. Conclusion: We thus propose that phosphorylation of
HSP20 during relaxation attenuates the kinase activity of PKCα which is essential for the
acetylcholine-induced phospho-caldesmon-mediated contraction of colonic smooth muscle.
Supported by NIH grant R01 DK057020
M2123
Effect of Lubiprostone On Rat and Human Colon Muscle; Possible
Involvement of Prostaglandin Ep Receptors
Anna K. Bassil, R. Thangiah, Richard A. Borman, Emma M. Jarvie, S. Vivekanandan, O.
Lalude, E. Z. Sung, P. Baragwanath, L. S. Wong, C. U. Nwokolo, Kevin Lee, Gareth J.
Sanger
Lubiprostone is a ClC-2 channel opener derived from prostaglandin E1 (PGE1) and is
indicated for treatment of constipation. However, it has recently been shown that lubiprostone
affects gastric smooth muscle tone, possibly via activation of prostaglandin E2 (EP) receptors
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(Bassil et al. 2007, Br J Pharmacol, In press). The aim of this study was to investigate the
effects of lubiprostone on colon smooth muscle from rat and human, and to investigate the
role of EP receptors in any such effects. Longitudinal or circular muscle strips from rat or
human colon were suspended in tissue baths in Krebs solution (37°C; 5% CO2 in O2) for
isometric recording. All samples of human colon were obtained from patients after fully
informed consent. The effect of increasing concentrations of lubiprostone (0.1nM-10µM)
was investigated on either basal tone or neuronally-mediated contractions (evoked by elec-
trical field stimulation (EFS) at 50V, 5Hz, 0.5ms for 10s every 60s), either in the absence
or presence of antagonists selective for EP receptors. In rat and human colon, lubiprostone
caused inhibition of EFS-induced contractions in circular muscle strips, with a pEC50 of
8.9±0.4 and 8.9±1.0 and maximal inhibition of 67±3 and 76±8% (n=7 and 5 respectively).
Pre-treatment with a selective EP4 receptor antagonist (GW627368X, 1µM which had no
effect on its own) reduced this inhibitory action (pEC50 of 6.7±1.1 and 7.8±0.1 respectively).
In rat colon longitudinal muscle, lubiprostone (10nM-10µM) caused direct contraction
(maximum at 10µM of 140±74% of the response to 1µM PGE2) and in some tissues,
potentiation of EFS-evoked contractions (n=5). In human colon longitudinal muscle, lubipro-
stone caused potentiation of EFS-evoked contractions, with a pEC50 of 6.5±0.6 (n=6) and
a maximum potentiation (at 10µM) of 320±106%. These excitatory effects were inhibited
by prior application of an EP1 receptor antagonist (GW567657X, 1µM, which had no effect
on its own), reducing the 10 µM lubiprostone-induced contraction in rat colon to 58±25%
of PGE2 and the potentiation of electrically-evoked contractions in human colon to 62±41%.
In summary, lubiprostone produces dual effects in both rat and human colon, consisting
of excitatory effects in longitudinal muscle and inhibitory effects in circular muscle. These
effects are mediated by EP1 and EP4 receptors respectively, and may contribute to the
clinical effects of lubiprostone in man.
M2124
Involvement of Prostanoids in the Ability of Lubiprostone to Stimulate Rat
Colonic Fluid Secretion In Vitro
Richard A. Borman, Anna K. Bassil, Emma M. Jarvie, Kevin Lee, Gareth J. Sanger
Lubiprostone is a selective ClC-2 chloride channel opener derived from prostaglandin E1
(PGE1), which increases chloride transport and thereby enhances fluid secretion into the
intestinal lumen. It is indicated for the treatment of constipation. However, it has been
reported that lubiprostone affects smooth muscle activity in the GI tract, and that its
mechanism of action may include activation of prostaglandin E2 (EP) receptors (Bassil et
al 2007, Br J Pharmacol, In press; Bassil et al, This meeting). The aim of this study was to
investigate the possible role of EP receptors in the secretory response to lubiprostone of rat
colonic mucosa. Full-thickness preparations of rat mid-distal colon were mounted in Ussing
chambers, bathed at either side by Krebs solution (37°C; 5% CO2 in O2), for measurement
of short-circuit current (Isc, an indicator of electrogenic fluid secretion). The effects of
lubiprostone (0.1nM - 10µM, applied either apically or basolaterally), on Isc were investigated
in the absence and presence of EP receptor antagonists. The receptor antagonists applied
both sides of the mucosa were: GW567657X (1µM; EP1 antagonist), AH6809 (10µM; EP1,2
and 3 antagonist), L-798,106 (1µM, EP3 antagonist) and GW627368X (1µM; EP4 antagonist).
Application of lubiprostone caused in increase in Isc after both apical and basolateral
application, with a pEC50 of 8.4±0.6 and 8.1±0.1 respectively (both n=6). In the presence
of antagonists of EP1-4 receptors (added together, which on their own had no effect on
Isc), the maximum secretory response to apical lubiprostone increased from 64±9µA.cm-2
to 129±16µA.cm-2 (p<0.05, n=6). In contrast, the maximum secretory response to basolateral
lubiprostone was not enhanced by the antagonists, but there was a significant decrease in
the potency, with a pEC50 in the presence of EP1-4 receptor antagonists of 7.4±0.3 (p<0.01,
n=6). These data confirm that, in full thickness preparations of rat colon, lubiprostone causes
an increase in Isc, consistent with enhanced chloride secretion. After apical application, the
secretory response to lubiprostone was increased by EP receptor antagonists, whilst in
contrast the secretion induced by basolateral application was inhibited by EP receptor
antagonism. This shows for the first time that the mechanisms underlying the secretory
effects of apical and basolateral lubiprostone may differ, and that the latter may involve
activation of EP receptors.
M2125
Segmental Accommodation and Clearance of Colonic Gas in Healthy Subjects
and Patients with Bloating
Fabrizio Tremolaterra, Carolina Malagelada, Jordi Serra, Fernando Azpiroz, Marta Mila,
Santiago Aguade, Juan-r. Malagelada
By means of a challenge test with jejunal gas loads we have previously shown that patients
with abdominal bloating (irritable bowel syndrome and functional bloating) exhibit impaired
gas transit through the small bowel. Our aim was to determine if segmentary distribution
and clearance of colonic gas is also impaired in these patients. METHODS. In 9 patients
with abdominal bloating, and 9 healthy subjects, a gas mixture (N2, CO2 , O2 in venous
proportions) marked with 74 MBq of 133Xe was continuously infused at 24 ml/min into
the rectum for 1 h, while rectal gas outflow was blocked (accommodation period). Thereafter,
gas infusion was stopped and free rectal gas evacuation was allowed for 30 min (gas clearance
period). During the study, volume and distribution of colonic gas was measured by abdominal
scintigraphy. RESULTS: During the accommodation period colonic gas was distributed along
all segments of the colon, without appreciable differences between patients and healthy
controls (Table I). During the gas clearance period patients expelled less gas than healthy
controls (final gas retention 414 ± 57 ml vs 279 ± 39 ml in health, p<0.05). Impaired
colonic gas clearance was largely due to an abnormally large gas retention in the proximal
colon (Table II). CONCLUSION: Patients with abdominal distension have normal accom-
modation to colonic gas, but impaired clearance of retained gas, mostly due to propulsive
failure in the proximal colon.
Table I. Gas distribution (in ml) after accomodation period
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Table II. Gas distribution (in ml) after gas clearance period
Data are mean±SEM * p<0.05 vs health
M2126
Small Intestinal Bacterial Overgrowth in Patients with Interstitial Cystitis and
Gastrointestinal Symptoms
Leonard B. Weinstock, Carl G. Klutke, Henry C. Lin
Introduction and Objective: Irritable bowel syndrome (IBS) patients often have interstitial
cystitis (IC), a disabling syndrome of pelvic pain, urgency and frequency with evidence of
immune activation and bladder hypersensitivity. Small intestinal bacterial overgrowth (SIBO)
may explain extraintestinal symptoms in IBS by increased intestinal permeability, immune
activation and visceral hypersensitivity. This prospective, pilot study tested hypotheses that:
1) IC patients with chronic gastrointestinal (GI) symptoms may have abnormal bacterial
fermentation to suggest SIBO; 2) a non-absorbable, gut-active antibiotic and subsequent
prokinetic therapy may improve symptoms. Methods: Consecutive, established IC patients
with chronic active GI symptoms completed questionnaires and had a lactulose breath
test (LBT). Those with abnormal LBT were offered rifaximin 1200-1800-mg/day/x10-days
followed by tegaserod 3-mg/nightly. Questionnaires addressed IC and GI global improvement
at time of completion of rifaximin and at the end of the study (mean 122 days; range 62-
162). Results: Of 21 patients evaluated, 17 (81%) had an abnormal LBT. In 15 patients
treated, GI global improvement immediately after rifaximin was a combined moderate-great
in 11 (73%) which was sustained in 10 (67%). IC global improvement was a combined
moderate-great in 6 (40%) and mild in 6 (40%) immediately after rifaximin. Combined
moderate-great IC global improvement was sustained in 7 (47%). Conclusions: A majority
of IC patients with GI symptoms were found to have an abnormal LBT suggesting SIBO.
IC and GI symptoms improved after 10-days of rifaximin and appeared to be maintained
by prokinetic therapy. A placebo-controlled study is underway to evaluate SIBO and IC.
M2127
Association of a Gnbeta3-C825t Genotype and Symptom Patterns in Patients
with Irritable Bowel Syndrome
Tobias Liebregts, Birgit Adam, Montri Gururatsakul, Christoph Bredack, Susan Lester,
Sarah Downie-doyle, Julia G. Junne, Winfried Siffert, Gerald Holtmann
Background: Functional gastrointestinal disorders such as Irritable Bowel Syndrome (IBS)
represent heterogeneous disorders with most likely different pathophysiological mechanisms
and distinct clinical manifestations. A C825T polymorphism in the GNB3 gene is known
to modulate receptor cell coupling in a broad spectrum of systems including adrenergic,
serotoninergic and opioidergic function. We have previously demonstrated (Gastroenterology
2004; 126, 971-979) that a homozygous GNB3 825C carrier status is associated with
functional dyspepsia, while the association with IBS symptoms remains controversial. Thus,
we aimed to compare the GNB3 genotype and allele frequencies in IBS patients and healthy
controls and to explore potential associations with specific clinical manifestations. Methods:
GNbeta3-C825T polymorphism was determined in 126 consecutive patients (all Caucasian)
with IBS (Rome II) referred for evaluation and treatment at a tertiary center and in 148
population based controls utilizing PCR-RFLP methods. Patients were categorized based
upon their symptoms utilizing the standardized Bowel Disease Questionnaire. The association
between the following symptoms and the GNB3 genotypes were determined: a) pain associ-
ated with more bowel movement b) pain associated with less bowel movements, c) >3 bowel
movements/day, d) <3 bowel movements/week, e) loose/watery stools, f) hard/lumpy stools,
g) incomplete evacuation and h) urgency. Results: Overall genotype distribution and allele
frequencies did not differ between patients with IBS (CC: 41.5%, CT: 43.6%, TT: 14.9%;
C 0.633, T 0.367) and healthy subjects (CC: 43.3%, CT: 48%, TT: 8.7%; C 0.673, T 0.327).
The GNB3 T allele was significantly associated with incomplete evacuation (OR 2.24, 95%
CI 1.02-4.87, p=0.033) and <3 bowel movements/week (OR 2.62, CI 95% 1.02-6.73, p=
0.04), while the C allele was associated with >3 bowel movements/day (OR 2.57, CI
95% 1.28-7.1, p=0.02) and urgency (OR 2.82, CI 95% 1.18-7.3,p=0.016). No significant
associations were found for any other symptom. Summary and Conclusion: Confirming
previous results from another group (Andresen V. et al. Gastroenterology 2006;130:1985-
94) genotype frequency does not differ between patients with IBS and healthy subjects.
However, consistent with the concept of a heterogeneous condition there are clear associations
between symptoms and GNB3 allele frequencies with C being linked to diarrhea and T
being associated with constipation. These data allow speculating on a genetic susceptibility
for the development of specific symptom patterns in patients with IBS.
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M2128
Body Mass Influence On Colonic Sensory-Motor Function and Gastrointestinal
Transit: A Study of 165 Healthy Participants
Silvia Delgado-aros, Irene Busciglio, Montse Andreu garcia, Duane Burton, Michael
Camilleri
Background: Increased body mass has been associated with decreased satiety and symptoms
after a standardized meal suggesting reduced visceral sensation. Community studies have
revealed increased diarrhea in overweight and obese subjects. The pathophysiology and
mechanisms underlying decreased visceral perception and diarrhea in association with
increased body mass are unknown. Aim: To assess the effect of body mass on colonic
sensory and motor functions and gastrointestinal transit in humans. Methods: We retrospect-
ively reviewed the data acquired over the period 2000-2006 from healthy obese and non-
obese subjects who underwent standardized measurement of colonic tone, compliance and
perception of colonic distensions using a barostat technique with ascending method of limits
and random order phasic distensions. Fasting and postprandial colonic tone were also
measured. Gastrointestinal transit was measured using a validated scintigraphic method and
summarized as gastric emptying at 4h (GE4), colonic filling at 6h (CF6), and colonic
geometric center at 24 h (GC24). We used regression analysis to assess the association of
body mass with transit and colonic sensory and motor parameters. Results: Among 165
participants (87 females and 78 males), median age was 28 y (range: 18-63) and median
BMI was 25 Kg/m2 (range: 17-44). Increased BMI was associated with decreased colonic
compliance (p<0.0006, adjusted for gender and age) and decreased pain during colonic
distensions (p=0.02, adjusted for gender, age, stress and colonic volumes during distensions).
The pressure threshold for pain was also higher with increased BMI (p=0.042, with same
adjustments), consistent with decreased sensation. Sensory ratings and pressure threshold
for gas were not significantly affected by BMI. There was no significant association of BMI
and transit parameters, colonic fasting tone or colonic contraction after meal ingestion,
although intestinal and colonic transit tended to be faster (p=0.077,adjusted by gender) in
heavier subjects (table). Conclusions: Increased body mass is associated with decreased
colonic compliance, and decreased colonic sensation, but there is no significant effect on
fasting and postprandial colonic tone or gastrointestinal or colonic transit. While the reduction
in compliance may reflect effect of visceral or abdominal wall fat, the mechanism for decreased
colonic sensation with increased BMI requires further study.
M2129
Changes in Sympathetic Neural Signaling in Chronic-Acute Combined Stress
Rat Model of IBS May Be Responsible for Abnormal Motility, Secretion and
Sensory Perception
Ning Zou, Hong Lv, Ji Li, Jiaming Qian
Abnormal colonic motility, visceral hypersensitivity and enhanced mucosa secretion are
important features of irritable bowel syndrome (IBS). The mechanisms responsible for these
abnormalities are not well understood. Sympathetic neural abnormalities have been reported
in IBS. Alpha 2 adrenoceptors (alpha2-ARs) are expressed in presynaptic terminals, intestinal
mucosa and muscle. Activation of alpha2-ARs inhibits neurotransmitter release, decrease
mucosa secretion and colonic motility. Specific norepinephrine reuptake transporter (NET)
which is responsible to terminate the action of NE (a sympathetic nerve transmitter) is
present in the nerve terminals of NE containing neurons. It is conceivable that abnormalities
of expression of alpha2-ARs and NET may be responsible for abnormal motility and visceral
sensation and secretion in IBS. To examine this possibility a well established rat model of
IBS were subjected to acute stress (AS) or chronic stress combined with acute stress (CAS).
Colonic motility was assessed by counting fecal pellets, epithelial secretion by In Vitro mucosa
short circuit current study and visceral sensation by abdominal muscle contractions in
response to colorectal balloon distension (CRD). Western blot analysis was used to investigate
the expression of alpha2-ARs and NET in the distal colon specimens. Colonic epithelial
secretion was significantly higher in colon tissues obtained from AS and CAS rats(47.13±4.55,
61.77±46.53 vs 33.43±4.01µA/cm2, n=6, p<0.01). In both group of rats, the fecal pellets
(5.86±0.51, 7.14±0.91 vs 0.50±0.34/hr, n=6, p<0.01) and numbers of abdominal muscle
contraction induced by CRD (22.86±1.72, 27.43±1.53 vs 14.33±1.12/five minutes, n=6,
p<0.01) were increased compared with control. Western blot analysis showed that the
protein expression of alpha2-ARs was lower in the CAS rats compared with AS rats and
control(0.296±0.123 vs 0.769±0.151 and 1.168±0.358, n=6, p<0.05). At the same time the
protein expression of NET was decreased in both AS and CAS rats (0.180±0.219, 0.198±0.264
vs 0.356±0.395, n=6, p<0.01). In conclusion, using a rat model of IBS, we showed that
exposure to AS and CAS caused an increase in secretion motility and visceral perception.
These changes were accompanied by a decrease in expression of alpha2-ARs and NET. These
changes in NE receptors and metabolism may be responsible for the pathogenesis of IBS.
M2130
Mucosal Serotonin Signaling Is Altered in Chronic Constipation
Meagan M. Costedio, Peter L. Moses, Elice Brooks, Lisa M. Glass, Michael Wood, Eric K.
Ganguly, Matthew D. Coates, Christian A. Speer, Neil H. Hyman, Gary M. Mawe
Serotonin (5-HT), released from enterochromaffin (EC) cells, stimulates nerve fibers in the
lamina propria to activate local motor, secretory and vasodilatory reflexes, and to stimulate
signals sent to the central nervous system. Changes in 5-HT signaling have been reported
in various intestinal disorders, including irritable bowel syndrome (IBS) and ulcerative colitis
(UC). The aim of this study was to test the hypothesis that 5-HT signaling is altered in
chronic constipation (CC). Rectal mucosal biopsy samples were collected from healthy
individuals undergoing screening colonoscopy (n=25) and from individuals experiencing
constipation (<3 bowel movements/week) in which pain was not a predominant symptom
(n=20). Samples were evaluated for EC cell numbers, 5-HT content, and basal and stimulated
5-HT release. Transcript levels for the 5-HT synthetic enzyme, tryptophan hydroxylase-1
(TpH1) and the 5-HT-selective reuptake transporter (SERT) were determined using real-
time quantitative PCR. Significant increases in 5-HT content, basal release, and stimulated
release were detected in CC samples, and consistent with this, an increase in TpH1 RNA
was detected in this group. However, mechanical stimulation resulted in a less dramatic
enhancement of 5-HT release in CC (1.6 fold increase) than in control samples (1.9 fold).
No differences in EC cells per gland, per epithelial cell, or per mm muscularis mucosa were
detected. Furthermore, SERT transcript levels were not significantly changed in CC. These
results suggest that EC cells in CC contain higher levels of 5-HT and this could explain the
enhanced release that was detected. The reduced effect of stimulation upon release in CC
compared to controls, however, suggests an impairment of mechanisms involved in active
release of 5-HT resulting in less efficient 5-HT release in CC. Unlike previous data obtained
from IBS and UC samples, SERT transcript levels were not altered in CC. It is possible that
increased 5-HT availability, resulting from increased synthesis and release without a change
in the uptake capacity, could lead to a desensitization of 5-HT receptors. Resultant attenuation
of motor and secretory reflexes may contribute to CC. It is also possible that 5-HT synthesis
is upregulated in response to constipation in order to augment motor and secretory activity.
Supported by Novartis Pharmaceuticals
M2131
Propagated Colon Contractions Induced By Jejunal Gas Perfusion in Healthy
Humans: A 5-HT3 Mediated Neural Colonic Reflex for Expulsion of Excess
Luminal Gas
Radoslav Coleski, William L. Hasler
Background: Recent studies of gas transit in healthy humans and IBS patients give insight
into the pathogenesis of bloating. Serotonin 5-HT3 pathways mediate many gut reflexes,
but neural control of gas transit is poorly understood. In healthy humans, we showed that
rectal gas evacuation during jejunal gas perfusion is pulsatile suggesting that propulsive
contractions promote expulsion. Hypotheses: We hypothesized (i) jejunal gas perfusion
elicits propagated colon contractions that stimulate gas evacuation and (ii) gas perfusion-
evoked colon contractions are mediated by 5-HT3 pathways. Methods: Perfusion catheters
were placed jejunally and manometry catheters with ports every 10 cm were colonoscopically
placed to the transverse colon under midazolam in 5 healthy humans. Each subject had a
control study and a study after the 5-HT3 antagonist granisetron (10 μg/kg IV). After 1 hr
basal manometry, jejunal gas perfusion (88% N2, 5.5% O2, 6.5% CO2) at 12 ml/min was
performed x 4 hr with ongoing manometry and measurement of rectal gas expulsion. Results:
In control basal recordings, colon contractions >25 mmHg occurred at 0.11±0.03/min with
pressures of 37±2 mmHg. 42±6% of contractions showed antegrade propagation. After
initiating gas perfusion, rectal evacuation was pulsatile with 40±3 boluses expelled (mean
volume: 74±5 ml; mean pressure: 2.8±0.3 mmHg). Contractions increased to 0.28±0.03/
min (P=0.05) and contractile pressures trended higher (48±3 mmHg, P=0.07). 87±2% of
expulsions were temporally related to contractions and had higher volumes (77±6 ml) and
pressures (3.0±0.4 mmHg) vs. those without contractions (52±5 ml, 1.6±0.3 mmHg, P<0.01).
During expulsions, propagated contractions increased (85±5%, P<0.03). Gas retention at
the end of perfusion was -36±104 ml. Basal contractions were less after granisetron
(0.03±0.02/min, P<0.05). Granisetron reduced bolus numbers during gas perfusion (25±5,
P<0.05) but did not affect bolus volumes (73±7 ml) or pressures (3.2±0.6 mmHg). Contrac-
tions during perfusion trended lower (0.19±0.03, P=0.08) but contractile pressures and %
of contractions that propagated were unaffected by granisetron. Final gas retention was
higher (1011±402 ml, P<0.05). Conclusions: Jejunal gas perfusion evokes propagative colon
motor activity in healthy humans that relates temporally to rectal bolus gas expulsions with
decreased gas retention. Granisetron promotes gas retention by reducing bolus expulsions
and decreasing propagating colon contractions. This suggests the presence of a 5-HT3
mediated neural colonic reflex to facilitate expulsion of excess colonic gas. Further studies
will test if this reflex is defective in IBS.
M2132
Repeated Rectal Distention (Rrd) Induces Visceral Hypersensitivity in Irritable
Bowel Syndrome (IBS) Patients; Possible Contribution of Corticotropin-
Releasing Factor (CRF)
Tsukasa Nozu
BACKGROUND: Visceral hypersensitivity induced by stress plays an important role in the
pathophysiology of IBS (Gastroenterology 112:55,1997). CRF is a key factor modulating
stress response (Pharmacol. Rev. 43:425,1991). AIM: To evaluate whether RRD (stress) and /
or CRF induces rectal hypersensitivity in humans. METHODS: In experiment 1, rectal pain
threshold (PT) was assessed by barostat with ramp distention (40 ml/min) before (basal
condition) and after RRD in IBS (n=7), functional abdominal pain syndrome (FAPS, n=6)
and controls (n=14). RRD consisted of phasic distentions (semirandomly ascending pressure
distentions of 60-sec duration separated by 30-sec intervals at the resting pressure of 0
mmHg) were given with tracking method until the subjects reported pain 6 times. Normal
values were defined by the 95% confident intervals of controls. Experiment 2 was conducted
to determine the effect of CRF on PT in controls (double-blind placebo-controlled study
design). PT was measured, and then CRF (100 μg, n=5) or vehicle (n=6) was injected
intravenously (iv) followed by RRD. After RRD, PT was measured again. In another experi-
ment, after basal PT was measured, CRF (n=5) or vehicle (n=5) was injected iv without
RRD. After 45 min, PT was determined again. RESULTS: Experiment 1: 5 of 7 IBS patients
and 1 FAPS patient showed rectal hypersensitivity in the basal condition. All patients with
IBS developed hypersensitivity after RRD, however, none of the FAPS patients did. RRD
significantly reduced PT in IBS group but did not change in controls and FAPS group.
Experiment 2: PT was not modified by RRD in placebo group, while it significantly reduced
in CRF-treated group. On the other hand, CRF or vehicle without RRD did not alter PT
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(table). CONCLUSIONS: RRD-induced rectal hypersensitivity seems to be reliable marker
for IBS. CRF mimicked the IBS patient-specific visceral response induced by RRD in healthy
humans, suggesting CRF may contribute to this response.
Effects of repeated rectal distention (RRD) and/or intravenous CRF on rectal pain threshold.
*:P < 0.05 vs before RRD, #: P < 0.05 vs respective controls (n = 5-14, Mean±S.E.).
M2133
Right-to-Left Shunting Through a Cardiac Patent Foramen Ovale and Irritable
Bowel Syndrome:Is There Any Relationship?
Onofre Alarcón, Jesus andres Alvarez fernandez, Raquel Perez-quintero, Juan salvador
Baudet, Elisa Borja, Pilar Borque, Dacil Diaz, Antonio Sanchez del rio
BACKGROUND:Recent studies have linked irritable bowel syndrome -IBS- with the increase
of plasma levels of some proinflammatory cytokines and other vasoactive peptides. In the
presence of a patent foramen ovale -PFO-,right to left shunting -RLSh- may cause that a
percentage of venous blood bypasses the lung filter and so increases some of these proinflam-
matory substances in blood. Moreover, both IBS and PFO have similar prevalence in general
population, affect more commonly women,decreases with age and are related with comorbidi-
ties such as migraine. So we hypothesized that RLS through a PFO could be more prevalent
in patients with IBS. METHODS:We prospectively evaluated the prevalence of RLSh in 95
functional patients from our Unit. 33 patients fulfilled Rome II criteria for IBS -IBS subgroup-
.The other 62 -no IBS subgroup- had no-IBS functional disorders (functional constipation,
functional diarrhea or functional bloating).RLSh detection included continuous transcraneal
Doppler(TCD) monitoring of mean blood flow velocities in one of the middle cerebral
arteries and injection of microbubles of air in saline solution through a peripheral vein of
the contralateral arm, both resting and after three different Valsalva maneuvers.In positive
cases for shunt, the PFO was confirmed with transesophageal echocardiography. We com-
pared the results with a previously-published group of 100 asymptomatic controls. RESULTS-
:Functional patients were younger(45± 15 vs 64± 13; p <0.001)and more frequently female
(72% vs 39%; p<0.01).IBS patients had higher incidence of migraine (26% vs 13%;
p<0.05)than controls. There were no other statistical differences between both groups regard-
ing smoking, hypertension, dyslipidemia, diabetes, cardiac diseases or other cerebrovascular
risk factors or PFO related factors.Prevalence of RLSh was 61% in patients group and 32%
in control group (p<0.001). Massive RLSh was also more frequent in patients than controls
(41% vs 21%; p<0.001). When examined specifically the IBS subgroup, 66% of patients
had RLSh and 43% massive RLSh, compared with 32% and 21% in control group respectively
(p<0.001). CONCLUSIONS: We have observed a higher prevalence of RLSh through a
cardiac PFO in patients with functional bowel disorders as compared with controls. RLSh
related with PFO may play a role in the physiopathology of IBS and other functional
gastrointestinal disorders. More studies are needed to confirm this preliminary hypothesis. .
IBS: irritable bowel syndrome; RLSh: right-to-left shunt
M2134
Cold Receptor Trpa1 Mediate the Smooth Muscle Contraction in Isolated
Mouse Lower Intestinal Tract
Kimihito Tashima, Angelica Penuelas, Shizuko Tsuchiya, Kenjiro Matsumoto, Tomonori
Nakamura, Shingo Yano, Syunji Horie
Background and Aim: TRPA1 and TRPM8, which are members of the transient receptor
potential (TRP) channels present in sensory nerve, are activated by cold or cool temperatures,
respectively. Previously, we have shown that activation of TRPV1-, a heat receptor, expressed
sensory nerve mediated transient relaxation followed by contraction in distal colon (Digestion
73: S2 1-P-4-21, 2006), yet there is no information about cold receptors expressed sensory
nerves involved in the regulation of lower intestinal motility. In this study, we investigated
the effects of TRPA1 and TRPM8 activation with agonists on smooth muscle tension in
isolated mouse intestinal preparations. Methods: The jejunum, ileum, and proximal and
distal colon were surgically isolated from male ddY mice. The longitudinal change in smooth
muscle was isotonically measured using Magnus apparatus. The expression of mRNA of
TRP channels was examined by RT-PCR. Results: Ally-isothiocyanate (a TRPA1 agonist;
10~100 μM) induced contraction in the proximal and distal colon, but not in the jejunum
and ileum, in dose-dependent manner. The reactivity to ally-isothiocyanate was more pro-
nounced in the distal colon than that in the proximal colon. Likewise, icilin (a TRPA1 and
TRPM8 agonist: 3~30 μM) also produced contraction in the proximal and distal colon, but
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not in the jejunum and ileum. Repeated application of maximal concentration of ally-
isothiocyanate or icilin produced desensitization of their contraction in the proximal and
distal colon. Moreover, contraction caused by TRPA1 agonist generates cross-desensitization
with icilin and capsaicin. The neurotransmission blocker tetrodotoxin (1μM) totally abolished
ally-isothiocyanate and icilin-induced contraction in the proximal and distal colon. However,
menthol (a TRPM8 agonist: 0.1~1 mM) induced long-lasting relaxation in the proximal and
distal colon, which was not inhibited by tetrodotoxin, suggesting that these relaxation is
produced by local anesthetic action of menthol on smooth muscle rather than by action on
nerves. RT-PCR analysis revealed the mRNA expression of TRPV1 and TRPA1, but not
TRPM8, in all tested portions. Conclusion: These results suggested that cold receptor TRPA1-
expressed sensory nerve facilitate the smooth muscle contraction in isolated mouse colon
and that TRPA1, but not TRPM8, is co-localized with TRPV1-expressed sensory nerve in
the mouse lower intestine.
M2135
Complications and Comorbidities of Constipation in Adults
Gurkirpal Singh, Shweta Vadhavkar, Huijian Wang, Annamaria Cerulli, Elizabeth Stanley,
George Triadafilopoulos
Introduction: Constipation is one of the most common gastrointestinal disorders in both
primary and specialist care, affecting up to 25% of the Western population. Although it
decreases patients' quality of life and imposes a substantial economic burden, constipation
is widely considered as a benign condition with minimal clinical and fiscal impact. In order
to evaluate the broader impact of constipation, we assessed medical complications and co-
morbidities in patients with constipation from a large state Medicaid program. Methods:
MediCal, the Medicaid program for the State of California, is the largest Medicaid program
in the US, with over 7 million participants per year. In order to link the development of
complications to constipation, we identified all cases with a diagnosis of constipation (ICD9
code 564.0x) who were 18 years and older, and had a minimum of 1 year follow-up before
and 1 year follow-up after their first physician visit for constipation. We then compared the
prevalence of several potential complications and co-morbidities in these patients during
the 1 year before and 1 year after the diagnosis of constipation. Results: The study included
147,595 patients with constipation (mean age 54.2 years, 69.7% women). Table shows the
prevalence and odds ratios of common co-morbidities and complications. Conclusion:
Patients with chronic constipation have clinically significant complications and co-morbidit-
ies, such as volvulus, intestinal obstruction and rectal bleeding. Despite its perceived benign
nature, constipation has far broader and clinically important implications.
Complications and Comorbidities of Constipation in Adults
All Odds Ratios are statistically significant.
M2136
A Comparative Study of Smartpill® and Radioopaque Markers for the
Assessment of Colonic Transit Time in Humans
Satish S. Rao, Richard Mccallum, Henry P. Parkman, Kenneth Koch, Richard J. Saad,
William D. Chey, John K. Dibaise, Alan Hutson, Jack Semler, Michael D. Sitrin, Jeffrey M.
Lackner, Leonard Katz, Braden Kuo
Traditionally, colonic transit time is assessed by ingesting radioopaque markers (Sitzmarks®)
followed by periodic x-ray(s) of the abdomen. Although useful, it is cumbersome, requires
radiation and is hampered by poor patient compliance and complex protocols. The SmartPill
wireless pH and pressure recording capsule may serve as ambulatory and alternative technique
of assessing colonic transit time. The aim of this multicenter study was to simultaneously
assess and compare the colonic transit time as measured by the SmartPill with that of
Sitzmarks in healthy humans. METHODS: After an overnight fast, normal healthy subjects
successively swallowed one Sitzmarks capsule containing 24 radioopaque markers and a
Smartpill capsule. A nutrient bar (260 Kcals) was also ingested. After 8 hours, subjects were
allowed to resume daily activities. Subjects were instructed to wear a data receiver for 5
days or until the SmartPill was expelled and to record their bowel habit on a stool diary.
An abdominal x-ray was obtained on day 2 (48 hrs) and on day 5 (120 hrs). Gastric emptying
(GE) was defined as a rise in pH > 4 units and cecal entry was detected by >1 unit pH
A-458AGA Abstracts
drop after GE. Anal expulsion of SmartPill was detected by abrupt temperature drop (>20°f).
The number and distribution of markers on the x-ray and the colonic transit time as measured
by both techniques were assessed and compared using Spearman's test. RESULTS: Twenty
healthy subjects (m/f=8/12, mean age =36.2yrs) participated in the study. All subjects expelled
the SmartPill. There were no adverse effects. The mean (sd) whole gut transit time of the
SmartPill capsule was 43 hrs (24 hrs:26 min). The x-ray on day 2 showed no markers in
5 (25%), and between 1-23 markers in 15 (75%) subjects. On day 5, no markers were seen
in 14 subjects and <5 (normal transit) in 4 subjects and >6 markers (slow transit) in 2
subjects. The SmartPill CTT correlated with % of markers expelled on day 2 (r=0.82,
p<0.0001). The mean GE time was 4.0 hrs (2:21) and mean small bowel transit time was
5 hrs 44 min (6:58). CONCLUSIONS: The SmartPill is a novel, safe, and possibly a more
useful technique of assessing colonic transit time. Colonic transit of SmartPill was highly
correlated with Sitzmarks, and hence this new technique provides comparable information
regarding colonic function. Additionally, it provides regional information on gastric and
small bowel transit time. Thus, SmartPill provides comprehensive data on whole gut and
regional transit time and may provide insights regarding overall gastrointestinal dysmotility
in functional GI disorders.
M2137
Compromised Parasympathetic Response to Colorectal Distension in Patients
with Irritable Bowel Syndrome
Robert Spaziani, Keith Redmond, Alfred Bayati, Haken Larsson, Subhas C. Ganguli,
Stephen M. Collins, Markad V. Kamath
Background: Autonomic dysfunction may play a role in the etiology of Irritable Bowel
Syndrome (IBS) and can be assessed using power spectral analysis of heart rate variability
(PS/HRV). Aims: To study the autonomic nervous system response to colorectal distension
(CRD) in patients with IBS and healthy volunteers. Methods: After a 20-minute baseline,
a barostat-controlled rectal bag (maximum volume 863 mL) was distended (0.5 mmHg/s),
to a maximum pressure of 70 mmHg, or 50% discomfort (whichever came first), and
maintained in this tonic state for 3 minutes. A 20-minute recovery period was recorded.
Subjects continuously indicated discomfort and pain. ECG was monitored throughout. PS/
HRV was computed using autoregressive modeling. The ratio of low frequency power (0.02-
0.15 Hz) to high frequency power (0.15-0.5 Hz) represents sympatho-vagal balance of the
autonomic nervous system. Results: Ninety-eight healthy volunteers (34±12 yrs., 52 F) and
38 IBS patients (38±11 yrs., 35 F) were studied. Patients had significantly (p<0.05) more
discomfort (69±22% vs. 56±21%), but not pain (9±14% vs. 6±14%) despite similar CRD
pressures (51±14 vs. 54±15 mmHg; NS) and volumes (394±108 vs. 398±134 mL; NS).
With CRD, heart rate significantly increased from baseline to tonic in both healthy volunteers
(66±10 to 71±10, p<0.05) and IBS patients (66±9 to 74±13, p<0.05) respectively. Systolic
blood pressure also increased in healthy volunteers(121±18 to 143±21 mmHg, p<0.05) and
IBS patients (126±20 to 153±24 mmHg, p<0.05). A similar increase was noted in diastolic
blood pressure in healthy volunteers (66±13 to 80±15 mmHg, p<0.05) and IBS patients
(68±14 to 84±16 mmHg, p<0.05). The systolic blood pressure increase during CRD was
significantly greater in IBS patients and remained significantly (p<0.05) elevated during
the recovery phase (139±21 mmHg) compared with healthy volunteers (129±19 mmHg).
Autonomic responses to CRD are described in Table 1. Discussion: CRD increased sympath-
etic tone. The systolic blood pressure increase was greatest in IBS patients and did not
recover post-distension. Vagal tone did not decrease significantly with CRD in IBS patients
compared with healthy volunteers, suggesting impaired vagal modulation of the heart rate.
Vagal dysfunction may play a role in the underlying etiology of IBS.
Table 1: Autonomic Response to CRD as assessed by Power Spectral Analysis of Heart
Rate Variability
* p < 0.05 versus baseline
M2138
Differences in Visceral Hypersensitivity and Hypercontractivity to Intraluminal
Distention Between Subtypes of Bowel Movement in Irritable Bowel Syndrome
(IBS)
Motoyori Kanazawa, Olafur S. Palsson, Syed Thiwan, Marsha Turner, Miranda A. Van
tilburg, Shin Fukudo, Douglas A. Drossman, William E. Whitehead
IBS patients show pain hypersensitivity and hypercontractivity in response to intraluminal
distention. However, there are limited data comparing subtypes of IBS. Aims: To determine
whether visceral pain sensitivity and phasic and tonic motility responses in the colon are
different between IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C) defined by
Rome III. Methods: 129 IBS patients (20 males, 36+12 yrs) and 30 healthy controls (HC;
8 males, 37+12 yrs) were studied. IBS patients were classified as IBS-D (n=44), IBS-C (n=
29), mixed IBS (IBS-M, n=45), and unspecified IBS (IBS-U, n=11) based on the proportion
of self-reported bowel movements that are loose or water vs. hard or like little balls. A
manometric catheter containing a 600 ml capacity plastic bag was positioned in the des-
cending colon. Pain threshold was assessed by the ascending method of limits using an
electronic barostat. Motility was assessed for 10 min with the bag inflated at the individual
operating pressure (IOP), 10 min at a bag pressure 20 mmHg above the IOP, and for a 15-
min recovery period with the bag deflated. Motility was also recorded for 30 min following
an 810-cal meal. A motility index (MI) was manually computed as the sum of the areas of
all contractions divided by recording time. Average barostat bag volume was recorded as a
measure of smooth muscle tone. Results: All IBS subtypes showed significantly lower pain
thresholds compared with HC (median 40 mmHg for HC, all p<.05). However, there were
no significant differences in pain threshold between IBS subtypes (IBS-D=32; IBS-C=28;
IBS-M=26; and IBS-U=36 mmHg). There were no significant differences in MI at baseline
between IBS subtypes and HC. The barostat bag volume at baseline was higher (muscle
tone lower) in HC compared to IBS-D (p<.05) and IBS-M (p<.05) but not to IBS-C or IBS-
U. Comparisons between IBS-D and IBS-C at baseline showed that IBS-D had a significantly
higher MI (370+37 vs. 271+35, p<.05) and lower bag volume (32.5+3.1 vs 48.7+7.0 ml,
p<.05). During distention, the MI was significantly lower in controls (563+78) compared
to all IBS subtypes: IBS-D=840+127, p<.05; IBS-M=914+99, p<.05; IBS-U=927+162, p<.05;
IBS-C=1001+208, p<0.1. However, neither MI nor bag volume was significantly different
between IBS-D and IBS-C during the distention, recovery, or postprandial periods. Conclu-
sions: Visceral hypersensitivity and hypercontractility define a pathophysiology that is com-
mon in IBS patients but is unrelated to their usual bowel habits. However, unstimulated
phasic and tonic motility are greater in IBS-D vs. IBS-C. [Supported by RO1 DK31369, R24
DK67674, and RR00046.]
M2139
Impact of Rectal Hyposensation in Patients with Intractable Constipation
Subash P. Vasudevan, Natalia Zarate, Marc A. Gladman, Peter J. Lunniss, Mark Scott
Background: Intact rectal sensation is central to normal defaecation. Previously, we have
shown that 25% of patients referred to our unit for physiological investigation, with intractable
constipation as their primary symptom, have rectal hyposensitivity (RH). However, it is
unclear how RH contributes to symptom development, and whether the finding deserves a
specific diagnostic approach. Aim: To investigate the influence of RH on clinical presentation
and colorectal function in patients with chronic constipation. Methods: 738 patients with
constipation (Rome II) were studied by rectal sensory testing and proctography. Threshold
volumes were determined by balloon distension, and patients were classified as RH if
they had ≥1 of the 3 standard sensory thresholds raised beyond the normal range, or as
normosensate (NS). On proctography, dyssynergic defaecation was diagnosed by ≥2 of the
following: time to evacuate >180 sec; % neostool evacuated <55%; poor anal canal opening.
Colonic transit was determined by radio-opaque marker study in 520 patients, in whom
there were symptoms of infrequency in addition to those of disordered rectal evacuation.
Parameters of global and regional colonic transit were further assessed in 126 patients with
delayed colonic transit (positive marker study) using scintigraphy. Clinical and physiological
parameters were compared between the RH and NS groups. Results: 33% of patients were
found to have RH. Clinical symptoms including: infrequency (P=0.13), straining (P=0.89),
and difficult (P=0.51), incomplete (P=0.96), or unsuccessful evacuation (P=0.84) were similar
between groups. On proctography, dyssynergic defaecation was demonstrated significantly
more frequently in patients with RH than those with NS (19% vs. 12%; P=0.04). Delayed
colonic transit (radio-opaque markers) was found in a similar proportion in both groups
(RH = 91/187 [49%], NS = 152/333 [46%]; P=0.51), as were parameters of global transit
as determined by scintigraphy (36 RH, 80 NS patients): estimated time for complete evacu-
ation (P= 0.40); % radioisotope retained at 96 h (P=0.16); and overall time-activity curves
(P=0.06). However, regional assessment showed that, in the RH group, radioactivity moved
faster through the right colon at 18 h (P<0.05), and % activity in the left colon was
significantly higher at 72 h (P=0.01). Conclusions: In patients with symptoms of chronic
constipation, the presence of RH does not appear to have a specific symptom profile; however,
RH is more frequently associated with dyssynergic defaecation and a left-sided delay in colonic
transit. These findings indicate that rectal hyposensitivity does impact on colorectal function.
M2140
Restless Legs Syndrome in Patients with Irritable Bowel Syndrome: Response
to Bacterial Overgrowth Therapy
Leonard B. Weinstock, Steve E. Fern, Stephen P. Duntley
Background: Bacterial overgrowth may be a common factor between irritable bowel syndrome
(IBS) and fibromyalgia. Because of an association between restless legs syndrome (RLS) and
fibromyalgia, a link between IBS, bacterial overgrowth, and RLS was considered in an open-
label, observational study of comprehensive bacterial overgrowth therapy for IBS and RLS.
Methods: Patients visiting a community-based gastroenterology clinic over a 4-month period
were eligible for the study if they presented with functional bowel symptoms and had an
abnormal lactulose breath test result. A diagnosis of RLS was confirmed using the Johns
Hopkins validated interview process. Patients received rifaximin 1200 mg/d for 10 days,
followed by tegaserod 3 mg long-term, and 1 month of both zinc 220 mg/d and a once-
daily, bifidobacteria-based probiotic. A questionnaire assessed IBS symptom improvement
at the end of rifaximin treatment (day 11), and individual IBS symptoms, overall IBS symptom
improvement, and overall RLS symptoms were assessed at the last visit. Results: Thirteen
patients with RLS and IBS were followed for a mean of 107 days (range, 22-450 days). On
day 11, substantial improvement from baseline in IBS symptoms was observed: abdominal
pain (74%), diarrhea (73%), bloating (70%), postprandial fullness (65%), constipation (64%),
and flatulence (47%). At the last visit, improvement from baseline was maintained: 81%,
68%, 76%, 67%, 59%, and 55%, respectively. Overall IBS symptom improvement from
baseline was rated as greatly improved (n=6), moderately improved (n=5), or mildly improved
(n=2). Ten of 13 patients exhibited ≥80% improvement from baseline in RLS symptoms.
All 10 patients indicated that the ≥80% improvement in RLS symptoms occurred by the
end of rifaximin treatment. Eight of these 10 patients were followed long-term (mean, 139
days; range, 54-450 days), with 5 maintaining complete (100%) resolution of RLS symptoms.
Conclusion: This pilot study provides preliminary data supporting the novel hypothesis that
bacterial overgrowth associated with IBS may be a contributory factor in some patients with
RLS. Comprehensive bacterial overgrowth therapy may provide long-term improvement in
both gastrointestinal and RLS symptoms, and further research on extra-gastrointestinal
manifestations of bacterial overgrowth are warranted.
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M2141
Electroacupuncture At Acupoint St36 Promotes Contractility of Distal Colon
in Conscious Rats
Shi Liu, Dan Luo, Xiaoping Xie, Xiaohua Hou
Background: Acupuncture is useful for functional gastrointestinal diseases. However, the
effects and mechanisms of electroacupuncture on gastrointestinal motility, especially colonic
motility, have scarcely been investigated. Aim: To investigate the effects of electroacupuncture
stimulation (EAS) at acupoint ST36 (Zusanli) on contractility of distal colon in conscious
rats and to explore the possible mechanism. Methods: Twenty four rats were randomized
into three groups, including the ST36 group, the non-acupoint and the atropine-plus-ST36
group. Needles were inserted into the acupoints, which were stimulated by EAS with
parameters of 10Hz and 3mA. The distal colonic motility was measured using a water
perfused system connected to a manometric catheter inserted into the colon 4cm distal to
the anus. The area under the contractile curve (AUC) was calculated for each recording
period to represent colonic motility. EAS was performed for 20min. The colonic motility
was recorded for 1 hour before EAS, 20 minutes during EAS, and 3 hours after EAS. Atropine
(0.5mg/kg) was injected intraperitoneally 60 min before EAS in the atropine-plus-ST36
group. Results: 1) EAS at the ST36 significantly increased the contractility of distal colon.
In the ST36 group, the mean AUC during and after EAS was significantly higher than that
before EAS (11.9±1.1 vs 9.3±0.7 P<0.001. 11.7±0.9 vs 9.3±0.7 P<0.001). 2) EAS at the
non-acupoint had no effects on the contractility of the distal colon. In the non-acupoint
group, the mean AUC were not significantly changed during or after EAS compared with
that before EAS (9.6±1.1 vs 9.5±0.9 P>0.05. 9.2±0.9 vs 9.5±0.9 P>0.05). 3) The excitatory
effect of EAS at ST36 on distal colonic motility was blocked by atropine. In the atropine-
plus-ST36 group, the mean AUC remained unchanged during or after EAS compared with
that before EAS (7.5±0.4 vs 7.2±0.5 P>0.05. 7.3±0.6 vs 7.2±0.5 P>0.05). Furthermore, the
mean AUC before EAS was significantly lower than that of the ST-36 group (7.2±0.5 vs
9.3±0.7 P<0.001). Conclusion: EAS at ST36 promotes the contractility of the distal colon
in conscious rats. This excitatory effect induced by EAS may be mediated via the cho-
linergic pathway.
M2142
Colonic and Rectal Responses to Distension and to Feeding in Spinal Cord
Injury
Vid P. Suttor, Clinton Ng, Sue Rutkowski, Ross D. Hansen, John E. Kellow, Allison
Malcolm
BACKGROUND: Reflex motor activity of the colorectum is poorly understood. Controversy
exists over the participation of spinal cord pathways in the enteral response to feeding and
in intestino-intestinal reflexes; comprehensive evaluation of these reflexes in spinal cord
injury (SCI) patients is lacking. AIM: (1) To evaluate the colorectal & rectocolic reflexes
(tonic responses of rectum and colon to distension of the opposing region respectively), as
well as the gastrocolonic & gastrorectal reflexes (tonic responses of colon and rectum to
feeding respectively) in patients with cervical SCI, and (2) to compare these responses to
those in healthy subjects. METHODS: 6 patients (5 M, age 42±4 yr) with established SCI,
and 6 healthy controls (5 M, 36±5 yr) were studied. All SCI patients had complete mid-
cervical level spinal cord lesions of at least 12 months duration. After an overnight fast and
bowel cleansing, a dual barostat assembly was positioned with balloons in the descending
colon and rectum. Two-minute phasic distensions of 20 mmHg above IOP were performed
in the colon and rectum, while the volume in the opposing balloon was recorded. Colonic
and rectal balloon volumes were recorded before and after a standard 1000 kcal liquid meal.
Colorectal and rectocolic reflexes were assessed by recording the mean volumes before,
during and after the distensions. Gastrocolonic and gastrorectal reflexes were assessed by
concurrently measuring volumes in each region 10 minutes prior to the meal, and then at
5 minute intervals post-prandially for 60 minutes. RESULTS: The colorectal reflex was
similar in SCI (volume change: -28±11%) and health (-15±5%; p=NS). The rectocolic reflex
was more variable, present in only 1 SCI (30%) and 2 controls (20±5%), but comparable
between both groups. The gastrocolonic reflex was similar in magnitude at 60 minutes for
both groups (volume change: -51±16% health, -59±14% SCI; p=NS), however there was a
significant delay (p<0.05) in both the early and late phases of this reflex in SCI compared
to controls. The gastrorectal reflex at 60 minutes was also comparable in magnitude for SCI
(-31±19%) and controls (-26±31%; p=NS), and was not delayed in SCI. CONCLUSION:
Intact neural transmission between the spinal cord and higher centres is not essential for
normal colonic and rectal responses to intestinal distension and to feeding; however a
modulatory role for the spinal cord in these reflexes is not excluded.
M2143
Colon Transit and Regional Colon Motor Activity in Diabetics with
Gastroparesis Compared to Healthy Volunteers and Diabetics with Near
Normal Gastric Emptying
William L. Hasler, Radoslav Coleski, Irene Sarosiek, Richard Mccallum, Braden Kuo,
Henry P. Parkman, Michael D. Sitrin, Jeffrey M. Lackner, Leonard Katz, Kenneth Koch,
John M. Wo, William D. Chey, Alan Hutson, Jack Semler
Background: Diabetics with gastroparesis often report constipation. Delayed whole gut
transit is found in these patients, suggesting diffuse motor dysfunction. Motor defects causing
delayed colon transit in diabetics with gastroparesis are uncharacterized. Aims: (i) To
quantify regional motor activity and correlate with colon transit in healthy subjects using
radiotelemetry capsules (SmartPill Corp.) and (ii) to compare colon transit and motor activity
in diabetics with gastroparesis vs. diabetics with near normal gastric emptying (GE) and
healthy subjects to test if those with gastroparesis show diffuse dysfunction. Methods: 42
healthy subjects, 8 diabetics with gastroparesis (90% GE time >270 min), and 13 diabetics
with near normal GE (<270 min) were studied. Lumen pH, contractions, and temperature
were measured every 5 sec after capsule ingestion. Cecal entry was detected by >1 unit pH
drops hours after GE. Anal expulsion was detected by abrupt temperature drops. Contraction
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numbers >25 mmHg and motility indices (MI)(areas under curve) were calculated. Transit
times were divided into defined time blocks to estimate regional profiles. Results: Colon
transit was 1315±149 min in healthy subjects with a mean 8.8±0.9 contractions/15 min
and a mean MI of 6.6±0.7. Contractions rose from 5.8±1.3 in the initial 15 min after cecal
entry to 10.6±1.0/15 min in the 4th quartile of transit and 19.1±2.4 in the final 15 min
before anal expulsion (P<0.01). MI increased from 3.9±0.8 in the initial 15 min to 8.6±1.0
in the 4th quartile and 14.7±1.9 in the final 15 min (both P<0.01). Transit in diabetics with
near normal GE was slower vs. controls (2047±209 min, P=0.03); transit in diabetics with
gastroparesis was slower vs. both other groups (3937±712 min, P=0.02). Mean contractions
(6.5±0.6/15 min) and MI (6.1±0.6) in diabetics with near normal GE were similar to healthy
subjects with normal early to late motor gradients. In diabetics with gastroparesis, mean
contractions (4.0±0.6/15 min) and MI (3.2±0.7) were lower than both other groups (P<0.05).
Defects were localized to late transit phases (4th quartile contractions: 5.5±1.2/15 min,
contractions in final 15 min: 5.4±1.7, MI in final 15 min: 5.1±2.2)(P<0.05). Conclusions:
Motor activity increases from early to late phases of colon transit in healthy humans with
bursts of activity before evacuation that may reflect rectal propulsive complexes. Diabetics
with near normal gastric emptying show mildly impaired colon function. Diabetics with
gastroparesis exhibit profound transit delay with reduced contractions most prominent
distally, demonstrating generalized enteric defects outside the stomach in these patients.
M2144
Effect of Laparoscopic Colectomy On Quality of Life, Urinary Symptoms and
Dyspareunia in Patients with Slow Colon Transit Constipation and Descended
Cecum with Delayed Emptying
William Y. Chey, Vincent Chang, Kaeyol Lee, Maxine Lubkin, G. Fox, K. Fulton, D.
Corcoran
BACKGROUND: Patients (pts) with colon inertia and slow colon transit suffer from abdominal
discomfort and/or pain, low quality of life (QOL), and pelvic symptoms including urinary
bladder symptoms, and dyspareunia. When medical treatment fails to improve their disabling
symptoms, colectomy is a therapeutic option. PURPOSE: We examined the clinical outcomes
including IBS-QOL and pelvic symptoms of pts with slow transit constipation and markedly
descended (ptotic) and enlarged cecum following laparoscopic colectomy. METHODS: Colon
transit time was determined with radio-opaque pellets and enlarged cecum reaching anterior
pelvic floor was identified fluoroscopically in 6 to 8 hrs following ingestion of a cooked
ground beef patty (170 g) with 300 ml of liquid barium. Cecal emptying of barium-mixed
feces was estimated by daily fluoroscopy. The size of cecum was estimated, using radiographs
of ceca in pts and controls without cecal ptosis. IBS-QOL, IBS Symptom Frequency Scores
(IBS-SFS), urinary frequency, stress incontinence, and dyspareunia were surveyed before
and after subtotal colectomy and ileo-proctostomy (103 pts) or hemicolectomy (4 pts).
RESULTS: One male and 106 female colon inertia pts with ages from 18-72 (median =42.5)
yrs had slow transit time ranging from 120 to 312 hrs (mean±SE: 169.4±4.3 hrs). Enlarged
cecum reached anteriorly on pelvic floor and contained barium-mixed feces longer than 24
hrs in these pts, whereas in controls, the emptying occurred in less than 24 hrs. The mean
estimated volume of ceca in 10 pts was 349±34.8 cm3 compared to 73.4±18.9 cm3 in 5
controls (p<0.001). Symptoms of IBS (Rome II) were found in 90 pts (92%). Duration of
post-colectomy follow up ranged from 6 to 36 (median=15) months. Seventy-two pts returned
pre- and post-colectomy QOL questionnaire forms. Mean QOL scores significantly decreased
from 113.0±3.3 to 60.5±2.8 (p<0.001) during post-colectomy period. Mean IBS-SFS also
significantly decreased from 49.6±1.3 to 28.5±1.7 (p<0.001). After colectomy, 63 pts with
increased urinary frequency score (4.26±0.21) had either no or markedly decreased frequency
(1.86±0.18, p<0.001), 23 of 24 pts with stress incontinence no longer experienced it, and
in 51 pts with dyspareunia, 46 experienced marked improvement or no longer experienced
it. CONCLUSION: We conclude that IBS-QOL and pelvic symptoms improve significantly
after colectomy in pts with slow colon transit constipation and markedly enlarged ceca. The
observations strongly suggest that urinary bladder symptoms and dyspareunia are attributable
to marked descended and stagnant cecum in pelvis and are common in these pts.
M2145
A Mutation in Telethonin in a Patient with Intestinal Pseudoobstruction Alters
NaV1.5 Channel Kinetics
Amelia Mazzone, Peter R. Strege, David J. Tester, Georgine Faulkner, Roberto Degiorgio,
Jonathan Makielski, Vincenzo Stanghellini, Simon J. Gibbons, Michael J. Ackerman,
Gianrico Farrugia
Background: Gastrointestinal smooth muscle cells and interstitial cells of Cajal (ICC) express
a variety of ion channels; their coordinated activity leads to organized motility patterns.
Previously, we identified a Na+ channel Nav1.5, encoded by SCN5A, expressed in human
smooth muscle cells and ICC. Patients with mutations in SCN5A causing heritable arrhythmia
syndrome have an increased prevalence of gastrointestinal symptoms suggesting that altera-
tions Nav1.5 may cause gastrointestinal disease. We therefore collected blood from patients
with idiopathic intestinal pseudoobstruction (n=21) and performed comprehensive muta-
tional analysis of SCN5A and several genes that encode sodium channel interacting proteins
(SCIPs) as candidate genes for intestinal pseudoobstruction. During mutation scanning, we
found a patient with a mutation in the TCAP-encoding telethonin. Aim: Determine if tele-
thonin is expressed in gut smooth muscle and determine if mutant telethonin alters Nav1.5
kinetics. Methods: Mutational analysis was carried out using denaturing high performance
liquid chromatography and the exact nature of the sequence variation determined by dye-
terminator cycle-sequencing. Telethonin expression in human jejunal smooth muscle cells
was determined by single cell RT-PCR and immunoblotting. Patch clamp recordings were
used to study the interaction of normal and mutant telethonin with SCN5A. Results: A
missense mutation, R76C, was identified in telethonin in a patient with pseudoobstruction
manometrically characterized as a mixed myo- and neuropathic pattern. Telethonin mRNA
and protein were identified in human jejunum smooth muscle cells by both single cell RT-
PCR and immunoblotting. Patch clamp recordings showed that co-expression of wild type
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telethonin and SCN5A in HEK293 cells altered Nav1.5 kinetics with a shift in the voltage-
dependent steady state inactivation of -6.5 mV and a smaller window current. When R76C-
telethonin was co-expressed, there was a significant left shift in steady state activation and
a right shift in steady state inactivation of Nav1.5. The net result was a larger window current
and therefore a predicted increase in excitability. Conclusions: This is the first report that
describes the expression of telethonin in human intestinal smooth muscle cells and the first
description of a mutation in telethonin in a patient with intestinal pseudoobstruction.
Telethonin appears to associate with Nav1.5 altering its kinetic behavior, therefore functioning
as a novel SCIP. The R76C mutation alters the interaction between telethonin and Nav1.5
changing the electrophysiological properties of Nav1.5. Supported by NIH grant DK52766
M2146
Where Does Bloating Come from: Abdominal Walls Or Content?
Frederic Perez, Anna Accarino, Fernando Azpiroz, Sergi Quiroga, Juan-r. Malagelada
BACKGROUND. Abdominal bloating is a frequent but poorly understood complaint in
patients with functional gut disorders. AIM. To determine the mechanism of functional
abdominal bloating. METHODS. In 36 patients with functional gut disorders, whose predom-
inant complaint was episodic abdominal bloating (33 F, 3 M; range, 19 to 74 years), two
abdominal CT scans were obtained during either mild (basal) or severe bloating, measured
on a 0-6 scale. One CT scan was obtained from 10 healthy subjects (9 F, 1 M; range, 21
to 62 years) as controls. The conventional CT scan technique does not yield sufficient
discriminatory accuracy to allow quantification of physiological variation in abdominal gas
and viscous content. Thus, we developed and validated a CT image based computer program
formed by independent software modules for specific morpho-volumetric analysis of the
abdominal cavity (Gastroenterology 2005; 128:A-675). RESULTS. In the basal scan (1.9±0.3
bloating score), the volume of gas in patients (107±11 mL) was similar to healthy subjects
(126±20 mL). During severe bloating (4.4±0.2 bloating score; p<0.001 vs basal) patients
exhibited objective abdominal distension (with an increment of 15±2 mm in the distance
between the spine and anterior abdominal wall; 2.2±0.4 cm of girth increment; p<0.001 vs
basal for both) but total abdominal volume and gas content only increased slightly (0.3±0.1
L and 35±15 mL respectively; p<0.05 vs basal for both). However, anterior wall protrusion
was associated with a significant diaphragmatic descent (by 12±4 mm; p<0.005) and both
exhibited a good correlation (R=-0.74; p<0.001). CONCLUSION. Patients with functional
bloating exhibit objective abdominal distension due to intraabdominal redistribution of
contents (diaphragmatic descent and anterior wall protrusion), with relatively small incre-
ments in gas and viscous content.
M2147
Excitatory Effects of Synchronized Intestinal Electrical Stimulation On Small
Intestinal Transit in Dogs
Jiande Chen, Jieyun Yin
Our previous studies showed that synchronized intestinal electrical stimulation (SIES)
induced small intestinal contractions in dogs. However, it is unknown whether SIES could
accelerate small intestinal transit and whether there is a correlation between small intestinal
contractions and transit time. The aim of this study was to investigate the effects of SIES
on small intestinal transit delayed by glucagon and the correlation between the transit time
and small intestinal contractions in dogs. Methods: Six healthy female dogs (18-24Kg) were
equipped with two dual cannulas for the assessment of small intestinal transit and contrac-
tions. The proximal cannula was located at 20 cm distal to the pylorus; The distal cannula
was at 1.5m distal to the first one. Two pairs of bipolar electrodes were implanted on the
small intestinal serosa with an interval of 5cm; The proximal one was 25 cm beyond the
pylorus and used for stimulation. The experiment consisted of three sessions in a randomized
order: control, glucagon (0.1mg/kg) and SIES plus glucagon. An additional session was
performed in four of the dogs using non-SIES. Small intestinal transit was assessed using
phenol red (0.5mg/ml) and 1.5% Methylcellulose solution injected through the proximal
cannula after a 237ml liquid meal. Glucagon was bolus injected immediately after feeding.
The small intestinal content was collected through the distal cannula every 2 min for the
first 10 min and then every 5 min until the disappearance of phenol red. The small intestinal
transit time was expressed as the time between the injection of phenol red and the complete
disappearance of phenol red collected from the distal cannula. Small intestinal contractions
were also recorded during the measurement of the intestinal transit. SIES was composed of
trains of pulse with 0.5s on, 20Hz, 2ms and 4mA; non-SIES was composed of the same
parameter except using the intrinsic frequency of 20cpm. Results: 1). SIES significantly
improved glucagon-induced hypomotility after the liquid meal (contractile index: 9.4 ± 1.4
vs. 12.8 ± 1.4, p = 0.02). 2). SIES significantly accelerated small intestinal transit time
delayed by glucagon (70.4 ± 3.1min vs. 44.5 ± 3.1min, P < 0.01). 3). Non-SIES failed to
accelerate small intestinal transit delayed by glucagon (70.4 ± 3.1min vs. 72.4 ± 7.9min,
P = 1.0). 4). There was a negative correlation between the contractile index and transit time
(r=-0.427, p=0.048). Conclusions: SIES improves small intestinal postprandial hypomotility
and delayed intestinal transit induced by glucagon. SIES may have a therapeutic potential
for treating diabetic patients with small intestinal disorders.
M2148
A Non-Digestible Device Discriminates Motility Patterns with a Luminal
Acidic pH Change Within the Distal Small Bowel and Proximal Colon
Alexandru Gaman, Alan Hutson, Judy Hwang, Kevin Stevens, Kenneth Koch, Henry
Parkman, Richard Mccallum, William D. Chey, Leonard Katz, Michael D. Sitrin, Jeffrey M.
Lackner, William Hasler, John M. Wo, Jack Semler, Braden Kuo
INTRODUCTION: The cecum pH is more acidic compared with the ileum due potentially
to the bacteria metabolic products that accumulate because of less active motility in the
proximal colon. The gut passage of a non-digestible capsule mounted with pH and pressure
sensors -SmartPill (SP) may be able to document motility patterns associated with these pH
differences. HYPOTHESIS: The pH change associated with transition from the ileum to
cecum is associated with changes in motility patterns as recorded by SP. AIMS: To quantify
and compare the motility patterns before and after the pH change. With a newly developed
analytic tool, we compared the area under the curve (AUC) of pressure in the periods of
interest along with the frequencies- 30min before and after the pH drop. METHODS: In a
multicenter study, after an overnight fast 104 volunteers (49 males, 55 females, mean age
35y) swallowed SP following a standardized meal containing 120 g Eggbeaters, 2 pieces of
bread with jam; 255 kcal, 2% fat) and 120 cc water. Approximately 5 ½ hours after the
gastric expulsion of the capsule as determined by a sharp pH rise of greater than 3 pH
units, a drop in pH > 1 unit for greater than 5 minutes was seen. The frequency and AUC-
pressure of contractions recorded by the capsule were analyzed in 30 min windows, before
and after the beginning point of the pH drop. These parameters were then compared by
paired T-test. RESULTS: The mean time between pH drop and gastric emptying in this
sample population is 5.5 hours (95% CI= [4h40min-6h08min]). The mean frequency of
contractions for the 30 min before the pH drop is 4.5ct/min (CI99.9%= [3.7-5.2], SD=2.2)
and 30 min after is 2.5/min (CI 99.9%= [1.9-3.1], SD=1.8) with p<0.001. The mean pressure-
AUC 30min before the pH drop is 53.8 (CI 99.9%= [43.4-64.2], SD=32.3) and after is 21.7
(CI 99.9%= [16.7-26.7], SD=15.5) with p<0.001. CONCLUSIONS: The pH drop that appears
hours after the gastric emptying of SP is associated with a highly significant change in
motility patterns, suggesting that this point could mark the ileo-colonic junction. The
SmartPill can be used to characterize motility patterns in the distal bowel and proximal colon.
M2149
Complete pH Profiling of the Gastrointestinal Tract in Healthy Volunteers
with An Ambulatory pH Capsule
Lenuta Kloetzer, Alexandru Gaman, Borko Nojkov, William D. Chey, Judy Hwang, Kevin
Stevens, Kenneth Koch, Henry Parkman, Richard Mccallum, Leonard Katz, Michael D.
Sitrin, Jeffrey M. Lackner, William Hasler, John M. Wo, Jack Semler, Braden Kuo
INTRODUCTION: Gastrointestinal luminal pH varies widely, affected by gut function and
luminal milieu. Traditional techniques to measure luminal pH provide access to only a
limited portion of the GI tract and are uncomfortable and inconvenient for the patient.
Current techniques do not provide access to the distal small bowel and proximal colon
where bacteria and gut motility may have a significant influence. An ingested non-digestible
capsule mounted with pH and pressure sensors -SmartPill (SP) may be able to document
the pH profiles in various regions of the GI tract in a non-invasive ambulatory manner.
AIMS: To quantify and compare the pH patterns at various regions within the GI tract with
the SP. METHODS: In a multicenter study, after an overnight fast, 36 healthy volunteers
(14 males, 22 females, mean age 32 yr) swallowed SP following a standardized meal containing
120 g Eggbeaters, 2 pieces of bread with jam; 255 kcal, 2% fat) and 120 cc water. Gastric
expulsion of the capsule was determined by a sharp pH rise of greater than 3 pH units from
the acidic stomach to an alkaline duodenum. Passage of the capsule from the ileum to the
cecum was denoted by a drop in pH > 1 unit for greater than 5 minutes at 5.5h after
emptying from the stomach. Expulsion of the capsule from the rectum was noted by a drop
of temperature of >20° F recorded as SP exited the body. Mean pH was recorded for 15
minutes intervals at landmarks throughout the GI tract including gastric antrum (time before
gastric emptying of SP), proximal small bowel (15 minutes after emptying of the capsule
from the stomach into duodenum), ileum (15 min before passage from ileum to cecum),
proximal colon (time that pH stabilizes after transition from ileum to cecum) and distal
colon (15 minutes before rectal expulsion of SP) The regional median pH data from various
locations were then compared by paired T-test and ANOVA. RESULTS: Mean region specific
pH profiles (95% CI) are presented in the table. ANOVA among median pH of the various
locations reveal statistical differences (p<0.05). Prox small bowel pH was sig lower than
ileum (p<0.01). Prox colon pH was sig lower than distal colon (p<0.01) CONCLUSION:
Using the SmartPill, the range of normal pH in different segments of the GI tract was
determined. Distinct region specific pH profiles are apparent in healthy volunteers. This
work paves the way for further research to define whether differences in luminal pH can
distinguish between healthy individuals and those with disease states.
M2150
Role of IL-4, IL-13 and 5-HT in the Maintenance of Muscle Hypercontractility
in a Murine Model of Post-Inflammatory Irritable Bowel Syndrome
Takahiro Mizutani, Hirotada Akiho, Hiromi Muta, Haruei Ogino, Kenji Kanayama,
Yorinobu Sumida, Kentaro Taki, Hiroyuki Murao, Naomi Higuchi, Soichi Itaba, Kazuhiko
Nakamura, Ryoichi Takayanagi, Waliul I. Khan
Background and Aims: Acute gastroenteritis is a strong risk factor for the development of
irritable bowel syndrome (IBS). In a postinfective IBS model of mice, cytokine TGF-β1
maintained hypercontractility at the level of smooth muscle cell (Akiho et al Gastroenterology
2005), but the mechanism for non-infective post-inflammatory IBS has not been investigated.
Mice injected with a T cell activating anti-CD3 antibody develop a transient diarrheal illness
(Merger et al Gut 2002). In this study, we investigated the mechanism underlying smooth
muscle hypercontractility that persists after acute inflammation in a murine model of T cell
induced enteropathy. Methods: BALB/c mice were injected with the anti-CD3 antibody
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(100μg). Histological changes were analyzed on hematoxylin-eosin stained tissue section of
the intestinal specimen. Isolated small intestinal smooth muscle cell contraction and protein
expression of cytokines (Th1, Th2 cytokines, TNFα) in the small intestine were examined
before and after injection. We also assessed serotonin (5-HT) expression in the small intestine,
and investigated the effect of 5-HT synthesis inhibitor, 4-chloro-DL-phenylalanine (PCPA)
on small intestinal smooth muscle cell contractility. Results: Small intestinal tissue damage
was observed from 24 hours after anti-CD3 antibody injection, and this histological change
had resolved by 5 days after injection. Carbachol-induced smooth muscle cell contractility
was significantly increased from 4 hours after injection, and this muscle hypercontractility
was evident in the post-inflammatory phase (at day 7) (p<0.05). Protein expression of Th2
cytokine (IL-4, IL-13) was significantly increased from 4 hours to 7 days after injection
(p<0.05). 5-HT expressing cells in the small intestine were also increased from day 1 to
day 7 (p<0.05). 5-HT synthesis inhibitor, PCPA decreased the muscle hypercontractility
(p<0.05) and reduced the increasing of 5-HT expressing cells induced by anti-CD3 antibody
in the post-inflammatory phase. Conclusions: These results suggest that muscle hypercontrac-
tility in the post-inflammatory phase is maintained at the level of smooth muscle cell. In
addition, Th2 cytokine (IL-4, IL-13) and 5-HT in the small intestine may contribute to the
maintenance of muscle hypercontractility at the post-inflammatory phase in this model.
M2151
Effects of Lubiprostone On Small Intestinal Afferent Fibre Activity in the Rat
David C. Bulmer, Holly Rossiter, Anne-marie Coelho, Kevin Lee, Wendy J. Winchester
Lubiprostone a selective activator of type 2 chloride channels (ClC-2) has recently been
shown to be effective in the treatment of chronic constipation, and is thought to act by
enhancing intestinal secretion (McKeage et al 2006). However, up to 31% of patients treated
with lubiprostone experienced nausea, which given the poor bioavailability of lubiprostone
is thought to be triggered by the activation of intestinal sensory nerves, a consequence of
raising intestinal pressure by enhancing secretion. The aim of the present study was to
investigate the effects of lubiprostone on sensory nerve activity from the rat small intestine.
Afferent mesenteric nerve activity was recorded from a cannulated segment of ileum in male
Sprague Dawley rats (300-450g) anaesthetised with sodium pentobarbitone (bolus 60 mg/
kg i.p.; followed by 10-50 mg/kg/hr i.v.) in accordance with the UK Animal Scientific
Procedures Act (1986). The effects of intra-venous injection (300 nmoles/kg i.v. n=4) and
intestinal perfusion of lubiprostone (10 μM lubiprostone against a 2-3 mmHg end pressure
at 0.1 ml/min for 30 min following a loading infusion of 1.0 ml/min for 2 min; n=5), were
examined on afferent nerve activity and luminal pressure. Statistical comparisons were made
against baseline ongoing nerve activity and luminal pressure for intra-venous injections of
lubiprostone and with a control perfusion of saline prior to administration of lubiprostone
using a Student's paired t-test P<0.05. Intra venous injection of lubiprostone elicited a robust
significant increase in mesenteric nerve activity (61.0 ± 7.2 spikes/s) and luminal pressure
(1.7 ± 0.4 mmHg). The increase in nerve activity was comparable to a subsequent injection
of PGE2 (300nmoles/kg, 65.1 ± 11.7 spikes/s n=3). Intestinal perfusion of lubiprostone
similarly elicited a significant increase in mean afferent nerve activity compared to saline
infusion (25.1 ± 8.6 spikes/s). However no significant change was observed in the mean
luminal pressure during infusion of lubiprostone compared to saline (2.5 ± 0.1 vs 2.4 ±
0.1 mmHg). The results of this study demonstrate that lubiprostone stimulates intestinal
sensory nerve activity following luminal or intra venous application. The mechanism underly-
ing this effect remains to be fully explored; however the rapid onset of the increase in
afferent fibre activity following intra venous injection of lubiprostone suggests that it is not
mediated secondary to an increase in intestinal secretion. McKeage K., Polsker G.I. and
Siddique M.A. Drugs 66(6) 873-9 (2006).
M2152
Effect of Hydrochloric Acid and Alcohol On Duodenal Chemosensitivity:
Duodenal Acid Exposure Paradoxically Reduces Chemosensitivity
Martina Führer, Johann Hammer
Introduction: Chemosensitivity for capsaicin that is independent from mechanosensitivity
has recently been demonstrated in the duodenum. Capsaicin stimulates the polymodal
vanilloid receptor of type 1 (VR1) on nociceptive afferent neurons and induces pain and
non-painful sensation. Other stimulators of VR1 include heat, acid, or alcohol. Aims: The
aims of the study were to evaluate the effects of duodenal acid and alcohol exposure on
chemo- and mechanosensitivity. Methods: N=17 healthy subjects swallowed a tube assembly
with an infusion site and a barostat in the mid-duodenum for pressure controlled random
distension and capsaicin perfusion (40μg/ml, 2.5 ml/min). Studies were performed on two
occasions, 1 week apart: in the HCl-group (N=8), studies were performed during infusion
of either hydrochloric acid (HCl; 0,1 mmol/l) or normal saline; The ETOH-group (N=9)
received ethanol (5% vol/vol) and normal saline infusions, respectively. A graded question-
naire that evaluated quality and intensity of eight upper abdominal symptoms was filled
out during distension and capsaicin infusion. Student's t'tests for paired observations were
performed, p-values <0.05 were considered significant, data are given as mean±SEM; NS=
not significant. Results: The table shows latency to discomfort (in minutes) and perception
scores reported 20 minutes after start of capsaicin infusion for both study groups. In the
HCl-group, duodenal distension induced discomfort at intraballoon pressures of 37±11
mmHg (HCl) and 35±7 mmHg (NaCl) (NS) and volumes of 146±28 ml and 149±20 ml,
respectively (NS). Similarly in the ETOH-group, balloon pressures (29±7 vs. 33±8 mmHg)
and volumes (141±32 vs. 143±39 ml) to induce discomfort were not significantly different
during ethanol and NaCl infusion, respectively. Compliance was also not altered by the
infusions. Conclusion: Duodenal chemonociception is reduced during acid exposure, while
ethanol has no effect on chemonociception. Mechanosensitivity remains unaltered by duo-
denal acid and ethanol exposure. Duodenal acid activates mechanisms that lead to a decreased
sensitivity for intraluminal capsaicin, possibly by thickening the mucosal protective layer
and impairing capsaicin permeation. This mechanism might protect duodenal chemonocicep-
tors from being sensitised by acid. Whether this mechanism is impaired in patients with
upper gastrointestinal functional disease remains to be determined.
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M2153
Chyme Overload Improves Manometric Evaluation of the Small Bowel
Encarna Arcos, Anna Accarino, Fernando Azpiroz, Juan-r. Malagelada
BACKGROUND. Conventional intestinal manometry is the current gold standard to evaluate
intestinal motility, and detects neuro- and myophathic abnormalities with a high specificity
but a relatively low sensitivity. AIM. To improve the diagnostic sensitivity of intestinal
manometry by means of a stress test. METHODS. In 26 patients with symptoms suggestive
of severe intestinal motor dysfunction, two studies were performed on separate days: a)
conventional manometry (3 h fast, 2 h after a normal meal) and b) a manometric stress test
with chyme overload (2 ml/min infusion of 1 Kcal/ml nutrient solution thickened with 6.5%
Veegum, 3 h perfusion and 1 h post-perfusion). The manometric stress test was also performed
in 10 healthy subjects as controls. Neuropathic patterns were identified using previously
established manometric criteria (Gut 1987; 28:5-12). RESULTS. Healthy subjects invariably
developed a normal postprandial pattern in response to chyme overload. Ten patients were
diagnosed of neuropathy by conventional manometry with 2.2±0.4 abnormalities per study
(1-6 range); in them, overload manometry identified significantly more neuropathic-type
abnormalities (4.2±0.5 per study; 1-8 range; p<0.05), 60% of them corresponded to non-
propagated burst activity. In 16 patients conventional manometry was normal but in 10 of
them, overload manometry identified 3.4±0.4 neuropathic-type abnormalities per study (1-
6 range), and the diagnosis was later confirmed by clinical and/or histological criteria on
full thickness biopsies. The most frequent dysmotility pattern induced by chyme overload
was isolated burst activity (3.4±0.4 bursts per study). In 6 patients both conventional and
overload manometry were normal; three of them were later diagnosed of visceral myopathy
and in the rest symptoms remitted during follow up. CONCLUSION. The manometric stress
test uncovers motor abnormalities undetected by conventional manometry and improves
the diagnostic sensitivity of intestinal neuropathy.
M2154
The H2-Inulin Breath Test Is An Inexpensive and Reliable Alternative to the
13C-Lactoseureide Breath Test to Determine Orocecal Transit Time
Arne R. Schneider, Kathrin Jepp, Lydie Murzynski, Wolfgang Caspary, Jurgen Stein
Introduction: In the past years, the 13C-lactoseureide breath test has been validated and
established as a reliable, noninvasive test for the assessement of orocecal transit time (OCCT).
More recently, small studies have demonstrated that inulin, a non-absorbable polysaccharide,
could be an inexpensive and reliable substrate for H2 breath testing of small bowel transit.
We compared the performance of the H2 inulin breath test (H2-INBT) with the 13C lactoseure-
ide breath test (13C-LUBT). Patients and Methods: 27 volunteers (13 men) underwent a
combined 13C-lactoseureide/H2-inulin breath test. 500mg of unlabeled lactoseureide was
ingested on the day before the test to induce adequate enzyme activity in colonic bacteria.
For the test, persons received 500mg lactose[13C]-ureide and 5g inulin, dissolved in 400ml
of water orally. Breath samples were collected every 30 minutes for 8 hours and analysed
for H2 [ppm] and 13CO2-enrichment (DOB [‰]). For the 13C-LUBT, the time at which a
DOB-increase of >2.5xSD above the running average of all previous points occurred was
considered the OCCT. The latter was defined as a rise of >10ppm above baseline with
respect to the H2-INBT. Results: In 4/27 patients, 13C-LUBT results were difficult to interpret
due to a constant increase in 13C-background production. Mean OCCT with the 13C-LUBT
was 325±58min and 294±67min for the H2-INBT (p=0.005). OCCTs determined with the
H2-INBT correlated fairly with 13C-BT results (r=0.72, p<0.0001). Bland-Altman analysis
(Fig.1) showed that the H2-INBT produced slightly shorter OCCTs compared with the 13C-
LUBT (bias -30.4 min). Discussion: Inulin is an inexpensive, alternative substrate for the
H2-based assessment of OCCT. The difference of OCCT was statistically significant, but not
for clinical purposes. In contrast to the 13C-LUBT, the H2-INBT does not necessitate patients
to refrain from physical activity during the long test procedure, which is an additional
advantage of the H2-INBT.
Bland-Altman plot comparing the results of the 13C-LUBT with the H2-INBT. Solid line =
bias; dotted line = SD.
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Delayed Small Bowel Transit Is Related to Gastrointestinal Symptoms and
Postmeal Insulin Levels in Liver Cirrhosis
Evangelos Kalaitzakis, Riadh H. Sadik, Einar Bjornsson
Gastrointestinal (GI) symptom severity has been reported to be increased in patients with
liver cirrhosis and may lead to malnutrition. Cirrhotics have also been shown to have
increased postmeal glucose and insulin levels and postmeal hyperglycemia has been proposed
to be related to poor food intake in cirrhosis. Hyperglycemia and hyperinsulinemia have
been shown to be related to reduced gut motility in healthy individuals. Gut transit has
been reported to be altered in patients with cirrhosis but it is unknown whether this is
related to GI symptoms and postprandial glucose and/or insulin increase. We aimed to
assess gut transit in cirrhotics compared to healthy controls and to evaluate its relation to
GI symptoms and to postmeal glucose and insulin increase in these patients. Methods: Forty-
two cirrhotics (median age 58 (IQR 51-64), 16F, 17 with alcoholic cirrhosis, Child-Pugh
score 6 (6-8), MELD 10 (9-14) were included. Half gastric emptying (GE) time and small
bowel transit time (SBTT) were measured with a validated radiological procedure utilizing
radiopaque markers (Sadik et al, Scand J Gastro 2003). 83 healthy subjects (age 28 (24-
39), 43F) served as controls. All subjects ingested the radiopaque markers together with a
standard 480-kcal meal. In 25 patients GI symptoms were evaluated using a validated
questionnaire (Gastrointestinal Symptom Rating Scale-GSRS) and blood was sampled for
fasting and 2h-postmeal serum insulin and glucose measurements. GSRS results were com-
pared with reference values obtained from the general population. Results: Prolonged half
GE time was observed in 6 (14%) cirrhotics vs 1 (1%) control (p=0.006). Prolonged SBTT
was observed in 5 (13%) cirrhotics vs 2 (2%) controls (p=0.038). Cirrhotic patients had
increased severity of GI symptoms (mean total GSRS score in cirrhotics 1.92, 95% CI 1.56-
2.29 vs 1.53, 95% CI 1.50-1.55 in the general population). Patients with vs without slow
SBTT had higher GSRS scores for abdominal pain (3.5 (2.3-3.5) vs 1.3 (1-2), p=0.04) and
indigestion (4.8 (3.5-4.8) vs 2.3 (1.1-3.3), p=0.048). In cirrhotics, half GE time was related
to the percent postmeal glucose increase (r=0.57,p=0.014) and the percent postmeal insulin
increase(r=0.48,p=0.043). SBTT was related to the percent postmeal insulin increase(r=0.53,
p=0.043) and the MELD (r=0.33, p=0.069). Conclusions: Cirrhotics have a prolonged
gastrointestinal transit compared to healthy controls. Increased postmeal glucose and insulin
may be of importance for slower gut transit observed in cirrhotics which is associated with
GI symptoms in these patients.
M2156
Differential Pathophysiological Changes in Mice Orally Sensitized to Casein
Or Whey Proteins
Bastiaan Schouten, Betty Van esch, Gerard Hofman, Lieke Van den elsen, Linette
Willemsen, Johan Garssen
Cow's milk allergy (CMA) is one of the leading causes of food allergy in children. Approxim-
ately 2.5% of infants exhibit CMA in Europe. Clinical features with IgE-mediated reactions
are mostly expressed as immediate symptoms, which may involve the skin, respiratory and
gastrointestinal tract. Most patients outgrow CMA by 3-5 years of age. However, IgE-mediated
CMA predisposes the development of other (food) allergies and even asthma. In order to
study local as well as systemic immunopathology a mouse model for orally induced casein
or whey allergy was introduced. For a period of 6 weeks, five week old female C3H-HeOuJ
mice were sensitized weekly by gavage (i.g.) with casein or whey (20 mg), using cholera
toxin (CT) as an adjuvant (methods adapted from Li et al. 1999 and Frossard et al. 2004).
At week 7 the mice were challenged subcutaneously (ear) (10 μg) and orally (100 mg).
Serum levels of mMCP-1, total IgE and allergen specific IgE, IgG1 and IgG2a were measured.
The acute allergic skin reaction was determined by measuring ear swelling. Immunohistoch-
emical staining for mMCP-1 was used to allow mast cell counting in ileum sections. Further-
more, isometric contraction of the ileum and colon was determined to get insight into
motility changes of the gut. An antigen specific acute allergic skin response was induced in
casein and whey sensitized mice (71.2 ± 8.4 vs 137.9 ± 21.7 µm resp., vs -4.6 ± 4.7 µm
for CT controls; p<0.01). Total IgE and mMCP-1 serum concentrations were enhanced in
both the casein and whey mice. In whey sensitized mice whey specific IgE, IgG1 and IgG2a
serum levels were enhanced, while in casein mice only casein specific IgG1 was increased.
In casein sensitized mice the number of mast cells per villus-crypt unit was enhanced
compared to whey and CT mice (1.0 ± 0.2 vs 0.1 ± 0.1 vs 0.3 ± 0.0; p<0.01). Organ bath
studies revealed motility changes in casein sensitized mice. Contractility of the ileum was
enhanced while reduced contractility of the colon was found after carbachol stimulation.
The mouse model to study orally induced allergy for cow's milk proteins, features an acute
allergic skin reaction and enhanced (specific) IgE, IgG1 and IgG2a serum levels. Furthermore,
intestinal motility changes and histopathological changes were observed revealing differences
between casein and whey sensitization.
M2157
Alcohol Use and Smoking in Chronic (CP) and Recurrent Acute Pancreatitis
(RAP): Preliminary Results from the North American Pancreatitis Study 2
(Naps2)
Dhiraj -. Yadav, M. M. Barmada, David C. Whitcomb, Consortium For the naps2
Background and Aims: NAPS2 is the largest multi-site US study to date for CP and RAP.
We used NAPS2 database to describe alcohol and smoking patterns in patients and controls,
and compared patient and physicians' responses to risk factor assessment. Methods: Experts
from 20 centers prospectively enrolled >1000 patients with CP (clinical and radiographic
criteria) or RAP (≥2 AP attacks, no firm evidence of CP) and >600 controls (unaffected
spouse, family or unrelated). Data from patient and physician questionnaires provided
detailed phenotypic, genetic and environmental information. These preliminary results
include 795 patients (54% CP, 46% RAP) and 559 controls. We classified subjects into 4
Alcohol Risk Groups using subjects' responses to any alcohol use (>20 drinks/lifetime) and
TWEAK criteria (“Hold-version”). TWEAK criteria uses 5 alcohol use questions (Tolerance,
Worry, Eye-opener, Amnesia, C/Kut-down) to determine at-risk drinking (Score range 0-7,
At-risk drinking ≥3). The groups were: 1) No alcohol use, 2) Occasional Alcohol use (>20
drinks/life, TWEAK score=0), 3) Low-risk Alcoholism (>20 drinks/life, TWEAK score 1 or
2), and 4) High-risk Alcoholism (>20 drinks/life, TWEAK score≥3). Smoking was classified
as ever, past and current. Results: RAP patients (median age 45 yrs, IQR 33-56) were younger
than CP (49, 38-59) and Controls (51, 40-60). Most subjects were Whites (≥84% all
groups), while males constituted 36%, 44% and 52% of Controls, RAP and CP respectively.
Table 1 provides alcohol use (max. drinking period) and smoking data. Physicians attributed
alcohol as risk factor in 36% (RAP) and 64% (CP) in Low-risk Alcoholism group and 74%
(RAP) and 91% (CP) in High-risk Alcoholism group. Smoking was identified as a risk factor
in only 30-45% of past and 40-80% of current smokers in Low and High-risk Alcoholism
groups. Conclusions: Alcohol and smoking are linked in CP. Alcohol use in Low-risk alcohol
groups was similar to controls, and High-risk CP group represented <1/3rd of all CP patients.
Large number of CP subjects in Low-risk alcohol exposure groups suggests that other factors
may define risk of CP in these subjects (e.g. smoking, genetic factors, other).
Drinking (max. drinking period) and smoking in Alcohol Risk groups
*No alcohol use group not included in Table (Controls 24.2%, RAP 25.3%, CP 21.3%).
Continuous data:Median (IQR). #Missing in some patients
M2158
Quality of Life (QoL) in Chronic (CP) and Recurrent Acute Pancreatitis (RAP)
with Varying Alcohol Use: Preliminary Results from the North American
Pancreatitis Study-2 (Naps2)
Dhiraj -. Yadav, M. M. Barmada, Stephen T. Amann, David C. Whitcomb, Consortium
For the naps2
Background and Aims: QOL in CP and RAP patients with varying amounts of alcohol use
is poorly understood. We used NAPS2 database to determine QOL in patients and controls
with varying amounts of alcohol use. Methods: Experts from 20 centers prospectively enrolled
>1000 patients with CP (clinical and radiographic criteria) or RAP (≥2 AP attacks, no firm
evidence of CP) and >600 controls (unaffected spouse, family or unrelated). This preliminary
evaluation is based on responses to clinical history, risk factor and QOL assessment (SF-
12) in 795 patients (430 CP, 365 RAP) and 559 controls in the NAPS2 dataset. SF-12 is a
validated multipurpose generic measure of QOL and depicts a Mental (MCS) and Physical
(PCS) summary score. The scores were norm based for easy comparison, 50 is the general
population norm. TWEAK criteria uses 5 alcohol use questions (Tolerance, Worry, Eye-
opener, Amnesia, C/Kut-down) to determine at-risk drinking (Score range 0-7, At-risk
drinking ≥3). We classified subjects into 4 Alcohol Risk Groups using subjects' responses
to any alcohol use (>20 drinks in lifetime) and TWEAK criteria (“Hold-version”): 1) No
alcohol use (<20 drinks in lifetime), 2) Occasional alcohol use (>20 drinks in life, TWEAK
score = 0), 3) Low-risk alcoholism (>20 drinks in life, TWEAK score 1 or 2), and 4) High-
risk alcoholism (>20 drinks in life, TWEAK score ≥3). Results: Proportion of subjects in
different Alcoholism groups were: No alcohol use (24.2% Controls, 25.3% RAP, 21.2% CP),
Occasional alcohol use (52.4% Controls, 43.3% RAP, 32% CP), Low-risk Alcoholism (11%
Controls, 15.4% RAP, 14.3% CP), and High-risk Alcoholism (12.4% Controls, 16% RAP,
32.5% CP). Tables below show PCS and MCS scores. Conclusions: Physical and mental
QOL is not affected in controls and RAP patients with increasing alcohol risk/use. The
reasons for severely decreased physical QOL in CP patients with extremes of alcohol use
(no alcohol and high alcohol exposure) may be different. The reasons for progressive decline
in mental QOL scores with increasing alcohol use in CP, but not control subjects is currently
unknown and need further study.
PCS in patients and controls in Alcohol Risk Groups
Values are Median (IQR)
MCS in patients and Controls in Alcohol Risk Groups
Values are Median (IQR)
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M2159
Cholecystokinin (CCK) Pancreatic Function Test Can Predict Future
Development of Pancreatic Exocrine Insufficiency in Patients with Chronic
Pancreatitis
Mansour A. Parsi, Darwin Conwell, Gregory Zuccaro, Rocio Lopez, John A. Dumot, John
J. Vargo
Background: In patients with chronic pancreatitis, the rate at which exocrine pancreatic
insufficiency develops is highly variable. Currently there is no test that can predict future
development of pancreatic exocrine insufficiency in patients with chronic pancreatitis. Aim:
To evaluate the role of CCK pancreatic function test in prediction of future development
of pancreatic exocrine insufficiency in patients with chronic pancreatitis. Methods: Twenty
four patients with chronic pancreatitis without any symptom of exocrine pancreatic insuffi-
ciency were prospectively evaluated. All patients underwent endoscopic pancreatic acinar
cell function test (ePFT) as part of their initial evaluation. The ePFT was performed after
continuous intravenous infusion of synthetic CCK (Kinevac, Bracco Diagnostics; Princeton,
NJ) as previously described. Duodenal fluid was collected with an upper endoscope
(Olympus, Melville, NY) during endoscopy at 30, 40, 50, and 60 minutes during the infusion
and the peak lipase concentration was determined in all patients. The patients had long
term follow up for detection of pancreatic insufficiency development. Diagnosis of pancreatic
exocrine insufficiency was based on development of steatorrhea responsive to pancreatic
enzyme supplementation.Results: The median duration of follow up was 6 years (Interquart-
ile range (IQR): 3, 7). Nine patients developed exocrine pancreatic insufficiency during the
follow up period with steatorrhea responsive to pancreatic enzyme supplementation. The
median peak lipase concentrations on initial CCK pancreatic function test in patients that
developed pancreatic exocrine insufficiency during the follow up period and those who did
not were 130 IU/ml (IQR 57 , 370) and 333 IU/ml (IQR 231 , 470) respectively; P = 0.043.
Peak lipase concentration was the only factor that was found to be significantly associated
with development of pancreatic exocrine insufficiency during the follow up period. For
every 2.7 fold decrease in the peak lipase concentration, the odds of pancreatic exocrine
insufficiency development during the follow up period increased by a factor of 3.8 (95%
CI: 1.1, 12.7); P=0.043. Conclusion: CCK pancreatic function test can be used in patients
with chronic pancreatitis to predict future development of pancreatic exocrine insufficiency.
M2160
Vitamin D in Exocrine Pancreatic Insufficiency (EPI): A U.K Experience
M. Srinivas, P. Basumani, Robert Ellis, R. Lord, Karna D. Bardhan
Background: Vitamin D deficiency is a recognised complication of fat malabsorption in EPI,
a problem more likely in the U.K., as periods of sunlight are less than tropical climates and
fortification of food products is not routinely practised. Aim: To study the prevalence of
Vitamin D deficiency in patients with EPI in a district general hospital in the U.K. Methods:
Prospective collection of data from patients seen with EPI (diagnosed by faecal elastase <
200, pancreolauryl test ratio < 30% or 13-C mixed triglyceride breath test < 22%) over the
last 5 years. Data collected include age and sex, cause of EPI, concurrent therapy with
enzyme supplements (Creon) or anti-oxidants (Antox), history of bone pain or fractures,
calcium profile, 25-OH Vitamin D3 levels and intact parathormone levels (iPTH). They were
grouped into those with severe (< 25 nmol/l), mild deficiency (25-50) and adequate (> 50)
levels of 25-OH Vitamin D3, in accordance with clinical practice in the U.K. Results: (see
Results table) Cause of EPI: Chronic pancreatitis 21 No cause identified 5 Conclusions:
●Vitamin D deficiency is common in EPI (21/26). When severe (12/26), it is associated
with elevated PTH in some (7/12) ●Lack of musculoskeletal symptoms does not exclude
Vitamin D deficiency ●Serum calcium, phosphate and alkaline phosphatase are poor indic-
ators of Vitamin D deficiency ●Increased awareness of Vitamin D deficiency and access to
its assay has led us to check 25-OH Vitamin D levels in all our EPI patients routinely
*Kruskal-Wallis non-parametric test (Tukey multiple comparison): p<0.05
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M2161
Association of Autoimmune Pancreatitis with Cytotoxic T-Lymphocyte Antigen
4 Gene Polymorphisms in Japanese Patients
Takeji Umemura, Masao Ota, Hideaki Hamano, Yoshihiko Katsuyama, Takashi Muraki,
Norikazu Arakura, Shigeyuki Kawa, Kendo Kiyosawa
Background & Aims: Autoimmune pancreatitis (AIP) is characterized by irregular narrowing
of the main pancreatic duct, swelling of the pancreas, high serum IgG4 concentrations, and
a favorable response to corticosteroid treatment. Although the HLA DRB1*0405-DQB1*0401
haplotype and Fc receptor-like 3 polymorphisms have been associated with AIP, the role
of other genetic factors is largely unknown. The cytotoxic T lymphocyte antigen 4 (CTLA4;
CD152) gene is an inhibitory receptor expressed on the cell surface of activated memory T
cells and on CD4+CD25+ regulatory T cells, and acts largely as a negative regulator of T
cell responses. As CTLA4 polymorphisms have recently been linked with several autoimmune
diseases, we sought to determine if CTLA4 polymorphisms and serum sCTLA4 levels were
associated with AIP as well. Methods: Five CTLA4 polymorphisms, located at -1722, -658,
and -318 in the promoter, +49 in exon 1, and +6230 in the 3' untranslated region, were
genotyped in 59 patients with AIP and 102 healthy subjects. Serum sCTLA4 levels were
also determined in cohorts of 52 patients and 32 controls using ELISA assay. Results: Analysis
of allelic frequencies revealed a significant difference between AIP patients and healthy
subjects for the SNP +6230 (χ2 = 7.50, P = 0.024). Positivity for SNP +6230A was significantly
decreased in patients with AIP (OR = 0.40; 95% CI, 0.21-0.78; P = 0.011) than in healthy
subjects, indicating a significant association of the +6230G/G genotype with AIP, which was
significantly increased (OR = 2.48; 95% CI, 1.28-4.81; P = 0.011) in comparison with
healthy controls. No other SNPs were found to be significantly associated with AIP. Haplotype,
which was the +6230A, was associated with AIP resistance (OR = 0.49; 95% CI, 0.29-0.83;
P = 0.011). Analysis of allelic frequencies revealed no significant difference between patients
with and without the HLA DRB1*0405-DQB1*0401 haplotype for +6230 SNPs. Additionally,
median serum sCTLA4 levels were significantly higher in patients with AIP (8.9 ng/mL;
IQR, 5.8-10.7) compared with healthy subjects (2.9 ng/mL; IQR, 2.1-3.8; P < 0.001).
Conclusions: Our findings suggest that AIP is associated with a genetic polymorphism in
CTLA4 and is positively correlated with serum sCTLA4 levels. The CTLA4 gene might play
a crucial role in the pathogenesis of this multi-factorial disease, and further studies are
needed to clarify its role in AIP.
M2162
Long-Term Prognosis of Autoimmune Pancreatitis Without and with
Corticosteroid Treatment
Kenji Hirano, Minoru Tada, Hiroyuki Isayama, Hiroshi Yagioka, Takashi Sasaki, Hirofumi
Kogure, Osamu Togawa, Toshihiko Arizumi, Yousuke Nakai, Naoki Sasahira, Takeshi
Tsujino, Takao Kawabe, Masao Omata
Objectives: Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis with a
favorable response to corticosteroid treatment (CST). However, little is known about the
long-term outcome of AIP. We aimed to document the prognosis without and with CST,
and to examine the indication for CST. Patients and Methods: Prognosis and clinical features
of 23 patients without CST were compared with those of 19 treated with CST from onset.
In addition, we examined factors concerning the late occurrence of unfavorable events related
to AIP. Results: The patients without CST were 19 men and 4 women, with an average age
of 66 years. After an average observation period of 25 months, 16 patients (70%) developed
unfavorable events including obstructive jaundice due to distal bile duct stenosis in 4, growing
pseudocyst in 1, sclerogenic changes of extrapancreatic bile duct in 9, hydronephrosis due
to retroperitoneal fibrosis in 1, and interstitial nephritis in 1. Patients with obstructive
jaundice at onset showed a higher cumulative event occurrence rate (P=0.025). The patients
treated with CST were 16 men and 3 women, with an average age of 64 years. After an
average observation period of 23 months, 6 patients (32%) developed unfavorable events
consisting of interstitial pneumonia in 3, and recurrence of obstructive jaundice in 3. The
cumulative occurrence rate of unfavorable events in the patients with obstructive jaundice
was lower in the CST group than in the non-CST group (P=0.032). Conclusion: CST could
reduce AIP-related unfavorable events. Early introduction of CST is recommended especially
for patients with obstructive jaundice.
M2163
Recurrent Pancreatitis: Effect of Alcohol On the Progression to Chronic Stage
Luca Frulloni, Chiara Scattolini, Antonio Amodio, Anna Katsotourchi, Cecilia Pravadelli,
Veronica Paon, Italo Vantini
Background: In Western countries, alcohol is epidemiologically associated to chronic pancre-
atitis (CP). However, its role on the pathogenesis of the disease is still unclear. Experimentally,
alcohol may activate pancreatic stellate cells and, therefore, induce pancreatic fibrosis. Alcohol
abuse may be a factor involved on the evolution from acute to CP. Aim of this study was
to investigate if alcohol is a key factor in the onset and progression toward CP. Patients and
methods: we retrospectively enrolled 133 patients (68 males and 65 females, mean age 50
± 14 yrs) suffering from recurrent pancreatitis (RP) (at least two episodes of pancreatitis)
without instrumental findings (CT, MR and RMCP, ERCP, EUS) of chronic disease, from
January 1997 to December 2003. The patients were then followed up to June 2006. For
each patients, we collected clinical, instrumental and biochemical data, as well as information
about alcohol and smoking habits. The mean follow up time from the onset of the disease
(first episode of acute pancreatitis) was 10 ± 8 years. 74 pts (56%) were non drinkers, 37
(28%) drank less than 80 g of alcohol/day and 22 (16%) 80 or more g of alcohol/day.
Results: A final diagnosis of CP was made on 77 pts (60%), 46% in non drinkers group,
62% in mild drinkers and 91% in heavy drinkers (p=0.001). Table shows the survival curve
for the diagnosis of chronic pancreatitis in the 3 groups. There was a strong association
between alcohol intake and cigarette smoking (R=0.41; p<0.0001). Other risk factors for
CP were male sex and the diagnosis of cystic distrophy of the duodenal wall, both strictly
A-464AGA Abstracts
associated with alcohol and smoking habits. Conclusions: in patients with recurrent pancreat-
itis, alcohol intake and cigarette smoking influence the progression toward chronic pancreat-
itis.
M2164
Are Abundant Igg4 Positive Cells in the Pancreas Unique to the Autoimmune
Pancreatitis?
Sung-jo Bang, Myung-hwan Kim, Tae yoon Lee, Sang soo Lee, Dong wan Seo, Sung koo
Lee, Dong eun Song, Se jin Jang
Background/Objectives: Autoimmune pancreatitis(AIP) is now well known entity with diverse
clinical manifestations and radiologic findings. Until now, several diagnostic criteria of AIP
have been proposed. However, consensus has not been made yet. Recently immunohistoch-
emical study using anti-IgG4 antibody showed unique features of AIP. Several studies
reported that lymphoplasmacytic infiltrate with abundant (>10 cells/hpf) IgG4 positive cells
in the pancreas are diagnostic for AIP. This study aimed to evaluate the usefulness of IgG4
immunohistochemical study for the diagnosis of AIP. Methods: Histologic examination and
immunohistochemical study using anti-IgG4 antibody was done in 27 patients of clinically
proven AIP with ultrasonography guided biopsy specimens or surgical biopsy specimens,
which were compared with 8 patients of surgically treated alcoholic chronic pancreatitis
and 10 patients of surgically treated pancreas cancer. Results: 37% of AIP patients group
(10/27) showed abundant IgG4 positive cells in the pancreas. 16% of non-AIP patients
group (3/18, 2 of alcoholic chronic pancreatitis and 1 of pancreas cancer) showed abundant
IgG4 positive cells in the pancreas. The sensitivity and specificity of IgG4 immunohistochem-
ical study for the diagnosis of AIP are 37% and 83%. Conclusions: The sensitivity of IgG4
immunohistochemical study for the diagnosis of AIP is low. Although the specificity is higher
than the sensitivity, abundant IgG4 positive cells in the pancreas are not unique to AIP.
Therefore, abundant IgG4 positive cells in the pancreas are only supportive findings for the
diagnosis of AIP, not diagnostic or pathognomonic for AIP.
M2165
High Association of Pancreatic and Liver Injury Caused By Alcohol
Consumption
Andrea Pace, Michael Tsokos, Katharina Hillbricht, Michael Bläker, Ansgar W. Lohse,
Andreas De weerth
Background: Chronic pancreatitis and liver cirrhosis are common sequelae of increased
alcohol consumption. Available data suggests that the two conditions are rarely associated
(1%) suggesting dissociated risk factors. Aim: The aim of this study was to establish the
prevalence of a simultaneous appearance of LC and CP in alcoholic individuals. Methods:
Post mortem autopsy analysis of 501 individuals with a history of increased alcohol consump-
tion and 100 non alcoholics as a control group was performed. The individuals were classified
in groups as follows: Pancreas: no pancreatic injury, pancreatic fibrosis, acute pancreatitis,
chronic pancreatitis. Liver: no liver injury, moderate steatosis, severe steatosis, liver cirrhosis.
Results: Out of 501 individuals 174 patients (34,7%) had no pancreatic injury, 220 (43,9%)
had pancreatic fibrosis, 29 (5,8%) had acute pancreatitis, 78 (15,6%) had chronic pancreatitis.
8 (1,6%) had no liver injury, 132 (26,3%) had moderate, 194 (38,7%) had severe steatosis
and 167 (33,3%) had liver cirrhosis. We found no CP or LC in the control group (n=100).
Out of the 167 patients with liver cirrhosis 32 (19%) had a CP and 89 (53%) pancreatic
fibrosis. Out of the 194 patients with severe steatosis 33 (17%) had CP and 88 (45%) were
found to have a pancreatic fibrosis. 32 (41%) with a CP had also a liver cirrhosis and 33
(42%) a severe steatosis. 40% of the patients with a pancreatic fibrosis were found to have
also liver cirrhosis and in another 40% a severe steatosis. Conclusion: In contrast to the
reported uncommon simultaneous occurrence of CP and LC caused by alcohol consumption
in the same individual of 1 %, we found that the two conditions are closely associated.
Moreover, also the precursor of LC and CP, steatosis and pancreatic fibrosis are commonly
found in the same individual, suggesting common risk factors being predominant.
M2166
Retroperitoneal Fibrosis Associated with Autoimmune Pancreatitis
Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta, Atsutake Okamoto
Background and Aims: Idiopathic retroperitoneal fibrosis is uncommon disorder character-
ized by formation of a dense plaque of fibrous tissue in the retroperitoneum, and its etiology
remains unknown. Autoimmune pancreatitis (AIP) is a rare group of pancreatitis characterized
by fibrosis with abundant infiltration of IgG4-positive plasma cells and lymphocytes and
obliterative phlebitis in the pancreas. AIP is frequently associated with various extrapancreatic
lesions including retroperitoneal fibrosis. Aim of this study is to clarify the clinicopathological
features of retroperitoneal fibrosis associated with AIP. Patients and Methods: During 25
years, we experienced 33 AIP patients (27 men and 6 women, average age 68.2) and 1
autopsy case (70-year-old male) of idiopathic retroperitoneal fibrosis. Clinicopathological
findings of retroperitoneal fibrosis associated with AIP were examined and compared with
those of idiopathic retroperitoneal fibrosis. Results: Retroperitoneal fibrosis was associated
in 4 (12%) AIP patients. All were male and age ranged from 62 to 76 years. Retroperitoneal
fibrosis and AIP were synchronous in 2 patients. Retroperitoneal fibrosis occurred 1 year
after choledochojejunostomy due to stenosis of the lower bile duct associated with AIP in
1 patient. The other patient underwent resection of the left lower ureter and ureterostomy
under diagnosis of a ureteral tumor. Retroperitoneal mass showed histologically marked
periureteral fibrosis with dense perivascular lymphoplasmacytic infiltration and obliterative
phlebitis, which were compatible with retroperitoneal fibrosis. Ten months later, jaundice
induced by AIP appeared. Retrospective immunostaining of the resected retroperitoneal mass
revealed abundant infiltration of IgG4-positive plasma cell similar to the pancreas. Steroid
therapy was effective for retroperitoneal fibrosis as well as AIP in all 4 patients. Idiopathic
retroperitoneal fibrosis was not responsive to steroid therapy. Autopsy revealed marked
fibrosis with few inflammatory cells in the retroperitoneum. Fibrosis invaded the pancreas,
but abundant infiltration of IgG4-positive plasma cell was not observed in the pancreas or
retroperitoneum. Conclusion: Retroperitoneal fibrosis was associated with 12% of AIP
patients. Retroperitoneal fibrosis associated with AIP respond well to steroid therapy and
showed abundant infiltration of IgG4-positive plasma cell in the retroperitoneal mass similar
to the pancreas, and seemed to be different from idiopathic retroperitoneal fibrosis.
M2167
Comparison of Diagnostic Criteria for Autoimmune Pancreatitis in Japan,
Korea and Usa
Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta, Atsutake Okamoto
Background and Aims: Nowadays, there are 3 major diagnostic criteria for autoimmune
pancreatitis (AIP) in the world. Revised Japanese criteria mandate presence of characteristic
imaging (pancreatic enlargement and irregular narrowing of the main pancreatic duct). AIP
is diagnosed when laboratory criterion (elevated levels of serum gammaglobulin, IgG, or
IgG4, or presence of autoantibodies) and/or histopathological criterion (lymphoplasmacytic
infiltration and fibrosis in the pancreas) are present in addition to imaging criterion. Korean
criteria, besides Japanese criteria, include response to the steroid and association with
extrapancreatic lesions. In criteria proposed from Mayo Clinic, AIP is diagnosed by only
diagnostic pancreatic histology; or by presence of both imaging criteria and elevation of
serum IgG4 levels; or response to steroid therapy with elevation of serum IgG4 levels and/
or other organ involvement. This study aims to discuss potential limitations of current
diagnostic criteria for AIP. Methods: Sensitivity of each diagnostic criteria was examined in
our experienced 23 AIP cases that were recently diagnosed from overall clinical standpoint.
Results: Sensitivity of diagnostic criteria in Japan, Korea and USA was 69% (16/23), 91%
(21/23) and 78% (18/23). In Japanese criteria, seronegative cases fulfilling imaging criterion
without histological examination, and cases without pancreatic enlargement could not be
diagnosed. In Korean criteria, cases without pancreatic enlargement and seronegative cases
showing spontaneous improvement could not be diagnosed. In American criteria, two
seronegative cases with other organ involvement and response to steroid therapy could be
diagnosed. Conclusions: Japanese criteria are based on minimum consensus features of AIP
and aim to avoid misdiagnosis of malignancy. When response to steroid therapy is added
to criteria, diagnostic sensitivity is indeed increased. Korean investigators recommended
diagnostic trial of steroid for cases that didn't fulfill Japanese criteria. However, as general
doctors who are not specialists of pancreatology use the criteria, we fear easy steroid trial,
when differentiation from malignancy is an issue, will result in delaying operation of pancre-
atic cancer in several cases. Characteristic histology may be a gold standard for diagnosis,
but sufficient core biopsy of the pancreas can be performed in a few limited institutes
in the world. From a point of an IgG4-related systemic disease, we recommend IgG4-
immunostaining of biopsied extrapancreatic lesions such as major duodenal papilla, bile
duct or minor salivary gland, as additional criterion to Japanese diagnostic criteria.
M2168
Autoimmune Pancreatitis: Disease Evolution and Mdct Features That Predict
Response to Steroid Treatment
Dushyant V. Sahani, Nisha Sainani, Dimitry L. Frinkelberg, William Brugge, Carlos
Fernandez del-castillo
Purpose Evaluate natural evolution of autoimmune pancreatitis (AIP) on MDCT and identify
features that may predict outcome following steroids. Materials and Methods 15/61 patients
with AIP, treated with steroids, with or without surgery and imaged, pre and post-therapy
were included in this study. Baseline and serial follow-up MDCT images were reviewed for
pancreatic, peri-pancreatic and ductal changes and correlated with clinical and laboratory
outcome. Results MDCT features noted were, diffuse swelling (13/15), loss of lobularity (15/
15), ‘halo' (12/15), focal pancreatic mass lesion (6/12), tail cut off (12/15), PD and CBD
narrowing (8/15). Following steroid therapy, there was complete resolution of findings in
5/9, partial resolution in 3/9 and no change in 1/9. 2/15 underwent surgery followed by
steroids and revealed partial improvement. Imaging features correlated with clinical outcome.
Conclusion The evolution of disease is in the form of swelling, heterogeneity and ‘halo' with
subsequent retraction of the tail of pancreas, decrease in swelling and strictures involving
the PD and CBD. Diffuse enlargement of the pancreatic parenchyma and ‘halo' are predictors
of good response to therapy. Presence of duct strictures, atrophy and focal mass in the
pancreatic head were poor predictors.
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M2169
Serum Igg4 Levels in Acute Recurrent Pancreatitis, Chronic Pancreatitis and
Pancreatic Cancer in the Usa
Amit Raina, Janette Lamb, Alyssa M. Krasinskas, Erin Fink, Arthur J. Moser, Herbert Zeh,
Adam Slivka, David C. Whitcomb
Purpose: Autoimmune pancreatitis (AIP) is an uncommon inflammatory disease of the
pancreas that usually presents with vague clinical symptoms. Histologically the affected
pancreatic tissue often shows IgG4 positive plasma cell infiltration and the serum IgG4 level
is usually elevated. AIP may be confused with pancreatic cancer (PC) on imaging studies
and because AIP usually responds to corticosteroid treatment, it is important to differentiate
it from PC. A previous study from Japan reported that elevated serum IgG4 >135 mg/dl
has 97% specific and 95% sensitive in differentiating AIP from PC. Herein we prospectively
measured the serum levels of IgG4 in subjects being evaluated for acute recurrent pancreatitis
(RAP), chronic pancreatitis (CP) and PC to determine the prevalence of unexpected AIP in
this population in the USA. Methods: Blood samples and phenotypic information on 128
consecutive patients with RAP and/or CP and 71 consecutive patients with PC were prospect-
ively collected. IgG4 levels were determined using the single radial immunodiffusion (SRID)
assay. Serum IgG4 > 135mg/dl was considered elevated. Results: No patients with RAP, CP
or PC were previously diagnosed with AIP on clinical, imaging, histological or laboratory
criteria prior to IgG4 screening. Adenocarcinoma was confirmed in all patients by pathology,
imaging and/or by clinical follow up (e.g. metastatic cancer and/or death). Two of 128
(1.6%) subjects with CP/RAP and 5 of 71 (7%) subjects with PC had elevated IgG4 levels.
Among PC patients with IgG4 elevation, mean serum IgG4 level was 160.8 mg/dl with a
range from 144.1- 194.0 mg/dl. Histology was available only for 3 (3/5, 60%) of these
patients. Immunohistochemical staining for IgG4- positive plasma cells identified a few
scattered foci in the pancreas adjacent to the cancer with significant infiltration of these
cells in the peri-pancreatic tissue (common bile duct, duodenum and lymph nodes). After
thorough evaluation, none of the patients in these cohorts with IgG4 between 135 and 200
mg/dl in these cohorts had AIP. Conclusion: Serum IgG4 between 135 and 200 mg/dl is
non specific for AIP in patients with RAP, CP and PC. In patients with established PC and
elevated IgG4 levels IgG4 rich inflammatory infiltrate was noted in surrounding non-pancre-
atic tissue. In patients with PC and elevated serum IgG4 histological evidence of underlying
AIP was not identified. Therefore in patients with pancreatic mass lesions and suspicion of
PC, IgG4 level < 200 mg/dl should be interpreted with great caution.
M2170
Smoking and Not Alcohol Consumption Predicts Disease Progression in
Chronic Pancreatitis
Julio Iglesias-garcia, Jose Larino-noia, Enrique Dominguez-munoz
BACKGROUND: Smoking and alcohol are recognised risk factors for chronic pancreatitis
(CP). Smoking has been described to enhance ethanol-induced pancreatic injury and to
accelerate the development and progression of CP. However, the effect of stopping tobacco
and alcohol consumption on the evolution of CP has not been well defined. AIM: to
investigate the effect of tobacco and alcohol consumption on the morphological progression
of CP. METHODS: 18 consecutive patients (16 male, mean age 47 years, range 38-61 years),
diagnosed of alcoholic CP by EUS were included in the study. EUS was performed under
conscious sedation by the lineal scanning Pentax EG-3830UT and the radial scanning EG-
3630UR echoendoscopes. Abstinence of alcohol and smoking was strongly recommended
to all patients. A second EUS was performed at least 24 months after the first EUS-based
diagnosis by an echoendoscopist blinded to the patients' toxic habits. EUS criteria for the
diagnosis of CP were consistently evaluated: parenchymal criteria included hyperechoic foci,
hyperechoic strands, lobularity, cysts and calcifications; ductal criteria included dilation,
duct irregularity, hyperechoic duct margins, visible side-branches and intraductal calcifica-
tions. Data regarding smoking and alcohol intake were recorded. Results are shown as
median, OR, and 95% CI, and compared by the Wilcoxon test for paired data and Fisher's
exact test as appropriate. RESULTS: The median time between first and second EUS was
27 months (range 24-41 months). Morphological disease progression was demonstrated in
10 patients (55.6%), in whom total EUS criteria increased from 6.5 (5-8) to 8 (6-9) (p<0.005),
ductal criteria from 3 (2-4) to 4 (3-5) (p<0.005), and parenchymal criteria from 4 (3-4) to
4 (3-5) (p<0.05). Six of these patients (60%) developed pancreatic calcifications. Chronic
pancreatitis progressed in only 1 out of 6 patients who stopped smoking (16.7%) vs 9 out
of 12 patients who continued smoking (75%). On the contrary, the disease progressed in
8 out of 13 patients who stopped alcohol consumption (61.5%) vs 2 out of 5 patients who
continued drinking (40%). Smoking (OR 15.0, 95%CI 1.2-185.2; p<0.05) but not alcohol
(OR 0.4, 95%CI 0.05-3.43; n.s.) was therefore associated to progression of CP. CONCLU-
SION: Smoking but not alcohol consumption predicts short-term disease progression in
chronic pancreatitis patients. Together with the usually recommended alcohol abstinence,
smoking cessation should be considered as a major therapeutic goal in these patients.
M2171
Fecal Elastase-1 Values in Patients with Chronic Pancreatitis Correlates with
Specific Parenchymal Findings On Standard MRI/MRCP
Samer Alkaade, Numan Balci, Kavitha R. Thudi, Kusal Mihindukulasuriya, Frank R.
Burton
Background: MRI with MRCP is increasingly accepted as the primary imaging modality for
the diagnosis of chronic pancreatitis, and evaluating the severity of the disease. Pancreatic
exocrine function has been well known to decrease with increasing severity of chronic
pancreatitis. Whether the decrease of exocrine function as measured by fecal elastase-1
reflects the severity of chronic pancreatitis by MRI/MRCP imaging is unknown. Purpose:
To determine whether fecal elastase-1 values in patients with established diagnosis of chronic
pancreatitis correlates with the severity of specific imaging findings. Methods: A retrospective
study of patients with ICD-9 code of chronic pancreatitis was conducted. Patients with
clinical and radiographic diagnosis of chronic pancreatitis who had pancreatic MRI/MRCP
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and fecal elastase-1 within 6 months interval were evaluated. MRI imaging was performed
using a 1.5 Tesla MR scanner (Intera, Philips Medical Systems). All MRI/MRCP images were
reviewed by two gastroenterologists and one experienced radiologist, who were blinded to
the fecal elastase-1 values. For the image assessment the following parameters were used:
1) The pre-contrast signal ratio of the pancreas to the spleen (P/S), 2) The pre-contrast
signal ratio of the pancreas to the paraspinal muscles (P/PSM), 3) the arterial to portal
venous enhancement ratio, 4) presence of atrophy, 5) morphology of the pancreatic ducts
on MRCP images. A composite total score was calculated which combines all the parameters
with an equal weight to each parameter. We used the SPSS software to calculate Pearson's
correlation between each parameter and fecal elastase-1 separately. We also calculated the
correlation between the total score of all parameters with fecal elastase-1 using the same
statistical analysis. Results: 255 patient charts were reviewed, 30 patients met the inclusion
criteria. Fecal elastase-1 levels were in a range of 10 to 600 and correlated best with the
ratio of P/PSM (Pearson 0.71, P<0.005). The decrease of pancreatic signal was proportional
to the decrease of fecal elastase-1 levels. There was also moderate correlation between fecal
elastase-1 values and the ratio of P/S (Pearson 0.55, P =0.007). There was no correlation
between fecal elastase-1 values and all the other parameters compared separately or combined
as a total score. Conclusion: In chronic pancreatitis the P/PSM ratio on MRI/MRCP images
is the most reliable parameter that correlates the best with fecal elastase-1 levels. Serial
elastase-1 levels may be as effective as the P/PSM ratio on MRI/MRCP in following the
progression of disease in chronic pancreatitis
M2172
Carbohydrate Digestion in Patients with Severe Pancreatic Exocrine
Insufficiency (PEI) Secondary to Chronic Pancreatitis (CP): Effect of Enzyme
Substitution Therapy
Enrique Dominguez-munoz, Julio Iglesias-garcia, Beatriz Cigarran, Laura Nieto
BACKGROUND: Fat maldigestion with steatorrhea is classically considered as the main
clinical problem in patients with PEI secondary to CP. Digestive action of pancreatic amylase
is partially compensated by salivary amylase, intestinal glycosidases and colonic flora, but
to what extent carbohydrate digestion is impaired in patients with PEI is unknown. AIM:
To evaluate the impact of severe PEI on carbohydrate digestion in patients with CP, and
the effect of enzyme substitution therapy in this setting. METHODS: A prospective, open,
comparative study was performed. Eight healthy subjects (age rage 28-43 years, 6 male)
and eight patients with CP and severe PEI (CFA 66-86%, age range 36-73 years, 5 male)
were included. Carbohydrate digestion was evaluated by means of a 13C-starch breath test.
A test meal consisting on a muffin (50g corn flour, 14 g fat) and 300 ml water was given
after overnight fast, and breath samples were collected in Exeteiner tubes before and in
30min intervals for 6 hours after test meal. The same test was repeated 7±2 days later in
healthy subjects by giving acarbose together with the test meal as a model of carbohydrate
maldigestion, and in CP patients under enzyme substitution therapy (40,000 USP U lipase/
meal, Creon®, Solvay Pharmaceuticals, Germany). The quotient 13CO2/12CO2 was meas-
ured by mass spectrometry. The area under the curve (AUC) of the global 13CO2 exhaled
over the 6 hour time, expressed as delta over baseline (DOB/6h), was considered as the
result of the test. Data are shown as mean±SD, and compared by ANOVA. RESULTS: Starch
breath test result tended to be lower in patients with CP compared to healthy subjects
(746.8±296.5 DOB/6h vs 1030.4±386.6 DOB/6h; p=0.12). Enzyme substitution therapy
slightly increased carbohydrate digestion in CP patients (929.8±718.6 DOB/6h, n.s. compared
to basal). Acarbose led to a marked reduction of 13CO2 elimination in healthy subjects
(AUC 272.0±144.1 DOB/6h; p<0.001 compared to basal). CONCLUSION: Carbohydrate
digestion is only slightly reduced in patients with CP and severe PEI, which does not
significantly improve under enzyme substitution therapy. Digestive action of pancreatic
amylase is greatly compensated by extrapancreatic mechanisms in patients with severe PEI.
M2173
Postprandial Protein Metabolism But Not Fecal Test Reveal Protein
Malabsorption in Chronic Pancreatitis
Airinei Gheorghe, Gaudichon Claire, Bos Cecile, Bon Cyriaque, Kapel Nathalie, Raynaud
Jean jeacques, Bejou Bakhtiar, Luengo Catherine, Fouillet Helene, Levy Philippe, Tome
Daniel, Benamouzig Robert
Consequences of pancreatic exocrine insufficiency on intestinal fat absorption are well
documented but few data exist about protein absorption. Protein digestibility, as measured
at the fecal level is not accurate because of the extensive nitrogen metabolism occurring in
the colon. In a cross-over design, we have studied the postprandial metabolism of dietary
nitrogen with and without enzymatic substitution in 9 chronic pancreatitis patients with
pancreatic exocrine insufficiency (7H, 2 F, 46 yrs). The patients ceased their enzymatic
substitution treatment 5 days before the 1st test. They took again their enzymatic treatment
3 days after this test. Five days later, a second metabolic test, identical to the first one, was
carried out. After fasting overnight, the patients ingested a single meal composed of 20 g
of 15N-labeled caseins, 73 g of carbohydrates and 18 g of sunflower oil, as well as 13C-
glycine used as a marker of gastric emptying. Blood was sampled every 30 min during 3 h
then every h during 5 h. Expired air was sampled every 30 min and urines were collected
every 2 h, during 8 h. The saddles were collected during the 5 days following the test. The
transfer of dietary nitrogen in the various nitrogen pools (feces, plasma urea, amino acids
and proteins, ammonia and urinary urea) was determining after measurements of the isotope
enrichments by Isotope Ratio Mass Spectrometry. After enzymatic treatment, 13C-glycine
oxidation did not differ from that reported without any treatment. The transfer of dietary
nitrogen tended to increase in the plasma amino acids (p = 0.09), and increased significantly
in plasma proteins and body urea. Finally, in the absence of enzymatic treatment, 18±7 %
of dietary nitrogen was transferred to the metabolic pools vs 23±7 % under treatment (p =
0.04). We did not found any differences in the faecal excretion of the food nitrogen, except
for one patient who exhibited the highest steatorhea. Conclusion: Chronic pancreatitis
patients exhibited variable protein malabsorption. This malabsorption is almost undetectable
by faecal tests, in particular when the exocrine insufficiency is moderate. Only the study
of dietary nitrogen postprandial metabolism reveal this protein malabsorption and allow
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assessment the efficiency of the enzymatic substitution. After simplification, this new test
could constitute a useful tool to better characterize pancreatic exocrine insufficiency in
particular among malnourished patients.
M2174
EUS Criteria to Diagnose Chronic Pancreatitis(CP): Should All Criteria Be
Counted Equally?
Seth A. Gross, Kanwar R. Gill, Mohammad A. Al-haddad, Timothy A. Woodward, Surakit
Pungpapong, Kyung W. Noh, Michael B. Wallace, Massimo Raimondo
Background: EUS diagnosis of CP is made when 4-5 of 9 features are present. This assumes
that all features are equivalent, but clinical experience suggests that some should carry more
weight. Aim: To identify which among all EUS known criteria are most predictive of CP.
Methods: Retrospectively, we reviewed 2 groups of pts, those with EUS criteria for CP and
those with chronic abdominal pain (CAP) without pancreatic disease. 64 pts in the CP group
had other imaging studies (CT, MRI, or ERCP) showing abnormal pancreas. Patients with
CAP had a negative work-up. EUS features were: hyperechogenic foci (HF), hyperechogenic
strands (HS), lobulations, cysts, pancreatic ductal dilation (PDD), irregular pancreatic duct
(IPD), hyperechogenic margins (HM), ductal side branches (DSB) and ductal stones. CP
was diagnosed at EUS if >4 features were identified. In the CAP group, EUS reports were
reviewed looking for the same CP criteria. Results: Over a 2-yr period, 99 pts met EUS
criteria for CP and 180 pts with CAP without CP. In the CP group, the most common
parenchymal features were HF (100%), HS (98%), and lobulations (85%). Using multivariate
logistic regression, there were marked variations in extent of association between each feature
and CP suggesting that some features are more predictive than others. PD stones, lobulations
and HS were highly associated whereas other features had less association. Ductal features
were HM (52.5%), DSB (47%), PDD (46%), and IPD (32%). There were 80 pts in the CAP
group whom had no features of CP. The remaining 100 pts had features of CP, but did not
meet criteria. The most common features included HF (29%), HS (20%), and HM (20%).
Only 2% of pts had lobulations or IPD (Table 1). Conclusions: This study suggests there
are parenchymal and ductal features which are more predictive of CP such as lobulation,
HS and IPD. This suggests certain features of CP might have more weight then others and
a weighted score may be more appropriate.
Table 1
M2175
Determination of Pancreas Specific CFTR Function with the Endoscopic
Pancreatic Function Test (Epft)
Darwin Conwell, Gregory Zuccaro, Frederick Vanlente, Edward Purich
Background.CFTR dysfunction is an etiologic factor in both acute / chronic pancreatic
disease. Current CFTR function methods(nasopotential difference, sweat chloride) have
limited availability and do not measure pancreas specific CFTR. Analysis of pancreatic fluid
for electrolytes could serve as surrogate for CFTR function. We have developed a purely
endoscopic test that collects pancreatic fluid for autoanalysis. Aims. 1)Analyze pancreatic
fluid after secretin stimulation in healthy subjects(HS). 2)Develop a regression model(LRM)
to predict nadir [Cl-] from peak [HC03-].Methods. HS underwent an IRB approved 1-hr
secretin ePFT. Pancreatic fluid electrolyte conc determined. Statistical analysis with SAS
software was performed(alpha level of 0.05.Results. A total of 32 HS had ePFT. Constant
[K+] and [Na+] and reciprocal [Cl-] and [HC03-]were observed. The mean (+/- SD)nadir
[Cl-] and peak [HC03-] was 46 +/- 14 meq/L and 103 +/- 10 meq/L, respectively. Both [Cl-
] and [HC03-]distributions passed tests for normality. Peak [HC03]determined to be highly
correlated to [Cl-]. A LRM was developed using peak [HC03-] (independent variable, x) to
predict nadir [Cl-] (dependent variable, y) (p<0.0001). The model is displayed in figure (R
square =0.7018. Model equation: [Cl-] meq/L = 150.3 - 1.0922 x [HC03-] meq/L. A [Cl-
] + [HC03-] product of 143 meq/L suggests normal CFTR function. Conclusions. 1)Pancre-
atic fluid nadir [Cl-]can be estimated after secretin stimulation. 2)The ePFT can be utilized
as a direct test of pancreas specific CFTR function.
Correlation of Peak [HC03] to Nadir [Cl-]
M2176
Epidemiologic Evidence to Support the Association and Impact of CFTR
Mutation (Exposure)On Development of Chronic Idiopathic Pancreatic
(Disease)
Darwin Conwell, Gregory Zuccaro
Background There is an increasing body of evidence that CFTR mutations may cause both
acute and chronic pancreatic disease(CP). A recent large case control study (Alazmi et al.,
GIE 2006;63:234-9) reported the “association” of CFTR mutations and chronic idiopathic
pancreatitis. This important study data can also be analyzed to measure the “impact” of
CFTR mutation exposure on chronic idiopathic pancreatic disease Aims 1) Determine
measures of association and impact of CFTR mutation exposure on idiopathic chronic
pancreatitis. Methods CFTR mutations determined by serologic genetic testing. Chronic
pancreatitis defined as abnormal pancreatogram imaging on ERCP. Analysis: Case control
specific epidemiologic analysis.Results A total of 287 subjects were reported in the case
control study. A 2x2 table is shown below. Measures of Association of CFTR exposure: The
odds of exposure in diseased and non-diseased was 0.409 and 0.230 respectively. The odds
ratio (OR) was 1.8 [1.02,3.09](Χ2 Mantel-Haenszel = 4.189, p-value 0.040). The risk of
disease in exposed and risk of disease in non-exposed was 62 and 48 percent respectively.
The relative risk (RR) was 1.29 [1.02, 1.63]. The overall risk difference was 51.5% [45.7,57.2].
Measures of Impact of CFTR exposure: The proportion of idiopathic chronic pancreatitis
due to CFTR mutation exposure (attributable risk percent, AR%) was 44%. The proportion
of chronic pancreatitis in the general population that would not have occurred in the abscence
of CFTR exposure(population attributable risk percent, PAR%) was 10.5%. Conclusions 1.
There is epidemiologic evidence that CFTR mutation exposure is associated and impacts
chronic “idiopathic” pancreatic disease. Clinical implication: All patients with “idiopathic”
chronic pancreatitis should be tested for CFTR mutations to determine disease etiology and
assist with family planning.
Comparison of CFTR Mutation Exposure and Chronic Idiopathic Pancreatic Disease
Odds Ratio: [odds exposed / odds unexposed] [(43x26)/(105x113)] = 1.8 [1.02, 3.09]
Attributable Risk Percent(AR%): [OR -1 / OR] x 100 = [(1.8 - 1) / (1.8) ] = 44% Population
Attributable Risk Percent( PAR%): AR% x Prevalence in exposed= 44 x (0.240) = 10.5%
M2177
Natural History and Phenotype-Genotype Correlations in Pancreatitis
Associated with CFTR Gene Mutations (CF-P)
Anne-laure Pelletier, Thierry Bienvenu, Dermot O'toole, Olivia Hentic, Vinciane Rebours,
Frédérique Maire, Alain Aubert, Marie-pierre Vullierme, Pascal Hammel, Philippe Lévy,
Philippe Ruszniewski
CFTR gene mutations are a well-established cause for recurrent acute/chronic pancreatitis.
Data about natural history of CF-P as well as genotype-phenotype correlations are scarce.
Aims and methods: 1) evaluate the frequency of CFTR gene mutations in patients referred
for “apparently idiopathic” recurrent acute/chronic pancreatitis compared to that of the
general population; 2) examine for a phenotype and genotype relation. All patients referred
between 1998 and 2005 with “apparently idiopathic” pancreatitis were included. All known
etiologies (mainly alcohol, bililary lithiasis, tumors, autoimmune, metabolic, hereditary…)
were carefully excluded. CFTR gene mutations were searched for after informed consent.
The 31 most frequent mutations were detected by oligonucleotide probe linkage, followed
by complete sequencing of the CFTR gene in positive cases. Results : 50 of the 100 patients
(50%) with “apparently idiopathic” pancreatitis had a CFTR mutation, as compared with
4% in the general population (p< 0.0001). At least 1 major mutation (mainly DF 508), 1
minor mutation (S1235R…) and a gene polymorphism were found in 16, 20 and 14 patients,
respectively. All patients but 1 (vas deferens agenesis) had no symptoms of cystic fibrosis.
Median age at first symptom (40 vs 34 years), duration of follow-up (4 vs 3 years), proportion
of patients with acute pancreatitis as first symptom (76 vs 74 %) were not different between
patients with and without CFTR gene mutations. CT severity score was higher in patients
with CFTR mutations (≥ 4 in 24 and 14 % of the patients, respectively; p <0.005). Pancreatic
calcifications, pseudocysts, biliary stenosis, exocrine or endocrine insufficiency occurred in
36, 26, 4, 10 and 12 % of the patients with CFTR mutations, respectively (NS as compared
with those without). No significant difference was found according to the type of CFTR
mutations. Conclusions: CF-P is diagnosed at a relatively old age. Its manifestations do not
differ from those of idiopathic pancreatitis. CF-P may be responsible for necrotizing pancreat-
itis and evolve towards chronic pancreatitis. No phenotype/genotype correlation was
observed.
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M2178
Hereditary Pancreatitis Age-At-Onset Is Associate with Multiple Genetic Risk
Factors
Narcis Zanescu, Sirvart Kassabian, Lori Kelly, Janette Lamb, Michael Barmada, David C.
Whitcomb
Background. Hereditary pancreatitis (HP) is an autosomal dominant disorder of recurrent
acute and chronic pancreatitis. The age of onset and disease severity differ widely between
individuals and families. The variability of phenotype expression in hereditary pancreatitis
may be determined by genetic or environmental factors. Methods: Subjects with HP and
controls were prospectively ascertained under IRB approved protocols. Fifty-five HP subjects
with established age-at-onset were classified into one of four 5-year intervals (A. 0-4y; B.
5-9y; C.10-14y; D.15 or >y). All subjects and 50 unrelated controls were genotyped for
PRSS1 (exon 2 and 3), SPINK1 (N34S/exon2) and CFTR intron 6a, 8, 9 and exon 3, 10,
14a and 24 polymorphisms by PCR and sequencing. Results: All HP patients had at least
one mutation in PRSS1 gene (R122H, N21I, A16V, R122C). SPINK1 N34S was detected in
11 HP patients and in two controls (p=0.018). In HP subjects CFTR gene variants were
identified in exon 3 (R75Q), intron 6 (875+40A>G), exon 10 (delF508, 1540A>G) and
intron 9 (1522-51A/G), intron 8 (GT repeats and polyT sequence), exon 14a (2694T>G)
and exon 24 (4521G>A). The number of mutations per patient (including PRSS1) was (A)
2.68, (B) 2.09, (C) 1.75, (D) 1.5 while controls averaged 0.32 mutations/patient. Conclusion:
Gain-of-function mutation in the PRSS1 gene are associated with hereditary pancreatitis.
The clinical feature, including age-at-onset is strongly influenced by other factors including
genetic risk factors in SPINK1 and CFTR genes.
M2179
Gp2 Mutations in Chronic Pancreatitis
Karen C. Kim, Peidong Shen, Peter Oefner, Stefan H. Seewald, Elizabeth Cruz, James W.
Ostroff, Roy M. Soetikno, Anson W. Lowe
Background: Several genetic mutations have been associated with chronic pancreatitis. These
known mutations, however, account for only a small proportion of all cases. This study
examined the potential role of GP2, a major zymogen granule membrane protein. Because
of strong structural similarity, GP2 is classified with the ZP domain protein family. Mutations
in other ZP proteins cause human disease and include uromodulin (medullary cystic kidney
disease) and a-tectorin (hereditary deafness). This study evaluated chronic pancreatitis
patients for GP2 mutations. Methods: Chronic pancreatitis patients meeting diagnostic criteria
were recruited after providing consent. Each patient provided a blood sample, and filled
out a questionnaire. Genomic DNA was isolated from leukocytes and examined with DHPLC
for each of the 10 GP2 coding exons by forming a heteroduplexed to a normal control.
DHPLC was initially performed on 20 samples, with 2 normal controls and 18 affected
patients. Alterations detected on DHPLC were subsequently analyzed and confirmed by
direct sequencing. The GP2 coding exons for an additional 20 affected patients from Germany
were amplified and directly sequenced. For controls, the GP2 sequence for DNA from the
CEPH-HGDP1-2-1 collection of anonymous donors from around the world was determined
(n=100). DNA sequence was analyzed using Sequencher(TM) to distinguish missense and
nonsense mutations. Results: Two missense mutations were detected among a total of 38
patients with chronic pancreatitis, one was a serine to proline mutation in Exon 3 in one
African-American female and an alanine to threonine mutation in Exon 3 in two German
male patients. No missense mutations were found in the controls from the Stanford Genome
Technology Center DNA bank. The SIFT program was then used, which is a sequence
homology-based tool that predicts whether or not amino acid substitutions will have a
phenotypic effect. The SIFT program predicts that the mutation seen in two German patients
would likely affect the protein's function. Conclusions: The present study describes two
missense mutations discovered among a total of 38 patients with chronic pancreatitis and
without a known family history of the disease. No such mutations, however, were found
in a random population of 100 normal individuals from a DNA bank. These findings
represent two candidate mutations in GP2 that may play a role in the pathogenesis of
chronic pancreatitis.
M2180
Association of Pancreas Divisum and Recurrent Acute Pancreatitis with the
Ivs8-5t-12g Allele of the CFTR Gene and CFTR Dysfunction
Xavier Dray, Isabelle Fajac, Thierry Bienvenu, Ariane Chryssostalis, Philippe Sogni,
Dominique Hubert
Pancreas divisum (PD) occurs in approximately 10% of individuals. Although a small minority
of patients with PD develop acute pancreatitis (AP), PD is found in up to 25% of patients
with unexplained AP. Mutations of the CFTR gene have been associated with idiopathic
pancreatitis. We report on two patients with PD, recurrent AP and CFTR-related disease.
They had similar clinical patterns (young female adults, non-severe onsets of AP, mild upper
airway manifestations, no major clinical criteria for cystic fibrosis). They had mild mutations
of the CFTR gene (one IVS8-5T-12TG allele associated with another mutation or variant
on the other allele) and mild abnormalities of the CFTR function (increased sweat chloride
concentrations and/or normal basal nasal potential difference but low responses to low
chloride and/or isoproterenol solutions, as shown in the figure below). These observations
suggest that impaired epithelial ion transport due to mild CFTR genotype (namely IVS8-
5T-TG12), might be involved as a triggering factor in acute onsets of pancreatitis in PD,
possibly through abnormal pancreatic fluid secretion.
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Nasal potential difference (NPD) tracings in patient 1 (A), 2 (B). Basal potential difference
was measured with a Kreb's HEPES solution (KH), after which the nasal epithelium was
superfused with amiloride (10-4 M) (Amil), Cl- free solution (0 Cl-) and isoproterenol (10-
5 M) (Iso). Basal NPD and response to amiloride, estimating Na+ transport regulated by
CFTR, were normal in patients 1 and 2. Responses to low chloride solution and isoproterenol,
indicative of basal and cAMP-dependent Cl- permeability, respectively, were abnormal in
our patients.
M2181
Frequent PRSS1 R122h Mutations in Westphalia (Germany) Do Not Result
from a Founder Effect
Frank U. Weiss, Martin Zenker, Peter Simon, Markus M. Lerch
Background: R122H , the most frequent point mutation in exon 3 of the trypsinogen gene
(PRSS1) is detected in approx. 75 % of patients with hereditary pancreatitis. Patients and
families with this particular mutation have been found world-wide and a large number of
affected families originate from within a small region of Westphalia in Germany. We investig-
ated whether an unknown relatedness between these kindreds ('founder effect') exists.
Patients and Methods: Patients and non-affected members over 2 or more generations could
be recruited from 10 HP-families (all R122H), and genomic DNA was isolated from peripheral
blood leukocytes. Using PCR and genomic sequencing we determined R122H associated
haplotype blocks by analysis of 8 SNPs (including 4 htSNPS) located in close vicinity of
the PRSS1 locus. Results: R122H mutations segregated with 7 different haplotypes indicating
that this specific mutation must have occured as an unrelated event in most of the analysed
HP-families. A comparison with data from the HapMap project indicates that the identified
R122H associated haplotypes correspond to the most frequently found haplotypes in the
central European population. Conclusions: The high prevalence of HP kindreds in Westphalia
could be accounted for by ascertainment bias in a tertiary referral center, inheritance from
a once existing founder or by multiple unrelated mutations at precisely the same site of the
PRSS1 gene. Our results do not support the notion of a founder effect as the cause of the
high prevalence of HP in Westphalia, but support the presence of a mutational hotspot in
codon 122 of the cationic trypsinogen gene.
M2182
Detection of Pancreatic Elastase Isoforms 3a and 3b By a Polyclonal Elastase
ELISA
Frank U. Weiss, Manuel Ruthenbuerger, Jan Gebel, Uwe Voelker, Elke Hammer, Markus
M. Lerch
Subject: The genes of five different isoforms of human pancreatic elastase ( 1, 2A, 2B, 3A,
3B) have been identified, of which human pancreatic Elastase 1 is not expressed in the adult
pancreas. Pancreatic elastase secretion from the pancreas, indicative of exocrine pancreatic
function in clinical routine, is anlysed using commercial Elastase stool tests. While the
diagnostic value of the specific elastase isoforms is unknown to date, two commercial Elastase
ELISAs (monoclonal or polyclonal) have been reported to recognise presumably different
proteins. We investigated the isoform specificity of the polyclonal elastase ELISA. Material
and Methods: Recombinantly expressed Elastase isoforms as well as human pancreatic juice
were analysed by one or two-dimensional electrophoresis, followed by Westernblot analysis
using polyclonal anti-Elastase antibodies that are used in the commercial ELISA (Bioserv
Diagnostics, Germany). MALDI-TOF-MS analysis was used to clarify protein identity and
elastase-activity of precipitated proteins was confirmed by a specific fluorogenic elastase
substrate. Finally cross-reactivity against pancreatin from porcine pancreas was also tested.
Results: The polyclonal antisera against human Elastase detect a single ~30kDa protein
which is associated with an elastase activity that can be detected by a specific fluorogenic
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Elastase substrate. MALDI-TOF-MS-Analysis of Elastase-crossreactive 2D-Gels revealed the
presence of pancreatic Elastase 3A and 3B isoforms. Western blot analysis of pancreatin
from porcine pancreas in addition revealed no cross-reactivity with the anti human Elastase
antisera. Conclusion: Antibodies that are commonly used in a polyclonal commercial Elastase
ELISA preferentially detect human Elastase Isoforms 3A and 3B, and do not cross-react with
porcine pancreatin. We demonstrate, that pancreatic elastase 3 isoforms clearly possess
Elastase activity against a fluorogenic Elastase substrate. Since it has been reported that
pancreatic elastase 1 is not expressed in the pancreas, the identity of isoforms detected by
the monoclonal Elastase ELISAs remain unknown. The diagnostic/prognostic value of specific
elastase 2 and 3 isoforms in the assessment of exocrine pancreatic insufficiency will need
further evaluation.
T1111
Medical Malpractice Data in Gastroenterology: Use of the Piaa Insurance
Claim Database
Laurie S. Conklin, Catherine Bernstein, Lori Bartholomew, Maria M. Oliva-hemker
INTRODUCTION: Gastroenterologists commonly perceive themselves to be at increased
legal risk among medical subspecialists due to their performance of procedures. However,
there is little published information about gastroenterology (GI) malpractice claims. Since
1985, the Physician Insurers Association of America (PIAA), an association of medical
malpractice insurance companies, has maintained a database of claims submitted by its 40
members. The goal of this study was to evaluate GI claim data to identify areas of legal risk.
METHODS: An analysis was performed of all claims within the GI field (patient age >18
years) submitted to the PIAA database from Jan 1, 1985 to Dec 31, 2005. A claim, defined
as any demand by a patient for compensation, must be reported by the physician to the
covering insurance company. A claim does not require legal papers to be filed in court and
may be closed prior to becoming a lawsuit. If it does become a lawsuit, it may be settled
or taken to trial, and then closed. When submitting claims, insurance companies enter
information into a series of data fields that are captured by the PIAA database. A secondary
analysis over the same time period compared GI claims to those of 27 other subspecialties.
RESULTS: Of the 236,641 total claims submitted, 2,394 (1%) were within GI. Of the 1,867
physicians involved in the GI claims, 97% were male, 96% were practicing full time, 66%
had previous claims experience, 84% were board certified, 75% were US medical school
graduates, and 78% were between the ages of 35 and 54. GI ranked 20th out of 28 among
specialties in total claims and 20th in total paid indemnity. The average indemnity paid was
$238,472. Among 1,954 GI claims, the most frequently identified medical misadventures
included “errors in diagnosis” in 545(28%), “improper performance of procedures” in
483(25%), and “no medical misadventure” (defined as having associated issues such as
consent/medical records) in 370 (19%). Among procedures, performance of colonoscopy
had the most total claims (52%). Resolution among 1069 reported GI claims was via
settlement in 765 cases (72%), involuntary dismissal in 156 claims (15%), judgement
for the defendant in 99 claims (9%), and judgement for the plaintiff in 22 claims (2%).
CONCLUSIONS: GI does not rank highly among medical specialties in the number of
malpractice claims or in paid indemnities. Only a quarter of the claims involved the actual
performance of a procedure. The majority of claims are settled out of court. Within the
U.S., the PIAA database is a useful resource for examining legal trends in the medical field.
T1112
Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus
Infection, and Sexually Transmitted Infections in Substance Abuse Treatment
Programs in the United States
Edmund J. Bini, Steve Kritz, Lawrence S. Brown, Jim Robinson, Don Alderson, John
Rotrosen
Background: Although substance abuse treatment programs are an important point of
contact to provide health services to diagnose, treat, and prevent transmission of HIV/AIDS,
hepatitis C virus (HCV) infection, and sexually transmitted infections (STI), many drug
treatment programs do not offer these services. The aims of this study were to determine
the proportion of substance abuse treatment programs that did not offer health services for
HIV/AIDS, HCV, and STI, and to identify barriers to offering these services. Methods: We
conducted surveys of drug treatment program administrators and clinicians within the
National Drug Abuse Treatment Clinical Trials Network across the United States to evaluate
the availability of 4 medical services (medical history/physical examination, biological testing,
medical treatment, medical monitoring), 4 non-medical services (provider education, patient
education, patient risk assessment, patient counseling), funding, and other key elements
involved in testing, evaluating, and caring for patients with HIV, HCV, and STI. Results:
Completed surveys were received from 269 of the 319 treatment program administrators
(84.3%) and 1,723 of the 2,210 randomly selected clinicians (78.0%). The majority of
substance abuse programs were private not-for-profit organizations (78.8%) and were free-
standing facilities (60.7%). One or more medical staff was present in 78.9% of programs,
and 41.2% of programs reported a current patient census of more than 500 clients. Of the
8 medical and non-medical services, the median number of health services offered was 6.0
(interquartile range [IQR], 3.0 - 7.0) for HIV/AIDS, 4.0 (IQR, 2.0 - 7.0) for HCV, and 4.5
(2.0 - 7.0) for STI (p <0.01). A high proportion of substance abuse treatment programs did
not offer any of the 4 medical services either on-site or by referral for HIV/AIDS (29.8%),
HCV (41.0%), or STI (39.8%) (p = 0.02). In contrast, a lower proportion of drug treatment
programs did not offer any of the 4 non-medical services on-site or by referral for HIV/
AIDS (4.7%), HCV (13.7%), or STI (13.6%) (p <0.01). The most common barriers identified
by program administrators and clinicians included funding, patient health insurance benefits,
patient acceptance, and staff training, with funding identified as the single biggest obstacle
to providing health services for these infections. Conclusions: Health service delivery for
HIV/AIDS, HCV, and STI is less than optimal in drug treatment programs, and there are
numerous barriers to providing these services. Public health interventions to overcome these
barriers to care afford an opportunity to enhance treatment and prevention.
T1113
Who Gets Listed for Liver Transplantation: Do Psychosocial Determinants
Contribute to Racial/Ethnic Disparities
Karen E. Kim, Rakesh Jotwani, Nancy Reau, Jennifer Frankel, Guiliano Testa, Donald M.
Jensen
Background: Disparities in receipt of liver transplantation (LT) among minorities have been
reported. To date no study has investigated the role of psychosocial factors and family
structure among minorities undergoing LT evaluation. Our pilot study evaluated the impact
of the psychosocial assessment as a contributing barrier to LT listing among Black (B) and
Hispanic(H) compared to White (W) patients. Methods: All patients evaluated for LT at the
University of Chicago from 2005-2006 were retrospectively analyzed using medical records
from the liver transplant group. Demographic data, socioeconomic status, LT status, time
on the wait list and psychosocial evaluation were compared between W, B and H populations.
Results: Between 2004-2006, 3101 patients were seen in the outpatient liver clinic. Race/
ethnicity data was available for 56% of this population; 53% B, 39% W, 5% H. Fifty three
patients underwent LT during this time; 67% W, 10% H and 16% B. Table 1 lists demographic
data from each group. Table 2 lists results of the psychosocial evaluation. Summary: Despite
the predominance of educated, insured African Americans patients seen in our liver clinic,
the majority of transplanted patients were White. On average, African American patients
spent over 4 times longer on the wait list, had higher MELD scores, were more likely to
reside within the surrounding community, were more likely denied transplantation due to
perceived lack of psychosocial support, were less likely to be assigned positive assets and
were significantly more likely assigned negative descriptors categorized as liabilities, including
cognitive weaknesses, poor social support and lack of motivation. Although Hispanic patients
were less likely to receive high rating for medicine and appointment compliance, time on
the wait list was similar to that seen in Whites. Conclusions: This pilot study underscores
the need for culturally competent pre-LT evaluation for minorities. In particular, understand-
ing the role of the extended family structure, and being aware of perceived biases and
stereotypes attributed to minority populations are important steps in reducing disparities
in receipt of LT.
Table 1: Demographic Data and LT status
Table 2: Psychosocial evaluation (perceptions)
T1114
Reflux Symptom Profiles Are Not Different in GERD Patients with and
Without Barrett's Esophagus
Sachin B. Wani, Amit Rastogi, Ajay Bansal, Sharad Mathur, Sandy Hall, Prateek Sharma
Background Screening for BE in patients >50 years of age with long-standing GERD symptoms
has been suggested. The efficacy of screening in patients with chronic GERD depends on
the sensitivity of this strategy for detection of BE. The holy grail of BE screening lies in risk
stratification - identification of GERD individuals at risk for BE. Aim To compare reflux
symptom profiles in newly diagnosed BE patients to patients with GERD without BE using
a validated GERD symptom questionnaire. Methods Consecutive patients presenting for
index endoscopy for GERD symptoms were prospectively enrolled. Patients completed a
validated GERD questionnaire (GERQ) that documents and grades onset, frequency and
severity of heartburn and acid regurgitation. For this analysis, duration was classified as <1,
1-5 and > 5 years; frequency as daily, weekly, 1/month or < 1/month; and severity as mild,
moderate, severe and very severe. Information was also collected on age, gender, ethnicity,
smoking and use of ASA/NSAIDs, and acid suppressive medications. BE was confirmed by
intestinal metaplasia on biopsy. Univariate followed by multivariate logistic regression ana-
lyses were performed. Results 840 pts completed the study (91% males, mean age 57.5
yrs). BE was diagnosed in 119 pts (overall frequency 14%). There was no difference in
mean age of BE pts compared to non-BE group (58.7 vs. 57.5 yrs, p=0.36); 22% of BE pts
were diagnosed before age 50 with no significant increase in BE prevalence with advancing
age. Mean BE length was 2.38 cm (range 0.5-12) with majority (74%) demonstrating short-
segment BE (<3cm). On univariate analysis, BE pts were more likely to be Caucasian (p=
0.007) and taking PPI (p=0.01) at index endoscopy. A longer duration (> 5 yrs) of heartburn
(69% vs. 58%, p=0.02) and regurgitation (65% vs. 50%, p=0.01) with severe symptoms
(40% vs. 28%, p=0.01) was observed in BE pts. Multivariate analysis, however, showed no
significant difference in duration, frequency and severity of heartburn or regurgitation
between BE and non-BE GERD pts. Conclusions In this large GERD population referred for
endoscopy, duration, severity and frequency of symptoms were not reliable indicators for
presence of BE. Also, 30% of BE patients did not suffer from long-standing GERD symptoms
(>5 years) and approximately 25% had BE diagnosed before age 50. Thus, the current
screening guidelines will fail to identify a significant proportion of BE patients explaining
the limited impact of current screening practices. Future screening strategies for BE should
not be linked to symptom profiles of GERD patients and age >50 years.
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T1115
Colorectal Cancer Screening with FOBT: Can We Extend Our Reach; A Meta-
Analysis and Model for Improving Widespread Adherence
Howard L. Saft, William Lawrence
Objective: To conduct a systematic review of the effectiveness of patient-targeted interventions
to improve adherence to colorectal cancer screening using fecal occult blood testing (FOBT)
and to estimate the number of people screened using different intervention target strategies.
Methods: The literature was reviewed from 1980 to 2004 for RCTs assessing patient-
directed interventions to improve adherence to FOBT. We used meta-analysis to compare
the interventions directed at different eligible target populations, including both inreach
(age appropriate patients seen by their caregiver within 1 year) and outreach (all age
appropriate patients). A decision analysis of a large scale intervention program was created
to compare outreach, inreach, and no intervention. Sensitivity analyses were performed to
incorporate either FOBT or endoscopy as a modality of screening. Results. The meta-analysis
showed that both outreach (OR 1.68; 95% CI 1.26- 2.24) and inreach (OR 1.47; 95% CI
1.12-1.92) had significant improvements in adherence to FOBT compared to no intervention.
The model showed large scale outreach programs would increase the rates of screening
compared to inreach and no intervention. Conclusion. Both inreach and outreach interven-
tions demonstrated significant improvements in screening rates, although the two categories
were not significantly different from each other. Patient-directed adherence interventions
should be considered as part of any screening strategy. Given the broader population affected,
outreach interventions should be considered a vital part of a screening program to increase
adherence to FOBT, and potentially any other screening modality.
T1116
Factors Associated with Immigrant Status Have a Complex Influence On the
Rate of Missed Appointments for Gastrointestinal (GI) Endoscopic Procedures
Anuj Datta, John M. Inadomi, Hal F. Yee
Missed procedure appointments are a major challenge to patient care, the economics of GI
practice, and correcting the demand:resource disparity for GI care. There has been much
discussion about the impact of immigration on healthcare utilization and several factors
associated with immigrant status have been shown to affect medical compliance. Aim: To
test the hypothesis that factors associated with immigrant status, particularly language,
income, and health insurance, influence the likelihood that a patient will show up for a
scheduled procedure. Methods: We conducted a case control study of all patients scheduled
from 01/01/04-12/31/04 for outpatient GI endoscopy at San Francisco General Hospital.
The following information was collected for each patient: did they show up (cases) or not
(controls), appointment time/date, procedure type and indication, patient language, birthdate,
gender, race, zip code, and health insurance status. Chi-square test assessed the relation
between categories for each variable. Logistic regression modeled the association between
the dependent variable and the independent variables that were significantly associated in
univariate analysis (p < 0.05). Multivariate analyses were performed to adjust for the contribu-
tions of the other factors. Results: We studied 1505 patients, of whom 76% showed up for
their procedure and 24% did not. Of the total, 61% spoke English, 20% a Chinese dialect
(no English), and 19% Spanish (no English); all zip codes in the city were represented; and
63% had medical insurance. Univariate analysis revealed that Chinese dialect speakers missed
appointments less often than English speakers and there was no difference in show rate
between English and Spanish speakers. Multivariate analyses confirmed that speaking a
Chinese dialect was a predictor of higher show rates, while Spanish language showed no
effect. Patients from the zip codes with lowest median household income had the lowest
show rates. Multivariate analyses confirmed this association with income. Finally, our analyses
demonstrated that the presence or absence of health insurance did not alter show rates.
Conclusions: Surprisingly, speaking a language other than English was not associated with
more missed appointments, and in the case of Chinese speakers there was an association
with fewer missed appointments. Also unexpected was the absence of an association between
the presence of health insurance and missed appointments. As predicted, lower income was
associated with more missed appointments. The factors associated with immigrant status
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appear to have a complex influence on the likelihood that a patient will show up for a
GI procedure.
T1117
Mass Media Influences Patients' Decisions to Undergo Colorectal Cancer
Screening
Darren M. Brenner, John M. Inadomi
Background & Aims: Colorectal Cancer (CRC) remains the second leading cause of cancer
related death in the United States despite evidence illustrating the mortality benefit from
screening. Prior studies have identified who could function as the best proponent for CRC
screening, and the “Katie Couric Effect” revealed that celebrity advocacy may increase
adherence. The purpose of this study was to prospectively define the role of multiple mass
media modalities in patients' decisions to undergo CRC screening. Methods: 112 (60 male/
52 female) average risk patients undergoing screening colonoscopy at a dual-site institution
completed a previously piloted survey instrument asking them to delineate factors associated
their decisions to undergo CRC screening. Demographic information including gender, race/
ethnicity, level of education and socioeconomic status was obtained. The data was analyzed
descriptively, and logistic regression was used to adjust the results for the influence of
demographic variables. Results: The proportion of subjects for whom mass media events
were reported to have some influence on their decision to undergo CRC screening was 46%
(television public service announcements [PSAs]), 47% (the American Cancer Society “Pink
Polyp” commercials) and 32% (the Katie Couric television campaign). However, mass media
events constituted the major influence behind the decision to undergo screening in only 3-
6% of the sample. Internet resources had no influence in the overwhelming majority of
subjects. Almost three quarters of subjects identified a recommendation from doctors/nurses
as the major reason for undergoing CRC screening. Inclusion of demographic factors did
not significantly alter the effect from mass media with regards to the decision to undergo
screening. Conclusions: While mass media influences peoples' decisions to undergo CRC
screening, the role of physician/nurse advocacy and patient education remains tantamount
for adherence to current CRC screening guidelines.
Mass Media Influences on Colorectal Cancer Screening
T1118
A Resident Physician Education Program Does Not Improve Colorectal Cancer
Screening Referral Rates
Sandi L. Manus, Omotayo Majekodunmi, Joel T. Bruggen, Richard B. Weinberg
Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the
USA. Although CRC screening (CRCS) programs can reduce the incidence of CRC, less than
50% of the US population ≥ age 50 undergoes CRCS at recommended intervals. Data
suggests that patients may be more responsive to CRCS recommendations from their personal
physicians than from other sources. We thus sought to determine whether educating resident
physicians about the importance, impact, and methods of CRCS would increase CRCS
referral rates. Design: Prospective, randomized, intervention trial. Methods: Internal Medicine
residents were recruited and randomly assigned to an intervention or a control group. The
intervention group (n=12) was given a 20 min lecture on CRCS; The control group (n=10)
was given a lecture on NSAID morbidity and mortality. Electronic reminders about the
lecture topics were sent every 3 months. Charts of all patients ≥ age 50, seen in each
resident's outpatient clinic during the 6 months before and 9 months after the lectures,
were reviewed to assess pre- and post- intervention CRCS referral rates. Results: Intervention
group physicians saw 196 patients; The control group saw 125 patients. The intervention
patient cohort contained more females (60.7% vs 48.8%, p=0.036) and had a lower incidence
of COPD/asthma (14.8% vs. 27.2%, p=0.006) than the control cohort; otherwise, there was
no difference between cohorts in mean age, ethnicity, or frequency of cancer, hypertension,
diabetes, renal insufficiency, ASCVD, dementia, or liver disease. There was no difference in
pre-lecture CRCS rates between the intervention and control groups (50.5% vs. 54.4%, p=
0.70). After the intervention, 30/97 (30.9%) of eligible patients seen by the intervention
group physicians and 18/55 (32.7%) of eligible patients seen by the control group were
referred for CRCS (p=0.85). Overall, 65.8% of patients in the intervention group and 68.8%
of patients in the control group were referred for CRCS. A univariate analysis using patient
age, gender, ethnicity, and the comorbid conditions listed above revealed that only the
presence of dementia decreased the likelihood of being referred for CRCS (0.5% vs. 4.0%,
p=0.02). Conclusion: Our data shows that a single brief educational lecture with quarterly
electronic reminders had little impact on CRCS refrerral rates in resident physicians' clinic.
Of a number of comorbid conditions, only dementia was found to decrease the likelihood
of being referred. The data suggests that a more intense educational intervention, such as
a lecture series and/or more frequent reminders, would be required to improve the rate of
referral for CRCS.
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T1119
Trends of Gastroparesis-Related Hospitalizations in the United States, 1995-
2004
Y. richard Wang, Robert S. Fisher, Henry P. Parkman
Gastroparesis is an increasingly recognized disorder. However, its true prevalence in the
United States is unknown. Aim. To obtain estimates for the number of hospitalizations for
gastroparesis in the United States and determine whether the number of hospitalizations
for gastroparesis has been increasing over time.Methods. The Healthcare Cost and Utilization
Project's Nationwide Inpatient Sample is a database that estimates annual hospital inpatient
stays in the United States from a representative sample of approximately 8 million hospitaliza-
tions per year. This database was used to determine the trends of gastroparesis-related
hospitalizations, i.e., those with a primary or secondary diagnosis of gastroparesis (ICD-9-
CM code 536.3). Results. Hospitalizations with gastroparesis as the primary diagnosis
increased nationally from 3,977 in 1995 to 10,252 in 2004 (+158%) and hospitalizations
with gastroparesis as the secondary diagnosis increased from 56,726 in 1995 to 134,146
in 2004 (+136%). These compared to smaller percent increases in diabetes-related hospitaliza-
tions (4,059,243 in 1995 and 6,296,517 in 2004; +55%) and all hospitalizations in the
United States (34,236,838 in 1995 and 38,661,786 in 2004; +13%). Notably, the number
of hospitalizations with gastroparesis as the primary diagnosis increased dramatically after
2000. In 2004, patients hospitalized with gastroparesis were more likely to be female (66%),
≧45 years of age (67%), and treated at non-teaching hospitals (58%). In 2004, patients
with the primary diagnosis of gastroparesis (7% of all gastroparesis-related hospitalizations),
when compared to all hospitalized patients, were more likely to be admitted through the
emergency department (63% vs 43%), had a longer length of hospital stay (median: 4 days
vs 3 days), a higher hospital charge (median: $12,736 versus $10,754), and a lower percentage
of in-hospital deaths (0.6% versus 2.1%). In 2004, the 10,252 hospitalizations with gastropar-
esis as the primary diagnosis totaled 62,537 in hospital days and $209,971,212 in hospital
charges. Conclusions. This study suggests that the number of gastroparesis-related hospital-
izations has been increasing in the United States. Whether this reflects better recognition/
diagnosis, changes in diagnostic criteria, an increase in severity, or an increasing prevalence
of diabetes is unclear. Since patients with gastroparesis were more likely to be admitted
through the emergency department, had a longer length of hospital stay, and generated
higher hospital charges compared with all hospitalized patients, the economic impact of
gastroparesis in the United States deserves future study.
T1120
Colonoscopy Quality and Outcomes in Clinical Practice
Cynthia W. Ko, Laura-mae Baldwin, Jason A. Dominitz
Background and Aims: Over 14 million colonoscopy procedures were performed in 2002.
The aims of this study were to examine colonoscopy quality and outcomes in routine clinical
practice, and to identify factors influencing these measures. Methods: We used Washington
state Medicare claims to identify patients undergoing outpatient colonoscopy in 2000 (n=
14,123). The performing physician and associated diagnoses and procedures were identified
from the colonoscopy claim. We extracted data for subsequent colon procedures (colonos-
copy, sigmoidoscopy, barium enema), emergency room visits, and hospitalizations in 2000.
The AMA Masterfile was used to identify endoscopist specialty. We examined measures of
colonoscopy quality and outcomes, including colonoscopy completion, polyp or cancer
detection, use of biopsy or polypectomy, as well as subsequent colon procedures, emergency
room visits, and hospitalizations. Results: Gastroenterologists performed 71% of exams,
with surgeons performing 19%, internists 8%, and family practitioners 3%. Screening or
surveillance indications were present in 17%. Significant differences by sex were found for
incomplete colonoscopy (0.7% in men vs. 1.1% in women, p<0.001) and detection of polyps
(52% in men vs. 42% in women, p<0.001) or colorectal cancer (3.2% in men vs. 2.4% in
women, p<0.05). Whites were more likely to have biopsy or polypectomy than non-whites
(58% in whites vs. 52% in non-whites, p<0.001). Urban residents had higher complete
exam and polyp detection rates (p<0.05), but lower rates of repeat colonoscopy in 2000
(p<0.001). Endoscopist specialty was associated with significant differences in exam indica-
tions, polyp/cancer detection rates, and later sigmoidoscopy in 2000, and showed a trend
towards association with repeat colonoscopy in 2000 (table 1). No association was seen
with rates of complete examination or hospitalization/ER visits within 30 days. Conclusions:
Colonoscopy quality and outcomes may be measured using administrative data. Patient
characteristics, as well as endoscopist specialty, may have significant influences on quality
and outcomes. Further work is needed to better define relevant quality measures using
administrative data.
T1121
Diagnostic Yield of Open Access Endoscopy for Dyspepsia Versus Endoscopy
Following Gastroenterology Consultation
Ching Y. Lam, Grant Caddy, Tony Tham
Open access endoscopy for dyspepsia remains popular among primary care physicians
although it is generally perceived among gastroenterologists that the diagnostic yield is low.
There are few studies comparing the diagnostic yield for open access dyspepsia compared
to those undergoing endoscopy following a gastroenterology consultation. Aim: To compare
the yield of upper gastrointestinal (GI) endoscopy for patients referred for open access
endoscopy with those who has had a prior consultation at gastroenterology ambulatory care
facilities in a teaching hospital. Method: This is a retrospective study over a period of 27
months, from June 2004 until September 2006. Patients were identified from a prospective
endoscopy database. Inclusion criteria for patients who had attended EGD were symptoms
of dyspepsia, nausea, reflux symptoms and abdominal pain. All patients with alarm symptoms
and other indications were excluded. Significant pathologic findings were defined as esophag-
itis, esophageal candidiasis, Barrett's esophagus, esophageal malignancy, gastric malignancy,
gastric ulcers, gastric polyps, gastric telangiectasia, duodenal ulcers and duodenal telangecta-
sia. Results: A total of 562 procedures were identified. 474 procedures were performed
without prior GI consultation (mean age 59; 168 males, 306 females) compared to 88 (mean
age 52; 36 males, 52 females) procedures performed after GI consultation. Indications in
open access endoscopy group: (reflux 47%, dyspepsia 12%, abdominal pain 8%, nausea
3% and more than 2 symptoms 30%). Indications in GI consult group: (reflux 36%, dyspepsia
2%, abdominal pain 13%, nausea 3%, more than 2 symptoms 45%). Significant pathological
findings were present in 31% of the open access group of patients compared with 45% of
the patients who had GI consult. Refer to Table 1. (p= 0.01) Conclusion: The yield of
significant findings in open access patients undergoing endoscopy for dyspepsia is less
than those undergoing endoscopy for dyspepsia following a gastroenterology consultation.
Therefore, the system of open access endoscopy that is currently practiced may need to
be reassessed.
Table 1: Breakdown of the findings
T1122
The Extent and Determinants of Using Acid Reducing Medications in Patients
with Barrett's Esophagus
Hashem El-serag, Maria D. Wieman, Peter A. Richardson
Background: Expert opinions have recommended the use of acid reducing medications
especially proton pump inhibitor (PPIs), in patients with Barrett's esophagus (BE) to amelior-
ate GERD symptoms and possibly reduce the risk of dysplasia. However, there are no large-
scale studies that examine the extent or the determinants of using acid-reducing medications
in clinical practice among patients with BE. Methods: We conducted a retrospective cross-
sectional study among patients with BE (ICD-9 code 5302) as well as with GERD and no
BE (ICD-9 53081, 53085) in the outpatient and inpatient files of the national computerized
databases of the Department of Veterans Affairs (VA). The records of these patients were
linked to the VA Pharmacy Benefit Management (PBM). Patients with esophageal or stomach
cancer or those who died during the study period were excluded. Filled prescriptions (at
least one week) for oral PPI and H2RA were identified. PPI or H2RA prescriptions were
compared in unadjusted as well as adjusted analyses. Results: We identified 27,093 patients
with BE, and 574,574 with GERD and no BE patients between 2000 and 2002. Patients
with BE were slightly older (64.2 vs. 63.0), were more likely men (97.2% vs. 94.9%), and
white (65.4% vs. 52.1%). PPI prescription were recorded in 91.5% of BE patients and 61.4%
among non-BE (odds ratio: 6.79 (95% CI 6.51-7.09); p<.0001), whereas H2RA was recorded
in 31.7% of BE and 59.4% of non-BE patients. Approximately 6.1% of patients with BE
were prescribed neither PPI nor H2RA, whereas among GERD patients with no BE, 21.1%
were prescribed neither medication. Based on a subgroup of patients who had 365 days of
follow up, the ratio of PPI or H2RA prescription to available follow-up among BE subjects
was .66 (i.e. 122.8 days were not covered a prescription for either medication), compared
with a ratio of .55 among GERD patients with no BE (i.e., 165.0 days on neither PPI nor
H2RA). The mean duration of PPI use was twice as long for BE patients (BE (221.7; [SD:
118.9] vs. non-BE (106.9; [SD: 130.6]). On the other hand, the duration of H2RA use was
shorter in BE patients than in non-BE (37.4 [SD: 82.7]) vs. (100.4 [SD: 122.7]). Conclusion:
Healthcare providers in the VA healthcare system seem to recognize the need or benefit of
PPI use in patients with BE. Patients with BE are 1.5 times more likely to be prescribed a
PPI compared with patients with GERD and no BE. However, on average PPI prescriptions
cover only 60% of the follow up time for BE patients. The reasons and possible effects of
these gaps need to be examined.
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T1123
Inaccurate Risk Perceptions Among Average Risk Women Who Are Non-
Compliant with CRC Screening Recommendations
David Weinberg, Eileen Keenan, Michelle Rodoletz, Suzanne Miller, Eric Bieber
Introduction: Only 40% of women at average risk are currently in compliance with colorectal
cancer (CRC) screening recommendations, a rate less than men. Healthy People 2010
endorses efforts aimed at enhancing adherence to CRC screening, and reducing health care
delivery disparities. Seventy percent of all women see their gynecologist (GYN) annually.
This routine visit represents an untapped platform to address CRC screening in women by
linking CRC risk-related attitudes and behavior with other cancer risk perceptions (i.e.,
breast/cervical) and screening behaviors (i.e. mammogram/pap smear). We present baseline
survey data from an ongoing, prospective trial that compares several types of patient-directed
interventions to increase CRC screening rates in previously non-compliant women seen in
GYN offices. Methods: Using an electronic medical record, consecutive women 50y and
older at average risk for CRC, not compliant with screening by any accepted method, and
scheduled to see their GYN were identified. Potential participants were contacted by tele-
phone, participation criteria including screening status were verified, consent obtained and a
baseline survey administered. This survey elicited demographic data, other health prevention
behaviors, knowledge, attitudes and beliefs about CRC and CRC screening. Results: To date,
190 women have enrolled. Participants are predominantly white, married and between 50-
59 years of age. About 60% have attended at least some college, while 40% report family
incomes less than $45,000/yr. Seventy one percent have had a mammogram in the preceding
year. Overall, most participants demonstrated appropriate knowledge about CRC and CRC
screening. For example, 98% correctly answered questions about the utility of CRC screening
in asymptomatic persons; 87% that early detection is of clinical benefit, and more than 75%
knew that screening could prevent most cases of CRC. However, 49% of participants felt
they were at less risk than similarly aged women and 50% thought their overall lifetime
risk was less than the general population. Conclusions: CRC screening rates for women
remain disappointingly low. Early results from a prospective study cohort of women suggest
that despite public education efforts that have effectively transmitted basic knowledge regard-
ing CRC and CRC screening, non-compliant women tend to perceive their risk for CRC to
be lower than average. Future programs designed to increase screening participation should
address risk perception more effectively.
T1124
Adenomatous Polyp Characteristics Associated with Recurrence of Advanced
Adenomas During Surveillance Colonoscopy
Essam R. Quraishi, Hemal K. Patel, Rana Sabbagh, Mei Lu, Osama H. Alaradi
Background and Aims: Surveillance colonoscopy (SC) accounts for a significant proportion
of procedures performed by gastroenterologists. The timing and urgency of SC is determined
by the findings at index colonoscopy. However, the factors on index colonoscopy that predict
the development of significant adenomas on SC are not well defined. We evaluate the
importance of adenoma size and other characteristics in the development of advanced
adenomas on SC. Methods: A retrospective analysis was conducted for all patients at Henry
Ford Hospital that had an index colonoscopy between 03/01/1999 to 04/01/2000 followed
by SC until the date 08/01/2006. Patients with prior colonoscopy or a history of colon
cancer, inflammatory bowel disease or high-grade dysplasia were excluded. The end point
of advanced adenoma on SC was defined by an adenoma > 10mm, multiple adenomas (>
3), or an adenoma with high-grade dysplasia or adenocarcinoma. Cox's proportion hazard
model was used to calculation the hazard ratio (HR) with 95% confidence intervals (CI).
First univariate and then multivariate analysis was performed. Results: A total of 408 patients
were evaluated. 206 (51%) had tubular, 53 (13%) tubulovillous and 177 (43%) had no or
non-adenomatous polyps. Mean patient age was 62 (+ 11) and 69% were African-American
(AA). Mean polyp size and number was 5 mm and 1 respectively. African Americans were
more likely to have larger polyps on index colonoscopy p<0.01. Four patients (1%) developed
adenocarcinoma and 73 patients (18%) had advanced adenomas during a median follow
up period of 6.8 years. Of the 73, 15 were identified within 3 years and 50 by year 5. In
the univariate analysis, baseline polyp size (HR 1.4: p =0.0005), polyp number (HR 3.4:
p<0.0001), histology-tubular (HR 3.1: p <0.0001) and tubulovillous (HR 2.1: p = 0.0062),
patient age (HR 1.03: p =0.0017) and male sex (HR=1.66: p =0.045) were predictive for
the development of advanced adenomas. On multivariable analysis, histology-tubular (HR
2.7: p =0.0005), tubulovillous (HR 2.2: p =0.0043) and polyp number >3 (HR 2.15: p =
0.0041) remained significant. The size of the initial adenoma was not predictive for develop-
ment of advanced adenoma in the multivariate model. However, subgroup analysis showed
that polyp size > 10 mm was predictive for the development of advanced adenoma compared
to a polyp size of 0-4 mm in Caucasian patients only (HR 2.99: p=0.045). Conclusion:
Tubular histology, tubulovillous histology, and polyp number of 3 or more, are predictive
for development of advanced adenoma at SC. Polyp size was not as important and achieved
mild significance (p = 0.045) only in Caucasian patients.
T1125
High Frequency of Barriers to Colorectal Cancer Screening in HIV-Infected
Patients in a Primary Care Setting
Najm M. Soofi, David J. Aizenberg, Craig T. Tenner, Michael Poles, Edmund J. Bini
Background: Although many HIV(+) patients are living well beyond 50 years of age as a
result of highly active antiretroviral therapy, a recent study showed that HIV(+) persons
were less likely to have received colorectal cancer (CRC) screening (Am J Gastroenterol
2005;100:1805-1812). The aims of this study were to determine the proportion of HIV(+)
patients that have been screened for CRC, and to identify barriers to CRC screening.
Methods: HIV(+) patients and uninfected control subjects ≥50 years old completed a
detailed questionnaire at the time of their scheduled outpatient primary care or infectious
diseases clinic visit. Data collected included HIV status, demographics, prior CRC screening
[fecal occult blood testing (FOBT), flexible sigmoidoscopy (FS), and colonoscopy], as well
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as knowledge, attitudes, and barriers to CRC screening. Results: Among the 273 subjects
enrolled (33 HIV(+) patients and 240 controls), HIV(+) patients were less likely to agree
that CRC is an important cause of death in the U.S. (69.7% vs. 85.8%, p = 0.02) and that
CRC can be cured if detected early (39.4% vs. 89.6%, p < 0.001). HIV(+) patients were
significantly less likely to report that their healthcare provider ever offered them FOBT
(57.6% vs. 75.8%, p = 0.03), FS (42.4% vs. 61.7%, p = 0.04), or colonoscopy (57.6% vs.
75.4%, p = 0.03). Compared with controls, a lower proportion of HIV(+) patients reported
ever having any CRC screening (72.7% vs. 90.4%, p = 0.003), FOBT (48.5% vs. 70.4%,
p = 0.01), FS (36.4% vs. 59.2%, p = 0.01), or colonoscopy (45.5% vs. 70.0%, p = 0.005).
Similarly, HIV(+) patients were less likely to have had FOBT within 1 year (6.1% vs. 27.9%,
p = 0.007), FS within 5 years (21.2% vs. 42.9%, p = 0.02), and colonoscopy within 10
years (45.5% vs. 70.0%, p = 0.005). HIV(+) patients were more likely to report ≥3 barriers
to screening colonoscopy (39.4% vs. 19.6%, p = 0.01). The 3 most common barriers to
colonoscopy reported by HIV(+) patients were concerns about having a reaction to the
sedation, that colonoscopy would lead to other unnecessary testing, and that colonoscopy
is a painful test. In contrast, the 3 most common barriers in the control subjects were that
colonoscopy is a painful test, that the preparation is too difficult, and that they feared having
bleeding or tearing of the colon. Conclusions: Compared with uninfected controls, HIV(+)
patients were significantly less likely to have ever had CRC screening, had more barriers to
CRC screening, and reported different types of barriers. Future studies are needed to explore
whether educational programs tailored to HIV(+) persons could overcome barriers to CRC
screening in this population.
T1126
Rate and Yield of Repeat EGD and Rate of Colorectal Cancer (CRC) Screening
in Patients with Dyspepsia in Clinical Practice
Viam Dinh, Uri Ladabaum
BACKGROUND: Dyspepsia often persists regardless of management strategy. In clinical
trials, 2-25% of dyspeptic patients randomized to prompt EGD underwent repeat EGD
within 1 year. The rate and yield of repeat EGD for dyspepsia in clinical practice is unknown.
The benefit of repeat EGD for dyspepsia is expected to be lower than that of CRC screening.
AIMS: 1) To estimate the rate and yield of repeat EGD with dyspepsia as an indication
(EGD-dys) in clinical practice; 2) to examine whether repeat EGD-dys is performed by a
different physician than first EGD-dys, possibly due to patients seeking second opinions;
3) to determine the rate of CRC screening among patients ≥50y undergoing repeat EGD-
dys. METHODS: The UCSF endoscopic database was searched to identify all patients who
underwent≥1 EGD-dys (“dyspepsia” defined as dyspepsia, abdominal pain and/or bloating).
Data on demographics, indications, findings, treating physician and dates were abstracted
and analyzed. Significant findings were defined as esophagitis, erosion, ulcer or mass.
RESULTS: From 1996-2006, 5,460 EGD-dys (22% of all EGDs) were performed. Of the
4,873 patients who had EGD-dys, 449 (age mean 53y, SD 19y; 65% women) or 9% had
repeat EGD-dys. The 587 repeat EGD-dys represented 11% of all EGD-dys and 2.4% of all
EGDs. Indications at first EGD-dys included only dyspepsia in 56% and additional indications
in the rest. Significant findings at first EGD-dys were seen in 36% of those with only
dyspepsia as an indication and in 44% of those with additional indications (p=0.07). The
mean time from first to second EGD-dys was 2.2y, SD 1.9y, and 77% of patients had the
same physician for both EGD-dys. Indications at second EGD-dys included only dyspepsia
again in 56% and additional indications (e.g. reflux 17%, dysphagia 9%, nausea 7%, anemia/
bleeding 3%, weight loss 4%, ulcer follow-up 1%) in the rest. Significant findings at second
EGD-dys were seen in 23% of those with only dyspepsia as an indication and in 27% of
those with additional indications (p=0.3), including esophagitis 13%, erosion 10%, ulcer
5%, mass 0.4%. Of the 306 patients ≥50y who had repeat EGD-dys, 275 (90%) had either
colonoscopy or sigmoidoscopy. CONCLUSION: The 9% repeat EGD-dys rate in this study
may underestimate the true rate due to possible EGD-dys at other facilities. In this endoscopy
unit, repeat EGD-dys accounted for a small fraction of EGD-dys and total EGDs, and the
diagnostic yield was modest. In most cases, first and repeat EGD-dys were performed by
the same physician. Repeat EGD-dys did not constrain resources for age-appropriate CRC
screening in patients undergoing EGD-dys.
T1127
The Compliance to Colorectal Cancer Screening By Faecal Occult Blood Test
in a Group of Subjects from Timisoara
Alina Popescu, Ioan Sporea, Camelia Cicala, Beata Besenyodi, Noemi Besenyodi, Calin
Cernescu, Mirela Danila, Roxana Sirli
The colorectal cancer is a worldwide health problem; many countries developed national
screening programs for this disease. The aim of this paper was to evaluate the compliance
of a group of subjects from Timisoara to a screening program for colorectal cancer based
on faecal occult blood testing (FOBT), after informative letters. Material and method: our
group consisted of 701 subjects with age ≥50 years, 314 male (44.8%) and 387 female
(55.2%), who are registered at the same general practitioner. We have sent an informative
letter to all these subjects and we have offered them the possibility to undergo a free of
charge test for the screening for colorectal cancer. Anyone who was interested could take
this test from his or her general practitioner. The same person developed the tests collected
from the patients. We have send after a month a second letter with the same message to
those that have not responded to the first one and we collected again the tests. Results:
from the 701 subjects from our group 160 (18.9% - primary compliance) came to the
general practitioner for further information. From these 2 had undergone a colonoscopy
recently and 2 refused the testing. 156 subjects took the FOBT but only 98 returned it.
After the second letter another 19 patients came to the GP, took the test and also returned
it. Thus, from our group of 701 patients 119 (17% - the real compliance) were compliant
to a screening test for colorectal cancer. From the 117 FOBT performed 112 were negative
and 5 positive (4,3%). In our group women were more compliant to the screening program
comparative to men (17,3% vs 15,9%, p=0,0262), and the most compliant age group was
60-69 years old with 26.9% (p=0.000014). Conclusion: in our study the compliance to a
colorectal screening program using FOBT in patients over 50 years old was relatively low
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(17% from those informed by letter) comparing with studies from other countries (for
example France 26-34% - Tazi MA-J Med Screen 1997, USA 43.4% - Ioannou GN - Am J
Gastroenterol 2003). This is probably most due to lack of information regarding the disease
and the role of a screening program. In our study women were more compliant comparative
to men, and the group aged 60-69 years was the most compliant, probably because is the
age of new retired persons who are more interested in their health.
T1128
Self-Reported Colorectal Cancer Screening Status: An Accurate Option for
Practice and Research
Deborah A. Fisher, Sally W. Vernon, Krysten Halek, Joseph Grill, Siamak Noorbaloochi,
Melissa Partin
Objective: Correct determination of colorectal cancer (CRC) screening status is essential for
clinical decision-making, systematic quality assessment and research to improve screening
rates. Although medical records are considered to be the most accurate data source, it is
not always feasible to use them, particularly in national studies. Record retrieval can be time
consuming and expensive because documentation from multiple facilities is infrequently
centralized or linked. Patient self-report is a more efficient and less expensive alternative.
Our purpose was to evaluate the accuracy of a National Cancer Institute (NCI) developed
questionnaire for determining compliance with CRC screening guidelines. Methods: We
mailed surveys to 890 primary care patients aged 50-75 years at a single VA (Veterans
Affairs) facility and requested release of non-VA medical records. Women and minorities
were over-sampled. VA and non-VA records were abstracted and combined with VA adminis-
trative data for the reference standard. Results: The response rate was 77% (686). The sample
was 67% Caucasian; 28% African American; and 65% male. Self-report for compliance with
CRC screening had 91% sensitivity, 53% specificity, 70% positive predictive value (PPV)
and 83% negative predictive value (NPV). For the subset (296) with which we had the
highest confidence of complete records (all reported non-VA charts or explicit designation
of only VA use) self-report was 95% sensitive, 57% specific, and had an 82% PPV and
83% NPV. There were no associations between self-report accuracy and gender or race.
Conclusions: Self report is a highly sensitive method to determine CRC screenings status
when using the NCI questionnaire. The PPV and NPV, useful measures for clinical practice
and quality assessment, were also high. Because there is no gold standard, the apparent
accuracy of self-report will vary with the accuracy of the reference standard. However, our
results were robust when comparing the entire sample to the subset with “most complete”
records which supports that our ascertainment of CRC documentation was generally compre-
hensive. Given the difficulty in obtaining charts and administrative data from multiple
facilities, self-report using the NCI survey is an attractive option in practice and research.
T1129
Reproducibility of Symptom-Reflux Association Analysis with 24-Hour
Esophageal Impedance-pH Recordings
Marissa C. Aanen, Albert J. Bredenoord, Andre J. Smout
Introduction Symptom association analysis is the gold standard to investigate whether
patients' symptoms are related to reflux episodes. Our aim was to determine the reproducibil-
ity of indices that express the relationship between symptoms and reflux episodes detected
with 24-hour esophageal impedance-pH studies. Methods Fourteen GERD patients (mean
age 46±12 years; 5♂) underwent 2 combined 24-h impedance-pH recordings after acid-
suppressive medication was stopped 1 week before the recording. The 2 recordings had to
be performed within 1 month and separated by at least 1 week. The occurrence of symptoms
was recorded by the patients in a diary. Liquid-containing (pure liquid +mixed gas/liquid)
and pure gas reflux events were measured. The relationship between reflux episodes and
symptoms was expressed using the symptom association probability (SAP), symptom index
(SI) and symptom sensitivity index (SSI). Cut-off values were 95%, 50%, and 10 % for SAP,
SI and SSI, respectively. Data are represented as median with 25th and 75th percentiles.
Reproducibility was expressed as Kendall's coefficient of concordance (K). A p-value <0.05
was considered significant. Results One patient did not have symptoms during one of the
measurements and therefore no symptom-reflux association indices could be calculated. The
total number of reflux episodes was comparable between day 1 (64 (55-99)) and day 2 (67
(67-80)) with a K-value of 0.65 (p<0.01). Although more liquid reflux was present on day
1 there was still a reasonable concordance (day 1: 42 (19-69) vs day2: 27 (14-55)), K-value
of 0.45 (p<0.05) as well as for gaseous reflux (day 1: 19 (13-37) vs day 2: 12 (22-32)), K-
value 0.50 (p<0.05). The number of symptoms experienced on day 1 (4 (6-6)) and on day
2 (4 (8-8)) was also reproducible (K 0.65, p<0.01). The SAP (day 1:100 (36-100); day 2:
100 (87-100)) and SI (day 1:57(13-89); day 2: 50(36-78) outcome values showed significant
reproducibility with K-values of 0.72 (p<0.01) and 0.55 (p<0.01) but SSI did not (4 (1-9),
5 (3-10), K value 0.41, ns). The concordance of the conclusion that symptoms are reflux-
related (positive index) or not was higher when expressed with SAP and SI (both 85%
concordance between day 1 and 2) compared to SSI (62%). Discussion Symptom association
analysis using the SAP and SI is a reproducible method to investigate the relationship between
reflux symptoms and reflux episodes during ambulatory pH-impedance reflux monitoring.
T1130
Importance of Acid Control Against Rebound Phenomenon of Proton Pump
Inhibitors and Prior Helicobacter pylori Eradication Therapy in Patients with
Gastric Ulcer By Endoscopic Mucosal Resection of Early Gastric Cancer: A
Prospective Study
Yoshihiro Wada, Masanori Ito, Shinji Tanaka, Hiroshi Masuda, Shunsuke Takata, Yoshiaki
Matsumoto, Shinobu Imagawa, Xue fei Xie, Masana Tatsugami, Syunsuke Kitamura,
Akemi Takamura, Masaharu Yoshihara, Kazuaki Chayama
Background: Helicobacter pylori (H. pylori) eradication therapy increases acid secretion in
patients with atrophic gastritis, and promotes the onset of gastroesophageal reflux disease
(GERD) and reflux esophagitis (RE). Rebound acid hypersecretion develops after the use of
acid inhibition, particularly by proton pump inhibitors (PPI). In addition, endoscopic mucosal
resection (EMR) is a widely accepted treatment for early gastric cancer, and endoscopic
submucosal dissection (ESD) is established as a new method recently in Japan. Aim: We
examined development of GERD and RE in patients after EMR/ESD of early gastric cancer,
in a condition of acid hypersecretion by two factors that is prior H. pylori eradication therapy
and discontinuation of PPI treatment for iatrogenic gastric ulcer by EMR/ESD. Further, we
examined whether there was the clinical necessity of acid inhibition under these conditions.
Methods: We examined 39 patients who underwent successful H. pylori eradication therapy
prior to EMR/ESD of early gastric cancer. After an 8-week treatment period with PPI
(rabeprazole 20mg/day) in patients with iatrogenic gastric ulcer by EMR/ESD, they were
randomly divided into two groups (treated with nizatidine 300 mg/day (N-group, n=22)
and sofalcone 300 mg/day (S-group, n=17)). Then they took each for 16 weeks. RE was
evaluated by gastoro-endoscopy at 0 and 16 weeks. GERD symptoms were assessed with
questionnaire for the diagnosis of reflux disease (QUEST) score at 0, 8 and 16 weeks. Results:
All patients showed corpus atrophy (moderate to severe) by histological examination (updated
Sydney system). There was no difference in the grade of corpus atrophy evaluated by
histological or serological (serum pepsinogens and gastrin) examinations between two groups.
Only one patient in N-group (4.5%) and 2 in S-group (11.8%) newly developed mild GERD
symptoms after a 16-week treatment. There was only one patient in N-group (1.0%) and
none in S-group (0.0%) who developed RE after a 16-week treatment. There was no difference
in the incidence of newly GERD and RE between two groups. Conclusions: The prior H.
pylori eradication therapy and rebound phenomenon of PPI have little influence on RE/
GERD formation in patients with gastric ulcer by EMR/ESD. In patients who suffer from
gastric ulcer with corpus atrophy, acid control may be unnecessary for rebound phenomenon
of PPI, even if they undergone H. pylori eradication therapy at early stage of treatment for
gastric ulcer.
T1131
Patient-Centered Goals in Fecal Incontinence
Stacy B. Menees, William D. Chey, Anne Mcleod, Raylene Marcum, Dee Fenner
Objective: Numerous measures exist in the literature to assess treatment effectiveness for
fecal incontinence(FI). However, none have assessed the patient's own goals in the treatment
of fecal incontinence. The purpose of this study is to describe patient-identified goals for
fecal incontinence and patient reported achievement of those goals after treatment. Methods:
At the time of initial visit, 28 consecutive patients with FI listed up to 5 personal goals for
treatment and completed the following validated surveys: patient health questionnaire(PHQ),
fecal incontinence severity index(FISI) and fecal incontinence quality of life(FIQOL). At 3
months, patients reported the degree(1-5) to which each goal had been met(1=strongly
disagree, 5=strongly agree). Demographic data, medical and surgical interventions were
recorded. Goals were categorized according to symptom relief, physical activity, general
health, social relationships or physical appearance. Preferences and belief in treatment options
were assessed. Rates of self-reported goal achievement will be calculated at 3 months along
with the difference in the proportion of goals achieved by category. Additionally, these
calculations will be correlated to changes in PHQ, FISI and FIQOL scores. Results: 24
women and 4 males completed the surveys, 93% of patients were Caucasian with a mean
age 52 years. Patients reported a mean of 3.7 goals. 16 of 28 (57%) subjects reported 4 or
more goals. Of the 107 goals listed, the majority (65%) dealt with symptom control, 19%
dealt with activity improvement, 9% dealt with social relationships, 8% listed general health
objectives and 8% dealt with physical image. 25 of 28 subjects (86%) listed symptom relief
goals such as reduce leakage, urgency, improve stool consistency. 14 (48%) listed activity
improvement goals (i.e. exercise, ADL's, sexual activity), and 6 (21%) listed general health,
physical image or social relationship related goals (feel normal, remove fear, family interac-
tions). At the time of initial survey, the average PHQ was 7.32(normal <4, max 27) with a
FISI(range 0-77, 0=no symptoms) and FIQOL(range 1 to 5-one=lower quality of life), of
3.51 and 2.34, respectively. For treatment of fecal incontinence, patients preferred dietary
intervention(32%) and access to medically trained staff(29%). Conclusion: Patients seeking
fecal incontinence treatment have a variety of goals primarily related to symptom control
and activity improvement. Continued study will determine if this will be a tool to enhance
research and patient care.
T1132
Impact of Clarithromycin On Second-Line Treatment Based On rabeprazole,
Amoxicillin and Metronidazole Regimen After Failure of Helicobacter pylori
Eradication Based On Proton Pump Inhibitor, Amoxicillin and Clarithromycin
in Japan
Nobue Ueki, Kazumasa Miyake, Masafumi Kusunoki, Tatsuhiko Hamamoto, Tomotaka
Shindo, Tetsuro Hiratsuka, Seiji Futagami, Katya Gudis, Taku Tsukui, Choitsu Sakamoto
Background In Japanese patients failing first-line triple therapy based on proton pump
inhibitor (PPI)/amoxicillin (AMPC) plus clarithromycin (CAM) for Helicobacter pylori (H.
pylori) infection, the resistance rates of H. pylori strains to CAM reach 60~80%, and efficacy
of a retreatment with PPI-AMPC-CAM has been reported to be limited. PPI-based AMPC
and metronidazole(MNZ) regimen for H. pylori infection is being accepted as the most
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appropriate second-line treatment. On the other hand, CAM could be effective as an antibiotic
in second-line treatments for patients with not only CAM-sensitive strains but also CAM-
resistant strains, by inhibiting PPI metabolism through its suppressive action on intestinal
CYP3A4. But the efficacy of CAM in second-line treatment based on PPI/AMPC plus MNZ
is unknown. Aim To evaluate the efficacy of PPI/AMPC plus MNZ based therapy and the
effects of CAM on PPI/AMPC plus MNZ as a second-line therapy. Methods Ninety eight
patients failing a first-line triple therapy based on PPI/AMPC plus CAM were entered into
this study. Patients were randomized to receive rabeprazole 10mg, AMPC 750mg, and MNZ
250mg with (RAMC group) or without CAM (RAM group); all treatment were administered
twice daily for 7 days. Before the therapy, susceptibility to antibiotics was determined. H.
pylori cure was determined by 13C-urea breath tests 8 weeks or more after the end of therapy.
Results On intention-to-treat / per protocol analysis, H. pylori cure rates were 84.6% /
93.6% and 80.8% / 84.0% for the RAMC and RAM groups, respectively. In addition, the
eradication rates for the CAM-sensitive strains (1μg/ml>MIC) in the RAMC and RAM groups
were 100% (4/4) and 100% (6/6), respectively; for the mild CAM-resistant strains
(1≧MIC>100μg/ml) the respective rates were 94.7%(18/19) and 90.5%(19/21), and for the
severe CAM-resistant strains (MIC≧100μg/ml) they were 89.5% (17/19) and 75.0% (15/
20). Resistance to CAM was observed in 89.5% (85/95), and to MNZ in 5.3% (5/95) of the
patients. Severe side effects were not found in each group except for skin rash (1 in RAMC
group) and soft stool (11 in RAMC group and 6 in RAM group). There is not a statistical
significant difference between cure rates of two regimens, although RAMC group showed a
tendency toward a high cure rate compared to RAM group. Conclusion A 7-day H. pylori
eradication therapy based on RAM is effective as a second-line treatment for Japanese patients
failing initial treatment with a PPI-AMPC-CAM regimen. Furthermore, addition of CAM to
RAM can safely improve the efficacy of RAM-based eradication, especially for patients with
CAM-resistant strains although the mechanism is unclear.
T1133
Prevalence of Peptic Ulcer in Dyspeptic Patients: Influence of H. pylori
Infection, Age and Sex
Huichao Wu, Biguang Tuo, Weimin Wu, Yuan Gao, Qingqing Xu, Kui Zhao
Background&Aims: Peptic ulcer is one of the most frequent diseases of the alimentary tract.
In the present study, we investigated the prevalence of peptic ulcer in dyspeptic patients
in China and analyze the influence of H. pylori infection, age and sex on it. Methods: The
study population consisted of consecutive patients with dyspeptic symptoms who underwent
upper gastrointestinal endoscopy in Endoscopic Units of Affiliated Hospital of Zunyi Medical
College and Zunyi Hospital from January 2000 to September 2006. Patients with previous
history of peptic ulcer were excluded. Detection of H. pylori was done on gastric antral
mucosal biopsy samples by rapid urease test or/and histopathologic examination. The patients
were divided into different age groups at an interval of ten years. Results: In a total of 55336
patients evaluated, 4234 (7.47%) had duodenal ulcer and 3913 (7.07%) had gastric ulcer.
The prevalence of duodenal ulcer did not correlate with age, whereas the prevalence of
gastric ulcer was increased with age. Duodenal ulcer was more common than gastric ulcer
in patients under 50 years old, whereas gastric ulcer was more common in patients over
50 years old. In the patients under 50 years old, the prevalence of duodenal and gastric
ulcers in female was markedly lower than that in male, especially in the prevalence of
duodenal ulcer. The prevalence of duodenal ulcer of female was markedly increased with
age in the patients over 50 years old, whereas the prevalence of duodenal ulcer of male had
no significant difference among the different age groups. In 55336 patients, 25591 (46.25%)
were H. pylori positive. There was no significant difference in H. pylori infection of different
age groups. The prevalences of duodenal ulcer and gastric ulcer in H. pylori-infected patients
were 14.78 % and 11.74% respectively, whereas they were 1.18% and 3.06% respectively
in patients without H. pylori infection (P<0.0001). In the patients under 50 years, sex
differences were still seen in both H. pylori positive and negative patients. The prevalence
of gastric ulcer was markedly increased with age in both H. pylori positive and negative
patients. Conclusion: H. pylori infection, sex, and age were independently associated with
the prevalence of peptic ulcer. Female sex hormones may decrease the risk of peptic ulcer,
especially duodenal ulcer.
T1134
Use of Proton Pump Inhibitors in Patients with Chronic Liver Disease
Norberto Chavez-tapia, Felix Tellez-avila, Jorge Garcia-leyva, Miguel A. Valdovinos
Indications for proton pump inhibitors (PPI) include non-variceal upper bleeding, esophageal
reflux disease, and peptic ulcer disease. Evidence that supports use of PPI in patients with
chronic liver disease (CLD) is scarce. Moreover the pattern of PPI prescription is not known.
Aim. To analyze the use of PPI in patients with CLD in an ambulatory setting. Methods.
This is a cross-sectional study in outpatients with CLD. Demographics, severity indexes of
CLD, Child-Pugh (CP) and MELD score, endoscopic findings, and use of PPI during previous
hospitalizations were assessed. The pattern of use of PPI was classified in four groups: G1)
clear indication for PPI with prescription of PPI, G2) unclear indication with prescription,
G3) clear indication without prescription and G4) unclear indication without prescription.
We considered G1+G4 as groups with appropiate use of PPI. Variables associated with
adequate use of PPI were determined. Results. 243 patients, 109 (45%) female, mean age
55.82±12.9 years, were included. Hepatitis C virus infection was the most common CLD
(n=108, 44%). 112 patients (46%) were on PPI therapy. The distribution of patients in the
different groups were: G1:12.3%, G2:33.7%, G3:5.8%, G4: 48.1% and G1+G4: 60.5%. In
univariate analysis CP score A (OR 1.7; CI95% 1.0-3.0) and MELD score ≤ 8 points (OR
2.1; CI95% 1.2-3.9) were associated with an adequate use of PPI. In contrast, abnormal
bilirubin (OR 0.54; CI95% 0.3-0.9), esophageal varices (OR 0.45, CI95% 0.2-0.8), congestive
gastropathy (OR 0.52; CI95% 0.2-0.9) and previous in-hospital use of PPI (OR 0.2; CI95%
0.1-0.5) were inversely associated with an adequate use of PPI. In multivariate analyzes,
only MELD score ≤ 8 points (OR 2.2; CI95% 1.2-4.0) and previous in-hospital use of PPI
(OR 0.78; CI95% 0.6-0.9) were associated with an adequate use of PPI. Conclusions. PPI
were prescribed in half of patients with CLD. In 60.5% PPI were used based on a clear
indication. Although endoscopic findings and severity of liver disease induced prescription
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of PPI, only MELD was associated with proper use of PPI. Further prospective studies are
needed to assess the appropiate use of PPI in CLD.
T1135
Do Nuclear Medicine Scans Effect Outcome in Acute Gastrointestinal Bleed?
Nayantara Coelho-prabhu, Norah J. Shire, Nathan Schmulewitz
Background: Lower gastrointestinal bleeding (LGIB) is commonly associated with a high
probability for inpatient morbidity. Previous studies have demonstrated the utility of
(99m)Tc-labeled erythrocyte nuclear scintigraphy (RBC scan) in risk stratifying patients,
determining site of hemorrhage, and in planning therapeutic interventions. However, there
is no evidence as to whether the use of this test has an impact on patient outcome. Aim:
To determine the effect of RBC scan results on outcomes in patients with acute LGIB. Primary
outcomes were hospital length of stay (LOS), transfusion requirements and 1 year mortality
rate. Secondary outcomes were utility of RBC scan in predicting recurrent bleeding episodes
or need for interventions (endoscopy, angiography and surgery). Methods: We performed
a retrospective chart review on all patients admitted between 2002 and 2005 to a tertiary
referral hospital for acute LGIB who underwent RBC scan as inpatients. Patients with normal
and abnormal scans were compared with respect to baseline demographic information,
comorbidities, severity of GIB, interventions undertaken, LOS, and mortality rates. Results:
130 RBC scans were performed on 107 patients. 46 (35.4%) scans were abnormal. 55% of
patients were male, and the mean age was 60.1 +/- 16 years. Patients with normal and
abnormal RBC scans did not differ in age, sex, or number of scans or colonoscopies performed.
Patients with abnormal scans, as compared to those with normal scans, had higher transfusion
requirements (10 units PRBC (95% CI 2-43) vs 4 units (95% CI 0-53), p<0.001), were less
likely to spontaneously stop bleeding (OR 0.20, 95% CI 0.08 - 0.47, p<0.001), were more
likely to undergo surgery (8/46 vs 0/84, p<0.001), angiogram (OR 2.50, 95% CI 1.54 -
4.08, p<0.001) or embolization (OR 6.15, 95% CI 1.03 - 64.0, p=0.02), and had fewer
days to intervention (median 0.25, range (0.08-6) vs 2 (0.08-300), p<0.001). Patients with
abnormal scans had longer LOS (median 12.5, range (3-110) vs 8 (0-87) days, p=0.001),
but there was no difference in rebleeding events (p=0.95) or 1 year mortality (p=0.59).
Regardless of RBC scan result, delay in obtaining the study was not associated with time to
intervention, but was associated with increased transfusion needs (p<0.001) and longer LOS
(p<0.001). Conclusions: In patients admitted with acute LGIB, RBC scans do not predict
long term mortality, but may improve outcomes in patients with more severe bleeding by
hastening therapeutic interventions.
T1136
The More the Merrier? Volume Versus Outcome of Upper Gastrointestinal
Procedures in the UK
Luke Evans, Nandita Pal, Ben Axisa, Michael Lewis, Michael Rhodes, Simon Wemyss-
holden, Robert Newcombe
INTRODUCTION: Correlation between unit volume and outcome for defined surgical pro-
cedures has been the subject of several studies(1-3). In the UK these have been used to
make the case for centralisation of such procedures(4). The recent availability of easily
accessible and independent data on hospital outcome for surgical services has provided the
opportunity to review any possible association between volume and outcome. METHODS:
Data was obtained from the Dr Foster® website, a 50:50 public:private organisation which
independently records outcome data from UK hospitals. Data were collected for four different
Upper GI procedures (gastrectomy, oesophagectomy, pancreaticoduodenectomy and liver
resection) for a six year period from 1999-2005. Data for each procedure were divided into
volume dependent quartiles to assess any differences in mortality outcome. RESULTS:
Summarised in table one. There was a significant trend in mortality favouring high volume
providers for oesophagectomy (7.8% vs 4%) and pancreaticoduodenectomy (6.5% vs 3.8%)
p<0.001 and p=0.016 respectively. There was no significant difference for gastric and liver
surgery between high and low volume providers. CONCLUSION: There is a small volume
asociated mortality benefit for oesophagectomy and pancreaticoduodenectomy. Reasons for
the difference are likely to be multifactorial. REFERENCES: (1)Birkmeyer et. al. Surgeon
volume and operative mortality in the United States. N Engl J Med 2003 (2)Begg CB et.al.
Impact of hospital volume on operative mortality for major cancer surgery JAMA 1998
(3)Schrag D et.al. Influence of hospital procedure volume on outcomes following surgery
for colon cancer JAMA 2000 (4)Guidance on commissioning cancer services: improving
outcomes in upper gastro-intestinal cancers the manual Department of Health. 15/06/2001
Table 1
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T1137
Utilization of Stool Guaiac Testing After Colonoscopy and Results of Repeat
Endoscopic Evaluation of Positive Tests
Visvanathan Murali-dharan, Anil Nagar, Harry Aslanian
Introduction: Available data suggests that stool guaiac tests after colonoscopy have a low
positive predictive value. The frequency of fecal occult blood tests (FOBT) and digital rectal
examination (DRE) following colonoscopy and repeat endoscopic evaluation of positive tests
is not well characterized. Methods: Retrospective analysis of the electronic medical records
of 200 patients who underwent colonoscopy at the West Haven, VA CT Hospital in the
year 2000 was performed. All subsequent medical encounters through August 2006 were
reviewed, including performance of FOBT/DRE [Hemoccult II], additional endoscopic testing,
and clinical outcome. Results: 98% of patients were male with a mean age of 70.9 yrs. 26
(13%) pts had a family history of colon cancer. Indications for the index colonoscopy were:
positive stool guaiac (82), hematochezia (36), screening (29), follow-up of colon polyps or
cancer (28), anemia (15) and other (10). 126 (63%) patients underwent stool guaiac testing
following index colonoscopy (40 FOBT, 59 DRE, 27 both). Stool guaiac testing was performed
an average of 21 months after index colonoscopy: as part of routine practice in 90 pts (71%)
and to evaluate anemia or hematochezia in 36 (29%). 46 of 126 patients (36.5%) had a
positive stool guaiac test [FOBT (17), DRE (29)] and endoscopic evaluation was performed
in 23 (50%). 8 of 23 pts evaluated endoscopically had additional symptoms/signs of gastroin-
testinal disease versus 3 of 23 with no endoscopic evaluation. New endoscopic findings
were seen in 4 of 13 pts (31%) undergoing repeat colonic evaluation and in 9 of 19 pts
(47%) undergoing upper endoscopy. New endoscopic findings were present in 75% of those
with new GI symptoms and positive stool guaiac versus 40% of those with positive guaiac
alone Conclusion: Stool guaiac testing was performed in the majority of patients following
colonoscopy, often as part of routine practice. Positive results were found in approximately
one-third of patients and were evaluated with repeat endoscopy in one half. New findings
were more commonly identified on upper endoscopy (47%) than with repeat colonic evalu-
ation (31%). Patients with new gastrointestinal symptoms and positive guaiac test following
index colonoscopy should undergo complete endoscopic evaluation
Repeat endoscopic evaluation in 23 patients with positive stool guaiac after index colonoscopy
T1138
Fear of Cancer Recurrence After Endoscopic and Surgical Treatment for Early
Neoplasia in Barrett's Esophagus
Wilda Rosmolen, Kimberly Boer, Jan Van lanschot, Jacques J. Bergman, Mirjam Sprangers
Introduction: Endoscopic treatment (ETx) of early neoplasia in Barrett's esophagus (BE) has
shown to be a safe and effective alternative for surgical treatment (STx). However the
preservation of the esophagus and the minimal invasiveness of the Tx may lead to more
anxiety in patients (pts). Aim: Investigate the fear of recurrence of cancer after ETx and STx
for early BE neoplasia, 12 to 60 months after treatment. Patients and Methods: Between
2001 and 2005, 81 pts with early BE neoplasia had ETx and 33 patients had STx. Selection
was based on tumoursize, depth of penetration (T1m vs. T1sm), or patients' preference.
Anxiety and fear of recurrence were measured using the Hospital Anxiety and Depression
Scale (HADS), the Worry of Cancer Scale (WOCS) and the Fear of Recurrence Scale (FORS).
Higher scores indicate more fear or anxiety. Analysis: Multivariate analyses with covariates
age, gender, histology and co-morbidity and history of cancer, were used to determine
differences in QOL between the ETx group and the STx group. Results: 91% and 93% of
the available pts in the ETx group and Stx group respectively completed the questionnaires.
Both groups were comparable in terms of age (64 vs. 63 years), gender (83% male vs. 82%)
and median follow-up after Tx (27.2 mo vs 27.4 mo). The groups differed in terms of length
of Tx (ETx 104± 92 days vs. hospitalization after STx 28± 25; p<0.001), cancer rate (53%
vs. 93%; p<0.001), and the presence of one or more co-morbidities (67% vs. 52%, p<0.05).
A patient history of cancer was found in 16% in the ETx group vs. 0 % in the STx group.
Due to this discrepancy and its anticipated effect on the outcomes of the study, we created
3 independent groups: ETx pts with a history of cancer (ETx+, n=10), ETx pts without a
history of cancer (ETx-, n=54), and STx pts (n=27). STx pts were found to report significantly
less fear of reccurrence on the WOCS than ETx- pts or ETx+ pts (scores respectively were:
7.3, 11.9 and 17.9; P=0.0026 and P<0.001). The FORS showed similar trends as the WOCS,
but these were not significant (STx: 57.5, ETx+: 64.9, ETx-: 60.3). There were no differences
in the HADS anxiety (STx: 2.7, ETx+: 3.9, ETx-: 4.2) and depressions scores (STx: 2.9 ,
ETx+: 3.9, ETx-: 2.9), scores <7 are within normal ranges. Conclusion: Pts treated for early
BE neoplasia report few depression and anxiety, 1-5 years after ETx or STx. ETx pts report
more fear of reccurrence of cancer than STx pts. This is most pronounced for ETx patients
with a prior history of cancer but the difference between ETx and STx remains apparent
on the WOCS, even when controlling for history of cancer.
T1139
Gastroesophageal Reflux Disease and Well-Being in the General Population of
Shanghai, China
Rui Wang, Jia He, Xiaoyan Yan, Xiuqiang Ma, Yang Cao, Cheng Wu, Jian Lu, Saga
Johansson, Mari-ann Wallander, Zheng Fu
Introduction. In Western populations, the pain and discomfort associated with gastroeso-
phageal reflux disease (GERD) impairs many aspects of everyday life, including physical
activity, sleep and work. Such data from Asian countries are scarce. The aim of this study
was to evaluate the impact of GERD on the everyday life of affected individuals in Shanghai,
China. Methods. In total, a representative sample of 1200 adult inhabitants of Shanghai
(aged 18-70 years) was selected using a randomized, stratified, multi-stage, cluster sampling
method. Subjects completed mainland Chinese versions of the Reflux Disease Questionnaire
(RDQ), GERD Impact Scale (GIS), Quality of Life in Reflux and Dyspepsia questionnaire
(QOLRAD) and Short Form-36 (SF-36). A clinically meaningful impairment of well-being
was defined as a statistically significant ≥ 0.5-point decrease in a 7-point QOLRAD domain
or a statistically significant ≥ 5-point decrease in a 100-point SF-36 domain. Results. In
total, 1034 subjects completed the survey (a response rate of 86.2%) and 919 responses
were suitable for analysis (mean age: 46.7 years; 55.4% female). The prevalence of GERD
(defined as an RDQ score ≥ 1) was 6.2%. Subjects with GERD had meaningfully impaired
well-being in comparison with subjects without GERD in terms of impaired vitality (mean
QOLRAD scores: 6.34 vs 7.00), food/drink problems (6.39 vs 7.00) and emotional distress
(6.46 vs. 7.00) (all P ≤ 0.001), but not sleep disturbance (6.54 vs 7.00; P ≤ 0.001) and
impaired physical/social functioning (6.67 vs. 7.00, P≤ 0.001), and in the SF-36 dimensions
of role-physical (mean SF-36 scores: 71.9 vs. 95.2), general health (49.2 vs. 70.1), role-
emotional (76.6 vs. 96.4), bodily pain (76.3 vs. 95.8), vitality (54.9 vs 72.9), mental health
(71.9 vs. 82.4) and physical function (81.4 vs. 90.3) (all P < 0.001) but not social function
(90.6 vs. 94.5, P = 0.02). According to the GIS, the most common problems caused by
GERD were interference with eating and drinking (4.1% of the study population as a whole),
sleep impairment (2.5%) and reduced productivity at work (2.5%). Conclusions. GERD has
a clinically meaningful impact on the everyday lives of affected individuals in the general
population of Shanghai, China. Further research is needed to assess how this effect responds
to appropriate acid-suppressive therapy.
T1140
The Sibdq Is More Suitable Than Sf-36 to Measure Improvement of Quality of
Life in Patients with Collagenous Colitis Treated with Budesonide
Ahmed Madisch, Andrea Morgner, Christine Henker, Birgit Bethke, Eberhard Kuhlisch,
Gustavo Baretton, Manfred Stolte, Stephan Miehlke
Background: Collagenous colitis (CC) is a chronic inflammatory bowel disease of unknown
origin clinically characterized by chronic watery diarrhea. The impact of CC on patient's
quality of life is poorly investigated. Aim: to assess quality of life in patients with CC before
and after treatment with budesonide using SF-36 and SIBDQ. Patients & Methods: We
investigated quality of life in consecutive symptomatic patients with CC baseline and after
6 weeks of budesonide (Entocort® 9 mg/ day) treatment. Clinical remission was defined
as stool frequency equal or less than 3 soft or solid stools per day on average during the
last week of treatment. Quality of life was assessed by using the validated Medical Outcome
Study Short (SF-36) and the short inflammatory bowel disease questionnaire (SIBDQ). The
SF-36 consists of 4 domains of physical health and 4 domains of mental health. The SIBDQ
consist of four subscales (Bowel symptoms, Systemic symptoms, Emotional function, and
Social function) represented by a total of 10 items. Results: Forty-two patients with colla-
genous colitis (36 females, median age 57 years) were included in the study. The median
stool frequency per day was 6.5 at baseline and mean duration of symptoms was 28.8
months. At baseline both the mean physical and mental health sumscores (SF-36) and the
SIBDQ score were severely reduced in patients with collagenous colitis compared to normal
controls. After 6 weeks of budesonide treatment 41 patients showed clinical remission (97,6
%) with a marked improvement of the SIBDQ score whereas the SF-36 subscores did not
change after treatment (Table).Conclusion: SIBDQ and SF-36 demonstrate severely reduced
quality of life in patients with collagenous colitis. Compared to SF-36, the SIBDQ appear
to be more suitable to measure treatment-associated improvement of quality of life in
collagenous colitis.
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T1141
Interpretation of Sf-36 Score Changes in Active Crohn's Disease (CD) Patients
Dorothy L. Keininger, Brian G. Feagan, Geoffroy Coteur, Mark Kosinski
Background: Minimal important difference (MID) thresholds allow improved interpretation
of score changes. The SF-36 consists of 8 domains,1 and physical and mental component
summary (PCS and MCS) scores can be derived.2 Until now, no MID for the SF-36 domains
and summary scores have been reported for active Crohn's disease (CD) patients. Aims and
methods: The MID for SF-36 domain and summary scores were determined using data
from PRECiSE 1,3 a randomized controlled trial evaluating the efficacy of certolizumab pegol
induction treatment in patients with active CD (n=659). SF-36 MIDs were estimated by
anchor-based methods using known meaningful changes in reference measures (the Inflam-
matory Bowel Disease Questionnaire [IBDQ] and the CD Activity Index [CDAI]). A regression
analysis of the change in each SF-36 score to the change in the selected anchor was performed.
The a priori approach was to select the SF-36 MID according to the most correlated anchor.
Agreement of the anchor-derived MIDs with results obtained using standardized effect sizes,
standard errors of measurement and standard errors of the difference was also evaluated.
The MIDs were then used to interpret the results of a study investigating certolizumab pegol
maintenance treatment (PRECiSE 2).4 Results: The two anchors, IBDQ and CDAI, gave
similar values of meaningful changes. The IBDQ anchor was most correlated to SF-36 score
changes and was thus selected to derive the SF-36 MIDs. Results obtained with other methods
were in agreement with the derived MIDs and were representative of small to moderate
changes (effect sizes ranging from 0.2 to 0.5). Based on these calculations, it was estimated
that 51% of patients in PRECiSE 2 showed a clinically meaningful response in the SF-36
PCS after 26 weeks of certolizumab pegol induction and maintenance treatment compared
to 34% for patients receiving placebo in the maintenance phase (p<0.001). For the SF-36
MCS, 44% of patients showed a clinically meaningful response in the certolizumab pegol
group compared to 32% for patients receiving placebo in the maintenance phase (p=0.016).
Conclusions: A multi-faceted approach to determining MIDs for the SF-36 domain and
summary scores was investigated for the first time in patients with active Crohn's disease.
This allows interpretation of SF-36 scores in CD patients in a more meaningful way. 1.
Ware JE, et al. SF-36: Manual and Interpretation Guide. Lincoln, RI. 2000 2. Ware JE,
Kosinski M. SF-36 Physical and Mental Health Summary Scales. Lincoln, RI. 2001 3.
Sandborn WJ, et al. Gastroenterology 2006;130(Suppl. 2):Abstract 745 4. Schreiber S, et
al. Gut 2005;54(Suppl. VII):A82 (Abstract)
T1142
Prevalence of and Factors Associated with Gastroesophageal Reflux Disease: A
Population-Based Study in Shanghai, China
Xiuqiang Ma, Jia He, Yang Cao, Rui Wang, Xiaoyan Yan, Cheng Wu, Zheng Fu, Jian Lu,
Mari-ann Wallander, Saga Johansson, Wu Chen
Introduction. The reported prevalence of gastroesophageal reflux disease (GERD) in China
is lower than that in Western countries at present, but appears to be increasing. The aim
of this study was to evaluate the prevalence of GERD in Shanghai, China, in relation to
potentially modifiable risk factors. Methods. In total, a representative sample of 1200 adult
inhabitants of Shanghai (aged 18-70 years) was selected using a randomized, stratified,
multi-stage, cluster sampling method. Subjects completed mainland Chinese versions of the
Reflux Disease Questionnaire (RDQ) and GERD Impact Scale. A nested case-control analysis
was used to examine potential risk factors for gastroesophageal reflux symptoms, and odds
ratios (OR) and 95% confidence intervals (CI) were calculated in a univariate and multivariate
logistic regression analysis. The Cochran-Armitage trend test was used for trend testing.
Results. In total, 1034 subjects completed the survey (a response rate of 86.2%) and 919
responses were suitable for analysis (mean age: 46.7 years; 55.4% female). The prevalence
of heartburn and/or regurgitation occurring at least once every two weeks, at least once a
week and every day was 8.16%, 6.20% and 0.87%, respectively. The prevalence of GERD
(defined as heartburn and/or regurgitation at least once a week) was 6.2%. Factors significantly
associated with GERD included asthma (OR: 9.2; 95% CI: 3.0-41.9), cerebrovascular disease
(OR: 7.3; 95% CI: 1.7-31.1), ischaemic heart disease (OR: 5.1; 95% CI: 1.5-17.4), hyperten-
sion (OR: 2.3; 95% CI: 1.2-4.4), anxiety (OR: 15.1; 95% CI: 1.2-196.6), depression (OR:
13.7; 95% CI: 1.2-155.6), a body mass index ≥ 28 kg/m2 (OR: 4.7; 95% CI: 1.3-16.3)
and increasing age (P value for trends test = 0.0068). Conclusions. In agreement with
previous studies in Chinese populations, upwards of 6% of adults in Shanghai have symptoms
of GERD. GERD appears to be associated with a range of comorbidities, including respiratory
and cardiovascular diseases, in mainland China.
T1143
Fatigue in Patients with Liver Cirrhosis
Evangelos Kalaitzakis, Einar Bjornsson
Fatigue is considered to be common in patients with chronic liver disease and may influence
health-related quality of life(QoL). Although there are several reports on fatigue in patients
with cholestatic liver disease, data on fatigue and its possible association with mood disorders
and QoL in patients with liver cirrhosis (LC) are scarce. Also, low hemoglobin and testosterone
levels are common in LC but their relation to fatigue in these patients is unexplored.
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Methods:83 consecutive patients with LC(median age 53(IQR48-59), 32F, 25 with alcoholic
etiology, 23 with cholestatic etiology, 27 with hepatitis C, Child-Pugh score 9(7-11), MELD
14(11-18), 14 with HCC) under pretransplantation evaluation were prospectively included.
Three validated questionnaires were used to measure fatigue (Fatigue Impact Scale-FIS),
anxiety and depression (Hospital Anxiety and Depression) and QoL(SF-36). Results were
compared with those obtained from a large random sample from the general population
(n=858, age range 25-75yr, 420F). In male patients, serum testosterone measurements were
performed. Results: Cirrhotics had, compared to controls from the general population, more
pronounced fatigue expressed as total FIS score (65(26-95) vs 42(15-74); p<0.001) and
profound reduction in QoL (mean Physical Composite Score(PSC) 36.8, 95%CI 34.1-39.5
and Mental Composite Score(MCS) 40.2, 95%CI 37.3-43.2 in cirrhotics vs 50.0, 95%CI
49.8-50.2 for both PCS and MCS in controls). The total FIS score was related to PCS(r=-
0.53, p<0.001) and MCS(r=-0.64, p<0.01). 14(17%) patients had significant depression(HAD
depression score>10) and 11(13%) had significant anxiety(HAD anxiety score>10). In univar-
iate analysis, increased fatigue was related to depression (p<0.001), anxiety(p<0.001), asci-
tes(p=0.027), HCC(p=0.028), encephalopathy(p=0.002), blood hemoglobin(r=-0.34,p=
0.002), hospital admission for complications of LC(p=0.004), the Child-Pugh score(r=0.32,
p=0.003) and MELD(r=0.27, p=0.015) but not the etiology of LC. In men lower testosterone
levels were also related to increased fatigue(r=-0.56, p=0.001). In multivariate analysis (both
men and women) fatigue was independently related to significant anxiety(r=0.38, p=0.006)
and depression(r=0.27, p=0.043) as well as hemoglobin levels(r=-0.32, p=0.01). In multivari-
ate analysis (men only) fatigue was independently related to serum testosterone(r=-0.58,p=
0.01). Conclusions: In patients with cirrhosis, fatigue is common and associated with impaired
health-related quality of life. Mood disorders and low hemoglobin levels contribute to fatigue
in cirrhotics in general. In male patients low testosterone seems to be of importance for fatigue.
T1144
Preliminary Validation of the Pac-QoL Questionnaire for Chronic Idiopathic
Constipation in Patients in the UK
Simon Cowlam, Elaine Mccoll, Suzanne Milburn, Yan Yiannakou
Introduction: The Patient Assessment of Constipation-Quality of Life (PAC-QOL) is a 28-item
self-administered measure assessing 4 domains; constipation related worries and concerns,
physical discomfort, psychosocial discomfort and satisfaction. A high score denotes poor
QOL. Validity and reliability of PAC-QOL have been assessed in patients with idiopathic
constipation in the US 1. Aim: Confirm reliability and validity of PAC-QOL for use in
UK patients with chronic idiopathic constipation. Method: Ethical approval obtained. 148
consecutive patients invited to participate. A single self-administration of PAC-QOL and SF-
36 performed. SF-36 measures generic QOL and includes eight domains, tapping physical
and mental well-being; high score = good QOL. Item-total correlations and Cronbach's α
coefficient calculated to test internal consistency reliability. Construct validity assessed by
strength of correlations with SF-36, and by comparing PAC-QOL scores between patients
with and without abdominal pain (known-groups validity). Results: Consent from 122
patients. Mean age; 43 yrs ± sd 14.0. Mean duration constipation; 17.7 years ±15.5. Females
n= 118 (97%). Norm-referenced SF-36 PCS score 36.2±14.7, MCS score 43.0±8.6 (general
population score = 50 for PCS and MCS). Mean overall PAC-QOL; 2.4±0.73. Mean domain
scores; worries & concerns 2.5±0.88, physical discomfort 2.7±0.77, psychosocial discomfort
1.8±0.95, satisfaction 3.3±0.72. PAC-QOL completeness high (86% subjects responding to
all items). Missing item rates low (0.8%-12.3%). Cronbach's α >0.7 for each domain (range
0.72 - 0.91). Item-total correlations >0.40 in all but two cases; item-total correlation for
item 4 and item 28 were 0.37 and 0.28 respectively. As anticipated, moderate inverse
correlations between SF-36 and PAC-QOL domains that shared construct similarities (range
-0.49 to -0.32). There were weak inverse correlations between SF-36 and PAC-QOL domains
that did not share construct similarities (- 0.3 to 0.03). 4% of the patients had no abdominal
pain; no difference in scores between patients with abdominal pain and patients without;
overall PAC-QOL 2.1±1.2 vs 2.4±0.7, p=0.37. Conclusion: Generic and constipation specific
QOL was impaired in these patients. Findings provide preliminary evidence of the reliability
and validity of the PAC-QOL in assessing QOL in patients with idiopathic constipation in
the UK. Further study with larger numbers and multiple administrations of PAC-QOL is
required to evaluate additional psychometric parameters. 1. Marquis P et al. Development
and validation of the PAC-QOL questionnaire. Scandinavian J Gastroenterology.2005;40.
T1145
Perceptions and Beliefs Concerning Gastroesophageal Reflux Disease -
Physicians and Patients Disagree
Christina Reimer, Peter Bytzer
Background: There is insufficient evidence to support an association between lifestyle and
GERD, even though lifestyle interventions are usually recommended. There is also a lack
of data on physicians' opinions on the association between lifestyle and GERD and about
goals for treatment success outside clinical trial settings. Perceptions and beliefs concerning
the impact of reflux symptoms on various aspects of patients' daily lives are largely unknown.
Exploring these issues might help refine physicians' approach to patients with GERD. Aims:
To investigate physicians' perceptions about the relationship between GERD and life-style
and to evaluate physician-patient agreement concerning impact of GERD on quality of life
and expectations related to therapy. Methods: A short questionnaire was mailed to all
Danish PCPs (n=3603, response rate 36%) and to all members of The Danish Society of
Gastroenterology (n=624, response rate 50%). Another questionnaire was completed by 176
primary care patients with GERD, who were currently on medical therapy (PPI 84 %). Both
questionnaires were concerned with the efficacy of treatment and the impact of reflux
symptoms on different aspects of daily living. Results: Data from all physician questionnaires
were grouped as there were no major differences in responses from PCPs compared to
gastroenterologists. 35% of physicians considered GERD to be predominantly caused by
life-style and 51% always recommended life-style modifications as a part of the treatment.
According to physicians, the three most frequently affected aspects of patients' quality of
life were sleep disturbances (24%), limitations in physical activities (22%) and lack of energy/
tiredness (18%). However, according to patients, the three most frequently reported aspects
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were dietary restrictions (63%), lack of energy/tiredness (49%) and health concerns (44%).
70% of physicians considered complete absence of symptoms as a useful goal for GERD
therapy. In contrast, 72% of patients reported reflux symptoms over the preceding two
weeks, despite on-going medical treatment. Furthermore, 49% of the patients reported
self-imposed life-style restrictions (e.g. changing dietary behaviours), to avoid recurrence/
aggravation of symptoms. Conclusions: Both PCPs and gastroenterologists consider lifestyle
and GERD to be strongly associated. Physicians and patients disagree on impairments of
quality of life. Most physicians consider complete absence of symptoms as a goal for successful
therapy in GERD. However, most GERD patients reported frequent symptoms, despite
ongoing PPI therapy and self-imposed life-style restrictions.
T1146
Frequency of Gastrointestinal Symptoms in Patients with Eating Disorders
and Its Influence in the Quality of Life
María- josé Martínez-velarte, Santiago-josé Rodríguez-gómez, Carlos Ochoa-sangrador,
Manuel A. Franco-martín
Background: Patients with eating disorders (ED) have frequently gastrointestinal symptoms.
These symptoms can affect the quality of life. Aim: To evaluate the frequency of gastrointesti-
nal symptoms and to investigate its impact in the quality of life of patients with ED. Patients
and methods: Patients with the diagnosis of ED were studied. In ED we included patients
with restrictive anorexia nervosa, purgative anorexia nervosa, bulimia nervosa and eating
disorder not otherwise specified. We used for the measurement of health-related quality of
life (HRQOL) of these patients a generic questionnaire, the Gastrointestinal Quality of Life
Index (GIQLI). GIQLI is a self-administered questionnaire to assess HRQOL for gastrointesti-
nal conditions. It consists of 36 specific items on symptoms collected up in 5 dominions:
19 questions about digestive symptoms, 7 physical dysfunction, 5 emotional dysfunction,
4 social dysfunction and 1 question about treatment effects. All the questions have five
possible answers, from 0 (worst HRQOL) to 4 (best HRQOL).Results: Thirty three patients
with ED were included (30 women). The mean age was 19.5 years. Eleven patients had
restrictive anorexia nervosa, 3 purgative anorexia nervosa, 6 bulimia nervosa and 13 eating
disorder not otherwise specified. The mean Body Mass Index (BMI) was 21.02±2.8. Table
shows the GIQLI scores for ED and control group*.The patients with bulimia nervosa had
lower GIQLY score than the other groups (92.3±9.3 vs 103.11±16) and the patients in
nutritional rehabilitation group had lower GIQLY score than prevention relapse group
(95.20±14 vs 103.74±15) . The GIQLI score was similar in patients with BMI&;20 or <20,
duration of disease >3 or <3 years, history of admission to hospital or outpatient treatment.
Abdominal pain, epigastric fullness, bloating, flatus, belching and bowel urgency are the
most frequents symptoms. Conclusions: Gastrointestinal symptoms are frequent in patients
with ED. These patients present a poor quality of life, especially patients with BN and
nutritional rehabilitation stage, not only because of the presence of gastrointestinal symptoms
but also because of their emotional, physical and social status. Bibliography: *Poves Prim
I, Macías GJ, Cabrera Fraga M, Situ L, Ballesta López C. Quality of life in morbid obesity.
Rev Esp Enferm Dig 2005;97:187-195.
T1147
Quality of Life of Stoma Patients
Stephane M. Schneider, Dominik Lee, Gisèle Cartier, Eric Balez, Jérôme Filippi, Xavier
Hebuterne
Rationale: Like the underlying disease responsible for it, a digestive stoma can affect health-
related quality of life (QoL). The aim of this study was to assess ostomy's poorly-known
effects in a non-selected population. Patients and Methods: A local stoma patients' association
forwarded a simple medical questionnaire as well as a validated generic QoL self-questionnaire
(SF-36) to its members. SF-36 assesses eight domains of QoL, ranking from 0 (worst) to
100 (best): physical functioning (PF), role-physical (RP), body pain (BP), general health
(GH), vitality (VT), social functioning (SF), role-emotional (RE) and mental health (MH),
allowing calculation of a physical (MCS) and mental component scales. Results in these
patients were compared to those of a general population (n=2474) and of patients receiving
home enteral nutrition (HEN) (n=24) mainly due to a head-and-neck tumor or a digestive
disease. Age and sex were comparable in all three populations which were compared using
Student's t tests. Results: Forty-eight patients, aged 67 ± 18 years (M ± SD), with a colostomy
(n=39) or an ileostomy (n=9) placed 10.1 ± 8.6 years before (1-43) replied (a response rate of
40%). Surgery was performed due to cancer (n=32), IBD (n=10) or other (n=6). Comparisons
between the three populations are presented in the table. QoL was neither influenced by
the type of ostomy, the disease or the social status. MH was higher in patients over the age
of 70 and SF lower in patients with an ostomy present for more than nine years. Conclusion:
Health-related QoL is low in stoma patients, both in physical and mental domains, compared
to the general population, with the exception of a preserved vitality. Compared to HEN
patients, presence of an ostomy my explain the more important pain and social disability.
† P < 0.05 vs general population, * P < 0.05 vs HEN patients
T1148
Validation of a Disease-Specific Quality-of-Life Questionnaire in a Large
Sample of Dutch Achalasia Patients
Rutger Frankhuisen, Roy Heijkoop, Margot A. Van herwaarden, Durk Vries, de, André J.
Smout, Astrid Baron, Melvin Samsom
Recently the development and validation of a new questionnaire was described which
measures disease-specific health-related quality-of-life in achalasia patients (achalasia-
DSQoL). The questionnaire comprises 10 items, addressing the effect of achalasia-associated
complaints on well being. Validation of this questionnaire in a population other than the
one in which the questionnaire was developed, did not occur. Aim: to validate a translated
version of an achalasia-specific quality-of-life questionnaire (achalasia-DSQoL) by examining
its psychometric properties in a Dutch cohort of achalasia patients. Methods: The achalasia-
DSQoL was administered to 171 treated achalasia patients together with the Eckardt clinical
severity score and the SF-36. The Dutch version of the achalasia-DSQoL was prepared from
the original Canadian version by a translation group consisting of one clinical researcher,
two gastroenterologists and one research nurse. Validity and reliability were determined
using factor analysis, calculation of Cronbach's alpha, Spearman rank correlation with other
questionnaires and assessment of feasibility. Results: 72.5% of the achalasia patients com-
pleted the questionnaires. The factor analysis revealed four factors. Examination of the scree
plot revealed three factors with eigenvalues >1. There was a break between the first (3.6)
and the second (1.2) eigenvalue. The first factor extracted accounted for 35.9% of the total
variance. The fourth factor had an eigenvalue of 0.88 and comprised one question only,
regarding heartburn. This question did not substantially load on any of the other factors.
Cronbach's alpha of the questionnaire as a whole was 0.77. Theoretical deletion of the
question regarding heartburn resulted in an increase of Cronbach's alpha to 0.79, whereas
deletion of any other question caused Cronbach's alpha to decrease. There was a moderate
correlation between the achalasia-DSQoL and the clinical severity score (r= 0.619, p<0.001)
and some correlation with the SF-36 subscales (all SF-36 subscales except mental health
and role limitation emotional; r>0.3, p<0.001). 69 patients (58%) found that the question-
naire was easy to use and 82 patients (68.9%) were able to complete the questionnaire in
less than 15 minutes. Conclusion: The translated version of the achalasia-DSQoL is a valid
and reliable instrument to compare groups of achalasia patients. The question concerning
heartburn should be excluded.
T1149
Validation of a Survey Methodology for Gastrointestinal Diseases in China
Yang Cao, Jia He, Xiuqiang Ma, Rui Wang, Xiaoyan Yan, Cheng Wu, Jian Lu, Weiwei Liu,
Zheng Fu, Saga Johansson, Mari-ann Wallander, Yalin Sun
Introduction. There is a paucity of epidemiological data about gastrointestinal diseases in
China. This is, in part, because gastrointestinal surveys in China present unique methodolo-
gical challenges, including those associated with language and sampling. The aim of this
study was to develop and validate a methodology for epidemiological surveys of gastrointesti-
nal diseases in China. Methods. In total, a representative sample of 1200 adult inhabitants
of Shanghai (Huangpu, Pudong and Songjiang districts) was selected using a randomized,
stratified, multi-stage, cluster sampling method. Subjects completed Mainland Chinese ver-
sions of the following validated questionnaires, which had been translated and cross-culturally
adapted according to international guidelines: the Reflux Disease Questionnaire (RDQ), the
Gastroesophageal Reflux Disease Impact Scale (GIS), the Quality of Life in Reflux and
Dyspepsia questionnaire (QOLRAD) and Short Form-36 (SF-36). A subset of 120 subjects
was approached for a repeat evaluation 2-7 days later. Results. In total, 1034 subjects
completed the survey (a response rate of 86.2%) and 919 responses were suitable for analysis.
Repeat interviews were conducted in 113 of 120 subjects (a response rate of 94.2%), of
whom 99 were eligible. Kappa values for the RDQ, GIS and QOLRAD and the intraclass
correlation coefficient for SF-36 were 0.803, 0.706, 0.935 and 0.964, respectively, indicating
reproducibility. Cronbach's alpha coefficients for the RDQ, GIS, QOLRAD and SF-36 were
0.856, 0.801, 0.981 and 0.897, respectively, supporting internal consistency. Each dimension
of the RDQ correlated most strongly with the individual items comprising it (Spearman
correlation coefficient: 0.615-0.936). All QOLRAD dimensions were highly correlated with
the total score (Spearman correlation coefficient: 0.770-0.910). Conclusions. The survey
methodology provided an excellent response rate and the translated and adapted question-
naires demonstrated reproducibility and internal consistency, although responsiveness was
not assessed. These results support the use of these versions of the RDQ, GIS, QOLRAD
and SF-36 in epidemiological surveys and clinical studies of gastrointestinal disease in China.
T1150
Age-Dependent Influence of Heartburn On the Quality of Life of Russian
Urban Citizens
Sergey V. Morozov, Vassili A. Isakov, Ekaterina S. Stavraki
Introduction. Heartburn is a common symptom of gastroesophageal reflux disease (GERD).
It was shown previously that the quality of life is disturbed in patients who suffered from
heartburn. The quality of life in patients who experiences heartburn in Russia was not
studied yet. Aim: To evaluate the quality of life (QOL) in patients who experienced heartburn
amongst Russian urban population. Methods. A questionnaire was designed for primary
A-477 AGA Abstracts
care patients. It included questions on the presence and frequency of heartburn, risk factors
provoking heartburn, influence of the symptom on the patients' quality of life. Eight structured
questions were organized in a self filled-in form. The questionnaire was validated in 115
GERD patients and 104 controls. The results of he validation showed an acceptable sensitivity
(89%) and specificity (92%). The study was performed in 11 largest cities in Russia. Results.
20,000 questionnaires were distributed; The response rate was 81.3% and 14,521 question-
naires were analyzed. Among the respondents, 8,661 reported heartburn (59.7%). The
presence of heartburn had an effect on the QOL of those subjects: general considerable
discomfort was noted by 56.8%, 38% avoided favorite dishes and beverages, 26% reported
limited physical activity, sleep disorders were found in 20%, low efficiency in 14.6% of the
respondents. Major differences in changes of the QOL between elderly and other patients
were found (Table 1). From those with heartburn women more often refused from the
intake of favorite dishes and beverages then men (40.2% vs. 35.4%, p<0.001). But low
efficiency and limited physical activity because of heartburn observed more often in men
(13.1% vs. 16.3%, p<0.001 and 13.1% vs. 15.3%, p=0.004, respectively). Frequent heartburn
(i.e. 2 and more times a week) was a predictive factor for the decrease of the QOL. In
patients with frequent heartburn decreased QOL observed more often then in those who
experienced infrequent symptoms (p<0.001 for comparisons by each of the QOL patterns).
Conclusion. In this large population-based study we found that: heartburn significantly
decreases the patients' quality of life; in elderly this decrease is less prominent than in
younger people; The degree of the quality of life decrease depends on the heartburn frequency
in both groups o patients.
Quality of life changes in elderly and younger subjects.
T1151
Delayed-Release mesalamine Significantly Improved Quality of Life (QoL) in
Patients with Mildly and Moderately Active Ulcerative Colitis (UC)
E. jan Irvine, Peter D. Higgins, Chyon-hwa Yeh
Purpose: Health-related QoL is vital to patients with chronic illnesses but has been rarely
examined as an outcome in UC clinical trials. The Inflammatory Bowel Disease Questionnaire
(IBDQ) is a validated, reliable tool for measuring health-related QoL in patients with UC.
This analysis was performed to evaluate improvement in QoL by delayed-release mesalamine
in patients with mildly and moderately active UC. Methods: Data from 2 multicenter,
randomized, double-blind, active-controlled trials of similar design (ASCEND I&II) were
combined and analyzed. QoL was assessed using the IBDQ in 687 patients with mildly or
moderately active UC treated for 6 weeks with delayed-release mesalamine 2.4g daily (mar-
keted 400mg tab, P&G Pharmaceuticals) or 4.8g daily (investigational 800mg tab). Treatment
arms were pooled for the QoL analyses. The primary endpoint was overall improvement
defined as improvement from baseline at week 6 in physician global assessment accompanied
by improvement in at least one other clinical parameter (rectal bleeding, stool frequency,
patient functional assessment, or sigmoidoscopy) and no worsening in any of the remaining
clinical features. Results: The mean baseline IBDQ score was 143. Mean IBDQ total score
and subscores improved significantly from baseline (ANOVA; p < 0.0001) at 3 weeks and
6 weeks (Table 1). Patients who met the primary endpoint of overall improvement at 6
weeks experienced a significantly greater mean QoL increase compared to patients with no
improvement (p<0.0001, Figure 1). Conclusion: Delayed-release mesalamine significantly
improved QoL in patients with mildly and moderately active UC as early as 3 weeks. Patients
who met the primary endpoint of overall improvement showed a greater improvement in QoL.
Table 1
*p<0.0001 vs. baseline
Figure 1
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T1152
Symptom Distribution and Characteristics of Patients with Functional
Dyspepsia: Data from Two Large Multicenter Trials
Salam Zakko, Nimish Vakil, William D. Chey, David L. Earnest, Gregory Ligozio, Jeffrey
Kralstein, Peter C. Rueegg
Background: Clinical diagnosis and clinical trials in functional dyspepsia (FD) are often
hampered by the heterogeneity of the disorder and lack of data on the frequency and
characteristics of the associated symptoms (sxs). We evaluated baseline (BL) sx characteristics
and functional status of a large patient (pt) cohort, selected using Rome II criteria for
dysmotility-type FD (D-FD), for 2 identical, randomized tegaserod trials (S1, S2). Methods:
Pts eligible for study entry were English-speaking women with persistent/recurrent upper
abdominal discomfort characterized by FD dysmotility sxs of postprandial fullness, early
satiety and bloating. Pts with active ulcer-like dyspepsia, GERD or active IBS were excluded.
Pts eligible for randomization reported ≥ mild discomfort during BL (≥3 on a self-rated
7-point severity scale) for ≥2 of 3 D-FD sx plus unsatisfactory overall sx relief ≥50% of
the time. Quality of life (QoL) and work productivity were assessed at BL using the Hospital
Anxiety Depression Scale (HADS) and Work Productivity and Activity Impairment-Dyspepsia
(WPAI-D) questionnaire. Results: Of 7149 pts screened, 2667 (S1 1307, S2 1360) were
randomized; mean age 44 yrs (range 18-87), mean BMI 27.4 kg/m2 (range 15-63) and most
were Caucasian (78%). Mean composite (bloating, postprandial fullness and early satiety)
daily sx severity score was 4.3 in both trials (moderate-moderately severe). During BL, 26%
of pts experienced vomiting. In both trials pts reported <1 day/week with satisfactory relief
during the 14-day BL. Constipation was the most frequently reported coexisting GI condition
in pts medical history in both studies (11.3-18.8%). Most pts did not experience heartburn;
in the last week of screening, 72.8% (S1) and 67.1% (S2) reported 0 days with heartburn.
At BL, pts reported approximately 40% of work time as missed/impaired and 46% of daily
activities as impaired (WPAI-D). At BL, approximately 33% and 8% of pts reported at least
mild anxiety or depression, respectively (HADS). Conclusions: BL data from these large-
scale trials indicate that bloating and postprandial fullness are the most common and
bothersome sxs in pts with FD and dysmotility sxs. Vomiting is an associated feature in
many pts. Most pts have moderate to severe symptoms. FD with dysmotility sxs places a
substantial burden on pts lives as seen with increased anxiety scores and reduced social
activity and work productivity. These data demonstrate the multi-symptom nature and
severity of this common disorder.
T1153
Mucosal Healing As Treatment Endpoint in Ulcerative Colitis Patients Treated
with Thiopurinic Immunomodulators
Guillermo Bastida, Pilar Nos, Mariam Aguas, Belen Beltran, Isabel Conde, Maria
Rodriguez-soler, Julio Ponce
Introduction: In ulcerative colitis (UC), mucosal healing is the gold standard for a complete
response to therapy. Despite the widespread acceptance of Azathioprine (AZA) and 6-
mercaptopurine (6MP) for the treatment of patients with UC there is not enough information
about the mucosal healing and its significance.Objectives: To assess the rate of endoscopic
remission obtained in UC patients treated with AZA or 6MP and to analyze its implications
on biological parameters, quality of life and its importance in sustaining long-term remission.
Methods: 24 UC patients (13/24 (54%) men, mean age 38 years, 15/24 (62%) with pancolitis)
were consecutively included. The treatment was started either by steroid-dependence 14/
24 (58%), steroid-resistance 5/24 (21%) or by remission maintenance in severely active UC
5/24 (21%). A full clinical assessment and blood monitoring were performed at weeks 0,
2 and 4, and afterwards at months 3, 6, 9 and 12. Assessment of disease activity was made
with the Truelove Witss index, inactive disease (remission) was defined as a Truelove Witss
index below 7 without any steroid treatment. Endoscopy was offered at the end of the follow
up period. An Endoscopic Activity Index 0 or I / III was considered as an endoscopic
remission. Quality of life was assessed at 0, 6 and 12 months using a generic, Spanish
validated SF-36, and specific ,IBDQ, questionnaires. Results: 8 and 16 patients reached 6
months and 1 year of follow up respectively. At month 6, 9/24 (37,5%) of patients were
in clinical remission. Mucosal healing was seen after 6 months in 42,8% of patients per
protocol and in 37,5% per intention to treat analysis. At this time patients had a significantly
improvement in overall IBDQ score and also in all IBDQ dimensions and improved all the
8 dimensions of SF-36. One year after the initiation of the study 11/16 (68%) patients were
in clinical remission. At that time mucosal healing was 8/16 (50%) per intention to treat
and 8/14 (57,1%) per protocol. Both IBDQ and SF-36 showed an improvement in the overall
score and in all dimensions. At 6 or 12 months all patients with mucosal healing were in
clinical remission. Patients in clinical remission without mucosal healing had worse Quality
of life assessed with IBDQ. Mucosal healing did not correlate with SF-36 parameters or with
biological parameters. After 24 months, 1/8 (12,5%) of patients with mucosal healing had
a relapse while 2/3 (66%) in the patients wiht no healing had a relapse, OR 5,9 (111-0,33).
Conclusions: mucosal healing could be used as a treatment endpoint in thiopurine-treated
UC patients since it has clinical implications and impact on qualitity of life.
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T1154
Predictive Factors of Response to Cyclosporine and Quality-of-Life in Steroid-
Refractory Ulcerative Colitis. A Long Term Follow-Up
H. Blokzijl, A. Mäkelburg, F. Jansman, A. Poen, B. Westerveld, J. Vecht
Introduction:Cyclosporine (CSA) has been effective in patients with corticosteroid-refractory
ulcerative colitis (UC). We previously reported follow-up data in a large cohort of patients
with UC. The aim of this study was to evaluate factors predictive of response to CSA in
corticosteroid-resistant UC in a non-referral regional hospital. A quality-of-life (QOL) analysis
was conducted in all patients in longterm treatment of CSA. Methods: A retrospective survey
was performed with 69 consecutive patients diagnosed with corticosteroid-refractory UC
who were treated with CSA between 1994-2006. Blood CSA levels, full blood count, renal
and liver function tests were documented. Medical charts were reviewed for possible side
effects and complications of cyclosporine therapy, and survival. QOL was assessed using
the Short Form 36 (SF-36) Health Survey. Results: Fifty-two patients (75,4%) had a response
on cyclosporine and avoided colectomy during their initial hospitalization. Follow-up varied
from 7-179 months (median 78 months). Thirteen patients relapsed and 4 patients (31%)
required colectomy subsequently. The main side-effects during treatment were infections
(4%), hypertension (6%) and reversible renal impairment (12%). A high clinical activity
index and pancolitis at admission was associated with a poor initial response to cyclosporine
(p<0.05). QOL assessment showed comparable results in medical and surgical treated
patients. Conclusion: CSA is an effective and safe alternative to colectomy in severe UC.
The use of CSA is further supported by comparable QOL in patients who were treated with
CSA to those who underwent colectomy. However, pancolitis on admission is predictive of
patients who are unlikely to respond to CSA, and who will require a colectomy.
T1155
Methylnaltrexone Improves Opioid-Induced Constipation and Reduces
Laxative Use in Patients with Advanced Illness
Sloan Karver, Robert J. Israel
Background: Patients with advanced illness (AI) often experience severe opioid-induced
constipation (OIC) that is refractory to laxative therapy. Methylnaltrexone is a selective mu-
opioid receptor antagonist that blocks peripheral side effects of opioids while maintaining
central analgesia. We previously reported in a phase 3 trial (Study 302) that subcutaneous
(SC) methylnaltrexone given every other day (QOD) was well tolerated and effective in
inducing laxation in AI patients with OIC.* The co-primary efficacy endpoints of Study 302
were as follows: Within 4 hrs of the first dose, 48.4% of methylnaltrexone-treated patients
vs 15.5% of placebo achieved laxation (p<0.0001); Percent of patients with laxation within
4 hrs following at least 2 of the first 4 doses (1 week) was 51.6% for methylnaltrexone
and 8.5% for placebo (p<0.0001, chi-square test). Aims: To evaluate the improvement in
constipation and use of laxatives in patients treated with methylnaltrexone over 2 weeks in
Study 302. Methods: In this double-blind placebo-controlled trial, 133 AI patients with OIC
were randomized to placebo or methylnaltrexone 0.15 mg/kg SC QOD for 2 weeks. Dose
escalation was allowed after 1 week to 0.30 mg/kg SC QOD. For entry into the study patients
had to be constipated, defined as <3 bowel movements (BM) per week or no BM for 48
hrs. Baseline laxatives were continued during the study; rescue laxatives were not permitted
for 4 hrs before and after each dose. Results: The baseline laxative use in patients receiving
placebo vs. methylnaltrexone was comparable. During the study, more patients on placebo
than methylnaltrexone reported use of several classes of laxatives (placebo vs. methylnal-
trexone: contact laxatives 93% vs. 86%; enemas 35% vs. 24%; Mg hydroxide 37% vs. 24%;
osmotic agents 41% vs. 33%, respectively). Significantly more patients on methylnaltrexone
had ≥3 rescue-free laxations per week than placebo patients (68% vs. 45%, p<0.01, chi-
square test). Conclusions: In this phase 3 study, methylnaltrexone significantly improves
constipation in patients with advanced illness and OIC. This efficacy is further supported
by the reduced need for rescue laxatives. * Gastroenterology, 2006;131(3): 950(Abst).
T1156
A Novel Rat Model to Determine the Pathogenic Association Between Reflux
Esophagitis and Bronchial Asthma
Takashi Sugawa, Yasuhiro Fujiwara, Masatsugu Okuyama, Tetsuya Tanigawa, Masatsugu
Shiba, Kazunari Tominaga, Toshio Watanabe, Nobuhide Oshitani, Kazuhide Higuchi,
Tetsuo Arakawa
Background: Reflux esophagitis (RE) is associated with bronchial asthma (BA). Detail patho-
genic association between RE and BA is not clear because of the lack of animal models.
Aim: To establish a rat model of RE and BA, and to examine their pathogenic interrelation.
Methods: RE was produced by ligating the forestomach and covering the duodenum with
a small piece of 18Fr Nelaton catheter by a method of Omura. BA was caused by aerosol
inhalation of ovalbumin (OVA) two weeks after sensitization by intraperitoneal injection of
OVA. In combination of RE and BA, rats were sensitized by OVA one week after induction
of reflux esophagitis. Rats were killed 4-48 hrs after inhalation of OVA, and bronchoalveolar
lavage fluid (BALF) , esophageal and lung tissue specimens were obtained. Studies: 1) Total
and differential cell counts in BALF. 2) IL-4, IL-10, IL-13, and TNF-α levels in BALF by
ELISA. 3) Macroscopic and histological examination of esophagitis. 4) The expression of
IL-4, IL-5, IL-10, IL-13, IFN-γ, TNF-α, RANTES, and Eotaxin mRNA by real time RT-PCR.
Results: The number of total cells and eosinophils as well as IL-13 and TNF-α level in BALF
significantly increased in BA rats. Although RE did not affect condition of BALF compared
with control, the number of total cells and eosinophils, and IL-13 and TNF-α level in BALF
significantly increased in RE+BA group compared with BA group (IL-13 level, 242.5 ± 164.3
pg/ml in RE+BA group versus 112 ± 43.8 pg/ml in BA group, p<0.05). There were no
macroscopic changes of esophagitis in RE+BA group compared with RE group, however,
significant increase in eosinophil infiltration to the submucosal layer of the esophagus was
observed in RE+BA group. IL-5, IL-10, IL-13, and RANTES mRNA expression in esophagitis
of RE+BA group was significantly increased compared with RE group. Conclusion: Significant
pathogenic interrelation was confirmed between reflux esophagitis and bronchial asthma in
this novel rat model.
T1157
Weakly Acidic Reflux and Gastric Aspiration After Lung Transplant
Kathleen Blondeau, Veerle Mertens, Bart Vanaudenaerde, Geert Verleden, Dirk Van
raemdonck, Lieven Dupont, Daniel Sifrim
In lung transplant patients (LTx), increased acid gastroesophageal reflux (GER) has been
associated with development of Bronchiolites Obliterans Syndrome (BOS) and anti-reflux
surgery has been suggested to protect the allograft. The aim of this study was to investigate
in LTx patients the prevalence of weakly acidic GER and aspiration of gastric contents.
Methods: In 66 LTx patients, acid and weakly acidic GER were measured with 24hrs pH-
impedance recordings and gastric aspiration was assessed by pepsin determination (ELISA)
in bronchoalveolar lavage fluid (BALF). 14 non-transplanted respiratory patients served as
controls. Lung function (FEV1) and degree of BOS were assessed on the study day. Results:
LTx patients had normal number of acid and weakly acidic GER events and normal esophageal
acid and volume exposures. All 66 LTx patients had detectable levels of pepsin in the BALF.
Pepsin levels in LTx recipients (545 ng/ml) were significantly higher compared to controls
(23.8 ng/ml). Patients with double LTx had significantly higher levels of pepsin in BALF
(768.8ng/ml) compared to patients with a single LTx (260.2ng/ml) or heart-LTx (109.8ng/
ml). There was no correlation between pepsin levels and number of reflux events (total,
acid or weakly acidic), esophageal acid exposure, esophageal volume exposure or proximal
extent of reflux. However, pepsin levels were significantly higher in patients with nocturnal
reflux episodes (611ng/ml) compared to patients without nocturnal reflux (242 ng/ml).
During the night, 21 patients had predominantly acid reflux, 14 patients had predominantly
weakly acidic reflux and 8 patients had both acid and weakly acidic reflux. There was no
correlation between pepsin levels and FEV1 values and pepsin levels in BALF could not
predict the presence or severity of BOS (no BOS 610 ng/ml vs. BOS 600.5 ng/ml. Conclusion:
All LTx patients had elevated levels of pepsin in the lungs, suggesting that gastric aspiration
is very common after LTx. Although our patients did not have 24hs increased reflux, the
occurrence of nocturnal reflux increased their risk for gastric aspiration. The amount of
pepsin in the lungs does not correlate with reflux parameters but is higher in double LTx
suggesting a worse lung clearance function. Pepsin is a marker of gastric aspiration but does
not, by itself, deteriorate lung function or provoke BOS.
T1158
Increase in Heart Rate During Esophageal Acid Reflux in Patients with Gastro-
Esophageal Reflux Disease (GERD)
Valentina Torella, Mariangela Spezzaferro, Flora M. Sacco, Sozio Federica, Laurino Grossi,
Leonardo Marzio
Introduction: There is evidence that the inhibition of acid secretion may improve cardiac
symptoms in patients with coronary heart disease and syndrome X. There is no evidence
however that acid juice refluxed into the esophagus changes cardiac function in someway.
Aim: to evaluate heart rate during spontaneous gastro-esophageal reflux (GER) in 19 patients
affected by GERD with abnormal 24hours pH-metry and 6 normal controls with normal 24-
hour pHmetry. Methods: Patients and subjects had hyperemic and normal gastro-esophageal
junction at upper endoscopy respectively. Both groups were studied with a simultaneous
recording of 24-hours esophageal pHmetry and 24-hours ECG recording. Mean heart rate
(MHR) of a 10-min period was computed 10 min and 20 min before, during a GER and
10, 20 and 30 min after a silent GER . The same calculation was performed for a total of
six 10-min consecutive periods during a period without reflux chosen randomly during the
recording. Comparison was performed with Student's t test for paired data (mean±SEM),
between MHR in the two 10-min periods preceding GER with the period of reflux, and
each of the three 10 min period after the reflux. Results: In GERD patients and controls a
total of 78 and 19 periods with reflux episodes and a total of 19 and 4 periods without
reflux were evaluated respectively A statistical significant increase in MHR was seen during,
and in the 10 min and 20 min period after GER in GERD patients, while no change was
present in controls (table). No change in MHR was also computed during the five 10-min
periods without reflux in GERD and controls (data not shown). MHR was significantly
increased for reflux below the pH value of 3.5 and longer than 120 sec duration (table).
Summary : GER induces a statistically significant increase in heart rate during GER, 10 and
20 min after the reflux in GERD patients and whle no change is found during GER in
normal controls. MHR is significantly modified by reflux below the value of 3.5 and longer
than 120 sec. Conclusion: This study supports the hypothesis that patients with GERD have
deranged esophageal mucosal barrier to acid.
*P<0.01 vs -10 min and -20 min
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T1159
The Role of a Liquid Alginate Suspension (UK Formulation) in the
Management of Laryngopharyngeal Reflux (LPR)
Julian A. Mcglashan, Peter W. Dettmar, Lesley M. Johnstone, John Sykes, Philip J. Berry
Background: Laryngopharyngeal Reflux (LPR) refers to the backflow of stomach contents
into the laryngopharynx. Increasing evidence has demonstrated that LPR is a contributing
factor in some cases of hoarseness, vocal fatigue, voice breaks, cough, globus and throat
clearing. However several randomised placebo-controlled trials of PPIs in the treatment of
LPR have been reported with the majority showing no significant benefit in symptoms scores
over placebo. Aim: To investigate the improvement in symptom score and clinical findings
in LPR achieved with liquid alginate suspension compared to control ( no treatment ).
Patients/Methods: Patients presenting to the Otorhinolaryngology Outpatient Department
at the Queen's Medical Centre, Nottingham, UK presenting with the symptoms of LPR were
considered eligible if they had a score of greater than 10 on the Reflux Symptom Index
(RSI) score a validated, self completed questionnaire and a Reflux Finding Score (RFS)
greater than 5 based on a fibreoptic examination of the larynx. The study was approved by
an independent ethics committee and informed consent obtained from all study patients.
Forty-nine Caucasian patients were randomised into the open, parallel group study. Twenty-
four (15 male/9 female mean age 50.8 SD 12.7) received 10ml liquid alginate suspension
(UK formulation) four times daily after meals and at bedtime and 25 (13 male/12 female
mean age 58.1 SD 11.6) were randomised into the control group. Patients were assessed
pre-treatment and at two, four and six months post treatment. 2 subjects in each group
were excluded from the efficacy analysis. Results: RSI and RFS pre-treatment scores were
(mean SD) 23.9 (7.0) and 10.4 (3.6) for the treatment group and 24.6 (7.4) and 10.3 (3.3)
for the control group respectively. Significant differences between treatment and control
were observed for RSI at the two month (11.2 (7.0)/ 16.8 (6.4), p=0.005) and six month
(11.2 (8.1)/18.3 (9.4), p=0.008) assessments respectively and for RFS at the six month
(7.1 (2.8)/9.5 (3.4), p=0.005) assessment. The treatment was well tolerated. Conclusion:
Significant improvement in symptom scores and clinical findings were achieved with liquid
alginate suspension compared to control and warrants further evaluation for the management
of patients presenting with LPR.
T1160
Temporal Relationship of Chronic Cough to Gastro-Oesophageal Reflux:
Assessed Using a New Validated Acoustic Cough Monitoring Technique
Samantha Decalmer, Angela Kelsall, Mcguinness Kevin, Helen P. Jones, Julie Morris,
Ashley Woodcock, Lesley A. Houghton, Jaclyn Smith
Gastro-oesophageal reflux is generally considered to be a major cause of chronic cough.
However, previous studies examining the temporal relationships between cough and reflux
events have used surrogate measures of cough, such as manometric changes in pressure,
event markers or diary annotations. Methods: We have used a recently validated 24 hour
acoustic cough monitoring system (Vitalograph UK Ltd) (1) and impedance/pH monitoring
(Sleuth, Sandhill Sci Inc) to concomitantly record cough sounds and acid/non-acid reflux
events in 30 tertiary care patients with chronic unexplained cough [mean age 55.8 (SD
±10.8) years, 18 female, median cough duration of 6 years (range 1.3 - 30)]. Impedance
recordings were manually evaluated with the assistance of Bioview Analysis®; bolus move-
ment defined as a rapid (≤2 sec) fall in resistance to 50% of baseline, in at least 2 consecutive
(of the distal 4) channels. Cough recordings were manually assessed and coughing quantified
by counting the number of explosive sounds and the number of cough bouts (consecutive
coughs ≤2 seconds apart). We examined both the occurrence of cough events before and
after reflux events and the occurrence of reflux events before and after coughing, using the
standard 2 minute time window. Results: Although the median 24 hour cough count was
290 explosive cough sounds (range 43-833) or 82.5 cough bouts (range 17-206) [median
of 3 coughs per bout (range 1-31)], the mean number of reflux episodes over 24 hours was
66.2 (SD ±26.1), therefore within the normal range (i.e. <73). Cough was present immediately
before a mean of 11.1% (range 0-27%) of reflux events and after a mean of 15% (2-39%)
of reflux events [mean difference 3.9% (95%CI 2.0%,5.8%), p<0.001]. There were no
significant relationships between the type of reflux (acid, non-acid or mixed acid/non-acid)
and the presence of cough before reflux (p=0.24) or after reflux (p=0.59). Reflux was present
before a mean of 14.4% (range 0-39%) and after a mean of 20.2% (4-42%) of cough bouts
[mean difference 5.8% (95%CI 2.3%, 9.2%), p=0.002]. Reflux after cough events occurred
significantly more often than coughing after reflux [mean difference 5.2% (95% CI -9.3%,
-1.1%), p=0.01]. Conclusions: In this group of chronic cough subjects the majority of cough
and reflux events were not temporally associated. Where events were related, cough was
most likely to precede reflux. Furthermore, it is interesting to note that the cough rate in
the present study was much greater than those previously reported, suggesting surrogate
measures of cough may underestimate the objective cough frequency. (1) Smith et al, Cough
2006;2:1-6
T1161
Mortality Associated with Gastroesophageal Reflux Disease and Its Non-
Malignant Complications: Two Database Analyses
Hashem El-serag, Anja Becher
Background and aim: Gastroesophageal reflux disease (GERD) is a chronic morbidity, and
the mortality associated with its malignant complications is well known. Non-malignant
complications of GERD include erosive esophagitis, esophageal strictures and esophageal
ulcers; these predispose to bleeding, aspiration, and esophageal rupture. The risk of mortality
associated with these complications is less well reported. We aimed to assess the mortality
associated with non-malignant complications of GERD. Methods: Mortality in GERD and
its non-malignant complications was determined from national population mortality statistics,
registered according to the tenth revision of the International Statistical Classification of
Diseases and Related Health Problems (ICD-10). Data were obtained from the Centers for
Disease Control and prevention (CDC) (www.cdc.gov) for the USA, and from the Office of
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National Statistics (www.statistics.gov.uk) for the UK (England and Wales). Results: In 2003,
GERD (ICD-10: K21) and its non-malignant complications (esophageal ulcer, obstruction
and perforation; ICD-10: K22.1-3) were reported as the cause of death in 1206 cases in the
USA (age-adjusted mortality: 4.1/million/year), and in 364 cases in the UK (age-adjusted
mortality: 5.7/million/year), this being the most recent years for which figures were available
in both countries. In the USA, the reported mortality from GERD (ICD-10: K21) (2.3/million
in 2003) was approximately threefold higher than in England and Wales (0.7/million in
2003). By contrast, mortality ascribed to esophageal ulcer, obstruction and perforation (ICD-
10:K22.1-3) was approximately threefold lower in the USA than in England and Wales (1.8/
million vs 5.0/million). These figures suggest that deaths due to GERD-related complications
are more likely to be coded as ‘GERD' than as the resulting complication in the USA than
the UK. Mortality from GERD and its non-malignant complications increased with increasing
age. An exception was the mortality from GERD and its non-malignant complications in
the 0-19 year age group, which was higher than that in the 20-39 year age group, mainly
due to deaths in children aged less than 1 year. Mortality from GERD and its non-malignant
complications was between 1.2-fold and 1.8-fold higher in men than in women. Time-trend
data suggest that mortality from GERD and its non-malignant complications has been
increasing. Conclusion: Data from the USA and UK show that GERD and its non-malignant
complications can be fatal, with remarkably close estimates from the two data sources,
although deaths from GERD and its non-malignant complications are rare.
T1162
Gastroesophageal Reflux Protects Against Periodontal Disease While
Worsening Dental Erosions
Hank S. Wang, Jeremy Wilgus, Ariana Anderson, Masood Mansour, Bijal Surti, David Oh,
Gordon V. Ohning, Joan A. Otomo-corgel, Joseph R. Pisegna
Purpose: Known oral manifestations of gastroesophageal reflux disease (GERD) include
halitosis and dental caries. To date, the incidence of periodontal disease in GERD has not
been thoroughly evaluated. Previous studies have shown that bacteria responsible for caries
have increased virulence at a low oral pH, while bacteria causing periodontal disease are
more virulent at a high pH. The aim of this study were to compare periodontal exam
parameters in patients with and without GERD. We hypothesized that patients with GERD
would have a greater incidence of dental erosions but a decreased incidence of periodontal
disease compared to matched controls without GERD. Methods: The study was conducted
as a single-center, prospective trial enrolling 60 patients including those with and without
GERD. All patients were naïve to proton pump inhibitor therapy. Patient demographic
variables were recorded. Periodontal exams included assessment for clinical attachment level,
gingival index, plaque index, and erosion index and were scored on a scale of 0 (no disease)
to 4 (severe disease). Clinical attachment level and gingival index reflected periodontal
disease while plaque index indicated the presence of oral bacteria responsible for periodontal
disease. Erosion index referred to caries. Scores were given for all areas in the mouth. Exams
were completed by 2 highly trained academic periodontists who self-calibrated at 10 sites
in 5 patients excluded from the study. Statistical analysis was performed using a paired t
test to assess for differences between patients with and without GERD. Results: 31 patients
with GERD with regurgitation and 29 patients without GERD were well matched regarding
all demographic and clinical characteristics assessed. Patients with GERD had a significantly
greater mean erosion index at every sight assessed (0.51 vs 0.12). However, they also had
a significantly lower mean plaque index (0.96 vs 1.3), mean clinical attachment level (3.3 vs
3.6) and mean gingival index (1.1 vs 1.4) compared to patients without GERD. Conclusions:
Overall, patients with GERD had more dental erosions than patients without GERD, con-
firming that gastric reflux into the oral cavity results in enamel destruction. Patients with
GERD had fewer plaque than patients without GERD, suggesting a decreased rate of infection
with bacteria associated with periodontal disease. Furthermore, patients with GERD had
decreased incidence and severity of periodontal disease as measured by clinical attachment
level and gingival index. The presence of acid within the oral cavity appears to have a
protective effect, inhibiting growth of oral pathogens responsible for periodontal disease.
T1163
Esomeprazole for Treatment of Unexplained Chest Pain in Primary Care: A
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study
Nigel Flook, Paul Moayyedi, John Dent, Nicholas J. Talley, Tore Persson, Björn W.
Karlson, Magnus Ruth
Introduction: Chest pain is one of the most common reasons for patients to present to
primary care physicians or emergency departments, and is often non-cardiac in origin. In
many patients, underlying gastroesophageal reflux disease is the source of the pain and a
trial of proton pump inhibitor therapy is often used to identify chest pain with reflux-
based etiology. Methods: This study compared esomeprazole with placebo for the relief of
unexplained chest pain or discomfort. Primary care patients with ≥2 weeks of pain or
discomfort in the chest (of moderate severity on ≥2 of the last 7 days) and of unidentifiable
cause were included. Patients with identifiable non-cardiac causes of chest pain (e.g. musculo-
skeletal disorders, gastroesophageal reflux disease) were excluded, as were patients with
known cardiac disorders, abnormal ECG, troponin or exercise test results at baseline. Patients
were randomized to esomeprazole 40 mg twice daily (bid) or placebo for 4 weeks, and were
stratified according to frequency of heartburn or acid regurgitation as follows: <2 d/week
(stratum 1); or ≥2 d/week (stratum 2). The primary variable was relief of chest pain or
discomfort (measured by daily dairy on a 7-grade Likert scale), analyzed by stratum. Relief
was defined as ≤1 d with minimal symptoms during the last 7 d of treatment. Results: A
total of 599 patients were included in the intention-to-treat population (316 men, mean
age 46.9 years); 297 patients received esomeprazole 40 mg bid (stratum 1, n=153 and
stratum 2, n=144) and 302 received placebo (stratum 1, n=161 and stratum 2, n=141).
Esomeprazole was significantly more effective than placebo for the relief of chest pain in
stratum 1 (38.7% vs 25.5%, p=0.018). However, the difference was not significant in stratum
2 (27.2% vs 24.2%). Esomeprazole was significantly more effective than placebo when the
two strata were combined in a post-hoc analysis (33.1% vs 24.9%; p=0.035). Esomeprazole
was well tolerated. One patient (placebo group) developed a non-fatal myocardial infarction
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during the study. Discontinuations due to adverse events were similar between the esomepra-
zole and placebo groups (3.3% and 2.9%, respectively). Conclusion: Esomeprazole is more
effective than placebo for relief of unexplained chest pain in primary care, when patients
with identifiable non-cardiac causes of chest pain or known cardiac disorders, abnormal
ECG, troponin or exercise test results have been excluded. This treatment regimen is generally
well tolerated in these patients.
T1164
Characteristics of Patients with Irritable Bowel Syndrome (IBS) Complaining
of Gastroesophageal Reflux
Apostolos Poulakis, Hasse Abrahamsson, Magnus Simren
Background: Patients with IBS often complain about symptoms from the upper gastrointesti-
nal tract, such as dyspepsia and gastroesophageal reflux. Characteristics of patients primarily
seeking health care for IBS, but who also have gastroesophageal reflux, are not well known.
Aim: Evaluate the correlation between the severity of reflux symptoms in IBS patients and
the way these patients apprehend their symptoms, their sense of well- being and demographic
characteristic such as age, gender and body mass index (BMI). Method: We included 603
IBS patients according to the Rome II criteria (431 females, 172 males; mean age 44 (18-
73) years; mean BMI 23.8 (16.4-38.2) kg/m2). Of these 217 had predominantly diarrhoea,
150 predominantly constipation and 236 alternating diarrhoea and constipation. The patients
completed questionnaires to assess gastrointestinal (Gastrointestinal Symptom Rating Scale,
GSRS) and psychological symptom severity (Hospital Anxiety and Depression scale, HAD)
and quality of life (Psychological General Well-Being, PGWB (n=342) or Short-Form 36,
SF-36 (n=261). Results: Ninety-one of the IBS patients had reflux symptoms of at least
moderate severity the last week according to GSRS (15%). These patients had more severe
GI symptoms (GSRS total score, 3.6±0.9 vs. 2.8±0.7 (mean±SD); p<0.0001) than patients
with mild or no reflux symptoms. This was due to more severe abdominal pain (3.7±1.2
vs. 2.9±0.9; p<0.0001) and indigestion (4.3±1.2 vs. 3.6±1.1; p<0.0001) in patients with
moderate to severe reflux symptoms, but only trends towards more severely disturbed bowel
habits. They also had more pronounced reductions in quality of life, as measured by PGWB
(81±19 vs. 91±17; p<0.0001) and the mental (38±15 vs. 44±12; p<0.05) and physical
component summaries of SF-36 (39±9.6 vs. 45±8.4; p<0.001), and more severe anxiety
(HAD-anxiety, 10±4.6 vs. 7.5±4.0; p<0.0001) and depression (HAD-depression, 6.7±4.4
vs. 5.0±3.6; p<0.001). However, BMI, gender and IBS subgroup based on the predominant
bowel habit was unrelated to the presence of reflux symptoms, but IBS patients with reflux
tended to be somewhat older (p<0.05). Conclusions: Patients with IBS and concomitant
gastroesophageal reflux is a highly selected group, characterized by high gastrointestinal and
psychological symptom burden, as well as reduced quality of life. However, BMI, gender
or IBS subgroup was not related to the presence of reflux in this group of patients.
T1165
Power Spectral Analysis of the Sleep Electroencephalogram in Heartburn
Patients with Or Without Gastroesophageal Reflux Disease (GERD)
Ron Schey, Rohit Budhiraja, Stuart F. Quan, Naresh M. Punjabi, Ram M. Dickman, Shira
S. Fass, Ronnie Fass
Background: GERD has been shown to adversely affect objective sleep parameters and
subjective sleep reports. Thus far, there are no studies evaluating power spectral analysis of
the EEG of heartburn patients with and without GERD. Aim: To compare the power spectrum
of the sleep electroencephalogram (EEG) in heartburn patients with gastroesophageal reflux
disease (GERD) versus those without evidence of GERD. Methods: Data were prospectively
collected from symptomatic patients with heartburn. Symptoms were evaluated using the
validated GSAS Survey. All patients underwent an upper endoscopy. Patients with erosive
esophagitis only were included in the GERD group. Patients without erosive esophagitis
underwent 24-hour esophageal pH monitoring. Those with normal pH test and history of
lack of response to PPIs were included in the heartburn-but-no-GERD group. Sleep was
polygraphically recorded in the laboratory. Spectral analysis of the sleep EEG was performed
to determine the power spectrum in the following four bandwidths: δ (0.8 - 4.0 Hz), θ (4.1
- 8.0 Hz), α (8.1 - 13.0 Hz) and β (13.1 - 20.0 Hz). Results: A total of 11 patients (mean
age 40, 75% males) was included in the heartburn and GERD group (all had erosive
esophagitis), and six patients (mean age 42, 66.7% males) were in the heartburn and no
GERD group. The total GSAS score was similar between the two groups. Overall, 82% and
50% of the patients with GERD and without GERD, respectively, reported that heartburn
disturbed their sleep. Heartburn patients with GERD had evidence of lower average δ-power
(42.4%, 95% CI: 40.9-43.9%) than heartburn patients without GERD (45.4%, 95% CI:
42.4%-48.3%). Because the overnight evolution of δ-power in the sleep EEG varies by
approximately 5%-8% (maximum to minimum amount), an absolute difference of about
3% between groups is of substantial magnitude. Patients with GERD had a greater overall
α-power in the latter half of the night (three hours after sleep onset) than patients without
GERD (21.1% vs. 18.8 %, p < 0.027). No significant differences were noted in conventional
sleep stage summaries between the two groups. Conclusion: Among heartburn patients with
GERD, EEG spectral power during sleep is shifted towards higher frequencies as compared
to heartburn patients without GERD despite similar sleep architecture.
T1166
The pH of the Proximal Esophageal Refluxate Influences Elicitation of
Aerodigestive Reflexes During Sleep
Jasmohan S. Bajaj, David Knuff, Kulwinder S. Dua, Muhammad Hafeezullah, Candy
Hofmann, Reza Shaker
Sleep represents a vulnerable state with regard to airway safety against gastro-esophago-
pharyngeal reflux. Recent studies indicate that simulated non-acid reflux events by proximal
esophageal water infusion during sleep elicits esophago-upper esophageal sphincter contract-
ile reflex (EUCR) and secondary peristalsis (2P) in stage I, II and REM sleep, potentially
helping prevent pharyngeal reflux of gastric contents. However, the effect of acid pH on
elicitation of these reflexes during sleep has not been studied. Our aim was to determine
the elicitation of EUCR/2P in awake and sleep states. Methods: 8 healthy subjects (35 ± 4
yrs; 5 M) were studied in supine position during awake & stage II using polysomnography.
Esophageal and UES pressures were measured continuously using a specially designed
catheter assembly with a posteriorly-directed proximal esophageal injection port passed
transnasally. Water and Hcl were infused at 2.7ml/min until swallow or cough occurred or
EUCR/2P was elicited. A 10 minute water washout was performed after each Hcl infusion.
Subjects were blinded to the nature of the infusions and a visual analog scale was used to
evaluate chest discomfort. Results: All subjects were monitored for at least 4 hours during
sleep and none reported chest discomfort during the study. In awake state, EUCR/2P was
successfully elicited in all subjects by infusion of water and acid. In contrast, during sleep
all subjects exhibitied EUCR/2P with water but only 3 subjects developed EUCR/2P with
Hcl. The remaining 5 responded by arousal and cough/swallow. There was no significant
difference in threshold volume (T vol) for EUCR/2P in stage II sleep compared to awake
state. T vol for EUCR/2P using water compared to acid in the awake state or stage II sleep
in the 3 subjects where it was elicited were similar. T vol for arousal and cough/swallow
were significantly higher than T vol for EUCR/2P (table). Conclusion: Proximal esophageal
reflux events are associated with different responses depending on the pH of the refluxate.
While in some healthy individuals acidic refluxate induces EUCR/2P without arousal, in
most, it causes arousal with cough/swallow without eliciting these reflexes. These findings
are different from universally elicited reflex response to water infusion and may help explain
some of the respiratory symptoms attributed to reflux disease.
* Significantly higher T vol compared to EUCR/2P elicitation
T1167
Weakly Acidic Reflux and Gastric Aspiration in Patients with Cystic Fibrosis
Kathleen Blondeau, Veerle Mertens, Lieven Dupont, Bruno Hauser, Anne Malfroot,
Vandenplas Yvan, Daniel Sifrim
Many patients with Cystic Fibrosis (CF) have increased acid gastroesophageal reflux (GER).
It is believed that acid GER is micro-aspirated into the airways and induces poorer lung
function. Consequently, CF patients are frequently treated with H2-blockers or PPIs. It is
now recognized that, together with acid, other gastric components i.e. less acidic liquids,
pepsin and bile acids might be part of the refluxate and can be associated with respiratory
symptoms. We aimed to study the prevalence of weakly acidic reflux and gastric aspiration
in patients with CF. Methods: Fifteen CF patients [11men (age 30(19-51)] underwent 24hrs
impedance-pH monitoring for detection of acid (pH<4) and weakly acidic GER (pH4-7).
Lung function (FEV1) was assessed in all patients on the study day. 8/15 patients were
studied after lung transplantation (LTx). Broncho-Alveolair Lavage (BAL) samples were
collected from LTx patients and were evaluated for the presence of pepsin (ELISA). Results:
Eleven of the 15 patients had increased GER. 8/15 had increased esophageal acid exposure
(8.4±2.6%/24hs) and 2 of them had exclusive nocturnal reflux. The total number of reflux
events /24hrs was 67 (55-86) of which 48 (25-57) were acid and 19 (17-36) were weakly
acidic. Seven patients had increased proximal extent of reflux (number of reflux events that
reach 15 cm above LES). Impedance measurements showed that 3 patients with normal
esophageal acid exposure still had increased reflux i.e. 2 patients with prolonged esophageal
volume exposure and 1 patient with increased number of weakly acidic reflux. There was
no correlation between lung function (FEV1) and reflux parameters. Reflux parameters were
similar in transplanted and non-transplanted subjects. All LTx patients had increased levels
of pepsin in the lungs (805 (584-918) ng/ml). Interestingly, 4 of these patients had normal
esophageal acid exposure. There was no correlation between pepsin levels and lung function
(FEV1). Conclusion: Increased GER is very prevalent in CF patients. Acid GER is common,
but increased number or volume of weakly acidic GER may also occur. Aspiration of gastric
contents, as measured by pepsin levels in BAL fluid, occurred in all CF patients after LTx,
independent of the degree and acidity of GER i.e. patients with spontaneous or PPI-induced
normal esophageal acid exposure may still aspirate less acidic gastric contents. There was
no correlation between the level of pepsin and lung function, suggesting that pepsin might
just be a marker of aspiration and other gastric components (e.g. bile acids) are more relevant
in a pathogenic mechanism of reflux-induced respiratory changes.
T1168
Proximal Esophageal Reflux in Cardiopulmonary Transplant(TX) Patients
Presenting with Symptoms Suggestive of Extra-Esophageal Reflux (EER)
Kevin Halsey, Courtney Barancin, Arnold Wald, Eric A. Gaumnitz
Background: Studies have demonstrated high levels of acid reflux in cardiopulmonary Tx
patients. Gastroesophageal reflux (GER) likely involves the proximal esophagus in order to
produce symptoms of EER. Full characterization of GER in the Tx population has not been
complete. Although 24 hour pH test has been the gold standard for diagnosing post-Tx
GER, it fails to identify weakly acid and non-acid reflux. Our aim was to use impedance-
pH monitoring to assess post-Tx patients for acid and non-acid GER. Methods: Six post-
Tx patients (5 lung,1 heart; 4 f; mean age 55 yr) presenting with suspected EER symptoms
underwent 24 hour pH-impedance testing (median of 9 mo after Tx). Parameters included
proximal bolus contact time (BCT), proximal and total reflux events (% acid and non-acid),
and symptom index correlation (RSI). Three patients were on high dose proton pump
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inhibition therapy (PPI) and 3 discontinued PPI therapy for 7 days. Results: All Tx patients
had increased numbers of proximal esophageal reflux events compared to established controls
(Mean On PPI: 33, Off PPI: 36 vs. normal: 8-9). There were substantial increases in BCT
and average total proximal esophageal contact time per patient in Tx patients compared to
normal values (32 sec and 837 sec vs. 6-11 sec and 48-99 sec, respectively). There was
significantly less proximal BCT in Tx patients off PPI therapy compared to on PPI (p=0.02)
despite no change in total proximal events. A higher proportion of proximal reflux events
were non-acid in patients on PPI vs no PPI therapy (62% vs 29%, p= 0.006). In the PPI
group, there was a trend towards decreased total BCT for acid events and an increase for
non-acid events (p=NS). All five symptomatic patients demonstrated a positive RSI defined
as having >50% of symptoms occurring within two minutes of a reflux event. Symptoms
included coughing, regurgitation, and acute breathing difficulty. One patient did not have
symptoms on PPI during impedance-pH testing. Conclusions: Cardiopulmonary Tx patients
with symptoms suggestive of EER have increased proximal esophageal reflux. Mean BCT
for individual proximal reflux events and total BCT are significantly elevated, perhaps due
to increased volumes of refluxate and/or clearance abnormalities. Proximal esophageal reflux
events consist of both acid and non-acid components which vary according to absence or
presence of PPI therapy. PPI therapy significantly decreases proximal BCT but does not
decrease the total number of reflux events.
T1169
Ent Symptoms and Non Acid Gastro-Esophageal Reflux. A Study with 24-Hour
Ambulatory Esophageal pH-Impedance in Patients Off and On PPI Therapy
Lamya Benkhaldoun, Sabine Roman, Alain Ropert, Philippe Pouderoux, Ulriikka Chaput,
Francois Mion, Frank Zerbib
Introduction - Gastro-esophageal reflux (GER) may be responsible of ENT symptoms. How-
ever, the potential role of acid reflux has been recently challenged (negative randomized
studies with PPIs) suggesting that other factors like non acid GER may play a role in eliciting
such symptoms. With pH-impedance studies, non acid GER can be detected and proximal
extent can be determined. The aim of this study was to assess the characteristics of GER
detected by esophageal pH-impedance in patients ENT symptoms. Patients and methods -
Patients from 5 academic centers with ENT symptoms possibly related to GERD were
included in this retrospective study. Reflux events were detected visually using impedance
(Sandhill, CO, USA) and then characterized by pHmetry as acid (AR), or nonacid (NAR)
reflux, i.e. weakly acidic, or weakly alkaline (Gut 2004;53:1024-31). Data were compared
with normal values obtained in normal subjects without (Zerbib et al, APT 2005) and with
double dose PPI (Tututian et al, DDW 2006). Results - 55 patients were included, 26 without
PPI (8 men, 50.3 yrs) and 29 with double dose PPIs (17 men, 49.1 yrs). Results are presented
in table 1 (Results are expressed as median (95th percentile)). In patients without PPI, 4
(15.3%) had a pathological AR including 2 with a proximal extent (15 cm above LES). Only
1 (3.8%) patient had excessive NAR (high number of reflux). In patients with PPIs, 2 patients
(6.9%) had a pathological AR, 4 (13.8%) patients had NAR in excess including 2 with
proximal extent. Overall, 5 (17.2%) patients on PPI had an abnormal number of proximal
reflux. Conclusions - Abnormal acid/non acid GER is rare in patients with ENT symptoms.
Our results suggest that pH-impedance studies may help to identify a small subgroup of
patients with excessive and/or proximal reflux who may have ENT symptoms related to GERD.
T1170
Patients with Throat Symptoms On Acid Suppressive Therapy: Do They Have
Reflux?
Abraham Khan, Ilseung Cho, Morris Traube
Background: Reflux laryngitis is a term used for patients having laryngeal inflammation and
symptoms, such as hoarseness, globus, and throat pain, thought to be secondary to esophageal
reflux. However, the role of reflux in such patients, especially those unresponsive to proton
pump inhibitor (PPI) therapy, remains controversial. Combined multichannel intraluminal
impedance and pH monitoring (MII-pH) can be used to detect proximal and distal reflux
events and categorize them as acidic or nonacidic. Aim: Our aim was to characterize proximal
and distal esophageal reflux events in patients with throat symptoms unresponsive to PPI
therapy. Methods: We retrospectively reviewed the records of patients seen in our Center
for MII-pH testing from 2/28/05 to 6/31/06 for either throat or typical esophageal (heartburn,
regurgitation, chest pain) reflux symptoms despite PPI therapy. All patients were studied
on their PPI therapy. Extracted data for each patient included the the number of acid (pH<4)
reflux episodes and the number of total reflux episodes. Based on data in healthy volunteers
studied on PPI medications, reflux values were considered abnormal if >48 total events or
>12 acid events at 5 cm above the LES, and >19 total events or >5 acid events at 15 cm
above the LES [GASTRO 2006;130(suppl 2):A-171]. The prevalence of abnormal reflux
events in the patients with throat and typical symptoms was compared using the χ2 test.
Results: 51 patients (34 females, mean age 50.84 years, range 20-77 years) were included
in this study. There was a high prevalence of abnormal acid and total reflux events in the
proximal and distal esophagus in patients studied for either throat or typical symptoms (see
table). There was no statistically significant difference in prevalence between these two
groups. Conclusion: In our study population, there is a high prevalence of abnormal acid
and total reflux events in patients who complained of throat symptoms despite PPI therapy.
This is seen for both distal and proximal reflux. The prevalence of abnormal reflux was not
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significantly different from that seen in our patients who complained of typical symptoms.
Given the similarity of prevalence and type of reflux in the two groups, it appears that other
unidentified factors are required in addition to esophageal reflux for the development of
throat symptoms unresponsive to PPI therapy.
Number of Patients with Abnormal Reflux
χ2 tests comparing prevalence were not significant
T1171
Long-Term Outcome of Patients Undergoing Ambulatory pH Monitoring (Phm)
for Chronic Unexplained Cough (Cuc)
Michael J. Hersh, Chandra Prakash, Ray E. Clouse
Gastroesophageal reflux disease (GERD) commonly is incriminated in pts with CUC, as
some eventually will respond to antireflux therapy (ART). Objective measures of GERD on
pHM have not predicted response in small treatment trials and may have little use in selecting
candidates for aggressive ART, including fundoplication. The value of a symptom association
probability (SAP) calculation from pHM has not been tested in outcome studies. This
observational study determined the long-term outcome of a large number of pts with CUC
who had been investigated with pHM to detect predictors of ART response in a clinical
setting. Methods: 62 subjects (age 56 ±3 yr; 51 F) had completed pHM (≥12 hr) off ART
for CUC. Symptom intensity ratings were scored before the study. Distal channel acid
exposure time (AET), symptom index (SI: considered positive if ≥25% in CUC), and
modified SAP (mSAP: positive if <0.05) were calculated. Subjects were interviewed 35 ±3
mo after the pH study to evaluate relevant comorbidities not thought to explain cough (e.g.,
lung disease), nature of interventions, and degree of subjective response to ART (HDR =
high degree response, definite, sustained). Logistic regression analyses were used to determine
independent predictors of HDR. Results: 27 pts (44%) had elevated AET, 12 (19%) pos SI,
18 (29%) pos mSAP, and 33 (53%) any of these GERD indicators. 31 pts (50%) had ≥1
comorbidity confirmed by adequate evaluation. 25 pts (40.3%) had HDR over the follow-
up period. HDR was directly related to the intensity of ART (minimal treatment 10.0%,
continuous but sub-maximal treatment 22.2%, continuous adequate treatment including
≥3 months BID PPI 43.8%, antireflux surgery 72.2%; p<0.001 across treatments). In
univariate analyses, HDR was associated with female sex (F 47.1% vs M 9.1%, p=0.04) but
not with objective GERD indicators on the pH study. In the regression analysis containing
demographics, GERD indicators, comorbidities, tobacco use, and ART intensity, only ART
intensity (p<0.01) and female sex (p<0.05) independently predicted HDR. Positive mSAP
or SI when entered separately because of their correlation (r=0.5, p<0.001) each trended
toward being additional predictors (p=0.1 for each). Conclusions: More than half of pts
with CUC have objective indicators of GERD on pHM even in the presence of potentially
confounding comorbidities. Over 3 yrs of follow-up, a prominent response to ART is reported
by 40% of CUC pts, predicted primarily by the intensity of ART and not by GERD indicators
(including mSAP). These outcomes support the importance of GERD in CUC, the value of
intensive ART, and the negligible role of pHM in directing therapy.
T1172
Esophageal Dysmotility and Proximal Gastroesophageal Reflux(GER) in
Patients with Symptoms Suggestive of Extra-Esophageal Reflux (EER)
Kevin Halsey, Courtney Barancin, Arnold Wald, Eric A. Gaumnitz
Background: Identifying and characterizing proximal GER which may be responsible for
EER is elusive. Many patients remain symptomatic after acid suppression, producing a
diagnostic dilemma as to whether GER is the cause of symptoms suggestive of EER. Ambulat-
ory pH testing has been the standard for diagnosing classic GER; however, it has been less
helpful for EER. Impedance-pH testing is useful to further characterize proximal esophageal
reflux. Our aim was to assess the relationship between esophageal dysmotility and proximal
reflux in patients with symptoms suggestive of EER using impedance-pH testing. Methods:
Eighty-five patients (64 f; mean age 52 yr) with symptoms suggestive of EER underwent
24 hour pH-impedance testing and esophageal manometry (59 normal motility, 26 dysmotil-
ity). We analyzed the effect of dysmotility on parameters of proximal reflux including:
proximal bolus contact time (BCT), proximal and total reflux events, % acid and non-acid,
and symptom correlation. Patients on acid suppression (PPIs, n=22) and those with positive
impedance tests (total events >73 off PPI and >48 on PPI; n= 27) were assessed independently.
We also correlated symptoms with the results of pH-impedance testing. Results: There was
significant higher proximal esophageal BCT in patients with esophageal dysmotility than
normal motility (p=0.039), with no difference between total proximal reflux events. Proximal
BCT was elevated in dysmotility patients on PPI therapy and in patients with positive
impedance test (On PPI: mean 49sec vs. 24sec; positive impedance: mean 60sec vs. 22sec)
(p=0.005, p=0.06 respectively). There were significantly higher numbers of proximal events
in dysmotility patients on PPI therapy compared to normal motility (p=0.038), and a similar
trend in dysmotility patients with positive impedance studies (p= NS). There were no
significant differences between RSI scores in patients with dysmotility and normal motility.
Only 10 of 22 symptomatic patients on PPI therapy were found to have a positive impedance
study. Conclusion: Our results indicate that esophageal dysmotility significantly increases
proximal esophageal reflux. However, symptoms suggestive of EER do not predict the results
of impedance studies in patients who do not respond to PPI. Further studies are needed to
determine if pH-impedance studies can distinguish patients with symptoms suggestive of
EER who will benefit from anti-reflux procedures.
A-482AGA Abstracts
T1173
Nocturnal Reflux Symptoms Correlate with Respiratory Events in Patients
with Obstructive Sleep Apnea
Ting kin Cheung, Bing Lam, Mary Ip, Nina Wong, Annie Chan, Siu kam Lam, Benjamin
c.y. Wong
Background: Both obstructive sleep apnea (OSA) and gastro-esophageal reflux disease (GERD)
are common diseases that share similar risk factors. There have been ongoing controversies
regarding the role of gastro-esophageal reflux (GER) in obstructive sleep apnea (OSA). Aims:
To determine whether the presence and the severity of GERD is related to the severity of OSA.
Methods: Consecutive patients with OSA diagnosed on polysomnography (PSG) (defined as
respiratory distress (RDI) index >5) were recruited. Subjects completed a validated GERD
questionnaire. The presence and the severity of nocturnal reflux were also assessed. Results:
A total of 47 cases were recruited. The median RDI was 17.3 (range 5.1-63.1). The median
arousal per hour was 23.5 (range 4.1 to 62.2). BMI positively correlated with RDI (r=0.606,
p<0.001) but not with the number of arousals (p=0.201). No correlation was found between
the presence of GERD and RDI (p=0.622) or number of arousals per hour (p=0.557). The
severity of GERD did not correlate with both RDI (p=0.551) or number of arousals per hour
(p=0.451). However, the severity of nocturnal reflux correlated with the number of arousals
per hour (r=0.299, p=0.048). The severity of nocturnal reflux was also linked to RDI
but it did not reach statistical significance (r= 0.293, p=0.054). Conclusions: This study
demonstrated that nocturnal reflux appeared to affect sleep quality and contribute to the
severity of sleep apnea. It is possible that the conflicting results of OSA and GERD from
the current literature is that the population studied may not all have nocturnal GERD.
Further study in this area should focus on patients that complain of nocturnal reflux.
T1174
Gastroesophageal Reflux and Endoscopic Findings in Patients Presenting with
Advanced Dental Erosions
Clive Wilder-smith, Petra Rothenbuehler, Maya Marincek, Petra Wilder-smith, Adrian
Lussi
Dental erosions are a frequently unrecognized manifestation of supraesophageal reflux. 25-
50% of patients with symptomatic GERD have dental erosions. The prevalence of dental
erosions in asymptomatic patients is unknown, as are the reflux characteristics in these
patients. Patients presenting to dentists with dental erosions (Lussi erosion index >2) and
not consulting a doctor for GERD symptoms were referred for upper GI endoscopy and
24h ambulatory esophageal pH-manometry after exclusion of extrinsic and non-reflux causes
of erosion. pH-thresholds of 4.0 and 5.5, the threshold for dental acid-induced damage,
were chosen. Results: 83 patients (54 males, 29 females) of mean age (±SD) 32 ±9yr were
studied; 12 had minimal reflux, 71 had reflux with a time of pH<4 greater than 4%. Of
the latter, 20 (28%) had any symptoms of GERD, 21 (30%) had esophagitis (8 grade A, 13
grade B - LA classification), 20 had hiatal hernias and 52% showed non-specific dysmotility.
Results of the pH-metry (means±SD) are shown in the table. Patients received proton pump
inhibitors longterm and were followed with regular quantification of dental damage and
repeat pH-metry. Conclusions: Acidic gastroesophageal reflux is significantly increased in a
majority of patients presenting with dental erosions unexplained by other causes and not
consulting a doctor for GERD symptoms. A majority of patients were asymptomatic but
many demonstrated esophageal pathology. The spectrum of associated characteristics suggests
these increasingly more common patients with largely silent reflux constitute a special subset
of refluxers. The only effective current treatment option is potent and longterm acid inhibition.
T1175
Arousal Reflex and Aerodigestive Reflexes: Layers of Airway Protection
Against Nocturnal Reflux During Slow-Wave Sleep
Jasmohan S. Bajaj, Kulwinder S. Dua, Shiko Kuribayashi, Muhammad Hafeezullah, Candy
Hofmann, Reza Shaker
Investigations of the effect of sleep on various aspects of physiology and pathophysiology
of reflux disease are hampered by the cumbersome nature of necessary instrumentation and
their tolerance during sleep. This difficulty is further exaggerated if various stages of sleep
are to be studied. We have previously shown that esophago-upper esophageal sphincter
contractile reflex (EUCR) and secondary peristalsis (2P) are absent in slow-wave sleep (SWS
Stage III/IV) (Bajaj et al Gastro 2006). In that study, simulated reflux events by injection of
water into the proximal esophagus in SWS resulted in arousal and cough without elicitation
of EUCR/2P, despite these reflexes being present in other stages of sleep. The explanation
for this arousal could not be ascertained because of limitation of instrumentation. The aim
of the present study was to determine whether arousal in response to simulated reflux in
SWS is neurally mediated or is induced by pharyngeal entry of the infusate. Methods: We
studied 5 healthy subjects using concurrent transnasal pharyngolaryngoscopy (Pentax FNL-
0AP), manometry (Dentsleeve, Australia) and polysomnography (REMbrandt, Amsterdam).
Reflux was simulated by infusion of colored water at 2.7ml/min into the proximal esophagus
during SWS. Infusate was colored blue for recognition of esophago-pharyngeal reflux.
Subjects were monitored continuously for stages of sleep. 2 volunteers could not reach SWS
because of the cumbersome nature of the instrumentation. The remaining 3 volunteers (1
male/ 2 female; age 23 ± 1.2 yrs) entered SWS and a total of 5 infusions (1, 2, 2 per
volunteer) were successfully delivered. Injections were continued until the development of
either (1) manometric (change in UES pressure and 2P), (2) polysomnographic (arousal/
awakening) or (3) endoscopic (entry of colored water into the pharynx) response. Results:
All 5 injections resulted in arousal and swallow without development of either manometric
changes or pharyngeal reflux of the infused colored water. Mean UES pressure averaged 3
± 3 mmHg before as well as during injection in. Volume of infusate resulting in arousal
with swallow averaged 5.4 ± 8.1 ml. Conclusion: Proximal esophageal reflux in SWS induces
arousal instead of elicitation of aerodigestive reflexes. This arousal response seems to be
mediated neurally from the esophagus rather than be caused by pharyngeal entry of refluxate.
This finding confirms that airway protective mechanism in SWS is different from other
stages of sleep.
T1176
The Association Between Gastroesophageal Reflux Disease and Asthma: A
Systematic Review
Benjamin D. Havemann, Catherine Henderson, Hashem El-serag
Background and aim: Gastroesophageal reflux disease (GERD) has been linked to a number
of extra-esophageal symptoms and disorders, primarily in the respiratory tract. Although a
causal association between GERD and asthma has been discussed for many years, no system-
atic assessment of the evidence has yet been performed. The aim of this systematic review
was to provide a realistic estimate of the true strength and direction of the association
between GERD and asthma. Methods: Studies that assessed the prevalence or incidence of
GERD in individuals with asthma, or of asthma in individuals with GERD, were identified
in Medline and EMBASE via a systematic search strategy. Two independent investigators
conducted the search and data abstraction, imposing strict exclusion criteria to ensure that
only high-quality studies were included. We determined overall prevalence estimates by
calculating average pooled values weighted by sample size. The temporal relationship and
severity-response relationship between the two disorders were also explored. Results: A total
of 66 relevant studies were identified, and 29 of these met our inclusion criteria. When
GERD was defined according to the presence of typical symptoms of heartburn and/or acid
regurgitation, the pooled sample-size weighted average prevalence of GERD in individuals
with asthma was 59.2%, whilst in controls this value was 38.1%. In patients with asthma,
the average prevalence of abnormal esophageal pH, hiatal hernia and esophagitis was 50.9%,
50.6% and 37.3%, respectively. The average prevalence of asthma in patients with GERD
was 4.6%, whilst in controls it was 3.8%. Amongst the 13 studies that included a control
group, 11 found a significant association between GERD and asthma, with risk estimates
ranging between 1.5 (95% CI: 1.1-2.0) and 3.13 (95% CI: 1.64-6.01). One longitudinal study
showed a significant association between a diagnosis of asthma and subsequent diagnosis of
GERD. Three studies found that there was an increased likelihood that patients with GERD
would receive a subsequent diagnosis of asthma, compared with controls. However, this
reached significance in only one study. The severity-response relationship was inconsistent
but was examined in only nine studies. Conclusions: This systematic review and analysis
indicates that there is a significant association between GERD and asthma. However, the
temporal association and severity-response gradient between GERD and asthma is poorly
examined in the literature. The available evidence suggests that patients with asthma have
an increased risk of developing GERD, whilst the question of whether GERD precedes
asthma remains unclear.
T1177
Evaluation of Symptom Relief After 1 Week of Esomeprazole Therapy As a
Predictor of Relief After 4 Weeks in Patients with Unexplained Chest Pain: A
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Nigel Flook, Paul Moayyedi, John Dent, Nicholas J. Talley, Tore Persson, Björn W.
Karlson, Magnus Ruth
Introduction: Chest pain is one of the main reasons that pts present to emergency departments
and primary care physicians. Although pts often assume their pain is of cardiac origin,
underlying gastroesophageal reflux disease (GERD) is the source of pain in many cases. In
order to identify pts with unexplained chest pain responsive to acid inhibition, we evaluated
whether relief of chest pain after 1 week of esomeprazole (ESO) therapy can predict symptom
relief after 4 weeks. Methods: This study (ClinicalTrials.gov Identifier: NCT00251901;
PEARL) compared ESO and placebo for the relief of unexplained chest pain or discomfort.
Primary care pts with ≥2 weeks of chest pain or discomfort (of moderate severity on ≥2
of the previous 7d) and of unidentifiable non-cardiac cause were included. Pts were excluded
if they had identifiable non-cardiac causes of chest pain, known cardiac disorders, or abnormal
ECG, troponin or exercise tests results at baseline. Pts were stratified according to frequency
of heartburn and acid regurgitation at baseline (≤1 [stratum 1] or ≥2d/week [stratum 2]),
and were randomized to receive ESO 40 mg twice daily or placebo for 4 weeks. Pts rated
the severity of their chest pain each day for the previous 24h on a 7-point scale, where 0=
no symptoms and 6=very severe symptoms. Using Receiver Operating Characteristic (ROC)
curves, the sum of symptom scores during the last 5d (range 0-30) of week 1 was used to
predict relief of chest pain or discomfort during the last week of treatment (defined as ≤1d
with minimal symptoms during the last 7d of week 4]) in pts treated with ESO. Results:
The intention-to-treat population comprised 599 pts (316 men; mean age 46.9y); 297
received ESO and 302 received placebo. In stratum 1, response rates for ESO and placebo
were 38.7% vs 25.5% (p=0.018), respectively, at week 4. In stratum 2, response rates were
27.2% vs 24.2% at week 4, for ESO and placebo, respectively. ROC analysis showed that
a 5-d score sum of at most 4 had a negative predictive value of 84.0% (95% CI: 75.3;92.6)
in stratum 1 and 84.8% (76.9;92.7) in stratum 2. The corresponding positive predictive
values were 67.8% (55.0;80.6) and 57.5% (40.9;73.0), respectively. Sensitivity and specificity
were: stratum 1, 75.5% (61.7;86.2) and 78.2% (68.9;87.4); stratum 2, 62.2% (44.8;77.5)
and 82.1% (73.9;90.3). The cut-off of 4 was found to give the most attractive test properties.
Conclusions: The negative predictive value of relief after the first week of treatment indicates
that a 1-week trial of esomeprazole may be helpful when identifying pts with chest pain of
a non-acid-related etiology.
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T1178
In the Larynx, What Is Red Is Not GERD
Michael F. Vaezi, Mohammed A. Qadeer, Douglas Hicks
Background: Laryngopharyngeal reflux (LPR) is usually diagnosed based on laryngeal findings
on laryngosocopy in patient with chronic throat symptoms. Recent studies raised questions
on the specificity of laryngeal signs for GERD. However, there are no prospective data on
correlation between laryngeal sign and symptom improvement post-therapy. We evaluated
symptom and laryngeal sign changes in a cohort of LPR suspected patients at baseline 6-
and 12-month post surgical fundoplication. Methods: Patients with persistent symptoms of
LPR despite 4-month double dose PPI therapy were evaluated for symptom severity and
laryngeal signs before, 6- and 12- months post fundoplication. A single laryngologist who
was blinded to the patients' history performed examination. Findings of erythema, edema,
redundant tissue, surface irregularities, and other lesions noted for: posterior cricoid wall
(PCW), posterior pharyngeal wall (PPW), arytenoids complex-AC, true vocal cords (TVC),
anterior commissure (AC), medial arytenoids wall (MAW). Primary study outcome: > 50%
improvement in the presenting laryngeal symptoms vs changes in laryngeal signs. Results:
15 patients (mean age = 50, male = 4) were enrolled in the study. The most common
laryngeal symptoms were sore throat (40%), hoarseness (30%), and cough (20%), while the
most common signs were medial arytenoid wall erythema/edema (60%), interarytenoid
erythema (50%) and arytenoid complex erythema/edema (50%). Despite time dependent
improvement in each evaluated laryngeal sign (Figure) in 80% (8/10) of patients, only 1/
10 (10%) patient experienced improvement in laryngeal symptoms. Conclusions: There is
discordance in degree of laryngeal sign and symptom improvement post therapy. Our data
calls into question the specificity of laryngeal signs for GERD.
T1179
A Diagnosis of Laryngopharyngeal Reflux (LPR) May Be Difficult to
Distinguish from Rhinosinus Diseases and Asthma
Chadwick W. Hatfield, Steven P. Harrell, Tim Edwards, Jennifer Eversmann, Welby I.
Winstead, John M. Wo
Lifestyle behaviors associated with GERD are well recognized, but data on LPR is limited.
Aim: To determine which risk factors and conditions are associated with LPR. Methods: A
prospective case-controlled study was performed. A questionnaire was developed based on
Behavioral Risk Factor Surveillance System from Center of Disease Control. Questionnaire
was analyzed and confirmed for validity and reproducibility. Study groups were the following:
1) Suspected LPR (patients with laryngeal complaints consistent with LPR), 2) normal
controls, and 3) typical GERD (patients with heartburn). Traditional reflux lifestyle behaviors
(coffee, chocolate, alcohol, eating late, fatty foods) and potential risk factors of LPR (voice
overuse, voice abuse, smoking, and 2nd hand smoke exposure) were quantified. Established
diagnoses of asthma, allergic rhinitis, sinusitis, sleep apnea, depression, and anxiety were
determined. Based on past literature, validated screening questions were used to detect
unrecognized asthma and allergic rhinitis with a specificity of 96% and 87%, respectively.
Analysis of variance (ANOVA) was used. Results: 68 subjects with suspected LPR (68%
female, age 47±15) were enrolled. Suspected LPR subjects were older than controls but
similar in gender and body mass index. Suspected LPR subjects had similar reflux lifestyle
behaviors compared to controls and typical GERD. Prevalences of depression and anxiety
were similar among the three groups. Other results are shown in table. Established diagnoses
of asthma and sinusitis were present in 39% and 58% of suspected LPR subjects, respectively;
significantly more than controls but similar to typical GERD. Asthma was detected in 47%
of suspected LPR subjects using the screening questions, compared to 14% in controls
(p<0.001) and 31% in typical GERD (p=0.15). Conclusions: 1) Dietary and lifestyle behaviors
were similar between patients with suspected LPR, typical GERD, and controls. 2) Unrecog-
nized asthma was present in nearly half of patients with suspected LPR. 3) A diagnosis of
LPR may be difficult to distinguish from rhinosinus diseases and asthma.
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*Mean ± SD; **p<0.01 or Ψp<0.05 compared to normal controls
T1180
Prevalence of Gastro-Esophageal Reflux Disease in Patients with Difficult to
Control Asthma and Effect of Proton Pump Inhibitor Therapy On Asthma
Symptoms, Reflux Symptoms, Pulmonary Function and On Requirement for
Asthma Medications
Pravin M. Rathi, Veerendra Sandur, Murugesh Mallayappan, Madhu Sasidharan, Umang
Rathi, Aravind Kate, Jyotsna Joshi, Shobna J. Bhatia
Aims:To investigate the prevalence of GER in patients with difficult to control asthma and
to determine the effect of omeprazole on asthma symptoms, reflux symptoms, pulmonary
function and on the requirement of asthma medications. Methods:Patients with difficult to
control asthma were recruited into the study. All patients underwent esophageal manometry
and 24 hour esophageal pH monitoring. Pulmonary function tests were done before and
after treatment. The severity of asthma and reflux was assessed by a 1 week pulmonary
symptom score and reflux symptom score respectively before and after treatment. Those
who had an abnormal pH study underwent anti-GER treatment with lifestyle changes,omepra-
zole 40 mg bid for 3 months. Asthma medications were added or deleted based on severity
of asthma. The pretreatment values for all parameters were compared to the post treatment
values using a paired t test and two-way analysis of variance for repeated measures. Results:
Out of 250 asthmatic patients screened, forty patients fulfilled the inclusion criteria.Twenty
eight of 40 patients (70%) were diagnosed to have GERD. Of the patients 28 with GER, 8
patients (28.5%) had no reflux symptoms. On 24 hr pH metry, the percentage time pH
<4.0 was 10.81 ± 4.72 and 1.11 ± 1.21; Deemester score was 37.65 ± 14.54 and 4.89 ±
6.39 (p-value is 0.0001) in GERD and non-GERD patients respectively. The lower esophageal
sphincter (LES) pressure in GERD and Non GERD group was 11.41 ± 4.70 and 16.67 ±
3.58 mmHg respectively (p-value is 0.001). In GERD group, post treatment reflux symptom
score (RSS) improved from 22.39 ± 14.99 to 1.04 ± 1.07, pulmonary symptom score (PSS)
improved from27.14 ± 7.49 to 13.82 ± 4.21and night time asthma symptom score (NASS)
improved from 6.71 ± 1.80 to 3.04 ± 1.23 (p-value <0.0001). After treatment, FEV1 and
PEFR increased from 1.38 ± 0.57 and 4.14 ± 1.97 to 1.47 ± 0.54 and 5.56 ± 1.72, respectively
(p-value 0.00114). In Non-GERD group there was no change in RSS, PSS, NASS, FEV1 and
PEFR. In GERD patients, after treatment, oral salbutamol dose decreased from 8 mg to 4.67
mg per day, oral theophylline dose from 400.00 ± 0.00 mg to 270.37 ± 60.86 mg per day
(p value is 0.018),long acting inhaler bronchodilator salmeterol and fluticasone propionate
inhaler dose decreased from 153 ± 50.79 to 76.79 ± 25.39 per day (p value < 0.0001).
Conclusion: There is a high prevalence of GER, often clinically “silent.” in difficult to control
asthmatic patients. PPI therapy improves nocturnal asthma symptoms, daytime asthma
symptoms, pulmonary function and decreases requirement of asthma medications in
these patients.
T1181
Evaluation of Upper Abdominal Symptoms Using the Frequency Scale for the
Symptoms of GERD (FSSG) in Patients with Laryngopharyngeal Reflux
Nobuhiko Oridate, Yasushi Mesuda, Noriko Nishizawa, Yasushi Furuta, Satoshi Fukuda
Background: According to reports emanating from Western countries, patients with laryngo-
pharyngeal reflux (LPR) rarely complain of typical gastroesophageal reflux disease (GERD)
symptoms. Accordingly, we conducted a study of upper abdominal symptoms in patients
attending our Department of Otolaryngology complaining of LPR symptoms. Methods: The
51 patients who attended the Department of Otolaryngology complaining of LPR symptoms
without acid suppression therapy. Their symptoms were evaluated using the frequency scale
for the symptoms of GERD (FSSG)and their LPR symptoms were evaluated using the LPR
symptoms scoring system based on the Reflux Symptom Index proposed by Belafsky et al.
All patients were then administered PPI(rabeprazole 20 mg/day) for at 4 weeks. In the 21
assessable patients, changes in upper abdominal symptoms and LPR symptoms with treatment
were evaluated. Results: Of the 51 subjects, the FSSG score for all upper abdominal symptoms,
excluding Question No. 7 (laryngopharyngeal symptoms), was 0 in only 2 subjects. Some
upper abdominal symptoms were therefore reported by 49 out of 51 subjects with LPR.
The breakdown for upper abdominal symptoms was that 43/51 were positive for at least 1
of the acid reflux-related symptoms (6 questions excluding No. 7); and 47/51 for the
dysmotility-like symptoms. No correlation was seen between the frequency of any of the upper
abdominal symptoms and the frequency of laryngopharyngeal symptoms (FSSG Question No.
7). In the 21 assessable subjects who underwent at least 4 weeks of acid suppression therapy,
statistically significant reductions were seen in the frequency of both acid reflux-related
symptoms and dysmotility-like symptoms, whereas the reduction in laryngopharyngeal
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symptoms (Question No. 7) was not significant. The LPR symptoms score for laryngopharyn-
geal symptoms dropped to less than 1/2 of its pretreatment value in 12/21 subjects (thera-
peutic response group). None of the pretreatment FSSG questions predicted therapeutic
effect in comparison with the therapeutic non-response group, however. Conclusions: Acid
reflux-related symptoms are not necessarily more common, indeed the frequency of dysmotil-
ity-like symptoms is similar. We found no correlation between the positive rate for FSSG
upper abdominal symptoms and the frequency of laryngopharyngeal symptoms, whereas
the rates of improvement before and after acid suppression therapy were different for acid
reflux-related/dysmotility-like symptoms and laryngopharyngeal symptoms. These findings
indicate that in LPR patients, the FSSG laryngopharyngeal symptom question (Question No.
7) is an independent question, unrelated to any other questions.
T1182
Acid Reflux in a Cohort of Patients with Subglottic Stenosis
Edward J. Frech, John C. Fang, Panagiotis Panagiotakis, Kristen Thomas, Kathryn A.
Peterson
Background: Subglottic stenosis (SGS) is a rare disease with high morbidity often requiring
multiple tracheal dilations. Prior small studies have shown gastroesophageal reflux (GER)
in up to 80% patients with SGS suggesting a significant relationship between GER and the
development and progression of SGS. The diagnosis of coexisting GER is clearly important
in the clinical evaluation of patients with SGS. The relationship of GER in patients with
idiopathic SGS remains unclear. Aim: To determine the prevalence of pathologic acid reflux
in a cohort of SGS patients at a University referral center. To determine whether there is a
difference in GER prevalence between idiopathic and non-idiopathic SGS patients. To deter-
mine the prevalence of abnormal acid reflux in the proximal versus distal esophagus.
Methods: A retrospective chart review on all SGS patients between 2000 and 2005 was
performed. Data abstracted from the charts included age, SGS subtype, results of esophageal
motility and pH testing, GER symptoms, and outcomes from GER-related medical/surgical
interventions. Prevalence of abnormal pH testing by proximal and distal sensors was deter-
mined. Data was analyzed using Ficher's and t-tests between idiopathic and non-idiopathic
SGS patients. Results: A total of 50 SGS patients were identified, of which 42 had pH
testing for analysis. Four patients received only distal pH monitoring due to intolerance of
the pH catheter. The remaining 38 patients received proximal and distal pH testing. Of the
42 patients analyzed, 29 were classified as idiopathic and 13 had a known etiology for their
SGS. Only 20 of the 42 patients (48%) had abnormal pH findings. Of those with abnormal
pH findings, 6 of the 20 patients (30%) were abnormal in the proximal channel only. There
was no significant difference in prevalence of abnormal pH testing between the idiopathic
(45%) and non-idiopathic patients (54%). Conclusions: GER was present in substantially
fewer SGS patients (48%) than has been previously described. There was no difference
between the prevalence of GER in idiopathic versus non-idiopathic SGS patients. This
suggests GER may be a manifestation of the airway obstruction itself rather than a cause of
SGS. In this cohort 30% of SGS patients with GER would be missed by distal pH monitoring
alone. Proximal pH testing in addition to distal pH testing should be considered in the
evaluation of SGS patients.
T1183
Sleep Disturbance As a Marker of “Silent Reflux” During Sleep
William C. Orr, Suanne Goodrich, Paula Fernstrom, Goran Hasselgren
Sleep disorders are now recognized as a common complaint among patients with gastroeso-
phageal reflux disease (GERD). Complicated reflux disease has been noted to occur in
individuals who are relatively asymptomatic with regard to heartburn. This raises the question
as to the extent to which “silent” reflux may occur during the sleeping interval, and how
this may be identified by symptoms in the waking state. Speculation exists with regard to
whether or not individuals with complaints of disturbed sleep may have sleep related reflux
causing their sleep complaint. To address this issue, we studied patients with documented
sleep disturbance without symptoms of heartburn, and a group of normal controls.
METHODS: 55 subjects with documented sleep disturbance and 40 controls without symp-
toms of sleep disorders or heartburn were studied for two nights via polysomnographic
evaluations which included distal esophageal pH recordings. Subjects kept a sleep log for
two weeks and the sleep disturbance group had to have at least 6 nights of reported
unrefreshed sleep to qualify, while the normals had to have at least 10 nights of satisfactory
sleep. The two nights in the sleep laboratory were separated by approximately two weeks.
RESULTS: Of the unrefreshed sleep group, 33% had at least one reflux event during the
two sleep nights, which was not significantly different from the control group (32%). The
average duration of reflux events was 40 minutes in the unrefreshed sleep group, and 17
minutes in the controls (p > .05). Acid contact time was significantly greater (4.4% versus
.59%) in the sleep disturbance versus control groups (p < .05). CONCLUSIONS: 1. Subjects
with sleep disturbance have significantly more severe reflux as defined by total acid contact
time; 2. An otherwise unexplained sleep disturbance may be an important marker for the
presence of significant gastroesophageal reflux.
T1184
Prospective Evaluation of Patients with Non-Cardiac Chest Pain in the
Emergency Department
Julia J. Liu, Ling Hua, Rie Maurer, Sangeeta Kaushik, Richard Zane, Christopher Cannon,
John R. Saltzman
Purpose: Non-cardiac chest pain (NCCP) is a common presentation in emergency department
(ED) patient populations. Evaluation of patients with NCCP in the ED has been limited and
typically focused on ruling out cardiac and immediately life-threatening causes of chest pain.
We performed this prospective study to evaluate the presence of upper gastrointestinal
pathologies in patients with NCCP presenting to the ED. Methods: Patients with NCCP
presenting to the ED with no other sources of chest pain identified were screened. Exclusion
criteria for the study included: recent history of ischemic heart disease (< 6 months); patients
on proton pump inhibitors, active psychiatric or unstable medical conditions. After patients
were ruled out for myocardial infarction with serial cardiac markers and ECG analysis and
provocative testing for coronary vascular disease, study patients underwent upper endoscopy
(EGD) with wireless ambulatory pH monitoring (Bravo study) within two weeks of their
initial ED visit. Biopsies were performed in patients with abnormalities seen on EGD. An
abnormal esophageal pH study was defined as pH < 4 more than 4 percent of total time
on at least one day of pH monitoring. Results: Over four months, we screened 197 patients
NCCP in the ED. A total of 82 subjects were found to be eligible to participate in the study
and 31 patients signed consent to the study and underwent EGD with pH study. There
were 20 female and 11 male study subjects, with a mean age of 47 years. Three pH studies
were excluded due to premature capsule release. Overall, 25 patients (81%) had upper GI
lesions (esophagitis, hiatal hernia, gastritis or duodenitis) seen on EGD and 25 patients were
biopsied. Esophageal lesions; 6 patients (19%) had esophagitis on EGD, 2 patients (6%)
had biopsy proven esophagitis, and 8 patients (26%) had a hiatal hernia. Gastric lesions;
20 patients (65%) had gastritis present on EGD, 18 patients were biopsied, and 16 (52%)
had gastritis seen on pathology including three (10%) with H. pylori infection. Duodenal
lesions; two patients (6%) had duodenitis seen on EGD and one had biopsy-proven duoden-
itis. Of the 28 patients with complete ambulatory pH studies, 10 (36%) had an abnormal
esophageal acid exposure. Five out of the 10 patients (50%) with abnormal pH studies had
endoscopic evidence of esophagitis. Conclusion: Our study found upper gastrointestinal
abnormalities in a very high percentage of patients with non-cardiac chest pain presenting
to the ED, suggesting that GI evaluation is warranted in patients in the ED found to have
NCCP. Future studies are warranted to evaluate a strategy of GI testing and directed treatment.
T1185
Prevalence of and Impact of Pantoprazole On Nocturnal Reflux Symptoms in
Primary and Secondary Care Oesophagitis Patients in Belgium
Sebastien Kindt, Johan Imschoot, Daniel Sifrim, Jan F. Tack
Studies in the U.S. have revealed that gastro-oesophageal reflux disease (GERD) patients
often suffer from nocturnal symptoms, sleep disturbance and impaired quality of life. In a
large subset of patients these symptoms persist in spite of acid suppressive therapy. The
aim of the present study was to assess the prevalence of nocturnal reflux symptoms and
the response to standard medical therapy with pantoprazole in primary and secondary care
oesophagitis patients in Belgium. Methods: Questionnaires were provided to consecutive
patients presenting to primary and secondary care physicians with oesophagitis. The question-
naire evaluated the presence of typical reflux symptoms, alarm symptoms, risk factors, and
sleep quality impairment due to reflux episodes. Results are shown as mean±SD and compared
by Student's t-test or Chi-square test. Results: A total of 4061 primary and 5261 secondary
care patients (50% female, mean age 53±0.2 years, BMI of 25.8±0.1 kg/m2) were recruited.
84% of patients reported sleep disturbance attributable to nighttime reflux, including typical
nighttime supine reflux symptoms (72%), difficulties to fall asleep (39%), waking up during
the night (45%), morning fatigue (35%) and reflux symptoms when waking up in the
morning (47%). Mild, moderate or severe nighttime heartburn were reported by respectively
30%, 35% and 12%, and these numbers were 26%, 28% and 6% for nighttime regurgitation.
Alcohol (19%), smoking (22%), higher oesophagitis grades (grades 2, 3 and 4 in respectively
31, 7 and 7%), alarm symptoms (27%) and more severe heartburn and regurgitation during
daytime were all significantly associated with all dimensions of sleep disturbance (p<0.0001).
Obesity was only related to reflux symptoms in supine position and when waking up
(p<0.0001). After 1.4±0.02 months of standard treatment with pantoprazole, any sleep
disturbance had improved in more than 75% of patients, with resolution of nighttime
heartburn and regurgitation in respectively 73 and 84%. Conclusion: The majority of
patients presenting with reflux symptoms and oesophagitis in primary or secondary care
experience nighttime heartburn and regurgitation, and sleep disturbance by nighttime symp-
toms is present in 84%. Smoking, alcohol use, higher grades of esophagitis, more severe
typical reflux symptoms during daytime and the presence of alarm symptoms are risk
factors for GERD-related sleep disturbance. On standard therapy with pantoprazole nighttime
symptoms improved in more than 75%. These observations support a direct relationship
between reflux and sleep disturbance.
T1186
Gastroesophageal Reflux Disease in Iranian General Population: The
Prevalence and Risk Factors
Akram Pourshams, Najmeh Aletaha, Seyed mehdi Nouraie, Akbar Fazeltabar malekshah,
Reza Malekzadeh
Background: although Gastroesophageal Reflux Disease (GERD) is a common disorder, its
etiologies are still largely unknown. We investigated the GERD prevalence, and the potential
risk factors including: gender, age, obesity, smoking, alcohol and opium consumption,
dietary habit, and psychosocial status among inhabitants in northern Iran. Methods: a total
of 1016 randomly selected subjects were invited to the study. A face to face interview was
conducted for the participants [1000 (771 female), aged 18 -40]. Subjects who reported
heart burn and/or regurgitation, at least once a week, during the last 12 months were defined
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as GERD patients and controls were persons without any compliant of those symptoms.
Dietary intake was assessed using a local validated Block 116 food frequency questionnaire
and psychosocial status by a reliable General Health Questionnaire for Iranian (GHQ-28).
A multiple logistic regression was used to assess the association between risk factors and
GERD. Results: the prevalence for weekly GERD was 12.3%. Gender, smoking, alcohol and
opium consumption did not affect the risk of GERD. Age [OR: 1.04, 95% CI: (1.00-1.07)],
BMI≤ 30 [OR: 1.14, 95% CI: (1.34-4.35)], and social disorders [OR: 1.95, CI: (1.21-3.17)]
had a weak association for GERD. Somatization [OR: 3.50, CI: (2.17-5.66)], anxiety [OR:
4.02, CI: (2.51-6.43)], and depression [OR: 3.29, CI: (1.95-5.50)], were associated with
developing GERD. Further risk factors included consumption of high amount of tomato
sauce and citrus fruits. No association was found between total calori and total intake of;
tea, spicy foods, fiber, fat, protein, and carbohydrate with GERD. Conclusion: the prevalence
of GERD in Iran is more than most Asian counties and comparable to western countries.
Psychosocial disorder was significantly related to GERD symptoms. Tomato sauce and citrus
fruits were the most potent dietary risk for GERD symptoms.
T1187
Effect of Esomeprazole On Gastroesophageal Reflux Measured By 24-H pH-
Impedance Monitoring in Preterm Infants and Neonates with Pathological
Acid Gastroesophageal Reflux
Taher Omari, Geoff Davidson, Ross Haslam, Patrik Bondarov, Mia Fjellman, Mohamed
Sagar, Per Lundborg
Introduction: At present, limited data are available on the effect of proton pump inhibitor
(PPI) therapy on gastroesophageal reflux (GER) in preterm infants and neonates. We have
previously shown that omeprazole (0.7mg/kg once daily) significantly reduces esophageal
acid exposure and the frequency of acid reflux episodes (1); however, the effect of PPIs on
the frequency and extent of bolus reflux as detected by pH-impedance monitoring has not
been determined. Methods: In this single-center, open-label study (SH-NEC-0002), preterm
infants and neonates (<1 month post-term, corrected age) with signs and symptoms suggestive
of GER disease (apnea, vomiting, irritability/crying, gagging/choking episodes) and patholo-
gical esophageal acid exposure (reflux index ≥5%) received oral esomeprazole 0.5mg/kg
once daily for 7 days. 24-h pH-impedance monitoring was performed at baseline and on
day 7/8, using a 2mm diameter pH-impedance probe. Established pH-impedance based
criteria were used to define bolus reflux events based on type (liquid, mixed, gas) and acidity
(acid, weakly acidic, non-acidic). Analysis of variance (mean, 95% confidence intervals [CI])
and the Wilcoxon test (median, range) were used for statistical inference. Results: Twenty
patients completed the pH-impedance assessment and were included in the analysis. Mean
age was 7.4 (range 1.0-15.9) weeks, with a mean gestational age of 32.6 (range 23.0-41.0)
weeks. Mean weight was 3.0 (range 1.9-4.1) kg. Esomeprazole significantly reduced the
median number of acid bolus reflux episodes (30.5 [95% CI 12, 72] at baseline vs 7.5 [95%
CI 0, 37] after 1 week of therapy, p<0.0001) and the mean acid clearance time (206s [95%
CI 158, 254] vs 96s [95% CI 48, 145], p<0.01). The median number of weakly acidic bolus
reflux episodes increased from 14 to 23 (p=0.065) and the number of non-acidic bolus
reflux episodes decreased from 57 to 53 (p=0.316). Esomeprazole 0.5mg/kg did not signific-
antly alter the median total number of bolus reflux episodes (103 [95% CI 62, 187] vs 88
[95% CI 63, 175]); The mean proximal extent of bolus reflux (8.6cm [95% CI 7.8, 9.4] vs
9.2cm [95% CI 8.4, 10.0]); The mean bolus clearance time (9.9s [95% CI 7.4, 12.3] vs
9.6s [95% CI 7.2, 12]); or the median number of liquid (78 vs 72), mixed (16 vs 14) and
gas bolus reflux (12 vs 9) events. Conclusions: In premature infants with pathological GER,
esomeprazole 0.5mg/kg significantly reduces the number of acid reflux episodes and acid
clearance time, but does not alter the overall burden of reflux volume, as defined by
parameters of bolus exposure, bolus type and bolus extent. (1) Omari et al. J Pediatr
Gastroenterol Nutr 2006 (in press)
T1188
Baclofen Inhibits Acid Induced Heartburn Sensation During Bernstein Test
Ibrahim Dogan, Bikram S. Padda, Valmik Bhargava, Hans Rydholm, A. Lehman, Ravinder
K. Mittal
Background and Aim: Acid infusion into the esophagus in patients with acid sensitive
esophagus causes heartburn (Bernstein test) sensation. Baclofen, a GABAB receptor agonist
diminishes afferent nerve signaling from the esophagus and stomach. The goals of our study
were to determine the effect of baclofen on the acid induced heartburn. Methods: We studied
9 patients (mean age 52.9±7.7 yr; 6 males, range 43-62 yr) with chronic heartburn symptoms
and an acid sensitive esophagus (positive Bernstein test). Manometry and ultrasound images
of the esophagus were recorded concurrently during esophageal infusion with normal saline
and 0.1 N HCl, each for 15 minutes using a special custom-built catheter. Studies were
performed on 2 separate days, 7 days apart. One hour before the study, subjects received
either placebo or baclofen (40 mg P.O.), in a blinded fashion. Patients scored symptoms,
every 2 minutes during the entire infusion period, on a visual analog scale from 0 to 100.
At the end of the each study, subject again scored overall heartburn score during the study.
Muscle thickness was measured using the M-Mode ultrasound imaging technique developed
in our laboratory. Results: Acid infusion induced heartburn symptom on both study days.
However, heartburn score was significantly lower on the baclofen day (34±6) as compared
to the placebo day (53±9, p=0.007). At the end of the study heartburn score was also
significantly lower on the Baclofen day (66.1±7.9) compare to the placebo day (38.9±8.8,
p=0.009). Esophageal muscle thickness increased significantly after acid infusion (1.48±0.15
mm vs. 1.59±0.15, p=0.006). Baclofen didn't alter muscle thickness significantly. Conclu-
sions: To our knowledge, Baclofen is the first pharmacologic agent that decreases acid
infusion induced heartburn symptoms.
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T1189
Prevalence and Incidence of Neoplasia Among pts with Reflux Disease in a
Large Prospective Cohort Study (Progerd): An Update After 5 Years' Follow-
Up
Michael Vieth, Manfred Stolte, Peter Malfertheiner, Andreas Leodolter, Joachim Labenz,
Stefan Willich, Marc Nocon, Emma Nauclér, Tore Lind, Daniel Jaspersen, Wolfgang
Meyer-sabellek
Introduction: In terms of incidence, Barrett's adenocarcinoma (BAC) is the most rapidly
increasing epithelial malignancy in the gastrointestinal tract. Depending on site of investi-
gation, the annual incidence of BAC in pts with Barrett's esophagus (BE) ranges from 0.5-
1%. Methods: This multicenter, prospective cohort study (ProGERD) in 3 European countries
enrolled 6215 pts with symptoms of gastroesophageal reflux disease (GERD). The prevalence
of BAC at baseline, and incidence at 0-2y and 3-5y follow-up was calculated for all pts and
for those with Barrett's epithelium (Bep, diagnosed histologically [h+], with or without
endoscopic [e+ or e-] evidence) or BE (e+ and/or h+). Results: At baseline, 702/6215 pts
(11.3%) were diagnosed with BE. Of these, 305 patients (4.9%) were classified as e+/h+,
180 patients (2.9%) were e-/h+ (microscopic Bep) and 217 patients (3.5%) were e+/h-. In
total, 485 patients (7.8%) had Bep. At baseline, 5 pts with BAC had submucosal invasion,
1 had infiltration of the muscularis propria and 1 had mucosal carcinoma (Table). One pt
with advanced esophageal squamous cell carcinoma died shortly after the baseline visit; all
others were alive at 5y. One pt had low-grade intra-epithelial neoplasia at baseline, with
high-grade intra-epithelial neoplasia 1y after initial diagnosis and mucosal BAC at 2y. Of
the 6 pts diagnosed with BAC at 2y, 5 had mucosal invasion and 1 had submucosal invasion.
Two further pts were diagnosed with low-grade intra-epithelial neoplasia. Five of the 13
pts diagnosed at baseline or during 2y follow-up had submucosal BAC, 1 had invasion into
the muscularis propria and 7 had mucosal BAC. No further neoplasms were detected at 3-
5y (n=449, 64% of initial Barrett's cohort), yielding a theoretical annual incidence of BAC
of 0.56%. All cases of BAC were detected in pts with Bep. Conclusion: As all neoplasms
were detected by 2y it is possible that all neoplasms were already present at baseline,
supporting a screening, rather than regular follow-up, strategy in Barrett's pts.
T1190
Inhibition of Acid Secretion By a Novel Proton Pump Inhibitor (PPI)
Richard H. Hunt, David Armstrong, Mohammad Yaghoobi, Cindy James, Ying Chen, Jai
moo Shin, George Sachs
Background: PPIs are the standard of treatment of acid related diseases. They are all prodrugs
requiring first, accumulation in the acidic space of the secretory canaliculus of the parietal
cell and second, conversion to the active form by protonation of the N of the benzimadazole
moiety. Therefore, they can only be activated during acid secretion by the H, K ATPase.
They have a relatively short plasma residence time and therefore pumps that become active
after the drug has disappeared continue to generate acidity. This accounts for their relatively
poor inhibition of night time acid secretion and slow onset of symptom relief. Aims: To
generate a new chemical entity PPI with delayed absorption to provide a long plasma
residence time and improve acid inhibition. Methods: An acid-stable Na salt of a sulfonamide
of omeprazole (OMP) was synthesized [AGN(201904-Z)]. A randomized, open-label, parallel-
group, investigator-blinded intra-gastric pH study was done in 24 healthy H. pylori negative
male volunteers. AGN enteric-coated capsules (600mg delivering ~ 50mg molar equivalent
of OMP) or esomeprazole (ESO) delayed-release tablets (40mg) were given once daily for
5 days. Ambulatory 24-h intra-gastric pH was recorded at days 0, 1, 3 and 5 of treatment
and the PK profile obtained. Subjects were maintained on a standard diet. Results: On day
1, nocturnal time pH ≥4 (50.3% vs 27.3%) and median pH (3.91±0.94 vs 2.53±1.08) were
significantly higher with AGN than ESO (P <0.004). At presumed steady state (day 5), both
24-h and nocturnal mean pH values and time pH ≥4 were significantly higher for AGN
than ESO and AGN provided 1.5 times 24-hr and 2.2 times nocturnal time pH ≥4. OMP
was the dominant species in blood after AGN dosing. Systemic AGN exposure was low after
A-486AGA Abstracts
single and repeated oral dosing. At day 5, average half-life of OMP and ESO was 3.78 and
1.99 hrs and average AUC was 5710 and 2730 ng.hr/mL for each, respectively. No safety
issues were observed with either drug. Conclusion: AGN produced significantly faster,
greater and more prolonged acid suppression and more consistent, higher blood levels of
active drug than ESO. Nocturnal acid suppression was also greater by over 2 pH units after
5 days and median nocturnal pH never dropped <5.0 with AGN.
T1191
R-Baclofen Prodrug Xp19986 Decreases Reflux Episodes and Is Well Tolerated
in GERD Patients
Donald O. Castell, Lauren B. Gerson, William K. Hirota, Sandra F. Reilley, Amine Hila,
Amit Agrawal, Ritu Lal, F. jacob Huff
Purpose: XP19986 is an investigational prodrug of R-baclofen, a GABA-b agonist. The study
objectives were to assess the efficacy of a controlled-release formulation of XP19986 for
decreasing the total number of acid and non-acid reflux episodes in patients with GERD,
the dose/exposure to response relationship, pharmacokinetic characteristics, and safety/
tolerability profile. Methods: This was a multi-center, randomized, double-blind, placebo-
controlled, crossover study. Separate cohorts of patients were enrolled at each of four
escalating single dose levels: 10, 20, 40, and 60 mg of XP19986. Enrolled patients (n =
50), who had a history of GERD symptoms at least 3 times per week and 20 reflux episodes
on impedance-pH monitoring over 2 hrs following a high-fat meal, received single doses of
XP19986 or placebo in test periods separated by 4 to 7 days. On test days, high-fat meals
were consumed at 2 and 6 hours after dosing, reflux episodes were recorded using impedance-
pH monitoring, and blood samples for XP19986 and R-baclofen levels were collected through
12-hours post-dose. Other measures included GERD symptoms, vital signs, ECG, and clinical
labs. Results: A statistically significant reduction in total reflux episodes over the 12-hour
monitoring period after dosing during XP19986 treatment compared to placebo was observed
for the combined dose groups (P = 0.005), with the 40 mg and 60 mg doses being the
most efficacious. Exposure quartiles among evaluable patients in the combined dose groups
were determined based on Cmax and AUC for R-baclofen blood levels. The top three quartiles
by Cmax showed fewer 12-hour total reflux episodes during XP19986 treatment than with
placebo, statistically significant for the highest quartile (P = 0.014). The top three quartiles
by AUC showed fewer 12-hour total reflux episodes during XP19986 treatment than with
placebo, significant for the second highest quartile (P = 0.023). XP19986 was well tolerated
at all dose levels. Adverse events occurred in 31.3% of patients during XP19986 treatment
and in 36.7% of patients during placebo treatment. There were no clinically significant
differences in ECG or clinical lab values between the XP19986 and placebo treatment periods.
Conclusion: The R-baclofen prodrug XP19986 reduces reflux episodes and is well tolerated
in patients with GERD. The efficacy is related both to dose and to R-baclofen exposure as
indicated by blood levels.
T1192
Fast, Convenient and Reliable Measurement of TLESRs and Gastric Emptying
in Conscious Beagle Dogs
Stefan Postius, Sam Jundler, Bernd Kress
BACKGROUND and AIM The current gold standard for the treatment of acid-related reflux
disease are still PPIs. Although potent therapeutic tools, they may particularly fail in patients
with low-grade GERD or NERD due to uncomplete inhibtion of gastric acid secretion. In
these patients, enhanced sensitivity against low- or no-acid reflux may be the reason for
noncardiac chest pain or heartburn. Inhibitors of transient lower esophageal sphincter
relaxations (TLESRs) may be a way out of this dilemma. To identifiy novel drugs, a new
animal model for fast, convenient and reliable assessment of potential TLESR inhibitors was
developed. In addition, the model concomitantly yields informations on gastric emptying.
Working hypothesis was that the induced belches are physiologically similar to human
TLESRs. METHODS The stomach of chronically instrumented, fasted gastric fistula dogs
was pressurized with 10-12 mmHg of a gas mixture containing 1% H2 in air by use of a
particularly designed dual-cylinder barostat (G&J Electronics) across the metallic fistula.
The number of induced belches was detected by measurement of H2 in the refluxated gas
being continuously evacuated in front of the mouth of the dog across a muzzle. Detection
of H2 was usually done for 10 min by means of a Sensistor H2000. Loss of pressurized gas
across the pylorus was quantified by addition of 5% SF6 and detected rearward the anus
of the dog by continuous gas evacuation and selective infrared detection. Characterisation
of the technique was done by i.v. testing of the GABA B agonists baclofen, AZD3355 and
SKF97541 and the mGluR5 receptor antagonist MPEP. RESULTS The median rate +- SD
of induced belches in 50 fasted controls was 8,3 +- 3,8 within 10 min. Within this period,
accomodation occurs and the rate of belching is greatly reduced. The number of belches
was inhibited by all 3 GABA B agonists and the mGluR5 RA MPEP, with ID50s in the rank
order of SKF97541 < AZD3355 < baclofen < MPEP, the ID50s amounting to < 0.07, 0.1,
4.5, > 9 µmol/kg. Duration of action of 7µmol/kg baclofen was less than 2 hours. Measurement
of rectal SF6 indicated enhanced discharge of gastric gas across the pylorus upon 7µmol/
kg baclofen. CONCLUSIONS The novel conscious dog model permits a fast and reliable
assessment of TLESR-inhibiting compounds with concomitant detection of effects on gastric
emptying. Whether the model yields human predictive results has to be awaited, but com-
pound ranking and characterisation seems to be conveniently and reliably feasible.
T1193
Effect of the GABA Analogue Pregabalin On 24-Hour Oesophageal Phmetry in
Healthy Subjects and in Patients with Gastro-Oesophageal Reflux Disease: A
Double-Blind Randomized Study Versus Placebo
Laurino Grossi, Mariangela Spezzaferro, Flora Sacco, Federica Sozzio, Valentina Torella,
Leonardo Marzio
Background: GABA, gamma-aminobutyric acid, is an inhibitory neurotransmitter involved
in the regulation of transient lower esophageal sphincter (LES) relaxations (TLESRs), the
main mechanism of GERD. Pregabalin is a novel structural analogue of GABA that inhibits
at a presynaptic level the release of various neurotransmitters; among them glutamate, which
also seems involved in the genesis of TLESRs. The main therapeutic indications of pregabalin
are at the moment neuropatic pain, anxiety and epilepsy. No data have been presented yet
about possible effects on the LES activity and consequently on the acidic esophageal exposure.
Aim of the study has been therefore to evaluate whether the administration of pregabalin
could improve the 24-hour esophageal acid pattern in patients undergoing pH-metry. Patients
and methods: 12 patients (7M, 5F, age 22-60) with typical symptoms of GERD underwent
a 48-hour oesophageal pHmetry, providing a wash-out from PPI of at least two weeks.
Patients received either 1 tablet pregabalin 75 mg or placebo before the two meals during
the first or second 24-hour period according to a double-blind randomized schedule. During
the 48 hours patients ate equicaloric meals. The number of reflux episodes and the time
percentage of pH<4 was then analysed, calculating the differences between the two 24-hour
periods. Results: 8 patients showed a pH pattern indicative of GERD (No.of refluxes/24hr:
96±5; %time pH<4: 8.3±2.5). After pregabalin these data were significantly reduced (No.of
refluxes/24hr: 67±6, p=0.011; % time pH<4: 5.3±1.2, p=0.013), with no differences after
placebo (No.of refluxes/24hr: 89±10; % time pH<4: 7.9±2.8). A similar statistical reduction
in the number of refluxes (p=0.018) and in the percentage of time with pH<4 (p=0.019)
was detected after pregabalin but not after placebo in the 4 subjects with normal pHmetric
profile. The drug resulted generally well tolerated. Summary and conclusions: the administra-
tion of pregabalin is followed during the 24 hours by a significant reduction of oesophageal
acid exposure in patients with GERD as well as in subjects with normal oesophageal acid
exposure. Whether this effect could have therapeutic implications needs to be better clarified.
T1194
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Evaluation of
Single and Multiple 60 Mg, 90 Mg, and 120 Mg Oral Doses of Modified
Release Tak-390 (Tak-390mr) and 30 Mg Oral Doses of Lansoprazole (Lan) in
Healthy Subjects
Weijiang Zhang, Jing-tao Wu, Stuart Atkinson
BACKGROUND: TAK-390MR is a modified-release formulation of the PPI, TAK-390, which
is an enantiomer of the marketed compound, LAN. This MR formulation is designed to
provide extended TAK-390 exposure and intragastric pH control. METHODS: Open-label,
multiple-dose, single-center, 4-period crossover phase 1 study to evaluate the PK, PD, and
safety profiles of 3 oral dosing regimens of TAK-390MR (60 mg, 90 mg or 120 mg) and
LAN (30 mg), each administered daily for 5 consecutive days in a randomly assigned
sequence. 15 blood samples from pre-dose to 24 hrs post-dosing were drawn on days 1
and 5 of each period to assess the PK profiles of TAK-390MR and LAN using standard non-
compartmental methods. 24-hr continuous intragastric pH monitoring was conducted on
days 1 and 5. Standard safety monitoring was performed. RESULTS: 40 subjects were
enrolled and analyzed. The MR formulation resulted in extended drug exposure compared
to LAN as evident by substantially higher 3-8 hr post-dose plasma concentrations and
delayed tmax. The mean tmax for TAK-390MR regimens ranged from 5.0-5.5 hrs on day
1 and 4.2-4.9 hrs on day 5, compared with the mean tmax for LAN (1.7 hrs and 1.5 hrs
on days 1 and 5, respectively). The exposure of TAK-390 on day 5 was similar to that on
day 1 for all TAK-390MR regimens. Approximate dose proportionality was observed for
both Cmax and AUC following single and multiple daily doses of TAK-390MR. On day 1,
except for 120 mg, mean 24-hr intragastric pH and the percent of time intragastric pH> 4
were comparable for 60 and 90 mg TAK-390MR regimens and LAN. On day 5, all TAK-
390MR regimens had significantly higher 24-hr mean pH than LAN (Table). There were no
serious adverse events (AEs) or premature discontinuations due to an AE. The incidence of
AEs did not appear to correlate with increasing TAK-390MR doses. All doses of TAK-390MR
were well tolerated in this study.. CONCLUSIONS: TAK-390MR provided extended drug
exposure and a prolonged pH profile across all dose levels compared to LAN. TAK-390MR
and LAN displayed comparable safety profiles.
a Least squares means *, **, *** p < 0.05, 0.01, or 0.001, respectively Note: p values are
from the tests of the differences in least square means between a given TAK-390MR regimen
and the LAN regimen
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T1195
Placebo Effect in the Treatment of Gastroesophageal Reflux Disease (GERD);
Considerations for Objective and Subjective Endpoints in Proton Pump
Inhibitors (PPI) Trials
Mohammad Yaghoobi, Richard H. Hunt
Background: Many trials have compared PPI with placebo in the treatment of GERD. The
significance of placebo effect in the treatment of GERD has not been yet determined in a
large meta-analysis. We aimed to examine this effect and compare the subjective and objective
responses to placebo in trials using PPI in GERD patients. Methods: A comprehensive
English literature search was performed using PubMed and Cochrane database from 1983
to September 2006. Strict inclusion/exclusion criteria were applied. Only double-blind
randomized controlled trials (RCTs) comparing placebo with commonly used doses of a
PPI in patients with GERD or NERD with endoscopic and/or symptomatic assessment of
outcome at 4 weeks were included. We only used intention-to-treat data from trials with
Jadad quality score ≥3. Meta-analysis of pooled odds ratio (fixed model) was performed
using Review Manager 4.2.8 separately for two subgroups of RCTs: Those with endoscopic
assessment of healing of erosive esophagitis (Objective group) and those with assessment
of relief of heartburn (Subjective group) as the primary outcome. Results: Eleven RCTs (n=
2963) were included (5 in subjective and 5 in objective groups and one in both) among
1570 potential citations. All were multicentre western studies. Test of heterogeneity was
significant for subjective but not for the objective group. Average response to placebo was
32.7% with subjective assessment vs 14.3% with objective assessment [p<0.0001, OR=2.9
(2.1-3.8)]. Moreover, the response to PPI was 47.0% in the subjective group vs 88.0% in
the objective group [p<0.0001, OR=8.0(6.2-10.2)]. The results of the only study using both
subjective and objective criteria did not significantly differ from those of our meta-analysis.
The odds ratio for the response to PPI therapy vs placebo was 17.3 (2.7-49.8) and 5.3
(1.82-32.1) in the objective and subjective groups respectively. Average efficacy of PPI was
significantly better than placebo in both subjective and objective categories (p<0.0001).
Conclusion: The relative efficacy of PPI to placebo is more than three times that in studies
using objective as compared with studies using subjective criteria. The average attributable
efficacy of PPIs in RCTs using placebo and subjectively assessing outcome is less than 15%,
largely due to a high response to placebo. There is also a significant difference in subjective
compared with objective responses to placebo. This effect should be considered in the design
of studies comparing a PPI with placebo and more robust less subjective measures are
needed especially when measuring therapeutic response based on symptom evaluation.
T1196
Effects of Serotoninergic Therapy On Esophageal Acid Exposure
Mauro Bafutto, S. Borges, Filho Rezende, H. Rosa
Background:Tegaserod(T), a selective serotonin 5-HT4 receptor agonist, has prokinetic and
secretory properties, which may decrease acid reflux in GERD1. Previous studies have
demonstrated that Ondansetron(O), a 5-HT3 antagonist reduced transient lower esophageal
sphincter relaxations in dogs2 and that both, 5-HT3 antagonists and 5-HT4 agonists, increase
gastric empting in rats3. Aim:To evaluate the effects of T and O on esophageal acid exposure
in patients with GERD. Methods:At baseline, 38 patients(18 years or older) with reflux
symptoms underwent 24-hour esophageal pHmetry(proximal electrode placed 20cm above
the lower esophageal sphincter(LES); distal electrode placed 5cm above the LES). Patients
were divided in three groups:Placebo Group(PG):10 patients received placebo bid for 7
days;T Group(TG):14 patients received T 6 mg bid for 7 days;T and O Group(TOG):14
patients received T 6 mg bid and O 4mg tid for 7 days. pHmetry was performed after 7
days of treatment. Statistical analyses were performed using Wilcoxon matched pairs test.
Results:TG presented statistically significant reduction of the duration of acid reflux at upper
esophagus (Baseline vs Treatment, mean+/-SD 29,50+/-28,31 vs 10,43+/-13,17), p=0.02.
Non-significant trends for reduced duration of acid reflux at lower esophagus and for reduced
number of acid reflux at upper and lower esophagus after Teg were also observed. TOG
presented statistically significant reduction of the number of acid reflux episodes at upper
(Baseline vs Treatment, mean+SD 10,07+/-8,76 vs 2,79+/-2,86)p=0.01 and lower esophagus
(Baseline vs Treatment, mean+SD 82,00+/-75,96 vs 24,07+/-15,08)p=0.007, and of the
duration of acid reflux at upper (Baseline vs Treatment, mean+SD: 12,21+/-9,56 vs 2,00+/-
2,45)p=0.008 and lower esophagus (Baseline vs Treatment, mean+/-SD: 147,21+/-155,76
vs 37,50+/-35,22)p=0.001. DeMeester Score was significantly reduced after treatment in
comparison with baseline in TOG group (Baseline vs Treatment, mean+SD 40,74+/-38,78
vs 12,05+/-10,12) p=0.002. Non significant results at upper and lower esophagus were
found in PG. Conclusion:T significantly reduced the duration of acid refluxes at upper
esophagus. The combined use of T and O significantly reduced the number and the duration
of acid refluxes at upper and lower esophagus, and the De Meester Score. These preliminary
findings suggest that serotoninergic therapy may be of clinical benefit in GERD patients and
warrants further investigation in larger patient groups. 1.Kahrilas. Aliment Pharmacol Ther
2000;14:1503-9 2.Rouzade. Gastroenterol Clin Biol. 1996;20(6-7):575-80 3.Yamano. Arzne-
imittelforschung. 1997 Nov;47(11):1242-6.
T1197
Effects of Tegaserod in GERD Patients with Extra-Esophageal Symptoms
Mauro Bafutto, Filho Rezende, H. Rosa
Background:Studies have shown that Tegaserod, a selective 5-HT4 agonist, enhances produc-
tion of salivary buffers, reduces post-prandial gastroesophageal reflux and improves gastric
emptying.1,2,3 The effect of Tegaserod on upper esophageal and pharyngeal acid reflux is
unknown.The aim of this study was to evaluate symptoms and esophageal and pharyngeal
acid exposure to reflux in patients treated with tegaserod. Patients and Methods:At baseline
(pre-Treatment), 30 symptomatics patients with signs suggestive of reflux disease at laryngos-
copy (4 male, 26 female, aged 18 years or older) were included. Patients answered a score
of symptoms protocol (max score = 24, min score = 1) and underwent 24-hour pHmetry
(Pharyngeal electrode placed 25cm above the lower esophageal sphincter(LES), proximal
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
esophageal electrode placed 20cm above the LES, distal esophageal electrode placed 5cm
above the LES).Patients were divided in two groups:Placebo Group(PG):(10 patients)
Received placebo bid for 14 days.Tegaserod Group (TG): (20 patients) Received tegaserod
(T) 6 mg b.i.d. for 14 days. In both groups pHmetry was repeated and patients answered
the score of symptoms protocol. in the 14th Day.Medications that may interfere with acid
secretion and/or gastric motility were not permitted.Statistical analyses were performed using
Wilcoxon Matched Pairs Test. Results:TG presented statisticaly reduction of episodes of acid
reflux at pharynx and upper esophagus (Before vs after -T, mean+/-SD 5,65+/-5,71 vs 0,85+/-
1,60) p=0,0004 (Before vs after - T, mean+/-SD 14,05+/-13,32 vs 7,20+/-5,80) p =0,002.
TG also presented statisticaly redution of duration (min) of acid refux at pharynx and upper
esophagus(Before vs after - T, mean+/-SD 7,15+/-10,75 vs 0,60+/-1,64) p=0,0004(Before vs
after - T, mean+/-SD 20,10+/-19,08 vs 8,00+/-8,39) p=0,016. TG presented statisticaly
reduction of duration(min) of acid reflux at lower esophagus(Before vs after - T, mean+/-
SD 123,30+/-125,93 vs 61,60+/-58,22) p=0,036.Non-significant trends for reduced number
of reflux episodes and DeMeester Score after-T were also observed at Lower esophagus. TG
presented statisticaly reduction of symptoms score(Before vs after - T, mean+/-SD 11,1+/-
5,62 vs 5,5+/-5,47)p=0,0001.Non significant results of symptom score and 24h pHmetry
at pharinx upper and lower esophagus were found in PG. Conclusion:Tegaserod terapy
reduced esophageal and pharyngeal exposure to acid reflux and improved extra-esophageal
symptoms of GERD. 1 Degen. Aliment Pharmacol Ther 2001;15:1745-51 2 Jaworski. Dig
Dis Sci. 2005;50:357-65 3 Kahrilas. Aliment Pharmacol Ther 2000;14:1503-9
T1198
PPI Enhancement with Co-Administration of Oral Parietal Cell Stimulator: A
Model for Enhanced Suppression of Gastric Acid Secretion During the Day
and At Night
Eitan Bardan, Moshe Nadler, Michael Naveh, Simon Bar-meir, Sabina Glozman, Yehuda
Chowers
Background: Proton pump inhibitors (PPIs) are the most effective drugs for inhibition of
gastric acid secretion. However, a major limitation in their efficacy is the necessity for pre-
activation of proton pumps. Several agents are capable of activating proton pumps through
induction of gastric acid secretion, one of which is parenteral Pentagastrin(PG). Previously,
we demonstrated in rats, that PG is active following oral administration. Aims: To test
whether oral administration of PG enhances the effect of Omeprazole(Omp) in human
subjects. Methods: Healthy volunteers were randomly assigned to receive 40mg Omp together
with 4mg(n=7), or 12mg(n=12) of buffered PG, or buffer only (n=12) and underwent 24hour
intragastric pH monitoring. Volunteers that received 12mg PG and buffer only were treated
and analyzed in a paired fashion with a washout of 14 days between treatments. Safety
measurements and Omp PK data were recorded. Results: The combination of 12mg PG and
Omp was superior to buffer and Omp (%-time pH>4, 12mg=40.1±2 Vs. buffer=31.6±2.1
respectively p=0.019). Superiority was also demonstrated during nighttime (%-time pH>4,
12mg=34.3+2.6, buffer=24.9+2.6, p=0.041). No adverse events were reported throughout
the trial. Conclusion: Oral PG-PPI was significantly superior over PPI alone in suppressing
intragastric acidity during the whole day and at nighttime. The combination was safe with
no reported adverse events. Our data supports a model wherein pharmacological stimulation
of acid secretion coupled with timely PPI administration significantly enhances the efficacy
of PPIs for suppressing gastric acid secretion. Currently, VB101, a small chemical entity, is
being tested in a clinical trial as an alternative to Pentagastrin.
T1199
Efficacy of Three Different Dosages of Esomeprazole in the Long-Term
Management of Reflux Disease. A Prospective, Randomized Study, Using the
Wireless BRAVO pH System
Kostas Vasiliadis, Nikos Viazis, John Vlachogiannakos, Gerasimos Stefanidis, Paraskevi
Gouma, Athanasios Archimandritis, Dimitrios G. Karamanolis
Background: Gastroesophageal reflux disease (GERD) is a chronic condition that usually
requires long-term maintenance therapy with proton-pump inhibitors (PPIs). In clinical
practice patients receive PPIs at the lowest dose to control symptoms. However, it is not
known whether this approach adequately controls reflux of acid into the esophagus. Aims:
We performed a prospective, randomized trial in order to investigate the efficacy of three
different dosages of esomeprazole in patients receiving maintenance therapy for GERD, using
the new Bravo™ pH system. Methods: Forty five patients with a previous history of mild
erosive esophagitis (LA classification A or B) that was healed at the time of enrollment or
non erosive reflux disease (NERD) documented with abnormal pH study, were randomized
to receive esomeprazole 40 mg twice daily (group A, n=15), once daily (group B, n=15),
and every other day (group C, n=15; these patients were instructed to take their medication
the first day of the study). Intraesophageal pH was monitored for two consecutive days
using the Bravo catheter free system 30 days after randomization. The parameters subjected
to analysis were percent of total time pH<4 and De Meester score. Reflux symptoms were
recorded and Symptom Index (SI) was calculated for all patients. Statistical analysis was
performed using one-way analysis of variance and the Bonferonni's Multiple Comparison
Test. Results: The first day of the study the mean percent of total time pH<4 and the De
Meester score were group A: 1,15±1,39 and 4,85±4,88; group B: 2,14±2,94 and 10,27±14,36;
group C: 2,58±2,79 and 9,34±8,82 respectively. These differences were not statistically
significant (p= 0.281 and p=0.303). The second day of the study the corresponding values
were group A: 0,83±1,10 and 5,16±7,09; group B: 1,94±2,10 and 7,90±7,87; group C:
6,33±3,88 and 26,47±17,93. These differences were statistically significant (p<0.0001 and
p<0.0001). Further analysis showed that patients not receiving PPI had a significantly higher
mean percent of total time pH<4 and De Meester score as compared to patients on PPI once
or twice daily (p<0.001 and p<0.001 respectively). One, 2 and 5 patients in groups A, B
and C reported reflux symptoms during the study period, however none of them had a
positive SI. Conclusions: The administration of esomeprazole 40 mg every other day does
not control acidic reflux the day off PPI. Since esomeprazole 40 mg twice daily does not
add any further benefit as compared to esomeprazole 40 mg once a day it seems that this
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could become the preferred long-term management of patients with NERD or previous
history of mild esophagitis.
T1200
Acid-Suppressive Effects and Pharmacokinetics After 7 Days Repeated Once-
Daily Dosing of Esomeprazole in Preterm Infants and Neonates with
Pathological Acid Gastroesophageal Reflux
Geoff Davidson, Taher Omari, Ross Haslam, Patrik Bondarov, Mia Fjellman, Marie
Sandström, Per Lundborg
Introduction: To date, limited data exist on the use of proton pump inhibitors in preterm
infants and neonates with gastroesophageal reflux disease. This study assessed the acid-
suppressive effects and pharmacokinetics of a 7-day course of esomeprazole in preterm
infants and neonates with pathological acid gastroesophageal reflux. Methods: In this single-
center, open-label study (SH-NEC-0002), preterm infants and neonates (<1 month post-
term, corrected age) with signs and symptoms suggestive of GERD (apnea, vomiting, irritabil-
ity/crying, gagging/choking episodes) and ≥5% time with esophageal pH <4 at baseline,
received oral esomeprazole 0.5mg/kg once daily for 7 days. 24-h esophageal and intragastric
pH and also intraluminal impedance (reported elsewhere) were measured at baseline and
on day 7/8, using a 2mm diameter impedance probe incorporating 2 pH sensors. Blood
samples (0.6mL) were collected at four different time points up to 8 h after dosing on day
7. Population pharmacokinetic analysis was applied using the software NONMEM v.5. An
analysis of variance and the Wilcoxon test were used for statistical inference. Results: Twenty-
six patients were included and 25 completed the study. Mean age was 7.8 (range 1.0-15.9)
weeks, with a gestational age of 32.1 (range 23.0-41.0) weeks. Mean weight was 3.0 (range
1.9-4.1) kg. The estimated mean percentage of time with intragastric pH >4 was 45.1% at
the 24-h baseline recording and was significantly higher (84.7%, p<0.0001) on day 7/8.
The estimated mean percentage of time with esophageal pH <4 at baseline was 15.7% and
decreased to a mean value of 7.1% on day 7/8 (p<0.0001). The median number of acid
reflux episodes, measured by pH only, decreased from 230 at baseline to 128 on day 7/8
(p<0.05), and the median number of acid reflux episodes longer than 5 min decreased from
9 to 2 (p<0.0001). The estimated oral clearance for esomeprazole was 1.89 L/h (0.6 L/h/
kg) with an inter-individual variability of 98% (CV). The geometric mean of the predicted
area under the plasma concentration-time curve (AUCtao) and maximum concentration at
steady state was 2.5 (range 0.2-6.6) µmol*h/L and 0.74 (range 0.1-1.5) µmol/L, respectively.
The percentage of time with intragastric pH >4 seemed to be positively related to AUCtao
of esomeprazole. No new safety concerns arose during the study. Conclusions: In preterm
infants and neonates aged 0-1 months with pathological acid gastroesophageal reflux, oral
treatment with esomeprazole 0.5mg/kg was well tolerated and provided significant acid sup-
pression.
T1201
S-Tenatoprazole-Na 30 Mg, 60 Mg and 90 Mg Versus Esomeprazole (Eso) 40
Mg in Healthy Male Volunteers (Hmvs)
Richard H. Hunt, David Armstrong, Mohammad Yaghoobi, Cindy James, Ying Chen
Background: A number of patients with acid-related disorders fail to respond adequately
to once or even twice daily PPIs due to their short plasma residence time. We have previously
shown that tenatoprazole, a new PPI with prolonged plasma half-life given 40 mg/day
provides superior acid-suppression to ESO 40 mg in HMVs. This study aimed at evaluating
the antisecretory effect of the Na salt of the S enantiomer of tenatoprazole (STE) at different
doses. Methods: A single-center, double blind, double dummy, randomized, 4-way cross-
over intragastric pH study was conducted in 32 H. pylori negative HMVs. STE 30, 60 or
90 mg, or ESO 40 mg combined with appropriate placebo were administered once daily
for 5 consecutive days with a 10-day wash out period between dosing periods. Ambulatory
24-h intragastric pH was recorded at baseline and on day 5 (presumed steady state) of each
treatment period. HMVs, on standardized diet could not smoke or drink. Results: See table.
One HMV withdrew after randomization. 3/155 pH recordings were invalid. On day 5,
median pH and % time with pH >4 for both 24-h (not significant for STE 30 mg) and
nocturnal (19h00-7h00) periods were higher with all doses of STE than ESO. There was
no difference in median pH and % of time pH >4 between STE 90 mg and STE 60 mg for
any period. Median durations of nocturnal pH <4 with all three doses of STE were significantly
shorter than those with ESO. The proportion of subjects with nocturnal acid breakthrough
(NAB) was significantly lower with STE than with ESO but did not differ significantly
between different doses of STE. The proportion of HMVs with >16 hrs of pH >4 was
significantly higher with STE 60 and 90 mg than with STE 30 mg or ESO. Conclusion: S-
tenatoprazole-Na produced significantly greater and more prolonged dose-dependent acid
suppression than esomeprazole and nocturnal acid suppression was also more prolonged
after 5-day use. The antisecretory effect of STE 90 mg did not differ significantly from that
of STE 60 mg. STE may provide a greater clinical efficacy compared to current PPIs for
patients in whom once daily therapy is ineffective.
Indices of acid suppression by different doses of STE vs ESO 40 mg (n=31)
¶ Each dose of STE vs ESO * Non-significant for STE 30 mg vs ESO
T1202
Does Suppression of 24-Hour Intragastric pH Predict Healing of Erosive
Esophagitis with Antisecretory Treatment; A Meta-Analysis
Yuhong Yuan, Marroon Thabane, Richard H. Hunt
Background:Gastric acid is central to the pathogenesis of erosive esophagitis (EE). It is
generally accepted that suppression of gastric acid secretion significantly correlates with the
healing of EE. Introduction of potent acid inhibition with Proton Pump Inhibitors(PPIs),
led to improved treatment of EE but there has been no recent meta-analysis of the correlation
between EE healing and gastric acid suppression. We aimed to explore the correlation and
any predictive relationship between EE healing and parameters of acid suppression through
meta-analysis. Methods:English-language searches for published studies to April 2006 in
adults were performed in MEDLINE, EMBASE and CENTRAL. Intragastric pH data obtained
by pH metry for 24hr was extracted from pharmacodynamic studies of PPIs or H2RA at
steady state (day 5-8) in healthy volunteers. For each dose regimen for which there was pH
data, the corresponding healing rate at 8 weeks for EE was derived from RCTs. Mean for
each pH parameter (16 different sets) and the corresponding EE healing rates were calculated
for each dose regimen; standard linear regression techniques were used with the healing
rate (ITT) at 8 weeks as the dependent variable, and pH as the independent variable. If the
pooled sample size was <50 for EE healing or <20 for pH values, the regimen was excluded
from final analysis. Regression coefficients and 95% CI were calculated by SPSS 11.0.
Results:78 studies (408 arms) provided intragastric pH parameters and 87 studies (189
arms) provided EE healing data for 3 H2RAs, 5 PPIs and placebo. Only 22 dose regimens
provided data for at least one pH parameter and EE healing rate; 17 regimens with adequate
sample sizes (vide supra) were analyzed. 9 pH parameters significantly correlated with 8
week healing rate, including 24hr mean or median pH, mean or median % of time pH >4
in 24hr, median daytime pH, mean or median % of time pH >4 in daytime, mean and
median % of time pH >4 during night-time (P<0.05). 24hr median pH (n=14) and mean
% of time pH >4 in 24 hr (n=15) were the most widely expressed pH parameters and
strongly correlated with EE healing rate at 8 weeks (r=0.862, constant=19.8, β=15.1, 95%CI
9.5-20.7, p=0.00 and r=0.904, constant=20.2, β=1.1, 0.8-1.5, p=0.00, respectively). Sensitiv-
ity analyses gave similar results. Conclusions:24hr median pH and % of time pH >4 in
24hr are good predictors for EE healing at 8 weeks. Our meta-analysis indirectly supports
the hypothesis that, the better acid suppression, the better the efficacy in healing esophagitis
(PPI&;H2RA>placebo). Moreover, the data provides a model for predicting response based
on analysis of parameters of acid inhibition.
T1203
Inhibitory Actions of GABAB Agonists On the Gastric Distension-Induced
Cardiovascular Reflex in Ketamine/Xylazine-Anesthetized Rats
Atsushi Nishiyori, Yasunori Nagakura, Katsuomi Ichikawa
Introduction: GABAB agonists suppress the occurrence of transient LES relaxation (TLESR)
in humans, dogs and ferrets presumably by inhibiting the vagovagal neuronal circuit originat-
ing from the stomach. Therefore, a surrogate small animal model for vagovagal reflex will
be useful for profiling TLESR modulators such as GABAB agonists, and provide utility and
more efficiency for screening of them. Aim: To establish a GABAB agonist-sensitive rat model
in which cardiovascular reflex responses are induced via the vagovagal circuit upon gastric
distension. Methods: Male fasted Sprague-Dawley rats (280-350 g) were used. After the rats
were anesthetized with ketamine/xylazine, the blood pressure and heart rate were monitored
through the left femoral artery of the rats. Gastric distension was given by injecting and
maintaining a given volume of air into a balloon indwelled in the stomach for 20 sec at 15
min intervals. After constant responses were obtained, the effects of bilateral vagotomy and
intravenously administered drugs were evaluated at 10 min after the treatments, respectively
(n=3). Data were represented as % of inhibition of the reflex responses before vagotomy or
drug treatments. Results: Under ketamine/xylazine anesthesia, gastric distension induced
transient hypotension and bradycardia responses. The hypotension and bradycardia were
diminished after bilateral vagotomy [Hypotension; 53 % inhibition, Bradycardia; 98 %
inhibition]. In this system, baclofen, a GABAB agonist, inhibited the cardiovascular reflex
responses in a dose-dependent manner [Hypotension; 34 % (1 mg/kg), 67 % (3 mg/kg),
Bradycardia; 70 % (1 mg/kg), 90 % (3 mg/kg)]. The inhibitory actions of 3 mg/kg baclofen
were significantly reversed by pretreatment with a GABAB antagonist, CGP35348 (45 mg/
kg) [Hypotension; vehicle+baclofen 83 % vs. CGP35348+baclofen 41 %, p<0.05 unpaired
t-test, Bradycardia; vehicle+baclofen 90 % vs. CGP35348+baclofen 53 %, p<0.05 unpaired
t-test]. In addition, another GABAB agonist, SKF97541, significantly inhibited the reflex
responses in a dose-dependent manner [Hypotension; 31 % (0.03 mg/kg), 35 % (0.1 mg/
kg), 81 % (0.3 mg/kg), Bradycardia; 40 % (0.03 mg/kg), 50 % (0.1 mg/kg), 83 % (0.3 mg/
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kg)]. Conclusions: Two different GABAB agonists abolished the bradycardia response in
which the vagovagal reflex participates upon gastric distension in ketamine/xylazine-anesthet-
ized rats. Thus, this simple rat model could be useful in characterizing and screening
modulators of the vagovagal circuit leading to TLESR, including GABAB agonists.
T1204
Helicobacter pylori Eradication Improves Symptoms, Acid Reflux and
Esophageal Motility in Patients with Gastroesophageal Reflux Disease and
Antral Gastritis
Theofanis Maris, Dimitrios Kapetanos, Anastasios Ilias, Antonios Augerinos, Panagiotis
Xiarhos, Asterios Gagalis, George Kokozidis, George E. Kitis
INTRODUCTION: The relationship between Ηelicobacter pylori (Hp) gastritis, the most
common infection worldwide and Gastroesophageal Reflux Disease (GERD), witch is common
in Western countries, remains controversial. AIM: To investigate the association between
Hp and GERD and the impact of Hp eradication on symptomatology, esophageal acid
exposure and esophageal motility in Hp positive patients with GERD. METHODS: Twenty-
seven Hp positive (group I) and 20 Hp-negative (group II) patients with GERD underwent
clinical examination, endoscopy-biopsy, esophageal manometry and 24-hour pH-metry. All
group I patients received standard eradication treatment and six months later they were re-
evaluated with clinical examination, pH-metry, manometry and endoscopy-biopsy.
RESULTS. All Hp-positive patients had antrum predominant gastritis and 17 esophagitis
grade I-II. There were no significant differences between the two groups regarding sex, age,
clinical pattern, grade of esophagitis, manometric and pH-metry findings. In all group I
patients eradication of Hp was successful. The symptoms improved significantly: (heart-
burn:p<0.001, regurgitation p< 0.001 ).Gastritis and esophagitis were healed in all patients.
The mean Lower Oesophageal Sphincter Pressure (LOSP) showed a significant improvement
being 11.7 mmHg before and 12.48 mmHg after eradication (p<0.01). Ineffective motility
of the esophageal corpus activity returned to normal in all seven affected patients. Finally
a significant decrease in DeMeester score was observed (mean score 62.92 before versus
41.88 after eradication (p<0.04). CONCLUSIONS: 1. In patients with GERD the presence
of Hp has no impact on clinical, manometric and Ph-metry findings. 2. The eradication of
Hp infection results in improvement in reflux symptoms and increase in LOSP with a
consequent decrease in esophageal acid exposure. The beneficial results of Hp eradication
in this study are most likely due to the type of gastritis (antrum predominant).
T1205
Distinct Secretory Profiles in Terms of Salivary Protective Factors in Response
to Tegaserod-Induced Stimulation of Serotonergic Pathway in Males and
Females with Gastroesophageal Reflux Disease
Marek Majewski, Tomasz Jaworski, Irene Sarosiek, Katherine Roeser, Sandra Sostarich,
Stanley Edlavitch, Richard Mc callum, Grzegorz Wallner, Jerzy Sarosiek
The protective characteristics of saliva in both genders of patients with gastroesophageal
reflux disease (GERD) are well established (Sarosiek et al. J Pract Gastroenterol, 18:20J-
20Q, 1994). Administration of tegaserod augments the rate of alimentary tract secretion
(Stoner et al. Gastroenterology 116:A648, 1999). The impact of gender on protective compon-
ents of salivary secretion in GERD patients during tegaserod administration remains to be
explored. Aim: To measure the rate of secretion of salivary protective factors in females (F)
and males (M) with chronic heartburn symptoms after 7 days of tegaserod (6 mg BID) or
placebo administration. Methods: The study was conducted in 38 GERD patients (26F &
12M; mean age of 41) in a double-blind, placebo-controlled, cross-over design. Saliva was
collected basally, during mastication as well as during the esophageal mucosal mechanical
(bolus) and chemical (HCl/pepsin) stimulation, to mimic the natural gastroesophageal reflux
scenario. Salivary volume and its content of bicarbonate and non-bicarbonate buffers, protein,
mucin, EGF, TGFα, and PGE2 were measured using standard methodologies. Data were
analyzed using SPSS statistical software. Results: Salivary flow rates (ml/min) during adminis-
tration of tegaserod increased significantly over corresponding values recorded during placebo
both in F (0.86 ±0.10 vs 0.70 ±0.10) & M (1.36 ±0.12 vs 1.13 ±0.14) during basal conditions
(P<0.05) and after stimulation with mastication (2.08 ±0.17 vs 1.82 ±0.18 and 3.03 ±0.29
vs 2.62 ±0.26, respectively; P<0.05). Salivary non-bicarbonate secretion (µEq/min) increased
significantly after tegaserod in F in basal conditions (5.67 ±0.90 vs 3.90 ±0.46; P<0.05)
and during intraesophageal mechanical stimulation (5.67 ±0.90 vs 3.90 ±0.46; P<0.05)
while increasing significantly in M during mastication (19.46 ±2.13 vs 15.59 ±1.39; P<0.05).
Salivary EGF secretion (pg/min; median, 25%-75% range) increased significantly after tega-
serod in F (182.9, 91-293 vs 107.9, 76-153; P<0.05) during mastication, whereas the other
growth peptide, TGFα (pg/min), increased significantly in M (15.21 ±2.65 vs 10.29 ±1.19;
P<0.05) in basal conditions. Conclusions: A significant enhancement of salivary protective
factors after tegaserod administration occurs in both genders indicating that secretion of
saliva in GERD patients is mediated by serotonergic pathway. The gender-related differences
observed in the serotonergic secretory profiles in response to tegaserod suggest that 5HT-
4 receptors in salivary glands are also influenced by sex hormones.
T1206
Does Non-Acid Reflux Causes Heartburn in Patients Refractory to the Proton
Pump Inhibition (PPI) Therapy?
Hariprasad R. Korsapati, Jeff Buehler, Debbie Den boer, Ravinder K. Mittal
Background: The mechanism of heartburn in patients who continue to have symptoms
despite adequate PPI therapy is not known. One of the possible causes of heartburn in
these patients is non-acid reflux. The use of multichannel intra-luminal impedance & pH
monitoring allows detection of acid and non acid gastro-esophageal reflux.Aim: To character-
ize the frequency of acid and non-acid reflux and their relationship to symptoms in patients
with chronic heartburn symptoms refractory to the PPI therapy. Methods and materials:
11 patients with persistent heartburn of at least 3 months duration, despite at least once a
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day PPI therapy, were included in the study. Patients were interviewed by a gastroenterologist
and only if found to have typical heartburn (retrosternal burning) were included in the
study. Patients were treated with Esomeprazole 40mg BID during the 4 week study period.
In addition, each subject received placebo or Baclofen, 20 mgs bid, each for 2 weeks during
the 4 weeks in a blinded fashion. Combined MII/pH 24 hour recordings were performed
twice in each subject, 2 weeks apart during the 4 week study period. Tracings were analyzed
for acid and non-acid reflux episodes. Heartburn symptom correlation, with acid and non
acid reflux was determined. Symptom index and symptom association probability were
calculated. Results: In 11 patients, a total of 22 - MII/Ph recordings were obtained and
analyzed. Acid reflux was minimal during the recording periods but significant non-acid
reflux was detected during both study days. Frequency of non acid reflux was significantly
lower during the Baclofen as compared to the placebo day. Sixty Heartburn episodes were
recorded during 11 of the 22 MII/Ph recording days, 8 during the placebo and 3 during
the Baclofen day. Symptom association probability in 21/22 recordings showed no correlation.
There was no difference in the GERD specific questionnaire score (QOLRD) between the
placebo and Baclofen periods. Conclusions: Poor association of heartburn with acid and
non acid reflux suggests that gastro-esophageal reflux is not the cause of heartburn symptom
in patients not responding to the PPI therapy.
T1207
Orally Administered Glycine Is Highly Effective Against Acid Reflux
Esophagitis in Rats
Shun Terashima, Yuuki Matsusaka, Hikaru Nishio, Shinichi Kato, Koji Takeuchi
Background/Aims: Reflux esophagitis is caused mainly by excessive exposure of the gastric
contents due to dysfunction of various protective mechanisms that prevent reflux into the
esophagus and resist against the refluxate. We recently established a simple method to
produce acid-reflux esophagitis in rats by ligating both the pylorus and forestomach, and
demonstrated an importance of pepsin in the pathogenesis of acid reflux esophagitis. In the
present study, we examined the effects of several amino acids on this model of esophagitis
in rats and demonstrated that glycine is highly effective against the acid reflux esophagitis.
Methods: Male SD rats were used after 18 h fasting. Acid reflux esophagitis was induced
by ligating both the pylorus and the transitional region between the forestomach and
glandular portion under ether anesthesia, and the animals were killed 4 h later. Pepstatin
(0.3 mg/kg), L-glycine (250-750 mg/kg), L-arginine (100 and 250 mg/kg), L-alanine (250
and 500 mg/kg), L-glutamine (250 and 750 mg/kg) or porcine pepsin (5 mg/kg) was
administered PO immediately after the ligation, while omeprazole (10 mg/kg) and cimetidine
(100 mg/kg) was given intraduodenally before. Gastric secretion was measured in pylorus-
ligated stomachs. Pepsin activity was determined according to the modified method of
Anson. Results: Both omeprazole, cimetidine and pepstatin prevented the development of
acid reflux esophagitis, while intragastric administration of exogenous pepsin markedly
worsened the severity of lesions. The development of the esophageal lesions was dose-
dependently reduced by L-glycine, the inhibition at 750 mg/kg being 100%. Likewise, L-
arginine also reduced the severity of the esophageal lesions, a complete inhibition being
obtained at 250 mg/kg. By contrast, both L-alanine and L-glutamine aggravated the esophageal
lesions in a dose-dependent manner. Either of these amino acids had no effect on acid
secretion but increased the pH of gastric content to 1.8~2.3, due to the buffering action.
Conclusions: These results confirmed the importance of acid and pepsin in the pathogenesis
of acid reflux esophagitis in a rat model and further suggested that amino acids given orally
affect the severity of the esophagitis in different manner, due to yet unidentified mechanisms;
both L-glycine and L-arginine are highly protective against the esophagitis, while both L-
alanine and L-glutamine.
T1208
Response to Proton Pump Inhibitor (PPI) Therapy in Different Grades of
Erosive Esophagitis
Mohammad Yaghoobi, Marroon Thabane, Richard H. Hunt
Background: A better response to PPI therapy is generally reported in lesser grades of erosive
esophagitis (EE). However, most PPI trials report efficacy without subgroup analysis in
different EE grades regardless of this and the possibility of a selection bias. Therefore, in
this weighted pooled analysis, we aimed at evaluating the response to PPI therapy in each
grade of EE and the importance of subgroup analysis in PPI clinical efficacy trials. Methods:
A recursive, English literature search in PubMed and Cochrane databases from 1983 to
November 2005 was performed. Double blind RCTs with Jadad score >2 comparing a
standard dose of a PPI with other PPIs, H2RAs or placebo using endoscopic assessment of
healing by Hetzel-Dent (HD), Savary-Miller (SM) or Los-Angeles (LA), or their modified
classification at 4 or 8 weeks, were included. Abstracts, studies without raw ITT data for
retrieval or clear definition of classification and duplicate publications were excluded. Data
of healing rate under the same EE grade and the same classification was pooled using a
precision weighted method. Results: Sixteen studies were included from 308 potential citations.
Of these, 10 compared PPI with another PPI and 6 with H2-RAs. 6285 patients at 4 weeks
and 7301 at 8 weeks comprised the study population in 38 PPI arms. The pooled average
healing rate with standard dose of PPI was 72.3% at 4 weeks and 87.0% at 8 weeks. Pooled
analysis at 4 weeks showed average healing rates of 81.5%, 76.4%, 59.4% and 41.5% for
grade 1-4 (A-D), respectively. These were 95.6%, 93.2%, 84.0% and 74.5% at 8 weeks,
respectively. Moreover, subgroup analysis showed that HD classification results in a lower
response rate for all grades than LA or SM at both 4 and 8 weeks (see table). Conclusion:
This study shows a negative relation between healing rate and the grade of erosive esophagitis
after PPI therapy and gives a numerical estimate of the rate. This difference should be
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considered to avoid selection bias in trials of PPIs. The determining role of the esophagitis
classification system in assessing the healing rate is also emphasized.
Subgroup pooled analysis of the healing rate of EE (%) for the same grade and the same
classification system.
T1209
Emerge Study: Results of An Observational, Multicenter, Clinical Study On
GERD Patients Followed Up to Six Months
Fabio Pace, Patrizia Dominici, Renata Cerutti, Giorgio Caspani, Giorgio Minoli, Enrico
Colombo, Gabriele Bianchi porro, Enzo Grossi
Background: Despite many suggested guidelines, the fate of patients treated according to
these rules is seldom reported. Aim: We conducted an observational study on GERD patients
(with and without erosive esophagitis at endoscopy) diagnosed by means of endoscopy and
a positive PPI test to assess: 1) the usefulness of PPI test compared to endoscopy, in patients
with erosive esophagitis (EE), and to a validated questionnaire (QUID), in those with NERD;
2) to assess the clinical usefulness of a therapeutic strategy based on step-down approach
during 6 months. Material and methods: 634 patients (311 women, mean age 43.5 ±12.4
(SD) years) with typical GERD symptoms were recruited by 60 Italian gastroenterology Units
during 2003-2005; patients were given a previously validated questionnaire, a psychometric
tool to assess quality of life (QoL), the PGWB, and were submitted to upper GI endoscopy,
on the basis of which 341 (54%) were classified as having (EE) and the remaining 293
(46%) as NERD. All patients underwent a PPI test, after which those positive were treated
with a PPI at standard dose for 3 months and if symptoms were completely controlled, with
a further 3 months at half dose with the same PPI previously used. At the end, all patients
were submitted to a second evaluation of QoL, a complete symptom assessment by QUID.
Results: 553 patients were recruited. The severity of esophagitis scored by means of Savary-
Miller classification was as follows: grade 1= 75.4%, grade 2 = 18.2%, grade 3 = 3.5% and
grade 4 = 2.9%. All patients underwent the PPI test and 519 (93.8%) had a positive test,
defined as a reduction of heartburn of more than 50% within 2 weeks; The test was positive
in 95.2% of and in 92.2 % of NERD EE patients. Following 3 months of therapy, the overall
percentage of heartburn-free patients was 84.5% (N= 463), whereas at 6 months they were
82.4 % (N= 410), respectively 87.7% (N= 261) and 88.1 % (N= 228) in EE patients and
80.2% (N= 202) and 75.3 (N= 182) in NERD patients. The difference between before and
after therapy among EE and NERD is highly significant (p< 0.01 at ANOVA). Conclusions:
This study is a proof of the validity of current guidelines on GERD management and in
particular 1) of the usefulness of a PPI test in diagnosing the disease, as shown by the fact
that only 15 EE patients had a negative PPI test, and 2) of the step-down approach, as
demonstrated by the very high percentage of patients still symptom-free (> 80%) at 6 months.
Interestingly, NERD patients responded to PPI therapy worse than EE patients, both acutely
and during maintenance.
T1210
Proton Pump Inhibitor Therapy in Patients with Symptomatic Gastro-
Esophageal Reflux Disease Reduces the Cellular Immune Response in the
Distal Esophagus
P. J. De jonge, R. C. Kiekens, E. J. Kuipers, D. J. Bac, I. Leeuwenburgh, R. J. Ouwendijk,
A. J. Van tilburg, J. G. Kusters, P. D. Siersema
Background: Reflux esophagitis (RE) is associated with a predominant cellular immune
response, which is characterized by the presence of macrophages and cytotoxic T cells.
Proton pump inhibitor therapy in patients with gastro-esophageal reflux disease (GERD)
often results in endoscopic remission of RE. Whether this treatment also leads to a decreased
activity of the cellular immune response is unknown. Aim: To study the effect of rabeprazole
treatment 1dd 20 mg on the cellular immune response in esophageal biopsies from patients
with symptomatic GERD. Methods: Symptomatic GERD patients underwent upper endos-
copy with biopsies from the distal esophagus, 1 cm above the Z-line. Patients were randomized
to either rabeprazole treatment for 4 or 8 weeks (1dd 20 mg) and underwent a follow-up
endoscopy with biopsies at the end of treatment. All antisecretory medications were stopped
for at least seven days prior to the baseline endoscopy. H&E staining was performed to
evaluate the grade of inflammation using the Ismail-Beigi classification. Immunohistochemical
studies were performed to quantify the number of cytotoxic T cells (CD8) and macrophages
(CD68) in the most densely populated field using high-power examination (400x). Results:
Twenty-five patients with erosive reflux disease (ERD) (56% male, mean age ± SEM: 49±4
yr) and 11 with non-erosive reflux disease (NERD) (63%, 43±4 yr), of whom 8 had a
positive pH<4 for >4% of time, were included. All biopsy specimens from patients with grade
2 and 3 esophagitis showed intraepithelial eosinophilic and/or neutrophilic granulocytes. The
number of CD8+ T cells correlated only moderately with the endoscopic grade of esophagitis
(r=0.48, p=0.4). At baseline, ERD patients had higher mean numbers of intraepithelial CD8+
T cells and macrophages as compared to NERD patients (19±2 vs. 10±3, p=0.04 and 14±2
vs. 6±2, p=0.013, respectively). Rabeprazole treatment did not affect the numbers of these
cells in NERD patients, whereas ERD patients, treated for a period of 4 weeks, showed a
significant decrease in the number of CD8+ T cells and macrophages (18±3 vs. 9±2, p=
0.01, and 13±3 vs. 6±2, p=0.01, respectively). A similar response in only ERD patients was
seen after 8 weeks (16±1 vs. 7±2, p=0.03 and 31±7 vs. 11±3, p=0.06, respectively). Conclu-
sion: Rabeprazole treatment in patients with symptomatic GERD reduces the cellular immune
response. It may well be that the presumed chemopreventive effect of proton pump inhibitors
is established by a reduction in the number of oxygen radical producing macrophages.
T1211
NO Rebound Acid Hypersecretion After short-Term PPI Treatment in
Helicobacter pylori-Negative Subjects
Nicole Hunfeld, Ernst J. Kuipers, William P. Geus
Background: The occurrence of rebound acid hypersecretion (RAHS) after cessation of
therapy with proton pump inhibitors (PPIs) has been debated during the last decade. This
issue is relevant since many patients use PPIs on-demand or intermittently and some studies
suggest that RAHS may promote therapy-dependence. Aim: To study RAHS with 24-hr
intragastric pH monitoring after discontinuation of short-term PPI treatment in H. pylori-
negative healthy subjects. Methods: 17 Caucasian H. pylori-negative healthy subjects (18-
27 years, 7 male, 10 female) were treated with either esomeprazole 40 mg (n=8) or pantopra-
zole 40 mg (n=9) p.o. for 5 days in a randomized investigator-blinded study. Intragastric
pH was measured the day before therapy (pre PPI), at day 5 of therapy (on PPI) and 16
days after PPI (post PPI). During the study days, pH-monitoring was performed continuously
for 24 hr with a glass electrode positioned in the gastric corpus, 5 cm below the cardia.
Subjects ate standardized meals at 9 AM, 14 PM and 18 PM and intake of fluid was
restricted and repeated at each study day. Differences between median pre- and post-
treatment intragastric pH values and % of time with intragastric pH < 4 over 24-hr time-
periods were calculated with Wilcoxon's signed rank test. Results: Results are displayed in
table 1. No significant differences (all p-values ≥ 0.21) in median intragastric pH and in
% of time with intragastric pH < 4 were observed with either drug between pre PPI and
post PPI treatment. Conclusion: Short-term PPI treatment does not induce RAHS in H.
pylori-negative healthy subjects.
Table 1 Median intragastric pH values and % of time with intragastric pH < 4 (25th-75th
percentile) before, during and 16 days after a 5-day course of esomeprazole 40 mg or
pantoprazole 40 mg
T1212
In Vitro and In Vivo Evaluation of Potassium-Competitive Acid Blockers for
Gastric Acid Suppression
Colin A. Campbell, Rejbinder Kaur, Stacey L. Wood, Jill Darton, Pam J. Gaskin, Kevin
Lee, Julia E. Smith, Peter G. Mclean
Acid suppression therapy for the treatment of acid related diseases (ARD) involves the use
of fast onset, short acting treatments (e.g. cimetidine) or slow onset, long duration mechanisms
(e.g. omeprazole). It is now recognised that neither mechanism produces satisfactory symp-
tom relief for many ARD patients, hence there is need for new therapies that combine
rapidity of onset with long duration of action. Potentially there are several new therapies
that combine rapidity of onset with long duration of action; one of which is potassium-
competitive acid blockade (PCAB). The present study compares the In Vitro and In Vivo
acid suppression profiles of two PCABs (AR-H047108 and AZD-0865). Activity of the PCABs
at H+/K+-ATPase was determined using pig gastric membranes. The activity of PCABs were
also investigated in isolated rat parietal cells to assess inhibition of histamine stimulated
acid secretion in a whole cell assay. In Vivo, AR-H047108 and AZD-0865 were evaluated
for In Vivo efficacy by the ability to inhibit pentagastrin-stimulated gastric acidity levels
using the rat and dog gastric fistula models. AR-H047108 and AZD-0865 were shown to
be competitive inhibitors of the H+/K+-ATPase antagonist (pIC50 = 7.2 and 8.2, burke-
weaver slope=1). In the parietal cells assay, the H+/K+-ATPase was inhibited by AR-H047108
with an IC50 of 22nM and by AZD-0865 with an IC50 of 51nM. In the rat gastric fistula
model, AR-H047108, AZD-0865 attenuated acid secretion within 1h of administration and
displayed various durations of action (Table 1). In dog pH-metry, AZD-0865 (1mg/kg p.o.)
produced suppression of acidity with percentage time (0-19h post-administration) above
pH 4 was 55±18% compared to control treated animals (14±8%, P<0.05). These data show
that AR-H047108 and AZD-0865 are PCABs that inhibit the isolated enzyme H+/K+-ATPase
and that in isolated parietal cells, they inhibit acid secretion In Vivo in the rat and dogs
gastric fistula models.
Table 1. Effect of AR-H047108 and AZD-0865 on gastric acid section in gastric fistula rats.
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T1213
Frequency Scale for Symptoms of Gastroesophageal Reflux Disease(GERD),
GERD-Specific Questionnaire(FSSG), Predicts Optimal Therapeutic Medicine
Selected By Patients
Masaki Miyamoto, Keisuke Takeuchi, Ken Haruma
Background: PPI maintenance therapy(MT) is the mainstay of treatment for GERD, a condition
prone to relapse. In some cases, combination therapy with prokinetics is needed, and in
others step-down therapy to H2RA is possible. Aims: We conducted a prospective study,
in following initial PPI therapy were asked to select the agent to be used for MT themselves.
We investigated whether FSSG could predict the optimal therapy selected by patients
themselves. Subjects and methods: The subjects were 255 GERD patients (age 51.4±16.5
years, M/F 107/148, endoscopic positive GERD/non erosive GERD 88/167). Following initial
3 months treatment with rabeprazole 10 mg, subjects were asked to select one of the
following 4 options at 3 monthly: Tx1: continued PPI, Tx2 : PPI + prokinetics, Tx3 : step-
down to H2RA; or Tx 4 : stoped therapeutic medicine. The treatment option selected by
each subject after 12 months commencement was considered the final optimal therapy. The
FSSG was administered pre, 3 and 6 months. FSSG results were considered in terms of the
total score (TS); reflux score, for 7 questions related to reflux symptoms(RS); and the
dyspeptic score, for 5 questions related to dyspeptic symptoms(DS). Results: 1) At the 3
month, the numbers of subjects selecting Tx 1/2/3/4 were 136/50/26/43. At 3 months,
16.9% of subjects selected Tx 4, ceasing therapeutic medicine, increasing to 32.1% at 6
months, reaching 42.0% at the final selection. 2) Using the system of subjects selecting their
own therapeutic medicine, the TS, RS and DS all decreased significantly with time from
pre-treatment to 3 and 6 months (P<0.001). 3) In subjects making the final selection of Tx
2, pre-treatment TS (16.6±1.2) was significantly higher than in those opting for Tx 1
(13.2±0.9), Tx 3 (12.0±1.2), or Tx 4 (13.0±0.7), (P<0.01). The pre-treatment RS for the
final Tx 2 group (9.5±0.9) was also significantly higher than for the other treatment groups,
whereas the pre-treatment DS for the final Tx 2 group (7.1±0.6) was significantly higher
than that for the Tx 1 group (5.3±0.5), but no significant difference was found for the other
groups. 4) Logistic analysis of the requirement for PPI MT showed that the RS was a
significant factor, with odds ratio for RS≧7 of 2.0 (P=0.0052). RS was also a significant
factor for cessation of therapeutic medicine at the final selection, with odds ratio for RS≦6
of 1.7 (P=0.0314). Conclusions: The FSSG can be used to predict the optimal therapeutic
medicine selected by patients themselves for GERD maintenance therapy. In particular, an
RS≧7 indicates a requirement for PPI MT, and an RS≦6 indicates that stoped therapeutic
medicine can be predicted.
T1214
Duodeno-Gastro-Esophageal Reflux: Is the Disease Better Than the CURE
Ayman O. Nasr, Susie Conlon, Chen Ghan, Adrian Ireland, Eamon Leen, David Bouchier-
hayes, Thomas N. Walsh
Background. Reflux of duodenal juice into the lower esophagus, isolated or combined with
acid, is associated with esophageal mucosal injury. The role of proton pump inhibitors
(PPIs) in modulating this injury remains unclear. Aims. This study aimed to investigate the
role of acid suppression in modulating lower esophageal injury associated with by duodenal
reflux. Materials and Methods. Four groups of male Sprague-Dawley rats aged 8-10 weeks
were studied; Group A (n=33) were unoperated controls, Group B (n=34) had combined
acid and alkaline reflux through an esophago-duodenostomy, Group C (n=34) had duodenal
reflux through esophago-duodenostomy and medical acid suppression using omeprazole,
Group D (n=35) had isolated duodenal reflux through esophago-duodenostomy and total
gastrectomy for surgical acid suppression. Group C received subcutaneous injection of
omeprazole (13.5mg/kg) on alternate days, while the other groups received equivalent volume
of saline injection. All groups were sacrificed at twenty-six weeks and the esophagus resected
for examination. Results. Chronic inflammation occurred in 9% of the control group versus
> 97% of the three reflux groups. Microscopic erosion or ulceration were identified in 0%
of controls, 52.9% and 79.4% in the combined reflux and the gastrectomy group (p=0.174
& 0.044); in 91.4% and 100% (p=0.016 & 0.001) of the gastrectomy group; and 76.5%
and 91.2% medically controlled group. Metaplasia developed in 0% of controls, 26.5% (9/
34) of combined refluxers, in 71.4% (25/35) of the gastrectomy group and 61.8% (21/34)
of the omeprazole group. The incidence of mucinous adenomatous change was 0%, 14.7%
25.7%, 14.7% amongst controls, combined refluxers, gastrectomy and omeprazole groups
respectively. Conclusion. Combined duodenal reflux causes esophageal mucosal injury but
surgical or medical acid suppression therapy may compound this injury. Long term proton
pump inhibition may induce an injury worse than the disease.
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T1215
The Effectiveness of Intensive Psychotherapy and Medical Therapy On
Symptom Intensity, Quality of Life and the Long-Term Outcome of Nerd
Sebastian Haag, Wolfgang Senf, Sefik Tagay, Angelika Pietsch, Ute Braun-lang, Nicholas J.
Talley, Gerald J. Holtmann
Background: Psychosomatic factors are believed to play a role for symptom manifestation
in patients with non-erosive reflux-disease (NERD) and concomitant functional dyspepsia
(FD). We thus aimed to compare in this analysis the long-term outcome of intensive medical
therapy (with or without supportive psychotherapy) versus standard medical therapy in
patients with NERD, referred to a tertiary referral medical center for the treatment of
symptoms that had not responded to conventional treatment. Methods: We identified out
of 100 consecutive patients referred with functional upper gastrointestinal symptoms who
participated in a clinical trial, 49 patients with long-lasting symptoms (all >5 years) of NERD.
All patients had a standardized upper gastrointestinal endoscopy and 24h pH-metry to
exclude structural lesions or acid reflux. All had failed to respond to PPI previously. Patients
were randomized to standard therapy (SMT, symptom-oriented medical therapy with prokin-
etics or antisecretory agents, n=13), intensive medical therapy (IMT, therapy targeted towards
abnormalities based upon function testing and/or treatment with tricyclic antidepressant, n=
19) or IMT in combination with a supportive psychotherapy (IMT-PT, n=17). The symptom
intensity (SI) and health-related quality of life (HRQoL) after 12 months were pre-specified
primary outcome parameters. In addition, a priori defined goal attainment scale ranging
from ‘symptoms worsened' to ‘goal achieved' was also used to assess treatment response.
Results: After 12 months there was numerically better improvement of SI in patients with
IMT-all (with or without psychological intervention) vs. SMT (5.1±1.5 vs. 3.1±2.4, p=0.51).
HRQoL did not improve significantly in IMT-all or SMT. Concomitant anxiety and depression
were not improved by IMT-all or SMT. There was no significant difference for the proportion
of patients reporting ‘complete' improvement of symptoms (5 in SMT [38.5%] and 12 in
IMT-all [34.3%]). Conclusion: Even in patients with long lasting symptoms of NERD,
complete relief of symptoms occurs in one out of three patients during a 12 months period.
Our pilot data do not support the assumption that intensified medical and psychological
treatment further improves the long-term outcome. However, samples sizes of more than
180 patients per group appear to be required to conduct a properly powered study.
T1216
Predicting PPI Responders and Non-Responders Using the Frequency Scale for
Symptoms of GERD (FSSG)
Nobuaki Yagi, Naoya Tomatsuri, Masahiro Arai, Shotarou Fujimoto, Takashi Ando,
Naoyuki Matsumoto, Tuyoshi Ishikawa
Aims: Although gastroesophageal reflux disease (GERD) is usually readily controlled using
PPIs, it is difficult to predict in advance which patients will be responders and non-responders.
The frequency scale for symptoms of GERD (FSSG), developed in Japan, a self-completion
GERD questionnaire comprising a reflux score (RS) with 7 questions related to acid reflux
and a dysmotility score (DS) with 5 questions related to dysmotility, can be used to assess
the efficacy of treatments. In this study, we followed GERD patients for 6 months, investigating
whether the FSSG can be used to predict responders and non-responders. Subjects and
methods: The subjects were 41 GERD patients (age 54.0±12.4 yr, M/F 24/17), who were
administered rabeprazole (RPZ) 10 mg daily for 6 months. The FSSG was administered pre-
treatment, and after 2, 8, 12, 16 and 24 weeks of treatment. A significant reduction in the
total FSSG score (TS) was seen in all subjects after 2 weeks of treatment, so subjects who
did not show further reduction in their FSSG score from 2 to 8 weeks were classed as the
non-responder group (NR-G), and those who did show a further decrease as the responder
group (R-G). Results: 1. The R-G comprised 24 subjects (58.5%), and the NR-G 17 (41.5%).
2. No significant differences were seen between groups in age (55.1±12.4 vs 52.4±13.3 yr),
gender (M/F 13/11 vs 11/6), TS (15.1±1.4 vs 14.4±1.9), RS (9.3±0.9 vs 7.5±1.2), or DS
(5.8±0.8 vs 6.9±0.8). 3. Comparison of rates of improvement in TS, RS and DS from pre-
treatment to after 2 weeks of treatment showed significantly higher rates of improvement
in TS and DS in the NR-G than in the R-G. 4. Logistic regression analysis of the risk of
becoming a non-responder if the TS, RS and DS improvement rates were less than 50%
after 2 weeks of treatment showed that the TS was a significant risk factor, with an odds
ratio of 5.67 (95% CI: 1.37-23.47, p=0.0167), as was the DS, odds ratio 6.67 (95% CI:
1.50-29.6, p=0.0127). The RS was not a significant risk factor. Conclusions: Our results
suggest that when the rate of improvement in the TS and DS is below 50%, a patient may
be a non-responder. This indicates that dyspeptic symptoms are present in GERD patients,
but usually overshadowed by reflux symptoms. The FSSG is useful in monitoring the
progress, and can be used to predict the efficacy, of treatment of GERD.
Improvement rate
T1217
Can Baseline Symptom Severity Predict Treatment Response in Patients with
Erosive and Non-Erosive Reflux Disease?
Ajay Bansal, Srinivas R. Puli, Sandy Hall, April D. Higbee, Sachin B. Wani, Amit Rastogi,
Prateek Sharma
Introduction: Symptom response to acid suppressive therapy is less predictable in patients
with non-erosive reflux disease (NERD) compared to those with erosive esophagitis (EE).
However, it is unclear if baseline symptom severity in NERD and EE patients can predict
response to proton pump inhibitor (PPI) therapy. The Reflux Disease Questionnaire (RDQ)
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is a valid, reliable and practical diagnostic questionnaire for GERD. The aim of the current
study was to correlate baseline symptom severity (baseline RDQ scores) with response to
PPI therapy in NERD and EE patients. Methods: Forty-one patients with reflux symptoms
completed the RDQ questionnaire at baseline (at the time of upper endoscopy) and after 1
month of PPI therapy (esomeprazole 40 mg QD). Compliance to PPI therapy was confirmed
by pill-count. The change in RDQ scores (i.e. a measure of treatment response) was expressed
as change in pre and post PPI RDQ score/standard deviation of the baseline RDQ score. A
linear regression model was used to analyze the baseline RDQ and the change in RDQ
scores. Results: Of the 41 GERD patients enrolled prospectively, 24 had EE and 17 had
NERD. The mean ages of the EE and NERD groups were 57 and 61 years respectively. The
majority of the patients (88%) were Caucasians with 2 female subjects in each group. The
mean baseline RDQ score was 14.4 for the EE group and 13.6 for the NERD group (p=
0.79). The mean scores at the end of treatment were 1.5 for the EE group and 4.1 for the
NERD group. There was a significant correlation between the baseline RDQ scores with the
change in RDQ post PPI therapy in EE patients (r=0.39, p<0.03) but not in the NERD group
(r=0.08, p=0.77). Conclusion: This study shows that higher the baseline severity of symptoms,
more likely is the response to PPI therapy in the EE group but not in the NERD group. In
clinical practice, reflux symptom severity cannot be used to predict response to acid suppres-
sion therapy in NERD patients.
T1218
Beneficial Effect of Pentoxyfilline, An Inhibitor of Tumor Necrosis Factor
Alpha (TNF-α), in Rat Model of Reflux Esophagitis
Michal Pawlik, Tomasz Brzozowski, Peter C. Konturek, Slawomir Kwiecien, Magdalena
Mazurkiewicz, Stanislaw J. Konturek, Wieslaw W. Pawlik, Eckhart G. Hahn
Reflux esophagitis, one of the most common disease of Western population, depends upon
the imbalance between the protective and aggressive factors leading to inflammation and
damage of the esophageal mucosa. Gastric acid/pepsin and proinflammatory cytokines were
implicated in the pathogenesis of reflux esophagitis but the effect of pentoxyfilline (PTX),
a metyloxanthine derivative that inhibits TNF-α biosynthesis, against the damage induced
by the reflux of gastric acid/pepsin content into esophagus has not been tested. We compared
the effect of PTX with that of proton pump inhibitor (PPI, pantoprazole) or histamine-H2
receptor antagonist (ranitidine) in experimental model of acid reflux esophagitis induced in
anesthetized rats by ligating of the pylorus and the limiting ridge (transitional region between
the forestomach and the corpus of stomach). Consequently, the capacity of the stomach to
store gastric juice was greatly diminished, resulting in the reflux of gastric juice into the
esophageus. Eighty rats with esophagitis were randomly divided into 5 groups and treated
with 1) vehicle (saline), 2) PTX (5-50 mg/kg i.p.) with or without L-NNA (20 mg/kg i.p.),
an inhibitor of NO-synthase, and 3) pantoprazole (10 mg/kg s.c.) or ranitidine (20 mg/kg
s.c.). Four hrs after induction of esophagitis, the damage was graded with lesion index (LI)
from 0-5 and by histology (H&E), the esophageal blood flow (GBF) was determined by H2-
gas clearance technique, plasma of IL-1β and TNF-α levels and mucosal expression of IL-
1β, TNF-α, cNOS and iNOS mRNAs was evaluated by RT-PCR. The esophagitis LI and wet
weight of esophagus were significantly higher than in the intact mucosa and the EDF was
decreased by about 35%. Histology revealed severe edema of the mucosa and submucosa
with the infiltration of numerous neutrophils. Both, PTX and PPI significantly reduced the
LI by 65% and 73%, respectively, and neutrophil infiltration of the esophageal mucosa
while causing a significant rise in the EBF but the treatment with ranitidine was less effective.
L-NNA, which by itself aggravated the esophageal damage, and significantly decreased EBF,
abolished PTX-induced protection and hyperemia and these effects were counteracted by
L-arginine (200 mg/kg i.p.) co-administered with L-NNA. Strong signals for IL-1β, TNF-α
and iNOS mRNAs were detected in the mucosa with reflux esophagitis and these effects
were significantly attenuated by PTX. We conclude that PTX exerts beneficial effect against
the esophageal damage induced by reflux esophagitis via suppression of expression and
release of TNF-α and IL-1β and enhancement in esophageal microcirculation possibly
mediated by NO.
T1219
Does Lifestyle Modification Improve Health-Related Quality of Life of Patients
with Reflux Esophagitis Who Receive Treatment with a Proton Pump
Inhibitor? : Data from Request Study (4)
Yoshikazu Kinoshita, Hiroto Miwa, Kiyoshi Ashida, Michio Hongo
Introduction: Lifestyle modification, such as reduce in intake of fatty foods or alcohol and
stop smoking, has been advised to patients with reflux esophagitis (RE). Such modification
is expected to improve health-related quality of life (HRQOL) of these patients. We analyzed
the impact of lifestyle modification advice on HRQOL in a multicenter trial which enrolled
10933 RE patients (REQUEST study). Objective: To clarify whether lifestyle modification
improves HRQOL in patients with RE undergoing proton pump inhibitor (PPI) treatment.
Methods: Of the patients enrolled in REQUEST study, 8748 patients who completed ques-
tionnaires before and after treatment were analyzed. Patients were treated with LPZ 15 or
30mg uid for 8 weeks. Physicians reported whether they advised any type of lifestyle
modification during the treatment period. At baseline and weeks 4 and 8 of treatment,
HRQOL was assessed by patients using SF-8 and a newly developed, RE-specific questionnaire
(RE-QOL). Physical component summary (PCS) and mental component summary (MCS)
of SF-8, and RE-specific summary (RES) scores of RE-QOL were calculated. Results: Of
the patients analyzed, 41% had been advised lifestyle modification from the time point of
LPZ administration (group A), 33% were advised to continue the same lifestyle modification
as previously advised (group B), and 26% did not receive any advice on lifestyle modifications
(group C). The difference in PCS before to after treatment in group A was 5.6±0.1 (mean±SE),
and significantly greater than those of groups B and C (TABLE). In addition, changes in
MCS and RES were significantly greater in group A than in the other groups. Subgroup
analysis showed that improvement in HRQOL by lifestyle modification was obtained to
similar extents irrespective of pretreatment status (Without acid-inhibiting treatment or
H2RA treatment one week before LPZ) and dose of LPZ (15 or 30 mg uid). Conclusion:
Lifestyle modification may have beneficial effect in improving HRQOL of patients with RE
who are going to have PPI.
Changes in PCS, MCS, and RES (mean+/-SD)
Differences before to after LPZ treatment. *P<0.01 vs Group B & C
T1220
Treatment Outcomes with rabeprazole (RAB) 20 Mg Vs Placebo (Pbo) in
Overweight/Obese Patients with Nonerosive Reflux Disease (NERD): Analysis
of 2 Us Multicenter Trials
Brian C. Jacobson, Byron Delemos, Yijun Sun, Jim Xiang, John Lococo, Anita Murthy
Background: The incidence of obesity is increasing in the US population; recent studies have
highlighted the association between increased body mass and symptoms and manifestations
of GERD. PPI efficacy in relation to BMI has not been previously explored. Objective: To
assess symptom relief with RAB in overweight/obese patients (BMI ≥25 kg/m2) with NERD
and moderately severe symptoms. Methods: Post hoc analysis by BMI on data from patients
enrolled in 2 multicenter, similarly designed, double-blind, PBO-controlled, US trials (Kah-
rilas Dig Dis Sci. 2005). Patients with ≥5 heartburn episodes in the last 7 days of a 2-week
PBO run-in period were randomized to receive RAB 20 mg or PBO for 4 weeks. Patients
recorded symptom frequency/severity (0=none, 4=very severe) and rescue antacid use. Treat-
ment groups were compared using log-rank, Cochran-Mantel-Haenszel, or ANOVA tests.
Results: Of the 261 patients randomized, 252 patients were in the ITT population, of whom
251 had BMI data available for post hoc analysis: 30 RAB and 25 PBO patients had a BMI
<25 kg/m2, and 96 and 100, respectively, had a BMI ≥25 kg/m2. Median time to first 24-
h heartburn-free interval (primary endpoint) was statistically significantly better with RAB
vs PBO in patients with a BMI ≥25 kg/m2: 2.5 vs 19.5 days (P<0.001). Results for this
measure in the BMI <25 kg/m2 subgroup were also in favor of RAB (9 vs 21 days) although
not statistically significant (P=0.143), possibly due to the relatively small sample size. Similar
results were seen for the secondary endpoints analyzed (Table), with differences in favor of
RAB in both BMI groups, reaching statistical significance in those with BMI ≥25 kg/m2.
RAB treatment was well-tolerated in both BMI groups. Conclusion: RAB 20 mg showed a
statistically significant effect in relieving heartburn and regurgitation and decreasing the
need for antacids in overweight/obese patients with NERD and moderately severe symptoms.
Sponsored by Eisai Inc., Teaneck, NJ; PriCara, Unit of Ortho-McNeil, Inc., Raritan, NJ.
Note: Analysis is based on data available for each endpoint. *P<0.05 vs placebo. †P<0.001
vs placebo. §Mean change from baseline.
T1221
Muscle-Derived Cell (MDC) Implantation in the Lower Esophageal Sphincter
for the Treatment of GERD: An Experimental Study
Maria A. Micci, Ijaz Ahmed, Rami Hawari, Rochelle R. Simmons, Kahrig M. Kristen,
Pankaj J. Pasricha
Introduction: Most patients with GERD who are being considered for surgery have low
LES pressure. Endoscopic delivery of bulking material may be a viable therapeutic alternative
for these patients. However, as the recent experience with Enteryx suggests, there is a need
for a safer material to perform this with. We hypothesized that auto-transplantation of
skeletal muscle-derived cells (MDC) into the LES may offer the ideal bulking therapy. To
test this, we have begun experiments to test the potential of MDC to survive and differentiate
within the GI smooth muscle in order to gain further knowledge on the biology of skeletal
muscle transplantation in GI smooth muscle sphincters as well as to test the safety and
feasibility of endoscopic injection of MDC in a large animal model. Methods: Adult male
Sprague-Dawley rats and adult male Beagle dogs were used. Rat-derived and dog-derived
MDC were provided by Dr. Ron Jankowski (Cook MyoSite Inc.). MDC were labeled with
DiI (Invitrogen/Molecular Probes) before transplantation in order to be able to visualize the
cells in the host tissue. Differentiation of grafted cells was assessed by immunofluorescence
using specific antibodies to markers of the smooth muscle phenotype (smooth muscle actin)
and of the skeletal muscle phenotype (skeletal muscle myosin).Results: (1) Rat experiments.
DiI-labeled rat-derived MDC (200,000/4 μl PBS) were injected bilaterally in the pyloric wall
of rats using a 10 μl Hamilton syringe and survival and differentiation was assessed 1 month
post-transplantation. Grafted cells were visualized based on DiI fluorescence and were
found to be localized within the muscle wall and in the muscularis mucosa. (2) MDC
transplantation in a canine model of GERD. In the first of a series of ongoing experiments,
A-493 AGA Abstracts
4.0x106 of labeled canine MDC were injected into the LES of a Beagle dog using a standard
variceal sclerotherapy needle. The dog was treated with daily cyclosporine and two weeks
later pH monitoring repeated and the esophagus examined histologically. A significant
reduction of acid reflux was observed with the fraction of time with pH<4 decreasing from
26.5% to 1.5%. Transplanted MDC were seen adding bulk to the lower esophageal area,
and were well integrated into the surrounding tissue particularly in the muscularis mucosa.
Immunofluorescence analysis revealed weak expression of skeletal muscle myosin in grafted
MDC and no expression of smooth muscle actin . Conclusions: MDC can survive and
integrate into GI smooth muscle and they have potential for the treatment of a variety of
conditions including GERD. Supported by a grant from Cook MyoSite Inc.
T1222
Positive Effect of Abdominal Breathing Exercise On Gastroesophageal Reflux
Disease: A Randomised, Controlled Study
Andreas J. Eherer, Karl M. Hoffmann, Felix Netolitzky, Georg Puschnig, Christoph
Högenauer, Thomas Hinterleitner, Stefan Scheidl, Wilfried Kraxner, Guenter J. Krejs
Introduction: The crura of the diaphragm together with the LES play an important role in
the prevention of gastroesophageal reflux (GER). To test the hypothesis that training of the
diaphragm could decrease GER and improve symptoms of GERD, we investigated the effect
of a diaphragmatic exercise regime on reflux symptoms and objective reflux measurements.
The training program was based on exercises for professional vocalists. The main principle
was to achieve active training of the diaphragmatic muscles by changing from thoracic to
abdominal breathing. Methods: The study included 19 patients with NERD who had had
at least 4 weeks of on-demand treatment with acid-blocking agents. Esophageal erosions or
a hiatal hernia >2cm were excluded. Patients assessed the effect of GERD on their quality
of life by completing GERD-HRQL questionnaires and a one-week medication report (PPI,
H2-blockers, antacids). After one week's abstinence from PPIs and H2-blockers, esophageal
manometry and standard pH-metry were performed. Patients fulfilling objective reflux criteria
were selected randomly for training or control. The training group, still taking medication on
demand, underwent a 4-week abdominal-breathing training program under the supervision of
a physiotherapist. After instruction, it was emphasised that patients should perform the
exercises for at least 30 minutes every day. The control group continued “on demand” therapy
as before. At the end of the 4-week period, patients again completed LQ questionnaires and
one-week medication reports. They again stopped medication for one week prior to manome-
try and pH monitoring. Results: All 19 patients completed life quality questionnaires and
medication reports; for 3 patients (2 training, 1 control) repeat pH-metry was not available
(2 technical defects, 1 withdrawal of consent to 2nd investigation). There was a significant
improvement of the GERD-HRQL in patients after respiration exercise (mean score ± SEM:14
± 2 before and 12 ± 2 after training, 14 ± 3 vs 14 ± 3 in control patients, p < 0.02). Dosing
of acid-blocking agents, albeit highly variable, showed no difference between the groups.
After training pH-metry improved significantly (pH below 4: mean 9.6% before vs 5.0%
after training). In 4 out of 8 patients, pH-metry normalized after training compared to 1
out of 8 control patients. After a follow up of 6 to 12 months 7 out of 9 patients remained
stable or further improved their GERD-HRQL. Conclusions: Abdominal breathing exercise
results in an improvement of GERD symptoms and an improvement of measurable GER.
T1223
The Preoperative Reflux Pattern As Prognostic Indicator for Outcome After
Nissen Fundoplication
Joris A. Broeders, Werner A. Draaisma, Durk Vries, de, Hein G. Gooszen
Aim: To optimize preoperative counselling, the impact of the preoperative reflux pattern
on postoperative outcome and the chance of recurrence, expressed in objective and subjective
gastroesophageal reflux disease parameters, were investigated for upright, supine and biposi-
tional reflux, both pre- and postoperatively. Background: “Upright reflux” has been nominated
as a relative contraindication for antireflux surgery. More recent studies, focused on either
symptomatic or objective outcome, disagree on whether patients with isolated upright reflux
should be discouraged to undergo surgery. In an era of growing need for preoperative
counselling, patients need differentiated information on their individual chance of recurrence
and reoperation. Methods: A total of 338 patients underwent laparoscopic or conventional
Nissen fundoplication. Of these, 289 patients had preoperative 24-h esophageal pH mon-
itoring. Of these, 234 had pathologic acid exposure and were classified as having upright
(n=81), supine (n=55) or bipositional (n=98) reflux. Total acid exposure and symptom
correlation on 24-h pH monitoring (SI and SAP), LES pressure, prevalence of esophagitis,
use of acid suppressing drugs and quality of life were compared for the three reflux patterns,
both before and after surgery. Results: Except for a higher total acid exposure before surgery
in the upright group (10.5 vs 7.3;P=0.017) objective GERD parameters were similar in the
unipositional reflux patterns, both pre- and postoperatively. Postoperative total acid exposure
(3.5 vs 1.3;P=0.036) and prevalence of recurrent pathological reflux were higher in the
bipositional group than in the upright group. Before surgery mean LES pressure was lower
compared to upright and supine reflux (1.0 vs 1.5 and 1.5;P=0.002 and P=0.036). Prevalence
of esophagitis was higher in bipositional reflux than in the upright reflux group, both
before (63.4% vs 43.2%;P=0.009) and after surgery (15.2% vs 3.2%;P=0.017). Surgical
reintervention was significantly more common in patients with bipositional reflux (in 20.0%
vs upright= 8.9% vs supine= 4.1%). No useful preoperative GERD parameters predicting
reintervention could be identified. Irrespective of the reflux pattern, all objective (all P<0.01)
and subjective (all P<0.03) parameters improved equally after surgery. Conclusion: Isolated
upright, supine and bipositional reflux patients have equal improvement of objective and
subjective parameters after surgery. Consequently, pathological reflux in any position is a
valid indication for Nissen fundoplication, but patients with bipositional reflux should be
informed about their higher chance for recurrence and reoperation.
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T1224
The Role of Multichannel Intraluminal Impedance (MII) in Selecting
Candidates for Laparoscopic Nissen Fundoplication (LFN)
Fabio Pace, Stefano Pallotta, Paola Molteni, Ornella Sangaletti, Greta Saino, Luigi
Bonavina, Gabriele Bianchi porro
Background: Present indications to LNF include GERD patients with typical or atypical
symptoms relieved by therapy with proton pump inhibitors (PPI). The indication is less
clear for patients with atypical symptoms without erosive changes (so called NERD) or with
symptoms refractory to PPI. Aim: to investigate with MII GERD patients with symptoms
refractory to PPI (group A) or NERD patients with atypical symptoms (group B) to ascertain
whether the cause of their symptoms could be ascribed to gastroesophageal reflux, either
acidic or non acidic, possibly requiring surgical therapy. Patients and methods: we investig-
ated 15 patients (8 males, mean age 46 years), 9 belonging to group A and 6 to group B.
All patients have undergone a negative esophageal endoscopic examination. Patients in group
A have received a standard dose PPI treatment for at least 3 months; patients in group B
have been suffering for chronic cough or laryngeal symptoms in the absence of any pulmonary
or laryngeal cause. MII was performed in patients of group A while on PPI therapy (the
same previously received), whereas patients in group B were investigated off therapy. MMI
was conducted and interpreted according to the recent literature (1). Results: In group A,
only 2/9 patients were still found to have a pathological exposure to acid reflux. In the
remaining seven, the bolus exposure (interval between a reflux episode and its clearing, BE)
was pathological for non-acid content. Finally, in the remaining 3/9 patients, a pathological
association with symptoms was found (either with a Symptom Index > 50%). In the group
B, 4/6 had a pathological exposure to acid reflux, the remaining 2/6 had in one case an
abnormal duration of non-acid BE and in one case a pathological SI. All patients were
submitted to LFN, 10 of whom on the basis of an abnormal MII only. and at a follow-up
between 3 and 17 months post-op all patients are completely asymptomatic and need no
therapy. Conclusion: This is the first study to our knowledge in which candidates to LFN
have been selected on the basis of MII only. The follow-up data confirm that this selection
is correct.
T1225
A Novel Endoesophageal Magnetic Valve to Prevent Gastroesophageal Reflux
(GER)
Mauro Bortolotti, Annamaria Grandis, Giosuè Mazzero
Background. The endoscopic methods to prevent GER show a scarce effectiveness and may
narrow the esophageal lumen more or less stiffly, sometimes impairing the bolus transit and
leading to dysphagia (Clin Gastro Hepatol 2005;3:831). We previously demonstrated that
a magnetic valve is able to create a high pressure zone (HPZ) sufficient to prevent GER,
that allows an easy transit of the content when it opens (J Biomech 2006;39:564). The aim
of this study was to demonstrate the possibility of implanting by endoesophageal way a
magnetic valve in the submucosa close to the incompetent lower esophageal sphincter (LES)
to prevent GER. Methods. The valve consists of a couple of small magnetic plaques of about
5x 20x1.5 mm with a magnetic force of 0.16 N/cm2 at 3 mm and a blunted bolt shape
that are to be implanted by means of a special endoluminal device in the esophageal
submucosa close to LES. The delivery device serves to make two pockets in the submucosa
one in front of the other, where the plaques are deployed with the opposite polarities face
to face, so that the magnets can attract themselves, closing the esophageal lumen. With this
method the valve was successfully positioned close to LES in 5 esophago-gastric specimens
taken from swines. A series of 5 slow pull-throughs in steps of 0.5 cm with a thin side-
hole manometric catheter, perfused with a pneumo-hydraulic pump and connected to a
polygraph, was carried out in each specimen before and after the insertion of the magnetic
valve and the mean pressure values obtained with and without the valve were compared
by means of Student “t” test for paired data. Results. The new HPZ showed a length of
about 2 cm and a pressure of 14.2+1.27 mmHg (mean+SD), significantly (p<0.001) higher
than that measured before the insertion of the magnetic valve (1.5+0.26 mmHg). Discussion.
The present research demonstrated that it is possible to implant in the esophageal submucosa
of swine gastroesophageal specimens, close to LES, a magnetic valve by means of a special
endoluminal probe and that the magnetic valve is able to give a HPZ that is considered
sufficient to prevent GER (N Engl J Med 1982;307:151). The main advantage of this system,
beside its reversibility and the possibility of tailoring the HPZ for each patient by choosing
magnets with different magnetic force, shape and size, lies in the fact that the magnetic
valve does not give a rigid lumen closure, as that obtained with other endoscopic methods,
but it leaves a wide passage that allows an easy content transit, when the magnetic plaques
are detached by the endoesophageal pressure.
T1226
Predictors of Long-Term Successful Outcome of Antireflux Surgery in
Children with Severe Gastroesophageal Reflux Disease (GERD)
Ilse Hoffman, Jan F. Tack, Antoon Lerut
The Nissen fundoplication is increasingly used to treat children with severe gastroesophageal
reflux disease (GERD). Although the efficacy of the intervention has been established by
endoscopic and esophageal pH follow-up studies, important complications may occur.
Identifying risk factors for complications might contribute to a better selection of children for
anti-reflux surgery. The aim of the study was to determine whether pre-operative esophageal
manometry or other factors are predictive of successful outcome of anti-reflux surgery in
children. Methods: All children who underwent anti-reflux surgery from January 1995 to
November 2005 were prospectively followed. At preoperative esophageal manometry, we
determined lower esophageal spincter (LES) pressure, and the presence duration and ampli-
tude of esophageal peristalsis. Long-term outcome assessed recurrence of GERD, dysphagia
and dumping syndrome. Results are shown as mean±SD and compared by Student's t-test.
Results: 174 children (108 boys, mean age of 7.2±5.6years), 72 of which had psychomotor
retardation (PMR), were studied with a mean post-operative follow-up of 13.2±10.7 months.
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Recurrent GERD, dysphagia and dumping syndrome were present in respectively 4, 15 and
11 children. No correlation was found between the different manometry parameters and
the long-term post-Nissen outcome. Patients with and without post-Nissen dysphagia had
preoperatively similar LES pressure (16.4±5.6 vs. 16.0±6.6 mm Hg, NS), peristaltic velocity
in the proximal and distal esophagus (0.8±0.2 vs. 0.8±0.4 cm/sec; 0.9±0.4 vs. 0.8±0.3 cm/
sec, both NS), peristaltic amplitude in the proximal, mid- and distal esophagus (49.7±24.2
vs. 56.3±27.1 mmHg; 60.3±18.5 vs. 74.7±26.5 mmHg; 73.0±35.9 vs. 79.2± 35.3 mmHg,
all NS), duration of peristaltic contractions in the proximal, mid- and distal esophagus
(3.3±1.0 vs. 3.0±1.0 sec; 3.4±0.8 vs. 2.9±0.8 sec; 3.1±0.7 vs. 3.0±0.9 sec, all NS) and
peristaltic progression (100 vs. 94±22%, NS). Similar results were obtained for recurrent
GERD and for dumping syndrome. In addition, initial symptom pattern (heartburn, dys-
phagia, coughing) and findings on barium swallow, upper g.i. endoscopy and pH-monitoring
alone or combined did not predict long-term complications. Conclusion: Preoperative eso-
phageal manometry is not a predictor of long-term complications after anti-reflux surgery
in children with GERD. Other clinical, endoscopic and radiological characteristics also failed
to predict long-term outcome. Although not present in the current series, manometry still
has the potential to detect severe motor disorders like achalasia of sclerodermia.
T1227
Lack of Association Between Meal-to-Bed Time and Supine Gastro-Esophageal
Reflux Disease As Measured By Wireless pH Monitoring (BRAVO)
Danise Schiliro, Ilseung Cho, Morris Traube
Background: Lifestyle modifications, such as avoiding food 3 hours before bedtime, have
been recommended to patients with gastro-esophageal reflux disease (GERD). However, the
benefit of avoiding late meals has not been supported by objective data. Our hypothesis
was that meal-to-bed time (MBT) and supine acid reflux, as measured by wireless pH
monitoring (BRAVO), would be inversely related. Aim: Our aim was to evaluate the association
between meals eaten <3 or >3 hours prior to bedtime and supine acid reflux. Methods:
Data from 88 consecutive patients who underwent 48 hr wireless pH monitoring (BRAVO)
at the NYU Center for Esophageal Disease were retrospectively analyzed. Exclusion criteria
were age > 89 years, proton pump inhibitor (PPI) use during monitoring, achalasia, sclerod-
erma, and inadequate studies. Extracted data included age; gender; reason for exam; day 1
and day 2 MBT (min); day 1, day 2, and combined percent reflux (total, upright, supine);
day 1, day 2 and combined Johnson-DeMeester scores. Supine reflux was defined as pH <4
for ≥1.2 % of the nocturnal recording time; A DeMeester score was graded as positive if
≥22. MBT data were used to divide the patients' data into groups having meals <3 hours
or > 3 hours prior to bedtime. Student's t-tests were used to compare groups, and correlation
coefficients were calculated to evaluate associations between MBT and supine reflux. Results:
Data from 65 patients (mean age 50; 60% female) were included in this study. There was
no significant difference in percent supine acid reflux between those with MBT <3 (5.6%)
and >3 hours (4.0%) (p=0.19). There was no overall correlation between MBT and supine
reflux (r2=0.0142). In the subgroup analysis of only patients with positive Johnson-DeMeester
scores or positive supine reflux, there was no significant difference in percent supine reflux
in those with MBT <3 hours (34.8%) or > 3 hours (26.4%) (p=0.22). Furthermore, in this
subgroup of patients, there was no statistically significant correlation between MBT and
percent supine reflux. Conclusion: In patients with suspected or proven GERD, meals within
3 hours of bedtime were not associated with increased supine reflux events. Therefore,
avoiding food prior to bedtime may not decrease supine or nocturnal acid reflux.
T1228
Successful Treatment of Chronic GERD with Durasphere: Long Term Results
of a Pilot Study
Robert A. Ganz, Tina Wittchow, Dean Klein
Background: Durasphere®, a unique, new, biocompatible, nonmigratory, nonabsorbable
pyrolytic carbon-coated bead suspension was previously reported to be safe and effective
in the treatment of mild to moderate GERD, in a 6 month pilot study (Ganz ‘06). We now
report the 12 month safety and antireflux efficacy of this material utilizing a submucosal
augmentation technique to affect the gastroesophageal reflux barrier. Methods: 10 GERD
patients (mean age 40) with PPI-responsive heartburn were enrolled. Clinical assessment
included: endoscopy, esophageal manometry, Bravo pH monitoring, a heartburn diary and
GERD-HRQL severity scoring at baseline, 3, 6, and 12 months. The procedure was performed
in an outpatient endoscopy clinic using conscious sedation. Using a simple sclerotherapy
catheter and technique, Durasphere® was injected into the submucosal space, at and just
below the squamocolumnar junction, in two sets of 1-2 cc four quadrant injections. The
mean initial injection volume of Durasphere was 8.6 (4.7-13.9) mls. Patients with early,
incomplete symptom relief were reinjected with a similar volume of material within 90 days
of enrollment. Outcome measures included PPI use, change in GERD-HRQL symptom scores,
Bravo pH scores and adverse events. Results: At 12 months, 90% (9/10) of patients had
reduced their PPI dose by ≥ 50% as compared to baseline, and 60% eliminated PPI use
entirely. The mean GERD-HRQL score was 32.3 at baseline (off PPI) and 4.5 at follow-up
(p=0.0002). All patients experienced a > 50% improvement in their HRQL score. The mean
percent total time with pH ≤ 4 was 13.2 at baseline and 7.4 following injection (p=0.01).
A 90% reduction in symptomatic reflux episodes was recorded on the 12 month Bravo as
compared to baseline. 4 patients normalized their DeMeester score. There was continued
symptomatic and pH improvement between the 6 and 12 month follow-up visit. There were
no serious adverse events. No patient reported any dysphagia, no post-operative analgesics
were needed after any of the treatments and antibiotics were not used. Conclusion: In this
pilot study, submucosal augmentation of the GE junction using Durasphere, a carbon-based
suspension, was technically easy, simple, safe and efficacious in the treatment of mild to
moderate GERD. The technique is very well-tolerated by patients, can be performed in an
outpatient endoscopy unit, and appears durable on a long term basis. Attributes of this
material appear to overcome the problems of previous injectables for GERD. If controlled
studies confirm these findings, Durasphere could represent an excellent alternative to long
term medical management in those with chronic reflux.
T1229
Antireflux Surgery Normalize Impedance Recording and Cures Symptoms
Associated with Non-Acid Reflux
Markku Luostarinen, Jyrki Kössi, Juha Virtanen, Ilkka Krekelä, Jouko Isolauri
Background: Patients who have normal pH-monitoring but are still symptomatic on PPI
medication are a difficult clinical problem. Some surgeons have tried to solve the problem
by operating these patients Results have not been always excellent and surgery is usually
avoided. Nevertheless, if it could be confirmed that the symptoms are caused by non-acid
reflux, surgery could be an effective choice. Impedance-pH recording is increasingly used
in reflux patients with extra-esophageal symptoms. Its usefulness in selecting patients for
surgery is largely unstudied. Patients and methods: 6 patients presenting mostly with extraeso-
phageal reflux symptoms in spite of continuous PPI medication had endoscopy, esophageal
manometry and 24-hour impedance-pH recording (Sandhill Inc.). Their leading symptoms
were cough, hoarseness and globus. All had normal motility and pH recordings, but imped-
ance monitoring showed pathologic number reflux episodes with good correlation to symp-
toms (Table). Laparoscopic Toupet posterior hemifundoplication was done to all these
patients and 3-4 months after operation impedance-pH study was controlled. Results: All
the patients were satisfied with the operative result. Symtoms were cured or greatly relieved.
Impedance monitoring was normalized and postoperatively there was no more symptom
correlation. Conclusion: Anti-reflux surgery seems to cure also non-acid reflux. Impedance
study can be used to select the patients for surgery also in absence of traditional objective
signs of reflux.
*mean(range)
T1230
Endoluminal Fundoplication (Elf) with the Esophyx™ Device for the
Treatment of GERD
Ger Koek, Wim Hameeteman, Ad A. Masclee, Eva E. De vries, Ronald Van dam, Nicole
Bouvy
Background: Recently the EsophyX™ has been introduced as a new technique to allow non-
surgical, endoluminal fundoplication for the treatment of gastro-esophageal reflux disease
(GERD). We report the first results of GERD patients treated with this device. Method: Pre-
operatively GERD patients were selected having documented reflux disease, a small hiatal
hernia (< 5 cm), abnormal acid exposure based on 24 hour pH metry and not willing to
use lifelong medication. Procedure: Under general anesthesia with the endoluminal device
over the endoscope, in a retroflexed view, a full thickness fundoplication of at least 180
degrees circumference is created. Immediately before and after ELF, valve grading is per-
formed according to the Hill classification (grades I-IV). Two weeks after ELF, patients were
asked to stop their PPI's. Parameters to evaluate efficacy (before and up to 3 months after
ELF) were: 24 hours pH metry, GERD specific quality of life score (GERD-HRQOL) and
use of PPI. Results: At present 18 GERD patients, mean age 51 years (range 32-79; 7 females)
have been treated with ELF. ELF was performed safely in all 18 patients without serious
complications. Intra-operatively solid full-thickness fundoplication over mean 200 degrees
(range 180-220) was achieved in all patients. The Hill grade decreased from mean 2.5 before
to mean 1.0 after ELF procedure. Mean procedure time was 91 minutes (range 55-145 min).
During short term follow up (3 months) GERD-HRQOL improved significantly from mean
31 to 16 (p<0.01; range 0-80). Thirteen patients (73%) were able to stop all medication
and in 5 patients PPI dose could be reduced by 50-75%. When analyzing the results in
more detail, it is apparent that patients with small hiatal hernia (<3cm) fared better than
those with larger hernia (3-5cm). Eight out of 9 patients in the group with small hernia
were able to stop all medication. Acid exposure time in the group with small hernia decreased
significantly from 8.0 to 4.7% (p<0.05). Conclusions: The EsophyX™ ELF appears to be a
safe and efficacious endoluminal procedure to control GERD on short time follow up. Best
results are obtained in patients with small hiatal hernia (<3cm).
T1231
The Efficacy of Injection Followed By Thermal Endoscopic Therapy in the
Management of High-Risk Patients with Acute Peptic Ulcer Bleeding: A Meta-
Analysis
Alan N. Barkun, Myriam Martel, Youssef Toubouti, Elham Rahme, Marc Bardou
BACKGROUND: There exist a large number of randomized clinical trials published to date
on the therapy of patients with acute peptic ulcer bleeding. Yet controversy still exists as
to the selection of endoscopic management, including with regards to the optimal role of
combination (injection followed by thermal) therapy. AIM: To assess the role of combination
therapy in the management of selected patients with acute peptic ulcer bleeding compared
to contemporary methods of endoscopic hemostasis. METHODS: Comprehensive searches
of MEDLINE, EMBASE and CENTRAL from 1990 to October 2006 with cross referencing
of identified articles and hand searched abstracts were performed. We selected randomized
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trials that compared the efficacy of combination therapy to other commonly used endoscopic
interventions (injection, thermal, clips) on rates of rebleeding (RB), surgery (S), and mortality
(M) in patients with bleeding ulcers exhibiting high risk endoscopic stigmata (Forrest Ia,
Ib, IIa, and IIb). Data were extracted by independent reviewers. Outcomes measured were
the decreases in rates of RB (primary outcome of the meta-analysis), S and M (both secondary
outcomes) according to treatment groups. Standard meta-analytical techniques were followed.
RESULTS: A total of 1414 high-risk patients from 11 trials were included. Compared to
sole injection, combination therapy significantly decreased rebleeding (OR= 0.26, 95%CI:
0.09 - 0.73) but not surgery or mortality (0.45 [0.20; 1.04], and 0.90 [0.35;2.33] respect-
ively). No outcome was significantly reduced with combination treatment compared to a
sole thermal modality, even though all values favored combination therapy (rebleeding: 0.79
[0.24; 2.62], surgery: 0.38 [0.08; 1.73], and mortality: 0.52 [0.24; 1.15]. When compared
to clips, no differences in outcomes were noted although all odds ratios computed tended
to favor clips application (rebleeding: 1.22 [0.42; 3.57]; surgery: 1.25 [0.09; 6.7]; mortality:
1.62 [0.14-20]). CONCLUSIONS: The present meta-analysis confirms the superiority of
injection followed by thermal therapy over sole injection, but not versus sole thermal therapy
- a comparison for which additional trials are required as these results may reflect a type
II error. Injection followed by thermal therapy is not superior to clip application, and in
fact may be less efficacious. Comparisons with other combination therapies such as clips
and injection need further study.
T1232
Bleeding Peptic Ulcers: Changing Trends in Helicobacter pylori Infection and
NSAID Use in North Western Switzerland
Shajan Peter, Wolfgang Polasek, Remy F. Meier, Niklaus Schaub, Christoph Beglinger
Background. Helicobacter pylori (H. pylori) and NSAIDs are risk factors for the development
of peptic ulcers. In 1992 and in 2003, prospective studies were conducted over a 1-year
period in patients with acute upper gastrointestinal bleeding. Aim. The prevalence of H.
pylori infection and NSAID use was determined in order to assess whether the etiology has
changed over a period of 10 years. Methods: 126 consecutive patients who presented with
acute upper GI bleeding in three major hospitals in North Western Switzerland in 2003
were compared to 112 patients collected in an analogues study in 1992. The data were
analyzed for H. pylori status (histology) and NSAID use. Comparisons were made by chi-
square Fisher's test. Results: The overall incidence of bleeding peptic ulcers was 16.4 cases
per 100.000 persons in 2003. The mean age of the group was 67.8 (SD 16) years; (58%
males, 42% females). Mortality during initial admission (30 days) was 11.1% (not significantly
different from 1992). No significant demographic changes occurred since 1992. The rate
of H. pylori infection and NSAID use are shown in the Table. Summary: In patients with
acute upper gastrointestinal bleeding: 1. The prevalence of H. pylori infection has markedly
decreased since 1992. 2. NSAID use was high and accounts for the majority of patients
with ulcer bleeding. 3. An increasing trend of duodenal ulcers was observed that was neither
associated with H. pylori infection nor NSAID use. 4. Mortality of acute ulcer bleeding remains
substantial. Conclusion: The time trend analysis documents a change in the prevalence of
the most common etiologies of acute peptic ulcer bleeding, but not a change in mortality.
*P<0.001 CHI SQUARE 2003 vs 1992
T1233
Gastric Vascular Ectasia Treated By Argon Plasma Coagulation: A Comparison
Between Patients with and Without Cirrhosis
Stéphane Lecleire, Emmanuel Ben-soussan, Michel Antonietti, Eric Lerebours, Philippe
Ducrotte
Introduction. Gastric vascular ectasia (GVE) are an uncommon etiology of gastrointestinal
bleeding. GVE occur more frequently in patients with cirrhosis but can also affect patients
with a variety of chronic diseases. Aim. The aim of the study was to compare the clinical
and endoscopic characteristics and the response to treatment by argon plasma coagulation
(APC) of bleeding GVE between patients with cirrhosis and non-cirrhotic patients. Patients
and methods. Between January 2001 and December 2005, thirty patients were treated by
APC for bleeding GVE revealed either by an overt bleeding or by an iron-deficiency anemia.
Clinical and endoscopic features, endoscopic APC treatment procedure and patient follow-
up were retrospectively collected and compared between patients with cirrhosis (group 1)
and non-cirrhotic patients (group 2). APC was performed using a coagulation varying from
50 to 70 W, and a gas flow rate ranging from 0.8 to 1 L/min. Endoscopic treatment efficacy
was assessed on the recurrence of symptoms after APC treatment. Results. In the 30 patients
treated by APC for bleeding GVE, 17 had cirrhosis (13 alcoholic, 2 HCV, one NASH and
one primary biliary cirrhosis) and 13 were non-cirrhotic patients, (7 with chronic renal
failure, 3 cardiac insufficiency, 2 auto-immune disease and one with myelodysplasia. Cirrhotic
patients presented more frequently with melena (65% vs 15%), and non-cirrhotic patients
with an occult bleeding with an iron-deficiency anemia (35% vs 85% ; p=0.01). Hemoglobin
level before and after treatment were not different between the two groups (7.29 g/dL vs
7.72 g/dL et 10 g/dL vs 10.3 g/dL). Prothrombin level and platelet count were significantly
lower in patients from group 1 (56% vs 84% ; p<0.0001 and 130/mm3 vs 245/mm3 ;
p<0.0001, respectively). Patients from group 2 used significantly more anticoagulation drugs
(0% vs 31%, p<0.03). Endoscopy in patients from group 2 revealed more frequently a
diffuse antral localization of GVE (23.5% vs 76.9% ; p=0.008). Endoscopic treatment by
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APC was successful in 82.6% of patients (87.5% vs 76.9%; ns). Patients from group 2
required significantly more APC sessions to achieve a complete treatment (2.18 vs 3.77 ;
p=0.04). Median follow-up of patients after the last APC session was 20 and 24 months in
group 1 and group 2, respectively (ns). Conclusion. APC treatment of bleeding GVE was
efficient and safe in cirrhotic and non-cirrhotic patients in more than 80% of cases. Non-
cirrhotic patients required significantly more APC sessions to treat symptomatic GVE, due
to the diffuse antral extension of GVE in these patients.
T1234
Outcome of Bleeding Ulcer Related to Nonsteroidal Anti-Inflammatory Drug
Use, Helicobacter pylori Infection and Idiopathic Cause: A Prospective Study
Chi-liang Cheng, Nai-jen Liu, Jui-hsiang Tang, Hao-tsai Cheng, Ching-song Lee, Yin-yi
Chu, Kai-feng Sung, Cheng-hui Lin, Yung-kuan Tsou
BACKGROUND: Peptic ulcer bleeding is an important medical emergency. The aims of this
study were to investigate the incidence and outcome of bleeding ulcers related to Helicobacter
pylori (H. pylori), NSAID (including antiplatelets), and non-H. pylori idiopathic cause.
METHODS: Between June 2005 and August 2006 all patients with peptic ulcer bleeding
were evaluated consecutively. The diagnosis of H. pylori infection was made at index endos-
copy, using rapid urease test and histology, or by serology in previously untreated patients.
NSAID ulcers were defined as exposure to NSAID within one week of bleeding, and non-
H. pylori idiopathic ulcers defined as negative tests for H. pylori and no exposure to NSAID
within one week. Severity of comorbid illness was graded by American Society of Anesthesiol-
ogy (ASA) classification. The outcome of ulcer bleeding was scored by Rockall classification.
Rebleeding episodes within 30 days and in-hospital mortality were prospectively recorded.
RESULTS: Total 390 patients were enrolled and 263 were men and 127 were women with
a mean (± SD) age of 63 (± 16) years. H. pylori infection was diagnosed by endoscopic
methods in 351 (90%) patients and serology test in 39 (10%). NSAID ulcers were noted
in 223 patients (57.2%), H. pylori ulcers in 102 (26.1%), and non-H. pylori idiopathic ulcers
in 65 (16.7%). Patients who had NSAID ulcers or non-H. pylori idiopathic ulcers were
generally older (p < 0.001), had a lower initial hemoglobin level (p < 0.001), a higher ASA
grade (p < 0.0001), and a higher Rockall score (p < 0.0001) than H. pylori ulcers. Patients
with NSAID ulcers appeared to have more gastric and less duodenal ulcer bleeding (p =
0.002), a higher percentage of patients with ulcer number more than 3 (p = 0.001), and a
higher percentage of patients with ulcer size more than 20 mm (p = 0.01), compared with
patients with H pylori ulcers. Patients with non-H. pylori idiopathic ulcer had a significantly
higher mortality rate than NSAID ulcers and H. pylori ulcers (12.3% vs 4.5% vs 2.9%,
respectively, p = 0.02). There was no statistically significant difference in terms of rebleeding
rates within 3 days (18.5%% vs 10.8% vs. 9.8%, respectively) and 30 days (23.1%% vs
13.9% vs 1 9.6%, respectively) between non-H. pylori ulcers, NSAID ulcers, and H. pylori
ulcers. CONCLUSIONS: More than half of all ulcer bleeding is associated with NSAID use.
Bleeding related to H. pylori-negative idiopathic ulcers is not uncommon and is associated
with a high in-hospital mortality rate.
T1235
Hemoclip Combined with Epinephrine Injection for Bleeding Ulcer, a Meta-
Analysis of Randomized Controlled Trials
Yuhong Yuan, Changcheng Wang, Richard H. Hunt
Background: Endoscopic therapy significantly improves outcomes of patients with peptic
ulecr bleeding (PUB) but rebleeding is still reported in ~ 20%. Endoscopic combination
therapy may be more effective than single therapy. The most commonly used technique,
epinephrine injection is associated with tissue injury, while hemoclip has the advantage of
not injuring tissues and is increasingly used. Whether hemoclip combined with injection
is more effective than injection alone for PUB is unknown. We aimed to review the evidence
through meta-analysis. Methods: A search of the literature was conducted to November
2006 using Medline, EMBase, and CENTRAL supplemented by a recursive hand search of
reference lists. Published, all-language, RCTs providing raw data for hemoclip plus epineph-
rine injection compared with injection alone to treat PUB were included. Relative risk (RR)
or weighted mean difference (random effects model) with 95% CIs were calculated by Review
Manager 4.2.9. Results: Four out of 12 hemoclip related RCTs met inclusion criteria, 3
from East Asia and 1 from Europe. In total, 149 patients received combination therapy and
173 received injection therapy alone. Observation endpoints varied from 24 hours to 8
weeks. Initial hemostasis was not significantly different between combination and injection
groups (94.6 % vs 93.6%, RR 1.02, 95%CI 0.96-1.09) with homogeneity between studies.
The rebleeding rate was nonsignificantly decreased in the combination group compared
with injection (8.7% vs 15.6%, RR 0.62, 0.20-1.91); significant heterogeneity was observed,
which may be due to the different time points. Emergency surgery was significantly decreased
in the combination group (RR 0.19, 0.04-0.83) with homogeneity but only 3 studies reported
this. Mortality rate was not significantly different between combination and injection groups
(RR 1.94, 0.44-8.61) but 2 studies reported all deaths and 2 reported bleeding related
deaths. All studies routinely used intravenous antisecretory therapy for 2-3 days (pantoprazole
n=1, ranitidine n=3) in both groups. The type of acid inhibitor was not associated with the
treatment effect. Conclusions: RCTs comparing a combination therapy of hemoclip and
epinephrine injection with injection alone for PUB are limited for comparison of the two
techniques. However, available evidence suggests that combination therapy is similarly
effective to injection alone, although the small sample size and non-representative populations
limit generalizability of the studies. The varied quality of studies warrants further, larger
clinical trials, with rigorous design and good reporting.
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Upper Gastroinestinal Bleeding (Ugb): Trend Changes in Epidemiology and
Outcome During the Last Decade (1991-94 Vs 2001-2004)
Esther Fort, Montserrat Figa, Xavier Aldeguer, Manuela Hombrados, Carme Lopez,
Doroteo Acero, Ferran Gonzalez-huix
INTRODUCTION: UGB is a very frequent cause of attendance at the emergency room (ER)
accounting for a total of 50-150 cases/ 100.000 adults par year.In the 90s there have been
important changes in the management of gastrointestinal conditions potentially leading to
a GI haemorrhage altogether with the acquisition of new drugs and endoscopic techniques
to treat the acute episode. We wanted to study how those changes have influenced on the
clinical profile and outcome of patients with UGB. AIMS & METHODS: We have included
all patients with acute UGB who were treated at our hospital in two periods of three
consecutive years separated by 10 years (April91- April 94 vs December 01-December 04).
All patient underwent an urgent upper gastrointestinal endoscopy during the first 24 hours
since ER attendance and endoscopic treatment concomitantly applied whenever required. We
recorded demographic and clinical variables, endoscopic variables (type of lesion, haemostasis
stigmata, blood presence) and outcome (re-bleeding, surgical intervention, blood transfusion
and mortality). RESULTS: 1,299 patients were included in the first period and 690 patients
in the second (a 46.8 % decrease). Mean age was higher in the second period (62.7 vs 65.4,
p<0.01). No gender differences were detected between both periods. Previous dicumarin
intake was increased in the second period (9.8% vs 15.5% p<0,001). There were no differ-
ences at the time of ER attendance in terms of hemodynamic instability, hemoglobine values.
Nonetheless, the aetiology changed significantly. Thus, in the second period, less duodenal
ulcers were observed altogether with an increase of patients with no lesions detected endos-
copically and more therapeutic endoscopy was performed (31% vs 36%; p<0.01). As for
the general outcome,with less patients receiving a transfusion (60% vs 52%, p<0.01), less
re-bleeding episodes ( 14.2 % vs 4.1 % p<0.001), surgical interventions (5.9% vs 1.3 %
p<0,001) and mortality (9.7% vs 5.4% p=0.01). Finally, a smaller number of hospital
admissions due to UGB (94% vs 75.2% p<0.001) and a shortening of hospital stay (11.4
vs 5 days p<0.001) were also detected. CONCLUSION: We can conclude that, in the last
decade, there has been a change in the general profile and aetiology of acute UGB attending
our emergency room altogether with a general improvement in the management and outcome
of this important condition.A major part of this change has depended on a decrease in
peptic ulcer disease and an increase in use of dicumarinics which has resulted in an elderly
population being attended.
T1237
Prognostic of Upper Gastrointestinal Bleeding: Results of a French Prospective
Study Including More Than 3000 Patients
Herve Hagege, Jean paul Latrive, Bernard Nalet, Isabelle Rosa, Bruno Bour, Roger Faroux,
Philippe Gower, Jean pierre Arpurt, Jacques Denis, Jean Henrion, Alex Pariente, Groupe
hdh Angh
INTRODUCTION: Upper gastrointestinal bleeding (UGIB) in general population represents
a common emergency in clinical practice. The aim of this study was to describe current
epidemiology, medical practices, morbidity and hospital mortality in a large, prospective
series of UGIB. AIMS & METHODS: The inclusion period is scheduled to be one year, from
March 1, 2005 to February 28, 2006. During this period consecutive patients with UGIB
were recruited in 53 French hospitals. Clinical, biological and endoscopic data were collected
until the hospital discharge. RESULTS: 3297 patients were included: 2176 men and 1121
women, of mean age 63 ± 18 years. The mode of presentation of the haemorrhage was:
hematemesis in 58% of the cases, melena only in 38% and acute anaemia in 4%. At admission,
systolic blood pressure was under 100 Hg mm or heart rate was upper 100/min in 54% of
the cases. Haemoglobin was 9 ± 3 g/dl. Comorbidities were noted in 62 % and cirrhosis in
33% of the cases. Before the UGIB episode, 20% of the patients had taken aspirin, 11%
non steroidal anti-inflammatory drugs, 9% vitamin K antagonists and 8% anti platelet agents.
During endoscopy, signs of recent bleeding were present in 57% of the cases. The cause of the
UGIB was attributed to: gastric ulcer in 13% of cases, duodenal ulcer in 20%, gastroduodenal
erosions in 6%, esophageal or gastric varices in 24%, portal hypertensive gastropathy in
3%, esophagitis in 15%, Mallory Weiss syndrom in 7%, oesophageal or gastric cancer in
4% and other lesions in 9%. Mean Rockall score was: 5.0 ± 2.3. Haemostatic therapy was
performed during the first endoscopy in 29% of the cases. Transfusion of 3.8 ± 2.7 units
was realized for 63% of the patients. Rebleeding occurred among 10% of the patients. In-
hospital mortality was 8.4%. In multivariate analysis, predictive factors of of rebleeding
were: transfusion, haemoglobin under 10g/dl, signs of recent bleeding, ulcers or erosions
(p<0.001). Predictive factors of death were: blood systolic pressure under 100 Hg mm,
comorbidities and Rockall score (p<0.001). CONCLUSION: Ulcer disease remains the first
cause of UGIB and is associated with greater risk of rebleeding. Proportion of haemorrhages
related to portal hypertension is increasing. Whereas the total severity evaluated by the
Rockall score remains important, rebleeding and hospital mortality are weaker. Reduction
of rebleeding and in-hospital mortality could be explained by the more frequent realization
of hemostatic therapy during the initial endoscopy and by the drugs used currently.
T1238
Practice Patterns of Antisecretory Use in High-Risk Nonvariceal Upper GI
Hemorrhage (Nvugih): Results of a National Vignette Survey
Brennan M. Spiegel, Ian M. Gralnek, Loren Laine, Dennis M. Jensen, Gareth S. Dulai,
Glenn M. Eisen, Eric Esrailian
Background: Antisecretory therapies, including proton pump inhibitors (PPI) and histamine-
2 receptor antagonists (H2RA), are a mainstay in the management of high-risk NVUGIH.
However, there remains uncertainty about the optimal agent, route, timing, and dosage of
these therapies. We conducted a national vignette survey to measure current practice patterns
in the use of antisecretories in high-risk NVUGIH. Methods: We developed an online survey
that included a clinical vignette of a high-risk NVUGIH patient. The vignette was developed
with a panel of content experts to ensure face validity and comprehensiveness. Respondents
viewed a standardized presentation of a high-risk patient (summary: 42 yo on ASA with
melena, epigastric pain, orthostatic BP, no stigmata of liver disease, Hgb=11), and then
received management questions guided by branching conditional logic. Upon EGD, respond-
ents viewed an image of an actively bleeding vessel in an ulcer. The survey elicited provider
knowledge and beliefs in various aspects of NVUGIH care, including use of antisecretories.
We surveyed a random sample of 360 GIs from the AGA, and 40 internationally-recognized
NVUGIH experts. Results: The response rate was 47% (N=188; 25 experts). 80% endorsed
IV PPI use prior to EGD, whereas only 3% and 1% endorsed PO PPI and IV H2RA,
respectively. More experts than “non-experts” chose to use no pre-EGD antisecretory therapy
(24% vs. 11%; p=0.03). The most common reason for using IV PPI was a belief that it is
more effective than PO PPI or IV H2RA. Of those using IV PPI pre-EGD, only 58% dosed
according to guidelines (loading bolus, then continuous infusion). Non-experts were more
likely to endorse BID or TID bolus dosing than experts (14% vs. 0%; p=0.04). All respondents
endorsed PPI use post hemostasis, although experts were more likely to use IV continuous
infusion than non-experts (92% vs. 57%; p=0.02), and non-experts were more likely to use
PO dosing (22% vs. 4%; p=0.03). The remainder used IV PPI bolus dosing. In multivariable
regression adjusting for provider demographics, practice setting, and experience, experts
remained over 4 times more likely to use IV PPIs “correctly” (bolus, then infusion) vs. non-
experts (OR=4.2; 95% CI=1.5-11.7). Conclusions: Compared to non-experts, NVUGIH
experts are more likely to withhold pre-EGD antisecretories, to use IV vs. PO PPI post-
EGD, and to dose IV PPI by prescribing guidelines. However, there is uniformity that H2RAs
have little role in high-risk patients. These variations between experts and “non experts”
indicate that further development and dissemination of evidence-based antisecretory guide-
lines is warranted.
T1239
Proton Pump Inhibitors Vs. Histamine2 Receptor Antagonist in Treatment of
Non Variceal Upper Gastrointestinal Bleed: A Meta-Analysis
Ruchi Gupta, Praveen Garg
Objectives- To evaluate whether proton pump inhibitors (PPI) are more effective than
histamine2 receptor antagonist (H2 RA) in treatment of non variceal upper gastrointestinal
(UGI) bleed and to compare the impact on mortality, rate of rebleed, surgical intervention,
length of stay and need for transfusion. Background- UGI bleed is a frequent problem in
United States with an annual incidence of 100 per 100,000 adults per year. Randomized
control trials on non vericeal upper GI bleed have conflicting results and are heterogeneous
with above mentioned primary outcomes. Study design- Meta analysis. Data sources- Pubmed,
Medline, Embase database from 1990-2006. Review methods- Comparative randomized
control trials of PPI vs. H2RA in non variceal UGI bleed (gastric ulcer, duodenal ulcer,
reflux esophagitis, Mallory Weiss tears). The included trials indicated one of the outcomes
as mortality, rebreed rate, surgical intervention, length of stay and transfusion requirement.
Data Collection and Synthesis- Two reviewers independently reviewed a total of 31 trials
with 3846 patients. These trials fulfilled the inclusion criterion and contained data for atleast
one of the planned comparisons. Most of the trials were done in peptic ulcer bleeding. 8
trials did have patients with UGI bleed due to Mallory Weiss tear, erosive gastritis, erosive
duodenitis or H. pylori related bleed. Conclusion- Recurrent bleed was noted in 7.3% (95%CI
5.5-9.2) of patients treated by PPI vs. in 13.9% (95% CI 11.4-16.3) of patients treated with
H2RA (OR 0.5 CI 0.31-0.62). Surgical intervention was needed in 4.8% (95% CI 2.9-6.0)
of patients treated with PPI vs. in 7.1% (95% CI 5.2-9.3) of patients treated with H2RA
(OR 0.6 95%CI 0.56-0.84). Mortality as an endpoint was seen in 1.8% (95% CI O.9-3.1)
patients treated with PPI vs. 2.5% (95% CI 1.5- 3.9) in patients treated withH2RA (OR
0.71 95% CI 0.49-1.72). 21% of patients treated with PPI required blood transfusion (95%
CI 16.2-26.9) vs. 29% of patients (95%CI 24.7-32.0%) treated with H2RA (OR 0.4 95%CI
0.6-0.92). Length of stay was 6.1 days for PPI (95% CI 3.4-7.8) vs. 6.9 (95% CI 3.9-8.2)
for patients treated with H2RA (OR 0.9 CI 0.78-1.18) Conclusion- Treatment with PPI
reduces rebleed rate when compared with H2 RA. At best the evidence suggests limited
superiority of PPI over H2RA when comparing the need for surgical intervention and
transfusion requirement. Use of PPI has no benefit on length of stay and overall mortality
when compared to H2RA in patients treated for non variceal upper GI bleed.
T1240
A Prospective Study to Validate the Blatchford Score As a Means to Prevent
Hospital Admission and Reduce the Need for Endoscopy, in Acute Upper GI
Bleeding
Maximillian Groome, Lynn Urquhart, Andrew Kinnon, Craig Mowat
Introduction:Acute Upper GI Bleeding [UGIB] is a common cause of hospital admission
ranging from low risk, not requiring admission and immediate investigation, to life
threatening. It is important to differentiate between the two groups. The Blatchford Score1
[Blatchford] is a clinically based score used on admission to determine the need for interven-
tion; calculated using Hb, urea, pulse, BP and medical history. A score of 0 should allow
immediate discharge and <2 discharge after senior review without inpatient intervention. It
may allow more accurate triage, avoid unnecessary endoscopy and reduce hospital stay Aims/
Methods:We wished to validate Blatchford in our population. We prospectively collected data
on all presentations with suspected UGIB to our hospital over a 3-month period (from Sept
06). Patient demographics, blood results, endoscopy findings (those discharged without
endoscopy were recalled within 4 weeks), length of stay and discharge diagnosis were
recorded. For each patient, we retrospectively calculated their Blatchford to determine if it
would have allowed accurate and safe triage of patients based on outcome. Results:The
preliminary data from the first 6 weeks showed that 134 patients presented [82 M: 52 F,
median age 62 (19-89)] median in patient stay was 4 days (0-33). Findings on upper GI
endoscopy included duodenal ulcers (19.5%), gastric ulcers (9.7%), oesophageal varices
(9.7%) and oesophageal carcinoma (1 case). Discharge diagnoses, other than causes of UGIB,
included delirium tremons, pneumonia, cholangitis and myocardial infarction. Blatchford
scores ranged from 0-19. 14 scored 0, of which 8 had an inpatient endoscopy with the
remaining 6 done within 4 weeks. 10/14 were discharged within 24 hours whilst 4/14 were
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admitted <7 days for reasons other than GI bleeding. Overall, of those with a score of <4
none required intervention, died or had a significant cause for UGIB found. An elevated
score >6 was associated with need for intervention [P<0.001] and a score >10 was associated
with an increased risk of death [p = 0.004]. If we had triaged using Blatchford then no
severe bleed or pathology would have been missed. 19 in patient endoscopies would have
been avoided and 64 in patient days would have been saved. More data will be available
by time of presentation. Conclusions:Blatchford is a suitable and safe means of triage for
UGIB; predicting need for intervention but it is not always an indicator for length of stay
as it does not account for other presentations manifesting as an upper GI bleed. 1Blatchford
O et al. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage.
Lancet 2000; 356: 1318-21.
T1241
Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients:
A Meta-Analysis
Co Q. d. pham, Alan N. Barkun, Marc Bardou, Myriam Martel, Lynda S. Welage
Background: Stress-related mucosal bleeding (SRMB) causes significant morbidity and mortal-
ity. H2-receptor receptor antagonists (H2RA) have been shown to reduce SRMB rates, yet
randomized trials (RCTs) assessing proton pump inhibitors (PPIs) have yielded conflicting
results. Objective: To evaluate the efficacy of PPIs versus H2RAs in the prophylaxis of SRMB
in critically ill adults with risk factors for bleeding. Methods: Searches of the past 4 decades
in MEDLINE, EMBASE, CENTRAL (Q4-2006), and ISI WEB OF KNOWLEDGE were con-
ducted. Only fully published RCTs published in English were included, if the required data
could be extracted. We reviewed all RCTs comparing the efficacy of PPIs to controls (H2RAs,
sucralfate, or placebo). Outcomes measured were the decreases in rates of clinically significant
bleeding (B, primary outcome of the meta-analysis), nosocomial pneumonia (P), and mortality
(M) (secondary outcomes). Study heterogeneity was sought and quantified. Results are
reported as odd-ratios (OR) with 95% confidence intervals using a random effect model
(Review Manager 4.1). Results: Three RCTs met the inclusion criteria; of the 8 arms contained
in these studies, the meta-analysis assessed the six treatments arms that compared PPIs
to H2RAs (omeprazole (n=3), cimetidine (n=1), ranitidine (n=1), and famotidine (n=1)).
Prophylactic PPI administration did not yield any significant decrease in the incidence of
bleeding (N=569 patients, OR 0.41, [0.15;1.14]); with no observed heterogeneity (p=0.26,
I^2=26.4%). Moreover, no statistical differences were apparent for the development of
nosocomial pneumoniae (n=3, N=569 pts, OR=0.72, [0.25;2.10]), in which moderate hetero-
geneity was found p=0.05 I^2=66.7%, or for mortality (n=2, N= 502 pts, OR=1.35,
[0.82;2.22]), for which there was no observed heterogeneity (p=0.95, I^2=0%). Interestingly,
although all studies showed lower rates of bleeding for PPIs versus H2RAs, only one study
with a high rate of bleeding in both groups compared to current general estimates significantly
favored their use. Conclusion: In critically ill patients with recognized risk factors for the
development of SRMB, PPI prophylaxis did not significantly decrease rates of clinically
significant bleeding, nosocomial pneumonia, or mortality. It is possible that the meta-analysis
is currently underpowered to show a significant improvement in bleeding attributable to
PPI's. Additional studies are required to definitively exclude any possible benefit, and as
initial step, an attempt at getting more complete information from trials published in English
only as abstracts is warranted.
T1242
Continuous Versus Intermittent Intravenous Proton Pump Inhibitor (PPI)
Infusion in Patients with Bleeding Peptic Ulcers
Walter W. Chan, J. drew Zimmer, Scott Micek, Sanjay Sikka, Chandra Prakash
The incidence of recurrent bleeding in peptic ulcers disease after hemostasis ranges 5-50%.
Prior studies have shown that treatment with IV PPI in peptic ulcer bleeding reduces
rebleeding rate and need for surgical intervention. However, the benefits of continuous PPI
infusion over intermittent bolus infusion have not been established. We compared rebleeding
rates, transfusion requirement, and need for surgery in patients administered continuous or
intermittent bolus PPI infusion after successful endoscopic hemostasis. Methods: Eligible
subjects were identified by interrogating the endoscopy database at Barnes-Jewish Hospital
from 2003-2005 for patients with acute peptic ulcer bleeding who underwent successful
endoscopic therapy of high risk stigmata (spurting, oozing, and visible vessels). All patients
needed to have received IV PPI therapy and remained hospitalized for at least 72 hours for
inclusion. Patients receiving at least 24 hours of continuous PPI infusion formed the continu-
ous group and the remainder formed the intermittent therapy group. The primary endpoint
was rebleeding, defined by the need for repeat endoscopy or a drop in hemoglobin of ≥ 2
g/dL from the peak level measured after endoscopy, within 7 days of hemostasis. Secondary
endpoints included transfusion requirement and need for surgery after successful hemostasis.
Results: 97 patients fulfilled inclusion criteria [age 65±17 years (range 21-92), 59 males/38
females, 59 (60.8%) gastric ulcers, 38 (39.2%) duodenal ulcers], with 34 (35.1%) in the
continuous infusion group and 63 (64.9%) in the intermittent group. There were no statistic-
ally significant differences in age, gender, symptoms, ulcer sites, stigmata of bleed, hemostasis
strategy employed, and ICU admissions between the two treatment groups. The overall re-
bleeding rate was 35.1% within 7 days of successful endoscopy, with no significant difference
between the continuous group and the intermittent group (15, 44% vs. 19, 30%, p=0.169).
The median number of packed red blood cells transfusion post-endoscopy was 2 (0-3) units
in the continuous group and 2 (1-4) units in the intermittent group (p=0.613). Ten patients
subsequently underwent surgery for refractory bleeding: 5 (15%) in the continuous group
and 5 (8%) in the intermittent group (p=0.296). There was no death in either treatment
group. Conclusions: After at least 24 hours of IV PPI therapy, no statistically significant
differences in re-bleeding rate, transfusion requirement, need for surgical intervention, and
mortality were identified between continuous and intermittent bolus PPI infusion. Clinical
benefits of continuous IV PPI infusion need further evaluation.
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T1243
Assessment of Risk of Gastro-Intestinal Haemorrhage in the Co-Prescription of
Proton Pump Inhibitors As a Gastroprotection Strategy
Glen Doherty, Karen M. Lynch, Karim Z. Ayoubi, Mary D. Cannon, Gavin C. Harewood,
Stephen E. Patchett, Frank E. Murray
AIM - Proton pump inhibitors (PPI) have shown efficacy in reducing the risk of upper
gastrointestinal haemorrhage (UGIH) associated with the use of drugs such as aspirin (espe-
cially in combination with other anti-platelet agents) and non steroidal anti-inflammatory
drugs (NSAIDs). We examined whether current PPI co-prescribing is based on a rational
assessment of the risk of UGIH. METHODS - The admission records of 160 unselected
patients admitted to a large general teaching hospital were reviewed. PPI use at the time of
admission was recorded. The relative risk of significant UGIH was estimated based on a
number of factors: age>70, history of cardiovascular disease, history of peptic ulcer disease
(PUD) or UGIH, use of aspirin, other anti-platelet agents (clopidogrel/dipyrodamole), antico-
agulants, NSAIDs, corticosteroids, Hb<11g/dL on admission to hospital. RESULTS - The
median age of the study population was 74 years (interquartile range 63-82 years). Regular
PPI use was recorded in 61/160 (38%) of the patient population at the time of admission
to hospital. 10% had a documented history of PUD. 61/160 (38%) of patients were taking
regular aspirin and 18/160 (11%) were taking clopidogrel. The proportion of patients
prescribed a PPI was significantly greater in aspirin users than non-users (51% versus 30%,
Fisher exact test, p=0.01) and in clopidogrel users than non-users (72% versus 34%, p=
0.003). PPI use was not significantly greater in those receiving combination anti-platelet
therapy (aspirin and clopidogrel) relative to non-users or those taking one agent only (p=
0.08). Rates of PPI prescription were not significantly different in those taking warfarin,
NSAIDs or corticosteroids. Nimesulide was the single most commonly prescribed NSAID
(6 of 14 patients receiving NSAIDs). PPI co-prescription showed a significant association
with increasing number of risk factors for UGIH (p=0.005, Chi squared test for trend). The
rate of PPI prescription increased from 5% (in those with 0 risk factors) to 57% in those
with 5 or more risk factors for UGIH, however, approximately half of all patients with
multiple risk factors (>3) for UGIH were not co-prescribed a PPI. CONCLUSION - PPI
prescribing as a gastroprotection strategy is widespread but currently does not consistently
take account of the relative risk of UGIH. A large proportion of patients with multiple risk
factors for UGIH are not receiving any gastroprotectant agent.
T1244
Hemostatic Efficacy of Endoscopic Local Injection, Hemoclipping, and Band
Ligation in Patients with Dieulafoy's Disease
Seung yup Lee, Chang keun Park, Hyang eun Seo, Changmin Cho, Wongyoung Tac,
Young oh Kweon, Seong kook Kim, Young hwan Choi
<aim> The Dieulafoy's disease is an uncommon cause of massive upper gastrointestinal
bleeding and surgical resection was believed to be the best treatment in the past. However,
recently endoscopic treatment had been attempted to control the bleeding. Therefore, we
compared the hemostatic efficacy of the local injection, hemoclipping, and band ligation in
the endoscopic management of bleeding Dieulafoy's disease. <method>From January 2000
to July 2004, twenty nine patients who had upper gastrointestional bleeding from Dieulafoy's
disease received endoscopic therapy and were divided into three groups according to proced-
ures: a hypertonic saline epinephrine injection group, hemoclipping group and band ligation
group. All patients had underwent second look endoscopy and were followed for 1 month.
We evaluated clinical and endoscopic characteristics of twenty nine patients and compared
the hemostatic efficacy of endoscopic therapy among three groups. <results> The initial
therapeutic method was hypertonic saline epinephrine injection in ten patients(33.3%),
hemoclipping in seven(26.7%), and band ligation in twelve(40%). There was no statistical
differences in age, sex, hemoglobin values at entry, blood units transfused and duration of
hospital stay among groups. Initial hemostatic success rate was 80% in hypertonic saline
epinephrine group, 71.4% in hemoclipping group, 91.7% in band ligation group. No
statistically significant differences were found among groups(p>0.05). In 11 patients with
successful hemostasis of band ligation group, healing stage ulcer was observed on the ligated
lesion during the follow up period after endoscopic therapy. Only one patient of them had
oozing around the ligated lesion. There was no exposed vessels or ulcers in both groups of
hypertonic saline epinephrine injection and hemoclipping. <conclusion> According to above
results, we suggest that therapeutic endoscopy is the first choice of therapy in arresting
massive hemorrhage found in Dieulafoy's disease. Although with no significant statistical
differences, but high success rate was achieved with band ligation even with complication
such as ulcers.
T1245
Capsule Endoscopy Does Not Interfere with Cardiac Pacemaker Function
Gerard A. Isenberg, Steven Kucera, Richard C. Wong, Amitabh Chak
Background: Capsule endoscopy is firmly established as a diagnostic modality in the evalu-
ation of obscure gastrointestinal bleeding and Crohn's disease and is utilized in the screening
for Barrett's esophagus and esophageal varices. Based on a hypothetical concern that radio
signals from the capsule could interfere with cardiac pacemaker and automated implantable
cardiodefibrillators (AICDs) functions, the FDA required that the manufacturer insert lan-
guage that specifically contraindicates the use of capsule endoscopy in patients with these
devices. Aim: This study was conducted in a prospective fashion to determine if the clinical
use of capsule endoscopy interfered with cardiac pacemaker function. Methods: Patients
with cardiac pacemakers requiring capsule endoscopy evaluation were enrolled. Each patient's
pacemaker was interrogated prior to ingestion and after the study was completed. Each
patient was monitored on telemetry throughout the procedure for a total of 12 hours. All
events associated with pacemaker malfunction and capsule imaging malfunction were
recorded. A retrospective review of all capsule endoscopy imaging malfunctions (in a pro-
spectively collected database) was conducted in patients who did not have cardiac pace-
makers. Results: 43 patients (31 men; 12 women; mean age 69, range 41 - 95) were
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enrolled. The indications for small bowel capsule endoscopy (41 total) were obscure-overt
gastrointestinal bleeding (22), obscure-occult gastrointestinal bleeding (13), possible small
bowel Crohn's disease (4), polyposis syndrome (1), and possible small bowel intussusception
(1). The indications for esophageal capsule endoscopy (2 total) were screening for esophageal
varices. No detectable pacemaker malfunction occurred with any of the patients. No arrhy-
thmia or other adverse cardiac event was noted during capsule transmission. A low signal
from the capsule device resulted in lack of localization in one patient. However, capsule
imaging was normal. Review of capsule imaging malfunction in patients without pacemakers
revealed 3 patients with low signals and 2 patients with failed capsule imaging. Conclusions:
In our single-center experience with 43 patients, the largest reported to date, there was no
demonstrated interference with cardiac pacemaker function in patients undergoing capsule
endoscopy. The radiofrequency band used by capsule image transmission does not appear
to be sensed by cardiac pacemakers. Conversely, the presence of a pacemaker does not
appear to interfere with capsule imaging. Consideration should be made to revise the
manufacturer's insert regarding contraindication in patients with cardiac pacemakers.
T1246
Superior Small Bowel Cleansing Is Associated with Improved Odds of
Definitive Treatment Following Wireless Capsule Endoscopy (WCE)
Theodore Schroeder, Corey S. Brotz, Neilanjan Nandi, Mitchell Conn, Constantine
Daskalakis, Michael Dimarino, Anthony Infantolino, Leo C. Katz, David M. Kastenberg
The current standard WCE prep, clears after lunch the day prior and then fasting after
10pm, may be inadequate. This is supported by studies utilizing a variety of non-validated
grading schemes to assess small bowel cleansing. We prospectively validated a new quantitat-
ive index (QI) to evaluate small bowel cleansing for WCE. As a secondary outcome, we
studied the relationship between prep quality and outcome after WCE as measured by
initiation of definitive treatment. Additionally, we evaluated the relationship between prep
quality and WCE findings. METHODS: 40 outpt WCE's were de-identified (except land-
marks), randomized, and prospectively scored by 5 investigators using our QI. 4 weeks
later, these 40 WCE's were again randomized and scored by 4/5 investigators. Studies were
read in the QuadView at a viewing speed of 30. The QI consisted of 5 elements - % mucosa
visualized, fluid & debris, bubbles, bile/chyme staining, brightness. Each was graded using
a 3-point scale (2=minimal/mild impairment, 1=moderate impairment, 0=severe impairment;
range 0-10, higher score=better prep). These 40 charts were retrospectively reviewed to
determine whether definitive treatment followed WCE, and to classify findings as “related”
or “unrelated” to the indication for WCE. We used logistic regression to investigate the
association between WCE prep quality (QI) and the receipt of definitive treatment as well
as the presence of WCE findings. RESULTS: Mean age was 49+19 yrs, and 62.5% were
female. The most common indications were: GI bleed (57.5%), abdominal pain (47.5%),
diarrhea (35%), and anemia (27.5%). Prior evaluation included EGD (67.5%), colonoscopy
(72.5%), and cross-sectional abdominal imaging (47.5%). Follow-up for pts ranged between
8 and 315 days (median = 127 days). Definitive treatment followed WCE in 25 (63%) pts.
Symptoms spontaneously improved for 6 (15%) pts and were unresolved in 9 (23%).
Adjusting for pt characteristics (age, sex, weight), each additional point in the QI increased
the odds of definitive treatment by 42% (adjusted OR = 1.42, p = 0.004). WCE revealed
findings in 31 pts (78%): 20 pts with 1 finding, 8 pts with 2 findings, and 3 pts with 3
findings. Fourteen patients (35%) had findings that were considered WCE-related, and 22
patients (55%) had findings that were considered WCE-unrelated. Superior prep quality
was not significantly associated with an increase in the number of related, or total, WCE
findings. CONCLUSIONS: As the quality of the small bowel prep improves, so too do the
odds of definitive treatment following WCE. However, the odds of detecting findings during
WCE did not increase as the quality of the prep improved.
T1247
Efficacy of Double Balloon Enteroscopy (DBE) Initiated Interventions and
Sensitivity of DBE Regarding Long Term Outcome - A Follow-Up Study of a
DBE Examined Single Center Patient Cohort
Christian Maaser, Maja Bokemeyer, Andre Schmedt, Hansjoerg Ullerich, Dirk Domagk,
Jan Heidemann, Wolfram Domschke, Torsten Kucharzik
Background: Double balloon enteroscopy (DBE) has become a standard endoscopic method
for the small bowel. Several studies have described the diagnostic and therapeutic potential
in initial patient cohorts examined. While DBE is a significant progress for evaluation of
the small bowel, several questions remain. The aim of this follow-up study was to determine
the effectiveness of therapeutic interventions for the long term outcome and to follow those
patients with a normal DBE regarding pathologic findings during follow up. Methods: Of
the 152 patients who received a DBE in our department at least 6 month before 09/06 (=
timepoint of follow-up), 132 (=87%) were followed regarding continuation or recurrence
of initial symptoms, reinterventions, and new pathologic small bowel findings. The remaining
20 (=13%) were lost to follow-up. Results: As most of the 132 patients were examined via
oral and anal route, a total of 245 procedures were performed. In 26/86 patients with
obscure bleeding a source was detected, which led to a therapeutic consequence in 23 of
those 26. A suspected Crohn s manifestation of the small bowel could be verified in 9/29
patients, which led to changes in therapy in 8/9. Furthermore, in 3/10 patients with suspected
small bowel neoplasia DBE actually detected a neoplasia, which led to a therapy in all 3,
and in 2/7 with various indications for DBE a pathologic finding (1 jejunal celiac disease,
1 foreign object) could be localized, leading to consequences in both patients. The overall
detection rate of 34% led to a therapeutic consequence in 90%. Of the 23 patients with a
therapeutic intervention due to bleeding, symptoms reoccurred in 4 within 3 month, all of
them needing further therapy. In the other 19 patients no further bleeding was detected
during follow up of >6 month after intervention. Of the 60 patients with initial obscure
bleeding but normal DBE, bleeding reoccurred and a small bowel bleeding source was
detected within the follow up of > 6 month post initial DBE in 10/60 patients (16.7%). 7/
8 patients treated for Crohn s disease significantly improved regarding clinical activity. In
2/20 (10%) patients with suspected small bowel Crohn s disease but normal DBE a Crohn
s manifestation could be detected in the following >6 month, while symptoms in the other
18 stoped. In 3/7 (42.9%) patients with initial normal DBE a neoplasia was detected during
follow up by various methods. Conclusions: DBE initiated interventions proofed effective
regarding long term outcome. However, as in 18% with initial normal DBE small bowel
pathologies were detected during follow up, further investigations are required to enhance
the sensitivity.
T1248
EUS-Guided Trucut Biopsy Versus EUS-Guided Fine Needle Aspiration; An
Evaluation of 67 Patients with Mediastinal Lesions
Robert C. Scheffer, Mark F. Stolk, Cees A. Seldenrijk, Peter Bruin de, Robin Timmer, Bas
Weusten
Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) is a sensitive method to
obtain cytological specimen from solid lesions in close proximity to the gastrointestinal tract.
Whilst FNA provides cells for analysis, large-calibre tru-cut biopsy (EUS-TCB) needles give
specimens that can be used for histopathological analysis as well. We assessed the additional
diagnostic yield of EUS-TCB in patients with solid mediastinal lesions in whom EUS-FNA
was performed. In the period from July 2003 to November 2006, 67 patients with mediastinal
lesions, accessible to EUS-FNA and EUS-TCB, were included in the study. In all patients,
a mean of three passes of EUS-FNA (EchoTipUltra 22 GA) was followed by EUS-TCB using
the Quick-Core (19GA) biopsy needle. Cytological and histological specimen were evaluated
by two pathologists, blinded for patients' condition. A final diagnosis was obtained by
combining all information present (EUS-FNA & EUS-TCB results, mediastinoscopy, broncho-
scopy (if performed) and other investigations). Mean size of the lesions investigated was
23.7 ± 13.6 x 43.1 ± 14.3 mm. A total of 72 biopsies were obtained. No puncture related
complications were encountered. The final diagnosis consisted of sarcoidosis (38%), non-
small cell lung cancer (5%), small cell lung cancer (7%), TBC (3%), and miscellaneous
(47%). The diagnostic accuracy of EUS-FNA and EUS-TCB was 90% and 83% respectively
(P>.05). In EUS-FNA-negative patients, EUS-TCB provided a final diagnosis in an additional
4 patients (6%), whereas EUS-FNA was positive in 5 EUS-TCB negative patients (7%). In
4 (6%), both FNA and TCB were inconclusieve. Conclusion: The diagnostic yield of EUS-
FNA and EUS-TCB is comparable. EUS-TCB can provide additional information leading to
a final diagnosis in a subset of patients in whom EUS-FNA is negative.
T1249
Can MRI Enteroclysis Distinguish Inflammatory Changes from Fibrosis in
Small Bowel Crohn's Disease?
Dev S. Segarajasingam, Chris Weltman, Jillian Philpott, Ian C. Lawrance
BACKGROUND: MRI enteroclysis to image the small bowel (SB) in Crohns' disease (CD)
has the advantage of no radiation and the potential to assess extraluminal pathology. Tradi-
tionally, MRI enteroclysis in adults requires nasojejunal intubation, often resulting in signific-
ant patient discomfort. METHODSs: Patients referred between Jan 2005 and April 2006 for
MRI enteroclysis with a history or suspicion of SB CD were assessed. The aims were to
assess adequacy of imaging using a paediatric protocol of oral PEG without nasojejunal
intubation, and to determine MRI ability to distinguish inflammatory from fibrotic SB CD.
The radiographic parameters of bowel wall thickness and enhancement, lymphadenopathy
and fibrofatty proliferation were used to distinguish inflammatory from fibrotic disease.
Clinical response to therapy in patients considered to have inflammatory disease on MRI
was determined using the Harvey Bradshaw Index (HBI) and inflammatory markers. The
pathological findings in patients who underwent surgery were correlated with the MRI
impression. RESULTS: Thirty patients were referred for MRI enteroclysis. Twenty-four had
and 6 were suspected of having SB CD. Only 1 patient did not tolerate the proceudre, but
in the remaining 29 (97%) adequate imaging of the SB was obtained. Fourteen patients had
suspected inflammatory disease of which 3 underwent surgical resection that confirmed
inflammatory and not fibrotic disease. The other 11 responded to therapy for inflammation
with normalisation of the HBI and the inflammatory markers. Three patients had suspected
isolated fibrotic disease, 2 of which underwent surgery that confirmed fibrotic disease and
1 refused surgery and responded to medical therapy. Five patients had MRI findings of
mixed inflammatory and fibrotic disease, 1 responded to anti-inflammatory medical therapy
and 4 underwent surgery that confirmed the MRI impressions. Eight patients had a normal
MRI, of which 7 responded to non-CD related therapy. The final patient with a normal MRI
had a SB resection with moderate ileal inflammation on pathology. MRI correctly determined
the pathology in 9/10 operated patents. In non-operated patients, MRI findings of inflammat-
ory changes accurately predicted response to anti-inflammatory medical therapy. CONCLU-
SION: MRI enteroclysis using oral administration of PEG instead of nasojejunal intubation
was well tolerated and achieved adequate imaging of the SB. MRI radiographic parameters
were able to distinguish inflammatory from fibrotic disease and predict response to anti-
inflammatory medical therapy.
T1250
Intravenous Glucagon As a Premedication for 3d-MRCP in Patients with
Contraindication of Scopolamine Butyl-Bromide (Buscopan)
Tetsuya Yamagishi, Takashi Kawai, Takao Itoi, Kimihiko Abe
Purpose: Three-dimensional (3D) MRCP tends to be affected by the motion artifacts of
gastrointestinal peristalses because of its relatively longer examination time than 2D method.
We evaluate the efficacy of intravenous Glucagon chloride (IVGC) for improving the delineat-
ing capabilities of 3D-MRCP in patients with contraindication of anti-cholinergic agents.
Methods and Materials: Thirty-six patients (42-78 year, glaucoma=10, cardiac arrhythmia=
14, prostate hyperplasia=12) scheduled for MRCP were allocated to this study. Before and
after 1mg of IVGC, the source slice data (0.8mm, 96 slices) were acquired in coronal planes
with a navigator gated respiratory-triggering (Prospective Acquisition Correction: PACE)
using a 1.5T MR system. Qualitative assessment was performed with maximum intensity
projection (MIP) images by five-point scoring by board-certified endoscopists immediately
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after examination (without any segmentation). Quantitative analysis was performed with the
source images by calculating contrast-to-noise ratio (CNR). The data after IVGC were com-
pared with those before statistically. The profit for reducing the burden of film reading was
also investigated. Results: The mean time of examination was 28.1 min (no significant
difference between before and after IVGC). All investigators scored the MIP after IVGC as
more excellent than before. The mean value of CNR after IVGC was significantly higher
than before (P<0.05) in all cases. Conclusion: Resultant images after IVGC could reduce
the motion artifacts due to spasmodic movements and facilitated an accurate grasp of
the entire pancreaticobiliary system, even in the degraded segments, by overlaid ghost of
motion artifact.
T1251
Capillary Diameter Distribution As a Biomarker for Pancreatic Ductal
Adenocarcinoma
Ken Y. Lin, Marco Maricevich, Ralph Weissleder, Umar Mahmood
Pancreatic ductal adenocarcinoma (PDAC) carries the worst prognosis of all cancers in part
because early diagnosis is difficult. Here we sought to detect changes in PDAC capillary
diameter distribution using a minimally invasive, micro-catheter guided intravital confocal
laser microscopic imaging system. We used a mouse model of orthotopic PDAC harboring
mutations in K-ras, Ink4a, ARF, and Smad4 genes - signature mutations found in human
PDAC. We tail-vein injected the fluorescent blood pool agent Angiosense 680 two weeks
after tumor implantation, and imaged the pancreas using the Cellvizio fiber-optic confocal
laser miniprobe. The miniprobe has a field of view of 423x423 micron, a lateral and axial
resolution of 3.5 and 15 micron, and a diameter of 1.5 mm. Dynamic sequences are acquired
at a frame rate of 12 images/second and single frames can be exported. Six random views
of pancreas were obtained in each mouse. A segmentation algorithm was applied to each
image to obtain the number of counts of a particular diameter capillary within an interval
of 0.5 micron. Normal pancreatic capillary's diameter histogram forms three peaks. First
peak (group 1) consists of capillaries with diameter from 0 to 10 micron. This group has
the highest proportion of the total capillaries (52.33±12.42%). The next peak (group 2)
consists of capillaries with diameter from 10 to 16 micron, and it represents 31.21±2.25%
of the total capillaries. The last major peak (group 3) of capillaries consists of those with
diameter from 16 to 26 micron, and it represents 4.13±0.98% of the total capillaries. Tumor
capillary diameter histogram also forms three peaks, but their proportion differs significantly
from that of the normal pancreatic capillaries. Group 1 capillaries comprises 35.55±6.11%
of the total capillaries while Groups 2 and 3 comprise 45.15±4.88% and 13.76±0.85% of
the total capillaries. Compared to the normal pancreatic capillaries, PDAC capillaries represent
a statistically significant shift from group 1 to the groups 2 and 3 capillaries. In other words,
PDAC capillaries are larger and may contribute to the increased volume fraction observed
in tumors. Using optical imaging, we found that PDAC microvasculature diameter histogram
can be characterized precisely and separated into 3 groups like the normal pancreatic
capillaries. However, PDAC capillaries show a significant increase in larger-diameter vessels
and a concurrent decrease in smaller-diameter vessels. This difference can potentially serve
as a biomarker for detecting early microvascular changes in PDAC, making this imaging
technique a possible component of the neoadjuvant therapy.
T1252
Usefulness of Contrast-Enhanced Ultrasonography in the Differential
Diagnosis of Cystic Lesions of the Pancreas
Naoko Kurihara, Hirofumi Kawamoto, Yuko Okamoto, Ryo Harada, Koichiro Tsutsumi,
Masakuni Fujii, Tsuneyoshi Ogawa, Etsuji Ishida, Hirotoshi Fukatsu, Kohsaku Sakaguchi
[Background] The differential diagnosis of cystic lesions of the pancreas is sometimes difficult
to make with imaging modality. The purpose of this study is to evaluate the usefullness of
contrast-enhanced ultrasonography (CE-US) in the differential diagnosis of cystic lesions of
the pancreas. [Patient and method] Between October 2003 and October 2006, 20 patients
with cystic lesions of the pancreas (8 women and 12 men; mean age, 69 (55-84) years old),
were enrolled in this study. They were 16 intraductal papillary mucinous neoplasms (IPMN),
2 serous cystic tumors (SCT), 1 solid-pseudopapillary tumor (SPT) and 1 pseudocyst. All
patients were treated surgically and the histological diagnosis was confirmed by resected
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specimen. CE-US was performed with SSA770A (TOSHIBA Aplio) by using the contrast
agent (Levovist) under the advanced dynamic flow (ADF). We evaluated lesion enhancement
in two phases (ie. the vascular image phase and the perfusion image phase). [Result] IPMN:
Thirteen of 16 resected specimen had mural nodule. Ten nodules (78.9%) were detected
by using CE-US. The mean size of nodules were 6 mm (range, 3-50 mm). In the vascular
image phase, small vessel in the mural nodule was detected in 7 (70%). In perfusion image
phase, cystic walls as well as mural nodules were also enhanced. SCT: The tumor was
strongly enhanced at the beginning of the vascular image phase. During the perfusion image
phase, the numerous tiny cystic structures were more clearly depicted by CE-US. SPT: The
tumor showed a peripheral rim enhancement in the vascular image phase. In the perfusion
image phase, the enhancement effect of the tumor emerged later than that of pancreatic
parenchyma was demonstrated. Pseudocyst showed a sharply delineated wall was only
enhanced. [Conclusion] CE-US with Levovist is feasible to evaluate the small vessel in the
mural nodules in IPMN. It is also useful differential diagnosis of pancreas cystic lesions.
T1253
A Validation Study of 3 Grading Systems to Evaluate Small Bowel Cleansing
for Wireless Capsule Endoscopy (WCE): A Quantitative Index, Qualitative
Evaluation, and Overall Adequacy Assessment
Corey S. Brotz, Neilanjan Nandi, Theodore Schroeder, Mitchell Conn, Constantine
Daskalakis, Michael Dimarino, Anthony Infantolino, Leo C. Katz, David M. Kastenberg
Adequate bowel cleansing is mandatory for WCE. The current standard prep is clears after
lunch the day prior and then fasting after 10pm. Several studies, published and in abstract,
suggest this protocol is inadequate. These reports utilize multiple, non-validated small bowel
grading schemes. We have prospectively validated 3 new grading systems for small bowel
cleansing - a quantitative index (QI), qualitative evaluation (QE), and overall adequacy
assessment (OAA). METHODS: 40 outpt WCE's were de-identified (except landmarks),
randomized, and prospectively scored by 5 investigators using our QI, QE and OAA. 4
weeks later, these 40 WCE's were again randomized and scored by 4/5 investigators. Studies
were read in the QuadView at a viewing speed of 30. The QI consisted of 5 elements - %
mucosa visualized, fluid & debris, bubbles, bile/chyme staining, brightness. Each was graded
using a 3-point scale (2=minimal/mild impairment, 1=moderate impairment, 0=severe
impairment; range 0-10, higher score=better prep). The QE consisted of 4 ratings - poor,
fair, good, or excellent; detailed descriptors were provided. The OAA was scored as adequate
or inadequate. We used the intraclass correlation coefficient (ICC) to assess intra-reader
(test-retest) and inter-reader reliability of the QI, and the unweighted kappa statistic to
assess the reliability of the QE and OAA. RESULTS: Mean age was 49+19 yrs, and 62.5%
were female. The most common indications were: GI bleed (57.5%), abdominal pain (47.5%),
diarrhea (35%), and anemia (27.5%). Intra-reader reliability for the QI was good with an
ICC value of 0.62 (95% CI, 0.35 to 0.79), and in the moderate-good range for the adequacy
assessment at 0.57 (95% CI, 0.285 to 0.755). The intra-reader overall kappa statistic for
the QE was in the fair-moderate range at 0.38. However, contrasting poor/fair cases to
good/excellent cases, this dichotomized qualitative evaluation had 96% sensitivity and 92%
specificity with respect to the overall rating (adequate/inadequate). Across physicians and
readings, the QI was significantly associated with the QE of the prep quality (p = 0.001),
as well as the overall adequacy rating (adjusted odds ratio, OR = 7.00, p = 0.001). Agreement
between physicians (inter-reader reliability) was consistently lower - moderate for the QI
(0.49; 95% CI, 0.22 to 0.68) and OAA (0.48; 95% CI, 0.357 to 0.597) and poor for the
QE (0.168; 95% CI, 0.083 to 0.243). CONCLUSIONS: We have developed and validated
3 grading systems that assess small bowel cleansing for WCE. Intra-reader reliability was
consistently better than inter-reader reliability. These grading systems may have practical
and research applications.
T1254
In Vivo Diagosis of Acute Intestinal Graft-Versus-Host Disease By Confocal
Endomicroscopy
Christian Bojarski, Kathrin Rieger, Christoph Loddenkemper, Ute Günther, Lutz Uharek,
Martin Zeitz, Jörg c. Hoffmann
Background: Graft-versus-Host-Disease (GvHD) is a rare but severe complication after allog-
eneic stem cell transplantation. The gold standard in diagnosing GvHD is conventional
histology with H & E staining. Diagnostic sigmoidoscopy is a useful method to get tissue
samples of the colon, immunhistological exclusion of CMV-colitis is obligatory. Since most
of these patients have thrombocytopenia acquisition of biopsies is associated with a high
risk of gastrointestinal bleeding. Methods: Patients scheduled for sigmoidoscopy with acute
diarrhea after stem cell transplantation were examined with the confocal laser endomicroscope
developed by Pentax, Tokyo (EC-3870CIFK), generating confocal images of the upper
mucosal layer from 0-250 µm during ongoing endoscopy. Intravenously injected Fluorescein
10% and topically applied Acriflavine 0.05% allowed the assessment of cellular and subcellu-
lar structures. Grading of GvHD was performed due to the classification of Sale & Shulman.
Results: 6 patients with acute diarrhea after stem cell transplantation were examined. In two
patients endomicroscopy and histology was negative for GvHD. In one of two patients with
GvHD grade I no endomicroscopic changes were visible. One patient with GvHD grade II
a showed high numbers of apoptotic epithelial cells on endomicroscopy. One patient was
identified having GvHD grade III-IV. In this patient a nearly complete destruction of the
crypts (“crypt-drop-out”) was clearly visible during endomicroscopy and was confirmed by
histology. Discussion: Confocal laser endomicroscopy can detect acute intestinal GvHD grade
II-IV in this small series while GvHD grade I was not detected in one patient. This seems
to indicate that confocal laser endomicroscopy when positive for GvHD has a high specificity
although the sensitivity in mild forms might be low. If larger studies confirm these data,
however, unnecessary biopsies in these patients can be avoided.
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T1255
Confocal Endomicroscopy with Topical Cresyl Violet Staining
Martin Goetz, Markus Neurath, Michael Vieth, Peter R. Galle, Ralf Kiesslich
Introduction: Confocal endomicroscopy with fluorescein has been shown to reliably predict
histology during ongoing endoscopy, but fluorescein has to be injected intravenously, leads
to a transient discoloration of the skin and might have allergic side effects. In this ongoing
study, we used topical cresyl violet (CV) for simultaneous chromoendoscopy and In Vivo
confocal microscopy of the lower GI tract in mice and men. Methods and Patients: To
establish the staining characteristics and optimal concentration of CV, the ileum and colon
of 7 BL6 mice were stained with CV (0.1 to 2%). In Vivo confocal imaging was performed
with FIVE1 (Optiscan, Australia), that has optical features comparable to the endomicroscope.
In n=10 patients so far, CV 1% was sprayed onto the mucosa, and subsurface serial confocal
images were generated at different depths with the endomicroscope (Pentax EC-3870CIFK,
Japan) in real time at 1024x1024 pixels with an optical slice thickness of 7µm and a lateral
resolution of 0.7µm. Results: Endomicroscopy with CV 1% applied topically yielded (sub-
)cellular details of the GI mucosa at different infiltration depths. Typical features of normal
mucosa, regenerative and neoplastic changes were visualized in similar resolution as with
the use of intravenous fluorescein, although infiltration depth was limited to the upper 50
µm of the mucosa. Endoscopic prediction correlated well with histopathology. Conclusions:
Cresyl violet can be applied topically and allows simultaneous confocal imaging at high
resolution and chromoendoscopy. It may therefore be an alternative to intravenous fluorescein
in endomicroscopy.
Confocal endomicroscopy with CV of normal human colon mucosa.
T1256
Endoscopic Full-Thickness Resection (EFTR), a New Technique for Treatment
of Gastric Malignancies
Masakazu Yasumaru, Shingo Tsuji, Masahiko Tsujii, Shusaku Tsutsui, Toshiyuki Yoshio,
Sachiko Nakajima, Shuji Ishii, Shinichiro Shinzaki, Satoshi Egawa, Takanobu Irie,
Tsutomu Nishida, Yoshimi Kakiuchi, Hideki Iijima, Sunao Kawano, Norio Hayashi
[Background and aim] Endoscopic mucosal resection (EMR) or endoscopic submucosal
dissection (ESD) has been widely accepted as a minimally invasive treatement for early
neoplastic gastrointestinal lesion. However, it is still difficult to resect mucosal lesions with
ulcerations or ulcer scars even using these procedures. Moreover, dissection of the mucosa
is disadvantageous for histological diagnosis of the cancer invasion. Neither EMR nor ESD
is applicable for evaluation and treatment of submucosal tumors including gastrointestinal
stromal tumors (GISTs). The aim of the present study was to develop a new technique,
endoscopic full-thickness resection (EFTR) to overcome these disadvantages of EMR and
ESD. [Materials and Methods] Porcine stomach was prepared and used as a stomach model.
A two-channnel endoscope was inserted in the stomach lumen, where the targeted corpus
legion was assumed. A metallic snare is passed through one channel and opened around
the lesion. A forceps was passed through the other channel to grasp and elevate the lesion.
The snare was gently closed around the lesion and was left throughout the procedure. The
other polypectomy snare is passed through the biopsy channel and gently snugged above
the first snare. Electric cautery is applied to resect the lesion and the remaining stomach
was sutured by clipping. The resected specimen and the remaining stomach were examined
macroscopically and histologically. [Results]Macroscopic and microscopic examination con-
firmed that the lesions were resected successfully with the surrounding gastric wall. A gastric
perforation did not occur macroscopically. [Discussion] The results demonstrate that EFTR
is a novel, safe and potentially promising procedure for the treatment of non-metastatic
gastrointestinal cancers and submucosal tumors. EFTR has several advantages over EMR
and ESD by minimizing technical difficulties and by making the histological evaluation easy.
Moreover, EFTR makes it possible to diagnose early stages of GISTs, where fine-needle
aspiration is difficult to perform. Further examination is warranted for the evaluation of the
efficacy and safety of the procedure using animal models In Vivo.
T1257
Diagnostic and Therapeutic Impact of Double-Balloon Enteroscopy (DBE) in a
Series of 100 Patients with Suspected Small Bowel Diseases
Alessia Cazzato, Giovanni Cammarota, Enrico C. Nista, Paola Cesaro, Lucia Sparano,
Paolo Fedeli, Giovanni Gasbarrini, Antonio Gasbarrini
Background: Double-Balloon Enteroscopy (DBE) is a newly developed endoscopic method
allowing non-surgical full-length exploration of the small bowel, biopsies sample and endos-
copic treatment of previously inaccessible lesions. Aim: To prospectively assess the diagnostic
yield and therapeutical impact of DBE in patients with suspected or documented small
bowel disease. Patients and Methods: One hundred consecutive patients referring to our
center for suspected small bowel disease, underwent Double-Balloon Enteroscopy (DBE).
Starting insertion route (anal or oral) of DBE was chosen according to the estimated location
of the suspected lesions basing on the clinical presentation and on the findings, when
available, of previous endoscopic (CE) or radiological investigations. Major indications for the
procedures were acute recurrent or chronic mid-gastrointestinal bleeding (n=71), suspected
gastrointestinal tumours (n=10), suspected Crohn's disease (n=6), chronic abdominal pain
and/or chronic diarrhoea (n=8), refractory celiac disease (n=5). Results: One hundred and
eighteen DBE procedures were carried out. Oral and anal routes DBEs were performed in 54
and 28 patients, respectively, while 18 patients underwent a combination of both approaches.
Overall diagnostic yield of DBE resulted 69%. Most common pathological findings included
angiodysplasias (n=39), ulcerations and erosions of various aetiologies (n=21), tumours (n=
7), and ileal stenosis in patients with Crohn's disease suspicion (n=2). In the 65% of the
patients examined, DBE findings influenced the subsequent clinical management (endoscopic,
medical or surgical treatment). No major complications related to the procedure occurred.
Conclusions: Our prospective analysis shows as DBE is a useful, safe and well-tolerated new
method with a high diagnostic yield and therapeutic impact for the management of suspected
or documented small bowel diseases.
T1258
Fourier Transform Infrared (FTIR) Spectroscopy of the Colon - An Application
Towards In Vivo Analysis of Colonic Neoplasia
Mark A. Mackanos, John Hargrove, Christine B. Du, Larry K. Wong, Rolf Wolters, Allen
Poirson, Christopher H. Contag, Thomas D. Wang
Background and Aims: In the U.S., 148,000 new diagnoses and 56,000 deaths occur each
year due to colon cancer. New methods for the early detection of this disease are needed.
Currently, random biopsies in the colon are recommended. The probability of detection
increases with the number of biopsies; however, time, cost, and probability of complications
also increase. The use of FTIR spectroscopy may allow for both more accurate guided
biopsies and discrimination between neoplastic tissues In Vivo. Based on our previous
esophageal studies, it is possible to distinguish between various pathologies on ex vivo
samples. We have two main goals: 1) analyze colon samples to determine whether or not
the method applied to the esophagus holds for colon cancer detection and discrimination,
2) study various probe designs and materials for an In Vivo application of this method.
Methods: We collected ex vivo FTIR spectra from fresh biopsy specimens of normal colonic
mucosa and polyps from patients undergoing routine colonoscopy at the Veterans Affairs
Palo Alto Health Care System. One pinch biopsy was taken from each polyp, or normal
sample, on which both standard pathology and FTIR measurement was performed. Samples
were dried via blowing cool air over the sample for 1 minute to remove the background
water signal prior to analysis with a Thermo Electron Nexus 470 spectrometer. Twenty co-
added scans were collected from 400 to 4000 cm-1 with a 2 cm-1 resolution. Standard
histopathology with H&E staining was performed on each biopsy for comparison. Concur-
rently, numerous probe materials, and geometries were modeled and tested to determine
the relevant parameters necessary for In Vivo application. Results: We collected 33 spectra
of 26 normal samples from 14 patients and 85 spectra of 70 polyp samples from 13 patients.
Spectra were classified using partial least-squares discriminant analysis. Thousands of unique
combinations of pre-processing methods and over the spectral range were investigated and
the classification accuracy of each was assessed through cross-validation. There is a marked
difference in the spectra between normal and hyperplastic tissue; particularly, due to the
absence of the phospholipid peak at 1750 cm-1. Adenomas were distinguished from normal
colon with a sensitivity and specificity of 83% and 77%, and from hyperplastic polyps with
a sensitivity and specificity of 86% and 78%. Conclusions: It is possible to detect and
distinguish between normal, hyperplastic, and adenomatous colon tissue through FTIR
spectroscopy. In addition, our analysis of probe materials and design show that further
development of an In Vivo probe is warranted.
T1259
Capsule Endoscopy Can Make the Diagnosis of Celiac Disease When
Duodenal Biopsy Fails
Shanti Eswaran, Moshe Rubin, Peter H. Green
Because severe and debilitating complications may occur in patients with even mild symptoms
of celiac disease (CD), diagnosis and treatment is important. It is recognized that relying
on duodenal biopsies for diagnosis may be problematic, and in equivocal cases, further
diagnostic tests are necessary. Video capsule endoscopy (VCE) findings in CD have been
characterized and have a very high sensitivity for the presence of severe villous atrophy.
We present 8 patients in whom VCE firmly established the diagnosis of CD when biopsies
were non-diagnostic or unavailable. Methods: Of 96 VCEs performed at our center on
patients diagnosed with CD between August 2002 and October 2006, 8 patients were
identified in whom the diagnosis of CD was made only after results of a capsule endoscopy.
Results [see table]: VCE demonstrated findings consistent with celiac disease in all patients.
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In patients 1, 2, 3, and 4, duodenal biopsies were negative for villous atrophy when reviewed.
Patients 1, 2, 3, and 5 had only extra-intestinal manifestations associated with CD. Patient
4 had a complicated clinical presentation with a significant travel history, a favorable HLA
genotype, heme positive stools, multiple negative endoscopies with negative serologies, and
a previous diagnosis of small bowel Crohn's disease. In patients 5, 6, and 7, EGD and biopsy
were not possible due to patient preference or bleeding diathesis. Patient 8 presented with
abdominal pain and intussusception on CT scan. Subsequent VCE showed findings consistent
with celiac disease, which was later confirmed with EGD and duodenal biopsy. Conclusions:
The diagnosis of celiac disease may be established by the presence of capsule findings that
have a high correlation with severe villous atrophy. VCE has a role in the diagnosis of CD,
and may in some cases obviate the need for biopsy.
T1260
The Standard Preparation for Wireless Capsule Endoscopy (WCE) Is
Substandard
Neilanjan Nandi, Corey S. Brotz, Theodore Schroeder, Mitchell Conn, Constantine
Daskalakis, Michael Dimarino, Anthony Infantolino, Leo C. Katz, David M. Kastenberg
Adequate visualization of the small bowel is mandatory for WCE, as this technology does
not permit flushing and suctioning. Currently, the standard WCE prep is clears after lunch
the day prior and then fasting after 10pm. Several studies, published and in abstract, suggest
this protocol is inadequate. These investigations utilize various non-validated small bowel
grading schemes. As part of a validation study of 3 new small bowel grading systems - a
quantitative index (QI), qualitative evaluation (QE), and overall adequacy assessment (OAA)
- we prospectively reviewed 40 standard prep WCE's performed at our institution.
METHODS: 40 outpt WCE's were de-identified (except landmarks), randomized, and pro-
spectively scored by 5 investigators using our QI, QE and OAA. 4 weeks later, these 40
WCE's were again randomized and scored by 4/5 investigators. Studies were read in the
QuadView at a viewing speed of 30. The QI consisted of 5 elements - % mucosa visualized,
fluid & debris, bubbles, bile/chyme staining, brightness. Each was graded using a 3-point
scale (2=minimal/mild impairment, 1=moderate impairment, 0=severe impairment; range
0-10, higher score=better prep). The QE consisted of 4 ratings - poor, fair, good, or excellent;
detailed descriptors were provided. The OAA was scored as adequate or inadequate. We
report the combined results for both readings of the 40 WCE's. RESULTS: Mean age was
49+19 yrs, and 62.5% were female. The most common indications were: GI bleed (57.5%),
abdominal pain (47.5%), diarrhea (35%), and anemia (27.5%). Using the OAA, 28.5% of
all studies were inadequate. The QE identified 29.3% of studies as either poor (8.9%) or
fair (20.4%) in quality. A dichotomized QE (contrasting poor/fair cases to good/excellent
cases) had 96% sensitivity and 92% specificity with respect to the overall rating (adequate/
inadequate). The QI was significantly associated with the qualitative score (p=0.001), with
scores of 4.0 when the prep was poor, 6.5 when it was fair, 9.1 when it was good, and 9.9
when it was excellent. The QI was also significantly associated with the OAA; A 1-point
increase in the QI score was associated with a sevenfold increase in the odds of the WCE
prep being judged adequate (adjusted odds ratio, OR = 7.00, p = 0.001). A chart review
revealed only 1 case (2.5%) in which a repeat WCE was recommended. CONCLUSION:
The current standard small bowel prep for WCE is inadequate ~ 30% of the time.
T1261
A Novel Intravenous Iron Formulation for Treatment of Anemia in IBD: The
Ferinject Randomized, Controlled Trial
Stefanie Kulnigg, Vitaly Rumyantsev, Simeon Stoinov, Vladimir Simanenkov, Elena
Levchenko, Waldemar Karnafel, Luis Chaires garcia, Geert D’haens, Christoph Gasche
BACKGROUND: Anemia is a common complication in IBD caused by various degrees of
iron deficiency and anemia of chronic disease. Recently, a new parenteral iron preparation,
iron carboxymaltose (FeCarb; Ferinject, Vifor Int.) was developed that can be administered
iv at single and repeated high doses up to 1000mg within 15 min. AIMS: This study
compared the efficacy (non-inferiority) and safety of FeCarb with oral ferrous sulfate (FeSulf)
in reducing iron deficiency anemia in IBD. METHODS: This randomized, controlled, multi-
center, phase-III trial was performed in IBD patients with a hemoglobin (Hb) ≤11g/dl and
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a transferrin-saturation (TfS) <20% or ferritin <100µg/l. Patients were randomized at a 2:1
ratio (FeCarb:FeSulf) to receive either an iv infusion of FeCarb at a maximum dose of
1000mg iron (or 15mg/kg) at 1 week (wk) intervals until the patient's calculated total iron
requirement was reached, or FeSulf (100mg BID) for 12 wks. The primary endpoint was
the change in Hb from baseline to wk 12. Secondary objectives were the assessment of
safety and the quality of life (by SF-36). RESULTS: 200 patients were randomized at 36
centers (57 CD, 143 UC), 137 into the FeCarb group, 63 into the FeSulf group. The mean
calculated iron deficit was 1449mg (range 937 to 2102mg). The Hb improved from 8.6±1.5g/
dl to 12.4±1.6 by FeCarb (p<0.001) and from 8.8±1.5 to 12.5±1.9g/dl by FeSulf (p<0.001).
A faster response (defined as proportion of patients with a Hb increase >2.0g/dl) was observed
for FeCarb at wk 2 (p=0.0065) and 4 (p=0.0257), and non-significant also at wk 8 (p=
0.0763). The mean serum ferritin level of patients in the FeCarb group increased from
9.9µg/L at baseline to 424.6µg/L at wk 2, followed by a constant decrease (178µg/L at wk
4, 97.4µg/L at wk 8 and 82.3µg/L at wk 12). Patients on FeSulf who had a mean baseline
ferritin of 21.7µg/L showed a modest increase (35.2µg/L at wk 2, 44.8µg/L at wk 4, 37.4µg/
L at wk 8 and 42.1µg/L at wk 12). TfS increased (7% to 24% FeCarb, 10% to 31% FeSulf)
and changes were not different between the two groups. Quality of life (93 to 108 FeCarb,
92 to 104 FeSulf) and disease activity improved to a similar extent. Drug related adverse
events (AE) occurred in 28.5% in the FeCarb group and 22.2% in the FeSulf group (p=
0.4). Study drug discontinuation due to AE occurred in 1.5% in the FeCarb group vs
7.9% in the FeSulf group (p=0.057). There was no serious AE related to the study drug.
CONCLUSION: Ferinject (FeCarb) is effective and safe in IBD-associated anemia. As it
provides a faster Hb response, a higher increase in iron stores, and a better patient tolerance,
it is superior to FeSulf.
T1262
Sargramostim Induces Steroid-Free Remission in Corticosteroid-Dependent
Crohn's Disease: Results of N.O.V.E.L. 2, a Phase II Multicenter Study
John F. Valentine, Richard N. Fedorak, Paul Fredlund, Brian G. Feagan
Background: Although corticosteroids (CS) effectively induce remission in Crohn's disease
(CD), adverse effects and lack of durable maintenance efficacy make prolonged exposure
to them undesirable. Unlike CD treatments that suppress adaptive immune system function,
sargramostim (SRG), an innate immunity activator, may have therapeutic value in CD. We
studied the ability of sargramostim to achieve CS-free remission in CS-dependent patients
with active CD. Methods: 127 pts were randomized in a 2:1 ratio to SRG 6 µg/kg subcutane-
ously once-daily or placebo (PBO) in a double-blind Phase II trial conducted at 39 sites in
North America for 12-22 wks. CS-dependency was defined as prednisone 10-40mg/day for
≥3 months prior to study entry with≥1 documented unsuccessful attempt at CS withdrawal.
Active CD was defined as a CD Activity Index (CDAI)>150 and ≤450 at entry. Study drug
was administered in 3 phases after a 2-wk screening period: adjunctive phase (4 wks; CS
+ study drug); forced CS tapering phase (4-14 wks; daily CS dose decreased by 5mg/wk
until reaching 20mg and then by 2.5mg/wk); observation phase (4 wks; study drug + 0-
7.5mg prednisone). The primary endpoint was CS-free remission at end of observation phase
(CDAI ≤150 while completely off CS). Secondary endpoints included CS-free response
(CDAI decreased ≥100) and remission/response in patients who, while unable to eliminate
CS completely, reduced their CS requirements to 2.5-7.5 mg/day. Results: Patient groups
were well-balanced for baseline demographics and CS dose (median CDAI, 263 vs 226 for
SRG and PBO groups, respectively). Most patients had received prior infliximab treatment
with failure/intolerance as the most frequent outcome. Significantly more SRG patients
achieved CS-free remission vs. PBO (18.6% vs. 4.9%, P=0.037, ITT analysis). Similar,
significant differences were seen for CS-free response, and for patients who tapered CS to
2.5-7.5mg/day. Significantly more patients in the PBO group withdrew from the study (80.5%
vs. 51.2%, P=0.0016). SRG treatment was also associated with significant improvements in
measures of health-related quality of life compared to PBO. The overall frequency of AEs
was similar between groups. Moderate intensity injection site reactions occurred more
frequently in the SRG group. Conclusions: Sargramostim significantly increased the rate of
patients achieving CS-free remission vs. PBO. This outcome is supported by secondary
efficacy parameters for remission, response, and QoL. Similar benefits were seen for patients
who tapered CS to 2.5-7.5 mg/day. The safety profile for sargramostim was similar to other
trials. Overall efficacy awaits further confirmation.
T1263
Rapid Response to Adalimumab in Crohn's Disease Patients Who Have Failed
Infliximab
Geert R. D’haens, Robert A. Enns, Gert Van assche, Jeffrey D. Kent, Ju Li, Paul F. Pollack,
David T. Rubin
BACKGROUND: Adalimumab (ADA), a fully human anti-TNF monoclonal antibody, has
shown efficacy in the induction and maintenance of remission in Crohn's disease patients
regardless of prior anti-TNF therapy. The rapidity of response is important given the severity
of the disease and the fact that these patients have already failed previous treatments.
OBJECTIVE: To assess the time to symptomatic response to ADA in Crohn's disease patients
who have failed prior treatment with infliximab. METHODS: This is a post-hoc analysis of
the GAIN trial, a Phase III, double-blind, placebo (PBO)-controlled induction study, in
which 325 infliximab-failure patients were randomized to receive either PBO or ADA (160mg/
80mg sc) at Weeks 0 and 2. The primary endpoint was remission (CDAI<150) at Week 4,
and secondary endpoints included response (CDAI decrease ≥70 or 100 points [CR-70,
CR-100]). Seven-day CDAI diaries were collected at baseline, and Weeks 1, 2, and 4. The
3 patient-reported diary components of the CDAI (frequency of abdominal pain, frequency
of loose stools, and general well-being) were summed and compared with PBO by Kruskal-
Wallis test. Maximum summed daily score was 7 plus number of liquid stools; lower
scores indicated improvement. RESULTS: Summation of the 3 patient-reported CDAI diary
components were significantly different from PBO by Day 4 and the significant difference
was maintained for the rest of the study for all available data points (Table). These data
were in agreement with the total CDAI scores where statistically significant differences
between ADA and PBO (CR-70) were seen by the 1st post-enrollment visit (PBO 21%, ADA
A-502AGA Abstracts
35%, p<0.05). CONCLUSIONS: Rapid symptomatic response to ADA is superior to PBO
in Crohn's disease patients who have failed infliximab. Significant responses were seen at
Day 4 and maintained for the rest of the study.
Table. GAIN, Onset of Response by Summation of 3 Patient-reported Diary Components
of 7-day CDAI Diaries
*p<0.05 vs. PBO.
T1264
Maintenance of Response and Remission Rates After 18 Months of Treatment
with Certolizumab Pegol in Patients with Active Crohn's Disease
Gary R. Lichtenstein, Stefan Schreiber, William J. Sandborn, Stephen B. Hanauer, Brian
G. Feagan
Background: Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal
tract that often requires long-term treatment with immunomodulators.1 Certolizumab pegol
is a subcutaneously (sc) administered PEGylated Fab' fragment of a humanized anti-TNFα
monoclonal antibody. The PRECiSE program assessed the efficacy and safety of sc certoli-
zumab pegol every 4 weeks in CD. PRECiSE 2 (P2) was a 26-week study, at the end of
which patients could enter the up to 5 years, long-term, open-level follow-up trial: (PRECiSE
3) (P3). The Harvey-Bradshaw Index (HBI) was prospectively calculated to assess CD activity
for long-term follow-up.2 Objective: To assess the maintenance of response and remission
in a long-term study of sc certolizumab pegol in patients with active CD by using the HBI.
Based on the results of a study correlating HBI to CD Activity Index (CDAI), the threshold
for clinical remission was defined as an HBI score of ≤4 and clinical response as a decrease
of ≥3 points from the baseline value.3 Methods: After induction at Weeks 0, 2, and 4,
responders in P2 (≥100-point decrease in CDAI from baseline to Week 6) received certoli-
zumab pegol 400mg sc or placebo every 4 weeks. Patients who completed the P2 maintenance
trial could enroll in the P3 program. In this analysis, we performed an ITT analysis for
response and remission with patients continuously exposed to certolizumab pegol. Results:
Of the 215 patients who responded to certolizumab pegol induction in P2, 141 entered P3
(65.6%). Response and remission rates remained high after 1 year of treatment (54.4% and
41.9%, respectively) [Table]. Of the 215 patients who responded at Week 6, 104, 90 and
80 patients were in remission at 6, 12 and 18 months, respectively. Certolizumab pegol
was well tolerated, with no new safety signals observed. Of the 141 P3 patients, 48 patients
withdrew from P3; The main reasons were adverse events (17.7%), patient's decision (13.5%)
and lack of improvement (9.2%). Conclusions: These long-term data support the efficacy
and tolerability of certolizumab pegol in the maintenance of response and remission for
patients with moderate to severe CD. 1. Panaccione R, et al. Curr Opin Gastroenterol
2004;20:351-359 2. Harvey RF, Bradshaw JM. Lancet 1980;1:514 3. Data on file
HBI-defined response and remission (ITT population)
*Week 0, **Week 26, *** Week 54 of P3
T1265
Pentasa (mesalazine) Once Or Twice Daily for the Management of
Maintenance of Remission of Ulcerative Colitis: Demographic and Baseline
Data of a 12 Month Single Blind Randomised Controlled Trial
Axell Dignass, Theo Stijnen, Michael R. Mross, Severine Vermeire, Henri Veerman,
Aomesh Bhatt
INTRODUCTION: Current 5-ASA treatments for ulcerative colitis (UC) usually require
multiple-daily dosing, which can lead to patient non-compliance and reduced drug efficacy.
Mesalazine sachets (PENTASA) are designed to release mesalazine with delivery of 5ASA
throughout the small bowel ensuring prolonged and consistent delivery of 5-ASA throughout
the entire colon. METHODS: Patients with maintenance of remission of UC who had had
a relapse within the past year were randomised to receive either mesalazine sachets 2g/day
given once daily or in divided doses in a 12 month phase III, multi-centre, investigator
blind study. Primary endpoint was clinical and endoscopic remission at one year defined
as UCDAI score of <2. RESULTS: 362 patients with mean age 48 years (range, 18-82 years)
and mean duration of UC of 10 years (sd 8.6) were randomised. There were 171(47%)
female, 191 (53%) male; 41 (11%) current smokers, 156(43%) ex-smokers and 164 (45%)
never smoked. 71 patients (19.6%) had relapsed, 38 (10.5%) completed the 12 month
study without relapse. 138 (38.1%) patients successfully completed their 4 month follow
up visit without events but not 8 month, and 82 (22.7%) have completed their 8 month
visit, but not completed 12 months. Based on an average follow-up period of 6 months,
the relapse rate was 23% calculated actuarially. To date, there were 3 patients with 4
serious adverse events (migraine, squamous cell carcinoma, post operative wound healing
impairment and chest pain). None were considered related to treatment. CONCLUSION:
During the course of the trial 2g mesalazine (PENTASA) sachets given once daily or in
divided doses were effective for the maintenance of remission of mild-to-moderate UC, were
well tolerated and both groups had comparable safety profiles. PENTASA dosed once daily
is expected to improve patient compliance and enhance treatment success in IBD and the
12 month results are awaited.
T1266
A Pilot Study in Crohn's Disease Comparing Two Strategies to Prevent
Formation of Anti-Infliximab Antibodies, Co-Administration of Azathioprine
and Pre-Treatment with IV Hydrocortisone, On the Long Term Efficacy of
Infliximab
Gerassimos J. Mantzaris, Chrysostomos N. Kalantzis, Stavroula Koilakou, Anastassios
Roussos, John Kalafatas, Nickolaos Apostolou, Efstratios Grivas, Nickolaos Raptis, John
Kalogeropoulos, Nickolaos Kalantzis
Background: It has been suggested that concomitant administration of azathioprine (AZA)
or pre-treatment with intravenous hydrocortisone (ivHC-PreRx) may prevent the formation
of antibodies to infliximab (ATIs) in patients with Crohn's disease (CD) on infliximab (IFX).
ATIs may influence the long term efficacy of IFX treatment necessitating an increase in the
dose or shortening of the interval between infusions of IFX. However, whether either strategy
offers any long term clinical advantage translated as prevention of IFX treatment failure has
not been adequately studied. Aim: To investigate whether ivHC-PreRx is equally effective
to the continuous AZA therapy in preventing long term secondary failure of IFX in a
prospective, single-centre study in CD. Patients and methods: Patients eligible for the study
had active steroid-dependent luminal CD as indicated by a recent ileocolonoscopy and/or
enteroclysis and a Crohn's Disease Activity Index (CDAI)>150 despite concomitant treatment
with oral steroids. Patients were stratified in a 1:1 ratio in two treatment arms: Those with
prior intolerance or side effects to AZA received IFX (5mg/kg at weeks 0, 2, 6 for induction
and then q8 weeks for remission maintenance) and 250mg ivHC-PreRx before each IFX
infusion. Patients naïve to AZA received oral AZA (2-2.5mg/kg/day) and IFX infusions as
previously without ivHC-PreRx. Steroids were tapered off within 6-8 weeks. Patients failing
to achieve remission on induction therapy or taper off steroids as well as those with side
effects or intolerance to AZA were withdrawn. Patients were followed with monthly clinical
assessments, CDAI measurements, and laboratory tests for two years or to relapse to disease.
Results: Overall, 17 patients received IFX/ivHC-PreRx and 17 IFX/AZA. There were no
significant differences at baseline in age, gender, smoking, disease location or activity but
patients on IFX/ivHC-PreRx had slightly longer disease duration. In the IFX/AZA arm, one
patient was withdrawn for primary IFX failure, two for AZA-related side effects whereas
two patients necessitated higher doses of IFX and/or shorter infusion intervals to maintain
CD remission. In the IFX/ivHC-PreRx arm, one patient was withdrawn for allergic reaction
to IFX after 12 months of treatment and two patients necessitated higher doses of IFX to
maintain CD remission. No severe adverse events were noticed. None of the patients
developed de novo dsDNA antibodies. Conclusion: This pilot-study has not confirmed
superiority of any of the currently available strategies to prevent formation of ATIs on the
secondary failure of IFX treatment during a two-year treatment period.
T1267
Long-Term Tolerability of Subcutaneous Certolizumab Pegol in Active Crohn's
Disease: Results from Precise 3 and 4
Jean-frédéric Colombel, Stefan Schreiber, Stephen B. Hanauer, Paul Rutgeerts, William J.
Sandborn
Background: Crohn's disease (CD) is a chronic disease requiring long-term treatment.
Efficacy and safety1 of certolizumab pegol were assessed in >1300 patients (pts) with active
CD (CD Activity Index score 220-450) in the pivotal Phase III 26-week (wk) studies PRECiSE
1 and 2 (P1, P2). Interim safety data from pts who continued follow-up in the long-
term, open-label extension studies PRECiSE 3 and 4 (P3, P4) are presented. Methods: Pts
completing P1 or P2 could enter P3 (n=595). Pts withdrawing from P1 or P2 due to
significant CD worsening could enter P4 (n=310). In P3 or P4, pts received certolizumab
pegol 400mg every 4 wks to Wk 54 or 52. Pts in P4 received an additional induction dose
of certolizumab pegol at Wk 2. Adverse events (AEs) were monitored (primary outcome).
Results: In P3 and P4, most AEs were mild or moderate. Most common AEs included
abdominal pain, nasopharyngitis, and headache. In P3, 74.5% of pts had an AE, of which
28.0% were at least possibly drug-related (90.3% and 46.1%, respectively, in P4). Serious
AEs were reported for 16.0% of pts in P3 and 29.0% of pts in P4. Twenty nine (25 pts)
serious infections AEs (SIEs) were reported in P3 and 25 (22 pts) in P4, including CD
abscess (8 P3; 14 P4), pneumonia (3 P3), abscess (1 P3; 2 P4), tuberculosis (2 P3; 1
on corticosteroids [CS] and 1 without CS/immunosuppressants [IS]), and staphylococcal
infection/sepsis (1 P3; 2 P4). Of the 47 pts with SIEs, 15 were on CS only, 11 on IS only,
and 12 on both at baseline (P1, P2). Two pts died during P3 (intestinal obstruction [unlikely
related]; tracheal obstruction due to food impaction [unrelated]); 1 pt who received a single
dose of certolizumab pegol died of Pneumocystis carinii pneumonia 12 wks after the last
study treatment in P4 (possibly related, pt had a history of IS, CS, and infliximab use).
There were 4 cases of malignancy in P3 (rectal cancer [on IS]; small intestine carcinoma
[no CS/IS]; small bowel carcinoma [on IS]; basal cell carcinoma [no CS/IS]) and 2 in P4
(rectal cancer [also reported in P1, on IS]; basal cell carcinoma [on IS]). One case of
sarcoidosis and 1 of systemic lupus erythematosus occurred in P3; none was reported in
P4. Pts negative for autoantibodies at baseline who became positive were: anti-nuclear 14.1%
P3, 3% P4; anti-double-stranded DNA 3.2% P3, 2.7% P4. The proportion of pts experiencing
injection-site reactions was low (< 2%; injection-site pain <1%). Conclusions: This interim
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analysis in >900 pts with CD suggests that long-term treatment with subcutaneous certoli-
zumab pegol 400mg is well tolerated. No new safety signals of concern were raised. 1
Schreiber S, et al. Gastroenterology 2006;130(Suppl. 2):479
T1268
Treatment of Crohn's Disease By Oral Administration of Alequel™, a Mixture
of Autologous Colon-Extracted Proteins: Results of a Double-Blind Clinical
Trial
Eran Israeli, Maya Margalit, Gadi Lalazar, Oren Shibolet, Hemed Nilla, Athalia Klein, Eran
Goldin, Yaron Ilan
Background: Oral immune-regulation is a method for modulation of the pro-(Th1)/anti-
inflammatory (Th2) paradigm. Current immunomodulatory treatments for Crohn's disease
(CD) are not antigen-specific. Aims: To evaluate the safety and efficacy of the induction of
a personalized mode of treatment for Crohn's disease by oral administration of Alequel™,
an autologous protein-containing colon extract, in subjects with moderate to severe Crohn's
disease. Methods: 49 patients with moderate to severe Crohn's disease were enrolled in two
randomized, placebo-controlled, double-blind trial studies. Patients were randomized to
receive either placebo or Alequel™. The studies were virtually identical, except that in one
all subjects received placebo during the first 3 weeks. Subjects were monitored for CDAI
and IBDQ. The analysis was conducted using an intent-to-treat (ITT) approach. To evaluate
possible surrogate markers for the clinical effect of the drug, antigen-specific T-cell immune
responses and peripheral blood T-cell subpopulations were analyzed for each subject. Results:
Oral administration of Alequel™ resulted in improved rates of clinical remission (39% vs.
22%), clinical response (50% vs. 30%) and improved quality of life as measured by the
IBDQ in the drug study group compared to placebo. No treatment-related adverse events
were noted. A decreased number of subject-specific antigen directed IFN spot-forming
colonies was observed in patients in the study drug-treated cohort who achieved clinical
remission (DR) in contrast to the subjects in the drug-treated group who did not achieve
clinical remission (DN), as well as to those subjects treated with placebo. An increased
percentage of peripheral NKT and CD4+ T lymphocytes, along with a decreased percentage
of CD8+ T cells were noted only in DR subjects. Conclusions: Oral administration of
autologous colonic extract, Alequel™, a patient tailored approach, may be a safe and effective
method for treatment of patients with moderate to severe Crohn's disease. Peripheral NKT
and CD4 lymphocytes may serve as surrogate markers to predict clinical response.
T1269
Maintaining Remission of IBD By Adacolumn Apheresis in Those At Risk of
Relapsing
Laurence P. Maiden, Rosie Baur, Ingi Bjarnason, Ken Takeuchi, John O'donohue, Ian
Forgacs, Guy Chung-faye, Jeremy Sanderson, Ingvar Bjarnason
Background Numerous, albeit largely uncontrolled studies, suggest that white cell apheresis
is an effective treatment for acute exacerbation of Inflammatory bowel disease (IBD). Our
purpose was to identify asymptomatic IBD patients at significant risk of clinical relapse (5
fold or greater increase in fecal calprotectin levels) and assess whether 5 treatment sessions
of Adacolumn apheresis avoided the clinical relapse as compared to a control group of
patients who had no change to their existing therapy. Methods Asymptomatic patients with
IBD (Crohn's disease activity index (CDAI) < 150) between the ages of 18 and 70 were
recruited from gastroenterology clinics in South East London, U.K for this open-label,
prospective, randomised, controlled study. Those with fecal calprotectin over 250mcg/g (so
at significant risk of clinical relapse) were eligible. Concurrent 5-amino salicylates were
permitted. Patients were randomly assigned to Adacolumn apheresis, undergoing 5, once
weekly, out patient sessions, or to unchanged treatment. Follow up was monthly for 6
months for a clinical relapse (CDAI >150 and >100 points above baseline). Secondary
outcome variables were the time to relapse (survival rates). Results Twenty-nine patients
were randomized to the apheresis group (15 male) and 31 to the control group (15 male).
The total number of patients who remained in clinical remission at 6 month was significantly
greater in the apheresis (72.4%) than in the control group (22.3%) (p = 0.0023, Fisher's
exact test). The time to first relapse was significantly delayed in the treatment group (161
± 44 days) as compared with unchanged treatment (99 ± 73 days) (log-rank test; p=0.0004).
Headache was reported by 16 of the 29 (55%) and pain or bruising from venepuncture in
5 (17%), feeling cold / cold peripheries in 5 (17%), lethargy in 5 (17%), nausea / vomiting
in 5 (17%), coryzal symptoms in 4 (14%), dizzy in 4 (14%) and a urinary tract infection
in 1 (3%) which were thought to be possibly or probably related to the apheresis. Discussion
This study demonstrates that leukocyte adsorption apheresis significantly reduces the number
of, and increases the time to, clinical relapse of asymptomatic patients with IBD who are at
high risk for relapse of disease. The treatment was well tolerated and without significant
side effects. Our results provide “proof of concept” for the apheresis technique for reducing
the likelihood of clinical relapse and in doing so delaying time to relapse.
T1270
Randomised Placebo Controlled Trial of Clarithromycin in Active Crohn's
Disease
Keith Leiper, Kate Martin, Tony Ellis, Tony Morris, Alastair J. Watson, Jonathan M.
Rhodes
Crohn's disease (CD) is characterised by defective innate immune responses to intestinal
bacteria. Clarithromycin is a broad-spectrum antibiotic that has particularly good penetration
into macrophages and may therefore be effective at eradicating the organisms at the centre
of the granulomatous reaction in Crohn's disease. Macrolide antibiotics have immunomodula-
tory properties independent of antibiotic activity which may be beneficial in CD. These
include stimulation of macrophage proliferation, phagocytosis and chemotaxis. Methods
Patients with active Crohn's disease (Crohn's disease activity index (CDAI) >200 and a CRP
>10mg/l) were allocated either clarithromycin 1g o.d. or placebo for three months in a
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single-centre randomised double blind controlled trial. Inclusion criteria included a stable
dose of corticosteroid (10mg or less prednisolone or 3mg or less budesonide) and a stable
dose of other medication (azathioprine for at least 3 months and 5-ASA preparation for at
least one month). Randomisation was by blinded pharmacist independent from the trial.
Primary outcome measure was remission (CDAI<150) or response (fall in CDAI >70 from
pretreatment level) at three months. Results The trial was stopped after 41 patients had
been randomised because of poor overall efficacy (initially assessed blinded to treatment
allocation). Baseline characteristics were similar in the two groups except baseline CDAI
[mean (SD)] was 246 (28) in the clarithromycin group (n=19) and 280 (68) in the placebo
group (n=22) (p=0.04). Median CRP at baseline was 28mg/l (range 10-200) in the clarithro-
mycin group and 26mg/l (range 10-109) in placebo. Intention to treat CDAI results are
shown in table. The mean (SD) fall in CDAI was 35 (80) clarithromycin and -2 (114)
placebo. Discussion Clarithromycin 1g for three months is ineffective in achieving remission
in active Crohn's disease. However some benefit was observed at one month. This suggests
that an initial antimicrobial effect may be attenuated by bacterial resistance to clarithromycin.
Combination or rotating antibiotic therapy may be more effective.
Intention to Treat Results
T1271
Long-Term Treatment with Certolizumab Pegol for Up to 18 Months in
Patients with Active Crohn's Disease: Precise 3 Efficacy Results
Stefan Schreiber, Stephen B. Hanauer, Brian G. Feagan, Ralph Bloomfield, Paul Rutgeerts,
William J. Sandborn
Background: Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal
tract often requiring long-term treatment with immunomodulators. Certolizumab pegol is
a subcutaneously (sc) administered PEGylated Fab' fragment of a humanized anti-TNF α
monoclonal antibody. It was effective and well tolerated in two distinct 26-week (wk) Phase
III studies: PRECiSE 11 (P1) and PRECiSE 22 (P2). The Harvey-Bradshaw Index (HBI) is a
simple index for measurement of CD activity that is highly correlated with the CD Activity
Index (CDAI).3 Objective: To assess the long-term efficacy of certolizumab pegol in patients
(pts) with CD as measured by the HBI. Clinical response was defined as a reduction in the
baseline HBI score of ≥3 points and clinical remission was defined as an HBI score ≤4.4
Methods: The PRECiSE 3 (P3) trial was an open-label extension study that recruited pts
from two placebo-controlled trials: P1 (pts received certolizumab pegol 400mg sc or placebo
at Wks 0, 2, and 4, then every 4 wks (4-weekly) during Wks 8-24); and P2 (responders
to open-label induction with certolizumab pegol 400mg sc at Wks 0, 2, 4 received certoli-
zumab pegol or placebo 4-weekly during Wks 8-24). In P3, pts received 4-weekly sc
certolizumab pegol 400mg. Results from P3 through 54 wks' follow up are presented here.
Two populations are analyzed: pts induced and treated for 24 wks with certolizumab pegol
in P1 or P2 (Group A) and pts who responded to induction therapy with certolizumab
pegol at Wks 0, 2, and 4 for 6 wks and were then randomized to placebo (drug holiday)
in P2 (Group B). Results: At Wk 80 (26 wks in P1 or P2 + 54 wks in P3) >80% of pts
achieved a clinically meaningful response. Remission was observed in approximately 75%
of pts (Table, observed cases). Conclusions: Certolizumab pegol 400mg sc every 4 wks is
an effective long-term maintenance therapy for patients with CD. References 1. Sandborn
WJ, et al. Gastroenterology 2006;130(Suppl. 2):107 2. Schreiber S, et al. Gut 2005;54(Suppl.
VII):82 3. Harvey RF, Bradshaw JM. Lancet 1980;1:514 4. Data on file
* Wk0; ** Wk 26; *** Wk 54 of P3
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Adalimumab Safety in Crohn's Disease Clinical Trials
Jean-frederic Colombel, William J. Sandborn, Walter Reinisch, Stephen B. Hanauer, Paul
J. Rutgeerts, Bruce E. Sands, Winnie Lau, Jeffrey D. Kent, Paul F. Pollack
BACKGROUND Adalimumab (ADA), a fully human anti-TNF monoclonal antibody approved
for treating rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has shown
efficacy in the induction and maintenance of remission in patients with Crohn's disease
(CD) who are anti-TNF naïve or who have failed prior anti-TNF therapy. OBJECTIVE: To
assess overall ADA safety across induction and maintenance datasets in CD clinical trials.
METHODS Data were grouped by period: INDUCTION (CLASSIC-I, GAIN, open-label [OL]
period of CHARM), double-blind (DB) MAINTENANCE (CLASSIC-II, CHARM), and ALL
EXPOSURE (all CD clinical trials including OL extension). Rates of adverse events (AEs),
serious AEs (SAEs), and events of special interest were assessed in each period. RESULTS
As of Feb 14, 2006, the ADA CD clinical trial safety database contained data for 1,459
patients representing 1,506 patient-years (PYs) of ADA exposure. INDUCTION: No clinically
meaningful differences in AEs were seen between ADA 160/80 mg and 80/40 mg induction
groups or between ADA 160/80 mg and placebo (PBO) groups; no differences were seen
between groups in serious infections or infectious AEs. DB MAINTENANCE: SAEs and AEs
leading to discontinuation (d/c) were significantly greater (p≤0.05) in PBO vs. ADA every-
other-week (EOW) or weekly (W) groups. No significant differences were seen between
ADA groups. When normalized for exposure, PBO had generally higher event rates than
ADA (Table). ALL EXPOSURE: Incidence and severity of AEs, SAEs, and AEs leading to d/
c overall were similar to those in Induction and DB Maintenance datasets. Two cases of
demyelinating disease, 3 cases of TB, 1 case of CHF, 3 lupus-like cases, and 2 deaths
(pulmonary embolus in an elderly patient with a history of arrhythmias and emboli; acute
myeloid leukemia in a patient on AZA) were reported in ADA-treated patients. CONCLU-
SIONS Analyses of the Induction, DB Maintenance, and All Exposure cohorts of the clinical
trial database demonstrate that ADA was generally safe and well-tolerated in the treatment
of patients with moderate to severe CD.
Double-blind Maintenance Period: Adverse Events of Interest
No CHF, Lupus-like illness, demyelinating disease, or fatal AE occurred.
T1273
Effects of Immunomodulators On Pharmacokinetics and Immunogenicity of
Infliximab Adminstered As 3-Dose Induction Followed By Systematic
Maintenance Therapy in IBD
William J. Sandborn, Carrie L. Wagner, Ade A. Fasanmade, Robert H. Diamond, Allan
Olson, Colleen W. Marano, Jewel Johanns, Gary R. Lichtenstein
Background and Methods: Although widely used, the effects of concomitant immunomodul-
ator (IMM) therapy with anti-TNF biologics are poorly understood in inflammatory bowel
disease. To address this question, pharmacokinetic and immune response (IR) data from 4
pivotal trials of infliximab (IFX) in Crohn's disease (ACCENT I & II) and ulcerative colitis
(ACT I & II) were assessed relative to medication use at study entry. Serum IFX (LLOQ =
0.1 ug/mL) and IR were measured using specific enzyme immunoassays. Trough IFX levels
are reported at the last clinical assessment visit, and IR results are summarized through the
last sample collection visit. Results: As shown in the table, there was no consistent trend
across studies for higher or lower median trough IFX levels for patients receiving or not
receiving concomitant IMM or corticosteroids. In contrast, there was an average 9.7% absolute
risk reduction (ARR) in IR incidence for patients receiving IMM, and 3.8% ARR with
corticosteroid use. At the 10 mg/kg dose, IMM and corticosteroid use did not consistently
decrease IR rates. For patients receiving only 5 mg/kg IFX maintenance treatment, IMM use
resulted in an average 14.4% ARR in IR incidence. Conclusions: No consistent difference
in IFX levels in the presence or absence of corticosteroid or IMM treatment was observed.
Patients administered IFX 5 mg/kg maintenance treatment with concomitant IMM had
approximately 14% ARR in IR rate relative to the absence of IMM. Using a number-needed-
to-treat analysis, approximately 7 patients receiving 5 mg/kg maintenance treatment with
IFX would be required to receive concomitant IMM to prevent one patient from developing
antibodies. Given the potential safety concerns of sustained IMM use, the benefits and risks
must be considered before prescribing concomitant IMM to patients receiving maintenance
IFX treatment.
T1274
RE-Induction and Maintenance Therapy with Subcutaneous Certolizumab
Pegol in Patients with Crohn's Disease Following Treatment Failure: Precise 4
Results
William J. Sandborn, Stephen B. Hanauer, Paul J. Rutgeerts, Jean-frederic Colombel,
Stefan Schreiber
Background: Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti tumor
necrosis factor α monoclonal antibody. Efficacy and tolerability in Crohn's disease (CD)
were demonstrated in two distinct 26-week (wk) Phase III pivotal qualifying studies (QS):
PRECiSE 1 (P1) and PRECiSE 2 (P2). The Harvey-Bradshaw Index (HBI) is a convenient
index to measure CD activity that can substitute for the CD activity index (CDAI).1 Objective:
To assess re-induction followed by maintenance therapy with certolizumab pegol in patients
(pts) who experienced a significant worsening of CD during previous treatment. Clinical
response was defined as a reduction in the baseline HBI score of ≥3 points and clinical
remission was defined as an HBI score of ≤4.2 Methods: Pts in P1 received subcutaneous
(sc) certolizumab pegol 400mg or placebo at Wks 0, 2, 4, then 4-weekly during Wks 8-
24. In P2, all pts received certolizumab pegol 400mg sc at Wks 0, 2, 4, then responders
(at least a 100-point decrease in CDAI from baseline to Wk 6) received certolizumab pegol
or placebo 4-weekly during Wks 8-24. Pts who withdrew after Wk 2 in P1 or Wk 6 in P2
with significant clinical worsening of CD (≥70-point increase in CDAI from baseline or
absolute CDAI≥350) could enter PRECiSE 4 (extension study [ES], P4). In P4, pts received
re-induction with certolizumab pegol 400mg sc Wks 0, 2, 4 then 4-weekly thereafter.
Baseline HBI values in the QS were used to assess response and remission rates. Interim
follow-up data up to 52 wks of P4 are reported for any pts who received certolizumab pegol
in the QS. Results: For the patients whose CD worsened in the QS, re-induction with
certolizumab pegol followed by maintenance therapy is a valid therapeutic option (Table).
No new safety concerns were raised. Conclusions: Re-induction with sc certolizumab
pegol can successfully induce and maintain response and remission in patients experiencing
worsening of CD. 1. Harvey RF, Bradshaw JM. Lancet 1980;1:514 2. Data on file
HBI response and remission*
* worsening was measured using the CDAI in the QS
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Rapid Onset of Response and Remission to Subcutaneous Certolizumab Pegol
and Lack of Influence of Concomitant Baseline Medications in Active Crohn's
Disease: Results from the Open-Label Induction Phase of the Precise 2 Study
Ole O. Thomsen, Stefan Screiber, Munaa Khaliq-kareemi, Stephen B. Hanauer, Ralph
Bloomfield, William J. Sandborn
Introduction: Open-label induction followed by a double-blind maintenance phase is a
well-established study design for assessment of biologics for Crohn's disease (CD), enabling
selection of patients (pts) most likely to benefit from long-term treatment.1-4 The pivotal,
Phase III PRECiSE 2 study assessed the efficacy and tolerability of certolizumab pegol, a
PEGylated Fab' fragment of a humanized anti-TNFα monoclonal antibody. Primary results
from the induction and maintenance phases have been presented.1 The current extensive
analysis addresses the rate of induction of response and remission during the initial open-
label phase of this study. Aims and methods: PRECiSE 2 was a multicenter, randomized,
double-blind, 26-week trial of pts with moderate-to-severe CD (CD Activity Index [CDAI]
220-450 points) who responded to induction therapy. In the 6-week induction period, 668
pts received open-label certolizumab pegol 400mg at Weeks 0, 2, 4. CDAI score was recorded
at each visit. Two definitions of clinical response (CR) were analyzed: a decrease in CDAI
score of ≥100 points (CR100) and a decrease of ≥70 points (CR70). Remission was
defined as a CDAI score of ≤150 points. CR100 and remission rates by concomitant
immunosuppressant (IS) or corticosteroid (CS) use were also determined. Results: Of the
428/668 (64.1%) pts who responded at Week 6, 52% (CR100) and 72% (CR70) were
already responders by Week 2, and 42% of pts who were in remission at Week 6 had
achieved remission by Week 2 (i.e. after one dose of certolizumab pegol) (Table). Nearly
all the Week 6 CR70 responders and over three-quarters of the Week 6 CR100 responders
had achieved a response by Week 4 (i.e. after two doses of certolizumab pegol). Week 6 CR100
rates were similar in pts with or without concomitant CS (62.9% vs 64.8%, respectively) or
IS use (66.3% vs 62.7%). Remission rates also did not differ substantially between subgroups.
Conclusions: A rapid response to certolizumab pegol was achieved by many pts after the
first dose during open-label treatment. These results from the induction phase of the PRECiSE
2 study compare favorably with those from studies of other monoclonal anti-TNFα treatments
for CD. Response and remission rates at Week 6 were unaffected by concomitant CS or IS
use. 1. Schreiber S, et al. Gut 2005;54(Suppl. VII):82 2. Hanauer SB, et al. Lancet
2002;359:1541-49 3. Sandborn WJ, et al. N Engl J Med 2005;353:1912-25 4. Colombel
JF, et al. Gastroenterology 2006(in press)
T1276
Safety and Efficacy of a Novel Extended Release Budesonide Formulation in
Patients with Active Left-Sided Ulcerative Colitis
Geert R. D'haens, ágota Kovács, Philippe Vergauwe, János Lonovics, Yoram Bouhnik,
Werner Weiss, Harald Brunner, Anne Lavergne-slove, Andrea F. Di stefano, Philippe
Marteau
Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with
relapses and episodes of remission. Many patients need systemic corticosteroids for the
induction of remission, which leads to important side effects. Aim: to study the safety and
efficacy of budesonide (BUD) MMX™-9 mg in active left-sided UC. Methods: Thirty-six
patients with moderately active left-sided UC (CAI or colitis activity index 4-14) were treated
with BUD MMX™ 9 mg extended release tablets (Cosmo Technologies Ltd, Ireland) for 8
weeks or placebo (PLA) for 4 weeks (blinded phase) followed by BUD MMX™ 9 mg for 4
weeks, all given as single tablet in the morning. Background therapy was kept unchanged
(oral 5-ASA up to 3 g/day and/or immunomodulators). Topical therapy, antibiotics, biologics
and systemic steroids were prohibited. The primary endpoint was the proportion of patients
with a reduction in the CAI of at least 50% or remission (CAI =<4) at week 4. Secondary
endpoints included the proportion of patients with a 70% reduction in CAI after 8 weeks
of BUD MMX™ 9 mg and changes in the Rachmilewitz endoscopic index (1). Morning
cortisol levels and a short ACTH-test were performed at week 4 and 8. Results: 32 patients
were available for analysis. Patients characteristics were comparable in both treatment arms.
The primary endpoint was reached by 8/17 patients in the BUD group (47.1 %) and 5/15
in the PLA group (33.3 %)(NS). The lack of significance might be due to the small sample
size. No change or worsening disease was seen in 1/17 BUD and 5/15 PLA patients. The
CAI decreased significantly from baseline to week 4 with BUD (p<0.0001) but not with
placebo (p=0.1). Adverse events included headache in 11.9 % and abdominal pain in 8.5
% of patients. Plasma cortisol levels and ACTH tests were not more frequently suppressed
in BUD than in PLA patients. Conclusions: 4 weeks of treatment with oral BUD MMX™ 9
mg induces clinical improvement in patients with active left-sided UC without significant
suppression of the adrenocortical function and without important toxicity. Further and
larger controlled trials with longer treatment episodes are warranted. 1. Rachmilewitz et al,
BMJ 1989;298:82-6
Clinical results after 4 weeks of treatment with BUD 9 mg or placebo
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T1277
Efalizumab, a Humanized Anti-Cd11a Monoclonal Antibody, in the Treatment
of Moderate to Severe Crohn's Disease
Dustin G. James, Julie A. Holinga, Da hea Seo, Christian D. Stone
Background & Aims: Efalizumab is a humanized monoclonal antibody targeted against
CD11a, an adhesion molecule involved in the activation and trafficking of T-lymphocytes.
This agent has proven efficacy in the treatment of plaque-type psoriasis, with a favorable
safety profile compared to other biologic agents. The purpose of this investigation was to
evaluate the efficacy and safety of efalizumab in the treatment of moderate to severe Crohn's
disease. Methods: This study was an open-label, single center clinical trial. Subjects who
were refractory to or intolerant of standard therapy and had active moderate to severe
Crohn's disease defined by a Crohn's Disease Activity Index (CDAI) > 200 were included.
Eight patients met inclusion criteria and received a weekly subcutaneous injection of efali-
zumab for 8 weeks at a dose of 1 mg/kg (first dose: 0.7 mg/kg). The primary endpoint was
clinical response defined by a decrease in the CDAI by ≥ 100. Secondary endpoints were
clinical remission (CDAI ≤ 150) and improvement in the Inflammatory Bowel Disease
Questionnaire (IBDQ) at the end of treatment. Adverse events were recorded. Results: At
entry, subjects had a mean CDAI of 298 ± 25 and a mean IBDQ of 126 ± 13. Fifty percent
(4/8) of patients had a clinical response to efalizumab. All responders achieved clinical
remission at week 8, with a mean CDAI of 75 ± 29. At week 8, the mean CDAI of subjects
was 215 ± 67 (p = 0.2). All responders also had improvement in quality of life measures,
with a mean IBDQ score of 188 ± 13 at 8 weeks. One subject with Crohn's colitis had pre-
and post-treatment colonoscopy that demonstrated mucosal healing. No serious adverse
events occurred. The most common side effects were headache (75%) and nausea/vomiting
(37.5%), all of which resolved within two weeks of initiation of efalizumab. Conclusions:
Efalizumab induced remission in 50% of subjects with difficult-to-treat Crohn's disease in
an open label trial. The results from this investigation warrant a randomized, placebo-
controlled trial to further evaluate the efficacy of the drug for both induction and mainten-
ance therapy.
T1278
Symptomatic Resolution Is An Inadequate Predictor of Complete Colonic
Mucosal Healing in Mild-to-Moderate Ulcerative Colitis
Asher Kornbluth, Michael A. Kamm, Gary R. Lichtenstein, William J. Sandborn, Karen
Barrett, Kirstin H. Lees, Raymond E. Joseph
Introduction: Following therapy with 5-aminosalicylic acid, patients with ulcerative colitis
(UC) who achieve symptomatic remission but not complete colonic mucosal healing are
more likely to relapse than those who achieve both.1 While some scoring systems used in
clinical trials in UC to evaluate disease activity may include regular sigmoidoscopy, in clinical
practice symptomatic resolution is often used as an endpoint to indicate disease remission. An
analysis of MMX® mesalamine study data was conducted to determine how often symptomatic
resolution (i.e. clinical remission) is accompanied by complete mucosal healing. Methods:
MMX mesalamine has been shown to be effective for the induction of clinical and endoscopic
remission of active mild-to-moderate UC following therapy with 2.4g/d (once daily [QD]
or 1.2g twice daily) or 4.8g/d (QD) in two phase III, placebo-controlled, randomized studies
(SPD476-301 and -302).2,3 Data from these studies were pooled and analyzed to determine
the proportion of patients with rectal bleeding and/or stool frequency scores of 0 who did
not achieve complete mucosal healing (i.e. those with a sigmoidoscopy score of ≥1, which
could include the presence of mucosal friability). Results: A total of 172, 174 and 171
patients received MMX mesalamine 2.4g/d (QD or 1.2g BID), 4.8g/d (QD) or placebo.
Overall, 41.9% of patients who achieved both rectal bleeding and stool frequency scores of
0 had sigmoidoscopy scores ≥1 and therefore did not achieve complete mucosal healing
(26/68 [38.2%], 25/64 [39.1%] and 19/35 [54.3%] in the MMX mesalamine 2.4g/d (QD
or 1.2g BID), 4.8g/d (QD) and placebo groups, respectively). Similarly, 45.1% of patients
who achieved a score of 0 for stool frequency and 50.6% of patients who achieved a score
of 0 for rectal bleeding did not achieve complete mucosal healing defined by a sigmoidoscopy
score of 0. Conclusions: In this analysis, a substantial number of patients who achieved
symptomatic resolution did not have complete mucosal healing. These data support the
need for sigmoidoscopic assessment at the end of an acute treatment period and emphasize
the importance of including an endoscopic assessment as an integral component of the
definition of remission. 1. Meucci G, et al. Gastroenterology 2006;130:A-197 (Abstract
S1302). 2. Lichtenstein GR, et al. Clin Gastroenterol Hepatol 2006; in press. 3. Kamm MA,
et al. Gastroenterology 2006; in press.
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Long-Term Clinical Outcome Following Visilizumab for the Treatment of
Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
William J. Sandborn, Daniel C. Baumgart, Stephan R. Targan, Bruce A. Salzberg, Lloyd
Mayer, Daan Hommes, Stephen B. Hanauer, Uma Mahadevan, Walter Reinisch, Scott
Plevy, Axel U. Dignass, Gert A. Van assche, Alan L. Buchman, Grigor Mechkov, Z. A.
Krastev, Jim Lowder, Tillman Pearce, Matthew Frankel
Purpose: Two clinical trials (Phase I and I-II) were conducted to investigate the safety and
efficacy of visilizumab, a humanized anti-CD3 monoclonal antibody, in hospitalized patients
with IVSR-UC. Long-term safety and clinical outcome data are presented. Methods: 138
subjects with IVSR-UC were treated with visilizumab at 5, 7.5, 10, 12.5 or 15 mg/kg
intravenously on two consecutive days (Days 1 and 2). Data were collected including time
to medical or surgical rescue therapy after treatment with visilizumab, time to recovery of
T-lymphocytes, and frequency of serious adverse events (SAE) and serious or opportunistic
infections. Results: Of the 138 subjects enrolled in these two studies, 79 (57%) demonstrated
a clinical response on Day 30 (defined as absolute MTWSI <10). Patients were followed for
a median of 356 days (range 21-792). During the follow-up period, 53% (73/138) received
medical or surgical rescue therapy: 45/59 (76%) of Day 30 non-responders and 28/79 (35%)
of day 30 responders. The median time to first rescue therapy was 310 days. Forty-six
patients (33%) underwent colectomy, either as first rescue therapy or subsequent to failed
medical rescue. CD4+ T-cell counts returned to baseline in 78% of patients by Day 30 (±
2 days), and in 89% by Day 60 (± 4 days). One hundred, twenty-nine patients (94%)
experienced some degree of cytokine release syndrome within the first 3 days of dosing.
Fifteen patients (11%) had serious or opportunistic infections (Oral candidiasis, Esophageal
candidiasis, Herpes simplex, Herpes Zoster, Gastroenteritis, & Abdominal abscess). No
serious or opportunistic infections were reported after Day 60. Conclusion: Visilizumab was
relatively well tolerated and produced a durable clinical response in the majority of patients
that exceeded its pharmacokinetic properties (ie, the elimination half-life of approximately
18 hours), and transient peripheral blood T-cell lymphopenia, which generally lasted less
than 30 days.
T1280
Determination of Harvey-Bradshaw Index (Hbi) Definitions for Response and
Remission Using the CDAI Data from PRECiSE 1 and Precise 2
Severine Vermeire, Stefan Schreiber, William J. Sandborn, Saghir A. Bashir, Paul Rutgeerts
Introduction and aims: The Crohn's Disease (CD) Activity Index (CDAI) is commonly used
in clinical trials to assess disease activity. It comprises 8 items and is a complex calculation
that requires hematocrit, physical examination, and completion of a patient (pt) diary for
7 days. The Harvey-Bradshaw Index (HBI) is a simple calculation that requires a limited
physical examination for abdominal mass and pt recall from just the previous day of general
well-being, abdominal pain, number of liquid stools, and complications. In a prospective
study of 112 pts with CD, the CDAI and HBI scores were highly correlated (r = 0.93).1
Two large Phase III studies (PRECiSE 1 [P1] and PRECiSE 2 [P2]) assessed the efficacy and
tolerability of subcutaneous certolizumab pegol, a PEGylated Fab' fragment of a humanized
anti-tumor necrosis factor α monoclonal antibody, in active CD. We aimed to determine
both the correlation between CDAI and HBI in P1 and P2 and the optimal HBI definitions
for response and remission. Methods: In P1, pts (n=660) received certolizumab pegol 400mg
or placebo (PBO) at Weeks (Wks) 0, 2, 4, and then every 4 wks up to Wk 24. In P2, pts
(n=668) received open-label certolizumab pegol 400mg at Wks 0, 2, 4. CDAI responders
(decrease from baseline ≥100 points [CDAI response 100]) at Wk 6 were randomized to
double-blind certolizumab pegol 400mg or PBO every 4 wks during Wks 8-24. CDAI scores
were recorded at each visit and remission defined as a score of ≤150 points. HBI data were
collected at Wk 0 and Wk 26/withdrawal. The correlation between CDAI and HBI was
calculated for the pooled intent-to-treat population from P1 and P2 using Spearman's
correlation coefficient, and the data were analyzed further using linear regression analyses.
Results: CDAI and HBI scores were positively correlated: Spearman's correlation coefficient
for P1 and P2 pooled together was 0.800 (95% confidence interval: 0.780, 0.819) and
ranged from 0.595 at baseline to 0.891 at last visit. CDAI response 100 corresponded to a
decrease from baseline in HBI score of 3.20 points. CDAI remission corresponded to an
HBI value of 4.66 points. HBI response (defined as a reduction of ≥3 points) misclassified
16.0% of pts and an HBI remission (defined as an HBI ≤4 points) misclassified 13.1% of
pts compared with a CDAI response 100 or remission. Conclusions: CDAI and HBI scores
positively correlated in P1 and P2. Our analyses support defining HBI remission as an HBI
score ≤4 and HBI response as a decrease in HBI score ≥3 points. The HBI is a simple and
easy to use measure of CD activity that may be used as an alternative to the CDAI. References
1. Harvey RF, Bradshaw JM. Lancet 1980;1:514
T1281
Elimination Diets in the Treatment of Mildly Active Crohn's Disease - Results
of a Randomized Controlled Trial
Ilana Dariel, Zohar Levi, Abigail Fraser, Bracha Hadad, Yaron Niv, Gerald Fraser
Background: An abnormal immune response to food antigens could be important in the
etiology of Crohn's disease (CD). If this hypothesis is correct then identification and removal
of aggravating food components should have therapeutic benefit. Elimination diets, using
rigorous nutrition data and methodology, have not been systematically investigated as primary
treatment for active CD. Objective: To establish methodology to identify food components
associated with disease activity and determine the efficacy of elimination diets in mildly
active CD. Methods: The composition and nutrition data for 450 food items available in
Israel were entered into a database. Elimination diets for 30 food components were prepared
using a specially designed computer program. 51 patients with mildly active CD (CDAI
150-250) not receiving corticosteroids and on stable therapy for at least 4 weeks were
included. Patients were randomized (3:2) to receive sequential elimination diets (32 patients)
for 2-week periods for each diet rotation or conventional nutritional advice (19 patients).
CDAI was determined at the beginning and end of each 2-week period and IBDQ at the
beginning and end of the study. The results were analyzed using a paired t-test and chi
square test. Results: Mean (±SD) age was 36.1±15y, 53% were females and mean CDAI and
IBDQ at recruitment were 199.1±53.7 and 149.2±21.2, respectively, with no difference
between the two groups. 20/32 treated patients and 19/19 controls adhered to the study
protocol and completed the study. Identification of an exacerbating food component was
possible in 16/32 treated patients requiring a median of 5 different diet protocols per patient.
Milk and yeast products were the main offending food components in 38% and 28% of
patients respectively. A significant improvement (>70 CDAI points) was observed for 16/
32 of the treated group vs. 1/19 for the controls (p<0.006). The CDAI (start 178.4 ±49.5,
end 82.6±65.5, p< 0.001) decreased significantly in the treatment group in contrast to the
controls (start 200.2±48.2, end 186.2±60.6; p=0.15). 16/32 patients achieved remission
(CDAI <150). Per protocol analysis demonstrated a significant improvement in IBDQ (start
155.0 ±20.3, end 175.9±28.8, p< 0.002) in the treatment group but not in the control
group (start 148±22.4, end 152.15±29.6; p=0.3). Conclusions: We developed a computerized
method that enabled systematic testing of elimination diets for Crohn's disease patient. An
appropriate elimination diet was found to be beneficial in the treatment of mild Crohn's
disease. The high response to elimination of yeast is of interest because of the presence of
ASCA in patients with CD.
T1282
Natalizumab Induces Sustained Response and Remission in Crohn's Patients
After Previous Infliximab Failure: Results from the Encore Trial
Daniel Present, Brian G. Feagan, Richard N. Fedorak, Bret Lashner, Remo Panaccione,
Paul Rutgeerts, William J. Sandborn, Martina E. Spehlmann, Zsolt Tulassay, Miroslava
Volfova, Douglas C. Wolf, Stephan R. Targan
Purpose: The phase 3 ENCORE (Efficacy of Natalizumab in Crohn's Disease Response and
Remission) trial demonstrated that natalizumab was effective in inducing durable response
and remission in Crohn's patients with active disease and evidence of inflammation. Forty-
eight percent of patients sustained response through Weeks 8 and 12, and 26% sustained
remission compared with 32% and 16% in the placebo groups (p≤0.002). Nearly 50%
(242/509) of patients in the ENCORE trial had been previously exposed to infliximab, and
over two-thirds of these patients (71%; 172/242) were considered by the study investigators
to have failed this anti-TNF therapy. This post-hoc analysis assessed the efficacy of
natalizumab in the ENCORE subpopulation of patients with prior infliximab failure.
Methods: Patients (N=509) with Crohn's Disease Activity Index (CDAI) scores ≥220 and
≤450 and C-reactive protein leves >2.87 mg/L were randomized 1:1 and received
natalizumab (300 mg; n=259) or placebo (n=250) infusions at Weeks 0, 4, and 8. Efficacy
and safety were assessed at Weeks 4, 8 and 12. The primary endpoint was the ability of
natalizumab to induce a clinical response (≥70 point decrease in baseline CDAI score) by
Week 8 that was sustained through Week 12. Results: Of the patients who had previously
failed therapy with infliximab (N=172), 38% had a sustained response to natalizumab
through Weeks 8 and 12 compared with 15% of patients treated with placebo (p<0.001).
Approximately 50% of natalizumab-treated patients with prior infliximab failure were in
response at either time point (52% at Week 8 and 49% at Week 12) compared with 22%
and 29% in the placebo group (p≤0.006). Patients treated with natalizumab also had higher
sustained remission rates. Remission was sustained through Weeks 8 and 12 in 17% of
patients treated with natalizumab compared with 5% of patients in the placebo group (p=
0.012). The incidence and types of adverse events were similar between groups and were
comparable to the overall treatment population. Conclusions: Natalizumab induced durable
response and remission in patients who had previously failed infliximab therapy. A statistically
greater proportion of natalizumab-treated patients achieved response or remission by Week
8 that was sustained through Week 12 compared with patients receiving placebo. Natalizumab
was well tolerated in this sub-population of patients, with adverse events not significantly
different than placebo or the overall ENCORE population
T1283
Natlizumab Does Not Require the Concomitant Use of Immunossupressants
for the Induction of Sustained Response and Remission in Crohn's Disease
Patients
Bret Lashner, Brian G. Feagan, Richard Fedorak, Remo Panaccione, Daniel Present,
Martina E. Spehlmann, Paul J. Rutgeerts, William J. Sandborn, Zsolt Tulassay, Miroslava
Volfova, Douglas C. Wolf, Stephan R. Targan
Purpose: The concomitant use of immunosuppressants (IMM) was previously shown to be
unnecessary to sustain the long-term efficacy of natalizumab in patients who initially
responded to natalizumab.1 The subanalysis described below was undertaken to assess the
need for concomitant IMM for induction of response or remission with natalizumab.
Methods: In the phase 3 ENCORE trial, 509 patients with active disease (Crohn's Disease
Activity Index [CDAI] scores ≥220 and ≤450) and evidence of inflammation (defined as
C-reactive protein levels >upper limit of normal [2.87 mg/L]) were randomized 1:1 and
received natalizumab (300 mg; n=259) or placebo (n=250) infusions at Weeks 0, 4, and 8.
Efficacy and safety were assessed at Weeks 4, 8 and 12. The primary endpoint was the
ability of natalizumab to induce a clinical response (≥70 point decrease in baseline CDAI
score) by Week 8 that was sustained through Week 12. The ENCORE protocol specified
that IMM be continued throughout the trial consistent with baseline use. Results: Two-
thirds (62%; 315/509) of the patients in the ENCORE trial were not taking IMM at baseline,
and therefore received natalizumab (n=162) or placebo (n=153) without concomitant IMM.
The remaining 194 patients received concomitant IMM during the trial (97 in each group).
Overall response and remission rates in the 2 groups of patients were comparable (see table).
Sustained response at Weeks 8 and 12 occurred in 50% of -IMM natalizumab- and 32%
of -IMM placebo-treated patients (p=0.001). The treatment effect was evident after one
infusion (Week 4) and response rates continued to improve at subsequent assessments
performed at Weeks 8 and 12. Conclusions: The induction benefit of natalizumab in the
ENCORE trial was comparable in those who used, or did not use concomitant IMM. A
significant difference in the proportions of natalizumab-treated patients that achieved
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response or remission was demonstrated as early as Week 4 in -IMM patients. Response
and remission were durable (sustained through Weeks 8 and 12) in natalizumab-treated
patients compared with placebo-treated patients regardless of IMM use. 1. Targan S et al.
Gastroenterology. 2006;130:A108.
ap≤0.003;bp<0.05
T1284
The Effect of Sigmoidoscopy Score At the Start of 5-Aminosalicylic Acid
Therapy On Long-Term Remission Rates in Patients with Mild-to-Moderate
Ulcerative Colitis
Gary R. Lichtenstein, Ron Diebold, Robyn G. Karlstadt, Karen Barrett, Raymond E.
Joseph
Introduction: MMX® mesalamine, a novel, high-strength (1.2g/tablet) formulation of 5-
aminosalicylic acid (5-ASA) has demonstrated efficacy for the induction of remission of
mild-to-moderate ulcerative colitis (UC) in two phase III, placebo-controlled trials (SPD476-
301 and -302), and for the maintenance of remission in an open-label extension study
(SPD476-303). We analyzed how the severity of mucosal inflammation at the start of therapy
affects long-term remission rates in patients (pts) receiving MMX mesalamine maintenance
therapy. Methods: At the outset of studies 301 and 302, a sigmoidoscopy was performed
for all pts using a predetermined scale (0=normal to 3=severe). In these two studies, pts
received MMX mesalamine 2.4g/d (once daily [QD] or 1.2g twice daily [BID]), MMX mesalam-
ine 4.8g/d (QD), ASACOL® (mesalamine) delayed-release tablets 2.4g/d (0.8g three times
daily) or placebo. Those pts not in clinical and endoscopic remission (modified UC Disease
Activity Index score ≤ 1, with rectal bleeding and stool frequency scores of 0, ≥ 1-point
reduction in sigmoidoscopy score from baseline, and no mucosal friability) following these
studies could receive an additional 8 weeks' MMX mesalamine therapy (4.8g/d [2.4g BID])
as part of study 303. Pts in clinical and endoscopic remission, or whose disease was deemed
by their physician to be sufficiently controlled, after studies 301, 302 or the 303 8-week
extension, could receive MMX mesalamine 2.4g/d (QD or 1.2g BID) for 12 months in the
303 maintenance study. Remission rates at 12 months were calculated and stratified by
sigmoidoscopy score at parent study baseline. Results: Of pts with mild, moderate or severe
endoscopic findings at baseline, 75.7, 82.1 and 70.0% of pts, respectively, were in clinical
and endoscopic remission upon entering the 12-month maintenance phase. After 12 months
of MMX mesalamine therapy, more than two-thirds of pts with a sigmoidoscopy score of
1 or 2 at baseline were in clinical and endoscopic remission compared with only 43% of
pts with a sigmoidoscopy score of 3 at baseline (Table). Conclusions: MMX mesalamine
2.4g/d maintains clinical and endoscopic remission for at least 1 year in pts with initial mild
or moderate sigmoidoscopic findings. Further studies are needed to determine if a higher
dose of MMX mesalamine maintenance therapy will increase the 12-month remission rate
in pts with UC who have severe endoscopic findings at baseline.
Table. 12-month remission rates stratified by baseline sigmoidoscopy score
T1285
Confirmed Benefits of Work Productivity and Daily Activities of Certolizumab
Pegol in Crohn's Disease Patients: Data from PRECiSE 1
Brian G. Feagan, William J. Sandborn, Martin Brown, Yves Brabant, Laetitia Gerlier
Background: Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNFα
monoclonal antibody, effective for induction and maintenance of clinical response in active
Crohn's disease (CD). Benefits on work productivity and daily activities were shown1 in the
maintenance trial PRECiSE 2.2 In the PRECiSE 1 induction and maintenance trial,3 patients
with moderate-severe CD (CD Activity Index [CDAI] score of 220−450, inclusive) received
sc certolizumab pegol 400mg or placebo (PBO) at Weeks (Wks) 0, 2, 4 and then every 4
wks until Wk 26. Methods: We assessed the impact of certolizumab pegol vs PBO on work
productivity and daily activities in PRECiSE 1. Overall work and daily activity levels were
evaluated at Wks 0, 6, 16, and 26 using the validated, self-reported Work Productivity and
Activity Impairment (WPAI) questionnaire. Mean % change in WPAI score from Wk 0 to
Wks 6, 16, and 26 was compared between groups using the Wilcoxon test. Conversion of
results into days was based on 5 working days per wk and a baseline overall work impairment
of 47.5%.4Results: There was a significantly greater improvement in overall work impairment
in patients treated with certolizumab pegol vs PBO at Wks 6, 16, and 26 (table). It approxim-
ately represents a gain of half a fully productive workday per wk vs PBO, while patients
reported on average 2.4 days lost or impaired per wk at baseline. A significantly greater
improvement was seen with less activity impairment in patients treated with certolizumab
pegol vs PBO at Wks 16 and 26 (table). Conclusions: The benefit of certolizumab pegol
on work productivity was seen as early as Wk 6 (the first assessment) in PRECiSE 1. These
results show the potential of certolizumab pegol to reduce the overall economic burden of
active CD when used to induce and maintain clinical response in CD patients. References:
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1. Feagan B, et al. Poster presentation UEGW 2006 (Abstract MON-G-219) 2. Schreiber S,
et al. Gut 2005;54(Suppl. VII):A82 (Abstract) 3. Sandborn WJ, et al. Gastroenterology
2006;130(Suppl. 2):Abstract 745 4. Feagan B, et al. Gastroenterology 2006;130(Suppl.
2):Abstract 1141
aintention-to-treat population; *p<0.05
T1286
The Crohn's Disease Specific Work Productivity and Activity Impairment
Questionnaire Is Responsive to Clinically Meaningful Changes: Data from
PRECiSE 1
Brian G. Feagan, Margaret C. Reilly, Martin Brown, Yves Brabant, Laetitia Gerlier
Background: A standard measure of efficacy in Crohn's disease (CD) is disease remission
defined by a CD Activity Index (CDAI) score≤150 points. The CD-specific Work Productivity
and Activity Impairment questionnaire (WPAI:CD) is less commonly utilized in clinical trials
of CD. It measures absenteeism, presenteeism, overall work productivity loss, and activity
impairment due to CD symptoms in the previous 7 days, which supplies important informa-
tion for healthcare professionals. The WPAI:CD's ability to discriminate between different
disease severity levels has been demonstrated previously.1 However, its sensitivity to clinically
relevant change has not been assessed. We evaluated the responsiveness of the WPAI:CD
using data from PRECiSE 1.2 Methods: Certolizumab pegol is a PEGylated Fab' fragment
of a humanized anti-TNF monoclonal antibody effective and well tolerated for the induction
and maintenance of remission in patients (pts) with moderate to severe CD. In PRECiSE 1,
660 pts received either subcutaneous certolizumab pegol 400mg or placebo at Weeks (Wks)
0, 2, and 4 and then every 4 wks until Wk 26. The WPAI:CD was administered at Wks 0
and 26. Mean changes in WPAI:CD scores were compared by remission status at Wk 26
using the Wilcoxon test. The responsiveness of the WPAI:CD was quantified using the
Standardized Response of the Mean (SRM) (mean change divided by standard deviation
[SD]). This effect size measure is judged as small <0.5, moderate 0.5 -0.8, and large ≥0.8.3
Results: Work productivity and daily activities improved more in pts achieving a remission
at Wk 26 (from 11% to 19% better). SRM were small in the nonremission group, while pts
achieving remission showed moderate to large SRM (Table). Conclusions: The WPAI:CD
is responsive to clinical changes in CD pts and is a valid instrument to measure the impact
of CD on work productivity and daily activities. References 1. Reilly MC, et al. Value Health
2006;9:A246-A247(Abstract PGI18) 2. Sandborn WJ, et al. Gastroenterology
2006;130(Suppl. 2):A1-A912 (Abstract 745) 3. Chassigny O, et al. Drug Inf J
2002;36:209-238
Mean change in productivity and activity impairment from Wk 0 to Wk 26 by remission
status at Wk 26
aEarly dropouts considered as ‘no remission'; bintention to treat population; ca larger negative
change indicates greater improvement
T1287
Induction of Health-Related Quality of Life Response and Remission in
Crohn's Disease Patients Following Subcutaneous Treatment with
Certolizumab Pegol 400mg: Data from PRECiSE 1
Stefan Schreiber, William J. Sandborn, Paul J. Rutgeerts, Geoffroy Coteur, Dorothy L.
Keininger, Brian G. Feagan
Introduction: Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNFα
monoclonal antibody being developed for Crohn's disease (CD) and other autoimmune
diseases. The PRECiSE 1 study evaluated the efficacy and safety of certolizumab pegol 400mg
administered subcutaneously (sc) for induction and maintenance of clinical response in
patients with moderate to severe active CD.1 Aims andmethods: The efficacy of certolizumab
pegol treatment for induction and maintenance of health-related quality of life (HRQoL)
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response and remission in the PRECiSE 1 study was assessed. Patients (n=659) were random-
ized at baseline to receive double-blind certolizumab pegol 400mg sc (n=331) or placebo
(n=328) at Weeks (Wks) 0, 2, 4, and then every 4 wks from Wks 8 to 24. HRQoL was
assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline and Wks
6, 16, 26. IBDQ response was defined as an increase from baseline ≥16 points in the total
score.2 A total score ≥170 points was defined as IBDQ remission.3 The effect of treatment
on IBDQ response and remission was assessed using logistic regression, with adjustment
for baseline IBDQ total score. Patients with missing data were considered as nonresponders.
Results: Certolizumab pegol-treated patients reported significant improvements in HRQoL
as measured by IBDQ response (Fig 1A) and remission (Fig 1B) compared to placebo.
The difference between the treatment arms significantly favored certolizumab pegol-treated
patients for both IBDQ response and remission at Wks 16 and 26. By Wk 26, 31% of
patients in the certolizumab pegol group were in IBDQ remission vs 21% in the placebo
group (p<0.01). Conclusions: Certolizumab pegol induced and maintained significant
improvements in HRQoL, including remission in patients with active CD compared to
placebo. 1. Sandborn WJ, et al. Gastroenterology 2006;130(Suppl. 2);Abstract 745 2. Irvine
EJ. J Pediatr Gastroenterol Nutr 1999;28:23-27 3. Irvine EJ, et al. Gastroenterology
1994;106:287-296
Figure. PRECiSE 1 study IBDQ (A) response and (B) remission rates as a function of time.
*p<0.05; **p<0.01
T1288
Short-Term Adalimumab Therapy Improves Quality of Life in Patients Who
Had Failed Infliximab Therapy: Results from the Gain Trial
Edward V. Loftus, Jean-frederic Colombel, Paul J. Rutgeerts, Geert R. D’haens, Robert A.
Enns, Parvez M. Mulani, Paul F. Pollack
BACKGROUND: Adalimumab, a fully human, anti-TNF monoclonal antibody, has shown
efficacy in the induction and maintenance of remission in patients with Crohn's disease
(CD) regardless of their experience with anti-TNF therapies. OBJECTIVE: To evaluate health
related quality of life for patients with moderately to severely active CD who had failed
infliximab therapy and received adalimumab induction therapy. METHODS: The GAIN trial
was a Phase III, double-blind, placebo-controlled induction study in which 325 infliximab-
failure patients were randomized to receive either placebo or adalimumab (160mg/80mg
sc) at Weeks 0 and 2. Disease-related patient outcomes were assessed by self-administration
of the Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline and Week 4. The 32-
item IBDQ ranges from 32-224, with higher scores indicating better patient function. Statist-
ical analysis was conducted to compare mean change in IBDQ total scores at Week 4 for
each treatment group vs. placebo, and four IBDQ dimensional scores — systemic, bowel
system, emotional function, and social function. RESULTS: At Week 4, patients randomized
to adalimumab had a greater mean change in total IBDQ score from baseline than placebo,
30.2 adalimumab vs. 15.1 placebo. In an ANCOVA model with treatment as a factor and
baseline value as a covariate, the least square mean difference between adalimumab and
placebo was 14.16 (p<0.001). Scores for each IBDQ domain score (social function, systemic
system, emotional function, and bowel symptoms) in the adalimumab group were all signific-
antly greater than placebo (p<0.001). In other words, all aspects of quality of life had a
better outcome with active therapy. CONCLUSIONS: Within 4 weeks of treatment initiation,
adalimumab improved all aspects of quality of life measured by the IBDQ in patients with
active CD who had failed infliximab therapy.
T1289
Natalizumab Induces Sustained Response and Remission in Patients with
Crohn's Disease Activity Index Scores ≥330: Results from the Encore Trial
Remo Panaccione, Brian G. Feagan, Richard Fedorak, Bret Lashner, Daniel Present, Paul
Rutgeerts, William J. Sandborn, Martina E. Spehlmann, Zsolt Tulassay, Miroslava Volfova,
Douglas C. Wolf, Stephan R. Targan
Purpose: Natalizumab has been shown to be effective in inducing response and remission
(by Week 8 and through Week 12) in patients with moderate to severely active Crohn's
disease in a large phase 3 randomized controlled trial: ENCORE (Efficacy of Natalizumab
in Crohn's Disease Response and Remission).1 Approximately 30% (155/509) of these patients
entered the ENCORE trial with a baseline Crohn's Disease Activity Index (CDAI) score ≥
330; this post-hoc analysis assessed the efficacy of natalizumab in this subpopulation.
Methods: Patients (N=509) with CDAI scores ≥220 and ≤450 and CRP >2.87 mg/L were
randomized 1:1 and received natalizumab (300 mg; n=259) or placebo (n=250) infusions
at Weeks 0, 4, and 8. Efficacy and safety were assessed at Weeks 4, 8 and 12. The primary
endpoint was the ability of natalizumab to induce a clinical response (≥70 point decrease
in baseline CDAI score) by Week 8 that was sustained through Week 12. Results: Of the
patients who entered the trial with a baseline CDAI score ≥ 330 (n=155), 51% had a
sustained response to natalizumab through Weeks 8 and 12 compared with 27% of patients
treated with placebo (p=0.002). Approximately 60% of patients with baseline CDAI ≥330
were in response at either time point (62% at Week 8 and 60% at Week 12, p≤0.005 for
both comparisons with placebo). The response to natalizumab was demonstrated early, with
57% responding after the first infusion of natalizumab (Week 4) compared with 39% in
the placebo group (p=0.029). Remission was sustained through Weeks 8 and 12 in 14%
of patients treated with natalizumab compared with 3% of patients in the placebo group
(p=0.025); remission rates at the Week 8 and 12 time-points were 21% and 23% in
the natalizumab-treated patients, compared with 7% and 10% in placebo-treated patients
(p≤0.039 for both comparisons with placebo). The mean change in CDAI score from
baseline exceeded 100 points at each time point in the natalizumab group and was statistically
significant compared with placebo (-103 vs -55 at Week 4, p=0.002; -135 vs -69 at Week
8, p<0.001; -146 vs -66 at Week 12, p<0.001). Conclusions: In patients whose baseline
CDAI score was ≥330 natalizumab induced rapid, statistically significant, and durable
response and remission (at Weeks 8 and 12) compared with placebo. Durable remission in
this patient population is particularly impressive due to the magnitude of the decrease in
CDAI scores necessary to achieve and sustain this endpoint. 1. Targan S et al. Gastroenterol-
ogy. 2006;130:A108.
T1290
Double Blind, Randomised Study to Evaluate Efficacy and Urinary Excretional
Rate of Two Doses of Rifaximin-Eir in Mild to Moderate Active Crohn's
Disease (Grace 02 Study)
Milan Lukas, Ales Novotny, Martin Bortlik, Jackie K. Leeder, Ernesto Palazzini
Introduction: Rifaximin is a semi-synthetic derivate of rifamycine with a large antimicrobial
spectrum and negligible intestinal absorption. The aims and methods: We performed this
prospective study to compare efficacy and urinary excretion of Rifaximin-EIR in subjects
with mild to moderate activity of Crohn`s disease (CD). Twenty four patients (16 woman)
with mild to moderate CD (220≤CDAI≤400) were included in this study. Patients were
randomised into two arms for 12 weeks of treatment with Rifaximin Gastroresistant Granules
(Rifaximin-EIR, sachet containing 800 mg): Group A) Rifaximin 800 mg daily plus placebo,
Group B) Rifaximin 800 mg twice daily. Results: The therapeutic effect was calculated as
the difference of CDAI value between baseline and week 12 based on ITT data set. The
mean CDAI differences in both arms were -85.5 and -91.6 points, respectively, the difference
between both groups was not statistically significant (p=0.241). An influence of the treatment
on the quality of life was assessed by standardized IBDQ calculation. The mean differences
of IBDQ between baseline and week 12 were +10.2 in Group A and +24.5 in Group B,
respectively. Again, the difference between both groups was not significant (p=0.245). The
24 hours urine excretion calculated as a percentage from total administered dose of Rifaximin
was 0.08% in Group A and 0.11% in Group B. Conclusions: Rifaximin-EIR in both doses
demonstrated significat decreased of CDAI during 12 weeks period of treatment. There was
no significant difference between both therapeutic arms as to the therapeutic efficacy. Even
higher dose did not lead to significantly increased intestinal absorption of Rifaximin.
T1291
Efficacy of Natalizumab in Crohn's Patients with Disease Duration Less Than
Three Years
Stefan Schreiber, Stephan R. Targan
Purpose: The phase 3 ENCORE and ENACT-2 trials demonstrated that natalizumab was
an effective induction and maintenance therapy for Crohn's disease (CD) patients. More
than half of the patients in either trial had a disease duration >7 years. This post-hoc analysis
examined remission rates with natalizumab in patients with disease duration ≤3 years in
these trials. Methods: In the ENCORE trial, patients (N=509) with Crohn's Disease Activity
Index (CDAI) scores ≥220 and ≤450 and C-reactive protein levels >2.87 mg/L were
randomized 1:1 and received natalizumab (300 mg; n=259) or placebo (n=250) infusions
at Weeks 0, 4, and 8. Twenty-four percent (120/509) of ENCORE patients had a mean
disease duration ≤3 years. In the ENACT-2 maintenance trial, adult patients with CD who
responded (≥70-point reduction in baseline CDAI score and CDAI score <220) to
natalizumab induction therapy in the ENACT-1 trial were re-randomized 1:1 to natalizumab
(300 mg; n=168) or placebo (n=171) and received up to 12 monthly infusions. Nearly 20%
(67/339) of ENACT-2 patients had a mean disease duration ≤3 years. Remission rates were
analyzed at the various endpoints of both trials (Table). Results: Natalizumab was signific-
antly superior to placebo (p<0.05) at all assessments in both groups studied (1 exception
noted). Remission induction rates with natalizumab were consistently higher for patients
with short disease duration than in the overall population of the ENCORE study, while
placebo rates were similar. Natalizumab was equally efficacious for long-term maintenance
of remission in both groups. Conclusions: Natalizumab was effective in inducing and
sustaining remission in CD patients with short disease duration (≤3 years) and in the overall
population, despite the fact that a large proportion of patients in natalizumab phase 3 trials
had extended disease duration. There were trends for higher induction remission rates for
patients with short disease duration compared to the overall population, while maintenance
therapy with natalizumab was efficacious irrespective of disease duration.
Percent of Patients in Remission According to Disease Duration
*not statistically significant compared with placebo at Week 4
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T1292
Absorption and N-Acetylation of Oral and Rectal mesalazine: Results from a
Clinical Trial in Healthy Subjects and Patients with Ulcerative Colitis
Karin Dilger, Dietmar Trenk, Martin Rossle, Meike Cap, Andreas Zähringer, Volker
Wacheck, Cornelia Remmler, Ingolf Cascorbi, Wolfgang Kreisel, Gottfried Novacek
Background: Mesalazine (5-ASA) is a standard treatment for induction and maintenance of
remission in ulcerative colitis. Extent of absorption and N-acetylation determine systemic
exposure to mesalazine, and are thereby relevant for safety of the treatment. Toxic effects
are a function of systemic concentration of the parent drug. The aim of the study was
to compare absorption and N-acetylation of mesalazine following rectal and oral drug
administration, and to evaluate the impact of chronic inflammation of colorectal mucosa
on disposition of mesalazine. Design: First, 12 healthy adults were randomized to receive
2 g of mesalazine by each of four different formulations: oral delayed release granules, 30
ml enema, 60 ml rectal foam, and 120 ml rectal foam. Second, 12 patients with active
ulcerative colitis received 60 ml rectal foam. Pharmacokinetic analysis was performed after
determination of mesalazine and its acetylated inactive metabolite (Ac-5-ASA) in plasma
and urine by validated liquid chromatography tandem mass spectrometry. Genotyping of
N-acetyltransferases 1 and 2 was performed in each individual. Results: First, systemic
exposure to mesalazine was markedly lower after rectal drug administration as compared
to oral dosing (P<0.001; e.g., median relative bioavailability of 60 ml rectal foam: 36%).
Formation of Ac-5-ASA was higher after oral intake of mesalazine (area under the curve
[AUC] ratio Ac-5-ASA/5-ASA: 3.6 ± 1.4, mean ± SD) than after rectal drug administration
(P<0.01) without significant difference among the rectal formulations (2.7 ± 0.9, 30 ml
enema; 2.3 ± 0.4, 60 ml rectal foam; 2.3 ± 0.7, 120 ml rectal foam). Second, N-acetylation
of rectal mesalazine was lower in patients than in healthy subjects (AUC ratio Ac-5-ASA/5-
ASA: 1.6 ± 0.5 vs. 2.3 ± 0.4, P<0.01). The fraction of the dose that was excreted unchanged
into urine was higher in patients than in healthy subjects (P<0.01). High peak plasma
concentrations of mesalazine were correlated with high microscopic disease activity (r=0.67,
P<0.05), but not related to endoscopic index or disease activity index, respectively. No
participant coded for reduced NAT1 activity, and different NAT2 phenotypes did not affect
biotransformation of mesalazine. Conclusions: Rectal delivery of mesalazine results in low
systemic drug exposure with potentially reduced toxicity in comparison with oral drug
administration. Chronic inflammation of colorectal mucosa might impair detoxification of
mesalazine. Our data supports the concept that in ulcerative colitis a defective mucosal
detoxification system leads to higher exposure of enterocytes to xenobiotics and toxic
endogenous luminal constituents.
T1293
Oral Calcium and Vitamin D Supplementation Helps Maintain Bone Mass and
Reduce Bone Turnover Markers in Patients with Inflammatory Bowel Disease.
A Randomized, Double Blinded, Placebo Controlled Trial
Peter F. Marden, Duncan A. Robertson, Ashok Bhalla, Gordon Taylor, Anne Holdoway,
Will Fickling
Background and Aims. Osteopaenia and Osteoporosis are complications of inflammatory
bowel disease.This study aims to examine the effect of oral calcium and vitamin D, on Bone
Mineral Density (B.M.D.) and bone turnover markers in patients with Crohn's disease and
ulcerative colitis (U.C.), over a two year period. Methods. Patients were randomised to one
tablet of 500mg of calcium and 400 units of cholecalciferol or placebo. Nutritional intake
was assessed by dietary recall and by ten-day weighed food intake.Bone mineral density
(B.M.D.)was measured at 0,6,12 and 24 months. Bone turnover markers were recorded at
0 and 12 months. Results. 102 patients were enrolled in the study. 44 with Crohn's disease
and 58 with U.C..Average age was 44 years for Crohn's patients and 49 years for U.C.
patients.At 12 months 77 patients were still recruited and at 24 months 61 remained.
Average daily oral calcium intake in patients with U.C. was 999mg and 1070mg for the
treated and placebo groups respectively. The Crohn's patients had an intake of 1111mg and
886mg in the treated and placebo groups respectively. In both Crohn's (p=0.217) and U.C.
groups (p=0.616) there was no statistically significant difference. In the Crohn's group at
12 months the change in mean Total BMD(TBMD) was 0.01 in the treated arm (n=13) and
-0.0013 in the placebo(n=12) (p=0.406). At 2 years it was 1.005 in the treated (n=13) and
-0.80 in the placebo groups(n=13) (p=0.27 ).In U.C. patients at 12 months the change in
mean TBMD was 0.01 in the treated (n=23) and -0.001 in the placebo groups (n=22) (p=
0.076). At 2 years it was 1.38 in the treated (n=21) and 0.63 in the placebo(n=16) (p=
0.514). In treated Crohn's subjects, osteocalcin(ng/l) levels changed from 7.73 to 7.80 (p=
0.627), pyridinoline(mcmol/mmol)from 17.88 to 17.31 (p=0.65), and deoxypyridinoli-
ne(mcmol/mmol) from 10.07 to 8.06 (p=0.248). In treated U.C. patients, osteocalcin levels
changed from 7.52 to 7.65 (p= 0.526), pyridinoline from 18.83 to 19.39 (p=0.557) and
deoxypyridinoline 9.4 to 9.0 (p=0.126). Conclusion. This study shows that BMD is preserved
and bone turnover markers are stabilised or reduced with the use of oral calcium and vitamin
D dietary supplementation in patients with IBD, and particularly Crohn's disease. Subject
numbers are relatively small and statistical significance was not achieved, but no other study
on the subject is placebo controlled and double blinded, or has dietary oral calcium intake
data for subjects. Although tolerability of the medication was good, results do not provide
enough evidence to support the use of oral calcium and vitamin D supplements in all
patients with inflammatory bowel disease.
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T1294
Efficacy and Safety of Balsalazide for Treatment of Pediatric Patients with
Mild to Moderate Ulcerative Colitis (UC): A Randomized, Double-Blind Study
Jose A. Quiros, John Pohl, Melvin B. Heyman, Thomas M. Attard, Dedrick Moulton,
William P. Forbes, Sandra R. Lottes, Ed Corsi, Michael R. Jiroutek, Michael A. Getter,
Paula Beitler
Purpose: Little data exist on the use of oral 5-aminosalicylates in pediatric patients with
active UC. We evaluated the efficacy and safety of the azo-bonded prodrug balsalazide in
pediatric patients with mild to moderate UC. Methods: In this randomized, double-blind,
multicenter study patients (aged 5-17 y) were treated for 8 weeks with balsalazide 6.75 g/
d (n=33) or 2.25 g/d (n=35) as intact capsules or sprinkled over pudding or applesauce.
The primary endpoint was clinical improvement (reduction in Modified Sutherland Ulcerative
Colitis Activity Index [MUCAI] of ≥3 points) at week 8. Endoscopy with biopsies was
performed at screening and week 8. Adverse events (AEs) were monitored throughout the
study. Results: Treatment with balsalazide 6.75 g/d compared with 2.25 g/d achieved clinical
improvement in 45% and 37%, respectively (P=NS), at week 8. A numerically higher
percentage of patients treated with balsalazide 6.75 g/d vs. 2.25 g/d experienced improvement
in each individual MUCAI subcomponent (stool frequency 33% vs. 23%, rectal bleeding
64% vs. 54%, mucosal appearance 61% vs. 46%, and physician's rating of disease activity
39% vs. 31%, respectively, P=NS for all comparisons). Twenty-six patients, 16 in the 6.75
g/d and 10 in the 2.25 g/d group, had histologic assessments at screening and week 8. A
larger proportion of patients in the 6.75 g/d vs. 2.25 g/d group experienced improvement
in histologic grade (50% vs. 30%, respectively, P=NS). Clinical remission (MUCAI score of
0 or 1) rates were similar for both groups (12% and 9%, respectively, P=NS). Both balsalazide
doses were well tolerated with similar AE profiles; most AEs were mild to moderate in
severity. Clinically important adverse events were experienced by fewer patients receiving
6.75 g/d compared with 2.25 g/d (e.g. pyrexia 0% vs. 11% and gastrointestinal disorders
39% vs. 49%, respectively). Four patients discontinued balsalazide due to AEs, including
2 discontinuations for moderate drug-related AEs (abdominal pain, urticaria, and/or frequent
bowel movements). No serious drug-related AEs were observed. Conclusion: Balsalazide is
effective and safe in pediatric (5-17 y) patients with mild to moderate UC. Pediatric patients
receiving 6.75 g/d reported fewer adverse events related to gastrointestinal disorders. The
6.75 g/d dose is safe and appears to be better tolerated compared with 2.25 g/d for pediatric
patients with mild to moderate UC. Wider use in the pediatric population may confirm if
the 6.75 g/d dose is better in achieving remission in children with UC.
T1295
Patients with Quiescent Mild-to-Moderate Ulcerative Colitis Receiving a
Multiple-Daily Dose 5-Aminosalicylic Acid Formulation Can Maintain
Remission with Once- Or Twice-Daily Mmx® mesalamine
Gary R. Lichtenstein, Ron Diebold, Robyn G. Karlstadt, Karen Barrett, Raymond E.
Joseph
Introduction: Current 5-aminosalicylate (5-ASA) formulations for the maintenance of remis-
sion of mild-to-moderate ulcerative colitis (UC) require multiple-daily dosing regimens.
Patient compliance with these regimens is poor, resulting in an increased risk of disease
flare. MMX mesalamine is a high-strength (1.2g/tablet) 5-ASA formulation designed for
once-daily (QD) dosing. Two phase III studies (SPD476-301 and -302) have shown MMX
mesalamine to be efficacious and well tolerated for the induction of clinical and endoscopic
remission of active, mild-to-moderate UC. Given the convenience of QD dosing compared
with multiple-daily dosing, it is important to determine if patients who achieve remission
on a multiple-daily dose 5-ASA formulation can maintain remission when switched to once-
or twice-daily MMX mesalamine. Methods: Data were combined from studies 301 and 302
where patients received MMX mesalamine 2.4g/d (QD; study 302, or 1.2g twice daily [BID;
study 301]), MMX mesalamine 4.8g/d (QD; studies 301 and 302) or ASACOL® (mesalamine)
delayed-release tablets 2.4g/d (0.8g three times daily [study 302]). Patients who achieved
remission (modified UC Disease Activity Index score of ≤1 with rectal bleeding and stool
frequency scores of 0, ≥1-point reduction in sigmoidoscopy score from baseline and no
mucosal friability), or whose disease was judged to be sufficiently controlled by their physi-
cian, could opt to receive 12 months' MMX mesalamine 2.4g/d (QD or 1.2g BID) maintenance
therapy as part of a phase III, randomized, open-label study (SPD476-303). Remission rates
following 12 months' MMX mesalamine maintenance therapy were calculated according to
the treatment received in studies 301 or 302. Results: A total of 198 patients who received
MMX mesalamine or ASACOL in the parent studies (301 and 302) directly entered the
maintenance phase of study 303. Of these, 151 were in clinical and endoscopic remission,
while 47 were considered well enough by their physician to receive maintenance treatment.
Remission rates at month 12 were similar irrespective of the prior 5-ASA treatment in the
parent studies: 58/79 (73.4%), 62/83 (74.7%) and 28/36 (77.8%) patients who had previously
received MMX mesalamine 2.4g/d, MMX mesalamine 4.8g/d or ASACOL 2.4g/d, respectively.
Relapse rates at 12 months in patients receiving MMX meslamine were low irrespective of
prior 5-ASA treatment in the parent studies: 6.3, 10.8 and 5.6%, respectively. Conclusion:
MMX mesalamine is an efficacious long-term maintenance therapy for patients with mild-
to-moderate UC, irrespective of the prior 5-ASA therapy (MMX mesalamine or ASACOL)
used to achieve remission.
T1296
A Randomized Comparison of Once- Versus Twice-Daily Mmx® mesalamine
for the Maintenance of Remission in Mild-to-Moderate Ulcerative Colitis
Michael A. Kamm, Jean-frédéric Colombel, Asher Kornbluth, Ron Diebold, Karen Barrett,
Robyn G. Karlstadt, Raymond E. Joseph
Introduction: Patients with quiescent ulcerative colitis (UC) are often non-compliant with
prescribed 5-aminosalicylic acid (5-ASA) treatment. This is, in part, due to the inconvenience
of currently available 5-ASA formulations, which often require multiple-daily dosing regimens
and a high number of tablets. Non-compliance with 5-ASA therapy can lead to a disease
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exacerbation. MMX mesalamine is a novel, high-strength (1.2g/tablet) formulation of 5-ASA
which uses Multi Matrix System® (MMX) technology designed to delay the initial release
of 5-ASA (until it reaches the terminal ileum) and extend its release throughout the colon.
This study (SPD476-303) investigated remission and relapse rates in patients with UC
receiving once- or twice-daily MMX mesalamine for maintenance of remission. Methods:
Study 303 was a 12-month, phase III, randomized, multicenter, open-label extension study.
Patients with active, mild-to-moderate UC who had achieved clinical and endoscopic remis-
sion (modified UC Disease Activity Index score≤1; with rectal bleeding and stool frequency
scores of 0; ≥1-point reduction in sigmoidoscopy score from baseline, and no mucosal
friability) during induction treatment with MMX mesalamine were randomized to MMX
mesalamine 2.4g/d (once daily or 1.2g twice daily) for 12 months. Remission was defined
as described above and relapse was defined as withdrawal from the study due to a requirement
for alternative treatment for a UC exacerbation (including a dose increase or surgery) based
on the physician's clinical assessment. Results: Of those patients in clinical and endoscopic
remission upon entering the maintenance phase, 171 and 191 patients received MMX
mesalamine 2.4g/d (once daily or 1.2g twice daily, respectively). At 12 months, 67.8 and
72.3% of patients in the once-daily and twice-daily groups were in strictly defined clinical
and endoscopic remission, respectively. 88.7% and 92.5% of patients in the once-daily and
twice-daily groups, respectively, had not relapsed by month 12. Conclusions: Less than
10% of patients experienced clinical relapse during 12 months' MMX mesalamine therapy.
More than two-thirds of patients remained in remission, using stringent clinical and endos-
copic criteria. Once-daily MMX mesalamine is an effective maintenance therapy in UC,
which should ensure good patient compliance.
T1297
Mmx® mesalamine As the Sole Medication for the Induction and Maintenance
of Remission of Mild-to-Moderate Ulcerative Colitis: Outcome in Patients
Treated Over 14—16 Months
Michael A. Kamm, Stephen B. Hanauer, Gary R. Lichtenstein, Ron Diebold, Karen Barrett,
Robyn G. Karlstadt, Raymond E. Joseph
Introduction: MMX mesalamine has been demonstrated to be efficacious for the induction
of remission of mild-to-moderate ulcerative colitis (UC) in two phase III, placebo-controlled
trials (SPD476-301 and -302) and for the maintenance of remission in a phase III, open-
label extension study (SPD476-303). Using data from these studies, we have calculated the
proportion of patients achieving clinical and endoscopic remission and not experiencing a
relapse when receiving MMX mesalamine as their sole therapy. Methods: Patients in studies
301 or 302 received MMX mesalamine 2.4g/d (once daily [302] or 1.2g twice daily [301]),
4.8g/d (once daily [302]) or placebo (301 and 302) for 8 weeks. Those patients who did
not achieve remission in studies 301 or 302 could receive an additional 8 weeks' MMX
mesalamine therapy (4.8g/d [2.4g twice daily; 303 8-week extension study]). Patients in
remission after studies 301, 302 or the 303 extension study could then receive 12 months'
MMX mesalamine 2.4g/d (once daily or 1.2g twice daily; 303 maintenance study). Clinical
and endoscopic remission rates (modified UC Disease Activity Index score of ≤1 with rectal
bleeding and stool frequency scores of 0, ≥1-point reduction in sigmoidoscopy score from
baseline and no mucosal friability) were calculated for patients after 8 weeks' initial MMX
mesalamine therapy and after an additional 8 weeks' MMX mesalamine therapy (303 8-
week extension study). Relapse in the 303 maintenance study was defined as a requirement
for alternative treatment for UC exacerbation. Results: INDUCTION OF CLINICAL AND
ENDOSCOPIC REMISSION: 36.1% of patients were in remission following 8 weeks' MMX
mesalamine therapy. 60.9% of the patients requiring 8 weeks' additional MMX mesalamine
also achieved remission. A total of 63.6% of patients achieved remission after 8—16 weeks
of MMX mesalamine therapy. MAINTENANCE OF REMISSION: During 12 months' mainten-
ance therapy with MMX mesalamine, 9.1% of all patients who were in remission upon
entering the maintenance phase of study 303 had relapsed. Using this preliminary analysis,
an estimated 57.8% of patients will achieve clinical and endoscopic remission from active
disease and will not relapse during a maximum of 16 months' therapy with MMX mesalamine.
Conclusions: In more than a half of patients with mild-to-moderate UC, MMX mesalamine
is an effective therapy for both achieving clinical and endoscopic remission and ensuring
no relapses over a 1-year period.
T1298
Superior Efficacy of Certolizumab Pegol in Early Crohn's Disease Is
Independent of Crp Status
Stefan Schreiber, Stephen B. Hanauer, Gary R. Lichtenstein, William J. Sandborn
Introduction: Certolizumab pegol, a PEGylated Fab' fragment of a humanized anti-tumor
necrosis factor (TNF) α monoclonal antibody administered subcutaneously, is effective for
long-term treatment of Crohn's disease (CD). A pivotal, Phase III study (PRECiSE 2, P2)
demonstrated induction and maintenance of response and remission by certolizumab pegol
in CD irrespective of baseline CRP levels.1 A post hoc analysis showed that efficacy of
certolizumab pegol was independent of disease duration.2 The exploratory analysis presented
here investigates whether the pronounced maintenance rates with certolizumab pegol in
early CD are independent of baseline CRP. Aims and methods: Data from P2, a multicenter,
26-week (wk) trial of patients (pts) with moderate-to-severe CD (CD Activity Index [CDAI]
220-450 points) and treated with certolizumab pegol or placebo, were analyzed. From 668
pts with CD, 428 responders (decrease of CDAI ≥100 points) were selected through a 6-
wk, open label induction period (certolizumab pegol 400mg at Wks 0, 2, and 4) and were
randomized to either double-blind certolizumab pegol 400mg or placebo every 4 wks.
Maintenance of response and remission (CDAI≤150 points) was assessed at Wk 26. Response
and remission rates at Wk 26 were calculated in an exploratory manner in the population
with early CD (duration of <2 years [<2yr] at baseline). The influence of baseline CRP levels
was evaluated with the cut-off at 10mg/L that was used to stratify the population during
randomization. Results:Treatment of early CD (disease duration <2yr) with certolizumab
pegol led to high response and remission rates (Table). As previously observed in the overall
population,1 baseline CRP levels did not predict response and remission in the early (<2yr)
CD population. Conclusions: A high rate for maintenance of response and remission was
observed at Wk 26 in pts with <2yr history of CD treated with subcutaneous certolizumab
pegol compared with placebo irrespective of baseline CRP levels. References 1. Schreiber
S, et al. Gut 2005;54(Suppl. VII):82 2. Sandborn W, et al. ACG 2006: Abstract 36A
Response and remission rates.
ap≤0.02, btrend vs placebo)
T1299
Long-Term Follow-Up of Lymphocyctic Colitis After Induction of Clinical
Remission with Budesonide
Ahmed Madisch, Susann Wonschik, Andrea Morgner, Renate Beckmann, Eberhard
Kuhlisch, Birgit Bethke, Manfred Stolte, Stephan Miehlke
Background & Aim: Lymphocytic and collagenous colitis share many clinical similarities.
We have recently shown that in collagenous colitis clinical relapses occur in about 60 % of
patients after induction of clinical remission with budesonide (Miehlke et al. AP&T). The
aim of this study was to assess the long-term outcome of patients with lymphocytic colitis
after induction of clinical remission with budesonide. Methods: Fourty-one patients with
chronic diarrhea and histological evidence for lymphocytic colitis were enrolled in a random-
ized placebo-controlled cross-over trial using budesonide (Budenofalk®) 9 mg daily for 6
weeks. Patients in clinical remission (CR) after budesonide treatment were followed using
standardized questionnaires. Clinical relapse was pre-defined as more than 3 loose stools/
day for at least 4 consecutive days. Results: A total of 28 patients left the trial in CR after
either initial (n=19) or cross-over (n=9) budesonide treatment (90% per protocol). Follow-
up data were available from all 28 patients. During a mean follow-up of 15 months (range
3-40 months), a total of 12 clinical relapses occurred (42,8 %) after a median time of 2
months. Age and gender were not associated with clinical relapse. In 7 patients, budesonide
was used for relapse treatment inducing again clinical remission. Conclusion: Budesonide
is effective in the treatment of lymphocytic colitis. The risk of clinical relapse after induction
of clinical remission with budesonide might be lower than in collagenous colitis.
T1300
The Prevalence and Risk Factors for Lymphoproliferative Disease in Patients
with Inflammatory Bowel Disease
Michael V. Chiorean, Jaya Adabala, Debra J. Helper, Bridget D. Galetti, Beverly S. Musick,
Cynthia S. Calley
Background and aims: Patients with inflammatory bowel disease (IBD) may be at increased
risk of lymphoma. Although immunomodulator (IM) therapy has been considered a risk
factor for lymphoma, the magnitude of the risk is unknown. The aims of this study were
to determine the prevalence and risk factors for lymphoma in a large IBD database. Methods:
Patients with lymphoma (cases) were included if their diagnosis of IBD predated that of
lymphoma. Severely immunocompromised patients were excluded. Demographic and clinical
data, including dose and duration of IM, were obtained from cases and a representative
sample of IBD patients from the database. The age-adjusted relative risk of lymphoma was
estimated by comparing cases with data from the SEER registry. The risk factors for the
development of lymphoma in the IBD patients were determined using logistic regression
analysis. Results: Seven patients with lymphoma were identified among 3863 IBD patients.
Three patients were excluded (1 each post-transplant, AIDS, lymphoma before IBD). The
median age at diagnosis of lymphoma was 47 (range 42-52), average IBD duration at
diagnosis was 20 years (range 7.5-31.5), 50% were male. All patients had non-Hodgkin
lymphoma. The overall prevalence of lymphoma in the IBD group was 0.10% (95% CI
0.03%, 0.27%). The age-adjusted relative risk of lymphoma was 3.1 (95% CI 1.2, 8.2)
compared to the US population based on the SEER data. Three patients in the IBD-lymphoma
group had UC (75%) and one received prior IM therapy (25%) vs. 36% and 46% percent
in the IBD control group, respectively. There was a significant positive association between
the diagnosis of lymphoma and longer IBD duration (p<0.0001), and a trend with a diagnosis
of UC vs Crohn's disease (RR=5.1, p=0.14). No correlation was seen with the use (p=
0.5770), dose (p=0.8141) or duration of IM therapy (p=0.3668). None of the patients with
lymphoma in this group received prior anti-TNF therapy. Conclusion: Patients with IBD
have an increased risk of lymphoma compared to the general population. The lymphoma
risk in this group was associated with IBD duration and possibly with a diagnosis of UC
and appeared independent of the use of immunomodulators.
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T1301
Prospective Evaluation of Influence of IBD Candidate Genes On Crohn's
Disease Course
Fabrizio Bossa, Maria R. Valvano, Anna Latiano, Orazio Palmieri, Renata D'inca', Maurizio
Vecchi, Giacomo carlo Sturniolo, Giuseppe Corritore, Tiziana Latiano, Angelo Andriulli,
Vito Annese
Background - CARD15, OCTN1/2, and DLG5 genes have been associated with predisposition
to Crohn's disease (CD) and specific phenotypes. Since disease behaviour changes over time,
we investigated the correlation between genotype and phenotype at diagnosis and during
the follow-up. Material and Methods - 624 well-characterized CD patients recruited in
three Italian referral centres were enrolled; clinical features were collected by means of a
standardized questionnaire. R702W, G908R, L1007finsC, SLC22A4, SLC22A5, and R30Q
polymorphisms were genotyped by DHPLC, RFLP, and TaqMan techniques, respectively.
Data were analyzed by stepwise logistic regression. Results - Mean age at diagnosis and
duration of follow-up were 32 ± 13 yrs (range 6-79), and 8.5 ± 6.5 yrs (range 1-37),
respectively. According to Vienna's classification, 270 patients had inflammatory (B1=43%),
139 stricturing (B2=22%), and 215 penetrating (B3=34%) behaviour at diagnosis; after 10
yrs of follow-up, 57 patients were B1 (28%), 56 B2 (27%), and 92 B3 (45%). The B2
behaviour was significantly more frequent in patients with ileal localization (p<0.001), while
the B1 was more frequent in those with colonic disease (p=0.0001), either at diagnosis and
during the follow-up (5 yrs = p<0.001; 10 yrs = p<0.004). 232 patients (37%) underwent
a surgical resection, more frequently in presence of ileal involvement (n=100; 41%), compared
to colonic disease (n=16, 6.9%; p=0.0001). Presence of at least one CARD15 variant, but
not OCTN1/2 and DLG5 polymorphisms, was significantly associated with B3 behaviour
(OR =1.8; p=0.002) at the time of diagnosis, and during the follow-up (OR 5yrs=1.9; OR
10yrs=1.7), also after correction for all covariates (including localization), and Montreal
classification. Surgical resection was independently associated with CARD15 variants either
at diagnosis (OR=1.6, p=0.007), and during the follow-up (OR=1.7, p=0.005). Subjects
carrying two CARD15 variants had an increased risk for surgery (OR=4 at diagnosis; OR=
4.3 during the follow-up). Conclusions - In our population of CD patients, disease localization
(ileal vs colonic) and CARD15 variants are independent major determinants of disease
severity and progression at diagnosis and during 10 years of follow-up, unlike age at
diagnosis (< or ≧ 40 yrs), gender, family history, smoking, ASCA, ANCA, OCTN1/2 and
DLG5 polymorphisms.
T1302
The Role of Diet in the Aetiology of Ulcerative Colitis - A European
Prospective Cohort Study
Andrew Hart
Background. The causes of ulcerative colitis (UC) are unknown, although it is plausible that
dietary factors are involved. Case-control studies of diet and UC are subject to recall biases.
Aims. To examine the prospective relationship between the dietary intake of both food
groups and nutrients and the development of ulcerative colitis in participants enrolled in a
large European cohort study. Methods. Dietary information was analysed on 263 824 men
and women aged 40-65 years, participating in a large prospective cohort study (EPIC Study,
European Prospective Investigation Into Cancer & Nutrition). The participants were residents
of the UK, Sweden, Denmark, Germany or Italy). Participants supplied information on diet
at recruitment and were followed up for the development of ulcerative colitis. Each incident
case was matched with four controls and dietary groups divided into quartiles. An analysis
was performed using multivariate conditional logistic regression adjusting for total energy
intake. Results. 134 incident patients with ulcerative colitis (69 women, 65 men) were
identified with a median age at diagnosis of 59.0 years (range 28.0-80.8 years). No significant
trends for food groups or nutrients were identified, apart from a significant positive association
with an increasing consumption of total polyunsaturated fatty acids (OR=2.33, 95% CI=
1.15-4.73, for highest vs lowest quartile of intake). Conclusions. Increased total polyunsatur-
ated fatty acid intake was associated with an increased risk of developing ulcerative colitis.
A possible biological mechanism exists in that polyunsaturated fatty acids are metabolised
to pro-inflammatory mediators. The study is on-going to identify more study participants
developing ulcerative colitis to increase the statistical power for further analyses.
T1303
A Prospective Analysis of Predictive Factors for the Diagnosis of Crohn's
Disease After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis
Gil Y. Melmed, Andrew F. Ippoliti, Eric Vasiliauskas, Marla C. Dubinsky, Konstantinos A.
Papadakis, Jerome I. Rotter, Stephan R. Targan, Phillip Fleshner
Background: About 5% to 10% of patients undergoing ileal-pouch-anal anastomosis (IPAA)
with a diagnosis of ulcerative colitis (UC) at the time of surgery are subsequently diagnosed
with Crohn's disease (CD). Predictors for CD post-IPAA have not been prospectively assessed.
In this prospective study, the association of preoperative clinical and serologic factors with
CD after IPAA in UC was evaluated. Methods: 238 consecutive patients with UC undergoing
IPAA at a tertiary referral center were prospectively enrolled into a longitudinally updated
database. Demographic and clinical factors were tabulated immediately after surgery. Serum
drawn before surgery was assayed for the IBD-associated antibodies anti-Saccharomyces-
cerevisiae (ASCA IgG and IgA), anti-outer membrane porin C (OmpC), anti-CBir1 flagellin,
and perinuclear antineutrophil cytoplasmic antibody (pANCA) using ELISA. CD was defined
by inflammation involving the small-bowel mucosa proximal to the ileal pouch or when a
pouch fistula or other perianal complication developed more than 3 months after ileostomy
closure. Clinical and serologic predictors were compared using univariate and time-dependent
multivariate methods. Results: Sixteen of 238 patients (7%) were diagnosed with CD; 14
underwent IPAA for refractory disease and 2 had surgery for dysplasia. Median time to CD
diagnosis was 5 months (range, 1-41 months); median followup was 41 months (1-153
months). CD was diagnosed on the basis of afferent ileal limb disease (n=12) and new perianal
disease (n=4). Univariate predictors of CD with a p-value <0.15 used in the multivariate model
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included: family history of CD, pre-colectomy platelet count, sero-positivity for ASCA-IgA
and pANCA. Multivariate Cox proportional hazards model identified family history of CD
(hazard ratio 8.1, 95% confidence interval (CI) 2.6 - 24.9, p<0.001) and ASCA-IgA sero-
positivity (hazard ratio 3.4, 95% CI 1.1 -10.5, p=0.03) as the 2 significant factors predictive
of CD after IPAA. CD developed in only 8 of 198 (4%) patients without these predictors
versus 8 of 40 (20%) in those with at least one of these factors (p=0.002). Conclusion:
Patients with UC who have a family history of CD or are ASCA-IgA sero-positive before
surgery are more likely to be diagnosed with CD after IPAA.
T1304
An Advance in the Categorization of Crohn's Disease (CD): Genetic, Serologic
and Environmental Factors Correlate with Montreal Classification (MC)
Alicia M. Sambuelli, J. B. Crusius, Silvia M. Negreira, Anibal H. Gil, Sergio P. Huernos,
Martin A. Toro, Andrea Czech, Silvina Goncalves, Pablo Tirado, Ana Cabanne, Amado S.
Pena
BACKGROWND: An International Working Party (2005 Montreal WCG) modified the CD
classification, to improve its applicability for clinical and research proposals. Its benefit must
be validated worldwide with the future aim of an integrated clinical molecular and serological
classification. AIM: To investigate associations between MC categories, genetic and serologic
markers, and smoking status. MATERIAL AND METHODS: 143 unrelated CD (fulfilled
data: 123) were categorized by MC in: Behavior: nonstricturing nonpenetrating (B1: n 58),
stricturing (B2: n 38), penetrating (B3: n 27 internal fistulas), perianal disease modifier (p: n
50), Location: L1: n 25 (ileal), L2: n 55 (colonic), L3: n 36 (ileocolonic), L4: n 7 (upper GI
disease, isolated or associated with L1, L2, L3), Age at diagnosis (yrs) A1: n16 (≦16) A2: n
76 (17-40) A3: n 32 >40). Smoking stratification: current smokers (heavy: 15 cigarettes daily-
5 yrs) ex-smokers, non-smokers. Disease duration: ≧ 5 yrs (B2 except. with postsurgical
death: N1) Median 10 yrs (2 - 57) from CD onset. Genetic studies: 3020insC (SNP13),
Gly908Arg (SNP12) and Arg702trp (SNP8) NOD2/CARD15 mutations by PCR. Serologic
determinations: IgA/IgG ASCA, Anti- E. coli outer membrane porin (OmpC) IgG (ELISA,
INOVA, CA), pANCA by IFI (INOVA, CA). Statistics: multiple logistic regression and survival
analysis. RESULTS: Behavioral positive independent associations: B2: with SNP13 (OR 5.5,
CI 95%: 1.6-19.4, p=0.007) and heavy smoking (OR 3.8, CI:1.4-10.5, p=0.007). B3: with
SNP12 (OR:9.9, CI:1.8-55.6 p=0.009) and ASCA (OR 5.6, CI 1.8-17.2, p=0.002). Shift B2-
B3 subset : (N 15) with SNP8 (OR 7.7, 95% CI 1.30-45.1, p<0.05), ASCA (OR 7.4 CI:1.4-
39.8, p=0.02) and OmpC (OR: 8.5, CI: 0.7-41.8, p=0.009). Perianal disease: with ASCA
(p<0.05). Location positive associations: L1: with smoking (OR 6.2, CI 2.2-17.4, p=0.0005).
Smoking, SNP13 and ASCA reached significance if S.bowel is categorized irrespective of
site. L3: with SNP12 isolated (OR 23.9, CI 2.8-203.9, p=0.004) or L4 combined. Negative
associations suggesting a protective role: perianal disease with SNP13. L2: (similarly to B1)
associated with ASCA and smoking (SNP13 as trend). L4 isolated: small sample. A1,A2,A3:
did not shown associations. Log-rank test showed significant probabilities to develop com-
plications for same variables described in logistic regression. CONCLUSIONS: We found
diverse associations with prognostic connotations between MC, genetic and serologic markers
and smoking, some of them not feasible to detect by Vienna Classification subsets. MC
seems to be a progress toward an integrated clinical, molecular and serological classification
of CD.
T1305
Lifestyle Patterns in People with Quiescent Crohn's Disease: A Role for Health
Promotion?
T. Nic suibhne, M. Shuhaibar, C. O'morain, Maria O'sullivan
BACKGROUND: Obesity, smoking, alcohol, sedentary lifestyles and stress are major public
health issues in western populations. In the context of Crohn's Disease (CD), how these
lifestyle factors interact against a background of inflammation and contribute to relapse,
comorbidity, long-term complications or disease course is unclear. AIM: This study aimed
to explore lifestyle patterns among people with quiescent CD compared with matched normal
controls. Specifically, to focused on obesity, smoking, physical activity, alcohol and stress.
METHODS: This was a cross-sectional study of 200 subjects comprising 100 CD patients
with quiescent/mild disease by CDAI and 100 age-sex and socioeconomic- matched normal
controls. We prospectively conducted comprehensive assessments of clinical, nutritional,
lifestyle and biochemical factors. Overweight and obesity were defined by body mass index
(BMI 20-25 and >30kg/M2) and body fat stores by Arm Fat Area. Physical activity was
assessed by the Exercise and Physical Activity Competence Questionnaire and expressed as
metabolic equivalent (METs). Anxiety was assessed by the Hospital Anxiety and Depression
scale. RESULTS: Obesity and overweight were common in both CD (40%, 40/100) and controls
(52%, 52/100). More CD patients than controls had high body fat stores (>85th percentile),
which was associated with higher BMI [14% (14/100) v 8% (8/100); r=0.7 P<0.001] Smoking
was more prevalent in the CD group than in controls (32% v 18%), especially among
females (CD 38% v controls 13% P=0.007 χ2). Total daily physical activity (combined work,
recreational, home) was lower for CD patients than controls, but this was not statistically
significant (130.2±8.2 v 153.4±11.4 METs; P=0.115). CD patients, however, did less and
lower intensity physical exercise than matched controls (score 0.7±0.08 v 1.0±0.07, P=
0.002). The CD group were less likely to consume alcohol (73% of CD v 86% of controls
P = 0.03 χ2) and consumed less than controls (median 4.0 v 7.7 units/week P=0.003,
consumers only). Anxiety was a feature particularly among female CD patients. Female CD
patients had significantly higher anxiety scores compared with female controls (8.49±3.95
v 6.67±3.40; P = 0.009) and correspondingly more were classed in the morbid or borderline
categories for anxiety [58% (34/59) v 37% (22/59); P=0.04 χ2]. Conclusion: This study
suggests that overweight, smoking, stress and low levels of exercise are common among
people with quiescent CD. Whether health promotion strategies would benefit patients
in terms of relapse, comorbid disease, long-term complications or disease course merits
further study.
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T1306
Colectomy Rates in Hospitalized Ulcerative Colitis Patients with Clostridium
difficile
Su min Cho, Miguel Regueiro
Background: Several studies have reported a high rate of Clostridium difficile(C Diff) infection
in patients with active IBD(Greenfield,Gut 1983,Trnka,Gastro 1981). The impact of C Diff
infection on natural course of ulcerative colitis(UC) is unknown. The aims of our study
were to determine the rate of C diff infection in hospitalized UC pts and determine the rate
of colectomy and length of hospital stay(LOS). Methods: We conducted a retrospective
observational study and identified all pts admitted to the University of Pittsburgh Medical
Center between 1982 and 2006 with an exacerbation of UC. We recorded data on C diff
toxin results, extent of colitis on colonoscopy, hospital LOS and rate of colectomy. We
excluded pts with indeterminate colitis and UC pts admitted to hospital for something other
than colitis. Each hospitalization was considered as an independent event for UC pts with
more than one admission. Results: There were 209 admissions related to active UC. The
Fisher's exact test was used to analyze data and compare independent variables. 24 of the
209 admissions(11.5%) were positive for C Diff. 10 of the 24 admissions(41.7%) required
colectomy. 185 UC admissions were C Diff negative and only 41 of 185(22%) required
colectomy. Colectomy rate was significantly higher in C Diff positive pts compared to C
Diff negative pts(41.7% vs 22%,p<0.05). In addition, the relative risk of having a colectomy
in UC patients with C diff were 1.88 times more than if they were negative(95% confidence
interval 1.09-3.243). There was no difference in the hospital LOS between C Diff positive and
C Diff negative pts(11 days vs 10 days; p>0.05). Conclusion: We found a high rate(11.5%)of C
Diff infection in our hospitalized UC pts. Although hospital LOS was not different between
C Diff positive and negative pts, the colectomy rate was significantly higher in C Diff infected
pts. These data highlight the increasing rate of C Diff in UC pts and its association with
colectomy. Better measures to screen for and adequately treat C Diff in UC pts are necessary.
Graph representing percentage of colectomy (in white) in association with C Diff toxin results
T1307
Permanent Work Disability in Crohn's Disease
Ashwin N. Ananthakrishnan, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Jeanne
Emmons, Mazen Issa, Sarah Lundeen, Mary F. Otterson, David G. Binion
Introduction: Crohn's disease (CD) frequently presents during early adulthood, a peak time
of work productivity. Previous studies of impaired work ability due to CD have used different
measures of disability and there is limited data from the US. Social security disability is the
largest federal assistance program to patients with permanent disability in the US. We
performed this study to determine the rate of and clinical factors associated with permanent
work disability in a Crohn's disease tertiary referral cohort. Methods: This was a retrospective
case-control study. Cases were identified as those patients who had ever received permanent
work disability compensation from the social security administration related to CD. Voluntary
work unemployment was not included among the cases. Four CD controls were selected
for each case from patients who had been seen in our IBD center within the past 1 year
but were not on disability. We collected information on demographics, disease characteristics,
and treatment regimens. Multivariate logistic regression was performed to determine charac-
teristics that were independently associated with permanent work disability Results: A total
of 737 patients with CD were seen in our center, and 185 CD patients were included in
our study (37 disability cases, 148 controls). The mean age of the cases and controls was
45.8 and 42.0 years respectively. The mean quality of life scores (SIBDQ) in cases and
controls were 40.4 and 54.6 respectively (p<0.05). The mean Harvey Bradshaw index was
6.5 and 2.7 among cases and controls (p<0.05). The patients on work disability had a mean
of 3.5 gastrointestinal surgeries compared to 1.4 in non-disabled patients (p<0.05). On
multivariate analysis, an SIBDQ score ≤ 50 (OR 12.44, 95% CI 4.45-34.79), undergoing
2 or more GI surgeries (OR 7.09, 95% CI 2.63-19.11), and 2 or more medical hospitalizations
(OR 2.76, 95% CI 1.03-7.37) were significantly associated with work disability in CD.
Disease location (small bowel vs. colon), type (inflammatory, stricturing, or fistulizing) or
specific treatment strategies were not associated with work disability in our analysis. Conclu-
sion: Permanent work disability administered through social security was encountered in
5.3% of the Crohn's patients followed in our cohort. Patients who consistently report low
quality of life, have frequent flares requiring surgical intervention or hospitalization for
medical management may be at risk for CD related work disability. Our data suggests that
patients with these clinical factors may identify a high risk subset of patients who may
warrant intervention trials to prevent CD related disability.
T1308
Childhood Environmental Factors in Hispanic Patients with Inflammatory
Bowel Disease: A Case-Control Study
Roberto Vendrell, Abdiel Cruz, Zhamarie Ortiz, Nelly Rabell, Michelle Rivera, Cynthia
Rivera, Huiying Yang, Maria Salas, Deborah Dutridge, Ling Mei, Jerome I. Rotter, Kent D.
Taylor, Esther A. Torres
Background: A relationship between childhood environmental factors and Inflammatory
Bowel Disease (IBD) has been postulated. The hygiene hypothesis suggests that multiple
childhood infections and poor public hygiene protect from developing Crohn's Disease by
allowing the host to develop immunity to agents that could trigger the disease later. In support
of this hypothesis, breast feeding has been negatively associated with IBD. Furthermore, the
prevalence of IBD appears to be increasing in minorities, including Hispanics. We evaluated
the association between childhood environmental factors in Puerto Ricans with IBD and
population controls. Methods: Epidemiological data from 191 subjects with Crohn's Disease
(CD), 132 with Ulcerative Colitis (UC), and 247 controls was obtained from questionnaires
completed for a collaborative genetic study between the University of Puerto Rico (UPR)
and Cedars-Sinai Medical Center, as part of the NIDDK IBD Genetics Research Consortium.
Patients were recruited in the UPR-IBD Center between April 2003 and July 2006. Childhood
epidemiological data included urban versus rural living, running water, toilet inside the
home, public sewer, and breast feeding history. Results: The mean age at diagnosis was 24
in patients with CD and 28 in patients with UC. Gender distribution for female IBD subjects
was similar for both CD and UC, with 72 and 75 cases respectively. Of the 176 male subjects
with IBD, 119 had CD and 57 had UC. Having running water (OR = 8.20, 95% CI = 4.11-
16.36, p = <0.001), a toilet inside the home (OR = 6.86, 95% CI = 4.05-11.62, p = <
0.001), and public sewer (OR = 2.71, 95% CI = 1.84-3.99, p = < 0.001), were significantly
associated with CD. A similar association was found between subjects with UC and having
running water (OR = 4.15, 95% CI = 2.20-7.81, p = <0.001), a toilet inside the home (OR =
2.73, 95% CI = 1.69-4.40, p = < 0.001), and public sewer (OR = 1.77, 95% CI = 1.15-
2.71, p = 0.009). A significant association was also found between urban living and Crohn's
Disease (OR= 1.78,95% CI = 1.22-2.61, p = 0003). No association was found between breast
feeding and IBD. Conclusions: A previous study demonstrated an increasing prevalence of
IBD in Puerto Rico. In the past decades, our public hygiene and health standards have
reached those of the industrialized world. This study reveals a negative consequence of the
improvement in health standards and an association between modern sanitary conditions
and the emergence of IBD.
T1309
Asca Positivity and Smoking Increase the Risk for a Second Ileocolic Resection
in Crohn's Disease
Lauren Anderson, Jonathan Unkart, Elisabeth B. Cole, Ellen Li, Candace Miller, David W.
Dietz, Christian D. Stone
Background & Aims: Studies have shown that about 90% of patients with ileal Crohn's
Disease (CD) will undergo an ileocolic resection (ICR) at some time during the disease
course, and half of these patients will have a second ICR for recurrent disease. We sought
to identify risk factors for a second ICR and time to second ICR. Methods: We performed
a retrospective cohort analysis of 165 CD patients who had had at least one ICR and were
followed over time to second ICR. We performed logistic regression to identify possible risk
factors for need for a second ICR. We also used Cox regression to determine whether certain
factors are associated with earlier time to second ICR. For these analyses we included the
following variables, which are thought to be important in this clinical setting: age, sex, race,
tobacco use, family history of inflammatory bowel disease, history of perianal disease, use
of immunomodulators, use of anti-TNF agents, and serum anti-Saccharomyces cerevisiae
antibody (ASCA) IgA and/or IgG positivity. Results: The adjusted odds ratios for need for
a second ICR were 4.5 (95% CI: 1.1 - 19.0) and 4.4 (95% CI: 1.9 - 10.0) for smoking and
ASCA positivity respectively. The median time to a second ICR was 7 years (range 1-42)
and 40% of subjects required a second ICR. 82.4% of subjects were positive for either ASCA
IgA and/or IgG and 47.9% were smokers at the time of first ICR. Cox regression analysis
revealed a hazard ratio for time to second ICR for smoking of 1.8 (95% CI: 1.0 - 3.1). ASCA
positivity and the other variables included in our models were not significant predictors of
need for earlier second ICR. Conclusions: ASCA positivity and smoking increase the risk
for a second ICR in CD patients. However, ASCA positivity was not associated with a risk
for earlier second ICR in this cohort. Additional factors, such as CD-associated genotypes,
will be included in future analyses to attempt to further define the risks for ICR.
T1310
Incidence and Risk Factors for Thromboembolism in Inflammatory Bowel
Disease (IBD)
Murtaza Arif, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Jeanne Emmons, Mazen Issa,
Sarah Lundeen, Mary F. Otterson, David G. Binion
INTRODUCTION: Patients with IBD have an increased risk of thromboembolism (TE), and
IBD is now recognized to be a potential hypercoagulable state. The pathogenesis of TE
in IBD is multifactorial. We determined the incidence of TE in IBD patients including
cerebrovascular accidents (CVAs), identifying the associated risk factors for TE, and character-
ized the distribution of TE in the vascular system in IBD patients. METHODS: This was a
retrospective observational study of all IBD patients (n= 951) followed in a tertiary referral
center over a 5-year period. Demographic information, type of IBD (Crohn's Disease (CD)
or Ulcerative Colitis (UC), number and distribution of TE events in the vascular system,
history of hypertension, surgeries, hospitalizations and disability were recorded for analysis.
TE events including arterial and venous thromboses, pulmonary emboli (PE) and ischemic
CVAs were included only if they had been confirmed radiographically. IBD patients with
no TE events served as the control group. RESULTS: TE events were identified in 92 out
of 951 (9.7%) IBD patients, including, 79 patients with arterial or venous thrombi and 13
patients with ischemic CVAs. 71 out of 692 (10.3%) CD patients had TE as compared to
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21 of 259 (8.1%) UC patients. Age of IBD patients with TE was 52 ± 2y (mean ± SD)
compared with 42 ± 0.5y of the control group (p<0.001). Out of the 92 patients identified
with TE, 43 (46.7%) had deep venous thromboses (DVT) of the lower extremities, 15
(16.3%) of the upper extremities, 24 (26.1%) had documented PE with or without DVT,
and recurrent TE events were recorded in 16 (17.4%) patients. There were 12 patients who
had TE at unusual sites including mesenteric, portal and retinal veins. 12 out of the 15
(80%) upper extremity DVTs were associated with intravenous catheter placement. In IBD
patients with TE, incidence of hypertension was 35.8% as compared to 15.7% in those
without TE (p<0.001). 54.9% patients with TE had history of surgeries as compared to
39.7% in the control group (p = 0.016). Among patients with documented TE, 67.4% were
hospitalized for IBD exacerbations as compared to 49.2% in the control group (p = 0.017).
Disability was recorded in 10.1% patients with TE and 4.1 % patients in the control group
(p = 0.015). CONCLUSIONS: IBD patients have elevated risk of TE. IBD patients at highest
risk for TE include those with central venous catheters, multiple hospitalizations, and
immobility during the perioperative period. TE is a potential fatal extraintestinal complication
of IBD, and increased awareness of risk and initiation of optimal prophylactic anticoagulation
management is warranted.
T1311
Patterns of Proton Pump Inhibitor Use in Inflammatory Bowel Disease (IBD)
and Concomitant Risk of Clostridium difficile Infection
Murtaza Arif, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Mazen Issa, Jeanne Emmons,
Sarah Lundeen, Mary F. Otterson, David G. Binion
INTRODUCTION: Proton pump inhibitors (PPIs) are frequently used in the care of patients
with inflammatory bowel disease (IBD; Crohn's Disease (CD), Ulcerative Colitis (UC)).
Published data has shown increased risk of Clostridium difficile (C. difficile) infection in
patients on PPIs. The use of PPI agents in the long term management of patients with IBD
has not been characterized and presently, it is unknown if chronic use of PPI agents in IBD
patients is associated with an increased risk of C. difficile infection. METHODS: This was a
retrospective observational study of all IBD patients (n= 1059) followed in a tertiary referral
center over a 5-year period. Chronic PPI use was defined as continued use for > 6 months.
Demographic information, type of IBD, class of PPIs, and dates of onset of C. difficile diarrhea
were recorded for analysis. Subsets of CD patients included those with upper GI tract
(i.e. esophageal, gastric and duodenal) and small bowel involvement, and isolated colonic
involvement based on endoscopic findings. Cohort patients with C. difficile infection were
included only if they had a documented diagnosis of the infection on the basis of a positive
stool assay result for C. difficile toxin. IBD patients with no chronic use of PPI agents served
as the control group. RESULTS: Chronic PPI use was identified in 306 out of 1059 patients
(28.9%) with IBD. Rates of PPI use was 28.3% (132/466) in males and 29.3% (174/593)
in female IBD patients. 55 out of 288 (19.1%) UC patients were using PPIs, as compared
to 251 out of 771 (32.6%) CD patients (p<0.0001). Among subsets of CD patients, chronic
PPI use was identified in 204 out of 546 CD patients (37.4%) with upper GI and small
bowel involvement, as compared to 47 out of 225 patients (20.9%) with exclusive colonic
disease (p<0.0001). In the cohort of IBD patients using PPIs, 92 (30.1%) were receiving
esomeprazole, 67 (21.9%) pantoprazole, 65 (21.2%) omeprazole, 54 (17.6%) lansoprazole,
and 28 (9.2%) were using rabeprazole. A total of 137 IBD patients had a history of C. difficile
infection. C. difficile was detected in 35 IBD patients (11.4%) who were using PPIs at the
time of the diagnosis of the infection. This was compared to 102 IBD patients (13.6%)
diagnosed with C. difficile infection in the control group (p=NS). CONCLUSIONS: Rates of
chronic PPI use were significantly higher in CD patients compared to UC. Among the subsets
of CD patients, there was increased use of PPIs in patients with upper GI and small bowel
involvement, as compared to CD patients with exclusive colonic disease. There was no
correlation between PPI use and C. difficile infection in IBD patients.
T1312
An Evaluation of Adalimumab On the Risk of Hospitalization in Patients with
Crohn's Disease, Data from Charm
Brian G. Feagan, Remo Panaccione, William J. Sandborn, Geert R. D’haens, Stefan
Schreiber, Paul J. Rutgeerts, Edward V. Loftus, Kathleen G. Lomax, Eric Q. Wu, Parvez
M. Mulani
BACKGROUND: Previous studies have shown that hospitalization is responsible for approx-
imately 60% percent of the direct cost of Crohn's disease (CD). OBJECTIVE: We evaluated
the effects of adalimumab (ADA) maintenance therapy on the risk of hospitalization in
patients who participated in the CHARM study. METHODS: 854 patients enrolled in the
Phase III, randomized, maintenance trial CHARM. 778 were randomized at Week 4 to 40
mg ADA every other week, 40 mg ADA weekly, or placebo, through 56 weeks. Week 4
responders (CDAI decrease ≥70 points) comprised the randomized responder population
(n=499) and were the primary analysis population. Kaplan-Meier estimates of CD-related
hospitalization rates were generated. A Cox proportional-hazards model assessed the inde-
pendent effects of ADA treatment and other prognostic factors (age, gender, smoking status,
presence/history of stenosis, presence of fistula, steroid use at baseline, duration of CD,
CDAI at randomization, and race) on these estimates. The ADA groups were pooled in these
analyses. RESULTS: Of 170 placebo patients, 22.4% were hospitalized compared with 14.0%
of those assigned to ADA (n=329). The 56-week actuarial CD-related admission rates for
the placebo and ADA groups were 13.9% and 5.9%, respectively (relative risk=0.43, p<0.01).
A difference in relative risk was apparent 2 weeks after randomization and at month 3,
placebo patients had 4.5 times the risk of CD-related hospitalization compared to ADA. The
only factor independently (negatively) associated was treatment group (hazard ratio 0.309,
p<0.01). CONCLUSIONS: Patients assigned to maintenance therapy with ADA had a
decreased risk for CD-related hospitalization evident from 2 weeks after randomization.
These findings demonstrate the importance of maintenance therapy and have significant
cost implications for society and third party payers.
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T1313
The Manitoba IBD Cohort Study: Differences Between Those with IBD and a
Matched Community Sample in Psychological Functioning and Coping
Lesley A. Graff, John R. Walker, Ian Clara, Norine Miller, Linda Rogala, Jason P. Ediger,
Patricia Rawsthorne, Cory Mcphail, Charles N. Bernstein
Our understanding of the impact of a specific disease on everyday functioning is often
limited by the lack of an adequate comparison group. In this study, we present a comparison
of individuals with IBD from the Manitoba IBD Cohort Study and a matched control
group from participants of a national random-sample health survey. The Cohort Study is a
longitudinal, population-based study of multiple determinants of health outcomes in IBD
in those diagnosed within 7 years at enrolment. Methods: Functioning of IBD participants
(n=388) was compared with gender, age, and region-matched community participants, using
the same interview measures. Psychological well-being, mastery, distress, stress management,
support, and illness interference were all assessed. Further comparisons were carried out
for disease type and activity. Results: Overall, the IBD sample had lower well-being and
mastery (perceived control/self-efficacy) than those in the community (PWB 77.45 vs 81.67;
Mastery 19.23 vs 26.99; p <.01). The IBD sample also had higher distress (p<.01) With
regard to stress management, those with IBD reported more avoidance and more ‘self-
medicating' behaviours (alcohol, smoking) for stress (p<.01). However both groups had
similar levels of active management strategies such as problem solving and doing something
enjoyable. There was no difference between IBD and community groups for level of support
from others, including practical support (eg, help to prepare meals), and emotional support
(eg, someone who listens or understands). Almost 2/3s of those in the community sample
reported other chronic health conditions ranging from hypertension to cancer. Those with
IBD were at least 2x more likely to report interference in their daily functioning, including
more days in bed and more days of reduced activity, both after controlling for chronic
conditions in the community sample. CD and UC participants had similar levels of psycholo-
gical functioning. Those with active disease had significantly poorer psychological functioning
than the community sample (p<.01), whereas those with inactive disease were not significantly
different from the community in well being, mastery, distress, as well as some facets of
stress management and illness interference. Conclusions: Those with IBD have significantly
poorer psychological functioning across several dimensions than a matched community
sample, although social support and adaptive stress management strategies were similar.
Those with inactive disease were not distinguished in their functioning from the community
group. Active disease should be a flag to consider psychological needs in the care of the
IBD patient.
T1314
Pregnancy Outcome and Fertility in Inflammatory Bowel Disease Is Influenced
By Disease Phenotype
Charlie Lees, Ruth E. Gailer, Natalie C. Johnston, Pamela Warner, Hilary O. Critchley,
Jack Satsangi
Introduction. Many females have IBD during their reproductive years and have concerns
surrounding fertility, pregnancy, and childbirth. CD patients have fewer babies than expected;
The most important determinant of fecundity is disease activity at conception. In UC there
is a three-fold increase in subfertility in women with previous ileal pouch anal anastamosis.
Aims. We aimed to describe pregnancy outcome, subfertility rates, and menstrual health
in a large population of accurately phenotyped Scottish women whose IBD was diagnosed
whilst they were of child-bearing age. Furthermore, we aimed to explore women's perception
as to how their IBD has affected their decisions regarding their family planning. Methods.
A detailed questionnaire was sent to 554 female IBD patients from a single tertiary referral
centre in Lothian, Scotland. All women were less than 50 years old at diagnosis (median
26.4 years; IQR 21.3-33.2). Data from 272 fully completed responses were analysed, compris-
ing 137 patients with UC and 135 with CD. The median age at enrolment was 40.5 years
(IQR 33.0-49.8). Control data on over 95% of the childbirths in Scotland were available
for comparison (http://www.isdscotland.org). These data are recorded back to 1976 and
include over 8000 births in Lothian from 2005. Results. 58.8% of women reported
attempting pregnancy, with 90.6% of these successful. 36/160 (22.5%) of women attempting
to be pregnant were referred for fertility treatment. 172/272 (63.2%) of respondents had
been pregnant, with data available on a total of 365 pregnancies. Whilst women with CD
took longer to conceive for each pregnancy than those with UC (6.64months vs. 3.83months,
p=0.03), they had equivalent numbers of pregnancies. The proportion of low birthweight
infants was more than expected in the background population (11.2% vs. 7.2%, p=0.01).
Women with IBD during their pregnancy years had shorter gestations than those diagnosed
after all pregnancies (38.9 vs. 39.7 weeks, p=0.0023) and more preterm babies (16.2% vs.
6.8%, p=0.021). Detailed phenotyping demonstrated that patients with ulcerative proctitis
(E1) had significantly heavier birthweights than those with left sided or extensive colitis (E2
& E3) (3.43kg vs. 3.20kg, p=0.03). Women reported that IBD made their periods heavier
and more painful, especially during periods of disease activity. Conclusions. Women with
IBD in Lothian have pregnancies of shorter duration and babies of lower birthweight than
the background population. However, women with limited ulcerative proctitis appear to be
protected from these problems.
T1315
Intravenous Corticosteroid Therapy for Severe Pediatric Ulcerative Colitis:
Predictors of Response and Outcome
Dan Turner, Catharine M. Walsh, Christy Chow, Thomas Walters, Robin A. Mclernon,
Anne M. Griffiths
BACKGROUND: A meta-regression of published cohort studies (Turner et al, Clin Gastro
Hepatol 2007) showed that 30% of adults admitted with severe ulcerative colitis (UC) fail
intravenous corticosteroid (IVCS) therapy. Only 43 children (divided in 3 small studies)
were reported in this systematic review (none analyzed predictors to IVCS response) despite
the greater prevalence of pancolitis in pediatric UC. AIMS: 1) To identify variables predictive
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of IVCS response in severe pediatric UC. 2) To evaluate the short (by discharge), medium
(1 year followup) and long term (6 years) outcome of IVCS therapy. METHODS: UC children
(0-18 years) admitted to SickKids Hospital, Toronto, for IVCS therapy during 1995-1999
were included, without repeated measures. Data were extracted by 2 independent investig-
ators, using standardized forms at day 1 and 3 of IVCS therapy, at discharge, during the
subsequent year and most recent followup. Predictors of IVCS failure were analyzed on the
first and third day of treatment using a univariate followed by a multivariate analysis, after
replacing the first admission with a subsequent admission leading to colectomy in 11 patients.
RESULTS: 63 children (57% males; age at diagnosis 10.9±4 years; 79% extensive colitis)
had 74 admissions for IVCS. Median disease duration at admission was 2 months (IQR 0-
13); 50% were admissions for first attack. The newly developed (Turner et al, JPGN 2006)
Pediatric UC Activity Index (PUCAI) was calculated at admission with a mean of 70±12.5
(i.e. severe disease). Children were treated with IV methylprednisolone 1-1.5 mg/kg/day up
to 40-60 mg. 26 of the 63 children (41%) failed IVCS by discharge and required 2nd line
therapy (n=22 colectomy; n=4 tacrolimus, of which 1 required colectomy) within 14.1±6.5
days of IVCS. At 1 year, 16 of the 40 children discharged without colectomy were steroid
responsive (39%), 13 (33%) were steroid dependent and 11 (28%) required colectomy.
Cumulative colectomy rates are shown in the Table. Short-term IVCS failure was predicted
at day 3 (but not at day 1) by: daily stool frequency (p=0.001), temperature (p=0.001) and
CRP (p=0.045). The PUCAI, calculated on day 3, most strongly predicted IVCS failure
(p<0.001, AUC of ROC curve: 0.8 (0.68-0.9)). CONCLUSIONS: Children hospitalized for
severe UC have high short-term and 1-year colectomy rates, but the risk dramatically
decreases thereafter. Clinical variables and the PUCAI, determined at day 3 of IVCS may
help to guide the introduction of 2nd line therapies.
Cumulative colectomy rates following the index admission
T1316
Low Body Mass Index Predicts Osteoporosis When Genetic and
Environmental Factors Are Considered in Patients with Inflammatory Bowel
Disease
Colin L. Noble, James Mccullough, Wenus K. Ho, Elaine R. Nimmo, Stuart Bear, Charlie
W. Lees, Hannan Jim, Carol Millar, Stuart Ralston, Jack Satsangi
Introduction: Low bone mineral density (BMD) and osteoporosis are recognised complica-
tions of inflammatory bowel disease (IBD). The aetiology of low BMD in IBD is multifactorial
encompassing genetic and environmental factors. In this study we have investigated the role
of genetic factors- Vitamin D receptor (VDR) variants, NOD2/CARD15 variants and IBD5
variants, and a number of environmental factors on the prevalence of osteoporosis in patients
with IBD. Methods: DEXA scans were performed using a Hologic QDR4500A machine on
286 patients with Crohn's disease (CD)- 107 males, 179 females, median age at DEXA 42.3
years, 153 patients with ulcerative colitis (UC)- 74 males, 79 females, median age at DEXA
43.0 years. 240 healthy controls were also genotyped. Phenotypic data was collected by
case note review and cumulative steroid data was calculated by the number of months on
corticosteroids. A T-score of <-2.5 at the lumber spine was classified as osteoporosis and a
T score between -1.5- -2.5 was classified as osteopenia. VDR gene polymorphisms Taq1
and Apa1 were genotyped using PCR-RFLP, IBD5 variants IGR2096, IGR2198, IGR2230,
OCTN1 variant (SLC22A4 1672C→T), OCTN2 variant (SLC22A5 -207G→C) and NOD2/
CARD15 variants R702W, and 1007fsinsC were genotyped using the Taqman system. NOD2/
CARD15 G908R genotyping was performed by PCR- RFLP. Results: 16% of the CD patients
and 13% of the UC patients were found to have osteoporosis. 18% of the CD patients and
19% of the UC patients were osteopenic. Univariate analysis showed that low body mass
index (BMI) (<18.5), smoking status and being post-menopausal (P= 0.008, 0.005 and
0.007 respectively) were associated with osteoporosis and osteopenia in CD patients. Low
BMI was also associated with osteoporosis on multivariate analysis (P=0.021, OR=5.83, CI=
1.31-25.94) in CD. No variable was associated with osteoporosis in UC and cumulative
steroid dosages were not associated with osteoporosis. No difference was observed between
Taq1 and Apa1 VDR polymorphisms in IBD, CD, UC and controls. However, CD males
were more likely to carry the mutant Taq1 allele than healthy control males (P=0.0018, OR
1.94, CI 1.28-2.92) and female CD patients (P=0.0061, OR 1.60, CI 1.17-2.44). No associ-
ation between VDR, IBD5 and NOD2/CARD15 variants and osteoporosis was observed in
the Crohn's disease cohort. Conclusions: In this well phenotyped cohort of IBD patients,
low incidences of osteoporosis were observed compared to previously published series. Low
BMI was the strongest risk factor associated with osteoporosis. Taq1 VDR variants were
more prevalent in the male CD population suggesting a sex specific effect.
T1317
Comorbidities and Complications in Patients with Crohn's Disease: A
Population-Based Matched Cohort Study
Gurkirpal Singh, Shweta Vadhavkar, Huijian Wang, Omar Dabbous, Mirza Rahman,
George Triadafilopoulos
Background: Crohn's disease is associated with local (obstruction, hemorrhage, perforation,
and fistula/abscess formation) and extra-intestinal complications (uveitis, episcleritis, arthritis,
and skin disorders) as well as complications related to malabsorption (steatorrhea and
diarrhea) but their exact prevalence is not well-known. In order to decrease the burden of
Crohn's disease we need to improve our understanding not only of the number of cases
but the prevalence and impact of its complications. In this study, we assessed co-morbidities
and complications in patients with Crohn's disease in a population-based matched cohort
study. Methods: MediCal, the Medicaid program for the State of California, is the largest
Medicaid program in the US, with over 7 million participants per year. Cases with a diagnosis
of Crohn's disease (ICD9 code 555.x) 18 years and older were age and gender-matched to
4 controls each. Complications and comorbidities were studied in the two years subsequent
to study entry. Results: The study included 7,465 patients with Crohn's disease and 27,003
controls (mean age for both groups 42 years, 63% women). Table shows the odds ratios of
common co-morbidities and complications, among others (not shown). Conclusions: Crohn's
disease is associated with several complications of variable prevalence and impact. In addition
to affecting disease activity indices, any successful therapeutic program, such as the use of
biological or immunosuppressive therapy, should be measured by decreases in incidence,
prevalence, and costs of these complications.
All Odds Ratios are statistically significant.
T1318
Comorbidities and Complications in Patients with Ulcerative Colitis: A
Population-Based Matched Cohort Study
Gurkirpal Singh, Huijian Wang, Shweta Vadhavkar, Omar Dabbous, Mirza Rahman,
George Triadafilopoulos
Introduction: Ulcerative colitis is associated with local (hemorrhage, megacolon, perforation)
and extra-intestinal complications (uveitis, episcleritis, arthritis, and skin disorders) but their
exact prevalence is not well-known. In order to decrease the burden of ulcerative colitis we
need to improve our understanding not only of the number of cases but the prevalence and
impact of its complications. In this study, we assessed co-morbidities and complications in
patients with ulcerative colitis in a population-based matched cohort study. Methods: Med-
iCal, the Medicaid program for the State of California, is the largest Medicaid program in
the US, with over 7 million participants per year. Cases with a diagnosis of Ulcerative Colitis
(ICD9 code 556.x) 18 years and older were age and gender-matched to 4 controls each.
Complications and comorbidities were studied in the two years subsequent to study entry.
Results: The study included 10,358 patients with ulcerative colitis and 37,239 controls
(mean age for both groups 51 years, 64% women). Table shows the odds ratios of common
comorbidities and complications. Conclusions: Ulcerative colitis is associated with several
complications of variable prevalence and impact. In addition to affecting disease activity
indices, any successful therapeutic program, such as the use of biological or immunosuppress-
ive therapy, should be measured by decreases in incidence, prevalence, and costs of these com-
plications.
Comorbidities and Complications in patients with Ulcertaive Colitis, compared to age- and
gender-matched controls over a two-year study period
All Odds Ratios are statistically significant.
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Blood and Guts: Thromboembolic Complications of Inflammatory Bowel
Disease
Gurkirpal Singh, Shweta Vadhavkar, Huijian Wang, Omar Dabbous, Mirza Rahman,
George Triadafilopoulos
Introduction: Patients with inflammatory bowel disease (IBD) are at increased risk of thrombo-
embolic events which occur at an earlier age than in non-IBD patients and are more frequent
in active disease, resulting in significant morbidity and mortality. Many factors (ie. active
intestinal inflammation, hyper-homocysteinemia, factor V Leiden mutation, increased anti-
phospholipid antibodies) are suspected to play a role. Although the incidence of such events,
reflecting an imbalance between coagulation and fibrinolysis in favor of coagulation, ranges
from 1 to 6 % in various small studies, the prevalence in large cohorts is not known.
Methods: MediCal, the Medicaid program for the State of California, is the largest Medicaid
program in the US, with over 7 million participants per year. Cases with a diagnosis of
Crohn's disease (ICD9 code 555.x) or Ulcerative Colitis (ICD9 code 556.x), 18 years and
older were age and gender-matched to 4 controls each. Thromembolic complications were
studied in the two years subsequent to study entry. Results: The study included 7,465
patients with Crohn's disease and 27,003 matched controls (mean age for both groups 42
years, 63% women; and 10,358 patients with ulcerative colitis and 37,239 matched controls
(mean age for both groups 51 years, 64% women). Table shows the odds ratios of common
thromembolic complications, both intestinal and extra-intestinal. Conclusions: IBD patients
are at increased risk for several types of thrombo-embolic events, mostly during active or
complicated disease and occur similarly in Crohn's and ulcerative colitis. To what degree
the use of biological or immunosuppressive therapy may decrease the incidence, prevalence,
morbidity, and costs of these complications remains unclear.
Odd Ratios (95% CI) for Thromboembolic Complications in patients with Crohn's Disease
and Ulcertaive Colitis, compared to age- and gender-matched controls
* p<0.05
T1320
International Differences in Patient Perceptions of the Benefits and Risks of
Infliximab
Corey A. Siegel, Puck Van der toorn, L. campbell Levy, Todd A. Mackenzie, C. J. Van der
woude
Background and Purpose: Based on data from the Netherlands and Belgium, the paradigm
of early aggressive use of infliximab (top-down therapy) for Crohn's disease is gaining favor.
This may be an effective approach; however, some patients may be unwilling to accept the
treatment associated risks of this strategy. Because patients are likely to vary in how they
perceive benefits and risks of therapy, treatment algorithms need to account for variations
in patient preferences. The purpose of this study was to determine national differences in
perceptions of the benefits and risks of infliximab between patients from the Netherlands
and the United States (US). Methods: Adult patients with inflammatory bowel disease (IBD)
from the Netherlands and the US were asked to complete a survey regarding benefits and
risks of infliximab. Surveys had identical content but were distributed in either Dutch or
English. Results are reported as simple descriptive statistics and associations were analyzed
using chi-square tests, correlations (Kendall's tau) and ordinal regression. Results: 236 surveys
were completed by patients from the Netherlands (149) and from the US (87). Mean age
of Dutch and US patients was 40 and 45, respectively (p=0.004). The majority of patients
(77% Dutch; 73% US) had Crohn's disease (p=0.12). Dutch patients had a longer duration
of IBD (p=0.01). 71% of Dutch and 23% of US patients were currently taking infliximab
(p < 0.001). Dutch and US patients had similar estimates for the benefit of infliximab (p=
0.15) and the risks of lymphoma and death attributable to infliximab (p=0.06 lymphoma;
p=0.66 death). When given a scenario of a hypothetical new drug for IBD with risks mirroring
those estimated for infliximab, 69% of Dutch and 81% of US respondents indicated that
they would not take the medication if the one year remission rate was less than 75%. This
difference between countries remained statistically significant (p=0.034) when adjusting for
patient age, duration of disease, and current use of infliximab. The odds ratio comparing
US to Dutch patients for demanding a higher treatment benefit was 2.3 (95% CI of 1.1 to
5.0). Conclusions: Dutch and US patients have similar perceptions of the benefits and risks
of infliximab, but US patients are 2x more likely to demand a higher treatment benefit. A
majority of patients in both groups would not accept treatment related risks if the one year
remission rate was < 75%. In adult studies, remission rates ≥ 75% have only been achieved
using a top-down approach. National variations in expectations of treatment benefit may
predict how individual patients make decisions regarding therapy for IBD.
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T1321
Orthotopic Liver Transplantation for Primary Sclerosing Cholangitis in
Patients with Ulcerative Colitis: Impact On Pouch Outcome After Ileal Pouch-
Anal Anastomosis
Katherine Freeman, Zhuo Shao, Feza H. Remzi, Rocio Lopez, Bo Shen
Background: Pouchitis is the most common complication of restorative proctocolectomy
with ileal pouch-anal anastomosis (IPAA). Concurrent primary sclerosing cholangitis (PSC)
increases risk for pouchitis. The most challenging form of pouchitis is chronic antibiotic-
refractory pouchitis (CARP). The effect of orthotopic liver transplantation (OLT) for PSC
and the use of post-operative immunosuppressants on the development of pouchitis is not
clear. The aims of the study were to compare frequency of CARP in PSC patients with or
without OLT and to assess potential risk factors for CARP in these patients. Methods:
Ulcerative colitis patients with PSC and IPAA with or without OLT were identified from an
IRB-approved, prospectively maintained Pouch Database from 1983 to 2006. CARP was
diagnosed based on persistent pouchitis (with Pouchitis Disease Activity Index score > 7
points) after 4-week single or dual antibiotic therapy. 19 demographic and clinical variables
were included for univariable and stepwise multivariable logistic regression analyses. Results:
A total of 63 PSC/IPAA patients were studied, including 19 patients with OLT and matched
controls of 44 patients without OLT. The mean follow-up after ileostomy take-down was
± 4.6 (SD) yrs. Fifty (79.4%) of the 63 patients with PSC had CARP; of these 50 subjects
14 (28.0%) had OLT. In both univariable and multivariable analyses, there was no evidence
to suggest that any of the factors (including age, gender, OLT, post-OLT immunosuppressants,
durations of UC, IPAA, and OLT, sequence of OLT vs colectomy, tobacco consumption,
and presence of other extra-intestinal manifestations) was significantly associated with CARP
(P > 0.20). Adjusting for OLT, there was no evidence to suggest that any of the factors
under study significantly associated with CARP (P>0.20). Conclusions: OLT and post-
transplantation immunosuppression in patients with ulcerative colitis and PSC does not
affect frequency of chronic antibiotic-refractory pouchitis. The results do support autoim-
mune theory in the pathogenesis of chronic pouchitis in patients with PSC.
T1322
Clinical Hypertension and Vascular Complication in Inflammatory Bowel
Disease
Murtaza Arif, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Jeanne Emmons, Mazen Issa,
Sarah Lundeen, Mary F. Otterson, David G. Binion
INTRODUCTION: Inflammation is increasingly recognized in the development of hyperten-
sion (HTN) and vascular disease. Plasma levels of C-reactive protein (CRP) are increased in
inflammation and predict future cardiovascular disease. Elevated CRP is often found in IBD
patients with active disease. We determined the incidence of HTN, analyzed its associated
vascular complications, and characterized the use of antihypertensive medications in IBD
patients. METHODS: This was a retrospective observational study of all IBD patients (n=
942) followed in a tertiary referral center over a 5-year period. HTN was defined as a
physician diagnosis or the initiation of antihypertensive treatment. Demographic information,
type of IBD (Crohn's Disease (CD) or Ulcerative Colitis (UC)), class of antihypertensive
medications, smoking status, and HTN associated complications were recorded for analysis.
IBD patients with no HTN served as the control group. RESULTS: HTN was identified in
164 out of 942 (17.4%) patients with IBD. 121 of 679 (17.8%) CD patients had HTN as
compared to 43 of 263 (16.4%) UC patients. Incidence of HTN was 18.1 % (76/421) in
males versus 16.9% (88/521) in females. 48 (29.3%) IBD patients with HTN were using
diuretics, 64 (39.0%) beta blockers, 30 (18.3%) calcium channel blockers, 38 (23.2%)
angiotensive converting enzyme inhibitors (ACE-Is), 21 (12.8%) angiotensin receptor block-
ers (ARBs), and 16 (9.8%) patients were receiving other antihypertensive medications. Among
IBD patients with HTN, history of tobacco use was identified in 34.8 % (57/164) compared
with 35.4% (275/778) in the control group. In IBD patients with HTN, 20 patients (12.2%)
had documented atherosclerotic disease including coronary artery disease, peripheral vascular
disease or myocardial infarction. This was compared to a total of 12 patients (1.5%) in the
control group with coronary or peripheral vascular disease (p<0.0001). There were 27 IBD
patients with HTN (16.5%) in whom thromboembolic events were recorded including deep
venous thrombosis, pulmonary embolism or nonhemorrhagic strokes. In contrast, 61 IBD
patients in the control group (7.8%) had any documented thromboembolic event (p<0.001).
CONCLUSIONS: Incidence of HTN in IBD patients is similar to rates in the general popula-
tion. However, IBD population with HTN is at a significant increased risk of vascular
complications (8 fold increase in atherosclerosis and 2 fold increase in TE events). The high
incidence of vascular complications associated with HTN in IBD suggests a need for better
recognition and management to decrease associated mortality and morbidity.
T1323
Cancer in Infliximab-Treated Or Untreated Crohn's Disease Patients: A 2 Years
Longer Follow Up from a Multicenter Matched-Pair Study
Livia Biancone, Ambrogio Orlando, Anna Kohn, Elisabetta Colombo, Raffaello Sostegni,
Erika Angelucci, Fabiana Castiglione, D. Checchin, Claudio Papi, Andrea Cocco, G.
Meucci, Gabriele Riegler, Francesco Mocciaro, Carmelina Petruzziello, Alessandra
Geremia, Emma Calabrese, Mario Cottone, Francesco Pallone
Background. The widespread use of Infliximab (IFX) in Crohn's Disease (CD) rises concerns
about cancer risk in the long term. In a cohort of matched-pair CD patients (pts.) followed
up from Apr. 1999 to Oct. 2004, we previously reported (Gut. 2006; 55:228-33) that the
frequency of newly diagnosed neoplasia did no differ between IFX-treated and untreated
pts. matched for clinical variables. The frequency of cancer in a longer follow up needed
to be investigated in this cohort of pts. Aims. We aimed to assess, in a 2 years longer follow
up, the frequency of new diagnoses of cancer in the same cohort of IFX-treated or untreated
CD pts. Methods. In a multicenter matched-pair study, the same cohort of 404 CD pts.
treated with IFX (CD-IFX) matched with 404 CD never receiving IFX (CD-C) included in
the previous study, was followed up for 2 more years (oct.2004-oct-2006). Cases and
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controls were already matched for sex, age (±5 yrs), CD site, age at diagnosis (±5 yrs),
immunosuppressants (ISS) use and follow up. A lower number of pts. completed the follow
up at 2 yrs, as not all CD-C were still in follow up on Oct. 2004, and few CD-IFX pts.
were lost to follow up. The following data from Oct. 2004-Oct. 2006 were recorded: newly
diagnosed cancer, outcome of previous cancer, new IFX or ISS use. Results. Pts. still in
follow up in Oct. 2006 included: 300 CD-IFX and 288 CD-C. The frequency of newly
diagnosed cancer did not significantly differ between CD-IFX (8/300; 2.6%) and CD-C 6/
288 (2.08%; p=0.48). Also when only matched-pair CD-IFX and CD-C pts. still in follow
up on Oct. 2006 were considered, the frequency of newly diagnosed cancer did not signific-
antly differ between CD-IFX (7/224; 3.1%) and CD-C 4/224 (1.78%; p=0.54). Among the
whole group of 588 pts., new diagnoses of cancer from Oct. 2004 to Oct. 2006 was observed
in 2 pts. in the CD-IFX group (2 breast cancers, both in pts with ISS use) and in 1 pt. in
the CD-C group (1 duodenal adenocarcinoma, with no ISS use). Both pts. are still in follow
up. Conclusion. Present findings from a longer follow up further support that the frequency
newly diagnosed cancer is comparable in pts. treated or untreated with IFX. However, the
new cases of cancer during the last 2 years recommend the need of a longer follow up to
appropriately assess the cancer risk in pts. treated vs untreated with IFX.
T1324
Prevalence and Prognostic Significance of Severe Malnutrition and
Hyperalimentation Among Hospitalized Inflammatory Bowel Disease Patients:
A Nationwide Study
Geoffrey Nguyen, Randa Serag, Themistocles Dassopoulos, Steven R. Brant, Mary L.
Harris
BACKGROUND - Patients with inflammatory bowel disease (IBD), comprising of Crohn's
disease (CD) and ulcerative colitis (UC), are at risk for malnutrition. Hospitalized IBD
patients with the most severe symptoms may be at greatest risk. Our objectives were to
determine the national prevalence of malnutrition among hospitalized IBD patients and its
impact on hospital outcomes. METHODS - All discharges with a primary or secondary
diagnosis of Crohn's disease or ulcerative colitis between the years of 1998 and 2003 were
queried from the Nationwide Inpatient Sample (NIS) using ICD9-CM codes. The NIS is the
largest all-payer hospital dataset in the United States and is representative of all non-federal
acute care hospitals. Severe malnutrition and utilization of parenteral hyperalimentation
were identified by ICD9-CM diagnosis and procedure codes. We estimated in-hospital
mortality, length of stay (LOS) and hospital charges between patients with and without
malnutrition. We adjusted for age, gender, health insurance, comorbidity, geographic region,
and hospital characteristic with multiple logistic regression. RESULTS - There were 62,876
discharges with CD and 38,401 discharges with UC in the NIS between 1998 and 2003.
The prevalence of severe malnutrition was 6.2% among CD patients and 7.2% among UC
patients. The proportion of patients requiring parenteral nutrition was 5.9% and 6.3% for
CD and UC, respectively. In the UC cohort, African Americans (OR 0.66; 95%CI: 0.54 -
0.80) and Hispanics (OR 0.63; 95%CI: 0.51 - 0.79) were less likely to be malnourished
compared to whites. Malnutrition was also less frequent among females with UC compared
to males (OR 0.87: 95%CI: 0.78 - 0.96). The presence of malnutrition was associated with
significantly higher in-hospital mortality for both CD (OR 4.7; 95%CI: 3.5 - 6.3) and UC
(OR 3.9; 95%CI: 3.0 - 5.1), after adjustment for confounders. The average LOS for those
with malnutrition was more than twice that for those without nutritional deficiency among
CD patients (11.4 vs. 5.5 days, p<0.0001) and UC patients (12.5 vs. 6.4 days, p<0.0001).
Similarly, mean hospital charges was notably higher in the presence of malnutrition in
patients with CD ($42,900 vs. $18,800, p<0.001) and in those with UC ($46,300 vs.
$22,200, p<0.0001). CONCLUSIONS - Severe malnutrition occurs with similar frequency
in hospitalized patients with CD and UC and is a harbinger of in-hospital mortality. Poor
nutritional status is also associated with significantly higher resource utilization. Further
studies are warranted to determine whether malnutrition is a risk factor for poor hospital
outcomes independent of disease severity.
T1325
Clinical Outcome of Ulcerative Colitis (UC) in Children: A Prospective 3 Year
Follow-Up from Diagnosis
Libia C. Moy, James Markowitz, David R. Mack, Jonathan S. Evans, Neal S. Leleiko,
Subra Kugathasan, Marian D. Pfefferkorn, Joel R. Rosh, Anthony Otley, Wallace V.
Crandall, Anne M. Griffiths, Maria M. Oliva-hemker, David J. Keljo, Adam G. Mezoff, M.
susan Moyer, Athos Bousvaros, Robert Wyllie, Christine Langton, Jeffrey Hyams
Background: UC causes significant morbidity in children. Increasingly, potent therapies are
used in an attempt to improve clinical outcome. Aim: To characterize the clinical outcome
of children with newly diagnosed UC. Methods: Subjects <16 yrs of age with newly diagnosed
UC and followed for ≥1 yr were accessioned from the Pediatric IBD Collaborative Group
Registry, a prospective, multicenter observational database started in 2002. All subjects were
managed according to the dictates of their physicians, not standardized protocols. UC severity
at presentation and at the end of every quarter of follow-up (f/u) was classified as inactive,
mild or moderate/severe based on the physician global assessment (PGA). Yearly UC activity
was classified as “inactive” if all 4 PGAs in the yr were recorded as inactive, “intermittent”
if ≥1 but <4 quarterly PGAs noted disease activity, and “continuous” if all 4 quarterly PGAs
noted active symptoms. Results: 152 subjects (mean age 11±4yrs, 55% male) were followed
for a mean of 28±11 mos. 10% had proctitis only, 11% left-sided disease and 79% pancolitis.
UC severity at diagnosis (dx) was mild in 35% and mod/sev in 65%. No differences in age
or extent of UC were seen between activity groups. Initial treatments included: 5ASA: mild
75%, mod/sev 54% (p=0.01), steroids: mild 22%, mod/sev 69% (p<0.0001), immunomodul-
ators (IM): mild 2%, mod/sev 8% (p=NS), infliximab (IFX): mild 0, mod/sev 1% (p=NS).
Over the first 3 yrs of f/u, only 20-40% of each group had a year of inactive disease, while
40-60% had intermittent activity and ~10% continuous activity. Treatments during the 3
yrs of f/u are noted in the Table. Colectomy rate in Yr 1 was 5.6% in the mild group and
7% in the mod/sev patients. In Yr 2-3, 0 mild and 3 mod/sev patients required colectomy.
Overall, 10/13 (77%) surgeries were in the first year after dx. Conclusions: UC remains an
illness of significant morbidity in children. Baseline activity does not predict disease activity
in the subsequent 3 yrs after dx. Despite frequent use of IM (~65% by Yr3), only ~50% of
children have inactive disease in any given year of f/u. Colectomy rates are similar between
groups and most common in the first year after dx. New approaches to treatment are needed
to improve the outcome of children with UC.
Treatments by Year of Follow-up
T1326
Long-Term Effectiveness of Azathioprine (AZA) for Crohn's Disease (CD) and
Ulcerative Colitis (UC)
Javier P. Gisbert, P. Niño, C. Cara, M. Bourgois, L. Rodrigo
OBJECTIVE: AZA has been shown to be effective both for inducing and maintaining remission
in CD. However, the long-term effectiveness of AZA and the beneficial effect of this drug
on UC, are both less clear. Our aim was to prospectively evaluate the long-term effectiveness
of AZA therapy in patients with CD and with UC, and to compare the beneficial effect on
both diseases. METHODS: In this prospective study, 394 patients with inflammatory bowel
disease treated with AZA (2.5 mg/Kg) for steroid-resistant, steroid-dependent or fistulizing
disease were consecutively included. Control visits were performed weekly for the first
month, monthly for the following 2 months, and then every 6 months. Truelove modified
index and CDAI were used to assess clinical response. Hospitalizations and surgical proced-
ures performed before and after starting AZA therapy were recorded. RESULTS: Of the 394
patients included, 238 (60%) had CD and 156 (40%) UC. Patients received AZA treatment
for a median of 34 months (range:1-187 months). Effectiveness: Clinical response and
remission was achieved, respectively, in 20% and 60% of the patients, without significant
differences between CD and UC. In the multivariate analysis, the type of disease (CD vs.
UC) did not influence the efficacy of AZA therapy. Differences were neither observed when
Kaplan-Meier curves were compared depending on type of disease (CD vs. UC). At the end
of the study, clinical relapse was documented in 8% of patients (9% with CD and 5% with
UC). Steroid treatment: At the beginning of the study, 49% of CD patients were receiving
treatment with steroids, while this therapy was necessary by only 8% of the patients at the
end of the study (p<0.01). Corresponding figures for steroid-dependency in UC patients
were 39% and 9%, respectively before and after AZA treatment (p<0.01). Hospitalizations:
Prior to AZA treatment, 82% of CD patients had been hospitalized, while after AZA treatment,
this figure decreased to 21% (p<0.01). Hospitalization rates in UC patients, before and after
AZA treatment, were 64% and 9% respectively (p<0.01). Surgical procedures: The cumulative
rate of surgical interventions performed in CD patients prior to and after AZA treatment
was 38% and 5% (p<0.01). Corresponding figures for UC patients were 22% and 1%,
respectively before and after AZA treatment (p<0.01). CONCLUSION: Long-term treatment
with AZA is similarly effective for the clinical management of both CD and UC. AZA therapy
reduced both the number of hospitalizations and of surgical procedures performed during
treatment. At the same time, a clinically meaningful steroid sparing effect was achieved by
the thiopurinic treatment.
T1328
S-Phase Specific Suppression of Pdcd4 Tumor Suppresser in the Cell Cycle of
Hela Cells
Kakimoto Takashi, Iwata Ozaki, Hiroshi Hamajima, Mayumi Nakashima, Kazuma
Fujimoto, Sachiko Matsuhashi
Background & Aim PDCD (programmed cell death ) 4 gene was isolated from a human
glioma cDNA library, by a monoclonal antibody, Pr-28, which recognized a nuclear antigen
involved in the cell cycle. PDCD4/Pdcd4 expression was stimulated at apoptosis, and was
shown to have a suppression activity of carcinogenesis. It was reported that Pdcd4 suppressed
CDK1/cdc2 via induction of p21 in Bon-1 human carcinoid cells. However, precise expression
mechanisms of PDCD4 in the cell cycle are not fully understood. The aim of this study is
to investigate the regulation of PDCD4 expression in the cell cycle. Methods HeLa cells were
synchronized at the G1-S phase with excess thymidine and then hydroxyurea treatments
and subjected to the assay of PDCD4 expression by quantitative RT-PCR and Western
blotting. Results PDCD4-protein was specifically suppressed in the S-phase but PDCD4-
mRNA levels were significantly not changed during the cell cycle. However, expression of
an isoform of PDCD4, H731, which is produced by alternative splicing of the same gene,
was stimulated in the S-phase, indicating that the isoform H731 might play an important
role for PDCD4 suppression at the S-phase. PDCD4 expression may be controlled by ubiquitin
system in the cell cycle because a proteasome inhibiter, MG132, up-regulated PDCD4-
protein levels. On the transfection of cells with PDCD4- and H731-plasmids, PDCD4-protein
was accumulated in the nuclei and induced apoptosis, while H731 localized in the cytoplasm
and did not induced apoptosis. When PDCD4-plasmid was co-transfected with H731,
PDCD4-protein was co-localized with H731 in the cytoplasm, and the nuclear amount
of PDCD4 was decreased. Conclusion These results indicated that PDCD4 expression is
differentially regulated in the cell cycle and H731, a splicing isoform of PDCD4 controlled
PDCD4 amount and localization. Our results also suggested that PDCD4 might be an
important factor to regulate cell cycle progression.
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T1329
Disruption of Transforming Growth Factor-Beta Signaling Through Beta-
Spectrin Elf Leads to Early Hepatocarcinogenesis Through Overexpression of
Cyclin D1
Krit Kitisin, Eugene A. Volpe, Sang S. Kim, Varalakshmi Katuri, Yi Tang, Wilma
Jogunoori, Jon Mendelson, Bibhutibhushan Mishra, Kirti Shetty, Lopa Mishra, Lynt B.
Johnson
Hepatocellular cancer (HCC) is increasing in the United States and is one of the most
common solid malignancies worldwide. Nearly 600,000 cases of HCC are diagnosed each
year with a mortality rate equivalent to its incidence. Recent studies have shown that
transforming growth factor-beta (TGF-beta) signaling members TGF-beta receptor type II
(TBRII), Smad2, Smad4 and Smad-adaptor ELF are prominent tumor suppressors in hepato-
carcinogenesis. Our lab has demonstrated that as many as 40% of elf+/- mice (16/40)
spontaneously develop HCC and phenotypic changes such as increased centrilobular steatosis
and dysplasia. Aims: 1. To analyze changes in cell cycle regulation in HCC tissues derived
from elf+/- mice. 2. To examine whether loss of ELF and cell cycle derangement occur in
human HCCs specimens and in human HCC cell lines. 3. To investigate whether restoration
of ELF can reverse the aberration of cell cycle regulation. Methods and Results: 1. Immunohis-
tochemical studies of elf+/- mouse's HCCs reveal markedly increased cyclin D1, Cdk-4, c-
Myc, and Mdm2 expressions. 2. Further analysis of the role of ELF in human HCC specimens
confirms markedly reduced nuclear expression of ELF in 9 out of 10 human HCC samples
by immunohistochemistry (p<0.039). These HCC samples have increased cyclin D1 expres-
sion. 3. ELF and other proteins involved in the TGF-beta signaling pathway, particularly
Smad4 and TGF-beta receptor II (TBRII), are examined in human HCC cell lines SNU-182,
SNU-398, SNU-449, and SNU-475. Western blot analysis demonstrates that ELF and TBRII
expressions are significantly decreased SNU-182, SNU-398 and SNU-475. 4. Restoration of
ELF and TBRII decreased cyclin D1 (by 80%) and hyperphosphorylated-retinoblastoma
(pRb-P) (by 65%). Thus, we show that TGF-beta signaling and Smad adaptor ELF suppress
human hepatocarcinogenesis, potentially through cyclin D1 deregulation. Loss of ELF could
serve as a primary event in progression towards a fully transformed phenotype and could
hold promise for new therapeutic approaches in human hepatocellular cancers.
T1330
Paracrine Mechanism for TGF-β Mediation of Hepatocellular Tumor Promotion
Natasha G. Deane, Karen C. Hobdy-henderson, Fei Wu, David B. Friedman, Mary K.
Washington, R. daniel Beauchamp
Purpose: Determine the mechanism of TGF-β mediated tumor promotion in transgenic
livers, leading to hepatocellular carcinoma (HCC). Background: HCC is a leading cause of
mortality due to cancer worldwide. A number of molecular features have been associated
with HCC including increased cyclin D1 and increased TGF-β expression. The LFABP-cyclin
D1 transgenic mouse model develops HCC with high penetrance at 12-15 months of age.
Tumor formation associated with hepatocellular apoptosis (cell turnover), inflammation and
loss of the TGF-β signaling intermediate, Smad4. Alb-TGF-β x LFABP-cyclin D1 exhibit
increased tumor burden and increased tumor vascularization. Surprisingly, loss of epithelial
cell TβRII has no effect on tumor formation. Methods: We profiled the proteomes of
transgenic livers using 2-Dimentional DIfference Gel Electrophoresis (2D-DIGE) technology.
In order to study the distinct molecular features of tumor associated epithelial cells and
stromal cells, we isolation pure cell lines from transgenic livers. Results: Network analysis
of proteome profiles demonstrated a metabolic shift toward cellular oxidative stress in
transgenic livers. We validated these molecular changes, as well as predicted changes in
COX-2 and hemoxygenase, in both transgenic livers and in purified transgenic cells lines.
We examined the responses of purified epithelial and myofibroblast transgenic cell lines to
TGF-β and demonstrated upregulation of COX-2 and hemoxygenase in tumor associated
myofibroblasts. Interestingly, while tumor associated epithelial cells produced significantly
more TGF-β than non-transformed transgenic epithelial cells, these cells require exogenous
TGF-β in order to undergo epithelial-to-mesenchymal transition (EMT), indicating that
extra-cellular factors or other paracrine factors required for TGF-β activation. Summary: We
found that transgenic tumors and associated cell lines are associated with increased TGF-β
production, loss of Smad4 expression, and upregulation of mediators of cellular oxidative
stress. We postulate that HCC promotion by TGF-β requires interaction between epithelial
and stromal cells and is enhanced by cellular oxidative stress.
T1331
Multicentric Recurrence of hepatocellular carcinoma and CD-34 Expression in
Background Liver
Naoko Tsuji, Shingo Ishiguro, Masatoshi Kudo
BACKBROUND: Metachronous multicentric recurrence of hepatocellular carcinoma (HCC)
is a well known problem after curative surgical resection. Capillarisation of hepatic sinusoids
is also a well known phenomenon in many liver diseases, especially in neoplastic liver
diseases. In order to predict multicentric recurrence, we investigated noncancerous hepatic
tissues of recurrent patients and long survivors without recurrences, and examined the
expression and distribution of CD34 in order to evaluate the meanings of this marker.
METHODS: Eighteen patients with multicentric recurrence of HCC diagnosed by histological
examination of repeated hepatectomy specimens and 72 HCC patients with more than 5-
year disease free survival after operation were enrolled in this study. Clinicopathological
comparisons were made between two groups. Noncancerous hepatic tissues were examined
by Berlin blue staining for iron deposition and immunohistochemistry using anti-CD34
antibody and CD34-labeling index (LI) were counted. RESULTS: CD34 immunoreactivity
was observed in peribiliary capillaries and periportal sinusoids. CD34-LI was significantly
higher in multicentric recurrent group (P<0.001), and staging scores of fibrosis was also
significantly higher in recurrent group (P=0.035). High histological activity grade (P=0.057)
and high alanin aminotransferases level (P=0.060) tended to be risk factors. There were no
significant differences in age, sex, HBsAg and HCV-Ab status, and the grade of iron deposition
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in both groups. On multivariate analysis, high CD34-LI was the only independent risk factor
(P=0.001) for metachronous multicentric recurrence. CONCLUSION: Increase of CD34-
positive capillaries and sinusoids in background liver is a risk factor for multicentric recur-
rence of HCC. Increased activity and severe fibrosis is also a good predictor. Histologic
assessment of background liver with CD34 immunohistochemistry might be useful for
prognostic evaluation of HCC patients after surgery.
T1332
Comparative Analysis of Tissue Proteomes for the Discovery of Biomarkers
Predicting High Risk of hepatocellular carcinoma
Ki-baik Hahm, Yeong min Park, Hyeon wook Paik, Dong jin Yim, Sung won Cho
In spite of many efforts to find biomarker to predict the risk of hepatocellular carcinoma
(HCC) through the proteomic approach, still many limitations were confronted, including
variation between individuals, non-disease related physiological or genetic causes, biomarker
existing in serum or tissue and comprehensiveness comprising of transcriptional, transla-
tional, and chromosomal informations. Moreover, since malignancy is arising through mul-
tiple steps of inflammation, transformation and dysplasia, we hypothesized that in situ
biomarkers can be drawn from comprehensive high throughput analyses of chromosomal
genomic hybridization, transcriptional gene expression and proteomic analysis of liver tissues
from various clinical stages. For that, we included liver tissues from 4 healthy HBsAg carriers,
3 chronic hepatitis subjects, 2 liver cirrhosis subjects with portal hypertension and 5 HCC
subjects, all of which are hepatitis B virus positive. 2-DE was performed with IPGphor
IEF, image acquisition analysis, tryptic in-gel digestion and MALDI-TOF/MS for protein
identification were done. 25 spots were found to be significantly associated with the develop-
ment and progression of chronic hepatitis B and 70 spots were identified to be involved in
HCC. The difference of proteome between normal and hepatitis and non-cancerous and
cancerous tissue of the identical person reveals potential candidate proteins related with
HCC risk. We also performed the comparative analysis with another data set obtained from
high throughput analysis of array comparative genome hybridization (aCGH) showing hot
clustered spots from chromosome 1q and 8q and biochip microarray expression analysis,
after which CD24, aldehyde dehydrogenase 1, acyl coenzyme A dehydrogenase, thiosulfate
sulfurtransferase, dimethylarginine dimethylaminohydrolase 2, proapolipoprotein, NM23-
H1, MMP-9 were selected as possible candidates for biomarker predicting the progression
of liver disease including HCC. Using these identified genomes, we are validating the value
of these identification with tailored low density diagnostic biochips.
T1333
Predictive Factors of hepatocellular carcinoma in Cirrhosis
Fierbinteanu - braticevici Carmen, Ionita Lucian, Tribus Laura, Usvat Radu, Petrisor Ana,
Bengus Andreea
The incidence of hepatocellular carcinoma (HCC) associated with cirrhosis have increased
over the last decade. The recognition of the risk factors of hepatic carcinogenesis could
improve the early diagnosis and prognosis of HCC. Aim: to investigate the predictive factors
for HCC occurrence in cirrhotic patients Methods: Between 1998 and 2003, 365 cirrhotic
patients, aged 35-65, admitted to the University Hospital Bucharest, were prospectively
followed up during a 3-year period for early diagnosis of HCC. HCC was diagnosed in 31
of them. The predictive value of different risk factors was evaluated using the Kaplan-Meier
method and Cox regression model. The clinical and biochemical parameters consisted of:
age, sex, etiology of cirrhosis, body mass index (BMI), serum aminotransferase, serum
glucose, serum lipid profile, INR, serum glutathione and platelet count. Results: The incidence
of HCC was 3.6 % in the first year, 1.9% in the second and 4.7% in the third. Multivariate
analysis demonstrated that: age (>55years), male sex, HCV (hepatitic C virus) etiology of
liver disease, LDL- cholesterol < 100mg/dl, INR>1. 8 and platelet count <80 × 10 3 /mm
3were important predictors of HCC. Comorbidities: obesity and diabetes mellitus also
increased the HCC risk. According to the contribution of each of these factors, a clinico-
biological score ranging between 0 and 5. 23 was calculated to allow the detection of high
risk patients. Conclusions: Not all patients with cirrhosis had an equal risk for developing
HCC. Parameters like: age, sex, etiology, lipid profile, comorbidity, platelet count and INR
interact to increase the risk of HCC and may be taken into account when selecting the
cirrhotic patients to be screened for this type of tumor.
T1334
Gene Expression Profiles in Gallbladder Cancer: A Very Close Genetic
Similarity Between Early and Advanced Gall Bladder Cancer May Explain the
Poor Prognosis and Invasiveness Gallbladder Cancer
Ji hyang Kim, Kyu taek Lee, Han na Kim, Jong kyun Lee, Seong-ho Choi, Seung woon
Paik, Jong chul Rhee
Purpose: We sought to screen for the cancer-related genes and to suggest the candidates
for tumor markers in gallbladder cancer. And we were to examine the genetic differences
between early and advanced gallbladder cancer. Methods: The total RNA of the tissues was
extracted from 17 gallbladder tissue specimens, including 6 advanced gallbladder cancers
(stage III and IV), 6 early gallbladder cancers (stage IA and IB) and 5 normal controls. DNA
microarrays were used to screen for a 2 fold or more differential expression of genes to
differentiate between gallbladder cancer and the normal controls, and for a 1.7 fold or more
differential expression to differentiate between advanced and early gallbladder cancer. The
screened-out genes were verified by performing real-time PCR. Results: When the gallbladder
cancer was compared with the normal control, we identified 4682 genes, including 2270
over-expressed and 2412 under-expressed genes in the gallbladder cancer. We selected 9
over-expressed genes (SERPINB5, BCL10, CD44, ARHGEF11, SERPINB2, RELA, PAK4,
PPARD and BUB1B) and 1 under-expressed gene (CAV2) for conducting real-time PCR.
Secondly, when the advanced gallbladder cancer was compared with the early gallbladder
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cancer, we identified only 12 genes with greater than a 1.7 fold change. SERPINB5 was up-
regulated in the early gallbladder cancer, even though this was not statistically different.
Conclusions: We have identified genes that may be tumor markers for gallbladder cancer.
A close genetic similarity between early and advanced gallbladder cancer may explain the
poor prognosis of this disease. SERPINB5 can be an early marker for gallbladder cancer.
T1335
The Ethnic Differences in the Trends of Gallbladder Cancer Incidence in
United States
Jehad Barakat, Charles Wiggins, Thomas Y. Ma
Background: Gallbladder cancer (GBC) has a unique ethnic distribution with the highest
incidence rate reported in American Indians in US. The incidence of GBC in US has declined
but incidence trends among different ethnic groups have not been evaluated over time. In
this study, we describe the incidence trends of GBC in different ethnic groups in the
US between 1973 and 2002 using the SEER database. Methods: Using the Surveillance,
Epidemiology, and End Results (SEER) database, the annual age adjusted incidence rates
were calculated and the incidence time trends were compared among the major four ethnic
groups in US, non-Hispanic Whites, American Indians, Hispanics, and Blacks. SEER data
was available from 1973 to 2002 for Whites and Blacks and from 1992 to 2002 for American
Indians and Hispanics. Results: American Indians continued to have the highest incidence
of GBC in US followed by Hispanics, non-Hispanic Whites, and Blacks (3.5, 2.9, 1.1, and
1.2 per 100,000 respectively). Females had higher incidence rates of GBC than males in all
ethnic groups. In non-Hispanic Whites, the incidence of GBC has declined by 40% (from
2.2 to 1.3 per 100,000) in females and by 33% (from 1.2 to 0.8 per 100,000) in males
between 1973 and 2002. In Hispanics, the incidence of GBC has declined by 15% (from
4.5 to 3.8 per 100,000) in females and remained unchanged in males (1.2 per 100,000)
between 1973 and 2002. In Blacks, the incidence trend remained unchanged in both females
and males between 1992 and 2002, the time period for which SEER data on Blacks was
available, (1.2-1.5 and 0.7-1.0 per 100,000 respectively). In American Indians, the incidence
of GBC has declined in males by 34% (from 3.2 to 2.1 per 100,000) but increased in females
by 31% (from 3.5 to 4.6 per 100,000) between 1992 and 2002. Conclusion: The GBC
incidence trends differ greatly between ethnic groups in the US. The incidence of gallbladder
cancer has declined in Whites and Hispanics over time, remained stable in blacks, but
interestingly has increased in American Indian females who have the highest incidence rate
of GBC in US.
T1336
Precancerous Lesions in the Gallbladder of Patients with a Long Common
Channel
Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta, Atsutake Okamoto
Background and Aim: Pancreaticobiliary maljunction (PBM) forms a long common channel
in which communication between the pancreatic and bile duct was maintained even during
sphincter contraction. As the sphincter of Oddi dose not functionally affect the junction of
the pancreatic and bile ducts, reflux of pancreatic juice into the biliary duct of patients with
PBM occurs, resulting in a high incidence of carcinogenesis in the gallbladder. To investigate
the clinical significance of a relatively long common channel, we defined high confluence
of pancreaticobiliary ducts (HCPBD) as presence of a common channel ≥6 mm in which
the communication was disrupted with sphincter contraction. Pancreatic ductal reflux was
detected in 11 of 13 patients with HCPBD in postoperative T tube cholangiography, and
amylase level in the bile was elevated in all cases. This study aimed to investigate histopathol-
ogical changes in the gallbladder of patients with a relatively long common channel. Materials
and Methods: We have treated 43 patients with PBM without biliary dilatation and 62
patients with HCPBD. We histopathologically examined the resected or autopsied non-
cancerous gallbladder lesions from patients with HCPBD (n=20), PBM without biliary dilata-
tion (n=15) and controls (n=10). Hyperplastic changes were defined as an increased number
of mucosal folds that were much longer than normal, irregular, and branched. The mucosal
height of each specimen was measured using a semiautomatic image analyzer. Proliferation
activity (Ki-67 Labeling Index) and K-ras mutations were examined. Results: Gallbladder
cancer occurred more frequently in PBM than in HCPBD (69.8% (30/43) cases vs. 9.7%
(6/62) cases (p<0.01)). The gallbladder mucosa was significantly higher in PBM (median
0.63 mm) than in HCPBD (0.46 mm) or controls (0.32 mm; p<0.01). Mucosal height in
HCPBD was also significantly greater than that in controls (p<0.05). Incidence of hyperplastic
mucosal changes was significantly higher in both PBM and HCPBD than in controls (PBM:
73.3% (11/15); p<0.01 vs. controls; HCPBD: 45.0% (9/20); p<0.05 vs. controls; controls:
0% (0/10)). Ki-67 LI of the gallbladder epithelium was 8.1% in PBM and 9.0% in HCPBD,
significantly higher for both conditions than for controls (1.4%; p<0.01). K-ras mutations
were detected in 33% in PBM and 25% in HCPBD. Conclusion: In HCPBD, although the
incidence of gallbladder cancer was lower and gallbladder height was less than that in PBM,
the gallbladder mucosa displayed hyperplastic changes with increased cellular kinetics which
might be caused by reflux of pancreatic juice and appeared precancerous, with a similar
appearance to that in PBM.
T1337
Preoperative Evaluation of Biliary Ductal Extent of Hilar Cholangiocarcinoma
with Multi-Detector CT and Cholangiography
Ji hyun Song, Jong kyun Lee, Dongil Choi, Kyu tak Lee, Jong chul Rhee
Backgrounds/Aims: In patients with hilar cholangiocarcimoma, defining the extent of biliary
ductal invasion and the exact tumor stage is crucial for therapeutic planning and is directly
connected with the prognosis. Currently, more patients may be candidates for extensive
curable or palliative surgery because of rapid advances in surgical technique and diagnostic
imaging. Multi-detector CT (MDCT) has made considerable advances in high-resolution
imaging and diagnosis has become more accurate. In this study, we analyzed the utility of
MDCT and cholangiography for preoperative evaluation of biliary ductal extent and the
influencing factors for over- or underestimation in hilar cholangiocarcinoma. Methods: From
January 2000 to March 2006, 78 patients (50 men, 28 woman; mean age ± standard
deviation, 59 years ± 8.4) with surgically confirmed hilar cholangiocarcinomas who under-
went preoperative MDCT and cholangiography were retrospectively analyzed with their
radiologic and pathologic findings. Results: For the 56 patients with a preoperative diagnosis
of 'resectable' hilar cholangiocarcinoma, 9 (16.1%) were found to be unresectable because
of Bismuth type 4 ductal extension (n=5), major vascular invasion (n=3), and periduodenal
lymph node metastasis (n=1). Forty-seven patients (83.9%) underwent resection with curative
intent. The margin of resection was negative (R0 resection) in 33 patients (70.2%), and
microscopically positive (R1 resection) in 14 patients (29.8%). CT and cholangiography
accurately predicted ductal extension in 40 (71.4%) of 56 patients. (κ= 0.605, p= 0.000)
Overestimation was noted in 3 patients and underestimation in 13 patients. Sixteen patients
were pathologically confirmed as Bismuth type 4, but only 4 patients were accurately
predicted. 11 patients were considered as type IIIa and 1 patient as type II. The preoperative
evaluation of biliary ductal extent was not affected by ductal wall enhancement, the shape
of ductal wall thickening, the degree or shape of luminal narrowing, tumor gross appearance,
or pathologic type. Conclusion: Combined interpretation of MDCT and cholangiographic
images resulted in 71.4% acuracy for prediction of biliary ductal extent of hilar cholangiocarci-
noma.
T1338
Carcinoma Arising in Congenital Choledochal Cyst
Terumi Kamisawa, Hitoshi Nakajima, Naoto Egawa, Kouji Tsuruta, Atsutake Okamoto
Background and Aims: Congenital choledochal cyst is almost always associated with pancre-
aticobiliary maljunction (PBM). Since the union of the pancreatic and bile ducts is located
outside the duodenal wall and the action of the sphincter muscle does not functionally affect
the union in PBM, there is continuous reciprocal reflux between pancreatic juice and bile.
Thus, choledochal cysts are sometimes associated with biliary carcinoma, but few previous
reports have dealt with the characteristic features of carcinoma arising in the cyst wall. Aim
of this study is to investigate the clinicopathological features and the surgical treatment of
choledochal cyst associated with carcinoma arising in the cyst wall. Methods: Bile duct
carcinoma and gallbladder carcinoma occurred in 8 of 40 patients (30 males and 10 females,
average age 50.6 years) with a choledochal cyst, respectively. The relationship of the surgical
treatment and the clinicopathological findings of 8 patients with histologically proven carcin-
oma that had developed in the wall of a choledochal cyst were examined to determine mode
of tumor spread, multicentric tumor origins, and coincidence with other neoplastic lesions.
Results: Papillary adenocarcinoma (n=5) had different clinicopathological features than tubu-
lar adenocarcinoma (n=3). Papillary adenocarcinoma displayed expansive growth in the duct
wall and a well- circumscribed tumor margin. Radiologically, papillary adenocarcinoma
presented as an eccentrically located polypoid mass in the cyst, while with tubular adenocarci-
noma, there was evidence of bile duct stenosis with irregular thickening of the bile duct
wall. Papillary adenocarcinoma was associated with extensive superficial spread (n=1), syn-
chronous (n=2), or metachronous (n=2) multicentric tumors. Pancreatoduodenectomy with
(n=1) or without (n=1) hepatic lobectomy, and repeated resection by hepatic lobectomy
(n=2) after initial excision of extrahepatic bile duct were performed for these circumstances
of tumors. Extensive or repeated resections allowed 3 patients to live longer than 2 years.
On the other hand, tubular adenocarcinoma was associated with scirrhously infiltrative
spread and only 1 tumor was noncuratively resected. All patients died with local recurrence
or distant metastases within 1 year. Conclusions: Papillary adenocarcinoma occurs frequently
in the choledochal cyst wall. Since aggressive resection offers survival benefits, the presence
superficial spread and multicentric tumors should be identified and taken into account when
planning surgery. Patients required close monitoring so that recurrent carcinoma of the
remnant bile duct can be identified early.
T1339
Irritable Bowel Syndrome and Negative Appendectomy: A Prospective
Multivariable Investigation
Ching-liang Lu, Chun-chu Liu, Jong-ling Fuh, Pei-yi Liu, Chew-wun Wu, Full-young
Chang, Shou-dong Lee
Background: Acute appendicitis is a common surgical emergency, however, negative append-
ectomy (NA) is frequently encountered (>15%). The factor leading to NA is unclear. Subjects
with irritable bowel syndrome (IBS) undergo disproportionately high rates of abdominal/
pelvic surgery and may be predisposed to NA. We prospectively examined whether IBS or
other factors can predict NA. Methods: We enrolled 430 consecutive patients underwent
emergent surgery for suspected appendicitis. Main outcome measures included Rome-II IBS
questionnaire, the Hospital Anxiety and Depression Scale, the Short-Form 36 survey, the
clinical, pathological and computed tomography (CT) findings. Results: The NA group (n=
68, 15.8%) had younger age with female-predominance, higher prevalence of Rome-II IBS
(32.4% vs. 13.8%, p<0.001), higher anxiety/depression scores (p<0.01), and lower levels of
HRQoL than the positive one (Figure). The NA patients tended to have atypical presentations
(absence of migration pain/fever/muscle guarding lower WBC count and percentage of
polymorphonuclear cell (PMNC), and lower rate of CT scan usage than the positive group
(p<0.01). The independent factors in predicting of NA were shown in Table. Conclusion:
Both patient (IBS, anxiety, atypical presentation) and physician (low CT scan usage) factors
are the independent determinants predicting of NA. Physicians should be cautious before
operating on or referring IBS patients for appendectomy. CT scan should be considered
in the patients with suspected appendicitis, particularly in those with IBS and atypical
clinical presentations.
The predictive variables of NA
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HRQoL is worse in NA group. *p<0.01
T1340
Psychosocial Factors Predict the Development of Abdominal Pain Following
Gynecologic Surgery
Ami D. Sperber, Carolyn Blank morris, Lev Greemberg, Shrikant I. Bangdiwala, David
Goldstein, Eyal Sheiner, Yefim Rusabrov, Yuming Hu, Miriam Katz, Douglas A. Drossman
Background. IBS patients undergo more gynecological surgery than population controls.
However, it is not known whether abdominal pain or IBS result from gynecological surgery.
The aims of this prospective, controlled study were to: 1) assess the incidence of abdominal
pain and IBS in women undergoing elective surgery for non-pain indications compared to
non-surgical controls, and 2) identify factors associated with the development of pain.
Methods. Women without IBS undergoing gynecologic surgery were compared to matched
non-surgery controls seen in gynecology clinic. We evaluated demographic, psychosocial,
and clinical features at enrollment (before surgery) and 3 and 12 months after surgery.
Logistic regression was performed on the women without baseline pain who underwent
surgery to determine the factors predicting the development of pain at 3 or 12 months post-
surgery. Results. 132 surgical patients and 123 matched controls participated. The drop-
out rate was 15%. Significantly more surgical patients developed abdominal pain at 3- or
12 months (13.9% vs. 1.9%, P=0.0012). Fourteen of the 101 surgery patients without
baseline pain developed pain. Bivariate analyses revealed that pain development was signific-
antly associated with the following variables: more severity/constancy of illness (IMIQ,
severity; P=0.02), more personal control over their illness (IMIQ, controllability; P=0.04),
lower sense of coherence (SOC, coping skills; P=0.001), and greater anticipated difficulty
recovering from surgery (P=0.03). The logistic regression model showed that pain develop-
ment was predicted by the psychosocial factors in the table below. Socio-demographic
including age and level of education and clinical variables including surgery type (hysterec-
tomy, tubal ligation, cystectomy, et al.), laparotomy vs. laparoscopy, surgery duration,
amount of post-operative analgesia, and surgical complications did not predict pain develop-
ment. There was no significant difference in the development of IBS between the surgery
and control groups. Conclusions. The results of this study show that abdominal pain
developed in women undergoing gynecologic surgery for non-pain indications. Only psy-
chosocial variables predicted its development, implying that pain development is associated
more with central registration and amplification of the afferent signal (via cognitive and
emotional input) than with the peripheral injury itself.
T1341
IBS & Chronic Fatigue in Functional Dyspepsia: Comorbidity and
Determinants of Symptoms
Lukas Van oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Benjamin Fischler,
Koen Demyttenaere, Jan Tack
Background Overlap between functional dyspepsia (FD), irritable bowel syndrome (IBS) &
chronic fatigue (CF) has been reported, suggesting a common pathophysiology. Aims 1.To
determine the frequency of IBS & CF co-morbidity in FD 2.To determine the relative
contribution of gastric sensorimotor function, psychosocial factors & somatization to IBS
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& CF co-morbidity in FD. Methods In 139 consecutive FD patients (102 women, mean
age 39), we studied gastric sensorimotor function with barostat (sensitivity, compliance,
accommodation) & gastric emptying test. We measured psychosocial factors (depression,
anxiety, alexithymia, perceived stress & abuse history) and somatization using self-report
questionnaires. Rome II IBS status was obtained from a 10-item questionnaire. CF status
was obtained from a VAS measurement of momentary fatigue and a chronicity (>6 months)
question. Gastric sensorimotor function, dyspepsia severity score (DSS) (10 symptoms),
weight loss, psychosocial factors & somatization were compared relative to IBS & CF status;
multiple logistic regression was used to identify determinants of IBS & CF status. Results:
50(36%) patients had co-morbid CF symptoms. 80(61%) patients had co-morbid IBS. IBS
status was associated with lower gastric discomfort threshold, less externally oriented thinking
(EOT) (factor of alexithymia), higher gastric accommodation, somatization & perceived
stress and with abuse history (overall abuse history as well as history of sexual, psychological
or physical abuse and childhood or adulthood abuse). The following model was found to
predict IBS status best (c=.86,p<.0001): gastric accommodation (β=.004,p=.07), gastric
discomfort threshold (β=-.19,p=.05), somatization (β=.27,p=.01), EOT (β=-.15,p=.03), his-
tory of psychological abuse (β=0.88,p=.08) and history of sexual abuse (β=0.96,p=.03). CF
status was associated with older age, slower liquid gastric emptying, more weight loss, higher
DSS, depression, somatization & perceived stress scores and with abuse history (overall
abuse history, overall childhood abuse history, childhood psychological abuse history and
adulthood physical abuse history). Age (β=.06,p=.02), weight loss (β=.11,p=.01), somatiz-
ation (β=0.68,p=.04) and overall abuse history (β=-.59,p=.04) were found to be independent
determinants of CF status (c=.83,p<.0001). Conclusion: Co-morbidity with IBS & CF is
high in FD, and abuse history is an important predictor of both. As abuse may alter the
reactivity of biological stress system and pain-processing systems, this may be relevant to
the pathophysiology and classification of functional gastrointestinal disorders as well as other
functional somatic syndromes.
T1342
Determinants of Somatization in Functional Dyspepsia: Gastric Sensorimotor
Function, Psychosocial Factors Or Comorbid Functional Somatic Syndromes?
Lukas Van oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Benjamin Fischler,
Koen Demyttenaere, Jan Tack
Background Somatization is considered an important mechanism contributing to the patho-
genesis of “functional somatic syndromes” (FSS) including functional dyspepsia (FD). Evid-
ence for a multidimensional model of somatization is growing, but the biopsychosocial
processes underlying this descriptively defined concept are not well known. Aim To deter-
mine the relative contribution of gastric sensorimotor function, psychosocial factors &
comorbid FSS to somatization in FD. Methods In 175 consecutive tertiary care FD patients
(mean age 40), gastric sensorimotor function was studied with barostat (sensitivity, compli-
ance & accommodation) and gastric emptying test. Psychosocial factors (depression, anxiety,
positive & negative affect, alexithymia, perceived stress & abuse history), FSS (dyspepsia,
IBS&fatigue symptoms) and somatization (excluding GI symptoms) were assessed with
self-report questionnaires. Gastric sensorimotor function, psychosocial factors & FSS were
correlated with somatization. Univariate correlates of somatization were entered into a
hierarchic multiple linear regression model. ResultsUnivariate associations Sociodemographic
factors Female gender, familial status & employment status were associated with somatization.
Gastric sensorimotor function Gastric discomfort threshold correlated negatively with somatiz-
ation; liquid half-emptying time correlated positively. Psychosocial factors Abuse history &
panic disorder were associated with higher somatization. Trait anxiety, depression, alexithy-
mia [especially difficulty identifying feelings (DIF)], negative affect & perceived stress correl-
ated positively with somatization; positive affect correlated negatively. Comorbid FSS Comor-
bid IBS & chronic fatigue symptoms were associated with higher somatization. Dyspepsia
symptoms (DSS) correlated positively with somatization. Hierarchical multiple linear regression
The following model was found to predict somatization best: gastric discomfort threshold
(β=-0.18,p=0.04), DIF (β=0.05,p=.39), abuse history (β=-0.94, p=.14), depression (β=
0.16,p=.02), panic (β=-1.1,p=.16) & DSS (β=0.26,p=.001) (model controlling for employ-
ment status, R2=.46,p<.0001). The “trait” psychosocial factors DIF & abuse did not have a
significant direct effect on somatization after the “state” psychosocial factors depression &
panic were entered into the model, but their effect was mediated by depression & panic.
Moreover, the effect of panic on somatization was mediated by depression. Conclusion
Somatization in FD is a multidimensional biopsychosocial phenomenon, related to dyspepsia
symptoms as well as gastric sensorimotor function, psychosocial & sociodemographic factors.
T1343
Double-Blind Placebo-Controlled Trial of Low-Dose Amitriptyline for the
Treatment of Irritable Bowel Syndrome in Adolescents
Ron J. Bahar, Brynie S. Collins, Barry A. Steinmetz, Marvin E. Ament
Objectives: Irritable bowel syndrome (IBS) is a common entity among adolescents. However,
little data exists to guide therapy for IBS in this age group. Amitryptiline (AMI) has been
successfully utilized to treat IBS in adults. The goal of this study was to determine the
efficacy of AMI therapy in adolescents with IBS. Methods: Upon enrollment, patients, ages
12-18 years, with newly diagnosed IBS based on Pediatric Rome II criteria, were asked to
complete data collection packets to evaluate their pain. Each packet contained an IBS quality
of life questionnaire, a symptom checklist, a pain rating scale, and a visual analog scale.
Subjects were then randomly selected in a double-blinded fashion to receive either AMI or
placebo, and then again asked to complete data packets at times 2, 6, 10, and 13 weeks.
The three phases of the study included two weeks of enrollment and symptom scoring,
eight weeks of therapy with AMI or placebo, and three weeks of “washout” and symptom
scoring. Results: 33 patients (24 female) were evaluated. When compared to the placebo
group, subjects receiving AMI were significantly more likely to experience an improvement
from baseline in dysphoria at 10 and 13 weeks (p = 0.003 and 0.014, respectively), interfer-
ence with activities at 6 and 10 weeks (p = 0.03 and 0.003, respectively), health worry at
10 and 13 weeks (p = 0.024 and 0.0002, respectively), food avoidance at 6 and 10 weeks
(p = 0.008 and 0.007, respectively), and overall score at 6, 10, and 13 weeks (p = 0.019,
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0.004, and 0.013, respectively). Subjects receiving AMI were significantly more likely to
experience a reduction in IBS-associated diarrhea at 6 and 10 weeks than those patients
who received placebo (p = 0.029 at both intervals). Subjects receiving AMI were significantly
more likely to experience a reduction in periumbilical abdominal pain at 10 weeks than
those patients who received placebo (p = 0.018). Subjects receiving AMI were significantly
more likely to experience a reduction in right lower quadrant abdominal pain at 6, 10, and 13
weeks than those patients who received placebo (p = 0.014, 0.039, and 0.004, respectively).
Conclusion: AMI significantly improves overall quality of life in adolescents with IBS, and
should be considered as a therapeutic option in these patients.
T1344
Excess Medical Diagnoses in Families of Irritable Bowel Syndrome (IBS)
Patients
Olafur S. Palsson, Miranda A. Van tilburg, Rona L. Levy, Marsha Turner, Denesh K.
Chitkara, Lisa M. Gangarosa, Motoyori Kanazawa, William E. Whitehead
Previous studies have indicated that intergenerational transmission of illness through
modeling and/or reinforcement may play a role in IBS. One confirmation of such influences
would be an excess frequency of chronic illness in IBS families of origin. Aims: To test in
a preliminary fashion whether the immediate families of IBS patients, and especially parents
(principal sources of childhood modeling of behavior and coping), have elevated frequency
of chronic medical problems, and whether such family backgrounds affect current disease
coping and morbidity. Methods: 209 IBS patients (Rome II criteria+ physician diagnosis;
83.4% females; mean age=35.3 years) and 60 control subjects without gastrointestinal
problems (87% females; mean age=37.6 years) reported whether they themselves, their
mother, father or siblings had ever been diagnosed with 12 chronic medical conditions
(Comorbid Medical Conditions Questionnaire; IBS and psychiatric conditions excluded).
Subjects also completed the IBS Severity Scale, the IBS-QOL, and the Recent Physical
Symptoms Questionnaire (RPSQ-an IBS-specific measure of somatization). Results: IBS
patients reported more instances of chronic illness in their families than healthy subjects
(3.60 vs. 1.96; p<.0001). The average odds ratio of total instances of the 12 chronic conditions
in IBS vs. healthy subject families was 2.39 (range: 1.18 - 4.22), the highest three being
4.22 for dysmenorrhea, 4.20 for chronic fatigue syndrome and 3.66 for insomnia. Illness
amount in the immediate family was correlated with the subjects' RPSQ somatization scores
in both IBS patients (Rho=.39; p<.0001) and healthy controls (Rho=.49; p<.0001). IBS-
QOL quality of life impairment was correlated with reported illness in only same-sex parents
(but not in siblings or opposite-sex parents) for both IBS males (Rho = -.40; p=.02) and
females (Rho= -.191, p=.01). Illness of mother, but not father or siblings, was also associated
with greater IBS severity in female patients (Rho=.16; p=.03). Conclusions: IBS patients
report a pronounced excess of chronic illness diagnoses in their immediate family compared
to controls. Family illness amount is correlated with subjects' somatization tendency. Only
same-sex parent illness is associated with quality of life impairment in IBS. These results
suggest an effect of modeling on IBS symptoms and life impact. However, this needs to be
further confirmed by surveying family members of IBS patients directly about their medical
history in future work. [Supported by grants RO1 DK31369, R24 DK67674 and RR00046]
T1345
Cognitive Behavior Therapy Improves Severity of IBS Symptoms By Modifying
Patients' Illness Beliefs: Results of a Randomized Clinical Trial
Jeffrey M. Lackner, Susan S. Krasner, Brian Quigley, Gregory D. Gudleski, Catherine
Powell, Leonard Katz, Praveen Sampath, Kenneth A. Holroyd
Background & Aims: While multiple clinical trials support the efficacy of a specific psycholo-
gical treatment called cognitive behavioral therapy (CBT) for reducing symptoms of IBS,
studies investigating the mechanisms responsible for symptomatic improvement are lacking.
The broader behavioral medicine literature suggest that CBT relieves painful physical condi-
tions (e.g., headache, TMD, fibromyalgia) by modifying patients' beliefs about their illness.
Methods: We used regression analyses to test whether changes in 3 cognitively oriented
treatment process variables (self efficacy [SE], locus of control [LOC], pain catastrophizing
[PC]) statistically explain improvement (global improvement, IBS symptom reduction, quality
of life [QOL]) resulting from a 10-wk regimen of CBT. Pre- and post-reatment measures
(IBS Symptom Severity Scale, IBS Management SE Scale, Clinical Global Impressions -
Improvement Scale, IBS-Specific LOC Scale, Catastrophizing scale of the Coping Strategies
Questionnaire, IBSQOL) were obtained from 30 CBT treated and 21 wait listed Rome II
diagnosed IBS patients. Results: Multiple regression analyses were utilized to evaluate the
relationship between changes in treatment process variables and treatment outcome with
age, baseline MD ratings of IBS severity, and gender entered as covariates. Treatment (CBT
> WL) significantly predicted changes in cognitive variables as well as global improvement,
symptom reduction, and QOL. Indications of mediation of the effects of treatment on IBS
Symptom Severity from pre to post treatment were found for changes in SE, F (5, 44) =
10.61, p < .001, R2 = .50, Z = 2.84, p < .05, and changes in LOC-Chance subscale, F (5,
44) = 10.00, p < .001, R2 = .48, Z = 2.52, p < .05. Similarly, the effect of treatment on
Changes in QOL pre to post treatment was mediated by changes in both SE, F (5, 44) =
7.61, p < .001, R2 = .46, Z = 3.16, p < .05, and LOC-Chance, F (5, 44) = 7.68, p < .001,
R2 = .41, Z = 2.83, p < .05. Mediation of QOL was also suggested for PC, F (5, 44) = 9.11,
p < .001, R2 = .45, Z = 1.97, p < .05. Paralleling the other 2 outcome measures, patients'
estimations of Global Improvement in IBS symptoms were mediated by changes in SE, F
(5, 32) = 17.40, p < .001, R2= .69, Z = 3.28, p < .05, LOC-Chance, F (5, 32) = 12.54, p
< .001, R2 = .61, Z = 2.21, p < .05, as well as by LOC-Internal, F (5, 32) = 14.16, p <
.001, R2 = .64, Z = 2.30, p < .05. Conclusion: Data from mediational analyses are consistent
with the hypothesis that CBT improves GI symptoms by systematically modifying patients'
causal (LOC) and control (SE) beliefs about managing IBS. Supported by NIH/NIDDK
grant #67878
T1346
Hypnosis and Satiety in Healthy Volunteers
Luis M. Bustos-fernandez, Patricia Alcaraz, Susana Fernández porto, Liliana Monastra
varrica, Carlos Malvezzi taboada, Guido Iantorno
Background: There is now good evidence that hypnotherapy can modify several gastrointesti-
nal functions (e.g. gastric acid secretion, orocecal transit time, rectal sensitivity) and it is useful
in the management of gastrointestinal functional disorders (e.g. irritable bowel syndrome,
dyspepsia, non-cardiac chest pain). Aim: To assess if hypnosis can modify satiety in healthy
volunteers (HV). Design: prospective, open, randomized, pilot study, with a crossover design
for hypnotic procedure. Material and methods: A total of 19 HV, 11 females, aged 22-55 years
(mean: 29,4) and 8 males, aged 23-34 years (mean: 27,37) fulfilling hypnotic susceptibility
according to a validated questionnaire (Absortion Scale) were evaluated. Mean weight in
females was 62,69 Kg (52-84,5) and in males 83,1Kg (62-112,7). Satiety drink test (SDT)
was performed using a balanced energetic drink (1,5 Kcal/ml) administrated at 15 ml/min
and expressed as the maximum Kcal tolerated per individual. All subjects attended for 3
sessions at weekly intervals and gave their written informed consent before entering in the
study. After a SDT at baseline, all subjects were randomized to 2 groups before performing
the SDT: Group 1 receiving only induction (I) of the hypnotic state and Group 2 receiving
induction plus a direct suggestion satiety oriented (I+S). At the third session, subjects in
Group 1 received (I+S) and conversely, subjects in Group 2 (I+S) were put on (I) before
performing the SDT. Results: In women, mean maximum Kcal tolerated was at basal 560,45
(mean SE 30,25) vs 638,18 (mean SE 45,13) after (I) and vs 482,68 (mean SE 38,53) post
(I+S), showing a significant difference (p<0.01) in satiety after (I+S) compared to basal
satiety. It is interest to note that a significant difference (p< 0.01) was also observed when
comparing mean maximum Kcal tolerated after (I) alone vs (I+S). No difference in satiety
(SDT) was found in men between basal compared to (I) and vs (I+S), being mean maximum
Kcal tolerated at basal 717,13 (mean SE 102,21) vs 767,81 (mean SE 68,22) after (I) vs
776,38 (mean SE 93,44) after (I+S). Conclusion: Satiety can be significantly modified by
hypnosis in female healthy volunteers. Mechanisms why women are more prone than men
to achieve a significant difference in satiety after hypnosis are not completely understood.
T1347
Effect of Psychosocial Stress On Esophageal Peristalsis, Sensitivity and Post-
Prandial Gastroesophageal Reflux
Radu Tutuian, Kerstin Suarez, Daniel Pohl, Bernadette Stutz, Michael Fried, Ulrike Ehlert
Background: Recent studies report on the influence of psychological stressors on upper
gastrointestinal tract motility and perception. There is limited information on the effect of
psychosocial stress on esophageal function, perception and gastroesophageal reflux. Aim:
To evaluate the influence of an acute psychosocial stressor (Trier Social Stress Test, TSST)
on esophageal peristalsis, sensitivity to balloon distension and post-prandial gastroesophageal
reflux in healthy volunteers. Methods: On two separate days healthy volunteers (males only,
age >18 years) underwent (1) high resolution manometry during liquid and bread swallows,
(2) esophageal balloon distensions using barostat (step-wise ramp distensions 3mmHg for
5 min up to max. 15mmHg) and (3) impedance-pH monitoring for 1 hour after consuming
a refluxogenic meal. Subjects were randomly assigned to undergo these tests under a) neutral
conditions or b) after administration of TSST. Serum cortisol levels were used to monitor
the general activation during TSST. A general lineal model (GLM) was used to evaluate the
effects of stress, first vs. second day of study and inter-subject differences on manometric,
barostat and impedance-pH parameters. Results: Following TSST 14 healthy male volunteers
had higher number of acid reflux episodes (3.9±0.6 vs. 2.2±0.4; p<0.05) compared to neutral
conditions, but had a tendency towards lower heartburn VAS scores (15±4 vs. 22±6; p=
0.402) and similar dysphagia VAS scores (24±5 vs. 24±7; p=0.16). Subjects reported higher
dysphagia VAS scores (29±6 vs. 18±6; p=0.01) during the first compared to the second
study day. Stress and test day had no influence on manometric parameters and esophageal
compliance. Summary and Conclusions: 1. While acute psychological stress changes the
composition of post-prandial reflux there is a tendency to decrease esophageal perception.
2. Decreasing intensity of esophageal sensations over time suggests habituation to unpleasant
stimuli. Suppressing visceral sensations under acute stress conditions might be a mechanism
to maintain attention to external stressors.
Data are presented as mean ± SEM
T1348
Subjective Experiences of Irritable Bowel Syndrome (IBS) Patients: An
Exploratory Study of the Social Stigma of IBS
Tiffany Havlicek, Jason Bratten, Laurie Keefer, Michael P. Jones
Introduction: As with many unexplained disorders and poorly treated disorders, IBS pts are
often regarded as neurotic, malingering or “stressed out.” Consequently, pts may not disclose
their condition or seek care. Therefore, stigma, due to its effects on care and quality of life,
may be a relevant determinant of outcome. There are minimal data regarding stigma in IBS.
We sought to identify potential sources of stigma in IBS pts via qualitative interviews.
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Methods: IBS pts attending a university outpatient gastroenterology clinic were evaluated
using an audio-recorded, 21-item structured interview as an initial step to develop a measure
of IBS Stigma. Interviews were transcribed for review and content analysis was done to
identify common stigma dimensions and sub-dimensions based on the stigma theoretical
framework. Based on the dimensions derived from the clinical interviews, a questionnaire
was given to community members (CM) via a focus group to further evaluate stigma in this
population. Results: A total of 34 clinic pts and 15 CM participated in the study. Participants
in both groups were predominantly female (31pt/11CM; p=0.1), Caucasian (32pt/11CM;
p=0.3), and college educated (23pt/10CM). No significant differences were found between
groups for age (pt=47±16 yrs; CM=47±19 yrs, p=.96), length of symptoms prior to diagnosis
(pt=11±14; CM=11±20, p=.94), severity of symptoms (mod to sev: pt=85%, CM=67%, p=
.55), or years since diagnosis (pt=10±9, CM=10±8, p=.80). 57% of pts and 22% of CM
reported feeling that IBS was not taken seriously by others. Other stigmatizing themes
included the belief that that IBS is “all in their head” (pts=29%, CM=31%) and that IBS
symptoms are self-inflicted or their fault (pts=39%, CM=58%). 64% of pts and 62% of CM
limited disclosure of IBS to others while 46% of pts and 75% of CM felt that public knowledge
about IBS was low. Conclusions: These data suggest that IBS sufferers perceive several
dimensions of illness stigma, limit disclosure of their illness to others and have concerns
regarding public attitudes and knowledge of IBS. This is similar to reports in other conditions
such as mental illness and HIV. Given that stigma may increase psychological stress, and
that stress may be a perpetuating factor in IBS, stigma may exacerbate and perpetuate IBS
symptoms. These findings warrant further investigation into the presence of stigma in IBS
patients and its effect on patient outcomes.
T1349
The Perceived Stigma Scale in IBS: A Preliminary Report On Development and
Validation
Michael P. Jones, Tiffany Havlicek, Laurie Keefer, Jason Bratten, Nancy J. Norton, Michael
D. Crowell, Rona L. Levy, Olafur Palsson
Introduction: As with many unexplained disorders and poorly treated disorders, IBS pts are
often regarded as neurotic, malingering or “stressed out.” These stigmatizing attitudes may
impact quality of life, healthcare seeking and generate symptom-associated stress that exacer-
bates or perpetuates IBS. Unfortunately, few studies have addressed stigma in IBS and
no condition-specific measure exists. Using information gathered from structured patient
interviews and expert panel opinion, we sought to develop a valid and reliable measure of
perceived stigma in pts with IBS. Methods: Structured interviews with 34 IBS clinic pts and
15 community members with IBS were used to identify relevant stigma dimensions. An
expert panel reviewed these data and developed a 10-item questionnaire that focused on
aspects of disclosure, attitudes and knowledge regarding IBS, condition validity and ser-
iousness and blame. Each item was evaluated with respect to family members, significant
other, friends, employer/supervisor and coworkers/classmates. The initial measure was
administered to a group of pts with an established diagnosis of IBS. An HIV stigma scale,
modified for IBS was concurrently administered to assess construct validity. Test-retest
reliability was determined by readministering the stigma measure after a two-week interval.
Results: At the time of abstract submission, 44 patients had completed the assessment (11M/
33F; mean age ±SDEV =36±14yrs) and 10 patients had completed the retest. Pts reported
symptoms being present for 8.4±8.3 years and had carried a diagnosis of IBS for 6.0±6.3
years. Using a 5-point Likert scale to rate symptoms from mild (0)to severe (5), the mean
score was 3.2±1.1. Scores for perceived stigma did not significantly correlate with age (r=
0.03), gender (p=0.96), symptom or diagnosis duration (r=-0.06 and r=0.22) or symptom
severity (r=0.24). Stigma scores were significantly correlated with scores from the modified
HIV stigma instrument (r=0.66; p<0.0001). Cronbach's α was estimated at 0.907. Mean
inter-item correlation was 0.494 and ranged from 0.211-0.732. Guttman's split-half reliability
coefficient was estimated at 0.904. Test-retest reliability was high (r=0.87; p=0.001). Conclu-
sion: These findings suggest that the Perceived Stigma Scale in IBS is a valid, reliable measure
of patient-perceived stigma related to their condition. Further validation of the instrument
is ongoing. This measure may be useful in clinical, research and educational settings to
better define, understand and address stigma related to IBS.
T1350
Anorectal Biofeedback Therapy Is As Effective for Non-Diarrhoea Predominant
Irritable Bowel Syndrome As for Functional Constipation
Vid P. Suttor, Gillian Prott, Ross D. Hansen, John E. Kellow, Allison Malcolm
BACKGROUND: Biofeedback therapy is the treatment of choice for constipation due to
pelvic floor dyssynergia (PFD), supported by recent randomised controlled trials. Irritable
bowel syndrome (IBS) patients may exhibit concurrent features of pelvic floor dyssynergia.
However biofeedback therapy is not part of the standard treatment algorithm for IBS. AIM:
To prospectively evaluate the efficacy of biofeedback therapy in female patients with non-
diarrhoea predominant IBS (non-D IBS) and features of PFD, compared to patients with
constipation due to PFD. METHODS: 30 consecutive female patients referred with constipa-
tion and two or more symptoms of PFD (straining, incomplete evacuation, sensation of a
blocked anus, digital evacuation, anal pain) were studied. 17 had non-D IBS (mean±SD age
48±15 yr) and 13 had functional constipation (FC; 51±9 yr), according to ROME II criteria.
Assessment at the beginning and end of a 6-visit (12 weeks) anorectal manometry-based
biofeedback therapy course included the Rome II Integrative Questionnaire, 10 cm visual
analogue scores for patient satisfaction with bowel habit and impact on quality of life, a
validated constipation questionnaire1 and a comprehensive anorectal physiology study. A
global clinical improvement score was recorded at the 6th visit. RESULTS: In both groups,
there was a major improvement in bowel satisfaction score with therapy (non-D IBS 5.4±2.5
cm, p<0.0001; FC 5.0±2.3 cm, p<0.0001). There was also a similar reduction in the impact
of their bowel habit on quality of life (non-D IBS 3.4±2.8 cm, p<0.001; FC 3.7±2.7 cm,
p<0.001). Physiologically, 6/6 non-D IBS patients with initial paradoxical anal contraction
on strain normalised with therapy (p<0.001), compared to 6/9 FC patients (p<0.05; p=NS
between groups). For those with abnormal balloon expulsion at baseline, 8/10 non-D IBS
and 2/2 FC were able to expel the balloon normally at the 6th visit (p<0.01 for both goups).
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The global clinical improvement score was similar for the two groups, with 75% of all
patients rated as “improved” or “very improved”. CONCLUSION: The efficacy of anorectal
biofeedback therapy in non-D IBS with PFD is similar to that in FC with PFD. Improvement
can be demonstrated in symptoms, physiology, patient satisfaction, and impact of bowel
habit on quality of life. Biofeedback therapy should be utilised in the management of IBS
patients with features of PFD. 1. Ref: Knowles et al; Dis Colon Rectum 2000.
T1351
Effects of Biofeedback On Psychologic Profiles & Quality of Life in
Dyssynergic Defecation (DD) - A Randomized Controlled Trial
Satish S. Rao, Kara Seaton, Konrad S. Schulze, Kice Brown, Bridget Zimmerman
Introduction: Patients with dyssynergia also exhibit profound psychological dysfunction and
impaired QOL (Gastroenterology 2005: 128: A783). Whether short term treatment (3
months) with biofeedback (BT) improves these dysfunctions is unknown. Methods: Patients
with DD [Rome II] enrolled in a RCT of 3 treatments were assessed at baseline and at end
of treatment (3 months) with SCL-90-R and SF-36 questionnaires. BT consisted of six
sessions of manometric-assisted pelvic floor relaxation; relaxation therapy (RT) consisted of
6 sessions of progressive muscle relaxation and standard therapy (ST) consisted of diet and
laxatives. Clinical improvement was assessed by number of complete spontaneous bowel
movements (CSBM) and presence of dyssynergia. Results: 65 patients (89% women) com-
pleted treatment. Psychological profiles were unaffected by BT, but 4 domains improved
with RT and 2 with ST (table). Three QOL domains improved with RT and one with BT
but other domains were unaffected. An ITT analysis showed that the number of CSBM
increased with BT when compared to baseline (p<0.02) or other treatments (p<0.05), but
not with RT or ST. Likewise, dyssynergia normalized in 81% of BT group (p<0.0001) but
not in other groups. Conclusions: Although biofeedback improved symptoms and anorectal
function, it did not affect psychological profiles or QOL. In contrast, RT improved some of
the psychological domains and QOL, possibly through its effect on stress reduction, although
constipation did not improve. Alterations in psychological behavior and QOL appear to be
independent of bowel dysfunction. Treatment of these dysfunctions may play an adjunct
role in the management of DD.
Bold = p<0.05 versus baseline; * = p<0.05, BT versus RT; # = p<0.05, BT versus ST
T1352
Dementia and Cognitive Impairment Are Not Associated with Earlier
Mortality After Percutaneous Endoscopic Gastrostomy
David I. Gaines, Mark H. Delegge, Valerie Durkalski
Abstract: Studies have shown varying results with regard to risk factors for mortality after
percutaneous endoscopic gastrostomy (PEG). We examined the time to death in patients
with a diagnosis of dementia or cognitive impairment due to neurologic injury who had
undergone PEG at the Medical University of South Carolina compared with patients without
these diagnoses. We also examined risk factors for 30-day mortality after PEG. Methods:
Patients who had undergone PEG from January 1, 2003 to December 31, 2004 were
retrospectively identified from the local database. The local medical records and Social
Security Death Index were reviewed to obtain information about the patients' age, gender,
serum albumin at the time of PEG, diagnoses, presence or absence of dementia or cognitive
impairment due to neurologic injury, presence or absence of complications related to PEG
placement, and length of survival after PEG. The Charlson Comorbidity Index (CCI) was
calculated for each patient based on the medical diagnoses at the time of PEG. Results: One
hundred ninety patients were identified. Forty-five carried a diagnosis of dementia and/or
cognitive impairment at the time of PEG compared with one hundred forty-five who did
not. The median survival of patients with dementia or cognitive impairment was fifty-three
days compared with seventy-eight days in patients without these diagnoses (p value =0.85).
Increasing age (OR 1.1, 95%CI 1.04-1.12) and decreasing serum albumin (OR 0.43, 95%CI
0.22-0.84) were associated with increased 30-day mortality, whereas gender (OR 1.2, 95%CI
0.47-2.90), CCI (OR 1.1, 95%CI 0.86-1.32), and presence of PEG-related complications
(OR 1.6, 95%CI 0.36-6.76) were not. Conclusion: Age and serum albumin at the time of
PEG are risk factors for 30-day mortality after PEG. Patients with dementia or cognitive
impairment do not have shorter survival after PEG than patients with intact cognitive function.
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T1353
Safety and Efficacy of Feeding Jejunostomy in Hyperemesis Gravidarum
Sumona Saha, Donna Diciccio, Victor Pricolo, Silvia Degli-esposti
Background and Aims: Hyperemesis gravidarum (HG) is severe nausea and vomiting during
pregnancy leading to dehydration, nutritional deficiency, and increased fetal morbidity and
mortality. Weight loss of greater than 5% of pre-pregnancy body weight distinguishes HG
from nausea and vomiting of pregnancy. The goal of therapy is to maintain fluid and
electrolyte balance and caloric intake. Strategies to treat HG include dietary modification,
hydration and pharmacotherapy. In refractory cases, total parenteral nutrition is used,
however, complication rates for TPN in pregnancy are high. Infection and thrombosis occur
in up to 50% of patients. Nutrition via nasoenteric and percutaneous endoscopic gastrostomy
tubes is limited by poor patient tolerance, tube dislodgement and altered anatomy in preg-
nancy. We describe nutrition by surgically placed jejunostomy tubes (J-tube) in 6 pregnancies
complicated by severe HG. All cases resulted in term deliveries of healthy infants. Complica-
tions were minor. Methods: Patients with severe HG who failed standard therapy were
offered J-tubes. Failure was defined as weight loss despite IV hydration, anti-emetics, acid
suppression and pro-kinetic drug use. All patients underwent surgical J-tube placement in
the second trimester of gestation. Isotonic tube feeds were administered to a goal caloric
intake calculated by the Harris-Benedict formula. Patients were monitored until delivery.
Results: Five women underwent J-tube placement at our institution between 1998 and 2005.
One patient underwent J-tube placement twice for consecutive pregnancies. Four women
had a history of HG with prior pregnancies. The mean body weight loss from pre-pregnancy
was 7.9% (range 4.0-15.9%). Patients underwent J-tube placement under general anesthesia
between 12 and 26 weeks of gestation (median 14 weeks). Catheters were 12-16 Fr in size
and were placed in the proximal jejunum. Maternal weight gain resulted in 5 of the 6
pregnancies. The mean duration of tube placement was 19 weeks (range 8-28 weeks). All
pregnancies ended with term deliveries (range 36-40 weeks of gestation) of healthy infants.
The mean infant birth weight was 2885 g (range 2270-4000 g). Tube-related complications
were limited to dislodgement in 2 patients at 30 and 34 weeks of gestation. There were no
cases of infection, preterm labor, or congenital anomalies. All patients had continued nausea
and vomiting requiring IV hydration and anti-emetics. Conclusions: J-tubes are an effective
alternative for protein-calorie delivery in women with refractory hyperemesis gravidarum.
All pregnancies in our series ended with term deliveries of healthy infants without major com-
plications.
T1354
The 13C-Sucrose Breath Test: A Novel, Non-Invasive Technique to Assess
Small Intestinal Mucosal Function in the Critically Ill Patient
Khaschayar Saadat-gilani, Laura K. Bryant, Carly Burgstad, Nam Q. Nguyen, Marianne
Chapman, Ross N. Butler, Geoff Davidson, Richard H. Holloway, Robert Fraser
Enteral nutrition is the preferred route for feeding mechanically ventilated critically ill
patients, but effective delivery of feed is hampered by delayed gastric emptying. Recent data
also suggest intestinal nutrient absorption is reduced independent of gastric emptying,
however the mechanisms underlying this are unknown. Aim: To determine the effects of
critical illness on small intestinal mucosal function, using a non-invasive 13C-sucrose breath
test. Methods: Studies were performed in 5 critically ill patients (5M; aged 53 ± 10 yrs;
APACHE II 14.4 ± 2.1) and 10 healthy subjects (8M; aged 42 ± 5 yrs). A bolus of 100ml
of Ensure® mixed with 20g of 13C-sucrose was infused over 5 min via a feeding tube
inserted into the distal duodenum. Breath samples were collected at 0, 30, 60 and 90 min
and analysed for 13CO2 concentration using isotope ratio mass spectrometry. All samples
were end-expiratory with a CO2 concentration >1%. Results were expressed as cumulative
percentage of administered 13C dose recovered over time (cPDR). Blood glucose concentra-
tions were measured every 15 min for 1 hour and every 30 min thereafter for 240 min
using a bedside glucometer. Results: There was no difference in ages between the healthy
and critically ill subjects. Critically ill patients had a significantly reduced recovery of 13CO2
(90min: 0.8 ± 0.7%) compared to healthy subjects (9.4 ± 0.3%; P<0.0001; Figure). Blood
glucose concentrations were higher in critically ill patients compared to healthy controls
(P<0.0001). Conclusion: Small intestinal sucrase activity is virtually absent in critically ill
patients, suggesting impairment of small intestinal absorptive mechanisms. This may have
implications for enteral feeding in these patients.
T1355
The Outcome of Early Oral Feeding in Patients with Acute Pancreatitis: A
Single Center Experience
Ari Wiesen, Mirela Meca, Kostas Sideridis, Prasun K. Jalal, Simmy Bank
Purpose: To evaluate the outcome of early oral feeding in patients admitted with acute
pancreatitis in a single center. Methods: Data from consecutive patients admitted with acute
pancreatitis in our center in the year 2003-2005 were retrospectively collected. All charts
were reviewed for Ranson's score at admission and 48 hrs and SOFA score daily for the
first 5 days. The total maximum SOFA score was calculated summing the highest scores
for all six systems. Organ dysfunction was considered as SOFA score of 1 or 2 points and
organ failure as a SOFA score of 3 or more. The pattern of feeding was recorded for all
patients. Outcomes of acute pancreatitis, such as mortality,necrosis, pseudocyst formation,
duration of hospital stay, and analgesic requirement were recorded and correlated with
feeding pattern. Patients with <18 years of age, known diagnosis of chronic pancreatitis or
serum amylase and lipase < 3 times normal were excluded. Results: 167 patients were
admitted to the hospital with a diagnosis of acute pancreatitis over the 2 year period (90
male, 77 female; median age 52 years, range 18-96 years). The etiology of pancreatitis was
alcohol (42, 25%), gall stone (68,40%), post-ERCP (9, 5%) or other (48, 30%). The Ranson's
score at admission was 1.26±1.07 and at 48 hrs 1.43±1.40. The maximum SOFA score at
admission was 1.64±1.76 and at 48 hrs was 1.47±1.65. 32 (19%) patients needed admission
to the intensive care unit. Seven patients (4%) died from complications of acute pancreatitis.
The median hospital stay for all patients with acute pancreatitis was 7 days (range 2-50
days). 12 patients (7%) had pancreatic necrosis involving >50% of pancreas and 10 patients
had pseudocyst (4 in patients with necrosis) and both Ranson's score and SOFA scores were
comparable in predicting the outcome in these patients. Only 8 (4.7%) patients required
TPN. In all other patients TPN could be avoided, and in 127 (76%) patients oral feeding
could be started on an average 4.2 days (range, 1-16 days) after admission. There was no
increased adverse outcome in patients with oral feeding group except increased requirement
of analgesia (p<0.05), when compared with patients with TPN or nasojejunal feeding.
Conclusions: Early oral feeding is possible and well-tolerated in majority of patients with
acute pancreatitis. This may decrease the need of other complicated and expensive methods
of nutrition in this group of patients.
T1356
Evaluation of Nutritional Risk Among Hospitalized Patients Using the
Malnutrition Universal Screening Tool ('Must')
Kavinderjit S. Nanda, Vichitra Sukumaran, Frank E. Murray, Stephen E. Patchett
Introduction: Malnutrition is common amongst hospitalized patients and is frequently unre-
cognized and untreated. The prevalence of malnutrition ranges from 15-40% for hospitalized
patients. This has serious negative implications for health, recovery, length of stay and
hospital costs. There are lack of accepted guidelines and gold standards for screening for
undernutrition in patients admitted into hospital. The British Society of Gastroenterology
(BSG) guidelines state that it should be hospital policy that the results of an admission
nutritional screening are recorded in the notes of all patients with serious illness/ those
requiring surgery. 'MUST' is a potential screening tool for this purpose. Aims: To characterize
the role of the Malnutrition Universal Screening Tool ('MUST') in acutely admitted medical
patients to determine the prevalence of undernutrition and to identify patients who are
nutritionally ‘at risk'. Methods: 100 consecutive acute medical admissions were assessed
using the 'MUST'. Cumulative scores were measured from 3 parameters: Weight status
(BMI), Percentage Weight Loss and Acute Disease Effect. Nutritional intervention referral
rates were also examined. If height or weight could not be obtained, BMI was estimated by
obtaining ulna length measurements or mid arm circumference. MUST score≥2 was deemed
to be 'at risk' for malnutrition and warrants further formal nutritional assessment and
intervention. Results: 44 males and 56 females were assessed. Median age was 67 years (45-
81) and median BMI was 27 kg/m2 (24-30). 12/100 (12%) were clinically undernourished
(BMI<20), while 30/100 (30%) were clinically obese (BMI&;30). 46/100 (46%) were deemed
to be nutritionally ‘at risk' using MUST (i.e. score of 2 or more). Of these only 10/46 (22%)
had weight recorded in their clinical notes and only 4/46 (9%) were referred for dietetic
intervention. Although only 82% of patients could be weighed, all (n 100) could be screened
with MUST. Conclusions: Malnutrition in hospital remains poorly recognized. The use of
'MUST' enabled the identification of both undernourished and obese patients, but also
detected those who were clinically ‘at risk' of developing malnutrition. Very few patients
had been weighed on the wards and the referral rate for dietetic consultation was low.
'MUST' is a simple screening tool that helps with early identification patients who require
further monitoring. Therefore, extra resources in this area seem appropriate.
T1357
Prophylactic PEG Placement in Head and Neck Cancer: How Many Feeding
Tubes Are Unused (and Unnecessary)?
Matt M. Blankenship, Mohammad Madhoun, Derek M. Blankenship, Greg A. Krempl,
William M. Tierney
Background: Percutaneous endoscopic gastrostomy (PEG) placement is commonly performed
for head and neck cancer (HNCA). Many PEG tubes are placed in anticipation of dysphagia
secondary to planned chemotherapy and radiation therapy (“prophylactic PEG”). The optimal
timing and utilization of PEG placement in this setting remain unclear. Methods: Retrospective
review of a prospectively maintained endoscopic database identified all patients with HNCA
undergoing PEG between 01/01/2004 and 06/30/2006. Patients (or their next-of-kin) were
surveyed by phone and all available medical records and cancer registry data were reviewed.
Prophylactic PEG was defined as placement in the absence of dysphagia and prior to radiation
or chemoradiation. Each patient with a prophylactic PEG was assessed for: cancer diagnosis,
type of therapy (radiation alone, chemoradiation, with or without surgery), whether the
PEG was ever used, duration and extent of PEG use, and complications related to PEG.
Patient demographics, including age, sex, and BMI were also recorded. Specific diagnoses
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and treatment modalities were examined for a correlation with PEG use vs. non-use or
limited use (defined as duration of use less than two weeks). Study was approved by the
local IRB. Results: 103 patients had PEG tubes placed for HNCA. 34 patients (33%) could
not be contacted for follow-up. 23 (22.3%) patients (19 males; 4 females; mean age 58
years) had prophylactic PEG tubes. Chart review revealed 5/34 patients not contacted likely
had prophylactic PEG. Of the 23 definitely prophylactic PEG tubes, 8 (34.7%) were never
used for feeding, and 11/23 (47.8%) were either never used or were used for less than 2
weeks. No association with PEG use vs. non-use was observed for cancer diagnosis, stage,
or specific cancer treatment. Non-use or limited use was observed in 3/6 (50%) treated with
radiation alone vs. 8/17 (47.1%) treated with chemoradiation (p=1.0), and 3 of 10 (30%)
treated with surgery vs. 8 of 13 (62%) not treated with surgery (p=0.21). Minor complications
(pain and leaking at the PEG site) were reported in 5/23 (21.7%). One (4.3%) major
complication (gastric perforation due to immature PEG tract at time of tube removal) was
reported. Conclusion: Prophylactic PEG placement for HNCA is a common practice in some
centers. The high rate of non-use or limited use and the inherent risk of complications
related to PEG call this practice into question, even among patients receiving highly toxic
combination chemotherapy and radiation therapy. Further prospective trials should be done
to define the optimal utilization of PEG in this patient population.
T1358
Malnutrition in the Hospitalized Elderly: A Randomized Controlled Trial of
Nutritional Intervention On Length of Stay, Weight Change and Readmission
Rates
Terry Bolin, Marian Bare, Gideon Caplan, Suzie Daniells, Peter Petocz, Margaret Holyday
Malnutrition affects in excess of 60% of elderly patients admitted to hospital. Causes have
been variously attributed to lack of access to food, anorexia and co-morbidity. Another
potential factor is malabsorption. AIMS To assess nutritional status as well as prevalence of
mucosal permeability and coeliac disease among elderly patients. METHODS Elderly patients
were recruited after being referred for rehabilitation. The patients had no current gastrointesti-
nal symptoms and gave signed consent to participate. Patients were excluded if they had
dementia or were incontinent of urine. The Mini Nutritional Assessment (MNA), including
body mass index (BMI: normal range 22-27 kg/m2), was used to determine all subjects'
nutritional status (normal score > 23.5). Mucosal permeability to 7.5g Lactulose and 1g L-
Rhamnose was tested after oral administration of the solution. Overnight urine samples were
analysed for sugar content by quantitative spectrophotometry and lactulose: rhamnose ratio
(L:R) determined (normal range 0.006 - 0.080). Coeliac Disease was tested by measurement
of serum IgA, transglutaminase, antigliadin and endomysial antibodies. RESULTS Of the
forty-eight subjects recruited (16 females) one was excluded due to morbid obesity. They
had a mean age of 83.7 (SD 6.1), BMI 21.8 kg/m2 (SD 3.9), MNA score 19.5 (SD 3.4).
Ten subjects had abnormal mucosal permeability (21%) with L:R ranging from 0.0860 to
7.706. These subjects were all ‘at risk' or malnourished according to the MNA score and
they had a significantly lower (2 sample t-test, p< 0.05) mean MNA score of 17.2 (SD 3.5)
compared to the normal absorbers with a mean of 19.5 (SD 3.4). Two of the 47 subjects
had coeliac disease, one of whom was previously diagnosed. CONCLUSION Increased
mucosal permeability has been found in 21% of elderly patients presenting for acute or
sub-acute care where all were ‘at risk' or malnourished. Four percent of the subjects had
coeliac disease, which is higher than the expected rate of one percent in Caucasian popula-
tions. The higher risk of potential malabsorption in the elderly population has significant
implications both for intervention, nutritional supplementation, and drug absorption. As
small bowel bacterial overgrowth due to dysmotility is a possible cause, intervention with
either non-absorbable antibiotics or probiotics may be appropriate.
T1359
Comparison of Therapeutic Efficacy of Elemental and Polymeric Enteral
Nutrition in the Patients with Quiescent Crohn's Disease: A Pilot Cross-Over
Trial
Ryosuke Shoda, Shigeru Yamato
Background: Elemental enteral nutrition has been utilized as the maintenance treatment for
quiescent Crohn's disease (CD) in Japan. Takagi et al. recently demonstrated that remission
of CD was maintained by partial elemental enteral nutrition with oral low-residue and low-
fat diet. On the other hand, meta-analyses revealed that enteral nutrition with polymeric
diet (PD) was as effective as that with elemental diet (ED) to induce remission in active CD.
Aim: We, therefore, compared the therapeutic efficacy of polymeric and elemental enteral
nutrition for quiescent CD in a cross-over trial. Methods: 6 patients with quiescent CD were
recruited and 5 of them completed the 8 month-experiment. They had been induced into
and maintained remission with drug and nutritional treatment. Treatment regimen other
than nutrition was not changed during the experimental period. Given total energy (600-
1500 kcal/day) had been kept but the content of the enteral nutrition was randomly allocated
during the experimental period. ED (Elental®) and PD (Enterude®) were used for 4 months
respectively. Serum cytokines (TNF-α, IL-6), selenium, prealbumin, CRP and fatty acid
composition were measured before and at 2, and 4 months during each experimental period.
Results: Cytokines and nutritional parameters were not different in each nutritional period.
CRP was significantly higher in PD period than in ED period (Pre: 0.23±0.04, ED2M:
0.29±0.07, ED4M: 0.26±0.05, PD2M: 0.38±0.09, PD4M: 0.34±0.08 mg/dl, p<0.02 by
repeated measures ANOVA). Subjective symptoms were tended to be higher in the PD
period than in the ED period (symptom score: 0.35±0.22 and 0.42±0.24 for the 1st and
2nd 2M of ED, 0.65±0.25 and 0.92±0.25 for the 1st and 2nd 2M of PD). Discussion: Result
of this pilot study suggested that elemental nutrition was superior to polymeric diet as a
maintenance treatment of CD. It has been hypothesized for decades that therapeutic efficacy
of enteral nutrition in CD was related to elimination of whole protein and/or reduction of
fat components, especially inflammation-producing n-6 polyunsaturated fatty acids. This
hypothesis could not explain why enteral nutrition with PD is also effective in the treatment
of CD. This result justifies further study to confirm appropriate selection of enteral nutritional
regimen for maintenance treatment of CD.
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T1360
Quantitation of the Benefits of Minimal Enteral Nutrition Versus Total
Parenteral Nutrition in a Pediatric Model of Intestinal Failure
Brian M. Chung, Kelly A. Tappenden
The goal of successful management of intestinal failure is to maximize the utilization of the
remnant bowel and minimize the requirement for parenteral nutrition. We sought to measure
the effects of minimal enteral nutrition following jejunoileal resection with the hypothesis
that enteral nutrition enhances structural and functional adaptations in piglets receiving
parenteral nutrition. Two-day old piglets were subject to 80% jejunoileal resection and
provided either total parenteral nutrition (TPN) or partial enteral nutrition (PEN; 20% enteral
with 80% parenteral). Tissues were harvested 4-, 48-hours and 7-days following surgery
for measurement of structural indices of adaptation and functional assessment of nutrient
transport capacity. In the duodenum, PEN stimulated (p<0.05) a 175% increase in dried
mucosal:submucosal weight compared to TPN (2.4±0.5 vs 0.9±0.5), however, PEN decreased
(p<0.05) glucose (15.01±11.38 vs 37.07±11.37 ΔIsc μA/cm2) and dipeptide transport
(2.77±2.00 vs 7.71±1.94 ΔIsc μA/cm2). PEN animals demonstrated 16% increased (p<0.05)
jejunal villus height compared to TPN (581.4±39.4 vs 497±39.9 μm), and while no alterations
to glucose or dipeptide transport were noted, PEN decreased (p<0.05) serotonin-induced
chloride secretion (7.51±3.16 vs. 15.61±3.26 ΔIsc μA/cm2). In the remnant ileum, PEN
increased (p<0.05) villus height by 25% (586.9±29.5 vs 476.4±31.7 μm) and crypt depth
by 7.5% (128.7±3.7 vs 119.7±3.7 μm). Despite a 21% increase in transmucosal resistance,
remnant ileal tissues from PEN animals also demonstrated decreased (p<0.05) glucose
(1.23±4.28 vs. 9.16±4.17ΔIsc μA/cm2 p<0.05) and glutamine transport (5.77±1.91 vs
11.10±1.98ΔIsc μA/cm2). Colonic crypt depth was increased (p<0.05) by PEN treatment
(372.1±22.5 vs 310.2±22.5 μm), but no functional alterations were noted. These data
indicate that while PEN is an effective stimulus of remnant bowel growth thereby increasing
absorptive surface area, these adaptations arrive at the cost of specific decreases in nutrient
transport. Thus, while the administration of PEN is clearly beneficial, additional efforts to
couple the structural adaptations with improvements in nutrient transport would greatly
improve the outcomes of small bowel resection in the pediatric setting.
T1361
Gastrostomy (PEG) in Incompetent Elderly: Poorly Informed, Constrained and
Paradoxical Decisions
Ilana Golan, Moshe Ligumsky, Mayer Brezis
Background: The frequency of PEG insertion in elderly patients with dementia has increased
dramatically during recent years. However, the decision-making process for performing PEG
in incompetent patients is problematic as family members or guardians are requested to
sign an informed consent. The literature points out that medical, ethical cultural and emo-
tional aspects in the decision making process for the procedure are not always respected,
which raises concern about the adequacy of the consent and the benefit for the patients.
Aim: To examine the decision making process regarding PEG insertion in elderly demented
subjects from the viewpoint and attitude of family members or guardians, referring physicians
and gastroenterologists. Methods: The study was designed as a survey which included
participants from 4 major medical centers: 126 family members whose demented relatives
were referred for PEG, 72 referring physicians and 34 gastroenterologists. Closed-ended
questionnaires designed for each study group were completed by the participants, and
computer analyzed and evaluated (SPSS for windows). Results: About 50% of family members
expressed dissatisfaction with the decision-making process and felt they were not provided
with sufficient information regarding the procedure, its outcome and alternative feeding
options. Moreover, only 31% of them felt supported by the medical staff. Referring physicians
reported that PEG insertion was often dictated by institutional need to transfer patients to
a nursing home. The majority of them also thought that PEG can prevent aspiration and
improve quality of life and longevity. Gastroenterologists expected no improvement in quality
of life of demented patients with PEG and think that administrative demands shouldn't
intervene with the decision to insert PEG. Summary and Conclusions: The decision-making
process for PEG insertion from the standpoint of the patient's family is unsatisfactory, often
takes place under pressure, and lacks sufficient information about the procedure and it's
outcome. Interpersonal communication with the medical team should improve significantly
and referring physicians should increase their sensitivity and compassion towards family
members, and provide them with complete information about the procedure. The physicians
must continuously update their own knowledge regarding PEG and act out of complete
professional autonomy, not being subjected to institutional or administrative demands.
Gastroenterologists should actively participate in the considerations to insert PEG.
T1362
Parental Expectation and Satisfaction with Gastrostomies in Children
Looi C. Ee, Helen M. Wilson, Alexia J. Murphy, Peter S. Davies
INTRODUCTION: Percutaneous endoscopic gastrostomies (PEGs) are frequently placed in
children with feeding difficulties or inadequate intake to improve their nutrition and overall
health. While this procedure is often perceived by medical and allied health staff to improve
quality of life and make caring for these children easier, the perception and satisfaction of
parents and carers with this intervention is not well known. METHODS: All children referred
to our service for PEG placement were recruited prospectively into this study. Consenting
families completed questionnaires on the day of the procedure, 3 months and at least 6
months after initial PEG placement. All children in this study had their PEGs converted to
a skin level device 3 months after initial placement. RESULTS: 36 families consented to
participate of which 21 have completed all 3 questionnaires. 27 parents completed initial
and 3 month follow up questionnaires. Most parents (97%, 35/36) felt they were sufficiently
informed about the procedure prior to insertion. According to parents, the main reasons
for having the PEG include insufficient intake (61%, 22/36), child too thin (47%, 17/36),
and unable to feed safely (42%, 15/36). Anticipated benefits of the PEG at the time of
insertion included making feeding easier (58%, 21/36), safer (47%, 17/36) and less stressful
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(47%, 17/36). Most parents at follow up reported that having a PEG made caring for their
children less stressful (74% at 3 mo and 86% at 6 mo) although a small number (15% at
3 mo and 5% at 6 mo) felt it was more stressful. All parents who found it stressful were
having problems with their tubes; The commonest being granulation tissue, pain, and leakage
from around the site. The frequency and level of mealtime stress and time spent feeding
decreased significantly after PEG insertion. At 6 mo follow up, all families were either happy
or very happy with the gastrostomy and would have it done again. 95% (20/21) of families
would also recommend it to other parents with some commenting that they should have
had it performed earlier. CONCLUSIONS: Most parents of children who have had PEGs
were very happy with it, felt it made caring for their children less stressful and would
recommend its insertion to other parents. All parents surveyed regardless of how they felt
said they would have it done again.
T1363
Nutritional Management After Total Proctocolectomy for Ulcerative Colitis - A
Randomized Controlled Trial Comparing Early Enteral Nutrition Containing
Probiotics Versus Total Parenteral Nutrition -
Ken-ichi Takahashi, Yuji Funayama, Kouhei Fukushima, Chikashi Shibata, Koh Miura,
Terutada Kobayashi, Hitoshi Ogawa, Tatsuya Ueno, Makoto Kinouchi, Atsushi Oyama,
Katsuyoshi Kudo, Atsushi Kohyama, Keiichi Hayashi, Iwao Sasaki, Tomoko Okamoto,
Naoko Inamura, Yoshinori Umezaki
Background: Patients with ulcerative colitis (UC) refractory to medical therapy need to
undergo total proctocolectomy (TC) and ileal pouch anal anastomosis (IPAA). These patients
are often malnourished prior to surgery, especially in patients with severe inflammation of
entire colon. So the proper nutrition management is needed after TC for UC. However, it
is not evaluated which is recommended nutritional therapy after TC for UC, early enteral
nutrition (EEN) or total parenteral nutrition (TPN). Meanwhile, disorder of intestinal bacterial
flora is thought to participate in the cause of pouchitis after TC and IPAA in patients with
UC. But the process of ileal bacterial flora formation after TC has not been fully evaluated
yet. Methods: 27 patients who underwent TC and IAA with loop ileostomy or subtotal
colectomy with end ileostomy were randomized to receive EEN containing probiotics (Bifid-
obacterium breve) with peripheral parenteral nutrition (13 patients) or TPN (14 patients)
from postoperative day (POD) 1 till POD 6. The amount of administered calorie was adjusted
in such a way that the calorie became equal between these two groups on the same POD.
In EEN group, enteral nutrition was fed up to 800 kcal/day. Nutritional assessment including
laboratory data, physical measurement and multifrequency bioelectrical impedance analysis
were performed in all patients. Moreover, analysis of ileal bacterial flora was performed by
quantitative PCR using specific primer to each enterobacterium. Results: In 6 of 13 patients
in EEN group, enteral nutrition could not be continued till POD 6 because of abdominal
pain and nausea. There was no significant difference in lean body mass, TSF and AMC
between two groups. There was also no significant difference in serum prealbumin and
retinol binding protein. However, in EEN group, these biochemical values on POD 7 were
significantly lower in patients in whom enteral nutrition could not be continued (15.2, 1.9
respectively) than in those in whom enteral nutrition could be continued till POD 6 (25.3, 3.3
respectively)(p<0.05). In the analysis of ileal intestinal flora, the detection rate of Clostridium
leptum group was higher in EEN group (45.5%) than in TPN group (7.1%) on POD 14
(not significant, p=0.056). Many members of Clostridium leptum group are known as
butyrate producing microorganisms, which may contribute to intestinal health. Conclusions:
Both EEN and TPN equally improve the nutritional status of the patients after TC for UC.TPN
is more acceptable than EEN. EEN containing Bifidobacterium breve may modulate the
process of ileal bacterial flora formation and increase the beneficial enterobacteria.
T1364
Comparison of Enteral Versus Parenteral Nutrition in Patients with Severe
Acute Pancreatitis: A Single Center Retrospective Study
Jimin Han, Ho gak Kim, Joon hyuk Choi, Jae kwon Jeong, Myungin Jin, Ju youn Cho,
Jin tae Jung, Chang-hyeong Lee, Chang heon Yang
Background: Gut rest with or without parenteral nutrition (PN) has been a standard care
for severe acute pancreatitis. Recently, studies comparing enteral nutrition (EN) to parenteral
nutrition in severe acute pancreatitis have shown that EN is better or equally effective, less
costly, and associated with lower rate of infectious complications. Aims: This retrospective
study intended to compare safety of EN to PN in patients with severe acute pancreatitis.
Patients and methods: Only patients with severe acute pancreatitis who had been admitted
between September 2003 and September 2006 were included. Their medical records were
reviewed. Nasojejunal tube was placed under fluoroscopic guidance for EN. Either peripheral
venous line or central venous lines was used for PN. Results: Of 95 cases hospitalized with
acute pancreatitis, 28 cases (29.5%) were severe. There were 24 male patients (92.3%).
Mean age was 53.9± 14.0 year old. Causes of pancreatitis included alcohol (n=22, 78.6%),
gallstone (n=5, 17.9%), and idiopathic (n=1, 3.6%). Comorbidities were present in 18 cases
(64.3%): alcoholic liver disease (n=10), diabetes mellitus (n=7), and others (n=6). Mean
Ranson criteria were 3.14±1.04 (range: 1-5) and mean Balthazar CT grade was 3.64±1.04
(range: 1-5). There were 13 cases in EN group and 15 cases in PN group. Between EN and
PN groups, there were no significant differences in age, male gender, Ranson criteria, and
use of antibiotics (55.8±16.4 vs. 52.3±11.9, p=0.530; 12/13 vs. 14/15, p=0.916; 2.9±0.8
vs. 3.3±1.2, p=0.294; 11/13 vs. 9/15, p=0.150, respectively). Length of hospital stay was
18.1± 7.8 days in EN, but 18.1±14.9 days in PN (p=0.998). Time to oral in take was
10.4±4.5 days in EN, but 5.9±3.1 days in PN (p=0.005). Average calories supplied was
1851.2±592.12 kcal/day in EN, but 850.8±425.1 kcal/day in PN (p=000). In EN group,
there were 8 cases of diarrhea, 4 cases of hyperglycemia, and 1 case of abdominal pain. In
PN group, there was 1 case of central venous catheter-related sepsis. There was no significant
difference between two groups regarding frequency of pancreatitis-related complication and
nosocomial infection (6/13 vs. 6/15, p=0.459; 1/13 vs. 2/15, p=0.637) There was no death
in both groups. Conclusions: In patients with severe acute pancreatitis, EN is comparable
to PN in regard to safety and infectious complications. Further prospective study with a
large number of patients is needed to establish EN as a standard care in patients with severe
acute pancreatitis.
T1365
Assessment of Dietary Intake with a 10-Point Analogical Verbal Scale: A
Prospective Pilot Study
Ronan Thibault, Nadine Goujon, Renaud Clairand, Véronique Sébille, Dominique
Darmaun
Background. In the daily clinical practice, the assessment of dietary intake takes part of the
nutritional assessment. The “gold standard” is currently the 3 to 6 day-diet record, which
may potentially delay the treatment of malnutrition. Therefore there is a place for methods
allowing a quick assessment of dietary intake. This study aims 1) to evaluate the possibility
to assess dietary intake with a 10-point analogical verbal scale (AVS) in patients with
nutritional risk, and 2) to search for a statistical correlation between the AVS and total daily
caloric intake calculated from a 3-day diet record. Patients and methods. We prospectively
included 37 men and 30 women (mean age 54±15 yr, mean BMI 23.5±4.7). Sixty-six %
were diagnosed a cancer of the digestive tract (n=27) or an inflammatory bowel disease (n=
17). Thirty-six % of patients were hospitalised and 64% were outpatients. The AVS consisted
in asking verbally the following inquiry: “if you consider that when you are in good health
you eat 10 out of 10, how much do you eat, at this moment, in quantity, on a scale from
0 to 10?” The AVS was performed in all patients by one interviewer. Simultaneously, the
total caloric intake was calculated from a 3-day diet record by one dietetician, who was
blinded for the results of the AVS. Weight, height and skin folds were measured in all
patients and serum albumin was available in 54 patients (80%). Statistical correlations
between AVS and daily caloric intake were determined with the Spearman r coefficient.
Results. Answers to AVS were obtained in 100% of cases. The main results of statistical
correlations are reported in the table. In the whole group, there was a significant correlation
between AVS and caloric intake. The correlation was stronger in hospitalised patients or in
patients with BMI<25. The strongest correlations were obtained in malnourished patients
defined as a Buzby index<97.5. There was no statistical correlation between AVS and caloric
intake in outpatients or patients with a BMI≥25. Conclusion. This study shows that our
AVS is easy to use, and that it is correlated to caloric intake in non-overweighed hospitalised
patients, with a nutritional risk. This AVS could be an useful tool for the quick assessment
of dietary intake, but it remains to be evaluated in the management of malnutrition in the
hospitalised patients.
Statistical correlations between daily caloric intake estimated with analogical verbal scale
and calculated from dietary record
T1366
Weight Loss Following Bariatric Surgery: Predictors of Outcome
Inessa Khaykis, Christine J. Ren, George A. Fielding, Warren Huberman, Barrie Wolfe,
Heekoung Youn, Stefanie Hong, Elizabeth H. Weinshel
Background: Bariatric surgery is an effective treatment for morbid obesity, but little data
exist that correlate pre-operative variables and weight loss outcome. Identifying patient
characteristics preoperatively may be important if they are linked to their prognosis. The
aim of this study is to identify predictors of the degree of weight loss after bariatric surgery.
Methods: The charts of all patients who underwent laparoscopic adjustable gastric banding
(LAGB) or Roux-en Y gastric bypass (RYGB) between 10/1/2000 and 10/31/2005 were
reviewed. Demographic data, social history, medical history, past psychiatric history, personal
and family history of obesity, history of prior weight loss attempts, data on eating behavior,
as well as post -operative data on excess body weight loss at 1, 3, 6 and 12 months follow-
up were collected for each patient. Patients were excluded from this study only if 12 months
follow-up data was not available. Postoperative weight loss success was defined as >50% of
excess weight loss (EWL) at 12 months follow-up for statistical purposes. Results: A total
of 1,130 patients had bariatric surgery and had follow-up data for one year: 994 (88%) had
the LAGB and 136 (12%) had RYGB. The mean age was 41.3 years for both groups, 69.5%
and 80.6% of patients were female in the LAGB and RYGB groups respectively. The racial
distribution was similar in both groups. The mean BMI was 51.0 kg/m2 and 47.0 kg/m2
for the LAGB and RYGB groups respectively. For the group as a whole there was a 52.5%
success rate (593/1130 patients); of those who did not succeed 52% (N=520) were in the
lap-Band group and 12.5 % (n=17) in the gastric bypass group. The following characteristics
as reported during pre-surgical evaluations were associated with a lower likelihood of
successful outcome from weight loss surgery: patients without bad late night eating habits
(OR 1.4, p=0.0179), patients who denied that their weight was affecting their social lives
(OR 1.8, p=0.0074), patients who denied that their weight was affecting the quality of their
marriage (OR 1.4, p=0.0207). The success rate in the LAGB group was similar for patients
who described themselves grazers and non-grazers, but in the RYGB group, non-grazers
had a higher success rate 93% than grazers 76% (p=0.0058). Conclusions: This study
identified patient characteristics which may influence surgical outcome. The relationship
between these factors is complex and needs more study.
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T1367
Gastroesophageal Reflux Disease and Esophageal Motility Disorders in Morbid
Obesity. The Effect of Roux-en-Y Gastric Bypass (RYGB)
Mariel Mejia-rivas, Alejandro Herrera-lopez, Miguel F. Herrera, Miguel A. Valdovinos
Gastroesophageal reflux disease (GERD) and esophageal motility (EM) disorders are more
prevalent among obese subjects and a positive association between increasing body mass
index (BMI) and GERD has been described. However the effect of gastric bypass on GERD
and EM is poorly known. Aim: To assess the impact of RYGB on GERD and EM in patients
with morbid obesity (MO). Methods: Consecutive patients with MO (BMI&;40kg/m2) were
prospectively evaluated before and six months after RYGB. The study protocol included: a)
Evaluation of GERD symptoms with the Carlsson-Dent Questionnaire (CDQ), b) Station
pull through esophageal manometry and c) 24h esophageal pH monitoring. Anti-secretory
therapy and agents that affect EM were suspended at least 7 days before the evaluation. A
score >4 in the CDQ was considered as positive for GERD and % of time pH<4 >4.2 was
considered as abnormal esophageal acid exposure. Results: Twenty patients with MO, 16
(80%) female, mean age 38.9± 6.9 were included. BMI before and after RYGB was 48.5±6.2
and 33.2±4.5 respectively (p<0.001). The mean weight loss was 42.5±9.7 Kg . All patients
had heartburn at least twice a week and abnormal esophageal acid exposure before surgery.
GERD symptom score and esophageal acid exposure significantly decreased after RYGB. The
mean % of time of pH < 4 before and after RYGB was 10.7±6.7% and 1.6±1.2% (p<0.001)
respectively. The LES basal pressure was 18±11 mmHg before and 20.1±5.6 mmHg (p=
0.372) after RYGB. The mean esophageal contraction amplitude was 104.2±47.2 mmHg
before and 75.1±36.2 mmHg (p=0.005) after RYGB. Two patients had nutcracker esophagus
and 1 nonspecifc EM disorder. Esophageal hypercontractility disappeared after RYGB. Con-
clusion: RYGB is a very effective procedure to control GERD symptoms, abnormal esophageal
acid exposure and hypercontractility of the esophagus in patients with MO.
T1368
Manipulation of Food Intake and Weight Dynamics Using Retrograde Neural
Gastric Electrical Stimulation in Chronic Canine Models
Paul Aelen, Emil Neshev, Kim Crisanti, Philip Mitchell, Estifanos Debru, Neil Church,
Martin P. Mintchev
Neural Gastric Electrical Stimulation (NGES) is a promising new technique for treating
obesity. However, chronic animal experimentation exploring the efficacy of this therapy is
lacking. In this study we present 2 research protocols exploring retrograde NGES in chronic
canine models. Five mongrel dogs (3 M, 2 F, 25.0 +/- 4.5 kg) underwent laparoscopic
surgery and implantation of a wirelessly-rechargeable electronic stimulator in an abdominal
subcutaneous pocket. The device was connected to two pairs of 1-cm bifurcated electrodes
inserted into the serosa of the anterior wall of the distal antrum in a transverse to the gastric
axis pattern. The ability of the electrodes from a single pair to invoke local lumen-occluding
contraction upon stimulation was verified visually at implantation and fluoroscopically after
recovery. Food intake and weight dynamics were regularly monitored during three distinct
14-days periods, baseline (no stimulation), stimulation and washout (no stimulation) in
each study protocol. Comparative statistical evaluation was performed using single-tailed
Student t-test (p<0.05). Stimulation parameters for the first research protocol included 100%
duty cycle, 50-Hz rectangular bipolar pulses with on- and off- times of 6 seconds for both
distal and proximal electrode pairs, and overlap of 0% between both channels. Stimulation
amplitudes were selected to be as high as possible without the dogs exhibiting symptoms
of pain or discomfort and ranged from 10 to 12 V. The second research protocol repeated
the stimulation parameters of the first, but voltage amplitudes started at 8 V and increased
by 2 V in 2-3 days, implementing a ramped pattern. At the end of the study the animals
were euthanized and the implant and electrode sites were examined at necropsy. Results
from the first research protocol exhibited a significant decrease in food intake for all dogs
in the first 7 days of stimulation compared to baseline, followed by an increase of food
intake in the washout compared to stimulation. Weight and differential weight dynamics
showed the same trends. Stimulation periods longer than 7 days demonstrated loss of
significance, possibly due to the adaptation of the smooth muscle to the stimulation para-
meters. The second protocol showed improved results compared to the first. Food intake
reduction during stimulation was significant in all animals for the entire protocol, indicating
no smooth muscle adaptation to the ramped voltage levels. Necropsies did not demonstrate
any abnormal tissue discoloration, injury or inflammation in the stomach or around the
implant. The proposed method could be a promising new technique for treating obesity.
T1369
Evaluation of Percutaneous Endoscopic Feeding Tube Placement in Obese
Patients
Travis Wiggins, Donald Garrow, Mark H. Delegge
Background: Percutaneous endoscopic feeding tube placement is generally a safe and effective
method for establishing enteral access. In certain subpopulations such as obese patients,
procedural outcomes data are lacking. We sought to evaluate the success rate and potential
for late complications with placement of feeding tubes in obese patients at our institution.
Methods: The GI-TRAC Endoscopy database at the Medical University of South Carolina
was queried for percutaneous endoscopic gastrostomy (PEG), gastrojejunostomy (PEG/J),
and jejunostomy (PEJ) placement procedures between the years 2000 and 2006. These
results were narrowed to include adult patients with a body mass index (BMI) ≥ 30.
Multivariable logistic regression using SAS version 9.1.3 was utilized to determine whether
obesity was independently associated with late complications after controlling for potential
confounders. Results: We found 67 subjects who met out inclusion criteria for obesity.
Percutaneous endoscopic feeding tube placement was successful in 60/67 individuals (89.6%)
with an average procedure time of 17.3 minutes (range 5-70 min). Post-placement complica-
tions occurred in 28/67 (41.8%) of procedures and included peristomal pain (7.7%), cellulitis
(7.7%), inadvertent removal (6.2%), peritubular leak (6.2%), nausea (3.1%), and hemoperi-
toneum (3.1%). In multivariable logistic regression analysis, weight > 200 pounds predicted
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a significantly increased likelihood of complications (adjusted Odds Ratio = 3.86, CI 1.02
- 14.57). Other covariates including age, sex, BMI, diabetes, dementia, and procedure location
did not significantly affect complication rate. Conclusions: We herein describe overall success
and complication rates of PEG, PEG/J, and PEJ placement in obese patients. To our knowledge,
such data has not yet been reported. After controlling for relevant confounders, the odds
of having a complication following percutaneous endoscopic feeding tube placement was
significantly higher among obese patients weighing more than 200 pounds. Careful considera-
tion should be taken in placing percutaneous endoscopic feeding tubes in this population.
T1370
An Indwelling Endoluminal Sleeve Induces Substantial Weight Loss and
Improvement of Glucose Homeostasis in Rats with Diet-Induced Obesity
Vincent Aguirre, Nicholas Stylopoulos, Ronit Grinbaum, Philip J. Davis, Andy H. Levine,
Lee M. Kaplan
Roux-en-Y gastric bypass (RYGB) induces durable weight loss and improvement of type 2
diabetes through neuroendocrine modulation of biological systems governing food intake,
energy expenditure, and glucose homeostasis. To help define the mechanisms of these effects,
it is useful to consider RYGB as a combination of five distinct GI manipulations: isolation
of the gastric cardia, exclusion of the distal stomach, exclusion of the duodenum, exposure
of the distal jejunum to undigested nutrients and partial vagotomy, some combination of
which result in the physiological effects of the procedure. We have developed a rat model
of a novel intestinal device that enables the analysis of two of these components in isolation
- duodenal exclusion and delivery of undigested nutrients to the jejunum - through implanta-
tion of an indwelling endoluminal sleeve (ELS). The ELS is a synthetic, 10 cm long, nutrient-
impermeable, highly flexible tube with an anchoring crown at the proximal end. Methods:
ELS devices were surgically implanted in the duodenal bulb of ten Sprague-Dawley rats
with diet-induced obesity. The devices extended 3-5 cm into the proximal jejunum. A
second group of animals underwent a similar procedure omitting the ELS device implantation
(sham-operated; SO). Body weight and food intake were determined serially, and glucose
metabolism evaluated by glucose tolerance and insulin tolerance testing. Results: In compar-
ison to SO animals, ELS-treated rats demonstrated an average 17% reduction of body weight
at 6 weeks after surgery (p<0.05). Weight loss was associated with reduced caloric intake,
as ELS-treated animals consumed an average 27% fewer kcal/day than SO rats (p<0.05).
There was no evidence of nutrient malabsorption after ELS implantation. ELS treatment was
associated with improved glucose tolerance, as demonstrated by a 30% decrease in the area
under the curve (AUC) of blood glucose in an oral glucose tolerance test. Conclusions: ELS
induces substantial weight loss and improved glucose homeostasis. While the exact mechan-
ism of action is unclear, results with this novel device suggest that selective bypass of the
duodenum and distal delivery of undigested nutrients to the jejunum mimic many of the
effects of RYGB and that ELS may be an effective treatment for obesity. Further studies with
this device will help elucidate the mechanisms of GI regulation of body weight and glucose
homeostasis. Since the ELS device is amenable to endoscopic placement, it may offer a
valuable alternative to more invasive surgical approaches in selected patients.
T1371
Stomal Ulcers Following Roux-en-Y Gastric Bypass: An Endoscopic Analysis of
273 Consecutive Patients
Amulya Konda, Navakanth Gorrepati, Kevin R. Krause, Mitchell S. Cappell, Mamtha
Balasubramaniam
Aim: The hypothesized etiologies of stomal ulcers (SU) after Roux-en-Y gastric bypass (RYGB)
include gastric hyperacidity, local ischemia, and surgical technique. The etiologic role of
Helicobacter pylori (HP) infection is currently undefined. We aim to analyze the etiopathogen-
esis and complications of SU. Methods: A retrospective chart review 1052 consecutive RYGBP
patients (pts), from 01/2002 to 04/2006 at William Beaumont Hospital was performed. Of
these, 273 pts underwent EGD for upper GI symptoms. A total of 62 (22.7%) pts had SU
(57 at EGD and 5 pts at surgery). SU was defined as a mucosal disruption of any size seen
at the gastrojejunal anastomosis. HP status was determined by pathologic examination of
endoscopic gastric biopsies. Acute GI bleeding was defined as gross bleeding requiring
urgent (<24Hrs) EGD. Perforation and reoperation were reported as complications only if
directly due to SU. Results: Of 273 pts undergoing EGD, 57 (20.8%) had SU (5.8% of all
RYGB pts). SU occurred on average 8.8 + 9.5 (S.D.) months (range 0-36) after surgery. The
mean patient age was 48.5 + 11.3 years. There were 42 female pts (female-to-male ratio=
2.1). Presenting symptoms included abdominal pain in 24 (39%), nausea/vomiting in 20
(33%), melena in 8 (13%), hematemesis in 5 (8%), dyspepsia in 5 (8%). Purported SU risk
factors included NSAID use in 37 (59%), smoking in 21 (34%), aspirin in 15 (25%), prior
peptic ulcer disease (PUD) in 9 (14%), corticosteroids in 4 (7%) and HP infection in 4 pts
(9%; n=43). Proton pump inhibitors were used in 23 (37%) and histamine2 antagonists in
5 pts (8%) before EGD. SU size was greater than 1cm in 32 pts (53%). Multiple ulcers were
noted in 15 pts (25%). Complications included acute GI bleeding needing EGD in 18 (28%),
of which 11 (17%) had clinically significant bleeding (Hgb drop>2gm/dl), refractory ulcers
in 11 (18%), perforation in 8 (13 %), and gastro-gastric fistula in 1 pt (2%). Repeat EGD
was required in 37 (59%) and repeat surgery was performed in 10 pts (17%; RYGB revision
in 5, patch closure of perforation in 5 pts). There were no deaths (mean follow-up after
EGD=15 months). Conclusions: Stomal ulcers are common in symptomatic RYGB patients
requiring EGD (20.8%). The low rate of HP infection among SU patients in our study (9%
vs. 70-90% for PUD) suggests that HP is not critical for stomal ulcerogenesis and that routine
biopsies should not be performed. However, detection of HP by gastric biopsy alone may
have introduced artifact because most of the stomach was bypassed. SU complications,
including acute GI bleeding and GI perforation, are relatively common, as is the need for
repeat EGD and reoperation.
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T1372
Step-By-Step Endoscopic Treatment of Obesity
Evzen Machytka, Pavel Klvana, Lada Hanuskova, Igor Janik
Introduction: The bioenterics intragastric balloon (BIB) has gradually become an ordinary
method of obesity treatment. Although this technique has proven to be effective and safe,
obesity specialists sometimes complain about its varying results after explantation. The
endoscopic application of botulotoxin A to the stomach antrum has appeared in recent years
to be a promising method of obesity treatment. However, the works published thus far have
not provided evidence of such weight losses in patients as would be equivalent to those
achieved by the application of BIB. Objective: The endoscopic application of botulotoxin A
to the stomach antrum following the explantation of BIB to maintain weight losses in the
long term. Methodology: Set of 10 patients. Application of 500MU botulotoxin A into the
stomach antrum within one month after the explantation of BIB. Comparison to a base set of
10 patients only subjected to BIB and sham endoscopy without the application of botulotoxin.
Results: The average weight loss after the explantation of BIB was 16.49kg. The patients
subjected to the application of botulotoxin A into the stomach antrum showed a further
weight loss of 4.56kg on average in the following 6 months. There were no undesirable
effects due to the treatment. The patients only subjected to BIB put on 5.21kg on average
in the 6 months following explantation. The difference is statistically significant. Conclusion:
The endoscopic application of botulotoxin A into the stomach antrum appears to be an
effective and safe method to maintain weight losses after the explantation of BIB. Our patients
continue to be treated by an obesity specialist and we are going to publish our results after
another year of monitoring the patients. The application of botulotoxin A can also be used
on its own in patients showing contra-indication for BIB. Authors around the world do not
use a unified term for this method yet; we suggest the abbreviation GABI (Gastric Antral
Botulotoxin Injection).
T1373
Concerns Over Complications in Laparoscopic Adjustable Gastric Band
Vinetta Hussey, John J. Kelly, Dominic Nompleggi
Background: Laparoscopic Adjustable Gastric Band (LAGB) surgery was approved for use
in the United States by the FDA in 2001. LAGB has been utilized in our tertiary care facility
over the past five years to assist patients in weight reduction. Recently several patients have
been complaining of a variety of esophageal symptoms. We recalled our first 30 patients
for an urgent office visit and obtained an upper gastrointestinal series (UGI) and manometry.
The results obtained are presented. Methods: This series includes the first thirty patients
who underwent LAGB placement in our facility. One fellowship trained laparoscopic surgeon
performed the primary procedure as well as all early adjustments of the bands. The first 30
were recalled and offered an urgent follow up for a symptom survey, UGI series and
esophageal manometry study. Results: Thirty patients underwent LAGB between October
2001 and February 2003. Fifteen (50%) patients who maintained the original band were
available for further testing with one patient refusing. Fourteen patients are scheduled to
undergo an upper gastrointestinal series and esophageal manometry. To date fourteen patients
have completed the UGI and eleven patients have completed both. The average excess weight
loss was 51.9% at their 2 year visit. All fourteen patients who underwent the UGI study
were found to have esophageal dilation from 5-9 cm. This was a change of 2-7cm when
compared to prior studies. There were 3 incidental band slippages noted. Eleven patients
(79%) completed their esophageal manometry studies. Nine (64%) patients reported symp-
toms. Symptoms included; reflux, regurgitation, hoarseness, and dysphagia. Five of eleven
(45%) had symptoms but normal peristalsis. Four of eleven (36%) had symptoms and
abnormal peristalsis. Manometry findings varied; hypotensive LES (55%), normotensive LES
(36%) and hypertensive LES (9%). Amplitudes in the esophageal body were normotensive
(36%), and hypotensive (64%). Peristalsis was noted in (63%), intermittent peristalsis (25%)
and aperistalsis in (13%). Conclusions: Laparoscopic Adjustable Gastric Band surgery is an
effective treatment for weight reduction. Esophageal symptoms are common (64%) in our
patients. Affected patients tended to be women. Esophageal symptoms were associated with
esophageal dilation, though esophageal dilation was not a true indicator of symptoms.
Esophageal manometry findings did not correlate well with symptoms or dilation. Further
study is needed to determine if esophageal symptoms and dilation are common in other
patients undergoing LAGB and if so what is the etiology of these findings.
T1374
Teaching Pediatric Obesity to the Teacher - Long-Term Impacts of An
Innovative Educational Initiative in a Large State
Jason E. Dranove, Sandeep K. Gupta
Introduction: Obesity is of epidemic proportions in the United States, and Indiana's pediatric
obesity rate is among the highest in the nation. One of the tools to stem this epidemic is
to educate health care providers on effective means of recognizing, preventing, and treating
obesity, and disseminating information in their local communities. Aims: To evaluate the
impact of Comprehensive Pediatric Obesity Audio-conferences (CPOA) on the knowledge
and practices of health care providers. Methods: A series of live CPOA were offered free-
of-charge to community based pediatric health care providers throughout the state of Indiana.
Each CPOA lasted 90 minutes, was delivered by one of the authors, and addressed several
aspects of pediatric obesity. The attendees dialed in from home or office and the presentation
slides had been provided to them at registration, prior to the CPOA. Attendees were encour-
aged to use the slides to advance obesity knowledge in the local schools/communities.
Immediate and long term program impact were assessed by attendee-completed evaluations
at end of each CPOA and a follow-up phone interview 3 months later, respectively. Results:
71 participants evaluated the program using a five-point scale. Of importance, 100% of
respondents agreed/strongly agreed that CPOA met the stated objectives, was of appropriate
level, was up-to-date, was effective, and was convenient. 97% felt CPOA met their personal
expectations and needs. 97% said they would apply the information learned to their clinical
practice, and 86% would use knowledge gained to educate others on obesity. Interestingly,
only 52% of attendees were aware of the Local Wellness Policy mandate prior to CPOA.
29 attendees completed the follow-up phone interviews. 100% indicated CPOA had added
to their knowledge of pediatric obesity, and 86% had re-accessed the information following
CPOA. 62% had made changes to their practice following CPOA. Conclusion: The innovative
CPOA helped narrow the knowledge gap of health care providers in Indiana local communit-
ies. The overall impression of CPOA was very positive and prompted changes in practice
by nearly two-thirds of respondents. Audio-conferences with distribution of presentation
slides for subsequent use by attendees can be an effective tool to prompt awareness and
action by health care providers in rural communities. We intend to expand this program
and provide CPOA to other health care providers in the state.
T1375
Improvement in Glucose Homeostasis Is Independent of Weight Loss After
Roux-en-Y Gastric Bypass in Diabetic Rats
Vincent Aguirre, Nicholas Stylopoulos, Philip J. Davis, Ronit Grinbaum, Lee M. Kaplan
Roux-en-Y Gastric Bypass (RYGB) results in durable weight loss and improvement of diabetes
through GI modulation of neuroendocrine function. The precise mechanisms mediating
these effects are unclear. Recent reports have noted improvement of diabetes within days after
surgery, before any appreciable weight loss. Thus, RYGB may regulate glucose homeostasis
independent of changes in adiposity, and surgical rearrangement of the GI tract may have
a direct physiologic effect on this endocrine regulatory system. To explore the mechanisms
by which RYGB affects glucose homeostasis, we examined the effects of RYGB on Goto-
Kakizaki (GK) rats, a genetic model of diabetes without obesity that exhibits minimal weight
loss after RYGB. Methods: RYGB or sham operations (SO) were performed on weight- and
age-matched, 10-week old GK rats. The RYGB-treated and one group of SO rats were fed
ad libitum. A second group of SO rats (WMS) was weight-matched to the RYGB group by
diet restriction. The effect of RYGB on weight and glucose homeostasis was determined after
suitable post-operative recovery. Glucose metabolism was assessed by fasting glycemia,
glucose tolerance testing (GTT) and insulin tolerance testing (ITT). Results: In comparison
to ad libitum-fed SO rats (ALS), GK rats after RYGB exhibited a 10% decrease in body
weight. Fasting glycemia was significantly decreased in both RYGB and WMS animals
compared to the ALS group (119±7; 109±14; and 141±28 mg/dL, respectively; p<0.05). In
contrast, post-prandial glucose tolerance was significantly improved after RYGB (45%
decrease in the area under the curve [AUC] of blood glucose vs. ALS rats; p<0.05), but not
in WMS animals. Surprisingly, despite the improvement in glucose tolerance, RYGB did not
induce significant changes in peripheral insulin sensitivity, as determined by ITT. Conclu-
sions: RYGB improves glucose homeostasis by at least two distinct physiological mechanisms.
(1) Fasting glycemia is improved as a direct consequence of minimal weight loss, even in
thin animals, since it occurs similarly in RYGB and WMS rats. This effect does not appear
to result from improved peripheral insulin sensitivity. (2) Post-prandial glucose tolerance
is improved by a process independent of weight loss since this effect does not occur with
comparable weight loss in WMS rats. Its mechanisms may include augmented insulin
secretion, redistribution of intracellular lipid stores, or altered neuronal modulation of glucose
homeostasis. Understanding these mechanisms should facilitate the identification of novel
GI-based targets for effective treatment of type 2 diabetes and development and testing of
new therapies aimed at these targets.
T1376
The Impact of Race On Long-Term Outcomes from Roux-en-Y Gastric Bypass
Surgery
Glenn K. Harvin, Donald Garrow, Mark H. Delegge
Background: Gastric bypass surgery for morbid obesity has dramatically increased in volume
over the past decade. There has been an anecdotal observation among bariatric surgeons at
out institution that Caucasians experience a greater percentage and sustained weight loss
following gastric bypass surgery when compared to African-Americans. A review of the
literature reveals a lack of clear data regarding this issue. Aim: To determine if race has a
significant effect on percentage weight loss at two years following Roux-en-Y gastric bypass
surgery. Methods: Retrospective analysis using a multivariate logistic regression model of
all patients undergoing Roux-en-Y gastric bypass surgery at the Medical University of South
Carolina from May 1993 thru December 2004 for whom 2 years of follow-up data was
available. Our dependent variable was percentage of weight lost from baseline, dichotomized
at 35%. Our primary independent variable was race, defined as Caucasian, African-American
or other. Relevant covariates were added to the model to control for their potential effects
on outcome. Results: 111 Patients (17 male/94 female; 85% Caucasian, mean age 44 years
(range: 18-68 years). In our model, Caucasian subjects (adjusted Odds Ratio = 7.60, CI
1.83-31.5) and late post-surgical complications (adjusted Odds Ratio = 2.67, CI 1.05-6.80)
significantly predicted weight loss at two years, after controlling for relevant confounders.
Other covariates including age, sex, insurance status, baseline presence of hypertension,
diabetes, sleep apnea, gastro-esophageal reflux disease, hypercholesterolemia, degenerative
joint disease, and stress incontinence did not significantly impact percentage of weight loss
at 2 years. Conclusion: Race and late post-surgical complications significantly impacted the
percentage of weight loss at two years for patients undergoing Roux-en-Y gastric bypass
surgery at our institution. Future research should be directed at determining potential genetic
and/or social reasons for these differences.
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T1377
Intragastric Balloon Tolerance Is Independent of Helicobacter pylori (HP)
Status in Patients with Morbid Obesity
Nicoletta G. Mathou, Konstantina D. Paraskeva, Konstantinos Zografos, George
Anagnostopoulos, John A. Karagiannis
Background: Endoscopic intragastric balloon consists an acceptable method for, at least
short-term, weight loss in morbid obese patients. Balloon insertion is usually followed by
poor tolerability with upper GI symptoms. It has not been studied if the presence of HP
infection affects balloon tolerability and if, therefore, HP eradication is indicated prior to
balloon insertion. Aim of the study: To assess if HP infection plays a role (negative or even
favorable) in intragastric balloon tolerance in morbid obese patients. Patients-Methods: 33
morbid obese patients (median BMI 38.1), 23 female, 10 male, age range 20-65 years were
studied. All had failed previous dietary attempts for weight loss. In all patients the intragastric
balloon (BIB, INAMED, USA) was inserted endoscopically by using the standard recom-
mended technique and was filled up to a median fluid volume of 550ml. HP status was
confirmed during the screening (before balloon insertion) upper GI endoscopy (rapid urease
test plus histology). Exclusion criteria for balloon insertion were large hiatal hernia, severe
esophagitis, peptic ulcer, severe gastritis or chronic NSAID's use. All patients were followed-
up daily in the first 7 days after balloon placement and monthly thereafter up to balloon
removal (6 months after insertion) by a standard questionnaire. Patients were allowed to
on-demand H2-RA/PPI's and/or prokinetics. Nausea and/or vomiting and/or crampy epigast-
ric pain were characterized as mild to moderate (nausea, vomiting <10 times/day, duration
<10days and/or pain without necessitating further management) or severe (intractable nausea
and/or vomiting>10 times/day, duration >10days and/or severe pain necessitating further
management and/or premature removal of the balloon). Results: 14 patients were found HP
positive (42.4%) while 19 negative (57.6%). All patients, independently to their HP status,
experienced mild to moderate symptoms immediately after balloon insertion with median
duration of 2 days (range 1-6). Seven (21%) experienced severe symptoms requiring further
management (3 HP positive, 4 HP negative) and in 4 of them (12% of total) the balloon
had to be removed within one month after insertion (3 HP negative, 1 HP positive). These
findings were not statistically significant, against or for, the HP status. Conclusions: HP
infection does not seem to impair tolerability of intragastric balloon, regarding neither the
presence of mild symptoms immediately after balloon insertion nor the need for early balloon
removal because of intractable symptoms. Therefore, HP eradication is not justified prior
to balloon insertion, unless indicated for other HP-related symptoms.
T1378
The Impact of Adjustable Laparoscopic Gastric Banding On 24 Hr pH
Monitoring
Zoi Gamagaris, Carlie Patterson, Fritz Francois, Christine J. Ren, Heekoung Youn,
Elizabeth Weinshel
BACKGROUND: Bariatric surgery, particularly the adjustable laparoscopic gastric band
(LAGB), has been widely and successfully used to treat morbid obesity. However, there is
limited information regarding the long-term effect of this increasingly utilized technique on
esophageal acid exposure. The aim of this study was to evaluate the extent of esophageal acid
exposure during 24-hour periods before and after adjustable laparoscopic gastric banding.
METHODS: Consecutive patients with a body mass index (BMI) > 35 referred for bariatirc
surgery were prospectively enrolled. A detailed medical history was obtained and esophageal
24-hour pH evaluation was performed preoperatively, 6 and 12 months postoperatively;
allowing for comparisons using the paired t-test with the patients serving as their own
controls. The 24 hour pH monitoring parameters evaluated included percent time of pH
<4.0, number and duration of reflux episodes, symptom correlation, and Johnson/DeMeester
score. RESULTS: A total of 13 individuals with a mean age of 42 ± 12 years and mean pre-
surgical BMI of 47 ± 9 were evaluated between April 2003 and April 2006. One patient
with a greater than 4 percent total time with pH<4 at baseline was excluded from further
analysis. The mean follow-up time was 14 ± 3 months. The total percent time with a pH
<4 did not change significantly from baseline to 6 months (p=0.86) or from baseline to 12
months (p=0.24). Although the total number of reflux episodes detected by pH-metry did
not change significantly between baseline and 12 months (p=0.094), the number of reflux
episodes while recumbent did increase significantly from a mean of 7 ± 11 to a mean of
29 ± 35; p=0.049. In spite of this, there was a trend towards fewer patient reported reflux
symptoms during follow-up (mean 2.7 ± 1 at baseline vs. 1.6 ± 0.5 at 6 months; p= 0.057).
Consistent with this finding, the number of symptoms that correlated with a drop in
pH significantly decreased from baseline compared to 6 months (p=0.038), and this was
accompanied by a 40% decrease in the Johnson/DeMeester score during the same follow-
up period (mean 16.5 ± 8 vs. 10 ± 4); p=0.029. CONCLUSIONS: Laparoscopic gastric
banding is not associated with an increase in total esophageal acidification time. Although
the number of detected recumbent reflux episodes increased, patient reported symptoms
and pH-correlated symptoms were decreased. Further evaluation of nighttime reflux is
warranted in patients who have undergone LAGB.
T1379
Medical Weight Management Is An Effective Therapy for Class III Obesity
Jeanette N. Keith, Walter Conwell, Kristen Kasza
Background: Medical weight management for class III obesity (BMI ≧40 or ≧ 35 with
obesity-related complications) is challenged by poor participation, high recidivism rates and
less weight loss when compared to surgery. The optimal method for treatment remains
unclear as surgery may not be available or is contra-indicated. New Beginning's Weight
Management program is an individualized program designed specifically for treatment of
class III obesity. The program provided both consultative services and a 26-week weight
management program. This retrospective study assesses the success of the program based
on Institute of Medicine 2002 guidelines for success in medical weight management programs.
Methods: A retrospective chart review of patients enrolled in the University of Chicago's
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Obesity Program between January 2002 and January 2003. Criteria for participation: Class
III obesity. Participant's completing 4 consecutive visits (average of 12 weeks enrollment)
were considered program completers versus non-completers who were enrolled less than 4
visits. Success was defined as: 1) stopping weight gain, 2) 5-10% weight reduction, or 3)
prevention of weight regain. Results: Of the 265 participants (85.7% Female, 53.6% Black,
BMI 49.9 ±12.4), 143 (53.9%) were consults only (data were not analyzed), 89 (33.5%)
were non-completers (group1) and 33 (12.5%) patients completed the program (group2).
Group 1 was enrolled 7.5 ± 3.1 weeks versus 23.2 ± 14.9 weeks for group 2 (p <0.0001).
The average length of time between visits for group 1 was 5.6 ±1.9 weeks versus 4.7 ±1.0
for group 2 (p = 0.0011). Average weight change from baseline was -1.6kg ±6 (-1.0% ±4.9)
for group 1, -3.2kg ± 5.3 (-2.0% ± 3.4) for group 2, and -2.0 ±5.8 (-1.3% ±4.6) for both
groups, (p<0.001). Overall, 68% of patients did not gain weight; 9% lost ≧5% of their
excess body weight. No significant difference in weight loss between blacks -1.5kg ±3.7 (p-
value < 0.01) and non-blacks -2.5kg ±7.2 (p-value ≦ 0.01), p=0.34 was seen. Among
completers, 77% of patients who lost weight by their second visit had a sustained weight
loss at their final visit. Conversely, only 45% of patients who had not lost weight by their
second visit lost weight at their final visit (Pearson correlation coefficient: 0.39, p=0.026).
Conclusions: Our results demonstrate that medical weight management can be successful
in preventing further weight gain in patients with Class III obesity and may result in
significant weight loss. Participants seen at shorter intervals were more likely to complete
the program with positive outcomes. Weight loss within the first few visits predicted may
also long term weight loss.
T1380
TNF-α Polymorphisms Increase the Risk of Acute Pancreatitis
Arun Sharma, Janette Lamb, Kim Corrado, Leena Kandula, Mark E. Lowe, Haritha Avula,
Adam Slivka, Micheal M. Barmada, David C. Whitcomb, Georgios I. Papachristou
Background: Acute pancreatitis (AP) is divided into mild (MAP) and severe (SAP), depending
on the intensity of the inflammatory response. Tumor necrosis factor α (TNF-α) is a pro-
inflammatory cytokine that has an early pivotal role in the inflammatory response following
pancreatic injury. Multiple polymorphisms in the promoter region of the TNF-α gene have
been described. An association between the TNF-α -308 A allele and an increased risk of
SAP has been described. Aims: To determine whether genotypes at 5 known polymorphic
loci in the promoter region of TNF-α gene affect the susceptibility and severity of AP.
Methods: 102 consecutive adult AP patients, 42 consecutive pediatric AP patients, and 92
adult controls were prospectively enrolled. Severity of AP was assessed in the adult population
and defined by the presence of organ failure. The polymorphisms of interest (-1031 C/T,
-863 A/C, -857 C/T, -308 A/G and -238 A/G) were evaluated by polymerase chain reaction
amplification and DNA sequencing. Statistical analysis was performed using chi-square and
Fisher's exact tests. Results: There were 73 females and 71 males with AP; their mean age
was 39 years. Etiologies of AP included idiopathic (28%), biliary (27%), post-endoscopic
retrograde cholangio-pancreatography (15%), alcohol-associated (10%), drug-induced (8%)
and multisystem disease (4%). Of the adult patients, 19 had SAP (19%) and 83 had MAP
(81%). AP patients had significantly different genotypes at the -857 C/T (Table 1) and the
-308 A/G loci (Table 2) when compared to controls (p=0.048 and p=0.007, respectively).
Of note, there were no significant differences between the adult and pediatric AP patients
with respect to genotypes at these 5 loci. There were no significant differences in the
genotypes at the 5 loci between SAP and MAP patients. Conclusions: Polymorphisms at the
TNF-α -857 and -308 loci appear to influence susceptibility to AP.
Table 1
Table 2
T1381
Novel Admission Clinical Prediction Rule for Mortality in Patients
Hospitalized for Acute Pancreatitis
Bechien Wu, Richard S. Johannes, Ying P. Tabak, Stephen Kurtz, Peter A. Banks
INTRODUCTION: There is a need for a population-based mortality prediction rule specific
to acute pancreatitis (AP). Ideally this rule would be rooted in admission-based data. Accurate
identification of patients at risk for mortality early in the course of AP has important clinical
and research implications. AIMS: We sought to derive and validate a mortality prediction
model using admission clinical parameters that would accurately stratify severity at admission
based on the predicted probability of in-hospital mortality. METHODS: Patient data was
generated from the Cardinal Health Research Database, a large population dataset that has
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supported publicly reported hospital performance in Pennsylvania for 20 years. The deriva-
tion cohort consisted of all cases from Jan 2000 thru Dec 2001 with principal diagnosis
ICD9-CM 577.0 (AP). An existing logistic risk adjustment model for mortality was recalibrated
on the AP population. This model contains 25 covariates including vital signs, laboratory
data, history and physical exam findings. For purposes of creating a parsimonious clinical
prediction tool, these covariates were narrowed to the most robust and clinically relevant
risk factors. The simplified prediction rule was then validated on the AP population from
Jan thru Dec 2004. RESULTS: There were 17,992 cases from 212 hospitals with 335 deaths
in the derivation cohort. Mean age was 55.6 and 49.3% were males. The c-statistic for the
25 covariate mortality predictive model was 0.886. Ten variables (age>60, altered mental
status, presence of SIRS, hypotension sbp<79, hypoxia by pO2<60 or Oxygen satura-
tion<90%, BUN>25, creatinine>2.5, albumin<2.4, elevation of PT/INR, and glucose>135)
produced an adjusted mortality risk model with c-statistic of 0.848 with excellent calibration
(Hosmer-Lemshow χ2=9.1, p=0.25.) These risk factors were incorporated into a risk-scoring
algorithm based on a 10 point-scale with each variable equally weighted at 1. Applying this
scoring system allowed admission mortality risk to be stratified from 0.2% to 96%. In the
validation cohort, there were 21,096 cases with 251 deaths. The c-statistic for the new
mortality model in the validation cohort was 0.862. CONCLUSIONS: Utilizing a large
population-based dataset, we derived and validated a clinical prediction rule for estimating
a broad range of admission mortality risk in the general AP population. By incorporating a
series of routinely collected admission parameters, this prediction rule may be potentially
useful for risk-stratification in future research studies.
T1382
Persistent Systemic Inflammatory Response Syndrome (Sirs) Correlates with
Severity in Acute Interstitial Pancreatitis (AIP)
Vikesh Singh, Thomas Bollen, Koenraad Mortele, Martha Vander vliet, Rie Maurer, Peter
A. Banks
Introduction: Two previous studies examined the relationship between persistent SIRS and
survival in acute pancreatitis but did not distinguish between necrotizing and interstitial
pancreatitis. The present study was undertaken to establish the relationship between SIRS
and the severity of AIP. Methods: We employed a database, which includes detailed clinical,
radiographic, and endoscopic data on patients with acute pancreatitis admitted or transferred
to our institution over a 1.5 year period. The present study focuses specifically on patients
admitted for their first episode of acute pancreatitis with interstitial disease confirmed by
appropriate abdominal pain, amylase and/or lipase levels ≥3x the upper level of normal,
and a contrast enhanced CT (CECT) scan of the abdomen. CT scans were further distinguished
on the basis of having only intrapancreatic involvement (normal or enlarged pancreas without
fat stranding or fluid collections) vs. extrapancreatic involvement (fat stranding or fluid
collections surrounding the pancreas). SIRS was defined as 2 or more of the following: (1)
T>38° or <36°C (2) Pulse >90 beats/minute (3) RR>20 or PCO2 <32 mm Hg (4) WBC
>12,000 cells/mm3 or <4,000 cell/mm3 or 10% immature band forms. SIRS was recorded
as absent, transient (<48 hours) or persistent (≥48 hours). Need for ICU care and length
of stay in days were also recorded. Statistical analysis was performed using SASÒ v9.1
(Cary,NC). Results: There were a total of 249 admissions for acute pancreatitis of which
there were 81 (32.5%) patients admitted for their 1st episode with confirmation of AIP.
Complete data was available for 71 (87.6%) and these were used for the final analysis. The
mean age was 55±17 yrs; 41 (58%) were females. 33 (46%) patients had persistent SIRS
and 38 (54%) had no or transient SIRS. There was a significant relationship between persistent
SIRS and the presence of extrapancreatic involvement on CECT scan (p=0.0076 by Fisher's
Exact test). There was a significant difference between the patients with persistent SIRS and
no or transient SIRS with regards to the need for ICU care, 10/33 (30.3%) vs. 0/38 (0%),
respectively (p<0.0001 by Fisher's Exact test). Patients with persistent SIRS had a significantly
longer median length of stay compared to those with no or transient SIRS, 8 (range 5-16)
vs. 3.5 (range 2-6) days, respectively (p<0.0001 by Wilcoxon test). Conclusions: Persistent
SIRS correlates with the severity of AIP as evidenced by the presence of extrapancreatic
manifestations on CECT scan, need for ICU care, and length of stay. SIRS may represent a
simple measurement for assessing severity in patients hospitalized with AIP.
T1383
Frequency and Characteristics of Acute Pancreatitis in Patients with Marked
Primary Hypertriglyceridemia
Anne-laure Pelletier, Celia Lloret linares, Vinciane Rebours, Pascal Hammel, Levy
Philippe, Dominique Rousselot, Eric Bruckert, Philippe B. Ruszniewski
Aim: assess the prevalence and risk factors of AP in a cohort of patients with severe type
IV/V hypertriglyceridemia, and determine the characteristics of lipid anomalies associated
with AP. Methods : all patients with hypertriglyceridemia > 10 g/L seen in a single institution
with an expertise in metabolic diseases were included. Prevalence of AP, alcohol and tobacco
intake, body mass index, diabetes mellitus, triglycerides levels, lipoprotein (LPL) and hepatic
lipase (HL) levels were determined. Severity of AP was assessed using usual criteria (organ
failure, need for intensive care, CRP, CT Balthazar's score). Other causes of AP, mainly
biliary, were carefully ruled out. Results : 26 of 129 patients (20%) with TG>10 g/L (type
IV 119, type V 10) had at least one AP. Sex ratio (male 80%), mean age (37.5 years),
proportion of alcohol users (43 %), mean BMI (25), diabetes mellitus (35%), LPL and HL
rates (62.4 and 47.4%, respectively) did not significantly differ from the patients without
AP. Hypertriglyceridemia was diagnosed earlier in patients with AP (-7.8 years, p=0.0003)
and maximal triglycerides levels were higher (44.7 vs 24.5 g/L, p<0.0001) than in patients
without AP. The relative risk of AP was 4 in patients with TG > 36 g/L, compared to those
with TG between 10 and 18 g/L. Full data about AP severity were available in 14 patients.
57% had at least one necrotizing zone. No correlation was observed between AP severity,
TG levels and LPL/HL activity. No patient had chronic pancreatitis and 3 (12%) had recurrent
bouts of AP. At distance from AP, mean TG levels were 7.3 g/L, not different from patients
without AP. Conclusion: AP is frequent (20%) and often severe in patients with triglycerides
levels > 10 g/L. AP occurs in patients with very high TG values independently from alcohol
intake. Relapses of AP are infrequent and chronic pancreatitis does not occur.
T1384
The Logistic Organ Dysfunction Score-Modified Atlanta Categorization of
Acute Pancreatitis
Srinivasan Balachandra, James M. Mason, Anil Bagul, Ajith K. Siriwardena
Introduction: The 1992 Atlanta consensus conference defined two categories of acute pancre-
atitis - severe and mild - according to the presence of absence respectively of organ failure
(OF). However OF can be transient. This study tests the hypothesis that application of a
contemporary, well-validated organ dysfunction scoring system such as the Logistic Organ
Dysfunction Score (LODS) will provide greater precision in categorization. Methods: A
prospective single-centre study was undertaken in a consecutive series of 181 patients with
a clinical diagnosis of acute pancreatitis (AP) presenting to a University Teaching Hospital
from June 2001 through November 2004. Patients with known chronic pancreatitis and
those transferred for tertiary care were excluded. In addition to demographic detail, data
were collected on critical care occupancy, in-patient stay and in-hospital mortality. Charts
were reviewed at end-of-episode for allocation of conventional Atlanta category (blind to
other scoring). Variables required for calculation of LODS (omitting hepatic score component)
were collected on admission and 24 hours with principal end-points being in-patient stay
and critical care occupancy as these translate across health-care systems. Data were analyzed
by receiver operator curves (ROC) with 95% confidence intervals (c.i.). The study was
approved by institutional review board. Results: The LODS-modified Atlanta, used as a
predictor of severity at admission generates sensitivity of 89% and specificity of 68%, AUC =
0.8 for LODS ≥ 1, and 41% sensitivity and 96% specificity when modelled with LODS ≥
2 as the definition of severity. Applied prospectively, in real-time, a LODS score cut-off of
1 or over at admission would correctly classify the level of care required by 89% of patients but
would misclassify 11% of patients subsequently needing HDU or ICU support. Conclusion:
Calculation of a one-off logistic dysfunction score on the day of admission in patients
with acute pancreatitis permits precise assessment of prognosis a with cut-off of LODS>1.
Calculation of the LODS-modified Atlanta score on admission in acute pancreatitis should
replace prognostic testing and combines the value of admission prognostic tests with
improved disease categorization.
T1385
Simple Systemic Inflammatory Response Syndrome Score Is As Good As An
Expanded Score in Predicting Outcomes of Morbidity in Patients with Acute
Pancreatitis On Initial Presentation
Santhi swaroop Vege, Mario Pelaez-luna, Ferga C. Gleeson, Randall K. Pearson, Mark D.
Topazian, Bret T. Petersen, Jonathan E. Clain, Michael J. Levy, Michael Farnell, Michael L.
Kendrick, Michael G. Sarr, Suresh T. Chari, Piet C. De groen
Background and aim: Systemic inflammatory response syndrome (SIRS) score was reported
to predict severity of acute pancreatitis (AP). Advanced age, overweight or obesity and
elevated hematocrit have also been reported to predict severity of AP. Our objective was to
compare SIRS score of AP patients on initial presentation, with an expanded score (including
advanced age, hematocrit and Body Mass Index [BMI]) to predict morbidity outcomes
(prolonged hospital stay (LOS ≥10 days), need for ICU admission and endoscopic/ radiolo-
gical intervention of local pancreatic complications), which help in clinical decision making
at the time of presentation. Methods: An 8 point admission scoring system determined by
age (≥ 65 yrs), BMI ( 25-29,1 or ≥ 30, 2 points), temperature, heart rate, respiratory rate,
white cell count and hematocrit levels and the accepted 4 point SIRS scoring systems were
applied to 82 (46% male) consecutive patients of AP, directly admitted to our institution.
Seventeen% and 22% had evidence of organ failure and a SIRS Score ≥ 2 respectively.
Adverse outcomes included LOS ≥10 days, ICU admission, endoscopic or radiological
intervention and 14 day mortality. Univariate and multivariate logistic regression analysis
were used to assess the association between the expanded and SIRS scores. ROC curves
were used to obtain the cut off score with best diagnostic accuracy and compare AUC of
both scores. Results: The SIRS score was independently associated with a prolonged LOS
(p=0.02) and ICU admission (p=0.01). The expanded score was independently associated
with ICU admission (p=0.01). However, no relationship between either score and mortality,
or intervention was found. ROC curves showed that an expanded score of ≥ 4 and SIRS
≥ 2 displayed an accuracy of 72% and 71% for LOS > 10 days and 76% and 74% for ICU
admission respectively. According to AUC, the expanded score and SIRS score were equally
reliable for LOS (0.62 vs 0.64, p>0.05) and ICU admission (0.76 vs. 0.68, p>0.05). Conclu-
sions: SIRS score predicted morbidity outcomes with similar accuracy as an expanded score,
which included more recently reported simple and inexpensive variables in patients with
AP on initial presentation. If these results are reproducible in larger AP patient populations
from other centers, simple SIRS score on day 1, could impact on early clinical decision
making, like early institution of enteral feeding.
T1386
Volume Assessment in Patients with Necrotizing Pancreatitis: A Comparison
of Intrathoracic Blood Volume Index (ITBI), CVP and Hematocrit (HCT)
Wolfgang Huber, Andreas Umgelter, Wolfgang Reindl, Michael Franzen, Roland M.
Schmid
Background: The mortality of necrotizing pancreatitis (NP) is up to 30%. Volume depletion
and/or increased hematocrit (Hct) are associated with poor prognosis. These data suggest
that early goal-directed volume management might improve the outcome of patients with
NP. Several recent studies have shown that modern hemodynamic parameters such as ITBI
might be superior to CVP with regard to volume assessment and volume responsiveness.
Nevertheless, to date there are no data available using ITBI-determination in patients with
NP. Therefore, it was the aim of our prospective study to evaluate the predictive value of
CVP and Hct with regard to ITBI. Materials/methods: Within 24h after ICU-admission, 44
hemodynamic measurements using the PiCCO system (Pulsion, Munich) were performed
in 11 patients with NP. Primary endpoint: The predictive value of CVP (n: 1-9mmHg) and
Hct (volume depletion assumed in patients with Hct>40% (female) or Hct >44% (male))
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with regard to ITBI. Statistics: SPSS-Software. Results: Patients characteristics: n=11 (6f,
6m); age 56.7+-15.4 years; APACHE II-Score 23.5+-6.6 (11-32). Mean CVP (12.8+-6.5
(median 12) mmHg was elevated, whereas mean ITBI (801+-146 (median 816; n: 850-
1000ml/m2) was decreased. 27 of 44 ITBI values were decreased. By contrast, none of the
CVP values was decreased. 29 CVP-measurements were elevated, although simultaneous
ITBI measurements indicated normal or decreased preload. Sensitivity, specifity, positive
(PPV) and negative predictive value (NPV) of CVP with regard to volume depletion (ITBI
<850ml/ m2), were 0%, 100%, 0% and 40%, and 67%, 34%, 7% and 93% with regard to
increased preload (ITBI >1000ml/ m2), respectively. The accuracy of CVP was 16%. There
was no correlation of CVP and ITBI (p=0.245).Mean Hct. was 35.0+-7.3 (median 34). An
increase of Hct. was found in 7 of 27 measurements with decreased ITBI. Sensitivity, specifity,
PPV and NPV of an increase of Hct. with regard to volume-depletion according to ITBI
were 26%, 76%, 64% and 39%. Hct. did not correlate with ITBI (p=0.307). Outcome: All
patients were volume-resuscitated according to PiCCO-parameters. ICU-mortality was 1/11
(9%). Conclusions: 1.) Volume depletion according to ITBI was found in more than half of
the patients on the day of ICU-admission. 2.) The predictive value of CVP and Hct. with
regard to volume depletion is very low in these patients. 3.) Possible reasons for increased
CVP despite decreased ITBI in NP might be elevated intra-abdominal and/or intra-thoracic
pressure as well as diastolic dysfunction. 4.) Our data with a 9%-mortality suggest an
improved outcome of patients with NP using early-goal-directed volume management.
T1387
CT-Guided Percutaneous Catheter Drainage in Necrotizing Pancreatitis: Can
Patients Be Safely Discharged with Drains in Place?
Tyler Berzin, Koenraad Mortele, Peter A. Banks
Background: CT-guided percutaneous catheter drainage is a valuable tool in the management
of seriously ill patients with necrotizing pancreatitis (NP), with consideration of later surgical
debridement if required. Patients who improve clinically after percutaneous radiologic drain-
age are occasionally discharged from the hospital for continued care with drains in place.
Our aim was to evaluate the ultimate success of discharging patients with pancreatic drains,
as defined by the eventual removal of drains and sustained clinical well-being. Methods:
We identified patients with necrotizing pancreatitis who were discharged with drains after
CT-guided catheter drainage at our institution between 2000-2006. We evaluated relevant
features on abdominal CT scans at admission, before drain placement, and prior to hospital
discharge. We assessed extent of pancreatic necrosis (<30%, 30-50%, >50%), dimensions
and extent of organization of the necrotic collection (not organized, moderately organized,
well-organized), and CT severity index scores (CTSI and Modified-CTSI). Data regarding
the number and caliber of drainage catheters, microbiologic results, and outpatient care
were also collected. Results: 46 patients with NP were identified who had undergone CT-
guided percutaneous catheter drainage, 15 of whom were discharged in stable condition
with drains in place. 7/15 patients had their catheters removed in the outpatient setting (6
patients remained well and 1 patient eventually underwent elective surgical debridement
for persistent pain 12 months later). Median cross-sectional area of collection at discharge
was 10.4 cm2 (range 0-31.2). Median duration of drainage prior to catheter removal was
94 days (range 41-358 days). 8/15 patients were readmitted because of inadequate drainage
or recurrent infection (median time to readmission 16 days, range 4-36). Median cross-
sectional area of collection at discharge was 28.5cm2 (range 2-85.2). Of the 8 readmitted
patients, 6 underwent surgical debridement (median time to debridement after readmission
8.5 days, range 1-78). 2/8 patients had drains manipulated or additional drains placed which
were later removed with sustained clinical well-being. Factors correlated with readmission
were inadequate resolution of the necrotic collection prior to hospital discharge and small
catheter caliber (less than 14 French). (M)-CTSI, initial size of necrotic collection, and total
number of catheters was approximately the same in both groups of patients. Conclusion:
Among patients discharged with pancreatic drains for NP, patients with CT evidence of
inadequate drainage are likely to do poorly following discharge.
T1388
Per-Endoscopic Necrosectomy for Management of Sevrere Acute Pancreatitis:
First Results of a Referral Center
Jean R. Escourrou, Pierre Andrau, Barbara Bournet, Jacques Moreau, Louis Buscail
Introduction: Infected necrosis is one of the severe complication of acute pancreatitis with
a mortality of 25 to 30% among severe acute pancreatitis. A surgical necrosectomy is possible
but the morbidity is high. We present here our experience of per-endoscopic necrosectomy.
Patients and methods: Nine men and one woman (mean age 54 years) with a Balthazar E
stage acute pancreatitis (biliary 6, alcoholic 2, idiopathic 2) have been treated by per-
endoscopic necrosectomy within 2 years. They all presented a necrotic mass in a retrogastric
situation (n=4) and/or extended to all the pancreas (n=6) (mean maximal diameter of 12.7
cm). The indication of necrosectomy was: severe sepsis uncontrolled by medical treatment
in all cases with jaundnice in one case and/or ileus in one case (3 patients previously
unsuccesssful per-endoscopic drainage). The necrosectomy was conducted as follow: duod-
eno/gastrostomy (EUS guided in 2 cases), hydrolic balloon dilatation of the stomy, nec-
rosectomy with tripode/dormia/basket snare through transgastric (n= 7) or transduodenal
way (n = 3). A drainage/wash procedure was set up during 3 days by mean of a 10 F drain
disposed in the cavity following necrosectomy. A CT-scan follow-up was perfomed 15 days,
1 , 3 and 6 months after the procedure. Results: The necrosectomy was possible in all cases
(mean of 1.5 procedures; 1 - 3). It was performed meanly 37.5 days after the acute pancreatitis
(21 - 50 days). There were 3 immediate complications (bacteriemia in 2 cases and treated
digestive bleeding endoscopically in one case), but no late complications and no mortality.
Sepsis disappeared 48 to 72 hours after the procedure with a 50% decrease of CRP serum
levels. At one month, all necrotic collection disappeared. In 2 cases collections developed
in others location than pancreas were drained under US or CT-scan. An endoscopic sphinc-
terotomy was performed in 7 patients, a stent in 2 patients (biliary and pancreatic). The
mean time of hospitalization after the procedure was of 12 days in 5 patients, 30 days in
5 others. No recurrence was observed with a median follow up of 10 months. Conclusion
: endoscopic necrosectomy is a safe (no mortality), and attractive therapeutic procedure
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with acceptable morbidity. In our experience, necrosis was successfully relinquished in few
therapeutic sessions. Such an approach should improve patient's feeding capacity, reduce
antibiotics' treatment, and hospitalization time, and, as a consequence, accelerate patient's
recovery. Thus, we believe that endoscopic necrosectomy might be of great interest to treat
severe complication of acute pancreatitis such as infected necrosis.
T1389
The Natural Course of Acute Pancreatitis and the Progression of the Disease
to Chronic Pancreatitis
Paul G. Lankisch, Nils F. Breuer, Patrick Maisonneuve, Albert B. Lowenfels
The natural course of acute pancreatitis and the progression to chronic pancreatitis are
unknown. Patients and Methods: The study is based on 513 patients who were admitted
to the department of internal medicine in Lüneburg between 1987 - 2006 with a first attack
of acute pancreatitis. Etiology was alcohol in 152 (30%), biliary in 216 (42%), other in 43
(8%), and unknown in 102 (20%) patients. The following parameters were evaluated: signs
of peritonitis, amylase, lipase, hematocrit, blood glucose, creatinine pO2, APACHE II score
on admission, Imrie and Ranson score after 48 hours, Balthazar score within 72 hours, and
smoking. The diagnosis of chronic pancreatitis was made only if imaging procedures showed
pancreatic calcifications and/or duct changes and if a direct/indirect pancreatic function test
had proven exocrine pancreatic insufficiency (Lüneburg score, a modification of the Mayo
Clinic score). Results: During a mean follow-up of 7.9 years, 19 (3.7%) patients developed
chronic pancreatitis: alcohol 18 (11.8%), biliary 0, other 1 (2.3%), idiopathic 0 patient(s);
p<0.00001. In the patient with an initial autoimmune pancreatitis (other etiology) chronic
pancreatitis developed when he became a heavy drinker. Among patients who had a first
attack of alcoholic pancreatitis, the cumulative rate (95% CI) of chronic pancreatitis was at
one year: 3% (0-6); 2 yrs: 7% (3-11%); 5 yrs: 11% (6-16%); 10 yrs: 13% (7-19%). The
risk of a progression to chronic pancreatitis was significantly elevated in patients with alcohol
abuse who smoked or had a high lipase elevation on admission (p=0.015; p=0.041). The
risk was independent on any other parameters of severity on admission, Balthazar score or
absence and presence of organ failure. Conclusion: Only alcohol-induced acute pancreatitis
progresses to chronic pancreatitis and smoking is the risk factor. For prevention of the
progression, patients should be advised to stop both drinking and smoking.
T1390
Calcium Infusion Predicts Development of Post-Operative Acute Pancreatitis
in Children Undergoing Posterior Spinal Fusion
Zhaoping He, Dalal Tonb, Tracey Nadal, Suken Shah, Kirk W. Dabney, Freeman Miller,
Randall Brenn, Mary Theroux, John Mccloskey, Devendra I. Mehta
Introduction: Acute pancreatitis (AP) is a common complication in children undergoing
posterior spinal fusion for correction of scoliosis. Association of increased blood loss and
development of pancreatitis has been documented (Zhaoping et al, 2005 Leichtner et al
1991). However, calcium infusions are utilized for low ionized calcium partly due to massive
blood loss. Calcium increase intracellularly is a key step in developing acinar injury and
acute pancreatitis. Calcium infusions in humans, as well as in hypercalcemia from miscellan-
eous causes, have been shown to result in acute pancreatitis (Izhak et al 1980). Objectives:
Assess intraoperative iv calcium use as a risk factor to developing acute pancreatitis. Methods:
After obtaining IRB approval, 152 patients, 90 NM and 62 ID were enrolled in the study.
The following parameters were collected and analyzed: scoliosis, gender, age, wt, hospital
stay, blood loss, length or number of levels fused, use of unit rod instrumentation, duration
of surgery, use of intra-operative calcium replacement and seizure medicine. Amylase and
lipase levels were followed, and AP was diagnosed using clinical criteria as well as greater
than threefold elevation of amylase or lipase. Data were analyzed using logistic regression
analyses. Results: Twenty two children (22/152=14%) had acute pancreatitis post-operatively,
most cases in those with neuromuscular scoliosis. Results from univarate analysis show that
except of duration of surgery and gender, all other variables significantly predicted the
outcome of pancreatitis with p value <0.05, and length of stay in those with AP was
significantly longer. However, using a stepwise logistic regression analysis, only age and
calcium replacement significantly predicted the outcome of pancreatitis with p value 0.041
and 0.012, and Odds Ratio 5.4 and 1.3 respectively. None of the other variables, including
blood loss or neuromuscular scoliosis remained significant independent predictors. Discus-
sions: Intra-operative calcium replacement and age are two risk factors that are independently
associated with the development of post-operative pancreatitis. Our data suggest that calcium
might play a role in the development of pancreatitis in these children.
T1391
Nutritional Management for Acute Pancreatitis: Adherence to Guidelines in a
Large Cohort of Patients in the Netherlands
B.w.marcel Spanier, Marcel.g.w. Dijkgraaf, Marco Bruno
Background: In 2003 a prospective cohort study of acute pancreatitis (AP) in the province
of Northern Holland (2,6 million inhabitants) was initiated (EARL study). One of its aims
is to investigate the clinical management of AP including nutritional interventions and
adherence to guidelines. In these guidelines it is stressed that the time of starvation should
be limited with early initiation of feeding preferably by the enteral route. Methods: Patients
were included from 18 hospitals. Hospital records and nursing reports were reviewed. Study
items were recorded in a database. These included length of hospital stay, department of
admission, severity of AP, the time period during which patients received no oral feeding;
naso-enteric feeding with/without oral feeding, and TPN. Results: For the present survey
sufficient data was available from 111 hospital admissions of 93 patients. 82% (76/93) of
patients had a first attack of AP and 17 patients had relapsing AP. 57% (63/111) of the
admissions took place in a non-academic hospital. The majority of patients suffered from
edematous pancreatitis (97,8%) and were admitted on a gastroenterology/ internal ward
(86% of admissions). Five patients were admitted to a MCU/ICU. Only two patients developed
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pancreatic necrosis on CT scan. The overall median hospital stay was 11 (1-51) days. Patients
admitted for more than 1 week had a median hospital stay of 14 (8-51) days. Nutritional
interventions (including starvation) occurred in 96% (107/111) of the admissions. In 75%
(80/107), the sole intervention was no oral feeding for a median period of 2 (1-12) days.
In 23% (25/107) a no oral feeding regimen was combined with naso-enteral feeding. The
median period of naso-enteral feeding (sole or in combination with oral feeding) was 8 (1-
47) days and in 80% delivered the jejunal route. TPN was administered to 2 patients only
for 5 and 21 days, respectively. The overall median period of starvation was 2 (0-12) days.
In patients admitted more than 1 week, 12% (7/57) were starved for more than 5 days. In
this subgroup the median percentage time of starvation was 43% (27%-60%) of the total
hospitalization time. Conclusions: The total time of starvation in patients with AP was
limited in the majority of cases. Nutritional measures were undertaken reasonably quickly
with enteral feeding via the jejunum as the preferred intervention. This is in alignment with
published guidelines. A small percentage of patients suffered from prolonged starvation
which may potentially hamper recovery and outcome. Therefore, awareness of a patients
nutritional status remains an important point of attention in the clinical management of AP.
T1392
Indication, Utilization, and Yield of Early CT Scan in the Management of
Acute Pancreatitis
B.w.marcel Spanier, Marcel.g.w. Dijkgraaf, Marco Bruno
Background: In 2003 a cohort study of acute pancreatitis (AP) in the province of Northern
Holland (2,6 million inhabitants) was initiated (EARL study). One of its aims is to analyze
the clinical management of AP in a population based setting, including the use of CT scan.
Many patients do not require a CT scan at admission or during hospitalization. An early
CT scan (within 96 hours after symptom onset) may be indicated to distinguish AP from
other serious intra-abdominal conditions or to identify early pancreatic necrosis in patients
with fever and septic signs or/and emerging organ failure to start prophylactic antibiotics
for the prevention of secondary infection. Methods: Patients were included from 18 hospitals
participating in this ongoing prospective cohort study. The following data were retrieved
from the study database: etiological factors, hospitalization time, timing (after the onset of
symptoms) of CT scan, Baltazar CT severity index, presence of pancreatic necrosis, and use
and timing of antibiotics. Results: For this survey 141 admissions of 128 patients were
analyzed. The etiology of AP was biliary (34,4%); alcoholic (15,6%); post-ERCP (14,1%);
idiopathic (14,1%) and miscellaneous (21,8%). The median hospital stay was 8 days (1-
52). At least one CT scan (range 1-6) was performed in 43,3% (61/141) of admissions and
in 63,9% (40/61) the CT was made within 96 hours after symptom onset: 22,5% at admission,
10% after 24 h, 17,5% after 48 h, 22,5% after 72 h and 22,7% after 96 h. In 7,5% (3/40)
there were differential diagnostic considerations to perform an early CT. In 27,5% (11/40)
the indication was persisting fever or a rising CRP. Only one patient (2,5%) showed evidence
of sepsis at the time of early CT. Importantly, in the remaining 62,5% (25/40) there were
no clinical signs of necrosis/sepsis at the time of early CT. The Baltazar CT severity index
was grade A (normal) in 17,5%; grade B in 22,5%; grade C in 45% and grade D in 15%.
None of the early CT scans showed pancreatic necrosis. In a minority of 10% (4/40), early
CT findings prompted the physician to start antibiotics. In 17,5% (7/40) (prophylactic)
antibiotics had already been started before obtaining the CT. Conclusions:An early CT scan
is frequently acquired in the early course of AP. Many early CT scans are performed at times
when there is no true clinical suspicion of necrosis. Therefore, the yield is low with little
clinical management consequences. Based on the outcome of this survey it seems prudent
that clinicians should be more restrictive in the use of early CT scan in AP.
T1393
Spectrum of MR Findings in Patients with Asymptomatic Hyperamilasemia
and/Or Hyperlipasemia
Luca Frulloni, Chiara Scattolini, Riccardo Manfredi, Franca Patrizi, Antonio Amodio,
Veronica Paon, Roberto Pozzi mucelli, Italo Vantini
Background: The spreading of the serum pancreatic enzymes dosage in clinical practice
results in a ever-increasing number of patients with elevated amylase and/or lipase serum
levels, without clinical evidence of pancreatic disease. A recent study shows that MRCP
yielded pancreatic findings in more than 50% of patients with asymptomatic pancreatic
hyperenzymemia[1]. Aim of this study was to assess the spectrum of MRCP findings in
patients with asymptomatic hyperamylasemia and/or hyperlipasemia. Patients and Methods:
From April 2004 to April 2006, we prospectively enrolled 32 asymptomatic patients (22
males and 10 females, mean age 50±11 years) with a documented (at least in three occasions)
increase of serum amylase (9 pts), serum lipase (3 pts) or both (20 pts) over the upper
normal limit. Patients who drank more than 40 g of alcohol/day were excluded. All patients
underwent MRCP before and after secretin stimulation. Radiological images were individually
analyzed by two abdominal radiologists without knowledge of the results of the standards
of reference or the final diagnosis. Discordant interpretation were settled by consensus.
Results: 14 out of 32 pts (44%) had a normal pancreatic ductal three, one of whom had a
cholangiocarcinoma. In the remaining 18 pts (56%), anatomic anomalies were observed in
6 pts (19%) (5 pancreas divisum and 1 annular pancreas), 2 of whom showed a dilated
main pancreatic duct. 7 pts showed a dilated main pancreatic duct (22%), 5 of whom with
dilation of the secondary ducts. 2 pts showed pancreatic changes compatible with IPMN (1
main duct-type and 1 branch-type). The last 3 pts (9%) showed alterations of the main
pancreatic duct (1 focal stenosis and 2 minimal changes). Conclusion: patients with asympto-
matic hyperamilasemia and/or hyperlipasemia showed abnormal MRCP in more than 50%
of cases. [1] Mortelè KG et al, Abdominal Imaging, 2004; 29: 109-114.
T1394
Racial Disparities in Cholecystectomy Rates Among Patients Hospitalized for
Acute Gallstone Pancreatitis: A National Survey
Geoffrey Nguyen, Anne Tuskey, Sanjay B. Jagannath
BACKGROUND: Cholecystectomy prior to discharge is recommended for the management
of gallstone pancreatitis. Racial disparities in utilization of major surgical procedures have
been reported in a broad spectrum of conditions. Our objective was to determine whether
there are racial differences in cholecystectomy rates in a nationally representative sample of
patients with gallstone pancreatitis. METHODS: We used ICD9-CM codes to identify all
discharges with a primary diagnosis of acute pancreatitis and an associated diagnosis of
cholelithiasis in the Nationwide Inpatient Sample (NIS) between 1998 and 2004. The NIS
is the largest geographically representative, all-payer database of acute-care hospital discharges
in the United States. We compared rates of cholecystectomy among non-Hispanic whites,
African Americans, and Hispanics. We used multiple logistic regression to determine the
relationship between race and cholecystectomy while controlling for demographic predictors.
We also assessed for racial differences in utilization of endoscopic retrograde cholangiopan-
creatography (ERCP). RESULTS: There were 68,954 admissions for acute gallstone pancreat-
itis between 1998 and 2004. The racial distribution of patients was: non-Hispanic whites
(69%), African Americans (AAs)(11%), Hispanics (15%), and Other (5%). The overall rate
of cholecystectomy during the same admission was 50.7%. The unadjusted cholecystectomy
rate was higher in non-Hispanic whites than African Americans (AAs) (50.5% vs. 43.3%,
p<0.001). After adjustment for confounders, the adjusted odds ratio for undergoing cholecys-
tectomy in whites compared to African Americans was 0.68 (95%CI: 0.64 - 0.72). African
Americans also had a longer time interval from admission to cholecystectomy than whites
(4.2 days vs. 3.7 days, p<0.001). Hispanics were slightly more likely to undergo cholecystec-
tomy than whites (OR 1.12; 95%CI: 1.06 - 1.18). In multivariate analysis, females were
more likely than males to undergo cholecystectomy (OR 1.19; 95%CI: 1.15 - 1.24). Compared
to those privately insured, patients with Medicaid (OR 0.83; 95%CI: 0.77 - 0.90) or had
no insurance (OR 0.74; 95%CI: 0.68 - 0.81) were less likely to receive cholecystectomy.
After controlling for other predictors, African Americans were also less likely to undergo
ERCP than whites (OR 0.87; 95%CI: 0.78 - 0.98). CONCLUSIONS: Only half of patients
with acute gallstone pancreatitis undergo cholecystectomy during the same hospital admission
as recommended. African Americans are much less likely to undergo cholecystectomy than
whites, and the underlying factors contributing to these disparities warrant further investi-
gation.
T1395
Prevalence of Extra-Pancreatic Cancers in Patients with Intraductal Papillary
Mucinous Neoplasms of the Pancreas: Results of a Case-Control Study
Isabelle Baumgaertner, Olivier Corcos, Anne Couvelard, Alain Sauvanet, Vinciane
Rebours, Marie-pierre Vullierme, Olivia Hentic, Frédérique Maire, Pascal Hammel,
Philippe Lévy, Philippe Ruszniewski
Several studies have suggested that patients with intraductal papillary mucinous neoplasms
of the pancreas (IPMN) have a high frequency of extra-pancreatic malignancies - especially
gastric and colorectal cancers- however these studies have included small sample sizes and
have not been case-controlled. The objective of the study was to examine the association
of extra-pancreatic neoplasms in a large series of patients with IPMN. Patients/methods: a
case-control study comparing 178 patients with IPMN (hyperplasia/low-grade dysplasia: n=
91; high-grade dysplasia/invasive cancer: n=87) to 365 age and sex matched controls (n=
356); emanating from patients consulting an ophthalmologic out-patients clinic). History
of cancers in IPMN patients and controls were examined for by directly questioning the
patients and by examining the medical charts (with pathological confirmation when possible).
In addition, family histories of cancer and alcohol and tobacco consummation were recorded.
Extra-pancreatic cancer development in IPMN patients included those developing before
the diagnosis of IPMN and those synchronous or metachronous to the diagnosis. Results:
no difference was observed between alcohol and tobacco intake in IPMN patients and
controls. A personal history of extra-pancreatic cancer was found in 30/178 (16.8%) IPMN
patients (two thirds before and one third after IPMN diagnosis) and in 30/356 (8.4%)
controls (p<0.05). The most frequent cancers in IPMN and controls included: breast (30%
in each group), prostatic (10% and 13%, respectively, NS); and colorectal (10 and 6%,
respectively, NS). The median age of cancer development in controls was 67.5 years compared
to 60.6 years in IPMN. patients (NS). No bias was observed in patients with IPMN with
extra-pancreatic cancers which occurred either before or after the diagnosis of IPMN. No
association was found between extra-pancreatic cancers and grade of IPMN. Conclusions:
1) the prevalence of extra-pancreatic cancers in IPMN patients is high compared to the
general population; 2) the existence of an extra-colonic cancer is not correlated to histological
grade of IPMN; and 3) these results suggest the existence of particular carcinogenic mechan-
isms in patients with IPMN and should be confirmed by a large cohort study.
T1396
A Predictive Model for Pancreatic Cyst Neoplasia to Assist in the Selection of
Patients for Surgical Treatment
Jonathan M. Buscaglia, Samuel A. Giday, Sanjay B. Jagannath, Sergey V. Kantsevoy,
Priscilla Magno, Christopher L. Wolfgang, Jason A. Daniels, Marcia I. Canto
Pancreatic cysts are increasingly recognized due to the widespread use of high resolution
cross-sectional imaging techniques (CT & MRI). Accurate prediction of the neoplastic poten-
tial of a cyst is important for timely referral for surgery. AIM: To develop a predictive
model for neoplasia in pancreatic cysts to improve patient selection for surgical resection
or conservative follow-up. METHODS: We performed retrospective analyses of EUS and
pathology databases, and electronic medical records, of pancreatic cyst patients with final
pathologic diagnoses confirmed by surgical pathology and/or definitive positive cytology.
We excluded main duct IPMNs and ductal adenocarcinomas without associated cystic lesions,
and incidental cystic tumors found after resection. Pancreatic neoplastic cysts requiring
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surgical resection were subdivided into branch duct IPMNs with carcinoma-in-situ or invasive
cancer, mucinous cystic adenomas/adenocarcinomas, islet cell tumors, and ductal adenocarci-
nomas with cysts. Patient demographics and symptoms, ductal dilation, cyst morphology,
and fluid cytology, amylase, and CEA levels were studied as candidate risk factors for
neoplasia. Receiver operating curve (ROC), univariate, and multivariate logistic regression
analyses were performed to determine independent risk factors for cyst neoplasia. RESULTS:
424 patients with >1 pancreatic cyst were studied; 270 (41% men, 85% white, mean age
61.8 years) had a final pathologic diagnosis (268 by surgical pathology, 2 by definitive
cytology obtained via EUS-FNA). The final diagnoses were IPMN (n=118), mucinous cyst
(n=36), serous cystadenoma (n=71), cystic islet cell tumor (n=4), pseudocyst (n=37), simple
cyst (n=3), and ductal adenocarcinoma masquerading as pseudocyst (n=1). Optimal cut-off
points for cysts needing resection by ROC analysis were: cyst fluid CEA > 3594 ng/ml, age
> 50 years, and cyst size > 1.5 cm. ROC analysis for amylase showed the optimal cut-off
point to be > 53 (AUC = 0.700) to diagnose pseudocysts. Univariate analyses revealed that
cystic neoplasms requiring resection were associated with white race, presence of symptoms
(particularly weight loss), cyst size > 1.5 cm, and high cyst CEA. Logistic regression analyses
demonstrated that only white race (OR= 4.4), symptoms (OR = 2.2), and high CEA > 3594
ng/ml (OR=8.7) were independent predictors of malignancy after controlling for age, gender,
and cyst size. CONCLUSIONS: This model for prediction of neoplasia in pancreatic cysts
suggests risk factors other than cyst size are important. A prospective validation study is
underway to improve the current model and optimize patient selection for surgical resection.
T1397
Significance of Branch Duct Type Intraductal Papillary-Mucinous Neoplasms
of the Pancreas As a High Risk Factor for Pancreatic Cancer: Long-Term
Follow-Up Results
Satoshi Tanno, Takeshi Obara, Yasuhiro Nakano, Madoka Minoguchi, Tomoya Nishikawa,
Kazumasa Nakamura, Yusuke Mizukami, Toshikatsu Okumura, Yutaka Kohgo
Background/Objective: The aim of this study was to elucidate the significance of branch
duct type intraductal papillary-mucinous neoplasms of the pancreas (IPMNs) as a high risk
factor for pancreatic cancer. Methods: Eighty patients (57 men and 23 women) with branch
duct type IPMNs were selected for follow-up. Patients who had apparent mural nodules
were excluded from follow-up study. All patients underwent initial endoscopic retrograde
pancreatography (ERP), endoscopic ultrasonography (EUS), magnetic retrograde cholangi-
opancreatography (MRCP), and computed tomography (CT). Serial changes of the maximum
cystic diameter and the presence of mural nodule were studied during the observation
periods ranged from 14 to 172 months (mean, 65.4 months). Results: Six (7.5%) of 80
patients exhibited obvious progression of cystic dilatation. New apparent mural nodules
were detected in 6 cases (7.5%) during the observation periods. These obvious changes
were observed after a 14 to 114 months follow-up period (mean, 80 months). Of six patients
with mural nodules, five cases underwent surgery after follow-up study, and the pathologic
diagnosis was adenoma in three and non-invasive carcinoma in two. Six patients with cystic
size enlargement alone were followed up without surgical resection. Ductal adenocarcinomas
were developed in four patients (5%) apart from IPMN in the same pancreas. None of the
remaining 64 patients (80%) showed changes in cystic diameter or new apparent mural
nodules. Conclusions: Most branch duct type IPMNs without apparent mural nodules
remained unchanged. However, branch duct type IPMNs seem to be significant as a high
risk factor for pancreatic cancer. Follow-up with careful examination is required to detect
ductal adenocarcinomas apart from IPMNs in the same pancreas.
T1398
Misdiagnosis in Patients Undergoing Surgery for Intraductal Papillary
Mucinous Neoplasias (IPMN) of the Pancreas
Pascal Hammel, Mohamed Bouattour, Vinciane Rebours, Frédérique Maire, Dermot
O'toole, Marie-pierre Vullierme, Anne Couvelard, Olivia Hentic, Philippe Ponsot, Alain
Aubert, Olivier Corcos, Anne-laure Pelletier, Alain Sauvanet, Philippe Lévy, Philippe
Ruszniewski
Preoperative diagnosis of IPMN may be difficult occasionally leading to unnecessary pancrea-
tectomy. Recent developments of non-invasive imaging techniques (MRI, instead of endos-
copic retrograde pancreatography [ERP]) and increased awareness of physicians might influ-
ence the rate of IPMN misdiagnosis. Aim: analyse the rate of IPMN misdiagnosis in two
consecutive time periods to evaluate the influence of the center's experience and the wide-
spread availability of pancreatic MRI. Patients and methods : clinical, morphological and
pathological data of patients operated on between 1996 and 2006 for suspicion of IPMN
in a single center were retrospectively reviewed. All patients underwent preoperative abdom-
inal CT and endoscopic ultrasound (EUS). ERP was performed until 2001 thereafter replaced
by MRI. EUS-guided biopsy was performed in doubtful cases. Results : 219 patients (108
men), median age 61 years (21-78) underwent surgery. The diagnosis of IPMN was secondary
to pancreatic pain or acute pancreatitis in 70% of the patients and was discovered incidentally
in 11 % of cases. Pancreaticodudoenectomy, distal pancreatectomy or other types of pancre-
atic surgery were performed in 59, 20 and 21% of the patients, respectively. Among 205
patients (94%) with confirmed IPMN, the main pancreatic duct was involved in 70%, while
the disease was limited to branch ducts in 30%. Infiltrating adenocarcinoma was found in
28%. Pathological examination of the surgical specimen ruled out IPMN in 14 patients (6%)
: chronic pancreatitis (n=4), acinar cystic transformation (n=3), endocrine tumor (n=3),
ischemic pancreatitis (n=1), polycystic disease (n=1), pseudocysts (n=1) and serous cystaden-
oma (n=1). Clinical, morphological features and preoperative imaging procedures did not
differ between the patients with/without IPMN, except median age (62 and 52 years, respect-
ively; p<0.001). Misdiagnosis occurred in 8/76 patients (11%) before 2001, and in 6/143
patients (4%) thereafter (p=0.003). Patients' characteristics, type of lesion and surgical
procedures did not differ significantly between the two periods. ERP and EUS-guided biopsy
were performed in 78 and 64% of cases respectively before 2001, and in 15 and 38%
thereafter (p=0.0001). Pancreatic MRI was performed in 13 and 100% of the patients before
and after 2001, respectively (p=0.0001). Conclusion: misdiagnosis rate in patients with
suspected IPMN decreased with time (4% in the last 5 years), while invasive procedures
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(ERP, biopsy) were less frequently performed. Although no direct comparison was made,
these results suggest that MRI might safely replace ERP in patients with suspected IPMN.
T1399
Benign Mucinous Cysts of the Pancreas
Gerard J. Oakley, Herb J. Zeh, Kenneth K. Lee, James Moser, Alyssa M. Krasinskas
The vast majority of mucinous cysts of the pancreas are either intraductal papillary mucinous
neoplasms (IPMNs) or mucinous cystic neoplasms (MCNs). The former have papillary
projections and involve the pancreatic ductal system, while the latter contain ovarian-type
stroma and do not communicate with the ducts. Pancreatic intraductal neoplasia (PanIN)
is mucinous neoplasm involving ducts less than 0.5 cm in diameter. Some mucinous cysts
lack characteristic features of MCN or IPMN and may represent the recently coined “mucinous
nonneoplastic cyst of the pancreas,” but it is also possible that these cysts represent dilated
ducts lined by PanIN, MCN without ovarian-type stroma or “flat” IPMNs. We sought to
classify a series of such “benign mucinous cysts” (BMC) based on their apomucin expression
profiles. Methods: Immunohistochemistry for MUC1, MUC2, MUC4, MUC5AC, MUC6 and
MUC7 was performed on 17 resected BMCs that were retrieved from the surgical pathology
files over a 2-year period. Resected MCNs (n=6), IPMNs (n=6) and pancreatic ductal aden-
ocarcinoma (n=5), as well as areas of low grade (n=13) and high grade (n=5) PanIN were
used as controls. Results: Patients with the BMC tended to be female (13F, 4M) and had a
mean age of 71 years (range, 61-82); The mean cyst size was 2.1 cm (range, 0.6-6.0 cm).
Patients with MCN were all female with a mean age of 46 years (range, 22-76); The mean
cyst size was 7.3 cm (range, 3.5-15 cm). Patients with IPMN had a mean age of 67 years
(range, 46-84) and there were 4M and 2F; The mean cyst size was 3.5 cm (range, 1.2-7.0
cm). The mucin profiles for the control groups are shown in table 1. When compared to
the controls, 6 of the 17 (35%) BMC had mucin profiles similar to PanIN, 6 (35%) were
similar to MCN, 2 (12%) were similar to IPMN, 2 (12%) had squamous differentiation and
mucin profiles most similar to MCN and 1 (6%) had focal mucin production and had a
profile similar to normal pancreatic ducts. Conclusions: Some mucinous cysts of the pancreas
are difficult to classify into known histopathologic entities. Based on our study, mucin stains
appear to be helpful in classifying these small cystic lesions. Since most of our “benign
mucinous cysts” had mucin profiles similar to MCNs, PanINs, or IPMN, even these small cysts
with bland epithelial lining appear to be early neoplasms, rather than “nonneoplastic” cysts.
T1400
Conditional Pancreatic Expression of Mutated Krasg12d and Tgfa Results in
Development and Progression of Cystic Papillary Neoplasms Resembling
Human IPMN
Jens T. Siveke, Henrik Einwächter, Bence Sipos, Dieter Saur, Roland M. Schmid
Pancreatic cancer is thought to develop from defined PanIN, IPMN and MCN precursor
lesions with PanIN lesions being the best characterized. Conditional activation of mutated
KrasG12D leads to progression of PanIN lesions to metastatic pancreatic cancer in a well
established mouse model. In addition to KrasG12D and tumor suppressors such as Tp53,
p16Ink4a or Smad4, growth factors such as Tgfa and Egfr signaling have been implicated
in pancreatic carcinogenesis. In this study we analyzed the effect of Tgfa overexpression in
addition to mutant KrasG12D by crossing Elastase-Tgfa mice to p48+/Cre;Kras+/LSL-G12D
mice. We show that concomitant expression of Tgfa and mutated KrasG12D not only leads
to accelerated progression of mPanIN lesions but also to development of cystic papillary
lesions with striking resemblance to human IPMNs. Microarray data revealed an IPMN
signature at an early age and IPMN-like lesions expressed Muc1 and Muc5AC but not Muc2
or Cdx2, similar to the pancreatobiliary type of human IPMN. In older KrasG12D;Tgfa mice,
progression of cystic papillary lesions to invasive and metastatic PDAC was notable suggesting
a novel precursor lesion in this model. Thus, Egfr signaling in addition to oncogenic Kras
may be a prerequisite for IPMN development and progression. This model may provide the
basis for further genetic and preclinical studies.
T1401
Clinicopathological Characteristics of the Cystic Neoplasms of the Pancreas in
Korea
Won jae Yoon, Yong bum Yoon, Ji kon Ryu, Yong-tae Kim, Kwang hyuck Lee, Jun kyu
Lee
Background : Cystic tumors of the pancreas are being recognized with increased frequency,
partly due to increased utilization of abdominal imaging for the evaluation of abdominal
complaints or for screening of other diseases. The present study was conducted to evaluate
the clinicopathological characteristics of the cystic neoplasms of the pancreas in Korea.
Methods : Cystic neoplasms of the pancreas diagnosed over a period of 12.5 years, from
January 1993 to June 2004 in 30 university hospitals throughout Korea were collected.
Demographic data, presenting symptoms and signs, diagnosis, grade of dysplasia, and factors
associated with malignancy were evaluated. Results : A total of 1573 cases of cystic neoplasms
of the pancreas were radiologically diagnosed. The diagnoses and percentages are as follows:
intraductal papillary mucinous neoplasm (IPMN), 652 (41.5%); mucinous cystic neoplasm
(MCN), 376 (23.9%); serous cystic neoplasm (SCN), 307 (19.5%); solid pseudopapillary
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neoplasm (SPN), 221 (14.0%); cystic endocrine neoplasm, 14 (0.9%); and acinar cell neo-
plasm, 3 (0.2%). Of these, 1076 cases were pathologically confirmed. The pathological
diagnoses are as follows: IPMN, 436 (adenoma 141, moderate dysplasia 141, carcinoma
135, not graded 19); MCN, 268 (adenoma 161, moderate dysplasia 30, carcinoma 77);
serous cystadenoma, 162; SPN, 195 (benign 179, carcinoma 16); cystic endocrine neoplasm,
13 (benign 4, borderline 2, malignant 2, not graded 5); and acinar cell cystadenocarcinoma,
2. Increase in the annual number of diagnoses was evident. In IPMN, advanced age (p=
0.046, hazards ratio 1.02), involvement of the pancreatic head (p=0.018, hazards ratio 1.86),
and presence of jaundice (p=0.011, hazards ratio 1.86) were associated with malignancy on
multivariate analysis. In MCN, involvement of the pancreatic head (p=0.015, hazards ratio
2.40) was associated with malignancy on multivariate analysis. Conclusion : Unlike the
western countries, IPMNs were the most frequently encountered cystic neoplasms of the
pancreas. SPNs were observed more frequently than had been previously reported from the
western countries. The numbers of diagnoses per year for cystic tumors of the pancreas are
increasing steadily, which may be attributed not only to increased interest to health and
subsequent screenings, but also to actual increase in the incidence of these tumors. In
IPMNs, increased mean age was associated with malignancy, suggesting an adenoma-carcin-
oma sequence. Involvement of the pancreatic head was associated with malignancy in both
IPMNs and MCNs, warranting extensive workups and possibly early surgical interventions.
T1402
Pancreatic Cyst Fluid Analysis: Correlation of K-RAS-2 and LOH Mutations
with CEA Levels and Histology
Jayaprakash Sreenarasimhaiah, Luis Armstrong, Luis F. Lara, Shou-jiang Tang, Carlton C.
Barnett
BACKGROUND: Analysis of fluid from pancreatic cysts is essential to determine clinical
course and optimal therapy. The presence of K-ras-2 point mutation and at least two
mutations of allelic imbalance or loss of heterozygosity (LOH) with good quality DNA has
been shown to occur in mucinous cystic neoplasms (MCN). OBJECTIVE: Identify the clinical
impact of DNA analysis of pancreatic cyst fluid with its correlation to cyst fluid chemistry
and histologic analysis. METHODS: This is a retrospective analysis of all consecutive patients
with pancreatic cysts who presented for endoscopic ultrasound (EUS) examination with
fine-needle aspiration (FNA) biopsy over a 12 month period until October 2006. DNA
analysis was performed by RedPath Integrated Pathology (Pittsburg, PA). RESULTS: A total
of 24 consecutive patients had samples submitted for DNA analysis. Average age was 62.2
years with 54% male and 46% female. In 11 (45.8%) patients, fluid analysis yielded normal
histology and was negative for both K-ras-2 and LOH mutations suggesting benign pathology.
In 6 (25%) patients, pancreatic pseudocyst was suspected by EUS imaging, benign histology
with debris, elevated fluid amylase levels, and low carcinogenic embryonic antigen (CEA)
levels less than 172 ng/mL in each case. MCN was documented by both FNA biopsy and
surgical resection in 3 of 24 (12.5%) patients. Cystic degeneration of pancreatic adenocarcin-
oma was found in 1 (4.1%) patient. In 8 patients (33%), LOH mutation was falsely positive
despite benign histology, K-ras-2 negativity, and CEA levels not exceeding 75.8 ng/mL when
available. In 1 (4.1%) patient, K-ras-2 mutation was positive while histology, LOH, and
CEA (2.7 ng/mL) suggested a benign cyst. The remaining 14 (58.3%) patients had benign
histology, equivocal CEA levels (mean of 189.1 +/-299 ng/mL) and negative K-ras-2 and
LOH analysis suggesting either serous cystadenoma or benign cyst of uncertain etiology. In
15 patients, both CEA and DNA analysis were available. In 3 of 15 (20%), histology suggested
MCN and CEA exceeded 365 ng/mL in those cases with a mean of 926.6 ng/mL. In 2 (66%)
cases, K-ras-2 mutation was present but significant LOH was detected in none. In 12/15
(80%), histology was benign with a mean CEA of 623.9 ng/mL along with K-ras-2 postive
in 1 case and LOH detected in 3 cases. CONCLUSIONS: Consistency in histology, K-ras-
2 and LOH mutations was seen in only 46% of cases, all of which were benign cysts. While
K-ras-2 mutations correlated well with CEA and histology in detection of MCNs, LOH
analysis was entirely negative in this setting. Furthermore, LOH mutations were falsely
positive in one-third of cases.
T1403
Prospective Evaluation of Cystic Lesions of Pancreas: Imaging, Surgical and
Pathological Correlation
Dushyant V. Sahani, Stefano Crippa, Nisha Sainani, Oswaldo Razo, Gregory Lauwers,
Carlos Fernandes-del castillo
Purpose 1) Differentiation of cystic pancreatic lesions into mucinous and non-mucinous
lesions on MDCT. 2) Accuracy of MDCT in differentiating benign from malignant cysts and
the features that predict malignancy. Material and Methods In this prospective study, 45
consecutive patients (M:F 21:24) (Age 23-89 yrs, Mean 61.5 yrs) with 50 cystic lesions
(Size 1.5-8.1 cm) underwent a dedicated thin section (< 1.25 mm thickness) pancreatic
protocol 16-MDCT. The morphological features of the lesions (viz. septa, mural nodules,
communication with MPD, MPD dilatation etc) were evaluated by an expert reader and
recorded on a pre-defined template. A 5-point scale of reader confidence was used for
diagnosis and characterization into benign or malignant. All patients underwent surgical
exploration, lesions were pathologically evaluated and the features were recorded on a pre-
defined template for standardization. PPV, NPV and accuracy of CT was mucinous and non-
mucinous lesions was Results Surgical resections were performed in 43 patients (2 were
unresectable due to advanced disease). Pathologically, 32/50 lesions were mucinous while
16/50 were non-mucinous. The features on CT favoring mucinous lesions were multi-
loculated macrocystic appearance, with or without MPD communication and mural or septal
calcification. MDCT accuracy for mucinous v/s non-mucinous lesions was 81%. 24/50
lesions were malignant, of these 18 were mucinous while 4 were non-mucinous (2 were
unresectable). PPV and accuracy of MDCT for malignancy in mucinous lesions was 76%
and 72% while that in non-mucinous lesions was 100% and 100% respectively. Features
favoring malignancy were mural nodules, thick septae, MPD dilatation and biliary obstruction.
The PPV of nodules, nodules with septae, MPD dilatation, nodules with MPD dilatation and
biliary obstruction on MDCT for malignancy was 85%, 66%, 74%, 93% and 87% respectively.
However, MDCT failed to predict the borderline changes in 7/50. Conclusion MDCT features
allow reliable differentiation of mucinous and non-mucinous lesions. Mucinous lesions had
higher incidence of malignancy. Cyst features on MDCT can permit accurate characterization
of malignant from non-malignant.
T1404
Conservative Management Strategy of Intraductal Papillary-Mucinous
Neoplasm (IPMN) of the Pancreas with Long-Term Follow-Up
Satoko Ito, Kenji Yamao, Nobumasa Mizuno, Hideki Ishikawa, Vikram Bhatia
Objectives: IPMN is being increasingly detected incidentally among the elderly, in whom
its natural history and indications for surgery are unclear. Our objective was to study the
natural course of this tumor among long term follow up patients. Methods: From 1971 to
2005, a total of 185 patients were diagnosed as IPMN at Aichi Cancer Center. We reviewed
clinical, imaging and pathological features of 36 patients with > 3 years follow up. Eleven
operated patients had a follow up duration of more than 3 years before they underwent
surgery. Nine of these operated patients and 27 conservatively managed patients fulfilled
the inclusion criteria and constituted the study group.Follow up protocol included at least
annual review of all new symptoms and signs, and annual EUS studies. The maximal cyst
size, MPD diameter, and mural nodule size were measured on EUS. If there was a change
in findings on follow up EUS studies, ERCP and CT scan of the abdomen were performed.
The indications of surgery in our institution were significant symptoms, rapid progression
in size of MPD, nodules, or cysts, and an absolute size of mural nodules and/or MPD >
10mm. Results: The patients included 22 males and 14 females. Six (16.7%) patients were
symptomatic for their disease when diagnosed. The remaining 28 patients were asymptomatic,
and were detected on incidental imaging during routine health check up. None became
symptomatic over a median follow up of 5 years (range: 3 to 27 years). An increase in MPD,
cyst, and/or mural nodule size occurred in 16 (44.4%) patients. 9 (25%) patients underwent
surgery after a median follow up of 9 years (range: 3 to 27 years). The pathological diagnosis
were: 2 adenomas, 1 borderline malignancy, 3 non-invasive and 3 invasive carcinomas.
Only 17.6% patients developed pancreatic cancer.All patients with carcinoma were detected
with serial EUS imaging. Four of 6 patients with malignancy but only 2 of 28 patients
without malignancy had a MPD size of > 10mm. Four of 6 patients with malignancy but
none of the patients without malignancy had mural nodules > 10mm. Dilatation of MPD
to> 10mm and/or mural nodules > 10mm could predict malignancy with accuracy of 88%
and 94%, respectively. Only one patient died of post-operative recurrence of IPMN. Cancers
of 5 other organs developed in 4 patients (11.1%), either concurrently or subsequently.
Conclusion: IPMN is a slow growing tumor, and non-operative follow up with serial imaging
is safe and feasible strategy in selected patients. Size of MPD >10mm, and mural nodules
> 10mm are predictive of malignancy, and can be used as indications for surgery.
T1405
Intraductal Biochemical and Tumor Markers Analysis Using EUS-FNA in
Predicting Malignancy in Patients with Intraductal Papillary Mucinous
Neoplasms of the Pancreas
Frédérique Maire, Hélène Voitot, Alain Aubert, Laurent Palazzo, Dermot O'toole, Anne
Couvelard, Olivier Corcos, Philippe Ponsot, Olivia Hentic, Vinciane Rebours, Anne-laure
Pelletier, Philippe Lévy, Philippe Ruszniewski, Pascal Hammel
Prediction of malignancy is primordial in the management of patients with intraductal
papillary mucinous neoplasms (IPMN). The feasibility of EUS-FNA with microbiopsy in
IPMN has been demonstrated. The performance of pancreatic juice analysis for biochemical
and tumor markers in the prediction of malignancy is unknown. Aim : Evaluate the value
of biochemical and tumor markers in intraductal fluid obtained by EUS-FNA in the prediction
of malignancy in patients with IPMN. Patients and Methods : From January 1994 and 2006,
41 patients with IPMN (22 men, median age : 64 years) underwent EUS-FNA. EUS-FNA
involved a dilated branch duct (n=39) or dilated main pancreatic duct (n=2). The following
markers were analysed : amylase, lipase, CEA, Ca 19-9, CA 72-4 and M1 mucins. The
sensitivity, specificity, and positive and negative predictive values for the diagnosis of malig-
nancy (i.e. high grade dysplasia or invasive carcinoma) were calculated following determina-
tion of a cut-off value for each marker. Results : No complications were observed following
EUS-FNA. The median values of amylase and lipase were 20,155 U/mL and 59,500 U/mL,
respectively. The median levels of CEA, Ca 19-9, CA 72-4 and mucins were 173 ng/mL,
6400 U/mL and 231 U/mL, respectively. All markers levels, with the exception of lipase, were
different in benign and malignant tumors. For the diagnosis of malignancy, the sensitivity,
specificity, and positive and negative predictive values for CEA > 200 ng/mL were 90, 71,
50 and 96%, respectively. The respective values for CA 72-4 > 40 U/mL were 87.5, 73, 47
and 96%. No discriminating value was found for Ca 19-9. Conclusion : Intraductal CEA
and CA 72-4 determinations provide excellent negative predictive values to assess malignancy
of IPMN preoperatively. Use of these markers should help in therapeutic decision-making
especially in avoiding surgery in patients with branch-duct IMPT types with low CEA and
CA 72-4.
T1406
Correlation of Fdg-PET and Mdct Features in Mucinous Lesions of Pancreas
for Lesion Characterization and Prediction of Malignancy
Dushyant V. Sahani, Nisha Sainani, Bindu Setty, Michael A. Blake, Carlos Fenandez del-
castillo
Purpose 1. To study MDCT features to characterize benign from malignant cystic lesions.
Can the FDG-PET can predict malignancy and correlate areas of increased FDG activity
with morphologic features on MDCT Materials and Methods In this ongoing study, 12
known/suspected mucinous lesions of pancreas, underwent a dedicated dual-phase 16-
MDCT scan of abdomen and whole body FDG-PET. Axial/2D/3D images were evaluated
for lesion morphology, diagnosis and characterization into benign or malignant on MDCT.
FDG uptake on PET was evaluated and SVU values were calculated. CT and PET images
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were fused, areas of increased uptake were correlated with morphological features on CT.
Results 5/12 lesions were main-duct IPMN's, 5/12 side-branch IPMN's, 2/12 unclassified
cysts, 10/12 were benign, 2/12 were malignant. The PPV of MDCT and FDG-PET for
malignancy was 50% and 66.6%, while the NPV for benignity was 100% for both. Gross
main ductal dilatation, thick-septation, mural-nodule and lymphadenopathy favored malig-
nancy on MDCT. Areas with increased FDG uptake correlated with regions of thick-septae,
mural-nodule and thick wall on MDCT. Higher values of SVU suggested higher grade of
malignancy. Conclusions MDCT is reliable for diagnosing the mucinous lesions of pancreas
and predicting malignancy. FDG-PET is complementary to CT and can increase the dia-
gnostic confidence.
T1407
A Markov Economic Model for Management of Benign-Appearing Intraductal
Papillary Mucinous Neoplasms of the Pancreas
Donald A. Garrow, Jonathan Duncan, Christopher Lawrence
BACKGROUND: Management of benign intraductal papillary mucinous neoplasm (IPMN)
of the pancreas is difficult because of the unpredictability of the lesion. Current practice
often recommends surgery at time of diagnosis. Many clinicians wonder whether expectant
management involving radiologic follow-up is comparable to up-front surgery in IPMNs up
to 2 cm in size. We sought to compare outcomes and costs associated with surgery versus
observation of benign-appearing IPMNs. METHODS: We used a Markov model to estimate
progression of disease in both surgical and observation groups. We included literature-
derived data concerning survival, transition probabilities and cost into the model. Transitions
between benign and malignant cancer states and death were modeled in 1-year transitions,
over a life-long time horizon. We incorporated a 3% annual discount rate to our cost analysis.
Sensitivity analyses were performed by adjusting each parameter in the model appropriately.
RESULTS: Survival for benign IPMNs did not differ significantly between the surgical and
observation groups. Overall costs were less expensive in the non-surgery group. These
findings were not substantially affected by reasonable adjustments of transition probabilities
or costs. CONCLUSIONS: This is the first known decision model to address management
of IPMNs. There is no observed survival benefit for patients undergoing surgery for small,
benign-appearing IPMNs. Furthermore, costs are less expensive in the observation group.
Based on this model, conservative management with observation and regular follow-up
results in equal survival and is less costly when compared to surgical intervention for benign-
appearing IPMNs.
T1408
A Retrospective Analysis of Pancreatic Cysts in Hemodialysis Patients
Takuya Ishikawa, Kinichi Takeda, Hiroshi Ukai, Masahiro Taga, Kazuo Yamawaki, Hidemi
Goto
Background: Because renal cell carcinomas frequently occur in acquired cystic kidney dis-
eases, abdominal ultrasonographies are regularly performed for hemodialysis patients in our
hospital, but pancreatic cysts are often found in these patients. Aim: to investigate the
prevalence and characters of pancreatic cysts in hemodialysis patients compared with non-
hemodialysis patients. Methods: We reviewed 83 consecutive patients ( M: F= 32: 51(1:1.5),
mean age 69.8, range 56-91 yrs, mean hemodialysis age 8.5, range 1-23 yrs, basic diseases:
chronic nephritis 44%, diabetic nephropathy 35%, others 12%, unknown 8% ) with pancre-
atic cysts out of 910 hemodialysis patients ( M: F= 568: 342(1.6:1), mean age 61, range
24-91 yrs, mean hemodialysis age 9, range 1-28 yrs, basic diseases: chronic nephritis 45%,
diabetic nephropathy 22%, others 18%, unknown 15% ) who underwent screening for
abdominal ultrasonographies between August 2003 and August 2005. Results: Both discovery
rates of pancreatic cysts and intraductal papillary mucinous neoplasm ( IPMN ) in screening
abdominal ultrasonography were higher in hemodialysis patients than in non-hemodialysis
patients, 9.12%: 0.13%( p<0.0001 ), 2.86%: 0.019%( p<0.0001). IPMN possession rate in
hemodialysis patients with pancreatic cysts were higher than that in non-hemodialysis
patients with pancreatic cysts, 31.3%: 14.6%( p<0.0001 ). 26 cases were diagnosed as IPMN,
but 4 of them which were thought to have high malignancy, based on examination such
as EUS or IDUS, underwent surgery. Pathological diagnoses were, intraductal papillary
mucinous carcinoma in 1 case and intraductal papillary mucinous adenoma in 3 cases.
Conclusion: This study showed that the prevalence of pancreatic cysts in hemodialysis
patients is higher than in non-hemodialysis patients. Moreover, it also suggests that pancreatic
cysts in hemodialysis patients are highly prone to be IPMN. Regular abdominal ultrasonogra-
phy is necessary, not only to check renal cell carcinoma, but to detect or observe pancreatic
cysts in hemodialysis patients. Especially given the malignancy potential of IPMN, we should
always bear this disease in mind when observing pancreatic cysts in hemodialysis patients.
T1409
Cripto-1 Is Involved in Early Tumorigenesis of Intraductal Papillary Mucinous
Neoplasm of the Pancreas
Sung pil Hong, Eun kyung Lee, Ji eun Lee, Tae youn Oh, Tae joo Jeon, Jeong youp Park,
Seungmin Bang, Seung woo Park, Jae bock Chung, Si young Song
Background/Aims Since intraductal papillary mucinous neoplasm (IPMN) of the pancreas,
which includes benign to malignant lesions, was first described in 1982, there have been
many efforts to validate the tumorigenesis of IPMN. Critpo-1 is known to play an important
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role in cell morphogenesis, differentiation, and proliferation, and the expression of Cripto-
1 and downstream proteins, such as Wnt and β-catenin is increased in premalignant and
malignant lesions of gastrointestinal tract. Our cDNA microarray data using Affymetrix HG
U133 in 17 normal pancreas tissues and 5 IPMN tissues indicated that Cripto-1 was also
increased 13-fold change in IPMN compared to normal pancreas. In this study, we investig-
ated the immunohistochemical expression and mRNA level of Cripto-1 in IPMN. Materials
and methods Thirty three pancreas specimens of IPMN (5 adenoma, 11 bordeline, 12
carcinoma in-situ, and 5 invasive carcinoma) from surgical resection were collected. Two
normal pancreatic tissues and 5 chronic pancreatitis tissues were collected to use as a control.
Immunostaining with anti-Cripto-1 monoclonal antibody was performed. More than 25%
of cells stained were regarded as the positive expression of Cripto-1. RT PCR of Cripto-1,
Wnt5a, and β-catenin were done with standard method in 6 IPMN specimens (1 adenoma,
1 bordeline, 3 carcinoma in-situ, and 1 invasive carcinoma) and 6 surrounding non-tumor
pancreas specimens. Result Immunohistochemical analysis showed that Cripto-1 was not
expressed at acinar and duct in normal pancreas, while was weakly expressed at cytoplasm
of metaplastic duct in chronic pancreatitis. Positive Cripto-1 staining was noted in 4 out of
5 (80%) adenoma, 7 out of 11 bordeline (63.6%), 7 out of 12 (58.3%) carcinoma in-situ,
and 2 out of 5 (40%) invasive carcinoma. The mRNA level of Cripto-1 was higher in 2 of
6 cases (1 adenoma, 1 carcinoma in-situ) compared to surrounding non-tumor pancreas
specimens. Two IPMN with elevated mRNA level showed moderate positive immunoreactivity
of Cripto-1, while the other 4 IPMN showed negative staining. The mRNA level of Wnt5a
and β-catenin were elevated in 2 of 6 cases correlating with that of Cripto-1. Conclusion
The expression of Cripto-1 and downstream proteins is elevated in IPMN, especially adenoma
and borderline tumor. Overexpression of Cripto-1 and its downstream molecules might be
associated with the early stage of tumorignesis of IPMN.
T1681
Multiple Regulatory Regions Control the Complex Expression Pattern of the
Cdx2 Homeobox Gene
Fairouz Benahmed, Frédéric Jehan, Stephen Gaunt, Elisabeth Martin, Michèle Kedinger,
Jean-noël Freund, Isabelle Duluc
Background and aims The homeobox gene Cdx2 plays a wide number of functions from
early embryonic development to adult life, linked to its complex expression profile. Extra-
embryonically, it is involved in trophectoderm determination and alantoic bud formation.
Embryonic expression starts at gastrulation to get an antero-posterior gradient involved in
axial patterning. By mid-gestation, Cdx2 becomes selectively expressed in the presumptive
gut endoderm and determines intestinal identity. In adults, it controls intestinal homeostasis
and has a tumor suppressor function in the colon. Here we analyzed the developmental
regulation of Cdx2 In Vivo. Methods We produced transgenic mice containing the reporter
gene LacZ downstream of different genomic fragments originating from the Cdx2 locus.
Enzymatic detection of b-Galactosidase was performed during embryonic development and
in adults, and compared to the immunohistological pattern of the endogenous Cdx2 protein.
Results The promoter fragment -654/+102 (with respect to the transcription start site) was
transcriptionally inactive whatever the developmental stage. It has already been reported
that the segment -900/+3912, encompassing intron 1 of the Cdx2 gene, is inactive in
extraembryonic tissues but turned on in gastrulating embryos (Gaunt et al, 2005, Int J Dev
Biol 42:901-908). Here we show that this -900/+3912 promoter was turned off at mid-
gestation. Extending the promoter to the region -5151/+3912 gave the same developmental
pattern. Like the above-tested fragments, the promoter fragment -9177/+102, overlapping
the entire intergenic region between Cdx2 and the first upstream gene was inactive in
extraembryonic tissues and it was turned on by late gastrulation in the posterior embryo.
However, while disappearing at mid-gestation in most posterior tissues, its activity was
retained in the presumptive gut endoderm, and specific expression was maintained in the
intestinal epithelium throughout adult life. In fetus and adult mice, this promoter was active
in the mid-part of the intestine including the distal ileum, cecum and proximal colon, which
corresponds to the region where endogenous Cdx2 expression is the highest. Conclusion
Multiple regulatory regions within the Cdx2 locus including elements within intron 1 and
the upstream segment between -9177/-5151, are involved in the complex stage and tissue-
specific expression of the gene. Regulatory regions required for extraembryonic expression
remain to be identified. We propose that the location of the regulatory elements is related to
the progressive recruitment of Cdx2 for multiple developmental functions during evolution.
T1682
Loss of Cathepsin L Enzymatic Activity Leads to Claudin-1 Overexpression
and Increase in Intestinal Neoplasia
Julie Drouin, Carine Lussier, Mathieu Darsigny, Sébastien Mongrain, Geneviève Doyon,
Francois Boudreau, Nathalie Perreault
BACKGROUND: Cathepsin L (CtsL) belongs to the cysteine protease class of the papain
superfamily and is involved in intracellular and extracellular protein degradation. CtsL
actively plays a role in tumorigenesis in various tissues. Claudins are components of tight
junctions important in intercellular barriers and cell polarity. It has been recently demon-
strated that misexpression of claudin proteins could lead to gastro-intestinal cancer. The
tumor suppressor gene APC also plays a critical role in intestinal cancer. The APC gene is
mutated in 85% of sporadic and inherited intestinal tumors. The disease phenotype is highly
variable even in patients with the same mutation in APC, suggesting the existence of modifier
loci. APCMin is an autosomal dominant mutation which predisposes mice to develop multiple
adenomas throughout the intestine. These mice are used as a model for intestinal carcinogen-
esis and can be employed to assess the effect of potential modifier genes. AIM: To study
the role of CtsL enzymatic activity in the maintenance of gut homeostasis. METHODS AND
RESULTS: We used Furless mice carrying a point mutation in the CtsL gene obliterating
CtsL enzymatic activity in order to asses its role in gastro-intestinal homeostasis. Manipulation
of the furless intestine revealed an extreme fragility of the intestinal mucosa. This observation
suggested a role for CtsL activity in the maintenance of intestinal epithelial junctional
integrity. Western blot and quantitative PCR analysis revealed an over-expression of claudin-
1 and claudin 2 in mice with defective CtsL enzymatic activity. Following this observation,
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we bred the furless mice with APCMin mice in order to assess the potential role of CtsL in
intestinal neoplasia. Three groups of mice were analyzed; APCMin, furless, and furles-
s;APCMin. Mice were sacrificed at 90-days and assessed for the formation of adenomas. The
gastro-intestina tract was opened longitudinally and overlayed with 1% methylene blue.
Polyps were then counted. Furless;APCMin mice revealed a significant increase (2.2 fold)
in the number of intestinal polyps when compared with the control APCMin mice. However,
no modification in tumorigenesis staging was observed in the furless;APCMin mice when
compared to the APCMin mice. No polyps were found in the furless animals even at one
year of age. CONCLUSION: The irregularity in the tight junction protein complex in furless
mice combined with the increase in intestinal neoplasia in furless;APCMin mice strongly
suggest an important role for Cathepsin L enzymatic activity in the maintenance of intestinal
homeostasis and suggest that this pathway could act as a modifier of min.
T1683
Effect of Lubiprostone, a Novel Type-2 Chloride Channel (Clc-2) Activator, in
Pregnant Rhesus Monkeys
Kory Engelke, Steve Harris, Birgit Roerig, Ryuji Ueno
Lubiprostone is a novel activator of ClC-2 used in the treatment of adult chronic idiopathic
constipation. To evaluate lubiprostone's effects on pregnancy in non-human primates, the
drug was administered by oral gavage to pregnant rhesus monkeys assigned to 1 of 2 dose
levels or placebo during the late gestation period. Monkeys were dosed daily from gestational
days (GD) 110-130, to total 21 days. Previous monkey PK analysis indicated lubiprostone
exposure at a single 5 mcg/kg dose. In the current study, pregnant rhesus monkeys were
randomized to receive 0 mcg/kg/day (vehicle; n=10), 10 mcg/kg/day lubiprostone (n=10),
or 30 mcg/kg/day lubiprostone (n=11). The selected doses were approximately 4.2 and 12.5
times greater, respectively, than the recommended daily clinical dose of lubiprostone (based
upon equivalent surface area dose conversion; doses were approximately 12.5 and 37.5
times greater, respectively, based upon equivalent mg/kg conversion). Maternal clinical
observations occurred regularly on dosing and non-dosing days. Fetal monitoring via ultra-
sound, maternal body weight, maternal food consumption, and maternal serum progesterone
sampling occurred at various timepoints throughout the study. Pregnancy was terminated
and fetuses were harvested by scheduled cesarean section on GD 150 or 151. Fetuses
obtained via scheduled cesarean section were euthanized and examined for body weight,
placental weight, gender, and external and placental abnormalities. Fetal carcasses and viscera
were retained. No maternal monkeys died, and no abnormalities were seen in clinical signs,
food consumption, or serum progesterone concentrations in any group. There was a slight
reduction in body weight gain observed in the 30 mcg/kg/day lubiprostone group; however,
this did not appear to be clinically relevant. Early delivery on GD 149 was observed in 1
monkey each in the 10 and 30 mcg/kg/day groups; both were delivered naturally and
survived. Spontaneous abortion occurred on GD 141 (11 days after the last dose was
administered) in 1 monkey in the 10 mcg/kg/day group. This event was assessed as unrelated
to lubiprostone because the incidence (10.0%) was within the historical control data of the
laboratory (12.9%) and no abortions occurred in the 30 mcg/kg/day group. No test article-
related changes were noted in fetal external examination, fetal body weight, placental exam-
ination, or placental weight in either lubiprostone group. Under the conditions of this study,
it was concluded that lubiprostone does not affect pregnant rhesus monkeys when dosed
from GD 110-130 at doses 4.2-12.5 times higher than the recommended daily clinical dose.
T1684
Commensal Bacteria Promote Recovery from DSS Colitis By Inducing Mip2-
Dependent Neutrophil Recruitment
Di Meng, Weishu Zhu, Kewei Zhang, Rex Pillai, Amy Baker, Sanjeeve Martyn, W. allan
Walker, N. nanda Nanthakumar
Inflammatory bowel disease (IBD) results from an inappropriate interaction between the
intestinal mucosa and its commensal microbiota. The commensal flora has been shown to
activate MyD88-dependent signals that play an important role in mucosal repair and restitu-
tion following intestinal injury. We found high mortality following DSS-induced colitis in
mice depleted of commensal bacteria by two weeks of broad-spectrum antibiotic treatment.
Conventionally raised wild-type mice, but not Myd88 -/- mice, recover completely from
DSS-induced intestinal colitis. However, restoration of the commensal bacteria, mono-associ-
ation with Bacteroides fragilis, or stimulation with LPS (a TLR4 ligand) in mice depleted
of their commensal bacteria prevented the mortality caused by DSS-induced colitis. We
investigated the mechanism for this protection. DSS treatment in mice following depletion
of commensal bacteria resulted in reduced MIP2 expression in the colon with significantly
reduced neutrophil infiltration compared to conventionally raised mice treated with DSS.
A potential role of MIP2 in neutrophil recruitment was discovered when treatment with
anti-MIP2 antibody in conventional mice fails to recover following DSS-induced colitis
with significantly reduced neutrophils in the inflamed colon. Furthermore, administering
exogenous MIP2 eliminated DSS-induced mortality in bacteria-depleted mice with increased
neutrophils infiltration in the inflamed mucosa. These results strongly suggest that recovery
from DSS-induced colitis is facilitated by MIP2-asociated signals induced by commensal
bacteria that lead to neutrophil recruitment to the injured gut. Thus, symbiotic microbiota
regulate intestinal innate immune responses that protect against mucosal injury, and their
absence can result in mortality following colitis induced by DSS. This work was supported
by NIH grants HD12437, HD31852, HD13021, DK33506, DK34987, DK40561, DK53347,
RR018603. DM was in part supported by a Fogarty Foundation/NICHD training grant
D43 TW1265.
T1685
Adaptive Bile Acid Homeostatic Responses in the Colon and Liver Post-
Ileocecal Resection in a Mouse Model
Christopher M. Dekaney, Beth A. Carter, Olga A. Taylor, Susan J. Henning, Michael A.
Helmrath
Clinically, colonic adaptation occurs in humans following surgical resection of the entire
ileum and proximal colon. The ability of the colon to aide in bile acid reclamation following
the loss of the ileum is currently not understood. We recently developed a murine model
of ileocecal resection (ICR) to investigate colonic adaptation. We hypothesized that 1) in
response to loss of the ileum the remnant colon would adapt by upregulating the molecular
machinery needed for bile acid reclamation and 2) loss of the ileum would cause the liver
to transiently upregulate the molecular machinery necessary to maintain the bile acid pool.
Methods: ICR or sham surgery was performed on 8-12 week old C57BL6 mice (n = 4-6
mice/group). Ascending colon and liver were harvested on postoperative day 3 and 7 for
histology and isolation of total RNA. Immunofluorescence was used to evaluate Asbt (apical
bile salt transporter) protein expression and localization patterns in the remnant colon. qRT-
PCR was performed to evaluate changes in bile acid homeostatic gene expression of Ostβ
(organic solute transporter), IBABP (intestinal bile acid binding protein), and FXR (farnesoid
X receptor) in the colon, and Ntcp (Na+ taurocholate cotransporting polypeptide), Bsep
(bile salt export pump), and Cyp7a1 in the liver. Results: Immunofluorescent staining
demonstrated that Asbt was absent from colonocytes from unoperated animals. Robust
expression of Asbt on the apical membrane of colonocytes occurred following ICR. Significant
increases in Ostβ (2-fold) and IBABP (5-10-fold) mRNA expression occurred in the colon
of ICR animals compared to sham-operated animals at both 3d and 7 d post-operation.
Colonic FXR mRNA expression did not differ between sham and ICR animals at either time-
point. At both 3 and 7 d post-operation, there was no statistical significance in hepatic
mRNA expression of Ntcp, Bsep, and Cyp7a1 between ICR and sham-operated mice. Conclu-
sion: Our data indicate that within 3 d post-ileal resection, reclamation of bile acids from
the intestinal lumen occurs in the remnant colon by increasing the mRNA and protein
expression of critical components necessary for luminal bile acid uptake and transport. At
this time, there appears to be no increased capacity for hepatic bile acid synthesis and
export, suggesting that the rapid colonic adaptation is sufficient to maintain enterohepatic
bile acid circulation. This work was supported by NIH grants K08 DK 067395 and CHRC
K12 HD41648 and AGA/Roche Liver Research Scholar Award.
T1686
GLP-2 Administration Results in Increased Proliferation But Paradoxically An
Adverse Outcome in a Juvenile Piglet Model of short Bowel Syndrome (SBS)
Prue M. Pereira-fantini, Sarah L. Vaughan, Eva Nagy, Russell Taylor, Jens J. Holst, Peter J.
Fuller, Julie E. Bines
Introduction:In adult rodent studies, epithelial cell proliferation is considered an important
hallmark of successful adaptation, and treatment with recombinant GLP-2 (rGLP-2) has
been shown to increase epithelial proliferation and enhance adaptation. GLP-2 has not been
tested in a juvenile, preclinical SBS model. This study utilises a juvenile piglet model of SBS
to examine the effect of rGLP-2 administration on proliferation and functional/morphological
adaptation following massive small bowel resection. Methods: 4-week-old piglets underwent
either a 75% massive small bowel resection (MSBR) or a sham operation. Post-op, piglets
received either a polymeric infant formula diet (PIF;n=3 sham, n=6 MSBR) or PIF and
subcutaneous rGLP-2 (1600μg/day for 7 days, 800μg/day thereafter;n=6/group). Piglets were
weighed fortnightly, and serum and stool samples collected. Piglets were sacrificed 6-8
weeks post-op and ileum removed for disaccharide quantitation and histological assessment.
Histology included Ki-67 immunohistochemistry to quantitate proliferative cells, apoptotic
cell quantitation, and standard villus/crypt measurements (10 measurements/animal). Results:
Conclusions: This is the first study to examine the effect of rGLP-2 administration in a
juvenile, preclinical SBS model. rGLP-2 administration resulted in increased numbers of
proliferative and apoptotic cells. Contrary to rodent studies, administration of rGLP-2 also
resulted in adverse outcomes including weight loss, and decreased serum calcium, albumin,
maltase, and villus height. We suggest that GLP-2 induced increases in proliferation and
apoptosis resulted in an imbalance in the number of functional enterocytes, leading to an
exacerbation of MSBR-related malabsorption. This information will have important implica-
tions for future paediatric clinical trials.
Significant results
p < 0 . 0 5 f o r a P I F ( s h a m ) v s G L P - 2 ( s h a m ) , b P I F ( M S B R ) v s G L P -
2(MSBR),cPIF(sham)vsPIF(MSBR),dGLP-2(sham)vsGLP-2(MSBR).Stat analysis=ANOVA
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T1687
Bacterial Symbionts Induce Their Fucosylated Niche in Mammalian Colon Via
a TLR-4 Sentinel Activating ERK and Jnk Signaling
Di Meng, David S. Newburg, Cheryl A. Young, Amy Baker, Susan L. Tonkonogy, R.
balfour Sartor, W. allan Walker, N. nanda Nanthakumar
Mammalian gut supports a complex microbial ecosystem; initial colonization by adult micro-
biota coincides with an abrupt increase in fucosylated glycans on the epithelium. However,
the receptor and the epithelial signaling that mediate this crosstalk between the microbiota
and the epithelium were unknown. To identify a receptor and its signaling pathway that
responds to microbiota by inducing α 1,2-fucosyltransferase (FT) enzyme activity and α
1,2-fucosylated glycan expression in the colonic epithelium. Bacteria-free (BF) mice were
generated by treatment with a cocktail of antibiotics and germ-free (GF) mice were used.
Gut microbiota were allowed to recolonize both GF and BF mice for two weeks. After
recolonization the ex-germ-free mice and bacteria-repleted mice were sacrificed along with
GF and BF mice and age-matched conventional mice. The colonic expression of FT mRNA,
FT activity, and fucosylated glycan expression were assayed. Activation of signaling pathways
in colonocytes was determined by western blot analysis using phosphospecific antibodies.
Mice were orally treated with a specific inhibitor of ERK (PD98059) and/or JNK (SP600125),
to confirm the role of the ERK and JNK pathway and mutant TLR4-/-, TLR2-/-, or Myd88-/-
mice were used to identify the role of TLR pathway in bacterial-epithelial crosstalk. Uncolon-
ized colon of GF and BF mice expresses little fucosylated glycan, but contains a fucosylated
form of TLR-4 not present in conventional mouse colon. In conventionally reared TLR4 or
Myd88 deficient mutant mice, the level of FT activity and glycan expression in mature colon
was low, similar to that seen in immature suckling mice or in uncolonized GF and BF mice.
TLR4 ligand, lipolysaccharide, is able to induce fucosylatation in BF mice, suggesting that
TLR4 is the receptor that senses and mediates initial bacterial colonization. Luminal bacteria
in wild type mice activate TLR-4-associated ERK and JNK pathways within the colonocytes,
activating transcription factors ATF2 and c-jun, respectively; inducing specific transcription
of fut2-mRNA, resulting induction of FT activity, and expression of the highly fucosylated
glycans of the intestinal mucosa characteristic of colonized adult mammalian gut. Inhibiting
ERK and JNK activation prevent this cascade. Pioneer mutualist bacteria activate fucosylated
TLR4 in the lumen, leading to expression of fucosylated glycans on the cell surface, where
fucose-binding bacteria may bind and colonize that promotes succession toward a complex
adult microbial ecosystem. This work was supported by NIH grants HD12437, HD31852,
HD13021, DK33506, DK34987, DK40561, DK53347, RR018603 and D43 TW1265.
T1688
Intestinal Adaptation After Small Bowel Resection in Mice
Emir Q. Haxhija, Hua Yang, Ariel U. Spencer, Xiaoyi Sun, Hiroyuki Koga, Daniel H.
Teitelbaum
Introduction: Intestinal adaptation after massive small bowel resection (SBR) is driven by
increased epithelial cell (EC) proliferation and apoptosis; however, the mechanisms which
guide these changes are not completely known. To address this, we studied the post-
resectional intestinal adaptation in mice. Methods: Two groups of mice (C57BL/6J) were
studied (n=10/group): 1) 60% mid-gut SBR (MSBR), 2) transection and re-anastomosis at
the mid-gut point (SHAM). Mice were sacrificed after 7 days, and small bowel EC and
intraepithelial lymphocytes (IEL) separately isolated. Morphometric adaptation was assessed
in jejunum at 3 cm distal to the ligament of Treitz by quantification of villus height, crypt
depth, goblet cell numbers, EC proliferation (%BrdU incorporation) and EC apoptosis
(TUNEL). Gene expression of a series of EC- and IEL- derived factors known to modulate
EC proliferation (EGFR, KGF, KGFR1, IL-7, IL-7R) and EC apoptosis (bcl-2, bax, bid, bak,
bad, bcl-xL, bcl-w, TNF-α, TNFR1, Fas, FasL, INF-γ) were analyzed by RT-PCR. Bcl-2, bax,
TNF-α, Fas, IFN-γ and IL-7 protein expression were determined by western blot, Elisa,
and/or immunofluorescence staining. Data were analyzed using t-test. Results: Villus height
(573±29 v. 348±21µm) and crypt depth (165±10 v. 95±8µm) increased significantly after
MSBR as compared to SHAM group (P<0.001). This was associated with post-resectional
increases in EC proliferation and EC apoptosis rates (Table), as well as goblet cell numbers
(20.9±2.4 v. 7.4±1.4; P<0.001). At 7-days after MSBR, significant increases in mRNA expres-
sion of IEL-derived KGF, and EC-derived IL-7 were found (Table), whereas expression of
EGFR, KGFR1, and IL-7R were unchanged as compared to SHAM group. EC mRNA expres-
sion of a pro-survival factor bcl-2, as well as IEL mRNA expression of FasL and IFN-γ increased
significantly after MSBR (Table). Western blot analysis confirmed the post-resectional increase
in protein expression of bcl-2 and IFN-γ (P<0.01), and showed in addition a significant
post-resectional increase in EC-derived bax and Fas (P<0.05). Post-resectional increases in
expression of bcl-2, bax, and IL-7 were further confirmed by immunofluorescence studies.
Conclusion: Our data indicate that the strong post-resectional up-regulation of EC-derived
bcl-2 expression might be one of the crucial protective mechanisms of EC against the
increased expression of various pro-apoptotic factors during the process of early post-
resectional intestinal adaptation.
* P<0.05; ** P<0.01; *** P<0.001;
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T1689
A Role for Cdx-1 and 2 in Maintenance of the Morphology of Adult Small and
Large Bowel
Jamie Murphy, Sahira Khalaf, Rebecca Hands, Jun Tian, Christopher L. Chan, Steven A.
Bustin, Norman S. Williams
INTRODUCTION: Expression gradients of CDX-1 and 2 in the embryonic gut, with levels
decreasing from putative anus to mouth, initiate and maintain endoderm differentiation.
Expression of both genes has been demonstrated in adult human gut and colonic adenocarcin-
oma. However, a role in health is unknown, and while expression is not altered in colorectal
cancer, they are reported to have both tumour suppressor function via the protective influence
of Vitamin D, in addition to oncogenic activity in cell lines. AIMS & METHODS: This study
investigated CDX-1/2 expression in adult human gut and colorectal cancer to: 1.) determine
if CDX-1/2 expression in the adult human gut matches embryonic gradients, suggesting
continued expression is required to maintain epithelial differentiation throughout life. 2.)
investigate regulation of CDX-1/2 genes in both normal colon and adenocarcinoma, by the
recently discovered CDX promoter Vit D response element. Normal tissue: Paired ileum
and ascending colon from 10 patients was harvested with 10 unmatched rectal tissue samples.
mRNA was extracted by standard techniques, quality assessed with 3':5' and inhibition
assays, prior to quantification by real-time reverse transcription polymerase chain reaction
(RT-qPCR). RNA translation was confirmed by immunohistochemistry. Adenocarcinoma:
Colorectal adenocarcinoma and adjacent normal tissue samples from 10 patients were har-
vested and cultured for 24 hours, with either Vit D or control medium. mRNA quantification
was performed as above. RESULTS: Normal tissue: CDX-1 expression decreased from rectum
> ascending colon > small bowel (p = 0.04). CDX-2 was expressed in a unimodal pattern
with rectum < ascending colon > small bowel (p= 0.02). Adenocarcinoma: Vit D culture
decreased CDX-2 mRNA expression in 7/10 tumours (p<0.02), and CDX-1 mRNA in 6/10
tumours (p=NS) compared to medium only. Tumours which did not show a decrease in
CDX-1/2 mRNA were poorly differentiated. Normal colon showed no change in CDX-1/2
when cultured with Vit D or control medium. CONCLUSION: In health, adult CDX-1/2
expression matches the embryo, suggesting this mechanism operates through life to maintain
tissue differentiation. In mild-moderately differentiated adenocarcinoma, Vit D decreases
CDX-1/2, suggesting altered regulation in these cancers, with non responding/poorly differen-
tiated tumours possibly representing complete deregulation. Thus, the multiple actions of
CDX-1/2 in maintaining gut differentiation and suppressing tumours are likely to reflect
one role, with ‘tumour suppression' being essential to both the development and maintenance
of mammalian gut structure.
T1690
Colostrum Supplementation Restores IGF-1 Levels and Alters Muscle
Morphology Following Massive Small Bowel Resection
Prue M. Pereira-fantini, Sarah L. Vaughan, Julie E. Bines
Introduction: Colostrum protein concentrate (CPC) contains a high level of IGF-1. It has
been suggested that IGF-1 and the IGF binding proteins (IGFBPs) play an important role
during the post-resection adaptation response. As smooth muscle is an important site for
IGF-1 action in the intestine, the current study aims to (i)investigate the effect of bovine
colostrum protein concentrate (CPC) supplementation on circulating levels and tissue expres-
sion of IGF-1, IGF-1R and IGFBPs following MSBR, and (ii) to characterise the effect of
CPC on the muscular adaptation response following MSBR. Methods:4-week old piglets
underwent either a 75% massive small bowel resection(MSBR) or a sham operation. Post-
operatively piglets received either a polymeric infant formula diet (PIF;n=3 sham,n=6 MSBR)
or PIF supplemented with bovine colostrum (PIF+CPC;n=6 sham, n=9 MSBR). At 8 weeks
post-op, piglets were sacrificed and the ileum was removed for molecular and histological
analysis. Circulating IGF-1, and IGFBP-1-3 ELISAs were performed using serum obtained
at 8 weeks post-op. Image analysis was used to measure circular/longitudinal muscle area,
and circular muscle cell size and number. mRNA levels were measured using semi-quantitative
RT-PCR and are expressed relative to the housekeeper L32. Results:summarised in table.
Conclusion: Strategies aimed at increasing muscular adaptation may decrease gastrointestinal
transit and allow greater mucosal contact time for nutrient and fluid absorption. In the
current study we have shown that colostrum supplementation following resection results
in increased levels of circulating IGF-1, IGFBP-2 and IGFBP-3 together with muscular
hypertrophy. Our results suggest that IGF-1 and its mediators play an important role in the
muscular adaptation response and warrant further exploration as a treatment option for SBS.
Significant results
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p<0.05; aPIF(sham)vs CPC(sham);bPIF(MSBR)vs CPC(MSBR) ; cP IF (sham)vs
PIF(MSBR);dCPC(sham)vs CPC(MSBR)
T1691
Time Lapse Imaging of Early Enteric Neurons
Marlene Hao, Richard Anderson, Heather Young
Enteric neurons and glia arise from precursors that originate in the neural crest and then
migrate into and along the developing gut. Previous studies have shown that as the precursors
migrate along the gut, a sub-population (around 10-20%) start to express neuron-specific
markers. These early differentiating neurons also transiently express the catecholamine
synthetic enzyme, tyrosine hydroxylase (TH). Recently, time-lapse imaging studies have
revealed many aspects of the migratory behaviour of the entire population of enteric crest-
derived cells. However, the behavior of cells in the gut that express neuron-specific markers
has not previously been examined. Of particular interest is whether early differentiating
neurons are capable of migrating, or whether enteric crest-derived cells cease migrating as
soon as they commence neuronal differentiation. To examine the behavior of early differentiat-
ing neurons, we used embryonic TH-GFP mice. Control experiments showed that all GFP+
cells in the gut of E10.5 and E11.5 TH-GFP+ mice also expressed the pan-neuronal markers,
TuJ-1 and neurofilament-M. Explants of gut were set up for time lapse imaging using
previously described methods, and TH-GFP+ cells were imaged for a minimum of 3 h. Time
lapse imaging showed that GFP+ cells were very variable in their behavior. Around 50% of
the GFP+ neurons were defined as stationary because their cell bodies did not change
location during the imaging period. However, the stationary GFP+ cells showed dynamic
behavior in that they extended and retracted processes and their cell bodies often underwent
significant changes in shape. Around 50% of the GFP+ neurons did migrate, at a mean
speed of about 10 μm/h. These cells usually had a prominent leading process, with the cell
body at the rear. Preparations that were fixed at the end of the imaging period revealed that
the GFP+ cells migrated along TuJ-1+ fiber tracts. These data show that, like some neuron
populations in the developing CNS, some enteric neurons in the embryonic gut are capable
of migration.
T1692
PRAJA, a TGF-β/BMP-Regulated E3 Ubiquitin-Ligase Represents a
Developmental Switch Between Liver and Cartilage Formation and Is
Potentially Important for Liver Progenitor Cell Maintenance
Young Kim, Varalakshmi Katuri, Tapas Saha, Hye jung Baek, Sangsoo Kim, Yi Tang,
Wilma Jogunoori, Eugene A. Volpe, Anton Sidawy, Bibhutibhushan Mishra, Lopa Mishra
PRAJA, a RING finger (RING-H2) E3 ligase expressed in liver progenitor cells ubiquitinates
TGF-β signaling molecules, Smad3 and ELF (Oncogene. 2006;25(5):693-705). In previous
studies, we have demonstrated that the β-spectrin ELF, isolated from gut endodermal
progenitor cells, is a crucial adaptor protein associating with Smad3 and Smad4 and leading
transport of the complex to nucleus (Science. 2003 Jan; 299 (5606): 574-7; Cancer Res.
2005; 65:4228-37) thereby playing critical TGF-β functions such as tumor suppression, cell
growth, aging, and development. Further genetic analysis has revealed that over 40% of
elf+/- mice spontaneously develop hepatocellular carcinoma (HCC) at 12-15 months, with
increased expression of PRAJA. In addition, PRAJA expression increases dramatically in
human hepatocellular cancer (HCC), suggesting a key role for PRAJA in liver progenitor
cell survival and hepatocellular cancer formation. Aims: In this study, we investigated: 1.
The role of PRAJA in liver formation by loss of function studies. 2. The molecular interaction
between PRAJA and Smad3 or ELF to elucidate the mechanism of PRAJA-mediated TGF-β
signaling and modulation of HCC. Methods and Results: Loss of function studies show that
PRAJA represents a switch between liver and cartilage formation. PRAJA inhibition in normal
embryonic liver explants showed early loss of hepatocytes, well-defined cartilage formation.
Confocal microscopy, immunoprecipitation analyses, and luciferase reporter assays with the
full-length or deletion mutants of PRAJA revealed the TGF-β dependent molecular interaction
between the N-terminal domain of PRAJA and the MH2 domain of Smad3, as well as the
17-aa repeat region of ELF containing the ankyrin binding domain and NLS; Ubiquitination
of ELF and Smad3 occurs via the C-terminal RING-H2 domain of PRAJA in a TGF β-
dependent manner. In conclusion, this study suggests that PRAJA is a key regulator of liver
formation, and its inhibition could represent a switch in cartilage formation. In addition,
PRAJA-mediated ubiquitination of ELF and Smad3 potentially leads to hepatocellular cancer,
and could represent new therapeutics targeted at this E3 ligase in HCC.
T1693
Intestine-Specific PDX-1 Inactivation in Mice Alters Duodenal Morphology and
Gene Expression
Chin Chen, Corrine Davis, Rixun Fang, Eric Sibley
Background: The transcription factor pancreatic duodenal homeobox-1 (PDX-1) is essential
for pancreatic development. PDX-1 null mutant mice are apancreatic and survive only a
few days after birth. The role of PDX-1 in intestinal pattern formation and gene expression,
therefore, has yet to be defined in viable mice with normal pancreatic development. Objective:
We aimed to characterize In Vivo the effects of intestine-specific PDX-1 inactivation on
morphology and gene expression in the small intestine. Methods: Conditional knockout
(KO) mice with PDX-1 inactivation restricted to the intestine were generated by crossing a
transgenic mouse strain expressing Cre recombinase driven by a 12.4 kb promoter fragment
of the mouse villin 1 gene with a mutant mouse strain homozygous for loxP site-flanked
pdx-1. Histological examination was performed on 35 organs from each of the conditional
KO and corresponding littermate control mice (3-13 months of age). Periodic acid-Schiff
(PAS) and immunohistochemical staining were performed to further assess duodenal morpho-
logy and the expression of proteins of interest. To investigate the impact of PDX-1 inactivation
on duodenal gene expression, real-time RT-PCR and microarray analysis were performed
with total RNA isolated from the most proximal segment of the small intestine from control
and conditional KO mice. Results: The conditional PDX-1 KO mice survive into adulthood,
are fertile and have no gross anatomical abnormalities. On histological examination, condi-
tional inactivation of PDX-1 in the small intestine results in prominent cystic structures
among Brunner's glands with attenuated PAS staining. The presence of PDX-1 positive islet
cells in the pancreas and the absence of PDX-1 staining in the epithelial cells of the duodenum
verified intestine-specific inactivation of PDX-1 and normal pancreas development in the
conditional KO mice. Real-time RT-PCR further confirmed that PDX-1 mRNA is reduced
by an average of 22-fold in the proximal duodenum of the conditional KO mice compared
to control littermates. mRNA abundance for the PDX-1-activated adenosine deaminase gene
is reduced to 57% in the proximal duodenum of the KO mice relative to control littermates.
Interestingly, glutathione peroxidase 2 (GPX2) mRNA is increased by 3-fold in the proximal
duodenum of the KO mice, suggesting that GPX2 is a potential novel intestinal target for
PDX-1 repression. Conclusions: PDX-1 is necessary for appropriate structure formation and
gene expression in the duodenum. The conditional PDX-1 KO mouse represents a useful
model for investigating In Vivo the role of PDX-1 in duodenal development and patterning
of gene expression.
T1694
Diurnal Expression of Circadian Clock Genes in Jejunum
Anita Balakrishnan, Adam Stearns, David Rhoads, Stanley W. Ashley, Ali Tavakkolizadeh
Introduction: The mammalian circadian clock consists of proteins expressed with a 24-
hour period via positive and negative feedback. Peripheral circadian clocks are found in
many tissues, often with a characteristic phase delayed from that in the SCN. To define the
peripheral clock in jejunal mucosa, we measured temporal expression of Clock, Bmal1, Per1,
Per2, Cry1 and Cry2 mRNAs. Methods: Rats acclimatized to a 12 hour photoperiod were
killed at ZT3, ZT9, ZT15 and ZT21 (Lights-on is ZT0; n=6 per time) to collect jejunal
mucosal scrapings. Clock mRNA levels were measured relative to Gapdh with quantitative
PCR and analyzed by ANOVA. Results: Significant rhythmicity was observed for Bmal1,
Per1 and Per2 mRNAs (Fig 1). Bmal1 mRNA peaked at ZT21 (p<0.05 vs. other times) and
Per1 and Per2 mRNAs were significantly higher at ZT9 and ZT15 (p<0.05 vs. ZT3 and
ZT21). Temporal changes were not detected for Clock, Cry1 or Cry2 mRNAs. Discussion:
Components of the circadian clock are expressed with diurnal rhythmicity in the proximal
bowel. The antiphasic behavior of Bmal1 vs. Per1 and Per2 is consistent with the negative
feedback found in other tissues. Phases of these genes are similar to that found in the liver,
another tissue strongly influenced by nutrient intake.
Fig 1. Diurnal variation of Bmal1 and Per1 in jejunum
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T1695
Gastrointestinal Pathology in a Mouse Model of Mucopolysaccharidosis Type
Iiia (MPS Iiia)
Ainslie L. Roberts, Simon Moretta, Janice M. Fletcher, Gordon S. Howarth, Kerry A.
Lymn, Mark S. Geier, Sharon Byers
Background: Mucopolysaccharidosis (MPS) is an inherited metabolic disorder with MPS IIIA
being the most common form affecting children. A deficiency in the enzyme sulphamidase
results in the storage of heparan sulphate in cells and widespread clinical symptoms such
as mental retardation, weight gain and diarrhea. A mouse model of MPS IIIA has been
previously shown to have elevated weight gain compared to their normal littermates and
affected mice attain a higher mature bodyweight (1). Heparan sulphate proteoglycans (HSPGs)
are implicated in the control of feeding behaviour and are localised to the basolateral surfaces
of normal tissues in the large and small intestine and stomach, where they are thought to
play a role in cell adhesion. The correlation between heparan sulphate accumulation and
weight gain in MPS IIIA has not been investigated. In this study we examined the GI tract
to determine if a primary abnormality in this system is a contributor to the weight gain
observed in MPS IIIA. Methods: Normal (n=6) and MPS IIIA (n=8) mice were sacrificed at
9.5 months of age. The weights and lengths of all gastrointestinal organs were recorded and
tissues collected for assessment of intestinal morphometry including villus height and width,
crypt depth, total wall, submucosal and muscularis thickness. Data is expressed as the
percentage increase in MPS IIIA compared to normal and statistical comparisons were made
by one-way ANOVA. Results: Absolute duodenum and colon weights were increased by
63% and 84% respectively in MPS IIIA compared to normal mice (p<0.05), with duodenum
weight remaining 72% higher in MPS IIIA when corrected for increased bodyweight (p<0.05).
Colon length was increased by 80% and duodenum weight/length was increased by 80%
respectively in MPS IIIA mice compared to normal mice (p<0.05). Stomach, caecum and
small intestine parameters did not change. Electron microscopic analysis of the small intestine
showed extensive storage in the lamina propria in the villi of MPS IIIA sections, which was
not evident in normal samples. The submucosa appeared to be thickened due to lysosomal
storage in the lamina propria. This was confirmed by gastrointestinal morphometry which
showed a 70% thicker ileum submucosa and 63% thicker colon submucosa (p<0.05) in
MPS IIIA compared to normal mouse sections. All other parameters remained unchanged.
Conclusions: The duodenum has a significant role in nutrient absorption and studies are
underway to characterise the morphological changes in this area of the GI tract and elucidate
the role of HSPGs and their turnover in gastrointestinal physiology and function. 1. Roberts
ALK et al. (2006) Ped. Res. 60(3):309-314
T1696
Ontogeny of the Proglucagon Derived Peptide Axis in Human Neonates
David L. Sigalet, Harish Amin, James Wright, Jens J. Holst, Laurie Wallace, Bolette
Hartman
Background and Aims: The regulation of intestinal growth and development is incompletely
understood in human neonates. The “hindgut” hormones Glucagon-like peptides 1 and 2
(GLP-1 and 2), have been shown to play important roles in the regulation of the growth
and function of islet β-cells and gut, respectively. We investigated the production of GLP-
1 and 2 in premature human infants, and examined fetal, neonatal, and adult autopsy
pancreas and colon specimens for cells producing GLP-1 and 2. Methods: With institutional
ethical approval and informed consent, premature infants admitted to a tertiary neonatal
intensive care unit at gestational ages of 28-32 weeks were monitored with weekly determina-
tions of postprandial GLP-1 and 2 levels. Comparisons were done to normal infants and
adults. Hormone levels were measured using specific RIA for GLP-1 (1-36)amide and GLP-
2 (1-33), modified for small sample volumes; accurate monitoring of enteral intake was
done at all sampling time-points. Pancreas and intestinal sections from 20 fetal (gestational
ages 16-40 wks) and neonatal autopsies were stained by immunoperoxidase for GLP-1 (7-
37) and GLP-2 (1-33), and pancreas sections stained for insulin, glucagon, and somatostatin,
and then the relative numbers of GLP+ cells were compared with normal control tissues
from adults. Results: 41 infants, of average gestational age 29.6±1.9 weeks were studied;
fasting levels of both GLP-1 and 2 were elevated (Neonatal GLP-1: 14.0±1.6 vs 7.0±1 pM/
L in adults, neonatal GLP-2: 60.6±10.1 vs 17.5±1 pM/L in adults). Post prandial levels were
even higher: Neonatal GLP-1: 67.4±7.4 vs 41.0±5.0 in adults, neonatal GLP-2: 191 ± 22
vs 72.3 ± 3.2 for normal infants and 49.5±3.7 for adults (all values as mean ± SEM in pM/
L, all comparisons p<0.05 by ANOVA or student's t-test). There was no correlation between
gestational age and GLP-2 output, however, both GLP-1 and 2 levels were highly correlated
with the caloric value of feeds. In the staining studies, numerous GLP+ α cells were identified
in fetal pancreatic islets but not adult control pancreatic islets. Increased numbers of L cells
were not seen in the intestines of fetuses or infants. Conclusions: The human fetal and
neonatal pancreas expresses a unique population of GLP-expressing α cells which likely
contributes to normal β cell proliferation and elevated fasting GLP levels; feeding of premature
neonates results in exaggerated production GLP-1 and 2, likely from this pancreatic source.
This may significantly affect development, and nutrient handling in developing premature
infants.
T1697
Loss of Bowel Motility Following Massive Small Bowel Resection in Piglets
Bridget R. Southwell, Katherine Neal, Joel C. Bornstein, Julie Bines
Vomiting and bacterial overgrowth are associated with short bowel syndrome but little is
known about how bowel motility changes following massive small bowel resection. In this
study we examined motility in segments of ileum In Vitro in unoperated animals and following
MSBR using a new method to study propagating contractions and the role of nerves and
pacemaker cells (interstitial cells of Cajal, ICC). Methods: 2/3 of the ileum was removed
from 2 week old pigs (n=6). Animals were euthenased 6 weeks post op. 10 cm segments
of ileum proximal to the anastomosis were removed and placed in organ baths containing
physiological saline. Saline was circulated separately through the lumen, blood vessels and
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outside of bowel. Ileum from 6 unoperated animals was also studied. A camera was mounted
above the bowel and images recorded (10 frames/sec). The diameter of the bowel was
measured along the length of the segment and converted to spatiotemporal maps showing
propagating contractions over time. The effect of cholinergic and nitrergic nerves was meas-
ured by addition of carbachol or NOLA and nerves were blocked by addition of tetrodotoxin
(TTX). Results: Control intestine showed propagating contractions that moved along the
length of the segment. Diameter of the control intestine was 1 cm. Carbachol induced
narrowing of the segment. Large propagating contractions (myogenic activity) were released
when nerves were blocked with TTX. Contractions propagated at the rate of slow waves
(9.2/min) suggesting they were related to pacemaker cells (ICC). Following MSBR, the
intestine was dilated to more than double the diameter of control intestine. Carbachol caused
narrowing of the diameter and the intestine remained narrow for long periods. Following
TTX, propagating contractions were missing and the bowel was mostly inactive. Conclusion:
Large propagating contractions are inhibited by neurons in normal pig ileum. Following
MSBR, ileum was dilated and propagating contractions were lost. The resulting bowel had
little ability to push contents and recovered slowly from cholinergic stimulation (contraction).
These results suggest that myogenic activity that underlies propagating contractions is lost
following MSBR. ICC generate the slow wave electrical activity and loss of myogenic activity
maybe related to loss of ICC or their function. Some of the features of poor adaptation
following MSBR may be related to a defect in intestinal motility related to loss of myog-
enic contractions.
T1698
EGF Activates PkcβI and Pkcε By PLCγ and Calcium-Dependent Mechanisms,
and Prevents Acetaldehyde-Induced Disruption of Tight Junctions
Takuya Suzuki, Ankur Seth, Radhakrishna (rk) Rao
Previous studies showed that PLCγ and PKC activities are involved in EGF-mediated preven-
tion of acetaldehyde-induced disruption of tight junctions (TJ) in Caco-2 cell monolayers.
In the present study, we investigated the role of PLCγ and intracellular calcium in the
activation of PKC isoforms and the protection of TJ from acetaldehyde. Methods: Caco-2
cells on Transwell inserts were incubated with acetaldehyde (400 μM) in the absence or
presence of EGF (30 nM), and the barrier function was evaluated by measuring TER, FITC-
inulin flux and junctional distribution of occludin and ZO-1 by confocal microscopy. Release
of TJ-proteins from the actin cytoskeleton was evaluated by immunoblot analysis of Triton-
insoluble fraction. PKC activation was analyzed by membrane translocation of different PKC
isoforms by immunoblot analysis. ET8OH3 (PLCγ inhibitor), BAPTA-AM (an intracellular
Calcium chelator, 10-20 μM) or Thapsigargin (an inhibitor of endoplasmic reticular Ca2+-
ATPase, 1-2 μM) were used to determine the roles of PLCγ and intracellular calcium in
EGF-induced membrane-translocation of PKC isoforms and the protection of TJ. Interactions
of PKCβI and PKCε with occludin was investigated by co-immunoprecipitation and pair
wise binding using GST-Occludin-C (C-terminal 150 A.a.) and recombinant PKCβI and
PKCε. Results: EGF prevented acetaldehyde-induced increase in inulin flux, decrease in
TER, and redistribution of occludin and ZO-1 from the junctions. ET8OH3, R0320125 (PKC
inhibitor), BAPTA-AM and Thapsigargin dose-dependently prevented the EGF-mediated
protection of TJ from acetaldehyde, suggesting that PLCγ, intracellular Ca2+ and PKC activity
are involved in EGF-mediated protection of TJ from acetaldehyde. EGF rapidly induced
translocation of PKCβI and PKCε to plasma membrane, which was completely prevented
by ET8OH3, indicating that activation of these PKC isoforms was mediated by PLCγ. BAPTA-
AM and Thapsigargin attenuated EGF-mediated membrane translocation of PKCβI, but not
the translocation of PKCε, indicating that translocation of PKCβI, but not PKCε, is mediated
by calcium. Immunoprecipitation of occludin failed to pull down PKCβI or PKCε. Similarly,
pair wise binding assay showed no sign of direct interaction of C-terminal region of occludin
with PKCβI or PKCε. These data suggest that PKCβI and PKCε affect down stream targets
(such as actin cytoskeleton) other than TJ, which in turn may help stabilize the TJ. Conclu-
sion: These results indicate that EGF-mediated protection of TJ from acetaldehyde involves
PLCγ and calcium-mediated activation of PKCβI and PKCε. Support: DK55532 and AA12307.
T1699
Erk1/2 Delays the Assembly of Tight Junction (TJ) in Undifferentiated Caco-2
Cell Monolayers, While It Mediates the EGF-Induced Protection of TJ from
Oxidative Stress in Differentiated Cell Monolayers
Sudhir Aggarwal, Aditi Bhargava, Radhakrishna (rk) Rao
TJ forms a barrier to the diffusion of toxins and pathogens across the GI epithelium. Activation
of MAP kinases disrupts the TJ in MDCK cells, whereas it preserves the integrity of TJ in
Caco-2 cells. In this study we show that ERK1/2 exhibit contrasting effects on TJ in undifferen-
tiated and differentiated Caco-2 cells. Methods: Caco-2 cell monolayers, 3-day old (undiffer-
entiated; low alkaline phosphatase) and 14-day old (differentiated, high alkaline phosphat-
ase), were incubated with 20 μM H2O2 in the absence or presence of 30 nM EGF (added
10 min prior to H2O2). TJ integrity was evaluated by measuring transepithelial resistance
(TER), inulin flux and confocal microscopy of occludin and ZO-1. Activation of ERK1/2 by
EGF was analyzed by immunoblot analysis of p-ERK. Caco-2 cells were transfected with
siRNA or antisense oligos to ERK1 and ERK2 (AS-oligo) or with missense oligo (MS-Oligo)
or control siRNA (C-siRNA); TJ assembly was assessed by calcium-switch method. GST-
occludin-C (C-terminal 150 A.a.) was incubated with ERK1, ERK2 or PKCζ in the presence
of ATP, and immunoblotted for p-Thr and p-Ser. Results: 1) In both 3 and 14-day old
cells, H2O2 reduced TER, increased inulin flux, and induced redistribution of occludin and
ZO-1 from the junctions. EGF increased the levels of p-ERK in both 3 and 14-day old cells.
EGF treatment attenuated H2O2-induced disruption of TJ in 14-day old cells. In contrast,
EGF exacerbated the effect of H2O2 in 3-day old cells. Similarly, EGF by itself reduced basal
TJ permeability in 14-day old cells, while it increased it in 3-day old cells. 2) siRNA and
AS-oligos specifically reduced the levels of ERK1 and ERK2 compared with controls. Basal
TER and junctional distribution of occludin and ZO-1 were greater and inulin flux was low
in siRNA and AS-oligo-transfected cells compared to MS-oligo or C-siRNA-transfected cells.
The rate of calcium-induced TJ assembly was significantly greater in siRNA and AS-oligo-
transfected cells, indicating that endogenous ERK delays the assembly of TJ in 3-day old
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cells, supporting the above data on EGF-induced disruption of TJ. 3) In 14-day old cells,
EGF-induced Thr-phosphorylation of occludin was prevented by U0126, a MAP kinase
inhibitor. However, active ERK1 and ERK2 failed to phosphorylate GST-Occludin-C In Vitro
on Ser or Thr; but PKCζ phosphorylated occludin on Ser and Thr. ERK1 and ERK2
significantly increased Thr-phosphorylation of PKCζ, suggesting that ERK may regulate
occludin phosphorylation indirectly by activating PKCζ. Conclusion: Results show that
ERK has contrasting effects on TJ in differentiated and undifferentiated cells. Support:
DK55532 and AA12307.
T1700
Transforming Growth Factor-Beta1 -509t Reduces Risk of Colorectal Cancer,
But Not Adenoma in Koreans
Su jin Chung, Joo sung Kim, Hyun chae Jung, In sung Song
The proliferation of colorectal epithelial cells is regulated by various stimuli including
cytokines and growth factors, thus the variants of those genes may modify the colorectal
cancer risk. Transforming growth factor-beta1 (TGF-beta1) can act as both a tumor suppressor
and a stimulator of tumor progression. TGF-beta1 C-509T polymorphism in the promoter
sequence has been associated with increased levels of plasma TGF-beta1 in individuals with
T allele. To evaluate the potential influences of this polymorphism on colorectal adenoma
and cancer risk, a case-control study was conducted in Korea. A total of 646 subjects were
prospectively enrolled in Seoul National University Hospital. Risk of colorectal neoplasms
was evaluated separately for 244 patients with colorectal adenoma, 152 patients with colorec-
tal cancer relative to 250 healthy controls. Genotypes were determined by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) method. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated by a multivariate logistic regression
analysis. The TGF-beta1 -509T allele containing genotypes posed a reduced risk of colorectal
cancer (OR = adjusted 0.59, 95% CI = 0.28-0.92). But there was no association between
this polymorphism and colorectal adenoma. Our results suggest that TGF-beta1 -509T allele
may have protective role in the development of colorectal cancer, possibly consistent with
its role as an inhibitor of epithelial malignant transformation.
Association of TGF-beta1 C-509T polymorphism with risk of colorectal neoplasms.
†Adjusted for age, sex, family history of colon cancer, smoking, and regular use of aspirin
or non-steroidal anti-inflammatory drugs (NSAIDs). OR, odds ratio; CI, confidence interval.
T1701
Constitutive Activation of Mek/ERK Mapk Pathway Induces Epithelial-
Mesenchymal Transition in Intestinal Epithelial Crypt Cells
Etienne Lemieux, Véronique Durand, Marie-josee Boucher, Nathalie Rivard
Epithelial-mesenchymal transition (EMT) is a key event in the tumor invasion process.
Strong evidences exist for the involvement of Ras/Raf/MEK/ERK cascade in intestinal epithelial
cell proliferation and tumorigenesis. Recently, it has been demonstrated that constitutive
activation of MEK1 induces oncogenic transformation in intestinal epithelial crypt cell lines.
However, the precise role of MEK1 in intestinal EMT has not been elucidated. Methods :
Retrovirus encoding the HA-tagged MEK1wild type (wtMEK) or constitutively active mutant
of MEK1 (MEK1-S218D/S222D, caMEK) were used to infect normal intestinal epithelial cells
(IEC-6). Modifications of gene expression were determined with Affymetrix rat microarrays.
Expression of specific genes was confirmed by western blot and RT-PCR. Matrix metalloprote-
ase (MMP) activities were determined by zymography and protein localisation was determined
by immunofluorescence. Cell morphology was verified by phase-contrast microscopy. Result:
1- Examination of cells revealed that caMEK-expressing cells acquired a fibroblastic morpho-
logy in contrast to non-infected epithelioid IEC-6 or wtMEK-expressing cells. 2- Microarray
data showed that caMEK1 expression induces genes involved in cell adhesion, migration
and resistance to anoikis/apoptose. 3- A significant induction of ETM markers including
vimentin (5-fold), Snail2 (3-fold), Slug (4-fold), SIP1 (2-fold), serpinE2 (12-fold), integrinα6
(4-fold), MMP2 (4-fold) and MMP9 (3-fold) was observed in caMEK-expressing cells; reduc-
tion of occludin (5-fold) and syndecan 1 (3-fold) was also noted. 4- Zymography studies
confirmed the elevated MMP2 and MMP9 activities in media of caMEK-expressing cells. 5-
Expression levels of Bcl-2, Bcl-XL and phosphorylated Bad (S-112) were enhanced correlating
with anoikis resistance of caMEK-expressing cells. 6- There is a decreased amount of E-
cadherin localized at sites of cell-cell contact in caMEK-expressing cells; A cytoplasmic
distribution of E-cadherin now forming a punctuate pattern was observed. A disruption in
the amount of F-actin localized at the sites of cell-cell contact was also observed in caMEK-
expressing cells in comparison to wtMEK-expressing cells in which E-cadherin and F-actin
co-localized at cell-cell interfaces. 7- Treatment of caMEK-expressing cells with UO126
(inhibitor of MEK1/2; 20 uM) markedly reduced cell survival, foci formation, migration
(Boyden chamber) and abolished the induced expression/activity of ETM markers. Conclu-
sion: Constitutive activation of the MEK1 induces an epithelium-mesenchymal transition
which may confer a growth advantage, survival and capacity of invasion to intestinal epithe-
lial cells.
T1702
Gastrin Releasing Peptide Promotes Cell Migration By Upregulation of
Integrins in Neuroblastoma Cells
Jingbo Qiao, Lan Pang, B. mark Evers, Dai H. Chung
Gastrin releasing peptide (GRP) acts as a mitogen by activating its cell surface membrane
receptor, GRP-R, to promote cell proliferation in various cancer cells. We have previously
found that increased expression of GRP-R, which increases GRP binding capacity, is noted
in more undifferentiated, malignant neuroblastomas. Recently, it has been reported that
GRP also demonstrates a morphogenic property in colon and prostate cancer cells. Bombesin,
a mammalian equivalent of GRP, stimulates the motility of human prostate carcinoma cells.
In this study, we sought to determine the molecular mechanism of GRP on cell migration
in human neuroblastoma cells. METHODS. Human neuroblastoma cell lines, SK-N-SH and
BE(2)-C, were used for our experiments. Small interfering (si) RNA directed against GRP-
R and integrin subunit α2, α3, and β1 were used to determine the exact role of GRP and
integrins on neuroblastoma cell migration. Cell migration assay was performed using Migra-
tion Kit. Wound scratch assay was also performed by plating cells on laminin or collagen-
coated plates, as an alternative method to assess cell migration. Western blot analyses were
performed to determine the protein level, and RT-PCR was used to measure the mRNA
levels. Gene array was performed using GEArray Q Series MicroArray, and flow cytometry
was used to assess the functional levels of integrins on plasma membrane. RESULTS. GRP
(10-7M) treatment promoted neuroblastoma cell migration in both SK-N-SH and BE(2)-C
cells. SK-N-SH cells, stably transfected to overexpress GRP-R, also demonstrated significantly
increased cell migration, which was attenuated by siRNA specifically targeted to GRP-R.
The extracellular substrate receptor expression of integrin subunits α2, α3, and β1 was
upregulated in GRP-R- overexpressing SK-N-SH cells. Correlative to protein expression,
upregulation of integrins by GRP-R overexpression was confirmed by flow cytometry. More-
over, siRNA targeted to the integrin subunit β1 significantly reversed cell migration in GRP-
R-overexpressing SK-N-SH cells. Knockdown of integrin subunitsα2,α3 did not significantly
alter cell migration in GRP-R-overexpressing SK-N-SH cells. CONCLUSIONS. Our findings
demonstrate that GRP/GRP-R promotes neuroblastoma cell migration. Subunit β1 is a neces-
sary downstream effector of GRP-mediated cell migration. These findings may lead to novel
strategies targeting GRP-R and integrin β1 in pediatric patients with undifferentiated, aggress-
ive neuroblastomas.
T1703
New Mechanisms Regulating the Function of Klf11, a Tumor Suppressor for
Pancreatic Cancer and a Diabetes Gene
Jin-san Zhang, Gwen A. Lomberk, Raul A. Urrutia
KLF11/TIEG2 was isolated by our group as a TGF beta-inducible Sp1-like transcription
factor that mainly functions as a transcriptional repressor. Functional studies have shown
that KLF11 is a candidate tumor suppressor for pancreatic cancer via the mSin3a-Histone
deacetylase (HDAC) corepressor complex. The interaction was mediated through a short
alpha helical motif, the R1 domain of KLF11 with the PAH2 (Paired Amphipathic Helix 2)
of mSin3a, which is necessary for growth regulatory activity of the tumor suppressor protein
KLF11. Recent reports indicate that loss of KLF11 expression correlates with the aggress-
iveness of additional malignancies including head and neck, leukemia, and esophageal cancer.
Furthermore, this protein is also shown to participate in regulation of cholesterol signaling
by silencing the LDL receptor and the caveolin-1 gene promoters. Importantly, the loading
of HDAC to the Sin3 corepressor protein is a key, yet poorly understood step for KLF11
to perform all these functions. Here we have studied how signaling molecules regulates the
interaction of HDAC with Sin3 and KLF11. In particular, we have examined the ability of
signaling pathways to modify: 1. PAH2 domain, the region of Sin3 that directly interacts
with KLF11 and 2: the PAH3-HID-PAH4 domain, the region that regulates the recruitment
of HDACs. To begin answering these questions, we tested the effect of 30 different kinases
that are key to the regulation of cell growth, apoptosis, gene insulin pathway, and cholesterol
signaling. Our findings indicate that distinct kinases differentially regulate each domain. In
particular, the IGF-PI3K-AKT pathway can phosphorylate the PAH2 domain, while, primar-
ily, mitotic kinases more readily modify the PAH3-HID (HDAC-Interaction Domain)-PAH4
domain. Together, these findings reveal the potential of distinct signaling pathway for
regulating the function of KLF11 by targeting specific domains of the Sin3a-corepressor.
Furthermore, this represents the first investigation on how the modular activity of a chromatin
scaffold such as Sin3a is potentially regulated by membrane-to-nucleus signaling pathways.
RU is supported by Mayo Cancer Center and NIH Grants DK52913
T1704
Feedback Stimulation of GαQ Function By Gβγ Subunits: A Novel Mechanism
Involving Inhibition of GαQ-Rgs4 Association and GαQ-Gtpase Activity
Karnam S. Murthy, Sunila Mahavadi, Wimolpak Sriwai
The intensity of Gα signaling is determined by a family of proteins known as Regulators of
G protein Signaling (RGS) that bind to activated Gα-GTP and accelerate its intrinsic GTPase
activity. The Gβγ dimer activates other signaling molecules (e.g., GRK2). Recent studies
have shown that Gβγ which binds with high affinity to inactive Gα to form a heterotrimeric
complex, also binds with lesser affinity to activated Gα-GTP, and modulates its activity. We
hypothesized that Gβγ competes with RGS for binding to activated Gα-GTP, and can thus
enhance Gα signaling by blocking inactivation of Gα-GTP. Aim. To examine whether Gβγ
decreases RGS4 binding to, and limits inactivation of Gαq-GTP. Methods. Gαq activity was
determined as the increase in PLC-β1 activity in response to substance P (SP) in rabbit
gastric muscle cells. The effect of Gβγ on Gαq activity was determined in permeabilized
muscle cells incubated with Gβ antibody and in cultured muscle cells expressing Gβγ-
scavenging peptide. To determine whether the effect of Gβγ on Gαq activity involved
competition with RGS4, Gαq activity was measured in cultured muscle cells expressing
Gαq(G188S) which lacks the ability to bind RGS4 and in cells expressing RGS4(L159F)
which lacks the ability to bind Gαq. Gα-GTPase activity was measured using [32P]GTP and
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Gαq:RGS4 association was determined by co-imunoprecipitation. Results. SP-stimulated PI
hydrolysis in permeabilized muscle cells was inhibited by PLC-β1 antibody but not by PLC-
β3 antibody, implying that PLC-β1 was activated via Gαq. Neutralizing Gβγ with a common
Gβ antibody in permeabilized muscle cells or by expression of a Gβγ-scavenging peptide
in cultured muscle cells significantly (P<0.01) attenuated SP-stimulated PLC-β1 activity
suggesting feedback augmentation of Gαq-dependent PLC-β1 activity by Gβγ. Consistent
with this notion, SP-induced Gα-GTPase activity was significantly augmented in cells
expressing Gβγ-scavenging peptide. SP-stimulated PLC-β1 activity was significantly (P<0.01)
augmented in cells expressing Gαq(G188S) or RGS4 (L159F); co-expression of Gβγ-scaven-
ging peptide had no effect on PLC-β1 activity in these cells, suggesting that the augmentatory
effect of Gβγ reflects interference with the inhibitory effect of RGS4. Consistent with this
notion, the increase in Gαq:RGS4 association induced by SP was augmented in cells expressing
Gβγ-scavenging peptide. Conclusion. This study provides the first evidence that Gβγ regu-
lates Gαq signaling via a novel mechanism involving competition with RGS4 binding to
activated Gα subunits, leading to inhibition of Gα-GTPase activity and augmentation of
Gαq-dependent response.
T1705
Erk1c, a Human Alternatively Spliced Form of Erk1, Is Involved in PGE2-
Stimulated Neurotensin Secretion in Bon Endocrine Cells
Jing Li, Emily E. Bayne, Tianyan Gao, Qingsong Cai, Courtney M. Townsend, jr., B. mark
Evers
Neurotensin (NT), a gut peptide localized predominantly to the small bowel, stimulates
growth of certain colon cancers and is associated with mucosal inflammation. We have
reported that prostaglandin E2 (PGE2), a product of arachidonate metabolism and a potent
mediator of inflammation, stimulates NT secretion from a novel human endocrine cell line
BON via PKA, but the mechanisms involved are not clear. PGE2 activates extracellular
signal-regulated kinases 1 and 2 (ERK1 and ERK2) which are important for proliferation.
Overexpression of the alternatively spliced form of ERK1 (ERK1c), recently identified in
humans, causes Golgi fragmentation, a process required for secretion; however, the precise
biological functions of ERK1c are not known. The purpose of our present study was to
determine whether ERK1c plays a role in PGE2-stimulated NT secretion. METHODS. (i) To
determine the involvement of ERK on NT secretion, BON cells were pre-treated with the
MEK/ERK inhibitor, PD98059, and then treated with PGE2 or PMA, a potent stimulator of
NT release; medium was collected and NT secretion measured; (ii) to determine the role
of ERK1c, BON cells were transiently transfected with ERK1c for 48 h, and treated with
PGE2 or PMA and NT secretion measured; (iii) to detect ERK1/2 expression, Western blot
analysis was performed. RESULTS. Both PGE2- and PMA-stimulated NT secretion was blocked
by PD98059. Interestingly, phosphorylation of ERK1 and 2 was only induced in BON cells
treated with PMA. PGE2 treatment did not affect ERK1 and 2 activities, suggesting that
isoforms (other than ERK1/2) which are also sensitive to PD98059, are involved in PGE2-
mediated secretion. Consistently, PGE2, but not PMA, enhanced NT secretion from BON
cells transfected with ERK1c, suggesting regulation of NT secretion through ERK1c (for
PGE2 and ERK1/2 (for PMA). Furthermore, NT secretion from BON cells, transfected with
ERK1c, was completely blocked by PD98059, suggesting that the effect of ERK1c is dependent
on MEK. CONCLUSIONS. ERK1c plays a critical role in PGE2-regulated NT secretion.
Importantly, we demonstrate, for the first time, that ERK1c, a novel ERK1 splice variant,
is involved in the regulation of hormone secretion, thus identifying this molecule as a critical
component for stimulated intestinal hormone release.
T1706
Mlc20 Dephosphorylation and Muscle Relaxation Mediated By PKA-Dependent
Phosphorylation of RHOA Requires Binding of PKA to the Anchoring Protein
Akap79
Sunila Mahavadi, Wenhui Hu, Fang Li, Karnam S. Murthy
In gastrointestinal smooth muscle, two RhoA-dependent pathways converge to inhibit MLC
phosphatase leading to sustained MLC20 phosphorylation and contraction. We have previ-
ously shown that cAMP- and cGMP-dependent kinase (PKA and PKG) induce MLC20
dephosphorylation and muscle relaxation in part via phosphorylation of RhoA at Ser188.
The residual relaxation is mediated via a post-RhoA mechanism involving direct inhibition
of MLC phosphatase by PKA and PKG. The actions of PKA are targeted by its binding to
A-kinase anchoring proteins (AKAP). Aim. To determine whether AKAP selectively targets
PKA to induce phosphorylation of RhoA, dephosphorylation of MLC20 and muscle relaxation.
Methods. RhoA phosphorylation was determined in gastric muscle cells labeled with 32P
and Rho kinase activity was measured by In Vitro kinase assay. The association of AKAP79 with
RhoA and PKA regulatory subunit was determined by immunoprecipitation with AKAP79
antibody, and MLC20 phosphorylation was determined using a phospho-specific (Ser19)
antibody. Relaxation was measured by scanning micrometry. The role of PKA:AKAP associ-
ation in mediating RhoA phosphorylation was examined using the cell-permeable AKAP-
PKA competing peptide Ht-31. Results. Immunoprecipitation with either AKAP or RhoA
antibody showed association of AKAP with both PKA and RhoA, but not with PKG, suggesting
that AKAP acts as a scaffolding protein for both PKA and RhoA. Treatment of cells with
Ht-31 disrupted the association of AKAP79 with PKA, but had no effect on association
of AKAP79 with RhoA. Activators of PKA (cBIMPS) and PKG (8-pCPT-cGMP) induced
phosphorylation of RhoA and inhibited acetylcholine-stimulated Rho kinase activity. RhoA
phosphorylation and inhibition of Rho kinase activity by PKA but not by PKG was blocked
by Ht-31. Acetylcholine-induced sustained MLC20 phosphorylation and contraction were
inhibited by both PKA and PKG; The effect of PKA, but not PKG was blocked by Ht-31.
The results imply that association of PKA with AKAP is necessary for PKA-induced RhoA
phosphorylation and inhibition of RhoA-dependent MLC20 phosphorylation and contraction.
Conclusion. RhoA and PKA are anchored to AKAP79 in gastric smooth muscle cells.
Association of PKA with AKAP79 is necessary for PKA to mediate phosphorylation of RhoA
and inactivation of RhoA-dependent pathways. PKG phosphorylates the same pool of RhoA
but does not require association with AKAP.
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T1707
Biological Actions of BMP-4 in Isolated Primary Gastric Epithelial Cells
Andrea Todisco, Nonthalee Pausawasdi, Mahdi Sareban, Masahiko Shinohara, Maria Mao
BACKGROUND: In the stomach, bone morphogenetic protein 4 (BMP-4), a member of the
BMP family of regulatory proteins, has been shown to inhibit cellular proliferation and to
promote gastric epithelial cell differentiation. In addition to these effects, the BMPs appear
to exert anti-inflammatory actions in intestinal tissues, suggesting that they might represent
novel and hitherto poorly characterized regulators of gastrointestinal inflammation. AIM:
We tested the hypothesis that BMP-4 inhibits the expression of markers of gastric epithelial
cell proliferation and that it modulates the activation of pro-inflammatory mechanisms in
the stomach. METHODS: Populations of canine gastric epithelial cells, that were enriched
in parietal and mucus cells, were isolated from the gastric fundus using previously published
techniques involving collagenase/EDTA cell dispersion followed by counterflow elutriation.
Expression of the IL-8 gene, a pro-inflammatory cytokine, was examined by Northern blots
with a canine IL-8 cDNA probe, while that of TFF-1, a tumor suppressor gene, was measured
by quantitative RT-PCR. MEK1, ERK2, Smad1 and Retinoblastoma protein (Rb) phosphoryl-
ation and activation were measured by western blots with anti-phospho-MEK1, -ERK2, -Rb
and -Smad1 antibodies. CyclinD1 expression was assessed by western blots with anti-
cyclinD1 antibodies. RESULTS: BMP-4 (20 ng/ml) induced a sustained phosphorylation of
Smad1 in the gastric epithelial cells that was detectable after 24, 48 and 72 h of stimulation.
BMP-4 inhibited both basal and Tnf-alfa (10 ng/ml)-stimulated IL-8 gene expression, while
it induced the expression of TFF1 more then three-fold. BMP-4 inhibited the stimulatory
effect of EGF (10 nM) on MEK1, ERK2 and Rb phosphorylation and activation and on
cyclinD1 expression. CONCLUSIONS: BMP-4 exerts inhibitory effects on the activation of
pro-inflammatory and proliferative mechanisms in gastric epithelial cells. Moreover, it induces
the expression of the tumor suppressor TFF1, an inhibitor of gastric carcinogenesis. These
results underscore the importance of BMP-4 in the regulation of gastric epithelial cell biology
and they might provide new clues for a better understanding of the mechanisms that
contribute to the development of both displastic and neoplastic lesions in the stomach.
T1708
Equally Efficacious Concentrations of Deoxycholyltaurine, Matrix
Metalloproteinase-7 (MMP-7), and Hb-EGF Selectively Phosphorylate
Epidermal Growth Factor Receptor (EGFR) Tyrosine(Y)992 and Stimulate
Post-Receptor Signaling and Colon Cancer Cell Proliferation
Kunrong Cheng, Jean-pierre Raufman
Bile acid-induced stimulation of H508 human colon cancer cell proliferation is mediated
by activation of EGFR and post-receptor signaling via the p44/42 MAP kinase and PI3K/
Akt signaling pathways (Biochem Pharmacol 2005;70:1035, Gastroenterology 130:A119,
2006). We were puzzled by the observation in H508 cells that, whereas EGF stimulates
phosphorylation of 5 C-terminal EGFR autophosphorylation sites (Y845, Y992, Y1045,
Y1068, and Y1173), incubation with deoxycholyltaurine (DCT) results in phosphorylation
of only EGFR Y992. To explore the basis for this discrepancy, we parsed the molecular
mechanisms upstream of bile acid-induced EGFR activation. Experiments using neutralizing
antibody and siRNA implicated DCT-induced MMP-7 activation, MMP-7-mediated release
of the EGFR ligand HB-EGF, and consequent EGFR activation as a mechanism underlying
the proliferative actions of DCT. Dose-response curves for the effects of exogenously added
MMP-7 and HB-EGF on cell proliferation were compared to the effect of a maximal concentra-
tion of DCT (50 μM). This analysis indicated that the magnitude of cell proliferation with
100 ng/ml MMP-7 and 0.1 ng/ml HB-EGF is the same as that observed with 50 μM
DCT. We treated H508 cells with these concentrations of MMP-7, HB-EGF and DCT, and
determined EGFR phosphorylation (EGFR immunoprecipitation followed by immunoblot-
ting with specific EGFR phosphotyrosine antibodies). Whereas a positive control (EGFR,
10 ng/ml) stimulated phosphorylation of Y845, Y992, Y1045, Y1068 and Y1173, only
phosphorylation of Y992 was observed with these equally efficacious concentrations of MMP-
7, HB-EGF and DCT. A higher concentration of HB-EGF (10 ng/ml) mimicked the actions
of EGF; phosphorylation of EGFR Y845, Y992, Y1068 and Y1173 was observed. Regarding
post-receptor signaling, EGFR immunoprecipitation experiments revealed that the equally
efficacious concentrations of MMP-7, HB-EGF and DCT stimulated binding of phospholipase
Cγ1 (PLCγ1) to EGFR. DCT-induced EGFR Y992 phosphorylation and PLCγ1 binding to
EGFR were both increased when a phosphatase inhibitor (0.1 mM Na vanadate) was added.
These equally efficacious concentrations of DCT, MMP-7 and HB-EGF also stimulated
phosphorylation of p44/42 MAP kinase. We conclude that HB-EGF-induced, dose-dependent
selective phosphorylation of EGFR Y992 mediates the downstream stimulatory actions of
DCT on H508 colon cancer cell proliferation. EGFR Y992 provides a novel, specific target
for inhibition of DCT-induced activation of EGFR and consequent stimulation of colon
cancer cell proliferation.
T1709
The Inhibitory Effect of Egcg On HSC Growth Mainly Results from Its
Antioxidant Capability By Increasing De Novo Synthesis of Glutathione
Yumei Fu, Shizhong Zheng, Shelly C. Lu, Anping Chen
BACKGROUND: Hepatic stellate cells (HSC) are the key effectors in hepatic fibrogenesis.
Enhanced cell proliferation and over-production of extracellular matrix (ECM) are two
characteristics of HSC activation and are promoted by cellular oxidative stress. Glutathione
(GSH) is the most important intracellular antioxidant. de novo GSH synthesis is regulated
by glutamylcysteine ligase (GCL). We previously reported that (-)-epigallocatechin-3-gallate
(EGCG), the major and most active component in green tea extracts, inhibited HSC activation
by reducing cell growth and suppressing ECM gene expression. We recently demonstrated
that EGCG suppressed ECM gene expression by interrupting TGF-β signaling through
attenuating oxidative stress. AIM AND HYPOTHESIS: The aim of this study is to explore
the underlying mechanisms of EGCG in the inhibition of activated HSC growth and in the
attenuation of oxidative stress. It is hypothesized that the inhibitory effect of EGCG on HSC
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growth might require de novo synthesis of glutathione by inducing GCL activity, resulting
from interrupting TGF-β signaling. RESULTS: EGCG increases the cellular GSH level in
HSC In Vitro, which is abrogated by the GCL inhibitor buthionine sulfoximine (BSO). Like
EGCG, the GSH precursor N-acetyl-cysteine inhibits cell growth of activated HSC. Both
antioxidants down-regulate expression of genes related with stimulating cell proliferation,
including PDGF-βR, EGFR and cyclin D1, and up regulate cell cycle inhibitory proteins
p21 and p27. In addition, both antioxidants reduce the level of anti-apoptotic Bcl-2 and
increase the abundance of pro-apoptotic Bax. The inhibition of GCL activity by BSO eliminates
the effects of EGCG on HSC growth and on expression of the genes. Further experiments
reveal that EGCG increases the activity of GCL and induces gene expression of GCLc, the
catalytic subunit of GCL, which might lead to the increase in the level of cellular GSH in
HSC. It is further observed that exogenous TGF-β suppresses GCLc gene expression and
reduces the level of GSH in activated HSC. Additional experiments are ongoing to elucidate
the mechanisms of TGF-β on regulation of gene expression of GCLc in HSC. CONCLUSIONS:
These results, together with our prior observation of the EGCG interruption of TGF-β
signaling in HSC, support our hypothesis and suggest that EGCG might increase the level
of cellular glutathione in HSC by stimulating gene expression of GCLc through interrupting
TGF-β signaling and thereby abrogating the inhibitory effect of TGF-β signaling on GCLc
gene expression, leading to the inhibition of cell growth. [The work was supported by the
grant DK 47995 from NIH/NIDDK to A. Chen].
T1710
Improvement By Ghrelin and Leptin of Gastric Ulcer Healing Under Diabetic
Conditions. Role of Endogenous Prostaglandins, Lipid Peroxidation and
Oxidative Stress
Robert Pajdo, Tomasz Brzozowski, Peter C. Konturek, Wladyslaw Bielanski, Sliwowski
Zbigniew, Michal Pawlik, Grzegorz Burnat, Stanislaw J. Konturek, Wieslaw W. Pawlik
It is known that gastric mucosa of diabetic rats is highly susceptible to acute gastric injury
but the influence of two major hormones involved in the control of food intake such as
ghrelin and leptin, on the healing of preexisting gastric ulcers under diabetic conditions has
been little studied. In this study, gastric ulcers were induced by serosal application of acetic
acid (ulcer area=28 mm2) in non-diabetic rats and those treated with streptozotocin (70
mg/kg injected intraperitoneally i.p.) to induce diabetes mellitus with or without daily treat-
ment with 1) vehicle (saline), ghrelin or leptin (20 μg/kg i.p.); 2) selective inhibition of
COX-1 (SC-561, 5 mg/kg i.g.) and COX-2 (rofecoxib, 10 mg/kg i.g.) and 3) blockade of
ghrelin receptors GHS-1a with D-Lys3-GHRP-6 (0.1 mg/kg i.p.). Area of gastric ulcers at
day 8 and 15 upon ulcer induction was measured by planimetry and gastric blood flow
(GBF) at the ulcer margin was assessed by H2-gas clearance technique. Plasma leptin and
ghrelin levels, proinflammatory cytokines IL-1β and TNF-α and superoxide dismutase (SOD)
activity and malonyldialdehyde (MDA) content as an index of lipid peroxidation in the
gastric mucosa and RT-PCR expression of ghrelin and leptin mRNA were also determined.
The area of gastric ulcers was significantly larger but GBF at ulcer margin was significantly
lower in diabetic animals (plasma glucose level ≥ 400 mg/dL) as compared to non-diabetic
ones. Both, leptin and ghrelin inhibited the area of gastric ulcers without or with diabetes
while raising GBF at ulcer margin, plasma leptin and ghrelin levels and mucosal generation
of PGE2. The mucosal MDA content and plasma IL-1β and TNF-αwere significantly increased
while SOD activity was significantly decreased in ulcerated animals without or with diabetes
and these effects were significantly reduced by treatment with ghrelin and leptin. SC-560
and rofecoxib as well as D-Lys3-GHRP-6, an antagonist of GHS-1a receptors, significantly
attenuated ghrelin- and leptin-induced increase in the ulcer healing and the rise in the GBF.
Expression of ghrelin- and leptin mRNAs was strongly upregulated at the ulcer margin
during ulcer healing. We conclude that 1) ulcer healing is markedly delayed in diabetes
possibly due to suppression of SOD activity, an increased lipid peroxidation and excessive
release of IL-1β and TNF-α, 2) both, exogenous leptin and ghrelin that acts via GHS-1a
receptors, accelerate ulcer healing in diabetes possibly due to an increase in the GBF at
ulcer margin mediated by PGs and the attenuation of oxidative stress and proinflammat-
ory cytokines.
T1711
Progastrin (PG) Peptide Co-Localizes with Annexin II (Anx-II), in Situ, in
Human Colon Cancer Cells (Hct-116), Expressing Autocrine PG, and in
Intestinal Epithelial Cells (IEC-18) in Response to PG Stimulation
Shubhashish Sarkar, Shahid Umar, Gurpreet Singh, Pomila Singh
Background: PG like peptides bind ANX-II with high affinity, and ANX-II mediates ~100% to
>50% of the growth effects of autocrine (HCT-116) and exogenous (IEC-18) PG, respectively
(Oncogene,2006). The in situ interaction of autocrine and exogenous PG with ANX-II is
not known. Aim: In order to understand the mechnisms by which ANX-II mediates growth
effects of PG, we examined possible co-localization of the ligand (PG) and the ‘receptor'
(ANX-II) in situ, by Immunofluorescence and confocal microscopy. Methods: Cells were
grown on sterile glass cover slips in the presence (HCT-116) or absence (IEC-18) of fetal
calf serum. Serum starved IEC-18 cells were stimulated with PG (0.1-1.0nM), followed by
fixing the cells at various time points (0-120min) after stimulation in ice cold methanol.
HCT-116 cells were fixed 24-48 h after seeding in 10% FCS. Results: Significant differences
in the localization and co-localization of PG and ANX-II were observed in HCT-116 vs IEC-
18 cells. In HCT-116 cells, almost all of ANX-II and PG present in the cell, was co-localized
in the cytosolic compartment with strong peri-nuclear staining. In IEC-18 cells, at initial
time points (<5min), PG was largely present on the outer surface of cell membrane, while
ANX-II was located intracellularly. After 5min, increasing co-localization of PG and ANX-
II was observed in ~ 10-20% of the cells; surprisingly most of the co-localization was at
the inner surface of the cell membrane. HCT-116 cells, down regulated for gastrin gene
expression (and hence PG), did not show significant signal for either ANX-II and PG,
suggesting that the expression and interaction of the two may be interdependent. As a separate
control ANX-II and alpha tubulin did not co-localize in either of the cells. Conclusions: The
strong co-localization of PG and ANX-II in a colon cancer cell line may explain the complete
attenuation of growth effects of autocrine PG on down regulation of ANX-II, as previously
reported by us for HCT-116 cells. On intestinal epithelial cells, ANX-II is generally present
as a tetramer, which may not be available for binding exogenous PG. Monomeric ANX-II
binds PG In Vitro, and may be the limiting factor; this may explain the time-dependent
increase in internalization of PG. The differential co-localization of PG and ANX-II in cancer
vs ‘normal' cells, is intriguing and may reflect the dynamics of autocrine vs exogenous PG,
which will be investigated in future.
T1712
Somatostatin Inhibits Gastrin By Stimulating Menin
Edith Mensah-osman, Yana Zavros, Juanita L. Merchant
INTRODUCTION: Gastrin is an important hormonal regulator of gastric acid secretion and
is a growth factor for the stomach. It is normally expressed in the pancreas during fetal
development, then expression switches to the gastric antrum and proximal duodenum in
the adult. In the multiple endocrine neoplasm type 1 (MEN-1) syndrome, the gastrinomas
that develop are primarily in the duodenum and to a lesser extent in the pancreas (Anlauf,
Gastro, 2005). In 1998, positional cloning identified menin, a nuclear protein of unknown
function, which is mutated in human MEN-1 subjects. Thus menin is a tumor suppressor
protein that is expected to suppress gastrin gene expression. By contrast, somatostatin a,
peptide secreted from gastric D cells, inhibits gastrin secretion and gene expression. Therefore
we hypothesized that somatostatin might mediate its inhibitory effect through menin.
METHODS: Serum starved AGS cells were treated with octreotide or Forskolin and changes
in menin protein were determined by immunoblots. FACs analysis was used to determine
expression of menin and SSTR2A receptor. Lipofectamine2000 was used to create both
transient and stable transfectants of SSTR2A in AGS cell lines, and changes in menin after
octreotide treatment was determined by immunoblot. AGS cells were co-transfected with
menin or siRNA-Menin and gastrin luciferase reporter constructs for luciferase activity.
RESULTS: Transfection of a menin expression vector inhibited gastrin expression by ~ 90%,
while siRNA on endogenous menin increased reporter activity by 3 fold. The somatostain
analog, octreotide increased the number of menin/SSTR2A expressing antral and duodenal
mouse cells as determined by FACs analysis. Octreotide treatment (100 nM) of AGS cells
stimulated a 4-fold increase in menin levels. Somatostatin inhibits cAMP signaling. Therefore
we tested the effect of PKA activation on menin levels. We found that forskolin suppressed
endogenous levels of menin. CONCLUSION: Somatostatin is a direct activator of menin
expression and therefore may be an important signaling pathway by which gastrin is inhibited.
T1713
Extracellular Calcium Sensing Receptor (CaSR) Stimulates IL-11 Secretion
from Colonic Subepithelial Myofibroblasts to Decrease Barrier Permeability
Ivan Pacheco, Craig Spencer, R. john Macleod
Background: Post-prandial Ca2+o variations could stimulate the extracellular calcium sensing
receptor (CaSR) on subepithelial myofibroblasts to regulate epithelial homeostasis. In the
current experiments the effect of CaSR activation in Co18 colonic myofibroblasts on IL-11
synthesis and secretion was determined. Results: CaSR activation in the myofibroblast by
ionized Ca2+o or other CaSR agonist, Gd3+ (25 uM), Neomycin sulphate (300 uM) or
Spermine (2 mM) stimulated the secretion of IL-11 as assessed by ELISA. Transfection with
dominant negative CaSR (R185Q) increased the EC50 from 3.75 mM Ca2+ o to 7.5 mM
Ca2+o (p <0.05). CaSR stimulation of IL-11 was prevented by siRNA duplex against the
CaSR. The CaSR-mediated secretion of IL-11 was reduced to basal levels by EGFR kinase,
p38 and ERK1&2 inhibitors, while blocking the src family of kinases accentuated the CaR-
mediated stimulation of IL-11 at the secretory and transcriptional level (RT-PCR). Western
analysis corroborated that CaSR activation induced the phosphorylation of ERK1&2. Treat-
ment with high calcium to high resistance T-84 cells increased the transcript for IL-11Rα.
Exogenous addition of rhIL-11 (100ng/mL) to T84 cells grown on Transwells increased the
transepithelial resistance (TER) within 24 hours of treatment. The paracellular permeability
of T84 monolayers (assessed by flux measurements of 3 and 10 kDa FITC-dextran) was
diminished ~90% by IL-11 treatment. “Ca2+-switch” experiments using 2 mM EDTA (5
min) showed that T84 cells treated with high Ca2+ and IL-11 recovered with greater TER
over the next 16h compared with cells treated with low Ca2+ and IL-11 alone (Ohms/cm2:
2166+/-234 vs 1702 +/- 156, p <0.05). Conclusions: We conclude that CaSR activation of
Co18 myofibroblasts regulates the synthesis and secretion of IL-11 by a mechanism involving
EGFR, ERK1&2 and p38 MAP kinase pathways. CaSR mediates increases of IL-11Rα on
epithelia and the ligand, IL-11 from the subepithelia. This unique paracrine relationship
promotes intestinal barrier recovery. This work was supported by CIHR, Dairy Farmers of
Canada, Crohn's and Colitis foundation of Canada.
T1714
Targeted Deletion of the P2ry14 Gene Accelerates Both Gastric Emptying and
Fecal Output
Sophie Bourdu, Alan Wheeldon, Alastair D. Morrison, Alejandro Abuin, Evelyn Grau,
George P. Livi, Lorraine Punter, Judith Latcham, Ying Qian, Christopher W. Crumbley,
Fiona M. Kelly, Kevin Lee, Wendy J. Winchester, Gary B. Moore
BACKGROUND & AIMS: Purinergic receptors have been shown to modulate gastrointesti-
nal functions. The newest member of the P2Y family is the nucleotide-sugar receptor P2Y14.
The mRNA for this receptor has been detected in human stomach and intestine but a role
for the receptor in gastrointestinal function has not been assigned. We examined the expres-
sion and role of the receptor in the rodent gut. METHODS: The distribution of the P2ry14
mRNA in rat and mouse tissues was measured using the real-time reverse transcriptase-
polymerase chain reaction. Cellular localization of the receptor in the rat gut and in rat
nodose ganglion neurons retrogradely-labelled with Fast Blue was determined using an
immunohistochemical analysis with an anti-P2Y14 antibody. Enteric neurons were identified
using an anti-HuC/D antibody. Knockout (KO) mice were generated by targeted deletion
of 88% of the P2ry14 gene coding region. Gastric emptying in adult KO mice backcrossed
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onto the C57BL/6J genetic background was performed through the use of a semi-solid
nutrient meal. Lower bowel function in the KO mice was assessed by measuring fecal pellet
output. The KO phenotyping results are expressed as mean ± SEM. RESULTS: The P2ry14
mRNA expression was highest in the abdominal aorta, lung and adipose tissue in mice, and
in blood vessels, lung and ovary in rats, and was detected throughout the GI tract in both.
Anti-P2Y14-immunoreactivity was detected in gastric Chief cells, in enteric neurons in the
stomach, small intestine and colon, and in vagal neurons projecting to the stomach. Gastric
emptying at 45 minutes following administration of the meal was increased by 94% in the
KO mice (percentage of meal emptied being 41.6 ± 3.5 for KO mice and 21.5 ± 3.1 for
wild-type (WT) control mice, n=7-8, P< 0.001). 24-hour fecal pellet output was increased
by 14% in the KO mice (pellet number being 119.1 ± 2.3 for KO mice versus 104.4 ± 3.3
for WT controls, n=14, P< 0.01). CONCLUSION: These results suggest a novel, possibly
neuronal mechanism for the regulation of gastric emptying and defecation via the P2Y14
receptor.
T1715
UDP-Glucose Modulates the Contractility of Mouse Forestomach In Vitro Via
the P2y14 Receptor
Anna K. Bassil, Emma M. Jarvie, Noureddine Zebda, Alastair D. Morrison, Alejandro
Abuin, Evelyn Grau, George P. Livi, Lorraine Punter, Judith Latcham, Christopher W.
Crumbley, Kevin Lee, Gareth J. Sanger, Gary B. Moore
BACKGROUND & AIMS: P2Y14 is the receptor for uridine 5'diphosphate (UDP) sugars,
the most potent agonists being UDP-glucose and UDP-galactose. Among human tissues,
P2RY14 mRNA has been reported to be expressed at a relatively high level in stomach and
intestine, with only the placenta and adipose tissue levels higher. In this study, we sought
to make a detailed examination of the distribution of P2ry14 mRNA in the rat gut, and to
investigate if the receptor was functional In Vitro in rat and mouse stomach. METHODS:
The mRNA distribution in the rat gut was determined using the real-time quantitative
reverse-transcriptase polymerase chain reaction. KO mice were generated by disrupting the
P2ry14 gene with a LacZ expression cassette. LacZ staining of stomach regions from KO
and wild-type (WT) mice was performed using X-gal. The effects of UDP-glucose and UDP-
galactose on muscle tension and contractions during electrical field stimulation (EFS; rat:
5Hz, 0.5ms, 25V, 30s every 3min; mouse: 3Hz, 0.5ms, 50V, 20s every 40s) were examined
in rat (longitudinal) and mouse (circular) isolated forestomach preparations and the results
expressed as mean ± SEM change in mN. RESULTS: P2ry14 mRNA expression was detected
throughout the rat gut, with the highest level found in the forestomach. In rat forestomach
preparations, both UDP-glucose (1-100 μM) and UDP-galactose (10-100 μM) increased the
baseline muscle tension (e.g. increases of 6.2 ± 0.6 and 1.6 ± 0.6 mN at 100 μM respectively,
P<0.05, n=3-4). Both agonists also increased the amplitude of contractions during EFS (e.g.
amplitudes were increased by 3.7 ± 1.7 and 4.3 ± 2.5 mN upon application of 100 μM
UDP-glucose or UDP-galactose respectively, P<0.05, n=3-4). In WT mice, 100 μM UDP-
glucose increased the baseline muscle tension by 1.0 ± 0.1 mN (P<0.05, n=6) but this effect
was lost in the KO mice (change of -0.1 ± 0.1 mN, n=6). 100 μM UDP-glucose also increased
contraction amplitude during EFS in the tissue from the WT animals (0.9 ± 0.4 mN, P<0.05,
n=6) but not from the KO mice (0.0 ± 0.2 mN, n=6). In both rats and WT mice, it was
unclear whether the apparent agonist-induced increase of contraction amplitude during EFS
represented a direct effect on a neuronal response or was a consequence of the simultaneous
increase in the baseline muscle tension. In KO mice, LacZ staining was localized to the
muscularis mucosae and muscularis externa in the forestomach.CONCLUSION: UDP sugars
contracted rodent forestomach preparations. The loss of this effect in the KO mice together
with the muscle LacZ staining suggests a predominant role for a smooth muscle P2Y14
receptor in the modulation of gastric motility.
T1716
VIP-Deficient Mice Exhibit Exacerbated Colonic Motility and Defecation in
Response to Stress
Muriel H. Larauche, Guillaume Gourcerol, David Oh, Yuxin Lu, James Waschek, Joseph
R. Pisegna, Yvette Tache
Background: Stress stimulates colonic motor functions in rodents via the activation of
corticotropin releasing factor (CRF) receptors (Gastroenterology, 119:1569-79, 2000).
Vasoactive intestinal peptide (VIP) is a non-adrenergic non-cholinergic inhibitor in the
gastrointestinal tract, however its role in the modulation of colonic motor functions under
conditions of stress is not well known. Aims: To assess and compare the defecation and
colonic motility patterns in wild type (WT), VIP deficient (VIP-/-) and VIP-/+ mice during
stress. Methods: WT (28.0 ± 0.6 g) (n=7), VIP -/- (15.8 ± 0.8 g) (n=8) and VIP -/+ (15.8
± 0.4 g) (n=8) mice were exposed to novel environment stress (placed individually in a new
cage) with or without pretreatment 30 min before the session with the peripherally-restricted
non selective CRF receptor antagonist astressin B (100 μg/kg, sc) and the fecal pellet output
(FPO) was determined every 15 min for an hour. The defecation score was expressed as
the number of pellets/hour/20g body weight. In Vivo colonic intraluminal pressure was
monitored using a pressure microtransducer (SPR-524, Millar system, Houston, TX) inserted
2cm in the distal colon. After a 15 min baseline, the motility index expressed as the area
under the curve (AUC) was measured for 1 hour in VIP KO (n=4) and WT (n=5) mice
placed in contention cages (restraint stress). Results: When exposed to novel environment
stress, VIP -/- and VIP -/+ mice showed a significant increase in FPO compared to WT (14.4
± 2.1, 9.4 ± 1.1 vs 4.6 ± 1.6 pellets/hour/20g bw, respectively; p<0.05, Unpaired t test).
The injection of astressin B (100 μg/kg, sc) 30 min before the session of novel environment
stress reduced the number of pellets expelled by WT over the period of 1h while it did not
affect the defecation in VIP -/- and VIP -/+ mice. Colonic motility under restraint stress
conditions measured for 1 h was highly increased in VIP -/- mice compared to WT (AUC
19103 ± 1743 vs 6415 ± 1485 respectively; p=0.01, Mann and Withney test). Conclusions:
The data show that mice deficient in VIP exhibit an exacerbated colonic motility and
defecation compared to WT in conditions of stress, suggesting that the VIPergic colonic
system may exert an inhibitory tone against stress-induced colonic activation. The potent
antagonist action of astressin B in WT but not in the VIP-/- mice response exposed to novelty
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stress suggests also that depletion of VIP and the subsequent colonic stimulation may override
the stress blocking action of astressin B in the VIP-/- mice. Supported by DK33061(Y.T.)
T1717
Ghrelin-Induced Contractions and Growth Hormone Secretagogue Receptor
Expression in the Chicken Gastrointestinal Tract
Takio Kitazawa, Hiroyuki Kaiya, Tetsuro Taneike
Background and aim. Ghrelin is the endogenous ligand for the growth hormone secretagogue
receptor (GHS-R), and stimulates food intake and gastrointestinal (GI) motility in mammals.
In chickens, on the other hand, ghrelin inhibits food intake. This discrepancy prompted us
to investigate whether ghrelin affects gastrointestinal motility in the chicken. Methods. The
contractile effect of chicken ghrelin was measured isometrically in muscle strips from different
regions of the GI tract suspended in an organ bath. The effect of chicken ghrelin was
compared with that of rat or human ghrelin. In addition, mRNA expression of ghrelin and
GHS-R was examined by quantitative RT-PCR. Results. Among the ghrelin peptides tested
(rat, human and chicken ghrelin), only chicken ghrelin caused contraction of muscle strips
from the GI tract. No effect was seen in des-octanoylated chicken ghrelin, suggesting that
octanoylation at Ser3 residue was essential for its activity. The contractile response to chicken
ghrelin in the crop was not affected by tetrodotoxin (TTX), but that in the proventriculus
was decreased by TTX and atropine to the same extent. D-Lys3-GHRP-6 (a GHS-R antagonist)
caused a transient contraction and inhibited the chicken ghrelin-induced contraction without
affecting the 50 mM high-K+-induced contraction. The amplitude of the chicken ghrelin-
induced contraction was different among GI regions: highest in the crop and colon (70%
of high- K+-induced contraction), moderate in the esophagus and proventriculus (30%),
and weak in the small intestine (10-20%) and the ranking order was consistent with GHS-
R mRNA expression in each region (colon > crop = esophagus > proventriculus > duodenum =
jejunum > ileum). GHS-R mRNA expression in the muscle preparations of crop and proven-
triculus without mucosa was 2 - 4 times higher than that in whole segments of crop and
proventriculus, indicating that the GHS-R is mainly expressed in smooth muscle layers
including enteric nerves. In contrast to the GHS-R expression, ghrelin mRNA was mainly
expressed in the mucosa of proventriculus and duodenum. Conclusion. These results indicate
that ghrelin stimulates GI contractility and preferentially affects the motor activity of eso-
phagus, crop and colon through myogenic and/or neurogenic mechanisms. These actions
are mediated through the GHS-R, which is highly sensitive to chicken ghrelin.
T1718
Effects of CP-464709, a Small Molecule Ghrelin Receptor Agonist, On Gastric
Emptying in the Rat
William Unsworth, Jill Darton, Karen A. Townson, Alan Wheeldon, Wendy J. Winchester,
Kevin Lee, Jason Witherington, Gareth J. Sanger
Recent observations have suggested a potential role for ghrelin in both food intake and the
control of gastrointestinal motility in several species. As exogenous administration of ghrelin
has been shown to accelerate gastric emptying in both rats and humans, the ghrelin receptor
has become an attractive target for pharmaceutical intervention. The aim of these studies
was to characterise the effect of CP-464709, a small molecule ghrelin receptor agonist, on
gastric emptying in conscious rats. Measurement of gastric emptying in the rat was achieved
via assessment of stomach contents at predetermined times following a 3ml intragastric
bolus administration of a methylcellulose-based nutrient meal. In the first study, CP-464709
was dosed at 0.1, 0.3 and 1 mg/kg s.c., 15 minutes prior to administration of the nutrient
meal, with the percentage of gastric emptying being assessed after 60 minutes. All doses
significantly accelerated gastric emptying with the maximally effective dose of CP-464709
being identified as 0.3 mg/kg: producing a 73% increase in the percentage of the nutrient
meal emptied (p<0.001, n=5-6/group). Increasing the pre-treatment time from 15 to 165
minutes still produced a significant enhancement of gastric emptying 60 minutes following
meal administration (46%, p<0.001, n=7/group). To investigate whether desensitisation can
be induced acutely, CP-464709 (3 mg/kg s.c.) was administered at 165 minutes, then at
90 minutes and finally at 15 minutes prior to administration of the nutrient meal. The
percentage of gastric emptying, 60 minutes after meal administration, was significantly
increased in rats receiving CP-464709 (76% increase, p<0.0001, n=7/group). In a final
study, the effect of CP-464709 (0.3 mg/kg s.c.) on the whole profile of gastric emptying in
the rat was investigated. Rats receiving CP-464709, 15 minutes prior to administration of
the nutrient meal, displayed significant increases in gastric emptying at 15, 30, 45, 60, 90
and 180 minutes following meal administration of 204%, 82%, 52%, 38%, 26% (all
p<0.0001) and 14% (p<0.01), respectively (n=8/group/timepoint). Our data show that
the ghrelin receptor agonist CP-464709 potently accelerates gastric emptying in the rat,
highlighting the opportunity for development of ghrelin receptor agonist compounds for
the treatment of gastrointestinal motility disorders.
T1719
Myogenic Basis for Peristalsis: Phosphorylation of Hsp20 (Serine 16) in
Colonic Smooth Muscle Cells May Modulate Sub-Cellular Localization of Pkcα
and Hsp27
Robert R. Gilmont, Sita Somara, Khalil N. Bitar
Background: In smooth muscle, cyclic nucleotide kinase (PKG or PKA)-mediated phos-
phorylation of HSP20 on serine 16 (ser16) is associated with relaxation, while PKC-mediated
phosphorylation of HSP27 is associated with contraction. Objective: To understand the
molecular myogenic basis of the response to divergent neuropeptides (Acetylcholine and
VIP) and to access the localization/translocation/activation of HSP20, HSP27 and PKCα in
colonic smooth muscle cells (CSMC) in response to these divergent neuropeptides. Methods:
1. Whole cell lysates from CSMC treated with vasoactive intestinal peptide (VIP) were
separated by Isoelectric focusing (IEF) to determine the level of HSP20 phosphorylation. 2.
Site directed mutations were created for ser16: 16 S/D: phosphomimic-HSP20 mutant and
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16 S/A: non-phospho-HSP20 mutant forms were produced and transfected into rabbit CSMC.
3. Lipid raft micro-domains were prepared by subjecting homogenized cultured CSMC to
buoyant density equilibrium centrifugation in a sucrose gradient. Results: 1. The physiolo-
gical relaxant neuropeptide, VIP (10-6 M) induced a robust rapid (by 5 min) and sustained
phosphorylation of HSP20. 2. The physiological contractile neurotransmitter, Ach (10-7 M)
induced (i) a rapid (30 sec) and sustained (4 min) translocation of HSP27 and of PKCα
into the caveolin-rich lipid raft microdomain fractions; and (ii) a rapid (30 sec) and sustained
(4 min) translocation of HSP20 out of the same fractions. 3. The profile of distribution of
HSP27 and PKCα in lipid raft fractions were different in CSMC transfected with either
phosphomimic (16 S/D) or non-phospho (16S/A) form of HSP20. Summary: Contraction-
induced by the physiological contractile neurotransmitter Ach is associated with simultaneous
translocation of HSP27 and PKCα into specific microdomains of the membrane and transloca-
tion of HSP20 out of the same lipid raft microdomains. VIP-induced relaxation is associated
with phosphorylation of HSP20. The phosphorylation status of HSP20 appears to affect the
distribution profile of both HSP27 and PKCα similarly in the lipid raft fractions. Conclusion:
The caveolin-rich lipid raft microdomain is an important dynamic docking/release hub for
specific molecules which modulate contraction (HSP27 and PKCα) and relaxation (HSP20)
of CSMC. The phosphorylation status of HSP20 appears to affect the translocation of both
PKCα and HSP27 and thus can be a major myogenic modulator of the response of individual
smooth muscle cells to signaling induced by either a contractile or relaxant neurotransmitter.
Supported by Grant NIH RO1 DK 042876
T1720
Substance P As a Novel Anti-Obesity Target
Iordanes Karagiannides, Daniel Espinoza, Daniel Torres, Yu-hua Tseng, Charalabos
Pothoulakis, Efi Kokkotou
Background and Aims: Substance P (SP) is an 11-amino acid peptide member of the
tachykinin family. SP has been previously shown to have proinflammatory effects in various
models of acute intestinal inflammation in rodents. Recently, we have demonstrated increased
expression of SP and its neurokinin-1 receptor (NK-1R) in the proximal mesenteric fat
depot of mice with TNBS-induced experimental colitis. The presence of NK-1R in isolated
adipocytes along with its inflammatory properties lead us to investigate a potential role of
SP in obesity, considered to represent a state of sub acute chronic inflammation. Methods:
We evaluated the metabolic effects of SP antagonism in a) lean mice fed a high fat diet, b)
obese mice due to high fat feeding and c) genetically obese mice due to leptin deficiency.
Mice were receiving daily injections of 150-600 mcg CJ 12,255 (CJ-Pfizer), an NK-1R
selective inhibitor, and their food consumption and weight were monitored daily for 1-2
weeks. In each cohort, a group of pair-fed to CJ treated mice was also included. Mouse fat
and lean mass were evaluated by DEXA scanning and insulin sensitivity by glucose and insulin
tolerance tests. Serum insulin and leptin levels were measured by EIA and hypothalamic
neuropeptide expression by real-time RT-PCR. Results: Lean mice treated with CJ for a week
lost 4% of their initial body weight, while vehicle-treated mice gained on average 7%
(p<0.05). Weight loss was due to a reduction in fat but not in lean mass, and was associated
with 50% lower serum leptin levels. CJ treated mice ate 25% less and had on average 60%
lower serum insulin levels, as well as improved insulin sensitivity. Likewise, CJ treatment
of obese mice resulted in 15% weight loss (p<0.01). CJ treatment was also effective in leptin
deficient mice, indicating that the SP effects on energy balance are, at least in part, leptin
independent. Conclusion: SP antagonism may represent a novel approach in preventing
weight gain and treating obesity.
T1721
Does the Preproghrelin-Derived Peptide, Obestatin, Regulate Food Intake in
Lean Or Obese Rodents?
Guillaume Gourcerol, Tamer Coskun, Libbey S. Craft, John P. Mayer, Mark L. Heiman,
Lixin Wang, Mulugeta Million, David H. St-pierre, Yvette Tache
BACKGROUND: Obestatin has been recently characterized as a new peptide derived from
the ghrelin precursor, which suppresses food intake and inhibits the orexigenic and prokinetic
actions of ghrelin when injected peripherally or centrally in mice (Science 2005;310:996-
999). However, reproducing these data remains conflictual. Reasons for the disparity may
be the use of different doses, routes and animal models. AIMS: To investigate the effects
of peripheral and central injection of obestatin on feeding, gastric motility and blood glucose
in rats as well as in diet-induced obese mice (DIO). METHODS: Food intake was quantified
after intraperitoneal (ip) injection of obestatin in non fasted rats at the dark feeding phase
(0.1 to 3 mg/kg) and DIO fasted mice (0.3 mg/kg). Gastric emptying of a semi-liquid caloric
meal was measured after obestatin in conscious rats (0.1 to 3 mg/kg, ip) and gastric phasic
motility was monitored in anesthetized fasted rats after intracisternal (0.1 mg/kg, ic) or
intravenous (0.3 to 3 mg/kg, iv) obestatin injection. Blood glucose was measured for 30
min after obestatin administration in anesthetized rats (3 mg/kg, iv, and 0.1 mg/kg, ic).
RESULTS: Obestatin injected ip up to 3 mg/kg did not decrease food intake for 3 h in rats
nor inhibit gastric emptying (p>0.05 vs. saline for each dose tested). Obestatin injected iv
up to 3 mg/kg and ic at 0.1 mg/kg did not modify fasted gastric phasic motility nor blood
glucose in anesthetized rats, while ghrelin (30μg/kg, iv) and vagotomy, respectively, increased
and suppressed gastric motility (+422% and -90.7% compared to saline, respectively;
p<0.05), and an oligosomatostatin analog (10 μg/kg, ic) decreased blood glucose at 30 min
(-30.8%; p<0.05). Obestatin injected ip (0.3 mg/kg) in DIO mice did not reduce feeding,
while urocortin 1 (10 μg/kg, ip) induced a 73.3% inhibition at 2 h. CONCLUSIONS: Our
data provide conclusive evidence that the newly discovered obestatin does not have biological
actions to influence food intake or gastric motor function in rats and obese mice. Supported
by NIH grants DK-33061, DK-41301, VA Career Scientist and Merit Awards, the French
Society of Gastroenterology, and the French Foreign Office (EGIDE Program).
T1722
Ghrelin Expression in Fundus Is Increased After Laparoscopic Adjustable
Gastric Banding in Obese Patients
Bernard Uzzan, Jean-marc Catheline, Christine Lagorce, Bakhtiar Bejou, Gheorge Airinei,
Cyriaque Bon, Regis Cohen, Jean-luc Fournier, Thomas Aparicio, Philippe Wind, Robert
Benamouzig
Ghrelin, a 28 amino-acid acylated orexigenic peptide mainly secreted by stomach (enteroen-
docrine cells of the oxyntic mucosa), is also present in hypothalamic arcuate nucleus which
is involved in the control of feeding behaviour. In man, serum concentration of ghrelin
increases during fasting and decreases after a meal. Ghrelin levels are low in obese patients;
A 5 % decrease in body weight results in an increase of ghrelin. We previously found a
statistically significant difference between a 23 % decrease in serum ghrelin after sleeve
gastrectomy in super-super-obese patients (body mass index or BMI > 60 kg/m2) and a 14
% increase after laparoscopic adjustable gastric banding (LAGB) (Cohen et al, Obes Surg
2005; 15: 1501-1502). Whether ghrelin is implied in weight loss after LAGB in obese patients
is still debated. Moreover, immunohistochemical (IHC) assessment of gastric expression of
ghrelin has been rarely performed in man. Methods: Fundic expression of ghrelin was
prospectively assessed by IHC using a rabbit anti-human ghrelin antibody (Phoenix Pharma-
ceuticals Inc, Belmont, CA, USA) simultaneously with its serum concentrations (RIA, Linco
Research, St-Charles, Missouri, USA) in 11 obese patients after an overnight fast (2 men, 9
women; mean age: 42 years; baseline BMI: 46 +/- 5 kg/m2; 6 with mild chronic gastritis;
4 with Helicobacter pylori), before LAGB and one year thereafter. Gastric IHC was performed
on deparaffinated slides using a Ventana automate. Immunostaining was blindly analysed
in triplicate by a single pathologist by measuring the density of stained fundic cells near
muscularis mucosa at x400, normalised to 1 mm2. Results: Ghrelin expression was always
identified, mainly on the inferior half of fundic glandular epithelial cells, predominating in
the cytoplasm of parietal cells. Immunostaining intensity was considered as moderate or
strong in 90 % of our cases. Mean density of stained fundic cells significantly increased (p
< 0.01, Wilcoxon test) one year after LAGB: 31/mm2 (21-38) vs 38/mm2 (27-57) before
surgery. This increase did not correlate with changes in BMI. Among the 9 patients studied,
there was no correlation between pre-or post-operative gastric expression of ghrelin or their
difference or ratio and the corresponding serum values. Conclusion: Our findings confirm
that fundic ghrelin assessed by IHC is intensely expressed in man. For the first time, we
show that this expression is significantly increased after LAGB, which seems to exclude a
pathogenetic role of ghrelin in weight loss after LAGB.
T1723
Obestatin and Ghrelin Receptor Mrnas Are Differentially Expressed in Human
Fat
Edward R. Seidel, Elizabeth Fontenot, James Devente
As was stated over 20 years ago, the gut is the largest endocrine organ in the body. The
gastrointestinal tract is the source of five named hormones and a large number of candidate
peptides whose range of functions and target tissues remain to be identified. By definition,
a gut peptide must be involved in digestion but may, in addition, have multiple effects
outside the gut. One of the potential extra-gastrointestinal target tissues is fat tissue. We
have employed qPCR in fat collected from adult women to identify receptor mRNA for a
number of gut peptides; we have examined the expression of receptors for the incretins,
GIP and GLP-1, the orexigenic peptides PYY-Y1 and -Y2 and ghrelin, and the anorexigenic
peptide obestatin in human omental fat. Five cohorts of women were examined: lean controls
(BMI < 23), obese (BMI > 41), obese diabetic and term pregnant women. Human fat expressed
receptor mRNAs for all six peptides. The PYY-Y1 receptor was expressed to high levels.
Indeed, RNA dilution experiments indicated that the PYY-Y1 receptor was expressed from
anywhere between 10 and 100 times that of the other receptors examined. Pregnant women
expressed roughly 3 times as much obestatin receptor than other women and less than half
as much ghrelin receptor. Both of these peptides regulate appetite and suggest the signal at
term pregnancy is to limit caloric intake. Obese women expressed lower levels of PYY-Y2
receptor material than didlean controls. These are the first data to suggest that human fat
may express receptor mRNA for the anorexigenic peptide obestatin. Thus it was of interest
to confirm that fat not only expressed the obestatin message but also translated that transcript
into obestatin receptor protein. An immunoblot employing an obestatin selective antibody
yielded a single band corresponding to the correct molecular weight (52kD) for the obestatin
receptor. Fluorescent immunohistochemistry of human fat employing the obestatin receptor
antibody indicated the obestatin receptor protein was localized to the adipocyte cell mem-
brane. In conclusion, receptor material in human omental fat for gut peptides involved in
the regulation of appetite are differentially expressed in both pregnancy and obesity suggesting
that these gut peptides may play in role in the regulation of fat metabolism.
T1724
The Expression of Elevated Levels of Ghrelin in Patients with Metastatic
Neuroendocrine Tumors Is Associated with An Orexigenic Effect That
Maintains Body Mass Index
Hank S. Wang, David Oh, Gordon V. Ohning, Joseph R. Pisegna
Purpose: Ghrelin, a potent orexigenic peptide, has been shown to be produced by neuroendo-
crine cells including neuroendocrine tumors (NETs). In non-neuroendocrine cancer cachexia,
it has been shown that cachexia can be overcome with administration of exogenous, but
not endogenous, ghrelin. In this study we sought to: a) establish serum ghrelin values for
the first time in a population of patients with NETs, and b) to evaluate the effect of hepatic
metastases on serum ghrelin. We hypothesized that the presence of hepatic metastases,
reflecting increased neuroendocrine cell tumor burden, would be associated with elevated
levels of ghrelin and an elevated body mass index. Methods: The study was conducted as
a single-center, prospective trial enrolling 35 patients with histologically and immunohistoch-
emically confirmed neuroendocrine tumors. All patients were evaluated for multiple clinical
parameters including cancer diagnosis and primary location, presence of hepatic metastasis,
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and multiple endocrine neoplasia type 1 status. Following an overnight fast, serum was
collected for measurement of total ghrelin and chromogranin A. Total ghrelin was measured
by radioimmunoassay. Statistical analysis was performed using a paired t test to assess for
differences between patients with and without hepatic metastases. Results: 17 patients with
hepatic metastases and 18 patients without hepatic metastases were well matched regarding
all clinical characteristics assessed including, subtype and primary location of neuroendocrine
tumors, and surgical/medical treatment history. Patients with hepatic metastases had statistic-
ally greater levels of serum ghrelin values compared to patients without hepatic metastases
(600 pg/ml vs 411 pg/ml, p<.05). These patients also had a greater mean body mass index
as compared to patients without hepatic metastases. Both groups had elevated levels of
ghrelin compared to the standard reference range for weight-matched controls. Conclusions:
We report that all 35 patients with NETs had elevated levels of ghrelin compared to the
standard reference range given for weight-matched healthy controls. Patients with increased
neuroendocrine cell tumor burden, manifested as hepatic metastases, had statistically greater
mean levels of ghrelin and greater mean body mass index compared to well matched controls.
This data supports the possibility that ghrelin is co-released from neuroendocrine tumors
and exerts an orexigenic effect in these patients, helping to maintain weight despite widely
disseminated disease.
T1725
Localization of Obestatin and Ghrelin in Gastrointestinal Tract and Pancreas
of Rats
Chun-mei Zhao, Marianne W. Furnes, Björn Stenström, Karin Tømmerås, Trine Skoglund,
Bård Kulseng, Duan Chen
Backgroud and aim: Both ghrelin and obestatin are derived from preproghrelin by posttransla-
tional processing. Ghrelin is known to have an appetite-stimulating effect, while obestatin
is claimed to antagonize the ghrelin effect. The aim of the present study was to localize the
cells that produce ghrelin and obestatin in rats. Methods: Adult male Sprague-Dawley rats
were freely fed, fasted or subjected to gastric bypass surgery. Tissue samples from the
gastrointestinal tract and pancreas were collected, and fixed in 4% formaldehyde (by either
immersion or perfusion). Double immuno-fluorescent-staining and immuno-electron micro-
scopy were used, and the planimetric analysis was performed. Results: Obestatin-immunore-
active cells were localized mainly in the stomach, and also found in the duodenum, jejunum,
colon, and pancreas. These cells seemed to be of the closed type in the stomach, but of the
open type in the intestine. In the stomach, they were distributed in the basal part of oxyntic
mucosa, and co-localized with preproghrelin, ghrelin, and chromogranin-A. Immuno-elec-
tron microscopy revealed the obestatin/ghrelin-producing cells to be the so-called A-like
cells, characterized by numerous high-electron dense granules in which ghrelin/obestatin
were found. The granules in the A-like cells exhibited even electron density with thin electron-
lucent halos, suggesting a place for monoamine. Indeed, vesicle monoamine transporter 2
was found in these cells. The monoamine was not histamine or serotonin, since neither
histidine decarboxylase nor serotonin was localized in the A-like cells. Starvation for 24 h
did not affect the A-like cells in terms of obestatin immuno-density and intensity, and of
the numerical and volume density of the granules. At 12 months after gastric bypass, the
serum levels of obestatin, but not ghrelin, were reduced, but the A-like cell density (by
pre-proghrelin, ghrelin, and obestatin immunostaining) was unchanged. In the pancreas,
obestatin was found in the peripheral part of the islets; distinct distribution from glucagon-
producing A cells but similar distribution with pancreatic polypeptide Y-producing cells.
Conclusions: Obestatin and ghrelin are co-localized in the gastric A-like cells, which may
contain an anticipated monoamine. The localization of obestatin in the pancreatic islet may
lead to the investigation of its role in the regulation of insulin release.
T1726
Substance P Induces Mesenteric Fat Proliferation Seen in Crohn's Disease
Through Pro-Proliferative and Anti-Apoptotic Pathways
Kara J. Gross, Iordanes Karagiannides, Hon wai Koon, Collin Bowe, Thomas Thomou,
Nino Giorgadze, James Kirkland, Charalabos Pothoulakis
Background and Objectives: It is becoming increasingly clear that white adipose tissue
(WAT) is actively involved in the regulation of immunity and inflammation, as well in the
pathogenesis of Inflammatory Bowel Disease (IBD), where fat hypertrophy, proliferation and
wrapping of the bowel (creeping fat) correlates significantly with the extent of transmural
inflammation. We recently showed that human mesenteric preadipocytes express a functional
high affinity, neurokinin-1 receptor (NK-1R) for the neuropeptide substance P (SP) that is
linked to proinflammatory pathways (Proc Natl Acad Sci U S A. 2006; 28;103:5207-12).
In the same study we also found that trinitrobenzene sulfonic acid-induced colitis in mice
was accompanied by increased expression of inflammatory cytokines as well as NK-1R in the
mesenteric fat, indicating that mesenteric depots may participate in intestinal inflammatory
responses via SP-NK-1R related pathways. Whether any neuropeptides, including SP, are
able to stimulate adipocyte proliferation is not known. In this study we examined the
hypothesis that SP directly enhances the proliferation of human mesenteric preadipocytes
by activating pro-proliferative and anti-apoptotic mechanisms. Methods: WAT tissue was
resected from subjects during gastric bypass surgery and pure mesenteric preadipocytes
were isolated. MTS, BrdU, and TUNEL assays, as well as Western blot analyses were used
to delineate pro-proliferative and anti-apoptotic pathways. Results: SP (10-7M) significantly
increased mesenteric preadipocyte cell viability (MTS assay), and proliferation (BrdU assay)
(1.7 fold), and time-dependently (15-30 min), induced Akt, EGF, alpha5-beta3 integrin and
PKC theta phosphorylation (Western blot analyses). The extrinsic apoptotic pathway is
initiated by engagement of cell surface death receptors. Fas is a well-known initiator of this
pathway when occupied by its ligand Fas (FasL). We found that exposure of FasL (100 uM)
to human mesenteric preadipocytes induced nuclear DNA fragmentation, as evaluated by
TUNEL assay, while co-treatment with SP significantly reduced the number of apoptotic
cells. Conclusions: These are the first results to indicate that SP may participate in the
changes of abdominal fat seen in IBD patients by enhancing the proliferation of mesenteric
preadipocytes. We speculate that SP-induced pro-proliferative and anti-apoptotic pathways
in fat depots might contribute to the creeping fat phenotype, and thus the inflammation,
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characteristic of Crohn's Disease. Supported by a F32 grant (KG), and RO1 DK47343 (CP)
from the National Institutes of Health.
T1727
Glucagon-Like Peptide-2 Activates β-Catenin Signaling in Mouse Intestinal
Crypt Through the Insulin-Like Growth Factor-1 Pathway
Philip E. Dubé, Katherine J. Rowland, Patricia L. Brubaker
INTRODUCTION: Glucagon-like peptide-2 (GLP-2) is a gut hormone that induces intestinal
growth. We have recently shown that insulin-like growth factor-1 (IGF-1) is necessary for
GLP-2-induced crypt cell proliferation in mice. We now hypothesize that GLP-2 induces
the specific growth signaling pathways, protein kinase B/Akt (Akt) and β-catenin, through
an IGF-1-dependent mechanism, and have tested this hypothesis using both IGF-1 receptor
(IGF-1R) inhibition and the IGF-1 null mouse (Igf1-/-). METHODS: Fasted wildtype and
Igf1-/- mice were administered saline, GLP-2 (50 µg/kg) or IGF-1 (500 µg/kg), i.p., with or
without prior IGF-1R inhibition, and were sacrificed 0.5-1.5h later. The jejunum was analysed
by western blot or immunohistochemistry for Akt phosphorylation and β-catenin localization,
respectively. mRNA for the β-catenin target gene, c-myc, was quantified by realtime RT-
PCR. RESULTS: GLP-2 and IGF-1 induced a 110±50% and 310±120% increase in Akt
phosphorylation, respectively, vs saline (P<.05), indicative of active Akt signaling. IGF-1R
inhibition had no effect on Akt phosphorylation in mice treated with GLP-2 (160±65%
above basal, P<.05) but abrogated the effect of IGF-1 (126±90% above basal, P>.05).
Furthermore, the effects of GLP-2 and IGF-1 on Akt were retained in Igf1-/- mice, with
160±40% (P<.05) and 570±100% (P<.01) increases in phosphorylation compared to saline,
respectively. Therefore, in order to identify a specific marker of GLP-2 and IGF-1 signaling,
β-catenin was immunolocalized in non-paneth intestinal crypt cells. In wildtype mice,
1.7±0.1 cells/crypt displayed intense β-catenin nuclear localization, indicative of active β-
catenin signaling. This was increased by GLP-2 by 88±11% (3.2±0.2 cells/crypt, P<.001).
Furthermore, GLP-2 increased mRNA levels of c-myc by 87±18% (P<.01) vs saline. IGF-
1R inhibition did not affect β-catenin localization in saline-treated mice (1.7±0.1 cells/crypt),
but prevented nuclear translocation in response to GLP-2 (2.0±0.2 cells, P>.05). Importantly,
GLP-2 did not affect β-catenin localization in Igf1-/- mice compared to saline (2.3±0.1 vs
2.1±0.1 cells/crypt), although IGF-1 treatment retained a significant effect in Igf1-/- mice
(3.8±0.1 cells, P<.001). CONCLUSION: We have identified a novel effect of GLP-2 on β-
catenin signaling in the mouse intestinal crypt and shown its dependency on IGF-1. These
findings provide further evidence that GLP-2-induced intestinal growth requires IGF-1. In
contrast, GLP-2 activated Akt signaling in an IGF-independent manner, suggesting the
existence of multiple mechanisms through which GLP-2 affects the intestine.
T1728
Isolation and Culture of Gastric Chief Cells Are Accompanied By Proliferation
and Co-Expression of Intrinsic Factor and Tff2
Songhua Zhang, Kimihito Tashima, Regina Ragasa, James R. Goldenring, Susan J. Hagen
Chronic Helicobacter pylori (HP) infection leads to gastric atrophy and the emergence of
trefoil factor family 2/spasmolytic polypeptide (TFF2)-expressing metaplastic cells (SPEM)
that occupy fundic glands in both human and mouse stomach. Many of the SPEM cells are
also intrinsic factor (IF) positive, suggesting that they transdifferentiate from a chief cell
lineage. Under this hypothesis, SPEM should derive from an IF positive chief cell population
that becomes proliferative in the absence of parietal cells. Here we show that isolated chief
cells in culture proliferate and contain dual TFF2/IF markers. Methods: Isolated chief
cells from the rat stomach were purified by centrifugal elutriation and density gradient
centrifugation and were then cultured on collagen coated dishes. To block cell proliferation,
1-10 mM hydroxyurea was added to the culture medium. The cells were fixed at 24, 36,
48, 72 and 96 hr after plating and multi-label immunofluorescence staining was performed
to localize Ki67, IF, and TFF2. In immunostaining experiments, cell number was determined
by using propidium iodide for the nucleus and actin to stain cell boundaries. In culture,
cell number was determined by the crystal violet assay. Results: Immediately after plating,
isolated chief cells covered the entire dish but by 24 hr, only a small number of isolated
chief cells remained attached. By 36-48 hr after plating, approximately 40% of the cells
were actively proliferating and all (>98%) were IF positive cells. Among all of the proliferating
cells, 80.8% were also TFF2 positive. The cell number increased accordingly. Proliferation
was significantly inhibited by hydroxyurea (P<0.05) as was the expansion of cell numbers.
By 72-96 hr, the cells were confluent and no more than 2% were positive for proliferation
markers. In confluent chief cell cultures, approximately 99% of cells were positive for IF,
among which TFF2/SPEM and IF co-localized in 16% of the cells. The remaining cells
in culture mainly consisted of parietal cells (0.23%) and surface mucous cells (0.74%).
Conclusions: Our data demonstrate that it is possible to culture a population of isolated
gastric chief cells that proliferate and express both TFF2 and IF in the absence of trophic
factors liberated by parietal cells. Our data support a model for the derivation of SPEM from
transdifferentiation of chief cells into proliferative cells dually expressing IF and TFF2.
T1729
Hypergastrinaemia and Hypochlorhydria Render Gastric Corpus Epithelial
Cells More Susceptible to DNA Damage-Induced Apoptosis In Vivo
Sabine M. Przemeck, Andrea Varro, Amy Osawa, Timothy C. Wang, D. M. Pritchard
Background and Aims: Plasma concentrations of the gastric antral hormone gastrin are
elevated by Helicobacter pylori infection and by gastric atrophy. Gastrin and hypopchlorhydria
act as cofactors during gastric carcinogenesis and both hypergastrinaemic transgenic INS-
GAS mice and hypochlorhydric gastrin-knockout mice are prone to developing gastric
adenocarcinoma. We hypothesised that the increased risk of gastric carcinogenesis observed
in these animals might result from altered susceptibility of gastric epithelial cells to undergo
apoptosis. Methods: Apoptosis was assessed using morphological criteria on a cell positional
basis in tissue sections prepared from the gastric antrum and corpus of 10-12 week old
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conventionally housed INS-GAS mice, gastrin-knockout mice, mice overexpressing progas-
trin (hGAS) or glycine-extended gastrin (MTI/G-Gly) and their wild-type counterparts (FVB/
N), 6h and 48h after 12Gy γ-radiation. Hypergastrinaemia and hypochlorhydria were induced
in wild-type mice using the proton pump inhibitor omeprazole and signalling pathways
were investigated using the CCK-2 receptor antagonist YM022. Results: Gastric corpus
apoptosis was significantly increased in hypergastrinaemic INS-GAS and omeprazole-treated
FVB/N mice 48h after 12Gy γ-radiation, and in both cases the effects were inhibited by
YM022. Gastric corpus apoptosis was significantly increased in gastrin-knockout mice 6h
after 12 Gy γ-radiation. This effect was not reversed by treatment of gastrin-knockout mice
with antibiotics to reduce gastric bacterial colonisation or by short term treatment with
gastrin for 2 days. Similar increases in corpus epithelial apoptosis were demonstrated 6h
following 12 Gy γ-radiation in hypochlorhydric omeprazole-treated FVB/N mice and these
effects were not inhibited by YM022. No altered susceptibility to γ-radiation-induced gastric
epithelial apoptosis was observed in mice overexpressing progastrin or glycine-extended
gastrin. Conclusions: (1) Increased susceptibility to γ-radiation-induced apoptosis was
observed in the gastric corpus epithelia of INS-GAS and gastrin-knockout mice, but the
timecourses of these responses were different. (2) The effects on apoptosis observed in INS-
GAS mice were specifically caused by hypergastrinaemia and the effects observed in gastrin-
knockout mice resulted from hypochlorhydria. (3) Altered susceptibility to apoptosis may
be one factor predisposing to gastric carcinogenesis in INS-GAS and gastrin-knockout mice.
(4) The non-amidated precursors of gastrin do not modulate the susceptibility of gastric
epithelial cells to undergo apoptosis.
T1730
Coordinate Adenylyl Cyclase Isoform Regulation in Colon Epithelial Cell
Differentiation
Lillian J. Choi, Gabriela Jenikova, Elaine Hanson, Lars Eckmann
Background: The colonic epithelium is in a dynamic state, with proliferation in the crypts
balanced by apoptotic cell death at the surface. Cyclic AMP, induced by agonists such as
PGE2 and cholera toxin, exerts anti-apoptotic effects in colon epithelial cells. For normal
apoptosis to occur, this function needs to be downregulated. Accordingly, agonist-induced
cAMP production was shown to be attenuated in differentiated cells. The aim of this study
is to define the underlying mechanisms of differentiation-associated cAMP downregulation.
Methods: T84 human colon epithelial cells, undifferentiated or after butyrate-induced differ-
entiation (10 mM, 48 h), were stimulated with PGE2, cholera toxin (CTX), or forskolin.
cAMP levels were measured by enzyme immunoassay. Expression of the nine known adenylyl
cyclase (AC) isoforms, stimulatory G protein (Gs), and the four known PGE2 receptors,
EP1-4, was assayed by RT-PCR. Stable transfectants of AC6, and appropriate empty vector
controls, were generated by transfection and antibiotic selection. Results: cAMP production
was 5-fold decreased after PGE2 or CTX stimulation of butyrate-treated T84 cells, which
was accompanied by 5- to 10-fold downregulation of AC3, AC4, AC6, and AC7, isoforms
of the critical rate-limiting enzyme involved in cAMP synthesis. Galpha s, which couples
different receptors to AC activation, was also decreased by >5-fold. Expression of the
predominant epithelial PGE2 receptors, EP2 and EP4, and AC9 was not altered, while AC1,
AC2, AC5, and AC8 were expressed at only low levels or not at all. Constitutive transgenic
expression of the most abundant AC isoform, AC6, in stable transfectants increased agonist-
stimulated cAMP production by 10-fold in differentiated cells. Conclusions: Colon epithelial
cells express a distinct profile of AC isoforms, several of which are differentially downregulated
upon differentiation. AC downregulation is functionally significant for attenuating cAMP
production, since it can be overcome by transgenic AC overexpression. These results suggest
that AC isoform downregulation is an integral part of the normal differentiation program
in the intestinal epithelium, and might serve to release cells from cAMP-dependent anti-
apoptosis as a prerequisite for normal cell death in terminally differentiated cells.
T1731
Effects of Protein On Glycemic and Incretin Responses, and Gastric Emptying,
After Oral Glucose in Healthy Subjects
Angela Karamanlis, Reawika Chaikomin, Selena Doran, Max Bellon, Dylan
Bartholomeusz, Judith Wishart, Karen L. Jones, Michael Horowitz, Chris Rayner
Dietary interventions represent a promising therapeutic strategy to minimize postprandial
glycemic excursions in type 2 diabetes. The addition of protein to oral glucose has been
reported to improve the glycemic profile. The purpose of this study was to evaluate the
mechanisms by which protein lowers blood glucose concentrations after oral glucose. 9
healthy males were each studied on three separate days, in random order. After an overnight
fast, subjects consumed 300 mL drinks containing either 50 g glucose (“glucose”), 30 g
gelatin (“protein”), or 50 g glucose with 30 g gelatin (“glucose + protein”) in water, each
labeled with 150 mg 13C-acetate. Blood and breath samples were collected subsequently
for 3 hours for insulin, GLP-1, GIP assays and gastric emptying measurement (data are
mean ± SEM). The blood glucose response was less after “glucose + protein” than “glucose”
(P < 0.005), with no differences in plasma insulin or GLP-1, and lower GIP (P < 0.005).
“Protein” alone stimulated insulin, GLP-1, and GIP (P < 0.05 for each), without elevating
blood glucose. The gastric half-emptying time was greater after “glucose + protein” (51.2 ±
1.4 min) than “glucose” (45.6 ± 1.3 min) (P < 0.05), and tended to be greater for “glucose”
than “protein” (42.1 ± 1.3 min) (P = 0.06). We conclude that, in healthy subjects, the
addition of protein decreases the glycemic response to oral glucose acutely, predominantly
by slowing gastric emptying, although protein also stimulates incretin hormone, and non-
glucose-dependent insulin release.
T1732
Transient, Early Release of Glucagon-Like Peptide-1 During Low Rates of
Intraduodenal Glucose Delivery
Paul Kuo, Reawika Chaikomin, Amelia Pilichiewicz, Deirdre G. O'donovan, Judith
Wishart, James H. Meyer, Karen L. Jones, Christine Feinle-bisset, Michael Horowitz,
Chris Rayner
The “incretin” hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insu-
linotropic polypeptide (GIP) account for some 50% of the stimulation of insulin by oral
glucose, but the determinants of their secretion from the small intestine are poorly understood.
Cells releasing GIP (K cells) are localized to the proximal small intestine, while GLP-1
releasing cells (L cells) predominate in the distal gut. In contrast to the load-dependent
release of GIP, which occurs in response to glucose loads <1 kcal/min, it has been suggested
that a threshold rate of duodenal glucose delivery (~1.4 kcal/min) exists, below which no
stimulation of GLP-1 occurs (Schirra J, J Clin Invest 1996). Our aim was to compile data
on GLP-1 concentrations during intraduodenal (ID) glucose infusion below this threshold,
since we had observed an early, transient peak in GLP-1 under these conditions. We included
all studies in our laboratory involving healthy humans administered ID glucose at 1 kcal/
min for at least 120 min after an overnight fast. Data are mean±SEM. GLP-1 and GIP
concentrations were available for 27 subjects (24 male; age 36±3 years; BMI 25.2±0.7 kg/
m2) studied over 4 years. 9 subjects had also been studied during ID saline infusion. During
ID glucose infusion at 1 kcal/min, plasma GLP-1 increased at 15 and 30 minutes (*P<0.001
for both) and returned to baseline thereafter; GLP-1 declined slightly over time during saline
infusion (P<0.005). By contrast, GIP increased to a plateau with ID glucose (P<0.001). We
conclude that there is early, transient stimulation of GLP-1 by glucose loads thought to be
“sub-threshold”. Studies are indicated to determine the mechanism of this effect, which
could involve rapid initial transit to jejunal L cells, or a duodeno-jejunoileal loop.
T1733
Effects of MID-Jejunal Compared to Duodenal Glucose Infusion On Gut
Hormone Release and Appetite
Reawika Chaikomin, Keng-liang Wu, Selena Doran, James H. Meyer, Karen L. Jones,
Michael Horowitz, Chris Rayner
Small intestinal exposure to glucose releases hormones including cholecystokinin (CCK),
and the “incretins” glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP),
which modulate appetite and glycemia. Enteroendocrine cells containing GIP and CCK
predominate in the upper small intestine, and those containing GLP-1 are located more
distally. The purpose of the study was to determine whether the hormonal, glycemic and
appetite responses to enteral glucose are dependent on the site of glucose delivery. 10 healthy
males were each studied on two days, in random order. After an overnight fast, a multilumen
catheter was positioned with one infusion channel terminating 15 cm beyond the pylorus
(“duodenal”), and a second terminating 100 cm beyond (“mid-jejunal”). On one day, glucose
(5%) was infused into the duodenum (1 kcal/min) while saline (0.9%) was infused into the
mid-jejunum, both at 5 mL/min, for 90 minutes. On the other day, the sites of infusion
were reversed. Blood was sampled for glucose, insulin, GLP-1, GIP, and CCK, and sensations
of hunger were scored using 100 mm visual analog scales. At 90 minutes, the tube was
removed and energy intake from a buffet meal was measured. Data are mean ± SEM. The
stimulation of CCK (incremental area under the curve) and suppression of hunger were
greater (P<0.05 for each), and energy intake less (1252±97 v 1413±62 kcal, P=0.05), with
duodenal compared with mid-jejunal glucose infusion. There were no differences in blood
glucose, GIP, or insulin responses, and there was minimal GLP-1 increment on either day.
We conclude that there is substantial regional variation in CCK, but not incretin hormone
release, in the upper small intestine, and that modest differences in the intestinal site of
glucose exposure affect appetite and energy intake.
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T1734
Serotonin 2c and 2b Receptor Stimulation Controls Ghrelin Secretion from the
Stomach
Hiroshi Takeda, Takehiko Katsurada, Koichi Nagai, Tatsuya Ohkawara, Tomohisa Hattori,
Masahiro Asaka
Background and aim: We previously reported that the administration of cisplatin (CDDP)
caused a decrease in the plasma acylated ghrelin level (AGA 2006). It is known that
administering CDDP releases a large amount of serotonin from EC cells, and serotonin
exerts a great influence on the function of the digestive tract. Therefore, we examined the
involvement of serotonin receptor activation in changes in food intake and the decrease of
plasma acylated ghrelin level in CDDP-treated rats. Methods: Cisplatin, serotonin and sero-
tonin receptor agonists (BW723C86, mCPP) were administered intraperitoneally to male
SD rats after fasting for 24 hours. The plasma level of acylated or desacyl ghrelin was
measured by ELISA. The content of ghrelin in the gastric mucosa was also determined.
Serotonin 2B receptor antagonist (SB215505) and serotonin 2C receptor antagonist
(SB242084HCl) were given 30 minutes before the administration of serotonin receptor
agonist or CDDP. The influence of serotonin 2B and 2C receptor antagonists on anorexia
induced by the administration of CDDP was examined. Results: Plasma acylated ghrelin
decreased significantly after the administration of CDDP or serotonin. In addition, the
administration of serotonin 2B receptor agonist or serotonin 2C receptor agonist significantly
decreased the plasma acylated ghrelin level. In contrast, both agonists significantly increased
the content of acylated ghrelin in the stomach mucosa. The decrease of the plasma acylated
ghrelin level after stimulation with serotonin 2B or serotonin 2C receptor was abolished by
administering each antagonist. The decrease in the plasma ghrelin level after CDDP treatment
was not influenced by the administration of serotonin 2C receptor antagonist, SB24084HCl,
but not serotonin 2B receptor antagonist, SB215505. In addition, CDDP-induced decrease
in the amount of food intake was improved by administering serotonin 2B receptor antagonist,
SB215505. Conclusions: From these results, it is suggested that serotonin negatively regulates
the plasma level of acylated ghrelin, and this effect involves the activation of both serotonin
2B and serotonin 2C receptors. Moreover, it was suggested that activation of the serotonin
2B receptor was involved in anorexia and the decreased plasma level of acylated ghrelin
after CDDP treatment.
Effects on plasma, gastric acylated ghrelin and food intake in serotonin 2B receptor agonist
treated rats
* and **: P < 0.05 and 0.01 vs control by Student's t-test, The mean ± S.E. of 5-8 rats
T1735
Orexins Control Intestinal Glucose Absorption By Targeting Neuronal,
Endocrine and Epithelial Cells
Robert Ducroc, Thierry Voisin, Adlil El firar, Marc Laburthe
Orexin-A and orexin-B are hypothalamic neuropeptides that promote their effects (i.e. control
of feeding, sleep, awakeness, and neuroendocrine homeostasis) through interaction with G
protein-coupled receptors, OX1R or OX2R. Their effect on peripheral glucose transport is
unknown. We investigated the effect of orexin A (OxA) and orexin B (OxB) on intestinal
glucose transport in the rat. I.p. injection of OxA or OxB decreased blood glucose levels in
oral glucose tolerance tests. Effects of orexins on glucose entry were analysed in Ussing
chamber using Na+-dependent increase in short-circuit current (Isc) to quantify jejunal
glucose transport. The rapid and marked increase in Isc induced by luminal glucose was
inhibited by serosal addition of 10 nM OxA or OxB applied two minutes before glucose
challenge (53% and 59% inhibition respectively). Concentration-response curves for OxA
and OxB were not significantly different with maximum inhibition observed at 100 nM and
IC50 at 0.9 and 0.4 nM, respectively. OxA-induced inhibition was found to be in part
sensitive to the neuronal blocker TTX, and also was blocked by CCK2-receptor antagonist,
indicating involvement of a neuronal pathway and also of endocrine CCK-releasing cells.
In addition, the OX1R antagonist SB334867 induced a significant shift to the right of the
dose-effect curve to OxB but not to OxA. The pathway activated by OxB was found to be
insensitive to TTX or to CCK-receptor antagonists, suggesting that OxB can act directly
through OX1R on enterocyte. These data delineate a new function for orexins in the control
of intestinal glucose absorption. They provide a rational basis for orexin-induced short-term
regulation of glucose transport and control of energy homeostasis.
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T1736
Class III PI3K Hvps34 Upregulates cAMP-Mediated Neurotensin Secretion in
the Human Endocrine Cell Line Bon
Jing Li, Emily E. Bayne, Tianyan Gao, Qingsong Cai, Courtney M. Townsend, jr., B. mark
Evers
The phosphatidylinositol 3-kinases (PI3Ks) are grouped into three classes: class I proteins
regulate glucose homeostasis and cell growth, class II regulates membrane trafficking and
the yeast class III PI3K, Vps34, is required for vesicle trafficking. Neurotensin (NT), a gut
peptide localized predominantly to the small bowel, stimulates growth of normal gut mucosa
and certain GI cancers. We have shown that PKA is important for cAMP-stimulated NT
secretion from a novel human endocrine cell line, BON. The purpose of this study was to
define the possible role of PI3K, which acts in concert with PKA for certain biologic processes,
on cAMP-mediated NT secretion. METHODS. (i) To determine the involvement of the PI3K
pathway, cells were stimulated with forskolin (FSK), an agent that increases cAMP levels
and therefore activates PKA, in the presence or absence of PI3K inhibitors, wortmannin or
LY294002, both of which inhibit class I and class III PI3K. Medium was collected and NT
secretion measured; (ii) RT-PCR was performed to detect PI3K subunit expression; (iii) to
delineate the role of PI3K subunits, BON cells were transfected with class I PI3K subunits
(110α, δ, p85α and p55α) as well as human class III PI3K, hVps34, and NT secretion
measured. RESULTS. (i) FSK-stimulated NT secretion was inhibited by both wortmannin
and LY294002, suggesting that class I and/or class III PI3Ks are involved. (ii) Expression
of class I subunits p110α, β, δ, p85 (α and β), p55 (α and β) and p101 but not p110γ
was detected; expression of class II (α and β) and class III (hVps34 and p150) subunits
were also identified. (iii) Overexpression of class I subunits did not affect FSK-stimulated
NT secretion. Surprisingly, the overexpression of the class III PI3K, hVps34, significantly
increased FSK-stimulated NT secretion, demonstrating the role of class III PI3K in cAMP-
mediated NT release. Furthermore, hVps34-stimulated NT release was attenuated by wort-
mannin and LY294002 and the PKA inhibitor H89, suggesting that PI3K activation of hVps34
is PKA-dependent. Finally, PGE2, a physiological agent which acts via PKA, enhanced NT
secretion in BON cells overexpressing hVps34, confirming the role of hVps34 in cAMP-
stimulated NT secretion. CONCLUSIONS. We demonstrate the role of the class III PI3K,
hVps34, in cAMP-regulated NT secretion. Furthermore, we show that the effect of hVps34
is PKA-dependent. Since both PKA and PI3K are crucial mediators for many biologic
functions, our findings suggest that the cAMP/PKA/Class III PI3K (hVps34) interaction may
represent an important and novel signaling pathway in the regulation of gut hormone release.
T1737
Multi-Track Signaling from Ang II Receptor and EGFR to ERK in Intestinal
Epithelial Cells: Roles of Pyk2, Src, and Pkc
Steven S. Wu, Enrique Rozengurt
Transactivation of the epidermal growth factor receptor (EGFR) has proven to be an important
mechanism in the cellular differentiation, growth and proliferation, in particular via activation
of the ERK1/2 members of the mitogen-activated protein kinase family. However, the mechan-
isms are complex and have not been defined. The aim of this study was to examine the
mechanisms of angiotensin II (Ang II)-induced activation of the ERK cascade in intestinal
epithelial cells, and particularly the roles of EGFR kinase, Pyk2, and PKC. Methods: Phos-
phorylation of activated Pyk2 and ERK was measured by immunoprecipitation and Western
blotting with phosphospecific antibodies. IEC-18 intestinal epithelial cells were stimulated
with Ang II, epithelial growth factor (EGF), or the protein kinase C (PKC) agonist phorbol
dibutyrate; selected cells were also preincubated with inhibitors of PKC, Src, or Ca2+
signaling. Pyk2 protein expression was specifically downregulated by transfection with small
interfering RNA. Results: Ang II stimulated ERK phosphorylation by 50 to 100-fold over
baseline, with a peak at 2.5 min, decreasing to half-maximal by 5-6 min. Either the EGFR
kinase inhibitor AG1478, or the Src inhibitor PP2, partially inhibited ERK phosphorylation
at 2.5 min; neither the PKC inhibitor Ro nor inhibition/depletion of Ca2+ release (Th/EGTA)
affected peak ERK phosphorylation. However, the combination of AG1478 and either Ro
or Th/EGTA significantly blocks ERK, as does the combination of PP2 with Ro or Th/EGTA.
When kinetics of ERK phosphorylation were examined, AG1478 completely blocked ERK
at later times (>5 min), while Ro-318820 inhibited primarily early ERK phosphorylation
(<2.5 min). If both AG1478 and Ro were used, ERK was inhibited at all times. PP2 decreased
ERK phosphorylation at both early and later times. When Pyk2 expression was downregulated
by siRNA, Ang II-induced ERK activation was partially decreased; it was further decreased
by the addition of AG1478 or PP2. However, Pyk2 knockdown did not affect ERK phos-
phorylation following direct activation of PKC. Conclusion: These results suggest that activa-
tion of the ERK cascade in response to Ang II occurs via distinct and complementary]
pathways in intestinal epithelial cells. One pathway involves EGFR transactivation, Src, and
to some degree Pyk2, and acts at earlier time points following GPCR stimulation, while
another pathway operates via PKC at later time points, and independently of Pyk2. This better
defines the mechanisms involved in growth-related signaling in the intestinal epithelium.
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T1738
Novel Association Between C-Type Natriuretic Peptide Receptor and Ahnak in
the Stomach
Abdel A. Alli, Dayami Lopez, William R. Gower
Background: Recently, we identified the expression of C- type natriuretic peptide receptor
(NPR-C) in epithelial cells derived from normal rat gastric mucosa (RGM1). NPR-C has
been reported to be coupled to the activation of phospholipase C through heterotrimeric
G proteins. Recent evidence suggests that AHNAK (desmoyokin) binds to and activates
phospholipase C-γ1 and is expressed in barrier tissues. Aim: To examine the expression of
AHNAK in gastric mucosa and to investigate the potential molecular interaction between
NPR-C and the giant phosphoprotein AHNAK in RGM1 cells. Methods: A polyclonal antibody
that recognizes a specific C-terminus sequence of NPR-C was used to immunoprecipate
potential NPR-C associated proteins. Coomassie blue staining was performed after Sodium
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Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS PAGE) to allow for sequence
analysis of the visualized protein bands by mass spectrometry. Co-immunoprecipitation
analysis using antibodies against NPR-C and AHNAK, and Far western analysis using rat
recombinant NPR-C GST fusion protein was performed to confirm the association of the
two proteins In Vitro. Immunohistochemistry was performed using AHNAK-C2 antibody
directed against the C-terminal region of AHNAK and AHNAK-KIS antibody directed against
the internal repeating units of AHNAK. NPR-C and AHNAK constructs were produced by
subcloning the desired coding sequence into Mammalian Two Hybrid expression vectors.
Constructs were verified by restriction digestion and DNA sequencing. In Vivo interaction
was confirmed by the Mammalian two hybrid dual luciferase assay system. Results: The
interaction between NPR-C and AHNAK was first observed by immunoprecipitation studies
and was then corroborated by mass spectroscopy analysis. Recombinant NPR-C GST fusion
protein bound to AHNAK in Far western analysis. Immunoreactive AHNAK was detected
in cytoplasm and plasma membrane of RGM1 cells and surface epithelial cells in human
organ donor stomach tissues. Conclusions: AHNAK is expressed in gastric surface epithelial
cells. NPR-C interacts with AHNAK in RGM1 cells. The association of NPR-C with AHNAK
may be an alternative means of activating phospholipase C in RGM1 cells. The interaction
between NPR-C and AHNAK suggests a new role for natriuretic peptides in gastric mucosal
epithelial cells mediated by NPR-C signaling.
T1739
Glucagon-Like Peptide-2 (GLP-2) Activates the Mtor Signaling Through a Pi3-
Kinase-Akt- Dependent Pathway
Xiaojie Li, Defa Li, Yi Wang, Shiyang Qiao, Benny Chang, Douglas Burrin, Lawrence
Chan, Xinfu Guan
GLP-2 is a nutrient-responsive enterotrophic neuropeptide that exerts diverse actions in the
gastrointestinal tract including enhancing mucosal cell survival and proliferation, inducing
mucosal blood flow and anabolic metabolism, and suppressing gastric motility and secretion.
GLP-2-stimulated mucosal growth occurred In Vivo with an increased rate of protein synthesis
in the neonatal intestine, which was associated with up-regulated phosphorylation of Akt
kinase and endothelial nitric oxide synthase (eNOS). GLP-2 receptor (GLP-2R, a G protein-
coupled receptor) is co-localized with eNOS in enteric neurons. Increasing evidence indicates
that protein translation and cell proliferation are mainly controlled by the mammalian target
of rapamycin (mTOR) signaling pathway. Thus, we hypothesized that GLP-2R activation
intracellularly stimulates the mTOR signaling through a phosphatidylinositol 3 (PI3)-kinase-
Akt pathway. Our aim was to establish whether GLP-2R activation induces mTOR phos-
phorylation through the PI3-Akt-dependent pathway. The HEK 293 cells transfected transi-
ently with full-length cDNAs of human GLP-2R and eNOS were treated with human GLP-
2 (20 nM) with/without pre-treatment of a PI3-kinase inhibitor (LY294002, 50 μM). Results
show that [1] GLP-2 stimulated Akt phosphorylation at Ser473 (+42%) and Thr308 (+42%),
which was suppressed by the inhibitor by 60% and 30%, respectively. [2] GLP-2 stimulated
eNOS phosphorylation at Ser1177 (+21%) and Ser633 (+55%), which was suppressed by
the inhibitor by 42% and 10%, respectively. [3] GLP-2 stimulated mTOR phosphorylation
at Ser2448 (+25%), thus activating p70S6 kinase and inactivating the elF4E inhibitor (4E-
BP1) by inducing phosphorylation of p70S6 kinase at Thr389 (+28%) and hyperphosphoryl-
ation of 4E-BP1 at Thr37/46 (+20%), which was suppressed by the inhibitor by 35% and
20%, respectively. We concluded that GLP-2R activation stimulated the mTOR signaling
pathway and was partially mediated by the PI3-kinase-Akt signaling pathway. The study
suggests that GLP-2 stimulate the mTOR-controlled protein synthesis in GLP-2R-expressed
cells, which indirectly mediates GLP-2-stimulated anabolic and tropic actions in the gut.
(Supported by NIH/NIDDK DK075489-01 and USDA/ARS 25337667381).
T1740
Bitter Stimuli Induce ERK Activation in Enteroendocrine STC-1 Cells
Monica C. Chen, Enrique Rozengurt
Background: Molecular sensing by gastrointestinal (GI) cells plays a critical role in the control
of multiple fundamental functions in digestion and also initiates hormonal and/or neural
pathways leading to the regulation of caloric intake, pancreatic insulin secretion, and metabol-
ism. Our previous studies showed that the enteroendocrine STC-1 cells express multiple bitter
taste receptors, including receptors for denatonium benzoate (DB) and phenylthiocarbamide
(PTC). GI endocrine cells and STC-1 cells also express G proteins, including gustducin and
transducin and other effectors implicated in taste signal transduction, namely PLCb2, and
ion channels. Addition of DB to STC-1 cells increases intracellular Ca2+ concentration
([Ca2+]i) and CCK release through Ca2+ influx mediated by the opening of L-type voltage-
sensitive Ca2+ channels (VSCCs) in STC-1 cells. However, the intracellular signal transduc-
tion cascades initiated by bitter stimuli in STC-1 cells have not been explored. The present
study was designed to characterize the activation of the ERK pathway in response to bitter
stimuli and to determine the role of Ca2+ influx in mediating ERK activation in response
to bitter stimuli. Methods: Clonal derivatives of STC-1 cells were stimulated with various
doses of DB or PTC. The cells were lysed and the active forms of various kinases were
detected by Western bloting using specific phospho-antibodies. Results: Stimulation of STC-
1 cells with DB or PTC induced a striking increase in the phosphorylation (activation) of
ERK-1/2, in a time- and dose-dependent manner. DB and PTC also induced the activation
of the 90KDa Ribosomal S6 Kinase (p90rsk), a downstream target of ERK. DB induced a
rapid and transient increase in the phosphorylation of MEK and PD98059 (10 uM) and
U0126 (5 uM) interfered with DB- and PTC- induced ERK and p90rsk phosphorylation,
suggesting that tastant-induced ERK1/2 activation requires functional MEK. Stimulation of
STC-1 cells with the Ca2+ ionophore ionomycin or with KCl or with Bay K8644 (VSCCs
channel opener), induced rapid ERK activation. These results are consistent with a link
between an increase in [Ca2+]i and ERK pathway activation in STC-1 cells. Treatment of
the cells with the specific L-type channel blockers verapamil, nitrendipine, or diltiazem,
abrogated DB-stimulated ERK activation, indicating the contribution of L-type VSCCs in
mediating ERK pathway activation in response to DB in STC-1 cells. Conclusion: Our results
demonstrated that bitter tastants DB or PTC stimulate a network of signal transduction
pathways in STC-1 cells, involving second messengers, ion fluxes and phosphorylation cas-
cades.
T1741
PKD Is Rapidly Activated By G Protein-Coupled Receptor Agonists Through a
Pkc-Dependent Pathway in Colonic Myofibroblasts
James Yoo, Terence T. Chiu, Christine Chung, James Sinnett-smith, Enrique Rozengurt
Introduction: Myofibroblasts are a subpopulation of cells in the gastrointestinal (GI) tract
that regulate important mucosal processes including repair, fibrosis, proliferation, and actively
participate in mounting immune and inflammatory responses. Therefore, the cell signaling
pathways that underlie their function are attracting great interest. PKD, the founding member
of a new family of protein kinases that includes PKD2 and PKD3, has been implicated in
the regulation of many essential cellular functions, including proliferation, migration, signal
transduction and gene expression, but its role in myofibroblast cell signaling has not been
explored. Methods: Human diploid 18Co cells were grown to confluence on 35x10mm cell
culture dishes and used from passages 8-14. 18Co cells were treated with bradykinin
(100nM), lysophosphatidic acid (LPA, 10 μM), carbachol (CCH, 100 μM) or endothelin
(100nM). Activation of PKD was assessed by Western Blot analysis using antibodies that
detect the phosphorylated state of Ser-744 and Ser-748 located in the activation loop of
PKD. The activity of PKD in intact cells was evaluated by monitoring the auto-phosphorylation
of PKD at Ser 916. Results: Treatment of cultures of 18Co cells with the G-protein coupled
receptor agonists CCH, LPA, bradykinin and endothelin led to rapid activation of PKD
(within 5 min) as shown by phosphorylation of Ser-744/748 at the activation loop and Ser-
916 at the auto-phosphorylation site. Activation by CCH, LPA, and endothelin was transient
(declined to base-line levels after 60 min), while bradykinin led to a more prolonged response
(detectable even after 120 min of stimulation). Pre-treatment with the PKC inhibitor Ro31-
8220 (2 μM) completely blocked bradykinin-induced phosphorylation at the activation loop
(Ser 744/748) and the auto-phosphorylation site (Ser 916). In contrast, pre-treatment with
Go6976 (5 μM), an inhibitor of conventional PKCs (PKCα, PKCβ1, PKCβ2 and PKCγ) and
PKD but not of novel PKCs (i.e. PKCδ, PKCε, PKCη and PKCθ) did not inhibit phosphoryl-
ation at the activation loop (Ser 744/748) but markedly decreased autophosphorylation at
Ser-916. Conclusions: PKD activation is stimulated by multiple G protein-coupled receptor
agonists (CCH, LPA, endothelin and bradykinin) in the human 18Co myofibroblast cell
line. PKD-induced activation by CCH, LPA and endothelin is rapid and transient, while
activation by bradykinin is more prolonged. Bradykinin-induced PKD activation at the loop
phosphorylation site (Ser 744/748) is mediated by novel PKC activation.
T1742
Identification of Key Amino Acids in the Human Orphan Bombesin (Bn)
Receptor Subtype-3 (Hbrs-3) Responsible for High Affinity Binding of
Selective Ligands
Nieves Gonzalez, Samuel A. Mantey, Tomoo Nakagawa, Robert T. Jensen
BKG: hBRS-3 shares 50% homology with other Bn receptors including the gastrin-releasing
peptide receptor (GRPR). BRS-3 is widely distributed in the CNS and GI tract and is receiving
increased attention because its disruption leads to obesity, diabetes and hypertension. Its
natural ligand or role in GI physiology is largely unknown. BRS-3 has unique pharmacology
with low affinity for all natural Bn-related peptides and nothing is known about the molecular
determinants of high affinity interaction with this receptor. We found a synthetic Bn analogue
[DTyr6,βApa11, Phe13, Nle14]Bn(6-14) (696) has high affinity for BRS-3 which allows
pharmacologic studies. AIM: To identify amino acids in hBRS-3 responsible for high affinity
interaction. METHODS: Four closely related synthetic Bn analogues were studied, 696;
([DTyr6,(R)Apa11, Phe13, Nle14]Bn(6-14)) (1326), ([DTyr6,(R)Apa11-4Cl, Phe13,
Nle14]Bn(6-14)) (1349) and Ac-Phe,Trp,Ala,His(rBzl),Nip,Gly,Arg-NH2 (BC) which are
reported to have high affinity and/or selectivity for BRS-3. Initially, 3 loss-of-affinity and 3
gain-of-affinity BRS-3 chimeric receptors were made by exchanging the 3 extracellular (EC)
domains of BRS-3 with corresponding GRPR domains and studied. Finally, critical point
mutants were made. Receptors were expressed in CHOP cells and affinities determinated
by binding studies. RESULTS: 696, 1326, 1349 and BC had affinities of 2, 5, 36 and 500
nM for BRS-3, and a 0, 55, 120 and > 60 fold higher affinity for BRS-3 over GRPR. Even
at 30 μM BC did not interact with GRPR. For BC, only the [E2GRPR] substitution decreased
affinity (21x) whereas for 1326 only the [E3GRPR] substitution (3x) and for 1349 both E2
(5x) and E3 (10x) GRPR substitutions decreased affinity. With gain of affinity chimerics,
substitution of [E2 BRS-3] into GRPR had the greatest effect for BC and 1349, whereas with
1326, E3 substitution had the greatest effect. To investigate the selectivity of BC and 1349
further, 9 point mutations were made in EC2 or adjacent to transmembrane regions. For
1349 [L98V], [V101A], [T106S] and [H107K]BRS-3 produced a small decrease (2-3-fold)
in the affinity, whereas with BC, [H107K]BRS-3 markedly decreased affinity (>30 μM), but
[V101A] and [G112R] caused only a loss of 3-fold in the affinity. CONCLUSION: These
results show the molecular determinants of high affinity/selectivity for the BRS-3, even for
four different closely related synthetic ligands, differ markedly. Not only does the relative
importance of the extracellular domains differ for these closely related ligands, but also the
importance of the key amino acids within these domains differ.
T1743
P2y12 Receptors Inhibit Mechanosensitve Release of 5-HT from Human
Carcinoid Bon Cells
Jianjing Xue, Fievos L. Christofi, Helen J. Cooke
Background: In many cells, P2Y1, P2Y12 and P2Y13 receptors (Rs) are activated by the
same ligand, ATP/ADP, but their signaling pathways may differ. Little is known about the
P2Y12R in regulating mechanosensitive 5-HT release. The human enterochromaffin derived
carcinoid BON cell is an established cell model to study release of 5-HT Aim: To investigate
the role of P2Y12Rs in mechanically evoked 5-HT release in a human enterochromffin cell
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model. Methods: BON cells were plated at a density of 1,000,000 cells and were grown for
48 hours. In order to over-express receptors, cells were transfected with the full length
sequence of the P2Y12R. Silencing RNAs were used to knock-down P2Y12R and P2Y13R
protein, verified by Western blotting. cAMP and 5-HT release were examined by kits. Results/
Discussion: Gene transcripts for P2Y1, P2Y12 and P2Y13Rs were detected in BON cells.
Mechanical stimulation (80 rpm; 20 min) increased cAMP and 5-HT in BON cells. Over-
expression P2Y12Rs in BON cells and HEK293 cells nearly abolished mechanically evoked
5-HT and cAMP, respectively. 5-HT released by mechanical stimulation of over-expressed
BON cells was associated with 160% increase in P2Y12R protein. Silencing the P2Y12R in
BON cells reduced P2Y12R protein by 68%. Basal 5-HT release ( 2.3 pmoles +/- 0.4/ml/
20 min) was increased by gene silencing. Antagonizing the P2Y12/13R with 2MeSAMP
increased basal and mechanically evoked 5-HT release. The maximal increase in mechanically
evoked 5-HT release occurred with the combined administration of P2Y12/13R antagonist
plus the silencing RNA. This result was due to an effect on the P2Y12 and not the P2Y13R,
because silencing P2Y13R did not have much effect on basal or stimulated 5-HT release
despite the reduction in receptor protein. Conclusions: These studies provide evidence for
inhibitory modulation of basal and mechanically evoked elevation of 5-HT via P2Y12Rs.
These observations provide potential new targets to modulate 5-HT release in motility and
secretory disorders of the gut (R01 DK37420)
T1744
Upregulation of Ghrelin Expression By Ngn-3 and E47
Guiyun Wang, Xiang Qi, Wei Wei, Ella W. Englander, George H. Greeley
Ghrelin is a major metabolic hormone that stimulates GH secretion, growth, food intake
and adiposity. Although ghrelin is produced primarily in the stomach, ghrelin is also
expressed in pancreatic ε-cells. Pancreatic ε-cell genesis is dependent upon neurogenin-3
(ngn-3), a basic helix-loop-helix (bHLH) transcription factor that binds to E-box sites. The
aim of these studies was investigate the influence of ngn-3 and E47, another bHLH protein
that can form heterodimers with ngn-3. Three adjacent E-boxes occur in a proximal region
of the human ghrelin promoter. Methods. Exp 1: in transient transfection experiments the
effects of ngn-3 and E47 over-expression either alone or in combination on luciferase (luc)
reporter activity of several 5'-upstream fragments of human ghrelin (-3161/-18,-2168/-18,-
1161/-18,-667/-18 and -197/-18 bp) were tested in rat insulinoma cells (RIN-m5F). Exp 2:
the effects of ngn-3 plus E47 on proximal ghrelin promoter-luc reporter constructs with E
boxes (-667/-18 bp) or without E boxes (-667/-198, -667/-282, -667/-368, -667/-468 bp)
were examined. Exp 3: effects of sequential 100 bp 3'-deletions of a -667/-18 bp ghrelin
promoter fragment on ngn-3 stimulated promoter activity was examined. Exp 4: effects of
sequential 20 bp 3'-deletions of a -667/-368 bp fragment on ngn-3 stimulated promoter
activity was examined. Results. Exp 1: Overexpression of ngn-3 alone increased ghrelin
promoter (-667/-18 bp) activity 5±1-fold, E-47 overexpression alone did not effect ghrelin
promoter activity. Overexpression of ngn-3 and E47 together increased activity 22±2-fold.
Exp 2: E-box deletion caused a 65% reduction in ngn-3 plus E 47-stimulated activity. Exp
3: a proximal 300 bp ghrelin promoter-luc reporter fragment (-667/-368 bp, does not include
E boxes) was more responsive to ngn-3 alone than a 200 bp fragment (-667/-468 bp). Exp
4: a 220 bp ghrelin promoter fragment (-667/-448 bp) was more responsive to ngn-3 alone
than a 200 bp fragment (-667/-468 bp). Conclusions and Discussion. ngn-3 and E47 act
in a synergistic manner to increase ghrelin promoter activity, this activity is mediated
primarily by the E box site. ngn-3 also acts on a site upstream of E boxes to stimulate
ghrelin promoter activity. Since this fragment is without E box sites ngn-3 can act indirectly
to increase ghrelin promoter activity. Sequence analysis of this responsive fragment identified
a putative Pax2 binding site. ngn-3 can elevate Pax4 and Pax6 transcription, therefore, ngn-
3 may activate ghrelin promoter activity by increasing Pax2 expression.
T1745
Hypoxia-Induced Apelin Expression Increase Cell Number
Song Han, Xiang Qi, Ella W. Englander, George H. Greeley
Apelin is the endogenous ligand for the APJ receptor, both are expressed in the GI tract
and involved in GI function. Enteric inflammation activates apelin expression. Inflammation
and hypoxia are linked. Purpose. The aim of this study was to examine the influence of
hypoxia on enteric apelin expression. Methods. Experiment 1 (Exp 1): the effect of hypoxia
(1, 3 days, 9.5% O2) in six-day-old rat pups on GI and liver apelin expression was examined.
Exp 2: the effects of acute hypoxia (24 h, 0.5% O2 or CoCl2) on apelin expression in liver
and enteroendocrine cells (HepG2, STC-1), and on primay rat colon cells were examined.
Apelin mRNA levels were measured by Northern analysis or real time RT-PCR. Exp 3: the
effect of overexpression of hypoxia inducible factor-1 (HIF-1) on apelin promoter activity
was tested in HepG2 cells transiently transfected with rat apelin 5'-upstream fragments-
luciferase reporter gene constructs. Exp 4: HepG2 cells were exposed to normoxia, hypoxia
(48 h) or CoCl2 and cell numbers measured. Results. Exps 1 and 2: In Vivo and In Vitro
hypoxia increased apelin mRNA levels in the liver and GI tract and in HepG2 and STC-1
cells significantly (Table 1). Exp 3: HIF-1α and HIF-1β overexpression increased apelin
promoter activity (2.5-fold, p<0.05). Exp 4: HepG2 cell number was increased (20%) by
apelin treatment (10-9 M) during hypoxia or CoCl2 exposure (Table 2). Conclusions and
Discussion. Our findings indicate that hypoxia increases apelin expression levels in the
liver and GI tract. Hypoxia-induced increase in apelin mRNA levels is due to enhanced
apelin transcription since HIF-1 stimulates apelin promoter activity. Treatment of cells
exposed to hypoxia with apelin increases cell number suggesting that increased apelin
expression during enteric inflammation serves to maintain cell homeostasis. The extent to
which apelin acts on proliferation, prevents cell death or exerts both activities will be tested.
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* P<0.05 vs. Control.
Table 2
*p<0.05 vs. CoCl2 alone or hypoxia
T1746
The Naturally-Derived Product Emodin Inhibits Neurotensin Expression and
Secretion and Decreases Neurotensin-Mediated Cancer Cell Migration
Xiao-fu Wang, Andrea Y. Ramirez, Jing Li, Sara M. Johnson, B. mark Evers
Neurotensin (NT), a gut peptide, binds to its receptor (NTR) to stimulate growth and
migration of human colon cancer cells and increase inflammation of gut mucosa. We have
recently shown that curcumin, a naturally-derived dietary product, inhibits NT-mediated
migration of HCT116 human colon cancer cells. The purpose of our present study was to
determine the role of Emodin (extracted from Rheum palmatum), which possesses potent anti-
inflammatory and possible anti-cancer activities, on NT expression, secretion and function.
METHODS. The human pancreatic carcinoid cell line, BON, and human liver cancer, Hep3B,
which both express high levels of NT mRNA, and the human colon cancers, HCT116 and
SW480, which express NTR, were treated with various concentrations of Emodin and the
following experiments performed: (i) Expression of NT mRNA (for BON and Hep3B) and
NTR mRNA (for HCT116 and SW480) was assayed by Northern blot. (ii) To determine the
effects of transcriptional regulation, BON cells were transfected with an NT promoter-
luciferase (-373/+26 bp) construct, treated with Emodin and promoter activity determined
by luciferase assay. (iii) Effect of Emodin on basal NT peptide secretion in BON cells was
determined by ELISA. (iv) To investigate possible signaling mechanisms for the Emodin
effects, AP-1 DNA binding activity was assessed by gel shift. (v) NT-mediated HCT116 cell
migration was determined using TransWell inserts coated with collagen. RESULTS. Emodin
significantly decreased NT mRNA in a dose-dependent fashion in both BON and Hep3B
cells and reduced NT promoter activity by ~60% in BON cells, suggesting transcriptional
regulation. In addition, Emodin decreased basal NT secretion in BON cells by ~85%. In
HCT116 and SW480 cells, Emodin decreased NTR expression in a time- and dose-dependent
fashion. Treatment with Emodin significantly attenuated AP-1 DNA binding, which we have
previously shown plays a critical role in constitutive NT expression. Finally, Emodin
decreased NT-mediated migration of HCT116 cells by ~35%. CONCLUSIONS. Our study
is the first to show that the naturally-derived product Emodin can significantly decrease
both NT and NTR expression, NT secretion and NT-mediated colon cancer migration; these
inhibitory effects of Emodin are, at least in part, mediated through reduction of AP-1 binding.
These findings identify Emodin as a possible inhibitor of NT-mediated inflammation and
colon cancer cell migration which may have broader clinical implications in the treatment
of gut inflammatory conditions and GI cancers.
T1747
Serotonin Regulates the Human NHE3 Gene Expression By Modulating Sp1/
Sp3 Transcription Factors in C2bbe1 Cells
Md ruhul Amin, Pradeep K. Dudeja, Krishnamurthy Ramaswamy, Jaleh Malakooti
Serotonin (5-HT), an important signaling molecule in the gut released from enterochromaffin
cells, plays a critical role in the regulation of gastrointestinal motility, secretion and absorption.
Increased serotonin levels have been implicated in the pathophysiology of diarrhea associated
with carcinoid syndrome, ulcerative colitis and irritable bowel syndrome. Our studies have
shown that serotonin decreases NHE2 and NHE3 activities via 5-HT4 receptors and activation
of PKCα in human intestinal epithelial cells under acute conditions. However, the effects
of serotonin on the NHE gene expression have not been investigated. Therefore, the effects
of 5-HT on the transcriptional regulation of the human NHE3 gene in differentiated C2BBe1
cells were examined. In transient transfection assays, serotonin treatment exhibited inhibitory
effect on the NHE3 promoter activity. Further reporter gene analyses identified the NHE3
core promoter (bp -95 to +5) as the region responsible for this effect of 5-HT. This region,
which harbors a number of cis-elements including Sp1 binding sites, showed maximum
repression (~55%) of the NHE3 promoter activity in response to 5-HT treatment at 20 μM,
which was used for subsequent studies. The maximum repression of the endogenous NHE3
mRNA expression was observed at 2 to 4 hrs in the presence of 5-HT. NHE3 protein
expression in C2BBe1 cells was also decreased by 5-HT treatment and maximum repression
was seen at 8 to 16 hrs. The inhibitory effect of 5-HT on the NHE3 core promoter was
blocked by 2 μM chelerythrine chloride, a PKC inhibitor. In gel mobility shift assay, the
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binding of Sp1 and Sp3 transcription factors to the NHE3 core promoter decreased signific-
antly, following treatment of C2BBe1 cells with 5-HT. However, serotonin showed no effect
on the expression of Sp1 and Sp3 proteins as assessed by Western blot analysis. Our data
suggest that the inhibitory effect of 5-HT on the human NHE3 promoter activity may be
mediated by modulation of the DNA binding affinity of transcription factors Sp1 and Sp3,
and that posttranslational modification of Sp1/Sp3 may play a role in these processes.
T1748
The Interruption of Nf-κB and ERK Signaling Pathways By Curcumin
Contributes to the Suppression of CTGF Gene Expression in Activated HSC
In Vitro
Shizhong Zheng, Anping Chen
BACKGROUND: Gene expression of connective tissue growth factor (CTGF) is significantly
induced in activated HSC, the major effector in hepatic fibrosis, resulting in the stimulation
of the production of extracellular matrix (ECM). We previously reported that curcumin, the
yellow pigment in curry from turmeric, significantly inhibited HSC activation by inhibiting
cell growth and suppressing ECM gene expression [Xu at el (2003) Am J Physiol. 285, G20-
30; Zheng & Chen (2004) Biochem J, 384, 149-157]. Further studies indicated that curcumin
suppressed gene expression of CTGF by interrupting TGF-β signaling, leading to the reduc-
tion in the production of ECM in activated HSC [Zheng & Chen (2006) Am J Physiol. 290,
G883-893]. AIM AND HYPOTHESIS: This study is to explore additional mechanisms by
which curcumin suppresses gene expression of CTGF in activated HSC. It is hypothesis that
besides on TGF-β signaling, the inhibitory effects of curcumin on other signaling pathways,
including NF-κB and ERK, might also contribute to the suppression of CTGF gene expression
in activated HSC. RESULTS: Curcumin suppresses CTGF gene expression and reduces the
trans-activation activity of NK-κB in activated HSC, which are dose-dependently eliminated
by lipopolysaccharide (LPS), an NF-κB activator. LPS significantly increases the abundance
of CTGF and type I pro-collagen in HSC In Vitro. The inactivation of NF-κB activity by the
NF-κB inhibitor pyrrolidine dithiocarbamate, like curcumin, dramatically inhibits CTGF
gene expression. These results collectively show the role of NF-κB activity in the curcumin
suppression of CTGF gene expression in HSC. Additional experiments demonstrate that
curcumin reduces the activity of ERK in HSC. The interruption of ERK signaling by the
ERK inhibitor PD98059 mimics the role of curcumin in the suppression of CTGF gene
expression. In contrast, the activation of ERK signaling by constitutively activated ERK dose-
dependently abrogates the inhibitory effect of curcumin on CTGF gene expression. The
activation of ERK signaling by constitutively activated ERK, or the interruption of ERK
signaling by dominant negative ERK, stimulates, or suppresses, the trans-activation activity
of NF-κB and the promoter activity of CTGF, respectively. CONCLUSION: The present
results support our hypothesis and demonstrate that the interruption of NF-κB and ERK
signaling pathways by curcumin contributes to the suppression of CTGF gene expression
in activated HSC. These results provide novel insights into the mechanisms of curcumin in
the inhibition of HSC activation [The work was supported by the grant DK 47995 from
NIH/NIDDK to A. Chen].
T1749
Angiotensin Converting Enzyme Modulates Intestinal Adaptation After Small
Bowel Resection
Emir Q. Haxhija, Hua Yang, Ariel U. Spencer, Xiaoyi Sun, Hiroyuki Koga, Daniel H.
Teitelbaum
Introduction: Angiotensin converting enzyme (ACE) is involved in regulation of apoptosis
in various tissues. We previously showed that use of ACE inhibitors reduces epithelial cell
(EC) apoptosis and improves intestinal adaptation. To further understand the role of ACE
during intestinal adaptation after small bowel resection (SBR), we utlized ACE knockout
mice (ACE-/-). Methods: Homozygous ACE-/- (Ace tm1Unc ) and littermate ACE+/+ (C57BL/
6J) mice underwent a 60% mid-SBR (8 weeks of age; n=6/group). Non-operated (N) mice
were used as controls. At 7 days after surgery adaptive response was assessed in ileum by
quantification of villus height, crypt depth, EC apoptosis (TUNEL) and EC proliferation
(%BrdU incorporation). The apoptotic and proliferation signalling pathways were addressed
by analysis of EC protein expression of bax, bcl-2, Fas, and TNF-α, and, mRNA expression
of KGFR1, EGFR and IL7R, respectively. ANOVA was used for statistical analysis. Results:
EC apoptosis rates were diminished in intestinal crypts of ACE-/- as compared to ACE+/+
groups, both at baseline and after SBR (Table). In both groups SBR led to a significant
increase in villus height, crypt depth and EC proliferation rates, with baseline values signific-
antly higher in the ACE-/- group. For ACE+/+ mice, the pro-survival protein bcl-2 and the
pro-apoptotic proteins bax and Fas increased significantly after SBR. Interestingly, ACE-/-
mice expressed at baseline lower levels of bcl-2 and higher levels of Fas. After SBR, ACE-/-
mice failed to increase bax, showed a decrease in TNF-α, and continued to significantly
increase bcl-2. KGFR1 showed a significant increase after SBR only in the ACE+/+ group
(0.16 v. 0.40; P<0.01). There was no significant change in gene expression of EGFR and
IL7R after SBR, but their expression was 2-fold higher in ACE-/- as compared to ACE+/+
mice. Conclusion: The absence of ACE results in markedly lower intestinal EC apoptosis
at baseline and after SBR. The mechanisms of this action may lie in diminished action of
pro-apoptotic proteins in the absence of ACE. Furthermore, ACE-/- mice have an increased
expression of genes known to mediate EC proliferation, which might explain their higher
morphometric values as compared to ACE+/+ mice. The data provide evidence that ACE is
an important mediator of intestinal homeostasis.
*P<0.05 (N v SBR, respectively); †P<0.05 (N-ACE+/+ v. N-ACE-/-);
T1750
Importance of the Rig-1-Ips-1 Signaling Pathway in the Activation of Cellular
Defense Mechanisms in Virus Infected Intestinal Epithelial Cells
Yoshihiro Hirata, Alexis Broquet, Luis A. Menchen, Martin F. Kagnoff
Background: Intestinal epithelial cells (IECs) are a first line of defense against microbial
pathogens that gain access to the host through the intestinal tract. Viral pathogens that infect
intestinal epithelium are an important cause of diarrheal illness and death. However, the
key epithelial signaling molecules and epithelial defense mechanisms that are activated in
response to intestinal viral infection are largely unknown. Since intracellular production of
dsRNA is a hallmark of infection with many enteric viruses, we defined the relevant signaling
molecules that are activated in IEC using the dsRNA analog, poly (I:C), and infection with
virus. Method: Intestinal epithelial cell lines, HT29, HCA7, SW480, were stimulated with
poly (I:C). Responses were assayed by real-time PCR for IFNβ and IFN regulated genes,
and by ELISA of IFNβ protein. The signaling pathways responsible for IFNβ induction were
determined by IFN stimulated response element (ISRE) reporter assays, ISRE EMSA. IRF3
activation was assessed by immunoblot. Expression of the dsRNA sensor molecules, TLR3,
PKR, and RIG-I in IECs was examined by RT-PCR. The contribution of these RNA sensors
to type I IFN responses was determined using dominant negative molecules and siRNA.
The importance of RIG-I in host anti-viral defense was assessed in virus infected intestinal
epithelial cells. Results: Recognition of dsRNA by IECs required its intracellular localization.
This was accompanied by IRF3 dimerization and phosphorylation, increased activation of
the ISRE, upregulated expression of RIG-1 and of IFNβ and type I IFN target genes. Dominant
negative RIG-I and siRNA for RIG-I abrogated the activation of the ISRE, IRF3 dimerization
and IFNβ production. ISP-1 (Cardif) was key in the signal transduction pathway downstream
of RIG-1. Although two other dsRNA binding proteins, TLR3, and PKR were expressed in
IECs, blocking signaling through those molecules did not decrease the type I IFN response
to poly(I:C). Consistent with the importance of RIG-I in signaling epithelial cell defense
mechanisms, virus replication and virus-induced cell death were significantly increased in
intestinal epithelial cells in which signaling through RIG-I was silenced. Conclusion: RIG-
I has a major role in viral recognition by IEC and in epithelial cell-mediated anti-viral innate
defense mechanisms that are mediated through the type I IFN response. Supported by NIH
Grants DK35105, DK 58960 and a grant from the Wm. K. Warren Foundation.
T1751
Vasoactive Intestinal Peptide Ameliorates Alterations in Intestinal Epithelial
Barrier Function Associated with Attaching/Effacing Pathogens
Xiujuan Wu, Bruce A. Vallance, Alison M. Buchan, Kevan Jacobson
Alterations in intestinal epithelial barrier function contribute to intestinal disease associated
with attaching/ effacing (A/E) enteropathogens EHEC,EPEC and C. rodentium. Vasoactive
intestinal peptide (VIP), a neuropeptide present in enteric nerves, is involved in regulation
of intestinal barrier function. Aim: To examine ameliorating effects of VIP on alterations in
intestinal barrier function associated with A/E pathogens In Vivo and In Vitro. Methods:
C57BL/6 mice received 2.5 × 108 C. rodentium by gavage on day 0. VIP was administered
by daily i.p. injection at different dosages (0.5, 1 and 5 nmol/per mouse) from day 1 up
until and including day 10, the day of sacrifice. Animal weights were monitored daily. All
animals were sacrificed on day 10, colons removed and assessed for epithelial barrier function,
histology, and expression and distribution of tight junction proteins ZO-1 and occludin.
Additionally, human polarized colonic epithelial cell monolayers (Caco-2) were infected
with EPEC. Trans-epithelial resistance, 3Hmannitol flux and alteration of tight junction
protein (ZO-1 and occludin)expression and distribution were examined during infection
with or without treatment of VIP. Results: C. rodentium infection In Vivo was associated with
a significant decrease in body weight by day 4 post-infection, (31% decrease from baseline)
with partial recovery by day 10, marked crypt hyperplasia, transmural infiltration on neutro-
phils and mononuclear cells and a disruption in epithelial barrier function. Morphological
alterations of tight junctions were characterized by re-localization of ZO-1 and occludin
away from the plasma membrane. Treatment with VIP (0.5 nmol/per mouse) significantly
attenuated the weight loss (13% decrease from baseline at day 4) with full recovery by day
10 and ameliorated the histological damage score (0.94±0.20 vs. 1.66±0.33). Moreover, VIP
attenuated the increase in mannitol flux (20.3±1.1 nm/cm2/hr vs. 31.2±3.3 nm/cm2/hr)
and normalized the forskolin response(95.7±5.8 µA/cm2 vs. 63.2±8.3 µA/cm2). Importantly,
the alteration of tight junction structure in infected colons was diminished with VIP treatment.
In Vitro, VIP (10-8 M) was associated with a significant, but partial reduction in increased
unidirectional mannitol flux at 4 hrs post-infection with EPEC. The disruption of tight
junction structure in Caco-2 monolayers induced by EPEC was also abrogated by VIP.
Conclusion: VIP ameliorated C. rodentium-induced colitis and maintained colonic epithelial
barrier integrity by regulating tight junction proteins ZO-1 and occludin expression and
distribution In Vivo and In Vitro. Supported by CCFC (Canada).
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T1752
Validation of Zebrafish As a Genetic Model for Studying How Bacterial Ab5
Toxins Intoxicate Host Cells - Evidence Against Sec61 As the Retro-
Translocation Channel
David Saslowsky, Himani Chinnapen, Wayne I. Lencer
Cholera toxin (CT) typifies the AB5-subunit bacterial toxins and causes the secretory diarrhea
seen in Asiatic cholera. CT enters host cells by trafficking from the plasma membrane (PM)
to the Golgi and into the ER, where a portion of the A-subunit, the A1-chain, is retro-
translocated to the cytosol to cause disease. The molecular mechanism of the retro-transloca-
tion reaction, including the identity of the protein-conducting channel for the A1-chain is
unknown. Here, we AIM to test if the Sec61 complex, the channel that transports nascent
polypeptides into the ER, is required for retro-translocation of the A1-chain as widely
postulated. METHODS: We defined the zebrafish as a genetic model for CT function and
used embryos wt, heterozygous, or homozygous for an inactivating-mutation in the α-
subunit of Sec61 (Sec61α-/-)(PNAS 101:12792). RESULTS: When exposed to CT, zebrafish
embryos develop an overt phenotype of swelling of the cardial cavity and digestive tract
regions, heart failure, and circulatory dysfunction. This phenotype has 100% penetrance
within the population. CT mutants that either lack the enzymatically-active A1-chain, or
cannot bind the toxin's receptor GM1, or cannot unfold in the ER, fail to induce toxicity,
showing that the zebrafish models all aspects of the cell biology co-opted by CT to cause
toxicity in mammalian cells. We also detect elevated cAMP levels within intoxicated embryos,
consistent with the mode of toxin action. Confocal microscopy of live embryos show that
CT is concentrated in Cl-- and H+-secreting cells. 3-day post fertilization (3-dpf) Sec61α-/-
embryos display a mild, but overt phenotype, which increases in severity, ultimately resulting
in 100% mortality by 5-dpf. Immunoblot analysis shows that Sec61α protein expression is
severely reduced (>10-fold) in Sec61α-/- embryos as compared to wt or heterozygotes.
Sec61α-/- embryos exposed to CT show the same degree of toxin-induced phenotype as wt
or heterozygotes at all toxin concentrations tested. Genomic analysis, however, predicts a
second Sec61α zebrafish isoform of unknown functional significance that is orthologous to
one found in humans (termed Sec61αb), which we have confirmed to be transcribed in 3-
dpf embryos. DISCUSSION: These results suggest that theα-subunit of Sec61 is not required
for CT function in zebrafish. Since the genetic lesion in Sec61α-/- embryos is sufficient to
cause morbidity by 3-dpf, the second Sec61αb isoform cannot be completely functionally
redundant. Thus, if Sec61α is critically involved in CT retro-translocation, some degree of
toxin resistance should be observed, especially at low toxin concentrations. This is not what
we observe.
T1753
Citrobacter rodentium Lymphocyte Inhibitory Factor a/Lymphostatin Regulates
Epithelial Barrier Function
Brian Babbin, Maiko Sasaki, Adil Akyildiz, Asma Nusrat, Jan-michael A. Klapproth
Introduction: lymphocyte inhibitory factor A (lifA) encodes for a large toxin, named lymphosta-
tin, in Gram negative bacteria. lifA is present in Chlamydia spp., Enteropathogenic- and
Enterohemorrhagic E. coli, as well as in mouse pathogen Citrobacter rodentium. lifA encodes
for a glycosyltransferase- and protease enzymatic activity. Hypothesis: lifA regulates epithelial
barrier function by modifying small GTPases. Material and methods: C. rodentium WT was
subjected to homologous recombination, creating in-frame mutations of sequence encoding
for the glycosyltransferase (CrGlM21) and protease motif (CrPrM5). Differentiated Caco-2
epithelial monolayers were infected with C. rodentium WT, CrGlM21, and CrPrM5 for four
hours. Barrier function integrity was examined by FITC-dextran flux. Small GTPases were
analyzed by pull-down assay for active RhoA, Rac-1, and Cdc42. Results: Assessment of
barrier function by FITC-dextran flux at 30 min and 60 min revealed significant less
translocation into the basolateral compartment during infection withCrGlM21 (1.298 ±0.078,
1.822 ±0.0623) in comparison to C. rodentium WT (1.88 0.125, 2.94 ±0.12) and CrPrM5
(1.5 ±0.11, 2.28 ±0.11). When analyzed by confocal microscopy, C. rodentium WT and
CrPrM5 redistributed ZO-1 from tight junctions, whereas CrGlM21 did not. In contrast, C.
rodentium WT and CrGlM21 both lead to disassembly of β-catenin and E-cadherin which
were unaffected by CrPrM5. In contrast to C. rodentium WT and mutant CrGlM21, CrPrM5
failed to activate RhoA. Both, C. rodentium WT and CrPrM5 inhibited activation of Cdc42,
whereas infection with CrGlM21 resulted in solid upregulation of Cdc42-GTP. Infection
with any strain did not lead to moderate activation of Rac1 was not activated or inhibited
by anyC. rodentium strain. Summary: The lifA glycosyltransferase motif is critical for inhibition
of Cdc42 and the protease motif essential for activation of RhoA. Inhibition of Cdc42 by
lymphostatin has a significant effect on barrier function. Conclusion: The glycosyltransferase
motif in lifA participates in the regulation of barrier function.
T1754
The Intestinal Epithelium Inhibits Cryptosporidium parvum-Induced Apoptosis
Downstream of Caspase-3 In Vivo
Jody L. Gookin, Stephen H. Stauffer, Maria R. Coccaro
Cryptosporidium parvum (CP) is a minimally-invasive protozoal parasite of intestinal epithe-
lium, where infection results in loss of absorptive epithelial cells, villous atrophy, mucosal
inflammation, and debilitating. In Vitro studies suggest that apoptosis is the primary means
for deletion of CP infected epithelial cells. However, epithelial continuity and barrier function
are well preserved In Vivo even in cases of intense infection. We hypothesized that the
induced expression of cytoprotective factors may impede epithelial cell apoptosis In Vivo as
a novel means to preserve barrier function and host survival. We used a neonatal piglet model
of CP infection, that fully recapitulates the clinical and pathophysiological manifestations of
human infection, to investigate the activational state of death signaling and apoptosis of the
intestinal epithelium In Vivo. CP resulted in accelerated epithelial cell turnover with severe
villous atrophy but maintenance of epithelial continuity in infected piglets despite oftentimes
overwhelming numbers of epithelial parasites. At peak infection (day 3-5 pi), both immuno-
fluorescence and Western blotting revealed pronounced cleavage of the downstream apoptosis
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executioner protein caspase-3 within the epithelium of infected and not control piglets.
Despite advanced activation of death signaling pathways, apoptotic cells were not seen
amongst cells residing on the villi. However, numerous TUNEL-positive apoptotic cells could
be observed in the intestinal lumen, suggesting that apoptosis is delayed until after epithelial
detachment. Further, TEM studies demonstrated conspicuous absence of apoptotic features
of parasite-bearing enterocytes In Vivo during extrusion from the epithelium. Repression of
overt apoptosis in the face of caspase-3 activation was additionally substantiated by incubation
of ileal mucosa from control and CP-infected piglets in Ussing chambers with rhFasL (100ng/
ml) and the exogenous inducers of apoptosis; etoposide (50μM), actinomycin D (25μM) or
cycloheximide (100μM). Mucosal epithelium from infected and not control piglets resisted
apoptosis induced by rhFasL, etoposide, or actinomycin D but remained susceptible to
apoptosis induced by cycloheximide. These findings suggest that the intestinal epithelium
employs novel means to control apoptosis and thus maintain barrier function and host
survival despite the compelling call to acutely delete infected epithelial cells. That such
events occur downstream of caspase-3 and can be overcome by the protein synthesis inhibitor
cycloheximide suggest that induction of short-lived inhibitor of apoptosis proteins (IAP) are
likely to play a key role.
T1755
Chitinase 3-Like-1 Enhances Bacterial Adhesion to Colonic Epithelial Cells
Through the Interaction with Chitin and Chitin-Binding Protein
Mayumi Kawada, Yuriko Hachiya, Atsuko Arihiro, Emiko Mizoguchi
Background & Aims: Dysregulated host/microbial interactions play a pivotal role in the
pathogenesis of inflammatory bowel disease (IBD). We previously reported that chitinase
3-like-1 (CHI3L1) enhances potentially pathogenic bacterial adhesion and invasion to colonic
epithelial cells (CEC). Therefore, this study was designed to identify the mechanism involved
in the CHI3L1-mediated enhancement of bacterial adhesion and invasion. Methods: Expres-
sion of chitin-binding protein 21 (CBP21) that has recently been discovered in Serratia
marcescence was examined by Coomassie blue stain under the existence of N-acetylglucosam-
ine (GlcNAc), chitin (polymer of GlcNAc) or glycerol. Existence of other CBP families that
have sequential homology with CBP21 was examined in some bacteria. A CBP21 fusion
protein was produced with CBP21 expressing pRSET vector that was transformed into E.
coli (BL21 strain). Adhesion rate of S. marcescens and CBP21 overexpressed E.coli to CECs
was examined. To identify the binding portion of CBP21 and CECs, mutant forms of CBP21
were generated. Results: We have found that Salmonella typhimurium, entero-pathogenic E.
coli, adherent invasive E. coli express the CBP21 homologue endogenously. A weak band of
CBP21 in the 4 day-culture supernatant of S. marcescens was detected endogenously by
Coomassie blue stain, and the band was disappeared or significantly increased after cultured
with glycerol or GlcNAc/chitin, respectively. Increased CBP21 expression on S. marcescens
after GlcNAc or chitin exposure significantly enhanced the adhesion ability to SW480 human
CEC line that express CHI3L1 endogenously. CBP21 overexpression significantly increased
the adhesion, but not invasion, of E.coli to SW480 cells. After overexpression of CHI3L1
on SW480 cells, the adhesion rate of CBP21-overexpressed E. coli further increased approxim-
ately 3-fold. As CBP21 possesses a highly conserved region at a surface patch (Thy-54, Glu-
55, Glu-60, His-114, Asp-182 and Asn-185) among many bacteria, we generated mutant
forms of the above amino acids. Genetically engineered E .coli with a single mutation of
either Thy-54 or Glu-55 position of CBP21 exhibited a decreased binding ability to CECs
as compared to wild type (WT)-CBP21 overexpressed E. coli. In addition, the binding ability
was 74 % diminished by the combined mutations of three amino acids of Thy-54, Glu-55
and Glu-60 as compared to WT. Conclusions: CHI3L1 is involved in the enhancement of
adhesion and invasion of intracellular bacteria into CECs. CBP21 and its homologues are
required for the CHI3L1-mediated enhancement of bacterial adhesion to CECs through the
conserved amino acid residues.
T1756
Activation of Pkc-λ (Lambda) Isoform Could Explain the Proinflammatory and
Non-Beneficial Effects of Bacterial Flagellin (Flg) On Monolayers of Intestinal
Cells: A Distinct Pkc-Dependent, Bacterial-Induced, Injurious Mechanism in
Epithelium
Ali C. Banan, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth, Yueming Tang, Ali
Keshavarzian
Despite a large number of studies attempting to study epithelial & microbial interactions,
major gaps in our knowledge still exist, not the least of which are the injurious interactions
of bacteria with gut epithelium & The molecular events that orchestrate their damaging
affects on gut barrier. Despite their affects, how bacteria cause barrier disruption is unclear,
& their precise mechanism of action has only been poorly evaluated in In Vitro models
appropriate for IBD. Because atypical λ isoform of PKC is key to gut cellular instability, we
hypothesized that PKC-λ activation is necessary for FLG-induced inflammation and tight
junctional & barrier dysfunction in intestinal epithelium. Methods: Cells were transfected
with a novel inducible system to stably overexpress PKC-λ or to underexpress it. Clones
were preincubated with FLG (1-100 ng/mL) or PKC activators or inhibitors or EGF±oxidant
(H2O2, 10-500 uM). Naive cells were treated similarly. We monitored barrier function
{fluorometry, TER}, tight-junction integrity {confocal microscopy}, PKC-λ subcellular distri-
bution {membrane, cytoskeletal, cytosolic}, PKC-λ subcellular activity {In Vitro kinase assay};
ZO/Occludin (immunofluorescence, SDS-PAGE fractionation), NF-kB activity (EMSA), n=
6/grp. Results: {A} Cells transfected to under-express PKC-λ or the WT cells pretreated
with PKC inhibitors were protected against FLG-induced damage as indicated by: PKC-λ
inactivation, NF-kB (p50/65 subunits) inactivation; occludin/ZO assembly (increased mem-
brane fraction, decreased cytosolic fraction), occludin/ZO architectural integrity, & mono-
layer barrier stability. All measures of protection against FLG induced by inhibition of PKC-
λ were synergized by added EGF. {B} Sense transfection to induce expression of full-length
endogenous PKC-λ caused NF-kB activation, and led to monolayer occludin/ZO & barrier
dysfunction, paralleling FLG-like injury in WT cells. {C} Pretreatment of transfected cells with
FLG also caused a large change in subcellular distribution of PKC-λ, increasing membrane &
cytoskeletal fractions of PKC-λ several fold while decreasing cytosolic fractions, indicating
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PKC-λ activation. In FLG treated cells, PKC-λ was active & endogenously complexed with
ZO/Occludin. Conclusions: These data demonstrate for the first time that FLG-induced injury
requires PKC-λ isoform activation. The ability of bacterial flagellin to promote dysregulation of
tight junctions & barrier function is novel mechanism not previously attributed to this PKC
isoform in cells. This mechanism suggests a useful target for development of new therapies
for the treatment of a variety of inflammatory GI disorders, including IBD.
T1757
Dmbt1 Is a Target Gene of NOD2/CARD15 and Protects Intestinal Epithelial
Cells from Bacterial Invasion
Philip Rosenstiel, Christian Sina, Stephan Hellmig, Susanna Nikolaus, Caroline End,
Markus Renner, Stephan Lyer, Burkhard Helmke, Mathias Hafner, Annemarie Poustka, Jan
Mollenhauer, Stefan Schreiber
Background&Aims: Mucosal epithelial cell layers are constantly exposed to a complex
resident microflora. DMBT1 (deleted in malignant brain tumors 1) belongs to the group of
secreted scavenger receptor cysteine-rich (SRCR) proteins and is considered to be involved
in host defense by pathogen binding. This report describes the regulation and function of
DMBT1 in intestinal epithelial cells, which form the primary immunological barrier for
invading pathogens.Methods:Expression of DMBT1 was determined by Taqman real time
PCR, Western blot and immunohistochemistry. Promotorstudies were performed using
luciferase reporter gene experiments. Bacterial invasion was tested by gentamicin protection
assay and siRNA approaches. Results: We demonstrate that DMBT1 is a target gene for the
intracellular pathogen receptor NOD2 via NF-κB activation. DMBT1 is strongly upregulated
in the inflamed intestinal mucosa of Crohn disease patients with wild-type, but not with
mutant NOD2. We show that DMBT1 inhibits cytoinvasion of Salmonella enterica and LPS-
induced Toll-like receptor 4 signalling. Silencing of DMBT1 in intestinal epithelial cells leads
to an increased invasion of bacteria. Conclusions: DMBT1 may play an important role in the
first line of mucosal defense conferring immune exclusion of bacterial cell wall components.
Dysregulated intestinal DMBT1 expression due to mutations in the NOD2/CARD15 gene
may be part of the complex pathophysiology of barrier dysfunction in Crohn disease.
T1758
Differential Transcriptional Responses of Intestinal Mucosa Upon Intake of
Log-Phase, Stationary and Dead Cells of Lactobacillus plantarum Wcfs1 In Vivo
in Humans
Freddy Troost, Peter Van baarlen, Patrick Lindsey, Willem De vos, Michiel Kleerebezem,
Robert jan Brummer
There is limited knowledge on the extent and dynamics of the mucosal response to commensal
and probiotic species in the human intestinal lumen. We investigated the effects of different
preparations of L.plantarum WCFS1, a strain originally isolated from human saliva, on
global gene expression in duodenum mucosa. Eight healthy volunteers participated in a
randomized double-blind cross-over study with four interventions. Subjects were instructed
to drink 100-ml beverages at 30-min intervals during 6 h. The beverages contained 1%
glucose and 8% maltodextrin (glucmalt; placebo), or, in glucmalt, a total of 1012 cells of
L.plantarum WCFS1 in mid-logarithmic (log) phase, stationary growing or rendered non-
viable by heat inactivation. Subsequently, duodenum tissue samples were obtained by flexible
gastroduodenoscopy. Mucosal gene expression profiles were determined using global Affyme-
trix U133 Plus 2.0 microarray chips, and analyzed applying a Gaussian linear regression
model. Only probe sets that were significantly regulated compared to placebo, with a fold
change≥ 10%, were considered for further analysis. Ingenuity pathway analysis and literature
exploration using Genbank's GeneRIFs and the iHOPS database was used to extrapolate the
gene results to biological processes. Intake of stationary, heat-killed and log-phase L.planta-
rum WCFS1 mediated the expression of 277 (245 up, 32 down), 281 (129 up, 152 down)
and 296 (275 up, 21 down) probe sets, respectively. At the pathway level, stationary
L.plantarum WCFS1 mainly affected cell-cell signalling and immune responses. Especially
genes that are associated with NFκB activation and apoptosis were mediated. Log-phase
L.plantarum WCFS1 induced an upregulation of oxidative phosphorylation, whereas both
stationary phase and heat-killed L.plantarum WCFS1 induced a downregulation of this
process. Log-phase L.plantarum WCFS1 also induced protein ubiquitination and antigen
presentation pathway, suggesting that exponentially growing L.plantarum WCFS1 induced
protein turnover and immune responses. Heat-killed L.plantarum WCFS1 induced minor
effects. Hematological system development and -function and integrin signalling, which are
involved in immune responses and cell death, were mediated. In conclusion, live bacteria
exerted different effects in the intestinal mucosal than dead cells, providing a molecular
support for the probiotic definition. Since a major difference between stationary and log-
phase cells relates to the presence of different cell-envelope proteins on the stationary cells,
it is plausible that the specific mucosal transcriptional response is caused by surface exposed
proteins of L.plantarum.
T1759
Endoplasmic Reticulum and Energy Stress Response Mechanisms in Intestinal
Epithelial Cells: Inhibitory Effects of Interleukin 10
Anja Messlik, Anna Shkoda, Pedro A. Ruiz, Sandra C. Kim, Gerhard Rogler, Hanelore
Daniel, Balfour R. Sartor, Dirk Haller
Background & Aim. The initiation of endoplasmic reticulum (ER) stress responses and
energy deficiency in intestinal epithelial cells (IEC) may contribute to the pathogenesis of
chronic intestinal inflammation. The aim of the study was to use functional epithelial cell
proteomics to characterize anti-inflammatory mechanisms of interleukin 10 (IL-10).
Methods. Primary IEC were isolated from Enterococcus faecalis- and Escherichia coli- monoas-
sociated IL-10 deficient (IL-10-/-) and wild type mice to perform 2D-gel SDS-PAGE and
MALDI-TOF mass spectrometry. In addition, IEC from 6 patients with active Crohn's disease,
ulcerative colitis and sigmoid diverticulitis as well as non-inflamed controls were purified.
Molecular protective mechanisms of IL-10 were characterized in TNF stimulated IL-10
receptor (IL-10R) reconstituted epithelial cells. Results. Primary IEC from IL-10-/- mice as
well as IBD patients revealed increased expression levels of the glucose-regulated ER stress
protein (grp)-78 under conditions of chronic inflammation. Vise versa, the protein and
mRNA expression levels of the mitochondrial creatine kinase (mCK) was dramatically reduced
in IEC under conditions of chronic inflammation. In parallel, the phosphorylation/activation
of the AMP kinase system was increased in the chronically inflamed epithelium. Consistent
with the observation that TNF induced ER stress responses through grp-78 redistribution
from the ER lumen to the cytoplasmic IkappaB kinase complex, grp-78 knock-down com-
pletely abolished TNF-induced NF-kappaB RelA phosphorylation in epithelial cell cultures.
Interestingly, IL-10 inhibited grp-78 protein and mRNA expression in IL-10R reconstituted
IEC. Chromatin immunoprecipitation (ChIP) analysis and immunofluorescence microscopy
revealed that IL-10-mediated p38 signaling inhibited TNF-induced recruitment of the ER-
derived activating transcription factor (ATF)-6 to the grp-78 promoter likely through the
blockade of ATF-6 nuclear translocation. Conclusion. The failure of energy homeostasis in
primary IEC from inflamed IL-10-/- mice was associated with activated ER stress responses
in the intestinal epithelium. In addition, IL-10 inhibits inflammation-induced ER stress
response mechanisms by modulating ATF-6 nuclear recruitment to the grp-78 gene promoter.
T1760
Apoe-Mimetic Peptide Inhibits Host Cell Activation By Citrobacter rodentium
Kshipra Singh, Rupesh Chaturvedi, Mohammad Asim, Michael P. Vitek, Keith T. Wilson
Background: Infection with C. rodentium, the rodent equivalent of enteropathogenic E. coli,
causes colitis in mice. We have reported that inducible nitric oxide (NO) synthase (iNOS)
is upregulated in both colonic epithelial cells and inflammatory cells in infected mice and
that iNOS deletion attenuates the colitis. Apolipoprotein (apo)E-mimetic peptides reduce
systemic inflammation in mice administered lipopolysaccharide and also are beneficial in
murine Experimental Allergic Encephalomyelitis, an inflammatory disease of the brain and
spinal cord similar to Multiple Sclerosis. We determined whether apoE peptides could inhibit
the host response to C. rodentium. Methods: RAW 264.7 macrophages were activated with
lysates of C. rodentium at a multiplicity of infection (MOI) of 100 and young adult mouse
colon (YAMC) cells were stimulated with intact bacteria at an MOI of 200, in the presence
and absence of an apoE peptide, COG112 (1-10 μM), which contains an antennaepedia
moiety that enhances cellular entry. Production of the oxidized product of NO, NO2-, was
assessed by the Griess reaction, and expression of iNOS mRNA and protein were assessed
by real-time PCR and Western blotting, respectively. Levels of macrophage inflammatory
factor (MIP)-2, a chemoattractant CXC chemokine that is increased in C. rodentium colitis,
were measured by real-time PCR. NF-ΚB activation was assessed by electromobility shift
assay (EMSA), as well as Western blotting and immunohistochemistry for p65. Results: In
macrophages, C. rodentium stimulated a 37.8 ± 1.3-fold increase in NO2- that was inhibited
by 82.6 ± 7.3% with COG112 at 5 μM (p < 0.001); this was paralleled by inhibition of
iNOS mRNA expression. In YAMC cells, C. rodentium induced a 20.8 ± 1.5-fold increase
in NO2- that was inhibited by 54.0 ± 3.3% with COG112 at 10 μM (p < 0.001). Similarly,
there was a 26.0 ± 4.0-fold increase in iNOS mRNA expression that was inhibited by 78.4
± 5.9% with COG112 (p < 0.001). iNOS protein induction was also inhibited by COG112.
C. rodentium induced activation of NF-ΚB in YAMC cells that peaked at 60 min after
stimulation; COG112 significantly attenuated the activation and nuclear translocation of
p65 protein. COG112 also significantly inhibited induction of NF-ΚB-inducible MIP-2 in
YAMC cells. Conclusions: The prototype apoE-mimetic peptide COG112 effectively inhibits
pro-inflammatory responses in colonic epithelial cells and macrophages. Its ability to block
NF-ΚB activation and production of pro-inflammatory mediators in C. rodentium exposed
cells indicates that COG112 may effectively modulate host mucosal innate immune responses
and therefore have therapeutic potential in IBD.
T1761
Changes in Ileal Mucin Composition Through Interactions with Intestinal
Microflora During Early Post-Hatch Development of Poultry
Rebecca Forder, Gordon S. Howarth, David R. Tivey, Robert J. Hughes
Background: The small intestinal epithelium is protected by a mucus layer consisting
primarily of mucus glycoproteins, synthesised and secreted by goblet cells. Changes in goblet
cell functions and mucin composition have been detected in response to a broad range of
stimuli, including microbial colonisation. We investigated mucin composition of the small
intestine in response to bacterial colonisation during early post hatch-development of poultry
as a model to study microbial-intestinal interactions. Methods: Chicks (n=42), incubated
under germ-free conditions were allocated to two groups at hatch. For 7 days, one group
was raised under conventional brooding conditions (C) and the other in a germ-free environ-
ment (GF). Proximal Ileal samples were collected at days 1, 4 and 7 post-hatch. Periodic
Acid-Schiff, High Iron Diamine and Alcian Blue pH 2.5 stains discriminated between neutral
and acidic mucins, the latter further discriminated as sulphated and sialomucin. Goblet cell
counts were expressed as number of cells per villous epithelial area (cells/mm2). Statistical
analysis was performed by 2-way ANOVA with a Bonferroni adjustment. Results: Numbers
of Ileal goblet cells containing total acidic and neutral mucins did not differ between groups
at any time point. In the C group there was a significant decrease in acidic and neutral
mucins from day 1 to 4 (p<0.05) but at day 7, the number had increased similar to day 1
values. All goblet cells contained sulphated mucins at day 1 for both groups but by day 4
a significant decrease in goblet cells was observed, with the most dramatic decrease occurring
in the C group (GF 1.88±0.38; C 0.69±0.41, p<0.05). Although not significant at day 7,
the GF group tended have greater numbers of goblet cells containing sulphated mucins than
the C group (GF 2.29±0.32; C 1.41±0.33, p=0.108). Ileal goblet cells containing sialomucins
were increased in the C group over the 7-day period compared to the GF group, which
continually exhibited low cell numbers (Day 4, GF 0.14±0.11; C 0.45±0.14 p<0.05), (Day
7, GF 0.26±0.15; C 1.02±0.23 p<0.001). Conclusion: Bacterial colonisation of the Ileum
during the first 7 days post-hatch caused an increase in sialomucins and a decrease in
sulphated mucins, with the most dramatic changes observed at day 4 post-hatch. These
findings provide insight into the influence of intestinal microflora on mucosal cytoarchitecture
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in poultry during early development, further providing a possible model system for studies
of human intestinal disorders characterised by altered mucin expression.
T1762
Ambient Oxygen Levels Modulate Immune Responses to the Enteric
Microbiota in Human Intestinal Epithelial Cells
Ann M. O'hara, Annamieke De kant, Ingrid Leegte, Aine Fanning, Kieran A. Ryan,
Cormac Taylor, Liam O'mahony, Fergus Shanahan
Background and aims: The availability of oxygen varies widely among tissues, and studies
have indicated that a healthy intestinal epithelium exists at approximately 4-5% oxygen.
Nevertheless, epithelial cell-culture studies have, for the most part, been conducted under
atmospheric oxygen levels. In this study, we investigated chemokine secretion and the
expression of hypoxia-inducible factor (HIF)-1α, the transcriptional regulator of adaptive
responses to hypoxia, at normoxic and atmospheric oxygen levels. Methods: Confluent HT-
29 human intestinal epithelial cell monolayers were incubated in a conventional 21% oxygen
incubator or in a normoxia chamber at 4.5% oxygen for 24 h prior to treatment with
Salmonella typhimurium UK1 or the commensal bacteria Bifidobacterium infantis 35624 for
varying times. The levels of the neutrophil-recruiting chemokine, interleukin (IL)-8, the
dendritic cell chemoattractant, CCL20, and the T cell chemoattractant CXCL10 were quanti-
fied in cell-culture supernatants. Cellular metabolic activity was assessed using biolumines-
cence. ELISA-based transcription factor assays were used to measure the activation of nuclear
factor (NF)-κB, c-Fos, c-Jun, or HIF-1α in epithelial nuclear extracts. HIF-1α protein levels
in cell lysates were measured by ELISA.Results: Ambient oxygen levels influenced chemokine
secretion. The baseline secretion of IL-8, CCL20, and CXCL10, as well as the levels of these
chemokines detected in bacteria-treated cell-culture supernatants were significantly less at
4.5% compared to 21% oxygen. Cellular metabolic activity was not significantly different
at either oxygen concentration. NF-κB, c-Jun, and c-Fos activity in untreated or bacteria-
treated nuclear extracts was unchanged at normoxic oxygen levels. In contrast, HIF-1α
DNA binding activity and protein expression were significantly elevated at 4.5% oxygen.
Conclusion: The data indicate that the attenuated release of immune mediators at normoxic
oxygen levels is associated with an enhanced activity and expression of HIF-1α. This molecu-
lar adaptation may help restrict epithelial cell inflammatory responses to the enteric microbi-
ota In Vivo, thereby avoiding excessive inflammatory cascades and cellular damage.
T1763
Alterations in Base Excision Repair of Oxidative DNA Damage After
Helicobacter pylori Infection in Gastric Epithelial Cells
Soumita Das, Ellen J. Beswick, Ranajoy Chattopadhyay, Peter B. Ernst, Victor E. Reyes,
Tapas K. Hazra
Background: H. pylori infection causes inflammation, increased production of reactive oxygen
species (ROS) and subsequent oxidative DNA damage in the gastric mucosa. The levels of
8-oxodG in DNA, often used as a marker of oxidative stress, isolated from leukocytes of H.
pylori infected patients were previously observed to be significantly higher than in uninfected
patients. In contrast, the mean level of excreted 8-oxodG in urine samples of the infected
patients was lower than the control group. Together these observations point towards elevated
oxidative DNA damage and/or decreased repair of the damaged DNA after H. pylori infection.
However, the detailed molecular mechanism(s) of elevated DNA damage after H. pylori
infection is still unknown. Commonly, oxidized bases are repaired via DNA base excision
repair (BER) pathway, initiated with the excision of the lesion by DNA glycosylases. We
recently found that human NEIL2 (Nei-like-2), a newly characterized oxidized base specific
DNA glycosylase stably interacts with Y box-binding protein (YB-1) and this interaction
plays an important role in repair of oxidative DNA damage including 8-oxodG. We have
also found that YB-1 stimulates overall DNA repair by stimulating NEIL2 activity. Thus,
coordination between NEIL2 and its associated proteins may play a critical role in genome
maintenance of gastric epithelial cells after H. pylori infection. Methods: NEIL2-FLAG stably
transfected AGS gastric epithelial cell (GEC) line was generated to study the NEIL2 interacting
protein partners in GECs. NEIL2-YB-1 interaction was tested by Western blot analysis of
NEIL2-FLAG immmunocomplex using anti-YB-1 antibody after H. pylori infection. Levels
of endogenous NEIL2 as well as other BER proteins were tested in GECs either by Real
Time Quantitative RT PCR and/or by Western Blot analysis following infection. Results:
NEIL2-YB-1 interaction was significantly diminished in GECs after H. pylori infection. The
level of NEIL2 but not YB-1 was specifically decreased after H. pylori infection in GECs.
The decreased levels of NEIL2 in GECs were dose and time dependent, after coculture with
H. pylori strains. Conclusions: These results suggest that decreased level of NEIL2 after H.
pylori infection play a significant role in elevated DNA damage in the GECs and may increase
the risk of gastric cancer during chronic H. pylori infection.
T1764
The Crohn's Disease Associated NOD2 Mutations Predispose to Dysbiosis
Christel Neut, Adeline Sivignon, Marie Joossens, Annie Standaert-vitse, Julien Branche,
Herbert J. Van kruiningen, Christian Libersa, Antoine Cortot, Corinne Gower-rousseau,
Franck Broly, Severine Vermeire, Arlette Darfeuille-michaud, Jean-frédéric Colombel,
Mathias Chamaillard
BACKGROUND Mutations in the bacterial recognition molecule NOD1 and NOD2 have
been shown to predispose to Crohn's disease (CD). Whereas NOD2 acts as a general
bacterial sensor, NOD1 detects only gram-negative bacteria and certain gram positive bacteria.
Dysbiosis has been reported in CD. However, its cause and the physiopathological role of
innate immune deficiency on the composition of the feces flora remain poorly understood
in CD. AIM Our aim is to investigate the impact of host innate immune mutations on the
bacterial flora in controls CD patients and their healthy relatives. METHODS Stool specimens
were collected from 63 CD patients, 97 healthy relatives (HR) and 38 controls for isolation,
identification and quantification of bacteria. Blood samples were collected for determination
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of three NOD2 (R702W, G908R and 1007fs), one NOD1 (ND(1)+32656), C10X CARD8
and A299G TLR4 CD-associated genotypes. RESULTS We observed a significant increase
of Enterobacteriacea (corrected P<0.01) in CD patients compared to their HR. When com-
pared to controls, CD patients and their HR showed decreased bacterial load of both
Clostridium innocuum (corrected P<0.05) and enterococcus sp. (corrected P<0.05). The
three CD-associated NOD2 mutations conferred with a significant decreased load of bifidob-
acteria sp. in both CD patients and HR. CD patients' genotypes analysis revealed a NOD2
gene-dosage effect with decreased bifidobacteria sp. load (corrected P<0.05). No significant
association was found with CARD8, NOD1 and TLR4 variants. CONCLUSION Our results
suggest that NOD2 mutations are predisposing to dysbiosis. Further work should now
investigate the role of NOD2 mutations in predisposing for the colonization by adherent-
invasive E. coli and how NOD2 control the composition of the intestinal flora.
T1765
Intestinal Epithelial Cell (IEC) Proteomics Under Condition of Chronic
Inflammation
Tanja V. Werner
Background. The loss of IEC function is a critical component in the initiation and perpetuation
of chronic intestinal inflammation in the genetically susceptible host. We applied proteome
analysis (PA) to characterize changes in the protein expression profile of primary IEC from
patients with Crohn's disease (CD) and ulcerative colitis (UC). In addition, protein expression
profiling of primary IEC was performed in native IEC of WT and IL-10-/- mice colonized
with E. faecalis for 2 and 14 weeks and for Mode-K cells stimulated with E.faecalis and rIL-
10. Methods. Surgical specimens from 18 patients with active CD (N=6), UC (N=6) and
colonic cancer (N=6) were used to purify primary IEC from ileal and colonic tissues. Primary
IEC from the large intestine were obtained and purified from germfree and colonized WT
and IL-10-/- mice. Mode-K cells were stably transfected with IL-10 receptor (IL-10R).
Changes in protein expression were identified using 2D-gel electrophorese and peptide mass
fingerprinting via MALDI-TOF mass spectrometry as well as Western Blot analysis. Results.
PA of primary IEC from inflamed ileal tissue of CD patients and colonic tissue of UC patients
identified 21 proteins with at least 2-fold changes in steady state expression levels compared
to the noninflamed tissue of control patients. Statistical significance was achieved for 9
proteins including the Rho-GDP dissociation inhibitor (Rho GDI) alpha that was up-regulated
in CD and UC patients. Additional 40 proteins with significantly altered expression levels
were identified in IEC from inflamed compared to non-inflamed tissue regions of single UC
(N=2) patients. The most significant change was detected for programmed cell death protein
8 (7.4-fold increase) and annexin 2A (7.7-fold increase). Interestingly, bibliometric analysis
comparing epithelial cells under inflammatory conditions from IL10-/- mice, Mode-K cells
and IEC from IBD patients showed an overlap of proteins including heat shock 70 kd
protein, heterogenous nuclear ribonucleoprotein A2/B1, KH-type splicing regulatory protein,
galectin 3, serin (or cysteine) peptidase inhibitor (clade B), Keratin 19, 14-3-3 protein,
creatine kinase, proteasome 28 subunit alpha (15.8%). Conclusion. PA in primary IEC from
IBD patients revealed significant expression changes of proteins that are associated with
signal transduction, stress responses as well as energy metabolism. Cluster analysis between
murine and human experiments revealed significant overlaps suggesting disease-relevant
mechanisms in relation to destruction of IEC homeostasis under condition of chronic intest-
inal inflammation.
T1766
Probiotic Pulse Therapy Imparts Ongoing Modulation of Intestinal Rmuc3
Mucosal Mucin Expression in Rats
Natalie Godwin, Lucie Hyde, David R. Mack
Mucins are large glycoproteins produced by intestinal epithelial cells, secreted over their
mucosal surfaces and act to limit noxious substances and enteropathogen access to their
mucosal surface. MUC3 is the main mucin gene of the human small intestine and is upregul-
ated by probiotics during In Vitro intestinal cell culture studies. This study investigates the
ability of continuous and intermittent probiotic administration in modulating rat Muc3
mRNA and protein expression In Vivo. Methods: Lactobacillus plantarum strain 299v (Lp299v)
or Bifidobacterium bifidum strain R0071 (BbR0071) were added to the drinking water of
Sprague-Dawley rats. Based on water intake, rats ingested 107 CFU for up to 20 consecutive
days or on an intermittent pulse basis consisting of two 2-day periods on probiotic ingestion
separated by 8 days of water without probiotics. Water bottles were changed on a daily
basis and bacteria strains were grown each night as required. Following group sacrifice,
jejunal segments were excised and mucosal scrapings were stored in a stabilizing reagent
(RNAlater™) until RNA was extracted (RNeasy™ kit). rMUC3 mRNA was quantified using
TaqMan® RT-PCR normalized to rodent GAPDH expression levels. Jejunal segments were
also preserved for immunofluorescent analysis using an anti-rMuc3 antibody. Results: rMuc3
mRNA expression was increased following 2 days (207±19% control, mean±SE, p<0.05)
and 5 days (155±14% control, p<0.05) of Lp299v but was not different than controls after
10 days or 20 consecutive days of ingestion. BbR0071 ingestion for 10 days followed by 2
days of Lp299v treatment did not result in an increase in mucin gene expression (p>0.05)
at day 12 analysis. Conversely, there was a significant increase in jejunum rMuc3 mRNA
expression (183±9.2% control, p<0.05) at day 12 following implementation of a probiotic
pulse regimen of 2 days Lp299v, 8 days no probiotic, followed by an additional 2 days
Lp299v administration. Immunohistochemistry of jejunal segments revealed positive rMuc3
fluorescent activity on mucosal surfaces. Consistent with mRNA expression levels, increased
fluorescent activity was seen at 2 days and 5 days of consecutive Lp299v ingestion and
following probiotic pulse administration. Conclusions: There is a time limited effect on
induction of rMuc3 mucin expression in the jejunum of rats following probiotic ingestion
however, this effect is reproducible following intermittent administration of a probiotic
organism. Pulse probiotic administration may thereby provide for a strategy for induction
of innate protective mechanisms such as mucin expression, which otherwise declines in a
time-dependent manner.
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T1767
Enteropathogenic Escherichia coli Nleh Encodes a Type III Secretion System
Dependent Effector Whose Expression Is Upregulated Under Conditions of
Infection
Sandhya V. Royan, Amy Yang, V. K. Viswanathan, Gail A. Hecht
Enteropathogenic E. coli (EPEC) is responsible for significant morbidity and mortality from
diarrhea, particularly in children in developing countries. EPEC, an extracellular pathogen,
adheres to intestinal epithelial cells and causes characteristic attaching and effacing lesions.
Additionally, EPEC disrupts intestinal epithelial barrier function and modulates host immune
responses. Pathogenesis is dependent on a bacterial type III secretion system (T3SS) which
delivers effector molecules into the host cell cytosol. Manipulation of host signaling pathways
by these molecules is thought to facilitate bacterial persistence and spread. The T3SS and
several effector molecules are encoded on a pathogenicity island known as the locus of
enterocyte effacement (LEE). Additional non-LEE encoded (Nle) effector molecules have
been described. NleH, a putative 303 amino acid protein, displays sequence similarity
with Shigella flexnerii OspG (27% identity, 46% similarity), a type III-secreted effector that
downregulates host pro-inflammatory signaling. The aim of this study was to examine the
expression, secretion and role of NleH in EPEC pathogenesis. RT PCR analysis revealed that
nleH expression, like that of other effector genes, was induced >2 fold by growing EPEC in
tissue culture medium (DMEM) as compared to growth in bacterial medium. Western blot
analysis confirmed the expression and secretion of plasmid-encoded myc-tagged NleH from
wildtype EPEC (WT); in contrast, myc-tagged NleH was expressed, but not secreted, from
a T3SS mutant confirming that NleH secretion is T3SS-dependent. An isogenic EPEC nleH
mutant (ΔnleH), generated by replacement of the gene with a kanamycin cassette, was not
impaired for growth or attachment to epithelial cells. ΔnleH was tested for its ability to
disrupt epithelial barrier function and stimulate the production of the pro-inflammatory
molecule, interleukin 8 (IL-8). The decrease in transepithelial electrical resistance (TER) of
Caco-2 monolayers by ΔnleH was not significantly different from WT (-60.0±17% vs -77.0±
5% for ΔnleH and WT; n=3, p>0.1). Similarly, WT and ΔnleH induced equal secretion of
IL-8 (591.7±11.9 vs 634.6±10.3 pg/ml for WT and ΔnleH, n=3, p=0.09). The presence of
an NleH paralog (NleH2) in EPEC may explain the lack of an identifiable phenotype for
this secreted effector.
T1768
Increased Intestinal Permeability in Patients with Small Intestinal Bacterial
Overgrowth (SIBO)
Alessia Cazzato, Emidio Scarpellini, Venanzio Valenza, Ernesto C. Lauritano, Lucia
Sparano, Giovanni Cammarota, Giovanni Gasbarrini, Antonio Gasbarrini
Background: Qualitative and/or quantitative alterations of enteric flora composition results
in the disruption of gut ecological equilibrium with morphologic, metabolic and immunologic
effects. Small intestinal bacterial overgrowth (SIBO), a frequent clinical condition defined
as an abnormally high bacterial population, exceeding 106 CFU/mL of intestinal aspirate
has been evoked as potential risk factor of altered intestinal permeability. SIBO can lead to
absorption of endotoxin and direct traslocation of bacteria across the intestinal epithelium
playing a role as potential risk factor for spontaneous bacterial peritonitis and steatohepatitis.
Aim: To explore the prevalence of impaired intestinal permeability in SIBO symptomatic
patients using the 51Cr-EDTA absorption test and to evaluate its possible relation to malab-
sorption syndrome. Patients and Methods: 30 consecutive pts with SIBO presenting at least
one of the following signs: anemia, steatorrhoea, weight loss in the last three months, were
enrolled. Besides, 20 healthy volunteers were used as control group. All pts enrolled under-
went glucose breath test (GBT) under standard conditions to detect SIBO and 51CrEDTA
absorption test to assess intestinal permeability. Diagnosis of SIBO was based on the occur-
rence of a peak of H2 values more than 12 ppm above the basal value after 50 gr glucose
ingestion. After an overnight fast, pts were given to drink 2,96 MBq of 51Cr-EDTA (Amersham
Health, England) in 10 ml of water; two 3-ml samples of 24/hours urine collection were
measured by gamma counter (LKB-Wallac 1282 Compugamma, Turku, Finland). The excre-
tion of 51Cr-EDTA was calculated using the following formula: (Mean Urinary Counts x
Urinary Volume) x (Standard counts x 50)-1; result was expressed as % of administered
dose. Results: The 80% of SIBO pts (24 out of 30 pts) showed an impaired intestinal
permeability (mean ± sd of 51Cr-EDTA-urinary excretion rate: 10.2±0.6%); besides, only
one out of the 20 healthy subjects (5%) had an altered test. Difference between the two
groups was statistically significant (p<0.00001). Conclusion: Our results demonstrate that
intestinal permeability is pathologically increased in SIBO pts. Unbalance among bacterial
species could be responsible of intestinal barrier disruption promoting malabsorption syn-
drome in SIBO pts. However, primary impairment of intestinal barrier could be responsible
of uncontrolled bacterial proliferation leading to SIBO. Inflammatory response to luminal
bacterial polymers, such as peptidoglycan and lipopolysaccharides, can favour endotoxin
absorbance and bacterial traslocation being a risk factor for liver damage and systemic sepsis.
T1769
Citrobacter rodentium Infection Causes a Decrease in cAMP Mediated Ion
Secretion in Mouse Intestinal Epithelial Cells
Christina L. Alexander, Wallace Macnaughton
Escherichia coli infections are the leading cause of infantile diarrhea in developing countries,
accounting for several thousand deaths per year. Citrobacter rodentium infection of mice,
which mimics the lesions of pathogenic E. coli infections in humans, was previously shown
to decrease ion transport in response to the Ca2+-dependent secretagogue carbachol (CCh).
In order to determine the cellular mechanism underlying these observations, we used an In
Vitro model, the mouse intestinal cell line CMT-93. CMT-93 monolayers were cultured on
semi-permeable membrane supports and exposed for 2-8 hr to log phase C. rodentium grown
in LB broth. Epithelial monolayers were mounted in Ussing chambers to measure the change
in ion secretion by short circuit current (ΔIsc) and area under the curve (AUC), representative
of maximal rate and total ion transport respectively. Both CCh and the cAMP-dependent
secretagogue, forskolin (FSK), caused a concentration-dependent increase in ΔIsc and AUC
when added to the basolateral side of uninfected CMT-93 monolayers. CCh (20 μM) and
FSK (10 μM) gave maximal responses that were abolished with the use of chloride-free
buffer. In additional experiments, monolayers were grown and similarly infected in culture
dishes with subsequent RT-PCR for the cAMP-dependent chloride channel, CFTR. The
response to FSK was significantly (p<0.05) decreased after 8 hr exposure in terms of ΔIsc
(control, 4.5±0.3; 8 hr, 1.9±0.1 μA/cm2) and AUC (control, 3.4±0.3; 8 hr, 0.8±0.1 mC/
cm2) with a multiplicity of infection (MOI) of 100. However, only the 4 hour The ΔIsc
response to CCh was significantly increased, but only at 4 hr and only with a high dose
(MOI=1000) of C. rodentium (control, 2.2±0.3; 4 hr, 4.3±0.3 μA/cm2). An MOI of 10 had
no effect on any responses. Exposure to LB broth or sterile bacteria culture medium for 24
hr did not alter secretagogue responses. However, heat-killed bacteria significantly reduced
the FSK response similar to infected cells (control, 3.9±0.4; heat-killed, 2.4±0.2 μA/cm2),
without affecting the CCh response. This implicates heat-stable bacterial factors in the
observed response. RT-PCR showed no difference in cellular CFTR mRNA levels after 8
hours exposure, suggesting that the C. rodentium-induced change in the response to FSK
was not due to changes in CFTR gene expression. In conclusion, C. rodentium exposure for
8 hours decreases cAMP-dependent, but not Ca2+-dependent, ion secretion in CMT-93 cells
without affecting CFTR gene expression.
T1770
Anti-GM-CSF Auto-Antibodies Regulate Neutrophil Function and Correlate
with Inflammatory Bowel Disease Phenotype
Subra Kugathasan, Kanji Uchida, Diana Mallin, Xiaonan Han, Ingrid Jurickova, Bruce
Trapnell, Lee Denson
Introduction: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) reduces disease
activity in Crohn's Disease (CD), suggesting that reduced GM-CSF bioactivity may contribute
to pathogenesis in a sub-set of patients. GM-CSF is required for priming of innate antimicro-
bial functions. We have identified anti-GMCSF auto-antibodies which reduce GM-CSF
bioactivity in normal healthy individuals. We hypothesized that anti-GM-CSF would be
up regulated in CD, within the range which inhibits innate immune functions. Methods:
Inflammatory Bowel Disease (IBD) phenotype was classified using the Montreal system in
two cohorts of pediatric onset IBD patients and age-matched healthy controls (n=265 with
a median of four years from diagnosis). CD patients with ileal (L1) or ileo-colonic (L3)
involvement were combined in the analysis (CDSB). Anti-GM-CSF serum concentration was
measured by ELISA, and the CARD15 single nucleotide polymorphisms (SNPs) 8, 12, and
13 were determined. Neutrophil phagocytic capacity was measured in healthy controls (NL)
and in GM-CSF deficient micE. colitis was induced in GM-CSF deficient mice and wild
type (WT) controls using TNBS administration. Results: The median anti-GM-CSF serum
concentration was increased five-fold in CDSB, relative to healthy controls and patients with
Crohn's Colitis (CC) or Ulcerative Colitis (UC). The Odds Ratio (OR) for ileal involvement
in CD patients with an elevated anti-GM-CSF level (≥ 2 mcg/ml) was 5.2, comparable to
the OR of 4.6 associated with CARD15 SNP carriage. Fifty percent of CD patients carrying
a CARD15 SNP also had an elevated anti-GM-CSF level, and in these the OR for ileal
involvement increased to 13. The median anti-GM-CSF level was increased four-fold in CD
patients with penetrating or stricturing behavior, compared to those with inflammatory
behavior. Consistent with this, the OR for surgery in CD patients with elevated anti-GM-
CSF was equal to 3.2. Anti-GM-CSF levels were stable during medical therapy. Neutrophil
phagocytic capacity correlated inversely with anti-GM-CSF serum levels, over the range
observed in IBD patients. GM-CSF deficient mice demonstrated reduced neutrophil phago-
cytic capacity, and increased weight loss and histological injury following TNBS administra-
tion. Conclusions: Anti-GM-CSF auto-antibodies reduce GM-CSF bioactivity and correlate
with susceptibility to ileal involvment in CD. This suggests an interaction with CARD15
SNP carriage which may involve impaired priming of innate antimicrobial functions. The
serum anti-GM-CSF level may guide therapy, in terms of whether augmentation of GM-
CSF bioactivity would be beneficial.
T1771
Pathophysiological Effects of the Intestinal Lipopolysaccharide in Host-
Commensal Interactions
Sang hoon Rhee, Sam eun Kim, Kristopher S. Strach, Charalabos Pothoulakis
Background & Objectives: Despite that the intestinal mucosa is in continuous contact to
LPS from commensal bacteria, the normal intestinal epithelium is hyporesponsive to LPS,
likely due to the low epithelial cell expression of TLR4 and/or the tight junctional intestinal
epithelial barrier. However, the level of microbial products in the intestine can be elevated
during bacterial infection increasing LPS. Our objective was to determine the effects of
elevated LPS in the intestine In Vivo. Methods: We administered LPS (1.5 mg/kg) to CD-1
mice (n=20) by rectal enema every day for 10d and observed them 3 times/d for morbidity,
weight loss, and diarrhea. Histological changes in the colonic and small intestinal mucosa
(jejunum) of LPS-treated mice were also evaluated. Since intestinal inflammation is associated
with excessive T cell activation, we investigated if elevated LPS in the colon influences
splenic regulatory T (Treg) cells (suppressing T cell proliferation), by flowcytometry using
the Treg cell markers CD25 and FoxP3. Since IL-10 drives the differentiation to Treg cells
and shifts the T cell response from Th1 to Th2, we studied the role of IL-10 using IL-10-/-
mice intracolonically injected with LPS. Lastly, to determine the role of T cell activation,
Rag-1-/- mice were exposed to LPS followed by evaluation of intestinal inflammation. Results:
Two to 3d after intracolonic LPS administration mice showed increased diarrhea and morbid-
ity, ~15% weight loss, and severe small intestinal inflammation and marked fluid secretion.
However, intestinal inflammatory changes became less evident after 4-5d and were absent
10d post-LPS. At 2-3d post-LPS, histologic analysis revealed significantly increased erosive
lesions and mucosal inflammation in the small intestine, characterized by degenerated villi
and crypts. However, no colonic inflammatory changes were evident during the entire
experimental period. Moreover, small intestine from LPS-exposed mice for 5d showed re-
generated villi and crypts in the epithelium, reflecting the transient nature of the intestinal
inflammation by LPS, while IL-10-/- or Rag-1-/- mice failed to recover from LPS-associated
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intestinal inflammatory changes. The Treg cell (CD4+/CD25+ or CD4+/FoxP3+) splenic
population was substantially reduced in LPS-treated mice (d 2 and 5 post-LPS). Conclusion:
Elevated intestinal LPS causes significant, but transient enteritis and reduces the number of
Treg cells. IL-10 and T cell activation are required for LPS tolerance in the intestine. Supported
by a Research Fellowship Award (SHR) and Senior Research Award (CP) from CCFA, and
by NIH DK DK072471 (CP).
T1772
Bacteria Induce Pro-Inflammatory Function By Human Small Intestinal
Dendritic Cells
Ernesto R. Drelichman, Akhil Maheshwari, Meg Mosteller-barnum, William Marion,
Ronald H. Clements, Devin Eckoff, Phillip D. Smith, Lesley Smythies
Background: The role of human small intestinal dendritic cells (DCs) in regulating mucosal
immunity has received little investigative attention, in contrast to that of intestinal macro-
phages (Smythies, et al. J. Clin. Invest. 2005). Therefore, we sought to (1) Isolate and
characterize resident DCs from human small intestine; (2) Determine whether antigen (E.
coli) applied to human intestinal mucosa induces DC migration and antigen-specific T cell
proliferation; and (3) Determine whether resident DCs in the non-inflamed mucosa of
patients with Crohn's disease are predisposed to inflammation and T cell activation. Methods:
Resident CD11b+/CD11c+ cells were isolated from human intestine by enzyme digestion
and flow cytometry, cultured 24 hr with bacterial antigens and tested for IL-6, -10 and -12
production. Explanted normal human small intestinal mucosa in a transwell system was
established to track the migration of DCs with/without cargo from the subepithelial space
into the sub-mucosa. CD11b+/CD11c+ cells were phenotyped for CD80, CD86 and CD83
and tested for induction of bacteria-specific T cytokine release and cell proliferation. Results:
(1) Resident CD11b+/CD11c+ DCs from normal intestinal mucosa are immature (CD83
negative) and inflammation anergic (unable to release inflammatory cytokines). (2) Bacteria
applied to the apical surface of normal mucosa drive resident DC migration and promote
maturity (increased CD83 expression, cytokine release and bacteria-specific antigen presenta-
tion). (3) DCs from the non-inflamed intestinal mucosa of patients with Crohn's disease are
more numerous, more mature (CD83 expression) and more activated (increased CD80 and
CD86 expression and cytokine release) than resident intestinal DCs from the non-inflamed
mucosa of healthy subjects. Conclusion: Resident intestinal DCs from uninflamed mucosa
of healthy subjects are down-regulated for inflammatory and immune responses but overcome
this inflammation anergy upon uptake of bacteria in situ. In contrast, resident intestinal DCs
from Crohn's disease mucosa are predisposed to enhanced inflammation and T cell activation.
T1773
Dendritic Cells Do Not Undergo Apoptosis When Exposed to Anti-TNF
Antibodies
Vinod K. Patel, Matthew Butler, Subrata Ghosh
INTRODUCTION: Anti-TNF therapy is effective in the treatment of IBD. Its effect on
dendritic cells(DCs) is not fully understood. DCs are important antigen presenting cells and
are activated via Toll-like receptors (TLR) by TLR ligands such as LPS. It has been demon-
strated recently that DC apoptosis is an important mechanism of immunoregulation. It is
not clear whether infliximab causes apoptosis of DCs. AIMS & METHODS: Monocytes
derived from IBD patients and controls were cultured in serum free medium in the presence
of GM-CSF and IL-4 to derive DCs. Monocyte derived-DCs from the above subjects were
activated with LPS and exposed to etanercept, adalimumab, or infliximab. Cytokine profile
of the culture supernatants were studied for IL-12p70, IL-10 and TNF. DCs were assessed
by flow cytometry after staining with Annexin V and Propidium Iodide in a calcium rich
medium. The remaining DCs were subjected to a mixed lymphocyte reaction (MLR) with
allogeneic lymphocytes (CD4+). Post proliferation IFN-gamma(Th1) and IL-13 (Th2) levels
from lymphocytes were assessed. RESULTS: There was no apoptosis seen in LPS activated
DCs at increasing concentrations of infliximab 1, 10,100mcg. In contrast, we were able to
demonstrate apoptosis of CD4 lymphocytes at concentrations of 0.1 to 10mcg. The cytokine
profile of the anti-TNF exposed LPS activated DCs showed that IL-10 concentration was
reduced, which was greatest with adalimumab followed by etanercept and then infliximab.
IL-12p70 concentration were also reduced, the greatest reduction being with etanercept,
followed by adalimumab and infliximab. TNF concentrations were reduced and the greatest
reduction was with infliximab followed by adalimumab. Etanercept did not show a change
in TNF levels. In the MLR reaction infliximab pulsed LPS activated DCs demonstrated a
20% reduction in proliferation at 10mcg/ml concentration and 30% at 100mcg/ml. Finally
the cytokine concentrations from supernatants after proliferation of CD4+ T cells in a MLR
with infliximab pulsed LPS activated DCs demonstrated an 45% reduction in IL-13 at a
concentration of infliximab 100mcg/ml as compared to IgG controls. Also IFN-gamma levels
showed a 6% reduction at 100mcg/ml as compared to IgG controls. CONCLUSION: Unlike
monocytes and lymphocytes, LPS activated (or immature) DCs do not undergo apoptosis
when exposed to anti-TNF agents. Anti-TNF agents do however cause a reduction in DC
derived IL-12, TNF and IL-10 and also reduce T-cell activation in an MLR in a dose
dependent manner. DC driven T lymphocytes show inhibition of both IL13 and IFN-gamma.
T1774
Mesenchymal Stem Cells from the Gastrointestinal Stroma in Inflammatory
Bowel Disease (IBD) and Colon Cancer: Isolation, In Vitro Expansion and
Characterization
Andrea Belluzzi, Giacomo Lanzoni, Giulia Roda, Francesco Alviano, Laura Bonsi, Cosetta
Marchionni, Francesca Tonon, Alessandra Caponi, Anna Tuci, Aldo Roda, Gian paolo
Bagnara, Enrico Roda
Aim:Mesenchymal Stem Cells (MSCs) are a class of multipotent adult progenitors capable
of differentiating into bone, cartilage, adipose tissue and a very potent immunomodulatory
functions expecially inhibiting the immune response. They reside into several adult tissues
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(bone, cartilage,adipose and a variety of other tissues deriving from mesoderm,endoderm
and ectoderm), but not much is known about their presence and role in the gastrointestinal
(GI) environment. The isolation from the GI stroma of mesenchymal populations displaying
MSC characteristics may lead to new insights on the poorly investigated GI stromal kinetics
and biological roles and an important new approach for Inflammatory Bowel Disease (IBD)
diagnosis and treatment Patients and Methods : 5 IBD patients undergoing colectomy and
7 colon cancer patients undergoing tumor resection, gave informed consent for the study.
We obtained 18 surgical specimen (average size: 2x3 cm) that were cultured for 24 hours
in disinfection medium (DMEM, Penicillin, Streptomycin, Cefoxitin, Lincomycin, Colimycin,
Vancomycin, Amphotericin B). Mucosa and Submucosa were mechanically separated and
enzymatically digested by Trypsin, EDTA, DNAse and Collagenase; cells where then cultured
in DMEM with 10% fetal bovine serum. Results: We successfully isolated and extensively
expanded mesenchymal stromal populations that at flow cytometry analysis showed the
typical MSC profile: CD105+, CD73+, CD29+, CD44+, CD166+ and CD14-, CD34-, CD45-
. Mucosal mesenchymal cultures showed CD117 positivity, submucosal cultures showed a
CD34 low positive subset. The cells displayed the ability to undergo In Vitro osteogenic
(induction with ascorbic acid, DEX, b-glycerophosphate phosphate; Von Kossa staining),
adipogenic (insulin, DEX, indomethacin, IBMX; Oil Red O staining) and chondrogenic (DEX,
sodium pyruvate, ascorbic acid, proline, ITS-LA, TGF-bIII; Collagen type II detection)
differentiation. Immunomodulating activity was shown coculturing PHA-stimulated T lim-
phocytes with GI-stroma derived MSCs: proliferation was measured by [3H] -thymidine
incorporation. Conclusions: The current study suggests that multipotent MSCs can be isolated
from the GI stroma and extensively expanded. MSCs show immunomodulatory activity in
ongoing ex vivo studies and could represent a potential novel therapeutic agent for IBD.
T1775
The Toll-Like Receptor (TLR) Adapter Molecule Myeloid Differentiation Factor
88 (Myd88) Is Required for Both T Cell Effecter Function and Regulatory
Function in a Murine Model of Inflammatory Bowel Disease
Masayuki Fukata, Keith Breglio, Anli Chen, Tyralee Goo, Daisy Conduah, Ruliang Xu,
Maria T. Abreu
Background: Abnormal T cell responses to commensal bacteria are involved in the pathogen-
esis of inflammatory bowel disease (IBD). MyD88 is an essential signal transducer for TLRs
and response to the luminal micro flora. The role of MyD88-dependent signaling in T cells
is unclear. We hypothesized that TLR signaling via MyD88 was important for development
of colitis in the murine CD4+CD45Rbhi T cell adoptive transfer model. Methods:
CD4+CD45Rbhi naïve T cells and/or CD4+CD45RblowCD25+ regulatory T cells (Tregs) were
isolated from MyD88-/- or wild-type (WT) spleens and adoptively transferred to RAG1-/-
micE. colitis was assessed by changes in body weight and histologic score. Cytokines and
integrin expression were assessed by ELISA and flow cytometry, respectively. In Vivo prolifera-
tion was assessed by BrdU and CFSE labeling. Results: Naïve T cells from MyD88-/- mice
did not induce wasting disease. Compared to the transfer of WT naïve T cells, transfer of
MyD88-/- T cells resulted in significantly lower colitis scores (11.8±4.0 vs. 3.9±4.0, P<0.05,
max: 20). In addition, Tregs from MyD88-/- mice did not protect against colitis induced
by WT naïve T cells. To understand the mechanism by which MyD88-/- T cells were defective
in effecter and regulatory functions, we examined number of colonic CD4+ T cells and
found that mice receiving WT T cells had twice as many lamina propria T cells than mice
receiving MyD88-/- cells. BrdU and CFSE labeling showed significantly greater proliferation
of CD4+ T cells in the MLN and lamina propria of mice receiving WT T cells compared
with MyD88-/- T cells. Moreover, α4β7 integrin expression in PBMC was higher in recipients
of WT T cells than in MyD88-/- T cell recipients. Secretion of IL-2 and IL-17 was significantly
higher in colonic and MLN T cells from WT recipients than MyD88-/- recipients. Treg
function was assessed ex vivo in CD4+CD25+ T cells from MyD88-/- mice. Although Treg
numbers were similar to WT, MyD88-/- Tregs had decreased ability to suppress proliferation
of effecter T cells challenged with anti-CD3 and anti-CD28. Conclusion: Signaling via MyD88
on T cells is required for proliferation, homing, and IL-17 differentiation of naïve T cells.
It is also required for Treg-mediated suppression of colitogenic T cells. These results suggest
a role for TLR signaling by T cells in development of IBD.
T1776
Crucial Role of the Transcription Factor Nfatc2 in the Pathogenesis of
Ulcerative Colitis
Benno Weigmann, Raja Atreya, Hans-anton Lehr, Peter R. Galle, Laurie Glimcher, Markus
Neurath
The cytokine production of CD4+ T-cells plays an important role in the pathogenesis of
inflammatory bowel disease (IBD) with its entieties Crohn's disease (CD) and ulcerative
colitis (UC). Although various data indicate a pathologic Th2 cytokine expression in UC,
the molecular mechanisms underlying this altered cytokine production are still unknown.
Transcription factors of the NFAT (nuclear factor of activated T-cells) family seem to have
a pivotel role in disease pathogenesis, as they modulate the cytokine production of T-cells.
The aim of this study was to further analyze this novel signal transduction pathway and its
pathogenic significance in UC. Isolated Lamina propria mononuclear cells (LPMC) from the
mucosa of patients with IBD were examined regarding their rate of apoptosis induction
upon treatment with Cyclosporin A (CsA). Cytometric analysis of annexin V/propidium
iodide stained cells indicated an induction of apoptosis upon CsA administration in UC
compared to LPMC's from CD and control patients. Further studies revealed that CD4+ T-
cells were the main cell population that underwent apoptosis. ELISA's of supernatants from
cultivated LPMC revealed a significant inhibition of IFN-γ and IL-13 after CsA treatment,
while IL-2 production was not suppressed. Next LPMC's from intestinal biopsies of patients
suffering from UC and CD were isolated and fluorescence-stained with NFATc2 antibodies.
A significantly higher expression of NFATc2 was found in UC and CD tissue compared to
control specimen. Finally, in the oxazolone induced colitis model, NFATc2 deficient mice
were significantly protected against the development of intestinal inflammation compared
to control mice. This could be demonstrated by loss of weight, histological score and
miniendoscopy. TUNEL staining of cyrosections of inflammed colonic tissue displayed a
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higher apoptotic rate in NFATc2 deficient mice. Our data identify a central regulatory role
of NFATc2 in the pathogenesis of UC. The examination of this novel signal transduction
pathway has important implications for the development of new therapeutic strategies.
T1777
Pparγ Is Involved in Butyrate-Mediated Inhibition of LPS-Induced NfκB
Activation
Markus Schwab, Jürgen Stein, Oliver Schröder
Introduction: NFκB plays a major role in the control of immune and inflammatory responses.
Recently, it has been demonstrated that the short chain fatty acid butyrate suppresses NFκB
activation in colorectal cancer cells. However, the underlying molecular mechanisms are yet
not fully understood. We therefore investigated a possible involvement of the Peroxisome-
Proliferator-Activated-Receptor γ (PPARγ) and the Vitamin D Receptor (VDR) in butyrate-
mediated inhibition of NFκB. Material and Methods: HT-29 cells were pre-treated with or
without butyrate (4 mM) for 24 h and then stimulated with TNFα(100 ng/mL) or LPS (10
µg/mL) for 30 min. Nuclear NFκB p50 and p65 dimer activity was analysed using the
TransAM® transcription factor assay kit. Cytosolic IκBα expression was examined by western
blot analysis. To scrutinize any involvement of PPARγ, experiments were also performed in
HT-29 cells transfected with a dominant-negative PPARγ mutant to inhibit wild-type PPARγ
action. Moreover, NFκB and IκBα levels were detected after challenge of HT-29 cells with
the PPARγ antagonist GW9662 (5 µM) or the VDR inhibitor ZK191732 (10 µM) in the
presence or absence of butyrate (4 mM) after 24 h, respectively. Results: Treatment of HT-
29 cells with butyrate reduced basal NFκB p50 dimer activity in the nucleus (-45%, p<0.001).
In contrast, p65 dimer activity was not affected. TNFα- and LPS-mediated up-regulation of
p50 (TNFα: +73%, p<0.001; LPS: +52%, p<0.001) and p65 (TNFα: +413%, p<0.001; LPS:
+205%, p<0.001) basal NFκB dimer activities were significantly attenuated in response to
butyrate (TNFα: p50: -63%, p<0.01; p65: -62%, p<0.001; LPS: p50: -63%, p<0.01; p65:
-49%, p<0.01). Cytosolic expression of IκBα was reduced by butyrate and TNFα but not
by LPS. Neither transfection of HT-29 cells with a dominant-negative PPARγ mutant vector
nor incubation with the PPARγ antagonist GW9662 did affect butyrate-mediated actions on
NFκB activity and IκBα expression. In contrast, butyrate-mediated inhibition of LPS-induced
NFκB activity was attenuated in dominant-negative PPARγ mutant cells. Challenge of HT-
29 cells with the VDR antagonist ZK191732 increased both, p50 (+58%,p<0.01) and p65
(+78%,p<0.001) basal NFκB dimer activities while reducing the expression of IκBα. Co-
incubation of ZK191732 abolished the inhibitory effect of butyrate on NFκB activity. Conclu-
sion: These findings provide evidence for an PPARγ dependent mechanism in the inhibition
of LPS- but not TNFα-induced NFκB activation caused by butyrate and may suggest new
possibilities in the treatment of inflammatory bowel diseases. Moreover, the VDR appears
to play an inhibitory role in the regulation of NFκB activation.
T1778
Rational Development of 6-Thio-GTP Analogues: A Novel Class of
Immunosuppressive Drugs for Inflammatory Bowel Disease
Imke Atreya, Alexandra Diall, Daniela Poppe, Gerhard Fritz, Radovan Dvorsky, Mathias
Grün, Peter R. Galle, Markus F. Neurath
Introduction: Azathioprine (aza) and 6-Mercaptopurine (6-MP) are considered to be the
gold standard for maintenance of remission in IBD. Their immunosuppressive capacity is
explained by the ability of its metabolite 6-Thio-GTP to bind to the GTPase Rac, to block
the GEF-activity of Vav and to inhibit activation of Rac. Blockade of Rac activation leads to
induction of apoptosis in CD3/CD28 co-stimulated T cells. The success of aza in treatment
of acute flares of IBD is limited by its delayed onset of action. This delayed onset of action
is due to the fact, that 6-Thio-GTP has a relatively low affinity to Rac. Therefore, we designed
chemically modified derivatives of 6-Thio-GTP with higher affinity to Rac, which might be
able to mediate faster and stronger immunosuppressive effects than aza. Methods: Using
steric modelling, a rational design of 6-thio-GTP analogues was achieved. Four different
main groups of chemically modified 6-Thio-GTP derivatives (Group A, B, C and D) were
then synthesized and testet In Vitro. Each of these groups consisted of 3-12 different derivat-
ives. After treatment of stimulated T cells with the new compounds, the rate of apoptotic
cells was analysed by caspase-3 activity assay and by AnnexinV/PI staining. The ability of
new derivatives to compete with binding of GTP to Rac and to inhibit the activation of Rac
in treated human T cells was tested in In Vitro assays. Results: Treatment of T cells with
Group B and Group D derivatives resulted in clear induction of apoptosis, whereas Group
A and C derivatives completely lost the capacity to induce apoptosis in our experimental
setting. We then identified the most promising candidates within Group B and D, which
were able to induce either increased levels of apoptosis or an earlier onset of apoptosis in
comparison to aza, 6-MP or its metabolite 6-thio-GTP. Derivatives, which fulfilled these
criteria, were further analysed for their capacity to inhibit Rac activity in human co-stimulated
T cells and to compete with GTP for the binding to Rac In Vitro. Based on these results,
we were able to identify chemically modified derivatives of 6-thio-GTP, which in comparison
to the original substance 6-thio-GTP showed increased capacity to induce T cell apoptosis,
to inhibit Rac activation and to compete with GTP binding to Rac. In Vivo, 6-thio-GTP
analogues were able to suppress NK cell mediated cell death. Conclusion: Rational modifica-
tion of 6-Thio-GTP emerges as a promising approach for the development of a novel class
of immunosuppressive drugs with improved short term effects in chronic inflammation
and transplantation.
T1779
Retinoic Acid Receptor Alpha Agonist Altered Dendritic Cells Differentiation
Into IL-12 Hypoproductive Phenotype and Revealed Therapeutic Efficacy On
Murine DSS Colitis Models
Yasuyo Wada, Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, Toshifumi
Hibi
<Background and aims>Vitamin A is an important regulator of human immune system,
especially in gut. It has been reported that retinoic acid (RA), a metabolite of vitamin A,
regulates T and B-cell immune functions. RA suppresses the T helper (Th) 1 development
and enhances the Th2 development. Moreover, RA enhances the expression of gut-homing
receptors on T-cell. However, little is known about the effect of RA on antigen presenting
cells. In the present study, we focused on the dendritic cells (DC), and assessed the effects
of RA on the differentiation and function of DC. And we investigated the therapeutic effect
of RA on murine dextran sodium sulfate (DSS) colitis. <Material and Methods>(1) Effect
on differentiation of DC: To obtain the monocyte derived DC, human peripheral blood
CD14 positive monocytes were isolated from healthy volunteers and cultured with GM-CSF
and IL-4 with or without synthetic retinoic acid receptor (RAR)-alpha specific agonist Am80
(100nM) for 6 days. Differentiated DCs were identified in their morphological types and
their surface marker expressions. Then DCs were stimulated with Lipopolysaccharide (LPS)
for 24 hours, and assessed cytokine secretion profiles. (2) Effect on murine colitis model:
Colitis was induced by administration of 2.0%DSS for 5days followed by 3 days of water.
Am80 (1mg/kg/day p.o.) administration was started 2 days before DSS administration and
was continued for the following 8 days. Mice were sacrificed at day 8 and assessed macro-
and microscopically. <Results>(1) DCs differentiated with RA showed different morphology
compared to vehicle controls. RA supplementation into the DC differentiation also suppressed
the expression of CD1a antigen on DC. Moreover, DCs differentiated with RA revealed less
production of IL-12p70 by LPS stimulation (vehicle= 725.6 ± 226.9 pg/ml vs RA = 15.5 ±
9.7 pg/ml), but IL-10 productions were not affected by RA. (2) RA treatment ameliorated
disease activity indexes, macro- and microscopic damages. Macroscopic findings revealed
that shortening of the colon were improved in the Am80 group (vehicle= 4.9 ± 0.1 cm vs
RA = 5.7 ± 0.2 cm). Histologic scores were also reduced in the Am80 group (vehicle= 9.3
± 0.4 vs RA = 5.1 ± 0.6). <Conclusions>RA induced DC showed less IL-12 productive
phenotype, which might prevent the development of Th1 immunity. And actually RA
treatment ameliorated the murine colitis model. Thus, RAR-alpha can be a new target of
Th1 dominant inflammatory diseases, such as Crohn's disease.
T1780
Mdp-Induced Apoptosis of Monocytes Is Mediated By NOD2/CARD15
Vanessa E. Beynon, Kerstin Maier, Alexander Faussner, Rudolf Gruber, Matthias
Folwaczny, Christian Folwaczny, Juergen Glas, Helga-paula Torok
Background: The underlying pathogenetic mechanisms linking Crohn's Disease (CD) to
mutations in NOD2 have not yet been elucidated. NOD2 mediates NF-κB activation in
response to muramyl dipeptide (MDP). This process is impaired in the presence of CD-
associated mutations. For several pathogen-associated molecular patterns pro- and also anti-
apoptotic effects have been described. Moreover, members of the NOD family have been
shown to have proapoptotic effects. In previous studies we have demonstrated that MDP
induces apoptosis in peripheral blood mononuclear cells (Beynon et al., Gastroenterology
2006, 130:A360). In order to analyze whether this effect is mediated by NOD2, monocytes
from NOD2 wildtype individuals and from individuals homozygous for the 1007fs NOD2
variant were studied. Methods: Monocytes from 8 NOD2 wildtype healthy controls, and 6
CD patients homozygous for the loss-of-function 1007fs mutation were isolated by gradient
centrifugation and subsequent purification with magnetic beads. Monocytes were cultured
either in standard cell culture plates or in plates precoated with a hydrogel layer preventing
attachment and minimizing activation of cells. Cells were treated with MDP for 24h in different
concentrations (100µg/ml and 100ng/ml) or medium alone. Apoptosis was determined by
flow cytometry analysis of annexin V binding population. Results: The percentage of apop-
totic wt-NOD2 monocytes significantly increased after treatment with MDP (19.4±5.6% and
18.1±3.9% for 100µg/ml and 100ng/ml MDP respectively) compared to untreated cells
(10.7±3.9% p<0.05). This effect was only observed for monocytes cultured in low attachment
plates and was absent when cells were cultured on adherent plates. In contrast, for monocytes
from individuals homozygous for the 1007fs mutation no significant increase in the percent-
age of apoptotic cells was observed after treatment with MDP (13.2±5.2 and 10.6±4.1
for 100µg/ml and 100ng/ml MDP respectively) compared to untreated cells (12.5±4.1).
Conclusion: This study demonstrates that MDP induces apoptosis in peripheral blood
monocytes. This effect is mediated by NOD2 and is abolished in the presence of the CD
associated 1007fs mutation. The described proapoptotic effect of MDP seems to be dependent
on the activation state of the cells. These observations are compatible with an implication
of the NOD2 protein in apoptosis. The impairment of this process caused by the 1007fs
variant could represent an important pathogenetic link between NOD2 mutations and CD.
It has to be further investigated whether other CD associated variants of NOD2 are also
affected in their ability to induce apoptosis of immunocompetent cells.
T1781
Ccr9 Expression Defines the Maturation Level of Dendritic Cells
Maureen Drakes, Thomas G. Blanchard
Background and Purpose: Chemokine-chemokine receptor binding guides the migration of
cells into tissues in health and disease. The chemokine receptor CCR9 directs T cells to
mucosal sites, but the function of this molecule on dendritic cells is unknown. Our studies
were designed to characterize the maturational state of CCR9 low and CCR9 high dendritic
cell populations. Methods: Myeloid DC were generated from bone marrow cells and cultured
in GM-CSF supplemented medium. Harvested low buoyant density non-adherent CD11c
positive cells were pulsed with bacterial CpG, interleukin-4 (IL-4), Lactobacillus plantarum
or Escherichia coli for an overnight period. Fluorescein labeled mAbs were used to detect
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surface expression of DC CCR9 and costimulatory molecules by double immunostaining.
Results: CCR9 was moderately expressed on BM derived DC (23%), while much lower levels
of CCR6 (6%) were observed. We earlier demonstrated the functional and phenotypic
properties of DC in response to the classical DC maturation factor IL-4. Addition of IL-4
or CpG (but not CpG control) resulted in DC maturation and a significant increase in CD40
and CD86 expression. Control PBS stimulated DC exhibited moderate levels of CCR9. This
parameter was significantly reduced (50%) in the presence of CpG or IL-4. Because of the
importance of CCR9 in homing of cells to the gut, we further examined the regulation of
DC CCR9 by L. plantarum, a probiotic bacterial species (effective against murine IBD), and
by control bacterium E. coli. Using a dose of 105 organisms/ ml, L. plantarum did not
significantly alter CCR9 or costimulatory molecule expression. However, over 3 experiments,
E. coli consistently reduced the percentage of CCR9 expressing cells with a concomitant
increase in cells expressing maturation markers CD40 and CD86. We have earlier studied
the potential of lamina propria DC from CD45RBhigh CD4 T cell transfer SCID mice to
contribute to murine IBD pathogenesis based on their preponderance to secrete or stimulate
the release of a dominant Th1 cytokine profile. Initial studies reveal moderate expression
of CCR9 on isolated lamina propria DC. Future studies will determine the function of this
molecule on gut DC. Conclusion: We present evidence that DC matured by several agents
exhibit a CCR9 low, CD40 high, CD86 high phenotype. In comparison unactivated/ immature
(L. plantarum or PBS treated) DC are CCR9 high, CD40 low, CD86 low in expression. We
propose that CCR9 expression is a relevant indicator of level of DC maturation.
T1782
Heme Oxygenase-1 Induced Macrophages Protect from DSS-Mediated Colitis
in Association with Stat1 Suppression
Ikuo Nakamichi, Takayuki Matsumoto, Aida Habtezion, Bishr Omary, Mitsuo Iida
Background: Heme oxygenase-1 (HO-1) is a stress-induced enzyme implicated in protection
from oxidative injury, while its related isoform HO-2 is constitutively expressed. We previ-
ously reported on the anti-inflammatory effect of HO-1 induced macrophages in acute
pancreatitis mouse models. Aim: We tested the involvement of HO-1 in inflammatory bowel
disease (IBD), and the hypothesis that pharmacologic induction of HO-1 by hemin ameliorates
the severity of dextran sodium sulfate (DDS)-induced colitis (a model of IBD). Methods:
Biopsy samples were taken from UC patients, to perform real-time PCR. Mouse colitis was
induced by drinking water containing 4% DSS. Hemin was given by intraperitoneal (ip)
injection to induce HO-1. Histopathologic, immunofluorescence, immunoblotting and real-
time PCR of isolated colon were carried out. Cultured RAW264.7 macrophage cells were
incubated with hemin for subsequent ELISA and real- time PCR. Results: In UC patients,
mRNA of HO-1 from active lesions was 2-3 times less than from inactive lesions. Hemin-
injection dramatically induced HO-1 but not HO-2 protein in the mouse colon. Pre-adminis-
tration of hemin before drinking 4% DSS water protected from body weight loss (p<0.01)
and disease activity (p<0.001). In addition, IFN-gamma mRNA of the colon was also reduced
about one third, implying a recovery from Th1 shift. In the colon, the induced HO-1 was
found mainly in macrophages. We then used RAW264.7 cells for ELISA and real-time PCR
analysis and showed that secretion of IL-12p40, a Th1 cyokine, was reduced (p<0.05) in
hemin-primed cells. Transcription of STAT1, a signaling factor of IFN-gamma receptor, was
suppressed significantly (p<0.05) in hemin-primed cells. Conclusion: HO-1 mRNA is reduced
in active lesions of the colon compared to inactive lesion in UC patients. Hemin administration
causes a dramatic induction of HO-1 in macrophages of the colon, which in turn protects
from colitis. STAT1 transcription is decreased in HO-1 induced macrophages which may
contribute to the down-regulation of IFN-gamma signaling, the suppression of IL-12 secretion
and the recovery from the shifted Th1 response of DSS-mediated colitis. Thus, hemin may
offer a novel therapeutic approach for the treatment of colitis in IBD.
T1783
Molecular Mechanisms of Infliximab Response in Crohn's Disease (CD)
Patients
Nancy Mah, Stefan Pierrou, Mårten Hammer, Susanna Nikolaus, Tanja Kühbacher, Eva
Skogman, Lars Stålhult, Magnus åstrand, Martin Kerick, Robert Häsler, Christine Costello,
Anders Thelin, Björn Mellgård, Maria Lagerstrom-fermer, Stefan Schreiber
Background/Aim: The molecular mechanisms of infliximab (IFX), an anti-TNF monoclonal
antibody, as an effective treatment in CD patients have largely been attributed to reverse-
signaling apoptosis, as well as effector mechanisms resulting from inhibiting soluble TNF from
further inflammatory signal transduction. To further elucidate the molecular mechanisms of
IFX response, microarray expression profiling was used to identify gene expression changes
during the course of IFX therapy. Methods: Sigmoidal colon biopsies were obtained from
CD patients (n=15, 9 female, mean age: 37.8 years) pre-IFX infusion and 1 week post-IFX
infusion. Patients were classified as responders if the Crohn's Disease Activity Index (CDAI)
decreased >70 points after 1 week of IFX treatment. Total RNA was extracted from the
biopsies and subjected to genome-wide microarray expression profiling on Affymetrix HG
U133 arrays (>44,000 gene transcripts). Differential gene regulation was determined accord-
ing to IFX treatment time point and responder status using a linear model (limma, Bioconduc-
tor). Differentially regulated genes were then classified into function-themed groups as
annotated by Gene Ontology (GO), and enrichment of genes in these functional groups was
determined by Fisher test (cutoff criteria: p<0.005, OR>3). Results: The effects of IFX
treatment and responder status were analyzed together and separately, yielding hundreds
of differentially regulated gene transcripts, which were then examined for enrichment in
GO functional groups. The net effect of IFX treatment highlighted functional groups such
as ‘homophilic cell adhesion' (p=0.004) and ‘vasculature development' (p=0.004). The net
effect of responder status pointed to GO groups such as ‘mitochondrial electron transport,
NADH to ubiquinone' (p=2 x 10-8) and ‘nerve-nerve synaptic transmission' (p=0.0009). Of
particular interest were the gene transcripts that exhibited differential regulation according
to both IFX treatment and responder status. Regulated genes from this contrast highlighted
GO groups such as ‘microtubule depolymerization' (p=0.001), 'copper ion binding' (p=
0.0004), and ‘extracellular matrix structural constituent' (p=0.001). Conclusions: Microarray
analysis points to particular functional groups of genes, such as those involved in vasculature
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development or energy production, that differentiate IFX time point or responder status.
Genes that differentiated responders and non-responders to IFX treatment were involved
in metal ion binding or cell structure. By understanding the mode of IFX action, these
findings have the potential to lead to new therapeutic targets in the treatment of CD.
T1784
Antibodies to Certolizumab Pegol in Patients with Crohn's Disease Do Not
Cross-React with Adalimumab, Etanercept, Or Infliximab
Olivia M. Vetterlein, Andrew M. Nesbitt, Sue Stephens
Background: Anti-tumor necrosis factor alpha (TNFα) therapies have shown clinical benefit
in a number of inflammatory diseases. Certolizumab pegol is a PEGylated Fab' fragment of
a humanized anti-TNFα antibody, administered subcutaneously every 4 weeks, and has
proven efficacy for the treatment of Crohn's disease.1,2 During pivotal clinical trials, a small
number of patients generated an antibody response to certolizumab pegol. Objective: To
determine whether antibodies to certolizumab pegol cross-react with the other anti-TNF
agents adalimumab, etanercept, and infliximab. Specificity of the antibody response for
certolizumab pegol and lack of cross-reactivity with the other anti-TNF agents may support
the option of subsequent alternative anti-TNF treatment for patients should they develop
antibodies to certolizumab pegol. Method: ELISA plates were coated with certolizumab
pegol and then blocked with 0.1% bovine serum albumin. Diluted plasma samples from
patients with antibodies (including neutralizing antibodies) to certolizumab pegol were then
added to the plate. Following a wash step, biotinylated certolizumab pegol plus a 1000-
fold excess of certolizumab pegol, adalimumab, etanercept, or infliximab was added. The
final layer was streptavidin horseradish peroxidase. The color was developed using 3,3',5,5'-
tetramethylbenzidine substrate and stopped with acid. The plates were read at 450nm with
reference at 630nm. Results: Plasma samples from 22 patients with antibodies to certoli-
zumab pegol were assayed by this ELISA. There was no reduction in the binding of these
antibodies to certolizumab pegol in the presence of the other anti-TNFα agents. This indicates
that the antibodies to certolizumab pegol in the plasma did not bind to adalimumab,
etanercept, or infliximab. Conclusions: Antibodies (including neutralizing antibodies) to
certolizumab pegol in patients' plasma did not cross-react with adalimumab, etanercept, or
infliximab. Consequently, patients initially treated with certolizumab pegol could sub-
sequently be treated with other anti-TNFα agents as needed with no risk of cross-reactivity
of antibodies with these other products. References 1. Schreiber S, et al. Gut 2005;54(Suppl.
VII):A82 2. Sandborn WJ, et al. Gastroenterology 2006;130(Suppl. 2):A1-A912 (Abstract
745)
T1785
Galectin-4 - A Potent Immunomodulatory Agent - Shows a Distinct Influence
On T Cell Proliferation and Apoptosis Compared to the Single N- and C-
Terminal Domains
Daniela Paclik, Claudia Guzy, Uta Berndt, Bertram H. Wiedenmann, Axel U. Dignass,
Hans-joachim Gabius, Andreas Sturm
BACKGROUND: Galectins, a growing family of animal lectins, have recently attracted the
interest of cell biologists and immunologists as master regulators of immune cell homeostasis.
Within this family, Galectin-4 (Gal-4) is of particular interest with regard to the mucosal
immune system since it is expressed in intestinal epithelial cells and the colonic mucosa.
Thus, we aimed to explore the effect of Gal-4 in the human immune system. METHODS:
PBT were stimulated with cross-linked anti-CD3 and anti-CD28 mAb and cultured in the
presence or absence of Gal-4 full length, Gal-4N and C-terminal domains for 6, 12 and 24
hours. The binding of annexin-V was used as a sensitive measurement of apoptosis and to
determine apoptotic pathways. T cells were incubated in the presence or absence of caspase
and calpain inhibitors and Ca2+-chelators. The mitochondrial membrane potential (rhodam-
ine 123), bax, and bcl-2 expression were determined by flow cytometric analysis. Cell
activation and co-stimulatory molecule expression was assessed by CD25, CD80, and CD86
staining, and cell cycle analysis by PI, Cyclin A and B1 staining, all followed by flow
cytometry analysis. T cell expansion was measured by flow cytometry analysis following
CFDA labeling. Cytokine secretion was determined by CBA analysis. RESULTS: Gal-4 and
Gal-4N, but not Gal-4C, significantly induced apoptosis of activated PBT in a dose- and
time-dependent manner (p<0.01). Gal-4 induced apoptosis could be abrogated by calpain-
inhibitors and Ca2+ chelators, but not caspase-inhibitors. Gal-4 and Gal-4N, but not Gal-
4C, decreased the mitochondrial membrane potential and increased the bax/bcl-2 ratio.
With regard to T cell activation, Gal-4, but not Gal-N or C, significantly reduced the
expression of CD25, CD80 and CD86 (CD25: 57±4.5%; CD80: 43±7%; CD86: 30±6%) (all
p<0.01). Consequently, cell cycle progression (inhibition of Cyclin A by 20±2.5% and Cyclin
B1 by 57±6.2%) and expansion following CD3/28 stimulation were significantly inhibited
by Gal-4, but not Gal-4N or -C. Furthermore, TNF-α and IL-6 release was significantly
reduced (mean: 80±5.4% and 93±6.8%, respectively; all p<0.01) by Gal-4 and Gal-4N.
CONCLUSION: Crohn's disease is characterized by an uncontrolled T cell proliferation and
impaired apoptosis. Consequently, the induction of T cell apoptosis is an effective therapeutic
option in the treatment of Crohn's disease. The induction of apoptosis and restriction of T
cell proliferation and expansion by Gal-4 may thus help to control an unrestricted T cell
expansion and might provide a new approach in the treatment of diseases with an impaired
T cell apoptosis, e.g. inflammatory bowel diseases.
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T1786
Colonic Lymphoid Aggregates and NOD2 Mutational Status in Crohn's
Disease
Riccardo Nascimbeni, Vincenzo Villanacci, Diego Di lorenzo, Simona Fisogni, Maria L.
Penza, Gabrio Bassotti, Bruno Salerni
Aim: The role of colonic lymphoid aggregates (CLA) in mucosal immune defense is controver-
sial, and their involvement in Crohn's disease (CD) is unexplored. Aim of this study was
to investigate the correlation between their morphologic features and NOD2 mutational
status in CD patients. Methods: Surgical specimens from 21 patients undergoing colonic
resection for Crohn's disease were analyzed for CLA density, intramural location, cellular
profile, and proliferation. Seventy-six colorectal cancer and diverticular disease specimens
were used as controls. CD-associated variants of the NOD2 gene (1007fs, R702W, and
G908R) were assessed by dHPLC and confirmed by DNA sequencing. Results: CD-associated
variants of NOD2 gene were found in 9 CD-patients (42.9%). CLA density in the uninvolved
colonic mucosa of CD patients harboring a NOD2 gene mutation was significantly lower
than density found in the uninvolved colon of CD patients without mutation (p=0.001),
and in control specimens(p=0.001). In actively CD-involved mucosa, CLA density was
markedly increased, together with the rate of CLA with germinal centers and with the rate
of basal CLA; however, no difference between patients with, and patients without NOD2
variants was recorded. Conclusions: This study demonstrates that NOD2-related susceptibil-
ity to CD is associated with a substantial reduction of CLA in the uninvolved colon of CD
patients. Our findings suggest that CLA-associated mucosal immune defense is defective in
NOD2 mutated CD patients thus favoring onset, extension and relapse of the disease.
T1787
Disturbed Expression of Alpha-Defensins and Tissue Inhibitor of Matrix
Metalloproteinase-1 in Neutrophils of Crohn's Disease Patients
Sara Bogaert, Harald Peeters, Debby Laukens, Martine De vos
Background & Aims: Neutrophils are the first line of defense against bacterial pathogens.
Inappropriate infiltration and activation of neutrophils is involved in severe tissue damage
and repair in Crohn's disease (CD). Human neutrophil peptides (HNP1-3), which belong
to the alpha-defensins, are major constituents of neutrophil azurophilic granules and assist
in killing phagocytized bacteria. Neutrophils express matrix metalloproteinases (MMP) -8,
-9 and tissue inhibitors of MMP (TIMP) -1 and -2. Matrix metalloproteinases represent a
group of enzymes involved in degradation of components of the extracellular matrix and
therefore participate in tissue remodeling associated with pathological situations. Their
activity is regulated by proteolytic activation of the secreted proenzyme and by interaction
with TIMPs. We wondered if neutrophils of CD patients show an altered expression of
alpha-defensins, MMPs and TIMPs. Methods: Neutrophils of 10 healthy controls and 10
CD patients, of which 4 CD patients carrying one of the CD-associated CARD15 polymorph-
isms, were isolated with CD15 magnetic labelling. They were infected with a CD-associated
adherent invasive Escherichia coli (AIEC) strain LF82 for 1 or 4 hours. Quantitative real-
time PCR was used to measure mRNA expression of HNP1-3, MMP-8, -9 and TIMP-1, -2.
Gene expression was correlated with the CARD15 genotype. Results: Basal expression of
HNP1-3 mRNA in unstimulated neutrophils was significantly lower in CD patients than in
healthy controls irrespective of CARD15 status (P=0.034). Bacterial challenge with AIEC
induced an upregulation in both CD patients and controls with a trend to lower expression
in CD patients (P=0.079). Four hours after stimulation, expression returned to basal levels
and a significant lower HNP1-3 expression was seen in CD patients (P=0.034). Furthermore,
expression of MMP-8, -9, TIMP-1 and -2 mRNA in unstimulated neutrophils was similar
in CD patients and controls. Only in the subgroup of patients carrying a CARD15 polymorph-
ism, a significantly lower expression of TIMP-1 mRNA was observed (P=0.016). Conclusion:
The reduced expression of HNP1-3 in CD patients can lead to impaired killing of phagocytized
bacteria by neutrophils. Moreover, the decreased expression of TIMP-1 in neutrophils of
CD patients with CARD15 polymorphisms might be implicated in a disturbed tissue
remodeling effect.
T1788
Hypermotility Induced By Mast Cell Activation After Oral Exposure to
Ovalbumin of Sd Rats Is Not Ige-Mediated
Estefania Traver, Patri Vergara, Fernando De mora
It is generally accepted that responses to food proteins are mediated by Immunoglobulin E
(IgE) and mast cells. We previously demonstrated that oral exposure to ovalbumin (OVA)
causes intestinal hypermotility accompanied by a significant increase of intestinal mucosal
mast cells' (IMMC) activity in Sprague Dawley (SD) rats (1). This chronic mast cell activation
could be responsible for the observed gut motor activity changes and explain some of the
clinical signs in IBS. Aims: Our objective was to study the mechanism of action of OVA on
mast cells to understand the mechanisms inducing hypermotility. Methods: SD rats were
orally exposed either to OVA (OVA, n=10) or to saline solution (sham, n=10) during 6
weeks. After ten days, half of the animals of each group received an oral dose of OVA
(challenge) 1 hour before sacrifice. IMMC were counted in duodenum, jejunum, ileum and
colon. Specific anti-OVA IgE and IgG, as well as IL-4 concentration, were measured in
serum. IL-4 content was also measured in the intestine. In addition, eosinophils and IgE+
cells were counted in jejunum. An additional group of Brown Norway rats (Th2 responders)
was used as control for Th2 type response. Furthermore, mast cells from a murine cell line
(C57) were stimulated In Vitro with OVA and assayed for histamine release in order to check
a possible direct stimulatory effect of OVA. Results: OVA exposed rats showed an increase
of the IMMC number in duodenum, jejunum and colon (i.e. in colon sham: 2,6±0,3; OVA:
5,3±0,4 IMMC/villi, p<0.001). All animals (sham and OVA) exposed to an OVA challenge
1 hour prior to sacrifice showed a slight decrease in the IMMC number compared to non-
challenged. This result suggests that IMMC had degranulated through OVA exposure. This
was particularly significant in the colon (sham: 2,2±0,2, OVA: 4,5±0,1 (p<0.05), compared
to non-challenged), However, none of the variables of an allergic Th2 type response appeared
to be affected after exposure to OVA; neither IgE nor IgG were altered, as for the cytokines
IL-4 was not increased and, accordingly, the number of eosinophils and IgE+ cells was
identical in the four groups. These results brought us to hypothesize on a possible non Ig-
mediated direct action of OVA on mast cells. Incubation of cultured mast cells with OVA
significantly increased histamine release with no changes of cell viability (over 93 %).
Conclusion: OVA can induce direct activation of IMMC through a non IgE dependent
mechanism. This suggests that intestinal reactions to food which are difficult to identify and
diagnose could be a contributory factor to IBS. 1) Saavedra Y & Vergara P. Neurogastro
Motil (2005) 17: 112-122.
T1789
Gpx2 and AQP8 As New Markers for Colonic Inflammation in Experimental
Colitis and IBD: An Important Role for H2O2?
Anje Te velde, Inge Pronk, Floor De kort, Pieter Stokkers
Background and Aims: Different mouse models of inflammatory bowel diseases (IBD) demon-
strate various aspects of the pathophysiology of IBD. We looked for overlapping gene
expression profiles in three different mouse models of experimental colitis in order to find
new genes that could be used as general markers in IBD and future therapeutic targets.
Methods: Using Agilent mouse TOX oligonucleotide microarrays, we analyzed the gene
expression profiles in three widely used models of experimental colitis: TNBS, DSS and
CD4+CD45RBhigh transfer and looked for overlapping gene expression in these models.
Overlapping genes were analyzed using Lightcycler in biopsy material from human IBD and
control tissue. Results: Compared to control mice, in DSS, TNBS and the CD45RB transfer
colitis mice five known genes: Expi, Gpx2, Mcpt1, Retnlb and Sulf2 and two unknown
genes were up regulated in all three models and two genes: Aqp8 and Klk5 were down
regulated. In human CD and CU biopsies one of the up regulated (Gpx2) and one of the
down regulated (Aqp8) genes in the mouse models were also differentially expressed in
affected colonic tissue of patients with IBD. Discussion: Since both Gpx2 and Aqp8 are
involved in H2O2 metabolism (Gpx2 as a radical scavenger while Aqp8 facilitates its diffusion
(Bienert et al, JBC 2006) up regulation of Gpx2 and down regulation of Aqp8 could be a
mechanism to defend against severe oxidative stress and indicate that H2O2 is an important
mediator in the inflammatory process in the colon. Conclusion: Gpx2 and Aqp8 are markers
for inflammation in the colon and are potentially new targets for future therapy.
T1790
Hyperresponsiveness of Cd4+ T Cells to the Antigens of Candida Albicans in
Crohn's Disease
Stéphane Nancey, Simoun Dibeh, Ivan Graber, Driffa Moussata, Jacques Bienvenu,
Bernard Flourié, Grégoire Cozon
Background : Crohn's disease (CD) is characterized by an aberrant immune response of
CD4+ T cells against intestinal microbial antigens and by a high prevalence of serum
antibodies directed against the yeast Saccharomyces cerevisiae (ASCA). A recent study
suggested that the yeast Candida albicans, a commensal organism of the human digestive
tract, might be involved in the occurrence of ASCA in CD (Gastroenterology 2006; 130 :
1764). Our goal was to compare in healthy volunteers and CD patients the ability of the
mannan of S. cerevisiae and total antigens of C. albicans to stimulate CD4+ T cells. Patients
and Methods : Venous blood samples were obtained in 35 CD patients (10 M/ 25 F) and
in 36 healthy volunteers (9 M/ 26 F). Twenty-five CD patients had an active disease. Blood
samples were cultured during 24 hours in RPMI culture medium alone (negative control)
or containing i) the antigens of the mannan of S. cerevisiae (Sigma-Aldrich) or ii) the total
antigens of C. albicans (Allerbio) or iii) phytohemagglutinine (PHA) (positive control). The
expression of the CD69, a cell surface marker of early T cell activation, was evaluated using
a triple immunofluorescence staining anti-CD3-FITC, anti-CD4-PE and anti-CD69-Cya5
mAb with a FACScan flow cytometer and analyzed with CellQuest software. Results (Table)
: The proportion of CD69-expressing CD4+ T cells among total CD3+ T cells in the absence
of antigen stimulation and after PHA stimulation was similar in CD patients and healthy
volunteers. In contrast, compared to healthy volunteers, the proportion of activated CD4+
T cells was significantly increased in CD patients after stimulation by both the antigens of
C. albicans (p<0.001) and of the mannan of S. cerevisiae (p<0.05). No significant difference
of CD69-expressing CD4+ T was found between active and quiescent CD patients after
stimulation. Conclusion : CD is associated with a hyperresponsiveness of the CD4+ T cells
against the antigens of the yeast C. albicans, and at a lesser degree against the mannan of
S. cerevisiae suggesting their contribution in the pathogenesis of CD. Confirmation of these
data in the intestine and further characterization of the responsible antigens deserve to
be studied.
Table
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T1791
Disturbed Neuroendocrine-Immune Communication in Inflammatory Bowel
Diseases (IBD)
Jost Langhorst, Peter Cobelens, Ayscha Lucas, Sven Benson, Annemieke Kavelaars, Cobi J.
Heijnen, Manfred Schedlowski, Gustav J. Dobos, Sigrid Elsenbruch
Background: Psychological factors, particularly psychological stress and depressive symp-
toms, have been found to play a role in disease initiation and exacerbation in inflammatory
bowel diseases (IBD - Ulcerative Colitis - UC; Crohns Disease - CD), but the mechanisms
remain unclear. The goal was to address neuroendocrine-immune interactions in patients
with IBD. Methods: IBD patients and healthy controls were recruited for two experiments:
(1) Neuroendocrine and cellular immune responses to public speaking stress were compared
in N = 23 with UC in remission vs. N = 25 controls, including analysis of the redistribution
of circulating lymphocytes and of the production of LPS-stimulated TNF-a and IL-10, and
of CD2/CD28-stimulated IL-10 and IFN-g. (2) The In Vitro effects of the b-adrenergic agonist
terbutaline on LPS-stimulated TNF- a and IL-10 production and of the glucocorticoid
agonist dexamethasone on LPS-stimulated TNF- a production by peripheral blood cells were
compared in N = 46 IBD (N = 32 in remission and N = 14 with active disease) vs. N =
19 controls. Results: (1) The stress-induced redistribution of circulating leukocytes and
lymphocyte subpopulations were comparable in IBD and controls. Significant stress-induced
increases in TNF-a, IL-10 and IFN-g were observed in both groups (all ANOVA time effects:
p < .01), with no difference between the groups. (2) Whereas controls showed a significant
and concentration-dependent increase in IL-10 production in response to terbutaline, this
response was significantly diminished both in IBD in remission as well as in active disease
(ANOVA group effects: both p < .01). Interestingly, this reduction in IL-10 response to
terbutaline was more pronounced in active IBD compared to IBD in remission (ANOVA
group effects: both p < .05). At the same time, concentration-dependent suppression of
TNF- a production by both terbutaline and dexamethasone was comparable in IBD and
controls. Conclusions: These data provide further evidence that altered adrenergic-immune
interactions are disturbed in IBD, irrespective of the diagnosis. Given the pivotal role of
pro-and anti-inflammatory cytokines in IBD pathophysiology, our findings of disturbed
adrenergic IL-10 regulation, which was particularly pronounced during disease exacerbation,
could be part of the mechanism(s) underlying the modulation of disease activity by psycholo-
gical stress.
T1792
Characterization of Foxp3+Cd4+Cd25+ Regulatory T Cells in Human Crohn's
Disease (CD)
Masayuki Saruta, Qi Yu, Lola Y. Kwan, Alison H. Banham, Konstantinos A. Papadakis
Background: Regulatory T cells (Treg) cells are able to control the development of experi-
mental colitis. but little is known about their presence and/or potential functional impairment
of these cells in CD. Aims: to determine the presence and functional characteristics of Treg
cells isolated from peripheral blood (PB) and mucosal lymphoid tissues in CD. Methods:
Lamina propria (LP) and mesenteric lymph node (MLN) lymphocytes were isolated from
patients with CD and non-IBD controls that were undergoing surgical resection. PBL were
isolated from patients with active and inactive CD and from healthy controls. Analysis of
FOXP3 expression in T cells isolated from LP, PB, and MLN were performed by flow
cytometry. Localization of FOXP3+ cells in mucosal lymphoid tissues was performed by
immunohistochemistry (IHC). Functional characterization of CD4+CD25+ T cells was per-
formed with proliferation assays following allogeneic or polyclonal T cell activation. Results:
The frequency of FOXP3+CD4+ T cells is significantly increased among LP lymphocytes
isolated from inflamed (14.3 ± 5.7%, p=0.00003) and non-inflamed areas (10.6 ± 4.9%,
p=0.006) of CD compared to normal intestine (5.3 ± 3.6%). There was no significant
difference in the frequency of FOXP3+CD4+ T cells among LP lymphocytes from inflamed
vs. non-inflamed CD intestine (p=0.09). However, FOXP3+CD4+ T cells were significantly
increased in CD MLN (16.9 ± 3.1%) compared to normal MLN (10.1 ± 2.7%, p=0.02).
FOXP3+CD4+ T cells were significantly increased in PBL in patients with inactive CD (10.3
± 1.3%) compared to active CD (7.9 ± 2.5%, p=0.005) or normal healthy controls (6.4 ±
2.2%, p=0.00003). FOXP3+ cells were detected by IHC in the intestinal mucosa in inflamed
areas, around granulomas and in the T cell rich areas of CD MLN. In Vitro simulation of
CD4+CD25- MLN and PB T cells with anti-CD3 + anti-CD28 Abs induced FOXP3 expression,
which was enhanced by the addition of TGF-beta. FOXP3+CD4+CD25+ cells isolated from
CD MLN suppress the proliferation of autologous MLN CD4+CD25- T cells to a similar
extent as FOXP3+CD4+CD25+ cells from normal MLN. However, addition of Pam3Cys
(TLR2 ligand) or LPS (TLR4 ligand) restored the proliferation of MLN and PB T cells in the
effector: Treg cell co-culture In Vitro. Conclusions: FOXP3+CD4+CD25+ T cells isolated
from human CD MLN display features of Treg cells, are increased in frequency in CD
intestine and in draining MLN, but are decreased in PB during active disease. Addition of
TLR ligands may inhibit their suppressor activity. These data may explain the persistent
inflammation in CD in spite the increased frequency of these regulatory T cells In Vivo.
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T1793
A New Agent for Tumour Necrosis Factor-Alpha Inhibition: In Vitro Effects of
Dipyridamole in Crohn's Disease
Sule Poturoglu, Sabahattin Kaymakoglu, Nuray Gurel polat, Duygu Ibrisim, Emel
Ahishali, Filiz Akyuz, Selim Badur, Kadir Demir, Zeynel A. Mungan
INTRODUCTION: Dipyridamole (DP) increases extracellular adenosine concentration and
acts as an anti tumour necrosis factor-alpha (TNF-alpha) agent. Methotrexate (MTX) used
for the treatment of Crohn's disease (CD), is also an agent with anti TNF-alpha effect. To
our knowledge, there is no study in the literature that discusses the effects of DP on cytokines
in CD. AIMS & METHODS: a) to investigate In Vitro effects of DP on TNF-alpha and
interleukin 10 (IL-10) on intestinal mononuclear cells of patients with CD and the healthy
control group b) to compare these effects with those of MTX. Colonoscopic examination
was performed in 13 patients with colonic-ileocolonic CD who had CDAI higher than 150
and in 17 healthy individuals. A total of 16 colonic biopsy samples were taken from each
case. Ten patients (5 males) with CD and 12 healthy individuals (7 males) where an
appropriate cell culture could be obtained were enrolled in the study. Cultured mononuclear
cells were preincubated with DP (0.7 microg/ml and 1.25 microg/ml, 15 minutes) and MTX
(0.5nmol/L and 1.5 nmol/L, 40 hours). The cells were then stimulated for 24 hours with
lipopolysaccaride (LPS) and phytohemagglutinin (PHA). The levels of TNF-alpha and IL-
10 in supernatants were measured with standard immunoassay monoclonal antibody method.
RESULTS: In LPS stimulated cells, MTX was superior to DP in suppressing TNF-alpha in
both groups (p<0.001). Low dose of MTX was superior to low dose of DP in PHA stimulated
cells in CD group (p<0.05). In the control group, DP was superior to MTX in suppressing
TNF-alpha (p<0.001). Both in CD and control groups, higher doses of DP had an equivalent
effect with MTX (p=0.154 and p=0.078, respectively). Compared with MTX, DP caused a
higher increase in IL-10 levels in LPS stimulated cells both in CD (p<0.05) and control
(p<0.001) groups. This effect of DP was dose dependent. Similar results were obtained in
PHA stimulated cells with low doses. Higher doses of DP increased IL-10 levels more than
MTX in both groups but results were only in CD group statistically significant (p<0.05).
CONCLUSION: DP suppresses TNF-alpha less than MTX, but its effect is similar to MTX
in higher doses. DP appears to be superior to MTX in increasing IL-10 levels. Given that
DP is a drug that suppresses TNF-alpha and increases IL-10, its addition to medications
such as sulphasalasine and MTX enhances the local levels of adenosine and may create a
synergy in cytokine modulation. Whether DP may be used in the management of CD should
be assessed with further clinical trials.
T1794
Expansion of Peripheral Cd14+Cd16+ Monocyte Population in Crohn's
Disease Is Associated with Increased Migration of Cd16+ Monocytes Through
Intestinal Endothelial Cells
Stefan Koch, Pia Lebiedz, Jan Heidemann, Thomas Krummenerl, Wolfram W. Domschke,
Torsten F. Kucharzik, Andreas Lügering
Background and Aims: Recruitment of peripheral monocytes into inflamed tissue is consid-
ered a key pathogenic event in Crohn's Disease (CD). CD16+ blood monocytes represent
a major source of pro-inflammatory cytokines, and previous reports have shown that these
cells are enhanced in various inflammatory disorders. In this study, we examined the
occurrence of CD16+ monocytes in CD, and characterized their migratory properties through
intestinal endothelium. Methods: The expression of CD14 and CD16 on peripheral blood
monocytes from 70 CD patients was determined by flow cytometry. Transmigration experi-
ments were performed using human intestinal microvascular endothelial cells (HIMEC), and
the expression of various surface markers was analyzed. CD16+ monocytes were detected in
mucosal specimens isolated from biopsy samples by flow cytometry. Results: The peripheral
CD16+ monocyte population is significantly enhanced in CD patients, especially in those
with severe disease activity. CD16+ monocytes differ from CD16- cells in their migratory
potential through endothelial cells and in the expression of cell adhesion molecules, particu-
larly ICAM-1 and LFA-1. In addition, pro-inflammatory stimulation of intestinal endothelium
results in a higher transendothelial migration which is limited to CD16+ monocytes. Flow
cytometry as well as immuno-histochemistry shows that an increased amount of CD16+
monocytes can be found in the colonic mucosa of CD patients. Conclusions: These data
suggest an important role of CD16+ monocytes in the perpetuation of inflammation in
Crohn's Disease. We show here that CD14+CD16+ cells are enriched in CD, efficiently
migrate through activated intestinal endothelium, and can be found in mucosal specimens
from CD patients. CD16+ monocytes might therefore represent an interesting therapeutic
target in the treatment of Crohn's Disease.
T1795
Foxp3+ T-Regulatory Cell Infiltrates in Orofacial Granulomatosis
Carlo Nunes, Jo Spencer, Michael Escudier, Pepe Shirlaw, Gareth Parkes, Liljana
Petrovska, Catherine Chinyama, Neil Rayment, Barry Hudspith, Miranda Lomer, Jonathan
Brostoff, Edward Odell, Stephen Challacombe, Jeremy D. Sanderson
Background: Orofacial granulomatosis (OFG) is a rare chronic inflammatory disease of
unknown aetiology presenting characteristically with lip swelling but also affecting many
intra-oral sites. Data from our group suggest that dietary antigens, in particular benzoates,
may drive the chronic inflammatory process seen in OFG. Regulatory T-cells expressing the
FOXp3 transcription factor are known to be associated with low dose oral tolerance. They
are also linked with several inflammatory pathologies. We have therefore quantified FOXp3
expression in histologically defined locations in lip biopsies from patients with OFG in the
context of the local T-cell infiltrate, with particular attention to the epithelium as the likely
direction of influx of dietary antigen(s). Aims: To determine whether there is any differential
distribution of putative regulatory T-cells in histologically defined areas of inflamed mucosa
in OFG Methods: Lip biopsy samples from 12 patients with a confirmed diagnosis of OFG
were used for immunohistochemical analysis, together with samples from normal mucosal
lymphoid tissue. Serial sections from each case were stained for CD3, CD4, CD8 and FOXp3.
A-558AGA Abstracts
CD4+ and FOXp3+ cell population infiltrates were counted in histologically defined locations
including intra-epithelial, granuloma and lamina propria infiltrates. FOXp3+ cells were
quantified as the percentage of CD4+ T-cells in each site. Results: The intra-epithelial cell
infiltrate was predominantly CD4+ T-cells. A relatively high proportion of T-cells expressed
FOXp3 in each location studied in all cases though this was also observed in normal mucosal
lymphoid tissue. The intra-epithelial cell infiltrate in OFG contained a lower proportion of
FOXp3+ cells on average. FOXp3+ cells were consistently present within the granulomas
with no particular distribution. Conclusion: FOXp3+ T-cells are abundant in mucosal
lymphoid tissue and in lip biopsies from patients with OFG but were decreased in frequency
at intra-epithelial sites. Since patients with OFG may fail to tolerate benzoate but mount an
inflammatory response, the relative lack of regulatory T-cells in the epithelial infiltrates may
be a significant factor in the pathogenesis of the disease though whether defective regulatory
properties may be responsible for a breakdown of oral tolerance remains to be determined.
T1796
Inhibition of Macrophage Function By Recombinant Lxr Alpha Agonitst As a
Novel Therapy for Inflammatory Bowel Diseases
Takaaki Nakai, Toshiro Sato, Susumu Okamoto, Toshifumi Hibi
Background and aims: Liver X receptor alpha (LXR alpha) is one of the nuclear receptors
and known to play an established role in lipid metabolism. It is expressed in macrophages
and recent studies have revealed its involvement in inflammation. However the role of LXR
alpha in inflammatory bowel diseases (IBD) remains unknown. In this study we examined
LXR alpha expression in intestinal tissues and investigated whether it could be a new
therapeutic target in IBD. Methods: (i) Lamina propria mononuclear cells (LPMC) were
isolated from surgically resected specimens from Crohn's disease (CD) and ulcerative colitis
(UC) patients. Expression of LXR alpha was determined using quantitative reverse transcrip-
tion-polymerase chain reaction (qRT-PCR) and western blot analysis. (ii) Localization of LXR
alpha in intestinal tissues was examined by immunohistochemistry (IHC). (iii) Expression of
ABCA1 in LPMC, which is LXR alpha target gene, was examined by qRT-PCR. (iv)The anti-
inflammatory effect of LXR alpha agonist GW3965 on cytokine production from LPMC
was examined with enzyme linked immunosorbent assay and cytometric beads array. (v)
Therapeutic efficacy of GW3965 was tested in murine DSS-induced colitis model. Results:
(i) LXR alpha was significantly up-regulated in UC and CD LPMC compared to normal
controls both at transcript and protein level. (ii) IHC revealed that macrophages were the
dominant cell type that expressed LXR alpha in inflamed intestinal tissues. (iii) ABCA1
expression was significantly lower in CD LPMC despite high expression of LXR alpha than
those in UC and normal controls. GW3965 up-regulated ABCA1 expression in CD LPMC,
which may suggest the lack of LXR alpha ligand in CD LPMC. (iv) GW3965 suppressed
TNF-a and IL-12 production from LPMC stimulated with E.faecalis. (v) GW3965 ameliorated
DSS-induced colitis with less clinical signs and histological inflammatory score. Conclusion:
LXR alpha agonist GW3965, targeting up-regulated LXR alpha in mucosal macrophages,
may be a novel therapeutic approach for IBD, especially for CD.
T1797
A Functional Role for Interleukin-21 in Promoting the Synthesis of the T Cell
Chemoattractant, Mip-3α, By Gut Epithelial Cells
Daniele Fina, Roberta Caruso, Ilaria Peluso, Carmine Stolfi, Massimo C. Fantini, Flavio
Caprioli, Angelamaria Rizzo, Thomas T. Macdonald, Francesco Pallone, Giovanni
Monteleone
Background & Aims. Interleukin (IL)-21, a T cell-derived cytokine, is produced in excess
in Inflammatory Bowel Diseases (IBD). The IL-21 receptor (IL-21R) is expressed by immune
and non-immune cells, raising the possibility that IL-21 has broad effects in gut inflammation.
In this study we have examined whether in IBD, intestinal epithelial cells express IL-21R
and respond to IL-21. Methods. IL-21R was evaluated in intestinal samples of IBD patients
and controls by immunohistochemistry and Western blotting. Intestinal epithelial cells were
stimulated with IL-21, and supernatants were evaluated by a protein array and ELISA. The
effect of IL-21-treated epithelial cell supernatants on blood lymphocyte migration was
assessed using a chemotaxis assay. Finally, we evaluated the effect of a neutralizing IL-21
antibody on MIP3-a synthesis in ex vivo organ cultures of IBD mucosal explants. Results.
Constitutive expression of IL-21R was seen in intestinal epithelial cells, but was higher in
IBD patients than controls. Stimulation of intestinal epithelial cells with IL-21 resulted in
enhanced phosphorylation of ERK1/2 and p38 and increased synthesis of MIP-3a, a T
cell chemoattractant. Inhibition of ERK1/2 but not p38 suppressed IL-21-induced MIP-3a
production. IL-21-treated cell culture supernatants enhanced In Vitro lymphocyte migration,
and this effect was inhibited by anti-MIP-3a antibody. Treatment of IBD explants with anti-
IL-21 reduced MIP-3a production. Conclusions. Data show that intestinal epithelial cells
are a target of IL-21 and that IL-21 is involved in the cross-talk between epithelial and
immune cells in the gut.
T1798
Effect of Anti-Tumour Necrosis Factor-Alpha(Infliximab)On Human Osteoblast
Cell Viability in Patients with Active Inflammatory Bowel Disease:An in-Vitro
Study
Sundaram G. Veerappan, Martin Healy, Bernard Walsh, Barbara M. Ryan, Jacqueline S.
Daly
Background: Bone mineral density (BMD) loss in patients with inflammatory bowel disease
(IBD) is common. Circulating inflammatory cytokines have been implicated in this process.
Recently, infliximab (anti-TNFα) has been shown to have beneficial effect on bone metabolism
markers in patients treated with this drug, although the mechanism of action are not known.
Aims: To try to unravel the mechanisms involved in IBD associated bone metabolism
derangement, and the beneficial effects of infliximab thereon, we developed a combined
clinical and osteoblast In Vitro model. Methods: BMD was measured using dual energy X-
ray absorptiometry (DEXA). Sera from 7 IBD patients( 5 ulcerative colitis, 2 crohn's disease)
and 6 controls, routine bloods, C-reactive protein, bone formation markers (PN1P- pro
collagen type 1 N propeptide and OC-osteocalcin) ,and bone resorption marker (sCTx-
serum carboxyterminal cross linking telopeptide of bone collagen) were measured pre and
six weeks post infusion. Parathyroid hormone (PTH) and vitamin D were also analyzed.
Human fetal osteoblasts were treated with serum from IBD patient's pre, post infliximab
and control. Cell viability was then measured using Alamar Blue assay. Results: Median age
[38 years -IBD, 45 years-control], bone mass index were normal, vitamin D [55.7-IBD,
81.3-control] and PTH [28.4-IBD, 22.8-control]. Bone formation markers [P1NP (ng/ml)-
21.58(pre); 44.17(post); 45.8(control)], [OC (ng/ml) - 13.46(pre); 25.3(post); 22.7(control)].
Bone resorption marker [sCTx (ng/ml) - 0.61(pre); 0.47(post); 0.44 (control)]. Interestingly,
osteoblast cell viability was higher in pre-treatment IBD sera compared to control sera, and
post treatment IBD sera at both 1 and 4 day; and 10% and 1% serum incubation. Control
sera and post treatment sera had similar effects on ostoeblast cell viability. Osteoblast cell
viability at 1 day sera exposure at 10% serum was 10.13%(pre), 6.52% (post); p=0.041
,5.72%(control);p=0.007 and at 1% serum exposure was 21.13%(pre), 15.62%(post);p=
0.002, 16.20%(control);p<0.001. Osteoblast cell viability at 4 day sera exposure at 10%
serum was 23.51 %( pre), 19.30 %( post); p=0.004, 17.72% (control); p=0.003 and at 1% sera
exposure 34.75 %( pre), 31.62% (post); p=0.001, 31.29 %( control); p=0.003. Conclusion:
Infliximab treatment has a beneficial effect on bone metabolism markers in patients with
both crohn's and ulcerative colitis. Interestingly, osteoblast cell viability In Vitro is increased
when co-cultured with pre treatment IBD sera whereas post treatment sera causes viability
to approximate that of controls. This requires further study and bone growth factors will
be measured in future study.
T1799
Resistance to the Trail (TNF-Related Apoptosis-Inducing Ligand) Mediated
Apoptosis in the Gut: Implication in Fibrosis and Stricture Formation in
Crohn's Disease
Reenaers Catherine, Oury Cecile, Belaiche Jacques, Bours Vincent, Delvenne Philippe,
Malaise Michel, Louis Edouard
Fibrosis and strictures of the bowel are common complications of Crohn's disease (CD).
The aetiology is unclear but deposit of collagen and proliferation of smoth muscle cells may
contribute. Activation and accumulation of fibroblasts due to an apoptosis resistance could
also be involved. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis via the
receptors TRAIL-R1 and TRAIL-R2 in tumour cells, virus-infected cells and rarely in normal
cells. TRAIL can also bind three antiapoptotic receptors: TRAIL-R3, TRAIL-R4 and the
soluble decoy receptor OPG. The aim of our work was to study the expression and the role
of TRAIL in CD Material and methods: Human fibroblasts were isolated from the gut of 6
healthy controls and 9 CD patients with strictures and characterized by immunocytochemis-
try. Total RNA was extracted from fibroblasts and gut samples (7 controls, 10 CD patients).
The expression of TRAIL and its receptors mRNA was studied by real time RT-PCR. Fixed
colonic samples from 14 CD patients and 6 controls were studied by immunostaining.
Fibroblasts survival after TRAIL stimulation was studied by MTS. We performed Western
Blot (WB) for Poly ADP-ribose Polymerase (PARP) and caspase 8 to study the apoptosis.
The influence of OPG and of the pro and anti-inflammatory cytokines on the apoptosis was
analyzed. The level of OPG in the gut was analysed by specific ELISA on supernatant of
cultured colonic biopsies (15 CD patients, 7 controls patients). Results: Transcripts for
TRAIL and its pro and antiapoptotic receptors were confirmed in the human gut and in the
fibroblasts by real time RT-PCR. We observed by immunostaining an important expression
of TRAIL, TRAIL R2 and TRAIL R3 in the gut of healthy and CD patients mainly in fibroblasts,
immune cells and epithelial cells. TRAIL induces apoptosis of the gut isolated fibroblasts in
a dose-dependant manner in controls and CD patients. The apoptosis was confirmed by
WB PARP and caspase 8. OPG inhibited the TRAIL mediated apoptosis in the fibroblasts
but no influence of the pro and anti-inflammatory cytokines was observed. Levels of OPG
were significantly increased in cultured colonic biopsies from CD, particularly in inflamed
areas. Conclusion: There is an expression of TRAIL, TRAIL R2 and TRAIL R3 in the gut.
TRAIL can induce the apoptosis of the gut isolated fibroblasts. This effect is inhibited by
OPG. A decrease of the TRAIL-mediated apoptosis due to an excess of OPG could be involved
in the accumulation of fibroblasts in structuring areas in CD. This study suggests that TRAIL
and OPG could be involved in the stricture formation in CD.
T1800
Aberrant Responses of Human Colonic Macrophage-Type Cells to
Lipopolysaccharide in Ulcerative Colitis: Upregulated Expression of Md-2 and
Production Inflammatory Cytokines
Rei Kawashima, Yuki I. Kawamura, Noriko Mizutani, Noriko Toyama-sorimachi, Yukio
Saito, Yutaka J. Kawamura, Fumio Konishi, Taeko Dohi
The normal colon maintains homeostasis with minimal immune responses to indigenous
flora. In contrast, evidences have indicated the aberrant responses to indigenous microflora
in the pathogenesis of inflammatory bowel diseases (IBD). To investigate the potential
mechanisms, lamina propria mononuclear cells (LPMCs) from human colonic mucosa were
cultured with lipopolysaccharide (LPS), and cytokine production was analyzed. We have
previously shown that the colonic LPMCs from non-IBD mucosa failed to produce inflammat-
ory cytokines in response to LPS prepared from Bacteroides vulgatus or Bacteroides flagilis,
as representatives of indigenous flora, or pathogenic Salmonella minnesota (J. Clin. Immunol.
24:42-52, 2004). Notably, we found that colonic macrophages, which were purified with
anti-CD33 antibody from non-inflamed non-IBD LPMCs expressed minimal mRNA for MD-
2, an essential association molecule for LPS signaling via Toll-like receptor 4 (TLR4). We
expanded the analysis to surgically resected colonic specimens of ulcerative colitis (UC) (51
samples from 29 cases). In response to LPS derived from Bacteroides vulgatus, LPMCs showed
increased secretion levels of TNFα (7 out of 40 samples and 6 out of 26 cases), IL-6 (22
out of 36 samples, 17 out of 24 cases), IL-1β (13 out of 29 samples, 12 out of 18 cases),
IL-10 (7 out of 11 samples, 5 out of 6 cases) and IL-12 (1 out of 11 samples and 1 out of
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6 cases) to the levels which was never seen in the LPMCs from non-IBD mucosa. In some
cases, there was high basal secretion of TNFα (8 out of 40 samples and 6 out of 26 cases),
IL-6 (27 out of 36 samples, 21 out of 24 cases), IL-1β (21 out of 29 samples, 11 out of 18
cases) and IL-10 (4 out of 11 samples, 3 out of 6 cases). Interestingly, some cases showed
dissociation between the levels of TNF-α and IL-6. Messenger RNA levels of MD-2 and
TLR4 in CD33+ cells were up-regulated in 17/33 samples (14/22 cases, ~10-111-fold of
non-IBD samples) and 19/33 samples (13/22 cases, ~71-350-fold), respectively, and enhanced
surface expression of TLR4 was also seen by flow cytometry (14/46 samples). These results
suggested that aberrant colonic macrophages in UC, which acquired potential to respond
to indigenous LPS and produce inflammatory cytokines, are significantly involved in the
pathophysiology of UC.
T1801
The Probiotic Yeast Saccharomyces Boulardii Modulates Human Myeloid
Dendritic Cells to Inhibit Activation of T-Cells
Saskia Thomas, Ingo Przesdzing, Diana Metzke, Bertram H. Wiedenmann, Daniel C.
Baumgart
BACKGROUND: Dendritic cells (DC) are interacting with microbial antigens through their
broadly expressed molecular pattern receptors (PRRs) such as toll like receptors (TLR). As
the most potent professional antigen presenting cells, they control T-cell activation thereby
inducing either immunity or anergy. Saccharomyces boulardii (SB) has been demonstrated
to be clinically effective in a variety of enteric disorders. We hypothesized that this effect
may be mediated by dendritic cells. MATERIALS AND METHODS: Highly purified myeloid
dendritic cells (>96%) (MDC) and naïve T-cells (99%) (TC) were isolated from human
peripheral blood. MDC and TC were co-cultured in the presence or absence of SB in an
allogeneic mixed lymphocyte reaction (MLR). SB was titrated from 1:4 to 1:64. Staphylococcal
enterotoxin B (SEB) was used as a positive control to rule-out T-cell anergy. FACS analysis
was used to identify, enumerate, and phenotype cells. Proliferation was measured after
CFSE staining. RESULTS: SB strongly modulates MDC to inhibit the proliferation of T-cells
(expressed as mean ± SD) in the allogeneic MLR. Table 1 This effect is dose dependent,
reproducible and requires intact yeast. CONCLUSION: We demonstrate, for the first time,
how human myeloid dendritic cells are modulated by Saccharomyces boulardii. The demon-
strated inhibitory effect of SB modulated MDC on T-cell activation could be exploited
in the management of other T-cell mediated intestinal inflammatory disorders, such as
inflammatory bowel disease (IBD), which is believed to result from an aberrant response of
DC to microbial antigens of commensals in genetically susceptible hosts.
Table 1
*** DC + TC vs. DC + TC and SB (p<0.0001)
T1802
Antibodies Against Human Tropomyosin Isoform 5 (hTM5) Induce
Complement-Mediated Lysis of Colonic Epithelial Cells (ECS) in Ulcerative
Colitis (UC)
Ellen C. Ebert, Kiron M. Das
Introduction: Tropomyosins (TMs) are cytoskeletal microfilament proteins found in all
eukaryotic cells. The main TM isoform found in human intestinal epithelium is hTM isoform
5 (hTM5). hTM5 is externalized on the colonic epithelial cell surface but not on small bowel
epithelial cells due to the presence of a membrane-associated colonic epithelial cell protein
that serves as a chaperone bringing hTM5 to the surface. Patients with UC have circulating
autoantibodies recognizing hTM5, and lamina propria B cells in the colon secrete anti-hTM5
IgG. The hypothesis of this study is that anti-hTM5 antibodies cause complement-mediated
lysis of colonic, but not small bowel, epithelial cells, contributing to the pathogenesis of
this disease. Methods: Colonic biopsies from normal-appearing mucosa were obtained from
patients with UC, Crohn's disease (CD), or from normal individuals (NI). These were
incubated at 370C with autologous sera for 30 min before staining by immunofluorescence
for an activated complement component, C3. Alternatively, the biopsies were incubated
with serum for 3 hrs before processing for hematoxylin & eosin (H&E) staining. All tissue
samples were coded and scored without knowledge of clinical information. Results: When
nine UC samples were exposed to autologous serum and then processed for C3 staining,
five (or 56%) showed immunofluorescence lining the epithelium. This was greatly reduced
by preincubating the serum with recombinant hTM5 that binds to anti-hTM5 autoantibodies
but not by preincubating with bovine serum albumin (BSA). When 16 UC samples were
exposed to autologous serum and then processed for H&E staining, seven (or 44%) showed
destruction of the glands with drop-out of the epithelial cells. This was specific for colon
since ileal mucosa was unaffected by autologous serum in two of these cases where the
colon was damaged. This was disease-specific since six CD samples that were similarly-
processed showed no change in the histology. There was no correlation between these
findings and the patient's age, disease duration or activity, location of disease, or the use
of immunosuppressive medication. Conclusion: Sera from half of the UC patients induce
C3 deposition in colonic epithelium by an hTM5-mediated mechanism. There is destruction
of colonic epithelium that is organ- and disease-specific.
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T1803
Solvin E1, An Endogenous Lipid Mediator Derived from Eicosapentaenoic
Acid, Products, Against 2,4,6-Trinitorobenzene Sulfonic Acid-Induced Colitis
in Mice
Tsukasa Ishida, Masaru Yoshida, Atsuhiro Masuda, Hideyuki Shiomi, Tetsuya Takagawa,
Hiroshi Tanaka, Ryo Chinzei, Yoshinori Morita, Hiromu Kutsumi, Hideto Inokuchi,
Makoto Arita, Charles N. Serhan, Takeshi Azuma
Omega-3 polyunsaturated fatty acids (PUFA) such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid(DHA), which are enriched in fish oils, are held to be beneficial in a
wide range of human inflammatory disorders, including cardiovascular diseases, rheumatoid
arthritis, Alzheimer's disease, lung fibrosis, and inflammatory bowel disease (IBD) . These
essential fatty acids are widely believed to act by means of several possible mechanisms,
such as preventing conversion of proinflammatory eicosanoids or serving as an alternative
anti-inflammatory products. Recently, Resolvin E1(RvE1), an endogenous lipid mediator
induced from EPA was identified, it has been shown to have a strong anti-inflammatory
effect such as the inhibition of leukocyte infiltration, dendritic cell migration and IL-12
production via RvE1 receptor, ChemR23, that is also recently identified. Crohn's disease is
a chronic inflammatory disorder and reported to be mediated by IL-12 driven Th1 CD4+
T cells producing IFN-γ. To investigate whether RvE1 suppressing IL-12 produced by
dendritic cells protects against Crohn's disease, we utilized the model of 2,4,6-trinitrobenzene
sulfonic acid-induced (TNBS) colitis, the models of Crohn's disease. The administration of
RvE1 led the increased survival rates, sustained body weight, improvement of histological
scores, reduced serum anti-TNBS IgG, decreased leukocyte infiltration, and proinflammatory
gene expression, including IL-12 p40, TNF-α, and inducible nitric oxide synthase, and
expression of ChemR23 in mouse colon. Thus, RvE1 regulates Th1-mediated colonic inflam-
mation. These findings indicate an possible mechanism that may underlie the beneficial
actions of omega-3 EPA and provide targeted approaches for the treatment of intestinal inflam-
mation.
T1804
Probiotics and Synbiotics Modulate Costimulatory Molecules, Chemokines
and Cytokines in the Mdr1a-/- Mouse Model of Colitis
Silvia C. Resta-lenert, Kim E. Barrett
Background: Ulcerative colitis (UC) is a chronic inflammatory disease of the gut with a
multifactorial etiology. Mdr1a knock out (KO) mice, characterized by an epithelial barrier
defect, develop a chronic colitis similar to UC when raised in conventional housing. Pathophy-
siological signs, as well as disease outcomes, can be improved significantly by treatment
with probiotics or synbiotics. We hypothesized that these effects are due in part to modulation
of costimulatory molecules, chemokines and cytokines expressed by antigen presenting cells,
dendritic cells and lymphocytes within the gut. Methods: Four- and 12-week-old KO mice,
i.e., before and after onset of clinical colitis, and matched wild type (WT) controls (6 mice
per group) were treated for 4 weeks with the probiotic combination, S. thermophilus-L.
acidophilus (ST/LA) or with the synbiotic, ST/LA plus inulin (ST/LA/IN). Portions of colonic
tissue from KO and WT mice were processed for total RNA extraction and reverse transcrip-
tion-polymerase chain reaction (RT-PCR). The RT-PCR primers (40 cycles amplification)
used in these studies were specific for: RANTES, MIP-1alpha and beta, MCP-1-3, B7-1,2
(CD80, CD86), CCR5, IL-8, and actin. Results: Of the molecules studied, mRNA for only
CD86 and CCR5 were increased in 4 wk old KO mice compared to WT controls before
treatment (1.5 and 2.2 fold increase, respectively; p<0.05), and neither was altered by
probiotic or synbiotic treatment. Among 12 wk old KO mice at baseline, mRNA for all of
the listed costimulatory molecules, chemokines and cytokines levels were increased compared
to WT controls (2.5 - 7.5 fold increase range for all parameters). After 4 wk of probiotic
or synbiotic treatment, expression of MIP-1alpha,beta, MCP-1, CD86, CD80, CCR5 and IL-
8 was significantly reduced (probiotics, p<0.05; synbiotics, p<0.001) in KO mice. However,
expression of MIP-1beta, MCP-2, CD86, CD80, and CCR5 mRNA remained elevated com-
pared to WT controls (p<0.05) at the end of the treatment period for both preparations.
Conclusions: Our results underscore the roles of costimulatory molecules, chemokines and
cytokines in the loss of tolerance of the colonic mucosa, and suggest that restoration of
normal levels of lactic acid bacilli in the microbiota can attenuate the immunological response
contributing to the pathogenesis of colitis in our mouse model. Supported by grants NIH-
AT01180 (KEB), and NIH-DK062096 (SRL)
T1805
The Opposite Changes in Expressions of Cd4+ T-Cells During LCAP and
GCAP for Active Ulcerative Colitis Patient Refractory to Conventional
Therapies
Kouji Kamikozuru, Ken Fukunaga, Yoko Yokoyama, Kazuko Nagase, Katsuyuki Tozawa,
Yoshihiro Ohda, Nobuyuki Hida, Yoshihiro Fukuda, Hiroto Miwa, Takayuki Matsumoto
Background and Aim: The etiology of ulcerative colitis (UC) is still incompletely elucidated,
but the autoimmune-disturbance, especially the CD4+ T-cell component, as either initial or
additional factor, plays a pivotal role in the development of this disease. Extracorporeal
leukocyte removal therapy (ELT) is an effective adjunct for active UC patient refractory to
conventional medications. The therapeutic mechanism of ELT is still unclear, but a primary
aim is to suppress unwanted immunological response by removing circulating leukocytes.
In the present study, we have evaluated the transition of CD4 expressing T-cells' modulation
during filtration Leukocytapheresis (LCA) and adsorptive Granulocyte/ Monocyte apheresis
(GMA), two major ELTs for UC. Patients and Method: This study was conducted on 38
acute UC patients, who marked the clinical activity index (CAI)>7 points in spite of giving
high dose steroid for 2 weeks, were enrolled to either LCA (20/38) or GMA (18/38) for
consecutive 5 weekly sessions. Their peripheral blood was sampled before and immediately
after every ELT procedure, and stained with CD4 expressing lymphocytes were stained with
fluorescent conjugated monoclonal antibody prior to flowcytometry. Results: We have judged
as responder if the patient's CAI was marked lower than 4 points after 5th weekly ELT.
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The results of CD4 expressing lymphocytes (%CD4) were compared between pre- and post-
ELT. Significant increases in %CD4 (37.4±10.4% to 41.5±9.0%; p<0.05) were observed
only in the first LCA of the responder group (n=10). These changes were not observed at
the 2nd to 5th LCAP in either group. Oppositely, the mean of %CD4 has not changed after
GMA in responder group although that of non-responder group (n=6) has been proven
significant increases in %CD4 (35.0±9.25% to 39.8±11.7%; p<0.03) during only in the first
GMA. Discussion: These results proved that the clinical response of CAP was reflected in
modulations of population and/or functions of leukocyte. An opposite results have been
proven in %CD4 between LCA and GMA. This discrepancy might be induced from differences
of their leukocyte removal strategies. LCA has a potential to remove 64% of lymphocytes
from processed peripheral blood although GMA removes small fraction of lymphocyte. We
have proven that GMA has a potential to increase CD25HighCD4+ lymphocyte (regulatory
T-cell) subset, but it has been assumed to ignore in the dynamic transition of %CD4 since
the regulatory T-cells occupies very small population among the whole CD4 expressing
lymphocytes. %CD4 might be the possible early marker to predict future response for active
UC patients treated with weekly LCA and GMA.
T1806
Influence of NOD2 Genotype On NF-KappaB Activation in Crohn's Disease
Katrin Menzel, Julia Brenmoehl, Daniela Vogl, Werner Falk, Juergen Schoelmerich,
Gerhard Rogler
Background: Crohn's Disease (CD) is thought to be caused by genetic and environmental
factors. Single nucleotide polymorphisms (SNPs) in the NOD2/CARD15 gene constitute a
risk factor to develop CD. NOD2/CARD15 is a member of a family of intracellular proteins,
containing a nucleotide-binding site domain flanked by a leucine-rich repeat domain and
is a sensor of peptidoglycane by binding the bacterial cell wall component muramyl dipeptide
(MDP) leading to activation of NF-kappaB. Currently there are conflicting data whether
NOD2/CARD15 variants lead to a “loss” or “gain” of function regarding NF-kappaB activation
In Vivo. We therefore investigated the activation of NF-kappaB and oxidative burst in
intestinal macrophages as indicators of innate immune functions from NOD2 wildtype (WT)
and NOD2 mutated (NOD2-mut) patients with and without CD. Methods: NF-kappaB
protein expression and activation was analyzed by Western Blot and immunohistochemistry
in specimens from NOD2-WT and NOD2-mut CD and control patients using an antibody
reacting with the activated subunit (p65) of the NF-kappaB protein. Immunohistochemically
stained cells were counted. NADPH Oxidase activity in human lamina propria mononuclear
cells (LPMNCs) was determined by FACS measuring intracellular H2O2 through oxidation
of dihydrorhodamin123 to rhodamin123, a peroxidase catalyzed reaction. Results: Expres-
sion of NF-kappaB(p65) protein was increased in CD patients compared to healthy controls.
Furthermore tissue of CD patients with NOD2 mutation(s) contained significantly increased
numbers of NF-kappaB(p65) positive cells compared to WT CD patients. Positive stained
cells were most prominent in areas around the crypts. LPMNCs isolated from CD mucosa
showed an increased oxidative burst activation and radical production compared to controls.
A trend for increased oxidative burst ratio was observed in patients with NOD2 mutations
with a significant higher oxidative burst ratio in patients with NOD2_SNP8. Conclusion:
Oxidative burst ratio correlates with NF-kappaB activation which is significantly increased
in CD patients with NOD2 mutation(s). These results clearly indicate that the loss of NOD2
function finally leads to an increase of activation of the innate immune system during CD.
Supported by DFG, SFB 585, A6
T1807
T Cell Selective Inhibition of Peripheral and Colonic Pro-Inflammatory
Cytokine Release By a Ca2+ Release-Activated Ca2+ Channel Blocker
Laurens Kruidenier, Rejbinder Kaur, Michael J. Wilson, Antonio Di sabatino, Nick A.
Leakey, Valerie D. Morisset, Lisa A. Lione, Kevin Lee, Thomas T. Macdonald, Peter G.
Mclean
Background: Cytokines released by hyperactive T lymphocytes play a crucial part in the
pathogenesis of inflammatory bowel diseases (IBD). An indispensable step in pro-inflammat-
ory cytokine production after T cell activation is a rise in intracellular Ca2+, mediated by
Ca2+ release-activated Ca2+ channels (CRAC). Aim/Methods: To establish whether targeting
CRAC would offer T cell selective immune modulation, we evaluated a CRAC antagonist
in cytokine release assays using blood and colon-derived cells from normal subjects and
IBD patients. Results: The CRAC antagonist compound potently reduced intracellular Ca2+
fluxes in a Jurkat T cell line, achieving a pIC50 of 6.0 (n=6). When administered to anti-
CD3/CD28-stimulated human peripheral blood mononuclear cells, it almost completely
prevented the release of interferon (IFN)-γ, interleukin (IL)-2, and tumour necrosis factor
(TNF)-α, with pIC50's between 6.1 and 6.3 (n>3), whereas the production of anti-inflammat-
ory IL-10 remained unchanged. Importantly, antagonising CRAC did not affect lipopolysac-
charide (LPS)-induced release of IL-1β, IL-6, and TNF-α from these cells (n=3). In lamina
propria mononuclear cells, isolated from resection specimens and biopsies from controls
and patients with Crohn's disease or ulcerative colitis, the CRAC antagonist completely
inhibited the production of IFN-γ, IL-2, and IL-17 (n>3), with a potency that was comparable
to that of cyclosporine A. In contrast, IL-8 release from these samples remained intact.
Conclusions: These results identify a CRAC antagonist with potent inhibitory effects on T
cell pro-inflammatory cytokine production, suggesting that CRAC are an attractive target to
achieve selective immunosuppression in patients with IBD.
T1808
Distinct Pro-Inflammatory Phenotype of Antigen Presenting Cells in Asca-
Positive/Mbl-Deficient Crohn's Disease Patients
Stefan Mueller, Thomas Schaffer, Beatrice Flogerzi, Frank Seibold
Background and aims: A subgroup of Crohn's disease (CD) patients develop antibodies
against cell wall mannans from the baker's yeast Saccharomyces cerevisiae (ASCA). ASCA-
positivity is associated with deficiency for mannan binding lectin (MBL). Furthermore, ASCA-
positive/MBL-deficient (ASCA+/MBL-) CD patients show measurable mannan-specific T cell
proliferation In Vitro. The aim of the present study was to characterize potential differences
of antigen presenting cells (APC) in response to yeast mannan between ASCA+/MBL-, and
ASCA-/MBL+ CD patients or healthy controls. Methods: Determination of TNF production,
and FACS analysis for the scavenger receptor CD163, mannose receptor (MR) and MHC
class II HLA-DR of irradiated monocytes (iAPC), and of monocytes-derived macrophages
(mono MØ) and dendritic cells (mono DC), respectively, from CD patients (n=8) and controls
(n=4) upon stimulation with mannan. Results: In contrast to ASCA-/MBL+ CD patients and
controls, monocytes of ASCA+/MBL- CD patients show a dose-dependent increase of TNF
production within the first 24h of stimulation with mannan (4.2 ± 2pg vs. 44.3 ± 20.1pg
per 10e5 cells, respectively, at 100ug/ml mannan). The scavenger receptor CD163 and the
mannose receptor (MR) are down regulated by 50% on mono MØ from healthy controls
in the presence of mannan while this down regulation was absent or diminished in mono
MØ from ASCA+/MBL- CD patients. Regarding mono DC, a much higher surface expression
level of MHC class II (HLA-DR) was observed in mono DC from ASCA+/MBL- CD patients
as compared to controls (mean fluorescence index of 1144 ± 294 vs. 393 ± 264, respectively).
This elevated HLA-DR expression was independent of the presence of mannan during mono
DC maturation, though. Conclusions: Binding of mannose-containing molecular patterns to
the MR per se can have pro- as well as anti-inflammatory effects. Here we demonstrate that
mannan delivers a pro-inflammatory stimulus to ASCA+/MBL- CD patients' but not control
monocytes. Lack of MR down regulation may lead to sustained signaling and activation of
MØ by mannan while lack of CD163 down regulation may reflect a deficit in proteolytic
shedding of soluble CD163 which is anti-inflammatory. Together these data indicate that
APC of the ASCA+/MBL- subgroup of CD patients have a special phenotype in that they
are predisposed to promote an aberrant, mannan-specific immune response.
T1809
Local Immunological Response Towards Dysplasia in Patients with Long-
Standing Ulcerative Colitis
Mats Karlsson, Per Karlen, Kenneth Lindberg, Olle Broström, Magnus Thörn, Ola
Winqvist, Michael Eberhardson
Background/aim: Patients with ulcerative colitis (UC) are at increased risk of developing
colorectal cancer. Colitis-associated colon cancer (CAC) is believed to follow the dysplasia-
carcinoma sequence (No dysplasia — Indefinite probably dysplasia IPD — Low-grade
dysplasia LGD — High-grade dysplasia HGD — Carcinoma). The immune surveillance
hypothesis suggests anti-tumor immune response as a defense against carcinoma. In the
present study, we have investigated whether dysplasia-draining mesenteric lymph nodes
(MLN) contain specific T-cell responses against earlier stages in the development of carcin-
oma. Method: In 13 UC patients undergoing total colectomy due to dysplasia, MLN draining
the dysplasia and normal mucosa were collected. Patent blue dye was injected into the
mucosa during surgery and blue-colored MLN were identified and harvested. The lymph
nodes were defined as draining non-dysplasia, indefinite dysplasia (IPD), or definite dysplasia.
MLN from 7 patients colectomized due to active UC were also collected for comparison.
Single T-cell suspensions were isolated from the lymph nodes and the CD4+/CD8+ ratio
analyzed by flow cytometry was used to assess the local T-cell response. Results: MLN
draining dysplasia showed increased CD4+/CD8+ ratio (4,9 + 0,74 SEM), compared to MLN
draining non-dysplastic mucosa (3,0+ 0,53 SEM), P<0.05 .The degree of inflammation was
equally distributed in both groups. When subdivided according to grades of dysplasia, the
CD4+/CD8+ ratio was higher in MLN draining LGD compared to IPD, P<0.05 (fig 1). The
immune response toward dysplasia was more pronounced (27 %) compared to active colitis
(ns) Conclusions: The MLN display an immune response against dysplasia. This may indicate
immune surveillance against stages preceding carcinoma. The development of colitis-associ-
ated cancer may be a result of an insufficient immune activation already at an early stage
of the dysplasia-carcinoma sequence.
FIG 1
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T1810
Increased Gut Plasmacytoid Dendritic Cells in Acute Ulcerative Colitis - Key
Mediators of Immunity and Inflammation?
Siew C. Ng, Sophie Plamondon, Michael A. Kamm, Stella C. Knight, Andrew J. Stagg
Background & Aim: Dendritic cells (DC) are heterogeneous, comprising phenotypically and
functionally distinct subpopulations. In the intestine, DC sample the luminal microbiota,
and help to maintain local immune homeostasis. Altered DC function in inflammatory
bowel disease is likely to contribute to the dysregulated recognition of bacteria that drives
inflammation but data in the human disease are limited. Properties of DC in long-standing
inflammation may not reflect those in the early stages of disease. Therefore, the aim of this
study was to identify changes in DC associated with acute flare-up of ulcerative colitis (UC).
Methods: Rectal biopsies were obtained from patients with active UC, symptomatic for < 4
weeks (Ulcerative colitis disease activity index > 3; sigmoidoscopy score > 2; n=20) and
from macroscopically and histologically normal tissue from controls (referred for rectal
bleeding; n=7). DC were identified by multi-colour flow cytometry (as HLA-DR+ lin-/dim
cells where lin is a mixture of antibodies to Cd3, 14, 16, 19 and 34) in freshly isolated
lamina propria mononuclear cells. The proportion and number, determined with reference
to FlowCount beads, of CD11c+ myeloid DC and CD11c- putative plasmacytoid DC were
assessed. Surface expression of activation/maturation markers CD40, CD86, and Toll-like
receptors (TLR), TLR-2 and TLR-4 was assessed on each cell population. Results: During
acute flare-up, there were significantly more intestinal DC in UC patients compared with
controls (a mean of 456 versus 108 per mg; p<0.05). The majority of additional DC present
in inflamed tissue were CD11c-, putative plasmacytoid DC (403 versus 51 per mg; p<0.005).
In contrast, the number of CD11c+ DC did not differ significantly between UC patients and
controls. Unlike CD11c+ myeloid DC, CD11c- DC from UC patients did not express TLR-
2 and TLR-4, and only a few expressed CD40 (22% CD11c- DC versus 60% CD11c+DC)
and CD86 (11% CD11c- DC versus 48% CD11c+ DC). Upon repeat sampling 8 weeks
later, reduction in macroscopic inflammation was associated with decreased numbers of
CD11c- cells. Preliminary data also suggested that these CD11c- cells lacked expression of
classic blood plasmacytoid DC markers (CD123, BDCA-2 and BDCA-4). Conclusion: UC
patients with acute flare-up have an increased number of intestinal DC, the majority of
which are CD11c- cells, the nature of which remains to be fully determined. Recruitment
of this specific group of cells in the intestine probably contributes to gut inflammation and
tissue damage. Further characterisation of these cells will provide new insights into their
role as a therapeutic target in active UC.
T1811
Role of Tlr2 and Myd88 in Modulation of Intestinal Goblet Cell Function
Elke Cario, Daniel K. Podolsky
Background: Commensal bacteria may assist the host to maintain mucosal homeostasis by
suppressing intestinal inflammation. Goblet cells (GC) contribute to mucosal protection and
epithelial barrier repair predominantly through production of trefoil peptides (TFF) and
mucins. However, the mechanistic and functional interrelations between commensals and
GC through regulation of TLR signalling have not been delineated yet. The aim of this study
was to determine the mechanistic relevance of TLR2 to control GC function via MyD88 to
balance mucosal homeostasis against inflammatory stress-induced damage. Materials &
Methods: TLR2 ligand (synthetic PCSK) - mediated GC modulation was assessed In Vitro
and In Vivo using western blotting and laser confocal microscopy (TFF3; MUC2). DSS-colitis
was induced by standard protocol in wild-type (WT), TLR2-/- and MyD88-/- mice. PCSK
was orally administered after DSS termination. GC morphology was determined by PAS+/-
AB; mucosal apoptosis by TUNEL, proliferation by PCNA and cytokine profile by array.
Results: In comparison with healthy WT intestine, TLR2-/- GC were hypotrophic and
demonstrated reduced expression of TFF3 and neutral mucins suggesting that GC morpho-
logy and differentiation are altered in the absence of TLR2. In contrast, MyD88-/- intestines
displayed GC hyperplasia with increased TFF3 levels, suggesting compensatory GC regulation
in the absence of MyD88. TLR2 stimulation of colonic GC-like Ls174T cells with PCSK
significantly increased secretion of TFF3 and MUC2 in a time- and concentration-dependent
manner. Supplemental PCSK administered in drinking water induced significant intestinal
GC proliferation in healthy WT mice correlating with enhanced TFF3 expression in terminal
ileum and distal colon which was abolished in the absence of TLR2. DSS-colitis induced
significant GC depletion with loss of TFF3 in both TLR2-/- and MyD88-/- which was
associated with severe intestinal barrier injury and inflammation. However, oral treatment
with PCSK of DSS colitis in WT, but not TLR2-/- mice, led to rapid induction of GC
regeneration with increased expression of TFF3 and acidic mucins (specifically MUC2)
which contributed to substantial preservation of tight junction architecture of the intestinal
epithelial barrier and significant suppression of mucosal inflammation and apoptosis. Conclu-
sions: TLR2 activation exerts trophic effects on intestinal GC leading to increase in cell
number and enhancement of TFF3 and acidic mucin production. Thus, GC-TLR2 may
provide a pharmacological target to protect epithelial barrier equilibrium and suppress
mucosal injury and intestinal inflammation.
T1812
Epithelial Barrier Function Is Regulated By Invasive E. coli Strains from
Inflammatory Bowel Disease Patients
Maiko Sasaki, Shanti V. Sitaraman, Joel A. Alpern, Adil Akyildiz, Arianne L. Theiss, Asma
Nusrat, Jan-michael A. Klapproth
Introduction: The intestinal epithelial functions as a barrier that separates luminal contents
from the underlying tissue compartments. The apical junctional complex (AJC) regulates
barrier function and is compromised in inflammatory bowel disease (IBD). These effects
are mediated in part by pro-inflammatory cytokines such as TNF-α and enteric bacteria.
Hypothesis: Disease specific invasive E. coli regulate barrier function in IBD. Material and
methods: Invasive E. coli were isolated from intestinal biopsies obtained from 15 patients
with Crohn's disease (CD), 12 with ulcerative colitis (UC), and 12 normal controls. Significant
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invasion was determined by an In Vitro invasion assay using a model intestinal epithelial
cell line, Caco-2. Bacterial effect on barrier function was determined by measurement of
transepithelial resistance (TER) and confocal microscopy for F-actin, and AJC proteins E-
cadherin, and ZO-1. Macrophage supernatant co-cultured with disease specific E. coli (MOI
10) was analyzed for TNF-α expression by ELISA after 24 h. Results: Epithelial invasion
indices for E. coli from CD were significantly higher (8.4%, ±5.5) in comparison to UC
(2.5%, ±0.4, p 1.22X10-7), and even higher when isolated from inflamed CD tissue (11.3%,
±4.3 vs. 7.3%, ±5.8 p 5.34X10-2). Regardless of clinical diagnosis, E. coli strains from both
IBD populations lead to a 79% decrease in transepithelial resistance (TER) over time whereas
commensal E. coli did not influence barrier function. This difference was statistically signific-
ant within four hours of starting the infection. Parallel to a decrease in TER, invasive E. coli
from patients with IBD lead to redistribution of F-actin and displacement of E-cadherin and
ZO-1 from the apical region of the lateral membrane. Infection of macrophage cultures with
IBD E. coli isolates lead to significantly higher expression of TNF-α in comparison to
LPS (CD: 2,604.8pg/ml, ±447.4, UC: 2,402.6pg/ml, ±276.3, LPS: 1,425.2 ±55.2). TNF-α
expression was even higher for E. coli from inflamed CD tissue in comparison to strains
isolated from macroscopically normal tissue (3,071.3pg/ml, ±226.0 vs. 2,476.5pg/ml, ±447.9;
p 5.16X10-6). Summary: Invasive E. coli from patients with IBD regulate barrier function
through redistribution and disassembly of the AJC. IBD specific strains also induce expression
of high TNF-α concentrations in macrophage cultures. Conclusion: We propose a mechanism
by which IBD specific invasive E. coli breach epithelial integrity, gain access to mucosal
macrophages, induce high concentrations of TNF-α, and further exacerbating loss of bar-
rier function.
T1813
Physiopathological Role of Crohn's Disease Associated Adherent-Invasive
Escherichia coli in Colonic Inflammation
Cecile Vignal, Frederic Carvalho, Nicolas Barnich, Elizabeth Pradel, Edmone Erdual,
Emilie Merour, Xavier Thuru, Laurent Peyrin-biroulet, Agathe Gellot, Christel Neut,
Pierre Desreumaux, Jean-frédéric Colombel, Lars Eckmann, Arlette Darfeuille-michaud,
Mathias Chamaillard
BACKGROUND No sign of spontaneous colitis have been reported in mice deficient for the
Crohn's disease (CD) predisposing NOD2 gene, suggesting that other factors are required
to trigger CD. The intestinal lesions of CD patients were abnormally colonized by adherent-
invasive Escherichia coli (LF82). However, the physiopathological role of LF82 in intestinal
inflammation remains poorly understood. AIM Our aim is to investigate the pathogenesis
of LF82 in resting and inflamed gastrointestinal tract of mice. METHODS Two experimental
models were used to characterize the virulence of LF82. BALB/c or C57BL/6 mice were
orally administered by 2% DSS and/or 10to8-9 bacteria/mice/day during 2 weeks (LF82 or
non pathogenic K-12 C600 or LF82-DompR isogenic mutant, deleted for the ompR gene
encoding a global regulation system of bacterial gene transcription). Alternatively C57BL/6
mice were given orally 2.5% DSS for 5 days and subsequently challenged by 10to10 LF82/
mice. The intensity of colitis was assessed by mortality rates, clinical and histologic inflammat-
ory scores. Inflammatory mediators and antimicrobial peptides expression were determined
by quantitative RTPCR. Finally, the LF82-induced cytokines production was determined in
both PBMCs from CD patients and macrophages from NOD2 2939insC mice, whose Nod2
locus harbours the homolog of the most common CD-associated NOD2 1007fs mutation.
RESULTS In Vivo bioluminescence imaging was first used to determine the route of infection
by LF82 in live animals, revealing persistent signals from the caecum and the proximal
colon over a period of couple days. Whereas LF82 did not trigger by itself colitis, DSS-
treated mice infected by LF82, but not by isogenic mutants or non pathogenic K-12 C600,
experienced more severe colitis compared to uninfected DSS-treated mice, as shown by the
increased mortality, clinical and histological scores. Consistently, gene expression of pro-
inflammatory cytokines Il-1b and MIP2 was significantly increased and mice infected with
bioluminescent LF82 strain showed significant increased systemic bacterial dissemination.
Finally, we investigated the role of normal and mutant NOD2 in macrophages response to
LF82. We found similar cytokines and chemokines production in both wild-type and mutant
NOD2 macrophages and in PBMCs from CD patients carrying or not CD-associated NOD2
mutations. CONCLUSION Our results suggest that LF82 is carried in mice caecum and
proximal colon and can aggravate preclinical model of inflammatory bowel disease. We also
reported a minor role, if any, of NOD2 in macrophages response to LF82. Further work
should now investigate the intestinal innate immune response to LF82.
T1814
NOD2, Human α Defensin 5 (Hd5) and Wnt Signalling in Paneth Cells
Suresh Sivanesan, Carolyn Koh, Sanjay Lala, Satish Keshav
Background: Polymorphisms in the NOD2 gene are implicated in the pathogenesis of ileal
inflammation in Crohn's disease (CD), and reduced expression of human α defensin 5
(HD5) has been detected in ileal tissue in CD. Furthermore, levels of HD5 are most reduced
in patients carrying polymorphisms in the NOD2 gene. Both the NOD2 and HD5 genes are
expressed in Paneth cells, located in the crypts of the small intestine, and the regulation of
HD5 expression is likely to involve the Wnt/β-catenin signalling pathway, as β-catenin/Tcf
4 binding sites are present in the HD5 promoter region. We therefore investigated if the
NOD2 protein interacts with Wnt signalling in intestinal epithelial cells. Methods: The
regulation of HD5 promoter activity was studied In Vitro using a luciferase reporter construct
transfected into SW480 cells, which constitutively express low levels of HD5 and NOD2.
Cells were treated with lithium chloride (LiCl), which activates β-catenin signalling, and
with muramyl dipeptide (MDP), which activates signalling via NOD2. Expression plasmids
encoding the wild type NOD2 cDNA (N2wt) or a frameshift polymorphism associated with
CD (N2mut) were co-transfected with the HD5 promoter reporter plasmid to study the
interaction between NOD2 and the HD5 promoter. Real-time quantitative RT PCR was used
to determine the effect of LiCl, MDP and other agonists on the expression of Wnt target
genes such as EphB3, matrix metalloproteinase 7 (MMP7) and HD5. Results: HD5 promoter
activity was increased in SW480 cells treated with LiCl and not with MDP. In cells co-
transfected with NOD2 expression plasmids however, the effect of LiCl was significantly
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reduced in the presence of the N2mut plasmid, and not in the presence of the N2wt plasmid.
MDP did not affect the expression of the HD5 reporter plasmid. Similarly, LiCl treatment
increased the expression of Wnt/β-catenin target genes in SW480 cells co-transfected with
the N2wt plasmid, and this effect was absent in cells expressing the N2mut plasmid.
Conclusions: The mechanisms by which ileal expression of HD5 is reduced in CD associated
with polymorphisms in the NOD2 gene remain unexplained. Our data, however suggest an
interaction between NOD2-mediated signalling and the expression of genes regulated by
the Wnt/β-catenin signalling pathway, such as EphB3 and HD5.
T1815
Luminal Human Defensin-5 Is Associated in a Complex with Paneth Cell-
Derived Chymotrypsin and Trypsin in Crohn's Disease But Not Controls
David Elphick, Yashwant R. Mahida
Antimicrobial human defensin (HD)-5 is stored in Paneth cells in precursor form. Our aim
was to study luminal HD-5 in ileostomy fluid of patients with Crohn's disease (CD) and
controls. METHODS. Ileostomy fluid HD-5 concentration was determined by comparison
of immunodot density against standard curve. HD-5 was characterised by reverse phase-
high performance liquid chromatography (RP-HPLC), acid urea-polyacrylamide gel electro-
phoresis (AU-PAGE) and SDS-PAGE Westerns, N-terminal amino acid sequencing and ES-
QToF mass spectrometry (MS). RESULTS: Ileostomy fluid HD-5 levels were lower in CD
(n=51) than control (n=20): median 7.9 (range 5.5 - 35.0) vs 10.5 (6.0 - 30.4) µg/ml (p=
0.05), most marked in CD NOD2 mutant homozygotes / compound heterozygotes (p=0.03).
Control (n=3) luminal HD-5 was present in mature form only. However, CD (n=7) luminal
HD-5 appeared in multiple forms on AU-PAGE Western: mature, pro-HD-5 and also bands
with electrophoretic mobility slower that pro-HD-5. RP-HPLC confirmed this, as CD luminal
HD-5 eluted at three acetonitrile concentrations: 39% (consistent with pro-HD-5), 50%
(mature HD-5), but majority eluted at 59% acetonitrile. Further analysis of latter fraction
from 4 CD patients (none with overt small intestinal disease) by ES-QToF showed sequences
for chymotrypsinogen/chymotrypsin in 3 and for trypsin in 4th (confirmed by N-terminal
sequencing) and also contained a mass consistent with mature HD-5 (3580.51 Da). On AU-
PAGE of CD ileostomy fluid, HD-5-immunoreactive bands with slowest electrophoretic
mobility (which elute at 59% acetonitrile on RP-HPLC) were in a similar position to chymo-
trypsin- and trypsin-immunoreactive bands. However, in SDS-PAGE Westerns (under dena-
turing/reducing conditions), the same samples showed distinct immunoreactive bands con-
sistent with sizes of mature HD-5 and chymotrypsin. AU-PAGE of CD crypt cell extract did
not show similarity in positions of HD-5 and chymotrypsin/trypsin-immunoreactive bands.
Pro-HD-5 purified from crypt cell extracts did not show chymotrypsin or trypsin immunore-
activity. Immunohistochemistry confirmed chymotrypsin-immunoreactivity in Paneth cells.
CONCLUSIONS: (i) HD-5 levels in CD ileostomy fluid were lower than in controls (ii)
unlike controls, HD-5 in CD ileostomy fluid exists in multiple forms: mature, precursor,
and majority in a complex with Paneth cell-derived chymotrypsinogen/chymotrypsin and
trypsin (iii) processing of HD-5 in CD small intestinal lumen is dysregulated, in the absence
of overt inflammation and thus may represent an underlying abnormality that (together with
reduced total levels) could lead to impaired function of this antimicrobial peptide.
T1816
Down-Regulation of Paneth Cell α-Defensin Expression and Function in
Patients with Crohn's Disease
Atsuo Maemoto, Tokiyoshi Ayabe, Hiroki Tanabe, Yuhei Inaba, Toshifumi Ashida, Rie
Fukaya, Naoki Sakai, Toru Kono, Yutaka Kohgo
Paneth cells contribute to intestinal innate immunity by sensing bacteria and secreting
microbicidal α-defensins. In Crohn's disease (CD), the microbe-epithelia interaction has
been suggested to contribute to its pathology. We aim to investigate expression of α-defensins
and their function in Paneth cells of patients with CD. Inflamed ileal mucosa were obtained
from surgical specimens resected from patients with CD, and normal ileum from patients
with colon cancer under informed consent. Intact crypts isolated by EDTA dissociation were
subjected to real-time RT-PCR for HD5 and HD6 mRNAs to quantify gene expression.
Immunohistochemical analyses on tissue specimens were conducted using anti-HD5 anti-
body. Isolated normal crypts or crypts from CD patients were co-cultured ex vivo for 30
min at 37°C with S. typhimurium, E. coli or Lactobacillus, and supernatants are assayed for
bactericidal activities against defensin-sensitive S. typhimurium. HD5 as well as HD6 mRNA
expression in isolated crypts from patients with CD was significantly diminished relative to
those from normal controls. HD5 co-localized in Paneth cell granules was decreased in
inflamed ileum of CD patients. Secretions from normal ileal crypts stimulated with S.
typhimurium, E. coli or Lactobacillus were all bactericidal. Bactericidal activities released from
isolated crypts from CD patients in response to bacteria were significantly diminished relative
to normal controls on a per crypt basis. Western blot analyses confirmed that Paneth cells
from CD patients secrete less HD5 than those from controls. In Crohn's disease, Paneth cell
α-defensin expression was down-regulated, and the impaired innate defense mechanisms
in Paneth cells might contribute the pathology of CD.
T1817
Tlr2 Signaling Is Selectively Regulated By Akap13, a RHOA Guanine
Exchange Factor
Oren Shibolet, Tobias Mueller, Cosmas Giallourakis, Ian M. Rosenberg, Ramnik Xavier,
Daniel K. Podolsky
Background: A-kinase anchoring Protein 13 (AKAP13) is a scaffolding protein with guanine
exchange factor (GEF) activity. We have previously identified AKAP13 as a regulator of NF-
kB activation via TLR2 stimulation. Aim: to examine regulatory mechanisms involved in
AKAP13 expression and evaluate the role of AKAP13 in TLR2 signal regulation. Methods:
The putative promoter area of AKAP13 was searched for conserved NF-kB binding sites.
AKAP13 expression following TLR ligand stimulation was assessed in SW480 intestinal
epithelial (IEC) and THP-1 monocyte cell lines using real-time PCR. Point mutations effecting
AKAP13 functions were generated and their effect on NF-kB activation following TLR2
ligand stimulation was assessed. Immunoprecipitation was used to identify potential binding
partners for AKAP13. AKAP13 membrane recruitment following TLR2 stimulation was
assessed by cytosol/membrane fractionation and immunohistochemistry. Results: we identi-
fied a conserved NF-kB binding site within 2000 bases of AKAP13 start codon. Stimulation
of SW480 and THP-1 cells with TLR2 but not TLR4 ligands (pam3CSK and LPS respectively)
induced a 4-8-fold increase in AKAP13 mRNA levels (normalized to GAPDH). Following
TLR2 ligand stimulation AKAP13 was recruited to the cell membrane starting at 3 minutes
following stimulation as shown by membrane fractionation and immunohistochemistry.
Transfection of AKAP13 pleckstrin homologue (PH)-domain-deficient mutant did not affect
AKAP13 membrane targeting as assessed by immunohistochemistry. Transfecting a GEF
domain deficient or a GEF/PH double-domain-deficient mutants significantly reduced NF-
kB activation following TLR2 stimulation in HEK293 cell stably transfected with TLR2.
Epistasis studies showed that AKAP13 signals downstream of MyD88, and upstream of
TRAF6. Conclusion: AKAP13 expression is selectively induced by TLR2 ligand but not other
TLR ligands. AKAP 13 regulates NF-kB activation in a TLR2 dependent manner forming a
TLR2 specific positive feedback loop. Membrane recruitment of AKAP13 may mediate its
activity but is independent of the PH domain. Our findings identify AKAP13 as a possible
drug target in inflammatory processes mediated via TLR2.
T1818
Prospective Evaluation of Fecal β Defensin in Active and Inactive
Inflammatory Bowel Disease
Yogesh Shastri, Nada Povse, Wolfgang Caspary, Oliver Schröder, Jürgen Stein
BACKGROUND: Defensins are endogenous antimicrobial peptides protecting the intestinal
mucosa against bacterial invasion. It has been already shown that deficient defensin expression
may underlie the chronic inflammation of Crohn's disease (CD). Most of the studies till
now have quantified its levels in the intestinal mucosa. However now it is possible to measure
its levels in stool samples which is much more convenient, non invasive and economical.
This is the first study reporting the fecal assay of β defensin in a large group of patients
with inflammatory bowel disease (IBD) and healthy controls. AIM: To determine the fecal
β defensin levels in patients with IBD and healthy controls and also to correlate it with
clinical disease activity. METHODS: 254 consecutive patients (115 male and 139 female)
with IBD who were being followed up at our department provided the stool samples for
performing fecal β defensin estimation. Activity of IBD was determined clinically, endoscop-
ically and by performing fecal calprotectin level (Active IBD >15 ng/ml). The fecal defensin
concentrations were measured using a commercial ELISA (Immunodiagnostik, Germany).
RESULTS: The levels of fecal β defensin in various groups of patients are as shown in Table.
P value was calculated to provide level of significance between IBD and healthy controls.
Patients with active ulcerative colitis (UC) had significantly higher levels of fecal β defensin
than that of those with CD and healthy controls while those with inactive CD had much
lower levels of it as compared to healthy controls. CONCLUSIONS: These results are
confirmation in feces of the findings of previous studies which have revealed (using PCR
techniques) in tissue samples, deficiency of β defensin levels in patients harbouring CD.
Although this clinical data indicates divergent innate mucosal defense responses in patients
with UC and CD, the exact clinical application of this vital information is still a matter of
further research.
Fecal β defensin levels in patients with various clinical diagnosis
T1819
A Role for Mtgr1 in Intestinal Epithelial Migration and Repair
Christopher S. Williams, Amy C. Moore, Joseph M. Amann, Michael E. Engel, Tiffany C.
Ellis, Robert H. Whitehead, Scott W. Hiebert
Chromosomal translocations that are closely associated with cancer often disrupt master
regulatory genes critical for control of proliferation, apoptosis, and differentiation. MTG8 is
a transcriptional co-repressor originally identified at the breakpoint of the t(8;21) transloca-
tion in acute myeloid leukemia (AML). Mechanistically, transcriptional co-repressors recon-
cile and integrate multiple inputs to fine tune gene expression. MTGR1 is the third MTG
family member identified. Mtgr1-null mice were engineered to further explore biologic
function. These animals display progressive secretory lineage depletion, and enhanced
enterocyte proliferation and apoptosis. Moreover, compared to wild type mice, Mtgr1-null
mice display a more severe acute colitis in response to dextran sodium sulfate (DSS) treatment
and develop histologic changes consistent with chronic colitis. An important component of
intestinal response to injury is restitution of epithelial barrier integrity. Epithelial migration
is an important process during the resolution phase of wound healing and migration abnor-
malities can contribute to both the severity and duration of injury. Time-course BrdU labeling
showed abnormal enterocyte migration in Mtgr1-null mice. Both E-cadherin and p120, a
member of the catenin family, contribute to epithelial migration, however, no differences
were observed in either their expression or localization. Wnt regulators, E-Cadherin and
p120 contribute significantly to epithelial migration. Interestingly, we found that MTG family
members influence Wnt target gene expression. Mtgr1-null animals have increased levels
of TCF4 target transcripts (cMyc and Id2). MTGR1 competes with β-catenin for TCF4
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binding, and represses both β-catenin dependent transcriptional responses and axis duplica-
tion in Xenopus oocytes. This suggests that MTGR1 functions as a transcriptional co-repressor
toward Wnt dependent gene expression. Therefore, we used cDNA microarray analysis to
evaluate for changes in the transcriptome in Mtgr1-null colons. In preliminary experiments,
we found expression differences in genes involved in proliferation (CD44, APC), differenti-
ation (homeobox genes, Lif, BMP3), gut development (homeobox genes: Hoxa3, Hoxa1,
Hoxa13, HoxA6) and patterning/migration (EphA1, EphA5 and the receptor EphrinA5). We
have generated a conditionally immortalized Mtgr1-null small intestinal cell line, an In Vitro
reagent for probing the mechanistic basis for these observations. These findings suggest that
MTGR1, and likely other MTG family members, are essential master regulators gut lineage
specification are critical for survival and regeneration in response to colonic injury.
T1820
Effect of EGF Treatment On Hepatic Tight Junctions in a Rat Model of
Experimental Necrotizing Enterocolitis
Ludmila Khailova, Dania Molla hosseini, Kelly M. Arganbright, Melissa D. Halpern,
Bohuslav Dvorak
Background: Necrotizing enterocolitis (NEC) is the most common intestinal disease of
premature babies. Although the intestine is the primary site of injury, severe NEC is associated
with pathological changes in the liver. Previously, we have shown that the overproduction
of TNF-α and bile acids by the liver further exacerbates intestinal damage in a rat NEC
model. We have also shown that administration of epidermal growth factor (EGF) reduces
the incidence of NEC, down-regulates the overproduction of intestinal and hepatic pro-
inflammatory cytokines, and improves intestinal barrier functions. Although increased inflam-
matory reaction and bile back-leakage are predicted consequences of epithelial tight junction
(TJ) dysfunction in the liver, the structure of hepatic TJ during NEC pathogenesis has not
been studied yet. Objective: The aim of this study was to investigate changes in the hepatic
tight junction composition during NEC pathogenesis and evaluate the effect of EGF treatment.
Methods: Premature rats were divided into three groups: dam fed (DF), formula fed (NEC),
or fed with formula supplemented with 500 ng/ml EGF. All groups were exposed to asphyxia/
cold stress to develop NEC. Hepatic iNOS, TNF-α, and IL-18 mRNA and protein levels
were measured. Gene and protein expression of the TJ proteins occludin and claudins were
also evaluated in the liver. Results: Increased levels of iNOS, TNF-α, and IL-18 were detected
in the liver of NEC rats compared to the DF rats. Hepatic occludin expression was significantly
increased in the NEC group. EGF treatment normalized these levels to values observed in
the DF group. In contrast, Claudin-3 levels were markedly reduced in both NEC and EGF
groups and there was no change in Claudin-1 levels. Conclusions: Alterations in hepatobiliary
tight junctional integrity during experimental NEC may be responsible for the leakage of
TNF-α and bile acids from the liver into the intestinal lumen. We speculate that EGF
treatment partially normalizes hepatic TJ dysfunction and consequently reduces the incidence
and severity of NEC. Supported by the NIH Grant HD039657 (to B.D.)
T1821
CDP/Cux Transcriptional Activity Controls Experimental Colonic
Inflammation Through Regulation of Claudin-2 Expression
Mathieu Darsigny, Francois Boudreau
INTRODUCTION: The intestinal epithelium serves as a first barrier to intraluminal content
and dysregulation of this physical function could be responsible for unwanted contact
between immune cells and bacterial antigens. It has become evident that innate functions,
like the ones played by the epithelium, ought to be challenged during the course of inflammat-
ory bowel diseases. CDP/Cux is a ubiquitous transcription factor previously reported to
regulate colonocyte identity by repressing the small intestinal specific gene sucrase-isomaltase.
AIM: Since modification of colonocytes' identity can lead to pathological conditions, we
sought the role played by CDP/Cux in the control of cell-cell adhesion molecules. METHODS
AND RESULTS: We first screened for CDP/Cux dependent modifications in the expression
of adhesion molecules with the use of stable expression of a short hairpin RNA against CDP/
Cux in the rat intestinal epithelial cell line IEC6/Cdx2. This analysis identified claudin-2, a
tight junction protein shown to be altered in ulcerative colitis, as being induced in absence
of CDP/Cux. The mouse knock-in model deficient for the homeodomain portion of CDP/
Cux was then further utilized. Western blots against claudin-2 showed an up-regulated
expression in the colonic mucosa of CDP/Cux mutants. This led us to test the impact of
such a defect in a colitis-inducing dextran sodium sulphate (DSS) treatment. CDP/Cux
mutants and control mice were challenged during 7 days with 2.5% of DSS in drinking
water after which animals were sacrificed, assessed for clinical manifestations of disease
(weight loss, stools aspect, rectal bleeding and colon length) and histological alterations.
Both assessments confirmed a significantly greater disease activity in CDP/Cux mutant mice.
Moreover, the expression of TNFα , IL-1β , TGFβ1 and IFNγ was significantly higher in
the treated mutant group compared to controls. CONCLUSION: Our results support that
CDP/Cux could be responsible for adequate tight junction assembly in the colonic epithelium,
a homeostasis shown necessary to sustain inflammatory stress. Claudin-2 is mostly expressed
in bottom crypts, while CDP/Cux expression increases with colonocyte differentiation. Loss
of CDP/Cux activity might lead to maintained expression of claudin-2 in differentiated cells,
thus changing their paracellular permeability. Further work is ongoing to characterize CDP/
Cux transcriptional action on claudin-2 gene promoter. (This work was supported by CIHR,
CFI and FRSQ).
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T1822
Intestinal Secretion of Murine Trefoil Factor 3 Via Orally Administered L.
Lactis Shows Strong Therapeutic Effect in 5-Fluorouracil Induced Mucositis
Karolien Van huynegem, Klaas Vandenbroucke, Bernard Coulie, Pieter Rottiers
Radiation and chemotherapy-induced intestinal injury, referred to as mucositis, is a major
side effect of cancer therapy. At the moment, there are no agents available that prevent or
heal the intestinal damage and this limits both the dose and duration of cancer treatment.
Trefoil factor 3 (TFF3) is present in the small and large intestine and is thought to play a
major role in tissue protection and healing after injury. TFF3 may also modulate the
response to cytotoxic agents like 5-fluorouracil (5FU). We previously demonstrated that
oral administration of TFF3 secreting Lactococcus lactis (LL) strains leads to active delivery
of TFF3 at the intestinal mucosa. Such treatment was shown to be effective in both prevention
of disease and healing of colitic mucosa. Here, we report on the effect of these strains on
5FU induced mucositis. Mucositis was induced in male C57BL/6 mice by daily IP injection
of 250 mg/kg 5FU for 3 days. This resulted in a reduction in crypt numbers, crypt depth
and villus height presumably due to stem cell damage, which is causing diarrhea and loss
of body weight. Mice were treated with LL-TFF3 or LL-pT1NX (empty vector control) or
mock for 4 consecutive days prior initiation of 5FU therapy (pre treatment) or for 6
consecutive days following 5FU therapy (post treatment). Post treatment with LL-TFF3
resulted in a stabilization of body weight and a remarkable restoration of functional crypts
and increased crypt numbers in the terminal ileum after five day treatment. This suggests
that local delivery of TFF3 hastens the recovery of intestinal injury caused by 5FU and may
have therapeutic value.
T1823
Bradykinin Mediates the Protective Action of Angiotensin Converting Enzyme
(ACE) Inhibition in Non Steroidal Anti Inflammatory Drugs-Related Injury of
the Small Intesitine
Ryszard Sendur, Jaroslaw Biernat, Rafal Obuchowicz, Teresa Pawlik, Artur B. Dembinski,
Tomasz Brzozowski, Wieslaw Pawlik
Bradykinin has been found to potentiate the release of endogenous prostaglandins and to
activate the vanilloid-sensitive neurons and thus protects the duodenum and proximal
jejunum against hydrogen ions-related injury. Its bioavailability depends not only on the
production but on the breakdown as well. Angiotensin converting enzyme (ACE) is mostly
responsible for degradation of locally generated kinins. Using the angiotensin converting
enzyme inhibitor we showed that ACE blockade has a protective role upon jejunum submitted
to ischemia and reperfusion and it is strictly related to the vasodilation of ACE blockade.
However the exact role of ACE inhibition in non-steroidal anti inflammatory drugs-related
injury of the small intestine has not been investigated yet. In addition we decided to
investigate the role of endogenous bradykinin and in this model of small intestine injury.
We performed the experiments on Wistar rats submitted to: placebo, COX-1, COX-2 and
COX-1 + COX-2 in ACE-blocked, bradykinin 1 and 2 (BK1 and BK2) receptor blocked
animals. In pentobarbital anesthetized rats arterial blood pressure (AP), mesenteric blood
flow (MBF) and microcirculatory intestinal blood flow (LDBF) were measured in proximal
and distal jejunum using laser-Doppler flowmetry. Segments of jejunum were excised at the
end of the experiment and the total ulcer area (mm2) was measured. Administration of
COX-1 and combination of COX-1 and COX-2 inhibitor induced the ulcers of 16 mm2
and 34mm2 respectively in the distal jejunum. In the group pretreated with ACE-inhibitor,
COX-1 inhibitor decreased total ulcer area by 35% (p< 0,05) and increased LDBF in the
distal jejunum by 23% (p< 0,05) in comparison to COX-1 alone pretreated animals. In the
group pretreated with BK2 receptor antagonist (but not BK1 receptor antagonist), COX-1
inhibitor increased total ulcer area by 29% (p< 0,05) and decreased LDBF in the distal
jejunum by 24% (p< 0,05) in comparison to COX-1 alone pretreated animals. However
when BK2 receptor antagonist was given to the rats pre-treated with ACE inhibitor, the
blockade of BK2 receptors completely reversed the action of ACE inhibitor in both the COX-
1 selective and combination of COX-1 and COX-2 inhibitor treated rats. Above results
indicate that inhibition of angiotensin converting enzyme protects distal jejunum against
COX-1 and combination of COX 1 + COX-2 induced mucosal injury and this action is
mediated by endogenous bradykinin acting on BK2-receptors.
T1824
Attenuation of Indomethacin-Induced Rat Intestinal Lesions, TNFα-Production
and iNOS Activity By Tdzd-8, An Inhibitor of Glycogen Synthase Kinase-3β
Brendan J. Whittle, Csaba Varga, Aniko Berko, Krisztina Horvath, Aniko Posa, Andor
Molnar, Christoph Thiemermann
Indomethacin provokes small intestinal inflammatory lesions in the rat by a sequential process
initially involving epithelial injury and cyclo-oxygenase inhibition followed by bacterial
translocation. Nitric oxide synthase (iNOS) is then induced, probably through local cytokine
release, with the resulting nitric oxide (NO) combining with superoxide to form injurious
peroxynitrite (Eur J. Pharmacol 500,427; 2004). It is now known that the protein kinase,
glycogen synthase kinase-3β (GSK-3β), facilitates activation of the nuclear factor, NF-κB
that promotes pro-inflammatory mediator synthesis including the cytokine, TNF-α and the
induction of iNOS. Thus, to explore the role of GSK-3β in modulating gut inflammation,
the effects of the selective GSK-3β-inhibitor TDZD-8, in doses that we have shown to reduce
gut NF-κB, have been investigated on indomethacin-provoked intestinal injury. Two days
after indomethacin (10mg/kg, s.c.), rat jejunal macroscopic inflammatory injury and the
levels of myleoperoxidase (MPO), TNF-α and iNOS were determined. TDZD-8 (0.125, 0.5
and 1.5 mg kg-1, s.c, b.i.d.), commencing 2h prior to challenge, caused a dose-dependent
reduction in the area of macroscopic jejunal injury, with a reduction from 69 ± 9% to 36
± 6% of the total area measured (n=9; P<0.01) at the intermediate dose. TDZD-8 also
attenuated the macroscopic severity score (0-5 scale), with TDZD-8 (0.5mg/kg) reducing
the score from 4.1 ± 0.3 to 2.3 ± 0.3 (P<0.001). The jejunal MPO, an index of neutrophil
infiltration, which was increased 48h following indomethacin (from baseline of 36 ± 2 to
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113 ± 27 mU/mg protein, n=9), was also dose-dependently inhibited by TDZD-8 (by 67%
at 0.5mg/kg; P<0.02). Moreover, the increased jejunal levels of TNF-α determined by ELISA
in the damaged tissue (from 131 ± 7.2 to 861 ± 167 pg/mg protein; P<0.02) were also
significantly inhibited by TDZD-8, the reduction being 69% (P<0.01) with 0.5 mg/kg.
Likewise, the jejunal iNOS activity, determined by the citrulline assay, which was not
detected under non-challenged conditions, was dose-dependently inhibited by TDZD-8,
being reduced by 75% (n=9; P<0.01) by the 0.5 mg/kg dose. These findings show that the
selective GSK-3β inhibitor, TDZD-8, reduces both the jejunal macroscopic damage and the
elevated inflammatory biomarkers, iNOS, TNF-α and MPO, determined 48h after indometh-
acin. This anti-inflammatory action is likely to reflect the down-regulation of NF-κB activity
and hence the suppression of TNF-α synthesis, iNOS expression and other pro-inflammatory
mediators, and could identify novel pharmacological interventions to alleviate such NSAID-
provoked intestinal damage.
T1825
Role of Secretory Phospholipase A2 (Spla2) in Lipopolysaccharide (LPS)-
Induced Gastrointestinal (GI) Injury in the Rat
Mayssa Zayat, Lenard M. Lichtenberger, Elizabeth J. Dial
BACKGROUND: A hydrophobic layer of phosphatidylcholine (PC) overlies the surface of
the GI tract and contributes to barrier integrity. We showed previously that sPLA2 activity
increases in the GI tract lumen after LPS treatment, where it may degrade PC and produce
injurious lyso-PC (Shock 25:67, 2006). The current study examined changes in LPS-induced
GI permeability as a measure of injury, and the effect of an orally-active, specific sPLA2
type IIA inhibitor (5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino) pentanoic acid).
METHODS: Male Sprague Dawley rats were treated with LPS (5mg/kg, ip) or saline, and
at 5 hours after the injection, GI permeability was assessed In Vivo (under anesthesia). For
gastric permeability, the duodenum was clamped and rats were gavaged with 2 ml of FITC-
Dextran 4000 (1.5 mM). One hour later, the FITC-D blood concentration was tested. For
intestinal permeability, the last 10 cm of the ileum was ligated at both ends and 1 ml of
FITC-D 4000 (1.5 mM) was injected into the sac. Half an hour later, the blood concentration
was tested. To determine if the changes in permeability are affected by inhibiting the sPLA2,
a specific sPLA2-IIA inhibitor (5 mg/kg, po) was given 1 h prior to LPS injection and the
permeability was assessed 5 h later. RESULTS: LPS treated rats showed an increase in GI
permeability to FITC-D (expressed in pmol of FITC-D/ml of blood). For gastric permeability,
there was a significant difference between the LPS treated versus the control group at 5 h
post injection (LPS=51.9 ± 16.6; control=3.14 ± 1.85 pmol/ml; p<0.05). Similarly, there
was a significant difference in intestinal permeability between the two groups at 5 h post
injection (LPS=43.0 ± 13.3; control=2.04 ± 2.04 pmol/ml; p<0.05). Giving the sPLA2
inhibitor orally 1 h prior to LPS injection gave an apparent decrease in gastric permeability
(not significant), and fully prevented the LPS-induced increase in intestinal permeability at
5 h (inhibitor + LPS=2.77 ± 1.5; LPS=29.2 ± 12.7 pmol/ml; p<0.05). CONCLUSIONS: In
response to LPS, sPLA2 activity increases in the rat GI tract lumen where it may degrade
the protective phospholipid layer and increase GI permeability. Pretreatment with an orally-
active sPLA2 inhibitor blocks the LPS-induced increase in GI permeability, and may suggest
a new approach to fortify the GI mucosal barrier and prevent sepsis in trauma and other
patients. (Supported by NIGMS P50 GM038529).
T1826
Simvastatin Inhibits Nf-κB Signaling in Intestinal Epithelial Cells and
Ameliorates Acute Murine Colitis
Jong yeul Lee, Joo sung Kim, Jung mogg Kim, Nayoung Kim, Hyun chae Jung, In sung
Song
Background/Aims: Statins, HMG-CoA reductase inhibitors exert pleiotropic anti-inflammat-
ory properties In Vitro and In Vivo, and are associated with the risk reduction of colorectal
cancer. It remains unknown, however, whether statin is effective for the treatment of inflam-
matory bowel disease (IBD). Therefore, we investigated anti-inflammatory effects of statin
on intestinal epithelial cells (IEC) and on an experimental murine colitis model, and elucidated
its molecular mechanisms. Methods: Colon epithelial cells COLO 205 were pretreated with
simvastatin (10-50 μM) and then stimulated with TNF-α. Interleukin (IL)-8 gene expression
was determined by real-time RT-PCR. NF-κB transcriptional activity and IκB phosphoryl-
ation/degradation were evaluated by NF-κB-luciferase reporter assay and Western blotting,
respectively. NF-κB binding activity was assessed by electrophoretic mobility shift assay
(EMSA). C57BL/6 mice were randomized into two simvastatin-treated groups (5 or 50 mg/
kg/day), dextran sulfate sodium (DSS) group and normal control. Simvastatin was adminis-
tered orally once daily for 2 days and then acute colitis was induced by giving 4% DSS in
drinking water for 6 days. Body weight, colon length, disease activity index (DAI: stool
consistency, hematochezia), and colonic histology were examined. Results: Simvastatin (50
μM) significantly inhibited TNF-α-induced IL-8 gene expression in COLO 205 cells. Simvas-
tatin (50 μM) blocked TNF-α-induced NF-κB transcriptional activity, IκB phosphorylation/
degradation and DNA binding activity of NF-κB. Administration of simvastatin significantly
reduced the severity of DSS-induced murine colitis as assessed by body weight, colon
length, DAI, and histology in a dose-dependent manner. Conclusions: Simvastatin inhibits
proinflammatory gene expression by blocking NF-κB signaling in IEC, and attenuates DSS-
induced acute murine colitis. Simvastatin could be a potential agent for the treatment of IBD.
T1827
Simvastatin Abrogates TGF-β1 Mediated Activation of Intestinal Fibroblasts
John P. Burke, R. william G. Watson, J. calvin Coffey, Neil G. Docherty, P. ronan
O'connell
Introduction: The intestinal fibroblast is the key cell type mediating stricture formation in
Crohn's disease and the cytokine transforming growth factor (TGF)-β1, acting through the
Smad pathway, is critical to this process. The HMG-Co reductase inhibitor simvastatin has
recently been shown to exhibit antifibrotic properties in models of renal fibrosis via Rho
kinase inhibition. Here in we assess the ability of simvastatin to modulate TGF-β1 mediated
intestinal fibroblast activation. Methods: following the acquisition of institutional ethical
approval human intestinal fibroblasts (hFBs) were cultured using a primary explant technique
from serosal biopsies in patients undergoing colonic resection (n=8). hFBs were treated with
TGF-β1 (1ng/ml; 24 hr) with or without simvastatin pre-treatment (1-10μM) or Y-27632
(10μM), a specific Rho kinase inhibitor. Whole cell connective tissue growth factor (CTGF)
was evaluated using western blot. Smad activation/phosphorylation was assessed using
Western blot. A fibroblast populated collagen lattice model (FPCL) was used to asses the
functional activity of hFBs in response to stimulation. Immunofluoresence microscopy was
used to assess filamentous (F)-actin accumulation. *P<0.05 was significant using students
t-test. Results: TGF-β1 treatment of intestinal fibroblasts induced Smad-2 and 3 phosphoryl-
ation, CTGF production, F-actin accumulation and FPCL contraction. Pre-treatment with
simvastatin resulted in a dose dependant inhibition in the induction of CTGF. This inhibition
was reversed with GGPP (a cholesterol pathway intermediate). TGF-β1 mediated CTGF
induction was also inhibited by Y-27632. Simvastatin pretreatment inhibited the TGF-β1
mediated phosphorylation of Smad-3 but not Smad-2. SMV pretreatment prevented TGF-
β1 mediated F-actin accumulation and FPCL contraction (*P<0.01). Conclusions: Simvastatin
abrogates TGF-β1 mediated activation of intestinal fibroblasts. This occurs through inhibiting
the Smad-3 dependant induction of CTGF and the F-actin mediated contraction of collagen.
These findings represent a novel therapeutic entry point for the management of fibrostenotic
Crohn's disease.
T1828
Role of NfκB Activation in Altered Small Bowel Epithelial Permeability
Following Ischemia/Reperfusion Injury
Zheng J. Zhang, Xiaojuan Chen, Yu Lu, Kang Chen, Jianhua Xu, Daniel R. Clayburgh,
Jerrold R. Turner, Dixon Kaufman, Terry Barrett, Jonathan P. Fryer
Ischemia/reperfusion (I/R) injury to small bowel (SB) tissue may play an important role in
alteration of post transplant SB mucosal barrier function and ultimately SB allograft rejection.
To determine the role of NFκB activation in I/R mediated increase of intestinal permeability,
we generated a novel transgenic mouse model with an inducible impairment in NFκB
activation through the tet-on transgenic system directing the expression of both a mutant
IαBκ (mIαBκ, a NFκB super-repressor) and a firefly luciferase reporter under control of the
human CMV immediate early gene promoter. Using In Vivo biophotonic imaging systems
(VivoVision) from Xenogen that captures bioluminescent light emitted from luciferase reac-
tion within living mice, we were able to non-invasively illuminate and monitor gene expres-
sion in real time. Based on changes in the bioluminescent signal level represented by photon
counts, we showed that treatment with Doxycycline (Dox) induced over 100 fold increased
expression of the transgene in the mice compared to the mice without Dox. We also observed
more than 100 fold increase of luciferase activity in SB following Dox treatment. To examine
if blocking NFκB activation protects SB barrier function in a SB I/R model, the mIαBκ
transgenic and wildtype mice fed with Dox (2mg/ml in drinking water) for 2 weeks were
subjected a I/R procedure in which the superior mesentery artery was clamped for 45min,
then unclamped. A segment (6 to 8cm) of jejunum was isolated and injected with two
different size molecular probes including Alexa Fluor dye labeled Dextran (3000MW) and
Dextran (10000MW). SB permeability to these molecular probes was determined by analyzing
probe concentration in serum samples and SB luminal eludes 3 hours later using a Spectro-
fluorimeter. We show that compared with normal SB without I/R, there were more than 10
fold and 26 fold increases of dextran 3000 and dextran 10000, respectively, in wildtype
mice, while blood concentrations for both probes were reduced by 50% in the transgenic
mice. These data indicate that activation of NFκB plays a critical role in altering SB mucosal
barrier function in this I/R model. In conclusion, these studies suggest that NFkB is potential
target for therapeutic intervention in SB barrier dysfunction including that resulting from
I/R injury.
T1829
Fibronectin Is Upregulated During Colitis and Promotes Cell Attachment and
Wound Healing Through NF-kB Activation in Intestinal Epithelial Cells
Rahul Bajaj, Vasantha L. Kolachala, Lixin Wang, Jeffery D. Ritzenthaler, Vinu Chandran,
Brittani K. Ruble, Didier Merlin, Jesse Roman, Shanthi V. Sitaraman
Introduction: Fibronectin (FN) is an extracellular matrix protein that plays important role
in cell adhesion, migration and wound healing. FN expression or its role in colitis is not
known. The goal of this study is to characterize FN expression during colitis and define its
role in intestinal inflammation. Methods: FVB/NJ mice and transgenic mice expressing
Luciferase(LU)-FN promoter were given water or 3% dextan sodium sulfate (DSS) for 5
days. Luciferase activity was measuring using a standard assay. Colitis was determined by
clinical and histological scores. Electrical Cell Impedance Sensing was used for cell attachment
and wound healing studies on Caco-2bbe cells plated with varying concentrations of FN(0-
20µg/ml) and in the presence of GRGDSPK(RGD). Results: FN expression was upregulated
during DSS-colitis in mice, both during the acute phase and the healing phase (DSS acute
phase: 73±12.36 LU/µg (p<0.029), healing phase 183.97±50.48 LU/µg (p<0.001)) compared
to controls (44.04±14.75 LU/µg)determined by LU activity. Immunohistochemistry demon-
strated that epithelial cells were a predominant source of FN. FN increased the expression
of FN receptor, α5β1 integrin in dose and time dependent manner. FN also induced NF-
kB activation with concomittent increase in p-IkB. The maximal effect was seen at 30 minutes
and 1 µg/ml FN. FN potentiated Caco-2bbe cell attachment and wound healing, which was
inhibited by RGD peptide. Conclusions: FN is transcriptionally upregulated during DSS
induced colitis and activates NF-kB signaling pathway. FN enhances cell attachment and
wound healing, which may be NF-kB dependent. Thus, FN plays an important role in the
pathogenesis of colitis through its effect on NF-kB signaling and cell-matrix interaction.
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T1830
Pathogenic Importance of Cysteinyl Leukotriens (Cyslts) in NSAID-Induced
Small Intestinal Ulceration: Protection By Pranlukast, a Cyslt Receptor 1
Antagonist
Hikaru Nishio, Yujiro Hayashi, Shun Terashima, Kohei Kamei, Koji Takeuchi
Background/Aims: Nonsteroidal antiinflammatory drugs (NSAIDs), such as indomethacin,
after short-term and long-term administration, cause intestinal ulceration in human and
laboratory animals. Several factors are involved in the pathogenic mechanism of indometh-
acin-induced intestinal lesions, such as enterobacterial, neutrophils and nitric oxide, in
addition to prostaglandin (PG) deficiency. On the other hand, cysteinyl leukotriens (CysLTs),
including LTC4, LTD4 and LTE4, have been implicated as important modulator in the
pathophysiology of several inflammatory disorders, most notably, asthma, rheumatoid arth-
ritis and inflammatory bowel disease. However, the participation of CysLTs in the occurrence
of NSAID-induced small intestinal lesion remains unclear. In the present study, we examined
the effect of pranlukast, a CysLTs receptor antagonist, on indomethacin-induced small
intestinal lesions in rats. Methods: Male SD rats without fasting were used. The animals
were given indomethacin (10 mg/kg) SC and killed various hours (3, 6, 12 and 24 h) after
the administration. Pranlukast (1~10 mg/kg) was given PO twice 30 min before and 6 h
after indomethacin. Levels of PGE2 and CysLTs in the small intestinal mucosa were measured
3 h after the administration of indomethacin, while enterobacterial count was determined
24 h after the treatment. Results: Indomethacin, given SC as a single injection, produced
multiple hemorrhagic lesions in the small intestine within 6 h, progressively increased and
reached a peak at 24 h later. These lesions were observed mainly in the jejunum and ileum
and accompanied by an increase in myeloperoxidase activity, microvascular permeability
and enterobacterial count in the mucosa. Indomethacin treatment significantly decreased
the mucosal PGE2 content in the small intestine, yet increased the mucosal content of
CysLTs when determined 3 h after the administration. Pretreatment of the animals with
pranlukast, a CysLTs receptor antagonist, dose-dependently reduced the severity of these
lesions and improved the pathophysiological alterations observed after indomethacin treat-
ment. However, this agent did not significantly affect the decrease in mucus secretion as
well as the increase of intestinal motility caused by indomethacin, the events being responsible
for bacterial invasion. Conclusions: These results showed that pranlukast prevents indometh-
acin-induced small intestinal lesions, probably through its inhibitory action, primarily on
bacterial invasion and secondly on neutrophil migration as well as vascular permeability, and
suggested the importance of CysLTs in the pathogenesis of NSAID- induced intestinal damage.
T1831
Inflammatory Response in the Small Intestine Induced By Hind Limb
Ischemia/Reperfusion (I/R): Role of iNOS-Derived Nitric Oxide
Kazuhiro Katada, Aurelia Bihari, Bigwei Sun, Kenneth A. Harris, Richard F. Potter,
Norimasa Yoshida, Toshikazu Yoshikawa, Gediminas Cepinskas
Systemic inflammatory response syndrome (SIRS), as a consequence of ischemia/reperfusion
(I/R) negatively influences the function of the affected organs. While SIRS-mediated dysfunc-
tion of the organs, such as heart and lung, were investigated more in depth, there is little
known with respect to the SIRS in the gut. In this study we assessed the potential mechanisms
(role of NO) of remote intestinal inflammatory response elicited by hind limb I/R. To this
end C57BL/6 (WT) and iNOS-deficient mice were subjected to 1h of bilateral hind limb
ischemia followed by 6h of reperfusion. Some WT mice were injected (s.c.) with iNOS
inhibitor, 1400W (5 mg/kg) immediately before induction of ischemia. Changes in gut
function were assessed 6 h after reperfusion. The obtained results indicate that hind limb
I/R results in dysfunction of the gut as assessed by the increase in total protein levels
(Bradford assay), TNF-α protein (ELISA) and NO (Griess reaction) in the lumen of small
intestine. In addition, hind limb I/R resulted in an increase in leukocyte rolling and adhesion
(intravital microscopy), PMN accumulation (index of inflammation; MPO assay), observation
of edema and PMN infiltration (histology), TNF-α protein (ELISA), and iNOS protein
expression (Western blot) in mucosa of the small intestine. Important to note, that the most
profound changes with respect to the gut dysfunction were found in jejunum and ileum,
whereas duodenum was affected the least. Interfering with iNOS activity (1400W and iNOS-
deficient mice) significantly attenuated hind limb I/R-induced leukocyte recruitment to the
gut mucosa and dysfunction of the small intestine. Taken together these data indicate that
hind limb I/R induces remote inflammatory response in the small intestine in iNOS-derived
NO-dependent manner. It appears that the magnitude of hind limb I/R-induced remote
injury to the gut varies between the individual segments of the small intestine.
T1832
Importance of Bile Acids in COX-2 and iNOS Expressions As Well As Lesion
Formation in Rat Small Intestines Following Administration of Indomethacin:
Relation to Farnesoid X Receptors
Yuka Takahira, Nahoko Izumi, Akiko Tanaka, Koji Takeuchi
Background/Aims: Nonsteroidal antiinflammatory drugs (NSAIDs), such as indomethacin,
cause intestinal damage as an adverse reaction in experimental animals and humans. We
have previously reported the up-regulation of cyclooxygenase (COX)-2 expression as well
as inducible nitric oxide synthase (iNOS) in this tissue following indomethacin and suggested
that these events are key to NSAID-induced intestinal lesions. Recent study showed that the
farnesoid X receptor (FXR), a nuclear receptor activated by bile acids, regulates many gene
expressions, including iNOS, in the small intestine. However, the relation of bile acids and
FXR to the above events remains unexplored. In this study, we investigated the roles of bile
acids and FXR in the intestinal ulcerogenic response to indomethacin and their relation to
the up-regulation of COX-2 and iNOS expressions. Methods: Male SD rats were given
indomethacin (10 mg/kg) SC and killed various intervals after the administration. Bile duct
ligation or cholestyramine treatment (bile acid sequestrant, 300~1000 mg/kg, PO) was
performed 30 min before or 3 h after indomethacin. Gugglesterone (FXR antagonist: 100
mg/kg) was given PO twice daily for 2 days before and once 6 h after indomethacin.
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Enterobacterial count was determined 6 h after the administration of indomethacin. The
expression of COX-1, COX-2 and iNOS mRNAs was examined by RT-PCR. Results: Indo-
methacin caused multiple hemorrhagic lesions in the small intestine, accompanied with the
enterobacterial invasion and the up-regulation of both COX-2 and iNOS expressions in the
mucosa. Cholestyramine, given 30 min before, dose-dependently prevented the development
of these lesions, whereas this agent, given 3 h after indomethacin, did not affect the ulcerogenic
response. Similar results were obtained by bile duct ligation. In addition, cholestyramine
given 30 min before prevented bacterial invasion in the mucosa and inhibited the up-
regulation of COX-2 and iNOS expression after the administration of indomethacin. Pretreat-
ment of the animals with the FXR antagonist gugglesterone significantly reduced the severity
of indomethacin-induced intestinal lesions. Conclusions: These results suggest that 1) the
presence of bile acids in the small intestine is essential for the occurrence of NSAID-induced
intestinal lesions, and 2) bile acids facilitate bacterial inversion in the mucosa and contribute
to the up-regulation of both COX-2 and iNOS mRNAs expression, confirming the expression
of these inducible enzymes as key events to NSAID-induced intestinal lesions, and 3) the
blockade of FXR prevents NSAID-induced intestinal damage, probably through suppression
of iNOS expression.
T1833
Osteopontin As Two-Sided Mediator of Inflammatory Processes
Katja Heilmann, Ute Hoffmann, Christoph Loddenkemper, Claudia Hayford, Verena
Moos, Martin Zeitz, Ursula Günthert, Bianca Wittig
Osteopontin (OPN), also known as Eta-1 (early T lymphocyte activation-1), is a key cytokine
promoting the release of interleukin (IL)-12 and hence inducing the development of a Th1
immune response, and it has been proposed as new interleukin family member. OPN is
secreted by macrophages and activated T cells and can bind to integrin receptors and the
CD44 isoforms v6 and v7. The role of OPN in inflammatory diseases has however been
controversially discussed. Recent studies showed an impact of OPN in inflammatory bowel
disease. In the serum of patients with active Crohns disease (CD) the OPN level correlated
with disease activity but this was not evident in patients with ulcerative colitis (UC) or
healthy controls. We investigated the role of OPN in experimental colitis, induced by dextran
sulfate sodium (DSS), in OPN-/- mice and WT mice. In acute DSS colitis OPN deficiency
caused a significant higher inflammation than in WT mice, which was distributed over the
whole colon. Whereas in chronic DSS colitis, OPN deficiency induced a protection from
mucosal inflammation. Therefore, we suggest a concentration dependent impact of OPN on
inflammatory processes. We found a decreased macrophage activation and phagocytosis in
OPN-/- mice which results in an impaired wound healing. Hence, wound healing (acute
colitis) required OPN, while the Th1 dominated inflammation (chronic colitis) was exacer-
bated by OPN. The concentration dependent impact of OPN could be demonstrated in
further experiments. The supplemental application of recombinant OPN significantly
enhanced disease activity in WT mice while blocking inflammation in OPN-/- mice and
exogenous OPN increased phagocytosis of human macrophages In Vitro and this process
was completely inhibited by anti-CD44v7-antibodies. Therefore, we suggest a dual function
of OPN: (i) it is essential for the persistence of chronic inflammation in CD and experimental
DSS colitis, and (ii) is required for phagocytosis and acute tissue repair.
T1834
Urocortin1 Is a Key Mediator of Microvascular Permeability During
Inflammation
Jen Chang, Gregory Victorino, Alexander Ereso, Brian Curran, Julia J. Hoy, Alden H.
Harken, Aditi Bhargava
Introduction: Urocortins (Ucns) regulate vascular tone and mediate intestinal inflammation.
Our hypothesis is that Ucn1 promotes microvascular permeability and exacerbates this effect
during systemic inflammation. The purposes of this study are: 1) to determine the effect of
Ucn1 on microvascular permeability, and 2) to determine the effect of Ucn1 on microvascular
permeability during inflammation. Methods: First, basal microvascular permeability (Lp) of
rat mesenteric post-capillary venules was measured using an In Vivo micro-cannulation
technique for 50 minutes (control 1). Second, the effect of Ucn1 on microvascular permeabil-
ity (Lp-Ucn1) was obtained by continuous perfusion of 10-7M Ucn1; Lp-Ucn1 was recorded
at 10 min intervals for 50 min. Third, a bolus of lipopolysaccharide (LPS, 10mg/kg) into
the rat femoral vein was used to induce inflammation. The effect of LPS on Lp was measured
for 50 min (control 2). Fourth, to examine if Ucn1 exacerbated the effects of LPS-induced
changes in Lp, LPS and 10-7M Ucn1 were continuously infused in post capillary venules
and changes in Lp were measured as above. Finally, to examine the specific role of Ucn1
in LPS-induced inflammation, Ucn1 expression was knocked down using RNAi interference
(RNAi) in rat mesenteric arcade. Scrambled dsRNA sequences were used in control rats.
Three day after injection of control and Ucn1 dsRNA, effects of LPS-induced changes in Lp
were measured in both control dsRNA (dsControl) and Ucn1 dsRNA (dsUcn1) treated
groups as above. Results: Ucn1 administration increased Lp 2-fold over baseline with a peak
effect at 30 min (Lp baseline = 0.96 ± 0.03, Lp Ucn1 = 2.02 ± 0.20) (p = 0.005). LPS-
induced inflammation also increased Lp 2-fold over baseline (Lp baseline = 0.92 ± 0.04,
Lp-LPS= 1.93 ± 0.14) (p = 0.005). Surprisingly, Ucn1 perfusion increased LPS-induced Lp
3-fold (Lp = 6.42 ± 0.23) within 2 minutes of administration and exhibited a maximum
effect of a 5-fold increase in Lp at 20 minutes (Lp = 9.87 ± 0.14) (p = 0.001). In the RNAi
studies, LPS induced a 2-fold increase in Lp over baseline in dsControl rats over 50 min,
whereas in dsUcn1 rats, LPS initially increased Lp by 1.5-fold at 10 min. However, this
effect of LPS was not sustained in rats lacking Ucn1 due to RNAi and after an initial transient
increase, the Lp fell to baseline levels. Conclusion: Ucn1 increases microvascular fluid leak.
Ucn1 acts synergistically with LPS to increase microvascular fluid losses during inflammation.
Knockdown of Ucn1 by RNAi is sufficient in preventing LPS-induced increases in microvascu-
lar fluid leak. Thus, Ucn1 acts as a key inflammatory mediator in endotoxic shock in the gut.
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T1835
Role of the Mast Cell Tryptase/Protease-Activated Receptor 2 Pathway in
Indomethacin-Induced Rat Enteritis
Tetsuya Okayama, Norimasa Yoshida, Toshimitsu Okuda, Osamu Handa, Tomohisa
Takagi, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Takeshi Okanoue, Toshikazu
Yoshikawa
<Background and Aims> Intestinal bacterial flora and mast cells have played important roles
in the pathogenesis of indomethacin-induced intestinal injury. Recently, mast cell tryptase
and luminal trypsin have been shown to activate protease-activated receptor 2 (PAR2), a
receptor highly expressed in human intestine, which in turn to induce the secretion of
nuclear factor-kappaB-mediated inflammatory cytokines from endothelial cells and various
epithelial cells. Therefore, the objectives of the present study were to estimate the role of
mast cell tryptase/PAR2 in indomethacin-induced intestinal injury and to determine the
effect of the anti-tryptase treatment. <Methods> Male mast cell deficient Ws/Ws rats and
W+/W+ control rats weighting 160-200 grams were given indomethacin (15mg/kg) subcuta-
neously and the intestinal mucosal damage was estimated after 24 hours. The area (mm2)
of macroscopic visible lesions, thiobarbituric acid-reactive substances (TBARS) as an index
of lipid peroxidation, myeloperoxidase (MPO) activity as an index of neutrophil, and mani-
festation as entelitis were evaluated. Mast cell tryptase and PAR2 mRNA were assessed by
the immunohistochemical staining using monoclonal antibody to mast cell tryptase and real-
time RT-PCR, respectively. Low dose of nafamostat mesilate (NM), a serine protease inhibitor
which inhibit tryptase and trypsin activity, was orally administered just before indomethacin
treatment. <Results> Mast cell tryptase was strongly stained in the intestinal mucosa of the
indomethacin-treated W+/W+ control rats compared to Ws/Ws rats. PAR2 mRNA was
constitutively expressed in the intestinal mucosa of rats. In W+/W+ rats, subcutaneous
administration of indomethacin resulted in severe intestinal mucosal injury with the increase
in TBARS and MPO activities, and microscopic findings which revealed the multiple
hemorrhagic erosions, edema and remarkable infiltration of inflammatory cells. However,
the same treatment had little effect in Ws/Ws rats and in rats treated with NM. <Conclusions>
These results indicate that mast cell tryptase/PAR2 pathway may contribute to indomethacin-
induced small intestinal lesions in rats, suggesting that anti-protease therapy using NM has
excellent potential to became a new therapeutic strategy for NSAIDs-induced enteritis.
T1836
Radiation-Induced Apoptosis Is Increased in Myd88-/- Mice and the Increase
Is Reversed By Pge2
Terrence Riehl, Matthew A. Ciorba, Thaddeus S. Stappenbeck, William Stenson
Previous studies demonstrated that DSS colitis is more severe in Myd88-/- mice suggesting
that commensal flora protect the colon from injury through TLR signaling. Moreover PGE2
was demonstrated to be a key downstream mediator of TLR signaling and administration
of PGE2 reversed the effects of the Myd88-/-. Objectives: We have hypothesized that these
protective effects of the commensal flora and the critical role of PGE2 as a downstream
signal extend to other kinds of gastrointestinal injury. To test this hypothesis we investigated
radiation injury in the small intestine in wild type and Myd88-/- mice. Methods: Mice
received 12Gy gamma irradiation and were sacrificed six hours later. Radiation-induced
apoptosis was assessed by counting the number of apoptotic cells in the small intestinal
crypts on a positional basis with position 1 at the base of the crypt. The apoptotic index is
the percentage of cells at each position that are apoptotic. We also performed immunohisto-
chemistry for COX-2 Results: Radiation-induced apoptosis was greater, at a statistically
significant level, in Myd88-/- mice at each cell position 6-20 but not at cell position 4, the
putative stem cell position. For example, at position 6 the apoptotic index for Myd88-/-
mice was 42 +/- 2 and for wild type mice it was 31 +/-2 (p<.01). Administration of dimethyl
PGE2 (0.5mg/kg), a stable analog of PGE2, one hour prior to irradiation reduced the
apoptotic index in both Myd88-/- and wild type mice to similar levels. There was no
difference between Myd88-/- and wild type mice in baseline epithelial proliferation as assessed
by BRDU incorporation or in crypt survival 3.5 days after irradiation, reflecting similar levels
of radiation induced apoptosis at the putative stem cell position. In the unirradiated animals
there were COX-2 expressing stromal cells in the lamina propria in the villi. After irradiation
there were COX-2 expressing cells adjacent to the epithelium in the lower crypt. Conclusions:
Myd88-dependent signaling decreases radiation-induced apoptosis in the small intestine in
a positional manner with increased apoptosis in positions 6-20. The increase in radiation-
apoptosis in Myd88-/- mice was reversed by administration of dimethyl PGE2 suggesting
that PGE2 is a downstream signaling molecule for Myd88. These results suggest that the
commensal flora protects the small intestine from radiation-induced apoptosis through a
mechanism mediated by TLR signaling and PGE2.
T1837
Breastfeeding for More Than 12 Hours Protects Mice Against Bowel Injury in
a Neonatal Mouse Model of Necrotizing Enterocolitis
Runlan Tian, Shirley x. Liu, Shannon Golden, Isabelle G. De plaen
Necrotizing Enterocolitis (NEC) is a common disease in premature newborns associated
with great morbidity and mortality. Multiple risk factors (bacteria, formula feeding, hypoxia,
cold stress and prematurity) have been incriminated in its pathogenesis. We recently
developed a neonatal mouse model induced by hypoxia, cold stress and formula feedings
that closely mimics the human disease. In this study, we hypothesized that breastfeeding
prior to the stress exposure would protect the neonatal mice against intestinal injury. Mice
were delivered by C/section at E19 or allowed to deliver naturally and left with the mother
for different length of time (<12 hours - between 12-24 hours). Pups were then exposed
to hypoxia-cold stress-formula feeding, following a previously described protocol of neonatal
NEC model. Mortality was recorded, and histological intestinal injury assessed in a blinded
fashion. We found that naturally delivered pups breastfed for 12 hours or more had a
decreased incidence of NEC of grade 2 or above (10/26) compared to those breastfed for
less than 12 hours (21/31) (χ2=4.88, p<0.05) and to those born by C/section and never
breastfed (26/31) (χ2=12.5, p<0.001). However, we found no statistical significance between
the incidence of NEC in the pups born naturally and breastfed for <12 hours and those
born by C/section and never breastfed. Median survival were 32.2 hours (95% CI= 29-38)
for pups delivered by C/section, 32.7 hours (95% CI= 29-39) for pups allowed to breastfeed
for less than 12 hours and 42 hours (95% CI= 37-54) for these allowed to breastfeed for
more than 12 hours. In conclusion, our data shows that a breastfeeding period of more
than 12 hours protects mice against intestinal injury in a neonatal mouse model of NEC.
It is possible that exposure to breastmilk during a critical period in the course of early
intestinal colonization might be essential to protect premature infants against necrotizing
enterocolitis (supported by IDPA and NIH-5KO8HD044558 grants).
T1838
The Role of Nuclear Factor-Kappa B in Edema-Induced Intestinal Dysfunction
Zachary E. Wright, Karen S. Uray, Ravi S. Radhakrishnan, Glen A. Laine, Charles S. Cox
Intestinal interstitial edema often develops during abdominal surgery and following fluid
resuscitation in trauma patients. In damage control surgical procedures, edema develops
due to elevation of abdominal venous pressures via abdominal packing and decreased plasma
oncotic pressure through crystalloid infusion. Edema has been shown to cause intestinal
dysfunction including slower transit and decreased intestinal contractile activity; however,
the mechanism by which edema induces dysfunction is unclear. In preliminary experiments,
increased NFkB activity was observed in the edematous intestine compared to non-edematous
tissue. Thus, we hypothesized that NFkB plays a role in mediating edema-induced intestinal
dysfunction. Male Sprague Dawley rats were randomly assigned to either a sham surgery
CONTROL or RESUS+VH group. Edema was induced in RESUS+VH group by a combination
of fluid administration and partial superior mesenteric venous constriction. Rats in both
groups were treated with a saline vehicle or PDTC (Sigma-Aldrich, 100 mg/kg, IP) 30
minutes before surgery. Rats were sacrificed 6 hours after surgery and samples were collected
from the distal third of the small intestine for transcription factor analysis and contractile
activity studies. A significantly greater NF-kB activation was observed in the RESUS+VH
group compared to the control (5.51±1.75 vs. 11.67±2.34 ng/mg nuclear protein, p<0.05).
PDTC treatment significantly reduced NF-kB activity and attenuated edema-induced
decreases in intestinal contractile activity compared to RESUS+VH treated with saline
(107.28±19.28 vs. 55.39±8.68 g/cm2/s, p<0.05). RESUS+VH rats treated with PDTC also
exhibited significantly lower STAT-3 activation compared to RESUS+VH rats treated with
vehicle (3.58±0.43 vs. 4.62±0.39 activity/mg protein, p<0.05). In conclusion, NF-kB plays
an important role in edema-induced intestinal dysfunction which can be attenuated by PDTC.
Furthermore, NFkB may interact with STAT-3 to decrease intestinal contractile activity.
T1839
Neo-Angiogenesis and the Effect of Doxycycline in Acute and Chronic
Radiation Proctitis of Rat
Jin soo Kim, Hiun suk Chae, Hyung keun Kim, Young-seok Cho, Sok won Han, Kyu
yong Choi, Hong seok Jang, Soo mi Jung, Eun sun Jung
Objectives : Various cytokines are involved in acute and chronic radiation enteritis. The
targets of ionizing radiation are blood vessel of involved organ. So it seems to be several
angiogenic factors related to radiation injury due to localized perfusion defects. But there
have been few reports on angiogenic factors contributing to radiation injury in the bowel.
. In this study we characterized that angiogenic factors are expressed in acute and chronic
radiation proctitis, and that doxycycline as a ionophore-metalloproteinase inhibiting agent,
would inhibit radiation injury and inflammation. Methods : Wistar rats (male) are divided
into 3 groups (group 1 control n=2, group 2 radiation n=5, group 3 radiation + doxycycline
n=5) in acute and chronic proctitis. 25 Gy is irradiated to distal rectum at once. In group
3, doxycycline 40mg/kg p.o. is given from 3rd day before radiation to 37th day after
radiation. Acute radiation injury was assessed at 14 day after radiation and chronic injury
was evaluated at 40 day after radiation. Expression of angiogenic factors such as VEGF,
MMP2 and MMP9 were evaluated by the use of immunohistochemistry. Angiogenic factors
are VEGF Ab (1:500, polyclonal Ab), MMP9 Ab (1:100, polyclonal Ab) and MMP2 (1:50 ,
polyclonal Ab Santa cruz biotechnology). Results: Acute and chronic inflammation in group
2 and group3 were more severe than those of normal control. But there was no difference
in inflammation between group 2 and 3 in acute and chronic colitis. The expression of all
angiogenic factors(VEGF, MMP2,9) is higher than that of normal control. VEGF expression
is also no difference between group2 and group3. MMP2 expression decreased more in
group 3 than in group 2. But, For MMP9 expression, no significant difference was observed
between group 2 and group 3 in acute and chronic colitis. Conclusion: In acute and chronic
proctitis, the expression of angiogenic factors (VEGF and MMP2, 9) increased with no
reduction of inflammation. Doxycycline administration has no effect on radiation injury but
reduced expression of MMP2 in acute and chronic radiation injury.
T1840
Low Doses of Acrylamide Stimulate a Stress-Response in Oesophageal Cells
Tasha A. Gandamihardja, Nicholas J. Beaumont, Marc C. Winslet
Background: Acrylamide is generated during the cooking of starchy foods such as chips.
Consequently, many people are chronically exposed to low levels of this neurotoxin with
unknown consequences. This study was designed to determine whether acrylamide, at levels
comparable to the contemporary diet, could alter the expression of a known stress-response
gene, β-defensin 2. The gastro-intestinal tract encounters high concentrations of dietary
acrylamide; therefore an oesophageal cell-line was studied. Methods: OE21 cells were exposed
to acrylamide at varying concentrations (up to 1000 µM) and durations (0-1200 minutes).
Total RNA was prepared (Qiagen) and subjected to RT-PCR (Ready-2-Go, GE Healthcare).
β-defensin 2 expression was normalized for GAPDH expression and compared using Quant-
ity-One software. Results: β-defensin 2 gene was constitutively expressed by OE21 cells.
Expression was increased over basal level when the cells were exposed to higher doses of
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acrylamide (~100 µM), which is a level found in some chips. 90 minutes exposure to 4
mM acrylamide induced an increase in β-defensin 2 expression that lasted for eight hours,
which returned to basal levels after 20 hours. Conclusions: β-defensin 2 is upregulated by
cellular stress, e.g. H. pylori infection. We found low concentrations of acrylamide also
caused upregulation of this gene. This shows that acrylamide at concentrations equivalent
to high dietary levels can cause a stress-response in epithelial cells. Further studies are
needed to determine which other genes and proteins are affected by acrylamide, whether
this stress occurs In Vivo and whether long-term exposure could stress the lining of the
gastrointestinal tract.
T1841
Inflammation Alters Enteric Cholinergic System in Mice Ileum
Vidhu Goyal, David I. Yule, Sadasivan Vidyasagar
Intestinal infection and inflammation profoundly effect fluid and electrolyte balance in the
gut, leading to either secretory or malaborptive diarrhea. Prior studies had shown that there
is a reduced Isc response to cholinomimetics in various animal models of colitis. FAE and
M cells that line the Peyer's patch (PP) are known to regulate the immune response in the
gut by transferring the antigenic substances from the gut lumen to the underlying lymphoid
tissue. Studies were therefore undertaken to specifically examine the cholinergic regulations
of transport in epithelium devoid of PP in normal mice and mice treated with anti CD3.
These results were then compared to that from FAE and M cells on PP. Simultaneous pH
stat experiments were done to determine the contribution of HCO3- secretion to the net
change in short circuit current (Isc).In anti-CD3mAb injected mice there was a substantial
decrease in carbachol (acetylcholine agonist) stimulated Isc and HCO3- secretion. Forskolin
(to raise intracellular cAMP) resulted in significant increase in Isc and HCO3- secretion in
anti CD3mAb treated mice. PP covering epithelia showed no increase in Isc to carbachol
(CCH) and Forskolin (FSK). These studies therefore show that there is marked decrease in
cholinergic responses during inflammation and a complete absence of cholinergic and cAMP-
mediated response in tissues regulating immune responses in gut. A better understanding
of the cholinergic regulation in FAE and M cells may help further understand the antigen
handling by these and the onset of inflammation.
T1842
Peptide in Clinical Trials for Inflammatory Bowel Disease (Pl14736, Pliva),
Gastric Pentadecapeptide Bpc 157 Is Effective in the Healing of the
Colocutaneous Fistulas in Rats
Ivan Zoricic, Robert Klicek, Marko Sever, Bozo Radic, Luka Brcic, Mario Udovicic, Sven
Seiwerth, Predrag Sikiric
Aim. Gastric pentadecapeptide BPC 157 (BPC 157) , safe in clinical trials for inflammatory
bowel disease (IBD) (PL14736, Pliva, Croatia)(Gastroenterology,2005), could be also useful
in IBD complications, i.e., the intestinal anastomosis (Surg Today, 2006 (in press)). Thereby,
this study investigates the therapeutic effect of the BPC 157 on colocutaneous fistula in rats.
Methods. (i) In anaesthetized rats, we create the colocutaneous fistula at 5cm from anus,
colon defect 5 mm, skin defect 5 mm. Medication was once daily, first application 30 min
following surgery, last 24 h before sacrifice (at the post-operative day 1,3,5,7,14,21,28)
sulphasalazine (50 mg/kg i.p.), 6-alpha-methylprednisolone ( 1 mg/kg i.p.), stable gastric
pentadecapeptide BPC 157 10 µg/kg, 10 ng/kg i.p.), or in drinking water till the sacrifice (J
Pharmacol Sci 2006, 102,269-277). Defect were assessed macroscopically, biomechanically,
functionally, and microscopically. Results. (i) Controls heal poorly, and this was not improved
by either sulphasalazine or 6-alpha-methylprednisolone, while pentadecapeptide BPC 157
consistently accelerates healing. (ii) In pentadecapeptide BPC 157 rats (both parenteral and
peroral regimens) closure of both skin and colon defect is accelerated by the day 3, water
volume that could be sustained without fistula leaking considerably increased by the day
5, decreased number of rats that defecate through fistula by the day 5. These were along
with lack of large necrotic area of superficial epithelium and broad band of necrotic subcutane-
ous tissue and muscle otherwise noted in controls. Later, BPC 157 (poor granulation tissue
formation, prominent regeneration of subcutaneous muscle fibers) prevails fistulous channel
walled with granulation tissue in controls. Conclusion. Useful in IBD therapy, BPC 157
could be also effective in the healing of the colocutaneous fistulas.
T1843
Will a Murine Model of Enteric Disease Evoked By Metabolic Stress Provide
Insight to the Pathogenesis of IBD Or IBS?
David Prescott, Derek M. Mckay
Background: An infectious etiology (either commensal or pathogenic bacteria) has been
proposed for both the initiation of, and relapses in inflammatory bowel disease (IBD) and
irritable bowel syndrome (IBS). We have shown that human colon-derived epithelial cells
cultured In Vitro displayed a significant loss of barrier function when exposed to a chemical
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metabolic stressor and non-invasive, non-pathogenic E. coli. We hypothesize that a similar
event In Vivo would act as a forerunner to inflammatory or functional disorders, such as
IBD and IBS. Methods: Male Balb/c mice (n=5) were given a 5mM intrarectal dose of 2,4-
dinitrophenol (DNP; uncouples oxidative phosphorylation) in 100 ul 5% DMSO/PBS, and
24h later segments of colon were excised and examined for evidence of inflammation, changes
in cytokine mRNA, altered nitric oxide synthase (NOS) expression, and internalization of
viable bacteria. Additionally, the spleen and mesenteric lymph nodes (MLN) were collected
and examined for presence of viable colonic bacteria. Results: DNP did not evoke any
obvious behavioral changes in the mice. On autopsy the intestine of treated mice appeared
distended and hyperemic, but this was not accompanied by evidence of macroscopic or
microscopic inflammation. However, DNP evoked a significant increase in the transit of
viable bacteria to the spleen and MLNs compared to time-matched controls, and there was
a trend towards increased bacterial translocation into colonic tissue (DNP did not affect the
total number of extracellular bacteria in the gut). Colon from DNP-treated mice revealed
significant reductions in IL-4 and IL-10 mRNA transcripts, normal levels of IFN-gamma,
IL-12, TNF-alpha and iNOS, and increased cNOS expression; The latter being supported
by elevated protein nitrosylation. Conclusions: A single exposure to the metabolic stressor,
DNP, resulted in increased uptake and transit of bacteria to secondary lymphoid tissue and
alterations in cytokine mRNA transcription in the colon that could tilt local immune responses
towards inflammation. We suggest that these changes, when coupled with other environ-
mental triggers and a genetic predisposition would precipitate active IBD or alternatively
functional IBS. Funding: Crohn's & Colitis Foundation of Canada, Canadian Institutes of
Health Research.
T1844
Indomethacin Induced-Apoptosis of Small Intestine; Role of Reactive Oxygen
Species
Tatsushi Omatsu, Yuji Naito, Osamu Handa, Ikuhiro Hirata, Tetsuya Okayama, Satoko
Adachi, Satomi Akagiri, Hitomi Okada, Katsura Mizushima, Takahiro Suzuki, Tomohisa
Takagi, Satoshi Kokura, Hiroshi Ichikawa, Norimasa Yoshida, Toshikazu Yoshikawa
Background: The spread of capsule endoscopy has led to a focus on small intestinal injury
induced by non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (Indo)
and aspirin. Although Indo has adverse effects on small intestinal mucosa, the precise
pathogenesis of this phenomenon is still unclear. Aim: In the present study, we investigated
the mechanism by which Indo induces mucosal injury by using In Vitro model of small
intestine. Materials and Methods: To this end, we used colon cancer cell line, CaCo-2, which
exhibits a small intestinal phenotype starting as a crypt cell and differentiating to a villous
phenotype. Differentiated CaCo-2 monolayer was exposed to Indo and cell death was
evaluated. To quantify the cell death, MTT assay and LDH release in the cell culture
supernatant was measured. At the same time, the cell death was qualified by florescent
microscopy using double staining method with Hoechst 33342 and propidium iodide. For
the further quantification, flowcytemetry was used with fluorescent probes (Annexin V and
propidium iodide). Indo-induced reactive oxygen species production in CaCo-2 was evalu-
ated by fluorogenic probes (dehydrorhodamine123 and Redox Sensor Red CC-1) using
fluorometer. In some experiments, anti-oxidants were used to clarify the role of ROS on
Indo-induced cell death. Results: We found that Indo caused cell death (mainly apoptosis)
of CaCo-2 in a dose- and time- dependent manner. Exposure of CaCo-2 with Indo also
resulted in a significant ROS production that was inhibited by the pretreatment of these cells
with anti-oxidants. Conclusion: Taken together, ROS production is one of the mechanisms by
which Indo induces small intestinal injury.
T1845
Prostaglandin E2 Induces Escape from G2/M Arrest Induced By Irradiation of
Hct-116 Cells Through the PI3K/Akt and Mek/ERK Pathways
Filipe Muhale, Suzanne Schloemann, Terrence Riehl, William Stenson
Introduction: It is well established that that prostaglandins play an important role in the
resistance of tumor cells to cell death induced by irradiation. PGE2 induces early cell cycle
re-entry after irradiation. Although we and others had shown that prostaglandin E2 (PGE2)
protects cells from radiation induced apoptosis via AKT activation and inhibition of Bax
translocation to mitochondria; The mechanisms by which PGE2 induces early cell cycle re-
entry remain undetermined. Objectives: Determine the mechanisms by which prostaglandin
E2 affects cell cycle progression in the irradiated mouse small intestine and in the HCT-
116 cells. Materials: C57B/6 mice (n=4) where intraperitoneally injected or not with dimethyl-
PGE2 (dmPGE2, 0.5 mg/Kg), one hour prior to irradiation (6 Gy). Mice were sacrificed 24
hours later, their intestines removed and processed for paraffin embedding. Similar experi-
ments were done with mice injected intraperitoneally with 1 mg of Ly 249002 (Ly, a PI3K
inhibitor) or 200μg U0126 (U0, a MEK inhibitor). Ki-67 labeling index was determined in
5µm tissue-sections. Similar experiments were done In Vitro using HCT-116 cells, and cell
cycle distribution assessed by FACS analysis of BrdU/propidium iodide positive cells. Results:
When compared to matched controls dmPGE2 increased significantly the labeling index of
Ki-67 after irradiation (p<0.05), 45% vs. 57%, 6Gy vs. 6Gy+dmPGE2. U0126 reduced the
Ki-67 labeling index and partially inhibited the effect of dmPGE2 on increasing Ki-67 labeling
index after irradiation (26% vs. 40%, 6Gy-U0 vs. 6Gy-U0+dmPGE2). Ly 294002 abolished
completely the ability of dmPGE2 to increase Ki-67 labeling index (36% vs. 36%, 6Gy-Ly
vs. 6Gy-Ly+dmPGE2). Studies using HCT-116 cells 24 hours post-irradiation revealed that
dmPGE2 decreases strongly the percent of G2/M cells. Both U0126 and Ly294002 completely
abolished the effects of dmPGE2 on reducing the % of cells on G2/M phase. HCT-116 cells
stably transfected with an active constitutive AKT plasmid recapitulated the effects of dmPGE2
on inducing early escape from G2/M phase arrest after radiation. Conclusion: PGE2 has the
ability to activate both PI3K/AKT and MEK/ERK pathways both In Vivo and In Vitro. Both
cell signaling pathways are needed to induce cell cycle re-entry after irradiation.
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T1846
Combined Transforming Growth Factor-β1 and 3 Fibroblast Stimulation
Modifies the Extracellular Matrix Gene Expression Through Smad
Independant Signaling
Yoke leng Ng, Frances Lloyd, Amber Appelbee, Borut Klopcic, Ian C. Lawrance
BACKGROUND: The inflammatory bowel diseases (IBDs) undergo intensive extracellular
matrix (ECM) remodeling that may result in intestinal fibrosis and its complications. Trans-
forming growth factor-β1 (TGF-β1) is profibrogenic and TGF-β3 when given alone In Vitro
stimulates collagen expression. The combination of TGF-β3 with TGF-β1, however, may
be associated with improved healing without excessive scar formation. AIMS: To examine
the effects of altering the ratio between TGF-β1 and -β3 in combination with PMA on the
expression of key ECM components and the intracellular TGF-β Smad signaling in isolated
adult murine intestinal fibroblast-like cells. METHODS: Isolated cells were exposed to TGF-
β1:3 ratios (20:1, 10:1, 5:1, 1:1, 1:5, 1:10, 1:20) at a total TGF-β concentration of 10ng/
ml combined with PMA (10ng/ml). Immunohistochemocal staining with alpha-smooth
muscle actin (SMA) vinentin and desmin was used to determine phenotypic changes. Real-
time PCR was used to assess of Col 1α1 and 3α1, MMP-3, 13, TIMP-1, TGF- β1: and 3
mRNA expression. Western blots quantified the phoshorylated-Smad2 (pSmad2), pSmad3
and Smad7 levels for each ratio (normalised to β-actin as well as Smad2 and Smad3 as
appropriate). RESULTS: The fibroblast-like cells did not alter their SMA, vimentin or desmin
immunohistochemical staining with the differing TGF-β1, -β3 and PMA stimulations. The
combination of TGF-β1:3 reduced MMP-3 and increased TIMP-1 and TGF-β1 mRNA expres-
sion consistent with TGF-β1 alone stimulation of fibroblasts. TGF-β3 expression did not
change. The combination of TGF-β1:3, however, suppressed Col 1α1 and 3α1, and enhanced
MMP-13 expression, which is in contrast to findings with TGF-β1 alone stimulation. Levels
of pSmad2 and pSmad3 were induced as expected with TGF-β stimulation. There was,
however, no difference between the various TGF-β1:3 ratios despite the observed mRNA
changes. Smad7 was not induced with the TGF-β1:3 stimulation. CONCLUSIONS: These
results suggest that ECM deposition and degradation balance can be altered by modulating
the TGF-β1 to -β3 ratios. Smad7, an inhibitor of Smad2 and Smad3 was not induced as
expected. These changes appear to be independent of the Smad2, 3 signaling pathway
suggesting that Smad independent pathways (MAPK pathways) may be involved when TGF-
β1 and 3 are used in combination, but this interaction requires further elucidation.
T1847
Inhibition of Colonic Pge2 and NO/iNOS Activities By the Antioxidant N-
Acetylcysteine Plus Mesalamine Promote Mucosal Healing in a Rodent Model
of Colitis
Hanumantha R. Ancha, Christine C. Mckimmey, Ravi R. Kurella, Stan A. Lightfoot,
Richard F. Harty
Background & Aims: Previous experiments have shown that rectal administration of the
antioxidant N-acetylcysteine (NAC) plus mesalamine (5-ASA) vs monotherapy caused signi-
ficant acceleration mucosal healing and reduction in tissue inflammation in chemically
induced colitis in rats. Aims: to examine the effects of combination (NAC plus 5-ASA) and
monotherapy (NAC or 5-ASA) on colonic PGE2 and NO/iNOS activities in rats with colitis
induced by trinitrobenzene sulphonic acid (TNBS). Methods: Three days following induction
of TNBS-colitis rats received daily enema of one of the following treatments: saline, NAC
(13 mg/kg), 5-ASA (100 mg/kg) and NAC plus 5-ASA for 8 days. Colonic microscopic injury
scores were determined, immunocytochemical staining for nitrotyrosine and measurement
of colonic levels of PGE2 and iNOS were performed 11 days after induction of colitis.
Results: Aggregate microscopic injury score (0-15) in TNBS treated animals was 14.2±0.4.
NAC plus 5-ASA caused a 94% reduction in injury (0.8 ± 0.4; P <0.0001). NAC and 5-
ASA alone also caused significant decrease in colonic injury (4.3 ± 2.2 and 4.3 ± 1.9,
respectively; P <0.03). The degree of reduction in microscopic injury with NAC plus 5-ASA
was significantly greater than that observed with either NAC or 5-ASA alone (P <0.05).
Colonic PGE2 levels were increased 20 fold in TNBS colitis rats compared to control: 114.6
± 14.9 vs control 5.6 ± 1.0 ng/0.1g. NAC plus 5-ASA treatment reduced PGE2 by 76% to
27.0 ± 0.6 ng/0.1g, P <0.007. This value was significantly less than that recorded for 5-
ASA alone (52.0 ± 6.9 ng/0.1g; P <0.02) but not for NAC alone (33.9 ± 5.9 ng/0.1g; P
>0.1). iNOS levels in TNBS colitis were increased 1.5 fold to 5.9 ± 0.7 vs control 2.3 ± 0.3
μM, P <0.001. Combination therapy with NAC plus 5-ASA reduced iNOS activity to control
levels (1.9 ± 0.3 μM, P <0.001 vs TNBS) and, furthermore, caused significant reduction in
iNOS levels when compared to NAC and 5-ASA alone (3.3 ± 0.3 and 3.6 ± 0.5μM, respectively
P <0.02). Tissue levels of nitrotyrosine immunostaining were markedly attenuated with
NAC plus 5-ASA treatment. Conclusion: NAC plus 5-ASA caused significant reductions in
colonic PGE2 and iNOS levels and nitrotyrosine immunostaining in TNBS colitis. These
changes in inflammatory mediators were associated with significantly greater mucosal healing
and decrease in tissue inflammation than either NAC or 5-ASA alone. NAC plus 5-ASA
exerts its therapeutic effects by reducing prostaglandin generation and inhibiting iNOS
activity and, thereby, inhibiting colonic inflammation and oxidative and nitrosative stress-
related injury.
T1848
A Crucial Anti-Inflammatory & Barrier Protective Mechanism in Gut
Epithelium: Pkc-Zeta (ζ) Isoform Is a Key Player in Protection of Cellular
Structural Components and Is a Novel Modulator of the I-kb Kinase (I-kK) -α
and -β Isotype Pathways
Ali C. Banan, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth, Yueming Tang,
Ashkan Farhadi, Ali Keshavarzian
NFkB activation & gut barrier/structural instability are key events in the pathogenesis of
inflammatory GI disorders. Using monolayers of intestinal cells, we found that NFkB activa-
tion (via degradation of its modulator IkB) leads to cytoskeletal & barrier disruption. EGF
prevents this injury, but the fundamental mechanisms are unclear. Since the atypical ζ
isoform of PKC modulates NFkB, we investigated if PKCζ is essential in EGF protection
against oxidant-induced I-kK isotype activation and consequent NFkB activation, and ensuing
cytoskeletal, tight junctional & barrier disruption. We used multiple GI clones stably trans-
fected to overexpress PKCζ or to inhibit its expression. Clones were preincubated with EGF
or PKC activators/inhibitors ± oxidant (H2O2). Wild type (WT) cells were treated similarly.
We measured monolayer barrier {fluorometry, TER}, cytoskeletal/tight-junctional integrity
{confocal microscopy}, PKCζ subcellular activity {immunoprecipitation, In Vitro kinase}, I-
kK-α/ β/ γ activities (immunecomplex kinase), IkB levels (PAGE), NFkB activity (ELISA,
EMSA); subcellular pools of tight-junctional proteins (occludin, claudins, ZO) & polymer-
ized/monomeric actin (SDS-PAGE), n=6/grp. Results: {1} Relative to WT cells exposed to
oxidant, transfected cells overexpressing PKCζ (2.9 fold) or the WT cells pretreated with EGF
were protected against oxidative injury as indicated by: PKCζ activation, I-kK-α activation, I-
kK-β inactivation, IkB stabilization; NF-kB (p50/65 subunits) inactivation; barrier proteins
(occludin, claudins, ZO) & cytoskeletal (actin) assembly (↑polymerization, ↓disassembly),
barrier proteins architectural integrity; & monolayer barrier normalization. {2} All measures
of protection induced by PKCζ were synergized by added EGF. Expressed PKCζ was found
residing in membrane, cytoskeletal, & barrier protein fractions (<9% in cytosolic fractions),
indicating endogenous activity. In both transfected clones & EGF pretreated WT cells, PKCζ
(72 kDa) was active & found with both I-kK-α (84 kDa) & I-kK-β (87 kDa), forming
novel endogenous PKCζ/ I-kK isotype complexes. {3} Antisense inhibition of native PKCζ
expression & activity attenuated all measures of EGF protection against I-kK-α/ β / NFkB
changes & monolayer instability. Conclusions: We report for the first time that A) Upregul-
ation of PKCζ activity is necessary for monolayer protection under stress of I-κK-β pathway
activation; B) PKCζ is a unique intracellular modulator of both I-kK-α & I-kK-β isotypes
in intestinal cells; C) We have identified a novel biologic mechanism -protection of barrier
through activation of I-kKα & inactivation of I-kKβ / NFkB- among the PKC isoforms.
T1849
Sildenafil, An Inhibitor of Phosphodiesterase Subtype 5, Inhibits NSAID-
Induced Small Intestinal Ulceration in Rats, Via a NO/cGMP-Dependent
Mechanism
Yuji Mashita, Yujiro Hayashi, Shinichi Kato, Koji Takeuchi
Background/Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause
hemorrhagic intestinal damage as a side effect in experimental animals and in humans.
Nitric oxide (NO) is an important mediator of intestinal mucosal defense, including mucus
secretion, and many of the biological actions are intracellularly mediated by cGMP. Sildenafil,
the inhibitor of phosphodiesterase (PDE) subtype 5, is known to increase the cellular levels
of cGMP in the gastrointestinal tract. In the present study, we examined whether sildenafil
increases the mucosal defensive ability to protect the small intestine against indomethacin-
induced ulceration via a NO/cGMP-dependent mechanism. Methods: Male SD rats were
used without fasting. Animals were given indomethacin (10 mg/kg) SC, killed 24 h later,
and the area of lesions, the number of enterobacteria as well as the mucosal myeloperoxidase
(MPO) activity was determined. Sildenafil (3~20 mg/kg) or NOR-3 (a NO donor: 3 mg/kg)
was given PO 30 min before the administration of indomethacin. In some cases, NG-nitro-
L-arginine methyl ester (L-NAME: 20 mg/kg, SC) was given 1 h before sildenafil, with or
without the co-administration of L-arginine (200 mg/kg, IP). The effects of sildenafil on
intestinal mucus secretion and motility were also examined according to the routine methods.
Results: Indomethacin (10 mg/kg, SC) induced multiple hemorrhagic lesions in the small
intestine, with a marked increase in bacterial counts and MPO activity in the mucosa.
Pretreatment of the animals with sildenafil significantly and dose-dependently reduced the
severity of these lesions, with concomitant suppression of the increase of MPO activity as
well as bacterial invasion in response to indomethacin. These effects of sildenafil were
significantly reversed by prior administration of L-NAME, in a L-arginine-inhibitable manner.
In addition, sildenafil significantly increased the secretion of mucus in the small intestine
and also suppressed the enhanced intestinal motility caused by indomethacin. On the other
hand, the NO donor NOR-3 increased mucus secretion, inhibited intestinal hypermotility
and decreased bacterial invasion in the presence of indomethacin, resulting in prevention
of the development of intestinal lesions. Conclusions: These results suggest that sildenafil,
an inhibitor of PDE5, prevents indomethacin-induced intestinal lesions, via a NO/cGMP-
dependent mechanism. This effect of sildenafil is functionally associated with suppression
of bacterial invasion due to both increase of mucus secretion and decrease of intestinal
hypermotility caused by indomethacin.
T1850
Biological Activity of the Human Muc17 Membrane-Bound Mucin Cysteine-
Rich Domain Is Mediated By ERK and PI-3 Kinase Pathways
Laurie L. Shekels, Rachel Moor, Joel Phillips, Christopher M. Baskerville, David B. Evans,
Robert L. Heinrikson, Samuel B. Ho
Membrane-bound mucins are highly expressed on the apical surface of intestinal epithelia,
and are regulated by inflammation and hypoxia. Mouse Muc3 contains two tandem cysteine-
rich domains (CRD1,2) that resemble epidermal growth factor-like motifs. Muc3CRD1,2
stimulates cell migration and inhibits apoptosis In Vitro independent of ErbB receptor
stimulation (Gastroenterology 2006;131:1501-17). The purpose of this study was to deter-
mine the biologic properties of recombinant human MUC17CRD1,2 and the signaling
mechanisms responsible for the effect. Methods: Rrecombinant MUC17 cysteine-rich domain
(CRD1,2) proteins were synthesized in E.coli. Cell migration was measured in Lovo, A431,
IEC6 cells. Apoptosis was induced by treatment with interferon gamma and anti-fas antibody
or 5-fluorouracil (5FU) and assessed by Hoechst nuclear staining. Activation of signaling
pathways was determined by western blotting with phospho-specific antibodies. Results:
Recombinant Human MUC17CRD1,2 forms high MW aggregates (>200kDa) that can be
resolved to a 30 kDa monomer by boiling in SDS and reducing agents, but remains in large
aggregates under non-reducing conditions. MUC17CRD1,2 at 10 ug/ml stimulated cell
migration and inhibited apoptosis induced by both anti-fas and 5FU to a similar degree as
100 ng/ml EGF. Separation of MUC17CRD1,2 monomers by size exclusion chromatography
did not enhance cell migration or anti-apoptotic activities. Incubation of Lovo cells with
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recombinant MUC17CRD1,2 induced phosphorylation of kinases erk1, erk2, akt1, akt2,
and the antiapoptotic protein BAD. In contrast, treatment with mouse Muc3CRD1,2 induced
erk1,2 phosphorylation only. Migration induced by MUC17CRD1,2 was inhibited by the
inhibitor of erk activation, U0126. Alternatively, migration induced by purified recombinant
EGF was not inhibited by U0126. The anti-apoptotic effects of both MUC17CRD1,2 and
EGF are reversed by incubation with U0126 and the PI-3 kinase inhibitor wortmannin.
Conclusion: Extracellular cysteine-rich domains of human MUC17CRD1,2 stimulate cell
migration and inhibit apoptosis, and appear to act via erk1,2 and PI-3 kinase mediated
pathways that are distinct from EGF-induced pathways. These data indicate that recombinant
MUC17CRD1,2 is a potent protein for restitution or re-epithelialization of colonic cells.
T1851
Roles of Endogenous Nitric Oxide (NO) and NO Synthase (NOS) in the
Healing of Indomethacin-Induced Intestinal Lesions in Rats
Ryo Hatazawa, Yoshikazu Kubo, Mayu Tanigami, Koji Takeuchi
Background/Aims: Endogenous NO plays an important role in modulation of the mucosal
defense as well as the healing of lesions in the stomach. We have recently reported that NO
produced by cNOS is important in maintaining the mucosal integrity of the small intestine
against NSAID-induced damage, yet the role in the healing of the intestinal ulcers remains
unknown. In the present study, we examined the roles of NO and NOS isozymes in the
healing of indomethacin-induced small intestinal lesions in rats. Methods: Male SD rats were
given indomethacin (10 mg/kg, SC) and killed 1, 4 and 7 days after the administration.
Indomethacin (2 mg/kg), L-NAME (a nonselective NOS inhibitor: 10 mg/kg) and aminoguan-
ine (a selective iNOS inhibitor: 20 mg/kg) were given SC once daily for 6 days, the first 3
days or the last 3 days during a 7-day experimental period. Expression of iNOS mRNA in
the mucosa was examined by RT-PCR, while the iNOS activity was measured by determining
the conversion of [3H]-L-arginine to citrulline. VEGF protein expression was examined by
western blotting. Vascular content was determined by the Carmine method. Results: The
intestinal lesions caused by indomethacin healed within 7 days. Both indomethacin (2 mg/
kg) and L-NAME significantly impaired the healing of these lesions, irrespective of whether
they were given for 6 days, first 3 days or last 3 days. The healing was also impaired by
aminoguanine given for the first 3 days but not for the last 3 days. The expression of iNOS
mRNA in the intestine was up-regulated after ulceration, persisting for 2 days thereafter.
Likewise, the iNOS activity was elevated with a peak response during 1~2 days after ulcera-
tion, with concomitant increase in NO content in the mucosa, and this response was
prevented by both L-NAME and aminoguanidine. Vascular content in the ulcerated mucosa
as measured by carmine incorporation was decreased when the healing was impaired by
indomethacin and L-NAME given for either the first or last 3 days as well as aminoguanidine
given for the first 3 days. In addition, VEGF protein expression in the intestinal mucosa
also increased during the first 2 days after indomethacin treatment and faded away thereafter.
Conclusions: These results suggest for the first time that endogenous NO is actively involved
in the healing of intestinal lesions induced by indomethacin, in addition to prostaglandins,
but the NOS isozyme mainly responsible for the production of NO differs depending on
the stage of healing; iNOS in the early stage and cNOS in the late stage. NO contributes to
the healing of intestinal ulcers by stimulating the angiogenic response through the up-
regulation of VEGF expression.
T1852
Interleukin-6 and Tumor Necrosis Factor Alpha Inversely Regulate Prohibitin
Expression in Intestinal Epithelial Cells
Arianne L. Theiss, Ngozi Okoro, Tracy S. Obertone, Didier Merlin, Shanthi V. Sitaraman
INTRODUCTION: Prohibitin (PHB) is a highly conserved protein and has pleiotropic func-
tions in the cell. We recently demonstrated that PHB is expressed in the mitochondria in
intestinal epithelia and its expression is decreased in animal models of colitis as well as
human inflammatory bowel disease (IBD). We demonstrated that PHB protects epithelial
cells from oxidative stress and oxidant-induced barrier dysfunction. Loss of barrier function
is thought to be an inciting event that underlies inflammation in IBD. Therefore, PHB may
play an important role in the pathogenesis of intestinal inflammation by acting as a potent
antioxidant. Little is known regarding the regulation of PHB expression in intestine.
METHODS: The 1192 bp human PHB promoter region was cloned and the transcription
start site was identified 1594 bp upstream from the translation start site due to an intervening
intron. The effects of IL-6 and TNFα on PHB promoter activation, protein and mRNA
expression were assessed. The importance of putative response elements in the PHB promoter
for maximal activation and cytokine responsiveness were determined. Since IL-6 proved to
be an important inducer of PHB expression in intestinal epithelial cells, we also assessed
PHB expression in IL-6-/- mice. RESULTS: IL-6 increases PHB protein and mRNA abundance
and PHB promoter activation. Conversely, TNFα decreases PHB promoter activation, mRNA
and protein expression. The IL-6 response element in the PHB promoter is required for
maximal basal promoter activity and responsiveness to IL-6. Furthermore, basal promoter
activity and IL-6 responsiveness are attenuated by SOCS-3. Confirming these In Vitro results,
IL-6-/- mice exhibit reduced PHB expression in the colon compared to WT mice. CONCLU-
SIONS: Together these results suggest that PHB expression is tightly regulated at the transcrip-
tional level by cytokines involved in IBD. While IL-6 is required for maximal basal expression
and induction of PHB, TNFα decreases its expression. These data have implications to
understand the regulation of PHB expression, which is altered during colitis.
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T1853
Attenuation of Ischemic Injury in Equine Jejunum By Administration of
Systemic Lidocaine
Vanessa Cook, Marsha Mcdowell, Jennifer Jones shults, Nigel Campbell, Jennifer Davis,
Anthony T. Blikslager
The incidence of gastrointestinal ischemic injury is increasing as survival from predisposing
diseases improves. Rapid repair of injured intestine is essential to restore the mucosal barrier.
We have chosen to investigate the response of equine jejunum to ischemic injury, as horses
are particularly sensitive to failure of the mucosal barrier. Previous studies in this model
showed that a non-selective cyclooxygenase (COX) inhibitor, flunixin meglumine (FM),
retarded recovery of the mucosal barrier. Lidocaine has novel anti-inflammatory effects and
reduces cardiac and cerebral ischemic injury. We hypothesized that treatment with systemic
lidocaine would hasten recovery of mucosal barrier function in ischemic-injured equine
jejunum. Horses were assigned to one of four groups (n=6/group): 1) 1mL/50Kg 0.9% NaCl
IV (control) 2) FM 1mg/kg IV q12 hours 3) Lidocaine 1.3mg/kg loading dose followed by
0.05mg/kg/min CRI 4) FM & lidocaine at the above doses. Sections of jejunum were subjected
to 2 hours of ischemia by temporary occlusion of the local blood supply, via a midline
celiotomy. Horses were euthanized 18 hours post ischemia and jejunum harvested for In
Vitro work. Mucosa was mounted in Ussing chambers for measurement of transepithelial
resistance (TER), and mucosal-to-serosal 14C-inulin and fluorescent labeled-LPS flux. Mucosal
damage was assessed by histomorphometry. COX-1 and COX-2 expression was examined
by Western blotting. Blood samples obtained at 0 & 8 hours post ischemia were analyzed
for prostanoids. Treatment with FM alone significantly reduced mucosal barrier function in
ischemic-injured sections compared to control, as evidenced by reduced TER and increased
permeability to inulin and LPS. There was no significant difference in TER and permeability
in ischemic-injured sections between lidocaine and control groups, even when treatment
was combined with FM. Treatment with lidocaine alone, or combined with FM, significantly
improved mean mucosal damage grade and reduced villous denudation in ischemic-injured
sections compared to FM alone. COX-2 was up regulated in ischemic-injured tissue regardless
of treatment group. Prostanoid concentrations were significantly increased 8 hours after
ischemia in horses treated with lidocaine alone, and significantly decreased in FM treated
horses, even in combination with lidocaine. Systemic lidocaine improved recovery of isch-
emic-injured equine jejunum compared to FM, and may ameliorate some of the inhibitory
effects of FM when treatment is combined. The mechanism of action of lidocaine in improving
mucosal repair has not yet been elucidated.
T1854
The Hydrogen Peroxide Scavenger, Catalase, Alleviates Ion Transport
Dysfunction in Murine DSS Colitis
Kim E. Barrett, Declan F. Mccole
Background: Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) contribute
to epithelial damage and dysfunction in inflammatory bowel disease (IBD). This study
investigated the role of ROS in ion transport dysfunction and colonic pathology in the
murine DSS colitis model. Methods: Colitis was induced by administering DSS (4%) in
drinking water for 5 days followed by 3 days on normal H2O. Mice were administered
either pegylated-catalase (40 units/g/0.01ml; i.p.) or saline at day -1, 0 and +1 of DSS
treatment. Ion transport responses to the Ca2+ agonist, carbachol (CCh, 300 μM), or the
cAMP agonist, forskolin (20 μM), were measured across distal colonic mucosa mounted in
Ussing chambers. Data are means ± SEM and analyzed by ANOVA. Results: The DSS-
induced loss in body weight (-3.6 ± 0.6 g) was partially alleviated by catalase treatment (
-2.3 ± 0.5 g; p<0.05; n=12). DSS treatment significantly reduced colon length compared
with control mice (9 ± 0.2 cm vs. 6.4 ± 0.2 cm; p<0.001; n=9). Catalase treatment,
significantly reduced DSS-induced colonic shortening (7.2 ± 0.2 cm; p<0.01 vs. DSS; n=
10). However, only a minimal protective effect of catalase on colonic histology versus DSS
was seen on H + E staining of colonic sections. This contrasted markedly with electrophysiol-
ogic data showing that catalase prevented the DSS-induced reduction in baseline ion trans-
port, expressed as short-circuit current (Isc), in distal colonic mucosa (12.6 ± 5.6 μA/cm2
in control, 10.6 ± 2.9 μA/cm2 in DSS + catalase, and -22.8 ± 3.6 μA/cm2 in DSS alone;
p<0.05; n=9). DSS treatment also significantly reduced CCh stimulated Isc from 15.9 ± 3.7
μA/cm2 in control colon, to 1.6 ± 1.6 μA/cm2 (p<0.01; n=9), whereas catalase significantly
protected the CCh response in DSS treated mice (10 ± 2 μA/cm2; p<0.05 vs. DSS alone;
n=10). DSS mice treated with catalase showed an improved Isc response to forskolin com-
pared with those treated with DSS + saline, although this did not reach significance (16.4
± 3.7 vs. 7.9 ± 3.5 vA/cm2; n=9). Immunostaining showed that mice treated with catalase
and DSS had less epithelial activation of extracellular signal-regulated kinase (ERK), a protein
that can negatively regulate ion transport, and showed normalized expression and localization
of the NKCC1 ion transport protein, compared with mice treated with DSS + saline. Conclu-
sion: Acute treatment with the H2O2 scavenger, catalase, partially prevents the loss of ion
transport properties in DSS colitis, and indicates a prominent role for ROS in ion transport
dysfunction in colitis. Therefore, our findings may suggest novel strategies for the treatment
of inflammatory diarrhea.
T1855
Single Oral Adminiatration of Geranylgeranylacetone (Gga) Induces Heat
Shock Protein70 and Prevents Ischemia-Reperfusion Injury in Rat Small
Intestine
Takashi Iwata, Greg Nowak, Shinji Yamamoto, Amit Sharma, Makiko Kumagai-braesch,
Kazuhito Rokutan, Mitsuo Shimada, Bo-goran Ericzon
Background: Heat shock proteins (HSP) are crucial for the maintenance of cellular homeost-
asis during normal cell growth and for survival during and after various cellular stresses.
Geranylgeranylacetone (GGA), a nontoxic anti-ulcer drug, reportedly induces HSP72 in the
gastric mucosa, liver, heart, brain and the small intestine. There are several reports of
expression of HSP with GGA in small intestine, but there are few cytoprotective examinations
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against ischemia reperfusion injury and bacterial translocation. In this study, we examined the
effect of GGA against ischemia-reperfusion injury in rat small intestine by oral administration.
Methods: Forty eight male Wistar rats (220 to 250g) were devided into six groups. Groups
of non pretreated with GGA and pretreated with GGA rats underwent sham operation, 40
minutes of ischemia by occlusion of the superior mesenteric artery just distal to its origin
with an atraumatic vascular clamp, or ischemia followed by 60 minutes of reperfusion. GGA,
an emulsion with 5% gum arabic and 0.008% alpha-tocopherol, was given orally. GGA or
vehicle was administrated one time 4 hours prior to ischemia. Samples of small intestine
were observed for determination of HSP70 production and for histological assessment of
mucosal injury and apoptosis. Serum levels of inflammatory cytokines, tumor necrosis factor-
alpha, interleukin-1beta, and interleukin-6 were compared among the groups. Results: The
expression of HSP72 was more strongly observed in GGA pretreated groups than that in
non pretreated groups. GGA pretreated group showed significant reduction of ischemia
reperfusion-induced mucosal injury, neutrophilic infiltration, and production of inflammat-
ory cytokines. GGA pretreated group showed significant suppression of liver injury which
induced 24 hours after reperfusion. Conclusions: These findings indicate that GGA safely
induced HSP, and protect against ischemia-reperfusion injury involves inhibition of neutro-
phil activation and chemotaxis. Single oral administration of GGA would be a useful cytopro-
tective modality against bacterial translocation which induced by mucosal injury after small
intestinal resection and transplantation.
T1856
Induction of Hsp32 By Curcumin Rescues Human Intestinal Microvascular
Endothelial Cells (HIMEC) from Irradiation Induced Apoptosis
Mary Otterson, David G. Binion, Vicky M. Nelson, Martin Floer, Yasmin Kanaa, Parvaneh
Rafiee
INTRODUCTION: High dosages of abdominal irradiation cause mucosal damage in the
gastrointestinal system. Radiation affects epithelial and endothelial populations in the gut,
with both acute and chronic changes. Although the pathogenesis of radiation induced
endothelial dysfunction is not clear, it is presumed to be an inflammatory process which
involves cytokines, reactive oxygen metabolites and apoptosis. Previous work from our group
has demonstrated that curcumin protects against radiation induced damage and dysfunction
in human intestinal microvascular endothelial cells. Mechanism of curcumin induced radio-
protection is not specifically define. Heat shock protein 32 (Hsp32) known as heme oxygenase
(HO) is an enzyme which possess free radical scavenging properties. Hsp32 induction has
been considered a protective mechanism in cells against oxidative injuries. The aim of this
study was to investigate the treatment effects of curcumin, on HIMECs exposed to 10 Gy
of radiation compared to HIMECs that were irradiated alone and the modulatory effect of
Hsp32 in radiation induced apoptosis. METHODS: HIMEC cultures were exposed to 10 Gy
ionizing radiation, then treated with 10 μm curcumin and incubated for 1-48h. We assessed
the effect of a combination of radiation and curcumin on Hsp32 induction by cell survival,
apoptosis and caspase-3 activity, using RT-PCR, Western blotting and Tunnel assay.
RESULTS: Irradiation (10 Gy) significantly increased caspase-3 activity, decreased cell survival
and enhanced HIMEC apoptosis. Curcumin treatment of HIMEC after radiation significantly
increased Hsp32 expression and protein and decreased caspase-3 activity. Increased NFκB
activity in irradiated cells resulted in enhanced cell death as demonstrated by Tunnel assay.
Blockade of NFκB with curcumin induced HIMEC expression Hsp32 and increased cell
survival. Thus, curcumin induced Hsp32 expression prevented radiation induced apoptosis,
at least in part by inhibition of NFκB activation. CONCULSION: These data demonstrate
that curcumin exerts a treatment effect on irradiated HIMEC by induction of Hsp32 and
NFκB inhibition. Curcumin may have therapeutic potential for the treatment of radiation
induced vascular injury.
T1857
Lyprinol™ Partially Ameliorates 5-Fluorouracil (5-FU)-Induced Mucositis in
the Rat
Diana M. Torres, Ross N. Butler, Gordon S. Howarth
Background: Intestinal mucositis (IM), a common and debilitating side effect of chemother-
apy, is associated with severe inflammation of the small intestine (SI). Marine oils rich in
long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), such as Lyprinol (stabilised
lipid extract of the New Zealand Green Lipped Mussel), have demonstrated therapeutic
potential for the treatment of certain inflammatory conditions. We assessed the effects of
Lyprinol on the severity of IM in Dark Agouti rats (DAR). Methods: Female DAR were
allocated to groups (n=8): saline+vehicle (control), 5-FU+vehicle, 5-FU+high dose Lyprinol
(HDL, 80%), 5-FU+low dose Lyprinol (LDL, 40%), 5-FU+olive oil (OO) and 5-FU+fish oil
(FO). Oil/water was administered daily via oro-gastric gavage from days 0-7. IM was induced
on day 5 by 5-FU injection (150mg/kg; intraperitoneal); controls received saline. DARs were
sacrificed on day 8. 13C-Sucrose breath tests, expressed as %cumulative dose at 90min
(%CD90), were conducted on days 0, 5 and 8. SI tissue was weighed and collected for
histological, proliferation (labeling index (LI) determined by proliferating cell nuclear antigen
immunostaining) and biochemical (sucrase and myeloperoxidase (MPO)) analyses. Histolog-
ical damage scoring data were compared using a Kruskal-Wallis non-parametric analysis of
variance (ANOVA) with a Dunn's post hoc test. Data otherwise presented as mean ± standard
error of the mean (SEM) and compared using a One-Way ANOVA with a Tukey post hoc
test. Results: SI weight was greater in control and Lyprinol-treated rats compared to 5-
FU+vehicle (p<0.05, p<0.001). On day 8, %CD90 was lower in 5-FU-treated groups than
in controls regardless of treatment (p<0.01). Similarly, sucrase levels decreased following 5-
FU treatment (p<0.001). In mid SI, MPO activity was significantly increased by 5-FU+vehicle
treatment compared to controls (383%, p<0.001). Following 5-FU injection, Lyprinol treat-
ment reduced MPO activity in mid SI compared to 5-FU+vehicle (HDL: 51%, p<0.05; LDL:
65% p<0.001). Histological analysis in mid SI showed HDL rats had increased crypt depth
(CD) by 68% compared with 5-FU+vehicle rats (p<0.01) while FO, OO and 5FU+vehicle
treatment revealed CD was significantly lower than controls (p<0.05). Damage severity was
higher in vehicle+5-FU (p<0.001), OO (p<0.001) and FO (p<0.05) rats compared to controls,
though Lyprinol tended to normalize 5-FU-induced damage. LI was 51% greater in mid SI
of HDL (42 ± 1.9 x 10-4) rats compared to 5-FU+vehicle (27 ± 1.8 x 10-4) (p<0.01).
Conclusion: Lyprinol partially ameliorates 5-FU-induced IM by normalising some indicators
of inflammation and enhancing parameters of repair.
T1858
Antigen Specific Colitis Abrogated By Antigen Feeding in a New Mouse Model
Pamela Holzlöhner, Ute Hoffmann, Christoph Loddenkemper, Claudia Hayford, Katja
Heilmann, Bianca Wittig
Introduction: In human inflammatory bowel disease (IBD) regulation of tolerance towards
food and bacterial antigen seems to be defective. To investigate mechanisms of oral tolerance
in IBD we established a new antigen induced colitis model in immunocompetent mice.
Material and Methods: TH1 cells from DO11.10 mice expressing a T cell receptor specific
for the chicken ovalbumin OVA peptide 323-339 were transferred from congenic Balb/c
mice. At day 1 and 4 after cell transfer OVA protein was applied intrarectally. Bovine serum
albumin served as control. At day 5 mice were sacrificed. The colon was scored histologically.
Lamina propria mononuclear cells (LPMC) and mesenteric lymph nodes (mLN) were isolated
and further analysed by FACS and ELISA. Results: Local application of OVA intralluminally
induced severe colitis (Histological score 3,2 ± 0,63 versus 0,75 ± 0,70 in BSA) which was
antigen specific, as demonstrated by significant increase of OVA TCR+ cells in the lamina
propria (LP) but not in the mesenteric lymph nodes and enhanced IFNγ production in the
mucosa. Daily low dose feeding of OVA both prevented and abrogated antigen-specific
colitis. This was accompanied by a significantly decreased amount of OVA-TCR+ cells in
the LP, decreased levels of INFγ and a normal gut histology. Interestingly, in the inflamed
mucosa FoxP3+ T regulatory cells were reduced, whereas antigen feeding restored the amount
of T regulatory cells in the mucosa to a normal level. Conclusion: We showed here a new
approach of antigen specific colitis in immunocompetent mice and demonstrate restoration
of established colitis by antigen feeding. This colitis model is a suitable approach to examine
the regulation of an antigen-specific immune response in the gut.
T1859
The Absence of Nf-κB P50 Subunit Protects Against Acute Bowel Injury
Isabelle G. De plaen, Shirley x. Liu, Runlan Tian, Wei Hsueh, Heather Baskind
Platelet activating factor (PAF), a potent pro-inflammatory phospholipid, mediates the bowel
injury induced by lipopolysaccharide (LPS) injection and by intestinal ischemia-reperfusion,
and might play a role in the pathogenesis of necrotizing enterocolitis. When PAF is injected
i.v., it produces systemic hypotension, increased vascular permeability, hemoconcentration
and a dose-dependent isolated bowel necrosis predominantly in the small intestine. We
previously found that PAF, i.v., induces nuclear factor-κB (NF-κB) p50-p50 activation in
the intestine. However, the role of its activation remains unclear. In this study, we examine
whether mice lacking the p50 subunit of NF-κB are protected against PAF-induced bowel
injury and systemic inflammation. Male homozygous (7-10 weeks old) NF-κB p50 knock-
out mice (B6;129P2-Nfkb1tm1Bal) and control mice (B6;129PF2/J) were obtained from
Jackson laboratory. Animals were anesthetized with Nembutal and tracheotomized. Their
carotid artery was cannulated for blood pressure monitoring, blood sampling and drug
injection. PAF 2.2 μg/kg diluted in albumin 5% (or an equivalent volume of albumin 5%)
was injected i.v. At the end of the experiment (2 hours), 0.2 ml of blood was collected and
animals were euthanized. The small intestine was removed and histological exam performed.
A microscopic injury score was determined by a pathologist blinded to the group (1: necrosis
limited to the tip of the villi, 2: mid-villous necrosis, 3: complete villous necrosis, 4:
transmural necrosis). Compared to wild-type mice, p50 deficient mice had a decreased 2
hour-mortality (2/10 vs 10/15, χ2=5.235 (p< 0.05)) and a decreased incidence of microscopic
intestinal injury (3/10 vs 11/14, χ2=5.66 (p< 0.05). Wild-type mice had a more persistent
hypotension compared to p50 deficient mice (blood pressure at 2hours of 47% of baseline
vs 71%, p<0.05). However, there was no significant protection against hemoconcentration
in p50 deficient mice. In conclusion, our study suggests that the NF-κB p50 subunit is
important in mediating bowel injury and hypotension induced by PAF (supported by IDPA
and NIH-5KO8HD044558 grants).
T1860
Effect of Intestinal Inflammation On Slow Synaptic Transmission in Myenteric
Neurons
Kulmira Nurgali, Trung V. Nguyen, Hayato Matsuyama, Michelle Thacker, Heather L.
Robbins, John B. Furness
Purpose: Intestinal inflammation alters electrophysiological properties of neurons in the
myenteric plexus of the guinea pig ileum. Post-inflammatory changes in these neurons
correlated with their morphological types: 45% of Dogiel type I (DI) neurons behaved like
Dogiel type II (DII) neurons by exhibiting late afterhyperpolarizing potentials (AHPs) due
to activation of intermediate conductance Ca2+-activated K+ channels. Both DII and DI
neurons with AHPs became hyperexcitable following intestinal inflammation. Changes in
slow synaptic transmission are likely to occur, but are currently unreported. Thus, we have
investigated changes in slow synaptic transmission in myenteric neurons during inflammation
and studied the underlying mechanisms. Methods: Intracellular recordings were made 7
days after induction of inflammation by injecting TNBS (30mg/kg in 30% ethanol) into the
guinea pig ileum. Neurons labelled with biocytin were identified morphologically. Inflamma-
tion was quantified histologically and immunochemically.Results: Stimulation of intergangli-
onic connectives by bursts of pulses at 20 Hz for 1 s caused long-term excitation that lasted
from 10 min to 3 hours after the slow excitatory postsynaptic potential (EPSP) had subsided
that was never seen in neurons from the control ileum. This event occurred in 5/24 DII and
1/7 DI neurons with late AHPs. Long-term excitation was characterized by little membrane
depolarization (7.1 ± 0.7 mV, n=6), increase in input resistance (Rin) by about 30% and a
large increase in the number of action potentials in response to depolarizing current pulses
(12.7 ± 5.6 APs/pulse above that before stimulation). In 9/32 DII, 6/11 DI neurons with
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late AHPs and 5/12 DI/S cells from the inflamed ileum, 20 Hz stimulation caused typical
slow EPSPs (membrane depolarization of 10-25 mV which subsided after 3 min) and slow
IPSPs in 3/12 DI/S cells. The properties of slow EPSPs compared between these groups and
to controls were not significantly different. The increase in excitability during slow EPSPs
in all groups of neurons never outlasted the membrane depolarization. Low frequency
stimulation of inputs (1 Hz, 4 min) also induced a long-lasting sustained slow synaptic
excitation in both DII and DI neurons with late AHPs. CsCl (5 mM), the PKC inhibitor
calphostin C (1 μM), the PKA inhibitor H-89 (1 μM) and the NK3 antagonist SB223412
(1μM) did not inhibit the hyperexcitability induced by 20 and 1 Hz stimulation in neurons
from inflamed intestine. Conclusion: Hyperexcitability of myenteric neurons and changes
in slow synaptic transmission in inflamed intestine are not due to activation of Ih current,
NK3 receptors, PKC or PKA.
T1861
5-Aminosalicylic Acid Protects Colonocytes from the Toxic Effects of Sulfide
In Vitro
Sundaram Ramasamy, Amrutha Ramu, Sukhdev Singh, Michael Langman, Margaret C.
Eggo
Introduction: Sulfate-reducing bacteria in the human colon produce hydrogen sulfide (H2S.
H2S is highly toxic and selectively inhibits butyrate oxidation in colonocytes resulting in
energy deficiency. Damage to the colonic epithelium may lead to ulcerative colitis (UC).
We have recently shown that thiosulfate sulfurtransferase (TST) can detoxify H2S. Inducing
differentiation in colonocytes (In Vitro) upregulates TST and protects cells from the toxic
effects of sulfide. 5-aminosalicylic acid (5-ASA) is a successful treatment for UC and maintains
patients in remission. Aim: To determine whether 5-ASA is able to preserve colonocytes
from the toxic effects of sulfide In Vitro and determine whether 5-ASA regulates TST
expression. Methods: Cell lines Caco2, HT-29 and HCT-116 were treated with 10 mM 5-
ASA and/or varying doses of NaHS for 24h or 48h. Toxicity was examined by uptake of
propidium iodide. Western blotting was used to examine regulation of TST expression.
Results: 24h treatment in 10 mM 5ASA increased TST expression in HT-29, and CaCo2
cells but not in HCT-116 cells. Sulfide (1 mM) was toxic to all the cells but preincubation
for 24h in 5-ASA prevented sulfide toxicity in CaCo2 and HT-29 cells but not HCT-116
cells. In cells incubated in NaHS for 24 h, there was a dose-dependent increase in PI-bound
DNA that reached >55.0 % at 0.3 mM NaHS. Preincubation in 5-ASA for 24 h before 24
h treatment with NaHS (0.3- 2.0 mM) prevented the NaHS-stimulated rise of cell death.
Conclusions: 5-ASA increases the expression of TST. This increased expression may protect
colonocytes from the toxic effects of H2S. This could be one of mechanisms by which 5-
ASA is beneficial in UC.
T1862
Oxidative Stress Increases IGF-Ir Expression and Pi3-K/Akt Activation in
Intestinal Epithelial Cells
Naira Baregamian, B. mark Evers, Dai H. Chung
Oxidative stress contributes to the pathogenesis of necrotizing enterocolitis (NEC); it activates
multiple signal transduction pathways, including the phosphatidylinositol 3-kinase (PI3-K).
We have previously shown that Hydrogen peroxide (H2O2)-induced PI3-K activation is
significantly enhanced with insulin like growth factor (IGF)-1. However, the mechanisms
involved in H2O2-mediated activation of the PI3-K remain largely unknown. The purpose
of our study was two-fold: (1) to determine whether oxidative stress alters IGF receptor
type I (IGF-IR) expression, and (2) to elucidate the role of the PI3-K/Akt pathway in oxidative
stress-induced IGF-IR activation in intestinal epithelial cells. METHODS. H2O2 (500µM) was
used to induce oxidative stress in rat intestinal epithelial (RIE-1) cells, and phosphorylation of
IGF-IR and Akt, a downstream effector, was determined by Western blot analysis. Immuno-
fluorescent and flow cytometry were used to evaluate IGF-IR cell surface and intracellular
expression after H2O2 treatment. To further elucidate the mechanisms of H2O2-induced
activation of IGF-IR/PI3-K signaling, we used pharmacologic inhibitors of PI3-K [wortman-
nin; (250nM); LY249002 (20µM)], siRNA directed against Akt1 as well as IGF-IR-specific
inhibitors [PPP (2µM); AG1024 (20µM); AG538 (400nM)]. To assess oxidative stress-induced
IGF-IR tyrosine phosphorylation, an IGF-IR tyrosine phosphorylation array targeting SH2
domain-binding proteins was performed. RESULTS. Hydrogen peroxide treatment rapidly
increased phosphorylation of IGF-IR at 1h; this increase peaked at 3h and returned to
baseline by 24h after treatment. A rapid increase in intracellular and surface IGF-IR expression
was noted at 1 and 3h after Hydrogen peroxide . As expected, H2O2 also induced Akt
phosphorylation over a time course (1-24 h). Inhibition of PI3-K/Akt pathway with wortman-
nin, LY249002 or Akt1 siRNA did not affect H2O2-induced phosphorylation of IGF-IR.
Further, inhibition of IGF-IR using PPP, AG1024, AG538 also did not abolish H2O2-induced
phosphorylation of IGF-IR and Akt. IGF-IR tyrosine phosphorylation array demonstrated
H2O2-induced IGF-IR tyrosine phosphorylation and recruitment of important SH2 domain-
containing proteins such as Src, PLCγ and growth factor receptor binding protein 2. CON-
CLUSIONS: Oxidative stress rapidly activates IGF-IR expression in intestinal epithelial cells.
IGF-IR phosphorylation, during oxidative stress, appears to be independent of the PI3-K/
Akt pathway, suggesting involvement of other signaling mechanisms. IGF-IR activation may
play an important role in balancing oxidative stress-induced intestinal epithelial cell injury
that occurs during NEC.
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T1863
Matrix Metalloproteinase-9 (MMP-9) Regulates Muc-2 Expression Through Its
Effect On Goblet Cell Differentiation: Implications of the Role of MMP-9 in
Colitis
Anupama Ravi, Pallavi Garg, Neal R. Patel, Jesse Roman, Andrew Gewirtz, Didier Merlin,
Shanthi V. Sitaraman
Background and Aims: We recently demonstrated that epithelial derived MMP-9, a gelatinase
upregulated during inflammatory bowel disease, is a critical mediator of tissue damage
during colitis. MMP-9 null mice (MMP-9-/-) develop dramatically reduced inflammatory
response to luminally administered colitic agents in the face of intact systemic immune
response and inflammatory cell recruitment, suggesting protected epithelial barrier in these
mice. In this study, we sought to address the role and mechanism by which MMP-9 influences
barrier protective function. Methods: WT and MMP-9-/- mice were used for In Vivo studies
and the goblet cell line, HT29-cl.16E, and enterocyte cell line, Caco2-BBE, were used for
In Vitro studies. Results: Compared to WT mice, MMP-9-/- mice had increased number of
goblet cells and MUC-2 expression. In addition, KLF-4 and Elf-3, transcription factors
involved in the terminal differentiation of goblet cells were upregulated, while notch
intracellular domain (NICD), which represents activated Notch-1, was downregulated in
MMP-9-/- mice, suggesting altered epithelial cell differentiation in these mice. Temporal
expression of MMP-9 inversely correlated with MUC-2 expression during maturation of
goblet cells In Vitro. MMP-9 overexpression inhibited goblet cell differentiation In Vitro.
Conversely, MMP-9 gene silencing in Caco2-BBE cells resulted in a change in their phenotype
towards goblet cells. Finally, MMP-9 overexpression in goblet cells increased Salmonella
typhimurium adherence. Conclusions: MMP-9 regulates goblet cell differentiation in the
colon. The effect of MMP-9 on goblet cells could contribute to alteration in mucosal defense
leading to inflammation. Together, our data uncover a novel function of MMP-9 in intestinal
epithelial cells.
T1864
Role of SCFA in Regulating the Function of the Epithelium Covering the Ileal
Peyer's Patch
Maria Benoy, Vidhu Goyal, David I. Yule, Sadasivan Vidyasagar
Past studies have shown that bacterial colonization of the colon is crucial in the development
of organized mucosal lymphoid tissue (Peyer's patch) and covering epithelia: the Follicle
Associated Epithelia (FAE) and membranous-cells (M-cells). However, it is not known if it
is the presence of bacteria or the fermentation product that ultimately brings about the fine
regulation of the mucosal immunity in ileum. Prior studies in our laboratory using the In
Vivo ileal and colonic dual-loop perfusion model showed that presence of SCFA in colonic
loop altered ileal electrolyte movement. SCFA thus, having an effect at a location distant
from its site of production. Experiments were therefore undertaken to determine 1. Effect
of SCFA in the colonic loop on transcytosis of lectin conjugated microspherules by epithelium
covering Ileal PP since FAE and M cells are known to transcytosis antigens from the lumen
to the organized lymphoid tissue in a regulated manor. 2. To study the effect of SCFA on
FAE and M cells in Ussing chamber experiments. Studies using the In Vivo ileal and colonic
dual-loop perfusion model showed that presence of SCFAs in the colonic loop inhibited
transcytosis of microspherules conjugated with Ulex europeaous-I lectins. Studies using
isolated Peyer's patches mounted on Ussing chambers showed that presence of 25 mM
butyrate on the lumen side but not basolateral side stimulated an electrogenic short circuit
current (Isc) that was absent in epithelium that were not covering the Peyer's patches.
Further Ussing chamber studies showed that SCFA-stimulated increase in Isc was lumen
Na-dependent. Western blot analysis using sodium coupled monocarboxylate transporter
(SMCT) antibodies showed increased abundance of SMCT in Peyer's patch compared to
ileal enterocytes. This experiment clearly shows the adjacent effect of SCFA. Increased
electrogenic current on addition of SCFAs in Ussing chamber studies may indicate an effort
by the FAE and M cells to concentrate SCFAs available for its role in immune regulation.
However, the exact mechanism by which SCFA alter ileal electrolyte movement and inhibit
the trancytosis of conjugated microspheres by FAE and M cells in In Vivo ileal and colonic
dual-lop perfusion model is not known. If the SCFAs regulate the transcytosis in M-cell it
may then be of significant clinical potential in terms of regulating inflammation in ileum.
T1865
Store-Operated Calcium Entry Downregulates Calcium-Dependent Chloride
Secretory Responses in T84 Colonic Epithelial Cells
April K. Hartford, Brian J. Harvey, Kim E. Barrett, Stephen J. Keely
Background: Cl- secretion, the predominant driving force for intestinal fluid secretion, is
promoted by agonists of Gq protein-coupled receptors (GqPCRs). Such agonists induce
biphasic increases in intracellular Ca2+ [Ca2+]i, due to an initial release from intracellular
stores followed by sustained influx from the extracellular milleu. However, despite prolonged
elevations in [Ca2+]i, Cl- secretory responses to GqPCR agonists are transient. Thus, we
have investigated the role of Ca2+ influx in regulating GqPCR-induced epithelial secretory
responses. Methods: All studies were conducted on the human colonic epithelial cell line,
T84. Changes in intracellular [Ca2+]i were measured by fluorescence microscopy. Cl- secretion
was measured as changes in short circuit current (Isc) across voltage-clamped T84 cells in
Ussing chambers. Carbachol (CCh; 100 μM), a prototypical GqPCR agonist, and thapsigargin
(TG, 1 μM), an inhibitor of the sarcoendoplastic Ca2+-ATPase, were used to release internal
calcium stores. Results: Both CCh and TG evoked rapid, biphasic increases in [Ca2+]i, the
secondary phases of which were abolished in the absence of extracellular Ca2+ confirming
the involvement of Ca2+ influx. Influx of Ca2+ in response to both TG and CCh was also
inhibited by pretreatment with a store-operated calcium entry (SOCE) inhibitor, SKF 96365
(SKF;100 μM), by 77.6 ± 13.1%, (n = 3; p < 0.05) and 58.3 ± 10.7% (n = 4; p < 0.05),
respectively. Furthermore, pretreatment of voltage-clamped T84 cells with SKF potentiated
subsequent Isc responses to both CCh and TG by 397.0 ± 93.6% (n = 6; p < 0.05) and
253.2 ± 52.0% (n = 5; p < 0.05), respectively. Interestingly, SKF was effective only when
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present on the apical side of the monolayer. Since, we have previously shown that GqPCR-
induced ERK MAPK activation also limits the extent of secretory responses, we examined
if SOCE is a signaling intermediate in this pathway. Western blotting revealed that CCh-
induced ERK activation was not altered by SKF. However, we found that similar to SKF,
an ERK inhibitor, PD 98059 (20 μM), attenuated CCh-induced Ca2+ influx by 64.7 ± 19.4%
(n = 6; p < 0.05). Conclusions These data demonstrate that ERK-mediated SOCE across
the apical membrane is required for sustained GqPCR-induced elevations in [Ca2+]i, in
colonic epithelia. This influx of Ca2+, as opposed to its release from stores, constitutes an
antisecretory mechanism that limits Ca2+-dependent secretory responses. The mechanism(s)
by which different pools of Ca2+, derived from intracellular stores or from the extracellular
milleu, exert differential effects on GqPCR-induced secretory responses remains to be deter-
mined.
T1866
Sodium Butyrate Increases Peptide Transporter (Hpept1) Expression and
Activity in Colonic Epithelial Cells
Guillaume Dalmasso, Yutao Yan, Laetitia Charrier, Shanthi V. Sitaraman, Didier Merlin
The intestinal epithelial apical membrane transporter, hPepT1, is expressed in the small
intestine and in colonic tissue from inflammatory bowel disease, with little or no expression
seen in the normal colon. The colonic flora is involved in inflammatory bowel disease, but
no previous study has examined whether bacterial products can affect PepT1 expression
and activity. To examine this issue, we stimulated Caco2-BBE cells with sodium butyrate,
a short-chain fatty acid produced in large amounts by bacterial fermentation. Our results
revealed that butyrate dose- and time-dependently increased hPepT1 promoter and transport
activities in Caco2-BBE cells, with maximal activity observed in cells treated with 5 mM
butyrate for 24 hours. Under these conditions, we observed a 22-fold increase in reporter
activity from the hPepT1 promoter; this stimulation could be blocked by actinomycin D,
confirming transcriptional activation. Mutation of CDX2 binding sites in the hPepT1 promoter
region and electrophoretic mobility shift assay demonstrated that binding of the Cdx2
transcription factor was essential for sodium butyrate-induced hPepT1 transcription. Further-
more, we observed increased hPepT1 mRNA expression, protein expression and transport
activity (measured by the uptake of [14C]Gly-Sar) in butyrate-treated cells. Finally 5 mM
sodium butyrate in drinking water induces a significant up-regulation of PepT1 mRNA
expression in mice colon. Collectively, these data suggest that a bacterial product may induce
or regulate PepT1 expression.
T1867
Regulation of Apical Cl-/OH- Exchange Activity By Neuropeptide Y in Human
Intestinal Epithelial Cells
Seema Saksena, Sangeeta Tyagi, Ravinder K. Gill, Amika Singla, Alpana Marwaha, Alka
Dwivedi, Waddah Alrefai, Krishnamurthy Ramaswamy, Pradeep K. Dudeja
Neuropeptide Y (NPY), an important hormone and neurotransmitter produced by the intrinsic
neurons of the intestine, has been shown to exert anti-secretory and pro-absorptive effects
including inhibition of chloride secretion and stimulation of NaCl absorption. Almost no
information is available on the direct effects of NPY on apical Cl-/OH- exchange activity in
the human intestine. Therefore, the current studies were designed to examine the effects of
NPY on Cl-/OH- exchange activity utilizing human intestinal Caco2 cell line as an In Vitro
experimental model. NPY (100 nM) was added to the basolateral side of Caco2 cells grown
on permeable support of Transwell inserts for 60 min and OH- gradient-driven DIDS sensitive
36Cl uptake was assessed. To ascertain the potential role of DRA (mutated in Congenital
Chloride Diarrhea) in the effects of NPY, the apical surface membrane expression of DRA
was determined by biotinylation studies utilizing DRA antibodies raised against C-terminal
of hDRA. Our results showed that basolateral NPY treatment of Caco-2 cells for 60 min
significantly increased Cl-/OH- exchange activity (~50 %, P<0.05). NPY elicited similar effects
in colonic cryptic T84 cells. NPY did not show any effect on Na+/H+ exchange activity in
Caco2 cells. The selective NPY/Y1 receptor agonist [Leu31, Pro34] mimicked the effects of
NPY in stimulating Cl-/OH- exchange activity. Cell surface biotinylation studies showed that
the increased Cl-/OH- exchange activity in response to NPY was associated with an increase
in the apical membrane expression of DRA protein parallel to a decrease in the intracellular
DRA pool. Conclusion: Our results demonstrate the stimulation of Cl-/OH- exchange activity
in Caco-2 cells by NPY via the NPY/Y1 receptor. In parallel, there was also an increase in
the surface plasma membrane expression of DRA. We suggest that the alteration in the
expression levels of DRA on the plasma membrane may be involved in the pro-absorptive
effects of NPY in the human intestine. (Supported by Dept. of Veteran Affairs and NIDDK).
T1868
Constitutive Expression of the Human Nhe2 Is Controlled By a Negative
Regulatory Element Located At the 5'-Untranslated Region
Ian Pears, Ying X. Zhu, Eleanor Murray, Pradeep K. Dudeja, Kris Ramaswamy, Jaleh
Malakooti
NHE2 is a member of the Na+/H+ exchanger (NHE) multigene family of transporters and
has been implicated in a number of physiological functions including regulation of intracellu-
lar pH, maintenance of cell volume and transepithelial Na+ absorption. To understand the
mechanisms involved in the transcriptional regulation of NHE2, we previously cloned the
NHE2 promoter and identified several regulatory factors that control the NHE2 promoter
activity by interacting with cis-elements in the upstream promoter region. In addition, we
showed that the highest promoter activity was contained within a plasmid harboring the
core promoter region, p-85/+249, compared to the largest cloned promoter fragment (3.2
kb) and its 5'-deletion derivatives. In this study, we report identification and characterization
of a repressor element in the NHE2 5'-UTR, which is localized to a region from bp +204
to +249 downstream of the transcription initiation site. Further analysis of this region
revealed the presence of a palindrome, which is composed of two inverted GC-rich motifs
resembling the Sp1 binding sites. The palindrome is capable of forming a potential secondary
structure with dG= -34. Cloning of the DNA region spanning the palindromic sequence
upstream from the NHE2 and SV40 promoters showed no effect on the activity of either
promoter in transiently transfected C2BBe1 cells. However, when cloned downstream from
these promoters, a considerable reduction in strength of both promoters was observed. In
gel mobility shift assays, four nucleoproteins were formed with a probe containing the
repressor element. Supershift analysis identified Sp1 and Sp3 as protein components of
three of these complexes. Finally, site-specific mutagenesis of the Sp1 binding site, which
prevents DNA-protein complex formation (or may act by destabilizing the secondary struc-
ture) attenuated the repressive effect of this element on the NHE2 promoter activity and
truncation of the palindromic region, blocked it completely. In conclusion, our data revealed
that a negative regulatory element exists in the NHE2 5'-UTR, which is involved in repression
of the NHE2 expression at basal conditions, and Sp1/Sp3 transcription factors along with
a potential stem-loop structure may mediate this effect.
T1869
In Human Intestinal Cells, Glutamine (Gln) Transport Induced By short-Term
Epidermal Growth Factor (EGF) Is EGF Receptor (EGFR) Mapk, PI3K and
Rho Dependent
Nelly E. Avissar, Harry C. Sax, Liana Toia
Epidermal growth factor (EGF) is crucial for repair of injured intestine. Glutamine (Gln) is
one of the key nutrients for the intestine. EGF-induced short-term increase in Gln transport
could be due to trafficking of preformed transporters to the cell membrane. We hypothesized
that short-term treatment of human intestinal cell line with EGF will enhance Gln transport
by increasing ASCT2 protein surface expression in a Rho and PI3K dependent signaling
mechanism. Confluent monolayers of C2BBe1 w/wo Rho siRNA transfection were treated w/
wo tyrphostin AG1478 (AG1478), wortmanin or PD98059 prior to 1 h incubation w/wo
EGF. Total and system's specific Gln transport was determined using 3H-labled Gln in the
presence or absence of sodium w/wo 5 mM specific amino acids inhibitors to system A and
B0,+ individually and together. ASCT2 protein was measured in crude extracts (CE) and in
the isolated biotinylated surface proteins fraction by Westerns. EGF nearly doubled Gln
transport activity by increasing systems B0/ASCT2 and B0,+ activities. The increased transport
activity by system B0/ASCT2 was eliminated by AG1478, wortmanin, PD98059 and by Rho
silencing, while the increase in system B0,+ was inhibited only by PD98059 and Rho silencing.
Despite the doubling of ASCT2 amount on the surface, total ASCT2 in crude extracts did
not change with EGF treatment. The increase in ASCT2 surface expression was eliminated
by AG1478, wortmanin, PD98059 and Rho silencing. Thus, differential pathways are involved
in short-term EGF induced increase in B0/ASCT2 Gln transport activity compared to those
involved in B0,+ activity.
T1870
CAMP-Dependent and Cholinergic Regulation of the Intestinal/Pancreatic Na+/
HCO3- Cotransporter Pnbc1 in Renal Hek293 Cells
Oliver Bachmann, Kristin Franke, Manoocher Soleimani, Michael P. Manns, Ursula Seidler
While mediating HCO3- reabsorption in the renal proximal tubule with its kNBC1 subtype,
Na+/HCO3- cotransporter (NBC) imports Na+ and HCO3- into the enterocyte via the intestinal/
pancreatic subtype pNBC1. Furthermore, renal and intestinal NBC differ in their N-termini
and are differentially regulated by cholinergic and cAMP-dependent agonists. Previous studies
have suggested that regulation of pNBC1 by an increase in intracellular cAMP is not only
influenced by its primary structure, but also by the cell type in which it is expressed.
However, data on the cell-type dependency of cholinergic regulation are lacking. After
previously having demonstrated activation of NBC by carbachol in murine colonic crypts,
we now set off to study pNBC1 regulation via this pathway in renal HEK293 cells transiently
expressing a green fluorescent protein (GFP)-tagged pNBC1 construct. Intracellular pH (pHi)
was monitored using the fluorescent dye BCECF, and the Na+- and HCO3--dependent pHi
recovery from an acid load was taken as a measure of NBC activity. While dpH/dt was
similar in non-transfected cells and transfected cells in the absence of CO2/HCO3- (0.45±0.04
vs. 0.43±0.06 pH units/min, n. s.), recovery was accelerated by factor 5 in GFP-positive
cells in its presence (0.23±0.03 vs. 1.18±0.07 pH units/min, p<0.01). Forskolin (10-5 M)
had no effect in non-transfected cells, but inhibited pHi recovery in cells expressing pNBC1
by 62% (p<0.05). When cells were preincubated with carbachol (10-4 M) in the presence
of 700 µM dimethyl-amiloride (to block Na+/H+ exchange), pHi recovery occurred faster in
non-transfected cells (0.084±0.016 vs. 0.28±0.061 pH units/min, p<0.05), pointing to the
possible activation of endogenous NBC which was also detected by PCR. However, no
additional effect was noticed in the presence of GFP-pNBC1 (0.61±0.14 vs. 0.82±0.21,
p<0.05). Taken together, our results show that acid-activated Na+/HCO3- cotransport via
pNBC1 expressed in renal cells is inhibited by an increase in intracellular cAMP and not
affected by cholinergic stimulation, which is in contrast to the findings in native intestinal
tissue. We conclude that not only cAMP-dependent, but also cholinergic regulation of pNBC1
occurs in a cell-type specific manner.
T1871
Sodium and Chloride Absorptive Defects in the Small Intestine in Slc26a6 and
NHE3 Null Mice
Ursula Seidler, Mingmin Chen, Ingrid Rottinghaus, Jutta Hillesheim, Brigitte Riederer,
Martin Wiemann, Gary E. Shull, Alicia A. Mcdonough, Zhaouhui Wang, Sharon Barone,
Manoocher Soleimani
PAT1 (SLC26A6) and NHE3 are located on the apical membrane of small intestinal villi
and mediate chloride/bicarbonate exchange and Na+/H+ exchange, respectively. To ascertain
the role of Slc26a6 and NHE3 in jejunal sodium and chloride absorption and their interplay,
muscle-stripped jejuna from Slc26a6 and NHE3 +/+ and -/- mice were mounted in Ussing
chambers, and electrical parameters, and 36Cl- and 22Na+ fluxes were measured. In parallel
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studies the expression of the apical Na+/H+ exchanger (NHE3) was examined by immunofluo-
rescence labeling and immunoblot analysis in brush border membrane (BBM). In the basal
state, net Cl- and Na+ fluxes were absorptive in both Slc26a6 -/- and +/+ jejuni, but
significantly decreased in -/- animals. Upon forskolin addition, net Na+ absorption decreased,
Isc strongly increased, and net Cl- flux became secretory in both Slc26a6 -/- and +/+
jejuni. When luminal glucose was added to activate Naglucose cotransport, concomitant
Cl- absorption was significantly reduced in Slc26a6-/- jejuni, while Na+ absorption increased
to the same degree in Slc26a6 -/- and +/+ jejuni. Identical experiments in NHE3-deficient
jejuni showed reduced Na+ and Cl- absorption. Results further demonstrated that the lack
of NHE3 rendered Na+ as well as Cl- absorption unresponsive to inhibition by cAMP, but did
not affect glucose-driven Na+ and Cl- absorption. Immunoblotting and immunofluorescence
labeling revealed comparable NHE3 abundance and distribution in apical membranes in
Slc26a6 -/- and +/+ mice. The data strongly suggest that Slc26a6 acts in concert with NHE3
in electroneutral salt absorption in the small intestine. Slc26a6 also serves to absorb Cl-
during glucose-driven salt absorption.
T1872
Corticosteroids Reverse the Inhibition of Na-Glutamine Co-Transport in the
Chronically Inflamed Rabbit Intestine
Subha Arthur, Jamil Talukder, Prosenjit Saha, Ramesh Kekuda, Uma Sundaram
BACKGROUND:It was previously demonstrated that in a rabbit model of chronic small
intestinal inflammation that Na-glutamine co-transport was inhibited in the villus cells
(B0AT1) while it was stimulated in the crypt cells (SN2). Whether and how corticosteroids,
commonly used to treat inflammatory bowel disease, may affect B0AT1 in villus cells and
SN2 in crypt cells was unknown AIM:Determine the effect of corticosteroids on B0AT1 in
villus cells and SN2 in crypt cells during chronic enteritis. METHODS:Villus and crypt cells
were isolated from the rabbit intestine by a Ca++ chelation technique. Brush border membrane
vesicles (BBMV) were prepared from villus and crypt cells by Ca++ precipitation and differen-
tial centrifugation. Uptake studies were done by rapid filtration technique using H3-glutam-
ine. Western blot was performed using protein extract from BBMV. Proteins were separated
on 4-20% gradient SDS-PAGE and detected by ECL™ kit RESULTS Na-dependent glutamine
uptake was inhibited in villus cell BBMV isolated from the chronically inflamed intestine
and this inhibition was reversed by treatment with MP (101±10 pmol/mg protein/30secs in
control; 24±1.5 in inflamed; 105±10 in inflamed MP treated, n=4, p<0.01). Na-dependent
glutamine uptake which was stimulated in crypt cell BBMV during chronic enteritis was
restored to its normal levels by treatment with MP (25±2 pmol/mg protein/30secs in control;
98±10 in inflamed; 12.2 in inflamed MP treated, n=4, p<0.01). MP treatment did not alter
Na-glutamine co-transport in the villus or crypt cells in the normal intestine (data not
shown). Kinetic studies demonstrated that MP reversed the inhibition of Na-glutamine co-
transport in villus cell BBMV by restoring the co-transporter numbers and in the crypt cells
BBMV by restoring the affinity of the co-transporter for glutamine. In rabbits with chronic
enteritis treated with MP, Western blot studies demonstrated that B0AT1 levels were restored
to normal levels in villus cell BBMV while SN2 levels remained unchanged in crypt cell
BBMV CONCLUSION:Two different Na-glutamine co- transporters specifically B0AT1 in
villus and SN2 in crypt are uniquely altered in the chronically inflamed intestine. Inhibition
of B0AT1 in villus cells from the chronically inflamed intestine is restored to near normal
levels by restoring co-transporter numbers by MP treatment. In contrast, stimulation of SN2
in crypt cells in the chronically inflamed intestine is reversed back to near normal levels by
restoration of its affinity for the amino acid by MP treatment. Thus, the alteration of B0AT1
in villus and SN2 in crypt cells during chronic enteritis is reversed by corticosteroid treatment.
T1873
The Oligopeptide Transporter Pept1 Activity Is Dependent of Its Association
to Lipid Rafts
Hang thi thu Nguyen, Laetitia Charrier, Shanthi V. Sitaraman, Didier Merlin
The brush border (BB) of small intestinal enterocytes is a rich source of lipid rafts, which
are membrane microdomains that are enriched in cholesterol and glycosphingolipids, and
contain some digestive enzymes, trafficking molecules and signaling proteins. The intestinal
epithelial apical transporter, PepT1, is expressed in intestinal epithelial cells, where it is
responsible for the uptake of a broad range of small peptides. To examine the mechanism
of PepT1-mediated peptide transport in more detail, we herein investigated the presence of
PepT1 in intestinal lipid rafts. Immunoblotting showed that PepT1 was enriched in low-
density fractions (LDFs; containing the lipid rafts) isolated from mouse intestinal BB and
polarized Caco2-BBE cells by detergent extraction and sucrose gradient fractionation. In
these fractions, PepT1 co-localized with N aminopeptidase, a well-known intestinal raft
resident, as well as the raft marker, ganglioside GM1. Disruption of lipid rafts by cholesterol
depletion with methyl-beta-cyclodextrin shifted PepT1 from the LDFs to the high-density
fractions and dramatically decreased the PepT1-mediated transport activity. Lastly, detergent-
insoluble fractions extracted from non-polarized Caco2-BBE cells were almost completely
devoid of PepT1. These findings collectively suggest that PepT1 is mainly distributed in the
lipid rafts from polarized enterocytes, where its activity may be lipid rafts-dependent.
T1874
Prostaglandins Regulate Cl:HCO3 But Not Butyrate:HCO3 Exchange in the
Chronically Inflamed Rabbit Intestine
Palani Kumar, Steven Coon, Prosenjit Saha, Ramesh Kekuda, Vazhaikkurichi M.
Rajendran, Uma Sundaram
Background: There are two distinct anion exchangers, Cl:HCO3 and butyrate:HCO3, on
the brush border membrane (BBM) of villus cells which are uniquely regulated in the
chronically inflamed rabbit intestine. While both are inhibited during chronic enteritis,
Cl:HCO3 is reduced secondary to a reduction in the affinity of the transporter for Cl, while
butyrate:HCO3 is diminished secondary to a reduction in exchanger numbers. We have
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previously shown that arachidonic acid metabolites (AAM) are responsible for the inhibition
of these exchangers in the chronically inflamed intestine. However, whether the AAM of
cyclooxygenase (COX) pathway regulates one or both of these anion exchangers present is
unknown. Aim: To determine the role of the COX pathway metabolites in the inhibition
of villus cell BBM anion exchangers during chronic enteritis. Methods: A rabbit model of
chronic enteritis induced by Eimeria magna was utilized. Villus cells were isolated from the
intestine by a Ca++ chelation technique. BBM vesicles (BBMV) were prepared from villus
cells by Ca++ precipitation and differential centrifugation. Rabbits were treated with an
inhibitor of COX, piroxicam (10mg/kg) or placebo. Uptake studies were done by rapid
filtration technique. Total RNA was isolated from villus cells using TRIzol reagent. DRA
mRNA was quantified by real time PCR. Results: In villus cell BBMV from the chronically
inflamed intestine, both Cl:HCO3 (1022±50 pmol/mg protein in normal and 315±30, in
inflamed p<0.01, n=5) and butyrate:HCO3 (713±41 in normal and 41±20 in inflamed,
p<0.01, n=3) exchangers were significantly inhibited. Piroxicam had no effect on these
transporters in the normal rabbit intestine (data not shown). Piroxicam reversed the inhbition
of Cl:HCO3 exchange in the chronically inflamed intestine (1022±50 in normal, 1045±50
in normal+piroxicam, 315±30 in inflamed and 1109±60 in inflamed+piroxicam, p<0.01,
n=3). However, piroxicam had no effect on the inhibition of butyrate:HCO3 exchange in
the chronically inflamed intestine. Kinetic studies demonstrated that the mechanism of
reversal of Cl:HCO3 exchange in the chronically inflamed intestine treated with piroxicam
was secondary to a restoration in the affinity of the transporter for Cl without a change in
Vmax. Real time PCR demonstrated that there was no significant change in DRA mRNA in
villus cells in any of the four conditions. Conclusions: These studies indicate that the
inhibition of Cl:HCO3 exchange, but not butyrate:HCO3 exchange, is mediated by the
COX pathway in the chronically inflamed intestine. Thus, these two villus cell BBM anion
exchangers are uniquely regulated during chronic enteritis.
T1875
Lubiprostone Activates Single Chloride Channels in the Apical Membrane of
A6 Epithelial Cells
Douglas C. Eaton, Hui-fang Bao, Lian Liu, Ryuji Ueno
Lubiprostone is known to activate ClC-2 chloride currents. To determine the properties of
lubiprostone-induced current, drug effects on A6 epithelial cells were investigated at the
single channel level with cell-attached patch clamp. At concentrations as low as 10 nM,
lubiprostone activated an anion channel with 3-4 pS conductance(Fig 1). The channel
properties were consistent with ClC-2. The activation EC50 was 81±43 nM. ClC-2 current
was inwardly rectifying, implying multiple anion binding sites in the conductance pore. The
open probability and mean open time of ClC-2 were voltage dependent decreasing in
depolarized patches(Fig 2). The channel favors even levels over odd, showing that the protein
has two conductance pathways (‘double-barreled') that open independently. The channel
was blocked by glibenclamide and diphenylcarboxcyclic acid. CLC-2 in A6 cells was indistin-
guishable from ClC-2 expressed in HEK293 cells. The combination of ClC-2 rectification
(small inward Cl flux) and voltage dependence of channel opening (channel opens during
Cl secretion, but opens infrequently during Cl reabsorption) means that ClC-2 is uniquely
suited to promote anion secretion over reabsorption. Thus, it is well-suited to lubiprostone's
clinical indication of promoting intestinal fluid secretion in patients with chronic idio-
pathic constipation.
Figure 1. Lubiprostone activates ClC-2. cell-attached patch recording before treatment (no
activity; histogram shows only closed level). Recording taken 5 minutes after lubiprostone
to the cell (patch maintained). Lubiprostone induces activity (1 open and 1 closed level in
histogram). Figure 2A. Lubiprostone-induced ClC-2 currents inwardly rectify. I-V from
single channels rectifies to allow inward Cl current (secretory flux). 2B. ClC-2 Po is voltage
dependent. Po decreases with depolarization promoting Cl secretion with no reabsorption.
T1876
Are There Functionally Active Muscarinic Receptors in the Apical Membrane
of Rat Colonocytes?
Julio M. Mayol, Elena Molina-roldan, Fernando Huete-toral, Jesus A. Fernandez-represa
Aim: Muscarinic receptors (mAChRs)are considered to be located in the basolateral but not
the apical membrane of intestinal epithelial cells. We investigated whether active mAChRs
are expressed in the apical membrane of rat colonocytes. Material and Methods: Rat distal
colon segments were mounted in modified Ussing chambers and bathed in buffer solution.
Transmural potential difference was monitored with a dual voltage/current clamp. Short-
circuit current (Isc, in μA×cm-2) was calculated by Ohm's law. Isc was normalized to baseline
currents. Carbachol (100 μM) and atropine (1 μg/ml) were used as a mAChRs agonist and
antagonist, respectively. Paraffin-embedded colon sections were used for immunohistochem-
ical analysis with a polyclonal M3 antibody. Data are presented as mean ± SEM. Student's
t and Mann-Whitney U tests were used for statistical analysis. Results: Luminal carbachol
caused a rise in currents with a peak Isc of 24.4 ± 9.3, compared to -6 ± 1.8 for buffer(n=
5 for each group; p=0.012) at 5 minutes. This effect was abolished by luminal atropine
(peak ΔIsc = 47.9 ± 19.3 for apical carbachol vs 1.7 ± 3.9 for apical carbachol + atropine;
n =4; p=0.04) and was not due to the activation of basolateral mAChRs, because basolateral
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atropine suppressed the effect of basolateral but no luminal carbachol (22.5 ± 6.8 for apical
carbachol + basolateral atropine vs 1.9 ± 10.0 for basolateral carbachol + basolateral atropine;
n = 3 for each group; p<0.0001). Immunohistochemical studies showed a dual pattern in
the expression of luminal M3 receptors. Staining was strongly positive in the lower third
of the crypt and in surface cells, but mild staining was observed in the upper two thirds of
the crypts. Conclusion: Our results suggest the presence of active mAChRs in the apical
membrane of rat colonocytes. Thus, luminal muscarinic agonists may be active regulators
of secretion and absorption in the colon.
T1877
Basal Activity of the Epithelial Brush Border Na/H Exchanger NHE3 Is
Dependent On Its Basal Phosphorylation By Casein Kinase 2 (Ck2)
Rafiq Sharker, Mark Donowitz, Sachin Mohin, Xuhang Li
The activity of NHE3 under basal conditions both in small intestine as part of neutral NaCl
absorption or in cell culture models is set at a partially activated state. This allows upregulation
and inhibition of NHE3, both of which occur as part of normal digestive physiology.
Previous studies with both ser/thr and tyr phosphatase inhibitors demonstrated that basal
phosphorylation affects NHE3 activity. However, the specific kinases that are involved in
NHE3 regulation under basal conditions have not been identified. The purpose of this study
was to test the hypothesis that basal NHE3 activity was dependent on NHE3 associated
protein kinases and to identify kinases involved in basal NHE3 regulation. In these studies,
NHE3 expressed in fibroblasts was immunoprecipitated and, following separation on SDS-
PAGE, was trypsinized in gel and analyzed by LC-MS/MS . A previously unidentified phos-
phorylation site in the cytoplasmic C-terminal domain of NHE3 at Ser719 was identified.
Bioinformatics analysis of this site (Scansite ) identified it as a potential substrate for CK2.
CK2 is a ubiquitously expressed, constitutively active ser/thr kinase. To study the functional
contribution of this phosphorylation, wild type NHE3 and the Ser719Ala mutant were
expressed in NHE null PS120 fibroblasts and NHE3 function examined by fluorometry/
BCECF. NHE3/Ser719Ala had a rate of NHE activity that was reduced by ~70% compared
to wild type). CK2 inhibitors (DMAT and TBB) inhibited wild type NHE3 activity by
~60% but had no effect on NHE3/Ser719Ala. While total NHE3 and NHE3/Ser719Ala were
expressed in similar amounts in PS120 cells, the percent of total NHE3/Ser719Ala compared
to wild type NHE3 on the plasma membrane , determined by cell surface biotinylation, was
reduced by ~50%. To determine whether NHE3 bound CK2, In Vitro overlay assays and
pulldown assays were performed, demonstrating that CK2 bound directly to NHE3 at a site
in the C-terminus between aa 590-667. This site is upstream of the CK2 phosphorylation
site of NHE3. Conclusions: 1) Basal NHE3 activity is partially determined by phosphorylation
of NHE3 under basal condition by CK2. 2) CK2 regulation of NHE3 under basal conditions
is by increasing the plasma membrane expression of NHE3. 3) CK2 binds to the NHE3 C-
terminus between aa 590-667. 4) CK2 phosphorylates the intracytoplasmic C-terminus of
NHE3 at aa 719. 4) The CK2 binding to the C-terminus of NHE3 at one site and phosphoryl-
ation at another site is an example of the scaffold function of the NHE3 C-terminus. 5)
CK2/NHE3 complex formation and regulation by phosphorylation accounts for a majority
of basal NHE3 activity.
T1878
Cloning and Functional Characterization of a Folate Transporter from the
Nematode Caenorhabditis Elegans: High Expression in the Digestive Tract
Krishnaswamy Balamurugan, Mustapha Moussaif, Ji ying Sze, Hamid M. Said
The C. elegans is an excellent animal model with which to study integrative aspects of
physiological processes at the whole animal level In Vivo. We have searched the genome of
the C. elegans and have identified two putative orthologs to the human reduced folate carrier
(hRFC) ceRFC-1 and ceRFC-2 that share a 33 and 31% identity with the hRFC sequence.
Functional characterization of the open reading frame of the putative ceRFC-1 and ceRFC-
2 showed that only the ceRFC-1 to be a folate transporter. Transport of folate by ceRFC-1
expressed in a heterologus expression system showed an acidic pH-dependence, saturability
(apparent Km of 1.23 ± 0.18 microM), similar degree of inhibition by reduced and substituted
folate derivatives, sensitivity to the anti-inflammatory drug sulfasalazine (apparent Ki of 0.13
mM), and inhibition by the anion transport inhibitors 4,4'-diisothio-cyanatostilbene-2,2'-
disulphonic acid (DIDS) and 4-acetamido-4'-isothiocyana tostilbene-2,2'-disulphonic acid
(SITS). The Characteristics are very similar to those found for folate transport in the human
intestine. Knocking down (silencing) or knocking out the ceRFC-1 gene led to a significant
inhibition in folate uptake by intact living C. elegans. We also cloned the 5'-regulatory
region of the ceRFC-1 gene, and confirmed promoter activity of the construct In Vivo in
living C. elegans. Using the transcriptional fusion construct (i.e., ceRFC-1::GFP), the pattern
of expression of the ceRFC-1 in different tissues of living C. elegans was investigated and
found to be highest in organs of the digestive tract. Furthermore, the ceRFC-1::GFP expression
was found to be developmentally regulated In Vivo, and it can also be adaptively regulated
by the substrate level in the culture medium. These studies demonstrate for the first time
the existence of a specialized folate uptake system in C. elegans that has similar characteristics
to that of the folate uptake system of the human intestine. Thus, C. elegans provides a
genetically tractable model that can be used to study integrative aspects of the folate uptake
process in the context of the whole animal level. {Supported by grants form the NIH and
the DVA}
T1879
Electrophysiological Evidence for Two Distinct Cell Types Involved in K+ and
Cl- Secretion in Human Colonic Crypts
John E. Linley, Arun Loganathan, Sashi Kopanati, Geoffrey I. Sandle, Malcolm Hunter
Background: The principal function of the colon is the absorption of NaCl and water,
thereby limiting water loss in the stools. However, the colon is also a secretory organ,
responsible for excreting ~10% of the daily dietary K+ intake. Furthermore, the colon is
capable of Cl- secretion when stimulated appropriately, which may contribute to diarrhea
in patients with cholera or several types of neuroendocrine tumor. Secretion involves ionic
movements across the luminal (apical) membrane, K+ exiting via maxi-K (BKCa) channels
and Cl- through CFTR. Although crypts contains several cell types, enterocytes and goblet
cells predominate, but it is generally assumed that enterocytes are the site of both K+ and
Cl- secretion, the type of ion secreted being stimulus-dependent. Aims: To evaluate the
relative contributions of apical BKCa and CFTR to the membrane conductance of cells within
human colonic crypts. Methods: Human distal colonic biopsies were obtained with consent
from patients undergoing routine colonoscopy for altered bowel habit. Whole-cell currents
were measured from the mid-third of colonic crypts using the perforated patch technique
(addition of amphotericin to the pipette). Results: Two distinct cell populations were
observed based on the biophysical characteristics, pharmacology and agonist responses of
the whole cell currents. 73% of cells (58/79) had basal inwardly-rectifying K+ conductances
(IRK) which were inhibited by clotrimazole (an intermediate conductance K+ channel (IKCa)
blocker) but insensitive to penitrem A (a BKCa blocker). In contrast, 27% (21/79) of cells
had a basal outwardly-rectifying K+ conductance (ORK) which was inhibited by penitrem
A (68 ± 6%, n = 8). Increasing cytosolic cAMP activated CFTR in IRK cells (0.97 ± 0.1nS
to 3.5 ± 0.5nS, n = 11) but had no effect on ORK cells (6.6 ± 1nS to 7.3 ± 1nS, n = 7).
Conclusions: We conclude that K+ and Cl- secretion occur in different cell types within
colonic crypts. Given the proportion of enterocytes and goblet cells within the human colon,
we speculate that Cl- secretion is mediated by enterocytes, whereas K+ secretion occurs in
goblet cells.
T1880
NHE3 Associates with NHERF Proteins Via An Internal Class II Pdz Domain
Binding Motif: Functional Consequences
Boyoung Cha, Yueping Chen, Annu Sharma, Rachyla Murtizana, Rafiq Sharker, Ming Tse,
Mark Donowitz
NHE3 associates with the NHERF family (NF) of multiple PDZ domain containing scaffold
proteins and the NF is required for many aspects of NHE3 regulation. The site at which
NHE3 binds the NF does not appear to be the C-terminal 4 amino acids but rather at an
internal site between aa 585-689. NHERF1 and NHERF2 bind simultaneously to both NHE3
and ezrin linking NHE3 to the cytoskeleton. In addition, this binding has been shown to
be necessary for some aspects of NHE3 complex formation. There are 3 classes of PDZ
binding domain sequences. Further studies were undertaken to identify the sites in the
NHE3 C-terminal at which it binds the NF and to determine the functional consequences
of that binding. Secondary structure predictions indicated a B-finger domain (B sheet-turn-
B sheet), a known PDZ binding domain, in NHE C-terminus (aa 590-610). By a combination
of point mutagenesis and In Vitro binding assays using the C-terminal domain of NHE3 (aa
585-689) and NHERF proteins, NHE3 binding to the NF was shown to involve aa 596 and
598, which is a Class II PDZ binding domain (X-hydrophobic(h)-X-h).The NHE3 mutant,
L596E, M598K failed to bind NHERF1 or NHERF2 In Vitro and failed to coprecipitate In
Vivo. Functional consequence of this mutation with the C-terminus blocked by a VSVG
epitope tag were examined after expression in PS120 fibroblasts expressing NHERF2. Effects
included: 1) Reduced basal activity to ~50% of wild type. This was not associated with a
change in total protein expression or percent on the plasma membrane determined by cell
surface biotinylation. 2) An acidic shift in the set point of the exchanger from 7.3 to 6.8.
3) Abnormal regulation, including reduced cAMP inhibition and abolition of cGMP inhibition.
4) A significant increase in mobility as determined by FRAP. 5) A significant reduction in
half-life of the total protein from ~11 hours to ~5.5 hours. Conclusion: 1) NHE3 binds to
the NHERF family via a type II PDZ binding domain using the C-terminal cytoplasmic
domain, which involves aa 596, 598. 2) NF association is involved with basal function of
NHE3 causing activation and an alkaline shift in the set point. 3) Association with the NF
fixes NHE3 in the plasma membrane via the cytoskeleton. 4) NF association prolongs the
NHE3 half-life. The major role of NHE3 in Na absorption and its regulation depends on
interactions with the NF via an internal PDZ domain binding site.
T1881
Regional Distribution of Slc mRNA Expression Along the Human Intestinal
Tract
Jyrki J. Eloranta, Yvonne Meier, Jutta Darimont, Manfred G. Ismair, Christian Hiller,
Michael Fried, Stephan R. Vavricka, Gerd A. Kullak-ublick
Background & Aims: Intestinal absorption of drugs, nutrients, bile acids, and other com-
pounds is mediated by uptake transporters expressed at the apical enterocyte membrane.
These compounds are returned to the intestinal lumen or released into portal blood by
intestinal efflux transporters expressed at apical or basolateral membranes, respectively. One
important transporter superfamily, multiple members of which are enterally expressed, is
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the solute carriers (SLCs). SLC expression levels may determine the pharmacokinetics of
drugs that are substrates of these transporters. We have determined the distribution of 15
human SLC mRNAs in histologically normal biopsies from 5 regions of the intestine of 10
patients. Methods: The study was approved by the local ethics committee and all patients
gave their informed consent. Biopsies from duodenum, ileum, colon ascendens, colon trans-
versum, and colon descendens were obtained from Caucasian subjects undergoing gastrointe-
stinal endoscopy. All patients exhibited normal histology. The information of each patient
(age, gender, reason for endoscopy, drug intake) was recorded. RNAs were isolated from
biopsies and the SLC expression levels determined by real-time PCR and absolute quantifica-
tion. Results: We observed considerable interindividual variation in intestinal SLC expression.
CNT1, CNT2, ASBT, SERT, PEPT1 and OCTN2 exhibit marked differences in mRNA
expression between different regions of the gut: the first 5 are predominantly expressed in
the small intestine, while OCTN2 exhibits strongest expression in the colon. Two transporters
(OCTN1, OATP2B1) are expressed at similar levels in all gut sections. The ENT2 mRNA is
present at low levels across the colon, but not in the small intestine. None of the SLC
mRNAs exhibited significantly different expression levels between the three colon segments.
Six SLC mRNAs (CNT3, OCT1, OAT2, ENT1, OATP1A2 and OATP4A1) studied were
undetectable in the gut. A patient receiving glucocorticoids exhibited elevated ASBT and
OATP2B1 mRNA levels and a patient on insulin therapy exhibited elevated OCTN1 expres-
sion levels. Thus, analyzing SLC expression levels combined with patient history may confirm
(ASBT) or suggest new (OATP2B1, OCTN2) signaling pathways that control their expression.
Conclusions: Quantitative knowledge of transporter expression levels along the human
gastrointestinal tract may be useful for designing intestinal delivery strategies for orally
administered drugs. Changes in transporter expression that occur in pathologies, such as
inflammatory bowel disease, can now be defined more precisely by comparison with the
expression levels measured in healthy subjects.
T1882
Pkc and Cyclooxygenase Isoform-Specific Signaling Mediates PAR2-Induced
Epithelial Chloride Secretion
Jacques Q. Van der merwe, Wallace K. Macnaughton
Proteinase-activated receptor (PAR)2 is activated endogenously by trypsin-like serine pro-
teinases and experimentally by selective synthetic peptides. PAR2 has been implicated in
intestinal inflammation, but its role in the regulation of intestinal mucosal function remains
unclear. We have previously shown that PAR2-induced chloride secretion involves Src-
dependent EGFr transactivation leading to subsequent ERK1/2 activation in a cell culture
model (SCBNs). We have now further studied the stimulus-secretion coupling mechanisms
of PAR2 activation on epithelial chloride transport in SCBNs, determining a role for specific
PKC isoforms and cyclooxygenase. METHODS: 1.SCBN monolayers were grown on Snapwell
supports and mounted in modified Ussing chambers. Short circuit current (Isc) was mon-
itored as a measure of net electrogenic ion transport elicited by the PAR2-selective activating
peptide, SLIGRL-NH2. The roles of specific PKC isoforms in PAR2-induced chloride secretion
by SLIGRL-NH2 were determined using specific inhibitors (GFX, Go6976, rottlerin, PKCζ
pseudosubstrate inhibitor). Arachidonic acid and cyclooxygenase (COX) involvement in the
response to PAR2 activation was examined and its role in PAR2-induced chloride secretion
determined using specific inhibitors of PLA2 (AACOCF3), COX-1 (SC560) and COX-2
(celecoxib). 3. Western blot analysis was conducted for ERK1/2 in response to PAR2 activation
by SLIGRL-NH2, and the role of PKC determined. Western blots for total amounts of each
protein were conducted as controls. RESULTS: 1. Pretreatment of the cells with GFX, rottlerin
and Go6976, but not the PKCζ pseudosubstrate inhibitor, resulted in a significant reduction
in the chloride secretory response to PAR2 activation by SLIGRL-NH2, thus suggesting a
role for PKCδ, PKCα and/or PKCβ1, but not PKCζ in PAR2-mediated chloride secretion.
Inhibition of PLA2, COX-1 and COX-2 each resulted in a significant reduction of PAR2-
induced chloride secretion. 2. Furthermore, inhibition of PKCδ, but not PKCα or PKCβ1,
prevented ERK1/2 phosphorylation, suggesting that ERK1/2 phosphorylation is dependent
on PKCδ, but that PKCα and PKCβ1 play a role in the chloride secretory response that
does not involve ERK1/2 activation. CONCLUSIONS: The ERK1/2-dependent component
of PAR2-induced epithelial chloride secretion is mediated by PKCδ, whereas the ERK1/2-
independent component is mediated by PKCα and/or PKCβ1. PAR2-activation also stimulates
PLA2 to release arachidonic acid which is metabolized by COX-1 and COX-2 to produce a
secretory prostanoid.
T1883
Organic Cation Transporters (OCT1, OCT2 and OCT3) and Organic Anion
Transporter (OAT3) Mediate the Uptake of Duodenal Ulcerogen Cysteamine in
Intestinal Epithelial Cells (IEC-6)
Tetyana Khomenko, Ganna Tolstanova, Longchuan Chen, Xiaoming Deng, Hamid M.
Said, Sandor Szabo
Cysteamine (C), a reducing aminothiol and a natural product of CoA metabolism, induces
ulcers in the rat proximal duodenum. Recently we showed that the absorption of C is higher
in the duodenum than in the stomach, jejunum or colon, and that [14C]cysteamine ([14C]C)
uptake by isolated enterocytes from duodenum, jejunum, colon and IEC-6 is related to a
carrier-mediated system with high C uptake at alkaline pH. To clarify the mechanisms of
C uptake by IEC-6, we now applied analog inhibition analysis. Methods: [14C]C uptake
was measured using IEC-6 incubated in Krebs-Ringer buffer (pH 7.4) alone or with 1 and
10mM C structural analogs, e.g., 2-(ethylthio)ethylamine, tyramine, taurine, choline, and
substrates (1, 10mM) or inhibitors (0.1, 1.0mM) of OCTs and OAT3. Results: A saturable
component for [14C]C uptake by IEC-6 was characterized with Km of 45±12μM and Vmax
of 164±42 nmol/mg protein/min. [14C]C uptake was found to be Na+-independent and
sensitive to C structure analogs such as 2-(ethylthio)ethylamine which inhibited [14C]C
uptake by 27 and 61% at 1 or 10mM, respectively. Similar inhibition was induced by
tyramine (44 and 68%) but ethanolamine, D-penicillamine, dopamine and serotonin were
able to inhibit [14C]C only by 47% or less, even at concentrations of 10mM. Taurine and
methionine failed to change [14C]C uptake. Surprisingly, L-cysteine accelerated [14C]C
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uptake by 2.0 and 2.2-fold at 1 or 10mM, respectively. The H2 receptor antagonists cimetid-
ine, nizatidine ranitidine, famotidine inhibited [14C]C uptake at 10mM by 78, 62, 61, and
25%, respectively (that is almost opposite to their potency of reducing gastric acid secretion)
and histamine produced only 32% inhibition. The β-adrenoreceptor antagonist propranolol
dramatically inhibited (3.5 and 4.5 fold) [14C]C uptake at 1 and 10mM, respectively. Since
almost all investigated chemicals are weak bases or organic cations at physiologic pH and
are substrates for OCT1, OCT2, OCT3 and OAT3, to further identify the specificity of C
transporters we used OCT inhibitors progesterone (OCT1 and OCT2 inhibitor), β-estradiol
(OCT3 inhibitor), disopyramide (OCT1 inhibitor) and probenecid (inhibitor for OAT3).
Progesterone at 0.1 and 1mM inhibited [14C]C uptake by 26 and 31%, respectively. β-
Estradiol showed similar inhibitory activity as progesterone. Disopyramide reduced [14C]C
uptake by 35 and 46% (0.1 and 1mM) and probenecid was less potent to inhibit [14C]C
uptake. Conclusions: Our result is the first demonstration that cellular uptake of the C by
IEC-6 is Na+-independent, sensitive to C analogs and is transported into duodenal enterocytes
by both organic cation and anion transporters.
T1884
Thyroid Hormone Regulated Expression of Sodium/Hydrogen Exchanger
Isoform-2 (Nhe-2) in Human Colonic Cells
S. hani Najafi-shoushtari, Jaleh Malakooti, Pradeep K. Dudeja, Krishnamurthy
Ramaswamy
In higher eukaryotes, the electroneutral exchange of Na+ and H+ is carried out by a widespread
class of integral membrane proteins (NHEs) that control numerous physiological processes
including intracellular pH, cell volume homeostasis, and Na+ absorption. Among the nine
distinct NHE isoforms identified so far, NHE-1 and NHE-3 were found to be functionally
associated in the pathogenesis of several diseases including essential hypertension, congenital
secretory diarrhea, diabetes, and tissue damage caused by ischemia/reperfusion. Thyroid
hormone (T3) has been shown to increase the NHE activity partly by transcriptional up-
regulation the NHE3 in renal cells. However, the effect of T3 on the NHE2 gene expression
is not known. Therefore, the effects of T3 on the transcriptional regulation of the human
NHE2 gene were examined. Treatment of differentiated human intestinal Caco-2 cells with
T3 resulted in up to 2.5-fold induction of the NHE2 mRNA level in a dose-dependent
manner, whereas treatment of cells at proliferating stage did not alter the NHE-2 mRNA
abundance. To examine the molecular mechanism of T3-regulated NHE2 expression, plasmid
p-1051/+249, containing the human NHE2 promoter, was transiently transfected into differ-
entiated Caco-2 cells and the promoter activity in presence and absence of T3 was evaluated.
In these cells, despite the enhanced expression of the endogenous NHE2 mRNA, T3 (500
nM) treatment resulted in a 50% reduction in luciferase activity, compared to untreated
cells. TRANSFAC motif search have shown the presence of several potential binding sites
for thyroid hormone receptors (TR) within the -1051 to +1 promoter region. To obtain a
possible correlation between these putative TR response elements and the effect of T3 on
the NHE2 promoter activity, reporter gene analyses using a series of 5-deletion constructs
of the NHE2 promoter were conducted. Our data showed nearly identical luciferase activities
in all 5'-truncated constructs in untreated cells, whereas in the presence of T3, the deletion
constructs that have lost sequences between bp -1051 to -415 and -1051 to -85 restored
promoter activity up to 85% of the parental construct. In conclusion, our data show an
opposite effect of T3 on promoter-reporter gene activity compared to the endogenous NHE2
mRNA expression. We speculate that this discrepancy may be the result of the stabilization
of the endogenous NHE2 mRNA by T3 and its repressor effect on the promoter activity.
T1885
Characterization of Taurodeoxycholate (TDC) Cytotoxic Effect On Human
Colon Mucosa By Electrophysiological Studies in Ussing Chambers
Piero Portincasa, Antonio Moschetta, Helen Wang, David q.-h. Wang, Donato F. Altomare,
Giuseppe Palasciano, Lucantonio Debellis
Ionic transports in human colonic mucosa are impaired by exposure to cytotoxic bile salt
TDC which induces prosecretory and detergent actions potentially relevant for bile salt
malabsorption and colon cancer. Whether effects of TDC depend on direct or indirect
interference of the bile salt with transporting systems is poorly known, mainly in animal
models. Aims: to study isolated human colon in Ussing chambers to evaluate TDC-induced
injury and to assess correlation between changes in epithelial function and involvement of
specific ion transporters. Methods: TDC (1, 2, 4, and 8 mM) was added to human colon
mucosa bathed in Krebs solution and lactate dehydrogenase (LDH) activity measured spectro-
photometrically in incubation media, as a sensitive marker of cell damage. Electrophysiolo-
gical parameters of human colon mucosa bathed in Krebs solution were studied with or
without addition of the chloride channel blocker 5-nitro-2-(3-phenylpropylamino) benzoic
acid (NPPB) or the Ca2+-dependent K+ channel blocker clotrimazole. Transepithelial poten-
tial (Vt), resistance (Rt) and short circuit current (Isc) were measured by a computerized
voltage clamp system. Results: Incubation of sigmoid colon specimen (1 cm2) with TDC (1
hour), yielded a significant concentration-dependent increase in LDH release, from
173±(S.E.)23% (n=5; p<0.05 vs. control) in 1 mM TDC, up to 376±75% (n=7; p<0.01) in
8 mM TDC. In 79 sigmoid colon specimens, basal Vt and Rt were -3.8±0.3 mV and 116±7
Ω*cm2, respectively, and Isc was 36.5±2.9 µA/cm2. After exposure to luminal TDC at 8
mM (n=13), Isc was increased by 85±25% (p<0.002) and Rt was decreased by 47±5.2%
(p<0.001) while Vt remained virtually unchanged. With 2 and 4 mM TDC, Isc was signific-
antly increased by 18% (p<0.02; n=15) and 32% (p<0.05; n=12), respectively, while Rt was
reduced by about 20%; 1 mM TDC was uneffective. Preincubation with mucosal NPPB (100
uM) or serosal clotrimazole (100 uM) blocked, and in some cases overwhelmed, the TDC-
induced increase of Isc. Differently, Rt reduction produced by 4 and 8 mM TDC, was
not affected by the inhibitors, inasmuch probably depends on bile salt detergent activity.
Conclusions: Secondary bile salt TDC at supraphysiological concentrations exerts prosecre-
tory and detergent activities on the isolated human colon, as assessed by LDH and functional
assays. The prosecretory effect appears to be mediated by direct or indirect influences on
the apical chloride channel and on the basolateral Ca2+-dependent K+ channel. Our findings
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contribute to define the mechanisms of bile salt detrimental activity and have implications
in colon cancer prevention.
T1886
An Investigation Into the Chronic Antisecretory Effects of Deoxycholic Acid in
Human Colonic Epithelial Cells
Gail Ferguson, Niamh Keating, Christine Marsh, Stephen J. Keely
Background: At pathophysiological (mM) concentrations bile acids acutely stimulate Cl-
and fluid secretion across colonic epithelial cells, leading to the onset of diarrhea. However,
our previous studies show that at physiological (µM) concentrations, the predominant colonic
bile acid, deoxycholic acid (DCA) chronically attenuates epithelial responses to both Ca2+
and cAMP-dependent secretagogues.Aim: To investigate mechanisms underlying the chronic
antisecretory effects of DCA in colonic epithelial cells. Methods: All experiments were
carried out on T84 colonic epithelial cells. Changes in intracellular Ca2+i were measured by
fluorescence microscopy. Ion transport was measured as changes in short circuit current (Isc)
across voltage-clamped monolayers of T84 cells. Selective permeabilization with amphotericin
(100 µM) or nystatin (100 µg/ml) was used to isolate apical or basolateral conductances,
respectively. Results: Basolateral addition of DCA (100 µM) for 24 hrs inhibited subsequent
Cl- secretory responses to the Ca2+- and the cAMP-dependent secretagogues, carbachol (CCh;
100 µM) and forskolin (FSK, 10 µM) to 39.4 ± 7.7% (n= 10; p <0.001) and 73.3 ± 5.9%
(n = 5; p < 0.01) of those in control cells, respectively. DCA did not alter CCh-evoked
changes in intracellular Ca2+, implying it exerts its antisecretory effects distal to second
messenger generation. We therefore studied the effects of DCA on the activity and expression
of key transport proteins of the Cl- secretory pathway. In DCA-pretreated cells, CCh-
stimulated K+ conductances, measured in apically permeabilized monolayers after estab-
lishing an apical to basolateral K+ gradient, were 90.8 ± 7.8% of those in control cells (n =
9; N.S.). Similarly, in DCA-pretreated cells, FSK-stimulated Cl- conductances, measured in
basolaterally permeabilized cells after establishing an apical to basolateral Cl- gradient, were
90.6 ± 10.6% of those in control cells (n = 8; N.S.). rtPCR analysis revealed that DCA did
not alter expression of the CFTR Cl- channel, the Na+/K+/2Cl- co-transporter, or the α
subunit of the Na+/K+ ATPase at the level of mRNA. Conclusion: The present data confirm
that at concentrations normally found in the colon, DCA downregulates epithelial secretory
responsiveness to Ca2+ and cAMP-dependent secretagogues. The precise mechanisms
involved remain to be determined. However, the antisecretory actions of DCA are exerted
downstream of 2nd messenger generation and do not involve alterations in apical Cl- or
basolateral K+ conductances or in the gene expression of several key transport proteins of
the Cl- secretory pathway.
T1887
Lubiprostone Activates Cl- Currents in Caco-2 Cells from the Apical Side
John Cuppoletti, Danuta H. Malinowska, Srinivas Ramisetti, Ryuji Ueno
Introduction: Lubiprostone is a new drug for idiopathic constipation that activates recombin-
ant human ClC-2 mediated electrogenic Cl- transport, but not recombinant human CFTR.
The human intestinal cell line T84 contains ClC-2 and studies using nystatin permeabilization
have shown lubiprostone activated Cl- currents across the apical membrane [Cuppoletti et
al AJP Cell 287:C1173-C1183, 2004]. ClC-2 protein is also present in human colonic Caco-
2 cells at the apical aspect of the tight junctions as determined in antibody studies, and
contributes to apical transport of Cl-(Mohammad-Panah, et al JBC 276: 8306-8313, 2001).
The purpose of this study was to determine whether lubiprostone also acts selectively at
the apical versus basolateral membrane of Caco-2 cells. Methods: Electrogenic Cl- transport
in Caco-2 cell cultures was examined using short circuit current (ΔIsc) after nystatin permeab-
ilization of the apical or basolateral membrane under a 12-fold basolateral to apical Cl-
gradient. Caco-2 cells were obtained from American Type Culture Collection (ATCC). Cell
growth conditions were as specified by ATCC. Cells were grown on Snapwell culture inserts
to confluence and used when transepithelial resistance was 500-700Ω/cm2. Apical and basal
solutions, nystatin permeabilization and ΔIsc measurement were as described in Cuppoletti et
al (see above). Results: Lubiprostone (1 µM) activated ΔIsc across the apical membrane of
Caco-2 cells (basolateral membrane permeabilized) reaching a peak of 12.2 ± 2.1 µA/cm2
(n=12) after 5 min. In contrast, with apical membrane permeabilization, peak basolateral
membrane ΔIsc was 1.2 ± 0.2 µA/cm2 (n=13) at 5 min. ΔIsc activated by lubiprostone at
the apical membrane was significantly greater (P<0.0005) than at the basolateral membrane.
Conclusions: These studies using Caco-2 cells confirm previous findings from T84 cells
that lubiprostone activates Cl- currents across the apical membrane. Supported by Sucampo
AG, NIH DK-43816 and HL-58399.
T1888
Modulation of Apical Cl-/OH- Exchange Activity By LPA in Caco-2 Cells Via
Lpa2 Receptor and PI-3 Kinase/Akt Dependent Pathways
Alka Dwivedi, Ravinder K. Gill, Nitika Pant, Seema Saksena, Amika Singla, Nitin Goel,
Waddah Alrefai, Krishnamurthy Ramaswamy, Pradeep K. Dudeja
Lysophosphatidic acid (LPA), a potent bioactive phosholipid, is a natural component of
food products like soy. LPA is released in high concentrations at the site of injury in the
GI tract and influences distinct cellular functions such as intestinal wound healing and
restitution. Previous studies have shown LPA to increase Na+/H+ exchanger 3 (NHE3) activity
in OK cells. However, the effects of LPA on electrolyte transport in human intestine are not
known. Electroneutral NaCl absorption in the human ileum and colon involves coupled
operation of NHEs and Cl-/OH- (HCO3-) exchange activities. Given an important role of
LPA as a signaling molecule that exerts growth-factor like effects, the present studies examined
its effects on apical Cl-/OH- exchange activity utilizing human intestinal Caco-2 cells as an
In Vitro model. Our results showed that LPA treatment (100 μM, 30 min) of Caco-2 cells
stimulated Cl-/OH- exchange activity (~60-70%; P<0.001). Specific agonist for LPA2/EDG4
receptor (350-1000 nM) mimicked the effects of LPA; however LPA1 and LPA3 receptor
agonists were ineffective. PI3 kinase inhibition (Ly294002, 25 μM and Wortmanin 100μM)
blocked the effects of LPA on Cl-/OH- exchange activity. LPA induced stimulation in Cl-/
OH- exchange activity was also abrogated by AKT inhibitor V (Triciribine, 1μM). Both LPA
and LPA2 receptor agonists induced AKT phosphorylation at 5-15 min, an effect blocked
by pretreatment with PI-3 kinase inhibitors, indicating that AKT acts as a downstream
effector of PI-3 kinase. Cell surface biotinylation studies were performed to evaluate the
effect of LPA on expression of the apical Cl-/OH- exchangers, DRA (SLC26A3) and PAT1
(SLC26A6). Consistent with functional activity, LPA treatment resulted in increased expres-
sion of DRA on the apical membrane (35% increase vs control; P<0.05). PAT-1 expression
remained unaltered. Conclusion: Our results suggested that LPA stimulated apical Cl-/OH-
exchange activity partly via increasing surface DRA expression through LPA2/EDG4 receptor
mediated process and sequential activation of PI3 kinase and AKT pathways. These studies
are important for increasing our understanding of the regulation of NaCl absorption in the
human intestine. (Supported by Dept of Veteran Affairs and NIDDK).
T1889
Bone Marrow Transplantation Improve Gut Dysmotility in W/WV Mouse
Model
Shuji Ishii, Shingo Tsuji, Masahiko Tsujii, Toshiyuki Yoshio, Shinichiro Shinzaki, Satoshi
Egawa, Takanobu Irie, Tsutomu Nishida, Yoshimi Kakiuchi, Masakazu Yasumaru, Hideki
Iijima, Sunao Kawano, Norio Hayash
(Background and Aims) Interstitial cells of cajal (ICCs) are in the musculature of the gut
and play important roles as the pacemaker cells. ICC loss or disruption of the ICC networks
may be an important cause in gut dysmotility. In humans, disturbed ICC networks have
been reported such as chronic intestinal pseudo-obstruction, infantile hypertrophic pyloric
stenosis, Hirschsprungs disease, slow transit constipation, and diabetic gastroparesis. On
the other hand, W/Wvmice harbour c-kit mutation and suffer GI dysmotility due to ICC in
sufficiency. Here we provide the evidence showing that bone marrow (BM) cells are able
to alter their phenotypes to the gut ICCs and improve gut dysmotility. (Methods) We used
W/Wv mouse as a recipient and made F1 mouse of WB mouse and GFP Tg mouse as a
donor. We collected whole bone marrow cell from the femurs and tibias of a donor and
did bone marrow transplantation to the recipient who did 8.5Gy radiation and made a
chimera mouse. After confirmation of success of transplant, each mouse was anesthetized
and perfused intracardially with 4% paraformaldehyde/PBS and stomach, small intestine,
and colon were fixed in cryo-enbedding compound. For intrinsic GFP analysis, 5μm frozen
sections cut from tisssue and immunostain in Anti ICC antidody (an AIC antibody) and
identified a cell. Immunofluorescence analysis was performed using a fluorescence micro-
scope and a confocal microscope. In addition, W/Wv mice transplanted BM cells of F1 mice,
and W/Wv mice transplanted with BM cells of W/Wv mice were measured whole gut transit
time and gastric empting. (Results) GFP+AIC+ cells were constantly found as murine gut
ICCs. W/Wv mice transplanted with BM cells of F1 mice had significantly shorter whole
gut transit time than W/Wv mice transplanted with BM cells of W/Wv mice(201.1 ± 38.4
min vs 275.8 ± 45.3 min ;p<0.01). Gastic Empting was significantly acceleted in mice that
transplanted with BM cells of F1 mice as compared with in mice transplanted with BM cells
of W/Wv mice(31.9 ± 13.8% vs 17.5 ± 7.6% ;p<0.05 ). (Conclusions) BM-derived stromal
cells are able to transdifferentiate to gut ICCs to improve gut dysmortility in W/Wv mice.
These findings may open a new therapeutic modality for a wide range of gut dysmortility.
T1890
Restoration of Function Following Mouse and Human Enteric Nervous System
Transplants Into An In Vitro Model of Hirschsprung's Disease
Dan Hawcutt, Richard Lindley, David Edgar, Simon Kenny
Background: Hirschsprung's disease affects 1 in 5000. Despite curative surgery, long term
complications affect 60% of patients. Recent advances have shown it is possible to transplant
human enteric nervous system stem cells (ENSC) into aganglionic embryonic bowel, and
achieve reinnervation. There is no functional data to assess whether this technique returns
bowel to the expected frequency of contraction. We have developed a novel gut culture
technique capable of measuring contractions across gestation, and used this system to
compared the functional effect of ENS reimplantation (murine or human) into aganglionic
mouse distal colon with normally innervated distal colon. Aim: To assess the functional
effect of transplanting murine and human ENSC into an In Vitro mouse model of Hirschs-
prung's disease. Methods: Colon explanted from E11.5 embryonic mice was kept in organ
culture conditions for 10 days. Samples were dissected to give either ganglionic or aganglionic
distal colon. Immunohistochemistry was used to determine the presence / absence of neurones
(PGP9.5) and glia (GFAP) and the distribution of neurones compared with colon from
age-matched mouse embryos. Aganglionic bowel was co-cultured with ENSC-containing
neurospheres isolated from human neonatal colon or neonatal mouse colon. Contractions
were recorded using optical digital image acquisition and the amplitude and frequency of
contractions measured using Diamtrak™ software. Fourier transformation was used to
perform amplitude-frequency spectral analysis. The effect of ENS blockade was assessed by
adding tetrodoxin (TTX) to the specimens; The effect of interstitial cell of Cajal blockade
was assessed using inactivating c-kit antibodies. Results: Anti-c-kit antibody abolished all
contractions in innervated and aganglionic distal colon. Transplantation with a murine ENS
neurosphere produces an identical rate of contraction at E19.5 to normally innervated distal
colon (37.1 v 42.2 mHz p=0.32), and treatment with TTX increases the frequency to that
seen in TTX treated innervated distal colon (62.5 v 73.7 mHz p=0.22). At E21.5, transplanta-
tion with a human ENS neurosphere also produced inhibitory neural control, which was
abolished with TTX (41.0 v 69.3 mHz p=0.0003), with post TTX treatment contraction
frequencies identical to that seen in E21.5 aganglionic distal colon (58.3 v 69.3 mHz p =
0.08). Conclusion: The transplantation of embryonic murine and human ENS stem cells
into aganglionic embryonic bowel results in a restoration of function. This is neurally
controlled, and can be blocked by addition of TTX. This finding has potential application
in the treatment of Hirchsprung's disease.
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T1891
Inflammation of the Gastric Antrum May Lead to Retrograde Pacemaking
Activity in the Stomach
Abigail S. Forrest, Kenton M. Sanders
Background: The interstitial cells of Cajal (ICC) generate electrical pacemaker activity in the
gastrointestinal (GI) tract. In the murine stomach, dominance of electrical activity has been
established by experiments showing that the corpus intrinsically produces 6-8 slow waves
per minute (wpm), whilst the antrum, once detached from the corpus will cease to run at
this frequency and instead display a slow wave frequency of between 2 and 4 wpm. This
functional coupling of the intact stomach regions allows co-ordination of activity. Neuro-
transmitters and hormones are known to alter slow wave frequency. Prostaglandins (PG)
are synthesized within the mammalian GI tract, and PGE2 is the predominant form produced
in the gastric antrum. The gastric antrum is particularly susceptible to these effects since it
can alter its rate of slow waves depending on circumstances. Prostaglandins can induce
nausea and vomiting, and clinical studies have demonstrated that blockage of endogenous
prostaglandin synthesis can prevent these symptoms. It is possible that localized PG release
may be responsible for the production of dysrhythmias in the stomach. Methods: Antral and
corpus muscles were studied by standard sharp electrode techniques to record intracellular
electrical activity. Duration, amplitude, frequency and max/min membrane potentials of
slow waves were measured. In addition, PCR for EP-receptors was performed. Results: All
four of the EP receptor subtypes were present in both corpus and antrum as determined
by qPCR, although significant difference in the level of expression in any of these subtypes
was found. Both the antrum and corpus muscles individually responded with a significant
positive chronotropic effect when PGE2 was applied. It was elucidated that this effect was
mediated through the EP3- receptor since EP3-receptor agonists produced a similar response.
In partition bath experiments, it was proved that on addition of PGE2 to the corpus only,
both the corpus and antral regions of the stomach muscle showed increased slow wave
frequency. Likewise, when PGE2 was added to the antrum only, an increase in corpus
activity was also observed. When the corpus and antrum regions were severed, the corpus
tissues went back to its original frequency whilst the antral slow wave frequency remained
high. No evidence of uncoupling between the corpus and antrum was observed in either
experiment. Conclusions: These experiments indicate that PG synthesis and release in
response to localized inflammation of the gastric antrum has the potential to produce a
retrograde slow wave gradient in the mouse stomach, even if functional uncoupling does
not occur.
T1892
STW 5 and STW 6 Inhibit Inflammation-Mediated Motility Disorders in the
Rat Small Intestine In Vitro
Sebastian Michael, Olaf Kelber, Bettina Vinson, Christa E. Mueller, Karen Nieber
Herbal preparations are widely used in the treatment of dyspepsia and motility-related
disorders of the gastrointestinal tract, but their effect on inflammatory processes in the gut
remains unclear. The phytotherapeutic agent STW 5 is a fixed combination of nine different
plant extracts successfully used in the therapy of these disorders. The aim of the present
study was to compare the effects of STW 5 and its lead component, STW 6 (Iberis amara
fresh plant extract) in a concentration equivalent to that of the combination (512µg/ml
versus 24µg/ml) on inflammation-induced disturbances of the rat small intestine motility
In Vitro and to characterize adenosine receptor subtypes (AR) involved in these effects. The
experiments were performed on isolated ileum/jejunum preparations in conformity with the
German Guidelines for Animal Care. The ACh-induced (1mM) contractions were measured
isometrically. The inflammation was induced with 2,4,6 trinitrobenzolsulfonic acid (TNBA,
0.01M). TNFa-mRNA was assayed using quantitative RT-PCR with SYBR® Green as detecting
agent. Morphological changes were visualized after van Gieson staining. Radioligand binding
assays were carried out to characterize the involvement of ARs. Preincubation of the tissue
preparations with TNBA (30min) resulted in an inhibition of the ACh-induced contraction.
STW 5 (64-512µg/ml) prevented this inhibition of contractility concentration dependently,
when it was coapplied with TNBA. STW 6 (3-24µg/ml) inhibited the TNBA-induced reduction
of the ACh-evoked contraction to a higher degree compared to STW 5. TNBA induced
morphological changes of the smooth muscle and the mucosa. The coincubation of STW 5
and STW 6, respectively, resulted in more intact mucosal and muscular layers. The TNF-
a gene expression significantly rose after the pretreatment of the preparations with TNBA.
STW 5 but not STW 6 diminished the TNBA-induced increase of TNFa-mRNA level. The
STW 5- and STW 6-mediated effects were blocked by 1,3,7-trimethyl-8-(3-chlorostyryl)xan-
thine (CSC; 0.2 µM), a selective A2AR antagonist. This was also apparent after van Gieson
staining. Radioligand binding assays confirmed the affinity of STW 5 to the A1R and A2AR,
whereas STW 6 bound to the A1R only. The results indicate that the pharmacological profile
of the combination STW 5 differs in some aspects from that of its lead component STW 6.
The involvement of adenosine receptors A1R and A2AR in the anti-inflammatory effect of
STW 5 and STW 6 could represent a novel mechanism of action involved in the clinically
proven therapeutic effects of these herbal preparations in gastrointestinal diseases.
T1893
Tetrahydrobiopterin (BH4), a Cofactor for nNOS Activity, Restores Gastric
Emptying in Female Diabetic Rats: Further Evidence for Gender Specific
Mechanisms in the Pathogenesis of Diabetic Gastroparesis
Pandu R. Gangula, Mengyi Ye, Shijie Cai, Keith M. Channon, William L. Maner, Shi
Shao-qing, Robert E. Garfield, Pankaj J. Pasricha
Background: Gastroparesis affects females predominantly but the biological basis of this
gender bias is unknown. We have recently shown that gastric emptying in female rats is
more dependent on nitrergic regulation than in males, and this is associated with increased
nNOS dimer (the active form of the enzyme) levels. Further, we have shown that nNOS
dimerization along with impaired nitrergic relaxation, is significantly reduced in female but
not male diabetics. In this study we have explored the mechanism of this effect further, by
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focusing on the role of tetrahydrobiopterin (BH4), a major co-factor for nNOS dimerization
and activity. Results: In Vitro studies on gastric LM-MPs showed that DAHP, an inhibitor
of BH4 synthesis, significantly (p<0.05) decreased nNOS dimerization and NO release
(0.26±0.03 vs. 1.35±0.38 µmole/mg tissue). In Vivo, diabetic female rats showed a significantly
(p<0.05) greater reduction in solid gastric emptying compared to male diabetics. This was
associated with a decrease in BH4/total biopterin ratio in the female (0.52±0.07 vs. 0.96±0.07)
but not in male (0.60±0.02 vs. 0.66±0.06) rat gastric pylorus. Supplementation of BH4
either from day 1 (36.0±7.09 % vs. 82±6.9 %) or 21 (p=0.07) days after diabetic induction
significantly attenuated delayed gastric emptying for solids in females but not in males. In
addition, diabetes induced decreased body weights were restored by BH4 (182±5.84
vs.171±2.4 grams) supplementation in females. Further BH4 treatment reversed (17.23±5.81
vs. 42.0±2.70 mmHg x sec) the diabetes-induced changes in intragastric pressures (IGP)
observed during In Vivo ambulatory telemetry. BH4 supplementation did not alter solid
gastric emptying rate in healthy male and female rats. Conclusions: The pathogenesis of
diabetic gastroparesis may be different in males and females, with the latter being more
vulnerable to changes in nitrergic regulation such as that caused by an acquired deficiency
in the nNOS cofactor, BH4. Supplementation of BH4 may be beneficial in diabetic female
patients with gastroparesis. Studies are ongoing to confirm whether In Vivo BH4 supplementa-
tion restores impaired nitrergic relaxation, nNOS activity and NO release in diabetic gast-
ric tissues.
T1894
Esophageal-Gastric Dysreflexia After Acute Experimental Spinal Cord Injury
in Rats
Gregory M. Holmes, Melissa Tong
Clinical reports of patients with a spinal cord injury (SCI) have identified the occurrence
of post-injury gastric stasis that develops in the acute phase of injury. Patients with cervical
injuries most often present a reduction in gastric emptying as well as an increased risk of
reflux and aspiration of gastric contents. It is well accepted that, unlike the extrinsic neural
control of the intestines, gastro-excitatory and -inhibitory neural control is mediated through
the vagus nerve. Since vago-vagal neurocircuitry remains intact after SCI, the purpose of
this study was to test basal gastric motility and reflex-evoked gastric relaxation in animals
that had received either a control (sham) surgery without SCI, spinal contusion at the third
thoracic spinal segment (T3 SCI) with a controlled impact device, or a complete T3 spinal
transection (T3 TX). An additional injury control, that retains rostral thoracic autonomic
outflow while still incurring comparable hindlimb paralysis, consisted of animals with a
ninth thoracic spinal segment contusion injury (T9 SCI). Three days following SCI surgery,
animals were fasted overnight and deeply anesthetized with thiobutabarbitol. A miniature
force transducer was implanted on the serosal surface of the gastric body in order to record
gastric circular smooth muscle activity. An inflatable esophageal balloon was placed orally
in the esophagus of the rat approximately 1 cm above the esophageal hiatus in order to
mimic the swallowing of a bolus of food. This physiological level of esophageal distension
triggers a reflexive relaxation of the stomach. Compared to surgical controls (n=10), animals
with T3 SCI (n=9) or T3 TX (n=10) had significant reductions in basal gastric motility peaks
(49.7±13.2 vs. 15.7±3.5 and 8.9±2.0, respectively, p<0.05) and reflexive gastric relaxation
following esophageal distension (-65.8±13.4 mV vs. -13.4±10.2 mV and -9.69±9.0 mV,
respectively, p<0.05). There was no significant reduction in gastric relaxation (-56.3±14.0)
after esophageal distension in T9 SCI (n=12) when compared to surgical controls. Further-
more, while basal gastric motility was reduced 41.8% (26.4±4.4 peaks) from control in T9
SCI rats, it was not significantly different from control. These data demonstrate that dimin-
ished gastric reflex function following acute SCI is partially due to the combined reduction
of a purely vagal gastric reflex (i.e., esophageal-gastric reflex) and reduced levels of vagally-
dominated gastric motility. The post-injury suppression of these vago-vagal gastric reflexes
suggests that SCI may interrupt ascending spinal afferent input to brainstem vagal nuclei.
Supported by NIH grant NINDS #49177
T1895
Role of Caveolar Cholesterol in the Pathogenesis of Gastroparesis in the
Transgenic OB/OB Mouse
Ling Cheng, Ping Cong, Piero Biancani, Jose Behar
The pathogenesis of gastroparesis in obese patients with type-2 diabetes has not been
elucidated. These studies examined the role of high plasma membrane (PM) cholesterol
(Ch) in the contraction of antral muscle from OB/OB mice. The OB/OB mouse strain is
characterized by obesity, type-2 diabetes, high serum Ch and delayed gastric emptying. We
studied the contraction induced by agonists that act on receptors internalized through
caveolae or clathrin rafts. It has been shown that abnormal levels of caveolar Ch disrupts
receptor recycling in muscle cells. The serum Ch in OB/OB mice (3.5 mM) was higher than
in control lean mice (1.5 mM) (p<0.001). The basal motility index of muscle strips from
the antrum of OB/OB mice was lower than in strips from lean mice (p<0.001). The response
to electrical field stimulation and to increasing concentrations of Ach and CCK-8 in muscle
strips from OB/OB was also lower than in lean mice (p<0.001). The contraction of dissociated
muscle cells induced by increasing concentrations of Ach and CCK-8 in OB/OB mice was
reduced compared to lean mice (p<0.001 per ANOVA). The Ch content in caveolae was
markedly increased in OB/OB compared to lean mice (p<0.01). In muscle cells from OB/
OB mice, the levels of caveolin-3 proteins (CAV-3) and CCK-1 receptors were higher in
caveolae and lower in the bulk plasma membrane (PM minus caveolae) than in lean mice
(p<0.005). Removing the abnormal levels of Ch from caveolae of muscle cells from OB/OB
treated with Ch-free liposomes for 90 min normalized the muscle contraction, reduced the
levels of Ch and CCK-1 receptors in the caveolae (p<0.01). The contraction of antral muscle
cells from lean mice induced by CCK-8 became defective after treatment with Ch-rich
liposomes for 90 min. There were no differences in the contraction induced by erythromycin
and met-enkephalin between OB/OB and lean mice. This contraction was blocked by the
clathrin inhibitor chlorpromazine and by the siRNA of the clathrin heavy chain protein. In
conclusion, high caveolar Ch levels impairs the antral muscle contraction in OB/OB mice
induced by agonists that act on receptors such as CCK-1 receptors that internalize through
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caveolar domains. It is normalized after the high Ch levels are removed from caveolae. The
actions of met-enkephalin are not affected by high levels of PM Ch because δ-opioid receptors
are known to internalize through clathrin rafts. Erythromycin acts on motilin-like receptors
that may also internalize through clathrin rafts. These studies suggest that drugs acting on
receptors that internalize through clathrin rafts may be effective in the gastroparesis that
affects the obese with type-2 diabetes.
T1896
Caspase-Dependent and Independent Pathways Are Involved in Glutamate-
Induced Selective Nitrergic Cell Death in the Rat Myenteric Plexus
Shiyi Zhou, Tin ming Mok, Chung Owyang
Chronic hyperglycemia induces selective damage to gastric nitric oxide (NO)-containing
neurons resulting in defective accommodation reflex. This appears to be mediated by endo-
genous NO, as the damage was prevented by pretreatment with the nNOS inhibitor, LAME.
NO is known to facilitate the release of glutamate and NMDA receptors are present in the
enteric nervous system. We demonstrated that administration of a NMDA antagonist pre-
vented the loss of NO neurons in diabetic rats suggesting that chronic activation of NMDA
receptors may cause excitotoxicity to enteric neurons. However direct evidence that glutamate
exerts differential toxicity to myenteric NO-containing neurons is lacking and the intracellular
signaling pathway responsible for apoptotic cell death has not been elucidated. To address
these issues, we performed studies on primary cultured gastric myenteric plexus neurons
from rats. Nitric oxide-sensitive probe, DAF-FM was used as a marker for nitrergic neurons.
In 3-5 days primary cultured gastric myenteric neurons, administration of glutamate (0.1-
1.0 mM) for 30 min induced selective cell death of NO neurons as measured by the viability
and toxicity assay using the dyes Hoechst 33342 and propidium iodide (PI). At 30 and 60
min of exposure to glutamate (0.1 mM) 27.8±7.7% and 97.0±15.2% of NO cells took up
PI, whereas only 13.0±10.6% and 48.2±14.1% of non-NO neurons were PI labeled. The
differential actions of glutamate on NO- and non NO-containing neurons were not due to
differences in receptor distribution as the percent of neurons processing NMDA receptors
in the two groups of neurons was similar (51.6±13.8% vs 64.4±15.0%). To examine the
signaling pathways responsible for the apoptosis of NO containing neurons, primary gastric
neurons were cultured for 48 hr following exposure to 0.1 mM glutamate. Apoptosis
was assessed by immunoreactive staining for caspase-3 and DNA fragmentation (TUNEL).
Following glutamate treatment 70.6±4.9% of gastric neurons stained positive for caspase-3
(accompanied by release of cytochrome-C from mitochondria) and 65.4±11.2% were TUNEL
positive. Caspase inhibitor (100 μM) significantly reduced caspase-3 activation to 5.4±1.9%
vs 70.6±4.9% in controls. However 25.9±4.8% of neurons remained TUNEL positive even
in the presence of Caspase-3 inhibitor I. Addition of PD 150606 (100 μM) a calpain inhibitor
almost completely blocked apoptosis induced by glutamate. This is the first demonstration
that gastric nitrergic neurons are selectively more susceptible to glutamate-induced death
in isolated cultured neurons. This process involves the participation of both caspase-depend-
ent and independent apoptotic pathways.
T1897
The Cannabinoid-1 (CB-1) Receptor Antagonist SR 141716a Reduces
Intestinal Afferent Nerve Sensitivity to Painful Stimuli in Mice In Vitro
Qian Gong, Mario H. Müller, Andrej Sibaev, Birol Yüce, Li Yongyu, Martin Storr, Martin
Kreis
Background: Cannabinoid receptors are involved in pain perception (Neurobiology of Disease
1998; 5:447-461) In the gastrointestinal tract, visceral hypersensitivity may occur during
functional bowel disorders. We aimed to determine whether intestinal afferent nerve sensitiv-
ity is modulated by the Cannabinoid-1 (CB-1)-receptor in mice. Methods: Wistar rats were
anesthetized with pentobarbitone (60 mgkg-1 i.p.) and ileal segments removed with the
mesenteric arcade attached. Segments were perfused In Vitro with Krebs' buffer (34 °C)
which was either supplemented with the CB-1 receptor agonist WIN 55,212-2 (10-5 mol/
l), the CB-1 receptor antagonist SR 141716A (10-5 mol/l) or vehicle (each n=6). Extracellular
multi-unit afferent nerve discharge was recorded from a mesenteric nerve. Responses were
evaluated as mean afferent nerve discharge minus baseline. Data are given as median (IQ-
range) and were analysed by ANOVA on ranks and posthoc Dunn's test. Results: Afferent
nerve discharge to the algesic mediator bradykinin (added at 1 µM to the organ bath) was
reduced to 1.5(1-4) impsec-1 following pretreatment with the CB-1 receptor antagonist SR
141716A compared to 10 (6.75-19.5) after vehicle and 8.5(8-12) impsec-1 after the CB-1
receptor agonist WIN 55,212-2 (both p<0.05). A reduction in afferent nerve discharge was
also seen following SR 141716A for noxious mechanical distension of the intestinal loop
(30 to 80 cmH2O) compared to vehicle controls and animals pre-treated with the CB-1
receptor agonist WIN 55,212-2 (both p<0.05). At the maximum distension pressure, the
response reached 25.5(22-43) impsec-1 following SR 141716A compared to 82(71-86) in
vehicle controls and 89(84.8-95.8) in the WIN 55,212-2 pre-treated subgroup (both p<0.05).
Afferent discharge to the inflammatory mediator 5-HT (500 µM) and to low level mechanical
distension (0-30 cmH2O) was not different in the pre-treated subgroups compared to vehicle
controls. Conclusions: The CB-1 receptor antagonist SR 141716A reduces intestinal afferent
nerve sensitivity to painful mechanical stimuli and the pain mediator bradykinin, while
sensitivity was unchanged following the CB-1 receptor agonist WIN 55,212-2. Thus, the
Cannabinoid-1 receptor may represent a potential therapeutic target for intestinal disorders
involving visceral hypersensitivity.
T1898
High Fat and High Carbohydrate Diets Effect On Gastric Emptying Response
to Duodenal Lipid
Dominique Bligny, Sylvie Guérin, Benoit Janson, Alain Chauvin, Charles-henri Malbert
Increasing evidence suggests that previous patterns of macronutrient intake affect gastrointes-
tinal function. High fat diet during 2 weeks reduces inhibition of gastric emptying by CCK
in rat and inhibits the pyloric motor response induced by duodenal lipids in humans.
However, it is not known if these effects are caloric or nutrient dependent. Furthermore,
this long-term modulation has been shown using high fat diet but not with other nutrients.
The aim of our study was to evaluate the effect of long term isocaloric high fat and high
carbohydrate diets on gastric emptying. Gastric emptying was measured by scintigraphy
using 99mTc-colloid-labelled solid meal in 12 conscious pigs (40 ± 2 kg) fitted with a
permanent access to the duodenal lumen. The animals were divided into 3 groups feed with
either: normal (N), high fat (40 % lipids, HF) and high carbohydrate (68 % carbohydrate,
HG). The energy density of each of these diets was identical (4.95 kcal.g-1). These diets
were ingested equally in each group for at least 2 weeks. Gastric emptying was evaluated
with and without duodenal intralipid infusion (IL, 1 ml.min-1) used as non-pharmacological
challenge. Gastric emptying was also estimated before the beginning of HG and HF diet
period. Half emptying time was obtained after fitting the raw data to a power exponential
function. In the absence of IL duodenal infusion, HF and HG diets did not change half
emptying time compared to N diet (74 ± 5.7, 76 ± 12.8, 67 ± 5.4 min for N, HF and HG
groups respectively, p>0.05). Furthermore, these values were not significantly different from
those obtained without duodenal intralipid infusion before HG and HF diet period (73 ±
11.0, 66 ± 8.2 min for HF and HG groups respectively, p>0.05). IL infusion increased, as
expected, gastric half emptying time for N group (118.14 ± 13.4, p<0.001) but surprisingly
was unable to alter emptying in HF and HG groups (71 ± 11.6 min, 83 ± 7.9 min for HF
and HG groups respectively). In conclusion, high fat diet suppresses gastric emptying
inhibition induced by IL infusion. Furthermore, using isocaloric normal and high fat diets,
we have demonstrated that this effect is not caloric dependant. Finally, diet dependant IL
effect is not limited to high fat diet since high carbohydrate diet is equally potent to suppress
the IL inhibition. While the origin, peripheral or central, of this cross de-sensitisation is still
unknown, it might explain the early feeling of hunger observed in patients with progressive
increase in weight.
T1899
Interleukin (IL)-1β-Induced Inhibition of Gastric Motility Involves
Corticotropin-Releasing Factor Receptor 2 (CRF2)
Lixin Wang, Mulugeta Million, Guillaume Gourcerol, Karina Pumbukchian, Yvette Tache
Background: Cytokines play a role in gastric ileus under pathological conditions. IL-1β-
induced inhibition of gastric emptying in rats has been shown being blocked by non-selective
CRF receptor antagonists. Aim: To determine the CRF receptor subtypes involved in IL-1β-
inhibited gastric motility. Methods: Adult C57BL/6 mice, CRF2 -/- and their wild type
control (+/+) mice, and Sprague-Dawley (SD) rats were used. A 20 min gastric emptying
rate of non-nutrient liquid was determined 70 min after ip injection of IL-1β (3, 10 and
100 µg/kg) or saline in overnight-fasted C57BL/6 mice. Gastric emptying was also assessed
in CRF2 -/- and CRF2+/+ mice following ip injection of IL-1β (10µg/kg). Subgroups of
C57BL/6 mice were pre-treated with CRF1 antagonist, CP-154,526 (20 mg/kg, sc) at 30
min before or CRF2 antagonist, astressin2-B (200 µg/kg ip) 15 min before IL-1β (10 µg/
kg) injection. The effect of astressin2-B (100 µg/kg, iv) on IL-1β (2 µg/kg, iv)-induced
inhibition of phasic gastric motility was tested in anesthetized rats by measuring intra-gastric
pressure using pressure microtransducer (SPR-524, Millar system, Houston, TX). Results:
IL-1β inhibited gastric emptying in conscious mice dose-dependently (41.3±4.2, 22.3±7.4
and 9.8±2.7% respectively vs. 65.7±12 in vehicle, p<0.05). CRF2-/- mice did not develop
delayed gastric emptying as CRF2+/+ mice did after IL-1β ip injection (Table 1). IL-1β
injected iv in anesthetized rats induced a 71.2±3.4% inhibition of phasic motility of the
stomach (p<0.05 vs. baseline and iv saline), whereas astressin2-B injected iv 5 min before
blocked the IL-1β effect for 10 min after injection (32.3±12.0% of inhibition vs. baseline;
p<0.05 vs. IL-1β alone) and then the intra-gastric pressure was decreased to the same level
as IL-1β alone. Systemic administration of CP-154,526 and astressin2-B did not show
significant effect on IL-1β-induced delay of gastric emptying in mice (Table 1). Conclusion:
The data suggest that CRF2 receptors are involved in IL-1β-inhibited gastric motility, and
the central ones are more likely to be prominently involved through IL-1β-induced activation
of brain CRF pathways. Supported by NIH grants DK33061 and DK57238.
Table 1: Effect of IL-1β on gastric emptying in C57BL/6 mice pre-treated with CRF receptor
antagonists and in CRF2-/- mice (n=6). *: P<0.05 vs vehicle respectively.
T1900
Mosidomine, a Nitric Oxide Donor, Prevents Damage of Diabetic Rat Gastric
Intramuscular Interstitial Cells of Cajal (IM-ICC)
Chun Hsu, Shi yi Zhou, Tin ming Mok, Chung Owyang
Defective accommodation and gastroparesis are serious complications of diabetes. ICC plays
an important role in regulation of gastric motility; IM-ICC damage has been shown to lead
to GI dysmotility. Studies suggest that nitric oxide (NO) regulates the frequency of ICC
currents and that both nitric oxide synthase (NOS) containing neurons and ICC are damaged
in the enteric system of diabetic animals. We hypothesize that diabetic animals have selective
loss of NOS containing neurons, which leads to gastric IM-ICC damage; and that treatment
of diabetic rats with NO donor would prevent IM-ICC damage. To test his hypothesis,
immunocytochemistry studies of whole mount preparations of gastric corpus longitudinal
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muscle strips with myenteric plexus was performed to evaluate for NOS containing neurons,
VACHT (acetylcholine) containing neurons, and IM-ICC cells (via c-kit immunoreactivity)
in steptozotocin-induced diabetic and age matched controls rats. Loss of NOS containing
neurons by 13%, 19%, and 38% were demonstrated in 4, 5, and 6-week diabetic rats
respectively, compared to age matched controls. Insulin rescued diabetic rats did not have
significant loss of NOS containing neurons. Diabetic animals did not have reduction in
VACHT containing neurons as compared to controls. These findings suggest that NOS cells
are selectively damaged in diabetic animals. We also immunocytochemically evaluated gastric
IM-ICC in diabetic rats. No significant damage of IM-ICC was observed in 4-week diabetic
as compared to age matched control rats. However, 6-week diabetic animals had a 16.7%
reduction of IM-ICC compared to age matched controls. This effect was not observed in
insulin treated rats, suggesting that ICC damage results from chronic hyperglycemia. Six
week diabetic rats orally fed with 8-12 mg per day of molsidomine, a NO donor, had
apoptotic loss of NOS containing gastric neurons similar to that in diabetic rats as evaluated
via caspase-3 immunostaining. However, the group of diabetic rats rescued with molsidomine
had gastric IM-ICC similar to that in normal controls. In conclusion, we showed that
diabetic rats have selective loss of NOS containing neurons in gastric myenteric plexus that
progressively worsens from 4 to 6 weeks. Six week diabetic rats had significant loss of IM-
ICC compared to age matched controls; treating diabetic rats with molsidomine, an NO
donor, prevented the loss of ICC but did not prevent apoptotic loss of NOS containing
neurons. These findings suggest that selective impairment of nitrergic function leads to
gastric IM-ICC damage in diabetic rats. NO donors may prevent gastric IM-ICC damage,
thus reducing gastric dysmotility in diabetics.
T1901
Specific Mechanisms of the Pyloric Electrical Activity in the Gastric Motility
Associated with Interstitial Cells of Cajal (ICC) Populations and Alternations
in the Activity During Endotoxaemia in Guinea-Pigs
Hiroe Yanagida
Coordinated motor activities of each region of the stomach regulate the gastric emptying.
The failure of the coordination causes dismotility. However, the mechanism of the based
electrical activity in this region is not well understood. The aim of this study was to evaluate
the electrophysiological features of the gastric pylorus associated with ICC population,
comparing them with other parts of the stomach, and to evaluate gastric disorder in the septic
animal model. Slow waves were recorded from the guinea-pig stomach, using intracellular
microelectrode techniques and ICC networks were examined with Kit-immunohistochem-
istry. In some experiments, animals were treated with lipopolysaccharide (LPS, 3mg/kg,
i.p.). In the normal pylorus, the resting membrane potential was 6.5 mV more hyperpolarized
than that in the antrum and slow waves were less frequently generated but had larger
maximum amplitudes than those of the antrum. The pyloric slow wave was characterized
by having multiple depolarizing peaks on each slow wave, and the chance of multiple-peaks
increased towards the sphincter. Pyloric slow waves showed a high sensitivity to caffeine;
0.5 mM caffeine abolished activity. 0.25 mM Ca2+ and 2-aminoethoxydiphenyl borate
abolished the activity and depolarized the membrane, suggesting slow wave generations
require certain levels of both internal and external Ca2+. Ca2+ dependent chloride channel
blockers greatly decreased the frequency and the amplitude of slow wave. Pharmacological
results from pyloric slow waves agreed with those reported in the secondary component of
antral slow waves, which is generated by intramuscular ICC (ICC-IM), but not the primary
component, which is generated by myenteric populations of ICC (ICC-MY). Immunohisto-
chemistry revealed decreased ICC-MY towards the sphincter, whereas networks of ICC-IM
remained. These observations suggest that pyloric slow waves may involve different generation
mechanisms, which was less affected by ICC-MY but more associated with ICC-IM, from
the antrum. In LPS-treated antrum, the resting membrane potential was 7 mV more hyperpol-
arized compared to that in the control, although the changes in the amplitude and frequency
of slow waves were less affected and the changes in the pyloric membrane potential were
less significant. The different features of electrical activity may play an important role in the
antro-pylorus-sphincter coordination in gastric emptying. The different levels of changes in
the electrical activity observed in LPS-treated model may results in the poor coordination
of this region, which associated with the delayed gastric emptying.
T1902
Imatinib Mesylate Inhibits ICC Development in the Zebrafish
Adam J. Rich, Chris R. Brown, Kyle S. Leonard, Stacey Hess, Scott J. Leddon, Simon J.
Gibbons, Gianrico Farrugia
Background: The GI tract of the zebrafish has a cellular anatomy that is essentially similar
to humans. We previously verified expression of kita and kitb mRNA in zebrafish GI tissues,
and identified cells expressing Kit-like immunoreactivity in the myenteric plexus region of
the zebrafish GI tract with morphological features of interstitial cells of Cajal (ICC). ICC
were first identified at 7 dpf. The role of Kit-positive cells in GI motility of the zebrafish
has not been determined. Aim: Characterize normal spontaneous contractile activity in larvae
and determine the functional role for ICC in zebrafish motility. Methods: Zebrafish larvae
are transparent and GI motility can be directly observed in intact larvae. Larvae (ages 5-14
dpf) were anesthetized and digital images of the intact larvae collected each second and the
propagating intestinal contractions annotated. Contraction length was measured directly
from the images and contraction velocity was calculated. The developmental time-course
for propagating contractions was determined from 5 days post fertilization (dpf) until 14
dpf. In a second series of experiments imatinib mesylate (50 μM) was added to the larvae
medium at age 5 dpf to block KIT function. Digital motion analysis was performed at 7
and 14 dpf. Results: Spontaneous contractions of intestinal smooth muscles were first
observed between 3 and 4 dpf. At 5 dpf spontaneous and disorganized contractions were
observed in all larvae. Contractions were more organized by 7 dpf and 65% propagated
along the entire length of the intestinal tract. By day 14 dpf all contractions fully propagated.
No change in contraction frequency occurred between 7 and 14 dpf, but propagation velocity
increased as well as the mean propagation distance. Application of imatinib mesylate resulted
in a decrease in the total number of contractions. Remaining contractions were unorganized,
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shorter and slower, similar to contractions before appearance of ICC. Conclusion: These
data show that propagating muscular contractions in the zebrafish intestine gradually develop
between 5 and 14 dpf. Inhibition of Kit function blocks the development of propagating
contractions. These data strongly suggest that ICC are necessary for propagating contractions
in the zebrafish GI tract. Supported by NIH DK07158801, NIH-NCRR 12546, and
DK52766, DK57061
T1903
Effect of Gastric Secretion On Gastric Volume Responses, Emptying and
Intragastric Dilution in Humans - A Magnetic Resonance Imaging (MRI) Study
Oliver Goetze, Reto Treier, Andreas Steingoetter, Mark R. Fox, Peter Boesiger, Michael
Fried, Werner Schwizer
Background: The formation of unbuffered acid layers in the stomach by gastric secretions
after ingestion of a meal is important for understanding gastroesophageal reflux. Hitherto,
an objective visualization of these phenomena and their relationship to meal and stomach
volume was not possible. Recently, we have developed a fast T1 mapping technique allowing
the quantitative assessment of dilution processes of labelled meals. (Treier et al., Magn Reson
Med 2007) Aims: To evaluate the effect of pentagastrin induced gastric secretion on gastric
volume responses and intragastric spatial and temporal dilution of a liquid meal by MRI.
Methods: Using a 1.5T whole-body MRI System, 12 healthy fasted volunteers were examined
in supine position on two separate days after consuming a 500ml, 200kcal viscous glucose
drink labelled with 1200μM Gd-DOTA. The first scan after the meal defines t0 and starting
volume V0. Placebo (0.9% NaCl) or pentagastrin (0.6 μg/kg/h) were administered intraven-
ously (i.v.) at the start of ingestion in double-blind randomized order over 60min. Stomach,
meal volumes and gastric secretion by T1 maps were assessed at 5min intervals for 90min.
Dynamics of stomach and meal volume change from V0, described by the parameter κ, and
half emptying times (t50) were quantified. The amplitude of volume changes due to secretion
was measured by of area under the curve during i.v. infusions (AUCinf). Results: Fasting
and initial postprandial gastric volumes were similar in both conditions (p>0.05). Pentagastrin
increased stomach and meal volumes during infusion, whereas volumes immediately
decreased for placebo (κ: 1.68±0.06 vs. 0.99±0.05, p<0.001). κ values were similar for
stomach and meal volume curves in both conditions (p>0.05). T50 was higher for pentagastrin
than for placebo (t50 meal: 84±7 vs. 56±4min, p<0.001). The increase of t50 was closely
associated with AUCinf (R2=0.73, p<0.001). Pentagastrin infusion caused distinct intraluminal
fluid layering only seen on T1 maps on the top of the meal extending from the gastric
fundus to the antrum with a dilution ratio of 1:3 (380±90µM Gd-DOTA). Conclusions:
Layers of secretion on intragastric contents can be visualized and quantified non-invasively
by rapid T1 mapping during pentagastrin infusion. This could be the anatomic correlate for
multilayered gastric acid distribution reported previously (,acid pocket'). Increases of meal
volumes during pentagastrin stimulated secretion prolonged gastric emptying and were
closely followed by changes in stomach volumes. This shows that changes in meal volumes
due to gastric secretion are major determinants of stomach volume responses and gastric emp-
tying.
T1904
A Novel Scintigraphic Technique for Assessing Duodenal Contractions During
Gastric Emptying in Humans
Tadeu T. Kubo, Luiz E. Troncon, Eder R. Moraes, Marie Secaf
Background - Duodenal contractions, which are thought to play a role in gastric emptying
control, has been traditionally characterized using manometry. Although newer non invasive
techniques, such as ultrasonography and magnetic resonance imaging, have been proposed
for studying duodenal contractility in humans, there are no reports on using scintigraphy
for this purpose. Aims: To describe a novel scintigraphic technique for assessing duodenal
contractility during gastric emptying in humans, and to present preliminary data on frequency
and amplitude of contractions detected in three different duodenal segments. Methods:
Fasted young healthy volunteers (N=7) ingested a standard liquid test meal (320 mL; 450
kcal) labeled with 99mTechnetium-phytate. During a conventional gastric emptying test,
dynamic images of the anterior aspect of the abdomen were acquired periodically in the
right oblique position, which was found in previous tests to yield a clear definition of the
duodenal loop in most subjects. Dynamic scintigraphy (1 frame per second) was performed
for 256 seconds at 15-30 min intervals, and “activity vs. time” curves were generated for
regions of interest (ROI) corresponding to proximal, middle and distal segments of the
second duodenal portion. Curves were digitally filtered and processed using “Mat Lab 7.0”
(“Math Works Inc.”) tools, in order to estimate both dominant frequency (Fast Fourier
Transform) and amplitude (“mean ejection fraction”) of post-prandial duodenal contractions.
Results: Oscillations corresponding to duodenal contractions were detected more frequently
in the middle (82.8%) than in the proximal (71.4%) or distal (40.0%) duodenal ROI, and
one hour after (100.0%) than soon after meal ingestion (70%). There were no significant
differences (Kruskal-Wallis test, p=0.36) regarding dominant frequency between proximal
(median; range: 8.6 cycles per minute; 6.1 - 11.4 cpm), middle (9.8 cpm; 7.9 - 12.4 cpm)
and distal duodenal ROI (7.1 cpm; 6.5 - 13.1 cpm), one hour after meal. Also, values for
the amplitude of duodenal contractions were similar (p=0.74) in the proximal (63.3%; 61.5
- 64.2%), middle (61.6%; 57.7 - 68.2%) and distal ROI (63.1%; 59 - 66.2%). Conclusions:
Scintigraphic characterization of duodenal contractility in humans is feasible and yields
consistent data for both frequency and amplitude of post-prandial contractions. This non
invasive technique could therefore be utilized for assessing duodenal contractility during
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gastric emptying in either health or disease conditions. Financial Support: CNPq, FAPESP
and FAEPA-HCFMRP-USP.
T1905
Cysteinyl Leukotriene Receptor Type 1 (CYSLT1) Mediates Contraction in
Guinea-Pig Gastric Fundus
Shih-che Huang
Leukotriene D4 (LTD4) has been demonstrated to cause contraction of the esophagus, ileum
and gallbladder. Two receptors for the cysteinyl leukotrienes, termed the type 1 and type
2 cysteinyl leukotriene receptors (CysLT1 and CysLT2 receptors, respectively) have been
identified. The action of cysteinyl leukotrienes on the gastric muscle was unknown. To
investigate the cysteinyl leukotriene effects in the gastric fundus, we measured contraction
of circular muscle strips from the guinea-pig gastric fundus caused by leukotriene LTC4,
LTD4, LTE4 and LTB4. In fundic muscle strips, LTC4, LTD4 and LTE4 but not LTB4 caused
moderate, concentration-dependent contraction. LTD4 caused detectable contraction at 0.1
nM, half-maximal contraction at 0.55 ± 0.27 nM and maximal contraction at 0.1 µM. LTC4
caused half-maximal contraction at 0.75 ± 0.25 nM. LTE4 was a partial agonist, causing
half-maximal contraction at 32 ± 12 nM. The relative potencies for cysteinyl leukotrienes
to cause contraction were LTD4 = LTC4 >> LTE4. The maximal tensions caused by LTD4,
LTC4 and LTE4 were 110 ± 10%, 100 ± 16% and 72 ±10% 1µM carbachol-induced tension,
respectively. The LTD4-induced contraction was markedly inhibited by selective CysLT1
receptor antagonists, montelukast and zafirlukast, as well as by the CysLT1 and CysLT2
receptor antagonist BAY u9773. These indicate the existence of the CysLT1 mediating
contraction. Furthermore, the LTD4-induced contraction was not affected by tetrodotoxin
or atropine, suggesting a direct effect on the gastric muscle. These results demonstrate that
cysteinyl leukotrienes cause muscle contraction through interaction with CysLT1 receptors
in the guinea-pig gastric fundus. The cysteinyl leukotriene may play an important role in
the control of gastric motility.
T1906
The Effects of Ghrelin On Proximal and Distal Gastric Emptying and Metabol
Control in Healthy Volunteers
Therese Edholm, Fredrik Levin, Peter T. Schmidt, Per M. Hellström, Erik Näslund
Background: Ghrelin was discovered 1999 in endocrine cells of the stomach and has been
shown to accelerate gastric emptying in rodents and in man. GLP-1 is known to decreased
gastric emptying in man. Aim: Since timing of gastric emptying and pre-absorptive delivery
of nutrients to the small intestine is the primary step in metabolic control we decided to
investigate the effect of ghrelin on proximal and distal gastric emptying, blood glucose and
plasma insulin levels in healthy human volunteers. Methods: Eight volunteers paid two visits
to the clinic, once were they received saline infusion and once receiving ghrelin at 10 pmol/
kg/min. Eight different volunteers paid two visits to the clinic, once were they received
saline infusion and once receiving GLP-1 at 0.75 pmol/kg/min. Infusions were started at
the onset of intake of a 99mTc-labeled omelette. Gastric emptying rate was measured using
scintigraphy. Blood samples were collected for analyzes of insulin and glucose. Results:
Proximal and distal gastric emptying was significantly faster for ghrelin compared with saline
(P <0.0001). Distal emptying was determined after 80 min (P <0.001). Peak blood glucose
was slightly elevated after infusion of ghrelin 6.0 ± 0.3 compared to saline 5.6 ± 0.1 (n.s.).
After 60 min, the glucose level rose and stayed elevated throughout the ghrelin infusion (P
<0.01). Peak plasma insulin was to some extent elevated after infusion of ghrelin 40.1 ±
4.7 compared to saline 33.0 ± 2.8 (n.s.). Infusion of GLP-1 caused a delay of the proximal
emptying compared to saline (P <0.001). The emptying was inhibited by GLP-1 infusion
compared to saline. Conclusion: ghrelin increased proximal gastric emptying in humans,
followed by slightly increased peak levels of blood glucose and plasma insulin. The strong
acceleration of distal emptying induces a clear late glucose rise, unbalanced by insulin,
indicating a role for ghrelin in postprandial glucose disposal. GLP-1 strongly inhibits proximal
and distal emptying.
T1907
Two- Channel Gastric Pacing with An Implantable Gastric Pacemaker
Accelerates Glucagon-Induced Delayed Gastric Emptying in Dogs
Junying Xu, Robert Ross, Richard Mccallum, Jiande Chen
Background & aim: Multi-channel gastric electrical stimulation (GES) with long-pulse has
been shown to be more efficient and more effective than conventional single-channel GES
in improving gastric emptying in dogs. However, it is difficult to implement long-pulse
stimuli with an implantable pacemaker. The aim of this study was to investigate the efficacy
of two-channel gastric pacing with a novel implantable pacemaker on delayed gastric empty-
ing and gastric dysryhthmia induced by glucagon in dogs. Methods: Six healthy female dogs
implanted with four pairs of gastric electrodes and a duodenal cannula were studied in four
randomized session (saline, glucagon, single-channel GES with glucagon, and two-channel
GES with glucagon). Saline or glucagon (0.1mg/kg) was injected intravenously immediately
after feeding. In the GES session, GES was applied via the first pair of electrodes for single-
channel GES or via the first and third pairs of electrodes for two-channel GES. Gastric
emptying was assessed every 15 min via the duodenal cannula by calculating the amount
of collected phenol red which was mixed with the test meal. Gastric slow waves were
simultaneously recorded. Results: 1). Glucagon significantly and substantially delayed gastric
emptying (P <0.001), increased blood glucose levels, and induced gastric dysrhythmias. The
delayed gastric emptying and gastric dysryhthmia were correlated with the blood glucose
level (R=-0.75, P<0.001, and R=-0.58, p<0.01, respectively). 2). Both Single-channel GES
and two-channel GES improved gastric dysryhthmia, the percentage of normal gastric slow
wave was 31.2 ± 8.2 % in glucagons session, and increased to 71.4 ± 8.4% and 72.6 ± 7%
in single-channel GES and two-channel GES session (P=0.026 and 0.004, respectively). 3).
Two-channel GES but not single-channel GES improved glucagon-induced delayed gastric
emptying at 30 min (14.96 ± 3.68 vs. 1.26 ± 0.44 %; P =0.02), 60 min (29.76 ± 3.01 vs.
6.39 ± 1.88 %; P =0.0008), and 90 min (63.89 ± 5.68 vs. 30.04 ± 7.38 %; P =0.02) without
decreasing blood glucose levels. Conclusion: Glucagon-induced gastric dysrhythmia and
delayed gastric emptying are correlated with the blood glucose level. The impaired gastric
slow waves can be normalized with one or two-channel gastric pacing, whereas the delayed
gastric emptying can be normalized only with two-channel gastric pacing. The normalization
of glucagons-induced gastric dysrhythmia and delayed gastric emptying with gastric pacing
is independent of the blood glucose level. This work was partially supported by grants from
NIH (DK058487 and DK055437).
T1908
Amplitude-Dependent Motility and Antiemetic Effects of Neural Gastric
Electrical Stimulation in Acute Human Experiments
Jacek Sobocki, Roman Herman, Michal Nowakowski, Martin P. Mintchev
Introduction. Previous studies have demonstrated that neural gastric electrical stimulation
(NGES) can manipulate gastric motility in animals and humans both in antegrade and
retrograde directions. However, systematic investigation of amplitude-related NGES effects
on the upper gastrointestinal (GI) motility in humans is lacking. Aim. The aim of the study
was to evaluate the effect of different NGES amplitudes on invoked gastric contractility in
acute human experiments. Materials & Methods. Six patients (2 M, 4 F, age 62.5+/-17.8,
weight 63.6+/-12.5 kg) scheduled for elective laparoscopic cholecystectomy consented to
be included in the study. Under general anesthesia (N2O 4l/min, Thiopental 400mg, Chlor-
succillin 70mg, Pancuronium 6mg, Fentanyl 0.5mg), one bipolar electrode pair was laparo-
scopically implanted in the distal antrum close to the large and small curvature 3-3.5 cm
from the pylorus according to an established technique [1]. The following NGES parameters
were applied for 6 seconds: 400-Hz, biphasic pulse of 2 ms width, with sequentially increased
amplitude from 12 to 20 mA (peak-to-peak) and a pause between each amplitude increment
of 1 minute. Contractile activity of the stomach and small bowel was observed and recorded
on DVD. Results. No side effects or adverse events related to the procedure were noted. All
patients recovered nicely and exhibited no postoperative nausea, in contrast to 46% of a
historical postoperative group that underwent the same operation [2]. The applied NGES
resulted in invoked amplitude-dependent local gastric contractions, which were clearly noted
at NGES amplitudes 16.0+/-2.19mA and higher, and became lumen-occluding at 17,6+/-
2.34mA. The average NGES amplitude that invoked secondary antral motility was 14.0+/-
2.19mA. This secondary motility occurred approximately 20s after the primary stimulation.
About 10 minutes after the administration of NGES, powerful jejunal contractions occurred
lasting several minutes until the end of the operation. Conclusions. NGES in humans can
produce both primary and secondary contractions in the stomach with a subsequent antiem-
etic effect during post-operative recovery. General anesthesia in this acute human experi-
mentation might have contributed to certain modulation of the invoked motility responses.
In addition, NGES induces secondary but powerful small bowel motility, possibly mediated
by intrinsic or extrinsic enteric nervous system (ENS) reflex. References. Neshev et al., Obes
Surg.,16:510-20, 2006. 2. Feo et al. Randomized clinical trial of the effect of preoperative
dexamethasone on nausea and vomiting after laparoscopic cholecystectomy. Brit J of Surgery.
93:295-9, 2006.
T1909
Effects of Synchronized and Non-Synchronized Dual Pulse Gastric Electrical
Stimulation (GES) On Gastric Motility and Autonomic Functions in Dogs
Geng-qing Song, Jiande Chen
Aims: The aim of this study was to evaluate and compare the effect of a combined method
GES - synchronized GES with dual pulses (SGES) (combined short pulses with long pulses)
and non-synchronized GES with dual pulses (nSGES) on gastric tone, antral contractions
and autonomic functions. Methods: Seven female hound dogs implanted with 4 pairs of
electrodes on gastric serosa were studied in two separate experiments. The first experiment
was designed for gastric tone and autonomic functions in 8 randomised SGES/nSGES sessions.
Each session included sequentially as follows: 20-min baseline, 20-min SGES/nSGES and
20-min recovery. SGES was applied via the electrodes at the greater curvature or lesser
curvature and synchronized with the intrinsic gastric slow waves. The stimulus for SGES
was composed of one or five short pulses of 0.3ms followed with a long pulse of 400ms
and 6mA. The stimulus for nSGES was the same as SGES expect that the frequency was 9
cycles/min. Gastric tone was recorded simultaneously with signs and heart rate variability. The
second experiment was performed to study the effect of SGES/nSGES on antral contractions in
3 randomised sessions. Sessions 1 (control) and 2 (SGES with five short pulses at greater
curvature performed during 2nd 20-min) were performed in fed state, consisting of two
20-min periods. Glucagon was injected after the first 20 min recording in Session 1 and 2.
Session 3 was the same as session 2 except without glucogon infusion. Antral contractions
were measured using a manometric catheter via the gastric cannula. Results: 1) nSGES but
not SGES significantly reduced gastric tone via lesser or greater curvature (P<0.05). 2) While
nSGES at a tacky frequency inhibited contractions (7.5 ± 0.9 vs. 3.2 ± 0.6, baseline vs.
nSGES, P<0.05), SGES induced antral contractions (1.8 ± 0.6 vs. 7.5 ± 0.9, baseline vs.
nSGES, P<0.01). 3) Both nSGES and SGES inhibited sympathetic activity and excited vagal
activity. 4) No signs were observed during stimulation. Conclusion: nSGES at a tacky
frequency inhibits gastric tone and contractions. This may be a good GES method for
obesity. However, SGES induces antral contractions, which suggests it may be helpful for
gastroparesis. Both nSGES and SGES inhibit sympathetic activity and excite vagal activity.
This indicates autonomic functions may be altered by short pulse.
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T1910
Ileal Electrical Stimulation Is More Potent in Inhibiting Gastric Tone Than
Duodenal Electrical Stimulation in Dogs
Yong Lei, Jiande Chen
Background: Intestinal electrical stimulation has recently been shown to inhibit gastric tone,
delay gastric emptying and reduce food intake in dogs. However, it is unknown where the
best location for intestinal electrical stimulation is. Ileal brake is well-known to inhibit gastric
emptying. Therefore, one wonders whether the ileum is a better location for inhibitory
electrical stimulation. Aims: To assess that the inhibitory effects of duodenal electrical
stimulation (DES) and ileal electrical stimulation (IES) on gastric tone and compare the
potency between DES and IES in dogs. Methods: Six dogs were implanted with a gastric
cannula (for the placement of a barostat balloon into the proximal stomach) at the anterior
stomach and two pairs of stimulation electrodes in the duodenum and distal ileum, respect-
ively. Gastric tone, evaluated with a barostat was measured in a series of randomized sessions
on different days with DES or IES of different parameters (long pulses with a fixed frequency
of 20 pulses/min, pulse width of 200 ms and amplitude of 2mA, 4mA, 6mA or 8mA).
Animal behaviors were noted and scored in each session during both baseline (30 min) and
stimulation (30 min). Gastric accommodation was measured in two sessions (control and
IES) with a liquid meal. Results: 1) Both DES and IES with amplitude of 4mA or higher
but not 2mA significantly increased gastric volume (Table. 1). 2) The increase in gastric
volume was significantly higher with IES than DES at amplitude of 4mA, whereas the increase
in the behavioral score was significantly lower with IES than DES at amplitude of 4mA or
higher. 3) At amplitude of 4mA, IES was significantly more potent in inhibiting gastric tone
but induced significantly less symptoms. 4) IES at amplitude of 6mA also significantly
reduced gastric accommodation (268.7±27.4 ml vs. 113.2±39.3ml, P=0.009). Conclusion:
Electrical stimulation at both duodenum and ileum inhibits gastric tone. However, IES is
more potent than DES in inhibiting gastric tone and induces less symptoms. Accordingly,
IES may be a better therapy for treating obesity than DES (Partially supported by an NIH
grant, DK063733).
Table. 1. Effects of DES and IES on gastric volume and symptoms
*p<0.05 vs DES session; **p<0.01 vs DES session.
T1911
Cabin Pressure At Regular Flight Conditions Alters Gastric Emptying and
Gastric pH
Heidemarie Hinninghofen, Axel Kowalski, Irmhild Moennighoff, Rita Kuhlbusch-ziklam,
Paul Enck
Passengers on long distance flights do often complain of gastrointestinal problems such as
bloating or feeling of distention. In a previous study (ASEM 2006;77:121-123) we could
show that gastric emptying (GE) is significantly delayed at simulated flight altitude of 2500
m with a high fibre diet. Here we investigated whether this change is associated with a
change in gastric pH prior to and/or after a meal. METHODS: We studied 15 healthy young
males (27.40 ± 9.52 years) in a hypobaric pressure chamber at two different flight conditions
defined by cabin altitude (1000m = 679 mmHg / 8 subjects vs. 2500m = 570 mmHg / 7
subjects). Subjects who were blinded for the flight condition received a 13C octanoid acid
labelled standard meal with 20g of fibres after “flight height” was reached. GE (T1/2) was
computed (Fischer Analysen Instrumente GmbH, Leipzig, Germany) and compared. All
subjects were equipped with a nasogastric pH-probe (iPH, Standard Instruments, Karlsruhe,
Germany) positioned 5 cm below the lower esophageal sphincter for continuous measurement
of gastric pH (sample frequency: 0.5 Hz). Mean pH prior to and after the meal and meal-
induced changes in pH were computed and compared between conditions. GE and meal-
induced pH were correlated by Pearson's correlation coefficient. RESULTS: ANOVA: GE
was 177.3 ± 61.7 min at 1000m and 273.50 ± 74.68 min at 2500m, the difference was
significant (F(1,14) p=.041) and was not affected by age, height, and body weight. Gastric
pH was significantly elevated prior to the meal (1000m: 1.05 ± 0.1; 2500m: 2.20 ± 0.2)
(p≤.0005), and meal-induced buffering was significantly reduced for 2500m (-0.12 ± 0.43)
compared to 1000m (1.14 ± 0.63) (p=.01). GE and pH-changes were negatively correlated
(r= -.34), but this did not reach significance (p>.05). CONCLUSION: We could confirm
previous data that cabin pressure at regular flight altitude prolongs gastric emptying; in
addition, it increases gastric pH and thus may counteract the buffering effect of eating on
gastric acid seen under normal pressure. However the interaction between alterations in
gastric emptying time and gastric pH should be object of further research.
T1912
Gastric Emptying During Long-Term Bed Rest Head-Down Tilt: Effects of
Dietary Sodium
Axel Kowalski, Heidemarie Hinninghofen, Tina Coprian, Petra Frings, Martina Heer, Paul
Enck
Long term human space flights as operated since the early 70s of the last century (Skylab,
Mir, ISS) have resulted in significant weight loss of many astronauts (known as “space
anorexia”) but little is known about the underlying mechanisms. Bedrest studies with a 6
degrees head down tilt (BR-HDT) are common ground-based models to simulate the effects
of Zero-G on the human body. We measured the impact of BR-HDT and different salt
contents of diets on gastric emptying of solids. METHODS: Eight healthy male subjects
(age: 26.12 ± 3.94 years) participated in the study at the German Aerospace Research
Facilities (DLR, Cologne, Germany) on two different occasions (M1: October 2005; M2:
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March 2006). On each occasion, 4 days of adaptation and baseline assessments were followed
by a 14-days strict BR-HDT and 3 days of recovery. During BR-HDT subjects received two
different diets varying in sodium content (low: 50 mmol/day; high: 550 mmol/day) (LSD,
HSD), such that half of the subjects received the LSD while the other half received the HSD
during M1, and conditions were switched for M2. Gastric emptying (assessed by 13C
octanoid acid breath test) of a solid standardized meal was determined as T1/2 (= half
emptying time, in min) using an infrared spectroscopy technique (IRIS, Wagner Analysente-
chnik, Bremen, Germany) during the run-in phase (day 2) on a normal diet, and after 7
days of HDT-BR during both M1 and M2. Baseline T1/2 were compared to BR-HDT values
for both diet conditions by t-tests for dependent samples (adjusted to α/3 = 0.05/3 = 0.16).
In addition, percent 13C exhalation per hour data across the 17 breath sample were used
to compute average 13C exhalation curves for baseline and BR-HDT conditions, and were
analysed by repeated measure ANOVA. RESULTS: T1/2 during adaptation was not different
for M1 and M2 (M1: 125.57 ± 20.86 min; M2: 122.68 ± 20.13.36 min). The comparison
between LSD and HSD showed a significant difference (LSD: 129.67 ± 23.87 min; HSD:
137.02 ± 11.76 min; p = 0.003). ANOVA revealed a significantly lower relative exhalation
per hour during BR-HDT versus baseline independent of the diet (p=.001). CONCLUSION:
We found that BR-HDT significantly prolonged gastric emptying and reduced overall 13C
exhalation, and this effect was stronger with a high sodium content of food. Thus, “space
anorexia” may in part be due to a delay in gastric emptying during zero-G, and dietary
factors may further contribute to it.
T1913
Upregulation of NMDA-NR1 Subunit in the Dorsal Root Ganglia (DRG) and
Esophagus Following Acid Exposure in Cats
Banani Banerjee, Bidyut K. Medda, Yue Zheng, Jyoti N. Sengupta, Reza Shaker
Background: N-methyl-D aspartate (NMDA) receptors are present in the peripheral and
central terminals of primary afferent neurons and appear to play an important role in
the development of visceral hyperalgesia. Understanding about the involvement of NMDA
receptors in acid-induced esophageal hypersensitivity is evolving. Our aim was to investigate
the effect of intraesophageal acid (0.1N HCl) infusion on the expression of NR1 and NR2
subunits of NMDA receptor in cat DRG (T1-T3) and distal esophagus. Method: Four groups
of animals (n=3, each) were studied. Group 1: received acute acid (Ac-A) exposure (0.1N
HCl, 1ml/min for 30 min); Group 2: PBS (Ac-P) infusion similarly; Group 3: chronic infusion
(Ch-A) of acid (1ml/min for 30 min/day for 5 days) and Group 4: chronic PBS (Ch-P)
infusion similarly for 5 days. Results: In DRGs, acute and chronic acid treatment resulted
in 16 and 8 fold increases in NR1 gene expression, respectively over the PBS-treated
cats.(Figure) In the esophagus (Eso), increase in expression was 4.6 and 8 fold in acute and
chronic acid-treated, compared to PBS-treated cats. No differences were observed in NR2A
and NR2D expression between acid- and PBS-treated animals. DRGs exhibited a 4 fold
increase in NR1 protein expression (Western Blot) in chronic acid treated cats compared
to PBS-treated cats. In immunohistochemistry, the intensity of NR1 expression in cells was
markedly higher in DRGs from chronic acid-treated cats compared to PBS group. Conclusions:
The NR1 subunit of NMDA receptor is upregulated in the DRG and esophagus by acute
and chronic esophageal acid exposure suggesting their involvement in the development and
modification of symptoms induced by gastroesophageal acid reflux. Supported in part by
R01 DK062312-01A2 and R01 DK025731-25.
T1914
Cholinergic Stimulation and Antagonism Induces Discordance Between
Circular and Longitudinal Muscle Contraction During Swallow-Induced
Peristalsis in the Normal Healthy Subjects
Hariprasad R. Korsapati, Arash Babaei, Valmik Bhargava, Ravinder K. Mittal
Introduction: Circular (CM) and longitudinal muscle (LM) of the esophagus are perfectly
coordinated during swallow-induced peristalsis in normal subjects. Patients with high ampli-
tude esophageal contractions of the esophagus (nutcracker esophagus) show discordance
between the 2 muscle layers, with the peak of contraction 1-3 seconds apart. Our goal was
to determine the effects of antagonist and agonist on the synchrony of the 2 muscle layers.
Methods: Intra-luminal ultrasound imaging and manometry were simultaneously recorded
for LM and CM contraction during swallow-induced peristalsis in 6 normals. A catheter
with 4 side holes located at the same axial location, and an US transducer placed in a water
balloon (same diameter as the catheter) was used for these studies. The US transducer was
located close to the side hole. Standardized 5 ml water swallow were recorded 2 cm above
the LES under 3 study conditions; Control, Edrophonium (IV 80 µgms/kg), and Atropine
(IV 5 µgms/kg). Data Analysis: M- mode images were created and aligned with esophageal
pressure signals to determine temporal correlation between the pressure events (CM contrac-
tion) and muscle thickness (LM contraction). Time difference between peaks of LM and
CM, and duration of LM and CM contraction were determined. Results: A close temporal
correlation existed between the peak pressure and peak wall thickness at control. After
Edrophonium, duration of both CM and LM contractions were increased and showed greater
asynchrony. After Atropine duration of contraction of both layers decreased with lesser
degree of asynchrony (vs Edrophonium). Conclusion: Cholinergic stimulation and antagon-
ism affects CM and LM differently and induces discordance between the two muscle layers
in normal subjects.
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T1915
New Evidence for Functional Hemispheric Asymmetry in the Cortical Control
of Human Swallowing: A 'Virtual Brain Lesion' Study
Satish Mistry, Eric Verin, Salil Singh, Samantha Jefferson, John C. Rothwell, Shaheen
Hamdy
BACKGROUND: Swallowing cortical control is bilateral but displays interhemispheric asym-
metry with dominant and non-dominant projections. However, the relationship between
these projections and their functional relevance is unclear. AIMS: By using 1Hz repetitive
transcranial magnetic stimulation (rTMS) induced ‘virtual lesions', applied to the bilateral
representations of human swallowing motor cortex (SMC), we aimed to establish the relevance
of functional asymmetry in the control of swallowing. METHODS: Eight right handed healthy
subjects (5M/3F; 26-47 years) participated. Single pulse TMS combined with pharyngeal
motor evoked potentials (PMEPs), recorded via a swallowed intraluminal catheter, were
used to assess SMC of both hemispheres. The hemisphere evoking the largest PMEPs was
termed 'dominant' (D-SMC), the other, contralateral ‘non-dominant' (ND-SMC). Swallowing
reaction time tasks were used to assess behaviour and comprised 3 cued tasks: normal, fast
and challenged swallows (within a 150ms time window) Baseline swallowing measurements
were followed by 10 minutes of 1Hz rTMS (active to D-SMC/ND-SMC and sham, randomised
to separate days). Swallowing measurements were then repeated, immediately (0), 30 and
60 minutes post-rTMS. Baseline vs. intervention data (active and sham) were analysed with
ANOVA. RESULTS: Compared to baseline, D-SMC rTMS displayed a reduction in both
normal (-12±3%, p<0.01) and fast (-9±4%, p<0.018) swallow reaction times (figure 1). ND-
SMC rTMS and sham had no effect. Moreover, challenge swallows showed a rise in successful
“hits” following sham (p<0.041) but no change following active rTMS to either hemisphere.
CONCLUSION: Our data demonstrate clear differences in swallowing behaviour following
virtual lesions to each hemisphere providing compelling evidence for functionally relevant
asymmetry in the swallowing motor system.
T1916
Electroacupuncture Decrease Transient Lower Esophageal Sphincter
Relaxation Via NO, CCK-A and Mu-Opioid Pathways in Cats
Chi Wang, Defeng Zhou, Xiaowei Shuai, Jianxiang Liu, Hongxia Hu, Pengyan Xie
Background: Transient lower esophageal sphincter relaxation (TLESR) is one of the most
important mechanisms underlying gastroesophageal reflux. As we know, the frequency of
gastric distention-induced TLESR can be influenced through the pathway of GABA-B, CCK-
A ,morphine, nitric oxide (NO) and acetylcholine. Traditionally, stimulation at the Neiguan
(pericardial meridian) has been used for treating functional gastrointestinal disorders. Aims:
We investigated the effects of electroacupuncture (EA) at Neiguan on gastric distention-
induced TLESR and to determined the mechanisms of this treatment. Methods: Protocol 1:
Twelve healthy cats were underwent gastric distention on the first day. Electrical acupoint
stimulation was applied at the Neiguan and a sham point on the hip in randomized order
on the third day and fifth day during gastric distention. We observed the frequency of
TLESRs and LES pressure by a perfused sleeve assembly. Protocol 2:Thirty six healthy cats
were divided into 6 groups randomly. We give saline(2ml iv.), phaclfen(5mg/kg iv. GABA-
B antagonist), CCK-A(1ug/kg/h iv.), L-Arginine(200mg/kg iv.), naloxone(2.5umol/kg iv.)
and tacrine(5.6mg/kg ip. cholinesterase inhibitor) respectively before EA at Neiguan and
gastric distention, and observed the frequency of TLESR and LES pressure. Results: The
frequency of gastric distention-induced TLESR in 60 min was significantly decreased by EA
at Neiguan(5 ± 4.04, n=12) compared to that of controls(9.58 ± 3.99, n=12, P<0.05). This
decrease was complete restored by pretreatment with CCK-A (26.1±17.6 vs 5.7±3.67, n=
6,P<0.05) ,L-Arginine(19.7±12.9 vs 5.7±3.67,n=6,P<0.05) and naloxone(14±6.1 vs
5.7±3.67, n=6,P<0.05) .On the contrary, the effect of acupoint stimulation was not inhibited
by phaclofen(5.33±2.9 vs 5.7±3.67, n=6,P>0.05) and tacrine(12±7.9 vs 5.7±3.67, n=
6,P>0.05). Acupoint stimulation at Neiguan had no effect on basal LES pressure(34.3±18.2
vs 37.7±18.7, n=12,P>0.05). Conclusions: Electric acupoint stimulation at the Neiguan
significantly inhibits the frequency of TLESR induced by gastric distention in cats. This
effect appear to be mediated through NO, CCK-A receptor and mu-opioid receptors. But
the GABAB receptor and acetylcholine were not involved in it. This research was defrayed
by National Nature Science Foundation of China. The application code is C03050309.
Address correspondence to: Dr PengYan Xie, E-mail: xiepengyan@medmail.com.cn
T1917
The Laplace Law Is Incorrect to Measure Gastro-Intestinal Wall Compliance
with Concurrent Imaging and Manometry: We Propose a Replacement
James G. Brasseur
The Laplace law is commonly used in the gastrointestinal community to estimate wall
stress and tension from manometric measurements of intraluminal pressure, together with
geometrical information on lumen cross section. Cross sectional data are typically obtained
using impedance planimetry, endoluminal ultrasound, and radiography. To quantify the
compliance of the muscle wall, in many works the stress computed with the Laplace law
is plotted against the relative distension of the lumen in order to estimate the “stiffness” of
the muscle wall (i.e., elastic modulus) from the slope of a stress vs. strain curve. However,
the Laplace “law” is a simple application of Newton's law force balance for the case when
muscle layer thickness T is vanishingly small compared to the lumen radius R. From the
derivation, one can estimate that the Laplace law is valid in the GI tract only when T/R is
less than ~0.01. In the esophagus, for example, T/R varies from about 0.7 in the resting
state to about 0.12 at full distension. Furthermore, to obtain true stiffness, only the part of
the stress related to distension should be plotted against strain. We have analyzed the validity
of the Laplace law for application to the GI tract, and we propose a replacement to the
Laplace law that is valid for quantifying true stiffness GI wall muscle. METHOD. We solved
exactly the model problem of an axisymmetric distended cylinder of muscle of arbitrary
thickness, linearly elastic homogenous material without residual wall stress. Using geometry
and parameters from physiological data for the esophagus, we analyzed the Laplace law in
detail. We developed a more accurate alternative and compared it to the Laplace law.
RESULTS. The Laplace law is not even approximately valid for predicting total stress in GI
applications at all real distensions. Although the way in which the Laplace law is generally
misused gives it qualitatively sensible behaviour, it is still in error by 40-80%, depending
on the degree of lumen distension. We derive a replacement to the Laplace law that is exact
for the model problem, and much more accurate in GI applications. CONCLUSIONS. The
Laplace law should not be used for estimating stress in the GI tract due to the thick nature
of the luminal wall. In its place we provide a new equation that is applicable to the GI tract
and other biological tubular vessels such as the arteries.
T1918
Eating Detection Using Lower Esophageal Sphincter (LES) Electrical Activity
Claudia P. Sanmiguel, Yuichiro Ito, Masanobu Hagiike, Jeffrey Conklin, Edy Soffer
Background: Electrical activity of the LES has been recorded mainly In Vitro and in anesthet-
ized animals. Swallowing produces an initial relaxation followed by contraction of the LES.
These changes should be related to specific changes in LES electrical activity. Aim: to
determine if there are characteristic changes in LES electrical activity that might potentially
be used to recognize the beginning of a meal. Such recognition can be useful when electrical
stimulation is given in conjunction with food, e.g. treatment of obesity. This is the first
chronic study to use electrodes implanted in the LES to measure its electrical activity.
Methods: 3 female mongrel dogs underwent an esophagostomy that allowed the introduction
of a sleeve manometry catheter into the esophagus. A bipolar electrode was implanted along
the longitudinal axis of the LES and connected to an implantable recording device. After
recovery, they underwent 2 tests: 1- telemetric recordings of LES electrical activity, 1 hour
fasting and 1 hour postprandial (400g of canned dog food). 2- Combined recordings of LES
electrical recording and esophageal manometry to test the effect of dry swallows, wet swallows
and also solid food swallows on LES electrical activity as follows: 20min for spontaneous
dry swallows, 20 min before and after the swallows of 10ml of water and 20 min before
and after the ingestion of 400gr of canned dog food. All amplitudes in mV, mean±SD,
ANOVA p<0.05. Results: Test 1: There was a dramatic and characteristic increase in amplitude
of LES activity during feeding: amplitude of 0.22±0.06 , fasting vs. 1.08±0.18 meal vs.
0.29±0.11 post-prandial, p<0.001, Figure. Test 2: LES electrical activity was also related to
the type of substance being swallowed: 0.34±0.2 baseline, vs. 0.52±.0.15 dry swallows, vs.
0.83±0.13 wet swallows, vs.1.22±0.23 solid meal swallows p<0.001. Conclusions: Beginning
and duration of meal can be identified by distinct, easily recognizable changes in the
amplitude of LES electrical activity. These changes also depend on the type of substance
being swallowed (saliva, liquid and solids), and are most prominent with solid food. Changes
in LES electrical activity can potentially be used for eating detection.
A-583 AGA Abstracts
T1919
Esophageal Tone and Sensation in the Transition Zone Between Proximal
Striated and Distal Smooth Muscle Esophagus
George Karamanolis, Fernando Fornari, Rita Vos, Jan Tack, Pere Clave, Daniel Sifrim
Previous studies have shown that the proximal striated muscle esophagus is less compliant and
more sensitive than the distal smooth muscle esophagus. Conventional and high resolution
manometry described a transition zone between striated and smooth muscle esophagus. We
aimed to evaluate tone and sensitivity of the esophageal transition zone in healthy volunteers.
Methods: Esophageal barostat was performed in 18 subjects (7 men, mean age: 28 yrs).
Tone and sensitivity were assessed using stepwise isobaric distensions with the barostat
balloon located at the transition zone and the smooth muscle esophagus. To study the effect
induced on smooth muscle esophageal tone and compliance by a previous distension at the
transition zone and vice versa, identical protocol was repeated after 7 days with inverted
order. Initial distension of a region is referred to as “naïf” distension. When distension of
a region followed the distension of the other segment is referred to as “primed” distension.
Assessment of 3 esophageal symptoms (chest pain, heartburn and “other”) was obtained at
the end of every distension step. Results: With “naif” distensions, compliance was signific-
antly higher in the transition zone than in the smooth muscle esophagus (1.47±0.14 vs.
1.09±0.09 ml/mmHg, p=0.03). This difference was not observed during “primed” distensions.
Higher sensitivity at transition zone level was found in 11/18 (61%) subjects compared to
6/18 (33%, p<0.05) at smooth muscle esophagus. Chest pain and “other” symptom were
more often induced by distention of the transition zone, whereas heartburn was equally
triggered by distension of either region. Conclusions: The transition zone is more complaint
and in 60% of the subjects more sensitive than smooth muscle esophagus.
T1920
Phospholipases Mediating Prostaglandin F2α (PGF2α)-Induced Contraction of
Human Lower Esophageal Sphincter Circular Smooth Muscle
Weibiao Cao, Karen M. Harnett, Jose Behar, Piero Biancani
We have previously shown that PGF2α contributes to maintenance of Lower Esophageal
Sphincter (LES) tone. In the present investigation we used circular smooth muscle cells
isolated by enzymatic digestion from human esophagus (ESO) and LES to examine the
contractile signal transduction pathway activated by PGF2α. PGF2α (10-11 to 10-7M) caused
dose-dependent contraction of ESO and LES. In ESO contraction in response to a maximal
dose of PGF2α was reduced by the phospholipase D (PLD) inhibitor propranolol, but not
by the selective phosphatidylcholine specific phospholipase C (PC-PLC) inhibitor D609 and
the phosphatidylinositol specific phospholipase C (PI-PLC) inhibitor U73122. In addition,
PGF2α-induced contraction of ESO was inhibited by the PKC antagonist chelerythrine, and
not affected by the calmodulin antagonist CGS9343B. These data indicate that ESO PGF2α
receptors activate a PLD and PKC-dependent pathway. In LES contraction in response to a
maximal dose of PGF2α was inhibited by U73122, D609, CGS9343B and chelerythrine, and
not affected by propranolol. In addition, PGF2α-induced contraction of LES was significantly
reduced by PI-PLCβ2 antibody, but not by PI-PLC β1, β3, β4, γ1, γ2, δ1, or δ2 antibody.
PGF2α-induced contraction of ESO was not affected by PI-PLC β1, β2, β3, β4, γ1, γ2, δ1,
or δ2 antibody. Western blot analysis showed that PI-PLC β2, β4, γ1, and γ2, but not β1,
β3, δ1, and δ2, were present in LES circular muscle. LES contraction in response to low
dose of PGF2α was inhibited by chelerythrine, but not by CGS9343B. These findings suggest
that in LES PGF2α at high dose activates a PI-PLC β2- and calmodulin-dependent pathway,
and at low dose a PC-PLC- and PKC dependent-pathway. Because LES tone of In Vitro
circular muscle strips, like single-cell contraction induced by low dose of PGF2α, is PKC-
dependent, the PC-PLC-dependent pathway may be relevant to maintenance of tone. Sup-
ported by NIH RO1-DK-28614.
T1921
Mechanisms of Intracellular Trafficking and Membrane Targeting of the
Human Sodium-Dependent Multivitamin Transporter (Hsmvt) in Polarized
Intestinal Epithelial Cells
Veedamali S. Subramanian, Jonathan S. Marchant, Hamid M. Said
Background: The human sodium-dependent multivitamin transporter (hSMVT) mediates
sodium-dependent cellular transport of the water-soluble vitamin biotin, a vitamin essential
for normal cellular functions and human health. Humans have lost the ability to synthesize
this vitamin, and thus, must obtain the vitamin from exogenous sources via absorption
through intestinal epithelia. Previous studies from our laboratory and others have shown
that the intestinal biotin transport process is saturable and Na-dependent in nature and
involves the hSMVT system. To date, however, there is nothing known about the mechanisms
involved in intracellular trafficking of the hSMVT protein and about the sorting sequence
in the hSMVT polypeptide that dictate its expression at the cell membrane of intestinal (and
renal) epithelial cells. Our aim in this study was to address these issues. Methods: We used
live cell (Caco-2 and MDCK) confocal imaging to determine the localization of full-length
hSMVT and truncated constructs fused to green fluorescent protein (GFP). 3H-Biotin uptake
was performed to determine the functional distribution of the over expressed hSMVT and
truncated constructs. Results: The full-length hSMVT protein fused to the GFP (hSMVT-
GFP) was found to be expressed exclusively at the apical membrane of living Caco-2 and
MDCK cells and was functional. Apical delivery of hSMVT was impaired by microtubule
disrupting agents. Evidence for the involvement of trafficking vesicles in the intracellular
trafficking of the hSMVT was also found. Expressing the dominant-negative dynamitin (p50),
a component of the dynactin complex, led to disruption in the apical delivery of hSMVT
thus suggesting a role for the minus-end directed microtubule motor protein dynein in
regulating the polarized delivery of hSMVT to the apical cell surface. Targeting of the hSMVT
protein to the apical membrane was found to be determined by a sequence in the cytoplasmic
C-terminal tail of the protein as truncations of this region led to a decrease in apical expression
of the hSMVT polypeptide. Conclusion: These results show for the first time that apical
delivery of hSMVT in epithelial cells depends on an intact microtubule network and on
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cytoplasmic dynein. In addition, the molecular determinant(s) that dictate expression of the
hSMVT protein at the apical membrane of polarized intestinal (and renal) epithelial cells is
embedded in the cytoplasmic tail of the protein. [Supported by grants from the DVA and
NIH (DK 56061, DK 58057 and DK 71538)].
T1922
Hcp, But Not Dcytb, Co-Migrates with Dmt1 from the Apical Surface to the
Cytoplasm of the Intestinal Epithelium After Iron Or Heme Feeding
Kwo-yih Yeh, Yeh Mary, Jonathan Glass
Iron, an essential nutrient, is mostly absorbed in the duodenum. To understand the molecular
biology of iron absorption, we have assayed gene expression by microarray analysis of
duodenal crypts and villus tops and identified as preferentially expressed in the villus tops
genes involved in iron uptake including duodenal cytochrome b (Dcytb), divalent metal
transporter (DMT1), ferroportin and hephaestin, and genes involved in heme uptake/excre-
tion including heme carrier protein (HCP1) and Abcg2. Using anti-sera raised against rat
Dcytb, DMT1, HCP1 and HO-1 and commercially available anti-Abcg2 antibodies, we
identified these proteins as being highly expressed on the brush border membrane (BBM)
of rat duodenal enterocytes. The presence of multiple proteins in the BBM provides a
model to address their functional relationship during iron and heme absorption. We used
immunofluorescent staining to observe subcellular location of the various proteins at 0, 30,
60, and 120 min after luminal infusion of iron (50 µM in FAC) or heme (100 µM in Hemin).
Specificity of the antibodies was confirmed by western blot analysis of duodenal lysates with
competition with the immunizing antigens. DMT1 was responsive to iron infusion with
migration from the BBM to cytoplasm most markedly at 60 and 120 min. Heme infusion
also generated DMT1 internalization at similar intensity at the same times. Interestingly,
both iron and heme infusion also stimulated HCP1 internal migration but at different rates
with iron slower than heme. Interestingly, Immunoreactive HCP1 increased gradually in
the basal lateral membrane (BLM) in association with BBM decreases. Western analysis
showed that after 60 min of iron and heme infusion, a 60% and 85% reduction of HCP1
in BBM respectively. At 120 min, HCP1 in the BBM was still reduced in the iron treated
rats but was recovering in heme infused animals. In contrast, Dcytb and Abcg2 were mostly
retained in the BBM at all times after iron or heme exposure suggesting a protein specific
phenomenon. To verify the movement of DMT1, HCP1 and Dcytb, rat DMT1, HCP1 and
Dcytb cDNAs were inserted into pEmGFP vectors and transiently transfected into Caco2
cells. The results showed internalization induced by iron or heme of EGFP-DMT1 and
EmGFP-HCP1, but not EmGFP-Dcytb. Thus, HCP1 and DMT1 co-migrated from the BBM
to cytoplasmic domains in response to luminal iron or heme and the migration was specifically
stimulated as Dcytb and Abcg2 remained in BBM. The physiological significance of HCP1
and DMT1 internalization in iron absorption remains to be determined. Supported by NIH
DK 065101 and DK 41279
T1923
Transgenic Rescue of Fatty Acid Transport Protein 4 (Fatp4) Mutant Mice
Indicates a Role for the Acyl-CoA Synthetase (Acs) Domain But Reveals That
Fatp4 Is Not Essential for Intestinal Lipid Absorption
Casey L. Moulson, Meei-hua Lin, Elizabeth P. Newberry, Jeffrey H. Miner, Nicholas O.
Davidson
Fatty acid transport protein 4 (FATP4), one of six members of the FATP multigene family,
has been hypothesized to be the major small intestinal fatty acid transporter. We previously
demonstrated that Fatp4 null mice are born with a defective epidermal barrier and die
shortly after birth due to restricted movement and dehydration. We have now rescued the
Fatp4 null mutation using a skin-specific FATP4 transgene that is expressed in granular
epidermal keratinocytes. Rescued mice are fertile and survive well into adulthood with FATP4
expressed only in skin, hair follicles, and some stratified squamous epithelia. Importantly,
transgene-derived mRNA and protein are not expressed in small intestinal enterocytes. We
used the same promoter to express a mutant form of FATP4 (mutFATP4) which does not
mediate fatty acid uptake In Vitro. FATP4 null mice expressing mutFATP4 exhibited the
usual skin phenotype, indicating that FATP4's fatty acid transport activity is required for
normal skin development. We also used the FATP4 transgene-rescued mice to determine
whether intestinal expression of FATP4 is required for normal lipid absorption. Intestinal
morphology of the rescued mice appeared grossly normal, and there was no significant
upregulation of other fatty acid transporters in the intestine. When consuming a normal
(low fat) chow diet, the rescued transgenic mice were hyperphagic, consuming approximately
10% more food than normal mice in order to maintain weight gain. When placed on a
high-fat Western diet for several weeks, however, rescued FATP4-tg mice exhibited only a
0.8% reduction in dietary lipid absorption measured by fat balance studies. The rescued
FATP4-tg mice also exhibited reduced serum triglycerides and cholesterol. These results
collectively suggest that the fatty acid transport activity of FATP4 is required for its function,
has a role in lipid metabolism, but seems dispensable for intestinal lipid absorption.
T1924
Hepatic Steatosis in Developing Rats from Dams Subjected to a Methyl
Deficient Diet Is Related to a Defective Synthesis of Carnitine
Sebastien Blaise, Jean-marc Alberto, Jean-luc Daval, Benedicte Nicolas, Jean-louis Gueant
Background: neonatal hepatic steatosis may be associated with genetic disorders of homocyst-
eine metabolism. In contrast, the neonatal consequences of a diet deficient in methyl pre-
cursors, folate, vitamin B12 and betaine, on fatty acid oxidation are unknown, despite a 6-
fold increase of carnitine synthesis during the perinatal period. Aim: to investigate these
consequences in rat pups with an early nutritional deprivation in these precursors. Methods:
pups were from dams fed during gestation with either a standard diet or a diet deficient in
folate, B12, and choline. Diets were maintained until weaning of the offspring at postnatal
day 21. Results: a microvesicular steatosis was observed in 21-day-old deprived pups,
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with a higher liver concentration of total lipids and triglyceride. Plasma homocysteine was
substantially increased, vitamin B2 unchanged, and vitamin B12 and folate dramatically
decreased. In the liver, there was no change in superoxide dismutase activity, an increased
level of malondialdehyde (MDA), a drop in total glutathione and glutathione peroxidase
activity, and a decreased level of total and free carnitine. Free carnitine and acylcarnitines were
correlated with concentrations of folate, S-adenosylmethionine and S-adenosylmethionine/S-
adenosylhomocysteine ratio. Liver cytochrome c N-lysine methyltransferase was characterized
by a KM at 29 µM for S-adenosylmethionine and an inhibition constant for S-adenosylhomo-
cysteine at 34 µM. The S-adenosylmethionine/S-adenosylhomocysteine ratio in the liver of
deprived rats was responsible for a 50% decrease of the enzyme activity. Reintroduction of
a normal diet after weaning (from day 21 up to day 80) restored a normal histology and
metabolic markers.In particular, the liver tissue did not present any inflammatory, fibrotic
or necrotic lesion. Conclusion: we have evidenced an association between early deficiency
in methyl precursors, carnitine synthesis and neonatal steatosis that could be involved in
the pathogenesis of neonatal liver steatosis, in a context of deficiency in folate and vitamin
B12 during pregnancy.
T1925
Deletion of Tis7, An Immediate Early Gene Induced in the Adaptive Gut Post-
Resection, Protects Mice from High Fat Diet-Induced Weight Gain
Cong Yu, Jenny Jiang, Yuan Wang, Elzbieta Swietlicki, Hristo Iordanov, Lihua Wang, Ilja
Vietor, Marc S. Levin, Deborah C. Rubin
Following loss of functional small bowel surface area due to surgical resection, the remaining
intestine undergoes an adaptive response characterized by increased crypt cell proliferation,
enhanced villus height and crypt depth, resulting in increased absorptive capacity. We have
previously shown that expression of the immediate early gene tis7 is markedly upregulated
in adaptive enterocytes. Transgenic mice that overexpress TIS7 in the intestine have increased
whole body adiposity, decreased lean muscle mass, decreased oxygen consumption, but
accelerated triglyceride absorption, and a more rapid and proportionately greater weight
gain on a high fat diet, compared to normal littermates. These results suggested a role for
TIS7 as a unique mediator of nutrient absorptive and metabolic adaptation. To further clarify
the mechanisms by which TIS7 promotes functional adaptation, male tis7-/- or wild type
(WT) littermate mice (kind gift L. Huber and I. Vietor;n=5 mice per group, experiment
repeated twice) were fed a high fat diet (21% w/w with 42% total cals. from fat) for 3
months. WT mice weighed significantly more than tis7-/- mice (p<0.05) after 1-2 months
on the high fat diet, and this difference persisted up to three months after the start of the
high fat diet. Whereas WT mice continued to gain weight on the high fat diet throughout
the three month period, weights of tis7-/- mice remained unchanged between 1 and 2
months and then began to increase. Fasting serum triglyceride, cholesterol and free fatty
acid levels were significantly lower in tis7-/- mice compared to WTs (p<0.01). There was
no difference in oxygen consumption (VO2 by Oxymax) or food consumption between WT
and tis7-/- mice. These results provide further evidence that TIS7 is a mediator of intestinal
triglyceride/fat absorption and metabolism and thus plays a role in functional adaptation
following gut resection.
T1926
Role of the Vitamin D Receptor in Vitamin D-Mediated Calbindin D(9k)
Expression in Caco-2 Cells
Vishal Bhagat, Valerie Andersen, Michael D. Sitrin
Introduction: Variation in intestinal vitamin D receptor (VDR) level has been proposed to
explain differences in the responsiveness of intestinal calcium absorption to 1,25 dihydroxyvi-
tamin D3 [1,25(OH)2D3]. However, in several studies VDR knockout mice showed only
modest reduction in intestinal calbindin D(9k) expression, a protein thought to play a critical
role in calcium transport. In the present study, we examined the role of the VDR in vitamin
D-mediated calbindin D(9k) expression in CaCo-2 cells. Methods: CaCo-2 cell lines were
stably transfected with a full length human VDR complementary DNA (cDNA) transgene
to increase cellular VDR content. Monoclonal cell lines (SG, SL, SP) were derived from serial
dilutions of the original polyclonal VDR transfectants (PS). EV7, EV11 and EV20 were
monoclonal cell lines derived from serial dilutions of CaCo-2 cells transfected with the
empty vector (PEV). These cell lines were treated either with ethanol or 10-7M 1,25(OH)2D3
for 4 days and calbindin D(9K), vitamin D 24-hydroxylase and VDR mRNAs quantified
using real-time PCR. The vitamin D 24-hydroxylase is highly transcriptionally regulated by
the VDR in intestinal cells. Human GAPDH mRNA expression was used as a housekeeping
gene to normalize the data. VDR protein levels in the cell lines were assessed by Western
immunoblotting. Data presented are the mean of 4-6 experiments. Results: VDR mRNA and
protein levels were significantly higher in the VDR transfectants than in the empty vector
controls. VDR levels were not affected by 1,25(OH)2D3 treatment in any cell line (data not
shown). 1,25(OH)2D3 treatment increased both the 24-hydroxylase and calbindin D(9k)
mRNA levels more in the VDR transfected cells than in the empty vector controls. In all
cell lines, 1,25(OH)2D3 stimulated the 24-hydroxylase mRNA expression far more than the
calbindin D(9k) expression. Conclusions: Vitamin D-dependent expression of calbindin
D(9k) in CaCo-2 cells is affected by the VDR content, but much less than expression of
vitamin D 24-hydroxylase.
T1927
Carbohydrate Digestion and Absorption in a Rat Model of Cholestasis
Leonie Los, Henk Wolters, Rick Havinga, Theo Boer, Klaas Bijsterveld, Juul Baller, Frans
Stellaard, Folkert Kuipers, Henkjan Verkade, Edmond Rings
Introduction: Cholestasis in children is frequently accompanied by an impaired nutritional
status, which decreases the chances of long-term survival. We previously showed in a rat
model of cholestasis that fat malabsorption importantly contributes to fecal energy loss (AJP
2000; 279:G1242-8). It is unclear, however, whether cholestasis also decreases the capacity
to absorb other macronutrients In Vivo, for example by interfering with small intestinal
differentiation. We reasoned that absorption of carbohydrates could serve as a quantifiable
marker for intestinal absorptive capacity during cholestasis. Aim: To determine the effect
of cholestasis on carbohydrate digestion and absorption in a rat model for obstructive
cholestasis In Vivo. Methods: Male Wistar rats underwent bile duct ligation (cholestatic group)
or sham operation (controls), (n=5-6 per group). Carbohydrate digestion and absorption were
assessed by bolus administration of 1 mg 2H-glucose and 0.25 g naturally enriched 13C-
sucrose via a duodenal catheter (ID), and subsequent determination of plasma 2H-glucose
and 13C-glucose concentrations, resp. (mass spectrometry). Gene expression and enzyme
activity of disaccharidases (sucrase) and gene expression of monosaccharide transporters
(Sglt1, Glut5 and Glut2) were quantified in duodenum, jejunum and ileum by RT-PCR and
enzymatic assays, resp. Results: Within 7.5 min after ID administration, plasma concentration
of 2H-glucose peaked to a similar extent in cholestatic and control rats (27±15 and 24±13
μmol/L, resp., NS). The plasma appearance of sucrose-derived 13C-glucose was slower, with
peak levels at 30 min, similarly in cholestatic and control rats (1.3±1.6 and 2.0±1.2 mmol/
L, resp., NS). mRNA levels and enzyme activity of sucrase did not differ between cholestatic
and control rats at any small intestinal segment, and neither did mRNA levels of the
monosaccharide transporter genes Sglt1, Glut5 or Glut2. Similar results were obtained in
rats with bile diversion for 1 week (n=6), i.e. with similar intestinal bile deficiency but without
cholestasis. Conclusions: Intestinal deficiency of bile salts, with or without cholestasis, does
not impair intestinal carbohydrate digestion or absorption in rats. These observations suggest
that increasing the dietary carbohydrate intake can counteract a poor nutritional status
induced by fat malabsorption in cholestatic children.
T1928
Wheat Dextrin (WD), Inulin, and Partially Hydrolyzed Guar Gum (PHGG)
Produce Unique short-Chain Fatty Acid Concentrations in Model Colonic
Fermentation
Maria L. Stewart, Hollie A. Rushton, Alberto Paredes-diaz, Vincenzo Savarino, Joanne L.
Slavin
Dietary fibers are fermented in the colon resulting in lowering of colonic pH, changes in
microflora, and production of short chain fatty acids (SCFA). Fiber fermentability is difficult
to study In Vivo due to the invasiveness of colon studies, the dynamic nature of the colon,
and rapid absorption of SCFAs from the colonic lumen shortly after they are produced.
No method has been developed to accurately measure SCFA absorption. Studying fiber
fermentability in a closed laboratory system provides an estimate of fiber fermentability
without losing SCFA to absorption. An In Vitro batch fermentation system with human fecal
inoculum was used to mimic colonic conditions. Samples were removed at 0, 4, 8, 12, and
24 hours. Glucose was used as a positive control to ensure active fermentation of the system.
This study determined the SCFA production of 3 fermentable fibers: WD, inulin, and PHGG.
Each of these fibers finds application in clinical nutrition since they are non-viscous and
can be easily added to foods and beverages. Total SCFA, acetate, propionate, and butyrate
were measured by gas chromatography. All fibers were readily fermented in the system,
although there were differences in rate of fermentation. At 24 hours, WD and inulin produced
significantly more total SCFA than PHGG (p=0.002). The total SCFA production with inulin
peaked at 4 hours, suggesting that it may cause excess gas production. In contrast, WD
produced a steady increase in total SCFA concentrations over 24 hours, while PHGG followed
a similar pattern until it reached a plateau at 8 hours. Acetate was the most prevalent SCFA
produced, about 49-70% of total SCFA production. WD produced significantly greater
concentrations of propionate at 12 and 24 hours than other fibers (p=0.002, p=0.003).
Propionate production with inulin was low over 24 hours. At 24 hours, WD and inulin
produced high concentrations of butyrate, an essential SCFA for colon health, but this was
not significantly different from PHGG. The time intervals between 0-4 hours and 4-8 hours
resulted in the highest fermentation rates for all fibers, suggesting that these products would
be fermented primarily in the proximal colon. WD had positive fermentation rates for all
SCFAs at all time intervals. The proportion of acetate, propionate, and butyrate production
with WD (49:39:12) and PHGG (50:38:12) were similar, while inulin was primarily an
acetate producer (70:16:15). WD, inulin, and PHGG showed a unique pattern of SCFA
production during the 24 hour fermentation. Fermentation properties and physiological
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effects of SCFA should be considered when recommending the addition of a fermentable
fiber to the diet.
T1929
Changes in Jejunal Enterocyte Protein Patterns Involving Endoplasmic
Reticulum (ER)-Stress in Mice Fed a High Fat Diet
Per-göran Gillberg, Henrik Ortsäter, Peter Bergsten
Aim: High fat diet (HFD) leads to that enterocytes are exposed to elevated levels of fatty
acids and bile acid. In the present study mice were fed HFD or normal fat diet (NFD) with
the aim to determine how such elevated levels affected protein expression of enterocytes
from different parts of the gut. Methods: Male C57BL/6J mice were fed with NFD (5%
fat) or HFD (50% fat). Body weight, blood glucose, serum insulin, cholesterol, 7-alpha-
hydroxylase-4-cholesten-3-on (C4, reflecting bile acid synthesis), lanosterol (cholesterol
synthesis) and sitosterol (cholesterol absorption) were measured at start of study, 5, 10, 15
and 20 weeks. At the end of the study, enterocytes were isolated from the jejunum, ileum
and colon and lysed. Levels of phosphorylated eIF2a (p-eIF2a), CHOP, PDI and BiP were
determined by western blotting. Protein patterns of enterocytes were obtained by surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry. Tissue specimens
were also preserved for histological examination using haematoxylin eosin. Results: Protein
profiling of enterocytes obtained from NFD animals resulted in about 40 defined peaks of
which several had a significantly higher expression in jejunum. Whereas jejunal enterocytes
isolated from HFD animals were 25 % taller (p<0.0001) than NFD animals, no difference
was observed in ileal and colonic enterocytes. When levels of ER-stress response proteins
were determined, chaperones BiP and PDI were elevated (p<0.05) in jejunal but not in ileal
enterocytes isolated from HFD animals compared to NFD animals. There was no change in
p-eIF2a or CHOP in the jejunum. After 20 weeks on HFD the cholesterol synthesis was
increased 3-fold and the cholesterol uptake was less than 50% compared to NFD animals.
In the HFD group serum cholesterol was increased after 5 weeks and continued to rise with
treatment time up to above 100% at week 20. In addition, C4 was not changed at the same
time point. The HFD animals did not show any significant increase in body weight when
compared with NFD group and had lower food consumption compared with control group.
Blood glucose and insulin levels were essentially not affected by the HFD. Conclusion:
Enterocytes showed regional differences in protein expression. HFD induced morphological
changes in jejunal enterocytes, which were associated with enhanced expression of chap-
erones without engaging pro-apoptotic pathways, indicating successful alleviation of jejunal
ER-stress.
T1930
Development of Primary Cultures of Mouse and Pig Enterocytes to Study Non-
Genomic Regulation of Intestinal Nutrient Absorption
Yasuhiro Kimura, Dwaine A. Braasch, Jerrold R. Turner, Randal K. Buddington
Lumenal exposure of intact mouse small intestine to 5 mM adenosine and adenosine 5'-
monophosphate disodium (AMP) rapidly (<10 min) and reversibly increases (~2-fold) glucose
uptake. Since the associated signaling networks and mechanisms of the responses are difficult
to define with intact tissues, we sought a relevant cultured cell model. The colon adenocarcin-
oma Caco-2 cell line is commonly used as an enterocyte model, yet exposure of Caco-2
cells to 25 mM adenosine and AMP rapidly and reversibly decreased glucose uptake by
70% and 15%, respectively. The contrasting responses relative to intact tissues may be
related to the different tissue sources and raise questions of relevance for evaluating adaptive
regulation of nutrient transporters In Vivo. IEC-6 cells, an undifferentiated cell line derived
from rat ileum crypt cells, exhibit low rates of glucose transport and minimal responses to
adenosine or AMP when cultured on plastic. Inducing IEC-6 differentiation by culturing
for 72 h on Matrigel, a cell attachment factor, with 100 nM dexamethasone for the final 24
h, increased glucose uptake by SGLT-1 and with 3.1- and 3.2-fold further increases after
exposure to 25 mM adenosine and AMP. We also explored primary cultures of enterocytes
for evaluating non-genomic regulation of glucose uptake. Enterocytes harvested from the
proximal small intestines of adult BALB/c mice and pigs were cultured on PET membrane
inserts (450,000 - 1,000,000 cells/insert) for 2, 4, 8, 12, and 24 h using DMEM supplemented
with 10% FBS, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.1 U/ml
bovine insulin (5% CO2; 37°C). Glucose uptake by mouse enterocytes (5 min accumulation of
4 µM 14C D-glucose) was maximal after 8 h, and exposure to 25 mM adenosine and AMP
further increased glucose uptake by 6- and 9-fold, with the response to adenosine exhibiting
concentration dependence. Compared to mouse cells, enterocytes from pigs have lower rates
of glucose uptake (per 100,000 cells) and a reduced response to 25 mM adenosine and
AMP (2.6- and 3.2-fold increases). Our findings indicate Caco-2 and IEC-6 cells provide
opportunities to explore the responses to regulatory molecules, the associated signaling
networks, and the mechanisms underlying bi-directional non-genomic regulation of nutrient
transporters. Primary cultures of freshly harvested enterocytes provide additional opportunit-
ies to evaluate regulation of nutrient transporters and other functions of enterocytes that have
been exposed to luminal conditions and host regulatory molecules, to obtain physiologically
relevant data, and for exploring differences among species, ages, and health states.
T1931
Evolutionary Expression of Glucose-Dependent Insulinotropic Polypeptide
(GIP)
Michelle C. Musson, Lisa I. Jepeal, M. michael Wolfe
Background: GIP is a potent stimulator of insulin secretion from pancreatic islet β-cells
and appears to function in concert with insulin to maintain nutrient efficiency, as well as
to promote obesity. A determination of the phylogeny of GIP, and in particular its relationship
to insulin, would serve to greatly improve our understanding of the precise role of GIP in
the development of obesity. Although GIP expression has been identified in mammals, little
information regarding this regulatory peptide in primitive vertebrates is presently available.
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Zebrafish and the sea lamprey represent two such vertebrates to develop distinct regions of
insulin secreting β-cells. Purpose: To characterize the expression and function of the GIP
gene in primitive vertebrates.Methods: cDNA was synthesized using total RNA from zebrafish
internal organs and the sea lamprey alimentary tract, and was amplified by PCR using
specific primers. A 431-bp GIP cDNA fragment from zebrafish was isolated and purified to
be used as probe for Northern analysis. PCR fragments of the full-length zebrafish GIP cDNA
were sequenced, cloned into a mammalian expression vector, and used to transfect mouse
βTC-3 cells. Conditioned media were collected 48 h after transfection and quantified for
GIP activity using a specific bioassay. Results: Although proglucagon transcripts were identi-
fied, GIP expression was not detected in the sea lamprey. In contrast, zebrafish GIP transcripts,
slightly smaller in size than mouse GIP mRNA (~800 bp), as well as insulin transcripts,
were identified in total RNA isolated from zebrafish internal organs. The full-length zebrafish
GIP cDNA was found to contain an open reading frame encoding a preprohormone of 112
amino acids. The zebrafish amino acid sequence demonstrated very little homology with
mammalian GIP downstream of the mature peptide sequence. Furthermore, homology within
the mature peptide was confined to the region before and including the dibasic cleavage
site at amino acids 32 and 33. Finally, transient transfections demonstrated that putative
zebrafish GIP cDNA, when expressed in βTC-3 cells, was able to bind to and activate a
mammalian GIP receptor. Summary and Conclusion: During initial screening, although
GIP transcripts were not detected in the sea lamprey, the zebrafish GIP gene was isolated,
and its product was capable of activating a mammalian GIP receptor. Thus, of the primitive
vertebrates, at least zebrafish possess both functional insulin and GIP. These data support
the theory that GIP may have evolved as a result of the translocation of insulin to the
pancreas and the need to develop an enteroinsular axis to maintain nutrient efficiency.
T1932
Increased Adiposity During High Fat Diet Does Not Participate in Suppression
of Stomach Ghrelin Production and Secretion
George H. Greeley, Jason T. Reed, Xiang Qi, Tatsuo Uchida
Ghrelin is a stomach hormone that stimulates GH secretion, food intake, body growth and
adiposity. In contrast to other GI hormones stomach ghrelin secretion is increased by calorie
restriction and decreased by caloric replenishment. In obese patients, ghrelin secretion is
reduced and in rodents fed high-fat (HF) diets, stomach ghrelin synthesis and plasma ghrelin
levels are decreased. The extent to which the increased adipose tissue during a HF diet
exerts an inhibitory action on stomach ghrelin production and secretion is not known. The
purpose of this study was to test the hypothesis that an increased adiposity resulting from
elevated dietary fat has an inhibitory effect on stomach ghrelin production and secretion.
Methods. Adult male Sprague-Dawley rats were fed either a standard AIN-76 (~12% calories-
fat) or a HF diet (~45% calories-fat) for 3 weeks. Rats fed the AIN-76 and HF diets were
treated concurrently with either triiodothyronine (T3, 150 μg/kg, SC, every other day) or
vehicle (VEH). T3 treatment will prevent body fat accumulation. At the end of the 3-week
HF diet regimen body weights (BW) were recorded and rats sacrificed. Blood was harvested
for measurement of plasma ghrelin levels and stomachs were collected for measurement of
ghrelin peptide and mRNA levels by immunoassay and Northern blotting. Results. BW of
rats fed the HF diet (HF + VEH) were increased significantly when compared to rats fed
the AIN diet (AIN + VEH). In contrast, BW of rats given HF diet plus T3 did not increase
when compared to rats fed the AIN diet. Plasma ghrelin levels were reduced significantly
in rats given HF + VEH or HF + T3 when compared to AIN + VEH or AIN + T3 rats.
Stomach ghrelin mRNA levels were lower in rats given HF + VEH or HF + T3 in comparison
to AIN + VEH or AIN + T3 rats. Conclusions and Discussion. A HF diet suppresses stomach
ghrelin production and secretion. Blockade of body fat accumulation by administration of
T3 did not reverse suppression of stomach ghrelin production and secretion in rats fed a
HF diet. This finding implies that the increased fat mass and circulating endocrine factors
secreted by adipose tissue do not play a role in inhibition of ghrelin homeostasis during
HF diets or obesity. * p<.05 vs. AIN + VEH; † p<.05 vs. HF + VEH; Δ p<.05 vs. AIN + T3.
T1933
Co-Localization of Gata4 and Hnf1α in the Gastrointestinal Tract Is Restricted
to the Distal Stomach and Proximal Small Intestine
Eva Beuling, Tjalling Bosse, Michael A. Buckner, Stephen D. Krasinski
Gata4, a member of the zinc finger Gata family, and Hnf1α, a homeodomain protein, are
transcription factors that are co-expressed in the small intestinal epithelium, and have
been hypothesized to physically interact to synergistically activate specific intestinal genes.
Inactivation of either Hnf1α or Gata4 results in an ~90% reduction in lactase-phlorizin
hydrolase (LPH) and liver fatty acid binding protein (Fabp1) mRNA abundances in adult
small intestine, indicating that LPH and Fabp1 are targets of both Gata4 and Hnf1α in the
intestine. Although it is thought that the absorptive enterocytes of the small intestine are
the only cells in the gastrointestinal tract that co-express Gata4 and Hnf1α, a methodical
analysis of co-expression of these two transcription factors has not been reported. In the
present study, we define in detail the expression patterns of Gata4 and Hnf1α in the adult
mouse gastrointestinal tract. Using semi-quantitative RT-PCR, we found that Gata4 and
Hnf1α mRNAs are both expressed in stomach, duodenum, jejunum and proximal ileum;
that neither are expressed in the esophagus; and that only Hnf1α is expressed in colon and
cecum. A more detailed analysis of the stomach in which it was divided into five segments
along the proximal-distal axis revealed that although both Gata4 and Hnf1α mRNAs are
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expressed throughout the distal ~75%, neither are expressed in the most anterior fundic
region. Immunofluoresence experiments revealed that in the body and antrum of the stomach,
Gata4 and Hnf1α proteins are co-expressed in the nuclei of both parietal and chief cells.
In the small intestine, immunofluorescence experiments using lineage markers revealed that
Gata4 and Hnf1α are co-localized in the nuclei of absorptive enterocytes on villi, and
throughout the crypt epithelium, including lysozyme-positive Paneth cells at the crypt base.
Neither Gata4 nor Hnf1α are expressed in goblet cells. Interestingly, Gata4 is not expressed
in chromogranin-positive enteroendocrine cells, whereas Hnf1α was readily detected in
these cells. Conclusion: Co-localization of Gata4 and Hnf1α protein in the adult gastrointesti-
nal tract is restricted to the parietal and chief cells of the distal stomach, and to the absorptive
entrocytes on villi and throughout the crypt epithelium of the proximal small intestine,
providing a topographic basis for possible interaction in regulating specific genes in these
cells. The specific expression of Hnf1α in enteroendocrine cells of the small intestine, and
in epithelial cells of the colon and cecum, suggests that Hnf1α has functions in these cells
that are independent of Gata4.
T1934
Fasting Enhances Hepatic TLR4 Expression in Response to LPS
Sasha D. Adams, Benjamin A. Delano, David W. Mercer
INTRODUCTION: Early enteral nutrition improves clinical outcomes and reduces septic
complications in critically ill trauma patients. In fact, stimulation of the gut mucosa with
luminal nutrients may have beneficial effects even when given in amounts less than that
required for full nutritional support. However, the protective mechanism remains to be fully
elucidated. In fasted rats, lipopolysaccharide (LPS) initiates an inflammatory cascade that
causes hepatic injury along with an upregulation of cyclo-oxygenase-2 (COX2). In some
models, LPS has been shown to elicit its deleterious effects through the Toll-Like Receptor
4 (TLR4). Whether TLR4 levels differ between fasted and unfasted rats is unknown. We
hypothesized that fasting predisposes rats to LPS induced hepatic injury via a TLR4 mediated
mechanism. METHODS: Male rats were either fasted or fed before treatment. Fasted rats
were allowed free access to water but no food 18 hours prior to injection. Fed rats were
allowed continuous access to water and standard rodent chow throughout the experiment.
On the day of experimentation, rats were given intraperitoneal LPS (20 mg/kg) or saline,
sacrificed 5h later and liver harvested. Serum AST was measured as an index of liver injury.
Hepatic TLR4 and COX2 were measured by Western immunoblot. Results are mean + SE
(n=8/group; ANOVA). RESULTS: In fasted rats, LPS significantly increased serum AST levels,
and increased hepatic TLR4 and COX2 when compared to saline controls. However, in rats
fed prior to challenge with LPS, there were significantly lower enzyme levels and a significant
down regulation of TLR4 and COX2 when compared to fasted rats receiving LPS. In rats
given saline, fasting did not significantly change TLR4 levels in the liver when compared
to fed rats. CONCLUSIONS: These data suggest that fasting predisposes rats to hepatic
injury from LPS by increasing TLR4, such that there is enhanced responsiveness to LPS.
Moreover, this data further support the concept that enteral nutrition in critically ill patients
is beneficial and that post-injury fasting may enhance the susceptibility of the liver to injury
from septic insults.
T1935
Glutamine Deletion Diet Induces the Colonic Hemorrhage in the New Born
Mice
Takayuki Motoki, Yoshio Naomoto, Junji Hoshiba, Nobuyuki Watanabe, Mitsuya Ito,
Toshio Nishikawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Minoru Haisa, Junji Matsuoka,
Noriaki Tanaka
Purpose: It is technically difficult to feed a new born mouse. Feeding tube method has been
commonly used for nutritional study. New feeding system has been developed. Recently
we reported that glutamine was a key regulator of amino acid controlled cell growth through
mTOR signaling pathway in rat intestinal epithelial cells. We developed new variable amino
acid milk. We fed new born mice with this diet, then subsequent clinical changes in each
organ were analyzed. Method: We prepared complete amino acid milk (CAM) according to
mother's milk, glutamine deletion milk (GDM), and glutamine rich milk (GRM) which
contained three times as much glutamine as CAM. 78 new born mice (CAM: 29, GDM: 30,
GRM: 28) were fed four times per day, and weighed before and after every feeding for seven
days. The mice were sacrificed on eight day, and their body weight gain, milk intake, fecal
condition, and intraabdominal findings (macro and micro) were examined. Result: There
were no differences in weight gain and milk intake among three groups. One mouse in
CAM group showed colonic hemorrhage and six mice revealed colonic hemorrhage in GDM
group (GRMvsGDM: p = 0.0089, CAMvsGDM: p = 0.0360). On the other hand, no mouse
in GRM group demonstrated colonic hemorrhage. The inflammation of colon and edema
of the intestinal tract as an intraabdominal finding were detected in the mice with hemorrhage.
Histopathological examination displayed hypertrophy and inflammatory change of intestinal
wall. In addition, destruction of micro villi and disappearance of glycocalyx were revealed
in the electron microscope image. Conclusion: It is interesting that massive colonic hemor-
rhage was caused by deletion of only one amino acid: glutamine. Our results suggest that
barrier on the intestinal mucosa has been destroyed with disappearance of glycocalyx that
has subsequently led the colonic hemorrhage. Further studies are need for the amino
acid metabolism.
T1936
The Monocarboxylate Transporter MCT1 Is a Marker of the Colonocyte
Exposure to Butyrate
Ronan Thibault, Pierre De coppet, Jean Menanteau, Bruno Buecher, Jean paul Galmiche,
Christine Hoebler, Jean-pierre Segain
Introduction : Butyrate is a short chain fatty acid produced by colonic bacterial fermentation
of dietary fibers. Butyrate could play an important role in the prevention of colorectal cancer.
There is no available molecular marker of the exposure of colonic epithelium to butyrate.
Butyrate uptake into the colonocyte has been shown to involve monocarboxylate transporter
1, MCT1. Our study aims to determine, 1) the functionality of MCT1 In Vivo, and 2) the
regulation of MCT1 expression by butyrate-producing dietary fibers and butyrate. Methods
: Two groups of Sprague-Dawley rats (n=6 each) received for 16 hours a cæcal infusion of
physiological serum (control) or 20 mM of alpha-cyano-4-hydroxycinnamate (CHC), a
specific MCT1 inhibitor. All rats were then infused with 10 mM butyrate for 6 hours. Ten
mice were fed for 21 days with a standard diet or a fructo-oligo-saccharides (FOS)-enriched
diet. The intestinal epithelial cell line, HT-29 cl.19A was cultured (24h) in presence of 2mM
butyrate. Ileal and colonic biopsies were collected from 10 healthy subjects undergoing a
screening colonoscopy. Colonic concentrations of butyrate were determined by gas chromato-
graphy. MCT1 expression was analyzed by RT-PCR and immunohistofluorescence in paraffin-
embedded sections obtained from rectal biopsies taken from 5 healthy volunteers before
(day 0) and after 15 days of 100 mM butyrate daily intra-rectal enemas. Results : Intra-
cæcal butyrate concentrations were higher in rats treated with CHC than in controls (35±10
vs 14±5 mmol/gram dry weight, P<0.01), whereas intra-colonic butyrate concentrations
were not different (20±5 vs 17±5, NS). Treatments did not modify MCT1 mRNA expression.
In healthy subjects and rats, MCT1 mRNA expression was higher in colon than in ileum
(P<0.01). The increase of intra-caecal butyrate concentrations in the FOS-fed mice was
associated with increased MCT1 mRNA levels in the caecum as compared to controls
(P<0.05). In the HT-29 cl.19A cells, butyrate significantly increased MCT1 mRNA expression.
In healthy volunteers, butyrate enemas induced a significant increase of MCT1 expression.
Conclusion : In rats, blockade of butyrate uptake with CHC suggests that MCT1 is the
butyrate transporter into the colonocyte In Vivo. In humans, rats and mice, MCT1 levels
are correlated with the site of butyrate production (colon). In Vivo (FOS-enriched diet and
butyrate enemas) and In Vitro (HT-29 cl.19A), butyrate positively regulates MCT1 expression.
Therefore MCT1 could be considered as a marker of butyrate exposure in the colonic
mucosa. Further studies will aim to determine the links between MCT1 expression and
colorectal cancer risk.
T1937
Vagal Afferents Do Not Directly Detect Intestinal Glucose Via a Sweet-Taste
Mechanism
Nektaria Pezos, Kate Sutherland, Stuart M. Brierley, Michael Horowitz, L. ashley
Blackshaw, Richard L. Young
The small intestine is equipped with sensors that detect nutrients, such as glucose, that can
trigger vagal reflex control of gastric motility and emptying. As vagal sensory fibers in the
intestine do not appear to penetrate epithelial layers to gain access to luminal contents [1]
they may possess glucose-sensors on their endings which directly detect absorbed glucose
transported across the epithelium. Alternatively, vagal sensory fibers may sense glucose
indirectly, secondary to detection by specialized epithelial cells and their subsequent release
of paracrine neurotransmitters. We have shown that α-gustducin (α-GD), a key G-protein
signal molecule of lingual sweet taste is specifically expressed in jejunal epithelial cells in
mice where it may mediate responses to glucose [2]. It is unknown however, whether vagal
afferent endings are also equipped to use α-GD or related lingual sweet-taste molecules to
‘taste' intestinal glucose directly. The aim of this study was to assess expression of sweet-
taste molecules in mouse nodose ganglion to test this possibility. METHODS: RNA was
extracted from tongue, jejunal mucosa and nodose ganglia of 4 mice and RT-PCR was
performed to detect transcripts for the sweet-taste G protein coupled receptor T1R2, for the
taste-specific G protein α-GD and for TRPM5, an ion channel essential to sweet taste
transduction. RESULTS: Gel electrophoresis of RT-PCR products revealed single intense
bands corresponding to the predicted size of T1R2, α-GD and TRPM5, identifying the
presence of the transcripts in tongue and jejunal mucosa. However, these transcripts were
absent from nodose ganglia. CONCLUSIONS: These findings show that vagal afferent endings
in mice do not directly detect absorbed glucose via lingual sweet-taste molecules. As a
consequence, epithelial cells are likely candidates to ‘taste' intestinal glucose and signal
vagal afferent endings indirectly via paracrine release of specific neurotransmitters. The
transduction pathways and identity of neurotransmitter(s) involved in signaling glucose in
the small intestine are the subject of ongoing studies in our laboratory. 1. Berthoud H.R.
et al Anat Embryol (Berl) 191(3) 203-12, 2. Sutherland K.S. et al Gastroenterol 130(4)
T2068. Supported by: University of Adelaide
T1938
Functional Gastrin Releasing Peptide-Receptor (GRP-R) Expression in Mouse
3T3-L1 Preadipocytes Mediates Cell Proliferation
Anita Ratnasari, Dongmei Xiao, Ajay Abichandani, Horst C. Weber
Mammalian bombesin-like peptides (BLP), such as gastrin-releasing peptide (GRP) and
neuromedin B (NMB), and their respective high affinity G protein-coupled receptors are
important in numerous physiological processes, including regulation of satiety and energy
metabolism. In GRP-receptor (GRP-R) deficient mice, a loss of receptor-dependent glucose
feeding inhibition was demonstrated. GRP-R stimulation has also been shown to stimulate
cell proliferation in various non-malignant and cancerous cells, specifically by MAP kinase
activation. However, GRP-R expression and cell proliferation in preadipocytes has not been
investigated. We hypothesized that cell proliferation in mouse 3T3-L1 preadipocytes might be
enhanced subsequent to agonist-dependent GRP-R stimulation. For thymidine incorporation
A-587 AGA Abstracts
experiments, preadipocytes were grown in 24-well plates to sub-confluency and serum-
starved for 24 hours prior to stimulation for 18 hours with bombesin (BN) at concentrations
of 1, 10, and 100 nM, NMB (100 nM), and a universal synthetic bombesin receptor agonist,
peptide 697 (100 nM). Additional experiments were performed with BN (100 nM) subsequent
to treatment with the selective GRP-R antagonists BW (1μM) and ME (100 nM) (gift from
Drs. Moody and Jensen) and the MEK1 inhibitor PD98059 (20μM). Intracellular calcium
mobilization was tested in fura-2 loaded preadipocytes. Time course experiments of BN
(100 nM) treated preadipocytes were analyzed by immunoblot using a phospho-specific
antibody to extracellular signal-related kinases (ERK1/2). Agonist-specific GRP-R activation
resulted in increased proliferation of preadipocytes in a concentration-dependent manner
(mean+/- SEM;1nM: 150+/-20%, 10nM: 180+/-30%, 100nM: 220+/-20%; all p<0.02) and
was either reduced or abolished after pretreatment with selective GRP-R antagonists BW
and ME, respectively, and MEK1 inhibitor PD98059. GRP-R induced ERK1/2 activation
occurred in a time-dependent manner with a maximum response at 5 minutes after BN
stimulation and was abolished in the presence of GRP-R antagonist. Stimulation with peptide
697 (195+/-20%, p=0.03) but not NMB, also resulted in enhanced preadipocyte proliferation.
Furthermore, mature 3T3-L1 adipocytes did not show enhanced proliferation after BN
stimulation. Intracellular calcium mobilization was detected subsequent to BN and 697
stimulation. In conclusion, mouse 3T3-L1 preadipocytes possess functional GRP-R, which
mediate cell proliferation by rapid activation of the MAP kinase pathway whereas mature
adipocytes do not proliferate in response to BN stimulation. Functional GRP-R in mouse
preadipocytes suggests a role in regulation of energy metabolism.
T1939
Sweet Taste Transduction Molecules Are Expressed in the Upper
Gastrointestinal Tract in Humans
Kate Sutherland, Stuart M. Brierley, Michael Horowitz, Chris Rayner, L. ashley Blackshaw,
Richard L. Young
Upper gastrointestinal motility disturbances, such as gastroparesis, are frequently experienced
by diabetic patients and may reflect a hypersensitivity of vagal sensing of glucose in the
small intestine [1]. Despite this evidence, the molecular mechanism of glucose-sensing
and signalling in the intestine remains poorly defined. In contrast, sweet-taste detection
mechanisms in the oral cavity are well defined, where natural and artificial sweeteners are
detected via the heterodimeric G-protein coupled receptors T1R2 and T1R3 and signalled
via a cascade involving the taste-specific G-proteinα-gustducin (α-GD) and transient receptor
potential ion channel, TRPM5. We showed that sweet-taste molecules are expressed in a
regional specific manner in the gastrointestinal epithelium of mice by immunolabeling and
RT PCR [2]. Here, sweet-taste molecules are expressed in specific ‘taste' cells suggesting that
the primary nutrient sensors are specialised epithelial cells that detect glucose and release
paracrine neurotransmitter to activate vagal sensory endings. To date however, no reports
exist on the expression of sweet-taste molecules in an equivalent region of the upper
gastrointestinal epithelium in humans. The aim of this study was to investigate expression
of sweet-taste molecules in this region of the gut in humans to test this possibility. METHODS:
Small intestinal biopsies were obtained with consent from non-diabetic patients undergoing
routine surveillance push-enteroscopy. Biopsies were collected from the distal esophagus,
gastric fundus, body and antrum, duodenum and proximal jejunum which were confirmed
to be of normal histology. RNA was subsequently extracted from each of the individual
biopsies and RT-PCR was performed to determine transcript expression of T1R2, α-GD and
TRPM5. RESULTS: Transcripts for T1R2, α-GD and TRPM5 were identified by RT PCR and
gel electrophoresis in human biopsies. Expression showed a region-specific pattern, with
sweet-taste molecules absent from the esophagus and proximal stomach but apparent from
the distal stomach and in all regions of the proximal small intestine. CONCLUSIONS: Key
sweet taste molecules are expressed in the upper gastrointestinal epithelium of humans and
display regional expression relevant to their potential role in nutrient signaling. Quantitative
and comparative RT-PCR analyses of these molecules in control and type-2 diabetic patients
is the subject of ongoing studies in our laboratory in order to determine any changes
occurring in diabetes. 1. Rayner C et al Am J Gastroenterol 2002 97:3123-30, 2. Sutherland
K.S. et al Gastroenterol 2006 130(4):T2068. Supported by: University of Adelaide
T1940
The Precocious Enhancement of the Developmentally Dormant Intestinal
Fructose Transporter Glut5 Involves Glucocorticoid Receptor-Mediated
Transcription
Veronique Douard, Carla Cerqueira, Ronaldo Ferraris
The intestinal fructose transporter GLUT5 is normally expressed at low baseline levels
throughout the suckling (0 ~ 13 d of age) and weaning (14 ~ 28 d) stages in neonatal rats.
GLUT5 expression and activity, however, are dramatically enhanced by precocious perfusion
of its substrate fructose for 4 h into the intestinal lumen, but only after ~14 d of age. Using
microarray, we compared the gene expression in the intestines of 10 and 20 d old pups to
identify fructose-responsive genes whose expression also changes with age. We identified a
cluster of fructose-specific and age-responsive genes regulated by glucocorticoids (G), sug-
gesting that G may modulate GLUT5 development. We then determined that priming the
gut with dexamethasone (dex, a corticosterone analog) allowed fructose to stimulate GLUT5
even in suckling pups. Hence, dex mimics the effect of age and induces maturation of the
intestine. To identify the mechanisms underlying the G-allowed, fructose-induced upregul-
ation of GLUT5 in suckling pups, we showed that the dex effect is RU486 (a specific G
receptor (GR) antagonist) sensitive, and is not affected by mineralocorticoid receptor (MR)
antagonists and by pregnane X receptor (PXR) agonists. This suggests that the priming effect
of dex is mediated by the GR and not by the MR or PXR. To determine the duration required
for G modulation, dex was injected to suckling pups 0.5, 4, 24, and 48 h before perfusing
the intestine with fructose for an additional 4 h to stimulate GLUT5. Control littermates
were injected with vehicle. A minimum of 4h is required for dex to allow luminal fructose
to induce GLUT5 expression and activity, while 24 h is required for optimal induction. In
contrast, the mRNA abundance of the proline transporter SIT was independent of dex
treatment or fructose perfusion. The stimulatory effect of dex on GLUT5 gene expression
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is therefore specific and likely indirect, involving signaling intermediates. To determine
whether G modulation is transcriptional, suckling pups were then injected with a transcrip-
tion inhibitor, actinomycin D prior to injection with dex 48 h before perfusion. Actinomycin
D did not block the effect of luminal fructose on fructose-responsive genes if injected >36
h before perfusion, hence its effect, if any, should only be on the dex-mediated GLUT5
induction by fructose. Actinomycin D prevented dex from allowing luminal fructose to
induce GLUT5 but had no effect on SGLT1 expression. Thus, in suckling rats, dex allows
fructose to precociously stimulate a developmentally-dormant GLUT5 probably via GR-
mediated, de novo synthesis of intermediary signals that requires ~24 h to achieve
optimal effects.
T1941
Role of Phospholipase A2 (PLA2) in the Genesis of Tone in the Internal Anal
Sphincter (IAS) Vs. the Rectum Smooth Muscle (Rsm)
Marcio A. De godoy, Satish C. Rattan
Background and Aims: PLA2 plays an important role in a broad range of cellular responses
including membrane phospholipids metabolism, signal transduction and in the smooth
muscle tone in the lower esophageal sphincter (Am J Physiol 277:G588-G598;1999), and
contraction by certain agonists. The role of PLA2 in the genesis of IAS tone remains undeter-
mined. Methods: Present studies were carried out in rat IAS and RSM. For the functional
studies, the investigation used measurements of the isometric tension of smooth muscle
strips in the basal state and in the presence of selective and non-selective PLA2 inhibitors.
The PLA2 activity and expression levels were tested through biochemical and molecular
biology studies. In addition, In Vivo measurements of the IAS pressure (IASP) in the anal
canal and of the mean systemic blood pressure (MSBP) were obtained. Results: IAS but
not RSM develops spontaneous tone. Inhibition of PLA2 by the non-selective inhibitor 4-
bromophenacyl bromide (BPB) produced a decrease in the IAS tone of 58.8 ± 6.9 % (n =
8). MJ33, the selective inhibitor of the secreted isoform of PLA2 (sPLA2) produced similar
decrease (Imax = 53.1 ± 2.1 %; n = 4). On the other hand, the selective inhibitors of the
cytosolic and calcium-insensitive isoforms of PLA2 aarachidonyl trifluoromethyl ketone
(AACOCF3) and bromoenol lactone (BEL) respectively had no significant effect (p > 0.05).
Additional studies revealed the following novel findings. Incubation with the exogenous
sPLA2 produced a low-grade tonic contraction in the RSM (Emax of 10.8 ± 1.3 % and pIC50
of 2.3 ± 0.1; n = 4). This effect was inhibited by BPB. The absorbance studies showed
greater (p < 0.05) activity of sPLA2 in the IAS (26.5 ± 4.9 U; n = 3) than in the RSM (3.2
± 0.4 U; n = 3). IAS also expressed greater levels of sPLA2 than the RSM as shown by
Western blot and RT-PCR studies. Administration of BPB produced a significant (p < 0.05)
decrease in the IASP (Imax = 66.7 ± 5.1 %; n = 5). Comparison of dose ratios showed that
BPB is ∼ 100 times more potent in decreasing IASP than the MSBP. Conclusions: All these
data suggest that sPLA2 plays a critical role in the basal tone of the IAS. The potency and
selectivity of PLA2 inhibition in causing decrease in IAS tone suggest a therapeutic potential
for PLA2 inhibitors in treating anorectal disorders without significant side effects in the
cardiovascular system.
T1942
Development of a 3-Dimensional Physiological Model of the Human Internal
Anal Sphincter Bioengineered in-Vitro from Human IAS Smooth Muscle Cells
Sita Somara, Amin Farokhrani, Robert R. Gilmont, Khalil N. Bitar
Background: Fecal incontinence affects people of all ages and social backgrounds and can
have devastating psychological and economic consequences. This disorder is largely attributed
to decreased mechanical efficiency of the internal anal sphincter (IAS), yet little is known
about the pathophysiological mechanisms responsible for the malfunction of sphincteric
smooth muscle at the cellular level. Objective: To develop a 3-Dimensional Physiological
Model of the Human IAS bioengineered in-vitro from Isolated Smooth Muscle Cells (SMC)
from Human IAS obtained from surgery. Methods: Smooth muscle cells isolated from the
IAS of Human were seeded on top of a loose fibrin gel, where they migrated and self-
assembled in circumferential alignment. As the cells proliferated, the fibrin gel shrunk and
contracted around a 5mm diameter SYLGARD mold, resulting in a 3-D cylindrical ring of
sphincteric tissue. Results: 1) A novel 3 dimensional bioengineered ring (3DBR) constructed
for the first time from isolated human IAS SMC. 2) 3DBR from human IAS SMC generated
a spontaneous basal tone. 3) Basal tone was not affected by the addition of the Rho Kinase
inhibitor Y27632. 4) Acetylcholine (Ach) induced a rapid and sustained force generation
which was dose-dependent. 5) Addition of PdBU, a known PKC activator, resulted in a
rapid and sustained force generation which was not inhibited by preincubation of the 3DBR
with Rho Kinase inhibitor Y27632. 6) Addition of 8-br-cAMP resulted in relaxation of the
basal tone. 7) Addition of PdBU post relaxation-induced by 8-br-cAMP resulted in rapid
and sustained force generation of similar magnitude as before relaxation. Summary: Human
IAS 3DBR was able to generate spontaneous myogenic basal tone. The 3DBR was able to
relax and contract in response to relaxants and contractile agents. The 3DBR was able to
contract after relaxation. Analysis of data suggests that human IAS 3DBR has the essential
characteristics of physiologically functional IAS. Conclusions: This is the first report of a
3-D in-vitro model of a human gastrointestinal smooth muscle IAS. Bioengineered IAS rings
demonstrate physiological functionality and may be used in the elucidation of the mechanisms
causing sphincter malfunction. We acknowledge the contribution of Rebecca Margulis, MD
and Dee Fenner, MD for obtaining the human IAS surgical samples. Supported by Grant
NIH RO1 DK 042876.
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Disturbed Distal Colonic Transit Contributes to Persistent Anorectal
Symptoms and Dysfunction in Patients Following External Beam Radiation
Therapy (RT) for Prostate Carcinoma (CAP)
Rochelle Botten, Addolorata Di matteo, Dylan Bartholomeusz, Robert Fraser, Richard H.
Holloway, Eric Yeoh
Diarrhoea is common after RT for CaP1. Although anorectal dysfunction is well recognised
after RT, the contribution of colonic dysfunction has not been evaluated. Methods: 38
patients (age 71(50-81) years) with early stage CaP, treated by RT, were prospectively
evaluated for colonic transit before RT, 1 month and 1 year after RT. Colonic transit was
measured by scintigraphy following 4MBq oral 67Ga citrate. Anterior and posterior abdominal
scans were acquired at 6, 24, 48 and 72 hours, a composite image of the bowel obtained,
and regions of interest drawn for right, left and rectosigmoid region. The geometric mean
of regional activity was calculated together with mean points of activity, activity profile along
the colon and whole colon half clearance. Anorectal symptoms (validated questionnaire),
anorectal motor (perfused sleeve sidehole manometry) and sensory function (graded balloon
distension) and anal sphincteric morphology (endoanal ultrasound) were also evaluated
before and after RT. Scintigraphic and manometric data were analyzed by ANOVA
(mean±SEM). Anorectal symptom data were analysed by χ2 test. Linear regression was used
to determine any relationships among colonic transit and parameters of anorectal dysfunction.
Results: Colonic transit measured by half colonic clearance and distal colonic retention was
faster 1 month after RT. Half colonic clearance returned to baseline but distal colonic
retention remained reduced at 1 year. Increases in stool frequency (55%) and urgency (42%),
fecal incontinence (18%) and rectal bleeding (13%) 1 month after RT was still present 1
year later in 45%, 39%, 21% and 29% of patients, respectively. Anal pressures in response
to squeeze and increased intra-abdominal pressures and rectal compliance were reduced in
patients at 1 year. Basal anal pressures, anorectal sensory function and anal sphincteric
morphology did not change. Distal colonic retention was related to rectal compliance at 1
month (r= 0.415, p<0.05) and half colonic clearance to frequency of defecation at 1 year
(r= -0.336, p<0.05). Conclusion: Total and distal colonic transit is faster 1 month after RT.
At 1 year total but not distal colonic transit has returned to baseline. These changes may
contribute to symptoms after RT and exacerbate anorectal dysfunction. 1 Bartholomeusz et
al, Gastroenterol 2002 122(4):A319
*p<0.05 cf Pre RT, **p<0.001
T1944
Gut Symptoms in Diabetes Correlate with Autonomic Activity and
Components of the Recto-Anal Inhibitory Reflex, Not Pudendal Nerve
Latencies
Kumaran Thiruppathy, Dave R. Chatoor, Amanda J. Roy, Charles D. Murray, Anton V.
Emmanuel
Introduction Anorectal dysfunction leading to faecal incontinence (FI) occurs in 20% of
patients with diabetes mellitus (DM), and a number of motor and sensory abnormalities
have been described. The problem occurs more often in patients with systemic autonomic
neuropathy, but it remains unknown whether gut-specific autonomic dysfunction is associ-
ated. The recto-anal inhibitory reflex (RAIR) is an enteric reflex that reflects the integrity of
the sampling mechanism in the physiology of faecal continence. We hypothesised that diabetic
patients with FI have gut specific abnormalities - autonomic disturbance and abnormal RAIR
parameters. Methods The following patients were studied: 31 type I DM (19 female, mean
age 32; 19 FI and 12 constipation); 42 type II DM (26 female, mean age 38; 26 FI and 16
constipation); 21 controls (14 female, mean age 35). Patients underwent two systemic
(cardiovagal autonomic tone [Mayo CAS score] and pudendal nerve terminal motor latency,
PNTML [St Mark's electrode]) and two gut specific (autonomic tone [rectal mucosal blood
flow-RMBF] and RAIR) neurological assessments. Three phases of the reflex were identified
- the latency from stimulus to maximal sphincter relaxation; The duration of maximal
relaxation; The time to recovery back to resting pressure. In addition, the amplitude of
maximal reflex relaxation was compared between groups. All subjects completed symptom
scores for FI (St Mark's) and constipation (Wexner). Results Systemic: CAS score in DM
patients was not correlated with symptom severity for either FI (r=-0.21, p>0.10) or constipa-
tion (r=0.14, p>0.20). PNTMLs were not correlated with symptom scores (FI or constipation),
RMBF or any component of the RAIR. Gut-specific: RMBF was lower in DM patients with
constipation than controls (124 vs 169, p<0.05) and correlated inversely with Wexner scores
(r=-0.79, p=0.004). RMBF correlated with FI scores in DM patients (r=0.65, p=0.02). RAIR
amplitude of relaxation was lower in constipated DM patients than controls (54 vs 77%,
p<0.03) and diabetics with FI (54 vs 68%, p<0.05). RAIR recovery back to resting pressure
was slower in diabetics with FI than constipation or controls (6.8 vs 4.4 and 4.3 resp,
p<0.01 both). This RAIR recovery time correlated with RMBF (r=0.58, p=0.04). Conclusion
Symptoms in patients with DM correlate with gut specific features but not systemic ones.
Specifically there were differences in the character of the RAIR, pointing towards a role for
sphincter muscle dysfunction in diabetics with constipation and for sphincter neuropathy
in diabetics with FI.
T1945
Is Methanogenic Flora Associated with Chronic Constipation and Altered
Colonic Transit & Stool Characteristics?
Ashok Attaluri, Jose M. Remes-troche, Jessica Paulson, Satish S. Rao
Background: About 35% of the US population has enteric bacteria that produce methane.
Methanogenic IBS pts were reported to be universally constipated. Prevalence of methanog-
enic flora in non-IBS chronic constipation (CC) and its effect on colonic transit and stool
characteristics has not been systematically assessed. Aim: 1) To evaluate the prevalence of
methanogenic flora in CC and 2) To examine the correlation between methane production,
colonic transit and stool characteristics. Methods: Pts with CC (Rome II) who also had either
glucose, fructose or lactose breath tests, as well as anorectal manometry, colonic transit
(Sitzmark) & balloon expulsion studies between 2004-6, were assessed. Pts were categorized
into either slow transit constipation (STC) (>20% retention of markers at 120 hrs) or normal
colonic transit with dyssynergia (NTC). Data were compared with 20 healthy controls who
also underwent breath tests. Data on H2 and CH4 responses to carbohydrate challenge,
presence of methanogenic flora (baseline CH4 value ≥ 1 ppm), stool frequency and consist-
ency (Bristol scale: 1-7) as recorded on a 7 day stool dairy, were assessed. Correlation was
analyzed with the Spearman test. Results: We identified 92 pts, 44 with STC and 48 with
NTC (Table). Prevalence of methanogenic flora was higher (p < 0.05) in STC than either
NTC or controls. Pts with STC also had higher (p < 0.05) CH4 production than NTC or
controls; as did pts with NTC, when compared to controls. Mean stool consistency, BM/
week and % retention of colon markers (at 120 hrs) were 2.8, 5.1 and 67% in the STC
group and 2.8, 5.9, and 17.5% in the NTC group. Among methane producing STC pts,
there was a significant (p<0.05) correlation between baseline (r=0.51), peak(r=0.54) and
AUC methane values (r=0.52) with colonic transit but not with stool characteristics. Conclu-
sions: The prevalence of methanogenic flora and CH4 response to carbohydrate challenge
was higher in STC than NTC patients, confirming an association between methanogenesis
and slow colonic transit. Stool patterns were however similar. Higher methane production
may correlate with slower colonic transit but not with altered stool characteristics. Whether
there is a cause-effect relationship between methanogensis and STC merits further study.
Mean ± SEM (ppm), * significant different from controls (p<0.05), † significantly different
from NTC (p<0.05)
T1946
Anal Canal Closure Mechanism Assessed By 3-Dimensional Ultrasound
Imaging
Sung-ae Jung, Dolores H. Pretorius, Bikram S. Padda, Milena M. Weinstein, Charles W.
Nager, Ravinder K. Mittal
Background & Aims: The study was to determine the relative contribution of internal anal
sphincter (IAS), external anal sphincter (EAS) and puborectalis muscle (PRM) to the anal
closure and compliance function. Methods: 10 asymptomatic nulliparous women were
studied using a 10 cm long polyethylene bag of 20 mm maximal diameter that was placed
across the anal canal and gradually inflated with water (volumes ranging from 20 to 45 cc).
At each bag volume, a 3-dimensional ultrasound (3D US) volume of the anal canal was
obtained while the subjects were at rest and during squeeze. 2D US images were visualized
along the length of anal canal to determine the relationship between bag cross sectional
area (CSA) and location along the anal canal. Results: Anatomical location and extent of
PRM, IAS and EAS were clearly identified in the US images. At low volumes, the bag was
shaped like an “hour glass” with a completely collapsed segment center and 2 funnel shaped
ends at the 2 ends of the anal canal. The flared ends of funnels at the 2 ends correspond
with the proximal margin of PRM and distal margin of EAS. With the increase in bag
volumes the length of the completely closed bag decreased- last anal segment to open was
the one surrounded by all 3 structures, i.e., IAS, EAS and PRM. Squeeze resulted in reduction
of the anal canal CSA - the least compliant area was the one surrounded by the IAS & EAS.
Conclusion: IAS, EAS and PRM are all involved in the closure function of anal canal at rest.
During squeeze the EAS plays the biggest role in anal canal closure function. Future studies
using our novel approach may provide novel insights into the nature of anal closure defect
in patients with fecal incontinence.
Cross sectional area of different zone of anal canal using 40 cc sized bag (*, p<0.01 vs. rest)
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A Prospective Assessment of Anorectal Functions and Symptoms One Year
After a Simple Hysterectomy
Adil E. Bharucha, Barbara M. Seide, Alan R. Zinsmeister
Background - Hysterectomy (Hys) ranks as the second commonest surgical procedure among
women in the USA with over > 600,000 procedures performed annually. One in three
women will have a hys by the age of 60 years. Dissection of the rectovaginal septum can
also damage the extensive network of nerve fibers surrounding the rectum, cervix, and
lateral vaginal surfaces during a hys. While a radical hys is known to impair anorectal
functions, the effects of a “simple” (i.e., vaginal or abdominal) hys on anorectal functions
are poorly understood. Aims - To prospectively assess the effects of a simple hys on anorectal
sensori-motor functions. Methods - In this ongoing study, bowel symptoms and anorectal
functions were assessed before, 2 months, and 1 year after a hys [vaginal (14) or abdominal
(2)] in 16 women [(age 47 ± 3 years (Mean ± SEM)]. Bowel symptoms were evaluated by
a validated questionnaire using Rome II criteria. Assessments include: (i) anal resting and
squeeze pressures; (ii) rectal compliance (balloon volume response to 4 mmHg stepwise
increments from 0-44 mmHg); (iii) rectal sensation, measured by thresholds for first sensa-
tion, desire to defecate (DD), and urgency during the staircase distention; and (iv) rectal
evacuation assessed by the external traction (gm) required to expel a balloon filled with 60
ml water. Analyses - Staircase distentions were summarized as Pr½ (the pressure at ½ max
volume) and rectal capacity. Anorectal functions were compared before and after a hys by 2-
tailed paired, parameteric or nonparametric tests. Results - After Hys, symptoms of functional
constipation resolved in 1 patient. However, at 1 yr after hys, 3 patients had new functional
constipation and weight required for rectal balloon expulsion increased in 9 pts suggesting
impaired rectal evacuation. The weight declined in 3 and was unchanged in 3 pts . Anal
pressures and rectal sensorimotor functions did not significantly change after a simple hys.
Conclusions - These prospective data demonstrate that some patients develop new symptoms
and objective features of impaired evacuation after a simple hys. Further analyses are necessary
to identify the risk factors for anorectal dysfunctions after a hys. Supported by HD 41129.
Effect of Hysterectomy on Anorectal Functions
‡ by Rome II criteria Values are Mean + SEM unless stated
T1948
Visceral Sensitivity and Intestinal Inflammatory Patterns in Patients with
Irritable Bowel Syndrome and Coeliac Disease
Maria pia Caldarella, Angelo Milano, Chrysanti Balatsinou, Mariaelena Serio, Flora Sacco,
Domenico Angelucci, Francesco Laterza, Franco Cuccurullo, Matteo Neri
Background: Abdominal symptoms such as pain and bloating are features of both irritable
bowel syndrome (IBS) and adults' coeliac disease (CD); while visceral hypersensitivity is a
key factor in IBS pathogenesis, little is known about symptoms generation in CD. Aim: To
evaluate rectal sensitivity and rectal mucosa inflammatory patterns in patients with IBS and
CD at diagnosis and after gluten free diet (GFD). Materials and Methods: 23 adult patients
with newly diagnosed CD (3 males, 20 females, mean age 36±6 yrs) were evaluated at
diagnosis, 6 months and 12 months after GFD introduction. Visceral sensitivity was evaluated
by rectal distensions performed by increasing tension at 4 gr steps at 64 gr or discomfort.
Symptoms were measure by means of the visceral sensitivity index (VSI; APT. 2004;20:89-
97). Rectal biopsies were performed to evaluate intraepithelial lymphocytes (IEL), enterocro-
maffin cells (EC), mast cells (MC) and immunohistochemical 5-HT. 20 IBS patients (4 males,
16 females, mean age 32±8 yrs) and 10 healthy subjects (1 male, 9 females, mean age 29±2
yrs) were also studied according to the same protocol. Results: 18/23 patients with untreated
CD complained of IBS-like symptoms. Patients with IBS and untreated CD exhibited rectal
hypersensitivity in comparison to controls (39+4 gr in IBS and 32+2 gr in CD vs 64 gr in
health, p<0.001). After GFD, visceral hypersensitivity progressively decreased in CD up to
disappearance. At 6 months 4 patients were still hypersensitive and only one at 12 months;
The average Sensitivity scores in CD at 64 gr were 3.9±0.2 and 3.2±0.4 respectively vs. 2.3±0.3
in health, p=ns). Symptoms improved accordingly (VSI: health 72.3±4.5; IBS 46.9±8.9*; CD
at diagnosis 61.3±6.8*; CD 6-month 71.6±2.4; CD 12-month 72.4±6.0 *p<0.05, ANOVA).
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At baseline, IELs, MCs, and ECs density (n/100 epithelial cells) were similar among groups
except for a non statistically significant increase of IELs in CD; cells numbers did not change
significantly across time. Conclusion: IBS and newly diagnosed adult CD patients show
visceral hypersensitivity in comparison to health. GFD improves visceral sensitivity and
symptoms patterns independently from rectal inflammatory cells density.
T1949
Baseline Cytokinesis Blocked Micronucleus (CBMN) Index Correlates with
Gastrointestinal Sequelae Including Anal Sphincter Morphology 1 Year After
Radiation Therapy (RT) for Carcinoma of the Prostate (CAP)
Eric Yeoh, Addolorata Di matteo, Rochelle Botten, Julie Butters, Carolyn Salisbury,
Varinder Dhillon, Ian Olver, Richard H. Holloway, Michael Fenech
Gastrointestinal (GI) sequelae following RT for CaP is an underestimated cause of morbidity1.
Despite wide individual variations in normal tissue tolerance2, the same techniques and
radiation doses are often used for all patients. The CBMN assay, an established method for
measuring both spontaneous and radiation induced DNA damage3, has been correlated with
late GI and genitourinary sequelae after RT for CaP2. However the relationship between GI
sequelae, particularly anorectal dysfunction and the CBMN assay in patients undergoing RT
for CaP has not been prospectively studied. Aim: To examine the utility of the CBMN assay
in predicting early and late GI sequelae, including anorectal dysfunction after standard (70
Gy/35 fractions/7 weeks) 3D conformal RT for localized CaP. Methods: Fasting venous blood
of 21 patients (55-79 years) and the baseline and 3Gy ex-vivo irradiation indices of peripheral
blood lymphocytes were determined before RT3. LENT-SOMA GI symptoms (questionnaire)4
and parameters of anorectal motor and sensory function (perfused sleeve anorectal manometry
and graded rectal balloon distension) as well as anal sphincteric morphology (endoanal
ultrasound)1 were evaluated before RT, 1 month and 1 year after RT. Data were analyzed
by ANOVA. Linear regression analysis was used to examine the relationships among baseline
and 3Gy-induced CBMN index data and (i) LENT-SOMA GI symptom scores, (ii) anorectal
motor and sensory function, (iii) anal sphincteric morphology and (iv) rectal volume irradi-
ated. A p value of ≤0.05 was considered significant. Results: LENT-SOMA GI symptoms
increased and persisted at 1 year after RT. The decreases in basal anal pressures (p=0.05)
and rectal compliance (p<0.01) were also sustained at 1 year but anorectal sensory function
did not change. However internal anal sphincter (IAS) thickness reduced after RT and
persisted at 1 year. Baseline but not radiation induced CBMN index was related to fecal
urgency at 1 month (r= 0.501, p<0.05) and also with the following parameters at 1 year
(i) frequency of defecation (r= 0.485, p<0.05), (ii) fecal incontinence (r= 0.467, p<0.05)
and (iii) IAS (r= -0.463, p<0.05). Conclusions: Our preliminary data suggest that baseline
but not radiation induced CBMN index correlated with GI sequelae and IAS thickness 1
year following RT. These findings may have important implications for radiotherapeutic
approaches in the treatment of patients with CaP. 1 Yeoh et al, Amer J Gastroenterol 2004,
2: 361-369, 2 Lee et al, Int J Radiat Oncol Biol Phys 2003, 57: 222-229, 3 Fenech, Mutation
Research 2000, 455: 81-95, 4 Yeoh et al, Int J Radiat Oncol Biol Phys 2006, 66: 1072-1083
T1950
Evaluation of Anal Sensation in Female Patients with Intractable Constipation
and Rectal Hyposensitivity
Subash P. Vasudevan, S. M. Scott, Marc A. Gladman, Peter J. Lunniss
Background: Intact rectal sensation is integral to normal defaecation and continence. Rectal
hyposensitivity (RH) relates to blunted rectal sensory perception, and is commonly found
in patients with intractable constipation, faecal incontinence or both. Anal sensation has
also been found to be impaired in patients with colorectal disorders, although its precise
role is not well understood. In patients with RH, a proportion have been found to have
impaired bladder sensation, possibly reflecting a pan-pelvic visceral neuropathy, given their
common innervation. However, although the rectum and the anal canal are anatomically
adjacent, they are innervated by different sensory pathways: sensory information from the
rectum is conveyed via the rectospinal (visceral) afferents that ascend predominantly via
parasympathetic pathways to reach the dorsal horn of the spinal cord; The sensory pathway
from the anal canal is via the pudendal nerves (somatic). Aim: To determine whether rectal
hyposensitivity is associated with anal hyposensitivity, which may reflect a combined viscero-
somatic neuropathy. Methods: 158 female patients (median age 49 years, range 19-80), with
chronic constipation as their primary presenting symptom, underwent anorectal physiological
investigations including rectal sensation to volumetric balloon distension, and distal anal
mucosal sensation to electrostimulation. Patients were classified as RH if they had one or
more threshold volumes on balloon distension raised beyond the normal range. Data were
compared with those of 32 healthy female volunteers (median age 43 years, range 18-
60). Results: Anal mucosal electrosensory thresholds were significantly higher in patients
compared to volunteers (median: 2.4 mAmp, range [0.4-19.6] vs.1.1 mAmp, [0.1-4.2],
respectively; P<0.0001). Individually, 34 patients (22%) had evidence of anal hyposensation.
Of the 158 patients, 113 had normal rectal sensation (NS) and 45 (28%) had RH; however,
there was no difference in the incidence of blunted anal sensation between these subgroups
(NS: 20%, RH: 24%; P=0.572). Irrespective of rectal sensory function, there was a strong
association between increasing age (P=0.018) and symptom duration (P=0.001) with anal
hyposensitivity. Conclusion: One-fifth of constipated female patients had evidence of dimin-
ished anal sensation. However, the presence of RH was not associated with an increased
frequency of anal hyposensitivity, suggestive of differing aetiopathogenic mechanisms. Fur-
ther studies in carefully selected, homogenous patient populations are necessary to elucidate
these mechanisms.
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The Role of RHOA/Rok in the Intracellular Regulation of Myogenic Basal Tone
in the Internal Anal Sphincter (IAS) Vs. Phasic Activity of Rectal Smooth
Muscle (Rsm)
Chirag A. Patel, Satish Rattan
Background & Aims:Internal anal sphincter (IAS) smooth muscle maintains basal tone via
spontaneous contractions in the IAS smooth muscle cells (SMC). However, cellular regulation
of basal tone in the IAS via the activity of various intracellular contractile proteins is not
known. Methods: The present studies investigated the role of RhoA/ROK in the SMC isolated
from IAS vs. those from phasic tissues of rectal smooth muscle (RSM) and anococcygeus
smooth muscle (ASM). We determined effects of C3-exoenzyme (RhoA inhibitor) on levels
of active RhoA in the form of RhoA-GTP, levels of inactive RhoA as GDP-RhoA-Rho GDI
complexes, cellular distribution of RhoA/ROK and levels of pThr696-MYPT1 (phosphorylated
target/regulatory subunit of myosin phosphatase). SMC lengths were determined following
pretreatment with C3-exoenzyme, Y 27632 (ROK inhibitor), Gö 6850 (PKC inhibitor), active
ROCK-II (smooth muscle predominant isoform of ROK) and active protein kinase C (PKC).
Results: A majority of RhoA/ROK was found to be localized at the cellular membrane in
the IAS SMC and in the cytosol in the case of RSM SMC. C3-exoenzyme and Y 27632
caused concentration dependent relaxation of the IAS SMC. C3-exoenzyme reduced the
levels of RhoA-GTP by trapping RhoA into RhoA-Rho GDI complexes and decreased levels
of pThr696-MYPT1. In addition, direct introduction of active ROCK-II restored spontaneous
contractions in the IAS SMC pretreated with RhoA inhibitor C3-exoenzyme. Injection of
ROCK-II (30 nM) produced greater shortening of IAS SMC (19.9% ± 1.6%) as compared
to 30 nM of active PKC (11.5% ± 2.2%). Y 27632 almost completely abolished the effects
of active PKC. In addition, IAS SMC contractions caused by active ROCK-II did not change
significantly in the presence of Gö 6850. Likewise at similar concentrations (10 µM) Gö
6850 causes less relaxation of IAS SMC (16.2% ± 2.3%) as compared to Y 27632 (31.7%
± 3.2%). Levels of RhoA, RhoA-GTP, ROCK-II, MLC20, and of phospho-MYPT1, and
-MLC20 were higher in the IAS SMC vs. RSM and ASM. Levels of inactive RhoA and MYPT1
were higher in the RSM and ASM SMC vs. IAS SMC. Conclusions: RhoA/ROK play a
significant role in the cellular regulation of basal tone in the IAS smooth muscle via inhibition
of myosin phosphatase.
T1952
In-Vivo and In-Vitro Studies of the Length-Tension Relationship of External
Anal Sphincter Muscle in Rabbit
Mahadevan R. Rajasekaran, Yanfen Jiang, Andrew Lee, Ravinder K. Mittal
Aim: Length of a muscle prior to contraction is an important determinant of the force
generated by the muscle during contraction. The length at which a muscle operates in-vivo
(operational length) and at which it generates maximal force (optimal length) may be quite
different. We studied active and passive length-tension characteristics of the EAS in-vivo
and in-vitro to determine the optimal and operational length of the external anal sphincter
(EAS) in the rabbit. Methods: For in-vivo studies, female rabbits (n=7) were anesthetized
and anal canal pressure was recorded using a sleeve sensor catheter that was placed in the
custom designed catheter holders of different diameters (4.5mm, 6 mm and 9mm). This
arrangement stretched the EAS to different diameter while at the same time recorded anal
pressure. Measurements were obtained at rest and during electrical stimulation of the EAS
(1-5 mA). For the in-vitro studies, the rings of EAS were prepared and studied in a muscle
bath with increasing baseline tensions, and under isometric conditions. Results: In-vitro
studies revealed a typical length tension curve with maximal contraction during EFS at the
baseline tension of 2. 5 g. Pancuronium did not affect the EFS increase in the EAS contraction
suggesting that the contraction was due to direct muscle excitation. In Vivo, increase in the
anal probe size as well as electrical stimulation of the EAS produced an increase in the anal
canal pressure and tension (pressure x probe radius) (Table). Pancuronium bromide abolished
80-90% of the pressure increase caused by electrical stimulation suggesting, 1; that the
contraction was related to the stimulation of the nerves to the EAS and, 2; it was an
active rather than passive increase in muscle tension. Conclusions: Our data show that the
operational length of the EAS is significantly smaller than the optimal length. These data
have relevance to the EAS repair technique, i.e. the degree of EAS margin overlap during
sphincteroplasty.
Rabbit Anal Canal Tension (g/cm2) After EAS Stimulation
T1953
H-RAS Inhibits RHOA/ROK Leading to Decrease in the Basal Tone in the
Murine Internal Anal Sphincter
Marcio A. De godoy, Chirag A. Patel, Scott A. Waldman, Motoya Katsuki, Raymond F.
Regan, Satish Rattan
Background & Aims: While H-ras emerges as a modulator of smooth muscle contractility,
the role of this signaling molecule and its downstream mediators in regulating basal tone
in the internal anal sphincter (IAS) remains unknown. Present studies evaluated the role of
H-ras in regulating basal tone in the IAS. The implications of H-ras on the RhoA/Rho kinase
(ROK) pathway were also evaluated. Methods: Studies were performed in the IAS from the
wild type (H-ras+/+) and knock-out (H-ras-/-) mice. The basal tone of smooth muscle strips
were measured by isometric force transducers. Length of smooth muscle cells (SMCs) isolated
from the IAS in the basal state was determined by phase contrast microscopy. Experiments
were repeated in the presence of Y 27632 a ROK inhibitor. Involvement of the RhoA/ROK
signal transduction machinery was analyzed by RT-PCR, Western blot and immunocytochem-
istry. Reversal of H-ras knock-out effect was evaluated by transfection of SMCs with the
pcDNA3.1(+) eYFP H-ras G12V (constitutively activated) mutant. Transfection efficiency
was checked by confocal microscopy for yellow fluorescence at 514 nm. Results: Basal tone
of the H-ras-/- IAS (0.048 ± 0.004 g/mg; n = 5) was significantly (p < 0.05) higher and
relatively resistant to relaxation by Y 27632, compared to the H-ras+/+ IAS (0.033 ± 0.005
g/mg; n = 6). Similarly, the length of SMC from H-ras-/- IAS was significantly shorter (15.1
± 0.94%; p < 0.05; n = 35 - 40) than that from H-ras+/+ IAS, and Y 27632 eliminated this
difference. The distribution of RhoA immunoreactivity shifted from cytoplasm to plasma
membrane in SMCs from H-ras-/-, compared to H-ras+/+ mice, a change typically associated
with contraction. Further, SMCs from H-ras-/- mice exhibited increased levels (p < 0.05,
n = 3) of the contractile proteins ROCK-II (an isoform of Rho kinase), phosphorylated-
Thr696-MYPT1 (a marker for increased ROK activity) and phosphorylated-myosin light chain
(critical for contraction). In addition, the constitutively activated H-ras mutant increased
(15.5 ± 1.2 %; p < 0.05; n = 37 - 42) the length of H-ras-/- cells. Conversely, transfection
with the dominant negative H-ras mutant (pcDNA(+)3.1 eYFP H-ras S17N) decreased (16.6
± 1.4 %; p < 0.05; n = 38 - 40) the length of H-ras+/+ cells. These data provide direct
evidence for increased smooth muscle tone in H-ras-/- IAS. Conclusions: H-ras negatively
regulates the basal tone in the IAS smooth muscle by inhibiting signaling through the RhoA/
Rho-kinase pathway. Studies may have significant relevance in the pathophysiology and
therapy of certain anorectal motility disorders associated with the IAS.
T1954
Effects of Pelvic Floor Muscle Contraction On the Anal Canal Pressure
Sung-ae Jung, Bikram S. Padda, Dolores H. Pretorius, Charles W. Nager, Ravinder K.
Mittal
Introduction: Role of pelvic floor muscle (puborectalis muscle) contraction in the genesis
of anal canal pressure is not clear. Recent studies suggest that the vaginal distension enhances
the pelvic floor muscle contraction. Methods: We studied the effects of vaginal distension
on the anal canal pressure in 15 nullipara asymptomatic women. Anal canal pressure, rest
and squeeze were measured using station pull-through manometry technique with no vaginal
probe, a 10 mm vaginal probe and a 25 mm vaginal probe in place. Results: Rest and squeeze
vaginal pressures were significantly higher when measured with a 25 mm as compared to
a 10 mm probe prooving that the vaginal distension enhances the pelvic floor contraction.
In the presence of 25 mm vaginal probe, rest and squeeze anal pressures in the proximal
part of the anal canal are significantly higher as compared to no vaginal probe or a 10 mm
vaginal probe. On the other hand, distal anal pressures are not affected by any of the vaginal
probes. Atropine, 15 mg/kg had no influence on the rest and squeeze anal canal pressure,
with or without vaginal distension. Discussion: Our data suggests that the pelvic floor
contraction increases pressure in the proximal part of the anal canal that is anatomically
surrounded by the puborectalis muscle (pelvic floor) but not in the distal part of the anal
canal that is anatomically surrounded by the external anal sphincter. We propose that the
pelvic floor contraction plays an important role in fecal continence mechanism by increasing
proximal anal canal pressure.
The effects on the pressure of vaginal distension on the two zones of anal canal (*, p<0.05
vs. no probe or 10 mm probe)
T1955
Puborectalis Muscle Function and 3-Dimensional Ultrasound Images of the
Vaginal High Pressure Zone
Sung-ae Jung, Dolores H. Pretorius, Milena M. Weinstein, Bikram S. Padda, Charles W.
Nager, Ravinder K. Mittal
Background/Aims: Puborectalis muscle (PRM) plays an important role in the anal continence
mechanism but it is difficult to assess the PRM function by anal manometry because the
anal segment containing PRM overlaps with the internal anal sphincter. Our previous work
suggests that the vaginal high pressure zone (HPZ) may be related to the PRM contraction.
We studied the characteristics of vaginal HPZ using 3-dimensional ultrasound (3D US)
A-591 AGA Abstracts
images of the pelvic floor muscles. Methods: 9 nulliparous females were studied; A 10 cm
long polyethylene bag of 35 mm maximal diameter was placed across the vagina and gradually
inflated with water, volumes ranging from 45 cc to 70 cc. At each bag volume, a 3D US
volume of the pelvic floor was obtained using a 3-9 MHz US transducer placed on the
perineum-at rest and during sustained pelvic floor contraction. A 2D US image in the axial
plane of a line connecting the lower end of pubic bone with the apex of the anorectal angle
(PRM axis) was analyzed for the bag dimensions in the anterior-posterior (AP) and right-
left lateral (RL) planes. Results: The bag in the region of the Vaginal HPZ was completely
collapsed at low bag volumes; increase in the bag volume resulted in a gradual opening of
the vaginal HPZ with a characteristic increase in the AP and RL dimensions. The last segment
to open was located in the plane of PRM axis. Pelvic floor contraction caused a decrease in
the AP but not the RL dimension along the PRM axis. Conclusion: Our findings suggest
that the force responsible for the genesis of vaginal HPZ is directed in the axis of the PRM
and is consistent with the hypothesis that the vaginal HPZ is related to the PRM contraction.
Effect of bag volume on the AP and lateral dimension of vaginal bag in the PRM axis (*,
p<0.01 vs. rest)
T1956
Components of the Recto-Anal Inhibitory Reflex Correlate with Gut
Symptoms in Functional and Neuropathic Conditions
Dave R. Chatoor, Kumaran Thiruppathy, Amanda J. Roy, Anton V. Emmanuel
Introduction The recto-anal inhibitory reflex (RAIR) is a transient relaxation of the anal
sphincter in response to rectal distension which reflects the integrity of an important aspect
of the mechanism maintaining faecal continence, the sampling mechanism. The anatomic
substrate of the reflex is at enteric nerve plexus level, being absent in Hirschsprung's disease
and after low anterior resections, but preserved in spinal cord injury (SCI). Our aim was
to analyse whether distinct components of this reflex can be differentiated in healthy volun-
teers (HV), patients with idiopathic faecal incontinence (FI), constipation, multiple sclerosis
(MS) and SCI. Methods As part of standard anorectal physiology, the following subjects had
assessment of their RAIR: 21 HVs (14 female, mean age 35), 78 FI (63 female, mean age
45; urge FI in 44, passive FI in 34); 74 constipation (59 female, mean age 32; slow transit
[STC] 47, evacuation dysfunction 27); 49 MS (31 female, mean age 40; 35 with FI, 14
constipation); 71 SCI (32 female, mean age 37; 46 supra-conal, 25 cauda equina). The reflex
was elicited by rapid inflation of 50ml of air into a latex balloon seated at the top of the
anal canal, while recording maximal resting pressure with an 8 channel water-perfused
manometry system. Results Three phases of the reflex were identified- the latency from
stimulus to maximal sphincter relaxation; The duration of maximal relaxation; The time to
recovery of resting pressure. FI patients: Neither urge nor passive FI was associated with
any significant difference in RAIR phases compared to controls. Compared with controls,
patients with post-defaecation soiling had longer maximal relaxation (0.5 vs 1.2s, p<0.03)
and longer recovery time (4.3 vs 6.3s, p<0.05). Constipation: Neither STC nor evacuation
dysfunction was associated with any changes in reflex phases compared to controls. MS:
MS patients with FI, not constipation, had longer latency (2.7 vs 1.8s, p<0.03) and longer
maximal relaxation (1.2 vs 0.7s, p<0.05). SCI: Compared to controls, both supra-conal and
cauda equina patients had longer latencies (1.6 vs 2.6 vs 2.0s, p<0.05 both), and cauda
equina patients only had longer recovery (6.6 vs 4.3s, p<0.02). Conclusion Analysing
components of the RAIR provides reproducible and helpful information regarding the patho-
physiology of gut symptoms in functional and neuropathic conditions. In functional FI,
post-defaecation soiling is associated with an abnormally prolonged RAIR, suggesting that
delayed recovery of internal sphincter tone is responsible for this symptom. Similar abnormal
phases of the RAIR are seen in patients with MS and SCI which may explain their FI.
T1957
PYY1-36 and PYY3-36 Reduce Sensitivity to Rectal Distension in IBS Patients
Per M. Hellstrom, Jens J. Holst, Peter T. Schmidt
PYY is released from endocrine cells of the gut after meal intake, and has been shown to
slow gastric emptying and to inhibit small bowel motility in man. Its effect on more distal
parts of the gastrointestinal tract remains unexplored. As PYY exerts inhibitory actions on
motility it has been suggested as a smooth muscle relaxing agent and possible remedy in
IBS. Therefore the aim of the present study was to investigate the effect of PYY1-36 and
PYY3-36 on rectal sensorimotor function in IBS patients with or without a meal. Methods:
Twelve IBS patients (10 females; mean age 33 (22-55) years) were included. On three
separate days they randomly received a subcutaneous injection of saline, PYY1-36 or PYY3-
36. After injection patients underwent a rectal barostat study to investigate rectal sensorimotor
function. Rectal sensitivity (sensory thresholds and VAS) to balloon distensions was assessed
before and after intake of an 400kcal liquid meal (60 % fat, 20% carbohydrates, 20%
protein). Moreover, changes in rectal balloon volumes were measured in the fasting state
and after intake of the meal to evaluate effects on phasic (phasic volume events, PVEs) and
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tonic motor activity. Plasma concentrations of PYY were measured after injection of saline,
PYY1-36 or PYY 3-36. Results: PYY1-36 was well tolerated and no adverse reactions were
observed, whereas PYY3-36 evoked severe nausea in half of the subjects. The fasting balloon
volumes were similar after PYY1-36 91±6.9 ml, PYY3-36 (86@±5.9 ml) and saline (88 ±5.3
ml). After the meal the rectal balloon volumes decreased similarly with PYY1-36, PYY3-36
and saline (44±7, 46 ±8.9 and 41±10%), indicating increased tone. With PYY1-36 and 3-
36 in the fasting state sensory thresholds were increased from 15±2 to 22±5 and 17±3 to
23±5 mmHg; NS) and defecatory urge from 26±5 to 35±5 mmHg; p < 0.05). The discomfort
threshold was increased from 44±5 to 52±4 and 42±3 to 57±4.1 mmHg; p=0.03). Postprandial
sensory thresholds change similarly with increased discomfort threshold with PYY1-36 and
PYY3-36 from 40±4 to 52±3 and 44±3 and 55±5 mmHg; p=0.05). The plasma levels of
PYY increased from 6.7±1.7 to 33.5±9.3 after the meal. Plasma levels of PYY and after
injection of PYY1-36 and PYY3-36 were 103±17 and 117±21 pmol/L. The perceived intensity
of discomfort during the distensions as measured by VAS was not affected by GLP-1. Rectal
compliance was similar during GLP-1 and saline infusions. Conclusion: PYY1-36 and PYY3-
36 relaxes the smooth muscle of the rectum and increases compliance which may indicate
a beneficial effect in patients suffering from IBS with low rectal compliance.
T1958
Treatment of Symptomatic Oesophageal Spasm with Sildenafil
Rami Sweis, Angela Anggiansah, Roy Anggiansah, Terry Wong, Mark R. Fox
Introduction: Patients with oesophageal spasm complain of chest pain, bolus impaction and
regurgitation. The condition is diagnosed by manometry. The clinical usefulness of current
treatments is limited by poor efficacy and troublesome side effects. Oesophageal spasm is
due to imbalance between inhibitory nitroxinergic and excitatory cholinergic neurotransmit-
ters that coordinate peristalsis and lower oesophageal sphincter (LOS) relaxation. Studies
in healthy volunteers and patients with oesophageal dysmotility have shown that sildenafil,
a medication that inhibits breakdown of endogenous nitric oxide, reduces contractile pressure
and slows distal peristaltic velocity in response to water swallows.[Lee et al. NGM03] However
the clinical efficacy of sildenafil in symptomatic oesophageal spasm has not been defined.
Method: Open-label sildenafil treatment in patients with treatment resistant, symptomatic
oesophageal spasm. The effects on esophageal function were documented by high resolution
manometry (HRM). Results: Two patients with long-standing dysphagia and chest pain on
swallowing with weight loss were studied. Endoscopy and barium swallow revealed no
mucosal or structural disease. Case 1 HRM revealed focal spasm in the mid-oesophagus on
50% of water swallows and all solid swallows, the latter associated with severe chest pain.
Median contractile pressure was 80mmHg, LOS pressure was high but relaxation was normal.
Sildenafil completely inhibited smooth muscle contraction in 90% of water swallows and
LOS pressure fell from 56 to 25mmHg; however normal, coordinated peristalsis was seen
with bread swallows. Self-reported chest pain fell from 9 to 2/10. Case 2 HRM showed
peristaltic velocity (5-6 cm/s) with diffuse oesophageal spasm in 30% of water swallows.
Diffuse, repetitive oesophageal spasms associated with chest pain and dysphagia were present
with solid swallows. Sildenafil reduced contractile pressure from median 150 to 40mmHg
for water swallows, LOS pressure fell from 12 to 8mmHg. Spasms with solid swallows
reduced from 100 to ~50%, contractile pressure fell from 200 to 50mmHg and repetitive
contractions were no longer present. Chest pain resolved from 7 to 1/10 and dysphagia
improved. Both patients remained symptom free on 25-50mg sildenafil b.i.d. without side
effects; however treatment was withdrawn due to cost. Conclusion: Sildenafil is a promising
treatment for symptomatic, treatment resistant oesophageal spasm. Increasing the local
availability of nitric oxide (NO) appears to normalize oesophageal function and relieve chest
pain without the systemic side effects associated with conventional NO donors.
T1959
Mechanisms of Esophageal Bolus Propulsion in Human Neonates: Primary and
Secondary Peristalsis
Alankar Gupta, Sudarshan R. Jadcherla
Esophageal motility facilitates bolus propulsion away from the aerodigestive tract and consti-
tutes an important antireflux mechanism providing airway protection. The propulsive charac-
teristics of spontaneous primary peristalsis (PP) and esophageal distention induced secondary
peristalsis (SP) in human neonates are not well understood. AIM: To test the hypothesis
that esophageal propulsive characteristics (amplitude and duration of waveforms, onset and
peak peristaltic velocities) are different depending on the locus of origin of peristalsis.
METHODS: We studied swallow integrated esophageal motility responses during spontan-
eous PP and esophageal provocation induced SP in 6 neonates (40 ± 7 wks) using a specially
built esophageal micromanometry catheter, concurrent submental EMG and respitrace. SP
resulting from esophageal stimuli (0.5, 1.0 and 2.0 ml, air and liquids) were compared with
spontaneous PP. All values shown as mean ± SD, unless stated otherwise. RESULTS: A total
of 58 PP and 65 SP events were analyzed. The contraction amplitude and duration at
proximal and middle esophagus were similar during PP vs. SP. However, at distal esophagus,
the amplitude (40 ± 19 vs. 32 ± 16 mmHg, P<0.05, PP vs. SP) and duration (3.1 ± 1.2 vs.
2.7 ± 1.0 sec, P<0.05, PP vs. SP) were different. Onset of waveform to peak, and from peak
to offset of waveform at proximal, middle and distal esophagus were similar (PP vs. SP).
Contractile amplitudes at proximal vs. middle vs. distal esophagus were different during PP
events (P<0.001)and SP events (P<0.001); in that pressure gradient existed between the
proximal and distal loci. Contractile duration of proximal vs. middle vs. distal esophagus
during SP events were different (P<0.001), and not with PP. The onset peristaltic velocity
from proximal to middle esophagus during SP vs. PP was 5.4 ± 9.4 vs. 2.4 ± 2.8 cm/sec
(P<0.05). The intra bolus pressure at proximal, middle and distal loci during PP and SP
were similar. However, infusion volume (0.5, 1.0, 2.0 ml) vs. intra bolus pressure (7 ± 6,
8 ± 5, 13 ± 6 mmHg) relationship during SP events was evident (P<0.005). CONCLUSIONS:
1) Contractile amplitude and duration at distal esophagus were lesser with SP compared to
PP. 2) Contractile gradient for amplitude and duration was noted between proximal, middle
and distal esophageal loci during both PP and SP. 3) Peristaltic velocity was faster with SP
(vs. PP). 4)Volume dependent increase in intra bolus pressure was noted with SP. 5)
Collectively, these propulsive mechanisms during PP or SP may protect the aerodigestive tract.
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T1960
Esophageal Motility in Children with Suspected Gastroesophageal Reflux
Disease and Neurological Inpairment
Ilse Hoffman, T. Degreef, Jan F. Tack, N. Haesendonck
Gastroesophageal reflux (GERD) is common in neurologically handicapped children and
can be a serious disorder with a higher complication rate. Esophageal dysmotility has been
described in both children and adults with GERD, but only limited data are available on
esophageal motor function in children with psychomotor retardation (PMR). The aim of the
study is to determine the influence of the neurological development on the esophageal
motility in gastroesophageal reflux disease (GERD). Methods: Consecutive children referred
for severe GER(D) symptoms all underwent a barium swallow, upper endoscopy, pH-
monitoring and stationary water-perfused esophageal manometry. Results are shown as
mean±SD and compared by Student's t-test. Results: The patient group consisted of 185
patients (76 girls, mean age 6.2±4.9 years), 72 of which had PMR. Endoscopy showed
erosive esophagitis respectively in 78 and 33 patients. Esophageal pH-monitoring showed
a mean % time pH<4 of 7.5±0.6 % vs. 12.2±2.0 % in those without and with neurological
impairment respectively (p<0.05). When patients with normal development and PMR were
compared, significant differences were found in the occurrence of peristaltic wave progression
(94±21 vs. 79±38 %; p=0.001), velocity of propagation in the distal esophagus (0.8±0.4 vs.
0.6±0.5 cm/sec; p=0.05) and duration of contraction in the distal esophagus (3.1±0.8 vs.
3.4±1 sec; p=0.05). No statistically significant differences were found for the resting lower
esophageal sphincter (LES) pressure (16.4±6.7 vs. 16.7±6.6 mmHg, NS), duration of LES
relaxation (6.0±1.6 vs. 6.1±1.6 sec, NS), mean and maximal contraction amplitude in the
proximal esophagus (46.1±21.1 vs. 43.8±18.9 mm Hg; 51.7±25.5 vs. 50.2±23.8 mm Hg,
NS), in the mid-esophagus (69.1±28.1 vs. 66.7±38 mm Hg; 79±32.4 vs. 74.2±41.4 m Hg,
NS) and in the distal esophagus (77±34.9 vs. 76.2±39 mm Hg; 84.6±37.5 vs. 84.3±44.6
mm Hg, NS), velocity of propagation in the proximal esophagus (0.8±0.8 vs. 0.9±0.4 cm/
sec, NS), and duration of contraction in the proximal (3.3±4.5 vs. 2.9±1 sec, NS) and mid-
esophagus (3.5±4.9 vs. 3.1±0.8 sec, NS). Conclusion: Children with PMR and suspected
GERD have higher esophageal acid exposure and more impaired motility in the distal
esophagus compared to children with normal neurological development and suspected
GERD. Abnormalities in distal esophageal peristalsis may, through impaired clearance, con-
tribute to the pathogenesis of GERD in children with PMR. In children with PMR, symptoms
suggestive of GERD should be actively considered and a lowered threshold for further
investigation may be appropriate.
T1961
The Effect of Electric Acupoint Stimulation On Lower Esophageal Sphincter
Motor Function and Gastro-Oesophageal Reflux in Healthy Volunteers
Edmund Tse, Guru Iyngkaran, Katrina Ching, Nam Nguyen, Richard H. Holloway
Acupuncture has been shown to modulate visceral sensation and function. Traditionally,
stimulation at the pericardial meridian (Neiguan, 3 cm proximal to flexor crease at wrist)
has been used to treat hiccups, belching, nausea and vomiting. We have shown previously
that electro-acustimulation (EAS) at Neiguan inhibits triggering of transient lower esophageal
sphincter relaxations (TLESRs) in response to balloon gastric distension (AJP,
2005;289(2):G197). The effects on post-prandial LES function and gastroesophageal reflux
are unknown. Aims: To investigate the effect of EAS on post-prandial lower oesophageal
sphincter (LES) function and gastroesophageal reflux in healthy volunteers. Methods: In
10 healthy volunteers, esophageal motility and pH were recorded in the sitting position for
3 hours after a standard meal with a multilumen assembly that incorporated a sleeve sensor.
Measurements were made during stimulation (100Hz, pulse duration 0.1ms, 10-20 mA) for
180 minutes at Neiguan or at a sham stimulation site at the hip. Neiguan and sham
stimulations were performed on the separate days in random order separated by at least 1
week. Results: EAS had no effect on the number of post-prandial TLESRs, esophageal acid
exposure or basal LES pressure (Table). Conclusions: In contrast to its effects on TLESRS
stimulated by balloon distension, electro-acustimulation at Neiguan did not inhibit triggering
of TLERS or gastro-oesophageal reflux stimulated by a meal. It is possible that meal-related
humoral or other stimuli responsible for meal-related triggering of TLESRS are not responsive
to electro acustimulation inhibition.
T1962
Diffuse Esophageal Spasm in Children
Jason Maxfield, John Rosen, Teri Lavenbarg, John Belmont, Samah Murad, Paul E.
Hyman
Diffuse esophageal spasm (DES) causes chest pain and/or dysphagia in adults but is rarely
reported in children. We defined DES as simultaneous contractions associated with >10%
of swallows and mean simultaneous contraction amplitude > 30 mmHg (Castell, 2004). We
reviewed charts of 283 subjects 0-18 years of age after esophageal manometry. Results
included normal motility 61%, nonspecific esophageal motility disorder 20%, DES 14% (n=
40), and achalasia 4%. Of 24 subjects with DES < 5 years, chief complaints were food
refusal (15), vomiting (3), choking (3), retching (1), and no symptoms (3). Of 15 subjects
with DES > 5 years, chief complaints were chest pain (5), dysphagia (3), vomiting (3), food
refusal (2), and retching (2). Food refusal was more common in infants and toddlers than
in children and teens (p<0.05). Esophageal manometry was the only motility test in 18
subjects; 22 subjects were evaluated with antroduodenal (15) or colonic manometry (3) or
both (4). Of these 22 subjects, 9 were diagnosed with DES only, and 13 were diagnosed
with generalized motility disorders. Prior to manometry, 26 subjects (67%) had surgery for
symptoms: 20 gastrostomies, 14 fundoplications, 3 pyloroplasties, 1 Collis gastroplasty, 1
gastrojejunostomy, and 1 patient underwent LES balloon dilation two times. Comorbid
medical conditions, often multiple, were found in 34 of 39 DES subjects: idiopathic develop-
mental delay (7), heart malformation (7), Down's Syndrome (6), cerebral palsy (4), seizures
(2), neuropathic pseudoobstruction (2), and mitochondrial disorder (2). Chromosome 3p25
deletion, chromosome X q26-28 duplication, mixed connective tissue disease, holoprosence-
phaly, Rett Syndrome, Charcot-Marie-Tooth disease, Ehlers-Danlos Syndrome, Hirschs-
prung's disease, isolated growth hormone deficiency, and celiac disease were each found in
one subject. Follow up treatment modalities and effects were variable. One 2 year old
progressed to achalasia by age 4years. We conclude that DES in infants and children is not
rare. DES should be considered when children present with food refusal, dysphagia, chest
pain, or unexplained vomiting. DES in infants and children usually presents as a comorbid
condition. We speculate that early diagnosis and treatment may prevent unnecessary surgery
in some cases.
T1963
Gender Affects Phonation Related UES Contraction
Lilani P. Perera, Linda Tatro, Candy Hofmann, Mark K. Kern, Reza Shaker
Earlier studies have documented the presence of UES contractile response during phonation.
These studies have also shown that the magnitude of this UES pressure increase is significantly
higher than phonation related pressure increases in the esophageal body, LES and stomach.
Since it is known that gender affects the larynx and voice and UES is also comprised of
striated muscle our aim was to determine the effect of gender on phonation related UES
contraction. METHODS: We studied 7 male and 10 female healthy volunteers (18-35yr) by
concurrent high resolution manometry (Manoscan, Sierra Scientific) to record UES and
upper GI tract pressure and voice analysis (Praat, University of Amsterdam). We tested high
and low pitch vowels (AA, EE) (30-60dB) for durations of 10 seconds. Each vowel was
repeated X3. RESULTS: Both high and low pitch vowels had significantly lower frequency
in males than females (Hz) (Mann- Whitney Rank Sum Test, #P<0.05) (Table). On the
contrary UES pressure increase during phonation was significantly higher for all of the
studied pitches in males than females (Mann- Whitney Rank Sum Test, *P<0.05) (Table).
There was no direct correlation between UESP and pitch. CONCLUSIONS: Phonation
related UES contraction is gender dependent. Females exhibit significantly weaker contractile
response during phonation compared to males. Supported in part by NIH grants T32
DK61923 and RO1 DK25731.
# male< female (p<0.05) * male>female (p<0.05)
T1964
Predicting Factors for Repeated Pneumatic Balloon Dilatation in Patients with
Primary Achalasia
J. Alderliesten, J. Conchillo, I. Leeuwenburgh, E. J. Kuipers
Background and aim: Pneumatic balloon dilatation (PD) is a regular treatment modality for
achalasia patients. The reported success rates of PD vary. Recurrence of symptoms often
requires repeated PD. Aim of this study was to identify predicting factors for symptom
recurrence requiring repeated PD in patients with primary achalasia. Methods: 391 patients
with primary achalasia (M/F 194/197, mean age 50.6 years) treated with PD between 1974
and 2006 were included in this longitudinal cohort study. Baseline PD was performed on
3 consecutive days with balloons of either the same diameter (40 mm), or incremental (30,
35, and 40 mm) diameter all inflated to a pressure of 300 mm Hg for 1 minute. Recurrence
of achalasia was defined as symptom recurrence (dysphagia, regurgitation and weight loss)
in combination with increased lower esophageal sphincter (LES) pressure on manometry,
requiring repeated PD. Patient's characteristics (age at presentation, gender), results of timed
barium esophagram and manometry before treatment, as well as PD balloon characteristics
(consistent vs incremental diameter and (in)complete obliteration of the balloon's waist
during PD) were evaluated as predictors for disease recurrence. Results: 117 patients (29.9
%) underwent repeated PD after a mean follow-up of 46.5 months (range 1-288). The mean
age of patients requiring repeated PD was significantly lower than the age of patients without
recurrence (43.2 vs 54.2 years, p < 0.001). Furthermore, incomplete obliteration of the
balloon's waist during baseline PD was associated with a higher chance of disease recurrence
during follow-up (recurrence in incomplete vs complete obliteration group 50.8 vs 19.9 %,
p < 0.001). Recurrence in the incomplete obliteration group also occurred earlier (after
mean 39.4 months vs 58.4 months in the complete obliteration group, p = 0.06). No
differences between groups were found regarding gender (p= 0.66), presence of mouse-tail
and/or esophagus dilatation on the timed barium esophagram before treatment (p=0.48 and
p=0.52, respectively), LES pressure (p=0.54), absence of LES relaxation before treatment
(p= 0.89) or balloon diameter (p= 0.73). Conclusion: In patients with primary achalasia,
young age at presentation and incomplete obliteration of the balloon's waist during PD are
predicting factors for the need of repeated PD during follow-up. These factors should be
taking into account in the follow-up strategy of achalasia patients.
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T1965
Relationship Between Nadir Lower Esophageal Sphincter (LES) Pressure and
Wave Amplitude On Esophageal Bolus Clearance
Nam Q. Nguyen, Katrina Ching, Marcus Tippett, Andrea J. Smout, Richard H. Holloway
Esophageal bolus clearance is determined primarily by wave amplitude and propagation of
the pressure wave. Incomplete LES relaxation impairs clearance. During swallowing, LES
relaxation is frequently not complete and a small but detectable nadir pressure remains.
The impact of nadir LES pressure on the relationship between wave amplitude and bolus
clearance is unclear. Aim. To assess the relationship between nadir LES pressure and wave
amplitude in esophageal bolus clearance. Methods. Concurrent esophageal manometry and
intra-luminal impedance was performed in 137 subjects (42=healthy, 24=non-obstructive
dysphagia (NOD) and 71=gastroesophageal reflux (GER)). Patients with achalasia and diffuse
esophageal spasm were excluded. In each subject, esophageal motility and bolus clearance
were measured concurrently at 4 sites, each 5 cm apart starting 2 cm above the lower
esophageal sphincter (LES). Ten, 5 ml liquid boluses and 10 x 5 ml viscous boluses were
tested in each subject. Impaired esophageal clearance was defined by prolonged bolus
presence time (BPT) and/or total bolus transit time (TBTT). Swallow responses were categor-
ized by nadir LES pressure. For each category of nadir pressure, wave amplitudes at the
distal 2 recording sites were grouped into bins of 10 mmHg and the proportion of waves
in each bin associated with a normal BPT was determined. Results. Nadir LES pressure,
distal BPT, TBTT and the proportion of impaired esophageal clearance in patients with NOD
were greater than those of healthy subjects and patients with GER. Overall, responses with
impaired esophageal clearance had significantly lower pressure wave amplitudes (7 cm above
LES: 54±1 vs. 81±1 mmHg; P<0.01) and higher nadir LES pressure (2.7±0.4 vs. 1.0±0.1
mmHg, P<0.01). For each level of nadir LES pressure, there was a direct relationship between
distal wave amplitude and successful bolus clearance of both liquid and viscous boluses
from the distal esophagus. As nadir LES pressure increased, the relationship between wave
amplitude and bolus clearance shifted to the right and higher amplitudes were required to
achieve the same effectiveness of clearance. Hypotensive responses (<30mmHg) with nadir
LES pressures ≥ 3mmHg were less likely to clear than those with nadir LES pressures
<3mmHg, for both liquid (7/29 vs. 162/276; P<0.001) or viscous boluses (11/46 vs. 176/
279; P<0.0001). Conclusions. Nadir LES pressure is an important determinant of bolus
clearance from the distal esophagus, particularly in patients with NOD. Even in the 3-
7mmHg range, nadir LES pressure has a significant impact on the relationship between
pressure wave amplitude and esophagus bolus clearance.
T1966
Reliability of Manometric and Impedance Findings During Combined
Impedance-Manometry Testing
Daniel Pohl, Edoardo Savarino, Mentore Ribolsi, Bernadette Stutz, Michael Fried, Radu
Tutuian
Introduction: Impedance manometry (MII-EM) is a clinically available tool to evaluate
esophageal function by measuring intraesophageal pressure changes and bolus transit. Cur-
rently there is limited information on the reliability and inter-observer agreement on MII-
EM findings. Aim: To evaluate the inter-observer agreement for liquid and solid swallows
in healthy volunteers. Methods: Combined MII-EM measurements were performed in healthy
volunteers (HV) during 10 saline (5ml) and 10 bread swallows in recumbent position.
Pressure data were recorded in the lower esophageal sphincter (LES) and 5, 10, 15 and
20cm above the LES. Bolus presence data were recorded at 2, 5, 10, 15 and 20 cm above
the LES. Each tracing was reviewed independently by 4 investigators (A, B, C, D) who
determined average bolus presence time (BTT), distal esophageal amplitude (DEA) and lower
esophageal sphincter residual pressure (LESRP) in each patient. Overall manometric and bolus
transit abnormalities were interpreted using previously published criteria (Am J Gastroenterol.
2004;99:1011). Results: In the group of 20 HV (8 f, mean age 28, range 20-44) 13 had
normal manometry, 5 features of IEM and 2 features of DES. 90% of individuals had normal
bolus transit. We found a very good correlation between the readings of all 4 investigators
for DEA (intra-class correlation coefficient (ICC) 0.996) and BTT (ICC 0.968) and a moderate
correlation for LESRP (ICC 0.783). With respect to the overall study evaluation the manomet-
ric and impedance interpretations of the 4 investigators were consistent (ICC between 0.826
and 0.929) with a moderate to very good agreement (see table 1 for kappa statistics).
Conclusion: The good consistency of manometric and bolus transit readings supports the
reliability of combined impedance-manometry findings.
Below diagonal are agreements (kappa values) between two investigators for manometric
findings, above the diagonal those for impedance findings
T1967
Hypercontracting Esophagus Is Associated with Hypertensive Lower
Esophageal Sphincter (LES)
Robin G. Kindig, Steven P. Harrell, Jennifer Koopman, Scheryl Woosley, John M. Wo
It is unclear if nutcracker esophagus and hypertensive LES represent a common diffuse
hypercontracting esophageal syndrome. Aim: To determine if there is a significant relationship
between the esophageal body and the LES. Methods: Comprehensive review was performed
on all pts undergoing esophageal manometry. LES pressure was defined as mean end
expiratory pressure with water-perfused station pull-through. Subjects were classified as
hypotensive LES (≤15 mmHg), normotensive LES (16-45 mmHg) or hypertensive LES (>45
mmHg). Distal esophageal peristaltic pressure was defined as mean pressure at 3 & 8 cm
above LES; nutcracker esophagus was defined if >180 mmHg. Impaired esophageal peristalsis
was defined if mean distal esophageal peristaltic pressure <40 mmHg or peristalsis <60%.
Pts with aperistalsis were excluded. Mann-Whitney U tests and Pearson correlation were
used. Results: 2,796 pts underwent esophageal manometry from 1997-2005. 45% of pts
had hypotensive LES, 52% had normotensive LES, and only 3.5% had hypertensive LES.
Pts with hypertensive LES were more likely to be female and present with dysphagia.
Nutcracker esophagus was present in 19% of pts with hypertensive LES, compared to only
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2.3% in normotensive LES and 0.2% in hypotensive LES (p<0.001). Impaired esophageal
peristalsis was more prevalent in hypotensive LES. Distal peristaltic pressures were greater
in hypertensive LES compared to other groups (p<0.001, see figure). Correlation (R) between
esophageal and LES pressures was 0.39 (p<0.001). Conclusions: 1) Nutcracker esophagus
and hypertensive LES did not overlap in most patients. 2) However, higher esophageal body
pressures were associated with higher LES pressures.
Box plots (median and 35th-75th percentile) of esophageal peristaltic pressure
T1968
The Role of Proximal Gastric Volume in Spatial Separation of Diaphragm and
Lower Esophageal Sphincter in GERD Patients and Controls
Robert C. Scheffer, Albert J. Bredenoord, Hein G. Gooszen, Geoff Hebbard, Melvin
Samsom
Spatial separation of the diaphragm and lower esophageal sphincter (LES) occurs frequently
in patients with a sliding hiatus hernia and favors gastroesophageal reflux. Although fundic
accommodation is associated with a lower basal LES pressure, its effect on esophagogastric
junction configuration and hiatal hernia is unknown. Therefore, the aim of this study was
to investigate of the relationship between proximal gastric volume, the presence of a double
high pressure zone (HPZ) (non-reduced hernia) or a single HPZ (reduced hernia) at the
EGJ and acid reflux. Twenty GERD patients (12 men, 8 women) were studied and compared
to 20 healthy controls (10 men, 10 women). High-resolution manometry and pH recording
was performed for 1 hour before and 2 hours following meal ingestion (500 mL/300 kcal).
Volume of the proximal stomach was assessed with three-dimensional ultrasonography
before and every 15 minutes after meal ingestion. During fasting the double HPZ (non-
reduced hernia) was present for 31.9 +/- 4.9 minutes/h (53.2%) in GERD patients, and 8.7
+/- 3.3 minutes/h (14.5%) in controls (P<.001). In GERD patients, the presence of non-
reduced hernia (double HPZ) fell during the first postprandial hour to 15.9 +/- 4.2 minutes/
h, 26.5%, P<.01 whilst this phenomenon was not observed in controls. The rate of transition
between the 2 profiles was 5.7 +/- 1.1 per hour in GERD patients and 2.5 +/- 1.0. per hour
in controls (P<.001). The pre- and postprandial reflux rate in GERD patients during double
HPZ (6.4 +/- 1.1/hr and 18.4 +/- 4.3/hr resp.) was significantly higher than during single
HPZ (2.1 +/- 0.6/hr; P<.05 and 3.8 +/- 0.9/hr; P<.05). A similar difference was found in
controls. Furthermore, an inverse correlation was found between fundic volume and the
time the non-reduced hernia state was present (r=-0.45; P<.05) in GERD patients, but not
in controls. Conclusions: 1. In GERD patients the majority of reflux occurs during the hernia
state. 2. A postprandial increase in proximal gastric volume is related to a decrease in
hernia prevalence.
T1969
Improved Diagnosis of Rumination Using Impedance-Manometry
Nathalie Rommel, Jan Tack, Daniel Sifrim
Rumination is an eating disorder clinically suspected in the presence of chronic regurgitation
of recently ingested food with subsequent re-mastication and swallowing. Esophageal mano-
metry is currently used to confirm the diagnosis, showing post-prandial episodes of straining
(abrupt rise in intragastric pressure), common cavity (cc) in the esophageal body and primary
or secondary peristalsis. In most patients the diagnosis is unequivocal. In some patients,
however, it is difficult to distinguish rumination from postprandial belching-regurgitation,
being the manometric pattern identical in both situations. Esophageal impedance allows
recognition between liquid and gas gastroesophageal reflux. We aimed 1) to improved
diagnosis of rumination using combined impedance-manometry; 2) to assess the gastric
pressure-esophageal flow pattern in rumination events. Methods: Sixteen patients with
clinically suspected rumination underwent impedance manometry monitoring for 1 hour
after a solid liquid meal. Manometry was first analyzed blindly to the impedance pattern.
All straining episodes were identified and tracings were characterized as rumination if the
majority of them were followed by esophageal cc and peristalsis. Thereafter, impedance
tracings were unblinded and each straining episode was analyzed for the presence of liquid
and/or gas esophageal retrograde flow. Rumination was confirmed by impedance if the
majority of strainings were associated with liquid retrograde flow. Results: Postprandial
manometry showed a pattern compatible with rumination in 12/16 patients. Impedance
confirmed the 4 manometric “excluded” patients and found straining-gas retroflow (belching)
in 4 of the 12 manometric “included” patients. In total, impedance-manometry confirmed
the clinical diagnosis of rumination in 8 of the 16 patients with clinical suspicion of
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rumination. In 102 clearly identified rumination events, the onset of gastric strain (manome-
try) occurred before the onset of esophageal liquid retroflow (impedance) (1.4 ± 0.4 sec)
in 58 % of cases or simultaneously in 37% of cases. In most cases (86%) esophageal
retrograde flow started before (2.2 ± 1.5 sec) the peak gastric strain pressure. Conclusion:
Clinical-manometric diagnosis was correct in half of the suspected rumination cases. Post-
prandial impedance-manometry monitoring improves diagnosis because it allows distinction
between rumination from postprandial belching-regurgitation. During rumination, eso-
phageal liquid retroflow is first driven by an early small rise in intragastric pressure preceding
the peak pressure observed during straining.
T1970
The Macrolide Antibiotic Azithromycin Reduces Gastroesophageal Reflux in
Lung Transplant Patients
Kathleen Blondeau, Veerle Mertens, Bart Vanaudenaerde, Geert Verleden, Dirk Van
raemdonck, Lieven Dupont, Daniel Sifrim
Azithromycin (AZI) is a macrolide antibiotic that improves lung function in a subgroup of
lung transplant patients (LTx) with Bronchiolites Obliterans Syndrome (BOS). Gastroeso-
phageal reflux (GER) has been implicated in the pathogenesis of BOS. Macrolide antibiotics,
such as erythromycin or AZY may affect GER by modifying esophageal and gastric motility.
The aim of our study was to evaluate the effect of AZI on gastro-esophageal reflux and
gastric aspiration in LTx recipients. Methods: In 52 LTx patients, acid and weakly acidic
GER were measured with 24hrs pH-impedance recordings and gastric aspiration was assessed
by pepsin determination (ELISA) in bronchoalveolar lavage fluid (BALF). AZI 250mg/day
was administered to 19/52 patients. Reflux parameters and pepsin levels were compared
between patients with and without AZI. Results: Patients “on” AZI had significantly lower
esophageal acid exposure (1.15% vs. 3.62%, p=0.018) and bolus exposure (0.6% vs. 1.2%,
p=0.04) compared to patients “off” AZI. The proximal extent of reflux (number of reflux
events that reach 15 cm above LES) was lower in patients “on” AZI (6 (2-11) compared to
patients without AZI (12 (6-22).The total number of reflux episodes was not affected (31
(9-50) vs. 37 (20-55) and AZI did not modify the ratio acid/weakly acidic reflux (30% acid
vs. 36% acid, p=0.8). In spite of its effects on reflux, AZI did not reduce pepsin levels in
BALF (715ng/ml vs. 531ng/ml, ns). Conclusion: AZI reduces GER by improving esophageal
clearance after reflux. This effect is probably due to enhanced esophageal motility and
accelerated gastric emptying. However, AZI did not reduce the levels of pepsin in BALF
suggesting that even with less gastroesophageal reflux, gastric content may accumulate in
the airway of lung transplant patients with poor lung clearance function.
T1971
Sex-Specific Association of the Ptpn22 C1857t Polymorphism with Achalasia
Juan L. Mendoza, Jose L. Santiago, Raquel Lana, Alfonso Martinez, Antonio Ruiz de leon,
Emilio G. De la concha, Elena Urcelay, Manuel Diaz-rubio
Background and aims: The protein tyrosin phosphatase N22 gene (PTPN22) on chromosome
1p13 encodes a lymphoid-specific phosphatase (LYP) which is an important downregulator
of T cell activation. A functional PTPN22 polymorphism, C1858T, was found associated
with different autoimmune diseases in different populations. In this study, we aimed at
elucidating for the first time the role of this variant in predisposition to achalasia. Subjects:
A case-control was performed with 231 Spanish white unrelated patients diagnosed of
achalasia and 554 healthy controls. Methods: Both patients and controls were genotyped
for PTPN22 C1858T using a TaqMan Assay by Design (Applied Biosystem, Foster City, Ca,
USA) analyzed in a 7900HT Fast Real-Time PCR System. Results: We found no significant
association of the 1858T allele with an increased risk for developing achalasia in our Spanish
population [carriers of allele T vs. CC: OR=1.38 (0.88-2.16); p=0.13]. However, a different
distribution of this allele was observed between female and male patients [carriers of allele
T vs. CC: OR=2.06 (0.96-4.42); p=0.042] and also between female patients and controls
[OR=1.94 (1.12-3.36); p=0.01], but no between male patients and controls [OR=0.94 (0.50-
1.77); p=0.85]. After HLA and antineural antibodies to myenteric plexus stratification, only
women DQA1*0103-negative [OR=2.23 (1.22-4.05); p=0.004)], autoantibody positive [OR=
2.14 (0.97-4.61); p=0.035] or presenting both characters simultaneously [OR=2.62 (1.13-
5.97); p=0.017] were different from controls. Conclusion: The PTPN22 1858T allele which
has been linked to increased activity of the gene is a susceptibility factor for Spanish women
suffering from achalasia.
T1972
How Should Symptom Index Be Calculated During 24 Hour Esophageal pH
Monitoring?
Vivan Talwar, Peter Wurm, John De caestecker
24 hour pH monitoring is the investigation of choice for diagnosing gastro-esophageal reflux
(GER) in endoscopy negative patients. Concordance between symptoms and reflux events
by calculating the symptom index (SI) improves the diagnostic value of the test but the best
way of calculating SI remains uncertain. Aim: To compare SI values calculated by different
established methods in patients with suspected GER and normal endoscopy in comparison
with symptom response to Esomeprazole therapy. Methods: Patients with suspected GER
and normal endoscopy underwent 24h esophageal pH monitoring. Patients with at least 2
symptoms during pH monitoring were randomised to Esomeprazole 40mg od or matching
placebo each for 2 weeks (1 week washout) using a double blinded crossover format.
Symptom response (‘GER score') was assessed by symptom diary with heartburn and acid
regurgitation scores being calculated (daily severity over last 7 days of both treatment arms).
The following indices were calculated: symptom specificity index (SSpI) - number of reflux-
related symptom episodes divided by total number of symptom episodes (%); positive if
>50%; Symptom sensitivity index (SSI) - number of reflux episodes associated with symptoms
divided by the total number of reflux episode (%); positive if >10%; symptom associated
probability (SAP) - comparing 2 minute epochs with or without symptoms and reflux using
Fisher's Exact Test; positive if p<0.05. For all calculations, a symptom-reflux association
was present if symptoms occurred within 2 minutes of a pH fall of either 1 pH unit or a
drop to below pH 4. A positive response was an improvement of GER score of >50%
comparing Esomeprazole treatment to placebo. Results: 20 of 24 patients completed the
trial with 12 considered responders to Esomeprazole {GER score comparing PPI vs. placebo
paired Student's t test; 12.4 (SD 17.1) vs. 23.1 (SD 21.1) (p=.03)}. 14 patients were found
to have abnormal acid reflux (% time pH<4 either for day >8.2% and/or for night >3%).
The positive (PPV) and negative (NPV) predictive values were: SSpI (positive in 14 patients)
71.4% and 66.6%, SAP (positive in 12) 66.6% and 50%, SSI (positive in 2 patients)100%
and 44.4%. Conclusion: SSpI, the ‘original' and simplest calculation, predicts response to
PPI as well or better than the other indices.
T1973
New Insight Into Phonation Induced Increase in the Upper Esophageal
Sphincter Pressure; Contraction Vs Compression
Lilani P. Perera, Mark K. Kern, Linda Tatro, Candy Hofmann, Shiko Kuribayashi, Krisna
Chai, Reza Shaker
Earlier studies have shown that phonation is associated with a significant increase in upper
esophageal sphincter pressure (UESP), providing a barrier against potential pharyngeal
reflux of gastric content. The mechanism of this increase during phonation has not been
systematically studied. One potential candidate could be posterior movement of the larynx
resulting in compression of the manometric catheter against spine. AIM: To determine and
correlate phonation induced laryngeal movement with UESP. METHODS: We studied 8
healthy volunteers (2M, 6F) by concurrent high resolution manometry (Manoscan, Sierra
Scientific), video fluoroscopy (30 frames/ second) and voice recording (Praat, University of
Amsterdam).We tested high pitch (HP) and low pitch (LP) vowels for durations of 10
seconds. Fluoroscopic images were digitized and analyzed for laryngeal movement. RESULTS:
HP and LP vowels (AA & EE) had significantly different frequencies 266± 29 vs.160 ± 15,
268 ± 28 vs. 151 ± 16 (Hz) respectively (P<0.05). The UES pressure (mmHg, Mean ± SE)
during phonation compared to that of the immediately prior to phonation was significantly
higher (*P<0.05) (table). None of the phonations were associated with posterior movement
of the larynx (table). CONCLUSIONS: Both high pitch and low pitch phonations induce a
significant increase in UES pressure unaccompanied by posterior laryngeal movement sup-
porting the notion of a neurally mediated contraction for this phenomenon. Supported in
part by NIH grants T32 DK61923 and RO1 DK25731.
T1974
Prevalence, Risk Factors and Conservative Management of Esophageal
Perforation Following Pneumatic Dilations for Achalasia
Tim Vanuytsel, Toni Lerut, Dirk Vanbeckevoort, Jan Tack
Background: Pneumatic dilation is a well established treatment for achalasia, with esophageal
perforation being the most serious adverse event. Surgical suture of the tear with or without
Heller myotomy is often considered as the gold standard for management of iatrogenic
esophageal tears, although not devoid of morbidity and mortality. The aim of the present
study was to evaluate the outcome of conservative treatment of esophageal perforation
following pneumatic dilation in achalasia patients. Results are given as mean±SEM and
compared by Student's t-test. Materials and methods: All medical records of patients treated
by pneumatic dilation for achalasia between January 1992 and October 2006 in our unit
were analysed for complications. Treatment and outcome at one month after hospital dis-
charge were reviewed. Results: From a total of 604 pneumatic dilations in 289 patients
(52±1.4 years, 53% men) with manometry-confirmed achalasia, 12 (67% men) (2% of
dilations, 4% of patients) were complicated by a transmural perforation of the esophagus,
confirmed by esophagogram. A multi-disciplinary team of gastroenterologists, surgeons and
radiologist was in charge of post-perforation management. In 9 patients (75%) perforation
occurred during the first series of pneumatic dilations. The other patients had been treated
by 1 (8%) or 2 (17%) previous series of dilations. Perforation occurred at balloon diameter
of 30mm in 3 patients (1% of dilations at this diameter), 35mm in 6 patients (3% of dilations
at this diameter) and 40mm in 3 patients (3% of dilations at this diameter). The only
significant difference associated with perforation was the patient's age (70±3.8 years in those
with perforation; p<0.01). All patients were treated conservatively with broad-spectrum
antibiotics (18±2.7 days) and no oral feeding (15±2.7 days). Eight patients (67%) received
parenteral nutrition for 12±2.5 days. Patients were discharged 22±2.9 days after the perfora-
tion. Five patients (42%) developed pleural effusion (3 bilateral, 2 left) requiring a pleural
drain in 3 (25%) and a mediastinal drain in 1 patient (8%) for a mediastinal collection. One
patient died acutely within 12 hours after the perforation, probably due to the combination of
the perforation and myocardial ischemia (extensive coronary stenoses on autopsy). With
regard to dysphagia, results were good to excellent in the majority of patients (75%).
Conclusion: Conservative treatment of perforations following pneumatic dilation for achalasia
is feasible with favourable long-term outcome, but not devoid of complications. Co-morbidity
should be taken into account when taking this management option.
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T1975
The Effectiveness of Frenotomy in Tongue-Tied Infants By Ultrasound
Evaluation
Robbyn E. Sockolow, Aliza Solomon, Catherine Watson genna, Elizabeth Coryllos,
Patricia Villa, Anita Price
Background: Infants born with tongue-tie have been found to have feeding difficulties.
Studies have demonstrated improved feeding after frenotomy, but no studies have addressed
the mechanisms contributing to this dysfunction. Our goal was to characterize the oral-
motor function pre and post frenotomy by use of ultrasound. Methods: 33 breast fed infants
with tongue-tie were identified after evaluation by lactation consultant for poor weight gain
or difficulty breast-feeding. 12 post frenotomy babies had exams performed. There were 4
normal breast fed controls. Evaluation by ultrasound was done using a submental approach
while breast-feeding. Exams were coordinated with their usual breast-feeding schedule. The
study was performed while breastfeeding on one or both breasts. Sonographic identification
of the hard and soft palate, muscles of the tongue and oropharynx were made. Nipple
position, relationship to the palate, maximum nipple compression, configuration of the
tongue, coordination of suck and swallow, and glossal waveform were recorded pre and
post frenotomy. Results: Patterns characteristic of tongue-tie was identified in all patients.
Factors including inadequate positioning of the maternal nipple in the oropharynx, fatigue
and tremor of the Genioglossus and intrinsic muscles of the tongue were seen in the subjects
prefrenotomy. There was poor anterior posterior translational motion of the tongue seen in
all infants prefrenotomy. Greater coordination of the glossal muscles resulting in effective
suck-swallow mechanism and more successful breast-feeding was identified in all infants
postfrenotomy. Breast-feeding was judged by improved maternal nipple comfort, improved
infant weight gain, and shorter feeding times. Improvement or complete resolution occurred
in all infants. Conclusion: Frenotomy results in correction of dysfunctional suck-swallow
pattern and improves feeding in breast fed infants allowing for a more rhythmic glossal
waveform and ability to express milk bolus from the nipple. Ultrasound provides an effective
tool for evaluating infants with feeding difficulties.
T1976
Esophageal Hypersensitivity Is Associated with Features of Psychiatric
Disorders and the Irritable Bowel Syndrome
Joel H. Rubenstein, Borko Nojkov, Sheryl Korsnes, Susan Adlis, Michael J. Shaw, Beth
Weinman, John M. Inadomi, William D. Chey
Background: Approximately 20% of patients with chronic heartburn do not respond fully
to therapy with proton pump inhibitors (PPIs). Many of these patients have normal esophageal
acid exposure. We hypothesized that such PPI nonresponders have heightened esophageal
sensitivity, and that the hypersensitivity is mediated by features of psychiatric disorders such
as somatization and anxiety, and is associated with the irritable bowel syndrome. Methods:
30 subjects with heartburn (21 PPI responders and 9 PPI nonresponders) and 20 healthy
volunteers, none receiving psychotropic medications, completed validated questionnaires of
psychiatric disorders (Brief Symptom Inventory), gastrointestinal symptoms (Digestive Health
Status Instrument), and quality of life (Short Form-12). Subjects underwent esophageal
sensory testing with acid perfusion and balloon distension, rating the intensity of sensation
and associated emotional response on validated 20 cm scales. Results: Heartburn subjects
had worse physical quality of life, and more features of the irritable bowel syndrome. Healthy
volunteers displayed higher thresholds for sensation and discomfort from balloon distension
than PPI responders and PPI nonresponders (median weak sensation: 18 mmHg, 12 mmHg,
14 mmHg, respectively, p=0.04; median discomfort: 22 mmHg, 14 mmHg, 22 mmHg, p=
0.14). Healthy volunteers also displayed numerical trends toward lower mean sensation and
discomfort from acid perfusion (sensation: 6.0 cm, 8.2 cm, 8.5 cm, p=0.33; discomfort: 5.1
cm, 6.5 cm, 6.5 cm, p=0.45). Controlling for subject grouping, age, and gender, each
standard deviation increase in the Global Severity Index (a measure of psychiatric disorders)
was associated with a 1.9 cm increase in intensity of sensation (p=0.01) and 1.3 cm increase
in discomfort from acid perfusion (p=0.01). A similar increase in somatization was associated
with a 1.3 cm increase in discomfort from balloon distension (p=0.006). Irritable bowel
syndrome was also associated with increased esophageal sensation and discomfort. Conclu-
sions: Heartburn subjects (both PPI responders and PPI nonresponders) tended to have
heightened esophageal sensation compared to healthy volunteers, suggesting that esophageal
hypersensitivity may persist despite therapy with PPI. Esophageal hypersensitivity is associ-
ated with features of psychiatric disease and with the irritable bowel syndrome, which might
partly explain the etiology of heartburn symptoms that are refractory to PPI. Funded by EisaiInc.
and PriCara, Unit of Ortho-McNeil, Inc., and Univ. of Michigan General Clinical Research Center. JHR was funded by NIH
Training Grants T32 DK07367 and DK062708.
T1977
Esophageal Pressurization As a Mechanism of Bolus Clearance in Achalasia
Patients Before and After Pneumatic Dilation
Rutger Frankhuisen, Margot A. Van herwaarden, Hein G. Gooszen, Geoffrey S. Hebbard,
Melvin Samsom
Background: To date it is unclear what mechanisms are involved in esophageal emptying
in patients with achalasia. It was recently demonstrated that an abrupt increase in esophageal
pressure can be followed by relieve in symptoms after several liquid swallows (“the pumpgun
hypothesis”). Aim: To investigate manometric parameters and videofluoroscopic bolus transit
across the EGJ in symptomatic achalasia patients before and after pneumatic dilation (PD).
Methods: Ten symptomatic patients with achalasia (4 men, median age 42.7 (26-52); Eckardt
clinical symptom score 7 (IQR 4-10); median duration since last treatment 2.5 years (range
0.5-15)) were enrolled and investigated two weeks before and 6-8 weeks after PD. Concurrent
high-resolution EGJ manometry (including an array of 11 side holes spaced by 1 cm,
positioned across the distal esophagus, EGJ and proximal stomach) and videofluoroscopy
was performed while swallowing three separate bolus of 10 cc and one bolus of 100 cc
barium. Analysis: Using the abrupt transitions in colour plot pressure topography, two
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virtual sleeves measured the highest esophageal pressure (Pes) and LES pressure (LESp) in
respectively the five cm region proximal to the upper border of the EGJ and across the EGJ.
Periods with a positive pressure gradient (Pes > LESp) and a negative pressure gradient (Pes
< LESp) were identified and periods with a positive pressure gradient (with a minimal
duration of 1 sec) were analyzed for visible videofluoroscopic bolus transit across the EGJ.
Finally, Pes and LESp were compared between those periods with a positive pressure gradient
and immediate preceding periods with a negative pressure gradient. Statistics: Student t-
test (data presented as mean ± SEM) Results: 81.7 ± 12.3% of the periods with a positive
gradient were accompanied with visible bolus transit (after PD 84.2 ± 9.5%). Pes was
significantly higher during periods with a positive gradient compared to preceding periods
with a negative gradient (23.6 ± 5.4 mmHg vs 8.3 ± 2.4 mmHg respectively; P<0.001),
while LESp was comparable (17.4 ± 3.3 mmHg vs 14.8 ± 4.0 mmHg vs respectively; P=NS).
After PD Pes during periods with a positive gradient was significantly decreased compared to
periods with a positive gradient before PD (12.2 ± 1.8 mmHg vs 23.6 ± 5.4 mmHg; P<0.05)
as well as the LESp (6.7 ± 2.3 mmHg vs 17.4 ± 3.3 mmHg; P<0.001). Conclusion: In
patients with previously treated achalasia and recurrent symptoms, esophageal emptying is
associated with intermittent increases in esophageal pressure. After successful pneumatic
dilation this mechanism of pressurization of the esophageal body is no longer required.
T1978
Non-Cardiac Chest Pain (NCCP) and Gastro-Esophageal Reflux (GER):
Randomised Trial of Esomeprazole Therapy
Vivan Talwar, Peter Wurm, John S. De caestecker
GER is the single commonest esophageal abnormality in patients with NCCP, but reflux is
common in the general population. Therefore finding of GOR does not prove that it is the
cause of chest pain. There have been few controlled trials to assess the value of proton
pump inhibitor (PPI) therapy in these patients. Aim: To investigate the efficacy of Esomepra-
zole 40mg od for symptomatic relief of NCCP in patients with abnormal GER and to identify
factors predicting response. Methods: Patients with recurrent chest pain, normal coronary
angiography and normal upper GI endoscopy underwent esophageal manometry, 24h pH
monitoring (with symptom index {SI} calculation) and provocation tests (acid perfusion
{AP}, edrophonium injection {EI}, balloon distension {BD}). All patients had abnormal GER
by 24-hour pH monitoring. Patients were randomised to receive Esomeprazole 40mg od or
matching placebo each for 4 weeks (with a 2week washout) using a double blind crossover
format. Chest pain was evaluated by symptom diary. A positive response was an improvement
of chest pain score (daily severity of chest pain over last 14 days of each treatment period)
>50% on PPI compared to placebo. Results: 23 patients of 24 recruited completed the trial.
5 patients were classified as responders to Esomeprazole. There was no overall difference
in chest pain scores {PPI vs. Placebo; 18.8 (SD 12.8) vs. 17.8 (SD 11.7; paired t test, p=
0.71)}. The best positive and negative predictive values were for SI (57% and 100%), followed
by AP (25% and 82%), EI (20% and 83%), BD (33% and 78%). Conclusions: 1. Somewhat
surprisingly, there was no overall benefit of PPI therapy despite carefully selecting patients
on the basis of 24h pH monitoring. 2. GER in association with NCCP may not be causal
but studies with higher doses/longer periods of acid suppression may be warranted. 3.
Calculation of SI during 24h esophageal pH monitoring appears the best predictor of response
to PPI.
T1979
Augmentation of Deglutitive Thyrohyoid Muscle Shortening By Exercise
Rachel Mepani, Stephen J. Antonik, Mark M. Kern, Krisna Chai, Jeri Logemann, Barbara
Pauloski, Alfred Rademacker, Reza Shaker
Background: Earlier studies of the effect of 6 weeks of upper esophageal sphincter (UES)
opening exercises (Shaker et al. Gastro 2002;122:1314-1321) have shown significant increase
in UES opening and anterior excursion of larynx and hyoid during swallowing in patients
with UES dysfunction, resulting in elimination of aspiration and resumption of oral feeding.
This effect is attributed to the strengthening of the suprahyoid muscles as evidenced by
EMG documented fatigue. However the effect of this exercise on thyrohyoid muscle
shortening (THMS) is unknown. THMS is instrumental in transmitting the pulling effect of
the suprahyoid muscle contraction to UES opening by locking together the thyroid and
hyoid. Aim: To determine the effect of the proposed exercise on THMS. Methods: We
studied 11 dysphagic patients with UES dysfunction. 6 were randomized to traditional
swallowing therapy and 5 to the Shaker exercise. The exercise involves isometric and
isokinetic head lift segments performed 3 times a day for 6 weeks. Swallows were recorded
using video fluoroscopy at 30 frames per sec. Recordings were digitized and analyzed by 2
observers in blinded fashion. Results: Frame by frame analysis of the video fluoroscopic
images showed that maximum THMS occurred at close proximity to the apogee of the
thyroid excursion. The thyrohyoid muscle length at initiation of deglutition and apogee of
thyroid excursion showed no statistically significant difference between the 2 groups prior
to either therapy (p=0.54). In contrast, after therapy the maximum THMS in the exercise
group was significantly greater compared to the traditional therapy (p=0.009). Conclusion:
The Shaker head lift exercise augments the thyrohyoid muscle shortening in addition to its
known effect on strengthening suprahyoid muscles. This effect may contribute to the reported
increase in UES deglutitive opening induced by this exercise. Supported in part by R01
DK062178-03 and T32 DK61923.
Traditional Therapy (TT) n=6 Shaker Exercise (SE) n=5
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T1980
Characterization of Pharyngo-Glottal Closure Reflex (PGCR) in Human
Neonates Using Novel Mano-Sonographic Methods
Sudarshan R. Jadcherla, Alankar Gupta, Brian Coley, Reza Shaker
Manometry and videoendoscopy methods to evaluate pharyngo-glottal relationships are not
practical in neonates. We validated glottal function and defined glottal closure (adduction
of vocal folds and arytenoids) using non-invasive ultrasonography in infants (Jadcherla et
al. Dysphagia 2006). The direct relationship between glottal closure and pharyngeal provoca-
tion is not known. AIM: To study: 1) the pharyngo-glottal closure reflex (PGCR) evoked
upon pharyngeal infusions, 2) the temporal relationships between the coordination of glottal
closure with pharyngo-UES interactions and 3) respiratory phases. METHODS: We evaluated
pharyngo-UES and glottal functions in 10 neonates (6 M, 43 ± 5 wk corrected gestation, 3
± 1 kg) in supine position using a concurrent manometry and ultrasonography (Mano-
Sonography), respitrace and submental EMG. Pharyngo-UES motility was evaluated with a
manometry catheter with UES sleeve and pharyngeal infusion port, and synchronized with
ultrasound images of glottis. Frame-by-frame analysis was done to define the temporal
relationships: 1)frequency occurrence of PGCR 2) response time for the onset of glottal
closure and for the change in UES tone, 3) duration of glottal closure, and 4) relationships
of PGCR with respiratory phase of infusion. All values shown as mean ± SD, unless stated
otherwise. RESULTS: PGCR occurred with 97% of pharyngeal stimuli (36 infusions) within
0.6 ± 0.8 sec from infusion onset. Glottis remain closed for 0.4 ± 0.3 sec. UES relaxation
(pharyngeal reflexive swallow) occurred in 78%, within 3.1 ± 1.2 sec from infusion onset.
Glottis closed again within 3.1 ± 2 sec from infusion onset, and remained adducted for 2.2
± 2.97 sec. The interval between first and second glottal closures was 2.2 ± 2 sec. The
response times for PGCR and UES relaxation were different (P<0.001). The response time
for PGCR when infusion was given in inspiration (0.4 ± 0.6 sec) vs. expiration (0.75 ± 1.0
sec)was similar. The response time for PGCR when glottal closure occurred in expiration(0.5
± 0.7 sec) vs. inspiration (0.6 ± 0.8 sec)was similar. With water and air stimuli respectively,
the frequency of PGCR was 100% vs. 92%, response time was 0.8 ± 0.9 vs. 0.1 ± 0.3 sec
(P<0.01), and PGCR duration was similar (0.4 ± 0.3 sec). The mean threshold volume to
evoke PGCR with air vs. water were 0.5 ml vs. 0.1 ml respectively. CONCLUSIONS: 1)PGCR
can be defined can be defined using Mano-Sonography at the crib-side in neonates and
precedes changes in UES tone. 2) Glottal adduction occurs again with UES relaxation(Swal-
low). 3) PGCR occurs in both respiratory phases.4) PGCR may provide airway protection
preceding primary peristalsis.
T1981
Effect of Atilmotin, a Motilin Receptor Agonist, On Esophageal, Lower
Esophageal Sphincter, and Gastric Pressures
Annapurna Korimilli, Amiya Palit, Rae Hardnett-mccoy, Marti Harrison, Sara Hatton,
Henry P. Parkman
Motilin is an endogenous GI hormone, which increases upper GI tract motility and is
associated with the gastric phase III migrating motor complex. The motilin receptor agonist,
atilmotin, is being studied for use in patients with postoperative ileus and other GI motility
disorders. Recent studies suggest that atilmotin increases the early phase of gastric emptying,
when given as an IV bolus injection (Park et al 2006). Aim: To determine the dose-related
effects of atilmotin on esophageal, lower esophageal sphincter (LES), and gastric contractility.
Methods: Five healthy volunteers underwent high resolution esophageal manometry using
a manometry catheter with 36 solid state circumferential pressure sensors spaced one cm
apart, spanning the pharynx, esophagus, LES, and proximal stomach (Sierra Scientific Instru-
ments). Subjects were studied three times each at different doses of atilmotin (6 μg, 30 μg,
and 150 μg IV bolus administration). An additional five subjects were studied at the highest
dose of 150 μg. Each subject was studied with 5 ml swallowed water boluses: 10 swallows
with no medication, 30 swallows after IV saline (placebo), and 30 swallows after IV atilmotin.
Results are expressed as Mean±SEM. Results: Atilmotin increased significantly proximal
gastric pressures in a dose dependant fashion. At the highest dose of 150 μg, proximal
gastric pressure increased by 8.5±0.7 mm Hg for atilmotin vs 1.5±0.4 mm Hg for placebo
(p=0.0005). Atilmotin increased LES pressure at all doses, but especially at 30 µg from
25.6±1.5 mm Hg for placebo to 33.1±2.2 mmHg for atilmotin (p=0.0005). Atilmotin did
not significantly change the LES residual pressures after swallowing. Atilmotin increased
the percentage of failed swallows at all doses. At 150 μg, the percentage of failed swallows
increased from 12±4% with placebo to 36±6% (p= 0.016). At 5 cm above the LES, atilmotin
decreased the amplitude of distal esophageal contractions, significantly after the highest
dose, 150 μg (79.5±7.0 mm Hg for placebo and 49.6±5.2 mmHg for atilmotin, p=0.02).
There were no serious adverse effects or episodes of chest pain with atilmotin. Conclusions:
This study demonstrates that the motilin receptor agonist, atilmotin, given by IV bolus
administration, affects esophageal, LES, and gastric motility. LES and gastric pressures were
increased whereas there was a disruption of esophageal contractions characterized by low
amplitude and failed contractions. The increase in the LES pressure occurs with a concomitant
increase in proximal gastric pressure. Whether atilmotin might be useful to treat disorders
of upper GI motility needs further study.
T1982
Esophageal Motility in Children with Suspected Gastroesophageal Reflux
Disease
Ilse Hoffman, Jan F. Tack, N. Haesendonck, T. Degreef
Motility abnormalities have been reported in adults with gastroesophageal reflux disease
(GERD) like non-transmitted contractions, reduced distal esophageal contraction amplitude
and simultaneous contractions. Information on esophageal motility in children with GERD
are scarce. Our aim was to study esophageal motility in childhood GERD and the correlation
with the presence of erosive esophagitis. Methods: Consecutive children referred for severe
GER(D) symptoms all underwent a barium swallow, upper endoscopy, pH-monitoring
and stationary water-perfused esophageal manometry. Results are shown as mean±SD and
compared by Student's t-test. Results: The study group consisted of 132 patients (81 girls,
mean age 6.2±4.9 years). Barium swallow revealed a malrotation in 3 patients and a distal
stenosis in 2 patients. Endoscopy was normal in 19 patients, and showed erosive esophagitis
I and II respectively in 78 and 33 patients. Esophageal pH-monitoring showed a mean
%time pH<4 of 7.0±0.7% and 9.9±1.5% in those without and with esophagitis respectively
(NS). When patients with normal and abnormal endoscopy were compared, no significant
differences were found in resting lower esophageal sphincter (LES) pressure (17.5±5.7 vs
16.6±7.0 mmHg), duration of LES relaxation (6.4±1.9 vs 6.1±1.6 sec), peristaltic wave
propagation (80.0±40.0 vs 91.0±27.0%), proximal (0.8±0.8 vs 0.9±0.4 cm/sec) and distal
peristaltic velocity (0.4±0.4 vs 0.7±0.4 cm/sec), proximal esophageal contraction amplitude
(42.7±13.6 vs 46.2±21.1 mm Hg), mid esophageal contraction amplitude (65.0±21.3 vs
70.9±35.5) and distal esophageal contraction amplitude (88.8±40.2 vs 77.7±35.5) and
duration of contraction in proximal (2.8±0.8 vs 2.9±1.0 sec), mid (3.2±0.8 vs 3.1±0.9 sec)
and distal esophagus (3.3±0.9 vs 3.2±0.9 sec). When patients were subdivided based on
normal or abnormal esophageal pH monitoring results, none of these esophageal manometry
characteristics differed significantly between both groups. Conclusion : in children, the
presence of erosive esophagitis is not accompanied by changes in distal esophageal motor
function.
T1983
Functional Heartburn Patients with Somatisation Trait Demonstrate
Generalised Visceral Hypersensitivity
Nora M. Thoua, Amanda J. Roy, Chrysostomos Kalantzis, Anton V. Emmanuel
Introduction Visceral hypersensitivity (VH) - heightened perception to experimental visceral
stimuli - is a commonly observed phenomenon in patients with functional gastrointestinal
disorders (FGIDs). It is often associated with somatic hypersensitivity. One proposed mechan-
ism of VH is augmented afferent input at spinal cord level (“central sensitisation”). With
overlap of afferent input from different regions of the GI tract, central sensitisation may
explain symptom overlap between different FGIDs. Functional heartburn (FH) is a FGID
characterised by heartburn with normal oesophageal mucosal appearances and normal acid
exposure. We hypothesised that FH patients without symptoms of irritable bowel syndrome
(IBS) have a tendency to visceral and somatic hypersensitivity, which may be related to
personality traits. Methods 18 consecutive patients with FH (7 male, mean age 40) and no
symptoms of IBS (Rome II) were compared with 16 patients with erosive reflux disease
(ERD, 9 male, mean age 42) and 16 naïve controls (8 male, mean age 42). All subjects
underwent (in random order) either infusion of pH1 HCl or saline >1 week apart. At
baseline and 30 minutes they underwent a rectal barostat study (perception and pain) , anal
electrosensation (pain) and VAS assessment of abdominal pain. All patients completed the
BSI questionnaire, particularly to assess somatisation (BSI-som score >61 suggests significant
somatisation tendency). Results With saline, FH patients had lower barostat thresholds than
ERD and controls (perception 22.9 vs 29.2 vs 28mmHg resp, p<0.03 for both; pain 36.9
vs 43.9 vs 43.4mmHg resp, p<0.01 for both). Anal pain threshold was lower in FH (11.1mA)
than ERD (13.6mA, p<0.05) but not controls (11.6mA, p=NS). Acid infusion reduced (1)
barostat thresholds in FH, not ERD or controls (perception 19.7 vs 30 vs 25.6mmHg resp,
p<0.01 for both; pain 27.8 vs 41.1 vs 36.1mmHg resp, p<0.05 for both) (2) VAS pain
intensity (3.2 vs 1.8 vs 1.1 resp, p<0.01 for both) and (3) anal pain threshold (10.1 vs 14.7
vs 12.3mA resp, p<0.03 for both). Compared to saline, acid infusion reduced thresholds
for barostat volumes and anal pain, and increased abdominal pain in FH patients only. This
VH was seen in 13 of 18 (72%) patients, all of whom had BSI-som >61. Of 5 patients not
showing VH, 1 had BSI-som >61. Conclusion Patients with FH - and not ERD or controls -
demonstrate central sensitisation to oesophageal acid infusion. This development of sensitivity
occurs in FH patients who do not have symptoms of IBS, suggesting an underlying tendency
that is present in a significant proportion of these patients, particularly those with somatis-
ation trait.
T1984
High-Resolution Manometry in Determining Bolus Transit Through the
Esophagogastric Junction: A Validation Study Using Flouroscopy
Nilesh Lodhia, Sudip K. Ghosh, Peter J. Kahrilas, Jennifer Post, Eric Volckman, John
Pandolfino
Background: The primary determinant of successful esophageal emptying is the generation
of a sustained level of intrabolus pressure (IBP) sufficient to overcome EGJ resistance. Our
aim was to validate a high-resolution manometry (HRM) technique for analyzing the bolus
driving pressure (BDP) and bolus transit through the EGJ using simultaneous fluoroscopy.
Methods: 8 normal subjects were studied with a 36-channel HRM assembly (1 cm spacing)
during both 5 and 10 ml barium swallows and concurrent fluoroscopy. The IBP was defined
as the pressure midway between a 30 mmHg isobaric contour front and the EGJ. The EGJ
resistance pressure was defined as the maximum pressure within the high-pressure zone.
The BDP was then defined as the simultaneous pressure difference between the IBP and the
EGJ resistance during the swallow (Figure). An independent and blinded assessment of
trans-hiatal emptying was made from fluoroscopy and compared with an independent
manometric assessment of the time where the BDP was positive (Kappa analysis). A tolerance
of + 0.3 seconds was considered agreement. Results: All 24 swallows (8 subjects) had
complete esophageal emptying. The average duration of flow on fluoroscopy was significantly
longer for the 5ml bolus compared to the 10 ml bolus (5ml, 3.93sec (SE,0.31); 10 ml, 5.33
sec(SE,0.55), p=0.01). The average error in assessing the duration of flow was 1.09 sec
(SE,0.24), however, flow was always associated with a positive BDP (Figure). The kappa
value for the agreement between the two modalities was 0.57 for flow duration. The average
BDP during fluoroscopic evidence of flow was 4.1 +/- 0.6 mmHg for the 5ml swallows and
6.2 +/- 0.9 mmHg for the 10ml swallows. Conclusions: HRM provides a reliable method
to define the IBP and the DP during swallowing. HRM also provides a reasonably accurate
assessment for the duration of bolus flow compared to fluoroscopy and may be able to
predict impaired bolus transit in instances of failed peristalsis.
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Gray Box- Flow on flouroscopy. Thick line =IBP, Thin line=EGJ resistance.
T1985
Longitudinal Muscle Contraction During Swallow Induced and Transient
Lower Esophageal Sphincter Relaxation: Assessed By Concurrent Ultrasound
Imaging and Manometry
Arash Babaei, Hariprasad R. Korsapati, Valmik Bhargava, Ravinder K. Mittal
Introduction: A recent study from our laboratory shows that an axial stretch on the lower
esophageal sphincter (LES) induces neurally mediated LES relaxation. We hypothesized that
under physiologic conditions longitudinal muscle contraction of the esophagus exerts an
axial stretch on LES, which may be the cause of swallow induced LES relaxation (SLESR)
and transient LES relaxation (TLESR). Our goal was to determine patterns of longitudinal
muscle contraction during SLESR and TLESR. Methods: High frequency intra-luminal ultra-
sound (US) imaging and simultaneous manometry were performed in 6 normal subjects.
Sleeve catheter recorded LES and esophageal pressures, and US imaging at 5 cm above the
LES recorded longitudinal muscle contraction. Recordings were synchronized using a video
timer and monitored for 2 hours after the ingestion of a 1000 Kcal meal. Data Analysis:
M-mode US images were constructed and time aligned with LES and esophageal pressures
to determine the relationship between circular and longitudinal muscle contractions.Results:
20 TLESR and 30 SLESR episodes were analyzed. Longitudinal muscle contraction, seen as
an increase in the esophageal muscle thickness, occurred earlier than the onset of the TLESR
and lasted longer than the duration of TLESR. The degree of esophageal longitudinal muscle
contraction was greater during TLESR as compared to the swallow induced pressure event
at the same level. The longitudinal muscle contraction during SLESR was temporally aligned
with the pressure event at the same level and not necessarily with the SLESR. Conclusion:
The patterns of longitudinal muscle contraction during TLESR and SLESR are quite distinct
and consistent with the hypothesis that the axial stretch induced by longitudinal muscle
contraction of the esophagus is likely the cause of LES relaxation.
T1986
Esophageal Compliance and Sensations During Esophageal Barostat
Measurements: Studies in Healthy Volunteers
Radu Tutuian, Daniel Pohl, Kerstin Suarez, Bernadette Stutz, Ulrike Ehlert, Michael Fried
Background: Clinical evaluation of esophageal function and perception is usually performed
by assessing esophageal peristalsis and response to rapid balloon distension. There is limited
information on esophageal tone and its contribution to esophageal symptoms. Aim: To
establish normal values for esophageal compliance and intensity of esophageal sensations
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during esophageal barostat. Methods: Healthy volunteers (HV) underwent esophageal baros-
tat (G&J, Canada) measurements using a polyethylene bag, 5 cm in length, max. capacity
200ml on a double-lumen tube (MUI, Canada). The barostat bag was positioned 5 cm above
the manometrically located LES. The intrabag pressure was stepwise increased by 3 mmHg
every 5 min up to 15 mmHg. Intrabag volume was averaged at each pressure step and
compliance was calculated as the slope of the volume-pressure curve. Subjects rated the
intensity of chest pain, heartburn and dysphagia on a VAS (0-100) at the end of each
pressure step. Results: All 15 HV tolerated the entire distension sequence. The average (±
SD) distal esophageal compliance was 2.1 ± 0.4 ml/mmHg. Table 1 and fig. 1 summarize
the intensity of symptoms and volume-pressure response. Conclusions: These data providing
standardized normal values for esophageal compliance and intensity of symptoms during
graded esophageal barostat distensions. These are essentially for the evaluation of patients
with functional esophageal symptoms.
Intensity of symptoms VAS (0-100)
Data are presented as mean ± SEM
T1987
Effect of Maturation On Esophageal Peristaltic Propulsion Parameters in
Human Neonates
Alankar Gupta, Sudarshan R. Jadcherla
Esophageal motility facilitates aboral bolus transport and provides airway protection against
bolus presence. The changes in esophageal propulsive characteristics during peristalsis
(amplitude and duration of waveforms, onset and peak peristaltic velocities) with maturation
in human neonates are not clear. AIM: To define the effects of maturation on esophageal
bolus propulsive characteristics during primary peristalsis (PP) and esophageal distention
induced secondary peristalsis (SP) in human neonates. METHODS: We studied swallow
integrated esophageal motility responses during spontaneous PP and esophageal provocation
induced SP in 6 neonates (29 ± 2 wks gestation, birth weight 1.2 ± 0.3 kg) using a specially
built esophageal micromanometry catheter, concurrent submental EMG and respitrace at
corrected gestation of 34 ± 4 wks (Time-1) and at 40 ± 7 wks (Time-2). Growth parameters
between Time-1 vs. Time-2 were different (P<0.01). Sp resulting from esophageal stimuli
(0.5, 1.0 and 2.0 ml, air and liquids) were compared with spontaneous PP at both Time-
1 and Time-2. All values shown as mean ± SD. RESULTS: Characteristics of 118 PP and
153 SP sequences were evaluated. Contractile amplitudes at proximal, middle, and distal
esophagus were similar between Time-1 vs. Time-2. However, the contractile durations were
different (P<0.05, Table). Velocity of propagation from proximal to distal esophagus during
PP was different (P<0.05, Table), but not during SP. Contractile amplitude gradients were
distinct within proximal-middle-distal esophageal segments during both peristaltic mechan-
isms at time-1 (P<0.001) and time-2 (P<0.001). Similar relationship between the segments
was not noted for the contractile duration. CONCLUSIONS: 1) Maturation modifies the
mechanisms of esophageal bolus propulsion, in that the waveform duration at each locus
shortens, onset and peak peristaltic velocities become faster. 2) The changes in these motility
parameters may in part facilitate improved esophageal bolus transport and enhanced airway
protection with maturation.
Esophageal body characteristics during maturation
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PE- proximal esophagus, ME-middle esophagus, DE-distal esophagus
T1988
High-Resolution Manometry (HRM) in the Assessment of Distal Esophageal
Peristaltic Abnormalities: Computerized Algorithms of Analysis Tested On
281 Non-Achalasic Patients
John Rice, John Pandolfino, Sudip K. Ghosh, Monica Kwiatek, Hyon Kim, Peter J.
Kahrilas
Aim: HRM capable of simultaneously monitoring the entire esophagus has recently become
available. We hypothesized that the technical advancements inherent in HRM coupled with
computerized algorithmic analysis should improve the assessment of peristaltic abnormalities.
Methods: 281 consecutive manometry patients with normal EGJ relaxation and 75 controls
were studied with a 36-channel HRM assembly (1 cm spacing) during water swallows.
Automated computer programs were written to calculate the pressurization front velocity
(PFV) and the distal contractile index (DCI). The PFV quantified the velocity with which a
30mmHg pressure front traversed the distal esophagus while the DCI integrates the magnitude
and duration of the distal esophageal contraction from the transition zone to the EGJ. Results:
The 95th percentile values from controls were PFV 4.5 cm/sec and DCI 5000 mmHg.sec.cm.
The most common abnormality was aperistalsis either in a scleroderma or IEM pattern (n=
68, 24%). A rapid PFV was seen in only 8 (2.8%) patients and of these, only 4 were
attributable to distal esophageal spasm (DES) (Table). A more common abnormality was a
normal PFV with a high DCI, seen in 45 (16%) patients. Although all of this group would
fit conventional criteria for nutcracker esophagus, there was extreme heterogeneity within
the group with DCI values ranging from 5004 to 21,445 mmHg.sec.cm. A threshold cutoff
of 8,000 mmHg.sec.cm was very abnormal, identifying a spastic nutcracker pattern that was
uniformly associated with dysphagia or chest pain (n=14, 5% overall). Conclusion: HRM
analysis paradigms provide great detail of peristaltic function with the potential to refine
the classification of esophageal motor disorders. DES, as conventionally defined by a rapidly
conducted contraction, was very rare. However, spasm associated with severe dysphagia
and chest pain occurred 3 fold more often in the setting of a normally conducted contraction
(spastic nutcracker?) challenging conventional diagnostic criteria of DES.
T1989
Temporal Relationship Between Deglutitive Glottal and UES Functions in
Various Phases of Respiration in Human Neonates
Sudarshan R. Jadcherla, Alankar Gupta, Brian Coley, Reza Shaker
Relationships between swallowing and laryngeal adduction have been determined using
invasive videoendoscopy and manometry methods in human adult and animal models.
However, invasive methods are difficult to adapt for infant use at crib-side. Recently, we
developed and validated methods to evaluate glottal motion characteristics using non-invasive
ultrasonography of the glottis (Jadcherla et al. Dysphagia 2006). Glottal closure was defined
as adduction of vocal folds and arytenoids. The direct relationship between glottal motion
changes with deglutition in human neonates is not known. AIM: To characterize the temporal
changes in glottal motion and upper esophageal sphincter (UES) tone during spontaneous
swallowing in different phases of respiration. METHODS: We studied 10 neonates (6 Males,
43 ± 5 wk corrected gestation, 3.4 ± 1.0 kg) in supine position using a concurrent manometry
and ultrasonography (Mano-Sonography), respitrace and submental EMG approach to evalu-
ate pharyngo-UES motility and glottal function.UES and esophageal function was evaluated
with a specially designed catheter with sleeve and synchronized with ultrasound images of
glottis. Frame-by-frame analysis was done to define the following temporal relationships
during swallows: 1) coordination of glottal adduction with UES relaxation, 2) duration of
glottal adduction with pharyngo-UES phase of swallow, 3) relationship of glottal closure
with respiratory phase of swallow. All values shown as mean ± SD, unless stated otherwise.
RESULTS: 33 swallows were evaluated. Glottal closure was observed with all swallows (100
%) and complete UES relaxation was noted in 94%. The interval between pharyngeal
waveform onset to the onset of glottal closure (minus 0.03 ± plus 0.2 sec)vs. pharyngeal
waveform onset to UES nadir onset (0.70 ± 0 .3 sec) were different (P<0.001). Duration of
complete glottal adduction (0.805 ± 0.518 sec) vs. nadir UES time (0.45 ± 0.63 sec) was
different(P<0.004). CONCLUSIONS: 1) Temporal relationships between swallowing and
glottal closure can be determined using Mano-Sonography. 2) Glottal closure occurs with
every swallow. 3) Early glottal closure suggests that ensuring airway protection precedes
swallow propagation. 4) Glottal adduction occurs faster than UES relaxation supporting
hyper-alert airway defenses. 5) Swallows and related glottal closure can occur in both phase
of respiration.
Relationships between pharyngeal swallow onset, glottal closure (GC) and respiratory phases
INS: Inspiration, EXP: Expiration
T1990
Natural History and Outcome of Non Specific Esophageal Motility Disorder
Timna Naftali, Tatiana Levit, Fred M. Konikoff
In about 10% of patients undergoing esophageal manometry abnormalities which are not
compatible with any well defined motor disorder are recorded. These patients are diagnosed
with Non specific esophageal motility disorder (NEMD) The natural history and clinical
significance of NEMD is unknown. The aim of our study was to follow patients who were
diagnosed with NEMD and to define the clinical and manometric progress of this disorder.
Methods: All patients diagnosed with NEMD on manometry were eligible for the study. The
manometries were reviewed to verify the diagnosis. The criteria for NEMD included one or
more of the following in 30% or more of swallows: low amplitude peristalsis; non progression
of peristalsis; prolonged, retrograde or triple picked peristaltic waves; incomplete relaxation
of the lower esophageal sphincter. Patients were contacted 3-5 years after the initial diagnosis
and were asked to fill a questionnaire regarding their symptoms and to have a second
manometry. Results: Between 1997 and 2004 137 patients were diagnosed with NEMD.
Upon re inspection of the manometries 36 did not fulfill the study criteria of NEMD, in 31
patients the initial manometry was not available and 7 patients died. Altogether 65 patients
aged 64 years (24-83), 36 males, entered the study. All were symptomatic at the first visit.
Symptoms included: Dysphagia in 28 (43%)patients, heart burn in 22 (34%), chest pain in
19 (29%), regurgitation in 12 (18%) and chronic cough in 7 (10%). Symptoms improved
in 46 (70%) of patients on the second visit and disappeared in 33 (50.8%). Symptoms that
improved were mainly heart burn and food regurgitation, whereas dysphagia, chest pain
and respiratory symptoms did not. Triple peaked waves were associated with persistence
of symptoms (70% compared to 21% in the others). Of the symptomatic patients, 16 (25%)
agreed to have a second manomtery. Of these 3 (19%) were diagnosed as Achalasia, 11
(69%) had NEMD and 2 (12%) had a normal second manometry. Conclusion: NEMD is a
benign manometric disorder that improves clinically in the majority of patients. Manometric
finding of triple peaked waves is associated with a worse prognosis. In some patients NEMD
may develop into Achalasia, justifying re examination of symptomatic patients.
T1991
Novel Redefinition and Characterization of Achalasia Based On High-
Resolution Manometry
Sam-ryong Jee, Mark Pimentel, Kimberly Low, Edy Soffer, Jeffrey L. Conklin
Background: High-resolution manometry (HRM) makes it possible to better evaluate spatial
and temporal characteristics of esophageal motor function. The advancements brought about
by this technique require reformulation of the definitions and findings in esophageal motor
disorders. This is the first study to re-characterize achalasia using HRM as compared to
esophageal motor findings in GERD and normal subjects. Methods: HRM was performed
on 27 patients with achalasia, 10 patients with gastroesophageal reflux disease (GERD) and
10 controls. The tools in the Manoscan™ Analysis Program were used to quantify the data.
In addition to the traditional findings of achalasia (no persitalsis, hypertensive LES and
failed LES relaxation), new findings in achalasia only seen with HRM are quantitatively
described. Results: As previously defined, LES resting pressure was greater in achalasia
than controls (P<0.001) and GERD (P<0.0001). Likewise, absence of peristalsis and failed
relaxation of the LES was noted. New characteristics of achalasia were seen by HRM -
esophageal shortening, pressurization of the esophagus between swallows, and lower UES
pressure. The resting length of the esophageal body in achalasia was not different from
GERD and controls. During swallowing, the length of the esophageal body in achalasia
shortened significantly (see table) compared to GERD and controls. The resting intraeso-
phageal pressure in achalasia was similar to GERD and controls before swallowing. During
the study, the intraesophageal pressure increased significantly in achalasia vs. GERD and
controls (see table). In 20/27 patients with achalasia the esophagus generated repetitive,
cyclical, isobaric pressure waves in the smooth muscle esophagus following swallows. These
pressure transients were associated temporally with contractions of the UES and striated
muscle esophagus. Venting of the esophagus by belching or vomiting decreased intraeso-
phageal pressure and attenuated cyclical activity seen in the UES, smooth and striated
muscle. The pressure of the UES in achalasia was also lower than GERD and controls before
and during swallowing (see table). Conclusions: High-resolution manometry demonstrates
novel findings that redefine the characteristics of achalasia.
*P<0.001 compared to GERD, P<0.05 compared to normal. +P<0.01 compared to GERD. †
P<0.01 compared to GERD and normal. P<0.0001 compared to GERD and normal.
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The Effect of Oral Buspirone, Pyridostigmine and Bethanechol On Esophageal
Function Evaluated with Combined Multichannel Esophageal Impedance-
Manometry (MII-EM) in Healthy Volunteers
Wojciech Blonski, Marcelo F. Vela, Janice Freeman, Neeraj Sharma, Donald O. Castell
Background. There are limited treatment options in patients with ineffective esophageal
motility (IEM). Studies in healthy volunteers have shown the potential role of direct cho-
linergic agonist bethanechol and serotonin receptor agonist in improving esophageal motility.
It has been also shown that a cholinestarase inhibitor, the short-acting drug edrophonium
administered intravenously caused more significant increase in the esophageal contraction
amplitude and duration than bethanechol. Edrophonium can not be used as a promotility
agent due to its short duration of action and i.v. administration. The effect of the cholinestarase
inhibitor pyridostygmine with longer duration of action has not yet been studied. The aim
of the study was to evaluate the effect of oral pyridostygmine (60mg), buspirone (20mg)
and bethanechol (25mg) on esophageal function assessed by combined MII-EM. Materials
and Methods. Ten healthy volunteers were enrolled in a double blind randomized three-
period crossover study. MII-EM recorded esophageal pressures and bolus transit data during
6 liquid and 6 viscous swallows at baseline and 20, 40 and 60 minutes after the randomized
oral administration of each drug. Results. There were significant increases in mean distal
esophageal amplitude for liquid swallows from baseline to 60 min. post-dosing after pyridos-
tygmine (87.6 vs. 118.0 mmHg, p<0.001), buspirone (85.1 vs. 101.9 mmHg, p<0.05) and
bethanechol (87.6 vs. 118.8 mmHg, p<0.01). Only pyridostygmine showed a significant
decrease in mean distal onset velocity for liquid swallows at 60 min. post-dosing (3.4 vs.
2.3 cm/s, p<0.01) and increase in total bolus transit time at 60 min. post-dosing (7.9 vs.
9.3 s, p<0.05). All three agents significantly increased mean LES residual pressure for liquid
swallows at 20, 40 and 60 min. post-dosing. All agents increased mean LES resting pressure,
but it did not reach statistical significance. Conclusions. Oral pyridostygmine, buspirone
and bethanechol augment esophageal motility with pyridostygmine showing the greatest
effect. Their further evaluation in patients with IEM is needed to fully evaluate their potential
in improving esophageal function and symptoms.
T1996
Transient Receptor Potential Vanilloid 4 (TRPV4) Mediates Inflammation-
Induced Sensitization of Colonic Afferent Nerves and Mechanical Hyperalgesia
Walter E. Sipe, Nathalie Vergnolle, Ben D. Phillis, Stuart M. Brierley, Chris M. Martin, L.
ashley Blackshaw, Nigel W. Bunnett
Introduction TRPV4 is a mechanically gated ion channel. Inflammatory mediators (e.g.
agonists of protease-activated receptor 2, PAR2), sensitize TRPV4 on nociceptive neurons
to induce somatic mechanical hyperalgesia. We hypothesized that colonic inflammation
sensitizes TRPV4 to cause visceral hyperalgesia to colorectal distension (CRD). Methods
Colonic spinal afferent neurons of mice were retrogradely labeled by injecting DiI (50 mg/
ml) into the musculature, and TRPV4 and PAR2 were localized in dorsal root ganglia (T9-
L2) by immunofluorescence. To assess nociception, viscero-motor responses (VMR) were
measured in TRPV4+/+ and TRPV4-/- mice by electromyography of abdominal muscles during
CRD using a barostat balloon. Activity of individual colonic primary spinal afferent nerves
was recorded in rats and mice. VMR and neuronal activity were measured before and after
intracolonic administration of zymosan (2.5 mg) or PAR2 activating peptide (AP, SLIGRL-
NH2, 0.1 mg). Inflammation was assessed by myeloperoxidase assay and histology. Results
TRPV4 was detected in >50% of DRG neurons, and most DiI-labeled colonic neurons
expressed TRPV4 and PAR2. In TRPV4-/- mice, basal VMR to CRD were reduced 82% at 30
mm Hg (p<0.05), 72% at 45 mm Hg (p<0.001) and 73% at 60 mm Hg (p<0.001) compared
to responses in TRPV4+/+ mice, indicating a role for TRPV4 in mechano-transduction. At 4
d post-zymosan, when there was no detectable colitis, VMR to CRD was sensitized in
TRPV4-/- and TRPV4+/+ mice. However, sensitized responses in TRPV4-/- mice remained
lower than baseline responses of TRPV4+/+ mice, and were reduced by 100% at 30 mm Hg
(p<0.01), 72% at 45 mm Hg (p<0.0001) and 70% at 60 mm Hg (p<0.0001) compared to
sensitized responses of TRPV4+/+ mice. AP induced a similar degree of inflammation in
TRPV4-/- and TRPV4+/+ mice after 6 h. Although AP sensitized VMR to CRD in TRPV4-/-
and TRPV4+/+ mice, responses at 60 mm Hg were 69% lower (p<0.02) in TRPV4-/- than
TRPV4+/+ mice. The TRP antagonist ruthenium red (100 µM) inhibited mechano-sensitivity
of colonic afferents in TRPV4+/+ mice. This inhibitory effect was strongly attenuated in
TRPV4-/- mice, suggesting that ruthenium red is a TRPV4 antagonist in this preparation.
Ruthenium red inhibited responsiveness of rat colonic afferents to AP (300 µM) by >50%,
probably by antagonizing TRPV4. Conclusion Deletion or antagonism of TRPV4 inhibits
the effects of zymosan and PAR2-AP on activity of colonic afferent nerves and nociceptive
behavior. Thus, TRPV4 may mediate inflammation-induced mechanical hyperalgesia of the
colon that is observed in disease states. Supported by NIH DK07762 and DK57840.
T1997
Fecal Supernatants from Diarrhea-Predominant IBS (IBS-D) Patients Affect
Visceral Sensitivity and Epithelial Cytoskeleton Contraction in Mice: A Serine-
Protease Dependent Mechanism
Helene Eutamene, Kristina Gecse, Mathilde Leveque, Christelle Salvador-cartier, Jean
Fioramonti, Vassilia Theodorou, Tibor Wittmann, Lionel Bueno
Background and aims: Compared with healthy subjects, fecal supernatants of IBS-D patients
have been shown to bear with 3-4 times higher serine-protease (SP) activity. Intracolonic
(IC) infusion of a selective protease-activated receptor-2 agonist produces visceral hypersens-
itivity in rats associated with increased paracellular permeability. The aims of this study
were to evaluate if the elevated fecal SP activity found in IBS-D patients alters colonic
sensitivity in mice and to investigate the underlying reorganization in the structure of
epithelial tight junctions. Method: Fecal materials from healthy subjects and IBS-D patients
(Rome II criteria) were collected, homogenised, centrifuged and filtered. Alterations in colonic
sensitivity to distension as well as phosphorylated myosin light chain (p-MLC) and ZO-1
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protein expression were determined 60 min after IC infusion of supernatant of healthy
subject (n=5), IBS-D patients (n=5) or supernatants previously incubated with SP inhibitors
(SBTI + aprotinin) in C57BL/6J mice. Electromyographic (EMG) activity of the abdominal
muscles was recorded as an index of visceral pain. Rectal distensions were performed as
noxious stimuli using a Fogarty probe (4F) inflated from 0 to 0.12 mL, in 0.02 mL steps,
each step lasting 10s. Colonic samples were embedded in Tissue Tek medium. Cryostat
sections were incubated with a rabbit p-MLC antibody or rabbit anti ZO-1 antibody followed
by incubation with Alexa fluor 488-conjugated IgG donkey anti-rabbit. Results: Compared
with healthy subjects, IC infusion of fecal supernatants from IBS-D patients significantly
increased the abdominal EMG response at low distension volumes (0.02 mL: 30.6 ± 5.9 vs
3.5 ± 1.7; 0.04 mL: 73.4 ± 7.9 vs 18.9 ± 7.5 mV/s). Previous incubation of SP inhibitors
with IBS-D supernatant significantly reduced colonic hypersensitivity (0.02 mL: 2.8 ± 1.4
vs 30.6 ± 5.9; 0.04 mL: 49.8 ± 2.9 vs 73.4 ± 7.9 mV/s). P-MLC immunostaining was
enhanced in colonic epithelial cells of mice infused with IBS-D supernatant vs healthy
subjects. ZO-1 immunofluoresence after IC infusion of fecal supernatant of healthy subjects
was localised only at the apical site of cell to cell contact of colonocytes; while, the immunolab-
elling was diffused in the cytoplasm after infusion of fecal supernatant from IBS-D patients.
SP inhibitors prevented the IBS-D fecal supernatant-induced overexpression of p-MLC and
ZO-1 relocalisation. Conclusion: Increase of serine-protease activity present in feces of IBS-
D patients may reflect a high colonic level of these proteases that may trigger visceral
hypersensitivity through alterations of the integrity of colonic epithelial cell barrier
T1998
Mechanical Hypersensitivity of Mouse Colonic Afferents After Activation of
the Ion Channel Trpa1
Stuart M. Brierley, Patrick A. Hughes, Amanda J. Page, L.ashley Blackshaw
Background: A characteristic feature of IBS is hypersensitivity to mechanical stimuli in the
colon. Therefore mechanotransduction mechanisms of colonic afferents are important targets.
We have shown that the ion channels ASIC1, 2, 3 & TRPV4 contribute to these processes.
A novel candidate mechanotransduction channel, TRPA1, has recently been implicated in
nociception(1)however it is unknown whether it contributes to colonic mechanosensation.
Aims: 1) To determine the relative expression of TRPA1 transcripts in identified colonic
sensory neurons within dorsal root ganglia (DRG)2) To investigate the role of TRPA1 in
colonic afferent mechanotransduction. Methods: Quantitative RT-PCR was used to determine
TRPA1 mRNA expression in whole thoracolumbar (TL; T10-L1) & lumbosacral (LS; L6-
S1) DRG. QRT-PCR was also used to determine expression specifically in colonic DRG cells
identified by retrograde labelling that were isolated via laser capture microdissection. In
addition cells expressing TRPA1 mRNA in TL & LS DRG were counted after fluorescence
in situ hybridisation (FISH). FISH combined with retrograde labelling determined which
colon-innervating cells express TRPA1. An In Vitro preparation of mouse colon with attached
splanchnic nerves was used to examine the mechanosensitivity of serosal & mesenteric
afferents to graded probing forces before & after the addition of the TRPA1 agonists allyl-
isothiocyanate (40μM)& cinnamaldehyde (100μM)(2). Results: QRT-PCR revealed TRPA1
mRNA expression in whole TL DRG in greater abundance than ASIC1, ASIC3 or TRPV4
mRNA. In whole LS DRG TRPA1 mRNA was expressed in greater abundance than ASIC1,2,3
& TRPV4. In laser-captured colonic DRG cells, QRT-PCR revealed a high level of TRPA1
expression relative to whole ganglia. FISH revealed 42±2% (N=6) of T10-L1 DRG neurons
& 40±2% (N=6) of L6-S1 DRG neurons expressed TRPA1, whereas TRPA1 was localised
in 54±2% (N=6) of colonic T10-L1 neurons & 59±2% (N=6) of colonic L6-S1 neurons.
The TRPA1 agonist allyl isothiocyanate (40μM) caused a significant & potent increase in
the mechanical stimulus response functions of colonic mesenteric (P<0.01, n=12) & serosal
(P<0.01, n=18) afferents. Cinnamaldehyde (100μM) similarly caused a similar significant
& potent increase in the responsiveness of both classes of afferents to mechanical stimuli.
Conclusions: TRPA1 is highly expressed in colonic neurons & activation of TRPA1 evokes
mechanical hypersensitivity of colonic afferents. TRPA1 is therefore a candidate for contribut-
ing to mechanical hypersensitivity that leads to pain in IBS. 1Kwan et al., 2006, Neuron
50, 277-289. 2 Bandell et al., 2004 Neuron 41:849-857. Supported by NHMRC Australia
T1999
Site-Specific Differences in Central Processing of Visceral Stimuli from the
Descending Colon and the Rectum in Humans
Motoyori Kanazawa, Toyohiro Hamaguchi, Satoshi Watanabe, Takahiro Terui, Hirotaka
Mine, Michiko Kano, Masatoshi Itoh, Shin Fukudo
Background: It has been reported that different cerebral activation areas are demonstrated
during somatosensory and visceral stimuli in the upper and lower digestive tracts. There
were no studies to investigate how activated patterns in the brain differ during different
sites of visceral stimuli in humans. The aim of this study was to determine possible site-
specific differences in brain responses and perceptions during two different sites of visceral
stimuli, intraluminal distentions of the descending colon and the rectum. Methods: Regional
cerebral blood flow was assessed in right-handed 32 healthy male subjects using H215O
positron emission tomography (PET) during noxious distention at 40 mmHg to the des-
cending colon (DC group, n=16) or the rectum (R group, n=16). A barostat catheter with
a 700-ml balloon was inserted into the rectum at 10 cm from the anal verge in R group,
whereas the catheter was inserted into the descending colon using X-ray fluoroscopy in DC
group. Statistical Parametric Mapping software (SPM2) made voxelwise group comparisons.
Results: In response to the visceral stimulus, DC group showed greater activation in the
bilateral ventromedial prefrontal cortex [Brodmann Area 9/10] and the perigenual anterior
cingulate cortex [BA32], whereas R group showed greater activation in the midcingulate
cortex [BA24], the bilateral insula and the left somatosensory cortex [BA2] (all p<.001,
uncorrected). R group reported significantly higher scores of abdominal pain (p<.05) and
urgency (p<.001) during the stimulus but not score of anxiety compared with DC group.
Conclusions: Central projections of visceral stimulus from the descending colon and the
rectum differ in affective, cognitive, and nociceptive networks in the brain, which may result
in different perception to visceral stimuli from the different sites.
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Distinct Mechanisms of Sensitization of Thoracolumbar and Lumbosacral
Colonic Sensory Neurons in a Rat Model of IBS-Like Chronic Visceral
Hyperalgesia
Guang-yin Xu, John Winston, Mohan M. Shenoy, Liansheng Liu, Pankaj J. Pasricha
Background and Aims: Colon specific sensory neurons originate in both thoracolumbar (TL)
and lumbosacral (LS) dorsal root ganglia (DRG). Little is known about how these two
populations differ in their respective electrophysiological properties and chemical pheno-
types, particularly in the context of chronic “functional” colonic hyperalgesia such as irritable
bowel syndrome (IBS). We therefore compared membrane properties, ATP responsiveness,
P2X3 receptor expression and expression of p38 and CaMKIIα in TL and LS neurons in a
rat model of IBS-like chronic visceral hyperalgesia. Methods: TL and LS colonic DRG neurons
of sensitized adult rats (using an established paradigm of colonic infusion of 0.5% acetic
acid (AA) at 10 days old pups) were identified by retrograde labeling. Membrane properties
of colonic neurons were examined by patch clamp recording techniques and expression of
receptor and protein kinases were determined by Western blot and immunofluorenscence
approaches. Results: In control rats, cell size, resting potential (RP), input resistance, action
potential (AP) threshold and rheobase (current threshold) were similar for both TL and LS
DRG neurons. TL neurons displayed greater AP duration (TL: 3.3±0.2 ms, n=12; LS: 2.6±0.2
ms, n=24, P<0.05) and frequency (TL: 1.9±0.2, n=20; LS: 1.2±0.1, n=31, P<0.05) but
smaller AP amplitude (TL: 96.6±0.3.4 mV, n=12; LS: 106.2±2.2 mV, n=24, P<0.02). Both
TL and LS neurons responded similarly to ATP. In AA-treated rats, both TL and LS neurons
displayed a significant decrease in rheobase (TL: CON: 0.47±0.08 nA, n=21, AA: 0.26±0.03
nA, n=34, P<0.05; LS: CON: 0.61±0.08 nA, n=31, AA: 0.21±0.03 nA, n=25, P<0.05),
indicating an increased excitability of these neurons. RP decreased only in TL neurons (CON:
-60.0±1.3 mV, n=16, AA: -52.8±1.4 mV, n=24, P<0.05); conversely, evoked AP frequency
increased only in LS neurons (CON: 1.2±0.1, n=31; AA: 1.8±0.2 mV, n=25, P<0.05). Both
types of neurons showed enhanced ATP-evoked inward currents (TL: CON: 3.9±1.1 pA/
pF, n=11, AA: 9.2±1.8 pA/pF, n=12, P<0.05; LS: CON: 6.0±1.3 pA/pF, n=20, AA: 13.2±3.2
pA/pF, n=19, P<0.05) and a significant increase in P2X3R expression. These changes were
associated with an increase in phospho-CaMKII and p38 expression in TL and LS DRG,
respectively. Neither TL nor LS DRG displayed a significant change in PKC expression.
Conclusions: Distinct electrophysiological and signaling mechanisms underlie the sensitiza-
tion of colon-specific TL and LS DRG neurons in chronic visceral hyperalgesia. This complex-
ity of colonic inputs has significant implications for the efficacy of therapies targeting patients
suffering from chronic abdominal pain such as IBS.
T2001
Glial Cells: A Newly-Discovered Role in Visceral Hypersensitivity?
Jing Wang, Kirsten Garner, Chunping Gu, Carl Y. Saab, Elie D. Al-chaer
Given the growing body of evidence for a glial role in pain modulation, it seems plausible
that the exaggerated visceral pain in chronic conditions may be regulated by glial activation.
In this study, we investigated a possible role for microglia in rats with chronic visceral
hypersensitivity, where we have already showed that neuronal functioning is indeed altered.
Experiments were performed on adult male Sprague Dawley rats pre-treated with neonatal
colon irritation (CI) and on control rats. Effects of fractalkine (a chemokine involved in
neuron to microglial signaling) and of minocycline (an inhibitor of microglia) on visceral
sensitivity were examined. Visceral sensitivity was assessed by recording the electromyo-
graphic (EMG) responses to graded colorectal distension (CRD) in rats mildly sedated with
isoflurane (1%). CRD was induced by rapidly inflating a latex balloon to 20, 40, 60 or 80
mmHg for 10s, with a 5min interval between distentions. Electromyographic (EMG)
responses to CRD were measured using a bipolar electrode inserted into the external oblique
abdominal muscle. The signal from the EMG electrode was amplified and fed into an A/D
converter (CED 1401+) and recorded as waveform using Spike3 software. Responses to
CRD were recorded before and after an injection of fractalkine (5 µL; 8 µg/mL; it), minocycline
(60 mg/kg; ip), or vehicle (PBS). Somatic thermal hyperalgesia was measured by latency of
paw withdrawal to radiant heat. The number of microglia at the L6-S2 level of the spinal
cord was also compared between CI rats and controls using fluorescence microscopy. The
results show: (1) Fractalkine significantly facilitated the EMG responses to CRD (n=5; p<0.05
compared with vehicle) in control rats. Fractalkine also induced thermal hyperalgesia in
control rats, consistent with previous reports. The latency of paw withdrawal decreased
from an average of 13.62 ± 2.79 s to 9.81 ± 0.91 s (left foot) and from 13.50 ± 2.02 s
to10.84 ± 0.85 s (right foot) (n=5, p < 0.05). (2) Minocycline inhibited EMG responses to
noxious CRD (80 mmHg) by 68.4% in rats with CI (n=3) and by 49.7% in control rats (n=
2), 60 min after injection. This inhibitory effect lasted for 180 minutes in rats with CI and
120 min in control rats reaching the noted peak values 60 min after injection. Our results
suggest that fractalkine enhances visceral and somatic nociception, whereas minocycline
inhibits visceral hypersensitivity in chronically sensitized rats; they also suggest an enhanced
number of microglia in CI rats compared to control, indicating a possible role for microglia
in visceral hypersensitivity. (Supported by NIH / NS40434 and RR020146)
T2002
Lack of Colonic Inflammation-Induced Visceral Hypersenstivity to Colorectal
Distension in Nav1.9 Knockout Mice
Silvia Melgar, Anna Ravnefjord, Lisa Karlsson, Vicente Martinez
Tetrodotoxin-resistant voltage-gated sodium channels subtype 9 (Nav1.9) are expressed in
small-diameter dorsal root ganglion neurons and have been involved in persistent somatic
hyperalgesic responses associated to inflammation (J Neurobiol 61:55, 2004; PNAS 102:9382,
2005). AIM: To assess the role of Nav1.9 channels on acute colonic inflammation-induced
visceral hypersensitivity in conscious mice, using Nav1.9 knockout (KO) animals.
METHODS: Colorectal distension (CRD)-induced visceral pain was assessed in conscious
wild-type and Nav1.9 KO mice (C57BL/6 background). The mechanical activity of the
abdominal muscles, assessed by measuring transient changes in intracolonic balloon pressure
(intracolonic manometry) during phasic ascending CRD (10-30-60 mmHg, 3 pulses of 10
s for each pressure level, with a 5 min interval between distensions), was used as a measure
of visceral pain (J Pain 7:108, 2006). Acute colonic inflammatory-like responses were induced
by intracolonic administration of the toll-like receptor (TLR) 7/8 activator, R-848 (40 µg/
animal). Controls received intracolonic vehicle (0.1 ml). CRD was performed 5 h after
treatments, thereafter animals were euthanized and the colonic content of the pro-inflammat-
ory cytokine IL-1β assessed by ELISA. Data are mean±SEM. RESULTS: Phasic CRD (10-
30-60 mmHg) evoked distension-related abdominal contractions that increased in magnitude
with the increase in pressure. Relative pain responses were similar in Nav1.9 KO (AUC for
the mechanical response: 0.18±0.02, n=13) and wild-type mice (0.16±0.03, n=14; P>0.05
vs the response in KO mice). In wild-type mice, R-848 administration increased the response
to phasic CRD by 62% compared with vehicle-treated animals (Vehicle: 0.16±0.04, R-848:
0.26±0.03, n=6-7, P<0.05). However, in Nav1.9 KO mice, intracolonic R-848 did not affect
the response to CRD (0.11±0.02, n=7) compared to animals treated with vehicle (0.17±0.03,
n=5; P>0.05). After R-848 administration, the colonic content of IL-1β was increased in
similar proportion in wild type (50% increase over control levels, n=7) and Nav1.9 KO
mice (76% increase over control, n=7), suggesting the presence of a similar acute-like
inflammatory reaction in both groups of animals. CONCLUSIONS: These results suggest
that Nav1.9 channels do not significantly contribute to visceral pain responses to acute
colonic mechanical stimulation but may be important for the development of inflammatory-
related hyperalgesic responses. Local activation of TLRs might represent a useful tool to
induce local inflammatory responses and to assess visceral hypersensitivity.
T2003
The ATP-Gated P2X7 Receptor Is Required for the Generation of Jejunal
Afferent Mechano-Hypersensitivity in Trichinella Spiralis Infected Mice
Christopher Keating, Annmarie Surprenant, David Grundy
Background: Visceral hypersensitivity is one of the hallmarks of post-infectious IBS. Following
Trichinella spiralis infection in mice, a self-limited acute gastrointestinal inflammatory
response occurs in association with long-term changes in sensory function. This includes
the generation of mechano-hypersensitivity in both low threshold (LT) and high threshold
(HT) jejunal afferents. Here we use P2X7 receptor knockout (KO) mice to test the hypothesis
that P2X7 receptors contribute to jejunal afferent mechano-hypersensitivity in T. spiralis
infected mice. Methods: Mice were infected with 300 T. spiralis larvae by oral gavage.
Multiunit recordings from mesenteric afferent bundles supplying In Vitro segments of mouse
jejunum were made from T. spiralis infected KO and WT animals (=>28 days post infection),
and from uninfected controls. Data presented as mean±SEM (N≥10) and analysed by one-
way ANOVA. P<0.05 was taken as significant. Results: In uninfected WT and KO animals,
ramp distensions of the jejunum produced a biphasic increase in afferent discharge, which
corresponded to the activation of LT and HT afferent units. At LT (0-10mmHg) and HT
(10-50mmHg) levels of distension, WT preparations responded with a change in afferent
discharge of 25.7±2 and 29.6±3 imp/s respectively, which was comparable to that obtained
in the KO animals (25.4±3 and 34.1±2 imp/s respectively, p>0.05). Furthermore, the pressure
volume curves were similar indicating that there was no difference in compliance of the gut
wall between the uninfected WT and KO animals. Following infection in the WT animals
there was a significant augmentation in the response to LT (38.3±3 imp/s, p<0.05) and HT
(42.7±2 imp/s, p<0.05) levels of distension, indicating afferent hypersensitivity. There was
also an increase in compliance which was reflected by an intraluminal volume of 241±13μl
being required for a 50mmHg distension pressure in the infected WT compared to 201±6μl
in the uninfected WT (p<0.05). In contrast, following infection in the KO animals the
hypersensitivity in response to both LT (29.4±4 imp/s, p>0.05) and HT (36±4 imp/s, p>0.05)
levels of distension was absent. However infection in the KO animals did result in an increase
in compliance (236±13μl in the infected KO compared to 196±8μl in the uninfected KO,
p<0.05). Conclusion: T. spiralis infection produces a sensitization of LT and HTmechanosen-
sitive afferent fibres. This sensitization appears to be dependent upon the activation of P2X7
receptors and suggests an important role for this receptor subtype in mediating visceral
hypersensitivity in response to transient enteric infection.
T2004
Trinitrobenzenesulphonic Acid (TNBS) Colitis Causes Differential Expression
of Voltage-Gated Sodium Channel mRNA in Mouse Dorsal Root Ganglia
(DRG) Neurons Innervating the Colon
Dale King, John Macleod, Iva Kosatka, Stephen Vanner
Our studies of day 7 mouse TNBS colitis have shown that colonic DRG nociceptive neurons
are hyperexcitable, and that increased Nav 1.8 currents are associated with these changes
(Beyak et al. AJP 287:845, 2004). It is unclear whether these increased Nav 1.8 currents
are due to transcriptional or post-translational changes in these channels, and therefore we
conducted quantitative PCR studies to quantify relative voltage-gated sodium channel (Nav)
alpha subunit transcript abundance. Mouse colonic sensory DRG neurons were identified
by injection of the retrograde label Fast Blue into the descending colon wall and colitis
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induced by injection of TNBS at the same site. Neurons were isolated from DRG using laser-
capture microdissection at two locations from each animal, ganglia at T9-T13 (i.e. Fast Blue
labeled neurons innervating the colon) and upper thoracic ganglia at T1-T3 (i.e. non-labeled
neurons innervating other targets) from control animals, and those receiving TNBS. TNBS
inflammation was studied at day 7 (n = 4 mice), which correlated with the previous
electrophysiological studies, and an earlier time point, day 2 (n = 4 mice). Intron spanning
primers were used to identify all Nav channel alpha subunits in DRG neurons, Nav 1.6,
1.7, 1.8, 1.9, and values were expressed as a ratio to the Alas I reference gene which
exhibited constant expression during inflammation and had similar levels to the target Nav
channels. Colons from TNBS treated mice had significantly increased colon weights (p <
0.05) compared to control mice, indicative of inflammation. Quantitative PCR on day 7
showed that TNBS colitis had no effect on Nav 1.8 alpha subunit transcription levels.
Similarly, Nav 1.7 and Nav 1.6 levels were unaffected, but Nav 1.9 levels were increased
(p < 0.05). At the earlier day 2 time point, TNBS colitis resulted in a marked 4-5 fold
decrease in Nav 1.8 (p = 0.0293) and Nav 1.9 (p =0.0010) mRNA but had no effect on
Nav 1.7 and 1.6. On both day 2 and 7, alpha subunit transcription levels of all four sodium
channels in neurons not innervating the colon (i.e. the T1-T3 site) were not altered by TNBS
colitis. Our data at day 7 show that our previously reported increase in Nav 1.8 currents
in the DRG neurons of mice with TNBS colitis was not due to an increase in transcript
abundance and suggest these changes result from post-translational events. The marked
decrease in Nav 1.8 (and Nav 1.9) at day 2 also exclude altered transcript abundance as a
primary determinant of the increased currents at later time points. These decreases may
reflect altered transcription or transcription half life of mRNA during colitis.
T2005
5-Hydroxytryptamine7 Mediated Mesenteric Afferent Responses Evoked By
Focal Ischemia/Reperfusion in Rat Jejunum In Vivo
Wen Jiang, David C. Bulmer, Wendy J. Winchester, David Grundy
Introduction: Serotonin (5HT) primarily released from enterochromaffin cells is implicated
in intestinal afferent activation in response to tissue injury, ischemia and inflammation. The
aim of the study was to examine the role of 5HT7 receptors in the mesenteric afferent
response to focal ischemia/reperfusion (I/R). Methods: Afferent discharge (AD) wa recorded
extracellularly from a distal end of mesenteric nerve bundle in pentobarbitone sodium
anaesthetized adult Wistar male rats. Ischemia was caused by clamping the mesenteric vessels
supplying an extrinsic dennervated jejunal loop for 8min; reperfusion followed removal of
the vessel-clip. Afferent and motor responses to I/R were compared before and after treatment
with either vehicle, metergoline (2.5 mgkg-1, I.V., 5HT1, 2, 6, 7, antagonist) 8-OH-DPAT (1
mgkg-1, I.V., 5HT1A, 7 agonist) and SB-2609970A (15 mgkg-1, I.V., 5HT7 antagonist). Data
are expressed as mean ±SEM (N=4-6) and compared using paired t-test. Results: Focal
intestinal ischemia caused a characteristic biphasic afferent discharges. The 1st-peak in AD
occurred with 2 min and was associated with an increase in luminal pressure (LP). The 2nd-
peak in AD occurred after about 5 min and was correlated to a prolonged inhibition of LP.
8-OH-DPAT showed no effect on basal AD or I/R afferent response. Metergoline significantly
reduced the ischemia-induced 2nd-peak in AD (Table). Neither treatments affected ischemia-
induced intestinal motor response. SB-269970A caused a marked reduction in basal AD
and both the 1st and 2nd-peak in AD caused by ischemia but not afferent response in
reperfusion. In addition SB-269970A significantly enhanced the baseline LP (3.5±0.5 vs.
4.4±0.4 mmHg) and reduced the early reperfusion evoked increase in motility (3.4±0.4 vs.
1.7±0.4 mmHg). Conclusion: Focal intestinal ischemia evoked extrinsic afferent activity
involves release of endogenous 5-HT acting on 5HT7 receptors. Supported by GSK
Effect of selective 5HT antagonists on baseline and ischemia induced afferent response
*:p<0.05; **:p<0.005 (paired t-test)
T2006
In Vivo Transduction of Vagal Sensory Neurons with Adeno-Associated Virus
Vectors
Fei Ru, Micheal J. Carr, Anita Umesh, Paula S. Tallman, Bradley J. Undem, Marian
Kollarik
We aimed to develop a method by which specified genes could be delivered to vagal sensory
neurons In Vivo. We evaluated the efficacy of the adeno-associated virus vectors (serotypes
AAV2/7, AAV2/8 and AAV 2/9) to transfect vagal sensory neurons in guinea pigs. The viral
vectors were designed to encode the enhanced green fluorescent protein (eGFP) allowing
for easy identification of transfected neurons. AAV vectors were microinjected into surgically
exposed vagal nodose ganglia. The eGFP expression was detected by fluorescent and confocal
microscopy. Five weeks after injection, eGFP was detected in the neurons in the nodose
ganglia injected with each AAV vector. AAV2/7 and AAV2/8 showed similar efficacy in
transfecting nodose neurons with eGFP being detected in ~ 30% of the nodose neurons.
AAV2/9 was less efficient in transfecting neurons. eGFP was detected as early as 1 week
after the injections of AAV2/8 into nodose ganglia and the number of eGFP-positive neurons
increased at the later time points (1wk<<2wks<5wks~10wks), evaluated in separate animal
groups. Immunostaining for neurofilament (NF) was used to evaluate the transfection of
the C-fiber (NF negative) neurons that are putative cell bodies of the vagal C-fiber (nocicep-
tors). Each AAV serotype was found to efficiently transfect both A- and C-fiber neurons.
The eGFP was transported from the cell soma to the terminals as evidenced by intense eGFP
labeling in the vagal nerve fibers and in the nerve terminals in the esophagus and trachea
(5wks). Using fluorescent microscopy in fresh tissues and confocal microscopy in fixed
preparations, numerous intensely eGFP-labeled nerve terminals consistent with the intragang-
lioncic laminar endings (IGLE) were identified in the esophageal muscle. To selectively
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transfect esophageal or tracheal afferent neurons, AAV2/8 was injected into the esophageal
muscle or tracheal wall. 5-7 wks after injection eGFP positive neurons were found in the
vagal nodose and jugular ganglia and in the spinal dorsal root ganglia. In these experiments
the intensity of the eGFP fluorescence was lower compared to the intraganglionic injections.
These data indicate that the sensory neurons are readily transfected with AAV2/8 injected
into their target tissues. The AAV virus vectors will allow for genetic manipulation of vagal
sensory neurons (e.g. activity reporters and shRNA). In addition, because the eGFP is
transported to the terminals, these techniques allow for morphological studies of the nerve
endings in living tissue. Funded by GlaxoSmithKline and American Gastroenterological
Association Institute Bridging Grant.
T2007
Trypsin IV Implication in Irritable Bowel Syndrome (IBS) and Visceral
Hypersensitivity
Nicolas Cenac, Christopher N. Andrews, Graeme S. Cottrell, Jose G. Ferraz, Eldon A.
Shaffer, Wolfgang Knecht, Anders Perterson, Nigel W. Bunnett, Nathalie Vergnolle
Background and Aims: We have recently reported that increased proteolytic activity was
released from IBS patient biopsies compared to biopsies from control (non pathologic)
patients. Further, we have shown that culture media of IBS patients incubated biopsies,
when injected intracolonically to mice, were able to induce allodynia and hyperalgesia.
However, the protease(s) released from IBS patient tissues that were responsible for these
effects, were not identified. We hypothesized that trypsin IV, an extrapancreatic protease
that can also be released by intestinal epithelial cells, is released from IBS patient colonic
tissues and can induce visceral hypersensitivity. Methods: Biopsies from 11 control and 12
IBS patients, diagnosed according to Rome II criteria, were collected at the rectum and
ascending colon levels. Specific primers designed to amplify trypsin IV products were
designed and used for RT-PCR in biopsy tissues. Purified trypsin IV was administered
intracolonically to C57Bl6 mice and spontaneous abdominal contractions or contractions
in response to increasing pressure of colorectal distention (15 to 60 mmHg) were recorded
through implanted electrodes. Results: Trypsin IV mRNA was amplified from tissues of both
control and IBS patients, and its expression was confirmed by sequencing of RT-PCR
products. Quantification of RT-PCR trypsin IV products showed a significant increase in
tissues from IBS patients compared to tissues from control patients. Intracolonic administra-
tion of purified trypsin IV (1 U per mouse) provoked spontaneous abdominal contractions
at 3 hours. While mice did not respond to 15 mmHg pressure of colorectal distension in
basal conditions, 3 hours after the intracolonic administration of trypsin IV (1 U per mouse),
mice showed strong abdominal contractions to that same pressure, characteristic of allodynia.
For higher pressure of distension (30, 45 and 60 mmHg), mice showed significant increased
abdominal contraction responses after intracolonic administration of trypsin IV, characteristic
of hyperalgesia. Conclusions: Trypsin IV message has been identified in mucosal biopsies
from IBS patients, and the intracolonic administration of purified trypsin IV to mice causes
spontaneous visceral pain, allodynia and hyperalgesia. These results suggest that trypsin IV
released by mucosal biopsies of IBS patients may be among the proteases responsible for
the visceral hypersensitivity symptoms associated with IBS. Overall, these results present
trypsin IV as a potential target for IBS therapies.
T2008
Visceral Hypersensitivity Following Induction of Chemical Colitis Is
Selectively Reduced Via Kappa Opiate Pathways - A Comparative Study of
Different Opioidergic Subtypes
Michael Stutz, Dominique Engel, Jerry C. Miller, Beatrice Flogerzi, Luis Tovar, Peter
Netzer, Gerald Holtmann, Ulrich Scheurer, Juergen M. Gschossmann
Background: Failure of anti-nociceptive pathways following an acute mucosal inflammation
is one hypothesis that may explain post-inflammatory hypersensitivity in patients with
functional bowel disorders. We have shown that a chemical colitis causes persistent visceral
hyperalgesia in an animal model (Gschossmann et al, 2004). Recently, a human study
comparing the opiate antagonist naloxone versus placebo in patients with irritable bowel
syndrome demonstrated no significant change in the pain score under naloxone treatment
(Hawkes et al, 2002). A possible explantation could be alterations of antinociceptive pathways
in these patients. Aim: a) to analyze and compare the effects of different opioidergic subtypes
on visceral sensory function and b) assess the long-lasting impact of a chemical colitis on
the effects of various opiate receptor agonists on visceral nociception in a rat model. Methods:
Six weeks after induction of a trinitrobenzene sulfonic acid (TNB) colitis (colitis group) or
saline (control group), abdominal electromyography (EMG) recordings (in uV) of 3 phasic
colorectal distensions (CRD) (40 mmHg/30sec) before (period A) and after (period B)
intraperitoneal injection of drug (1S,2S-U50.488 (18mg/kgBW) (k-opiate agonist), morphine
(3mg/kgBW) (m-opiate agonist) or SNC80 (10mg/kgBW) (d-opiate agonist) or placebo
(saline) were performed in 40 male Lewis rats. Results: The visceromotor response (VMR)
increased after TNB (p=0.003) but not after saline (p>0.1).While 1S,2S-U50.488 significantly
reduced the EMG response to CRD in both treatment groups (p=0.003 and p=0.013), the
administration of morphine and SNC80 caused a significant decrease of the VMR only in
the control group (p=0.011 and p=0.005). Conclusion: In our animal model with male
Lewis rats, a TNB colitis augments the VMR to CRD. Only the k-opiate agonist reduced the
VMR in the TNB colitis group and during the control condition whereas m- and d-opiate
agonists were not effective after pre-treatment with TNB. The pathophysiological mechanisms
why the analgesic effects of m- and d-opiate agonists are abolished in this experimental
setup have to be analyzed in upcoming studies.
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T2009
Autonomic Effector Organ Responses to Mild (Near Threshold) Rectal Balloon
Distensions in Healthy Women
Iris Posserud, Karin Rylander, Mikael Elam, Magnus Simren
Introduction: Studies examining autonomic responses to visceral stimulation have mainly
used stimulation levels eliciting discomfort/pain, focusing on gastrointestinal functional
disorders. We aimed to characterize peripheral autonomic responses to mild (physiologically
relevant) visceral stimuli in healthy women. Methods: We delivered mild rectal balloon
distension (not painful) in 7 healthy women (age 26.4±5.5) while measuring autonomic
variables. Individual perception thresholds were determined by stepwise increasing rectal
balloon pressure in steps of 2 mmHg, until subjects barely, but reproducibly, perceived the
distension. A series of distensions were then delivered at threshold (T), 50% below (T-) and
50% above (T+), in a randomized order. Distensions were 30 s and inter stimulus interval
was 30, 60 or 90 s to prevent habituation. For evaluation of autonomic effector function,
ECG (for calculation of R-R interval), skin vasoconstrictor (laser Doppler flowmetry) and
electrodermal (galvanic skin; GSR) responses were monitored. To statistically establish the
T- stimuli as unperceivable, we performed a forced choice paradigm. Results: The mean
threshold for perception was 18±7 (2SD) mmHg, and the forced choice paradigm for T-
stimulations established that such stimuli were not perceived. T- stimuli left all autonomic
effector variables unaffected. T+ elicited a significant (p<0.05) skin vasoconstriction in 5/7
subjects, a GSR in 4/7 and a transient prolongation in R-R interval (bradycardia) in 2/7
subjects. Combining skin vasoconstrictor and sudomotor (GSR) responses, all subjects
showed a cutaneous sympathetic response to T+ stimuli. T stimuli elicited a significant skin
vasoconstriction in 2/7 subjects, a GSR in 2/7 and left R-R interval unchanged in all subjects.
Notably, none of the subjects showed reduced R-R interval (tachycardia) in response to any
stimulus level. Conclusion: Mild rectal distension elicited a transient bradycardia in a few
subjects, and tachycardia in none, suggesting an orienting response rather than a generalized
(hemodynamic) startle response. Combined with the consistent responses of cutaneous
sympathetic effector organs, our data indicate that mild rectal stimuli elicit a differentiated
autonomic activation pattern. Subthreshold rectal stimuli elicited no autonomic effector
responses, in agreement with an ongoing fMRI study showing no CNS activations in response
to such stimulus intensities. The characterization of physiological autonomic responses to
rectal stimulation now forms our basis for investigating putative autonomic dysfunction in
gastrointestinal functional disorders.
T2010
A Review of CNS Activation Patterns from Fmri Studies in IBS Patients
Versus Healthy Controls
Alexandru Gaman, Braden Kuo
BACKGROUND: Increasing numbers of studies using brain imaging methods have been
done to elucidate the differences in CNS activation between patients with Irritable Bowel
Syndrome (IBS) and healthy controls. The general consensus has been that brain activation
in IBS is greater than controls in CNS regions involved in emotional/cognitive modulation.
AIMS: To evaluate the CNS regions activated with rectal stimulation when comparing IBS
and healthy controls by categorizing which group had greater activity and to assess the
laterality of activations within the two groups. METHODS: Medline was reviewed from Jan
1997 to Nov 2006 using key search terms IBS, PET, and fMRI. Only original scientific
articles assessing differences between IBS and Control subjects were considered for review.
Studies were grouped and tabulated according 11 brain areas known to have major import-
ance in somatic and visceral sensation. Each region was categorized into % of studies with
greater activation in IBS, % greater in Controls and % with no difference. In addition,
laterality of activation was assessed if declared from each of the groups where IBS>Controls
or Controls>IBS. RESULTS: 11 articles were extracted from the literature with data sufficient
for review. Ant and post insula, thalamus and hippocampus were more frequently reported
to have higher activation in IBS (50%, 42%, 44% and 60% of studies). Fewer studies reported
higher activation in these areas in controls (12%, 14%, 11% and 20% respectively). ACC
(anterior cingulate cortex) (54%), prefrontal cortex (45%) and periaqueductal grey (PAG)
(66%) were reported more frequently to have higher activation in controls. Across studies,
regions showing higher activation in controls tended to present more bilaterally. Regions
with higher activation in IBS had a trend for some type of laterality: left (5/11 areas considered)
or right (4/11). All the studies that showed ant and post insula activation IBS>Controls had
predominantly left sided activation. Amajority (66%) that found hippocampusmore activated
in IBS also reported predominantly left sided activation. CONCLUSIONS: The literature is
quite heterogeneous with results and there is not a single consistent activation pattern that
is demonstrated in 100% of studies. The insula is more commonly activated in IBS patients
with predominance for the left side. But interestingly, the literature reports more frequently
that ACC and prefrontal cortex have greater activity in Controls compared to IBS suggesting
that the emotional/cognitive modulation of visceral sensation is more complex than just
defectively increased emotional/cognitive modulation in IBS as previously thought.
T2011
Delayed Increase in Urinary Bladder Permeability Parallels Mast Cell
Migration in TNBS Colitis
Elena E. Ustinova, Dmitriy W. Gutkin, Matthew O. Fraser, Michael A. Pezzone
Background: Irritable bowel syndrome and interstitial cystitis often overlap and occur con-
comitantly as do other chronic pelvic pain disorders. We have demonstrated that colonic
irritation with trinitrobenzenesulfonic acid (TNBS) leads to the development of bladder
sensitization as evidenced by irritative micturition patterns and increased sensitivity of
bladder afferents to mechanical and chemical stimuli. During the resolution phase of TNBS
colitis (2-3 months after the acute insult), both the urinary bladder and colon remain
sensitized, and significant mast cell migration occurs in both organs. Moreover, in the
bladder, mast cell infiltration was the only histologic finding in this model of neurogenic
cystitis. We hypothesize that chronic mast cell infiltration of pelvic organs following an
acute pelvic organ insult may play a role in chronic pelvic organ sensitization and cross-
sensitization. Specifically, we hypothesize pelvic organmastocytosis leads to increased epithe-
lial permeability, and increased permeability may lead to afferent activation by physiologic
stimuli. Methods: Colonic irritation was induced by intra-colonic TNBS (30 mg in 0.5 ml
50% ethanol), and 4-10 days later, cystometry was performed in urethane anesthetized
animals during infusion of normal saline or normal physiologic urinary concentrations
of potassium chloride (300mM). Bladder permeability was concurrently measured with
fluorescein, and mast cells were quantified using a Giemsa stain. Results: Four days following
intra-colonic TNBS, micturition rates, bladder permeability, and bladder mast cells counts
were not significantly different from controls. Ten days following TNBS, however, the number
of mast cells in the bladder increased from 3.1 ± 1.0 to 18.0 ± 1.2 per 100x field (p<0.001).
Concurrently, bladder permeability was increased 6-fold (p<0.001), and likewise, voiding
frequency wasmarkedly increased as compared to controls. Saline cystometry was no different
from controls suggesting sensitivity to physiologic potassium concentrations. Conclusion:
In our model of chronic neurogenic cystitis, increased bladder permeability and changes in
micturition coincide with bladder mast cell infiltration. Such changes in pelvic organ epithelial
permeability may allow normally non-irritating physiologic stimuli to adversely activate
pelvic afferents and may account for chronic pelvic pain and sensitization. Similar studies
of the colon are underway. Supported by National Institutes of Health Grants DK02488
and DK066658 (to M.A.P.).
T2012
Effect of a Novel Molecule ENMD-1068 On Protease-Activated Receptor-2
Evoked Small Intestinal Motor and Afferent Responses in Rats
Wen Jiang, David C. Bulmer, Wendy J. Winchester, David Grundy
Introduction: Exogenous application of SLIGRL, a synthetic activating peptide for the pro-
tease-activated receptor-2 (PAR2), stimulates small intestinal afferent discharge and increases
intraluminal pressure (Kirkup, Jiang et al., J. Physiol. 2003). The aim of the present study
was to examine the effects of a novel small molecule PAR2 antagonist, ENMD-1068 In Vivo,
on SLIGRL evoked jejunal motor and afferent responses. Methods: Mesenteric afferent nerve
activity (AD) was recorded extracelluarly from a cannulated jejunal segment in pentobarbitone
sodium anaesthetized adult male Wistar rats. Peak changes in mesenteric afferent nerve
activity and intestinal luminal pressure (LP) following systemic application of SLIGRL at
doses of 0.1, 0.3 and 1 mgkg-1 were examined before and after treatment with ENMD-1068
(100 mgkg-1, I.V.). Changes in luminal pressure were determined overall and additionally
at the point of maximal afferent activity. Data were expressed as mean ±SEM (N=4-7) and
compared using paired t-test. Results: SLIGRL caused a rapid, transient, dose-dependent
increase in afferent discharge and a prolonged increase in luminal pressure (see Table). Both
the increase in mesenteric nerve activity and luminal pressure to 0.1 and 0.3 mgkg-1 SLIGRL
were significantly attenuated following pre treatment with ENMD-1068. The increase in
afferent activity and luminal pressure to 1mgkg-1 SLIGRL were also reduced following pre-
treatment with ENMD-1068 however this did not reach significance. Conclusion: The results
of this study demonstrate that ENMD-1068 antagonized SLIGRL activation of extrinsic
primary afferent fibers and intestinal motility. This compound may therefore provide a tool
for studying the role of endogenous activation of PAR-2 receptors in models of disease.
Supported by GSK
Effect of ENMD-1068 on PAR2-agonist evoked afferent and motor responses
*: p<0.05; **: p≦0.005 (paired t-test)
T2013
Increased TRPV1 Expressing Nerve Fibres in Colonic Biopsies from IBS
Patients and Their Correlation with Abdominal Pain
Ayesha Akbar, Yiangos Yiangou, Paul Facer, Praveen Anand, Subrata Ghosh
Introduction: TRPV1, the heat and capsaicin receptor expressed by nociceptor fibres, on
activation leads to burning pain and local release of neuropeptides CGRP and substance P
(SP). It has been linked to GI disorders including painful IBD and rectal hypersensitivity,
where increased TRPV1-expressing fibres correlated with rectal hypersensitivity to distension
and heat. Our objective was to characterise the molecular basis of visceral hypersensitivity
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in IBS patients by quantifying TRPV1 and SP fibres, and relating these to pain severity.
Methods: Patients were defined as suffering from IBS using Rome II criteria. Daily pain
diaries (using the SF-MPQ) were recorded for 1 week after colonoscopy by IBS patients and
controls. All subjects had normal mucosa at colonoscopy/flexible sigmoidoscopy. Recto-
sigmoid biopsies were taken for histology to exclude inflammation, and immunostained
with antibodies to TRPV1, nerve markers (Neurofilaments and Peripherin PGP 9.5) and SP.
TRPV1- immunoreactive nerve fibres were expressed as fibres /mm2, while PGP 9.5 and SP
fibres were analysed by computerised image analysis. The area of TRPV1 immunoreactivity
was correlated with abdominal pain. Results: Fine mucosal TRPV1-immunoreactive fibres
were seen in all control (n = 22) and IBS (n=23) biopsies. There was a significant increase
in TRPV1 fibres in IBS (fibres/mm2, mean ± SEM, 4.0±0.6) compared to controls (1.6 ±0.3;
P<0.0001). Substance P immunoreactive fibres were significantly increased compared to
controls (P=0.0024) as were PGP 9.5 (P=0.0002). TRPV1 fibres/mm2 (but not SP) including
both groups correlated with pain score VAS (max) (Spearman r=0.61; p<0.0002). Biopsies
had no inflammation. Conclusion: We have demonstrated significantly increased TRPV1
and SP nerve fibres, and total number of nerve fibres, in IBS patients. TRPV1 fibres correlated
with pain, providing a rationale for the treatment of IBS with TRPV1 antagonists.
TRPV1 fibres in mucosal biopsies of control and IBS in recto-sigmoid, * P<0.0001
T2014
A Functional MRI Study of the Neural Correlates of Visceral Hyperalgesia
Induced By Fearful Faces and Anhedonia for Happy Faces Induced By Visceral
Pain
Peter A. Paine, Qasim Aziz, Mary L. Phillips, Steve Williams, Elizabeth A. Moore, Vincent
Giampietro, Lloyd J. Gregory
Background: It is known that a fearful emotional context can heighten the sensation of
non-painful visceral stimulation via central mechanisms(1). However, it is not knownwhether
this is the same for visceral pain. Also, it is not known whether visceral pain can influence
the perception of emotional stimuli. Aims: To explore the neural correlates of (i) the effects
of varying emotional contexts on visceral pain and (ii) the effects of visceral pain on the
perception of varying emotional valence and intensity. Methods: 8 healthy volunteers (all
female, aged 24-52) swallowed a catheter with a balloon situated 30 cm ab orus. Oesophageal
pain thresholds to phasic stimulation were determined with the subject lying in the scanner.
100% & 50% intensity happy and fear faces and neutral faces were paired with either no
oesophageal stimulus or a painful oesophageal stimulus. 30 presentations each of 10 possible
combinations of these were delivered to each subject in a randomised sequence at a rate of
one every 12 seconds. After each stimulus pair, the subject rated either their perception of
the intensity of the balloon stimulation or their perception of the emotional intensity in the
face displayed using an on-line visual analogue score. Whole brain fMRI BOLD signal was
acquired continuously during the 300 stimulus pair presentations. Results: 7 out of 8
subjects had an increased perception of pain intensity during 100% fearful faces compared
with neutral (mean (SEM) 7 (0.8) v 6.4 (0.8) p = 0.009). A repeated measures ANOVA of
BOLD signal differences between these two conditions revealed significant activation in
cerebellum, L insula, brainstem, L corpus striatum, L superior temporal lobe and L thalamus.
All 8 subjects perceived 100% happy faces as less happy during pain compared with during
no oesophageal stimulus (7.6 (0.2) v 8.3 (0.2) p = 0.006). Repeated measures ANOVA for
these two conditions showed activation in R insula and L dorsolateral prefrontal cortex.
Conclusions: there is a bidirectional relationship between visceral pain and emotional
context in that a negative emotional context (fear) can induce visceral hyperalgesia and
conversely visceral pain has an anhedonic effect on perception of a positive emotional context
(happy). The neural mechanisms underpinning these effects may however be quite different
and require further exploration. Reference: (1) Phillips ML, Brain (2003)126:669-84.
T2015
Abnormal Endogenous Somatic Pain Modulation in IBS
Clive Wilder-smith, Guang hui Song, Khay guan Yeoh, Khek yu Ho
Sensory sensitization with visceral and somatic hyperalgesia and allodynia is postulated to
be an important mechanism in Irritable Bowel Syndrome (IBS). Endogenous pain modulation
is central to sensory sensitisation and is part of a cortico-limbic-pontine neuromatrix integrat-
ing cognitive, emotional, autonomic and motor responses to pain. Abnormal endogenous
modulation of visceral pain has previously been demonstrated in IBS patients using hetero-
topic stimulation (Wilder-Smith CH. Gut 2004;53:1595-1601) and has been shown to
activate areas minimally overlapping with anticipatory effects (Song GH et al. Gastroenterol-
ogy 2005;128(suppl 2):M1491). However, the impact of aberrant modulation on somatic
sensory function in IBS is unclear. This study examines somatic sensory function and
endogenous somatic pain modulation in IBS. Somatic endogenous pain modulation was
assessed using heterotopic stimulation (effect of a heterotopically, simultaneously applied
second pain on primary pain) in 14 IBS and 11 matched healthy subjects. Somatic pain
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thresholds were determined using an electrical stimulus to the left hand. Heterotopic stimula-
tion was performed by simultaneous electrical hand pain (pain threshold+20%) and cold
pain to the left foot (water at 4°C) for 30s. Hand pain intensity was rated by VAS (0-100)
during 7 randomised stimuli without and with heterotopic foot stimulation. Heterotopic
stimulation on the foot significantly decreased the pain intensity due to stimulation on the
hand in controls but not in IBS. The mean change (95% CI) in hand pain due to heterotopic
stimulation was +0 (-5.4 - 4.4) in IBS and -8.6 (-16.4 - 0) in controls (p<0.05). In IBS
patients hypersensitive to somatic stimulation (i.e. <95% CI of controls' values), the change
was +3.7 (-3.6 - 10.4)(p<0.05 vs controls). Pain intensity on the hand and foot and abnormal
pain modulation correlated significantly in IBS patients (R>0.45, p<0.01) Patients with IBS
demonstrated abnormal endogenous pain modulation of somatic stimuli, with most patients
lacking the inhibition seen in controls and showing facilitation instead. This replicates the
earlier finding of abnormal endogenous modulation of visceral pain and implies a generalised
dysfunction of endogenous pain modulation as a plausible cause for sensory sensitisation
and hypersensitivity in IBS.
T2016
Long Term Telemetry of Gastrointestinal Motility in Rats: Oral Pretreatment
with Civamide Decreases Postoperative Ileus in Rats
Tobias Meile, Helena Gruja, Jörg Glatzle, Petra Jacob, Alfred Koenigsrainer
Background: Over the past few years our research group has developed a telemetry unit
to measure long term gastrointestinal motility in rats, using strain gauge transducers. This
are the first data obtained with this new device. Civamide is the oral absorbable cis-isomer
of Capsaicin, which is known to increase postoperative gastrointestinal motility. Aim: First
goal was to evaluate the telemetry system under experimental condition. We expected oral
applied Civamide to increase gastrointestinal postoperative motility in comparison to vehicle.
Material and Methods: Strain gauge transducers were either sutured to the gastric corpus
the small intestine 10 cm distal of the ligament of treitz or to the right colonic flexure of
male Sprague Dawley rats. Wires were exteriorized between the scapulae and connected to
the telemetry device stored in a backpack. Oral applied Civamide (20 µmol) or Vehicle (6
ml) was given at day 3 of the experiment and the ileus was induced by gentile manipulation
of the cecum at day 5 of the experiment followed by 2 hours and 4 hours of motility
measurement. At day 6 fasting and fed state postoperative motility was measured again. All
data is given as percent of baseline index ± SEM. Results: Oral application of Civamide or
Vehicle decreases gastric, small intestinal and colonic motility. Postoperative motility is
decreased for at least 4 hours. 24 hours after surgery gastrointestinal motility exceeds
preoperative levels in Civamide pretreated animals and is even more increase after food war
offered. Conclusion: Long term measurement of gastrointestinal motility with strain gauge
transducers in rats is possible using our telemetry system. Oral Civamide pretreated rats
seem to recover faster from postoperative ileus than vehicle animals.
T2017
Supernatant from Human Biopsies of Ulcerative Colitis Induce
Hyperexcitability of Mouse Nociceptive DRG Neurons
Charles Ibeakanma, Francisco Bautista-cruz, Ian Spreadbury, Rustum Karanjia, Melanie
Tsang, Stephen Vanner
The effect of single inflammatory mediators on the excitability of nociceptive DRG neurons
has been widely studied, and pro- and anti-nociceptive factors have been identified. However,
little is known about the effect of the complete repertoire of human inflammatory cytokines
on nociceptive neurons. Therefore, the aim of this study was to examine the effect of the
supernatant from colonic biopsies obtained from a patient with ulcerative colitis on the
excitability of nociceptive mouse DRG neurons. Eight biopsies were obtained from the
inflamed sigmoid colon of a patient with bloody diarrhea for eight weeks receiving steroid
therapy. Biopsies were incubated in 2 ml of Hanks solution for 24 hours. This solution was
extracted, and acutely dissociated mouse DRG neurons from T9-13 were incubated for 12
hours in 200 µl of supernatant, or control Hanks solution, combined with 500 µl of culture
medium. Neurons were superfused in standard extracellular media and perforated patch
recordings were obtained from small nociceptive neurons (capacitance < 30 pF) 15- 30 min
after removal from the incubatingmedia. In current clampmode, resting membrane potential,
rheobase, action potential discharge at two times rheobase, and input resistance were com-
pared in neurons incubated in inflammatory supernatant (n = 13) or control media (n =
11). The mean resting membrane potential did not differ between inflammatory (mean = -
44.4 ± 1.4 mV) and control (mean = - 45.1 ± 1.3 mV) groups. The rheobase was also not
different between groups, but there was a 76 % increase in number of action potentials
discharged at two times rheobase in inflammatory (mean = 5.6 ± 0.8 ) compared to control
(3.2 ± 0.6) groups (p = 0.026). Input resistance did not differ between groups. The effects
of individual cytokines were also tested to determine if they mimic this effect. Superfusion
of PAR2 activating peptide (SLIGRL 100 µM; rheobase decrease, p < 0.05) and NGF (100
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ng/ml; increased action potential discharge, p < 0.05) increased excitability, IL-β (100 nM),
TNFα (1 µM), and histamine (10 µM) had no effect, while PAR4 activating peptide (AYPGKF
100 µM; decreased action potential discharge, p = 0.004) decreased excitability. Our findings
demonstrate that incubation of supernatant containing a representative repertoire of inflam-
matory cytokines in ulcerative colitis increases the intrinsic excitability of nociceptive DRG
neurons. The increase in action potential discharge may result from changes in voltage gated
Na+ and/or K+ channels. These findings may differ from those obtained with supernatants
from Crohn's disease, where the repertoire of inflammatory mediators differs.
T2018
Stimulation of Vagal Afferent a Fibers Reduces Visceral Pain: Mediation By
Activation of Periaqueductal Gray-Descending Pain Inhibitory Pathway
Shengliang Chen, Xiaoyin Wu, Zhijun Cao, Chung Owyang, Ying Li
The contribution of the vagus nerve to visceral pain remains unresolved. Previous studies
reported that patients following vagotomy have lower pain thresholds, and altered vagal
function is found in patients with irritable bowel syndrome. We recently showed that low-
intensity electrical vagus nerve stimulation (EVS), which activates vagal A fibers, reduces
anterior cingulate cortex neuronal firing in response to colorectal distension (CRD) in rats.
We hypothesize that stimulation of vagal afferent A fibers reduces visceral pain, and that
this is involved activation of the periaqueductal gray (PAG)-descending pain inhibition
pathway. Visceromotor responses (VMR) to graded CRD were recorded from the abdominal
(external oblique-pelvic) muscles in conscious rats. Responses to CRD were monotonic with
increasing distending pressure and were reproducible. Chronic subdiaphragmatic vagus
nerve sections induced 470%, 106 %, 51%, and 54% increases in VMR to CRD at 20, 40,
60 and 80 mm Hg, respectively. Similarly, in the rats at a light level of anesthesia, topical
application of lidocaine to the subdiaphragmatic vagus nerve increased VMR to CRD at 60
and 80 mm Hg (34 ± 3 and 65 ± 5 contractions/5 s vs. 16 ± 2 and 38 ± 4 in control).
Electrical vagal stimulation (EVS) of A or C fibers were distinguished by calculating their
conduction velocity. EVS of A fibers (40-100 µA, 20 Hz, 0.5 ms for 30 s) reduced VMR to
CRD at 40, 60 and 80 mmHg by 41%, 52%, and 58%, respectively. In contrast, EVS of C
fibers (400-1000 µA, 1 Hz, 0.5 ms for 30 s) did not affect VMR to CRD. In separate studies,
bilateral ibotenic acid lesions of the PAG produced 6%, 12% and 16% increases in VMR
to CRD at 20, 40, and 60 mm Hg, respectively. Lesioning the PAG eliminated the reduction
of VMR evoked by EVS of A fibers. Further, to determine if EVS of A fibers modulates
spinal nociceptive transmission, electrophysiological studies were performed. Extracellular
potentials of single L6-S1 spinal neurons in response to CRD were recorded in 9 rats. A
total of 17/56 neurons with spontaneous firing 4.2 ± 0.5 imp/s were stimulated by CRD.
CRD at 60 and 80 mm Hg increased neuronal firing to 9.2 ± 2 and 13.5 ± 3 imp/s,
respectively. EVS of A fibers reduced neuronal firing to 5.4 ± 0.7, and 7 ± 1 imp/s, respectively.
Conclusion: we demonstrated that vagal afferent nerves play an important role in the
modulation of visceral pain. Stimulation of vagal afferent A fibers reduced visceral pain, and
this required activation of the PAG-descending pain-inhibitory pathways which reduced
spinal nociceptive transmission. This result suggests EVS may potentially have a role in the
treatment of chronic visceral pain.
T2019
Anticipated Acid Exposure to Distal Esophagus Does Not Activate the Cortical
Region in Healthy Subjects - An Fmri Study
Yanli Zhang, Hui You, Meiyun Ke, Xiucai Fang, Yu Zhao, Dabo Xu
Background: Studies using BOLD-fMRI technique revealed the different patterns of brain
activation in response to esophageal stimulus between the health and NERD patients. It is
unclear the anticipated esophageal acid perfusion may induce the similar response to actual
acid exposure in the brain fMRI. Aim: To investigate the brain responses to actual and
anticipated acid perfusion in distal esophageal in the healthy subjects. Methods: Five healthy
female (20-44 years) participated in the study. There were two stages in a paradigm-driven
fMRI experimental protocol. The first stage was actual acid perfusion, including two rounds,
each round contained alternating 5-min intervals of 0.1 N HCl and saline perfusion following
an initial 3-min interval of saline perfusion (both in rate of 1 ml/min). In the second
stage(anticipated stage), the subjects were told being acid perfusion, but perfusion liquid is
saline (Figure). fMRI scans were performed on a 3.0-T system (GE Signa VHi EXCITE II)
using quadrature head coil. Gradient-echo planar imaging sequences were used(TR=6000ms;
TE=40ms; FOV=240×240mm; flip angle=90°;matrix size=64×64). Data analysis was carried
out using AFNI software package. Results: All subjects tolerated the acid perfusion well.
Acid perfusion increased fMRI signal intensity without inducing heartburn. Initial fMRI
signal increase averaged 3.67±1.10min and the average maximum percent signal increase was
1.75%±0.52%. Activated cortical regions included bilateral sensory/motor, frontal/parietal
operculum, cingulate gyrus, and the insular. The anticipation of acid perfusion did not
activate cortical regions in all subjects. Conclusion: Distal esophageal acid exposure activates
extensive cortical regions in the healthy, and anticipated acid perfusion does not activate
cortical regions. This stimulation model can be introduced to investigation for brain-gut
role in the acid-related disorders.
The protocol of intraesophageal actual and anticipated acid perfusion in fMRI scanning
T2020
Inhibitory Response to Colorectal Distension Within the Ventral Posterolateral
(VPL) Nucleus of the Thalamus: Effects of Gabapentin
Amanda J. Woods, David C. Bulmer, Andrew S. Lowe, Lloyd J. Gregory, Qasim Aziz,
Steven C. Williams, Wendy J. Winchester
Background and aims: Neurons within the ventral posterolateral (VPL) nucleus of the
thalamus have been shown to respond to noxious mechanical and chemical stimulation of
the colorectum, implicating the VPL in the processing of visceral pain (Al-Chaer et al., 1996).
The aim of the present study was to further characterise changes in neuronal activity in the
VPL following colorectal distension (CRD) and to examine the effects of gabapentin.Methods:
Multi-unit neuronal activity was recorded from the VPL in male Sprague-Dawley rats (280-
330g) anesthetised with sodium pentobarbitone (bolus 60 mg/kg i.p.; followed by 10-50
mg/kg/hr i.v.) in accordance with the UK Animals (Scientific Procedures) Act 1986. Changes
in neuronal activity in response to two sets of phasic CRD were examined. Each set of CRD
consisted of four 60 second distensions at incremental pressures (20, 40, 60 and 80mmHg)
which were separated by 10 minutes. The two sets of CRD were separated by 15 minutes.
Gabapentin (10mg/kg i.v.; n=5) or vehicle (saline i.v.; n=5) was administered 10 minutes
prior to the second set of CRD. Neuronal activity was counted using a spike processor and
expressed as a rate histogram. The change in neuronal activity during CRD was expressed
as a percentage of the baseline activity for each distension. Neuronal activity during CRD
was compared to baseline values using a paired Student's t-test with statistical significance
set at p<0.05. Results: Ongoing neuronal activity in the VPL was reduced, in a stimulus
dependent manner, by CRD. In the first set of CRD, this reduction in activity was statistically
significant at 60 and 80mmHg (% reduction in baseline activity: 20mmHg = 7±5%,
40mmHg = 20±8%, 60mmHg = 27±4%, 80mmHg = 36± 8% (mean±SEM)). No statistically
significant change in ongoing activity was observed in response to a second set of CRD in
vehicle treated animals (60mmHg = 6±7%). However, in rats pre-treated with gabapentin,
the reduction of ongoing activity was still seen during a second set of phasic CRD (60mmHg =
33±3%). Conclusion: Results demonstrate a reduction of ongoing activity within the VPL
in response to CRD. This inhibitory response is not seen during a repeated second set of
phasic CRD in vehicle treated rats which may reflect sensitisation of pain signalling to CRD.
Pre-treatment with gabapentin maintains the reduction of ongoing activity during a second
set of phasic CRD, further supporting a role for this effect in pain processing. Al-Chaer, E.D.
et al. Neuroreport 7,1635-1639 (1996)
T2021
Mast Cells Mediate Colitis-Induced Allodynia to Colorectal Distension in Rats
Katsuyo Ohashi, Yasushi Sato, Mitsuhisa Kawai
Background & Aim: Irritable bowel syndrome (IBS) is characterized by abdominal pain and
altered intestinal secretion and motility, by unknown mechanisms. There is increased num-
bers of mast cells in close proximity to nerve fibers in the colonic mucosa of some patients
with IBS. Mast cell mediators may induce alterations in the excitability of primary spinal
afferent and enteric neurons, and thereby induce pain and altered secretion and motility.
The aim of this study was to assess the role of mast cells in visceral hypersensitivity of the
colon. Method: To induce colitis, 2, 4, 6-trinitrobenzene sulfonic acid (TNBS, 50 mg/kg,
in 30% ethanol) was injected into the proximal colon of Sprague-Dawley (SD) and mast
cell deficient (Ws/Ws) rats, which was exposed by laparotomy. Control groups underwent
sham surgery. On the 7th day post surgery, pain thresholds to colorectal distension (CRD)
were measured by balloon at the pressure inducing the first observed muscular contraction.
Inflammation was assessed by histological examination and tissue myeloperoxidase (MPO)
assay, andmast cells were identified by toluidiene blue staining. The Animal Ethics Committee
at Nagoya Laboratories of Pfizer Global R&D approved the studies. Results: After 7 days,
TNBS induced a similar degree of colitis in the proximal colon of SD and Ws/Ws rats
assessed by histological examination and MPO assays. However, there was no detectable
inflammation in the distal colon, the site of CRD stimulation, of SD and Ws/Ws rats. In SD
rats treated with TNBS, the CRD threshold to induce pain responses was lower than in
sham-operated control SD rats, indicative of allodynia (Sham:53 ± 2.1 vs. TNBS: 28 ± 1.3
mmHg, p<0.05 by U-test). In contrast, in Ws/Ws rats treated with TNBS, the CRD threshold
was not statistical significant difference in sham operated control Ws/Ws rats and in control
SD rats (Sham-Ws/Ws: 50 ± 2.4 vs. TNBS-Ws/Ws: 43 ± 2.4 mmHg, p>0.05). There was a
~1.5-fold increase in mast cell numbers in the distal colon of SD rats treated with TNBS
relative to control SD rats (100 ± 39 vs. 141 ± 27 /mm2). The mast cell stabilizer doxantrazole
(5 mg/kg, s.c., 2 hrs), significantly reduced the colonic allodynia evoked by CRD in the
TNBS-treated SD rats (SD-Sham/vehicle: 51 ± 2.0, SD-TNBS/vehicle: 24 ± 1.4 vs. SD-TNBS/
doxantrazole: 38 ± 2.5 mmHg, p<0.05). Conclusion: In SD rats, TNBS-induced inflammation
of the proximal colon induces influx of mast cells and allodynia to distensible stimulation
of the distal colon. A mast cell stabilizer prevents this allodynia, and allodynia is not observed
in mast cell-deficient rats. Thus, mast cells play a critical role in allodynia of the colon.
T2022
PAR2 Agonist Trypsin Sensitizes Esophageal Vagal Sensory Afferent C-Fiber's
Mechano-Excitability
Shaoyong Yu, Justina Ju, Ann Ouyang
Background: Inflammation-induced visceral hypersensitivity plays an important role in eso-
phageal nociception. The mechanism by which mediators of inflammation sensitize eso-
phageal nociceptive afferents is still unclear. We have previous shown that mast cell degranu-
lation potentiates the mechano-excitability of esophageal vagal nociceptive-like C-fibers,
using an ex vivo guinea-pig esophageal-vagal preparation. The major mediators released by
mast cell degranulation, in the guinea-pig, are histamine and tryptase. Aim: To test the
hypothesis that tryptase and/or histamine participate in potentiation of esophageal vagal C-
fiber's mechano-excitability. Methods: The esophagus and attached vagus was removed from
guinea-pigs (100-300g) and prepared for extracellular recording of action potentials in vagal
nodose afferent C-fibers. Mechanical sensitivity of esophageal vagal nodose C-fibers was
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determined by applying esophageal distension before and after 30-min perfusion with either
histamine or trypsin (similar to tryptase as PAR2 agonist). Immnuo-staining of PAR2 on
nodose ganglion was performed. Results: Perfusing the esophagus with histmine (10 μM)
either had no (n=6) or activation (peak of action potential discharges = 1.3 Hz/s, n=5) effect
on the vagal C-fibers. The excitability of these C-fibers in response to esophageal distensions
was not changed in the presence of histamine. In contrast, perfusion with PAR2 agonist,
trypsin (1-10 μM) substantively enhanced C-fiber responses to esophageal distension
(p<0.01). The peak of action potential discharges in response to distention pressure of 10,
30 and 60 mmHg averaged 5±1, 12±2 and 19±2 action potentials, respectively. This response
was increased by trypsin perfusion (14 ±3; 23±3, and 30±4 respectively, n=8, P<0.01).
Trypsin itself either had no (n=5) or weak activation (peak= 2-3 Hz/s, n=3) effect on vagal
C-fibers. Immuno-staining identified PAR2 in the nodose ganglion and mostly on small-
diameter neurons. Conclusion: The PAR2 agonist trypsin increases the excitability of vagal
afferent C-fibers to mechanical distention of the esophagus, indicating that the potentiation
effect of mast cell degranulation on vagal C-fiber's mechano-excitability is mediated by
tryptase via PAR2 pathway. (this study is supported by a grant from AstraZeneca)
T2023
The Effect of 5-HT1A Ligands 8-OH DPAT, WAY100635 and Buspirone On
Visceral Pain Behaviours Elicited By Intra Rectal Mustard Oil in the
Conscious Rat
David Bulmer, Karen Gray, Alan Wheeldon, Kevin Lee, Wendy J. Winchester
Administration of 5-HT1A agonists has been shown to be analgesic in models of noxious
gastric and colorectal distension (Rouzade et al 1998, Sivarao et al 2004). The aim of the
present study was to examine the potential analgesic action of 5-HT1A ligands in a model
of noxious chemical stimulation of the colorectum. Male Sprague Dawley rats (130g - 160g)
were briefly sedated with 50% oxygen / 50% carbon dioxide and 0.2ml of 3% mustard oil
injected 1.5cm from the anus, and animals placed in observational cages to which they had
previously been acclimatised for 45 minutes prior to mustard oil injection. The number of
visceral pain related behaviours were counted for 25 minutes following which the animals
were culled by cervical dislocation. In the first study buspirone (10 mg/kg s.c., n=10) and
8-OH DPAT (1.0 mg/kg s.c., n=10) were compared to vehicle treated animals (saline s.c.,
n=10). All injections were made 30 min prior to injection of mustard oil. In the second
study 8-OH DPAT was tested at 0.1, 0.3 and 1.0 mg/kg s.c. (n=10 per group) and the
effects of the 5-HT1A antagonist WAY100635 (3 mg/kg s.c., n=10) examined alone and in
combination with 8-OH DPAT (1.0 mg/kg s.c., n=10). All compounds were dissolved in
saline. 8-OH DPAT was injected 30 min and WAY100635 40 min prior to mustard oil.
Vehicle treated animals (n=10) received two injections of saline at 30 and 40 minutes.
Results are expressed as mean ± sem and were statistically compared to vehicle treated
animals using a one way ANOVA with Dunnett's comparison p<0.05. Both buspirone 10
mg/kg (16.3 ± 3.3 behaviours) and 8-OH DPAT 1.0 mg/kg (7.6 ± 2.3 behaviours) produced
a significant reduction in pain behaviour compared to vehicle treated animals (25.3 ± 3.3
behaviours). The effect of 8 OH-DPAT was dose related (20.2 ± 3.4 behaviours at 0.1 mg/
kg, 19.7 ± 3.0 behaviours at 0.3 mg/kg and 5.5 ± 1.1 behaviours at 1.0 mg/kg vs 27.5 ±
3.1 behaviours in vehicle treated animals). Pre-treatment with WAY100635 alone also
produced a significant reduction in pain behaviours (15.6 ± 2.9 behaviours). While combined
administration of WAY100635 and 8-OH DPAT significantly attenuated the effects of 8-OH
DPAT, producing a reduction in behaviours similar to WAY100635 given alone (12.6 ± 3.0
behaviours). The results of this study demonstrate that 5-HT1A ligands significantly attenuate
pain behaviour in response to intra rectal mustard oil. Both the 5-HT1A antagonist and
agonists display visceral analgesic activity indicating a complexmechanism of action. Rouzade
M-L et al Digestive Diseases and Sciences. 43(9) 2048-2054 (1998). Sivarao D.V. et al
European Journal of Pharmacology. 494 23-29 (2004).
T2024
Atrial Natriuretic Peptide (ANP) Regulates Gastric Endocrine and Exocrine
Secretion
Wei Hou, William R. Gower, James N. Casey, Robert Flynn, Carol Landon, Shyamal
Premaratne, John Dietz, Robert W. Mccuen, Ari Hirsch, Mitchell L. Schubert
RATIONALE. In fundus of rat stomach, we have localized ANP to enterochromaffin cells
and detected its receptor, NPR-A, within the mucosa. AIM. The aim of the present study
was to determine the physiologic role and mechanism of action of ANP in the regulation
of endocrine (i.e., somatostatin and histamine) and exocrine (i.e., acid) secretion in the
fundus of the stomach. METHODS. Rat fundic segments were superfused with Krebs buffer
and the superfusate collected at 5-min intervals for measurement of somatostatin and histam-
ine by radioimmunoassay. Isolated stomachs from wild-type and somatostatin subtype 2
receptor knockout (sstr2 ko) mice were luminally perfused with saline and the perfusate
collected at 5-min intervals for measurement of acid by titration. Rat parietal cells were
isolated by counterflow elutriation and density gradient centrifugation then cultured to
99% purity. Acid secretion in isolated parietal cells was measured by [14C]aminopyrine
accumulation and NPR-A expression identified by immunoblot and RT-PCR. RESULTS. In
superfused rat fundic segments, ANP (0.1 pM to 0.1 μM) caused a concentration-dependent
increase in somatostatin secretion (EC50, 0.1 nM; maximal, 72±14% above basal level at
0.1 μM; P<0.005) and reciprocal decrease in histamine secretion (EC50, 26 pM; maximal,
60±3% below basal level at 0.1 μM; P<0.001). In isolated stomachs of wild-type mice, ANP
(0.1 pM to 1 μM) caused a concentration-dependent increase in acid secretion (EC50, 0.5
nM; maximal, 27±2% above basal level at 1 μM; P<0.001); in isolated stomachs of sstr2 ko
mice, the acid responses to ANP were augmented >2-fold to 63±8% above basal level at 1
μM (P<0.01 for the difference). The results imply that ANP exerts dual inhibitory and
stimulatory effects on acid secretion; The inhibitory effect is mediated by changes in somatos-
tatin secretion whereas the stimulatory effect is mediated perhaps by a direct effect of ANP
on parietal cells. In support of the latter, in isolated rat parietal cells: (i) we detected the
expression of the NPR-A receptor and (ii) ANP (1 nM to 10 μM) caused a concentration-
dependent increase in acid secretion (EC50, 400 nM; maximal, 38±3% above basal level at
10 μM; P<0.001). CONCLUSION. ANP, released from enterochromaffin cells within the
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oxyntic mucosa, regulates gastric acid secretion. The dominant effect is stimulatory and
mediated via NPR-A receptors on parietal cells. A concurrent inhibitory effect is mediated
via stimulation of somatostatin and inhibition of histamine secretion.
T2025
Involvement of Prostaglandin E Receptor Ep3 Subtype and Prostacyclin IP
Receptor in Decreased Acid Secretion in Mouse Stomach After Damage
Hikaru Nishio, Yuuki Matsusaka, Eitaro Aihara, Koji Takeuchi
Background/Aims: The application ofmild irritants to the stomach causes luminal alkalization,
mainly by inhibiting acid secretion. We have previously reported that the decreased acid
response after mucosal exposure to taurocholate Na (TC) is mediated by endogenous prosta-
glandins (PGs) produced by COX-1. However, it remains unknown which type(s) of PG
receptors is involved in this phenomenon. In the present study, we investigated the role for
PGE receptor EP1 and EP3 subtypes or prostacyclin IP receptor in the decreased acid
response in the stomach after exposure to TC, using knockout (-/-) mice lacking these
receptors. Methods: Male C57/BL6 mice, including wild-type (WT), EP1 (-/-), EP3 (-/-) and
IP (-/-), were used after 18 h fasting. Under urethane anesthesia, the stomach was mounted
on an ex-vivo chamber, perfused with saline, and the acid secretion (luminal pH) as well
as transmucosal potential difference (PD) was measured before and after exposure to 20
mM TC for 20 min. Mucosal PGE2 content was measured by EIA. Indomethacin (2 mg/
kg), SC-560 (selective COX-1 inhibitor: 5 mg/kg), rofecoxib (selective COX-2 inhibitor: 5
mg/kg) or AE5-599 (EP3 antagonist: 10 mg/kg) was given intraduodenally 30 min before
TC. Results: Mucosal exposure to TC in WT mice caused a marked PD reduction of the
stomach, and this PD response was similarly observed in the animals lacking either EP1,
EP3 or IP receptors. In WT mice, indomethacin did not affect by itself both PD and luminal
pH (basal acid secretion) but significantly attenuated the decrease in acid secretion (the
increase of luminal pH) seen after the exposure to TC. This effect of indomethacin was
mimicked by SC-560 but not rofecoxib, yet neither of these drugs had any effect on the
reduced PD response. The decreased acid response following TC treatment was similarly
observed in EP1 (-/-) mice but apparently mitigated in mice lacking either EP3 or IP receptors,
although the reduction of PD was observed in all groups. Furthermore, the decrease acid
response to TC was significantly attenuated by prior administration of the EP3 antagonist
AE5-599 but not the EP1 antagonist ONO-8711. Mucosal levels of PGE2 and 6-keto
PGF1αsignificantly increased in the stomach after exposure to TC in all groups of mice.
Sulprostone (EP1/EP3 agonist: 1 mg/kg) given IV significantly decreased the histamine-
stimulated acid secretion, and this effect was completely blocked by AE5-599. Conclusions:
These results suggest that the reduced acid response in the stomach after damage is mediated
by endogenous PGs derived from COX-1 through the activation of both PGE2/EP3 receptors
and prostacyclin/IP receptors.
T2026
The Effect of Gastrin Antagonists, Somatostatin Analogues and Dopamine
Receptor Agonists On Gastric Enterochromaffin-Like Cell Proliferation and
Histamine Secretion
Mark Kidd, James Black, Malcolm Boyce, Michael Culler, Irvin M. Modlin
Introduction: Gastrin regulates ECL cell function via histamine release and thereby is a
critical determinant of acid secretion. Acid suppression results in hypergastrinemia which
engenders cell proliferation that is ECL targeted and may also involve gene activation
associated with the development of Barrett's esophagus. ECL cell function and gastrin release
is inhibited by somatostatin but little is known about the role of dopamine agonists in this
process. The modulation of acid secretion by ECL cell regulation as opposed to direct parietal
cell targeting is worth evaluation. Since the ECL cell exhibits all 3 classes of receptor we
sought to evaluate the effects of the gastrin receptor antagonist, (YF476), lanreotide (SST
agonist) and novel dopamine agents (BIM53061 and BIM27A760) on ECL cell histamine
secretion and proliferation using pure ECL cell preparations. Methods: >98% pure ECL cells
were prepared from rat gastric mucosa using a FACS approach. Real-time PCR confirmed
presence of gastrin, somatostatin and dopamine receptors and the effects of YF476, L365,260,
lanreotide, dopamine antagonists were evaluated on basal and gastrin-stimulated histamine
release (ELISA assay) and proliferation (MTT uptake) in short-term (24 hr) cultured cells.
Results: ECL cells expressed CCK2, SS2 and SS5 and D1 receptor. YF476 inhibited histamine
secretion and proliferation with IC50 = 1.25nM and 1.3x10-12M respectively, values 10-
1000x more potent than L365,260. Lanreotide inhibited secretion and proliferation (2.2nM,
1.9x10-10M) and augmented YF476-mediated proliferation 2-fold. The dopamine agonist,
BIM53061, inhibited ECL cell function (17nM, 6x10-10M) as did the novel dopamine/
somatostatin chimera BIM23A760 (22nM, 4.9x10-10M). Conclusion: These studies demon-
strated that the gastrin receptor antagonist, YF476, is the most potent inhibitor of ECL cell
histamine secretion and proliferation. Lanreotide, a dopamine agonist and a dopamine/
somatostatin chimera inhibited ECL cell function but were 10-1000x less potent than YF476.
Agents that effectively target the gastrin receptor may provide alternative regulatory control
mechanisms for gastrin-mediated gastrointestinal cell proliferation. Since hypergastrinemia
is a potential activating event in mucosal proliferation (Barrett's) the use of gastrin antagonists
as therapeutic agents has considerable clinical relevance.
T2027
Importance of Muscarinic Acetylcholine Receptor Subtype 4 in Carbachol-
Induced Pepsinogen Secretion in Mice
Takuya Endo, Nobuaki Takahashi, Kikuko Amagase, Takeshi Aihara, Minoru Matsui,
Susumu Okabe, Koji Takeuchi
Background/Aims: Muscarinic acetylcholine receptors (mAChRs) consist of five subtypes
(M1~M5) and are widely expressed to mediate diverse autonomic functions in many peri-
pheral organs, including the gastrointestinal tract. It is considered that both M1- and M3-
receptors play an important role in the regulation of gastric pepsin secretion in response to
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acetylcholine. However, this idea is mainly derived from the data obtained by use of selective
antagonist or those on their expressions in the stomach, and the precise role remains unclear.
Especially, the data on pepsin secretion have mainly been obtained in-vitro but not in-vivo
studies. In the present study, we investigated the roles of mAChRs subtypes in the cholinergic
regulation of pepsin secretion using muscarinic receptor knockout (KO) mice such as lacking
M1~M5 receptors and demonstrated the importance of M4-receptor in the response to
carbachol. Methods: C57BL/6J mice (12-20 wks old) of wild-type (WT) and M1-, M2-, M3-
, M4- or M5-knockout (KO) were used. Under urethane anesthesia, the abdomen was
incised, the cardiac portion was ligated, and an acute fistula prepared with a polyethylene
tube was provided in the stomach through a pylorus. Then, the stomach was instilled with
saline (0.4 ml) through the fistula, and the solution was changed every 20 min. Carbachol
(30 μg/kg) was given SC as a single injection. Atropine (0.3 mg/kg) or pirenzepine (3 mg/
kg) was given SC 20 min before the administration of carbachol. Results: Carbachol caused
an increase of pepsinogen secretion in WT mice, and the effect was completely inhibited
by prior administration of atropine. This response to carbachol was similarly observed in
the animals lacking M1-, M2- or M5-receptors. However, the secretion of pepsinogen in
response to carbarchol significantly decreased in the animals lacking M3- or M4-receptors
as compared with WT mice, and especially, the response was all but completely abolished
in M4-KOmice. Pirenzepine also significantly reduced the carbacol-induced pepsin secretion
and this effect was observed in M1-KO animals but disappeared in M3-KOmice. Conclusion:
These results suggest that under cholinergic stimulation the secretion of pepsinogen is
mediated mainly by the activation of M4-receptors and partly through M3-receptors but
does not involve other muscarinic receptor subtypes including M1-, M2- and M5-receptors.
The anti-pepsigogic action of pirenzepinemay be attributable to the blockade ofM3-receptors.
T2028
A Novel Method for Studying Intra-Gastric pH Over Prolonged Periods of
Time in Freely Moving Rats
Tobias Rudholm, Colin A. Campbell, Peter G. Mclean, Per M. Hellstrom, Erik Naslund
Background: We have previously reported on measuring rat intra-gastric pH with the Bravo
Capsule system over short-term periods. The aim of the present study was to assess the use
of the Bravo system to study the effect of using 24 hour infusions of pentagastrin and/or
proton pump inhibitors on intra-gastric pH to assess potential utility of this model in
evaluating nocturnal acid breakthrough, tolerance and rebound. Method: In male Sprague-
Dawley rats (350g), a calibrated Bravo Capsule was placed inside the stomach with the pH
sensor pointing distally and anchored with a suture in the mucosa of the stomach. An
intravenous catheter was placed in the jugular vein and connected to a swivel and harness
system. Studies commenced 2 days after surgery. The intra-gastric pH profile was studied
during free feeding of standard chow for 5 consecutive days. The effects of an infusion for
24 hours were studied with saline, esomeprazole (3 mg/kg/h), or pentagastrin (8μg/kg/h)
(n=4-6). In addition a 12-hour nightly infusion of pentagastrin, and a 24-hour infusion with
both esomeprazole and pentagastrin employing the same doses were studied. Results: All
rats rapidly recovered after surgery and placement of the Bravo capsule, gained weight and
were not under duress by the swivel and harness system The average 24-hour pH with
infusion of saline during free feeding was 2.1 ±0.2. After treatment with esomeprazole the
average 24-hour pH was 5.7 ±0.3. Nightly pentagastrin slightly decreased the intra-gastric
pH (2.0 ±0.4). Adding pentagastrin to the 24 hour esomeprazole infusion at the used dose
did not significantly alter the intra-gastric pH compared to esomeprazole alone (6.3 ±0.4).
Conclusion: This study demonstrates the feasibility of using the Bravo Capsule system with
a swivel and harness for long-term intravenous administration of various compounds studying
intra gastric pH. The attenuated variations in pH as seen after administration of a proton
pump inhibitor indicate that true biological responses were recorded. The animals are free
roaming and not subjected to stress as they would using traditional methods such as gastric
fistula models to study acid secretion and represent the first animal system that may be
used to model the phenomenon of nocturnal acid breakthrough, tolerance and rebound.
T2029
Discrepancy of Decreased Food Intake and Increased Eating Frequency in Rats
Subjected to Total Gastrectomy
Marianne W. Furnes, Björn Stenström, Karin Tømmerås, Trine Skoglund, Loraine Tung,
Suzanne L. Dickson, Chun-mei Zhao, Duan Chen
Background and aim: Total gastrectomy (Gx) surgery reduces body weight and food intake.
Gastric hormones, including ghrelin and obestatin, have been thought to play important
roles in regulation of appetite; stimulated by ghrelin and suppressed by obestatin. Our aim
was to study the mechanism underlying the reduced body weight and food intake after Gx.
Methods: Adult male Sprague-Dawley rats were subjected to Gx or sham-operation. The
body weight and body composition were measured manually and by dual energy X-ray
absorptiometry. The food intake and appetite were assessed by Comprehensive Laboratory
Animal Monitoring System (automatically recording). Results: Serum concentrations of ghre-
lin, obestatin, leptin, and gastrin, measured by radioimmunoassay, were markedly reduced
following Gx (p<0.001 vs. before surgery or sham-operated controls). Gx rats had about
20-30% body weight reduction (p<0.01 vs. sham-operated rats) at 6-8 weeks after surgery.
Total fat pad weight, including gonadal and retroperitoneal but not inguinal and mesenteric
pads, was reduced by Gx (p<0.01). The total bone mineral content and density were reduced
(p<0.01) already 6 weeks after Gx. This surgery reduced the food intake in terms of grams
of food/24 hr/rat (19.55 ± 1.16 vs. 24.40 ± 0.64, p< 0.01) and grams of food/meal/rat (0.55
± 0.07 vs.0.91 ± 0.12, p<0.05), while eating frequency was increased in Gx rats compared
with sham-operated rats (38 ± 4 vs. 30 ± 3 meals/24 hr/rat, p<0.01). In addition, Gx did
not affect drinking (both frequency and amount), urine production, energy expenditure,
energy content in faeces (measured by adiabatic bomb calorimeter), and ambulatory activity.
Conclusions: Gx reduced the body weight, food intake, and circulating ghrelin, obestatin
and leptin levels. Increased meal frequency following Gx could be indicative of increased
appetite that is secondary to the reduced food intake that results from removal of the whole
stomach. Indeed, increased appetite after Gx may explain the paradoxical increased mRNA
expression of the orexigenic peptides neuropeptide Y and agouti-related peptide in the rat
hypothalamus that occurs despite the reduction in circulating ghrelin levels. We may suggest
that the Gx rats have a disorder of their appetite regulation system and that this disorder
is an important factor in the aetiology of malnutrition after this surgery.
T2030
Changes of Uncoupling Protein 2 in Mouse Gastrointestinal Tract: Different
Expression Correlate with Different Function of Gastrointestinal Tract?
Hong-jie Zhang
AIM: To assess the distribution of UCP2 in gastrointestinal tract and its potential physiological
functions. METHODS: C57BL/6 mice (body weight 30g) were maintained with a regular
light-dark cycle. Total cellular RNA was extracted using TRIzol reagent (GIBCO-BRL), We
assessed the expression of UCP2 mRNA in the fundus and antrum parts of the mouse
stomach, small intestine, proximal and distal colon from the samples of C57BL/6J mice by
quantitative real-time RT-PCR and assessed the expression of UCP2 protein by western blot.
We also investigated the relationship between the changes of UCP2 and the amounts of
mitochondrion by western blot. RESULTS: UCP2 mRNA level is higher in the fundus part,
compared to pyloric antrum(P<0.05). UCP2 mRNA level both in the small intestine and in
the proximal colon were higher than that in the distal colon(P<0.01)There was a strong
linear correlation between UCP2 mRNA and protein expression, suggesting that increased
UCP2 expression in gastrointestinal tract is largely determined at the transcriptional level.
Immunohistochemistry staining indicated that the brown positive UCP2 granules were mainly
expressed in the cytoplasm of mucosal epithelial cells. Furthermore, to investigate the
relationship between the different expression of UCP2 and the amounts of mitochondrion,
we analyzed the expression of cytochrome C in the fundus part, pyloric antrum., small
intestine , proximal and distal colon from the samples .The results showed that the expressions
of cytochrome C in the fundus part, pyloric antrum, small intestine, proximal and distal
colon were not significantly different(P=0.234) . These suggest that the different expression
of UCP2 in different part of gastrointestinal tract is not related to the amounts of mitochon-
drion. After administration of glucose, UCP2 mRNA levels in the small intestine samples
was increased, whereas, UCP2 mRNA levels in fundus of stomach, proximal colon and distal
colon were decreased(P<0.01, P<0.001.) CONCLUSIONS: UCP2 were mainly expressed in
the cytoplasm of mucosal epithelial cells. The expression of UCP2 in gastrointestinal tract
may be related to the function of absorption and secretion of mucosal epithelial cells .
T2031
Acid-Suppressive Effects of OMEPRAZOLE in Helicobacter pylori-Negative
Cyp2c19 Homozygous Extensive Metabolizers: Which Regimen Has the
Strongest Effect?
Tomohiko Shimatani, Tomoko Kuroiwa, Mutsuko Moriwaki, Jing Xu, Susumu Tazuma,
Masuo Nakamura, Masaki Inoue
Background: Insufficient gastric acid suppression is one of the main causes of refractory
gastroesophageal reflux disease and the failure of eradication therapy for Helicobacter pylori
(H. pylori).Aims: To compare the acid-suppressive effects of different regimens of omeprazole.
In particular, focusing on the effectiveness of divided doses. Methods: In seven Japanese
healthy H. pylori-negative CYP2C19 homozygous extensive metabolizers, omeprazole was
administered for seven days in five regimens utilizing a crossover method; 10 mg, 20 mg
and 40 mg once daily (od), and 10 mg and 20 mg twice daily (bid). Intragastric pH was
measured six times for periods of 24-h during the administration of a placebo and the five
omeprazole regimens. Results: The values of median intragastric pH and % time pH > 4.0
for 24-h increased dose-dependently with omeprazole 10 mg od [median 2.0 (range 1.7-
2.7)* and 20% (9%-30%)*], 20 mg od [3.6 (2.4-5.2)*,# and 46% (27%-66%)*,#], and 40
mg od [5.1 (3.9-6.0)*,#,† and 62% (47%-87%)*,#,†], compared with the placebo-controlled
data [1.6 (1.4-1.8) and 10% (6%-21%)] (*P < 0.05 vs. the placebo, #P < 0.05 vs. omeprazole
10 mg od, and †P < 0.05 vs. omeprazole 20 mg od). Omeprazole 10 mg bid [3.6 (2.2-5.4)
and 46% (29%-70%)] and 20 mg bid [5.5 (3.8-6.1) and 88% (47%-98%)] were comparable
to 20 mg od and 40 mg od, respectively. However, significant differences were observed in
these two values between 10 mg bid and 20 mg bid (P < 0.05). Concerning % time pH >
4.0 during the nighttime period (20:00 h-8:00 h), omeprazole 20 mg bid [84% (46%-96%)]
was significantly superior to 40 mg od [51% (22%-84%)], as well as 10 mg bid [36% (5%-
71%)] (P < 0.05). In four of the five regimens, all seven subjects had nocturnal gastric acid
breakthrough, defined as intragastric pH < 4.0 lasting for more than 60 min during the
mid-nighttime period (22:00 h-6:00 h), whilst, with omeprazole 20 mg bid this occurred
in only three. The longest time of continuous intragastric pH < 4.0 during the mid-nighttime
period was significantly shorter during omeprazole 20 mg bid [43min (2min-208min)] than
with the placebo [377min (201min-480min)], 10 mg od [311min (234min-480min)], 20
mg od [312min (123min-341min)], and 40 mg od [238min (68min-328min)] (P < 0.05).
Conclusions: In Japanese H. pylori-negative CYP2C19 homozygous extensive metabolizers,
omeprazole 20 mg bid has the strongest acid-suppressive effect, especially considering its
superior nighttime acid-suppression: Omeprazole 20 mg bid is superior to 40 mg od.
However, omeprazole 10 mg bid is not superior to 20 mg od. Thus demonstrating that
divided doses of omeprazole are not always more effective.
T2032
The Significance of Soluble Triggering Receptor Expressed On Myeloid Cells
(Strem-1) in the Pathogenesis of Peptic Ulcer Disease
Vassilios Koussoulas, Spyridon Vassiliou, Thomas Tsaganos, Georgios Tassias, Charis
Pilichos, Charalambos Barbatzas, Helen Giamarellou, Evangelos J. Giamarellos-bourboulis
Introduction The present study targeted to investigate the pathophysiological role of sTREM-
1 in peptic ulcer disease. Patients and Methods Seventy two patients were enrolled; 56 with
peptic ulcer disease and 16 with chronic gastritis. Patients were endoscoped and gastric
juice was aspirated. Patients with peptic ulcer underwent a second endoscopy post-treatment.
Biopsies samples were incubated in the absence/presence of endotoxins or gastric jiuce.
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Supernatants were collected and sTREM-1 and TNFα were measured by enzyme immunoab-
sorbent assays. Scoring of gastritis was performed before and after treatment according to
Sydney. Results Patients with peptic ulcer disease and those with chronic gastritis had similar
scores of gastritis. sTREM-1 was found increased in supernatants of cultures of biopsies
taken from patients with peptic ulcer before treatment compared to cultures of biopsies
taken either from the same patients post-treatment or from patients with chronic gastritis
(P: 0.001). Similar differences for sTREM-1 were recorded among LPS-triggered tissue
samples of patients (P: 0.001). Similar differences were not found for TNFα. Positive
correlations were found between sTREM-1 of supernatants of biopsies taken from patients
with peptic ulcer before treatment and the degree of infiltration by neutrophils andmonocytes.
Similar correlations were not observed with supernatants of biopsies taken from patients
with chronic gastritis. Discussion sTREM-1 secreted by the gastric mucosa is an independent
mechanism connected to the pathogenesis of peptic ulcer. Only mucosa of patients with
peptic ulcer was potent for its secretion whereas the same mucosa lost its potential for
secretion of sTREM-1 upon treatment.
T2033
Influence of Cytochrome P450 2c19 Polymorphisms On Intragastric Acidity
During Treatment with High-Dose Esomeprazole and Pantoprazole
Christian Kirsch, Eberhard Kuhlisch, Franziska Lindner, Dana Grossmann, Andrea
Morgner, Ahmed Madisch, Joachim Labenz, Stephan Miehlke
Background: Genotype-dependent differences in cytochrome P450-2C19 affect the metabol-
ism of proton pump inhibitors (PPI). Patients with severe or complicated reflux disease may
require higher than standard doses of a PPI for sufficient acid suppression. Aim: To investigate
the influence of CYP2C19 polymorphisms on intragastric acidity during treatment with
high-dose esomeprazole and pantoprazole. Methods: In a randomized, single-blinded, two-
way crossover study, 30 healthy subjects received esomeprazole 40 mg bid or pantoprazole
40 mg bid orally for five consecutive days. Continuous ambulatory 24-hour intragastric pH
was recorded on day 5 of each treatment (Miehlke et al, AP&T 2005). CYP2C19 polymorph-
isms were determined by PCR-RFLP from whole blood and included in a post-hoc analysis
of the pH data. Results: Twenty-one subjects (70%) were homozygous extensive metabolizers
(homEM), 8 (26,7%) were heterozygous extensive metabolizers (hetEM), and 1 subject
(3,3%) was poor metabolizer (PM). The percentage of time with intragastric ph>4 was lower
in homEMs compared to hetEM/PM (p=0.048) during both esomeprazole (87.6% vs. 94.8%)
and pantoprazole (67.6% vs. 78.5) therapy. Esomeprazole provided significantly higher
intragastric pH-values over the 24-h-period both in homEMs and hetEMs/PM compared to
pantoprazole (median intragastric ph 6.2 vs 5.0, p<0.001, and 6.8 vs. 5.4, p=0.002, respect-
ively). In homEMs, an intragastric pH>4 for more than 16 h was achieved in 20 subjects
(95,2%) during esomeprazole therapy and in 11 subjects (52,4%) during pantoprazole
therapy (p=0.012). Conclusions: Esomeprazole 40 mg twice daily provides better intragastric
acid control than pantoprazole 40 mg twice daily irrespective of the CYP2C19 genotype.
T2034
Safety and Response of Esophageal Dilation in Adults with Eosinophilic
Esophagitis (EE): A Single Center Experience of 81 Patients
Nirmala Gonsalves, Kunal Karmali, Ikuo Hirano
Background: Dysphagia and food impaction are common in adults with EE. In addition to
endoscopic features of mucosal rings and furrows, approximately 30% of patients (pts) have
strictures. Dilation of these strictures is considered to have an increased risk of esophageal
perforation. Aims:We reviewed our center's experience in adults with EEwho have undergone
esophageal dilations to assess for complications and duration of response to dilation. Methods:
Charts from 173 adults diagnosed with EE from 2001 to October 2006 were reviewed. EE
was diagnosed based on ≥20 eosinophils per high power field. Common presenting symp-
toms were dysphagia (90%), food impaction (62%), and heartburn. Of 173 pts, 81 had a
total of 152 dilations, 97 at our institution and 55 at other hospitals. Mean dilations per pt
was 1.9 (range 1-8). 50% of pts undergoing dilation required repeated sessions. Methods
of dilation included 40 Savary (range 27-57F) and 69 balloon dilations (range 10-22mm).
61% of dilations were performed before 2004. Of dilations prior to 2004, only 34% were
also treated with medication (acid suppression ± fluticasone) vs. 88% of those done after
2004. (Fig) Complications included odynophagia and chest pain in 1 pt each. No perforations
occurred at our hospital, but 1 pt did have prior history of perforation after dilation.
Median response to dilation was 18 months (range 0-56). Conclusions: 1) Complications
of esophageal dilation in adults with EE are uncommon. 2) 50% of pts undergoing dilation
therapy required repeated dilation. 3) Despite the rise in EE cases over the past several years,
the number of dilations performed decreased suggesting that medical therapy is effective.
T2035
Structural Changes in Esophageal Wall Detected By Endosonography in Adult
Patients with Eosinophilic Esophagitis
Lukas Degen, Susanne Portmann, Christoph Beglinger, Alex Straumann
Background: Eosinophilic esophagitis (EE) is an increasingly recognized, chronic inflammat-
ory disorder of the esophagus characterized by a dense (>24/high-power field) eosinophilic
infiltration of the esophageal epithelium. EE is restricted to the esophagus, leads to persistent
dysphagia and structural esophageal alterations but does not impact the nutritional state
(Straumann et al. Gastroenterology. 2003 Dec;125(6):1660-9). Endosonography (EUS) stud-
ies in children demonstrate a thickening of mucosal, submucosal and muscularis propria
layers. Adult patients with EE have not been thoroughly investigated by EUS. The aim of
the present study was therefore to characterize the esophageal wall of patients with EE at
3 different levels by EUS and compare them with a control group. Methods: 11 patients
with histological proven EE but without treatment and 11 patients with normal esophagus
were investigated. After a conventional endoscopy, high resolution EUS was performed using
Olympus GF-UM 160. Corresponding anatomic layers were assigned to the sonographic
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images using accepted standards. Measurements were taken from the thickest representative
portion of the wall. Results: (view table) Due to stenosis in the middle part of the esophagus
only in 6/11 EE-patients a complete endosonographic examination was possible (EUS endos-
cop: distal end diameter 12.7mm). All patients could be investigated in the proximal part
of the esophagus. 1. EE patients had increased values for thickness of the total wall, submucosa
and muscularis propria (p=0.03-0.005). 2. EE patients had increased values for thickness
of mucosa, but the difference was not significant compared with controls. Summary: EUS
reveals a significant thickening of the esophageal wall and of individual tissue layers in
patients' with EE. The changes induce fixed organic stenosis not appreciated by the clinical
symptoms or by conventional endoscopy.Conclusion: EE leads to relevant structural changes
of esophageal wall which are most apparent in the submucosa and muscularis. Whether
these changes are transient or permanent needs to be investigated in patients under treatment.
Layer thickness of the esophageal wall (mm)
Mean±SEM; *p=0.008, **p=0.005, ***p=0.029
T2036
Thymic Stromal Lymphopoietin Expression in Reflux and Eosinophilic
Esophagitis
James D. Lord, Melissa Upton, Steven F. Ziegler, Michael Gluck
Eosinophilic esophagitis and reflux esophagitis have both been associated with eosinophils
infiltrating the squamous esophageal epithelium. However, the molecular mechanisms gov-
erning these eosinophilic infiltrates remain unclear. Thymic stromal lymphopoietin (TSLP)
is a cytokine capable of promoting CD4+ T cell differentiation into a Th2 phenotype through
its actions on dendritic cells. Consequently, elevated epithelial TSLP expression has been
described in atopic conditions such as asthma and atopic dermatitis, where local eosinophilia
is also encountered. We therefore hypothesized that elevated TSLP expression may also be
associated with eosinophilic esophagitis, given the latter's association with atopic conditions,
allergies, eosinophilia and elevated serum IgE levels. To this end, we developed an assay to
detect TSLP by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue.
Archived biopsies from patients with eosinophilic versus reflux esophagitis were then stained
for TSLP by IHC. Patchy expression of TSLP was identified in squamous epithelial cells in
the esophagus and in mononuclear subepithelial cells in the gastric lamina propria. Surpris-
ingly, while elevated TSLP expression was seen in a subset of reflux esophagitis cases, it
was not evident in eosinophilic esophagitis. Ongoing analyses will clarify whether the extent
of TSLP expression evident in reflux esophagitis correlates with inflammation, eosinophilia,
Barrett's metaplasia, or other clinical parameters. Thus, while TSLP may contribute to
eosinophilic inflammation in reflux esophagitis, as it appears to in asthma and atopic
dermatitis, our data suggests that eosinophilic esophagitis is promoted by an alternative
mechanism, not requiring robust TSLP expression. To our knowledge, this is the first
description of a human eosinophilic inflammatory condition in which TSLP expression is
not increased.
T2037
Short-Term and Long-Term Clinical Response to Corticosteroids in Children
with Eosinophilic Esophagitis (EE): Do These Vary By Food Allergy (FA)
Testing Results?
Elizabeth Schaefer, Sandeep K. Gupta
INTRODUCTION: EE is increasingly recognized in children and adults. Clinical risk factors
and outcome data guiding pediatric EE therapy are limited. Extra-esophageal allergic disease
has been associated in EE patients. It is not known if absence/presence of FA predicts initial
response to corticosteroid therapy or risk for recurrence when weaned off corticosteroids.
AIM: To determine if positive FA testing is associated with short-term and long-term clinical
response to systemic or topical corticosteroid therapy. METHODS: FA testing to several
foods was performed routinely in 80 children with EE. Patients were randomized to receive
prednisone (P) (1mg/kg/dose bid; maximum 30mg bid) or swallowed fluticasone (F)
(110mcg/puff for age <11 yrs and 220mcg/puff for age >11 yrs; 2 puffs qid) for 4 weeks
(wks), followed by an 8 wk weaning protocol. Clinical assessments were performed at Wks
0, after full dose therapy at Wk 4, and off medications at Wks 12, 18, and 24. RESULTS:
80 patients with EE were enrolled: 40 in P arm (31 males; mean age 7.0 yrs; range 1.1-
15.8 yrs) and 40 in F arm (28 males; mean age 7.2 yrs; range 1.1-16.1 yrs). FA testing was
positive in 58% of patients. 35% of children had elevated serum IgE levels and 44% had
a personal history of atopy. 32P and 36F patients completed Wk 4 at which time all P and
35/36F children were free of presenting symptom(s). The single F patient with persistent
symptoms at Wk 4 had positive FA testing. By Wk 24, 12P and 11F patients had symptom
recurrence; of these, positive FA testing was found in 9/12 (75%) P and 5/11 (45.5%) F
patients. The positive and negative predictive values for symptom recurrence in presence
of FA in the P arm were 52.9% and 70% respectively, and in the F arm were 38.5%
and 45.5% respectively. CONCLUSION: In this large prospective, randomized study of
corticosteroid therapy in children with EE, short-term clinical response did not depend on
FA presence/absence, as nearly all patients had clinical response after full dose therapy (Wk
4). Similarly, symptom recurrence was not dependent on presence/absence of FA during
follow up off therapy. Additional longitudinal studies to identify factors predicting response
to EE therapy are urgently needed.
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T2038
Natural History of Eosinophilic Esophagitis in Children: A 12 Year Follow Up
Study
Jeffery D. Lewis, Aminu Mohammed, Rafael Kozielski, Robert Yost, Benjamin D. Gold
Background: No studies of the long term natural history of untreated children with eosino-
philic esophagitis (EE) have been published. Prior to 1996 this disorder was not recognized
as a distinct entity at our institution. An understanding of the true natural history of the
disease is critical to forming treatment and surveillance strategies. Aims: 1)To identify and
prospectively follow up untreated children with EE; 2) to characterize the natural history
of these patients. Method: Under an IRB approved protocol, biopsies from upper endoscopies
(EGD) from 1994 were reviewed. Cases of possible EE, as defined by areas of greater than
20 eosinophils per high power field, were identified by blinded review of esophageal biopsies.
Patients with eosinophilic gastroenteritis, candida esophagitis, or Crohn's disease were
excluded. Medical records were reviewed and patients were surveyed by phone. Results:
There were 512 EGD's in 1994; 136 EGD's (26%) demonstrated esophagitis, 21 of these
(4%) met EE criteria. Of those 4 were excluded because of the presence of abnormal
eosinophilic infiltrates in the duodenum and 1 patient excluded because of premature death
from multisystem disease unrelated to EE. To date, 11 of 16 remaining patients were
consented and interviewed; All 11 were originally diagnosed with GERD. The age range at
presentation was 2 to 18 years. One presented with food impaction, 3 with dysphagia, and
6 abdominal pain. 2 had asthma and 5 had food allergies. 6/8 with a WBC differential had
eosinophilia ranging from 5 to 19%. 2 underwent fundoplication in 1994. Currently, 3/11
have persistent mild dysphagia and 6/11 take medications for GERD. Of those with peripheral
eosinophilia, 2/8 have ongoing dysphagia. To date none have been diagnosed with EE,
required repeat endoscopy, had esophageal stricture or food impaction in 12 years without
EE treatment. Data collection from cases identified prior to 1994 continues and a control
set of patients with noneosinophilic esophagitis has been identified. Conclusions: While we
can not be certain that some of these patients did not have GERD in conjunction with EE,
only a minority of patients continue to have GI symptoms after 10 years without EE treatment.
No patients were found to have developed strictures, experienced recurring food impactions
or required repeat EGD. Blood eosinophilia did not appear to predict outcomes in this small
smaple size. The natural history of EE in children appears to be quite variable but does not
have major clinical sequelae in this small group of untreated children. Additional case
identification and comparison to the control group is ongoing.
T2039
Eosinophilic Esophagitis (Eoe): Perspectives of Adult Gastroenterologists (Agi)
and Pediatric (PGI)
Jeremy L. King, Seema Khan
Background: The care of EoE patients is guided by expert opinion and several low grade
studies. PGI and AGI are perceived as holding differing opinions, thus making EoE evaluation
and management contentious. We polled PGI and AGI for an insight into the patterns of
their clinical approach toward EoE. Objectives: Evaluate and compare PGI and AGI percep-
tions about etiology, diagnosis and management of EoE. Methods: A 25-item survey was
emailed to the PEDSGI Bulletin Board and to 2 AGI per Electoral College vote, randomly
selected from each state. The survey was voluntary and consent was assumed based on
survey submission. The responses were submitted anonymously to a secure website. Results:
Led by US NorthEast, 240 (PGI 168) complete and 60 incomplete surveys were received,
70% from a teaching hospital. All 44 non-US respondents were PGI. Mean new EoE diagnoses/
6 mo was 4 (0-30). While 92% AGI vs. 54% PGI (P<0.001) chose EGD as initial test for
EoE with dysphagia, both groups opted to do proximal and distal biopsies regardless of
gross findings. Eos/hpf ≥15, ≥20, ≥25 were chosen by 19% vs. 16%, 44% vs. 58%, &
28% vs. 21% of AGI and PGI (NS) respectively to define EoE. More PGI than AGI (77%
vs. 16%, P<0.001) refer EoE cases for food allergy tests. Both chose fluticasone as therapy
for symptomatic EoE without allergies and elimination diet for allergic EoE. However, the
majority of AGI (68% vs. 39%, P <0.001) would not treat asymptomatic EoE without
allergies, but both groups agreed on elimination diet for asymptomatic allergic EoE (62%
vs. 70%). A symptom based follow up was the popular choice of 92% AGI vs. 77% PGI.
The majority of AGI and PGI worry about complications, though variably: impactions (60%
vs. 82%), strictures (56% vs. 80%), poor quality of life (43% vs. 57%); 11% PGI in contrast
to 0% AGI worry about malignancy. Food allergy was rated by more PGI (57% vs. 22%)
as causing EoE. Combined mean Likert scores (5=strongly agree) were: food allergies 4.26,
airborne allergies 3.73, idiopathic 3.67 and genetics/familial 3.52. Conclusions: The survey
is a poll of popular opinions and points to contentious issues. These include evaluation for
food allergies in EoE, management of asymptomatic non-allergic EoE, potential complications
and food allergy as its cause. Pleasantly, both subspecialists seem to agree on most other
items. The survey is limited by a low AGI response rate and lack of non-US AGI responses.
It does not explore rationale for current patterns of practice, but may be an impetus to well-
designed studies on the pathogenesis, natural history, and effects of different interventions
in pediatric and adult EoE patients.
T2040
A Case-Control Study to Differentiate Allergic / Idiopathic Eosinophilic
Esophagitis (Aee/Iee) from Gastroesophageal Reflux Disease in Adults
Sayeeda A. Jabeen, Syed M. Hashmi, Larry Hughes, Sara Choudary, Jordan Mann, Betty
E. Ryan, Howard B. Chodash
Background: AEE/IEE is an underrecognised disease in adults. It is important to differentiate
and appropriately treat these patients to reduce their discomfort and health cost. Very few
studies have compared these two entities. AIM: To distinguish AEE/IEE from GERD in an
adult cohort, based upon the number of eosinophils, correlated with demographics, clinical,
endoscopic, and pathologic findings. Additionally, modalities of treatment received by AEE/
IEE patients were tabulated. Methods: Slides with eosinophils on the biopsy were blindly
reviewed. A total of 151 patients were retrieved over a period of 6 years. 37 patients met
the criteria for AEE/ IEE with > 20 eosinophils/HPF; 114 patients were classified as GERD
< 20 eosinophils/HPF. Statistical Analysis: ANOVA and Pearson Chi-Square Limitation:
Retrospective study Results: Patients were significantly younger on average in the AEE/ IEE
group (49 yrs vs 61 yrs, p<0.01). Certain characteristics were noted more often in patients
with AEE/ IEE than in GERD: male gender (62% vs 47%); dysphagia (86% vs 32%, p <
0.01); allergies (70% vs 9%, p < 0.01); endoscopic evidence of ringed/feline esophagus
(30% vs 3%, p < 0.01); basal cell hyperplasia, lamina propria papillae elongation, spongiosis
(78% vs <1%, p < 0.01). Esophageal ulcer or esophagitis (38% vs 19%, p < 0.035) was
more common in GERD. Mucosal furrows (16%) and eosinophilic mircoabscesses (16%)
were only seen in AEE/IEE. No significant difference in number of eosinophilis noted between
the proximal or distal biopsy in either group. No statistical difference was noted in regards
to: ethnicity, although Caucasians were predominant in both groups, (89% vs 70%); acid
reflux (51% vs 50%); chest pain (11% vs 7%); Schatzki's ring (22% vs 17%); Hiatal Hernia
(38% vs 35%); Barrett's esophagus (16% vs 15%). Treatment received for AEE/IEE: PPI
(43%) and Nissen's fundoplication (3%) with no symptom relief; Symptomatic relief was
noted in majority of patients with esophageal dilation (32%), oral prednisone (11%), and
fluticasone spray (5%) Conclusion: Allergic or Idiopathic Eosinophilic Esophagitis is a disease
of young Caucasian males, presenting with dysphagia or food impaction, with or without
acid reflux with no clinical response to acid suppressants, especially with allergies. When
clinical suspicion is high, multiple biopsies are recommended either from the distal or
proximal esophagus, particularly with mucosal furrows or subtle rings, as these findings
may be overlooked on EGD. Symptomatic relief is noted with systemic or topical steroid
and esophageal dilatation. Diagnosis is critical before the patient is subjected to Nissen's Fun-
doplication.
T2041
Eosinophilic Esophagitis in Patients Presenting with Dysphagia: A Prospective
Analysis
Scott H. Mackenzie, Mae F. Go, Barbara Chadwick, Kristen Thomas, Sue Lamphier, John
C. Fang, Kathryn A. Peterson
Background: Eosinophilic Esophagitis (EoE) is thought to be a rare inflammatory condition
in adults, but the incidence may be rising. EoE is becoming more prevalent in adults
presenting with dysphagia. There are no prospective studies looking at the prevalence of
EoE in patients presenting with dysphagia. Methods: Patients with dysphagia referred for
EGD at University Hospital (UH) and the VAMC were asked to participate. All patients
completed a detailed questionnaire followed by EGD with four quadrant biopsies in the
distal and mid esophagus. EoE was defined as >20 eosinophils/hpf averaged over 5 random
specimens in either the distal or mid esophagus. Primary endpoint was the prevalence of
EoE; secondary endpoints included age, gender, asthma, food allergies, GERD/dysphagia
score, and endoscopic findings. Fisher's exact and paired T-analysis were used for analysis.
Results: (See Table) 209 patients enrolled between December 2005 and November 2006
(106 VAMC, 103 UH). Four patients did not undergo esophageal biopsies and were excluded
from the analysis (205 total patients). Median age was 58 years, and 145/205 were male
(71%). Twenty-five patients (12.2%) met pathologic criteria for EoE. No significant difference
in EoE cases between male and female (p=0.2). Mean age of EoE patients 44±16 vs. 60±16
for non-EoE patients (p<0.001). EoE was diagnosed in 19% of patients less than 55 years
(RR 6.7 for age <55 vs. ≥55). Asthma was present in 11/25 (44%) of EoE cases vs. 34/180
of controls (19%) (p<0.05). Food allergies present in 9/25 (36%) of EoE cases vs. 14/180
(8%) of controls (p<0.005). There was no difference in GERD or dysphagia scores between
EoE and non-EoE patients. 11/25 (44%) of EoE patients did not have the classic EGD
findings (rings ± furrows) and would have been missed without esophageal biopsies. Con-
versely, ringed esophagus was seen in 10 patients whose biopsies did not meet histologic
criteria for EoE. Conclusions: EoE was diagnosed in 12% of patients presenting with
dysphagia with relative risk of 6.7 if age <55. Asthma and food allergies are significantly
associated with EoE. Esophageal biopsies are warranted in patients presenting with dysphagia
especially in the younger population. Patients may not present with classic endoscopic
findings and EoE can be missed without biopsies.
T2042
Epidemiology of Eosinophilic Esophagitis: Data from a Community-Based
Longitudinal Study Work Carried Out By the Swiss EE Study Group,
Switzerland
Susanne Portmann, Pius Heer, Christian Bussmann, Christoph Beglinger, Hans-uwe
Simon, Alex Straumann
Background: Eosinophilic Esophagitis (EE), a chronic-inflammatory disease that may lead
to esophageal narrowing and stricture, is clinico-pathologically defined by esophagus-related
symptoms in combination with a dense esophageal eosinophilia, both of which persistent
despite treatment with PPI's. There is evidence, that EE has a startling increasing prevalence,
but there is still a debate about how common this disorder is, as there is limited demographic
information available. Methods: We report on 30 adult cases selected from a national database
commenced in 1989 that prospectively enrolls EE patients. All patients presented here lived
in Olten County, a well defined area having one community-based gastroenterology center,
one pathology center and approximately 100'000 inhabitants without relevant demographic
changes within recent decades. Database inclusion criteria are typical history, consistent
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endoscopic abnormalities and a peak infiltration of the esophagus with ≥ 24 eosinophils/
hpf. Results: Throughout an observation period of almost 18 years, an average annual
incidence of 1.667/100'000 inhabitants was noted (range 0-8) with a marked increase in
newly-diagnosed cases during the last years, leading to a current prevalence of 30/100'000
(see Figure) inhabitants. Conclusions: Given the stability of demographic and recording
conditions, it is very likely that this remarkable trend reflects a real increase in EE and not
just enhanced awareness. This community-based demographic study demonstrates that in
adults, EE once believed to be a rare anomaly, occurs at a considerable frequency and may
soon reach that of chronic inflammatory bowel diseases. We believe that EE is one of the
leading causes of dysphagia, particularly among male individuals with an atopic background.
Furthermore, our frequency calculations have to be considered as a minimum and probably
reflect the “tip of the iceberg”; many oligo- or asymptomatic cases may remain undiagnosed.
T2043
Sliding Hiatal Hernia As a Complication of Eosinophilic Esophagitis
Chris A. Liacouras, Jonathan M. Spergel
Eosinophilic esophagitis (EE) is characterized by a severe, isolated esophageal eosinophilia.
Recently, a new finding, sliding hiatal hernia (SHH), has been appreciated in a large number
of EE patients. METHODS: We conducted a retrospective study of 442 EE patients identified
between January 1 1997 and January 1, 2006. A SHH was defined as the transient develop-
ment of gastric mucosa sliding into the distal esophagus identified either by an upper
gastrointestinal series (UGI) or during upper endoscopy. RESULTS: Over 10 years, 26
patients (5.8%), 18 male, were identified as having a SHH; 12 were identified at the time
of initial diagnosis while 14 developed a SHH during a follow up exam. The characteristics
of the 12 patients (average age 13.4±3.5 years) who were initially diagnosed with a SHH
included the presence of gastroesophageal reflux symptoms for 6.7±2.6 years; 9 were dia-
gnosed when they were older than 10 years of age; 2 diagnosed by UGI (10 by upper
endoscopy). The characteristics of the 14 patients (average age 12.6±4.2 years) who developed
a SHH during a follow visit included all 14 patients refusing therapy for EE for more than
5 years; 12 with worsening clinical symptoms including 5 with new onset dysphagia and
7 with increased vomiting; and 13 diagnosed by repeat upper endoscopy (1 by UGI series).
Additionally, all 14 follow-up patients had no evidence of a SHH at the time of initial
diagnosis (normal endoscopy and UGI series). CONCLUSION: SHH's may develop in EE
patients who have been untreated for more than 5 years. The etiology of SHH is unknown;
however, chronic esophageal eosinophilia may lead to foreshortening of the esophagus and
the creation of a SHH.
T2044
The Faces of Eosinophilic Esophagitis (Eoe) in Adults and Children
Cristina Almansa, Kenneth R. Devault, Anna M. Buchner, Sami R. Achem
Eosinophilic Esophagitis (EoE) has been recognized in children and recently in adults. It is
not well known whether adults have different clinical presentation compared to children.
Aims:Compare the clinical presentation of children with EoE from available literature to
adult cases at our center and adult series from published literature. Hypothesis: Our patients
with EoE have similar clinical characteristics compared to adult patients from other series.
There are differences in clinical presentation between children and adults.Methods: Compu-
terized search of the literature. The two largest series in children combined for inclusion:
N =381 (1) and N= 104 (2). For adult patients we identified all cases from a comprehensive
review N= 371 (3) involving mostly case reports from 1-31 patients, and the single largest
series of patients N=74 (4).We compared those series to consecutive adult cases seen at our
center in the last year (N=46). Demographics, clinical, endoscopic findings and N eosinophils/
HPF X400 included. Results: Table 1. Clinical and endoscopic findings in adults. Table 2.
Adults vs children.Conclusions: The clinical presentation of EoE in adults is similar across
series except for higher prevalence of food impaction in series other than ours. Most adult
patients complain of dysphagia, but, a sizable proportion also report reflux. By contrast, the
majority of children present with reflux. The most prevalent endoscopic sign in adults is a
ringed esophagus. A normal endoscopy should not exclude EoE, particularly in children.
References: 1 Liacouras CR, et al. Clin Gastroenterol and Hepatol 2005;3:1198. 2 Noel RJ
and Rothenberg MC. Curr Opinion in Pediatrics 2005; 17:690. 3 Sgouros S et al. Eur J of
Gastro & Hepatol 2006; 18 (2) 211. 4 Gonsalves N, et al. Gastrointest Endosc 2006;64:313.
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Table 1. Clinical and Endoscopic Findings in Adults
Table 2. Adults Compared to Children
*Endoscopy description only available in 381/484 patients
T2045
Characteristic Endoscopic Features of Eosinophilic Esophagitis in Patients
Without Tissue Eosinophilia: True Or False Negative?
Joan Chen, Nirmala Gonsalves, Sam Rao, Ikuo Hirano
BACKGROUND: Eosinophilic esophagitis (EE) is an increasingly recognized cause of dys-
phagia with the diagnosis based on biopsy demonstration of esophageal mucosal eosinophilia.
Characteristic endoscopic findings includemucosal rings, longitudinal furrows, and exudates.
The specificity of these findings is unknown with controversy arising when the endoscopic
features of EE are encountered in the absence of significant esophageal eosinophilia.
METHODS: Patients (pts) with endoscopic features consistent with EE, including rings,
furrows, and plaques, but biopsies demonstrating < 15 eosinophils per high power field
(hpf) were included in this analysis. Medical records, medication lists and endoscopic images
were evaluated. Biopsy results were reviewed with a senior GI pathologist. RESULTS: 28
Patients were included in this analysis. The median age was 48 yrs (range 20-74), and 15
pts were female. 12 pts (43%) reported environmental allergies (allergic rhinitis), and 5
(18%) had asthma. 21 pts (75%) had dysphagia as an indication for endoscopy. Other
presenting symptoms included reflux (29%) and food impaction (18%). At the time of
endoscopy, 10 pts (36%) were on antihistamines, 2 pts (7%) were on nasal steroids, 2 pts
(7%) were on inhaled steroids, and 1 pt was on a nasal cromolyn spray. 10 pts (36%) were
taking a PPI. Endoscopy revealed that 27 pts (96%) had evidence of rings (11 prominent,
16 subtle); 19 pts (68%) had furrows (7 prominent, 12 subtle), and 18 pts (64%) had both
rings and furrows on EGD. One pt had subtle plaques on EGD. Patients had a minimum
of 4 esophageal biopsies (median 7 biopsies per pt). Histologic review of the biopsies revealed
no pathologic change in 18 pts (64%); reflux changes in 8 pts (17%) and mild eosinophilia
(<15) in 4 pts (14%). 8 pts underwent esophageal dilation, 6 pts received swallowed
fluticasone and 12 pts received PPI therapy. CONCLUSIONS: Patients with characteristic
esophageal features of EE on endoscopy but less than 15 eosinophils per hpf present both
a diagnostic and therapeutic conundrum. False negative explanations for such patients
include: 1) biopsy sampling error owing to patchy eosinophil infiltration 2) medication
(antihistamines, inhaled steroids, other anti-inflammatory agents) suppression of eosinophilia
and 3) temporal or seasonal variability in EE. True negative explanations include: 1) endos-
copic features secondary to GERD and not EE 2) over interpretation of subtle endoscopic
features and 3) possible non-EE, non-GERD etiology.
T2046
Title: Association of Eosinophilic Esophagitis with Furrows
Humaira Hashmi, Susan S. Baker, Robert J. Baker, Eduardo Tran
ABSTRACT BODY:. Linear furrowing has been described as being associated with eosinophilic
esophagitis (EE), but to date no evidence for a direct relationship between the two has been
established. The purpose of this study is to determine the association between linear eso-
phageal furrows and EE. Method: 301 patients, 1-18 years of age, undergoing upper endos-
copy ( 08/05-06/06) were evaluated for linear furrowing by one endoscopist (HH). Furrows
were defined as linear groves with adherent white plaques. Biopsies were taken at three
levels of esophagus in all the patients. EE was diagnosed by the presence of >20 eosinophils
per high power field in the lamina propria of the esophageal biopsies Reflux esophagitis
was diagnosed by the presence of <20 eosinophils/high power field , basilar layer hyperplasia,
elongation of rete pegs, or squiggle cells.Association of furrows with eosinophilic esophagitis
was estimated. Results: Total 301 EGD were performed. Furrows were identified in 65. EE
was diagnosed in 25 patients and EE with furrows was found in 18 patients. Conclusion:
Presence of furrows does not establish the diagnosis of EE . Although the absence of furrows
is strong evidence against EE. Our Positive predictive value(PPV) is 0.28 and Negative
Predictive value(NPV) is 0.97.Specificity is 83%,sensitivity is 72%.Our patient pre test
probability is 0.1 and pre test odds are 0.1.Post test odds are 0.5 and post test probability
is 0.32.
Eosinophilic Esophagitis and furrows
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T2047
Risk Stratification Analysis in Adult Eosinophilic Esophagitis
Adam B. Kaufman, Matthew S. Cohen, Juan P. Palazzo, Daniel Nevin, Anthony J.
Dimarino, Sidney Cohen
Introduction: Sporadic reports suggest a high risk profile for esophageal complications in
eosinophilic esophagitis (EoE). The clinical features that predict this risk profile is not well
delineated. Aim: The purpose of this study is to perform a retrospective comparison of
complicated and uncomplicated cases of EoE. Eleven patients were identified with complica-
tions of instrumental perforation, spontaneous rupture (Boerhaave's syndrome), or deep
vertically extending mucosal tears were compared to thirty-five patients without complica-
tions. Materials and Methods: Thirty-six subjects were identified over a sixty-four month
period with diagnosed EoE from the Division of Gastroenterology of Thomas Jefferson
University Hospital. Two pathologists reviewed esophageal biopsies and included these
subjects with ≥ 15 eosinophils in at least 2 high power fields (HPF), or ≥ 25 eosinophils
in any single HPF. Retrospective analysis included review of all outpatient charts, inpatient
records, radiographic studies, and endoscopy reports. Eleven complicated cases were identi-
fied by documentation of mucosal lacerations during endoscopy or by radiographic evidence
of pneumomediastinum from esophageal perforation. Results: The mean age of 33.9 +/- 2.2
years was similar in both groups. Dysphagia for solids was longer in duration for the
complicated cases, 13.2 +/- 4.0 years vs. 6.7 +/- 1.5 years for the uncomplicated cases, but
this change was not significant (p>0.05). In both groups, Caucasian males were predominant.
Degree of mucosal eosinophils and depth of eosinophila were greater in the complicated
cases suggesting a greater severity of illness, but again not significantly noted (p>0.05).
Presence of a stricture was a significant risk factor (p<0.05), even when not dilated. Conclu-
sions: 1) This retrospective analysis indicates that EoE is predominantly a disorder of young,
Caucasian males with relatively long duration of solid food dysphagia prior to seeking
medical consultation. 2) Prospective prediction of risk for perforations or lacerations is
greatest with stricture and possibly depth and severity of eosinophilic infiltration. We suggest
that all patients with known or suspected EoE be approached with great caution during
endoscopy because of the great difficulty in prospective risk stratification.
T2048
An Eight-Year Study of 30 Consecutive Patients with Eosinophilic
Gastroenteritis in One Gastroenterology Practice: Eosinophilic Gastroenteritis
Is More Common Than Previously Appreciated and May Not Necessarily
Require Corticosteroid Therapy
Navakanth Gorrepati, Harsha Desai, Steven Fox, Mitul Amin, Veslav Stecevic, Tusar Desai
Purpose: Eosinophilic gastroenteritis (EG) is considered an uncommon disease of unknown
etiology characterized by patchy or diffuse eosinophilic infiltration of the gastrointestinal
tract wall.We analyzed 30 consecutive cases of EG diagnosed by one gastroenterologist during
an 8-year period. Methods: EG was diagnosed on the basis of gastrointestinal symptoms; >20
eosinophils /HPF on endoscopic mucosal biopsy; and exclusion of inflammatory bowel
disease or parasitic infestation. Medical charts, endoscopic reports, and biopsy reports were
reviewed in the 30 patients satisfying these criteria from November, 1998 to October, 2006.
The mean length of follow up was 2.9 +/- 2.1 years (range 0-7.9 years). Results: Thirty
patients were diagnosed with eosinophilic gastroenteritis (frequency of diagnosis at EGD=
0.67%). Male-to-female ratio was 2:1. The mean age at presentation was 54.4 +/- 18.6 years
(range 21-85 years). Presenting symptoms were abdominal pain in 13, nausea and vomiting
in 11, dysphagia in 6, pyrosis in 8, gastrointestinal bleeding in 3 and weight loss in 3
patients. Eosinophils were detected in the stomach in 28, duodenum in 18, ileum in 3, and
colon in 6 patients (6 patients had concomitant eosinophilic esophagitis). Major endoscopic
findings included gastric ulcers in 4, and duodenal ulcers, duodenal stenosis, or pyloric
stenosis in 2 patients each. Four patients had Helicobacter pylori diagnosed on gastric biopsy
by diff quik stain (14%; N=28). Twenty-one patients had peripheral eosinophilia. Nine
patients had iron deficiency anemia. Important radiologic findings included mural thickening
in 2, delayed gastric emptying in 2, and duodenal stenosis in 1. Fourteen patients responded
to proton pump inhibitors without requiring corticosteroids. Thirteen patients responded
to oral corticosteroid therapy. Two patients refused corticosteroids when offered. One patient
did not respond to corticosteroid therapy. Four patients with H. pylori infection were treated
with standard multidrug regimens and had H. pylori eradication confirmed. Two (50%) of
these patients responded to this therapy, but the other two patients required corticosteroids.
Repeat endoscopic biopsy in 10 patients NOT treated with corticosteroids revealed a signific-
ant drop of eosinophilic density in 7 patients (70%). Conclusions: EG may be more common
than heretofore believed (0.67% rate). Nearly one-half of patients were successfully treated
with only PPI therapy, and nearly all the other patients were successfully treated with
corticosteroids. Eosinophilic density diminishes without steroid treatment in a significant
number of patients with EG.
T2049
Influences of Pro- and Anti-Inflammatory Cytokine Polymorphisms On
Eradication Rates of Clarithromycin-Sensitive Strains of Helicobacter pylori By
Triple Therapy
Mitsushige Sugimoto, Takahisa Furuta, Naohito Shirai, Chise Kodaira, Masafumi Nishino,
Mutsuhiro Ikuma, Akira Hishida
Backgrounds and Aims: Polymorphisms of pro-inflammatory cytokines, such as IL-1β and
TNF-α, are associated with individual differences in gastric mucosal inflammation and acid
inhibition in response to Helicobacter pylori (H. pylori) infection. We investigated whether
inflammation-related cytokine polymorphisms would influence the eradication rates of H.
pylori by a triple regimen. Methods: 360 patients infected with clarithromycin-sensitive
strains of H. pylori were genotyped for IL-1B-511, IL-1RN, TNF-A-857/-863/-1031, IL-10-
1082/-819/-592 and cytochrome P450 2C19 (CYP2C19), and underwent 1-week triple
therapy with a proton pump inhibitor (omeprazole 20 mg, lansoprazole 30 mg or rabeprazole
10 mg) bid, clarithromycin 400 mg bid, and amoxicillin 750 mg bid. Influences of the
abovementioned polymorphisms on the eradication rates were analyzed. Results: The inten-
tion-to-treat-based total eradication rate was 83.6% (301/360). The logistic regression analysis
revealed that polymorphisms of CYP2C19 and IL-1B-511 were independently associated
with the eradication rates, but other cytokine polymorphisms were not associated. Eradication
rates in patients with IL-1B-511 C/C, C/T and T/T genotypes were 72.2% (70/97), 87.7%
(164/187) and 88.2% (67/76), respectively (p = 0.0017). When patients were stratified by
CYP2C19 genotype status, IL-1B-511 genotype-dependent differences in eradication rates
were observed in homozygous extensive metabolizers (EMs), but not in heterozygous EMs
and poor metabolizers of CYP2C19. The eradication rate in homozygous EM patients with
the IL-1B-511 C/C genotype was quite low (51.1%, 22/43). Conclusions: IL-1B-511, but
not IL-1RN, TNF-A or IL-10, polymorphism is one of the determinants of a triple therapy
for clarithromycin-sensitive strains of H. pylori in the CYP2C19 homozygous EMs.
T2050
Bismuth Subcitrate-Based Therapy Is More Effective Than Proton Pump
Inhibitors (PPI) Therapy in Eradicating H Pylori in Pangastritis
Carola Severi, Mohamed Abdullahi, Roberto Tari, Gabriele Capurso, Amelia Pasquali,
Gianfranco Delle fave, Renzo Caprilli, Bruno Annibale
Background: Despite good early results obtained in clinical trials on H pylori eradication
with (PPI)-based triple therapies, the results have been disappointing in clinical practice
with an eradication rate around 70%. H pylori -induced inflammation of the gastric corpus
inhibits parietal cell secretion. Studies of the effects of gastritis on gastric secretion have
consistently shown that acid secretion is inversely related to the presence and severity of
corpus-involved gastritis. The use of PPI in pangastritis is therefore debatable. Aim of the
present study was then to compare the efficacy of two triple therapy, either Bismuth or PPI
plus two antibiotics in pangastritis H pylori patients. Methods: 112 consecutive patients
with pangastritis were randomized to receive for the first week two antibiotics (amoxicillin
1 gr t.i.d; clarithromycin 250 mg t.i.d or metronidazole 250 mg t.i.d) and either bismuth
240 mg b.d. (n=55) or PPI standard doses o.d. Multiple gastric biopsies and 13C-Urea
breath test (UBT) were performed before treatment. H pylori successful eradication was
sought by 13C- urea breath test at 3 months. Results: H pylori eradication rates were, by
intention-to-treat (ITT) and per-protocol (PP) analyses, 90% (50/55) and 93% (50/54) for
Bismuth groups and 44% (27/57) and 50% (27/54) for PPI group (p<0.001, OR 9.3). Not
significant differences were found as far as age, sex, smoking habits were concern, either at
ITT or PP analysis. Furthermore no significant difference of eradication rate was observed
to the antibiotic combination of the two treatments (Table I). Bismuth based therapy was
not associated with reduced compliance or higher incidence of adverse effects. Two and
one patients in the PPI group and Bismuth treatment groups, respectively, were lost to
follow-up. One patients of PPI group was non-complaint. Conclusion: Bismuth Subcitrate-
based therapy was more effective in eradicating H pylori than PPI-based triple therapy in
patient with pangastritis. Eradication therapy containing bismuth and two antibiotics should
be used as a first-line treatment in pangastritis.
T2051
Third-Line Levofloxacin-Based Rescue Regimen in Patients with Two H. pylori
Eradication Failures: A Spanish Multicenter Study
Javier P. Gisbert, M. Castro-fernandez, F. Bermejo, A. Perez-aisa, J. Ducons, M.
Fernandez-bermejo, A. Cosme, F. Bory, L. M. Benito, L. Lopez-rivas, E. Lamas, J. A.
Carneros, M. Pabon, P. Valer
AIM: Eradication therapy with proton pump inhibitor (PPI), clarithromycin and amoxicillin
fails in a considerable number of cases. A rescue therapy still fails in more that 20% of the
cases. Our aim was to evaluate the efficacy and tolerability of a third-line levofloxacin-based
regimen in patients with two consecutive H. pylori eradication failures. METHODS: Design:
Prospective multicenter study. Patients: in whom a first treatment with PPI-clarithromycin-
amoxicillin and a second with PPI-bismuth-tetracycline-metronidazole (or ranitidine bismuth
citrate with these antibiotics) had failed. Intervention: A third eradication regimen with
levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.) and omeprazole (20 mg b.i.d.) was
prescribed for 10 days. Outcome: Eradication was confirmed with 13C-urea breath test 4-
8 weeks after therapy. RESULTS: One-hundred and forty patients have been initially included.
All patients but 9 (6.4%) took all the medications correctly. Per-protocol and intention-to-
treat eradication rates were 71% (95%CI=63-78%) and 69% (61-78%). Adverse effects were
reported in 25% of the patients, mainly including nauseas (7.9%), metallic taste (7.1%),
myalgia/arthralgia (7.1%), abdominal pain (5%), and diarrhea (4.3%); none of them were
severe. CONCLUSION: Levofloxacin-based rescue therapy constitutes an encouraging empir-
ical third-line strategy after multiple previousH. pylori eradication failures with key antibiotics
such as amoxicillin, clarithromycin, metronidazole and tetracycline.
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T2052
The Effect of Mdr1 C3435t Polymorphism On the Rescue Eradication Rates of
H. pylori By the High Doses of a Proton Pump Inhibitor and Amoxicillin
Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Naohito Shirai,
Mutsuhiro Ikuma, Akira Hishida
We have previously reported that dual therapy with high doses of a proton pump inhibitor
(PPI) and amoxicillin is useful as the rescue regimen for H. pylori infection after the standard
triple therapy fails eradication of H. pylori infection. However, there are some patients
who are refractory to this rescue regimen. P-glycoprotein (P-gp), ATP-dependent efflux
transporter, is involved in the metabolism of PPIs. Recently, the polymorphism of MDR1
gene (from C to T at the position 3435) has been made clear to be associated with the
activity of P-gp. Then, we intended to examine whether the rescue eradication rate of the
dual therapy with a PPI and amoxicillin were associated with the MDR1 polymorphism at
the position 3435. Methods: One hundred and twenty-eight patients who failed to eradicate
H. pylori infection by the initial triple therapy with lansoprazole 30 mg bid, amoxicillin 750
mg bid and clarithromycin 400 mg bid for 1 week underwent the 2-week dual therapy with
rabeprazole 10 mg qid or lansoprazole 30 mg qid and amoxicillin 500 mg qid. MDR1
C3435T mutations were assessed by the PCR-RFLP method. Results: The frequency of MDR1
C3435T genotypes were C/C; 32.8% (n = 42), C/T: 37.5%% (n = 48), and T/T: 29.7% (n =
38). The ITT analysis of the total eradication rate was 90.6Åì (116/128). Eradication rates
in the different MDR1 genotypes were 97.6% (41/42) in C/C group, 91.7% (44/48) in the
C/T group, and 81.6% (31/38) in the T/T group (P = 0.0464). Conclusion. The rescue
eradication rate by the dual therapy with high doses of a PPI and amoxicillin is influenced
by the MDR1 C3435T genotype status.
T2053
Usefulness of Combination Assay of Cyp2c19 and Mdr1 Polymorphisms in
Dual Therapy with Proton Pump Inhibitor and Amoxicillin for Eradication of
H. pylori
Chise Kodaira, Mitsushige Sugimoto, Masafumi Nishino, Naohito Shirai, Mutsuhiro
Ikuma, Akira Hishida, Takahisa Furuta
Backgrounds and Aims: The pharmacokinetics and pharmacodynamics of proton pump
inhibitor (PPI) depend on CYP2C19 genotypes. We previously reported that sufficient
eradication rates could be attained in patients with poor metabolizer (PM) genotypes of
CYP2C19 by a dual therapy with a PPI and amoxicillin without second antibiotics. The
pharmacokinetics of PPIs is also influenced by the activity of an ATP-dependent efflux
transporter, P-glycoprotein (P-gp). The activity of P-gp is influenced by the MDR1 poly-
morphism. Then, we examined whether eradication rates by dual PPI/amoxicillin therapy
was influenced by the MDR1 polymorphism in relation to CYP2C19 genotypes. Methods:
A total of 116 patients infected with H. pylori underwent the dual therapy with a PPI, such
as OPZ 20mg bid, RPZ 10mg bid or LPZ 30mg bid, and amoxicillin 500 mg tid for 2 weeks.
Genotypes of MDR1 C3435T and CYP2C19 were determined by PCR-RFLP methods. MDR1
genotypes were classified into 3435T allele carriers (C/T or T/T) or non-carrier (C/C).
CYP2C19 genotypes were classified into rapid metabolizer (RM), intermediate metabolizer
(IM) and PM. Eradication of H. pylori was judged based on 13C-UBT. Results: The total
eradication rate was 69.8% (81/116, 95%CI: 60.6%-78.0%). The eradication rate in RMs
was 54.5% (24/44), that in IMs was 78.0% (46/59) and that in PMs was 84.6%(11/13) (P =
0.0176). The eradication rate in the MDR1 3435T allele carriers (C/T or T/T) was 64.1%
(50/78), which appeared lower than that of non-carriers (C/C) (81.6% 31/38) (P = 0.0543).
When eradication rates were re-analyzed based on the combination of CYP2C19 genotype
status and MDR1 3435T allele-carriage status, the eradication rates in PM patients with and
without the MDR1 3435T allele were 71.4% (5/7) and 100% (6/6), respectively and those
in IMs were 69.2% (27/39) and 95% (19/20), whereas those in RMs were 56.3% (18/32)
and 50% (6/12), respectively. Conclusion: Patients with CYP2C19 hetEM or PM genotypes
and with the MDR1 3435 C/C genotype could attain eradication rates higher than 95% by
a dual PPI/amoxicillin therapy without second antibiotics. Because of very low prevalence
of amoxicillin-resistant strains of H. pylori, the combination assay of CYP2C19 and MDR1
polymorphisms is useful for the selection of patients who can attain sufficiently high eradica-
tion rates by the dual PPI/amoxicillin therapy without the testing of the susceptibility of H.
pylori to antimicrobial agents.
T2054
Eradication Resistance Index As a Predictor of Response to Metronidazole-
Containing Second-Line Treatment for Helicobacter pylori Infection
Toshihiro Nishizawa, Hidekazu Suzuki, Tatsuhiro Masaoka, Eisuke Iwasaki, Toshifumi
Hibi
Background and Aim. It is reported that the eradication rates following second-line treatment
of Helicobacter pylori infection with the proton pump inhibitor (PPI)-amoxicillin (AMX)-
metronidazole (MNZ) regimen was 97 % for infections with MNZ-sensitive strains and 82
% for infections with MNZ-resistant strains (Aliment. Pharmacol. Ther. 2003;17:119-23).
This indicates that, unlike the resistance to clarithromycin (CLR), the resistance to MNZ
can be overcome to some extent even with higher minimal inhibitory concentration (MIC).
Therefore, it is difficult to predict the effect of MNZ-containing second-line treatment
regimens by only determining the MIC of MNZ. The results of urea breath test (UBT) in
which the intragastric urease activity is measured, are correlated with the Helicobacter pylori
bacterial load (Am. J. Gastroenterol. 2001;96:359-66). The purpose of the present study
was to develop a useful predictor of the response to MNZ-containing second-line regimens
for the treatment ofHelicobacter pylori infection by combining bothMIC andUBT information.
Patients and Methods. One hundred seven patients who showed eradication failure following
first-line triple therapy with a PPI, AMX and CLR were enrolled for the study. Eradication
failure was confirmed by the UBT. Endoscopic biopsy specimens of the subjects were used
to examine the MIC of MNZ and AMX. Eradication resistance index was defined as: [Pre-
treatment UBT result (‰)] x [AMX MIC (μg/ml)] x [MNZ MIC (μg/ml)]. Second-line
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eradication therapy with a regimen consisting of daily lansoprazole 60mg, AMX 1500mg
and MNZ 750mg for one week was administered to the patients. Eradication was confirmed
if the UBT was negative at 12 weeks after the treatment. Results. The eradication rate
following second-line eradication therapy was 89.7 % (96/107). The eradication resistance
index in the subjects showing eradication failure and those showing successful eradication
was 9.72±6.63 and 1.25±2.31 (mean ± S.D.), respectively. The difference in the index
between the two groups was significant (P < 0.001). When a cutoff value of 3 was used,
the eradication resistance index predicted the response to therapy with a specificity of 81.8
%, sensitivity of 93.8 %, positive predictive value of 60.0 %, negative predictive value of
97.8 % and accuracy of 92.5 %. Conclusion. The eradication resistance index is a useful
predictor of response to MNZ-containing regimens as second-line treatment of Helicobacter
pylori infection.
T2055
Second-Line Levofloxacin-Based Rescue Regimen in Patients with One H.
pylori Eradication Failure: A Spanish Multicenter Study
Javier P. Gisbert, F. Bermejo, A. Perez-aisa, M. Fernandez-bermejo, M. Castro-fernandez,
A. Tomas, J. Barrio, P. Sanchez-pobre, S. Khorrami, V. Ortiz, A. Cosme, X. Calvet, P.
Almela, P. Nino, Luis M. Benito, J. A. Carneros, E. Lamas, I. Modolell, E. O'callaghan, A.
Franco, J. Ortuno, F. Garcia-duran, L. Rodrigo, J. Ponce
AIM: Quadruple therapy (that is, PPI, bismuth, tetracycline and metronidazole) has been
generally used as the optimal second-line therapy after PPI-clarithromycin-amoxicillin failure.
However, this regimen requires the administration of 4 drugs with a complex scheme, and
is associated with a relatively high incidence of adverse effects. Our aim was to evaluate the
efficacy and tolerability of a triple second-line levofloxacin-based regimen in patients with
one H. pylori eradication failure. METHODS: Design: Prospective multicenter study. Patients:
in whom a first treatment with PPI-clarithromycin-amoxicillin had failed. Intervention: A
second eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.) and
omeprazole (20 mg b.i.d.) was prescribed for 10 days. Outcome: Eradication was confirmed
with 13C-urea breath test 4-8 weeks after therapy. Compliance with therapy was determined
from the interrogatory and the recovery of empty envelopes of medications. Incidence of
adverse effects was evaluated by means of a specific questionnaire, RESULTS: Up to now,
178 patients have been included. Mean age was 48 years, 47% were males, 37% had peptic,
and 63% functional dyspepsia. Almost all (98%) patients took all the medications correctly.
Per-protocol and intention-to-treat eradication rates were 78% (95% CI, 72-84%) and 76%
(70-83%). Cure rates were similar in peptic ulcer disease and in functional dyspepsia.
Adverse effects were reported in 24% of the patients, mainly including nausea (8%), metallic
taste (7%), asthenia/anorexia (4%), abdominal pain (3%), and myalgia/arthralgia (3%); none
of them were severe. CONCLUSION: Ten-day levofloxacin-based rescue therapy constitutes
an encouraging second-line strategy, representing an alternative to quadruple therapy in
patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of simplicity
and safety.
T2056
A Prospective Randomized Trial of High-Dose Versus Low-Dose Esomeprazole-
Based Triple Therapy for Helicobacter pylori Eradication in Taiwan
Ping-i Hsu, Kwok-hung Lai, Gin-ho Lo
OBJECTIVE: This prospective, randomized, controlled study was conducted to compare
the efficacies of high-dose and low-dose esomeprazole-based triple therapies for H. pylori
eradication among Taiwanese. METHODS: From January 2004 to August 2006, two hundred
and forty H. pylori-infected patients were randomly assigned to undergo high-dose (40 mg
b.d.) or low-dose (40 mg o.d.) combined with clarithromycin (500 mg b.d.) and amoxicillin
(1 g b.d.) and for one week. Follow-up endoscopy was performed at 8 weeks after the
end of treatment to assess the treatment response. RESULTS: Intention-to-treat analysis
demonstrated there were no differences in eradication rates between high-dose and low-
dose groups (92% vs. 90%, respectively, P > 0.05). Per-protocol analysis also showed
comparable results (94% vs. 92%). Both groups had similar frequencies of adverse events
(13% vs. 10%) and drug compliance (98% vs. 93%). Multivariate analysis disclosed that
only good compliance (Odds ratio: 51.1, 95% CI, 8.6 - 301.7) was an independent predictor
of treatment success. CONCLUSION: Our study demonstrates that low-dose esomeprazole-
based triple therapy can achieve similar eradication rate as high-dose esomeprazole-based
therapy. Since the cost of low-dose regimen is lower than that of high-dose regimen, it is
reasonable to recommend low-dose esomeprazole-based triple therapy for first-line H. pylori
eradication in Taiwan.
T2057
The Influence of the Cyp2c19*17 Allele On the Eradication Rates of H. pylori
By a Triple Therapy with Lansoprazole, Clarithromycin and Amoxicillin in
Japan
Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Naohito Shirai,
Mutsuhiro Ikuma, Akira Hishida
Backgrounds: The therapeutic efficacy of a proton pump inhibitor is affected by genotypic
differences in the S-mephenytoin hydroxylase (CYP2C19) in the liver. The activity of this
enzyme can be estimated by the examination of 2 mutated alleles, *2 and *3. Recently, the
CYP2C19*17 allele was discovered, which has been thought to be associated with the ultra
rapid extensive metabolizer phenotype of CYP2C19. Then, we examined the prevalence of
this allele and its effect on the eradication rates of H. pylori by a PPI-based triple therapy.
Methods: a total of 203 patients infected with H. pylori underwent the eradication therapy
of H. pylori by triple regimen with a lansoprazole 30 mg bid, clarithromycin 200 mg tid
and amoxicillin 500 mg tid for 1 week. Genotyping procedures for identifying the CYP2C19
wild-type (CYP2C19*1) gene (*1) and the three mutated alleles, CYP2C19*2 (*2),
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CYP2C19*3 (*3), and CYP2C19*17 (*17) were performed by a polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method using allele-specific primers.
The prevalence of these allele and effect of them on the eradication rates were determined.
Results: The incidences of CYP2C19*1 and *2 alleles were as follows: *1/*1: n = 66 (32.5%),
*1/*2: n = 74 (36.5%), *1/*3: n = 31 (15.3%), *2/*2: n = 17 (8.4%), *2/*3: n = 11 (5.4%),
and *3/*3: n = 4 (2.0%). The incidences of CYP2C19*17 were as follows;*1/*17: n = 2
(1.0%) and *17/*17: n = 0 (0.0%). Of 203 patients, 186 underwent the 13C-urea breath
test at 1 month after the treatment. Eradication rates in different CYP2C19 genotypes were
as follows; *1/*1: 47/61 (77.0%), *1/*2: 63/68 (92.6%), *1/*3: 25/26 (96.1%), *2/*2: 16/
16 (100.0%), *2/*3: 11/11 (100.0%), *3/*3: 4/4 (100.0%). Two patients with the *1/*17
genotype could eradicate their infection. Conclusion: The incidence of CYP2C19*17 allele
is low. The CYP2C19*17 allele is of limited clinical importance in Japan.
T2058
Comparative Evaluation of E-Test and Agar Dilution Method for Susceptibility
Testing to Detect Levofloxacin-Resistant Helicobacter pylori Isolates with Gyra
Mutations
Hideyuki Miyachi, Daisuke Shirasaka, Nobuo Aoyama, Ikuya Miki, Yuko Matsumoto,
Toshio Tanaka, Yoshinori Morita, Takao Tamura, Hiromu Kutsumi, Hideto Inokuchi,
Takeshi Azuma, Masato Kasuga
[Background] Levofloxacin (LVX), a fluoroquinolone, is considered one of the most effective
agents for refractory Helicobacter pylori (H. pylori) infection to clarithromycin (CLR) and
metronidazole, and this agent has been administered not only in salvage therapy but also
in first-line therapy. Recent studies have shown that the quinolone-resistance determining
region (QRDR) in gyrA plays a critical role in LVX resistance, and that the existence of gyrA
mutation shows a tendency toward worse treatment outcomes in LVX-based therapy. In
such a current condition, however, the methodology for determining LVX resistance is not
standardized, and the interpretation of resistance concerning minimum inhibitory concentra-
tions (MICs) is controversial. In CLR-resistance assessment, MICs assessed by E-test and
agar dilution method are well investigated in comparison with molecular genetic testing,
while no reports are available in LVX-resistance assessment according to gyrA mutations
using a lot of clinical isolates. [Aim] To evaluate the reliability of E-test and agar dilution
method in comparison with the existence of gyrA mutation. [Methods] H. pylori strains were
clinically isolated from 223 adult patients. Genomic DNA was extracted from each strain,
and the QRDR in gyrA was directly sequenced. LVX susceptibility was examined using both
E-test and agar dilution method in 44 strains with gyrA mutations. The associations between
MIC values (≥1 µg/ml vs. <1 µg/ml, ≥2 µg/ml vs. <2 µg/ml, ≥4 µg/ml vs. <4 µg/ml)
assessed by E-test and agar dilution according to the existence of gyrA mutations were
analyzed using two-tailed Fisher's exact test. [Results] Of 44 strains, 31 strains had gyrA
mutations at amino acid 87 (Asn to Lys, Ile or Tyr), and 13 strains had at amino acid 91
(Asp to Asn, Gly or Tyr). No double mutations were found. In most strains, MIC values
were lower by E-test compared to agar dilution. Thirty-six and 43 strains showed MICs of
≥1 µg/ml, 24 and 43 strains showed MICs of ≥2 µg/ml, and, 12 and 41 strains showed
MICs of ≥4 µg/ml by E-test and by agar dilution, respectively. Regarding gyrA mutants as
LVX-resistant, agar dilution showed more correct resistance assessment than E-test (P <0.05)
regardless of MIC value setting. [Conclusion] Although E-test is widely used for H. pylori
susceptibility testing to antimicrobial agents, as for LVX, agar dilution method showed
excellent agreement with the existence of gyrA mutations. Considering gyrA mutants LVX-
resistant, it should be reasonable to regard an MIC of ≥2 µg/ml by agar dilution, but not
by E-test, as resistant to LVX in susceptibility testing against H. pylori.
T2059
Third-Line Rescue Therapy with Levofloxacin Is More Effective Than
Rifabutin Rescue Regimen After Two H. pylori Treatment Failures
Javier P. Gisbert, J. L. Gisbert, S. Marcos, I. D. Pousa, M. Velasco, M. Luna, R. Moreno-
otero, J. M. Pajares
AIM: To compare rifabutin and levofloxacin rescue regimens in patients with two consecutive
Helicobacter pylori eradication failures. METHODS: Patients in whom a first treatment with
omeprazole-clarithromycin-amoxicillin and a second trial with omeprazole-bismuth-tetracyc-
line-metronidazole (or ranitidine bismuth citrate with these antibiotics) had failed, received
10 day treatment with either rifabutin (150 mg b.i.d.) or levofloxacin (500 mg b.i.d.), plus
amoxicillin (1 g b.i.d.) and omeprazole (20 mg b.i.d.). Cure rates were evaluated by 13C-
urea breath test. RESULTS: Twenty patients received rifabutin, and 20 levofloxacin. All the
patients returned for follow-up. Compliance in the rifabutin group was 100%. Four patients
in the levofloxacin group did not take the medication correctly (in two cases due to adverse
effects: myalgias and rash). Side effects in the rifabutin and levofloxacin groups were reported
in 60% and 50% of the cases, respectively. Five patients (25%) treated with rifabutin
presented leucopenia, and six (30%) treated with levofloxacin presented myalgias. Per-
protocol cure rates were 45% (95%CI, 26-66%) in the rifabutin group, and 81% (57-93%)
in the levofloxacin group (p<0.05). Intention-to-treat cure rates were, respectively, 45% (26-
66%) and 85% (64-95%) (p<0.01). CONCLUSION: After two previous H. pylori eradication
failures, 10-day triple levofloxacin-based rescue regimen is more effective than the same
regimen with rifabutin.
T2060
The Efficacy of One-Week Low-Dose Triple Therapy for Helicobacter pylori
Eradication in Korea
Woo hyun Paik, Young su Park, Jin hyeok Hwang, Jin wook Kim, Suk hyang Jung, Na
young Kim, Dong ho Lee
Background/Aims : The recommended regimen of H. pylori eradication in Japan is standard
dose proton pump inhibitor twice a day, amoxicillin 750 mg twice a day, and clarithromycin
200-400mg twice aday for 7 days.Whereas the recommended regimen ofH. pylori eradication
in Korea is standard dose proton pump inhibitor twice a day, amoxicillin 1000 mg twice
a day, and clarithromycin 500 mg twice a day for 7 days. We could expect patients' good
compliance, decrease of drug side effects and cost reduction by using low-dose triple therapy.
But, the efficacy of low-dose triple therapy is questionable in Korea. In this study, we
compared the efficacy of low-dose triple therapy with standard-dose triple therapy. Patients
& Methods : Four hundred and eighty patients who visited Seoul National University
Bundang Hospital from 2005 January till 2006 April with documented H. pylori infection
were enrolled. H. pylori infection was diagnosed by endoscopy with biopsy or CLO test.
Thirty patients were excluded due to malignancy or previous antibiotics medication. Two
hundred and eighty patients received standard-dose tripe therapy (Pantoprazole 40 mg twice
a day, amoxicillin 1000 mg twice a day, and clarithromycin 500 mg twice a day), and 170
patients received low-dose triple therapy (Pantoprazole 40 mg twice a day, amoxicillin 750
mg twice a day, and clarithromycin 250mg twice a day). Eradication was confirmed by Urea
Breath Test 1 month after medication Results : The two groups had no significant difference
in baseline clinical characteristics. The H. pylori eradication rate was 77.5% (217 patients)
in standard-dose triple therapy group, and 74.7% (127 patients) in low-dose triple therapy
group. There was no significant difference in H. pylori eradication rate between two groups.
(p=0.257) The adverse events were significantly more frequent in those who received stand-
ard-dose triple therapy, but all the adverse events were mild symptoms. Each 1 patient
discontinued medication because of adverse event in both group. Conclusions : The efficacy
of low-dose triple therapy is similar to standard-dose triple therapy, and the adverse events
are less frequent. This suggests that low-dose triple therapy would be preferred considering
cost-benefit and low drug adverse events.
T2061
Efficacy and Safety of RE-Treatment with Quadruple Regimen in Patients with
Helicobacter pylori Infection After Failure of Second Line Quadruple Therapy
Sung woo Jung, Sang woo Lee, Ja seol Koo, Hyung joon Yim, Jong jae Park, Hoon jai
Chun, Hong sik Lee, Jai hyun Choi, Chang duck Kim, Ho sang Ryu
Backgrounds/Aims: A quadruple therapy based on proton pump inhibitor, bismuth, tetracyc-
line and metronidazole is frequently accepted as a standard second line therapy for Helicob-
acter pylori (H. pylori) infection, achieving the eradication rate of about 80% in Korea.
Currently, a standard regimen for third line therapy is not established and various protocols
have been proposed. We performed this study to evaluate the efficacy and safety of re-
treatment with quadruple therapy before third-line treatment with new drugs. Methods:
Two hundred twenty patients were treated by a second line quadruple therapy (PBMT;
omeprazole or esomeprazole, bismuth, metronidazole and tetracycline) in our center from
January 2002 through September 2006. Out of 220 patients, 33 patients were reported with
treatment failure and these patients were eligible for this study. Eradication of H. pylori was
assessed by repeated endoscopy or 13C-urea breath test 4 weeks after therapy. The patients
with treatment failure were retreated with PBMT for two weeks and were reevaluated for
efficacy and safety of the treatment. Results: The eradication rate of 2nd line PBMT therapy
was 85% (187/220). Out of 33 patients who failed to eradicate H. pylori in initial 2nd line
PBMT therapy, 18 patients were retreated with the same PBMT regimen and 15 patients
were excluded from the study either due to patients' refusal or loss of follow-up. Out of 18
patients who were retreated, 2 patients were lost during the follow-up and were excluded
from final evaluation. The eradication rate of the re-treatment was 87.5% (14/16) with only
mild adverse events being observed in 5 patients. All of these patients completed the re-
treatment. Conclusions: Re-treatment with quadruple therapy before the 3rd line therapy
may be an effective and safe option in patients with treatment failure after the 2nd line
quadruple therapy.
T2062
Regional Difference in the Recovery of Gastric Acid Secretion After H. pylori
Eradication: Long-Term Evaluations with Congo-Red Chromoendoscopy
Katsunori Iijima, Hitoshi Sekine, Tomoyuki Koike, Yasuhiko Abe, Akira Imatani, Shuichi
Ohara, Tooru Shimosegawa
We recently reported changes in the distribution of acid-secreting mucosa following H. pylori
(HP) eradication with Congo red chromoendoscopy which is capable of visualizing the acid-
secreting fundic mucosa by means of a pH-dependent color reaction (GIE 2006). In that,
in patients with fundic atrophy, the area of the acid-secreting mucosa increased by 1 month
after eradication, and further increased by 7 months. However, the expansion of acid-
secreting mucosa following eradication remained incomplete at that time. The aim of this
study is to clarify the change in acid secreting area after eradication in a long-term follow-
up over 2 years. Methods. Twenty-three (17 men) HP-positive patients with fundic atrophy
(mean age: 62 y.o.) received eradication therapy and each patient underwent Congo red
chromoendoscopy with histological evaluation of biopsy specimens prior to, 1 months, 7
months, and finally more than 2 years after eradication. The mean observation period
was 61 months (range 28 - 101). The areas of the acid-secreting mucosa were evaluated
semiquantitatively as recent reported (GIE 2006). Two gastric biopsy specimens were taken
in the fundus from the acid-secreting and non-acid secreting areas within 2 cm of the
boundary between two areas, and were subjected to histologic evaluation using the Updated
Sydney system and immunohistochemistry for Ki-67 as proliferation index. Result. After
gradual increase in acid-secreting areas up to 7 months after eradication, the acid-secreting
areas further increased in 74% subjects between 7 months and final observation. However,
there still existed various degrees of non-acid-secreting mucosa in the fundic area in all
subjects, indicating that the expansion of acid-secreting mucosa following eradication
remained partial. Compared with acid-secreting area, non-acid secreting area was character-
ized histologically by higher degrees of residual inflammation, mucosal atrophy, and intestinal
metaplasia. Non-acid-secreting area was also characterized by sustained increase in prolifera-
tion compared with the counterpart (Ki-67 labeling index: 33.5±8.5 vs. 17.1±10.3, P<0.01).
Conclusion. Functionally irreversible gastric mucosa (non-acid secreting area) after HP
eradication was associated with both residual premalignalt condition such as intestinal
metaplasia and sustained increase in epithelial cell proliferation, suggesting that such mucosa
still possesses malignant potentials. There are sporadic cases of gastric cancer even after
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successful eradication. Congo red chromoendoscopy may be useful for determining the site-
specific susceptibility to the development of gastric cancer following successful HP eradica-
tion.
T2063
Effect of Cyp2c19 Polymorphism On the Eradication Rate of Helicobacter
pylori Infection By Pantoprazole Or Esomeprazole Based Triple Therapy in
Korea
Jung mook Kang, Nayoung Kim, Joo sung Kim, Hyun chae Jung, In sung Song
Background: It has been suggested that differences of Helicobcter pylori eradication rates
by proton pump inhibitor (PPI)-based triple therapy could be originated from CYP2C19
polymorphisms. We investigated whether CYP2C19 genotype status could affect on the
eradication rate of Helicobcter pylori infection by Pantoprazole- or Esomeprazole-based
triple therapy. Methods: A total of 200 patients infected with H. pylori were randomly treated
with either pantoprazole (40 mg b.d.) or esomeprazole (20 mg b.d.), plus amoxicillin (1000
mg b.d.) and clarithromycin (500mg b.d.) for 7 days. The CYP2C19 genotype was determined
by pyrosequencing method. H. pylori eradication was evaluated by C13-urea breath test 4
weeks after completion of treatment. Endoscopic biopsies of gastric antrum and body were
taken to assess the grade of atrophic gastritis and intestinal metaplasia before triple therapy.
In addition, serum pepsinogen I and II levels were checked by latex agglutination method
before triple therapy. Results: Overall eradication rate was 82% for pantoprazole-amoxicillin-
clarithromycin (PAC), not different from the 89.4% for esomeprazole-amoxicillin-clarithro-
mycin (EAC). The frequencies of homozygous extensive metabolizer (HomEM), heterozygous
extensive metabolizer (HetEM) and poor metabolizer (PM) groups were 45.5%, 43.5% and
11.0%, respectively. When the effect of CYP2C19 genotype of HomEM, HetEM and PM on
the eradication of H. pylori was analyzed the eradication rates were 85.7%, 83.9% and 81.8%
in the PAC regimen, and 100%, 86% and 90% in the EAC regimen, respectively. In
addition, the eradication was different according to the intestinal metaplasia (IM). That is,
the eradication rate in the absence of corpus IM was 87.2%, higher than that in the presence
of IM, 77.6% (P = 0.08). However, there was no significant differences either in the level
of serum pepsinogen I, II levels and PG I/PG II ratios or atrophic gastritis between the
eradicated and non-eradicated group. Conclusion: Gastric acidity might not be a critical
factor for the successful eradication of H. pylori. Marginal inhibitory effect of intestinal
metaplasia in the corpus might be related with some other factor rather than with acid secre-
tion.
T2064
The Current Antimicrobial Resistance of Helicobacter pylori in Korea
Jae G. Kim, Young H. Seo, Ki S. Kim, Jeong W. Kim, Sill M. Park
Background and Aims: The resistance of Helicobacter pylori to antimicrobials is an important
factor compromising the efficacy of eradication therapy. It is known to be increasing in
many countries. Therefore, the aim of this study is to analyze the current susceptibility
status of H. pylori in Korea. Materials and Methods: 181 strains of H. pylori were isolated
from 141 subjects that had not received antibiotics, proton pump inhibitor, or nonsteroid
anti-inflammatory drugs during preceding three months between January 2005 and July
2006 in Chungang University Yongsan Hospital. The MIC values of H. pylori isolates to the
antibiotics were determined using the serial two-fold agar dilution method. ATCC 43504
was used as standard strain. The resistance breakpoints for amoxicillin, metronidazole, and
tetracycline were defined as > 0.5, >8, and >4 µg/mL, respectively. The resistance breakpoints
for clarithromycin, ciprofloxacin, and moxifloxacin were defined as >1.0 µg/mL. Results:
Prevalence of H. pylori resistance to clarithromycin, metronidazole, amoxicillin, tetracycline,
ciprofloxacin, and moxifloxacin were 8.8% (16/181), 36.5% (66/181), 7.7% (14/181), 0%
(0/181), 16.6% (30/181), and 13.3% (24/181). Thirty-five out of 181 (19.3%) strains showed
multi-drug resistance. The most common multi-drug resistance was to metronidazole and
moxifloxacin. Heteroresistance among the two biopsy sites was present in 6 of 141 subjects
(4.3%). Conclusions: The prevalence of clarithromycin resistance of H. pylori is relatively
lower than expected. The PPI-based triple therapy including clarithromycin may be still
effective eradication therapy of H. pylori in Korea. Nation-wide surveillance of antibiotic
resistance should be needed for further evaluation.
T2065
Eradication of Helicobacter pylori for the Prevention of Peptic Ulcer
Rebleeding
Javier P. Gisbert, X. Calvet, F. Feu, F. Bory, A. Cosme, P. Almela, S. Santolaria, R. Arnarez,
M. Castro, N. Fernandez, R. Garcia-gravalos, N. Canete, A. Benages, M. Montoro, F.
Borda, A. Perez-aisa, Jose-maria Pique
AIM: Eradication of H. pylori is associated with a very low rate of ulcer recurrence. Our
purpose was to verify the effect of H. pylori eradication on ulcer bleeding recurrence in a
prospective, long-term study including more than 400 patients. METHODS: Patients with
peptic ulcer bleeding were prospectively included. Prior NSAID use was not considered
exclusion criteria. H. pylori infection was confirmed by rapid urease test, histology or
13C-urea breath test. Several therapies were used, mainly PPI-based regimens. Afterwards,
ranitidine 150 mg o.d. was administered until eradication was confirmed by 13C-urea breath
test 8 weeks after completing eradication therapy. Patients with therapy failure received a
second or third course of therapy. Patients with eradication success did not receive mainten-
ance anti-ulcer therapy, and were controlled yearly with a repeated 13C-urea breath test.
NSAID use was not permitted during follow-up. RESULTS: Four-hundred and twenty-two
patients have been followed up for at least 12 months, with a total of 906 patient-years of
follow-up. Mean age was 59 years, 75% were males, and 35% were previous NSAID users.
Sixty-nine percent had duodenal ulcer, 24% gastric ulcer, and 7% pyloric ulcer. Recurrence
of bleeding was demonstrated in 2 patients at 1 year (incidence: 0.22% per patient-year of
follow up), which occurred after NSAID use in both cases. CONCLUSION: Peptic ulcer
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rebleeding does not occur in patients with complicated ulcers after H. pylori eradication.
Maintenance anti-ulcer (antisecretory) therapy is not necessary if eradication is achieved.
However, NSAID intake may cause rebleeding in H. pylori-eradicated patients.
T2066
Fourth-Line Rescue Therapy in Patients with Three H. pylori Eradication
Failures
Javier P. Gisbert, M. Castro-fernandez, E. Lamas, J. L. Cabriada, L. M. Benito, J. L.
Gisbert, S. Marcos
AIM: In same cases, H. pylori infection persists even after the administration of 3 consecutive
eradication treatments. It is unknown whether a 4th eradication regimen may be effective
and safe in this difficult scenario. Our aim was to evaluate the efficacy and tolerability of a
forth-line rescue regimen (with rifabutin or with levofloxacin) in patients with 3 consecutive
H. pylori eradication failures. METHODS: Twenty-eight patients in whom 3 consecutive H.
pylori eradication treatments had failed were prospectively studied. In all cases, a first
treatment with PPI-clarithromycin-amoxicillin and a second with ranitidine bismuth citrate-
tetracycline-metronidazole had been administered. In 13 patients, a 3rd eradication regimen
with PPI-amoxicillin-rifabutin had been prescribed, and therefore a 4th eradication regimen
with PPI, amoxicillin (1 g b.i.d.) and levofloxacin (500 mg b.i.d.) was prescribed for 10 days.
In the remaining 15 patients, a 3rd eradication regimen with PPI-amoxicillin-levofloxacin had
been prescribed, and therefore a 4th eradication regimen with PPI, amoxicillin (1 g b.i.d.)
and rifabutin (150 mg b.i.d.) was prescribed for 10 days. Antibiotic susceptibility was
unknown and, therefore, rescue regimens were chosen empirically. Eradication was con-
firmed with 13C-urea breath test 4-8 weeks after therapy. RESULTS: Thirteen patients
received a 4th treatment with levofloxacin, and 15 with rifabutin. All patients but one
(receiving rifabutin) completed the follow-up. Compliance in the levofloxacin group was
100%, whereas 2 patients receiving rifabutin did not take correctly the medication (due to
adverse effects: fever, myalgia, abdominal pain and diarrhea in one case, and vomiting in
another). Overall incidence of adverse effects with the 4th rescue treatment was 39% (none
of them were severe): 33% in those treated with rifabutin (including leucopenia in one
patient, and thrombopenia in another one) and 46% in those treated with levofloxacin
(mainly myalgias). Per-protocol and intention-to-treat eradication rates were, respectively,
59% (95% CI, 41-75%) and 57% (95% CI, 39-73%). Corresponding intention-to-treat cure
rates for levofloxacin and rifabutin 4th line regimens were, respectively, 69% and 47%.
CONCLUSION: Even after 3 previous H. pylori eradication failures, an empirical fourth-line
rescue treatment (with levofloxacin or with rifabutin) may be effective to eradicate the
infection in more than 50% of the cases.
T2067
Lactobacillus Casei Dg Effectiveness On Helicobacter pylori Eradication
Treatment-Side Effects; A Placebo- Controlled, Double-Blind Randomized Pilot
Study
Maurizio Giovannone, Fausto Barberani, Sandro Boschetto, Alessandro Gigliozzi, Mauro
Tosoni
BACKGROUND: Helicobacter pylori (HP) plays an important role in chronic active gastritis,
peptic ulcer, gastric cancer and low-grade mucosa associated lymphoid tissue (MALT -
lymphoma) development. Occurrences of antibiotics resistance and/or side effects induce
eradication treatment failure in about 20% of patients. Probiotic supplementation has been
demonstrated to improve patient tolerance. AIM: To investigate effects of probiotic supple-
mentation (Lactobacillus Casei DG - ENTEROLACTIS - Sofar S.p.A.) on the tolerance and
efficacy of HP eradication treatment in a randomized, double-blind, placebo-controlled trial.
METHODS: 60 HP positive patients by the 13C-urea breath test were randomly screened
to receive: a) a standard 7 days week eradication triple therapy with esomeprazole 40 mg.
o.d., clarithromycin 500 mg. b.d. and amoxicillin 1 gr. b.d. supplemented with Lactobacillus
casei DG (16 billions of alive cells) o.d. for 28 days starting from 7 days before the beginning
and finishing 14 days after the end of eradication treatment; b) the same 7 days eradication
therapy supplementedwith placebo o.d. with the same dosage and frequency of the probiotics.
Side effects were assessed using a validated questionnaire and were recorded for 6 week
from the start therapy with probiotics or placebo. RESULTS: No differences in adherence
to treatment or drop out were registered; cumulative HP eradication rate was 72% with no
significative differences in the two groups. No differences were found between the two
groups for diarrhoea, taste modification, oral burning and inappetence. Otherwise the probi-
otic group showed less nausea, bloating and epigastric pain only when evaluated at the end
of eradication week and 7 days after, even if these differences were not statistically significant.
Patient global opinion about eradication treatment tolerability was better in the probiotic
group at the same time points. CONCLUSIONS: In this pilot study, even if probiotic
supplementation did not significantly reduce the frequency of symptoms during HP eradica-
tion, improves nausea, bloating and epigastric pain during and immediately after eradication
treatment. Cumulative HP eradication rate was 72%, showing an increasing clarithromycin-
resistence in Europe, not statistically modified by probiotic supplementation anyway able
to improve patients' compliance.
T2068
Quadruple Therapy Using Esomeprazole, Furazolidone, Amoxicillin-
Clavulanate, and Colloidal Bismuth Subcitrate in Patients Who Failed to
Eradicate H. pylori with Triple Therapy
Zaigham Abbas, Javed Yakoob, Shahab Abid, Wasim Jafri
Introduction: There is an increasing evidence of Helicobacter pylori (H. pylori) resistance to
classical triple therapy consisting of a proton-pump inhibitor (PPI) and clarithromycin with
either amoxicillin or nitroimidazoles. This study is aimed at establishing the efficacy and
safety of a 14-day quadruple regimen to eradicate of H. pylori in patients who have failed
with the classical triple therapy given for 14 days. Methods: The patients were diagnosed
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to have H. pylori infection by any two of these tests: histopathology, rapid urease test, anti-
H. pylori antibody level and urea breath test (UBT). They were given classical triple therapy
for 14 days. The patients who failed to respond to triple therapy as evident from positive
urea breath test (UBT) done 4-6 weeks after the completion of triple therapy were offered
a quadruple regimen, comprising of esomeprazole 40 mg b.i.d, furazolidone 200 mg b.i.d,
amoxicillin-clavulanate 1 gram b.i.d, and colloidal bismuth subcitrate 240 mg b.i.d for 14
days. The patients were evaluated for compliance and drug associated symptoms. To docu-
ment eradication of H. pylori, UBT was repeated 4 weeks after the completion of treatment
with patients off the PPI for at least two weeks. Results: Total number of patients so far
completed this on going study are 17 (male 13), median age 36 years (range 22-67).
Predominant pre-triple therapy presenting symptomwas abdominal pain in 9 (53%), dyspep-
sia 5 (29%) and retrosternal burning 3 (17%). Pre-triple therapy endoscopy was done in
14 patients which showed pangastric erythema in 9 and antral erythema in 5 patients.
Associated gastric ulcer and duodenal erosions were present in one each. All the patients
tolerated the quadruple therapy well and completed the 14 day regimen. H. pylori infection
was eradicated in 15 patients (88%) as documented by negative UBT. Side effects with this
therapy were mild which included nausea and altered color of stools, each observed in 13
(76%) patients. Conclusions: This new quadruple regimen represents a suitable rescue
therapy for H. pylori eradication.
T2069
Pharmacogenetics of Cytochrome P450 (Cyp2c19) in the Eradication of H.
pylori in North Indians
Rakesh Kochhar, Amarjit Singh, Krishan Kohli
Aims: Genetic polymorphism of CYP2C19 has been shown to play a role in the eradication
of H. pylori in various ethnic groups. Since no studies on this aspect were available in the
Indian population, the present research work was envisioned. Methods: Two hundred North
Indian patients consisting of 91 H. pylori positive and 109 H. pylori negative gastritis were
phenotyped for CYP2C19 by high performance liquid chromatography and genotyped for
CYP2C19*2 to *8 mutant alleles by polymerase chain reaction-restriction fragment length
polymorphism. Initial eradication therapy for all patients consisted of 20 mg omeprazole
(OPZ) (bid), 750 mg amoxicillin (AMC) (bid) and 500 mg tinidazole (TNZ) (bid) for 7
days. Noneradicated extensive metabolizers (EMs) were retreated with dual therapy consisting
of 40 mg OPZ (bid) and 500 mg AMC (qid) for 14 days whereas noneradicated poor
metabolizer (PM) was retreated with 20 mg OPZ (bid) and 500 mg AMC (qid) for 14 days.
Results: Significant difference (p<0.01) was observed in 5-OH-OPZ excreted in 8 h by EMs
and PMs viz., 4.84 and 0.71 mmol, respectively. Mean % dose of OPZ excreted as 5-OH-
OPZ in 8 h by PMs viz., 1.22 mmol was 6.8 fold decreased compared to EMs viz., 8.36
mmol. Mean log hydroxylation index values in EMs and PMs were 1.1 and 1.9, respectively.
After initial triple therapy, EMs and PMs demonstrated 37% and 92% eradication of H.
pylori, respectively. Noneradicated EMs retreated with 40 mg OPZ (bid) and 500 mg AMC
(qid) for 14 days demonstrated 90% eradication of H. pylori. The sole noneradicated PM
retreated with 20 mg OPZ (bid) and 500 mg AMC (qid) for 14 days demonstrated eradication
of H. pylori. Conclusion: The present study demonstrated a direct correlation between
pharmacogenetics of CYP2C19 and eradication of H. pylori in North Indian patients. EMs
have to be treated with higher doses of OPZ and AMC and for longer duration to achieve
90% eradication of H. pylori compared to PMs. Results warrant personalized anti H. pylori
therapy and shall help in better management of patients with gastritis, gastric ulcers and
duodenal ulcers.
T2070
Does Pretreatment with Lansoprasole Influence the Eradication Rate of
Helicobacter pylori and Quality of Life?
Masafumi Inoue, Hiroyuki Okada, Ryuta Takenaka, Daisuke Tanioka, Takao Tsuzuki,
Satoru Yagi, Yoshiro Kawahara, Seiji Kawano, Keisuke Hori, Kosaku Sakaguchi, Shinichiro
Hori, Masaki Wato, Masatsugu Miyoshi, Toshihumi Yoshioka, Yasuhiro Onishi, Masahiro
Takatani, Tatsuya Toyokawa
Background: Our aim was to assert whether pretreatment with proton pump inhibitor
followed byHelicobacter pylori (HP) eradication regimen (amoxicillin/ clarithromycin/ lansop-
rasole) recommended in Japan influences the eradication rate and patients' quality of life
(QOL). Materials andMethods: In this prospective multi-center controlled study, 114 patients
having gastric and/or duodenal ulcer detected by endoscopy and HP infection proved by
urease activity, histological examination, or culture of the gastric mucosa biopsies were
enrolled in this study. All patients were randomly assigned to two groups. The patients in
Group A (n=57) received lansoprasole 30 mg once daily for 4 weeks before administration
of lansoprasole 30 mg, amoxicillin 750 mg, and clarithromycin 200 mg twice daily for one
week. Those of Group B (n=57) received the same eradication therapy as group A and then
lansoprasole 30 mg once daily for 4 weeks. At least four weeks after completing the treatment,
the cure of infection was evaluated by the urea breath test, histological examination, and
culture of the gastric mucosa biopsies. To assess the patients' QOL, a questionnaire of
Gastrointestinal Symptom Rating Scale (GSRS) was used four times per patient. Results: In
an intention-to-treat analysis, the cure rates were 79% (45/57 patients) (95% CI; 68-90%)
in group A, and 74% (42/57 patients) (95% CI; 62-85%) in group B. In a per-protocol
analysis, the cure rates were 83% (45/54 patients) (95% CI; 73-93%) in group A and 86%
(42/48 patients) (95%CI; 78-92%) in group B. In this GSRS analysis, there were no significant
differences between group A and group B before the initial treatment, and during assessment
of eradication. In both groups, a significant improvement of GSRS score was observed after
treatment (group A; p=<0.001, group B; p=<0.001). Conclusions: In the HP eradication
with amoxicillin, clarithromycin and lansoprasole, pretreatment with lansoprasole did not
influence the cure rates. Successful eradication improved the patients' QOL greatly, but this
QOL did not improve despite pretreatment with lansoprasole.
T2071
Changing Pattern of Antibiotic Resistance of Helicobacter pylori in Korean
Patients with Peptic Ulcer Disease
So young Bang, Dong soo Han, Tae yeob Kim, Chang soo Eun, Yong cheol Jeon, Jung
oak Kang
Background. Antibiotic resistance of Helicobacter pylori (H. pylori) is a significant clinical
problem because it reduces the efficacy of eradication therapy. The aim of this study was
to assess the changing pattern of antibiotic resistance of H. pylori strains in peptic ulcer
patients, and the eradication rates of antibiotic resistant H. pylori strains, and to detect the
mutation foci of clarithromycin-resistance strains. Methods. 144 H. pylori isolates obtained
from 466 patients with peptic ulcer disease in Korea between January 2001 and December
2005 were tested for antimicrobial resistance. The minimum inhibitory concentrations (MIC)
for metronidazole, clarithromycin and amoxicillin were determined by the broth microdilu-
tion and E- test method. To detect H. pylori 23S rRNA mutations, polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) was performed. Results. Resistance
rates to metronidazole and clarithromycin were detected in 48.6% and 16.7% of patients,
respectively between January 2001 and December 2005. Amoxicillin-resistantH. pylori strains
was 11.8% over the past 5 years. Multi-drug resistance rate of H. pylori was 16.7%. The
success rates of clarithromycin-containing triple therapies is low (7.8%) for clarithromycin-
resistant strains. Among clarithromycin-resistant H. pylori strains, mutation at position 2143
(A2143G) in the 23S rRNA gene by PCR-RFLP method was common. Mutation at position
2182 (T2182C) was also noted and showed a tendency of higher levels of MIC to clarithromy-
cin than the A2143Gmutants. Conclusions. In Korea, clarithromycin and amoxicillin resistant
H. pylori strains have been increased significantly over the 5-year period. There was an
increasing tendency for the emergence of strains with multi-drug resistance. The increase
in resistance to clarithromycin results in a decrease in eradication efficacy for H. pylori.
Many of the clarithromycin-resistant strains possessed the A2143G mutation.
T2072
Low Serum Pepsinogen I/II Ratio Is a Risk Factor of Obesity and
Gastroesophageal Reflux Disease After CURE of Helicobacter pylori Infection
Hiroyuki Suto, Takashi Ohno, Shinsuke Matsunaga, Ryuho Masaki, Tomoko Inagaki,
Masahiro Ohtani, Soshoku Lee, Yoshiyuki Ito, Yukinao Yamazaki, Masaru Kuriyama,
Takuji Kato, Takeshi Azuma
Background and aims: Recently some reported that the eradication of H. pylori induces an
increase in the body mass index (BMI) or it improves abdominal symptoms. However the
relationships between the eradication and the change in the BMI or the symptoms are still
controversial. We investigated the relationships between the change in the BMI or abdominal
symptoms after the eradication ofH. pylori and the serum pepsinogen (PG) I/II ratio. Methods:
One hundred and ninety five H. pylori positive patients with atrophic gastritis were chosen
from subjects who visited multiphase health testing services and they underwent the eradica-
tion therapy for H. pylori. Cure of H. pylori infection was evaluated with 13C-urea breath
test 3 month after treatment. They were examined the relationship between the effect of
infection cure in terms of the BMI or abdominal symptoms and the serum PG I/II ratio
before treatment. All these employees were investigated the BMI and abdominal symptoms
before and 1 year after treatment. A standardized questionnaire was used to assess seven
abdominal symptoms; epigastric pain, heartburn, regurgitation, nausea, vomiting, upper
abdominal fullness and appetite loss. The intensity of respective symptoms was scored as
0 (absent), 1 (mild intensity), 2 (moderate intensity) or 3 (severe intensity). The BMI changes
were calculated by subtracting the BMI before treatment from that after treatment. Results:
The serum PG I/II ratio was classified into three groups; group A was PG I/II<2, group B
was 2≦PG I/II<3 and group C was 3≦PG I/II. The BMI changes (kg/m2) in 1 year after
treatment in the groups A, B and C were 0.78±0.67, 0.16±0.66 and 0.04±0.71, respectively.
The mean BMI change in the group A was significantly higher than those in the groups B
and C (p<0.01). There was the negative correlation between the serum PG I/II ratio and
the change in the BMI in 1 year after treatment (p<0.01). Heartburn was significantly
exacerbated in the group A, however it significantly improved in the group C after treatment.
Epigastric pain, regurgitation, nausea and vomiting significantly improved in the group C
after treatment. The increase of BMI and the exacerbation of heartburn were observed in
the group A, while the improvement of several symptoms was observed in group C. Conclu-
sions: Low serum pepsinogen I/II ratio is a risk factor of obesity and gastroesophageal reflux
disease after the cure of Helicobacter pylori infection.
T2073
Experience with High-Dose and Standard-Dose Levofloxacin-Based Therapy of
Helicobacter pylori Infection with Known Antimicrobial Susceptibility Pattern
Ahmed Madisch, Christine Hänel, Andrea Morgner, Elke Bästlein, Wulf Schneider-
brachert, Christian Haferland, Manfred Stolte, Norbert Lehn, Stephan Miehlke
Background & Aim: Levofloxacin-based triple therapy has been proven superior to quad-
ruple-therapy for rescue treatment of H. pylori infection. The aim of this study was to
compare the efficacy and tolerability of high-dose versus standard-dose levofloxacin-based
triple therapy in patients with known antimicrobial susceptibility pattern. Patients &
Methods: Consecutive patients (mean age 47 years, range 23-70 years; 24 female) with an
indication for anti-H. pylori treatment according to the 2/2000 Maastricht guide lines and
documented antibiotic sensitivity (E-Test) received either esomeprazole 2x40mg, levofloxacin
2x500mg, and amoxycillin 2x1g for 7 days (high-dose ELA, n=23), or esomeprazole 2x20mg,
levofloxacin 1x500mg and amoxycillin 2x1g for 7 days (standard-dose ELA, n=23). Check
of eradication was performed 4 to 6 weeks after the end of therapy. Results: Pretreatment
resistance to metronidazole, clarithromicin and levofloxacin and amoxicillin resistance was
present in 63%, 28%, 2 %, 0 %. Twenty patients of the high-dose ELA group (95,2%, 95
CI: 76-99%; ITT 86,9% 95% CI:66-97%) and 16 patients (72,2 %, 95 % CI: 49-89 %; ITT
69,5 95%CI:47-86) of the standard-dose ELA group becameH. pylori-negative.Minor adverse
events occurred in 52.2% and 43.5%, respectively. No patient discontinued prematurely due
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to adverse events. None of the patients who failed H. pylori eradication therapy developed
a levofloxacin resistance. Conclusion: This pilot study suggest that the high dose levofloxacin-
containing 7-day triple therapy might be more effective than the standard dose. The results
have to be confirmed by a larger randomized trial.
T2074
Levofloxacin- Vs. Ranitidine Bismuth Citrate-Based Second-Line Therapy After
H. pylori Treatment Failure
Javier P. Gisbert, Jose-luis Gisbert, Santiago Marcos, Ines D. Pousa, Marta Velasco, Marta
Luna, Ricardo Moreno-otero, Jose-maria Pajares
AIM: Ranitidine bismuth citrate and levofloxacin-based second-line regimen may be an
alternative to quadruple therapy after H. pylori eradication failure. Our aim was to compare
two seven-day triple second-line regimens based on ranitidine bismuth citrate or levofloxacin.
METHODS: Patients in whom a first eradication trial with omeprazole-clarithromycin-amox-
icillin had failed were randomized to receive 7 day treatment with: 1) ranitidine bismuth
citrate (400 mg b.i.d.), tetracycline (500 mg q.i.d.), and metronidazole (250 mg q.i.d.), or
2) levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.) and omeprazole (20 mg b.i.d.). Cure
rates were evaluated by 13C-urea breath test. RESULTS:One-hundred patients were included:
50 received the ranitidine bismuth citrate regimen, and 50 the levofloxacin one. Groups
were comparable in terms of demographic variables. Two percent of the patients (one in
each group) did not return for follow-up. Compliance was similar in both groups (90%
took all the medications correctly). Side effects (only mild/moderate) in the two groups were
also comparable (38% with ranitidine bismuth citrate and 36% with levofloxacin). Per-
protocol cure rates were 69% (95%CI=54-80%) in the ranitidine bismuth citrate group, and
71% (57-82%) in the levofloxacin one. Intention-to-treat cure rates were, respectively, 68%
(59-79%) and 68% (59-79%) (non-statistically significant differences). CONCLUSION: Both
7-day ranitidine bismuth citrate- and levofloxacin-based second-line regimens represent
alternatives to quadruple therapy in patients with previous omeprazole-clarithromycin-
amoxicillin failure.
T2075
Follow-Up After Helicobacter pylori Eradication in Adolescents with Iron
Deficiency Anemia
Yoshiko Nakayama, Akira Horiuchi, Hoda M. Malaty
Background: It is known that lactoferrin serves as a source of iron for Helicobacter pylori
(HP) in gastric mucosa. Clinical and epidemiological studies suggest that infection with HP
infection is associated with iron deficiency and iron deficiency anemia (IDA). Aim: We
investigated the long term effect of HP eradication therapy on the iron status following
treatment of IDA in adolescents. Methods: From July 2002 to October 2005, adolescents
identified with IDA at routine school testing were studied. IDA was defined based on
hemoglobin and serum ferritin levels. Hp infection was diagnosed by 13C-UBT, HpSA and
serum IgG antibody. In HP positive patients, upper GI endoscopy was performed and biopsy
specimens were taken from the antrum, angulus, lower corpus lesser curvature, and upper
corpus greater curvature to evaluate histopathology. IDA patients were treated with oral
iron supplements for three months. Hp positive patients were treated with by anti-HP
therapy and followed-up to assess the HP and IDA status. Results: Forty three adolescents
(ages 8 to 17, 63% girls) were diagnosed with IDA; 23 were Hp positive (23/43; 53%). Hp
was positive in 8 of 16 boys (50%) and 15 of 27 girls (56%). All Hp positive and negative
patients showed good response to oral iron supplements. EGD was performed in all Hp
positive patients. All of them had pangastirits accompanied with Hp and two had duodenal
ulcers. Hp was successfully eradicated in 18 of 23 Hp infected patients. The mean follow-
up period after eradication therapy was 16 months (range 2 to 36 months) for boys and
12 months (range 2 to 33 months) for girls. Hemoglobin and ferritin levels remained in
the normal range for boys (14.9 ± 0.98 g/dl and 44.8 ± 37.9 ng/ml, respectively), they were
at the lower level among girls (12.1 ± 1.7 g/dl and 5.1 ± 2.7 ng/ml, respectively). Among
girls, IDA has relapsed in 5 patients, 2 of them relapsed 2months later of eradication therapy,
and iron deficiency (serum ferritin <10 ng/ml) was observed in other 4 patients although
Hp had been successfully eradicated.. Conclusion: Hp-related IDA occurs in both boys and
girls. Eradication of Hp prevented recurrent IDA among all boys but as girls remain prone
to other causes of IDA especially hyper-menorrhea, follow-up is recommended.
T2076
Efficacy of One Week Triple Therapies (Contain: Pantoprazole Or Ranitidin
Bismuth Citrate and Clarithromycin with Amoxicillin Or Tinidazole )for
Eradication of Helicobacter pylori
Alajos Takats, Gabor Egri, Janos Novak, Zoltan Csiki, Pal Demeter, Peter Kupcsulik
Aim:The present randomised study was conducted to evaluate the effi-cacy and tolerability
of the “one week triple therapy”(containing in the group 1[PCA]: pantoprazole [PAN]40
mg bid, clarithromycin[CLA]500 mg bid, amoxicillin[AMO]1000 mg bid., in the group 2
[PCT]:PAN40mg bid, CLA500 mg bid, tinidazole[TIN]500 mg bid., in the group 3 [RBCCA]:
ranitidin bismuth citrate [RBC] 400 mg bid, CLA 500 mg bid, AMO 1000 mg bid, in group
4 [RBCCT1]: RBC 400 mg bid, CLA 500 mg bid, TIN 500 mg bid and in group 5 [RCCT2]:
RBC 400 mg bid, CLA 250 mg bid, TIN 500mg bid) for eradication of Helicobacter pylori
[HP]. Methods:61 patients [PTS] (PCA), 44 PTS (PCT), 46 PTS (RBCCA), 41 PTS (RBCCT1)
and 37 PTS (RBCCT2) were recruited, who were suffering from peptic ulcers [PUs] associated
with HP infection proven by histology and/or culture.PTS were endoscopically reinvestig-
ated in 4 weeks after the end of eradication therapy including the assessment of the HP
status by means of culture and histology. We assessed in all groups the healing rate of the
PU, the tolerability of the TR. Results: In PCA 57 out of 61 PTS (25 male, 32 female, mean
age 49,5 years, 26 smokers), in PCT 42 out of 44 PTS (18 male, 24 female, mean age 50.5
years, 20 smokers), in RBCCA 44 out of 46 PTS (20 male, 24 female, mea age 49,07 years,
17 smokers), in completed the trial. Complete ulcer healing in PCA 20/22 (90,9%), in PCT,
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RBCCA, RBCCT1, RBCCT2 all (15/14/14/13) active PU-PTS. The data of HP eradication in
all groups are shown in the following table (table 1). The both drug regimes were very well
tolerated (only in 4 /PCA/ and 3/PCT/ cases a side effect was observed: diarrhoea, nausea,
distension). Conclusion: The both TR protocols were effective in eradicating HP. The differ-
ence in rate of eradication between the two groups was not significant. The difference of
eradication of HP was significant between the non smokers and smokers in PCA group. In
ulcer groups the rate of eradication was markedly more favourable (95.4 and 86.7%) than
in the gastritis groups (82,9 and 81.8%)
T2077
Lar-14 Levofloxacin Triple Therapy Against Helicobacter pylori Is Successful
As Rescue, Why Not As a First Line? Report of Mexico's Levofloxacin-
Amoxicillin-rabeprazole 2003 Open Prospective Clinical Trial
Antonio A.g.a.f. Orozco-gámiz, Lourdes Barba-villavicencio, Guillermo Juárez-lópez
Background: In Mexico therapies less than 14 days have not been effective, as Bosques et
al reported in Helicobacter 2004;9,417-21, also it is recognized that triple therapy with
clarithromycin, (Clari) amoxicillin (Amoxi) and a PPI is the effective therapy lasting 14 days
to eradicate Helicobacter pylori (HP) with rates of 65-92%. We have a serious rate of resistance
to metronidazole and an increase of resistance to Clari has been documented, so new
treatments looking for low resistance are a need. Levofloxacin (Levo) was included because it
has demonstrated effectiveness against HP in addition that Rabeprazole (Rabe) has bactericidal
effect against HP. Aim: To demonstrate Efficacy, Safety and Tolerability of LAR-14 treatment.
Disclosure and Ethics: There were no support from any health or related company. As an
inclusion criteria a previous informed consent was signed. Materials and Methods: This is
an open prospective clinical trial and studied 60 patients at year 2003, with evidence of
dyspeptic symptoms (Rome II Criteria) and presence of infection of HP confirmed with
both: endoscopy plus histology and C14-urea breath test. The patients took therapy with
Rabe 20 mg. OD Levo 750 mg. OD and Amoxi 1 gram BID for 2 weeks. A month after
finished therapy a quantitative C14 urea breath test was done. Results: The intention to
treat analysis had an eradication rate of 88.3% (53/60) with a CI of +/4.64% (95%CI=84-
93). The Per protocol analysis obtained a 93% (53/57) CI +/-3.6% (95%CI=89-97). Excellent
tolerance of 90% of the patients to the treatment with attachment of 95% during the two
recommended weeks of treatment. 6 reported non serious adverse effect (Headache 3,
diarrhea 2, rash 1) Conclusions: The 14 day triple therapy with Levo+Amoxi+Rabe (LAR-
14) was well tolerated without the obvious side effects of Clarithromycin, with rates per
protocol of eradication higher than 93% making it a very good alternative for the eradication
of HP that has been reported resistant to clarithromycin. Why not use LAR-14 as first line
therapy against HP?
T2078
Helicobacter pylori Infection Is the Main Causal Factor for Developing
Atrophic Corpus Gastritis During the PPI Therapy. - New Findings from the
Recent Animal Experiments
Tadashi Hagiwara, Ken-ichi Mukaisho, Hiroyuki Sugihara, Takanori Hattori
Background: Use of proton pump inhibitors (PPIs) for the treatment of acid peptic disorders
has increased during the past two decades. On the other hand, several adverse effects have
been reported. It has been reported that corpus atrophic gastritis increased after long-term
PPI maintenance therapy in Helicobacter pylori (Hp) -infected patients. Several papers have
reported that PPIs promote gastric carcinogenesis in rats with duodenogastric reflux, and it
is also debated if long-term PPIs therapy may promote esophageal carcinogenesis. Moreover,
the development of fundic gland polyps and various lesions (vacuolar degeneration, pseudo-
hypertrophy, and glandular cysts) was reported related to PPIs. To clarify whether PPIs in
fact induce these adverse effects, especially promotion of atrophic gastritis in Hp-infected
cases, we studied the histological features of gastric mucosa after treatment of omeprazole
(OPZ) in Mongolian gerbils (MGs) with and without Hp infection and Wistar rats. Materials
and Methods: MGs at 2 and 10 months after the infection with H. pylori (ATCC43504) and
those without infection as a control were sacrificed after 4 weeks of subcutaneous administra-
tion of OPZ (10 and 50 mg/kg body weight/day) once daily. In the other experiment using
Wistar rats, rats were provided with OPZ (100 mg/kg body weight/day) containing diet for
1 year according to the method we established recently (Dig Dis Sci, 2007, in press).
Morphological changes in gastric mucosa of each animal were examined by HE staining. In
the experiment of MGs, pathological changes were determined according to the updated
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Sydney system. Serum gastrin level and a wall thickness of fundic mucosa for estimating
atrophy were also studied. Results: In the stomach of MGs infected with H. pylori, without
OPZ administration, corpus gastritis was not detected at 3 months after infection. However,
severe pangastritis was developed at 11 months after infection. The OPZ-administrated MGs
developed atrophic corpus gastritis at 11 months than at 3 months after infection. On the
other hand, in rat models, long-term OPZ therapy caused hypergastrinemia, pancreatic
acinar cell metaplasia and hypertrophy of fundic gland mucosa, but did not develop atrophic
gastritis, intestinal metaplasia or neoplastic lesions. Conclusion: Although long-term PPI
administration causes morphological changes and hypergastrinemia, PPIs seem to be safe
regarding neoplastic development. The main causal factor for developing atrophic corpus
gastritis during the PPI therapy is corpus gastritis induced by H. pylori infection. Therefore,
one has to consider H. pylori eradication when PPI maintenance therapy is needed.
T2079
14-Day Treatment with Clarithromycin, Metronidazole and Amoxicillin for the
Eradication of Helicobacter pylori in Pasto, Colombia
Lori A. Fischbach, Luis eduardo Bravo, Guillermo Zarama rosero, Alba lucy Casabon
ordonez, Tito Collazo, Lorena Guerrero zambrano, Pelayo Correa
Background: Hundreds of trials have tested the efficacy of Helicobacter pylori treatments in
developed countries, while few trials have been conducted in developing countries. The
efficacy of anti-H. pylori regimens in developing countries tends to be low relative to
comparable treatments in developed countries. Thus, there is still a need to find effective
treatment options for the developing world, especially in populations with a high rate of
stomach cancer. Methods: We performed a randomized controlled trial to test the efficacy
of a 14-day triple therapy containing clarithromycin 500 mg bid, metronidazole 500 mg
tid and amoxicillin 500 mg tid (CMA) in subjects from Pasto, Colombia, a population with
a high rate of gastric cancer. We randomized subjects with precancerous lesions to CMA
or the 10-day regimen containing clarithromycin 500 mg bid, amoxicillin 1 gm bid and
omeprazole 20 mg bid (CAO). We also randomized subjects without precancerous lesions
to a 14-day quadruple therapy of CMA plus omeprazole 20 mg bid (CMA-O) or the 10-
day CAO regimen. We only added omeprazole to the group without precancerous lesions
due to the high prevalence of hypochlorhydria observed in subjects with precancerous lesion
in Pasto. Urea breath tests were used to evaluate eradication 4-6 weeks after treatment.
Results: To date, we have randomized, treated and performed post-treatment evaluations in
90 subjects. A total of 4%, 10%, and 23% of subjects withdrew from treatment due to
adverse events during treatment with CAO, CMA, and CMA-O respectively. Using intention-
to-treat analyses, CMA eradicated 90% (95% CI: 73%, 98%) and CAO eradicated 77% (95%
CI: 59%, 90%) ofH. pylori infections in subjects with precancerous lesions; CMA-O eradicated
69% (95% CI: 39%, 91%) and CAO eradicated 88% (95% CI: 62%, 99%) of infections in
subjects without precancerous lesions. Using per-protocol analyses, CMA eradicated 96%
(95% CI: 80%, 100%) and CAO eradicated 80% (95% CI: 61%, 92%) of infections in
subjects with precancerous lesions; CMA-O eradicated 90% (95% CI: 56%, 100%) and CAO
eradicated 93% (95% CI: 68%, 100%) of infections in subjects without precancerous lesions.
Conclusion: In Pasto, Colombia, 14-day triple therapy containing clarithromycin, metronida-
zole, and amoxicillin is efficacious for the eradication ofH pylori in subjects with precancerous
lesions, while 10-day therapy containing clarithromycin, amoxicillin and omeprazole is
efficacious for the eradication ofH pylori in subjects without precancerous lesions. Quadruple
therapy containing clarithromycin, metronidazole, amoxicillin and omeprazole is not well
tolerated in Pasto.
T2080
How Accurate Is Endoscopic Ultrasound for T Staging in Gastric Cancers?: A
Meta-Analysis and Systematic Review
Jyotsna Bk reddy, Srinivas R. Puli, Mainor R. Antillon, John B. Marshall, Jamal A. Ibdah
Background: Prognosis and modality of treatment in patients with gastric cancers depends
on the tumor staging (T staging). The published data on accuracy of Endoscopic Ultrasound
(EUS) for T staging in gastric cancer patients has varied. Aim: To evaluate the accuracy of
EUS for T staging of gastric cancer patients. Method: Study Selection Criteria: Only EUS
studies confirmed by surgery were selected. EUS criteria used for T staging were: T1-tumor
invades the lamina propria or submucosa but does not invade the muscularis propria, T2-
tumor invades but does not extend beyond the muscularis propria, T3-tumor invades the
periesophageal tissues but does not invade adjacent organs, and T4-tumor invades adjacent
structures. Only studies from which a 2 X 2 table could be constructed were included. Data
collection & extraction: Articles were searched in Medline, Pubmed, Ovid journals, CINH,
and Cochrane control trial registry. Two reviewers independently searched and extracted
data. The differences were resolved by mutual agreement. 2 X 2 tables were constructed
from the extracted data. Statistical Method: Meta-analysis for the accuracy of EUS was
analyzed by calculating pooled estimates of sensitivity, specificity, likelihood ratios, and
diagnostic odds ratio. Pooling was conducted by both Mantel-Haenszel method (fixed effects
model) and DerSimonian Laird method (random effects model). The heterogeneity of studies
was tested using Cochran's Q test based upon inverse variance weights. Results: Initial search
identified 1620 reference articles, in which 360 relevant articles were selected and reviewed.
20 studies (N= 1750) which met the inclusion criteria were included in this analysis. Pooled
accuracy data for T staging is shown in table 1. All the pooled estimates calculated by fixed
and random effect models were similar. The p for chi-squared heterogeneity for all the
pooled accuracy estimates was > 0.05. Conclusion: EUS is an accurate imaging modality
for T staging of gastric Ca. EUS performs better with advanced disease than early disease.
If EUS says that a patient has advanced disease i.e. T3 or T4 rather than T2 or T1, the odds
are 500 times higher to have the correct anatomic diagnosis. EUS should be the imaging
modality of choice for T staging of gastric cancers.
Table 1: Shows the accuracy of EUS with confidence intervals to diagnose T stages in gastric
cancer patients
T2081
Fundic Gland Polyp Dysplasia Is Common in Familial Adenomatous Polyposis
Laura K. Bianchi, Ana Bennett, Rocio Lopez, Hasson Hennie, Lisa Laguardia, James
Church, Carol A. Burke
Background: Fundic gland polyps (FGPs) are common in Familial Adenomatous Polyposis
(FAP), but have been considered non-neoplastic. The prevalence of FGP dysplasia has not
been well studied and gastric carcinoma has been reported arising from FGPs in FAP. Aims:
1. To prospectively determine the prevalence of FGPs and FGP dysplasia in FAP by a
systematic biopsy protocol 2. To identify endoscopic or demographic features associated
with FGP dysplasia. Methods: Demographic and medical information including NSAID
use, PPI/H2RA use, and tobacco use were collected from FAP patients undergoing upper
endoscopy. If FGPs detected, size and number were noted and biopsies obtained equally
from three segments of involved mucosa. Biopsies obtained from duodenal and antral polyps,
normal fundic mucosa; antrum to detect H pylori. Stage of duodenal polyposis was assessed.
Results: Study group: 64 subjects: mean age 43.5 (± 12.3) yrs, 52% M. FGPs found in 55
subjects (82.9%). FGP dysplasia: 40% low grade (LGD) 3.6% high grade (HGD), and 7.3%
indefinite. H. pylori infection detected in 50% of subjects without FGPs and 1.8% of subjects
with FGPs (p=0.007). Univariable analysis comparing LGD/HGD to no dysplasia found no
demographic or endoscopic factor significantly associated with dysplasia (P>0.05). Multivari-
able logistic regression analysis was performed: final model included PPI/H2RA use, stage
of duodenal polyposis, antrum histology, number of FGPs, and size of largest polyp. Adjusting
for all factors in the model, subjects who did not use PPI/H2RA were nearly 7 times more
likely to have LGD/HGD (OR 6.96, 95% CI 1.31, 37.10). For every increase in stage of
duodenal polyposis the odds of having LGD/HGD increased significantly (OR 2.1, 95% CI:
1.04, 4.22). Biopsies from only one of three segments of FGPs would have missed dysplasia
in 32-64% of subjects; biopsies from any two of three segments missed dysplasia in 17-
32%. Conclusions: 1. The majority of FAP patients have FGPs and FGP dysplasia is common
in FAP. 2. There is a negative association between FGPs and presence of H pylori. 3.
Dysplasia in FGPs is less common in patients taking PPI/H2RA. 4. In patients with FGPs,
biopsies should be obtained from more than one region of involved mucosa to increase the
rate of dysplasia detection.
T2082
Decreased Expression of the Gastric Trefoil Factor 1-Binding Protein Tfiz1 in
Human Gastric Cancer: Influence of Tumor Histology and Relationship to
Prognosis
Steven F. Moss, Jin-woo Lee, Sabo Edmund, Anna K. Rubin, John Rommel, Bruce R.
Westley, Felicity E. May, Rose Tavares, Murray B. Resnick
Background: Transcriptional profiling of over 20,000 genes in H. pylori-infected human
gastric epithelial cells In Vivo identified the trefoil-binding protein TFIZ1 as the gene whose
expression is the most highly down-regulated in H. pylori-associated gastritis. Expression of
TFIZ1 (also known as GDDR or blottin) is decreased 7-fold after H. pylori eradication. TFIZ1
is bound covalently via a disulphide bond to the gastric tumor suppressor trefoil factor 1
(TFF1) in normal gastric mucosa, and preliminary reports suggest that TFIZ1 mRNA expres-
sion is decreased in gastric cancer. Aim: To examine TFIZ1 and TFF1 protein expression
in gastric adenocarcinoma and to determine their prognostic value.Methods: Tissue microar-
rays were created from paraffin-embedded samples from 155 patients with distal gastric
adenocarcinoma, 65 intestinal subtype and 90 diffuse or mixed subtype. The microarrays
were immunohistochemically stained for TFIZ1 and TFF1 and the expression was correlated
with clinical outcome (Kaplan-Meier survival analysis). The expression of TFIZ1 protein
was also evaluated by western blotting in 10 paired samples of gastric cancer with adjacent
non-neoplastic mucosa. Results: TFIZ1 was moderately to strongly expressed by normal
gastric foveolar epithelium and in areas of intestinal metaplasia. Gastric adenocarcinomas
demonstrated significantly decreased TFIZ1 expression compared to normal gastric mucosa
and intestinal metaplasia. TFIZ1 expression was decreased or absent in 84% of diffuse type
cancers and 51% of intestinal type cancers (p<0.0001, comparing diffuse with intestinal
cancer expression). A marked reduction in TFIZ1 expression was confirmed by western
blot. There was no correlation between TFIZ1 and TFF1 expression in gastric cancer. In
intestinal type cancers, TFIZ1 expression was associated with better prognosis in univariate
analysis (p=0.04), whereas positive TFF1 expression was associated with poor prognosis in
the diffuse subtype (p=0.04). Multivariate analysis adjusting for treatment regimen, revealed
only TFF1 expression and stage to be significant independent predictors of survival (p=
0.004 and p=0.001, respectively). Conclusions: TFIZ1 expression is lost in gastric adenocar-
cinomas, especially in the diffuse subtype, and this loss is associated with shorter overall
survival in the intestinal subtype. Reduced expression of TFIZ1 may be involved in the
association of H. pylori infection with gastric carcinogenesis.
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T2083
The Long-Term Impact of H. pylori Eradication On Gastric Histology: A
Systematic Review and Meta-Analysis
Theodore Rokkas, Dimitrios Pistiolas, Panos Sechopoulos, Ioannis Robotis, Georgios
Margantinis
H. pylori infection is a crucial factor in the multistep carcinogenic process of gastric cancer.
In this process the gastric mucosa evolves through the stages of acute gastritis, chronic
gastritis, gastric atrophy (GA) and intestinal metaplasia (IM) before developing gastric cancer.
It is of fundamental importance therefore to answer the question of whether histological
lesions are reversible , because if this is the case, then therapeutic intervention may be
possible. Aims: The main aim of this study was to systematically review the H. pylori
eradication long-term effects on gastric histology (i.e., effects on GA and IM for both antrum
and corpus) by meta-analyzing all relevant studies. Secondary aims were to investigate the
possible sources of heterogeneity between studies and to look for the existence of publication
bias. Methods: Extensive English language medical literature searches for human studies
were performed through October 2006, using suitable keywords. Pooled estimates [odds
ratio (OR) with 95% confidence intervals (CI)] were obtained using random-effects model.
Heterogeneity between studies was evaluated with the Cochran Q test whereas the likelihood
of publication bias was assessed by constructing funnel plots. Their symmetry was estimated
by the Begg and Mazumdar adjusted rank correlation test. Results: For antrum GA the
pooled OR with 95% CI were 0.554 (0.372-0.825) with test for overall effect Z= -2.91 and
p=0.004. The heterogeneity Q value was 14.83, I2= 59.55, p=0.022. There was no publication
bias (Begg and Mazumdar p two tailed value 0.133). For corpus GA the pooled OR was
0.178 (0.072-0.442), Z= -3.72, p<0.001. The respective heterogeneity Q value was 41.237,
I2= 87.87, p<0.001. There was no publication bias (p=0.133). For antrum IM the pooled
OR was 0.842 (0.650-1.092), Z= -1.296, p=0.198. The heterogeneity Q value was 8.101,
I2=13.587, p=0.324. There was no publication bias (p=0.386). For corpus IM the pooled
OR was 0.953 (0.716-1.267), Z= -0.332, p=0.740. The respective heterogeneity Q value
was 8.093, I2=13.507, p=0.324. There was no publication bias (p =0.536). Conclusion:
Compared with no eradication, the long-term eradication histology results showed significant
improvement for GA for both antrum and corpus, whereas such an improvement was not
shown for IM at both anatomical sites. It seems that the development of IM in the stomach
is not reversible by H. pylori eradication and represents the “point of no return”. Therefore
efforts should be directed at preventing the development of such a lesion by treating the
infection early in life.
T2084
Overexpression of Notch 1 Signaling Associates with the Tumorigenesis of
Gastric Adenoma and Intestinal Type of Gastric Cancer
Sung pil Hong, Eun kyung Lee, Kyung hwa Park, Tae joo Jeon, Wen Jing, Jeong youp
Park, Seungmin Bang, Seung woo Park, Jae bock Chung, Si young Song
Backgounds Stomach cancer is classified into intestinal type and diffuse type, which show
different prognosis. Recent study shows that diffuse type of gastric cancer is associated with
activation of Hedgehog signaling, but the tumorigenesis of intestinal type of gastric cancer
and its premalignant lesions, gastric adenoma has not been validated. The Notch signaling
pathway is known to regulate cell differentiation and proliferation. Although the expression
of Notch pathway elements has been observed in several solid tumors, it has not yet been
validated in gastric cancer. In this study, we investigated the expression of Notch 1, its
downstream molecules, and ligands in gastric adenoma and carcinoma. Materials and
methods Tissue microarray was made with 180 stomach tissues (18 adenoma, 162 carcin-
oma), which were collected from gastrectomy specimens. Immunostaining was performed
using standard procedure with anti-Notch 1 polyclonal antibody and anti-Hes 1 polyclonal
antibody. The positive expression of Notch 1 and Hes 1 was defined as more than 25% of
cells being stained. RT PCR of Notch 1, Hes 1, and Jagged 1 were performed with standard
method in 9 normal gastricmucosa, 3 gastric adenoma, and 10 carcinoma. Results Immunohi-
stochemical analysis showed that Notch 1 and Hes 1 were not stained in gastric pit cell and
mucus neck cell, and were moderately stained at cytoplasm and nucleus in parietal cell and
goblet cell. The positive expressions of Notch 1 and Hes 1 in gastric adenoma and carcinoma
were noted in 17 (99.4%) and 17 (99.4%) of the 18 cases, and 110 (67.9%) and 122
(75.3%) of the 162 cases, respectively. The positive expressions of Notch 1 and Hes 1 in
intestinal type and diffuse type of gastric carcinoma were noted in 93 (76.9%) and 106
(87.6%) of the 121 cases, and 17 (41.5%) and 16 (39%) of the 41 cases, respectively (p=
0.00). The mRNA level of Notch 1 was elevated in 2/3 (66.7%) adenoma, 4/6 (66.7%)
intestinal type of gastric cancer, and 0/3 (0%) of diffuse type compared to 9 normal gastric
mucosa. The mRNA level of Hes 1 and Jagged 1 was elevated correlated with that of Notch
1. Conclusion Notch 1 and Hes 1 were expressed highly in gastric adenoma and intestinal
type gastric cancer compared to normal gastric mucosa. These data indicated that Notch 1
signaling pathway might be involved in tumorigenesis of intestinal type gastric cancer.
T2085
Differential Expression of Angiogenesis-Related Genes in Human Gastric
Cancers with and Those Without High-Frequency Microsatellite Instability
Nobuki Miyamoto, Hiroyuki Yamamoto, Hiroaki Taniguchi, Chie Miyamoto, Katsuhiko
Nosho, Tadateru Maehata, Yasushi Adachi, Fumio Itoh, Kohzoh Imai, Yasuhisa
Shinomura
Gastric cancers with and those without high-frequency microsatellite instability (MSI-H)
represent distinctive pathways of carcinogenesis. The aim of this study was to clarify if
expression of p53 related genes involved in angiogenesis is differentially regulated between
these cancers. We systematically analyzed the expression of vascular endothelial growth
factor A (VEGFA), fibroblast growth factor 2 (FGF2), thrombospondin 1 (THBS1), and
brain-specific angiogenesis inhibitor 1 (BAI1), and we correlated the results with microvessel
count (MVC), MSI status, p53 mutations, and prostaglandin-endoperoxide synthase 2
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(PTGS2) expression in gastric cancers. Expression of VEGFA in carcinoma cells was immu-
nohistochemically seen in 46% of 200 cases. VEGFA positivity was significantly associated
with higher MVC, vascular invasion, lymph node and distant metastasis, and advanced
tumor stage. FGF2 positivity was significantly associated with poor differentiation, depth of
invasion, and higher MVC. VEGFA and FGF2 positivities and MVC were lower in MSI-H
cancers than in MSI-L or MSS cancers. VEGFA expression was associated with both p53
mutations and PTGS2 expression. Methylation of the THBS1 gene was detected in 6 of 11
cancer cell lines and in 44% of 200 cases. THBS1 methylation was significantly associated
with distal location, vascular invasion, distant metastasis, MSI-H, wild-type p53, and higher
MVC. The prognosis was worst in patients with cancers that were VEGFA-positive and
THBS1 methylation-positive. Gastric cancers with MSI-H were characterized by lower MVC,
low frequency of VEGFA, FGF2, and PTGS2 overexpression, and high frequency of THBS1
methylation. Our results suggest that gastric cancers with and those without MSI-H represent
distinctive pathways of carcinogenesis, including aberrant expression of factors regulating
angiogenesis. The difference may be associated with less aggressive phenotype of these
cancers with MSI-H and affect future molecular targeted therapeutics.
T2086
Gastric Phenotype and GERD Symptoms Indicate Two Distinct Aetiologies of
Cardia Cancer
Mohammad H. Derakhshan, Reza Malekzadeh, Valerie Fyfe, A. Yazdanbod, A. Kazemi, N.
Rakhshani, R. Didehvar, M. Sotoudeh, Kenneth E. Mccoll
BACKGROUND: The gastric cardia is a common site of malignancy but the aetiology of these
tumours and their relationship to non-cardia gastric cancer and oesophageal adenocarcinoma
remain unclear. Non-cardia cancer is strongly associated with atrophic gastritis while oeso-
phageal adenocarcinoma occurs in subjects without atrophy. We have investigated the
relationship between atrophy and cardia cancer comparing it with non-cardia cancer and
oesophageal adenocarcinoma. METHOD AND MATERIALS: 138 patients, including 66
gastric non-cardia cancer, 53 gastric cardia cancer and 19 oesophageal adenocarcinoma and
similar number of age and sex matched controls with normal endoscopy have been studied.
Serum pepsinogen I/II was use as a serologic marker of atrophic gastritis and categorised
to five quintiles. History of gastroesophageal symptoms was incorporated in logistic regression
analysis. RESULTS: The risk of gastric non-cardia cancer progressively increased with decreas-
ing PG I/II quintiles indicating positive association with atrophy. There was a trend for
reduced risk of oesophageal adenocarcinoma with decreasing PG I/II quintiles suggesting
an inverse relationship of the cancer with atrophy. The association of cardia cancer with
atrophy was quadratic in form with the lowest PG I/II quintile (1st) being associated with
significantly increase cancer risk, but a progressive falling risk associated with quintiles 5
to 2. GERD symptoms showed a significant inverse relationship with non-cardia cancer, and
a potent direct association with oesophageal adenocarcinoma, There was a direct relationship
between severe form of GERD symptoms and cardia cancer. CONCLUSION: The positive
association of severe atrophy with cardia cancer indicates some cases being similar to non-
cardia gastric cancer.The relationship with severe GERD indicates other cardia cancers are
similar to oesophageal adenocarcinoma.
T2087
Mcp-1 and Cd40 Ligation Have Synergistic Effects On Tumorangiogenesis Via
Ccr2 Expression Through COX-2 Upregulation in Gastric Cancers
Seiji Futagami, Tetsuro Hiratsuka, Tomotaka Shindo, Tatsuhiko Hamamoto, Nobue Ueki,
Masafumi Kusunoki, Kenji Suzuki, Kazumasa Miyake, Katya Gudis, Taku Tsukui, Choitsu
Sakamoto
Background&Aims:Recent studies have reported that MCP-1, its receptor (CCR2) expression
and CD 40 ligation on mesenchymal cells respectively have important roles in tumor
development. We examined the interaction between MCP-1 and CD40 ligation in mesenchy-
mal cells bordering gastric cancer to determine the effect of these factors on gastric tumor
angiogenesis. Methods: COX-2 and CCR2 mRNA and COX-2 protein expression levels
were evaluated in CD40L-stimulated HUVECs, peripheral macrophages and lamina propria
mononuclear cells (LPMCs) surrounding gastric cancer tissue. VEGF levels in media from
CD40L-stimulated cells were quantified by ELISA. Localizations of MCP-1, CD40L, CD34,
CD40, and CCR2 in 34 gastric cancer tissue specimens were evaluated by immunohistochem-
istry. CD40L, CD40, and MCP-1 mRNA levels in gastric cancer tissues were evaluated by
real-time PCR. Results: COX-2 mRNA and protein expression levels were significantly higher
in CD40L-stimulated cells. MCP-1 stimulation led to significant elevation of CD40 expression
levels. CD40L-stimulated COX-2 significantly elevated VEGF production. MCP-1 had a
synergistic effect on COX-2 and CCR2 mRNA expression levels in CD40L-stimulated cells.
These upregulated CCR2 mRNA expression levels were completely suppressed by NS-398,
a selective COX-2 inhibitor. Exogenous prostaglandin (PG) E2 reversed the inhibition.
CD40L and MCP-1 mRNA levels were significantly higher in poorly-differentiated gastric
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cancers than in H. pylori infected-gastritis. In gastric cancer tissue, a significant correlation
was also seen between microvessels density, and scores for CD40L, MCP-1 and CCR2. In
Vivo, mesenchymal cells at the periphery of gastric cancer tested positive for MCP-1, CD40L,
CD40 and CCR2; with CD40 and COX-2 co-localization. MCP-1 had a synergistic effect
on COX-2 and CCR2 mRNA expression levels in CD40L stimulated-LPMCs of that same
area, without a concomitant synergistic effect on CD40 mRNA expression. Conclusions:
COX-2 expression induced by CD40 engagement in gastric cancer-associated mesenchymal
cells increases VEGF production, upregulates CCR2 expression and thereby appears to be
involved in gastric tumor angiogenesis.
T2088
Menstrual and Reproductive Factors and Gastric Cancer Risk in a Large
Prospective Study of Women
Neal D. Freedman, Wong-ho Chow, Yu-tang Gao, Xiao-ou Shu, Bu-tian Ji, Gong Yang, Jay
H. Lubin, Hong-lan Li, Nathaniel Rothman, Wei Zheng, Christian C. Abnet
Gastric cancer incidence rates are consistently lower in women than men in both high and
low risk regions worldwide. One provocative hypothesis suggests that sex hormones, such
as progesterone and estrogen, protect women against gastric cancer. To help evaluate this
hypothesis, we investigated the associations of menstrual and reproductive factors and gastric
cancer risk in a prospective study of 73, 442 Shanghai women. After more than 455, 562
person-years of follow-up, 154 women were diagnosed with gastric cancer. We calculated
hazard ratios (HR) and 95% confidence intervals (CI) using age adjusted Cox proportional
hazards models. We observed no associations between gastric cancer risk and age of menar-
che, number of live births, number of pregnancies, breast feeding, or oral contraceptive use.
In contrast, we observed associations with age of menopause (HR: 0.80 per five years, 95%
CI: 0.66-0.96), years of fertility (participants with less than 30 years of fertility were at
increased risk relative to those in the referent group (30-36 years of fertility), HR: 1.88,
95% CI: 1.24-2.85), years since menopause (HR: 1.26 per five years, 95% CI: 1.04-1.51),
and intrauterine device use (HR for users: 1.57, 95% CI: 1.06-2.32). These results support
the hypothesis that female hormones play a protective role in gastric cancer risk.
T2089
Overexpression of Sonic Hedgehog in Gastric Adenoma and Intestinal Type
Gastric Cancer and Its Association with Good Prognosis
Tae joo Jeon, Kyung hwa Park, Eun kyung Lee, Jing Wen, Sung pil Hong, Jeong youp
Park, Seungmin Bang, Seung woo Park, Jae bock Chung, Si young Song
Introduction: The Hedgehog (HH) signaling pathway is involved in cell growth and differenti-
ation of embryonic tissue. Recently there are several studies about the role of the HH
signaling pathway in gastrointestinal cancer but there are few studies about the role of Sonic
hedgehog (Shh) in gastric adenoma, intestinal and diffuse type gastric cancer. This study
was to validate the role of Shh in gastric carcinogenesis by analyzing the expression of Shh,
patched (PTCH) and Gli1 in gastric adenoma and carcinoma. In addition, the correlation
between the expression intensity of Shh and clinicopathologic parameters in gastric carcinoma
was investigated. Method: We obtained total 209 (40 adenoma, 45 early gastric cancer
(EGC), 124 advanced gastric cancer (AGC), 124 intestinal type and 41 diffuse type) tissue
specimens from individuals who underwent gastrectomy or endoscopic mucosal resection
of gastric adenoma or carcinoma. From the specimens, tissue microarray was obtained. RT
PCR was performed at each gastric tissues. Immunohistochemical staining was performed
using standard procedures with antibody to Shh, PTCH and Gli1. For evaluation of immu-
nohistochemical staining data, the expression intensity of Shh was subclassified as 0, 1, 2
and 3 which quantified as a percentage of stained cancer cells: 0, <5%; 1, 5~25%; 2, 26~50%;
and 3, > 50%. Positive expression of Shh was defined as more than grade 1. Result: In RT
PCR, the mRNA expression of Shh in gastric adenoma, EGC, and AGC was stronger than
surrounding normal gastric tissues in 3 of 3, 2 of 2 and 6 of 8 cases respectively. The
expression of Shh in RT PCRwas consistent with immunohistochemical staining. The positive
expression of Shh and Gli1 was noted in 90/92.5 % of gastric adenoma, 73.3/77.7 % of
EGC and 62.1/65.3 % of AGC respectively. The expression intensity of Shh was negatively
correlated with tumor differentiation. The immunoreactivity of Shh and Gli1 in intestinal
type gastric cancer (73.4% and 78.2%) were higher than in diffuse type (39.1% and 34.1%).
The expression intensity of Shh was negatively correlated with pTNM stage. According to
stage I, II, III and IV, the expression of Shh and Gli1 was positive in 78.3/84%, 72/76%,
51.1/44.4% and 50/50% respectively. Overall survival rate at 5 years in patients with Shh
positive gastric carcinoma was better than Shh negative gastric carcinoma.(70% vs 40%,
p<0.05) Conclusion: Shh and Gli1 are highly expressed in gastric adenoma and intestinal
type gastric cancer. The expression level of Shh in early stage gastric cancer is higher than
in late stage. The Shh pathway may play a role in gastric adenoma & intestinal type
gastric cancer.
T2090
Lauren Subtyping of Gastric Cardia Cancer Provides Further Evidence of Two
Distinct Aetiologies
Svein Hansen, Stein emil Vollset, Mohammad H. Derakhshan, Valerie Fyfe, Kjetil K.
Melby, Steiner Aase, Egil Jellum, Kenneth E. Mccoll
There are several reports of cardia cancer resembling oesophageal adenocarcinoma in being
negatively associated with H. pylori infection and positively associated with reflux symptoms.
However, there are also reports of a positive association between cardia cancer and serological
evidence of atrophy in H. pylori-positive subjects, suggesting that some cardia cancers are
aetiologically similar to non-cardia gastric cancers. AIM To determine whether cardia cancers
in patients with gastric atrophy have a Lauren histological subtype resembling non-cardia
gastric cancer whereas cardia cancers in subjects without atrophy are predominantly intestinal
in histological subtype resembling oesophageal adenocarcinoma. METHODS AND MAT-
ERIALS We have studied the Lauren histological subtypes of 129 non-cardia cancers and
forty-four cardia cancers and related the histological findings to the serological presence of
gastric atrophy (pepsinogen I/II <2.5). This was performed in a case-control study nested
in Norwegian JANUS cohort. RESULTS The non-cardia gastric cancers were 46% intestinal,
27% diffuse and 24% of mixed histological subtype. In these non-cardia cancers, gastric
atrophy increased the risk of each histological subtype to a similar extent. In the 36 cardia
cancers without serological evidence of gastric atrophy, the major histological subtype was
intestinal (75%) with only 11% being diffuse and 11% mixed (p<0.05). The proportion of
cancers with the intestinal histological subtype was significantly greater in these cardia
cancers without atrophy compared to the non-cardia cancers. In the cardia cancers with
evidence of gastric atrophy, the histological subtype resembled that of the non-cardia cancers
being 38% intestinal, 25% diffuse and 37% mixed. DISCUSSION AND CONCLUSIONS
These findings provide further support for two distinct aetiologies of cardia cancer, one
resembling oesophageal adenocarcinoma occurring in subjects without atrophy and being
predominantly of intestinal histological subtype; The other being similar to non-cardia gastric
cancer being associated with atrophy and with an equal proportion of intestinal and diffuse
histological subtypes. Gastric atrophy and the histological subtype of cardia cancer may
allow division of cardia cancers into those, which are gastric versus oesophageal in origin.
T2091
Sentinel Lymph Node (Sn) Distribution and Setting of Lymphadenectomy in
Gastric Cancer
Sumito Hoshino, Yu Takagi, Yoshiaki Osaka, So Katayanagi, Motoo Shinohara, Hideo
Sudo, Shingo Tachibana, Takeshi Suda, Yasuhiro Hibi, Mana Yoshimura, Takashi Kawai,
Akihiko Tsuchida, Tatsuya Aoki
[Aims] In late years, Sentinel node navigation surgery (SNNS) is performed for breast cancer,
but on the other hand, as for the surgery for gastric cancer, phylogenetic lymphadenectomy
has been still performed as well as gastrectomy. In Japan, verification of Sentinel lymph
node (SN) concept in digestive cancer, gastric cancer in particular, is being pushed forward.
In this study, we inspected distribution of SN and evaluated application to optimal lymphad-
enectomy for gastric cancer. [Patients and Methods] 201 patients who had gastric cancer
in clinical T1/T2N0 (T1 : T2 = 166 : 35 cases) underwent gastrectomy, and lymph node
metastasis was present in 34 patients. SN was identified using RI method or RI and dye
combined method (RI : RI and Dye = 99 : 102 cases). We classified lymph nodes in five
vessel basins such as left gastric artery (l-GA), right gastric artery (r-GA), left gastroepiploic
artery (l-GEA), right gastroepiploic artery (r-GEA) and posterior gastric artery (p-GA). And
we evaluated SN distribution according to tumor location and compared it with phylogenetic
lymphadenectomy extent. [Results] SN was identified in all cases, and the average number
of SN was 5.3. The proper diagnosis rate was 98%, because there were three false negative
cases.We recognizedmacroscopic lymph nodemetastasis in all false negative cases, intraoper-
atively. As for the SN distribution according to tumor locations, all cases (100%) who had
tumor in upper third of the stomach (U area) showed distribution of SN in l-GA basin. SN
was found in l-GA basin in 88% of cases with tumor in middle third of the stomach (M
area). SN distribution in patients with tumor located in lower third of the stomach (L area)
was in r-GEA (75%) and l-GA (66%) basins. SNs were found in over two vessel basins in
31%, 49%, and 54% of cases in U area, M area, and L area respectively. As for the SN
distribution by N category based on Japanese Classification of Gastric Carcinoma, 42% of
cases showed SN in the “Group 2” lymph nodes. [Conclusion] The application of SN concept
was thought with utility for individual setting of lymphadenectomy in gastric cancer.
T2092
GRP-Induced Up-Regulation of Heat Shock Protein Hsp72 Promotes Cd16+/
94+ Natural Killer (NK) Cell Binding to Colon Cancer Cells Resulting in
Tumor Cell Cytolysis
Lauren Taglia, Richard V. Benya
When gastrin releasing peptide (GRP) and its receptor (GRPR) are aberrantly expressed in
the colon post malignant transformation they act as morphogens, promoting the assumption
of a better-differentiated phenotype and retarding metastasis. However, the mechanism
whereby GRP/GRPR attenuates metastasis remains unclear. We previously showed that GRP/
GRPR up-regulate a number of proteins including HSP70 (J Proteome Res 2006; 5: 1460).
Given HSP70's ability to alter tumor immunogenicity, the aim of this study was to identify
the specific member of this family expressed in response to GRPR activation, and determine
its function when present. Using specific antibodies, non-malignant epithelial cells lining
the colon expressed low levels of the constitutive form of HSP70, or Hsc73, in the nucleus;
whereas these cells did not express the inducible form, or Hsp72, in any cellular compartment.
In contrast, human colorectal cancers (CRC) express both forms. However, whereas CRC
cells ubiquitously expressed Hsc73, inducible Hsp72 was expressed only by better-differenti-
ated tumor cells and as a function of GRP/GRPR expression. We previously showed that
human CRC cell lines Caco-2 and HT-29 variably express GRP/GRPR when pre-confluent,
but not when confluent. Hsp72 was expressed in the plasma membrane in GRP/GRPR-
expressing pre-confluent cells but not by confluent cells. Exposing pre-confluent cells to
the GRPR-specific antagonist eliminated Hsp72 expression in GRP/GRPR-expressing pre-
confluent cells. In contrast, antagonist or degree of tumor cell confluence did not alter Hsc73
expression. We previously showed that GRP/GRPR promote tumor cell attachment to the
extracellular matrix as well as motility in the context of remodeling. Hsp72 inhibition did
not alter tumor cell attachment or motility. Because of Hsp72's ability to promote the binding
of immunological cells, we systematically determined the cluster of differentiation (CD)
status of WBC's located in the stroma surrounding Hsp72/GRP/GRPR-positive tumor cells
in resected human CRC. We found that the majority of WBC present were positive for
CD16 and CD94, markers for NK cells. We found that purified CD16+/94+ NK cells bound
avidly to Hsp72-positive Caco-2 cells, promoting rapid tumor cell lysis; and that this effect
was eliminated by pre-incubating with Hsp72 antibody or exposing cells to GRPR-specific
antagonist. Thus GRP/GRPR-mediated up-regulation of Hsp72 promoting NK cell binding
and cytolysis represents a novel mechanism whereby these proteins attenuate metastasis.
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T2093
Chromosomal Abnormalities in Gastric MALT Lymphomas Predictive for
Malignant Progression
Sonia Toracchio, James Luca, Leif Peterson, Hiroyoshi Ota, Tsutomu Katsuyama, Massimo
Rugge, David Graham, Maha m.t. El-zimaity, Hala M. El-zimaity
Background: The chronic lymphoid stimulation caused by H. pylori infection is associated
with the development of both gastric adenocarcinoma and gastric MALT lymphoma. The
molecular basis for the development and progression of gastric MALT lymphoma remains
to be clarified. Aims: To identify the chromosomal abnormalities in gastric MALT lymphomas
using comparative genomic hybridization (CGH) and RNA gene expression using cDNA
microarray. Methods: We investigated gastric biopsies from 81 patients including 20 patients
with high-grade MALT lymphoma, 33 patients with low-grade MALT lymphoma of the
stomach and, 28 patients with chronic gastritis. DNA was extracted from paraffin-embedded
material and tested for chromosomal gains and losses by CGH. mRNA expression was
analyzed using cDNA microarray (Affymetrix X3P chip). Results: Using CGH, chromosomal
aberrations were observed in 18.9% lymphoma cases (10 of 53): 12% (4 of 33) had low-
grade lymphoma and 30% (6 of 20) had high-grade MALT lymphomas. The most frequent
alterations were at chromosomes 1p, 5p, 9q, 13p, and 18q (P < 0.005). We used cDNA
microarray to compare expression profiles between low- and high-grade lymphomas and
identified a number of genes that were differentially expressed. However, only the B-
cell CLL/lymphoma 2 (Bcl-2) pathway was significantly over expressed in the high-grade
lymphoma. Conclusions: Our results suggest that Bcl-2 overexpression predicts a predisposi-
tion for the progression to high grade lymphomas. Bcl-2 is an apoptosis inhibitor localized
on chromosome 18q. It is likely that dysregulated expression of the BCL2 gene interferes
with normal apoptosis (controlled cell death) of B-cell lymphocytes. Acknowledgments: Dr.
Sonia Toracchio was supported by a fellowship from Fondazione Italiana per la Ricerca sul
Cancro (FIRC), Milan, Italy.
T2094
Switch-On of Twist1 Expression During Colorectal Cancer Progression
Luigi Laghi, Paolo Bianchi, Andrea Zecchini, Elisa Cattaneo, Katia Villa, Jacob Sabates-
bellver, Alessandro Repici, Massimo Roncalli, Giancarlo Marra, Alberto Malesci
INTRODUCTION AND AIM. Evidence exists that the genetic background influences colorec-
tal cancer (CRC) metastatic potential, thus CRC with microsatellite instability (MSI) are
considered to have a less metastatic behaviour than microsatellite-stable (MSS) chromo-
somally unstable CRC. In addition, cancer cells can acquire invasive and migratory properties
by activating epithelial-to-mesenchimal transition (EMT). Twist1 is a regulator of human
morphogenesis which is activated in human epithelial malignancies and considered to
participate in EMT. We wanted to assess whether MSI and MSS CRC express Twist1, and
whether the expression eventually correlates with invasive and metastatic disease. MAT-
ERIALS AND METHODS. In the context of a transcriptome analysis, Twist1 mRNA was
investigated in 32 colorectal adenomas and matched normal mucosa, 13 MSS CRC, and 18
CRC cell-lines. In 119 primary CRC (MSS:MSI 94:25; stage I 20:1, stage II 21:15, stage III
29:9, stage IV 24:1) Twist1 expression was studied by immunohistochemistry (expression
scores: -, +, ++). RESULTS. Normalized Twist1 mRNA levels were very low in normal colonic
mucosa (range 0.1-1.9; mean 0.95±0.38), adenomas (range 0.1-1.7; 0.81±0.35), and CRC
cell-lines (range 0.1-8.5; mean 0.98±2.08), but increased by 5-fold in CRC (range 1.5-9.6;
3.6±2.2; p<0.001 vs. other subsets at Mann-Whitney). Twist1 protein was expressed in 55
(58.5%; 50 scored ++) MSS and in 3 (12.5%; 1 scored ++) MSI CRC (p<0.0001). Among
MSS CRC, the rate of ++Twist1 expression increased with the depth of tumor invasion (2/
13 T1, 7/15 T2, 31/50 T3, and 10/16 T4; p=0.015 by Fisher's test), with an OR of 3.5
(95%CI 1.4-8.8; p=0.008) for CRC invading beyond the muscolaris propria. The ++Twist1
pattern was more frequent with advancing MSS cancer stage (5 stage I, 12 stage II, 19 stage
III, and 14 stage IV; p= 0.03), with an OR of 2.3 (95%CI 1.1-5.3, p=0.03) for metastatic
cases. CONCLUSION. During colorectal carcinogenesis Twist1 mRNA increases significantly
with malignat transformation, and this increment is likely due to tumor microenvironment
rather than to clonal alterations, as suggested by the high expression in CRC tissues but
not in cell-lines. However, the type of genetic instability correlates with the ability to express
Twist1, and possibly with EMT activation in MSS but not in MSI CRC, a difference that
can help to explain the reduced metastatic potential of MSI CRC. By contrast, in MSS CRC
the switch to protein expression mirrors tumor invasion and the presence of metastasis,
indicating that Twist1 participates in the progression of most CRC.
T2095
Endoscopic Ultrasound (EUS) Diagnosis of Microscopic Metastasis to Celiac
Ganglia
Michael J. Levy, Mark D. Topazian, Gary L. Keeney, Maurits J. Wiersema, Elizabeth Rajan,
Jonathan E. Clain, Kenneth K. Wang
Background: Preoperative TNM staging of malignancy determines prognosis and guides
patient care. Inspection of surgical specimens and autopsy studies show that cancers can
metastasize to the celiac ganglia providing a source of recurrence and negatively impacting
survival. Until now, preoperative evaluation of the ganglia has not been possible. We recently
noted the ability to visualize and sample celiac ganglia during EUS. We now report the
finding of microscopic metastasis to the celiac ganglia from a variety of tumor types. Aims:
To demonstrate that EUS guided biopsy of celiac ganglia can detect microscopic tumor
spread. Methods: The Mayo Clinic, Rochester EUS database was reviewed to identify all
patients undergoing EUS in whom malignant infiltration of the celiac ganglia was identified.
Results: We identified 8 patients (4 males, 4 females); average age 71 years (range 59-82)
in whom microscopic metastasis to celiac ganglia was discovered by EUS tissue sampling.
The sites and types of the primary tumors included pancreatic adenocarcinoma (n=3),
esophageal adenocarcinoma (n=3), gastric adenocarcinoma (n=1), and non small cell lung
cancer (n=1). Tissue specimens were acquired by trans-gastric EUS FNA (n=7) or EUS TCB
(n=1). Trans-tumoral biopsy was avoided and in none of the cases was there evidence of
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direct tumor extension to the celiac ganglia. A mean of 2.4 (range 1-3) ganglia were identified.
A mean of 2.3 (range 1-3) biopsies was taken from a mean of 1.3 (range 1-2) ganglia. EUS
FNA and TCB produced transient pain during the biopsy and a brief period thereafter.
Specimen review identified malignant cells (positive, n=6; or highly suspicious, n=2) and
neural tissue in the absence of lymphocytes. In 6 (75%) patients, the ganglia were the only
site of distant metastasis identified preoperatively, while in 1 (12.5%) patient, regional
lymphadenopathy was detected and in 1 (12.5%) patient distant lymphadenopathy was
found. The 3 patients with pancreatic cancer had T4, T3, and T1 tumors. Of the 3 patients
with a luminal cancer two had T3 disease and the third patient who had undergone
chemoradiation prior to EUS, had T0 disease at both EUS and surgical resection. For the
patient withNSCLC, the ganglionmetastasis was the only site of distant disease.Conclusions:
Microscopic metastases to celiac ganglia may be demonstrated in patients with a variety of
cancers using EUS-guided sampling. The recognition that we can now inspect and sample
this potential site of metastasis pre-operatively is likely to impact staging, prognosis, clinical
decision making, and patient outcomes. Further study is needed to address these issues.
T2096
Lymphatic Metastasis in Gastric Cancer May Be Influenced By the Local
Angiotensin II System
Stacy Carl-mcgrath, Uwe Lendeckel, Matthias Ebert
Introduction: The main components of the local angiotensin II (AngII) system (LAS), angiot-
ensin-converting enzyme (ACE), and the receptors type 1 (AT1R) and type 2 (AT2R), are
involved in the pathogenesis of a range of cancers, and are up-regulated in gastric cancer.
Our previous investigations have shown that AT1 expression in tumor cells and the insertion/
deletion (I/D) polymorphism of the ACE gene highly significantly and independently correlate
with the development of lymph node metastases, and the combination of ACE polymorphism
status and AT1R expression predicts nodal spread in gastric cancer. The presence and extent
of lymphatic metastasis is the most important independent prognostic risk factor in gastric
cancer, indicating that the LAS in involved in processes important for lymphatic metastasis.
Methods: Using immunohistochemistry, we investigated the expression of ACE, AT1 and
AT2 in lymph node metastases of gastric cancer. Gastric cancer cell lines were evaluated
for the mRNA expression of ACE, AT1, and AT2, and the ACE I/D polymorphism. The effects
of AngII, ACE inhibition (enalapril), and AT1 (olmesartan, valsartan) and AT2 (PD123319)
antagonism on In Vitro cell proliferation and invasion were examined. DNA synthesis was
measured after thymidine incorporation with scintillation counting. As a measure of metabolic
activity, an MTT conversion assay was used. Apoptosis was quantified with a ssDNA ELISA.
The relative proliferation and invasiveness of the cells was determined in a Matrigel invasion
assay. Results: ACE was expressed in 58%, AT1 in 65%, and AT2 in 85% of lymph node
metastases. ACE, but not AT1 and AT2, occasionally exhibited a very localised expression
directly surrounding the lymph follicle. All the gastric cancer cell lines expressed ACE-,
AT1-, and AT2-mRNA. AGS has the DD-genotype associated with higher ACE expression,
but exhibits comparatively low expression of ACE mRNA. AngII promoted proliferation at
low concentrations, but significantly inhibited the proliferation and promoted the invasion
of the cell lines at higher concentrations, and ACE inhibition and AT1 antagonism resulted
in up-regulation of proliferation, which was combined with a significant reduction in the
invasive ability. Inhibition of AT2 also significantly inhibited the extent of invasion. Conclu-
sions: The LAS mediates cell proliferation and invasive ability in gastric cancer cells,
depending on the local AngII concentration, and the balance of AT1/AT2 expression. Since
the levels of ACE and AT1 are associated with lymphatic metastasis, LAS inhibitors and
antagonists may offer novel anti-neoplastic or anti-metaplastic strategies for gastric cancer.
T2097
Pathological Predictors for Lymph Node Metastasis in T1 Colorectal Cancer
Using Immunohistochemical Staining
Akifumi Suzuki, Kazutomo Togashi, Mitsuhiro Nokubi, Yasuyuki Miyakura, Hisanaga
Horie, Hideo Nagai
Background: Recent studies have shown that tumor budding (TB), lymphatic channel involve-
ment (LC-I) and venous involvement (V-I) are useful pathological predictors for lymph node
metastasis (LNM) in T1 colorectal cancer (CRC). However, evaluation of such pathological
predictors is sometimes difficult with haematoxylin and eosin staining. The aim of this study
was to clarify pathological predictors for LNMusing immunohistochemical staining. Methods:
This study was approved by our Institutional Review Board and informed consent was
waived. One hundred and seventeen patients who underwent bowel resection for single T1
CRC from 1990 to 2004 in our institution were enrolled. Patients with synchronous CRC
were excluded from the study. Immunohistochemical staining methods were used to detect
LC-I and TB using the monoclonal antibody D2-40 and anticytokeratin antibody CAM5.2,
respectively. Elastica van Gieson staining was used to identify V-I. Histology was reviewed
by 2 surgeons and 1 pathologist, all were blinded to histologic LNM. TB was assessed
according to the criteria proposed by Ueno H et al. (2004 Gastroenterology); Grade 2
(moderate) and Grade 3 (severe) were defined as positive. LNM in the surgical resection
specimen was the gold standard to which immunohistochemistry was compared. A logistic
regression model was applied to analyze significant risk factors for LNM. Kappa analysis
was performed to evaluate inter-observer variability between the surgeons and the pathologist.
Results: The rate of LNM was 13.7%. Rates of presence of pathologic factors as assessed by
the surgeons were 29.1% for LC-I, 26.5% for V-I and 43.6% for TB. Univariate analysis
demonstrated significant differences in V-I (p<0.001) and TB (p=0.036). Following multivari-
ate analysis, only V-I (p<0.001) remained significantly associated with LNM. Rates for the
pathologist were 32.5% for LCI, 34.2% for VI and 41.9% for TB. Univariate analysis showed
significant differences in LC-I (p=0.009), V-I (p=0.004) and TB (p=0.007). After multivariate
analysis, V-I (p=0.011) alone was significantly associated with LNM. Kappa values were
0.56 for LC-I, 0.50 for V-I and 0.48 for TB. Conclusion: V-I evaluated based on elastica van
Gieson staining is a useful pathological predictor for LNM in T1 CRC. Immunohistochemical
staining and elastica van Gieson staining might reduce the inter-observer variability in
evaluating histology.
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T2098
Elevated Hba1c Is An Independent Predictor of Aggressive Clinical Behavior
in Patients with Colorectal Cancer
Serag Dredar, Byron L. Cryer, Ali Siddiqui, Sergio Huerta
Introduction: The high level of circulating insulin in diabetic patients and the potential
proliferative properties of in insulin as a result of its cross interaction with insulin-growth
factor-I (IGF-I) receptors suggest a proto-oncogenic role on the colonocyte. Aim: The aim
of our study was to determine if poor control of diabetes is associated with aggressive clinical
behavior in patients with colorectal cancer (CRC). Methods: We conducted a retrospective
longitudinal cohort study of type 2 diabetes mellitus (DM2) patients who also had a diagnosis
of CRC. All patients with both diagnoses were included in our study. Hemoglobin A1c
(HbA1c) levels were evaluated as in index of glycemic control over the year that preceded
the diagnosis of colorectal cancer. Factors associated with high levels of HbA1cwere examined
by univariate analysis (UA). Significant variables by UA were included in a multivariate
regression analysis (MVA) model to determine independent predictors of aggressive clinical
behavior. All values are presented as means ± SE, statistic significance was determined at a
p ≤ 0.05. Results: From 1997 to 2001, 156 patients with DM2 and CRC were identified
(mean age 68.8 + 1.1 y.o., 4% Hispanic, 71% Caucasian, 25% African American). Stage of
CRC at diagnosis was stage 1 in 25%(n=39), stage 2 in 30%(n=47), stage 3 in 27%(n=42),
and stage 4 in 18%(n=28). The mean HbA1c for the overall group was 7.3 + 0.6%. The
overall 5-year mortality was 54%. Patients with advanced CRC (stage 3 and 4) had a higher
mean HbA1c of 7.7+0.2% compared to 7.2+0.3% in patient with localized disease (stage 1
and 2); p=0.03. These patients were presented at a younger age (64.8+1.4 yo vs. 70.6+1;
p=0.001) and. The mean HbA1c also correlated with 5-year survival. The mean HbA1c at
the time of diagnosis of CRC was 7.19 + 0.5% for survivors compared to 7.76+ 0.7% in non-
survivors (p=0.04). Patients with right sided CRC had a higher mean HbA1c of 7.6+0.04%
compared to 7.1+0.6% in patient with left sided disease. MVA demonstrated that patients
with an elevated HbA1c (>7.5%) independently predicted early onset of CRC (p<0.001), a
more advance stage at the time of presentation (p<0.001) and poor 5 year survival (p=0.03).
Conclusions: Poor glycemic control in DM is associated with a younger age of CRC onset,
a more advanced stage at the time of diagnosis and a decreased 5 year survival. Small
differences in HbA1c elevation, and by inference small difference in circulating insulin levels,
may lead to large variations in prognosis of CRC. A poor glycemic control may result in
stimulation of proliferation in patients predisposed to CRC.
T2099
Allelic Loss of 18q21.1 (D18s474) As Independent Prognostic Marker in
Colorectal Cancer
Eduard Rosler, Contantin Reiter, Theodor Kudlich, Hardi Luehrs, Betram Illert, Tiemo
Katzenberger, Andrea Gostner, Michael Scheurlen, Wolfgang M. Scheppach, Ralph
Melcher
In colorectal cancer, frequently deleted chromosomal regions are 1p32-36, 4p14-16, 8p21-
22, 17p13 and 18q12.3. Tumor suppressor genes localized in these regions are p53 (17p13)
and DCC (18q12.3). A deletion of each of these five regions was described to be associated
with a worse patient prognosis. We established a comparative analysis (tumor vs. normal
colon-mucosa DNA) enabling an indirect molecular genetic characterization of primary
colorectal carcinomas. We chose microsatellite markers in these regions which has been
described as relevant for patient prognosis (HY-TM1, D4S2397, D8S254, D17S1303,
D18S474), analyzed 170 colorectal carcinoma specimen which had been collected within
1999-2004 for this reason by the members of the interdisciplinary Colon Cancer Research
Group Wuerzburg and correlated the results with tumour stage and prognosis of patients.
There was no significant differences of LOHs in UICC I-IV stage. A statistic evaluation of
the LOH and prognosis of patients showed no significant association of a LOH of one of
the markers HYTM1, D4S2397, D8S254, and D17S1303. However, a loss of the D18S474
marker was significantly associated with a worse patient prognosis (p=0,036) and this
association was also stage independent. The prognosis of stage II patients with LOH D18S474
was similar to patients in stage III. Thus, a high risk subgroup of stage II patients harbouring
LOH D18S474 can be defined which may profit from adjuvant chemotherapy.
T2100
Loss of Heterozygosity and Microsatellite Instability Predict the Recurrence
Pattern and Prognosis of Gastric Cancers
Eun jung Jeon, Mun-gan Rhyu, Sang-wook Choi, Jung-hwan Oh
Background/Aims: A loss of heterozygosity (LOH) and the presence ofmicrosatellite instability
(MSI) are used as accurate parameters for the genetic staging of cancer. Gastric cancers were
examined to determine if the clinical course can be predicted based on the level of LOH
and MSI. Methods: Tumor specimens were obtained from 145 gastric cancer patients and
were examined for their microsatellite genotypes using the microsatellite markers on 8
cancer-associated chromosomes (3p, 4p, 5q, 8p, 9p, 13q, 17p, 18q). The correlations
between the microsatellite genotypes and metastasis, recurrence pattern and survival rate
of gastric cancers were analyzed. Results: Gastric cancers with a high-level LOH and diffuse-
type cancers with a baseline-level LOH commonly spread to the lymph node irrespective
of the tumor size. Disease relapse is common in gastric cancers with high-level LOH through
both hematogenous (51%) and non-hematogenous (49%) routes, and diffuse-type cancers
with a baseline-level LOH through the non-hematogenous route (83%). These two high-
risk genotypes were associated with a poor prognosis in the stage II and stage III disease
compared with low-level LOH and MSI (P=0.0005, P<0.0001). Intestinal-type gastric cancers
demonstrated a higher frequency of LOHs on 5q (43% vs. 19%, P<0.05), 17p (67% vs.
34%, P<0.01) and 18q (50% vs. 22%, P<0.05) than diffuse-type cancers. Conclusions: The
recurrence pattern and poor prognosis of gastric cancers can be predicted based on the level
of LOH and the presence of MSI.
T2101
Likelihood of Metastases At Diagnosis and Disease-Specific Survival in
Patients with Microsatellite Unstable Colorectal Cancer
Luigi Laghi, Alberto Malesci, Paolo Bianchi, Gabriele Delconte, Ann E. Randolph, Carlo
Carnaghi, Armando Santoro, Roberto Doci, Riccardo Rosati, Marco Montorsi, Masimo
Roncalli, Leandro Gennari
Background & Aims: The outcome of patients with colorectal cancer (CRC) is more favorable
when the tumor exhibits high-frequency microsatellite instability (MSI). Although associated
with earlier-stage tumors, MSI has been proposed as an independent predictor of survival.
We wanted to test the prognostic value of MSI in a large series of patients diagnosed with
CRC in the last decade. Methods: The disease-specific survival of 893 consecutive patients
with CRC characterized by microsatellite status, was analyzed. The 89 (10%) patients with
MSI cancer were further classified according to tumor mismatch-repair (MMR) defect, MMR
germline mutation, hMLH1 and p16 promoter-methylation, BRAF and K-ras mutations, and
frameshift mutations of target genes. Results: Survival was significantly better (p=0.02) in
patients with MSI cancer than in those with stable tumor (MSS). However, MSI did not
predict a significantly lower risk of death if tumor stage was included in the multivariate
analysis (HR 0.72; 95%CI 0.40-1.29; p=0.27). Instead, MSI was strongly associated with a
decreased likelihood of lymph-node (OR 0.31; 95%CI 0.17-0.56; p<0.001) and distant-
organ (OR 0.13; 95%CI 0.05-0.33; p<0.001) metastases at diagnosis, independently of any
tumor pathological feature. Molecular predictors of reduced metastatic risk, and then of
more favorable prognosis, included TGFbRII mutation for all MSI tumors, hMSH2 deficiency
for HNPCC, and absence of p16 methylation for sporadic hMLH1-deficient cancers. Conclu-
sions: Tumor MSI is a stage-dependent predictor of survival in patients with CRC. The
decreased likelihood of metastases in patients with MSI cancer is associated with specific
genetic and epigenetic changes of the primary tumor.
T2102
Stage III Colon Cancer Prognosis Prediction By Gene Expression Profiling
Alain Barrier, Pierre-yves Boelle, Didier Brault, Sidney Houry, Antoine Flahault, Sandrine
Dudoit, Antoinette Lemoine
Background and aims. Postoperative chemotherapy has become part of the standard treatment
for stage III colon cancer patients. Since approximately half of patients are cured by surgery
alone, adjuvant chemotherapy should not be used in all stage III colon cancer patients. This
study aimed to assess the possibility to use microarray-based gene expression profiles to
predict the prognosis of stage III colon cancer patients. Material and methods. Forty-two
patients, operated on for a stage III colon cancer, were included in this study. Twenty-one
patients have received an adjuvant chemotherapy (a 6-month association of fluorouracil and
levamisole), while the other 21 have received no postoperative treatment. Twenty patients
have developed a liver metastasis, while the other 22 have remained disease-free for at least
5 years. Tumor mRNA samples were profiled using the Affymetrix HGU133A GeneChip.
Two separate analyses were performed: one with the 42 patients, the other with the 21
patients who did not receive any adjuvant chemotherapy. For each analysis, patients were
repeatedly and randomly divided into 10,000 training (TS) and validation sets (VS) of 10
different sizes. For each TS/VS split, a 30-gene prognosis predictor (PP), identified on the
TS by selecting the 30 most differentially expressed genes and applying diagonal linear
discriminant analysis, was used to predict the prognoses of VS patients. Performances of a
15-gene PP and a 34-gene PP, proposed by another research team, were also assessed on
the same TS and VS. Results. First analysis (42 patients). The 10,000 30-gene PP yielded
the following average prognosis prediction performance measures: 73.8% accuracy, 74.6%
sensitivity, 73.0% specificity. Improvements in prognosis prediction were observed with
increasing TS size. The 30-gene PP were found to be highly-variable in composition across
TS/VS splits. A total of 4,446 genes were included in the 10,000 PP; The higher number
of selections for a gene was 7,831. The 15-gene PP yielded a 69.7% accuracy, while the
34-gene PP yielded a 71.2% accuracy. Second analysis (21 patients). The 10,000 30-
gene PP yielded the following average prognosis prediction performance measures: 77.7%
accuracy, 75.8% sensitivity, 79.7% specificity. Improvements in prognosis prediction were
observed with increasing TS size. A total of 5,478 genes were included in the 10,000 PP.
The 15-gene PP yielded a 78.5% accuracy, while the 34-gene PP yielded a 81.9% accuracy.
Conclusions. Microarray gene expression profiling is able to predict the prognosis of stage
III colon cancer patients and, thus, might be used for an appropriate use of adjuvant chemo-
therapy.
T2103
The Prognosis of Patients with Advanced Gastric Cancer Is Correlated with
the Index Derived By Multiplying the Ratio of Cd8/Cd4 Expressions On
Cd57αβT Cells and the Proportion of Cd4αβT Cells Present in the
Circulating Peripheral Blood
Hirohito Magari, Eiji Takayama, Toru Niwa, Tatsuya Shiraki, Kosaku Moribata, Hiroki
Maeda, Hisanobu Deguchi, Izumi Inoue, Mikitaka Iguchi, Kimihiko Yanaoka, Hideyuki
Tamai, Kenji Arii, Masashi Oka, Masao Ichinose
BACKGROUND: CD57-expressing and αβTCR-positive T cells (CD57αβT cells) bearing
CD8 play an important role in anti-tumor immunity, including the induction of anti-tumor
cytokine production. On the other hand, the proportion of CD57αβT cells bearing CD4
increases with tumor progression. We determined the correlation between prognosis and
the expressions of CD8/CD4 on CD57αβT cells, which are among peripheral blood mononu-
clear cells (PBMCs), in patients with gastric cancer. METHODS: Twenty-nine gastric cancer
patients treated between 2002 and 2004 at the Wakayama Medical University (Wakayama,
Japan) were enrolled in this study (22 men, 7 women; median age 66.1±9.7 years, range
45-83 years). Early gastric cancers were defined as those confined to themucosa or submucosa
and advanced cancers as those invading the muscularis propria or beyond. Twelve healthy
volunteers (9 men, 3 women; median age, 60.6±12.6 years, range 43-80 years) were also
enrolled in this study as controls.The expressions of CD8 and CD4 on CD57αβT cells from
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the PBMCs of gastric cancer patients were analyzed using a flow cytometric analyzer. The
correlation between CD8/CD4 expressions on the CD57αβT cells and the stage of each
cancer case was analyzed statistically. Furthermore, the correlation between the expression
ratio and the survival of each case was investigated in advanced stage cancers. RESULTS:
The ratio of CD8/CD4 expressions on CD57αβT cells from the PBMCs of gastric cancer
patients decreased with tumor progression (healthy volunteers=5.6±3.0, early stage cancer =
4.4±4.7, advanced stage cancer = 3.8±3.8); The ratios were clearly correlated with prognosis,
measured as survival days in advanced gastric cancer patients (correlation coefficient (|R|)=
0.741, p=0.0010). Furthermore, the prognosis was significantly correlated with the index
obtained by multiplying the proportion of αβTCR-expressing cells bearing CD4 (CD4 helper
T cells, CD57-negative) and the ratio of CD8/CD4 expressions on CD57αβT cells (|R|=
0.936, p<0.0001); however, the proportion of CD4 helper T cells was not correlated with
prognosis (|R|=0.328, p=0.2149). CONCLUSIONS: The observed strong correlation between
the above - mentioned index and the survival of advanced stage gastric cancer cases strongly
indicates the usefulness of the index in the prediction of the prognosis of the cancer. Further
studies of the clinical importance of the index are warranted.
T2104
Colorectal Cancer in Females Is Associated with Poorer Outcomes
Jenn H. Koo, Bin Jalaludin, Cyril S. Wong, Val Poxon, Andrew Kneebone, Susan J.
Connor, Rupert W. Leong
Background and Aims: There are few studies on gender specific outcomes of colorectal cancer
(CRC). Appreciation of gender disparities from this study can assist in the implementation
of specific measures to address these differences and improve the overall outcomes of all
patients with CRC. Methods: The South Western Sydney Colorectal Tumour Group registry,
a population-based registry in South West Sydney with a population in excess of 800,000
(representing 15% of the population of Sydney), prospectively collects data on patients
with CRC identified through hospitals, pathology laboratories and cancer therapy centres.
Information collected includes demography, CRC site, grade, histopathology, stage, treatment
and survival. Data from 1997 to 2004 were used to identify CRC-related outcomes pertaining
to sex. Statistical analysis methods used include Chi square, Mann-Whitney U, Cox regression
and log-rank tests. Results: A total of 2,050 consecutive patients (44% females) were recruited.
Compared to males, females were older at diagnosis (median 69 years <range: 62-79 years>
compared to 67 <range: 59-76 years>; P=0.001), had more emergency surgery for CRC
complications such as bowel obstruction (18.8% compared to 15%; P=0.03), more proximal
colon cancers (42.2% compared to 31.5%; P<0.001) and more poorly differentiated cancers
(17% compared to 13%; P=0.01). The cancer specific survival was significantly poorer in
females than males (5 year survival: 66% compared to 70%; log rank P= 0.04). On Cox
regression multivariate analysis, female gender predicted a significantly poorer cancer specific
survival independent of age, comorbidity, emergency surgery, site, grade and Duke's stage
(Hazard Ratio: 1.24; 95% CI: 1.01 - 1.51; P=0.04). When analysed in 2 age groups, the
gender disparity in survival was most apparent. Below the age of 51 years, males had
significantly poorer survival (HR 1.95; 95% CI: 1.18-3.5; P=0.001), while over 51 years,
females had worse survival (HR: 1.34; 95% CI: 1.14-1.62; P=0.003). There were no gender
differences in histopathology, Duke's stages, complications from treatment or utilisation of
adjuvant chemoradiotherapy. Conclusions: The cancer specific survival in females is signific-
antly poorer than males, most evident over the age of 51 years, suggesting significant effect
of menopause on CRC outcomes. Females have more proximal colon cancers implying
limitations of flexible sigmoidoscopy as a screening modality.
T2105
The Impact of Ethnicity and Culture On Clinical Outcomes of Colorectal
Cancer in Sydney South West
Jenn H. Koo, Andrew Kneebone, Bin Jalaludin, Val Poxon, Cyril S. Wong, Susan J.
Connor, Rupert W. Leong
Background and Aims: The impact of ethnicity on the clinical outcomes of colorectal cancer
(CRC) in Australia is not known. Addressing inequalities in health care provision due to
ethnic and cultural factors are essential to improve the overall quality of care to all patients
with CRC through equitable distribution of available resources. Methods: The South Western
Sydney Colorectal Tumour Group registry prospectively collects data on patients with CRC
in South West Sydney, a region with a population in excess of 800,000 (representing 15%
of the population of Sydney). Data collected include demography, ethnicity according to
birthplace and spoken language, comorbidity, CRC site, grade, stage, treatment and survival.
Mortality data were obtained from hospitals and NSW Registry of Birth Death and Marriages.
Statistical analysis was performed on data from 1997 to 2004 with Chi square, Mann-
Whitney U, Cox regression and log-rank tests. Results: A total of 1,767 public hospital
patients (56% males) were recruited and divided according to ethnic origins as follows:
Australia/ New Zealand/ United Kingdom/ North America (“Anglo-Saxon”) 60%, Europe
23%, Asia 10%, Middle East and Africa 5%, and others 2%. Compared to Anglo-Saxons,
Asians were diagnosed at significantly younger age (median 62 years [52 - 74] compared
to 70 [62 -79]; P<0.001) and had fewer poorly differentiated cancers (9% compared to
18%; P=0.005). Twenty five percent of Asians were diagnosed below 50 years of age compared
to 8% of Anglo-Saxon patients (P<0.001). Asians had significantly better overall survival
than Anglo-Saxons (5 year survival: 68% compared to 49%; log rank P<0.001). Asian
ethnicity was a significant predictor of overall survival independent of age, comorbidity,
emergency surgery, grade and Duke's stage (Hazard ratio: 0.6; 95% CI: 0.4-0.85; P=0.004).
CRC screening, emergency surgery for complications of CRC, Duke's stage and adjuvant
chemoradiotherapy utilisation were not significantly affected by birthplace or spoken lan-
guage. Conclusions: There is heterogeneity in the CRC presentation and outcomes according
to ethnicity with Asian patients having improved overall survival. Asian patients are diagnosed
at significantly younger ages and the implications of this relate to CRC screening practices,
specifically age of first screening. There is no significant difference in the provision or
acceptance of cancer care based on ethnic origins, indicating equitable distribution of
resources.
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T2106
The Prognostic Significance of Mucin Phenotype and Its Relationship with
Histologic Classifications of Gastric Cancer
Ok-jae Lee, Hyun-jin Kim, Jang-rak Kim, Hidenobu Watanabe
Background/Aim: Gastric adenocarcinoma is histologically classified in two manners, intest-
inal vs diffuse, or differentiated vs undifferentiated, based on the tendency of gland formation.
The prognostic value of the histological classifications of gastric cancer is controversial,
although these have been commonly used. The clinical significance of mucin phenotype
has also not been clarified. We investigated the mucin phenotypic expression of gastric
adenocarcinomas to determine its correlations with clinical and histopathological factors as
well as its clinical significance as a possible prognostic factor. Methods: Histochemical and
immunohistochemical stainings for paradoxical concanavalin A, 45M1, MUC2 glycoprotein
and CD10 of mucin were performed in surgically obtained paraffin embedded specimens
from 74 gastric adenocarcinomas diagnosed at Gyeongsang National University Hospital
during June 1998 though June 1999. We determined mucin phenotype and analyzed its
relationships with clinical and histopathological variables. Additionally, overall survival for
8 years was analyzed. Results: There was no significant relationship betweenmucin phenotype
of gastric cancers and patients' sex, tumor location, stage, and presence of lymph node
invasion or distant metastasis. Helicobacter pylori infection rates were 86.7%, 94.7%, 86.7%,
and 80.0% in G-, I-, M-, and U-phenotypes, respectively (p=0.687). However, Mucin
phenotype was correlated well to histologic differentiation (p=0.002) and Lauren's classifica-
tion of tumor (p=0.002). Among 27 well differentiated adenocarcinomas, 13 (48.1%) expre-
ssed I-phenotype and only 5 (18.5%) G-phenotype. Twenty-five out of 30 (83.3%) G-
phenotype cancers were poorly differentiated and 13 out of 19 (68.4%) I- phenotype cancers
were well differentiated. Fifteen out of 19 (78.9%) I-phenotype cancers were Lauren's
intestinal type and 20 out of 30 (66.7%) G-phenotype cancers were Lauren's diffuse type.
For over 8 years, the overall survival rate was 45.9%. Univariate analysis showed no specific
difference of survival between mucin phenotypes. However, multivariate analysis revealed
higher cumulative survival rate in I-phenotype tumors than non I-phenotypes (p=0.016).
Conclusions: Mucin phenotype was correlated well with differentiation and Lauren's class
of gastric adenocarcinoma. I-phenotype cancers showed higher survival rate than non I-
phenotypes. It is suggested that mucin phenotype may have a role as a prognostic factor of
gastric adenocarcinomas.
T2107
Current Surveillance Practice of Pre-Malignant Gastric Lesions Inconsistent
with Gastric Cancer Risk; A Long-Term Nationwide Study in the Netherlands
A. C. De vries, N. C. Van grieken, M. K. Casparie, B. E. Hansen, G. A. Meijer, E. J.
Kuipers
Background: Gastric cancer is the fourth most common cancer and second leading cause
of cancer-related death worldwide. A cascade of recognizable precursor lesions, i.e. atrophic
gastritis (AG), intestinal metaplasia (IM) and dysplasia (DYS), precedes most gastric adenocar-
cinomas. Surveillance of patients with these pre-malignant lesions could mean a basis for
gastric cancer prevention. However, gastric cancer risk in patients with pre-malignant gastric
lesions is unclear. Aim: To evaluate current surveillance practice and gastric cancer risk in
patients with pre-malignant gastric lesions in the Netherlands. Methods: A cohort-study was
performed through analysis of data obtained from the Dutch nationwide pathology database
(PALGA). All patients with a first diagnosis of a pre-malignant gastric lesion between 1991
and 2004 were included in the cohort; follow-up data were evaluated until December 2005.
Patients with a history of esophageal or gastric resection or cancer prior to or simultaneously
with the first diagnosis of a pre-malignant lesion and patients with a previous or simultaneous
diagnosis of Barrett's esophagus were excluded from analysis. Results: A cohort of 90.316
patients was identified, with a male: female ratio of 1:1 and a median age of 66 years. The
cohort consisted of 21.905 (24%) patients with a first diagnosis of AG, 60.488 (67%) with
IM and 7.923 (9%) with gastric DYS. Age at diagnosis was significantly higher with increasing
severity of the categories of pre-malignant gastric lesions (AG:IM:DYS 61:67:69 yrs; p<0.001).
Patients with a diagnosis of AG or IM received a re-evaluation endoscopy in respectively
26% and 28% of cases, compared to 41% after a diagnosis of DYS (p<0.001). During follow-
up 1.497 (1.7%) patients developed gastric cancer. Follow-up data were available on 25.793
patients. Progression to gastric cancer within 5 years was 3.4% for patients with an initial
diagnosis of AG, 6.7% for patients with IM, 13.6% for patients with mild/ moderate DYS
and 67.7% for patients with severe DYS. Increasing severity of the categories of pre-malignant
gastric lesions at initial diagnosis (hazard rate severe dysplasia 21.9), increasing age at initial
diagnosis (HR >85 yrs 10.3) and male sex (HR 1.7) were identified as independent risk
factors for gastric cancer development (p<0.001). Conclusions: The risk of gastric cancer is
substantial after a diagnosis of pre-malignant gastric lesions. However, surveillance of pre-
malignant gastric lesions is omitted in the vast majority of patients in current clinical practice,
even when overt dysplasia is diagnosed. Therefore, development of surveillance guidelines
is indicated.
T2108
Has the Surge in Media Attention Educated the Public About Colorectal
Cancer (CRC) and Screening?
Paul C. Schroy, Julie T. Glick, Patricia Robinson, Maria Lydotes, Suzette Levenson,
Stephen Evans, Karen Emmons
Background: The creation of National Colorectal Cancer Awareness Month in March 2000
heralded a surge in mass media campaigns to promote awareness about CRC and stimulate
interest in screening. Many of these campaigns incorporated key messages proposed by the
National Colorectal Cancer Roundtable (NCCRT) in its strategic plan [Cancer 2002;95:1618-
28]. The objective of this study was to assess whether these campaigns have achieved their
goal of educating the public about CRC and screening. Methods: The study sample was
comprised of average-risk, English-speaking, primary care patients participating in a clinical
trial designed to assess the impact of a web-based decision aid on screening behavior.
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Subjects were deemed eligible if they were 50 to 75 years of age and without prior screening
other than fecal occult blood testing [FOBT]. Knowledge was assessed at baseline using a
12-item true/false questionnaire that asked about information contained in the NCCRT's
key messages. Multiple linear regression was performed to identify demographic correlates
of knowledge. Results: A total of 356 subjects (83% < age 65, 58% female, 60% Black, 7%
Hispanic, 60% ≤ high school [HS] degree, 31% prior FOBT ) were surveyed. The mean
cumulative knowledge score was 7.7 + 2.7 (max score = 12). Most subjects were aware that
both men and women are at risk (84%), risk increases after age 50 (71%), all racial and
ethnic groups are affected (88%), the goal of screening is to find polyps and cancer before
the onset of symptoms (82%), early-stage cancers may be curable with surgery (72%), and
that screening should begin at age 50 (73%). Fewer patients were aware that both CRC
(58%) and polyps (49%) may be asymptomatic, most CRC arises from polyps (52%),
removing polyps can prevent CRC (46%), CRC can occur in the absence of a family history
(33%), and that CRC is the most common cause of cancer death among non-smokers (26%).
Race and education were independent correlates of knowledge. Cumulative scores were
lower among Blacks than Whites (7.4 vs. 8.3, P<0.005) and lower among those with ≤ HS
degree than those > HS degree (7.3 vs. 8.4, P< 0.001). There was no difference in knowledge
based on age, sex, or ethnicity, or prior FOBT. Conclusion: Our data suggest that the recent
surge in media attention has been effective in educating the public about certain aspects of
CRC and screening. Nevertheless, these campaigns have been relatively ineffective in both
reaching certain segments of society, particularly Blacks and the less educated, and in
communicating key messages about the importance of polyps, asymptomatic nature of early
disease and risk independent of a family history.
T2109
Pre-Procedural Group Education Significantly Improves Screening
Colonoscopy Compliance Rate in a Predominantly African American Inner
City Population
Henry C. Olejeme, Aja Smith, Vincent W. Yang
Background and Aims: Inadequate patient education may contribute to the low screening
colonoscopy rates and disproportionately high incidence as well as late stage diagnosis of
colorectal cancer amongst African Americans. Long wait times experienced at inner city
hospitals are further barriers to screening.We sought to determine the effect of pre-procedural
group education sessions on compliance rate, wait time and yield of screening colonoscopy
in a predominantly African American (AA) patient population. Methods: The study was
conducted in Grady Memorial Hospital in Atlanta, Georgia, where at least 75% of the patients
are AA. We initiated a weekly pre-procedural group education session in October 2005, as
opposed to the open access approach prior to this time. Patients referred by primary care
physicians for screening colonoscopies were scheduled to attend a group education session
given by GI nurses who were supervised by a gastroenterologist. Patients were counseled
on colon cancer screening, provided with answers to their questions and scheduled for their
procedure on a convenient date. We reviewed statistics on compliance rate, wait time and
pathological yield of screening colonoscopy for the first 8 months of this initiative and
compared them to an identical period from the preceding year with open access colonoscopy.
As a comparison, similar statistical data were collected for diagnostic colonoscopies following
a clinic visit for both periods. Results: 130 patients were scheduled weekly for the education
session. The attendance rate for screening colonoscopies rose from 31% to 70% with the
introduction of the education sessions and was comparable to that of a diagnostic colonoscopy
following a clinic visit (71%). The average wait time decreased from 12 months to 4 months.
Importantly, there was a 44% increase in the number of adenomas removed, a 150% increase
in the number of adenomas with high grade dysplasia removed, and a 54% increase in
colorectal adenocarcinomas detected due to the education sessions. Conclusions: Pre-proced-
ural group education session prior to screening colonoscopy is a more effective model when
compared to open access colonoscopy amongst a disadvantaged AA population. It has the
added benefit of reducing long wait times for screening colonoscopy experienced at many
city hospitals, by allowing for optimized use of limited resources towards patients that desire
a colonoscopy. Our initiative increased the number of screening colonoscopies and led to
an increase in the identification of colorectal neoplasia. Efforts to improve screening compli-
ance in similar patient populations should be directed at education.
T2110
Longitudinal Use of Colorectal Cancer (CRC) Screening in Medicare
Beneficiaries
Gregory S. Cooper, Doug Kou
Background: Most CRC screening recommendations specify procedures to be performed
within specific intervals. Thus, cross-sectional data on the prevalence of screening at a given
time point may not accurately profile receipt of screening. Methods: We identified a 5%
random sample of cancer-free Medicare beneficiaries aged≥ 70 in 1998. Inpatient, outpatient
and physician claims from 1991 through 1997 were examined. Patients with yearly FOBT,
sigmoidoscopy or barium enema within 5 years, and/or any colonoscopy were considered
to have had complete screening. Patients were considered to be at increased CRC risk if
codes for polyps, polypectomy, CRC family history or IBD were present in 1991-1997. We
then examined claims from 1998-2003 for the use of CRC screening. Patients met guidelines
during this period if they had yearly FOBT, any flexible sigmoidoscopy or barium enema,
or colonoscopy if not previously performed. Fulfillment of guideline recommended procedure
use during follow up was compared according to whether patients underwent previous
screening and risk status, and patients were accordingly divided into 4 subgroups. Patients
were censored at death or disenrollment. Results: We identified 183,580 patients, including
68,517 with previous screening and 115,063 (62.7%) without. Codes for increased neoplasia
risk were present in 16,977 patients (9.2%). Average risk patients with previous screening
were more likely to be white, aged 75-84 and female. Subsequent screening according to
subgroup is shown in the Table. Within each subgroup, screening use decreased with
advancing age (i.e., Group 1: 70-74 52.4%, 75-85 42.3%, 85+ 23.5%, p<0.0001) and
nonwhite race (i.e., Group 1: 43.8% whites, 40.5% blacks, 39.0% others, p<0.0001), and
varied across geographic regions (i.e., Group 1 range 54.4% to 67.5%, p<0.0001). Only
modest differences were observed within subgroups according to gender. Conclusion: Sub-
sequent CRC screening occurs disproportionately in patients who have already undergone
some screening as opposed to those who have not been screened. Neoplasia risk also increases
the likelihood of subsequent screening. However, a significant proportion of each patient
subgroup does not meet guidelines during follow up.
T2111
Provider Intervention to Improve Fecal Occult Blood Test Follow-Up
Meaghan F. Larson, Cynthia W. Ko, Jason Dominitz
Background and Aims: Screening with fecal occult blood tests (FOBT) has been shown to
significantly reduce cancer mortality. However, many abnormal FOBT are not properly
followed up. The aim of this study was to examine the impact of a provider reminder upon
the proportion of patients referred for evaluation of abnormal FOBT and the proportion
who received colonoscopy. Methods: A provider reminder intervention was implemented
in July 2005. A program assistant entered an electronic reminder note for patients with a
positive FOBT who lacked a referral to gastroenterology. This reminder alerted the ordering
provider of the positive result, and offered choices (e.g. refer for colonoscopy, defer colonos-
copy due recent colonoscopy, severe comorbidity, patient refusal or other). A retrospective
chart review was performed comparing referral to gastroenterology and performance of
colonoscopy prior to and after the intervention. Cox proportional hazards multivariable
models were used to evaluate the association between the intervention and time to consulta-
tion and colonoscopy, adjusting for patient age, gender, Charlson/Deyo comorbidity score,
as well as FOBT ordered by primary care vs. other clinics. Comorbidity was determined by
reviewing ICD-9 diagnoses within 1 year prior to the positive FOBT. Results: 1,102 patients
had a positive FOBT between July 18, 2004 and July 18, 2006. 95% were male, 82% had
their FOBT ordered by primary care. The intervention was associated with a significant
increase in patients with a consult by 30 days (85.7% vs. 70.0%, p<0.0001), faster consulta-
tion (median 3 vs. 6 days, p<0.0001) and provided chart documentation of reasons for non-
consultation for 45/51 (88%) patients. Likewise, more intervention patients had colonoscopy
within 90 days (44.9% vs. 34.7%, p=0.0006). The multivariable model (Table) shows that
the intervention was associated with shorter time to consult and colonoscopy. Older patients
had slower evaluation, while those in Primary Care had more rapid evaluation. Comorbidity
was not significantly associated with the outcomes. Conclusion: This simple provider
reminder was associated with significantly improved proportion and rapidity of positive
FOBT evaluation. Most importantly, this system may lead to a timelier diagnosis of colorectal
cancer, with the potential for improved patient outcomes.
Cox Proportional Hazard Model for Each Outcome (Hazard Ratio and 95% CI)
Model results for comorbidity not shown as p=ns
T2112
A Comparison of Fecal RNA Test with Immunochemical Fecal Occult Blood
Test for Detecting Colorectal Cancer and Adenoma
Shigeru Kanaoka, Tetsunari Takai, Ken-ichi Yoshida, Yasushi Hamaya, Mutsuhiro Ikuma,
Akira Hishida
Background and Aims: It was reported that the sensitivity of a single immunochemical Fecal
Occult Blood Test (IFOBT) for detecting advanced neoplasia and invasive cancer was 27.1%
and 65.8%, respectively in the asymptomatic population (Gastroenterology 2005; 129: 422-
428). We reported that Fecal COX-2 assay, one of Fecal RNA Test, is useful for detecting
CRC (Gastroenterology 2004; 127: 422-427). We compared the results of Fecal RNA Test,
combination of cyclooxygenase 2 (COX-2), matrix metalloproteinase 7 (MMP-7) and Snail
as biomarkers, with those of a single IFOBT for detecting colorectal cancer and advanced
adenoma. Methods: Standard histological techniques were used to classify adenoma or
malignancy at I to IV stages according to TNM classification. We purified RNA from routinely
collected stool samples and screened mRNA using COX-2, MMP-7 and Snail specific nested
RT-PCR, consequently compared the results with those of a single immunochemical FOBT
(Magstream 1000/HemSp; FUJIREBIO, Inc., Tokyo, Japan) on same stool samples. Results:
Stool samples from 68 patients with CRC, 14 patients with advanced adenoma and 33
control patients without neoplastic disease were studied. The specificity of Fecal COX-2
assay, Fecal MMP-7 assay and Fecal Snail assay was significantly higher than that of IFOBT
(100% vs. 73.5%, P= 0.03). The sensitivity of each Fecal RNA Test for CRC was 85.3%
(95% CI; 74.6%-92.7%) for COX-2, 64.2% (95% CI; 53.1%-76.8%) for MMP-7 and 51.5%
(95% CI; 39.0%-63.8%) for Snail, respectively, while that of IFOBT was 73.5% (95% CI;
61.4%-83.5%). The sensitivity of each Fecal RNA Test for advanced adenoma was 57.1%
for COX-2, 50.0% for MMP-7 and 57.1% for Snail, respectively, while that of IFOBT was
35.7%. The sensitivity of each Fecal RNA Test for CRC or advanced adenoma was not
significantly higher than that of IFOBT, however, the sensitivity of total Fecal RNA Test was
significantly higher than that of IFOBT (89.7% vs. 73.5%; P= 0.03, 85.7% vs. 35.7%; P=
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0.02, respectively). COX-2 and/or MMP-7 and/or Snail mRNA was detected in 76.9% of
stage I (n=13), 96.6% of stage II (n=29), 88.5% of stage III or IV (n=26), while IFOBT was
positive in 38.5% of stage I, 79.3% of stage II, 84.6% of stage III or IV. Noteworthy, the
sensitivity of Fecal RNA Test for advanced adenoma to stage II cancer was significantly
higher than that of IFOBT (89.3% vs. 67.1%, P= 0.001). Conclusions: Fecal RNA test is
superior to a single IFOBT for detecting colorectal advanced neoplasia. These results strongly
suggest that this test would be a promising approach for CRC screening.
T2113
Testing FOBT Positive Individuals with a Fit with Novel Simple Card
Collection Technique Improves a Bowel Cancer Screening Program
Catriona M. Matthew, Robert J. Steele, Callum G. Fraser
Our aim was to assess whether testing guaiac faecal occult blood test [FOBT] positive
individuals further with a sensitive faecal immunochemical test [FIT], based on a novel
simple card collection technique, would be able to direct our scarce colonoscopy resource
to those with relevant pathology. Over the first year of Phase 1 of the Scottish Bowel
Screening Programme, 1124 individuals who had a final result of FOBT positive were invited
to take part in this study and asked to provide samples from two stool collections on a single
card [hema-screen DEVEL-A-TAB] and return this by mail. 558 individuals participated, 320
refused and 246 did not return samples. 59.7% were male and 40.3% were female. There
was no evidence of sampling bias according to gender. In addition, there was no sampling
bias with regard to FOBT positivity. Of the 558 individuals who participated, using hema-
screen SPECIFIC, a qualitative FIT, 256 were positive and 302 were negative. For the 301
negative participants for whom colonoscopy data were available, 2 [0.7%] had cancer and
13 [4.3%] had large or multiple [high risk] adenomatous polyps. In marked contrast, of
the 246 participants who were FIT positive, 44 [17.9%] had cancer and 50 [20.3%] had
high risk polyps. 92 [30.6%]of the negative individuals had a normal colonoscopy but only
34 [3.8%] of the positive individuals had no evidence of some pathology. In consequence,
the testing of FOBT positive individuals with a FIT in this “reflex two-tier” aproach does
allow colonoscopy to be directed to those who warrant this investigation. Bowel cancer
screening using either FOBT or FIT as a single test can be efficient and effective but this
novel approach, combining the two tests in a reflex manner, improves both. Our results
have informed the Scottish Bowel Screening Programme in which all eligible 50-74 year
olds will be offered screening. All participants will be sent a simple inexpensive FOBT.
Participants who are strongly FOBT positive are more likely to have bowel disease and thus
will be offered colonoscopy immediately. Participants who are weakly positive will be asked
to do a FIT since this will direct colonoscopy to those with significant disease: then, positive
individuals will be offered colonoscopy. Negative individuals will be invited for screening
again after two years.
T2114
Incidence Trends of Pre-Malignant Gastric Lesions; A Long-Term Nationwide
Study in the Netherlands
A. C. De vries, M. K. Casparie, N. C. Van grieken, C. W. Looman, B. E. Hansen, G. A.
Meijer, E. J. Kuipers
Background: Although the incidence of gastric cancer has declined over the past decades
in Western countries, mortality remains high. Pre-malignant gastric lesions, i.e. atrophic
gastritis, intestinal metaplasia and dysplasia, have been identified as important risk factors
for gastric cancer since decades. However, the epidemiology of pre-malignant gastric lesions
is largely unknown. Aim: To evaluate the diagnostic incidence and time trends of pre-
malignant gastric lesions in the Netherlands. Methods: Patients with a first diagnosis of
gastric atrophy, intestinal metaplasia or dysplasia between 1991 and 2005 were identified
in the Dutch nationwide network and registry of histo- and cytopathology (PALGA), which
contains 42 million records in total. To evaluate diagnostic incidence, number of new
diagnoses per year, relative to total number of patients with a first gastric biopsy was
evaluated. Time trends were evaluated with logistic regression analysis. Results: 97.732
patients received a new diagnosis of a pre-malignant gastric lesion during the investigated
period, with a 1:1 male to female ratio. 23.278 patients were newly diagnosed with atrophic
gastritis, 65.937 patients with intestinal metaplasia, and 8.517 patients with gastric dysplasia.
Significantly more females were present in the atrophic gastritis group (M/F 45/55%) than
in the group of patients with intestinal metaplasia (52/48%) or dysplasia (54/46%) (p<0.001).
Median age at diagnosis was 65,7 years; within all categories of pre-malignant gastric lesions
female patients were significantly older than male patients (p<0.001). 2.1% of patients
suffered from concomitant Barrett's esophagus. The incidence of atrophic gastritis has
declined over the past 15 years with 8.2% per year [95% CI 7.9 - 8.6] and gastric dysplasia
with 8.1% per year [95% CI 7.5-8.6], this decline was similar for male and female patients
(p=0.32 and p=0.73). The decline in the number of diagnoses of intestinal metaplasia was
2.4% per year [95% CI 2.2-2.6] for female patients and 2.9% per year [95% CI 2.7-3.1]
for male patients (p=0.02). The number of patients with a first gastric biopsy increased with
3.7% per year during the investigated period. Conclusions: Pre-malignant gastric lesions are
frequently encountered in routine biopsies obtained during upper gastro-intestinal endoscop-
ies, however, the incidence of atrophic gastritis and gastric dysplasia is declining. This sharp
decline implies that a further decrease in the incidence of gastric cancer may be anticipated
in the next two decades in Western countries.
T2115
Smokers As a High Risk Group for Colorectal Cancer Screening: What Is the
Critical Exposure Level?
Michael Latreille, Joseph C. Anderson, Zvi Alpern, Carol M. Martin, Patricia Hubbard-ells
Background: Smoking has been observed to be a significant risk factor in screening popula-
tions (Leiberman JAMA 2003;Anderson AJG 2003).In both studies, the risk for colorectal
neoplasia for smokers was similar to patients with a family history of CRC. If smokers are
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to be considered a high risk group, more data regarding the amount of tobacco exposure
are needed. Our goal was to determine the number of pack years needed to increase the
risk by two fold over non-smokers. Methods: We collected age, gender, family history of
CRC, smoking (pack years/year quit), medications, alcohol use, aspirin/NSAID use, exercise
and fruit/vegetable intake from asymptomatic screening patients > 40 years. We divided the
patients into 3 groups: 1)Heavy smokers or those who had smoked more than 10 pack
years and who were currently smoking or had quit in the past 10 years 2)Low exposure
smokers were those who had smoked < 10 pack years or who had quit > 10 years ago
regardless of total pack years 3) People who never smoked. Significant colorectal neoplasia
(SCRN) was defined as villous tissue, high-grade dysplasia, large (> 1 cm), adenomas and
multiple(> 2)adenomas of any size. Results: 2695 patients were screened; The prevalence
for SCRN for the heavy smokers (72/530;13.6%) was higher than the never (113/1525;7.4%)
or low exposure smokers (49/640;7.7%) (p<0.001). For the analyses, we excluded low
exposure smokers, comparing the heavy and never. Table 1 demonstrates the increasing
risk for pack years for SCRN (p-value for trend = 0.024). Since age was a very strong
predictor of SCRN and correlated with pack-years, we divided the patients into 10 year age
groups and observed that 20 pack years was the critical exposure for increasing risk of
SCRN. Conclusions: Our data suggests that smoking continues to be a significant risk
factor. If smokers are targeted as a high risk group, perhaps 20 pack years should be
considered the threshold.
Risk for SCRN when compared to non-smokers
Risk for SCRN by Pack Years and Age
p-values for both pack-years groups the “0” pack-year group is the reference
T2116
Colonoscopic Screening in Individuals with a Familial Risk of Colorectal
Cancer: Results of a Prospective Program
Susana Mão de ferro, Paula Rodrigues, Pedro Lage, Alexandra Suspiro, Isabel Claro, Paulo
Fidalgo, Sara Ferreira, Rita Sousa, Paula Chaves, Cristina Albuquerque, Carlos Nobre
leitão
Introduction Screening colonoscopy is effective for colorectal cancer (CRC) prevention in
individuals belonging to families with hereditary nonpolyposis colorectal cancer (HNPCC).
Its efficacy and periodicity, in cases with a familial aggregation of CRC that does not fulfil
Amsterdam Criteria (AC) for HNPCC, has not been proven. Aims and Methods To evaluate
the incidence and prevalence of colorectal adenomas and CRC in asymptomatic individuals
with a familial history of CRC submitted to colonoscopy. We conducted a prospective study
of 760 individuals. Four groups were considered based on the number and age at diagnosis
of CRC in the families: GI-2 CRC or 1 CRC <50 years; GII-3 CRC or 2 CRC <50 years;
GIII-AC for HNPCC. GIV-pathogenic mutation for HNPCC. Colonoscopic screening program
was performed with interval of 5 (GI), 3 (GII), 2 or 1 years (GIII e GIV, respectively).
Adenomas sized >10mm, with a villous component or high-grade dysplasia were classified
as at-risk adenomas. Statistics: χ2, t-student and anova. Results In the first colonoscopy we
detected 341 lesions in 209 individuals, including 78 with multiple adenomas, 88 with at-
risk adenomas and 9 with CRC (table 1). 278 individuals were submitted to 459 follow-
up colonoscopies (mean follow-up of 46 months). 345 patients are waiting for a second
exam. We detected 155 lesions in 80 individuals, including 33 with multiple adenomas,
24 with at-risk adenomas and 2 with CRC - one violation of the program (table 2). Patients
with adenomas in the first exam had more adenomas at follow-up (p<0,001). No at-risk
lesions were detected in patients from GI with a normal first colonoscopy. Conclusions 1)
Colonoscopy in patients with a familial history of CRC allowed the detection of a significant
number of colorectal lesions; 2) In HNPCC, particularly when a mutation was present, a
lesser prevalence of adenomas in combination with a higher rate of CRC may signify an
accelerated carcinogenesis; 3) In individuals from GI, with a normal first colonoscopy, the
interval of the exams may probably be increased; 4) Our results suggest that screening
colonoscopy is efficient for CRC prevention in individuals with a high-risk for its develop-
ment, due to familial history.
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T2117
Efficacy of Colonoscopy, Sigmoidoscopy and Barium Enema in Reducing the
Incidence of CRC
S. A. Mulder, J. Dieleman, M. E. Van leerdam, E. Van soest, L. G. Van rossum, R. J.
Ouwendijk, E. J. Kuipers
Introduction: Colorectal cancer (CRC) screening programs have been implemented in many
countries. The efficacy of different screening methods in reducing the incidence of CRC is
however much debated. We therefore investigated the uptake of endoscopy (colonoscopy
and sigmoidoscopy) and barium enema prior to diagnosis in CRC patients, compared with
a matched control group to estimate the effect of these examinations on the incidence of
CRC. Methods: We conducted a case-control study using the Integrated Primary Care
Information database, a general practice research database containing the complete, longitud-
inal electronic medical records of more than 500.000 persons throughout the Netherlands.
All incident CRC cases during the study period were identified. The mean follow-up time
within the database prior to CRC diagnosis was 4 yrs (range 1-10 yrs). For each CRC case,
up to 20 controls (mean 13 per case) were identified, matched for age, sex, index date and
follow-up time. All colorectal examinations (including colonoscopies, sigmoidoscopies and
barium enemas performed >1 yr prior to the index date) in CRC cases and their controls
were considered in the analysis. Results: In total, 595 incident cases of CRC (M/F 301/294,
mean age 69 yrs, range 25-99) were identified. In the period >1 yr prior to the CRC diagnosis,
2.5% (15/595) of the CRC cases had undergone a colorectal examination, compared with
4.5% (348/7790) in the control population (odds ratio, 0.58, 95% CI 0.40 to 0.98, p<0.05,
univariate analysis). One percent of the cases had undergone at least one colonoscopy, 0.5%
a sigmoidoscopy, and 1% a barium enema. In the control group 2% had undergone a
colonoscopy, 1% a sigmoidoscopy and 2% a barium enema. Significantly fewer CRC patients
than controls had been examined for the purpose of surveillance after polypectomy (0.5%
vs 7%, p<0.001). Change of bowel habits and abdominal pain had been the main indications
for colorectal examination of the control group, respectively 28% vs 20% and 25% vs 13%
compared to CRC patients (p<0.001); rectal blood loss was the main indication in CRC
patients (36% vs 21% in controls (p<0.01)). Conclusion: Patients who are diagnosed with
CRC have previously undergone significantly fewer colorectal examinations than matched
controls. This supports the concept that colorectal examination by various modalities exerts
a long-term preventive effect on the incidence of CRC. This effect is of considerable magni-
tude, even after a single investigation.
T2118
A Novel Method to Capture Methylated Human DNA from Stool: Implications
for Colorectal Cancer Screening
Hongzhi Zou, Jonathan J. Harrington, Rafaela L. Rego, David A. Ahlquist
Background: Assay of methylated DNA markers in stool represents a promising approach
for colorectal cancer screening. A method to capture hypermethylated CpG islands from
stool would enrich target analyte and allow optimal assay sensitivity. Aim: To develop a
method for universal capture of methylated human DNA sequences from stool using a
methyl-CpG binding domain protein (MBD). Methods: MBD was produced using a
pET6HMBD plasmid with MBD DNA sequence cloned from rat MeCP2 gene and bound to
a column of nickel-agarose resin. The feasibility of the MBD column to extract methylated
human DNA in a high background of fecal bacterial DNA was first established. To explore
the impact of the MBD enrichment on detection sensitivity, the tumor-specific methylated
vimentin gene was assayed in blinded fashion from stools spiked with low amounts of cancer
cell DNA (0-50 ng) and from stools of 8 colorectal cancer patients with methylated primary
tumors and 6 colonoscopically normal individuals. Cancer stools were selected with low
concentrations of human DNA (median 24 ng/g, range 3-6027 ng/g). Human DNA in stools
was quantified using a real-time Alu PCR method (Cancer Epi Bio Prev 2006;15:1115-9).
Results: Bacterial DNA had low affinity to the MBD column and was readily eluted with
NaCl concentrations <0.6 M, while methylated human DNA had high affinity and required
NaCl concentrations >0.6 M for elution. With MBD enrichment, methylation specific PCR
detected the vimentin marker in stools spiked with ≥10 ng of cancer cell DNA and in
colorectal cancer stool aliquots across the range of native human DNA concentrations.
Without MBD enrichment, methylated vimentin was detected in none of the spiked stools
and in only one cancer stool with the highest human DNA concentration (6027 ng/g).
Methylated vimentin was not detected in normal stools either with or without MBD enrich-
ment. Conclusions: Methylated human DNA can be selectively extracted from stool by
MBD capture. MBD capture increases assay sensitivity for detecting methylated DNA markers
in stool. Applied clinical studies for stool cancer screening are indicated.
T2119
Tp53 Mutation Screening As a Possible Marker of Increased Colorectal
Malignancy Risk: Results from a Cross-Sectional Screening Study Among
Patients with Long-Standing and Extensive Ulcerative Colitis
Karen V. Winther, Lars Andresen, Eywin Bruun, Thomas Horn, Per Guldberg, Jorn
Brynskov, Vibeke Binder
Background and Aims: Previous long-term clinical follow-up of ulcerative colitis patients
diagnosed and treated in Copenhagen County, Denmark, has not revealed any increased
occurrence of colorectal cancer. We have previously suggested that this favourable outcome
was explained by the treatment strategies used in Copenhagen County, but endoscopical
surveillance to detect premalignant changes has not been carried out systematically. We
therefore performed a cross-sectional screening for both colorectal dysplasia and the hitherto
most promising malignancy marker that is mutations in the tumor suppressor gene TP53.
Methods: The original population-based cohort from Copenhagen County was searched for
all patients with at least 20 years of disease duration, disease extending beyond the sigmoid
colon, and no previous colorectal surgery. Included patients underwent colonoscopy with
collection of > 60 random mucosa biopsy specimens which were examined for histological
changes and molecular screening for any type of mutation in the tumor suppressor TP53
exons 5 - 9. Results: A total of 223 patients fulfilled the inclusion criteria among which 129
patients accepted to participate (58%), and 94 (42%) refused. One case of adenocarcinoma in
the right colon and 6 cases of dysplasia were detected. The expected number of colorectal
cancers calculated for a matched background population was 1.5 cases. The expected number
of patients with dysplasia could not be reliably calculated as no valid background data are
available so far. A total of 14 patients (11%) had a TP53 mutation detectable in all colon
segments. All mutations were heterozygote single-base substitutions. In 4 cases the mutation
was located within exon 6, and in 2 and 8 cases within introns 6 and 9, respectively,
which are non-coding regions of the TP53 gene. The detected types of mutations were all
polymophisms with no reported influence on TP53 amino acid sequence or function.
However, 21% of the patients who had a TP53 polymorphism had also dysplasia or carcinoma
vs. only 3% of patients with wild type TP53 (P<0.05), a possible association which remains
to be further elucidated. Conclusion: No increased occurrence of colorectal carcinoma was
detected in this selected group of high-risk ulcerative colitis patients recruited from our
regional cohort. Only 5% of the patients in the present study had detectable premalignant
histological changes and 11% had a TP53 polymorphism in all cases without any known
clinical significance. These results support our previously published follow-up data from
Copenhagen County where no increased long-term risk of CRC was found among patients
with ulcerative colitis.
T2120
Diagnostic Yield of Sigmoidoscopy and Colonoscopy in Daily Clinical Practice:
Implications for Colorectal Cancer Screening
Jochim S. Terhaar sive droste, Michael E. Craanen, Joep F. Bartelsman, Kim R.
Cappendijk, Rene W. Van der hulst, Gerrit A. Meijer, Linde Morsink, Pleun Snel, Hans A.
Tuynman, Roy Van wanrooy, Eric C. Wesdorp, Chris J. Mulder
Introduction: Currently, the scale and optimal mode of colorectal cancer (CRC) screening
is still being debated. One of the major issues - among others - is whether a sigmoidoscopy
or colonoscopy should be performed in this setting with particular emphasis on the potential
differences in yield and spatial distribution of colorectal carcinomas and (advanced) aden-
omas. Hence, we analysed the diagnostic yield of sigmoidoscopies and colonoscopies in a
cohort of Dutch patients referred for lower GI endoscopy. Methods: A prospective multi-
centre study (N=18; 2 academic hospitals, 16 general/teaching hospitals) evaluating all
colonoscopies and sigmoidoscopies performed in Northern Holland during a three month
period in 2005. Results: In total, 5,574 colonoscopies and 3,522 sigmoidoscopies were
performed in 8,638 patients. The caecal intubation rate for colonoscopy was 82%. Most
common findings are listed in Table 1. In patients with CRC (N=390), the tumor was located
in the distal colon and proximal colon in 74% and 26% of cases, respectively. The distal
colon was defined as the rectum, sigmoid, and descending colon including the splenic
flexure. The proximal colon was defined as the transverse colon, the ascending colon and
the caecum. Of all patients with right-sided cancer (N=99), 69% had a normal appearing
distal colon, whereas 31% had a synchronous polyp (29% adenoma, 71% hyperplastic/not
specified). Conclusion: More than 10% of lower G-I endoscopies yielded an advanced
neoplasia (CRC/advanced adenoma). Although our study included patients clinically referred
for lower GI endoscopy, extrapolation of our findings indicate that screening sigmoidoscopy
would have missed 26% of CRC's. Moreover, the presence of a right-sided carcinoma can
not be adequately predicted by distal colonoscopic findings. Finally, colonoscopy in daily
clinical practice was incomplete in nearly 20% of cases, frustrating future colonoscopy-based
screening programs and stressing the importance of continuous quality control in terms of
reporting and appropriate training.
Most common findings in all procedures
* i.e. adenomas at least 1.0 cm and/or villous architecture and/or high-grade dysplasia
T2121
Colorectal Cancer Detection Using Cpg Island Methylation Profiling of DNA
from Human Stools
Giles O. Elliott, Jane Scarll, Jack Dainty, Rob Foxall, Amanda Coupe, D. Garg, John
Mathers, Ian Johnson, Nigel J. Belshaw
Aberrant CpG island methylation has been identified as an early event during colorectal
carcinogenesis and recent studies have demonstrated its detection in human DNA residues
from stools. This suggests a possible role for CpG island methylation profiling as a fecal
biomarker in non-invasive screening. We investigated this possibility further by applying a
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highly sensitive, quantitative methylation-specific PCR (Q-MSP) assay to determine the levels
of CpG island methylation of 6 genes (CDH1, HPP1, APC, ESR1, MLH1 and p14), previously
shown to aberrantly methylated during colorectal carcinogenesis, in stool samples from 56
endoscopy patients (19 with cancer, 18 with adenoma and 19 free of neoplasia) and also
from 172 healthy, free-living individuals (~10 males and 10 females from each decade from
0 to 80 years old). Levels of CpG island methylation in DNA from stool were significantly
higher than in DNA from the flat mucosa, and a significant correlation between stool and
mucosa was observed only for ESR1. By using the level of methylation of each CpG island
in stool DNA as a continuous variable, multivariate statistical analyses using bionomial
logistic regression modelling revealed a highly significant (p=0.003) classification of cancer
vs non-cancer (adenoma+normal) patients with a sensitivity of 65% and a specificity of
81%, comparing very favourably with existing non-invasive technologies. The application
of this model to the CpG island methylation profiles of the free-living, healthy subjects
classified 84% as free of disease, in good agreement with the level of specificity obtained
for the endoscopy patients. In conclusion, the CpG island methylation profiles observed in
stool DNA in general do not precisely reflect the methylation status of the colonic mucosa
from which they were derived; however, biologically meaningful information regarding
disease state is retained. Using the sensitive, quantitative assay for CpG island methylation
in DNA isolated from stools in combination withmultivariate statistics may provide a valuable
approach for the non-invasive diagnosis of colorectal cancer.
T2122
The Importance of Identifying High Risk Patients in a General Screening
Colonoscopy Population: Results from the National Colonoscopy Study
Pedigree Analysis
Jonathon S. Stillman, Noah Kauff, Georgia Close, Ann G. Zauber, Sidney J. Winawer
BACKGROUND: Family history has an important role in current screening and surveillance
colonoscopy guidelines. Identification of familial risk is a critical factor in determining timing
of first colonoscopy and surveillance intervals. When applied properly, this identification
should decrease the risk of interval cancers. AIM: To review all pedigrees from Phase 1 of
The National Colonoscopy Study (NCS) and report the frequency of pedigrees suggestive
of high risk in a general screening population. METHODS: The NCS is a Randomized
Controlled Trial of Screening Colonoscopy in the general population involving 3 clinical
centers (Group Health Cooperative Seattle, Louisiana State University, University of Minne-
sota). 1380 of 1405 enrolled subjects submitted a family history questionnaire. A panel of
clinical geneticists and gastroenterologists reviewed each pedigree using strict criteria for
high risk families. Pedigrees were considered diagnostic for HNPCC if the proband or FDR
met the originally defined Amsterdam II Criteria (Vasen et al. DisColRec 1991) or the less
stringent Amsterdam II Criteria (Vasen et al. GE 1999). Additionally, each pedigree was
reviewed to see if it was suggestive of HNPCC by meeting the Bethesda criteria (Umar et
al. JNCI 2004) adapted as follows: (a)CRC or endometrial cancer (EC) in a patient less than
50, (b)CRC or EC in a patient with one or more FDR's with an HNPCC related tumor, with
one of those diagnosed at < 50, (c)CRC or EC diagnosed in a patient with 2 or more FDR's
or SDR's with HNPCC tumors at any age, (d)synchronous or metachronous HNPCC tumors,
one of which had to be CRC or EC, at any age. Criteria applied only to the proband or
FDR of the proband. RESULTS: 3 families satisfied Amsterdam II criteria as originally defined
in 1991. An additional 5 families satisfied the Amsterdam criteria as more broadly defined
in 1999. Thus a total of 8 Amsterdam families (.58%) were discovered. 55 families (4%)
met our adapted Bethesda criteria. CONCLUSION: This screening colonoscopy study of a
general population revealed 8 of 1380(.58%) family histories to be consistent with HNPCC.
Applying our adapted Bethesda criteria increased the identification of high risk families
almost 10 fold (.58% to 4%). Nearly 5% of families had histories that warranted either more
aggressive colonoscopic surveillance or genetic work-up. Identification of these families
should decrease the rate of interval cancers. Obtaining a detailed family history is critical
in order to determine appropriate screening for colon and related cancers.
T2123
Patients with Sporadic Duodenal Adenoma Represent a High-Risk Group for
Advanced Colorectal Neoplasia
Pierrick Péquin, Sylvain Manfredi, Vincent Quentin, Denis Heresbach, Jean Boyer,
Laurent Siproudhis, Jean-françois Bretagne
Aim: Patients with sporadic duodenal adenoma may represent a high-risk group for colorectal
neoplasia, but little is known about this risk in the literature. Therefore, we conducted a
retrospective case control study to determine this risk. Patients and methods: Cases corre-
sponded to 35 patients referred to 2 teaching hospitals for endoscopic treatment of sporadic
duodenal adenoma who underwent a colonoscopy. We compared the colonoscopy findings
with those from a control group of patients (2 controls per case) without duodenal adenoma,
matched for age and sex. Patients with familial adenomatous polyposis, von Recklinghausen
disease or ampullary adenomas were excluded from cases. In the control group, the indica-
tions for gastrointestinal endoscopy exams were dyspepsia and changes in bowel habit.
According to the most advanced lesion found, colonoscopy findings were divided into
adenoma, advanced adenoma (size ≥ 10 mm, villous component or high grade dysplasia)
or cancer. Advanced neoplasia was defined as the sum of cancer and advanced adenoma.
The chi square test was used to compare the 2 groups. Odds ratio and 95% confidence
intervals (CI) were calculated. Results: (see Table) Results were unchanged after excluding
patients of both groups with family history colorectal cancer. Conclusions: 1) The relative
risk for colorectal advanced neoplasia in patients with duodenal adenoma is about 9 when
compared to controls. 2) The absolute risk for advanced adenoma in these patients is quite
similar to that found in subjects with a positive FOBT result. 3) Patients with duodenal
sporadic adenoma represent a high-risk group for colorectal advanced neoplasia and should
therefore undergo a complete colonoscopy.
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T2124
Racial Disparities in Adenoma Location and Size: A Retrospective Analysis of
CRC Risk
Apurv Varia, Abdul Khan, Ahsan Arozullah, Richard V. Benya, Robert E. Carroll
Background: Ethnic differences in the incidence and location of colon cancers have been
noted. African Americans in particular have been previously shown to have an increased
rate of right-sided cancers; while Hispanics have lower overall rates as compared to other
ethnic groups. Less is known about the risk factors for and distribution of adenomas
within ethnic groups. Therefore, we decided to retrospectively evaluate patients from our
colonoscopy database for differences in polyp location, size, and histology; as well as altered
environmental factors and rates of CRC screening between these groups. Methods: Colonos-
copy data were evaluated from patients in the UIC electronic clinical database over a 12-
month period. Ethnic backgrounds were compared with adenoma incidence, location and
size by X2 analysis. Additionally, we reviewed clinical records for age, gender, family history,
tobacco use, alcohol use, and/or NSAID use and calculated the relative risk of adenomas at
both proximal and distal locations for each group. Results: A total of 1658 patients were
evaluated of which 758 were African American (46%), 460 Caucasian (28%), 327 Hispanic
(20%) and 113 other (7%). Mean age was ~62 yrs in all groups with similar male-to-female
ratios (~1:1) in the three groups. Screening accounted for 48% of colonoscopies in AA, 39%
in Caucasians and 36% in Hispanics respectively. The adenoma incidence was higher in
African Americans (19%) as compared to Hispanics (8%) and Caucasians (8%). Furthermore,
adenomas were proximally located in 49% of AA but only in 32% and 37% of Caucasians
and Hispanics, respectively (p= 0.01). High risk adenomas (i.e., >1 cm) were more prevalent
in AA (20%) and Caucasians (36%) than Hispanics (8%) (p= 0.05) while diminutive polyps
(<5mm) were more prevalent (67%) in the latter group (p= 0.025). Large adenomas were
more proximally distributed in African Americans (50% vs 26% in Caucasians and 33% in
Latinos); while neither adenoma size nor location could be linked to variances in tobacco,
alcohol or NSAID use. Conclusions: Overall, African Americans tend to have increased
numbers of adenomas as well as high-risk adenomas in proximal locations compared to
other groups. The increased frequency of right-sided adenomas correlates with their known
cancer distribution patterns. In contrast, Hispanics had the lowest levels of high-risk lesions.
The presence of genetic mismatch repair defects as well as dietary differences to account
for the discrepancies in proximal and high risk neoplasms between ethnic groups should
be evaluated.
T2125
Development of An RNA-Based Fecal Screening Panel Test for Colorectal
Cancer
Anne F. Van rijn, Corinne Lauppe, Evelien Dekker, Marcel Beld, Rene Minnaar, James C.
Hardwick
Background: Many Western countries have adopted screening for colorectal cancer using a
non invasive fecal occult blood test (FOBT). Blood as a biomarker is not specific for colorectal
cancer and leads to a relatively high percentage of false positives and lack of sensitivity and
specificity for early lesions. DNA, protein, or RNA from exfoliated colonocytes in stool are
potentially both more sensitive and specific than blood as a marker for CRC. A commercial
test involving the detection of tumor specific DNA has been developed, but is complex and
expensive involving separate assays for each possible mutation in a panel of genes. In contrast
the detection of RNA markers of CRC only needs one assay, and can be adapted to detect
multiple different markers simultaneously by multiplex PCR. It is thus potentially more
amenable to automation, simpler and cheaper. Aim: The aim of this study was to assess
reverse transcription-PCR assay methodology originally developed for the detection of entero-
viruses, for the detection of colorectal cancer. This non invasive test can be used as a RNA
based fecal test for CRC screening. Method: RNA was isolated from 20 stool samples, 10
with CRC and 10 without. RT-PCR was performed using primers specific for seven of the
most highly upregulated genes in CRC as found by SAGE analysis. Methodology developed
and patented in our hospital for the detection of entero-viruses (M. Beld, et al., J Clin
Microbiol, 2004) was used for improved RNA extraction and neutralization of inhibitors of
PCR found in feces. This RT-PCR is a non-nested and fast assay. All assays included a
negative control. The results were sequenced to confirm specificity for marker-RNA. Results:
Decay Accelerating Factor (DAF) was detected in 7/10 CRC stools; Cyclooxygenase II (COX-
II) mRNA in 5/10 CRC stools; Dipeptidase-1 (DPEP-1) in 3/10 CRC stools. Other tested
markers (Macrophage inhibitory cytokine-1 , Cytokeratin-18, cytokeratin-19, regenerative
islet derived-2, insulin growth factor-II) were inconclusive. By combining DAF, COX-II and
DPEP the sensitivity of this mRNA panel was 8/10 true positive CRC stools 80% and
specificity was 2/10 false positive controls (80%) for finding CRC. Conclusion: An easy to
use RT-PCR protocol can successfully detect multiple mRNAs in feces with encouraging
sensitivity and specificity for CRC when combined. These preliminary findings are promising
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for the future non-invasive detection of CRC, suggesting that by using a panel of different
mRNA markers the sensitivity and specificity will increase beyond those attainable with the
fecal occult blood test.
T2126
Olga Gastritis Staging in Young Adults and Country-Specific Gastric Cancer
Risk
Massimo Rugge, Jong Kim, Varocha Mahachai, Stephan Miehlke, Gianmaria Pennelli,
Valentina Russo, Chin-lin Perng, Full-young Chang, Rakesh Tandon, Dinesh Singal,
Joseph Sung, Jorge Valenzuela, Giuseppe Realdi, Maria Dore, David Graham
Background and Aims: H. pylori infection is associated with gastric inflammation, peptic
ulcer, and gastric cancer. Significant geographical differences, however, have been shown
in the clinical outcomes of the disease, in gastritis phenotypes and in H. pylori-associated
gastric cancer risk. The OLGA International Group recently proposed a gastritis staging
system (OLGA-staging) that integrated atrophy score (obtained by biopsy) and atrophy
topography (achieved through biopsy mapping). This study tested whether, in young adults,
the OLGA-staging correlated with gastric cancer risk in different populations recruited from
3 continents. Methods: Mapped gastric biopsies were obtained from 316 consecutive young
adults (<41 years) dyspeptic patients recruited from 8 geographic areas that differed in
gastric cancer risk. Gastric atrophy was histologically assessed according to internationally
validated criteria and gastritis Stage was established according to the OLGA-staging system.
Results: Among all the considered populations, the most prevalent gastritis Stages were 0
to II, which included all subjects entered from Chile, Germany, India, Italy, and Thailand.
Although, the prevalence of H. pylori varied among geographic regions, gastritis Stages III
and IV were limited to the Chinese and Korean populations. Indians had a high prevalence
of infection without high Stage gastritis. Conclusions: Among the 8 examined populations,
the prevalence of H. pylori infection did not per se predict gastric cancer risk. In populations
at different cancer risk, the gastritis OLGA-Stage mirrored the gastric cancer incidence.
Gastritis staging identifies a subgroup of high-risk patients in whom cost benefit interventions
could be addressed to secondary gastric cancer prevention.
T2127
NMR Spectroscopy Can Differentiate Between Normal and Cancerous Rectal
Tissue
Meixian Zhao, Roger D. Soloway, Hongwei Yao, Xiuxiang Gao, Yizhuang Xu, Qinghua
Pan, Bingbing Wang, Jian Qi, Jinguang Wu
Examination of the contribution of various forms of spectroscopy has been used by an
increasing number of groups to demonstrate that spectroscopy of normal and cancerous
tissues can be used to obtain information concerning the presence or absence of malignancy.
Aim: To separate the NMR spectra of normal from malignant rectal tissue. Normal or
malignant tissue was obtained from patients after removal at operation after obtaining
informed consent. Samples were bisected, with one-half used for pathology examination
and one-half used for spectroscopy after storage in liquid N2. An 80 mg sample was used
for 1H/13C analysis and a 300 mg sample was used for 31P-NMR analysis. Results: 1H-NMR
analysis demonstrated that the 4 characteristic peaks from fatty acids were decreased in
malignant tissue indicating replacement or local utilization of fatty acids. This change is
supported by our Fourier transform infrared (FT-IR) spectroscopy analysis of rectal cancer.
In addition malignant tissue demonstrated an increased intensity at 4.09 ppm compatible
with increased lactate or inositol. In 31P-NMR, a chemical shift from 1.89 ppm to 1.27 ppm
was noted. Using a series of proportions of the buffers Na2HPO4 and KH2PO4, a curve of
shifts was demonstrated that showed that as the chemical shift decreased, the pH of the
buffer decreased in a sigmoidal fashion, as expected. This suggested that the decreased
chemical shift reflected an increase in acidity of malignant rectal samples. 5/6 malignant
samples had a 31P chemical shift lower than 6/6 normal tissues if a cut-off of 1.6 ppm was
used for separation. Conclusions: (1)1H-NMR spectroscopy showing changes in the intensity
of multiple peaks confirms findings using FT-IR spectroscopy and light microscopy that fat
content of rectal cancer is decreased. (2) 31P-NMR demonstrated a decrease in peak from
1.89 to 1.27 ppm in rectal malignancies suggesting a decrease in pH, perhaps through
increases in lactate compared to controls.
T2128
The Optimal Colon Cancer Screening Interval for Liver Transplant Patients
Madhavi Rudraraju, Elizabeth J. Carey, Vandana Singh
Background: Organ transplant recipients are at higher risk for developing malignancies,
which is thought to be due to the use of immunosuppression. The aim of our study was
to determine the risk of development of colon polyps with advanced features and colon
carcinoma in liver transplant(LT) patients when compared to individuals with chronic liver
disease(CLD) and patients with out liver disease. Methods: Case-control analysis of 89 liver
transplant recipients who underwent post-transplant colonoscopy; matched for age, gender,
and year of colonoscopy to 89 patients with chronic liver disease and 89 patients with out
liver disease(normal) undergoing screening colonoscopy. Data collected includes age, race,
gender, date of transplant, immunosuppression used, etiology of liver disease, date and
findings on colonoscopy and pathology reports. Incidence of advanced adenomas (polyps
>1cm, high grade dysplasia, villous histology) and colon carcinoma is documented. Patients
less than 45 years age, at high risk for colon cancer (Inflammatory Bowel Disease, strong
family history of colon cancer, history of colon carcinoma on pre transplantation colonoscopy)
and colonoscopy done at outside institution were excluded. Results: The groups are similar
in age and sex, but there are more Hispanic patients in the liver transplant group. The mean
age is 57.8 (SD of 7.4) for liver transplant group, 57.5 (SD of 7.9) for chronic liver disease
group and 58 (SD of 7.7) for normal group. 7.9 %(7/89) of liver transplant group, 3.4%
(3/89) of chronic liver disease group and 1.1% (1/89) of normal population had the outcome
of interest, but the p- value is not significant. The mean duration from transplant to the
occurrence of event is 8.8 years. Immunosuppression used is Prograf and Cellcept in 4
patients, Prograf only in 1 patient and Cyclosporine in 2 patients. There is only one case
of colon cancer, which occurred in the liver transplant group. Conclusions: There is a trend
towards increased incidence of advanced colon polyps and colon carcinoma in immunosup-
pressed patients after liver transplantation. Larger studies are needed to determine if, post
transplant colon cancer surveillance should be more frequent than currently recommended
for non-transplant patients.
T2129
Colorectal Cancer Diagnosis Following a Negative Colonoscopy
Essam R. Quraishi, Jorge Zuniga, Richard Zuniga, George Divine, Surinder K. Batra
Background and Aim: Colonoscopy is recommended as a screening strategy to detect cancers
at an earlier stage and to detect and remove premalignant lesions of the colon, thereby
reducing the risk for development of colon cancer. We present 27 cases of colorectal
carcinoma (CRC) that were diagnosed following a negative colonoscopy. Methods: All patients
that were diagnosed with CRC between 2000-2004 at Henry Ford Health System were
identified using the tumor registry. The medical records of all these patients were reviewed
to identify which of these patients had prior negative colonoscopy within 5 years of the
diagnosis of CRC. Results: A total of 922 patients were diagnosed with CRC within the
specified time. Twenty-seven (2.9%) of these patients had prior colonoscopy that was missed.
The mean interval of diagnosis of CRC after colonoscopy was 33.3 months. Patients with
missed colonoscopy were older 71.7 vs. 68.4 years (p=0.012). Twelve patients (23%) of
patients were asymptomatic at the time of diagnosis in the missed colonoscopy group vs.
94 (11%) among the rest of the group (p=0.007). CRC was more commonly located in the
hepatic flexure 8 (16%) vs 51 (6%) among the rest of the group (p=0.095). Nineteen patients
39% had stage 0 and 1 cancer in the missed colonoscopy group vs 179 (24%) among the
rest of the group (p=0.072). There was no statistically significant difference in race and sex
between the two groups. Thirty seven (77%) patients had curative surgery in the missed
colonoscopy group vs 545 (67%) in those without prior colonoscopy, the difference was
not statistically significant. There was no statistically significant difference in other symptoms
at diagnosis. Twenty out of 27 colonoscopies in themissed diagnosis groupwere performed by
Gastroenterologists and 7 were performed by Colo-rectal surgeons. Conclusion: Colonoscopy
failed to identify 27 out of 922 (2.9%) cases of CRC over a five-year period. Increased
diligence during endoscopy and improvement in endoscopic technique may improve the
diagnostic accuracy of colonoscopy.
T2130
Mortality from Gastric Cancer in Patients Followed By Endoscopies
Masako Ogura, Yohko Hikiba, Shin Maeda, Masayuki Matsumura, Kenichi Okano, Ryushi
Sassa, Haruhiko Yoshida, Takao Kawabe, Masao Omata
Backgroud & Aims: Although commonly practiced in Japan, the effectiveness of regular
endoscopic examinations against gastric cancer has not been well evidenced. Methods:
Medical records were analyzed of patients, 833 patients with gastric ulcer (GU) and 2547
without ulcer (NU), who received a long-term endoscopic follow-up between 1969 and
2004. Gastric cancer incidence, death by gastric cancer, and overall survival were compared
with those in Japanese general population by calculating standardized incidence andmortality
ratios (SIR and SMR). Results: The interval of endoscopies was 1.4 ± 1.4 years in GU and
1.8 ± 1.5 years in NU. During follow-up, 32 patients in GU and 61 in NU developed gastric
cancer, showing annual incidence rates of 0.40% (95% CI: 0.24 - 0.56%) and 0.38% (0.28
- 0.48%), and SIRs of 2.21 (1.44 - 2.98) and 1.72 (1.29 - 2.15), respectively. The 5-year
survival exceeded 80% among the patients who developed gastric cancer. SMRs for gastric
cancer and overall deaths were 0.50 (0.01 - 0.99) and 1.05 (0.87 - 1.23) in GU, and 0.45
(0.15 - 0.74) and 0.78 (0.69 - 0.88) in NU. There were no significant differences between
the two groups in gastric cancer incidence, mortality from gastric cancer, and overall survival.
Conclusions: The mortality from gastric cancer was reduced by regular endoscopic examina-
tions in a population with high incidence of gastric cancer.
T2131
The Effect of Ethnicity On the Presentation and Management of Esophageal
and Gastric Cancer: A UK Perspective
Gareth J. Sadler, Mark R. Anderson, Ulises Zanetto
BACKGROUND Studies have shown consistent disparities in esophageal and gastric cancer
incidence, histology, and mortality between ethnic groups. Esophageal adenocarcinoma
incidence in white males in the US is four times higher than in Blacks or American Asians
(AA). Gastric adenocarcinoma incidence is five times greater amongst AA than whites. Studies
suggest Asian patients present with less advanced disease and are more likely to undergo
curative resection. For esophageal cancer the rate of curative surgery in black patients is
half that of whites and the age-adjusted mortality is poorer. To date, such studies have taken
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place in the US where ‘Asian' groups originate from East Asia. The majority of UK Asians
originate from the Indian subcontinent. Consequently, little is known about the role of
ethnicity on the presentation, symptomatology, treatment and outcomes in the UK.
METHODS We undertook a 5-year retrospective case-note audit of patients diagnosed with
esophageal and gastric cancer at City Hospital, Birmingham, United Kingdom (UK), which
serves a local population of fairly uniform socio-economic status and access to healthcare.
It serves three major ethnic groups; Caucasians (C), Blacks (B) and Asians (Ax). Results
were analysed with statistical significance taken at the 95% level. RESULTS 201 patient
records, consisting of 151 C (69% male), 28 B (93% male) and 22 Ax (50% male) were
analysed. Ax were less likely to be referred for urgent endoscopy than C (p=0.03). Presenting
symptoms differed, with B and Ax more likely to present with abdominal pain, and C with
dysphagia (p<0.05). C (73%) were more likely to present to medical attention within 3
months of symptom onset than B (47%) or Ax (50%), (p<0.05). Ratios of esophageal adeno/
squamous cell carcinoma were 66/34% C, 50/50% B and 38/62% Ax. The majority of B
had gastric cancer, which was not true of other ethnic groups (p=0.03). The stage of disease
did not differ between groups. There was an apparent lower rate of curative operation for
Ax but this did not reach significance. Median survival in months, regardless of treatment,
was 7 (C), 6 (B), and 3 (Ax). CONCLUSIONS Ethnicity appears to influence health-seeking
behaviour and symptom reporting, with C more likely to present earlier to medical attention
than other ethnic groups. Ax patients aremore likely to report abdominal pain than dysphagia,
and are less likely to be referred for urgent endoscopy. Improvements in symptom education
amongst patients and health professionals alike may facilitate more rapid referral and improve
outcome. The favourable features reported in US ‘Asians' have not been demonstrated in
UK ‘Asians'.
T2132
The Impact of Colorectal Cancer Family History Clinic On Yield of
Colonoscopic Screening
Bianca Desouza, Tim Elliott, I. Rowe, Melissa Smith, Fiona Hibberts, Claire Coughland,
Anaar Sajoo, Sara Levene, Gillian Scott, Louise Izatt, Jeremy Sanderson
INTRODUCTION: Approximately 20% of patients with colorectal cancer (CRC) have a
positive family history (FH). Public awareness of CRC is high and there has been an increase
in the number of referrals seeking screening in those with a FH of CRC. Guidelines for
screening in this group vary and many individuals are screened too early with a resulting
low yield of adenomas. In this study, we have compared the yield of screening by colonoscopy
in those with a FH of CRC prior to and following the introduction of a CRC family history
clinic introducing screening according to agreed guidelines. AIMS & METHODS: Cases
undergoing colonoscopy between October 1994 and May 2003 prior to introduction of
the CRCFH clinic (Group1) were identified from the endoscopy database. Cases referred
subsequently (Group 2) were identified from prospective clinic records and the endoscopy
database. Demographic data, adherence to agreed guidelines and adenoma detection rate
were compared between the two groups. RESULTS: 133 individuals were identified in Group
1. 87 (65%) of these were screened earlier than recommended by guidelines with a mean
of 7.7 years in advance of these recommendations. This premature screening was more
marked in those with lesser familial risk. Only 9 adenomas (6.8%) were detected. Adenoma
detection rate increased with age but not with increased familial risk. Of 136 patients referred
to the CRCFH clinic in Group 2, 108 attended and were placed into a risk category (average,
moderate or high) according to agreed guidelines based on number/degree of relative(s)
affected by CRC. 28 were deemed average risk, counselled regarding general population
risk screening and discharged from the clinic. A further 11 patients were excluded from
analysis because of symptoms (n=6) or a previous diagnosis of CRC (n=5). Of the remaining
69 patients, 48 have been screened to the time of this review. 10 of these had one or more
adenoma (21%) which is significantly higher than yield in group 1 and more in keeping
with that found in other studies of screening patients with a family history of CRC. 54%
of adenomas were right sided, 15% were greater than 10mm in diameter and 40% patients
had 2 or more adenomas. Adenoma detection rate increased with age and increased familial
risk. CONCLUSION: The introduction of a CRCFH clinic significantly improves the adenoma
detection rate in individuals with a FH of CRC. It also eliminates unnecessary endoscopy
for those who do not have a significantly increased risk of CRC based on their family history.
The high incidence of right sided adenomas confirms that total colonoscopy is an appropriate
screening tool.
T2133
Differences in Colon Polyp Prevalence and Location By Race and Gender
Eli Penn, Donald A. Garrow, Joseph Romagnuolo
Background: African-Americans (AAs) have been noted recently to have a higher incidence
of colorectal cancer (CRC), to present with more advanced disease, to develop cancer at an
earlier age and to be more likely to have right-sided CRC. It is not clear if this is an access
to care issue, a polyp progression rate issue, or if polyps actually develop more frequently
and/or earlier in AAs. In addition, despite gender equality in lifetime CRC risk, recent studies
suggest higher polyp prevalence in men. We sought to explore the effect of race and
gender on polyp prevalence in a large decade-long endoscopic database of a racially diverse
population. Methods: The study was sponsored by the Center for Health Disparities Research
and IRB-approved. We included outpatient colonoscopies entered prospectively into GI-
TRAC at the Medical University of South Carolina (Jan 1996 - Sep 2006), coded as done
primarily to “screen for neoplasia”. We excluded anemia, diarrhea, inflammatory bowel
disease, known/prior CRC or polyps, prior colonoscopy, or prior colon surgery. Using SAS
v9.1.3, 3 multivariable logistic regression models were created to determine predictors of:
polyp prevalence, polyp number (dichotomized at 3) and right-sided location. Relevant
demographic, clinical and procedural covariates were considered, including prep quality,
to control for potential confounding, and interactions were explored. Results: 3,732 patients
met the criteria: 2910 had no active symptoms; The rest had minor rectal bleeding or altered
bowel habit. 39% were male, 29% AA, 11% family history of CRC and 6% fecal occult
blood positive (FOB+). Independent predictors for polyps only included age (odds ratio
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(OR) for >65 yrs = 1.51, 95% CI: 1.3-1.7) and male gender (OR 1.23; CI: 1.1-1.4). Right-
sided polyps were similarly predicted by age > 65 (OR 1.27; CI: 1.1-1.6) and male gender
(OR 2.01; CI: 1.6-2.5). Three polyps or more was predicted by male gender (OR 2.79; CI:
1.8-4.3) and FOB+ (OR 2.10; CI: 1.1-4.2). Other variables, e.g. race, bowel preparation, or
health status, were not independent predictors in any models. There was no effect modifica-
tion by symptom status or rectal vs. non-rectal location of polyps. Conclusion: In this series
of colonoscopies, male gender predicted presence of polyps and increased number of polyps.
Predictors of polyp prevalence surprisingly do not appear to always parallel predictors of
risk of CRC, which has implications for how best to adjust screening guidelines to reduce
cancer risk in these subgroups. Access to care and/or polyp progression rates may play a
role in explaining these discrepancies.
T2134
T-Darpp Suppresses Ceramide-Induced Apoptosis: Upregulation of Bcl2 and
Preservation of the Mitochondrial Membrane Potential
Abbes Belkhiri, Wael M. El-rifai
We have identified Darpp-32 (Dopamine and cAMP-regulated phosphoprotein of Mr 32,000)
as a major target at the 17q12 amplicon in gastric cancer. We have also cloned and
characterized a novel truncated Darpp-32 isoform that we named t-Darpp. We found over-
expression of Darpp-32 and t-Darpp in a number of common adenocarcinomas such as
colon, breast, prostate, and stomach. Herein, we report the biological function of t-Darpp
in gastric cancer. We performed a TUNEL assay on transiently transfected RKO cells with
t-Darpp expressing pcDNA3.1 vector following treatment with 5 μM camptothecin. The
results indicated a significant reduction in apoptosis in t-Darpp expressing cells. This strong
anti-apoptotic activity for t-Darpp was independently confirmed by Annexin V assay and
FACS analysis following treatment with CPT, ceramide, and butyrate. The results from
luciferase assays using the p53 and p21 reporter plasmids and western blot with antibodies
specific for p53 transcriptional targets, such as Hdm2 and p21, indicated that t-Darpp does
not interfere with p53 function. Moreover, we demonstrate that t-Darpp confers antiapoptotic
property to cancer cells through transcriptional up-regulation of Bcl2 and protection of
mitochondrial transmembrane potential. Furthermore, the mitochondrial release of cyto-
chrome c and activation of caspase 9 were inhibited by t-Darpp expression in ceramide-
treated cells. The use of siRNA-specific oligo for t-Darpp confirmed that protein expression
of Bcl2 was regulated by t-Darpp. In addition, luciferase, EMSA, and quantitative real-
time RT-PCR assays, indicated that t-Darpp transcriptionally upregulates Bcl2 expression.
Increased expression and phosphorylation of CREB andATF-1 transcription factors correlated
with t-Darpp mediated upregulation of Bcl2. The use of siRNA-specific oligos for CREB and
ATF resulted in a significant decrease of Bcl2 protein levels in t-Darpp expressing cells.
Taken together, these results confirm that the t-Darpp-mediated up-regulation of Bcl2
requires active CREB and ATF-1 transcription factors. Further studies are ongoing to charac-
terize the oncogenic pathways of the novel t-Darpp protein.
T2135
5' -Untranslated RNA of the Human Vegf Transcript Is a Novel Regulatory
RNA That Promotes Tumor Malignancy of Human Colon Cancer Cells
Kiyoshi Masuda, Shigetada Teshima-kondo, Yuta Yamamoto, Kensei Nishida, Hideyuki
Sasaki, Kumiko Tominaga, Tomoko Kawai, Atsuo Sekiyama, Keiya Nakamura, Kazuhito
Rokutan
There is increasing evidence that VEGF acts as a critical tumor promoting factor that not
only induces tumor angiogenesis but also protects cancer cells against anticancer agents by
autocrine signaling pathway in diverse types of human cancer. Here we show a novel function
of VEGF that the 5'untranslated region (UTR) of VEGF transcript could promote tumor
malignancy of colon cancer HCT116 cells. Transient overexpression of cDNA expressing
the full-length or the 5'UTR of VEGF, but not VEGF ORF, induced a multidrug resistance
in the cells. To further examine the effect of the VEGF 5'UTR on malignant phenotypes,
we established stable transfectants expressing the chimeric VEGF 5'UTR-YFP (HCT116/
VEGF 5') mRNA or control YFP mRNA (HCT116/YFP). As expectedly, HCT116/VEGF 5'
cells showed an abnormal cell growth, which was demonstrated by their higher proliferation
rate and cell cycle progression in low-serum conditions, higher degree of anchorage-inde-
pendent growth, and increased resistance to apoptosis induced by anticancer drugs including
5-fluorouracil, doxorubicin and etoposide. To further examine the impact of the 5' UTR on
malignant tumorigenicity In Vivo, HCT116/VEGF 5' or control HCT116/YFP cells were
injected subcutaneously into nude mice. At 30 days after injection, HCT116/VEGF 5' cells
formed 10-fold larger tumors than control cells. To identify genes specifically modulated by
the 5' UTR, we performedDNAmicroarray analysis and showed that constitutive expression of
VEGF 5' UTR RNA specifically down-regulated several pro-apoptotic genes and up-regulated
growth-associated genes. Our results indicated that the VEGF 5' UTR is a novel class of
regulatory RNAs that can promote tumor development and malignancy through modulating
several gene expression and strongly suggest that the VEGF transcripts can be a critical
therapeutic target for tumor.
T2136
Atdc, a Novel DNA Damage Response Protein Overexpressed in Pancreatic
Cancer, Is a Phosphorylation Target of Atm
Lidong Wang, Mary Davis, Theodore Lawrence, Mats Ljungman, Diane M. Simeone
Background: Pancreatic cancer is a deadly disease characterized by late diagnosis, early
metastasis, and resistance to therapy. We have previously shown that Ataxia-Telangiectasia
Group D Associated gene (ATDC) is upregulated in 90% of invasive pancreatic cancers. We
have recently determined that ATDC enhances growth and confers a survival advantage to
pancreatic cancer cells in response to ionizing radiation (IR). We hypothesize that ATDC
may function as a novel DNA damage response protein important in the ATM signaling
cascade. Methods: Silencing of either ATDC and/or ATMwas performed by stable transfection
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of shRNA targeting these molecules in Panc-1 cells. Participation of ATDC in cell cycle
checkpoint signaling was analyzed by assessing radioresistant DNA synthesis (RDS) and
phosphorylation of p53 and Chk2. The effect of ATDC on the number of DNA double
strand breaks was measured by examining phosphorylation of the histone variant γH2AX
following IR. Participation of ATDC in DNA repair foci in response to IR was determined by
immunohistochemistry. ATDC phosphorylation was determined by co-immunoprecipitation
experiments using antibodies directed against ATDC and phospho-serine/threonine. Results:
ATDC is a nucleocytoplasmic shuttling protein that following exposure to IR (10 Gy) becomes
phosphorylated by ATM and localizes to DNA repair foci. Silencing of ATDC in Panc-1
cells results in RDS (indicating a disruption of the S phase checkpoint) and decreased
phosphorylation of p53 and Chk2 in response to IR as well as increased γH2AX phosphoryl-
ation. Silencing of ATDC in Panc-1 cells did not alter IR-induced ATM phosphorylation or
participation of ATM or γH2AX in DNA repair foci. However, silencing ATM completely
abolished IR-induced trafficking of ATDC to DNA repair foci. Further, treatment of Panc-
1 cells with IR resulted in ATDC phosphorylation which was blocked by silencing ATM,
indicating that ATDC is a phosphorylation target of ATM. Conclusions: ATDC is a novel
DNA damage response protein that is expressed in the majority of pancreatic cancers and has
dual functions of promoting pancreatic cancer cell growth and regulating cellular responses to
DNA damage. This work has important implications for better understanding pancreatic
tumorigenesis, as well as for exploring the potential role of ATDC in growth regulatory
mechanisms and DNA damage responses in both neoplastic and normal cells, a topic which
has not been previously explored. Furthermore, targeting ATDC for inactivation should have
therapeutic value by both reducing proliferation and increasing susceptibility to radiotherapy
of pancreatic cancer cells.
T2137
Endogenous Acetylcholine Synthesis and Autocrine Stimulation of Human
Colon Cancer Cell Proliferation
Roxana Samimi, Kunrong Cheng, Sanjit Roy, Jasleen Shant, Guofeng Xie, Cinthia
Drachenberg, Jean-pierre Raufman
Acetylcholine (ACh), traditionally regarded as a neurotransmitter, may be produced by non-
neuronal cells. M3 muscarinic receptors (M3R) are expressed by colon epithelial cells and
the majority of colon cancers over-express M3R (Clin Can Res 5:2532, 1999; Carcinogenesis
21:1789, 2000). In Vitro, activation of muscarinic signaling stimulates human colon cancer
cell proliferation. We hypothesized that endogenous ACh produced by colon cancer cells
causes autocrine stimulation of cell proliferation. H508 human colon cancer cells, which
have high-level expression of M3R, were used to: (1) Examine actions of muscarinic receptor
antagonists, ACh-esterase (AChE) inhibitors, and choline transport inhibitors on cell prolif-
eration; (2) Determine expression of choline acetyltransferase (ChAT), an enzyme required
for ACh synthesis; and (3) Identify ACh production by incubating cells with radiolabeled
substrate. Atropine (10 µM), pF-HHsid (100 μM), a selective M3R antagonist, and hemicholi-
num-3 (100 μM), a choline transport inhibitor, all inhibited basal cell proliferation by ~40%
(p<0.005). Proliferation was not inhibited by antagonists for other muscarinic receptor
subtypes. AChE inhibitors (eserine, 100 μM, and Bis-THA, 500 μM) increased cell prolifera-
tion by 2.5- and 2-fold (p<0.005), respectively. ChAT expression in H508 cells was evidenced
by (1) immunofluorescence microscopy and immunoblotting and (2) reverse transcription
and quantitative real-time PCR. RT-PCR results (200-bp product using cDNA prepared from
DNAse I-digested total RNA) were verified using quantitative PCR with two sets of exon-
spanning primers for ChAT. For each primer set, 78-bp products were identified (Ct cycles
from 50 ng total RNA were 36-37). Synthesis of ACh was demonstrated by incubating H508
cell homogenates with 3H-acetyl-CoA and identifying 3H-ACh formation. Newly formed 3H-
ACh was separated from radiolabeled substrate by solvent extraction controlled using 3H-
ACh and 3H-acetyl-CoA standards. 3H-ACh production was abolished by boiling cell homo-
genates prior to adding substrate. To determine whether ChAT expression is common in
colon cancer, we obtained specimens of human colon cancer (n=10) and normal colon (n=
5) for immunohistochemistry (peroxidase method). Epithelial cytoplasmic ChAT expression
was observed in the 10 cancer specimens tested, but not in normal colon or in cancer slides
incubated without primary antibody. In conclusion, endogenous ACh production mediates
basal H508 human colon cancer cell proliferation and colon cancers commonly express
ChAT, an enzyme necessary for ACh production. Endogenous ACh production in colon
cancer may provide a novel therapeutic target.
T2138
Net1, a Novel Gastric Adenocarcinoma-Associated Gene, Drives Tumor
Migration and Invasion Via Cytoskeletal Rearrangement Events
David W. Murray, Padraic Macmathuna, Peter Doran
Introduction. The most lethal aspects of gastric adenocarcinoma (GA) are its invasive and
metastatic abilities. The molecular mechanisms underpinning this aggressive phenotype
therefore represent ideal therapeutic targets. Background Aims. We have recently identified
enhanced NET1 expression in GA in comparison with adjacent normal tissue [Murray et al
Br J Cancer. 2006 94(8): 1204-1212] Our previous studies have utilized a knockdown
approach to show that NET1 expression is of functional importance in the disease setting
as knockdown resulted in a decrease in the proliferative, migratory and invasive phenotype
of gastric cancer cells. In this study we aimed to delineate the role of NET1 in cytoskeletal
modification driving gastric tumor cell invasion and migration. Methods. AGS gastric cancer
cells were treated with 20 μM (lysophosphatidic acid) LPA, 4 μg/ml C3 Exoenzyme, 2 μg/
ml Cytochalasin D. NET1 knockdown was achieved in 6 well format, using 2.5 μg RNAi.
Gene expression was quantitated using real time PCR. Immunoblot analysis was used to
detect levels of total and active RhoA as well as B-Actin. Cell proliferation was investigated
using an MTS assay (Promega Corp.). Cell invasion and migration were investigated using
the transwell assay system. Cells were immuno-fluorescently stained for FAK & Actin.
Results. Upon RNAi-mediated knockdown of NET1 in AGS gastric cancer cells, a decrease
in the active levels of RhoA, a key player in cytoskeletal regulation, was observed. Similarly,
NET1 expression was increased 10-fold in response to treatment with LPA (P<0.05), resulting
with an increase in active levels of RhoA and a 2-fold increase in cell invasion (P<0.05).
LPA-induced cell invasion and migration were significantly inhibited (P<0.05) using either
NET1 siRNA or a RhoA Inhibitor (C3 Exoenzyme) thus indicating the importance of both
NET1 and RhoA in gastric cancer progression. Furthermore, LPA-induced invasion and
migration were also significantly reduced in the presence of cytochalasin D, an inhibitor of
cytoskeletal rearrangements (P<0.05). Conclusion. These results highlight the importance
of NET1 in the gastric tumor setting. NET1 is clearly driving tumour cell invasion via
modulating the gastric cancer cell cytoskeleton.
T2139
Inhibition of Telomerase By Mutant Template Telomerase RNA and Anti-
Telomerase Sirna Induces ALT in Immortalized Human Esophageal Epithelial
Cells and in Generated Human Squamous Cancer Cells
Angela Queisser, Michaela Doebele, Alexander V. Werder, Eva Egenter, Steffen Heeg, Nina
Hirt, Heike Kunert, Sarah Hauss, Hideki Harada, Hiroshi Nakagawa, Shang Li, Elizabeth
H. Blackburn, Hubert E. Blum, Oliver G. Opitz
Introduction: Immortalization is an important step in malignant transformation of human
cells depending on telomere maintenance. This is either mediated through activation of the
enzyme telomerase, which contains a template RNA moiety (hTER) and the core protein
(hTERT) or through a recombination based alternative mechanism (ALT). Little is known
about the regulation of these two mechanisms in a single cell. Previously, we demonstrated
that the induction of the respective telomere maintenance mechanism is cell-cycle dependent.
Now we investigated, whether ALT can be induced in genetically defined immortalized or
malignant transformed cells by specific genetic telomerase inhibitors. Methods: We generated
immortalized human esophageal epithelial cells overexpressing Cyclin D1 or hTERT, respect-
ively (EPC D1 and EPC hTERT) as well as human oral squamous cancer cells by overexpres-
sion of Cyclin D1, d.n.p53, EGFR, c-myc (OKF6 D1/d.n.p53/EGFR/c-myc) by retroviral
transduction. To genetically inhibit telomerase, all cell types were transduced with mutated
versions of hTER, anti-hTER siRNA or a combination of both by lentiviral mediated gene
transfer. Transduced cells were sorted by GFP-coexpression, telomerase activity (TRAP-
assay), telomere length (PFGE-TRF and Q-FISH) and indirect immunofluorescence (APBs)
were assayed. Results: Overexpression of MT-hTER, anti-hTER siRNA and the combination
of both showed a reduction of telomerase activity in all cell types, whereas TRF analysis
revealed telomere elongation, which is characteristic for ALT. Q-FISH analysis suggested a
heterogeneous pattern of telomere length on a chromosomal level. In contrast, control cells
displayed a robust telomerase activity and a shorter telomere length in immortalized as
well as in malignant transformed cells. Additionally, in indirect immunofluorescence ALT-
associated PML bodies (APBs) were observed in a higher frequency in immortalized hTER-
inhibited cells. Summary: Genetically defined immortalized human esophageal epithelial cells
and the generated cancer cells can elongate their telomeres using both telomere maintenance
mechanisms. ALT can be induced by the inhibition of telomerase using a lentiviral delivery
system of mutant template telomerase RNA and anti-telomerase siRNA. These findings
suggest that immortalized and malignant transformed cells and therefore eventually all
telomerase positive cancer cells treated with telomerase inhibitors as potential anti-cancer
strategy might find alternative ways to maintain their telomeres.
T2140
Possible Role for Nucleostemin in Intestinal Progenitor Cells
Jian Zhang, Alan N. Mayer
Nucleostemin (NS) encodes a nucleolar GTP-binding protein that is selectively expressed
in rat neuronal stem cells and human cancer cells. It is markedly down-regulated during
cellular differentiation. Mice constitutively null for NS die in the preimplantation stage. Here
we sought to characterize the expression of NS in the intestine, and to determine its role
during gut development. We performed immunostaining for nucleostemin in adult mouse
intestine, in Caco-2 cells and analyzed the phenotype of the nucleosteminmutant in zebrafish.
In the adult mouse duodenum, NS was strictly localized in the crypts. Double immunofluo-
rescence showed expression nearly identical to Rbm19, another nucleolar protein expressed
in stem/progenitor cells. NS was highly expressed in actively dividing Caco-2 cells, but was
not detected in post-confluent cultures. Histologic analysis of a zebrafish mutant containing
an insertion in the ns gene revealed the intestine to be severely affected. At 5 dpf, the
intestine in ns mutant appeared immature and poorly differentiated, akin to the intestine
at 48-60 hpf. Based on these data and previous work in other organ systems, we conclude
that nucleostemin may play an essential role in the specification and/or maintenance of
intestinal progenitor cells. Further characterization of the zebrafish phenotype will likely
provide additional insight into the functional role of nucleostemin in the intestine.
T2141
TGF-β-Induced Epithelial to Mesenchymal Transformation Requires Epidermal
Growth Factor Receptor Activity
Karen C. Hobdy-henderson, Cindy L. Kanies, Bakula Trivedi, Nipun Merchant, Robert J.
Coffey, R. daniel Beauchamp
Introduction: Transforming growth factor-β (TGF-β) normally inhibits epithelial cell growth.
However, in many cancers TGF-β signaling is altered leading to resistance of tumor cells
to TGF-β's growth inhibitory effects. We have previously demonstrated that TGF-β augments
oncogenic Ras induced cellular transformation through mechanisms that are incompletely
understood. Microarray analysis of rat intestinal epithelial cells that conditionally express
oncogenic H-RasV12 (RIE:iRas) revealed a set of cooperatively regulated genes in response
to combined oncogenic Ras expression and TGF-β treatment. Among these, several members
of the epidermal growth factor (EGF) family of receptors and ligands were significantly
increased, such as EGFR and TGF-α . . Purpose: In this study we examine a role for EGFR
signaling in mediating TGF-β-induced transformation and loss of growth inhibition in
epithelial cells. Results: The induction of TGF-α by oncogenic Ras and TGF-β was confirmed
at both the mRNA and protein levels. While Ras robustly induces TGF-α mRNA expression
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in the presence or absence of TGF-β treatment, oncogenic Ras and TGF-β cooperate to
synergistically increase TGF-α protein expression. TGF-β also induced attachment and EMT,
as well as TGF-α expression, in the colon cancer cell line LIM1863, which normally grow
as floating organoids. Treatment RIE:iRas cells with EKI-785, an EGFR tyrosine kinase
inhibitor, blocked TGF-β-induced EMT, as confirmed by examining cell morphology and
the expression of EMT markers, such as decreased E-cadherin. Furthermore, EKI-785 also
blocked TGF-β-induced matrigel invasion of LIM1863 cells. Conclusion: We found that
during TGF-β induced EMT, epithelial cells show increased EGFR signaling. Induction of
EMT requires EGFR signaling since EKI antagonized cellular changes indicative of EMT,
therefore we conclude that TGF-β induced EMT requires EGFR activity.
T2142
Decreased Expression of Hmlh1 Correlates with Reduced 5-Fluorouracil-
Mediated Apoptosis in Colon Cancer Cells
Hideyuki Fujita, Jun Kato, Joichiro Horii, Keita Harada, Sakiko Hiraoka, Hidenori
Shiraha, Yasushi Shiratori
Background and aims: Recent evidence suggests that patients with sporadic microsatellite
instable (MSI) colorectal cancers, most of which the function of hMLH1 mismatch repair
(MMR) gene is impaired, lack a survival benefit with 5-fluorouracil (5-FU)-based chemother-
apy. The effect of MMR on drug cytotoxicity has been usually examined with one common
system with the hMLH1-deficient HCT116 human colon cancer cell line and a corrected
clone (HCT116 3-6), in which a normal human chromosome 3 was introduced by microcell
fusion. However, that system is problematic on the point that the restored choromosome
3 also contains several vital oncogenes and tumor suppressor genes other than hMLH1. In
this study, we assessed strictly the effect of hMLH1 status on cytotoxicity and apoptosis
induced by 5-FU administration by using the newly developed cell lines in which only the
expression of hMLH1 is regulated. Methods: We constructed two cell lines. One line is the
hMLH1-proficient SW480, in which expression of the siRNA targeted to hMLH1 reduced
expression of hMLH1. The other is hMLH1-deficient HCT116, in which expression of
hMLH1 can be tightly regulated by doxycycline with the help of the TetOff system. Firstly,
clonogenic survival assays were performed with these cell lines, to determine the effect of
loss of hMLH1 on response to 5-FU. To assess the apoptotic effects in these cells, the
DNA-specific fluorochrome 4,6-diamidino-2-phenylindole (DAPI) stain and flow cytometry
analysis by Annexin-V-FITC and propidium iodide staining were used. Since recent evidence
indicated that 5-FU incorporated into DNA mediated toxicity toward cells, incorporation
of 5-FU into DNA in our cell lines was determined using tritium labeled 5-FU. Results:
Both in our two cell lines, hMLH1-deficient cells exhibited approximately 2.4-fold clonal
surviving fraction compared to hMLH1-proficient cells for 10 days administration with 5
μM of 5-FU. hMLH1-deficient cells treated with 5 μM of 5-FU for 4 days exhibited 34-
45% less apoptosis than hMLH1-proficient cells by DAPI stain and flow cytometry analysis.
Furthermore, hMLH1-knocked-down SW480 cells treated with 1 μM tritium labeled 5-FU
for 4 days contained approximately 2-fold greater incorporated radioactive 5-FU than control
SW480, suggesting that recognition of 5-FU-incorporated-DNA is impaired in hMLH1-
deficient cells, to result in reduced apoptosis. Conclusions: Decreased expression of hMLH1
in colon cancer cells reduced apoptosis induced by 5-FU. This phenomenon may be related
with impairment of recognition of 5-FU-incorporated-DNA in hMLH1-deficient cells.
T2143
α-Actinin-1 Phosphorylation Modulates Pressure-Induced Colon Cancer Cell
Adhesion Through Regulation of Focal Adhesion Kinase-Src Interaction
David H. Craig, Beatrice Haimovich, Marc D. Basson
Metastatic progression is dependent on the adhesion of tumor cells to distant tissues.
We have previously reported that a pathophysiologically relevant (15 mmHg) increase in
extracellular pressure stimulates colon cancer cell adhesion to matrix proteins, endothelial
cell monolayers, and surgical wounds In Vivo by a β1-integrin-dependent mechanism that
requires an intact cytoskeleton and activation of both FAK and Src. α-Actinin facilitates
focal adhesion formation and physically links integrin-associated focal adhesion complexes
with the cytoskeleton. We therefore hypothesized that α-actinin may be necessary for the
mechanical response pathway that mediates pressure-stimulated cell adhesion. We reduced
α-actinin-1 and α-actinin-4 expression with isoform-specific siRNA and analyzed the effect
on pressure-activated colon cancer cell adhesion as well as the effect of increased pressure
on α-actinin-1 phosphorylation and α-actinin-1-FAK and -Src interaction. Transfection with
a Y12F α-actinin-1 phosphorylation mutant was used to assess the necessity of α-actinin-
1 tyrosine 12 phosphorylation in the pressure response. Silencing of α-actinin-1, but not
α-actinin-4, blocked pressure-stimulated cell adhesion in human SW620, HT-29 and Caco-
2 colon cancer cells as well as pressure-activated FAK Y397 and Y576 phosphorylation. Cell
exposure to increased extracellular pressure stimulated α-actinin-1 tyrosine phosphorylation
in cultured cell lines and primary human colon cancer cells as well as α-actinin-1 interaction
with FAK and Src. Transfection with the Y12F mutant blocked pressure-mediated adhesion,
disrupted the association of α-actinin-1 with FAK and Src, and inhibited pressure-induced
FAK activation. Moreover, siRNA-mediated reduction of α-actinin-1 disrupted pressure-
stimulated FAK-Src interaction. These results suggest that α-actinin-1 phosphorylation at
tyrosine 12 plays a crucial role in pressure-activated cell adhesion and mechanotransduction
by potentiating FAK-Src interaction and facilitating FAK phosphorylation at Y397 and Y576.
α-Actinin-1 may therefore provide a unique therapeutic target for the modulation of pressure-
induced cell adhesion and subsequent tumor metastasis.
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T2144
Control of Epithelial Morphogenesis By βPix, a Guanine Nucleotide Exchange
Factor for the Small Gtpases Cdc42 and Rac
Steen H. Hansen
Epithelial morphogenesis is essential to the development and function of the gastrointestinal
tract. Perturbation of epithelial polarity and of normal cell-cell and cell-matrix interactions
occurs during intestinal development and disease, notably IBD and cancer, and must be
restored during differentiation and wound repair. Previously, the machinery controlling
cell-cell interactions was considered distinct from constituents of cell-substratum contacts
comprised by focal adhesions (FAs). FAs are macromolecular complexes assembled on the
inner leaflet of the plasma membrane where integrins tether the cell to the extracellular
matrix. However, we have determined that p21-activated kinase, PAK, a FA-associated
effector molecule of the small GTPases Cdc42 and Rac, translocates to membranes engaged
in cell-cell contacts as epithelial cells polarize and that interference with normal PAK function
perturbs contact inhibition leading to cell multilayering (EMBO J., 22:4155). These effects
of mutant PAK forms are entirely dependent on the direct interaction with βPIX, a Cdc42/
Rac guanine nucleotide exchange factor, which exhibits a similar dynamic distribution in
epithelial cells as activated PAK. βPIX possess numerous protein-protein interaction motifs
in additional to its catalytic domain for which specific function-abrogating mutations have
been identified. Our AIM is to determine the molecular basis for βPIX functions in polarized
epithelial cells using Madin-Darby Canine Kidney (MDCK) cells as a model system.
METHODS: We have developed a technology permitting RNA interference-mediated knock-
down of gene expression followed by reconstitution with derivatives harboring silent muta-
tions that resist knockdown (EMBO J., 25:1848). We are using this technology to condition-
ally deplete endogenous βPIX from MDCK cells combined expression of RNAi-insensitive
βPIX derivatives that harbor function-abrogating mutations. This will allow us to determine
the properties of βPIX that are required for its epithelial functions. RESULTS&DISCUSSION:
Depletion of βPIX from MDCK cells fundamentally perturbs epithelial morphogenesis akin
to what has previously been described for the βPIX interactor hScrib, the mammalian
homologue of the tumor suppressor and polarity determinant Scribble in Drosphila. Interest-
ingly, hScrib is also lost during tumor progression in colon carcinoma. Using the reconstitu-
tion strategy we are currently testing whether the similarities between βPIX and hScrib
depleted cells result from disruption of the interaction between the two molecules, which
would indicate the an intact βPIX-Scribble complex is essential for epithelial morphogenesis.
T2145
Sialylation Protects α5β1 Integrin Expressing Tumor Cells from Galectin-1
Stimulated Anoikis
Hugo Sanchez ruderisch, Martina Welzel, Katharina Detjen, Hans-joachim Gabius,
Wolfgang Kemmner, Stephan Hinderlich, Bertram H. Wiedenmann
Background & Aims: In previous studies we identified the endogenous lectin Galectin-1
(Gal-1) as a functional interaction partner of the fibronectin receptor α5β1 integrin in
epithelial cancer cells including hepatocellular, pancreatic neuroendocrine and colorectal
cancer cells. Specifically, transfection of α5 integrin conferred Gal-1 binding, Gal-1 mediated
growth inhibition and anoikis susceptibility to α5 deficient colonic cancer cells. To further
delineate the mechanisms underlying Gal-1 mediated growth regulation, we studied Gal-1
interaction with α5β1 integrin in detail. Methods: Interaction between Gal-1 and α5β1
integrin were analyzed with biotinylated Gal-1 and/or fluorescence labeled anti-integrin
antibodies by flow cytometry or by western blotting. Anoikis was measured based on the
preG1 fraction of cell cycle analyses. Neuroaminidase was used to remove sialic acid residues
from glycosylated proteins. Results: Comparison of α5 expression and Gal-1 induced growth
effects in a large panel of cell lines revealed good overall correlation, but also identified
individual cell lines that failed to respond to Gal-1 despite α5 presence on the cell surface.
In these cell lines, binding of Gal-1 was reduced when compared to responsive cell lines
with matched α5 expression, indicating a proximal disruption of Gal-1 effects. As Gal-1
binds to β-galactosides on responsive cells, we hypothesized that access to these sites was
blocked in resistant cells due to tumor associated alterations of glycosylation. Of these, α2-
6 sialylation could potentially account for altered Gal-1 binding, prompting us to examine
the effects of sialidase treatment on Gal-1 binding and biological response. Sialidase treatment
of Gal-1 resistant cell lines increased the electrophoretic mobility of the β1 subunit of the
fibronectin receptor and rescued Gal-1 surface binding in α5 expressing cells. Importantly,
sialidase treatment sensitized resistant cells to Gal-1 stimulated anoikis. Furthermore, restitu-
tion of anchorage dependence by the tumor suppressor p16 in Capan I pancreatic cancer
cells was accompanied by (i) increased Gal-1 surface binding (ii) reduction of sialic acid
content and (iii) altered glycosylation of the fibronectin receptor. Conclusions: Taken together
our results identify altered sialylation of epithelial cancer cells as a critical mechanism
for tumor cells to escape from growth control imposed by Gal-1 interaction with the
fibronectin receptor.
T2146
The Functions and Mechanisms of Zinc Ribbon Domain-Containing 1 (Znrd1)
in Multidrug Resistance of Gastric Cancer
Liu Hong, Daiming Fan
AIM: To evaluate the functions and mechanisms of ZNRD1 in multidrug resistance of gastric
cancer. METHODS: The mouse monoclonal antibody against ZNRD1 was prepared. The
eukaryotic expressed vector and the small interfering RNA vector of ZNRD1 was constructed
by gene recombination. Stable transfectants with increased or decreased ZNRD1 expression
were obtained by G418 screening and further identified by RT-PCR and Western blot. The
In Vitro and In Vivo drug sensitivity analyses were made using 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide assay and mice assay. Accumulation and detention of
adriamycin in gastric cancer cells were examined by flow cytometry. Apoptosis of tumor
cells after treated with adriamycin was examined by transmission electron microscopy, DNA
Ladder electrophoresis and PI staining. Cell cycle distribution of gastric cancer cells was
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investigated by flow cytometry. Profiling of ZNRD1-responsive genes was investigated by
cDNA microarray and further identified by RT-PCR and Western blot. The effects of ZNRD1
on the transcriptional activity of multidrug resistance gene 1 (MDR1) gene were detected
by gene reporter assay. RESULTS: One monoclonal antibody named H6 (IgG1) effective in
detecting ZNRD1 was prepared. The gastric cancer cell models with increased or decreased
ZNRD1 expressionwere successfully established. Down-regulation of ZNRD1 led to enhanced
sensitivity of gastric cancer cells towards vincristine, adriamycin, 5-fluorouracil and cisplatin.
What'more, down-regulation of ZNRD1 increased the intracellular adriamycin accumulation,
inhibited the anti-apoptosis activity of tumor cells, and promoted cells from G1 to S phase.
Up-regulation of ZNRD1 led to decreased sensitivity of gastric cancer cells towards chemo-
therapeutic drugs, inhibited drug accumulation, and enhanced the anti-apoptosis activity
of tumor cells. ZNRD1 could regulate the expression of up to 62 genes, including up-
regulation of P-glycoprotein, Inosine monophosphate dehydrogenase 2 (IMPDH2), Bcl-2,
P21, P27, and down-regulation of Cyclin D1 and CDK4. ZNRD1 could up-regulate the
transcriptional activity of MDR1 gene. The inhibitors of P-glycoprotein and IMPDH2 might
reverse ZNRD1-induced multidrug resistance of gastric cancer to a degree. Conclusion:
ZNRD1 might play important roles in multidrug resistance of gastric cancer through regula-
tion of drug transportation, cell cycle and apoptosis. ZNRD1might be considered as a possible
target in gene therapy. KEYWORDS: multidrug resistance; ZNRD1; gastric cancer; RNAi
T2147
Indian Hedgehog (Ihh)- A New and Potent Agonist of the Extracellular
Calcium-Sensing Receptor (CaSR): Evidence of a Feed-Forward Cycle in the
Colon
R. john Macleod, Dinithi Pieris, Ivan Pacheco
Hedgehog signaling is responsible for congenital malformations in the intestine and has
been implicated in maintaining stem cell niches in the stomach and directing epithelial
differentiation in the colon. Two mammalian homologues of hedgehog exist in the intestine:
Indian hedgehog (Ihh) and Sonic hedgehog (Shh). To understand if the CaSR contributed
to Ihh homeostasis in the gut, we activated the CaSR on adenocarcinoma derived HT-29
cells and on 18Co cells, a sub-epithelial myofibroblast cell line. High Ca2+ (5 mM) increased
Ihh transcripts (RT-PCR) and protein (Western blots) in both cell types. No Shh was present
in HT-29 cells, but high Ca2+ obliterated Shh transcripts in 18Co cells. Transient transfection
with dominant negative CaSR (R185Q) prevented the increase in Ihh protein in both 18Co
and HT-29 cells. Other Gq/11 activators ADP or Endothelin did not stimulate Ihh transcripts
or protein on either cell type. CaSR-mediated stimulation of Ihh was prevented by inhibitiors
of ERK1&2, but not PI3K or p38 MAP kinase. We tested whether recombinant N-terminal
Ihh (rh-Ihh) peptide influenced CaR activity using stably CaR-transfected HEK cells with
pERK as an index of CaSR activation. Simulation of CaSR to rN-Ihh peptide was bell-shaped
with maximal stimulation at 2.5 pM (0.1 pM to 2.5 nM) suggesting activation of a mitogen
kinase phosphatase. rN-Ihh peptide was 1000X more potent then rN-Shh peptide. Neither
rN-Ihh or rN-Shh peptide stimulated pERK in non-CaSR expressing HEK cells. Bacterial
contaminant of the rh peptide was not the source of activation as conditioned medium from
293 cells transfected with full length Ihh, dose-responsively stimulated pERK in the CaSR-
HEK cells. Together our results suggest that regulated secretion of Ihh may occur after CaR
activation in the colon from both epithelia and sub-epithelial cells. Both native and rN-Ihh
peptide will stimulate the CaSR. The ability of native Ihh and rN-Ihh peptide to potently
stimulate the CaSR suggests that a feed-forward mechanism exists which may account for
Ihh homeostasis in the adult colon. Supported by operating grants from CIHR, CCFC and
the Dairy Farmers of Canada.
T2148
Hct-116 Human Colon Adenocarcinoma Cells Tumor Xenografts Grown in
Cox1 and Rag1 Double-Knockout Mice Have Impaired Angiogenesis and
Proliferation
Filipe Muhale, Suzanne Schloemann, Terrence Riehl, William Stenson
Introduction: Prostaglandin E2 (PGE2) exerts an essential role in mediating local inflamma-
tion including cell proliferation, apoptosis, tumor invasiveness and progression. HCT-116
cells produce negligible amounts of PGE2. Methods: In order to determine the outcome of
HCT-116 cells implanted in a mouse deficient on prostaglandin production we first intro-
duced the inactive mice Cox-1 gene in RAG1 deficient mice both in the C57/B6 mice.
One million HCT-116 cells contained in 1:1 McCoy media and Matrigel were injected
subcutaneously in the mouse flanks. All mice used were RAG1 knock-out and Cox-1 wild-
type (WT), or Cox-1 heterozygote (het.) or Cox-1 knock-out (KO). The tumors were
harvested one month after injection. Tumor xenografts were studied by macroscopic and
H&E analysis, and by immunohistochemistry. Results: All mice injected with HCT-116 cells
had grown tumors regardless of the host Cox-1 genotype. Tumor volumes were 110mm3±18
in the Cox KO mice; 802mm3±420 in the Cox-1 het. and 910mm3±269, in Cox-1 WT
host mice. Macroscopic analysis and H&E staining showed that tumor xenografts from Cox-
1 KO mice were poorly vascularized opposed to the conspicuous large vessels surrounding
the tumors grown in both Cox-1 wild-type and Cox-1 heterozygote mice. Numerous Ki-67
positive human cells were detected at the surface and the inner core of the tumors issued
from Cox-1 wild-type and Cox-1 het. mice. The number of Ki-67 positive cells was reduced
in the tumors fromCox-1 knock-out. Tumor vascularizationwas analyzed by immunostaining
with the antibody directed against the von WilleBrand factor VIII. Positively stained cells
were found in all areas of the tumors issued from the Cox-1 wild-type and Cox-1 heterozygote
mice, but mostly restricted to borders of the tumors grown in the Cox-1 knock-out mice.
Conclusion: Our results suggest that low levels of prostaglandin E2 diminish HCT-116
tumor cells xenografts vascularization and reduces tumor cells proliferation.
T2149
Pkc-δ Mediates Pro-Inflammatory Responses in Raw 264.7 Macrophage Cells
and Is Down-Regulated in Human Colon Cancer Stromal Cells
Sonia Cerda, Reba Mustafi, Pratyaya Majumder, Anusara Chumsangsri, Alessandro
Fichera, Maria Tretiakova, Amikar Sehdev, Urszula Dougherty, Jorge Delgado, Marc
Bissonnette
Introduction:We recently demonstrated a tumor suppressor role for serine/threonine kinase
PKC-δ in human colon cancer cells (Cerda et al. Oncogene, 2006). In human colon cancers
PKC-δ protein levels were significantly decreased in 13 of 14 malignant lesions compared
to adjacent colonic mucosa. These findings indicated that loss of PKC-δ occurs in the majority
of human colon cancers. The stroma plays important roles in inflammatory responses to
cancer. Since PKC-δ is ubiquitous, we examined its expression in the stroma of human
colon cancer specimens. We also studied this isoform's role in mediating stromal cell
inflammation In Vitro. Methods: Resected human colonic cancers were examined for PKC-
δ by immunostaining. To assess the potential significance of PKC-δ in stromal inflammation,
we examined murine RAW 264.7 macrophage cells In Vitro. RAW cells were cultured for
48 hr in DMEM medium containing 2.5% serum, 2.5% serum supplemented with albumin
(fatty acid vehicle control) alone, or with 100 μM indicated fatty acid: ω-3 [eicosapentaenoic
acid (EPA), docosahexaenoic acid (DHA)]; or ω-6 [linoleic acid (LA)]. Cells were then treated
with LPS (50 ng/ml) for an additional 8 hr. Cox-2, PKC-δ, p65 and iNOS expression levels
were measured by Western blotting in cell lysates. Results: In colonic specimens, PKC-δ
expression was decreased by 50% in cancer-associated stromal cells, compared to stromal
elements in adjacent normal appearing colonic mucosa (n=6). As an In Vitro model of cell
signaling, we treated RAW macrophage cells with LPS (50 ng/ml). LPS activated PKC-δ and
induced the expression of pro-inflammatory mediators p65, iNOS and Cox-2 (p< 0.05).
Pre-treatment with phorbol 12-myristate 13-acetate (TPA, 100 nM, 12 hr), down-regulated
PKC-δ expression and blocked iNOS induction by LPS, suggesting that PKC-δ pathways
participate in inflammatory responses induced by LPS. Furthermore, anti-inflammatory ω-
3 (EPA), but not pro-inflammatory ω-6 (LA) fatty acids, inhibited PKC-δ activation and
iNOS induction by LPS. These LPS-induced changes were completely blocked by pre-
treatment with TPA (p< 0.05). Results were confirmed in two independent platings in
duplicate. Conclusions: PKC-δ is down-regulated In Vivo in colonic tumor stromal cells
and mediates inflammatory signals In Vitro in RAW macrophage cells. PKC-δ activation in
innate stromal immune cells may play important roles in anti-tumor immune surveillance
and we speculate loss of this isoform could favor tumor growth. Further elucidation of PKC-
δ dependent pathways in stromal cells will be important to understand the role of this
isoform in stromal modulation of cancer growth.
T2150
Matrix Metalloproteinase-9 (MMP-9) Mediates Neo-Angiogenesis By Releasing
Vegf from Colon Cancer Cells
Lukas Hawinkels, Kim Zuidwijk, Hein W. Verspaget, Eveline S. De jonge-muller, Wim
Van duijn, Ruud Fontijn, Valerie Ferreira, Izak Biemond, Daan Hommes, Cornelis
Lamers, Cornelis Sier
Angiogenesis plays a major role in the outgrowth and metastasis of colon carcinomas.
Vascular Endothelial Growth Factor (VEGF) is considered the primary angiogenic factor for
solid tumors. Matrix metalloproteinase-9 (MMP-9) is, besides degradation of extra-cellular
matrix components, also involved in the modulation of regulators of cell growth and chemot-
axis. We evaluated the role of MMP-9 in the release and activation of VEGF in colon
cancer. VEGF and MMP-9 levels were significantly upregulated in cancer tissue homogenates
compared to normal mucosa from colon cancer patients. Immunohistochemistry revealed
that VEGF expression was confined to tumour cells, whereas MMP-9 staining was observed
mainly in stromal cells. The direct effect of MMP-9 on VEGF was evaluated In Vitro. Addition
of active MMP-9 to 3-dimensionally growing extracellular matrix producing HT29 colon
carcinoma cells resulted in dose-dependent release of VEGF into the medium, as determined
by ELISA. Moreover, the medium from the MMP-9 treated HT29 cells induced sprout
formation of endothelial cells in a 3-dimensional angiogenesis model, similar to recombinant
human VEGF. Addition of an MMP-inhibitor (Marimastat®) or the clinically used VEGF
inhibiting antibody Bevacizumab (Avastin®) significantly reduced sprout formation. Active
MMP-9 did not induce sprouting in the absence of tumor cells. Conclusions: The expression
of both MMP-9 and VEGF is enhanced in colon carcinoma tissues. Our In Vitro experiments
indicate that MMP-9 is involved in the release/activation of VEGF from colon cancer cells
resulting in neo-vascularisation. We propose that stromal cell-derived MMP-9 is required
for VEGF release from tumor cells resulting in tumor-associated endothelial cell neo-angiog-
enesis.
T2151
Effect of An Estrogen Receptor Beta (ERβ) Selective Agonist (Silymarin) Upon
Intestinal Adenoma Development in a Mouse Model of Adenomatous
Polyposis Coli (APC)
Alfredo Di leo, Eugenio Maiorano, Marcella Margiotta, Sabina Tanzi, Raffaella Guido,
Lucia Demarinis, Maria principia Scavo, Doriana Francioso, Antonio Francavilla
BAKGROUND. ERβ is the predominant isoform of the estrogens receptor in the normal colon.
Weyant et al. (1) have investigated the role of the estrogens in the intestinal tumorigenesis in
APC Min/+ mice undergoing ovariectomy. Their results pointed out that endogenous estrog-
ens protect against APC-associated tumor formation and this effect is associated with an
increase of ERβ and enterocyte migration in the intestinal crypt-villus. AIM. In this study
we evaluated the effect of silymarin on tumor number and volume, cellular migration and
ERβ at protein and mRNA levels, in C57BL/6J-Min/+ (APC Min/+) male mice developing a
colorectal cancer. METHODS. Thirty 5-6-week-old APC Min/+ male mice were divided in
two groups an fed on either a standard CK20 or a silymarin-enriched (0.2‰) CK20 diet.
At 15 weeks of age, all mice were sacrificed and their intestinal tract was examined under
magnification (x3) for polyp count and diameter determination by two independent observers
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blinded to the animal's treatment. Cellular migration was valued as described by Javid et
al. (2). Shortly, BrdU (0,75 mg/mouse) was injected and 5 animals of each group were
sacrificed at 24, 48 and 72 hours. Cellular migration was evaluated by establishing the
position of the highest BrdU-labeled cell in the crypt/villus (expressed as the percentage of
the crypt/villus length covered) in at least 10 well oriented crypts/villi. ERβmRNA levels were
measured by real time PCR while Western Blotting was used for ERβ protein determination.
Statistical analysis was performed by T-test. RESULTS: The number of polyps diminished
from 54.8 ± 20.2 in control group to 37.2 ± 9.1 in silymarin fed animals (p<0.005), and
the same behaviour was observed for the volume that varied from 242.1 ± 105.1 to 120.2
± 69.0 mm3 respectively (p<0.001). The highest BrdU-labeled cell value at 24 hours was
28.0 ± 2.6% and 46.6 ± 7.0% in control and sylimarin fed mice, respectively (p<0.05). ERβ
mRNA levels in sylimarin group increased about 60% as compared to control group (p<0.04).
This increase was associated to a parallel striking augment of ERβ protein expression as
compared to control. CONCLUSIONS: The silymarin administration determined a significant
reduction of polyp formation and development. This biological effect is associated to a
significant increase of intestinal cell migration probably related to the augment of ERβ. These
results suggest a possible role of sylimarin in the prevention of rectal colon tumors. 1 Cancer
Res 2001, 61:2547-51 2 Carcinogenesis 2005, 26:587-95
T2152
Solute Carrier Slc22a4 Confers Sensitivity of Cancer Cells to Cisplatin and
Carboplatin
Mitsunori Okabe, Gergely Szakacs, Toshihiro Suzuki, Michael M. Gottesman
Cancer cells may evade chemotherapy by mechanisms that keep the intracellular level of
drugs below a cell-killing threshold. Such mechanisms rely on decreased influx, as well as
increased efflux of anticancer drugs. Thus, concurrence of influx and efflux transporters
might influence the sensitivity of cancer cells by controlling drug accumulation. Earlier work
by one of us (M.O.) showed that the plasma membrane protein that is encoded by SLCO1B3,
which belongs to the solute carrier (SLC) family, is expressed in gastrointestinal cancers
and mediates the cellular influx of methotrexate, which is used in chemotherapy for gastric
cancer. It has been recently reported that two further SLC family members, SLC22A1 and
2, confer sensitivity of colon cancer cell lines to oxaliplatin, platinum-based anticancer drug
that is effectively used as chemotherapeutic agents to treat colorectal cancer. We assumed
that other SLC family members might also contribute to the cellular influx of anticancer
drugs. The aim of this study was to evaluate the contribution of all 29 SLC22 and SLCO
family members to the resistance or sensitivity of cancer cells. We performed real-time
quantitative RT-PCR measurements to profile the mRNA expression of all SLC22 and SLCO
family members in the NCI-60 cancer cell panel used by the National Cancer Institute to
screen for compounds with anticancer activity. Some SLCs showed moderate to high expres-
sion in the colon cancer cell lines in the NCI-60 cancer cell panel. By correlating those
expression patterns with the growth inhibitory profiles of 1,429 candidate anticancer drugs
tested on the cell panel, we identified SLC22A4 as a transporter that may confer sensitivity
of cancer cells to cisplatin and carboplatin. To test if the correlations reflect actual ability
to confer sensitivity, we established stable transfectants of SLC22A4 and determined the
drug sensitivity of the transfectants. Results showed that the SLC22A4 transfectants were 2
- 3 fold more sensitive to the drugs than the mock-transfected cells. In conclusion, our data
suggests that SLC22A4 contributes to the sensitivity of cancer cells to cisplatin and carbopla-
tin. Further evaluation of the role of SLCO and SLC22 family members in drug sensitivity
of cancer cells should provide important information to improve the choice of drugs in chemo-
therapy.
T2153
Characterization of the Integrin α8β1 - Nephronectin Interaction in the
Human Intestinal Mucosa
Yannick Benoit, Inga Teller, Elizabeth Herring, Jean-francois Beaulieu
INTRODUCTION: Integrin α8β1 interacts in an RGD dependent way with the extracellular
matrix in order to control various physiological mechanisms such as cell adhesion, migration
and proliferation as well as cell survival. The interaction between nephronectin (NPNT), an
element of the extracellular matrix expressed by epithelial cells, and α8β1 has been well
documented in the fetal kidney. Our group has shown in the past that integrin α8β1 is
expressed by the fetal mesenchyme in the intestinal mucosa but appears to be restricted to
smooth muscle cells in the adult stroma. Moreover, it has been shown in mice that NPNT
is over-expressed by some primary tumours having strong metastatic potential compared
to those of low metastatic potential. AIM: The object of our work was to characterize the
expression of NPNT in the human intestinal mucosa and to study the role of a possible
interaction of NPNT and α8β1 in physiological and pathological processes. METHODS AND
RESULTS: By western blot and semi-quantitative PCR, we have shown that NPNT is expressed
in small amounts by human enterocytes and colonocytes but is strongly produced by some
colon cancer cell lines while other cancer cell lines produce NPNT at levels equivalent to
normal epithelial cells. Using differents sets of PCR primers, we demonstrated that there
are two different mRNAs that potentially encode for two different NPNT isoforms in intestinal
epithelial cells. By semi-quantitative PCR, we found that one of these two isoforms is
predominantly produce by the human intestinal epithelial cells. Furthermore, the expression
of NPNT has been found by real-time PCR to be up-regulated from between 3.5 and 72
fold in specimens of human colon cancer (n=10). Finally, some preliminary results by semi-
quantitative RT-PCR have shown an increase in the amounts of α8β1 and NPNT in human
colorectal cancer specimens as the tumour progresses in the carcinogenesis cascade. CON-
CLUSION: These results show for the first time that NPNT is produced by intestinal epithelial
cells and that the interaction of NPNT with the integrin α8β1 could be a key regulator of
human colon cancer progression.
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T2154
Less Frequent Expression of Cyclooxygenase-2 in Colorectal Serrated Polyps
Than in Colorectal Traditional Adenomas
Hiromi Bamba, Shinichi Ban, Yoshiya Goto, Shin Arai, Keiko Ishikawa, Yukinori Imai,
Akihiko Takeda, Yoshihide Otani, Isamu Koyama, Michio Shimizu
Cyclooxygenase-2 (COX-2) is expressed in interstitial cells of colorectal adenomas, a pre-
cursor lesion of adenoma-carcinoma sequence. Recently, serrated polyps (hyperplastic polyps
and serrated adenomas) have attracted attention as precursor lesions in another pathway of
colorectal carcinogenesis. However, roles of COX-2 in serrated polyps are not clear. To
investigate whether COX-2 has a role in serrated polyps similar to that in traditional aden-
omas, we examined the distribution of COX-2 expressing cells in serrated polyps. Methods:
Colorectal tumors were obtained from endoscopic polypectomy and surgical resection mat-
erials at Saitama Medical University Hospital and its related hospitals. They included 16
traditional adenomas, 11 hyperplastic ployps, and 14 serrated adenomas. The expression
of COX-2 protein was immunohistochemically examined on formalin-fixed and paraffin-
embedded tissue sections using the anti-COX-2 antibody (IBL 18515). The COX-2 immuno-
reactivity was scored semi-quantitatively. The type of cells expressing COX-2 was further
immunohistochemically identified using anti-CD68 antibody (KP1, DAKO) as a marker of
macrophages and anti-α-smooth muscle action antibody (1A4, DAKO) as a marker of
myofibroblasts. Results: Normal-appearing colorectal mucosa adjacent to the lesions was
negative for COX-2 expression. COX-2 expression was shown in 83.1% of traditional
adenomas, in which COX-2 was strongly expressed in subepithelial interstitial cells distrib-
uted in the surface area of these lesions. The distribution of CD68 positive macrophages
was overlapped at least partly with that of COX-2 positive cells. In contrast, COX-2 expression
was significantly infrequent in serrated polyps (hyperplastic polyps = 9.1%, serrated aden-
omas = 6.3%), although some COX-2 positive cells were idenfied in the area with CD68
positive macrophages in only one lesion of hyperplastic polyp, and serrated adenoma,
respectively. There was no difference in COX-2 expression between hyperplastic polyps and
serrated adenomas. Conclusions: COX-2 is rarely expressed in colorectal serrated polyps
in contrast to traditional type colorectal adenomas. This might provide a insight in the
aspect of different carcinogenetic process between traditional adenomas and serrated polyps.
T2155
Effect of Gemcitabine Combined with Hyperthermia On the Cytotoxicity in
Cultured Human Pancreatic Cell Lines
Satoko Adachi, Satoshi Kokura, Takeshi Ishikawa, Tomohisa Takagi, Osamu Handa, Yuji
Naito, Norimasa Yoshida, Toshikazu Yoshikawa
Background and Aim: The transcription factor NF-kB is constitutively activated in many
human cancers, and induces the expression of multiple genes including anti-apoptotic genes.
Therefore, the blocking of NF-kB activity may be associated with the induction of apoptosis.
It is also reported that NF-kB is further activated by chemotherapy in some cancer cell lines
and NF-kB activation is one of mechanisms by which tumors are induced to become resistant
to chemotherapy. Thus, it is expected that the blocking of NF-kB could attenuate the tumor
growth, and enhance the anti-tumor effect of chemotherapeutic compounds. In this study,
we examined the relevance of NF-kB in the resistance of pancreatic carcinoma cell lines
against for gemcitabine. We and other groups reported that hyperthermia-induced Hsp70
could inhibit Ikk, resulting in the inhibition of NF-kB activation. Therefore, we speculated
that the activated NF-kB in pancreatic cell line might be inhibited by hyperthermia, resulting
in the enhancement of gemcitabine-induced cytotoxicity. Methods: We used human pancre-
atic carcinoma cell lines, AsPC-1 and MIAPaCa-2. AsPC-1 and MIAPaCa-2 were treated with
various concentration (0, 5, 10, 20 and 30μM) of gemcitabine for 24 hours. Hyperthermia
(43 degrees Celsius 1hr) was combined with gemcitabine at the various timing. The effect
of gemcitabine and heat treatment on cell survival was determined by WST-8 assay. The
status of NF-kB in carcinoma cells exposed to gemcitabine was investigated by EMSA and
immunocytochemistry. We analyzed apoptosis and necrosis in AsPC-1 and MIAPaCa-2 by
flow cytometry. Furthermore the levels of Hsp70, cyclin D1, caspase-3, VEGF in each
treatment group were detected by Western bloting. Results: 1) A significant cytotoxicity was
observed with gemcitabine. 2) Gemcitabine activated NF-kB binding activity in both cell lines.
3) Hyperthermia inhibited the gemcitabine-induced activation of NF-kB. 4) Hyperthermia
enhanced the cytotoxicity of gemcitabine especially when hyperthermia was performed 24h
before the treatment of gemcitabine.5) The levels of Hsp70 was increased by hyperthermia.
Gemcitabine did not affect the protein level of Hsp70. The levels of pre-caspase-3 were
decreased by hyperthermia combined with gemcitabine. Conclusions: Hyperthermia inhib-
ited gemcitabine-induced activation of NF-kB, resulting in the enhancement of the cytotox-
icity of gemcitabine. It is important to investigate the schedule-dependency of hyperthermia
combined with gemcitabine.
T2156
A Role for Iron in Wnt Signalling and Human Colorectal Carcinogenesis
Matthew J. Brookes, Boult Jessica, Tariq Ismail, Tariq Iqbal, Chris Tselepis
Introduction and Aims: There is an emerging body of evidence implicating iron in colorectal
carcinogenesis. What remains unclear however is what effect, if any, iron has on Wnt
signalling. Wnt signalling is the major oncogenic signalling pathway which is activated in
colorectal cancer due to aberrations in several key proteins, including adenomatous polyposis
coli (APC). Truncating mutations in APC occur in the majority of sporadic colorectal cancers
and are associated with early adenoma formation rather than late stage disease. Along with
several other associated proteins namely GSK-3β and Axin, APC functions to regulate the
cellular levels of beta-catenin by binding and marking this protein for degradation. However,
in instances where APC is non-functional beta-catenin accumulates and complexes with
transcription factors of the Tcf/Lef-1 family. This culminates in target gene activation, amongst
which are oncogenes such as c-myc and cyclin D1. The aims of this study were to determine
if iron could induce Wnt signalling and if so whether this was APC or E-cadherin dependent.
Methods: APC wild type (HEK-293 and primary dermal fibroblasts (E-cadherin negative))
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and colorectal APC mutant lines (Caco-2, SW480) were all challenged with either FeSO4
[100μM] or hemin [50μM] in the presence or absence of 20mM LiCl (GSK-3β inhibitor)
for 24 hrs. Cellular iron levels and Wnt signalling were assayed using the ferrozine and
TOPFLASH assays respectively. Wnt signalling was also assessed in SW480 cells transfected
with full length wild type APC. mRNA levels of Nkd-1 and c-myc (known targets of Wnt
signalling) were assayed by Real Time PCR. Results: All cell lines demonstrated significant
iron loading following culture with FeSO4 or hemin. Challenging APC mutant lines with
FeSO4 or hemin resulted in significant increases in Wnt signalling as evidenced by increased
TOPFLASH activity and increased c-myc and Nkd-1 mRNA expression. This iron mediated
Wnt signalling effect in SW480 cells could be silenced by transfection of wild type APC.
Wnt signalling was only induced in APC wild type and E-cadherin -negative cells when
they were cultured with FeSO4 or hemin along with the GSK-3β inhibitor LiCl. Conclusions:
This study demonstrates that iron can induce Wnt signalling, only in a background of a
loss in APC, but is not dependent on E-cadherin. Patients with colorectal adenomas are
highly likely to have a mutated APC and we predict that high colonic luminal iron could
exacerbate carcinogenesis. This this work introduces the potential for iron chelators in the
management of colonic polyps.
T2157
Cholecystolithiasis Is a Risk Factor for Colorectal Adenoma Together with Life
Habit Factors
Yutaka Yamaji, Makoto Okamoto, Takao Kawabe, Toru Mitsushima, Masao Omata
Introduction: A modest risk for colorectal cancer in post-cholecystectomy patients has been
reported. However, the relationship between cholecystolithiasis and colorectal adenoma has
scarcely been reported. We aimed to evaluate this issue on the basis of screening examination
of colonoscopy and ultrasonography on asymptomatic Japanese. Methods: We reviewed a
subgroup of the subjects of our prospective annual colonoscopy screening survey (GIE
2006;63:453). The subjects who underwent ultrasonography screening simultaneously at
the initial total colonoscopy and answered the questionnaire about life habit were evaluated.
The subjects with regular use of NSAID were excluded. A total of 5,270 subjects (male/
female = 3,705/1,565, mean age = 46.0) were entered into analysis. The risk of colorectal
adenomas in subjects with findings of cholecystolithiasis or post-cholecystectomy was invest-
igated in comparison with those with normal gallbladder. Results: Among 5,270 subjects,
cholecystolithiasis was found in 204 subjects (3.9%) and 61 subjects (1.2%) were post-
cholecystectomy, whereas 4,138 had normal gallbladder. Colorectal adenomas were found
in 985 subjects (18.7%). In the subjects with cholecystolithiasis, the prevalence of colorectal
adenoma was 30.9% (63/204), which was significantly higher than that in normal subjects,
17.4% (718/4,138, p<0.001). In the post-cholecystectomy subjects, it was 16.4% (10/61)
with no significant difference. In a multivariate analysis controlling sex, age, family history
of colorectal cancer, alcohol, smoking, and body mass index, cholecystolithiasis was shown
to be an independent risk factor for colorectal adenoma (adjusted Odds Ratio: 1.71, p=
0.001). All the other factors except family history were also independent risk factors.
In subgroup analyses according to size, multiplicity and location of colorectal adenomas,
cholecystolithiasis was especially associated with multiple (>=3 lesions, adjusted OR: 2.11,
p=0.02) or left-sided colorectal adenomas (adjusted OR: 1.92, p<0.001). Conclusion: Chole-
cystolithiasis is a risk factor for colorectal adenoma.
T2158
Isolation of Gastric Cancer-Initiating Cells Using Cell Surface Marker Cd44
Shigeo Takaishi, Tomoyuki Okumura, Shuiping Tu, Sheng-wen Wang, Frederic Marrache,
Iva Smirnova, Alexander Dubeikovskiy, Zinaida Dubeikovskaya, Wandong Ai, Melitta
Penz-oesterreicher, Emi Osawa, Jacqueline Baumgartner, Kelly S. Betz, Timothy C. Wang
Background & Aims: Recently it has been reported that cancers are heterogeneous, with
only a small subset of cells able to initiate disease. This subset has been designated cancer-
initiating cells or cancer stem cells (CSCs), and the identification and purification of CSCs
has been reported for leukemia, breast, brain, prostate and colon cancer. In this study, we
have investigated potential markers for gastric cancer stem cells. Methods: Human gastric
cancer cell lines N87, MKN45, KATO-III and AGS were analyzed for surface markers and
sorted by FACS, then inoculated in 96-well plates (10 cells/well) and tested for proliferation
in serum-free media (RPMI1640 plus EGF 20ng/ml & bFGF 10ng/ml). Side-population (SP)
and non-SP cells were also analyzed. In addition, we analyzed gastric cells isolated from a
gastric cancer mouse model (INS-GAS mice infected with H. pylori SS1 for 7-8 months).
Results: CD44 was expressed in a distinct subpopulation of all 4 cell lines, while CD24 was
expressed in a subpopulation in 3 cell lines (not KATO-III). CD133 expression was noted
in only KATO-III. As shown in table1A-C, CD44+ cells showed superior growth in serum-
free culture compared to CD44- cells in 3 cell lines examined. In addition, by using ultra
non-cluster 96-well plates for N87 cells, CD44+/CD24- cells produced 5 spheroid colonies,
while the other 3 fractions had no colonies. In contrast, CD24+ and CD24- cells did not
show significant difference of cell growth (table1D). SP and non-SP cells were observed in
3 cell lines (not AGS), and they did not show significant difference of cell growth (table1E).
Fractionated cell implantation into SCID mice is currently under way. By immunohistochem-
istry, CD44 was strongly expressed in invasive gastric cancer lesions in H. pylori-infected
INS-GAS mice, while CD24 was primarily expressed in immune cells and weakly positive
in selected areas of cancer lesions. CD133 was expressed in the submucosa and immune
cells. Among CD45 negative fraction (non-hematopoietic cells), there were 3 fractions,
CD44+/CD24-, CD44-/CD24+ & double negative cells, but no double positive cells. In
serum-free culture, there were 9 cell-growth(+) wells for CD44+/CD24-, but only 3 and 4
(+) wells for CD44-/CD24+ & double negative cells, respectively. Conclusions: The
CD44(+)CD24low/- fraction may contain possible gastric cancer stem cells, and thus an
important target for the design of gastric cancer therapies.
Table1: Numbers of cell-growth positive well
T2159
Effect of Aspirin On Interleukin-8 Production in Human Colonic
Myofibroblasts Stimulated with TNFα and IL-1β
Nicola J. Hellen, Lopa Leach, Christopher J. Hawkey
Introduction Clinical and epidemiological data suggest that low-dose aspirin is protective
against colorectal cancer. Inhibition of tumour angiogenesis is a potential mechanism, which
is important in tumour growth and metastasis. Myofibroblasts are thought to form pericytes
In Vivo and are a source of IL-8. We have previously shown that expression of IL-8 by
human intestinal myofibroblasts in culture is markedly suppressed by aspirin (Hellen et al,
2005; Gut, 54 (suppl VII) A243). We now investigate release of IL-8 by human intestinal
myofibroblasts under the stimulation of tumour necrosis factor alpha (TNFα) and Interleukin-
1β (IL-1β) and the effects of aspirin on this. Methods Human intestinal myofibroblasts were
isolated from patients undergoing surgery as previously described and established in limited
passageable culture. Myofibroblasts from normal mucosa (passages 2-5) were cultured in
monolayer in 24 well plates. IL-8 released into culture supernatant or remaining within the
cells (lysis with 0.05% saponin) upon stimulation with TNFα (10ng/ml) or IL-1β (10ng/
ml) for 24 hours in the presence or absence of aspirin, 10-5M or 10-4M, was determined
using Duoset® Human IL8/CXCL8 ELISA (R&D systems). Cell viability was assessed using
CellTiter 96® AQueous one solution cell proliferation assay (Promega). Results IL-1β, TNFα
and aspirin (10-5M, 10-4M) did not affect cell viability compared to untreated controls
(p>0.5, students t-test, n=5). The ratio of IL-8 in culture supernatant compared to intracellular
levels was 11:1 showing that the majority was released. IL-8 release was increased 50 fold
by IL-1β and 32 fold by TNFα. Aspirin had opposite effects in the presence of IL-1β and
TNFα. In the presence of TNFα there was a reduction in IL-8 synthesis and release (by
43% at 10-5M and by 45 % at 10-4M). Interestingly, a bi-phasic response to aspirin was
witnessed in IL-1β stimulated cells. 10-5M aspirin treatment resulted in a 17% decrease in
IL-8 release whereas 10-4M produced a 43% increase. Conclusions These data confirm at
a protein level that aspirin can have profound effects on release of pro-angiogenic interleukin-
8 by myofibroblasts that are capable of forming pericytes. Differences between the effects
of aspirin with TNFα andwith IL-1βmay reflect the predominant use by TNFα of intracellular
signalling pathways involving NFκB which can be inhibited by aspirin compared to IL-1β
which signals through other pathways.
T2160
Oncogenic RAS and TGF-β Cooperatively Regulate Gene Expression Through
a Post-Transcriptional Mechanism of mRNA Stabilization
Cindy L. Kanies, Lisa Young, Lauren Sims, Hana Abulleef, Christian Kis, Carl Schmidt,
Bonnie Lafleur, Khalid Khabar, Natasha Deane, Dan A. Dixon, R. daniel Beauchamp
Oncogenic Ras activation contributes to cellular transformation and increased invasiveness
of intestinal epithelial cells. Treatment of Ras-transformed intestinal epithelial cells with
TGF-β promotes cellular changes associated with epithelial to mesenchymal transition (EMT).
In this study, we characterized global changes in gene expression during Ras-induced
transformation and TGF-β-induced malignant behavior using microarray analysis. The genes
cooperatively regulated by the combined activation of Ras and TGF-β signaling include a
high proportion containing AU-rich element (ARE) motifs known to regulate mRNA stability,
examples of which include COX-2 and VEGF. While 5-8% of the transcriptome is estimated
to contain such elements, transcripts that were cooperatively or uniquely regulated by Ras
and TGF-β in our microarray experiment were enriched with ARE-containing genes to 41%
of the total. We further demonstrate synergistic upregulation of VEGF mRNA and protein
expression by Ras and TGF-β through a post-transcriptional mechanism of mRNA stabiliza-
tion. VEGF mRNA half-life was increased 2-fold in response to either Ras induction or TGF-
β treatment alone and synergistically increased 4- to 5-fold by combined activation of both
Ras and TGF-β signaling. Consistent with the observed mRNA stabilization, expression of
oncogenic Ras and TGF-β-treatment induced cytoplasmic accumulation of the ARE-binding
mRNA stability factor HuR. These studies demonstrate that oncogenic Ras and TGF-β
synergistically increase VEGF and a significant proportion of genes containing AREs in
intestinal epithelial cells, suggesting that post-transcriptional regulation of mRNA stability
is an important mechanism of gene regulation during EMT.
T2161
Ectopic Expression of Activation-Induced Cytidine Deaminase in Ulcerative
Colitis-Associated Colorectal Cancers
Tadayuki Kou, Hiroyuki Marusawa, Yoko Endo, Hiroshi Nakase, Shigehiko Fujii, Kazuo
Kinoshita, Takahiro Fujimori, Tasuku Honjo, Tsutomu Chiba
Background & Aims: Activation-induced cytidine deaminase (AID) is involved in somatic
DNA alterations of the immunoglobulin gene for amplification of immune diversity. The
fact that aberrant expression of AID in mice caused tumors in various epithelial tissues
including liver and lung as well as lymphoid tissues suggests the important role of the
aberrant editing activity of AID on various tumor-related genes for carcinogenesis. We
previously demonstrated that overexpression of AID is observed in human hepatocytes with
several pathological settings including liver cirrhosis and hepatocellular carcinoma, suggesting
that pro-inflammatory condition causes the aberrant expression of AID in human epithelial
cells. The aim of this study is to clarify the role of AID on carcinogenesis in the colonic
A-633 AGA Abstracts
epithelial cells underlying inflammatory bowel disease.Methods: The transcriptional regula-
tion of AID expression and the possible effect of ectopic AID expression on genetic susceptibil-
ity to mutagenesis were investigated in cultured cancer cells. Expression of endogenous AID
was analyzed in colon tissues of 22 ulcerative colitis (UC) lesions, 15 colitic cancers,
five sporadic colon cancers from non-UC patients and two normal controls. Results: AID
expression is induced in response to tumor necrosis factor-α (TNF-α) stimulation in cultured
cells. The pro-inflammatory cytokine-mediated expression of AID is achieved by IκB kinase-
dependent NF-κB signaling pathways. Aberrant expression of AID resulted in accumulation
of multiple genetic alterations in the tumor-related genes including p53 and c-myc, suggesting
that inappropriate expression of AID acts as a DNA mutator that enhances the genetic
susceptibility to mutagenesis in human epithelial cells. In normal human colonic epithelial
cells, immunohistochemistry detected no evidence of the AID expression. In contrast,
immunostaining for AID was detectable in 12 of 22 UC lesions. Strongly AID positive cells
were mainly observed in the colonic specimens accompanied with the submucosal infiltration
of the lymphocytes. Moreover, increased AID expression was detected in 12 of 15 colitic
cancer lesions. On the other hand, AID immunoreactivity was positive in two of five sporadic
colon cancers originating from the non-UC cases. Conclusions: Our findings indicate that
a potential DNA mutator, AID, is induced in the colonic epithelial cells in response to
inflammatory stimuli. The ectopic expression of AID by pro-inflammatory cytokine may
provide the link between colonic inflammation and the development of colitic cancers.
T2162
Hetes Enhance COX-2 Message Stability Via An NAD(P)H Oxidase-Dependent
Generation of Reactive Oxygen Species
John Di mari, Randy C. Mifflin, Suimin Qiu, Don W. Powell
Background: Lipoxygenase metabolites are key paracrine modulators of intestinal inflamma-
tion and their hydroxy-eicosatetraenoic acid (HETE) derivatives regulate apoptosis and
proliferation in the malignant epithelium. We have demonstrated that HETEs enhance
cyclooxygenase-2 (COX-2) expression in colonic myofibroblasts (CMF), a key site of COX-
2 expression in colonic adenomas. HETEs increase COX-2 mRNA stability by activating
p38, MAPKAPK-2 (MK-2) and HuR, stabilizers of COX-2 mRNA. Furthermore, treatment
with HETEs causes intracellular accumulation of reactive oxygen species (ROS), a process
required for IL-1-induced COX-2 expression in CMF. Aims: The aims of this study were
to determine if increased ROS levels generated by HETEs cause the observed enhanced
COX-2 message stability and to determine the mechanism of HETEs- induced ROS produc-
tion.Methods: To determine the effect of ROS on the activation of COX-2mRNA stabilization
pathways, cultured CMFs were pretreated with peroxide (100 and 200 μM) for 10 minutes
prior to the addition of IL-1 (500 pg/ml). Total protein was used for Western blot analysis
to determine p38 and MK-2 phosphorylation and the cytosolic fraction was used to monitor
HuR migration. To determine the mechanism of HETE-induced ROS generation, cultured
CMFs were treated with inhibitors of NAD(P)H oxidase, cytochrome p450s, 5-lipoxygenase
, cytochrome c-reductase, xanthine oxidase and nitrous oxide synthase for one hour prior
to the addition of IL-1 (500 pg/ml) and/or 5(S) HETE (10 μM). Protein was isolated and
COX-2 expression levels were determined by western blotting. Single cell ROS generation
was determined by DCF (2',7'-dichlorofluorescin diacetate) fluorescence. Results: Peroxide
induced p38 and MK-2 activation and HuR migration and augmented the activation of these
molecules by IL-1 (2 fold for HuR, and 4 fold for both p38 and MK-2). The inhibitor studies
demonstrated that only DPI (diphenyleneiodonium chloride), an NAD(P)H oxidase inhibitor,
blocked the augmentation of IL-1-induced COX-2 expression by 5(S) HETE. DPI also
completely blocked IL-1 or IL-1 + 5(S) HETE-induced COX-2 expression and inhibited
HETE-induced ROS generation by 50% (310.5 + 38 versus 157.8 + 13, for HETE and HETE
+ DPI, respectively at 35 minutes). Conclusion: Our data demonstrate that HETEs augment
IL-1-induced COX-2 expression via an NAD(P)H oxidase -dependent ROS generation and
that peroxide mimics this effect. ROS augment COX-2 by activating p38, MK-2 and HuR.
Thus, along with their ability to increase carcinoma cell survival and proliferation, HETEs
may also contribute to carcinogenesis by augmenting COX-2 expression in the tumor stroma.
T2163
Role of Toll Like Receptor 4 (TLR4) in the Development of Colitis-Associated
Adenocarcinoma in Interlukin-10 Deficient (IL-10-/- ) Mice
Rui Zhang, Donna-marie Mccafferty
Background: Current evidence suggests that chronic inflammation in patients with inflammat-
ory bowel disease is due to an aberrant immune response to enteric flora. Lipopolysaccharide
(LPS) is a potent proinflammatory component of gram negative bacteria which signals
through the transmembrane toll like receptor 4 (TLR4). Here we examined the role of TLR4
signaling in the development of colitis-associated adenocarcinoma in IL-10-/- mice. Method:
Wild type (WT; 129Sv/Ev), IL-10-/- or IL-10-/-/TLR4-/- mice were studied at 3 months for
signs of colitis. Inflammation was assessed usingmacroscopic and histological scoring systems
and by granulocyte infiltration assessed by measuring myeloperoxidase activity (U/mg tissue).
Neoplastic changes were assessed using macroscopic mucosal polyp score and histological
identification (epithelial hyperplasia, aberrant crypt foci, abnormal crypt formation, submu-
cosal invasion of crypts, neoplastic nuclei). Message for iNOS was measured by real-time
PCR. Serum NO production was measured by Griess Reaction. Chemokines and cytokines
were measured by Rnase protected assay (RPA). Results: IL-10-/- mice had significantly
increased macroscopic (3.9+0.3) and microscopic scores (5.5+0.4) over WT mice (0.6+0.03
and 2+0.6, respectively). An increase in granulocyte infiltration was also noted (5.0+1.0 U/
mg vs 1.9+0.4 U/mg, in WT). In IL-10-/-/TLR4-/- mice a significant increase in macroscopic
score (4.8+0.4) and histological scores (6.6+0.3) but not granulocyte infiltration (5.4+1.2)
was observed over IL-10-/- mice. Interestingly, a significant increase in macroscopic polyp
score (3.2+0.2) was noted in IL-10-/-/TLR4-/- mice compared with IL-10-/- (2.7+0.2). In
addition, neoplastic criteria identified histologically were significantly increased (4.8+0.5 vs
3.3+0.5 respectively). WT mice did not develop mucosal polyps on histological examination.
10/19 of IL-10-/-/TLR4-/- mice had submucosal crypt invasion compared with 1/8 in IL-10-/-
mice at 3 months. Colonic iNOS mRNA and serum NO were significantly decrease in IL-
10-/-/TLR4-/- (6.2+5.4; 72.7+5.8uMol/L) over IL-10-/- (1241+448; 109+12uMol/L) mice.
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Concomitantly, IL-10-/-/TLR4-/- mice had significantly lower chemokine levels (e.g. RANTES,
MIP-1α,β, MCP-1, Tac-3 and IP10, p<0.05) than IL-10-/- mice. Conclusions: Absence of
TLR4 results in enhanced adenocarcinoma development in IL-10-/- mice, possibly through
by inhibition of iNOS expression, NO production or leukocyte recruitment in the gut.
Supported by a CIHR Operating Grant and CIHR Group Grant.
T2164
Expression of a Novel Colon Cancer Marker, Tc22, in Ulcerative Colitis
Mucosa: A Possible Molecular Tool for Screening
Xin Geng, Yingxin Kong, Angela Sefah, Michael Papper, Kiron M. Das
Introduction: Chronic ulcerative colitis (UC) is a pre-cancerous condition of the colon. The
incidence of colon cancer increases after 8 yrs. of the disease. Identification of dysplastic
changes by colonoscopy and biopsy is clinically challenging. We have identified a novel
tropomyosin (TM) isoform, TC22, which is expressed by neoplastic but not by the normal
colon epithelial cells (Gastroenterology 123:152,2002). TC22 is identical to the normal
epithelial TM isoform, hTM5, except for the C-terminal domain, amino acid 222-247 coding
the exon 9. TC22 is an alternatively spliced variant of hTM5. Ninety-five% of adenocarcinoma
of the colon express TC22, and 55% of adjacent normal colon tissue also expressed TC22.
Materials and Methods: Utilizing a specific monoclonal antibody (mAb) against TC22
(TC22-4) developed by us, we have examined colonoscopic biopsy specimens from the
recto-sigmoid area from 65 patients (36 male) with UC. Expression of TC22 and hTM5 was
measured by quantitative Western blot assay (software, Kodak 1D 3.5) utilizing the mAb
TC22-4 for TC22 and CG3 for hTM5. Using specific primers, we also quantitated TC22
and hTM5 at the gene expression level by real time RT-PCR. Results: The mean age of all
patients was 43 yrs., (range 11-71). Twenty-one patients had pancolitis and 44 had distal
colitis. Twenty-four patients were symptomatic and 41 were in remission. Thirty-six patients
(mean age 48) had UC for >8 years and 29 (mean age 40) for <8 years. TC22 concentration
is measured in relation to hTM5 concentration from the same tissue and expressed as follows:
TC22 ÷ hTM5 X 100. In patients with UC for >8 years, the mean TC22 value was 20 ±
4.6, and the patients with <8 years duration, the value was 11 ± 2.7 (p<0.05). The patients
with active disease had higher TC22 expression, with a value of 23 ± 5.8 and 12 ± 2.8 for
patients in remission (p<.05). However, among the total patients with UC in remission (n=
41), patients >8 years of duration (n=26) had a higher value of 15.5 ± 4.1 when compared
to the value of 4.4±2 for patients (n=15) in remission and <8 years. This difference was
statistically highly significant (p<0.01). Real time RT-PCR measurement of TC22 at the gene
expression level was significantly higher in patients with disease for >5 years compared to
<5 years (p<0.05), with a mean value of 4.1 ± 0.6 vs. 2.5 ± 0.5. Six patients with the highest
TC22 expression (2- to 6-fold higher than the mean value of all patients <8 yrs. duration)
had UC for 10-30 years. Conclusion: Expression of TC22 in colonoscopic biopsy specimens
may provide a novel molecular tool and help to identify high risk patients with UC.
T2165
Colorectal Cancer Risk in Crohn's Disease in Japanese Patients
Toshiyuki Matsui, Yutaka Yano, Fumihito Hirai, Hiroyuki Uno
Background and aims: The number of Japanese patients with Crohn's disease (CD) is
increasing, mainly in adolescents and the elderly. Based on annual governmental reports,
the number of patients with CD reached 20000 people in 2003 and the incidence, which
is increasing gradually, has been estimated to range between 0.9 and 1.2 /100000 recently.
This study aimed to elucidate the relative risk of colorectal cancer in patients with CD in
our hospital (a tertiary referral center for IBD). Patients and methods: The subjects were
512 patients (357 male, 155 female, average age at diagnosis 22.7 years; range 6-67) treated
at Fukuoka University Chikushi Hospital who were followed up for long periods of time
(from 1987-2005, average 12.1 years; range 0.1-52.4). Sites of CD involvement were; small
intestine 181 (35.5%), large intestine 71 (12.4%), small and large intestine 175 (34.2%)
and other types 85 (16.7%). The cumulative rate of colorectal cancer was observed in CD
patients and in normal controls whose sex and age were adjusted to those of the patients
group (by an actuarial method). The relative risk of colorectal cancer was estimated by
comparison with observed and expected numbers of cancer patients. The expected number
for colorectal cancer was calculated by age, while sex adjusted risks were estimated by
government statistics in an average Japanese population in 1999. Results; Six patients in
our cohort had colorectal cancer (2 male and 4 female; 1 with cancer at an ileocolonic
fistula, 3 with anal canal cancer and 2 with rectal cancer). Other cancers such as rectal
carcinoid, gastric, uterine cancer and leukemia were excluded from study. The cumulative
cancer rate in our hospital based on the 512 CD patients after diagnosis increased gradually
from 0.0% at 5 years, 0.6% at 10 years and 0.6 % at 15 years. The cumulative cancer rate
of the normal controls was estimated to be 0.09% at 5 years, 0.03% at 10 years and 0.06
% at 15 years. The relative risks for male and female patients were 60.6 (2/0.066) and 80.0
(4/0.025), respectively, while total relative risk was estimated to be 65.9 times that of
controls. Five of the six patients died within 6 months. Conclusion: Relative risk of colorectal
cancer for CD patients in our hospital was estimated to be very high with poor prognosis.
We need to consider appropriate surveillance to avoid the high morbidity and mortality
resulting from colorectal cancer in our CD patients.
T2166
The Predictive Value of Low-Grade and Indefinite Dysplasia in Chronic
Ulcerative Colitis
Jeremy T. Hetzel, Jami A. Rothe, David T. Rubin
Although colectomy is clearly indicated for a finding of high-grade dysplasia (HGD) or
colorectal cancer (CRC) in chronic ulcerative colitis (CUC), the approach to low-grade
dysplasia (LGD) is controversial and the approach to indefinite dysplasia (IND) is undefined.
We performed a retrospective review of CUC patients with IND and LGD to determine the
likelihood of progression to higher grades of neoplasia. Methods: Patients were identified
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from the previously described University of Chicago IBD Endoscopy Database. Included
were CUC patients with LGD or IND. The index date was defined as the date of dysplastic
findings at our institution. Neoplasia detected at index colonoscopy was defined as “preval-
ent”, and subsequent neoplasia was defined as “incident”. “Immediate colectomy” was defined
as < 90 days from index date and “delayed colectomy” was defined as > 90 days from index
date. Details of neoplasia were recorded and survival analysis with Coxmodels was performed.
Results: 41 patients were included with median duration of CUC of 18.8 years (IQR 11.0-
27.0). 36 patients had LGD at index colonoscopy (21 polypoid, 17 flat, 5 irregular mucosa,
4 DALM), and 7 patients had IND (1 polypoid, 6 flat). One IND and 3 LGD patients
underwent immediate colectomy. Survival analysis progression rates are summarized in the
table below. Number of colonoscopies did not influence progression in Cox modeling. Mean
follow-up time was not statistically different between patients progressing to HGD/CRC and
not progressing. Conclusions: In this tertiary center cohort of CUC patients with IND or
LGD, 8.3% of LGD was associated with concurrent HGD/CRC and 12.5% progressed to
HGD/CRC at 5 years. Although IND did not have concurrent HGD/CRC, it was associated
with a high risk of progression over time. These findings add to our understanding of LGD
prognosis, but furthermore show that IND requires careful follow-up examinations.
T2167
Ulcerative Colitis-Related Colon Cancer Is Associated with Loss of Expression
and Genotypic Variation of HLA-DR
Megan M. Garrity-park, Edward Loftus, William J. Sandborn, Thomas Smyrk
Background: Ulcerative colitis (UC) patients are at an increased risk for colorectal cancer
(CRC). Increased extent and duration of UC are risk factors and some studies have estimated
the cumulative risk of developing CRC to be as high as 23% after 20 years of UC. Multiple
studies have shown linkage between UC and the HLA region of Chromosome 6. However,
little is known about the role of HLA in UC-CRC carcinogenesis specifically. We therefore
investigated HLA-DR in UC-CRC to determine 1) if there was decreased HLA-DR expression
in UC-CRC tumors relative to non-adjacent normal and 2) if decreased expression correlated
with HLA-DR allele frequencies and/or pathology. Methods: We identified 84 patients (1980-
2006) who developed CRC after≥10 years of UC and had archived blocks from the original
colectomywith sufficient tissue for immunohistochemistry (IHC) and genomic DNA isolation.
HLA-DR expression was evaluated using IHC and slides were scored from 0-3+. Normal
HLA-DR expression was defined as equivalent or greater presence of HLA-DR in the tumor
relative to the non-adjacent normal. Altered HLA-DR expression was defined as decreased
expression in the tumor as compared to non-adjacent normal. DNA was extracted and HLA-
DR genotypes were determined using SSO. RESULTS: Overall, 44 tumors (52%) showed a
decrease in HLA-DR expression with the majority of samples (86.4%) showing a complete
loss of HLA-DR. Mucinous pathology was observed in 19 tumors (23%). Of those tumors
that were mucinous, 15 also displayed a decrease in HLA-DR expression (p=0.04). HLA
typing was possible on 79 samples. No allele reached significance with regard to predicting
loss of HLA-DR. However, mucinous pathology was associated with an increased allele
frequency of DR1 (p=0.05). CONCLUSIONS: Alterations of HLA-DR expression have been
reported in multiple cancers, but few studies have investigated its role in UC-CRC. We
report for the first time in a large cohort of unselected UC-CRC cases that over half of these
cancers involved a decrease in HLA-DR expression, with most displaying a complete loss
of expression. This loss tended to be associated with a specific, aggressive, mucinous patho-
logy which itself correlated with an increased frequency of the DR1 allele.
T2168
Enhanced Ppm1α Levels and Blunted TGFβ Signaling in Colonic Epithelia
Lacking GIα2 In Vivo and In Vitro
Kehui Wang, Mei X. Wu, Robert A. Edwards
Abstract: Giα2-/- mice spontaneously develop muscle-invasive mucinous colon cancers as
early as 16 weeks of age. We have found that the colonic epithelium in 6 week old colitis-
free Giα2-/- mice proliferates at a significantly higher rate (15.6+/- 4.1% BrdU+ cells/crypt,
vs. 6.8 +/- 3.2% in WT littermates), suggesting a direct role for Giα2 signaling in epithelial
growth control. TGFβ and BMP signaling between gut epithelium and the underlying stroma
have been implicated in the development of colon cancer. We have previously identified
defects in TGFβ responses in Giα2-/- T-cells (Wu et al. J. Immunol. 174: 6122). Recently,
PPM1α was identified as both a TGF-Smad and BMP-Smad phosphatase (Lin et al., Cell
125:915). To test whether the lack of Giα2 leads to changes in PPM1α expression that
correlate with altered growth regulation, we generated human colon cancer cell lines (RKO
and HT-29) stably expressing dominant negative mutant Giα2 (Giα2-G203T). These cells
expressed PPM1α at levels significantly higher than WT cells. These cell lines proliferated
more rapidly than controls and were resistant to camptothecin-induced caspase 3 activation
and apoptosis. Expression of PPM1α was also higher in primary colonic epithelial cells
harvested from Giα2-/- mice. With respect to stroma, TGFβ treatment of WT subepithelial
myofibroblasts resulted in enhancement of BMP2 expression, but was without effect on
Giα2-/- myofibroblasts. Together, these data suggest that loss of Giα2 signaling leads to
blunted TGFβ and BMP responses which may contribute to enhanced epithelial proliferation
and the development of colon cancer in Giα2-/- mice.
T2169
Nitric Oxide in Colitis-Associated Colonic Neoplasis: Role of Wnt-Induced
Secreted Protein-1 (Wisp-1)
Hongying Wang, Rui Zhang, Donna-marie Mccafferty, Paul L. Beck, Stefan J. Urbanski,
Wallace K. Macnaughton
Nitric oxide (NO) derived from the inducible NO synthase (iNOS) is an important inflammat-
ory mediator in ulcerative colitis (UC) and has been implicated in the development of
colorectal cancer (CRC). However, the role that NO plays in tumorigenesis is not clear.
Members of the Wnt signaling pathway, such as β-catenin and APC, have been implicated
in colorectal cancer. Recently, Wnt-inducible secreted protein-1 (WISP-1), a member of the
connective tissue growth factor family, was shown to be overexpressed in 84% of tumours
compared with patient-matched normal mucosa. In this study, we aimed to test the effect
of iNOS/NO on WISP-1 expression in the normal colon, UC and CRC. Endoscopic colonic
biopsy samples were obtained from UC and CRC patients. The expression of mRNA for
iNOS and WISP-1 was determined by semiquantitative RT-PCR. Both were higher in ulcerat-
ive colitis samples compared with those from uninflamed colon (p<0.05). Immuno-histoch-
emistry revealed positive WISP-1 staining in UC and CRC samples. In separate cell culture
studies, the NO donor, DETA-NONOate (0.05-0.5 mM), significantly elevated WISP-1
mRNA expression in several human colonic epithelial cell lines (HT-29, RKO and Caco-2).
Furthermore, the NO donor activated the cyclic AMP response element binding protein
(CREB), a potent transcriptional regulator of WISP-1 expression, by stimulating the phos-
phorylation of CREB at ser-133. Finally, WISP-1 expression was assessed in mouse models
of colitis. TNBS colitis was induced in both wild type and iNOS-deficient mice. In addition,
colitis associated with IL-10 deficiency was observed in 3-month old IL-10 knockout mice
and IL-10/iNOS double knockouts. Colitis was associated with a significant increase in
WISP-1 expression. However, the absence of functional iNOS significantly blocked the
colitis-related WISP-1 increase. Taken together, the data suggest that during colitis, iNOS-
derived NO increases WISP-1 expression through a CREB-dependent pathway. The demon-
stration of an interaction between iNOS/NO and WISP-1 in inflamed gut implicates a new
mechanism whereby iNOS and NO participate in tumorigenesis in ulcerative colitis. (H.
Wang is supported by a CAG-CCFC Fellowship)
T2170
Risk of Colorectalcancer (CRC) in IBD. A Clinical and Histopathological
Study of 67 Cases Examined At 3 University Clinics in Oslo
Stephan Brackmann, Solveig N. Andersen, Geir Aamodt, Frøydis Langmark, Ole petter
fraas Clausen, Erling Aadland, Olav Fausa, Andreas Rydning, Morten H. Vatn
Background: Risk of CRC in IBD is related to early onset and duration of disease,but clinical
risk factors predicting disease duration until CRC are lacking.The study aimed at prospective
re-analysis of clinical parameters including course of symptoms and treatment from onset
of IBD to diagnosis of CRC (colitis-CRC interval). Materials: Patients diagnosed with IBD
prior to 01.05.2005 at three University hospitals in Oslo,were matched against the CRC
files at the Cancer Registry of Norway.Only histological re-confirmed ulcerative colitis(UC),-
Crohn's disease(CD),indeterminate colitis(IC) and adenocarcinoma of the colorectum were
included. Results: Sixty-one UC,6 CD,including 13 PSC,covered a follow-up of 1572 patient
years.The colitis-CRC interval was normally distributed.Median age at onset of IBD symptoms
was 23 years,at IBD diagnosis 25 years,at CRC diagnosis 44 years.Sixty patients had one
CRC and 7 patients syn-/metachronous CRC.Median time from IBD symptoms to CRC was
18 years,from IBD diagnosis to CRC 17 years.Patients with extensive colitis at diagnosis of
IBD were younger at diagnosis of IBD (27ys) compared to patients with left sided colitis
(39ys,p=0.069),but the colitis-CRC interval was similar.By regression analysis,young age at
onset of IBD symptoms predicted a prolonged colitis-CRC interval (p=0.008).Short colitis-
CRC interval was predicted by activity of symptoms (p=0.039),and use of Mesalazine (p=
0.021),but not of Sulfasalazine or systemic corticosteroids.In a multivariate regression
model,only Mesalazine and active symptoms independently predicted rapid onset of CRC.
Patients with PSC were significantly younger at onset of IBD symptoms (19ys vs. 29ys, p=
0.04),but the colitis-CRC interval and the distribution of CRC in the colon was similar to
IBD without PSC. Conclusion: In this cohort of patients with IBD and CRC, young age at
onset of IBD symptoms unexpectedly predicted prolonged duration of IBD until CRC,
whereas duration of Mesalazine treatment, independent of symptom activity, significantly
predicted rapid development of CRC. PSC did not show rapid development of CRC.The
results may be of importance for surveillance of IBD.Further studies evaluating the effect of
Mesalazine on carcinogenesis are needed.
T2171
Title: Is a Colonoscopic Surveillance Program Required for Patients with
Chronic Crohn's Colitis; A Prospective Study
Sonia Friedman, Peter Rubin, Carol Bodian, Noam Harpaz, Daniel Present
Background: Since 1980, we have followed 259 patients with chronic Crohn's colitis in a
prospective colonoscopic surveillance program. Our initial results through August 1998
showed a 22% chance of developing definite dysplasia or cancer by the fourth surveillance
exam. We now update the results of all examinations between January 1980 and April 2005.
Methods: Patients with Crohn's colitis affecting at least 1/3 of the colon and at least 7 years
of disease duration were enrolled in a prospective colonoscopic surveillance program. Patients
were recalled every 1-2 years or sooner if dysplasia was found. Biopsies were performed at
10cm intervals and from strictures andmasses. Polypoid dysplastic lesions deemed “adenoma-
like” were totally removed. All removed polypoid lesions included in this study were located
within areas of microscopic or macroscopic colitis. Pathology was classified as normal,
dysplasia (indefinite, low-grade (LGD), high-grade (HGD)), or carcinoma. Lesions were
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classified as flat, polyp, or mass. Results: A total of 1424 examinations were performed on
259 patients. 90% had extensive colitis. A median of 5 exams was performed per patient
(range 1-23). Median age at diagnosis was 22 years (2-61), median disease duration 18 (7-
49), and median age at colonoscopy 42 (16-80). Forty-four patients (17%) had increased
symptoms at the initial screening exam. Neoplasia (LGD, HGD, or cancer) was found in 18
patients (7%). 13 patients had LGD (7 polyps, 6 flat), 2 had HGD (2 flat), and 3 had cancer
(3 masses). Neoplasia was associated with age > 45 years (p=0.01) and recently increased
symptoms (p=0.09). The median interval between surveillance examinations was 18 months.
On surveillance exam, a first positive finding of neoplasia was found in an additional 30
patients (14%). Twenty-two patients had LGD (14 polyps, 8 flat), 4 HGD (2 polyps, 2 flat),
and 4 cancer (2 polyps, 2 masses). Increased symptoms, age > 45, or disease duration were
not associated with neoplasia on surveillance exams. The cumulative risk of detecting an
initial finding of any LGD, HGD or cancer after a negative screening colonoscopy was 25%
by the 10th surveillance exam. The cumulative risk of detecting an initial finding of flat
HGD or cancer after a negative screening colonoscopy was 7% by the 9th surveillance exam.
One person died of colon cancer while in the program having refused surgery for HGD
(polyp). Conclusion: With our findings of an increased risk of colonic dysplasia and cancer,
we conclude that periodic surveillance colonoscopy should be part of routine management
of chronic extensive Crohn's colitis.
T2172
Her2/Neu and C-Myc Proto-Oncogene Amplifications Are Important Genetic
Abnormalities in the Progression of Barrett Esophagus
Agnieszka M. Rygiel, Francesca Milano, Fiebo J. Ten kate, Kenneth K. Wang, Wilda
Rosmolen, Jacques J. Bergman, Maikel P. Peppelenbosh, Kausilia K. Krishnadath
BACKGROUND: Barrett esophagus (BE) is a condition associated with an increased risk for
developing adenocarcinoma. The progression of BE to cancer is a gradual process that is
characterized by increasing dysplasia and the accumulation of several genetic abnormalities.
AIM: To evaluate the amplification status of the proto-oncogenes Her2/neu, EGFR, c-myc
and 20q13 region in the sequence of no dysplasia (ND) to low grade dysplasia (LGD),
high grade dysplasia (HGD) and adenocaricnoma (EAC) in BE patients. MATERIAL AND
METHODS: Multi-color FISH using a panel DNA probes for the centromeric regions of
chromosome 17 and 7 and probes for the locus specific regions of 17q (Her2/neu) 7p12
(EGFR), 8q24.12 (c-myc) and 20q13 was applied on 86 brush cytology specimens taken
from BE patients (37 ND, 24 LGD, 15 HGD, 10 EAC). RESULTS: Aneusomy of chromosomes
7 and 17 was detected in 21% (8/37) of ND, 25% (6/24) of LGD, and this increased to
66% (10/15) in HGD and 88% (8/10) in EAC cases. Her2/neu amplification was detected
in 4% (1/24) of LGD, 46 % (7/15) of HGD and 30% (3/10) of EAC patients. Amplification
of c-myc was observed only in HGD and EAC cases in frequency of 26% (4/15) and 20%
(2/10), respectively. EGFR and 20q13 region amplification were seen in 1 of 15 patients
(7%) with HGD only. CONCLUSIONS: Chromosomal aneusomy is an early genetic event
debatable in BE without dysplasia, increasing with the disease stage. Her2/neu and c-myc
amplification are frequent events in BEwith dysplasia whichmay contribute to the progression
of BE.
T2173
Nitric Oxide in the Molecular Pathogenesis of Barrett Esophagus and
Esophageal Adenocarcinoma
Nadine Vaninetti, Kimberley Macdonald, Laurette Geldenhuys, Harvey Risch, Geoffrey
Porter, Duane Guernsey, Alan G. Casson
Background: Nitric oxide (NO) has been implicated as a potential causative factor for
endogenous p53 mutations in gastrointestinal malignancy. To investigate the role of NO in
the molecular pathogenesis of esophageal adenocarcinoma (EADC), we studied patterns of
p53 mutations, expression of inducible nitric oxide synthase (iNOS) and the tissue accumula-
tion of nitrotyrosine (NTS), a stable reaction product of NO and a marker for cellular protein
damage, in esophageal epithelia from patients with gastroesophageal reflux disease (GERD),
Barrett esophagus (BE) and primary EADC. Molecular findings were correlated with dietary
nitrite consumption which has been reported to increase NO concentration in the lower
esophagus. Methods: Esophageal tissues were obtained from patients with GERD-induced
esophagitis (n=76), BE (n=119) and EADC (n=54), defined according to strict clinico-
pathologic criteria, and dietary nitrite consumption was calculated from a validated food
frequency questionnaire. DNA sequencing was used to characterize p53 mutations, RT-
PCR to study iNOS mRNA expression, and immunohistochemistry to study NTS protein
expression. Results: The frequency of p53 mutations, iNOS and NTS expression (relative
to matched normal epithelia) in esophageal tissues is summarized in Table 1. Dietary nitrite
consumption did not vary between patient groups, and did not correlate with iNOS or NTS
expression. Among patients with EADC, NTS was expressed more frequently in tumors with
p53 mutations (11/21; 52%) compared with tumors with wild-type p53 (9/33; 27%; P=
0.063). Twelve of 21 (57%) EADC p53 mutations were at CpG dinucleotides. NTS was
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
expressed more frequently in tumors with p53 mutations at CpG dinucleotides (10/12;
83%) compared with non-CpG p53 mutations (1/9; 11%; P=0.008). Conclusions: The
increasing frequency of iNOS overexpression in GERD, BE and EADC supports the hypothesis
that an active inflammatory process, most likely a consequence of GERD, underlies molecular
progression to EADC. The highly significant association between NTS, reflecting chronic
NO-induced cellular protein damage, and endogenous p53 mutations at CpG dinucleotides,
provides further evidence for a molecular link between chronic inflammation and EADC.
Table 1. Frequency of p53 mutations, iNOS and NTS overexpression
GERD, gastroesophageal reflux disease; BE, Barrett esophagus; EADC, esophageal adenocarci-
noma; iNOS, inducible nitric oxide synthase; NTS, nitrotyrosine
T2174
At Motif Binding Factor 1 (ATBF1) Upregulates P21 Transcription in
Cooperation with P53 and Runx3
Yoshinori Mori, Hiromi Kataoka, Tsuneya Wada, Eiji Kubota, Naotaka Ogasawara, Makoto
Sasaki, Takeshi Kamiya, Yutaka Miura, Takashi Joh
Background and aims: AT motif binding factor 1 (ATBF1), a homeotic transcription factor,
has recently been identified as a tumor suppressor and is frequently mutated and lost in
prostate cancer (Nat. Genet. 2005). We previously showed the evidence that ATBF1 expres-
sion inversely correlated with the malignant character of gastric cancer cells (Oncogene
2001) and we found that ATBF1 enhanced the promoter activity of the p21 (Cancer Res
2003). RUNX3 (runt domain transcription factor 3), a tumor suppressor of gastric cancer,
is reported to be the upstream regulator of p21. However, the molecular mechanism of
ATBF1-mediated p21 up-regulation is unknown. In this study, we investigated the molecular
mechanism of p21 activation by ATBF1 in cooperation with p53 and RUNX3. Materials
and Methods: 1. To analyze the expression of ATBF1 in gastric cancer, we performed
immunohistochemistry in 123 resected gastric cancer tissues. 2. For immunoprecipitation
(IP), ATBF1 and RUNX3 were over expressed by transfecting myc-tagged ATBF1 expression
vector and flag-tagged RUNX3 expression vector. IP between ATBF1 and p53 was performed.
3. Dual-luciferase assays were performed by transfecting ATBF1 and RUNX3 expression
vectors with internal control vector and p21 reporter vector containing a RUNX3-binding
site. Dual-luciferase assays were performed by transfecting ATBF1 and p53. 4. Cell cycle
analyses by using FACScan were performed. 5. To analyze the localization of ATBF1 and
RUNX3, we performed transfection with ATBF1 and/or RUNX3, and observed the localization
of them by fluorescence microscope. Results: 1. Of 123 gastric cancers (GCs), the nuclear
localization of ATBF1 was observed in 33(26.8%) GCs and the cytoplasm localization of
ATBF1 was observed in 61(49.6%) GCs. ATBF1 expression was not observed in 29(23.6%)
GCs and normal gastric epithelium. 2. IP revealed the physical interaction of ATBF1-p53
and ATBF1-RUNX3. 3. ATBF1 and RUNX3 synergistically up-regulated p21 promoter activity
up to 3.5-fold compared with basal activity. Moreover, ATBF1 stimulated p21 promoter
activity up to 4-fold compared with basal activity in the p53-dependent manner. 4. Over
expressed ATBF1 induced the accumulation in the G0/G1 phase by FACScan analysis. 5.
Over expressed RUNX3 tended to induce the nuclear localization of ATBF1. The localization
of ATBF1 and RUNX3 coincided with each other. Conclusion: ATBF1 physically interacts
with p53 and RUNX3 and induces cell cycle arrest through the activation of p21. Cytoplasm-
nuclear transition of ATBF1 might be important for the regulation of cell cycle in gastric
cancer.
T2175
Oncogenic Role of Agr2 in Esophageal Adenocarcinoma
Zheng Wang, Ying Hao, Cindy Yim, Anson W. Lowe
The incidence of esophageal adenocarcinoma (EA) has increased at a faster rate than any
other cancer in the United States. Barrett's esophagus is a neoplastic lesion that carries a
40-fold increase risk for developing into invasive EA. Gene expression profiling previously
performed by our lab detected high expression of anterior gradient 2 homolog (AGR2) in
Barrett's esophagus, EA tissue, and the EA cell lines SEG-1 and OE33 compared to normal
esophageal tissue. AGR2 encodes for a predicted secretory protein that has also been detected
in many other glandular tumors such as pancreatic, stomach, breast, and prostate cancers.
AGR2 was first described as a secreted protein in Xenopus and is responsible for the
development of the cement gland. The role of AGR2 in tumor biology remains unknown.
Two cell lines were produced to study AGR2: SEG-1 cells in which AGR2 expression was
suppressed with RNA interference (RNAi) and stable AGR2 expression in NIH3T3 cells that
was accomplished through transfection. The cell lines were subsequently tested with well-
established assays designed to test malignant transformation, including colony formation in
soft agar, foci formation, and growth as xenografts in nudemice. A retroviral vector containing
shRNA-mirs targeting AGR2 successfully reduced AGR2 protein expression by over 90%.
AGR2-deficient SEG-1 cells produced 5-fold fewer colonies compared to controls in soft
agar, which suggests an impaired capacity for In Vitro anchorage-independent growth.
Consistent with this result, AGR2-deficient SEG-1 cells also produced xenograft tumors In
Vivo in nude mice that were 60% smaller than the control cells. These studies demonstrate
that AGR2 influences SEG-1 cell growth. AGR2's role in transformation was tested through
expression in NIH3T3 cells. Stable transfected NIH3T3 cells displayed a 5-fold increase in
colony formation in soft agar and a dramatic increase in foci formation. No foci formed in
NIH3T3 cells transfected with only the vector, whereas 139 foci (diameter >2mm) were
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seen in cells expressing AGR2. We conclude that AGR2 is a novel oncogene expressed by
all Barrett's esophagus tissues and adenocarcinomas, and is important in malignant trans-
formation.
T2176
Molecular Characterization of Hsrbc, a Candidate Tumor Suppressor Gene At
11p15, in Human Colon Cancer
Wan jung Kim, Hyo jong Kim, Sung gil Chi, Jin oh Kim, Joo young Cho, Chan sup Shim
Background: hSRBC [human Serum deprivation response(sdr)-Related gene product that
Binds to c-kinase] has a similar sequence to sdr and was identified using PKCδ as a probe.
Frequent LOH of human breast cancer, lung cancer, and ovarian cancer found in 11p15.5-
p15.4, where hSRBC is located. The expression of hSRBC protein was decreased in 70% of
breast cancer, lung cancer, and ovarian cancer cell-lines, suggesting that hSRBC might be
a putative tumor suppressor. Methods: The expression status of hSRBC mRNA was analyzed
in 50 normal colon epithelial cells and 50 primary colon tumors resected from surgery and
11 human colon cancer cell lines (Caco2, Colo205, HCT116, HT-29, KM12C, KM12SM,
Widr, Lovo, RKO, SNU-C1, SW620). Transcript and protein expression of hSRBC was
studied by quantitative RT-PCR and Western blot, respectively. For the analysis of DNA
hypermethylation, 5`-aza-2-deoxycytidine treatment and bisulfite DNA sequencing was car-
ried out to determine the CpG site methylation status. Mutational study of the hSRBC gene
was carried out using PCR-single strand conformational polymorphism analysis. SiRNA-
mediated knockdown of hSRBC expression was utilized to examine the role for hSRBC in
tumor cell growth and its association with p53. Results: Both mRNA and protein expression
of hSRBC was decreased in 46% (5/11) of colon cancer cell lines and 44% (22/50) of patient's
colon cancer tissues. The expression level of hSRBC mRNA was significantly decreased in
tumors compared to noncancerous cells (1.0 vs. 1.7, p<0.001), while genomic level of hSRBC
was not decreased in tumors. hSRBC expression was increased by 5`-aza-2-deoxycytidine
treatment and hypermethylation of CpG site was strongly associated with decreased expres-
sion. Both basal and etoposide-mediated p53 expression was decreased by siRNA-mediated
knockdown of hSRBC expression. Conclusion: hSRBC expression is frequently decreased
in human colon cancers by promoter CpG site hypermethylation. hSRBC might be a novel
upstream regulator of p53 and epigenetic inactivation of hSRBC down-regulate p53 expres-
sion, thus providing a selective growth advantage for colon tumor cells under various
stressful conditions.
T2177
Cdx2 Overexpression Enhanced the Production of Goblet Cells in a
Transgenic Mouse Small Intestine
Rong J. Guo, Mary ann S. Crissey, Eunran Suh, John P. Lynch
Introduction Cdx2 is a homeodomain transcription factor that, in the adult, is specifically
expressed in the epithelial cells of both small intestine and colon. It is known that Cdx2
regulates the intestine-specific expression of a number of genes. Cdx2 also regulates cell
proliferation and apoptosis, however its contribution to colorectal carcinogenesis, whether
as a tumor-suppressor or oncogene, remains unclear. Moreover, it is not well elucidated
what role, if any, Cdx2 plays in regulating cell differentiation and lineage determination in
the small intestine and colon. Ectopically expressed Cdx2 in the stomach induces an intestinal
phenotype characterized by intestinal goblet cells and was associated with gastric neoplasia
in some of the mice. In this study, we attempted to address these questions by specifically
overexpressing the Cdx2 in the epithelial cells of the small intestine and colon. Methods:
Transgenic mice were generated containing a construct with 12.4 Kb mouse villin regulatory
sequences (promoter/exon1/intron 1/start of exon 2) driving expression of a full-length flag-
tagged mouse Cdx2 cDNA. Histological analysis was performed to observe the phenotypic
alterations in the small intestine and colon and search for polyps at age 1,3, and 6 months.
Animals were injected with BrdU 1 hour before sacrifice, and BrdU incorporation determined
immunohistochemically. Goblet cells were identified by alcian blue staining for intestinal
mucins. Results: We obtained a single line of transgenic mice that overexpress Cdx2 protein
by 7-10 fold on western blot staining. We observed the mice for up to 6 months and did
not observe polyp or tumor formation in the Cdx2 transgenic mice. Histologically, the small
intestine and colon in the transgenic mice appeared similar to the wild type mice. Alkaline
phosphatase and Brdu staining patterns did not show obvious alteration. However, alcian
blue staining revealed that Cdx2 overexpression nearly doubled goblet cell number in the
small intestine (in transgenic, 22.8 +/-1.7 goblet cells/villum-crypt, In wild type, 12.9+/-
1.3 goblet cells/villum-crypt, respectively) . Moreover, the goblet cells were larger and
stainined more strongly. However, no change in goblet cell number or staining pattern was
observed in the colon of transgenic mice Conclusion: Overexpression of the homodomain
transcription factor Cdx2 in the murine small intestine is associated with increased Goblet
cell number and size. We conclude the transcription factor Cdx2 may play a role in goblet
cell lineage formation in the small intestinal but its overexpression does cause small intestine
or colonic polyps in mice
T2178
Aberrant Methylation of Follistatin-Like 1 (Fstl1) in Esophageal Squamous
Cell Carcinoma
Shigeru Tsunoda, Eric Smith, Neville J. De young, Zi-qing Tian, Jun-feng Liu, Glyn G.
Jamieson, Paul A. Drew
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most lethal cancers
of the gastrointestinal tract, with a dismal survival rate despite recent advances in multidisci-
plinary therapy. Aberrant DNA methylation is frequent in ESCC as well, and is thought to
contribute to the disease progression and to influence outcome. Knowledge of gene methyl-
ation may assist in diagnosis, treatment, and understanding the biology of the disease. Aim:
To discover genes which have expression altered by methylation in ESCC. Materials and
Methods: The ESCC cell line OE21 was demethylated with 5-aza-2'-deoxycytidine (aza-
dC). Gene expression was compared between cells grown with and without aza-dC, using
Affymetrix GeneChip HG-U133 Plus 2.0. Methylation was measured by melt curve analysis,
and gene expression by quantitative real time RT-PCR. Six tumor cell lines (PC3, DU145,
TE7, OE19, OE21 and OE33) were used to explore the relationship between methylation
status and gene expression. Tumors and proximal resection margins were obtained from 65
patients operated on for esophageal ESCC at the 4th Hospital of Hebei Medical University,
China. Results: Twelve genes (CLDN1, NMES1, PHLDA1, FSTL1, DTR, CDH13, DUSP6,
TFPI2, DUSP4, TNFRSF10D, THBS1 and CTGF) were selected for further study from the
array screen. Among them, 4 genes (FSTL1, CDH13, TFPI2 and TNFRSF10D) showed
methylation in melt curve analysis and up-regulation of mRNA expression after aza-dC
treatment was confirmed by RT-PCR. Of these follistatin-like 1 (FSTL1) had not previously
been reported as methylated in cancer. FSTL1, which is also called follistatin-related protein
(FRP) or TSC-36, is the smallest member of the SPARC family, which can down-regulate
cancer cell proliferation and migration. Methylation status and mRNA expression correlated
in the six cell lines, and aza-dC treatment induced demethylation in the promoter of FSTL1
and increased its mRNA expression in methylated cell lines (DU145, TE7, OE19, OE21 and
OE33), but not in an unmethylated cell line (PC3). Moreover, 19/65 (29.2%) of the tumors
had methylation in the FSTL1 promoter, significantly higher (p=0.0001) than in the matched
normal epithelium (4/65) (6.2%). Conclusion: This is the first report of aberrant methylation
of FSTL1 in any cancer. This is consistent with FSTL1 being a tumor suppressor in ESCC.
T2179
The Cables Gene On Chromosome 18q Is Silenced By Promoter
Hypermethylation and Allelic Loss in Human Colorectal Cancer
Do youn Park, Sandra D. Kirley, Gregory Y. Lauwers, Mari Mino-kenudson, Daniel C.
Chung, Lawrence R. Zukerberg
Background & Aims: Cables is a cyclin-dependent kinase-binding nuclear protein that
inhibits cell proliferation and maps to human chromosome 18q11-12, making it a candidate
tumor suppressor gene in colorectal cancer (CRC). Our objectives in this study were to
assess Cables expression in a large series of CRCs and to identify potential mechanisms of
Cables gene inactivation. Methods: Expression levels, promoter methylation and mutational
status of Cables were investigated by real time RT-PCR, immunohistochemistry, bisulfite
PCR and direct sequencing in human colon tumors. Chromosome 18q loss of heterozygosity
(LOH) was also evaluated by PCR using two polymorphic microsatellite markers (DS18S44,
DS18S1107). Results: Cables expression was decreased in 65% (105/160) of primary CRCs
by immunohistochemistry. No mutations were detected in any of the 10 exons of Cables
in 20 primary colon tumors. Methylation analysis of the Cables promoter region revealed
increasedmethylation in cell lines with decreased Cables expression and vice versa. Demethyl-
ation with 5-aza-C resulted in a marked increase of Cables expression in the methylated
cell lines. Sixty percent of primary colon tumors showed promoter methylation and there
was significant correlation between methylation and Cables downregulation. Thirty-five
percent of the primary colon tumors demonstrated 18q11-12 LOH, and Cables expression
was decreased in most of these cases. Conclusions: Loss of Cables expression in 65% of
CRCs suggests that it is a common event in colonic carcinogenesis, and both promoter
methylation and LOH appear to be important mechanisms in Cables gene inactivation.
T2180
Oncogenic Conversion of Caveolin Effect in the Malignant Progression of
Human Colon Cancers
Nam-hoon Kim, Hyo jong Kim, Sung gil Chi, Young soo Moon
Background/Aims: Abnormal reduction of Caveolins (Cav-1 and Cav-2) has been found in
many human cancers while its overexpression also correlates with increased metastatic
progression of some tumors. To explore the possible implication of Caveolin abnormality
in human colon tumorigenesis, the expression and mutational status of Caveolins was
explored. Methods: We investigated 11 human colon cancer cell lines, 49 primary carcinoma
tissues, and its matched normal colonic tissues obtained from the same cancer patients.
Both mRNA and protein levels of Caveolins in colonic cancers were evaluated by quantitative
RT-PCR and immunoblotting assays. Effect of Cav-1 expression on tumor growth was tested
using cell counting and colony formation assay. Cav-1expression was restored in Cav-1-
nonexpressing cells, whereas Cav-1 expression was inhibited by siRNA-mediated knock-
down. in Cav-1-expressing cells. Also, Cav-1 nonexpressing cell lines were treated with 5-
aza-dC. Methylation status of 38 CpG sites within the Cav-1 gene promoter region was
evaluated by bisulfite DNA sequencing. Results: Low expression of Cav-1 transcript was
found in 54.5% (6 of 11) of cancer cell lines, whereas 45.5% (5 of 11) of cancer cell lines
showed strong expression of Cav-1. In overall, expression patterns of Cav-2 mRNA among
11 cell lines were comparable to those of Cav-1. Expression level of Cav-1 protein was very
low in majority of cancer cell lines except two cell lines (HCT 116, LOVO). Based on the
mRNA expression levels of normal colonic tissues, expression levels of Cav-1 less than a
half and more than 2-folds of normal mean were arbitrarily set as abnormally low and
abnormally high expression, respectively. Approximately 47% (23 of 49) and 10% (5 of
49) of primary carcinomas exhibited significant reduction and elevation in Cav-1 expression
(p<0.001, p<0.005), respectively, compared to its matched normal tissues. Likewise, Cav-
2 expression also showed up-and down-regulation in 28% (9 of 32) and 3% (1 of 32) of
primary tumors respectively. Cav-1 transcript was re-expressed in nonexpressing cells by
5-aza-dC treatment, and aberrant promoter CpG sites hypermethylation was associated with
Cav-1 reduction. Restoration of Cav-1 inhibited growth of Cav-1-negative cells and reduced
phospho-Erk level, whereas ectopic overexpression of Cav-1 further stimulated Cav-1-
expressing cells and activated p53 and its downstream target p21. Conclusions: Collectively,
this study suggests that Caveolin suppresses growth of early stage colon tumors while its
elevation in advanced tumor might provide tumor cells with a selective growth advantage.
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T2181
Mutations in K-RAS Are Frequent in Normal Colorectal Mucosa
Hans Olivecrona, Henrik Zetterqvist, Ulrik Lindforss
We previously reported (DDW 2002) that within colorectal carcinoma 47 % of the tumors
harbored k-ras mutations, distributed almost homogeneously absent or present throughout
the tumors. Mutations of the k-ras oncogene has been evaluated in numerous studies of both
colorectal carcinoma and adenomas. Interestingly, no clear-cut difference in the frequency
of k-ras mutations between these stages of colorectal neoplasia has been demonstrated.
Accordingly, k-ras mutations has been proposed to occur early in the adenoma-carcinoma
progression. However, the mutational status of this gene in normal colonic mucosa has not
been characterized. We studied biopsies obtained during colonoscopy in two groups of
individuals: patients with a previous history of colorectal carcinoma without signs of residual
disease three years after treatment (cancer patients; n = 23; mean age 73,1yrs) and healthy
individuals referred for colonoscopy with a macroscopically normal mucosa (controls; n =
20; mean age 60,9 yrs). From each subject five biopsies were sampled in a standardized
manner throughout the bowel. DNA was PCR-amplified and point mutations of the K-ras
gene were studied by temperature gradient gel electrophoresis. In 15 of the 23 patients
(65%) at least 1/5 of the biopsies throughout the large bowel harbored a mutation; in the
control group, 14 of the 20 individuals had one or more biopsies with k-ras mutations (70
%). We conclude that k-ras point mutations is a frequent finding in macroscopically normal
colorectal mucosa. The frequency in this study did not differ from that reported in studies
of adenomas and carcinomas. Based on our earlier findings of the distribution pattern in
colorectal carcinoma, difficulties to correlate the presence of k-ras mutations to survival or
tumor features, and the present results, we suggest that mutations of the k-ras gene is not
a prerequisite for carcinoma development. Furthermore, we propose that k-ras mutations
may be of physiological importance in the turnover of normal colonic mucosa in the
normal individual.
T2182
Influence of Race On the Prevalence of Pik3ca, Tgfbrii Mutations, and
Microsatellite Instability in Sporadic Colorectal Cancer
Xiang jun Shen, Nikhil Gupta, Janie Peacock, Michelle Wolfe, Lauren Burcal, Chris
Martin, Robert S. Sandler, Temitope O. Keku
Background: Microsatellite instability (MSI) is one form of genomic instability that is common
in sporadic colorectal cancers. PIK3CA encodes for PI3-K oncogenic protein, and is frequently
mutated at hotspots in cancer cell lines, and colorectal cancer. PIK3CA somatic mutations
and microsatellite instability (MSI) status in colorectal cancer have been widely studied in
Asians and Caucasians. However, there are few data on the rate and spectrum of these
mutations in colorectal tumors from African Americans. We evaluated somatic mutations
in PIK3CA, TGFBRII and MSI instability in colorectal tumors from subjects (148 Whites
and 44 African Americans) enrolled in a population-based study of colorectal cancer (Can-
CORS) and assessed whether these tumor molecular characteristics could be useful as
prognostic and predictive factors of colorectal cancer. Methods: DNA was extracted from
tissue microarrays (TMAs). MSI status was determined using the NCI panel of microsatellite
markers (BAT25, BAT26, D5S346, D2S123 and D17S250). PIK3CA exon 9 and 20 mutations
and TGFBRII poly A tract deletion were assessed from the same tumor DNA used for MSI
analyses. Results: Overall the frequency of MSI-high (MSI-H) was 20.9% (38/192), PIK3CA
mutation was 14.3% (18/126), and the TGFBRII poly A tract deletion was 4% . Thirty two
MSI-H tumors were from Whites and 6 from African Americans. MSI-H was associated
with PIK3CA mutations (41%) compared to MSI-H tumors without mutations (23%). The
distribution of MSI-H tumors by stage of disease was 40.9% local, 50% regional and 9.1%
distant. PIK3CA mutated tumors were more frequent in Whites (15.2%) than in African
Americans (9.5%). There was an association between PI3K mutations and local and regional
stage but not distant stage. Seven of 8 TGFBRII mutations were found in tumors without
PI3K mutations and in one tumor harboring PI3K mutations. Conclusions: We observed
that MSI and PIK3CA mutations were more frequent in Whites than in African Americans
and also both mutations were associated with early stage of disease. These results suggest
that PIK3CA and MSI may influence tumorigenesis and progression of colorectal cancer at
the early stage of disease. The combination of MSI and PIK3CA mutation status could be
useful as prognostic and predictive factors for early stage colorectal cancer.
T2183
Colorectal Cancer: Mapping Expression Studies from Murine Models Onto
Human Disease
Fei Song, Owen J. Sansom, John R. Jenkins, Andrea Jorgensen, Alan R. Clarke, Alastair J.
Watson
Background: Inactivation of APC gene is recognised as one of the first important genetic
lesions in the pathogenesis of colorectal cancer. Inactivation of APC stabilises β-catenin,
which translocates into the nucleus activating TCF/LEF with subsequent transactivation of
many target genes through the Wnt signalling pathway. A Cre-Lox mouse model has been
previously developed, wherein an inducible loss of APC within the intestinal epithelium
causes immediate activation of the Wnt signalling pathway, failure in cell migration and
differentiation, perturbation of the normal crypt/villus homeostasis, induction of cell death
and proliferation (Genes Dev. (2004) 18:1385-1390). A microarray analysis of this unique
mouse model has identified a cohort of Wnt regulated gene alterations for which there has
been little previous association with neoplasia. We aimed to determine if genes we had
previously identified as dysreglated following deletion of APC in mice also showed altered
expression in human colorectal cancers. Methods: Taqman real-time PCR analysis of the
homologous genes on colorectal cancer tissues with matched neighbouring normal mucosa
from random patients was carried out in parallel with comprehensive human microarray
analysis performed on normal and tumour tissues from patients in series stagings. The
selections of candidate genes for both analyses were based on the previous work from the
Cre-Lox mouse model. A minimum of 16 patients were studied. Results: Data from the
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taqman assay showed that 8 homologous human candidate genes were significantly upregul-
ated, which is largely consistent with the data of human microarray. 4 genes expression
levels even dramatically elevated as the fold change median values: AXIN2 (5.6-fold, P=
0.001); Fn14 (5.5-fold, P<0.0001); CITED1 (6.4-fold, P=0.002); CD44 (5.2-fold, P=0.001),
respectively. EPHB2 (2.3-fold, P<0.0001), EPHB3 (2.5-fold, P=0.0001), EPHB4 (2.2-fold,
P<0.0001) and FZD6 (2.4-fold, P=0.001) also overexpressed at the level not dramatically
high as the top 4 genes. Conclusions: Data from taqman andmicroarray analysis demonstrated
how transferable the candidate genes identified in the mouse model are to the study of
human colorectal cancer. Elevated AXIN2 and CD44 gene as well as EPHB2, EPHB3, EPHB4
and FZD6 gene expressions and corresponding gene encoded protein functions have been
well studied, which again validates the process in human. The up-regulations of Fn14 and
CITED1 gene have not previously been detected as Wnt pathway target in human colorectal
cancer and therefore are the novel candidates for future investigation.
T2184
Opcml As Tumor Suppressor Gene in Gastric Cancer
Xiaoqi Zhang, Qiang Li, Lingyun Wu, Xitai Sun, Quan Wen, Lihua Zhang, Yongzhong
Yao, Yudong Qiu, Xiaoping Zou, Zhaomin Xu, Minyue Zhang, Yitao Ding
Background: Opioid binding protein/cell adhesion molecule-like gene (OPCML), located at
11q25, has recently been reported to function as a tumor suppressor gene (TSG) in ovarian
cancer. Even 11q has been shown to be the frequently lost locus in gastric cancer (GC),
the expression profile of OPCML and its possible functions in GC progression and metastasis
have not been determined. We thereby set out to evaluate the expression profile of OPCML
in GC and to characterize the function of OPCML on GC cell both In Vitro and In Vivo.
Methods: We first employed cDNA microarray and laser microdissection to assess different
expressions of various genes during the process of tumorigenesis and lymph node metastasis
in GC to identify OPCML. Then, we transfected OPCML into a GC cell line BGC823 and
examined the effect of OPCML over-expression on cancer cells using cell proliferation assay,
soft agar colony formation assay, cell migration assay, and subcutaneous tumor growth assay.
Results: In our microarray studies, we first identified 3 genes, which have the characteristic
expression profile of a TSG in GC progression and metastasis. OPCML was one of them.
Then, we found that the proliferation rate of OPCML-transfected cells was significantly
decreased at 24, 48 and 72 hours as compared to that of control cells (p<0.01), suggesting
that OPCML has a growth suppression function on GC cells. We also found the number
of colonies formed in soft agar containing OPCML-transfected cells was 1.8-fold lower than
that containing control cells (p<0.01) after 14 days growth. The number of OPCML-trans-
fected cells migrated was 1.5-fold less than that of control cells (p<0.01). These findings
suggested that OPCML could suppress the migration ability of GC cells, therefore, inhibit
the metastatic ability of cancer cells from primary lesions. Finally, the volume of tumors
formed in the mice injected with OPCML-transfected cells was significantly smaller than
that injected with control cells (p<0.01). Collectively, these findings suggest that OPCML
is able to suppress the formation and migration of GC cells both In Vitro and In Vivo.
Conclusions: OPCML can function as a TSG in GC, regulating not only carcinogenesis but
also the process of metastasis of GC. These findings suggest OPCML is a candidate of TSG
in GC and can be a potential target for preventing and treating GC.
T2185
Disruption of the Arf/P53 Pathway Promotes Rhabdomyosarcoma in
Transgenic Mice Overexpressing Hepatocyte Growth Factor/Scatter Factor
Takeshi Ichikawa, Linan Ha, Miriam Anver, Norman E. Sharpless, Ronald A. Depinho,
Glenn Merlino
INTRODUCTION: The relevance of the Arf/p53- and Ink4a/pRb-tumor suppressor pathways
to the development of most, if not all types of cancer is unequivocal. It is significant to
identify how the relative role of Arf/p53-and Ink4a/pRb pathway varies depending on
tumor origin. Rhabdomyosarcoma (RMS) is the most common soft tissue tumor in children.
Although carcinosarcoma of the stomach or pancreas is a rare entity in previously reported
human cases with gastric or pancreatic carcinosarcoma, RMS differentiation has been
reported. We use a mouse model to show that the ARF/p53 pathway is associated with RMS
susceptibility. METHODS: Hepatocyte growth factor/scatter factor (HGF/SF) transgenic mice
and the mice carrying specific inactivation mutations in Arf, Ink4a or p53 were made as
previously described. To study the specific roles of these tumor suppressors in oncogenesis,
the HGF/SF transgene was bred onto a background deficient in either Arf, Ink4a or p53.
Tissues were prepared for histopathological and immunohistochemical analysis. Analysis of
loss of heterozygosity at tumor suppressor genes in mouse tumors was done by allele-specific
PCR. RESULTS: Every HGF/SF p53-/- mouse developed RMS with a mean age of onset of
1.1 months. RMS appeared in 35% of HGF/SF Arf-/- mice at a mean age of 2.5 months. In
heterozygous mice, the appearance of RMS was 65% of HGF p53+/- mice and 6% of HGF
Arf+/- mice. Moreover, virtually every RMS from HGF p53+/- mice exhibited loss of the
wild-type p53 allele, supporting a role for the p53 locus in RMS suppression. Notably, RMS
appeared in just 5% of HGF/SF p16-/- mice. HGF/SF transgenic mice without inactivation
of Arf, Ink4a or p53 developed no RMS. HGF/SF p53-/- and HGF/SF p19-/- mice were
highly prone to RMS. All RMS arising in HGF/SF p53-/- mice were of skeletal muscle origin
such as trunk and limb. In contrast, RMS arising in HGF/SF p19-/- mice were mostly of
non-skeletal muscle origin such as stomach and pancreas. Normal or atypical ectopic skeletal
muscle appeared in the stomach and pancreas before the appearance of RMS. Most HGF/
SF p19-/- mice showed dramatic ectopic skeletal muscle in the stomach and pancreas.
Ectopic skeletal muscle was minimal or mild in HGF/SF p53-/- mice. HGF/SF p16-/- mice
and HGF/SF transgenic mice without inactivation of Arf, Ink4a or p53 developed no ectopic
skeletal muscle. CONCLUSIONS: The Arf/p53 pathway plays a more critical role in RMS
relative to the Ink4a/Rb pathway. However, p53 loss is not identical to Arf loss in rhabdomyos-
arcomagenesis.
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T2186
Somatic Mutagenesis in the Mouse Intestine: A Forward Genetic Screen for
Tumor Suppressors in Colorectal Cancer
Blair B. Madison, Eric M. Ostertag, Haig H. Kazazian, Klaus Kaestner
DNA damage is a major cause of cancer, yet few causative mutations are characterized. Of
all familial colorectal cancer (CRC) syndromes (about one third of all CRC cases), only 10%
have described loci with germline mutations, responsible for less than 3% of all CRC cases.
Germline mutations in the tumor suppressor APC cause the highly penetrant syndrome
called familial adenomatous polyposis (FAP), but APC germ line mutations are present in
less than 1% of all CRC patients. While it is speculated that sporadic (non-familial) CRC
often arises through somatic APC mutations, it is difficult to pinpoint the initiating causative
mutation(s) within a cancer containing many mutations, including large chromosomal
rearrangements/deletions; thus, it is possible that in many CRC patients APC mutations
occur secondarily. Therefore, it is likely that other key tumor suppressors and/or oncogenes
remain unidentified in both familial and sporadic CRC. To uncover additional causative
mutations of CRC, we have developed a mouse model for somatic mutagenesis in the
intestinal epithelium by transgenic expression of a modified human L1 retrotransposon using
the intestinal-specific Vil1 (Villin) promoter. The Vil1 promoter directs high-level expression
in all epithelial cells, including proliferating progenitors and stem cells in the crypt. Transgenic
mice were generated which express transcripts containing the L1 ORF1 and ORF2 sequences,
in addition to a loss-of-function gene trap cassette containing potent bidirectional splice
acceptors. The rapid turnover of the intestinal epithelium and the numerous proliferative
crypt compartments (1.8 x 106) provide an opportunity to generate a substantial number
of insertional mutations to drive the formation of aberrant crypt foci (ACF) and adenomatous
polyps. Several transgenic lines have been established, and retrotransposed sequences were
detected by PCR of genomic DNA from the stomach and intestinal epithelium of F0 and
F1 offspring, proving the feasibility of the approach.We anticipate the generation of numerous
pre-cancerous lesions caused by retrotransposon insertion on the C57BL/6 genetic back-
ground, or on a genetically sensitized background such as the Blm mutant, which has an
increased rate of mitotic recombination and loss of heterozygosity. Mutations will be easily
identified by the fact that they are tagged by the insertional mutagen, the human L1
retrotransposon. This novel approach will afford the rapid identification of loci that suppress
ACF and polyp formation, the earliest steps in the progression to carcinoma and meta-
static cancer.
T2187
XAF1 Inhibits Angiogenesis of Mouse Endothelial Cells
Liang Qiao, Qing Gu, Yun Dai, Zan Shen, Xingyuan Liu, Juan Ma, Benjamin c.y. Wong
BACKGROUND/OBJECTIVES XIAP associated factor 1 (XAF1) is a tumor suppressor gene
and is expressed at low or undetectable levels in many cancers. In cancer cells, it is also
densely hyper-methylated. Up-regulation of XAF1 leads to a sensitization of cancer cells to
anticancer drug-induced apoptosis and growth inhibition. Angiogenesis is regarded as an
important mechanism of tumor growth and development, and thus become a promising
focus for cancer therapy. In this study, we tried to investigate whether XAF1 has any
anti-angiogenesis effect. MATERIAL AND METHODS MS1 cells (a mouse pancreatic islet
endothelial cell line, ATCC) are cultured in 6-well plates in DMEM supplemented with 10%
fetal bovine serum (FBS). When cells were 60-70% confluent, they were transiently trans-
fectedwith pCDNA3.1-XAF1-sense (XAF1-S) or an adenoviral vector ZD55-ZAF1-S. Controls
were transfected with empty vector and ZD55-EGFP, respectively. The migratory ability of
transfected cells were detected by wound healing assay, and the new blood vessel forming
ability of the cells was evaluated by tube formation assay using the In Vitro Angiogenesis
Assay Kit (Chemicon). Western blot analysis was used to determine the expression of
angiogenesis associated genes. Cell proliferation was detected by WST-1 assay, and apoptosis
was detected by APOPercentageTM Assay. To prepare the conditioned medium (CM) from
colon cancer HCT116 cells, cells were cultured in McCoy's 5A medium supplemented with
10% FCS, infected with ZD55-XAF1 or ZD55-EGFP for 48 h, and medium from each
treatment condition was collected. This medium was then used to treat the mouse endothelial
cells, and the effect of such treatment on the proliferation of mouse endothelial cells was
detected by WST-1 assay. RESULTS Forty eight hours after transfection, both XAF1-S and
ZD55-XAF1 induced a significant up-regulation of XAF1 at mRNA and protein levels in
MEC cells. Cells transfected with XAF1-S and ZD55-XAF1 showed a decreased migration
and a suppressed tube formation. Over-expression of XAF1 in MS1 caused a significant
decrease in the expression of Tie-1, Ang-1, and c-myc. The expression of VEGF was not
significantly affected. Enhanced expression of XAF1 also reduced the proliferation of MS1
and induced apoptosis in MS1 cells. CONCLUSIONS Our preliminary data suggest that
XAF1 possess a potential anti-angiogenesis effect, possibly through inhibition of the angiog-
eneic factor Tie-1 and Ang-1. Suppression of cell growth and induction of apoptosis may
also play a role. More studies are needed to unveil the potential anti-angiogenesis role of
XAF1 and the underlying molecular mechanisms.
T2188
Regulation of Colon Tumor Angiogenic Signaling By p16
Amelie Boquoi, Tina Chen, Michael Dews, Andrei Thomas-tikhonenko, Greg H. Enders
Colorectal carcinoma is the second most common fatal malignancy in the United States and
serves a prototype of tumor progression. Circumstantial evidence has suggested that the
Ink4a/Arf locus suppresses colorectal carcinoma. Its two products, p16Ink4a (p16) and Arf,
are potent tumor suppressors and their promotors are frequently methylated in human colon
carcinomas, implying a functional role for the locus in this tumor type. We previously
demonstrated that Min (Multiple intestinal neoplasia) colon tumors harvested from mice
selectively deficient for the locus as a whole or p16 displayed increased vascularity and
elevated levels of vascular endothelial growth factor (VEGF). The possibility of relatively
direct regulation of VEGF by p16 was supported by In Vitro studies in which p16 expression
in human colon tumor cells inhibited VEGF production. To further delineate mechanisms
through which p16 regulates angiogenic signaling in colon tumors we performed microarray
analysis of Min colon tumors in mice with or without selective deficiency for p16. The
results suggest several potential targets of p16. One potential target we are investigating is
c-Myc. Myc is known to have pro-angiogenic properties involving both upregulation of
VEGF and downregulation of anti-angiogenic Tsp1. We have recently shown that Myc
augments colon tumor angiogenesis, in part through induction of a microRNA cluster that
inhibits Tsp1 expression. We have now found that p16 expression in human colon tumor
cells In Vitro promptly antagonizes expression of Myc protein. Real-time PCR revealed a
p16-mediated reduction in Myc mRNA levels. Ongoing studies are directed toward further
validating candidate p16 target genes identified by the microarray analysis and elucidating
the molecular pathways linking p16 to angiogenic signaling in human and mouse colon
tumor cells through Myc.
T2189
Isoform of P73 Protein, Deltanp73, Induces Drug Resistance in Human Gastric
Cancer Cells
Anna Vilgelm, Wael El-rifai, Jinxiong Wei, Alexander I. Zaika
Background: The p73 protein is a transcription factor and member of the p53 tumor
suppressor family. p73 expresses as a complex variety of isoforms that originate from two
p73 gene promoters and extensive gene splicing at the NH2- andCOOH- termini. DeltaNp73a
is an NH(2)-terminally truncated isoform that lacks the transactivation domain. It is also a
bona fide proto-oncogene that acts as a dominant-negative inhibitor of p53 and another full-
length p73 isoform, TAp73. In our previous studies, we have demonstrated that DeltaNp73a
counteracts the effect of chemotherapeutic drugs. However, the underlying mechanism by
which this p73 isoform contributes to chemotherapeutic drug response remains to be
identified. Results: We have found that DeltaNp73a is overexpressed in more than 60% of
primary human gastric carcinomas. We also demonstrated that DeltaNp73a (but not the
TAp73 isoform) activates the human multidrug resistance 1 (MDR1) gene promoter that
leads to a 30-fold increase in the endogenous MDR1 mRNA level and protein accumulation
in transient transfected gastric cancer cells. Similar results were observed in our stable clones,
which express DeltaNp73a in a doxycycline-inducible manner. To test whether the observed
up-regulation causes the increase in drug chemoresistance, we performed the multidrug
resistance assay based on accumulation of the fluorescent MDR1 substrate calcein. We found
a three-fold reduction of the drug uptake in the cells expressing DeltaNp73a compared to
the control cells or cells expressing TAp73. This data strongly suggests that DeltaNp73 is
involved in the chemotherapeutic drug response in these cells. Next, we investigated the
mechanism of MDR1 gene regulation by DeltaNp73a and found that the effect of DeltaNp73a
on MDR1 gene expression is cell line-dependent. It was observed only in the cells expressing
wild-type (wt) p53 (AGS, U2OS); whereas, p53 null (H1299) and mutant p53 expressing
cells (Caco-2) did not show any changes in MDR1 expression. More importantly, co-
transfection of wtp53 together with DeltaNp73a abrogates the ability of DeltaNp73a to
induce MDR1 gene expression at either the transcript or protein levels. Furthermore, addition
of p53-specific siRNA increased MDR1 mRNA accumulation in response to DeltaNp73a in
gastric cancer cells. Thus, DeltaNp73 is involved in MDR1gene regulation through p53.
Conclusion: When combined, our results demonstrate that DeltaNp73a induces chemoresist-
ance in gastric cancer cells by up-regulation of MDR1 gene expression. DeltaNp73 may be
a potential target for diagnosis and/or treatment of gastric cancers resistant to chemotherapy.
W1000
Randomized, Controlled Trial of Antimicrobial Treatment in Whipple's
Disease (Simw)
Gerhard E. Feurle, Matthias Maiwald, Thomas Marth
Whipple's disease (WD) is a rare, systemic bacterial illness. No prospective trials on antimicro-
bial treatment are available. In retrospective series, 9% do not achieve remission and 24%
relapse after therapy. METHODS: We calculated that 62 patients (pt) with untreated WD
would be necessary to detect a 20% difference in response rate, power of 0.9. If we would
recruit 20 pt yearly, the enrolment period would last 3 years (y); at a rate of 10, it would
last 6 y. An alternative was therefore to admit 42 pt to detect a 20% difference in response
with a power of 0.5 to stay within an enrolment time of 4 y. After 2 y of recruitment, it
became clear that we had to select the scenario with 42 pt. Inclusion criterion was diagnosis
of WD by a reference pathologist and the main exclusion criterion was previous antibiotic
treatment for WD. Randomization was in blocks of two; 21 pt to 2 g ceftriaxon (cef) and
21 pt to 3x1 g meropenem (mer) each for 14 days IV. In both arms, initial treatment was
followed by 12 months of 2x1 of cotrimoxazole (cotrim). The investigators were not involved
in the randomization. Follow-up examinations were scheduled for 36 months. The trial was
intent to treat. Endpoint was clinical and bioptic remission maintained for 3 years. RESULTS:
After obtaining informed consent, the open labelled trial started in 1999. We admitted 7
pt with untreated WD per y. In each arm, the diagnosis was not confirmed in one pt, so
that 20 pt in each arm were analyzed after the last had completed follow-up in 2006. No
pt was lost for follow-up. There were two deaths (aspiration of food and myocardial infarc-
tion). Neither had evidence of active WD at the time of death. All pt achieved remission
maintained for the follow-up time. Odds ratio was 1.0, 95% CI 0.06-16.09. At present,
duration of follow-up in the cef arm is 32.5±12.5 (biopsy) and 36.5±9 (clinic) and in mer
36.8±13 and 41.4±15 months resp. (M±SD). In 2 pt (1 cef, 1 mer) there were more than
a few regressive, PAS-positive macrophages in the last duodenal biopsy. Cerebrospinal fluid
(CSF) was initially positive for Tropheryma whipplei (TW) by polymerase chain reaction
(PCR) in 9 pt; one had a positive cytology. PCR for TW was negative in the CSF of 17
others at trial entry. In all 10 with initially positive CSF, the PCR was negative 6 months
after treatment (5 cef, 5 mer). Conclusion: Randomized controlled trials can provide valuable
results even in rare diseases. This first trial in WD has revealed that treatment with cef and
with mer followed by cotrim resulted in no treatment failure, in no recurrence within 3 y,
and in no difference in efficacy of the two antimicrobial regimens. (ISRCTN45658456)
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Treatment of Postoperative Dumping Syndrome with the Long-Acting
Somatostatin Analogue Octreotide L.a.R
Joris Arts, Lieselot Holvoet, Raf Bisschops, Philippe Caenepeel, Piessevaux Hubert, Stefan
Bourgeois, Dominiek Dewulf, Daniel Sifrim, Jozef Janssens, Jan Tack
Dumping syndrome is a complication occurring mostly after esophageal or gastric surgery.
Short-term studies in limited numbers of patients suggest a therapeutic benefit of the
somatostatin analogue octreotide t.i.d. s.c., but clinical use is hampered by the mode of
administration. The use of a monthly i.m. injection of long-acting octreotide 10mg (Sandostat-
ine LAR®) was evaluated in one small study.(Penning 2005). The aim of the present study
was to prospectively evaluate the efficacy of octreotide s.c. and Sandostatine LAR 20 mg
i.m. Methods: 28 consecutive patients with typical dumping symptoms (6 after [partial]
gastrectomy, 9 after gastric bypass, 4 post esophagectomy and 7 post-Nissen, 11 men, mean
age 41±2 years), a pathological dumping provocative test (oral glucose tolerance testing with
assessment of glycemia and hematocrit), and insufficient response to dietary measures, were
recruited. The dumping provocative test, symptom score (summary score 0-3 for 8 early
and 6 late dumping symptoms), and quality of life (QOL) were evaluated after 3 days
treatment with octreotide s.c. 50 ug t.i.d. and after 1 and 3 months treatment with monthly
Sandostatine LAR 20 mg i.m. Results (mean±SEM) were compared using Student's t test.
Results: After treatment with octreotide s.c. 50 ug t.i.d., total (21.2±4.3 vs. 11.5±1.7,
p<0.001), early (12±2.4 vs. 6.5±0.9, p<0.001) and late (9.2±1.9 vs. 5.0±0.7, p<0.001)
dumping scores improved significantly. After 1 month and 3 months of treatment with
Sandostatine LAR 20 mg i.m., total (respectively 15±3.2 and 14.8±3.3, both p<0.005)
and early (respectively 7.7±1.6 and 7.8±1.7, both p<0.005) dumping scores improved
significantly. Improvement in late dumping scores (7.3±1.6 and 7.0±1.6) did not reach
significance. At baseline, the glucose challenge test was associated with an increase in pulse
rate of 12.5±5.1 bpm, an increase in hematocrit of 1.5±0.6% and a nadir glycemia of
55.7.0±7.2 mg/dl. After octreotide s.c. 50 ug t.i.d. and after 3 months Sandostatine LAR 20
mg i.m., pulse rate increase (respectively -1.2±3.3 and 1.6±2.8 bpm, p=0.04 and 0.08
respectively), the increase in hematocrit (respectively 0.4±0.5 and 0.6±0.1 %,NS) were
inhibited. Nadir glycemias were significantly higher after s.c. octreotide (95±7.9 mg/dl,
p<0.0001), but not after i.m. LAR octreotide (60.2±5.1 mg/dl,NS). Conclusion: The efficacy
of octreotide s.c.was confirmed. Octreotide L.A.R. 20 mg i.m. monthly is effective for
improving overall dumping symptoms, and especially early dumping symptoms and the
associated hemodynamic parameters on a challenge test. Late dumping symptoms and the
associated hypoglycemia's seem to respond less consistently.
W1002
Efficacy of Eradication Regimen Tailored for Clarithromycin Susceptibility
Using Human Feces in Japan
Takashi Kawai, Tetsuya Yamagishi, Ikuko Yukawa, Fuminori Moriyasu, Emiko Rimbara,
Norihisa Noguchi, Masanori Sasatsu, Yu Takagi, Tatsuaya Aoki
Decrease in eradication rate of Proton pump inhibitor (PPI) + amoxicillin (AMPC) + clarithro-
mycin (CAM) (PPI/AC)therapy for H. pylori has been recognized in Japan. It has been
reported that this was induced by an increase in CAM resistant-H. pylori. On the other
hand, it has been reported that PPI + AMPC + metronidazole (MNZ) (PPI/AM) therapy have
a high eradication rate for CAM-resistant H. pylori. We have investigated the usefulness of
the regimens tailored for CAM-susceptibility using human feces. Method: 72H. pylori positive
patients were recruited. We divided the patients into two groups. In one group, patients
received PPI/AC (lansoprazole (LPZ) 60mg + AMPC 1500mg + CAM 800mg 1wk) regimen
without investigation into CAM-susceptibility before treatment (control group). In the other
group, patients received PPI/AC regimen for CAM-sensitive (S), or PPI/AM regimen (rabepra-
zole (RPZ) 20mg + AMPC 1500mg + MNZ 500mg 1wk) for CAM resistance (R) with
investigation into CAM-susceptibility before treatment (tailored group). The CAM susceptibil-
ity test was conducted using patients feces by RFLP & nested PCR (Rimbara E, et al
Curr Microbiol 2005; 51: 1-5). CYP2C19 phenotype status was also determined. Result:
Eradication rates (ITT; intention to treat, 95% CI) were 91.7% (78-98) and 72.2% (54-85)
in the tailored group and control group, respectively, with this difference being significant
(p<0.05). Moreover Eradication rates were 95.0% and 87.5% for the PPI/AC regimen for
CAM-S and PPI/AM regimen for CAM-R in tailored group. The eradication rates according
to CYP2C19 phenotype were, for homoEM, hetEM and PM, respectively: 100% (6/6), 100%
(8/8) and 100% (5/5) in PPI/AM, 100% (5/5), 75.0% (6/8) and 100% (5/5) for PPI/AC in
tailored group. Conclusion: Tailored H. pylori-eradication therapy for CAM-susceptibility is
very useful regimen in modern Japan where the CAM-resistance rate is high.
W1003
Current Prescribing Practices of Domperidone Exposed Hospitalized Patients
to Unnecessary Increased Cardiac Risks: A Canadian Tertiary Centre
Evaluation
Ted Xenodemetropoulos, Frances Tse, Marroon Thabane, Louis Liu
Background: Approved indications for domperidone in Canada include gastroparesis, dys-
pepsia, and as adjunctive therapy for the treatment of Parkinson's disease. However, QT
prolongation, life-threatening ventricular tachyarrhythmias, and even sudden cardiac death
have been reported after the use of domperidone. Aims: 1. to review the appropriateness
of domperidone prescription in relation to the approved indications at a single tertiary center
in Canada; 2. to identify potential problems in prescribing practices that may necessitate
intervention to optimize utilization and patients' safety. Methods: A retrospective chart
review was conducted for consecutive patients at Hamilton Health Sciences who were
prescribed domperidone during the first quarter of 2006. Study patients included those
prescribed domperidone during hospital stay and those with preexisting prescription. The
outcome measures were consistency of domperidone indication with approved indications
based on Health Canada, dosing regimens, monitoring of serum potassium (K) and magnes-
ium (Mg) levels, QTc intervals, and the presence of left ventricular (LV) dysfunction. The
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concurrent use of other QT-prolonging drugs was recorded. Chi-squared test was used to
assess significance of differences in proportions. Results: During the study period, 250
patients received domperidone. Prescriptions were initiated during hospital stay in 78% of
patients. However, only 17% of these patients had an approved indication: gastroesophageal
reflux disease - 84%, gastroparesis - 8%, and esophageal dysmotility - 8%. Dosages of
domperidone were highly variable. Non-indicated use was highly associated with prescrip-
tions that were started during admission (chi-squared = 21; p < 0.001). Thirty-two percent
and 99% of patients had Mg and K levels done prior to or during the prescription; 2% had
hypo-Mg, and 8% had hypo-K. Furthermore, 8% had no ECG done; 22% had documented
QTc prolongation; 51% were concurrently on other QT-prolonging drugs; and 14% had at
least moderate-severe (Grade 3 or 4) LV systolic dysfunction. Conclusion: Over 80% of
domperidone were prescribed inappropriately in hospitalized patients even in the 22% of
patients with known prolong QTc intervals. Furthermore, cardiac risk assessments and
necessary laboratory tests were not routinely done. Higher awareness of the indications and
adverse effects of domperidone may improve the quality of care, patient safety, and lead to
substantial cost savings.
W1004
Efficacy and Long-Term Outcome of Radiation Therapy for Gastric Mucosa-
Associated Lymphoid Tissue Lymphoma
Hiroyuki Okada, Yoshiro Kawahara, Ryuta Takenaka, Satoru Yagi, Seiji Kawano, Masafumi
Inoue, Daisuke Tanioka, Takao Tuzuki, Keisuke Hori, Mitsuhiro Takemoto, Kouichi
Ichimura, Tadashi Yoshino
Objectives: This prospective study was done to evaluate the efficacy and the long-term
outcome of radiation therapy (RT) for gastric mucosa-associated lymphoid tissue (MALT)
lymphoma. Methods: We prospectively examined 19 patients with primary low-grade gastric
MALT lymphoma, including 12 patients with no evidence of HP infection and 7 patients
with persistent lymphoma after Helicobacter pylori (HP) eradication. There were 12 men and
7 women, and their mean age was 63 years. The endoscopic features of the gastric lesion
were as follows; superficial spread type in 14 patients, ulcerative type in 1 patient, and
protruding type in 4 patients. Seventeen patients had MALT lymphoma limited to the
stomach, and 2 had colonic lesions as an extra-gastric extension of the disease. The depth
of tumor invasion as determined by EUS was mucosal invasion in 2 patients, submucosa
in 15, and muscularis propia in 2. The t (11; 18) (q21; q21) translocation occurred in 7
of 19 cases; all of them were HP negative. The total radiation dose was 30 Gy in daily
fractions of 1.5 Gy within 4 weeks to the stomach and adjacent lymph nodes. The histologic
responses were evaluated according to Wotherspoon's grading (WG). Complete regression
(CR) was defined as a histological grade of 0-2. The patients were scheduled for the first
follow-up upper gastrointestinal endoscopic examination with EUS at the time of 18 Gy of
RT, then upon completion of RT. Follow-up examination was then repeated every 3 months
until 1 year after completion of RT, and every 6 months thereafter. Results: Eighteen patients
showed histologically CR at the time of 18 Gy of RT. One patient showed WG3 upon
completion of RT and ultimately gained CR 6 months after completion of RT. Eventually,
all patients showed histologically CR. RT was generally well tolerated without any serious
toxicity. The follow-up period was 10-109 months with a median of 45 months, and the
overall survival was 100%. None of the 19 patients showed local recurrence of MALT
lymphoma. Nevertheless, distant recurrence was detected in two patients, both of whom
were HP negative and showed the t (11; 18) (q21; q21) translocation; one patient in the
left lung 26 months after completion of RT, the other in the cervical region after 31 months.
These lesions in both patients were from the same clones as the primary gastric lesions.
Conclusions: RT provides excellent local control of the gastric MALT lymphoma in the
patients with no evidence of HP or showing no response to HP eradication treatment.
Moreover, RT led to a favorable long-term outcome. However, continuous follow-up is
mandatory as relapse may occur in other sites.
W1005
Redesigning the Process of Colorectal Cancer Care: Impact On Quality of Care
and Cost
Francoise Vaessen, Desiree Walta, Marius Nap, Pieter Platteel, Hans Van der bijl, Jaao
Wals, Meindert Sosef, Jelle Goedhard, Peter J. Van der schaar
After the endoscopic finding of colorectal cancer (CRC) patients usually are worked up for
surgery and possibly (chemo-)radiotherapy. The CRC care process involves many doctor
visits and many diagnostic and therapeutic procedures. This complexity may lead to redund-
ancies or omissions in the CRC care process. We analyzed the CRC care process and
implemented changes to optimize its quality. Materials and Methods: A retrospective analysis
of 100 CRC cases was done (waiting times, number of outpatient visits, diagnostic/therapeutic
procedures, in hospital length of stay (LOS) and complications), including a financial analysis.
A multidisciplinary expert group defined which diagnostic and therapeutic procedures were
essential. The group developed a fast track procedure in order to omit redundant and
nonessential procedures and reduce the number of hospital visits. In depth interviews with
patients defined psychosocial needs in the CRC care process. An enhanced postoperative
recovery program was implemented. The function of a case manager was instituted. The
case manager had tasks both at the patient level and at the organizational level. She was
present at all patient's hospital visits and was available for additional questions or requests.
Also she was responsible for coordination of the process. Goals were set with respect to
time from endoscopy to surgery, number of hospital visits, in hospital LOS, total costs and
patient satisfaction, both in patients with colon cancer (CC) and rectal cancer (RC) Results:
In CC time from endoscopy to surgery: prior to start program, goal and after implementation
(n=40) was resp 40, 14, 10 days. In RC time from endoscopy to surgery was resp 55, 40,
36 days (n=10). LOS in CC was resp 10, 6, 8 days, in RC resp 12, 8, 10 days. Number of
hospital visits in CC resp 8, 4, 4, in RC 12, 6, 6. Goals and actual reduction in cost per
patient in CC were Euro 1365 resp 830, in RC Euro 817 resp 405. Patient satisfaction was
significantly increased. A similar approach for an esophageal cancer care process is being
started. Conclusion: A structured multidisciplinary approach to optimize complicated care
processes can significantly increase quality of the process and simultaneously reduce costs.
A-640AGA Abstracts
A case manager to coordinate and monitor the process is essential and cost effective. Once
this type of approach has been instituted, it can easily be transplanted to optimize other
complicated care processes.
W1006
Quality of Barrett's Surveillance in Non-University Hospitals; A Systematic
Retrospective Review of Endoscopy and Pathology Reports
Wouter L. Curvers, Femke Peters, Brenda Elzer, Annet Schaap, Cyril Ponsioen, Rosalie
Mallant-hent, Jacques Bergman
Introduction Optimal Barrett's surveillance (BS) requires adequate endoscopic inspection of
the Barrett's segment, obtaining a sufficient number of biopsy specimens, good communica-
tion of the endoscopic findings to the pathologist, and accurate description of the histological
findings by the pathologist. The aim of this study was to assess the quality of BS in daily
practice in non-university hospitals in the Amsterdam region. Methods In 2004 and 2005,
the Amsterdam Gastroenterological Association initiated a retrospective Barrett's surveillance
registration of all 16 hospitals in the Amsterdam region. A structured scoring list was
developed to systematically evaluate the quality of endoscopy reports (ER) and pathology
reports (PR). The list was developed based on literature, recent guidelines, and our expertise
in this field. 10 ERs and their corresponding PRs were randomly obtained from the 14 non-
university hospitals participating in the registration. Reports were separately scored by 2
observers. In case of disagreement, the observers re-evaluated the reports in a consensus
meeting. Results 134 ERs and their corresponding PRs were evaluated. The indication for
endoscopy was reported in 87%. Location of the squamoclumnar junction and gastric folds
were described in 59% and 55%, respectively. The presence of a hernia was described in
75% and the presence/absence of esophagitis was reported in 32%. The length of the BE
could be extracted from 69% of the reports; median BE length: 3 cm (IQR 2-6). In 132
procedures biopsies were obtained, with a median number of 4 (IQR 3-5) specimens. We
calculated the number of biopsies obtained as a percentage of the number of biopsies that
should have been obtained according to the Seattle protocol. Adherence to the Seattle
protocol decreased with increasing Barrett's length: 0-5cm: 74%; 5-10 cm: 42%; 10-15 cm:
30%. The indication for the endoscopy was mentioned in 24% of the PRs. In 3% the
presence/absence of esophagitis was communicated, and in 20% the exact location of biopsies
was described. In 36% of PRs only a conclusion without corresponding microscopic descrip-
tion was reported. The presence/absence of dysplasia was mentioned in 94% of PRs. But
only in 3 of 14 cases that reported dysplasia, the degree of dysplasia was described according
to the revised Vienna criteria. Conclusion ERs and PRs in current practice do not include
all relevant information for an adequate BS. In short segment BE the adherence to the Seattle
protocol is acceptable but in longer segments (with a higher risk for neoplastic progression)
this is clearly insufficient. The communication between endoscopists and pathologist is
suboptimal.
W1007
Gut Balance of Sodium During Treatment of Adult Cholera Patients with Two
Different Oral Rehydration Solutions (Ors)
Nur H. Alam, Hasan Ashraf, Remy Meier, Niklaus Gyr
Background: Recently, WHO and UNICEF have recommended a reduced osmolarity oral
rehydration solution (Na+ 75 mmol/L, glucose 75 mmol/L) in place of previous formulation
(Na+ 90 mmol/L, glucose 111 mmol/L) for the treatment of all causes of diarrhea in all age
groups for its better efficacy. As adult cholera patients excrete much higher amount of
sodium in stool than the sodium contained in the reduced osmolarity ORS, so there is a
concern of negative sodium balance during treatment of cholera patients with this recom-
mended ORS. Aim: To study the extent of negative sodium balance(excretion is more than
intake) during treatment of adult cholera patients with reduced osmolarity ORS compared
to the old formulation of ORS. Methods: In a double blind randomized controlled trial, 36
adult male with cholera were studied; a) 18 received reduced osmolarity ORS (study group);
b) 18 received old ORS formulation (control group). Before randomization all patients were
rehydrated with intravenous fluid within 4 hours. The patients received ORS matching
approximately the stool output tomaintain hydration.Written informed consent was obtained
from all patients. First 24 hours intake of ORS was measured and intake of sodium (mmol)
was estimated. Similarly, stool output during this period was measured and excretion of
sodium was estimated by measuring the stool sodium (mmol). Gut balance of sodium was
determined by the formula (intake of sodium in ORS minus excretion of sodium in stool).
The main outcome measure was number of patients with negative sodium balance. Secondary
outcomes such as intake of ORS and output of stool were also compared between the groups.
Results: Baseline clinical characteristics were comparable between the groups. The number
of patients with negative sodium balance was more in the group receiving reduced osmolarity
ORS (13 vs. 9; RR, 1.44; 95% CI, 0.84 to 2.49,), however the difference was not statistically
significant (p=0.3). The mean ± SD of the extent of sodium balance in the first 24 hours
in those patients was also not significantly different (study ORS vs. control ORS, -272 ±230
vs. -220 ± 259, p=0.61) between the groups. The ORS intake and stool output during this
balance period were also similar in patients of both groups. Conclusion: Treatment of adult
cholera patients with either oral rehydration solution might cause negative sodium balance
during the early phase of the disease and treatment with the new reduced osmolarity ORS
does not cause significantly more negative sodium balance in those patients that prevents
the use of reduced osmolarity ORS in adult cholera patients.
W1008
Long-Term, (6 year) Follow Up of Patients with Iron Deficiency Anemia After
a Negative Gastrointestinal Evaluation
Mark Mcloughlin, Tony Tham
INTRODUCTION: Current practice guidelines (such as those put forward by the British
Society of Gastroenterology) recommend that EGD and a lower GI investigation (colonoscopy
or barium enema with or without sigmoidoscopy) are sufficient in the evaluation of iron
deficiency anemia (IDA). These guidelines are based on 2 small studies from the mid 1990s
which concluded, after long term follow up of patients with IDA, that this approach was
safe. AIMS: To determine if patients who have had a negative GI evaluation for IDA are
subsequently found to have recurrent anemia or significant pathology. METHODS: Patients
who had upper and lower GI investigations for IDA between 1997 and 2000 in our hospital
were identified from a prospective endoscopy database. Those with overt GI bleeding or a
positive diagnosis (gastric carcinoma, colorectal carcinoma, celiac disease, inflammatory
bowel disease) were excluded. Hospital records were reviewed to determine outcome. Where
these were incomplete the patient's primary physician was contacted. RESULTS: 69 patients
(54 female, 15 male) with negative upper and lower GI investigations were followed up for
a median of 5 years and 10 months (range 7-109 months). Average age at presentation was
65.8 years (range 29-87). In 57 patients (83%) the anemia resolved after the initial treatment
period. 13 patients (19%) died of other illnesses during the follow-up period, 4 of these
(6%) with non-GI malignancies. 3 patients (4%) developed chronic IDA severe enough to
require recurrent blood transfusions and 3 patients (4%) required regular iron transfusions.
2 of these were pre-menopausal women with menorrhagia. 4 patients (6%) were diagnosed
with GI malignancies during follow-up. One of these was diagnosed with colonic carcinoma
on barium enema 9 months after a normal EGD and enema. Another patient was diagnosed
with a small bowel adenocarcinoma 13 months after his initial investigations, which included
a small bowel series, and a third patient was found to have a gastric tumour 42 months
after a negative evaluation. One other patient was diagnosed with a malignant colonic polyp
7.5 years after her first presentation. CONCLUSIONS: In the majority of patients with a
negative GI evaluation for IDA the outcome is favorable, although a small percentage (6%)
may subsequently be diagnosed with significant GI pathology. The current approach to IDA
investigation is probably safe, although a change in symptoms or persistent anemia should
prompt further investigations.
W1009
Effect of Yacon, a Root Crop Rich in Fructo-Oligosacharides, On Colonic
Transit in Healthy Volunteers
Lukas Degen, Martin Geyer, Thomas Bernet, Christoph Beglinger
Yacon is a root crop from the Andean region classified under the Asteraceae family (Genta
SB et al. Food Chem Toxicol. 2005; 43 (11) 1657-65). The root is consumed since pre-
Inca times. The root contains the highest levels of naturally found fructo-oligosaccharides
(FOS). FOS are low in calories and consumption is known to promote health and digestive
functions (Coussement PA. J Nutr 1999; 129: 1412S-7S). FOS are recognized as soluble fibres
which cause several favorable effects on the GI tract: an increase of peristaltic movements, an
increase in the amount of water retained by the fecal matter and an osmotic effect similar
to a laxative. These properties suggest that Yacon with its high content in FOS could be
used for the treatment of constipation. A thorough evaluation of Yacon on colonic transit
has, however, not been done yet. The aim of this double-blind, randomized, placebo-
controlled cross-over trial was to evaluate the effect of Yacon on colonic transit in healthy
volunteers. Methods. Yacon syrup or a placebo syrup was administered to16 healthy indi-
viduals (8 males, 8 females) in a dose of 20g per day for two weeks. After a 2-week wash-
out phase, the second treatment was given for another 2 weeks. Segmental (right colon, left
colon, rectosigmoid) and total transit time was determined using the radio-opaque marker
technique. Safety and tolerability was assessed by recording side effects and by laboratory
tests. Results. Yacon syrup was well tolerated. Adverse effects included bloating, but the
rate of adverse events was not significantly different from placebo. The results on colonic
transit are given in the Table. Yacon markedly accelerated total colonic transit time both in
males and females compared with placebo (p=0.0018 and P=0.0097, respectively). Segmental
colonic transit time was also accelerated, but did not reach statistical significance. The
number of daily bowel movements increased as did the stool consistency showing a tendency
for softer stool (assessed by the Bristol stool score). Both parameters did not reach significance
due to the limited number of subjects.. We conclude that Yacon syrup significantly accelerates
colonic transit time in healthy volunteers. This findings suggest a potential application for
yacon syrup as a natural product for the treatment of constipation. Further studies in
constipated patients are necessary to evaluate the potential of this compound.
§ = significant difference vs placebo
W1010
Comparative Usefulness of Deamidated Gliadin Antibody Measurements in
the Diagnosis of Celiac Disease
Shadi Rashtak, Michael W. Ettore, Henry A. Homburger, Joseph A. Murray
BACKGROUND: Serological tests are frequently used to screen for celiac disease and to
monitor the effect of a gluten free diet. Gliadin antibodies (AGA) in general lack the sensitivity
required for efficient screening. Recent findings have demonstrated that AGA from celiac
patients have greater avidity for deaminated gliadin peptides than for native gliadin. AIM:
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To evaluate the value of deamidated gliadin antibody (AGA II) measurements in the diagnosis
and follow up of celiac disease and compare their potential utility with that of AGA and
tissue transglutaminase antibodies (tTG). METHODS: Serum samples from 97 biopsy-proven
non-celiac controls (70% female; mean age 43 y) and 40 biopsy-proven celiac patients (83%
female; mean age 48 y, 52.5% with total villous atrophy and 47.5% with partial villous
atrophy) before and after treatment with gluten free diet (median 9 months) were assayed.
AGA II, AGA, and tTG were measured by commercial enzyme-linked immunosorbent assays
(ELISA). A conjugate, reactive to both isotypes was used for detection of AGA II IgA+IgG
which gives a positive if either isotype is present. McNemar exact test was employed to
compare sensitivity, specificity, and accuracy of AGA II isotypes with that of AGA and tTG.
RESULTS: The sensitivity and accuracy of AGA II were superior to AGA and similar to tTG
testing before treatment. The sensitivity of AGA II IgA was greater than AGA II IgG and the
proportion of positive test results for all tests decreased significantly after treatment (table).
CONCLUSION: ELISA based detection of AGA II is a useful test for the diagnosis of celiac
disease and the evaluation of response to gluten exclusion, and it should replace the AGA
test for celiac disease screening and monitoring.
*P value=0.02 Vs AGA IgA, ΩP value=0.02 Vs AGA IgG, γP value=0.001 Vs AGA IgG, ΦP
value<0.0001 Vs before GFD, εP value=0.001 Vs before GFD, ΔP value=0.006 Vs before
GFD, μP value=0.01 Vs before GFD, ψP value=0.0005 Vs AGA II IgG. All p-values obtained
with the McNemar exact test.
W1011
Patient-Centered Scheduling for GI Clinics Results in Lower NO-Show Rates
and Decreased Delays in Cancer Diagnosis
Erik J. Van kleek, Kathleen Viveiros, Michelle Meek, Scott Renslow, Timothy Dresselhaus,
Samuel B. Ho
Background: Delivery of quality care in medicine depends upon many factors including
service supply and demand, patient compliance, access to care and provider availability. In
fields such as gastroenterology, prompt endoscopy after referral is important for earlier
diagnosis. Patient-centered scheduling may lead to greater compliance with the primary
provider's request and improved outcomes. Aim: To determine how implementation of
patient-centered scheduling impacts appointment scheduling, no-show rates, and time to
diagnosis of GI cancers. Methods: On June 13, 2006 the scheduling policy for GI procedure
and clinic appointments at the San Diego Veterans Affairs Medical Center was changed to
require patients to respond to an invitation letter prior to scheduling. Previously, all approved
requests were automatically scheduled without patient input. Under the new system, consult
requests for patients that did not respond within 30 days or missed appointments were
cancelled and the requesting provider notified. We compared trends in appointments sched-
uled, no-show rates, patients seen within 30 days, and cancer diagnoses made within 60
days of the consult before and after the policy change. Where appropriate a t-test and chi-
squared test were used. Results: Following the scheduling policy change, 66% (374/577)
of invited patients scheduled endoscopic procedures and clinic appointments during a 2
month period. No-show rates for GI clinics decreased from an average of 35% (range 26
to 45%) to 20% (range 12 to 34%). The endoscopic procedure no-show rate decreased
from an average of 21% (range 18 to 23%) to 16% (range 15 to16%). The number of new
consults seen within 30 days increased from 47% (range 41 to 51%) per month to 80%
within 3 months of the scheduling change. GI cancers diagnosed within 60 days of referral
increased from 49% (16/33) to 93% (13/14), p=0.01. The mean time to diagnosis of GI
malignancies decreased from of 82 days to 27 days, p=0.0007. Conclusions: Procedure and
clinic scheduling based on primary physician request alone without patient input was
associated with high no show rates and long delays in scheduling. Requiring patients to
actively participate in the scheduling process improved no-show rates andmarkedly increased
the percentage of patients seen within 30 days. In this group, there was a significant reduction
in the time to diagnosis of GI cancers.
W1012
How Long Should Patients Be Observed After Percutaneous Liver Biopsy?
Hellan Kang, Erin Ford, Fran Schultz, Anna Lok
Background: Liver biopsy may be complicated by pain, bleeding, hemo/pneumothorax, and
very rarely death. Currently, there are no standardized guidelines in regards to the duration
of post-procedure recovery. Aim: To determine the minimum duration of post-liver biopsy
recovery that will identify all patients with significant symptoms or major complications.
Methods: Records of 238 consecutive outpatient percutaneous liver biopsies performed by
gastroenterologists at our center between Apr-Oct 2006 were reviewed. Standard post-
procedure observation duration was 2 hrs but was extended for multiple passes, high risk
of bleeding, significant post-procedure pain or hemodynamic changes or at the discretion
of the physician. Pain was scored by patients on a scale of 0-10 and the maximum pain
score (MPS) for each time period was analyzed. Patients were contacted within 3 days of
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the procedure to determine if they required hospitalization or emergency room visit post-
liver biopsy. Results: Recovery data were available on 222 patients (11 had platelet count
<100k, 6 with INR >1.2 and 45 had liver allografts), 130 were observed for 2 hrs and 91
for 2-4 hrs. The most common symptom post-procedure was pain (Table). No pain was
experienced by 32% of patients in the first hour while 23% had MPS of 7-10. Between the
1st and 2nd hr, 4% patients had increase and 50% had a decrease in the MPS, 31% remained
without pain, 11% and 4% of patients had similar MPS of <7 and 7-10 respectively. Among
the patients who were observed for >2 hrs, none had increase in MPS after the 2nd hr. 4
patients were hospitalized, 2 had MPS of 9 in the 1st hr and both were discharged without
complications. 1 post-transplant patient had cholangiogram earlier that day and developed
hypotension due to cholangitis. The 4th patient developed severe pleuritic pain within the
1st hr and was discharged after 4 hrs when pain improved. This patient was admitted the
same night for hemothorax. 4 patients presented to ER within 24 hrs of the biopsy, 3 had
pain and 1 had light headedness, none had complications and all were discharged. Conclu-
sion: Among outpatients undergoing a percutaneous liver biopsy, 48% had little or no pain
during the 1st hr, 4% had an increase in MPS during the 2nd hr, no patient had increase
in MPS after 2 hrs. Extending the observation period beyond 2 hrs would not have identified
additional patients who required ER visit or hospital admission.
W1013
Predictive Factors of Sustained Virological Response to Peginterferon Alpha-2a
Therapy in the Patients with Chronic Hepatitis C Despite the Discontinuation
of Peginterferon Alpha-2a Therapy Due to Adverse Events
Ken Sato, Kenichi Hosonuma, Takeshi Itikawa, Satoru Kakizaki, Hitoshi Takagi,
Masatomo Mori
Background: Interferon (IFN) therapy in the patients with chronic hepatitis C is occasionally
discontinued due to various adverse events and ends up failing. However we encounter the
patients who achieved sustained virological response (SVR) despite the discontinuation of
IFN due to adverse events. We herein clarify predictive factors of SVR to peginterferon
alpha-2a therapy in the cases of chronic hepatitis C despite the discontinuation of peginter-
feron alpha-2a therapy due to adverse events. Methods: Thirty-two patients with the disconti-
nuation of peginterferon alpha-2a due to adverse events such as depression and appetite
loss were enrolled in this study. The cases with the intended short periods of peginterferon
alpha-2a therapy were excluded. The definition of the discontinuation of peginterferon
alpha-2a is that peginterferon alpha-2a is discontinued at least four weeks shorter than the
standard therapies (48 weeks) which are approved in Japan. The definition of SVR is that
serum HCV-RNA level remains negative for 24 weeks after the discontinuation of peginter-
feron alpha-2a therapy. Results: SVR and Non-SVR (NR) were achieved in 14 and 16 cases,
respectively. The sex ratio (M/F) in the cases with SVR and NR was 7/7 and 3/13, respectively.
The average age in the cases with SVR and NR were 59 years (range 25-74) and 59 (range
49-74), respectively. The average periods of peginterferon alpha-2a therapy in the cases
with SVR and NR were 21 (range 5-32) and 16 weeks (range 2-38), respectively. Average
pretreatment serum HCV-RNA in the cases with SVR and NR was 183 (range 4-1760) and
869 (range 15-2100) KIU/ml, respectively. The HCV genotypes included 1b (n = 4 and 7),
2a (n = 8 and 4) and 2b (n = 2 and 5) in the patients achieving SVR and NR, respectively.
The numbers of the patients achieving SVR and NR with serum HCV-RNA level below
0.5KIU/ml within 4 weeks after peginterferon alpha-2a therapy were all 14 and 5, respectively.
Univariate analysis showed pretreatment serumHCV-RNA level and the periods of disappear-
ance of serum HCV-RNA were significant predictive factors of SVR. In addition, by multivari-
ate analysis, pretreatment serumHCV-RNA level (p=0.0059) and the periods of disappearance
of serum HCV-RNA (p=0.0004) were independent predictors of SVR in all patients. Conclu-
sions: Pretreatment serum HCV-RNA level and the periods of disappearance of serum HCV-
RNA behave as predictive factors of SVR to peginterferon alpha-2a therapy in the patients
with chronic hepatitis C. Thus, these factors may enable us to shorten the periods of
peginterferon alpha-2a therapy by design.
W1014
Common Errors in the Management of Acute Pancreatitis: A Survey of
Internal Medicine Residents and Physicians
Shahzad Iqbal, Rana Khan, Veron Browne-mcdonald, Mehjabin Zahir, Hashem
Vahabzadeh-monshie, Bishnu Sapkota, Rekha Khurana, Maurice A. Cerulli
Background: The mortality of acute pancreatitis (AP) has remained relatively constant after
the initial decrease in early 1990's due to improved intensive care. The management of mild
disease likely affects the complications that follow and portend severe disease. Studies suggest
that a proportion of complications could have been prevented or treated more appropriately.
The survey was conducted to assess the common errors in the management of AP so that
current teaching patterns could be focused on these areas. Methods: A 14-question survey
was administered in multiple choice formats to internal medicine residents and primary
care physicians at two large teaching hospitals. The questions and responses are shown in
table 1. Results: There were total 149 persons who participated in the survey (39 PGY-1,
38 PGY-2, 31 PGY-3 and 41 Primary Care Physicians). The results are shown in tables 1
and 2. Overall, both residents as well as physicians did not do well. Although they were
able to detect and order early ERCP for gallstone-pancreatitis, they failed to recognize
Hematocrit level as the best predictor of severity on admission and optimal level of IV
hydration in AP. They also performed poorly in the management of sterile and infected
pancreatic necrosis (PN), importance of morphine in pain control, as well as incidence
and diagnostic work-up in idiopathic acute pancreatitis (IAP). Conclusions: The lack of
understanding and inconsistent management of AP is a cause for concern. The current
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teaching programs should focus on common errors in the management of AP in order to
decrease the mortality as well as to curtail ineffective use of costly resources.
Table 1
Table 2
W1015
Three Months of Iron Deficiency Anemia; Are We Scoping the Right People?
Validating Investigations in An Era of Reimbursement
Sheena Patel, Bu H. Hayee, John O'donohue, David M. Reffitt
Introduction. NHS and private hospitals now compete to provide diagnostic services; hence
appropriate use of endoscopic facilities is essential. Investigating iron deficiency anaemia
(IDA) places a considerable burden on gastrointestinal (GI) service provision. British Society
of Gastroenterology (BSG) guidelines recommend that patients should have an upper GI
endoscopy and either colonoscopy or barium enema unless carcinoma or celiac disease is
found. Aims and Methods. To determine adherence to published BSG guidelines, casenotes
were analysed for consecutive patients with anemia referred for endoscopic investigation
(defined by referring physician) from Feb to April 06. IDA was defined as the presence of
anemia: hemoglobin (Hb) < 12.5 g/dl M or < 11.5 g/dl F with either ferritin < 15mcg/l (or
50mcg/l if ESR elevated) or MCV < 76. Patients not fulfilling these criteria were termed
non-IDA. The IDA group and the non-IDA group were compared for detection of GI
malignancy. The potential cost savings from inappropriate investigations was calculated.
During the same period, the hematology database was examined to determine whether,
undoubted IDA patients (anemia with both ferritin < 15 + MCV < 76, age > 50y), were
appropriately referred for investigation. Results. 119 patients (67M) were referred for investi-
gation of ‘anemia'. 52 patients (43.6%) had proven IDA; 67 patients (56.3%) had non-IDA
with either normal ferritin/MCV or no ferritin measured prior to referral. 6/52 (11.5%)
patients with proven IDA had GI cancer; whereas 2/67 (3.0%) patients with non-IDA had
GI cancer (p = 0.057, chi squared test). Of the non-IDA cancers, one patient with colonic
cancer had no ferritin measured prior to endoscopy, the other with gastric cancer had a
ferritin = 17 and alarm symptoms of anorexia and weight loss. The number of inappropriate
tests performed in the non-IDA patients = 5 celiac, 63 OGD and 35 lower GI. Based on
current NHS tariffs, over one year the estimated cost is $305,764/ year. 37 patients (30 F)
were identified from the haematology database with undoubted IDA, however, only 7 had
both upper and lower GI investigations, 9 had a lone OGD and 3 had lower GI alone. For
the total number of patients with IDA in this study = 89 (endoscopy referrals plus haematology
database), there were 7 celiac screens; 52 OGDs and 50 with lower GI investigation. Potential
lost revenue = $454, 323/ year. Conclusion. Many patients with IDA are being inappropriately
investigated with consequent clinical risk and burden on endoscopy resources and finances.
The BSG criteria appear sensitive for determining which patients with IDA require investi-
gation to detect GI cancer.
W1016
Incidence and Determinants of Acute Complications in a Series of 145,401
Outpatient Colonoscopies
A. Crispin, Berndt R. Birkner, Ulrich Mansmann, A. Munte
Objective: To assess the risk of acute complications in a large series of outpatient colonoscop-
ies and to identify patient characteristics associated with a higher rate of complications.
Since 2000, only few prospective studies have provided risk estimates of acute complications
during screening and curative colonoscopies. Current data on bleeding rates are especially
sparse. Patients andmethods: Since the beginning of 2006, outpatient colonoscopies delivered
by Compulsory Health Insurance Physicians in Bavaria, Germany are documented via online
access to a central colonoscopy database. As of September 2006, 145,401 colonoscopies
have been recorded (110,658 diagnostic and tumor aftercare, 34,743 screening). The database
covers demographic patient characteristics, indications for colonoscopy, process quality
indicators, macroscopic and histological findings (including tumor staging, if applicable), final
diagnosis, acute complications, and further diagnostic and therapeutic recommendations. We
present results of descriptive and exploratory logistic regression analyses. Results: 508 patients
(0.35%, 95% CI 0.32 - 0.38) suffered at least one of the following complications: 381
bleedings (0.26%, 95% CI 0.24 - 0.29), 44 perforations (0.03%, 95% CI 0.02 - 0.04), and
88 cardio-respiratory complications (0.06%, 95% CI 0.05 - 0.07). 99% of bleedings (95%
CI 97.0 - 99.6) and 20% of perforations (95% CI 10 - 35) could be managed conservatively.
97% of cardio-respiratory complications (95% CI 90 - 99) were reversible. Patient character-
istics associated with a higher overall complication rate were patient age (OR 1.03 per year,
95% CI 1.02 - 1.04), presence of adenomas including polypectomies (OR 40.1, 95% CI
14.3 - 112), and presence of carcinomas (OR 67.3, 95% CI 6.0 - 756). There was no
difference between curative and screening colonoscopies. Sessile adenomas had a lower risk
of complications than peduncular lesions (OR 0.63, 95% CI 0.49 - 0.81), as had smaller
adenomas (OR for adenomas sized 0.5 - 1 cm vs. > 3 cm: 0.21, 95% CI: 0.15 - 0.30).
Conclusions: In accordancewith the literature, our results demonstrate the safety of outpatient
colonoscopy in routine practice with a low incidence of acute complications. The data show
specific patient and adenoma related risk profiles for acute complications. Unbiased reporting
of late onset complications and mortality requires a more elaborate documentation system,
which will be implemented within the near future.
W1017
Body Mass Index and Degree of Villous Atrophy Correlate with Bone Mineral
Content Deficits in Children At Time of Diagnosis with Celiac Disease
Muralidhar Jatla, Babette S. Zemel, Aqiba Bokhari, Patricia Bierly, Pierre Russo, Ritu
Verma
No guidelines exist for the role or timing of screening for osteopenia in pediatric celiac
disease (CD). We assessed whether spine (SP) or whole body (WB) bone mineral content
(BMC) in children at time of CDdiagnosis was related to albumin, hemoglobin, transaminases,
symptom type, duration, BMI, or degree of intestinal damage to determine the utility of
dual energy x-ray absorptiometry (DEXA). Design: A retrospective study where 44 children
who had DEXA at CD diagnosis at CHOP between 10/03 and 6/06 were compared with an
age-matched control population of 646 from the Philadelphia area. Duodenal biopsies were
stratified according to Marsh grade. Regression analyses were performed for SP and WB
BMC to assess for differences in CD vs controls and ANOVA and t-test analyses were
performed to assess for differences in BMC in the presence of villous blunting, anemia,
hepatitis, low BMI as well as symptom type and duration. Results: No significant differences
were found in SP or WB BMC between CD patients and controls. SP (p=0.02) and WB
(p<0.001) BMC correlated with BMI percentile. 3% of patients had Marsh grade I (MI), 5%
had MII, and 92% had MIIIa-c {IIIa (20.4%), IIIb (33.2%), IIIc (38.3%)}. SP BMC was
different between these groups (p=0.03), however the lowest Z score was with IIIb; IIIa
+0.31, IIIb -1.20, IIIc -0.09. The mean ALT value was 27.7 (SD 21.6), AST 43.7 (SD 22.8);
hepatitis was seen in 29% of patients. SP (p=0.50) and WB (p=0.19) BMC were not different
in hepatitis versus no hepatitis groups. Mean albumin was 4.0 (SD 0.4), with no hypoalbumi-
nemia seen. Mean hemoglobin was 12.9 (SD 1.3), and mean MCV was 81.1 (SD 5.3); one
patient had microcytic anemia. The most common symptoms were abdominal pain (55%)
and diarrhea (14%). Symptom duration was less than 12 months in 57% and over 12
months in 43%. SP (p=0.96) and WB (p=0.81) BMC did not differ by presenting symptom
or duration of symptoms. Conclusion: SP and WB BMC abnormalities were not seen in
pediatric CD at diagnosis at our institution. Marsh grade at diagnosis correlates with osteop-
enia, however, the most severe grade did not correlate with the lowest BMC. BMI percentile
in CD correlates with osteopenia, as in healthy children. Hepatitis did not correlate with
BMC. Anemia and hypoalbuminemia were rare in this cohort. A larger number of children,
perhaps with anemia or hypoalbuminemia may need to be studied to assess the prevalence
of osteopenia in this population. DEXA should be considered in patients with low BMI or
severe blunting (Marsh IIIb or above). Routine screening with DEXA may not be warranted
in all newly diagnosed pediatric CD patients.
W1018
Tuberculous Chemoprophylaxis Requirements and Safety in Inflammatory
Bowel Disease Patients Prior to Anti-TNF Therapy
Eugeni E. Domenèch, Yamile Y. Zabana, Antonio A. López san roman, Belén B. Beltrán,
José luis J. Cabriada, Cristina C. Saro, Robert R. Aramendiz, Daniel D. Ginard, Joaquin J.
Hinojosa, Javier J. Pérez-gisbert, Miquel angel M. Gassull
Preventive actions are advised since the use of anti-TNF agents is known to increase the
risk of tuberculosis (TB). No data related to the effectiveness and security of the prevention
chemoprophylaxis (ChP) for TB upon inflammatory bowel disease (IBD) patients are available.
Aims: To evaluate the effectiveness and safety profile of TB chemoprophylaxis (ChP) in IBD
patients. Methods: Patients with latent TB (positive purified protein derivate (PPD) plus a
normal chest-X-ray) where identified from databases of IBD patients from 9 Spanish centres.
Epidemiological and clinical data, risk factors for hepatotoxicity, ChP regimens, and side
effects, were registered. Results: Sixty four out of 497 IBD patients (13%) had latent TB.
72% were receiving immunemodulators when PPD was performed, and 24% were on
systemic corticosteroids. ChP was indicated for 5-10mm PPD in 10 patients, >10mm in 43,
< 5mm initial PPD but a booster > 5mm in 9, and recent TB contact in 2. ChP consisted
in isoniazid during 6 (55%), 9 (40%), or 12 months (3%). Rifampicin+isoniazid for 6 months
was used in only in 1 patient. 95% completed the planned ChP regimen. 67% followed
treatment with thiopurines and 16% with methotrexate during ChP. Hepatotoxicity was
registered in 10 cases that solved without any specific action and only in one case required
ChP discontinuation. 78% received anti-TNF therapy after a median of 2 months (range,
0-16) of starting ChP. No cases of active TB were noticed. Conclusions: More than 10% of
Spanish IBD patients who are evaluated for anti-TNF therapy have latent TB. The booster
PPD test identifies up to 15% of latent TB in this subset of patients; in turn, routine booster
test in initially PPD negative patients should be considered. TB ChP is effective and safe in
IBD patients in spite of the concomitant use of potential hepatotoxic drugs.
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W1019
Is the Incidence of Post-Endoscopic Cholangiopancreatography (ERCP)
Pancreatitis Reduced in Patients Undergoing Hydrophilic Guide Wire
Cannulation of the Common Bile Duct (Cbd) Versus Standard Cannulation
with Dye Injection: A Randomized Controlled Trial
Steven Gruchy, Donald G. Macintosh, Dana Farina, Michele Molinari, M. Khaliq-kareemi
Background: Pancreatitis is the most common complication of ERCP with published rates
of 5-8%. Repeated injection of the pancreatic duct with contrast has been reported to increase
the risk of post-ERCP pancreatitis. A hydrophilic guidewire may be used for cannulation if
attempts at duct cannulation have been unsuccessful. We hypothesized that a priori use of
a hydrophilic guide wire to cannulate the CBD may result in a significant decrease in the
incidence of post-ERCP pancreatitis when compared to the standard cannulation with dye
injection by avoiding unintended contrast injection of the pancreatic duct. Methods: Patients
about to undergo their first ERCP who had not previously been diagnosed with pancreatitis
were consecutively enrolled and randomly assigned to undergo cannulation of the CBD with
either a guidewire or dye injection. Serum amylase levels were obtained prior to the ERCP
and twenty-four hours post procedure. The primary outcome was the incidence of post-
ERCP pancreatitis as defined by standard criteria. Secondary outcomes included the incidence
of significant bleeding, success of CBD cannulation and immediate complications. Analyses
were performed on an intention to treat basis. Results: 228 patients were enrolled in this
study. 216 patients met the inclusion criteria and were randomized (110 guidewire, 106
dye). 25 patients were lost to follow up. The overall incidence of post-ERCP pancreatitis
was 4.2%. There was no significant difference in the incidence of pancreatitis for the two
groups (guidewire 4.0% vs. dye 4.4%; p=0.892). There were 2 cases of post-sphincterotomy
bleeding in the wire access group and none in the dye group (p=0.241). There was no
statistically significant difference in the rate of successful CBD cannulation comparing the
two study groups (95% wire, 88% dye; p=0.08). Conclusions: Interim analysis of this
ongoing trial indicates that there may be no significant reduction in the incidence of post-
ERCP pancreatitis using wire cannulation.
W1020
Adherence to Surveillance Guidelines - An Opportunity to Enhance Efficiency
of Endoscopic Practice
Omar I. Rathore, Gavin C. Harewood, Stephen Patchett, Frank Murray
Introduction: The growing demand on endoscopy services has increased the importance of
optimal resource utilization in gastroenterology. Strict adherence to recommended surveil-
lance intervals is important in ensuring timely access for patients awaiting endoscopy. This
study aimed to characterize adherence rates to published surveillance guidelines in a high
volume gastroenterology referral centre. Methods: All endoscopic procedures scheduled for
surveillance indications between January and December 2006 were reviewed. Surveillance
indications were classified as: a) Barrett's oesophagus, b) chronic Inflammatory Bowel Disease
(IBD), c) prior adenomatous colorectal polyps and, d) prior surgical resection of colorectal
cancer. Results: 441 endoscopies were scheduled for surveillance of which 195 (44.2%)
were scheduled at an inappropriate interval; all of these were scheduled prematurely. Of
these, 50 of 133 (37.6%) Barrett's patients, 17 of 47 (36.2%) patients for IBD surveillance,
92 of 213 (43.2%) patients with prior colonic polyps and 36 of 48 (75.0%) patients with
prior colonic malignancy and were scheduled prematurely (figure). Conclusion: Almost half
of all surveillance procedures are scheduled prematurely, most commonly patients with
prior colorectal cancer. This ‘over-surveillance' represents an unnecessary additional burden
on the current workload. Attempts to remedy this practice could enhance timely access for
patients awaiting endoscopic procedures.
W1021
Factors Associated with Colonoscope Withdrawal Time During Screening
Colonoscopy
Arati Pratap, Tim Heeren, Paul C. Schroy
BACKGROUND: Recent studies have shown that adenoma detection rates during screening
colonoscopy are inversely related to colonoscope withdrawal time. Consequently, withdrawal
time has been identified as a quality indicator for screening colonoscopy. The aim of this
study was to identify factors that influence withdrawal time and may be amenable to quality
improvement interventions. METHODS: We examined the association between withdrawal
time and endoscopist experience (years in practice, mean number of colonoscopies performed
annually), endoscopist work load (mean number of procedures and colonoscopies per 4
hour session and per day over 6 month period), procedure-related factors (scope insertion
time and percentage of preps rated fair or poor) and patient factors (mean age, sex and
race/ethnicity). Insertion and withdrawal times (mean ± S.E.) were defined for each endoscop-
ist (N=12) based on a minimum of 10 (range, 10-31; median, 15) normal screening colonos-
copies with good or excellent preps. Total procedural time and cecum-to-anus withdrawal
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time, starting with the time at which the endoscopist photographed the appendix, were
measured by the endoscopy nurse. Endoscopists were blinded to documentation of timed
procedures. Our electronic endoscopic database (Provation®) was used to calculate the
mean number of colonoscopies per year between 2000 and 2005, work load during the
same 6-month period used to define withdrawal times, quality of bowel prep and patient
factors described above on a per endoscopist basis. RESULTS: Mean withdrawal times per
endoscopist ranged from 4.5 ± 0.5 minutes to 9.6 ± 1.1 minutes. Endoscopist experience,
defined by the number of years in practice, was positively correlated with withdrawal time
(r = +0.60, P= 0.039). Mean number of procedures (r = -0.34) and colonoscopies (r = -0.38)
per session and mean number of procedures per day (r = -0.46) showed fair to good
correlation but did not achieve statistical significance (P > 0.05). Mean number of colonoscop-
ies performed per year, insertion time, quality of prep and patient factors showed little or
no correlation (r < 0.25). CONCLUSIONS: Colonoscope withdrawal times during screening
colonoscopy vary among endoscopists and appear to correlate directly with years of experi-
ence. Because experience is a non-modifiable determinant of withdrawal time, quality
improvement initiatives must focus on behavioral rather than system-based interventions.
Future studies with larger samples of endoscopists, however, are needed to better define
the association between withdrawal time and work load.
W1022
Empowered IBD Patients - Doing Good and Needing Less Care
Jorgen Tholstrup, Martin Rejler, Anna Spangeus, Wojciech Broda, Miroslaw Wielondek
Background: The unit of gastroenterology serves 115.000 people, of whom 465 suffer from
IBD. As previously reported (DDW 2004) the follow-up strategies 2001 were re-designed
into a system where follow-up for suitable patients (i.e. stable disease, no treatment with
purines or if the patient demands visit) earlier followed up with routine visits at the office
were changed to annual, structured telephone contacts with a nurse. Prior to this contact,
basic blood tests are controlled as well as a short QoL- questionnaire (SHS). The patients
are offered instantaneous on-demand telephone contact with a nurse and on-demand visits
at the office within 3 days. Methods: To record medical results, a quality register containing
basic demographic data, diagnose, simple biochemical markers (Hb, CRP, Albumin), actual
medication and QoL, using SHS (Short Health Scale), is used, celiac disease in remission
(CE) is used as control group. Data for waiting times and patient satisfaction are monitored.
The number of in-patient occasions has been analyzed retrospectively and compared to
national data. To measure compliance the computerized database of receipts and patient
records has been reviewed. Results: The number of patients with Hb >120 gr/l is 96,7%
for UC, 92,2% for CD as compared to 92,0% for patients with CE. QoL measurement show
high levels in all dimensions, CD patients scoring slightly lower in anxiety and symptoms.
Access to our clinic has improved dramatically with no waiting list for referrals, follow-up
or endoscopies. Patient satisfaction is high. The number of patients needing in-patient care
has diminished by 55% compared to national data from 1999 to 2005. The number of acute
on-demand visits to our office has diminished by nearly 80% when comparing data from
2001 to 2006. Compliance to treatment with 5-ASA preparations, as measured by number
of patients demanding receipt of medication, is 83% of patients with total UC and 67% of
patients with left-sided UC. Conclusion: A re-designed practise for IBD follow-up, where
the patients are taken greater personal responsibility and so has been empowered, is producing
results of high medical quality as measured by rate of anaemia and QoL as well as high
degree of patient satisfaction. Waste is diminished as the physicians time is used in an more
optimal way. Rather unexpectedly, the number of patients needing in-patient care has
diminished substantially as well as the need of acute consultations. The reason for this is
unclear, but one explanation may be a higher compliance to treatment in combination with
a high level of empowerment and self-assurance.
W1023
Related Factors That Affect the Success Rate of Endoscopic Resection for
Submucosal Tumor of the Upper Gastrointestinal Tract
Jae chul Hwang, Sung jae Shin, Kee myung Lee, Kwang jae Lee, Jin hong Kim
INTRODUCTION: Submucosal tumors (SMTs) may have malignant potential, and it is
important to distinguish the malignant from benign lesions. Although endoscopic ultrasonog-
raphy (EUS) may be a useful adjunctive diagnostic technique, EUS is still inadequate for
differential diagnosis between benign and malignant SMTs. The methods of endoscopic
resection have been developed for the pathologic diagnosis and eradication of SMTs of upper
gastrointestinal tract. AIMS & METHODS: The aim of our study is to evaluate related factors
that affect the success rate of endoscopic resection for SMTs of the upper gastrointestinal
tract. Endoscopic resection was attempted between September 1994 and August 2006 by
using the snare polypectomy method and incisional enucleation method in 207 patients
(103 men, 104 women; mean age 48 years) with SMTs of the upper gastrointestinal tract.
EUS was performed to select appropriate patients for endoscopic resection in the majority
of cases and inclusion criteria for endoscopic resection of SMTs included endoluminal growth
and size less than 5cm. The following parameters were recorded and analyzed, retrospectively
; method of resection, success rate, pathologic findings, site of SMTs, and EUS findings.
RESULTS: Snare polypectomy was performed in 130 patients and incisional enucleation in
77 patients. The success rate of endoscopic resection was 89.4% (snare polypectomy 96.9%,
incisional enucleation 76.6%). The mean size of the SMTs was 14.6mm (snare polypectomy
10.8mm, incisional enucleation 20.9mm, p<0.001). The pathological findings included
leiomyoma(n=120), gastrointestinal stromal tumor(n=32), schwanoma(n=3), glomus
tumor(n=2), ectopic pancreas(n=16), granular cell tumor(n=7), carcinoid(n=3), lipoma(n=
5), lymphangioma(n=5), inflammatory fibrinoid polyp(n=6), gastritis cystica profunda(n=
5), and submucosal cyst(n=2). The success rate of resection by the site of stomach was as
follows ; cardia 93.3%, fundus 83.3%, body 70.3% and antrum 96.2%(p = 0.016). The
success rate of resection by the layer of origin on EUS was as follows ; The second layer
94.8%, the third layer 91.9%, and the fourth layer 81.2%(p=0.014). The success rate of
resection by the size of SMTs was as follows ; <10mm 97.8%, 11-20mm 87.5%, 21-30mm
63.2%, and >30mm 57.1%(p<0.001). The success rate of resection of SMTs that had a clear
margin on EUS was higher than those with an unclear margin(p<0.001). CONCLUSION:
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The success rate of endoscopic resection for SMTs of upper gastrointestinal tract was related
to EUS findings of SMTs. EUS can be helpful in appropriate selection of patients for
endoscopic resection of SMTs.
W1024
Safety and Usefulness of Colonoscopy Within 48 Hours of Admission in
Patients with Right-Sided Diverticulitis
Yeon-ho Joo
Background and Aims: Colonoscopy during the acute phase of left-sided diverticulits which
is common at western countries should not be performed because of the risk of perforation.
However, the safety or risk of colonoscopy during the acute phase of right-sided diverticulitis
which is increasing in westernizing Asian countries is not well known. Subjects and Methods:
During the period from January 2005 to June 2006, 39 consecutive right-sided diverticulitis
were diagnosed with abdominal ultrasound and CT examinations at Chang-Won Fatima
hospital. Of these, 20 patients were randomly assigned to antibiotics alone group and 19
patients were assigned to antibiotics plus colonoscopy group. Colonoscopy was perfomed
within 48 hours of admission after bowel preparation with Colyte. Results: The mean age
was 39(15-67) years and male:female ratio was 26:13. 27 cases had uncomplicated diverticul-
its and 12 cases had Hinchey stage 1 paracolic abscesses. The size of abscesses were between
1.0 cm and 3.6 cm. The 19 patients who underwent colonscopy showed no problem at
swallowing the Colyte solution. The scope was inserted until the appndiceal orifice was
noted without any immediate or delayed complications in all 19 patients. The mean hospital
stay of 19 patients was 4.6 days (3-8 days), which was shorter than 5.4 days (3-11 days)
of 20 patients who received antibiotics only. Fecalith removal or catheter irrigation at the
culprit diverticulum was possible at 11 of the 19 patients. In these cases, the mean hospital
stay was 4.4 days (3-6 days). Conclusion: Colonoscopy during the acute phase of right-
sided diverticulitis can be safely performed. Bowel preparation with Colyte and removal of
fecalith might reduce the hospital stay for about 1 day.
W1025
Overuse of Stress Ulcer Prophylaxis in Hospitalized Internal Medicine Patients
Bassel Atasi, Soley Seren, Jorge Guzman
BACKGROUND: Many hospitalized patients may receive acid-suppressive therapy (AS) for
stress ulcer prophylaxis (SUP) without proper justification, resulting in increased medical
costs and potential side effects. OBJECTIVES: The aims of this study were 1) to determine
the documented rationale for using SUP in hospitalized internal medicine patients, and 2)
to determine whether hospitalized patients also received SUP upon discharge from the
hospital. MATERIALS AND METHODS: A retrospective review of medical records of 275
consecutive patients admitted to internal medicine teaching and non-teaching services in
Detroit Medical Center (DMC) was conducted. We assessed the type, indications and fre-
quency of SUP use according to our institutional andwidely accepted guidelines. The accepted
indications for SUP use are mechanical ventilation, organ transplantation, coagulopathy,
head injury, spinal injury, burns, shock, bone marrow transplantation, gastrointestinal (GI)
bleeding within 12 weeks of admission, and hepatic encephalopathy. We excluded 55
patients from analysis because they were started on AS appropriately for GI diseases on
admission, or were continued on AS as part of their home regimen. RESULTS: Of the 220
patients, a total of 116 (53%) received AS. Fifty-six (48.2%) were women and 60 were
(51.8%) men. Seventy percent of patients on AS were above 46 years old. Proton-pump
inhibitors were the most frequently (72 %) used agents. Based upon our criteria, only 4%
(5 of 116) of those on AS were found to have an acceptable indication. Of the 111 patients
who received AS without an acceptable indication, 83% received it for SUP. Of those, 5%
had SUP for steroids, 4% for sepsis and 3% for pancreatitis. The rest (71%) were given SUP
for no discernable indication. AS was given for non-specific GI complaints in 17% of the
111 patients. No significant difference was observed for inappropriate use between teaching
and non-teaching services. Among patients started on AS, 32% (38 of 116) were also
discharged on AS, with 92% not having a medical indication. CONCLUSION: AS is increas-
ingly misused for SUP in hospitalized low-risk patients. This pattern of practice was independ-
ent of the type of service to which patients were admitted (teaching vs non-teaching).
This was compounded by continued AS misuse upon discharge. KEY WORDS: stress-ulcer
prophylaxis, acid-suppressive therapy, proton-pump inhibitors.
W1026
The Usefulness of Anti-H. pylori Antibody in Urine for Detection of H. pylori
in Young Japanese Patients
Tomoari Kamada, Kuniaki Sugiu, Aki Tanaka, Noriaki Manabe, Hiroaki Kusunoki, Jiro
Hata, Ken Haruma
Background: Urine-based anti-Helicobacter pylori (H. pylori) antibody assay (immunochroma-
tographical method) is now used in the diagnosis of H. pylori infection. We evaluated the
accuracy of this method for detection of H. pylori compared to that of histologic and serologic
detection. Subjects: Subjects comprised 98 patients less than 35 years old (47 men, 51
women; mean age, 26.2 years) who visited Kawasaki Medical School Hospital between
March 2003 and July 2005. Methods: Immunochromatographical detection of anti-H. pylori
antibody was performed with a kit (RAPIRUN®, Otsuka Pharmaceutical Co., LTD, Tokyo,
Japan). If, after the test strip was dipped in urine, both the control line (C) and test line
turned red, results were considered positive. If only C tuned red, results were considered
negative. Histologic examination was of Giemsa-stained biopsy specimens obtained from
each patient (one each of the greater curvature of the antrum and greater curvature of the
corpus). Serologic examination was by enzyme-linked immunoabsorbent assay of serum
IgG antibody to H. pylori (HM-CAP). Histologic and serologic findings were taken together
as the definitive measure of H. pylori infection. Results: Sensitivity of the urine antibody test
was 97.1% (34/35), and specificity was 87.3% (55/63); agreement was 90.1% (89/98). Three
of eight patients with false-negative results had gastric atrophy, and the others had taken
proton pump inhibitors. Conclusion: The urine-based anti-H. pylori antibody test is a useful
for diagnosis of H. pylori infection in young Japanese patients.
W1027
Comprehension of Informed Consent in Healthy Volunteer Trials
Paul Fortun, Joe West, Lisa Chalkley, Anthony Shonde, Christopher J. Hawkey
Background Information sheets for clinical research are becoming increasingly complex but
the extent to which they are understood is uncertain. Aims To assess comprehension by
healthy volunteers of a patient information sheet in a phase 3 clinical trial. Methods 82
healthy volunteers participating in a capsule endoscopy study were given a 13 page written
information sheet and allowed to asked questions. The trial compared as a primary endpoint
the incidence of small bowel erosions or ulcers in subjects randomised to take a COX2
inhibitor, non-steroidal anti-inflammatory (NSAID) plus proton pump inhibitor, or placebo.
After indicating they were ready to give consent and had read and understood the information
sheet, the volunteers were asked to complete a 6 item questionnaire covering the identity
and adverse effects of trial treatments and of the procedure, the duration of the trial and
value of the inconvenience allowance. Results 82 healthy volunteers were questioned Seventy
four (90%) of the volunteers had university level education and 49 (60%) were clinical
medical students. Only 10 subjects (12%) could name the three trial drugs. The maximum
number of potential adverse events recalled was 6 (n=2) of 23. Only 14 (17%) could name
3 or more potential risks of the medication they might be exposed to, whilst 17 (20%)
could identify none. Most subjects (77/82, 90%) identified capsule endoscopy as the trial
procedure and impaction/obstruction as its main risk (52/82, 64%). All but one subject
(98.8%) could recall the exact value of the inconvenience payment. The overall performance
of the volunteers is shown in table 1: Conclusion A comprehensive information sheet resulted
in limited understanding or recall of trial risks. Shorter information sheets with a test and
feedback session should be trialled so that informed consent becomes valid informed consent.
Overall comprehension of trial information sheet
W1028
Determinants of Patient Satisfaction At the Initial Outpatient Encounter
Laurie Keefer, Gregory S. Sayuk, Michael Williams, Robert Rahimi, Jason Bratten, Michael
P. Jones
Introduction: Pt satisfaction (pSAT) is determined by a variety of factors incl access to care,
cost, accuracy of diagnosis and treatment efficacy. Equally important is the physician-pt
interaction, which impacts diagnosis and treatment. We sought to measure pSAT and
evaluated physician practice parameters that might influence pSAT. Methods: Subjects were
new pt attendees at 3 university GI clinics and their gastroenterologists (GE). PSAT with
the initial visit was rated using a 5-point Likert Scale (1=very satisfied; 5=very dissatisfied).
Using the same scale, pts rated SAT with expectations being met; SAT with time spent and
SAT with GE interaction style. Pts identified which of these factors they regarded as the
dominant determinant of pSAT. Pts characterized GE interaction styles as “disease focused,”
“person focused,” “balanced disease and person approach” (biopsychosocial) or “controlling.”
For each pt, GE rated their impression of pt SAT (geSAT) and indicated their interaction
style. Results: 159 pts (age=46±16 yrs; 115F/44M) were seen by 20 GE (age=40±8 yrs,
14M/6F; yrs in GE practice=8±7yrs). 71% pts were very satisfied with the visit and 25%
were satisfied. GE & pt demographics did not influence pSAT. GE scored 45% pts as very
satisfied and 48% pts as satisfied. pSAT and geSAT was modestly correlated (ρ=0.18; p=
0.03). Pts rated interaction style (57%) and expectations being met (31%) as the most
important determinants of pSAT. GE regardedmeeting expectations (59%) as more important
than interaction style (31%). Pts felt that amt of time spent (9%) & improvemt in symptoms
(1%) were less important. Highest pSAT was associated with the proportion of physicians
who pts believed to employ the biopsychosocial approach(χ2=20.8;p=.01). 37% of GE
believed they employed a biopsychosocial approach while 50% reported focusing on biolo-
gical aspects of care, 10% focused on the person rather than the disease and 2% reported
a controlling style. Pt and GE agreement on interaction style was modest (ρ=0.17; p=0.04).
Conclusions: The majority of pts were satisfied after their initial visit. GE interaction style,
particularly a biopsychosocial approach and having expectations met were primary determin-
ants of pSAT. GE recognized these factors but placed different levels of emphasis on their
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importance. Concordance btwn pt and GE perceptions of interaction styles was low. While
pSAT is good, broader implementation of a balanced biopsychosocial approach and direct
queries regarding pt expectations could further enhance outcome.
W1029
Endoscopy Training and General Surgery Residents
Ralph F. Lee, Alaa Rostom, Feng xiao Li, Jonathan R. Love, Eldon A. Shaffer
Background: The demand for colonoscopic procedures in Canada and the US has escalated
with the introduction of national guidelines for colorectal cancer screening and increased
public awareness. A 2004 US study estimated 34,060 additional gastroenterologists would
be required to endoscopically screen all eligible persons by the current guidelines. One
single medical specialty cannot meet this challenge alone; as such, gastroenterologists (GIs)
and general surgeons (GSs) will often share this responsibility. The Royal College of Physicians
and Surgeons of Canada mandates a ‘mastery of surgical skills of [endoscopy]' in a general
surgical residency. However, no consensus exists concerning the ownership, format or goals
of this training. Methods: A survey was sent to the division heads and program directors
of both general surgery (GS) and gastroenterology (GI) programs across Canada (n=62).
Results: 47 (76%) responded, including 24 (51%) GIs and 23 (49%) GSs. Overall, 63% felt
both GI and GS should be responsible for the endoscopic education of GS residents; 30%
chose GI alone and 7% stated GS alone. By specialty, 61% of GIs specified GI alone should
be responsible, 39% both and 0% GS alone. Conversely, 87% of GSs chose both, 13% GS
alone and 0% GI alone (p<0.001). Similarly patterned, statistically significant differences
were detected from responses relating to who was believed to be currently responsible (p=
0.001). Generally, 37% defined ‘competency' by the number of procedures performed, while
28% used ileal/cecal/duodenal intubation percentages as the main criteria. The majority
(58%) of GIs felt that GS residents should be trained to competency, yet 25% believed they
should only receive exposure to endoscopy. In contrast, 61% of GSs felt GS residents should
attain competency, whereas 39% felt they should achieve mastery (p<0.02; vs. GIs). Moreover,
while 78% of GSs believed GS residents achieved endoscopic competence, 67% of GIs felt
they were only exposed to endoscopy, but did not achieve this goal (p<0.001). Whether
acquisition of endoscopy skills should be the primary mandate for GS residents on a GI
rotation, 65% of GIs said ‘no', though 74% of GSs felt the opposite (p<0.03). Conclusion:
There are marked differences of opinion between gastroenterologists and general surgeons
regarding the training of general surgery residents in gastrointestinal endoscopy. These
disparities involve the ownership of this responsibility, the form by which it occurs and the
end-points achieved. Given the respondents' intimate roles in education, national or societal
consensuses are needed to clarify this form of instruction.
W1030
A Prospective Randomized Comparison of Ultrathin Versus Thin
Esophagoduodenoscopy in Unsedated Outpatient Practice
Jin hong Kim, Jai hak Jeung, Sung jae Shin, Jae youn Jung, Kee myung Lee, Kwang jae
Lee
Background: EGD can be performed transnasally in adult by using small diameter endoscopes.
A prospective randomized study was carried out in unsedated patients to compare feasibility,
safety, performance and patient tolerance among ultrathin transnasal(UN), thin trans-
nasal(TN) and ultrathin oral(UO) esophagoduodenoscopy. Method: Each patient was given
the choice of a transnasal or a per oral approach. 200 patients who chose the transnasal
approach, were randomly assigned to UN or TN. 100 patients who chose per oral approach
were assigned to UO. Two prototype narrow diameter endoscopes(Olympus GIF-N 260,
Ø=5.2mm for UN and UO, Olympus GIF-XQ 260, Ø=6.5mm for TN) were used. Operator
assessed global quality of exam, vision, handling, easiness to pass the pylorus, procedure
time, and gag reflex frequency. Patient quantified global satisfaction, nausea, throat pain,
choking sense by visual analogue scale(10,9-very good; 8,7-good; 6,5-fair; 4,3-bad; 2,1,0-
very poor). After undergoing the procedure, the patients were asked if they would choose
the same procedure, if another examination became necessary in the future. Result: The
procedure was successfully completed in 100 of 100 patients in the UO group. The TN
group, when compared with the UN group, accounted for a significantly higher portion of
failure(14% vs 3%, P=0.005) , case of epistaxis(11% vs 3% P<0.05), and more complaints
of nasal pain(17% vs 6%, P<0.05). The global quality of exam was significantly higher in
the UN group(UN,8.7; TN,8.1; UO,8.2; P<0.05). Gag reflex frequency was significantly
lower in UN group(UN,1.3; TN,1.5; UO,2.9; P<0.05). No significant difference was noted
concerning other operator assessment items. The patients' score for the global satisfaction
was higher in the UN group(UN,8.5; TN,7.8; UO,7.7; P<0.05). Nausea was significantly
reduced the in UN group( UN,8.2; TN,7.8; UO,7.3). No significant difference was noted
concerning throat pain and choking sense. Patients in UN were more willing to repeat the
same procedure.(UN,82%; TN,65%; UO,71%; P<0.05) Conclusion: Ultrathin transnasal
endoscopy is more feasible, safe and comfortable compared with the thin transnasal endos-
copy or when compared with either instrument passed trans orally. The nasal route, and
not a small diameter ,is the factor that explains improved patient global satisfaction, decreased
gag reflex frequency, and degree of nausea.
W1031
Related Factors That Affect the Complication of Endoscopic Resection for
Submucosal Tumor of the Upper Gastrointestinal Tract
Jae chul Hwang, Sung jae Shine, Kee myung Lee, Kwang jae Lee, Jin hong Kim
INTRODUCTION: Submucosal tumors (SMTs) may have malignant potential, and it is
important to distinguish the malignant from benign lesions. Recently technical advances in
endoscopic ultrasonography(EUS) as well as new devices designed for endoscopic mucosal
resection have the potential to impact on the management of SMTs. The methods of endos-
copic resection have been developed for the pathologic diagnosis and eradication of SMTs
of upper gastrointestinal tract. AIMS & METHODS: The aim of our study is to evaluate
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related factors that affect the complication of endoscopic resection for SMTs of the upper
gastrointestinal tract. Endoscopic resection was attempted between September 1994 and
August 2006 by using the snare polypectomy method and incisional enucleation method
in 207 patients (103 men, 104 women; mean age 48 years) with SMTs of the upper
gastrointestinal tract. EUS was performed to select appropriate patients for endoscopic
resection in the majority of cases and inclusion criteria for endoscopic resection of SMTs
included endoluminal growth and size less than 5cm. The following parameters were recorded
and analyzed, retrospectively ; method of resection, complications, pathologic findings, site
of SMTs, and EUS findings. RESULTS: Snare polypectomy was performed in 130 patients
and incisional enucleation in 77 patients. The success rate of endoscopic resection was
89.4% (snare polypectomy 96.9%, incisional enucleation 76.6%). The mean size of the
SMTs was 14.6mm (snare polypectomy 10.8mm, incisional enucleation 20.9mm, p<0.001).
Serious bleeding mandating transfusion or surgical treatment occurred in three patients.
Two cases of serious bleeding were controlled by endoscopic treatment. Perforation occurred
in seven patients(esophagus 1, stomach 5, duodenum 1). Three cases of perforation were
controlled by endoscopic application of hemoclips. The perforation rate by the layer of
origin on EUS was as follows ; The second layer 0%, the third layer 2.7%, and the fourth
layer 7.5%(p=0.025). The perforation rate by the size of SMTs was as follows ; <10mm
2.0%, 11-20mm 4.5%, 21-30mm 0%, and >30mm 12.5%(p=0.159). The perforation rate
of endoscopic resection for SMTs that had an unclear margin on EUS was higher than those
with a clear margin(p=0.014). CONCLUSION: The cases of serious bleeding were not
numerous in the endoscopic resection of SMTs. The perforation rate of endoscopic resection
for SMTs was related to the layer of origin and the margin of the lesion on EUS. Endoscopic
resection of SMTs appears to be an effective method for accurate histopathologic diagnosis
and eradication of the tumor, if appropriate indication is used in experienced hands.
W1032
A Comparison Study of Covered and Uncovered Metal Stents for the Palliation
of Malignant Gastric Outlet Obstrunction
Yu kyung Cho, Sang woo Kim, Chang nyol Paik, Jae myung Park, Jung hwan Oh, In
seok Lee, Myung gyu Choi, In sik Chung
Background and aim: Membrane covered stents have been developed to prevent tumor
ingrowth, but have high migration rate. The aim of the study was to compare the efficacy
of covered stents to uncovered stents in prospective controlled trial for the palliation of
malignant gastric outlet obstruction Method: Covered or uncovered stent were inserted for
fifty two patients with gastric outlet obstruction caused by gastric cancer (50), pancreatic
cancer (1) and CBD cancer(1) (M: F=34:18, 66±12 years) from March 2003- December,
2005 in Kangnam St. Mary's hospital. The principal outcome measurement was the needs
for reintervention because of reobstruction or migration. Median follow up period was 46.5
days (5-364 days) The 41/52 patients were observed until death or after 2 months. Results:
Covered stents were inserted in 30 patients and uncovered stents were inserted in 22 patients.
Technical success was 100%. Perforation occurred in 1 patient after 1 day from stenting.
There were one patient whom the stent was removed because of pain and poor symptom
improvement. Stent migration was occurred only in 4 (13%) patients of covered stent group
(1, 30, 30, 52 days) and reintervention was needed in all cases. Reobstruction because of
tumor ingrowth or outgrowth were occurred more frequently in uncovered stents group
(n=10 (45%):n=5 (17%), p<0.05) also earlier time (7-71 days, median 28.5 days vs. 30-
210 days, median 126 days) restenting or bypass surgery were performed in 71% of patients.
Stent misplacement which didn't cause obstruction occurred only in 2 patient in covered
stents group. Conclusion: The covered metal stents seem to be more effective than bare
stents because of less frequent reobstruction by tumor growth and longer time until reobstruc-
tion despite high migration rate.
W1033
Acid Suppressive Effects of S Pantoprazole in Equal to the Original Racemate
Pantoprazole: A Wireless Phmetry Analysis
Rupa Banerjee, Mohan Ramchandani, Manu Tandan, G venkat Rao, D. N. Reddy
Introduction: Proton pump inhibitors are racemic mixtures containing equal amounts of
the R and S enantiomers. The S enantiomers are known to reduce the interaction potential
and thereby increase pharmacokinetic predictability and therapeutic efficiency. The efficacy
of the S enantiomers of Pantoprazole has not been studied so far. Limitations of the traditional
catheter based ph monitoring have been discomfort, inconvenience and interference with
normal activity in addition to the difficulty in accurate placement of the ph electrode.
Endoscopy guided wireless ambulatory ph recording system ensures uniform and accurate
localization with minimal discomfort (1, 2). Aim: The objective of this study was to evaluate
the intragastric pH profile of oral S Pantoprazole and compare with the original racemate
of Pantoprazole. Methods: A randomized double blind crossover study was done. 10 H.
pylori negative healthy volunteers were randomized to S Pantoprazole 40mg and Pantoprazole
40mg for six days after a baseline pH study. 48 hour intragastric pH was measured on Day
5-6 with a 10day wash out period in between dosing periods. The wireless pH radiotelemetry
capsule (Bravo, Medtronic) was used to ensure accurate results with minimal discomfort.
Results: S Pantoprazole and Pantoprazole showed no significant difference in the % time
for which intragastric pH >4 (30.1% vs. 29%) and pH>3(83 % vs. 81%) respectively.
However interpatient variability was significantly less with S Pantoprazole. Conclusion: Our
study shows for the first time that the S isomer of Pantoprazole is as efficacious as the
regular Pantoprazole. Also the interpatient variability in intragastric pH with S Pantoprazole
is low. 1. Banerjee R, Lakhtakia S, Tandon M, Rao GV, Reddy DN. Endoscopy-assisted
wireless intragastric pH measurement. Endoscopy. 2005 Sep; 37(9):922. 2. Banerjee R,
Reddy DN. Bravo capsule pH monitoring. Am J Gastroenterol. 2006 Apr;101(4):906;
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W1034
Evaluation of Beta-Blocker Therapy in Esophageal Varix Bleeding Prophylaxis
As a Performance Standard
Barry Kisloff, Melissa Saul, Georgios Papachristou, James B. Mcgee
Background: Meaningful clinical practice standards in gastroenterology are needed to satisfy
anticipated pay-for-performance [P4P] mandates. Objective: To evaluate the current use of
Beta-blocker [BB] therapy in the primary and secondary prophylaxis of esophageal varix
bleeding as a potential performance standard. Design: Review of medical records using an
electronic health records system for the calendar years 2003 and 2004. Setting: Inpatient
and outpatient gastroenterology and general medicine clinics of a tertiary university medical
center. Participants: 1086 patients with recorded ICD 9-CM diagnosis of non- bleeding and
bleeding esophageal varices. Measurements: The number of patients with esophageal varices
in both the inpatient and outpatient setting receiving beta-blockers for the prevention of
esophageal varix bleeding, The potential inhibiting effect of co-morbid conditions on the
introduction of this class of medication was evaluated. The influence of gender, race &
insurance status was considered, In addition, we examined the potential difference in applying
beta-blockers in the primary and secondary prophylaxis of bleeding esophageal varices.
Results: Of the 1086 patients identified with esophageal varices 267 received a beta-blocker.
Gender, the presence of active varix bleeding and race played no role in the application of
this therapy. Older patients were more likely to receive BB as were those with co- morbidities
which might have been expected to inhibit BB use. Insurance status also significantly
influenced beta blocker use but this probably reflects the effect of age upon those receiving
beta-blockers. Limitations: The sub-types of beta-blockers, non-selective and beta 1 selective
(cardio- selective), were not differentiated in our study. Conclusions: The use of beta-blocker
therapy in the setting of esophageal varices is an appropriate and easily measured performance
standard. Its introduction as a pay-for-performance benchmark should be incremental and
should reflect the age of the patients being serviced. Innovative educational tools will be
needed to increase the percentage of those with esophageal varices who receive this beneficial
class of medications.
W1035
Do Patients with Pre-Dialysis Chronic Kidney Disease and Anemia Merit
Gastrointestinal Tract Investigation?
Nick Powell, Alistair Mcnair
Anemia frequently complicates chronic kidney disease (CKD) and the prevalence significantly
increases when the glomerular filtration rate (GFR) falls below 60 ml/min/1.73m2. Although
anemia in this setting is usually due to intrinsic renal disease, the presence of overt iron
deficiency anemia (IDA) should trigger GI investigation to exclude potential bleeding lesions.
Deciding which patients merit GI investigations is difficult because serum ferritin concentra-
tion, the most commonly employed marker of iron deficiency, is frequently elevated in
patients with CKD. We conducted a retrospective, case control study of patients referred
for endoscopic investigation of asymptomatic anemia. We identified 94 patients with anemia
and CKD. All patients with CKD had an estimated GFR <60 ml/min/1.73m2 based on the
abbreviated MDRD equation. None of the CKD patients were dialysis dependent. CKD
patients were subdivided into patients with supporting evidence of iron deficiency (serum
ferritin <30mcg L-1) and those without. The control group comprised 217 patients with
normal serum creatinine and iron deficiency anemia (IDA) defined by reduced haemoglobin
and low serum ferritin concentration (<30mcg L-1). All patients underwent upper GI endos-
copy and 92.2% of control patients and 55.3% of CKD patients underwent a colonic
investigation (colonoscopy or double contrast barium enema). The prevalence of bleeding
lesions potentially accountable for the anemia was then calculated. In patients with CKD
without supporting evidence of iron deficiency there were significantly fewer upper (11.5%
vs 24.4%, OR=0.40 95% CI 0.20-0.83) and lower (6.5% vs 19.8%, OR=0.28 95% CI 0.10-
0.79) GI lesions potentially accountable for IDA as compared to controls. The prevalence
of GI malignancy was 0% in patients with CKD without evidence of iron deficiency as
compared to 17.1% in controls (P<0.0001). In patients with CKD and evidence of iron
deficiency (ferritin concentration <30g mg L-1) the number of benign and malignant lesions
with potential to cause IDA was statistically equivalent to control patients with normal renal
function and IDA. In patients with pre-dialysis CKD and anemia without supporting evidence
of iron deficiency, the diagnostic yield of GI evaluation is significantly lower than in control
patients with normal renal function and confirmed IDA. However, patients with CKD and
a reduced serum ferritin concentration have a statistically comparable number of potential
bleeding GI lesions to patients with normal renal function and reduced serum ferritin levels.
W1036
Transition of Adolescent IBD Patients from Pediatric to Adult Health Care: A
National Survey On Adult Gastroenterologists' Perspectives
Renée M. Barendse, Elizabeth J. Hait, Janis H. Arnold, Bruce E. Sands, Joshua R.
Korzenik, Laurie N. Fishman
Background. Successful transition of pediatric Inflammatory Bowel Disease (IBD) patients
to adult settings ensures continuous and age-appropriate health care. Pediatric providers
should understand adult providers' expectations to better prepare their patients. This is the
first national study addressing the insights of adult gastroenterologists in the transitioning
process. Methods. An IRB approved survey was sent to 1132 gastroenterologists with an
interest in IBD, identified by membership to the Crohn's and Colitis Foundation of America
(CCFA). Respondents were asked to indicate the importance of various issues involved in
transition, and to report which problems occurred often in their own practice. The survey
also elicited respondents' attributed importance to knowledge of medical and developmental
issues unique to adolescence, and their personal competency about these issues. Broad
demographic features were then identified. Results. A response rate of 32% was achieved.
The majority of respondents often experience problems in the patients' knowledge of their
medication (69%) and medical history (55%), their awareness of intoxication-risks (51%),
and in receiving adequate medical history from the pediatric provider (51%). They rarely
experience problems in the patients' ability to gather resources (21%), identify health care
providers (19%), attend office visits by themselves (15%), or undergo procedures under
conscious sedation (13%). Female providers and physicians in practice less than 5 years
tended to indicate a higher frequency of problems in the identified items. Importance is
frequently attributed to medical (96%) and developmental (89%) issues in adolescence.
However, competency regarding those issues was reported in a much smaller proportion of
respondents (72% and 46%, respectively). Gastroenterologists in private settings, and those
in practice for more than 15 years, felt significantly more competent regarding developmental
issues unique to adolescence (p=.008 and p=.015, respectively). Conclusion. The goal of
successful transition is continuous and age-appropriate health care. To this end, patients
need improved education about their medications and medical history. Pediatric providers
need to ensure better communication with the receiving physicians. Adult providers would
benefit from familiarity with medical and developmental issues in adolescence. These adjust-
ments will improve transition and may lead to better adherence and better medical outcomes.
W1037
The Consenting Process: Do Patients Understand What They Are Consenting
to Prior to Endoscopic Procedures?
Rajeev Chhaya, Alkiviadis Efthymiou, Sheck Matsiko
BACKGROUND - AIM: Informed consent of the patient before endoscopic procedures is
very important due to medico-legal issues. The aim of this study was to assess the level of
patients' understanding after the procedure had been explained to them and they had given
formal consent. We also looked at recommending any changes to the consenting process
based on the data acquired. MATERIALS - METHODS: This was a prospective study involving
60 patients who were interviewed immediately after giving formal consent for either gastros-
copy or colonoscopy. Patients with a mini mental state examination score (MMSE) of <24
were excluded due to poor cognition. Patients were asked specific questions regarding the
information that they had received prior to consenting. They were then asked to recall
information relating to four specific aspects of the procedure they had consented to: reason
for the procedure, risks of the procedure, details of the procedure, post-procedure care.
Patients' comprehension of the procedure was then assessed using a score that was calculated
according to a scoring system with 4 different variables (Table). 1 point was given for each
word (or similar), maximum possible points 12/12. If score≤3, patients had no comprehen-
sion; score 4-5, poor comprehension; score 6-7, fair comprehension, score≥8, good compre-
hension. RESULTS: All 57 patients that were included in the study had signed a written
consent form and had received an information leaflet. 9% of patients were able to obtain
further information from a health care professional, therefore a route for this was available.
5% of patients did not have the procedure explained to them before attending endoscopy.
42.1% and 31.5% of patients had no understanding or poor understanding of the procedure,
respectively. Comprehension of the procedure was poor in ages between 31-40 and 81-90.
There was no correlation between the MMSE and the level of patients' comprehension of
the procedure (r=-0.057, p=0.67). CONCLUSION: Most of the patients had the procedure
explained to them and had also received information leaflets before giving formal consent.
However, their understanding of the procedure was poor and this was not related to
their level of cognition. Better quality of information leaflets may be one way to improve
comprehension. However, further studies are required to identify factors affecting patients'
understanding of the endoscopic procedures.
Definitions for comprehension scoring system
W1038
Prediction of Severity of Acute Pancreatitis Using the Apache-O Scoring
System At Kern Medical Center
Ricardo Borsatto, Mary E. Yokota, Jose A. Perez
Introduction: Severe acute pancreatitis is defined as that associated with organ failure and/
or local complications such as necrosis, abscess or pseudocyst and the mortality rate in this
group is quiet significant. Predict the severity has been the goal of many studies and the
search for a ideal score system is still a challenger. The APACHE II scoring system is not
exclusive to acute pancreatitis but has been used to assess severity. Knowing that many
patients with severe acute pancreatitis are overweight, recently Johnson et al.(2004) proposed
a new scoring system named APACHE-O , which consist in adding the body mass index (
BMI ) to the APACHE II. When used in the first 24 hours of hospital admission, it could
better predict the severe cases . Objective: The objective of this study is to validate the
APACHE-O scoring system in prediction of severe AP and to analyze its feasibility and
usability when compared with APACHE II. Methods: After applying the Atlanta criteria, 145
cases of severe AP were identified from July 1, 1999 to June 30, 2004. Twenty-two were
excluded because the BMI could not be calculated, at the time of the admission. The
remaining 123 cases of severe AP were analyzed and the APACHE II and APACHE-O
scoring system was applied to these. Following previous investigators, the obesity score was
considered as 0 for BMI<26, 1 for BMI 26-30 and 2 for BMI >30. Data on the etiology of
severe AP, complications and comparisons of the APACHE II and APACHE-O scoring systems
were done.Results: Alcohol was the most frequent cause of severe AP followed by idiopathic
cause and hypertriglyceridemia. Curiously, biliary causes accounted for only 8.9% of cases
of severe AP. Pancreatic pseudocyst and renal failure were the most common local and
systemic complications, respectively. Among patients with severe AP, BMI >26 is more
commonly observed (61.8% versus 38.2%, p=0.002) making the APACHE-O score higher
then APACHE -II score in the same proportion. Using the APACHE -II scoring system we
predicted the severity in 78.8% of the patients against 83.7% with APACHE-O. Comparing
these results by 95% Confidence interval it's not significant different.Discussion:This study
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demonstrated that in this hospital the majority of patients with severe AP are overweight,
as shown in the study that proposed this modified score system. Use of the APACHE-O
scoring system does not require additional testing or cost. Although no significant difference
in score was found, we did observe a trend toward better prediction of severe AP using the
APACHE-O score. This should be validated in future prospective studies.
W1039
Y-Shaped Endoscopic Bilateral Stenting in Malignant Hilar Obstruction: Long-
Term Results
Jae chul Hwang, Byung moo Yoo, Jin hong Kim
INTRODUCTION: Endoscopic or percutaneous placement of bilateral metal stents has been
widely performed in malignant hilar obstruction, although there is still controversy as to
the necessity for drainage of both liver lobes. However, endoscopic bilateral stenting using
dual conventional self-expanding metal stents is technically difficult, despite best efforts,
because passing of the second stent is not easy when the first stent is present in the common
hepatic duct. We designed a new kind of self-expanding metal stent with central wider-
mesh portion to facilitate passing of the second stent during bilateral stenting. AIMS &
METHODS: The aim of our study is to evaluate the long-term results of Y-shaped endoscopic
bilateral stenting in malignant hilar obstruction. The newly designed stent was a self-
expanding nitinol biliary stent (Y-stent, Taewoong Inc., Seoul, Korea) with cylindrical config-
uration with a wider-mesh portion in the center and smaller-mesh portions at both ends.
Two stents were inserted in turns for the drainage of both liver lobes with Y-shaped
arrangement in patients with unresectable malignant hilar obstruction. The first stent with
the central wider-mesh portion was placed in the left or right hepatic duct, wherever was
more difficult to access, in the ordinary method. A guiding catheter and guidewire were
advanced into the first stent after dilation of a biliary dilating balloon, and the guidewire
was directed through the central wider-mesh portion of the stent into the contralateral
hepatic duct. The large opening in the wider-mesh of the first stent permitted easy passage
of the delivery catheter for the second conventional biliary metal stent and release of the
second stent. We retrospectively analyzed 20 patients (15 men, 5 female; mean age 69 years)
of unresectable hilar cancer from October 2002 to June 2006. RESULTS: The malignant
strictures were due to Klatskin tumor, 13; gallbladder(GB) carcinoma, 6; hepatoma 1. Based
on the ERCP radiographs all patients were classified according to Bismuth (type II: 7, type
IIIa: 11, type IIIb: 1, type IV: 1). Technical success in endoscopic bilateral stenting was
achieved in 16 patients (80%). After stent placement, bilirubin level significantly decreased
in all of the patients. During the follow-up (mean 220 days), the mean stent patency period
was 141 days (Klatskin tumor 164 days, GB cancer 78days). CONCLUSION: Endoscopic
bilateral metal stent placement with the new wider-mesh biliary stent and conventional
biliary stent in a Y-shaped arrangement appears to be an effective method for palliation in
cases, which require drainage of both liver lobes in malignant hilar obstruction.
W1040
Investigation of Health Care and Cost of Medication in Inflammatory Bowel
Disease in the Rhein-Main Region, Germany. A Multi-Center, Prospective,
Internet-Based Study
Irina Blumenstein, H. Bock, C. Weber, A. Rambow, W. Tacke, R. Kihn, R. Pfaff, S.
Orlemann, R. Schaeffer, Axel U. Dignass, F. Hartmann, Jürgen Stein
OBJECTIVE: Studies examining treatment reality of IBD patients (ulcerative colitis (UC),
Crohn's disease (CD), and indeterminate colitis (IC)) in Germany are few, as networking
between deliverers of care as well as a reliable documentation ofmedical, socio-demographical
and economical data is lacking. The AIM of the study was to establish an internet-based
treatment registry in order to evaluate treatment reality in IBD patients in a region in central
Germany (2.2 million inhabitants). PATIENTS AND METHODS: Prevalent IBD outpatients
of one of 10 gastroenterological private practices and 3 hospitals were eligible for inclusion
in the study. An internet-based, username and password secured registry was established,
including data about past medical history, disease status (CAI, HBI, Vienna Classification),
diagnostic procedures, laboratory values and medical treatment. From November 1st 2005-
November 30th 2006, 872 patients were enrolled (UC n=384, CD n=474, ID n=14). Data
for private practices and hospitals were pooled in order to compare treatment habits. 1004
follow up visits for 500 patients were recorded in the course of 13 months. Cost of medication
was calculated according to electronic prescriptions made. RESULTS: There was no significant
difference between the two groups (hospital vs. private practice) in terms of patient sex,
patient age, duration of disease, and disease activity (CAI 4.33 ± 3.66 vs. 4.6±3.84; HBI
5.39±4.75 vs 6.72±4.15), rate of bowel resection (33% vs 36%) and fistula operation (26%
vs. 17.5%) in CD patients, and colectomy rate in UCpatients (4% vs. 6%). 37% ofMC patients
treated in private practice take mesalamine alone or in combination with corticosteroids. 48%
of these patients take mesalamine for maintainance of remission, 42% show mild-moderate
activity and 10% have a high activity (HBI&;16). Only 7% of CD patients treated in hospitals
take mesalamine. Azathioprine/6-MP plays a marginal role in private practices. In contrast,
azathioprine/6-MP is predominantely used in UC and CD patients for maintainance of
remission in hospitals. Infliximab is used for treatment in patients with fistulizing CD (25%
vs. 12.5%). The median cost of medication per patient per year was 1574€. CONCLUSION:
The registry provides first detailed data about the treatment reality of IBD patients in
Germany. Concerning the medical treatment, marked differences between hospitals and
private practice could be revealed. Thus, networking of providers of care for IBD patients
is mandatory in order to establish a more efficient treatment which corresponds to national
and international treatment guidelines.
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W1041
Provider Knowledge Assessment As An Initial Step Towards Quality
Improvement
Millie Long, Lisa M. Gangarosa
Osteoporosis is a major public health problem, resulting in more than 1.5 million bone
fractures per year in the United States. Although it is often viewed as a disease of elderly
Caucasian females, it can affect younger people of any race or gender if certain risk factors
are present. In 2003, a patient survey on osteoporosis risk factors and management in our
tertiary GI clinic at University of North Carolina demonstrated that only 28% of the time
were our physicians recommending the basic intervention of calcium supplementation in
at-risk patients on glucocorticoid therapy. PURPOSE: The overarching purpose of our newly
initiated study is to perform interventions on bone health and then assess whether manage-
ment of GI and hepatology patients at risk for osteoporosis improves, as compared to baseline
data collected from our clinic in 2003. As a first step towards this goal, our aim was to assess
the baseline osteoporosis knowledge of the outpatient providers in our clinic. METHODS:We
administered a 20 question web-based true/false quiz to our outpatient providers including
attending physicians, fellows and physician extenders. The quiz was based on a previously
validated Osteoporosis Knowledge Assessment Tool and the AGA Guidelines for the manage-
ment of osteoporosis in GI and hepatic disorders. The quiz contained 10 questions on risk
factor assessment, 3 questions on screening and 7 questions on treatment. RESULTS: Of
30 available providers in the outpatient clinic, 23 completed the quiz (76.7%). The overall
mean score on the osteoporosis quiz was 79.3 (+/- 8.4). The mean score for attending
physicians was 77.5 (+/- 7.0) and for fellows the mean score was 80.9 (+/- 4.5). By t-test,
there was no significant difference between the scores of attending physicians and fellows
(p=.36). On average, 1.34 questions on risk factors, 1.30 questions on screening and 1.48
questions on treatment were missed. Inter-rater agreement was assessed with a kappa statistic
for all providers. Kappa= .381 (p<0.001). CONCLUSIONS: Mean scores on the osteoporosis
knowledge quiz demonstrate that our providers have room for improvement in regards to
bone health knowledge, independent of level of training. Also, the low kappa demonstrates
that providers' answers vary significantly on multiple questions throughout the quiz. There-
fore, we have designed a provider knowledge improvement intervention targeting all three
components of bone health: risk factor assessment, screening and treatment. Both provider
knowledge and data on the management of bone health in our clinic patients will be
reassessed post-intervention.
W1042
The Usefulness of the Conventional Criteria of Endoscopic Findings for
Predicting Depth of Invasion in Early Gastric Cancer
Jin S. Jang, Seok reyol Choi
Endoscopic mucosal resection (EMR) has been widely used as a treatment option for early
gastric cancer (EGC). The aim of this study was to evaluate the usefulness of the conventional
criteria of endoscopic findings for diagnosing depth of invasion in EGC. We retrospectively
analyzed the characteristics of endoscopic findings of 558 EGC patients diagnosed after
gastrectomy or EMR at Dong-A University Hospital between 2000 and 2006 by dividing
them into two groups according to the depth of invasion (mucosa group versus submucosa
group). Nine factors were assessed according to their EGC type (Type I or IIa ; surface
color, surface irregularity, Yamada type, pitting on apex. Type IIb ; surface color, surface
irregularity, marginal definiteness. Type IIc or III : ulcer base irregularity, shape of converging
folds, center of converging folds, marginal elevation) by endoscopic finding. Tumor size
and histologic type were assessed commonly in all EGC type by post operative pathology.
Of all eleven endoscopic factors, ulcer base irregularity (p=0.005), marginal elevation(p=
0.001), and shape of converging folds(p=0.041) showed significant correlation with depth
of invasion in type IIc or III EGC. Tumor size ( < 2cm ) showed a significant correlation
with mucosal invasion in all EGC type. These results seemed to support the usefulness of
endoscopic findings as a therapeutic criteria for EMR through predicting depth of invasion
in EGC.
W1043
Changing Trends in Histological Pattern of Gastric Cancer Over the Last
Years: Implications for Upper GI Endoscopy Guidelines
Anthia Gatopoulou, Ioannis Pilpilidis, Konstantinos Soufleris, Panagiotis Katsinelos,
Anestis Tarpagos, Ioannis Katsos
Introduction: A rising time-trend incidence of the diffuse type of adenocarcinoma has been
demonstrated in other countries. Since, diffuse type seems to have worse impact on prognosis
than the intestinal type and occurs in younger group of age, confirmation of such a change
in our population would have implications for screening and early diagnosis of gastric cancer.
Aims and Methods: Among 10.199 upper GI endoscopies that were performed between
1999 and 2005, a total of 368 new cases of gastric adenocarcinoma were diagnosed. Based
on the retrospectively collected data, we analyzed the differences in clinicopathological
patterns for two consecutive periods: 1/ 1999-6/2002 (group I, 196 patients) and 7/2002-
12/2005 (group II, 172 patients) and time-related trends were assessed. Results: Of the 368
patients (239 male, 64.9%, 129 female, 35.1% mean age 61.2 years old), 34 (9.2%) were
diagnosed under the age of 45 years old. Diffuse type was predominantly observed (193
cases, 52.4% intestinal 163, 44.3%, mixed 12, 3.3%). In the younger group of age (< 45
years old) diffuse type was more prevalent (29/34 vs. 164/334 in patients over 45, p< 0.001).
A statistically significant increase in the incidence of the diffuse type gastric cancer was
detected between the two groups of patients (from 45.9% group I to 66.9%, group II, p=
0.001), mostly, due to the decrease of the intestinal type. This finding is accompanied by
a progressive upward trend in the rate of patients younger than 45 years old (from 4.5%
group I, to 14.5% in group II). Between the two groups I and II, no differences, either in
location or differentiation were identified. Conclusion: Changing trends in histological pattern
of gastric cancer, with rising incidence of diffuse type, was confirmed over the analyzed
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period of time. Observed differences are probably related to fluctuations in carcinogenic
factors and have diagnostic as well as therapeutic implications.
W1044
Digestive Diseases in the Native American Population of the U.S. Central
Plains: Disparities in Prevalence, Screening, and Treatment
Bob Kizer, Harry Lazarte, Gleb Haynatzki, Reshma Patel, Asma Dajani, John O'brien
Background: Little is known about the prevalence of digestive diseases among the Native
American population from the United States central plains. The Fred Leroy Clinic of Omaha,
NE, provides free medical care exclusively for over 4,000 Native Americans from 70 tribes
throughout the Dakotas, Nebraska, and Kansas. Methods: A retrospective study of 449
randomly selected Fred Leroy charts. Each patient chart was reviewed for medical and social
history, and the documentation of the prevalence, clinical presentation, and treatments of
the ten most common digestive diseases in the United States. Data was also collected on
health screening for these conditions. The one-sample z-test for proportions was used in
all statistical analyses. Results: 449 patient charts were reviewed. 138 patients were male;
311 were female. 330 patients were 19 to 50 years old; 119 patients were aged 50 to 79.
The Body Mass Index could be calculated for all but 2 patients. 113 patients were overweight
(BMI 25 to < 30), 131 were obese (BMI 30 to < 35), and 137 were morbidly obese (BMI
> 35). The prevalence in this study population of overweight / obesity is 85.3 % (p<0.00001,
U.S. prevalence of 65%), the prevalence of obesity and morbid obesity is 60.0% (p<0.00001,
U.S. prevalence of 30%). No statistical difference existed between the study population and
the U.S. population with regards to the prevalence of colorectal cancer (CRC). However, of
123 persons eligible for CRC screening, only 14 (11.4%, p<0.00001) were offered screening
- well below the 42.5% of eligible U.S. patients who underwent screening in year 2000. 61
patients (13.6%) have a history of cholelithiasis. No statistically significant difference exists
between the prevalence of cholelithiasis in this Native American population and the U.S.
prevalence of 10-15% (p<0.00001). 27 patients (6%, p<0.00001) have a history of Hepatitis
C infection (U.S. prevalence 1.7%). Conclusion: This is the first study looking at the
prevalence of digestive diseases in the Native American population of the U.S. central plains.
This population has a dramatically higher prevalence of overweight/obesity and hepatitis C
compared to the general U.S. population. This population also lacks access to age and family
history-appropriate colorectal cancer screening, which is a standard-of-care in the United
States. The prevalence of cholelithiasis in this population is less than the rate reported in
the Pima Indians, suggesting geographic variability. This indicates that data on prevalence
of digestive diseases from Native Americans of the southwest United States cannot be applied
to all Native American populations.
W1045
Assessment of Pre-Gastroscopy Fasting Period Using Ultrasonography
Thomas W. Spahn, Anne Wessels, Michael K. Mueller
Background: A six hours fasting period is frequently recommended prior to standard esophag-
ogastroduodenoscopy (EGD) in order to prevent aspiration of gastric contents during the
procedure. This long period of absence from fluid or solid nutrition frequently causes
discomfort in patients undergoing EGD. Aims: We assessed the period of time required for
the stomach to clear fluids with or without glucose in order to shorten the fastening period
for patients undergoing EGD. Patients: 34 patients were assessed for gastric emptying
function. Exclusion criteria included ileus, gastric emptying dysfunction, diabetes and med-
ication known to slow down gastric emptying function. Informed consent was obtained
from all patients prior to the study according to federal legislation. Methods: Patients drank
300 ml of water (n=20), 200 ml of water containing 75 g of glucose (n=9) or 200 ml of
apple juice (n=5). The gastric antrum surface area as a standard method to determine gastric
fluid content was sonographically assessed prior to, immediately after and 30, 60 and 90
minutes after ingestion of fluids. EGD was performed subsequently. Results: Immediately
after drinking water, the mean gastric antrum surface increased x 3.6 from its initial size
(before: 540 ± 268 mm2; after: 1923 ± 768 mm2, p>0.001) and rapidly declined to x 1.3
of the initial size (718 ± 278 mm2, p=0.048) after 30 minutes. 90 minutes after ingestion
of water gastric antral surface was at the same level as before the ingestion (491 ± 221 mm2;
not significant vs. before). Drinking of water containing glucose required additional 30
minutes for gastric emptying (before: 670 ± 274 mm2; immediately after: 1510 ± 370 mm2;
30 minutes: 1107 ± 251 mm2; 60 minutes: 841 ± 376 mm2; 90 minutes: 646 ± 419 mm2,
not significant vs. before). The clearance of apple juice proceeded at a similar speed as water
with glucose (before: 591 ±. 98 mm2; 90 minutes: 712 ±. 106 mm2; not significant vs.
before) Conclusions: Ingestion of water or water containing glucose prior to EGD in patients
without a history of gastric emptying dysfunction is safe as long a latency period of 90
minutes is considered. Patients might thus be saved from prolonged fasting periods without
jeopardizing the safety of the endoscopic procedure.
W1046
Prothrombin Time Predicts Mortality in Critically Ill Patients with
Gastrointestinal Pathology
Fiona Leitch, Euan J. Dickson, Angela Mcbain, Simon Robertson, Clement W. Imrie
AIMS Current markers of outcome in critically ill patients, such as organ failure scores,
require serial measurements and complex calculations to predict mortality. This results in
delayed identification of the high risk patients who are most likely to benefit from early
intervention. Our aim was to evaluate prothrombin time (PT) as a simple marker which
could be used to predict outcome in surgical patients with gastrointestinal pathology at the
time of admission to a critical care facility. METHODS In a prospective study conducted in
a Surgical High Dependency Unit (SHDU), 63 consecutive patients were evaluated. Full
Ethics Committee approval was obtained. Serum PT was measured on admission to the
HDU and was evaluated with respect to in-hospital mortality. RESULTS Prothrombin time
on admission to SHDU discriminated survivors from non-survivors (p<0.0001, ANOVA).
A PT of greater than 14 seconds correlated very strongly with mortality. The mortality in
patients with a PT of less than or equal to 14 seconds (n=26) was 3.8%. The mortality in
patients with a PT of greater than 14 seconds (n=37) was 29.7% (p<0.0001, Chi-Square).
The mean PT in survivors was 14.7 seconds, and 21.2 seconds in those who died (p=0.009,
Student's T Test). CONCLUSIONS Prothrombin time is a powerful predictor of mortality
(p<0.0001) in surgical patients with gastrointestinal pathology. It may be used to identify
the most critically ill patients at the time of admission, and in contrast to current markers
of disease severity, it does not require serial measurements or complex calculations.
W1047
Fecal Calprotectin and Gastrointestinal (GI) Permeability Correlate with
Disease Activity Index, and Histologic, Endoscopic, and Radiologic Findings
in Children with Crohn Disease (CD)
Robert J. Shulman, Michelle Eakin, Nina Tatevian
Background: Fecal calprotectin and permeability are noninvasive measures of GI inflamma-
tion and damage, respectively. However, there are scant data as to the possible association
between the tests and CD disease activity in children. We hypothesized that levels of fecal
calprotectin and permeability would correlate with disease activity index and histologic,
endoscopic, and radiographic findings. Design/Methods: Children with CD were identified
from the Texas Children's Hospital Gastroenterology Clinic Database. The Pediatric CD
Activity Index (PCDAI) was calculated at the time of study. Within two weeks of carrying
out an ileocolonoscopy and biopsy and/or upper GI series with small bowel followthrough
a random stool was collected for determination of fecal calprotectin and a permeability
test was carried out to measure gastric/duodenal (sucrose/lactulose ratio), small intestinal
(lactulose/mannitol ratio), and colonic (sucralose/lactulose ratio) permeability. Histology was
graded 1-4 (normal to severe, acute vs chronic), ileocolonoscopy 1-3 (normal to mucosal
disease/no ulcerations to mucosal disease/ulcerations), radiography 1-3 (normal to possibly
abnormal to definitely abnormal). Results: 43 children were studied (Mean ± SEM age 13.9
± 0.3 yr, range 4-19). The PCDAI was 24.0 ± 2.0. Fecal calprotectin (µg/g stool) was 1229
± 157 (normal <50). There was a significant positive correlation between fecal calprotectin
and the PCDAI (P=0.02). There was no relationship between permeability measurements
and the PCDAI. Results for histology, endoscopy, and radiography are given in the Table.
Neither fecal calprotectin nor permeability correlated with gastric or colonic histology.
Conclusions: 1) Both fecal calprotectin and permeability are abnormal in children with IBD;
2) Both fecal calprotectin and permeability reflect small intestinal histological inflammation,
particularly chronic inflammation; 4) Fecal calprotectin appears useful as a noninvasive
measure of small intestinal involvement whereas permeability appears useful as a measure
of gastric/duodenal involvement. (Supported by a grant from the CCFA)
W1048
Non-Invasive Assessment of Crohn's Disease Intestinal Lesions with 18f-
Fluorodeoxyglucose Positron Emission Tomography Coupled with
Computerized Tomography
Edouard Louis, Geoffrey Ancion, Arnaud Collard, Veronique Spote, Jacques Belaiche,
Roland Hustinx
Pilot studies have shown good sensitivity and specificity of 18F-fluorodeoxyglucose (FDG)
positron emission tomography (PET) in detecting gastro-intestinal lesions of Crohn's disease
(CD).The combination of FDG PET with CT scanning may further improve the location
and characterization of the lesions associated with increased FDG uptake. Our aim was to
assess FDG PET/CT in the evaluation of CD activity and location along the gastro-intestinal
tract. Methods: After informed consent, 22 patients with Crohn's disease were prospectively
studied. They underwent FDG PET/CT, followed by ileo-colonoscopy within 1 week. Qualit-
ative (location of FDG uptake, association with bowel wall thickening) and quantitative
(FDG uptake assessed by SUVmax) assessment of FDG PET/CT were performed. CDAI was
calculated, serum CRP and fecal calprotectin were measured before endoscopy. CDEIS was
calculated during endoscopy. Global CDEIS score as well as endoscopic sub-scores for
various ileo-colonic segments were used for analysis. Results: Globally, 95 intestinal and
colonic segments in 22 patients were analysed. FDG PET/CT detected 35/48 endoscopically
affected segments (sensitivity for the detection of endoscopic lesions= 72.9%). The sensitivity
of FDG PET/CT for the detection of severe endoscopic lesions (deep ulcers and strictures)
was 100%. Intensity of the FDG uptake in a considered intestinal or colonic segment
significantly increased with the severity of endoscopic lesion (P<0.0001) and the SUVmax
significantly correlated with CDEIS segment subscores (r=0.46 (0.28-0.61); P=0.0001). A
global PET/CT score significantly correlated with CDEIS (r=0.51 (0.09-0.77); P=0.017),
CDAI (r=0.58 (0.19-0.81); P=0.005) and CRP (r=0.56 (0.19-0.81); P=0.007). Conclusions:
FDG PET/CT was globally well correlated to clinical, endoscopic and biological activity of
CD. Above all, this technique had a very good sensitivity for the detection of intestinal and
colonic segments with moderate to severe mucosal lesions. The potential impact of this
A-649 AGA Abstracts
promising tool on the global management of CD patients should be further evaluated in
prospective studies.
W1049
In Vivo Assessment of Inflammatory Activity in Mouse Colitis Using High
Throughput Magnetic Resonance Imaging
Silvia Melgar, Helena Utkovic, Per-göran Gillberg, Paul D. Hockings, Lars E. Olsson
Background and aim: Advances in abdominal Magnetic Resonance Imaging (MRI) have
resulted in increased clinical use for the diagnosis of inflammatory bowel disease (IBD). Of
special interest is the capacity to assess inflammatory activity. Less attention has been applied
to MRI in IBD animal models. One obstacle is that animal preparation and acquisition
protocols have been fairly time consuming (Larsson et al., 2006, IBD). The aim of the present
study was to investigate if a rapid MRI screening protocol (< 5 minutes) for small animals
could be used to characterize the grade of inflammation in the colon wall. Methods: Chronic
colonic inflammation was chemically induced by exposing mice (n=10) to dextran sulphate
sodium (DSS) for 5 days followed by 14 days of water. A control group of healthy mice
was also included (n=5). MRI was used to assess colon wall thickness and T2w signal
intensity, which mainly reflects the presence of edema. The animals were anaesthetized but
no respiratory triggering or spamolytic agent was used during acquisition. At the end of
MRI-scanning, colonic inflammation was assessed by the inflammatory score and colon
weight and plasma was collected to analyze the levels of the acute phase protein haptoglobin.
Results: The screening protocol resulted in images with excellent signal to noise ratio (SNR
>20). There were some artifacts from respiratory motion and intestinal motility, but they
rarely affected the evaluation. Mice exposed to DSS have an increased levels of inflammatory
markers compared to healthy mice (Table). Colon wall thickness and the T2w signal intensity
measured by MRI correlated (Pearson) with inflammatory score (r=0.95 and 0.94), colon
weight (r=0.92 and 0.93) and plasma haptoglobin (r=0.89 and 0.95). Conclusion: We have
shown that without special preparation and using only a few minutes imaging time per
animal, In Vivo MR screening can be used to assess inflammation in the colon wall. Thus,
usage of high throughput MRI enables longitudinal studies, whereupon the efficacy of new
IBD therapies can be followed on each individual animal.
Inflammatory parameters and MRI
p < 0.01 between DSS and healthy for all parameters
W1050
Identification of Symptom Domains in Ulcerative Colitis That Are Responsive
to Changes in Disease Severity
Tahira M. Khan, Patricia Wren, Joel Joyce, Akbar K. Waljee, Ellen M. Zimmermann,
Maneesh Dave, Peter D. Higgins
Background: None of the current disease activity indices for ulcerative colitis (UC) were
derived with patient input. Previous focus group interviews identified a set of symptom
domains that are important to patients. Several of these are not represented in current disease
activity indices, and some of the items in disease activity indices were not identified as
important to patients. Our goal was to identify symptom domains that are both important
to patients and responsive to changes in disease severity. Aims: 1) To identify which symptom
domains in UC are most likely to reproducibly worsen during flares; 2) to identify which
symptom domains are most likely to reproducibly improve during effective therapy for UC;
and 3) to identify which symptom domains are most likely to resolve during remission.
Methods: Surveys of 34 individual UC patients were performed. Each patient was presented
with 28 symptom domains (17 from standard UC disease activity indices, and 11 novel
domains from focus group data). Subjects were asked to rate each symptom domain on a
100 mm VAS scale for each of 3 endpoints: 1) occurs with flares; 2) improves with effective
therapy; and 3) resolves when in remission. The a priori definition of an important symptom
domain was one with a median rating of at least 65/100 on all of the 3 VAS scales. Results:
Nine of the 28 domains achieved the a priori definition of important symptom domains. These
included the rarely measured domains of urgency, stool mucus, night bowel movements, and
fatigue. Four domains - cramping, flatulence, loud bowel sounds, and rapid bowel movements
after eating - were close to the endpoint, with all medians >57 for the three VAS scales.
Several domains used in standard indices, including erythema nodosum and pyoderma
gangrenosum, were not sensitive to changes in disease severity, with average VAS scores of
<10. Patients report that several symptoms, including loose stools, frequent stools, and stool
blood, do not always completely resolve when patients are in remission. Conclusions: Patient-
focused methods have identified different and additional symptom domains for UC from
those used in standard disease activity indices. Current methods may not measure disease
activity very effectively, leading to evaluations of therapies that may not accurately reflect
the patient's point of view. A requirement of complete resolution of all symptoms for
remission does not concur with patients' definition of remission. Future research will develop
reproducible and responsive questions for each of these symptom domains to develop an
optimized, patient-focused disease activity measurement for ulcerative colitis.
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W1051
Prevalence of Penetrating Disease and Extraintestinal Manifestations of
Crohn's Disease Detected with CT Enterography
David H. Bruining, Hassan A. Siddiki, Joel G. Fletcher, William J. Tremaine, William J.
Sandborn, Edward V. Loftus
BACKGROUND: The use of computed tomography (CT) enterography in patients with
Crohn's disease has dramatically increased at many tertiary care centers. This imaging
modality not only provides information about the extent and severity of small bowel inflam-
mation, but it also detects penetrating disease and extraintestinal manifestations of inflammat-
ory bowel disease (IBD). There is a paucity of data, however, regarding the prevalence of
these findings noted by CT enterography (CTE). METHODS: We identified the records of
357 consecutive patients with Crohn's disease evaluated at our institution who underwent
a CTE between 8/1/04 and 10/31/05. Radiology reports were reviewed for the presence of
penetrating disease (abscess, fistula, or phlegmon) or extraintestinal manifestations (nephroli-
thiasis, cholelithiasis, sacroiliitis, avascular necrosis (AVN), deep vein thrombosis, primary
sclerosing cholangitis (PSC), or lymphoma). Additional non-IBD related abnormalities were
also recorded, including any mass or cystic lesion. Urgent findings were defined as those
that were deemed by the original radiologist or ordering physician to require medical follow-
up within 3 months of CTE imaging. RESULTS: Of 357 patients identified (49% males),
median age was 41.6 years, and median disease duration was 9.9 years. Of this cohort,
21.3% had penetrating disease (new finding in 12.9%) and 17.9% had extraintestinal IBD
manifestations (new finding in 12.0%) (Table 1). In addition, 52.9% had non-IBD related
abnormalities, the most common being renal cysts (19.6%), hepatic cysts (12.6%), and
adrenal nodules (5.0%). Of these abnormalities, 11.1% required urgent follow-up. Three
malignancies were detected, including a lymphoma, renal cell carcinoma, and endometrial
adenocarcinoma. CONCLUSION: CT enterography is a valuable diagnostic modality for
detecting both penetrating disease and extraintestinal IBD manifestations. This data adds to
a growing body of evidence that supports the use of CTE in Crohn's disease diagnostic and
management strategies.
Table 1. Penetrating Disease and Extraintestinal Manifestations Detected by CT Enter-
ography in Patients with Crohn's Disease
W1052
Molecular Imaging of Intestinal Inflammation with 2-Deoxy-2-[18f]Fluoro-D-
Glucose (Fdg) and Positron Emission Tomography (PET)
Michael Mcpherson, Sarah Brewer, Jonathan Braun
An important unmet need in IBD is a toolset to non-invasively categorize and quantitate
intestinal inflammation. As a molecular imaging technique, PET is used to visualize a
variety of In Vivo biological processes including cell interactions, gene expression, and drug
metabolism. Clinically, 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has emerged as an important
molecular biomarker for PET imaging of cancer, based on the up-expression of GLUT-1
glucose transport activity in the malignant state. GLUT-1 transport activity is also induced
upon antigen receptor lymphocyte activation. In this study, we explored the possibility that
FDG and PET could be used to image the pathogenic lymphocyte activity in mouse models
of immune colitis. C3H/HeJ.IL-10-/- mice, which undergo spontaneous immune colitis at
6-8 weeks, were i.p. injected with 250μCi FDG, followed by one-hour uptake time, and
finally scanned by PET and CT. The large intestine was identified by CT contrast agent, 0.5
cm cylindrical regions-of-interest (ROIs) throughout the colon were quantitated for FDG
signal (decay corrected %ID/g) and the means of the % ID/g compared between groups.
Data was compiled longitudinally in individual C3H/HeJ.IL-10-/- mice as they progressed
in disease activity, and also in age-matched C3H/OuJ control mice. The resultant values
were statistically analyzed by a two-tailed student T test. The results demonstrated that
C3H/HeJ.IL-10-/- mice, compared to control C3H/OuJ, had significantly higher FDG signal
in the large intestine (p< 0.05) at time points 9 weeks and later, but at 7 weeks had similar
%ID/g means. Longitudinal analysis revealed that a mean of 7% ID/g reliably separates C3H/
HeJ.IL-10-/- and C3H/OuJ mice after onset of colitis (week 9+). In a parallel study, mice
were injected i.p. with 3H-2-deoxyglucose; after an hour of uptake, mice were sacrificed,
intestinal cells were fractionated, and quantified for 3H-2-deoxyglucose levels. These prelim-
inary data demonstrated increased 2-deoxyglucose transport selectively in intestinal lympho-
cytes rather than epithelial cells. This suggests that increased FDG uptake in immune colitis
is attributable to increased GLUT-1 activity by the intestinal lymphocyte population. These
findings suggest the feasibility of the FDGmolecularmarker and PET imaging as a noninvasive
diagnostic tool to detect and measure the severity of lymphocyte-mediated colonic inflamma-
tion. Further studies are underway to further define the cell types responsible for FDG/PET
signal in immune and non-immune colitis.
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Microalbuminuria Is NO Predictor for Relapses in Crohn's Disease
Johan Tielen, Martijn Van oijen, Annerike Davids, Ton Naber, Dirk j De jong
Background: In previous reports, microalbuminuria was associated with disease activity in
patients with Crohn's disease (Mahmud et al. Gut 1994 and 1996) and ulcerative colitis
(Poulou et al 2006). This may be related to the increase of inflammatory mediators, but
also to medical therapies. Valuable markers to establish the degree of disease activity or to
predict the course of disease are scarse. Therefore, the aims of the present study were to
determine disease characteristics related to microalbuminuria and the value of microalbumin-
uria as predictor for relapses in quiescent Crohn's disease. Methods: In a one-year prospective
maintenance trial with oral budesonide in patients with Crohn's disease in remission (CDAI
below 150 points), microalbuminuria was measured at randomisation and after 2, 6 and
12 months, plus at time of a relapse event. All other medical treatment for Crohn's disease
was discontinued before randomisation. Relapse was defined by a CDAI above 150 points
with an increase of at least 60 points. The association of microalbuminuria with disease
characteristics and course of disease was analysed with regression analysis. Time-dependent
Cox regression was undertaken to study the association between microalbuminuria and
relapse. Results: We included a total of 137 patients (M/F 57/80, mean age (SD) 36.5 yr (14)).
At randomisation, microalbuminuria was present in 21 (15%) patients, without significant
correlations between microalbuminuria and demographic or disease characteristics at base-
line. During one year of follow-up 27 (20%) patients relapsed. Patients that relapsed were
younger (mean age (SD) 32.6 (10) versus 37.5 yr (15), p=0.04), and used more often
systemic corticosteroids or immunosuppressive medication before randomisation (p=0.01).
In 11% (3/27) of patients with a relapse, microalbuminuria was present during the relapse.
We found no statistically significant association between microalbuminuria and relapse
(Odds ratio 0.92, 95% confidence interval 0.76-1.13). Time-dependent analysis also revealed
no statistical predictive values for microalbuminuria. Conclusion: Microalbuminuria was not
associated with disease chararteristics or type of medication before randomization and was
not a predictor for relapses during maintenance therapy with budesonide in Crohn's disease.
W1054
Wireless Capsule Endoscopy Versus Small Intestine Contrast Ultrasonography
for Assessing the Postoperative Recurrence of Crohn's Disease: A Prospective
Longitunal Study
Livia Biancone, Emma Calabrese, Carmelina Petruzziello, Sara Onali, Francesca Zorzi,
Marta Cossignani, Giuseppe Sica, Francesco Pallone
Background. Small intestine contrast ultrasonography (SICUS) is a non-invasive technique
able to detect small bowel lesions in Crohn's Disease (CD). Videocapsule endoscopy (WCE)
allows the visualization of the small bowel inner surface. As CD patients require endoscopic
assessment after surgery, non-invasive techniques able to detect the postoperative recurrence
may well be of use. The usefulness of SICUS and WCE for assessing the postoperative
recurrence of CD is unknown. Aims. We aimed to investigate, in a prospective, longitudinal
study, the usefulness of SICUS in comparison with WCE for assessing the postoperative
recurrence of CD patients 1 year after ileo-colonic resection, when using ileocolonoscopy
(CC) as gold standard. Methods. 22 patients (11 M, median age 33, range 22-67 yrs)
undergoing ileo-colonic resection for CD were prospectively followed up from July 2003
to May 2006. After surgery, all patients underwent clinical assessment (CDAI) every 3
months for 1 year. At 1 year, CD recurrence was assessed by 3 independent investigators
by SICUS and CC, followed by WCE. CD recurrence was assessed by CC (Rutgeerts' score).
SICUS was performed after PEG ingestion (375 ml). WCE was performed by using the M2A
Given. Lesions compatible with recurrence assessed by SICUS and WCE were reported.
Results. No patients showed side effects. At 1 year, all 22 patients were clinically inactive
(CDAI<150). In 5 pts, WCE was not performed due to peri-anastomotic lumen narrowing
or stricture. Comparison between these 3 techniques was therefore made in 17 patients.
CC detected CD recurrence in 21/22 patients. Lesions compatible with recurrence were
detected by SICUS in 22/22 patients (1 FP). When considering only the 17 patients studied
by all the 3 techniques, recurrence was detected by CC in 16/17 pts, while lesions compatible
with recurrence were detected by SICUS in 17/17 patients (16 TP, 1 FP) and by WCE in
16/17 pts (16 TP, 1 TN). Conclusions. Present findings from a prospective longitudinal
study suggest that SICUS and WCE may represent alternative non-invasive techniques for
assessing the early CD recurrence in patients under regular follow-up after ileo-colonic
resection. WCE use however requires the exclusion of lumen narrowing or strictures related
to recurrence or to surgery itself.
W1055
Wireless Capsule Endoscopy in Crohn's Disease: Clinical Relevance of Upper
GI Lesions and Feasibility 2 Years After Ileo-Colonic Resection
Livia Biancone, Carmelina Petruzziello, Emma Calabrese, Giovanna Del vecchio blanco,
Sara Onali, Marta Cossignani, Giuseppe Sica, Francesco Pallone
Introduction. Wireless capsule endoscopy (WCE) is a non invasive technique able to visualize
small bowel lesions in Crohn's disease (CD). The clinical relevance of upper gastrointestinal
(GI) lesions detected by WCE in CD is unknown. Undefined is also the feasibility of WCE
in CD pts. in regular follow after surgery, in relation to the impact risk. Aim. Primary
endpoint was to assess, in a prospective longitudinal study, the clinical relevance of upper
GI lesions detected byWCE in CD pts. 1 year after ileo-colonic resection. Secondary endpoint
was to evaluate, in the same cohort of pts., the feasibility of WCE 2 years after surgery, in
relation to strictures. Materials and methods. 18 CD pts. (8M, median age 34 yrs, range
24-65; NSAIDs users 2; smoking habits: yes 6, no 10, ex 2) undergoing ileo-colonic resection
were followed up from May 2003 to Nov. 2006 (median 25 mths, range16-47). Study
Protocol. Group A. At 1 year, all 18 pts. underwent colonoscopy, followed by WCE (M2A,
Given, Israel) in absence of strictures. Lesions at WCE were separately assessed in the peri-
anastomotic (PA)-area and in the upper GI. Lesions were graded as: absent (0), erythema/
loss of villi (1), erosions/aphtoid ulcers (2) or deep ulcers (3) by 2 observers. At 1 yr, clinical
activity (CDAI), epigastric pain, Hb, serum iron and ferritin were recorded. Group B. The
same 18 pts. were followed up, with small bowel follow throught (SBFT) at 2 yrs. Results.
Group A. At 1 yr, all 18 pts. were in remission (CDAI< 150), with no strictures (recurrence
in 17/18; 94%). WCE was performed in 17/18 pts, as 1 pt. had incomplete preparation.
Upper lesions were detected in 8/17 pts. (47%): 7 erosions/aphtoid ulcers (G2), 1 deep
ulcers (G3). Among these 8 pts. (3 F, median age 40 range 24-65; 2 smokers, 4 no smokers,
2 ex-smokers), both NSAIDs users showed upper lesions. Epigastric pain was referred by
2/8 pts., with anaemia in 1 (Hb 12,9 g/dl, iron: 43 ug/dl). In the 9 pts (F 7, median age
32, range 27-54) with no upper lesions, 1 pt. had epigastralgia, 6 pts. anaemia (in 1 with
epigastralgia), 3 were smokers, none were NSAIDs users. Interobserver variability showed
an agreement very good for the upper lesions (k=0.859), good for PA-lesions (k=0.611).
Group B. At 2 yrs, SBFT was performed in 12/18 pts. (2 lost at follow up, 2 not at 2 yrs).
In 9/12 (75%) pts. (all in remission) SBFT showed strictures, thus contraindicating WCE.
Conclusions. In CD. upper GI lesions detected by WCE may have no clinical relevance.
Two years after ileo-colonic resection for CD, WCE is not recommended in the majority of
patients, due to the high risk of impact related to asymptomatic strictures.
W1056
The Use of Azathioprine for the Treatment of Inflammatory Bowel Disease in
Clinical Practice: A Multicenter, Retrospective Study
Simone Saibeni, Tiziana Virgilio, Luisa Spina, Renata D'incà, Martina Paccagnella, Aurora
Bortoli, Michela Peli, Renato Sablich, Enrico Colombo, Carlo M. Girelli, Giovanni Casella,
Alberto Grasso, Roberto De franchis, Maurizio Vecchi
Background: Azathioprine is the most commonly used immunomodulatory drug in the
treatment of Inflammatory Bowel Diseases (IBD). The majority of data suggests that azathiop-
rine is effective both in inducing and maintaining remissions of Crohn's disease (CD) and
ulcerative colitis (UC); however, important toxicities may limit its clinical use. Aim: to
retrospectively evaluate the use, the therapeutic and side effect profiles of azathioprine in a
large series of IBD patients. Methods: we reviewed 3353 case histories of IBD patients
referred to 9 Italian centers. The analysis has been performed on 569 patients (280 with
UC, 281 with CD, 8 with indeterminate colitis; 307 men, 262 women) whose clinical data
were considered to be exhaustive. Azathioprine has been administered at an initial dosage
of 1,5-2,5 mg/Kg daily. Results: Indications for azathioprine treatment were: steroid-depend-
ence in 334/569 (58.7%), steroid-resistance in 111/569 (19.5%), fistulae in 27/569 (4.7%),
prophylaxis after surgical resection in 20/569 (3.5%), other in 77/569 (13.5%). Side effects
have been observed in 147/569 (25.8%); The main side-effects were: myelotoxicity (anemia
and/or leucopenia) in 42/147 (28.6%), liver toxicity in 26/147 (17.7%), pancreatic toxicity
in 23/147 (15.6%). Optimal efficacy of azathioprine was observed in 258/569 (45.3%),
partial efficacy in 103/569 (18.1%), inefficacy in 85/569 (14.9%), while in 123/569 (21.6%)
the effect of azathioprine has not been assessable due to the short time of assumption and/
or early withdrawal due to side effects. Azathioprine has been discontinued in 246/569
(43.2%), for the following reasons: side effects in 99/569 (17.4%), long-standing assumption
in 18/569 (3.2%), patient's decision in 35/569 (6.2%), inefficacy in 45/569 (7.9%), other
in 49/569 (8.6%). Azathioprine has been discontinued because of side effects after a mean
time of 11 month (range 1-118 months). The mean time of observation of the 323/569
(56.8%) IBD patients who are still on azathioprine is 37 months (range 1-168 months).
Azathioprine has been continued during pregnancy in 14/262 women (5.3%) without nega-
tive effects on outcomes. Conclusions: in our series, azathioprine confirms its clinical use-
fulness and its acceptable safety profile in managing complicated IBD patients. However,
its use appears to be complicated by quite a number of side effects, some of them leading
to drug discontinuation.
W1057
Clinical Impact of Double-Balloon Enteroscopy in Crohn's Disease Patients
P. B. Mensink, M. J. Groenen, H. R. Van buuren, J. Haringsma, C. J. Van der woude, E. J.
Kuipers
Introduction: Since the introduction of double-balloon enteroscopy (DBE) in 2001 by Yama-
moto, this novel technique has been used for diagnosing and treatment of various small
bowel diseases. So far, the experience in Crohn's disease (CD) is limited. In this study we
present our experience with DBE in patients with known or suspected CD. Methods:
Retrospective assessment of all cases with CD who had DBE. Clinical data were collected
from the medical charts and laboratory results (15 days before, or after DBE) were analyzed.
Results: During a period of 3 years 174 DBE procedures were performed, including 35
procedures in CD patients (26 patients); 15 females, median age 36 (14-72) years. Indications
for DBE where: ill-defined or unexplained abdominal complaints (n=22), anemia (n=10),
hypomagnesemia (n=2) and suspicion of CD (n=1) after conventional work-up. The oral
route was used in 20 (57%), the anal route in 1 (3%) and both in 14 (40%) patients. Median
oral insertion depth was 225 (80-370) cm and anal insertion depth 64 (5-150) cm; complete
small bowel visualization was achieved in 4 (12%) DBE procedures. No complications
occurred. In 25 (71%) DBE procedures, active CD was found: mild in 13, moderate in 5,
severe in 3 and previous unknown strictures were seen in 4 patients. In the 22 patients
with abdominal complaints, 15 (68 %) patients had active small bowel disease: 7 mild, 3
moderate, 1 severe and strictures in 4 patients. Of these 15 patients, 13 had no and 2 had
minor colonic activity. Serum CRP, leukocyte counts and magnesium did not significantly
differ between the active and non-active CD patient groups; respectively 5.1 (1-21) and 2.6
(1-4) mg/l, 6.6 (3.5-12.8) and 7.7 (4.5-10.2)*10E9/l, 0.7 (0.5-1.0) and 0.8 (0.5-0.8) mmol/
l. In all 15 patients with active small bowel disease the results of DBE lead to changes in
(medical) therapy. Conclusion: DBE is feasible and save in CD patients. In CD patients with
ill-defined or unexplained symptoms after conventional work-up, almost 70% showed active
small bowel involvement, in spite of normal laboratory parameters and normal findings at
colonoscopy. In the era of optimizing therapy and mucosal healing, DBE can play a major
role in the diagnostic work-up of CD patients with otherwise ill-defined, unexplained or
persistent symptoms.
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Chemical Stability of Thiopurine Metabolites in Erythrocytes During 6-
Mercaptopurine and Azathioprine Treatment
Peer De graaf, Rene M. Vos, Nanne K. De boer, Arno Sinjewel, Bindia Jharap, Agnes I.
Veldkamp, Adriaan A. Van bodegraven
Introduction Thiopurines are considered first line maintenance immunosuppressives in the
treatment of inflammatory bowel disease (IBD). Usually, 6-Methylmercaptopurine (6-MMP)
reflects thiopurine s-methyltransferase (TPMT) activity and in particular 6-thioguanine nucle-
otides (6-TGN) are suggested to be the pharmacological active metabolites of the thiopurines
azathioprine (AZA) and 6-mercaptopurine (6-MP). Determination of these metabolites in
daily routine is performed by High-Pressure Liquid Chromatography and UV-detection,
usually by methods described by Lennard or Dervieux et al. However, data concerning the
(long-term) chemical stability of these metabolites after sampling are sparse. These data are
pivotal, considering logistic routing of monitoring thiopurines for treatment or study pur-
poses. Aims & Methods We prospectively investigated the chemical stability of thiopurine
metabolites (6TGN and 6MMP) in blood samples during thiopurine treatment for inflammat-
ory bowel disease. Patients were on a stable mono-therapeutic regime of 6-mercaptopurine
or azathioprine. Blood was sampled in lithium-heparin tubes and divided immediately in
equal portions for storage at room temperature or refrigeration at 4 degrees Celsius. A
validated analytical method (by Dervieux et al) was used with a within-day precision of
5,7% and 4,9% and a between-day precision of 6.9% and 7.2% for 6-TGN and 6-MMP
respectively. Analysis for metabolites in erythrocytes was performed according to local
procedure at baseline and on day 1, 4, 5, 6 and 7 after sampling. Red blood cells were
counted in the final suspensions to report the levels of metabolites according to literature.
Results Nine patients on steady state 6-mercaptopurine or azathioprine therapy and one
patient on 6-thioguanine treatment were sampled as part of routine therapeutic monitoring.
Average 6-TGN-levels dropped to 57% and 92% of the original values at day 7 during
storage at room temperature and refrigeration respectively; 6MMP-levels decreased to 54%
and 86% of original values at day 7 after sampling. Conclusion This study shows an (clinically)
essential decrease in 6MMP but particularly in 6TGN levels when stored at room temperature,
or -to a lesser extent- at 4 degrees Celsius. In clinical practice and (future) multi-center
studies, this factor is of pivotal importance to interpret thiopurine metabolism in IBD-patients.
W1059
Antibody Panel in the Diagnosis of Inflammatory Bowel Disease (IBD)
Ellen C. Ebert
Introduction: Patients with IBD have antibodies against various food proteins. They also
may have anti-cytokine antibodies, such as those against IL-1β and interferon-α. These have
been described in certain patients with autoimmune (such as rheumatoid arthritis) and
infectious (such as hepatitis and varicella) diseases but have not been reported in IBD. The
hypothesis of this study is that these antibodies could be used to diagnose IBD in patients
who present with diarrhea. Methods: Serum samples were collected from 137 patients with
ulcerative colitis (UC), 83 patients with Crohn's disease (CD), 51 normal individuals (NI),
and 21 disease controls (DC) with pseudomembraneous, infectious, ischemic, or microscopic
colitis. ELISAs were performed with cytokine (IL-1, IL-2, IL-4, or IL-10) or food (casein or
lactoglobulin) attached to the plate, followed by serum, then goat anti-human IgG, and
color development. Results: The percentage of IBD sera with optical density (OD) values
greater than those for all NI and DC were recorded. For IL-1, 14% of UC patients and 18%
of CD patients had antibody levels higher than all NI and DC. Similar percentages were
obtained for the other substances. When antibodies against all six substances were tested
as a panel, 45% of UC and 60% of CD patients were positive for at least one antibody. This
was also true of the 18 patients with new-onset IBD, where 9 had antibodies against at least
one of the substances. Conclusion: Measuring antibodies against IL-1, IL-2, IL-4, IL-10,
casein, and lactoglobulin can be used as a panel to diagnose 45 to 60% of IBD patients
presenting with diarrhea with 100% specificity. This test may alter management permitting
the early introduction of anti-IBD therapy.
W1060
Prevalence of Igg Food-Specific Antibodies in Inflammatory Bowel Disease: A
Case-Control Study
Stephen J. Inns, Anton V. Emmanuel, Stephen Hurel, Stuart Bloom
BACKGROUND: Many patients with IBD report food sensitivities but the immunological
correlates of these are unknown. IBD patients have higher levels of specific IgG and IgM
antibodies to yeast and cows milk proteins than controls but do not have higher levels of
IgA or IgE antibodies to the same proteins. While testing for food specific IgG antibodies
has shown some promise in IBS, no data on immunoglobulin subtype antibodies in IBD
has been published. AIMS and METHODS : We aimed to investigate the prevalence of IgG
antibodies to food antigens in patients with IBD compared to a control hospital population.
Sequential patients with quiescent UC or CD were enrolled from the UCLH IBD clinic.
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Control patients were enrolled from the UCLH thyroid nodule clinic and had normal thyroid
biochemistry and no history of GI disease. Blood was collected for assay of 92 food specific
antibodies using the Yorktest Foodscan test. All patients completed a questionnaire relating
GI symptoms of food intolerance to specific foods. RESULTS: Between February and August
2006 77 patients (25 with UC, 28 with CD and 24 with thyroid nodules)were enrolled.
CD patients, not UC, had significantly higher total titres compared to controls (mean
340 (95% CI 197,484) vs 200 (84,318) vs 84 (-7,175) arbitrary units, p<0.01 and p=NS
respectively). CD and UC patients reported gastro-intestinal sensitivity to a significantly
greater number of foods than controls (median (range): 3 (0,33), 4 (0,29), 0 (0,20) respect-
ively, p=0.02).The greatest, statistically significant, difference in median titre between CD
patients and controls were seen for Yeast, Gliadin, Corn, Buckwheat,Wheat, Lentils, Soyabean
and Barley. For UC vs control they were Buckwheat, Coffee, Cola Nut, Barley, Corn, Pork
and Turkey (p<0.05 for all observations). No significant correlation between patient reported
food sensitivity and IgG titre was seen. DISCUSSION: This study is the first report of the
prevalence of IgG antibodies to food antigens in IBD. It confirms the high rates of subjective
food sensitivity in IBD seen previously. It demonstrates increased total levels of food-specific
IgG levels in CD compared to controls and IgG antibodies to particular foods in CD and
UC compared to controls. The absence of significant correlation between food antibodies
and patient reported sensitivity may be a result of the small number of patients in this
study. These results suggest further experiments to investigate whether IgG antibodies can
predict foods that provoke disease on double blind placebo controlled food challenge and
conversely, whether specific food avoidances based on antibody titres might be worthwhile.
W1061
The Role of Colonoscopy in the Assessment of Mild to Moderately Active
Ulcerative Colitis
Michael F. Picco, Jeremy C. Davis, John R. Cangemi, Donna Shelton
Background: Colonoscopy may not be necessary in all outpatients with mild to moderately
active ulcerative colitis (UC). Results correlate poorly with clinical activity but would be
important if severe or quiescent disease is found. We determined if clinical impression is
likely to be altered by colonoscopy in these patients. Methods: Clinical assessment of disease
activity was compared to endoscopic appearance among 142 consecutive outpatients with
mild to moderate UC. Patients were stratified based on previous gross extent (left sided vs.
pan) and medications(oral corticosteroids vs. no corticosteroids ).The no corticosteroid group
was further stratified into those on optimal (>3.6g Asacol,>3g Pentasa or>4g sulfasalazine
and enema therapy for previous left sided disease) vs. suboptimal mesalamine. Steroid
dependent and refractory patients were also compared. Clinical activity was based the clinical
component of the Mayo score (excludes endoscopy) and endoscopic activity was based the
endoscopic component of the Mayo score. Results: Overall comparisons are shown in the
table.Gross extent remained the same in 84% when compared to previous colonoscopy with
11% increasing and 5% decreasing in distribution. This was not affected by medication
usage. Among those not on prednisone, colonoscopy confirmed mild to moderate disease
in 90% with severe disease in 8% and quiescent disease in 2%. There were no differences
in these findings after stratification for optimal mesalamine use. Among steroid dependent
and refractory patients those with clinically moderate disease benefited most from endoscopy
with 24% having endoscopically severe disease (P=0.016) and 50% having endoscopic
activity different than clinical impression. Steroid dependent patients with clinically moderate
disease benefited most from colonoscopy with 40% having endoscopic severe disease com-
pared to 0% with clinically mild disease (p=0.013).Among steroid refractory patients endos-
copy revealed unexpected severe disease in 10% with no difference in those with clinically
mild or moderate disease. Conclusion: Clinical assessment alone is sufficient among mild
to moderately active UC patients not taking corticosteroids since colonoscopy is unlikely
to alter clinical impression. Conversely, patients taking corticosteroids, especially steroid
dependent patients, should undergo colonoscopy since clinical impression tends to underes-
timate severity.
p=0.001
W1062
Serum Levels of AMCA, ALCA, ACCA and GASCA in Conjunction with
pANCA May Contribute to the Diagnosis and Differentiation of Inflammatory
Bowel Disease
Florian Rieder, Alexandra Wolf, Stephan Schleder, Andrea Dirmeier, Michal Gruengard,
Ulrike Strauch, Florian Obermeier, Bernd Salzberger, Gerhard Rogler, Nir Dotan, Frank
Klebl
Introduction: Inflammatory bowel diseases (IBD) present clinically with a heterogenous
picture. In about 10% of the cases a discrimination between Crohn`s disease (CD) and
Ulcerative Colitis (UC) is not possible. New serologic markers may be useful for differentiating
these two entities. We therefore tested a new panel of antibodies against glycan epitopes in
IBD. Methods: Sera of 247 patients of the German “Kompetenznetz CED” (149 Crohn`s
disease (CD), 50 Ulcerative colitis (UC) and 48 healthy controls (HC) were tested for the
presence of Anti-Chitobioside Ig A Carbohydrate Antibodies (ACCA), Anti-Laminaribioside
Carbohydrate IgG Antibodies (ALCA), Anti-Mannobioside Carbohydrate IgG Antibodies
(AMCA) and Anti Saccaromyces cervisiae IgG and IgA-Antibodies (gASCA IgG and IgA) by
ELISA (Glycominds Ltd., Lod, Israel) and for atypical pANCA (IFA) in a blinded fashion.
Full clinical data on diagnosis based on clinical, endoscopic, histologic and radiologic criteria
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was available. In the algorhythm used in table 2 patients were classified as CD, when the
serum was positive for at least one marker out of ACCA, ALCA, AMCA and gASCA IgG. If
negative, patients positive for pANCA were classified as UC and patients negative for all
markers were classified as HC. Results were analysed using SPSS software, significance was
detemined using t-test. Results: Levels of ALCA, AMCA, gASCA IgG and IgA were signific-
antly higher in CD compared to UC (p=0.0001, 0.02, 0.0001 and 0.034) and HC (p=
0.0027, 0.0014, 0.0001 and 0.0001). ACCA levels were significantly elevated in CD vs. HC
(p=0.012). The diagnostic performance of each marker separately for the differentiation
between CD and non-CD or UC is depicted in table 1. 21% of gASCA IgG negative CD
patients were positive for AMCA, ALCA or ACCA. Accuracy for stratification of the cohort
to CD, UC and HC using a combination of all markers is shown in table 2. Conclusion:
The novel serum antibodies AMCA, ALCA, ACCA and gASCA in conjunction with pANCA
showed a high diagnostic accuracy for CD vs. non-CD or UC. Sensitivity increased, when
a combination of all markers was used. The favorite single antibody was gASCA with the
highest sensitivity. AMCA, ALCA, ACCA and gASCA in combination with pANCA may
contribute to the first-line diagnosis of CD in the future.
W1063
Long-Term Safety of Azathioprine Treatment in Inflammatory Bowel Disease:
Results from a Single Referral Center
Konstantinos Katsanos, Marc Ferrante, Herma Fidder, Liesbet Henckaerts, Dimitrios
Christodoulou, Gert A. Van assche, Epameinondas V. Tsianos, Severine Vermeire, Paul
Rutgeerts
AIM: To describe the long-term safety including the prevalence of malignancies in a large
cohort of IBD patients treated with azathioprine (AZA) in a single referral center. PATIENTS-
METHODS: Retrospective data collection from a database of 1815 IBD patients (1355 Crohn's
[CD], 447 ulcerative colitis [UC], 13 indeterminate colitis [IC]). All patients who previously
received or were currently taking AZA were reviewed. RESULTS: We identified 729 IBD
patients previously or currently on AZA (555 CD, 169 UC, 5 IC). Median disease duration
was 12 years (interquartile range [IQR] 7-19 years) and follow up on AZA/6-MP was (median,
IQR) 7.1 (4.4-9.7) years. Combination therapy with Infliximab (IFX) was administered in
232 patients (208 CD). Before and during AZA segmental bowel resection was performed
in 190 (26.2%) patients and total colectomy in 74(10.2%). A total of 15 patients [2%] (12
CD, 3UC / 12 females, 3 males) were diagnosed with 17 cancers, all extra-intestinal but no
lymphoma.There was no significant difference in age, gender, duration of disease, and
duration of AZA therapy between AZA-cancer and AZA non-cancer patients. In the whole
AZA cohort mortality rate was 0.82% (6/729 patients) while all AZA-cancer patients were
alive on latest follow up. We identified 88/729 (12%) patients with AZA-related bone marrow
toxicity (BMT) necessitating dose adjustment or interruption of therapy. Infections were
diagnosed in 27 BMT patients (30%), 8 of them were severe and 4/8 were of viral origin.
CONCLUSIONS: In this large single center cohort of 729 IBD patients on AZA, the mortality
rate was 0.82% and prevalence of cancer was 2%, all extra-intestinal. Duration of therapy,
disease duration, age and presence of BMT were not associated with a higher cancer risk.
BMT was associated with infections and half of severe infections were viral.
W1064
Presenting Symptoms of Crohn's Disease in Pediatric Patients
Neera Gupta, Melvin B. Heyman, Alan G. Bostrom, George D. Ferry, Benjamin D. Gold,
Stanley A. Cohen, Robert N. Baldassano, Barbara S. Kirschner, Michael Durant, Harland
S. Winter
Background: Little data have been reported on the presenting symptoms of pediatric patients
with Crohn's disease (CD) in large multicenter studies. We describe the presentation of
disease in a large pediatric cohort of patients with CD.Methods: Data stored in the Pediatric
IBD Consortium Registry were analyzed to characterize the presentation of CD in 989
patients, age 0-17 years, diagnosed between 1979-2003. Results: Mean age at diagnosis
was 11.5 ± 3.8 years, 43% were female, and 83% were Caucasian. Abdominal pain, diarrhea,
rectal bleeding, weight loss, and fever were the most prevalent individual symptoms at onset.
(Table) However, the percentages of patients manifesting these symptoms of CD were less
than previously reported. Conclusions: In our cohort of pediatric patients with CD, the
prevalences of typical symptoms, specifically abdominal pain, diarrhea, rectal bleeding,
weight loss, and fever, are lower than previously reported, substantiating the subtle presenta-
tion of Crohn's disease in pediatric patients. Supported in part by grants from the NIH
(DK007762, DK064544, and DK060617) and the CCFA.
Presenting Symptoms of Crohn's Disease in 989 Pediatric Patients
W1065
Evaluation of Crp, Fecal Lactoferrin and Activity Indices for Assessing
Intestinal Inflammation in IBD and IBS Patients Classified By Ileocolonoscopy
Jost Langhorst, James H. Boone, Andreas Rueffer, Andreas Michalsen, Gustav J. Dobos
Background: The differentiation of noninflammatory functional symptoms like Irritable Bowel
Syndrome (IBS) from Inflammatory Bowel Disease (IBD) can prove difficult. Clinical indices
have proven too complex for daily routine practice. Serologic parameters such as C-reactive
protein (CRP) and sedimentation rate are hampered by a low sensitivity and specificity for
intestinal inflammation. Lactoferrin, a neutrophil-derived protein, has been shown to be a
sensitive marker for discriminating active ulcerative colitis (UC) and Crohn's disease (CD)
from cases of IBS. Aim: To compare fecal lactoferrin (FLA) to CRP, clinical activity indices and
ileocolonoscopy and histopathology for assessing patients with chronic intestinal illnesses.
Methods: A total of 97 adult patients with a mean age of 42 yr and a male to female ratio
of 1:2 were classified for disease status by ileocolonoscopy and histopathology using a score
of 0-3 (0 = no inflammation to 3 = high inflammation). Serum and fecal specimens were
collected and analyzed for elevated serum CRP (>=0.5 mg/dl) and FLA (>= 7 µg/ml),
respectively, using enzyme-linked immunoassay (EIA). Clinical activity indices were calcu-
lated for UC using the Colitis Activity Index (CAI - Rachmilewitz-Index; score of > 5
indicating active disease) and for CD with the Crohn's Disease Activity Index (CDAI; A
score of > 150 indicating active disease). Results: Study subjects were classified into 3 groups,
37 CD, 31 UC and 29 IBS. In the IBD group, 77% (52) had endoscopic signs of active
disease while 24% (16) were inactive. There were a total of 29 cases of IBS. A linear
relationship was observed between patient groups stratified by endoscopy scores 0 to 3 with
CRP levels (mean±SE) of 4.4±1.5, 1.5±0.5, 1.6 ±0.3 and 0.5±0.1 (r2=0.80) and LFA of
553±205, 194±86, 70±12 and 15±4 (r2=0.86). A significant difference (p£0.05) was achieved
with LFA between endoscopy groups for 3vs1, 3vs0, and 1vs0 (p=0.04, 0.02 and 0.0002,
respectively). Serum CRP showed a significant difference between endoscopy groups for
3vs0 and 1vs0 (p=0.02 and 0.005, respectively). Serum CRP and FLA showed sensitivity
of 62% and 71%, and specificity of 83% and 76% for intestinal inflammation, respectively.
ROC analysis for LFA and CRP compared to endoscopy score showed a good fit (AUC 0.82)
and fair fit (AUC 0.74), respectively. The CAI and CDAI showed sensitivity of 71% and
25%, and specificity of 100% and 100%, respectively. Conclusion: FLA outperformed CRP
for indicating active IBD and showed a higher linear correlation to severity of disease.
The CAI had a higher sensitivity for detecting active inflammation compared to the poor
performance of the CDAI.
W1066
Prospective Study of Exhaled Nitric Oxide in Crohn's Disease Patients
Receiving Anti-TNF-A Maintenance Therapy
Severine Hommel, Guillaume Savoye, Eric Verin, Monica Stetiu, Eric Lerebours
Exhaled nitric oxide is becoming a common clinical tool to evaluate bronchial inflammation
in asthmatic patients. Our aim was to study exhaled nitric oxide in Crohn's disease patients
receiving anti-TNF-a maintenance therapy in order to describe the prevalence of residual
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bronchial inflammation in these patients and to search for correlation between exhaled nitric
oxide and clinicobiological activity indexes. Patients and methods: Between November 2005
and September 2006 a measurement of exhaled nitric oxide after an usual pulmonary
functional testing was performed to determinate the total exhaled nitric oxide (NO), the
bronchial NO output and the alveolar NO concentration. The clinical activity of the disease
was assessed by Harvey-Bradshaw index. CRP level, ESR and platelet count were recorded.
Patients were stratified according to the presence or absence of remaining clinical or biological
activity. Resuls: Twenty five Crohn's disease patients (15 female, mean age 39±13 years, 24
infliximan, one adalimumab) were studied after in mean 5 anti-TNFa infusions. No patients
complained for respiratory symptoms, 12% exhibited an obstructive syndrome at functional
testing and 64% had at least one abnormal exhaled nitric oxide parameter as compared to
healthy subjects, p=0,0001. In patients with an abnormal total exhaled NO bronchial NO
output rates a significant positive correlation Harvey-Bradshaw index (r=0.79, p<0.004) and
both ESR and platelet count (r=0.85, p<0.003). A negative correlation between alveolar NO
concentration and Harvey-Bradshaw index was observed (p=0,02, r=-0,467). Bronchial NO
output was significantly more elevated in patient with remaining clinical activity in mainten-
ance anti-TNFa therapy 62±10 versus 34±5 ml/min in patients with no remaining clinical
activity, p=0,04. Conclusion: Exhaled nitric oxide seems to be an interesting tool to diagnose
subclinical bronchopulmonary inflammation in Crohn's disease patients on maintenance
therapy with anti-TNFa as 64% of patients had abnormal exhaled NO levels. These abnormal
exhaled NO levels were correlated with clinical activity index and usual biological tests.
These results needs to be confirmed in a larger group of patients.
W1067
Glucagon-Like Peptide-2 (3-33) Inhibited Ileal Mucosal Mass, But Not
Intestinal Function Following Intestinal Resection in Rats
Kristin L. Faust, Brian M. Chung, Kristy Powell, Kelly A. Tappenden
Glucagon-like peptide-2 (GLP-2) 3-33 is the truncated, inactive fragment of the full-length
peptide reported to be a competitive antagonist of the GLP-2 receptor. To investigate GLP-
2(1-33) involvement in the process of intestinal adaptation, we hypothesized that inhibiting
GLP-2 activity via GLP-2(3-33) receptor antagonism would inhibit intestinal adaptation
following resection. Male Sprague-Dawley rats (308±3 g; n=36) received a control transection
or 70% proximal jejunoileal resection, and were then randomized to receive subcutaneous
injections every 12h of: 1) normal saline; 2) 0.012 nM GLP-2(3-33), or; 3) 6 nM GLP-2(3-
33). Structural and functional adaptations were measured in the residual jejunum and ileum
14d post surgery. In the jejunum, tissue weight increased following resection compared to
transection (p<0.0001; 136±5 vs 74±5 mg/cm), regardless of 3-33 treatment. Similarly,
jejunal mucosal architecture was not impacted by 3-33 treatment, but compared to transec-
tion, resection increased villus length (p<0.0001; 1364±58 vs 973±56 μm), crypt depth
(p<0.0001; 539±25 vs 376±24 μm) and DNA content (p<0.0001; 2.41±0.15 vs 1.55±0.15
μg/mg). Jejunal ion and nutrient transport, measured in modified Ussing chambers, was
not altered by 3-33 treatment, but resection increased transmucosal resistance (p=0.0005;
95.5±8.5 vs 47.9±8.8 Ω●cm2) and decreased glucose (p=0.0409; 1.4±7.5 vs 24.6±7.8 ΔIsc/
cm2), glutamine (p=0.0180; 2.4±2.5 vs 11.1±2.4 ΔIsc/cm2) and peptide transport (p=
0.0347; 0.7±0.4 vs 1.9±0.4 ΔIsc/cm2). In the ileum, tissue weight increased following
resection (p<0.0001; 143.2±6.7 vs 89.7±6.7 mg/cm); however, within the resection groups,
ileal weight of the 0.02 nM 3-33 group was significantly higher (p<0.0001) than the control
resection group. The proportion of the ileum comprised of mucosa was impacted in a dose-
dependent manner by 3-33 - positively following transection (p=0.0269), but negatively
following resection (p=0.05). 3-33 did not alter ileal mucosal architecture, but resection
increased villus length (p<0.0001; 1183±42 vs 822±50 μm), crypt depth (p<0.0001; 572±29
vs 461±34 μm) and DNA content (p=0.0004; 1.55±0.15 vs 2.41±1.53 μg/mg). Ileal ion and
nutrient transport was not altered by 3-33, however, resection increased transmucosal
resistance (p=0.0013; 116±14 vs 47±15Ω●cm2), but decreased glucose (p=0.0244; 7.5±5.2
vs 24.8±5.2 ΔIsc/cm2) and glutamine transport (p=0.0185; 2.3±3.3 vs 14.2±3.3 ΔIsc/cm2).
In conclusion, at the doses studied, GLP-2(3-33) produced modest effects on ileal mucosal
mass, but did not impact functional adaptations following intestinal resection.
W1068
Infliximab-Induced Lupus Syndromes - A Case Series and Review of the
Literature
Jennifer Williams, Liam Martin, Susan G. Barr, Marv Fritzler, Remo Pannaccione
Background: Infliximab has been a significant advance in the management of immune-
mediated diseases including Crohn's disease and ulcerative colitis. A number of published
reports illustrate varying degrees of autoantibody conversion following treatment with inflixi-
mab ranging from 16% to upwards of 45%. Several cases of lupus like syndrome have been
described. Aim: To identify and review the cases of infliximab induced lupus in the Calgary
Health Region and describe the course of these patients. Methods: Cases of suspected
infliximab induced idiopathic systemic lupus erythematosus (SLE) were identified from the
Rheumatology and Inflammatory Bowel Disease Databases. Charts were reviewed and the
clinical course was compared to what is expected in typical courses of drug induced lupus.
Results: A total of eight cases were identified. Three cases in patients following infliximab
treatment for rheumatoid arthritis and five cases in patients with inflammatory bowel disease.
All patients had positive ANA and positive Anti-dsDNA. Symptoms included photosensitivity
dermatitis (1), pleuropericarditis (2), a chylous/chyliform pleural effusion (1), alopecia (1),
lupus cerebritis (2), and inflammatory polyarthritis (5). All cases resolved with discontinu-
ation of infliximab and appropriate treatment for lupus. Conclusion: This represents the
largest case series of SLE following treatment with infliximab. Many patients in our series
developed systemic manifestations other than poylarthritis. Most cases resembled idiopathic
SLE rather than drug induced lupus. Clinicians who treat patients should be aware of this
rare but potentially serious side effect.
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W1069
Urinary PGE-M, a Metabolite of Pge2: A Novel Biomarker of Ulcerative Colitis
Activity
David Schwartz, Leah Griggs, Prashant Joshi, Bonnie Lafleur, Ginger Milne, Jason
Morrow, Holly Borntrager, Alexander A. Parikh, Nipun Merchant
INTRODUCTION: The available clinical measures of ulcerative colitis (UC) activity can be
overly influenced by functional symptoms. Placebo response rates in clinical trial are high.
What is needed is a simple, non-invasive biologic measure of UC disease activity. Cyclooxy-
genase-2 (COX-2) is involved in prostaglandin E2 (PGE2) synthesis and is expressed in
epithelial inflammatory conditions and some cancers.We have developed an assay to quantify
the major urinary metabolite of PGE2, PGE-M. PGE-M has been previously shown to be
elevated in the urine of patients with advanced colorectal neoplasia relative to controls. The
purpose of this study was to determine whether urinary PGE-M levels correlated with
UC disease activity METHODS: Twenty-six patients with a known diagnosis of UC were
prospectively enrolled. Disease activity was quantified using the DAI Score for assessing
ulcerative colitis activity. Urine specimenswere collected at the time of colonoscopy. Similarly,
urine specimens were obtained from 72 healthy individuals who were endoscopically proven
to have no neoplastic or inflammatory colorectal disease. Urine PGE-M levels were determined
by mass spectroscopy. PGE-M levels were correlated with the DAI Score using the Spearman
rank correlation coefficient. Differences between the UC and normal samples were examined
using the Wilcoxon rank-sum test statistic. RESULTS: The median urine PGE-M level for
patients with UC was 77 ng/mg Cr (range: 26.7 - 182.2) compared to 12.0 ng/mg Cr (range:
0.53 - 60.7) for the healthy patients (Wilcoxon rank-sum p-value < 0.0001). There was a
positive correlation between PGE-M level and the DAI Score (Spearman's rank correlation
coefficient 0.48; p = 0.014). CONCLUSIONS: Urine PGE-M levels are significantly elevated
in patients with UC relative to healthy individuals. There appears to be a correlation between
urinary PGE-M levels and UC activity as measured by the DAI Score. These findings suggest
that this assay may be a useful objective measure of disease activity.
W1070
Double Balloon Enteroscopy in Crohn's Disease: Findings and Impact On
Management
Andrew S. Ross, Jonathan A. Leighton, Drew Schembre, Lauren B. Gerson, Simon Lo,
Irving Waxman, Charles E. Dye, Carol E. Semrad
Background: Crohn's disease (CD) frequently involves the small bowel. Detection of disease
is difficult when it involves small bowel that is not reached by standard endoscopy. While
video capsule endoscopy (VCE) has diagnostic value in the detection of small bowel CD1,
ulcers may be missed due to noncircumferential inspection, tissue sampling is not possible,
and the risk of capsule retention is significant in those with obstructive symptoms. Double
Balloon Enteroscopy (DBE) is effective in the diagnosis of small bowel diseases. However,
only a limited number of patients with CD have undergone examination. In the largest
study of patients with known CD, DBE was reported to be helpful in evaluating small bowel
lesions2. Aim: To evaluate the usefulness of DBE in suspected and known CD patients and
its impact on management. Methods: A retrospective study was performed on a prospectively
collected data base from 5 U.S. tertiary centers with equivalent training in DBE. Patients
with known CD or suspected CD based on abnormal small bowel imaging or video capsule
studies were included. Results: A total of 35 patients [24 female, 9 male, 2 children (ages
10 and 14 years)] were studied. The average age of males was 52.3 + 5.3 and females
46.9 + 2.8 years. Forty-three DBE procedures were performed (15 oral, 25 anal, 2 stoma
approaches). Of 35 patients studied, 17 had known CD and 18 had suspected small bowel
CD by abnormal VCE and imaging studies. Indications for DBE in known CD patients
included abdominal pain, GI bleeding, anemia, and abnormal VCE or imaging studies. In
26 (74%) patients, a lesion was reached or excluded facilitating a diagnosis. In 9 (26%)
patients, DBE failed to reach the lesion identified on VCE (6 patients) or imaging study (3
patients) due to fixed bowel. In 12 patients with VCE lesions reached by DBE, 10 were
biopsied [7 (58%) consistent with CD, 2 nonspecific, and 1 NSAID injury], 1 mass lesion
was a false positive finding, and 1 ulcer in a known CD patient was not biopsied. There
were 2 complications in patients with known CD, 1 transient fever and 1 perforation at an
ulcerated anastomotic site. In 22 (63%) patients, the DBE findings impacted on management
decisions. Conclusions: DBE is useful in the diagnosis of small bowel disease in both
suspected and known CD and impacts on management decisions. 1 Triester et al. Am J
Gastroenterol. 2006;101:954. 2 Oshitani et al. Am J Gastroenterol. 2006;101:1484-1489
W1071
Fistulae in Pediatric Crohn Disease: Frequency and Time Course
David J. Keljo, James F. Markowitz, Christine Langton, Trudy Lerer, Subra Kugathasan,
Anne M. Griffiths, Anthony R. Otley, Joel R. Rosh, Marian D. Pfefferkorn, David R. Mack,
Jonathan Evans, Athos Bousvaros, M. susan Moyer, Robert Rothbaum, Robert Wyllie,
Maria M. Oliva-hemker, Adam G. Mezoff, Neal S. Leleiko, Wallace V. Crandall, Jeffrey S.
Hyams
Aims: We sought to characterize the course of perianal fistulae (PF) in children newly
diagnosed with Crohn Disease (CD). Methods: Data from a prospective, observational registry
recording clinical and laboratory outcomes in newly diagnosed children under 16 yrs of
age with IBD were examined to identify study subjects. The frequency and course of PF
over 24 months following diagnosis was characterized. Patients with any draining perianal
fistulae or abscesses were identified using the fistula subscore of the PCDAI. PF was classified
as: Resolving = present in the first 30 days after CD diagnosis, resolving by 12 months;
Chronic = present at 30 days and persisting >12 months. Late onset = PF which developed
after 30 days of CD diagnosis. Results: 228 children (61% males, mean age 11.8) with CD
had follow-up for at least 2 years. 59 (26%) developed perianal fistulae, 39 within the first
30 days. Of the 39 with early onset fistulae, 10 became chronic and the remaining 29
resolved by a median 3 mo. There were no significant differences between the groups or
subgroups in gender, race, age or BMI z-score at diagnosis. Fistulizing vs non-fistulizing
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patients: Fistulizing patients were more likely to receive antibiotics than non-fistulizing
patients (within first 3 months OR =3.3, p=0.000, within 2 years OR = 3.2, p=0.001). These
groups did not differ with regards to usage or timing of usage of 5-aminosalicylates, rectal
medications, immunomodulators, infliximab, hospitalizations or IBD surgeries. Fistulizing
subgroups: Average ESR at diagnosis was higher in the resolving than in the chronic group
(44 vs 26mm/hr, p=0.03). Treatment with prednisone in the first 90 days was more common
in the resolving (23/29, 79%) than in the chronic group (3/10, 30%,OR= 8.9, p=0.008).
Surgery within 2 years was more common in the chronic (4/10, 40%) than in the resolving
group (1/29, 3.4%,OR =18.7, p=0.011). Initial PCDAI was higher in the resolving than in
the late onset group (39 vs 20, p=0.025). The chronic group was more likely to have been
treated with immunomodulators within the first 90 days (9/10, 90%) than was the late
onset group (7/20, 35%,OR= 16.7, p= 0.007). 6 of the 29 resolving did so after infliximab
was started. Only 5 of the 10 patients with chronic fistulae received infliximab. Conclusions:
26% of this cohort of newly diagnosed CD patients developed perianal fistulae within 2
yrs, 66% presented with or developed them within 30 days of diagnosis and 74% of these
resolved with medical therapy alone. Treatment with prednisone within the first 90 days
did not appear to predispose to development of chronic fistulae.
W1072
Mortality, Morbidity, and Costs Associated with Colectomies in Ulcerative
Colitis Patients in the Us
Gilaad G. Kaplan, Ellen P. Mccarthy, John Z. Ayanian, Joshua R. Korzenik, Richard A.
Hodin, Bruce E. Sands
Background: The mortality, morbidity, and costs associated with colectomies in ulcerative
colitis patients have varied widely in previous reports. Most prior studies of this topic have
been conducted in academic medical centers with specialized colorectal surgeons and may
not represent outcomes in the general US population. Therefore, we assessed the mortality,
morbidity, and costs associated with ulcerative colitis patients undergoing a colectomy in a
nationally-representative sample of US hospitals. Methods: We analyzed the 2004Nationwide
Inpatient Sample (NIS), which includes 8million discharge abstracts from over 1000 hospitals
representing a stratified 20% random sample of all non-federal US hospitals. We identified
all discharges for ulcerative colitis patients undergoing a total or subtotal colectomy (n=
1,211) using International Classification of Diseases (ICD-9-CM) diagnosis and procedure
codes. We describe the in-hospital mortality, postoperative complications, length of stay,
and total hospital charges for this sample. All analyses accounted for the complex sampling
design of the NIS, and were weighted to reflect national estimates. We present point estimates
with 95% confidence interval for each outcome. Results: In 2004 an estimated 5898 dis-
charges (95% CI: 4634-7162) were reported for patients with ulcerative colitis who under-
went a colectomy. The average age was 49 years, 55% were male, 14% were non-white,
and 58% had an elective procedure. The in-hospital mortality rate was 4.5% (2.9% - 6.0%).
Morbidity was high with 40.1% (36.5% - 43.7%) of discharge abstracts recording at least one
postoperative complication including: gastrointestinal [19.6% (16.5% - 22.6%)]; infectious
[15.0% (12.7% - 17.3%)]; pulmonary [8.3% (6.6% - 10.1%)]; and cardiovascular [6.3%
(4.8% - 7.7%)] complications. The average length of stay in hospital was 13.0 days, with
an average in-hospital charge per admission of $66,018. In total $376.4 million was spent
on in-hospital costs for ulcerative colitis patients undergoing a colectomy in 2004 in the
US. Conclusions: Colectomy for ulcerative colitis is a significant burden to patients and the
health care system as postoperative mortality, morbidity, and costs are extensive.
W1073
Clinical Features and Outcome of Patients with Inflammatory Bowel Disease
Who Use Narcotics: A Case-Control Study
Karen A. Hanson, Edward V. Loftus, William S. Harmsen, Nancy N. Diehl, Alan R.
Zinsmeister, William J. Sandborn
Purpose: Narcotics are used for acute and chronic pain in patients (pts) with inflammatory
bowel disease (IBD). The role of narcotic use in IBD pts is poorly defined, and pt requests
for chronic narcotics can challenge the provider-pt relationship. We sought to determine
the clinical features of IBD pts referred to a tertiary care center who use narcotics, and
factors associated with continuation or discontinuation of narcotics. Methods: A centralized
index was used to identify potentially eligible pts: new pts evaluated in the IBD Clinic at
our institution with Crohn's disease (CD) or ulcerative colitis (UC) from 1/99 to12/02 who
were receiving narcotics. Records were reviewed until 100 IBD pts on narcotics for IBD at
baseline (cases) were identified. A control group of 100 IBD pts not on narcotics at baseline
was identified and matched 1:1 for IBD subtype and geographic location of residence. The
associations of clinical factors with case/control status were assessed using McNemar's test
and summarized as overall percentages of cases vs. controls. Associations within cases were
assessed using Fisher's exact test. Results: A total of 361 charts were reviewed to identify
100 cases (78 CD, 22 UC), and 100 matched controls were identified. Most were on medical
therapy at presentation (78% of cases vs. 62% of controls, p=0.03). Case/control status was
significantly associated with: female gender (64% cases vs. 45% controls, p=0.01), ≥2 IBD-
related surgeries (42% vs. 17%, p<0.001), moderate to severe pain (93% vs. 20%, p<0.001),
and moderate to severe symptoms (83% vs. 33%, p<0.001), but not with endoscopic (p=
0.87), histologic (p=0.83) or radiographic (p=0.26) severity. Associations were detected for
depression (42% vs. 19%, p<0.001), anxiety (19% vs. 7%, p=0.02), and a history of abuse
(sexual, 13% vs. 2%, p=0.007; emotional, 13% vs. 3%, p=0.01; physical, 10% vs. 2%, p=
0.04). Substance abuse (excluding alcohol) was also associated with narcotic use (14% vs.
1%, p=0.001). Thirty-nine cases and 37 controls returned for ≥ 1 follow-up visits. Of the
39 cases that returned, 17 (44%) had discontinued narcotics. Discontinuing narcotics was
associated with medical treatment adherence (100% vs. 53% in those still on narcotics,
p<0.001), none to mild pain (27% vs. 82%, p=0.001) and none to mild clinical activity
(20% vs. 76%, p=0.004). Conclusions: Narcotic use in IBD pts is associated with female
gender, ≥2 previous surgeries, moderate to severe pain, moderate to severe clinical disease
activity, depression, anxiety, sexual, emotional and physical abuse, and substance abuse.
Adherence to medical therapy may aid in discontinuation of narcotics in some pts.
W1074
A Comparison of Self-Perceived General and Mental Health and Stress Levels
in IBD and IBS Patients from a National Canadian Survey
Linda Y. Tang, Alice Nabalamba, Lesley A. Graff, Charles N. Bernstein
OBJECTIVE:We aimed to determine if differences exist with regards to self-perceptions of
physical and mental health as well as stress levels in patients with inflammatory bowel
disease (IBD) compared to patients with irritable bowel syndrome (IBS). METHODS:The
data were obtained from the 2005 Canadian Community Health Survey including 132,947
Canadians representing the Canadian population. Respondents were asked whether they
had Crohn's disease (CD), ulcerative colitis (UC), or irritable bowel syndrome (IBS). 4516
respondents (490 CD, 645 UC and 3,381 IBS) further completed a questionnaire where
they answered questions regarding their perception of their health, perception of their mental
health, and the amount of stress in their life. The data were evaluated using SAS and adjusted
for multiple comparisons with exacted Alpha/L Method. The prevalence of CD was 0.4%,
UC was 0.5% and IBS was 2.5% in the population surveyed. RESULTS: Overall, IBD patients
had similar reports of self-perceived health compared to IBS patients but there was a tendency
to report being in fair condition (p=0.01) and less often in very good condition (p=0.06).
With regards to self-perceived mental health, IBS patients were more likely than IBD patients
to report fair or poor self-perceived mental health (p=0.0002). In addition, IBS patients
were more likely than IBD patients to report that most days are quite a bit or extremely
stressful (p=0.0002). IBD alone did not significantly limit activity at home or work (OR
1.51, 95%CI 0.79-2.87) compared to patients with other chronic diseases (OR 3.95, 95%CI
3.71-4.20) but having both IBD and another chronic disease was significantly associated
with self-reported limited activity (OR 6.48, 95%CI 5.18-8.09). In contrast, IBS was not
associated with activity limitations (OR 0.40, 95%CI 0.28-0.59) and IBS combined with
another chronic disease (OR 2.53, 95%CI 2.23-2.86) offers less activity limitations than
having another chronic disease alone (OR 3.59, 95%CI (3.39-3.81). CONCLUSIONS: While
IBD is an inflammatory condition and compared to IBS more typically requires hospitalization
and even surgery, self-perceived general health was similar between IBD and IBS. The
increase in self-reporting fair health in IBD might reflect the small group with chronically
active disease. However, IBS patients report greater self-perceived stress and less mental
well being compared to IBD patients. Another interesting finding is that the addition of
another chronic disease to IBD significantly impaired the patient's activity level at home and
work. The advantage of our study is the use of a countrywide population-based database.
W1075
The Manitoba IBD Cohort Study: Fatigue, Sleep Difficulties, and Daytime
Drowsiness in a Population-Based IBD Sample
Lesley A. Graff, Norah Vincent, John R. Walker, Ian Clara, Jason P. Ediger, Linda Rogala,
Norine Miller, Cory Mcphail, Patricia Rawsthorne, Charles N. Bernstein
Fatigue is common in IBD. However, there has been little measurement of fatigue or sleep
quality in IBD and studies have used small convenience samples or unidimensional scales
of fatigue and sleep. This study reports on fatigue and sleep quality data from the Manitoba
IBD Cohort Study, a longitudinal, population-based study of multiple determinants of health
outcomes in IBD in those diagnosed within 7 years at enrolment. Methods: IBD participants
(n=356) were assessed by interview and blood sample. Fatigue, sleep quality, daytime
drowsiness, and psychological functioning were measured with validated scales. Hemoglobin
(Hb) and C-reactive protein (CRP)were measured. Differences were tested across disease
activity and disease type. Results: 52% had CD; 40% had inactive disease in the previous
6 months. 12% had low Hb, with similar rates across disease type and activity. 29% of
those with CD had high CRP vs 16% with UC (p<.01); CRP rates were similar for active/
inactive disease. Overall, fatigue subscale scores, including general fatigue, physical fatigue,
mental fatigue, reduced activity and reduced motivation, (8.3-12.2) were greater than
expected for healthy controls (6.3-7.0). General fatigue levels were similar to those with
rheumatoid arthritis, chronic liver disease, and cancer. The active disease group had higher
fatigue subscale scores (8.8-13.3), and those with inactive IBD also had higher mean fatigue
scores vs healthy controls (7.5-10.6). Regarding global sleep quality, 56% scored above the
clinical cutoff. Those with active vs inactive disease reported poorer sleep quality (8.5 vs
5.9, p <.01). The active disease subgroup had greater daytime drowsiness than those with
inactive disease (7.8 vs 6.7,p=.03), although the means for both groups were still within
the normal alert range. ANOVAs found that active disease, higher CRP, and low Hb levels
each contributed to poorer sleep quality, and greater general and physical fatigue. Fatigue,
drowsiness, and sleep quality were not differentiated by disease type. Finally, general fatigue
and global sleep quality had strong correlations in expected directions with disease-specific
QOL (IBDQ r=-.62; -.53), psychological well-being (-.66; -.47), mastery (-.35;-.27), distress
(.55; .49) and perceived stress (.55;.41). 21% of those with sleep difficulties and 19% with
significant fatigue did not have abnormal Hb/CRP or active disease. Conclusions: Active
disease is associated with greater fatigue and poorer sleep than inactive disease, although
both are still significant for many with inactive disease. Fatigue and sleep quality are closely
related to poorer psychological functioning.
W1076
The Manitoba IBD Cohort Study: The Prevalence of Psychiatric Comorbidity
in IBD
John R. Walker, Jason P. Ediger, Lesley A. Graff, Jay M. Greenfeld, Ian Clara, Patricia
Rawsthorne, Norine Miller, Linda Rogala, Cory Mcphail, Charles N. Bernstein
The presence of a chronic medical condition has been associated with higher rates of anxiety,
mood, and substance use disorders compared to the general population. Much of the
disability and functional impairment that occurs in chronic health problems is associated with
comorbidity with psychiatric disorders. Several studies reporting higher rates of psychiatric
disorders in IBD are limited by problems of inadequate comparison groups, biased samples,
and lack of appropriate diagnostic criteria. Many studies only assess major depression and
not the other common disorders seen in the community. The one published study that used
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a structured psychiatric interview (gold standard for diagnosis), used a less sensitive format
developed 25 years ago. The current study utilized the the Comprehensive International
Diagnostic Interview (CIDI), the structured psychiatric interview used most extensively in
research world-wide. Participants in the Manitoba IBD Cohort study were assessed with
the CIDI, allowing comparison to recently published prevalence rates from community
epidemiological studies in the US andCanada. The Cohort Study is a longitudinal, population-
based study of multiple determinants of health outcomes in IBD in those diagnosed within
7 years at enrolment. Methods: Participants were initially recruited from a provincial IBD
registry. They (n=352) were interviewed by clinical staff at the 2 year contact point. Results:
12 month prevalence rates determined by the CIDI were considerably higher than those
found in large scale recent representative population surveys in the United States (the
National Comorbidity Survey - Revised, NCS-R, 9,282 respondents, 2005) and in Canada
(the Canadian Community Health Survey, CCHS, 36,984 respondents, 2005) which also
used the CIDI. There were notable differences in the rates of major depression (11.4% IBD
cohort, 6.7% US, 4.8% Canada), post-traumatic stress disorder (8.0% IBD cohort, 3.5%
US), panic disorder (4.3% IBD cohort, 2.7% US, 1.5% Canada), agoraphobia without panic
(1.4% IBD cohort, 0.8% US, 0.7% Canada), specific phobia (12.8% IBD cohort, 8.7% US),
social anxiety disorder (6.0% IBD cohort, 6.8% US, 3.2% Canada). The IBD-related rates
for generalized anxiety disorder were similar to rates reported in broader community samples
(2.6% IBD cohort, 3.1% US). Conclusions: The 12-month prevalence of depressive and
anxiety disorders was higher in this community sample with IBD than in general community
samples representative of the US and Canadian populations. The presence of these comorbid
psychiatric disorders has implications for effective clinical management and quality of life
W1077
Clinical, Surgical and Genetic Risk Factors for Development of Pouchitis
Following IPAA for Ulcerative Colitis
Marc Ferrante, Sarah Declerck, Tamara Coopmans, Marie Pierik, Gert De hertogh, Paul
Rutgeerts, Gert Van assche, Andre D'hoore, Karel Geboes, Freddy Penninckx, Severine
Vermeire
BACKGROUND & AIMS: Pouchitis is the most frequent complication after ileal pouch-anal
anastomosis (IPAA) for ulcerative colitis (UC). The pathogenesis is unclear, although faecal
stasis and bacterial overgrowth are judged important etiologic factors. We therefore investig-
ated the role of microbial pattern recognition receptor genes in prediction of pouchitis after
IPAA. METHODS: A total of 132 (77 male) consecutive patients with IPAA for UC were
studied. Median (interquartile range, IQR) age at surgerywas 39.8 (31.6-47.8) years. Fourteen
percent were active smokers at surgery, while 49% percent had never smoked. Fifty-two
percent had extra-intestinal manifestations (EIM), 73% had extensive colitis, 6% had back-
wash ileitis. Surgery was performed in 1, 2 or 3 stages in, respectively, 16%, 69% and 15%
and laparoscopic assisted in 47%. All patients were genotyped by PCR-RFLP for 56 non-
synonymous polymorphisms in Toll Like Receptors (TLRs) 1-10, 3 common CARD15
mutations, TNF -G308A, CD14 -C260T and a variable number tandem repeat in intron 2
of IL1-RA. Diagnosis of pouchitis was based on clinical, endoscopic and histological criteria.
Pouchitis was defined acute relapsing if patient had 3 or more acute episodes of pouchitis;
and chronic if symptoms lasted for more than 4 weeks, despite a full dose of standard
therapy. RESULTS: With a median (IQR) follow-up of 6.5 (3.3-9.8) years, 64 patients
(48%) developed pouchitis (24 acute, 11 relapsing and 29 chronic). One patient needed
pouchectomy for pouch necrosis. Median (IQR) duration between restoration of transit and
first pouchitis episode was 12 (5-28) months. In multivariate analysis young age at surgery
(36.0 vs. 42.5 years, Odds ratio (OR) 1.04, 95% CI 1.01-1.08, p=0.015), presence of EIM
(59% vs. 38%, OR 2.25, 95% CI 1.21-5.30, p=0.014) and presence of a T allele in TLR1
S87I (57% vs. 41%, OR 2.13, 95% CI 1.02-4.45, p=0.044) were independently associated
with pouchitis, and with faster onset of pouchitis (Kaplan-Meier respectively, p=0.017, p=
0.001 and p=0.066). Chronic pouchitis was inversely associated with disease duration before
surgery (3.6 vs. 7.8 years, OR 0.91, 95% CI 0.83-0.99, p=0.036) and presence of a CD14
-260C allele (36% vs. 68%, OR 0.23, 95% CI 0.06-0.83, p=0.025). DISCUSSION: Young
age at surgery, presence of EIM and TLR1 S87I were independently associated with early
development of pouchitis in UC. Short duration of disease and presence of CD14 -260C
allele were associated with chronic pouchitis. Both TLR1 and CD14 are co-factors of the
lipopolysaccharide receptor complex and support the hypothesis that bacterial recognition
is important in the onset of this complication after IPAA.
W1078
Identification of Bacteria from Blood in Febrile Patients with Ulcerative
Colitis By Terminal Restriction Fragment Length Polymorphism Profile
Analysis of 16s Rdna Gene
Akira Harada, Toshifumi Ohkusa, Mitsuo Sakamoto, Yoshimi Benno, Kazuko Beppu,
Tomoyoshi Shibuya, Naoto Sakamoto, Sumio Watanabe
Background & Aim: Although antibiotics can bring about an afebrile state in UC patients,
blood culture is usually negative for bacteria in febrile patients with UC. Recently, highly
sensitive molecular-biological approaches using the 16S rDNA gene sequence have been
carried out for the detection of bacteria. The aim of this study was to detect bacteria in
blood using a new molecular approach. Methods: Fifteen febrile patients with relapsing UC
were enrolled consecutively at our hospital. Fifteen healthy volunteers, who were afebrile,
participated in the study as normal controls. Blood samples were analyzed for bacteremia
using nested PCR with universal bacterial primers (27F, 529F, 1492R). We investigated the
bacterial DNA by means of terminal restriction fragment length polymorphism (T-RFLP)
with five restriction enzymes (Alu I, Hha I, Hae III, Msp I, and Rsa I). Sixty-three organisms
were selected as having a high incidence of isolation from blood cultures at our hospital
and as commensal gastrointestinal bacteria. We extended the utility of T-RFLP by producing
a TRF profile database (TRFPD) populatedwith the 63 bacteria from 16S rDNA sequence data,
which were exported from the Entrez Nucleotide database (National Center for Biotechnology
Information (NCBI), USA). The prediction of T-RF lengths obtained by Alu I, Hha I, Hae
III, Msp I, and Rsa I digestion was simulated using the GENETYX-MAC program (Soft
Developing Co., Tokyo, Japan). T-RF lengths were also analysed by a T-RFLP profiler
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(MicrobiotaProfiler, Infocom Co., Tokyo, Japan). Results: The bacterial gene was detected
in 9 out of 15 UC patients (60%), showing a higher detection rate than that in healthy
controls (8/15, 53%) (not significant). The number of Hae III- and Rsa I-digested and average
number of five different restriction enzyme-digested T-RFs were significantly higher in UC
patients than in healthy controls (p = 0.0189, 0.0151, 0.0092, respectively). In UC patients,
the most prevalent species included the seven common species in healthy controls and ten
species - Corynebacterium aquatium, Enterococcus hirae, Fusobacterium varium, Helicobacter
pylori, Lactobacillus fermentum, Listeria monocytogenes, Staphylococcus aureus, Staphylococcu
epidermidis, Staphylococcu saprophyticus, and Streptococcus pneumoniae. Conclusions: In febrile
UC patients with relapse, bacteremia undetected by culture was found at high frequency
by PCR methods. Therefore, antibiotic treatment for UC can be justified on the basis of the
finding of bacteremia in this study.
W1079
Clinical Outcomes of Patients with Ulcerative Colitis and Co-Existing
Clostridium difficile Infection
Daniela Jodorkovsky, Maria T. Abreu
BACKGROUND: The incidence of Clostridium difficile (C. diff) infection has been reported
to be increasing in the United States. The aim of our investigation was to compare long-
term outcomes of patients admitted with a UC flare and co-existent C. diff to those of
non-infected patients. METHODS: A retrospective chart review was undertaken examining
admissions at Mount Sinai Hospital between June 2004-June 2005 using ICD-9 criteria for
UC. Charts were abstracted for those patients for whom C. diff testing was performed. Data
examined included: demographics, laboratory values, medications used during hospitaliza-
tion, cyclosporine use, length of stay, surgery during indexed hospitalization and year
following admission, and number of hospitalizations at Mount Sinai in the year following
admission. RESULTS: Of 288 charts reviewed, only 99 had documented testing for C. diff
and met inclusion criteria. 52 patients were C. diff negative and 47 were positive. Demo-
graphic data and laboratory values on admission did not differ between the two groups.
Patients who were C. diff positive had significantly more hospitalizations in the year following
initial admission (1.11 visits vs. 0.519 p=0.027). However, length of hospitalization stay
(11.7 vs. 11 days), necessity for cyclosporine (44.2% vs. 40.2% of patients), number of
emergent colonic resections (23% vs. 13.4% of patients), and patients requiring colectomies
in year following admission (38% vs. 25%) was numerically different between the groups
albeit not statistically different. CONCLUSIONS: Our data suggests that patients presenting
with a UC flare who are infected with C. diff have worse clinical outcomes than those that
are C. diff negative. Further studies are warranted to elucidate how infection can alter the
natural history of UC.
W1080
Spatial Clustering of Inflammatory Bowel Disease in South-Eastern Norway
During 1990-93
Geir Aamodt, Jørgen Jahnsen, Bjørn Moum, Morten H. Vatn
Research aims: To study spatial clustering of cases with inflammatory bowel disease (IBD)
and characterise municipalities with high incidences. Methods: In this study we included
patients diagnosed with inflammatory bowel disease in three counties in south-eastern
Norway during 1990-1993. The presence of spatial clusters was studied with a spatial scan
statistic (SaTScan). We conducted an ecological analysis to study the relationship between
risk of IBD in the municipalities and characteristics such as population (rural/urban, age-
and family composition), health care (number of medical doctors), and socio-economic
change. Analyses were conducted for Crohn's disease, ulcerative colitis, and both diseases
together. Results: One cluster consisting of four municipalities was identified for both diseases
in Østfold county, but this cluster was not significant (p=0.077). The risk of developing
the diseases in this high-risk area was 1.6 times the risk in the surrounding municipalities.
We found a significant cluster for women in the same region (p=0.048), but not for men.
The ecological analysis showed that the risk of IBD increased with 50% (95% CI: 10% -
220 %) for municipalities with historical large economic change, using the beta-coefficient
of tax income from the near past as a measure of economic change. The risk of IBD in the
municipalities also increased dependent on the percentage of the population living in urban
areas: For each percentage of change of the population living in urban areas, the risk of
IBD increased with 0.6% (95% CI: 0.0% - 1.1%). Conclusions: The geographic distribution
of persons diagnosed with IBD is related to economic changes within the municipalities
where the individuals are living. A hot-spot cluster was identified for women only with IBD.
It is likely that the differences in the geographic distribution are explained by social factors,
but since the potential cluster is not fully concurrent with municipalities showing social and
economic change, environmental factors as well as genetic disposition in these populations can
not be ruled out.
W1081
Nutritional Status and Growth Retardation At Diagnosis and Follow-Up in
Pediatric Crohn's Disease: A Population-Based Study
Francis Vasseur, Béatrice Merlin, Mamadou Baldé, Gwenola Vernier-massouille, Véronique
Merle, Franck Brazier, Jean-louis Dupas, Eric Lerebours, Raymond Marti, Olivier
Mouterde, Jean-louis Salomez, Antoine Cortot, Jean-frédéric Colombel, Dominique Turck,
Corinne Gower-rousseau
Introduction: Growth retardation and malnutrition are well established features of pediatric
Crohn's disease (CD). However, few data are available regarding their outcome in adulthood.
The aims of this study were 1) to look at nutritional and growth parameters from diagnosis
to maximal follow-up in a population-based pediatric cohort; 2) to determine clinical charac-
teristics associated with these parameters. Patients and Methods: In a population-based
incidence cohort diagnosed from 1988 to 2002 in Northern France (Registre EPIMAD) we
identified 472 patients with onset of CD before the age of 17 years. Height and weight were
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available at diagnosis and follow-up in 275 patients (156 boys and 119 girls) with a median
age at diagnosis of 14 years [Q1=11-Q3=16] and a median follow-up of 68 months [41-
101]. Height/age (HAZ) and BMI Z-score were determined using a reference population
(Cole, 1990). Wilcoxon test was used to compare continuous variables, paired t-test to
compare variables between diagnosis and maximal follow-up and multivariate stepwise
regression to study parameters (sex, age, disease location, BMI Z-score at diagnosis, time
between onset of symptoms and diagnosis, and follow-up duration) associated with BMI Z-
score at maximal follow-up. Results: Mean HAZ and BMI Z-score at diagnosis were -0.32±1.36
and -1.3±1.55 respectively (p<10-4, compared with reference population). Growth failure
(HAZ<-2) was present in 27 children (10%) and malnutrition (BMI Z-score <-2) in 82
(30%). At diagnosis, BMI Z-score was lower in stricturing than in inflammatory disease (-
1.6 vs -1.0; p=0.01). HAZ and BMI Z-score were not different according to age, sex, and
disease location. At maximal follow-up, mean HAZ and BMI Z-score were -0.20±1.41
and -0.59±1.43 (p=0.003 and p<10-4 respectively, compared with reference population).
Significant improvement from diagnosis to maximal follow-up was observed in BMI Z-score
(p<10-4) but not in HAZ (p=0.3). Growth failure was still present in 12 patients (4.3%)
and malnutrition in 28 (10%). HAZ and BMI Z-score at maximal follow-up were positively
correlated with the same variables at diagnosis (r2=0.72 p<0.0001 and r2=0.55 p<0.0001,
respectively). In multivariate analysis, only age at diagnosis was negatively (p=0.001) and
BMI Z-score at diagnosis was positively (p<0.0001) correlated with BMI Z-score at maximal
follow-up. Conclusions: 1) in this CD cohort, malnutrition was present in 30% of children at
diagnosis whereas growth failure was present in only 10%; 2) Only malnutrition significantly
improved during follow-up; 3) Age and BMI Z-score at diagnosis were significantly associated
with nutritional status evolution.
W1082
Pain Management -Still Insufficient in IBD
Anne Reichert, Anja Grabig, Carsten Buning, Bianca Wittig, Bertram H. Wiedenmann,
Daniel C. Baumgart, Axel U. Dignass, Andreas Sturm
BACKGROUND: Although IBD therapy has advanced in the last years, pain still restricts
the quality of life. Thus, the aim of our study was to characterize and compare the intensity
and localizations of pain in IBD patients, find triggers and assess the quality of life, in order
to optimize the pain management. METHODS: 255 adult Caucasian patients with IBD (CD=
130, UC=125; male=105, female=150) visiting several IBD out-patient clinics were evaluated
using a standardized questionnaire that assessed the frequency, severity and possible triggers
of pain episodes which were then correlated to the lifestyle. The quality of life (QoL) was
assessed by the SIBDQ. Data analysis was performed using the SPSS and tested for significance
using explorative data analyses and theMann-Whitney-U-Test. RESULTS: 90% of the patients
suffered from pain (CD 90.4%, UC 90%; male 84%, female 93%), 37.9% only during flare-
ups and 52.1% had chronic pain. 46% of the IBD patients experience arthralgia. In CD,
pain intensity was significantly higher than in UC and the pain level was significantly higher
in females than in males (p<0.005), therefore explaining that the QoL score was lower in
females than in males (p<0.001), especially in CD. Significant factors which increased pain
intensity in IBD patients and reduced the QoL were younger age, BMI<18.5, unemployment,
extra intestinal manifestation, and arthropathy. Smokers had more pain attacks than non-
smokers and the disease onset of both, CD and UC, was earlier in smokers than in non-
smokers (CD -2 years, UC -4 years), however, the SIBDQ was comparable. Steroid treatment
reduced significantly the QoL in females, but not males (p<0.005), whereas in contrast, the
QoL was higher in patients treated with azathioprine compared to patients without azathiop-
rine (p<0.05), regardless their gender. 30% of the patients received analgesic treatment.
However, regardless if treated with metamizole or opioids, their mean pain intensity was
still significantly higher and the QoL lower than in patients without analgesic treatment
(p<0.05). CONCLUSION: Pain is an overwhelming problem which dramatically reduces
the QoL in IBD patients. Pain levels are dependent on many factors and improving the
mucosal inflammation does not necessarily increases the QoL. Pain therapy in IBD seems
to be difficult and is often insufficient, forcing the need to improve the QoL by a more
intensified, individualized, and optimized pain management in IBD.
W1083
The Influence of Active Smoking, Passive Smoking and Smoking Cessation On
the Disease Course and Behaviour of Inflammatory Bowel Disease
Frans Van der heide, Arie Dijkstra, Rinse K. Weersma, Frans Albersnagel, Wim J. Sluiter,
Jan H. Kleibeuker, Gerard Dijkstra
Smoking has a remarkable opposite effect on Crohn's disease (CD) and ulcerative colitis
(UC). The effects of smoking are modulated by gender, genetic background, disease location
and activity, and cigarette/nicotine dose. In this study we studied the influence of smoking,
passive smoking and smoking cessation on both the disease course and disease behaviour
in a Dutch university hospital IBD population.Methods: Medical charts were reviewed of
864 patients concerning smoking behaviour, drug treatment, surgery, hospitalisations, extra-
intestinal manifestations, family history, disease location and disease behaviour at diagnosis
and end of follow up. In addition patients received a detailed questionnaire concerning
smoking. Results: At the end of follow up (median 9 years) of the 864 patients (490 CD,
354 UC), 24 (3 %) were deceased and 693 (82.5%) responded to the questionnaire. At
diagnosis smoking CD patients had a later onset of disease (> 40 y: 23.2 % vs. 13.4
%;p<0.001) and a lower education level (26.8% vs. 9.7 %;p<0.001); smoking UC patients
also had a later onset of disease (> 40 y: 20.7% vs. 12.7 %;p<0.05) than UC patients that
never smoked. At the end of follow up smoking CD patients had more surgery (63.1% vs.
57.5%; p<0.02) but no differences in other outcome parameters compared to CD patients
who never smoked or stopped smoking. Smoking UC patients had less hospitalisations (0.88
vs. 1.13;p<0.001), a lower colectomy rate (14.6 vs. 27.8%;p<0.02) and less PSC (2.4 vs.
12.7 %;p<0.005)) but pouchitis was more frequent (100 % vs. 60 %;p<0.03) than in UC
patients who never smoked. In UC 29.3 % had stopped smoking before diagnosis vs. 12.7
% of CD patients. The diagnosis changed smoking behaviour in 44.5 % CD and 22.2 %
UC patients. However, smoking cessation (13.4 % vs. 9.0 %) and stop plans (89.3 % vs.
88.8 %) were not different between CD and UC patients respectively. Passive smoking CD
patients needed more frequently immunosuppressants (67.9 % vs. 49.2 %;p<0.04) and
infliximab (28.6 % vs. 10.8 %;p <0.01) and passive smoking UC patients had more backwash
ileitis (16.3 % vs. 4.1 %;p <0.02).Conclusion: We showed a detrimental effect of active
(increase in surgery and hospitalisations) or passive smoking (use of immunosuppressants
and infliximab) in CD. Except for the development of pouchitis and backwash ileitis, active
or passive smoking had beneficial effects (less colectomy, hospitalisations and PSC) in UC.
Although 89 % of IBD patients have smoking cessation plans only 11.2 % quit smoking.
Tailor made smoking cessation programs and basic research concerning the underlying
beneficial molecular mechanism of smoking in UC patients are needed.
W1084
Colorectal Neoplasia in Patients with Crohn's Disease - A Retrospective Age
Matched Cohort Analysis -
Arthur Hoffman, Luara Kuehlewein, Peter R. Galle, Markus Neurath, Ralf Kiesslich
Background: Recent data indicates that Crohn's colitis is associated with an increased risk
for colorectal cancer. Possible risk factors are young age of onset, extend and duration of
disease. Thus, aim of the current study was to evaluate the prevalence of (pre)neoplastic
colonic lesions in patients with Crohn's disease (CD). Method: Consecutive patients with
histologically and clinical proven CD and complete colonoscopy with targeted and random
biopsies were identified from an endoscopic database (University of Mainz; 1/2000-11/
2006). Colonoscopic and histological findings were compared with age matched controls
(exclusion criteria; IBD, familiar cancer) undergoing screening colonoscopy based on the
national screening programme for colorectal cancer. Furthermore, clinical characteristics of
CD patients were analyzed (onset, symptoms, extend) and the amount of colonoscopies per
patient in both groups. Chi square analysis was used comparing both groups. Results: 287
patients with CD were identified (age 18-86; colitis 41%; ileocolitis 24%; colon resection
29%; others 6%) and matched with 5127 screening patients. The amount of colonoscopies
(per lifetime) was significant higher in the CD group with polyps (2.3/per patient) compared
to the control group (1.2/per patient) [p<0.0001], 20/287 (7%) patients (age 35-72) with
CD showed polypoid changes. Targeted biopsies revealed low grade dysplasia in 5 (1.7%)
and non-neoplastic changes in 15. In contrast polypoid lesions were seen in 11% (566/
5127) in patients undergoing screening colonoscopy and 5.7% showed neoplastic changes
(291/5217), including 264 low grade, 11 high grade dysplasias and 16 cancers. CD patients
compared with age matched controls showed significant lower dysplasia rates (p<0.001).
Multivariate analysis showed no differences for the presence of dysplasia in CD concerning
location, extend and duration of inflammation. Conclusion: Dysplasia in patients with Crohn's
disease occurs less frequent compared to the age matched control population. No difference
was seen for the presence of dysplasia in respect to duration, localisation and extend of
inflammation. This finding is in contradiction to previous reports and might be caused due
to more frequent colonoscopies in patients with CD compared to the normal population.
W1085
Outcome of Clostridium difficile Infection in Patients with Ulcerative Colitis
Revital Kariv, Yehuda Kariv, Aaron Brzezinski, Jean-paul Achkar, Rocio Lopez, Bret A.
Lashner, Bo Shen
Background: Clostridium difficile (C diff) infection is becoming more prevalent and may lead
to adverse clinical outcome. C diff infection may exacerbate clinical course of active Ulcerative
colitis (UC). However, the association between C diff infection and clinical outcome of UC
has not been well studied. Aim: To identify risk factors for C diff infection in patients with
UC, and to assess outcome of UC in patients with C diff infection. Patients and Methods:
Patients with UC, who had positive results for C diff ELISA test during 2000-2006, were
identified and matched for age and gender to UC patients who had a negative C diff test
and have never been diagnosed with C diff infection. Records were reviewed for clinical
outcome, defined as colectomy within 3 months of C diff testing, and for 38 clinical
parameters. Conditional logistic regression was used to analyze univariable and multivariable
associations of interest. A final multivariablemodel was selected by stepwise selectionmethod.
Results: A total of 78 subjects were analyzed (39 C diff positive),60% were males. Median
age was 39. There was no mortality in either group. Among patients with C diff infection,
50% failed treatment with the first antibiotic course, and 20.5% had recurrent infection.
Table 1 lists potential risk factors for C diff infection in UC pts. In addition, C diff infection
was not associated with any IBD medication in univariable analysis. Colectomy rates within
3 months of C diff testing were 12/39(30.7%) for the C diff positive group, and 13/39(33.3%)
for the negative group (P=0.75). Adjusting for C. diff, lack of 5ASA use and fulminant colitis
were significantly associated with colectomy with odds ratio of 2.8(95% CI: 1.03, 8.0) and
4.4(95% CI: 1.1, 17.3), respectively. Conclusions: C diff infection in UC patients is associated
with recent admission or antibiotic use. C diff infection does not adversely affect clinical
outcome (i.e. need for colectomy) in UC patients.
Table 1
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Ulcerative Colitis: Risk Factors and Characteristics of Disease Progression
María josefina Etchevers, Montserrat Aceituno, Miquel Sans, Josep m Piqué, Elena Ricart,
Julián Panés
AIM: The main objective of this study was to identify risk factors of progression in distal
ulcerative colitis and establish distinct characteristics between ulcerative colitis with progres-
sion and stable forms of distal and extensive ulcerative colitis. The secondary objective was
to determine the clinical characteristics of disease flare at the time of progression. PATIENTS
AND METHODS: Clinical and demographical data were obtained from a prospectively
established database. Distal colitis was defined as disease limited to rectum and sigmoid
colon (n=176), extensive colitis as disease affecting at least the descending colon at the time
of diagnosis (180) and colitis with progression when there was a change of category from
distal to extensive colitis (63). To study clinical characteristics at the time of progression,
a nested case-control study was performed. Controls paired by age at diagnosis, sex and
disease duration were choosen from the extensive colitis group. RESULTS: Comparison
between distal colitis and colitis with progression demonstrated that both groups were
similar in predominance of female sex, age at diagnosis, family history, tobacco history and
apendectomy. Compared to distal colitis, progressive colitis was associated to high prevalence
of extraintestinal manifestations (36.5%vs 14.9%; p<0.05), therapeutic requirements includ-
ing thiopurines (44.3%vs 17.3%; p<0.05), cyclosporine (26.2%vs 1.9%; p<0.05), infliximab
(9.5 % vs 1.2%; p<0.05)and surgery (20.6% vs 0.6%; p<0.05), and neoplasia (6.3% vs 0%;
p<0.05). However these differences appeared only after progression. Comparison between
colitis with progression with extensive colitis since diagnosis, showed a higher predominance
of female sex (0.7% vs 34.4%; p<0.05) and more frequent family history in the first group
(12.7% vs 4.5%; p<0.05). The nested case-control study showed that at the time of progres-
sion the flare was considerably more severe in cases than in controls in terms of hospital
admission, hospital stay, biomarkers of disease severity (CRP, ESR and albumin), stool
number, steroid refractoriness and dependence and surgery requirements. CONCLUSIONS:
Ulcerative colitis with progression from distal to extensive disease follows a more severe
course than distal colitis but similar to extensive colitis since diagnosis. No clinical factors
predictive of progression were identified, however, at the time of progression, disease is
particularly severe.
W1087
Hospitalizations and Inpatient Corticosteroid Usage Among Ulcerative Colitis
Patients from Olmsted County, Minnesota, 1970-2001
Steven B. Ingle, Edward V. Loftus, William S. Harmsen, Alan R. Zinsmeister, William J.
Tremaine, William J. Sandborn
BACKGROUND: Ulcerative colitis (UC) contributes significantly to health care costs and
resource utilization. Hospitalizations for disease flares, complications, and surgeries are
common. Despite recent therapeutic advances, hospital admissions for UC appear to be
increasing. METHODS: We have previously identified all Olmsted County residents dia-
gnosed with UC between 1970 and 1999. We identified all UC-related hospitalizations that
occurred in these patients (pts) from UC diagnosis through 2001. Overall proportions of
pts hospitalized, rates of hospitalization per 1000 pt-yrs and cumulative incidence to first
hospitalization were estimated. Cox proportional hazards regression was used to assess the
association of clinical and demographic features with time to first hospitalization. RESULTS:
A total of 270 UC pts (58% males) were followed for 3,548 person-yrs (median follow-up
per pt, 12.3 yrs [range, 0.3-31 One-hundred fourteen pts (42%) were hospitalized at least
once during the follow-up period for a total of 301 hospital admissions, 33% of which were
surgical. The crude incidence rate was 85 admissions per 1,000 pt-years. Forty-three patients
(16%) required hospitalization within 30 days of diagnosis. One patient required surgery
at the time of diagnosis. For pts hospitalized at least once, the median time to first hospitaliza-
tion was 27 months (0-308), with a median of 2 (1-28) hospitalizations per pt. Fifty-four
percent required re-hospitalization within 5 yrs. The median length of stay for medical
hospitalizations was 8.6 days (2-368). Pts with extensive disease were nearly twice as likely
to be hospitalized compared to those with left sided involvement or proctitis: the 10-yr
cumulative risk of hospitalization was 49% in those with extensive disease vs. 33% and
29%, respectively, for left-sided disease and proctitis. Age at diagnosis, gender, and decade
of diagnosis were not associated with time to first hospitalization. Crude hospitalization
rates (per 1000 pt-yrs) were 124 for 1970-80, 104 for 1980-1990, and 71 for 1990-2001.
Corticosteroids were given during 53% of UC-related hospitalizations, and 33% of these
pts required more than one hospitalization for inpatient steroids. CONCLUSION: In this
population-based cohort, 42% of the pts were hospitalized at least once between 1970 and
2001. Hospitalizations decreased over the past three decades. UC hospitalizations average
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8.6 days, occur later in disease course compared to CD, and frequently involve administration
of corticosteroids (53%). Extensive disease increases the risk of hospitalization. These data
highlight the disease burden of UC in the community.
W1088
Hospitalizations and Inpatient Corticosteroid Usage Among Crohn's Disease
Patients from Olmsted County, Minnesota, 1970-2001
Steven B. Ingle, Edward V. Loftus, William S. Harmsen, Alan R. Zinsmeister, William J.
Tremaine, William J. Sandborn
BACKGROUND: Crohn's disease (CD) contributes notably to health care costs and resource
utilization. Hospitalizations for disease flares, complications, and surgeries are common.
Despite recent therapeutic advances, national data suggest that hospital admissions for CD
may be increasing. METHODS: We previously identified all Olmsted County residents
diagnosed with CD between 1970 and 1999. We identified all CD-related hospitalizations
that occurred in these patients (pts) from CD diagnosis through 2001. Overall proportions
of pts hospitalized, rate of hospitalizations per 1000 pt-yrs, and cumulative incidence to
first hospitalization were estimated. Cox proportional hazards regression was used to assess
the association of clinical and demographic features with time to first hospitalization.
RESULTS: A total of 234 pts (49% males) were followed for 2,974 person-yrs (median
follow-up per pt, 10.9 yrs [range, 0.15-31.5]). One-hundred sixty-one pts (69%) were
hospitalized at least once for a total of 564 hospital admissions, 39% of which were surgical.
Crude incidence rate was 190 admissions per 1,000 pt-yrs. For pts hospitalized at least
once, median time to first hospitalization was 1.2 yrs (0-29.8) with a median of 2 (1-22)
hospitalizations per pt. Eighty-two pts (35%) were hospitalized at time of diagnosis +/- 30
days. Thirty-five pts (15%) required surgery at the time of diagnosis. Sixty percent required
re-hospitalization within 5 years. Median length of stay was 8 days (1-376). Having small
bowel or ileocolonic disease increased the chance of hospitalization two-fold compared to
colonic disease: the 10-yr cumulative risk of hospitalization among pts with small bowel
and ileocolonic extent was 81% and 74%, respectively, vs. 50% in pts with colitis. Age at
diagnosis, gender, and decade of diagnosis were not associated with time to first hospitaliza-
tion. Crude hospitalization rates (per 1000 pt-yrs) were 315 for 1970-79, 222 for 1980-
89, and 144 for 1990-2001. Corticosteroids were given during 50% of hospitalizations, and
35% of these pts required more than one hospitalization for inpatient steroids. CONCLU-
SION: In this population-based cohort, nearly 70% of pts were hospitalized at least once
between 1970 and 2001. Hospitalization rates decreased over the past three decades, but
time to first hospitalization did not change. CD hospitalizations average 8 days, frequently
occur at diagnosis or early in disease course, and frequently involve administration of
corticosteroids (50%). Small bowel and ileocolonic disease increase the risk of hospitalization.
These data highlight the need for early aggressive therapy in CD.
W1089
Behavior and Location Phenotypes But Not Patient Age Drive Health Care
Costs in Crohn's Disease. A European Collaborative Study Based On the
Montreal Classification
Selwyn H. Odes, Hillel Vardi, Michael Friger, Frank Wolters, Pia Munkholm, Bjorn
Moum, Reinhold W. Stockbrugger
BACKGROUND: In an era of increasing constraints on health budgets, economic analysis
of chronic diseases is required for proper allocation of resources per welfare economics. We
have previously reported a 10-year cost-analysis of Crohn's disease (CD) in a multi-national
community-based prospectively incepted cohort defined by strict and uniform diagnostic
criteria (Gastroenterology, 2006). AIM: To determine whether the phenotype of CD affects
health care cost. METHODS: Clinical and economic data were obtained from patients and
their physicians from centers in Denmark, Greece, Ireland, Israel, Italy, Netherlands, Norway,
Portugal and Spain. The Montreal classification (ALB) of phenotypes in CD was applied.
Variation in estimated prices of utilities across countries was minimized by applying the
median purchase prices (2004 values) to all centers. Outcomes are expressed as mean Euros/
patient-phenotype-year. RESULTS: There were 425 Crohn's disease patients in the cohort,
with 10 year follow-up. The total cost of health care for inflammatory (B1), stricturing (B2),
penetrating (B3) and penetrating with perianal fistula (B3p) was 1971, 2443, 4128 and
3757 respectively (P<001). The corresponding cost for surgery (including hospitalization)
was: 251, 884, 1704 and 1428 (P<.001). By Scheffe test B1 and B2 were not different (P=
.13), and B3 and B3p were not different (P=.80). There was a similar trend of cost for
medical hospitalizations, diagnostics and drug usage. By the disease location phenotype (L),
colon, ileum, ileo-colonic and “upper GIT + other locations” respectively had the following
total health care costs: 2066, 2218, 2303 and 2132 (P=.61); and the following surgical
costs: 247, 654, 564 and 657 (P<.001). Division of the patients by age (A) categories revealed
lower total and surgical costs in the older patients (>40 years at disease onset), but P=ns.
CONCLUSIONS: In this CD cohort, the cost of total health care was driven by the behavior
phenotype, and the surgical cost by behavior and location phenotypes; there was no effect
from patient age. In this economic analysis, the Montreal classification of perianal fistula as
a separate entity from penetrating disease was unhelpful as a predictor of health care cost.
W1090
Despite Active Surgical Approach in Inflammatory Bowel Disease, Primary
Sclerosing Cholangitis Remains a Risk Factor of Colorectal Neoplasia
Harry Sokol, Jacques Cosnes, Olivier Chazouilleres, Laurent Beaugerie, Emmanuel Tiret,
Raoul Poupon, Philippe Seksik
Background and aims: Inflammatory bowel disease associated with primary sclerosing cholan-
gitis (PSC-IBD) may have a distinct IBD phenotype and a high risk of colorectal cancer
(CRC). The increased risk of CRC in IBD may be lowered by early colectomy in refractory
disease [1], however it is not known whereas such a strategy is efficient in PSC-IBD. The
aim of this study was to evaluate the risk of CRC in PSC-IBD in the setting of an active
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surgical approach. Methods: Clinical, endoscopic, histological and outcome informations
from all patients with IBD and concomitant PSC evaluated at the Saint Antoine hospital
between 1963 and 2006 were collected. A control group, matched to sex, birth date, IBD
diagnosis date and initial disease location consisted, in IBD patients without PSC (2 controls
for 1 case). The cumulative risk of colorectal neoplasia and CRC was calculated using Kaplan-
Meier survival curves after censoring observations at the time of proctocolectomy. Search
for risk factors for CRC was performed using logistic regression. Results: There were 75
PSC-IBD patients (41 males), with a mean age at PSC diagnosis of 36 years. Follow up after
IBD diagnosis was longer in PSC-IBD than in controls (mean, 172 vs 132 months, p=0.02).
In PSC-IBD, rectal sparing and backwash ileitis were observed in 20% and 19% respectively.
Compared to controls, PSC-IBD patients were less often admitted to hospital (6 vs. 12 %
of patient-years, p<0.001), received more 5-ASA (8.7 years/patient vs 2.9 years/patient,
p<0.0001), required less immunosuppressants (24 vs 46% at 10 years ; p<0.001) and less
ileal and/or colonic excisional surgery (10 vs 44% at 10 years, p<0.001). The 25-year
cumulative rate of colectomy was 20% in PSC-IBD and 31% in controls (p=0.002). The 25-
year cumulative incidence of colorectal neoplasia and CRC were 16 and 13%, respectively,
in PSC-IBD. These features were significantly higher than in controls (neoplasia, 1.5%, p=
0.02; CRC, 0%, p=0.01). On the total cohort, CSP was the only independent risk factor
found for the development of CRC, with an Odds Ratio of 7.9 IC 95% (2.67-23.33). Overall
survival without liver transplantation was reduced in PSC-IBD patient with a 25-year survival
rate since the diagnosis of IBD of 67.5 % in PSC-IBD group vs 91.2% in the control group;
p,0.001. Conclusion : An active surgical approach, although very efficient to decrease the
risk of CRC in IBD patients without PSC, does not preclude CRC in patients with PSC-IBD.
In those patients, the risk of CRC is higher despite lower disease activity and larger use of
5-ASA. Alternative measures of prevention and surveillance are needed. [1] Winther KV et
al. 2004
W1091
Changes in Serum Creatinine During short and Long Term Exposure to
mesalamine Therapy
Seymour Katz, William J. Sandborn, Simon H. Magowan, David L. Ramsey, Simon Travis
Background: Renal disorders are a potential rare adverse effect of all mesalamine-based
products. Renal impairment may also be an extra-intestinal manifestation of IBD in the
absence of treatment with mesalamine-based drugs. Objective: To assess the renal safety of
delayed release mesalamine in ulcerative colitis patients by determining the change from
baseline serum creatinine in relation to cumulative drug exposure. Methods: This analysis
was a retrospective cohort study of 1,461 ulcerative colitis patients, aged 9-99 years, receiving
daily doses of delayed release mesalamine between 0.4 g and 7.2 g in an open label,
compassionate use study for up to 8 years. Baseline creatinine clearance (CrCl) was estimated
using Cockcroft-Gault methodology. Estimated renal function was based on FDA classifica-
tion criteria; normal (≧80ml/min), mild impairment (≧50-<80ml/min), moderate impair-
ment (≧30 - <50ml/min). Mean change from baseline serum creatinine according to cumulat-
ive dose and CrCl classification using the last recorded serum creatinine level for each patient
were calculated. Results: There was no observed deleterious effect on mean change from
baseline on serum creatinine according to cumulative dose of mesalamine (up to 12,000g),
or baseline creatinine clearance (Table 1). Conclusion: Mesalamine therapy in ulcerative
colitis patients with normal renal function and mild and moderate renal insufficiency resulted
in no meaningful mean changes of serum creatinine over a range of cumulative doses.
Table 1: Serum Creatinine Change from Baseline (mg/dL) According to Baseline CrCl and
Cumulative Drug Exposure
*median time from first drug dose in days to final serum creatinine value
W1092
Inflammatory Bowel Disease Occurring Before and After Liver Transplantation
Raja Tamaz, Etienne Nadeau, Mikael Bouin, Denis Marleau
Background: Previous reports investigating the clinical course andmanagement of inflammat-
ory bowel disease (IBD) after orthotopic liver transplant (OLT) have revealed conflicting
results. Others have described patients who developed IBD after transplantation despite
immunosuppression. Objectives: To determine the natural history of IBD in pateints with
liver transplant. Methods: Retrospective analysis of the data regarding IBD and liver trans-
plantation in our university transplantation center. We reviewed the records of 24 patients
who underwent OLT between 1984 and 1999 and who had diagnosis of IBD. The diagnosis
was made prior to OLT in 18 patients; 14 had history of ulcerative colitis (UC) and 4 had
Crohn's disease. Of this group of patients 13 had primary sclerosing cholangitis, 2 had auto-
immune hepatitis, one had liver granulomatosis, one had sickle cell disease and multiple
hepatholithiasis and the other had mixed PSC and AIH. Six patients developed IBD after
OLT: UC in 2 patients and Crohn's disease in 4 patients. Mean follow-up after OLT was
59 months. Results: IBD course after OLT was the same in 11 patients (61%), worse in 6
patients (33%) and better in one patient. It remained quiescent in 11 and worsened in 3
of the 14 patients with pre-transplant quiescent course, whereas it worsened in 3 patients
of the 4 with pre-transplant active course. Four of the 6 patients with a post-transplant
active course became steroid dependant; one of them had curative surgery. Average time
to exacerbation post-OLT was 19 months. All of them where still on steroid on the time of
exacerbation. Of the 6 patients with de novo IBD, 4 had aggressive course with the need
to add new immunomodulatory drugs, 2 became steroid dependant, and one of them had
curative surgery. Conclusion: Immunosuppression including steroid in the post-transplant
setting does not prevent exacerbation of IBD. In our study, globally one patient out of three
had a worse IBD clinical course post-transplant. De novo IBD may develop post-OLT, with
a more aggressive course needing new immunomodulatory therapy or surgery.
W1093
Infliximab Use in Children with Crohn Disease: Relationship to
Immunomodulator Therapy
Jeffrey Hyams, Subra Kugathasan, Trudy Lerer, Anne M. Griffiths, Anthony Otley, Marian
D. Pfefferkorn, M. susan Moyer, Neal S. Leleiko, Jonathan S. Evans, David R. Mack,
Robert Wyllie, Joel R. Rosh, James F. Markowitz
Background/Aim: The development of a rare form of T-cell lymphoma in young patients
with Crohn disease (CD) treated with infliximab (IFX) and immunomodulator (IM) therapy
has prompted re-examination of the need for dual therapy in optimizing patient outcomes.
We compared the outcome of children enrolled in a prospective observational registry
who were treated with IFX and IM, particularly focused on those switched from dual to
monotherapy. Methods: Since 2002 the Pediatric IBD Collaborative Group Registry has
prospectively enrolled children ≤16 yr of age newly diagnosed with IBD in a natural history
study at 20 centers. All patients are managed according to the dictates of their physicians,
not by standard protocols. Data on subjects receiving IFX/IM and their outcomes were
identified. Patients receiving IFX were classified as CM (continuous maintenance), EPIS
(episodic), or DIS (IFX therapy stopped) as of the database lock on 9/1/06. Results: 588
children with CD (mean age 11.8±2.8 yr) have been entered in the Registry. 159 (19%)
received IFX and all but 2 also received IM that were started at the following times in
relation to IFX: ≥3 mon before 55%, 2-3 mon before 7%, concomitantly in 33%, after in
4%. Outcomes were examined in the 113 IFX treated subjects with ≥1 yr follow-up since
first IFX infusion. Comparing those who started IM at least 2 mon before IFX with those
who started IM and IFX concomitantly, no differences were found in the ability to stop
corticosteroids (CS) within 3 mon of IFX (84% vs. 68%), need for repeat CS during follow-
up (15% vs. 19%), % patients becoming and staying inactive/mild (66% vs. 63%), %
hospitalized (27% vs. 30%), or % needing surgery (11% vs. 14%). 77 (68%) were CM, 7
(6%) EPIS, and 29 (26%) DIS. Reasons for stopping IFX were elective (17), loss of effect
(4), primary non-response (3), allergy (3), and other (2). Among the 17 in whom IFX was
electively stopped, 14 (83%) remained inactive/mild on IM therapy alone (median follow-
up 2 years). There were no obvious differences in outcome after stopping IFX based on
when IM was started in relation to IFX. For the 6 patients who continued IFX but stopped
IM (all on IM≥3mon prior to IFX), 3 remained inactive/mild while 3 became moderate
(median follow-up 1.5 years). Conclusion: Step-down from dual therapy (IFX/IM) to mono-
therapy (IM or IFX alone) was uncommon. However, in the subgroup of patients in whom
IFX was electively stopped and IM continued, the majority of patients did well. To date
only a small number of patients have discontinued IM and continued IFX and a larger
experience will be necessary to assess outcomes in that group of patients.
W1094
The Mode of Delivery in Females with Crohn's Disease
Marieke Smink, Lisette Albers, Zohra Nawabi, Fred K. Lotgering, Dirk j De jong
Background: Crohn's disease is frequently diagnosed at young age and perianal fistulae will
develop in up to one third of patients. For females in the reproductive years, this could be
a problem when giving birth to a child. Studies about perianal disease and delivery mode
are scarce and small numbered. Although the evidence is weak, elective cesarean section
(CS) is frequently recommended in pregnant women with Crohn's disease. In this retrospect-
ive cohort study we examined the rate of CS with respect to disease characteristics and the
effects of the mode of delivery on the course of Crohn's disease. Methods: All female patients
aged 18-80 years with Crohn's disease from our IBD database and obstetric database were
eligible for the study. A questionnaire was sent to all these patients, which contained questions
about disease characteristics and the current situation. In case of a positive history for
pregnancies, a second part contained questions about the pregnancies and the course of
Crohn's disease. After 3 months, a reminder was sent to non responders. Data obtained
where collected in a database and SPSS software version 12.0 was used for analysis. Results:
From 398 questionnaires, 307 patients responded (77%), but 7 patients gave no consent
for different reasons. Therefore, 300 questionnaires were analysed. At time of the study, 95
(32%) women had never been pregnant, 53 were diagnosed with Crohn's disease after their
latest pregnancy and 152 (51%) had at least one pregnancy after the diagnosis of Crohn's
disease. Questionnaires were complete in 140 of 152 women with a positive history for
pregnancies during Crohn's disease. From these 140 women the first reported pregnancy
was analysed and 24 of them (17%) reported active symptoms of Crohn's disease at the
onset of pregnancy. In total 43 CS (31%) were performed and 25 of the CS were preventive
advises. In the 61 patients known with fistulae, the rate of CS was even higher (44%). In
27 of 97 patients with vaginal deliveries a forceps of vacuum was needed and in 67 patients
an episiotomy was performed. Within 6 weeks after delivery, 97 women (69%) reported
no worsening of disease and 23 (16%) had increased abdominal symptoms without significant
differences between the mode of delivery. In 3/97 females (3%) worsening of fistulizing
disease was reported after vaginal delivery compared with 5/43 females (12%) after CS.
Conclusion: Cesarean section in Crohn's disease is more frequent compared with numbers
from the general population in the Netherlands and even more frequent in fistulizing disease.
After vaginal delivery, 3% of females reported worsening of fistulae compared with 12%
after CS.
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Alterations of Enteric Glial Cells in Inflammatory Bowel Disease
Yann Touchefeu, Arnaud Bourreille, Mathurin Flamant, Damien Masson, Claudine
Azoulay, Jean-paul Galmiche, Michel Neunlist
Introduction : Enteric glial cells (EGC) represent a major component of the enteric nervous
system. Under physiological conditions, EGC have been shown to modulate both intestinal
permeability and cell proliferation. In animal model, selective EGC ablation results in severe
intestinal inflammation. S100b is secreted by glial cells and is commonly used as a marker
of EGC, but its role in the regulation of intestinal epithelial barrier remains unknown. Our
aim was to characterize mucosal EGC network in Crohn's disease (CD) and to evaluate the
effect of EGC and S100b on intestinal epithelial permeability. Materiel and Methods : Colonic
biopsies and serum samples were collected from patients with CD or healthy subjects.
Mucosal glial network was assessed by immunohistochemistry using anti-S100b antibodies.
Colonic mucosal S100b secretion was measured by ELISA following a 3-hour organoculture
of biopsies. S100b serum levels were measured by electrochemoluminescence in 35 CD
patients at different phases of their disease and in 27 healthy subjects. In 23 patients with
active CD, S100b serum concentrations were measured before and after infliximab therapy.
Effect of 10 nM S100b on intestinal permeability to sulfonic acid-FITC was mesured in
mini-Ussing chambers. Results : S100b staining was decreased in colonic inflamed areas
(n=3) in CD patients compared to non-inflamed areas (n=3) and to healthy subjects (n=3).
Secretion of S100b was decreased by 33% in biopsies of inflamed areas (n=5,) and by 46%
in non-inflamed areas (n=5), as compared to controls (n=5) (P=0.04 and P=0.02, respectively).
Serum S100b levels were also decreased in patients with active CD as compared to patients
in remission and healthy subjects (P<0,05). Following infliximab therapy, S100b serum
levels increased in clinical responders (n=19, P=0.001) but failed to increase in non responders
(n=4). Ex vivo, 10 nM S100b decreased by 30% colonic permeability to sulfonic acid (n=
5, P=0.138). Conclusion : Our results show that S100b levels are decreased in both inflamed
and non inflammed areas in CD. These alterations could be involved in the impaired
intestinal permeability observed in CD. Whether serum S100b could be used as a predictor
of therapeutical response to infliximab should be further assessed. This study was partially
supported by Schering Plough (BREMICI grant).
W1096
Prevalence and Management of Comorbid Depression in Inflammatory Bowel
Disease (IBD)
Murtaza Arif, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Mazen Issa, Jeanne Emmons,
Sarah Lundeen, Mary F. Otterson, David G. Binion
INTRODUCTION: IBD is a chronic illness with debilitating symptoms, including some with
considerable social stigma. IBD patients are at risk for behavioral and emotional dysfunction
leading to depression. We determined the prevalence of clinical depression in IBD patients
in the present age of immunomodulator and biologic therapy, investigating the factors
associated with psychological distress in IBD and characterized the use of antidepressant
medications. METHODS: This was a retrospective observational study of all IBD patients
(n= 925) followed in a tertiary referral center over a 5-year period. Incident depression was
defined as a physician diagnosis of major depression or the initiation of antidepressant
treatment. Demographic information, type of IBD (Crohn's Disease (CD) or ulcerative colitis
(UC), class and number of antidepressant medications used, and factors associated with
stress in IBD including hospitalizations, surgeries and disability were recorded for analysis.
RESULTS: Depression was identified in 191 out of 925 patients (20.7%) with IBD. 143 of
667 (21.4%) CD patients had depression as compared to 48 of 258 (18.6%) UC patients.
Prevalence of depression was 14.7% (61/414) in males versus 25.4% (130/511) in females
(p<0.001). 177 patients (92.7%) diagnosed with depression were using antidepressant med-
ications including 21 patients (10.9%) who were using more than one medication. There
were 14 patients (7.3%) who had a diagnosis of depression but were not on antidepressant
medication. Among IBD patients taking antidepressant medications, 124 (64.9%) were using
Selective Serotonin Reuptake Inhibitors (SSRIs). 74 patients were using other pharmacologic
agents including bupropion (n=27), venlafaxine (n=25), amitriptyline (n=11), mirtazapine
(n=8) and trazodone (n=3). Among patients with depression, 135 out of 191 patients (70.7%)
had documented hospitalizations directly related to the clinical course of IBD. 104 of these
191 patients (54.5%) patients had a history of IBD-related surgery, and 21 patients (10.9%)
were on disability as a consequence of debilitating symptoms secondary to IBD. CONCLU-
SIONS: The prevalence of depression is elevated in patients with IBD at the present time,
with 1 in 5 IBD patients diagnosed with depression. Women with IBD had higher rates of
depression than men. Screening for depression in IBD population is warranted because it
can help to improve the quality of life for these patients.
W1097
The Development of Fistulizing and Fibrosing Complications of Crohn's
Disease in a Pediatric Cohort
Neera Gupta, Melvin B. Heyman, Alan G. Bostrom, Harland S. Winter, Robert N.
Baldassano, Stanley A. Cohen, Benjamin D. Gold, Robert A. Cannon, George D. Ferry,
Barbara S. Kirschner
Background: Studies that document the development of fistulizing and fibrosing complica-
tions over time in children with Crohn's disease are lacking. Methods: Data stored in
the Pediatric IBD Consortium Registry were analyzed to determine the development (i.e.,
cumulative incidence) of fistulizing and fibrosing complications in 989 patients (43% female,
83% Caucasian), diagnosed with Crohn's disease at 0-17 years of age between 1979-2003.
Results: Mean age at diagnosis was 11.5 ± 3.8 yrs. Median follow-up time was 2.8 yrs
(range 1 day-16.7yrs). The cumulative incidence of development of fistulas, strictures and
abscesses increased from about 3% in the first year after diagnosis to more than 20% by
10 years and over 40% by 15 years after diagnosis. (see Table; N=total with reported
complications) Conclusions: The development of fistulizing and fibrosing complications of
Crohn's disease is common in patients diagnosed during childhood. Identifying risk factors
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for the development of these complications could facilitate new strategies for the earlier
institution of more aggressive medical management in targeted populations to improve
outcomes. Supported in part by grants from the NIH (DK007762, DK064544 and DK060617)
and the CCFA.
Cumulative Incidence (95% CI) of Disease Complications
Year(s) refers to time after diagnosis
W1098
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong
District, Seoul, Korea, 1986-2005: A Kasid Study
Suk-kyun Yang, Sungcheol Yun, Jin-ho Kim, Joon yong Park, Hak yang Kim, Young-ho
Kim, Dong kyung Chang, Joo sung Kim, In sung Song, Jong beom Park, Eui-ryun Park,
Kyung jo Kim, Gyoo Moon, Soo hyun Yang
Background and Aims: Ulcerative colitis (UC) and Crohn's disease (CD) are regarded as
rare diseases in developing countries, but accurate data are generally lacking. We performed
the present study to evaluate the incidence and prevalence of UC and CD in Korea. Methods:
A retrospective study was performed from 1986 to 2005 in the Songpa-Kangdong district
of Seoul, Korea. To recruit patients as completely as possible, multiple information sources
including all medical facilities in the study area and three referral centers located nearby
but outside the study area were used. The incidence and prevalence rates were adjusted
using the 2005 Korean population statistics. Results: During the study period, a total of
341 incident cases of UC (M:F=170:171) and 138 incident cases of CD (M:F=102:36) were
identified. The median age at diagnosis (UC, 35 years; CD 21.5 years) and the median
interval from onset of symptoms to diagnosis (UC 5 months; CD 12 months) were fairly
constant throughout the study period. At the diagnosis of UC, proctitis was noted in 149
cases (43.7%), left-sided colitis in 107 (31.4%), and extensive colitis in 85 (24.9%) of the
341 incident cases. At the diagnosis of CD, both small and large bowel disease was noted
in 92 cases (66.7%), isolated small bowel disease in 29 (21.0%), and isolated large bowel
disease in 17 (12.3%) of the 138 incident cases. The age- and sex-adjusted mean annual
incidence rate of UC and CD for the entire study period was 1.51 (95% CI, 1.34-1.67) and
0.53 (95% CI, 0.44-0.62) per 100,000 inhabitants, respectively. When analyzed by 5-year
intervals, the mean annual incidence rate of UC and CD increased significantly from 0.34
and 0.05 per 100,000 inhabitants in 1986-1990 to 3.08 and 1.34 per 100,000 inhabitants
in 2001-2005, respectively (p <0.05). The incidence ratio of UC and CD decreased from
6.8 in 1986-1990 to 2.3 in 2001-2005. On December 31, 2005, 329 patients with UC and
130 patients with CD lived in the study area, giving an adjusted prevalence rate of 30.87
(95% CI, 27.47-34.27) and 11.24 (95% CI, 9.29-13.18) per 100,000 inhabitants. Family
history of inflammatory bowel disease was noted in only 2.7% of the patients. Conclusions:
The incidence and prevalence rates of UC and CD in our study area are still low compared
with those of Western countries, but are steadily increasing. Although the mean annual
incidence of UC is higher than that of CD, the incidence ratio of UC and CD is decreasing
in Korea.
W1099
Recurrent Clostridium difficile Colitis in Inflammatory Bowel Disease Patients
Mazen Issa, Lydia R. Weber, Yasmin Kanaa, Jeanne Emmons, Susan Skaros, Joshua F.
Knox, Mary F. Otterson, David G. Binion
Introduction: Infection with Clostridium difficile (C. diff) poses a significant challenge in pts
with IBD, which may lead to increased rates of hospitalization and colectomy. Recent reports
have described an increased impact of C. diff in the IBD pt population. C. diff infection
may recur in patients at early and late time periods. We characterized overall rate of C. diff
infection in a cohort of IBD pts, and described patterns of recurrent disease. Methods: This
was a retrospective observational study of all IBD pts followed in a tertiary referral center
between 1998 and 2006. History of confirmed C. diff infection was recorded. C. diff
recurrence was identified and categorized: “early” recurrence was within 2 months of a
previous confirmed infection, while “late” recurrence was beyond 2 months. Demographic
data, disease type (Crohn's disease (CD), ulcerative colitis (UC)), anatomic location, number
of documented recurrences and time intervals of infections were recorded. Results: There
were a total of 1180 IBD pts in our center's database (CD = 832, UC = 336, indeterminate
colitis = 12). There were 148 pts (12.5%) with history of documented C. diff infection
(CD = 89; UC = 56; indeterminate colitis = 3). There were 23 IBD pts who had a history
of recurrent C. diff infection (2% of the total cohort; 15.5% of the patients with a history
of C. diff infection). Among the 23 IBD pts with recurrent C. diff there were a total of 32
episodes of recurrence. The maximum number of documented C. diff recurrences in a single
IBD pt was 4. Among pts with recurrent C. diff infection, there were 7 males (30%) and
16 females (70%) with mean age of 37.4 + 13.4 (mean + SD). Among the recurrent C. diff
pts, the majority (15 pts (65.2 %)) had CD (33.3% inflammatory, 40% stricturing and
26.7% penetrating) and the remaining 8 patients (34.8%) had UC. Anatomic location of
IBD in the recurrent C. diff infected patients was small bowel 13%, isolated large bowel
69.5% and both small and large bowel 17.5%. Mean age of disease onset was 29.9 + 13.3.
Mean number of C. diff recurrence was 1.4 + 0.8 with mean time interval of 8.3 + 11.4
month. Four of the recurrent C. diff infected IBD pts required colectomy (17%). Conclusion:
A-660AGA Abstracts
A history of C. diff infection was identified in 1 out of 8 IBD pts followed in our center.
Recurrent C. diff was encountered in 15.5% of the IBD pts with a history of C. diff infection.
Recurrent C. diff affected a disproportionate number of IBD colitis patients, andwas frequently
associated with colectomy. Practitioners caring for IBD pts need to be aware of the high
rates of C. diff infection and recurrence in this population.
W1100
Autistic Enterocolitis in Childhood: The Early Evidence of the Later Crohn's
Disease in Autistic Adulthood?
Federico Balzola, Daniela Clauser, Francesca Curri, Marina Caldognetto, Alessandro
Repici, Claudio Barletti, Alessandro Musso, Mauro Bruno, Giorgio Saracco, Anna Sapino,
Isabella Castellano, Dario Reggio, Teresa Cammarota, Pietro Lerro, Pierluigi Calvo, Marco
Forni, Isabella Morra, Marina Gandione, Roberto Rigardetto, Mario Rizzetto
Autism is defined by qualitative impairments in social interaction, communication and
repetitive behaviours with typical onset in early childhood (15-36 months). An unexpected
10-fold increase in prevalence has been described in the last 2 decades. Gastrointestinal
symptoms have frequently been overlooked or attributed to the behavioural and sensory
dysfunction associated with the disorder, although they affect from 20-70% of pts. Autistic
Enterocolitis (AE), an IBD-like pathology characterized by ileo-colonic lymphoid hyperplasia
(LNH) and chronic inflammation of the small and large intestine, was first reported in the
1998 and later confirmed by other independent studies. We aimed to evaluate the prevalence
of AE and the characteristics of the intestinal disease by age at diagnosis of AE in an Italian
cohort of autistic subjects. Among the 25 pts (23 male, mean age 15 yrs; range 2-32) that
underwent to upper/lower endoscopies with biopsies and wireless enterocapsule, 22 of them
(88%) showed an AE with different localization in the bowel districts and grading of
inflammation. Pts were divided into 5 groups by age-at-diagnosis: A=2-6 yrs; B=7-12 yrs;
C=13-18 yrs; D=19-24 yrs; E=25-32 yrs. Macroscopic lesions were observed in the 70% of
the pts in both upper and lower gastrointestinal tract. Microscopic inflammation was observed
in the 70%, 65% and 90% of pts in the upper gastrointestinal tract, terminal ileum, and
colon, respectively, with different histological grade. A pathological high-grade of LNH was
present in the 100% of pts in group A, 66% in group B; 50% in group C and D and in
none group E. Ulcers and erosions were present in none of groups A and B; 20% of group
C and D, and 75% of group E. In the terminal ileum the intraepithelial CD3 count was
more then 20 per 100 epithelial cells in 50% of group A; 100% of group B; 50% of group
C; 66% and 75% of groups D and E, respectively. In the colon, the CD3 count was more
then 20 per 100 epithelial cells in 80% of group A; 100% of group B; 25% of group C;
50% and 75% of group D and E, respectively. The endoscopic and histological data showed
that the prevalence of ulcers and erosions were directly proportional to age at diagnosis of
bowel disease, with an inverse relationship between LNH and age. There was no correlation
between ileal or colonic CD3 count and age at diagnosis. Despite a relatively small number
of pts, the results are consistent with the possible evolution of the AE to Crohn's disease
later in the life, opening new aspects for the natural history or the finding of a new
experimental model of such unknown disease as IBD is.
W1101
Fertiliy, Pouch Function & QoL in Australian Ileal Pouch-Anal Anastomosis
(IPAA) Patients
Steven J. Brown, Suzanne Mahady, Sally J. Bell, Ross Elliott, Mark Lust, Greg Moore,
Michael Johnston, Jamie Keck, Rod Woods, Jack Mackay, Alexander Heriot, William
Connell
Introduction. IPAA surgery is considered a ‘cure' for ulcerative colitis (UC) though comprom-
ised fertility, pouchitis, frequent medication use and poor quality of life (QoL) are long-
term considerations. We examined outcomes in Australian IPAA recipients via a mail survey.
Results. 86 subjects responded (female n=47), representing 612 years of pouch follow up
(mean 7.1 years/subject). The mean age of IBD onset, age of surgery and current age was
29.7, 37.6 and 44.7 years respectively. Daytime stool frequency was >8 in 17% and night-
time stool frequency >2 in 26%. Stool leakage occurred daily in 12%. Regular pad use was
reported by 10%. Previous pouchitis was reported in 50% of subjects, and was predicted
by young age of IBD onset but not by peri-operative complications. 39% of pouchitis sufferers
had used 3 or more courses of antibiotics during the last 12 months. Subjects with a
history of pouchitis had a higher clinical PDAI subscore, higher daytime & night-time stool
frequencies and higher rates of stool leakage compared to those who had never had pouchitis.
58% of subjects took anti-diarrhoeal medications, and 29% took regular medications to
prevent pouchitis. Pouch function was durable with just 6% reporting deterioration compared
to 12 months after their surgery. Only 8% considered their pouch function was worse than
their pre-operative expectations. Mean Fazio QoL score was 22.3/30. Improvement in all
Mayo performance domains except for ‘sex-life' was reported by 40-50% of subjects. 39
women had pouch surgery aged <45yrs. To this cohort, 25 children were born after IBD
onset but prior to surgery, and 3 children were born after surgery. Using national fertility
figures, observed to expected birth ratios were 0.87 pre-surgery and 0.13 post surgery. A
fertility defect was not seen in an age-matched cohort of women with medically treated UC.
Sexual dysfunction affected 33% of females and 24% of males. Summary/Conclusions. IPAA
surgery results in generally satisfactory and durable outcomes, though high rates of pouchitis
and medication use are seen. Pouchitis predicts poor pouch function in general. QoL, while
improved for many, remains restricted, and significant defects in fertility and sexual function
are observed.
W1102
Osteoporosis Screening Guidelines in Inflammatory Bowel Disease: Do We
Need to Look Beyond Conventional Risk Factors?
Ashish Atreja, Jhony Doumit, Bret Lashner
Background: Low bone mineral density (BMD) is a common complication in IBD. ACG and
AGA guidelines recommend screening IBD patients with Dual Energy X-ray Absorptiometry
(DEXA) if they have one of the following risk factors: postmenopausal state, ongoing corticos-
teroid treatment, cumulative prior use of corticosteroids exceeding 3 months, history of low
trauma fractures, or age over 60. Our objective was to determine the utility of IBD guidelines
in identifying patients at risk for developing osteoporosis and ascertain provider adherence
to the current guidelines. Methods:We utilized institutional clinical data repository to identify
patients seen in the last five years in our tertiary care IBD practice and having a diagnosis
of crohn's disease (CD, ICD-9-CM code 555.xx) or ulcerative colitis (UC, ICD-9-CM code
556.xx). We extracted data on demographics, conventional risk factors for low BMD (age,
steroid use, post-menopausal status), non- conventional risk factors (low body mass index
-BMI <21 kg/m2, cigarette smoking, total/subtotal colectomy, elevated INR) and DEXA
reports. Results:A total of 1703 patients were included in the IBD cohort (1046 CD, 657
UC). Of these, 1004 patients (59%) had at least one risk factor for osteoporosis screening.
DEXA was ordered in only 263 patients (provider adherence, 26.2%), and 69.7% of these
patients had low BMD (osteoporosis 23.2%, osteopenia 46.5%). 96 patients without any
conventional risk factor underwent DEXA screening, and 54.1% of these patients had low
BMD (osteoporosis 12.5%, osteopenia 41.6%). INR levels did not correlate with low BMD
(CD, 0.96 vs. 0.95, P=0.65; UC, 0.95 vs. 0.92, P= 0.07). Multivariate logistic regression
analysis showed that low BMI was a strong risk factor for low BMD (OR 2.46; 95% CI,
1.24 to 4.89). Cigarette smoking had a variable effect on low BMD with the odds ratio of
1.1 in CD (95% CI, 0.55 to 2.19) and 0.27 in UC (95% CI, 0.10 to 0.70).72.4 % of patients
with osteoporosis and 38.6% with osteopenia were documented to be on antiresorptive
agents. Conclusions:Physician adherence to current osteoporosis screening guidelines in IBD
patients is suboptimal. However, even if this adherence increases, guidelines are likely to
miss a significant proportion of patients who are at risk for low BMD. Inclusion of low BMI
to current guidelines will lead to 75 more DEXA screenings per 1000 IBD patients but may
help identify additional one-third of patients at risk for osteoporosis. Inclusion of non
smoking status in UC will lead to 225 more DEXA screenings per 1000 UC patients and
may help identify additional one-half of UC patients at risk for osteoporosis.
W1103
Healthcare Costs of Patients with Ulcerative Colitis After Colectomy Surgery
Chenglong Han, Allan Olson, Mohan Bala
Background: Few studies have been conducted to evaluate healthcare costs in patients who
have had a colectomy. Objective: To evaluate the healthcare costs of patients who underwent
colectomy, the total medical costs prior to and post to colectomy were compared using data
from the MarketScan database. Methods: The MarketScan Research database is a longitudinal
healthcare claims database. We identified patients who had UC (ICD-9 of 556.x) and received
a colectomy during study period of year 2000-2004. Colectomy was defined using CPT-4
code (44140-44147, 44150-44156, 44160, 44202-44208, 44210, 44212) or ICD-9 codes
(45.70-45.79). The total medical costs, including inpatients costs, outpatient costs, and
prescription drug costs, were accumulated for each patient. A 3-month period prior and
post to surgery was used to exclude any costs that may be related with the primary surgery.
The 12-months post surgery costs were accumulated starting from 3 months after last
colectomy procedures up to 15 months. Similarly, these costs were accumulated from 3-
15 months prior to the first colectomy (prior surgery costs). Results: We identified about
761 patients who had colectomy-related hospitalizations. The mean colectomy-related inpa-
tients costs were $27296 per patient. The 12-months prescription drug costs decreased from
$2810 prior to colectomy to $1928 post to colectomy. However, the 12-months inpatients
and outpatient costs post to colectomy increased significantly ($15941, $6492) compared
to the costs prior to colectomy ($4120, $4744). The total 12-months healthcare costs prior
to colectomy were $11673 while the total 12-months costs post to colectomy was $24360,
a net increase of $12687 (Table). Additional analyses showed that total 6-months costs one
year after colectomy (months 12-18) were still significantly higher than the costs of the
same period one year before colectomy. Conclusion: Although colectomy is considered as
curative for UC, total healthcare costs increased significantly after surgery. The optional use
of colectomy in the management of UC needs to be further examined.
Healthcare Costs of Patients with UC Prior and Post to Colectomy
W1104
Comorbidities, Crohn's Disease, and Infliximab: A Comparative Profile
G. Watson, M. Rahman, M. Kugel, H. Thompson, R. Arjunji, M. Ziskind, B. Tang, O.
Dabbous
Purpose: We explored comorbidities present in Medicare beneficiaries diagnosed with CD,
and how the incidence of these comorbid conditions varied between beneficiaries with CD
who were treated with infliximab (IFX) and those not treated with IFX. Methods: We used
the Medicare 5% Standard Analytic Files (SAF) for 2001 - 2004, which has a sample size
of approximately 2,157,074 individuals. This sample included 8,131 beneficiaries with CD.
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There were 571 beneficiaries receiving IFX. IFX usage was determined by HCPCS code
J1745 - “Injection, infliximab, 10 mg”. We compared those with CD who were treated with
IFX to the general Medicare population. Results: We examined all claims for the presence
of the following primary diagnoses: CD, myocardial infarction (MI), congestive heart failure
(CHF), diabetes, stroke, cerebral vascular disease, renal failure, and hypertension. For all
of the diagnoses, we found higher incidences in the CD population than in the general
Medicare population. In the CD population, 18.9% were diagnosed with CHF, 27.5% with
diabetes, 10.8% with stroke, and 64.1% with hypertension, while the overall Medicare
population were diagnosed 18.2%, 25.4%, 8.0%, and 57.4% with each disease respectively.
When comparing the subset of CD patients treated with IFX to CD patients not treated
with IFX, we found lower incidences of MI, CHF, diabetes, and hypertension (chi-squared
P-value of: 0.0041, <0.0001, 0.0027, and <0.0001 respectively). Logistic regression adjusting
for age and gender, showed that the IFX-treated group had fewer comorbidities than the
group not receiving IFX. Odds ratios for IFX are seen in the table. Conclusion: Our findings
indicate that for nearly every comorbid condition examined, beneficiaries with CD had a
higher incidence of the comorbid condition compared to the non-CD Medicare population.
When compared to the general Medicare population and CD beneficiaries who did not
receive IFX, the beneficiaries with CD who received IFX had lower incidences of three
comorbid conditions: CHF, diabetes, and hypertension.
W1105
Presence of Ileitis Is a Risk Factor for Dysplasia in Patients with Ulcerative
Colitis As Well As in Patients with Primary Sclerosing Cholangitis with
Ulcerative Colitis
Murali K. Nalluri, Naishadh N. Raghuwanshi, Timothy M. Smith, Prabhakar P. Swaroop
METHODS: The medical records of all patients with PSC-UC evaluated at the Saint-Louis
University clinic between Jan 2002 and Jan 2006 were abstracted for information on endos-
copic and histological features. Conventional colonoscopic and histological criteria were
used to diagnose IBD. All cases were required to have had at least one colonoscopy with
biopsies at the Saint-Louis University. Conventional radiographic criteria of beading, duct
ectasia, and stricturing of the intra- or extrahepatic bile ducts were used to diagnose PSC.
All patients were required to have had a cholangiogram (either retrograde or percutaneous)
performed or interpreted at the Saint-Louis University. Patients with colectomy prior to a
diagnosis of PSC or first Saint-Louis University clinic visit were excluded from the study.
Likewise, cases that had been diagnosed with colorectal dysplasia or cancer elsewhere prior
to evaluation at our institution were excluded. Patients who did not have ileoscopy with
biopsies were excluded. A control group of CUC patients matched 3:1 for age was identified,
and similar information was abstracted. RESULTS: 39 PSC-UC patients and 115 CUC patients
without PSC were identified. In PSC-UC group there were 11 patients with ileitis . Among
the ileitis patients 4(36%) had dysplasia and 7(64%) did not have dysplasia. Among 28
patients in PSC-UC group with no ileitis there were 8 (28%) patients with dysplasia. The
odds ratio of dysplasia in the presence of ileitis in PSC-UC group is 1.42 with 95% confidence
intervals between 0.32-6.25 In CUC group there were 23(20%) patients with ileitis. 1 (4%)
of patients had dysplasia in ileitis group 1(1%) had dysplasia in non ileitis group. The odds
ratio of dysplasia in the presence of ileitis in CUC group was 4.136 with 95% confidence
intervals between 0.24 to 68.75. 62% of Ulcerative colitis patients had pancolitis as compared
to 97% of patients with PSC-UC. CONCLUSION AND DISCUSSION: It is not well known
whether ileitis is a risk factor for dysplasia. In both PSC and CUC groups ileitis probably
represents longstanding inflammation . Our results indicated ileitis as a risk factor in both
groups for dysplasia. Backwash ileitis may increase the risk of dysplasia in UC more than
patients with PSC-UC as it may represent longstanding colitis in UC group.
Ileitis and Risk of Dysplasia
W1106
A Survey of Gastroenterologists' Awareness and Implementation of AGA
Guidelines On Osteoporosis in Inflammatory Bowel Disease Patients: Are the
Guidelines Being Used and What Are the Barriers to Their Use?
Julianne H. Wagnon, David A. Leiman, Greg D. Ayers, David Schwartz
Background: The American Gastroenterology Association (AGA) published guidelines to
assist clinicians in the evaluation and management of osteoporosis in inflammatory bowel
disease (IBD) patients (Pts). Two studies suggest that when clinicians utilized the guidelines,
the majority of their IBD Pts were appropriately screened and treated for metabolic bone
disease Aim: To study whether physicians who use the AGA guidelines are in fact following
the recommendations and to assess the barriers preventing the use of the guidelines in the
management of osteoporosis in their IBD Pts. Methods: 1000 physicians were randomly
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selected from the AGA membership list and mailed a survey inquiring about awareness and
implementation of the guidelines on osteoporosis in IBD Pts. The barriers to implementation
of the guidelines were also assessed. The sum of 21 self-reported clinical practices (absence=
0, presence=1) was used to evaluate adherence to the guidelines. A value of 0 implied no
adherence while a score of 21 meant complete adherence. Results: Of 278 responders, 17
fellows and 14 retirees were not included in the analysis; thus 258 respondents were the
subject of this analysis. Less than half of the responders used the guidelines in decision-
making [126 (49%)] or in the management [110 (42%)] of their IBD Pts. According to the
scoring system described above, clinicians using the guidelines had a significantly higher
clinical practice score than those who did not use the guidelines (Wilcoxon rank sum test;
p<.0001) Only 18% (12 of 68) of clinicians whose practice was comprised of ≤ 25% IBD
Pts used the guidelines compared to 60% (113/187) physicians who cared for more IBD
pts. (Chi-square test; p<0.0001). Physicians who saw more IBD Pts (>25%) were also more
likely (97/187=52%) to assess and treat osteoporosis in their IBD Pts themselves. Conversely,
only 16% (11/68) of physicians who saw 25% IBD Pts treated osteoporosis themselves (Chi-
square test; p<0.0001) The main reason physicians (n=115) gave for not utilizing the
guidelines was because they felt that IBD should be the focus of the visit [48 ( 42%)]; 34
(30%) reported that osteoporosis should be managed by another. Other barriers cited were
lack of time [13 (11%)] cost [10 (9%)]; and lack of knowledge [10 (9%)]. Conclusion:
Most physicians do not utilize the AGA guidelines on metabolic bone disease in IBD Pts.
The physicians who utilized the guidelines were actually adhering to the recommendations.
Further education regarding the impact of metabolic bone disease in IBD Pts and the
importance of the guidelines is needed, in particular as it addresses the barriers set forth above.
W1107
High Risk of Vitamin D Deficiency in Wintertime in Adults with Crohn's
Disease
T. Nic suibhne, Martin Healy, G. Cox, V. Crowley, B. Egan, C. O’morain, Maria O'sullivan
BACKGROUND: People with CD have an increased risk of low bone mineral density,
osteopenia and osteoporosis. Bone disease in CD is multifactorial in origin including corticos-
teroid use, malabsorption, inflammation, hormonal, genetic and nutritional factors, notably
vitamin D and calcium. AIM: To assess serum vitamin D status in non-hospitalised adult
CD patients and to explore associated factors. METHODS: A prospective cross-sectional study
in which comprehensive nutritional, clinical and biochemical assessments were performed on
81 CD patients and 81 age-, sex- and socioeconomic matched healthy controls. Serum 25-
hydroxyvitamin D was measured by radioimmunoassay (DiaSorin, USA). Levels of deficiency
were classified according to criteria by Lips 2004. RESULTS: The prevalence of vitamin D
deficiency was high in both CD (63%) and controls (53%) (NS). Significantly more CD
patients were deficient in winter than in summer (69% v 49%, P<0.001 chi-square). Corres-
pondingly, vitamin D levels were significantly lower in winter than in summer in CD
(43.08±24.53 nmol/L v 60.57±30.83 nmo/L; P = 0.01), a trend noted also in controls
(45.80±22.94 nmol/L v 56.29±24.99 nmol/L, P = 0.09). In CD, vitamin D levels were lowest
in April (32.36±4.75) and highest in June (76.50±18.52: P=0.003). On liner regression
analysis factors significantly associated with serum vitamin D levels in CD were winter season
(coefficient -21.06, CI -35.18 to -6.95, P = 0.004); longer duration of CD (-1.19, CI -2.18
to -0.19, P = 0.019); vitamin D intake (1.09, CI -0.13 to 2.3, P = 0.079) and smoking (non
smoking 13.09, CI 0.14 to 26.33, P = 0.053). In the control group wintertime was the only
predictor identified (-11.84, CI -24.79 to 1.09, P = 0.072). Bone formation, as estimated
by serum osteocalcin levels, was significantly lower in CD than in controls (6.6±3.1ng/ml
v 8.9±3.3ng/ml; P < 0.001). Of note, this CD group were young (36±11 yrs), predominantly
pre-menopausal females, with inactive disease (by CDAI, CRP) and otherwise well nourished
(by BMI, muscle stores, albumin, total protein, haemoglobin) and not typically considered
at risk for vitamin D status. This group, however, offer an opportunity to preserve maximum
bone mass and prevent osteoporosis and fracture. CONCLUSION: This study shows a high
level of vitamin D deficiency in CD especially in wintertime. Low serum 25 hydroxyvitamin
D levels were associated with winter, longer disease duration, smoking and low vitamin D
intake. The data raises the question if vitamin D supplementation should be considered in
CD during winter months.
W1108
High Incidence Rate of Inflammatory Bowel Disease (IBD) in Navarra (North
of Spain). Results of a Prospective, Population-Based Study (2001-2003)
Antonio Arin, Fernando Borda, Javier Jimenez, Juan Vila, M. jesus Burusco, Ana
Martínez, Matilde Laiglesia, Carlos Prieto, Elena Macias
Introduction: Differences between northern and southern european countries concerning
Ulcerative Colitis (UC) and Crohns Disease (CD) incidence trend to decrease as it was
demonstrated by de European Collaborative Study on Inflammatory Bowel Disease (1991-
1993). In Navarra (North of Spain) available data came from a retrospective study of the
period 1983-1993 and show a low incidence of IBD in comparison with published rates in
northern european countries. No further studies have confirmed these results in our commun-
ity. Aim: The aim of this study is to determine the present incidence of IBD in Navarra and
to analyse the clinical characteristics of all new cases diagnosed during the study period.
Patients and Methods: A prospective, population-based was performed to determine the
incidence of IBD in Navarra during the period 2001-2003. Total population: 569.628
inhabitants (284.620 males) Every case of IBD diagnosed in any public o private hospital
of our community was included in the study. Crude rates and specific age and sex adjusted
rates to European Standard Population were calculated. Results: 288cases were diagnosed
(UC:176; CD: 102; Indeterminate colitis:10). Crude rates of UC, CD and indeterminate
colitis were 10,29, 5,96 and 0,58 cases/100.000 inhabitants/year respectively (population
under 14 years of age is included). Specific rates were 9,57 (CI 95%: 7,27-12,57) and
5,85(CI 95%: 3,99-8,14) cases/100.000 inhabitants/year for UC and CD. Results concerning
clinical data were the following: UC (proctitis: 32,4%; left-sided colitis: 40,3%; extensive
colitis: 27,3%). CD location (Ileal: 46%; colonic: 14,7%; ileo-colonic:30,4%; Upper GI:
8,8%). CD clinical pattern (Inflamatory: 53,9%; Stricturing: 27,5%; Penetrating: 18,6%)
Extraintestinal manifestations (IBD 14,2%; CD 19,6%; UC 10,2%). IBD family history (IBD
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8,3%; CD 13,7%; UC 5,1%). Smoking habits (UC: Yes 16%; No 48,6%; Ex-smokers 35,4%.
CD: Yes 45,1%; No 43,1%; Ex-smokers 10,8%) Conclusions: 1. The incidence of UC and
CD in Navarra has increased during the last decade, with rates close to those of northern
european countries and higher than recently published spanish prospective studies rates.
2. Clinical characteristics of diagnosed cases are similar to those observed in previous studies
W1109
Racial Differences in Extent and Severity in Ulcerative Colitis: A Retrospective
Cohort Study
Mark Flasar, Sandra Quezada, Roger Wu, Priti Bijpuria, Raymond K. Cross
Introduction: Ulcerative colitis (UC) is primarily a disease of Caucasians; however the
incidence is increasing in African Americans (AA). Little is known about the extent of disease
and severity in AA. Our objectives were to assess the differences in extent of disease and
disease severity in patients with UC by race. Methods: Adult outpatients with UC evaluated
at the University of Maryland and Baltimore VA, from 1997 to 2005 were identified. We
assessed extent of disease according to the Montreal criteria and disease severity as measured
by >2 steroid courses, steroid dependence or need for colectomy. Results: 197 patients were
identified, of which 47 were AA (24%). Differences in demographic variables in AA included
a lower proportion of reported 1st-degree relative with IBD (2% vs. 11%; p=0.036) and a
higher proportion of AA evaluated at the VA (51% vs. 30%; p=0.0083) compared to
Caucasians. Of AA, 23% had proctitis, 23% had left-sided colitis, and 53% had extensive
colitis compared to 10, 31, and 59% of Caucasians respectively (p=0.056). When compared
to Caucasian UC patients, AA were less likely to ever receive steroids (45% vs. 61%; p=
0.0359), be treated with >2 courses of steroids (25% vs. 43%; p=0.029) or be steroid
dependant (13% vs. 27%; p=0.049). Colectomy was performed in 11% of AA compared to
15% of Caucasians (p=0.4835). After adjustment for multiple variables, only steroid depend-
ence (OR 2.32, 95% CI 1.08-5.00) male gender (OR 3.59, 95% CI 1.84-7.01) and age at
diagnosis < 40 (OR 2.56, 95% CI 1.34-4.89) were associated with extensive colitis. Being
AA (OR 0.32, 95% CI 0.11-0.94), needing colectomy (OR 15.9, 95% CI 5.94-42.41) and
male gender (OR 0.45, 95% CI 0.20-0.99) were associated with steroid dependence. Finally,
steroid dependence (OR 16.31, 95% CI 5.96-44.61) and male gender (OR 4.27, 95% CI
1.34-13.59) were associated with the need for colectomy. Conclusion: After adjustment for
multiple factors, race was not associated with extent of colitis or need for colectomy. However,
AA had lower odds of steroid dependent UC compared to Caucasians, which may suggest
a less severe disease course in these patients. Prospective evaluation is needed to further
evaluate this finding.
W1110
Distinct Phenotypes of Inflammatory Bowel Disease in U.S. Minority
Populations: Comparison of African American and Asian Subgroups
Manuraj Rajagopal, Lydia R. Weber, Joshua F. Knox, Susan Skaros, Mazen Issa, Sarah
Lundeen, Mary F. Otterson, Kia Saeian, Jasmohan S. Bajaj, David G. Binion
Introduction: Epidemiologic studies have revealed distinct patterns of inflammatory bowel
disease (IBD; Crohn's disease (CD), ulcerative colitis (UC)) emerging in different populations
worldwide. Although historic data has demonstrated highest incidence in Caucasian and
Ashkenazi Jewish populations, minority groups in the U.S. are now at increased risk for
development of IBD. 1st and 2nd generation Asian émigrés to the US are at risk population
for the development of IBD and limited information is available regarding their presentation
and natural history. We characterized patterns of IBD among minority patients followed in
a tertiary referral center focusing on phenotypic comparisons between subgroups. Methods:
This was a retrospective observational study of IBD patients at a tertiary referral center
between 1998 - 2006. Minority patients were identified by self-reporting on the intake
history. Ethnodemographic minority populations were defined using the U.S. Census Bureau
criteria, which included African American (AA), Hispanic (H), Native American (NA), Asian
populations, and others. Demographic information, type of IBD, anatomic distribution of
disease, duration of disease, age at onset, medication history, surgical history, and tobacco
use were recorded. Results: There were 1130 IBD patients in the registry at the time of
analysis. Sixty one patients met criteria for minority IBD (5.4%), including 40 CD, 19 UC
and 2 indeterminate colitics. Ethnodemographic distribution included AA (n=41), H (n=7),
NA (n=1), Asian (n=10), Others (n=2). AA IBD included 80% CD and 20% UC while Asian
IBD showed 60% UC, 20% indeterminate and 20% CD. AA and Asian IBD showed 76%
and 70% female predominance respectively. Age of onset was lower in the AA (34% <20
y) compared with Asians (10% <20 y). Extraintestinal IBD manifestations occurred more
commonly in AA (66%) compared with Asian (30%). Family history of IBD was similar
(AA- 9%, Asian-10%). Tobacco use in AA was 39% and 10% in Asians. Fistulizing CD was
found in 58% of AA patients, while no Asians had fistula. Colectomy rate in AA was 24%
and 10% in Asians. Hospitalization rates were similar (AA-66%, Asian- 60%). Maintenance
medical therapy in AA and Asian IBD were similar (purine analog - AA-37%, Asian-40%;
infliximab AA-34%, Asian-30%). Conclusions: Distinct patterns of IBD emerge in minority
populations in the U.S. Asian IBD represents a rising minority population at risk for IBD.
In the U.S., AA IBD demonstrates CD predominance which is not seen in Asian IBD at the
present time.
W1111
Different Evolution of Terminal Ileum and Proximal Small Bowel Lesions in
Crohn's Disease Patients. A Prospective Long-Term Follow-Up Study
Nadia Pallotta, Naima Abdulkadir hassan, Danila Guagnozzi, Giuseppina Vincoli, Enrico
Corazziari
Several studies have assessed long-term evolution of Crohn's disease (CD) behavior but there
are no systematic long-term studies on the evolution of the small bowel lesions since, mainly
radiological and endoscopic evaluations were performed at the discretion of the investigators,
could detect only luminal alterations, and endoscopy was limited to duodenum and terminal
ileum. Small intestine contrast ultrasonography (SICUS) accurately assesses presence , num-
ber, extension, and sites of the small bowel transmural alterations and luminal stenoses (1).
Aim. To assess long-term evolution of CD small bowel lesions by means of SICUS. Patients
& Method. Follow-up visits and SICUS were performed at least yearly for 47.7±24 months
in 83 patients (M 52, Age: M±SD, 33±13 yrs) with CD lesions in the small bowel. At SICUS
wall thickness and lumen diameter of the entire small bowel were observed and measured
at the level of maximally distended, and not contracting, loops following ingestion of 375
ml of polyethylene contrast solution. A wall thickness >3 mm defines an intramural lesion
(2). Stenosis was defined at SICUS as lumen diameter <1cm of the maximally distended
loop, confirmed in at least two consecutive follow-up observations, and at endoscopy if
located in the terminal ileum. Results. At first referral (time 0), patients with stenosis (n=
51 ) had a longer extension of the lesion (31±15 cm) than those (n=32) without stenosis
(21±16 cm, p<0.002). At the last observation the lesions were more extended (23±11 cm)
in 13 patients who developed a stenosis during the follow-up period that in those who did
not (18±14 cm, p<0.05). During the follow-up period 30 patients were operated upon after
10±21 months. All the remaining 53 patients at time 0 had lesions of the terminal ileum
(extension 22.6±12.4 cm), and 12 of them also of the jejunum-proximal ileum (extension
12.5±11.4 cm). At the last follow-up observation the average extension of the terminal ileum
lesions was 24±15.8 cm (n.s. vs time 0), that of the jejunum-proximal ileum 25.4±24 cm
(p<0.04 vs time 0). In the 12 patients with both terminal ileum and proximal bowel lesions
the extension of terminal ileum lesion was 20±16.4 cm at time 0 and did not vary significantly
(23.6±16.5 cm) at the last observation. Conclusions. In patients with similar Crohn's Disease
duration and treatment, lesions of the proximal small bowel extend more over time than
those of the terminal ileum. In comparison to patients without stenosis, those with stenosis
show a greater extension and progression of the lesions. 1) Pallotta et al Inflamm Bowel Dis
2005 2) Pallotta et al Ultrasound Med Biol 1999
W1112
Rising Trends in Hospitalization Rates for Inflammatory Bowel Disease in the
United States Between 1998 and 2004
Geoffrey Nguyen, Anne Tuskey, Themistocles Dassopoulos, Mary L. Harris, Steven R.
Brant
BACKGROUND: There have been significant advances in medical therapy for inflammatory
bowel disease (IBD), comprising of Crohn's disease (CD) and ulcerative colitis (UC). We
sought to determine whether the advent of biologics have had an impact on nationwide
inpatient resource utilization. METHODS: We queried the Nationwide Inpatient Sample
(NIS) for all discharges with a primary or secondary diagnosis of CD or UC between 1998
and 2004. The NIS is a nationally representative 20% sample of acute-care hospitals in the
United States. National estimates for incidence of hospitalization and surgery were derived
using U.S. census estimates as the denominator. Total hospital charges were expressed in
2005 U.S. dollars after adjustment for inflation. RESULTS: There were 359,124 and 214,498
admissions for CD and UC, respectively. The overall hospitalization rate for CD was 18.0
per 100,000 and that for UC was 10.8 per 100,000. There was a 4.3% annual relative
increase in hospitalization rate for CD (p<0.0001) and a 3.0% annual increase for UC
(p<0.0001)(see figure). Similar trends were observed after exclusion of one-day admissions.
Surgery rates were 3.38 bowel resections per 100,000 for CD and 1.15 colectomies per
100,000 for UC, and there were no consistent time trends. There were no temporal patterns
for average length of stay for CD (5.8 days) or for UC (6.8 days). The national estimate of
total inpatient charges attributable to CD increased from $762 million to $1,330 million
between 1998 and 2004, and that for UC increased from $592 million to $945 million.
CONCLUSIONS: Hospitalization rates for IBD, particularly CD, have increased within a
relatively short 7-year period, incurring a substantial rise in economic burden. Future studies
must delineate factors contributing to these trends.
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Decreasing Rates of Colectomy Despite High Rates of Hospitalization in C.
difficile Infected IBD Patients: A Tertiary Referral Center Experience
Mazen Issa, Lydia R. Weber, Susan Skaros, Dawn M. Borromeo beaulieu, Jeanne Emmons,
Joshua F. Knox, Sarah Lundeen, Mary F. Otterson, David G. Binion
Introduction: Clostridium difficile (C. diff) infection has increased in the U.S. and exerts a
negative impact on pts with inflammatory bowel disease (IBD). The present challenge of
C.diff includes increased morbidity and mortality, resistance to metronidazole and increased
relapse rates, which has prompted changes in diagnostic and treatment strategies. We
describe our 2 year institutional experience with C. diff infected IBD pts, looking at rates
of hospitalization and colectomy. Methods: This was a retrospective observational study of
all IBD pts in 2005 and 2006 who were diagnosed with C. diff colitis (positive stool C. diff
toxin A/B ELISA). Demographic data, disease type (Crohn's disease (CD) and ulcerative
colitis (UC)), disease behavior, anatomic location and IBD medications were collected.
Management evolved over the studied time period, and we recorded type of anti-C. diff
antibiotic therapy used. We compared the 2005 and 2006 rates of hospitalization and
colectomy. Results: There were 46 IBD pts out of 999 with confirmed C. diff in 2005 (21
M (46%) and 25 F (54%) with mean age of 39+14.6 yrs (mean + SD)). Mean age of onset
was 30.5+15 yrs. CDwas in 65% (43% inflammatory, 30% stricturing and 26.7% penetrating)
and UC in 35% of pts. Isolated small bowel disease was found in 17.4% and large bowel
involvement in 82.6%. Current therapy with immunomodulators included: purine analog-
54%; methotrexate-17%; infliximab (alone or in combination)-32.5%. Total number of
hospitalizations was 27 with 7 pts (15%) requiring colectomy. In 2006, there were 41 IBD
pts with C. diff out of 1180 (15 M (37%) and 26 F (63%) with mean age of 41+14 yrs).
63% had CD (11.5% inflammatory, 65.5% stricturing and 23% penetrating) and 37% had
UC. Mean age of disease onset was 30.8 +14 yr. Isolated small bowel disease was in 17%
and large bowel involvement in 83%. Active immunomodulators included: purine analog-
36.5 %; methotrexate-17%; infliximab (alone or in combination)-29%. Total number of
hospitalizations was 28 with only 1 pt (2.4%) requiring colectomy (P<0.04 compared to
2005). All hospitalized pts in 2006 received oral vancomycin in combination with rifaximin
as first-line antibiotic therapy for C. diff, which was used in 30% of hospitalized pts during
2005. Conclusion: The significant decrease in the colectomy rate, from 15% to 2.4%, despite
an unchanged rate of hospitalization correlated with heightened awareness and testing for
C. diff, as well as oral vancomycin in combination with rifaximin as first line therapy in
hospitalized pts. These data suggest a need for combination antibiotic trials for the treatment
of C. diff in IBD pts at the present time.
W1114
Patient Demographics, Disease Activity, and Extent of Surgery Are Not
Predictive of the Development of Small Intestinal Bacterial Overgrowth in
Patients with Crohn's Disease Who Have Undergone Ileocecal Resection
Andrew Rhim, Joshua E. Stern, Mical Campbell, Monina Pascua, Vinay Nair, Lalkrushna
Malaviya, Thomas Henry, Gary R. Lichtenstein
BACKGROUND: Patients with Crohn's disease (CD) who have undergone ileocolonic resec-
tions are predisposed to the development of small bowel bacterial overgrowth (SBBO).
However, no studies have critically analyzed if there are specific patient characteristics that
predict who will develop SBBO. METHODS: Prospective data collection was performed on
all patients with a history of CD and an ileocolonic resection who were referred for a lactulose
breath test (LBT) performed from March to November 2006 at the University of Pennsylvania
Medical Center. All patients had active CD excluded via SBFT and/or colonoscopy. Univariate
and multivariate logistic regression analyses were then performed comparing patients who
eventually tested positive and negative for SBBO as determined by LBT. Chi-square tests
and Fisher's exact tests were used in our analyses. Multiple variables were assessed including:
patient age, duration of disease, extent of disease, gender, smoking status, the presence of
hypothyroidism, osteoporosis, hypertension, anemia, extent of surgical resection. RESULTS:
34 patients with CD and ileocolonic resection underwent LBT. 9 (26%) were nonfermenters
and were excluded from further consideration. 16 (47%) had a positive LBT, and 9 (26%)
had a negative LBT. After statistical analysis of the tested variables, it was found that no
specific variable evaluated was associated with a positive LBT (all p-values were greater than
0.05). CONCLUSION: This is the first study to attempt to characterize factors that might
be predictive of SBBO in patients with CD referred for LBT who had undergone ileocecal
resection and who were eventually diagnosed with SBBO. Many of the variables we analyzed
have been shown to be associated with the diagnosis of SBBO in the general population.
However, our data suggest that these trends cannot be applied to the patients in our study,
thus making the diagnosis of SBBO in CD without the use an LBT extremely difficult. We
thus suggest that patients who are suspected of SBBO in the appropriate clinical scenario
should be referred for objective LBT.
W1115
Clinical Characteristics of Microscopic Colitis in Patients with Celiac Disease
Jun Yang, Jianfeng Cheng, Russell B. Mcbride, Maria T. Minaya, Govind Bhagat, Peter H.
Green
Background & Aims: Microscopic colitis (MC) (lymphocytic colitis (LC) and collagenous
colitis (CC)) occur in association with celiac disease and MC is considered as a cause of a
poor response to the gluten-free diet (GFD) in patients with CD. Our aim in this study was
to determine if MC occurs more commonly in patients with celiac disease than the general
population, and to characterize the illness in these patients. Methods: Our prospectively
maintained database of 1009 patients with CD at the Celiac Disease Center of Columbia
University was analyzed. The age-adjusted standardized morbidity ratios (SMR) were calcu-
lated, using data from a population-based study conducted in Spain between 1993 and
1997. Results: MC was identified in 4.3 % of the patients (44 patients, LC: 31, CC: 11,
Mixed: 2). The female:male ratio was 3.9:1 for the patients with MC compared to 2.1:1 for
the CD patients as a whole. This prevalence was significantly increased compared to the
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general population: for males (SMR=273; 95% CI: 242-307), females (SMR=100; 95% CI:
82-122) and both (SMR=143; 95% CI: 122-169). Among our patients 68% were diagnosed
after the diagnosis of CD, because of persistent diarrhea despite GFD, 11% with MC first
and 21% simultaneously. Colitis was universal in 74%, only left sided in 12% and only
right sided in 14%. All the patients were on GFD. Pepto-bismol was used in 50%, steroids
61% (budesonide and/or prednisone) and immunosuppressant 25% (azothioprine and/or
cyclosporine). Four were lost to follow-up. Of those with follow up 36% lost their diarrhea
and was off all medications. The remainder, 57% required maintenance drug therapy with
persistent symptoms despite therapy in one third of them. Logistic regression was performed
to identify factors predicative of good clinical response, neither age, gender, medication nor
the order of diagnoses (MC or CD first) was significant. Follow-up duodenal biopsies were
performed in 33 patients, showing improvement in villous atrophy in 21, and 10 of 22
colonic biopsies showed improvement/resolution of MC. Conclusions: MC occurs more
commonly in CD than the general population. It is usually diagnosed in poorly responsive
patients. While some patients have a remission of their diarrhea, most require maintenance
therapy to control their diarrhea. MC colitis is not common in CD, though when it occurs
can be difficult to manage.
W1116
The Utility of Capsule Endoscopy in the Management of Celiac Disease
Shanti L. Eswaran, Moshe Rubin, Peter H. Green
In the majority of patients with celiac disease (CD), the diagnosis is easily established and
treatment with a gluten-free diet (GFD) results in clinical improvement. In some patients,
diagnosis is difficult and in up to 30% the response to the diet is poor. Patients may develop
new symptoms on the diet raising the suspicion of refractory CD or malignancy and undergo
extensive evaluation. As CD affects the small bowel mucosa, video capsule endoscopy (VCE)
has become a valuable tool with which to monitor this disease. In this study we examined
the impact of VCE on the management of celiac disease on patients in whom it was used.
Methods: We maintained a database of patients with CD and identified 96 patients in whom
VCE was performed between 8/2002 and 10/2006. The majority was symptomatic despite
GFD or had a suspicion of malignancy, evidence of bleeding, or abnormal imaging. Also
included were patients in whom the diagnosis of CD was established by VCE alone. Results:
VCE findings of normal mucosa or those only consistent with celiac disease were seen in
69 patients (78%), thus excluding small bowel malignancy. VCE changed management in
19 patients (22%) with CD, either by leading to new diagnoses or by identifying small
bowel lesions that prompted further intervention or diagnostic testing. A new diagnosis of
Crohn's disease was made in 2 patients, 2 cases of intussusception were found, and 11 lesions
were seen including AVMs (5), significant ulcers (2), polyps (2), and an adenocarcinoma (1).
VCE led to medication changes in 5 patients. A new diagnosis of CD was made in 8 patients
in whom the diagnosis was not yet definite. The cecum was not reached in 10 patients and
2 patients had a retained capsule, one that required endoscopic retrieval and one that passed
spontaneously. Conclusion: VCE served an important function in all patients by firmly
establishing the diagnosis of CD, excluding malignancy, and identifying treatable lesions.
VCE is indicated in the patients in whom the diagnosis of CD remains unclear. Persistently
symptomatic patients on GFD should be strongly considered for VCE.
W1117
Is Celiac Disease Different in the Elderly Compared to the Young?
Ikenna Egbuna, Pardeep Brar, Peter H. Green
Background; Celiac disease over the years has shown a change in demographics from a
disease of childhood to a disease of all ages. Few studies have been conducted looking
specifically at presentation and disease characteristics in the elderly compared to a younger
control population. Aims; to study the clinical presentations, pathological characteristics
and associations of patients presenting with biopsy confirmed celiac disease in the elderly.
Methods; A review of patients (n =1008) from a prospectively generated database was
performed on all patients presenting with biopsy confirmed celiac disease at ages≥ 65 years.
Mode of presentation, duration of symptoms, clinical findings, small intestinal pathology,
associated medical illnesses including autoimmune diseases were evaluated and compared
to a subpopulation of patients diagnosed at ages 18 - 30 years. Both populations were
evaluated for significant differences to try to define elderly presentation. (Mann-Whitney
rank sum test and Pearson correlation were used) Results; Elderly patients (n = 125) were
compared to young adults (n = 149). There was a female predominance in both age groups
(male: female = 1:1.3 vs. 1: 3.9 for elderly vs. younger). Female predominance was more
marked in the younger age group (79% vs. 57% females p=<0.001) with a trend toward
more males in the older age group. There was no difference in the mode of presentation
between the groups (diarrhea 50 % vs. 50 % silent/atypical) in the elderly vs. (diarrhea 48
% vs. 52 % silent /atypical) in the younger group. There was no difference in duration of
symptoms prior to presentation (6.1 yrs ± 12.6 vs. 5.8 yrs ± 12.0; p=0.119 in the elderly
vs. younger groups respectively), nor degree of villous atrophy. A greater percentage of
females tended to present with diarrhea in both groups (63% vs. 85%; ≥65yrs vs. 18-30yrs)
with no statistically significant difference. The prevalence of males presenting with diarrhea
was higher in the elderly group vs. the younger group (37%vs.15%; p=0.006). There was
no difference between the two groups in overall autoimmune disease (p=0.133), however
there was a higher prevalence of thyroid disease and neuropathy in the older population
compared to the younger population (14% vs. 7%, p=0.037) and (11% vs.4%, p=0.023)
respectively. Conclusions; The characteristics of celiac disease in the elderly are similar to
those in young adults apart from a greater male presence in the elderly and a greater
prevalence of thyroid disease and neuropathy. It is unclear why patients present at any given
age. Studies need to be conducted to identify factors responsible for triggering presentation.
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Celiac Disease: Do the Clinico-Pathologic Characteristics of Patients Detected
By Screening Differ from Those with Classical Presentation?
Alexander K. Han, Govind Bhagat, Peter H. Green
Purpose: Many patients are diagnosed with celiac disease (CD) secondary to screening of
at-risk groups, especially those with a family history (FH) or CD-associated autoimmune
diseases. The clinico-pathologic characteristics and prognosis of screen-detected CD patients
are not well established because all patients are advised to start a gluten-free diet as therapy
upon diagnosis. We compared the manifestations of CD in a large cohort of patients detected
by screening with those who presented with the classical, diarrhea-predominant form.
Subjects and Methods: Patients were identified from a prospectively maintained database of
individuals with CD (n=1009) seen at a specialized CD center. Only biopsy-proven subjects
who had been followed for > 1 year were included. Clinical, laboratory, and histopathologic
findings of screen-detected patients and those presenting with diarrhea were compared
regarding age at diagnosis, gender, body mass index (BMI), degree of villous atrophy on
biopsy, and presence of associated conditions including iron deficiency, osteoporosis, autoim-
mune diseases and malignancies. Results: CD was diagnosed in 86 patients screened because
of FH n=76, primary biliary cirrhosis (PBC) n=4, type 1 diabetes (T1DM) n=5, and congestive
heart failure n=1. These patients were compared to 300 patients who presented with classical
CD. The screen-detected group was on average 8 years younger at diagnosis (37.2±1.9 SE
vs. 45.3±1.1 SE, p<0.001). There was no difference between groups regarding BMI, degree
of villous atrophy, or incidence of osteoporosis, hypothyroidism, iron deficiency anemia,
and IgA deficiency (p=1). Both groups had a similar distribution of patients with autoimmune
diseases (p=1). There was a trend towards more malignancies in patients with classical CD
(1/86 vs. 20/300, p=0.1). Among the screen-detected group, those with PBC were older
than those with T1DM and FH (53.3±2.3 SE vs. 21.8±1.8 SE and 36.5±2 SE, p<0.05) but
there was no difference between those screened for T1DM, PBC, and FH with respect to
gender or degree of villous atrophy. Conclusions: Screen-detected CD patients are younger
than those presenting with classical symptoms. No differences regarding other disease mani-
festations, including severity of villous atrophy or associated complications/conditions, were
observed between the two groups. The younger age of the screen-detected group raises the
possibility that these patients may develop symptomatic CD if left untreated. However,
longer-term studies are warranted to determine the true biology of silent or asymptomatic
CD and elucidate the reasons why some patients develop diarrhea and others do not.
W1119
Endocytoscopy Reliably Identifies Key Morphologic Findings in Patients with
Celiac Sprue
Heiko Pohl, Barbara T. Tanczos, Birgit Rudolph, Karsten Schlüns, Bertram H.
Wiedenmann, Thomas Rösch, Daniel C. Baumgart
BACKGROUND: Upper endoscopy with duodenal biopsies is part of the diagnostic work-
up in patients with suspected or refractory celiac sprue. Endocytoscopy (EC) is a novel
endoscopic technique that allows 450x and 1125x magnified live inspection of the intestinal
mucosa. We hypothesized that it may identify lymphocyte clusters and other hallmark
histologic features indicative of ongoing inflammation in celiac sprue. MATERIALS AND
METHODS: Nineteen celiac patients aged 40.8 ± 17.3 years with either well controlled
disease or ongoing inflammatory activity presented for endoscopic evaluation. EC images
were recorded from pre-marked duodenal areas using Argon beamer coagulation spots.
Biopsies were taken from the same area to allow precise comparison with histology. Using
a newly developed scoring system we systematically analyzed EC findings on still images and
video recordings from 108 mucosal sites. RESULTS: 42.6% of biopsies showed pathological
changes consistent with celiac sprue. Staining and resolution were sufficient in most sites
using 450x and 1125x magnifications (90.8% and 100% vs. 79% and 75%). Epithelial width
and presence of the intestinal brush border were reliably detected at both magnifications
(98.7% and 84.4% vs. 98.7% and 84.4%). Villous width was best visualized at lower
magnification (55.3% vs. 6.2%) and the lymphocyte infiltrate can only be assessed at higher
magnification (0% vs. 37.5%). Figure 1 depicts a typical EC image of celiac sprue at 1125x
magnification. CONCLUSION: EC can detect several hallmark features of intestinal pathology
in celiac patients.
Fig. 1: EC image of celiac sprue at 1125 x magnification.
W1120
High Rate of Misinterpretation of Histological Diagnosis of Celiac Disease in
the Clinical Practice
Ines Pinto, Edgardo Smecuol, Roberto Mazure, Ana Cabanne, Sonia Niveloni, Eduardo
Mauriño, Juilio C. Bai
BACKGROUND/AIM: The histological analysis of small bowel mucosa is considered the
gold standard for diagnosing celiac disease (CD). However, misinterpretation of specimens
maybe source of potential pitfalls in clinical practice. Thus, poor sample quality, inadequate
orientation and cutting could determine over- or under- interpretation of intestinal morpho-
logy. Our aim in the present study was to analyze the histological diagnostic performance
in clinical practice reviewing a series of intestinal biopsies studied by general pathologists.
MATERIAL AND METHODS: We performed a retrospective analysis of 186 consecutive
specimens from patients referred for a second opinion to a tertiary center from September
2003 to October 2006. Original pathologic reports produced by many different clinical
pathologists were retrieved. Characterization of CD by the expert reviewer was based on
morphological grounds (Marsh's type II or greater enteropathy). According to original reports,
129 samples had been considered as compatible with CD and 57 as having normal histology.
Agreement was also established according to the Cohen's kappa statistics for dichotomy
variables. RESULTS: According to the expert review, 12 samples (6.4%) were not valuable
at all because bad or poor quality of specimens. Both, original pathological reports and the
review agreed diagnosis in 120 samples (64.5%). This included 77 specimens identified as
CD and 43 having normal histology. Respect to original reports, 54 specimens (29.0%) had
a divergent diagnosis by the expert pathologist (final diagnosis was CD in 11 and normal
histology in 43). Using the kappa statistic, inter-observer agreement was 0.38. Based on the
final diagnosis, misinterpretation was mainly produced by an over-diagnosis as CD of normal
histological samples (40% vs. 25%; OR 0.48, 95% CI 0.24-0.97; p<0.05). CONCLUSIONS:
Our study detected major differences in the histopathological assessment of small intestinal
biopsies between non-experienced and expert pathologists. Overall, misinterpretation by
general pathologists was produced in 35.5% of specimens. These pitfalls in clinical practice
may have profound negative implications for patients.
W1121
Azathioprine Therapy in Type I and Type II Refractory Sprue: Analysis of
Long-Term Results
Eduardo Mauriño, Sonia Niveloni, Alejandra Cherniavsky, Emilia Sugai, Ana Cabanne,
Horacio Vazquez, Edgardo Smecuol, Roberto Mazure, Juilio C. Bai
Background/aim: Treatment of refractory sprue (RS) is empiric and includes several pharma-
cological approaches usually with unsatisfactory results. Our aim is to evaluate the long-
term results of azathioprine in patients with RS with and without abnormal intraepithelial
lymphocyte (IEL) clonal population in an open-label study. Patients: From 1998, all patients
(n=37) with a well-established diagnosis of RS were invited to participate in a prospective
two-step trial of a gluten-free diet (GFD) plus oral and/or parenteral corticosteroids with
enteral and/or parenteral nutrition in the 1st phase. Eighteen patients not responding to
these measures (12 female; median age: 46 yr; range 28-62) were offered the administration
of azathioprine (AZT) (2mg/kg/day) for one year (8 with a type I RS and 10 with type II
RS). Ulcerative jejunoileitis was present in 4 and 6 patients in each group, respectively. All
patients tested (n=14) had the HLA DQ2/8 haplotypes and 13 had a positive CD serology
at diagnosis. CT scans, enteroscopy, intestinal histology, HLA DQ2/8 status, TCRγ gene
rearrangement and celiac disease (CD) serology were assessed at diagnosis. Results: Overall,
6 patients (33%) died. Seven patients did not completed the 1-yr trial, four f these died
during treatment (2 due to sepsis) and 3 are still in the first 6-mo of treatment presenting
good to excellent outcome. Eleven patients completed 12 mo on AZT and 3 of them required
an additional course because progressive deterioration (2 died, 1 due to sepsis). Nine of
these patients (3 type I and 6 type II) are alive on a GFD (median follow-up: 33 mo; range
14-80) and showed significant histological and clinical improvement (final vs. baseline
determinations: BMI [p<0.06], serum albumin [p<0.02], haemoglobin [p<0.03]). The
response was observed in both types of RS and progression to overt lymphoma was not
detected in the follow-up. Conclusions: AZT treatment can be beneficial in a subset of
patients with type I and type II RS. Although mortality is still high (33%), it seems to be
lower than previously estimated. Interestingly, 3/6 deaths were secondary to infections
probably related to the immunosupresive therapy. Most RS patients (66%) had a favourable
long-term response to intensive measurements and immunosupression irrespective of the
type of IEL infiltration.
W1122
Intestinal Permeability and Tight Junctions Protein Genes Expression in
Gluten Sensitive Patients
Anna Sapone, Valeria Familiari, Maddalena Generoso, Maria Carteni', Carlo Tolone,
Alfonzo Papparella, Carolina Bologna, Giuseppe Paolisso, Laura Demagistris, Gabriele
Riegler, Alessio Fasano
Background: Reaction to gluten can involve an allergic (wheat allergy), non-allergic [gluten
sensitivity (GS)], or an autoimmune [celiac disease (CD)] mechanism. Recent evidences
suggest that early changes in intestinal permeability (IP) may play a pivotal role in the
pathogenesis of CD. Conversely, no data are currently available on the role of intestinal
barrier dysfunction in the pathogenesis of GS. Aims: To investigate the changes in IP and
tj protein genes expression in GS. Methods: Biopsy samples were obtained from 8 GS
patients, 13 patients with active CD, 3 patients with CD in remission, and 10 healthy
controls. Quantitative gene expression of tight junctions proteins Claudin (CL) 1, CL2, CL3,
CL4, and ZO-1 was performed by Real-time PCR. IP was evaluated by means of the lactulose/
mannitol test (LA/MA). Results: Expression of CL4 was increased three folds in GS subjects
compared to both CD patients and healthy controls, while no changes in CL1, CL2, CL3,
and ZO-1 expression were detected. Up-regulation of CL4 did not influence IP, since GS
patients IP (0.014±0.015) was similar to that detected in healthy controls (0,019±0,018).
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Conversely, in CD patients an over-expression of both CL1 and CL2 was observed, while
no significant changes in CL3, CL4, and ZO-1 were detected. The increased expression of
CL1 and CL2 was associated to an increase in IP (0.052±0.048). In CD patients in remission
both IP (0.014±0.004) and CL1 and CL2 expression returned to normal levels. Conclusions:
Compared to CD patients, GS subjects showed normal IP and CL1 and CL2 expression.
These results suggest that the pathogenesis of GS is different from that of CD and does not
involve the lost of intestinal barrier function.
W1123
Quantitative Measurement of Nodular and Mosaic Mucosa in Active Celiac
Disease Patients for Assessment of Villous Atrophy
Edward J. Ciaccio, Afzal J. Naiyer, Lincoln Hernandez, Govind Bhagat, Peter h. R. Green
Background and Aim: We sought to determine whether the abnormality of the duodenal
mucosa present in endoscopic images of celiac disease (CD) patients could be quantified
and correlated with the histologic grade of villous atrophy. Method: Semiquantitative assess-
ment of the degree of villous atrophy was performed using H&E stained sections of biopsies
from four adults with CD. Images were classified as partial, subtotal, or total villous atrophy.
The degree of abnormality (mosaic pattern and/or nodularity) was measured from endoscopic
images as the total length (L) of abnormal mucosal edges contained within a 7.5mm x
7.5mm area (56.25mm2). Image analysis software (ImageJ) was used to skeletonize the
abnormal mucosal edges and to automatically compute L. The mean±SE of 2-4 random
locations from each image was calculated. One way ANOVA and linear regression were used
to determine the statistical significance between the L value and the degree of villous atrophy
as expressed in integer form. Results: The L value for partial (n=4), subtotal (n=4), and total
(n=4) villous atrophy was 19.9±6.0mm, 40.2±3.5mm, and 64.2±3.1mm, respectively (see
Table), and the difference between the means was significant (p=0.026). There was a highly
significant correlation between L value and the integer degree of villous atrophy (r2=0.95,
p<0.001; see Figure). Conclusions: The total length L of abnormal mucosal edges per unit
surface area is an unbiased means to quantitatively assess the degree of villous atrophy in
endoscopic images. Since the technique can be automated and since it correlates with
histologic assessment, this method is potentially useful to map changes in the degree of
villous atrophy over large surface areas of small bowel.
Table: Comparison of L Value to VA
W1124
Urinary Stones in Celiac Disease: Correlates and Effects of Treatment
Carolina Ciacci, Anna Merchionda, Raffaella Tortora, Cristina Bucci, Fabiana Zingone,
Carmelina Cappello, Franzese Domenica, Massimo Cirillo
BACKGROUND: Urinary stone disease (USD) is frequent in malabsorptive diseases because
of enteric hyperoxaluria and/or diarrhea-induced dehydration. Research data are missing
for USD in celiac disease (CeD). AIMS: Cross-sectional and longitudinal analyses on urinary
stone disease in CeD. METHODS: USD was assessed by standardized questionnaire in CeD
patients at time of diagnosis (untreated conditions) and after 8-yr follow-up on gluten-free
diet (GFD). Control group was a sample of the general population examined during the
same period with use of the same methods (Kidney Int 2003 63:2200). A history of USD
was defined as the evidence of stone(s) at x-ray or ultrasound, and/or the urinary excretion
of stone(s), and/or surgical or endoscopical procedures for stone removal. Compliance
to GFD was assessed by yearly measurements of serum anti-transglutaminase antibodies.
RESULTS: CeD cohort (n=566) differed from population sample (n=4,640, Gubbio Study)
for lower age and higher prevalence of female gender (P<0.001). USD was more prevalent
in untreated CeD than in general population (8.5% and 6.3%, P=0.042). The difference was
consistent in both sexes and all age strata. Odds ratio of USD in CeD was 1.39 in univariate
analysis (95%CI = 1.02/1.91), 3.64 with control for sex and age (2.50/5.30). USD prevalence
was cross-sectionally associated with duration of CeD (P<0.05), not with its clinical presenta-
tion (type and number of associated disorders). A 8-yr follow-up on GFD was completed
by 257 CeD patients. Nutritional status of CeD patients improved on GFD (mean changes
at 8-yr follow-up: +4.9 kg in body weight, +1.5 g/dL in blood haemoglobin, P<0.001).
Incidence of USD was similar in treated CeD and general population (3.5% and 3.6%, P=
0.935). Relative risk of incident USD in treated CeD compared to general population was
0.97 in univariate analysis (95%CI = 0.49/1.93), 1.34 in analysis controlled for sex and age
(95%CI = 0.65/2.77). CONCLUSIONS: Untreated CeD is associated with high prevalence
of USD also in the absence of overt malabsorption and diarrhea. GFD is able to keep USD
incidence in CeD patients as low as in the general population.
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
W1125
Lymphocytic Duodenosis (LD) in a Population Based Study (Kalixanda) -
Sorting the Wheat from the Chaff
Marjorie M. Walker, Joseph A. Murray, Jukka A. Ronkainen, Pertti Aro, Tom Storskrubb,
Michael Vieth, Nicholas J. Talley, Lars Agreus
Background: The prevalence of LD (increased intraepithelial lymphocytes (IELs)/ 100
enterocytes with normal villous architecture) in patients presenting for endoscopy is reported
at 2% and approximately 10% of these may have celiac disease. Aim: To determine the
prevalence of LD in a population based study Methods: A random sample of an adult
Swedish population (n = 1000; mean age 54 years; 51% female) underwent upper endoscopy
and biopsy of the upper gastrointestinal tract including the first (D1) and second (D2) parts
of the duodenum. All subjects had celiac serology (human rTTg-IgA ELISA with EMA for
positives). D1 and D2 biopsies of 16 seropositive subjects were evaluated histologically, and
a further 500 D1 and D2 biopsies from seronegative subjects were then evaluated for villous
architecture and IEL counts. Results: Of 16 subjects with positive TTg/EMA, 3 had LD with
normal villous architecture and >25 IELs. The overall prevalence of celiac disease based on
TTg+, EMA+,+/- villous atrophy, + IELS> 25 in this group was 1.6%. In the seronegative
group, 19/500 had LD in either D1 or D2 (3.8%). 16/22 with LD had evidence of H. pylori
infection (72%). No concurrent autoimmune disease, Giardia or inflammatory bowel disease
was reported. Conclusions: The prevalence of LD in seronegative subjects in this setting is
3.8%. Celiac disease, supported by serology, comprises aminority of lymphocytic duodenosis.
The majority are most likely due to H. pylori but other treatable causes should be excluded
W1126
Prevalence of Human Anti-Transglutaminase Antibodies (H-Tga) in Patients
with Unexplained Infertility and Infertility with a Known Cause
Emanuele Rondonotti, Valeria Saladino, Flaminia Cavallaro, Christian Folli, Simone
Saibeni, Guido Ragni, Raffaella Borroni, Anna E. Nicolosi, Maurizio Vecchi
BACKGROUND: Several infertility problems have been previously reported in patients (par-
ticularly women) with celiac disease (CD). Anti human transglutaminase antibodies (h-TGA)
assay is the most sensitive test for CD diagnosis. AIM: To evaluate the prevalence of h-TGA
in patients with unexplained infertility (UI) and patients with infertility with a known cause
(IWKC). PATIENTS: We enrolled 86 UI patients (43 men, 43 women) and 376 (240 men,
136 women) IWKC patients. METHODS: We screened all the enrolled patients with h-
TGA; all h-TGA positive patients were planned for duodenal biopsy. RESULTS: 6 patients
were h-TGA positive (6/462; 1.3%). So far, 3 h-TGA positive patients have undergone
duodenal biopsy that showed villous atrophy in all. 2 out of 86 UI patients (2.3%) and 4
out of 376 IWKC patients (1.0%) were h-TGA positive (p=0.31). Two out of 46 (4.6 %)
men and none of 43 women with UI were h-TGA positive (p=0.49). Among 240 men with
IWKC, 1 (0.4%) was h-TGA positive while 3 out of 136 (2.2%) women with IWKC
were h-TGA positive (p=0.13). CONCLUSIONS: In this large series of infertile patients the
prevalence of h-TGA is 1.3%. The prevalence of h-TGA is particularly high (4.6 %) in men
with UI.
W1127
Gastric Emptying and Tissue Ghrelin in Adult Coeliac Disease
Alba Rocco, Giovanni Sarnelli, Debora Compare, Patrizia De colibus, Giovanni Autiero,
Loredana Pica, Rosario Cuomo, Gerardo Nardone
Delayed gastric emptying of solids has been described in a paediatric population affected
by celiac disease. However, until now, no data are available on adult celiac patients. Ghrelin
is a 28 amino acid peptide produced predominantly in the stomach which acts at gastrointesti-
nal level by increasing gastric acid secretion, gastrointestinal motility and gastric emptying.
Serum ghrelin levels are altered in coeliac disease, but whether this alteration is related to
nutritional impairment or to inflammatory changes of duodenal mucosa is yet unclear. Aim
of this study was to evaluate the gastric emptying rate of solids and tissue ghrelin levels in
adults celiac patients before and after one year gluten-free diet. Twenty-four celiac patients
(mean age 35, M 10) and ten age-sex matched controls underwent 13C-octanoic acid breath
test to measure gastric emptying of solids. Upper endoscopy with gastric and duodenal
bioptic sampling and 13C-octanoic acid breath test was performed in celiac patients before
and after one-year gluten free diet. Half emptying time (t1/2) and lag phase [t(lag)] were
calculated. Ghrelin tissue levels were evaluated by immunohistochemistry on gastric speci-
mens. Results: In untreated celiac patients, T1/2 and t(lag) were significantly delayed than
in controls (247 +/-70 vs 90 +/- 25 and 170 +/- 42 vs. 57 +/- 15, respectively; p<0.0001).
In all celiac patients, gluten withdrawal was effective to normalize the gastric emptying rate.
Interestingly, in two patients not compliant to gluten-free diet both t/2 and t lag remained
significantly delayed. Gluten withdrawal resulted in duodenal mucosa healing and a concom-
itant reduction of gastric ghrelin-positive cells (2.5 vs 0.9). In patients not compliant to diet
number of ghrelin- positive cells did not change.
A-666AGA Abstracts
W1128
Very High Performance of Deamidated Gliadin Peptide Antibodies in Subjects
with Low Risk for Celiac Disease
Maria L. Moreno, Emilia Sugai, Ana Cabanne, Horacio Vazquez, Julio Argonz, Fabio
Nachman, Sonia Niveloni, G. La motta, B. Pizarro, Roberto Mazure, Juan C. Gomez,
Eduardo Mauriño, Juilio C. Bai
Background: Serology has an essential role in screening and diagnostic algorithms to detect
celiac disease (CD). However, most studies reporting the performance of non-invasive tests
were conducted using selected cohorts that may not be adequately representative of clinically
relevant populations. Indeed, the assessment of CD serology in populations with a low
prevalence for CD would be of major diagnostic importance. Aim: to determine prospectively
the performance of serology test for detecting CD in a population with a low risk using
intestinal biopsy as entry criteria. Materials and methods: We evaluated a series of 391
randomized patients from all those derived to endoscopy for upper GI symptoms. Serum
samples for CD serology were obtained at the time of endoscopy. Serologic tests determined
were: IgA a-tTG, IgA and IgG anti-deamidated gliadin-derived peptide (a-DGP), a conjugate
detecting IgA + IgG a-DGP in a single assay and IgA antiactin antibodies (AAA). Characteriza-
tion of patients at entry was based on histological grounds (Marsh's type II lesion or greater).
Results: According to the histology, 10 patients (2.6%) had newly diagnosed CD and 381
subjects had a normal intestinal histology. The table shows the statistical performance of
each assay. The new a-DGP tests had the highest performance for detecting CD in the
proposed clinical setting. The analysis of combination of tests did not show substantial
advantages to the performance of individual assays. Conclusions: Our preliminary results
on the value of non-invasive assays in the detection of CD in a low probability population
have shown the greatest values for the a-DGP tests. According to the impressive NPV of all
assays, no further tests should be required to discard CD when serology was negative. If
these results are confirmed in larger populations, these new assays should be used in case
finding processes in populations at risk for CD.
W1129
Pedigree Baboons Affected with Hereditary Chronic Diarrhea As a Possible
Non-Human Primate Model of Celiac Disease
Debby Kryszak, Henry C. Mcgill, Michelle Leland, Alessio Fasano
Background: Celiac disease (CD) represents a unique model of autoimmunity in which, in
contrast to most other autoimmune diseases, a close genetic association with HLA genes
(DQ2 and/or DQ8), a highly specific humoral autoimmune response (autoantibodies to
tissue transglutaminase, (TTG)), and, most importantly, the triggering environmental factor
(gluten), are known. Given the undisputable role of gluten in causing inflammation and
immune-mediated tissue damage, CD could provide unique opportunities to tackle the
pathogenic basis of autoimmune processes. However, the lack of an animal model of the
disease represents a major limitation in reaching goals. We have previously reported that a
subset of pedigreed colony of baboons all related to 4 sires suffered of non-infective chronic
diarrhea associated to increase TTG IgG. Aims: To establish if the pedigreed colony of
baboons with hereditary chronic diarrhea at the Southwest Foundation for Biomedical
Research, could be used as a possible non-human primate model for celiac disease. Methods:
Four baboons from the pedigreed colony at the Southwest Foundation for Biomedical
Research (SFBR) in San Antonio, Texas were admitted to the SFBR clinic with chronic
diarrhea and placed on a Gluten Free Diet (GFD) and monitored for 6 months. Blood
samples and duodenal biopsies were collected at baseline, midway and at the conclusion
of the study. Results: Within the first 4-6 weeks of implementation of the GFD the 4 baboons
experiencedweight gain and their diarrhea resolved. Of the baboons that have been completed
the first part of the study, one showed a normal villous architecture with increase intraepithel-
ial lymphocytes and a positive TTG IgG at baseline. After 3 months, the duodenal biopsy
was unchanged, while the TTG IgG decreased but was still positive. A second baboon
showed patchy duodenal villous blunting with increased intraepithelial lymphocytes at
baseline, while his TTG was normal. After 3 months of implementation of a GFD, the
duodenal biopsies showed a normalization of the villous architecture and persistence of
intraepithelial lymphocytes. Conclusions: These preliminary observations suggest that an
enteropathy that resembles the human CD histological damage is present in the pedigreed
baboon colony studied. One of the baboons showed an improvement of its enteropathy
following the implementation of the GFD. The clinical, serological, and histological features
of the chronic diarrhea of these primates suggest a similarity to human CD and, therefore,
that the progeny of this sire can be potentially used as a primate non-human model of CD.
W1130
Serologic, Anthropometric, and Laboratory Correlation with Degree of
Intestinal Damage At Diagnosis in Pediatric Celiac Disease; A Comparison of
Diabetic Versus Non-Diabetic Children
Muralidhar Jatla, Ritu Verma, Patricia Bierly, Aqiba Bokhari, Pierre Russo
Children with diabetes mellitus (DM) have a higher prevalence of celiac disease (CD). Used
for screening and surveillance, tissue transglutaminase (TTG) and endomysial (EMA) antibody
tests are less reliable in adults with mild enteropathy but no such studies exist in children.
We assessed the correlation between albumin, hemoglobin, transaminases, symptom type
and duration, BMI, TTG and EMA in different degrees of intestinal damage at time of CD
diagnosis in children with and without DM. Design: Retrospective review of patients seen
at CHOP between 1/02 and 6/06 revealed 60 children (46 girls, 14 boys; mean age 9.8 yrs)
who had laboratory evaluation, TTG and EMA performed at time of histologic CD diagnosis
from endoscopically obtained small intestinal biopsies. 21 of 60 children had DM. All
children were stratified for histologic damage according to Marsh classification. Results:
Marsh (M) I lesions were seen in 2 (3.3%), MII in 2 (3.3%), MIII in 56 (93.3%) {IIIa(23.3%),
IIIb(25%), IIIc(45%)}. TTG testing was positive in all and EMA testing was positive in all
but one child. Among all children with CD, mean TTG values were 96, 277, 415 in MIIIa-
c, respectively; IIIa vs c (p<0.001) and IIIa vs b (p=0.01). Mean +EMA dilutions were 197,
302, 466; IIIa vs c (p=0.001). Mean BMI% were 66, 57, 41; IIIa vs c (p=0.01). Mean hgb
were 13.2, 13.5, 12.2; IIIb vs c (p=0.02). Mean MCV were 82.5, 84.5, 77.2; IIIb vs c (p=
0.01). Among children with CD but no DM, mean TTG values were 79, 295, 385 in MIIIa-
c; IIIa vs b (p=0.01) and IIIa vs c (p=0.003). Mean +EMA dilutions were 173, 318, 464;
IIIa vs c (p=0.008). Mean BMI% were 60, 58, 31; IIIb vs c (p=0.01) and IIIa vs c (p=0.02).
Mean hgb were 13.2, 13.5, 11.8; IIIb vs c (p=0.007) and IIIa vs c (p=0.04). Mean MCV
were 82.7, 86.7, 75.5; IIIb vs c (p<0.001) and IIIa vs c (p=0.02). Among children with CD
and DM, mean TTG were 120, 204, 477 in MIIIa-c. Mean +EMA were 230, 240, 469 in
MIIIa-c. Differences not significant. No significant differences were seen among BMI%, hgb,
or MCV in MIIIa-c in this group. Duration of symptoms, type, cereal introduction age,
hypoalbuminemia (seen in 7%), and hepatitis (seen in 26%) did not differ between MIIIa-
c groups or DM vs no DM groups. Conclusion: TTG and EMA mean values are higher in
CD children with severe blunting (MIIIc) than in those with mild blunting (MIIIa). This
correlation was not significant when only diabetics were assessed. BMI percentile, hemo-
globin, and MCV also significantly correlate with degree of damage but not in diabetics.
Symptom duration, type, cereal introduction age, albumin, or transaminases did not correlate
with degree of damage in any group.
W1131
Incidence of Enteropathy Associated T -Cell Lymphomas
Wieke Verbeek, Abdulbaqi Al-toma, Gerrit A. Meijer, Joost J. Oudejans, Chris J. Mulder
Background: Enteropathy-associated T-cell lymphomas (EATL) are T-cell non-Hodgkin
lymphomas of the small bowel (SB), which are associated with Celiac Disease (CD). EATLs
arise in patients with either previously known or newly diagnosed CD. In a subgroup of
patients EATL is preceded by a progressive deterioration, a refractory form of CD. There is
little information about the incidence of EATLs. Aim: To study the incidence and clinical
characteristics of patients with EATL in The Netherlands. Design and Methods: A survey in
the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA)
was performed including all T-cell lymphomas with an initial presenting tumour in the
small bowel. The data on patients diagnosed with small bowel T-cell lymphomas between
2000 -2004 were analysed. Results: Clinico-pathological data were gathered for 91 cases of
EATL; 19% occurred in the duodenum, 20% in the jejunum, 7% in the ileum, 5% in more
than one site and 49% in non-specified sites of the intestine. There is a predominance of
males (65%) versus females (35%). The overwhelming majority (89%) of patients are 50
years and over. Conclusions: This study indicates EATL is a rare complication of therapy
refractory celiac disease with an incidence of 0.12 per 100.000 inhabitants per year. EATL
occurs mainly in patients over the age of 50, mean age 62 years (SD ± 11), primarily in
the proximal small bowel. Because celiac disease in old age patients is sometimes not noted,
it is possible that the actual incidence is considerably higher. It might be interesting to look
for CD associated T-cell lymphomas outside the gastrointestinal tract.
W1132
Serological Responses to Bacterial Antigens in Celiac Disease Patients
Sara Ashorn, Hanna Raukola, Tuuli Välineva, Merja Ashorn, Katri Kaukinen, Immo
Rantala, Bo Wei, Jonathan Braun, Pekka Collin, Markku Mäki, Tiina Luukkaala, Mikko
Hurme, Sari Iltanen
Background: Commensal luminal bacteria are involved in activating dysregulated mucosal
immune responses. The aim of this study was to seek for evidence of possible bacterial
targets related to celiac disease (CD) by determining anti-I2 and anti-OmpW levels in the
sera of patients suspected for CD. Methods: 242 patients with CD suspicion referred to the
Departments of Paediatrics and Gastroenterology, Tampere University Hospital and 80
adult control persons were included to the study. Upper gastrointestinal endoscopies were
performed to all 242 patients. Sera from patients were tested for antibodies to P. fluorescens
associated sequence I2 and to a Bacteroides caccae TonB-linked outer membrane protein,
OmpW. Results: The diagnosis of CD was confirmed in 126 patients (40 children and 86
adults). CD was excluded on biopsy in 116 cases (29 children, 87 adults). Frequency of I2
positivity (73%) and OmpW positivity (61%) was increased in CD patients. Anti-I2 and
anti-OmpW levels in the sera were significantly higher in adult CD patients when compared
to healthy controls (p<0.001, p<0.001). Serum anti-OmpW levels seem to increase with
age in healthy adults. Conclusions: These novel results give evidence of positive seroreactivity
to I2 and OmpW in CD. Strong serological responses to microbial antigens observed here
suggest that immune responses to commensal enteric bacteria play important role in inducing
mucosal damage in the small intestine.
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W1133
The Myo9b Gene Is a Strong Risk Factor for the Development of Refractory
Celiac Disease
Victorien M. Wolters, Wieke Verbeek, Alexandra Zhernakova, Charlotte Onland-moret,
Marco W. Schreurs, Alienke J. Monsuur, Willem Verduijn, Cisca Wijmenga, Chris J.
Mulder
Background & Aims Celiac disease (CD) is associated with HLA-DQ2 and HLA-DQ8 and
has been linked to genetic variants in the MYO9B gene on chromosome 19. HLA-DQ2
homozygosity is associated with complications of CD such as refractory celiac disease type
II (RCD II) and enteropathy-associated T-cell lymphoma (EATL). We investigated whether
MYO9B also predisposes to RCD II and EATL. Methods Genotyping of MYO9B and molecular
HLA-DQ2 typing was performed on 62 RCD II and EATL patients, 421 CD patients and 1624
controls. Results Three SNPs in MYO9B showed a significantly different allele distribution in
RCD II and EATL patients compared to controls (p=0.00002, 0.05 and 0.04, respectively).
The rs7259292 T allele was significantly more frequent in RCD II and EATL patients
compared to CD patients (p=0.0003, OR 3.61 (95% CI 1.78-7.31)). The frequency of the
haplotype carrying the T allele of this SNP was significantly increased in RCD II and EATL
patients (11%), compared to controls (2%) and CD patients (3%) (OR 6.76 (95% CI 3.40-
13.46), p=2.27E-09 and OR 4.22 (95% CI 1.95-9.11) p=0.0001, respectively). Both MYO9B
rs7259292 and HLA-DQ2 homozygosity increase the risk for RCD II and EATL to a similar
extent when compared to CD patients (OR 4.3 (95% CI 1.9-9.8) and 5.4 (95% CI 3.0-9.6),
respectively) without evidence for interaction between these two risk factors. Conclusion
This study shows that both MYO9B and HLA-DQ2 homozygosity might be involved in the
prognosis of CD and the chances to develop RCD II and EATL.
W1134
Meta-Analysis of Observational Studies On the Prevalence of Fractures in
Celiac Disease
Martin Olmos, Marina Antelo, Horacio Vazquez, Edgardo Smecuol, Eduardo Mauriño,
Julio C. Bai
Background/Aims: Evidences of an increased bone fracture risk in celiac disease (CD) are
on debate. Our aim was to review systematically the current published information on
fractures in CD and to perform a meta-analysis. Methods: Controlled studies with cross-
sectional, case-control and cohort designs were identified by searching MEDLINE (1966-
2006) and LILACS (1982-2006). Participants were CD patients of both sex and the outcome
measure was the presence of any fracture. Studies were screened for inclusion by two authors
who independently extracted the data.Methodological quality was assessed using the STROBE
(Strengthening the Reporting of Observational Studies in Epidemiology Statement) recom-
mendations. Data were analyzed using the RevMan Analyses statistical package in Review
Manager (version 4.2.8) and reported as pooled odds ratio (OR) using a random effect
model. Heterogeneity was investigated (standard chi-square test) and sensitivity analysis was
performed based on the reported quality and design type. Results: While 59 of 404 studies
met the initial screening criteria, only seven fulfilled inclusion criteria after detailed review.
These studies evaluated a total of 6,789 CD patients having 808 (11.9%) fractures and
27,750 controls with 2,119 (7.6%) fractures (pooled OR= 1.59; 95% CI 1.12-1.55) and
showed considerably heterogeneity among studies (p<0.00001). As sensitivity analyses, we
assessed study subgroups formed according to the quality of the results and the types of
participants. Excluding the study with the widest confidence interval, an almost 50%
increased risk of fractures for CD patients (OR= 1.46, 95% CI 1.05-2.03) was shown.
Furthermore, studies only enrolling hospital-based participants (n=5) showed a significant
increase in fractures (OR: 1.90; 95% CI 1.16-3.11). In contrast, the analysis of cohort studies
reporting population-based data (n=2) did not evidence increased risk (OR: 0.99; 95% CI
0.68-1.44). Conclusions: Our meta-analysis confirms a significant association between bone
fractures and CD. However, qualitative and quantitative differences among studies were
evident. Further research is necessary to overcome this heterogeneity and to determine if
the fracture risk may differ in concordance with the intensity of the clinical compromise as
it is suggested by sensitivity analyses.
W1135
Usefulness of Intraepithelial Lymphocyte Profiling in Celiac Disease Diagnosis
Marta Alvarez, Santiago Vivas, Maria luisa Fernandez, Hector E. Torres, Jose maria Ruiz
de morales
Background/Aims: Intraepithelial lymphocyte (IEL) analysis would be helpful to diagnose
borderline celiac disease (CD) cases. However, the diagnostic value of the commonly increased
γδ-IELs on its own is controversial. The clinical value of IEL profile analysis and its efficacy
in borderline CD cases were assessed. Methods: Mucosal biopsies were taken by endoscopy
from the distal duodenum. Flow-cytometry analysis of IELs was performed in 43 subjects:
17 CD patients, 11 controls and 15 borderline (e.g.: increased IELs, crypt hyperplasia or
mild villous atrophy at histopathology; low antibody titters with normal biopsy). IEL analysis
was divided into: total IELs, γδ-IELs and NK-like IELs. HLA-DQ and CD serologic markers
were determined. Results: An increased total IELs (8,5% vs 4,6%) and γδ-IELs count (33,4%
vs 6,9%) was observed in the CD cases when compared with the borderline group (p<0,01).
NK-like IELs were significantly decreased in the CD cases vs the borderline group (5% vs
9%; p=0,002). When IEL profile was compared between the borderline group and the
control group, no differences were observed. The overall analysis showed a sensibility for
total IELs, γδ-IELs and NK-like IELs of 58%, 94% and 76% respectively and a specificity
of 84%, 88% and 69% respectively. Finally, CD was ruled out in all of the 15 borderline
patients: 7 showed HLA-DQ2-8 negative; 7 did not improve after gluten free diet and their
histological abnormalities disappeared during follow-up; eosinophilic enteritis features were
present in the remaining one. When γδ/NK-like IELs ratio ≥ 2 was employed as a criteria
for the diagnosis of CD, the sensibility and specificity were 100% and 94% respectively.
Only the patient suffering from eosinophilic enteritis scored a ratio >4. Conclusions: IEL
profile combining γδ+ and NK-like IELs percentages may increase CD diagnosis efficacy.
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The γδ+/NK-like ratio might be applied in borderline CD cases in order to clarify a definit-
ive diagnosis.
W1136
The Prevalence of Celiac Disease in a Well-Defined North American
Population
Joseph A. Murray, Tricia L. Shugart, Brian Lahr, Alan R. Zinsmeister, Carol T. Van dyke,
Robert L. Kyle, L. joseph Melton
Celiac disease is an under diagnosed condition in North America. Different strategies for
detection of celiac disease have been suggested: one of which is case finding in those who
are at high risk for the disease; and another general population screening. Our population
has been extensively studied and documented an increase in clinically detected cases and
subsequently the contribution of at risk groups has been measured. The aim of this study
is to report the prevalence of celiac disease in 2 samples (people under 40 and a second
over 50 years of age)of the general adult population from this community. Methods; Serolo-
gical testing has been performed on 9,965 serum samples derived from county residents
(total adult population ~ 90,000 adults). Thosewith positive or equivocal TTg -IGA antibodies
were submitted for EMA-IgA testing. Those found to be TTG negative were considered as
negatives and those that are EMA positive were considered positive and used a surrogate
for likely celiac disease. Results: Of the 9965 adults tested, a total of 88 were positive for
TTG-IgA. 69 were positive for EMA-IGA Subsequently, the rate of those classified as positive
was 1:144 or 0.7% of the adult population. There was a greater proportion of females tested,
however the rate of celiac disease related seropositivity was not greater in females than
males. There was no difference in seroprevalence between older and younger cohorts.
Conclusions: Seroprevalence of celiac disease is much more common in this population
that was clinically determined or even estimated by study of high risk groups. Studies of
comorbidities are necessary and underway to determine significance of these undiagnosed
cases
W1137
Usefulness of Gluten-Free Diet in Gluten-Genetically Predisposed Subjects
Positive to Intestinal-Mucosa Anti-Transglutaminase Antibodies
Tarcisio Not, Fabiana Ziberna, Serena Vatta, Stefano Martelossi, Roberto Marzari, Fiorella
Florian, Vincenzo Villanacci, Daniele Sblattero, Alessandro Ventura
Celiac disease (CD) auto-antibodies against tissue transglutaminase (anti-tTG) are produced
in the intestinal mucosa even when not measurable in serum. Aim: To investigate by means
the phage display libraries technique, whether the intestinal mucosa production of IgA anti-
tTG could be important in the diagnostic work-up of early-stage CD, when mucosal histology
is not yet diagnostic among subjects with high risk of CD such as first degree relatives of
CD patients (FDR) or subjects with autoimmune disease (SAD) tested negative for serum
anti-tTG but positive for CD related HLA DQ2 or DQ8. Methods: We propose to FDR with
or without symptoms and to SAD a prospective study to uncover early-stage of gluten
intolerance by measuring the mucosal VH5 restricted gene family anti-tTG clones in two
biopsies: before and after one year of gluten free-diet (GFD). We report clinical, histological
and biomolecular features before and after GFD. The present study was approved by the
independent ethical committee of our hospital. Results: From March 2005 we enrolled 38
subjects (25F,median age 25y): 34 FDR and 4 SAD. 14 FDR were with autoimmune disease,
3 FDR with anaemia, 1 with unexplained hypertransaminasaemia, 1 with diarrhoea, 1 with
severe constipation and 16 FDR were asymptomatic. 4 SAD were 1 with alopecia, 1 type1-
diabetes and anemia, 1 with thyroiditis, 1 with thyroiditis and chronic urticaria . 29/38
subjects were positive for CD related HLA (26 DQ2,3 DQ8) and 27 agreed to the study.
Intestinal biopsy showed normal mucosa in 22 and type 2 lesion in 5. Anti-tTG mucosal
clones were present in 22/27 biopsies. 23/27 agreed to the GFD (4 asymptomatic and 19
symptomatic subjects). During GFD (median 10 m. range 4-12 m.) symptoms and signs
that could have been related to gluten had disappeared in 12/19 (63%) symptomatic subjects.
Haemato-chemical parameters returned to normal ranges in 4 subjects with iron deficiency
anemia and in one with hypertransaminasemia. Overall, 2 subjects with severe constipation,
1 with dermatitis herpetiformis 1 with chronic urticaria and 1 with diarrhoea completely
improved. One FDR with autoimmune hepatitis reduced for the first time the need for
immunosuppressive therapy and one with autoimmune pancytopenia dramatically improved.
Conclusion: In the contest of genetic predisposition to gluten intolerance intestinal anti-tTG
antibodies may represent the earliest marker of gluten dependent immune response. The
GFD strongly improved symptoms and autoimmune disease supporting that gluten is harmful
in these subjects. We are working on the second biopsies to measure the mucosal anti-tTG
antibodies after one year of GFD.
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W1138
Survival in Patients with Refractory Celiac Disease and Enteropathy
Associated T Cell Lymphoma
Wieke Verbeek, Abdulbaqi Al-toma, Mohammed Hadithi, Mary Von blomberg, Chris J.
Mulder
Background: Celiac disease may be regarded as refractory disease (RCD) when symptoms
persist or recur despite strict adherence to a gluten free diet. RCD may be subdivided into
types I and II with a phenotypically normal and aberrant intraepithelial T-cell population,
respectively. RCD I seems to respond well to azathioprine/prednisone therapy. RCD II is
usually resistant to any known therapy and transition into Enteropathy-Associated T-cell
Lymphoma (EATL) is common. Aim: The aim of this study is to provide further insight
into RCD and the development of EATL, by reporting on long term survival, risk of transition
of RCD into EATL in one of the the largest cohorts of patients with complicated celiac
disease in a single center. Design and Methods: We have retrospectively compared four
groups of patients with complicated celiac disease: 43 RCD-I, 50 RCD II (total), of whom
26 RCD II who developed EATL after a period of refractoriness to a gluten free diet (secondary
EATL) and 13 EATL patients without preceding history of complicated celiac disease (de
novo EATL). Every effort was made to ensure correct classification and accurate patient
allocation. Results: No celiac disease related mortality is recognized in the RCD I group.
The overall five year survival in RCD I is 96%, in RCD II (total) is 58% (P=0.001) and in
RCD II after developing EATL is only 8%. The 2 year survival in the de novo EATL is 20%
versus 15% in secondary EATL (P=0.63).Twenty eight (56%) from 50 patients with RCD-
II died, 23 (46%) due to EATL and 4 due to progressive refractory state with emaciation
and one from neuroceliac disease. Conclusion: Remarkably, no patient with RCD I developed
RCD II or EATL within mean follow up of five years (range 2-15 years). Fifty two percent
of the RCD II patients developed EATL within 4-6 years after the diagnosis of RCD II. More
aggressive therapy seems necessary in RCD II and EATL.
W1139
Azathioprine Toxicity in the Treatment of Inflammatory Bowel Disease:
Outpatient Clinic Experience of Seven Years
Ibrahim Hatemi, Birol Baysal, Ebubekir Senates, Yusuf Erzin, Aykut Celik
Aim: Azathioprine is frequently used in the treatment of inflammatory bowel disease (IBD).
The aim of this study is to determine the incidence and the causes of withdrawal and dose
reduction of azathioprine in patients with IBD. Methods: Patient charts of IBD patients
followed in our dedicated IBD outpatient clinic from 1999 to 2006 were reviewed for side-
effects of azathioprine. Results: 590 IBD patients (including 21 with Behçet's syndrome)
were treated between 1990 and 2006. Among these, 151 received azathioprine (66 female
85 male, mean age 36.3 ± 11.3 years). The diagnosis of these patients was Crohn's disease
(n=100), ulcerative colitis (n=36), and Behçet syndrome with gastrointestinal involement
(n=15). The mean disease duration was 3.2 ± 3.9 years and the mean initial dose was 1.9
± 0.4 mg/kg. The mean Crohn disease activity index, Seo index and CRP levels were 168.7
± 97.9, 148 ± 55.3 and 30.4 ± 44.9 mg/dl respectively. The average duration of treatment
was 23.8 ± 19.6 months. These patients had 2.1 ± 1.5 visits per month during their follow-
up. Drug toxicity was observed in 26 of 151 (17.2%) patients who received azathioprine.
In 13 (13/151, 8.6%) of these patients, azathioprine treatment was discontinued. The causes
of drug withdrawal were hepatotoxicity (n=3), pancreatitis (n=2), leukopenia (n=1) and
gastrointestinal intolerance (n=7). Leukocyte count was below 3000 /µL in 3 patients and
one of them had accompanying fever which was controlled with antibiotic thearpy. The
mean azathioprine dose of these patients was not significantly different from those who did
not experience toxicity (1.8 ± 0.4 mg/kg versus 1.9 ± 0.4 mg/kg p= 0.76). The current
drug dose in patients who are using azathioprine is 2 ± 0.4 mg/kg. Conclusion: Although
azathioprine therapy is considered to be relatively safe in IBD, toxicity was observed in
17.2% and discontinuation of the drug was necessary in approximately 9 % of patients due
to side effects. Pancreatitis and gastrointestinal intolerance appears earlier than hepatotoxicity.
Leukopenia is a rare cause of azathioprine discontinuation.
Types of toxicity and mean time to toxicity appearance
F:female M:male CD: Crohn's disease UC:Ulcerative colitis BS: Behçet syndrome
W1140
Bone Mineral Density in Corticosteroid Naive Crohn's Disease Patients
Birol Baysal, Ibrahim Hatemi, Ebubekir Senates, Yusuf Erzin, Aykut Celik
Aim: The aim of this study is to determine if there is a difference between the bone mineral
density (BMD) of corticosteroid naive Crohn's disease (CD) patients and irritable bowel
disease (IBD) patients as a control group. Methods: CD patients who were referred to our
inflammatory bowel disease outpatient clinic were involved in the study. Exclusion criterias
were: past or current corticosteroid therapy, medical history of intestinal operation, other
disease which can result in osteoporosis, and for women being in postmenopausal period.
The same criterias were used for control group which was selected as age and sex matched
with CD group between IBD patients. BMD measurements were performed in all patients.
Results: 109 consecutive CD patients were included in the study, 76 of them were excluded
according to the criterias (corticosteroid therapy (n= 40), intestinal operation (n=28), post-
menopausal period (n=5), celiac disease (n=1), ankylosing Spondiylitis (n=2) ). A total of
33 CD patients (11 female, 22 male, mean age: 36,9 ± 12,4 years) and 33 control group
patients (12 female, 21 male, mean age: 39,3 ± 9,9 years) were involved in the study. There
was no bone fracture history in CD patients either in the control group. The mean disease
duration time and mean time period from the begining of symptoms were 5,4 ± 7,7 and
25 ± 24,3 months respectively. The mean Crohn's disease avtivity index and CRP levels at
the time of DXA investigation were 194 ± 73 and 33 ± 36,4 mg/dL. At the time of DXA
investigation 19 patients (7 female,12male) were usingmedications other than corticosteroid,
14 patients (4 female, 10 male) were not using any drugs. The BMD of both groups are
shown in the table. There was no relation between lomber and vertebral BMD and age of
the disease or symptom duration time in CD patients. There was no statistically significant
difference between lumbar spine and femoral BMD of patients who were using therapy and
who were therapy free (p=0,36 and 0,44). There was no statistically significant difference
in BMD of femoral and lumbar spine region between two groups (p= 0,37 and 0,49 ). The
incidence osteoporosis and osteopenia in CD patients were 18,2 % (6/33) and 54,5 % (18/
33) and was not statistically different from control group (p=0,47 and 0,21). Conclusion:
In steroid naive Crohn disease patients BMD and incidence of osteoporosis is not different
from control group.
* p=0,37 † p=0,49
W1141
Infliximab Therapy Does Not Worsen Heart Function in Children with
Inflammatory Bowel Disease
Maria Barbato, Mario Curione, Franca Viola, Paolo Versacci, Fabiana Parisi, Claudia
Castro, Silvia Di menna, Salvatore Cucchiara
Anti-TNF-alpha monoclonal antibody is thought to be an effective treatment for severe
pediatric IBD,unresponsive to corticosteroids(CS)and/or immunomodulators.However,there
are many concerns on the safety of such therapy.Recently,sporadic cases of new-onset heart
failure have been reported in non cardiopathic adult IBD patients receiving IFX and in a
previous study we have reported a cardiac involvement in 7 children during IFX therapy,5
of whom received also CS(InflammBowelDis2006;12:828-9).IFX is also contraindicated in
subjects with heart failure. Aims: we have monitored prospectively cardiac function in
consecutive children recruited for IFX therapy due to severe active IBD,unresponsive to
traditional drugs. Methods:22 children(15 males,median age 9.0 years;range:7-17),14 with
Crohn's disease,8 with ulcerative colitis received a course of i.v.IFX(5 mg/kg)at weeks 0,2,6
and then every 8 weeks;11 also received courses of CS.Computed standard 12-lead ECG
and doppler heart ultrasound(US)were performed in all patients,at baseline and before
each IFX infusion.The US z-score measurement of the following cardiac functions was
performed:Ejection Fraction(EF), Ventricular Diastolic Diameter(LVDD),Left Ventricular Sys-
tolic Diameter(LVSD),Thickness both of Interventricular Septum(TIVS)and Posterior
Wall(TPW).Twenty children(median age:10 years,range 6-16 years),without organic diseases
served as controls. Results:no ECG or US alterations were detected in the controls,whereas,at
baseline,20 patients had abnormalities in at least one of the US variables evaluated.Abnormali-
ties in LVDD,LVSD,TIVS,TPW were detected in 13,13,18 and in 12 patients,respectively,be-
fore beginning IFX therapy.There was no statistical difference in baseline US z-scores between
children on CS and those without CS(Fisher test:1-tiled p=0.762;2-tiled p=1.00).During the
IFX course,no patient showed a worsening in ECG and US variables before each IFX infusion
and at a 6-month follow up during the re-treatment program.No linear correlation was
found between number of positive US z-scores and the number of IFX infusions(r=0.28).
Conclusions:abnormalities in heart function are present in a high percentage of children
with active IBD;these features do not seem to be related to CS and are not worsened during
repeated infusions of IFX.Our data suggest that heart can be affected in children with active
IBD irrespective of therapy and that IFX can be safely administered despite the presence of
functional heart abnormalities;however,until a prolonged follow up evaluation of the heart
function will be available,a strict functional cardiac control of patients undergoing IFX
therapy is recommended.
W1142
NO Association Between the Tucan (Card8) Cys10stop Mutation and
Inflammatory Bowel Disease (IBD) in a Large Retrospective German and a
Prospective Norwegian Sample
Andre Franke, Philip Rosenstiel, Tom hemming Karlsen, Tobias Balschun, Oliver Von
kampen, Jochen Hampe, Stefan Schreiber
Background and Aim: The nonsense mutation Cys10Stop (rs2043211 A→T) in the gene
TUCAN (tumor-upregulated CARD-containing antagonist of caspase nine) has recently been
found to confer risk in British (McGovern et al., Gastroenterology 2006) and Hispanic
(Dutridge et al., abstract on ASHG 2006) patients with inflammatory bowel disease (IBD).
Because of its gastrointestinal expression and its regulatory function of NF-κB, TUCAN is
a sensible IBD susceptibility gene. It was therefore aimed to replicate the association in two
patient panels from Germany and Norway. Methods: The German study population included
1925 Crohn's disease (CD) and 725 Ulcerative colitis (UC) patients along with 1615 healthy
controls. This panel had a pre hoc power of 88% (UC) and 99% (CD) to replicate the
previous finding (α=0.05, OR=1.35, p0=64%). Along with 564 of the CD and 376 of the
UC patients, healthy parents were genotyped to allow for transmission disequilibrium tests
(TDTs). In addition, clinically well-characterised Norwegian CD (n=141), UC (n=237),
and healthy controls (n=364) were included. Genotyping was performed using TaqMan®
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technology (Applied Biosystems). Results: No significant association between the A allele at
rs2043211 and risk for CD or UC was detected neither in the case-control, nor in the family-
based analyses. Furthermore, no association was found between this allele and disease
extension as in the original report. There was also no significant association in the NOD2-
negative CD subgroup as reported for the British sample. The frequency of the rs2043211
A allele was 67%, 64% and 65% for the German CD, UC and healthy controls, respectively.
Frequencies for this allele in the Norwegian cohorts were 68% (CD), 69% (UC), and 68%
(healthy controls). In comparison, the frequencies were 64% (controls, n=365), 71% (CD,
n=372), and 69% (UC, n=373) in the British and 69% (controls, n=110) vs. 77% (CD, n=
128) in the Puerto Rican population. Conclusions: We were unable to replicate the previously
reported association between a coding TUCAN risk variant and susceptibility for CD or UC
in a well-powered enquiry in German and the Norwegian cohorts. Although it cannot be
excluded that other variants in TUCAN contribute to risk for IBD in these populations, our
findings raises the possibility of a type I error in the original studies. Comparable allele
frequencies among the healthy controls states it less likely that underlying genetic heterogen-
eity causes the discrepant findings, and further studies are needed prior to establishing
TUCAN as an IBD susceptibility gene explaining previous linkage to chromosome 19p13
(IBD6).
W1143
Variants in NOD2 Genotype Are Associated with Decreased Numbers of
Foxp3+ T Cells in Both the Periphery and Lamina Propria of Patients with
Crohn's Disease (CD)
Meher Rahman, Thomas C. Smyrk, Phyllis A. Svingen, James D. Lord, William A.
Faubion
Background and Aim: The mechanism by which NOD2 and single nucleotide polymorphisms
predispose to CD is poorly understood. Current data demonstrate the presence of pathogen
recognition receptors (PRRs) including NOD2 in T regulatory cells (Tregs) but little is known
about the function of NOD2 in relation to CD. Understanding that other PRRs affect Treg
homeostasis, we aim to evaluate if the number of FOXP3+ Tregs in the periphery and
mucosa of CD patients is affected by NOD2 polymorphisms. Methods: CD4+T cells were
isolated from the peripheral blood of 21 CD patients (7 with active, 14 with inactive disease,
mean age 41.4 ± 13.3 yrs) and 5 healthy controls (mean age 36 ± 7.8 yrs) by a MACS sort.
An aliquot was subjected to flow cytometry for FOXP3. NOD2 genotype was assessed by
pyrosequencing. Immunohistochemistry (IHC) for CD4 and FOXP3 was performed on
colonoscopic biopsies. Treg survival upon growth factor withdrawal was assayed in
CD25++CD127lo T cells in the presence and absence of the NOD2 ligand MDP (100ng/
ml). Results: The median number of peripheral FOXP3+ cells was markedly reduced in
patients with CD compared to controls [8,300 (IQR 5,280-18050) vs 57566 (IQR 50398 -
67580); p<0.01]. The number of FOXP3+ cells in CD patients was not affected by disease
activity or medications including immunomodulators, steroids and anti-TNF agents. This
absolute decrease was not secondary to lymphopenia as the mean percent FOXP3 was also
significantly decreased (3.9± 3.7% vs 7.9± 1.7%). The frequency of NOD2 homozygous
(HM) variants was 9% (2/21) and represented 2 of the 3 patients with the lowest number
of peripheral Tregs. On IHC the HM variant had half the number of FOXP3+ Tcells compared
to the heterozygous (HT) and wild type (WT) variants, 17/100 vs 34/100 CD4+cells. Sixty
eight percent of Tregs isolated from healthy WT controls survived 3 days of growth factor
withdrawal. StimulationwithMDP significantly enhanced survival [(68± 1.9% vs 76± 0.67%),
p<0.05]. While the overall survival was poorer in Tregs from CD patients, the effect of
NOD2 ligation was maintained in cells of WT genotype (46± 14% vs 57± 17%). Importantly,
no MDP effect was seen among cells of the variant NOD2 genotype. Conclusions: These
results demonstrate a deficiency in the absolute number of Tregs in the periphery of patients
with Crohn's disease which is unrelated to disease activity and medication use. NOD2 HM
variants have lower numbers in the periphery and tissue. Survival of peripheral Tregs from
CD patients, especially those with NOD2 variation, is decreased. Further mechanistic studies
are needed to define the role of NOD2 in Treg survival.
W1144
High Placebo Response Rates in Randomized Controlled Trials of Ulcerative
Colitis: A Meta-Analysis
Alphonso Brown, Ciaran Kelly, Adam S. Cheifetz, Sagar Garud
Background: As for other diseases randomized controlled trials (RCTs) are considered the
gold standard for evaluation of new drugs in Ulcerative Colitis (UC). The placebo response
rate in these trials varies from 0% to 76%. Purpose: To quantify the pooled placebo response
rate in RCTs studying UC and identify the factors affecting it. Data Sources: MEDLINE,
OLDMEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) and biblio-
graphies of previous meta-analyses and review articles were searched for RCTs from 1955
to 2005. Study selection: Double blind placebo controlled randomized clinical trials published
in full in English language. Only RCTs reporting results as the percentage of participants
achieving the endpoint were selected. Data extraction: Two investigators independently
extracted data on study design, participant characteristics and placebo response rates for
various endpoints. Results: One hundred and nineteen studies involving 9341 participants
were selected. The pooled placebo remission rate was 23% (95%CI: 18.4%-28%) and
the pooled placebo response rate was 32.1% (95%CI: 28.1%-36.3%). Studies carried out
exclusively in United States had significantly lower placebo remission rate (10.9%; 7.4%-
14.9%) as compared to studies not carried out exclusively in US (25.7%;20.4% - 31.4%)
(P=0.03). Placebo response rate was significantly lower for studies carried out exclusively
US (22.7%; 16.3% - 30.0%) as compared to studies not carried out exclusively in US (36.1%
31.4% - 41.0%) (P = 0.04). Trials with duration >4 weeks had a higher endoscopic remission
rate as compared to trial with duration < 4 weeks (P = 0.001). Diary keeping was associated
with lower placebo response rate in univariate analysis (P = 0.04) but was not significant
in the multivariate analysis. Limitations: Studies reporting outcomes in forms other than
percent improvement were not included. We may have missed some factors modifying the
placebo response because of lack of patient level data. Conclusions: Placebo remission and
response rates in RCTs of UC are highly variable and are significantly influenced by the
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country where the RCT is performed and its duration. More research needs to be done to
define why studies done in different countries have different placebo response rates. The
reasons for these differences may lie in themechanisms of patient recruitment and assessment,
rather than the characteristics of the disease or study design. It might be useful to compare
outcomes at individual centers in multicenter trials conducted in both US and European
countries. This is clearly of major importance for multi-national trials.
W1145
Long-Term Episodic Infliximab Treatment in Crohn's Disease. A Danish Crohn
Colitis Database Study
Natalia Pedersen, Sarah Caspersen, Margarita Elkjær, Lene Riis, Vibeke Wever, Pia
Munkholm
BACKGROUND: It has been debatedwhether CDpatients obtain the same long-term response
on “episodic” (EPI) as on “maintenance” (MAIN) Infliximab (INF) therapy. The argument
against EPI therapy has been loss of response and mucosal healing due to dev. of anti-
bodies against INF. Thus INF therapy on demand regime is usually not recommended.
However, data on long-term outcome is sparse. AIM: To compare long-term outcome in
patients with moderate to severe CD on EPI vs. MAIN INF therapy. METHODS and MAT-
ERIAL: EPI regimen (on demand +/- induction week 0, 2, 6) was compared to MAIN regimen
(induction week 0, 2, 6 + maintenance every 8th week) at an INF dosage of 5 mg/kg.
Immediate response after 1 month was classified in complete (CR), partial (PR) and non
responders (NR). Three months after ending INF, prolonged response was assessed in 3
outcome groups: Prolonged (PRO) responders maintaining CR or PR, INF dependent (ID)
regaining CR or PR at any infusion, and NR. Chi-square was used for comparison of groups.
p<0.05 was considered significant. RESULTS: From 1999-2006 124 consecutive patients
were treated with INF. 84 patients (68%) had EPI, 18 (15%) MAIN and 22 (17%) had
induction therapy only. The last group was excluded. In the EPI group 50 (60%) had luminal
CD, 34 (40%) combined fistulising and luminal vs. in MAIN 13 (72%) with luminal CD
and 5 (28%) combined, p=0.3. Median (M) age in EPI vs. MAIN was 39 years (r 20-68)
vs. 40 years (r 16-62), ns. A total of 593 INF infusions were administered. EPI: 440 (M: 3,
r: 1-22) vs. MAIN: 153 (M:7, r: 4-14). Duration of treatment was in M 15 weeks (1-244)
vs. 41 weeks (14-120), ns. The shortest period between INF infusions given episodically
was 6 weeks and the longest 50 weeks. 72 (86%) patients in EPI group and all in the MAIN
group were treated concomitantly with AZA or MTX The immediate response in EPI vs.
MAIN group revealed that 39 (46%) obtained CR, 30 (36%) PR and 15 (18%) NR compared
to 11 (61 %) obtaining CR, 7 (39%) PR and 0 NR, p=0,06. Long-term response showed
that on EPI therapy, 39 (47%) patients obtained PRO, 22 (26%) ID, and 23 (27%) NR vs.
on MAIN 2 (11%) PRO, 12 (67%) ID and 4 (22 %) NR. No significant difference was
revealed in responders (PRO + ID) vs. non-responders (NR) (p=0.6) in the two regimens.
However significantly more patients on episodic therapy gained PRO and less became ID,
p=0.0008. Surgery was performed only in the NR groups and no significant difference was
found in EPI 28 (33%) vs. in MAIN 4 (23%). CONCLUSION: Episodic INF therapy seems
to have long-term benefits over maintenance therapy, as more patients achieve prolonged
response and less develop INF dependency.
W1146
Effect of Infliximab On Circulating Levels of Leptin, Adiponectin and Resistin
in Inflammatory Bowel Disease
Konstantinos Karmiris, Ioannis E. Koutroubakis, Costas Xidakis, Maria Polychronaki,
Elias Kouroumalis
Background: There is evidence that adipocytokines play an important role in chronic inflam-
mation. Tumor necrosis factor (TNF) a is a critical mediator in inflammation-related altered
metabolism in inflammatory bowel disease (IBD). A number of studies have described an
interaction between TNFα and adipocytokines in various chronic diseases, including IBD.
Infliximab is a well-established anti-TNFα treatment in IBD. To our knowledge, concerning
adipocytokines, only leptin has been examined in relation to infliximab therapy in IBD so
far (1). Aim & Methods: We measured serum levels of leptin, adiponectin and resistin in
20 IBD patients [17 with Crohn's disease (CD) and 3 with ulcerative colitis (UC)] before
and after infliximab treatment using commercially available enzyme-linked immunosorbent
assays (ELISA). Leptin, adiponectin and resistin levels were correlated with disease activity,
alterations of body mass index (BMI) and C-reactive protein (CRP) and response to treatment.
Results: Infliximab induced clinical response or remission in CD patients (P<0.0001). A
significant decrease in CRP levels (P=0.02) and a significant increase in BMI (P=0.006) in
all IBD patients were observed. Mean serum leptin levels were 4.6±0.5 ng/ml and 5.1±0.5
ng/ml before and after infliximab treatment respectively (P=0.41). Mean serum adiponectin
levels were 10513.9±1216.9 ng/ml and 9653.5±1031.5 ng/ml/ml before and after infliximab
treatment respectively, (P=0.36). Mean serum resistin levels were 26.3±4.1 ng/ml and
13.9±1.4 ng/ml before and after infliximab treatment respectively, (P=0.004). No significant
differences were found between patients with clinical response and patients with clinical
remission after infliximab therapy, concerning the circulating levels of the examined adipocy-
tokines (P>0.05). Furthermore no significant correlations between changes of serum adipocy-
tokines and alterations of the BMI after therapy were found. Conclusions: Serum levels of
leptin and adiponectin have no significant alterations after infliximab treatment in patients
with IBD. On the other hand, serum resistin levels are significantly decreased after infliximab
therapy suggesting a possible proinflammatory status of this adipocytokine in IBD. This
alteration of resistin levels indicates a close relationship with TNFα levels. Future studies
will show if resistin can be used as a clinical marker for monitoring inflammatory changes
in IBD patients. Reference 1. Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti
Y, Gervy M-C, Deviere J, Van Gossum A. Impact of infliximab on serum leptin levels in
patients with Crohn's disease. J Clin Endocrinol Metab 2005; 90: 3510-6.
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W1147
Ulcerative Colitis and Irritable Bowel Syndrome: Relationships with Quality of
Life
Reza Ansari, Fatemeh Attari, Hadi Razjouan, Hiva Amjadi, Shahin Merat, Reza
Malekzadeh
Backgrounds and aims: Quality of life is reduced in inflammatory bowel disease (IBD).
Irritable bowel syndromes (IBS)-like symptoms seem to be common in IBD patients during
the remission phase. We aimed to 1) assess the prevalence of IBS-like symptoms during the
remission phase of ulcerative colitis (UC) as compared to healthy controls and 2) evaluate
the relative impact of IBS-like symptoms on health- related quality of life (HRQOL) of UC
patients in remission as compared to those in active phase. METHODS: Ninety-five patients
with UC (47.5% male, 52.5% Female; mean age: 37.8 yr ± 14.8) were included: 45 cases
in active phase and 50 in remission (for at least 6 months). One hundred healthy subjects
formed the control group. All patients and controls completed the SF-36 questionnaire. The
controls and UC patients in remission also completed a questionnaire to evaluate IBS-like
symptoms according to ROME II criteria IBS-like symptoms and their influence on HRQOL
of UC patients in remission were compared with those in active phase. RESULTS: The
prevalence of IBS-like symptoms in UC patients in long-standing remission was fourty-six
percent, which was significantly higher than normal population (13%) (OR: 5.7, 95% CI:
2.5-12.7, P<0.05). HRQOL appeared to be significantly reduced in both active UC patients
and “UC patients in remission with IBS symptoms” in comparison to UC patients in remission
without IBS and normal controls. In active UC patients, the mean scores for elements of
physical functioning, social functioning, mental health and vitality (as measured by SF36)
were significantly lower than UC patients in remission (P<0.05). The average SF36 scores
on the various items of UC patients in remission with IBS-like symptoms were considerably
lower than the patients without IBS (P<0.05). No significant scoring differences were found
in different dimensions of SF36 between active UC patients and UC patients with IBS.
CONCLUSIONS: Our study shows, the prevalence of IBS-like symptoms in UC patients in
long-standing remission is over three times higher than normal population. HRQOL of UC
patients in remission with IBS symptoms is affected as much as in matched UC patients
with active disease. Meanwhile, those UC patients in remission who have no IBS symptoms
have a quality of life as good as the general population.
W1148
Colitis in Multiple Myeloma Patients Undergoing Chemotherapy and
Autologous Stem Cell Transplantation: Incidence, and Risk Factors
Somashekar Krishna, Zhao Weizhi, Pavan Chepyala, Monica Grazziutti, Marisa Miceli,
Basma A. Jalil, Kevin W. Olden, Bart Barlogie, Elias Anaissie
Background: Chemotherapy and Melphalan-based autologous stem cell transplant (Mel-
ASCT) is standard therapy for multiple myeloma, but it is associated with colitis including
C. difficile (CDAD) and neutropenic colitis (NC). Purpose: To identify the incidence and
risk factors for developing colitis during chemotherapy and Mel-ASCT. Patients and Methods:
184 consecutive patients (pts)with newly diagnosed myeloma (March 2004- July 2006)
were enrolled in a treatment protocol consisting of 2 induction cycles with multi-agent
chemotherapy, tandem Mel-ASCT (200 mg/m2 body surface area (BSA), and two consolida-
tion cycles. Potential covariates included demographics, serum albumin (alb), total bilirubin
(TbIL), creatinine clearance (CrCl) , mg/kg melphalan dose received, and colitis. Colitis was
diagnosed according to NCI toxicity index. Multiple logistic regression was used to compute
adjusted odds ratio and 95% confidence intervals. Results: 60 pts had colitis (33%) pts;
CDAD 27 (15%) and NC 30(16%); both (3 pts). Recurrence was observed in 13 /27 (48
%) CDAD pts vs. 3/30 (10%) NC pts. Risk factors for colitis at baseline and at various
treatment stages are shown in table. Among 111 IgG myeloma pts, low baseline serum IgA
increased the risk for colitis by tenfold. Conclusions: low ALB, low CrCL, elevated TBIL
and high mg/kg melphalan dose and colitis in prior episode increase the risk for colitis.
Risk factors for colitis at baseline and at various treatment stages are shown in table.
W1149
Rifaximin As a Steroid-Sparing Medication in the Management of Patients with
Mild to Moderate Inflammatory Bowel Disease
Tejal Shah, Robin Baradarian, Kadirawel Iswara, Jian jun Li, Scott Tenner
Broad-spectrum antibiotics are often used in patients with Inflammatory Bowel Disease (IBD)
despite the lack of well-designed, placebo-controlled trials. Rifaximin is a relatively new
synthetic antibiotic that has a broad sprectrum of activity and few side effects due to minimal
absorption from the gastrointestinal tract. Unlike ciprofloxacin and metronidazole, rifaximin
has similar coverage with no systemic side effects. In order to determine the role of Rifaximin
in the management of patients with IBD, the following study was undertaken. 57 patients
with IBD, 21 with Crohn's disease and 36 with Ulcerative colitis were included in the study.
There were 27 female, 30 male patients, mean age 36 +/- 11. All patients presented with
mild to moderate disease manifested as diarrhea and/or abdominal pain. All patients were
currently being treated with mesalamine at high dosage (mean 4.5 +/- 0.9 grams). Patients
were excluded if they had taken other medications, such as infliximab, 6-mercaptopurine
or azathioprine. Due to persistent (n = 29) or recurrent disease (n= 28), the patients were
given either prednisone 40 - 60 mg orally daily (Group 1) or rifaximin 400 mg orally twice
daily (Group 2). If the patients improved, the prednisone was continued for 2 weeks and
then tapered. The rifaximin was continued for 2 months and then tapered. Response was
defined as induction of remission without the addition of other medications. At the judgment
of the clinician caring for the individual patient, additional therapy was provided. Of the
57 patients included in the study, 38 patients were given prednisone, 19 patients were given
rifaximin. 36/38 patients in the prednisone group responded to therapy. The two patients
who did not respond had Crohn's disease and was subsequently given infliximab resulting
in a complete response. Of the nineteen patients given rifaximin, all but 5 responded;
these patients required the addition of corticosteroids, one was hospitalized. This study
demonstrates that the broad spectrum antibiotic rifaximin is effective in patients with IBD
who need treatment with corticosteroids. However, the steroid sparing efficacy must be
considered in a well-defined subset of patients with mild to moderate disease. The use of
rifaximin in ulcerative colitis and Crohn's disease requires further evaluation in larger studies.
W1150
Antiviral Treatment in Crohn 's Patients with Chronic Hepatitis C Is Well
Tolerated and Effective
Thomas-matthias Scherzer, Katharina Staufer, Calin Gurguta, Gottfried Novacek, Peter
Ferenci, Harald Vogelsang
INTRODUCTION: : Due to surgery and/or blood transfusions patients with Crohn 's disease
(CD) are at risk to be infected with hepatitis C. The potential side effect profile of antiviral
combination therapy in patients with CD is unknown. Therefore hepatitis C is rarely treated
in CD. AIM was to analyze the efficacy and tolerability of antiviral IFN/ribavirin therapy in
patients with CD. End of treatment response (ETR) and sustained virologic response (SVR;
undetectable virus PCR at 6 month follow up) rates, were evaluated. METHODS: Nine CD
patients (29-56a; f:5,m:4; colon disease: 1, ileum disease: 2, ileocolon disease: 6; disease
duration: mean 23.4a (range 5-33) and hepatitis C (genotype 1:7, 1 with genotype 3:1,
unknown:1) received either interferonα-2bmonotherapy (n=2) or 180µg/week peginterferon
α-2a (PEGASYS®, Roche, Basel, CH) and 800-1200 mg/d ribavirin (COPEGUS®, Roche,
Basel, CH) combination therapy (n=7) for 24 to 54 weeks. CD specific therapy (mesalazin:
4, azathioprin: 2, mycophenolate-mofetil:1) was maintained throughout antiviral therapy.
Before treatment CDAI was <150 for more than 2 years. Routine blood samples including
CRP, α1-acid glycoprotein and HCV-PCR were taken monthly during therapy and for 6
months follow up. The CDAI was evaluated at baseline (BL) and one month follow up in
seven patients. RESULTS: Of the 9 patients, 8 have finished treatment. All 8 had an ETR;
The remaining patient is HCV-RNA negative on therapy. So far, 6 patients completed follow
up, 4 achieved a SVR, 2 relapsed. Overall, therapy was well tolerated. Due to mildly increased
CD activity (rise of α1-acid glycoprotein: n=5; diarrhea: n=4, increased CRP: n=1) CD
specific treatment was modified in 5 (55%) patients, including 3 requiring glucocorticoids
(2 per os, 1 topical). One patient received antibiotics for exacerbation of preexisting fistula.
No clinically significant major flares in CD activity were noted. The typical side effects of
antiviral therapy required the administration of hemopoetic growth factors: four patients
became anemic (Hb ≤8.1 mg/dl) and were treated with erythropoetin, one patient received
filgrastim because of neutropenia. CDAI was similar at BL (10.5 - 86.8) and 1 months after
end of antiviral treatment (45 - 103). Due to the typical side effects of antiviral therapy
(haematocrit decrease, fever, arthralgia, reduced general condition, loss of weight) the CDAI
cannot be assessed during treatment. CONCLUSION: Hepatitis C treatment is effective and
well tolerated in CD patients. Since immunosuppression favours progression of chronic
hepatitis C, antiviral combination therapy should be offered to patients with inactive CD.
W1151
Changes of the Serum Bile Acid Profile in Patients with Ulcerative Colitis
Receiving Combined Antibiotic Therapy
Hidenari Nagai, Teppei Matsui, Masahiro Kanayama, Kouichi Momiyama, Hidenori
Kurakata, Katsuhiko Matsumaru, Wataru Yamamuro, Yasukiyo Sumino, Kazumasa Miki
BACKGROUND/AIM: It was reported that combined antibiotic therapy (amoxicillin, tetracyc-
line, andmetronidazole) against Fusobacterium varium,whichmight be one of the pathogenic
factors in ulcerative colitis (UC), is effective in patients with severe active UC. We have
already reported that the ratio of total chenodeoxycholic acid to total bile acids (%CDAC)
was significantly higher in patients with UC than in healthy volunteers (HV), while the
percentage of deoxycholic acid (%DCA) of UC was significantly lower than in HV. The ratio
of glycine-conjugated bile acids (BA) to total serum BA was significantly lower during the
active phase of UC compared with the level in HV. These changes did not depend on the
extent of UC (DDW 2006, Los Angeles). The aim of the present study was to elucidate the
serum BA profile in patients with UC receiving combined antibiotic therapy. PATIENTS/
METHODS: The study population included 22 patients in whom UC was diagnosed from
clinical, endoscopic, and histological findings. All patients underwent ileocolonoscopy with
appropriate biopsies. They were divided into 2 subgroups based on endoscopic findings as
follows: 16 patients with UC controled by mesalazine or salazosulfapyridine (5-ASA), and
8 patients with UC that required combined antibiotic therapy plus 5-ASA (ATM). The control
group was composed of 8 HV. Routine laboratory tests were done on the basis of clinical
need, and fasting serum samples for BA measurements were obtained in the active and
remission stages of UC. Serum BA fractions were analyzed by HPLC. RESULTS: There were
no significant differences of serum total BA levels among the 3 groups. CDAC was significantly
higher in the 5-ASA and ATM groups than in the HV group, while the %DCA of the 5-
ASA and ATM groups was significantly lower than that of the HV group. These significant
differences were still observed in the 5-ASA and ATM groups during remission. The ratio
of glycine-congugated BA to total serum BA was significantly lower in the 5-ASA and ATM
groups during the active phase of UC compared with the level in HV. This finding also
continued the ATM group during the remission of UC. CONCLUSIONS: These results
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suggest that a decrease of bacteria with 7a-dehydroxylase activity was not improved during
remission of UC in the 5-ASA and ATM groups. The decrease of intestinal bacteria involved
in deconjugation failed to improve during remission of UC in the ATM group, although it
improved during remission in the 5-ASA group. It seems possible that combined antibiotic
therapy altered the bacterial flora involved in deconjugation.
W1152
Cyclophosphamide Pulse Therapy in Patients with Active, Steroid-Refractory
Inflammatory Bowel Disease
Klaus juergen Schmidt, Juergen Buening, Gunther Weitz, Nils Homann, Diether Ludwig
Background: Cyclophosphamide (CYC) has proven efficacy in various forms of systemic
vasculitis. Two recent pilot studies showed safety and efficacy of the drug in acute steroid
refractory inflammatory bowel disease (IBD) as well (Stallmach A, Gut 2003;52, Schmidt
C, Aliment Pharmacol Ther 2006;24). Aims: To determine the clinical benefit of intravenous
cyclophosphamide pulse therapy in steroid-refractory inflammatory bowel disease for induc-
tion and maintenance of remission. Methods: Ten patients (Crohns disease, n=9; Indetermin-
ate Colitis n=1) with moderate to severe steroid-refractory inflammatory bowel disease (CDAI
245-518) received 2-6 cycles (median 3.5) of a four weekly treatment with intravenous CYC
(750 mg) in a prospective pilot study. Six patients were on additional immunosuppressive
therapy with azathioprine/6-mercaptopurine (Aza/6-MP)(n=4) or methotrexate (Mtx)(n=2).
Results: Eight patients (80%) had a significant clinical response, six of them (60%) entered
complete remission (CDAI<150) after 8 weeks. Remission lasted for more than 12 months
in the majority of patients (median 13.6 months, range 6-36 months). One patient had a
relapse after 6 months, two patients did not respond to treatment. Median CDAI decreased
from 378 (245-518) to 148 (42-420) points and steroids could be reduced from 44 mg/
d before CYC therapy to 13.5 mg/d. Two of three patients with relevant extraintestinal
manifestations (arthritis, erythema nodosum and episcleritis) responded completely. Patients
not responding (n=2) and the patient with early relapse were not compliant with respect
to standard immunosuppressive therapy (Aza/6-MP, Mtx). CYC was well tolerated in all
patients and caused no relevant adverse events or side effects. Conclusion: Cyclophosphamide
pulse therapy has been found safe and highly effective for induction and maintenance of
remission in patients with steroid-refractory Crohns disease. Further studies should aim to
find out ideal regimen, way of application and its role in actual immunosuppressive strategies.
W1153
Influence of Disposal Blood Volume On Efficacy of Granulocytapheresis
(GCAP) in Patients with Ulcerative Colitis (UC)
Takayuki Shirai, Tetsuya Mine, Masashi Matsushima, Takayoshi Suzuki, Akemi Ito,
Kennichi Watanabe
[Purpose] To investigate the ideal conditions for GCAP in patients with UC, we compared
the effect of therapy in two groups of patients with high and low disposal blood volumes.
[Methods] Eighteen patients with UC (M:13, F:5), of whom 14 were seriously ill (based on
modified Truelove's criteria), and 4 were corticosteroid resistant (including 2 cases refractory
to intra-arterial prednisolone injection), were treated with GCAP therapy (enforced 1 or 2
courses, 5 or 6 sessions per course), and were evaluated based on government approved
clinical trial and CAI (clinical activity index). We assigned the 18 patients to two groups
with low (L) and high (H) flow rates and circulating times (L:30ml/min. X 60min.; 9 cases
vs. H:50ml/min. X 120min.; 9 cases) in the 1st course, and calculated the number of
absorbed leukocytes by integration of the numerical differences of entity time between the
number of influx cells and efflux cells through the column in 10 patients. [Results] Thirteen
of 16 patients (excluding two intractable CMV infected cases) improved by the end of 2
courses of treatment. Nine patients were in remission (5 patients without steroid intake), 4
showed moderate improvement, while 3 showed no improvement. Three cases recurred in
the early stage less than 3 months after the treatment, and all three were cases who could
not accomplish 2 courses. Absorbed cell (granulocyte) numbers per treatment were signific-
antly higher in the H group (4831X106) than in the L group (3171X106). Clinical efficacy
was seen in 88% of the 9 cases in the H group in the 1st course vs. 67% of the 9 cases in
the L group. Mean values of CAI markedly declined from (13.8: 13.2) before treatment to
(1.8: 5.0) after treatment. Following treatment, the mean duration of remission time was
20.7 months in the H group vs. 4.3 months in the L group. [Conclusions] Treatment in
the high flow rate group was superior to that in the low flow rate group in granulocyte
removal effect. GCAP under these conditions in early stages of treatment was advantageous
and may provide a good response and longer remission time.
W1154
Active Inflammatory Bowel Disease:Head-to-Head Comparison Between 99mtc-
Hmpao-WBC and 99mtc (V) Dmsa Scintigraphy
Maria Stathaki, Ioannis E. Koutroubakis, Sophia Koukouraki, Konstantinos Karmiris, Elias
Kouroumalis, Nikolaos Karkavitsas
Background: Technetium 99m (99mTc) pentavalent (V) dimercaptosuccinic acid (DMSA)
scintigraphy has been suggested as a non-invasive, practical, and accurate method of assess-
ment of inflammatory bowel disease (IBD) activity (1).On the other hand 99mTc-hexamethyl-
propyleneamine oxime (99mTc-HMPAO) white blood cell (WBC) scintigraphy is widely
used in the assessment of IBD. Aim & Method: The purpose of this study was to evaluate
and compare 99mTc (V) DMSA and 99mTc-HMPAO-WBC scintigraphy in the detection
and assessment of disease activity in patients with active IBD. 99mTc (V) DMSA was
performed in 23 patients with clinically and endoscopically confirmed active IBD (17 ulcerat-
ive colitis - 6 Crohn's disease) and true positive 99mTc-HMPAO-WBC. The interval between
the scintigraphic studies ranged from 3-4 days. 10mCi of 99mTc-HMPAO-WBC and 15mCi
of 99mTc (V) DMSA was iv injected in all patients. With the patient in the supine position,
planar views of the abdomen were obtained 2 hrs after 99mTc-HMPAO-WBC and 4 hrs
after 99mTc (V) DMSA injection. The bowel was divided in five segments: small bowel (A),
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ascending colon (B), transverse colon (C), descending colon (D) and rectosigmoid (E).
Images were considered positive when an area of increased uptake was observed. To assess
severity of IBD, semiquantitative measurements were included with reference to the uptake
in the iliac crest. Scintigraphic results were compared with endoscopic, radiologic and clinical
data. Results: In all IBD cases 99mTc-HMPAO-WBC scans were positive and correlated with
endoscopic findings. 99mTc (V) DMSA scintigraphy findings were compared with HMPAO-
WBC findings in 135 bowel segments. 99mTc (V) DMSA findings were in full agreement
with HMPAO-WBC concerning 98 bowel segments (72.6%). 99mTc (V) DMSA disagreed
with HMPAO-WBC in 37 segments (27.4 %). Concerning the agreement between the two
scintigraphic methods the weighted kappa statistics (and 95% CI) were as follows: 0.75
(0.41 to 1.00), 0.61 (0.22 to 1.00), 0.56 (0.24 to 0.87), 0.52 (0.17 to 0.86) and 0.60 (0.24
to 0.96) for segments A to E respectively. Conclusion: These results confirm our previous
study that 99mTc(V)DMSA could provide a useful non-invasive alternative method for the
assessment of disease activity in patients with IBD (1). However, it is inferior to 99mTc-
HMPAO-WBC scintigraphy especially in the evaluation of disease localization. These are
the preliminary results of a prospective study. Reference 1.Koutroubakis IE, Koukouraki SI,
Dimoulios PD, Velidaki AA, Karkavitsas NS, Kouroumalis EA. Active inflammatory bowel
disease: evaluation with 99mTc (V) DMSA scintigraphy. Radiology 2003; 229: 70-74.
W1155
Stress Maladjustment in the Pathoaetiology of Ulcerative Colitis
Tsukasa Kuroki, Nozomi Sugimoto, Ryosuke Shiraishi, Takehiro Fujise, Kenichiro
Watanabe, Hibiki Ootani, Seiji Tsunada, Ryuichi Iwakiri, Kazuma Fujimoto
Aim: The aims of this study were to: 1) measure levels of cytokines and stress hormones
in ulcerative colitis (UC) patients, and determine if there are any disturbances in the nervous,
endocrine or immune systems, and 2) measure the ability to cope with stress (sense of
coherence, SOC) and perceived self-efficacy in UC patients, elucidating their response to a
stress load. Subjects and methods: We administered a questionnaire and took blood samples
from 42 outpatients and 8 inpatients with ulcerative colitis, and 21 healthy volunteers. In
addition, we evaluated blood samples from the inpatients and healthy volunteers following
a mental calculation stress test. The criteria for quiescent phase UC in the outpatient group
were a C-reactive protein (CRP) level no greater than 1.0 mg/dl, and a low International
Organization for the Study of Inflammatory Bowel Disease (IOIBD) assessment score (0 or
1). The inpatients, who had similarly been lying down for 10 min, also responded to the
questionnaires, and blood was taken, following which they underwent the mental calculation
stress test, and further blood samples were taken. The 21 age-matched healthy volunteers
responded to the same questionnaires as the inpatient group, and had blood taken before
and after the mental calculation stress test. Results: The questionnaire results revealed that
self-efficacy was significantly decreased in the patient groups. Levels of ACTH, b-endorphin
and interleukin-6 (IL-6) were significantly higher in the outpatient than in the control group.
In the control group, level of cortisol increased in concomitant with the degree of the stress
level evaluated by Japanese Perceived Stress Scale (JPSS) and Sense of Coherence (SOC)
scale score. In contrast, this response of cortisol to the stress was not observed in UC
patients. IL-6 levels significantly increased following the mental calculation stress test in
ulcerative colitis patients, which was not observed in the control group. Conclusion: These
results indicated that UC patients 1) had hypersensitive nervous, endocrine and immune
systems, and 2) this hypersensitivity was augmented by the mental calculation stress test.
Serum levels of neurological, endocrinological and immunological markers
*p<0.01, **p<0.05
W1156
Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Recurrent
Urogenital Infection
Marialuisa Novi, Maria assunta Zocco, Cristiano ernesto Lauritano, Emidio Scarpellini,
Maria elena Ainora, Davide Roccarina, Andrea Lupascu, Enrico Nista, Maurizio Gabrielli,
Giovanni Cammarota, Giovanni Gasbarrini, Antonio Gasbarrini
Background: The interaction of host-specific and microbial factors are responsible for recur-
rent urinary tract infections (rUTI). It is already known that the anatomical properties of the
female urogenital tract favour colonization by uropathogens. However there is an increasing
evidence that other factors such as glucose concentration of the urine, stability of the
lactobacilli population, and disturbance of the systemic defense mechanisms are able to
determine infections susceptibility. Small intestinal bacterial overgrowth (SIBO) is a clinical
condition characterized by an abnormal increase in the number of bacteria in the small
intestine associated with malabsorption syndrome and immune defense alterations. Based
on these background we hypothesize a role of SIBO in the pathogenesis of recurrent urogenital
infection. Aim: To assess the prevalence of SIBO in a population of patients with recurrent
urogenital infection compared to healthy controls. Methods: 30 female patients with recurrent
urogenital infection (15 with vaginitis and 15 with cystitis; mean age 25±5) were enrolled.
All subjects underwent routine vaginal examination and urine culture to detect urogenital
infections and lactulose breath test to detect SIBO. The control population consisted of 30
healthy subjects, matched for sex and age. Differences between groups were assessed by the
χ2 Yates test. A p value <0.05 was considered to be statistically significant. Results: A total
of 19 out of 30 pts resulted to be positive to lactulose BT (63.3%) with respect to 2 out of 30
control subjects (6.7%). The difference between groups resulted to be statistically significant
(p<0.0001). Conclusion: SIBO seems to be associated with the recurrence of urogenital
infections. Based on these results intestinal dysmicrobism could be considered a predisposing
factor for recurrent urogenital infections.
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Prediction of Death On the Waiting List for Liver Transplantation Based On
MELD Score Variations
Speranta Iacob, Razvan Iacob, Liana Gheorghe, Cristian Gheorghe, Irinel Popescu
Background: Due to the increasing discrepancy between the number of cirrhotic patients
included on the waiting list (WL) for liver transplantation (LT) and the available organs,
the need to allocate livers to patients who are most likely to benefit is increasing. Currently,
the most recent MELD score available for each waiting list patient is used to prioritize organs.
Aim: To identify the variation of MELD scores at certain time intervals and their predictive
value for death on WL Methods: During each reevaluation the MELD score was recalculated
and the WL has been sorted according to the new MELD score values. At each recalculation
the variation of the MELD score from the time of first calculation and from the last evaluation
was also computed as well as the variation of MELD score within the last 3 months and
the maximal MELD variation, and based on the c-statistic it has been investigated the
predictive value of death on the WL for these parameters. Results: During 2004-2006, 208
adult patients have been evaluated on the WL with a total of 535 reevaluations; 5.3% patients
have been transplanted, 74.9% patients are still waiting, 19.8% patients have died. Forty
two patients did not have a good compliance to the follow-up protocol. The 12 months
actuarial survival was 81%. The dynamics of the WL suggests that patients with an initial
MELD score <18 remain in the same risk category also at the final evaluation in a proportion
of 70%. Patients with MELD score 19-24 have the most important dynamics, 34.8% having
a favorable evolution with decreased MELD score at the last evaluation and 21.7% had
progression of the liver disease. Patients with a MELD score at inclusion on the WL of >25
can regress in a lower MELD category in a proportion of only 40%. The c-statistics for
prediction of death on the WL are 0.73 for MELD score at the moment of inclusion on the
WL, 0.85 for MELD score at last evaluation, 0.59 for MELD variation from the last recalcula-
tion, 0.62 for MELD variation from inclusion on WL, 0.86 for MELD variation within the
last 3 months. Conclusions: Dynamic evaluation of MELD scores with its recalculation within
the last 3 months has the best predictive value for death on WL. MELD score variation from
the last recalculation or from first listing have a lower predictive value of death compared
with MELD score at last recalculation.
W1158
Polyclonal Gammopathy in Patients with Liver Disease Before and After Liver
Transplantation
Rodney A. Engel, Elizabeth J. Carey, Jorge L. Rakela
Background: Polyclonal gammopathy (PG) is a common finding in patients with liver disease;
A review of consecutive cases of PG at a referral center revealed that over 60% occurred in
this group. Proposed theories for the pathogenesis of PG in patients with liver disease include
increased antigen exposure from a “leaky gut” as a result of portal hypertension, or due to
the failure of the diseased liver to sequester antigens from the central circulation. We sought
to determine the prevalence of PG in patients with end-stage liver disease (ESLD) and to
assess the effect of liver transplantation on PG. Methods: A chart review of all liver transplant
recipients at our institution was performed. Serum protein electrophoresis (SPEP) results
from the pre-transplant evaluation and from subsequent routine post-transplant follow-up
(4 months, 1 year, and annually thereafter) were extracted. Post-transplant protocol biopsies
taken at the same intervals were reviewed for fibrosis and inflammation. Patient age, etiology
of liver disease, and co-morbid medical conditions were also reviewed. Results: From June
1999 through March 2006, 302 patients (96F, 206M) underwent liver transplantation at
our institution. Mean age at transplantation was 52.3 years. Etiology of liver disease was:
HCV (162), ALD (38), cryptogenic and NASH (35), PSC and PBC (31), misc (21), AIH
(10), and HBV (5). Prior to transplantation, 75.5% of patients had evidence of PG. This
number declined to 9.4% at the 4-month post-transplant evaluation but increased thereafter:
22.5% at one year, 29.8% at 2 years, 31.2% at 3 years, 36.7% at 4 years, and 43.8% at 5
years after liver transplantation. PG occurred at similar frequency in all etiologies of liver
disease. After transplantation, recurrence of PG occurred with similar frequency in all groups
except for NASH. After transplantation, no relationship was found between the recurrence
of PG and fibrosis or inflammation based on protocol liver biopsy. Conclusions: We found
that PG decreases markedly after soon after liver transplantation, but then increases steadily
with time. PG does not seem to be associated with recurrent liver disease (i.e., viral), nor
with advanced fibrosis. The etiology of PG after liver transplantation is unclear and is
potentially caused by a different mechanism than pre-transplant. Immunosuppression may
play a role: one hypothesis is that suppression of T-cell function causes a compensatory
response in B-cells. It is also possible that steroids given in the early months after transplanta-
tion suppress PG but that this recurs further out from transplantation as steroids are weaned
and immunosuppression is lifted.
W1159
Frequency and Management of Biliary Complications After Living Donor Liver
Transplantation
Vijay Poreddy, Johanne Rigaux, Kirti Shetty, Lynt B. Johnson, Amy Lu, Firas H. Al-kawas
BACKGROUND: Living Donor Liver Transplantation (LDLTx) has been associated with
increased incidence of biliary complications compared to Deceased Donor Liver Transplanta-
tion (DDLTx). As LDLTx is being increasingly performed over the last decade, there is a need
to further define the frequency of biliary complications and their management. PURPOSE: To
assess the frequency of biliary complications following LDLTx and evaluate the efficacy of
non surgical intervention in the management of these complications. METHODS: Retrospect-
ive review of all LDLTx performed between 1999-2006 at our institution and comparison
with an age matched cohort of DDLTx performed during the same time period. Sixty-nine
patients were identified. Variables included age, gender, reason for LTx, surgical technique,
biliary complications and their management, graft and survival rate. Statistical analysis was
performed using t test. RESULTS: 21 patients underwent LDLTx from October 1999 to
August 2006. Eleven were male (52%). Mean age was 42.6 years (range 2-68 years). Duct
to duct anastamosis (DD) was performed in 3 patients (14%) and Roux-en-Y hepaticojejunos-
tomy (HJ) was performed in 18 patients (86%). Biliary complications were present in 7 of
21 LDLTx (33%) with 4 strictures (BS), 1 bile leak, 1 perihepatic abscess, and 1 patient with
presumed ascending cholangitis. Two (28%) patients with BS were treated endoscopically.
Percutaneous drainage by Interventional Radiology (IR) was performed in four patients
(57%). The patient with cholangitis was treated with antibiotics. Retransplant was required
in 2 patients. The 6-month patient/graft survival rate was 76%/71%. None of the patients
were retransplanted for biliary cirrhosis nor did any patient die of biliary complications.
CONCLUSIONS: 1) Biliary complications appear to be more frequent in LDLTx, however,
the difference was not statistically significant, probably due to the smaller size sample. 2)
More bile leaks were observed in DDLTx, due to higher rate of T tube placement. 3)
Radiologic management is the first-line treatment used for biliary complication in LDLTx,
secondary to the higher rate of Roux-en-Y HJ. 4) Endoscopic treatment was more commonly
utilized in DDLTx, and could still be the first-line treatment for LDLTx in case of DD.
5) The majority of biliary complications after LTx can be effectively managed by non-
surgical intervention.
W1160
Diagnostic and Therapeutic Implications of Biliary Complications Post Liver
Transplant- A 10 Year Review of a Single Center Experience
Julian Perez, Ramesh Koka, Cosme Manzarbeitia, David J. Reich, Santiago J. Munoz, Jorge
Uribe
BACKGROUND: Biliary complications after Orthotopic Liver Transplantation (OLTx) are a
significant cause of morbidity occurring in up to 30% of cases. We retrospectively reviewed
the incidence rate of biliary complications and successful resolution with ERCP at our
institution. METHODS: Retrospective analysis of our all liver transplants done from January
1995 to December 2005. Review included endoscopy reports, radiology and operative notes.
RESULTS: 522 OLTx were done in 489 patients at Albert Einstein Medical Center. 4 patients
died the same day of surgery and were excluded from analysis. Mean age was 50.85 years,
66.2% male. 96 patients post OLTx were suspected to have a biliary complication (BC). 89
of the 518 transplants (17%) were confirmed (80 with ERCP, 9 with PTC).16 were resolved
surgically. Most of the BC occurred in the first three months after liver transplant. 73 (91%)
complications identified with ERCP were resolved endoscopically. A total of 117 ERCP were
performed in 80 patients. Cause of Biliary complications: Table 1 CONCLUSION: In this
large, single center series, biliary complications commonly occur at the anastomotic site,
most of them occur within three months of OLTx. Common complications are Bile leak
(particularly when T tube anastomosis performed) and anastomotic stricture. Yield of thera-
peutic success for resolution with ERCP was very high.
Table 1
W1161
Increased Risk of Colorectal Neoplasia in Asymptomatic Liver Transplant
Recipients
Jan J. Koornstra, Jelle Wesseling, Andrea E. De jong, Hans F. Vasen, Jan H. Kleibeuker,
Elisabeth B. Haagsma
Background: Controversy exists whether liver transplant recipients carry an increased risk
of colorectal neoplasia. We previously found an increased risk of colorectal cancer in liver
transplant recipients compared to the general population (J Hepatol 2001). The aim of this
study was to determine the prevalence of colorectal neoplasia in asymptomatic liver transplant
recipients. Methods: Liver transplant recipients who underwent screening colonoscopy in
our institution at least 5 years following liver transplantation were retrospectively evaluated.
Patients with previous colorectal adenomas or carcinomas were excluded. Lesions identified
and removed on endoscopy were revised by a gastrointestinal pathologist and categorized
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according to the most advanced lesion. Advanced neoplasia was defined as an adenoma at
least 1 cm in diameter and/or with villous features and/or high-grade dysplasia, or cancer.
Results were compared with prevalence data in the literature obtained in asymptomatic
average-risk populations undergoing screening colonoscopy, including a Dutch cohort (de
Jong et al, Am J Gastro 2005), adjusted for age. Results: Ninety-two asymptomatic liver
transplant recipients had undergone colonoscopy at a median age of 53.5 years (range 35.8-
71.2). Adenomas were found in 20 patients (21.7 %). Advanced neoplasia was diagnosed
in 8 patients (8.7 %), none of which concerned cancer. Compared with the Dutch control
cohort, the relative risk (RR) in patients under 50 years of age for neoplasia was 3.6 (95 %
CI: 1.1-12.2, p < 0.05) and 8.9 (1.7-46.3, p < 0.01) for advanced neoplasia. Compared
with prevalence data reported in the literature in asymptomatic average-risk populations,
prevalence rates of colorectal neoplasia, especially advanced neoplasia, were higher in liver
transplant recipients, particularly in patients under 60 years of age. Conclusion: Liver
transplant recipients have an increased risk of developing colorectal neoplasia, possibly due
to the use of immunosuppressive agents. Offering screening colonoscopy to asymptomatic
liver transplant recipients should strongly be considered.
W1162
Phase 1 Human Trial of Autologous Mesenchymal Stem Cell Transplantation
(Msc TX) for the Treatment of Decompensated Cirrhosis
Mehdi Mohamadnejad, Kamran Alimoghaddam, Mandana Mohyeddin bonab, Mohamad
Bagheri, Maryam Bashtar, Hossein Ghanaati, Hossein Baharvand, Ardeshir Ghavamzadeh,
Reza Malekzadeh
Background: The standard treatment for decompensated cirrhosis is liver transplantation.
But, it has several limitations. Recent animal studies suggest that bone marrow stem cell Tx
can lead to regression of liver fibrosis. The aim of this study was to evaluate safety and
feasibility of autologous bone marrow MSC Tx in decompensated cirrhosis. In a recent
study, infusion of hematopoietic stem cells through the hepatic artery was used to treat
cirrhosis (Gordon MY, et al. StemCells; 2006). However, we usedMSCs (e.g. non-hematopoi-
etic stem cells) through a peripheral vein. Methods: After protocol approval by the ethic
committee, four patients with decompensated cirrhosis (1 male, 3 female) aged 30 to 56
were included. The etiology of cirrhosis was autoimmune hepatitis or cryptogenic. Their
bone marrow was aspirated (80-100ml), and MSCs were cultured, and a mean 31.73 million
MSCs were infused through the cubital vein of the arm. Primary aims were safety and
feasibility of the procedure. Secondary aims were changes in liver function tests, MELD
score, liver volume (as measured by CT volumetry), and quality of life six months after Tx.
During follow up, patients' medications remained the same as before MSCs Tx. Results:
Mean duration of culture was 73 days. The results of flow cytometry analysis for CD13,
CD31, CD44, CD 90, CD105, and CD166 were positive; and for the hematopoetic markers
- CD34 and CD45 - were negative. Also, reverse transccriptase polymerase chain reaction
showed that cultured MSCs were positive for some endodermal and hepatocyte-specific
genes such as cytokeratin 18, alpha1 antitrypsin and CEBP. MSCs transplantation was safe
and there was no any adverse effect. Peripheral edema decreased or disappeared in all
patients after 6 months. Serum albumin, prthrombin time, and MELD scores in 3 of 4
patients improved at the end of follow up (Table). Liver volumes of 3 patients increased.
Also, quality of life of all 4 patients improved at the end of follow up. Conclusion: MSCs
Tx is a novel approach to treat cirrhosis. This procedure is safe and feasible, and signs of
improvement found in some of our patients are promising. Although, further phase 2, and
3 studies should be contemplated. Antifibrotic effects of MSCs may be related to over-
expresion of liver fibrolytic cytokines.
Paraclinical data of the patients at baseline and at the end of follow up
W1163
Persisting Abdominal Symptoms After Giardia Infection - A Post-Infectious
Functional Bowel Disorder?
Kurt Hanevik, Mette H. Morken, Elisabeth A. Strand, Kristine Mørch, Peter Coll, Lars
Helgeland, Nina Langeland, Trygve Hausken
Background: In fall 2004 a waterborne epidemic of Giardia-infection occurred in Bergen,
Norway. Giardia lamblia was found in fecal samples of 1300 patients. Some of these patients
experienced continuing abdominal symptoms despite several courses of metronidazole treat-
ment and were referred by general practitioners over a 15 months period. Patients and
methods: A total of 124 patients (61.3% females, mean age 31.0 years; range 15.7-76.3, no
previous abdominal complaints in 84.6%) were included in a prospective cohort analysis.
The standardised work-up included upper endoscopy with duodenal biopsies, symptom
score and faecal samples for microscopy. All giardia positive patients were then successfully
treated. To assess prevalence of persisting abdominal symptoms a follow-up questionaire
was mailed to patients two years after the epidemic. Results: Giardia parasites were found
in faecal samples in 40 patients (32.3%). Duodenal biopsies showed signs of inflammation
in 57 patients (45.9%); grade 1 pathology in 18.2% and grade 2 pathology, which also
included shortening or blunting of villi, in 28.9%. Microscopic duodenitis was present in
34 (87.2%) of giardia positive and 23 (28.0%) of the giardia negative patients. Patients still
being giardia positive reported higher levels of diarrhoea (p=0.013), abdominal pain (p=
0.04) and nausea (p=0.04) than giardia negative patients. Over time, an increasing fraction
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of patients presented without persisting giardia infection, nor duodenal pathology. The
follow-up questionaire was answered by 100 patients (80.4%). Continuing abdominal symp-
toms elicited by the giardia infection was reported by 78.0% with abdominal bloating
reported to be most severe, followed by abdominal pain and diarrhoea. Complete recovery
was reported by 12.0% and the remaining 10.0% were not sure. Discussion: We examined
a group of previously largely healthy young adults with persisting abdominal symptoms
between 2 and 18 months after acute giardiasis. One third of these still had ongoing giardia-
infection. The remaining two thirds had cleared the infection, but remained symptomatic
although no other cause could be found to explain their symptoms. The presence of duodenal
inflammation, especially early in the study, points towards a strong immune activation in
many of the patients in our study. A substantial number of patients remained symptomatic
even 6 to 18 months after clearing giardia infection. Persisting symptoms of such long
duration after giardia infection indicates the development of a post-infectious functional
bowel disorder.
W1164
The Characteristics of High School Students with Irritable Bowel Syndrome
and Functional Bowel Disorder
Yuka Endo, Shin Fukudo, Tomotaka Shoji, Yasuhiro Sagami, Joe Morishita, Yuko Kimura,
Tomomi Machida, Takatsugu Machida, Motoyori Kanazawa, Michio Hongo
Background: Irritable bowel syndrome (IBS) is believed to begin in the early life but analysis
in detail was lacking. We hypothesized that prevalence of IBS in high school students is
high enough to be comparative to adults. Methods: High school students (1,150 boys and
273 girls) (age: 16-18 y.o.) fulfilled self-reported IBS questionnaires, Generalized Self-Efficacy
Scale (GSES) and SF-36. Results: Based on Rome II criteria, students were divided into 3
groups: IBS students (107 boys, 46 girls), functional bowel disorder (FBD) students (548
boys, 166 girls) and control students (495 boys, 61 girls). Both IBS and FBD students had
lower scores in all SF-36 subscales (p<0.005, respectively), GSES (p<0.0001) and perceived
stress (p<0.0001) than control students. Between IBS and FBD students, IBS students had
lower scores in subscales of SF-36 except Role-Physical and Social Functioning (p<0.05,
respectively), but there was no significant difference in GSES score and perceived stress.
The prevalence of IBS was significantly higher in girls (16.8%) than in boys (9.3%)
(p<0.0005), however, none of them had not consulted medical care. Over 80% of IBS
students had frequent abdominal pain and complained loose/watery stool with abdominal
pain or discomfort. Relief of abdominal symptoms with defecation was seen more frequently
in IBS boys (p<0.05). On the other hand, passing mucus (p<0.0001), abdominal fullness
(p< 0.01), anticipatory anxiety (p<0.05), limitations of daily activity (p<0.005), exaggeration
of IBS symptoms under stress (p<0.0005), laxative use (p<0.0001) were seen more frequently
in IBS girls. IBS scores that reflect severity of IBS symptoms were also significantly higher
in IBS girls (p=0.001). There was no significant difference in scores of GSES between IBS
boys and IBS girls. IBS girls had higher scores in Mental Health (p<0.05) and Role-Emotional
subscales (p=0.051) of SF-36 than IBS boys. Many IBS students complained that they
experienced the difficulty in going to school and/or places they could not find rest rooms
easily. Conclusion: Because the prevalence of high school students with IBS was comparative
to that of adults, our hypothesis was supported. Despite disturbed quality of life, IBS
adolescents did not seek medical care. IBS symptoms in girls were suggested to be severer
than those in boys.
W1165
The Risk of Non-Enteric Infection and Antibiotic Use in Functional
Gastrointestinal Disorders
Helga Paula, Smita L. Halder, G. richard Locke, Cathy Schleck, Alan R. Zinsmeister,
Nicholas J. Talley
Abstract Gastrointestinal infections, such as Salmonella or Campylobacter gastroenteritis,
have been shown to be risk factors for functional gastrointestinal disorders (FGID) in
particular irritable bowel syndrome (IBS) and functional dyspepsia (FD). It is unclear if
non-gastrointestinal infections or antibiotic exposure are associated with FGIDs. Aim: To
determine if non-enteric infection as well as antibiotic exposure is associated with the
development of IBS and FD symptoms. Methods: Random samples of Olmsted County,
MN, were mailed valid self-report questionnaires from 1988 to 1994 and then follow-up
questionnaires from 1990 to 2003. Survey responders who did not report any IBS or FD
symptoms at baseline, but then reported such symptoms on at least one subsequent survey
were identified as cases of new onset FGID. These cases were frequency matched for age
and sex with controls who did not have FGID symptoms on any survey. The comprehensive
medical records of these 566 subjects (316 cases and 250 controls) were reviewed to identify
any infections recorded in the time between the two surveys. Results: The overall response
rate to the questionnaire was 68%. Among cases 9% had a GI infection and 76% had a
non-GI infection between surveys. Among controls 9% had a GI infection and 66% had a
non GI infection. The table shows the results of the regression analysis adjusted for age and
gender. Among subjects who had a non GI infection and received antibiotics, 62% were
cases (OR 1.9 95% CI 1.2-3.0). No other significant associations were detected. Conclusion:
Non-gastrointestinal infection treated with antibiotics is a risk factor for IBS and func-
tional dyspepsia.
Table. Logistic model summary
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Prenatal Exposure to Famine and Functional Bowel Disorders
Tamira K. Klooker, Breg Braak, Rebecca C. Painter, Susanne R. De rooij, Ruurd M. Van
elburg, Rene M. Van den wijngaard, Guy E. Boeckxstaens, Tessa J. Roseboom
BACKGROUND/AIM: Prenatal exposure to famine is an intrauterine stressor that is associated
with cardiovascular diseases and glucose intolerance (Roseboom et al. Early Hum Dev.
2006). As early life events are accepted as predisposing factor to develop functional bowel
disorders (FBD) later in life, we evaluated whether exposure to famine in utero and growth
retardation are associated with an increased prevalence of FBD in adulthood. METHODS:
The Dutch Famine Birth Cohort consists of adults born as term singletons in the Netherlands,
around the time of the 1944-1945 Dutch famine. Subjects exposed during late, mid and
early gestation are compared to non exposed subjects born before or conceived after the
Dutch famine. An individual is considered prenatally exposed to famine if the average daily
ration for adults during any 13-week period of gestation was less than 1000 calories.
Participants were invited to fill out the Rome II questionnaire to evaluate the presence of
irritable bowel syndrome or functional dyspepsia. RESULTS: A total of 851 subjects filled
out the Rome II criteria. 349 Subjects (41%) were prenatally exposed to famine, 147 (17
%) during late, 123 (15%) during mid and 79 (9%) during early gestation, and were
compared to 502 non exposed subjects. The prevalence of FBD in adults with and without
prenatal exposure to famine was 13% and 15%, respectively (NS) and was not significantly
influenced by exposure during late (11%), mid (15%) or early (14%) gestation. Gastrointesti-
nal symptoms (constipation, diarrhea or abdominal pain) not fulfilling the Rome II criteria
for FBD were reported in 18% of the exposed compared to 22% of the non exposed subjects
(NS). Birth weight and ponderal index (birth weight/heights x 100) were comparable between
controls (3353.1 ± 20.0 g, 26.2 ± 0.1 103g/cm3, respectively) and FBD patients (3356.0 ±
39.0 g, 26.3 ± 0.2 103g/cm3, respectively, NS). CONCLUSIONS: This study shows that
the 1) prevalence of FBD is not increased in adults exposed to famine during gestation and
2) that there is no relation between low birth weight or ponderal index and FBD. Therefore,
we conclude that intrauterine undernutrition or growth retardation are not considered risk
factors in developing FBD later in life.
W1167
Constipation in a Medicaid Population: Trends in Prevalence, Age, Gender,
and Costs in the 12 Months After Diagnosis from 1997 to 2002 Using a
Random Sample of California Medicaid (Medi-Cal) Data
Jeonghoon Ahn, Nicholas J. Talley, Richard A. Brook, Mike B. Nichol, Jeff Mccombs,
Robert W. Baran
Background: Chronic constipation (CC) may be more common among females and in
certain socioeconomic groups. Although the Medicaid population is more likely to be at
greater risk, little is known about the burden of CC among Medicaid beneficiaries.Objective:
To assess the prevalence of CC among the California Medicaid (Medi-Cal) population,
explore the demographics by gender and age, and examine the cost trends for newly diagnosed
patients in the year following diagnosis. Methods: A retrospective study using a random
20% sample of Medi-Cal population from 1995 to 2003 was performed. CC was defined
as two or more constipation diagnoses (ICD9 codes 564.0, 564.00, 564.01, 564.09) or a
diagnosis and a claim for a constipation-related prescription more than 30 days after the
diagnosis date. The annual prevalence of CC was calculated for beneficiaries who were
eligible for a whole year. The average age and percent female were also calculated. Costs
per patient for one year after the initial diagnosis (no previous diagnosis for 24 months)
were calculated from paid claims in total and for the following categories: outpatient care
(OUT); inpatient care (IN); prescriptions plus available over-the-counter agents (Drug); and
long-term care (LTC). Results: The annual CC prevalence rate increased from 1.77% (13,633
patients with CC) in 1997 to 2.18% (20,975 patients with CC) in 2002. Over the same
time period, the mean age of CC patients decreased from 64.8 to 55.7 years and the gender
composition decreased from 66% female to 60% female. Changes in CC costs per patient
from1997 to 2002 by category: OUT increased 247% from $4,995 to $12,338; IN decreased
29% from $5,864 to $4,177; Drug increased 266% from $1,926 to $5,116; LTC changes
varied by year There was a 156% increase in total costs from $14,487 in 1997 to $22,947
in 2002. Conclusion: There is a significant burden of constipation in the Medi-Cal popula-
tion. The prevalence rate increased overall from 1997 to 2002 and each year from 1999 to
2002. Prevalence is likely underreported due to limitations in coding methodology. The
total costs per newly diagnosed patient also increased over this time frame. The burden of
illness for chronic constipation appears to be steadily rising.
W1168
Poor Quality of Life Predicts the New Onset of Irritable Bowel Syndrome. A
Longitudinal Ten-Year Follow-Up Study
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: Studies indicate that irritable bowel syndrome (IBS) is associated with poor
quality of life, but it is unclear whether IBS causes poor quality of life, or whether those
with poor quality of life are more likely to develop IBS. This is the first study to address
this issue. Methods: The authors performed a longitudinal ten-year follow-up study of
individuals previously recruited into a community screening program for Helicobacter pylori.
All surviving, traceable participants were contacted via postal questionnaire that utilized
the Manning criteria to diagnose IBS. Baseline demographic data (including: age; gender;
socioeconomic status; tobacco, alcohol, and coffee consumption; and ethnicity), quality of
life (assessed via the psychological and general well-being index and split into tertiles), IBS
symptom data, and dyspepsia symptom data (captured via validated questionnaire) were
on file. Written informed consent was sought to examine primary care records, and data
on use of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin over the ten-year
period were extracted from these. The associations between these data and new onset of
IBS at ten years in those asymptomatic at baseline were explored using univariate analysis.
Independent risk factors were determined by performing multivariate logistic regression to
control for all these demographic data and lifestyle factors. Results: Of 8407 individuals
originally involved, 4003 (48%) responded to the questionnaire. Mean age of responders
was 55 years, and 2247 (56%) were female. 220 (5.6%) of 3948 individuals providing data
at baseline had IBS, compared to 696 (18%) of 3925 individuals providing data at ten-year
follow-up, when dichotomized according to questionnaire data. Of the 3728 individuals
without IBS at baseline, 542 (14.5%) developed new onset IBS at ten years. Female gender
(odds ratio (OR) 2.15; 99% confidence interval (CI) 1.66-2.79), dyspepsia at baseline (OR
2.23; 99% CI 1.71-2.92), lower socioeconomic status (low versus high: OR 1.99; 99% CI
1.35-2.93), NSAID use (OR 1.78; 99% CI 1.35-2.36), and low quality of life (bottom versus
top tertile: OR 4.60; 99% CI 3.26-6.48) all significantly increased likelihood of new onset
IBS at ten years, whilst consumption of alcohol reduced the likelihood (OR 0.57; 99% CI
0.39-0.84). Following multivariate logistic regression female gender, dyspepsia at baseline,
NSAID use, and lower quality of life remained significant risk factors for new onset of IBS.
Conclusions: New onset IBS developed at a rate of almost 1.5% per year. Low quality of
life at baseline exerted a strong effect on development of IBS at ten years in our model.
W1169
The Prevalence, Characteristics and Impact of Bloating, Distention, and Gas in
Patients with Irritable Bowel Syndrome (IBS)
Yehuda Ringel, Linda Kalilani, Suzanne F. Cook, Rachel E. Williams
BACKGROUND: Bloating, distention and gas (bloating symptoms) are common complaints
among IBS patients seen in primary and GI clinics. However, the underlying mechanisms
for these symptoms are poorly understood and there is lack of data about their prevalence,
characteristics, and impact in IBS. AIM: To examine the prevalence, characteristics and
impact of bloating symptoms in patients with IBS. METHODS: IBS patients were identified
by Rome II criteria in a US population representative web-based survey. The prevalence
and characteristics of bloating symptoms were determined from the patients' reports on the
quality, frequency and severity of their GI and non-GI symptoms. The impact of bloating
symptoms was investigated by assessing patients' health related quality of life (QOL), psycho-
logical status, utilization of health care, and use of IBS and anti-gas medications. RESULTS:
Out of 337 IBS patients who participated in the study 82.5% (n=278) reported bloating
symptoms. Bloating symptoms were rated as the second most bothersome symptom in IBS
patients, preceded only by abdominal cramping and followed by bowel related symptoms
(e.g., loose/watery stools, straining, and urgency). The symptoms were more prevalent in
females 87.4% (n=209) than in males 70.4% (n=69) (p<0.0001) and in patients with
constipation (IBS-C) 88.7% (n=47) and alternate symptoms (IBS-A) 88.8% (n=135) than
in patients with diarrhea (IBS-D) 72.7% (n=96), (p=0.02, p<0.01, respectively). Bloating
symptoms were the most common reported symptom in IBS-C 88.7% (n=47) and IBS-A
88.8% (n=135) and the third most common symptom in IBS-D 72.7% (n=96). In addition,
bloating symptoms were the fourth (out of 14) most important reason medical care was
sought and more than half of the patients reported regular use of anti-gas medications.
People with bloating sought more health care for abdominal symptoms in the last year than
those without (17% vs. 5% sought care 4 or more times, respectively, p=0.01). Those with
bloating also had lower energy (p=0.04), food intake (p<0.01), and a trend toward lower
physical functioning (p=0.06), as measured by the IBSQOL instrument. CONCLUSIONS:
Bloating symptoms are very common in IBS patients. The prevalence and relative severity
of these symptoms differ by gender and the IBS subtype. Bloating symptoms are associated
with decrease in QOL, increase in health care utilization, and add substantially to use of
medications. (Supported by grant K23 DK075621-01)
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Irritable Bowel Syndrome in the Elderly: An Overlooked Problem?
Anurag Agrawal, Mashkur H. Khan, Peter J. Whorwell
Introduction- It is well known that IBS patients commonly consult about their problem
between the ages of 30 and 50, although in a large proportion of these individuals, symptoms
have been present for many years.[1] . It is also known that in secondary care, irritable
bowel syndrome(IBS) is commonly associated withmultiple non-colonic symptoms including
lethargy, backache, urinary symptoms and chest pain which result in referral to different
specialities and the condition remaining unrecognised [2]. However, there is very little
information on whether the condition persists into old age, and no data on how it manifests
itself in the elderly or its prevalence in elderly care clinics. Aim and Methods- Using the
previously validated Elderly Bowel Symptom Questionnaire (EBSQ) [3], this study aimed
to assess the extent of this problem in consecutive outpatients attending elderly care clinics
relating the results to the presenting complaint, non-colonic symptomatology and final
diagnosis. Of the 230 consecutive patients who attended the Elderly clinics in Wythenshawe
Hospital, 211 completed the questionnaire and were included in the study. Results- 56
(26%) of 211 patients had symptoms compatible with a diagnosis of IBS irrespective of
their presenting complaint. However despite the exclusion of abdominal pathology a diagnosis
of IBS was only documented in one patient. 69.6% of patients had suffered from their IBS
symptoms for over 5 years. Not surprisingly abdominal pain, bloating and bowel dysfunction
including urgency were more common in IBS patients(p<0.001). However other symptoms
significantly more common in the IBS compared to non-IBS patients were backache (76.7%
vs 52.9%, p<0.001), constant lethargy (73.2% vs 49.7%, p=0.002), chest pain(62.5% vs
44.5%, p=0.02), headaches(55.3% vs 26.4%, p<0.001)and urinary frequency (37.5% vs
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23.2%, p=0.04). Independent predictors of IBS on logistic regression have been listed in
Table 1.Conclusions- IBS appears to be seriously under-recognised in elderly care clinics
even after negative investigation. Making the diagnosis, despite the presence of co-existent
disease, could reduce the overall burden of suffering, improve quality of life, prevent repetitive
investigations and have significant economic advantages. References- 1)Lea R et al. Gut
2002;51:305-306. 2)Whorwell PJ et al. Gut. 1986;27:37-40. 3) Talley NJ et al. Gastroenterol-
ogy. 1992;102:895-901.
Table 1
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SERT-P Polymorphism in the Serotonin Transporter Gene and Irritable Bowel
Syndrome: What's Going On?
Beate Niesler, Catherine Fell, Johannes Kapeller, Dorothee Moller, Wendy Atkinson,
Christine Fischer, Peter J. Whorwell, Lesley A. Houghton
Some studies assessing the association between polymorphisms in the promoter region of
the serotonin reuptake transporter (SERT) and irritable bowel syndrome (IBS) have shown
increased frequency of the SERT deletion/deletion (ss) genotype in IBS patients with diarrhea
(IBS-D)(1, 2) and others an increase in IBS patients with constipation (IBS-C)(3,4) compared
with healthy volunteers. The lack of consensus between studies may be partly due to varying
ethnic origin between the populations studied and gender differences, although one study
has reported no difference between Korean males and females (2). Aim: To reassess the
potential association between SERT polymorphisms in both male and female patients IBS-
D and IBS-C compared with healthy volunteers. Methods: A total of 178 Caucasian Rome
II IBS patients (87 IBS-D (62 female) and 91 IBS-C (87 female)) and 94 Caucasian healthy
volunteers (61 female) recruited in Manchester were subjected to genotyping. Genomic DNA
was extracted from peripheral blood and genotyping of the SERT-P polymorphism performed,
as described previously (1). Results: The frequency of the ss genotype was significantly lower
in both IBS-D (14.6 %) and IBS-C (14.3 %) patients compared with controls (25.5 %;
p<0.05 for both; OR for ss versus non-ss (95% CI) = 0.499 (0.268-0.930)). However, the
reduced ss genotype appeared to be related to a reduction in males, particularly those with
IBS-D (IBS-D 8 %, IBS-C 25 %, controls 36.4 %; p=0.012 for IBS-D v controls; OR (95%
CI) for ss v non-ss = 0.152 (0.030-0.761)) rather than in female (IBS-D 17.8 %, IBS-C 13.8
%, controls 19.7%) IBS patients. There were no differences in the frequencies of either the
l/l (IBS-D 34.8 %, IBS-C 33 %, controls 25.5%) or ls (IBS-D 50.6 %, IBS-C 52.7%, controls
49%) genotypes between any of the three groups. Conclusion: Unlike previous studies, a
significant reduction in the SERT ss genotype was found in both IBS-D and -C patients
compared with controls, which appeared to be related to a reduction in male rather than
female IBS patients. These results question the significance of SERT polymorphisms in IBS,
and suggest both the possible importance of gender and the need for much larger studies
in the future. Refs: (1) Yeo et al Gut 2004; 53: 1452, (2) Park et al Neurogastroenterol
Motil 2006; 18: 995, (3) Pata Am J Gastroenterol 2002; 97:1780, (4) Kim et al DDW 2002.
W1172
Diagnosis, Management and Comorbidities of Irritable Bowel Syndrome (IBS)
in a Large Cohort of Patients in General Medical Practice
Uri Ladabaum, Wei K. Zhao, Annie Sharabidze, Theodore R. Levin
BACKGROUND: Practice patterns relating to IBS are not well described. A limited screen
for organic disease is recommended in suspected IBS. Novel agents and antidepressant
studies have expanded IBS treatments. Celiac disease is increasingly recognized in a subset
of IBS patients. It is not clear to what extent clinicians incorporate emerging data on
IBS into their practice. AIMS: To characterize practice patterns relating to diagnosis and
management of IBS and to identify other relevant diagnoses in a diverse cohort of IBS patients
from a large health maintenance organization (HMO). METHODS: Northern California Kaiser
Permanente databases were searched to identify all HMO members diagnosed with IBS and
to determine their demographics, tests, other diagnoses and treatments. RESULTS: From
1995-2005, 2.4-3.2 million persons (51% female, 75% adult) belonged to the HMO. IBS
was diagnosed in 141,295 (age mean 46, SD 17; 74% female; 53% white, 6% black, 9%
Hispanic, 6% Asian, 4% other, 23% unknown; HMO coverage before IBS diagnosis mean
5yr, SD 3yr, and after diagnosis mean 4yr, SD 3yr). Generalists made 68% of IBS diagnoses,
gastroenterologists 13%, others 20%. Tests included: blood count 95%, chemistry 88%,
liver 87%, thyroid 88%, sedimentation rate 48%, celiac antibodies 3% (all after 2001); stool
studies <5%; sigmoidoscopy 42% (50% of these before IBS diagnosis), colonoscopy 14%
(37% of these before IBS diagnosis), barium enema 17%. Comorbidities included: anxiety
35%, depression 39% (55% of these before IBS diagnosis), migraine 37%, chronic pain
19%. Alternative diagnoses possibly related to symptoms included diabetes 10%, celiac
disease 0.1%, inflammatory bowel disease 1%. Treatments included: antispasmodics 57%,
alosetron or tegaserod <1%, anxiolytics 61%, antidepressants 55% (38% of these after IBS
diagnosis; by class: tricyclics 60%, serotonin reuptake inhibitors 66%, other 48%). The
frequency of operations included: rectal 1%, intestinal 5%, biliary 6%, gynecologic 9%.
CONCLUSION: Most IBS diagnoses in this large, diverse cohort of patients were made by
generalists. Patients frequently had general blood tests andmost did not have lower endoscopy
before diagnosis. Celiac antibody testing, which has been advocated by some only recently,
was uncommon. Psychiatric comorbidity was very common and antidepressants were fre-
quently used, most often before IBS diagnosis. Diagnosis of other gastrointestinal diseases
was rare. This study confirms the importance of psychiatric comorbidity and antidepressant
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treatment in IBS in general practice. It remains to be determined whether more widespread
celiac disease testing should be encouraged.
W1173
Genetic Susceptibility for a Low Anti-Inflammatory Component in IBS Rome
II Positive Subjects in Mexico
Rosalinda Martinez-garcia, Maria-abel Ramos-valencia, Norma Morales-rochlin, Carmen
Escobar-villanueva, Daniela Pulido, Blanca Farfan-labone, Concepcion Gutierrez ruiz,
Gabriela Gutierrez-reyes, Max Schmulson
Increased immune markers have been found in a subset of Irritable Bowel Syndrome (IBS)
suggesting that inflammation may play a role in the physiopathology of the disease (Gastroen-
terology 2003;125:1651). We have previously reported a lower frequency of the high
producer polymorphism of the anti-inflammatory cytokine IL-10 in a group of IBS females
in Mexico, and the absence of the low producer polymorphism of the pro-inflammatory
cytokine TNF-α both in IBS and controls, suggesting a genetic predisposition to develop
IBS due to a lower protective anti-inflammatory component in them. (Gastroenterology
2006;130:A512). However, the relationship of these polymorphisms and their correspondent
cytokine levels is unknown. AIMS: To investigate the serum levels of IL-10 and TNF-α
according to their respective polymorphisms in IBS and controls in Mexico. METHODS:
Thirty five IBS Rome II positive subjects were compared with 35 healthy controls. Blood
samples were obtained from each volunteer for genomic extraction of DNA from peripheral
blood leucocytes and genotyping was carried out by amplification refractory mutational
system PCR methods, using allele specific primers to identify the high and low producer
alleles of each biallelic polymorphic site of the IL-10 gene (-1082*G and -1082*A) and the
TNF-α gene (-308*G and -308*A), respectively. Amplified DNA products were then analyzed
using electrophoresis on 2% agarose gel and viewed under UV light. Genotypes were
expressed as homozygous for the High and Low Producers, and heterozygous or Intermediate
Producers. Serum IL-10 and TNF-α levels were determined by ELISA. Statistical analysis
was done by the chi-sq and ANOVA when appropriate. A p≤0.05 was considered significant.
RESULTS: Gender distribution (F%: 80 vs. 74) and age (mean±SE: 33±2 vs. 34±2 years)
were similar between IBS and Controls. Serum IL-10 levels were lower in IBS vs. Controls
(pg/ml): 15.1±0.3 vs. 18.4±0.2 (p<0.0001) while no differences were found in TNF-α:
29±0.8 vs. 31.3±1 (NS). In IBS, IL-10 polymorphisms were associated with their correspond-
ent serum levels, High: 16.2±0.8, Intermediate: 15.5±0.5 and Low: 14.2±0.3 pg/ml (p=
0.05), this was not seen in controls. In contrast, TNF-α polymorphisms were associated
with their respective serum levels in Controls, High: 33±1.4, Intermediate: 29±1.0 pg/ml
(p=0.04), but not in IBS. There were no differences in the frequency of the polymorphisms
of IL-10 and TNF-α between IBS and controls. CONCLUSIONS: Our results support a
genetic susceptibility for the presence of a low anti-inflammatory component translated into
lower serum levels of IL-10, which may predispose the development of IBS in Mexico.
W1174
Validation of Rome III Criteria for Functional GI Disorders
Rok seon Choung, Nicholas J. Talley, Michael D. Crowell, H. jae Kim, G. richard Locke,
Cathy Schleck, Alan R. Zinsmeister
Background: Although the Rome III criteria have been recommended for use in the diagnosis
of functional gastrointestinal disorders, in practice these diagnoses remain ones of exclusion.
Furthermore, it is uncertain if the Rome III criteria can discriminate functional gastrointestinal
disorders from organic gastrointestinal diseases. Aims: We aimed to evaluate the validity of
the new Rome III criteria for functional gastrointestinal disorders (FGID) by assessing the
sensitivity and specificity against documented clinical diagnoses. Methods: Outpatients (n =
425) and patients from a functional dyspepsia and IBS registry (n= 279) completed the
Rome III version of the bowel disease questionnaire. The medical records of the 704 subjects
were reviewed to identify the clinical diagnosis. Based on the medical records, 117 were
categorized as having upper functional gastrointestinal disorders, 356 as having lower func-
tional gastrointestinal disorders, 157 as upper organic gastrointestinal disease, and 104 as
lower organic gastrointestinal disease. The sensitivity and specificity of the Rome III classifica-
tions of dyspepsia and IBS to discriminate functional from organic diagnosis was estimated.
Results: The sensitivity and specificity of the Rome III criteria to diagnose functional as
opposed to organic diseases by clinical diagnosis are given in the table below. Conclusions:
The Rome III criteria were not found to be sensitive for differentiating functional GI disorders
from organic disease, but the Rome III criteria for subgroups of functional dyspepsia and
IBS had good specificity.
The Sensitivity and Specificity of Rome III criteria FGIDS compared to clinical diagnosis
W1175
Abdominal Pain and Bloating Differ in Relation to Eating and Defecation in
IBS Patients
Samantha Carboni, Rosanna Cantarini, Danilo Badiali, Nadia Pallotta, Enrico Corazziari
Symptomatic Diagnostic criteria of Irritable Bowel Syndrome (IBS) is based on the time-
relationship of abdominal pain or discomfort with bowel pattern i.e. relieved with defecation
or associated with a change in frequency or consistency of stools (1). However IBS patients
often complain of after meal abdominal pain or discomfort and a previous study reported
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that after meal abdominal pain is more frequently associated with eating than defecation in
IBS patients (2). Aim of this study was to prospectively assess the time relationship between
abdominal pain and bloating, meals and bowel movements. Twenty nine consecutive patients
(F 21, age range 22-25 years) matching Rome II Criteria for IBS were asked to report for
15 consecutive days timing of each meal, of gastrointestinal symptoms, if any, and of bowel
movements on an ad hoc preprinted diary with predefined items. Results. Abdominal pain
occurred at least once after one of the three meals in all patients. Abdominal bloating
occurred at least once after one of the three meals in 68% of the patients. Abdominal pain
occurred in 78.5%, 82% and 85.3% of the patients, respectively after breakfast, lunch and
dinner. Abdominal pain and was relieved by bowel movements in 86.3%, 72%, and 45.8%
(p<0.002) of the patients, respectively after breakfast, lunch, and dinner. Bloating, occurred
in 39.2%, 60.7% and 46.4% of the patients respectively after breakfast, lunch, and dinner.
Bloating was relieved by bowel movements in 54.5%, 40%, and 45%, of the patients,
respectively after breakfast, lunch and dinner. Conclusions. In IBS patients abdominal pain
and bloating are more likely to be related to eating than to bowel movements. After meal
abdominal pain is more frequently relieved by defecation after breakfast and lunch than
after dinner. After meal bloating is more frequent after lunch then breakfast and dinner and
is equally, but scarcely, relieved by bowel movements irrespective of the meal. 1) Drossman
et al. Functional Gastrointestinal Disorders RomeIII 2006. 2) Ragnarsoon, Bodemar. Eur J
Gastroenterol Hepatol 1998
W1176
Distinguishing Functional Disorders from Organic Disease
Rok seon Choung, Nicholas J. Talley, Michael D. Crowell, G. richard Locke, H. jae Kim,
Cathy Schleck, Alan R. Zinsmeister
Backgrounds: Published diagnostic guidelines have recommended the use of symptom-based
criteria to establish the diagnosis of functional GI disorders (FGIDs). However, the symptom-
based Rome criteria have been criticized for being too complex for clinical use. Clinically
applicable symptom-based criteria could help establish a differential diagnosis in these
patients. Aims: We aimed to evaluate the predictive utility of gastrointestinal symptoms for
differentiating FGIDs from organic disease. Methods: Outpatients (n = 425) and patients
identified patients from a functional dyspepsia and IBS registry (n= 279) completed the
Rome III version of the bowel disease questionnaire. From chart reviews, patients were
categorized as upper functional GI disease (n=117), lower functional GI diseases (n=356),
upper organic GI disease (n=157), and lower organic GI disease (n=104). Forty variables
(include age, gender, BMI, and gastrointestinal symptoms) were evaluated to assess which
distinguished functional disorders from organic disease. Results: Three items distinguished
patients with upper functional disorders from those with upper organic disease - namely,
BMI, pain or discomfort more than 6 months, and feel uncomfortably full after a regular
size meal(OR (95% CI), 0.72 (0.54,0.95), 0.92 (0.88,0.98), 0.56 (0.31,1.01), respectively).
Five items were significantly associated with lower functional disorders compared to lower
organic disease- namely, older age, female gender, pain or discomfort more than 6 months,
pain occurring 30 minutes to 2 hours after meals, and straining during at ¼ of BM (Table).
However four items were negatively associated with lower functional disorders- namely,
pain wake you from sleep, more than 3 BM/day, bowel habit change in the last year, and
unable to finish a regular size meal (Table). Conclusion: Patient characteristics and specific
GI symptoms distinguished the functional disorders from organic disease. These will help
develop a data driven set of criteria for clinical use.
Table. Predictors for lower functional disorders compared to lower organic disease
W1177
External Validation of the Natural History of Irritable Bowel Syndrome: A
Comparison of Ilos and LOGIC
G. richard Locke, Pierre Pare, Kris Kahler, Martin Barbeau, Nadia Lesnikova, Rob Balshaw
Background: Little is known about the natural history of irritable bowel syndrome (IBS).
Observational studies are often criticized for selection bias. Objective: To evaluate differences
in outcomes measured during two large observational studies of IBS patients, one from the
US and the other from Canada. Methods: The IBS longitudinal observational study (ILOS),
a 6-month prospective study, enrolled 380 subjects across the US with physician diagnoses
of non-diarrhea-predominant IBS. The longitudinal outcomes study of gastrointestinal symp-
toms in Canada (LOGIC), a 12-month prospective study, enrolled 1556 subjects across
Canada with physician diagnoses of abdominal pain and bloating, constipation, or alternating
bowel pattern between constipation and diarrhea. Both studies were natural history studies,
and patients may or may not have been receiving treatment for IBS symptoms Although
LOGIC was a 12-month study, we compared change in outcomes from baseline to 6
months. Outcomes of interest were the domains and total score from the IBS-QOL and
work productivity as measured by the Work Productivity and Activity Impairment (WPAI)
questionnaire. Results: Baseline characteristics were similar between ILOS and LOGIC with
regard to age (42 y, 46 y), female gender (93%, 85%), Caucasian race (84%, 87%), percentage
who met ROME II criteria (78%, 70%), mean symptom score (36.7, 37.9), and mean IBS-
QOL total score (70.0, 66.6), respectively. Percentages used at baseline were different: 75%
in ILOS and 59% in LOGIC. Change in symptom score (-5.11) was measured in ILOS but
not LOGIC. Comparisons of outcomes between studies are shown in the table. Conclusions:
These large, observational studies from different countries with different healthcare delivery
systems had remarkably similar results with regard to outcomes at 6 months, suggesting
that these observational studies accurately describe the natural history of patients with IBS
with constipation or an alternating bowel pattern.
W1178
Functional Dyspepsia: Patient Knowledge, Fears, and Attitudes
Abigail Kennedy, Brian E. Lacy, Kirsten T. Weiser, Michael D. Crowell, Nicholas Talley
Background: Functional dyspepsia (FD) significantly affects patients' quality-of-life. Although
highly prevalent, very little is known about how patients perceive this disorder. The aim of
this study was to use a validated questionnaire to assess patient knowledge, fears, and
attitudes. Methods: ICD-9 codes identified adult patients (≥18 years) with dyspepsia and
were used to exclude patients with organic disorders. Records were individually reviewed
to confirm the absence of organic disorders, to verify that patients met the Rome III criteria
for FD, and to document a normal upper endoscopy. A validated questionnaire was mailed
to patients meeting these criteria. Responses were anonymous and data was analyzed using
SPSS (V14.0) statistical software. This study was approved by the Dartmouth-Hitchcock
Medical Center IRB. Results: 120 patients met all inclusion criteria and 80 patients (66%)
returned questionnaires. The respondents' mean age was 51 (± 13) years; 76% were women,
92% were Caucasian, 51% had completed college or entered graduate school, and 38%
earned more than $50,000 per year. Respondents had a mean of 7 (± 9) years of FD
symptoms, which were rated as moderate (60%) or severe (28%). The most bothersome
symptom was abdominal pain (40%), followed by abdominal burning (15%). Patients' most
significant fears were that their symptoms would never go away (43%) and that FD could
turn into cancer (20%). Patients also felt that FD increased their risk of cancer (32%) or
ulcer disease (49%). Respondents noted that FD may be caused by genetic factors (37%),
dietary factors (72%), and anxiety or depression (68%). To diagnose FD, 53% stated that
blood work needs to be performed, while 66% and 41% stated that an EGD or ultrasound
is required. A majority of respondents agreed that FD symptoms can be relieved by diet
(87%) or medications (77%). Only 12% believed that FD symptoms could be improved by
surgery. Regarding the prevalence of FD, a minority (27%) of respondents recognized that
FD is more common than diabetes, 47% were unsure as to whether FD was more prevalent
than colon cancer, and 34% believed that FD is more common in women compared to
men. Conclusions: This is the first study, to our knowledge, to assess patient knowledge,
fears, and attitudes regarding FD using a validated questionnaire. Respondents had significant
misconceptions regarding the etiology, prognosis, and treatment of FD. These misconcep-
tions, in combination with significant symptom burden, may contribute to high utilization
rates of healthcare and associated direct and indirect costs. These data highlight the need
to better educate FD patients about their condition.
W1179
Non-Digestible Capsule Technology to Measure Frequency of Gastric
Contractions- Comparison Between Healthy and Gastroparetic Subjects
Savio Reddymasu, Irene Sarosiek, Kenneth Koch, William L. Hasler, Jeff Lackner, Leonard
Katz, Michael D. Sitrin, Henry P. Parkman, John M. Wo, William D. Chey, Jack Semler,
Judy Hwang, Braden Kuo, Richard Mccallum
Introduction: The SmartPill(tm) wireless pH and pressure recording capsule has recently
been approved by the Food and Drug Administration to assess gastric emptying. The gastric
residence time (GET) measured by this device has a strong correlation with gastric emptying
assessed by scintigraphy (GES) in healthy and gastroparetic subjects. The aims of this study
were to determine whether differences could be identified in the number of contractions
per minute of gastric motor activity using data obtained from the SmartPill(tm) pressure
measurements between normal subjects and gastroparetic(GP patients with diabetic and
idiopathic etiologies. Methods:In a multicenter trial, after an overnight fast, 44 subjects
(Healthy-24, History of GP-20; DM12, idiopathic-8) swallowed the SmartPill(tm) capsule,
and then ingested a 99m Eggbeater meal to measure gastric emptying by scinitgraphy. At
the completion of the study pressure, and pH data were analyzed. The GET was measured
as the difference between the time of ingestion of the capsule to a sudden and sustained
rise of pH to >4 and at least 3 pH units above baseline. Frequencies of gastric contractions
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were calculated for the entire duration of the GRT and expressed as number of contractions
per minute (cpm). GES was considered abnormal if >10% of the radio-labeled meal was
retained in the stomach at the end of 4 hours. A two tailed unequal variance t-test was used
for statistical analysis, and a p < 0.05 was considered significant. 95% confidence intervals
(CI) were also calculated. Results:11/20 patients with a history of GP had normal GES on
the day of the test and for statistical analysis were considered as having a history of GP with
a normal GES. The remaining 9 patients who had a delayed GES on the day of the test
were termed as true GP. Mean number of gastric contractions for normal subjects was 1.8
cpm (1.5-2.1), which was statistically different (p-0.0005) from the true GP group -1 cpm
(0.7-1.3), and also from patients with a history of GP and normal GES 1.1 cpm (0.8-1.4).
(p-0.004) There was no difference between true GP and GP with a normal GES, with regards
to the cpm (p-0.399). Conclusions: 1) Gastric contraction frequency data analyzed from
both the postprandial period and that associated with emptying of a non-digestible capsule
can diagnose GP using the SmartPill(tm) pressure sensor. 2) The frequency of gastric
contractions, in both true GP and those with a history of GP but a normal GES is significantly
less than in normal subjects. 3) SmartPill(tm) is a novel, safe, and non-invasive technology
suitable for use in the office setting to measure gastric emptying and assess gastric motility.
W1180
Antecedent Event-Specific Associations for Diarrhea and Constipation with
Functional Bowel Disorder
Stephan R. Weinland, Spencer D. Dorn, Carolyn B. Morris, Yuming Hu, Christine B.
Dalton, Brenda B. Toner, Nicholas E. Diamant, William E. Whitehead, Douglas A.
Drossman
Background: Diary card data are often averaged among patients within a group and over
time in order to assess group differences. However, this approach cannot address symptoms
that vary over short periods of time or identify event-specific associations. The aim of this
study was to evaluate the onset of diarrhea or constipation with associations of pain, stress
and general well being antecedent to, and at the time of, symptom onset. Methods: 402
women with functional bowel disorders enrolled in a clinical trial reported daily levels of
well being, stress, abdominal pain, and bowel function (stool frequency and consistency)
on daily diary cards over five, two-week periods in 15 months. Diary cards from each subject
were examined to isolate events where two days of normal bowel functioning (Bristol Stool
Scale Score 3 to 5) were followed by one day of either diarrhea (BSS 6 or 7) or Constipation
(BSS 1 or 2). Measured variables of VAS Pain, VAS Stress andWell being were then examined
using repeated measures analysis to look for event specific differences. Results: 14,917 diary
cards were collected over the course of the study. Diarrhea onset events (N=396) and
constipation onset events (N=314) were identified and compared. Onset of diarrhea symp-
toms was associated with significantly more pain than was the onset of constipation symptoms
(Diarrhea (D) 38.24 + SD 28.58 vs. Constipation (C) 28.38 + SD 24.47, p=0.036). Addition-
ally, the onset of diarrhea was also associated with a decrease in well being compared to
the onset of constipation ((D) 2.69 + SD 1.06 vs. (C) 2.95 + SD 1.01, p=0.08). No significant
differences were found in event-specific reports of VAS stress between the two groups. The
onset of constipation symptoms was associated with little variability on any of the variables
measured. Conclusions: The association of reduced well-being and increased VAS pain at the
onset of diarrhea suggests that diarrhea symptomsmay bemore distressing or discomforting to
individuals than the onset of constipation. Additionally, the lack of variability in measures
associated with the onset of constipation suggests that constipation may be less reactive to
environmental and enteroceptive stimuli, and thus a more stable symptom. These findings
suggest the need for further studies on diarrhea that are time-specific, due to the greater
variability associated with this symptom, and on constipation to confirm its greater level of
stability. Grant Support: supported by National Institutes of Health grants R01DK49334,
R24DK067674, and T32DK7634, GCRC 00024.
W1181
Determinants of Irritable Bowel Syndrome Severity
Olafur S. Palsson, Motoyori Kanazawa, Miranda A. Van tilburg, Syed Thiwan, Yehuda
Ringel, Spencer D. Dorn, Lisa M. Gangarosa, Marsha Turner, Douglas A. Drossman,
William E. Whitehead
A number of different factors have been proposed as modulators of irritable bowel syndrome
(IBS) morbidity, but little is known about their relative impact on IBS severity. The present
study aimed to identify which factors play the greatest role in determining clinical pain
intensity and overall IBS symptom severity, by using data from a study in our laboratory
where a broad range of physiological and psychosocial variables were measured in a single
patient sample. Methods: 122 IBS patients (Rome II criteria + physician diagnosis; 84.4%
females; mean age=34.7 years, age range 18-73) completed the validated IBS Severity Scale
(APT 1997;11:395-402) and were tested on the following predictor variables: Life stress
(Family Inventory of Life Events), sexual abuse history, anxiety and depression (Brief Symp-
tom Inventory 18), the “Big Five” personality traits (NEO Personality Inventory), somatization
(Recent Physical Symptoms Inventory), catastrophizing (Coping Strategies Inventory sub-
scale), fecal incontinence severity, Body Mass Index, sigmoid colon pain and urge thresholds
(barostat AML method), perceptual sensitivity and report criterion (inverse of psychological
response bias) to both pain and urge sensations, colonic motility index scores, and bowel
wall compliance. Contributions to symptom severity were assessed with multiple regression
analysis, which calculates additive influences of multiple predictors on a variable while
excluding overlapping effects from inter-correlated predictors. Results: When all predictors
were combined in stepwise multiple regression equations to explain variance in IBS severity
and abdominal pain, AML pain thresholds (beta= -.291), catastrophizing (beta=.504) and
motility reactivity to distention (beta=.268) collectively explained 40.1% of overall IBS
severity variance (adjusted R2). The same 3 variables contributed significantly to clinical
abdominal pain variance (adjusted R2=.26; respective betas: -.369, .249, .275).Conclusions:
When a broad range of potential physiological and psychosocial predictors are tested in a
single analysis, just 3 variables—AML pain thresholds, catastrophizing andmotility reactivity
to intraluminal stimulus — explain 40% of all variability between patients in IBS severity
and 26% in clinical pain. We conclude that these three variables are the key determinants
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of IBS severity among all the variables measured in this study. [Supported by grants RO1
DK31369, R24 DK67674 and RR00046]
W1182
Yield of Diagnostic Testing in Patients with Suspected Irritable Bowel
Syndrome (IBS): A Prospective, Us Multi-Center Trial
Brooks D. Cash, Cecelia Kim, Dong Lee, Allan H. Andrews, John H. Smith, Richard J.
Saad, Jennifer Rai, Borko Nojkov, William D. Chey
Background: A recent systematic review examining the yield of frequently recommended
tests concluded that there was little evidence to support exhaustive testing in patients with
suspected irritable bowel syndrome (IBS) without alarm symptoms. We report preliminary
results from a prospective, multi-center US trial intended to validate these findings. Methods:
Consecutive adults with suspected non-constipation IBS (Rome II criteria) were invited to
participate. Exclusion criteria included alarm symptoms such as hematochezia or weight
loss, a family history of organic gastrointestinal (GI) disease, a previous evaluation for
IBS, or conditions precluding an evaluation. Patients underwent colonoscopy with random
biopsies and the following: CBC, metabolic panel, thyroid function testing (TFT), antibodies
for celiac disease (CD-ab) and inflammatory bowel disease (IBD-ab), and lactase genomics.
These latter 3 “non-standard tests” were also collected from asymptomatic patients undergoing
screening colonoscopy. Positive CD-abs were confirmed with EGD and small bowel biopsy
and patients with + IBD -ab were offered small bowel evaluation if colitis was not found.
Results: 366 IBS (mean age 39.3 years, 68.6% female) and 276 controls (mean age 54.1
years, 42.4% female) have been enrolled. 2.5% (9/366) IBS were identified with organic
disease felt to be responsible for their symptoms. The prevalence of abnormal TFT was 20
(5.5%) in IBS, consistent with population norms. CD was confirmed in 4 (1.1%) IBS and
2 (0.7%) controls (p≥.05), however the prevalence of abnormal CD-ab was significantly
greater in IBS. Conclusions: There does not appear to be a significant difference between
IBS and asymptomatic controls in organic GI disease diagnosed via colonoscopy and random
biopsies or blood tests for thyroid disease, IBD, and lactose intolerance, suggesting that such
testing should not be routinely obtained as part of an initial evaluation of IBS pts without
alarm features. Abnormal CD-ab, but not biopsy proven CD, are more common in IBS pts,
perhaps indicative of gluten hypersensitivity. Testing for CD should be advised in patients
with IBS symptoms if it can be proven that dietary interventions are of benefit in this
population. Currently, this remains to be determined.
Selected Results
W1183
Air Swallowing, Belching, Acid and Non-Acid Reflux in Patients with
Functional Dyspepsia
José M. Conchillo, Mohamed Selimah, Albert Bredenoord, Melvin Samsom, André J.
Smout
Background and aim: Belching is a common symptom in patients with functional dyspepsia
(FD) with a reported incidence up to 80%. We hypothesized that patients with FD possibly
have a higher frequency of belching than healthy subjects secondary to frequent air swal-
lowing. Aim of this study was therefore to assess air swallowing, belching, acid and non-
acid reflux patterns of patients with FD. Methods: Combined 24-hr impedance and pH
monitoring was performed in 10 FD patients (8 women, mean age 32.6 years) and 10
healthy controls (8 women, mean age 33 years). FD patients with excessive belching were
excluded from the study. Analysis of the impedance-pH signals included incidence of air
swallows, belching, acid and non-acid reflux. Results: The incidence of air swallows in FD
patients was significantly higher compared to controls (153 ± 15 vs 79 ± 10, p<0.001),
while the incidence of liquid-only swallows was not significantly increased. In FD patients,
a tendency towards a higher incidence of reflux episodes was found (35 ± 6 vs 24 ± 2, p=
0.11) and the proportions of gas-containing reflux episodes (belches) and non-acid reflux
episodes were significantly higher when compared to controls (66.4% vs 44.4%, p=0.04
and 70.1% vs 45.9%, p=0.009, respectively). When only gas-containing reflux episodes
(belches) were taken into consideration, FD patients also showed a higher incidence of
episodes of the non-acidic type (18 ± 5 vs 5 ± 2, p=0.04), whereas the incidence of episodes
of the acidic type was similar in the two groups (p=0.84). No differences between groups
were found regarding mean clearance time and proximal extent of the refluxate. Conclusion:
Patients with FD swallow air more frequently than controls and this is associated with an
increased incidence of non-acid gaseous gastro-esophageal reflux.
W1184
Impact of Fecal Incontinence On Irritable Bowel Syndrome
Olafur S. Palsson, Yehuda Ringel, Miranda A. Van tilburg, Lisa M. Gangarosa, Marsha
Turner, Motoyori Kanazawa, Syed ismail M. Thiwan, Douglas A. Drossman, William E.
Whitehead
Although fecal incontinence (FI) is a bowel problem distinct from irritable bowel syndrome
(IBS), the two often overlap. The added impact of FI on quality of life (QoL) impairment
in IBS is unknown. Aims: The aims of this investigation were to quantify that effect, and
to examine characteristics of IBS patients with fecal incontinence.Methods: 113 IBS patients
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(Rome II criteria + physician diagnosis; 82% females; ages 18-73 years, mean=34.2) completed
the validated Fecal Incontinence Severity Index (Dis Colon Rectum 1999;42:1525-32),
ROME II modular questionnaire, IBS Severity Scale, Brief Symptom Inventory 18 (BSI) and
IBS-QOL. The patients' height and weight were measured and Body Mass Index calculated.
Results: 65% of patients reported some degree of incontinence for mucus, liquid or solid
stool in the past month. In Analysis of Covariance test where IBS symptom severity was
controlled for, patients with fecal incontinence had significantly lower IBS-QOL scores (F=
31.3; p<.0001) than continent patients. IBS-QOL scores of patients with FI every day were
60.2 + 6.6 (mean + S.E.) compared to 73.8 + 2.5 for those with FI less than once a week
(p=.02). FI severity correlated positively with anxiety scores (r=.26; p<.05) but not other
psychological variables, and with BMI (r=.32; p<.001), hard stools (r=.21; p<.05) and loose
stools (r=.28; p<.01), but was unrelated to stool frequency, bloating, abdominal pain, overall
IBS severity, gender or age. When all of these potential predictors were combined in a
multiple regression analysis, hard stools, loose stools and BMI each made independent
additive contributions to FI severity, collectively accounting for 35% of the total variance
(adjusted R2) in severity scores. Conclusions: Fecal incontinence is very common in IBS
patients, and adds substantially to Qol impairment associated with the bowel symptoms.
Higher body mass and loose or hard stool consistency increase risk for FI in IBS. [Supported
by grants RO1 DK31369, R24 DK67674 and RR00046]
W1185
Is the Prevalence of Methanogenic Flora in Functional Gastrointestinal
Disorders Influenced By Gender and Age?
Ashok Attaluri, Jose M. Remes-troche, Jessica Paulson, Satish S. Rao
Background: Methane productionmay play a role in the pathogenesis of functional gastrointe-
stinal disorders. In the healthy population, women have a higher prevalence of methanogenic
flora when compared to men but there are no age related differences. Whether the prevalence
of methanogenic flora in common functional GI disorders is influenced by gender and age
is unknown. Aim: To examine the effects of gender and age on the prevalence of methanogenic
flora in three common functional GI disorders. Methods: We reviewed charts of consecutive
patients over 12 months who had glucose, fructose or lactose breath tests performed as part
of their clinical evaluation for gastrointestinal symptoms. Using Rome III criteria, we identified
76 patients with functional bloating (FB) (no diarrhea and negative breath tests), 55 with
IBS-D (negative breath tests) and 92 with chronic functional constipation. Presence of
methanogenic flora was defined as a baseline CH4 value ≥ 1 ppm. Age and gender data
was examined. Chi square test was performed to compare the prevalence between the groups.
Logistic regression was performed to assess the effects of age & gender on methanogen
prevalence in each disorder. Results: There were 175(78%) women and 48 (22%) men in
the group. Women had higher prevalence (p < 0.05) of methanogenic flora in the CC group,
while men had a higher prevalence (p < 0.05) in the IBS-D group (Table). No gender
differences were found (p >0.05) in the FB group. Prevalence was not affected by age in
any of the groups. However, in a logistic regression model, age and gender did not affect
the association of methanogenic flora with any of the disease groups. Conclusion: We found
significant gender differences in the prevalence of methanogenic flora in CC and IBS-D.
Women with chronic constipation and men with IBS-D are more likely to have methanogenic
flora. However, the prevalence of methanogens in these disorders was independent of the
effects of gender and age, suggesting that higher methane production is an independent phe-
nomenon.
Prevalence of methanogenic flora in the study groups
* Significantly different from males (p<0.05)
W1186
Altered Rectal Perception in Irritable Bowel Syndrome (IBS) Is Associated
with Symptom Severity
Iris Posserud, Gisela Ringstrom, Hasse Abrahamsson, Magnus Simren
BACKGROUND: The importance of visceral sensory dysfunction in IBS is controversial.
Diverging results exists regarding the connection between altered visceral perception and
gastrointestinal (GI) symptoms, as well as the effects of psychological status on visceral
sensitivity. We sought to investigate different aspects of rectal perception in IBS patients
and the association to GI and psychological symptoms. METHODS: We included 109 IBS
patients fulfilling the Rome II criteria (77 females; mean age 42 years). They underwent a
rectal barostat distension protocol determining sensory thresholds for discomfort and pain.
Patients reported perceived intensity of discomfort and pain on visual analogue scales
(VAS), and marked the corresponding area for these sensations on schematic body maps
(viscerosomatic referral). The 5th percentile (thresholds) and 95th percentile (VAS and
referral area) in healthy controls was used to define altered perception. Questionnaires were
used to assess severity of IBS related GI symptoms (Gastrointestinal Symptom Rating Scale-
IBS (GSRS) and presence of psychological symptoms (Hospital Anxiety and Depression
scale). RESULTS: Thirty-nine percent of the patients had lowered pressure thresholds for
discomfort and/or pain during rectal balloon distensions, 37% had increased perceived
intensity of discomfort, and 37% had altered viscerosomatic referral areas. When combining
these three aspects of perception, 65% of the patients were found to have altered rectal
perception. About 2/3 of all patients reported moderate or severe (score ≥4) pain (61%)
and bloating (57%), while about 1/3 reported moderate or severe constipation (29%),
diarrhea (36%) and satiety (28%). Patients with altered perception (65%), compared to
normosensitive patients, more frequently reported moderate or severe pain (73% vs 44%;
p<0.01), bloating (71% vs 36%; p<0.01), diarrhea (46% vs 19%; p<0.01) and satiety (38%
vs 14%; p=0.01). Only 8% of the normosensitive patients had a total GSRS-score ≥4,
compared to 44% of the patients with altered perception (p<0.001). Anxiety (score ≥11)
was more common in patients with altered perception, especially in patients with lowered
distension thresholds, compared to normosensitive patients (38% vs 16%; p<0.01). The
presence or absence of depression was not associated with altered rectal perception. CON-
CLUSION: About 39% of IBS patients have lowered thresholds for rectal distensions, but
when combining different aspects of perception, altered rectal perception is present in 65%.
This seems to be an important pathophysiological factor associated to GI symptom severity,
as well as the presence of clinically significant anxiety.
W1187
Functional Dyspepsia: Visceral Hypersensitivity, Impaired Gastric Compliance
and Accommodation. What Impact Do They Have On Quality of Life?
Linda anh B. Nguyen, Shelly Parker, William J. Snape
Background: Functional dyspepsia (FD) is known to cause impairment in quality of life.
The pathophysiology of FD is multifactorial among which includes visceral hypersensitivity,
impaired fundic compliance or accommodation, H. pylori infection, as well as psychosocial
factors. Aims: The aim of our study is to determine if there is any correlation between
visceral hypersensitivity, impaired compliance or accommodation with quality of life. Patients
and methods: 36 patients (M=8, F=28; mean age=39.5+2.2 years) with H. pylori negative
functional dyspepsia and normal gastric emptying by nuclear scintigraphy underwent evalu-
ation for visceral hypersensitivity, compliance and accommodation with a gastric barostat.
Quality of life (QOL) was assessed with the SF-36 questionnaire (overall mean = 71.3+2.8,
MCS=35.5+2.1, PCS=35.6+1.7). QOL was compared between patients with impaired compli-
ance and accommodation (dV) to those with normal compliance and accommodation.
Impaired compliance was defined as compliance < 20 mL/mmHg (Samsom et al. Dig Dis
Sci 1995), dV was defined as a postprandial change in volume < 64 mL (Thumshim et al.
Gut 1999) while visceral hypersensitivity was defined as threshold volume < 200 mL (Tack
et al. Gastro 2001). Results: 5/36(13.9%) patients had impaired compliance. 15/36(41.7%)
patients had impaired accommodation. 8.3% had both impaired compliance and accom-
modation. Visceral hypersensitivity was present in 17/36(47.2%) patients. 8/36(22.2%)
patients had a normal study. There was no difference in SF-36 score between patients who
had a normal study compared to those with an abnormal study (SF-36: 74.8 ± 4.3 vs. 70.2
± 3.4, p=0.51; MCS: 40.6 ± 5.2 vs. 34.0±2.2, p=0.20; PCS: 34.2±3.0 vs. 36.0±2.0, p=0.66).
There was also no difference in QOL scores when patients were grouped by compliance
(SF-36: 73.0±3.1 vs. 60.8±4.4, p=0.14; MCS: 36.6±2.2 vs. 28.5±5.9, p=0.19; PCS: 36.11±1.9
vs. 32.4±2.8, 0.44), accommodation (SF-36: 66.5±4.6 vs.73.3±5.1, p=0.34; MCS: 34.8±3.0
vs. 36.4±3.0, p=0.71; PCS: 34.7±2.0 vs. 36.9±3.0, p=0.53) or sensory threshold (SF-36:
74.0±4.0 vs. 68.0±3.9, p=0.23; MCS: 37.6±2.9 vs. 33.2±3.0, p=0.31; PCS: 36.5±2.5 vs.
34.6±2.3, p=0.60). Conclusions: 1) Patients with FD have impairment in QOL compared
with the U.S. norm. 2) Impairment in QOL is not associated with abnormal compliance,
accommodation or visceral hypersensitivity. This suggests that the affect of FD on QOL is
not impacted by physiologic abnormalities alone.
W1188
Gastrointestinal Symptoms Are Not Associated with Small Bowel Bacterial
Overgrowth Diagnosed Using the Lactulose Breath Test
Cathleen N. Cabansag, Linda B. Nguyen, Margaret Allen, Shelly Parker, William J. Snape
Background: The lactulose breath test (LBT) has been established as a simple and noninvasive
method of diagnosing small bowel bacterial overgrowth (SBBO). Constipation predominant
IBS has been found to be associated with methane production on lactulose breath testing
(Pimentel 2003). It is unclear whether GI symptoms are associated with abnormal LBTs in
all disorders associated with SBBO. Hypothesis: SBBO is not the sole cause of gastrointestinal
symptoms such as an altered bowel habit, abdominal pain or bloating. Aim: To assess the
association between gastrointestinal symptoms including abdominal pain, bloating or an
alteration in bowel habit with hydrogen or methane production on lactulose breath testing
in patients with SBBO. Patients and Methods: 105 patients (27 male/78 female, mean age
46.8+1.5 years) were evaluated for the presence of the following symptoms: abdominal pain,
bloating, diarrhea, constipation, nausea, and vomiting. All subjects underwent LBTs to
evaluate the presence of SBBO. The LBT was considered abnormal if there was a rise in
breath hydrogen or methane concentration of >20 ppm within 90 minutes of lactulose
ingestion. Three abnormal gas patterns in patients with SBBO were identified as described
by Pimentel and colleagues in 2003: 1) Hydrogen-producers 2) Hydrogen- and methane-
producers 3) Methane-producers. The chi squared test was used to determine statistical
significance. Results: SBBO was present in 55/105 (52.4%) subjects. Forty five (42.8%)
patients met Rome II criteria for IBS. Within the IBS group, 26 subjects tested positive for
SBBO. Subgroup analysis showed 6/15 (40.0%) patients with diarrhea-predominant IBS
(IBS-D) had SBBO; 13/21 (61.9%) patients with constipation-predominant IBS (IBS-C) had
SBBO; and 7/9 (77.8%) patients with alternating diarrhea and constipation (IBS-DC) had
SBBO. Hydrogen producing SBBO was significantly more prevalent in IBS-DC (77.8%)
compared to IBS-C (38.1%, p = 0.046) and IBS-D (26.7%, p = 0.015). Methane producing
SBBO was present in 20.6% of patients with IBS-D and diarrhea alone and in 34.8% of
patients with IBS-C and constipation alone (p = 0.366). Summary: This investigation shows:
1) LBT is positive in 52.4% of patients with gastrointestinal symptoms. 2) Patients with
IBS-DC had significantly higher rates of SBBO than patients with IBS-C or IBS-D alone.
There was no difference between patients with IBS-C and IBS-D. 3) Methane is not a marker
solely for constipation. Conclusions: Gastrointestinal symptoms do not predict a specific
abnormality in LBT. Thus, empiric antibiotic treatment in patients with symptoms suggestive
of SBBO may not be warranted.
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Satisfactory Relief of Overall IBS Symptoms Correlates Strongly with
Improvements in Patients Individual Symptoms
William D. Chey, Peter J. Whorwell, Andrea Viegas, Michael Dolker, Michael A. Shetzline
Background: Evaluation of medical interventions is complicated by the fact that patient
benefit, a subjective outcome, must be assessed objectively. Also, disorders like IBS result
from multiple symptoms (sx) that may differ between patients (pts). This has resulted in
the use of global sx improvement, either as ‘satisfactory' or ‘adequate' relief, to discern clinical
benefit. We studied the correlation between the global measure, ‘satisfactory relief' and
individual pt reported sx in a large cohort of IBS suffers. Methods: Women, ≥18 years,
with IBS-C (Rome II) or IBS with a mixed bowel pattern (IBS-M, Rome II adapted and based
on ≥1 diarrhea and ≥1 constipation criteria) were recruited into a placebo-controlled,
double-blind, randomized trial of tegaserod. The primary endpoint was pts' assessment of
satisfactory relief during the 4 weeks of treatment (tx). Pts also characterized their individual
IBS sx daily: stool consistency was rated on the Bristol Stool Scale, abdominal discomfort/
pain and bloating were rated on a 7-point scale (0 = none to 6 = very severe). Mean change
from baseline scores at end of tx was evaluated in responder (R) (≥2 of 4 weeks [≥50%];
≥3 of 4 weeks [≥75%]) and non-responder (NR) subgroups for satisfactory sx relief. Mean
differences in individual sx (R vs. NR, tx arms pooled) were estimated (LS Means from an
ANCOVA model). Results: In R pts, individual sx improvements were noted significantly
more often than in NR. R reported statistically and clinically relevant improvements in
abdominal discomfort/pain, bloating, bowel movement (BM) frequency, stool consistency
and straining (table). Furthermore, R reported one additional BM per week and one additional
day with normal stool consistency vs. NR. Urgency improvement did not correlate with
global satisfactory relief. Conclusions: Improvements in individual sx including abdominal
pain, bloating, BM frequency and straining correlate strongly with achieving satisfactory
relief of IBS sx. No individual symptom predicted satisfactory relief. These data support the
use of a global endpoint such as satisfactory relief when establishing drug efficacy in IBS pts.
†(n=352 vs. 291) ‡(n=258 vs. 385) Missing values excluded
W1190
Subtyping Irritable Bowel Syndrome (IBS) By the Predominant Bowel Habit:
Agreement Between Rome II and Rome III
Amanda Ersryd, Pia Agerforz, Gisela Ringstrom, Iris Posserud, Hasse Abrahamsson,
Magnus Simren
Background: The Rome II criteria for IBS classified patients into subtypes based on the stool
form and frequency, combined with the presence or absence of defection straining and
urgency. However, the recently published Rome III criteria proposes subtyping of IBS patients
based on the stool form alone, suggesting that researchers use the Bristol Stool Form Scale.
The agreement between subtyping of IBS patients based on Rome II versus Rome III is
unknown. Methods: We included 249 IBS patients according to the Rome II criteria (179
females; mean age 40 (18-74) years). They completed the Rome II Modular Questionnaire
to divide patients into subgroups according to Rome II. During one week the patients also
completed the Bristol Stool Form Scale for subtyping according to Rome III, and rated the
severity of bloating, flatulence and abdominal discomfort. Based on the Rome II criteria
patients were defined as having diarrhea- or constipation predominant IBS (c-IBS or d-IBS),
and patients not fitting into these groups as alternating IBS (a-IBS). Based on the Rome III
criteria patients were divided into IBS with constipation (IBS-C), IBS with diarrhea (IBS-D),
mixed IBS (IBS-M) or unsubtyped IBS (IBS-U). Agreement between Rome II and Rome III
was assessed with kappa statistics. Results: Subtyping based on the questionnaires resulted
in the following groups: Rome II: 92 d-IBS, 45 c-IBS and 112 a-IBS; Rome III: 97 IBS-D,
77 IBS-C, 16 IBS-M and 59 IBS-U. Of the 92 patients with d-IBS (Rome II) 51 had IBS-D,
12 IBS-C, 2 IBS-M and 27 IBS-U based on Rome III, whereas of the 45 patients with c-IBS
(Rome II), 28 had IBS-C, 7 IBS-D, 1 IBS-M and 9 IBS-U based on Rome III. The 112 patients
with a-IBS (Rome II) were divided into the following subgroups according to Rome III: 39
IBS-D, 37 IBS-C, 13 IBS-M, and 23 IBS-U. The agreement between subtyping by Rome II
and Rome III was poor (kappa value=0.19). An effect of gender was seen on Rome II (c-
IBS more common in females; p<0.0001), but not on Rome III subtyping. Except for expected
differences regarding stool frequency and consistency (p<0.0001, both Rome II and III),
subgroups based on Rome II differed regarding severity of bloating (more severe in c-IBS;
p=0.03), whereas subgroups based on Rome III differed regarding severity of abdominal
discomfort (more severe in IBS-M; p=0.005). Conclusion: There is poor agreement between
subtyping of IBS patients based on the Rome II and III criteria, with a substantial proportion
of patients belonging to different subtypes depending on the criteria used. Also characteristics
of the subgroups other than stool frequency and consistency differ based on the criteria used.
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W1191
Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome
(IBS)
Brennan M. Spiegel, Amy Strickland, Lin Chang
Background: Despite increasing consensus that “severity” is an important outcome measure
in IBS, there is uncertainty about how best to measure this construct. Published conceptual
models (Lembo et al. CGH 2005) suggest that “IBS severity” is a multidimensional outcome
that combines intestinal and extraintestnal components, and that is related to, yet distinct
from, health related quality of life (HRQOL). Existing severity instruments are largely based
on physician rather than patient-based ratings. Since severity is a patient-centered outcome,
it is essential that future instruments are based on patients' self-perceptions of disease severity.
We sought to measure patient-derived predictors of severity in a large cohort of IBS patients.
Methods: We performed a cross-sectional analysis in 1391 Rome II IBS patients recruited
at a university-based center. Subjects completed a comprehensive bowel symptom question-
naire, the SCL-90 psychometric checklist, and the SF-36. The main outcome was patient-
assessed “overall severity of gastrointestinal symptoms,” as measured on a 0-20 scale (20=
most severe). We first developed a conceptual model of IBS severity based on a systematic
review of the literature, and then performed univariate analyses to identify biological, psycho-
logical, and social predictors of severity. Finally, we entered significant predictors into a
stepwise multivariable model to measure the independent association of each predictor with
severity. Results: The average age was 47+15, and 69% were women. The mean severity
score was 11.8+4. Six factors predicted severity in multivariable analysis: (1) abdominal
pain rating (p<0.001; t=11.2); (2) belief that “something serious is wrong with body”
(p<0.001; t=3.9), (3) straining with defecation (p=0.001; t=2.7); (4) myalgias (p=0.02; t=
2.4); (3) urgency with defecation (p=0.03; t=2.2), and (6) bloating (p=0.05; t=2.0). Severity
correlated highly with HRQOL in univariate, but not multivariate, analysis. Severity was
not independently associated with some previously identified predictors of HRQOL in IBS,
such as “low energy,” “tiring easily,” or “feeling tense.” Conclusions: These data confirm
the hypothesis that patient-derived severity in IBS is related to, yet distinct from, HRQOL.
Severity appears highly related to symptoms of visceral hypersensitivity (e.g. abdominal pain,
bloating), extraintestinal somatic symptoms (e.g. myalgias), outlet symptoms (e.g. straining,
urgency), and disease-related concerns (e.g. “something seriously wrong”). These data may
assist in future efforts to define and measure severity in IBS. Supported by VA grant RCD
03-179-2; NIH P50 DK64539 & R24 AT002681
W1192
A Meal Test to Study the Symptom Pattern in Irritable Bowel Syndrome (IBS)
Iris Posserud, Anette Lindh, Linda Samuelsson, Pernilla Jerlstad, Johan Olsson, Hans
Strid, Hasse Abrahamsson, Magnus Simren
Background: Patients with IBS often complain of worsening of symptoms after meal intake.
Meal provocation tests have previously been used to study symptoms and pathophysiology
in functional dyspepsia. Aim: To evaluate a standardized meal test with assessment of GI
symptoms in IBS. Methods: We included 67 patients with IBS (Rome II) (47 females; mean
age 43 years), and 16 healthy controls (8 females; mean age 37 years). They came fasting
to our laboratory and were served breakfast (540kcal; 36% fat, 15% proteins, 49% carbohyd-
rates; 9.2g fibre), and lunch 4h later (600kcal; 32% fat, 20% protein, 48% carbohydrates;
4.3g fibre), and then returned home. They completed visual analogue scales (VAS) assessing
severity of six GI symptoms (abdominal pain, distension, discomfort, nausea, gas and fullness)
before breakfast (baseline), every 30 min after breakfast, 2 and 4 h after lunch, at bedtime
and before breakfast the following morning. A composite score combining the 6 symptoms
at each time point was created. The patients completed the IBS symptom severity score
(IBS-SSS) and performed the test twice, 10 weeks apart as part of a trial assessing the effects
of probiotics vs. placebo. Results: Patients scored higher than controls on all symptoms
during the test, except for fullness 30, 60 and 90 min after breakfast. Compared with
baseline the composite score was higher in both groups at 30, 60 and 90 min, and 2h after
lunch (also at 4h in patients). In controls only VAS for fullness changed during the day
(p<0.0001). In the patients the VAS for all symptoms changed during the day (p<0.001),
with diverging patterns for the different symptoms. Fullness and abdominal distension was
more severe after breakfast, whereas VAS for pain and discomfort was higher only 2h after
lunch. Perceived intensity of abdominal distension and gas increased 2h after lunch and
was sustained at 4h and bedtime. IBS-SSI improved after treatment (217±119 vs. 270±97;
p<0.0001), as did the composite score after breakfast (60 min, 115±96 vs. 133±102; p=
0.04) and lunch (2h, 125±117 vs. 154±128; p=0.01), but not in the morning or at bedtime.
Correlations were found between the IBS-SSS and the composite scores during the meal
test, most clearly seen 2h after lunch (r=0.56; p<0.0001). Among the different symptoms
IBS-SSS was most clearly correlated with pain and abdominal distension 2 h after the lunch.
No differences between IBS subgroups based on the bowel habit were seen. Conclusion: A
standardized meal test seems to be a promising tool to study the symptom pattern in IBS
and potentially to follow the effect of interventions. Further refinement and evaluation of
this test is warranted.
W1193
Cardiovascular Autonomic Regulation, Quality of Life and Stress Perception in
IBS and Healthy Controls
Heidemarie Hinninghofen, Axel Kowalski, Anna Lueb, Anna Matheis, Ute Martens,
Stephan Zipfel, Paul Enck
Impaired autonomic function has been recognized in many studies with IBS patients and
is believed to contribute to visceral hypersensitivity and abnormal gastrointestinal motility.
The aim of our studie was to describe and compare cardiovascular autonomic function at
baseline and after laboratory tests as well as quality of life and stress perception in IBS
patients and healthy controls. METHODS: We examined 17 IBS patients (10 females, mean
age: 38.5 ± 15.3 yrs, bmi: 22.3 ± 3.7) and 17 healthy controls closely matched for sex, age
and body mass index (age: 39.1 ± .14.1, bmi: 22.5 ± 3.4) with no history of gastrointestinal /
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psychological disorders. All patients and subjects completed the SF36 and the Perceived
Stress Questionaire (PSQ). Cardiovascular autonomic function (heart rate, non-invasive
blood pressure) were assessed with a standardized laboratory protocol (Task Force Monitor,
CNSystems GmbH, Graz, Austria) in supine position after an initial 10 minutes adjustment
period. A baseline resting period (8 minutes) was followed by paced breathing (6 cycles
per minute), valsalva manoeuvre (40 mmHg for 15 sec) and 60° head-up tilt (3 min) (HUT),
and were analysed for heart rate variability (HRV). Power of the low frequency (LF, 0.04 -
0.15 Hz) and high frequency (HF, >0.15-0.4 Hz) components of HRV were calculated. The
spectral components were log transformed to reduce the skewness of their distribution,
results are given in mean ± SD in absolute values (ln ms2). RESULTS: In IBS patients we
found a decreased quality of life (IBS: 41.3 ± 19.9; Controls: 78.2 ± 13; p = .001) and a
higher stress perception (IBS: 0.603 ± 0.19; Controls: 0.285 ± 0.20; p = .0001) compared
to the healthy controls. In autonomic testing no differences were found for the baseline,
but significant differences during deep breathing and in response to the valsalva maneuver:
IBS patients showed significant higher LF (IBS: 8.09 ± .57; Controls: 7.08 ± .91; p = .0001)
and HF (IBS: 6.20 ± 1.2; controls: 5.30 ± 1.3 p = .039) for deep breathing, as well as higher
LF (IBS: 7.63 ± 1.0; controls: 6.26 ± .96; p = .0001) and HF (IBS: 6.90 ± 1.24; Controls:
5.78 ± 1.23; p = .001) for the valsalva maneuver. HUT yielded no group differences.
CONCLUSION: The present findings confirms autonomic sympathetic and parasympathetic
cardiovascular dysregulation in IBS compared to healthy controls when the ANS is challenged,
while it appear normal under resting conditions (Supported by a grant from DFG).
W1194
Comparison of Bowel Habits Characterized By Bowel Diaries Versus
Questionnaires in Health and Fecal Incontinence
Barbara M. Seide, Adil E. Bharucha, Alan R. Zinsmeister, L. joseph Melton
Background - Though symptom questionnaires are widely used to characterize bowel habits,
they only provide a snapshot at one point in time. It is unclear if recall bias and day-to-
day fluctuations influence bowel symptoms recorded by questionnaires, particularly for
symptoms that occur infrequently. Our aims were to compare bowel habits recorded by
questionnaire to daily bowel diaries, in asymptomatic subjects and in fecal incontinence
(FI). Methods - Using a validated mailed questionnaire, we previously identified 507 women
with FI among an age-stratified random sample of 5200 Olmsted County, MN women
(Gastroenterology 2005). From this group of 507, 154 women with fecal incontinence (FI)
[(age 60 ± 1 years (Mean ± SEM)] and 129 controls (age 61 ± 1 years), selected at random,
have participated in a case-control study during which a single gastroenterologist interviewed
subjects about their bowel habits over the past year and completed a validated bowel
symptom questionnaire (FICA) (Alimentary Pharmacology and Therapeutics 2004). Sub-
sequently, subjects recorded the details of every (i.e., continent and incontinent) bowel
movement (bm) in detailed diaries for 2 weeks. Urgency was assessed by asking subjects if
they had to rush to the toilet to pass a bm. Stool consistency was assessed by the Bristol
scale. The observed agreement for symptoms and their severity, assessed by Rome II criteria,
was analyzed by the kappa or the weighted kappa statistic. Results - The Table provides
symptom frequencies assessed by both indices and the level of agreement between them.
The observed correlation between the stool diary and questionnaire methods was fair (κ =
0.21 - 0.40) to moderate (κ = 0.41 - 0.60) Conclusions - When compared to a daily diary,
bowel questionnaires are reasonably accurate for assessing symptoms. These data suggest
that bowel diaries may provide a refined assessment over questionnaires, particularly for
characterizing certain symptoms (e.g., straining). For other symptoms (e.g., rectal urgency),
a questionnaire may suffice. Differences between questionnaires and diaries may partly reflect
fluctuating bowel symptoms over time. Supported by HD 41129
‡ Prevalences and agreement are for symptoms occurring often, i.e., > 25% of the time
W1195
Comparison of Comorbidity in Japanese and U.S. Patients with Irritable
Bowel Syndrome
Motoyori Kanazawa, Olafur S. Palsson, Masae Shinozaki, Yasuhiro Sagami, Yuka Endo,
Tomotaka Shoji, Michio Hongo, William E. Whitehead, Shin Fukudo
Patients with irritable bowel syndrome (IBS) in the U.S. and other Western countries show
a high rate of comorbid medical diagnoses and symptoms. No direct comparisons exist
between Japanese andWestern patients in this regard. Aims: To compare comorbid symptoms
and diagnoses in Japanese and U.S. patients. Methods: One hundred twelve patients who
had GI symptoms but no organic diseases (57 IBS; 33 females; mean age 37 yrs) were
recruited from Tohoku University Hospital in Sendai, Japan. The Recent Physical Symptoms
Questionnaire (RPSQ) and the Comorbid Medical Conditions Questionnaire (CMCQ) (Gas-
troenterology 2002; 122: A502) were translated from English into Japanese through two
independent forward translations, resolution, back translation, and resolution of differences.
Forty-nine patients completed the Japanese RPSQ and CMCQ twice within 14 days, and
29 also completed the Cornell Medical Index (CMI). Proportion of individual symptoms/
conditions in patients with IBS from Japan was compared with data collected in a previous
U.S. study (Gastroenterology 2003; 124: A388) from 661 IBS patients (513 females; mean
age 51 yrs) in a large Seattle-area HMO. Results: Like the original U.S. questionnaires, the
Japanese versions of RPSQ and CMCQ demonstrated high internal consistency (Cronbach's
alpha; .83 and .73), high test-retest reliability (r=.95 and .93), and significant correlation
with total number of non-GI physical symptoms on the CMI (r=.72 and .61, p<.001). Age
and gender did not affect scores on the two measures. Patients in Japan had fewer symptoms
in the past month on the RPSQ compared to US patients (8.5 +/- 5.1 vs. 11.0 +/- 5.6,
p<.001), but identical number of comorbid diagnoses on the CMCQ (3.2 diagnoses for both
groups). Seven of the 26 symptoms on the RPSQ were different in frequency (Fisher's exact
test, p < .01) between the Japanese and U.S. samples; muscle aches (29.8% vs.74.9%),
frequent urinating (24.6% vs. 59.2%), teeth grinding (14.0% vs. 41.0%), jaw pain (8.8%
vs. 27.2%), flushing of face and neck (8.8% vs. 33.6%), low sex drive (29.8% vs. 49.0%),
and eye pain (43.9% vs. 25.1%). On the CMCQ, Japanese and US patients only reported
different frequencies of lifetime diagnoses by physicians for 3 of the 16 listed diagnoses:
tension headaches (12.2% vs. 45.7%), depression (19.3% vs. 44.8%) and interstitial cystitis
(24.6% vs. 2.4%). Conclusions: The Japanese version of RPSQ and CMCQ are reliable and
valid instruments to assess comorbidities in IBS. The great majority of comorbid symptoms
and diagnoses of IBS patients occur at similar rates in Japan and the U.S., but overall non-
GI symptom expression is somewhat higher in U.S. patients.
W1196
Functional Dyspepsia: Validation of a Survey Instrument Evaluating Economic
Impact and Patient Perceptions
Abigail Kennedy, Brian E. Lacy, Kirsten T. Weiser, Michael D. Crowell, Nicholas Talley
Background: Functional dyspepsia (FD) is prevalent, reduces quality-of-life (QOL), and
increases healthcare utilization. Patients' perceptions of FD may affect illness behavior. We
developed an instrument to assess FD symptoms, knowledge, fears, and associated costs.
Our primary goal was to establish the psychometric properties of this instrument, including
validity and reliability. Methods: A 66 item questionnaire was generated from literature
review and expert consensus. Content validity was established through expert review and
face validity confirmed through a patient focus group. Items assessed domains of patient
knowledge, concerns, and the economic impact of FD. FD patients meeting Rome III criteria
were identified by ICD-9 codes and chart review. Patients received identical questionnaires
2 weeks apart. Internal consistency of items and scales was assessed using Cronbach's
alpha. Test-retest reliability was evaluated using intra-class correlation (ICC [95% CI])
and Spearman's correlation coefficient. Specific agreement was also computed. Principal
Component Analysis (PCA) with Varimax rotation and Kaiser Normalization (SPSS v14)
was used to evaluate the dimensionality of specific components. Unidimensionality was
determined by the simple structure and eigenvalues >1 with item loading exceeding 0.40,
while minimizing cross-loadings. Results: 78 patients returned the first questionnaire and
47 (60%) returned both. Respondents' mean age was 50; 81% were women. Internal consist-
ency was good for most scale level measures (α = 0.70-0.84). Two scales related to therapy
demonstrated low consistency (α = 0.30-0.39). Reliability coefficients were good for measures
of symptoms (ICC = 0.74-1.0), consulting behaviors (ICC = 0.78-0.94), medical costs (ICC =
0.69-0.90) and QOL ratings (Rho = 0.78-0.81). PCA supported unidimensionality for the
scales measuring knowledge and concerns. Multidimensionality was noted within the FD
symptom domain that supported 2 components accounting for 58% of total variance;
fullness, early satiety and bloating (35%), and abdominal pain, burning and nausea (23%).
Multidimensionality was also noted for the treatment scale with one component preferring
prescription therapies and another preferring alternative and counseling interventions. Con-
clusion: The questionnaire demonstrated good initial validity and reliability in FD patients.
The instrument can be further refined by elimination of items with low consistency and by
addressing the multidimensionality of the symptom and treatment scales. Identification
of patients' perceptions of FD and its therapies may help modify attitudes and reduce
healthcare utilization.
W1197
Gender-Specific Patterns of Bowel Symptoms in Irritable Bowel Syndrome
(IBS) Patients
Joseph Zimmerman
Reported gender-differences in digestive symptoms of IBS patients are inconsistent. Aim: to
elucidate whether the pattern of bowel symptoms that discriminates IBS patients from
controls of the same gender differs between males and females. Methods: IBS patients (n=
150) and a control group of non-patient hospital visitors (n=460) were studied. All patients
met the Rome I criteria for IBS and denied an enteric infection prior to onset of their
symptoms. All had normal results of blood count, ESR, blood chemistry, serum calcium,
TSH, tissue transglutaminase antibodies; A stool examination for occult blood and parasites
and flexible sigmoidoscopy. Symptomatic lactase deficiency was ruled out by a trial of a
lactose-free diet. Patients were followed up for at least 1 year with no change in the diagnosis.
Symptoms were gauged on 3 validated scales: Diarrhea, constipation and pain/gas symptoms
( Dig Dis Sci, 2003; 48:743-749). Results: The distribution of patients and controls according
to age and sex (51% females) was similar. The scores on all bowel scales were independently
associated with IBS (P<0.001). However, an interaction between sex and the scores on the
diarrhea and pain/gas scales was observed (p=0.041 and 0.014 respectively). To further
corroborate these findings, the study population was randomly divided into two groups, A
and B comprising 2/3 and 1/3 of the sample respectively. In females of group A, a discriminant
analysis using the 3 bowel scores to classify IBS patients from controls yielded the standardized
coefficients 0.653, 0.166 and 0.474 for the scores of diarrhea, constipation and pain/gas
symptoms respectively. In males of the same group, the corresponding coefficients were
0.470, 0.162 and 0.624. The above coefficients were used as weighting factors for their
respective scales and composite weighted total bowel scores were calculated for each gender
as the sum of the respective weighted scores on the 3 scales. Receiver-operating curves
(ROC) of these composite scores in the discrimination between IBS patients and controls
yielded cutoff scores with sensitivities of 86.5 and 88.9% and specificities of 93.5 and 94.3%
in females and males respectively. These cut point scores were then applied to group B,
where they proved 89.0 and 93.4% specific in the discrimination of IBS patients from controls
in females and males respectively. Conclusions: The pattern of symptoms distinguishing IBS
patients from controls of the same gender differed significantly according to sex. The dominant
A-681 AGA Abstracts
symptom complexes were diarrhea in females and pain/gas in males. These findings support
a true gender-specific pattern of bowel symptoms in IBS.
W1198
Lack of Agreement for Irritable Bowel Syndrome Subtypes for Rome III
Between Retrospective Questionnaire and Prospective Diary Cards
Spencer D. Dorn, Carolyn B. Morris, Stephan R. Weinland, Yuming Hu, Brenda B. Toner,
Nicholas E. Diamant, William E. Whitehead, Shrikant I. Bangdiwala, Douglas A.
Drossman
BACKGROUND: The Rome III committees recommend basing the criteria for IBS subtypes
(i.e., IBS-Constipation, IBS-Diarrhea, IBS-Mixed, and IBS-Unsubtyped) on stool consistency
(i.e., the proportion of hard/lumpy or loose/watery stools). These symptoms can be assessed
retrospectively by recall on a questionnaire or prospectively by filling out daily diary cards.
However, the accuracy of these methods for use in treatment trials is unclear. AIM: To
determine the level of agreement between Rome III IBS subtype assignments made using
retrospective assessment of stool habit on a single questionnaire compared to prospective
assessments of stool habit on daily diary cards. METHODS: Female patients (n=148) with
Rome II defined IBS reported their daily stool consistency using the Bristol Stool Scale Form
(1 or 2 = hard/lumpy and 6 or 7 = loose/watery stools) on diary cards for two weeks.
Subsequently, subjects recalled their stool consistency (hard/lumpy or loose/watery) over
the prior three months on a single questionnaire. Subtype classification was then made
based on Rome III recommendations: IBS-D = loose watery >25% and hard/lumpy <25%
of time; IBS-C = hard/lumpy >25% and loose watery <25%; IBS-M = both loose/watery and
hard/lumpy >25%; or IBS-U = neither loose/watery nor hard/lumpy >25%. RESULTS: The
level of agreement between Rome III subtype assignments using a single questionnaire
compared to two weeks of diary cards was 62.0%. The level of chance adjusted agreement
(Kappa) was 0.39. (See Table) CONCLUSIONS: Stool consistency that is recalled on a
questionnaire or prospectively assessed using daily diary cards results in considerably different
Rome III IBS subtype assignments. In particular, subjects who were classified as IBS-M by
diary cards were frequently classified as either IBS-C or IBS-D by questionnaire. It is unclear
whether these differences reflect recall bias, fluctuations in symptoms over longer periods
of time (i.e. two weeks vs. three months), or the effect of evaluation using time frames that
did not completely overlap. Further studies are needed to evaluate the contribution of these
factors in explaining these differences. Grant Support: supported by National Institutes
of Health grants R01DK49334, R24 DK067674, and T32 DK7634, GCRC 00024 and
Novartis Pharmaceuticals.
W1199
Multinational Survey of Perceived Causes and Attitudes Towards Treatment
Among Persons with Self-Defined Constipation
Arnold Wald, Michael A. Kamm, Stefan Mueller, Carmelo Scarpignato, Kenneth G.
Mandel, Ursula Koehler, Chris Schuijt
BACKGROUND & AIMS: Misconceptions among physicians regarding constipation have
been recently reviewed (Am.J.Gastroenterol. 2005; 100: 232-42). However, perceptions of
lay persons regarding causes and management of constipation are less well studied. We
conducted a multinational survey assessing perceptions of causes and attitudes toward
treatment, among personswith self-defined constipation in the US, UK, France (FR), Germany
(GE), Italy (IT), Brazil (BR), and South Korea (SK). METHODS: In each country, ≥ 200
individuals reporting ≥ 2 yrs history of constipation and having symptoms ≥ once every 3
months during the past year completed moderator-conducted interviews using appropriately
translated standardized questionnaires. Results of a previous survey among a representative
population sample in these countries set stratification criteria for gender (70% female),
laxative use (40%), and age distribution. Questions addressing patient perceptions of general
and specific causes for constipation and its treatment are reported herein. RESULTS: Over
94% of the 1435 respondents in total rated nutrition/eating habits as the leading general
cause for constipation (89% (FR) - 99% (SK)). In rank-order, stress (44% - 79%), immobility
(39% - 81%) and “bowel problems” (21% - 76%) were generally perceived as causes of
constipation. Respondents maintained the same rank-order, but reported lower values for
nutrition (68% (FR) - 91% (US)), stress (21% (UK) - 57% (FR)), immobility (21% (BR) -
45% (GE)) and “bowel problems” (4% (SK) - 58% (IT)) as causes of their own constipation.
Interestingly, while over 18% (10% (SK) - 24% (GE)) considered use of laxatives to be a
general cause of constipation, < 4% considered this as a causative factor for their own
symptoms. With the exception of FR and IT, less than half of respondents reported consulting
a physician for constipation (13% SK - 56% FR); > 85% of consultations were with GPs/
internists, 8% with gastroenterologists. Long- and short-term treatment varied among coun-
tries. Improving nutrition and increasing exercise were leading long-term treatment options.
Laxatives use was more common as treatment once constipation occurs (31% (IT) - 40%
(US)) than as preferred for long-term treatment (22% (UK) - 32% (FR)). Most laxatives,
whether prescribed or recommended by physicians or self-selected, were OTC products.
CONCLUSION: Similar to physicians, persons with self-defined constipation have miscon-
ceptions about the causes and treatment of constipation. There is a need to provide up-to-
date information on the causes and treatment of constipation to both lay persons and health
care providers.
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W1200
Overlap of Common Gastrointestinal (GI) Motility and Sensory Disorders:
Six-Month Data from Progress
G. richard Locke, Suzanne Clark, Annamaria Cerulli, Josh Marehbian, Kris Kahler,
Michael A. Shetzline
Background: Clinically functional GI disorders show considerable overlap, a clinical finding
not well examined in longitudinal studies. Most data on patients' symptoms come from
studies that may have significant measurement error. Objective: To assess in a dynamic
longitudinal study the symptom overlap of common GI motility and sensory disorders in
a primary care setting. Methods: 400 patients were enrolled in the Patient Registry for
Observational Gastrointestinal Research-Epidemiology and Symptom Severity (PROGRESS)
study between April and October 2005. Patients were included if they had irritable bowel
syndrome with constipation (IBS-C), chronic constipation (CC), or functional dyspepsia
(FD) per Rome II criteria or gastroesophageal reflux disease (GERD) confirmed by their
primary care physician. Symptom frequency was assessed biweekly for 6 months with a
symptom assessment survey specifically developed and validated for this study. Using factor
analysis, 4 symptom scales were identified: constipation, diarrhea, dysmotility, and reflux.
Symptom scale score range was 0-100; higher scores represented increasing severity. Symp-
tom overlap was compared between and within cohorts, and trends across time were analyzed
with generalized linear models. Results: This study enrolled 86 IBS, 39 CC, 36 FD, and
239 GERD patients. Mean response rate across surveys was ~67%. Mean age was 51 y; 69%
were women; 82% were Caucasian. Within each disease cohort, most patients (77%-100%)
reported symptoms consistent with an additional GI disorder (Table 1). Patients in all disease
cohorts consistently identified dysmotility symptoms. Patients with CC had the highest and
patients with FD the lowest mean total symptom scores compared with other cohorts (P=
.05). A downward trend in overlap was observed over time. Conclusions: This prospective
6-month real-world study in the primary care setting demonstrates that patients with GI
motility and sensory disorders have multiple symptoms potentially attributable to different
pathologies that likely represent a common underlying problem with GI dysmotility.
Table 1. Mean symptom scale scores (% > 0) over 6 months by cohort
*P<.05; significant difference between cohorts. †Totals do not add up due to missing scale
data for some patients. ‡P<.05; significant difference within cohorts.
W1201
Overweight, High Age and the Presence of Loose and Frequent Stools Are
Suggestive of Bile Acid Malabsorption in Patients with the Irritable Bowel
Syndrome (IBS)
Antal Bajor, Jenny Wallin, Hans Strid, Hasse Abrahamsson, Kjell-arne Ung, Magnus
Simren
Background: The noxious effects of bile acids (BA) on the colonic mucosa may play a
pathophysiological role in IBS. The 75SeHCAT test corresponds inversely to the fecal excretion
of BA, and there is a direct correlation between the hepatic BA and triglyceride synthesis.
In patients presenting with chronic diarrhea BA malabsorption (BAM) is present up to 40
%, but the prevalence of BAM in IBS is unknown. Aims: The primary aim of the study was
to find predictors of BAM by evaluation of symptoms, anthropometric data and laboratory
analysis in IBS patients. The secondary aim was to investigate the prevalence of BAM in IBS
subgroups according to the Rome II and III criteria. Methods: IBS patients adhering to the
ROME II criteria were consecutively included in the study. They completed the Rome II
modular questionnaire and the Bristol Stool Form scale during one week for registration of
stool form and frequency, and performed a 75SeHCAT test. Samples for plasma triglyceride
(TG), total cholesterol (TC), and HDL concentrations were drawn and analyzed under
standardized conditions. The body mass index (BMI) was calculated. A subset of the patients
also underwent an oroanal transit test (OATT) (n=41). Results: Twenty-five (18.5%) out of
the 135 (71.5% female) included patients had a 75SeHCAT value≤10% on day 7, compatible
with BAM. In the IBS subgroups according to the Rome II criteria BAM was seen in 12
patients with diarrhea predominant IBS (d-IBS) (20%), in 3 with predominantly constipation
(c-IBS) (13%) and in 8 with alternating diarrhea and constipation (a-IBS) (19%) (p=0.7).
According to the Rome III criteria 4 patients with IBS with constipation (15%), 16 with
diarrhea (25%), 2 with mixed IBS (40%) and 3 with unsubtyped IBS (8%) had BAM (p=
0.13). The 75SeHCAT retention values differed significantly between the Rome II subgroups,
with c-IBS patients having a higher median value (38%) than patients with d-IBS (23%; p=
0.005) and a-IBS (19%; p=0.006). Patients with overweight were more likely to have an
abnormal 75SeHCAT retention than those with normal weight (p<0.0001). There were
statistically significant correlations between 75SeHCAT values and age (R=-0.28; p=0.001),
stool frequency (R=-0.29; p=0.001), consistency (R=-0.20; p=0.02), BMI (R=-0.37: p=0.002),
OATT (R=0.47; p=0.002) and plasma TG (R=-0.29; p=0.001) and HDL (R=0.22; p=0.02)
concentrations. Conclusions: IBS patients with high age, overweight and frequent loose
stools are more prone to have BAM. However, subtyping of IBS based on the Rome II or
III criteria cannot reliably predict the presence of BAM. Our results suggest that BAM in
IBS may be part of the metabolic syndrome.
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W1202
Cytokines and Caspase-1 in the Peripheral Blood of Irritable Bowel Syndrome
Patients and Controls
Paula Carlson, Hugh Gorman, Irene Busciglio, Alan R. Zinsmeister, Michael Camilleri
Background: Prior studies have documentedminor inflammation in irritable bowel syndrome
[(IBS) Chadwick et al. GE 2002;122:1778]. A prior study supports increased plasma cytokines
such as IL-6, IL-8 and TNFα (Dinan et al. GE 2006:130:304-11), and another study showed
an increase in myeloperoxidase (Lattesio et al. J Gastro 2006:41:54-9). Gwee et al. (Gut
2003;52:523-6) showed increased IL-1β levels in the rectal mucosa of patients with IBS,
specifically post-infectious patients. We have shown (Aerssens et al. GE, DDW abstract in
press, 2007) that the caspase gene is differentially expressed in sigmoid mucosa of patients
with IBS relative to mucosa from healthy controls. Our hypothesis is that there is evidence
of systemic inflammation in patients with IBS. Aim: To compare levels of selected cytokines
and Caspase-1 in peripheral blood in healthy controls and IBS. Methods: We recruited 15
healthy controls and 30 IBS participants (with no history to suggest post-infectious etiology)
for a blood draw in a study of patients undergoing biopsies of the rectum and sigmoid
colon to study mucosal molecular signatures in IBS. IBS phenotype was assessed using a
standard and validated bowel disease questionnaire.Wemeasured the peripheral blood levels,
using commercially available ELISA for IL-1β, IL-6, IL-8, IL-10 (Biosource International Inc.
Camarillo, CA) and Caspase-1 (Bender MedSystems Inc. Burlingame, CA). Results were
compared using an ANOVA on ranks for the 16 C-IBS, 14 D-IBS and 15 healthy controls.
Results (table): All biopsies were essentially normal except that 1 healthy and 2 D-IBS had
acute focal colitis and 3 C-IBS had melanosis coli. IL-1β, and IL-8 were not detectable in
the blood of any participant. There were no differences detected between the controls and
IBS groups for IL-6, IL-10 or Caspase-1. Conclusion: We are unable to confirm significant
increases in circulating cytokines or altered Caspase-1 in peripheral blood of IBS patients.
In the future, comparisons of these circulating biomarkers of inflammation should be con-
ducted in post-infectious IBS.
W1203
Do Patients with Self-Defined Constipation Fulfill Rome III Criteria for
Functional Constipation?
Arnold Wald, Michael A. Kamm, Stefan Mueller, Carmelo Scarpignato, Kenneth G.
Mandel, Ursula Koehler, Chris Schuijt
BACKGROUND & AIMS: A recent multinational (7-countries; 13,879 responders) survey
reported prevalence of self-defined constipation to range from 5% in Germany (GE), to 18%
in the US (Gastroenterology 130:A508, 2006). The Rome III criteria offer a consensus
definition for functional constipation as a tool for research and diagnosis. Whether subjects
with “self-defined” constipation also fulfill Rome III criteria can help to determine the utility
of these criteria as a reflection of patient definitions. This study assessed whether self-defined
constipation in persons in 7 countries (at least 200 respondents per country) fulfilled Rome
III criteria for functional constipation. METHODS: In each of 7 countries (US, UK, GE,
France (FR), Italy (IT), Brazil (BR) & South Korea (SK)), at least 200 individuals having ≥
2 yrs history of constipation with symptoms at least once every 3 months during the past
year completed moderator-conducted interviews using appropriately translated standardized
questionnaires. Participants with self-defined constipation were further assessed as to whether
constipation was in accordance with the Rome III questionnaire. The study population was
stratified for gender (70% female), laxative use (40%), and age distributions. RESULTS:
Between 79% (GE) and 95% (BR) of 1435 respondents in total considered normal stool
frequency as at least 1 bowel movement (BM) a day. This definition did not differ among
subjects who were using or not using laxatives to treat their constipation. The percentage
of subjects who considered themselves to be constipated if they did not have a BM for 2
days ranged from 10% (SK) to 63% (US) and if for 3 days, from 66% (SK) to 91% (US).
In all countries, common concurrent complaints of constipated subjects included irregular
bowel movements, bloating, discomfort due to gas, and passing hard/dry stools. In general,
study participants reported 7-10 complaints associated with their constipation. Overall, more
than 80% of subjects from this study fulfilled two or more of the Rome III criteria for
functional constipation (range 78% (UK) to 92% (IT, SK)). Very few respondents (0% (FR,
SK) - 6% (IT)) did not satisfy any of the components of the Rome III criteria. CONCLUSION:
The majority of persons having ≥ 2 years history of self-defined constipation with episodes
occurring at least once every 3 months in the last 12 months also fulfill Rome III criteria
for functional constipation. Rome III criteria have utility in defining subjects for inclusion
in studies of both long-term chronic and short term episodic treatment of constipation.
W1204
Herbal Medicine for the Treatment of Functional Dyspepsia: A Systematic
Review of the Literature and Meta-Analysis
Gerald Holtmann, Sanjay Nandurkar, Nicholas J. Talley, Paul Moayyedi
BACKGROUND: Herbal medicines are used in many countries for the treatment of patients
with functional dyspepsia. OBJECTIVES: We aimed to conduct systematic review of evidence
from randomized controlled trials (RCTs) that studied herbals (single plant extracts, combina-
tion or Chinese herbal medicine) for the treatment of patients with functional dyspepsia.
SEARCH STRATEGY: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, major
conference proceedings and textbooks were searched up to September 2006. SELECTION
CRITERIA: RCTs in patients with functional dyspepsia or non-ulcer dyspepsia in whom a
peptic ulcer and/or esophagitis were excluded by endoscopy were eligible. Studies needed
to compare a herbal remedy with either placebo or active medication. Outcome measures
that were eligible included improvement of the dyspepsia score and the proportion reported
to be without symptoms or with improved symptoms at the end of the study. DATA
COLLECTION AND ANALYSIS: Three reviewers assessed the eligibility criteria of each
study and the data regarding outcomes and factors affecting methodological quality. MAIN
RESULTS: We identified 11 trials evaluating 1351 patients. Two trials evaluated different
Chinese herbs, one trial red pepper, one artichoke and one peppermint/caraway oil compared
with placebo. All studies suggested herbal therapies were superior to placebo. One study
compared peppermint/caraway oil and one study Iberogast to prokinetics and both suggested
the interventions had similar efficacy. There were 4 trials with 637 patients comparing
Iberogast to placebo. There was a statistically significant reduction in the dyspepsia score
in patients randomized to Iberogast compared to placebo (standardized mean difference
DerSimonian and Laird random effects model = -1.1; 95% CI = -1.72 to -0.49, p=0.0005)
although there was statistically significant heterogeneity between studies (Cochran Q = 33.8
P < 0.0001, I2 = 91.1% (95% CI = 79.3% to 94.9%). The proportion remaining dyspeptic
was reported in two of these trials and relative risk of remaining dyspeptic on Iberogast
was 0.89 (95% CI = 0.82 to 0.97, p = 0.006) with a number needed to treat of 10 (95%
CI = 6 to 33). CONCLUSIONS: Treatment with the herbal preparations assessed in this
systematic review appears to be efficacious since all published RCT with placebo reported
a significant improvement of symptoms. Most herbal preparations are evaluated with only
one RCT. The exception is Iberogast which has been compared to placebo in 4 RCTs.
Iberogast is significantly more effective than placebo. The magnitude of the effect is variable
as reflected by the heterogeneity of the studies.
W1205
Pilot Study of Two New Injectable Bulking Agents for the Treatment of Faecal
Incontinence
Yasuko Maeda, Carolynne J. Vaizey, Michael A. Kamm
Background: The use of injectable bulking agents for passive faecal incontinence appears to
provide reasonable short term results. However experience with different agents is limited.
We report on the outcome of perianal injections with new bulking agents. Methods: Each
patient received injections of either Bulkamid™(hydrogel cross-linked with polyacrylamide)
or Permacol™(porcine dermal collagen). Assessment included clinical evaluation, anorectal
physiological testing, endoanal ultrasonography, and questionnaires including the St Mark's
Incontinence Score, one week bowel diary card, the Faecal Incontinence Quality of Life
(FIQOL) Scale, and the Short Form-36 (SF-36) health survey. Follow up was at six weeks
and six months. Results: Ten patients (nine female), median age 68 years (range 45-79),
were treated, half receiving each treatment. St Mark's incontinence score (0=best, 24=worst)
was 15 (range 11-24) at baseline, 13 at six weeks (range 3-18), and 14 (range 6-22) at six
months. The one week bowel diary and SF-36 also showed temporary improvement but
this was not sustained at six months. Conclusion: Bulkamid™ and Permacol™ injections
improved faecal incontinence in the short term, but this was not sustained. This may relate
to dissipation or resorption of the agents.
St Mark's Incontinence Score at baseline, at six weeks and six months after injection with
the bulking agents.
W1206
Stimulation of Mucosal Secretion By Lubiprostone in Guinea-Pig Small
Intestine and Colon
Guijun Fei, Sumei Liu, Guo-du Wang, Mei-hua Qu, Xiyu Wang, Fie Zou, Yougin Du, Yun
Xia, Laura M. Bohn, Jackie D. Wood
Lubiprostone is a novel type-2 chloride channel (ClC-2) activator approved for the treatment
of chronic idiopathic constipation in adults. Lubiprostone enhances intestinal fluid secretion
via activation of ClC-2. We investigated actions of lubiprostone on mucosal secretion in
guinea-pig small intestine and colon. Muscle-stripped preparations were mounted in Ussing
flux chambers for recording changes in short-circuit current (Isc), which reflect secretion.
Lubiprostone applied to the serosal side of 6 ileal preparations in 8 concentrations ranging
from 1 to 3000nM evoked increases in Isc from 2.6±0.9 to 50.26±4.5µA/cm2 in a concentra-
tion-dependent manner with an EC,50 of 227.2nM for serosal side application and an increase
in Isc from0.78±0.7 to 37.8±7.9µA/cm2with an EC50 of 42.5nM formucosal side application.
A-683 AGA Abstracts
Lubiprostone applied to the serosal side of 6 colonic preparations in 8 concentrations
ranging from 1 to 3000nM evoked increases in Isc from 1.3±0.7 to 26.8±4.7µA/cm2 in a
concentration-dependent manner with an EC50 of 31.7nM for serosal side application and
an increase in Isc from 3.4±0.9µA/cm2 to 58.9±12.3µA/cm2 with an EC50 of 48.9nM for
mucosal side application. Blockade of enteric neuronal conduction by 1-µM tetrodotoxin
(TTX), applied to the serosal side, had no significant effect on stimulation of Isc by serosally-
applied 300-µM lubiprostone (with TTX Isc = 28.5±3.5μA/cm2, n=12 preparations; without
TTX Isc = 32.8 ± 2.1μA/cm2, n=6 ileal preparations, P=0.30). Substitution of gluconate for
Cl- in the solution on mucosal and serosal sides abolished all responses to 300-nM lubipro-
stone, when it was applied to the mucosal or serosal side of 6 ileal preparations. In the
presence of 1-µM TTX, serosal application of 1-µM carbachol evoked typical increases in
Isc, which reflected direct actions at muscarinic receptors on the enterocytes of 6 ileal
preparations. Lubiprostone (300nM), applied on the mucosal side, significantly increased
the responses to carbachol from 27.6±7.6 μA/cm2 for carbachol alone to 45.1 ± 9.4 μA/
cm2 in the presence of lubiprostone (P <0.01). The results suggest that lubiprostone acts
directly on the epithelium to stimulate mucosal Cl- secretion and acts to augment the
secretory responses evoked by action of muscarinic agonists. None of the stimulatory action
of lubiprostone on secretion can be attributed to stimulation of secretomotor neurons in
the submucosal plexus. Stimulation of mucosal secretion by lubiprostone is expected to
increase the liquidity of the intestinal contents and can explain its efficacy in the treatment
of chronic constipation. (Supported by a grant in aid from Sucampo Pharmaceuticals, Inc.)
W1207
Corticotrophin Releasing Hormone Increases Postprandial Bloating But Not
Distension in Patients with Irritable Bowel Syndrome
Anurag Agrawal, Peter J. Whorwell, Lesley A. Houghton
Background: Corticotrophin releasing hormone (CRH) mediates the stress response causing
increases in both visceral sensitivity and motility (1, 2). The effect of stress on the symptom
of bloating and abdominal distension (ie change in girth) in patients with IBS, which are
also modulated by changes in visceral sensation (3) and gastrointestinal (GI) transit (4),
remain unknown. Aim: To assess the effect of CRH on postprandial bloating and distension
in patients with IBS compared with healthy volunteers. Methods: A randomised, double-
blind, placebo controlled, cross-over study in which the effect of CRH on meal induced
bloating and distension were compared between 17 female IBS (Rome II) patients with a
history of bloating (aged 21-42 yrs) and 10 healthy female volunteers (21-32 yrs). Abdominal
girth was measured using the technique of Ambulatory Inductance Plethysmography (5)
and bloating using a Likert Scale of 0-5 (5=very severe) for one hour before and two hours
after a standard meal (1114 kcal). CRH 1 µg/kg or placebo was intravenously administered
immediately after the meal and patients were studied during the luteal phase of the menstrual
cycle or whilst taking the contraceptive pill. Results: In IBS patients, CRH significantly
increased postprandial bloating (change fasting to fed: CRH, +1.35 (1.04, 1.66), (mean
(95%CI)) v placebo, +0.53 (0.23, 0.83); p=0.001) but not distension (+2.02 cm (1.37, 2.67)
cm v +1.28 cm (0.74, 1.82) cm) compared with placebo control. No such effects were seen
in healthy volunteers (bloating: +0.50 (0.1, 0.9) v +0.27 (0.09, 0.45), distension: +1.41 cm
(0.30, 2.52) cm v +1.38 cm (0.85, 1.91) cm). Thus, the postprandial bloating response to
CRH compared with placebo was greater in IBS patients compared with healthy volunteers
(p=0.02). Conclusions: IBS patients exhibit an enhanced postprandial bloating response to
CRH compared with healthy volunteers. This may be due to the sensation of bloating in
IBS patients being in part related to visceral sensitivity (3), which is increased by CRH (1).
The lack of effect on distension, which has previously been shown to be directly related to
transit time in IBS (4), is probably explained by the fact that CRH increases motility and/
or transit. References: (1) Sagami et al, Gut 2004; 53: 958, (2) Fukudo et al, Gut 1998; 42:
845, (3) Agrawal et al Neurogastroenterol Mot 2006, 18: A183, (4) Agrawal et al Gastroenterol
2006; 130: A93, (5) Houghton et al Gastroenterol 2006; 131: 1003-1010.
W1208
Tegaserod: A Serotonin Uptake Inhibitor
Stephan R. Vavricka, Manfred G. Ismair, Randy D. Blakely, Michael Fried, Gerd A.
Kullak-ublick
Background& Aims: Tegaserod is a novel drug for the treatment of constipation-predominant
irritable bowel syndrome (IBS-C) and chronic idiopathic constipation. Tegaserod is thought
to exert its prokinetic effect as a selective partial agonist of 5-HT4 receptors located in the
enteric nervous system. It is unknown, however, whether tegaserod interacts with the human
serotonin reuptake transporter (hSERT) and the uptake transporters for dopamine (hDAT)
and norepinephrine (hNET). Therefore, the aim of the present study was to investigate the
influence of tegaserod on SERT-, DAT-, and NET-mediated transport. Methods: Tegaserod
inhibition of SERT-mediated [3H]5-HT and NET- and DAT-mediated [3H]dopamine uptake
was measured in HEK293 cells stably expressing hSERT, hDAT, and hNET in comparison
with untransfected control HEK293-FT cells. Results: Tegaserod inhibited SERT-, DAT-,
and NET-mediated transport with IC50-values of 11.7 µmol/l, 20.7 µmol/l, and 3.2 µmol/
l, respectively, while 100 µmol/l estrone-3-sulfate or taurocholic acid, used as negative
controls, failed to inhibit hSERT-mediated transport. Using Dixon plot analysis, inhibition
kinetics yielded a non-competitive type of inhibition with an apparent inhibition konstant
(Ki) of 3.1 µmol/l for SERT-mediated 5-HT transport. Conclusion: In the present study we
propose a novel mechanism of action for tegaserod as a serotonin uptake inhibitor. By
inhibiting SERT and increasing local 5-HT concentrations in the gut wall, tegaserod might
exert its prokinetic action via a synergism between 5-HT4 agonism and low affinity SERT
inhibition.
A
G
A
A
bs
tra
ct
s
A
G
A
A
bs
tra
ct
s
W1209
Effect of MA-2029, An Orally Active Motilin Antagonist, On Interdigestive
Motility, Gastric Accommodation and Gastric Emptying in Dogs
Ken-ichi Ozaki, Hiroyasu Muramatsu, Hirokazu Sudo, Shoushin Yoshida, Kenji Yogo,
Osamu Cynshi, Kenshi Kamei, Osamu Kuromaru, Theo L. Peeters, Hisanori Takanashi
INTRODUCTION:MA-2029 is a novel orally active motilin receptor antagonist synthesized
in our laboratory. It inhibits porcine motilin (pMTL) induced contractions of rabbit duo-
denum In Vitro, and pMTL-induced colonic motility In Vivo in conscious rabbits (see other
abstract). In this study, the motilin antagonist activity of orally administered MA-2029 was
studied in conscious dogs. METHOD: Gastrointestinal contractile activity was measured by
chronically implanted force-transducers. Gastric accommodation was studied by measuring
proximal intragastric volume with a barostat under constant pressure. Gastric emptying rate
was investigated by the acetaminophen (AAP) method. RESULTS: MA-2029 (0.3-10 mg/
kg p.o.) administered in the interdigestive state inhibited gastric and colonic contractions
induced by pMTL (3 µg/kg, i.v.) in a dose-dependent manner (Fig. A), even though MA-
2029 did not change the gastric and colonic basal tone and the basal gastric emptying rate
even at 30 mg/kg p.o. The inhibitory effects of MA-2029 in the stomach and the colon
corresponded to its plasma concentration. After dosing of pMTL (3 µg/kg, i.v.), nine of
eleven dogs showed diarrhea. Pretreatment of MA-2029 (1-30 mg/kg, p.o.) reduced the
incidence of diarrhea induced by pMTL in a dose-dependent manner. In a barostat analysis,
pMTL (0.3 µg/kg, i.v. infusion) decreased the stomach volume. MA-2029 (1-10 mg/kg p.o.)
reversed this effect in a dose-dependent manner (Fig. B). CONCLUSION: MA-2029, after
oral administration, inhibited pMTL-induced gastrointestinal motility, diarrhea, and impair-
ment of gastric accommodation, but was without effect on the basal gastrointestinal tone
or normal gastric emptying rate in dogs. These results indicate that MA-2029 might have
potential in the treatment of gastrointestinal disorders accompanied by hyper-motility.
W1210
Influence of NK-1 Receptor Antagonist-Aprepitant On Rectal Sensitivity and
Compliance in Healty Volunteers
Filiz Akyuz, Kostas Mimidis, H. Nikolai, Rita Vos, Jan Tack
Background and Aim: Tachykinins mediate their biological actions through specific neuroki-
nin receptors and have been implicated in the control of gastrointestinal sensorimotor
function and in the pathogenesis of visceral hypersensitivity. Aprepitant, a selective neuroki-
nin-1 (NK-1) receptor antagonist, is approved for the treatment of chemotherapy-induced
emesis, but its effect on sensorimotor function of the gastrointestinal tract has not been
studied. Methods: Sixteen healthy volunteers (7 male, mean age 27.7±5.2 years) underwent
a rectal barostat study on 3 separate occasions, with administration of placebo or aprepitant
80 or 125 mg in a controlled, double-blind cross-over design. Stepwise distentions (4 mmHg
for isobaric and 40 ml for isovolumetric steps at 2-minute intervals, until discomfort or
pain) were performed to assess rectal sensitivity and compliance before and after drug
administration; continuous isobaric distention was used to measure drug-induced changes
in rectal tone. Subjects were instructed to score their perception of abdominal sensations
at the end of every distending step, using a visual analogue scales (VAS). Results are given
as mean±SEM and compared by Student's t-test and ANOVA. Results: Rectal compliance
did not differ after placebo, aprepitant 80 or aprepitant 125 mg (respectively 10.6±1.2,
10.0±0.9 and 10.6±1.0 ml/mmHg, NS). However, during isobaric tone measurements, a
gradual increase in intra-balloon volume occurred during the placebo condition (volume
increase up to 33±10 ml), but not after aprepitant 80 mg (ANOVA, p=0.01) or 125 mg
(ANOVA, p=0.03). The pressure needed to induce first perception (respectively 11.3±1.5
vs. 9.8±1.6 vs. 10.8±1.4 mmHg) or discomfort (respectively 30±1.6 vs. 27.8±0.1 vs. 27.5±1.3
mmHg) did not differ between placebo and aprepitant 80 or 125 mg. The corresponding
VAS scores were also not significantly different. However, the intra-balloon volumes at
perception threshold were significantly different between placebo and aprepitant 80 mg
(111±24 vs. 65±15 ml; p<0.01) and at discomfort threshold between placebo and aprepitant
125 mg (273±25 vs. 235±23 ml; p<0.05). Conclusion: The NK-1 antagonist -aprepitant
does not alter sensitivity to rectal isobaric distention, but abolishes rectal accommodation
to a continuous distention and decreases intra-balloon volumes that induce perception or
discomfort. These observations suggest that the neurokinin-1 receptor is involved in control
of rectal tone rather than rectal sensitivity.
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Otilonium Bromide Inhibits Stretch Activated Smooth Muscle Response in the
Human Colon Probably Trough L-Type Calcium Channel Inhibition
Diana Gallego, Jordi Aleu, Victor Gil, Mariona Auli, Pere Clave, Marcel Jimenez
Otiloniumbromide (OB) is a spasmolytic agent used for the treatment of functional gastrointe-
stinal (GI) disorders in EU countries. OB probably acts as an L-type calcium channel blocker
as it has been demonstrated both in the rat colon (1) and human jejunum(2). Distention
of the intestinal wall is an important factor causing pain and discomfort. Distention initiates
neuronal afferent mechanisms and possibly also modifies smooth muscle properties due to
the presence of stretch activated calcium channels in smooth muscle cells of the GI tract(3).
However, stretch activated responses are not characterized in the human colon. Accordingly,
the aim of the present work has been to study “In Vitro” 1- the effect of stretch on the
smooth muscle response, 2- the effect of OB on the stretch activated responses, 3- the effect
of OB on calcium transients. Muscle bath experiments were performed with strips obtained
from surgical specimens obtained for rectal neoplasm (n=20). After a period of equilibration
(1h), stretch was applied from 0 to 7g in steps of 1g. During each step the spontaneous
motility was recorded for 30 minutes. Preparations displayed spontaneous contractions. The
frequency, amplitude and tone (baseline) was measured during the last 10 minutes of each
stretch. To avoid neuraly mediated responses, the study was performed in the presence of
the neural blocker TTX (1µM). Stretch (n=15) did not modify the frequency of spontaneous
contractions (2-3 contractions/min). In contrast, the amplitude of spontaneous contractions
and tone were progressively increased by stretch (ANOVA p<0.001). OB was tested at 4
different concentrations from (1nM to 1μM, n=5 each). Amplitude of stretch induced
contractions was significantly decreased by OB (Two way ANOVA p<0.001), significant
differences were observed at the concentrations of 1μM. Stretch induced-tone was also
significantly reduced by OB (Two way ANOVA: p<0.001), significant differences were
observed at 0.1 μM and 1μM. Calcium imaging technique was used to investigate the effect
of OB on isolated smooth muscle cells from human colon. Calcium transients induced by
KCl were dose dependently (15 cells, N=5) inhibited by OB (log IC50 -6.61±0.07: R2=
0.89, ). We conclude that Otilonium bromide inhibits stretch induced miogenic responses
trough a mechanism that probably involves an L-Type calcium channel. In this work we
provide further data about the mechanism of OB as a spasmolytic agent in human disorders.
(1)-Martin MT et al. Neurogastro & Motil 2004 April;16(2):175-83. (2)-Strege PR et al
Neurogastro & Motil 2004 April;16(2):167-73. (3)-Farrugia G et al. Gastroenterology 1999
October;117(4):900-5.
W1212
Effects of Ginger On Gastric Emptying and Motility
Keng-liang Wu, Chris Rayner, Seng-kee Chuah, Chi-sin Changchien, Sheng-nan Lu, King-
wah Chiu, Chuan-mo Lee
Background: Ginger is reported to have anti-emetic properties. However, the effects of ginger
on gastric motor function have not been well studied. Aim: To investigate the effects of
ginger on gastric emptying, antral motility, proximal gastric dimensions, and postprandial
symptoms. Methods: Twenty-four healthy subjects were studied twice in a randomized
double-blind manner. After an 8 hour fast, subjects ingested a ginger capsule (1200 mg)
or placebo, followed after one hour by 500 mL low-nutrient soup. Antral area, fundus area
and diameter, and the frequency of antral contractions were measured using ultrasound at
frequent intervals over 90 minutes, and the gastric half-emptying time (T50) was calculated
from the change in antral area. Gastrointestinal sensations and appetite were scored using
visual analog questionnaires. Data are mean ± standard deviation. Results: Antral area
decreased more rapidly (P<0.001) and the T50 was less after ginger than placebo (13.1±1.1
vs 26.7 ±3.1 minutes, P<0.01), while the frequency of antral contractions was greater
P<0.005). Fundus dimensions did not differ, and there was no difference in any gastrointesti-
nal symptom. Conclusions: Ginger accelerates gastric emptying and stimulates antral contrac-
tions in healthy subjects. These effects could potentially be beneficial in symptomatic
patient groups.
W1213
Efficacy of the Peripheral Kappa Opioid Agonist, Asimadoline, On Pain
Episodes of Moderate Severity in Females with Irritable Bowel Syndrome: A
Randomized, Placebo-Controlled, On-Demand Study
Lawrence A. Szarka, Michael Camilleri, Duane Burton, Jean C. Fox, Sanna Mckinzie,
Timothy Stanislav, Julie Simonson, Nancy Sullivan, Alan R. Zinsmeister
Background: In animal models of irritable bowel syndrome (IBS), peripheral kappa opioid
agonists have been demonstrated to decrease sensation to colonic distention. In healthy
subjects and IBS, asimadoline (ASI), a kappa opioid agonist, was associated with reduced
sensation of colonic distension. Aims: To compare the effects of ASI and placebo (PLA) on
episodes of abdominal pain in patients with IBS. Methods: Following a 2-week run-in
period, 100 patients with IBS were randomized (3:2 ratio) to receive ASI, up to 1 mg 4
times daily, or PLA for 4 weeks under double-blind. Pain was scored using a 100 mm visual
analog scale. During pain episodes, patients recorded the pain severity, took studymedication,
and recorded pain score 2 hours later. Primary endpoint was the average reduction in pain
severity 2 hours after treatment. We also assessed effect of treatment on bowel function,
anxiety, depression and quality of life using validated instruments [Hospital Anxiety and
Depression Inventory (HAD) and IBS QoL Questionnaire]. Results: In the 2 treatment arms,
there were no differences in age (ASI 39±2, PLA 36±2), baseline symptoms and bowel
function [constipation (C), diarrhea (D), alternators (Alt)], number of days with pain during
treatment, proportion of days when medication was used, and number of tablets used per
day with pain. The average pain reduction 2 hours post-treatment was not significantly
different between the groups (Table). However, post-hoc analyses suggest ASI was effective
in IBS-Alt [Δ pain intensity: 37.8±3.7 ASI (n=23) vs. 22.0±3.0 PLA (n=16); p=0.003,
unadjusted], and may be worse in IBS-D [Δ pain intensity: 25±2.9 ASI vs. 37.5±6.5 PLA;
p=0.053]. Anxiety score was modestly reduced by ASI. No significant adverse effects were
noted. Conclusions: A flexible dosing schedule of ASI was not effective in reducing severity
of abdominal pain in IBS. Further studies of asimadoline in patients with visceral pain and
IBS-alternators appear warranted.
W1214
In Vitro and In Vivo Characterization of Ma-2029, a Novel Orally Active
Motilin Receptor Antagonist, in Rabbits
Hirokazu Sudo, Shoushin Yoshida, Ken-ichi Ozaki, Hiroyasu Muramatsu, Kenji Yogo,
Osamu Cynshi, Kenshi Kamei, Osamu Kuromaru, Theo L. Peeters, Hisanori Takanashi
AIM: The pharmacological properties of MA-2029, a novel motilin receptor antagonist
synthesized in our laboratory, were investigated in rabbits In Vitro and In Vivo. METHODS
&RESULTS: In VitroMA-2029 (3-30 nM) inhibited contractions induced by porcine motilin
(pMTL) in longitudinal strips from rabbit duodenum in a competitive manner, with a pA2
of 9.17 ± 0.01 (mean ± SE, n=5), but had no effect (at 1 μM) on the the contractile responses
to acetylcholine and substance P. Both MA-2029 and pMTL competitively inhibited 125l-
pMTL binding to motilin receptors in homogenates of rabbit colon smooth muscle tissue.
The pKi of MA-2029 and the pKd of pMTL were 8.58 ± 0.04 and 9.03 ± 0.05 (each n=4),
respectively. In Vivo colonic contractile activity was measured by a chronically implanted
force-transducer in conscious rabbits. MA-2029 administered orally (3-30mg/kg) inhibited
colonic contractions induced by pMTL (3 μg/kg i.v.) in a dose-dependent manner. This
inhibitory effect of MA-2029 was continued over 4 hours after oral administration of 30
mg/kg. The inhibitory effect of MA-2029 was related to the plasma concentration of MA-
2029. In order to examine the effect of MA-2029 on viscerosensory response, the number
of abdominal contractions caused by a combination of colorectal distention and pMTL-
induced colonic contractions was measured using a myoelectrical electrode. Intravenous
infusion of pMTL (3 μg/kg/hr) together with colorectal distention increased the number of
abdominal contractions. Orally administered MA-2029 (1-3 mg/kg) significantly decreased
the number of abdominal contractions in a dose-dependent manner (Fig.).CONCLUSIONS:
These results indicate that MA-2029 is an orally active, selective, and competitive motilin
receptor antagonist in rabbits. MA-2029 may have therapeutic potential in the treatment of
gastrointestinal disorders characterized by hypermotility such as IBS.
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Mitemcinal (GM-611), An Orally Active Motilin Receptor Agonist, Accelerates
Gastric Emptying in a Diabetic Gastroparesis Dog Model
Ken-ichi Ozaki, Kenji Yogo, Hirokazu Sudo, Hiroyasu Muramatsu, Kenshi Kamei, Yoshiki
Kawabe, Zen Itoh, Satoshi Omura, Hisanori Takanashi
BACKGROUND & AIM: Symptom relief after oral administration of mitemcinal in patients
with diabetic gastroparesis has been confirmed in a PIIb clinical trial (Gastroenterology,
130, A598, 2006). In preclinical studies, the acceleration of gastric emptying by mitemcinal
has also been demonstrated in delayed gastric emptying models induced by truncal vagotomy
or clonidine in dogs. However, the efficacy of mitemcinal in diabetic animals has not been
examined. In this study, its efficacy was investigated in streptozotocin (STZ)/alloxan (ALX)-
induced diabetic dogs.METHODS:Diabetes was induced by intravenous (i.v.) administration
of STZ (30 mg/kg) and ALX (50 mg/kg) in female beagle dogs. The animals maintained
moderate hyperglycemia (200-300 mg/dL) without an insulin treatment. Dogs were fed a
dog food paste including 300 mg acetaminophen (AAP) and the gastric emptying rate was
measured using an AAP method. Motor nerve conduction velocity (MNCV) of tibial and
ulnar nerves as an index of neuropathy was measured under general anesthesia. The effect
of mitemcinal (0.125-0.5 mg/kg, oral) on gastric emptying and MNCV was examined after
STZ/ALX injection. RESULTS: Diabetes had developed after i.v. injection of STZ/ALX to
gradually increase the fasting plasma glucose level (FPG) to about 200 mg/dL at 12th month.
Then, FPGs were almost the same at 1 year (222.4 ± 28.0 mg/dL) and at 5 years (211.5 ±
19.7 mg/dL) after reaching to 200 mg/dL. Severe liver failure or renal failure was not observed
during the 5 years of hyperglycemia. At 1 year, the MNCV of the tibial nerve was significantly
decreased (57.6 ± 0.4 vs. 65.5 ± 1.7 m/s for Diabetic vs. Normal). However, there was no
difference in the gastric emptying rate between normal and diabetic dogs. On the other hand,
at 5 years, delayed gastric emptying was observed in diabetic dogs. The peak concentration of
AAP in diabetic dogs (2.86 ± 0.39 μg/mL) was lower than that of normal dogs (4.33 ± 0.28
μg/mL, P=0.022). Oral administration of mitemcinal increased plasma AAP concentration
in a dose-dependent manner and the peak concentration of AAP was significantly elevated
at a dose of 0.5 mg/kg (8.15 ± 2.03 μg/mL, P=0.014 vs. vehicle) in diabetic dogs. Thus,
mitemcinal accelerated gastric emptying even in the diabetic gastroparesis dog model. CON-
CLUSIONS: STZ and ALX-induced diabetic dogs may be useful models for investigating
the diabetic complication of gastroparesis. In addition, the present study demonstrates that
mitemcinal may be a useful treatment for diabetic gastroparesis.
W1216
Nitric Oxide-Releasing Beads Restore Delayed Gastric Emptying in Diabetic
Rats
Mark S. Niedringhaus, Patrick G. Jackson, Robert R. Raulli, Joseph G. Verbalis, Richard
A. Gillis, Niaz Sahibzada
Background & Aim: Diabetes Mellitus contributes to a wide range of health disorders.
Among these is gastroparesis, a disorder that is characterized by abnormal gastric motility and
markedly delayed gastric emptying (GE). Although recognized as a multifactorial problem, a
dysfunctional role of the pylorus (i.e., excessive tonic and/or phasic contractions) is now
thought to be an important contributing factor to gastroparesis. This dysfunction has been
demonstrated to result from damage to the nitric oxide synthase (NOS)-containing neurons
in the pylorus. Based on these observations, we investigated the use of NO-releasing polysty-
rene beads (NORB) to see if intragastric release of NO in the stomach would counteract the
effect of diabetes-induced delay in GE in an animal model of diabetic gastroparesis.Methods:
Experiments were carried out in adult male Sprague-Dawley rats (200-400g). To induce
diabetes, daily injections of streptozotocin (STZ; 60mg/kg, IP) were administered for 5 days.
Animals were followed for 7.5 weeks before GE studies were performed. Control animals
received only vehicle injections (IP). Prior to the experiment, animals were fasted overnight.
A 20% sucrose solution (0.5 ml vol) containing phenol red (1mg/ml) was delivered into
the stomach via a gavage needle. Half of the animals (from both the STZ group and the
control group) received NORB (10mg/kg) in the sucrose solution, whereas the other half
received only polystyrene beads (RB; 10mg/kg). Following a 15-min interval, all animals
were euthanized and their stomachs were ligated at the lower esophageal and pyloric
sphincters, removed, homogenized and centrifuged. The amount of phenol red retained in
the stomach was determined via spectroscopy of the supernatant at 410nm. GE was evaluated
as the percentage of phenol red retained in the stomach. Results: GE in STZ+RB group (n=
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7) was significantly less (p<0.01) compared to the control+RB group (n=5) (82.5±4.1%
versus 52.2±4.7%, respectively). In contrast, the STZ+NORB group had significantly (p<0.01)
improved GE (56.4±5.8%; n=7) compared to the STZ+RB group. There were no significant
differences between the control+RB group and the control+NORB group (39.0±5.3%; n=5),
or between the control+RB and the STZ+NORB groups. Conclusions: The results indicate
that intragastric release of NO in the stomach via NORB can improve GE in STZ-induced
diabetic rats to the GE values seen in non-diabetic animals.
W1217
A Cost-Utility Analysis of Tegaserod in the Treatment of Constipation-
Predominant Irritable Bowel Syndrome (IBS) Based On the Real-World Trial,
LOGIC
Marg Hux, Michael Maschio, Martin Barbeau, Brenda Lee, Shawn Barry, Jim Gray
Abdominal pain/discomfort, bloating and constipation are gastrointestinal (GI) symptoms
related to irritable bowel syndrome (IBS) and are associated with impaired quality of life
(QoL). Tegaserod, a selective 5-HT4 receptor agonist, is the only agent shown to relieve all
three symptoms of constipation, abdominal pain and bloating. Longitudinal Outcomes
of GastroIntestinal symptoms in Canada (LOGIC) was a one-year prospective real-world
observational study of 1,556 patients with symptoms of constipation-predominant IBS to
assess QoL, as well as IBS treatments received, related health resource use and work productiv-
ity. A regression-based cost-utility analysis was undertaken to estimate and compare costs
and outcomes of tegaserod versus other prescription treatment in constipation-predominant
IBS. The analysis was based on clinical outcomes and health resource use data from LOGIC.
Patients reporting prescription medication use for the target symptoms during the first
month were included and those reporting tegaserod (n=355) were compared to those
reporting other prescription medication use (N=370) on an intent-to-treat basis regardless
of subsequent treatment, with covariate adjustments applied to manage non-outcome-related
differences between the groups. Cost utility measures were developed using QALYs based
on the EQ5D (UK tariff) as the primary outcome measure and considering both Healthcare
system and societal cost perspective. A series of sub-group analyses were undertaken to
explore key drivers within the analysis. Bootstrap methods were utilized to evaluate uncer-
tainty resulting from underlying variation in the trial data. The results of the base case
analysis showed tegaserod to be the dominant strategy. Tegaserod use resulted in better
quality of life outcomes and approximately 25 days of quality adjusted time over a one-
year period compared to usual care. While the costs of medication were higher for the
tegaserod group, other direct medical costs were consistently lower with the net result being
a lower cost for the tegaserod group. A summary of the base case analysis is provided in
the following table. Sensitivity analyses through the use of bootstrapping methods lead to
the conclusion that this result is robust. There is approximately a 70% chance that tegaserod
is cost-saving. At a willingness-to-pay threshold of $10,000 (CDN) per additional QALY,
the chance that tegaserod should be considered cost-effective rises to over 95%.
W1218
A Study to Examine the Synergistic Effect of a Cholinesterase Inhibitor and a
5ht(4) Agonist On Colonic Transit
Kristen Campbell-dittmeyer, Gareth A. Hicks, Beverley Greenwood
Cholinergic stimulation is a common mechanism of gastrointestinal (GI) prokinetics. Current
approaches to treat slow GI transit include the use of cholinesterase inhibitors that prevent
the breakdown of acetylcholine (ACh) following its release from cholinergic terminals. These
agents augment the motor activity of the bowel, especially the colon, and are often used to
stimulate colonic transit in patients with pseudo-obstruction, post-operative ileus and colonic
inertia. Another approach for chronic constipation is to use 5HT4 receptor agonists, such
as tegaserod, to stimulate GI transit via a mechanism involving presynaptic facilitation of
ACh release. Since these two agents work independently on either side of the synapse to
elevate synaptic levels of ACh, we aimed to investigate the potential synergy that may occur
with a combination of the two agents in the amplification of cholinergic neurotransmission
and thus GI transit. Methods: In male rats (200-300g) fecal pellet output was measured
every 30 mins for 2 hr following administration of tegaserod (0.01-1.0 mg/kg i.p.), neostig-
mine (0.01-0.1 mg/kg i.p.) or a combination of both compounds. Results: When dosed
alone, tegaserod or neostigmine caused a dose and time-dependent increase in fecal pellet
output. In combination, the lower doses of the two agents, which did not produce significant
effects alone, increased fecal pellet output that was significantly different from the sum of
the two compounds alone (Table 1). This synergistic effect was not seen at the higher doses
of each compound, which may be explained by a bell shaped dose response in this model.
Summary & Conclusion: When combined, tegaserod and neostigmine synergize in the
production of their stimulatory effect on colonic transit. This synergistic effect of a combina-
tion of a 5HT4 receptor agonist and an anti-cholinesterase agent may prove to be a useful
approach treating conditions associated with slow colonic transit.
Table 1: Effect of Low Dose Tegaserod (Teg) or Neostigmine (Neo) alone or in Combination on
Fecal Pellet Output.
A-686AGA Abstracts
Sum of tegaserod and neostigmine alone vs. tegaserod plus neostigmine * P<0.05, * P<0.01,
*** P<0.001 using 2-way ANOVA and Bonferroni post tests.
W1219
Effect of the NK3 Receptor Antagonist, Talnetant, On Rectal Sensory Function
and Compliance in Healthy Humans
Lesley A. Houghton, Filippo Cremonini, Michael Camilleri, Irene Busciglio, Catherine
Fell, Victoria Cox, David H. Alpers, Odile E. Dewit, George E. Dukes, Emily Gray,
Richard Lea, Alan R. Zinsmeister, Peter J. Whorwell
Background & Aims: Visceral hypersensitivity is important in the pathophysiology of
irritable bowel syndrome and thus a target for modulation in drug development. Neurokinin
(NK) receptors, including NK3 receptors, are expressed in the motor and sensory systems
of the digestive tract. The study aim was to compare effects of two different doses (25mg
and 100mg) of the NK3 receptor antagonist, talnetant (SB223242), with placebo on rectal
sensory function and compliance in healthy volunteers studied at two centers. Methods:
Rectal barostat tests were performed on 102 healthy volunteers, randomized to receive either
oral talnetant, 25mg or 100mg, or placebo over 14-17 days. On three occasions, tests were
performed: day 1, immediately prior to 1st dose; day 1, four hours post-dose (D1); and
after 14-17 days on therapy (D2). We measured compliance and pressure thresholds using
ascending method of limits, and sensory intensity ratings during four random phasic disten-
sions (12, 24, 36 and 48 mmHg) using visual analogue scales. Pre-drug results have been
reported (NGM 2005;17:810-20). Results: Talnetant had no effect on rectal compliance
[Pressure at ½ max volume on D1 (mean±SEM): 25mg, 13.7±0.6; 100mg, 13.0±0.6; control,
12.6±0.6; and D2: 14.7±0.7, 14.9±0.7, 13.3±0.7 respectively], Kaplan-Meier estimates of
pressure thresholds for sensation (median pain threshold on D1: 34, 34 and 32 mmHg;
and on D2: 36, 40 and 36 mmHg), or intensity ratings (aggregate intensity score for pain
over 4 distensions for D1: 35.8±2.4, 41.1±2.5, 34.2±2.5 and for D2: 36.6±2.9, 39.8±3.1,
35.6±3.0) compared with placebo. Figure shows thresholds on Day 1, post-drug. In general,
the results obtained at the two centers differed minimally, with intensity scores at one center
consistently somewhat lower. Conclusion: At the doses tested, talnetant has no effect on
rectal compliance or distension-induced sensation in healthy participants.
W1220
Efficacy of Long-Term Tricyclic Antidepressant Therapy in Cyclic Vomiting
Syndrome in Adults
Savio Reddymasu, Farid Namin, Pernilla Foran, Teri A. Lavenbarg, Richard Mccallum
Introduction: Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder being
increasingly recognized and reported in the adult population. It is characterized by recurrent
and stereotypic episodes of nausea, vomiting, and abdominal pain with symptom free
intervals. It is a cause of disability and recurrent hospitalizations. Prevention of these episodes
is the best available treatment option for this syndrome. Aims of this study were to investigate
the effects of long-term therapy with tricyclic antidepressants (TCA) on the frequency
and duration of episodes of CVS, and frequency of emergency department (ED) visits or
hospitalizations related to this disease. Methods: Open labeled study of 21 (10 female) Mean
age 35 years (18-58) CVS patients who were prescribed a TCA and followed in our clinic
for >1 year. Demographic data, TCA dosage, duration and frequency of CVS episodes, ED
visits and hospitalizations at baseline and during TCA therapy were recorded. Adverse effects
with TCA were monitored. A two tailed unequal variance t-test was used for statistical
analysis, and a p < 0.05 was considered significant. 95% confidence intervals (CI) were also
calculated. Results: Results are summarized in table 1 after 1-year follow-up. 18 subjects (9
females) continued to take the TCA class of medications for greater than 1 year. 16 were
on amitriptyline and 2 on nortriptyline. 3 stopped the medication within 3 months, 2 as
their symptoms had completely resolved and 1 because of a lack of response. Average dose
of TCA was 1 mg/kg (Range 0.3 mg/kg-1.8mg/kg). Side effects noted in 4 (22%); included
hypersomonolence, postural hypotension, constipation, and weight gain. The frequency of
episodes, and ED visits or hospitalizations was significantly reduced in CVS patients receiving
chronic TCA therapy. Interestingly when a CVS cycle did require hospitalization, the duration
was the same as before therapy. Conclusions: Long-term use of TCA therapy is efficacious
in the adult population with CVS resulting in a significant reduction in morbidity and health
care utilization. This data is consistent with the hypothesized role of the brain-gut axis in
the pathogenesis of this disorder.
W1221
Pharmacological Characterization of Central and Peripheral Opioid Receptor
Involvement in Rat Models of Gastrointestinal Function
Christina C. Sandlund, Scott R. Armstrong, Tina Pham, Carrie Richardson, Adrienne
Winans, David T. Beattie
Opioid receptor ligands can act peripherally or centrally to influence gastrointestinal (GI)
transit. In this preclinical study, the GI activities of the centrally-penetrant opioid receptor
antagonists, naltrexone and naloxone, were compared to those of alvimopan, a peripherally-
restricted μ opioid antagonist, and its active, primary human metabolite, ADL 08-0011.
Morphine was selected as a centrally-penetrant opioid receptor agonist, and its activity was
compared to that of loperamide and N-methylmorphine, two peripherally-selective opioid
agonists. In rat models of morphine (10 mg/kg, s.c.)-delayed small intestinal transit and
loperamide (1 mg/kg s.c.)-delayed gastric emptying, the agonists or vehicle were dosed 15
minutes after s.c. antagonist or vehicle administration. A charcoal meal was orally gavaged,
and small intestinal transit or gastric weight was recorded 60 minutes later. Morphine,
loperamide and N-methylmorphine, inhibited small intestinal transit (ID50 values of 7.2,
>3 and >100 mg/kg, respectively) and gastric emptying (ID50 values of 0.58, 0.2 and 7.6
mg/kg, respectively). Each opioid agonist was less potent at reducing small intestinal transit
than inhibiting gastric emptying. The centrally-penetrant opioid receptor antagonists,
naloxone and naltrexone, produced a complete reversal of morphine-delayed small intestinal
transit (mean ED50 values of 0.085 and 0.018 mg/kg, respectively), while the peripherally-
restricted antagonist, alvimopan, only achieved a 50% reversal (ED50 = 0.01 mg/kg). Unlike
its parent, ADL 08-0011 produced a complete reversal (ED50 = 0.05 mg/kg). Each antagonist
produced a potent and complete reversal of the loperamide-induced delay in rat gastric
emptying (mean ED50 values of 0.35, 0.04, 0.003 and 0.008 mg/kg for naloxone, naltrexone,
alvimopan and ADL 08-0011, respectively). The lack of agonist potency of loperamide and
N-methylmorphine, and limited antagonist activity of alvimopan in the intestinal transit
model, relative to that in the gastric emptying assay, indicate that the roles of the CNS and
periphery in opioidergic regulation of GI motility depends on the region of the GI tract in
rats. The finding that ADL 08-0011, but not alvimopan, is associated with a complete reversal
of morphine-induced delays in intestinal transit, is consistent with a higher degree of CNS
penetration than its parent.
W1222
Td-5108, a Selective, High Intrinsic Activity 5-HT4 Receptor Agonist - In Vitro
Profile At Human Recombinant 5-HT4 Receptor Splice Variant and Human
Isolated Colon
Jacqueline Smith, David T. Beattie, Alan W. Cuthbert, Anna Ropenga, Daniel Marquess,
Jeng-peng Shaw, Ross Vickery, Patrick P. Humphrey
5-HT4 receptors are expressed throughout the gastrointestinal (GI) tract, and play an import-
ant role in the control of GI function. 5-HT4 receptor agonists (e.g. tegaserod) are efficacious
in GI disorders such as irritable bowel syndrome and chronic constipation. An opportunity
exists for a selective 5-HT4 receptor agonist with improved pharmacokinetic properties,
offering enhanced efficacy and convenience of dosing relative to tegaserod (Kellow et al.,
2003 Gut 52: 671; Johanson, 2004 Aliment. Pharmacol. Ther. 20: 20). Radioligand binding
and cAMP accumulation techniques examining the interaction of TD-5108 with human (h)
recombinant 5-HT4 receptors stably-transfected in HEK293 cells showed it to be a potent,
high intrinsic activity (I.A.) agonist (Table 1). TD-5108 was ≥ 25-fold selective for h5-
HT4(c) over other biogenic amine receptors (e.g. pKi = 6.3, 6.1, 5.9, 5.9 and 5.8 at guinea
pig H1, hM2, hM1, hM4, and hM3 receptors respectively). Furthermore, TD-5108 was >
1000-fold selective over other 5-HT receptors (including h5-HT2B and h5-HT3A) and > 250-
fold selective over hERG K+ channels (pIC50 = 5.3). TD-5108 produced a concentration-
dependent contraction of the longitudinal muscle of the guinea pig colon, and relaxation
of the carbachol-precontracted rat isolated esophagus (Table 1). In human colon (used with
approval from the Cambridge Research Ethics Committee), TD-5108 produced a robust,
concentration-dependent inhibition (pEC50 > 6.0 in 4/5 tissues; mean =6.3) of electrically-
evoked contractions while tegaserod, cisapride and mosapride had only modest (≤ 30%
inhibition at 1 μM; n=5-6) effects. Spontaneous contractions were attenuated by TD-5108
and tegaserod (pEC50 > 6.0 in 4/5 tissues; mean =6.5 and 6.6, respectively). In summary,
TD-5108 is a potent, full agonist at human 5-HT4 receptors and, unlike tegaserod (Beattie
et al., 2004 Br. J. Pharmacol. 143: 549), displays preferential binding to 5-HT4 over other
5-HT receptor subtypes.
Table 1. In Vitro Properties of TD-5108 and comparator agents (n≥4, independent determina-
tions).
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Treatment of Irritable Bowel Syndrome with Tegaserod Leads to Significantly
Greater Improvements in Health-Related Quality of Life, Health Status and
Work Productivity As Compared to Controls in a Usual Care Setting
Pierre Pare, James R. Gray, Sy Lam, Robert Balshaw, Rose Liu, Martin Barbeau, Suzanne
Kelly, Mohamed Omar
Background: Longitudinal Outcomes Study of GastroIntestinal Symptoms in Canada (LOGIC)
was a 12-month, prospective, observational study designed to evaluate the impact of tegaserod
treatment in the setting of usual care on the health-related quality of life (HRQoL), health
status and work productivity of irritable bowel syndrome (IBS) patients in Canada. Methods:
A total of 1,556 IBS patients were enrolled from 147 community and specialist sites across
Canada. Clinical data and patient-reported outcomes (PROs) were collected at baseline. In
addition, PROs were completed at Months 1, 3, 6, 9 and 12. HRQoL, health state, and
work productivity were assessed with the IBS-QOL, EuroQol 5D (EQ-5D) and Visual Analog
Scale (EQ-VAS), and Work Productivity and Activity Impairment (WPAI) questionnaires,
respectively. Results were analyzed by subjects' tegaserod usage during the first month of
the study. P values were calculated using the likelihood ratio test. Results: Of the 1,375
evaluable subjects, 362 (26.3%) were tegaserod users and 1,013 (73.7%) were non-tegaserod
users. At baseline, tegaserod users demonstrated greater severity of symptoms and lower
HRQoL and work productivity; however, after adjusting for baseline covariates, tegaserod
users showed significantly greater improvement than non-tegaserod users in IBS-QOL scores
over the course of the study (mean gain of 0.69 vs. 0.31 points per month, p<0.001).
Tegaserod patients' gains were particularly noticeable in the dysphoria, body image, health
worry and food avoidance domains, for which the baseline IBS-QOL scores were lowest.
Patients taking tegaserod also showed significantly greater improvements in health state than
non-tegaserod users (mean gain of 0.42 vs. 0.08 points on the EQ-VAS per month, p=0.007;
mean gain of 0.006 vs. 0.001 points on the EQ-5D per month, p=0.002). Patients taking
tegaserod also showed greater improvement than non-users in all items of the WPAI (absent-
eeism, p=0.086; presenteeism, p=0.002; overall productivity impairment, p=0.009; daily
activity impairment, p<0.001), reducing work productivity loss by approximately 3 hours
more than the non-tegaserod users, as averaged over a 40-hour work week. Conclusions:
The LOGIC results are the first indication that subjects treated with tegaserod in a usual
care setting experience significantly greater improvements in HRQoL, health status and work
productivity than patients not treated with tegaserod. The results are consistent with the
LOGIC 6-month results previously presented at this meeting as well as with previous reports
from clinical trials on the beneficial effects of tegaserod on patients' lives.
W1224
A High Bile Acid Load in the Colon and a Positive Response to a Bile Acid
Binder Suggest a Pathophysiological Role of Bile Acids in a Subset of Patients
with Irritable Bowel Syndrome (IBS)
Antal Bajor, Jenny Wallin, Hans Strid, Hasse Abrahamsson, Kjell-arne Ung, Magnus
Simren
The pathophysiology of IBS is unknown, although luminal irritants, such as bile acids, have
been suggested to play a role. Bile acid binding agents improve symptoms in patients with
idiopathic bile acid malabsorption and collagenous colitis. However, it is not known whether
bile acid binders are effective in IBS. The 75SeHCAT retention test, which is used to diagnose
bile acid malabsorption, corresponds indirectly to the faecal excretion of bile acids. Aims:
To explore the role of bile acids in IBS Methods: Patients who fulfilled the ROME II criteria
for IBS were consecutively included in the study. All patients performed a 75SeHCAT retention
test. A 75SeHCAT retention <10% on day 7 is considered abnormal. All patients with a
75SeHCAT value <20% on day 7 were offered an open label treatment with a gradually
increasing dose of the bile acid binder cholestipol (starting at 1g bid) during 8 weeks. During
the eight-week treatment period they recorded their daily bowel habits according to the
Bristol Stool Form (BSF) scale. The IBS Symptom Severity Score (IBS-SSS) and the dose of
cholestipol were registered once a week before and during the treatment period, and the
subjects were asked if they had had adequate relief of their IBS symptoms. Results: Twenty-
five (18.5%) out of the 135 investigated patients had an abnormal 75SeHCAT retention and
57 (42%) had a value <20%, of whom 27 (14 females; mean age 43 years) accepted to start
the treatment. The GI symptom severity was reduced at the last treatment week compared
with baseline (IBS-SSS, 220±109 vs. 277±106; p < 0.001) and this was also seen for
extracolonic symptoms (124±75 vs. 155±68; p=0.007). During the treatment period the
stool frequency was reduced (2.3±1.2 vs. 2.8±1.3 stools/day; p=0.05) and a tendency towards
more solid stools was seen (BSF, 3.9±1.1 vs. 4.5±1.2; p=0.07). Fifteen of the 27 patients
were responders (55%) reporting adequate relief of their IBS symptoms at week 7 and/or
8. There was no difference in improvement of symptoms between IBS subgroups based on
the predominant bowel habit, and no correlation between the 75SeHCAT value and the
symptomatic response was detected. The mean weekly cholestipol doses increased from 21
g at week one to 71 g at week eight. Conclusion: A high prevalence of abnormal 75SeHCAT
retention values corresponding to high concentrations of bile acids in the colon, suggests a
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possible patophysiological role of bile acids in a subset of IBS patients. The high symptomatic
response rate to open label treatment with bile acid binders in IBS patients with low
75SeHCAT values further support such a role, but placebo-controlled studies are warranted.
W1225
Effects of Probiotics On the Intestinal Gas Volume Score and Symptoms in
Patients with Irritable Bowel Syndrome. A Randomized Double-Blind Placebo-
Controlled Study
Jong tae Moon, Hee sun Kim, Hyojin Park
Backgrounds/Aim : The cause of irritable bowel syndrome(IBS) is unknown. Imbalance of
gut flora may play a role in promoting low grade inflammation that is considered as one
of the accepted mechanism of IBS. Koide et al reported that abdominal gas can be analyzed
objectively by using gas volume score(GVS), and GVS was a useful tool for the diagnosis
of IBS.1 Probiotics may target one or more pathophysiologic pathways in IBS and may
improve symptoms of IBS. However, the results of studies about probiotics on IBS are
controversial. Therefore, we aimed to investigate that probiotics may improve the IBS symp-
toms associated with reducing the gas production from the microflora. Methods : Forty
patients with IBS were recruited and they are randomized into two groups. We blindly
administered a capsule composed with Bacillus subtillis and Streptococcus faecium (250mg,
three times/day) to one group(group I) and placebo to the other group(group II) for 4
weeks. We evaluated the daily life mood, bloating, degree of abdominal pain with score,
number of gas out, abdominal pain, defecation and change of stool form with Bristol scale(1-
7) during one week before administration, and last one week of the study. We also evaluated
the GVS with software(Image-pro Plus, USA) which analyzed the simple abdominal X-rays
taken before, after 2 weeks and after 4 weeks of medication. Results : Finally, 34 patients
were enrolled. In group I (n=17), number of abdominal pain was significantly decreased
after 4 weeks(p <0.05), and degree of abdominal pain(p=0.073) and stool form change(p=
0.061) showed trend of improvement. In both groups, daily life mood was improved, but
GVS was not changed. Conclusion : Probiotics improved the IBS symptom, especially
abdominal pain, which is independent of intestinal GVS. 1. Koide A, Yamaguchi T, Odaka
T, et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients
with irritable bowel syndrome. Am J Gastroenterol 2000;1735-1741
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Influence of Itopride and Domperidone On Gastric Tone and On the
Perception of Gastric Distention in Healthy Subjects
Filiz Akyuz, Kostas Mimidis, H. Nikolai, Rita Vos, Jan Tack
Background and Aim: Itopride is a prokinetic with dopamine D2-antagonistic and cholinester-
ase inhibitor properties, which is currently under evaluation for the treatment of functional
dyspepsia (FD). The effects of itopride on the perception of gastric distention and on
postprandial fundus relaxation, two major pathophysiological mechanisms in FD besides
delayed gastric emptying, are unknown. The aim of this study was to evaluate the effect of
itopride on the sensitivity to gastric distention and on meal-induced gastric accommodation
in healthy volunteers, in comparison with the D2-antagonist domperidone. Methods: Fifteen
healthy volunteers (6 male, mean age 28.3±5.8) were studied on four separate occasions,
after pre-treatment for two days with placebo (P), itopride 50mg (I50), itopride 100mg
(I100) or domperidone 10mg (D10) t.i.d. in a placebo-controlled, double-blind cross-over
design. A gastric barostat study was performed to assess gastric compliance, sensitivity to
distention and accommodation. Symptoms were evaluated by visual analogue scales (VAS).
Results are given as mean±SEM and compared by Student's t-test and ANOVA. Results:
D10, I50 or I100 did not influence pre- and postprandial gastric compliance and sensitivity
to gastric distension compared to placebo before and after meal. Consequently, the pressures
needed to induce first perception or discomfort and corresponding intra-balloon volumes
did not differ significantly between placebo and drugs. No significant differences in gastric
tone and accommodation were observed after I100 (preprandial 261±32 ml, postprandial
429±28 ml, accommodation 167±32 ml) compared to P. Preprandial intragastric volumes
were similar with D10, I50 or P (respectively 244±21, 225±25, and 262±35 ml, NS)..
Postprandial gastric volumes after I50 and D10 were significantly lower compared to placebo
(respectively 303±34 and 334±37 vs. 448±50 ml, both p<0.05). Gastric accommodation
(mean volume increase after the meal) was significantly lower after D10 (90±26 ml) and
I50 (78±25 ml) compared to P (186±37 ml, both p<0.0001). VAS scores during balloon
distentions and before and after meal ingestion did not differ between placebo and any of
the treatment arms. Conclusion: In healthy subjects, itopride and domperidone do not alter
gastric compliance or sensitivity to distension. Itopride 50 mg and domperidone 10 mg
t.i.d. inhibit gastric accommodation to a meal. No consistent effect on distention-induced
symptoms was observed.
W1227
Topical Intragastric Application of the TRPV1 Agonist, Resiniferatoxin (RTX),
Attenuates Experimental Nausea and Vomiting
Rami Hawari, Jieyun Yin, Hanaa Sallam, Karim Dhanani, John Winston, Jiande Chen,
Pankaj J. Pasricha
BACKGROUND: One of the major disabling symptoms of gastroparesis is nausea and
vomiting which can be difficult to control with currently available treatments. It is postulated
that activation of vagal afferent nerves triggers the central emetic pathway in gastrointestinal
nausea. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the
vanilloid receptor TRPV1 and respond to capsaicin with initial activation and subsequent
desensitization. Resiniferatoxin is a very potent capsaicin analogue that has a much more
favorable ratio of desensitization to excitation than capsaicin leading to more effective
desensitization without irritation. We hypothesized that desensitization of TRPV1 responsive
gastric sensory neurons would attenuate nausea and vomiting. METHODS: 4 dogs with
surgically created jejunocutaneous fistulae 20 cm distal to the pylorus were used in this
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study. Nausea and vomiting were induced using two different stimuli, both of which are
vagally dependent, at least in part: (1) Balloon inflation in the jejunum (2) Intravenous
vasopressin infusion (0.5 U/Kg infused over 20 minutes). Nausea was assessed using a
previously validated behavioral scoring system in addition to counting actual episodes of
vomiting. After baseline observations, RTX (250 ml of a 100nM solution) was administered
endoscopically using a spray catheter to coat the mucosal lining of the stomach under general
anesthesia. One week later, the response to balloon distention and vasopressin infusion was
recorded again. RESULTS: RTX infusion resulted in marked attenuation of nausea and
vomiting to both stimuli: the mean score with balloon distention decreased from 26.3 ±
4.0 to 11.7 ± 4.2 (p=0.01) while the mean score with vasopressin decreased from 29.0 ±
6.2 to 16.3 ± 5 (p= 0.05). Dogs appeared healthy throughout the subsequent two-week
observation period. CONCLUSION: (1) TRPV1-dependent pathways play a major role in
the pathogenesis of nausea and vomiting (2) Topically applied RTX may be potentially
beneficial in patients with intractable nausea in conditions such as gastroparesis.
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The In Vivo Preclinical Profile of TD-5108, a Selective, High Intrinsic Activity
5-HT4 Receptor Agonist
David T. Beattie, Scott R. Armstrong, Daniel Marquess, Jeng-peng Shaw, Jacqueline A.
Smith, Patrick P. Humphrey
The clinical efficacy of the 5-HT4 receptor agonists, tegaserod, cisapride and mosapride,
has been demonstrated in patients with disorders of reduced gastrointestinal (GI) motility
(Camilleri, 2001; Aliment. Pharmacol. Ther., 15, 277-289). This study investigated the In
Vivo preclinical profile of a structurally novel and selective 5-HT4 receptor agonist, TD-
5108, in comparison to that of tegaserod, cisapride and mosapride. Models of guinea pig
colonic transit (measurement of the passage of carmine red dye), rat esophageal relaxation
(use of digital sonomicrometry to record the distance between two piezoelectric crystals
secured to the tissue), and dog GI smooth muscle contractility (use of strain gauges implanted
on the antrum, fundus, duodenum and jejunum) were used in the study. Subcutaneous
(s.c.) administration of TD-5108 and tegaserod, but not cisapride or mosapride (0.03-3 mg/
kg), produced a statistically significant increase in colonic transit, compared to vehicle (doses
producing a 25% increase: 0.01, 0.19, 0.47 and >3 mg/kg, respectively). Piboserod (1 mg/
kg s.c.), a selective 5-HT4 receptor antagonist, inhibited the TD-5108-mediated prokinetic
effect. Intravenous dosing of TD-5108, tegaserod (both 0.03-1 mg/kg), cisapride (0.03-3
mg/kg) and mosapride (0.03-10 mg/kg) evoked a dose-dependent relaxation of the rat
esophagus (indicated by an increased inter-sonomicrometry crystal distance; mean ED50
values of 0.03, 0.01, 0.14 and 1.82 mg/kg, respectively). Piboserod (1 mg/kg s.c.) inhibited
the esophageal effects of TD-5108. Following intraduodenal (i.d.) dosing, TD-5108, tegaserod
(both 0.03-10 mg/kg), cisapride and mosapride (both 0.3-10 mg/kg) evoked a dose-depend-
ent relaxation of the rat esophagus (i.d. doses associated with a relaxation of 0.2 mm: 0.6,
3.2, 10 and >10 mg/kg, respectively). Following oral (p.o.) dosing, TD-5108 and tegaserod
(0.3 mg/kg) produced an increase in contractility of the antrum, fundus, duodenum and
jejunum of dogs. At a lower dose (0.1 mg/kg p.o.), only TD-5108 produced a robust increase
in contractility. It is concluded that TD-5108 has robust In Vivo activity in the digestive
tract of guinea pigs, rats and dogs. Robust prokinetic effects have also been demonstrated
in healthy volunteers, and a Phase 2 trial in patients with chronic constipation is in progress.
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Long Term Survival and Prognostic Indicators in Small (< 2 CM) Pancreatic
Cancer
Supot Pongprasobchai, Thomas C. Smyrk, William Bamlet, Rahul Pannala, Suresh S.
Pitchumoni, Andrei Ougolkov, Mariza De andrade, Gloria M. Petersen, Suresh T. Chari
Background/Aims: In pancreatic ductal adenocarcinoma (PaC), tumor size is an important
prognostic factor, with small (<2 cm) PaC representing early cancer and reportedly having
better prognosis and survival after surgery than large PaC. However, there is limited data
on the characteristics of small PaC that predict improved survival. In a matched analysis,
we investigated clinical, histopathological, and survival characteristics of small PaC as com-
pared to large PaC. Methods: From the Mayo Clinic surgical pathology database, we identified
41 consecutive patients from 1985-2001, who underwent curative resection and were found
to have small PaC. Controls (n= 94) with margin-negative PaC >2 cm were selected, blinded
to the survival data and tumor stage, and matched for age, gender, tumor location, surgery
type (pancreaticoduodenectomy vs. distal pancreatectomy) and date and, if possible, surgeon.
Demographic, clinical, and vital status data were abstracted from medical records. All
histopathological specimens were reviewed by two pathologists and tumors were staged
according to TNM classification and tumor differentiation was based on WHO classification.
Kaplan-Meier survival analysis and Cox proportional hazards models were applied for data
analyses. Results: Small and large PaC groups were similar in terms of mean age, gender,
tumor location, and duration of symptoms. Small PaC, compared to large PaC, were more
likely to be stage I (32% vs. 12%, p = 0.005), well-differentiated (44% vs. 15%, p=0.001),
and had better overall 5-yr survival (38% vs. 15%, median survival 28 mo vs. 17 mo, p =
0.014). Survival was not different between small and large PaC in patients with localized
disease (stage I and II). However, survival of small PaC with regional node metastasis (stage
III) was significantly better than that of similar stage large PaC (5-yr survival 44% vs. 7%,
median survival 58 mo vs. 18 mo, p <0.001). Well-differentiated small and large PaC had
similar survival (56% vs 50%, median survival 76 mo vs 74 mo). On multivariate analysis,
tumor differentiation, not tumor size, was the only independent factor predicting survival
in PaC (risk ratio [RR] for moderate vs. well- differentiated 2.6, 95% confidence interval
[CI] 1.5-4.5, and poorly differentiated vs. well-differentiated, RR 5.0, 95% CI 2.4-10.1).
Conclusions: Small pancreatic cancers are detected at an early stage and are often well
differentiated. However, regardless of tumor size, well differentiated cancers have an excellent
prognosis. Tumor differentiation may be a better predictor of survival in resectable PaC
than tumor size.
W1230
Analysis of Methylated Genes in the Plasma of Patients with Pancreatic
Cancer
Il hyun Baek, Yong-tae Kim, Ji kon Ryu, Yong bum Yoon, Rin Chang
Background: CpG islands of promotor region of some genes are aberrantly methylated in
pancreatic cancer tissue and the detection of this methylation has been suggested to be
useful in the diagnosis of various cancers. The aim of this study was to investigate whether
the detection of methylated CpG islands in the plasma can be used in the diagnosis of
pancreatic cancer. Methods: The plasma DNA was collected from the patients with pancreatic
cancer, chronic pancreatitis, and normal controls. The methylation status of six genes such
UCHL1, NPTX2, SARP2, ppENK, p16, and RASSF1A was checked by methylation specific
PCR and was subsequently confirmed by direct sequencing after bisulfite treatment. Results:
The CpG island hypermethylation was detectable in 13 of 16 (81.3%) pancreatic cancers,
1 of 29 (3.5%) normal controls, and 8 of 13 (61.5%) chronic pancreatitis. Mean number
of methylated genes was 1.6±1.2 in cancer, 0.04±0.19 in normal controls, and 1.2±1.1 in
chronic pancreatitis. Among 6 genes, p16wasmore specifically hypermethylated in pancreatic
cancer compared with chronic pancreatitis (p=0.016). The methylation status was not correl-
ated with smoking history, tumor size, or cancer stage. Conclusion: The detection of aber-
rantly methylated genes in the plasma can be used in the differential diagnosis between
pancreatic cancers and normal controls. However more specifically methylated genes in
pancreatic cancer such as p16 are needed for the differential diagnosis between pancreatic
cancer and chronic pancreatitis.
Table 1. Comparison of positive detection rate of methylation in at least one gene among
the patients with pancreatic cancer, chronic pancreatitis, and normal controls
*, p<0.05 pancreatic cancer or pancreatitis vs. pancreatitis †, p>0.05 pancreatic cancer vs.
chronic pancreatitis
Table 2. Comparison of proportion of CpG islands methylation among the methylated genes
between pancreatic cancer and chronic pancreatitis
p16 was more specifically methylated in pancreatic cancer than in chronic pancreatitis
(p=0.016).
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Dose-Dependent Effects of Alcohol(Etoh) and Tobacco(Tob) On Age of
Presentation in Pancreatic Cancer(PC)
Eugene Zolotarevsky, Diane M. Simeone, Jesica M. Pedroza, Michelle A. Anderson
TOB use is a well described risk fx in PC and may effect age of diagnosis (dx). In this
prospective cohort, we studied the absolute and dose-response effects of ETOH and TOB
(alone and in combination) on the age of PC dx. METHODS: The Pancreatic Cancer Registry
at the University of Michigan was queried. ETOH use: never, min-mod (< 39 gm/d), heavy
(> 39 gm/d), and past (quit >10 yrs); and TOB use: pack-year hx & yrs ago quit were
assessed. There were 464 pts with proven PC(93% Caucasian, 58% males); 190(41%) were
diagnosed with DM within 2 yrs, and 42(9%) identified family history of PC. ANOVA and
linear regressionwere used for statistical analysis. RESULTS: Among nondrinkers we observed
a significantly younger age of dx in current smokers compared to nonsmokers (56.7 vs.
67.5; p < 0.001), and those who quit <10 years before dx (56.7 vs. 60.0; p < 0.001). We
found no difference in age of PC dx in nonsmokers vs those who quit >10 yrs prior to dx
(67.5 vs. 67.8). Current smokers were younger at dx than pts who quit<10 yrs ago but not
statistically significant(56.7 vs 60.0). A clear dose-response effect was seen for TOB use on
age of dx (Table 1). Among nonsmokers or those who quit >10 yrs before dx, increasing
levels of ETOH use were associated with earlier age of PC dx while those who had quit >10
years previous had similar age of dx to those who had never drank (Table 1). Among current
TOB users, heavy ETOH use was associated with the earliest age of PC dx (53.8) although
this did not reach statistical significance; Patients with minimal to moderate ETOH use had
similar age of dx when compared to nondrinkers (59.9 vs. 56.7; p=0.09). CONCLUSION:
Combined current tobacco and heavy alcohol use are associated with the earliest age of PC
dx. Among non-drinking pts, TOB appears to have a clear dose-dependent effect on age of
presentation. Interestingly, ETOH use <39 grams/day may have protective effects for age of
dx among smokers. The excess risk of early PC dx was reduced among those who quit
ETOH or TOB more than 10 yrs prior to dx and was similar to nonsmoking/non-drinking
pts. This study is the first to show dose-dependent effects of TOB and ETOH on age
of presentation in pancreatic cancer and suggest that these toxins may be important in
disease pathogenesis.
Table 1.
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Has Improvement in EUS Technology Over the Past Two Decades Affected
Endoscopic Ultrasound's Accuracy in Diagnosing Vascular Invasion By
Pancreatic and Periampullary Ca? - A Meta-Analysis & Systematic Review
Srinivas R. Puli, Jyotsna Bk reddy, Daphne Antillon, Jamal A. Ibdah, Mainor R. Antillon
Purpose: To evaluate if technologic advancements over years affected the accuracy of Endos-
copic Ultrasound (EUS) in diagnosing vascular invasion (VI) in pancreatic and periampullary
cancers. Method: Study Selection Criteria: Only EUS studies in which VI was confirmed by
surgery or angiography were selected. EUS criteria used for vascular invasion were: tumor
in the lumen, abnormal vessel contour, the presence of collateral vessels in the absence of
a main vascular structure, and loss of the hyperechoic interface between the tumor and the
vessel. Data collection & extraction: Articles were searched in Medline, Pubmed, Ovid
journals, Cumulative index to nursing&Allied health literature, International pharmaceutical
abstracts, old Medline, Medline nonindexed citations, and Cochrane control trial registry.
2 X 2 tables were constructed with the data extracted from each study. Statistical Method:
EUS studies were grouped into three time periods to standardize the change in EUS technology
and also to standardize the change in EUS criteria for vascular invasion. These time periods
were 1988 to 1994, 1995 to 1999, and 2000 to 2004. Meta-analysis for the accuracy of
EUS was found by calculating pooled estimates of sensitivity, specificity, likelihood ratios,
and diagnostic odds ratio. Pooling was conducted by both Mantel-Haenszel method (fixed
effects model) and DerSimonian Laird method (random effects model). The heterogeneity
of studies was tested using Cochran's Q test based upon inverse variance weights. Results:
Initial search identified 4432 reference articles, of which 424 relevant articles were selected
and reviewed. Data was extracted from 29 studies (N= 1308) which met the inclusion
criteria. All the pooled estimates during the three time periods are given in table 1. The p
for chi-squared heterogeneity for all the pooled accuracy estimates was > 0.05. Conclusion:
Although EUS is a good imaging tool to diagnose VI in pancreatic cancer, there was no
significant change in the accuracy of EUS in diagnosing vascular invasion during almost
two decades. EUS sensitivity has decrease but could be the result of lesser number of studies
in the earlier periods. Refinements in EUS technologies are needed to improve the sensitivity
and specificity of EUS for detecting VI in pancreatic cancer.
Pooled diagnostic accuracy estimates of EUS for different time periods with 95 % confid-
ence intervals
W1233
A Prospective Study for the Early Diagnosis of Pancreatic Cancer
Sachiko Tanaka, Akihiko Nakaizumi, Tatsuya Ioka, Rena Takakura, Tetsushi Ishida,
Yasuna Takano
Background: We have reported that main pancreatic duct dilatation and pancreatic cysts
are high-risk signs of pancreatic ductal adenocarcinoma. The periodic-checkup for high
risked people supposed to be effective for the early diagnosis of pancreatic cancer. Subjects:
From May 1998 to December 2002, 754 patients with some abnormal ultrasonographic
(US) findings in the pancreas were registered for the periodic-checkup trial with written
informed consent, after ruling out of pancreatic cancer. At the initial US examination, 246
(32.6%) of them had cyst(s), 406 (53.8%) of them showed main pancreatic duct (MPD)
dilatation (≧2.5 mm at the body) and 556 (73.7%) showed either of the findings. They
were followed up with special US focused on pancreas and tumor markers, every three or
six months. When abnormal findings are developed, detailed examination such as contrast
enhanced US, contrast enhanced CT, MRCP, pancreatic juice cytology through ERCP and/
or EUS guided fine needle aspiration biopsy. Results: The subjects were followed up until
the end ofOctober 2006 (mean follow-up period: 73.1months). Pancreatic ductal adenocarci-
noma was detected in 12 patients. The period from the initial examination to the final
diagnosis of pancreatic cancer was 15 to 82 months (mean: 46.4 months). Out of these 12
cases, three cases (25%) were diagnosed at Stage 0, two others (16.7%) at Stage IA and
four others (33.3%) at Stage IIB. Surgical resection was performed in 7 (58.3%) cases. Nine
cases were alive at the end of October 2006 and the cumulative 5-year survival rate after
final diagnosis was 75%. At the initial US examination, all these 12 cases showed either
cyst or slight MPD dilatation (cyst: 8, MPD dilatation: 10). The annual incidence of pancreatic
cancer showed 533.9/100,000 among the subjects with pancreatic cyst, and 354.3/100,000
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among the subjects with either pancreatic cyst or MPD dilatation. While, according to Osaka
cancer registry the annual pancreatic cancer incidence in 2001 was 31.1/100,000 among
the 60' age residences of Osaka prefecture, Japan. Comparing the data of general population
in Osaka, the patients with pancreatic cyst(s) showed 17.2 times higher, and those who
had either pancreatic cyst or MPD dilatation showed 11.4 times higher incidence of pancreatic
cancer. Conclusion: Our prospective study has proved that the pancreas with dilatation of
main pancreatic duct and/or cyst(s) is high risk for pancreatic ductal adenocarcinoma. And
also the periodic check-up for these patients with US is effective for the early detection of
pancreatic cancer and may lead to the improvement of long-term survival rate.
W1234
Endoscopic Ultrasonography: A Valuable Tool in Screening High-Risk Patients
for Pancreatic Cancer
Jan-werner Poley, Anja Wagner, Ernst J. Kuipers
Introduction: of all pancreatic cancers (PC) 5-15% is considered to be familial or hereditary
in origin. Despite improvement in imaging and surgical therapy, overall prognosis of PC
remains dismal. Five-year survival in patients after curative surgery is no more than 10%.
Early detection of cancer and especially premalignant lesions could improve outcome.
Unfortunately abdominal ultrasound, ERCP, CT scan and MRI have proven to be of very
limited value for screening in high-risk patients. Endoscopic ultrasonography (EUS) could
be a valuable tool in screening as it enables the endoscopist to examine both pancreatic
parenchyma and pancreatic duct in detail. Furthermore, cytological specimens can be
obtained safely and accurately. Drawbacks however are that EUS is considered an invasive
procedure and that it is highly operator dependent. Methods: since 2005 patients with
familial or hereditary PC were offered EUS screening. Procedures were carried out under
conscious sedation and performed by an experienced endoscopist. An electronic linear
echoendoscope was used in all procedures. When abnormalities were found, EUS was
followed by CT and/or MRI. Results: 17 patients from 12 families (M/F 8/9) were screened.
Genetic background was diverse: patients with at least two first-degree relatives with PC
(familial PC, n=7), patients with familial PC and/or familial atypical multiple mole melanoma
syndrome (FAMMM) with unclassified variants (UV) in the p16 gene (n=5), Peutz-Jeghers
syndrome (n=2), genetically proven FAMMM syndrome (n=3)and one carrier of a pathogenic
BRCA2 mutation in a family with familial PC. No procedure related complications occurred.
Significant pathology was found in three patients (18%): in a patient with a p16 UVmultifocal
side-branch intraductal papillary mucinous neoplasms (IPMN) were found, all less than 1,5
cm. in size. In a patient with familial PC one side-branch IPMN of 5 mm was found.
Furthermore, one small pancreatic tail cancer (22 mm) in an asymptomatic BRCA2 carrier
was found. Conclusions: EUS screening is feasible and has a significant yield in selected
high-risk patients.Whether this improves outcome in these patients remains to be proven.
W1235
Diagnostic Performances of Oncogene K-RAS Mutation Analysis Coupled to
Fine Needle Aspiration Biopsy Under Endoscopic Ultrasound (EUS-FNA) for
the Diagnosis of Solid Pancreatic Masses: Afrench Multicenter Prospective
Study
Barbara Bournet, Anny Souque, Marc Barthet, Pierre Senesse, Nathalie Lesavre, Dermot
O'toole, Alain Aubert, Pascal Hammel, Philippe Levy, Philippe Ruszniewski, Pierre
Cordelier, Michèle Bouisson, Lucien Pradayrol, Jean R. Escourrou, Louis Buscail
Introduction Activating single base mutation of k-ras oncogene is detected in 85 to 95 %
of pancreatic carcinoma (PC). The diagnostic accuracy of EUS-FNA for the diagnosis of
solid pancreatic masses varies from 81 to 85% in intent to sample. Aim of this prospective
multicenter (4 french clinical centers) study was to evaluate if the cumulative analysis of k-
ras mutation and cytology/histology by EUS-FNA improve the diagnosis of PC and the
differential diagnosis between PC and pseudotumorous chronic pancreatitis. Patients and
methods: EUS-FNA was performed in 119 patients with pancreatic solid masses (M: 70,
W: 49, mean age 65 years, range: 31 - 88 years). DNA was extracted (microkit) from a
fraction of cellular material sampled by EUS-FNA and was then subjected to nested PCR;
codon-12 mutation analysis was assessed by RFLP. In case of positive result, a systematic
confirmation was obtained by direct sequencing. The final diagnosis was obtained on EUS-
FNA analysis and/or surgical resection and/or clinical follow and /or a second EUS-FNA or
biopsy by CT-scan (including biopsy on another site such as metastasis). This final diagnosis
was: pancreatic adenocarcinoma 79 cases, pseudotumorous chronic pancreatitis 16 cases,
other pancreatic tumors 14 cases (endocrine, metastasis), no precise diagnosis could be
obtained in 10 patients that are still followed up. Results: No failure of DNA amplification
was observed (i.e. yield of k-ras codon-12 analysis on EUS-FNA materials = 100%). A k-
ras mutation was found in 51 cases of PC, in 2 cases of pancreatic metastasis while no
mutation was found in chronic pancreatitis cases. The diagnostic values of FNAB under
EUS associated or not with k-ras mutation analysis in cellular material of EUS-FNA for the
diagnosis of PC and the differential diagnosis between PC and pseudotumorous chronic
pancreatitis were: (Specificity/PPV/NPV/Accuracy)(PPV : positive predictive value; NPV =
negative predictive value): EUS-FNA alone (89%/100%/100%/67%/92%),k-ras alone(65%/
100%/100%/36%/71%), EUS-FNA + k-ras (95%/100%/100%/57%/96%). Conclusion On
this large scale multicenter evaluation, we have demonstrated that the k-ras mutation analysis
in the cellular material from EUS-FNA improve the diagnosis of PC by reducing the false
negative results of EUS-FNA analysis alone (cytology and/or histology). Its high specificity
can also reinforce the differential diagnosis between PC and pseudotumorous chronic pancre-
atitis by an absence of k-ras mutation. A technologic transfer to current clinical practice is
possible regarding the reproducibility and accuracy of our k-ras mutation detection method
on EUS-FNA materials.
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Antigen Specific Ige and Igg Anti-Pancreatic Antibodies in Patients with
Pancreatic Cancer
Sophia L. Fu, Domenico Viterbo, Yin-yao Lin, Cathy M. Mueller, Joelle Pierre, Tamar A.
Smith-norowitz, Wilbur Bowne, Matthew R. Pincus, Michael E. Zenilman, Martin H.
Bluth
Background: We have recently demonstrated that serum levels of IgE and its low affinity
receptor, soluble CD23 (sCD23), are significantly increased in patients with pancreatic cancer
(panc-CA). We further investigated the relationship of other immunoglobulin (Ig) isotypes
and the presence of Ig specificity for panc-CA antigens in patients with pancreatic adenocarci-
noma. Methods: Serum Ig levels (IgG, IgM, IgA) were studied (nephelometry) in confirmed
panc-CA patients (n=12), who have been previously shown to contain elevated levels of IgE
and sCD23. Serum samples were collected prior to any intervention. Serum from these
patients were cultured with human pancreatic cancer cell lines Panc-1, HPAC, and MiaPaCa-
2 and the presence of IgE and IgG anti-cancer cell antibodies to cell surface antigens was
determined (flow cytometry, immunofluorescence microscopy). The presence of IgE and
IgG antibodies to specific panc-CA antigens was determined on whole cell line lysates
(western blot). Serum obtained from healthy volunteers (n=15) served as controls. Patients
and controls did not have any history of atopy or parasitic infections. Data (mean +/-SE)
are expressed as g/L (Ig levels) and percent fluorescence (flow cytometry) with significance
between groups set at p < 0.05 (Student's t-test). Results: Serum levels of IgG, IgM and IgA
were similar between patients and controls (IgG: 11.21±4.48 vs. 13.20±5.28, IgM: 2.39±1.64
vs. 1.66±0.87, IgA: 2.72±1.46 vs. 1.92±0.86, p=>0.05 for all comparisons). In addition,
flow cytometry analysis of IgE and IgG anti-panc-CA cell line antibodies to cell surface
antigens were similar between patients and controls (IgE: 12.91±0.02% vs. 11.31±0.01%,
IgG: 30.98±0.15% vs. 44.81±0.28%, p=>0.05). Immunofluorescence microscopy demon-
strated increased fluorescence of IgE and IgG anti-panc-CA cell antibodies in patients com-
pared with controls. Interestingly, analysis of panc-CA cell lysates revealed IgE and IgG
antibodies specific to a 50kD antigen present in patients compared with controls while IgE
and IgG antibodies specific to different cell antigens (100&37kD) were present in healthy
controls compared with patients (western blot). Conclusions: Serum levels of IgG, IgM and
IgA were similar in Panc-CA patients with elevated IgE and sCD23 compared with controls.
Serum from panc-CA patients contained IgE and IgG antibodies to specific panc-CA antigens
which differed from healthy individuals. These data suggest that IgE, IgG, sCD23 and specific
anti-panc-CA antibodies may provide humoral surveillance and control of malignancy, and
may be important in the immune response to this disease.
W1237
Nek2a Regulates the Hec1-Cenp-H Interaction in Mitosis and Pancreatic
Cancer Cell Growth In Vivo
Xia Ding, Feng Yan, Jianhui Yao, Xin Cai, Haiying Hu, Renming Hu, Xuebiao Yao
Chromosome segregation in mitosis is orchestrated by the interaction of the kinetochore
with spindle microtubules. Our recent study shows that NEK2A interacts with MAD1 at
the kinetochore and possibly functions as a novel integrator of the spindle checkpoint
signaling. However, it is unclear how NEK2A regulates kinetochore-microtubule attachment
in mitosis and whether NEK2A function in mitosis is essential for tumor cell growth In
Vivo. Hec1 (highly expressed in cancer), a substrate of NEK2A, plays an important role in
chromosome segregation by regulating kinetochore microtubule interaction dynamics and
plasticity. To delineate the molecular function of Hec1 in cell growth regulation, we carried
out biochemical assays and identified that Hec1 interacts with CENP-H In Vitro and In Vivo
via extended coiled-coil domains located in the middle of the two molecules, respectively.
Our immunofluorescence study revealed that Hec1 is localized at the metaphase kinetochore
exterior to CENP-H with the globular domain oriented toward microtubule plus end. NEK2A
phosphorylates Hec1 at Ser165 during mitosis while such phosphorylation regulates Hec1-
CENP-H interaction In Vitro and In Vivo. Interestingly, phosphorylation of Ser165 is not
essential for assembly of Hec1 to kinetochore as non-phosphorylatable mutant Hec1S165A is
localized to the kinetochore and remains associated with kinetochore microtubules. However,
there was a significant increase in attachment errors, including syntelic attachment and
monotelic attachment. In addition, these Hec1S165A-overexpressing cells display a chromo-
some-bridging phenotype with sister chromatids inter-connected. These findings reveal a
key role for the NEK2A-mediated phosphorylation of Hec1 in governing proper kinetochore-
microtubule attachment and support a notion by which NEK2A integrates kinetochore-
microtubule attachment into spindle checkpoint signaling. To assess the role of Hec1 in
tumor cell growth in animal, we have used adenovirus vector-based expression system to
manipulate Hec1 protein level. Vector-expressed short hairpin RNAs (shRNAs) caused very
efficient depletion of Hec1 protein in human pancreatic adenocarcinoma CAPAN-1 cells.
Significantly, suppression of Hec1 protein expression or overexpression non-phosphorylat-
able Hec1 in CAPAN-1 cells implanted in nude mice show significant reduction in size
compared with control treatment. These results indicate that depletion of Hec1 or manipula-
tion of Hec1-CENP-H interaction could be used as a novel strategy to modulate pancreatic
cancer cell growth in animal.
W1457
KLF5 Promotes Migration of Esophageal Keratinocytes By Activating the
Integrin Linked Kinase Pathway
Yizeng Yang, Yuliya Yermolina, Bree G. Goldstein, Jonathan P. Katz
Background: The migration of epithelial cells out of the proliferative compartment and along
the radial axis of the gut is critical for differentiation and normal homeostasis. Nonetheless,
the specific factors regulating cell migration in gastrointestinal epithelia are poorly under-
stood. Klf5 is a transcriptional regulator highly expressed in proliferating esophageal basal
cells but not in differentiating suprabasal and superficial cells. Like Klf5, the integrin-linked
kinase (ILK) is localized to basal keratinocytes. ILK is a key mediator of intracellular signaling
by transmembrane integrin receptors and an important regulator of cell migration, motility,
adhesion, and contractility. We hypothesized that Klf5 regulates esophageal epithelial cell
migration via the ILK signaling pathway. Methods: We stably transduced mouse primary
esophageal keratinocytes with retrovirus to overexpress Klf5 or to express siRNA directed
against Klf5. We investigated cell migration on transwell plates and evaluated cell adhesion
and cell spreading on matrigel. We determined expression and activation of ILK and down-
stream targets of ILK by real-time PCR, Western blots, and kinase assays. To determine
whether Klf5 directly regulated ILK, we performed luciferase assays, ChIP assays, and
electrophoretic mobility shift assays (EMSA). Results: Overexpression of Klf5 increased cell
migration, adhesion, and spreading, while these processes were inhibited by Klf5 suppression
with siRNA. Expression of Klf5 correlated directly with ILK expression and activation.
Adenoviral expression of ILK partially rescued the decrease in cell migration resulting from
Klf5 suppression while ILK siRNA blocked the effects of Klf5 overexpression on cell migration.
Klf5 overexpression induced the expression and/or activation of the ILK targets CDC42 and
myosin light chain (MLC), while Klf5 siRNA had the opposite effect, but Klf5 did not alter
the expression or activation of Rac, AKT, and GSK3β, which are ILK targets in other cell
types. Notably, both CDC42 and MLC have been shown to be critical for cell migration
and motility. ChIP assays and EMSA demonstrated Klf5 binding to a triple-BTEB binding
element in the 5'-regulatory region of ILK, demonstrating that ILK was a direct target
for Klf5 in esophageal keratinocytes. Conclusion: Klf5 increases migration in esophageal
keratinocytes by transcriptionally upregulating ILK, leading to activation of the ILK targets
CDC42 and MLC. These results provide important new insights into the regulation of cell
migration in epithelia of the luminal gastrointestinal tract.
W1458
Arachidonate 12-Lipoxygenase Is Strongly Induced By Iron-Deficiency and Is
Expressed in Goblet Cells in Rat Small Intestine and Colon
James F. Collins, Richard W. Browne, Zihua Hu
Iron-deficiency results in the induction of genes related to intestinal iron transport. In an
effort to identify novel genes associated with this process, we performed extensive microarray
analyses with intestinal mucosa from iron-deprived rats across several stages of postnatal
development and from adult rats with a mutation in the principal intestinal iron transporter
DMT1 (e.g. Belgrade rats; genetic iron-deficiency). Bioinformatics analysis and clustering
algorithms identified a large group of differentially expressed genes that were similarly
induced across all experimental groups, which contained several known iron-responsive
genes in addition to many novel genes. Gene ontology analysis of the data revealed a statistical
enrichment of genes related to lipid metabolism and specifically arachidonic acid (AA)
metabolism. Most striking was induction of arachidonate 12-lipoxygenase (Alox12) in the
duodenum and jejunum of Belgrade rats. Alox12 metabolizes AA to the lipid mediators 12-
and 15-HpETE in a 3:1 molar ratio. Additional studies were initiated to further delve into
this observation. Quantitative real-time PCR confirmed that Alox12 was strongly induced
throughout the length of the intestine and also in the liver of iron-deficient rats. Strongest
induction was noted in duodenum and jejunum (up to 275-fold). Immunolocalization studies
were subsequently performed with a polyclonal Alox12 antiserum. Results showed expression
of Alox12 in the intestinal epithelium, with very strong expression seen in goblet cells.
Goblet cell expression was much stronger in the iron-deficient rats and was observed not
only in the small intestine, but also in the colon. We next performed lipid analysis of
the intestinal mucosa by HPLC and noted greatly increased hydroxy and hydroperoxy
polyunsaturated fatty acid levels in the iron-deficient intestine, indicative of AA peroxidation.
The overall pattern of products was consistent with an enzymatic rather than a free radical
mediated mechanism. In conclusion, we have documented significant regulation of Alox12
by iron in the mammalian small intestine and alterations in lipid homeostasis. These findings
may be of significance in relation to increased villus length and surface area and crypt depth
previously observed during iron-deficiency, as Alox12 may be involved in intestinal epithelial
cell differentiation and proliferation. Moreover, the induction of Alox12 in the distal small
and large bowels may have relevance to chronic inflammatory states, such as Inflammatory
Bowel Diseases and colon cancer, as these and other pathological conditions are known to
result in Anemia of Chronic Disease and iron-deficiency.
W1459
Role of the Nfat Transcription Factor in Intestinal Cell Differentiation
Qingding Wang, Yuning Zhou, Lindsey N. Jackson, Chi-wing Chow, B. mark Evers
The precise cellular mechanisms regulating intestinal cell differentiation are not defined.
The nuclear factor of activated T cells (NFAT) proteins represent a family of transcription
factors involved in the regulation of keratinocyte and adipocyte cell differentiation We have
shown that the tumor suppressor protein, PTEN, enhances intestinal cell differentiation.
The purpose of this study was to investigate the possible role of NFAT in intestinal cell
differentiation and determine whether NFAT regulates PTEN. METHODS. The human colon
cancer cell lines, HT29 and Caco-2, and rat intestinal epithelial cells (RIE) were treated with
sodium butyrate (NaBT) in the presence or absence cyclosporin A (CSA), an NFAT inhibitor;
intestinal alkaline phosphatase (IAP) activity and expression of villin (markers of differenti-
ation) and p27kip (a downstream target of PTEN) were assayed. Cells were transfected with
NFATc1, 2, 3 or 4 siRNA, constructs overexpressing PKCθ (which induces activation of
NFAT-dependent transcription in certain cells) or NFATc1 together with an active form of
NFATc4 mutant, the IAP promoter or NFAT-luciferase reporter (which contains 4 copies
of the NFAT consensus sequence) plasmids. PKCθ, NFATc4 and PTEN expression was
analyzed by Western blot (in cells) and by immunohistochemistry (in human colon mucosa).
NFAT binding activity was detected by EMSA. RESULTS. (i) CSA treatment attenuated NaBT-
induced IAP activity and p27kip and villin expression. (ii) NaBT-increased NFAT binding
activity and expression of NFATc1, NFATc2, NFATc4 but not NFATc3. Knockdown of
NFATc1, NFATc3 or NFATc4, but not NFATc2, attenuated NaBT-induced IAP activity,
villin and p27kip expression, suggesting a role of NFATc1 and NFATc4 in intestinal cell
differentiation. Overexpression of NFATc4 active mutant increased IAP activity and expres-
sion of villin and p27kip. (iii) Cotransfection of the active form of PKCθ increased NFAT
reporter luciferase activity and IAP promoter activity compared with control vector. (iv)
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Knockdown of NFATc1 and NFATc4, but not NFATc2 and NFATc3, attenuated NaBT-
induced PTEN expression in HT29 cells. Overexpression of active form of PKCθ, NFATc1
and NFATc4 active mutant increased PTEN expression. (v) PKCθ, NFATc4 and PTEN
demonstrated similar expression patterns with localization to the upper crypts (i.e., most
differentiated region) of the colonic mucosa. CONCLUSIONS. Our results suggest that
NFATc1 and NFATc4 play an important role in the regulation of intestinal cell differentiation.
Moreover, PKCθ regulation of intestinal cell differentiation may be through the regulation
of NFAT-dependent PTEN/kip expression.
W1460
The Retinoblastoma Protein, Rb, Is Required for Enteroendocrine Cell
Precursors to Exit the Cell Cycle, But Not for Differentiation and Expression
of Hormone Genes
Yang Wang, Subir K. Ray, Andrew B. Leiter
RB family proteins inhibit cell cycle progression by blocking S phase genes. In addition, RB
proteins function as transcriptional coactivators of tissue specific genes. The aim of the
present study was to determine the role of RB family proteins in cell cycle control and
differentiation of enteroendocrine cells. We generated mice with conditional deletion of the
RB gene in neurogenin 3 (Ngn3) expressing enteroendocrine precursor cells by crossing
mice expressing Cre under control of the Ngn3 gene to mice with one RB null allele and
one RB allele flanked by loxP sites. All enteroendocrine cell types appeared to differentiate
in normal numbers with the exception of the antral stomach where we observed increased
numbers of serotonin cells and reduced numbers of ghrelin cells. Examination of the gastroin-
testinal tract of Ngn3-Cre; RBFlox/Flox mice revealed a fraction of enteroendocrine cells
stained for the S phase marker, PCNA, including up to 40% of serotonin cells, whereas we
virtually never observed PCNA staining of enteroendocrine cells in wild type mice. We also
generated mice conditionally null for RB in a p107 knockout background and observed
identical results to the RB null animals, suggesting that the presence of the RB related protein,
p107 does not functionally compensate for the loss of RB. We previously showed that the
basic helix loop helix (bHLH) protein, BETA2/NeuroD was important for coordinating both
cell cycle arrest of enteroendocrine cells and expression of the hormone secretin in secretin
cells. To determine whether RB regulates secretin gene transcription, we examined the effects
of RB in transfection assays. RB overexpression had no effect on BETA2/NeuroD dependent
transcription, suggesting that RB does not function as transcriptional coactivator. In summary,
our results suggest that RB is required for all enteroendocrine cells, particularly serotonin cells,
to undergo cell cycle arrest as they terminally differentiate. Loss of RB favors differentiation of
serotonin cells over ghrelin cells in the antral stomach. We conclude that enteroendocrine
cells can differentiate in the absence of functional RB protein. Our results indicate that the
differentiation of enteroendocrine cells is not absolutely dependent on cells undergoing cell
cycle arrest.
W1461
Delineation of a Novel Signaling Mechanism Regulating P27Kip1 Expression in
Ht29 Human Colon Cancer Cells
Salil Bose, Lindsey N. Jackson, Owen J. Sansom, B. mark Evers
Tumor necrosis factorα-related apoptosis inducing ligand (TRAIL) is a pro-apoptotic member
of the TNF-α superfamily. The apoptosis-inducer forkhead (FOXO) family of transcription
factors, a downstream target of Akt, modulates cell apoptosis by affecting phosphatidylinositol
3-kinase (PI3K)-dependent signaling. PI3K and its downstream effector protein, Akt, play
a major role in intestinal cell proliferation and survival. Previously, we showed that PI3K
inhibition up-regulates TRAIL expression which plays a role in intestinal differentiation. The
aim of the present study was to determine whether TRAIL is regulated by FOXO and, in
turn, regulates the cyclin-dependent kinase inhibitor p27Kip1, which has been integrally
linked to intestinal differentiation. METHODS. (i) HT29 human colon cancer cells were
transfected with TRAIL siRNA or non-targeting control and protein extracted for determina-
tion of p27Kip1 expression. Additionally, RNA was extracted and real time (RT)-PCR per-
formed to assess p27Kip1 and TRAIL mRNA levels after TRAIL inhibition or treatment with
sodium butyrate (NaBT; 5 mM), a known differentiation inducer in transformed colon cancer
cells. (ii) To further elucidate the role of the PI3K/Akt/FOXO pathway in the regulation of
TRAIL and p27Kip1, we used a novel genetic model of a selective and inducible Pten gene
knockout limited to the small intestine and colon. Immunohistochemistry was performed
on small bowel sections from Pten+/+ and Pten-/- mice to detect expression of pFOXO1,
pFOXO3a, pFOXO4, TRAIL and p27Kip1. RESULTS. (i) siRNA mediated TRAIL inhibition
decreased p27Kip1 protein and p27Kip1 mRNA expression levels; this decrease could not be
reversed even when the cells were treated with NaBT. (ii) Additionally, Pten-/- mice showed
increased expression of pFOXO1, pFOXO3a, pFOXO4, TRAIL and p27Kip1 in the most
differentiated portion of the intestinal mucosa (i.e., mid-to-upper villi) when compared with
Pten+/+ mice. CONCLUSIONS. Inhibition of TRAIL decreased p27Kip1 protein and mRNA
levels suggesting TRAIL regulation of p27Kip1 in intestinal cells. The regulation of intestinal
differentiation by the PI3K/Akt/FOXO pathway was further confirmed In Vivo by induction
of pFOXO1, pFOXO3a, pFOXO4, TRAIL and p27Kip1 expression in the intestine of Pten-/-
mice. Importantly, changes in TRAIL and p27Kip1 protein and mRNA levels, modulated
by the PI3K/Akt/FOXO pathway, could play a critical role in the regulation of intestinal
cell homeostasis.
W1462
Identification of Hath-1 Target Genes Using Chip-On-Chip Analysis
Mikayo Aragaki, Kiichiro Tsuchiya, Atsushi Yoshioka, Ryuichi Okamoto, Takanori Kanai,
Mamoru Watanabe
Background & aims : ATOH1, a bHLH transcriptional factor, is a downstream of the Notch
signaling pathways and plays a key role in differentiation to secretory cells in intestinal
epithelium. It is reported that ATOH1 and its human homolog Hath-1 form a heterodimer
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with E47 and bind to E-box sequence to activate transcription. Although Essential transcrip-
tional factors for terminal differentiation such as NeuroD, klf4, Ngn3 are necessary for the
expression of Hath-1, whether those factors are direct target genes of Hath-1 remains
unknown. And moreover, the direct target genes of Hath-1 in intestinal epithelium have
not been identified yet. In this study, we performed Chromatin immunoprecipitation experi-
ment on promoter arrays (ChIP on chip) to investigate the direct target genes of Hath-1.
Methods : An expression plasmid encoding flagged-Hath-1 gene was transiently transfected
into kidney-derived cell line 293T. Hath-1 proteins were cross-linked with Hath-1 binding
sites of genomic DNA with 1% formealdehyde. Cells were sonicated to shear DNA into
500bp in length. The sonicates were immunoprecipitated with flagged-Hath-1 antibody.
The ChIPed DNA and total DNA as controls were amplified for microarray analysis using
the ligation- mediated PCR(LM-PCR) methods. The amplified samples were labeled and
hybridized to arrays containing 50-mer probes in 1.5kbp promoter region for a set of genes.
We compared scaled log ratio data for individual probes (ChIPed DNA /total DNA) of 293T
with of flagged-Hath-1-transfected 293T. Result:We obtained 173 genes holding supraliminal
log ratio data of the comparative analysis. 30 genes including E-box sequence on the promoter
regions were further selected by computer search. We performed RT-PCR with these 30
genes to identify upregulated genes by Hath-1 expression in human colon cancer cell line
LS174T. Finally we clarified the direct target genes of Hath-1 by ChIP assay in human
intestinal cells. Conclusion: Using ChIP on chip assay, we identified the direct target genes
of Hath-1 in human intestinal cells. These results will lead to clarify the molecular mechanism
of differentiation and allocation of secretory cells of intestinal epithelium.
W1463
Small Heterodimeric Protein Is a Downstream Target of Tor Signaling During
Intestinal Development in the Zebrafish
Khadijah Makky, Amber J. Tomasini, Alan N. Mayer
Growth of the intestine is subject to tight developmental controls which remain to be defined.
Previously we identified TOR signaling as a critical mediator of intestinal mucosal growth
and morphogenesis in the zebrafish (Makky, K. et al Dev Biol (2007), in press), but the
downstream mediators of TOR signaling in this context remain to be defined. In an effort
to characterize themolecular components downstream of TOR during intestinal development,
we performed expression profiling of rapamycin-treated embryos using an Affymetrix mic-
roarray. Among the upregulated genes was the atypical nuclear receptor, Small Heterodimeric
Partner (SHP, also known as NRB-02). We verified the microarray data by semi-quantitative
RT-PCR. Whole mount in situ hybridization revealed shp expression to be dynamically
expressed in and around the digestive organs during the TOR-dependent developmental
window we identified previously. Morpholino-mediated gene knockdown of SHP resulted
in no detectable phenotype in untreated embryos. However, SHP knockdown conferred
increased sensitivity to rapamycin treatment as measured by the effect of rapamycin on
intestinal growth and morphogenesis. These results suggest that SHP antagonizes the effect
of rapamycin, and thus works in concert with TOR to regulate intestinal development. To
our knowledge, these data provide the first demonstration of a functional link between SHP
and TOR signaling. SHP is a negative regulator of multiple nuclear hormone receptors,
including those previously implicated in mediating intestinal development (eg. HNF-4, RXR).
Exactly how TOR and SHP interact to mediate intestinal development remains the focus of
ongoing studies.
W1464
Intestinal Morphogenesis in the Zebrafish: Fine Dissection of the Endoderm-
Intestine Transition
Kathryn E. Marshall, Alan N. Mayer
The zebrafish intestine arises from a primitive endoderm comprised of a simple cuboidal
epithelium. Between 60 and 84 hours post-fertilization (hpf) the intestinal epithelial cells
become more columnar and polarized as they progress toward differentiation. While much
is known regarding intestinal development before and after this transition, the cellular
mechanism by which the cells adopt their mature configuration remains poorly understood.
In this study we sought to finely dissect the endoderm-intestine transition in the zebrafish
from a morphogenic standpoint. We used conventional histology and e-cadherin immuno-
fluorescence to characterize discrete stages of morphogenesis between primitive endoderm
and mature intestinal epithelium, corresponding to the 60-72 hpf stages. We performed
analysis of at least 6 embryos at 2 hour intervals. In the endoderm between 60 and 72 hpf
we noted multiple foci of cellular disorganization, nuclear pleiomorphism, partial loss of
contact with neighboring cells and delamination from the basement membrane. Also we
noted numerous apical-to-apical bridges between non-adjacent cells. In the sections with
these features, the adherens junction marker E-cadherin was detected in both the baso-
lateral and apical domains of the epithelial cells, suggesting at least partial loss of cell polarity.
As the epithelium took on a more differentiated architecture, E-cadherin was localized strictly
to the baso-lateral surface, the apical cross-bridges were no longer present, and the nuclei
adopted a uniform oval morphology and basal localization. The transient loss of an epithelial
organization and delocalization of E-cadherin suggest that the endoderm may be adopting
mesenchymal features in order to complete its morphogenesis to a mature epithelium. Since
regulators of epithelial-mesenchymal transitions (such as hepatocyte growth factor and
transforming growth factor-β) have been implicated as important for intestinal development,
we hypothesize that they may be acting to promote a quasi-mesenchymal intermediate
during the endoderm-intestine transition.
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W1465
Novel Laminin-10 Receptors of the Lutheran Glycoprotein Family in the
Human Small Intestine
Inga Teller, Elizabeth Herring, Caroline Francoeur, Steve F. Parsons, Jean-francois Beaulieu
Lutheran blood group glycoproteins (LuGps) have recently been recognized as specific
receptors for the α5-chain of laminin-10 (Ln) and Ln 11 (511 and 521, respectively). The
two membrane proteins known as Lu and Lu(v13), also known as B-CAM, result from
alternative splicing of the same gene and are, based on their structure, members of the
immunoglobulin superfamily. They are expressed on the surface of muscle and epithelial
cells in diverse tissues. So far, the majority of research has been done in the context of
erythrocytes, blood group antigens and sickle cell disease. Little is known of their expression
and function in the intestinal epithelium, a tissue where Ln-10/511 has been shown to
induce differentiation. In this study, we have examined the expression of Lu and Lu(v13)
in the developing and adult human small intestine at both the protein and transcript levels.
Indirect immunofluorescence revealed co-localization of LuGps at the base of epithelial cells
with Ln-10 in the basement membrane (BM) of the developing gut but not in the adult
epithelium. LuGps remained expressed in blood vessels and muscle cells. To investigate the
involvement of LuGps in differentiation, we determined their transcript and protein levels
in the Caco-2 cell line. These cells represent fetal enterocytes and spontaneously differentiate
upon reaching confluence. Lu expression at both the transcript and protein levels increased
with the differentiation status of the cells. Lu(v13) transcript levels remained stable while
the protein was at the limit of detection by Western blot. In the past it has been shown
that these receptors are located at the lateral side of filter grown Caco-2 cells. Here we have
shown, that the receptors also relocate to the base of the cells in a co-culture experiment
where the laminin ligand is deposited in a BM-like fashion. Taken together, our data strongly
suggest a crucial role for the Lu receptor in the development of the human small intestine
and differentiation status of enterocytes.
W1466
Cell-Cycle Apoptosis Regulatory Protein(Carp-1): A Novel Signal Transducer
of EGFR and Its Family Members Is Involved in Regulating Colonic Mucosal
Growth During Aging
Arun K. Rishi, Jianhua Du, Hu Xu, Yingjie Yu, Nataliya Razumilava, Edi Levi, Adhip N.
Majumdar
Although the regulatory mechanisms for the age-related rise in proliferation and reduction
in apoptosis in the colonic mucosa are yet to be defined, we reported that these events are
associated with increased expression and activation of EGFR/ErbB-1 and some of its receptor
family members, particularly, HER-2/ErbB-2 suggesting their roles in the regulation of
mucosal growth in aging. However, the signal transduction pathways induced by EGFR
and/or its family members (EGFRs) remain to be fully delineated. Recently, we isolated a
novel growth signaling regulator, CARP-1, a 130 kDa perinuclear protein that participates
in EGFRs-dependent signaling. Expression of CARP-1 is elevated following attenuation of
EGFRs activation that leads to inhibition of growth, whereas depletion of CARP-1 inhibits
EGFRs-dependent apoptosis (JBC 281: 13188-98, 2006). Further, we reported that phos-
phorylation of CARP-1 on Tyr-192 regulates EGFRs signaling and subsequent mucosal
growth. In the current investigation, we examined the role of CARP-1 in transducing EGFRs
signals and in turn colonic mucosal growth during aging. Overnight fasted 3-5 months
(young) and 20-23 months (aged) old male Fischer-344 rats were used. We observed
that the age-related increase in proliferation (determined by PCNA immunoreactivity) and
reduction in apoptosis (determined by TUNEL assay and caspase-9 activity) in the colonic
mucosa was associated with increased expression and tyrosine phosphorylation of not only
EGFR but also its family members (ErbB-2, ErbB-3 and ErbB-4). In contrast, protein and
mRNA levels (as determined by Western-blot, immunohistochemistry and in-situ hybridiza-
tion) as well as tyrosine phosphorylation of CARP-1 were found to be significantly lower
in the colonic mucosa of aged than in young rats. Additionally, we observed that inhibition of
phosphatidylinositol 3-kinase (PI3-K) activity by Wortmannin, which we found to accelerate
apoptosis in the colonic mucosa of aged rats (AJP:GI: 290: 49-55, 2006), caused a marked
increase in expression and tyrosine phosphorylation of CARP-1. The age-related decline in
CARP-1 expression in the colonic mucosa could be attributed to increased methylation of
the CARP-1 promoter. Taken together, our data suggest that not only EGFR but also its
other members are involved in regulating colonic mucosal growth during aging and that
CARP-1 plays a crucial role in transducing EGFRs signals
W1467
Fog Cofactors Partially Mediate Gata4 Function in the Adult Mouse Small
Intestine
Eva Beuling, Tjalling Bosse, Daan Aan de kerk, Christina M. Piaseckyj, Yuko Fujiwara,
Stuart H. Orkin, Stephen D. Krasinski
Friend of Gata (Fog) is a multi-zinc finger cofactor family whose members mediate Gata
function through physical interaction with the N-terminal zinc finger of Gata factors. Fog1
and Fog2, the two members discovered thus far, mediate Gata function in hematopoiesis and
cardiogenesis, respectively. However, the expression patterns and function of Fog cofactors in
the adult small intestine are unknown at present. We recently showed that conditional,
inducible inactivation of Gata4 in the adult mouse jejunum results in a partial jejunum-to-
ileum transformation characterized by an attenuation of genes highly expressed in jejunum
but not ileum (activation pathway), including lactase-phlorizin hydrolase (LPH) and liver
fatty acid binding protein (Fabp1); an induction of genes normally absent in jejunum but
highly expressed in ileum (repression pathway), including the apical sodium-dependent bile
acid transporter (Asbt) and ileal lipid binding protein (Ilbp); and expansion of the secretory
cell population with a parallel induction in the secretory cell mediator, Math1 (cell fate
pathway) (Bosse et al, Mol Cell Biol, 2007, In Press). To test the hypothesis that Fog cofactors
mediate Gata4 function in the adult small intestine In Vivo, an inducible, intestine-specific
Gata4 knock-in (Gata4ki) model was established in which a Gata4 mutant that contains a
point mutation in the N-terminal zinc finger rendering it unable to bind Fog cofactors
(V217G) is expressed in the mature intestinal epithelium. Sequencing of cDNAs confirmed
that Gata4ki was the sole Gata4 synthesized in these mice. LPH, Fabp1, and Math1 mRNA
abundance (real-time qRT-PCR) and goblet cell numbers (N=6) were similar to controls,
indicating that the activation and cell fate pathways of Gata4 do not require interaction
with Fog co-factors. However, Asbt and Ilbp mRNAs were increased 3-fold and 10-fold,
respectively, from controls, although did not reach the levels of those in the conditional
Gata4 knockout mice. To define which Fog cofactor mediates these effects, the expression
patterns of Fog1 and Fog2 were determined using real-time qRT-PCR and in situ hybridiza-
tion. Fog1 mRNAwasmore abundant than that of Fog2, and displayed a decreasing proximal-
to-distal pattern similar to that of Gata4, whereas Fog2 was low proximally and increased
distally. Fog1 was localized to the nuclei of epithelial cells in crypts and on villi by immuno-
histochemistry, whereas Fog2 could not be detected. Conclusion: These data are consistent
with the hypothesis that Fog1 mediates, in part, the repression pathway of Gata4 in the
adult mouse small intestine.
W1468
A Krüppel-Like Factor 4-Regulated Transcriptional Network Is Essential for
Normal Intestinal Development and Colon Cancer Repression
Xi Chen, Weisong Gu, B. mark Evers, Chunming Liu
Background: The development and differentiation of the intestine is controlled by multiple
transcription factors. The normal transcriptional network is usually misregulated in neoplasia
of the intestine. Among them, Krüppel-like factor 4 (KLF4) is a zinc finger transcription
factor which is required for normal intestine development, and is a tumor suppressor that
is down-regulated in colorectal cancer. Several KLF4-regulated genes have been reported in
colon cancer cells by gene expression microarray, however it is not possible to identify
direct target genes of KLF4 simply by gene expression studies. Here, using a ChIP-on-chip
method, we identified a KLF4-regulated transcriptional network that is essential for intestinal
homeostasis and tumor repression. Methods: In order to identify direct target genes regulated
by KLF4, we have designed a promoter array, containing 40,000 oligonucleotides that
represent the general promoter regions of the whole human genome. We have generated a
stable colon cancer cell line that expresses doxycycline-induced KLF4. The KLF4-associated
DNA fragments were enriched by ChIP (chromatin immunoprecipitation). The amplified
DNA probes were then hybridized to the promoter array. Results: We have identified about
600 putative KLF4-target genes using the ChIP-on-chip method. The expression levels of
selected genes were analyzed by RT-PCR, and around 100 genes have been confirmed to
be regulated by KLF4. We also confirmed that KLF4 directly binds the promoters of these
genes by independent ChIP experiments. We have identified several key molecules belonging
to the TGFβ, WNT and Hedgehog pathways, all of which are involved in intestinal develop-
ment and differentiation. We have shown that KLF4 promotes intestine cell differentiation
and represses tumor growth using a xenograft model. To further uncover the role of KLF4
in intestine development and tumorigenesis, we examined the expression of these novel
KLF4 target genes in normal human intestinal tissue and colorectal cancers. Conclusions:
Our results indicate that KLF4 is a critical transcriptional factor within a complex regulatory
network. Through regulating different signaling pathway, KLF4 governs intestinal homeost-
asis and tumorigenesis.
W1469
EGF-Mediated Inhibition of mRNA Splicing Results in Decreased Cugbp2
mRNA Translation: A Novel Method of EGF Mediated Inhibition of Tumor
Suppressor Gene Expression in Tumorigenesis
Satish Ramalingam, Dharmalingam Subramaniam, Brain K. Dieckgraefe, Courtney W.
Houchen, Shrikant Anant
CUGBP2 is an RNA binding protein that can interacts with AU-rich sequences in the
3'untranslated region and inhibits COX-2 mRNA translation. On the other hand, we have
previously demonstrated that cyclooxygenase-2 (COX-2) derived prostaglandin E2 (PGE2)
inhibits CUGBP2 expression. Furthermore, CUGBP2 overexpression induces cancer cells to
undergo apoptosis suggesting that CUGBP2 is a proapoptotic protein. Since PGE2 levels
are significantly higher in tumorigenesis, the aim of the current study was to determine the
effect of tumorigenesis on CUGBP2 expression. Real Time PCR analysis demonstrated that
CUGBP2 expression is significantly less in human colon cancer when compared to paired
uninvolved tissues. Furthermore, CUGBP2 expression is lower in intestinal polyps from
APCmin mice, the animal model of intestinal FAP. Recently, three variants of CUGBP2 were
identified due to alternative promoter usage and alternative exon 1. This results in inclusion
of additional 19-24 amino acids in the N-terminus of variants 2 and 3, and different
5'untranslated regions (5'UTR). RT-PCR analyses of total RNA from HCT116, HT29 and
SW480 colon cancer cells with primers that amplified the full length 5'UTRs demonstrated
that variant 1, the original CUGBP2 variant is the predominant isoform in all the three cell
lines. Epidermal growth factor (EGF) is an inducer of tumorigenesis. We next determined
the effect of EGF on CUGBP2 expression. RT-PCR analysis of RNA from EGF-treated HCT116
cells revealed that expression of variants 2 and 3 were lost, while that of variant 1 was
decreased. Surprisingly, EGF treatment resulted in the amplification of a novel higher
molecular weight variant 1 isoform, termed variant 1A resulting from inclusion of intron
1. This lack of intron 1 splicing was also observed in HCT-116 nude mice tumor xenografts.
The 5'UTR region of both variant 1 and intron-included variant 1A were cloned upstream
of the luciferase reporter gene and the transcripts were expressed in HCT116 cells. Addition
of variant 1 5'UTR increased the translation of luciferase mRNA by 3-fold suggesting that
this region encoded that induced mRNA translation. However, addition of the variant 1A
5'UTR decreased luciferase mRNA translation to baseline levels. Furthermore, while EGF
treatment increased the translation of luciferase mRNA with variant 1 5'UTR, it decreased
translation from the variant 1A 5'UTR. Taken together, these data suggest that EGF inhibits
expression of the CUGBP2 tumor suppressor gene by a coupled switching of promoter
usage, inhibition of intron 1 splicing and suppression of translation from this novel 5'UTR
isoform during tumorigenesis.
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W1470
Activation of PKA Inhibits Intestinal Cell Differentiation Through Reduction
of Pten and P27Kip1 Expression in Ht29 Cells
Yuning Zhou, Qingding Wang, B. mark Evers
The tumor suppressor protein, PTEN, plays an important role in multiple cellular processes
by antagonizing phosphatidylinositol 3-kinase (PI3K) which we have shown enhancing
sodium butyrate (NaBT)-mediated intestinal cell differentiation. Cyclic AMP (cAMP)-depend-
ent PKA activation inhibits enterocyte differentiation; however, the mechanisms through
which cAMP/PKA signaling modulates differentiation of human intestinal epithelial cells are
not well understood. The purpose of this study was to determine: (i) PKA regulation of
intestinal cell PTEN expression, and (ii) the subsequent effect of this regulation on the
expression of the cell cycle dependent kinase inhibitor, p27kip1, a downstream target of
PTEN in intestinal cells. METHODS. (i) The human colon cancer cell line, HT29, was treated
with either forskolin (FSK), which increases cellular cAMP and thus activates PKA, or 8Br-
cAMP, an activator of PKA, in the presence or absence of the PKA inhibitor, H89. Intestinal
alkaline phosphatase (IAP) activity was assayed as an indicator of differentiation. PTEN,
villin (a marker of differentiation) and p27kip1 expression was determined by Western blot.
(ii) To elucidate whether PKA plays a role in PTEN regulation, HT29 cells were transfected
with pCMV-PKA, which encodes the catalytic subunits of PKAα or empty control vector;
stably transfected clones were selected in medium containing G418. (iii) To further determine
the role of PKA in PTEN regulation, HT29 cells were transfected with siRNA directed to
PKA catalytic subunits, PKAα or PKAβ, or the respective non-targeting control siRNAs.
RESULTS. (i) Treatment of HT29 cells with FSK or 8Br-cAMP repressed NaBT-induced
IAP activity, suggesting a negative regulation of PKA on NaBT-mediated intestinal cell
differentiation. (ii) Treatment of HT29 cells with FSK or 8Br-cAMP repressed NaBT-induced
villin and p27kip1 expression; treatment with H89 prevented this repression, suggesting PKA
regulation of intestinal cell differentiation through p27kip1. (iii) Overexpression of PKA
catalytic subunits repressed PTEN expression; A synergistic suppression of PTEN was noted
after FSK treatment. Moreover, transfection with siRNA to PKAα or PKAβ increased PTEN
expression in HT29 cells. CONCLUSIONS. Our results demonstrate a negative regulation of
PTEN expression by PKA and identify PTEN as a downstream target of the cAMP/PKA
pathway in intestinal cells. Given the importance of p27kip1 in intestinal cell differentiation,
the cAMP/PKA signaling pathway may alter intestinal cell differentiation through the regula-
tion of PTEN-dependent p27kip1 expression.
W1471
Identification of Hnf4α Regulated Promoters and Transcription Factor
Networks in Intestinal Epithelial Cells
Mette Nielsen, Jørgen Olsen, Jesper T. Troelsen
Gene regulation during the differentiation of intestinal epithelial cells is a complicated and
tightly regulated process important for the phenotype and the function of the intestine.
HNF4α is one of the candidate transcription factors suggested to be involved in this process.
In order to identify which genes that are under HNF4α control In Vivo, we performed a
chromatin immunoprecipitation (ChIP) of HNF4α-associated DNA from differentiated Caco2
cells. The HNF4α-associated DNA was used as probe to hybridize to a promoter array
containing ~22000 promoter sequences (ChIP on chip analysis). Promoters, like HNF1α
and apolipoproteins, that have been found to be regulated by HNF4α, were positive for
HNF4α binding when analysed using the ChIP-on-chip analysis thus demonstrating the
ability of the ChIP-on-chip technology to identify the HNF4α regulated promoters. Interest-
ingly we identified several new promoters that are regulated by HNF4α, e.g. digestive
hydrolases, homeodomain transcription factors and transcription factors in the wnt-signalling
pathway. Using the ChIP-on-chip approach we have been able to identify new transcription
factor networks that are likely to be important for maintenance of the differentiated phenotype
of the intestinal epithelium. We have furthermore gained an insight in which specific
pathways and cellular functions that are under genetic control of HNF4α.
W1472
Functional Domains of RNA Binding Protein Cugbp2
Pavel Rodriguez, Dharmalingam Subramanian, Randal May, Brian Dieckgraefe, Courtney
W. Houchen, Shrikant Anant
Cyclooxygenase-2 (COX-2) is a key enzyme in the generation of the prostaglandins eicosano-
ids. Early development of human colon cancer and other epithelial malignancies depend
on the overexpression of COX-2. Furthermore, increased production of prostaglandin E2
(PGE2¬) confers radioprotection on intestinal epithelial human and mice cells subjected to
radiation. We have previously shown that CUGBP2 acts a posttranscriptional regulator of
COX-2. CUGBP2 binds to the AU-rich elements (AREs) in the 3' untranslated region (UTR)
of COX-2 mRNA and stabilizes the transcript. Contrary to the established paradigm of RNA
stabilizing proteins, this stabilizing effect leads to translation inhibition. Conversely, HuR,
a well studied ELAV protein and structural homolog of CUGBP2, facilitates translation of
the transcript by binding and competing for the same region of COX-2 mRNA. As a first
step in understanding the mechanism of CUGBP2, we performed a structure-function study
by generating deletion mutants. Both CUGBP2 and HuR encode three RNA recognition
motifs (RRMs) with the first two RRMs (RRM1, RRM2) in tandem, and the last one (RRM3)
separated from the first two by an A/Q rich linker region present only in CUGBP2. To
understand the role of the different domains, we generated constructs that encoded the
individual domains RRM1, RRM2, RRM3 and the A/Q-rich linker region. The full-length
cDNA was used as template for PCR with specific primers. The cDNAs were cloned into
plasmid pPCR-Amp Script, and sequenced to determine that no PCR-mediated mutations
were introduced into the sequence. After confirmation of the validity of the sequence, the
cDNAs were isolated and cloned into plasmid pCMV-Tag2B for expression in mammalian
cells. Validity of the cloned cDNA was confirmed by sequencing the forward and reverse
strands. Using immunocytochemistry, we have determined the localization of the individual
proteins in two human cell lines, HC-T116 (colon adenocarcinomas cells) and HeLa (cervical
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carcinoma cells). This led us to propose the location of the nuclear localization signal (NLS)
in CUGBP2. All four mutants localized within the nucleus, and their amino acid sequences
included consensus-like NLS sequences. Immunoprecipitation of the individual mutants
using anti-CUGBP2 IgG was used to detect coprecipitation of COX-2 mRNA. Studies are
ongoing to assess the effects of the mutants on the stability and translation of COX-2 mRNA.
W1473
PH Dependent Hydrophobic Properties of Cysteine Rich Pig Gastric Mucin
(Muc5ac) Domains Expressed in Pichia Pastoris
Bradley Turner, Rama Bansil, Nezam H. Afdhal
BACKGROUND: Gastric mucins, large secreted glycoproteins, provide a viscous protective
barrier to the underlying epithelium from the harsh luminal environment of acid, enzymes,
bacteria and shear forces. Pig gastric mucin (PGM) forms a viscoelastic gel that exhibits a
sol-gel transition at the low pHs found in the stomach. It has been demonstrated that the
non-glycosylated cysteine-rich (Cys-rich) regions of the protein core of PGM are instrumental
in the hydrophobic, electrostatic and disulfide bonds involved in its aggregation and gel
forming properties. We have previously cloned and sequenced the cDNA encoding the full
length Cys-rich C-terminal domain (Z13) and a Cys-rich region (2X) that is interspersed
within the tandem super-repeats of PGMMuc5AC. AIM: The present study seeks to determine
whether peptides from the Cys-rich regions of PGM exhibit hydrophobic changes as a
function of pH. METHODS: The cDNA clones encoding the cys-rich C-terminal (Z13) and
interspersed (2X) domains of PGM Muc5AC were amplified by PCR, recombined into the
HIS6 secretion vector pDEST911, transformed into the protease deficient SMD1163 Pichia
pastoris strain and grown in shake flask culture. The secreted recombinant peptides were
purified from culture supernatant by nickel affinity chromatography. Hydrophobic properties
were investigated by intrinsic peptide fluorescence of tryptophan (Trp) residues and binding
of the fluorescent hydrophobic dye 1-anilinonaphthalene-8-sulfonic acid (ANS). RESULTS:
Peptides were secreted to a level of 5-8mg/L in culture broth. Both peptides induced a
concentration dependent (4ug/ml-16ug/ml) increase in the ANS fluorescence intensity (3-
fold) and a concomitant decrease in the peak emission wavelength (blue shift, from 520 to
460nm) indicating binding of ANS to hydrophobic regions of the peptides. Similarly, at
constant peptide concentration (12ug/ml), decreasing the pH from 6 to 2 again caused an
increase in the ANS fluorescence intensity and blue shift in the peak intensity indicative of
ANS binding to hydrophobic regions. Conversely, the intrinsic fluorescence fromTrp residues
within the peptide exhibited a decrease (8%) in fluorescence intensity and a red shift (370nm
to 390nm) with decreasing pH (6 to 2), indicating a net movement of the hydrophobic
peptide Trp residues to a more exposed aqueous environment. CONCLUSION: Decreasing
pH causes an increase in the exposure of and binding to hydrophobic sites of recombinant
peptides from the Cys-rich regions of PGM. We speculate that these increased hydrophobic
interactions may be one of the mechanisms underlying the pH induced aggregation and
gelation of PGM Muc5AC. Supported by NIH.
W1474
Gene Expression Profiling of Math1-Mutant Adult Intestinal Crypts Identifies
Novel Secretory Lineage Specific Genes
Noah F. Shroyer, Jennifer Norris, Susan J. Henning, Huda Y. Zoghbi
Background:Math1 (Mouse atonal homolog 1; Atoh1) is a basic helix-loop-helix transcription
factor essential for formation of the intestinal secretory lineages - Paneth, goblet, and enteroen-
docrine cells. We hypothesized that gene expression analysis of Math1 Δintestine crypts
would identify novel secretory lineage specific genes. Methods: We isolated crypts from
wild-type and Math1 Δintestine mice (in which Math1 was ablated in the terminal ileum
and colon) using laser capture microdissection. RNA was purified and used to interrogate
Affymetrix 430v2 GeneChips for expression differences between wild-type andMath1 Δintest-
ine crypts. Dchip and GeneSpring analysis was used to identify probe sets that showed a
2-fold difference and P<0.05 between genotypes. Taqman quantitative RT-PCR was used to
assess gene expression inMath1 -/- versus wild-type embryonic intestine. In situ hybridization
on intestine from Math1 Δintestine mice was used to identify gene expression patterns of
differentially expressed genes. Results: This LCM-based microarray analysis identified 143
genes misexpressed in Math1 Δintestine crypts. qRT-PCR confirmed misexpression of 10/11
genes in whole intestine from E18.5 Math1 -/- embryos, including Agr2, Bambi, Gfi1, Lyzs,
Math1, Mmp7, Muc2, Pyy, Spdef, and TFF3. In situ hybridization demonstrated goblet-cell
specific expression of Agr2 and Spdef, and crypt-specific expression of Bambi. Conclusions:
We identified novel secretory specific genes by analysis of Math1 Δintestine crypts, but fewer
than expected compared to our previous analysis that identified 560 gene expression changes
in whole embryonicMath1 -/- intestine. However, genes identified by LCM-microarray include
those with crypt and secretory epithelial expression patterns as characterized by our ongoing
in situ hybridization studies, whereas some transcripts identified in whole embryonic intestine
show non-epithelial expression patterns. We conclude that our crypt-specific analysis allowed
us to identify novel secretory lineage specific genes. These data will allow us to begin to
assemble a complete picture of the genetic pathway for intestinal epithelial differentiation.
This work was supported by the NIH (F32 DK63747, K01 DK071686, P30 DK56338), the
FDHN (Research Scholars Award) and the Howard Hughes Medical Institute.
W1475
Gene Expression Profiling of Gfi1-Mutant Adult Intestinal Crypts Identifies
Secretory Lineage Genes and a Potential Role for Gfi1 in Regulation of Cell
Cycle Within the Intestine
Noah F. Shroyer, Jennifer Norris, Avedis Kazanjian, Susan J. Henning
Background: Gfi1 (Growth factor independent 1) is a transcriptional repressor that we
recently showed to function downstream of Math1 in the formation of intestinal secretory
lineages - Paneth, goblet, and enteroendocrine cells. We hypothesized that gene expression
analysis of Gfi1 -/- crypts would identify novel secretory lineage specific genes. Methods:
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We isolated crypts from wild-type and Gfi1 -/- mice using laser capture microdissection.
RNA was purified and used to interrogate Affymetrix 430v2 GeneChips for expression
differences between wild-type and Gfi1 -/- crypts. Dchip and GeneSpring analysis was used
to identify probe sets that showed a 2-fold difference and P<0.05 between genotypes,
some of which were confirmed by Taqman quantitative RT-PCR on whole intestine. Semi-
quantitative in situ hybridization comparing duodenum, jejunum, ileum, and colon from
wild-type and Gfi1 -/- mice was used as another validation technique and to identify gene
expression patterns of differentially expressed genes. Results: This LCM-based microarray
analysis identified 691 genes misexpressed in Gfi1 -/- crypts, of which 10/13 were confirmed
by qRT-PCR on whole intestine, including Bambi, Insm1, Lyzs, Mmp7, Msi1, Muc2, Rab27a,
Rab27b, Spdef, and TFF3. Comparitive in situ hybridization data was performed for over
30 genes, most of which revealed epithelial specific expression patterns, including many
confined to the crypts. Conclusions: Our results confirm that Gfi1 is required for intestinal
secretory cell allocation, as we identified increased expression of enteroendocrine genes and
loss of goblet and Paneth cell genes. Interestingly, we also identified a subset of misexpressed
genes involved in regulation of proliferation including p21, and potential stem cell markers
including Msi1 and Sox4. Our in situ hybridization results characterized novel secretory
lineage specific genes, especially those expressed in enteroendocrine and Paneth cells.
Together with our related results in Math1-mutant crypts, we are assembling the genetic
pathway for intestinal secretory lineage differentiation. This work was supported by the NIH
(F32 DK63747, K01 DK071686, P30 DK56338), and the FDHN (Research Scholars Award).
W1476
Use of Plasma Proteomics and Metabolomics to Assess Metabolic Changes
Associated with Weight Loss in Laparoscopic Adjustable Gastric Banding
(Lagb) Patients
John Bennett, Abigail Polley, Mike Rhodes, Ian J. Johnson, Gwendoline Le gall, Ian
Colquhoun
Background: Morbid obesity is associated with an increased prevalence of inflammatory
related diseases and cancer. The risk of these co-morbidities has been shown to decline
with weight-loss after bariatric surgery. The development of methods to separate and quantify
all the components of the human proteome allows us to explore the entire plasma response
to obesity and obesity surgery but these have not previously been be used to examine the
metabolic changes of patients undergoing surgery to aid weight-loss. Method: We conducted
a prospective controlled study of six morbidly obese patients with median age 40 yrs (range
27-55) and mean pre-op BMI 48.1 Kgm-2 (range 41.4-59) undergoing LAGB. Fasted blood
tests were taken pre- and 3 and 6 months post- surgery, and from age/sex matched controls.
Proteomic analysis was conducted by 2-D gel electrophoresis of albumin/ IgG depleted
plasma, using isoelectric focusing on pH 3-11) gradient strips followed by gel separation
on 10% homogenous polyacrylamide gels. The resultant images were examined on Prote-
omweaver® software. Selected protein spots were picked with a robotic system and identified
by MALDI-TOF and Q-TOF mass spectrometry. Further analysis of plasma was conducted
using liquid chromatography-mass spectrometry and nuclear magnetic resonance spectro-
scopy. Results: Analysis of pre-, 3 months post- and 6months post-operative samples showed
a complex spectrum of protein changes. Selective analysis revealed reduced expression of
complement C3 precursor and C4b, transthyretin and the gelsolin precursor. Further statist-
ical analysis to detect further subtle changes in the plasma proteome is being completed as
more samples become available at each time point. Metabolomic analysis has enabled us to
quantify plasma 30 constituents simultaneously, and demonstrate progressive changes in
lipid profiles, with a trend towards control levels with increasing time post-op. Conclusions:
These preliminary results show the value of proteomic andmetabolomic techniques for broad-
spectrum metabolic assessment in this group. Weight-loss was associated with reductions in
inflammatory proteins and metabolomic assessment revealed lipid profile changes consistent
with those detected by other methods. Inflammation plays a key role in the development
of many obesity related diseases. Proteomic and metabolomic analysis can be utilised to
develop a systems biology approach to weight loss.
W1477
Micrornas Detected By Microarray in the Small Intestine
Anne M. Hutson, Preethi H. Gunaratne, Chad A. Shaw, Susan J. Henning
BACKGROUND: Numerous factors have been identified that are important for intestinal
epithelial cell proliferation and differentiation, but many details as to how they are regulated
remain to be discovered. MicroRNAs (miRNAs) are a new class of regulatory molecules that
inhibit gene expression by binding the 3-untranslated region of target mRNAs to block
translation or cause mRNA degradation. Studies in other tissues indicate that miRNAs
regulate the expression of factors important in cell proliferation, cell fate choices, and cell
differentiation. To date, the potential roles of miRNAs in regulating these cellular processes in
mammalian gastrointestinal tissues have not been explored. In the small intestinal epithelium,
proliferating and differentiated cells are spatially separated along the crypt-villus axis. Thus,
we hypothesize that miRNAs confer a novel mode of regulation in small intestinal epithelium
and speculate that there are gradients of miRNA expression along the crypt-villus axis.
METHODS: Villus and crypt epithelial cell fractions were prepared from mouse jejunum
using a modification of the Bjerknes and Chang method (1981). High quality small RNAs
were extracted from these fractions as well as intact jejunum. These RNAs were hybridized
to custom miRNA microarray chips spotted with 356 known mouse miRNAs. RESULTS: A
total of 111 miRNAs were detected in RNA from intact mouse jejunum. Of these, 92 were
expressed in RNA from villus epithelia, and 89 in crypt epithelia. A small number of these
miRNAs displayed 2-fold or greater differential expression in the villus or crypt fractions:
8 showed greater expression in the villus fractions, and 4 in the crypt fractions (p<0.05).
CONCLUSIONS: The 8 villus miRNAs are attractive candidates for regulating transcripts
whose expression are necessary for proliferation, whereas the 4 crypt miRNAs might inhibit
translation necessary for cell differentiation and maturation. Identification of the targets of
these miRNAs could provide insights into the regulation of proliferation and differentiation
of the small intestinal epithelium in both physiological and pathological conditions.
W1478
Epithelial Stem Cell-Related Alterations in Trichinella Spiralis-Infected Small
Intestine
Rebecca Walsh, Rashmi Seth, Yashwant R. Mahida
T. spiralis infection leads to T cell-dependent alterations in the small intestinal mucosal
architecture and an increase in Paneth, intermediate and goblet cells. Our aim was to
investigate alterations in the epithelial proliferative compartment and genes that may affect
stem cell function. Methods. Female Balb/c mice were infected with 300 T. spiralis larvae
and duodenal tissue was collected at 5 time points post infection (p.i.) and worm burden
determined. Uninfected mice were used as controls. Paneth and intermediate cell numbers
were determined in phloxine tartrazine-stained sections and expressed as number of cells per
10 crypt-villous units. The proliferative population was examined by immunohistochemistry
using an anti- Ki-67 antibody and data analysed using the WinCrypts program where
labelling was related to cell position along crypt-villous axis (cell 1 = cell at centre of base
of crypt). Expression of transcripts for Math1, isoforms of transforming growth factor (TGF)-
β and hypoxanthine guanine phosphoribosyl transferase (HPRT; housekeeping gene) was
studied by real-time RT-PCR. Data are expressed as mean (±SEM). Results. Worm burden
was maximal on day 6 p.i., with full clearance by day 18 p.i. When compared to controls,
Paneth and intermediate cell numbers were significantly increased from day 6 p.i. onwards,
to peak at day 12 [40.0(±3.42) vs 139.2(±12.4); p<0.0001]. Significantly lower numbers
of Ki-67 positive cells were found at positions 2 - 9 (but not at positions 1 and 10 - 30)
in day 12 infected small intestine, compared to uninfected samples (p<0.02). Compared to
uninfected controls, there was a 2.37(±0.13) fold increase (p<0.001) in expression of TGF-
β1 at day 6 p.i., 1.64(±0.19) fold increase (p<0.05) in TGF-β2 expression at day 12 p.i.
and 1.57(±0.21) fold increase (p<0.05) in TGF-β3 expression at day 6 p.i. Math1 gene
expression was significantly increased at days 6 [2.21(±0.17) fold; p<0.001] and 12
[1.84(±0.10) fold; p<0.001] p.i. Conclusions. T. spiralis infection was confirmed by the
observation of the expected increase in Paneth/intermediate cells. Ki-67 positive epithelial
cells were significantly reduced at lower crypt cell positions at day 12 p.i., implying a
shortening of the proliferative zone. An isoform-specific pattern in increased TGF-β expres-
sion was observed after infection. We postulate a role for TGF-β in limiting excessive
epithelial proliferation during T. spiralis-induced intestinal inflammation. The increase in
expression of Math1 (important in secretory cell lineage commitment) was concordant with
the time points showing an increase in the number of Paneth and intermediate cells.
W1479
Characterisation of Stem Cell-Containing Isolated Human Colonic Crypt
Epithelial Cells and Their Interactions with Intestinal Myofibroblasts
Sunil Samuel, Adrian Robins, Yashwant R. Mahida
Introduction. Characterisation of isolated intestinal epithelial stem cells will facilitate investi-
gation of factors regulating their function. Bone marrow stem cells can be identified by the
‘side-population' (SP) phenotype. SP cells' differential ability to efflux Hoechst dye is sensitive
to verapamil and fumitremorgin C. Adherence to extracellular matrix (secreted by adjacent
myofibroblasts) is likely to be an important property of intestinal stem cells. Methods. Crypt
epithelial cells were isolated and disaggregated from normal human colonic mucosal samples
using ethylenediaminetetraacetic acid and pancreatin. Transcripts for musashi1, Hes1, Hath1
and collagen1 were studied by RT-PCR. Flow cytometry was used to study integrin expression
and SP cells after staining with Hoechst 33342 in presence or absence of verapamil or
fumitremorgin C. Adherence of epithelial cells to collagen I and isolated intestinal myofibrob-
lasts was studied in the presence or absence of anti-β1 integrin antibody. Data are expressed
as mean (SEM). Results. Single colonic crypt epithelial cells with an average viability of
71.8(1.8)% (n=64) were obtained and their expression of musashi1, Hes1 and Hath1 tran-
scripts was confirmed by RT-PCR (n=3). Cells able to efflux Hoechst dye (SP cells) represented
0.18(0.04)% of the total viable colonic crypt cell population (n=10). Cells with SP character-
istics decreased by 73.1(5.5)% and 87.8(8.0)% in the presence of verapamil (n=6) and
fumitremorgin C (n=4) respectively. The isolated colonic crypt epithelial cells expressed β1
integrin, as demonstrated by significantly increased mean fluorescence intensity using β1
integrin-specific antibody compared to isotype control antibody [190.3(47.8) vs 11.6(4.1),
p<0.02]. Anti-β1 integrin antibody significantly reduced adherence of colonic crypt epithelial
cells to collagen I [cells/cm2: 196.3(58.7) vs 33.2(10.4), n=6; p<0.03] but did not affect
adherence to intestinal myofibroblasts [cells/cm2: 2329(923.5) vs 3147.5(543.4), n=6;
p>0.05]. Expression of collagen I transcripts by myofibroblasts was confirmed by RT-PCR
(n=3). Adhesion to myofibroblasts did not enrich for colonic crypt epithelial cells expressing
high levels of β1 integrin. Conclusions. 1. Disaggregated human colonic crypt epithelial
cells showed good viability, expressed musashi1, Hes1 and Hath1 transcripts and β1 integrin
on the cell surface. 2. They contain a very small population of cells with SP phenotype,
similar to that described for stem cells in the bone marrow. 3. Adherence of colonic crypt
epithelial cells to monolayers of collagen I-expressing intestinal myofibroblasts was not
mediated through β1 integrin.
W1480
Modelling the Expansion of Mutated Clones Within Human Colonic Crypts
and Their Migration Through the Colon
Stuart A. Mcdonald, Laura Greaves, Maesha G. Deheragoda, Simon Leedham, Robert
Taylor, Chung-yin Lee, Manuel Rodriguez-justo, George Elia, Marco Novelli, David
Stoker, Douglas Turnbull, Janusz A. Jankowski, Nicholas A. Wright
Recent data from our laboratory has shown that mitochondrial DNA (mtDNA) mutations
can spread through the human colon by a process of crypt fission, where one crypt is able
to divide into two daughters(Proc. Natl. Acad. Sci. 103:714-19). Here we show how cells
from partially mutated crypts expand through the human colonic crypt. 3D modelling of
cytochrome c oxidase deficient cells from serial sections throughout single crypts was used.
We have shown, for the first time, that it is possible to trace the migration of individual
stem cell progeny within a human colon crypt. This has highlighted that cellular migration
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within crypts is more complex than originally thought and gives insights into actual stem
cell location. Furthermore, the rate at which normal human crypts undergo fission is
unknown. Bjerknes (J. Theor. Biol. 179:381-5) developed a mathematical model by which
he calculated the rate at which crypts within aberrant crypt foci were able to expand. This
predicts that if an aberrant crypt population was expanding at the same rate as normal
crypts then the number of single aberrant crypts should be half of the number of those
within foci. Here we use this model to show that crypts deficient in mitochondrial cytochrome
c oxidase (CoxSU1) expand at the same rate as those with normal CoxSU1 expression. We
have counted the total number of deficient crypts within tissue sections stained with CoXSU1
from normal colons of 35 patients. 1298 deficient crypts were observed of which 597 were
single. This gives a ratio of singletons to patches of 0.46 which are expanding only at 1.15
times faster than positive crypts. These data suggest that crypts with or without mtDNA
mutations expand at the same rate and that this is an appropriate model to calculate the
crypt fission rate of the human colon.
W1481
Intestinal Epithelial Cells Express the Functional Receptor Complex for the
Novel Cytokine IL-31 and Its Expression Is Up-Regulated in Inflammatory
Bowel Disease
Julia Dambacher, Florian Beigel, Kathrin Zitzmann, Christoph J. Auernhammer, Julia
Seiderer, Thomas Ochsenkuehn, Burkhard Goeke, Stephan Brand
Background: Human interleukin-31 (IL-31), primarily expressed in activated lymphocytes,
signals through a heterodimeric receptor complex consisting of IL-31RA and OSMR. Aim:
The aim of this study was to analyze IL-31 receptor expression, signal transduction and
specific biological functions of this cytokine system in intestinal epithelial cells (IEC) and
the regulation of IL-31 expression in In Vivo models of intestinal inflammation including
inflammatory bowel disease (IBD). Methods: Expression studies were performed by RT-PCR
and quantitative PCR. Signal transduction was analyzed by Western blot experiments and
ELISA. Cell proliferation was measured by MTS assays, cell migration by restitution assays.
IL-31 mRNA expression was analyzed in murine In Vivo models of intestinal inflammation
(TNF DeltaARE mouse model and C57BL/6 mice infected with murine cytomegalovirus,
MCMV) and in colonic biopsy samples of IBD patients. Results: The IEC lines SW480 and
HCT116 express IL-31RA and OSMR, the two receptor subunits necessary for IL-31 signaling.
IL-31 binding to its receptor complex activates ERK-1/2, Akt, STAT1 and STAT3. At high
doses and high cell density, IL-31 increased IEC proliferation and migration. Moreover, IL-
31 stimulation increased IL-8 protein expression up to 3-fold. Ileal IL-31 mRNA expression
is increased in TNF DeltaARE mice (up to 13-fold) compared to wildtype controls. A slight
increase of colonic IL-31 mRNA expression was also seen in C57BL/6 mice infected for 45
hours with MCMV (1.3fold increase vs. uninfected controls). Moreover, IL-31 mRNA expres-
sion was higher in inflamed colonic lesions compared to non-inflamed tissue in 8 out of
12 patients with Crohn's disease (CD; average 2.4-fold increase) and in 8 out of 10 patients
with ulcerative colitis (UC; average 2.5-fold increase) and correlated with the IL-8 expression
in these lesions (r=0.564 for CD patients; r=0.650 for UC patients). Conclusion: IEC express
the functional IL-31 receptor complex. Binding of IL-31 to its receptor activates MAP kinases
and STAT signaling pathways resulting in proinflammatory protein expression. IL-31 mRNA
expression is up-regulated in In Vivo models of murine intestinal inflammation and human
IBD suggesting a potential role for this novel cytokine system in the pathogenesis of IBD.
W1482
Alterations in Myeloid Dendritic Cells in the GαI2-Deficient Mouse Model of
Colitis
Peter Calkins, Jeremy A. Pena, George J. Snipes, Karen Bustos, Xin Shi, Nina Tatevian,
Milton J. Finegold, Luann Thompson-snipes
The inhibitory G protein alpha subunit type-2 (Gαi2)-deficient mouse develops inflammatory
bowel disease (IBD), with disease severity influenced by mouse genetic strain. Gai2-deficient
(Gαi2-/-) mice on a 129SvEv(129) background develop severe colitis, while mice reared on
a C57BL/6(B6) background are resistant. A sequela of this mutation is the development of
invasive adenocarcinoma in older mice. Since dendritic cells (DCs) are key inducers and
regulators of immune function, we hypothesized that in Gαi2-/- mice, DCs suffer functional
defects relating to the appropriate recognition of lumenal bacteria which may play a role in
the pathogenesis of IBD. We reared Gαi2-/- mice and wild-type (WT) litter-mates on 129
and B6 backgrounds and compared DC function. Our previous studies using bone marrow
derived dendritic cells demonstrated that DC subsets have discrete responses to toll-like
receptor ligands and may contribute differentially to IBD in Gαi2-/- mice by producing
different levels of inflammatory or anti-inflammatory cytokines. Different DC responses
correlated with mouse strain susceptibility. Mice with Gαi2-deficiency displayed intestinal
inflammation above their WT counterparts. In the present study we have found expression
of the cytokines IL-17, TNF-α, INF-γ and IL-12 (p40), are increased in the colons of Gai2-/-
versus WT 129 mice. This increase in cytokine expression correlates with an increase in
the inflammation as detected by histology. However, increased TNF-α and IL-6 in the 129
strain of mice correlated with the higher level of inflammation seen in 129 mice. In the
Gαi2-/- model of IBD, we have detected increases in DCs in the lamina propria of the colon
compared to WT mice, even before the onset of colitis, suggesting that there is an intrinsic
difference in DC function in the Gai2-/- mouse. To further test this hypothesis we have
developed a transgenic mouse that expresses a dominant negative form of Gαi2 (G204A)
in DCs driven by the CD11c promoter. The Gαi2 (G204A) mutation causes the Gai2 to
stably associate with the βγ subunits leading to an inactive state. The ability of the G204A
mutation to inhibit Gαi2 activity was demonstrated in both fibroblasts and Jurkat cells. We
developed a transgenic mouse line that has spontaneously developed adenocarcinoma of
the distal colon in the setting of localized colitis. In conclusion, changes in DC function in
129 Gαi2-/- mice could result in aberrant immune responses to normal bacterial flora
resulting in inflammation and ultimately adenocarcinoma. (Supported by a PFA from the
Texas Gulf Coast DDC Grant #P30 DK5623803/05 and the Moran Foundation).
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W1483
Regulation of A20 Expression in Human Intestinal Epithelial Cells
Monica Gallas, James P. Lodolce, Melisa Williams, Jeff Schneider, David L. Boone
Mice with a targeted deletion of the cytosolic protein A20 (A20-/- mice) develop IBD,
demonstrating the essential role of this protein in intestinal homeostasis. A20 is rapidly
induced in multiple cell types in response to TNF or other NF-kB activating stimuli. This
rapid induction allows A20, which is a deubiquitinating enzyme (DUB) and an ubiquitin
ligating enzyme (E3), to modify ubiquitin conjugation on cell signaling molecules and turn
off NF-kB activation. A20 is also anti-apoptotic and this may be important for protection
of cells from TNF-induced death once NF-kB activity is inhibited by A20. Thus protection
from IBD may involve the concerted activity of A20 as both an anti-inflammatory protein
and an anti-apoptotic protein and this may occur in many different cell types in the gut.
We have described an essential role for A20 in the regulation of innate and adaptive immune
cells but little is known about the role of A20 in intestinal epithelial cells (IEC). Further,
although NF-kB activation and TNF levels are increased in the mucosa IBD patients, the
expression and regulation of A20 in human intestinal epithelial cells has not been investigated.
We therefore examined the potential role of A20 in the regulation of mouse IEC and in
IECs freshly isolated from normal and IBD patients. Wild-type (WT) and A20-/- mice were
treated with LPS or TNF and examined for acute effects on the intestinal epithelium. LPS
or TNF treatment induced dramatic sloughing of the IEC from A20-/- mice within two
hours of administration In Vivo. This demonstrates an important role for A20 in maintenance
of the intestinal epithelium, but it is not known whether this reflects a direct role for A20
in the IEC themselves, an indirect effect of the essential role of A20 in the immune system
or a combination of both. We therefore examined the regulation of A20 in cultured mouse
or human IEC lines. A20 expression was found in all IEC lines tested, including YAMC,
HCT116, HT29 and Caco2 cells, and the expression of A20 was rapidly and dramatically
induced by TNF treatment. A20 expression was also detected in human IEC isolated from
normal and IBD patient biopsy specimens. In IEC lines, the induction of A20 by TNF
treatment was inhibited by pretreatment of the IEC with interferon-gamma (IFNg). This
effect on A20 expression may contribute to the capacity of IFNg to facilitate TNF-induced
apoptosis in IEC. Together these studies demonstrate that the ubiquitin-modifying enzyme
A20 is important for the maintenance of the intestinal epithelium and that A20 may have
a direct role within IEC to regulate NF-kB activation and apoptosis and to preserve intest-
inal homeostasis.
W1484
Purinergic Signaling Impacts Experimental Inflammatory Bowel Disease (IBD)
Beat M. Kunzli, Gregory Moore, Pascal O. Berberat, Yousif I. A-rahim, Eva Csizmadia,
Keichi Enjyoji, Tony D'apice, Simon C. Robson
Background: Crohn's disease (CD) and ulcerative colitis (UC) are characterized by intestinal
and vascular inflammation. Extracellular nucleotides are released from injured tissues and
bind specific purinergic-type 2 receptors tomodulate inflammation and immunity. Ectonucle-
otidases, such as CD39/NTPDase1, hydrolyze extracellular nucleotides to regulate purinergic
signaling. The role of CD39 in modulating inflammatory bowel disease (IBD) is poorly
understood. Aims: We have investigated CD39 expression in human CD and UC biopsies
and in parallel examined the development of IBD in experimental models of CD and UC
in CD39-null and wild type (wt) mice. Methods: Biopsies from patients' colons involved by
CD (n=8) and UC (n=9) were obtained for analysis. In CD39-null and -wt mice, IBS was
induced using two Th1-type colitis models (3% Dextran Sodium Sulfate (DSS) in drinking
water for 7 days or trinitrobenzene sulfonic acid (TNBS, 125mg/kg) intrarectally). IBD was
induced in the same type of mice using the oxazolone Th2-type colitis model (1.5% oxazolone
in 50% EtOH). Bowel morphology, clinical parameters, cytokine expression in plasma,
mRNA and protein analyses and immunohistochemistry were performed. Flow cytometric
analyses of lamina propria mononuclear cells was done to determine phenotype of colonic
inflammatory infiltrates. Results: CD39 was significantly increased in human colonic biopsies
in CD and UC at RNA and protein levels. In mice, marked weight loss, elevated disease
activity indices (DAI) were noted in DSS colitis in CD39-null mice (p<0.05). In contrast,
TNBS colitis was characterized by improved survival of and minimal weight loss in CD39-
null mice, as compared to wt (p<0.05). Histologically, colonic tissues from CD39-null mice
subjected to TNBS colitis exhibited minimal ulcerations when compared to wt mice. Lamina
propria mononuclear cells from wt mice undergoing TNBS colitis had significantly increased
amounts of T cells (CD3+) and macrophages (CD11b+) that were not seen in CD39-null
mice (p<0.05). Higher levels of serum IL-6 were noted in the TNBS model in CD39-null
mice (p<0.05). In the oxazolone model, CD39-null and wt mice responded in comparable
manners. Conclusions: Deletion of CD39 exacerbated DSS colitis in mice. In contrast, the
hapten dependent TNBS model resulted in minimal disease in CD39-null mice. Oxazolone-
induced colitis was not altered by CD39 deletion. The markedly different outcomes of
these models of colitis in CD39-null mice suggest highly complex modulation of colonic
inflammatory disease by multiple-mediated purinergic pathways.
W1485
IL-19 and IL-22 Signal Through the IL-10 Receptor 1 and Its Variant S138g
Sabine Gruber, Maria gloria Luciani, Paul Grundtner, Christoph Gasche
A family of IL -10-related cytokines has been recently identified; these include IL-19, IL-
20, IL-22, IL-24, and IL-26. The predicted helical structure of these homodimeric molecules
is conserved. Some of the receptor subunits are shared, but the extent of cross-reactivity
has not been entirely defined. Inhere, we tested for biological interaction of human IL -10
homolog cytokines with the IL -10R1 wildtype and the S138G variant (Gasche, J Immunol
2003). This is specifically important for our understanding of mucosal homeostasis as
intestinal epithelial cells express IL-10 receptors and as the S138G variant prevents from
ulcerative colitis. METHODS: Recombinant cytokines (IL -10, IL-19, IL-20, IL-22, IL -24,
and IL-26) were cloned into pCEP4 and transiently expressed in HeLa. Supernatants were
collected, concentrated with Macrosep centrifugal devices (Pall Inc.) and stored at -70C.
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The cDNAs of IL-10R1 wildtype and S138G were cloned into pIRESpuro3 and stably
expressed in HeLa cells. Single cell clones were treated with various concentrations of
cytokine supernatants or supernatant from mock-transfected cells for 30 min at 37°C, cells
were harvested and STAT3 phosphorylation at Y705 was analyzed by western blotting. To
ensure receptor specificity, clones were pre-incubated with a neutralizing anti-IL-10R1
antibody (100 ug/mL, R&D) prior to exposure to cytokines. RESULTS: STAT3 phosphoryl-
ation was observed with IL -10, IL-19, IL-22 and somewhat weaker also IL-20, but not
with IL -24, IL-26 or mock supernatant (fig). The receptor specificity was confirmed for
IL-19 and IL22 by neutralizing STAT3 phosphorylation with anti-IL-10R1 antibody. In
clones carrying IL -10R1-S138G, moderate STAT3 activation was detected with IL-10, IL-
19 and IL-22. CONCLUSION: Both the IL -10R1 wildtype and the S138G variant receptor
can be activated by the IL-10 homolog cytokines IL -19 and IL-22. Our finding suggests
that these cytokines may either compete with IL -10 for its receptors or activate cells that
carry IL -10R1 in the absence of IL -10 or in the absence of their specific receptors (i.e. IL-
20R1, IL -22R). Our observations add to the complexity of interactions of IL -10 homologs
with the cytokine receptor family type 2 and help understanding the impact of these cytokines
in mucosal homeostasis and IBD.
W1486
Lamina Propria Mononuclear Cell P2x7 Receptor As An Anti-Inflammatory
Target in IBD
Diane J. Stevenson, Keith Bowers, Mandy Lawson, Christopher J. Hawkey
Introduction The extracellular purine receptor P2X7 is a membrane ion channel known to
be expressed in peripheral blood lymphocytes and monocytes. Activation is characterised
by fast influx of sodium and calcium, plasmamembrane de-polarisation and (frommonocytes)
processing and release of interleukin-1 (IL-1)β, probably by a vesicular mechanism charac-
terised by reversible eversion of cell membrane phosphatidylserine. Aims We investigated
whether human lamina propria mononuclear cells (LPMCs) expressed a functionally active
P2X7 receptor, its changes in inflammation and its role in IL-1β release. Methods LPMCs were
isolated from resected human colonic mucosa maintained in culture after de-epithelialisation.
Uptake of ethidium bromide was used to show functional receptor expression and the
potency relationship between ATP and benzyl ATP stimulation to establish specificity as
P2X7. Annexin V binding was used as evidence of phosphatidylserine eversion, measured
using flow cytometry. Results ATP and benzyl ATP cause dose dependant increases in
ethidium bromide uptake, IL-1β release and annexin V binding, consistent with P2X7
mediated vesicular secretions of IL-1β from lamina propria macrophages. For all phenomena,
benzyl ATP was approximately one order magnitude more potent than ATP, compatible
with a specific P2X7 mediated effect. Basal and stimulated IL-1β release from LPMCs and
spontaneous release from colonic mucosa in organ culture increased progressively with
increasing mucosal inflammation (LPMCs, basal release: 65 ± 25 pg/106 cells uninflamed
vs 157 ± 65 pg/106 cells inflamed, stimulated release: 562 ± 222 pg/106 cells uninflamed
vs 2311 ± 1254 pg/106 cells inflamed; organ culture: 3.6 ± 0.8 pg per mg uninflamed vs
18 ± 7.3 vs inflamed). In both LPMCs and organ culture the P2X7 antagonist oxidised ATP
reduced release by up to 95% in a dose dependant way. Conclusions The P2X7 receptor
is expressed and functionally active in LPMCswhere it may play a central role in the processing
and release of IL-1β. It appears to be a valid anti-inflammatory target in inflammatory bowel
disease.
W1487
TNF Regulation By the Functional Interplay Between Tristetraprolin, P38 MAP
Kinase, and Polya Binding Protein
Mark T. Worthington, Robert M. Rowlett, Mary Harp, Carol A. Chrestensen, Thomas W.
Sturgill
Tumor necrosis factor (TNF) is pathogenic in inflammatory bowel diseases and alcoholic
hepatitis. TNF production is predominately regulated by mRNA stability and translation
through proteins that act on the AU-rich element (ARE) of the TNF mRNA 3'-untranslated
region (3'-UTR). One of the most potent regulators of TNF mRNA stability is the ARE-
binding protein tristetraprolin (TTP), which we found to select for the UUAUUUAUU TNF
ARE repeat by SELEX. TTP is a target for both p38 MAPK and downstream MK2 kinases.
p38 is required for TNF production and antagonizes the TNF ARE through phosphorylation
of ARE regulatory proteins by p38 and MK2.We found that PABP1 blocks TTP deadenylation
in a cell-free system, but it is unknown whether PABP1 affects macrophage TNF production.
We created stable GFP-PABP and GFP RAW264.7 cells using published reagents. LPS
activation revealed no significant differential increase in TNF production, but led to apparent
counter-regulatory increases in TTP protein production and TTP half-life in response to LPS
stimulation in the PABP cells. TTP was not expressed in unstimulated GFP or GFP-PABP
cells, like the parent cell line. Cycloheximide inhibition of protein synthesis by Western
blotting reveals that PABP inhibits TTP degradation, and also inhibits the ability of p38 to
shorten TTP half-life. Using recombinant proteins, PABP inhibits TTP deadenylation, which
maps to a portion of the PABP molecule lacking the polyA binding domains, suggesting
more complex regulation than simple competition at the polyA tail. PABP inhibits TTP
action on the TNF 3'-UTR and also prolongs TTP half-life, but does so without increasing
macrophage TNF production. TTP binding to TNF mRNA is constitutive in macrophages.
TTP and PABP are both known to travel with TNF to polysomes in macrophages, where
active translation occurs. Taken together, these findings suggest that the RNA decay function
of TTP is masked by PABP during ribosomal transit and that the previously described
translational regulation inmacrophages is dominant over factors that increase mRNA stability.
Our conclusion is that the role of PABP is to stabilize the TNF mRNA, (which also stabilizes
mRNA-bound TTP), but requires additional regulatory events for increased TNF translation.
When unmasked by progressive loss of the polyA tail and therefore RNA-bound PABP, we
predict that the role of the previously latent RNA-bound TTP is to flag the TNF mRNA for
immediate degradation. Drugs that impair the ability of PABP to block TTP function may
provide new pharmacologic approaches to silence TNF.
W1488
Functional Modulation of Crohn's Disease Myofibroblasts By Anti-TNF
Antibodies
Antonio Di sabatino, Sylvia L. Pender, Claire L. Jackson, John N. Gordon, Lucia
Picariello, Giovanni Monteleone, Francesco Tonelli, Gino R. Corazza, Thomas T.
Macdonald
Background & Aims: Infliximab induces immune cell apoptosis by outside-to-inside signal-
ling through transmembrane tumor necrosis factor (TNF)-α (mTNF). However, in inflamed
gut, myofibroblasts also produce TNF-α, and the effects of anti-TNF-α on these structural
cells has not been studied. We therefore investigated the action of infliximab on apoptosis,
matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP)-1 produc-
tion, and migration of Crohn's disease (CD) myofibroblasts. Methods: Colonic myofibroblasts
were isolated from patients with active CD and controls. mTNF was evaluated by Western
blotting and flow cytometry. Infliximab-treated myofibroblasts were analysed for apoptosis
by Annexin V staining and caspase-3. TIMP-1 and MMPs were measured byWestern blotting,
and fibroblast migration was assessed using In Vitro wound-healing assay. Results: CD
myofibroblasts showed higher mTNF expression than control myofibroblasts. Infliximab
had no effect on CD myofibroblast apoptosis, caspase-3 activation and production of MMP-
3 and MMP-12. However, infliximab induced a significant dose-dependent increase in TIMP-
1 production, which was inhibited by the p38 mitogen-activated protein kinase inhibitor
SB 203580. The anti-TNF-α antibodies adalimumab, certolizumab pegol, onercept and
etanercept also increased TIMP-1 production. Migration of CD myofibroblasts was signific-
antly enhanced by infliximab and recombinant human TIMP-1, and infliximab also decreased
collagen production. Conclusions: Our findings show a novel therapeutic pathway for anti-
TNF-α therapies in enhancing TIMP-1 production and myofibroblast migration which may
reduce MMP activity, and facilitating the wound healing.
W1489
Induction of IL-13 Triggers TGF-Beta1-Dependent Tissue Fibrosis Via Egr-1 in
Recurrent TNBS-Colitis
Stefan Fichtner-feigl, Atsushi Kitani, Hans-jürgen Schlitt, Warren Strober
One major long-term complication of inflammatory bowel disease, especially Crohns Disease,
is the development of intestinal fibrosis. To investigate the immunopathogenesis of inflamma-
tion-associated fibrosis we analyzed the recurrent colitis and late-developing fibrosis occurring
in BALB/c mice administered weekly doses of intra-rectal trinitrobenzene sulfonic acid
(TNBS). We showed first that in this model an initial Th1 response involving IL-12p70 and
IFN-gamma subsides after three weeks only to evolve into a IL-23/IL-25 response beginning
after 4-5 weeks. This evolution is followed by gradually increasing production of IL-17 and
cytokines ordinarily seen in a Th2 response, particularly IL-13, that reaches a plateau at 8-
9 weeks. In Vitro stimulation studies suggest that this IL-13 production is dependent on
IL-23 and IL-25, but not on IL-12p70. We then show that IL-13 production results in the
induction of a novel IL-13 receptor formerly thought to function only as a decoy receptor,
IL-13receptor-alpha2, and this receptor is critical to the production of TGF-beta1 and the
onset of fibrosis. Thus, if IL-13 signaling through this receptor is blocked by administration
of soluble IL-13receptor-alpha2-Fc, or by administration of IL-13receptor-alpha2-specific
siRNA, TGF-beta1 is not produced and fibrosis does not occur. Moreover, in this disease
TGF-beta1 induced EGR-1 (early growth response gene 1) expression is essential for the
apoptosis of alpha-sma (smooth muscle actin) positive myofibroblasts in the course of
intestinal fibrogenesis. These studies show that in recurrent TNBS colitis, fibrosis is dependent
on the development of an IL-13 response that acts through a novel cell-surface-expressed
IL-13 receptor to induce TGF-beta1 and subsequent apoptosis. A similar mechanism may
obtain in certain forms of human IBD.
W1490
Interleukin-11 Antagonizes Fas-Mediated Apoptosis At the Level of Caspase 9
Activation in IEC-18 Cells in An Mek1,2-Dependent Manner
Mark J. Ropeleski, Kaitlin M. Naugler, Kathy A. Baer
Interleukin-11 (IL-11) is a mesenchyme-derived anti-inflammatory cytokine whose reported
cytoprotective effects span diverse models of intestinal injury. While its anti-apoptotic effects
on intestinal epithelia have been described, mechanisms remain unclear. Fas/CD95 death
receptor signaling is up-regulated in Ulcerative Colitis, which likely contributes to the
epithelial damage characteristic of this condition. We hypothesized that IL-11 inhibits Fas
Ligand (FasL)-mediated apoptosis in intestinal epithelia. Apoptosis was monitored in IEC-
18 cells by microscopy, caspase and PARP cleavage, mitochondrial release of cytochrome c
and the abundance of cytoplasmic oligonucleosomal DNA by ELISA. RT-PCR was used to
monitor Fas, cIAP1, cIAP2, and XIAP, cFLIP, and survivin and Bcl2 family members while
Fas expression in membrane fractions was monitored by immunoblot. Inhibitors of JAK2,
PI3-Kinase, MEK 1/2 and p38 MAPK were used to determine the mechanism IL-11's anti-
apoptotic effect. No IL-11 induced changes in Fas mRNA or membrane expression were
observed. Pre-treatment of IEC-18 cells with IL-11 (100ng/ml) for 2 to 24 hours prior to
FasL (4ng/ml) reduced cytoplasmic oligonucleosomal DNA accumulation by 92.7% (+/-
7.2% SEM; n=3) at 24 hours. IL-11 also attenuated FasL-mediated caspase-3, 9 and PARP
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cleavage while no IL-11-dependent differences in activated caspase 8 p20 or cytochrome c
release were observed. IL-11 did not affect cFLIP, survivin, cIAP1, 2, XIAP or BclXL by RT-
PCR. The MEK 1/2 inhibitor U0126 (10uM) reversed protective effects of IL-11 on caspase
3 and 9 cleavage. We propose that IL-11-dependent MEK 1,2 signaling leads to caspase 9
phosphorylation and its inhibition thus leading to significant attenuation of FasL-induced
apoptosis in IEC-18 cells. This may represent a common mechanism of IL-11's cytoprotective
effects in various pathophysiological settings which involve intrinsic apoptotic pathway
activation. (Supported by the Crohn's and Colitis Foundation of Canada and CIHR through
the GIDRU GI Training Grant)
W1491
Intact Tnfr Signaling Is Necessary for Colon Epithelial Repair Following
Injury
Ilana S. Fortgang, Kay Washington, Tatsuki Koyama, D. brent Polk
Background & Aims: Tumor necrosis factor (TNF) is a pro-inflammatory cytokine active in
the pathogenesis of gastrointestinal disorders including inflammatory bowel disease (IBD).
TNF activates two discrete receptors with opposing results—R1 governing apoptosis, R2
determining proliferation—with implications for extent of injury and rapidity of repair.
Given the associations of IBD and TNF, we sought to determine the consequences of
differential TNFR activation on experimentally-induced colitis. Methods: Acute colitis was
induced in 6-week-old C57Bl/6 (WT) mice, TNFR1-/-, TNFR2-/-, TNFR1/R2-/- mice by
providing 3% dextran sulfate sodium (DSS) in drinking water for 4 days. Mice were sacrificed
at the end of treatment, after 3 or after 7 days of recovery. Outcome measures included
body weights and extent of hematochezia. Colonic mucosal injury and recovery were assessed
and scored in five categories to give a total histologic injury score with a possible maximum
of 15. Proliferation and apoptosis were determined by immunostaining as the number of
positive cells per 100 crypts. Results: TNFR1/R2-/- mice experienced 30% mortality over
the course of treatment in contrast to 100% survival of all other genotypes. The 3-day
recovery phase for TNFR1/R2-/- was notable for an increase in colon epithelial cell prolifera-
tion compared to WT (1600 cells/100 crypts vs 900 cells/100 crypts). Deletion of either or
both receptors demonstrated higher histologic injury scores (TNFR1-/-=9.7; TNFR2-/-=9;
TNFR1/R2-/-=9.4) thanWTmice (5.6). TNFR1/R2-/- and TNFR1-/- mice showed comparable
weight loss and hematochezia during DSS treatment, however TNFR1/R2-/- mice failed to
resume pre-treatment growth velocity in contrast to other genotypes. TNFR2-/- mice had
no growth impairment and limited hematochezia, similar toWTmice. Conclusions: Inhibition
of TNF signaling and function predispose to increased injury, and complete blockade of
TNFR activity leads to increased proliferation during recovery. These findings support the
role of TNF as an important mediator of colon epithelial cell response to injury.
W1492
Ulcerative Colitis Is a TGFβ Deficient State Induced By Intrinsic Neutralizing
Antibodies
Ellen C. Ebert, Kiron M. Das, Asit Panja
Introduction: Ulcerative colitis (UC) is an immunologically-mediated disorder that shares
features with certain murine knockout models of colitis. It is unknown whether any of these
models are physiologically relevant to the human condition. The hypothesis of this study
is that neutralizing antibodies against transforming growth factor (TGF)β create a relative
immunodeficient state that predisposes to UC. Methods: Serum samples from patients with
UC (n=161) or Crohn's disease (CD)(n=81), as well as from healthy individuals (HI) (n=
58) were studied by enzyme-linked immunoabsorbent assays (ELISAs) with cytokines coating
the microwells. Immobilized TGFβ was used to remove specific antibodies from pooled UC
sera that were then studied by Western blot assay. Anti-TGFβ IgG antibodies were tested
for neutralizing activity. Results: The presence of serum anti-TGFβ antibodies as evidenced
by the optical density (OD) readings by ELISA were significantly increased in UC compared
to healthy individuals (HI) (p<0.01). Seventeen percent of UC patients had OD values
exceeding that for all HIs. The OD values for CD, in contrast, were the same as HI. Antibodies
were more abundant in left-sided and pan-colitis than in proctitis. To further examine the
specificity, immobilized TGFβ was exposed to UC sera; The attached proteins proved to be
exclusively IgG as verified by Western blot assay. In contrast, antibodies against interferon
(IFN)γ were present in equal amounts in all patient groups (as determined by ELISA and
Western blot) and did not correlate with anti-TGFβ antibodies. This indicates that the
increase in anti-TGFβ antibodies in UC is specific rather than representing a general increase
in anti-cytokine IgG. The anti-TGFβ antibodies proved to be primarily IgG1 with similar
amounts recognizing each of the three isoforms of TGFβ. To evaluate the neutralizing activity
of these antibodies, the TGFβ-specific IgG from UC sera was incubated with TGFβ before
addition to HT-29 colon cancer cells. In a colorimetric assay, the TGFβ-induced reduction
in viable cell numbers was reversed by the TGFβ-specific IgG. Conclusion: This study shows
that UC patients have a relative TGFβ-deficient state due to an increased production of
specific neutralizing IgG1 antibodies against TGFβ. This abnormal immune response may
contribute to the pathogenesis of UC.
W1493
Protein Kinase Cα Negatively Regulates Akt Activation By Neurotensin and
Promotes Apoptosis in Colonic Epithelial Cells
You sun Kim, Hon wai Koon, Dezheng Zhao, Iordanes Karagiannides, Hua Xu, Mary P.
Moyer, Charalabos Pothoulakis
Background& Aims: Neurotensin (NT) is an important neuropeptide with diverse gastrointe-
stinal functions, such as enhancement of inflammation as well as cell proliferation. Recent
evidence indicates that NT plays a protective role in the development of chronic colitis.
Protein kinase B (Akt) mediates cell survival and growth in colonocytes. In the present
study, we investigated whether NT mediates anti-apoptotic functions in colonocytes and
examined the participation of Akt in this response. Methods: The mRNA expression of NT
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and NTR1 of the colonic tissue was measured in the colon of mice treated with trinitrobenzene
sulfonic acid (TNBS) by real-time RT-PCR. The effect of NT on the activation of Akt-
dependent pathways was evaluated in human colonic epithelial NCM460 cells overexpressing
NTR1 (NCM460-NTR1). The anti-apoptotic effect of NT in FasL-induced apoptosis was
evaluated by western blotting and TUNEL assays. Results: The NT mRNA expression of the
colonic tissue was significantly increased during the healing phase (day 7) of TNBS colitis
(p<0.05) while colonic mucosal NTR1 expression was unchanged. NT induced Akt Ser476
phosphorylation in NCM 460-NTR1 cells that was diminished by the p38 inhibitor
SB203580. Protein kinase C activation by PMA (100 nM) treatment showed significant
attenuation of NT-induced Akt phosphorylation. On the other hand, treatment of NCM
460-NTR1 cells with NT inhibited FasL-induced caspase-7 cleavage, and FasL-mediated
DNA fragmentation (measured by TUNEL assays). Moreover, co-treatment of cells with NT
and the Akt inhibitor V (40 µM) abolished the rescue effect of NT in colonocytes. Compared to
NT administration alone, co-treatment of colonocytes with NT and the PKCα pseudosubstrate
inhibitor enhanced the anti-apoptotic effects of NT against FasL-induced DNA fragmentation.
Conclusions: In colonocytes, NT activates anti-apoptotic pathways by phosphorylating Akt
via a p38-dependent mechanism, while PKCα negatively regulates this NT response. We
speculate that these NT-dependent mechanisms may be involved in the healing effects of
NT during recovery from colitis. Supported by NIH grants DK-60729 (CP), and K01
DK064920 (DZ), and by a Research Fellowship Award from CCFA (HWK).
W1494
The Effect of Human Monoclonal Antibody to IL-12/23p40 (Cnto 1275) On
Serum Levels of Inflammation-Related Proteins in Patients with Moderately to
Severely Active Crohn's Disease
Willem De villiers, Gary Toedter, Grace Liu, Marion Blank, Scott Plevy
Background: Type 1 cytokines IL-12 and IL-23 are both implicated in the pathophysiology
of Crohn's Disease (CD). The effect of CNTO 1275 treatment on serum levels of proteins
associated with inflammation and repair in CD patients was evaluated. Methods: Serum was
collected from 121 patients with moderate to severe CD despite conventional therapy (CDAI
≧220-≦450) who had been randomized to treatment with IV or SC CNTO 1275 or placebo.
Population 1 patients were randomized in a placebo-controlled study (approx. 25 patients/
group), while additional patients (Population 2) who previously failed to respond to IFX
were enrolled in an open label study. Serum collected at Weeks 0, 1, 4, and 8 was analyzed for
biomarkers using commercially available multiplex analysis (Pierce SearchLight, MesoScale
Discovery). Week 1 data following IV infusion are presented (Table 1). Results: Baseline
median serum levels of proinflammatory molecules were generally consistent across treatment
groups, and detectable levels of EGF, ENA78, FGF, IL-1ra, IL-8, IL-6, IP-10, MCP-1, MIP-
1β, MMP3, MMP-9, MPO, TIMP-1, VEGF, and TNFα were measured in 90 to 100% of
serum samples. Notable decreases in serum levels of IP-10, MCP-1, MMP-9, TNFα, EGF,
ENA-78, MPO, MIP-1β, and VEGF (median percent change from baseline) at Wk 1 were
observed in Population 1 following a single CNTO1275 IV infusion relative to placebo. IL-
12p40 levels increased in CNTO1275 treated patients, consistent with biologically inactive
IL-12p40 bound to CNTO 1275. At Wks 4 and 8, the median percent change from baseline
in serum levels of IP-10, TNFα, MMP-3, IL-6, and ENA-78 continued to distinguish CNTO
1275 IV-treated patients from placebo. Conclusion: Short-term treatment with CNTO 1275
modulated inflammation and repair related serum proteins in patients with moderate to
severe CD. Several of these proteins may serve as novel biomarkers of clinical response, and
future analyses will correlate these levels with CDAI and pharmacokinetics of CNTO 1275.
Table 1. Percent change from baseline for selected markers at Wk 1
W1495
Enhanced Expression of Noncanonical Wnt 5a in the Colonic Mucosa of
Patients with Ulcerative Colitis
Andrea Buda, Renata D'inca', Sandra Voltan, Daniela Pizzuti, Davide Checchin, Alessandra
Garribba, Massimo Pignatelli, Giacomo carlo Sturniolo
Background. Ulcerative colitis (UC) is a chronic inflammatory disease characterized by cycles
of inflammation and ulceration of colonic mucosa. Active colitis is accompanied by an
increased cell proliferation. Recruitment and activation of monocytes/macrophages play a
major role in mediating chronic inflammation. Besides being essential for cell-fate determina-
tion, Wnt signalling components also influence cell proliferation, differentiation and migra-
tion of intestinal epithelial cells. Since little is known about the Wnt signalling cascade in
UC, we examined the expression and localization of Wnt signalling components in mild to
moderate active and inactive colonic mucosa from UC patients. Material and Methods. After
obtaining informed consent, biopsies were taken at routine diagnostic colonoscopies from
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10 patients with UC and from 5 healthy controls. Biopsies were taken from involved and
uninvolved UC areas. Expression of Wnt-1 and -5a and the transmembrane receptors frizzled
(fz) -1/2 and 5 were evaluated by immunohistochemistry and immunofluorescence on
paraffin-embedded and frozen sections respectively. mRNA expression was measured by
quantitative RT-PCR. Beta catenin expression and subcellular localization was assessed by
immunohistochemistry. Results. Wnt-5a and fz-5 expression was upregulated in UC patients
compared to controls. When paired specimens of inflamed and noninflamed UC mucosa
were analyzed, a significantly (P < 0.01) increased Wnt-5a and fz-5 was detected in the
inflamed segments, whereas no differences were found between uninvolved segment and
mucosa from controls. Wnt5a was expressed both in epithelial and stromal cells. No signific-
ant difference in Wnt-1 expression was found between UC and normal mucosa samples.
Little or no apparent Fz 1/2 expression was detected in both active and non active UC
specimens and in controls. Although beta catenin surface luminal expression of inflamed
mucosa was reduced, membranous beta catenin expression was detected in both active and
inactive disease, with a staining pattern similar to normal colonic mucosa. Conclusion.
Upregulation of Wnt-5a and its receptor fz-5 suggests the involvement of the noncanonical
beta catenin-independent Wnt signalling pathway in cell renewal and tissue regeneration
during chronic inflammation in ulcerative colitis.
W1496
Chemerin and Its Receptor, Chemr23 - Implicated in Ulcerative Colitis (UC)?
Tim J. Brown, Clare L. Price, Hafid omar Al-hassi, Carolynne J. Vaizey, Michael A. Kamm,
Andrew J. Stagg, Stella C. Knight
Background and aims. ChemR23 (also known as human chemokine like receptor-1 CMKLR1)
is a G-protein coupled receptor believed to be expressed on professional antigen presenting
cells including immature plasmacytoid (CD11c-, CD123+) dendritic cells (DC) and macro-
phages although reports of expression vary. DC, at the interface between innate and adaptive
immune response, sample immunogenic molecules and stimulate pro-inflammatory or anti-
inflammatory responses. Chemerin, a molecule highly specific for the receptor ChemR23
may act as an attractant at early stages in immune responses, bringing DC to sites of potential
damage. We sought to explore the hypothesis that this system is involved in gut lesions in
inflammatory bowel disease and developed systems for studying these molecules. Methods
DC were identified in freshly isolated blood mononuclear cells from normal individuals (n=
12) by multi-colour flow cytometry (as HLA-DR+ lin-/dim cells where lin is a mixture of
antibodies to CD3, 14, 16, 19 and 34). The proportion and number, determined with
reference to FlowCount beads, of CD11c+ myeloid DC and CD11c- putative plasmacytoid
DC that stained for ChemR23, were measured. Staining was confirmed by fluorescence
microscopy. Initial studies on UC samples (n=3) were also undertaken. Control sections
from colon specimens were stained for chemerin using fluorescent antibodies to identify
whether this molecule was expressed at that site Results. We showed an abundance of cell
surface expression of ChemR23 in freshly isolated HLA-DR+ monocytes and in CD11C- DC
and CD11c+DC. However, different ChemR23 antibodies gave very variable levels of staining,
and on culture of cells for 2-24 hrs expression increased and then decreased again providing an
explanation for variability of staining levels previously reported. Using carefully standardised
conditions we showed that in 3 individuals with ulcerative colitis the expression of ChemR23
was significantly lower than that on DC from parallel control samples. Staining of sections
from the human colon using fluorescently labelled antibody showed that chemerin was
expressed both in the lamina propria and particularly immediately below the epithelium.
Conclusions. ChemR23 is expressed on both monocytes and transiently on maturing myeloid
and plasmacytoid DC. Early indications are that there is less expression in blood antigen
presenting cells in UC. Taken together with the expression of chemerin, which may act as
an attractant for ChemR23-bearing cells, in the gut these findings suggest that DC could
be migrating to inflamed gut in response to the formation of chemerin.
W1497
Distinct Th1/Th2/Th17 Profiles Identified in Gene and Cytokine Expression
Signatures from Patients with Inflammatory Bowel Disease
Philip Alex, Mark B. Frank, Christopher Sutton, Craig Cadwell, Igor Dozomorov, Sean
Turner, Vera Levy, Philip B. Miner, Xuhang Li, Michael Centola
<p align=”justify”>The clinical heterogeneity of IBD, its multifactorial etiopathogenesis and
chronic progressive nature has made it imperative to procure a further understanding of
the distinct immunopathogenic mechanisms of UC and CD. Peripheral blood, affected &
unaffected colonic biopsies was obtained after informed consent from 17 patients with active
IBD (9 CD & 8 UC) by clinical, laboratorial, and pathologic criteria. Peripheral blood was
also obtained from 17 age/sex matched healthy controls. Neutrophils (anti-CD15 immunom-
agnetic extraction) and PBMCs (Ficoll density gradient extraction) were isolated, and total
RNA extracted was purified & analyzed by capillary gel electrophoresis. Cy-labeled cDNA
generated was hybridized to microarrays (probes for 21,329 genes) and fluorescent intensities
were quantified, followed by a 2-step normalization procedure. Approximately 9500 genes
for each sample were expressed 3SD above the background. Associative analysis with jack-
knife-based reproducibility revealed 96 genes differentially expressed in IBD patients relative
to normal controls. These genes include novel biomarkers, proliferative, oncogenic genes,
& noteworthy genes of autoimmunity and infection. Quantitative PCR confirmed gene
expression results for 5 selected genes with significant differential expression. Categorically,
14% of the differentially expressed genes corresponded to key regulatory Th1, Th2 and
Th17 pathways, including those of IL-5, IL-6, IL-10, IL-12, IL-17, TNF, and IFNγ. Partial
correlational coefficients and Pathway Assist were used for gene networking, which revealed
the differential modulation of the IL23/IL17, IL12/IFNγ, & The IL4/IL5 axis in IBD. Interest-
ingly, novel unique distinct patterns of Th1/Th2/Th17 with differential expression were
observed in UC relative to CD & relative to that of controls. Biometric sandwich ELISA's
confirmed these findings on 5 serum cytokines. Of the differential genes, 10 were selected
by a high stringency 'discriminant function analysis' (DFA) as having the highest power for
class discrimination between patients and controls. More intriguingly, on a 3D plot of DFA
root values, UC and CD patients & controls were grouped into 3 distinct positions, suggesting
that this is also directly proportional to intergroup gene expression variation and intragroup
heterogeneity in overall disease pathology. Multivariate analyses of gene expression and
cytokine profiles in IBD have identified novel functionally distinct Th1/Th2/Th17 regulatory
interconnections with a dynamic representation of UC and CD disease pathogenesis and
have further provided a new understanding of the Th paradigm in IBD.
W1498
Expression of Nociceptin/Orphanin Fq and Nociceptin Receptor in the
Patients with Inflammatory Bowel Diseases
Shingo Kato, Masataka Ito, Kyoko Takeuchi, Junko Imaki, Kazuro Itoh, Soichiro Miura,
Koji Yakabi
Backgrounds & Aims: Patients with inflammatory bowel diseases(IBDs), especially ulcerative
colitis, often relapse and exacerbate after physical and psychological stresses. Nociceptin/
orphanin FQ (Noc/oFQ), internal opioid-like peptide, is reported to be a trigger of pain
and relate to allodynia in the neurogenic inflammation. We previously reported that the
amelioration of DSS-induced colitis in Noc/oFQ receptor knockout mouse (Kato S et al. J
Neuroimmunol. 2005,161:21-8). However, whether Noc/oFQplays a role in the pathogenesis
of human IBDs remains unknown. The aim of this study was to investigate the expression
of Noc/oFQ and opioid receptor-like 1 (ORL1) in human IBDs by real time-PCR and
immunohistochemistry. Materials & Methods: Real-time PCR; Endoscopic biopsy specimens
were obtained from ulcerative colitis (UC) (n=18), Crohn's diseases (CD) patients (n=17)
and normal subjects (n=6) with informed consents. RNA was extracted using RNeasy Mini
Kit (Qiagen). First-strand cDNA was synthesized from 1.5 maicrogram of total RNA. Prepro-
nociceptin and TNF mRNA expression against human 18S ribosomal RNA was examined
by real-time PCR method . Immunohistochemistry; ORL-1-immunoreactivity was examined
against operated specimens from three UC patients, four CD patients and three colon cancer
patients as normal controls. Double immunostainings were examined using primary antibody
against KOR-3 (ORL-1) combined with antibodies against CD45RO (UCHL-1), CD20 (L26)
and myeloperoxidase, respectively. Both FITC-labeled anti-goat antibody and rhodamine-
labeled anti-mouse antibody were used as secondary antibodies. Data was shown as mean
± standard error. Non-parametrical statistical analysis was performed by Kruskal-Wallis test
and Scheffe F test. Results: Prepronociceptin mRNA expression of active UC patients was
significantly larger than those of inactive UC patients and normal controls (513 ± 198, 80.2
± 31.0 and 14.6 ± 4.00, respectively. P<0.01), as well as TNF mRNA expression of active
UC patients was larger than that of inactive UC patients (5.08 ± 1.88, 1.58 ± 0.38).
Prepronociceptin mRNA expression of active CD patients was larger than that of inactive
CD patients (167 ± 96.2, 86.1 ± 28.6). The increase of ORL-1-immunoreactivity was
recognized in infiltrating cells containing T-cell, B-cell and neutrophils, as well as in vessels
in inflamed mucosa. Conclusions: These results suggest that Noc/oFQ might play a role
in inflammation by increase of migration of inflammatory cells via ORL1 , especially in
ulcerative colitis.
W1499
Influence of Sphingomyelinases On the Expression of Matrix
Metalloproteinase-1 in Intestinal Epithelial Cells
Jessica Bauer, Christian Huy, Julia Brenmoehl, Juergen Schoelmerich, Gerhard Rogler,
Florian Obermeier, Juergen Bock
Background: Many signaling molecules associated with inflammatory bowel disease (IBD)
like TNF, IL-1β and IFN-γ are also known to activate sphingomyelinases (SMases) with
consecutive formation of ceramide. Expression of some matrix metalloproteinases (MMPs)
seems to be associated with ceramide metabolism. MMPs have gained increasing attention
in the pathogenesis of IBD, especially for development of fistula and ulceration. We therefore
aimed to define the role of SMase for the expression of MMPs. Methods: Affymetrix gene
array analysis of Caco-2 epithelial cells after stimulation with exogenous SMase was per-
formed. Protein expression of MMP-1 was verified by ELISA or Western Blot. To elucidate
the role of acid sphingomyelinase (ASM), human fibroblasts with a genetic deficiency for
ASM were compared with control fibroblasts after stimulation with IL-1β, TNF, IFN-γ or
exogenous SMase. Fibroblasts from IBD patients with Crohn's disease, ulcerative colitis,
fistula or stenosis were used to evaluate the effects of IL-1β or exogenous SMase on MMP-
1 expression. Results: Gene array analysis revealed a more than 15-fold increase of RNA-
expression of MMP-1 in Caco-2 cells upon stimulation with exogenous SMase. Protein
expression of MMP-1 in the supernatant of Caco-2 cells was increased more than 3-fold by
exogenous SMase used at concentrations as low as 0.01 U/ml. ASM deficient fibroblasts
showed less increase of MMP-1 expression (1.4-fold +/- 0.4) upon stimulation with IL-1β
(1ng/ml) when compared to control fibroblasts (3.1-fold +/-1.4, p<0.05). Conclusions:
Exogenous SMase strongly induced the expression of MMP-1 in Caco-2 epithelial cells. IL-
1β induced expression of MMP-1 in fibroblasts seems to be ASM-dependent. Inhibition of
sphingomyelinases may therefore be a possible strategy to reduce expression of MMP-1.
W1500
Interleukin-1β Transcription Is Not Influenced By Infliximab
Ole haagen Nielsen, Laura Ferrero-miliani, Joergen Olsen
Background: NOD2 is an intracellular receptor activated by muramyl dipeptide (MDP) which
is the minimal bioactive peptidoglycan component common to all bacteria; wild type NOD2
induces NF-κB. NOD2 has been linked to Crohn's disease (CD); however, the role of NOD2
mutants in relation to CD is still unclear. CD is characterized by elevated levels of NF-κB
targets, including the proinflammatory cytokine interleukin (IL)-1β; which is controlled
both at transcriptional and posttranslational level; as it requires to be cleaved from its 31kDa
pro-form into the mature 17kDa form by caspase-1. Caspase-1 itself needs to be activated
by the mutiprotein complexes termed 'inflammasomes'. The inflammasome most thoroughly
described is the NALP3 inflammasome, which consists of NALP3, CARD8, ASC and two
caspase-1 molecules. It is activated by RNA, bacterial toxins and uric acid crystals; but it
has also been suggested that is activated by MDP; which could imply some sort of functional
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connection between NOD2 and NALP3. CD is in many cases effectively treated with the
anti-TNF-α antibody infliximab, which has been known to downregulate cytokine produc-
tion. Aims: To study the transcriptional response of IL-1β, TNF-α, NALP-3 and caspase-1
inmonocytes of healthy subjects to stimulation with MDP and after treatment with infliximab.
Methods: Monocytes were isolated from blood of healthy subjects (n=12), using the MACS
monocyte isolation technique. Cells were grown overnight in serum supplemented RPMI
media. Subsequently media was changed to Optimem I and combinations of MDP 5µg/mL
and infliximab 10µg/mL. The cells were harvested at time 0, 1, 4, 6 and 24 h. RNA and
protein was extracted using NucleoSpin® RNA/Protein. RNA was quantitated by real-time
RT-PCR. Results: All targets showed an increased response to MDP stimulation at all times;
The response was maximal at 1 h for TNF-α and 4h for both IL-1β, caspase-1 and NALP3.
IL-1β and TNF-α showed the strongest response with an 8 and a 6 fold upregulation,
respectively. Infliximab inhibited the upregulation of caspase-1, NALP3 and TNF-α in
response to MDP; but did not affect the upregulation of IL-1β in response to MDP. Conclu-
sions: These results indicate that MDP is able to induce upregulation of NALP3, caspase-1
and TNF-α via a regulatory loop involving TNF-α itself. In contrast MDP increases IL-1β
transcription via a TNF-α independent pathway. These data also suggest that infliximab
exerts its effects over IL-1β by regulating other molecules (i.e. caspase-1, NALP3) that
participate in the posttranslational control of this cytokine.
W1501
Nicotine Regulates the Immune Response of Human Lamina Propria T-
Cells(Lpt)
Kikuchi Hidezumi, Jugoh Itoh, Shinsaku Fukuda, Akihiro Munakata
PURPOSE: The etiology of inflammatory bowel disease (IBD) has not been clarified yet.
However, it is assumed that immune imbalance is related to pathogenic physiology of IBD.
In previous epidemiologic study, cigarette smoking resulted in a protective influence on the
course of ulcerative colitis (UC). In addition, an administration of the nicotine to patients
with UC reduced symptoms of the colitis. We have reported that nicotine corrected the
imbalance of the cytokine production in oxazolone-induced colitis, experimental model of
UC, to improve the colitis. In this study, we have investigated the effect of nicotine on
human lamina propria T cells (LPT), to elucidate the mechanisms of action of nicotine in
UC. METHOD: Lamina propria mononuclear cells (LPMC) were isolated from normal colonic
specimen. LPT were further purified by the magnetic isolation. The expressions of nicotinic
acetylcholine receptor (nAChR) subunits in LPT were investigated by RT-PCR. Next, stimu-
lated LPMC were co-cultured with IL-2 and various concentration of nicotine (0M, 10-9M,
10-7M, 10-5M) for nine days. Then, the productions of IFN-γ and IL-4 after stimulation
with PMA and ionomycin were evaluated by ELISA. RESULT: The mRNA of α7 nAChR
was universally expressed, while α2, α3, α5 and β1 nAChR were differently expressed in
each individual. Nicotine affected the productions of both IFN-γ and IL-4 with greater extent
in IL-4 production. In the IFN-γ/IL-4 production ratio, nicotine skewed the immune balance
towards Th1-predominant pattern in low concentration (10-9M), and towards that of Th2
in middle to high concentrations (10-7M, 10-5M). CONCLUTION: It has been reported
that nicotine affects macrophage through α7 nAChR to reduce the inflammation, termed
cholinergic anti-inflammatory pathway. We revealed that LPT have also universally express
α7 nAChR, and nicotine may regulate their immune response through α7 nAChR. The
immuno-regulatory effect of nicotine on T cells might explain the therapeutic effect of
nicotine on UC.
W1502
Butein Blocks Tumor Necrosis Factor(TNF)α-Induced Interleukin 8 and
Matrix Metalloproteinase 7 Production By Inhibiting P38 Kinase and
Osteopontin-Induced Pathways in HT-29 Cells
Geom seog Seo, Sung hee Lee, Suck chei Choi, Young sung Kim, Yong ho Nah, Sang
wook Kim, Dong hwan Sohn
Background: Dysregulation of interleukin 8 (IL-8) plays a key role in the pathogenesis of
inflammatory bowel diseases(IBDs). Hence, agents that control the secretion of IL-8 are
important to maintain a normal intestinal steady state. In addition, matrix metalloproteinases
(MMPs) are the predominant proteinases in the gut mucosa during active IBD and they are
thought to play an important role in the tissue remodeling and ulceration associated with
the disease. Therefore, specific inhibition of MMP gene expression by pharmacological
modulation may represent a novel target of therapeutic intervention for IBD. We have shown
previously that butein has anti-inflammatory properties in RAW 264.7 cells. In this study,
we evaluated whether butein has anti-inflammatory properties in HT-29 human intestinal
epithelial cells. Methods: Expression of IL-8 and MMP-7 were assessed by measuring mRNA
and secreted protein levels. To investigate whether the transcription factor NF-κB is an
important target for the action of butein, we performed an electrophoretic mobility shift assay.
Results: Butein significantly inhibited TNFα-induced IL-8 secretion and mRNA expression.
Moreover, butein suppressed the expression of MMP-7 mRNA and extracellular pro-MMP-
7 secretion. The signal transduction study revealed that butein significantly attenuates TNFα-
mediated p38 phosphorylation, inhibitory factor κB(I-κB) degradation, and nuclear factor
κB(NF-κB) mediated transcription activation. In addition, butein significantly inhibits osteo-
pontin-induced I-κB phosphorylation in TNFα stimulated HT-29 cells. Using specific kinase
inhibitors, SB203580 or LY294002, we also found that blocking the p38 pathway is critical
for, and blocking of osteopontin-induced I-κB phosphorylation pathway is at least partially
important for the inhibitory effect by butein on TNFα-induced inflammation. Furthermore,
using a MMP inhibitor, we showed that IL-8 lies upstream of MMP-7 in the TNFα-induced
signaling process in HT-29 cells. Conclusion: Butein has anti-inflammatory potential based
on its blocking effects on TNFα-induced IL-8 and MMP-7 expression. The inhibition by
butein appears to be mediated mainly through the inhibition of p38 and partially through
the inhibition of osteopontin induced I-κB phosphorylation. In light of the role of MMP-7
in the pathophysiology of several intestinal inflammatory disorders, the specific inhibition
of MMP-7 by butein may represent a novel agent for therapeutic intervention.
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W1503
Intestinal Cytokine Production By Dendritic Cells in Acute Ulcerative Colitis -
An Immunoregulatory Role?
Siew C. Ng, Sophie Plamondon, Michael A. Kamm, Stella C. Knight, Andrew J. Stagg
Background & Aim: Intestinal dendritic cells (DC) interact with the luminal flora and play
a key role in maintaining immune homeostasis. Altered DC function and an unbalanced
cytokine production are likely to contribute to the dysregulated recognition of bacteria that
drives inflammation. Cytokine profile in chronic inflammation may be different from those
in the early stage of active disease. The roles of individual cytokines in acute intestinal
inflammation remain unclear.We therefore aimed to assess spontaneous intracellular cytokine
production by colonic DC and lymphocytes in patients with an acute exacerbation of
ulcerative colitis. Methods: Colonic biopsies were obtained from inflamed tissue of patients
with active ulcerative colitis, symptomatic for less than four weeks (n=18; sigmoidoscopy
score >2) and controls (n=7; macroscopically and histologically normal intestine of patients
referred for rectal bleeding). DC subsets (CD11c+ HLA-DR+ lineage- myeloid DCs; CD11c-
HLA-DR+ lineage- plasmacytoid DCs) and lymphocytes were identified by multi-colour
flow cytometry of cells extracted from collagenase digested intestinal tissue. Spontaneous
interleukin [IL]-10, IL-12, IL-6, and IL-13 production by lamina propria DC and lymphocytes
was measured by intracellular staining of permeabilised cells in the absence of exogenous
stimulation. Results: In patients with acute ulcerative colitis, a significantly greater proportion
of CD11c+ DC and lymphocytes produced IL-10 than cells from control tissue (p<0.05).
In contrast, production of IL-12p40, IL-6 and IL-13 by DC in ulcerative colitis patients was
present but this did not differ significantly from that of control DC. In cells from healthy
colonic mucosa from controls, there was no detectable DC production of IL-12p40, IL-6
or IL-13. Compared with CD11c+ DC and lymphocytes, intestinal CD11c- DC were poor
spontaneous cytokine producers in ulcerative colitis patients. Conclusion: Acute ulcerative
colitis is associated with increased IL-10 production by DC which may represent an attempt
to antagonise inflammation and re-establish homeostasis during the initial phase of inflamma-
tion. This observation suggests that local modulation of DC cytokine contributes to the
intestinal immune homeostasis.
W1504
All-Trans Retinoic Acid Activates NF-KappaB Signaling in Colonic Epithelial
Cells
Tadahito Shimada, Takero Koike, Michiko Yamagata, Akihiro Tajima, Kyoko Tabei,
Masashi Yoneda, Akira Terano, Hideyuki Hiraishi
Background and Aim: All-trans retinoic acid (ATRA) is a ligand for retinoic acid receptor
(RAR), a member of the nuclear receptor superfamily. RARs are known to be involved in
the development and differentiation of a variety of organs including gastrointestinal tract.
Since evidence suggests a possible association between the use of retinoic acids and inflammat-
ory bowel diseases, we investigated whether ATRA affects the activity of NF-kappaB in
colonic epithelial cells. Methods: HCT116, a cell line derived from human colonic carcinoma,
was used. Caco2 cells and SW480 cells were also used in some experiments. Activation of
RAR was assessed with pRARE-TA-SEAP vector (Clonetech), which contained multiple copies
of retinoic acid response element (RARE) upstream of the SEAP gene. NF-kappaB activity
was assessed with NF-kappaB-Luc vector (Clonetech), which contained multiple copies of
NF-kappaB binding element upstream of the luciferase gene. phRL-TK vector (Promega)
was always co-transfected for standardization. Endogenous IL-8 mRNA expression was
analyzed by real-time quantitative RT-PCR. Results: (1) ATRA up-regulated the transcription
of RARE-driven SEAP genes in a dose-dependent manner, suggesting that HCT116 cells
possess functional RARs. Maximum effects were observed with 20 microM ATRA. (2) ATRA
(8 h-incubation) activated NF-kappaB in a dose-dependent manner. Maximum effects were
observed with 20 microM ATRA. 13-cis RA (20 microM) was also found to activate NF-
kappaB. (3) TNF-alpha-induced and IL1-beta-induced activation of NF-kappaB was further
potentiated by co-incubation with ATRA. (4) ATRA had similar stimulatory effects on the
NF-kappaB activity in Caco2 cells and SW480 cells. (5) Endogenous IL-8 mRNA expression
was induced by ATRA in a dose-dependent manner in HCT116 cells. Eight hour incubation
with 20 microM ATRA caused about an 8-fold increase in the expression of IL-8 mRNA.
(5) ATRA also potentiated the induction of IL-8 expression by TNF-alpha or IL1-beta.
Conclusion: These results suggest that ATRA and 13-cis RA can activate NF-kappaB cascade
and potentiate inflammatory responses of colonic epithelial cells.
W1505
Differences in the Intestinal Microbiota Between Inflamed and Non-Inflamed
Mucosa in Crohn's Disease
Liljana Petrovska, Jeremy D. Sanderson, Alan Walker, Carol Churcher, Neil R. Rayment,
Barry N. Hudspith, Gareth Parkes, Carlo Nunes, Jonathan Brostoff, Julian Parkill, Gordon
Dougan
Background: It is generally accepted that alterations in the bacterial microbiota associated
with the human intestinal mucosa play a critical role in the pathogenesis of IBD. Previous
studies on the composition of the mucosal and faecal bacterial flora in Crohn's disease (CD)
patients and healthy controls using fluorescent in-situ hybridisation (FISH) or culture suggest
higher content of Bacteroides spp. and Clostridia in patients with CD. The exact difference
in the microbiota between inflamed and non-inflamed mucosal sites in CD patients and
comparison with the microbiota of the healthy individuals has not been fully established.
Aim: To undertake detailed molecular characterisation of the mucosal-associated microbiota
in inflamed and non-inflamed mucosal sites in CD patients using high throughput bacterial
16S ribosomal RNA sequencing. Methods: DNA was extracted from paired biopsies of
inflamed and non-inflamed mucosa from 6 patients with CD and from biopsies of healthy
mucosa of 6 normal controls. Bacterial DNA was amplified using universal bacterial 16S
ribosomal RNA gene primers and cloned to generate libraries. 11,160 bacterial clones were
sequenced and the data analysed to identify individual operational taxonomic units (OTU's)
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within the sequence set. Data from the species-level differences between inflamed and non-
inflamed sites was analysed using Chi Square test and integral-libshuff analysis. Results: The
clone libraries yielded 11,160 sequenced clones, with up to 101 OUT's per library, repres-
enting a large sample population. Chi Square analysis on species level data showed a highly
significant difference (p-value= 8.23 E-52) between inflamed and non-inflamed tissue in all
of the CD patients. The communities in inflamed and non-inflamed mucosal tissues were
shown to be significantly different by integral-libshuff analysis. Higher numbers of Firmicutes,
(including all Clostridia spp.) were found in the inflamed mucosa of all of the CD patients.
The most abundant species in all of the 6 CD patients were Firmicutes and Bacteroidetes.
Tissues from the healthy controls contained similar percentage of Firmicutes, Bacteroidetes
and Fusobacteria. Conclusions: This is the most extensive 16S ribosomal RNA sequence
analysis of the intestinal microbiota in CD undertaken to date and shows a highly significant
difference between inflamed and non-inflamed mucosa in CD. The findings of increased
numbers of Firmicutes and Bacterioidetes in inflamed mucosa complement those obtained
by FISH. Further detailed analysis of these speciesmay reveal phenotypic properties important
in the pathogenesis of CD.
W1506
Alteration in the Transcriptional Activity of Dominant Intestinal Bacterial
Communities in Chronic Inflammatory Bowel Diseases
Stephan J. Ott, Ateequr Rehman, Stefan Schreiber
Introduction: There is evidence that dysbiosis of the mucosa-associated intestinal microbiota
plays a pivotal role in the pathophysiology of the inflammatory bowel diseases (IBD) and
may reflect the net influence of life-style factors associated with the development of the
disease. However, dysbiosis only describes the altered composition of the different bacterial
populations, but little is known about the transcription activity, the metabolism, and the
“live” status of the mucosa-associated microbiota that may have more relevance for the host,
e.g. by direct secreting pro-inflammatory cytokines. Aims: To study the transcriptional
activity of the dominant intestinal bacterial populations in patients with active Crohn disease
(CD), active ulcerative colitis (UC) and healthy controls by comparison of their 16S rDNA
and rRNA profiles. Methods: Colonic mucosal biopsy samples from patients with active CD
(n=10), active UC (n=19), and healthy individuals (n=10) were compared. Simultaneous
extraction of DNA and RNA from the complex intestinal communities was performed to
create 16S rDNA and rRNA profiles by using clone libraries and community fingerprinting.
Results: The formal analysis of bacterial richness was significantly lower in clone libraries
derived from rRNA (3.33) compared to rDNA (4.25) in CD, but showed no difference for
healthy individuals (rRNA 4.31 vs. rDNA 4.25) and UC (rRNA 4.03 vs. rDNA 4.43). The
qualitative composition of rRNA and rDNA clone libraries was significantly different: in
healthy controls and CD, Bacteroidetes was the most active group (p<0.01) compared to
other populations. In contrast, Actinobacteria (Roseburia) and Firmicutes were inactive in
CD. In UC, Enterobacteriacaea were found to be the most active population. In the group-
specific analysis of Bacteroidetes clone libraries, Prevotella showed significantly more activity
(2.1% in rDNA and 25.5% in rRNA clone libraries). Conclusion: Not only the composition
of the bacterial intestinal microbiota as previously assessed by rDNA signatures, but also
their transcriptional activity is significantly different in active CD and UC compared to healthy
individuals. Our findings indicate that specific bacterial populations (e.g. Bacteriodetes and
Enterobacteriaceae) are transcriptionally activated during onset or progression of intestinal
inflammation in IBD, whereas other groups, such as Firmicutes and Actinobacteria, represent
an inactive or “dormant” status. The transcriptional activity point to a more functional role
of intestinal mucosal microbiota and may open new perspectives in the identification of
therapeutic targets in the active modulation of microbial factors.
W1507
Dynamics of Bacterial Populations in Ulcerative Colitis During Remission:
Changes Preceding Clinical Relapse
Stephan J. Ott, Sophie Plamondon, Alisa Hart, Alexander Begun, Ateequr Rehman,
Michael A. Kamm, Stefan Schreiber
Introduction: Several studies independently demonstrated that reduced intestinal bacterial
diversity might be a marker of inflammatory bowel diseases (IBD). Most of these studies
compared separate cohorts of IBD and control patients. Aims: To investigate intra-individual
alterations of intestinal bacterial diversity over time in patients with UC during remission
and relapse usingmolecular methods and complex statistical analysis. Methods: The intestinal
mucosa-related bacterial communities of 13 patients with UC and 5 healthy controls were
analysed by their 16S rDNA signatures using broad-range oligonucleotides. UC patients
were followed up by colonoscopy during remission till a relapse occurred. Biopsy specimens
of healthy controls were collected twice over a period of 6 months. Results: A total of 43
different band classes could be identified in the UC patients, 61 band classes were found
in the controls indicating a baseline reduction in bacterial richness by 15% between controls
and UC patients. A total of 91 different OTUs could be identified including 17 (18.7%)
sequences assigned to uncultured bacteria. Bacterial richness in the UC patients showed a
significant reduction of bacterial OTUs as compared with the controls (25.31 vs. 18.38 in
UC patients, 38.4 vs. 36.4 in the control sample, p < 0.03125). The diversity scores showed
the same trend. Significant decrease of band intensities towards replapse were found for 5
bands (p < 0.0105) representing normal intestinal bacterial taxa, such as Bacteroides, Escher-
ichia, Eubacteria, Lactobacilli, or Ruminococcus. Long-term follow-up additionally demon-
strates that bacterial communities are instable over time. Neural network analysis of the
complex bacterial patterns indicate that some linear combinations of band intensity levels
disappear continuously from the bacterial pattern after the treatment of UC patients and
this bacterial pattern loses its richness with time. Conclusions: The findings clearly demon-
strate that bacterial richness and diversity are reduced in UC patients compared to controls.
During remission, bacterial patterns show an additional tendency towards a simplification
of intestinal microbiota as revealed by statistical and neural network analysis. The reduction
of diversity is caused by a loss of normal intestinal microbiota. Our data suggest that bacterial
diversity might act as a marker of relapse in UC.
W1508
Enterotoxigenic Bacteroides Fragilis Induces Colonic Inflammation and
Epithelial Hyperplasia in C57bl/6 Mice
Ki-jong Rhee, Franck Housseau, Shaoguang Wu, David L. Huso, Drew M. Pardoll,
Cynthia L. Sears
BACKGROUND & AIMS: Enterotoxigenic Bacteroides fragilis (ETBF) are associated with
diarrheal disease and, in more limited data, inflammatory bowel disease and colorectal
cancer. In this report, we examined the pathology of ETBF-colonized mice histologically
and by examining immune cells from the colon by flow cytometry. METHODS: Four-week-
old wild-type C57BL/6 mice were orally inoculated with ETBF or a non-toxigenic strain of
B. fragilis (NTBF). At varying times post-inoculation, the small intestine, cecum and colon
were examined by histology. To evaluate cytokine secretion, colonic lamina propria mononu-
clear cells of mice (n=3) colonized with either ETBF or NTBF for 1 week were stimulated
in vitro with PMA+ionomycin and stained for IL-17, IL-4 or IFN-γ production by intracellular
staining.RESULTS: ETBF andNTBF colonizationwas similar (~1x1010 colony forming units/
gm stool) by day 2 post-inoculation. ETBF caused severe and acute intestinal inflammation in
the cecum and proximal colon within 3 days associated with significant weight loss in the
ETBF group (P<0.005). Intestinal histopathology consisted of mucosal thickening with
edema, infiltration of acute inflammatory cells into both the mucosa and submucosa, and
destruction of epithelial cells with ulceration. The small intestine was unaffected. Mice
colonized with NTBF exhibited no histopathology. Within 1 week, ETBF-colonized mice
exhibited enlarged spleens and mesenteric lymph nodes suggesting a systemic immune
response to ETBF. By 2 weeks post-inoculation, acute inflammation lessened while there
was an increased infiltration of lymphocytes and macrophages along with crypt hyperplasia
in the colonic mucosa. ETBF-colonized mice exhibited a 5-fold increase in the percentage
of CD4+IL-17-producing cells in the lamina propria whereas the percentage of CD4+IFN-
γ-producing cells and CD4+IL-4-producing cells were equivalent in both ETBF- and NTBF-
mice. CONCLUSIONS: Our data suggest that colonization of wild-type C57BL/6 mice with
ETBF induces inflammation of the cecum and colon with concomitant increase in IL-17-
producing CD4+ T cells. We propose that the newly described IL-17 dependent inflammatory
pathway contributes to the ETBF-mediated inflammatory disease in the colon.
W1509
Lack of P-Glycoprotein Expression Increases Tlr9 Mediated Epithelial Immune
Response
Reed A. Dimmitt, Matthew Hull, Elizabeth Staley, Robin Lorenz
Background: Deficiency of the transmembrane pump p-glycoprotein (a product of the MDR1
gene) results in severe colitis. Gastrointestinal P-glycoprotein functions to mediate the clear-
ance of xenotoxins against steep concentration gradients. As many bacterial products have
the potential to be transported by p-glycoprotein, we hypothesized that the ligand-induced
responses of bacterial pattern recognition receptors that are expressed in the cytoplasm of
cells, such as TLR9, would be altered in p-glycoprotein deficient cells; while pattern recogni-
tion receptors that are solely expressed on the cell surface, such as TLR5, would not be
affected. Methods: HEK-293 cells expressing single murine TLRs were transfected with
MDR1 siRNA and incubated for 72 hours. Subsequently, murine CpG (ODN 1826) at a
concentration of 2, 0.2, or 0 μM CpG was added to the TLR9 expressing cells; while TLR5
expressing cells received S. dublin flagellin at 500, 5, or 0 ng/mL. After 24 hours, the
supernatant was evaluated for IL-8 expression by ELISA and the cellular RNA was isolated
for evaluation of MDR1 expression via RT-PCR. The mean IL-8 concentration and MDR1
RNA expression was analyzed with Students t-test. Results: MDR1 expression was significantly
reduced following siRNA transfection. No difference in IL-8 production was seen in TLR5
cells with and without siRNA. In contrast, IL-8 production in TLR9 cells treated with siRNA
and 2 μM CpG was significantly greater (4.9±1.3 ng/mL) than non-siRNA treated cells
(1.6±0.44 ng/mL, p=0.03). Conclusions: The TLR9 mediated epithelial inflammatory
response may be regulated via p-glycoprotein. We hypothesize that the p-glycoprotein
normally pumps CpG taken into the cell, attenuating the TLR9/MyD88/NFκB pathway.
Supported by NIH grant P01DK071176/R24DK064400
W1510
Apoptosis and Inflammation in Clostridium difficile Enteritis Is Mediated By
Pge2-Stimulaltion of Fasl
Ho Kim, Sang hoon Rhee, Charalabos Pothoulakis, J. thomas Lamont
Background & Aims: C. difficile toxin A causes acute inflammation and fluid secretion in
experimental animals and patients with C. difficile infection. We previously reported that
toxin A increased COX-2/PGE2 expression and apoptosis in human colonocytes. We assessed
the role of secreted PGE2 in colonocyte apoptosis in response to toxin A. Methods: TUNEL
staining and FACS analysis were performed to assess whether blockage of PGE2 and COX-
2 prevents toxin A-induced colonocyte apoptosis In Vitro. Effects of PGE2 or toxin A on
the FasL (FasL) induction in human colonocytes were analyzed by FACS and western
blotting. The involvement of PGE2-dependent FasL/Fas activation in toxin A enteritis was
further assessed in FasL and Fas deficient mice exposed to toxin A. Results: Inhibition of
COX-2 by NS-398 and of PGE2 using a blocking antibody markedly attenuated apoptosis
in colonocytes exposed to toxin A. Enhanced expression and release of Fas ligand occurred
following PGE2 or toxin A exposure In Vivo and In Vitro, and also was significantly attenuated
by treatment with NS-398 and PGE2 blocking antibody. PGE2, acting through an EP1
receptor on the basolateral membrane of colonocytes, activated NFkB which induced tran-
scription of FasL. Toxin A enteritis was accompanied by increased IL-6 and IL-8, increased
cellular infiltration, fluid secretion and mucosal damage in control mice, but this response
was markedly reduced in both Fas-/- and FasL-/- mice. Conclusions: Toxin A enteritis
involves release of PGE2 which activates the Fas/FasL system, causing enterocyte apoptosis
and massive neutrophil infiltration.
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W1511
Oral Iron Potentiates Immune-Mediated Colitis in IL-10 Deficient Mice
Kang moon Lee, R. balfour Sartor
Background: Diet and commensal enteric bacteria are two of the most obvious environmental
factors influencing the pathogenesis of inflammatory bowel diseases (IBD). Iron, ubiquitous
in the Western diet and environment, is required for the growth and virulence of most
bacteria. Flare of clinical symptoms was reported during oral but not parenteral iron therapy
for anemia in IBD patients. We postulate that acquisition of iron enhances bacterial growth
and virulence that subsequently induces intestinal inflammation in susceptible hosts. We
investigated the effects of dietary iron on immune-mediated colitis and bacterial growth.
Methods: In Vitro growth of murine E. coli in response to iron was assessed by spectrophoto-
metry. To evaluate the dietary effect of iron, germ free IL-10-/- mice were colonized with
SPF commensal bacteria, fed a low iron, low aluminum diet and allocated to one of four
different iron concentration groups: 0, 1, 5, 25 mM FeSO4 in drinking water (N=6-8/
group). Inflammation was quantified by blinded histology scores (0-4), spontaneous IL-
12p40 secretion by cultured colonic strips, and IFNγ secretion from mesenteric lymph node
(MLN) cells stimulated with cecal bacterial lysates from SPF mice. The effect of iron on
enteric bacterial flora In Vivo was assessed on fresh stool pellets on 1, 3, 5 days and cecal
contents on day 7 after bacterial colonization in mice fed water or iron (1.3 mg/kg) (N=6/
group). Quantitative bacterial culture was done on BHI and McConkey plates. Results: In
Vitro growth of E. coli was enhanced by iron in all concentrations (10-1000 μM). The 1
mM oral iron group had more severe colitis (histological score 2.9+/-0.2 iron vs. 2.2+/-0.3
water, p=0.05) and higher IL-12p40 production (1.5 +/-0.3 ng/ml iron vs. 0.9+/-0.1 ng/ml
water, p=0.07) compared to the water group, with no significant effect of higher iron
concentrations. Oral iron enhanced bacteria-induced secretion of IFNγ by MLN cells (Table
1). Dietary iron increased the number of bacterial colonies on BHI and McConkey by aerobic
and anaerobic culture of feces and cecal contents. Conclusion: Dietary iron enhanced colitis
and pathogenic immune responses in IL-10-/- mice, perhaps due to increased bacterial
proliferation induced by iron. These results suggest that increased iron intake may be one
cause of the recent increase of IBD in Western countries and countries adopting the Western
life style.
Table 1. IFNγ production (ng/ml). Mean (SEM)
* p<0.05 vs. control
W1512
Investigating the Arrival of T Cells and Mechanisms of Neutrophil
Recruitment in a Kinetic Study of the Early Inflammatory Responses in H.
pylori-Infected Immunized and Unimmunized Mice
Elizabeth Delyria, Raymond W. Redline, Thomas G. Blanchard
Background: Helicobacter pylori is a bacteria that inhabits the gastric mucosa, and infection
may lead to ulcers and cancer. A vaccine is desirable because antibiotic treatments are
complex and not practical for use in endemic areas. Mouse models of H. pylori vaccination
achieve protection. CD4+ T cells are necessary for facilitating this, but little is known about
which immune cells actually clear the bacteria and how T cells may be mediating this. We
therefore investigated the contribution of T cells to the recruitment of neutrophils, which
are likely to be a major effector of clearance, to model the early immune responses to
infection and immunization. Methods: We performed a kinetic study in which immunized
and unimmunized mice were challenged with H. pylori and sacrificed at days 1, 2, 3, 5, 7,
9, and 13 post-infection. Stomach biopsies were harvested for bacterial load, inflammation
grading, and RNA isolation. The mRNA expression levels of CD3 and the neutrophil chemok-
ines KC, MIP-2, and LIX were determined by quantitative PCR. Co-culture assays were
performed with dendritic cells (DC), macrophages (MΦ), fibroblasts, epithelial cells, and
neutrophils stimulated by H. pylori and T cell cytokines to evaluate the production of KC,
MIP-2, and LIX. Results: Immunized mice had significantly higher inflammation than
infected mice by day 5, preceding the significantly lower bacterial load by day 7. Infected
mice exhibited no significant inflammation, despite an increasing bacterial load. Similarly,
T cells were present in immunized mice by day 3, whereas they were not detected in infected
mice until day 13. There were also significantly higher mRNA levels of KC, MIP-2, and LIX
in immunized versus infected mice for days 5-13, with infected mice expressing essentially
none. LIX was expressed approximately 3 fold more than KC and MIP-2 in immunized
mice. DC and MΦ secreted MIP-2 In Vitro at 24 hours in response to H. pylori, and DC,
epithelial cells, and fibroblasts produced LIX. Conclusions: Significant differences exist
between the initial immune responses of infected and immunized mice as soon as 3 days
post-infection. Although epithelial cells and DC, which likely contact H. pylori In Vivo,
secrete chemokines for neutrophil recruitment, they do not produce meaningful levels in
infected mice within 2 weeks of infection. In immunized mice, these chemokines are not
produced in significant amounts until day 5, subsequent to T cell arrival. It is likely that T
cells, which are required for protection, are necessary for driving the acute immune response
in immunized mice resulting in abundant neutrophil recruitment and bacterial clearance.
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W1513
Presence of Enterobacteria Modulates Lipopolysaccharide Induced T
Lymphocyte Migration in Intestinal Mucosa
Koichi Takebayashi, Ryota Hokari, Yoshikiyo Okada, Keisuke Okudaira, Chie Kurihara,
Hisayuki Matsunaga, Syunsuke Komoto, Chikako Watanabe, Atsushi Kawaguchi, Shigeaki
Nagao, Kazuro Itoh, Yoshikazu Tsuzuki, Soichiro Miura
BACKGROUND & AIMS: Enterobacteria have been implicated in the pathogenesis of inflam-
matory bowel diseases, and reported to be essential in the initiation of experimental colitis
or enteritis. Toll-like receptor 4 (TLR-4) mediates lipopolysaccharide (LPS)-induced cellular
signaling through activation of NF-κB pathway in intestinal epithelial cells. The aim of this
study is to compare the T lymphocyte migration in intestinal mucosa between germ free
(GF) and specific pathogen free (SPF) conditions. We also examined whether LPS from
outside could affect the migration pattern in these mice. Signaling pathway downstream of
TLR-4 was studied as well. MATERIALS & METHODS: Male IQI mice bred under GF or
SPF conditions were used. Fluorescence-labeled splenic T cells from SPF mice were adminis-
tered into GF or SPF mice via vein. T cell migration in ileal microvessels was monitored
using intravital microscope. Rolling and adherence of T cells were quantified. In another
experiments LPS (0.3-0.4 mg) was administered into murine peritoneal cavity or stomach
before lymphocyte injection. The expression of β7-integrin and MAdCAM-1 in ileal mucosa
was evaluated immunohistochemically. Messenger RNA (mRNA) of TNF-α, MAdCAM-1,
IRAK-M, IkB-NS, Bcl-3, Tollip, SIGIRR, IkB-Z, SOCS1 and SOCS3 were measured by
quantitative RT-PCR. RESULTS: Rolling and adherence of T cells in microvessels of the
terminal ileum were significantly fewer in GF mice compared with SPF mice. The expression
of Bcl-3 and SOCS1 was stronger in SPF than GF mice under non-treated condition.
Intraperitoneal administration of LPS significantly increased adherence of T cells both in
GF and SPF mice, although the magnitude of increase was larger in SPF mice. These increases
were accompanied with β7-integrin, MAdCAM-1, and TNF-α expression. On the other
hand, oral administration of LPS induced significant adherence of T cells only in GF mice,
and there was no significant increase in T cell migration or MAdCAM-1 expression in SPF
mice. The increase in expression of IRAK-M, IkB-NS, Bcl-3, IkB-Z, SOCS1, or SOCS3 was
similarly observed after LPS-treatment of either route in both SPF and GF mice and did not
explain the hyporesponsiveness to orally-administered LPS in SPF mice. The degree of
expression of Tollip and SIGIRR mRNA was not different between GF and SPF mice after
oral LPS treatment. CONCLUSIONS: Presence of normal bacterial flora increased T cell
migration via β7-integrin-MAdCAM-1 interactions in the intestinal mucosa. However oral
exposure to large amount of endotoxin did not stimulate T cell migration, and the downstream
signal of TLR-4 may not be directly involved in this hypo-responsive mechanism.
W1514
Amelioration of Murine Colitis By Feeding Colifagina, a Novel Preparation of
8 Lysed Bacteria
Stefania Vetrano, Elena Borroni, Benedetta Savino, Tommaso Stefanelli, Salvatore
Comunale, Massimo Locati, Alberto Malesci, Alessandro Repici, Silvio Danese
Immune reactivity towards the bacterial intestinal flora plays an important part in the
pathogenesis of inflammatory bowel disease. Intestinal inflammation can be positively influ-
enced by the administration of living probiotic bacteria. However, little is known about the
administration of soluble bacterial antigens in intestinal inflammation. We investigated the
therapeutic effects Colifagina in experimental colitis. C57BL/6 mice with 2.5% dextran
sulphate sodium-induced colitis were treated with Colifagina, a novel preparation of 8 lysed
bacteria containing E. coli (O1,O2, O55 and O111), Bacillus pumilus, Morganella morgani,
Alcaligens faecalis, Shigella fexneri, Enterococcus faecalis, Bacillus subtilis and Proteus vul-
garis, or with a placebo, for a period of 10 days. Mice were monitored and inflammation
was assessed by a colitis activity index (CAI), based on stool consistency, bloody stools and
weight loss. A colitis histological score was assigned blindly. Analysis of fecal IgA concentra-
tion, and measurement of IgA and inflammatory chemokine production in organ colonic
culture were performed by ELISA. Clinically and histologically, bacterial-lysate-treated mice
revealed significantly fewer signs of colitis than placebo-treated mice, as assessed by a 30%
reduction in CAI (p < 0.05) and by a reduction of colonic histological inflammation (p<0.05).
Treatment of healthy mice with colifagina significantly (p<0.05) increased the fecal concentra-
tion of IgA (from 30±3 to 70±5 ng/ml) and IgA production in organ culture (from 2.6±0.4
to 10.3±2.2 ng/ml, p=0.02). Colifagina administration in DSS-treated mice significantly
increased the fecal concentration of IgA (from 110±3 to 215±12 ng/ml, p<0.001) and IgA
production in organ culture (from 18±2 to 29.8±2.1 ng/ml, p<0.05). MIP-1, MIP-2 and
RANTES concentrations in colonic organ culture were significantly lower (p < 0.05) in
colifagina-treated mice than in the placebo group. The use of Colifagina is effective in the
amelioration of murine colitis. This effect may be due to an increased enhancement of
mucosal barrier, as assessed by IgA production and to an induction of tolerance against
bacterial antigens.
W1515
Molecular Analysis of Mucosa-Associated Bacterial Diversity in Crohn's Ileitis
Martin Baumgart, Belgin Dogan, Mark Rishniw, Gil Weitzman, Brian P. Bosworth, Rhonda
Yantiss, Kendra Nightingale, Renato Orsi, Martin Wiedmann, Sung Kim, Guillaume.
Bruant, Josee Harel, David Russell, Douglas Berg, Ynte Schukken, Ellen Scherl, Kenneth
W. Simpson
Background: Crohn's disease is widely considered a consequence of uncontrolled intestinal
inflammation in a genetically susceptible host in response to a combination of incompletely
understood environmental, luminal microbial, and immunoregulatory factors. Here, we
describe the culture-independent analysis of bacterial diversity in Crohn's ileitis, and sub-
sequent in situ and culture-based characterization of the mucosa-associated flora. Results:
Analysis of 16s rDNA libraries constructed from the ileal mucosa of patients with Ileal
Crohn's Disease ((ICD) n=7; 217sequences) and individuals with normal ileum (7 healthy
subjects and 6 with colonic Crohn's disease (CCD); 399 sequences ) yielded 9 clades that
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segregated according to their origin (p<0.0001). ICD libraries were selectively enriched in
sequences for E. coli (p<0.001), but were depleted in two subsets of Clostridiales (p<0.05).
The validity of this finding was confirmed with quantitative PCR to E. coli uidA normalized
to 18s rRNA content. Species-specific PCR of mucosal DNA was negative for Mycobacterium
avium subspecies paratuberculosis, Shigella and Listeria. Fluorescence in situ hybridization
(FISH) of ileal biopsies from ICD, CCD and healthy subjects revealed increased Enterobacteri-
aceae and E. coli in ICD as compared to normal ileum. Invasive E. coli was restricted to
ICD. FISH counts correlated with the degree of ileal inflammation determined by endoscopy
(E. coli rho 0.617, p<0.001) and histology (E. coli rho0.621, p<0.001). E. coli isolated from
healthy (2 strains), CCD (9 strains) and ICD (12 strains) mucosa were genetically diverse,
belonged to undefined clonal groups and generally lacked common virulence genes of
diarrheagenic E. coli. Over half of the E. coli strains cultured from both healthy and inflamed
ileum were able to invade and persist within epithelial cells, and replicate in macrophages
In Vitro. Microarray analysis showed that invasive ileal E. coli contained relatively few genes
associated with virulence of diarrheagenic and extraintestinal pathogenic E. coli. Genome
subtraction revealed commonality with exPEC, and likely acquisition of genes from patho-
genic Enterobacteriaceae. Phylogenetic analysis indicated that ileal E. coli did not segregate
by multilocus sequence type into distinct ileitis-associated clades. Conclusions: Our findings
reveal dysbiosis of the ileal mucosa-associated flora, characterized by a selective increase in
invasive E. coli of novel phylogeny, and depletion of Clostridiales, may be a key factor
promoting Crohn's ileitis.
W1516
Characterization of the Mucosal Microbiota in Patients with Pouchitis After
Ileal Pouch-Anal Anastomosis
Martina E. Spehlmann, Andreas Marx, Christine Paulicke, Alexander Begun, Christian
Hagel, Guido Sauter, Udo Helmchen, Andreas Raedler, Stefan Schreiber
Background and aims: The composition of the mucosal microbiota plays a crucial role in
the pathophysiology of pouchitis, the most frequent complication after ileal pouch-anal
anastomosis. The aim of this study was to compare the bacterial microbiota in the inflamed
and non-inflamed pouch mucosa compared to the non-inflamed afferent loop mucosa.
Methods: The pouch and afferent loop microbiota of endoscopic biopsies and stool samples
from 15 patients (8 with pouchitis, 7 with non inflamed pouch) were analyzed using
ribosomal DNA/RNA-based community fingerprint analysis and clone libraries. Transmission
electron microscopy was also performed to illustrate the spatial relationship between bacteria
and the pouch mucosa. Results: Intra-individual afferent loop/pouch bacterial profiles were
more similar (92.1% ± 8.9) than the afferent loop/pouch profiles of two different patients
(42.1% ± 14.7). No distinct clusters were observed for the stool samples. Biodiversity, as
assessed by the number of SSCP bands, was significantly higher in patients with no pouchitis
than in inflamed patients in both the pouch mucosa (32.9 ± 4.3 bands versus 25.5 ± 8.9,
respectively; p<0.05) and afferent ileal loop (31.5 ± 5.4 versus 27.2 ± 9.3; p<0.05). In stool
samples the number of bands was 42.1 ± 6.4 in inflamed patients and 45.8 ± 5.1 in non
pouchitis patients (p<0.05). Analysis of bands from SSCP revealed that most bacterial species
were present in both the afferent loop and the pouch mucosa from a same patient. Differences
were only detected in the spectrum of Gamma-Proteobacteria/Enterobacteriaceae and Bactero-
ides groups with a lower diversity in patients with pouchitis than in controls. Taxa-specific
clone libraries of Lactobacilli and Bifidobacterium species showed only minor differences
between the tissues under study. In all groups, diversity was higher in feces than in the
mucosa but these differences were not significant. Transmission electron microscopy showed
that in all patients bacteria live in close relationship to the mucosa. Conclusions: The
microbial diversity in patients with pouchitis was sigificantly lower than in non pouchitis
controls. Remarkably, this was true for both mucosal and fecal compartments. Diversity of
the afferent loop did not significantly differ from that of the pouch mucosa, confirming that
the bacterial microbiota remains stable along the digestive tract. Clone libraries revealed
that non inflamed status was associated with higher diversity of bacterial species that include
members of the normal, anaerobic enteric microbiota.
W1517
The Role of FC Gamma Receptors in Defending Against Citrobacter rodentium
Infection
Atsuhiro Masuda, Masaru Yoshida, Tetsuya Takagawa, Hideyuki Shiomi, Ryo Chinzei,
Hiroshi Tanaka, Tsukasa Ishida, Yoshinori Morita, Hiromu Kutsumi, Hideto Inokuchi,
Richard S. Blumberg, Takeshi Azuma
Background: Secretory Igs such as IgA, IgM, IgG that are present in mucosal surfaces
potentially provide a first line of defence against microorganisms. Secretory IgA is well
known to be transported across epithelial cells into the lumen through an active unidirectional
process by the polymeric Ig receptor. Despite all that is known about IgA transport and its
relation to mucosal host defence, it is unknown how IgG arrives into the lumen or what
role IgG plays in mucosal secretions. Neonatal Fc receptor for IgG (FcRn) plays a major
role in regulating host IgG levels and transporting IgG and associated antigens across polarized
epithelial barriers. We have previously shown that FcRn expression in intestinal epithelial
cells contributes to the protection against an epithelium-associated pathogen, Citorobacter.
rodentium infection but only in the presence of specific IgG antibodies. These results indicate
that FcRn integrates luminal antigen encounters with systemic immune compartments and,
as such, provides essential host defense and immunoregulatory functions at the mucosal
surfaces. Transported antigen/IgG complexes by FcRn across the epithelial barrier could be
taken up by antigen presenting cells in lamina propria via Fc gamma receptors (FcgR).
Therefore, FcgR on antigen-presenting cells should affect the downstream events of the
immune responses. Aim: We sought to examine the role of FcgR in the mucosal immune
response to C. rodentium. Methods and Results: The immunoreceptor tyrosine-based activa-
tion motif (ITAM) bearing FcgR-gamma chain-deficient (FcgRg-/-) mice and the immunore-
ceptor tyrosine-based inhibitory motif (ITIM) bearing FcgRIIb-deficient (FcgRIIb-/- ) mice
are used. 3-week-old FcgR-/- mice, FcgRIIb-/- mice and control mice were orally inoculated
with C. rodentium. Body weight was monitored and feces collected at day 21 after the
infection. FcgRg-/- mice exhibited more body-weight loss, higher bacterial concentrations
in the feces, and severer mucosal inflammation in the distal colon. In contract, FcgRIIb-/-
exhibited lesser mucosal inflammation in the distal colon. These results indicate that FcgRg-/-
mice are susceptible and FcgRIIb-/- mice are resistant to infection with C.rodentium. Conclu-
sion: FcgRs may play a role for the mucosal immune response against enteric bacterial infec-
tion.
W1518
Preliminary Study On Bacterial Translocation in Serum of Patients with
Inflammatory Bowel Disease
Ana Gutiérrez, Rubén Francés, Pedro Zapater, José Such, Marta Garmendia, Rodrigo
Jover, Miguel Pérez-mateo
Background: The pathogenesis of inflammatory bowel disease (IBD) involves the interaction
between genetic susceptibility, mucosal immunity and intestinal bacteria. Bacterial DNA
(bactDNA) derived from luminal bacteria may contribute to the perpetuation of chronic
intestinal inflammation. Blood microbiological cultures, though, are frequently negative in
these patients and bacterial translocation episodes may be put out of sight. Aims: To evaluate
the presence of bacterial translocation in patients with IBD by means of detection of bacterial
DNA in blood. Patients and Methods: 23 patients with IBD not treated with antibiotics the
month before inclusion were considered in the study and distributed into the following
groups: Group I: active Crohn's disease (CD); Group II: inactive CD; Group III: active
ulcerative colitis (UC); and Group IV: inactive UC. A blood sample was collected in endotoxin-
free tubes and a broad-range PCR of a highly conserved region of the bacterial 16SrRNA
gene was performed using the following primers: 5'-TTCCGGTTGATCCTGCCGGA-3' as
forward, and 5'-GGTTACCTTGTTACGACTT-3' as reverse. Bacterial genomic fragments were
purified (QIAquick, QIAgen) and identified by automated nucleotide sequencing analysis
(ABIPRISM 310, Applied Biosystems). Sequence alignments were carried out with NCBI
database (www.ncbi.nih.gov), using the advanced BLAST search tool. Microbiological cul-
tures were carried out among all the patients. Results: Four patients out of 7 from Group
I (57%), 4 out of 7 from Group II (57%), 8 out of 11 from Group III (73%) and none from
Group IV showed bactDNA in serum; Bacteria identifications included E. coli, Enterococcus
spp and Staphylococcus spp. Blood cultures were negative in all cases. Conclusion: Molecular
detection tools in patients with IBD are able to identify a subgroup of patients with presence
of circulating bacterial DNA that remain undetected by microbiological culture. The presence
of bacterial translocation in patients with inactive CD, the surprising prevalence of bacterial
DNA from Enterococcus spp in patients with active UC, and the likely existence of immune
consequences associated to these facts require new investigations.
W1519
Validation of 16s Rdna PCR-Based Methodology for the Identification of
Specific Bacteria in Bowel Biopsies: An in Silico Analysis
Gert De hertogh, Jeroen Aerssens, Peter Van eyken, Nadine Ectors, Paul Rutgeerts, Karel
Geboes
Background & Aims: The intestinal bacterial flora is involved in the pathogenesis of Crohn's
disease (CD). It is thus of interest to know the bacterial species in CD bowel biopsies.
Bacterial identification can be based on its 16S rDNA gene sequence. For tiny samples (e.g.,
microdissected material), a nested PCR approach may be needed. We questioned specifically
for bowel bacteria: 1) whether all parts of the 16S gene are equally well amplifiable with
current universal primers; 2) whether all parts of the 16S gene are equally informative for
bacterial identification. Methods: 251 bacterial species from 7 phyla were selected on the
basis of literature data on their presence in the normal bowel flora or their involvement in
gastrointestinal diseases. The most reliable 16S rDNA sequence was retrieved from GenBank,
and its complementarity to 9 standard universal primers (8F, 342F, 518F/539R, 907F/926R,
1114R, 1513R, 1541R) was examined in order to assess amplifiability by PCR. Next, gene
sequences were divided in fragments using combinations of universal primers, thereby
simulating products obtainable by a hemi-nested PCR approach. Each fragment was subjected
to a BLAST search against GenBank and all hits with sequence identity >98% were recorded.
Universal primer combinations were then evaluated for identification specificity. Results:
We detected systematicmistakes against specific universal primer sequences in 15/45 bacterial
families, most notably: Pseudomonadaceae and Bacteroidaceae (1114R); Campylobactera-
ceae, Helicobacteraceae and Bifidobacteriaceae (907F/926R); and Fusobacteriaceae (1541R).
The number of bacteria with inconclusive identifications of putative PCR products was
highest (n = 81) for primer pair combination 518F/926R (middle part of the 16S gene) and
much lower for the combinations 8F/539R (n = 14) and 907F/1513R (n = 19) (5'- and 3'-
end of the 16S gene, respectively). Primer combinations 342F/1513R and 518F/1513R
(extended middle part of the 16S gene) showed similar low numbers of bacteria with
inconclusive identifications (n = 8 and 13, respectively). Of all major bowel bacteria families,
Enterobacteriaceae showed the highest number of inconclusive identifications irrespective
of the gene segment investigated. Conclusions. We predict that a hemi-nested PCR for parts
of the 16S gene on DNA obtained from microdissected bowel lesions may fail to identify
some bacterial families. To maximize bacterial species specificity, amplification of the 5'- or
3'-end of the gene is preferred, or alternatively the extended middle part of the gene. Accurate
identification of Enterobacteriaceae at species level may require a non-nested PCR approach.
W1520
Proinflammatory Effects of Ehec-Derived Extracellular Serine Protease (Espp)
in Human Intestinal Microvascular Endothelial Cells
Jan Heidemann, Jens Brockmeyer, Stefan Koch, Helge Karch, Wolfram Domschke,
Matthias Bruwer, Torsten F. Kucharzik, Christian Maaser
Background: Human Hemolytic Uremic Syndrome / Thrombotic Thrombocytopenic Purpura
(HUS/TTP) ist frequently associated with preceding hemorrhagic colitis caused by Shiga
Toxin-producing enterohemorrhagic Escherichia coli (EHEC) O157:H7 infection. Various
EHEC-associated exotoxins have been linked to the pathogenesis of HUS/TTP. Clinical
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manifestations of HUS/TTP include microvascular thrombosis and endothelial activation
within vital organs, leading to hemorrhagic colitis, acute renal failure, as well as to cerebral
and myocardial infarctions. Extracellular serine protease P (EspP) is a secreted immunogenic
protein encoded by the large plasmid of EHEC O157:H7, which belongs to the autotrans-
porter protein family. The aim of this study was to characterize the proinflammatory effects of
EHEC-associated EspP in primary human intestinal microvascular endothelial cells (HIMEC).
Material / Methods: Recombinantly expressed EspP was purified from EHEC O157:H7.
Defective EspP mutants lacking any specific serine protease activity were constructed by
site-directed mutagenesis of the catalytic triad (EspPΔACC). Purity and absence of endotoxins
were monitored by column electrophoresis and the limulus amoebocyte lysate assay. Primary
cultures of HIMEC were isolated and purified from resected normal human colon. HIMEC
were stimulated with recombinant EspP and the expression of cell adhesion molecules ICAM-
1 and VCAM-1 was monitored by RT-PCR and FACS analysis. Further, endothelial activation
was assessed by stress fiber assembly and leukocyte transmigration assays using the U937
monocytic cell line. Results: Stimulation of HIMEC with EspP led to a dose and time
dependent up-regulation of ICAM-1 and VCAM-1, as assessed on the RNA and protein
levels. This was accompanied by rapid stress fiber induction andmarkedly increased leukocyte
transmigration in HIMEC. EspP activity was significantly less pronounced in heat-inactivated
samples (indirect endotoxin control) and mutant variants, including EspPΔACC. Conclusion:
Verotoxin-producing EHEC encode and secrete EspP which exhibits pronounced proinflam-
matory effects in human intestinal microvascular endothelium. In addition to well-character-
ized EHEC toxins, including Shiga toxins, EspP might contribute to the pathogenesis of
both hemorrhagic colitis as well as systemic microvascular disease associated with the clinical
picture of HUS/TTP.
W1521
Mast Cells Play a Pivotal Role in Peptidoglycan of Staphylococcus Aureus
Induced Diarrhea
Ping-chang Yang, Shao-heng He, Peng-yuan Zheng, Linda Wu, Bai-sui Feng
Background: Bacterial diarrhea results in about 2-2.5 million people death each year. The
mechanism needs to be further understood. Staphylococcus aureus (S. aureus) infection has
close relation with intestinal disorders; its cell wall component peptidoglycan (PGN) has
strong activity on immune cells and may play a critical role in S. aureus-induced diarrhea.
Methods: Peptidoglycan (PGN) of S. aureus was administered to mice by gavage. Induced
diarrhea was inspected in a period of 3 h after oral PGN. PGN absorption was quantified
by enzyme-linked immunoassay (ELISA) and visualized by immune electron microscopy
(EM). PGN inducedmast cell activation was determined by EM andmeasurement of histamine
and serotonin release. The expression of Toll-like receptor (TLR) 2 and nucleotide-binding
oligomerization domain (NOD) 1 in mast cells were determined by immunocytochemistry,
RT-PCR and Western blot. TLR2 blockade experiments with anti-TLR2, TLR2 RNA interfer-
ence (RNAi) and NOD1 RNAi were carried out to inhibit PGN induced mast cell activation
or diarrhea. Results: Oral PGN induced diarrhea in mice in a dose-dependent manner that
started from 1 to 2 h after the oral PGN. Intestinal epithelial cells absorbed PGN was
visualized by immune EM and quantified by ELISA as 33.2 +/- 4.2 to 125.3 +/- 11.2 ng/g
intestinal tissues. Intestinal mast cells were activated after oral PGN manifesting as extensive
degranulation (7.8% to 31.2%), release of histamine (25.4~124.6 pg/g) and serotonin
(30.2~254.6 pg/g). TLR2 expression was detected in mast cells of both intestine tissue
and murine mast cell line p815 cells at both mRNA and protein levels and visualized by
immunocytochemistry. Blocking TLR2 with anti-TLR2 or TLR2 RNAi efficiently abolished
PGN-induced mast cell activation and inhibited PGN induced diarrhea. Treatment with
NOD1 RNAi alone also abolished PGN-induced mast cell activation. Mast cell mediator
histamine and serotonin had synergistic effect on inhibition of PGN-induced diarrhea.
Conclusions: the present study has demonstrated that intestinal mast cells play a critical
role in PGN-induced diarrhea; TLR2 and NOD1 mediate the effect of PGN by activating
mast cells; A synergistic effect of histamine and serotonin from mast cells on PGN induced
diarrhea has been identified. Pretreatment with mast cell stabilizer, blocking TLR2 or NOD1
can prevent PGN-induced diarrhea that has potential therapeutic value in the treatment of
PGN-related intestinal disorders.
W1522
Secretion of Intestinal Antigens On Chylomicrons
Erik Eckhardt, Sarbani Ghoshal, Willem J. De villiers
BACKGROUND AND AIM: Several studies point to a role of small intestinal absorption of
bacterial antigens in intestinal and systemic immunity. In rabbits, orally applied radiolabeled
LPS is detectable in the liver and oral vaccination of mice with Mycobacterium bovis (Bacillus
Calmette Guerin, BCG) requires administration of the bacteria in the presence of a fatty
emulsion. This prompted us to hypothesize that bacterial antigens are secreted on chylomic-
rons. These lipoproteins represent the main vehicle for dietary fat and are initially transported
through the lymph. METHODS: CaCo-2 cells and T84 cells were grown on permeable
supports until fully differentiated into small intestinal and large intestinal enterocytes, respect-
ively. The cells were incubated apically for 4h with radiolabeled lipopolysaccharide (125I-
LPS; E. coli 0111:B4) or overnight with 1e7 cfu/ml of live BCG. After extensive washing,
the cells were incubated apically with a mixture of lipids known to induce chylomicron
secretion (0.5 mM taurocholate (TC) + 1.6 mM oleic acid(OA)) or a control mix with butyric
acid (BA) instead of OA. The next day, LPS in the basolateral medium was measured with
a gamma counter. Basolateral medium obtained from BCG-infected or uninfected cells was
added to PBMCs isolated from donors immunized in their childhood with BCG (with positive
PPD skin tests) or from non-immunized subjects. Lymphocyte proliferation was measured
with the wst-1 formazan reagent. RESULTS: In CaCo-2 cells, which differentiate into small
intestinal enterocytes, formation of chylomicrons was associated with a significant increase
in basolateral secretion of LPS (46% vs. 11%, P<0.001). In T84 cells, not known to secrete
chylomicrons, translocation of LPS was significantly lower (9% vs. 2%). Strikingly, basolateral
medium obtained from BCG-infected CaCo-2 cells (but not T84 cells), free from live BCG
after 21 days of culture onMiddlebrook agar, induced proliferation of PBMCs from vaccinated
volunteers only when chylomicron formation had been induced (TC/OA/BCG group). Media
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from the TC/BA/BCG group or from uninfected cells did not induce proliferation. Proliferation
was significantly reduced when infected CaCo-2 cells had been incubated with Pluronic L-
81, an inhibitor of chylomicron formation. No proliferation was observed in PBMCs from
non-vaccinated volunteers in any group. CONCLUSION: Luminal antigens acquired by
enterocytes are secreted on chylomicron particles which can subsequently stimulate an
immune response. We propose this to be a novel mechanism allowing the immune system
to rapidly respond to food-borne pathogens.
W1523
Faecal Bacterial Dgge Profiles of Crohn's Disease Patients Are Different from
Those of Their Healthy First Degree Relatives and Matched Healthy Controls
Marie Joossens, Tom Vanhoutte, Vicky De preter, Kristel Van steen, Liesbet Henckaerts,
Ingrid Arijs, Geert Huys, Kristin Verbeke, Peter Vandamme, Paul Rutgeerts, Severine
Vermeire
INTRODUCTION AND AIM Crohn's disease (CD) is a chronic recurrent disease. Although
general dysbiosis has been described in CD, no causative pathogens have been identified
so far. Since recent findings suggest that the host genotype affects the bacterial community
in the human gastrointestinal tract, microbiota of CD patients, their unaffected relatives and
matched healthy controls were compared. METHODS Total bacterial DNA was extracted
from faecal samples of 66 CD patients and 82 unaffected relatives from 25 families and 26
healthy controls from 5 matched control families. A culture-independent approach using
PCR-DGGE (Denaturing Gradient Gel Electrophoresis) population fingerprinting was applied
to determine the composition of the predominant faecal flora, using universal 16S primers
targeting the V3 region of the 16S rRNA gene. The presence and the intensities of the bands
on DGGE profiles were analysed with BioNumerics 4.6 software and statistics were done
using SPSS 14.0. RESULTS On the total of 174 PCR-DGGE profiles, 79 band-classes were
identified. Both the presence and the intensities of the bands per class were analysed. A
highly significant difference between CD patients and unaffected controls (unaffected relatives
and healthy controls) was observed based on three band-classes bc24, bc48 and bc52 with
a Mann-Whitney U test and after Bonferroni correction for 79 classes (p= 1.8 10-5; 4.7 10-
4; 1.8 10-5 respectively). These band classes could tentatively be assigned to enterobacterial
organisms for bc24 and to clostridial organisms for bc48 and bc52 based on position. At
positions of bifidobacterial organisms no significant differences were observed. The three
differing band-classes were further analysed in a Kruskal Wallis Test comparing patients,
unaffected relatives and healthy controls. Even after simple correction for multiple testing
highly significant results were again obtained for bc24, bc48 and bc52 (p=3.2 10-4; 7.1
10-3; 1.9 10-4 respectively). DISCUSSION AND CONCLUSION Comparison of DGGE
banding patterns indicated three band-classes bc24, bc48 and bc52 which significantly
differed between CD patients, unaffected relatives and matched healthy controls. Band-
classes bc24 and bc52 were more frequently absent or less intense in patients whereas bc48
was more frequently present or more intense in patients compared with both healthy
control groups. To confirm our hypothesis that these band-classes contain possible causative
organisms, we are currently performing band sequencing analysis.
W1524
Interleukin-10 Prevents Colitis Despite Epithelial Invasion By Enterobacter
Cloacae
Beate C. Sydora, Alexander Swidsinski, Maryla Lupicki, Sarah M. Macfarlane, Thomas A.
Churchill, Karen Madsen, Richard N. Fedorak, Levinus A. Dieleman
Background: Intestinal microflora is essential for the development of colitis in Interleukin-
10 gene-deficient (IL-10 KO) mice. Monoassociation of germ free IL-10 KOmice has revealed
that some bacteria such as Escherichia coli and Enterobacter faecalis are able to induce colitis
in these mice, whereas other bacteria such as Bacteroides vulgatus, Streptococcus viridans, or
Lactobacillus species have no effect. Purpose: Enterobacter cloacae (E. cloacae) is another
commensal bacterium found in the intestinal tract of humans and rodents. To investigate
the effect of E. cloacae on the development of chronic intestinal inflammation we fed this
organism to germ free IL-10 KO mice and their wild type 129/SvEv littermates. Methods:
Germ free IL-10 KO and wild type 129/SvEv mice were orally gavaged with 5x107 CFU of
E. cloacae. Five and 10 weeks post feeding the mice were sacrificed and various parts of the
intestine were collected for histology, cytokine release in colonic explant cultures, and
fluorescence in situ hybridization (FISH) to study the location of E. cloacae in these tissues.
Splenocytes and mesenteric lymph node (MLN) lymphocytes were stimulated with sonicates
prepared from pure cultures of E. cloacae or various other commensal bacteria as well as
fecal lysates derived from germ free, E. cloacae-monoassociated, or SPF littermates to measure
proliferative responses and cytokine production. Results: In E. cloacae-monoassociated wild
type mice the highest numbers of bacteria were observed in the proximal colon. E. cloacae
entered crypts and goblet cells in high numbers and invaded epithelial cells at the crypt
bottom, but did not induce colitis. In contrast, in monoassociated IL-10 KO mice single
bacteria were only sporadically observed in crypts and were absent in the cecal and colonic
epithelium. Despite these findings, E. cloacae induced rapid onset of inflammation in the
cecum with a vigorous bacteria-specific Th-1 cytokine response in these mice. Conclusions:
E. cloacae had a profound pro-inflammatory effect on the intestinal and systemic immune
system of IL-10 KO mice as determined by a Th-1 cytokine response specific for its disease-
inducing organism, resulting in early onset cecal inflammation. Despite penetration of E.
cloacae into the intestinal epithelium the presence of endogenous IL-10 prevented the
development of colitis in monoassociated wild type mice.
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A Lower Proportion of Firmicutes On Resected Ileal Crohn's Mucosa Is
Associated with Endoscopic Recurrence At 6 Months
Philippe Seksik, Nadia Vasquez, Patricia Lepage, Mangin Irene, Jean-paul Duong, Harry
Sokol, Matthieu Allez, Jean-claude Soulé, Xavier Treton, Gwenola Vernier-massouille,
Stephanie Blum, Eduardo Schiffrin, Joel Dore, Philippe Pochart, Philippe Marteau
Background and aims:Mucosa-associated microbiota (MAM) plays a role in Crohn's disease
(CD). Our aim was to investigate if changes of MAM were related to risk of postoperative
recurrence of ileal CD. Patients and Methods: Within a clinical trial conducted by the
GETAID testing the probiotic Lactobacillus jonhsonii LA1 (Nestlé) versus placebo to prevent
endoscopic recurrence in CD, we obtained surgical samples from 22 patients with ileal CD
and biopsy samples of their neo-terminal ileum six months later. Ten patients received LA1
4x109 cfu per day and 12 received placebo 1 to 3 days before surgery and thereafter for 6
months.We analysed the composition of the ileal MAMusing fluorescent in-situ hybridization
with 7 group-specific probes (Eubacteria, Bacteroides, Enterics and relatives, Bifidobacterium
genus Lactobacillus-Enterococcus, Clostridium coccoides and Faecalibacterium prausnitzii). Com-
parisons were performed using Student's t test or Wilcoxon's test when appropriate. Results:
At the time of surgery, groups distribution of the MAM was Bacteroides 31.7 +/- 8.6%, C.
coccoides 15.5 +/- 6.0%, Enterics 8.8 +/- 5.4%, Bifidobacterium 3.9 +/- 1.9%, Lactobacillus-
Enterococcus 3.0 +/- 1.6% and F. prausnitzii 1.2 +/- 0.7%.(and 30% of the bacteria did not
belong to the7 major groups). At 6 month (n=20), the global distribution was similar to
initial assessment. There was no difference in the composition of the MAM between LA1
and placebo groups at the time of surgery or 6 months after. Thirteen patients (LA1 n=6,
placebo n=7) had endoscopic recurrence (Rutgeerts score ≥ 2). Focussing results on recur-
rence status, two differences were observed. (I) At the time of surgery proportions of F.
prausnitzii were significantly lower in CD patients who exhibited endoscopic recurrence six
months later (0.2 +/- 0.2% vs 3.2 +/- 1.7%, respectively; p=0.03), (II) 6 months after, the
proportion of Firmicutes (C. coccoides and F. prausnitzii) was lower in CD patients with
endoscopic recurrence as compared to those in remission (14.7 +/- 5.7% vs 35.5 +/- 5.0%,
respectively, p=0.02). Conclusion: After an ileo-caecal resection for CD, overall composition
of the ileal MAM remained stable between pre and postoperative conditions but proportions
of Firmicutes were low in patients with recurrence. Lower proportions of F. prausnitzii were
observed in patients who exhibited endoscopic recurrence six months later. These results
confirm the decrease in bacteria of the dominant phylum Firmicutes previously observed in
CD microbiota.
W1526
Dextran Sulfate Sodium Colitis Exacerbated By Enterotoxigenic Bacteroides
Fragilis
Shervin Rabizadeh, Shaoguang Wu, Ki-jong Rhee, David L. Huso, Cynthia L. Sears
INTRODUCTION: Inflammatory bowel disease (IBD) is proposed to result from a dysregul-
ated mucosal immune response to the colonic flora in genetically susceptible individuals.
Enterotoxigenic Bacteroides fragilis (ETBF), a molecular subclass of the common human
commensal, Bacteroides fragilis, has been associated with IBD. We chose the dextran sulfate
sodium (DSS)-induced colitis murine model to test the hypothesis that ETBF triggers and
exacerbates colitis. METHODS: Four week old C57BL/6 male mice were pre-treated with
streptomycin (5 g/L) and clindamycin (100 mg/L), in their drinking water, to enhance
bacterial colonization with B. fragilis strains and a subset had received 2% DSS for 5 days
prior to bacterial inoculation. Wild-type (WT) nontoxigenic Bacteroides fragilis (NTBF) strain
9343(pFD340) and WT ETBF strain 86-5443-2-2 were inoculated via orogastric tube (~109
bacteria or 0.2 ml); sodium bicarbonate (0.2 ml) was used for sham inoculation. Assessment
of clinical status (weight, activity, appearance) was daily; mice were sacrificed 2 to 4 days
post-inoculation. Cecal or colon sections (5 μm) were graded for inflammation on a scale
from 0 (none) to 4 (severe with complete destruction of epithelium). Unpaired t-test was
used for statistical analysis.RESULTS: All mice, including those receiving DSS, were clinically
well with positive weight gain prior to bacterial inoculation. NTBF and ETBF colonization
was similar (~1010 colony forming units/gm stool). On days 2 to 4 post-inoculation, the
mean weight gain in the ETBF+DSS group was significantly less than all other groups
(p<0.005). There was no significant difference in the weight change between other groups.
All mice appeared clinically well, except the ETBF+DSS group who had rectal bleeding (2/
10), mucosal ulceration of the anus (2/10), lethargic appearance (5/10), or death (2/10) by
day 2 post-inoculation. Average cecum and colon inflammation scores (Table 1) were
significantly higher in the ETBF+DSS group compared to all other groups (p<0.05). The
average cecum, but not colon, inflammation scores of the ETBF group were significantly
higher than all other groups (p<0.01) except the ETBF+DSS group. CONCLUSION: ETBF,
a colonic commensal, significantly worsens cecitis and colitis in DSS-treated mice. This
study suggests that ETBF may be a trigger to exacerbate inflammation in patients with
underlying IBD.
Cecum and Colon Inflammation
W1527
Escherichia coli in the Intestinal Mucosa of Crohn's Disease Patients: Just a
Commensal Bacterium?
Margarita Martinez-medina, Xavier Aldeguer, Doroteo Acero, Ferran Gonzalez-huix,
Mireia Lopez-siles, Jesus Garcia-gil
The role of bacteria in Crohn's disease (CD) has received special attention in the last few
years. In particular, Escherichia coli (EC) has been suggested to play a role in the onset of
the inflammatory response [1-4]. This bacterium has recently been shown to be more
prevalent in CD patients [5] EC strains isolated from CD patients have been analyzed and
compared with those from healthy controls in order to identify and characterize the patho-
genic strains. A total of 1600 presumptive EC from fresh ileo-colonic biopsies corresponding
to 8 CD patients, 10 healthy controls and 2 patients suffering from Ulcerative Colitis, were
isolated. Biopsies were subjected to a mild sonication in order to discard the transient and
loosely attached bacteria followed by a mild osmotic shock, to release any intracellular
bacteria from those outer epithelium cells. EC was isolated on TBX agar medium and further
confirmed by indole assay. The clonaltity of isolates was checked by PFGE using two enzymes
(XbaI and SpeI). The presence of virulence genes cnf1, cnf2, hly, iuc, papG, sfa/foc, afa,
cdtB, neuC, stx1, stx2, eae, bfp, ipaH, pCDV432, eltA and est was tested by PCR. A total
of 1600 presumptive E.coli from 8 CD patients, 10 healthy controls and 2 patients suffering
from Ulcerative Colitis, were isolated. After analyzing the clonality of the isolates, a total of
31 different EC subtypes were obtained. On average, 1.93 ± 0.96 different strains per
individual were found, with no significant differences between CD patients and controls.
Except for 5 subtypes, which were found in two patients each, every EC clone were unique
to each human carrier, which supports the idea that the host-microbe relationship in the
gut ecosystem is controlled by complex factors. We have not found genetic relatedness
among EC from CD patients in terms of presence of certain known virulence genes, neither
by their PFGE profile. Our results so far indicate that there is not a common strain inhabiting
the colonic mucosa of CD patients, as previously suggested. Nevertheless, the pathogenic
features of the isolates are currently under study, since the possibility of certain common
features of EC from CD patients in terms of pathogenicity cannot be ruled out. [1] Darfeuille-
Michaud A et al, 2004. Gastroenterology; 127(2):412-21. [2] Helen M. Martin et al, 2004.
Gastroenterology;127(1):80-93 [3] Masseret E et al, 2001. Gut; 48:320-325. [4] Ryan M.D
et al, 2004. Am J Gastroenterol; 99:1539-1543. [5] Martinez-Medina et al. 2006. Inflammat-
ory Bowel Diseases ; 1136-1145
W1528
Prior Enteric Nematode Infection Alters Mucosal Defense to Infectious Colitis
Diana C. Riera, Allen Smith, Thomas L. Sutton, Kathleen B. Madden, Rex Sun, Jennifer
A. Stiltz, Carolyn A. Sullivan, Joseph Urban, Aiping Zhao, Terez Shea-donohue
A major tenet of the hygiene hypothesis is that nematode-induced upregulation of Th2
cytokines protects against the development of proinflammatory Th1-driven pathologies.
Intestinal bacteria play a key role in the pathogenesis of IBD, however, there are no studies
on possible changes in the response to bacterial infections following resolution of a Th2
immune reaction. Aim: To determine the effects of prior Heligmosomoides polygyrus (Hp2)
infection on subsequent Citrobacter rodentium (Cr) infection-induced alterations in colonic
mucosal function. Methods: BALB/c mice received vehicle (Cont) or a Hp2 infection of the
small intestine. After 21 days, half of the mice in each group were given Cr to induce an
infectious colitis. All mice were studied 12 days later. In Cr infected mice, fecal bacterial
loads were measured at 3, 7 and 11 days. Muscle-free sections of colonic mucosae were
mounted in microsnapwells to determine transepithelial resistance (TER) or in Ussing cham-
bers to measure changes in short circuit current (Isc) in response to acetylcholine (Ach), 5-
HT, or histamine (HIST). Real-time PCR (RT-PCR) was used to determine expression of IL-
13, a prototypic Th2 cytokine, and IL-17A, a proinflammatory cytokine implicated in IBD.
Results: Bacterial loads were similar in both groups at all days post Cr infection indicating
that prior Hp2 infection did not alter clearance of Cr. Expression of IL-13 was similar in
all groups. In contrast, when compared to Cont, IL-17A expression was elevated significantly
(p<0.05) in Cr (3.3±1 fold) and in Hp2+Cr (3.2±1 fold). When compared to Cont, TER
was unchanged in mice in response to Hp2 or Cr alone, but was elevated after Hp2+Cr. Cr
inhibited colonic secretion in response to Ach, 5HT or HIST. In contrast, Hp2 alone had
no effect on colonic secretion, but was unable to alter the effects of Cr. Conclusion: Prior
upregulation of Th2 cytokines by Hp2 did not impact the subsequent Cr-induced effects
on IL-17A expression or colonic mucosal secretion that may be part of the protective immune
response to this pathogen. In contrast, prior upregulation of Th2 cytokines improved colonic
mucosal barrier function upon subsequent bacterial infection. This effect may contribute to
the beneficial effects of Th2-based therapies in IBD.
Values=mean±SE; *p<0.05 vs Cont; TER=Ω*cm2; changes in Isc=μA/cm2; secretagogues=
100 μM
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Magnitude and Duration of Virus Shedding of Norwalk Virus in a Human
Challenge System
Antone R. Opekun, Robert A. Atmar, Mark A. Gilger, Mary K. Estes, Frederick H. Neill,
Ananda Chandrasekaran, Crystal L. Ugarte, David Y. Graham
Noroviruses are the most common cause of epidemic gastroenteritis. Noroviruses are noncul-
tivatable and no small animal model exists, so pathogenesis studies must be conducted in
humans. We developed a new challenge pool of Norwalk virus (NV) consisting of the
prototype Norovirus strain, and administered 4800 RT-PCR units to 9 volunteers. Two
additional volunteers received placebo. Six of the subjects administered NV were infected,
four of whom developed clinical gastroenteritis (watery diarrhea or vomiting). Symptomatic
illness lasted 1-2 days. All six infected subjects shed virus as measured by antigen ELISA
and RT-PCR, and all six had >4-fold increases in serum antibody as measured by antibody
ELISA. Virus shedding was first detected by RT-PCR ~19.5 hours after inoculation and
lasted 28-32 days after inoculation in five of the six subjects. Virus shedding as measured
by antigen ELISA was first detected ~38.5 hours after inoculation and was last detected 9
days after inoculation. The peak amount of viral shedding was 0.5 to 100 million genomic
copies per mg stool as measured by qRT-PCR, and one subject shed > 0.5 million copies
per mg stool until day 14. The virus concentration in stools collected after day 14 was low
(range: 225-40,000 genomic copies per mg). This study demonstrates that peak virus
shedding is higher than expected when compared to previous results seen in electron
microscopy studies and that low levels of viral RNA are present in the stool for up to 4
weeks after infection. Support: NIH N01-AI-25465
W1530
Cytomegalovirus Blocks Apoptosis in Patients with Active Ulcerative Colitis
and Colonic Viral Infection
Roser Vega, Hussila Keshaw, Eugeni Domenech, Isabel I. Ojanguren, Miquel angel
Gassull, Alastair Forbes, Richard Day
Introduction: The immunological response of the colonic mucosa to cytomegalovirus (CMV)
infection in patients with active ulcerative colitis (UC) remains unknown. TNF-related
apoptosis-inducing ligand (TRAIL) mediated apoptosis is increased in patients with inflam-
matory bowel disease. Human CMV is known to block apoptosis in different types of cells
despite an up-regulation of TRAIL and TRAIL membrane receptors. Aim: To examine the
apoptosis rates in active UC patients with and without CMVinfection; and investigate the
expression of TRAIL and TRAIL R1 and R2 in the colonic tissue of these patients. Materials
and methods: Paraffin embedded colonic tissue specimens were obtained from 8 non-steroid
resistant active UC patients, 8 steroid-resistant active UC, and 6 steroid-resistant active UC
with colonic infection by CMV, which were included in a clinical prospective study to
investigate the prevalence of CMV in UC. Apoptosis of epithelial and lamina propia cells
was assessed by immunohistochemical staining for cleaved caspase-3. Immunohistochemical
staining was also performed for TRAIL, TRAIL-R1 and R-2. Results: There was no significant
difference in disease activity index, CRP and ESR among the patient groups when the biopsies
were obtained. Histology assessment showed moderate to severe colonic inflammation.
Colonic CMV infection in the samples was confirmed by immunohistochemical staining for
CMV. TRAIL was strongly expressed in the epithelial cells in all samples, especially in the
upper 1/3 area of the crypts. The expression of TRAIL-R2 in lamina propia was higher in
infected patients compared to the patients without viral infection regardless to steroid
response. There were no differences in TRAIL-R1 expression among the different groups.
Apoptotic indices (proportion of caspase-3 positive cells from the total of cells counted) in
intestinal epithelial cells were significantly lower (0.27±0.15) in patients with CMV infection
compared with steroid-resistant patients (0.53±0.13) and non-steroid-resistant patients
(0.66±0.22) p<0.05. No significant differences in the apoptosis indices were seen in lamina
propia cells among the different groups. Conclusions: Apoptosis in colonic epithelial cells
decreases in CMV infected patients despite the presence of TRAIL and the expression of
TRAIL-R2. This may be explained by the capacity of the human CMV to encode proteins,
such as viral inhibitor of caspases-8-induced apoptosis (vICA) and viral mitochondrial
inhibitor of apoptosis (vMIA), which directly interfere with the apoptotic signalling pathway
in infected tissues. CMV may contribute to steroid resistance in UC infected patients
W1531
Elevated Antibodies Against Flagellin Support the Concept of Low Grade
Mucosal Inflammation in Irritable Bowel Syndrome
Alain Schoepfer, Thomas Schaffer, Beatrice Seibold-schmid, Stefan Mueller, Frank Seibold
Background: Irritable bowel syndrome (IBS) is thought to arise amongst other reasons by
low grade mucosal inflammation. Flagellin, the primary structural component of bacterial
flagellae, leads in inflammatory bowel disease to the activation of the innate and also adaptive
immunity. So far it is not known if IBS patients have elevated antibodies to flagellin. Aim:
to analyze the frequency of antibodies to flagellin in different patient groups and to compare
them with IBD antibodies. Methods: In 116 patients (34 Crohn's disease, 31 ulcerative
colitis, 21 irritable bowel syndrome (IBS) and 30 healthy controls) we measured antibodies
to Flagellin (FAB, type F2), ASCA (both ELISA), anti-pancreas antibodies (PAB) and p-
ANCA (both IF). Diagnosis was established upon the clinical presentation and endoscopic
workup, all IBS patients additionally had an upper endoscopy and measuring of fecal
calprotectin (Phical-test). Results: All IBS patients fulfilled the ROME II criteria and had
normal fecal calprotectin (mean 21mg/mL, SD 6.6). Frequency of antibodies: see Table 1.
IBS patients had FAB significantly more frequently than HC (p=0.003, Fisher exact test).
Frequency of ASCA was not different in IBS compared to HC (p=1.0, Fisher exact test).
Conclusions: In contrast to ASCA, PAB and p-ANCA, the FAB were found in a significantly
higher frequency in IBS patients compared to HC. This observation supports the concept
that low grade mucosal inflammation has a putative role in the development of IBS at least
in a subgroup of patients.
Frequency of antibodies in different patient groups
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W1532
Bacterial Translocation in the Mesenteric Lymph Nodes of Patients Operated
On for Ileal Crohn's Disease
Patricia Lepage, Joel Dore, Nadia Vasquez, Irene Mangin, Philippe Seksik, Harry Sokol,
Stephanie Blum, Eduardo Schiffrin, Philippe Pochart, Philippe Marteau
Introduction: Bacterial translocation (BT) is defined as the phenomenon by which live
bacteria or their products, cross the intestinal barrier. The first organ encountered by the
translocated organism is the mesenteric lymph node (MLN). In Crohn's disease (CD),
increased intestinal barrier permeability could result in a higher occurrence of bacterial
translocation and permanent immune stimulation. As most of the gut bacteria are uncultiv-
able, we used microbial molecular methods to analyse BT in mesenteric lymph nodes of
patients with Crohn's disease. Patients and Methods: MLN were sampled during surgery
from 10 CD patients undergoing ileo-caecal resection. These patients were included in a
therapeutic trial, conducted by the GETAID, testing the efficacy of the probiotic strain LA1
(Nestlé) in preventing postoperative recurrence. Biopsies were also taken from the resected
ileum in macroscopically non-ulcerated (NU) and ulcerated (U) regions. Bacterial DNA
extracted from both biopsies and internal fractions of the MLN were then analyzed using
temporal temperature gradient gel electrophoresis (TTGE) after 16S rDNA amplification
whereas occurrence of bacterial cells was assessed in 8 of these MLN by fluorescent in situ
hybridization. Results: TTGE profiles of bacterial DNA were detected in 6 out of 10 MLN.
Dominant bands were arbitrarily removed from the gels and sequenced. These 16S rDNA
showed over 98% similarities with known sequences isolated from the intestinal microbiota.
A high similarity was observed between the dominant bacterial profiles of 3 of the MLN
and the ileal mucosa with average similarity percentages of 93.2% ± 4.7 with NU mucosa
and 92.9% ± 5.2 with U mucosa. For the 3 others, average similarity percentages were
65.0% ± 28.6 with NU ileum and 8.7% ± 5.9 with U ileum. Interestingly, bands observed
in MLN profiles were always observed in ileal ones. Bacterial cells were detected on the
surface of 3 out of 4 TTGE positive MLN but none was observed inside the MLN. No
bacterial cells were observed for the MLN driving no TTGE profiles. Conclusion: In CD
patients, bacterial DNA translocation was frequently observed albeit no entire bacterial cells
were detected. Factors responsible for a “total” or “sampled” bacterial DNA translocation
should be elucidated on a bigger cohort. Considering the potential impact of BT on the
human immune system, a better understanding on mechanism and features of BT in health
and disease is a main challenge.
W1533
Colonization Densities of Altered Schaedler Flora Remain Stable in the Ceca
of Colitic C3h/Hen Mice Infected with Helicobacter bilis
Meghan Wymore, Albert E. Jergens, Zhiping Liu, Jennifer Wilson-welder, Abigail
Henderson, Andrea Dorn, Michael J. Wannemuehler
Background: Infection with Helicobacter bilis has been shown to trigger aggressive immune
reactivity to the resident flora that is associatedwith the development ofmucosal inflammation
in gnotobiotic C3H mice. However, changes in the composition of the resident microflora
that contribute to host immune reactivity after experimental infection are not well understood.
Aim: To evaluate temporal changes in colonization densities of the resident, defined flora
(e.g., the altered Schaedler flora [ASF]) in gnotobiotic mice concurrently infected with
Helicobacter bilis and to correlate these observations to the development of colitis. Methods:
Gnotobiotic C3H/HeN mice harboring the eight members of the ASF were selectively colon-
ized with H. bilis. Quantitative PCR protocols using unique 16s RNA sequences for each
of the ASF bacteria and H. bilis were performed on DNA extracted from cecal contents to
quantitatively evaluate differences in the ASF at weeks 3, 6, and 10 following H. bilis
colonization. Data on the levels of ASF and H. bilis were compared between control and
infected groups using a two-tailed t test. Results: All primers used provided the necessary
sensitivity and specificity for each of the ASF bacterial strains. Overall, the relative numbers
of the ASF strains did not vary between control (non-infected) and H. bilis-colonized mice.
ASF457 and ASF500 showed decreased (P < 0.05) abundance in mice colonized with H.
bilis at 3 weeks post-colonization but returned to background levels by 10 weeks post-
colonization. The colonization density of H. bilis was greatest (P < 0.05) 3 weeks post-
colonization versus more chronic time points and this correlated with the severity of colitis.
Conclusions: Molecular assessment of cecal contents obtained from the defined-flora mice
using qPCR assays allowed for quantitative analysis of the ASF flora and was a useful tool
for studying changes in the microecology of the murine gut following colonization with H.
bilis. While inducing immune reactivity to commensal members of the resident microflora,
colonization of gnotobiotic C3H/HeN mice with H. bilis did not significantly alter ASF
bacterial levels. These results suggest that the onset of aberrant immune responses to the
bacterial flora observed in IBD do not develop as a result of overt changes in the density
or composition of the resident flora.
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Molecular Characterization of Mucosal Enterobacteriaceae Isolated from
Patients with Inflammatory Bowel Disease
Liljana Petrovska, Barry Hudspith, Iruka Okeke, Gareth Parkes, Neil B. Rayment, Carlo
Nunes, Jonathan Brostoff, Gordon Dougan, John Wain, Jeremy D. Sanderson
Background: A number of groups, including our own, have reported consistent isolation
of Enterobacteriaceae (predominantly E.coli) from the inflamed mucosa of patients with
Inflammatory Bowel Disease (IBD). Previous studies from our group using fluorescent in-
situ hybridization suggest these bacteria lie within lamina propria macrophages in both
Crohn's disease (CD) and ulcerative colitis (UC). The exact phenotype of these bacteria has
not been fully established and any role in the pathogenesis of CD or UC remains uncertain.
Aim: The aim of this study was to undertake detailedmolecular characterization of Enterobac-
teriae isolated from the mucosa of patients with CD and UC. Methods: Paired mucosal
biopsies of inflamed mucosa from patients with CD (n=15), UC (n=11) and of normal
mucosa from healthy controls (n=8) were cultured in selective liquid media with and
without gentamicin (100ug/ml) for 30mins. Samples were then disrupted and transferred
to McConkey agar and cultured overnight. Initial typing of resulting colonies was undertaken
by API20E strips and serotyped. Finally, bacterial DNA was extracted and used for multi-
locus sequence typing (MLST) which types isolates according to the DNA sequence of 7
bacterial housekeeping genes. Results: All biopsies cultured without gentamicin produced
isolates, with one isolate being typed as Klebsiella and all the rest being typed as E.coli by
API20E. Colony numbers fromCD and UCwere 4 fold higher than controls.With gentamicin,
isolates were obtained from 12 of 15 (80%) CD, 4 of 11 (36%) UC but none from controls.
Higher colony numbers without gentamicin predicted an isolate with gentamicin. API20E
defined these as E.coli apart from the one patient with the isolate typed as Klebsiella spp
in the non-gentamicin culture who again was positive for this species. Standard HPA serotyp-
ing of gentamicin E.coli isolates defined these as E.coli 08, 0 rough or 0 unidentifiable
serotype. MLST analysis showed a different allelic profile in each isolate including 3 previously
unreported MLST profiles. Furthermore, in each patient the non-gentamicin and gentamicin
isolates were identical. Conclusions: The MLST profiles suggest that intracellular isolates of
Enterobacteriaceae (predominantly E.coli) are those resident at the mucosal surface. Some
isolates have a unique and previously unidentified serotype and genotype suggesting that
certain specific properties, as yet undefined, may permit submucosal access. Alternatively,
the colony numbers support an entirely passive phenomenon. Further molecular analysis
of known virulence factors may reveal common properties predicting submucosal presence
in IBD.
W1535
Tribbles 2 (Trb2) Is a Negative Regulator of Nf-κB Signaling
Shu-chen Wei, Ian M. Rosenberg, Alan Huett, Emiko Mizoguchi, Ramnik Xavier, Daniel
K. Podolsky
Background: Toll-like receptors (TLRs) play a crucial role in the detection of invading
pathogens as well as triggering of subsequent immune and inflammatory responses. Recogni-
tion of microbial components by TLRs triggers a cascade of cellular events that culminates
in the activation of NF-κB, which leads to inflammatory gene expression, and clearance of
the infectious agent. To identify cDNAs that encode NF-κB inhibitors downstream of TLR
signaling we have developed and implemented a high-throughput expression cloning plat-
form. Through these approaches we have identified Tribbles2 (TRB2). The mammalian TRB
genes are the orthologs of the Drosophila tribbles genes. Aims: To examine the role of TRB2
in experimental models of mouse colitis and the regulation of NF-κB in the TLR signaling
pathway. Materials and Methods: The expression of TRB2 mRNA in colonic epithelial cell
lines was assessed by RT-PCR. To determine the involvement of TRB2 in the NF-κB pathways,
TRB2 as well as the NF-κB reporter and renilla construct were transfected into HEK293/
TLR4MD2CD14 cells. After 24 hours, the cells were treated with Lipopolysaccharide (LPS)
for 6 hours, and luciferase assays were subsequently performed. cDNA was prepared from
colonic tissue taken on days 0 and 8 from mice orally treated with DSS (4% DSS for 5 days;
regular water as a control group) and days 4 and 8 TNBS induced murine colitis (ethanol
as a control group). The expression of TRB2 was analyzed by quantitative PCR with GAPDH
as an internal control. Independent student t-test was used for the statistical analysis. Results:
TRB2 is expressed in SW480, HCT116, HT29 human colonic epithelial cell lines. TRB2
expression was up-regulated (3 fold, compared to no treatment) after 4 hours of 10ng/ml
LPS treatment. TRB2 expression decreased on day 4, acute phase of TNBS colitis, and
returned to baseline on day 8, recovery phase from the acute colitis. For the DSS colitis,
TRB2 also decreased on day 8 (inflammatory phase) compared to day 0. Over expression
of TRB2 in the stably transfected TLR4 cells significantly inhibited NF-kB activation (p=
0.001). Conclusion: TRB2 is a negative regulator of NF-κB in the TLR signaling pathway,
and is significantly down-regulated during the inflammatory phase in mousemodels of colitis.
W1536
Altered O-Glycosylation Pattern On the Muc2 Mucin in Patients with Active
Ulcerative Colitis
Jessica M. Holmén larsson, Hasse Karlsson, Jessica J. Gråberg, Malin E. Johansson,
Lisbeth Eklund, Henrik Sjövall, Gunnar C. Hansson
Introduction: The colon commensal flora is surprisingly stable. The mechanisms for this
are not understood, but one important reason for the specific occupation of their habitat is
interactions of bacteria with the mucus. This can be mediated by more or less specific
mechanisms, where the specific interaction of bacterial adhesins with mucin glycans is the
most likely. The main mucin building the mucus of colon is the heavily glycosylated MUC2
mucin and it is thus relevant to study this in relation to ulcerative colitis. Methods: We
have recently developed a high-throughput and sensitive approach for analyzing mucin O-
glycosylation in the small scale by the combination of a simple mucin preparative method,
agarose-PAGE gel electrophoresis, blotting, release of the O-glycans with OH—NaBH4 and
analysis by graphite nanoLC-mass spectrometry. Using this approach, we have analyzed
single sigmoid biopsies from 25 control and 25 ulcerative colitis patients. Results: We found
a surprisingly uniform distribution of the more than 50 glycans found in MUC2 of the
control patients, despite that these had different blood groups. Almost all glycans were of core
3 type with a NeuAc attached to the C-6 of the GalNAcol (-GlcNAc-3(NeuAc-6)GalNAcol) and
negatively charged due to one or several sialic acids or sulfate groups or a combination of
both. Most of the ulcerative colitis patients in remission also had a similar glycan pattern
as the control patients. However, most of the patients with an active disease had smaller
amounts of certain more complex glycans and an increased amount of smaller, precursor
type pf glycans. Conclusions: The MUC2 mucin of normal patient sigmoid colon reveals a
complex mixture of glycans, but still relatively uniform between individuals. We have
previously shown in different systems that inflammation/infection can cause altered mucin
glycosylation (1,2). Ulcerative colitis patients with active disease showed a simplified glycosyl-
ation of the MUC2 mucin, most likely triggered by the inflammation. This may cause other
bacteria to occupy the colon mucus at active ulcerative colitis. 1. Olson, F. J., et al. (2002)
J. Biol. Chem. 277, 15044-52 2. Thomsson, K. A., et al. (2002) Biochem. J. 367, 609-16
W1537
Colon Is Protected By Two Mucus Layers Both Made Up By the Muc2 Mucin,
But with Different Properties
Malin E. Johansson, Joel Petersson, Mia Phillipson, Lena Holm, Gunnar C. Hansson
Introduction: The mucus covering the colonic mucosa was previously shown to consist of
two layers, the inner firmly adherent to the epithelia and the outer loosely adherent layer
that can be readily removed [1]. The firmly adherent layer could serve as an important
barrier to avoid contact between the normal flora and the epithelial cells. Pathogens, as
shown for the parasite Entamoeba histolytica, can penetrate the mucus by a specific cleavage
in the MUC2 mucin [2]. A more detailed understanding of the mucus composition is
important for targeting treatments to regenerate and improve this barrier upon infections
and inflammatory diseases. Methods: The two mucus layers in colon of C57Bl/6 mice were
removed and extracted in PBS or guanidinium chloride . Samples were separated by agarose-
acrylamide gel electrophoresis, stained with Alcian blue and quantified using the ImageJ
program. Bands were excised, trypsinized and peptides were analyzed by nanoLC-MS/MS.
Data was searched with the Mascot software using both the IPI and an in-house mucin
database. Results: Analysis of the two mucus layers in the colon by proteomics revealed that
both have the gel-forming Muc2 mucin as the main component. The mucus layers do not
only contain Muc2, but also a large number of associated molecules as identified by proteom-
ics. Some molecules are more strongly associated with the Muc2 mucin and most likely
attached by covalent linkages. Extraction of the two layers in guanidinium chloride revealed
a soluble loosely adherent layer whereas the firmly adherent layer is insoluble showing
different physical properties. The loosely adherent layer, 100µm thick, contains less Muc2
mucin as compared to the 50µm thick firmly adherent layer. This implicates that the firmly
adherent mucus gel is more compact and dense, hence a stronger physical barrier. The
volume expansion of the loosely adherent layer can be inhibited In Vivo by the addition of
protease inhibitors. The resulting loosely adherent layer is more compact containing more
Muc2 mucins including fragments normally observed only in the firmly adherent layer.
Conclusions: The colon is protected by two mucus layers made up of the Muc2 mucin. It
is likely that the loosely adherent mucus layer is generated from the firm layer and that the
volume expansion is due to proteolytic cleavages. These results give a more detailed picture
of how the colonic mucus gel is organized and will allow a better understanding of the
weakened mucus barrier in patients with ulcerative colitis. 1. Atuma, C. et. al. (2001) Am
J Physiol Gastrointest Liver Physiol 280, G922-G929 2. Lidell, M.E. et. al. (2006) Proc Natl
Acad Sci U S A. 103, 9298-9303.
W1538
Colonic Administration of Tlr7/8 Ligand R-848 Induces An Acute Local and
Systemic Inflammatory Response in Mice
Silvia Melgar, Agneta Karlsson, Lisa Karlsson, Helena Utkovic, Ake Jagervall, Per-göran
Gillberg, Erik Michaëlsson
Background/Aim: Imidazoquinoline compounds, such as Imiquimod (R-837) and Resiqui-
mod (R-848) are known to be topically active immune modulators that promotes Th1
immune responses. The aim of this study was to investigate the effect provoked by colonic
administration of R-848. Methods: R-848 was administrated intrarectally to BALB/c mice
and the inflammatory response was assessed by inflammatory markers in plasma and colon
homogenate using multiplex technology and quantitative PCR collected at several time
points. In addition, to validate if the inflammatory response could be modulated, mice were
pre-treated with methyl-prednisolone (1,10, 30, 100mg/kg p.o.) or anti-TNF antibody (3,
10, 30, 100 mg/mouse i.p.) one hour before R-848 administration whereupon tissue and
plasma was collected 3h post-R-848 administration. Result: Application of R-848 to colon
induced a transient elevation of plasma cytokines with a peak production of TNF at 60-90
min, KC at 90-120min, IL-6 at 120min, and IL-12p40 at 180min after R-848 administration.
The levels of all plasma cytokines were normalised 24h after R-848 administration. Colonic
mRNA expression of iNOS, IL-6, TNF and IL-12p40 was similarly increased in a time
dependent manner. However, histological analysis on R-848 treated colonic tissue showed
no infiltration of immune cells suggesting a local activation of resident cells. The inflammatory
response induced by R-848 could be attenuated bymethyl-prednisolone or anti-TNF antibody
by inhibiting the elevated production of plasma cytokines (TNF, IL-6, IL-12p40 and KC)
as well as by reducing the colonic TNF and iNOS mRNA expression in a dose dependent
manner. Conclusion: Local administrating of R-848 induces an acute systemic and local
inflammatory response, which can be attenuated by steroids or anti-TNF antibody, suggesting
that the R-848 induced inflammatory model can be useful in future validation of new targets
for intestinal inflammation e.g. IBD.
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TLR - Responsiveness of Cells in Adipose Tissue - A Possible Contribution to
Chronic Inflammation?
Arvind Batra, Markus M. Heimesaat, Stefan Bereswill, Jeannette Pietsch, Thorsten Stroh,
Rainer Glauben, Inka Fedke, Martin Zeitz, Britta Siegmund
Background: Even though hypertrophy of the mesenteric fat is a common feature in Crohn's
disease, it's biological significance is unknown so far. Recent data revealed that fat tissue is
far more than a sole site of energy storage, but a potent producer of various mediators
including pro-inflammatory adipokines and cytokines like leptin, IL-6 and TNF-α. Our
previous studies revealed the expression of functional TLR in adipocytes and preadipocytes.
To further evaluate the role of leptin in TLR-specific responsiveness in these cells, expression
of TLR-mRNA was quantitatively assessed in wildtype (WT) as well as leptin- (ob/ob) or
leptin-receptor-deficient (db/db) cells. Besides this, the regulatory effect of leptin substitution
on TLR-specific cytokine production was assessed. To further clarify whether In Vivo a direct
contact with, and thus a direct stimulation, of the mesenteric adipose tissue by bacteria
occurs, bacterial translocation was assessed in experimental colitis models.Methods: Expres-
sion patterns of TLR receptors (TLR) -2, -4, -5, -7 and -9 mRNA were evaluated in ob/ob,
db/db, wildtype (WT), as well as 3T3L1 preadipocytes and adipocytes by quantitative real-
time PCR (qPCR). To assess bacterial translocation into fat tissue, acute and chronic DSS-
colitis models were investigated in WT (C57Bl/Ks) mice, as well as BL6 and MyD88+/- mice,
and tissue samples including mesenteric fat were analyzed for the presence of life bacteria
by culture. Results: qPCR analysis revealed in ob/ob and db/db preadipocytes a significant
increase in TLR2, -4, -5 and -7 mRNA when compared to WT cells. In parallel, stimulation
of TLR4 induced 10-20 times higher IL-6 production in ob/ob and db/db cells as compared
to WT or 3T3L1 cells. Accordingly, substitution of preadipocytes with 500 ng/ml leptin
reduced LPS induced IL-6 production. Whereas no life bacteria were detectable in mesenteric
fat of mice suffering from acute DSS-colitis, chronic DSS-colitis resulted in bacterial transloca-
tion not only into mesenteric lymph nodes, spleen, and liver, but also into abdominal fat
of MyD88+/- mice. Conclusion: Our data provide strong evidence that during chronic
colonic inflammation bacterial translocation into mesenteric fat occurs. Hence, stimulation
of preadipocytes and adipocytes via TLR is likely, with TLR-expression and responsiveness
being furthermore affected by the adipokine leptin. Since TLR-specific stimulation of pread-
ipocytes and adipocytes induces production of the pro-inflammatory cytokine IL-6, a link
might exist between fat hypertrophy seen in chronic inflammatory disorders such as Crohn's
disease and the inflammation itself.
W1540
Toll-Like Receptor-4 (TLR4) Regulates Expression of Cx3cl1 (Fractalkine) and
Its Receptor Cx3cr1 in a Murine Model of Inflammatory Bowel Disease (IBD)
Tyralee Goo, Masayuki Fukata, Anli Chen, Daisy Conduah, Keith Breglio, David Hsu,
Maria T. Abreu
Background: Defects in innate immunity have been implicated in the pathogenesis of inflam-
matory bowel disease. We have previously shown that TLR4 -/- mice with acute colitis
have decreased neutrophil and monocyte recruitment, and increased bacterial translocation
compared to wild-type (WT) mice. Intestinal epithelial cells (IEC) interact with mucosal
dendritic cells to distinguish commensal bacteria from pathogens. The chemokine CX3CL1
is a monocyte chemoattractant that is necessary for dendritic cell intercalation into the
epithelium and sampling of intestinal bacteria. Aim: We hypothesized that TLR4 regulates
CX3CL1 expression in the intestinal mucosa. Methods: IEC lines expressing TLR4 (SW480),
deficient in TLR4 (T84), and SW480 cells transfected with small interference RNA (siRNA)
against TLR4 were stimulated with LPS and production of CX3CL1 and its receptor CX3CR1
were evaluated through quantitative real time-PCR. Additionally, TLR4-/- and WT mice
were evaluated in control and 7d oral dextran sodium sulfate (DSS) induced acute colitis.
Samples of the proximal colon were evaluated for CX3CL1 and CX3CR1 by real-time PCR.
Finally, lamina propia dendritic cells were isolated from TLR4-/- and WT mice by sorting
with anti-CD11c followed by ELISA for CX3CL1 secretion. Results: We found significant
induction of CX3CL1 and CX3CR1 by LPS in TLR4+ cells (SW480) but not TLR4 null cells
(T84). In addition, siRNA knock-down of TLR4 on SW480 cells resulted in significant
inhibition of CX3CL1 or CX3CR1 by LPS. Consistent with our In Vitro data, production of
CX3CL1 was 4 fold higher in WT mice compared to TLR4-/- mice in the setting of colitis.
CXCR1 was 15 fold higher in WT mice compared to TLR4-/- mice. Murine dendritic cells
were similar in number in WT and TLR4-/-, however, CX3CL1 secretion was significantly
lower in TLR4-/- mice. Conclusion: Our findings demonstrate that TLR4 regulates expression
of CX3CL1 and CX3CR1 in both IEC and dendritic cells in the colon. Thus, bacterial derived
signals are directly responsible for the induction of innate immune function in the intestine.
Polymorphisms in the TLR pathway may result in bacterial sampling defects in the intest-
inal mucosa.
W1541
Fractalkine Regulates TNF-α Secretion By Macrophages with Induction of
Peroxisome Proliferator-Activated Receptor-γ and Its Ligand
Noriko Mizutani, Toshiharu Sakurai, Takahiro Shibata, Koji Uchida, Jun Fujita, Rei
Kawashima, Yuki I. Kawamura, Noriko Toyama-sorimachi, Toshio Imai, Taeko Dohi
Fractalkine (CX3CL1, FKN) is a unique chemokine produced as a membrane boundmolecule
that consists of an intracellular tail, a short membrane-spanning region, and a glycosylated
mucin-like stalk that extends from the cell surface holding the chemokine domain. Besides
induction of chemotaxis, FKN also functions as an adhesion molecule to support leukocyte
adhesion and transmigration. Although expression of the chemokine FKN is enhanced in
inflamed tissue of inflammatory bowel diseases, considerable amount of FKN are detected
at steady state in the intestine, and its receptor CX3CR1 is highly expressed in intestinal
resident-type dendritic cells and macrophages. We found that colonic myofibroblasts as well
as epithelial cells produced FKN. Therefore, we hypothesized that FKN might regulate the
function of the immune competent cells. Murine macrophages were pretreated with FKN
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and then stimulated with lipopolysaccharide (LPS) to analyze cytokine secretion and signaling
pathways. Cells that were treated with FKN followed by LPS stimulation secreted 50% less
TNF-α than cells treated with LPS alone. Cells treated with FKN and LPS also showed
reduced phosphorylation of Erk1/2 and reduced nuclear translocation of nuclear factor
(NF)-κB p50 subunit. Interestingly, the p65 subunit of NF-κB translocated to nuclei but
redistributed to cytoplasm in the early phase, forming a complex with peroxisome pro-
liferator-activated receptor (PPAR)-γ. Exogenous 15-deoxy-Δ12,14-prostaglandin J2 (15-
dPGJ2), a natural ligand for PPAR-γ, also induced redistribution of p65 with decreased
TNF-α secretion after LPS challenge. Finally, we found that pretreatment with FKN increased
the cellular levels of 15-dPGJ2 as well as mRNA of PPAR-γ. These anti-inflammatory effects
of FKN provide novel insight into the role of physiological levels of FKN for maintenance
of intestinal immune homeostasis.
W1542
Apoptosis Down-Regulation Characterizes the Improved Intestinal Repair
Mediated By Osteopontin Deficiency in DSS-Induced Colitis
Jian Zhong, Erik Eckhardt, Helieh S. Oz, Munira Nasser, Dennis C. Bruemmer, Willem J.
De villiers
Background: Osteopontin (OPN), a secreted glycoprotein that promotes Th1 immune
responses, is involved in several inflammatory conditions. Previously we showed that OPN
deficiency attenuates dextran sodium sulfate (DSS)-induced colitis in OPN-/- Black Swiss
mice (Inflamm Bowel Dis 2006; 12: 790-796). OPN has also been reported to have an
important role in the regulation of apoptosis. Here we further studied the potential mechanism
of OPN in the regulation of colitis in mice. Methods: Colitis was induced in OPN -/- mice
and matched wild-type C57BL/6 control mice by adding 3.5% DSS to their drinking water
for 7 days. Disease progression was evaluated for 10 days by measuring body weight, stool
consistency and rectal bleeding, colon lengths, histology, and immunohistochemistry. Levels
of the acute phase protein serum amyloid A (SAA), OPN, the pro-inflammatory cytokines
IL-6 and IL-12, and the anti-inflammatory cytokine IL-10 were measured in the serum and,
in the case of IL-10 and IL-12, also from colonic tissue at the end of treatment. 5-bromo-
2-deoxyuridine (BrdU) was injected 24 h prior to sacrifice to assess epithelial proliferation.
Caspase-3 activity assay was evaluated in colon tissue. Colonic Bcl-2, Bcl-Xl, Fas, Fas-L, Bax
and Bad immunoblots were performed and intestinal proliferation was evaluated by PCNA
immunolabeling. Results: OPN-/- mice consistently showed markedly less severe DSS-
induced colitis as shown by death rate, clinical scores, decreased SAA and colonic IL-6 and
IL-12 levels and decreased colonic histological damage scores. Macrophage infiltration into
inflamed colonic tissue was also markedly attenuated in DSS-treated OPN -/- mice compared
to wild-type mice. Colonic epithelial cell proliferation was significantly increased in OPN-/-
mice compared to wild-type mice after DSS treatment as shown by BrdU labeling and PCNA
immunolabeling studies. Caspase-3 activity was decreased in OPN-/- mice. Colonic Bcl-Xl,
Fas, Fas-L,Bax and Bad protein expression remained the same during DSS treatment in both
OPN-/- and C57BL/6 mice. However, in OPN-/- mice Bcl-2 level was significantly increased
at the end of the treatment. Conclusion: These results confirm that OPN deficiency protects
against the development of colitis. The protective effect is Bcl-2 related and the underlying
mechanisms include increased epithelial cell proliferation and tissue repair as well as suppres-
sion of pro-inflammatory cytokines and macrophage chemotaxis.
W1543
Lactococcus Lactis Modulates T-Cells Through An Antigen-Specific Effect On
Dendritic Cells
Inge L. Huibregtse, Toni Van capel, Henri Braat, Esther C. De jong, Sander J. Van
deventer
Introduction: Mucosal delivery of ovalbumin (OVA) by genetically modified Lactococcus
lactis (LL-OVA) induces suppression of local and systemic inflammatory OVA specific T-
cell responses in OVA-TCR transgenic mice (DO11.10). The suppression is mediated by
the induction of an unusual population of CD4+CD25- ‘adaptive' regulatory T-cells which
are critically dependent on TGF-β. Here, we further investigated the mechanism by exposing
bone marrow-derived dendritic cells (bmDC) to viable L.lactis (LL) with or without purified
OVA and by assessing subsequent instruction of antigen-specific T-cell responses. Methods:
BmDC were generated from femurs of OVA-TCR+ mice (DO11.10) and primed with LL
with or without OVA or LL that were engineered to express OVA. After 48 h DC were
analysed for their phenotype using FACS analysis on different maturation markers as well
as used to stimulate enriched DO11.10 CD4+ T-cells. To characterise the direct T-cell
response, proliferation and differentiation was measured by 3H-thymidine incorporation
and intra-cellular IFN-γ and IL-4 measurements. Results: OVA at various concentrations
had no effect on DC maturation, but LL increased the expression of CD80 and CD86 albeit
to a lesser extent than LPS. The presence of LL increased the fraction of OVA-specific IFN-
γ positive cells (3.18 vs 1.74%), but also decreased antigen-specific T cell proliferation
compared to 100nM purified OVA alone (3747.5 +/- 199.5 vs 11469.5 +/- 2370.5). Conclu-
sion: These data indicate that LL alter the phenotype of (mature) DC, leading to decreased
antigen-induced proliferation of CD4+ T cells. Utilizing genetic modified bacteria for the
induction of antigen-specific oral tolerance is a new possibility for the treatment of several
common intestinal autoimmune and inflammatory diseases of the gastro-intestinal tract.
W1544
Tnfa Production Is Reduced But the Number of Internalized Viable Bacteria Is
Increased in Metabolically Stressed Macrophages
Jackie L. Caldwell, Derek M. Mckay
Macrophages are an important component of innate immune and link innate and adaptive
immune responses. We have shown that metabolically stressed T84 epithelial cell monolayers
display a pronounced decrease in barrier function following exposure to non-pathogenic,
non-invasive E. coli. Postulating that metabolic stress evoked by, for instance, ischemia or
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NSAIDS would not be restricted to the epithelium, we hypothesized that macrophages under
metabolic stress would have a perturbed ability to respond to bacteria that crossed the
epithelium. This hypothesis was tested using the human THP-1monocytic cell line, differenti-
ated into a macrophage-like phenotype by exposure to phorbol myristate acetate. Methods:
THP-1 cells were treated with E. coli (strain HB101, 10^6 cfu/ml) ± dinitrophenol (DNP;
uncouples oxidative phosphorylation, 0.1mM) and 6h later the following parameters were
examined: mitochondrial activity via the MTT assay, caspase 3 cleavage as an indicator of
apoptosis, bacterial internalization (expressed as a percentage of the extracellular bacteria),
TNFα measured by ELISA, and toll-like receptor (TLR)-4 mRNA levels determined using
RT-PCR. Results: THP-1 cells treated with DNP displayed ~50% reduction in mitochondria
activity as assessed by the MTT assay (n=3), but remained viable as the level of caspase 3
cleavage was unaltered (n=4). The metabolically stressed THP-1 cells displayed a consistent
and significant increase in viable intracellular bacteria (6.8% in stressed vs 4.5% in non-
stressed THP-1 cells; p<0.05; n=6) (DNP did not affect the viability of extracellular bacteria).
Additionally, DNP-treated THP-1 cells exposed to E. coli produced significant amounts of
TNFa (1.7±0.4 ng/mL), although less than that made by non-stressed macrophages (3.9±0.5
ng/mL, p<0.05, n=5). TLR4 mRNA levels were unchanged as a consequence of E. coli +
DNP (n=4). Conclusions: Resident and recruited macrophages are key elements of the enteric
immune system that have been implicated in IBD. Here we show that metabolic stress,
which can arise from many insults, has marked effects on how macrophages respond to
bacteria. We speculate that the enhanced bacterial survival in stressed macrophages coupled
to the production of pro-inflammatory cytokines (substantial amounts of TNFa were made)
would be of pathophysiological significance in IBD by rendering the immune response more
vulnerable to bacteria and via cytokine-induced increases in epithelial permeability. Funded
by Crohn's & Colitis Foundation of Canada and Canadian Institutes for Health Research.
W1545
Paneth Cell Alterations in Necrotizing Enterocolitis and Intestinal Innate
Defense
Patrycja J. Puiman, Nanda Burger-van paassen, Maaike W. Schaart, Adriaan cj M. De
bruijn, Ronald R. De krijger, Dick Tibboel, Johannes B. Van goudoever, Ingrid B. Renes
Background: Paneth cells (PCs), normally present in the crypts of Lieberkühn in the small
intestine only, synthesize and secrete anti-microbial peptides that play an important role in
innate immunity. Little is known about PC-functions in necrotizing enterocolitis (NEC), the
most common gastrointestinal disease in premature infants. Aim: To study the presence and
functions of PCs in the intestine of preterm infants with acute NEC and those recovering
from NEC. Methods: Small intestinal (n= 23) and colonic tissue (n=17) was obtained at
bowel resection for acute NEC and at consecutive stoma closure. Presence of PCs was
determined by phloxine tartrazine staining. Expression of the antimicrobial peptides lyso-
zyme, trypsin and secretory phosholipase A2 (sPLA2) was studied immunohistochemically
as parameter for PC-specific functions. Moreover, lysozyme and sPLA2 levels in ileostomic
outflow fluids from these infants were analyzed to determine PC secretion capacity. Results:
In both acute and regenerative NEC, PCs in the small intestine were present and positive
for lysozyme, trypsin, and sPLA2. PC numbers seemed increased during the regenerative
phase of NEC. Furthermore, metaplastic PCs were detected in colonic tissue obtained
during stoma closure, in contrast to the absence in acute NEC. In the metaplastic PCs,
immunohistochemical staining was positive for lysozyme, trypsin, and sPLA2. Finally,
secreted lysozyme and sPLA2 were present in the ileostomic outflow fluid of NEC patients.
Conclusions: PCs in the small intestine of premature infants with NEC synthesize and secrete
anti-microbial peptides. Increased numbers of PCs in the small intestine and metaplastic
PCs in the colon at stoma closure suggest increased innate defense in regenerative NEC. In
conjunction, our data suggest an important role of PCs in intestinal innate immunity in
preterm infants with NEC.
W1546
Patterns and Distribution of Gastrointestinal (GI) Pathology in Patients with
Common Variable Immunodeficiency (CVID): A Disease with Many
Presentations
Jason A. Daniels, Anirban Maitra, Howard M. Lederman, Elizabeth A. Montgomery
Background: Patients with CVID develop a host of gastrointestinal (GI) lesions that mimic
other conditions, leading to misdiagnosis and delay in therapy. Methods: After IRB approval,
we reviewed 108 GI specimens from 16 CVID patients obtained over a 25 year period,
including samples from the colon (31), esophagus (13), small intestine (32), stomach (29),
gallbladder (2), and appendix (1). Results: There were 7 females and 9 males. Five were
children and 11 were adults. Age at diagnosis ranged from 6 months to 58 years (median,
38 years), and age at biopsy ranged from 10 months to 67 years (median, 38 years).
Immunoglobulin levels at diagnosis showed decreases in IgG, IgA, and IgM. IgG levels
showed a mean of 150 mg/dL; range <3 to 448 mg/dL (normal 690 to 1620 mg/dL). IgA
levels showed a mean of 24 mg/dL; range 0 to 170 mg/dL (normal 70 to 380 mg/dL). IgM
levels showed a mean of 47 mg/dL; range 7 to 126 mg/dL (normal 60 to 260 mg/dL).
CVID was associated with many autoimmune/immunologic diseases including autoimmune
hepatitis (1), autoimmune metaplastic atrophic gastritis (3), scleroderma (1), sarcoidosis
(3), arthritis (1), juvenile rheumatoid arthritis (1), thyroiditis (1), diabetes mellitus (1),
autoimmune neuropathy (1), myocarditis (1), and anti-IgA antibodies (1). Neoplasms identi-
fied included gastric adenocarcinoma (1), large cell lymphoma (1), squamous cell carcinoma
(1), renal cell carcinoma (1), and meningioma (1). Multiple infectious agents were identified
in the biopsies, including Cryptosporidium, Cytomegalovirus (CMV), Candida, Helicobacter
pylori (HP), and Giardia. The histology is shown in Table 1. Conclusions: GI tract CVID
displays many histologic patterns. Its features can mimic lymphocytic colitis, collagenous
colitis, celiac disease, lymphocytic gastritis, granulomatous disease, acute graft-versus-host
disease, and inflammatory bowel disease (IBD). In fact, in our series, cases were initially
misdiagnosed as celiac disease (5) and IBD (6), including Crohn's disease (3), resulting in
a delay of diagnosis of CVID. The correct diagnosis may be suspected based upon the lack
of plasma cells in a GI biopsy.
Table 1: Histology of CVID
W1547
Mannose-Binding Lectin Deficiency Does Not Predispose to Helicobacter pylori
Infection
Daniel L. Worthley, Charles G. Mullighan, Melinda M. Dean, David L. Gordon, Peter
Phillips, Susan Heatley, Graeme P. Young, Peter G. Bardy
Introduction: Mannose-binding lectin (MBL) is a pattern-recognition molecule that can bind
to pathogens and initiate the lectin-complement cascade. In certain clinical situations, MBL
deficiency can increase the risk of infectious and other disease specific complications. Muta-
tions in the MBL2 gene can significantly impair MBL function and up to 40% of the
general population is heterozygous (A/O) or homozygous (O/O) for a deficient allele. MBL2
deficiency, specifically the HYD haplotype, has recently been associated with an increased
risk of gastric cancer. We examined whether MBL status influences the prevalence of H.
pylori infection. Methods: Two healthy populations were evaluated. The first consisted of
166 volunteer blood donors, the second included 108 peripheral blood stem cell donors.
All were tested for serological evidence of H. pylori infection, and had their MBL status
characterized by genotyping and quantification of plasma MBL activity by performing the
antigenic MBL level, mannan binding and C4 deposition assays. Genotyping assessed the
-550 (H/L), -221 (X/Y), and the codon 52Cys, 54Asp, and 57Glu MBL2 polymorphisms
using the polymerase chain reaction and sequence-specific primers. H. pylori seropositivity
was determined by a quantitative IgG ELISA. Results: H. pylori positive blood donors had
higher blood MBL levels, as measured by C4 deposition (median 0.67 v. 0.40, p=0.009,
HR 2.82, 95% CI 1.29-6.19) and mannan-binding assays (median 1.83 v. 1.26, p=0.02,
HR 1.28, 95% CI 1.03-1.59). These results were reflected in a trend between the low-
activity MBL2 genotypes (O/O, A/O, and LXA/LXA) and a reduced prevalence of H. pylori
(Chi-square 3.25, p = 0.07). No significant associations were found in the second population,
nor when the two groups were combined. In the total cohort the rate of H. pylori positivity
was 27.8% in those with no coding mutation (A/A) Vs 26.3% in those homozygous for a
coding mutation (O/O), and. when plasma MBL activity was used to define MBL sufficiency,
the rate of H. pylori positivity was 27.8% in the sufficient group Vs 23.6% in the insufficient
group (both were not significant). There was no association between theMBL2HYD haplotype
and H. pylori seropositivity. Conclusions: MBL deficiency does not increase the risk of H.
pylori infection, and in one group there was the suggestion that MBL deficiency might protect
against H. pylori, for which there is a theoretical basis. This study is particularly relevant,
given the recent association demonstrated between MBL deficiency and gastric cancer. Our
study suggests that this association does not result from an increased risk H. pylori infection.
W1548
Gsno Modulates Aggression of Intestinal Epithelial Barrier By Shigella
Flexneri
Mathurin Flamant, Arnaud Bourreille, Philippe Aubert, Emmanuel Coron, Philippe
Sansonetti, Jean paul Galmiche, Tor Savidge, Michel Neunlist
Introduction: Enteric glial cells (EGC), surrounding epithelial cells regulate intestinal epithe-
lial barrier (IEB) functions. In a precedent study, we demonstrated their protective role upon
IEB during its aggression by Shigella flexneri (SF). The glial factors involved remain unknown.
GSNO (S-nitrosoglutathione), produced by EGC, has antiinflammatory and neuroprotective
properties. The aim of our study was therefore to determine whether the protective effects
of EGC upon IEB could be mediated by GSNO. Materials and methods: A coculture model
composed of EGC and confluent human colonic epithelial cells (Caco-2) was used. Transwell
filters were cocultured in absence (Caco-2/—) or in presence of EGC (Caco-2/EGC), in
presence of enteric glial cells supernatant (Caco-2/S) or in presence of GSNO (50mM) (Caco-
2/GSNO) for 24h prior to infection with the invasive strain of SF (M90T). Following 90
min of infection, the filters were incubated for another 30minwith culture medium containing
gentamicin. Caco-2 filters were then maintained an additional 16 hours in coculture. At
16h post-infection, we measured a) the monolayer resistance, b) the IL-8 levels in the apical
and basolateral medium by ELISA, c) the infection sites on the filters by immunohistochemical
analysis with antibodies against SF. Results: In the Caco-2/EGC model as compared to Caco-
2/— model we observed a) a reduction in the decrease of resistance induced by SF of 39%
(n=7,P=0.02), b) a reduction of IL-8 secretion by 42% in the apical medium (n=7, P=0.009)
and 54% in the basolateral medium (n=7,P=0.008), c) a reduction of 64% of Caco-2
monolayer infection (n=7, P=0.016). In the Caco-2/S model as compared to Caco-2/—, we
observed a) a reduction of IL-8 secretion in the basolateral medium by 44% (n=3) and b)
a reduction of Caco-2 monolayer infection by 47% (n=3). Finally, in the Caco-2/GSNO
model as compared to Caco-2/—, Il-8 secretion was reduced by 22% in the apical medium
(n=5, P=0.009) and by 23% in the basolateral medium (n=6,P=0.03). Caco-2 monolayer
infection was reduced by 49% (n=3). Conclusion : Protective effects by EGC upon IEB
during its aggression by SF can be related to the production of a soluble factor. Our results
suggest that GSNO could be in part responsible for these effects. The mechanisms and
signaling pathways remain to be identified.
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Bacterial TLR and NOD2 Ligands Decrease In Vitro Radiation-Induced Cell
Death of Colonic Epithelial Cells in a P38mapk Dependent Fashion
Nikolas W. Gerstgrasser, R. balfour Sartor
Background: Ionizing radiation (IR) dose-dependently damages the DNA of rapidly dividing
cells, leading to cell cycle arrest, apoptosis and activation of the transcription factor nuclear
factor κB (NFκB). Several exogenous agents that activate NFκB, including bacterial lipopoly-
saccharide (LPS), interleukin 1 (IL-1) and tumor necrosis factor (TNF), prevent IR-induced
intestinal injury when administered before In Vivo IR exposure. Commensal and pathogenic
microbial components activate NFκB and the mitogen-activated protein kinases (MAPK) by
selectively binding to pattern recognition receptors, such as the toll-like receptors (TLR)
and the intracellular bacterial recognition domain NOD2/CARD15. Aim: Determine the
influence of bacterial TLR and NOD2 ligands on the sensitivity of intestinal epithelial
cells (IEC) to IR-induced injury and the intracellular signaling pathways that mediate this
protection. Material & Methods: CMT-93 murine colonic cells were incubated with various
doses of 16-16 dimethyl PGE2 (dmPGE2), LPS (E.coli K-235), peptidoglycan (PG-PS) from
group A streptococcus, synthetic muramyl dipeptide (MDP) and TNF 24h before exposure
to increasing single doses of IR, using a 137Cesium source at a dose rate of 77 cGy/min.
The specific inhibitors NS-398 as well as Bay11-7082 and SB239063 were used to block
COX-2 as well as the NFκB- and p38MAPK-pathways, respectively. To determine clonogenic
survival following IR, cells were incubated for 8±2d at 37°C in ambient air with 5% CO2.
Colonies of >50 cells were counted after staining with crystal violet. Cell survival was
corrected for plating efficiency. Results: Clonogenic survival of CMT-93 cells was dose-
dependently reduced with a cell survival rate of 37±5.1% at 2 Gy, 18±3.5% at 4 Gy and
<5% at >6 Gy. Incubation with LPS, PG-PS, MDP, TNF and PGE2 showed dose-dependent
radioprotective effects. At 2 Gy, pretreatment with PG-PS 1µg/ml, 2µg/ml, 5µg/ml and 10µg/
ml increased clonogenic survival 1.4, 2.1, 2.3 and 2.1-fold, respectively, compared to
untreated controls. This increased survival with PG-PS could be 91% inhibited by SB239063.
However, administration of Bay11-7082 or NS-398 did not show significant effects. Conclu-
sions: These results suggest that TLR and NOD2 ligands protect IEC from IR-induced cell
death by a p39MAPK-dependent mechanism.
W1550
Ghrelin Agonist Activity Restores Gut Transit and Normalizes Food Intake in
a Rodent Model of Post-Operative Ileus
Kalina M. Venkova, Graeme L. Fraser, Hamid R. Hoveyda, Beverley Greenwood
Postoperative ileus (POI) is characterized by delayed gastrointestinal (GI) transit and reduced
food intake. Previous studies showed that a novel ghrelin receptor agonist TZP-101 normal-
ized delayed gastric emptying and intestinal dysmotility in rats with POI. The aim of this
study was to determine whether TZP-101 restores colonic transit and normalizes food intake
in a rodent model of POI. Methods: Fasted rats were treated with morphine (3 mg/kg s.c.)
and subjected to laparotomy and manipulation of the bowel. Following surgery a dye-marker
was injected into the proximal colon and colonic transit time was measured by the appearance
of the first dye-marked fecal pellet. Food intake and fecal output were measured 24 and
48 h post-surgery. TZP-101 (0.03-1 mg/kg) or vehicle was administered as 3 bolus i.v.
infusions (1st infusion 15-min after the end of surgery, 2nd and 3rd infusion following 2-
h intervals). Colonic transit and food intake in naïve animals, not subjected to surgery or
drug treatment, were evaluated. Results: Colonic transit time in fasted naïve rats was 8 ±
1 h, cumulative fecal pellet output for 24 hours was 48 ± 8 pellets or 3.5 ± 0.7 g/100 g
body weight (b.wt.) and food intake was 3.5 ± 0.7 g/100 g b.wt. In rats with POI colonic
transit time was increased, while fecal pellet output and food intake were reduced during
0-24 h post-surgery. TZP-101 (0.3 and 1 mg/kg) reversed the inhibition of colonic transit
and increased fecal pellet output and food intake in rats with POI (Table 1). Summary:
TZP-101 improved colonic transit and increased food intake in a rat model of POI, suggesting
that activation of ghrelin receptors prevents and/or reverses surgery-induced delay in colonic
transit. The decrease in colonic transit time and increase in food intake may be a consequence
of the previously reported, direct effect of TZP-101 to increase gastric emptying after surgical
ileus. In addition, TZP-101 may have direct effects on pathways regulating food intake and
colonic transit. Conclusion: The effect of TZP-101 on GI transit and food intake implies
that synthetic ghrelin receptor agonists may be useful in clinical practice to prevent and
reverse the symptoms of POI.
Table 1.
One-way ANOVA: p<0.01; * p<0.05 compared to vehicle Dunnett's MCT
W1551
Stabilization of Atoh1 Protein Induces Mucin2 Gene Expression in Human
Colon Cancer Cells
Kiichiro Tsuchiya, Ryuichi Okamoto, Takanori Kanai, Mamoru Watanabe
Background & Aims: A member of bHLH transcription factors, Atoh1 and its human
homolog; Hath1 act as a critical factor for terminal differentiation of epithelial cell toward
to the secretory cells in intestine. We showed a novel function of the Wnt-GSK3 axis that
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plays an important role in balancing cellular differentiation and proliferation via the inverse
regulation of Hath1 and β-catenin protein stability (Gastroenterology inpress). Turning off
the Wnt signal forces GSK3 to degrade β-catenin and to stabilize Hath1 protein by using
ubiquitin-proteasome system, which subsequently causes goblet cell-type differentiation
represented by the expression of Mucin2 gene. However, it remains unclear whether the
stabilization of Hath1 protein itself has the potential to direct differentiation toward the
secretory lineage cells. In this study, we tested the possibility whether the stabilization of
Hath1 protein might directly induces the differentiation toward the secretory cells despite
the aberrant Wnt signal. Methods: An expression plasmid encoding Hath-1 or mutant Hath1
gene was transfected into 293T cells or colonic carcinoma-derived SW480 cells or DLD1
cells, and expression level of Hath-1 protein was analyzed byWestern blotting. The molecular
domain responsible for degradation and transcriptional activity of Hath1 protein was deter-
mined by using various mutant proteins. Transcriptional activity and mRNA expression of
the Mucin2 gene under expression of various mutant Hath1 proteins were analyzed by
Luciferase assay and RT-PCR, respectively. Results: The Hath-1 protein was actively degraded
in both SW480 cells and DLD1 cells where Wnt signal is constitutively activated. Mutational
analysis of Hath-1 showed that the N-terminal lesion of Hath1 is essential for both degradation
of Hath1 protein and transcriptional activity for Mucin2 expression. Partial deletion of the
N-terminus of Hath1 protein enabled stable expression of the protein in colon cancer cells,
but disrupted its transcriptional activity at the same time. Conversely, replacement of 54th
and 58th Serine on Hath1 protein by Alanine, which corresponds to the consensus sequence
of GSK-3 substrates, enabled stable expression of the Hath1 protein, maintaining its transcrip-
tional activity for Mucin2 gene expression in DLD1 cells. Conclusion: We showed that
Hath1 mutation replacing two distinct Serines by Alanines has a potential to direct differenti-
ation toward the secretory cells even in cancer cells with aberrant Wnt signal, providing
novel molecular basis for the development of colon cancer therapeutics.
W1552
Phenotypic Characterization of Human Myofibroblasts Isolated from Sporadic
Colonic Adenocarcinomas
Randy C. Mifflin, John Di mari, Suimin Qiu, Iryna V. Pinchuk, Jamal I. Saada, Pat R.
Gulhati, Don W. Powell
Background & Aims: While colorectal cancer is viewed as a disease of the epithelium, the
stroma, through epithelial-mesenchymal interactions, plays a key role in the process of
carcinogenesis. We have demonstrated that global myofibroblast activation occurs in neo-
plastic human colorectal tissue and that activated myofibroblasts occupy a significant portion
of the tumor stroma. We tested the hypothesis that cancer-associated myofibroblasts contrib-
ute to an abnormal tumormicroenvironment and are phenotypically distinct frommyofibrob-
lasts isolated from non-neoplastic tissue.Methods: Primary cultures of humanmyofibroblasts
were established from excess surgical tissue comprised of either histologically normal colonic
tissue or colonic adenocarcinoma (n=4 each). General growth properties of each isolate were
monitored. Functional differences were assessed by co-culturing either rat IEC-6 or human
CaCo-2 epithelial cells upon confluent myofibroblast monolayers. Differences in gene expres-
sion were analyzed by microarray analysis. Results: Cancer-derived myofibroblasts exhibited
a retarded growth rate with population doubling times at least twice that of cells isolated
from normal tissue. CaCo-2 cells cultured upon normal myofibroblasts grew as tightly
associated clusters, or islands, with clear demarcations between epithelial and stromal com-
partments. In contrast, CaCo-2 cells cultured upon cancer-derived myofibroblast isolates
did not form such clusters and were spread about the monolayer suggesting reduced homo-
typic cellular adhesion. No differences were observed between IEC-6 cells cultured upon
lawns of either myofibroblast type. At a confidence level of 99.9%, 117 genes were differenti-
ally expressed between the two groups. These genes were associated with extracellular matrix
assembly (e.g. CSPG4, p=7.7x10-5; fibulin 1, p=1x10-4), TGFβ signaling (e.g. TGFβR3, p=
2x10-4), transcription factors (e.g. cEBPδ, p=1x10-4; FOXP4, p=4x10-4), and intracellular
signaling cascades (e.g. RhoQ, p=9.3x10-5; RhoGAP22, p=3x10-4). Conclusions: These data
demonstrate that cancer-associated myofibroblasts of colorectal adenocarcinomas are distinct
from those of normal tissue and that many of these phenotypic differences persist when
cells are placed in culture. The altered growth properties of the cancer-derived myofibroblasts
are similar to the replicative senescence observed in stromal cells from other tumor types.
The expression profiling studies indicate that remodeling of the extracellular matrix may be
responsible for the differences observed in the co-culture studies and pinpoint potential
targets for intervention. (Supported by DK55783 and UTMB GRIP)
W1553
Wnt Signaling Plays a Critical Role in Intestinal Mucosal Repair Through
Interaction with Lrp-Receptors After Injury
Lan Liu, Rao Jaladanki, Tongtong Zou, Bernard Marasa, Lan Xiao, Ai-hong Zhang, Jie
Chen, Douglas Turner, Jian-ying Wang
In response to mucosal injury, epithelial cells modify the patterns of expressed genes in
order to repair damaged tissue rapidly. Our previous studies have shown that the transcription
factor c-myc is necessary for stimulation of epithelial cell renewal during mucosal healing,
but the up-stream signaling initiating c-myc gene expression after injury remains unknown.
Wnts are cysteine-rich glycoproteins that act as short-range ligands to locally activate receptor-
mediated signaling pathways. Recently, Wnt signaling has been established importance in
determining intestinal mucosal development and cell fate, and activation of Wnt signaling
often correlates with the increased expression of the c-myc gene. The current study tested
the hypothesis that Wnt signaling is implicated in intestinal epithelial cell renewal during
healing by stimulating c-myc expression. Methods: Studies were conducted in IEC-6 cells,
derived from rat intestinal crypts. Wnt signaling was provided by co-culture of IEC-6 cells
with stable Wnt3-transfected fibroblasts (Wnt-Fs). Levels of Wnt and LRP proteins were
examined by Western blot. Functions of LRP-6 receptors were investigated by transfection
with specific siRNAs targeting LRP6 mRNA (siLRP). Repair was measured in an in co-culture
model thatmimics cell division-dependent mucosal healing. Results:Wnt-Fs highly expressed
Wnt3, and the level of Wnt3 protein was ~50-folds the control value. When Wnt-Fs were
co-cultured with IEC-6 cells, they activated LRP-receptors and stimulated epithelial repair
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after wounding. The denuded area was covered with newly divided cells by ~98% in co-
culture system 16-h after wounding, while denuded areas were covered by ~40% when
IEC-6 cells were cultured alone or with parental fibroblasts. This increased repair was
repressed by inactivation of Wnt signaling by either transfection with specific siRNA targeting
Wnt3 mRNA or addition of immunoneutralizing anti-Wnt3 antibody. Furthermore, transfec-
tion with siLRP not only dramatically decreased levels of LRP6 protein but also significantly
repressed repair process after wounding. Levels of LRP6 protein were decreased by ~90%
after transfection with siLRP in co-culture system, while repair was repressed by ~80%.
Consistently, activation of Wnt signaling after wounding was associated with a significant
increase in c-myc expression as indicated by induction of its promoter activity, mRNA, and
protein. Conclusion: These results indicate that 1) Wnt signaling plays a critical role in
intestinal epithelial repair through interaction with LRP-receptors and 2) activation of Wnt
is associated with an increase in c-myc expression during healing.
W1554
Myofibroblast Wnt-5a Facilitates Intestinal Epithelial Repair Through a Non-
Canonical Pathway
Meera Sebastian, Amina Mohamed, James W. Wilson, Julio Galvez, Ian R. Sanderson,
Laurens Kruidenier
Background: Subepithelial myofibroblasts are closely involved in the initiation and coordina-
tion of intestinal epithelial repair in the inflamed gut, but the molecular signalling pathways
are largely unknown. The cellular adaptations that occur during repair range from de-
differentiation and migration to proliferation and re-differentiation, in a way that is strongly
reminiscent of normal crypt-to-villus epithelial maturation. Because theWnt/β-catenin signal-
ling pathway has emerged as one of the key regulators of the self-renewing capacity of the
intestine, we hypothesised that it has a similarly pivotal role in intestinal epithelial wound
repair. Method: We used an established scratch wound method in Caco-2 cells to monitor
the effects of colonic myofibroblasts (CCD-18co) on intestinal epithelial repair. Results:
Caco-2 wound closure over 24 hours was increased almost 2-fold by the presence of
conditioned media from IL-1β stimulated, but not untreated, CCDs. In parallel, IL-1β-
stimulated CCDs down-regulated the differentiation markers sucrase-isomaltase and villin
in the Caco-2 cells, while the proliferation marker c-myc was up-regulated. Expression
profiling identified Wnt-5A as the one Wnt-related gene that was differentially expressed
between the IL-1β stimulated (up 27-fold) and untreated CCDs. Increased Wnt-5A protein
expression was confirmed by Western blot analysis. Specific removal of Wnt-5A from the
IL1β-CCD conditioned media by immunodepletion completely abrogated the repair benefit
of these media. Wnt-5A is thought to signal through a non-canonical, β-catenin-independent,
pathway. Indeed, the canonical Wnt antagonist Dickkopf-1 could not prevent IL1β-CCD-
mediated repair. Furthermore, total and phosphorylated β-catenin protein levels in Caco-2
cells did not change after exposure to IL-1β-stimulated CCDs, and we confirmed that IL1β-
stimulated CCDs did not antagonize LiCl-induced canonical signalling. Conclusions: These
results identify an important role for myofibroblast-derived, non-canonical, Wnt-5A signal-
ling in the de-differentiation and migration stages of epithelial wound repair in the gut.
W1555
Polyamines Modulate Cytoplasmic Levels of RNA-Binding Proteins Hur
Through AMP-Activated Protein Kinase and Importin-α1 in Intestinal
Epithelial Cells
Tongtong Zou, Lan Liu, Jaladanki N. Rao, Bernard S. Marasa, Lan Xiao, Myriam Gorospe,
Jian-ying Wang
Maintenance of intestinal mucosal epithelial integrity requires cellular polyamines that regu-
late expression of various genes. We have recently found that polyamine depletion increases
cytoplasmic levels of HuR stabilizing nucleophosmin and p53 mRNAs, thus leading to
inhibition of intestinal epithelial cell (IEC) proliferation. However, how polyamine depletion
causes HuR abundance in the cytoplasm remains unknown. The AMP-activated protein
kinase (AMPK) is shown to reduce the cytoplasmic levels of HuR and its regulatory effect
is mediated by an adaptor protein importin-α1 (Impα1). The current study tested the
hypothesis that polyamines regulate cytoplasmic levels of HuR by altering AMPK/Impα1
activity in IECs. Methods: Studies were conducted in the IEC-6 cells derived from rat small
intestinal crypts. Levels of cytoplasmic, nuclear, and total AMPK, Impα1, and HuR proteins
were examined by Western blot analysis and immunofluorescence staining. Ectopic expres-
sion of the APMK gene was induced by infection with the recombinant adenoviral vector
containing wild-type AMPK cDNA (AdAMPK), while functions of Impα1 were investigated
by stable transfection with various Impα1 mutants. Results: Deletion of cellular polyamines
by DFMO, the specific inhibitor of polyamine synthesis, repressed AMPK activity as indicated
by decreases in total and phosphorylated AMPK proteins (by ~80%). Inactivated APMK
decreased levels of Impα1 protein, which was associated with an enhanced cytoplasmic
abundance of HuR. In contrast, increased cellular polyamines by overexpression of the
ODC gene activated AMPK, increased Impα1, and reduced cytoplasmic levels of HuR. In
polyamine-deficient cells, stimulation of AMPK activity, by either treatment with its chemical
activator antimycin-A or infection with AdAMPK, not only induced Impα1 levels but also
prevented the increased cytoplasmic HuR. Stable wild-type Impα1-transfected cells exhibited
a significant reduction of cytoplasmic HuR, while cells overexexpressing Impα1 mutant
proteins, including Impα1-K22R (lacking acetylation site), Impα1-S105A (lacking phos-
phorylation site), and Impα1-K22R/S105A (lacking both sites), displayed a dramatic increases
in levels of HuR in the cytoplasm. Ectopic expression of Impα1mutant proteins also prevented
the increased levels of cytoplasmic HuR following polyamine depletion. Conclusions: These
results indicate that 1) polyamines are necessary for AMPK activation triggering HuR nuclear
import through Impα1 and 2) polyamine depletion increases cytoplasmic levels of HuR as
a result of inactivation of AMPK/Impα1 signaling.
W1556
Molecular Identity and Cellular Distribution of Na-Glutamine Co-Transporters
Along the Villus-Crypt Axis of Rabbit Small Intestine
Prosenjit Saha, Ramesh Kekuda, Jamil Talukder, Uma Sundaram
BACKGROUND: Glutamine is the preferred substrate for the enterocytes. However, the
molecular identity of the transporters responsible for glutamine assimilation along the villus-
crypt axis of the small intestine was unknown. AIM: Identification and determination of the
distribution of Na-glutamine co-transporters along the villus-crypt axis in the rabbit small
intestine. METHOD: Villus and crypt cells were isolated from the rabbit intestine by a Ca++
chelation technique. Brush border membrane vesicles (BBMV) were prepared from villus
and crypt cells by Ca++ precipitation and differential centrifugation. Uptake studies were
done by rapid filtration technique with 3H-Glutamine. Total RNA was isolated from the
enterocytes using TRIzol reagent. Real-time quantitative PCR was performed to determine
the levels of B0AT1 and SN2 message. Immunohistochemical analysis of B0AT1 and SN2
was done in formalin fixed, paraffin embedded tissue sections using anti-B0AT1 and anti-
SN2 polyclonal antibody raised in goat and chicken respectively. Secondary antibodies
conjugated with FITC were used for immuno-fluorescence. Western blot was performed
using protein extract of BBMV in RIPA buffer. Proteins were separated on 4-20% gradient
SDS-PAGE and detected by ECLTM kit. RESULTS: Na-dependent glutamine uptake was
significantly higher in villus cell BBMV as compared to crypt cell BBMV (91±1.8 pmole/mg
protein in villus and 21±3, in crypt, p<0.01, n=3). RTQ-PCR analysis showed that the
message level of B0AT1 was more in the villus (8 fold, p<0.01, n=3) in comparison to crypt.
In contrast, SN2 message was significantly higher in crypt cells (10 fold, p<0.01, n=3).
Immunohistochemistry of rabbit intestinal epithelium revealed that B0AT1 is the Na-glutam-
ine transporter in the villus cells while SN2 is responsible for Na-glutamine co-transport in
the crypt cells. Densitometric analysis of Western blot expression revealed that B0AT1
transporter was expressed more (5 fold, p<0.01, n=3) in villus cell BBMV. In contrast SN2
was greater in crypt cell BBMV (6 fold, p<0.01 n=3). CONCLUSION: Uptake studies, RTQ-
PCR analysis, immunohistochemical localization and protein analysis showed that B0AT1
is the predominant Na-Glutamine co-transporter in the villus cells. In contrast, SN2 is the
predominant co-transporter in the crypt cells. Thus, different Na-glutamine co-transporters
are responsible for the assimilation of this important nutrient along the villus crypt axis of
the small intestine.
W1557
Ethanol Causes Apoptosis of Human Colon Cancer Cells Through
Mitochondrial Translocation of Bax Phosphorylated By Stress-Activated
Protein Kinases
Young-mi Lee, Bong-jo Kim, Suck-chei Choi, Ki-jung Yun, Yong-ho Nah, Byoung-joon
Song
Numerous studies suggest that ethanol can damage various cells in culture. In addition,
mitochondrial translocation of pro-apoptotic Bax prior to apoptosis is well-established under
apoptosis-inducing conditions or after treatment with many cell death stimulants including
ethanol. However, the mechanism of cell damage is still unknown with respect to early
signaling cascades including mitogen activated protein (MAP) kinases and the mechanism
of mitochondrial translocation of Bax in HT-29 cells. The aim of current research is to
investigate the mechanism of Bax activation and mitochondrial translocation to initiate
apoptosis in HT-29 cells exposed to ethanol. Ethanol caused time- and dose-dependent cell
death in HT29 cells. Ethanol also stimulated the activities of JNK and p38 kinase in a time-
dependent manner. The activation of JNK and p38 kinase was important in cell death since
treatment with a respective inhibitor of JNK or p38 kinase significantly reduced the rate of
ethanol-induced cell death. Phosphorylation of Bax after ethanol exposure was demonstrated
by the shift of the pI value of phosphorylated Bax on 2-D gels. Phosphorylation of Bax and
apoptosis were mediated through stress-activated JNK and p38 kinase, since specific inhib-
itors of JNK and p38 kinase significantly inhibited Bax phosphorylation, mitochondrial
translocation of Bax, cytochrome c release, caspase-3 activation, and apoptosis in HT-29
cells. In conclusion, our current results show that Bax is phosphorylated by stress-activated
JNK or p38 kinase and that phosphorylation of Bax leads to mitochondrial translocation
prior to apoptosis of HT29 colon cells.
W1558
Proteome of the Murine Jejunal Brush Border (BB)
Mark Donowitz, Siddharth Sing, Farah Salahuddin, Boris Hogema, Marjen Gucek, Robert
E. Cole, Yueping Chen, Nicholas Zachos, Olga Kovbasnjuk, Lynn Lapierre, James R.
Goldenring, Hugo Dejonge, Xuhang Li
The apical plasma membrane of epithelial cells of the GI tract have unique components. In
the small intestine, the BB and tight junctions are highly developed domains which perform
many of the unique functions of the gut. These include digestion, absorption, andmaintaining
permeability and selectivity barriers. Identification of the proteins in this domain, called the
BB proteome, is an important step in fully understanding normal and abnormal function
of the intestine. To define the BB proteome, jejunal villus epithelial cells from 12-20 wk
male mice were isolated by vibration, and BB membranes subsequently prepared by Mg
precipitation. The BB were studied for enrichment of BB markers and contamination of
other organelles by western blotting (IB). 3 separate BB preparations showed 50x enrichment
of BB markers alkaline phosphatase and NHE3, deenrichment of basolateral marker Na-
K-ATPase, and no identifiable contamination with ER (calnexin), Golgi (Golgin-84), or
mitochondria. All BB contain tight junctional tags with only small amounts of basolateral
membranes. The BB were digested with trypsin, exposed to iTRAQ reagents (Isobaric Tagging
for Relative and Absolute Quantitation) , fractionated by strong cation exchange (SCX)
chromatography/HPLC and each SCX fraction analyzed by Qstar-Pulsar MS (LC-MS/MS).
The MS/MS spectra were analyzed with ProteinPilot software with cutoff of 90% certainly
and validation of some proteins performed by PCR or IB. A total of 570 proteins were
identified in the BB membranes based on identification in at least one of the 3 separate BB
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preparations. Of these 155 (27%) were present in 1 preparation, 278 (49%) in 2 and 137
(24%) in all 3. 123 of these proteins were known residents of other organelles and 17 were
from immunologic cells. The remaining 430 proteins, were in the following categories:
transporters (46), 10.7%; BB digestive enzymes (20), 4.6%; tight junction (10), 2.3%;
cytoskeletal (71), 16.5%; endosomal/membrane trafficking (27), 6.3%; signaling (105),
24.4%; metabolic (95), 22.1%; degradative (19), 4.4%; stress related (15), 3.5%; unknown
(22), 5.1%.. Multiple transporters had never been identified as being present in the intestine,
although they were known resident in other epithelia. Conclusions: As the initial effort in
profiling the small intestinal BB proteome, this report not only confirms the presence of a
large number of known BB components, but also identifies many previously unknown BB-
associated proteins, some of which might be transiently present in BB as a part of regulatory
process rather than as permanent BB residents.
W1559
Transcriptional Regulation of Rabbit Intestinal Na-Glucose Co-Transport - Role
of Hnf-1 and Sp1
Ramesh Kekuda, Prosenjit Saha, Steven Coon, Jamil Talukder, Uma Sundaram
Background: Na+ and Cl- absorption and nutrient absorption is inhibited in small intestine
during inflammatory bowel disease. Our earlier data showed that Na-glucose co-transporter
(SGLT1) is inhibited in the chronically inflamed rabbit intestine and this inhibition is
secondary to a decrease in the number of co-transporters indicating that the regulation of
SGLT1 during chronic inflammation is at the level of transcription. However, the transcription
factors responsible for the inhibition of SGLT1 and the pathways by which various inflammat-
ory mediators modulate SGLT1 expression have not been studied. Aim: Determine the
molecular identity of rabbit SGLT1 promoter and transcription factors necessary for rabbit
SGLT1 regulation during chronic inflammation. Methods: Rabbit SGLT1 promoter region
was identified using the genomic sequence available in the public database. The promoter
region was cloned into a firefly luciferase gene containing pGL 4.10 (luc2) vector. For the
determination of minimal promoter sequence, deletion constructs were made with varied
lengths of the promoter region using PCR. Promoter activity was deciphered by firefly
luciferase activity by transfecting Caco-2 cells with SGLT1 promoter constructs. Transfection
efficiency was normalized by co-transfection with renilla luciferase containing pRL-TK vector.
Mobility shift assays were performed using consensus sp1 and HNF-1 transcription factor
binding oligonucleotides and the nuclear extract obtained from villus cells. Results: Even
though rabbit SGLT1 promoter did not have considerable overall homology with other
mammalian SGLT1 promoters, two sp1 and a HNF-1 binding sites were highly conserved
between species. Rabbit SGLT1 was encoded by 15 exons, even though the exact size of
the genomic DNA sequence encoding SGLT1 could not be determined due to the incomplete
genomic sequence available in the public database. Minimal promoter region determination
showed that upstream 196 bp from the transcription start site were enough for optimal
promoter activity. This region encompassed one sp1 factor binding site and one HNF-1
factor binding site. The role of sp1 binding site and HNF-1 binding site was additive,
indicating that two separate regulatory pathways are involved in their regulation. Further,
mobility shift assays confirmed sp1 and HNF-1 transcription factor binding to these sites.
Conclusions: These data indicate that transcription factors, sp1 and HNF-1, are involved in
the regulation of rabbit SGLT1. Promoter deletion constructs will be useful in future experi-
ments for characterization of pathways involved in the regulation of SGLT1 by various
inflammatory mediators.
W1560
Protein Kinase C Alpha and P21waf1 Expression Are Increased in the
Remnant Jejunum After Ileal Resection in the Rat
Huilan Cheng, Eiad Nasser, Elias Khawam, Valerie Andersen, Michael D. Sitrin
Introduction: In normal crypt to villusmaturation of the small bowel, cessation of proliferation
and induction of differentiation is associated with expression of protein kinase C alpha
(PKCα) and p21waf, an inhibitor of progression from G0/1 to the S phase of the cell
cycle. After bowel resection, the remnant small intestine undergoes a proliferative response,
enhancing intestinal absorption (intestinal adaptation). The ileum is more capable of hyper-
plasia and adaptation than the jejunum, perhaps because of elaboration of glucagon-like
peptide 2 and other growth factors from the distal intestine after proximal resection. Aim:
The goal of this study was to examine expression of PKCα and p21waf1 in the remnant
intestine following resection of proximal or distal small bowel. Methods: 150 g male Sprague
Dawley rats underwent resection of either the proximal or distal small bowel. The proximal
resection extended from the ligament of Treitz 50 cm distally; The distal resection extended
from 10 cm proximal to the ileal-cecal valve 50 cm proximally. Rats that had transection
of the intestine, but no bowel removed were used as controls. The rats were given sucrose
in water for 48 hrs. post-surgery, and then resumed normal chow. After 3 months, the
remnant small bowel was removed, divided into proximal and distal jejunal and/or ileal
segments and immediately frozen in liquid N. Total RNA was extracted, and PKCα and
p21waf1 mRNAs quantified by reverse transcriptase—real-time PCR. Beta2 macroglobulin
mRNA was used as a housekeeper to normalize the data. Data are presented as the ratio of
the mRNA level from the resected rat intestinal segments to the mRNA level from the
transected rat intestine. Data are given as mean and SD with 4-6 rats per group; non-paired
T test was used for statistical analysis. Results: PKCα mRNA was significantly reduced in
the ileum after jejunal resection; there was a trend toward reduction in p21waf1 mRNA. In
contrast, there was no change in either PKCα mRNA or p21waf1 mRNA in the jejunum
after ileal resection. Conclusion: PKCα and p21waf1 mRNAs are reduced in the remnant
ileum after jejunal resection and may be important mediators of intestinal hyperplasia
and adaptation.
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*p<.05 resected vs transected rats; **p<.10 resected vs transected rats
W1561
Functional Characterization, Localization and Molecular Cloning of Rabbit
Intestinal N-Amino Acid Transporter
Ramesh Kekuda, Jamil Talukder, Prosenjit Saha, Puttur D. Prasad, Vadivel Ganapathy,
Uma Sundaram
Background: Glutamine, the primary metabolic fuel for enterocytes, is absorbed by Na-
glutamine co-transporters in the small intestine. Using functional studies, we previously
showed that glutamine transporters in rabbit villus and crypt cells are different. Specifically
we showed that SN2 (SLC38A5) is a likely candidate responsible for glutamine uptake in
crypt cells. However, the molecular identity and distribution of SN2 in the villus-crypt axis
have not been studied thus far. Aim: Determine the molecular identity and distribution of
SN2 along the villus-crypt axis in the normal rabbit small intestine. Methods: Crypt cells
were isolated from the rabbit intestine by a Ca2+-chelation technique. Crypt cell brush
bordermembrane vesicles were isolated by CaCl2 precipitation and differential centrifugation.
Uptake studies were done by rapid filtration technique using 3H-glutamine. Total RNA was
isolated from enterocytes using TRIzol reagent. RTQ-PCR was performed to determine the
levels of SN2 message using total RNA. Western blotting was performed using anti-SN2
polyclonal antibody raised in chicken using solubilized BBMV. ECL™ Western Blotting
Detection Reagent was used to detect SN2 in the crypt cells. Rabbit SN2 cDNA was cloned
by screening a rabbit intestinal cDNA library using human SN1 cDNA as a probe. SN2
cDNA was functionally characterized in mammalian cells using vaccinia virus transient
expression system. Results: Functional studies using crypt cell BBMV showed that SN2 is
the major transporter present in the rabbit small intestinal crypt cells. Rabbit cDNA clone
obtained was 2108 bp long, encoding an open reading frame of 473 amino acids. The
encoded protein showed 87% Identity and 91% similarity to human SN2. When expressed
heterologously in mammalian cells, the cloned transporter showed Na+-dependent, Li+-
tolerant, uptake of glutamine, asparagine, histidine, and serine. RTQ-PCR results showed
that SN2 message is about 10-fold (p<0.01, n=3) more in crypt cells when compared to
villus cells. On the other hand, SN2 protein, as determined by Western blotting, is about
3-fold (p<0.01, n=3) higher in crypt cells. Conclusions: Functional data using BBMV and
molecular data indicated that SN2 is the major Na-glutamine co-transporter in crypt cells.
Functional characterization of the cloned rabbit SN2 has established its role in Na-coupled
transport of glutamine. Asparagine, histidine, and serine are recognized as substrates by the
cloned transporter.
W1562
5-Aminosalicylic Acid Selectivity Modulates Bacterial Gene Expression At
Concentrations Which Are Not Inhibitory to Growth
Sue Ness, Kevin P. Rioux, Mike G. Surette
BACKGROUND AND AIMS: Mesalamine (5-aminosalicylic acid, 5ASA) is widely used to
treat inflammatory bowel diseases. Although not traditionally considered to have antibiotic
properties, we have previously demonstrated that 5ASA alters the community of intestinal
bacteria in healthy subjects, and propose that this may be relevant to its mechanism of
action in IBD. Quorum sensing refers to the ability of small molecules to potently and
specifically modify bacterial gene expression and thus alter an organism's competitiveness
and affect community structure. In this study, we explored the impact of 5ASA on bacterial
promoter activity. METHODS: A high-throughput screen was carried out to identify genes
that responded to 5ASA at concentrations where no growth effect was observed. This screen
was based on established methods used to identify transcriptional responses to sub-inhibitory
concentrations of antibiotics (Goh et al. PNAS 99:17025-30, 2003). Briefly, a Salmonella
typhimurium strain ATCC 14028 random promoter library consisting of ~6500 clones
coupled to a luciferase reporter (luxCDABE) was screened in the presence of various concen-
trations of aminosalicylates. RESULTS: 5ASA induced specific transcriptional responses in
a small number of clones (<2% of the library) in a concentration-dependent manner, and
at doses that are not inhibitory to Salmonella growth but are relevant to intra-luminal
concentrations of 5ASA in IBD patients. The effects of 5ASA on promoter activities were
distinct from its parent compound sulfasalazine, or the therapeutically inactive compounds
4-ASA and sulfapyridine. The affected promoters are involved in a variety of functions
including acid resistance, multi-drug resistance, and a known regulator of virulence in
Salmonella. CONCLUSIONS: In this model system, 5ASA potently affects bacterial gene
regulation at concentrations that do not impact growth of the organism. The resulting
changes in physiological functions of specific groups of bacteria may translate to a measurable
impact of 5ASA at the population level within complex bacterial communities such as exist
in the human intestinal tract.
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W1563
Salmonella Typhimurium Utilizes a Mannosyl Epitope for Infecting Epithelial
Cells and a Fucosyl Epitope for Infecting Lymphoid Cells in the Pathogenesis
of Salmonellosis
N. nanda Nanthakumar, Meena Theva, Rupak Shivakodi, Di Meng, David S. Newburg,
W. allan Walker
Salmonella typhimurium is a major diarrheal pathogen. Its pathogenesis involves initial
mucosal infection in the epithelium that spreads to lymphoid tissues through infected
mucosal lymphocytes. For most enteropathogens, initial binding to a mucosal cell surface
glycan is the critical first step to infection. For Salmonella, putative receptors on intestinal
epithelial cells and on lymphoid cells were characterized by testing the ability of a panel of
lectins (agglutinins) to block the binding necessary for infection. S. typhimurium infection
of cultured human intestinal epithelial cells (Caco-2) was blocked by Wheat Germ Agglutinin
(WGA) a lectin for mannosyl epitopes (Man β1,4 GlcNAc β1,4 GlcNAc-), but not by lectins
to other epitopes. This was confirmed by WGA inhibition of S. typhimurium infection of
fetal intestinal mucosa organ culture. In contrast, S. typhimurium infection of cultured
human lymphoid cells (Hel) were inhibited by Ulex europaeus agglutinin (UEA-1), a fucose
binding lectin (Fuc α1,2 Gal β1,4 GlcNAc-), but not by WGA or lectins to other epitopes.
Pretreatment of Hel cells with α1,2-fucosidase made them resistant to S. typhimurium
infection, confirming the essential role of fucosylglycans to infection of the lymphoid cells.
This suggests that the putative receptor that initiates the adhesion of S. typhimurium in the
human intestinal epithelium is a mannosylglycan, and the putative receptor in the lymphoid
cell is a fucosylglycan. Thus, cell specific receptors that mediate the initial infection and
subsequent spreading of the pathogen are distinct, and present two distinct targets for
preventing initial infection or preventing systemic spread of infection by Salmonella. This
work was supported by NIH grants HD12437, HD31852, HD13021, DK33506, DK34987,
DK40561, DK53347, RR018603. MT and RS were supported by summer student fellowship
by the Crohn's and Colitis Foundation and American Physiological Society, respectively.
DM was in part supported by a Fogarty Foundation/NICHD training grant D43 TW1265.
W1564
The Effect of the Bacterial Peptide Formyl-Methionyl-Leucyl-Phenylalanine
(FMLP) On Intestinal Function in the Chronic Relapsed Phase of Colitis
Myrella L. Cruz, Edelmarie Rivera, Caroline B. Appleyard
We have previously shown that the ability of bacterial peptides, such as formyl-methionyl-
leucyl-phenylalanine (fMLP), to exacerbate the inflammation in chronic ‘relapsed' colitis
depends on the integrity of the mucosal barrier. The pathophysiological role of bacterial
peptides in the symptoms associated with colitis, such as diarrhea and abdominal pain, is
not yet known. We hypothesized that fMLP contributes to enhanced water and electrolyte
secretion which will result in altered colonicmotility and diarrhea in chronic colitis.Methods:
Colitis was induced in rats by the administration of trinitrobenzene sulfonic acid (TNBS;
30mg in 50% ETOH i.c.). Chronic ‘relapsed' inflammation was induced six weeks later by
administration of TNBS (5mg/kg i.v.), with or without the bacterial peptide (1.0mM in 6%
DMSO i.v.) at 24 hour time intervals over three days. Controls received TNBS + vehicle.
The colons were removed and scored for macroscopic and microscopic damage, and tissues
taken for myeloperoxidase (MPO) activity. Cytokine levels were measured by ELISA. Sections
of muscle-free mucosa were mounted in Ussing chambers and epithelial short circuit current
responses to acetylcholine (Ach;10-9 - 10-3 M) were used as an index of mucosal function.
Segments of longitudinal and circular smooth muscle from proximal and distal colon were
mounted in tissue baths for isometric recording in response to Ach. Results: Administration
of fMLP exacerbated the macroscopic and microscopic damage in this chronic model of
colitis (p<0.05). These animals had a higher incidence of diarrhea (42%) than those receiving
the vehicle (16%), and increased MPO. Both proximal and distal colonic mucosa responded
to Ach with concentration-dependent secretory responses. Mucosal function was significantly
decreased in the distal colon compared to vehicle treated controls (p<0.05). No significant
differences were found in the proximal colon. Longitudinal and circular muscle from the
distal colon of the experimental group exhibited higher tensions in response to Ach than
controls. This was less evident in the proximal colon. Protein levels of TNF-alpha and IFN-
gamma were higher after administration of fMLP, whereas those of anti-inflammatory IL-
10 were decreased (p<0.05). Conclusions: Bacterial peptides such as fMLP can influence
the ion transport processes and contractile responses of the colon in chronic ‘relapsed' colitis.
This is particularly evident in the distal region. These components of the intestinal microflora
may thus drive a dysregulation of the immune system and contribute to the symptoms
observed in patients with inflammatory bowel disease. NIH-NCRR/RCMI 2G12RR03050.
W1565
Lateral Flagella Regulation of the Enteropathogen Aeromonas hydrophila
E. H. Bull, K. D. Bardhan, J. G. Shaw
Introduction Aeromonads are water-borne bacteria that can cause gastroenteritis ranging
from a minor watery diarrhoea to an acute invasive dysentery-like illness. Aeromonas species
express a single polar flagellum for swimming motility. Upon contact with a surface, however,
they express an additional lateral flagella system which forms a vital component of the
bacteria's ability to swarm over surfaces, form biofilms and colonise the host. Understanding
more about the regulation of lateral flagella therefore has implications for host cell interactions
and pathogenicity. The expression of lateral flagella is regulated by a cluster of 38 genes,
of which one is a response regulator. This encodes the protein LafK which, it has been
proposed, is the master regulator. Aim To study the activation of lateral flagella and the
interactions of the LafK protein. Experiment & Results (1) Lateral flagella expression The
38 genes of the lateral flagella gene locus are located in a series of operons; gene transcription
increases upon contact with a surface. To demonstrate this, the promoter region of each
operon was fused to a reporter gene called gusA, which on activation produces an enzyme.
The enzyme activity was measured when the bacteria were grown on solid versus liquid
media. This showed a 30% to 300% increase across the range of the different lateral flagella
promoters when the A.hydrophila cells were grown on solid media, i.e. on a surface. (2)
LafK regulatory function The LafK protein is predicted to be the primary regulator of the
lateral flagella genes. To test this a copy of the lafK gene was inactivated using insertional
mutagenesis and introduced into A.hydrophila by double homologous recombination. PCR
analysis of genomic DNA confirmed these cells had the inactivated copy of the lafK gene
and that the wild-type gene was absent. The presence or absence of lateral flagella expression
was then determined by targeting the protein of these structures with a specific antibody
and differentiating the cells by fluorescence-activated cell sorting. This confirmed that the
wild-type cells expressed lateral flagella but that the LafK-deficient mutant did not. Conclu-
sion The protein LafK in A.hydrophila is essential for the production of the lateral flagella
system by this organism, and which in turn is important for its virulence. Acknowledgement
Eddie Bull is a Research Fellow of the Bardhan Research and Education Trust (Registered
Charity no. 328452)
W1566
Vibrio cholerae Sequesters Both Its Chromosome Origins, and the Seqa Gene
May Have Novel Functions in This Organism
Djenann Saint-dic, Brian P. Frushour, Lyn sue Kahng
Vibrio cholerae is the cause of the epidemic diarrheal disease cholera, and studying its
replication is a key aspect of understanding its persistence in the environment. Vibrio species
contain divided genomes, and thus coordinating the replication of its two chromosomes is
crucial. In V. cholerae, replication of the chromosomes initiates simultaneously, and during
slow growth they are maintained in a 1:1 ratio. However, because of the size discrepancy
between a 2.96 MB chromosome and a 1.07 MB chromosome, there must be a means of
delaying reinitiation of the smaller chromosome origin to coordinate with that of the large
one. In E. coli, which has only one chromosome, the SeqA protein binds newly-synthesized,
hemimethylated DNA: this “sequestration” function is critical in coordinating the timing of
initiation of multiple origins within the same cell. We hypothesized that V. cholerae can
similarly coordinate its origins under varied growth conditions. Using flow cytometry, we
confirmed that during slow growth (doubling time 110 min), V. cholerae contains only one
or two genome equivalents per cell. However, during rapid growth (doubling time 30 min),
we observed two and four genome equivalents per cell; this 2n DNA content pattern confirms
synchronous origin firing over a range of growth rates. We then sought evidence for origin
sequestration, by analyzing the methylation state of genomic DNA in different chromosomal
locations. DNA within the large chromosome origin was 50.4 ± 4.9% hemimethylated, and
within the small chromosome origin it was 32.5 ± 6% hemimethylated. In contrast, DNA
test sites located >20 kb from either replication origin had no detectable hemimethylated
DNA. Finding hemimethylated DNA indicates the origins are indeed protected from methyl-
ation during a prolonged time relative to the rest of the chromosome. Since we observed
sequestration of both V. cholerae origins, we wished to further study the role of seqA. seqA
is not essential in E. coli, where it has modest knockout and overexpression phenotypes.
However, it cannot be deleted from V. cholerae. We studied its overexpression by cloning
it under the arabinose promoter on a low-copy plasmid to yield pSD37. In media containing
glucose, strains containing pSD37 or control plasmid grew normally. Upon arabinose induc-
tion, the control strain grew normally but the strain with pSD37 developed an extremely
filamentous morphology, with condensed DNA in the center. In contrast to E. coli, these
cells ceased growth and rapidly lost viability. We therefore conclude that seqA appears to
have novel and critical roles in the physiology of V. cholerae.
W1567
Prior Enteric Nematode Infection Impairs Intestinal Mucosal Defense to
Bacteria
Thomas L. Sutton, Jennifer A. Stiltz, Rex Sun, Diana Riera, Kathleen B. Madden, Carolyn
A. Sullivan, Allen Smith, Joseph Urban, Aiping Zhao, Terez Shea-donohue
Host resistance to invasive pathogens is orchestrated largely through Th1 and Th2 cytokine
responses. Imbalance between these profiles can result in significant morbidity. There is
growing concern about the possible deleterious effects of pathogen interaction in intestinal
infections, particularly in children in underdeveloped regions. Aim: To determine the effects
of sequential pathogen infections on intestinal barrier and secretory function. Methods:
BALB/c mice were inoculated orally with vehicle(CONT)or Heligmosomoides polygyrus(Hp),
a nematode that colonizes the small intestine, inducing a Th2-dependent increase in mucosal
permeability at 12 days post infection. After 21 days, half of the mice in each group were
infected with Citrobacter rodentium (Cr), a gram negative bacteria that colonizes the colon,
inducing a Th1-driven response. All mice were studied 12 days later. In Cr infected mice,
fecal bacterial loads were measured at 3, 7 and 11 days. Muscle-free sections of intestinal
mucosae were mounted in microsnapwells to determine mucosal transepithelial resistance
(TER) or in Ussing chambers to measure changes in Isc in response to acetylcholine (ACH),
5-HT, or histamine (HIST). Quantitative real-time PCR (RT-PCR) was performed to assess
expression of cytokines. Results: Bacterial loads were similar in Cr and Hp+Cr at all time
points post infection indicating that prior Hp infection did not impede Cr clearance. Expres-
sion of the prototypic Th2 cytokine, IL-13, was similar in all groups, consistent with
resolution of the Hp-induced Th2 response. The proinflammatory cytokines IL-12p40 and
IL-17A were also unchanged indicating that Cr did not induce a proinflammatory response
in the small intestine. When compared to CONT, TER was unchanged in response to Hp
or Cr alone, but was reduced significantly after Hp+Cr. Neither Hp nor Cr significantly
altered secretion in response to ACH, 5HT or HIST. In contrast, Hp+Cr significantly inhibited
secretion in response to 5-HT and HIST. Conclusions: These data indicate that prior
alterations in mucosal barrier function associated with a Th2 response impair intestinal
defense against subsequent exposure to a Th1-pathogen. This effect occurs even when the
intestine is not the site of colonization. This predisposition may be exaggerated in children
in underdeveloped regions where health is already affected by malnutrition and poor hygiene.
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W1568
Transcriptomic Analysis of C.jejuni Induced Changes in Gene Expression in
Human Colonic Cells
Kenneth Mellits, Michael Loughlin, Peter Clarke, Julie Smith, Ian Connerton, Christopher
J. Hawkey
Introduction We have previously shown that strains of C jejuni that invade epithelial cells
enhance elaboration of NF-KB dependant genes such as IL8 whilst non invasive strains do
not, and moreover that the NF-KB activating activity resides within a purified boiled cell
extract of C jejuni. We now report the full range of genes whose expression is affected by
C jejuni boiled cell extract, analysed by transcriptomic analysis using human gene array
together with Ingenuity Pathway Assist programme. Methods Boiled cell extracts were pre-
pared from broth cultures of the well characterised pro-inflammatory Cjejuni (11168) as
previously described. Confluent mono layers of HCA7 human colonocytes were exposed to
boiled cell extract for 6 hours, before RNA was extracted. Changes in gene transcription
were analysed by hybridisation to the affymetrix Human gene array HG-U133A The sscore
algorithm of the Bioconductor package was used to analyse the differential expression of
these genes, which were then confirmed using Real time RT-PCR. Results Using A total of
428 genes were up regulated and 76 were down regulated (with a sscore of >2.5). NF-KB
up regulated a number of genes (Fig 1) including immediate early genes, a number of
cellular receptors including TLR2 and many pro-inflammatory cytokines. Ingenuity grouped
all regulated genes into interrelated networks. Network analysis indicated that a number of
canonical signalling pathways, disease and disorder states and molecular and cellular func-
tions were affected significantly. Conclusions Invasive strains of c jejuni are capable of
orchestrating an extensive colonocyte based response causing cell death and inflammatory
processes. NF KB is central to many of these changes, and analysis of gene array data
confirms transcriptional activation of a number of proinflamatory cytokines. In addition we
have discovered number of signalling pathways are regulated hitherto unknown to be induced
by Campylobacter.
Fig. 1 Genes up regulated as a result of NF-KB regulation are shown, darkest shade indicates
most significant up regulation.
W1569
Induction of Epithelial Cell Ccl20 By Listeria monocytogenes Is Dependent
Upon Entry to the Host Cell Cytosol
Sinead C. Corr, Ann M. O'hara, Liam O'mahony, Fergus Shanahan, Colin Hill, Cormac G.
Gahan
Background & Aim: During Listeria monocytogenes infection, the intestinal epithelium pro-
vides an important link between establishment of innate and adaptive immune responses
via production of chemo-attractant molecules such as Chemokine ligand 20 (CCL20). We
wished to assess the mechanism by which L. monocytogenes triggers host cell chemokine
responses.Methods: Balb/c mice were deliberately infected with L. monocytogenes and serum
CCL20 levels quantified. HT-29 gastrointestinal epithelial cells were incubated In Vitro with
L. monocytogeneswild-type strain, or a number of mutant knock-outs, for 6 hours. Supernatant
CCL20 chemokine levels were measured using ELISA. Results: L. monocytogenes infection
of mice induced significant levels of CCL20 in sera. HT-29 epithelial cells released significant
quantities of CCL20 when exposed to wild-type L. monocytogenes In Vitro. A flagellin-
deficient strain of L. monocytogenes EGDe also induced significant amounts of CCL20 secretion
indicating a flagellin-independentmechanism. An invasion-deficient strain of L. monocytogenes
EGDe did not induce significant levels of CCL20 secretion while a haemolysin-deficient
strain, incapable of entry into the host cell cytoplasm, induced only minimal levels of CCL20
from epithelial monolayers. Conclusion: Induction of CCL20 protein in response to L.
monocytogenes is dependent upon invasion and localisation of the pathogen in the cytoplasm
of infected gastrointestinal epithelial cells.
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W1570
C57bl/6j Mice Provide An In Vivo Model for Assessing Physiological
Consequences of Enterohemorrhagic E. coli Infection On the Intestinal
Epithelium
Samuel Tesfay, Jennifer L. Roxas, Donnie E. Shifflett, Athanasia Koutsouris, Jerrold R.
Turner, V. K. Viswanathan, Gail A. Hecht
Enterohemorrhagic E. coli (EHEC) associated illness ranges frommild diarrhea to hemorrhagic
colitis and hemolytic uremic syndrome. EHEC infection of cultured intestinal epithelial cells
induces attaching and effacing (A/E) lesions, alters intestinal epithelial barrier function and
stimulates inflammation. The lack of a small animal model of EHEC infection has hampered
investigation of physiologic consequences on the intestinal epithelium. The aim of this study
was to determine if C57BL/6J mice would serve as an In Vivo model to study the effects of
Stx-negative EHEC on physiologic parameters of the intestinal epithelium. Since antibiotic
treatment of mice may independently alter barrier function, specific pathogen free C57BL6/
J mice were used for these studies. C57BL/6J mice were gavaged with ~2 x 108 Stx-negative
EHEC (WT) or PBS. Mice were sacrificed at 1 or 5 days post-infection and intestinal tissues
were assessed for colonization/attachment, morphologic changes, transmucosal electrical
resistance (TER) and short circuit current (Isc). Colonization was evaluated by plating stool on
selective sorbitol MacConkey plates. Bacterial recovery from stool and immunofluorescence
microscopy using EHEC specific antibodies revealed adherence and colonization of the
cecum and colon at 5 days post-infection. While there was no difference in the recovery of
WT and a type III secretion deficient strain ΔescN from the stool at day 1 (1.69E5±1.01E5
vs 6.61E5±4.73E5, for WT and ΔescN, n=3, p=0.37), by day 5, the recovery of ΔescN
was less (4.34E4±1.68E4 vs 3.27E3±1.58E3, for WT and ΔescN, n=3, p=0.076). Electron
microscopy revealed microvillus effacement in the colon, but not the ileum, of infected
mice, correlating with the pattern of infection seen in humans. Histological assessment of
H&E stained colonic tissues revealed a small increase in the number of apoptotic bodies
but no significant inflammatory response. Colonic epithelial barrier function, measured as
TER in Üssing chambers, was reduced at 1 and 5 days post-infection in infected mice (45%
for day 1, n=2 and 40% for day 5, n=4, p < 0.01). Isc was not altered by EHEC infection
at day 1 or 5. Immunofluorescence microscopy revealed that barrier disruption was accom-
panied by redistribution of occludin, but not ZO-1, in the colonic epithelium of EHEC-
infected mice. In summary, these data demonstrate that C57BL/6J mice can serve as an In
Vivo model to study the physiological effects of EHEC infection on the intestinal epithelium.
W1571
Pro-Inflammatory Effect of Helicobacter pullorum On Human Intestinal Cell
Lines
Arnaud Duriez, Christine Varon, David Laharie, Frank Zerbib, Armelle Menard, Philippe
Lehours, Francis Megraud
Introduction: Helicobacter pullorum is an entero-hepatic Helicobacter species of avian origin
detected in patients with acute diarrhea and inflammatory bowel disease (IBD). Its direct
effect on intestinal epithelial cells is currently unknown. Aim: to determine whether H.
pullorum exerts a direct effect on human intestinal epithelial cells In Vitro and to characterize
the bacterial factors and the signaling pathways involved.Material andmethods: The following
methods were used 1. Comparison of interleukin-8 (IL-8) secretion by gastric epithelial cells
(AGS) induced by H. pullorum or Helicobacter pylori (J99 & B38 strains), assessed by ELISA.
2. Measurement of IL-8 production induced by avian and human H. pullorum strains on
CaCo-2 and HT-29 intestinal cell lines. 3. Evaluation of H. pullorum adherence on IL-8-
induced secretion by intestinal epithelial cells using bacterial supernatants and Transwell
inserts. 4. Determination of the role of the nuclear factor κB (NF-κB) by using specific
pharmacological inhibitors (SN50), RNA-interference (siRNA)and immunofluorescence(IF).
Results: 1. On AGS cells, H. pullorum strains induced higher IL-8 levels than controls;
these levels which were intermediary between the potent inflammatory J99 and the mildly
inflammatory B38 H. pylori strains. 2. On HT-29 and CaCo-2 intestinal cells, H. pullorum-
induced IL-8 secretion was increased with human and avian strains, in comparison to
controls. 3. Coculture with H. pullorum supernatants did not induce high IL-8 levels as
compared to the whole bacteria. The same trend was observed with Transwell inserts. 4.
NF-κB inhibition with SN50 and siRNA reduced H. pullorum-induced IL-8 production. H.
pullorum induced a rapid nuclear translocation of NF-κB visualized by immunofluorescent
staining. Conclusion: Human and avian H. pullorum strains induce IL-8 secretion on gastric
and intestinal cell lines. This effect requires bacterial adherence and implies NF-κB activation.
These results confirm that H. pullorum is a potent human pathogen which could be involved
in acute and chronic digestive diseases such as IBD.
W1572
Norovirus Non-Structural Protein P20 Leads to Epithelial Barrier Dysfunction
By Inhibition of Actin Cytoskeleton Remodelling
Joachim Mankertz, Bernd Hillenbrand, Dorothee Günzel, Martin Zeitz, Eckart Schreier,
Joerg D. Schulzke
Background and aims: Norovirus infection is a major cause of acute gastroenteritis
worldwide. Infections are characterised by vomiting, nausea and severe watery diarrhea.
Because of the lack of a cell culture system, pathomechanisms and replication cycle of
norovirus are largely unknown. In this study we addressed the issue of how norovirus
infection could lead to epithelial barrier dysfunction. Methods: Intestinal epithelial HT-29/
B6 cells were stably transfected for inducible expression of the p20 gene of norovirus genotype
GGII.4 strain (Acc.no. AY485642). After induction of p20 gene expression, transepithelial
electrical resistance was monitored. Tight junction protein expression was measured by
immunoblotting. Gap filling assays were performed to determine cell motility. Apoptosis
was detected histologically by TUNEL staining. Restitution of single cell lesions was analysed
by conductance scanning. Actin remodelling was studied by confocal laser scanning micro-
scopy. Results: Activation of the norovirus non-structural protein p20 expression through
a tetracycline sensitive promoter reduced transepithelial resistance. Changes in the expression
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of the tight junction proteins occludin or claudin-1, -2,- 3, -4, -5, -7 and -8 could not be
detected. Cell motility was unaltered under p20 expression. Investigation of epithelial
apoptosis revealed an increase (2.23±0.25 %) compared to vector control (1.13±0.24 %).
Epithelial restitution was evaluated 16 minutes after the induction of single cell lesions and
was found to be inhibited in p20 expressing cells while in controls it was almost complete.
Fluorescence microscopy revealed an inability for accumulation and redistribution of cellular
actin after induction of p20 expression. Conclusion: Rearrangement of the cellular cytoskel-
eton after virus infection is a well known phenomenon. Here we describe for the first time
a phenotype of actin arrest induced by norovirus gene expression. Norovirus protein p20
seems to be able to impair the redistribution of actin in the cell. This is accompanied by a
perturbation of the epithelial barrier. These data suggest an important role of p20 in the
molecular mechanism leading to barrier dysfunction during norovirus infection.
W1573
Aspergillus oryzae -Fermented Grain Germ Increases short Chain Fatty Acids
in the Colon of Rats with Loperamide-Induced Constipation
Tadashi Shimoyama, Ryoki Takahashi, Shinsaku Fukuda
Background: Several probiotics have been shown to have beneficial effects on constipation.
A traditional Japanese medicine, which based on Aspergillus oryzae-fermented grain germ
(A. oryzae NK-koji ), contains both probiotic and prebiotic elements. In this study, we studied
the effects of A. oryzae NK-koji on rats with loperamide-induced constipation. Methods: 14
SD rats (male, 5 weeks, body weight 250 g) were administrated loperamide 10 mg/day/kg
for 4 days and sacrificed. 7 rats were received the diet containing 5% (w/w) of A. oryzae
NK-koji from 11 days before the administration of loperamide while 7 rats received the diet
without A. oryzae NK-koji . As the control, 7 rats were also fed without both loperamide
and A. oryzae NK-koji . Number and weight of feces were measured before and during
administration of loperamide. Amount of short chain fatty acids (SCFAs) in the feces and
cecal contents after sacrifice was also compared between groups. Results: Number and
amount of feces were decreased by the administration of loperamide (p<0.01) while the
decrease was smaller in rats fed with A. oryzae NK-koji (p<0.05). Amount of propionic acid
and butyric acid of the feces was decreased by administration of loperamide (p<0.01 and
p<0.001, respectively). In rats fed with A. oryzae NK-koji , these decrease were significantly
smaller (p<0.01). In the cecal contents, loperamide also decreased both propionic acid and
butyric acid (p<0.001), andA. oryzae NK-koji suppressed these changes significantly (p<0.01).
Conclusions: Administration of loperamide caused constipation and decreased amount of
SCFA, particularly butyric acid, in cecal contents and feces in rats. A. oryzae NK-koji improved
the decrease of SCFA and constipation induced by loperamide.
W1574
Lactobacillus fermentum Br11 and Fructo-Oligosaccharide Partially Reduce
Jejunal Inflammation But Not Overall Damage Severity of 5-Fluoro-Uracil-
Induced Mucositis in Rats
Cassie L. Smith, Ross N. Butler, Gordon S. Howarth
Background: Mucositis is a severe side-effect of chemotherapy with a deficiency in effective
treatment strategies. This study investigated the probiotic, Lactobacillus fermentum BR11
(BR11) and the prebiotic, fructo-oligosaccharide (FOS) both individually, and in synbiotic
combination, for their potential to reduce 5-Fluoro-uracil (5-FU)-induced small intestinal
(SI) damage in rats. Methods: From days 0-9 rats consumed either: BR11 at a low dose
(LD; 1x106 cfu ml-1) or high dose (HD; 1x109 cfu ml-1), FOS at a LD (3% of casein-based
diet) or HD (6% of casein-based diet), a synbiotic combination of HD BR11 and HD FOS
or vehicle (skim milk; SM). On day 7, rats were injected intra-peritoneally with 5-FU (150
mg kg-1). Daily monitoring of a disease activity index (DAI) was undertaken. The 13C-
sucrose breath test (SBT) was conducted to assess disaccharidase activity. At sacrifice on
day 10, SI tissue was measured, weighed and collected for quantitative histology, sucrase
and myeloperoxidase (MPO) assays. Results: SI weight and length were reduced by 27%
and 8% respectively, following 5-FU+SM-treatment compared to saline+SM controls. On
day 10, 5-FU+HD-FOS and 5-FU+synbiotic increased DAI compared to saline+SM (4.1±1.1
and 4.0±0.9 vs. 2.2±0.6). Jejunal MPO activity was increased by 87% in 5-FU+SM-treated
controls compared to saline+SM (943±215 vs. 118±26). The following treatments all
decreased MPO activity (p<0.05) compared to 5-FU+SM-treated controls: 5-FU+LD-BR11
(35% decrease); 5-FU+HD-BR11 (37%), 5-FU+LD-FOS (33%), 5-FU+HD-FOS (39%) and
5-FU+synbiotic (32%). 5-FU+SM-treatment reduced sucrase activity in all regions of the
small intestine compared to saline+SM-treated controls as detected by the SBT and sucrase
assay (p<0.05). No treatment increased sucrase activity compared to 5-FU+SM-treated con-
trols. Villus height, crypt depth and crypt cell proliferation were reduced following 5-
FU+SM-treatment compared to saline+SM-treated controls (p<0.05) with no differences
observed in BR11, FOS and synbiotic treated rats compared to the 5-FU+SM-treatment.
Jejunal histological damage severity scores were increased by 99% in 5-FU-treated rats
compared to saline+SM-treated controls [0(0-1) vs. 24.5(21-28)]. Histological severity scores
for all BR11, FOS and synbiotic-treated rats did not differ significantly from 5-FU+SM-
treated controls. Conclusions: BR11 and FOS independently reduced some characteristics
of jejunal inflammation in a dose-independent manner although neither treatment was
effective at reducing the 5-FU-induced structural or functional changes in the small intestine.
The synbiotic combination of BR11 and FOS did not provide additional protection.
W1575
Probiotic Prevention of Digestive Enzyme Damage in a Mouse Model of
Salmonella
Erin L. Symonds, Caitlin O'mahony, David O'mahony, Liam O'mahony, Fergus Shanahan
Background & Aim: Salmonella infection has been shown to damage the small intestinal
villi, resulting in a decrease in the activity of digestive enzymes. This can lead tomalabsorption
of nutrients and diarrhea. The aims of this study were to determine the changes to the brush
border enzyme activity in a mouse model of salmonella infection, and to determine if pre-
treatment with a probiotic could attenuate intestinal damage.Methods: The effect of salmon-
ella dose on brush border enzyme activity was assessed by challenging Balb/c mice with
Salmonella typhimurium UK1 at a dose of 1x106 colony forming units (cfu) (n = 11), 1x107
cfu (n = 8), or 4x108 (n = 8) and were compared to mice that received no salmonella (n=
12). The effect of the probiotic Bifidobacteria infantis 35624 on brush border enzyme activity
was assessed by administering B. infantis (1x108 cfu per day) in the drinking water for 2wk
prior to and during S. typhimurium challenge (1x106 cfu, n = 6). All mice were sacrificed
at 6 days following the salmonella challenge and the small intestine was removed. Sections
of the jejunum and ileum were homogenised and assessed for sucrase-isomaltase, maltase
and alkaline phosphatase activity and calculated as activity/mg protein. Results: Infection
with S. typhimurium significantly reduced the activity of sucrase-isomaltase, maltase and
alkaline phosphatase of both the jejunum and the ileum compared to healthy mice (p <
0.05), however the reduction in enzyme activity was not different between the salmonella
doses given (p > 0.05). The average percentage reduction of the enzyme activity compared
to healthy mice was a 73% reduction in the jejunum and 68% in the ileum for sucrase-
isomaltase, a 69% reduction in the jejunum and 67% in the ileum for maltase, and a 54%
reduction in the jejunum and 61% in the ileum for alkaline phosphatase. Pre-treatment
with B. infantis was found to protect brush border enzyme activity in the jejunum and the
ileum compared to placebo fed animals (p < 0.05). Conclusion: Salmonella infection reduces
the brush border enzyme activity of the jejunum and the ileum in mice, with the level of
reduction unrelated to the dose of salmonella given. Pre-treatment with B. infantis 35624
significantly attenuated the effect of salmonella infection on brush border enzyme activity
in this placebo controlled study.
W1576
Gastrointestinal Adaptive and Innate Immunological Responses to Rotavirus
Infection in the Neonatal Piglet
Aline Andres, Sarah A. Taylor, Beth A. Helregel, Theresa B. Kuhlenschmidt, Mark S.
Kuhlenschmidt, Sharon M. Donovan
Rotavirus (RV) infection is the most common cause of severe diarrhea in young children
and results in more than 600,000 deaths per year worldwide. Our long-term goal is to
develop nutritional interventions to reduce the incidence and severity of RV infections. As
a first step, our aim was to define the time-course of gastrointestinal adaptive and innate
immunological responses to RV infections in the neonatal piglet. Colostrum-deprived caesa-
rean-derived piglets were artificially reared using a cow-milk based formula and infected at
d4 postpartum with group A porcine rotavirus strain OSU (P9[7],G5). Following euthanasia,
intestinal samples were collected at 0, 4, 8, and 12 h, and 1, 2, 3, 4, 6 and 8 d post-infection
(PI). Statistical analyses were performed using PROC MIXED and Pearson's Correlation
Coefficients. Stool consistency was assessed on a scale of 1 (normal) to 4 (watery diarrhea).
Diarrhea was observed at 2d, peaked at 3d, and began to decrease by 4d, but was still
present at 8d PI compared to 0h (p<0.05). Weight gain was positive throughout the study,
except at 2d PI (-0.23 ± 0.05 kg; mean ± SEM). Jejunal and ileal villus height were reduced
50% at 2d, and did not recover by 8d compared to 0h (p<0.05). Crypt hyperplasia was
observed on 2d and 3d PI compared to 0h (p<0.05). RV non-structural protein 4 (NSP4)
mRNA expression increased (p<0.05) in a biphasic manner at 2d (3353 ± 34fold over 0h)
and 4d (4951 ± 29 fold over 0h), and returned to baseline by 6d. Messenger RNA expression
of the chemokine CXCL-8 was 2- to 3-fold greater (p<0.05) than 0h between 2d and 6d,
but returned by baseline by 8d PI. Both NSP4 (r=0.59) and CXCL-8 (r=0.58) mRNA
expression were strongly (p<0.0001) correlated to diarrhea scores. In addition, the protein
abundance of NF-κB p65 in jejunal nuclear extracts was positively correlated to CXCL-8
mRNA abundance (r=0.72, p<0.0001). Lastly, the numbers of jejunal CD3+ T lymphocytes,
assessed by immunohistochemistry, were significantly higher at 2d, 3d and 4d PI compared
to 0h. In conclusion, RV infection in the neonatal piglet caused severe diarrhea and villus
blunting within 2d PI, which did not recover by 8d PI. However, the acute innate and
adaptive immune responses, which peaked between 2-6d PI, were normalized by 8d PI.
Funded by USDA AG-05-34505.
W1577
Polar Flagella Glycosylation in Aeromonas caviae
Michaela Day, P. Hitchen, A. Dell, Karna dev Bardhan, Jonathan G. Shaw
Introduction Aeromonas species cause gastroenteritis in humans, ranging from an acute
watery diarrhoea to a dysentery-like illness. Most Aeromonas species produce a single polar
flagellum for motility, an important determinant of virulence required for colonisation. The
polar flagella filaments are made up of the FlaA and FlaB proteins. These proteins appear
to be post-translationally modified, which our previous work suggests is by the addition
of sugars (glycosylation). Aim Pilot study to identify the nature of the post-translational
modification of the Aeromonas flagellins and to investigate its role. Results Glycosylation
Tryptic digests of the flagellae were examined by mass spectrometry. This confirmed glycosyl-
ation, each flagellum containing 6-10 residues of the sugar pseudaminic acid. Observations
& Hypothesis Pseudaminic acid is found on the flagella of Helicobacter pylori and Campylob-
acter jejuni. It has also been observed that bacterial flagellin proteins interact with toll-like
receptor-5 (TLR-5) on host cells and stimulate an inflammatory response. This results in
interleukin-8 (IL-8) release, a measure of cell stimulation. Based on the above, we hypo-
thesised pseudaminic acid on aeromonad flagellae may mask these structures from the
immune system. IL-8 production To test this hypothesis, aeromonad flagellins with and
without pseudaminic acid additions were engineered (as His-tagged proteins to facilitate
their purification). Both Aeromonas (glycosylation system positive) and E. coli (glycosylation
system negative) were used, and the flagellins tested on the human cell line A549, which has
the TLR-5 receptor. Unglycosylated flagellins, both FlaA and FlaB proteins, were confirmed to
cause IL-8 production at a concentration of 100,000 pg/ml. This response is comparable to
that produced by flagellins of other bacterial pathogens. Studies with glycosylated flagellin
proteins are in progress. Discussion & Conclusion (1) The presence of pseudaminic acid
in the flagellae of other bacterial species suggests such glycosylation may serve a wider
general purpose, e.g. defence. (2) Like other bacterial pathogens, the flagellins of Aeromonas
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stimulate host cells to release IL-8. Conceivably, glycosylation masks this process, the next
step in our studies. Acknowledgement Michaela Day is a Research Fellow of The Bardhan
Research and Education Trust (Registered Charity No 328452)
W1578
Inbred Mice of Swiss Origin Differ in Susceptibility to C. rodentium
Diana Borenshtein, Katherine A. Schlieper, Barry Rickman, Arlin B. Rogers, James G. Fox,
David B. Schauer
Citrobacter rodentium, an attaching and effacing pathogen, typically causes severe but tempor-
ary epithelial hyperplasia with varying degrees of inflammation in the distal colon of adult
laboratory mice. Among the lines of mice that have been characterized, C3H is the only
inbred strain that consistently develops fatal infection. We have recently observed that adult
inbred FVB/NTac mice are also susceptible to C. rodentium infection and develop clinical
disease, colitis, and alterations in intestinal ion transport that lead to mortality. Here we
characterize C. rodentium infection in other inbred mice of Swiss origin, namely SWR/J and
SJL/J, compared with FVB/NJ. Susceptible C3H/HeOuJ and resistant C57BL/6J mice were
used as non-Swiss control strains. Twelve-week old female mice were experimentally inocu-
lated with C. rodentium or broth, and followed for 14 days post inoculation (dpi). FVB/
NJ and C3H/HeOuJ mice exhibited severe clinical disease and 62% and 100% mortality,
respectively. Both SWR/J and SJL/J strains, as well as C57BL/6J mice, were resistant and
survived the infection. C. rodentium colonization and intestinal lesions were comparable
between the infected inbred strains. Stool water content increased from ~60% to 75-78%
in resistant strains. The increase in fecal water concentration was rapid and severe in
susceptible C3H/HeOuJ, reaching 88% by 9 dpi, whereas moribund FVB/NJ mice failed to
develop well-formed feces at 9 and 12 dpi. The expression of genes involved in intestinal
ion transport was profoundly altered in susceptible strains compared with resistant mice.
Abundant mast cells and overexpression of Adora2b were found in distal colon of FVB/NJ
mice compared with other inbred strains. These results indicate that (1) C. rodentium-infected
FVB and C3H mice develop mortality, which is most likely caused by severe diarrhea and
dehydration; (2) fatal disease is independent of colitis and not associated with bacterial
counts or disseminated disease; (3) common pathogenic mechanisms may cause fluid and
ion misbalance in susceptible FVB and C3H mice; and (4) the role of mast cells in the
pathogenesis of fatal infectious diarrhea in FVB mice deserves further investigation. In
conclusion, we have developed an animal model for fatal infectious diarrhea useful in
studying the mechanisms of host response to pathogens and intestinal ion transport.
W1579
Luminally Released 5-HT from EC Cells Plays An Important Role to Regulate
Colonic Motility in Rats
Kiyoshi Tsukamoto, Erito Mochiki, Hajime Ariga, Cindy Chen, Christopher R. Mantyh,
Theodore N. Pappas, Toku Takahashi
Background; Enterochromaffin (EC) cells of the epithelial cells release 5-HT into the lumen
as well as basolateral border. However, the physiological role of released 5-HT into the
lumen is poorly understood. Central corticotropin releasing factor (CRF) released by stress
accelerates colonic transit via stimulating vagal efferent and 5-HT3 receptors in rats. We
tested the hypothesis that restraint stress and central CRF stimulate colonic motility via a
luminal release of 5-HT of the proximal colon in rats. Methods; To investigate whether
intraluminal 5-HT accelerates colonic transit, 5-HT and 51Cr were administered into the
lumen of the proximal colon, and colonic transit was measured. To investigate whether 5-
HT is released into the colonic lumen, we utilized ex vivo model of isolated vascularly and
luminally perfused rat proximal colon. To investigate whether 5-HT is released into the
lumen in response to stress and central CRF, 5-HT concentration in the feces was measured
by HPLC. To study whether central CRF receptors are involved in mediating the luminal
release of 5-HT in response to restraint stress, rats received intracisternal (ic)-injection of
CRF1 receptor antagonists, NB1-27914 (100 microg), prior to loading the restraint stress.
After euthanized, feces in the proximal colon were taken for 5-HT assay. Results; Luminal
administration of 5-HT (10-6-10-5M) significantly accelerated colonic transit in rats (n=7).
Elevation of intraluminal pressure (10 cm H2O) increased the luminal concentration of 5-
HT by 8 fold, but not vascular concentration of 5-HT. Restraint stress significantly increased
5-HT concentration in the feces of the proximal colon (1,120 +/- 165 pg/wet weight,),
compared to that of non-restraint rats (694 +/- 95 pg/wet weight, p<0.05, n=7). Ic-injection
of NB1-27914 attenuated the increase of fecal concentration of 5-HT in response to restraint
stress to 854 +/- 174 pg/wet weight (p<0.05, n=6). Ic-injection of CRF (1 microg) significantly
increased fecal concentration of 5-HT of the proximal colon (1,656 +/- 215 pg/wet weight),
compared to that of saline-injected rats (880 +/-101 pg/wet weight, p<0.01, n=8). Conclusion;
It is suggested that intraluminal pressure increase stimulates the release of 5-HT into the
colonic lumen. Restraint stress also stimulates luminal release of 5-HT from the proximal
colon via central CRF1 receptors. Luminally released 5-HT may activate 5-HT3 receptors
located at the colonic mucosa to stimulate colonic motility. Thus, the main target of restraint
stress is EC cells of the proximal colon. Luminally released 5-HT from EC cells plays an
important role to regulate colonic motility in rats.
W1580
Inhibition of Gastric Motility By Hyperglycemia Is Mediated By Nodose
Ganglia KATP Channels
Yuanxu Lu, Shi yi Zhou, Chung Owyang
We have recently showed that the inhibitory action of hyperglycemia is mediated by vagal
afferent fibers innervating the stomach and duodenum. Our In Vitro studies demonstrated
a subset of nodose ganglia are excited by rising ambient glucose and this involves inactivation
of KATP channels leading to membrane depolarization and neuronal firing. To explore the
physiological significance of this observation we performed In Vivo gastric motility studies
to examine the effects of activators and inactivators of KATP channels. Intragastric pressure
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was recorded in anesthetized rats by a balloon attached to a catheter placed in the body of
the stomach. Hyperglycemia was induced using a glucose clamp protocol. Intravenous
infusion of 20% dextrose induced gastric relaxation in a dose dependent manner. Maximum
relaxation was observed at a blood level of 250 mg/dl. This inhibition effect of hyperglycemia
was completely blocked by IV infusion of diazoxide (a KATP channel activator) given at 30
mg/kg. Conversely, IV infusion of tolbutamide (an inactivator of KATP channel) (20-40 mg/
kg) induced dose dependent gastric relaxation, an effect similar to hyperglycemia. Vagotomy
or administration of hexamethonium prevented the inhibitory action of tolbutamide. The
inhibitory effects of tolbutamide were blocked by L-NAME (10 mg/kg) an inhibitor of
NOS suggesting the involvement of a NANC inhibitory vagal pathway. Perivagal capsaicin
treatment also prevented gastric relaxation induced by tolbutamide. To provide direct evid-
ence the inactivation of KATP channel at the nodose ganglia level induces gastric relaxation,
electroporation of the nodose ganglia with siRNA of Kir 6.2 (a subunit of KATP) and plasmid
PEGFP-N1 carrying the gene for green fluorescent protein (GFP)was applied. Immunocytoch-
emistry of GFP demonstrated diffuse presence of GFP in nodose neurons. The success in
knocking down gene expression of Kir 6.2 was validated by RT-PCR and Western blot
analysis. In rats whose nodose ganglia were treated with Kir 6.2 siRNA, no gastric response
to hyperglycemia or tolbutamide was observed. However, these rats continued to respond
to secretin (IV 5.6 ng/kg/min) which acts via vagal afferent pathway independent of KATP
channel. These studies provide In Vivo evidence that hyperglycemia induces gastric relaxation
via vagal afferent pathway. This is mediated through inactivation of KATP channels in the
nodose ganglia.
W1581
Olfactory Receptors On Human Intestinal Enterochromaffin (EC) Cells
Function As Sensors for Spices and Odorants
Petra Voland, Thomas Braun, Lars Kunz, Manfred Gratzl, Christian Prinz
Background: Release of serotonin from intestinal mucosal enterochromaffin (EC) cells trig-
gered by luminal substances is the key event in regulation of gut motility and secretion.
We investigated whether nasal olfactory receptors (OR) are also expressed in the human
gut mucosa on EC cells and whether their ligands, odorants present in spices, fragrances,
detergents and cosmetics, cause serotonin release. Methods: Receptor expression was studied
by RT-PCR in a cell line derived from human enterochromaffin cells (BON cells), in human
mucosal biopsies and EC cells isolated by laser microdissection. Activation of the cells by
odorants was investigated by digital fluorescence imaging using the fluorescent Ca2+ indicator
Fluo-4 and BON cells, a well established model for studying EC cell function. Serotonin
release was measured in BON cell culture supernatants by a serotonin enzyme linked
immunoassay (ELISA) and amperometrical recording using carbon fiber microelectrodes
placed on single cells. Results: RT-PCR experiments revealed expression of four ORs (OR73,
hOR17-7-711, OR1G1, hOR17-210) in the human enterochromaffin BON cell line, in human
mucosal biopsies from small intestine and isolated microdissected human EC cells. Ca2+
imaging studies showed that ligands of the identified ORs, odorants like thymol, eugenol,
bourgeonal, helional caused Ca2+ influx and elevation of intracellular free Ca2+ levels in
BON cells. This effect was specific because other odorants (e. g. campher, phenol) did not
induce Ca2+ influx at comparable concentrations. These effects could be inhibited by known
competitive antagonists (e.g. methylisoeugenol) and blocking of L-type Ca2+ channels with
nifedipine. Using a serotonin ELISA we found a concentration dependent serotonin release
into the culture supernatant of BON cells induced by a selection of odorants of the identified
ORs up to 10 fold compared to basal conditions (medium alone). These findings were
confirmed by amperometrical recording of quantal serotonin release by single BON cells.
Conclusions: Our results show that odorants present in the luminal environment of the gut
may stimulate serotonin release via ORs expressed in human EC cells. Serotonin controls
both gut motility and secretion, and is implicated in pathological conditions such as vomiting,
diarrhea and irritable bowel syndrome. Thus olfactory receptors are potential novel targets
for the treatment of gastrointestinal diseases and motility disorders.
W1582
Role of Spinal Microglia Activation in Visceral Hyperalgesia Following
Chronic Psychological Stress in Wistar Rats
Sylvie Bradesi, Camilla I. Svensson, Joanne Steinauer, Charalabos Pothoulakis, Tony L.
Yaksh, Emeran A. Mayer
Background: It is becoming increasingly appreciated that spinal glia plays a key role in
central sensitization in models of chronic pain evoked by peripheral inflammation, spinal
cord or nerve injury. Experimental stress in rats can activate immune functions in the
central nervous system and modulate viscero-somatic nociception. Aims: To assess spinal
glia activation in a validated rat model of chronic stress associated with sustained visceral
hypersensitivity, and determine the correlation between glia activation and enhanced visceral
nociception. Method: Four groups of male Wistar rats were exposed to 1-hour water avoid-
ance stress (WA) or shamWA daily for 10 consecutive days. Rats were treated with minocyc-
line (inhibitor of microglia activation, 20 mg/kg, IP, daily, 1 hour before WA or sham WA)
or saline. At day 11, we collected spinal L6S1 samples and performed immunohistochemistry
for the phosphorylated mitogen-activated protein kinases p38 (Pp38), microglia (OX42)
and neurons (Neu). Pp38 protein level in spinal cord extracts was quantified by Western
blot. Four groups of rats receiving similar treatments and implanted with electrodes for
abdominal electromyography were measured for visceromotor response (VMR) to colorectal
distension (CRD) at baseline and day 11. Results: 1) Rats exposed to chronic WA exhibited
enhanced Pp38 staining co localizing predominantly with dorsal horn microglia, but also
with a subpopulation of neurons, as compared with control. Western blot revealed greater
level of Pp38 in WA rats compared with control (213±42 vs 100±22 % control, P<0.05).
This increase was inhibited by minocycline treatment (98±9 vs 213±42 % control, P<0.05)
2) WA rats treated with vehicle showed significant increase of VMR to CRD at day 11
compared with baseline (P<0.05), whereas minocycline treated rats failed to developed such
visceral hyperalgesia. The VMR mean change from baseline in WA/vehicle rats (+69±28 and
119±54 at 40 and 60 mmHg respectively) was significantly greater compared with WA/
minocycline (+4±14; and +34±15; P=0.02 and 0.04, respectively). VMR to CRD in sham
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WA rats was not different between minocycline and saline treated groups. Conclusions: The
present data demonstrate the functional activation of spinal microglia and dorsal horn
neurons after chronic WA stress. The results showing that minocycline treatment prevents
the development of visceral hyperalgesia supports the contribution of activated microglia
in the process of spinal sensitization of the visceral nociceptive signals after chronic stress.
This is the first evidence for a role of spinal immune activation in the sensitization of
visceral nociception.
W1583
A Functional Innervation of the Crural Diaphragm By the Vagus
Richard L. Young, Amanda J. Page, Nicole J. Cooper, L. ashley Blackshaw
The gastroesophageal reflux barrier is secured by both the inner lower oesophageal sphincter
(LES) and the external crural diaphragm (CD). During gastroesophageal reflux both transient
LES relaxation and CD inhibition occur concomitantly, permitting esophageal common
cavity, and acid reflux. Our group has characterized how the LES is controlled by the vagus
during reflux events (Blackshaw L.A. et al J Auton Nerv Syst 1997 66:179-88) and has
recently shown that the vagus provides a novel sensory and motor innervation of the CD
in ferrets (Young R.L. et al Gastroenterol. 130(4) Suppl. 2: 453; 2006). However, the
functional significance of vagal innervation of the CD has not been investigated. An under-
standing of this vagal pathway to the CD and its relation to LES control may provide new
insights into the mechanisms of gastroesophageal reflux. The aims of this study were therefore
to determine if the vagus provides a functional sensory and/or motor innervation of the CD
in ferrets. METHODS: A ferret In Vitro diaphragm preparation with attached vagus nerves,
similar to our In Vitro gastroesophageal preparation described previously (Page A.J. &
Blackshaw L.A. J Physiol 512, 907-916; 1998), was used to record vagal afferent fiber
responses to mechanical stimuli in the CD. A similar diaphragm preparation with attached
vagus and phrenic nerves was used to record EMG responses of the CD to nerve stimulation.
Choline acetyltransferase (ChAT) and neuronal nitric oxide synthase (nNOS) immunolabeling
were also tested in vagal motor neurons in the dorsal motor nucleus of the brainstem that
were retrogradely traced from the CD. RESULTS: Vagal sensory fibers with receptive fields
within the diaphragmatic crus muscles were identified which responded to blunt probing
or low-level von Frey hair stimuli (10mg). Phrenic nerve stimulation triggered EMG responses
in the CD, as expected. In addition, vagal stimulation triggered EMG responses in the CD
which showed frequency-dependent fatigue. Identified CD vagal motor neurons in the
dorsal motor nucleus were exclusively ChAT immunopositive and nNOS immunonegative.
CONCLUSIONS: These findings indicate that the CD is functionally innervated by vagal
sensory neurons of high and low threshold mechanosensitivity. Moreover, these findings
show that vagal motor input to the crural diaphragm is functionally and neurochemically
excitatory and suggest that vagal motor pathways to the LES and CD converge within the
dorsal motor nucleus. Further characterization of the function and phenotype of vagal
sensory and motor neurons innervating the CD is the subject of ongoing studies in our
laboratory. Supported by: AstraZeneca
W1584
Effect of Tegaserod On Visceral Sensitivity to Tonic and Phasic Colorectal
Distension in Male Rats
Sylvie Bradesi, Gareth A. Hicks, Emeran A. Mayer
Tegaserod is a 5-HT(4) receptor partial agonist approved for the treatment of the multiple
symptoms of irritable bowel syndrome with constipation (IBS-C) in women, and of both
men and women with chronic idiopathic constipation. The basis for the reduction of abdom-
inal pain with tegaserod is not clear, but it is thought to involve both relief of distention-
induced afferent activity following resolution of constipation, and an additional inhibition
of sensory nerves, independent of the effect upon GI transit. Our aim was to evaluate the
effect of tegaserod on visceral sensitivity using two different paradigms of colorectal distension
(CRD) in control and stress-induced sensitized conditions. Methods: Male Sprague Dawley
(SD) or Wistar rats were equipped with electrodes implanted into the abdominal muscles.
One week after surgery, the visceromotor response (VMR) to CRD was recorded. 1) We
first tested the effect of tegaserod (1 mg/kg, IP, 10 min pre CRD) or vehicle, on tonic CRD
(2x60 mmHg for 10 min, 10 min interstimulus interval) in SD rats. 2) Next, we tested the
effect of tegaserod (1 mg/kg IP, 10 min pre CRD) on phasic graded pressure CRD (2x(0-
60 mmHg), 20 sec each, 4 min interstimulus interval,) in Wistar rats sensitized by previous
exposure to chronic water avoidance stress (WA: 1 hour WA daily for 10 consecutive days)
or control sham WA rats. Results: 1) Tegaserod significantly attenuated the VMR during
both tonic 60 mmHg CRDs, by 41 and 42%, compared with vehicle (p=0.0256 and 0.0380)
respectively. 2) Rats exposed to chronic WA stress exhibited enhanced VMR to CRD at 40
and 60 mmHg at day 11 compared with baseline (P<0.05). Sham WA did not affect VMR
to CRD. Tegaserod significantly abolished stress-induced visceral hyperalgesia in stressed
rats (P<0.05) whereas it had no effect in control sham WA rats. Conclusion: These results
suggest a stimulus specific inhibitory effect of tegaserod on the visceromotor response to
colorectal distension: 1. Under basal conditions, tegaserod inhibits the response to tonic,
but not phasic distension. 2. Following chronic stress, tegaserod reverses stress-induced
visceral hyperalgesia. These data suggest that 5-HT4 receptor activation can inhibit colorectal
sensory signaling under conditions of sustained bowel distention, and also of shorter term
distending stimuli, when a chronic sensitized state is induced.
W1585
Rhythmic Expression of a Subset of Genes in the Murine Colon Suggests a
Role for Clock Genes in the Regulation of Biological Rhythms in the
Gastrointestinal Tract
Willemijntje A. Hoogerwerf, Mala Sinha, Bruce A. Luxon
Background. Disruption of biological rhythms such as time zone traveling has been associated
with gastrointestinal symptoms. These observations suggest a functional correlation between
biological rhythms and gastrointestinal physiology. Biological rhythms are controlled by
clock genes. A central clock is located in the suprachiasmatic nucleus of the brain. Clock
genes have been identified in peripheral organs as well. Within a peripheral organ, clock
genes control the expression of a subset of tissue-specific genes, which may impact directly
on its physiological function. We previously reported rhythmic expression of clock genes
in the murine colon. The aim of this study was to identify genes that may potentially be
under control of these gastrointestinal clock genes. Methods. Affymetrix® GeneChip®
microarray analyses were performed using distal colonic RNA isolated from C57BL/6J mice
q4 hours for a total of 24 hours on a regular light/dark cycle. Data were analyzed using
STEM (Short Time-series Expression Miner), a statistical program that identifies significant
temporal expression profiles and the genes associated with these profiles. Results. In the
distal colon, genes involved in (1) immunity such as the toll-like receptors TLR7 and TLR9
showed 2- to 3 fold oscillation between peak and trough, with a peak at the onset of the
light cycle, (2) motility such as vasoactive intestinal peptide, gastrin releasing peptide and
the histamine 1 receptor showed 2-to 3 fold q12 hour oscillation with a peak at the end
of the light and dark cycle respectively and (3) carcinogenesis such as beta-catenin, casein
kinase delta, casein kinase gamma and glycogen synthase kinase 3 beta (components of the
Wnt signaling cascade) showed 19-, 2-, 10-, 6-, and 13 fold oscillations between peak and
trough respectively with a drop in expression levels at the end of the dark cycle. Conclusion.
Subsets of genes in the murine colon are expressed in a rhythmic manner and their expression
may therefore be controlled by clock genes. As disruption of biological rhythms has been
associated with the development of gastrointestinal symptoms (ie time zone traveling) and
an increased risk for colon cancer (ie shiftworkers: data from Nurses Health Study), we
speculate that clock genes play an important role in the regulation of rhythmic physiological
functions and that disruption of clock gene expression will contribute to the development of
gastrointestinal disease through a downstream effect on tissue specific clock controlled genes.
W1586
Functional Brain Activation and Visceral Pain Measurements in Response to
Colorectal Distension in Unrestrained Conscious Rats
Zhuo Wang, Sylvie Bradesi, Jean michel I. Maarek, Kevin Lee, Wendy J. Winchester,
Emeran A. Mayer, Daniel P. Holschneider
Background: Current pre-clinical drug development for candidate compounds for visceral
pain relies almost exclusively on measuring pseudo affective reflex responses to colorectal
distension (CRD) in restrained animals. While techniques such as c-fos, fMRI or PET have
provided valuable information about the brain regions involved in processing visceral pain
in rats, these imaging approaches have limitations such as spatial/temporal resolution, and
the use of anesthetized animals. Aim: To apply autoradiographic methods of cerebral perfu-
sion imaging to the model of CRD in rats. This model allows tracer injection in the unres-
trained, conscious animal and mapping of changes in cerebral blood flow with a temporal
resolution of 10s and spatial resolution of 100mm. Method: Two groups of 7 Wistar rats
were implanted with a telemetry transmitter for abdominal electromyography (EMG), and
cannulated through the external jugular vein for perfusion of the tracer [14C]-iodoantipyrine.
Animals were habituated to the un-inflated colorectal balloon for 1 hour/day for 3 days
prior to CRD experiments. Tracer was injected 35s after the onset of CRD (60 mmHg x
60s), followed by rapid euthanasia. Control animals received a colorectal balloon that
remained un-inflated through the experiment (0 mmHg). Simultaneously, EMG signals were
recorded telemetrically and animal behavior was recorded with two digital camcorders. Brains
were frozen, sliced and processed for autoradiographic analysis using statistical parametric
mapping of the 3-D reconstructed brain, as well as region-of-interest analysis. EMG activity
was expressed as area under the curve. Behavioral scoring of pain behavior was manually
conducted offline. Results: Colorectal distension at 60 mmHg evoked significant increase
of EMG activity compared with control (253 ± 30% of baseline vs. 120 ± 14%, AUC±SEM,
P < 0.003) and significant behavioral responses indicative of visceral pain (81.7 ± 5.8% of
time spent in pain posture at 60 mmHg vs. 5.7 ± 5.7%, at 0 mmHg, P < 0.001). The EMG
and behavioral responses were positively and significantly correlated (r = 0.715, P = 0.004).
Preliminary ROI analysis showed trends in blood flow increase in the amygdala, hypothal-
amus, CA1 region of the hippocampus, and primary somatosensory area of the hindlimbs.
Trends for decrease were seen in the olfactory and piriform cortex, and some somatosensory
areas. Conclusion: The model of brain imaging presented herein provides a new powerful
tool of high temporal- and spatial-resolution for the assessment of functional brain activation
during painful visceral stimuli in unrestrained, conscious rats.
W1587
Early Weaning Activates Mast Cell Signaling Pathways in a Porcine Model of
IBS
Adam J. Moeser, Kathleen A. Ryan, Anthony T. Blikslager
Previous studies demonstrate that piglets subjected to early life psychological stress, induced
by early weaning, develop clinical and pathophysiological characteristics of Irritable Bowel
Syndrome (IBS) in humans. For example, piglets that were weaned early from their dams (19
days-of-age) displayed exaggerated stress-induced serumCRF levels, visceral hypersensitivity,
and elevated numbers of mucosal mast cells six weeks after weaning compared with pigs
that were weaned later (28 days-of-age). The mechanisms underlying early weaning stress
and long-term intestinal dysfunction in pigs are unclear. The objective of this experiment
was to investigate the acute effects of early weaning stress on gastrointestinal function in
piglets. Nursing piglets were weaned either at 19 days-of-age (early weaned, EW, n=8) or
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28 days-of-age (late weaned, LW, n=8) and housed in nursery pens. Additional piglets from
each weaning age group remained with the dam and served as unweaned (UW), age-matched
controls. Twenty-four hours post-weaning, segments of jejunum and colon were harvested
and mounted on Ussing chambers for measurement of transepithelial electrical resistance
[TER], mucosal-to-serosal 3H-mannitol fluxes [3H-mannitolm-s], and short circuit current
[Isc]. Compared with UW controls, TER was reduced in EW piglet jejunum (TER = 55±6
and 31±3 Ω.cm2 in UW and EW piglets, respectively, p<0.01) and colon (TER = 86±12
and 57±5 Ω.cm2 in UW and EW piglets, respectively, p<0.05). Elevations in 3H-mannitolm-
s fluxes were also observed in EW intestinal tissues compared with UW piglets (p<0.05).
In addition, Isc was elevated (p<0.01) in EW intestinal tissues and this response was inhibited
by In Vitro serosal application of the enteric neural blocker, tetrodotoxin (10-7 M) in Ussing
chambers. In contrast, LW piglets did not exhibit deleterious changes in barrier function
or Isc in response to weaning. Intestinal mucosa from EW piglets had increased mucosal
mast cell tryptase protein expression and immunofluorescence staining patterns compared
with UW and LW control tissues. Pre-treatment of EW pigs with the mast cell stabilizer agent,
cromolyn, injected intraperitoneally (20 mg/kg) 30-minutes prior to weaning, abolished EW-
induced intestinal barrier dysfunction and Isc disturbances. Results from these experiments
indicate that stress associated with early weaning induces acute mucosal barrier dysfunction
mediated by mucosal mast cell activation and enteric nerves. Activation of these pathways
may represent early mucosal events that trigger long-term stress hypersensitivity and intestinal
dysfunction in pigs thereby providing insight into the pathogenesis of IBS in humans.
W1588
Trinitrobenzene Sulfonic Acid (TNBS) Colitis-Induced BDNF Expression in
Lumbosacral Dorsal Root Ganglia (DRG) Is Mediated By Activation of the
MAP Kinase Pathway
Li-ya Qiao, Melisa A. Gulick, Jack Grider
We have previously reported that TNBS colitis increases the expression of brain-derived
neurotrophic factor (BDNF) in lumbosacral DRG. We also reported that the phosphorylation
of mitogen-activated protein kinase (MAPK) ERK was increased in DRG following TNBS
colitis. Aim: To examine the involvement of ERK in colitis-induced BDNF expression in
DRG. Methods: Rats were implanted with a spinal intrathecal catheter connected to an
osmotic mini-pump filled with the selective ERK antagonist PD98059 (0.15 mg/mL diluted
with saline) or salinE. colitis was induced by intracolonic instillation of TNBS (0.25ml of
60mg/ml in 50% ethanol) two days after mini-pump implantation. Control rats received
intrathecal saline followed by colitis or intrathecal PD98059 without induction of colitis.
At day 7 of colitis, BDNF expression in lumbosacral L1 and S1 DRG was measured as
BDNF protein concentration by ELISA and as number of BDNF-immunoreactive cells by
immunohistochemistry. Results: Colitis induced a significant increase in BDNF content in
L1 DRG (colitis: 230.8 ± 68.4 vs. control: 42.2 ± 3.8 pg BDNF/mg protein, p<0.01) and
S1 DRG (colitis: 434.3 ± 99.39 vs. control: 101.6 ± 14.1 pg BDNF/mg protein, p<0.01).
Similarly, colitis induced a significant increase in the number of BDNF immunoreactive cells
in L1 DRG (colitis: 42.1 ± 12.2 vs. control: 23.2 ± 5.1 cells per section, p<0.01) and S1
DRG (colitis: 41.6 ± 14.3 vs. control: 18.7 ± 2.1 cells per section, p<0.05). Intrathecal
PD98059 significantly attenuated the colitis-induced increase in BDNF expression to 33.7
± 0.2 pg BDNF/mg protein and 27.8 ± 4.5 cells per section in L1 DRG (p<0.01 when
compared to colitis alone or intrathecal saline with colitis). Similarly, intrathecal PD98059
attenuated the colitis-induced increase in BDNF expression to 162.5 pg BDNF/mg protein
and 22.3 ± 5.0 cells per section in S1 DRG (p<0.05 when compared to colitis alone or
intrathecal saline with colitis). Intrathecal injection of saline had no effect on the colitis-
induced increase in BDNF levels in L1 and S1 DRG. Intrathecal injection of PD98059 had
no effects on the level of BDNF expression in animals in which colitis was not induced.
Conclusion: TNBS colitis-induced increase in BDNF expression in lumbosacral DRG is
mediated by activation of the MAPK pathway.
W1589
TRPV1-Receptors and CGRP Mediate Pelvic Afferent Sensitization in Colitis-
Induced Gastroparesis in Rats
Heiko U. De schepper, Joris G. De man, Luc Van nassauw, Jean-pierre Timmermans,
Arnold G. Herman, Paul A. Pelckmans, Benedicte Y. De winter
Introduction: Patients with inflammatory bowel disease often suffer from impaired gastric
emptying (GE). We previously reported that gastroparesis induced by distal colitis in rats
is mediated via primary afferent neurons situated in the pelvic nerve (De Schepper et al.,
Gut Epub ahead of print). The aim of the current study was to identify the mediators
involved by using specific antagonists for transient receptor potential vanilloid (TRPV1) and
calcitonin gene-related peptide (CGRP)-receptors. Methods: Distal colitis was induced in
male Wistar rats by a colorectal enema of 7.5 mg trinitrobenzene sulphate (TNBS) in 50%
ethanol 72 h prior to the experiment. GE was measured 30 min after intragastric instillation
of a semi-liquid bolus of Evans blue. All drugs were administered intraperitoneally 1 h
earlier. Immunocytochemical detection of TRPV1 receptors was performed on Fast blue-
traced DRG L6-S1 pelvic neurons. Results: (table) TNBS-colitis reduced GE significantly
compared to controls (P<0.05). The novel TRPV1 antagonist BCTC (5 mg/kg i.p.) decreased
GE in controls (NS) but improved it in rats with TNBS colitis (P<0.05). The CGRP receptor
antagonist CGRP [8-37] (150 μg/kg i.p.) decreased GE in controls (NS) but restored it to
normal levels in TNBS-treated rats (P<0.05). Both antagonists had no effect on the macro-
scopic or microscopic degree of colitis. Immunocytochemistry revealed that TNBS-colitis
induced a twofold increase in TRPV1 immunoreactivity in pelvic afferent neuronal cell bodies
(DRG L6-S1). Conclusion: These data provide pharmacological and immunocytochemical
evidence that distal colitis inhibits gastric motor function through sensitization of pelvic
afferent neurons involving TRPV1 receptors and CGRP.
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Table: The effect of BCTC and CGRP (8-37) or their vehicles (25% hydroxypropyl-β-
cyclodextrin and saline respectively) on gastric emptying in control and TNBS-treated rats.
GE is presented as a mean percentage ± s.e.m.*P<0.05, significantly different from vehicle-
treated controls; #P0.05, significantly different from vehicle-treated TNBS-rats (n=11-13,
Two-way ANOVA, post-hoc SNK).
W1590
Acid in the Cervical Or Thoracic Portions of the Esophagus Activates
Different Sets of Medullary Nuclei
Ivan M. Lang, Bidyut K. Medda, Reza Shaker
The effects of acidification of the whole esophagus on medullary nuclei have been examined,
but the physiological responses to HCl of the cervical and thoracic portions of the esophagus
differ suggesting a differential central control. AIM: To determine whether acidification of
the cervical or thoracic portions of the esophagus activates different sets of medullary nuclei.
METHODS:Cats (N=24), anesthetized using alpha-chloralose (50mg/kg), were instrumented
for the perfusion of the cervical (N=7, CE cats), thoracic (N=5, TE cats), or entire esophagus
(N=12, EE cats) only at 1ml/min. All CE and TE cats, and 4 EE cats (previously vagotomized
bilaterally), were perfused with 0.1N HCl for 1 hr followed by 0.1M PBS for 2 hrs. For a
control group, 8 EE cats were perfused with 0.1M PBS for 3 hrs. At the end of the experiments,
the brains were removed, sliced and processed for c-fos immunoreactivity. RESULTS: We
found that HCl perfused through the esophagus activated neurons in the medulla and the
pattern of activation between cervical or thoracic portions differed significantly from each
other and from control (Table). The nuclei of greatest difference include the NTSim, NTSis
and AP. Vagotomy blocked the medullary responses to esophageal acidification. The Table
lists the number (N±SE) of c-fos positive neurons in each nucleus and only nuclei which
showed differences are listed. CONCLUSIONS: We conclude that: 1 HCl in the cervical
or thoracic portions of the esophagus activates different sets of medullary nuclei; 2. The
preferential activation of NTSis and NTSim by cervical HCl may cause the preferential
activation of swallowing by the cervical esophagus (these nuclei are also the main medullary
nuclei activated by pharyngeal stimulation-induced swallowing (Lang et al 2004)) 3. The
preferential activation of the AP by cervical esophageal acidification suggests that the cervical
esophagus is the source of receptors mediating esophagus-induced emesis as the AP is a
primary nucleus mediating GI-induced emesis. 4. The medullary responses to esophageal
acidification are mediated by the vagus nerves
Values are N±SE of the number of c-fos positive neurons per section. NTS, nucleus tractus
solitarius; AP, area postrema; DMN, dorsal motor nucleus of the vagus. Groups with same
superscript differ at P<0.05 using ANOVA plus Tukey's; EE(HCl,vx) not tested. Subscript
indicates mm from obex.
W1591
5-HT3 Receptors On Rat Vagal Afferent Sensory Neurons and Nerve Terminals
Function As a Glucose Sensor
Kirsteen N. Browning, Thomas Starke-peterkovic
Glucose in the gastrointestinal tract induces the release of 5-hydroxytryptamine (5-HT) from
enterochromaffin cells that subsequently activates 5-HT3 receptors present on peripheral
vagal afferent (sensory) nerve terminals. This study aimed to determine whether glucose
can also act upon primary vagal afferent neurons and nerve terminals to modulate the 5-
HT3 receptor mediated response. Whole cell patch clamp recordings were made from acutely
dissociated GI-projecting nodose ganglion neurons in control and hyperglycemic conditions
(2-5 days after streptozotocin (STZ) injection). 5-HT, applied via superfusion (0.1-100μM)
or pressure ejection (10mM), induced a rapid onset, quickly desensitizing inward current
that was abolished by the 5-HT3 receptor selective antagonist, ondansetron (1μM; n=4).
STZ-hyperglycemia increased the sensitivity of vagal afferent neurons to 5-HT and increased
the magnitude of their response. Furthermore, acute perfusion (10min) with hyperglycemic
Krebs' solution increased the amplitude of the 5-HT-induced inward current by approxim-
ately 60%, whereas acute perfusion with normal Krebs' solution reduced the 5-HT-induced
inward current in neurons from STZ-hyperglycemic rats by approximately 40%. Whole cell
patch clamp recordings from second order nucleus tractus solitarius neurons in brainstem
slices (300μm) confirmed that presynaptic 5-HT3 receptors on vagal afferent central nerve
terminals facilitate excitatory (glutamatergic) synaptic transmission. The amplitude of evoked
excitatory currents was increased by acute perfusion (10min) with hyperglycemic Krebs'
solution. The ability of normal Krebs' solution to reduce the amplitude of evoked excitatory
currents in STZ-hyperperglycemic rats was abolished by the Golgi-disrupting agent, Brefeldin
A (5mM) suggesting the involvement of 5-HT3 receptor trafficking. In STZ-hyperglycemic
rats, ondansetron decreased excitatory current amplitudes by 12.3±1.9%, compared to
29.5±1.9% in control rats (n=3), suggesting hyperglycemia increases 5-HT3 receptor number.
These results imply that the density and function of 5-HT3 receptors on vagal afferent
neurons and central nerve terminals is modulated by glucose, suggesting that these receptors
function as glucose sensors. By modulating the response of vagal afferents to 5-HT3 receptor
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activation, glucose may be able to induce a more discrete, finely tuned sensory transduction.
Supported by a LaEPSCoR grant
W1592
Duodenal Afferent Input Converges Onto T9-T10 Spinal Neurons Responsive
to Gastric Distension in Rats
Chao Qin, Jiande Chen, Jing Zhang, Robert d Foreman
Clinically, the overlap of gastroduodenal symptoms such as visceral hypersensitivity or pain
is often observed in functional gastrointestinal disorders. The underlying mechanism may
be related to intraspinal neuronal processing of noxious convergent visceral inputs from the
stomach and the intestine. The purpose of this study was to examine if single low thoracic
(T9-T10) spinal neurons respond to both gastric and duodenal mechanical stimulation.
Extracellular potentials of single T9-T10 spinal neurons were recorded in pentobarbital
anesthetized, paralyzed, and ventilated male rats. Graded gastric distensions (GD, 20, 40,
60 mmHg, 20s) were induced by air inflation of a latex balloon surgically placed in the
stomach. Graded duodenal distensions (DD, 0.2, 0.4, 0.6 ml, 20s) were produced by water
inflation of a latex balloon placed into the duodenum. Of 61 deeper (depth from dorsal
surface of spinal cord: 0.3-1.2 mm) spinal neurons responsive to noxious GD (≥ 40 mmHg),
37(61%) also responded to noxious DD (≥ 0.4 ml). Similarly, 12/15 (80%) superficial
neurons (depth < 0.3 mm) responded to both GD and DD. Of 49 gastroduodenal convergent
neurons, 33 (67%) had excitatory and 4 had inhibitory responses to both GD and DD; The
remaining neurons exhibited multiple patterns of excitation and inhibition. 10/36 (28%)
gastroduodenal convergent neurons had high-threshold (≥ 40 mmHg) for excitatory
responses to GD, whereas 28 (78%) of these neurons had high-threshold (≥ 0.4 ml) for
excitatory responses to DD. In addition, 89% (42/47) of gastroduodenal convergent neurons
had somatic receptive fields on the back, flank, and medial/lateral abdominal areas. These
results suggested that superficial and deeper T9-T10 spinal neurons received innocuous and/
or noxious mechanical convergent inputs from the stomach and duodenum. Gastroduodenal
convergent spinal neurons might contribute to the intraspinal sensory transmission for cross-
organ afferent-afferent communication between the stomach and duodenum in visceral
nociception and reflexes. (Supported by DK066709, HL075524)
W1593
Intracerebroventricular Mouse Urocortin III Opposing Acyl Ghrelin-Induced
Orexigenic Effect in Conscious Rats
Chih-yen Chen, Han-chieh Lin, Shou-dong Lee
Background & Aims: Mouse urocortin III (mUcn III), a novel 38-amino acid peptide,
was recently identified and characterized. mUcn III represents the endogenous ligand of
corticotropin-releasing factor (CRF) receptor subtype 2 for maintaining homeostasis after
stress. Although mUcn III has been shown to suppress food intake, delay gastric emptying
and decrease heat-induced edema inmice, no previous studies have examined the interactions
of this novel stress-related peptide and acyl ghrelin on food intake in rats. Methods: We
first examined the effects of intracerebroventricular (ICV) administration of mUcn III and
ghrelin on food intake in conscious free-feeding rats. Second, mUcn III and ghrelin were
ICV co-administered to investigate their interactions on food intake. The novel selective
CRF2 receptor antagonist, astressin2-B, was ICV injected before co-administration of ICV
mUcn III and ghrelin. Then, 1-h, 2-h, 4-h, 8-h, 12-h, 24-h and 36-h cumulative food intake
was measured, respectively. Results: ICV injectedmUcn III (2 nmol/rat) significantly inhibited
8-h, 12-h and 24-h cumulative food intake in free-feeding rats, whereas ICV injected ghrelin
(0.1 nmol/rat) significantly stimulated 1-h, 2-h, 4-h, 8-h and 12-h cumulative food intake
in free-feeding rats. ICV administration of mUcn III blocked ghrelin-induced orexigenic
effect on 1-h, 2-h, 4-h, 8-h and 12-h cumulative food intake. Pre-treatment with ICV
injection of the selective CRF2 receptor antagonist, astressin2-B, completely blocked ICV
injected mUcn III-induced inhibition of ghrelin-induced stimulation on food intake. Conclu-
sions: The results suggest that ICV mUcn III suppresses food intake in free-feeding rats,
and its anorexic effect is up to 24-h. ICV mUcn III opposes acyl ghrelin-induced stimulation
of food intake. In the brain, CRF receptor subtype 2, is involved in this anorexigenic
mechanism on ingestive behavior.
W1594
Separate Central Destinations of Muscular and Mucosal Gastric Vagal
Afferents?
Richard L. Young, Nicole J. Cooper, L. ashley Blackshaw
Muscular and mucosal vagal afferents from the upper gastrointestinal tract can initiate vastly
different central behavioural and reflex functions. Gastric vagal afferents, in particular, have
been shown to terminate in specific vagal subnuclei in the rat brainstem [1]. However, no
report has addressed whether vagal afferents with endings in muscular or mucosal layers
of the stomach terminate in different brainstem regions tuned to processing of mechanical
or chemosensory information. The aims of this study were to develop a differential retrograde
tracing approach to identify muscular and mucosal gastric vagal afferents in the ferret nodose
ganglion, and map their specific termination sites in the nucleus tractus solitarius (NTS).
METHODS: Differential retrograde tracing was performed from the proximal stomach by
cholera toxin-B based tracers. Muscular afferents were retrogradely traced after multiple (4)
subserosal microinjections (total 20 μl), while mucosal afferents were traced after application
of tracer (20 μl) to the gastric mucosa after mucolytic treatment (10% N-acetyl cysteine).
RESULTS: Muscular gastric afferents represented 9 ± 1% of nodose neurons; mucosal afferents
6 ± 1% and only 1% were dual traced with no evidence for regional distribution within the
ganglia. Proportions were identical when tracer application sites were reversed. Central
terminals of muscular afferents were evident in the subnucleus gelatinosus (SG) immediately
caudal to obex (opening of the fourth ventricle floor) and extended through +2.5 mm rostral
of obex where they extended into dorsal regions of the medial subnucleus of the NTS (MN).
Tracing from muscular layers also labeled vagal motor neurons in the dorsal motor nucleus
(DMN) and their dendrites in the MN over a wide rostrocaudal range (-1.5 to +2.5 mm).
Terminals of mucosal afferents were located in regions of the SG that overlapped muscular
afferent terminal fields but importantly no DMN neurons were traced, indicating restriction
of mucosal tracer. CONCLUSIONS: We demonstrate an approach whereby gastric vagal
afferents can be differentially traced from their endings in muscular or mucosal layers to
the nodose ganglia or brainstem. Moreover, we show that central terminals of both afferent
types overlap in the SG and rostral MN. As a consequence, second-order NTS neurons are
likely to be the site of complex integration of CNS responses, rather than a labelled-line
with connectivity with higher functions. 1. Shapiro & Miselis J Comp Neurol 1985 238:473-
87 Supported by: AstraZeneca
W1595
The Mechanism of Accelerated Gastric Emptying in the Early Stage of
Diabetes: Endogenous Ghrelin Plays An Important Role in Enhanced
Manifestation of Antro-PYLORIC Coordination in STZ-Induced Diabetic
Rats.Coordination in STZ-Induced Diabetic Rats
Hajime Ariga, Cindy Chen, Christopher R. Mantyh, Theodore N. Pappas, Toku Takahashi
Background: A certain populations of diabetic patients have gastroparesis. However, rapid
gastric emptying (GE) can be seen in other groups of patients with the early stage of diabetes
(New Eng J Med.1991;324:130, Gut.1995;37: 23). GE is also accelerated in the early stage
of diabetes in rats (J Lab Clin Med.1994;123:110). Rapid GE promotes hyperphagia and
hyperglycemia, which may aggravate diabetes. However, the mechanism of rapid GE in the
early stage of diabetes has not been fully studied. Postprandial antro-pyloric coordination
(APC) plays an important role in mediating solid GE. It has been shown that administration
of ghrelin stimulates GE in normal rats and that postprandial plasma level of ghrelin is high
in diabetic rats (Endocrinol.2002;143:4934). These led us hypothesize that elevated plasma
ghrelin level after feeding enhances postprandial APC, resulting in rapid GE in the early
stage of diabetes. Methods: In male SD rats, diabetes was induced by streptozotocin (STZ)-
injection (55 mg/kg, ip) 2 weeks prior to GE and APC study. After a 24-hour fasting, rats
received intraperitoneal injection of ghrelin antibody (Ghr-Ab, 16 microg/kg) or vehicle.
Thirty min later, they were given 1.5 g of solid meal. Ninety minutes after the feeding, rats
were euthanized and the stomach was removed. Gastric content was recovered and GE
was calculated. Strain gauge transducers were implanted on the antrum and pylorus and
contractions of the antrum and pylorus were monitored in response to the feeding. The
incidence of postprandial APC was evaluated every 20 min up to 120 min after the feeding, as
previously described (Auton Neurosci.2002;95:112). Results: In STZ rats, GE was significantly
accelerated (81.8 +/- 8.2%, n=6), compared to that of control rats (58.3 +/- 3.7%, n=6,
p<0.05). Ghr-Ab attenuated GE in STZ rats (50.1 +/- 3.5 %, n=6) vs vehicle-injected STZ
rats (p<0.05). The number of incidence of APC at 20-40 min after the feeding, which was
not obvious in control rats (1.8 +/- 0.6 times/20 min, n=4), was significantly increased to
11.5 +/- 3.5 times/20 min (n=4, p<0.05) in STZ rats. The number of incidence of APC was
higher in STZ rats than that of control rats in all of the postprandial state. Ghr-Ab significantly
suppressed the incidence of APC at 20-40 min after the feeding to 1.3 +/- 0.8 times/20 min
(n=4) in STZ rats. Conclusion: Solid GE was significantly accelerated in 2 week-duration of
diabetic rats. Accelerated GE is, at least in part, due to the enhanced APC. Our study suggests
that elevated plasma level of ghrelin accelerates GE and enhances APC in the early stage
of diabetes.
W1596
Site-Specific Effects of Electroacupuncture (EA) On Gastric Motility in
Conscious Rats; Stimulatory Effect of EA At ST-36 Is Mediated Via Vagal
Pathways, While Inhibitory Effect of EA At ST-25 Is Mediated Via Sympathetic
Pathways
Kenji Imai, Cindy Chen, Christopher R. Mantyh, Theodore N. Pappas, Toku Takahashi
Background; Electroacupuncture (EA) has been used for autonomic dysfunction including
gastrointestinal and cardiovascular diseases. We have previously showed that EA at ST-36
(hind limb) caused gastric contractions, while EA at ST-25 (abdomen) caused gastric relaxa-
tions in rats. However, the mechanism of site-specific effects of EA on gastric motility remains
unclear. The spectral analysis of heart rate variability (HRV) of electrocardiogram (ECG) has
been used to evaluate the balance of parasympathetic and sympathetic activity in humans.
To clarify the mechanism of site-specific effects of EA on gastric motor function, we studied
the simultaneous recording of gastric motility and ECG in freely moving conscious rats.
Methods: Seventeen male Sprague-Dawley rats (260-340 g) were used. To record gastric
motility, a strain gauge transducer was implanted on the serosal surface of the gastric antrum.
To record ECG, three electrodes were implanted on the subcutaneous tissues of the back
and shoulders. One week after the surgery, gastric motility and ECG were recorded before,
during and after EA (10 Hz for 10 min). EA were performed at bilateral ST-36 or ST-25.
EA at BL-21 (lower back) was used as a control. Overall power spectral analysis was applied
to the HRV signal and the power in each frequency sub-band was calculated. The power
in the low frequency (LF) band (0.04-1.0 Hz) mainly represents sympathetic activity, while
the power in the high frequency (HF) band (1.0-0.3 Hz) represents parasympathetic activity.
LF/HF ratio was calculated to evaluate the balance between the parasympathetic and sympath-
etic activity. Gastric motility index (MI) and LF/HF ratio were compared before and after
EA in each rat. Results: EA at ST-36 significantly increased gastric MI to 182+/-53% of basal
(P<0.05, n=7). In contrast, EA at ST-25 significantly decreased gastric MI to 80+/-23% of
basal (P<0.05, n=7). EA at ST-36 significantly decreased the LF/HF ratio from 2.35+/-0.48
(basal) to 1.41+/-0.27 (P<0.05, n=7). In contrast, EA at ST-25 significantly increased the
LF/HF ratio (basal) from 2.18+/-0.30 to 2.7+/-0.29 (P<0.05, n=7). EA at BL-21 had no
significant effects on gastric MI and LF/HF ratio. There was a significant correlation observed
between the changes of gastric MI and LF/HF ratio after EA at ST-36 and ST-25 (P<0.05).
Conclusion: Our results indicate that the stimulatory effect of EA at ST-36 on gastric motility
is associated with its stimulatory effect on vagal activity. In contrast, inhibitory effect of EA
at ST-25 is associated with its stimulatory effect on the sympathetic activity.
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Vagal Versus Non Vagal Gastric Afferent Signals Processing in the Brain
Eve Lapouble, Alain Chauvin, Sylvie Guérin, Charles-henri Malbert
Central networks involved in the processing of non vagal vs vagal afferent information
originating from gastric distension are poorly understood (Sengupta et al.,1994). Functional
imaging of the pig brain using before and after vagotomy might give some insights since
porcine brain vascularisation is identical to humans (Vodicka et al., 2000). The aim of this
study was to identify brain activation and deactivation during proximal gastric distension
before and after juxta-diaphragmatic vagotomy. Brain activation was evaluated using SPECT
imaging after IV injection of 99mTc-HMPAO in 5 pigs (30 ± 5 kg). This radiolabeled
molecule once injected IV provides a snap shot of brain perfusion (Warwick, 2004). Proximal
gastric distension was achieved using a gastric barostat. The barostat bag was inserted in
permanent stoma and afterwards inflated to reach 10 or 20 mmHg for 60 s. This procedure
was repeated before and 2 weeks after juxta-diaphragmatic vagotomy. Retroprojection of
brain images were normalized against a SPECT pig template build using 16 animals. Once
normalized, the data were analyzed using statistical parameter mapping adapted to the
characteristics of the pig brain. The activated/deactivated regions were determined using co-
registered MRI atlas (Watanabe et al., 2001). Brain areas activated/deactivated by gastric
distension are different before and after vagotomy. As expected, those involved in vagal
afferent information processing were modulated only before vagotomy e.g. pons, thalamus,
pre-frontal and hippocampus cortices. Furthermore, non vagal related brain areas such as
the globus pallidus were also activated proportional to proximal gastric pressure. On the
contrary, after vagotomy, brain areas which were quiescent in intact animals were activated/
deactivated during proximal gastric distension e.g. colliculus superior and subsections of
the cerebellum. The activation of the globus pallidus disappeared. Finally, left amygdala
was always deactivated by distension irrespective of the integrity of the vagus. In conclusion,
brain processing of vagal vs non vagal afferent information originating from the proximal
stomach comprised mostly different networks. One of them includes process reward informa-
tion network that was involved during distension on intact animals only. On the contrary,
the left amygdala might represent a common pathway to process information originating
from the stomach since it is deactivated before and after vagotomy.
W1598
Viability of Synaptic Circuitry in a Brainstem Slice Preparation
Zhongling Zheng, R. alberto Travagli
There is abundant evidence to suggest that gastric vago-vagal reflexes are composed of
glutamatergic inputs from vagal afferent (sensory) fibers that project to neurons of the
nucleus tractus solitarius (NTS). NTS neurons, in turn, project to the dorsal motor nucleus of
the vagus (DMV) using principally glutamate, GABA and catecholamines as neurotransmitters.
DMV neurons then provide the preganglionic efferent motor output to the viscera. The
present study was designed to validate, in an In Vitro preparation, the In Vivo data suggesting
that a tonic GABA neurotransmission sets the motor vagal output. Whole cell patch clamp
recordings were made from 14 DMV neurons to investigate the ability of ionotropic glutamate
(kynurenic acid, 1mM) and GABA (bicuculline, 50μM) receptor antagonists to alter the
basal firing properties of gastric-projecting DMV neurons. Neurons were clamped at a holding
potential that resulted in a stable baseline firing rate (0.76±0.11 action potentials s-1). In
nine neurons, perfusion with bicuculline increased the firing rate from 0.78±0.15 to
1.59±0.23 action potentials s-1. The firing rate returned to baseline upon washout of
bicuculline (0.80±0.15 action potentials s-1). These results suggest that in brainstem coronal
slice preparations the neuronal circuitry is still intact and gastric-projecting DMV neurons
receive a tonic GABAergic inhibitory input. In four neurons, perfusion with kynurenic acid
increased the firing rate from 0.72±0.24 to 1.15±0.35 action potentials s-1. These puzzling
results may suggest that the GABAergic inputs from NTS to DMV neurons are driven by a
tonic glutamatergic input originating from either extrinsic (i.e. vagal afferent fibers) or
intrinsic (i.e. interneurons) fibers. Our preliminary results appear to confirm previous In
Vivo studies reporting that GABAergic neurotransmission within the brainstem is of critical
importance in determining gastrointestinal parasympathetic outflow. These data further
indicate that the brainstem slice preparation is indeed an excellent model for the study of
brainstem gastrointestinal vago-vagal circuits. Supported by NIDDK 55530.
W1599
Alterations in CGRP mRNA Expression in Lumbosacral DRG and Spinal Cord
Following Trinitrobenzene Sulfonic Acid (TNBS) Colitis
Li-ya Qiao, Jack Grider
We have previously reported that TNBS colitis increases calcitonin gene-related peptide
(CGRP) immunoreactivity in DRG and in bladder afferent neurons. Colitis also increased
the co-localization of CGRP and tyrosine kinase receptor TrkB in DRG neurons. Following
colitis, the level of brain-derived neurotrophic factor (BDNF) was increased in both DRG
and spinal cord. We postulate that the increased BDNF acts on TrkB, activates signal
transduction pathways, and induces CGRP gene expression and protein production in these
neurons. AIMS: 1) To examine the changes in CGRP mRNA transcription in DRG and spinal
cord following colitis. 2) To determine the direct effect of BDNF on CGRP expression in
DRG neurons. METHODS: Inflammation was induced in rats by intracolonic instillation of
TNBS (0.25ml of 60mg/ml in 50% ethanol). After 3 or 7 days, lumbosacral L1 and S1 DRG
and spinal cord were freshly extracted and processed for mRNA by real-time PCR. DRG
were also isolated from control rats, dispersed, and cultured in DMEM-10 plus Ara C (10
uM) alone and in the presence of BDNF (100 ng/mL) for 5-min to 14-hour time periods.
The expression level of CGRP in these neurons was determined and presented as the
percentage of PGP9.5-immunoreactive neurons expressing CGRP. RESULTS: In L1 DRG,
CGRP mRNA levels were increased by 2.5-fold, p<0.01 at 3 day but not at 7 day after
colitis. In S1 DRG, CGRP mRNA levels were increased by 2.4-fold, p<0.01 at 3 day and
1.9-fold, p<0.01 at 7 day after colitis. Conversely in L1 and S1 spinal cord, there were no
changes in CGRP mRNA levels at both day 3 and 7 after colitis. Co-localization studies
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showed that about 50% of BDNF neurons expressed CGRP before and after colitis. In
cultured DRG neurons, acute BDNF treatment (5 to 30 min) did not cause significant
changes in the percentage of DRG neurons expressing CGRP (32 % before vs 25-28 % after
BDNF stimulation); however, overnight incubation with BDNF significantly augmented
CGRP expression (1.5-fold, p<0.05) in these neurons. Pre-incubation with K252a (100 nM),
a selective antagonist of Trk, inhibited BDNF-induced CGRP expression to control level in the
DRG neurons. CONCLUSION: TNBS-induced colitis results in increased CGRP expression in
DRG neurons but not in spinal cord. The prolonged increase in BDNF that accompanies
colitis is likely to act on TrkB and induce CGRP expression in DRG.
W1600
Deterioration of Rectal Distension-Sensitive Afferent Neural Pathways in the
Elderly: A Study of the Subliminal Viscero-Sensory Domain By Fmri
Mark K. Kern, Venelin Kounev, Patrick Sanvanson, Adeyemi Lawal, Candy Hofmann, B
douglas Ward, Reza Shaker
Earlier studies in healthy young subjects have identified a range of unperceived (subliminal)
mechanical rectal distension pressures that are associated with brain fMRI activity. We used
this approach to determine the effect of aging on rectal distension-sensitive afferent neural
pathways without the influence of stimulus-related cognition. Methods: Eleven healthy
elderly (7 F, age range: 71-85 years) and 9 healthy young (5 F, age range: 20-28 years)
subjects were studied using a barostat controlled, paradigm-driven fMRI scanning procedure
(high spatial resolution MRI, 2.5x2.5mm within slice resolution, TR=6 s, TE=40 mS) during
a range of phasic subliminal and perceived distensions of the rectum. Results: Subliminal
rectal distension pressures ranged from 5 to 30 mmHg in the elderly and 5 to 25 mmHg
in the young subjects. The average perception pressure was significantly higher (p=0.014)
in the elderly (26±2 mmHg) compared to the young (20±1 mmHg). The number of activated
voxels across the subliminal range of distension pressures in the elderly groupwas significantly
less than that of the young. (Figure, *p<0.05) Both age groups showed a dose-response
relationship between the level of subliminal rectal distension pressure and the number of
activated voxels. (Figure) Similar findings were seen for the percent increase from baseline
of the magnetic signal intensity across the range of subliminal distension pressures. Conclu-
sions: At all levels of subliminal viscero-sensory domain and at the perception threshold,
comparable rectal distension induces significantly less cortical activity compared to young
indicating deterioration of visceral afferent function in the elderly.
W1601
Functional and Morphological Identification of Pelvic Afferent
Mechanoreceptors in the Aganglionic Rectum of a Mouse Model of
Hirschsprung's Disease
Melodie Muto, Aoife Kerrin, Vladimir Zagorodnuk, Grant Hennig, Orla Mc donnell,
Simon Brookes, Nicholas J. Spencer
Background: Recent studies have shown that the mechanotransduction sites of pelvic afferents
in the rectum lie in themyenteric plexus1. It is reasonable to assume then, that the aganglionic
rectum of mammals with Hirschsprung's disease would be devoid of pelvic afferent mechano-
receptors. In fact, many investigators have assumed that the aganglionic rectum is devoid
of all afferent innervation. In this study, we investigated whether functional pelvic afferents
innervate the aganglionic rectum in a mouse model of Hirschsprung's disease and if so,
where these sensory endings (mechanoreceptors) innervate. Methods: Extracellular nerve
recordings combined with anterograde labeling were made from pelvic nerves in piebald
lethal (Ednrbs-l/Ednrbs-l) mice and C57BL/6 controls. Results: Recordings from control
mice (16 units, n=16 mice) revealed that a spontaneous discharge of action potentials arose
from the pelvic nerves innervating the ganglionic rectum. Surprisingly, a similar discharge
of action potentials was also recorded from the pelvic nerves innervating the aganglionic
rectum of Ednrbs-l/Ednrbs-l mice (49 units, n=46). Graded circumferential stretch applied
to both ganglionic and aganglionic preparations elicited graded increases in firing of slowly-
adapting mechanoreceptors. Focal von Frey hair compression stimuli (200-500mg) applied
to aganglionic and ganglionic preparations identified discrete mechanosensitive “hot spots”
in both control and mutant preparations. In the aganglionic rectum a mean of 3.4 ± 1.8
hot spots were identified per single unit, while in control mice 2.5 ± 0.8 hot spots/single
unit. Anterograde labeling combined with confocal microscopy revealed that pelvic mechano-
receptors innervated the circular and/or longitudinal muscle of the aganglionic rectum; and
exclusively the myenteric ganglia in wild type mice. Mechanoreceptors were immunoreactive
for Vglut1 or Vglut2, but not cholinergic or adrenergic markers (n=10). Conclusions: In
wild type mice, pelvic mechanoreceptors reside within the myenteric plexus, similar to larger
mammals1. However, in Ednrbs-l/Ednrbs-l mice, pelvic afferents still enter the rectal wall
and terminate within the aganglionic smooth muscle, despite the absence of enteric ganglia.
These “intramuscular afferent endings” monitor dynamic myogenic contractions of the agang-
lionic musculature. We suggest the existing notion that the aganglionic rectum is redundant
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and devoid of all afferent innervation requires some revision. 1. Lynn PA et al. Gastroenterol-
ogy 2003 Sep;125(3):786-94 This work was supported by P20 RR 018751-01 to NJS and
RO1-DK56986 from NIH (USA) and #275530 from NH& MRC (Australia) to SJB.
W1602
Ghrelin Administration Causes Early Manifestation of Postprandial Antro-
Pyloric Coordinations, Resulting in Rapid Gastric Emptying in Rats
Hajime Ariga, Yukiomi Nakade, Cindy Chen, Christopher R. Mantyh, Theodore N.
Pappas, Toku Takahashi
Background: Ghrelin is known to stimulate gastric motility (Biochem Biophys Res Com-
mun.2000;276:905) and gastric emptying (GE) (Scand J Gastroenterol.2004;39:1209) in
rats, but the correlation between gastric contractions and GE in response to ghrelin is still
unclear. The postprandial gastric motor pattern in response to a solid meal involves a
grinding and emptying period in humans (Gastroenterol.1993;105:433) and rats (Am J
Physiol. 2001;281:R1522). Solid GE is regulated by antro-pyloric coordination (APC), which
can propel the gastric contents to the duodenum. The aims of this study are to investigate
the change of GE after ghrelin administration and to explore how APC is altered by ghrelin.
Methods: After a 24-hour fasting, rats were given 1.5 g of solid meal. Immediately after the
feeding, ghrelin (0.4-8.0 microg/kg) or saline was applied by intraperitoneal (IP) injection.
Ninety minutes after the feeding, rats were euthanized and the stomach was removed. Gastric
content was recovered and GE was calculated. In other rats, strain gauge transducers were
implanted on the antrum and pylorus and contractions of the antrum and pylorus were
monitored in response to feeding with IP-injection of ghrelin or saline. The incidence of
postprandial APC was evaluated and compared between ghrelin- and saline-injected rats,
as previously described (Auton Neurosci.2002; 95:112). Results: In saline-treated rats, GE
was 58.3 +/- 3.7% (n=6). IP-administration of ghrelin (0.4-8.0 microg/kg) dose dependently
accelerated GE. Maximum effect was obtained by ghrelin (4.0 microg/kg), which accelerated
GE to 77.4 +/- 3.7% (n=6). The number of incidence of APC, which was not obvious within
20-40 min after the feeding in saline-injected rats, was significantly increased in ghrelin-
injected rats (Fig. 1; n=4, p<0.05). Conclusion: Ghrelin stimulates the coordinated motor
pattern between the antrum and pylorus in response to solid food ingestion, which in turn
accelerates solid GE in rats.
Figure 1 The number of incidence of antro-pyloric coordination in ghrelin- and vehicle-
injected rats (mean±SE, n=4, * p<0.05 vs control rats).
W1603
Stimulation of the Brain-Gut Axis By Intracolonic Mustard Oil Is Enhanced in
Mice with Low-Grade Colitis
Peter Holzer, Martina Mitrovic, Anaid Shahbazian, Martin Edelsbrunner
Introduction and Aims: The gut-brain axis is under the control of primary afferent neurons
monitoring the physical and chemical environment in the lumen and wall of the gut. The
transient receptor potential of type A1 (TRPA1) is a multimodal sensor that is expressed by
primary afferent neurons innervating the colon and is selectively stimulated by mustard oil
(MO). This study examined (1) whether intracolonic administration of MO stimulates the
gut brain axis in terms of afferent input to the spinal cord, activation of the hypothalamic-
pituitary-adrenal (HPA) axis and stimulation of colonic motor activity and (2) whether
this effect is altered by low-grade colonic inflammation. Methods: Following intracolonic
administration of MO (2 % in peanut oil) to female Him:OF1 mice defecation (5 min post-
treatment), circulating corticosterone (20 min post-treatment) and immunocytochemical
expression of c-Fos in the superficial dorsal horn (laminae I-IIo) of the sacral (S1) spinal
cord (1 h post-treatment) was determined. Mild colitis was induced by adding dextrane
sulfate sodium (DSS, 36-50 kDa; 1%) to the drinkingwater for 1week before the experiments.
Results: Relative to vehicle (peanut oil), intracolonic MO increased the number of c-Fos
positive cells in the superficial dorsal horn of the spinal cord, the preferential termination
area of visceral afferent neurons. The level of circulating corticosterone, an index of HPA
axis activity, was also enhanced by intracolonic MO. In contrast, the number of fecal pellets
expelled after intracolonic treatment was not enhanced by MO. Addition of DSS to the
drinking water caused mild colitis as assessed by a moderate increase of myeloperoxidase
activity in the colonic wall. The spinal c-Fos response to intracolonic MO was enhanced in
DSS-pretreated mice whereas the c-Fos response to vehicle was not altered. Likewise, DSS-
pretreated mice responded to intracolonic MO by expulsion of more fecal pellets and had
higher levels of circulating corticosterone than control mice. Conclusions: The current data
show that stimulation of the multimodal sensor TRPA1 in the colon induces afferent input
to the spinal cord and activates the HPA axis. These responses are exaggerated in animals
with mild colitis in which, in addition, TRPA1 activation stimulates defecation. Taken
together, these findings identify TRPA1 and TRPA1-expressing neurons as potential factors
in the pathological manifestations of the irritable bowel syndrome. Supported by the
Zukunftsfonds Steiermark and the Austrian Scientific Research Funds.
W1604
Corticoid Receptors in the Amygdala Modulate Spinal Cord Sensory
Responses to Colorectal Distension
Kalina M. Venkova, Beverley Greenwood
The relationship between anxiety and abdominal pain in patients with irritable bowel syn-
drome (IBS) is well established. Our previous studies in the rat showed that activation
of the central amygdaloid nucleus (CeA) with corticosterone (CORT) produced anxiety,
hypersensitivity to colorectal distension (CRD) and increased excitation of lumbosacral spinal
neurons to CRD. In the present study we investigated the role of amygdalar glucocorticoid
receptors (GR) and mineralocorticoid receptors (MR) in CORT-induced modulation of spinal
neuronal responses to CRD. Methods: Bilateral micropellet implants were placed stereotax-
ically at the dorsal boundary of the CeA in male Fischer-344 rats. The implanted micropellets
contained: 1) 30 µg CORT; 2) 30 µg CORT + 15 μg mifepristone, a selective GR antagonists;
3) 30 µg CORT + 15 μg spironolactone, a selective MR antagonist; 4) 30 µg cholesterol,
inactive control. On day 7 post-implantation, single cell responses to CRD were recorded
from L6-S1 spinal cord neurons in anesthetized rats. A total of 6 rats (15-20 cells per rat)
were studied in each experimental group. Results: The number of neurons responding to
CRD was similar in all groups. Between 19% and 23% of the neurons in each group showed
excitation (< 20% increase in the spontaneous firings of action potentials) in response to
nociceptive CRD at 80 mmHg. However, the increase in firing frequency evoked by graded
pressure (20-80 mmHg) of CRD was significantly higher in rats with CORT implants
compared to cholesterol-implanted control rats. The effect of CORT was prevented by
spironolactone, but not mifepristone (Table). Summary: Activation of MR, but not GR in
the amygdala is associated with the development of hyperexcitability of spinal cord neurons
to CRD. Conclusion: Our results suggest that descending pathways, originating in the CeA
and triggered by activation of MR, contribute to the excitation of spinal nociceptive circuits
involved in abdominal pain.
Two-way ANOVA: p<0.001 Bonferoni post-test: * p<0.05 compared to cholesterol; † p<0.05
compared to CORT.
W1605
Cd39 Promotes Fibrogenesis in Chronic Pancreatitis
Beat M. Kunzli, Pascal O. Berberat, Eva Csizmadia, Keichi Enjyoji, Helmut M. Friess,
Simon C. Robson
Background: Extracellular nucleotides are released from injured cells and bind specific
purinergic-type 2 receptors (P2-R), e.g. P2X7, to modulate inflammation, cellular death and
immune responses. Ectonucleotidases, such as CD39/NTPDase1, hydrolyze extracellular
nucleotides to regulate purinergic signaling and inflammation. High levels of CD39 and select
P2-R are noted in human pancreatitis biopsies. Aims: The role of extracellular nucleotides
and ectonucleotidases in mediating pancreatic fibrosis is poorly understood. We therefore
examined the development of pancreatic fibrosis in experimental models of cerulein-induced
pancreatitis in CD39-null and wild type (wt) mice. We also investigated how CD39 deletion
impacts on pancreatic stellate cell (PSC) function, important in extracellular matrix depos-
ition. Methods: Chronic pancreatitis was induced in CD39-null (n=10) and CD39 wt (n=
13) mice by repetitive intraperitoneal cerulein injections (50 μg/kg, 6 intraperitoneal injec-
tions daily, 3 times a week). Mice were sacrificed either after day 2, 21 and 42. Analyses
of pancreatic morphology and -fibrosis, clinical parameters, cytokine expression in blood
plasma, mRNA and protein expression of purinergic and fibrotic parameters and immuno-
histochemistry were performed in pancreatic tissues and PSC isolated from CD39-null and
-wt mice and cultured In Vitro. Proliferation of primary PSC and effects of CD39 deletion
on PSC were determined In Vitro. Results: Wt mice control developed morphological features
of pancreatitis with significant parenchymal atrophy and fibrosis. In contrast, although
CD39-null displayed pronounced acute inflammatory infiltrates these mice developed only
minor degrees of fibrosis and atrophy. CD39-null mice exhibited nomortality andmaintained
pancreatic weights at 42 days. CD39 and P2X7, a proinflammatory P2-receptor, were
overexpressed at 21 and 42 days. Interferon-γ was significantly increased in tissues and
plasma of CD39-null mice at baseline and during evolution of CP. CD39 is expressed at
high levels by wild type PSC. CD39-null PSC exhibited impaired growth and proliferation
but appeared to differentiate normally In Vitro. Production of procollagen-α1 by CD39-null
PSC was significantly impaired. Finally, CD39-null PSC failed to proliferate to growth factors
such as platelet derived growth factor (PDGF), and transforming growth factor β (TGF-β).
Conclusions: CD39 deletion and the resulting perturbation in purinergic signaling impacts
experimental pancreatitis by inhibiting fibrogenesis. Our data implicate CD39 as a modulator
of PSC in chronic pancreatitis.
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Interleukin 10 Is Essential for Prevention of Murine Autoimmune Pancreatitis
Induced By Poly I: C Administration
Akiyoshi Nishio, Masanori Asada, Keiichi Kiriya, Masahiro Kido, Takuji Akamatsu,
Kazuyuki Saga, Jyunya Tanaka, Norihiko Watanabe, Tsutomu Chiba
Background and Aim: Autoimmune pancreatitis (AIP) is a newly established entity of chronic
pancreatitis and characterized by infiltration of mononuclear inflammatory cells and destruc-
tion of the exocrine pancreatic tissue. The pathogenesis of the disease remains unclear
although the autoimmune mechanism has bee speculated. We previously reported that
polyinosinic polycytidylic acid (poly I: C) administration accelerated the development of
AIP that spontaneously occurs in senile MRL/MpJ mice and that various autoantibodies
including anti-lactoferrin (LF) antibody and anti-carbonic anhydrase (CA) II antibody were
produced in these mice, resembling human AIP. In this study, we aimed to investigate the
role of interleukin 10 (IL-10) in the pathogenesis of murine AIP. Materials and Methods:
Six-week-old female wild type C57BL/6 (WT) and IL-10 deficient (IL-10 KO) mice were
used for the experiments. Poly I:C at a dose of 5 mg/kg of body weight was administered
twice a week up to 8weeks. Mice treated with phosphate-buffered saline were served as
controls. Mice were serially sacrificed and histologically and serologically examined. Serum
titers of autoantibodies against LF, CA II and pancreatic secretory trypsin inhibitor (PSTI)
were examined by ELISA. Serum levels of IL-12, TNF-a, and interferon-a were measured
by ELISA. CD4 and CD8 T cell subsets of spleen cells from mice with AIP were separated by
magnetic cell sorting column and transferred into C57BL/6 RAG2-deficient mice, respectively.
Results: Administration of poly I:C did not induce pancreatitis in WT mice. In contrast, the
pancreas from IL-10 KO mice treated by poly I:C showed destruction of the pancreatic
acini accompanied by intense infiltration of inflammatory cells. Serologically, autoantibody
production against CA II, LF and PSTI was elevated only in poly I:C-treated IL-10 KO mice.
Serum levels of IL-12, TNF-a, and interferon-a were elevated only in poly I:C-treated IL-
10 KO mice although a single administration of poly I:C induced serum production of IL-
12, TNF-a and interferon-a both in WT and IL-10 KO mice. The incidence of colitis was
not different between poly I:C-treated and control IL-10 KO mice, indicating that colitogenic
T cells were not activated by poly I:C administration. Adoptive transfer of CD4 T cells
induced pancreatitis in RAG2-deficient mice. Conclusions: Administration of poly I:C specif-
ically induced AIP in IL-10 KO mice, suggesting that IL-10 plays an inhibitory role on the
activation of autoreactive CD4 T cells which leads to the development of the disease.
W1607
The Role of Innate Immunity in the Pathogenesis of Murine Experimental
Model of Autoimmune Pancreatitis
Masanori Asada, Akiyoshi Nishio, Keiichi Kiriya, Takuji Akamatsu, Kazuyuki Saga, Jyunya
Tanaka, Masahiro Kido, Shinya Ohashi, Norihiko Watanabe, Tsutomu Chiba
Background& Aim: Autoimmune pancreatitis (AIP) is a unique type of chronic pancreatitis.
Hypergammaglobulinemia, increased serum levels of total IgG or IgG4, and various autoanti-
bodies are often observed in patients with AIP. However, the autoimmune mechanisms
leading to AIP still remain unclear. We previously reported that murine autoimmune pancre-
atitis (AIP) induced by administration of polyinosinic polycytidylic acid (poly I:C), synthetic
double strand RNA, resembles human AIP. Because the onset and aggravation of autoimmune
diseases after bacterial and viral infection has been reported, we investigated the role of
innate immunity in the pathogenesis of murine experimental model of AIP. Materials &
Methods: Six-week-old female MRL/+ mice were intraperitoneally injected with poly I:C at
a dose of 5 mg/kg of body weight, or lipopolysaccharide (LPS) of the same dose, twice a
week up to 12 weeks, respectively. Control mice were injected with phosphate-buffered
saline. Mice were serially sacrificed and the severity of the pancreatitis was graded based
on the histological scoring system (0 to 4). Inflammatory infiltrates into the pancreas was
analyzed immunohistochemically. Serum levels of cytokines were measured by ELISA. To
investigate the role of the innate immunity for the disease development, gene expression of
toll-like receptors (TLRs) in pancreatic tissues were examined in mice with long term or a
single treatment by TLR ligands. Results: All mice developed pancreatitis after 12 week
injection of poly I:C, but LPS-treated and controls mice did not. Histological examination
demonstrated destruction and fatty degeneration of the pancreas accompanied by intense
infiltration of inflammatory cells. The severity of the pancreatitis increased according to the
treatment period. (histological score: 6wk; 1.8 ± 0.4, 12wk; 3.3 ± 0.6) Immunohistochemistry
revealed that B220+ B cells diffusely infiltrated into the pancreatic parenchyma. Both CD4+
and CD8+ T cells, and CD205+ plasma cells were mainly observed around the pancreatic
ducts. Serum IL-12 levels increased and pancreatic mRNA expression of TLRs (2, 3, 4 and
9) and type-1 interferon were upregulated only in poly I:C-treated mice. A single administra-
tion of poly I:C increased gene expression of TLR3 in the pancreas and serum IFN-α
concentration, but administration of LPS did not.Conclusions:TLR3 stimulation induced the
development of murine experimental AIP, suggesting that activation of the innate immunity
through viral infection may be related with human AIP.
W1608
Role of IP-10/Cxcl10 in the Progression of Pancreatitis in Mice After Murine
Retroviral Infection
Yusuke Kawauchi, Kenji Suzuki, Shiro Watanabe, Satoshi Yamagiwa, Gi dong Han,
Hiroyuki Yoneyama, Shosaku Narumi, Suresh s Palaniyandi, Punniyakoti t Veeraveedu,
Kenichi Watanabe, Hiroshi Kawachi, Yoshiaki Okada, Fujio Shimizu, Hitoshi Asakura,
Yutaka Aoyagi
BACKGROUND: We previously reported that exocrinopathy and autoimmune-like pancreat-
itis developed in mice infected with LP-BM5 murine leukemia virus, which induces murine
AIDS (MAIDS). Both Th1 and Th2 type CD4+ T cells, although with Th2 predominance
over Th1, accumulated in the pancreatic lesion of the mice. The role of chemokines, especially
CXCL10/interferon-γ-inducible protein 10 (IP-10), which is known as a chemokine to attract
CXCR3+ Th1 type CD4+ T cells, was largely unknown in the pathogenesis of pancreatitis.
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AIM: To reveal the role of IP-10 in the development of pancreatitis of MAIDS mice, we
injected the mice with a monoclonal antibody against IP-10. METHODS: four weeks old
female B6 mice were inoculated intraperitoneally with LP-BM5. Following the virus inocula-
tion, these mice were injected either with a mAb against IP-10 once a week, or with a
control Ab on the same time schedule. Eight weeks later, the mice were assessed for infection
by the virus by PCR, and for the lesions of pancreas by immunofluorescence (IF) and flow
cytometry. The expressions of IP-10, CXCR3, IFN-γ, and IL-10 were also analyzed by RT-
PCR and double-color IF for the mesenteric lymph nodes (mLN) and pancreas of the
mice. RESULTS: Anti-IP-10 treatment did not change the generalized lymphadenopathy and
hepatosplenomegaly of MAIDS mice. IP-10- and CXCR3- positive cells were detected in the
mLN and pancreas of MAIDS mice, and their numbers were significantly decreased by anti-
IP10 treatment. The phenotypes and gross number of cells in the mLN were not significantly
changed by IP-10 neutralization. In contrast, the number of mononuclear cells infiltrating
into the pancreas was decreased by blockade of IP-10. Anti-IP-10 treatment did not change
the number of IFN-γ+ and IL10+ cells in the mLN, but significantly reduced their numbers
in the pancreas of MAIDS mice. Double-color staining IF revealed that blockade of IP-10
significantly reduced IFN-γ+ and IL-10+ CD4+ T cells and IFNγ+Mac-1+ cells in the pancreas
of MAIDS mice. CONCLUSION: IP-10 neutralization ameliorated the pancreatic lesions of
MAIDS mice by blocking cellular infiltration of CD4+ T cells (both Th1 and Th2 type), and
IFNγ+ Mac-1+ cells into the pancreas, suggesting that IP-10 and these cells might play a
key role in the development of chronic autoimmune pancreatitis. IP-10 neutralization could
be a unique organspecific therapeutic strategy for chronic autoimmune pancreatitis.
W1609
Influence of Glial Cell Line-Derived Neutotrophic Factor and the Enteric
Nervous System On β-Cell Mass and Glucose Homeostasis
Simon Mwangi, Chaithanya Mallikarjun, Xiaokun Ding, Manami Hara, Alexander
Parsadanian, Christian P. Larsen, Peter Thule, Frank A. Anania, Shanthi V. Sitaraman,
Shanthi Srinivasan
Pancreatic β-cells share several similarities with enteric neurons, including expression of the
receptors for glial cell line-derived neurotrophic factor (GDNF), but the influence of the
enteric nervous system in β-cell survival is unknown. GDNF is a growth factor that plays
an important role in the development and survival of the enteric nervous system. We
here show that GDNF promotes the survival of primary mouse pancreatic β-cells and the
proliferation of the insulin-secreting β-TC-6 mouse pancreatic cell line In Vitro. GDNF
signals through the PI3K pathway to promote the phosphorylation of Akt and its downstream
target glucogen synthase kinase-3β (GSK-3β) in β-TC-6 cells. GDNF transgenic (Tg) mice
overexpressing GDNF in glia have 2.5 fold (P<0.001) higher β-cell mass, 3.2 fold (P<0.05)
higher pancreatic insulin content and 4 fold higher islet proliferative activity than wild type
(WT) littermates. GDNF Tg mice also have significantly (P<0.05) lower fasting blood glucose
levels, superior glucose tolerance, and higher plasma c-peptide and insulin levels than WT
mice. Following exposure to repeated low doses (75 mg/Kg body wt) of streptozotocin
(STZ), GDNF Tg mice exhibit increased resistance to STZ-induced hyperglycemia and β-
cell destruction than WT mice. Pre-culture of mouse islets with GDNF before intra-hepatic
transplantation improves their survival 4 fold compared to vehicle-cultured islets. Thus,
GDNF and its signaling pathway may provide novel therapeutic targets for improving β-
cell mass and survival.
W1610
Keratin 18 Glycosylation Protects Transgenic Mice from Streptozotocin-
Induced Pancreatic and Liver Injury
Nam-on Ku, Pavel Strnad, Diana Toivola, M. bishr Omary
Background: Keratin 18 (K18) is an abundant and major intermediate filament protein in
digestive epithelia. One major physiological function of K18 to provide mechanical integrity
to cells and mutations in K18 predispose patients to liver disease. We previously reported
that K18 undergoes dynamic glycosylation (Gly) at Ser29/30/48. This glycosylation consists
of O-linked single N-acetylglucosamines (O-GlcNAc), a modification found in many nuclear
and cytoplasmic proteins. Although the functions of glycosylation of many other proteins
were studied In Vitro cell-culture systems, In Vivo function of the glycosylation in animal
model was not reported. Aim: We studied the In Vivo significance of K18 glycosylation by
generating transgenic mice that express Gly-mutant K18. Methods: Transgenic mice that
overexpress K18 wildtype (WT) or Ser29/30/48-to-Ala (Gly-) were generated by introducing
point mutations into a 12-kb K18 WT genomic DNA construct that we previously used to
generate mice that overexpress K18WT or the phospho-mutant K18 Ser52Ala. This construct
maintains the normal tissue-specific K18 expression. The K18 Gly- mice were characterized
and compared with K18 wild-type (WT) or nontransgenic mice for their susceptibility to
streptozotocin (STZ)-mediated pancreatic injury. STZ inhibits the glycosidase that removes
protein O-GlcNAcs. K18 glycosylation was analyzed by In Vitro galactosylation of isolated
keratin precipitates. Apoptosis was analyzed by caspase activation. Results: Human K18
transgene copy number and protein expression were comparable in the WT and Gly- mice,
and were nearly equal to the endogenous K18. Absent K18 transgene Gly was confirmed
in Gly- mouse tissues. There was no significant effect of the Gly mutation on mouse
viability, digestive organ histology or keratin filament organization. However, Gly- mice are
significantly more susceptible to STZ-induced injury as compared with nontransgenic and
WT mice (70%, 43% and 30% lethality, respectively; p<0.04). Most deaths occurred within
one week after STZ administration and were initiated by islet cell injury accompanied
by marked pancreatic edema and liver injury and apoptosis. Serum glucose and alanine
aminotransferase (ALT) were significantly higher in Gly- mice as compared with control
mice after STZ injection (glucose: 305±36 vs 445±38 mg/dL; ALT: 1532±491 vs 2921±819
IU/L when comparing nontransgenic+WT with Gly- mice). Conclusion: We present the first
In Vivo targeting of an O-GlcNAc-type glycosylation. We hypothesize that K18 glycosylation
protects from pancreatic and other epithelial cell injury by serving as a glycosylation sink.
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W1611
Ethanol Feeding Impairs Recovery from Acute Pancreatitis
Ilya Gukovsky, Aurelia Lugea, Mohammad Shahsahebi, Jason H. Cheng, Mark Awad,
Samuel W. French, Stephen J. Pandol
Background & Aims: Pathogenesis of alcoholic chronic pancreatitis (ACP) remains obscure.
We recently developed a model of alcohol mediated pancreatitis, termed “the CsA model
of ACP”, which reproduces key responses of ACP: loss of parenchyma, sustained inflamma-
tion, and fibrosis. These changes result from synergistic effect of ethanol diet, an episode of
acute pancreatitis, and cyclosporin A (CsA) treatment. We hypothesized that one mechanism
mediating the “chronic” responses in our model is that ethanol impairs the recovery from
acute pancreatitis. To test this hypothesis, we measured the time-course of the responses.
Methods: Rats were pair-fed for 8 weeks Lieber-DeCarli ethanol (E) or control (C) diet. For
the last 2 weeks, they received CsA (20 mg/kg once daily). After 1 week on CsA, rats were
subjected to 1 episode of cerulein (Cer) pancreatitis (4 x 20 μg/kg), and killed at 3 h, and
2, 4 or 7 d after the Cer treatment. Results: By all parameters measured, ethanol feeding
impaired and/or delayed pancreatic repair/regeneration after acute pancreatitis, resulting in
dramatically exacerbated injury in E+CsA+Cer rats. In contrast, there was little difference
in acute responses (at 3 h) between E+CsA+Cer rats and their control-fed C+CsA+Cer
counterparts. Histologically, inflammatory infiltration, fibrosis, and loss of acinar tissue in
E+CsA+Cer rats were most pronounced at 4 and 7 d, whereas pancreas of C+CsA+Cer rats
showed progressive restoration of parenchyma and resolution of pathologic responses. Using
ED1 and ED2 stains, we showed that macrophages/monocytes were prominent in the
infiltrate. The pancreatic amylase levels (by Western blot) showed a transient decrease
in C+CsA+Cer rats, which was exacerbated and prolonged in E+CsA+Cer rats. The pro-
inflammatory transcription factors NF-κB and AP-1 were induced by acute pancreatitis, and
their activity (by EMSA) remained 2-3 times higher in E+CsA+Cer than in C+CsA+Cer
rats. The differential effect of ethanol feeding was observed in mRNA expression of some
chemokines, e.g., CXCL5 and CCL17. Collagen I level (by hydroxyproline content) in
pancreas of C+CsA+Cer rats transiently increased up to 1.8-fold, whereas in E+CsA+Cer
rats it remained 4 times higher. Perpetuation of fibrosis was also evidenced by increases in
fibronectin and smooth muscle actin, a marker of activated stellate cells. Conclusions: Our
model revealed that ethanol feeding impairs pancreatic repair/regeneration, resulting in
sustained mononuclear cell infiltration, fibrosis, and loss of parenchyma, thus supporting
our hypothesis. This may be a mechanism whereby ethanol facilitates the progression to
chronic pathologic changes in ACP.
W1612
Alcohol Cholecystokinin Evoked Pancreatic Acinar Basolateral Exocytosis Is
Mediated By Pkcα Phosphorylation of Munc18c
Laura Cosen-binker, Patrick Lam, Marcelo Binker, Joseph Reeve, Stephen Pandol, Herbert
Gaisano
The pancreatic acinus is the functional unit of the exocrine pancreas whose role is to secrete
zymogens into the gut lumen for food digestion via apical exocytosis. We previously reported
that supramaximal CCK induced apical blockade and redirected exocytosis to ectopic sites
on the basolateral plasma membrane (BPM) of this polarized cell, leading to pancreatitis.
Basolateral exocytosis was mediated by PKC phosphorylation of BPM Munc18c, causing its
displacement into the cytosol and activation of BPM-bound Syntaxin4 to form a SNARE
complex. To mimic the conditions of alcoholic pancreatitis, we now examined whether low-
dose alcohol followed by submaximal CCK might mimic supramaximal CCK in inducing
these pathologic exocytotic events. We show that non-secretory but clinically relevant low-
dose alcohol (20mM) inhibited submaximal CCK (50pM)-stimulated amylase secretion by
blocking apical exocytosis and redirecting exocytosis to less efficient BPM, indeed mimicking
supramaximal CCK (10nM) stimulation. We further demonstrate that basolateral exocytosis
caused by both stimulation protocols is mediated by PKCα-induced phosphorylation of
Munc18c: 1) PKCα is activated, which binds and induces phosphorylation of PM-Munc18c
at a Thr site, and these events can be inhibited by PKCα blockade; 2) PKCα inhibition
blocks Munc18c displacement from the BPM; 3) PKCα inhibition prevents basolateral
exocytosis but does not rescue apical exocytosis.We conclude that low-dose alcohol/submaxi-
mal CCK as well supramaximal CCK stimulation can trigger pathologic basolateral exocytosis
in pancreatic acinar cells via PKCα-mediated activation of Munc18c which influences BPM
SNARE complex assembly; and we further postulate this to be an underlying mechanism
contributing to alcoholic pancreatitis.
W1613
A Cytosolic Splice Variant of Cab45 Interacts with Munc18b and Impacts On
Amylase Secretion By Pancreatic Acini
Patrick P. Lam, Kati Hyvärinen, Maria Kauppi, Laura Cosen-binker, Saara Laitinen, Sirkka
Keränen, Vesa M. Olkkonen, Herbert Y. Gaisano
We identified in a yeast 2-hybrid screen the EF-hand Ca2+-binding protein Cab45 as an
interaction partner of the Sec1-Munc18 family member Munc18b. While the previously
characterized Cab45 resides in the Golgi lumen, we characterize here a cytosolic splice
variant, Cab45b, which is expressed in pancreatic acini. The endogenous Cab45b in rat
acini is shown to co-immunoprecipitate with Munc18b, syntaxin 2, and syntaxin 3, SNARE
proteins with key roles in the Ca2+-triggered zymogen secretion. Furthermore, we show by
immunofluorescence microscopy that Munc18b bound to co-expressed syntaxin 3 is able
to recruit Cab45b onto the cellular plasma membrane. Cab45b contains three EF-hand
motifs, of which EF-hand 2 is demonstrated to be crucial for binding of 45Ca2+. Antibodies
against Cab45b are shown to specifically inhibit amylase release from acini permeabilized
with streptolysin O. A series of site-specific mutants with EF-hands inactivated, as well as
N- or C-terminally truncated Cab45b recombinant proteins, were used to dissect the function
of Cab45b in amylase exocytosis. While an excess of the wild-type Cab45b had no effect
on amylase secretion, a mutant with both EF-hands 2 and 3 inactivated, leading to defect
in Ca2+ binding, significantly inhibited secretion. Also an N-terminally truncated protein
showing enhanced association with Munc18b but normal Ca2+ binding, was inhibitory.
Furthermore, an EF-hand 3 mutant with no detectable defects in either Ca2+ or Munc18b
interaction, induced mild stimulation of amylase release from the acini. The present study
identifies Cab45b as a novel Munc18b interaction partner involved in the regulated exocytosis
of zymogens by pancreatic acini. (Supported from: Finnish Cultural Foundation (to V.M.O.)
and the Canadian Institute for Health Research (to H.Y.G.) P.P.L.L. is funded by graduate
doctoral studentships from the Canadian Digestive Health Foundation and Canadian Institute
of Health Research)
W1614
Xbp1 Plays a Critical Role in Protecting Pancreas Against Ethanol-Induced
Endoplasmic Reticulum Stress
Aurelia Lugea, David A. Tischler, Samuel W. French, Fred S. Gorelick, Stephen J. Pandol
Background&Aims: Endoplasmic reticulum (ER) stress, an important factor in the pathogen-
esis of alcoholic-related diseases, can be triggered by accumulation of misfolded proteins in
the ER. To cope with this stress cells activate a signal transduction system called the unfolded
protein response (UPR). A key mediator of the protective UPR is the transcription factor,
X-box binding protein 1 (XBP1). XBP1 is activated in response to ER stress and regulates
genes required for efficient protein folding and degradation. XBP1 is also essential for the
development of the ER and the secretory machinery of the exocrine pancreas. Therefore,
modulation of XBP1 levels can regulate ER function in the exocrine pancreas. We showed
previously that chronic ethanol administration induced a protective UPR in the rat pancreas
with upregulation of XBP1 and ER chaperones. Here we examined whether reduction in
XBP1 levels increases ethanol-induced ER stress in the exocrine pancreas. Methods: Since
genetic deletion of XBP1 results in embryonic lethality, we used XBP1+/- mice with a null
mutation in one XBP1 allele and wild type controls (+/+). Previous studies showed that
XBP1+/- mice have a normal phenotype but are more susceptible to ER stress. Mice were
fed for 4 weeks control or ethanol-containing diets using the Tsukamoto-French intragastric
model.Measurements taken at the conclusion of ethanol feeding included pancreatic histology
by H&E and electron microscopy and detection of XBP-1 and transcription factor ATF-6
protein expression levels byWestern blot analysis. Results: Although ethanol feeding upregul-
ated pancreatic XBP1 protein expression in both genotypes, levels of XBP1 were 45% lower
in XBP1+/- mice compared to XBP1+/+. Ethanol feeding also induced increases in pancreatic
active ATF-6, to 1.5 fold in wild type mice and 1.9 fold in XBP1+/- mice compared to control
fed mice. Histological examination revealed that ethanol feeding-induced abnormalities in
the exocrine pancreas found in both genotypes were augmented in XBP1+/- mice. In XBP1+/-
mice fed ethanol we observed severe loss of zymogen granules, acinar cell vacuolization and
occasional islet hyperplasia in scattered areas. Ultrastructural examination of the acinar cells
showed ER dilatation and vacuolization, observations consistent with ER stress. In conclusion,
ethanol administration induces ER stress and activates a UPR response in mouse pancreas.
XBP1 appears critical in protecting the exocrine pancreas against ethanol-induced ER stress.
Suppression of this protective pathway can lead to pathologic responses such as acinar cell
death and pancreatic dysfunction.
W1615
CCK Causes Pkd1 Activation By Pkc-δ and Pkc-Independent Pathways in Rat
Pancreatic Acini
Marc J. Berna, Karl M. Hoffmann, Jose Tapia, Michelle Thill, Andrea Pace, Robert T.
Jensen
Introduction: Protein kinase D (PKD) is a serine-threonine kinase that has been implicated
in cell survival, proliferation,migration, invasion and protein trafficking.We recently reported
that PKD is expressed in rat pancreatic acini and phosphorylated in response to pancreatic
secretagogues and that CCK induces PKD phosphorylation by signaling through the high-
(20%) and low (80%) affinity state of the CCKA receptor. However, the detailed upstream
pathways leading to PKD phosphorylation and the effect of PKD phosphorylation on kinase
activity in pancreatic acini remain unclear. Methods: In dispersed rat pancreatic acini, PKD
isoforms were studied by using specific PKD total and phospho-antibodies after SDS-PAGE
and Western blotting. Pancreatic acini were cultured and infected with adenovirus as
described previously. Results: CCK caused not only serine phosphorylation [S916 (autophos-
phorylation), S744/748(transphosphorylation by PKC)] of PKD1, but induced also a highly
significant increase in PKDkinase activity as assessed by kinase assays. Inhibition of phosphol-
ipase C caused an 88% inhibition of PKD1 S744/748 phosphorylation but only a 56%
inhibition of S916 phosphorylation. Classical/novel PKC inhibitors GF109203X and Go6983
caused a significant inhibition of PKD1 S744/748 phosphorylation, but the classical PKC
inhibitor Go6976 and the PKC-ζ pseudopeptide inhibitor had no effect, suggesting that
novel PKC isoforms mediate PKD1 phosphorylation in rat pancreatic acini. Only PKC-δ
translocation inhibitor and expression of a dominant negative PKC-δmutant inhibited PKD1
S744/748 phosphorylation. However, after down-regulation of classical/novel PKC isoforms
by 24h incubation with the phorbol ester TPA, CCK still induced PKD1 phosphorylation
(20% of maximum). Inhibitors of tyrosine phosphorylation, mitogen associated protein
kinases, phosphatidylinositol 3-kinases and Src kinases had no effect on CCK-mediated
PKD1 phosphorylation. Conclusions: In rat pancreatic acini, CCK causes activation of PKD1
mostly by PLC/PKC-dependant pathways that are mediated by PKC-δ and not by PKC-ε as
in a number of other studies. However, in contrast to other, mostly transformed or transfected
cells, in rat pancreatic acini, 20% of CCK's effect on PKD1 phosphorylation is mediated by
PLC/PKC independent pathways. Contrary to findings in other experimental models, tyrosine
phosphorylation, PI3K and Src kinases do not regulate PKD1 phosphorylation in pancreatic
acini. These results show a number of novel aspects of PKD1 activation in pancreatic acini.
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W1616
Caspase 8-Mediated Apoptosis Induced By Oxidative Stress Is Independent of
the Intrinsic Apoptotic Pathway and Requires Cathepsin Activation
Heidi K. Baumgartner, H. louise Ashurst, Julia V. Gerasimenko, Robert Sutton, Alexie V.
Tepikin, Ole H. Petersen, Alastair j M. Watson, Oleg V. Gerasimenko
Background: Oxidative stress plays an important role in the pathogenesis of acute pancreatitis.
Increased generation of reactive oxygen species is a well known initiator of apoptosis and
has been shown to induce apoptosis in mouse pancreatic acinar cells (Gerasimenko et al.,
J Cell Science 115, 485-497, 2002). Opening of the permeability transition pore, release of
cytochrome c, and activation of caspase 9 occurs in these cells in response to oxidative
stress; however, a small population of cells can still undergo apoptosis when the opening
of the permeability transition pore is blocked. We investigated the possible role and mechan-
ism of action of alternative apoptotic pathways versus the intrinsic pathway in pancreatic
acinar cells exposed to oxidant stress. Methods: Mouse pancreatic acinar cells were loaded
with a fluorescent substrate for caspase 2, 8, 9, 10, or 12. Using confocal microscopy,
fluorescence of cleaved substrate was imaged in real time in response to the oxidant mena-
dione (30 µM). Caspase 9 or caspase 8 activity was examined in control cells and cells pre-
treated with 25 µM BAPTA-AM to prevent cytoplasmic calcium elevations, 50 µM bongkrekic
acid to block opening of the mitochondrial permeability transition pore, 50 µM GPN or
100 nM bafilomycin A1 to disrupt lysosomes, or cathepsin B, G, L, and D inhibitors. Results:
Caspase 2, 10, and 12 were not activated within 30 minutes after treatment with menadione.
Caspase 9 was activated within a few minutes (t1/2 = 129 ± 43 s) after administration of
menadione in 66±12% of cells. Activation of caspase 9 was inhibited in cells pre-treated
with BAPTA-AM and bongkrekic acid, but no change was observed in the presence of GPN
or bafilomycin A1. Caspase 8 was activated (t1/2) within 26 ± 3 minutes after treatment
with menadione in 15±2% of cells. Activation of caspase 8 was not altered by the presence
of BAPTA-AM or the inhibition of the intrinsic apoptotic pathway with bongkrekic acid.
However, caspase 8 activation was inhibited when lysosomes of the cells were destroyed
with GPN and bafilomycin A1. Pre-treatment with cathepsin D and L inhibitors blocked
menadione-induced caspase 8 activation. Conclusions: Both, the caspase 9-mediated and
caspase 8-mediated apoptotic pathways are rapidly activated in response to oxidative stress
in the pancreatic acinar cell. Caspase 9 activation is calcium-dependent and does not require
functional lysosomes. Caspase 8 is activated independently of the intrinsic apoptotic pathway
and does not require calcium for activation. Caspase 8, however, does require lysosomal
cathepsin D and L activity for activation in response to oxidative stress.
W1617
Ellagic Acid Regulates Apoptosis and Proliferation in Pancreatic Cancer Cells
Through Inhibition of NF-kB
Mouad Edderkaoui, Izumi Ohno, Ilya Gukovsky, Stephen J. Pandol, Anna S. Gukovskaya
Background & Aims: Pancreatic cancer is a very aggressive disease that is resistant to different
radio and chemo-therapies. One reason for that is the resistance of pancreatic cancer cells
to apoptosis is constitutive activation of the pro-survival transcription factor NF-kB. Ellagic
acid is a phenolic compound found in fruits such as berries, and pomegranates. The anticanci-
nogenic effects of ellagic acid were shown in several types of cancer. However, nothing is
known on the effect of ellagic acid on pancreatic cancer cells. In general, little is known on
the mechanisms underlying effects of ellagic acid on cancer cells. Methods: Human pancreatic
adenocarcinoma cells MIA PaCa-2 and PANC-1 were cultured for up to 48h in the presence
or absence of ellagic acid. Apoptosis was assessed by measuring DNA fragmentation using
Cell Death ELISA kit, AnV/PI staining, and caspase activity. Changes in mitochondrial
membrane potential were detected with the potential-sensitive probe 3,3'-dihexyloxacarbocy-
anine (DiOC6). Cytochrome c release was detected in cytosolic fractions with Western Blot.
Proliferation was assessed by measuring H3-thymidine incorporation. NF-kB binding activity
was measured in nuclear fractions using electromobility shift assay (EMSA). Results: Ellagic
acid dose-dependently (10-50 μM) increased apoptosis in MIA PaCa-2 and PANC-1 cells.
In particular, ellagic acid (20 μM) increased DNA fragmentation 4 fold. Ellagic acid at
concentration of 10 μM did not affect necrosis. Ellagic acid stimulated typical mitochondria
pathway of apoptosis. For example, 20 μM of ellagic acid stimulated caspase-3 activity (by
2 fold) decreased mitochondrial membrane potential (by 50%) and induced cytochrome c
release. Ellagic acid markedly decreased NF-kB binding activity in MIA PaCa-2 and PANC-
1 cells. On the other hand, we found that the inhibition of NF-kB by transfection with IkB
suppressor significantly (2 times) stimulated apoptosis in MIA PaCa-2 cells, indicating pro-
survival role of NF-kB in these cells. Conclusion: Ellagic acid stimulates apoptosis in pancre-
atic cancer cells. One mechanism through which ellagic acid stimulates apoptosis is by
inhibiting transcription factor NF-kB, which plays pro-survival role in pancreatic cancer
cells. The data suggest that ellagic acid represents a potential novel therapeutic agent for
treatment of pancreatic cancer.
W1618
Successful Treatment of Diabetic Rat Via Cell Therapy with GLP-1 Expressing
Adult Pancreatic Duct-Like Precursor Cells Established from Acinar to Ductal
Transdifferentiation
Ji-eun Lee, Jeong youp Park, Wen Jing, Si young Song
The cellular differentiation during neoplastic and metaplastic transformation in the adult
pancreas recapitulates the regulation of embryonic development-related genes in the primitive
pancreatic ductal cells. The exocrine pancreas undergoes metaplastic changes to ductal
epithelium from predominant acinar cell tissue in both chronic pancreatitis and pancreatic
cancer. Recently, it is reported that acinar to ductal transdifferentiation in adult pancreas is
mediated by initial dedifferentiation of latent precursor cells within mature mammalian
epithelium. We established and characterized rat pancreatic normal duct-like cell lines In
Vitro through transdifferentiation, which had the potential to be considered pancreatic
precursor cells, exhibiting the multipotency of cells undergoing the developmental cascade.
The aim of the present study was to provide information for cell therapy with GLP-1
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expressing adult pancreatic duct-like precursor cells established from acinar to ductal transdif-
ferentiation, whichwas relevant to the development of β-cell replacement therapy for diabetes.
Rat pancreatic ductal progenitor cells transdifferentiated from acinar cells contained markers
for pancreatic exocrine and endocrine development and expressed increase islet-specific
genes after glucagon-like peptide-1 (GLP-1) treatment, which was a key stimulator of β-cell
differentiation in the pancreas. We then co-expressed green fluorescent protein (GFP) and
GLP-1 in the ductal progenitor cells, under regulation by a zinc ion-inducible murine
metallothionein promoter. Zinc-induced insulin production by these cells was identified in
cell culture. Intravenously infusing the engineered cells in streptozotocin - induced diabeteic
rats ameliorated hyperglycemia, elevated plasma insulin, and co-localized insulin and GFP
in the acinar and islet areas of recipient pancreas was noted. These data indicates that the
adult pancreatic ductal progenitor cells established from acinar to ductal transdifferentiation
can differentiate into insulin-producing β-cells and that the homing of intravenously trans-
planted cells is possible. It has implications for potential use of adult pancreatic stem cells
in regenerative therapy of injured or diseased tissues in pancreas.
W1619
Sox2 Expression in Panin Lesions and Invasive Ductal Carcinoma of Pancreas
Eun taek Park, Myoung joo Kang, Eun uk Jung, Sang hyuk Lee, Sung jae Park, Sam
ryong Jee, Youn jae Lee, Sang youn Seol, Young s. Kim
Background & Purpose: Since MUC5AC expression in the normal GI tract is limited to
gastric surface mucous cells, MUC5AC expression in IBD and colonic polyps and cancers
could reflect the presence of transcription factors, or even a differentiation program, character-
istic of the gastric epithelium. Transcription factor SOX2 has recently been identified as an
important determinant of gastric epithelial biogenesis. The aim of this study was to assess
the possible role of SOX2 in the development of pancreatic intraepithelial neoplasia (PanIN)
lesions and invasive ductal carcinoma (IDC) of pancreas carcinomas. Experimental Design:
Immunohistochemistry (IHC) and In situ Hybridization(ISH) were used to examine SOX2
expression in normal gastric mucosal epithelium and PanIN lesions and IDC of Pancreas.
We also analyzed the transactivation of MUC5AC promoter/reporter constructs by a SOX2
expression vector. Results: SOX2 expression transactivated MUC5AC promoter/reporter
constructs, SOX2 can up regulate MUC5AC transcription. By using IHC and ISH, SOX2
was expressed in the nuclei of foveolar epithelium and glandular cells of stomach (Fig. 1).
SOX2 was found to be strongly expressed in the nuclei of PanIN 3 lesion and IDC of
pancreas but repressed in normal and PanIN 1a, 1b and 2 lesions (Fig. 2). Conclusions:
This study confirms the importance of SOX2 for the development of gastric mucosal epithelial
cells biogenesis. The results further suggest that SOX2 is an important factor in the up-
regulation of MUC5AC expression that occurs in PanIN 3 lesion and IDC. In addition, the
expression of SOX2 in PanIN lesions lends support to the hypothesis that these neoplasms
are frequent precursors in IDC of pancreas development.
W1620
EUS-FNA Citology Samples Obtained from Pancreatic Tumors Are Able to
Provide Viable Tumor Cells That May Be Cultured and Allow One to Perform
Cytogenetic and Immunohistochemical Analysis
Enrique -. Vazquez-sequeiros, Angel Martinez-ramirez, Alejandro Rojo-sebastian, Diego
Juzgado-lucas, Juan fernando Garcia-garcia
Background: EUS-FNA permits a cytologic diagnosis of pancreatic masses (PM) and also to
perform sophisticated laboratory analysis (K-ras, etc). However, there is no study investigating
if tumor cells obtained from PM by EUS-FNA are viable and may be cultured in specific
culture mediums. Wether cytogenetic analysis may be performed from cultured tumor cells
(to identify chromosome mutations associated with tumor development or response to
therapy) is unknown. Aims: To assess if EUS-FNA samples of PM may be cultured for
subsequent cytogenetic analysis. To characterize PM specific caryotypes to develop future
targets for therapy. Methods: Design: Prospective. Inclusion Criteria: 1.) Patients (PT) with
PM of unknown etiology referred for EUS-FNA. EUS exam: GF-UCT160-OL5 Olympus®,
22 Gauge needle. First pass for cytology; second pass for laboratory cytogenetic analysis.
Cell cultures/cytogenetics: EUS-FNA collected cells from PM were washed from the needle
in a specific tumor cell culture medium (RPMI medium supplemented with 10% fetal calf
serum and an antibiotic cocktail). The final pellet was resuspended in culture medium and
plated in 25 cm2 plastic flasks coated with Vitrogen 100. The culture medium RPMI 1640
with L-Glutamine containing 25 mM Hepes buffer with the addition of 100 U/ml penicillin
and 100 μg/ml streptomycin and supplemented with 10% fetal calf serum. Cells were
cultured during 1-3 weeks (depending on the amount of the initial cell inoculate). Culture
was exposed to 0.015 μg/ml of Colcemid for 3-14 hours and harvested 1-3 times each.
Cells were detached from the surface by trypsin/EDTA and, after immersion in 0.06MKCl
for 30 min followed by repeated fixations, were dropped onto wet slides for cytogenetic
analysis. Results: A total of 11 PT (adenocarcinoma: 9; focal pancreatitis: 2) were included
in the study. Cells were observed to grow in the RPMI culture in 7 PT (7/11 = 64%; 95%
CI: 31-89%), all of them with a malignant tumor. Among the 4 samples that did not grow
(4/11 = 36%; 95% CI: 11-69%), 2 of the PT had a benign condiction. Although an antibiotic
cocktail was added to the culture medium in all cases, 3 of 11 samples presented bacterial
contamination (3/11 = 27%; 95% CI: 6-61%), precluding cytogenetic analysis. Cells cultured
demonstrated for the first time that viable tumor cells may be obtained from EUS-FNA, and
caryotypes/cytogenetic analysis may also be conducted from those cultured cells. Conclusions:
EUS-FNA samples of PMmay be cultured in at least 2/3 of PT, allowing to conduct cytogenetic
analysis that may help identify PM specific caryotypes that will permit to develop future
targets for therapy.
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W1621
NADPH Oxidase Plays a Pivotal Role in the Activation of Pancreatic Stellate
Cells
Atsushi Masamune, Kazuhiro Kikuta, Takashi Watanabe, Tooru Shimosegawa
Background & Aims: Pancreatic stellate cells (PSCs) and oxidative stress play a pivotal role
in pancreatic fibrosis and inflammation. A possible source of reactive oxygen species (ROS)
in the injured pancreas is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.
We aimed to clarify (1) whether NADPH oxidase mediated activation and cell functions of
PSCs In Vitro, and (2) the effect of diphenylene iodonium (DPI), an inhibitor of NADPH
oxidase, on the development of pancreatic fibrosis In Vivo. Methods: PSCs were prepared
from rat and human pancreas tissues, and used in their activated, myofibroblast-like pheno-
type unless otherwise stated. Expression of NADPH oxidase was examined by reverse tran-
scription-PCR. ROS formation was examined using redox-sensitive dye 2',7'-dichlorofluores-
cin diacetate. We evaluated the effects of DPI on proliferation, chemokine production, and
expression of α-smooth muscle actin (SMA) and collagen genes. In addition, the effect of
DPI on the spontaneous transformation of freshly-isolated cells to myofibroblast-like cells
was assessed. In Vivo, DPI was administered in drinking water (1 mg/kg body weight/day)
to 10-week-old male Wistar Bonn/Kobori (WBN/Kob) rats for 10 weeks. The parameters of
inflammation and fibrosis including collagen content and α-SMA expression were assessed.
Results: PSCs expressed key components of NADPH oxidase. Growth factors and cytokines
such as platelet-derived growth factor, interleukin-1β, and angiotensin II induced ROS
formation, which was prevented in the presence of DPI. DPI inhibited proliferation, monocyte
chemoattractant protein-1 production, and expression of α-SMA and collagen genes. DPI
also inhibited the spontaneous transformation to myofibroblast-like cells. In Vivo, DPI attenu-
ated gross alterations in the pancreas inWBN/Kob rats. This protective effect was accompanied
by significant decreases in the expression of collagen content and α-SMA, at both mRNA
and protein levels, in the pancreas. Conclusion: NADPH oxidase plays a key role in the
activation and cell functions of PSCs both In Vitro and In Vivo, suggesting a novel target for
the treatment of pancreatic fibrosis.
W1622
Hypoxia Induces Collagen Production in Pancreatic Stellate Cells
Atsushi Masamune, Kazuhiro Kikuta, Tooru Shimosegawa
Background & Aims: Pancreatic cancer is characterized by excessive desmoplastic tissue
remodeling and by a hypoxic microenvironment within the solid tumor mass. Fibroblasts
in the area of desmoplastic reaction associated with pancreatic cancer are now recognized
as activated pancreatic stellate cells (PSCs). Previous studies have shown that hypoxia directly
affected cell behaviors in pancreatic cancer cells. But, the effects of hypoxia on PSCs are
largely unknown. This study aimed to clarify the effects of hypoxia on cell functions and
gene expression in PSCs. Methods: PSCs were isolated from rat and human pancreas tissues,
and used in their activated, myofibroblast-like phenotype unless otherwise stated. PSCs were
treated under hypoxia (1 % O2) or normoxia (20 % O2). The effects of hypoxia on
proliferation, migration, chemokine production, production of collagen, and the spontaneous
transformation of freshly-isolated cells to myofibroblast-like cells were assessed. Activation
of mitogen-activated protein kinases and the expression of hypoxia-inducible factor were
assessed by Western blotting. In addition, RNA was isolated from hypoxic and normoxic
PSCs, and the gene expression profiles were compared using the Affymetrix cDNAmicroarray.
Results: Hypoxia induced migration and collagen production in PSCs. Hypoxia did not
induce the production of monocyte chemoattractant protein-1 or initiate the transformation
of freshly isolated PSCs in culture. Hypoxia induced the expression of hypoxia-inducible
factor and the activation of mitogen-activated protein kinases. In addition to collagens,
hypoxia induced the expression of hypoxia-responsive genes including vascular endothelial
growth factor. Conclusion: Hypoxia directly affected the signal transduction pathways, gene
expression, and profibrogenic and proangiogenic functions in PSCs, thus leading to the
development of desmoplastic reaction.
W1623
Engulfment of Damaged Cells By Pancreatic Stellate Cells Modulates the
Invasive Activity of Pancreatic Cancer Cell Lines
Kyoko Shimizu, Junko Tahara, Keiichi Morishita, Keiko Shiratori
Background and Aims: Progression of a localized tumor to an invasive tumor involves
changes in cell motility, and an epithelial-mesenchymal transition is commonly associated
with acquisition of metastatic potential. Pancreatic stellate cells (PSCs) are known to play
a role in the desmoplastic reaction in pancreatic cancer. We recently reported finding that
PSCs engulfed apoptotic neutrophils and damaged acinar cells and that the engulfment of
the damaged cells by PSCs induced the death of the PSCs themselves and inhibition of
fibrogenesis. The aim of the present study was to investigate whether engulfment of damaged
cells by PSCs affects the phenotypic features of pancreatic cancer cell lines. Methods: Rat
PSCs were cultured and characterized as myofibroblast-like cellsmorphologically. Rat pancre-
atic acinar cells were incubated for 8-48 hours to induce cell death, and they were then
exposed to PSCs for 48 hours. Acinar cell death was assessed by both Annexin V and
propidium iodide staining followed by flow cytometry or detection of DNA fragmentation.
The culture medium of PSCs that internalized dead acinar cells and that internalized no
acinar cells (control PSCs) was collected and maintained at -80°C until used. The supernatant
was then added to pancreatic cancer cell lines Panc-1, MIA PaCa-2, AsPC, and BxPC. Tumor
growth was assessed by MTT assay. Cells were preincubated with serum-free medium for
48 hours, and a migration assay and an invasion assay were then performed. The TGF-beta
concentration of the culture medium was measured by ELISA. Results: After 48 hours of
culture with dead acinar cells, a large number of the dead cells had been engulfed by PSCs.
When pancreatic cancer cell lines were cultured in medium collected from control PSCs,
the cell growth of the BxPC line significantly increased. Addition of culture medium collected
from PSCs that had ingested acinar cells dose-dependently decreased cell growth by the
Panc-1, MIA PaCa-2, and BxPC lines, compared with addition of medium from control
PSCs. The migration activity and invasive activity of Panc-1, BxPC, and AsPC cells, but not
MIA PaCa-2 cells were significantly inhibited by the culture medium collected from the
PSCs that had engulfed cells. There was no difference between the concentrations of TGF-
beta in the medium of the control PSCs and the PSCs that had engulfed acinar cells.
Conclusions: Engulfment of acinar cells by PSCs inhibits the cell growth, migration, and
invasive activity of pancreatic cancer cell lines. These results suggest that the phagocytic
activity of PSCs may contribute to preventing the acquisition of metastatic potential by
pancreatic cancer cells.
W1624
Pressure Activates Pancreatic Stellate Cells Via Generation of Intracellular
Reactive Oxygen Species
Hiroshi Asaumi, Shiro Watanabe, Masashi Taguchi, Mitsuo Tashiro, Makoto Otsuki
Introduction: In chronic pancreatitis, pancreatic tissue pressure is higher than that of normal
pancreas. We have reported that pressure induces synthesis of extracellular matrix (ECM)
and cytokines in pancreatic stellate cells (PSCs), and that strong antioxidant, green tea
polyphenol epigallocatechin gallate (EGCG), inhibits transformation of PSCs from quiescent
to activated phenotype and ethanol-induced synthesis of ECM and cytokines in PSCs.
Therefore our previous observations suggest that oxidative stress and reactive oxygen species
(ROS) are important factors in PSC activation. The aim of the present study is to clarify the
effects of ROS on activation and functions of pressure-stimulated PSCs. Methods: We used
isolated rat PSCs between passage one to three. Pressure was applied to cultured rat PSCs
by adding compressed helium gas into the pressure loading apparatus to raise the internal
pressure. PSCs were cultured with or without EGCG (25 μM) in the absence or presence
of pressure (80 mmHg). Results: In the presence of pressure, intracellular ROS generation
in PSCs was detected after stimulation for 30 sec and greatly increased after stimulation for
1 h. Incubation with EGCG, generation of ROS in PSCs was strongly suppressed. Pressure
significantly increased protein levels of α-smooth muscle actin (SMA) and type I procollagen
α1 and mRNA levels of α-SMA, type I procollagen α1 and transforming growth factor-β1
in PSCs. EGCG inhibited pressure-induced increase of these protein and mRNA levels in
PSCs. EGCG abolished pressure-induced phosphorylation of p38 mitogen activated protein
kinase. In addition, EGCG inhibited pressure-induced transformation of freshly isolated
PSCs to activated, myofibroblast-like phenotype. Conclusion: Our result indicates that ROS
is a key player in pressure-induced PSC activation and ECM synthesis. Antioxidants may
be presumably effective as therapeutic reagents against development of pancreatic fibrosis
in chronic pancreatitis.
W1625
Do Pancreatic Stellate Cells Play a Role in Exocrine Pancreatic Secretion?
Zhihong Xu, Alain Vonlaufen, Arthur Shulkes, Ron C. Pirola, Jeremy S. Wilson, Minoti V.
Apte
Background: Cholecystokinin (CCK) is a major secretagogue for pancreatic digestive enzyme
secretion. However, human pancreatic acinar cells lack functional CCK receptors. We postu-
late that a non-parenchymal cell, the pancreatic stellate cell (PSC), may mediate CCK-
induced digestive enzyme secretion by acting as the primary target for CCK in the pancreas
and secreting the neurotransmitter acetylcholine (ACh) which, in turn, stimulates acinar
cell enzyme secretion. We have previously shown that human PSCs exhibit activation of
extracellular signal regulated kinase (ERK1/2) and p38 kinase pathways in response to CCK.
Aims: To determine whether i) PSCs express CCK receptors; ii) the effects of CCK on PSCs
can be prevented by a CCK receptor antagonist; and iii) PSCs have the capacity to produce
ACh. Methods: Primary cultures of human PSCs were used for all studies. i) CCK1 and
CCK2 receptor expression by PSCs was assessed by immunostaining and immunoblotting
analysis using specific antibodies; ii) CCK receptor antagonist studies - PSCs were incubated
with medium alone (control) or with CCK (500pM) in the presence and absence of the
CCK2 receptor antagonist L365260 (1μM) and ERK activation assessed by immunoblotting;
iii) expression of the ACh synthesizing enzyme choline acetyltransferase (ChAT) and the
vesicular acetyl choline transporter (VAChT) by PSCs was assessed by immunoblotting and
immunofluorescence, using specific antibodies. Results: i) Human PSCs express both CCK1
and CCK2 receptors as assessed by immunoblotting as well as immunofluorescence. ii) The
CCK-induced activation of ERK1/2 in PSCs was reduced by the CCK2 receptor antagonist
L365260, but this decrease did not reach statistical significance [data expressed as % of
control densitometry units, mean±SEM: Control - 100; CCK - 151±20.6; CCK+L365260 -
114±24.9; n = 3 separate PSC preparations]; iii) PSCs express both ChAT and VAChT.
Conclusions: Human PSCs possess CCK receptors 1 and 2; The effect of CCK on ERK
activation in PSCs, may be mediated, at least in part, via the CCK2 receptor. Importantly,
PSCs have the essential elements for ACh production, namely the ACh synthesizing enzyme
ChAT as well as the protein required to transport ACh through the cell. Implications: Our
findings support the concept that the pancreatic stellate cell may be an intermediary cell
that is a primary target for CCK and that the response of PSCs to CCK may represent a
previously unrecognised intrapancreatic pathway regulating pancreatic enzyme secretion.
W1626
Par-1 (Protease Activated Receptor-1) Regulates the Expression of Mmp-1
(Matrix Metalloprotease-1) and the Activation of Human Pancreatic Stellate
Cells
Shigenari Hozawa, Hiromitsu Souma, Keita Saeki, Naoki Miyata, Yoshiyuki Yamagishi,
Toshifumi Hibi
Introduction: PAR-1 is a G protein-coupled receptor that is cleaved and activated by a ligand
such as thrombin. MMP-1 has been recently recognized as a ligand for PAR-1 (Cell 120:
303-13, 2005). PAR-1 antagonism inhibits hepatic stellate cell activation In Vitro and protects
against fibrosis development in a rodent model of liver cirrhosis (Hepatology 39; 365-75,
2004). PAR-1 is also thought to be a strong candidate for targeting in the treatment of
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pancreatic fibrosis, and the activation of PAR-1 may regulate MMP-1 expression. In the
current study, we examined whether PAR-1 agonist/ antagonist can regulate human pancreatic
stellate cell activation and its MMP-1 expression In Vitro. Methods: Human pancreatic
periacinar fibroblast-like cells (hPFC) which posses characteristics of pancreatic stellate cells
(Pancreas 14: 1997) were used in this study. Morphologic changes, proliferation assay, cell
motility, mRNA expression of alpha 1(I) procollagen and alpha SMA were examined in
order to explore the activation of stellate cells treated by PAR-1 agonist (TFLLR-NH3) /
antagonist (RWJ-58259). RWJ-58259, which is given by Dr Andrade-Gordon in Johnson
& Johnson Pharmaceutical Research & Development in collaboration with us, is a potent
and selective inhibitor of PAR-1 identified as part of a synthetic chemistry program based
upon a de novo design approach. Northern blot analysis and gelatin zymography were
performed to examine mRNA and protein expression of MMP-1 respectively. Results: Treat-
ment of hPFC by 50nM of TFLLR-NH3 suppressed the expression of MMP-1 and enhanced
the mRNA expression of procollagen and alpha SMA, while changes of the other parameters
for stellate cell activation such as cell shape, motility and proliferation were not observed
by the treatment. Treatment by 50 nM of RWJ-58259 has enhanced MMP-1 expression,
and has slightly suppressed cell motility andmRNA expression of procollagen and alpha SMA.
Conclusions: It was suggested that PAR-1 agonist/antagonist might regulate the activation of
human pancreatic stellate cells as well as their MMP-1 expression. PAR-1might be a candidate
for targeting in the treatment of pancreatic fibrosis in the future. The molecular mechanisms
for the regulation should be explored next.
W1627
Evidence for Central Hyperexcitability in Interstitial Cystitis (IC)
Bruce D. Naliboff, Christian Twiss, Lisa Kilpatrick, Veronica Triaca, Michelle Craske, Hana
Ibrahimovic, Shlomo Raz, Edward M. Ornitz, C. A. Buffington, Larissa V. Rodríguez,
Emeran A. Mayer
BACKGROUND: Pain in IC, a condition frequently comorbid with irritable bowel syndrome
(IBS), may result in part from alterations in central pain modulatory pathways. The startle
blink reflex (SBR) is a defensive, involuntary eye-blink in response to sudden intense stimuli.
This reflex is modulated by the amygdala, an important component of arousal and emotion
regulation circuits. Central pain amplification has been linked to increased responsiveness
of these arousal circuits. Increases in SBR magnitude represent an objective index of affective
response to stimuli, such as threat of pain. AIM: To test the hypothesis that IC patients
have an upregulation of central arousal responses that may influence pain modulation
pathways, we compared the SBRs of 19 female healthy controls (age=27.0±6.4) with that
of 8 female IC patients (age=49.1±9.3).METHODS: SBRs were examined during alternating
periods in which subjects either could receive an aversive muscle stimulation to the lower
abdomen (Threat) or not (Safe). Each threat period consisted of an early and late phase and
if stimulation was to occur, it would occur during the late phase. Only one stimulation was
actually given. Mixed-effects analysis for repeated measures was applied to determine the
influence of diagnosis (IC, Control), threat (Danger, Safe) and phase (Early, Late) on the
square-root transformed SBRs. RESULTS: Significant main effects were observed for dia-
gnosis (p=.002), threat (p<.001), and phase (p<.001), as well as an interaction between all
3 parameters (p=.004). Patients with IC had significantly greater estimated mean SBRs than
controls across all conditions except for the late threat condition. A follow-up analysis
indicated that IC subjects did show a significant increase in the late threat after receiving
the stimulation, but not before (p<.05). CONCLUSIONS: This initial data that IC patients
have greater SBRs than controls during baseline and non-imminent threat periods is evidence
of anxiety potentiation of startle. A similar context increase of the startle reflex is observed
in anxiety disorders, post-traumatic stress disorder and IBS. This provides objective evidence
that IC patients may have upregulation of amygdala-related arousal circuits involved in
central pain modulation. Further investigation is needed to determine if this upregulation
is a causative agent or a secondary effect of the IC disease process. Supported by NIH
grants P50 DK64539, R24 AT002681, VA Medical Research and the Fishbein Family IC
Research Foundation.
W1628
Central Nervous System (CNS) Regulation of Nocturnal Esophageal Acid
Exposure
Gregg S. Gagliardi, Ashish P. Shah, Leonardo Salese, Karl Doghramji, Sidney Cohen,
Anthony J. Dimarino
Background: Nocturnal esophageal acid exposure has been implicated as a major factor in
the complications associated with gastroesophageal reflux disease (GERD). Most clinical
observations have focused on the esophagus, itself, as the major acid clearance protective
mechanism. However, the role of the CNS in this protective mechanism has not been
investigated. Aim: The purpose of this study is to define the role of the CNS as an important
factor in nocturnal esophageal acid clearance. Methods: Simultaneous polysomnography and
esophageal pH recordings were obtained in 8 patients without nocturnal GERD and in 16
subjects with documented nocturnal GERD. All 24 subjects had normal esophageal peristalsis.
An acid GER event was considered to have occurred when the pH recording was < 4.0.
Arousals and awakenings were reflux associated if they occurred during the reflux event
and up to 5 minutes after the pH had returned to ≧ 4.0. The first part of this analysis
focused on the effects of sleep stage. Esophageal acid reflux events were scored during non-
rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. None of the
patients reviewed received sleep hypnotics. This same group of patients was also a part of
a randomized trial to determine the effects of sleep hypnotics on nocturnal GER events. In
the second part of this analysis, we reviewed the effect sleep hypnotics had on acid induced
arousals and awakenings when compared to placebo. Results: In NREM sleep, an arousal
or awakening, which initiates a protective esophageal mechanism, occurred in response to
92.3% of the GER events. In REM sleep, an arousal or awakening occurred in only 16.7%
of the GER events (p < 0.05). As a result, the mean acid clearance time (ACT) was 1.13 ±
0.33 s in NREM sleep and 77.31 ± 75.75 s in REM sleep. In the second analysis, an acid
GER event resulted in an arousal or awakening 82% of the time when the patients received
a placebo. When the sleep hypnotic was given, an arousal or awakening occurred in only
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25% of the GER events (p < 0.05). The mean ACT in the placebo group was 60.4 s ± 38.9
s and 148.2 ± 75.0 s in the sleep hypnotic group (p < 0.05). Absence of an arousal or
awakening following an acid GER event resulted in prolonged acid exposure in all cases.
Conclusions: 1) In subjects with normal peristaltic function, sleep stage and sleep hypnotic
use can greatly influence nocturnal esophageal acid exposure. 2) The CNS and its protective
arousal induced swallow must be considered along with GE junction incompetence and
impaired peristalsis as an additional important factor for GERD and its complications.
W1629
Differential Noradrenergic (NE) Modulation of Brain Metabolic and Electrical
Activity in IBS Patients and Healthy Controls
Steven Berman, Brandall Suyenobu, Bruce D. Naliboff, Joshua Bueller, Jean Stains, Heng
Wong, Mark Mandelkern, Emeran A. Mayer
BACKGROUND: IBS patients show altered event related potential (ERP) responses (↑P1
amplitude) to tones (Berman et al, 2002). The P1 amplitude is modulated by the central
NE system. AIMS: To determine the effect of pharmacological modulation of the central NE
system on regional brain metabolic and ERP responses. METHODS: In an ongoing double-
blind, study, 9 IBS patients (6 men) and matched controls (Ctrls) were studied during an
auditory selective attention task on 3 days after ingestion of the α2 receptor antagonist
yohimbine (YOH; 40 mg), the α2 agonist clonidine (CLO; 0.2 mg) or placebo (PLA). ERPs
and [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) brain images
were acquired 30 min. after drug, randomized for order. SPM2 software contrasted relative
regional glucose metabolism between conditions and groups within 8 regions of interest
(ROIs): The amplitude at the P7 electrode from 118-128 ms was extracted and examined
for covariation with relative FDG activity. RESULTS: ERP: Patients produced larger P1 than
Ctrls over left parietal scalp under PLA (t=2.3 at 121 ms), CLO (t=2.8 at 125 ms), and YOH
(t=2.4 at 123 ms). FDG: Across all subjects, YOH elicited less activity than CLO in bilateral
insula (both p<.002), the middle (both p<.002) and infragenual cingulate (iACC) (both
p<.01), dorsal brainstem (both p<.05), and amygdala (AMYG)(both p<.02). Most regions
showed also greater CLO effects compared to PLA. AMYG effects were more marked in IBS,
producing group-drug interactions contrasting CLO with PLA (R.AMYG p=.03, L.AMYG p=
.004) and YOH (L.AMYG p=.006). In all interactions, CLO was associated with more AMYG
activity in IBS patients (all p<.01), with no significant effect in Ctrls. Infra/perigenual ACC
effects were most marked in Ctrls, producing group-drug interactions contrasting CLO
withYOH (all 4 p<.01). In all interactions, CLO was associated with more iACC activity in
Ctrls (all p<.002), with no significant effect in IBS. ERP covariation with FDG: P1 amplitude
covaried directly with activity in the right parabrachial nucleus for all subjects (p=.04) and
indirectly with L. AMYG activity in all males (p=.02), and IBS males (p=.01). There was a
group-drug interaction in R. AMYG (slope test, p=.04) due to IBS patients having a more
negative covariate slope than controls. CONCLUSIONS: 1. The effects of of central NE
system modulation differ between IBS and Ctrls. 2. Reduction of NE tone by CLO increased
AMYG activity in IBS patients, and AMY showed altered correlation with P1. These findings
are consistent with abnormal NE regulation of AMYG in IBS. Supported by DK48351, R24
AT002681, P50DK64539 (EAM), NR04881 (BN)
W1630
Hypnotic Modulation of Regional Brain Activity to Rectal Stimulation Using
Positron Emission Tomography
Satoshi Watanabe, Motoyori Kanazawa, Richard D. Lane, Toyohiro Hamaguchi, Takahiro
Terui, Hirotaka Mine, Kazuhiko Yanai, Masatoshi Itoh, Shin Fukudo
Background & Aims : Hypnosis treatment is known to induce dramatic improvement of
symptoms of IBS patients who are intractable to usual medical treatment. Right insula,
anterior cingulate and right prefrontal cortex have been implicated in awareness of visceral
sensations. However, knowledge about the brain processing related to hypnotic modulation
of visceral sensation in human is sparse. We examined the hypotheses that neural activity
in right insula, right anterior cingulate cortex (ACC) and right lateral prefrontal cortex (PFC)
are greater during hypnotic modulation of visceral sensation. Methods: We used H215O
positron emission tomography (PET) to identify neural activity in 14 healthy male subjects
during the modulation of rectal sensation via hypnotic suggestion. During each scan, the
rectum of the subject was stimulated with bag pressures of 0, 20 or 40 mmHg for 80 s.
The instructions for hypnotic induction were taken from the HarvardGroup Scale of Hypnotic
Susceptibility form A. 3 type indirect suggestions for modulation of pain affect (analgesic,
hyperalgesic or neutral) were given before the beginning of each stimulus and scan. Hypnotiz-
ability was also evaluated for pre-screening before scanning day. Results: The analgesic
suggestion resulted in a significant reduction in subjective abdominal discomfort (p<0.05).
Activation within right dorsolateral PFC (DLPFC) was significantly greater (p<0.001, uncor-
rected) during rectal distention with analgesic suggestion compared with neutral suggestion.
The direct contrast of the analgesic and hyperalgesic conditions revealed that neural activation
within the right DLPFC, right dorsal ACC and right inferior parietal cortex [Brodmann Area
40] was higher in the analgesic condition compared to the hyperalgesic condition (p<0.001,
uncorrected). The interaction analysis revealed that the interaction of hypnotizability and
suggestion-induced activations were significantly showed in the right ventrolateral PFC,
right posterior insula and primary sensory cortex. Increases in right DLPFC activity during
hypnotic modulation of rectal distention were negatively correlated with subjective abdominal
discomfort (r = -0.60, p<0.01). Conclusions: This is the first evidence for the hypnotic
modulation of brain processing during gastrointestinal stimulation. Right lateral PFC and
right dorsal ACC may reflect the cognitive control and top-down mechanisms involved in
the inhibitory control over conflict or undesirable visceral sensation.
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W1631
Postprandial Vagal Dysfunction in Patients with Functional Dyspepsia
Takeshi Kamiya, Hiroshi Adachi, Makoto Hirako, Michiko Shikano, Eriko Matsuhisa,
Makoto Sasaki, Hiromi Kataoka, Takashi Joh
Background: Functional dyspepsia (FD) is a clinical syndrome characterized by persistent
or recurrent upper abdominal symptoms such as epigastric pain, bloating, and early satiety
without organic disease. Various factors contribute to the cause of these symptoms, but the
underlying mechanisms have not been elucidated. Several studies indicated that FD patients
have abnormal gastrointestinal motility including delayed gastric emptying and impaired
gastric myoelectrical activity. Autonomic nervous dysfunction as well as disturbed gastric
motility may be important factors for the pathogenesis of FD. There are few studies of
simultaneous evaluation of gastric myoelectrical activity and autonomic function in patients
with FD. Aims: To investigate gastric myoelectrical activity, autonomic nervous function
and their relationship in patients with FD by the simultaneousmeasurement of electrogastrog-
raphy (EGG) and heart rate variability (HRV). Methods: The study was performed in 31
patients with FD and 10 matched healthy controls. Gastric myoelectrical activity was meas-
ured using cutaneous recorded EGG. Autonomic function was evaluated with HRV derived
from electrocardiography (ECG). EGG and ECG were recorded simultaneously for 30 min
during fasting and after the test meal, respectively, and the EGG percentage of normal 2-4
cpm slow wave (normogastria) and power ratio were evaluated for each subject. All R-R
intervals of ECG were measured, and low frequency (LF) components, high frequency (HF)
components, and LF/HF ratio were calculated to assess the autonomic nervous function.
Results: In the control group, the dominant frequency of EGG increased significantly after
the meal, but this response was not observed in patients with FD. The percentage of
normogastria was significantly lower in FD patients compared with the control group in
both fasting and postprandial state. The EGG power ratio (postprandial power/fasting power)
in FD patients was significantly lower than in the control group. A significant decrease in
the HF component of HRV, which represents vagal tone, was observed after the meal in
the control group, but it was unchanged in FD patients. There were no significant changes
in the LF/HF ratio between before and after the meal in either the control group or FD
patients. EGG power ratio showed a reverse correlation to the postprandial HF component
of HRV (p<0.05). Conclusions: FD patients demonstrated impaired gastric myoelectrical
activity and disturbed vagal activity in the postprandial state. This impaired vagal modulation
may play one of the important roles of causing dyspeptic symptoms and disturbed gastric
motility in patients with FD.
W1632
Colonic Mucosal Cellular Infiltrate Correlates with Symptom Severity in
Irritable Bowel Syndrome (IBS)
Elizabeth J. Videlock, Arlene Licudine, Miyoshi Hirano, Dorina Gui, Galen Cortina,
Emeran A. Mayer, Lin Chang
BACKGROUND: Increased cellularity in the colonic mucosa, e.g., 5-HT-containing enter-
ochromaffin (EC) cells and mast cells, has been reported in some patients with post-infectious
IBS (Dunlop, Gastro 2003) or unselected IBS patients (Barbara, Gastro 2004). While certain
mast cell indices have been shown to correlate with abdominal pain ratings, it is not entirely
clear if the cellular infiltrate in the mucosa is associated with IBS symptoms. AIMS: 1) To
compare numbers of immune and endocrine cells in the colonic mucosa and lamina propria
between IBS patients and healthy controls, 2) To determine if sex differences exist, and 3)
To determine if cell counts correlate with measures of symptom severity in IBS.METHODS:
37 IBS patients (26F, 11M, 46% IBS-C, 27% IBS-D, 27% IBS-A) and 22 age-matched controls
(11F, 11M) underwent a sigmoidoscopy with sigmoid colon biopsies. Tissue was stained
for mast cells (tryptase), all EC cells (chromogranin), 5-HT-EC cells (5-HT), and CD3, CD4
and CD8 T lymphocytes. In a blinded fashion, we performed digital image analysis of
the immunoperoxidase-stained slides using MetaMorph software. The number of cells was
calculated from the total number of cells in ≥4 high power fields (400x) divided by the
total tissue area (expressed as number per 0.25 mm2). Current IBS severity ratings (0-20
scale) were collected. RESULTS: IBS vs. controls: There were no statistically significant
differences between the groups for any cell type. Sex differences: Healthy women had
significantly higher numbers of 5-HT-EC cells vs. healthy men (12.9±1.8 vs. 6.4±2.0, p<0.05)
but there were no other significant differences. Correlation with IBS symptoms: There was
a significantly positive correlation between mast cell number and lower abdominal pain
ratings (r=0.39, p<0.05). In contrast, the proportion of 5-HT-EC cells (%5-HT-EC/all EC
cells) negatively correlated with unpleasantness ratings of current IBS symptoms (r=-0.42,
p<0.05). Similarly, the ratio of CD4/CD8 lymphocytes negatively correlated with overall IBS
symptoms (r=-0.35, p<0.05) and lower GI discomfort ratings (r=-0.36, p<0.05). There was
no association between bowel habit and cell counts. CONCLUSION: The observed patterns
of mucosal cell counts with subjective symptom measures may indicate a causative relation-
ship of mucosal alterations on IBS symptoms. For example, mast cells may have a pro-
nociceptive effect, while 5-HT-EC cells and CD4 cells may have a protective role in IBS.
Alternatively, theymay represent a consequence of altered stress response systems onmucosal
neuroimmune interactions. Supported by NIH grants P50 DK64539 and R24 AT002681.
W1633
Sex Differences in Plasma Catecholamines and Colonic Tissue Markers of
Noradrenergic Activity in Irritable Bowel Syndrome (IBS)
Elizabeth J. Videlock, Efi Kokkotou, Charalabos Pothoulakis, Arlene Licudine, Miyoshi
Hirano, Emeran A. Mayer, Lin Chang
BACKGROUND: Alterations in autonomic nervous system (ANS) modulation of GI motility,
secretion, and immune function have been reported in IBS. Stress-related ANS alterations
appear to be sex-dependent, i.e., higher cardio-sympathetic and lower cardio-vagal tone is
present more in men than women with IBS (Tillisch, Gut, 2005), but also in women with
more severe IBS-C (Heitkemper, DDS 2001). AIMS: To examine the main effects of disease
group (IBS vs. controls) and sex on peripheral measures of sympathetic nervous system (SNS)
activity (plasma norepinephrine [NE] and epinephrine [EPI], colonic mucosal expression of
α2adrenergic receptors [α2AR], neuropeptide Y [NPY], and dopamine hydroxylase [DH])
in IBS and healthy controls. METHODS: 37 IBS patients (26F, 11M, 46% IBS-C, 27% IBS-
D, 27% IBS-A) and 22 age-matched healthy controls (11F, 11M) underwent sigmoidoscopy
with biopsies of mucosa and lamina propria. Basal NE and EPI levels were collected in all
but 8 subjects. Colonic tissue levels of α2AR, NPY and DH mRNA were measured in a
randomly selected subset (27 IBS [18F, 9M] and 18 controls [9F, 9M]) using real-time PCR.
Severity of overall IBS, abdominal pain, discomfort and bloating were assessed (0-20 scale).
RESULTS: Although IBS and controls had similar levels of SNS markers, there were signific-
ant sex differences (see table, *p<.05). Men had higher plasma NE and EPI and lower tissue
α2AR expression. Because presynaptic α2AR on enteric motor neurons are inhibitory, lower
expression suggests greater NE and acetylcholine (Ach) release. In IBS patients, correlations
between SNS measures and symptoms were evaluated and the only significant finding was
that α2AR positively correlated with bloating (r=.47, p<.05). CONCLUSION: These findings
suggest that there is greater peripheral SNS outflow in men regardless of group, reflected
by higher plasma levels of NE and lower α2AR expression in the colonic mucosa. Downregul-
ation of α2AR inmenmay be associated with increased release of Ach and possibly contributes
to the lower prevalence of constipation in men. This is supported by the finding that lower
levels of α2AR expression are associated with lower ratings of bloating which is a common
symptom in constipation. Supported by NIH grants P50 DK64539 and R24 AT002681.
W1634
Ileal 5ht4Receptor Immunoreactivity Is Decreased in Patients with IBS-D
Elizabeth J. Irvine, Catherine J. Streutker, Gesine L. Alders, Elizabeth C. Colley, Maria
Braganza, Elaine Fraser, Jennifer Whiteley-osmond, Gabor Kandel, Terrence L. Moore,
Paul P. Kortan, Clifford A. Ottaway, Gary R. May, Khursheed N. Jeejeebhoy, Jeffrey P.
Baker, Ronald H. Stead
Background: Serotonin (5HT) is an important biogenic amine affecting both motility and
nociception in the gastrointestinal tract. 5HT receptor ligands have been used to treat specific
IBS patient subgroups as 5HT metabolism may be perturbed in some patients. We recently
reported extensive 5HT4 receptor immunoreactivity (IR) in several gut mucosal cell types
but it is currently unknown if levels of 5HT4-IR expression differ in IBS patients compared
with controls. Aim: To measure 5HT4-IR in ileal biopsies of IBS patients. Methods: A series
of IBS patients attending one centre were classed by physician diagnosis according to the
dominant symptom. Ileal biopsies were obtained from 54 patients (44 female) with IBS
(constipation, diarrhea or mixed) and 24 control patients without IBS, and fixed in formalin
before processing to paraffin. Sections were stained for 5HT4 using an antiserum raised
against the third cytoplasmic loop of 5HT4(Lifespan Biosciences, WA). Integrated optical
densities (ΣIODs) were measured using Quantimet image analysis software (Leica, ON).
Kruskal-Wallis and Mann-Whitney tests were used to analyze the data. Results: The average
patient age was 46.4 ± 10.1 yrs. The mean 5HT4-IR ΣIOD was significantly different among
groups and decreased in patients with IBS-D compared with controls (table).These findings
were similar in male and female subjects. Mean Physical Component Summary (PCS) scores
of the SF-12 quality of life index were significantly poorer in IBS vs. Controls (44.3 + 10.2;
55.5 + 5.9; p<.001) and in each of the IBS subtypes (p<.05 vs. control). The mean Mental
Component Summary (MCS) scores were also significantly worse in IBS vs. controls. MCS
and PCS scores were similar in the three IBS subgroups.Conclusions: 5HT4-IR is diminished
in IBS patients, particularly the subgroup with predominant diarrhea. The apparent down-
regulation of 5HT4-IR could, therefore, represent a compensatory mechanism to reduce
bowel activity (motility and secretion) in diarrhea patients. Further assessment of 5HT4
function and receptor expression in IBS subjects is warranted.
5HT4ΣIOD
Kruskal-Wallis p=0.022;*p=.003 compared to Control (Mann-Whitney test)
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W1635
Neuroregulation of the TLESR Reflex By Sensory Mechanisms Sensitive to
Luminal Contents At the Esophago-Gastric Junction: A Study in Neonates
with Adult Implications
Michiel P. Van wijk, Marc A. Benninga, John Dent, Ros Lontis, Louise Goodchild, Ross
Haslam, Taher I. Omari
Background: Gastric distension stimulates tension receptors and hence triggers the vago-
vagal transient lower esophageal sphincter relaxation (TLESR) reflex causing TLESRs and
gastroesophageal reflux (GER). Despite faster gastric emptying, infants in the right lateral
position (RLP) trigger more TLESRs and GER when compared to the left lateral position
(LLP).1 We hypothesized that pooling of milk at the level of the esophago-gastric junction
(EGJ) augments triggering of TLESRs.Methods: Seven healthy infants (3 male, post menstrual
age: 36wks(range:35-37), weight:2060-2730g) were studied twice using an esophageal
impedance-manometry catheter incorporating a feeding tube. After tube placement with the
infusion port of the catheter 2.5cm distal to the midpoint of the lower esophageal sphincter,
infants were randomly positioned either at their RLP or LLP. They were then tube fed their
normal feed (65ml (40-75ml)) at a constant infusion rate of 160ml/hr. Recordings were
made during the feed and 15 min thereafter. The next day, the study was repeated with
the infant in the opposite position. Tracings were analyzed using standard criteria. Results:
In the RLP, the time from the start of infusion to the triggering of the first TLESR was
significantly shorter than when infants were on the LLP (4min31sec ± 3min25sec vs. 8min22-
sec ± 1min19sec respectively, p=0.01) meaning that volume of feed required to meet the
threshold for initiation of the TLESR reflex was also significantly lower (12.0±9.1ml (range:
0.3-23.8) vs. 22.3±3.5ml (range:19.5-28.3) respectively, p=0.01). Under these standardized
feed infusion conditions more TLESRs and liquid GER episodes were triggered in the RLP
compared to LLP (4.6±1.5 vs. 2.3±1.5, p<0.01 & 4.1±1.7 vs. 1.7±1.7, p<0.05 respectively).
Gas and mixed GER episodes were rarely seen in both positions. Therefore the difference
in liquid GER triggering was not related to change in reflux type. Discussion: In the RLP,
TLESRs and reflux are triggered earlier after the commencement of feed infusion and more
frequently during the feed overall. In this experimental paradigm the rate of gastric distension
was assumed to be similar in both positions by virtue of the volume, rate and type of feed
infused being kept constant. These findings provide clear evidence for the presence of
mechanisms for luminal sensing of gastric contents at the level of EGJ which regulate the
threshold for triggering of the TLESR reflex by gastric distension. Such mechanisms have
yet to be described but are likely to involve vagal mucosal receptors localized to the EGJ
and may prove to be a novel target for therapeutic interventions. 1Omari T et al. J Pediatr 2004
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